DrugMAP Full Data Download File Title - DrugMAP drug information in raw format Version 1.01 (2022.07.20) Provided by Lab of Innovative Drug Reasearch and Bioinformatics (IDRB) College of Pharmaceutical Sciences Zhejiang University https://idrblab.org/ Any question about data provided here, please contact with: Dr. Li (lifengcheng@zju.edu.cn) and Dr. Yin (yinjiayi@zju.edu.cn) ID: Drug ID DN: Drug Name HS: Highest Status SN: Synonymous CP: Company TC: Therapeutic Class DT: Drug Type SQ: Sequence PC: PubChem CID MW: Molecular Weight FM: Formula IC: InChI CS: Canonical SMILES IK: InChIKey IU: IUPAC Name CA: CAS Number CB: ChEBI ID DE: Disease Entry DMMHNU2 ID DMMHNU2 DMMHNU2 DN (S)-(+)-Dimethindene maleate DMMHNU2 HS Approved DMMHNU2 SN UNII-J43ZL3WTLN; J43ZL3WTLN; 136152-65-3; DSSTox_RID_83231; DSSTox_CID_28966; DSSTox_GSID_49040; Dimethindene maleate, (+)-; CAS-1217457-81-2; NCGC00025158-01; 121367-05-3; Dimethindene maleate, (S)-(+)-; DTXSID8049040; CHEMBL2356801; MolPort-023-276-095; HMS3267J12; Tox21_113582; AKOS024456589; Tox21_113582_1; NCGC00025158-02; 1H-Indene-2-ethanamine, N,N-dimethyl-3-((1S)-1-(2-pyridinyl)ethyl)-, (2Z)-2-butenedioate (1:1); B6734; (S)-(+)-Dimethindene maleate, > UNII-6LL60J9E0O component DMMHNU2 TC Antiinflammatory Agents DMMHNU2 DT Small molecular drug DMMHNU2 PC 56972160 DMMHNU2 MW 408.5 DMMHNU2 FM C24H28N2O4 DMMHNU2 IC InChI=1S/C20H24N2.C4H4O4/c1-15(19-10-6-7-12-21-19)20-17(11-13-22(2)3)14-16-8-4-5-9-18(16)20;5-3(6)1-2-4(7)8/h4-10,12,15H,11,13-14H2,1-3H3;1-2H,(H,5,6)(H,7,8)/b;2-1-/t15-;/m1./s1 DMMHNU2 CS C[C@H](C1=CC=CC=N1)C2=C(CC3=CC=CC=C32)CCN(C)C.C(=C\\C(=O)O)\\C(=O)O DMMHNU2 IK SWECWXGUJQLXJF-HFNHQGOYSA-N DMMHNU2 IU (Z)-but-2-enedioic acid;N,N-dimethyl-2-[3-[(1S)-1-pyridin-2-ylethyl]-1H-inden-2-yl]ethanamine DMMHNU2 CA CAS 136152-65-3 DMMHNU2 DE Pruritus DMIAHVU ID DMIAHVU DMIAHVU DN 2-deoxyglucose DMIAHVU HS Approved DMIAHVU SN 154-17-6; Deoxyglucose; 2-Deoxy-D-mannose; 2-Deoxy-D-arabinohexose; UNII-9G2MP84A8W; D-Arabino-hexose, 2-deoxy-; HSDB 5484; arabino-Hexose, 2-deoxy-; D-Glucose, 2-deoxy-; 9G2MP84A8W; (3R,4S,5R)-3,4,5,6-tetrahydroxyhexanal; AK-44445; 2 Deoxyglucose; 2 Deoxy D glucose; 2 Desoxy D glucose; D-arabino-2-desoxyhexose; d-2-glucodesose; D-2dGlc; deoxy-d-glucose, 2-; 2-DEOXYLGLUCOSE; 2-INNo-D-AEIIC; SCHEMBL7670; AC1L33KH; KSC175S5P; 4-01-00-04282 (Beilstein Handbook Reference); Jsp003004; CHEMBL2074932; CTK0H5957; MolPort-002-317-302; 2-deoxy-D-glucose DMIAHVU CP Threshold Pharmaceuticals DMIAHVU DT Small molecular drug DMIAHVU PC 108223 DMIAHVU MW 164.16 DMIAHVU FM C6H12O5 DMIAHVU IC InChI=1S/C6H12O5/c7-2-1-4(9)6(11)5(10)3-8/h2,4-6,8-11H,1,3H2/t4-,5-,6+/m1/s1 DMIAHVU CS C(C=O)[C@H]([C@@H]([C@@H](CO)O)O)O DMIAHVU IK VRYALKFFQXWPIH-PBXRRBTRSA-N DMIAHVU IU (3R,4S,5R)-3,4,5,6-tetrahydroxyhexanal DMIAHVU CA CAS 154-17-6 DMIAHVU DE Solid tumour/cancer DMYFBMS ID DMYFBMS DMYFBMS DN 99mTc-fanolesomab DMYFBMS HS Approved DMYFBMS SN LeuTech; NeutroSpec; RB5-IgM; Technetium (99mTc) fanolesomab; Anti-SSEA-1; Technetium-99m-fanolesomab; 99mTc RB5-IgM; 99mTc anti-SSEA-1; 99mTc-labeled anti-CD15 antibody DMYFBMS CP Palatin Technologies DMYFBMS DT Antibody DMYFBMS DE Appendicitis DMVZO01 ID DMVZO01 DMVZO01 DN 99mTc-sestamibi DMVZO01 HS Approved DMVZO01 SN Sestamibi; RP-30; Tc-MIBI; Technetium-99m sestamibi DMVZO01 CP Bristol-Myers Squibb Pharma Co DMVZO01 DT Small molecular drug DMVZO01 PC 9832136 DMVZO01 MW 777.9 DMVZO01 FM C36H66N6O6Tc+7 DMVZO01 IC InChI=1S/6C6H11NO.Tc/c6*1-6(2,8-4)5-7-3;/h6*5H2,1-2,4H3;/q;;;;;;+7/i;;;;;;1+1 DMVZO01 CS CC(C)(C[N+]#[C-])OC.CC(C)(C[N+]#[C-])OC.CC(C)(C[N+]#[C-])OC.CC(C)(C[N+]#[C-])OC.CC(C)(C[N+]#[C-])OC.CC(C)(C[N+]#[C-])OC.[99Tc+7] DMVZO01 IK ZGDBEIODOXIKGQ-KTTJZPQESA-N DMVZO01 IU 1-isocyano-2-methoxy-2-methylpropane;technetium-99(7+) DMVZO01 DE Breast cancer DMMN36E ID DMMN36E DMMN36E DN Abacavir DMMN36E HS Approved DMMN36E SN Trizivir; Ziagen; Abacavir [INN]; Abacavir (INN); Ziagen (TN); Ziagen (TM)(*Succinate salt*); [(1S,4R)-4-[2-amino-6-(cyclopropylamino)purin-9-yl]cyclopent-2-en-1-yl]methanol; {(1S-cis)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]cyclopent-2-en-1-yl}methanol; (+/-)-4-[2-Amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol; (+/-)-Abacavir; (1S,4R)-4-[2-Amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol; ABC DMMN36E CP GlaxoSmithKline DMMN36E TC Anti-HIV Agents DMMN36E DT Small molecular drug DMMN36E PC 441300 DMMN36E MW 286.33 DMMN36E FM C14H18N6O DMMN36E IC InChI=1S/C14H18N6O/c15-14-18-12(17-9-2-3-9)11-13(19-14)20(7-16-11)10-4-1-8(5-10)6-21/h1,4,7-10,21H,2-3,5-6H2,(H3,15,17,18,19)/t8-,10+/m1/s1 DMMN36E CS C1CC1NC2=C3C(=NC(=N2)N)N(C=N3)[C@@H]4C[C@@H](C=C4)CO DMMN36E IK MCGSCOLBFJQGHM-SCZZXKLOSA-N DMMN36E IU [(1S,4R)-4-[2-amino-6-(cyclopropylamino)purin-9-yl]cyclopent-2-en-1-yl]methanol DMMN36E CA CAS 136470-78-5 DMMN36E CB CHEBI:421707 DMMN36E DE Human immunodeficiency virus infection DMOERGM ID DMOERGM DMOERGM DN Abaloparatide DMOERGM HS Approved DMOERGM SN Tymlos DMOERGM CP Radius Health DMOERGM DT Recombinant protein DMOERGM SQ Abaloparatide N-terminal peptide sequence: AVSEHQLLHDKGKSIQDLRRRELLEKLLXKLHTA DMOERGM PC 76943386 DMOERGM MW 3961 DMOERGM FM C174H300N56O49 DMOERGM IC InChI=1S/C174H300N56O49/c1-26-93(20)136(228-165(274)126(80-232)224-141(250)101(39-28-32-56-176)200-129(236)78-195-140(249)100(38-27-31-55-175)201-161(270)123(73-133(243)244)223-160(269)121(71-98-76-190-82-197-98)220-158(267)118(68-90(14)15)216-155(264)114(64-86(6)7)213-148(257)107(45-50-127(180)234)207-159(268)120(70-97-75-189-81-196-97)219-151(260)111(49-54-132(241)242)209-164(273)125(79-231)225-167(276)135(92(18)19)227-139(248)94(21)179)168(277)210-108(46-51-128(181)235)149(258)222-124(74-134(245)246)162(271)217-112(62-84(2)3)152(261)205-105(44-37-61-194-173(187)188)143(252)203-103(42-35-59-192-171(183)184)142(251)204-104(43-36-60-193-172(185)186)144(253)206-110(48-53-131(239)240)150(259)214-115(65-87(8)9)154(263)215-113(63-85(4)5)153(262)208-109(47-52-130(237)238)147(256)202-102(40-29-33-57-177)145(254)211-116(66-88(10)11)156(265)218-119(69-91(16)17)166(275)230-174(24,25)170(279)226-106(41-30-34-58-178)146(255)212-117(67-89(12)13)157(266)221-122(72-99-77-191-83-198-99)163(272)229-137(96(23)233)169(278)199-95(22)138(182)247/h75-77,81-96,100-126,135-137,231-233H,26-74,78-80,175-179H2,1-25H3,(H2,180,234)(H2,181,235)(H2,182,247)(H,189,196)(H,190,197)(H,191,198)(H,195,249)(H,199,278)(H,200,236)(H,201,270)(H,202,256)(H,203,252)(H,204,251)(H,205,261)(H,206,253)(H,207,268)(H,208,262)(H,209,273)(H,210,277)(H,211,254)(H,212,255)(H,213,257)(H,214,259)(H,215,263)(H,216,264)(H,217,271)(H,218,265)(H,219,260)(H,220,267)(H,221,266)(H,222,258)(H,223,269)(H,224,250)(H,225,276)(H,226,279)(H,227,248)(H,228,274)(H,229,272)(H,230,275)(H,237,238)(H,239,240)(H,241,242)(H,243,244)(H,245,246)(H4,183,184,192)(H4,185,186,193)(H4,187,188,194)/t93-,94-,95-,96+,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,135-,136-,137-/m0/s1 DMOERGM CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NC(C)(C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC2=CN=CN2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC3=CN=CN3)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)N DMOERGM IK BVISQZFBLRSESR-XSCWXTNMSA-N DMOERGM IU (4S)-4-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-aminopropanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-4-carboxybutanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-5-oxopentanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-carboxypropanoyl]amino]hexanoyl]amino]acetyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]-3-methylpentanoyl]amino]-5-oxopentanoyl]amino]-3-carboxypropanoyl]amino]-4-methylpentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-1-amino-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-2-methyl-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-oxopentanoic acid DMOERGM CA CAS 247062-33-5 DMOERGM DE Postmenopausal osteoporosis DM2RX0I ID DM2RX0I DM2RX0I DN Abametapir DM2RX0I HS Approved DM2RX0I SN 5,5'-Dimethyl-2,2'-bipyridine; 1762-34-1; 5,5'-Dimethyl-2,2'-dipyridyl; 5,5'-Dimethyl-2,2'-bipyridyl; 6,6'-Bi-3-picoline; 2,2'-BIPYRIDINE, 5,5'-DIMETHYL-; HA-44; 6,6'-Di-3-picolyl; 6,6'-Di-3-picoline; UNII-6UO390AMFB; 5-methyl-2-(5-methylpyridin-2-yl)pyridine; MFCD01740554; 6UO390AMFB; CHEMBL2205807; 5,5'-dimethyl-2,2'-bipyridinyl; 5,5 -Dimethyl-2,2 -bipyridine; Xeglyze; BRN 0123183; Abametapir [USAN:INN]; Xeglyze(Abametapir); Xeglyze (TN); PubChem24353; Abametapir (USAN/INN); ACMC-209eb4; SCHEMBL351152; HA44; 2,2 -Bis-(5-methylpyridyl); DTXSID00170095; ZINC403335; 9238AA; ANW-22814; BDBM50401351; LT0042; s5752; 5,5''-Dimethyl-2,2''-bipyridine; AKOS005257775; CS-W004546; DB11932; MCULE-8581798506; SB17220; 5,5 inverted exclamation marka-Dimethyl-2,2 inverted exclamation marka-dipyridyl; 5,5'-Dimethyl-2,2'-dipyridyl, 98%; AK-63331; DS-15219; SY052805; FT-0689891; D10687; W-108621; Q27265547; 5,5 inverted exclamation mark -Dimethyl-2,2 inverted exclamation mark -bipyridyl DM2RX0I DT Small molecular drug DM2RX0I PC 15664 DM2RX0I MW 184.24 DM2RX0I FM C12H12N2 DM2RX0I IC InChI=1S/C12H12N2/c1-9-3-5-11(13-7-9)12-6-4-10(2)8-14-12/h3-8H,1-2H3 DM2RX0I CS CC1=CN=C(C=C1)C2=NC=C(C=C2)C DM2RX0I IK PTRATZCAGVBFIQ-UHFFFAOYSA-N DM2RX0I IU 5-methyl-2-(5-methylpyridin-2-yl)pyridine DM2RX0I CA CAS 1762-34-1 DM2RX0I DE Head and body lice DM5WFNP ID DM5WFNP DM5WFNP DN Abarelix DM5WFNP HS Approved DM5WFNP SN Plenaxis; Abarelix [USAN]; Plenaxis depot; PPI 149; R 3827; PPI-149; Plenaxis (TN); R-3827; Abarelix (USAN/INN); Abarelix-Depot-M; N-Acetyl-3-(2-naphthyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridyl)-D-alanyl-L-seryl-N-methyl-L-tyrosyl-D-asparginyl-L-leucyl-N6-isopropyl-L-lysyl-L-prolyl-D-alaninamide; N-Acetyl-3-(2-naphthyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridyl)-D-alanyl-L-seryl-N-methyl-L-tyrosyl-D-asparaginyl-L-leucyl-N(sup 6)-isopropyl-L-lysyl-L-prolyl-D-alaninamide; N-acetyl-3-(2-naphthyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(pyridin-3-yl)-D-alanyl-L-seryl-N-methyl-L-tyrosyl-D-asparginyl-L-leucyl-N(6)-isopropyl-L-lysyl-L-prolyl-D-alaninamide; D-Alaninamide, N-acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-N-methyl-L-tyrosyl-D-asparaginyl-L-leucyl-N6-(1-methylethyl)-L-lysyl-L-prolyl-10 DM5WFNP CP Speciality European Pharma DM5WFNP TC Anticancer Agents DM5WFNP DT Small molecular drug DM5WFNP PC 16131215 DM5WFNP MW 1416.1 DM5WFNP FM C72H95ClN14O14 DM5WFNP IC InChI=1S/C72H95ClN14O14/c1-41(2)32-54(64(93)80-53(17-10-11-30-77-42(3)4)72(101)87-31-13-18-60(87)69(98)78-43(5)63(75)92)81-68(97)58(38-62(74)91)84-70(99)61(37-46-22-27-52(90)28-23-46)86(7)71(100)59(40-88)85-67(96)57(36-48-14-12-29-76-39-48)83-66(95)56(34-45-20-25-51(73)26-21-45)82-65(94)55(79-44(6)89)35-47-19-24-49-15-8-9-16-50(49)33-47/h8-9,12,14-16,19-29,33,39,41-43,53-61,77,88,90H,10-11,13,17-18,30-32,34-38,40H2,1-7H3,(H2,74,91)(H2,75,92)(H,78,98)(H,79,89)(H,80,93)(H,81,97)(H,82,94)(H,83,95)(H,84,99)(H,85,96)/t43-,53+,54+,55-,56-,57-,58-,59+,60+,61+/m1/s1 DM5WFNP CS C[C@H](C(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCNC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(=O)N)NC(=O)[C@H](CC2=CC=C(C=C2)O)N(C)C(=O)[C@H](CO)NC(=O)[C@@H](CC3=CN=CC=C3)NC(=O)[C@@H](CC4=CC=C(C=C4)Cl)NC(=O)[C@@H](CC5=CC6=CC=CC=C6C=C5)NC(=O)C DM5WFNP IK AIWRTTMUVOZGPW-HSPKUQOVSA-N DM5WFNP IU (2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]-methylamino]-3-(4-hydroxyphenyl)propanoyl]amino]-N-[(2S)-1-[[(2S)-1-[(2S)-2-[[(2R)-1-amino-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-6-(propan-2-ylamino)hexan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]butanediamide DM5WFNP CA CAS 183552-38-7 DM5WFNP CB CHEBI:337298 DM5WFNP DE Prostate cancer DMSA8RU ID DMSA8RU DMSA8RU DN Abatacept DMSA8RU HS Approved DMSA8RU SN Orencia (TN) DMSA8RU CP Bristol-Myers Squibb DMSA8RU TC Antirheumatic Agents DMSA8RU SQ Abatacept monomer sequence: MHVAQPAVVLASSRGIASFVCEYASPGKATEVRVTVLRQADSQVTEVCAATYMMGNELTFLDDSICTGTSSGNQVNLTIQGLRAMDTGLYICKVELMYPPPYYLGIGNGTQIYVIDPEPCPDSDQEPKSSDKTHTSPPSPAPELLGGSSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK DMSA8RU DE Rheumatoid arthritis DMJO6GV ID DMJO6GV DMJO6GV DN Abciximab DMJO6GV HS Approved DMJO6GV SN ReoPro (TN) DMJO6GV CP Eli Lilly DMJO6GV TC Anticoagulants DMJO6GV DT Monoclonal antibody DMJO6GV SQ 1TXV:H ReoPro-like antibody Heavy Chain 1: EVQLQQSGAELVKPGASVKLSCTASGFNIKDTYVHWVKQRPEQGLEWIGRIDPANGYTKYDPKFQGKATITADTSSNTAYLQLSSLTSEDTAVYYCVRPLYDYYAMDYWGQGTSVTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLYTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK >1TXV:L ReoPro-like antibody Light Chain 1DILMTQSPSSMSVSLGDTVSITCHASQGISSNIGWLQQKPGKSFMGLIYYGTNLVDGVPSRFSGSGSGADYSLTISSLDSEDFADYYCVQYAQLPYTFGGGTKLEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEYERHNSYTCEATHKTSTSPIVKSFNRNEC >1TXV:H ReoPro-like antibody Heavy Chain 2EVQLQQSGAELVKPGASVKLSCTASGFNIKDTYVHWVKQRPEQGLEWIGRIDPANGYTKYDPKFQGKATITADTSSNTAYLQLSSLTSEDTAVYYCVRPLYDYYAMDYWGQGTSVTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLYTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK >1TXV:L ReoPro-like antibody Light Chain 2DILMTQSPSSMSVSLGDTVSITCHASQGISSNIGWLQQKPGKSFMGLIYYGTNLVDGVPSRFSGSGSGADYSLTISSLDSEDFADYYCVQYAQLPYTFGGGTKLEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEYERHNSYTCEATHKTSTSPIVKSFNRNEC DMJO6GV DE Angina pectoris DM8V75C ID DM8V75C DM8V75C DN ABIRATERONE DM8V75C HS Approved DM8V75C SN Abiraterone (AR inhibitor) DM8V75C DT Small molecular drug DM8V75C PC 132971 DM8V75C MW 349.5 DM8V75C FM C24H31NO DM8V75C IC InChI=1S/C24H31NO/c1-23-11-9-18(26)14-17(23)5-6-19-21-8-7-20(16-4-3-13-25-15-16)24(21,2)12-10-22(19)23/h3-5,7,13,15,18-19,21-22,26H,6,8-12,14H2,1-2H3/t18-,19-,21-,22-,23-,24+/m0/s1 DM8V75C CS C[C@]12CC[C@@H](CC1=CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC=C4C5=CN=CC=C5)C)O DM8V75C IK GZOSMCIZMLWJML-VJLLXTKPSA-N DM8V75C IU (3S,8R,9S,10R,13S,14S)-10,13-dimethyl-17-pyridin-3-yl-2,3,4,7,8,9,11,12,14,15-decahydro-1H-cyclopenta[a]phenanthren-3-ol DM8V75C CA CAS 154229-19-3 DM8V75C CB CHEBI:68642 DM8V75C DE Prostate cancer DMANBZI ID DMANBZI DMANBZI DN Abiraterone acetate DMANBZI HS Approved DMANBZI SN CB-7630; JNJ-212082; Zytiga DMANBZI TC Anticancer Agents DMANBZI DT Small molecular drug DMANBZI PC 9821849 DMANBZI MW 391.5 DMANBZI FM C26H33NO2 DMANBZI IC InChI=1S/C26H33NO2/c1-17(28)29-20-10-12-25(2)19(15-20)6-7-21-23-9-8-22(18-5-4-14-27-16-18)26(23,3)13-11-24(21)25/h4-6,8,14,16,20-21,23-24H,7,9-13,15H2,1-3H3/t20-,21-,23-,24-,25-,26+/m0/s1 DMANBZI CS CC(=O)O[C@H]1CC[C@@]2([C@H]3CC[C@]4([C@H]([C@@H]3CC=C2C1)CC=C4C5=CN=CC=C5)C)C DMANBZI IK UVIQSJCZCSLXRZ-UBUQANBQSA-N DMANBZI IU [(3S,8R,9S,10R,13S,14S)-10,13-dimethyl-17-pyridin-3-yl-2,3,4,7,8,9,11,12,14,15-decahydro-1H-cyclopenta[a]phenanthren-3-yl] acetate DMANBZI CA CAS 154229-18-2 DMANBZI CB CHEBI:68639 DMANBZI DE Prostate cancer DMZT2P0 ID DMZT2P0 DMZT2P0 DN Abobotulinum toxin A DMZT2P0 HS Approved DMZT2P0 SN AbobotulinumtoxinA; Azzalure; Dysport; Reloxin; Abobotulinum toxin A for injection; CNT-52120 DMZT2P0 CP Ipsen DMZT2P0 DE Cervical cancer DM7GCVW ID DM7GCVW DM7GCVW DN Acalabrutinib DM7GCVW HS Approved DM7GCVW SN Calquence; UNII-I42748ELQW; I42748ELQW; Acalabrutinib [INN]; Acalabrutinib [USAN:INN]; Calquence (TN); Acalabrutinib(ACP196); Acalabrutinib (ACP-196); GTPL8912; Acalabrutinib (JAN/USAN/INN); SCHEMBL14637368; EX-A881; WDENQIQQYWYTPO-IBGZPJMESA-N; KS-000006AT; KS-000006AD; s8116; BDBM50175583; AKOS030526094; ZINC208774715; DB11703; CS-5356; DS-3326 DM7GCVW CP AstraZeneca/Acerta Pharma DM7GCVW PC 71226662 DM7GCVW MW 465.5 DM7GCVW FM C26H23N7O2 DM7GCVW IC InChI=1S/C26H23N7O2/c1-2-6-21(34)32-15-5-7-19(32)25-31-22(23-24(27)29-14-16-33(23)25)17-9-11-18(12-10-17)26(35)30-20-8-3-4-13-28-20/h3-4,8-14,16,19H,5,7,15H2,1H3,(H2,27,29)(H,28,30,35)/t19-/m0/s1 DM7GCVW CS CC#CC(=O)N1CCC[C@H]1C2=NC(=C3N2C=CN=C3N)C4=CC=C(C=C4)C(=O)NC5=CC=CC=N5 DM7GCVW IK WDENQIQQYWYTPO-IBGZPJMESA-N DM7GCVW IU 4-[8-amino-3-[(2S)-1-but-2-ynoylpyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1-yl]-N-pyridin-2-ylbenzamide DM7GCVW CA CAS 1420477-60-6 DM7GCVW DE Chronic lymphocytic leukaemia; Mantle cell lymphoma DMO381I ID DMO381I DMO381I DN Acamprosate DMO381I HS Approved DMO381I SN AOTA; Acamprosato; Acamprosatum; Acamprostate; Aotal; Campral; Calcium acetyl homotaurinate; Calcium acetylhomotaurinate; Calcium acetylhomotaurine; Sodium acetylhomotaurine; Acamprosate 6473; Acamprosate (Campral); Acamprosate (INN); Acamprosate [INN:BAN]; Acamprosato [INN-Spanish]; Acamprosatum [INN-Latin]; Aotal (TN); Campral (TN); N-Acetylhomotaurine; 3-(Acetylamino)propanesulphonic acid; 3-Acetamido-1-propanesulfonic acid; 3-acetamidopropane-1-sulfonic acid DMO381I TC Alcohol Deterrents DMO381I DT Small molecular drug DMO381I PC 71158 DMO381I MW 181.21 DMO381I FM C5H11NO4S DMO381I IC InChI=1S/C5H11NO4S/c1-5(7)6-3-2-4-11(8,9)10/h2-4H2,1H3,(H,6,7)(H,8,9,10) DMO381I CS CC(=O)NCCCS(=O)(=O)O DMO381I IK AFCGFAGUEYAMAO-UHFFFAOYSA-N DMO381I IU 3-acetamidopropane-1-sulfonic acid DMO381I CA CAS 77337-76-9 DMO381I CB CHEBI:51041 DMO381I DE Alcohol dependence DMRM3AW ID DMRM3AW DMRM3AW DN Acarbose DMRM3AW HS Approved DMRM3AW SN acarbose; 56180-94-0; Glucobay; Precose; Prandase; C25H43NO18; CHEBI:2376; CHEMBL3734896; BAY-g 5421; 4,6-dideoxy-4-{[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-en-1-yl]amino}-alpha-D-glucopyranosyl-(1->4)-alpha-D-glucopyranosyl-(1->4)-D-glucopyranose; SMR000466376; SR-01000759407; Acarbose/; Acarbose [USAN:BAN:INN:JAN]; Acarbose,(S); Precose (TN); AC1L26GM; Acarbose (JAN/USAN/INN); MLS006011898; MLS000759506; MLS001424056; SPECTRUM1505172; SCHEMBL5316305; CHEMBL404271; BDBM23406; MolPort-002-507-369 DMRM3AW CP Bayer DMRM3AW TC Hypoglycemic Agents DMRM3AW DT Small molecular drug DMRM3AW PC 41774 DMRM3AW MW 645.6 DMRM3AW FM C25H43NO18 DMRM3AW IC InChI=1S/C25H43NO18/c1-6-11(26-8-2-7(3-27)12(30)15(33)13(8)31)14(32)19(37)24(40-6)43-22-10(5-29)42-25(20(38)17(22)35)44-21-9(4-28)41-23(39)18(36)16(21)34/h2,6,8-39H,3-5H2,1H3/t6-,8+,9-,10-,11-,12-,13+,14+,15+,16-,17-,18-,19-,20-,21-,22-,23?,24-,25-/m1/s1 DMRM3AW CS C[C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)O[C@@H]2[C@H](O[C@@H]([C@@H]([C@H]2O)O)O[C@@H]3[C@H](OC([C@@H]([C@H]3O)O)O)CO)CO)O)O)N[C@H]4C=C([C@H]([C@@H]([C@H]4O)O)O)CO DMRM3AW IK XUFXOAAUWZOOIT-UGEKTDRHSA-N DMRM3AW IU (3R,4R,5S,6R)-5-[(2R,3R,4R,5S,6R)-5-[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-en-1-yl]amino]oxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,4-triol DMRM3AW CA CAS 56180-94-0 DMRM3AW CB CHEBI:2376 DMRM3AW DE Diabetic complication; Cardiovascular disease DM0TI4U ID DM0TI4U DM0TI4U DN Acebutolol DM0TI4U HS Approved DM0TI4U SN Acebrutololum; Acebutololo; Acebutololum; Acetobutolol; Neptal; Prent; Sectral; Acebutolol HCL; RP 21823; Acebrutololum [INN-Latin]; Acebutololum [INN-Latin]; Acetobutolol [INN-Spanish]; Dl-Acebutolol; M & B 17803A; Prent (TN); Sectral (TN); Acebutolol (USAN/INN); Acebutolol [USAN:INN:BAN]; M&B-17803 A; N-(3-Acetyl-4-[2-hydroxy-3-(isopropylamino)propoxy]phenyl)butanamide; N-[3-acetyl-4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]phenyl]butanamide; N-[3-acetyl-4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]butanamide; N-{3-acetyl-4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl}butanamide; (+-)-3'-Acetyl-4'-(2-hydroxy-3-(isopropylamino)propoxy)butyranilide; (+-)-Acebutolol; (+-)-N-(3-Acetyl-4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)phenyl)butanamide; 1-(2-Acetyl-4-n-butyramidophenoxy)-2-hydroxy-3-isopropylaminopropane; 3'-(Acetyl-4'-(2-hydroxy-3-(isopropylamino)propoxy)butyranilide; 3'-Acetyl-4'-(2-hydroxy-3-(isopropylamino)propoxy)butyranilide; 3'-Acetyl-4'-(2-hydroxy-3-isopropylaminopropoxy)butyranilid; 5'-Butyramido-2'-(2-hydroxy-3-isopropylaminopropoxy)acetophenone DM0TI4U CP Promius Pharma Llc DM0TI4U TC Antihypertensive Agents DM0TI4U DT Small molecular drug DM0TI4U PC 1978 DM0TI4U MW 336.4 DM0TI4U FM C18H28N2O4 DM0TI4U IC InChI=1S/C18H28N2O4/c1-5-6-18(23)20-14-7-8-17(16(9-14)13(4)21)24-11-15(22)10-19-12(2)3/h7-9,12,15,19,22H,5-6,10-11H2,1-4H3,(H,20,23) DM0TI4U CS CCCC(=O)NC1=CC(=C(C=C1)OCC(CNC(C)C)O)C(=O)C DM0TI4U IK GOEMGAFJFRBGGG-UHFFFAOYSA-N DM0TI4U IU N-[3-acetyl-4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]butanamide DM0TI4U CA CAS 37517-30-9 DM0TI4U CB CHEBI:2379 DM0TI4U DE Hypertension DMOLNCZ ID DMOLNCZ DMOLNCZ DN ACECLIDINE DMOLNCZ HS Approved DMOLNCZ SN (-)-aceclidine; R-(-)-aceclidine; GTPL288; ZB016005; [(8R)-1-azoniabicyclo[2.2.2]octan-8-yl] acetate DMOLNCZ DT Small molecular drug DMOLNCZ PC 1979 DMOLNCZ MW 169.22 DMOLNCZ FM C9H15NO2 DMOLNCZ IC InChI=1S/C9H15NO2/c1-7(11)12-9-6-10-4-2-8(9)3-5-10/h8-9H,2-6H2,1H3 DMOLNCZ CS CC(=O)OC1CN2CCC1CC2 DMOLNCZ IK WRJPSSPFHGNBMG-UHFFFAOYSA-N DMOLNCZ IU 1-azabicyclo[2.2.2]octan-3-yl acetate DMOLNCZ CA CAS 827-61-2 DMOLNCZ CB CHEBI:93847 DMOLNCZ DE Glaucoma/ocular hypertension DMZDF0B ID DMZDF0B DMZDF0B DN Aceclofenac DMZDF0B HS Approved DMZDF0B SN Airtal; Barracan; Biofenac; Bristaflam; Falcol; Gerbin; Preservex; YT-919 DMZDF0B CP Almirall Prodesfarma SA DMZDF0B DT Small molecular drug DMZDF0B PC 71771 DMZDF0B MW 354.2 DMZDF0B FM C16H13Cl2NO4 DMZDF0B IC InChI=1S/C16H13Cl2NO4/c17-11-5-3-6-12(18)16(11)19-13-7-2-1-4-10(13)8-15(22)23-9-14(20)21/h1-7,19H,8-9H2,(H,20,21) DMZDF0B CS C1=CC=C(C(=C1)CC(=O)OCC(=O)O)NC2=C(C=CC=C2Cl)Cl DMZDF0B IK MNIPYSSQXLZQLJ-UHFFFAOYSA-N DMZDF0B IU 2-[2-[2-(2,6-dichloroanilino)phenyl]acetyl]oxyacetic acid DMZDF0B CA CAS 89796-99-6 DMZDF0B CB CHEBI:31159 DMZDF0B DE Inflammation DMH75KV ID DMH75KV DMH75KV DN Acenocoumarol DMH75KV HS Approved DMH75KV SN Acenocoumarin; Acenocoumarolum; Acenocumarol; Acenocumarolo; Acenocumarolum; Acenokumarin; Ascumar; Minisintrom; Neositron;Nicoumalone; Nicumalon; Nitrovarfarian; Nitrowarfarin; Sincoumar; Sinkumar; Sinthrom; Sinthrome; Sintrom; Sintroma; Syncoumar; Syncumar; Synthrom; Syntrom; Zotil; Acenocoumarol Alliance Brand; Acenocoumarol Novartis Brand; Acenocoumarol [INN]; Acenocumarolo [DCIT]; Acenokumarin [Czech]; Alliance Brand of Acenocoumarol; Ciba Geigy Brand of Acenocoumarol; Mini Sintrom; Novartis Brand of Acenocoumarol; G 23350; Acenocoumarol (INN); Acenocoumarol Ciba-Geigy Brand; Acenocoumarolum [INN-Latin]; Ciba-Geigy Brand of Acenocoumarol; G-23350; Mini-sintrom; Sinthrome (TN); Sintrom (TN); AB-014/25000129; G-23,350; Mini-sintrom (TN); Nitrophenylacetylethyl-4-hydroxycoumarine; 2-hydroxy-3-[1-(4-nitrophenyl)-3-oxobutyl]-4h-chromen-4-one; 2-hydroxy-3-[1-(4-nitrophenyl)-3-oxobutyl]chromen-4-one; 3-(alpha-(4'-Nitrophenyl)-beta-acetylethyl)-4-hydroxycoumarin; 3-(alpha-(p-Nitrophenol)-beta-acetylethyl)-4-hydroxycoumarin; 3-(alpha-Acetonyl-4-nitrobenzyl)-4-hydroxycoumarin; 3-(alpha-Acetonyl-p-nitrobenzyl)-4-hydroxycoumarin; 3-(alpha-Acetonyl-para-nitrobenzyl)-4-hydroxy-coumarin; 3-(alpha-p-Nitrophenyl-beta-acetylethyl)-4-hydroxycoumarin; 4-Hydroxy-3-(1-(4-nitrophenyl)-3-oxobutyl)-2H-1-benzopyran-2-one;4-Hydroxy-3-[1-(4-nitrophenyl)-3-oxobutyl]-2H-chromen-2-one DMH75KV TC Anticoagulants DMH75KV DT Small molecular drug DMH75KV PC 54676537 DMH75KV MW 353.3 DMH75KV FM C19H15NO6 DMH75KV IC InChI=1S/C19H15NO6/c1-11(21)10-15(12-6-8-13(9-7-12)20(24)25)17-18(22)14-4-2-3-5-16(14)26-19(17)23/h2-9,15,22H,10H2,1H3 DMH75KV CS CC(=O)CC(C1=CC=C(C=C1)[N+](=O)[O-])C2=C(C3=CC=CC=C3OC2=O)O DMH75KV IK VABCILAOYCMVPS-UHFFFAOYSA-N DMH75KV IU 4-hydroxy-3-[1-(4-nitrophenyl)-3-oxobutyl]chromen-2-one DMH75KV CA CAS 152-72-7 DMH75KV CB CHEBI:53766 DMH75KV DE Thrombosis DM1SRQT ID DM1SRQT DM1SRQT DN Aceprometazine DM1SRQT HS Approved DM1SRQT SN Aceprometazina; Aceprometazinum; Acepromethazine; Aceprometazina [INN-Spanish]; Aceprometazine [INN:DCF]; Aceprometazinum [INN-Latin]; Mepronizine (TN); KETONE, 10-(2-(DIMETHYLAMINO)PROPYL)PHENOTHIAZIN-2-YL METHYL; Ethanone, 1-(10-(2-(dimethylamino)propyl)-10H-phenothiazin-2-yl)-(9CI); 1-(10-(2-(Dimethylamino)propyl)-10H-phenothiazin-2-yl)ethanone; 1-[10-[2-(dimethylamino)propyl]phenothiazin-2-yl]ethanone; 1-{10-[2-(dimethylamino)propyl]-10H-phenothiazin-2-yl}ethanone; 10-(2-(Dimethylamino)propyl)phenothiazin-2-yl methyl ketone; 1664 CB DM1SRQT TC Antihistamines DM1SRQT DT Small molecular drug DM1SRQT PC 26035 DM1SRQT MW 326.5 DM1SRQT FM C19H22N2OS DM1SRQT IC InChI=1S/C19H22N2OS/c1-13(20(3)4)12-21-16-7-5-6-8-18(16)23-19-10-9-15(14(2)22)11-17(19)21/h5-11,13H,12H2,1-4H3 DM1SRQT CS CC(CN1C2=CC=CC=C2SC3=C1C=C(C=C3)C(=O)C)N(C)C DM1SRQT IK XLOQNFNTQIRSOX-UHFFFAOYSA-N DM1SRQT IU 1-[10-[2-(dimethylamino)propyl]phenothiazin-2-yl]ethanone DM1SRQT CA CAS 13461-01-3 DM1SRQT CB CHEBI:53770 DM1SRQT DE Sleep-wake disorder DMUIE76 ID DMUIE76 DMUIE76 DN Acetaminophen DMUIE76 HS Approved DMUIE76 SN acetaminophen; 4-Acetamidophenol; Paracetamol; 103-90-2; Tylenol; N-(4-Hydroxyphenyl)acetamide; APAP; Acetaminofen; Panadol; Datril; p-Hydroxyacetanilide; N-Acetyl-p-aminophenol; p-Acetamidophenol; Algotropyl; Naprinol; Lonarid; 4'-Hydroxyacetanilide; Multin; Acenol; Acamol; Anelix; p-Acetaminophenol; Liquagesic; Acetagesic; Gelocatil; Servigesic; Acetalgin; Abensanil; Pyrinazine; Injectapap; Clixodyne; Valgesic; Tussapap; Finimal; Paracet; Homoolan; Febrolin; Febrilix; Febridol; Dymadon; Anaflon; Apamide; Valadol; Tralgon; Tabalgin; Lestemp; Alvedon; Abenol; Abrol; Abrolet; Acephen; Acertol; Acetaco; Acetamol; Acetavance; Acetofen; Actamin; Actimol; Afebrin; Afebryl; Aferadol; Algesidal; Algina; Algomol; Alpiny; Alpinyl; Amadil; Aminofen; Analter; Anapap; Andox; Anhiba; Antidol; Anuphen; Apacet; Apadon; Apitrelal; Arfen; Arthralgen; Asetam; Asomal; Aspac; Asplin; Atasol; Atralidon; Babikan; Bacetamol; Banesin; Benmyo; Biocetamol; Cadafen; Calapol; Calmanticold; Calonal; Calpol; Capital; Captin; Causalon; Cefalex; Cetadol; Codabrol; Codalgin; Codapane; Codicet; Codisal; Codoliprane; Cofamol; Conacetol; Cosutone; Cuponol; Curadon; Curpol; Custodial; Dafalgan; Darocet; Darvocet; Daygrip; Deminofen; Democyl; Demogripal; Desfebre; Dhamol; Dimindol; Dirox; Disprol; Dolcor; Dolefin; Dolegrippin; Dolgesic; Doliprane; Dolko; Dolofugin; Doloreduct; Dolorfug; Dolorstop; Dolotec; Dolprone; Dorocoff; Dresan; Dristancito; Duaneo; Dularin; Duorol; Duracetamol; Durapan; Dypap; Ecosetol; Elixodyne; Empracet; Enelfa; Eneril; Excipain; Exdol; Fanalgic; Farmadol; Febranine; Febrectal; Febrectol; Febrex; Febricet; Febrin; Febrinol; Fendon; Fensum; Fepanil; Fevor; Finiweh; Fluparmol; Geluprane; Genapap; Genebs; Grippostad; Gynospasmine; Hedex; Ildamol; Inalgex; Infadrops; Janupap; Kataprin; Korum; Labamol; Lekadol; Lemgrip; Lemsip; Liqiprine; Lupocet; Lyteca; Magnidol; Malgis; Malidens; Maxadol; Medocodene; Mexalen; Minafen; Minoset; Miralgin; Momentum; NEBS; Napafen; Nealgyl; NeoCitran; Neodol; Neodolito; Neopap; Neotrend; Neuridon; NilnOcen; Nina; Nobedon; Nodolex; Noral; Ofirmev; Oltyl; Oralgan; Ortensan; Oxycocet; Paceco; Pacemo; Pacemol; Pacet; Pacimol; Paedialgon; Paedol; Painex; Paldesic; Pamol; Panacete; Panadeine; Panadiene; Panaleve; Panamax; Panasorb; Panasorbe; Panets; Panex; Panodil; Panofen; Pantalgin; Paracemol; Paracenol; Paracetamole; Paracetamolo; Paracetanol; Paracetol; Paracin; Paracod; Paracodol; Parador; Paradrops; Parakapton; Parake; Paralen; Paralief; Paralink; Paralyoc; Paramol; Paramolan; Paranox; Parapan; Parasedol; Parasin; Paraspen; Parcetol; Parelan; Parmol; Parogal; Paroma; Pasolind; Pediapirin; Pediatrix; Pedric; Perfalgan; Phendon; Phenipirin; Phogoglandin; Pinex; Piramin; Pirinasol; Plicet; Polmofen; Predimol; Predualito; Prodol; Prompt; Prontina; Puernol; Pulmofen; Pyrigesic; Pyromed; Redutemp; Reliv; Remedol; Rivalgyl; Robigesic; Rounox; RubieMol; Rubophen; Rupemol; Salzone; Sanicet; Sanicopyrine; Scanol; Scentalgyl; Schmerzex; Sedalito; Semolacin; Seskamol; Setakop; Setamol; Setol; Sifenol; Sinaspril; Sinedol; Sinmol; Stanback; Stopain; Sunetheton; Supofen; Suppap; TYL; Tachiprina; Tapanol; Tapar; Tazamol; Temlo; Tempanal; Tempra; Termacet; Termalgin; Termalgine; Termofren; Tiffy; Titralgan; Treuphadol; Tricoton; Tylex; Tylol; Tymol; Upsanol; Utragin; Valorin; Veralgina; Vermidon; Verpol; Vips; Viruflu; Vivimed; Volpan; Zatinol; Zolben; Aceta Elixir; Actifed Plus; Aspirin free anacin; Bayer Select; D oliprane; Dymadon Co; Fortalidon P; Gattaphen T; Gripin Bebe; Helon N; Influbene N; Jin Gang; Lonarid Mono; Lyteca Syrup; Malex N; Panadeine Co; Panale ve; Pasolind N; Spalt N; Supadol mono; Toximer P; Treupel N; Treupel mon; Ty lenol; Tylex CD; Anacin 3; A-Per; Accu-Tap; Ultracet DMUIE76 CP Beximco Pharma DMUIE76 TC Analgesics DMUIE76 DT Small molecular drug DMUIE76 PC 1983 DMUIE76 MW 151.16 DMUIE76 FM C8H9NO2 DMUIE76 IC InChI=1S/C8H9NO2/c1-6(10)9-7-2-4-8(11)5-3-7/h2-5,11H,1H3,(H,9,10) DMUIE76 CS CC(=O)NC1=CC=C(C=C1)O DMUIE76 IK RZVAJINKPMORJF-UHFFFAOYSA-N DMUIE76 IU N-(4-hydroxyphenyl)acetamide DMUIE76 CA CAS 103-90-2 DMUIE76 CB CHEBI:46195 DMUIE76 DE Pain DM1AF5U ID DM1AF5U DM1AF5U DN Acetazolamide DM1AF5U HS Approved DM1AF5U SN Acetadiazol; Acetamidothiadiazolesulfonamide; Acetamox; Acetazolam; Acetazolamid; Acetazolamida; Acetazolamidum; Acetazolamine; Acetazoleamide; Acetozalamide; AkZol; ApoAcetazolamide; Atenezol; Cidamex; Dazamide; Defiltran; Dehydratin; Diacarb; Diakarb; Diamox; Didoc; Diluran; Diuramid; Diuramide; Diuriwas; Diutazol; Donmox; Duiramid; Edemox; Eumicton; Fonurit; Glauconox; Glaumox; Glaupax; Glupax; HumaZolamide; Natrionex; Nephramid; Nephramide; Phonurit; Storzolamide; Vetamox; Acetazolamide Apotex Brand; Acetazolamide Chiesi Brand; Acetazolamide Dioptic Brand; Acetazolamide Grin Brand; Acetazolamide ICN Brand; Acetazolamide Jumer Brand; Acetazolamide Llorens Brand; Acetazolamide Medphano Brand; Acetazolamide Novopharm Brand; Acetazolamide Orion Brand; Acetazolamide Wassermann Brand; Ak Zol; Apo Acetazolamide; Apotex Brand of Acetazolamide; Chiesi Brand of Acetazolamide; Ciba Vision Brand of Acetazolamide; DiamoxSequels; Dioptic Brand of Acetazolamide; Grin Brand of Acetazolamide; Huma Zolamide; ICN Brand of Acetazolamide; Jumer Brand of Acetazolamide; Llorens Brand of Acetazolamide; Medphano Brand of Acetazolamide; Monosodium Salt Acetazolamide; Novopharm Brand of Acetazolamide; Orion Brand of Acetazolamide; Storz Brand of Acetazolamide Preparation; Wassermann Brand of Acetazolamide; Wyeth Brand of Acetazolamide Preparation; A 6011; Carbonic anhydrase inhibitor 6063; Acetazolamida [INN-Spanish]; Acetazolamide (AAZ); Acetazolamide, Monosodium Salt; Acetazolamidum [INN-Latin]; Ak-Zol; Apo-Acetazolamide; Carbonic Anhydrase Inhibitor No. 6063; Diamox (TN); Diureticum-holzinger; Huma-Zolamide; SK-acetazolamide; Acetazolamide Sodium, (Sterile); Acetazolamide [INN:BAN:JAN]; Acetazolamide (JP15/USP/INN); 4-Diamox DM1AF5U TC Anticonvulsants DM1AF5U DT Small molecular drug DM1AF5U PC 1986 DM1AF5U MW 222.3 DM1AF5U FM C4H6N4O3S2 DM1AF5U IC InChI=1S/C4H6N4O3S2/c1-2(9)6-3-7-8-4(12-3)13(5,10)11/h1H3,(H2,5,10,11)(H,6,7,9) DM1AF5U CS CC(=O)NC1=NN=C(S1)S(=O)(=O)N DM1AF5U IK BZKPWHYZMXOIDC-UHFFFAOYSA-N DM1AF5U IU N-(5-sulfamoyl-1,3,4-thiadiazol-2-yl)acetamide DM1AF5U CA CAS 59-66-5 DM1AF5U CB CHEBI:27690 DM1AF5U DE Glaucoma/ocular hypertension DM4SJ5Y ID DM4SJ5Y DM4SJ5Y DN Acetic Acid, Glacial DM4SJ5Y HS Approved DM4SJ5Y SN ethanoic acid; 64-19-7; Ethylic acid; Acetic acid glacial; Acetic acid, glacial; Methanecarboxylic acid; Glacial acetic acid; Vinegar acid; Acetasol; Acide acetique; Essigsaeure; Aci-jel; Azijnzuur; Vinegar; Kyselina octova; Acido acetico; Octowy kwas; Pyroligneous acid; HOAc; Azijnzuur [Dutch]; Ethanoic acid monomer; acetyl alcohol; Aceticum acidum; Essigsaeure [German]; ethoic acid; Caswell No 003; Otic Tridesilon; Octowy kwas [Polish]; Otic Domeboro; Acetic acid (natural); Kyselina octova [Czech]; Acide acetique [French]; Orlex; Vosol; Acetic Acid 025% In Plastic Container DM4SJ5Y CP Actavis Mid Atlantic Llc DM4SJ5Y TC Antiinfective Agents DM4SJ5Y DT Small molecular drug DM4SJ5Y PC 176 DM4SJ5Y MW 60.05 DM4SJ5Y FM C2H4O2 DM4SJ5Y IC InChI=1S/C2H4O2/c1-2(3)4/h1H3,(H,3,4) DM4SJ5Y CS CC(=O)O DM4SJ5Y IK QTBSBXVTEAMEQO-UHFFFAOYSA-N DM4SJ5Y IU acetic acid DM4SJ5Y CA CAS 64-19-7 DM4SJ5Y CB CHEBI:15366 DM4SJ5Y DE infection in the ear canal DMR6N7H ID DMR6N7H DMR6N7H DN Acetohexamide DMR6N7H HS Approved DMR6N7H SN Acetohexamid; Acetohexamida; Acetohexamidum; Dimelin; Dimelor; Dymelor; Gamadiabet; Hypoglicil; Metaglucina; Minoral; Ordimel; Tsiklamid; Acetohexamide Lilly Brand; Acetohexamide Salvat Brand; Lilly Brand of Acetohexamide; Ord imel; Salvat Brand of Acetohexamide; U 14812; A-178; Acetohexamida [INN-Spanish]; Acetohexamidum [INN-Latin]; Dimelin (antidiabetic); Dymelor (TN); U-14812; Acetohexamide (JP15/USP/INN); Acetohexamide [USAN:INN:BAN:JAN]; N-(p-Acetylbenzenesulfonyl)-N'-cyclohexylurea; N-(p-Acetylphenylsulfonyl)-N'-cyclohexylurea; 1-((p-Acetylphenyl)sulfonyl)-3-cyclohexylurea; 1-(4-acetylphenyl)sulfonyl-3-cyclohexylurea; 1-(p-Acetylbenzenesulfonyl)-3-cyclohexylurea; 3-cyclohexyl-1-(p-acetylphenylsulfonyl)urea; 4-Acetyl-N-((cyclohexylamino)carbonyl)benzenesulfonamide; 4-Acetyl-N-[(cyclohexylamino)-carbonyl]benzenesulfonamide; 4-Acetyl-N-[(cyclohexylamino)carbonyl]benzenesulfonamide; 4-acetyl-N-((cyclohexylamino)carbonyl)benzenesulf onamide DMR6N7H TC Hypoglycemic Agents DMR6N7H DT Small molecular drug DMR6N7H PC 1989 DMR6N7H MW 324.4 DMR6N7H FM C15H20N2O4S DMR6N7H IC InChI=1S/C15H20N2O4S/c1-11(18)12-7-9-14(10-8-12)22(20,21)17-15(19)16-13-5-3-2-4-6-13/h7-10,13H,2-6H2,1H3,(H2,16,17,19) DMR6N7H CS CC(=O)C1=CC=C(C=C1)S(=O)(=O)NC(=O)NC2CCCCC2 DMR6N7H IK VGZSUPCWNCWDAN-UHFFFAOYSA-N DMR6N7H IU 1-(4-acetylphenyl)sulfonyl-3-cyclohexylurea DMR6N7H CA CAS 968-81-0 DMR6N7H CB CHEBI:28052 DMR6N7H DE Diabetic complication DMYX7NI ID DMYX7NI DMYX7NI DN Acetohydroxamic Acid DMYX7NI HS Approved DMYX7NI SN AHA; Acethydroxamsaeure; Acethydroxamsaure; Acetohydroxamate; HAE; Lithostat; Acethydroxamic acid; Acethydroxamsaeure [German]; Acetohydroximic acid; Acetyl hydroxyamino; Acetylhydroxamic acid; Acide acetohydroxamique; Acide acetohydroxamique [French]; Acido acetohidroxamico; Acido acetohidroxamico [Spanish]; Acidum acetohydroxamicum; Acidum acetohydroxamicum [Latin]; Cetohyroxamic acid; Methylhydroxamic acid; SJX HLdmMAH; AHA (TN); Acetic acid, oxime; Acetohydroxamic acid [USAN:INN]; Lithostat (TN); N-Acetyl hydroxyacetamide; N-Acetylhydroxylamine; N-Hydroxyacetamide; N-hydroxyacetimidic acid; N-hydroxyethanimidic acid; S14-0751; Acetohydroxamic acid (USP/INN); Acetamide, N-hydroxy-(9CI) DMYX7NI TC Antiinfective Agents DMYX7NI DT Small molecular drug DMYX7NI PC 1990 DMYX7NI MW 75.07 DMYX7NI FM C2H5NO2 DMYX7NI IC InChI=1S/C2H5NO2/c1-2(4)3-5/h5H,1H3,(H,3,4) DMYX7NI CS CC(=O)NO DMYX7NI IK RRUDCFGSUDOHDG-UHFFFAOYSA-N DMYX7NI IU N-hydroxyacetamide DMYX7NI CA CAS 546-88-3 DMYX7NI CB CHEBI:27777 DMYX7NI DE Urinary tract infection DMZV2PJ ID DMZV2PJ DMZV2PJ DN Acetophenazine DMZV2PJ HS Approved DMZV2PJ SN Acephenazinum; Acetophenazina; Acetophenazinum; Tindal; Acetophenazine [INN]; Acetophenazina [INN-Spanish]; Acetophenazinum [INN-Latin]; Ketone, 10-(3-(4-(2-hydroxyethyl-1-piperazinyl)propyl)phenothiazin-2-yl methyl; 1-(10-{3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl}-10H-phenothiazin-2-yl)ethanone; 1-[10-[3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl]phenothiazin-2-yl]ethanone; 10-(3-(4-(2-Hydroxyethyl)-1-piperazinyl)propyl)phenothiazin-2-yl methyl ketone; 2-acetyl-10-[3-[4-(b-hydroxyethyl)piperazinyl]propyl]phenothiazine DMZV2PJ TC Antipsychotic Agents DMZV2PJ DT Small molecular drug DMZV2PJ PC 17676 DMZV2PJ MW 411.6 DMZV2PJ FM C23H29N3O2S DMZV2PJ IC InChI=1S/C23H29N3O2S/c1-18(28)19-7-8-23-21(17-19)26(20-5-2-3-6-22(20)29-23)10-4-9-24-11-13-25(14-12-24)15-16-27/h2-3,5-8,17,27H,4,9-16H2,1H3 DMZV2PJ CS CC(=O)C1=CC2=C(C=C1)SC3=CC=CC=C3N2CCCN4CCN(CC4)CCO DMZV2PJ IK WNTYBHLDCKXEOT-UHFFFAOYSA-N DMZV2PJ IU 1-[10-[3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl]phenothiazin-2-yl]ethanone DMZV2PJ CA CAS 2751-68-0 DMZV2PJ CB CHEBI:2401 DMZV2PJ DE Bipolar disorder DMDF79Z ID DMDF79Z DMDF79Z DN Acetylcholine DMDF79Z HS Approved DMDF79Z SN acetylcholine; Choline acetate; O-Acetylcholine; Acetyl choline ion; Acetylcholinum; 51-84-3; (2-Acetoxyethyl)trimethylammonium; Acetyl choline cation; Choline acetate (ester); 2-(Acetyloxy)-N,N,N-trimethylethanaminium; Ach; Azetylcholin; ethanaminium, 2-(acetyloxy)-N,N,N-trimethyl-; UNII-N9YNS0M02X; BRN 1764436; CHEBI:15355; Bromoacetylcholine; EINECS 200-128-9; CHEMBL667; N9YNS0M02X; [2-(acetyloxy)ethyl]trimethylazanium; Ethanaminium, 2-(acetyloxy)-N,N,N-trimethyl- (9CI); 2-acetyloxyethyl-trimethylazanium; [3H]acetylcholine; Miochol; Miochol-e DMDF79Z CP Novartis Pharmaceuticals Corp DMDF79Z TC Cardiovascular Agents DMDF79Z DT Small molecular drug DMDF79Z PC 187 DMDF79Z MW 146.21 DMDF79Z FM C7H16NO2+ DMDF79Z IC InChI=1S/C7H16NO2/c1-7(9)10-6-5-8(2,3)4/h5-6H2,1-4H3/q+1 DMDF79Z CS CC(=O)OCC[N+](C)(C)C DMDF79Z IK OIPILFWXSMYKGL-UHFFFAOYSA-N DMDF79Z IU 2-acetyloxyethyl(trimethyl)azanium DMDF79Z CA CAS 51-84-3 DMDF79Z CB CHEBI:15355 DMDF79Z DE Cataract DMHAUO0 ID DMHAUO0 DMHAUO0 DN Acetyldigitoxin DMHAUO0 HS Approved DMHAUO0 SN Acedigal; Acetildigitoxina; Acetyldiginatin; Acetyldigitoxinum; Acigoxin; Acylanid; Acylanide; Adicin; Acetyldigitoxin [INN]; Desglucolanatoside A; Acetildigitoxina [INN-Spanish]; Acetyldigitoxin (INN); Acetyldigitoxinum [INN-Latin]; Acylanid (TN); Alpha-Acetyldigitoxin; Alpha-Acetyldigitoxins; Alpha-Monoacetyldigitoxin; Acetyl-digitoxin-alpha; Digitoxin 3'''-acetate; Digitoxin, 3'''-acetate; (3beta,5beta)-3-((O-3-O-Acetyl-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl)oxy)-14-hydroxycard-20(22)-enolide; (3beta,5beta)-3-((O-3-O-Acetyl-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl)oxy)-14-hydroxycard-20(22)-enolide; (3beta,5beta)-3-{[3-O-acetyl-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl]oxy}-14-hydroxycard-20(22)-enolide; 3beta-[3-O-acetyl-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyloxy]-14-hydroxy-5beta-card-20(22)-enolide; [3-hydroxy-6-[4-hydroxy-6-[4-hydroxy-6-[[14-hydroxy-10,13-dimethyl-17-(5-oxo-2H-furan-3-yl)-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-yl]oxy]-2-methyloxan-3-yl]oxy-2-methyloxan-3-yl]oxy-2-methyloxan-4-yl] acetate DMHAUO0 CP Norvatis Phamaceuticals Corporation DMHAUO0 TC Cardiotonic Agents DMHAUO0 DT Small molecular drug DMHAUO0 PC 5284512 DMHAUO0 MW 807 DMHAUO0 FM C43H66O14 DMHAUO0 IC InChI=1S/C43H66O14/c1-21-38(48)33(54-24(4)44)19-37(51-21)57-40-23(3)53-36(18-32(40)46)56-39-22(2)52-35(17-31(39)45)55-27-9-12-41(5)26(16-27)7-8-30-29(41)10-13-42(6)28(11-14-43(30,42)49)25-15-34(47)50-20-25/h15,21-23,26-33,35-40,45-46,48-49H,7-14,16-20H2,1-6H3/t21-,22-,23-,26-,27+,28-,29+,30-,31+,32+,33+,35+,36+,37+,38-,39-,40-,41+,42-,43+/m1/s1 DMHAUO0 CS C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5CC[C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)C)C)C)OC(=O)C)O DMHAUO0 IK HPMZBILYSWLILX-UMDUKNJSSA-N DMHAUO0 IU [(2R,3R,4S,6S)-3-hydroxy-6-[(2R,3S,4S,6S)-4-hydroxy-6-[(2R,3S,4S,6R)-4-hydroxy-6-[[(3S,5R,8R,9S,10S,13R,14S,17R)-14-hydroxy-10,13-dimethyl-17-(5-oxo-2H-furan-3-yl)-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-yl]oxy]-2-methyloxan-3-yl]oxy-2-methyloxan-3-yl]oxy-2-methyloxan-4-yl] acetate DMHAUO0 CA CAS 1111-39-3 DMHAUO0 CB CHEBI:53773 DMHAUO0 DE Congestive heart failure DMYLOVR ID DMYLOVR DMYLOVR DN Aciclovir DMYLOVR HS Approved DMYLOVR SN acyclovir; Acycloguanosine; 59277-89-3; Zovirax; Vipral; Virorax; Wellcome-248U; 9-[(2-Hydroxyethoxy)methyl]guanine; Aciclovirum; Zovir; Aciclovirum [Latin]; Sitavig; Aciclovier; Zyclir; 9-HYROXYETHOXYMETHYLGUANINE; Aciclovirum [INN-Latin]; 2-Amino-9-((2-hydroxyethoxy)methyl)-1H-purin-6(9H)-one; W-248-U; 9-(2-Hydroxyethoxy)methylguanine; Acyclovir-side chain-2-3H; ACYCLOVIR SODIUM; 9-((2-Hydroxyethoxy)methyl)guanine; Acicloftal; Cargosil; BW-248U; UNII-X4HES1O11F; DRG-0008; NSC 645011; CHEBI:2453; CCRIS 1953; Iontophoretic acyclovir DMYLOVR CP GlaxoSmithKline DMYLOVR TC Antiviral Agents DMYLOVR DT Small molecular drug DMYLOVR PC 135398513 DMYLOVR MW 225.2 DMYLOVR FM C8H11N5O3 DMYLOVR IC InChI=1S/C8H11N5O3/c9-8-11-6-5(7(15)12-8)10-3-13(6)4-16-2-1-14/h3,14H,1-2,4H2,(H3,9,11,12,15) DMYLOVR CS C1=NC2=C(N1COCCO)N=C(NC2=O)N DMYLOVR IK MKUXAQIIEYXACX-UHFFFAOYSA-N DMYLOVR IU 2-amino-9-(2-hydroxyethoxymethyl)-1H-purin-6-one DMYLOVR CA CAS 59277-89-3 DMYLOVR CB CHEBI:2453 DMYLOVR DE Virus infection; Herpes simplex virus infection DM8BKU9 ID DM8BKU9 DM8BKU9 DN Acitretin DM8BKU9 HS Approved DM8BKU9 SN Acitretina; Acitretine; Acitretinum; Etretin; Isoacitretin; Isoetretin; Neotigason; Soriatane; TMMP; Acitretina [Spanish]; Acitretine [French]; Acitretinum [Latin]; Retinoid etretin; U0279; Ro 10-1670; Ro 13-7652; Soriatane (TN); Soriatane, Acitretin; Acitretin (USAN/INN); Acitretin [USAN:INN:BAN]; All-trans-Acitretin; Ro 10-1670/000; Ro-10-1670; Ro-13-7652; Ro-10-1670/000; All-trans-3,7-Dimethyl-9-(4-methoxy-2,3,6-trimethylphenyl)-2,4,6,8-nonatetraenoic acid; (2E,4E,6E,8E)-3,7-dimethyl-9-[2,3,6-trimethyl-4-(methyloxy)phenyl]nona-2,4,6,8-tetraenoic acid; (2E,4E,6E,8E)-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoic acid; (all-E)-9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic acid; 13-cis-Acitretin; 9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic acid; 9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoic acid DM8BKU9 TC Keratolytic Agents DM8BKU9 DT Small molecular drug DM8BKU9 PC 5284513 DM8BKU9 MW 326.4 DM8BKU9 FM C21H26O3 DM8BKU9 IC InChI=1S/C21H26O3/c1-14(8-7-9-15(2)12-21(22)23)10-11-19-16(3)13-20(24-6)18(5)17(19)4/h7-13H,1-6H3,(H,22,23)/b9-7+,11-10+,14-8+,15-12+ DM8BKU9 CS CC1=CC(=C(C(=C1/C=C/C(=C/C=C/C(=C/C(=O)O)/C)/C)C)C)OC DM8BKU9 IK IHUNBGSDBOWDMA-AQFIFDHZSA-N DM8BKU9 IU (2E,4E,6E,8E)-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoic acid DM8BKU9 CA CAS 55079-83-9 DM8BKU9 CB CHEBI:50173 DM8BKU9 DE Psoriasis vulgaris DMLFZHD ID DMLFZHD DMLFZHD DN Aclarubicin DMLFZHD HS Approved DMLFZHD SN Aclacin; Aclacur; Aclarubicine; Aclarubicino; Aclarubicinum; Jaclacin; Aclacinomycin A; Aclucinomycin A; Antibiotic MA 144A; Antibiotic MA 144A1; Antibiotic MA 144G1; MA 144G1; Aclarubicine [INN-French]; Aclarubicino [INN-Spanish]; Aclarubicinum [INN-Latin]; Antibiotic MA144-A1; MA 144-A1; MA-144A1; Acene-1-carboxylate; Aclarubicin (USAN/INN); Aclarubicin [USAN:BAN:INN]; Alpha-L-lyxo-hexopyranosyl]-oxy]-1-naphthacenecarboxalic acid methyl ester; 10-epi-Aclacinomycin A DMLFZHD TC Anticancer Agents DMLFZHD DT Small molecular drug DMLFZHD PC 451415 DMLFZHD MW 811.9 DMLFZHD FM C42H53NO15 DMLFZHD IC InChI=1S/C42H53NO15/c1-8-42(51)17-28(33-22(35(42)41(50)52-7)14-23-34(38(33)49)37(48)32-21(36(23)47)10-9-11-26(32)45)56-30-15-24(43(5)6)39(19(3)54-30)58-31-16-27(46)40(20(4)55-31)57-29-13-12-25(44)18(2)53-29/h9-11,14,18-20,24,27-31,35,39-40,45-46,49,51H,8,12-13,15-17H2,1-7H3/t18-,19-,20-,24-,27-,28-,29-,30-,31-,35-,39+,40+,42+/m0/s1 DMLFZHD CS CC[C@]1(C[C@@H](C2=C(C3=C(C=C2[C@H]1C(=O)OC)C(=O)C4=C(C3=O)C(=CC=C4)O)O)O[C@H]5C[C@@H]([C@@H]([C@@H](O5)C)O[C@H]6C[C@@H]([C@@H]([C@@H](O6)C)O[C@H]7CCC(=O)[C@@H](O7)C)O)N(C)C)O DMLFZHD IK USZYSDMBJDPRIF-SVEJIMAYSA-N DMLFZHD IU methyl (1R,2R,4S)-4-[(2R,4S,5S,6S)-4-(dimethylamino)-5-[(2S,4S,5S,6S)-4-hydroxy-6-methyl-5-[(2R,6S)-6-methyl-5-oxooxan-2-yl]oxyoxan-2-yl]oxy-6-methyloxan-2-yl]oxy-2-ethyl-2,5,7-trihydroxy-6,11-dioxo-3,4-dihydro-1H-tetracene-1-carboxylate DMLFZHD CA CAS 57576-44-0 DMLFZHD CB CHEBI:77980 DMLFZHD DE Acute myeloid leukaemia DM7JT24 ID DM7JT24 DM7JT24 DN Acocantherin DM7JT24 HS Approved DM7JT24 SN Ouabain; Ouabagenin L-Rhamnoside; Ouabagenin L-rhamnoside; Acocantherin; Acocantherine; Acolongifloroside K; Astrobain; G-Strophanthin; G-Strophanthin (JAN); G-Strophicor; Gratibain; Gratus strophanthin; Kombetin; O 3125; OBN; Ouabagenin-L-rhamnosid; Ouabagenin-L-rhamnosid [German]; Ouabain (anhydrous); Ouabain anhydrous; Ouabain octahydrate; Ouabain, Octahydrate; Ouabaine; Oubain; Purostrophan; Quabain; Rectobaina; Solufantina; Strodival; Strophalen; Strophanthin G; Strophanthin-G; Strophoperm; Strophosan; Uabaina; Uabanin DM7JT24 TC Cardiotonic Agents DM7JT24 DT Small molecular drug DM7JT24 PC 439501 DM7JT24 MW 584.7 DM7JT24 FM C29H44O12 DM7JT24 IC InChI=1S/C29H44O12/c1-13-22(34)23(35)24(36)25(40-13)41-15-8-19(32)28(12-30)21-17(3-5-27(28,37)9-15)29(38)6-4-16(14-7-20(33)39-11-14)26(29,2)10-18(21)31/h7,13,15-19,21-25,30-32,34-38H,3-6,8-12H2,1-2H3/t13-,15-,16+,17+,18+,19+,21+,22-,23+,24+,25-,26+,27-,28+,29-/m0/s1 DM7JT24 CS C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@H]2C[C@H]([C@@]3([C@@H]4[C@@H](CC[C@@]3(C2)O)[C@]5(CC[C@@H]([C@]5(C[C@H]4O)C)C6=CC(=O)OC6)O)CO)O)O)O)O DM7JT24 IK LPMXVESGRSUGHW-HBYQJFLCSA-N DM7JT24 IU 3-[(1R,3S,5S,8R,9S,10R,11R,13R,14S,17R)-1,5,11,14-tetrahydroxy-10-(hydroxymethyl)-13-methyl-3-[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy-2,3,4,6,7,8,9,11,12,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]-2H-furan-5-one DM7JT24 CA CAS 630-60-4 DM7JT24 CB CHEBI:472805 DM7JT24 DE Heart failure; Atrial fibrillation DMTIGA0 ID DMTIGA0 DMTIGA0 DN Acrivastine DMTIGA0 HS Approved DMTIGA0 SN Acrivastin; Acrivastina; Acrivastinum; Semprex; Acrivastina [Spanish]; Acrivastinum [Latin]; Benadryl allergy relief; BW 0270C; BW 825C; BW A825C; BW-825C; Acrivastine (USAN/INN); Acrivastine [USAN:INN:BAN]; E-(9CI); (2E)-3-{6-[(1E)-1-(4-methylphenyl)-3-pyrrolidin-1-ylprop-1-en-1-yl]pyridin-2-yl}prop-2-enoic acid; (E)-3-[6-[(E)-1-(4-methylphenyl)-3-pyrrolidin-1-ylprop-1-enyl]pyridin-2-yl]prop-2-enoic acid; (E)-6-((E)-3-(1-Pyrrolidinyl)-1-p-tolylpropenyl)-2-pyridineacrylic acid; (E)-6-((E)-3-(1-Pyrrolidinyl-1-p-tolylpropenyl)-2-pyridinacrylsaeure; (E,E)-3-[6-[1-(4-methylphenyl)-3-(1-pyrrolidinyl)-1-propenyl]-2-pyridinyl]-2-propenoic acid; 3-{6-[1-(4-methylphenyl)-3-(pyrrolidin-1-yl)prop-1-en-1-yl]pyridin-2-yl}prop-2-enoic acid DMTIGA0 CP Pfizer Pharmaceuticals DMTIGA0 TC Antiinflammatory Agents DMTIGA0 DT Small molecular drug DMTIGA0 PC 5284514 DMTIGA0 MW 348.4 DMTIGA0 FM C22H24N2O2 DMTIGA0 IC InChI=1S/C22H24N2O2/c1-17-7-9-18(10-8-17)20(13-16-24-14-2-3-15-24)21-6-4-5-19(23-21)11-12-22(25)26/h4-13H,2-3,14-16H2,1H3,(H,25,26)/b12-11+,20-13+ DMTIGA0 CS CC1=CC=C(C=C1)/C(=C\\CN2CCCC2)/C3=CC=CC(=N3)/C=C/C(=O)O DMTIGA0 IK PWACSDKDOHSSQD-IUTFFREVSA-N DMTIGA0 IU (E)-3-[6-[(E)-1-(4-methylphenyl)-3-pyrrolidin-1-ylprop-1-enyl]pyridin-2-yl]prop-2-enoic acid DMTIGA0 CA CAS 87848-99-5 DMTIGA0 CB CHEBI:83168 DMTIGA0 DE Allergic rhinitis DMQMV1B ID DMQMV1B DMQMV1B DN Adalimumab DMQMV1B HS Approved DMQMV1B SN Humira; Adalimumab (genetical recombination); Humira (TN); Adalimumab (USAN/INN); Adalimumab (genetical recombination) (JAN) DMQMV1B CP Abbott Laboratories DMQMV1B TC Antirheumatic Agents DMQMV1B DT Antibody DMQMV1B SQ Light chain:: DIQMTQSPSSLSASVGDRVTITCRASQGIRNYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCQRYNRAPYTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC > Heavy chain:EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSAITWNSGHIDYADSVEGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAKVSYLSTASSLDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSC DMQMV1B DE Rheumatoid arthritis DMX2358 ID DMX2358 DMX2358 DN Adapalene DMX2358 HS Approved DMX2358 SN Adaferin; Adapaleno; Adapalenum; Differin; Differine; CD 271; CD271; Adaferin (TN); Adapaleno [INN-Spanish]; Adapalenum [INN-Latin]; CD-271; Differin (TN); Differin, Adapalene; KS-1196; Adapalene [USAN:BAN:INN]; Adapalene (JAN/USAN/INN); 6-(3-(1-Adamantyl)-4-methoxyphenyl)-2-naphthoic acid; 6-(3-adamantan-1-yl-4-methoxyphenyl)naphthalene-2-carboxylic acid; 6-[3-(1-adamantyl)-4-methoxyphenyl]naphthalene-2-carboxylic acid; 6-[3-(adamantan-1-yl)-4-methoxyphenyl]-2-naphthoic acid DMX2358 CP Galderma Laboratories DMX2358 TC Dermatologic Agents DMX2358 DT Small molecular drug DMX2358 PC 60164 DMX2358 MW 412.5 DMX2358 FM C28H28O3 DMX2358 IC InChI=1S/C28H28O3/c1-31-26-7-6-23(21-2-3-22-12-24(27(29)30)5-4-20(22)11-21)13-25(26)28-14-17-8-18(15-28)10-19(9-17)16-28/h2-7,11-13,17-19H,8-10,14-16H2,1H3,(H,29,30) DMX2358 CS COC1=C(C=C(C=C1)C2=CC3=C(C=C2)C=C(C=C3)C(=O)O)C45CC6CC(C4)CC(C6)C5 DMX2358 IK LZCDAPDGXCYOEH-UHFFFAOYSA-N DMX2358 IU 6-[3-(1-adamantyl)-4-methoxyphenyl]naphthalene-2-carboxylic acid DMX2358 CA CAS 106685-40-9 DMX2358 CB CHEBI:31174 DMX2358 DE Acne vulgaris DMM278X ID DMM278X DMM278X DN Adefovir DMM278X HS Approved DMM278X SN ((2-(6-Amino-9H-purin-9-yl)ethoxy)methyl)phosphonic acid; 2-(6-aminopurin-9-yl)ethoxymethylphosphonic acid; 9-(2-(Phosphonomethoxy)ethyl)adenine; 9-(2-Phosphonylmethoxyethyl)adenine; ADEFOVIR; GS 0393; GS 393; GS-0393; N-(2-Phophonomethoxyethyl-2,6-diaminopurine); N-(2-Phosphonylmethoxyethyl)adenine; PMEA; {[2-(6-Amino-9h-Purin-9-Yl)ethoxy]methyl}phosphonic Acid DMM278X DT Small molecular drug DMM278X PC 60172 DMM278X MW 273.189 DMM278X FM C12H14Cl2N2 DMM278X IC InChI=1S/C8H12N5O4P/c9-7-6-8(11-3-10-7)13(4-12-6)1-2-17-5-18(14,15)16/h3-4H,1-2,5H2,(H2,9,10,11)(H2,14,15,16) DMM278X CS C1=NC2=C(C(=N1)N)N=CN2CCOCP(=O)(O)O DMM278X IK FIKAKWIAUPDISJ-UHFFFAOYSA-L DMM278X IU 2-(6-aminopurin-9-yl)ethoxymethylphosphonic acid DMM278X CA CAS 106941-25-7 DMM278X CB CHEBI:2469 DMM278X DE Hepatitis B virus infection; Herpes simplex virus infection DMMAWY1 ID DMMAWY1 DMMAWY1 DN Adefovir dipivoxil DMMAWY1 HS Approved DMMAWY1 SN Adefovirdipivoxl; Hepsera; Preveon; YouHeDing; Adefovir depivoxil; Adefovir pivoxil; GS 0840; GS 840;Piv2PMEA; Adefovir dipivoxil (USAN); Adefovir pivoxil (JAN); Bis(pom)PMEA; Bis-POM PMEA; GS-0840; GS-840; Hepsera (TM); Hepsera (TN); Preveon (TN); Bis(POM)-PMEA; Bis-POM PMEA, Adefovir Dipivoxil; Bis-POM PMEA, Preveon, Hepsera, Adefovir Dipivoxil; Bis(pivaloyloxymethyl)-9-(2-phosphonylmethoxyethyl)adenine; [2-(6-aminopurin-9-yl)ethoxymethyl-(2,2-dimethylpropanoyloxymethoxy)phosphoryl]oxymethyl 2,2-dimethylpropanoate; Propanoic acid,2,2-dimethyl-(((2-(6-amino-9H-purin-9-yl)ehtoxy)mehtyl)phosphinyldiene)bis(oxymehtylene)ester; Propanoic acid, 2,2-dimethyl-, (((2-(6-amino-9H-purin-9-yl)ethoxy)methyl)phosphinylidene)bis(oxymethylene) ester; (((2-(6-Amino-9H-purin-9-yl)ethoxy)methyl)phosphinylidene)bis(oxymethylene) 2,2-dimethylpropanoate; ((2-(6-Amino-9H-purin-9-yl)ethoxy)methyl)phosphonic acid, diester with hydroxymethyl pivalate; 9-(2-((-Bis((pivaloyloxy)methoxy)phosphinyl)methoxy)ethyl)adenine; 9-(2-((Bis((pivaloyloxy)methoxy)phosphinyl)methoxy)ethyl)adenine; ADV DMMAWY1 CP Gilead Sciences DMMAWY1 TC Antiviral Agents DMMAWY1 DT Small molecular drug DMMAWY1 PC 60871 DMMAWY1 MW 501.5 DMMAWY1 FM C20H32N5O8P DMMAWY1 IC InChI=1S/C20H32N5O8P/c1-19(2,3)17(26)30-11-32-34(28,33-12-31-18(27)20(4,5)6)13-29-8-7-25-10-24-14-15(21)22-9-23-16(14)25/h9-10H,7-8,11-13H2,1-6H3,(H2,21,22,23) DMMAWY1 CS CC(C)(C)C(=O)OCOP(=O)(COCCN1C=NC2=C(N=CN=C21)N)OCOC(=O)C(C)(C)C DMMAWY1 IK WOZSCQDILHKSGG-UHFFFAOYSA-N DMMAWY1 IU [2-(6-aminopurin-9-yl)ethoxymethyl-(2,2-dimethylpropanoyloxymethoxy)phosphoryl]oxymethyl 2,2-dimethylpropanoate DMMAWY1 CA CAS 142340-99-6 DMMAWY1 CB CHEBI:31175 DMMAWY1 DE Hepatitis B virus infection DMYQDBO ID DMYQDBO DMYQDBO DN Ademetionine DMYQDBO HS Approved DMYQDBO SN Ceritan; Samyr; Transmetil; Ademetionine butandisulphonate; Ademetionine disulfate tosylate; Ademetionine sulfate tosilate; FD-1561; FO-1561 DMYQDBO CP Bioresearch SpA DMYQDBO DT Small molecular drug DMYQDBO PC 34755 DMYQDBO MW 398.4 DMYQDBO FM C15H22N6O5S DMYQDBO IC InChI=1S/C15H22N6O5S/c1-27(3-2-7(16)15(24)25)4-8-10(22)11(23)14(26-8)21-6-20-9-12(17)18-5-19-13(9)21/h5-8,10-11,14,22-23H,2-4,16H2,1H3,(H2-,17,18,19,24,25)/t7-,8+,10+,11+,14+,27?/m0/s1 DMYQDBO CS C[S+](CC[C@@H](C(=O)[O-])N)C[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)O DMYQDBO IK MEFKEPWMEQBLKI-AIRLBKTGSA-N DMYQDBO IU (2S)-2-amino-4-[[(2S,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl-methylsulfonio]butanoate DMYQDBO CA CAS 29908-03-0 DMYQDBO CB CHEBI:67040 DMYQDBO DE Cerebrovascular ischaemia; Hepatic fibrosis DMZLHKJ ID DMZLHKJ DMZLHKJ DN Adenine DMZLHKJ HS Approved DMZLHKJ SN ADE; ANE; Adenin; Adeninimine; Adenine [JAN]; Pedatisectine B; AD2; Vitamin B 4; Vitamin B4; ALBB-005925; Adenine (8CI); Adenine-ring; B 4, Vitamin; Leuco-4; Leucon (TN); Purine, 6; USAF CB-18; Vitamin-B4; Adenine (JAN/USP); Adenine-8-14C; 1,6-Dihydro-6-Imnopurine; 1,6-Dihydro-6-iminopurine; 1H-Purin-6-amine; 1H-Purin-6-amine (9CI); 1H-Purine, 6-amino; 2'-DEOXY-ADENOSINE-3'-5'-DIPHOSPHATE; 3,6-Dihydro-6-iminopurine; 4, Vitamin B; 6-Amino-1H-purine; 6-Amino-3H-purine; 6-Amino-7H-purine; 6-Amino-9H-purine; 6-Aminopurine; 7H-Purin-6-amine; 9H-Purin-6-amine DMZLHKJ TC Dietary supplement DMZLHKJ DT Small molecular drug DMZLHKJ PC 190 DMZLHKJ MW 135.13 DMZLHKJ FM C5H5N5 DMZLHKJ IC InChI=1S/C5H5N5/c6-4-3-5(9-1-7-3)10-2-8-4/h1-2H,(H3,6,7,8,9,10) DMZLHKJ CS C1=NC2=NC=NC(=C2N1)N DMZLHKJ IK GFFGJBXGBJISGV-UHFFFAOYSA-N DMZLHKJ IU 7H-purin-6-amine DMZLHKJ CA CAS 73-24-5 DMZLHKJ CB CHEBI:16708 DMZLHKJ DE Malnutrition DMM2NSK ID DMM2NSK DMM2NSK DN Adenosine DMM2NSK HS Approved DMM2NSK SN Adenosine, homopolymer; Adenine 9-beta-D-arabinofuranoside; Adenine-9-beta-D-ribofuranoside; Beta-D-Ribofuranoside, adenine-9; EA6C60C2-6AFB-4264-A2F0-541373DB950E; (2R,3R,4S,5R)-2-(6-Aminopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol; (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol; 4-Aminopyrazolo[3,4-d]pyrimidine ribonucleoside; 6-Amino-9-.beta.-ribofuranosyl-9H-purine; 6-Amino-9-beta-D-ribofuranosyl-9H-purine; 6-Amino-9beta-D-ribofuranosyl-9H-purine; 9-(beta-D-Arabinofuranosyl)adenine; 9-beta-D-Ribofuranosidoadenine; 9-beta-D-Ribofuranosyl-9H-purin-6-amine; 9-beta-D-Ribofuranosyladenine; 9beta-D-Ribofuranosyladenine DMM2NSK TC Antiarrhythmic Agents DMM2NSK DT Small molecular drug DMM2NSK PC 60961 DMM2NSK MW 267.24 DMM2NSK FM C10H13N5O4 DMM2NSK IC InChI=1S/C10H13N5O4/c11-8-5-9(13-2-12-8)15(3-14-5)10-7(18)6(17)4(1-16)19-10/h2-4,6-7,10,16-18H,1H2,(H2,11,12,13)/t4-,6-,7-,10-/m1/s1 DMM2NSK CS C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O)N DMM2NSK IK OIRDTQYFTABQOQ-KQYNXXCUSA-N DMM2NSK IU (2R,3R,4S,5R)-2-(6-aminopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol DMM2NSK CA CAS 5536-17-4 DMM2NSK CB CHEBI:16335 DMM2NSK DE Paroxysmal supraventricular tachycardia DMNIJT0 ID DMNIJT0 DMNIJT0 DN Adenosine monophosphate DMNIJT0 HS Approved DMNIJT0 SN ASMP; Adenovite; Adenyl; Adenylate; Cardiomone; Lycedan; Monophosphadenine; Muskeladenylsaeure; Myoston; PAdo; Phosaden; Phosphaden; Phosphentaside; AMP dianion; Adenine polynucleotides; Adenosine phosphate; Adenosini phosphas; Adenylic acid; Ergadenylic acid; Fosfato de adenosina; Muscle adenylic acid; POLY A; Polyadenylic acids; Vitamin B8; A-5mp; AMP (VAN); AMP (nucleotide); Adenosine Monophosphate (Amp); Adenosine-monophosphate; Adenosine-phosphate; Adenosini phosphas [INN-Latin]; Adenyl (TN); Adenylic acid (VAN); Ado5'P; Fosfato de adenosina [INN-Spanish]; Muskeladenosin-phosphorsaeure; Phosphate d'adenosine; Adenosine 5'-monophosphate; Adenosine 5'-monophosphoric acid; Adenosine 5'-phosphate; Adenosine 5'-phosphoric acid; Adenosine phosphate (USAN/INN); Adenosine phosphate [USAN:BAN:INN]; Adenosine phosphate [USAN:INN:BAN]; Adenosine-5'P; Adenosine-5-monophosphate dianion; Adenosine-5-monophosphoric acid; Adenosine-5-phosphate; Formycin 5'-monophosphate hydrate; Formycin 5'-phosphate; Formycin 5'-phosphate hydrate; Formycin A 5'-monophosphate hydrate; My-B-Den; Phosphate d'adenosine [INN-French]; ADENOSINE-5'-PHOSPHATE; Adenosine 5'-(dihydrogen phosphate); Adenosine, mono(dihydrogen phosphate) (ester); Adenosine-5'-monophosphate; Adenosine-5'-monophosphoric acid; Adenosine-5-monophosphate(2-); GAMMA-ARSONO-BETA, GAMMA-METHYLENEADENOSINE-5'-DIPHOSPHATE; [(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate; (S)-1-C-(7-Amino-1H-pyrazolo(4,3-d)pyrimidin-3-yl)-1,4-anhydro-D-ribitol, 5-(dihydrogen phosphate); 1H-Pyrazolo(4,3-d)pyrimidine, 7-amino-3-beta-D-ribofuranosyl-, 5'-(dihydrogen phosphate)-, hydrate; 5'-Adenylic acid, homopolymer; 5'-Deoxy-5'-thioadenosine 5'-monophosphate; 5'-O-phosphonatoadenosine; 5'-O-phosphonoadenosine; 5'-Thio-5'-adenylic acid; 5'-adenosine monophosphate; 5'-adenylic acid; 7-Amino-3-beta-D-ribofuranosyl-1H-pyrazolo(4,3-d)pyrimidine 5'-(dihydrogen phosphate) hydrate; 7A8E6D15-9136-44C1-88C9-E1A224638E56; 7gpb; 8-Aminoadenosine 5'-monophosphate; 8gpb DMNIJT0 TC Dietary supplement DMNIJT0 DT Small molecular drug DMNIJT0 PC 6083 DMNIJT0 MW 347.22 DMNIJT0 FM C10H14N5O7P DMNIJT0 IC InChI=1S/C10H14N5O7P/c11-8-5-9(13-2-12-8)15(3-14-5)10-7(17)6(16)4(22-10)1-21-23(18,19)20/h2-4,6-7,10,16-17H,1H2,(H2,11,12,13)(H2,18,19,20)/t4-,6-,7-,10-/m1/s1 DMNIJT0 CS C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)O)O)O)N DMNIJT0 IK UDMBCSSLTHHNCD-KQYNXXCUSA-N DMNIJT0 IU [(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate DMNIJT0 CA CAS 61-19-8 DMNIJT0 CB CHEBI:16027 DMNIJT0 DE Malnutrition DM79F6G ID DM79F6G DM79F6G DN Adenosine triphosphate DM79F6G HS Approved DM79F6G SN Adenylpyrophosphate; Triphosadenine; Triphosadenine (DCF); Adenosine 5'-triphosphate(4-); [[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate; [[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-oxidophosphoryl]oxy-oxidophosphoryl] phosphate; [[[(2R,3S,4R,5R)-5-(6-Aminopurin-9-yl)-3,4-dihydroxy-oxolan-2-yl]methoxy-hydroxy-phosphoryl]oxy-hydroxy-phosphoryl]oxyphosphonic acid; 3b2q; 5-(6-Aminopurin-9-yl)-3,4-dihydroxy-oxolan-2-ylmethoxy-hydroxy-phosphoryloxy-hydroxy-phosphoryl oxyphosphonic acid; 9H-purin-6-amine, 9-[5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl] DM79F6G TC Dietary supplement DM79F6G DT Small molecular drug DM79F6G PC 5957 DM79F6G MW 507.18 DM79F6G FM C10H16N5O13P3 DM79F6G IC InChI=1S/C10H16N5O13P3/c11-8-5-9(13-2-12-8)15(3-14-5)10-7(17)6(16)4(26-10)1-25-30(21,22)28-31(23,24)27-29(18,19)20/h2-4,6-7,10,16-17H,1H2,(H,21,22)(H,23,24)(H2,11,12,13)(H2,18,19,20)/t4-,6-,7-,10-/m1/s1 DM79F6G CS C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O)N DM79F6G IK ZKHQWZAMYRWXGA-KQYNXXCUSA-N DM79F6G IU [[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate DM79F6G CA CAS 56-65-5 DM79F6G CB CHEBI:15422 DM79F6G DE Bradycardia; Heart disease; Malnutrition DMBHO9Y ID DMBHO9Y DMBHO9Y DN Adinazolam DMBHO9Y HS Approved DMBHO9Y SN Adinazolamum; Deracyn; Adinazolam [USAN]; U 41123; Adinazolamum [INN-Latin]; Deracyn (TN); U 41,123;U-41123; Adinazolam (USAN/INN); Adinazolam [USAN:BAN:INN]; 1-(8-chloro-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-1-yl)-N,N-dimethylmethanamine; 8-Chloro-1-((dimethylamino)methyl)-6-phenyl-4H-s-triazolo(4,3-a)(1,4)benzodiazepine; 8-chloro-1-[(dimethylamino)methyl]-6-phenyl-4h-s-triazolo[4,3-a][1,4]benzodiazepine DMBHO9Y TC Antidepressants DMBHO9Y DT Small molecular drug DMBHO9Y PC 37632 DMBHO9Y MW 351.8 DMBHO9Y FM C19H18ClN5 DMBHO9Y IC InChI=1S/C19H18ClN5/c1-24(2)12-18-23-22-17-11-21-19(13-6-4-3-5-7-13)15-10-14(20)8-9-16(15)25(17)18/h3-10H,11-12H2,1-2H3 DMBHO9Y CS CN(C)CC1=NN=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4 DMBHO9Y IK GJSLOMWRLALDCT-UHFFFAOYSA-N DMBHO9Y IU 1-(8-chloro-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-1-yl)-N,N-dimethylmethanamine DMBHO9Y CA CAS 37115-32-5 DMBHO9Y CB CHEBI:251412 DMBHO9Y DE Anxiety disorder DMVWHTG ID DMVWHTG DMVWHTG DN Afamelanotide DMVWHTG HS Approved DMVWHTG SN [Nle4,dPhe7]alpha-MSH; alpha-NDP-MSH; NDP-MSH DMVWHTG DT Small molecular drug DMVWHTG PC 16197727 DMVWHTG MW 1646.8 DMVWHTG FM C78H111N21O19 DMVWHTG IC InChI=1S/C78H111N21O19/c1-5-6-19-52(91-75(116)61(41-101)97-72(113)57(34-46-24-26-49(103)27-25-46)94-74(115)60(40-100)88-44(4)102)68(109)92-54(28-29-64(105)106)70(111)96-59(36-48-38-83-42-87-48)73(114)93-56(33-45-16-8-7-9-17-45)71(112)90-53(22-14-31-84-78(81)82)69(110)95-58(35-47-37-85-51-20-11-10-18-50(47)51)67(108)86-39-63(104)89-55(21-12-13-30-79)77(118)99-32-15-23-62(99)76(117)98-65(43(2)3)66(80)107/h7-11,16-18,20,24-27,37-38,42-43,52-62,65,85,100-101,103H,5-6,12-15,19,21-23,28-36,39-41,79H2,1-4H3,(H2,80,107)(H,83,87)(H,86,108)(H,88,102)(H,89,104)(H,90,112)(H,91,116)(H,92,109)(H,93,114)(H,94,115)(H,95,110)(H,96,111)(H,97,113)(H,98,117)(H,105,106)(H4,81,82,84)/t52-,53-,54-,55-,56+,57-,58-,59-,60-,61-,62-,65-/m0/s1 DMVWHTG CS CCCC[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@H](CC2=CC=CC=C2)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N5CCC[C@H]5C(=O)N[C@@H](C(C)C)C(=O)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC6=CC=C(C=C6)O)NC(=O)[C@H](CO)NC(=O)C DMVWHTG IK UAHFGYDRQSXQEB-LEBBXHLNSA-N DMVWHTG IU (4S)-4-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]-5-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-6-amino-1-[(2S)-2-[[(2S)-1-amino-3-methyl-1-oxobutan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxohexan-2-yl]amino]-2-oxoethyl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid DMVWHTG CA CAS 75921-69-6 DMVWHTG DE Vitiligo; Erythropoietic porphyrias DMT3D5I ID DMT3D5I DMT3D5I DN Aflibercept DMT3D5I HS Approved DMT3D5I SN Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye DMT3D5I CP Sanofi DMT3D5I SQ Protein sequence for aflibercept: SDTGRPFVEMYSEIPEIIHMTEGRELVIPCRVTSPNITVTLKKFPLDTLIPDGKRIIWDSRKGFIISNATYKEIGLLTCEATVNGHLYKTNYLTHRQTNTIIDVVLSPSHGIELSVGEKLVLNCTARTELNVGIDFNWEYPSSKHQHKKLVNRDLKTQSGSEMKKFLSTLTIDGVTRSDQGLYTCAASSGLMTKKNSTFVRVHEKDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG DMT3D5I DE Metastatic colorectal cancer DMPOD47 ID DMPOD47 DMPOD47 DN Ajmalicine DMPOD47 HS Approved DMPOD47 SN MLS000111555; methyl 19-methyl-16,17-didehydro-18-oxayohimban-16-carboxylate; NSC72115; SMR000107477; Oxayohimban-16-carboxylic acid, 16,17-didehydro-19-methyl-, methyl ester, (19.alpha.)-; 6474-90-4; WLN: T F6 D5 C666 EM ON SO TU& TTTJ R1 UVO1; Isoarteril; Oxayohimban-16-carboxylic acid,17-didehydro-19-methyl-, methyl ester, (19 DMPOD47 DT Small molecular drug DMPOD47 PC 441975 DMPOD47 MW 352.4 DMPOD47 FM C21H24N2O3 DMPOD47 IC InChI=1S/C21H24N2O3/c1-12-16-10-23-8-7-14-13-5-3-4-6-18(13)22-20(14)19(23)9-15(16)17(11-26-12)21(24)25-2/h3-6,11-12,15-16,19,22H,7-10H2,1-2H3/t12-,15-,16+,19-/m0/s1 DMPOD47 CS C[C@H]1[C@H]2CN3CCC4=C([C@@H]3C[C@@H]2C(=CO1)C(=O)OC)NC5=CC=CC=C45 DMPOD47 IK GRTOGORTSDXSFK-XJTZBENFSA-N DMPOD47 IU methyl (1S,15R,16S,20S)-16-methyl-17-oxa-3,13-diazapentacyclo[11.8.0.02,10.04,9.015,20]henicosa-2(10),4,6,8,18-pentaene-19-carboxylate DMPOD47 CA CAS 483-04-5 DMPOD47 CB CHEBI:2524 DMPOD47 DE Circulatory disorder DMDJW5K ID DMDJW5K DMDJW5K DN Ajmaline DMDJW5K HS Approved DMDJW5K SN (17R,21 DMDJW5K DT Small molecular drug DMDJW5K PC 6100671 DMDJW5K MW 326.4 DMDJW5K FM C20H26N2O2 DMDJW5K IC InChI=1S/C20H26N2O2/c1-3-10-11-8-14-17-20(12-6-4-5-7-13(12)21(17)2)9-15(16(11)18(20)23)22(14)19(10)24/h4-7,10-11,14-19,23-24H,3,8-9H2,1-2H3/t10-,11-,14-,15-,16-,17-,18+,19+,20+/m0/s1 DMDJW5K CS CC[C@H]1[C@@H]2C[C@H]3[C@H]4[C@@]5(C[C@@H]([C@H]2[C@H]5O)N3[C@@H]1O)C6=CC=CC=C6N4C DMDJW5K IK CJDRUOGAGYHKKD-RQBLFBSQSA-N DMDJW5K IU (1R,9R,10S,12R,13S,14R,16S,17S,18R)-13-ethyl-8-methyl-8,15-diazahexacyclo[14.2.1.01,9.02,7.010,15.012,17]nonadeca-2,4,6-triene-14,18-diol DMDJW5K CA CAS 4360-12-7 DMDJW5K DE Atrial fibrillation DML6SRO ID DML6SRO DML6SRO DN Alacepril DML6SRO HS Approved DML6SRO SN Cetapril (TN) DML6SRO CP Dainippon DML6SRO DT Small molecular drug DML6SRO PC 71992 DML6SRO MW 406.5 DML6SRO FM C20H26N2O5S DML6SRO IC InChI=1S/C20H26N2O5S/c1-13(12-28-14(2)23)19(25)22-10-6-9-17(22)18(24)21-16(20(26)27)11-15-7-4-3-5-8-15/h3-5,7-8,13,16-17H,6,9-12H2,1-2H3,(H,21,24)(H,26,27)/t13-,16+,17+/m1/s1 DML6SRO CS C[C@H](CSC(=O)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)O DML6SRO IK FHHHOYXPRDYHEZ-COXVUDFISA-N DML6SRO IU (2S)-2-[[(2S)-1-[(2S)-3-acetylsulfanyl-2-methylpropanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoic acid DML6SRO CA CAS 74258-86-9 DML6SRO CB CHEBI:31182 DML6SRO DE Cardiovascular disease DMYZ57N ID DMYZ57N DMYZ57N DN Albendazole DMYZ57N HS Approved DMYZ57N SN Albendazol; Albendazolum; Albendoral; Albenza; Bendapar; Bilutac; Digezanol; Disthelm; Endoplus; Eskazole; Gascop; Lurdex; Metiazol; Proftril; Valbazen; Zental; Zentel; Albendazole Armstrong Brand; Albendazole Diba Brand; Albendazole Fustery Brand; Albendazole Hormona Brand; Albendazole Liferpal Brand; Albendazole Monohydrochloride; Albendazole Pfizer Brand; Albendazole Sanicoopa Brand; Albendazole Valdecasas Brand; Armstrong Brand of Albendazole; Diba Brand of Albendazole; Fustery Brand of Albendazole; Hormona Brand of Albendazole; Liferpal Brand of Albendazole; Mediamix V Disthelm; Noe Socopharm Brand of Albendazole; Pfizer Brand of Albendazole; Sanicoopa Brand of Albendazole; SmithKline Beecham Brand of Albendazole; Valdecasas Brand of Albendazole; SKF 62979; SKF62979; Albendazol [INN-Spanish]; Albendazole Noe-Socopharm Brand; Albendazolum [INN-Latin]; Albenza (TN); Disthelm, Mediamix V; Eskazole (TN); Monohydrochloride, Albendazole; Noe-Socopharm Brand of Albendazole; SK&F 62979; SK&F62979; SKF-62979; Smith Kline & French Brand of Albendazole; V Disthelm, Mediamix; Zentel (TN); SK&F-62979; Albendazole (JAN/USP/INN); Albendazole [USAN:INN:BAN:JAN]; Albenza, Eskazole, Zentel, Andazol, Albendazole; Methyl 5-(propylthio)-2-benzimidazolecarbamate; Methyl [5-(Propylthio)benzimidazol-2-yl]carbamate; Methyl-5-[propylthio]-2-benzimidazole carbamate; [5-(Propylthio)benzimidazol-2-yl]carbamic Acid Methyl Ester; Methyl 5-(propyl-thio)-2-benzimidazolecarbamate; Methyl [5-(propylsulfanyl)-1H-benzimidazol-2-yl]carbamate; Methyl [5-(propylthio)-1H-benzimidazol-2-yl]carbamate; Methyl [6-(propylsulfanyl)-1H-benzimidazol-2-yl]carbamate; [5-(Propythio)-1H-benzimidazol-2-yl]carbamic acid methyl ester; MethylN-(6-propylsulfanyl-1H-benzimidazol-2-yl)carbamate; O-Methyl N-(5-(propylthio)-2-benzimidazolyl)carbamate; Carbamic acid, [5-(propylthio)-1H-benzimidazol-2-yl]-, methyl ester; Methyl N-[6-(propylsulfanyl)-1H-1,3-benzodiazol-2-yl]carbamate; CARBAMIC ACID, (5-(PROPYLTHIO)-1H-BENZIMIDAZOL-2-YL)-, METHYL ESTER; Methyl [(2Z)-5-(propylsulfanyl)-1,3-dihydro-2H-benzimidazol-2-ylidene]carbamate; ((Propylthio)-5 1H-benzimidazolyl-2) carbamate de methyle; ((Propylthio)-5 1H-benzimidazolyl-2) carbamate de methyle [French]; (5-(Propylthio)-1H-benzimidazol-2-yl)carbamic acid methyl ester; (5-Propylsulfanyl-1H-benzoimidazol-2-yl)-carbamic acid methyl ester; 5-(Propylthio)-2-carbomethoxyaminobenzimidazole DMYZ57N CP GlaxoSmithKline DMYZ57N TC Antiprotozoal Agents DMYZ57N DT Small molecular drug DMYZ57N PC 2082 DMYZ57N MW 265.33 DMYZ57N FM C12H15N3O2S DMYZ57N IC InChI=1S/C12H15N3O2S/c1-3-6-18-8-4-5-9-10(7-8)14-11(13-9)15-12(16)17-2/h4-5,7H,3,6H2,1-2H3,(H2,13,14,15,16) DMYZ57N CS CCCSC1=CC2=C(C=C1)N=C(N2)NC(=O)OC DMYZ57N IK HXHWSAZORRCQMX-UHFFFAOYSA-N DMYZ57N IU methyl N-(6-propylsulfanyl-1H-benzimidazol-2-yl)carbamate DMYZ57N CA CAS 54965-21-8 DMYZ57N CB CHEBI:16664 DMYZ57N DE Worm infection DM1JEGF ID DM1JEGF DM1JEGF DN Albiglutide DM1JEGF HS Approved DM1JEGF CP GSK DM1JEGF SQ Albiglutide sequence: HGEGTFTSDVSSYLEGQAAKEFIAWLVKGRHGEGTFTSDVSSYLEGQAAKEFIAWLVKGRDAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQCPFEDHVKLVNEVTEFAKTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEPERNECFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFYAPELLFFAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKCASLQKFGERAFKAWAVARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDLLECADDRADLAKYICENQDSISSKLKECCEKPLLEKSHCIAEVENDEMPADLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYARRHPDYSVVLLLRLAKTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFEQLGEYKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAEDYLSVVLNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALEVDETYVPKEFNAETFTFHADICTLSEKERQIKKQTALVELVKHKPKATKEQLKAVMDDFAAFVEKCCKADDKETCFAEEGKKLVAASQAALGL DM1JEGF PC 122173812 DM1JEGF MW 3284.6 DM1JEGF FM C148H223N39O46 DM1JEGF IC InChI=1S/C148H223N39O46/c1-16-76(10)119(144(229)165-79(13)124(209)173-103(59-85-62-157-90-35-24-23-34-88(85)90)134(219)175-99(55-73(4)5)135(220)184-117(74(6)7)142(227)172-91(36-25-27-51-149)126(211)159-66-111(197)168-97(147(232)233)38-29-53-156-148(153)154)186-136(221)101(56-82-30-19-17-20-31-82)176-131(216)96(46-50-115(203)204)171-130(215)92(37-26-28-52-150)169-123(208)78(12)163-122(207)77(11)164-129(214)95(43-47-108(152)194)167-110(196)65-160-128(213)94(45-49-114(201)202)170-132(217)98(54-72(2)3)174-133(218)100(58-84-39-41-87(193)42-40-84)177-139(224)105(68-188)180-141(226)107(70-190)181-143(228)118(75(8)9)185-138(223)104(61-116(205)206)178-140(225)106(69-189)182-146(231)121(81(15)192)187-137(222)102(57-83-32-21-18-22-33-83)179-145(230)120(80(14)191)183-112(198)67-161-127(212)93(44-48-113(199)200)166-109(195)64-158-125(210)89(151)60-86-63-155-71-162-86/h17-24,30-35,39-42,62-63,71-81,89,91-107,117-121,157,188-193H,16,25-29,36-38,43-61,64-70,149-151H2,1-15H3,(H2,152,194)(H,155,162)(H,158,210)(H,159,211)(H,160,213)(H,161,212)(H,163,207)(H,164,214)(H,165,229)(H,166,195)(H,167,196)(H,168,197)(H,169,208)(H,170,217)(H,171,215)(H,172,227)(H,173,209)(H,174,218)(H,175,219)(H,176,216)(H,177,224)(H,178,225)(H,179,230)(H,180,226)(H,181,228)(H,182,231)(H,183,198)(H,184,220)(H,185,223)(H,186,221)(H,187,222)(H,199,200)(H,201,202)(H,203,204)(H,205,206)(H,232,233)(H4,153,154,156)/t76-,77-,78-,79-,80+,81+,89-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,117-,118-,119-,120-,121-/m0/s1 DM1JEGF CS CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)N)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@H](CC6=CNC=N6)N DM1JEGF IK OGWAVGNOAMXIIM-VTAHJYCESA-N DM1JEGF IU (4S)-5-[[2-[[(2S,3R)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[2-[[(1S)-4-carbamimidamido-1-carboxybutyl]amino]-2-oxoethyl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-2-oxoethyl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-4-[[2-[[(2S)-2-amino-3-(1H-imidazol-4-yl)propanoyl]amino]acetyl]amino]-5-oxopentanoic acid DM1JEGF CB CHEBI:78425 DM1JEGF DE Type-2 diabetes DM5JTPU ID DM5JTPU DM5JTPU DN Albumin Human DM5JTPU HS Approved DM5JTPU SN Albumin (Human); Kedbumin DM5JTPU CP Ge Healthcare DM5JTPU DE Hypoalbuminemia DM5J1NH ID DM5J1NH DM5J1NH DN Alcaftadine DM5J1NH HS Approved DM5J1NH SN Lastacaft (TN) DM5J1NH CP Vistakon Pharmaceuticals DM5J1NH DT Small molecular drug DM5J1NH PC 19371515 DM5J1NH MW 307.4 DM5J1NH FM C19H21N3O DM5J1NH IC InChI=1S/C19H21N3O/c1-21-9-6-15(7-10-21)18-17-5-3-2-4-14(17)8-11-22-16(13-23)12-20-19(18)22/h2-5,12-13H,6-11H2,1H3 DM5J1NH CS CN1CCC(=C2C3=CC=CC=C3CCN4C2=NC=C4C=O)CC1 DM5J1NH IK MWTBKTRZPHJQLH-UHFFFAOYSA-N DM5J1NH IU 11-(1-methylpiperidin-4-ylidene)-5,6-dihydroimidazo[2,1-b][3]benzazepine-3-carbaldehyde DM5J1NH CA CAS 147084-10-4 DM5J1NH CB CHEBI:71023 DM5J1NH DE Allergic conjunctivitis DMAE84F ID DMAE84F DMAE84F DN Alclometasone DMAE84F HS Approved DMAE84F SN Aclometasone; Aclovate (TN); Alclometasone (INN); Alclometasone [INN:BAN]; (7R,8S,9S,10R,11S,13S,14S,16R,17R)-7-chloro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one; (7alpha,11beta,16alpha)-7-chloro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione; 7alpha-Chloro-16alpha-methylprednisolone DMAE84F CP GlaxoSmithKline DMAE84F TC Antiinflammatory Agents DMAE84F DT Small molecular drug DMAE84F PC 5311000 DMAE84F MW 408.9 DMAE84F FM C22H29ClO5 DMAE84F IC InChI=1S/C22H29ClO5/c1-11-6-14-18-15(23)8-12-7-13(25)4-5-20(12,2)19(18)16(26)9-21(14,3)22(11,28)17(27)10-24/h4-5,7,11,14-16,18-19,24,26,28H,6,8-10H2,1-3H3/t11-,14+,15-,16+,18-,19+,20+,21+,22+/m1/s1 DMAE84F CS C[C@@H]1C[C@H]2[C@@H]3[C@@H](CC4=CC(=O)C=C[C@@]4([C@H]3[C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)C)Cl DMAE84F IK FJXOGVLKCZQRDN-PHCHRAKRSA-N DMAE84F IU (7R,8S,9S,10R,11S,13S,14S,16R,17R)-7-chloro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one DMAE84F CA CAS 67452-97-5 DMAE84F CB CHEBI:53776 DMAE84F DE Inflammation DM2U4XQ ID DM2U4XQ DM2U4XQ DN ALCURONIUM DM2U4XQ HS Approved DM2U4XQ SN Alcuronium DM2U4XQ DT Small molecular drug DM2U4XQ PC 21158560 DM2U4XQ MW 666.9 DM2U4XQ FM C44H50N4O2+2 DM2U4XQ IC InChI=1S/C44H50N4O2/c1-3-17-47-19-15-43-35-9-5-7-11-37(35)45-26-34-32-24-40-44(16-20-48(40,18-4-2)28-30(32)14-22-50)36-10-6-8-12-38(36)46(42(34)44)25-33(41(43)45)31(23-39(43)47)29(27-47)13-21-49/h3-14,25-26,31-32,39-42,49-50H,1-2,15-24,27-28H2/q+2/b29-13-,30-14-,33-25-,34-26-/t31-,32-,39-,40-,41-,42-,43+,44+,47-,48-/m0/s1 DM2U4XQ CS C=CC[N@@+]12[C@@H]3[C@]4(C5=CC=CC=C5N/6[C@H]4/C(=C\\N7[C@H]8/C(=C6)/[C@@H]9/C(=C\\CO)/C[N@+]4([C@H]([C@]8(C5=CC=CC=C75)CC4)C9)CC=C)/[C@@H](C3)/C(=C\\CO)/C1)CC2 DM2U4XQ IK MUQUYTSLDVKIOF-CHJKCJHBSA-N DM2U4XQ IU (2E)-2-[(1S,9Z,11S,13S,14R,17S,25Z,27S,30R,33S,35S,36S,38E)-38-(2-hydroxyethylidene)-14,30-bis(prop-2-enyl)-8,24-diaza-14,30-diazoniaundecacyclo[25.5.2.211,14.11,26.110,17.02,7.013,17.018,23.030,33.08,35.024,36]octatriaconta-2,4,6,9,18,20,22,25-octaen-28-ylidene]ethanol DM2U4XQ CA CAS 23214-96-2 DM2U4XQ CB CHEBI:55313 DM2U4XQ DE Anaesthesia DM4YMIS ID DM4YMIS DM4YMIS DN Aldesleukin DM4YMIS HS Approved DM4YMIS SN Proleukin (TN) DM4YMIS CP Chiron DM4YMIS TC Anticancer Agents DM4YMIS SQ Aldesleukin sequence: MAPTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTRMLTFKFYMPKKATELKHLQCLEEELKPLEEVLNLAQSKNFHLRPRDLISNINVIVLELKGSETTFMCEYADETATIVEFLNRWITFCQSIISTLT DM4YMIS DE Renal cell carcinoma; Non-hodgkin lymphoma DM9S2JW ID DM9S2JW DM9S2JW DN Aldosterone DM9S2JW HS Approved DM9S2JW SN ALDOSTERONE; 52-39-1; Electrocortin; Aldocortin; Aldocortene; Aldocorten; (+)-Aldosterone; Elektrocortin; d-Aldosterone; Reichstein X; 18-Oxocorticosterone; Aldosteronum; Aldosterona; Aldosteronum [INN-Latin]; Aldosterona [INN-Spanish]; [3H]aldosterone; 18-Aldocorticosterone; Aldosterone [INN:BAN:DCF]; 11beta,21-Dihydroxypregn-4-ene-3,18,20-trione; 11beta,21-Dihydroxy-3,20-diketo-4-pregnen-18-al; 11beta,21-Dihydroxy-3,20-diketopregn-4-ene-18-al; NSC 73856; 18-Formyl-11beta,21-dihydroxy-4-pregnene-3,20-dione; UNII-4964P6T9RB; Aldocorten; D-Aldosterone; Aldosterone, (11 beta,17 alpha)-Isomer; Aldosterone, (+-)-Isomer; (11BETA)-11,21-DIHYDROXY-3,20-DIOXOPREGN-4-EN-18-AL; (8S,9S,10R,11S,13R,14S,17S)-11-hydroxy-17-(2-hydroxyacetyl)-10-methyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthrene-13-carbaldehyde; 11beta,21-Dihydroxy-3,20-dioxo-4-pregnen-18-al; 11beta,21-Dihydroxy-3,20-dioxo-4-pregnen-18-al, 18,11-halbacetal; 11beta,21-dihydroxy-3,20-dioxo-pregn-4-ene-18-al; 11beta,21-dihydroxy-3,20-dioxopregn-4-en-18-al DM9S2JW TC Antihypertensive Agents DM9S2JW DT Small molecular drug DM9S2JW PC 5839 DM9S2JW MW 360.4 DM9S2JW FM C21H28O5 DM9S2JW IC InChI=1S/C21H28O5/c1-20-7-6-13(24)8-12(20)2-3-14-15-4-5-16(18(26)10-22)21(15,11-23)9-17(25)19(14)20/h8,11,14-17,19,22,25H,2-7,9-10H2,1H3/t14-,15-,16+,17-,19+,20-,21+/m0/s1 DM9S2JW CS C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@H]2[C@H](C[C@]4([C@H]3CC[C@@H]4C(=O)CO)C=O)O DM9S2JW IK PQSUYGKTWSAVDQ-ZVIOFETBSA-N DM9S2JW IU (8S,9S,10R,11S,13R,14S,17S)-11-hydroxy-17-(2-hydroxyacetyl)-10-methyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthrene-13-carbaldehyde DM9S2JW CA CAS 52-39-1 DM9S2JW CB CHEBI:27584 DM9S2JW DE Hypertension DMP1I6Y ID DMP1I6Y DMP1I6Y DN Alectinib DMP1I6Y HS Approved DMP1I6Y SN 1256580-46-7; CH5424802; CH 5424802; AF-802; Alecensa; UNII-LIJ4CT1Z3Y; AF 802; LIJ4CT1Z3Y; Alectinib (CH5424802); 9-ethyl-6,6-dimethyl-8-(4-morpholinopiperidin-1-yl)-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile; CHEMBL1738797; AF802; 9-Ethyl-6,6-Dimethyl-8-[4-(Morpholin-4-Yl)piperidin-1-Yl]-11-Oxo-6,11-Dihydro-5h-Benzo[b]carbazole-3-Carbonitrile; 9-Ethyl-6,11-dihydro-6,6-dimethyl-8-[4-(4-morpholinyl)-1-piperidinyl]-11-oxo-5H-benzo[b]carbazole-3-carbonitrile; AK170451; C30H34N4O2; Alectinib; 9-ethyl-6,6-dimethyl- DMP1I6Y DT Small molecular drug DMP1I6Y PC 49806720 DMP1I6Y MW 482.6 DMP1I6Y FM C30H34N4O2 DMP1I6Y IC InChI=1S/C30H34N4O2/c1-4-20-16-23-24(17-26(20)34-9-7-21(8-10-34)33-11-13-36-14-12-33)30(2,3)29-27(28(23)35)22-6-5-19(18-31)15-25(22)32-29/h5-6,15-17,21,32H,4,7-14H2,1-3H3 DMP1I6Y CS CCC1=CC2=C(C=C1N3CCC(CC3)N4CCOCC4)C(C5=C(C2=O)C6=C(N5)C=C(C=C6)C#N)(C)C DMP1I6Y IK KDGFLJKFZUIJMX-UHFFFAOYSA-N DMP1I6Y IU 9-ethyl-6,6-dimethyl-8-(4-morpholin-4-ylpiperidin-1-yl)-11-oxo-5H-benzo[b]carbazole-3-carbonitrile DMP1I6Y CA CAS 1256580-46-7 DMP1I6Y CB CHEBI:90936 DMP1I6Y DE Lung cancer; Non-small-cell lung cancer DMMYPWO ID DMMYPWO DMMYPWO DN Alefacept DMMYPWO HS Approved DMMYPWO SN Amevive (TN) DMMYPWO TC Analgesics DMMYPWO SQ Alefacept heavy chain : CFSQQIYGVVYGNVTFHVPSNVPLKEVLWKKQKDKVAELENSEFRAFSSFKNRVYLDTVSGSLTIYNLTSSDEDEYEMESPNITDTMKFFLYVLESLPSPTLTCALTNGSIEVQCMIPEHYNSHRGLIMYSWDCPMEQCKRNSTSIYFKMENDLPQKIQCTLSNPLFNTTSSIILTTCIPSSGHSRHRYALIPIPLAVITTCIVLYMNGILKCDRKPDRTNSNRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPQVKFNWYVDGVQVHNAKTKPREQQYNSTYRVVSVLTVLHQNWLDGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK >Alefacept light chainMVAGSDAGRALGVLSVVCLLHCFGFISCFSQQIYGVVYGNVTFHVPSNVPLKEVLWKKQKDKVAELENSEFRAFSSFKNRVYLDTVSGSLTIYNLTSSDEDEYEMESPNITDTMKFFLYVLESLPSPTLTCALTNGSIEVQCMIPEHYNSHRGLIMYSWDCPMEQCKRNSTSIYFKMENDLPQKIQCTLSNPLFNTTSSIILTTCIPSSGHSRHRYALIPIPLAVITTCIVLYMNGILKCDRKPDRTNSN DMMYPWO DE Pain DMZL3IV ID DMZL3IV DMZL3IV DN Alemtuzumab DMZL3IV HS Approved DMZL3IV SN Campath (TN); MabCampath (TN); Campath-1H (TN) DMZL3IV CP Bayer Schering Pharma DMZL3IV TC Anticancer Agents DMZL3IV DT Antibody DMZL3IV SQ 1CE1:H CAMPATH-1H:Heavy Chain 1: QVQLQESGPGLVRPSQTLSLTCTVSGFTFTDFYMNWVRQPPGRGLEWIGFIRDKAKGYTTEYNPSVKGRVTMLVDTSKNQFSLRLSSVTAADTAVYYCAREGHTAAPFDYWGQGSLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK >1CE1:L CAMPATH-1H:Light Chain 1DIQMTQSPSSLSASVGDRVTITCKASQNIDKYLNWYQQKPGKAPKLLIYNTNNLQTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCLQHISRPRTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR >1CE1:H CAMPATH-1H:Heavy Chain 2QVQLQESGPGLVRPSQTLSLTCTVSGFTFTDFYMNWVRQPPGRGLEWIGFIRDKAKGYTTEYNPSVKGRVTMLVDTSKNQFSLRLSSVTAADTAVYYCAREGHTAAPFDYWGQGSLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK >1CE1:L CAMPATH-1H:Light Chain 2DIQMTQSPSSLSASVGDRVTITCKASQNIDKYLNWYQQKPGKAPKLLIYNTNNLQTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCLQHISRPRTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR >1bey_H|CAMPATH-1H|Humanized||VH-CH1 (VH(1-121)+CH1(122-210))|||||||219||||MW 23397.3|MW 23397.3|QVQLQESGPGLVRPSQTLSLTCTVSGFTFTDFYMNWVRQPPGRGLEWIGFIRDKAKGYTTEYNPSVKGRVTMLVDTSKNQFSLRLSSVTAADTAVYYCAREGHTAAPFDYWGQGSLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKV >1bey_L|CAMPATH-1H|Humanized||L-KAPPA (V-KAPPA(1-107)+C-KAPPA(108-214))|||||||214||||MW 23571.3|MW 23571.3|DIQMTQSPSSLSASVGDRVTITCKASQNIDKYLNWYQQKPGKAPKLLIYNTNNLQTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCLQHISRPRTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC >8005_H|alemtuzumab|||H-GAMMA-1 (VH(1-121)+CH1(122-219)+HINGE-REGION(220-220)+CH2(221-330)+CH3(331-437))|||||||437||||MW 47976.2|MW 47976.2|QVQLQESGPGLVRPSQTLSLTCTVSGFTFTDFYMNWVRQPPGRGLEWIGFIRDKAKGYTTEYNPSVKGRVTMLVDTSKNQFSLRLSSVTAADTAVYYCAREGHTAAPFDYWGQGSLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK >8005_L|alemtuzumab|||L-KAPPA (V-KAPPA(1-107)+C-KAPPA(108-214))|||||||214||||MW 23571.3|MW 23571.3|DIQMTQSPSSLSASVGDRVTITCKASQNIDKYLNWYQQKPGKAPKLLIYNTNNLQTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCLQHISRPRTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC >1ce1_H|CAMPATH-1H|Humanized||VH-CH1 (VH(1-121)+CH1(122-219))|||||||220||||MW 23526.4|MW 23526.4|QVQLQESGPGLVRPSQTLSLTCTVSGFTFTDFYMNWVRQPPGRGLEWIGFIRDKAKGYTTEYNPSVKGRVTMLVDTSKNQFSLRLSSVTAADTAVYYCAREGHTAAPFDYWGQGSLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVE >1ce1_L|CAMPATH-1H|Humanized||L-KAPPA (V-KAPPA(1-107)+C-KAPPA(108-211))|||||||211||||MW 23282.0|MW 23282.0|DIQMTQSPSSLSASVGDRVTITCKASQNIDKYLNWYQQKPGKAPKLLIYNTNNLQTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCLQHISRPRTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR DMZL3IV DE Chronic lymphocytic leukaemia; Multiple sclerosis DMY2KX9 ID DMY2KX9 DMY2KX9 DN Alendronate DMY2KX9 HS Approved DMY2KX9 SN Arendal; Fosamax; ALENDRONATE SODIUM; ALENDRONIC ACID; Acide alendronique; Acido alendronico; Acidum alendronicum; MK 217; Acide alendronique [INN-French]; Acido alendronico [INN-Spanish]; Acidum alendronicum [INN-Latin]; Alendronic acid (INN); Alendronic acid [INN:BAN]; Bisphosphonate, 65; Fosamax (TN); MK-217; Phosphonic acid, (4-amino-1-hydroxybutylidene)bis; (4-Amino-1-hydroxybutylidene)bisphosphonic acid; (4-Amino-1-hydroxybutylidene)diphosphonic acid; (4-amino-1-hydroxy-1-phosphonobutyl)phosphonic acid; (4-amino-1-hydroxybutane-1,1-diyl)bis(phosphonic acid); 4-Amino-1-hydroxybutane-1,1-diphosphonate; 4-Amino-1-hydroxybutane-1,1-diphosphonic Acid; 4-Amino-1-hydroxybutylidene-1,1-bis(phosphonic acid); 4-Amino-1-hydroxybutylidene-1,1-bisphosphonate DMY2KX9 CP Teva Pharmaceuticals DMY2KX9 TC Bone Density Conservation Agents DMY2KX9 DT Small molecular drug DMY2KX9 PC 2088 DMY2KX9 MW 249.1 DMY2KX9 FM C4H13NO7P2 DMY2KX9 IC InChI=1S/C4H13NO7P2/c5-3-1-2-4(6,13(7,8)9)14(10,11)12/h6H,1-3,5H2,(H2,7,8,9)(H2,10,11,12) DMY2KX9 CS C(CC(O)(P(=O)(O)O)P(=O)(O)O)CN DMY2KX9 IK OGSPWJRAVKPPFI-UHFFFAOYSA-N DMY2KX9 IU (4-amino-1-hydroxy-1-phosphonobutyl)phosphonic acid DMY2KX9 CA CAS 66376-36-1 DMY2KX9 CB CHEBI:2567 DMY2KX9 DE Paget's disease; Osteoporosis DMCKPUR ID DMCKPUR DMCKPUR DN Alfaferone DMCKPUR HS Approved DMCKPUR SN Alfaferon; Cilferon-A; Alpha-IFN, ASW; Interferon, ASW (alpha) DMCKPUR CP Alfa Wassermann SpA DMCKPUR DE Hairy cell leukaemia DMVO0UB ID DMVO0UB DMVO0UB DN Alfentanil DMVO0UB HS Approved DMVO0UB SN Alfenta; Alfentanilum; Alfentanyl; Alfenta (TN); Alfentanil (INN); Alfentanil [INN:BAN]; Alfentanilum [INN-Latin]; Rapifen (TN); N-[1-[2-(4-Ethyl-5-oxo-2-tetrazolin-1-yl)ethyl]-4-(methoxymethyl)-4-piperidyl]propionanilide; N-[1-[2-(4-ethyl-5-oxotetrazol-1-yl)ethyl]-4-(methoxymethyl)piperidin-4-yl]-N-phenylpropanamide; N-(1-(2-(4-Ethyl-4,5-dihydro-5-oxotetrazolyl)ethyl)-4-(methoxymethyl)-4-piperidyl)propionanilid; N-(1-(2-(4-Ethyl-5-oxo-2-tetrazolin-1-yl)ethyl)-4-(methoxymethyl)-4-piperidyl)propionanilide; N-(1-(2-(4-Ethyl-4,5-dihydro-5-oxotetrazolyl)ethyl)-4-(methoxymethyl)-4-piperidyl)-N-phenylpropionamid; N-{1-[2-(4-ethyl-5-oxo-4,5-dihydro-1H-tetrazol-1-yl)ethyl]-4-(methoxymethyl)piperidin-4-yl}-N-phenylpropanamide; N-{1-[2-(4-ethyl-5-oxo-4,5-dihydro-1H-tetrazol-1-yl)ethyl]-4-[(methyloxy)methyl]piperidin-4-yl}-N-phenylpropanamide DMVO0UB CP Janssen Pharmaceutica DMVO0UB TC Anesthetics DMVO0UB DT Small molecular drug DMVO0UB PC 51263 DMVO0UB MW 416.5 DMVO0UB FM C21H32N6O3 DMVO0UB IC InChI=1S/C21H32N6O3/c1-4-19(28)27(18-9-7-6-8-10-18)21(17-30-3)11-13-24(14-12-21)15-16-26-20(29)25(5-2)22-23-26/h6-10H,4-5,11-17H2,1-3H3 DMVO0UB CS CCC(=O)N(C1=CC=CC=C1)C2(CCN(CC2)CCN3C(=O)N(N=N3)CC)COC DMVO0UB IK IDBPHNDTYPBSNI-UHFFFAOYSA-N DMVO0UB IU N-[1-[2-(4-ethyl-5-oxotetrazol-1-yl)ethyl]-4-(methoxymethyl)piperidin-4-yl]-N-phenylpropanamide DMVO0UB CA CAS 71195-58-9 DMVO0UB CB CHEBI:2569 DMVO0UB DE Anaesthesia DMZVMKF ID DMZVMKF DMZVMKF DN Alfuzosin DMZVMKF HS Approved DMZVMKF SN Alfusosine; Alfuzosina; Alfuzosine; Alfuzosinum; Alphuzosine; Alfuzosina [Spanish]; Alfuzosine [French]; Alfuzosinum [Latin]; Alfuzosin (INN); Alfuzosin [INN:BAN]; Xatral (TN); N-[3-[(4-amino-6,7-dimethoxyquinazolin-2-yl)-methylamino]propyl]oxolane-2-carboxamide; N-(3-((4-Amino-6,7-dimethoxy-2-quinazolinyl)methylamino)propyl)tetrahydro-2-furancarboxamide; N-{3-[(4-amino-6,7-dimethoxyquinazolin-2-yl)(methyl)amino]propyl}tetrahydrofuran-2-carboxamide DMZVMKF CP Sanofi-Aventis DMZVMKF TC Antihypertensive Agents DMZVMKF DT Small molecular drug DMZVMKF PC 2092 DMZVMKF MW 389.4 DMZVMKF FM C19H27N5O4 DMZVMKF IC InChI=1S/C19H27N5O4/c1-24(8-5-7-21-18(25)14-6-4-9-28-14)19-22-13-11-16(27-3)15(26-2)10-12(13)17(20)23-19/h10-11,14H,4-9H2,1-3H3,(H,21,25)(H2,20,22,23) DMZVMKF CS CN(CCCNC(=O)C1CCCO1)C2=NC3=CC(=C(C=C3C(=N2)N)OC)OC DMZVMKF IK WNMJYKCGWZFFKR-UHFFFAOYSA-N DMZVMKF IU N-[3-[(4-amino-6,7-dimethoxyquinazolin-2-yl)-methylamino]propyl]oxolane-2-carboxamide DMZVMKF CA CAS 81403-80-7 DMZVMKF CB CHEBI:51141 DMZVMKF DE Benign prostatic hyperplasia DM4LOD0 ID DM4LOD0 DM4LOD0 DN Alglucosidase alfa DM4LOD0 HS Approved DM4LOD0 SN Lumizyme (TN); Myozyme (TN) DM4LOD0 CP Genzyme Corporation DM4LOD0 TC Enzyme Replacement Agents DM4LOD0 SQ Alglucosidase alfa: AHPGRPRAVPTQCDVPPNSRFDCAPDKAITQEQCEARGCCYIPAKQGLQGAQMGQPWCFFPPSYPSYKLENLSSSEMGYTATLTRTTPTFFPKDILTLRLDVMMETENRLHFTIKDPANRRYEVPLETPHVHSRAPSPLYSVEFSEEPFGVIVRRQLDGRVLLNTTVAPLFFADQFLQLSTSLPSQYITGLAEHLSPLMLSTSWTRITLWNRDLAPTPGANLYGSHPFYLALEDGGSAHGVFLLNSNAMDVVLQPSPALSWRSTGGILDVYIFLGPEPKSVVQQYLDVVGYPFMPPYWGLGFHLCRWGYSSTAITRQVVENMTRAHFPLDVQWNDLDYMDSRRDFTFNKDGFRDFPAMVQELHQGGRRYMMIVDPAISSSGPAGSYRPYDEGLRRGVFITNETGQPLIGKVWPGSTAFPDFTNPTALAWWEDMVAEFHDQVPFDGMWIDMNEPSNFIRGSEDGCPNNELENPPYVPGVVGGTLQAATICASSHQFLSTHYNLHNLYGLTEAIASHRALVKARGTRPFVISRSTFAGHGRYAGHWTGDVWSSWEQLASSVPEILQFNLLGVPLVGADVCGFLGNTSEELCVRWTQLGAFYPFMRNHNSLLSLPQEPYSFSEPAQQAMRKALTLRYALLPHLYTLFHQAHVAGETVARPLFLEFPKDSSTWTVDHQLLWGEALLITPVLQAGKAEVTGYFPLGTWYDLQTVPVEALGSLPPPPAAPREPAIHSEGQWVTLPAPLDTINVHLRAGYIIPLQGPGLTTTESRQQPMALAVALTKGGEARGELFWDDGESLEVLERGAYTQVIFLARNNTIVNELVRVTSEGAGLQLQKVTVLGVATAPQQVLSNGVPVSNFTYSPDTKVLDICVSLLMGEQFLVSWC DM4LOD0 DE Pompe disease DM1BV7W ID DM1BV7W DM1BV7W DN Aliskiren DM1BV7W HS Approved DM1BV7W SN Rasilez; SPP 100; Rasilez (TN); Tekturna (TN); Aliskiren (USAN/INN); (2S,4S,5S,7S)-5-amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-8-methyl-2-(propan-2-yl)nonanamide; (2S,4S,5S,7S)-5-amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-4-hydroxy-7-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-8-methyl-2-propan-2-ylnonanamide; (2S,4S,5S,7S)-N-(2-Carbamoyl-2-methylpropyl)-5-amino-4-hydroxy-2,7-diisopropyl-8-[4-methoxy-3-(3-methoxypropoxy)phenyl]octanamide; Octanamide, .delta.-amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-.gamma.-hydroxy-4-methoxy-3-(3-methoxypropoxy)-.alpha.,.zeta.-bis(1-methylethyl)-, [.alpha.S-(alpha.R*,.gamma.R*,.delta.R*,.zeta.R*)] DM1BV7W CP Norvatis Phamaceuticals Corporation DM1BV7W TC Antihypertensive Agents DM1BV7W DT Small molecular drug DM1BV7W PC 5493444 DM1BV7W MW 551.8 DM1BV7W FM C30H53N3O6 DM1BV7W IC InChI=1S/C30H53N3O6/c1-19(2)22(14-21-10-11-26(38-8)27(15-21)39-13-9-12-37-7)16-24(31)25(34)17-23(20(3)4)28(35)33-18-30(5,6)29(32)36/h10-11,15,19-20,22-25,34H,9,12-14,16-18,31H2,1-8H3,(H2,32,36)(H,33,35)/t22-,23-,24-,25-/m0/s1 DM1BV7W CS CC(C)[C@@H](CC1=CC(=C(C=C1)OC)OCCCOC)C[C@@H]([C@H](C[C@@H](C(C)C)C(=O)NCC(C)(C)C(=O)N)O)N DM1BV7W IK UXOWGYHJODZGMF-QORCZRPOSA-N DM1BV7W IU (2S,4S,5S,7S)-5-amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-4-hydroxy-7-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-8-methyl-2-propan-2-ylnonanamide DM1BV7W CA CAS 173334-57-1 DM1BV7W CB CHEBI:601027 DM1BV7W DE Hypertension DMME8LH ID DMME8LH DMME8LH DN Alitretinoin DMME8LH HS Approved DMME8LH CP Ligand Pharmaceuticals DMME8LH TC Anticancer Agents DMME8LH DT Small molecular drug DMME8LH PC 449171 DMME8LH MW 300.4 DMME8LH FM C20H28O2 DMME8LH IC InChI=1S/C20H28O2/c1-15(8-6-9-16(2)14-19(21)22)11-12-18-17(3)10-7-13-20(18,4)5/h6,8-9,11-12,14H,7,10,13H2,1-5H3,(H,21,22)/b9-6+,12-11+,15-8-,16-14+ DMME8LH CS CC1=C(C(CCC1)(C)C)/C=C/C(=C\\C=C\\C(=C\\C(=O)O)\\C)/C DMME8LH IK SHGAZHPCJJPHSC-ZVCIMWCZSA-N DMME8LH IU (2E,4E,6Z,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenoic acid DMME8LH CA CAS 5300-03-8 DMME8LH CB CHEBI:50648 DMME8LH DE Kaposi sarcoma DMB4HFI ID DMB4HFI DMB4HFI DN Alkavervir DMB4HFI HS Approved DMB4HFI CP 3m Pharmaceuticals Inc DMB4HFI TC Cardiovascular Agents DMB4HFI DE High blood pressure DMNLHAC ID DMNLHAC DMNLHAC DN Allopregnanolone DMNLHAC HS Approved DMNLHAC SN 516-54-1; Brexanolone; Allotetrahydroprogesterone; Allopregnan-3alpha-ol-20-one; 3alpha-hydroxy-5alpha-pregnan-20-one; SAGE-547; UNII-S39XZ5QV8Y; 3-alpha,5-alpha-Pregnanolone; 3alpha-OH DHP; 3alpha,5alpha-THP; 5alpha-Pregnan-3alpha-ol-20-one; 3a-Hydroxy-5a-pregnan-20-one; 3a,5a-THP; (3alpha)-Allopregnanolone; 3-alpha,5-alpha-Tetrahydroprogesterone; BRN 3211363; S39XZ5QV8Y; 3alpha-Hydroxy-5alpha-dihydroprogesterone; 3-alpha-Hydroxy-5-alpha-pregnan-20-one; CHEMBL207538; CHEBI:50169; SGE-102 DMNLHAC DT Small molecular drug DMNLHAC PC 92786 DMNLHAC MW 318.5 DMNLHAC FM C21H34O2 DMNLHAC IC InChI=1S/C21H34O2/c1-13(22)17-6-7-18-16-5-4-14-12-15(23)8-10-20(14,2)19(16)9-11-21(17,18)3/h14-19,23H,4-12H2,1-3H3/t14-,15+,16-,17+,18-,19-,20-,21+/m0/s1 DMNLHAC CS CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC[C@@H]4[C@@]3(CC[C@H](C4)O)C)C DMNLHAC IK AURFZBICLPNKBZ-SYBPFIFISA-N DMNLHAC IU 1-[(3R,5S,8R,9S,10S,13S,14S,17S)-3-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]ethanone DMNLHAC CA CAS 516-54-1 DMNLHAC CB CHEBI:50169 DMNLHAC DE Postpartum depression; Essential tremor or related tremors; Status epilepticus seizure; Depression DMLPAOB ID DMLPAOB DMLPAOB DN Allopurinol DMLPAOB HS Approved DMLPAOB SN Adenock; Ailural; Ailurial; Allohexal; Allohexan; Alloprin; Allopur; Allopurin; Allopurinolum; Allorin; Allozym; Allpargin; Allural; Aloprim; Alopurinol; Aloral; Alositol; Aluline; Anoprolin; Anzief; Apulonga; Apurin; Apurol; Atisuril; Bleminol; Bloxanth; Caplenal; Capurate; Cellidrin; Cosuric; Dabrosin; Dabroson; Embarin; Epidropal; Epuric; Foligan; Geapur; Gichtex; Gotax; Hamarin; Hexanuret; Jenapurinol; Ketanrift; Ledopur; Lopurin; Lysuron; Milurit; Milurite; Miniplanor; Monarch; Nektrohan; Novopurol; Progout; Pureduct; Purinol; Remid; Riball; Rimapurinol; Roucol; Sigapurol; Suspendol; Takanarumin; Tipuric; Urbol; Uribenz; Uricemil; Uridocid; Uriprim; Uripurinol; Uritas; Urobenyl; Urolit; Urosin; Urtias; Xanthomax; Xanturat; Xanturic; Zygout; Zyloprim; Zyloric; Dura Al; Pan Quimica; A 8003; BW 56158; Urtias 100; AL-100; Allo-Puren; Allohexal (TN); Allopurinol(I); Allosig (TN); Apo-Allopurinol; BW 56-158; Ketobun-A; Progout (TN); Puricos (TN); Quimica, Pan; Zyloprim (TN); Zyloric (TN); BW-56-158; B. W. 56-158; 4-HPP DMLPAOB CP GlaxoSmithKline DMLPAOB TC Antimetabolites DMLPAOB DT Small molecular drug DMLPAOB PC 135401907 DMLPAOB MW 136.11 DMLPAOB FM C5H4N4O DMLPAOB IC InChI=1S/C5H4N4O/c10-5-3-1-8-9-4(3)6-2-7-5/h1-2H,(H2,6,7,8,9,10) DMLPAOB CS C1=NNC2=C1C(=O)NC=N2 DMLPAOB IK OFCNXPDARWKPPY-UHFFFAOYSA-N DMLPAOB IU 1,5-dihydropyrazolo[3,4-d]pyrimidin-4-one DMLPAOB CA CAS 315-30-0 DMLPAOB CB CHEBI:40279 DMLPAOB DE Hyperuricaemia DM0SYAN ID DM0SYAN DM0SYAN DN Almitrine DM0SYAN HS Approved DM0SYAN SN Almitrin; Almitrina; Almitrinum; Vectarion; Almitrine bismesylate; Almitrine dimesylate; S 2620; Almitrina [INN-Spanish]; Almitrine (INN); Almitrine Bis(methanesulfonate); Almitrine [BAN:INN]; Almitrine [INN:BAN]; Almitrinum [INN-Latin]; N,N'-diallyl-6-{4-[bis(4-fluorophenyl)methyl]piperazin-1-yl}-1,3,5-triazine-2,4-diamine; 2,4-Bis(allylamino)-6-(4-(bis(p-fluorophenyl)methyl)-1-piperazinyl)-s-triazine; 2,4-bis[allylamino]-6-[4-[bis(p-fluorophenyl)methyl]-1-piperazinyl]-s-triazine; 6-(4-(Bis(4-fluorphenyl)methyl)-1-piperazinyl)-N,N'-di-2-propenyl-1,3,5-triazin-2,4-diamin; 6-[4-[bis(4-fluorophenyl)methyl]piperazin-1-yl]-2-N,4-N-bis(prop-2-enyl)-1,3,5-triazine-2,4-diamine DM0SYAN TC Antiinflammatory Agents DM0SYAN DT Small molecular drug DM0SYAN PC 33887 DM0SYAN MW 477.6 DM0SYAN FM C26H29F2N7 DM0SYAN IC InChI=1S/C26H29F2N7/c1-3-13-29-24-31-25(30-14-4-2)33-26(32-24)35-17-15-34(16-18-35)23(19-5-9-21(27)10-6-19)20-7-11-22(28)12-8-20/h3-12,23H,1-2,13-18H2,(H2,29,30,31,32,33) DM0SYAN CS C=CCNC1=NC(=NC(=N1)N2CCN(CC2)C(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F)NCC=C DM0SYAN IK OBDOVFRMEYHSQB-UHFFFAOYSA-N DM0SYAN IU 6-[4-[bis(4-fluorophenyl)methyl]piperazin-1-yl]-2-N,4-N-bis(prop-2-enyl)-1,3,5-triazine-2,4-diamine DM0SYAN CA CAS 27469-53-0 DM0SYAN CB CHEBI:53778 DM0SYAN DE Chronic obstructive pulmonary disease DM7I64Z ID DM7I64Z DM7I64Z DN Almogran DM7I64Z HS Approved DM7I64Z SN Almotriptan; Axert; Almotriptan (USAN); Axert (TN); LAS-31416; PNU-180638; Almotriptan [USAN:INN:BAN]; N,N-dimethyl-2-[5-(pyrrolidin-1-ylsulfonylmethyl)-1H-indol-3-yl]ethanamine; N,N-dimethyl-2-{5-[(pyrrolidin-1-ylsulfonyl)methyl]-1H-indol-3-yl}ethanamine; 1-(((3-(2-(Dimethylamino)ethyl)indol-5-yl)methyl)sulfonyl)pyrrolidine DM7I64Z CP Almirall Prodesfarma DM7I64Z TC Antimigraine Agents DM7I64Z DT Small molecular drug DM7I64Z PC 123606 DM7I64Z MW 335.5 DM7I64Z FM C17H25N3O2S DM7I64Z IC InChI=1S/C17H25N3O2S/c1-19(2)10-7-15-12-18-17-6-5-14(11-16(15)17)13-23(21,22)20-8-3-4-9-20/h5-6,11-12,18H,3-4,7-10,13H2,1-2H3 DM7I64Z CS CN(C)CCC1=CNC2=C1C=C(C=C2)CS(=O)(=O)N3CCCC3 DM7I64Z IK WKEMJKQOLOHJLZ-UHFFFAOYSA-N DM7I64Z IU N,N-dimethyl-2-[5-(pyrrolidin-1-ylsulfonylmethyl)-1H-indol-3-yl]ethanamine DM7I64Z CA CAS 154323-57-6 DM7I64Z CB CHEBI:520985 DM7I64Z DE Migraine DMFG5ST ID DMFG5ST DMFG5ST DN Almotriptan malate DMFG5ST HS Approved DMFG5ST SN Almotriptan; Almotriptan (malate); Almotriptan malate; Almotriptan malate (USAN); Almotriptan malate [USAN]; Almotriptan maleate; CHEBI:53781; LAS 31416; LAS 31416 D,L-malate acid; PNU 180638E; PNU-180638E; Almogran; Almotriptan [USAN:INN:BAN]; Axert; CHEBI:520985; DSSTox_CID_24289; DSSTox_GSID_44289; DSSTox_RID_80142; LAS-31416; N,N-dimethyl-2-(5-((pyrrolidin-1-ylsulfonyl)methyl)-1H-indol-3-yl)ethanamine; N,N-dimethyl-2-[5-(pyrrolidin-1-ylsulfonylmethyl)-1H-indol-3-yl]ethanamine; N,N-dimethyl-2-{5-[(pyrrolidin-1-ylsulfonyl)methyl]-1H-indol-3-yl}ethanamine; NCGC00095135-01; UNII-1O4XL5SN61; WKEMJKQOLOHJLZ-UHFFFAOYSA-N; 1-(((3-(2-(Dimethylamino)ethyl)indol-5-yl)methyl)sulfonyl)pyrrolidine; 154323-57-6; 1O4XL5SN61; 1-(((3-(2-(Dimethylamino)ethyl)-1H-indol-5-yl)methyl)sulfonyl)pyrrolidine, hydroxybutanedionate (1:1); 1-(((3-(2-(Dimethylamino)ethyl)indol-5-yl)methyl)sulfonyl)pyrrolidine malate (1:1); 1-[[[2-(Dimethyl-amino)ethyl]-1H-indol-5-yl]methyl]sulfonyl]pyrrolidine Malate; 181183-52-8; AK110510 DMFG5ST PC 123607 DMFG5ST MW 469.6 DMFG5ST FM C21H31N3O7S DMFG5ST IC QHATUKWEVNMHRY-UHFFFAOYSA-N DMFG5ST CS CN(C)CCC1=CNC2=C1C=C(C=C2)CS(=O)(=O)N3CCCC3.C(C(C(=O)O)O)C(=O)O DMFG5ST IK 1S/C17H25N3O2S.C4H6O5/c1-19(2)10-7-15-12-18-17-6-5-14(11-16(15)17)13-23(21,22)20-8-3-4-9-20;5-2(4(8)9)1-3(6)7/h5-6,11-12,18H,3-4,7-10,13H2,1-2H3;2,5H,1H2,(H,6,7)(H,8,9) DMFG5ST IU N,N-dimethyl-2-[5-(pyrrolidin-1-ylsulfonylmethyl)-1H-indol-3-yl]ethanamine;2-hydroxybutanedioic acid DMFG5ST CA CAS 181183-52-8 DMFG5ST CB CHEBI:53781 DMFG5ST DE Migraine DM8WI3R ID DM8WI3R DM8WI3R DN Alogliptin DM8WI3R HS Approved DM8WI3R SN 850649-61-5; UNII-JHC049LO86; alogliptina; 2-({6-[(3r)-3-Aminopiperidin-1-Yl]-3-Methyl-2,4-Dioxo-3,4-Dihydropyrimidin-1(2h)-Yl}methyl)benzonitrile; SYR-322; JHC049LO86; (R)-2-((6-(3-aminopiperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl)benzonitrile; CHEBI:72323; AK322010; 2-({6-[(3R)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl}methyl)benzonitrile; vipidia; Alogliptin [INN]; Alogliptin (SYR-322); alogliptinum; alogliptine; HSDB 8203; UNII-JHC049LO86 DM8WI3R CP Takeda DM8WI3R DT Small molecular drug DM8WI3R PC 11450633 DM8WI3R MW 339.4 DM8WI3R FM C18H21N5O2 DM8WI3R IC InChI=1S/C18H21N5O2/c1-21-17(24)9-16(22-8-4-7-15(20)12-22)23(18(21)25)11-14-6-3-2-5-13(14)10-19/h2-3,5-6,9,15H,4,7-8,11-12,20H2,1H3/t15-/m1/s1 DM8WI3R CS CN1C(=O)C=C(N(C1=O)CC2=CC=CC=C2C#N)N3CCC[C@H](C3)N DM8WI3R IK ZSBOMTDTBDDKMP-OAHLLOKOSA-N DM8WI3R IU 2-[[6-[(3R)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxopyrimidin-1-yl]methyl]benzonitrile DM8WI3R CA CAS 850649-61-5 DM8WI3R CB CHEBI:72323 DM8WI3R DE Type-2 diabetes DML2A03 ID DML2A03 DML2A03 DN Alosetron DML2A03 HS Approved DML2A03 SN Lotronex; Lotrpnex; ALOSETRON HYDROCHLORIDE; Alosetron HCl; Alosetron hydrochloride [USAN]; Alosetron monohydrochloride; GR 68755; GR 68755X; GR 68755c; GR68755; Alosetron (INN); Alosetron [INN:BAN]; Alosetron hydrochloride (USAN); GR-68755C; Lotronex (TN); Lotrpnex (TN); 1H-Pyrido(4,3-b)indol-1-one, 2,3,4,5-tetrahydro-5-methyl-2((5-methyl-1H-imidazol-4-yl)methyl)-, monohydrochloride; 1H-Pyrido(4,3-b)indol-1-one, 2,3,4,5-tetrahydro-5-methyl-2-((5-methyl-1H-imidazol-4-yl)methyl)-, monohydrochloride; 1H-Pyrido[4,3-b]indol-1-one, 2,3,4,5-tetrahydro-5-methyl-2-[(4-methyl-1H-imidazol-5-yl)methyl]-, hydrochloride (1:1); 1H-Pyrido[4,3-b]indol-1-one, 2,3,4,5-tetrahydro-5-methyl-2-[(5-methyl-1H-imidazol; 1H-Pyrido[4,3-b]indol-1-one, 2,3,4,5-tetrahydro-5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-(9CI); 2,3,4,5-Tetrahydro-5-methyl-2-((5-methyl-1H-imidazol-4-yl)methyl)-1H-pyrido(4,3-b)indol-1-one; 2,3,4,5-Tetrahydro-5-methyl-2-((5-methylimidazol-4-yl)methyl)-1H-pyrido(4,3-b)indol-1-one monohydrochloride; 2,3,4,5-tetrahydro-5-methyl-2-((5-methylimidazol-4-yl)methyl)-1H-pyridol(4,3-b)indol-1-one monohydrochloride; 2,3,4,5-tetrahydro-5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-1H-pyrido[4,3-b]indol-1-one, monohydrochloride; 5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indol-1-one; 5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indol-1-one hydrochloride; 5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-3,4-dihydropyrido[4,3-b]indol-1-one; 5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-3,4-dihydropyrido[4,3-b]indol-1-one hydrochloride DML2A03 CP Prometheus Laboratories Inc DML2A03 TC Gastrointestinal Agents DML2A03 DT Small molecular drug DML2A03 PC 2099 DML2A03 MW 294.35 DML2A03 FM C17H18N4O DML2A03 IC InChI=1S/C17H18N4O/c1-11-13(19-10-18-11)9-21-8-7-15-16(17(21)22)12-5-3-4-6-14(12)20(15)2/h3-6,10H,7-9H2,1-2H3,(H,18,19) DML2A03 CS CC1=C(N=CN1)CN2CCC3=C(C2=O)C4=CC=CC=C4N3C DML2A03 IK JSWZEAMFRNKZNL-UHFFFAOYSA-N DML2A03 IU 5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-3,4-dihydropyrido[4,3-b]indol-1-one DML2A03 CA CAS 122852-42-0 DML2A03 CB CHEBI:253342 DML2A03 DE Irritable bowel syndrome DMEXMYK ID DMEXMYK DMEXMYK DN Alpelisib DMEXMYK HS Approved DMEXMYK SN alpelisib; 1217486-61-7; BYL-719; BYL719; UNII-08W5N2C97Q; BYL 719; Alpelisib (BYL719); (S)-N1-(4-Methyl-5-(2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl)thiazol-2-yl)pyrrolidine-1,2-dicarboxamide; NVP-BYL719; (2S)-N1-[4-Methyl-5-[2-(2,2,2-trifluoro-1,1-dimethylethyl)-4-pyridinyl]-2-thiazolyl]-1,2-pyrrolidinedicarboxamide; CHEMBL2396661; 08W5N2C97Q; AK146107; C19H22F3N5O2S; (S)-N1-(4-Methyl-5-(2-(1,1,1-trifluoro-2-methylpropan-2-yl)-pyridin-4-yl)thiazol-2-yl)pyrrolidine-1,2-dicarboxamide DMEXMYK CP Novartis DMEXMYK DT Small molecular drug DMEXMYK PC 56649450 DMEXMYK MW 441.5 DMEXMYK FM C19H22F3N5O2S DMEXMYK IC InChI=1S/C19H22F3N5O2S/c1-10-14(11-6-7-24-13(9-11)18(2,3)19(20,21)22)30-16(25-10)26-17(29)27-8-4-5-12(27)15(23)28/h6-7,9,12H,4-5,8H2,1-3H3,(H2,23,28)(H,25,26,29)/t12-/m0/s1 DMEXMYK CS CC1=C(SC(=N1)NC(=O)N2CCC[C@H]2C(=O)N)C3=CC(=NC=C3)C(C)(C)C(F)(F)F DMEXMYK IK STUWGJZDJHPWGZ-LBPRGKRZSA-N DMEXMYK IU (2S)-1-N-[4-methyl-5-[2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl]-1,3-thiazol-2-yl]pyrrolidine-1,2-dicarboxamide DMEXMYK CA CAS 1217486-61-7 DMEXMYK CB CHEBI:93752 DMEXMYK DE Solid tumour/cancer; Breast cancer DMXC1K9 ID DMXC1K9 DMXC1K9 DN Alpha 1-PI DMXC1K9 HS Approved DMXC1K9 SN Ifenprodil; 23210-56-2; Vadilex; ifenprodil tartrate; Dilvax; Creocral; 4-(2-(4-benzylpiperidin-1-yl)-1-hydroxypropyl)phenol; Ifenprodil [INN:DCF]; RC 61-91; Ifenprodilum [INN-Latin]; UNII-R8OE3P6O5S; EINECS 245-491-4; R8OE3P6O5S; CHEMBL305187; 4-Benzyl-alpha-(p-hydroxyphenyl)-beta-methyl-1-piperidineethanol; 2-(4-Benzylpiperidino)-1-(4-hydroxyphenyl)propanol; 4-[2-(4-benzylpiperidin-1-yl)-1-hydroxypropyl]phenol; NCGC00024643-03; IFENPRODIL HEMITARTRATE; alpha-(4-Hydroxyphenyl)-beta-methyl-4-(phenylmethyl)-1-piperidine DMXC1K9 DT Small molecular drug DMXC1K9 PC 3689 DMXC1K9 MW 325.4 DMXC1K9 FM C21H27NO2 DMXC1K9 IC InChI=1S/C21H27NO2/c1-16(21(24)19-7-9-20(23)10-8-19)22-13-11-18(12-14-22)15-17-5-3-2-4-6-17/h2-10,16,18,21,23-24H,11-15H2,1H3 DMXC1K9 CS CC(C(C1=CC=C(C=C1)O)O)N2CCC(CC2)CC3=CC=CC=C3 DMXC1K9 IK UYNVMODNBIQBMV-UHFFFAOYSA-N DMXC1K9 IU 4-[2-(4-benzylpiperidin-1-yl)-1-hydroxypropyl]phenol DMXC1K9 CA CAS 23210-56-2 DMXC1K9 CB CHEBI:93829 DMXC1K9 DE Alpha-1 antitrypsin deficiency; Cancer related pain DMAS02L ID DMAS02L DMAS02L DN Alpha-acetyldigoxin DMAS02L HS Approved DMAS02L SN Dioxanin (TN); Lanatilin (TN); Sandolanid (TN) DMAS02L DT Small molecular drug DMAS02L PC 11765960 DMAS02L MW 823 DMAS02L FM C43H66O15 DMAS02L IC InChI=1S/C43H66O15/c1-20-38(49)32(55-23(4)44)18-37(52-20)58-40-22(3)54-36(17-31(40)46)57-39-21(2)53-35(16-30(39)45)56-26-9-11-41(5)25(14-26)7-8-28-29(41)15-33(47)42(6)27(10-12-43(28,42)50)24-13-34(48)51-19-24/h13,20-22,25-33,35-40,45-47,49-50H,7-12,14-19H2,1-6H3/t20-,21-,22-,25-,26+,27-,28-,29+,30+,31+,32+,33-,35+,36+,37+,38-,39-,40-,41+,42+,43+/m1/s1 DMAS02L CS C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)OC(=O)C)O DMAS02L IK HWKJSYYYURVNQU-DXJNJSHLSA-N DMAS02L IU [(2R,3R,4S,6S)-6-[(2R,3S,4S,6S)-6-[(2R,3S,4S,6R)-6-[[(3S,5R,8R,9S,10S,12R,13S,14S,17R)-12,14-dihydroxy-10,13-dimethyl-17-(5-oxo-2H-furan-3-yl)-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-yl]oxy]-4-hydroxy-2-methyloxan-3-yl]oxy-4-hydroxy-2-methyloxan-3-yl]oxy-3-hydroxy-2-methyloxan-4-yl] acetate DMAS02L CA CAS 5511-98-8 DMAS02L DE Cardiovascular disease DMN7Y9K ID DMN7Y9K DMN7Y9K DN Alpidem DMN7Y9K HS Approved DMN7Y9K SN ALPIDEM; 82626-01-5; Ananxyl; Alpidemum [Latin]; UNII-I93SC245QZ; SL 80.0342-00; 2-(6-Chloro-2-(4-chlorophenyl)imidazo[1,2-a]pyridin-3-yl)-N,N-dipropylacetamide; 6-Chloro-2-(p-chlorophenyl)-N,N-dipropylimidazo(1,2-a)pyridine-3-acetamide; CHEMBL54349; I93SC245QZ; S-800342; NCGC00182850-01; 6-Chlor-2-(4-chlorphenyl)-N,N-dipropylimidazol(1,2-a)pyridin-3-acetamid; DSSTox_RID_83237; DSSTox_CID_28972; DSSTox_GSID_49046; Alpidemum; 6-Chloro-2-(4-chlorophenyl)-N,N-dipropyl-imidazo[1,2-a]pyridine-3-acetamide DMN7Y9K DT Small molecular drug DMN7Y9K PC 54897 DMN7Y9K MW 404.3 DMN7Y9K FM C21H23Cl2N3O DMN7Y9K IC InChI=1S/C21H23Cl2N3O/c1-3-11-25(12-4-2)20(27)13-18-21(15-5-7-16(22)8-6-15)24-19-10-9-17(23)14-26(18)19/h5-10,14H,3-4,11-13H2,1-2H3 DMN7Y9K CS CCCN(CCC)C(=O)CC1=C(N=C2N1C=C(C=C2)Cl)C3=CC=C(C=C3)Cl DMN7Y9K IK JRTIDHTUMYMPRU-UHFFFAOYSA-N DMN7Y9K IU 2-[6-chloro-2-(4-chlorophenyl)imidazo[1,2-a]pyridin-3-yl]-N,N-dipropylacetamide DMN7Y9K CA CAS 82626-01-5 DMN7Y9K CB CHEBI:135649 DMN7Y9K DE Anxiety disorder DMC7XDN ID DMC7XDN DMC7XDN DN Alprazolam DMC7XDN HS Approved DMC7XDN SN Alcelam; Algad; Alpaz; Alplax; Alpram; Alprax; Alprazolamum; Alprazolan; Alpronax; Alprox; Alviz; Alzam; Alzolam; Alzon;Anpress; ApoAlpraz; Azor; Bestrol; Cassadan; Constan; Esparon; Frontal; Helex; Intensol; Ksalol; Mialin; Neurol; Niravam; NovoAlprazol; NuAlpraz; Panistat; Panix; Pharnax; Prazam; Prazolan; Prinox; Ralozam; Relaxol; Restyl; Solanax; Tafil; Tensivan; Tranax; Trankimazin; Tranquinal; Tricalma; Unilan; Valeans; Xanagis; Xanax; Xanolam; Xanor; Zacetin; Zanapam; Zaxan; Zenax; Zolam; Zolan; Zolarem; Zoldac; Zoldax; Zopax; Zopic; Zotran; Alphapharm Brand of Alprazolam; Alprazolam Alphapharm Brand; Alprazolam Apotex Brand; Alprazolam Kenral Brand; Alprazolam Novopharm Brand; Alprazolam Orion Brand; Alprazolam Pfizer Brand; Alprazolam Temmler Brand; Alprazolam extended release tablets; Alprazolam intensol; Alprazolam solution; Apo Alpraz; Apotex Brand of Alprazolam; Arzneimittelwerk Dresden Brand of Alprazolam; Kenral Brand of Alprazolam; Novo Alprazol; Novopharm Brand of Alprazolam; Nu Alpraz; Nu Pharm Brand of Alprazolam; Orion Brand of Alprazolam; Pfizer Brand of Alprazolam; Tafil D; Temmler Brand of Alprazolam; Xanax TS; Xanax XR; D 65MT; D65MT; TGAR01P; Tus 1; U 31889; AP-1002; AZ-002; Alprazolam Nu-Pharm Brand; Alprazolam-d5; Alprazolamum [INN-Latin]; Apo-Alpraz; D-65MT; Gen-Alprazolan; Niravam (TN); Novo-Alprazol; Nu-Alpraz; Nu-Pharm Brand of Alprazolam; Staccato-alprazolam; TUS-1; U-31889; U31,889; Xanax (TN); Xanor (TN); U-31,889; Alprazolam (JP15/USP/INN); Alprazolam [USAN:INN:BAN:JAN]; 8-Chloro-1-methyl-6-(phenyl-d5)-4H-(1,2,4)triazolo[4,3-a][1,4]benzodiazepine; 8-Chloro-1-methyl-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine; 8-Chloro-1-methyl-6-phenyl-4H-s-triazolo(4,3-a)(1,4)benzodiazepine; 8-Chloro-1-methyl-6-phenyl-4H-s-triazolo(4,3-alpha)(1,4)benzodiazepine; 8-Chloro-1-methyl-6-phenyl-4H-s-triazolo[4,3-a][1,4]benzodiazepine DMC7XDN CP Pfizer Pharmaceuticals DMC7XDN TC Hypnotics and Sedatives DMC7XDN DT Small molecular drug DMC7XDN PC 2118 DMC7XDN MW 308.8 DMC7XDN FM C17H13ClN4 DMC7XDN IC InChI=1S/C17H13ClN4/c1-11-20-21-16-10-19-17(12-5-3-2-4-6-12)14-9-13(18)7-8-15(14)22(11)16/h2-9H,10H2,1H3 DMC7XDN CS CC1=NN=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4 DMC7XDN IK VREFGVBLTWBCJP-UHFFFAOYSA-N DMC7XDN IU 8-chloro-1-methyl-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine DMC7XDN CA CAS 28981-97-7 DMC7XDN CB CHEBI:2611 DMC7XDN DE Anxiety disorder; Epilepsy DMWH7NQ ID DMWH7NQ DMWH7NQ DN Alprostadil DMWH7NQ HS Approved DMWH7NQ SN Prostaglandin E1; alprostadil; 745-65-3; PGE1; Muse; Edex; Caverject; Prostin VR; Alprostadilum; Femprox; Befar; Vitaros; Prostandin; Liprostin; PGE-1; Prink (TN); Befar (TN); Prostavasin; Vasaprostan; MR-256; Minprog; UNII-F5TD010360; Alprostadil(Caverject); CHEMBL495; (11alpha,13E,15S)-11,15-dihydroxy-9-oxoprost-13-en-1-oic acid; Prostivas; Lipoprost; 11alpha,15alpha-Dihydroxy-9-oxo-13-trans-prostenoic acid; (13E)-(15S)-11alpha,15-Dihydroxy-9-oxoprost-13-enoate; FemLife; RayVa; Sugiran; Viridal; MR 256; PGE1 Oligomer; BML1-F06; Caverject (TN); Edex (TN); HEI-507; Muse (TN); Prostin VR pediatric (TN); U-10136; Alprostadil (JP15/USP/INN); Prost-13-en-1-oic acid, 11,15-dihydroxy-9-oxo-, (11alpha,13E,15S)-, homopolymer; (11alpha,13E,15S)-11,15-Dihydroxy-9-oxoprost-13-enoic acid; (13E,15S)-11alpha,15-dihydroxy-9-oxoprost-13-en-1-oic acid; 7-[(1R,2R,3R)-3-hydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]-5-oxocyclopentyl]heptanoic acid; Lipo-alprostadil DMWH7NQ CP Pfizer Pharmaceuticals DMWH7NQ TC Vasodilator Agents DMWH7NQ DT Small molecular drug DMWH7NQ PC 5280723 DMWH7NQ MW 354.5 DMWH7NQ FM C20H34O5 DMWH7NQ IC InChI=1S/C20H34O5/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25/h12-13,15-17,19,21,23H,2-11,14H2,1H3,(H,24,25)/b13-12+/t15-,16+,17+,19+/m0/s1 DMWH7NQ CS CCCCC[C@@H](/C=C/[C@H]1[C@@H](CC(=O)[C@@H]1CCCCCCC(=O)O)O)O DMWH7NQ IK GMVPRGQOIOIIMI-DWKJAMRDSA-N DMWH7NQ IU 7-[(1R,2R,3R)-3-hydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]-5-oxocyclopentyl]heptanoic acid DMWH7NQ CA CAS 745-65-3 DMWH7NQ CB CHEBI:15544 DMWH7NQ DE Erectile dysfunction; Diabetic foot ulcer DMB47TQ ID DMB47TQ DMB47TQ DN Alseroxylon DMB47TQ HS Approved DMB47TQ TC Antihypertensive Agents DMB47TQ DE Hypertension DMRJ3YX ID DMRJ3YX DMRJ3YX DN Alteplase DMRJ3YX HS Approved DMRJ3YX SN Activase (TN) DMRJ3YX CP Boehringer Ingelheim Ltd DMRJ3YX TC Thrombolytic Agents DMRJ3YX SQ Alteplase sequence: SYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP DMRJ3YX DE Pulmonary embolism DMKLAYG ID DMKLAYG DMKLAYG DN Altretamine DMKLAYG HS Approved DMKLAYG SN Altretamina; Altretaminum; HEXAMETHYLMELAMINE; HMM; HTM; HXM; Hemel; Hexalen; Hexastat; Hexinawas; Altretamine Bellon Brand; Altretamine Chiesi Brand; Altretamine Wassermann Brand; Bellon Brand of Altretamine; Chiesi Brand of Altretamine; MGI Pharma Brand of Altretamine; Rhone Poulenc Rorer Brand of Altretamine; Wassermann Brand of Altretamine; A 8723; ENT 50852; NC 195; Altretamina [INN-Spanish]; Altretaminum [INN-Latin]; Hexalen (TN); Hexalen, Altretamine; KB-913; Rhone-Poulenc Rorer Brand of Altretamine; Altretamine (USP/INN); Altretamine [USAN:INN:BAN]; No-s-triazine; N,N,N',N',N'',N''-hexamethyl-1,3,5-triazine-2,4,6-triamine; N~2~,N~2~,N~4~,N~4~,N~6~,N~6~-Hexamethyl-1,3,5-triazine-2,4,6-triamine; 2,4, 6-Tris(dimethylamino)-1,3,5-triazine; 2,4,6-Tris(dimethylami; 2,4,6-Tris(dimethylamino)-1,3,5-triazine; 2,4,6-Tris(dimethylamino-s-triazine; 2-N,2-N,4-N,4-N,6-N,6-N-hexamethyl-1,3,5-triazine-2,4,6-triamine DMKLAYG TC Anticancer Agents DMKLAYG DT Small molecular drug DMKLAYG PC 2123 DMKLAYG MW 210.28 DMKLAYG FM C9H18N6 DMKLAYG IC InChI=1S/C9H18N6/c1-13(2)7-10-8(14(3)4)12-9(11-7)15(5)6/h1-6H3 DMKLAYG CS CN(C)C1=NC(=NC(=N1)N(C)C)N(C)C DMKLAYG IK UUVWYPNAQBNQJQ-UHFFFAOYSA-N DMKLAYG IU 2-N,2-N,4-N,4-N,6-N,6-N-hexamethyl-1,3,5-triazine-2,4,6-triamine DMKLAYG CA CAS 645-05-6 DMKLAYG CB CHEBI:24564 DMKLAYG DE Ovarian cancer DMO9WDS ID DMO9WDS DMO9WDS DN Altropane DMO9WDS HS Approved DMO9WDS SN Carbon-11-Altropane; Iodine-123-Altropane; 11C-Altropane; 123I-Altropane DMO9WDS CP Harvard University DMO9WDS DT Small molecular drug DMO9WDS PC 6440180 DMO9WDS MW 429.3 DMO9WDS FM C18H21FINO2 DMO9WDS IC InChI=1S/C18H21FINO2/c1-23-18(22)17-15(12-3-5-13(19)6-4-12)11-14-7-8-16(17)21(14)10-2-9-20/h2-6,9,14-17H,7-8,10-11H2,1H3/b9-2+/t14-,15+,16+,17-/m0/s1 DMO9WDS CS COC(=O)[C@@H]1[C@H]2CC[C@H](N2C/C=C/I)C[C@@H]1C3=CC=C(C=C3)F DMO9WDS IK GTQLIPQFXVKRKJ-UNSMHXHVSA-N DMO9WDS IU methyl (1R,2S,3S,5S)-3-(4-fluorophenyl)-8-[(E)-3-iodoprop-2-enyl]-8-azabicyclo[3.2.1]octane-2-carboxylate DMO9WDS CA CAS 180468-34-2 DMO9WDS CB CHEBI:135696 DMO9WDS DE Attention deficit hyperactivity disorder DM6ECN9 ID DM6ECN9 DM6ECN9 DN Aluminium DM6ECN9 HS Approved DM6ECN9 SN ALUMINUM; Adom; Aluminio; Metana; AO Al; Al alloy; Alaun [German]; Allbri aluminum paste and powder; Alumina fibre; Aluminium bronze; Aluminium flake; Aluminum alloy; Aluminum dehydrated; Aluminum dust; Aluminum metal; Aluminum powder; Aluminum production; Aluminum pyro powders; Aluminum soluble salts; Aluminum welding fumes; Emanay atomized aluminum powder; Metana aluminum paste; Noral Extra Fine Lining Grade; Noral Ink Grade Aluminum; Noral aluminium; Noral aluminum; Noral ink grade aluminium; A 00; A 95; A 99; A 995; A 999; AA 1099; AA1199; AD 1; AD1M; AO A1; AV00; AV000; Aa1193; Aluminum 27; Aluminum A00; Aluminum hydride [UN2463] [Dangerous when wet]; JISC 3108; JISC 3110; L16; NA9260; Pigment metal 1; ALUMINUM, ATOMIZED; Al(0); Aluminium(0); Aluminium, elementar; Aluminum (dust or fume); Aluminum (fume or dust); Aluminum (metal); Aluminum metal, alkyls; Aluminum metal, pyro powders; Aluminum metal, respirable fraction; Aluminum metal, soluble salts; Aluminum metal, total dust; Aluminum metal, welding fumes; Aluminum powder, coated [UN1309] [Flammable solid]; Aluminum powder, uncoated [UN1396] [Dangerous when wet]; Aluminum, elemental; Aluminum, molten [NA9260] [Class 9]; Aluminum, pyro powders; Aluminum, soluble salts; Aluminum, welding fumes; C-Pigment 1; C-Pigment 1 [German]; Noral non-leafing grade; Aluminum, pyro powders/welding fumes; C.I. 77000; ALUMINUM (SEE ALSO ALUMINUM OXIDE 1344-28-1); ALUMINUM, 99.999%; AQUANAL-plus aluminum (Al) 0.02-0.2 mg/L; AQUANAL(R)-plus aluminum (Al) 0.02-0.2 mg/L; 11008_ALDRICH; 11008_RIEDEL; 11009_ALDRICH; 11009_RIEDEL; 11010_ALDRICH; 11010_RIEDEL; 13Al DM6ECN9 TC Antiinflammatory Agents DM6ECN9 DT Small molecular drug DM6ECN9 PC 5359268 DM6ECN9 MW 26.981 DM6ECN9 FM Al DM6ECN9 IC InChI=1S/Al DM6ECN9 CS [Al] DM6ECN9 IK XAGFODPZIPBFFR-UHFFFAOYSA-N DM6ECN9 IU aluminum DM6ECN9 CA CAS 7429-90-5 DM6ECN9 CB CHEBI:28984 DM6ECN9 DE Hyperhidrosis DMHR8KW ID DMHR8KW DMHR8KW DN Alvimopan DMHR8KW HS Approved DMHR8KW SN Alvimopan anhydrous; LY 246736; LY246736; Adl 8-2698; Entereg (TN); Trans-3,4-dimethyl-4-(3-hydroxyphenyl) piperidine; Glycine, N-[2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl; 2-[[(2S)-2-benzyl-3-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethylpiperidin-1-yl]propanoyl]amino]acetic acid DMHR8KW CP GSK DMHR8KW TC Analgesics DMHR8KW DT Small molecular drug DMHR8KW PC 5488548 DMHR8KW MW 424.5 DMHR8KW FM C25H32N2O4 DMHR8KW IC InChI=1S/C25H32N2O4/c1-18-16-27(12-11-25(18,2)21-9-6-10-22(28)14-21)17-20(24(31)26-15-23(29)30)13-19-7-4-3-5-8-19/h3-10,14,18,20,28H,11-13,15-17H2,1-2H3,(H,26,31)(H,29,30)/t18-,20-,25+/m0/s1 DMHR8KW CS C[C@H]1CN(CC[C@@]1(C)C2=CC(=CC=C2)O)C[C@H](CC3=CC=CC=C3)C(=O)NCC(=O)O DMHR8KW IK UPNUIXSCZBYVBB-JVFUWBCBSA-N DMHR8KW IU 2-[[(2S)-2-benzyl-3-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethylpiperidin-1-yl]propanoyl]amino]acetic acid DMHR8KW CA CAS 156053-89-3 DMHR8KW CB CHEBI:135686 DMHR8KW DE Gastrointestinal disease DMS3YE9 ID DMS3YE9 DMS3YE9 DN Amantadine DMS3YE9 HS Approved DMS3YE9 SN Adamantamine; Adamantanamine; Adamantylamine; Amant; Amantadina; Amantadinum; Amantidine; Aminoadamantane; Endantadine; Mantadine; Symadine; Wiregyt; Amantadine Base; BIA4304; OR14310; Amantadina [INN-Spanish]; Amantadine (INN); Amantadine [INN:BAN]; Amantadinum [INN-Latin]; Gen-Amantadine; Pk-merz; Symmetrel (TN); TCMDC-125869; ADAMANTANE,1-AMINO; Adamantan-1-amine; Adamantan-1-ylamine; Tricyclo[3.3.1.1^3,7]decan-1-amine; Tricyclo(3.3.1.13,7)decan-1-amine; Tricyclo[3.3.1.1(3,7)]decan-1-amine; Tricyclo[3.3.1.1(3,7)]decan-1-ylamine; Tricyclo[3.3.1.1(3,7)]decane-1-amine; Tricyclo[3.3.1.1(sup3,7)]decan-1-amine; Tricyclo(3.3.1.1(sup 3,7))decan-1-amine; Tricyclo(3.3.1.1(sup 3.7))decan-1-amine; Tricyclo[3.3.1.1~3,7~]decan-1-amine; Tricyclo(3.3.1.1(3,7))-decan-1-amine; 1-Adamantamine; 1-Adamantanamine; 1-Adamantanamine (8CI); 1-Adamantylamine; 1-Aminoadamantane; 1-Aminotricyclo(3.3.1.1(sup 3,7))decane DMS3YE9 TC Antiviral Agents DMS3YE9 DT Small molecular drug DMS3YE9 PC 2130 DMS3YE9 MW 151.25 DMS3YE9 FM C10H17N DMS3YE9 IC InChI=1S/C10H17N/c11-10-4-7-1-8(5-10)3-9(2-7)6-10/h7-9H,1-6,11H2 DMS3YE9 CS C1C2CC3CC1CC(C2)(C3)N DMS3YE9 IK DKNWSYNQZKUICI-UHFFFAOYSA-N DMS3YE9 IU adamantan-1-amine DMS3YE9 CA CAS 768-94-5 DMS3YE9 CB CHEBI:2618 DMS3YE9 DE Influenza A virus infection DMOP0BL ID DMOP0BL DMOP0BL DN Ambenonium DMOP0BL HS Approved DMOP0BL SN Ambenonum; Ambenonium Base; Ambenonium kation; Mytelase (TN); (2-chlorophenyl)methyl-[2-[[2-[2-[(2-chlorophenyl)methyl-diethylazaniumyl]ethylamino]-2-oxoacetyl]amino]ethyl]-diethylazanium; 2,2'-[(1,2-dioxoethane-1,2-diyl)diimino]bis[n-(2-chlorobenzyl)-n,n-diethylethanaminium] DMOP0BL CP Sanofi Aventis Us Llc DMOP0BL TC Antiarrhythmic Agents DMOP0BL DT Small molecular drug DMOP0BL PC 2131 DMOP0BL MW 537.6 DMOP0BL FM C28H42Cl2N4O2+2 DMOP0BL IC InChI=1S/C28H40Cl2N4O2/c1-5-33(6-2,21-23-13-9-11-15-25(23)29)19-17-31-27(35)28(36)32-18-20-34(7-3,8-4)22-24-14-10-12-16-26(24)30/h9-16H,5-8,17-22H2,1-4H3/p+2 DMOP0BL CS CC[N+](CC)(CCNC(=O)C(=O)NCC[N+](CC)(CC)CC1=CC=CC=C1Cl)CC2=CC=CC=C2Cl DMOP0BL IK OMHBPUNFVFNHJK-UHFFFAOYSA-P DMOP0BL IU (2-chlorophenyl)methyl-[2-[[2-[2-[(2-chlorophenyl)methyl-diethylazaniumyl]ethylamino]-2-oxoacetyl]amino]ethyl]-diethylazanium DMOP0BL CA CAS 7648-98-8 DMOP0BL CB CHEBI:2627 DMOP0BL DE Myasthenia gravis DMD1QXW ID DMD1QXW DMD1QXW DN Ambrisentan DMD1QXW HS Approved DMD1QXW SN Letairis; Ambrisentan [INN]; Gilead brand of ambrisentan; BSF 208075; BSF208075; LU 208075; LU208075; BSF-208075; LU-208075; Benzenepropanoic acid, .alpha.-[(4,6-dimethyl-2-pyrimidinyl)oxy]-.beta.-methoxy-.beta.-phe; (+-)-(2S)-2-((4,6-Dimethylpyrimidin-2-yl)oxy)-3-methoxy-3,3-diphenylpropanoic acid; 2-(4,6-dimethylpyrimidin-2-yl)oxy-3-methoxy-3,3-diphenyl-propanoic acid; 2-(4,6-dimethylpyrimidin-2-yl)oxy-3-methoxy-3,3-diphenylpropanoic acid; 2-[(4,6-dimethylpyrimidin-2-yl)oxy]-3-methoxy-3,3-diphenylpropanoic acid DMD1QXW CP GSK DMD1QXW DT Small molecular drug DMD1QXW PC 6918493 DMD1QXW MW 378.4 DMD1QXW FM C22H22N2O4 DMD1QXW IC InChI=1S/C22H22N2O4/c1-15-14-16(2)24-21(23-15)28-19(20(25)26)22(27-3,17-10-6-4-7-11-17)18-12-8-5-9-13-18/h4-14,19H,1-3H3,(H,25,26)/t19-/m1/s1 DMD1QXW CS CC1=CC(=NC(=N1)O[C@H](C(=O)O)C(C2=CC=CC=C2)(C3=CC=CC=C3)OC)C DMD1QXW IK OUJTZYPIHDYQMC-LJQANCHMSA-N DMD1QXW IU (2S)-2-(4,6-dimethylpyrimidin-2-yl)oxy-3-methoxy-3,3-diphenylpropanoic acid DMD1QXW CA CAS 177036-94-1 DMD1QXW CB CHEBI:135949 DMD1QXW DE Pulmonary arterial hypertension DMWJE9D ID DMWJE9D DMWJE9D DN Ambroxol DMWJE9D HS Approved DMWJE9D SN Ambroxol hydrochloride; 23828-92-4; Ambroxol HCl; Mucosolvan; Mucoangin; Ambroxolhydrochloride; cis-4-((2-Amino-3,5-dibromobenzyl)amino)cyclohexanol hydrochloride; UNII-CC995ZMV90; Ambroxol hydrochloride; trans-4-((2-Amino-3,5-dibromobenzyl)amino)cyclohexanol hydrochloride; Ambroxol Hydrochloride [JAN]; CC995ZMV90; 15942-05-9; Ambroxol hydrochloride (JAN); 2-Amino-3,5-dibromo-N-[trans-4-hydroxycyclohexyl]benzylamine; 4-((2-amino-3,5-dibromobenzyl)amino)cyclohexan-1-ol hydrochloride DMWJE9D CP Exsar DMWJE9D DT Small molecular drug DMWJE9D PC 2132 DMWJE9D MW 378.1 DMWJE9D FM C13H18Br2N2O DMWJE9D IC InChI=1S/C13H18Br2N2O/c14-9-5-8(13(16)12(15)6-9)7-17-10-1-3-11(18)4-2-10/h5-6,10-11,17-18H,1-4,7,16H2 DMWJE9D CS C1CC(CCC1NCC2=C(C(=CC(=C2)Br)Br)N)O DMWJE9D IK JBDGDEWWOUBZPM-UHFFFAOYSA-N DMWJE9D IU 4-[(2-amino-3,5-dibromophenyl)methylamino]cyclohexan-1-ol DMWJE9D CA CAS 18683-91-5 DMWJE9D CB CHEBI:92994 DMWJE9D DE Bronchitis DMM1JL9 ID DMM1JL9 DMM1JL9 DN Amcinonide DMM1JL9 HS Approved DMM1JL9 SN Amcinonida; Amcinonido; Amcinonidum; Cyclocort; Cyclort; Triamcinolonacetatcyclopentanonid; Visderm; CL 34699; Amcinonido [INN-Spanish]; Amcinonidum [INN-Latin]; CL 34,699; CL-34699; Cyclocort (TN); Amcinonide (JAN/USP/INN); Amcinonide [USAN:INN:BAN:JAN]; Triamcinolone 16,17-cyclopentylidenedioxy-21-acetate; 1,4-Pregnadiene-2,20-dione-16,17-cyclopentylidenedioxy-9-fluoro-11,21-dihydroxy-21-acetate; 16alpha,17alpha-(cyclopentane-1,1-diyldioxy)-9-fluoro-11beta-hydroxy-3,20-dioxopregna-1,4-dien-21-yl acetate; 19alpha-Fluor-11beta,21-dihydroxy-16alpha,17alpha-(tetramethylen)methylendioxy-1,4-pregnadien-3,20-dion 21-acetat; 9-Fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with cyclopentanone, 21-acetate DMM1JL9 TC Antiinflammatory Agents DMM1JL9 DT Small molecular drug DMM1JL9 PC 443958 DMM1JL9 MW 502.6 DMM1JL9 FM C28H35FO7 DMM1JL9 IC InChI=1S/C28H35FO7/c1-16(30)34-15-22(33)28-23(35-26(36-28)9-4-5-10-26)13-20-19-7-6-17-12-18(31)8-11-24(17,2)27(19,29)21(32)14-25(20,28)3/h8,11-12,19-21,23,32H,4-7,9-10,13-15H2,1-3H3/t19-,20-,21-,23+,24-,25-,27-,28+/m0/s1 DMM1JL9 CS CC(=O)OCC(=O)[C@@]12[C@@H](C[C@@H]3[C@@]1(C[C@@H]([C@]4([C@H]3CCC5=CC(=O)C=C[C@@]54C)F)O)C)OC6(O2)CCCC6 DMM1JL9 IK ILKJAFIWWBXGDU-MOGDOJJUSA-N DMM1JL9 IU [2-[(1S,2S,4R,8S,9S,11S,12R,13S)-12-fluoro-11-hydroxy-9,13-dimethyl-16-oxospiro[5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-diene-6,1'-cyclopentane]-8-yl]-2-oxoethyl] acetate DMM1JL9 CA CAS 51022-69-6 DMM1JL9 CB CHEBI:31199 DMM1JL9 DE Inflammation DMIG6FY ID DMIG6FY DMIG6FY DN Amdinocillin DMIG6FY HS Approved DMIG6FY SN Coactin; Hexacillin; Mecilinamo; Mecillinam; Mecillinamum; Selexidin; Amdinocillin Mecillinam; Amdinocillin [USAN]; Penicillin HX; FL 1060; Ro 109070; Amdinocillin (USAN); Coactin (TN); FL-1060; Mecilinamo [INN-Spanish]; Mecillinam (INN); Mecillinamum [INN-Latin]; Ro 10-9070; Ro-10-9070; Rel-(2R,6S)-6-{[(1E)-azepan-1-ylmethylene]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-(((Hexahydro-1H-azepin-1-yl)methylene)amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid; (2S,5R,6R)-6-(azepan-1-ylmethylideneamino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-[(azepan-1-ylmethylidene)amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-{[(1E)-azepan-1-ylmethylidene]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 6-((Hexahydro-1H-azepin-1-yl)methyleneamino)penicillanic acid; 6beta-[(azepan-1-ylmethylidene)amino]-2,2-dimethylpenam-3alpha-carboxylic acid DMIG6FY CP Leo Pharmaceutical DMIG6FY TC Antibiotics DMIG6FY DT Small molecular drug DMIG6FY PC 36273 DMIG6FY MW 325.4 DMIG6FY FM C15H23N3O3S DMIG6FY IC InChI=1S/C15H23N3O3S/c1-15(2)11(14(20)21)18-12(19)10(13(18)22-15)16-9-17-7-5-3-4-6-8-17/h9-11,13H,3-8H2,1-2H3,(H,20,21)/t10-,11+,13-/m1/s1 DMIG6FY CS CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)N=CN3CCCCCC3)C(=O)O)C DMIG6FY IK BWWVAEOLVKTZFQ-NTZNESFSSA-N DMIG6FY IU (2S,5R,6R)-6-(azepan-1-ylmethylideneamino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid DMIG6FY CA CAS 32887-01-7 DMIG6FY DE Bacterial infection DM6I2WQ ID DM6I2WQ DM6I2WQ DN Amezinium DM6I2WQ HS Approved DM6I2WQ SN Amezinium methyl sulfate DM6I2WQ DT Small molecular drug DM6I2WQ PC 71927 DM6I2WQ MW 202.23 DM6I2WQ FM C11H12N3O+ DM6I2WQ IC InChI=1S/C11H11N3O/c1-15-11-7-9(12)8-13-14(11)10-5-3-2-4-6-10/h2-8,12H,1H3/p+1 DM6I2WQ CS COC1=[N+](N=CC(=C1)N)C2=CC=CC=C2 DM6I2WQ IK VXROHTDSRBRJLN-UHFFFAOYSA-O DM6I2WQ IU 6-methoxy-1-phenylpyridazin-1-ium-4-amine DM6I2WQ CA CAS 41658-78-0 DM6I2WQ CB CHEBI:145698 DM6I2WQ DE Hypotension DM9YSNQ ID DM9YSNQ DM9YSNQ DN Amfepramone DM9YSNQ HS Approved DM9YSNQ SN Diethylpropion; DIETHYLPROPION; Diethylpropione; Amfepramon; Tepanil; Anorex; Nopropiophenone; Frekentine; Amphepramon; Amfepramonum; Amphepramone; Adiposon; Tylinal; Magrene; Dobesin; Neobes; Danylen; alpha-Benzoyltriethylamine; Anfepramona; Cegramine; Obesitex; Silutin; Regenon; Prefamone; Derfon; alpha-Diethylaminopropiophenone; 90-84-6; Diethylcathinone; Amfepramonum [INN-Latin]; Anfepramona [INN-Spanish]; Amfepramone [INN]; Parabolin; Modulor; Keramik; Keramin; Anfamon; 2-(Diethylamino)propiophenone; 1-Phenyl-2-diethylamino-1-propanone; Adiposon; Danylen;Derfon; Phepranon; Reginon; Amfepramone HCL; Amfepramone hydrochloride; Amphepramonum hydrochloride; Diethylpropion HCL; Diethylpropione hydrochloride; Tenuate hydrochloride; UR 1423; Alpha-Benzoyltriethylamine; Alpha-Diethylaminopropiophenone; Amfepramone (INN); Diethylpropion (BAN); Fenyl-(1-diethylaminoethyl)keton; Fenyl-(1-diethylaminoethyl)keton [Czech]; (+-)-diethylpropion; 2-(Diethylamino)-1-phenyl-1-propanone; 2-(diethylamino)-1-phenylpropan-1-one; 2-Diethylaminopropiophenone DM9YSNQ DT Small molecular drug DM9YSNQ PC 7029 DM9YSNQ MW 205.3 DM9YSNQ FM C13H19NO DM9YSNQ IC InChI=1S/C13H19NO/c1-4-14(5-2)11(3)13(15)12-9-7-6-8-10-12/h6-11H,4-5H2,1-3H3 DM9YSNQ CS CCN(CC)C(C)C(=O)C1=CC=CC=C1 DM9YSNQ IK XXEPPPIWZFICOJ-UHFFFAOYSA-N DM9YSNQ IU 2-(diethylamino)-1-phenylpropan-1-one DM9YSNQ CA CAS 90-84-6 DM9YSNQ CB CHEBI:4530 DM9YSNQ DE Obesity; Migraine DMK08L3 ID DMK08L3 DMK08L3 DN Amifampridine DMK08L3 HS Approved DMK08L3 SN 3,4-DIAMINOPYRIDINE; pyridine-3,4-diamine; 3,4-Pyridinediamine; Firdapse; Diamino-3,4 pyridine; 4,5-Diaminopyridine; 3,4-DAP; SC10; amifampridin; Zenas; UNII-RU4S6E2G0J; EINECS 200-220-9; NSC 521760; BRN 0110232; RU4S6E2G0J; OYTKINVCDFNREN-UHFFFAOYSA-N; WT559; NCGC00167560-01; SMR000752913 DMK08L3 CP Catalyst Pharmaceuticals DMK08L3 PC 5918 DMK08L3 MW 109.13 DMK08L3 FM C5H7N3 DMK08L3 IC InChI=1S/C5H7N3/c6-4-1-2-8-3-5(4)7/h1-3H,7H2,(H2,6,8) DMK08L3 CS C1=CN=CC(=C1N)N DMK08L3 IK OYTKINVCDFNREN-UHFFFAOYSA-N DMK08L3 IU pyridine-3,4-diamine DMK08L3 CA CAS 54-96-6 DMK08L3 CB CHEBI:135948 DMK08L3 DE LambertEaton myasthenic syndrome DM5FL14 ID DM5FL14 DM5FL14 DN Amifostine DM5FL14 HS Approved DM5FL14 SN Ethiofos; Ethyol; Gammaphos; WR-1064; WR-2721; WR-2721C; YM-08310 DM5FL14 CP Medimmune Oncology Inc DM5FL14 DT Small molecular drug DM5FL14 PC 2141 DM5FL14 MW 214.23 DM5FL14 FM C5H15N2O3PS DM5FL14 IC InChI=1S/C5H15N2O3PS/c6-2-1-3-7-4-5-12-11(8,9)10/h7H,1-6H2,(H2,8,9,10) DM5FL14 CS C(CN)CNCCSP(=O)(O)O DM5FL14 IK JKOQGQFVAUAYPM-UHFFFAOYSA-N DM5FL14 IU 2-(3-aminopropylamino)ethylsulfanylphosphonic acid DM5FL14 CA CAS 20537-88-6 DM5FL14 CB CHEBI:2636 DM5FL14 DE Mucositis DM5PDRB ID DM5PDRB DM5PDRB DN Amikacin DM5PDRB HS Approved DM5PDRB SN Amicacin; Amikacina; Amikacine; Amikacinum; Amikavet; Amikin; Arikace; Briclin; Kaminax; Lukadin; Mikavir; AMIKACIN SULFATE; Amikacin Base; Amikacin Dihydrate; ANTIBIOTIC BB-K8; Amiglyde-V; Amikacin & Tumor Necrosis Factor; Amikacin (USP); Amikacina [INN-Spanish]; Amikacine [INN-French]; Amikacinum [INN-Latin]; Amikin(Disulfate); Antibiotic BB-K 8; BB-K 8; BB-K8; Amiglyde-V (TN); Amikacin (USP/INN); Amikacin [USAN:BAN:INN]; O-3-Amino-3-deoxy-alpha-D-glucopyranosyl-(1-4)-O-(6-amino-6-deoxy-alpha-D-glucopyranosyl-(1-6))-N(sup 3)-(4-amino-L-2-hydroxybutyryl)-2-deoxy-L-streptamine; O-3-amino-3-deoxy-alpha-D-glucopyranosyl-(1->4)-O-(6-amino-6-deoxy-alpha-D-glucopyranosyl-(1->6))-N(3)-(4-amino-L-2-hydroxybutyryl)-2-deoxy-L-streptamine; O-3-Amino-3-deoxy-.alpha.-D-glucopyranosyl-(1->6)-O-[6-amino-6-deoxy-.alpha.-D-glucopyranosyl-(1->4)]-1-(4-amino-2-hydroxy-1-oxobutyl)-2-deoxy-D-streptamine; (2S)-4-amino-N-[(1R,2S,3S,4R,5S)-5-amino-2-(3-amino-3-deoxy-alpha-D-glucopyranosyloxy)-4-(6-amino-6-deoxy-alpha-D-glucopyranosyloxy)-3-hydroxycyclohexyl]-2-hydroxybutanamide; (2S)-4-amino-N-[(1R,2S,3S,4R,5S)-5-amino-2-[(2S,3R,4S,5S,6R)-4-amino-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4-[(2R,3R,4S,5S,6R)-6-(aminomethyl)-3,4,5-trihydroxyoxan-2-yl]oxy-3-hydroxycyclohexyl]-2-hydroxybutanamide; (2S)-4-amino-N-{(1R,2S,3S,4R,5S)-5-amino-2-[(3-amino-3-deoxy-alpha-D-glucopyranosyl)oxy]-4-[(6-amino-6-deoxy-alpha-D-glucopyranosyl)oxy]-3-hydroxycyclohexyl}-2-hydroxybutanamide; 1-N-(L(-)-gamma-Amino-alpha-hydroxybutyryl)kanamycin A DM5PDRB CP Abbott Laboratories DM5PDRB TC Antibiotics DM5PDRB DT Small molecular drug DM5PDRB PC 37768 DM5PDRB MW 585.6 DM5PDRB FM C22H43N5O13 DM5PDRB IC InChI=1S/C22H43N5O13/c23-2-1-8(29)20(36)27-7-3-6(25)18(39-22-16(34)15(33)13(31)9(4-24)37-22)17(35)19(7)40-21-14(32)11(26)12(30)10(5-28)38-21/h6-19,21-22,28-35H,1-5,23-26H2,(H,27,36)/t6-,7+,8-,9+,10+,11-,12+,13+,14+,15-,16+,17-,18+,19-,21+,22+/m0/s1 DM5PDRB CS C1[C@@H]([C@H]([C@@H]([C@H]([C@@H]1NC(=O)[C@H](CCN)O)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)N)O)O)O[C@@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CN)O)O)O)N DM5PDRB IK LKCWBDHBTVXHDL-RMDFUYIESA-N DM5PDRB IU (2S)-4-amino-N-[(1R,2S,3S,4R,5S)-5-amino-2-[(2S,3R,4S,5S,6R)-4-amino-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4-[(2R,3R,4S,5S,6R)-6-(aminomethyl)-3,4,5-trihydroxyoxan-2-yl]oxy-3-hydroxycyclohexyl]-2-hydroxybutanamide DM5PDRB CA CAS 37517-28-5 DM5PDRB CB CHEBI:2637 DM5PDRB DE Bacterial infection; Tuberculosis DMRTSGP ID DMRTSGP DMRTSGP DN Amiloride DMRTSGP HS Approved DMRTSGP SN Amiclaran; Amilorida; Amiloridum; Amipramidin; Amipramizid; Amipramizide; Amiprazidine; Amyloride; Guanamprazin; Guanamprazine; Midamor; Amiloride HCL; Amiloride hydrochloride hydrate; Amiclaran (TN); Amikal (Hydrochloride dihydrate); Amilorida [INN-Spanish]; Amiloride (INN); Amiloride [INN:BAN]; Amiloridum [INN-Latin]; Biduret (TN); Midamor (Hydrochloride dihydrate); MK-870 (Hydrochloride dihydrate); AMILORIDE (SEE ALSO: AMILORIDE HCL (2016-88-8)); N-Amidino-3,5-diamino-6-chloropyrazinecarboxamide; N-Amidino-3,5-diamino-6-chlorpyrazincarboxamid; Pyrazinecarboxamide, 3,5-diamino-N-(aminoiminomethyl)-6-chloro-, monohydrochloride; 3,5-Diamino-N-(aminoiminomethyl)-6-chloropyrazinecarboxamide; 3,5-diamino-6-chloro-N-(diaminomethylidene)pyrazine-2-carboxamide; 3,5-diamino-N-[amino(imino)methyl]-6-chloropyrazine-2-carboxamide; 3,5-diamino-N-carbamimidoyl-6-chloropyrazine-2-carboxamide; Amiloride (Na-Ca chanel blocker) DMRTSGP CP Tornett pharmaceutical DMRTSGP TC Diuretics DMRTSGP DT Small molecular drug DMRTSGP PC 16231 DMRTSGP MW 229.63 DMRTSGP FM C6H8ClN7O DMRTSGP IC InChI=1S/C6H8ClN7O/c7-2-4(9)13-3(8)1(12-2)5(15)14-6(10)11/h(H4,8,9,13)(H4,10,11,14,15) DMRTSGP CS C1(=C(N=C(C(=N1)Cl)N)N)C(=O)N=C(N)N DMRTSGP IK XSDQTOBWRPYKKA-UHFFFAOYSA-N DMRTSGP IU 3,5-diamino-6-chloro-N-(diaminomethylidene)pyrazine-2-carboxamide DMRTSGP CA CAS 2609-46-3 DMRTSGP CB CHEBI:2639 DMRTSGP DE Congestive heart failure DMFGND4 ID DMFGND4 DMFGND4 DN Aminocaproic acid DMFGND4 HS Approved DMFGND4 SN 6-Aminohexanoic acid; 6-aminohexanoic acid; 6-Aminocaproic acid; aminocaproic acid; 60-32-2; amicar; Epsikapron; Caprocid; Capramol; Epsamon; EACA; Caprolisin; Acepramin; Hemocaprol; Epsicapron; Respramin; Amikar; EPSILON-AMINOCAPROIC ACID; Hexanoic acid, 6-amino-; Epsilcapramin; Aminokapron; Caplamin; Acepramine; Capracid; Hemopar; Ipsilon; Afibrin; Atsemin; Hepin; Epsilon S; Aminocaproic; Capralense; epsilon-Leucine; EACS; epsilon-Norleucine; epsilcapramine; 6-Amino-n-hexanoic acid; omega-Aminocaproic acid; epsilon-Aminohexanoic acid; 6-amino-hexanoic acid; ACS; Amicar; Aminocaproate; Capranol; Caproamin; Epsicaprom; Epsilcapramine; Hemopar;Hepin; Acide aminocaproique; Acide aminocaproique [French]; Acide aminocaproque; Acido aminocaproico; Acidum aminocaproicum; Acidum aminocaproicum [Latin]; Aminocaproic Acid In Plastic Container; Aminocaproic Acids; Aminohexanoic acid; Eaca kabi; Epsilon Aminocaproic Acid; A 7824; CL 10304; CY 116; CY116; JD 177; Acide aminocaproique [INN-French]; Acido aminocaproico [DCIT,Spanish]; Acido aminocaproico [INN-Spanish]; Acidum aminocaproicum [INN-Latin]; Amicar (TN); Aminocaproic acid (USP); CL-10304; CY-116; Epsilon-Ahx; Epsilon-Aminocaproic acid; Epsilon-Aminocapronsaeure; Epsilon-Aminohexanoic acid; Epsilon-Leucine; Epsilon-Norleucine; Epsilon-aminocaproate; Epsilon-aminocapronzuur; Fullevir (TN); Kyselina omega-aminokapronova; Kyselina omega-aminokapronova [Czech]; Omega-Aminocaproic acid; Omega-Aminohexanoic acid; S04-0132; Acid, 6-Aminocaproic; Acid, 6-Aminohexanoic; Acid, epsilon-Aminocaproic; Aminocaproic acid (USP/INN); Aminocaproic acid [USAN:BAN:INN]; Aminocaproic acid [USAN:INN:BAN]; Epsilon-Aminocaproic acid (JAN); HEXANOIC ACID,6-AMINO; Epsilon-Amino-n-caproic acid; Epsilon-Amino-n-hexanoic acid; Amicar, A-amino caproic acid, A-Ahx, 6-aminohexanoic acid, Aminocaproic acid; 6 Aminocaproic Acid; 6 Aminohexanoic Acid; 6-amino-n-caproate; 6-amino-n-caproic acid; 6-aminohexanoate; 6-Amino Hexanoic Acid DMFGND4 CP Intelfarm Co. DMFGND4 TC Antifibrinolytic Agents DMFGND4 DT Small molecular drug DMFGND4 PC 564 DMFGND4 MW 131.17 DMFGND4 FM C6H13NO2 DMFGND4 IC InChI=1S/C6H13NO2/c7-5-3-1-2-4-6(8)9/h1-5,7H2,(H,8,9) DMFGND4 CS C(CCC(=O)O)CCN DMFGND4 IK SLXKOJJOQWFEFD-UHFFFAOYSA-N DMFGND4 IU 6-aminohexanoic acid DMFGND4 CA CAS 60-32-2 DMFGND4 CB CHEBI:16586 DMFGND4 DE Bleeding disorder; Postoperative hemorrhage DMWFHMZ ID DMWFHMZ DMWFHMZ DN Aminoglutethimide DMWFHMZ HS Approved DMWFHMZ SN Aminoglutethimidum; Aminoglutetimida; Cytadren; Elipten; Orimeten; Ciba Vision Brand of Aminoglutethimide; Novartis Brand of Aminoglutethimide; A 9657; Ba 16038; AG-1; Aminoglutethimide (AG); Aminoglutethimide [INN:BAN]; Aminoglutethimidum [INN-Latin]; Aminoglutetimida [INN-Spanish]; Ba-16038; C 16038-BA; Cytadren (TN); Dl-Aminoglutethimide; P-Aminoglutethimide; Aminoglutethimide (USP/INN); Glutethimide, para-amino; Alpha-(p-Aminophenyl)-alpha-ethylglutarimide; (+-)-3-(p-Aminophenyl)-3-ethyl-2,6-piperidinedione; (+/-)-p-AMINOGLUTETHIMIDE; (inverted question mark)-p-Aminoglutethimide; 2-(p-Aminophenyl)-2-ethylglutarimide; 3-(4-Aminophenyl)-3-ethyl-2,6-piperidindion; 3-(4-Aminophenyl)-3-ethyl-2,6-piperidinedione; 3-(4-aminophenyl)-3-ethylpiperidine-2,6-dione; 3-(p-Aminophenyl)-3-ethylpiperidine-2,6-dione; 3-Ethyl-3-(p-aminophenyl)-2,6-dioxopiperidine DMWFHMZ CP Norvatis Phamaceuticals Corporation DMWFHMZ TC Anticancer Agents DMWFHMZ DT Small molecular drug DMWFHMZ PC 2145 DMWFHMZ MW 232.28 DMWFHMZ FM C13H16N2O2 DMWFHMZ IC InChI=1S/C13H16N2O2/c1-2-13(8-7-11(16)15-12(13)17)9-3-5-10(14)6-4-9/h3-6H,2,7-8,14H2,1H3,(H,15,16,17) DMWFHMZ CS CCC1(CCC(=O)NC1=O)C2=CC=C(C=C2)N DMWFHMZ IK ROBVIMPUHSLWNV-UHFFFAOYSA-N DMWFHMZ IU 3-(4-aminophenyl)-3-ethylpiperidine-2,6-dione DMWFHMZ CA CAS 125-84-8 DMWFHMZ CB CHEBI:2654 DMWFHMZ DE Cushing disease DMS4BLQ ID DMS4BLQ DMS4BLQ DN Aminolevulinic acid hci DMS4BLQ HS Approved DMS4BLQ SN Aminolevulinic acid; 5-Aminolevulinic acid; 5-Amino-4-oxopentanoic acid; 106-60-5; 5-Aminolevulinate; delta-aminolevulinic acid; Pentanoic acid, 5-amino-4-oxo-; Aladerm; 5-Amino-4-oxovaleric acid; Kerastick; Ameluz; Aminolevulinate; 5-ALA; delta-ALA; 5-Amino-4-oxopentanoate; 5-amino-levulinate; 5-amino-levulinic acid; 5-amino-4-oxo-pentanoic acid; CCRIS 8958; UNII-88755TAZ87; EINECS 203-414-1; Levulinic acid, 5-amino-; CHEMBL601; 4-oxo-5-amino-pentanoic acid; CHEBI:17549; ZGXJTSGNIOSYLO-UHFFFAOYSA-N; 88755TAZ87; Levulan (TN) DMS4BLQ DT Small molecular drug DMS4BLQ PC 137 DMS4BLQ MW 131.13 DMS4BLQ FM C5H9NO3 DMS4BLQ IC InChI=1S/C5H9NO3/c6-3-4(7)1-2-5(8)9/h1-3,6H2,(H,8,9) DMS4BLQ CS C(CC(=O)O)C(=O)CN DMS4BLQ IK ZGXJTSGNIOSYLO-UHFFFAOYSA-N DMS4BLQ IU 5-amino-4-oxopentanoic acid DMS4BLQ CA CAS 106-60-5 DMS4BLQ CB CHEBI:17549 DMS4BLQ DE Acne vulgaris; Actinic keratosis DMWNHPC ID DMWNHPC DMWNHPC DN Aminolevulinic Acid Hydrochloride DMWNHPC HS Approved DMWNHPC SN Levulan; Levulan Kerastick DMWNHPC CP Dusa Pharmaceuticals Inc DMWNHPC DT Small molecular drug DMWNHPC PC 123608 DMWNHPC MW 167.59 DMWNHPC FM C5H10ClNO3 DMWNHPC IC InChI=1S/C5H9NO3.ClH/c6-3-4(7)1-2-5(8)9;/h1-3,6H2,(H,8,9);1H DMWNHPC CS C(CC(=O)O)C(=O)CN.Cl DMWNHPC IK ZLHFONARZHCSET-UHFFFAOYSA-N DMWNHPC IU 5-amino-4-oxopentanoic acid;hydrochloride DMWNHPC CA CAS 5451-09-2 DMWNHPC CB CHEBI:132969 DMWNHPC DE Actinic keratosis DML2NIB ID DML2NIB DML2NIB DN Aminophylline DML2NIB HS Approved DML2NIB SN Aminocardol; Aminodur; Aminofilina; Aminofillina; Aminophyllin; Ammophyllin; Cardiofilina; Cardiomin; Cardophylin; Cardophyllin; Carena; Cariomin; DOBO; Diaphilline; Diaphyllin; Diaphylline; Diophllin; Diophyllin; Diuxanthine; Ethophylline; Eufilina; Euphyllin; Euphylline; Euphyllinum; Eurphyllin; Euufilin; Euufillin; Genophyllin; Grifomin; Inophylline; Lasodex; Linampheta; Lixaminol; Metaphyllin; Metaphylline; Minaphil; Miofilin; Neophyiline; Norofilina; Peterphyllin; Phylcardin; Phyllindon; Phyllocontin; Phyllotemp; Somophyllin; Stenovasan; Syntophyllin; Theodrox; Theolamine; Theolone; Theomin; Theophyldine; Thephyldine; Truphylline; Vasofilina; A 1755; BY 108; Minomal(TN); Phyllocontin (TN); TH/100; Truphylline (TN) DML2NIB TC Bronchodilator Agents DML2NIB DT Small molecular drug DML2NIB PC 9433 DML2NIB MW 420.43 DML2NIB FM C16H24N10O4 DML2NIB IC InChI=1S/2C7H8N4O2.C2H8N2/c2*1-10-5-4(8-3-9-5)6(12)11(2)7(10)13;3-1-2-4/h2*3H,1-2H3,(H,8,9);1-4H2 DML2NIB CS CN1C2=C(C(=O)N(C1=O)C)NC=N2.CN1C2=C(C(=O)N(C1=O)C)NC=N2.C(CN)N DML2NIB IK FQPFAHBPWDRTLU-UHFFFAOYSA-N DML2NIB IU 1,3-dimethyl-7H-purine-2,6-dione;ethane-1,2-diamine DML2NIB CA CAS 317-34-0 DML2NIB CB CHEBI:2659 DML2NIB DE Bronchial asthma; Asthma DMENSL5 ID DMENSL5 DMENSL5 DN Aminosalicylic acid DMENSL5 HS Approved DMENSL5 SN 4-Aminosalicylic acid; 65-49-6; Aminosalicylic acid; P-AMINOSALICYLIC ACID; Rezipas; Aminopar; Pamisyl; Parasalindon; Ferrosan; Deapasil; Apacil; Parasal; Paser; Paramycin; Gabbropas; Parasalicil; Pasnodia; Osacyl; Aminox; Pasolac; Pasmed; Propasa; Pasalon; Entepas; Pasdium; Pasara; Pamacyl; Pasem; Pasa; 2-Hydroxy-4-aminobenzoic acid; PASK; APAS; Para-Pas; Sanipirol-4; Hellipidyl; Pascorbic; PAS-C; Benzoic acid, 4-amino-2-hydroxy-; PAS (acid); Aminosalicylic Acid Resin Complex; Aminosalicylate Sodium DMENSL5 CP Panray Corp Sub Ormont Drug And Chemical Co Inc DMENSL5 DT Small molecular drug DMENSL5 PC 4649 DMENSL5 MW 153.14 DMENSL5 FM C7H7NO3 DMENSL5 IC InChI=1S/C7H7NO3/c8-4-1-2-5(7(10)11)6(9)3-4/h1-3,9H,8H2,(H,10,11) DMENSL5 CS C1=CC(=C(C=C1N)O)C(=O)O DMENSL5 IK WUBBRNOQWQTFEX-UHFFFAOYSA-N DMENSL5 IU 4-amino-2-hydroxybenzoic acid DMENSL5 CA CAS 65-49-6 DMENSL5 CB CHEBI:27565 DMENSL5 DE Pulmonary and extrapulmonary tuberculosis; Inflammatory bowel disease DMUTEX3 ID DMUTEX3 DMUTEX3 DN Amiodarone DMUTEX3 HS Approved DMUTEX3 SN Amidorone; Aminodarone; Amiobeta; Amiodarex; Amiodarona; Amiodarons; Amiodaronum; Amiohexal; Amjodaronum; Ancar; Aratac;Arycor; Braxan; Corbionax; Cordarex; Cordarone; Kordaron; Labaz; Ortacrone; Pacerone; Rytmarone; Sedacoron; Sedacorone; Tachydaron; ASTA Medica Brand of Amiodarone Hydrochloride; Alphapharm Brand of Amiodarone Hydrochloride; Amiodarone Base; Armstrong Brand of Amiodarone Hydrochloride; Berenguer Infale Brand of Amiodarone Hydrochloride; Betapharm Brand of Amiodarone Hydrochloride; Cordarone Intravenous; G Gam Brand of Amiodarone Hydrochloride; Hexal Brand of Amiodarone Hydrochloride; Leurquin Brand of Amiodarone Hydrochloride; Pharma Investi Brand of Amiodarone Hydrochloride; Sanofi Winthrop Brand of Amiodarone Hydrochloride; Wyeth Brand of Amiodarone Hydrochloride; Ethylaminoethoxy)benzoyl]benzofuran; L 3428; L3428; SKF 33134A; Amio-Aqueous IV; Amiodarona [INN-Spanish]; Amiodaronum [INN-Latin]; Aratac (TN); Arycor (TN); Atlansil (TN); Cordarone (TN); L-3428; Pacerone (TN); Pms-Amiodarone; SKF 33134-A; Amiodarone (USAN/INN); Amiodarone [USAN:BAN:INN]; Ketone, 2-butyl-3-benzofuranyl 4-(2-(diethylamino)ethoxy)-3,5-diiodophenyl; Ketone, 2-butyl-3-benzofuranyl 4-[2-(diethylamino)ethoxy]-3,5-diiodophenyl (7CI,8CI); (2-Butyl-3-benzofuranyl)(4-(2-(diethylamino)ethoxy)-3,5-diidophenyl)methanone; (2-butyl-1-benzofuran-3-yl)(4-{[2-(diethylamino)ethyl]oxy}-3,5-diiodophenyl)methanone; (2-butyl-1-benzofuran-3-yl)-[4-(2-diethylaminoethyloxy)-3,5-diiodophenyl]methanone; (2-butyl-1-benzofuran-3-yl){4-[2-(diethylamino)ethoxy]-3,5-diiodophenyl}methanone; (2-butylbenzofuran-3-yl)-[4-(2-diethylaminoethoxy)-3,5-diiodo-phenyl]-methanone; (2-{4-[(2-butyl-1-benzofuran-3-yl)carbonyl]-2,6-diiodophenoxy}ethyl)diethylamine; 2-Butyl-3-(3,5-diiodo-4-(2-diethylaminoethoxy)benzoyl)benzofuran; 2-Butyl-3-(3,5-diiodo-4-(beta-diethylaminoethoxy)benzoyl)benzofuran; 2-Butyl-3-(4'-beta-N-diethylaminoethoxy-3',5'-diiodobenzoyl)benzofuran; 2-Butyl-3-[3,5-diiodo-4-(2-di; 2-Butyl-3-benzofuranyl 4-(2-(diethylamino)ethoxy)-3,5-diiodophenyl ketone; 2-Butyl-3-benzofuranyl p-((2-diethylamino)ethoxy)-m,m-diiodophenyl ketone; 2-Butyl-3-benzofuranyl p-[(2-diethylamino)ethoxy]-m,m-diiodophenyl ketone; 2-n-Butyl-3',5'-diiodo-4'-N-diethylaminoethoxy-3-benzoylbenzofuran DMUTEX3 CP Wyeth-Ayerst Laboratories DMUTEX3 TC Antiarrhythmic Agents DMUTEX3 DT Small molecular drug DMUTEX3 PC 2157 DMUTEX3 MW 645.3 DMUTEX3 FM C25H29I2NO3 DMUTEX3 IC InChI=1S/C25H29I2NO3/c1-4-7-11-22-23(18-10-8-9-12-21(18)31-22)24(29)17-15-19(26)25(20(27)16-17)30-14-13-28(5-2)6-3/h8-10,12,15-16H,4-7,11,13-14H2,1-3H3 DMUTEX3 CS CCCCC1=C(C2=CC=CC=C2O1)C(=O)C3=CC(=C(C(=C3)I)OCCN(CC)CC)I DMUTEX3 IK IYIKLHRQXLHMJQ-UHFFFAOYSA-N DMUTEX3 IU (2-butyl-1-benzofuran-3-yl)-[4-[2-(diethylamino)ethoxy]-3,5-diiodophenyl]methanone DMUTEX3 CA CAS 1951-25-3 DMUTEX3 CB CHEBI:2663 DMUTEX3 DE Tachyarrhythmias DMSJVAM ID DMSJVAM DMSJVAM DN Amisulpride DMSJVAM HS Approved DMSJVAM SN Aminosultopride; Amisulpiride; Amisulprida; Amisulpridum; Deniban; Socian; Solian; Amisulpride [INN]; DAN 2163; Amisulprida [INN-Spanish]; Amisulpride (INN); Amisulpridum [INN-Latin]; DAN-2163; Deniban (TN); Solian (TN); Solian, Amisulpride; SL-91.1077; 4-Amino-N-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-2-anisamid; 4-Amino-N-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-2-methoxybenzamide; 4-Amino-N-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-o-anisamide; 4-Amino-N-[(1-ethyl-2-pyrrolidinyl)methyl]-5-(ethylsulfonyl)-2-methoxybenzamide; 4-amino-N-[(1-ethylpyrrolidin-2-yl)methyl]-5-(ethylsulfonyl)-2-methoxybenzamide; 4-amino-N-[(1-ethylpyrrolidin-2-yl)methyl]-5-ethylsulfonyl-2-methoxybenzamide DMSJVAM CP Sanofi-Aventis DMSJVAM TC Antipsychotic Agents DMSJVAM DT Small molecular drug DMSJVAM PC 2159 DMSJVAM MW 369.5 DMSJVAM FM C17H27N3O4S DMSJVAM IC InChI=1S/C17H27N3O4S/c1-4-20-8-6-7-12(20)11-19-17(21)13-9-16(25(22,23)5-2)14(18)10-15(13)24-3/h9-10,12H,4-8,11,18H2,1-3H3,(H,19,21) DMSJVAM CS CCN1CCCC1CNC(=O)C2=CC(=C(C=C2OC)N)S(=O)(=O)CC DMSJVAM IK NTJOBXMMWNYJFB-UHFFFAOYSA-N DMSJVAM IU 4-amino-N-[(1-ethylpyrrolidin-2-yl)methyl]-5-ethylsulfonyl-2-methoxybenzamide DMSJVAM CA CAS 71675-85-9 DMSJVAM CB CHEBI:64045 DMSJVAM DE Schizophrenia DMK7F9S ID DMK7F9S DMK7F9S DN Amitriptyline DMK7F9S HS Approved DMK7F9S SN Adepress; Adepril; Amitril; Amitriprolidine; Amitriptilina; Amitriptylin; Amitriptylinum; Amitryptiline; Amitryptyline; Amytriptiline; Amytriptylin; Damilan; Damilen; Damitriptyline; Elanil; Elavil; Flavyl; Lantron; Laroxil; Laroxyl; Proheptadiene; Redomex; Sarotex; Seroten; Sylvemid; Triptanol; Triptilin; Triptisol; Tryptanol; Amitriptilina [Italian]; Amitriptylin [German]; MK 230; N 750; TP0; Amitriptilina [INN-Spanish]; Amitriptyline (INN); Amitriptyline [INN:BAN]; Amitriptylinum [INN-Latin]; Elavil (TN); Laroxyl (TN); Ro 4-1575; [3-(10,11-Dihydro-dibenzo[a,d]cyclohepten-5-ylidene)-propyl]-dimethyl-amine; 10,11-Dihydro-5-(gamma-dimethylaminopropylidene)-5H-dibenzo(a,d)cycloheptene; 10,11-Dihydro-N,N-dimethyl-5H-dibenzo(a,d)heptalene-delta(5),gamma-propylamine; 10,11-dihydro-5-(gamma-dimethylaminopropylidene)-5H-dibenzo[a,d]cycloheptene; 3-(10,11-Dihydro-5H-dibenzo(a,d)cyclohepten-5-yliden)-N,N-dimethylpropylamin; 3-(10,11-dihydro-5H-dibenzo[a,d][7]annulen-5-ylidene)-N,N-dimethylpropan-1-amine; 5-(3'-Dimethylaminopropylidene)-dibenzo-(a,d)(1,4)-cycloheptadiene; 5-(3'-Dimethylaminopropylidene)-dibenzo-[a,d][1,4]-cycloheptadiene; 5-(3-Dimethylaminopropylidene)-10,11-dihydro-5H-dibenzo(a,d)cycloheptatriene; 5-(3-Dimethylaminopropylidene)-10,11-dihydro-5H-dibenzo(a,d)cycloheptene; 5-(3-Dimethylaminopropylidene)-5H-dibenzo[a,d]-10,11-dihydrocycloheptene; 5-(3-dimethylaminopropylidene)dibenzo[a,d][1,4]-cycloheptadiene; 5-(gamma-Dimethylaminopropylidene)-10,11-dihydro-5H-dibenzo(a,d)cycloheptene; 5-(gamma-Dimethylaminopropylidene)-5H-Dibenzo[a,d][1,4]cycloheptadiene; 5-(gamma-Dimethylaminopropylidene)-5H-dibenzo(a,d)(1,4)cycloheptadiene; 5-(gamma-Dimethylaminopropylidene)-5H-dibenzo[a,d]10,11-dihydrocycloheptene; 5-(gamma-Dimethylaminopropylidine)-5H-dibenzo(a,d)(1,4)cycloheptadiene DMK7F9S CP Hoffmann La Roche Inc DMK7F9S TC Analgesics DMK7F9S DT Small molecular drug DMK7F9S PC 2160 DMK7F9S MW 277.4 DMK7F9S FM C20H23N DMK7F9S IC InChI=1S/C20H23N/c1-21(2)15-7-12-20-18-10-5-3-8-16(18)13-14-17-9-4-6-11-19(17)20/h3-6,8-12H,7,13-15H2,1-2H3 DMK7F9S CS CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31 DMK7F9S IK KRMDCWKBEZIMAB-UHFFFAOYSA-N DMK7F9S IU N,N-dimethyl-3-(2-tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,11,13-hexaenylidene)propan-1-amine DMK7F9S CA CAS 50-48-6 DMK7F9S CB CHEBI:2666 DMK7F9S DE Depression DM0DQM5 ID DM0DQM5 DM0DQM5 DN Amlexanox DM0DQM5 HS Approved DM0DQM5 SN ANW; Amlenanox; Amlexanoxo; Amlexanoxum; Amoxanox; Aphthasol; Aptheal; Apthera; Elics; OraDisc; OraRinse; Solfa; Amlexanoxo [Spanish]; Amlexanoxum [Latin]; GlaxoSmithKline brand of amlexanox; OraDisc A; AA 673; CHX 3673; AA-673; Aphthasol (TN); CHX-3673; Solfa (TN); Amlexanox [USAN:INN:JAN]; Amlexanox (JAN/USAN/INN); 2-Amino-7-isopropyl-5-oxo-5H-(1)benzopyrano(2,3-b)pyridine-3-carboxylic acid; 2-amino-5-oxo-7-(propan-2-yl)-5H-chromeno[2,3-b]pyridine-3-carboxylic acid; 2-amino-5-oxo-7-propan-2-ylchromeno[2,3-b]pyridine-3-carboxylic acid; 2-amino-7-(1-methylethyl)-5-oxo-5H-chromeno[2,3-b]pyridine-3-carboxylic acid; 2-amino-7-isopropyl-5-oxo-5H-(1)benzopyrano(2,3b)pyridine-3-carboxylic acid DM0DQM5 CP Access Pharmaceuticals DM0DQM5 TC Antiulcer Agents DM0DQM5 DT Small molecular drug DM0DQM5 PC 2161 DM0DQM5 MW 298.29 DM0DQM5 FM C16H14N2O4 DM0DQM5 IC InChI=1S/C16H14N2O4/c1-7(2)8-3-4-12-9(5-8)13(19)10-6-11(16(20)21)14(17)18-15(10)22-12/h3-7H,1-2H3,(H2,17,18)(H,20,21) DM0DQM5 CS CC(C)C1=CC2=C(C=C1)OC3=NC(=C(C=C3C2=O)C(=O)O)N DM0DQM5 IK SGRYPYWGNKJSDL-UHFFFAOYSA-N DM0DQM5 IU 2-amino-5-oxo-7-propan-2-ylchromeno[2,3-b]pyridine-3-carboxylic acid DM0DQM5 CA CAS 68302-57-8 DM0DQM5 CB CHEBI:31205 DM0DQM5 DE Respiratory tract inflammation DMBDAZV ID DMBDAZV DMBDAZV DN Amlodipine DMBDAZV HS Approved DMBDAZV SN Amlocard; Amlodipino; Amlodipinum; Amlodis; Amlopres; Amlor; Coroval; Intervask; Lipinox; AMLODIPINE BASE; Amlodipine Free Base; Amlodipino [Spanish]; Amlodipinum [Latin]; Racemic Amlodipine; Amlodipine (INN); Amlodipine [INN:BAN]; Dailyvasc (TN); Istin (TN); Norvasc (TN); Perivasc (TN); UK-4834011; R,S)-Amlodipine; 2-[(2-Aminoethoxy)methyl]-4-(2-chlorophenyl); 3,5-Pyridinedicarboxylic acid, 2-((2-aminoethoxy)methyl)-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-, 3-ethyl 5-methyl ester; 3,5-Pyridinedicarboxylic acid, 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-, 3-ethyl 5-methyl ester; 3-Ethyl-5-methyl (+-)-2-(2-aminoethoxymethyl)-4-(o-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate; 3-Ethyl-5-methyl (+/-)-2-[(2-aminoethoxy)methyl]-4-(o-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate; 3-Ethyl-5-methyl (-)-2-((2-aminoethoxy)methyl)-4-(2-chlorphenyl)-1,4-dihydro-6-methyl-3,5-pyridindicarboxylat; 3-Ethyl-5-methyl (-)-2-((2-aminoethoxymethyl)-4-(o-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate; 3-O-ethyl 5-O-methyl 2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate; 3-ethyl 5-methyl 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate; 3-ethyl 5-methyl 2-{[(2-aminoethyl)oxy]methyl}-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate DMBDAZV CP Dainippon Sumitomo DMBDAZV TC Antihypertensive Agents DMBDAZV DT Small molecular drug DMBDAZV PC 2162 DMBDAZV MW 408.9 DMBDAZV FM C20H25ClN2O5 DMBDAZV IC InChI=1S/C20H25ClN2O5/c1-4-28-20(25)18-15(11-27-10-9-22)23-12(2)16(19(24)26-3)17(18)13-7-5-6-8-14(13)21/h5-8,17,23H,4,9-11,22H2,1-3H3 DMBDAZV CS CCOC(=O)C1=C(NC(=C(C1C2=CC=CC=C2Cl)C(=O)OC)C)COCCN DMBDAZV IK HTIQEAQVCYTUBX-UHFFFAOYSA-N DMBDAZV IU 3-O-ethyl 5-O-methyl 2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate DMBDAZV CA CAS 88150-42-9 DMBDAZV CB CHEBI:2668 DMBDAZV DE Hypertension DMOEVK6 ID DMOEVK6 DMOEVK6 DN Ammonia DMOEVK6 HS Approved DMOEVK6 SN Ammonia N13 DMOEVK6 CP Feinstein DMOEVK6 DT Small molecular drug DMOEVK6 PC 222 DMOEVK6 MW 17.031 DMOEVK6 FM H3N DMOEVK6 IC InChI=1S/H3N/h1H3 DMOEVK6 CS N DMOEVK6 IK QGZKDVFQNNGYKY-UHFFFAOYSA-N DMOEVK6 IU azane DMOEVK6 CA CAS 7664-41-7 DMOEVK6 CB CHEBI:16134 DMOEVK6 DE Coronary artery disease DM0GQ8N ID DM0GQ8N DM0GQ8N DN Amobarbital DM0GQ8N HS Approved DM0GQ8N SN AMAL; Amasust; Amital; Amobarbitale; Amobarbitalum; Amobarbitone; Amospan; Amybal; Amylbarbitone; Amylobarbital; Amylobarbitone; Amytal; Barbamil; Barbamyl; Binoctal; Dorlotyn; Dormytal; Eunoctal; Isomyl; Isomytal; Mylodorm; Pentymal; Pentymalum; Robarb; Schiwanox; Sednotic; Somnal; Stadadorm; Sumital; Talamo; Amobarbital suppository dosage form; Amobarbitale [DCIT]; Barbamyl acid; Component of Dexamyl; Ethylisopentylbarbituric acid; Isoamylethylbarbituric acid; Amobarbital [INN:JAN]; Amobarbitalum [INN-Latin]; Component of 15-90; Component of Amo-Dextrosule; Component of Q-Caps; Isomytal (TN); Amobarbital (JP15/INN); 5-Ethyl-5-(3-methylbutyl)-2,4,6(1H,3H,5H)-pyrimidinetrione; 5-Ethyl-5-(3-methylbutyl)barbituric acid;5-Ethyl-5-isoamylbarbituric acid; 5-Ethyl-5-isoamylmalonyl urea; 5-Ethyl-5-isopentylbarbituric acid; 5-Ethyl-5-isopentylbarbitursaeure; 5-Isoamyl-5-ethylbarbituric acid; 5-ethyl-5-(3-methylbutyl)-1,3-diazinane-2,4,6-trione; 5-ethyl-5-(3-methylbutyl)pyrimidine-2,4,6(1H,3H,5H)-trione DM0GQ8N TC Hypnotics and Sedatives DM0GQ8N DT Small molecular drug DM0GQ8N PC 2164 DM0GQ8N MW 226.27 DM0GQ8N FM C11H18N2O3 DM0GQ8N IC InChI=1S/C11H18N2O3/c1-4-11(6-5-7(2)3)8(14)12-10(16)13-9(11)15/h7H,4-6H2,1-3H3,(H2,12,13,14,15,16) DM0GQ8N CS CCC1(C(=O)NC(=O)NC1=O)CCC(C)C DM0GQ8N IK VIROVYVQCGLCII-UHFFFAOYSA-N DM0GQ8N IU 5-ethyl-5-(3-methylbutyl)-1,3-diazinane-2,4,6-trione DM0GQ8N CA CAS 57-43-2 DM0GQ8N CB CHEBI:2673 DM0GQ8N DE Insomnia DME4RA8 ID DME4RA8 DME4RA8 DN Amodiaquine DME4RA8 HS Approved DME4RA8 SN Amodiachin; Amodiachinum; Amodiaquin; Amodiaquina; Amodiaquinum; Basoquin; CQA; Camochin; Camoquin; Camoquinal; Camoquine; Flavoquin; Flavoquine; Miaquin; Sunoquine; Amodiaquine hydrochloride; Amodiaquine USP24; SN 10751; AMODIAQUINE, FLAVOQUINE; Amodiaquina [INN-Spanish]; Amodiaquinum [INN-Latin]; CAM-AQ 1; CAM-AQI; Cam-AQ1; Camoquin (TN); Flavoquine (TN); SN 10,751; WR-002977; Amodiaquine (USAN/INN); Amodiaquine [USAN:INN:BAN]; Amodiaquine, ring-closed; S. N. 10751 DME4RA8 TC Antimalarials DME4RA8 DT Small molecular drug DME4RA8 PC 2165 DME4RA8 MW 355.9 DME4RA8 FM C20H22ClN3O DME4RA8 IC InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23) DME4RA8 CS CCN(CC)CC1=C(C=CC(=C1)NC2=C3C=CC(=CC3=NC=C2)Cl)O DME4RA8 IK OVCDSSHSILBFBN-UHFFFAOYSA-N DME4RA8 IU 4-[(7-chloroquinolin-4-yl)amino]-2-(diethylaminomethyl)phenol DME4RA8 CA CAS 86-42-0 DME4RA8 CB CHEBI:2674 DME4RA8 DE Malaria DML8QSZ ID DML8QSZ DML8QSZ DN Amosulalol DML8QSZ HS Approved DML8QSZ SN Lowgan; LY-137224; YM-09538 DML8QSZ CP Yamanouchi Pharmaceutical Co Ltd DML8QSZ DT Small molecular drug DML8QSZ PC 2169 DML8QSZ MW 380.5 DML8QSZ FM C18H24N2O5S DML8QSZ IC InChI=1S/C18H24N2O5S/c1-13-7-8-14(11-18(13)26(19,22)23)15(21)12-20-9-10-25-17-6-4-3-5-16(17)24-2/h3-8,11,15,20-21H,9-10,12H2,1-2H3,(H2,19,22,23) DML8QSZ CS CC1=C(C=C(C=C1)C(CNCCOC2=CC=CC=C2OC)O)S(=O)(=O)N DML8QSZ IK LVEXHFZHOIWIIP-UHFFFAOYSA-N DML8QSZ IU 5-[1-hydroxy-2-[2-(2-methoxyphenoxy)ethylamino]ethyl]-2-methylbenzenesulfonamide DML8QSZ CA CAS 85320-68-9 DML8QSZ CB CHEBI:135592 DML8QSZ DE Hypertension DMKITQE ID DMKITQE DMKITQE DN Amoxapine DMKITQE HS Approved DMKITQE SN Amoxan; Amoxapina; Amoxapinum; Amoxepine; Ascendin; Asendin; Asendis; Defanyl; Demolox; Desmethylloxapin; Desmethylloxapine; Moxadil; CL 67772; A-129; Amoxapina [INN-Spanish]; Amoxapinum [INN-Latin]; Asendin (TN); Asendis (TN); CL-67772; Defanyl (TN); Demolox (TN); KS-1197; Moxadil (TN); CL-67,772; Amoxapine (JP15/USP/INN); Amoxapine [USAN:BAN:INN:JAN]; 2-Chlor-11-(1-piperazinyl)dibenz(b,f)(1,4)oxazepin; 2-Chloro-11-(1-piperazinyl)-dibenz[b,f][1,4]oxazepine; 2-Chloro-11-(1-piperazinyl)dibenz(b,f)(1,4)oxazepine; 2-Chloro-11-(1-piperazinyl)dibenz[b,f][1,4]oxazepine; 2-chloro-11-(piperazin-1-yl)dibenzo[b,f][1,4]oxazepine; 2-chloro-11-piperazin-1-yldibenzo[b,f][1,4]oxazepine; 8-chloro-6-piperazin-1-ylbenzo[b][1,4]benzoxazepine DMKITQE TC Antidepressants DMKITQE DT Small molecular drug DMKITQE PC 2170 DMKITQE MW 313.8 DMKITQE FM C17H16ClN3O DMKITQE IC InChI=1S/C17H16ClN3O/c18-12-5-6-15-13(11-12)17(21-9-7-19-8-10-21)20-14-3-1-2-4-16(14)22-15/h1-6,11,19H,7-10H2 DMKITQE CS C1CN(CCN1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl DMKITQE IK QWGDMFLQWFTERH-UHFFFAOYSA-N DMKITQE IU 8-chloro-6-piperazin-1-ylbenzo[b][1,4]benzoxazepine DMKITQE CA CAS 14028-44-5 DMKITQE CB CHEBI:2675 DMKITQE DE Major depressive disorder DMUYNEI ID DMUYNEI DMUYNEI DN Amoxicillin DMUYNEI HS Approved DMUYNEI SN AMPC; Actimoxi; Amoclen; Amolin; Amopen; Amopenixin; Amoxi; Amoxibiotic; Amoxicaps; Amoxicilina; Amoxicillanyl; Amoxicilline; Amoxicillinum; Amoxiden; Amoxil; Amoxivet; Amoxycillin; Anemolin; Aspenil; Biomox; Bristamox; Cemoxin; Clamoxyl; Delacillin; DisperMox; Efpenix; Flemoxin; Hiconcil; Histocillin; Hydroxyampicillin; Ibiamox; Imacillin; Lamoxy; Larotid; Moxacin; Moxal; Moxatag; Ospamox; Pamoxicillin; Piramox; Polymox; Robamox; Sumox; Tolodina; Trimox; Unicillin; Utimox; Vetramox; Wymox; AMOXICILLIN CRYSTALLINE; AMOXICILLIN PEDIATRIC; Amoxicillin anhydrous; Amoxicilline [INN]; Amoxycillin Trihydrate; Metafarma capsules; Metifarma capsules; Sawamox PM; BLP 1410; AMK (TN); Actimoxi (TN); Alphamox (TN); Amoksibos (TN); Amoksiklav (TN); Amoxi-Mast; Amoxibiotic (TN); Amoxicilina (TN); Amoxicilina [INN-Spanish]; Amoxicillin (INN); Amoxicillin (TN); Amoxicillin (anhydrous); Amoxicilline [INN-French]; Amoxicillinum [INN-Latin]; Amoxiclav (TN); Amoxidal (TN); Amoxil (TN); Amoxin (TN); Apo-Amoxi; Augmentin (TN); BL-P 1410; BRL-2333; Bactox (TN); Betalaktam (TN); Cilamox (TN); Clamoxyl (TN); Curam (TN); D-Amoxicillin; Dedoxil (TN); Dispermox (TN); Duomox (TN); Enhancin (TN); Geramox (TN); Gimalxina (TN); Hiconcil (TN); Isimoxin (TN); Klavox (TN); Lamoxy (TN); Moxatag (TN); Moxilen (TN); Moxypen (TN); Moxyvit (TN); Nobactam (TN); Novamoxin (TN); Ospamox (TN); P-Hydroxyampicillin; Pamoxicillin (TN); Panamox (TN); Panklav (TN); Polymox (TN); Ro 10-8756; Samthongcillin (TN); Sandoz (TN); Senox (TN); Sinacilin (TN); Tolodina (TN); Trimox (TN); Wymox (TN); Yucla (TN); Zerrsox (TN); Zimox (TN); Apo-Amoxi (TN); Alpha-Amino-p-hydroxybenzylpenicillin; D-2-Amino-2-(4-hydroxyphenyl)acetamidopenicillanic acid; D-(-)-alpha-Amino-p-hydroxybenzylpenicillin; (-)-6-(2-Amino-2-(P-hydroxyphenyl)acetamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo-(3.2.0)heptane-2-carboxylic acid; (2S,5R,6R)-6-[[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-{[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-(2-amino-2-(p-hydroxyphenyl)acetamido)-3,3-dimethyl-7-oxo-, D-(8CI); 6-(D-(-)-alpha-Amino-p-hydroxyphenylacetamido)penicillanic acid; 6-(D-(-)-p-Hydroxy-alpha-aminobenzyl)penicillin; 6-(p-Hydroxy-alpha-aminophenylacetamido)penicillanic acid; 6beta-[(2R)-2-amino-2-(4-hydroxyphenyl)acetamido]-2,2-dimethylpenam-3alpha-carbonyl; 6beta-[(2R)-2-amino-2-(4-hydroxyphenyl)acetamido]-2,2-dimethylpenam-3alpha-carboxylic acid DMUYNEI CP AstraZeneca DMUYNEI TC Antibiotics DMUYNEI DT Small molecular drug DMUYNEI PC 33613 DMUYNEI MW 365.4 DMUYNEI FM C16H19N3O5S DMUYNEI IC InChI=1S/C16H19N3O5S/c1-16(2)11(15(23)24)19-13(22)10(14(19)25-16)18-12(21)9(17)7-3-5-8(20)6-4-7/h3-6,9-11,14,20H,17H2,1-2H3,(H,18,21)(H,23,24)/t9-,10-,11+,14-/m1/s1 DMUYNEI CS CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=C(C=C3)O)N)C(=O)O)C DMUYNEI IK LSQZJLSUYDQPKJ-NJBDSQKTSA-N DMUYNEI IU (2S,5R,6R)-6-[[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid DMUYNEI CA CAS 26787-78-0 DMUYNEI CB CHEBI:2676 DMUYNEI DE Bacterial infection DMSZQAK ID DMSZQAK DMSZQAK DN Amphetamine DMSZQAK HS Approved DMSZQAK SN Amphetamine (tamper and abuse-resistant, Bio-MD/MPAR, ADHD); Amphetamine (tamper and abuse-resistant, Bio-MD/MPAR, ADHD), PharmacoFore; PF-08 (Bio-MD/MPAR/prodrug/oral, ADHD), PharmacoFore DMSZQAK CP PharmacoFore Inc DMSZQAK DT Small molecular drug DMSZQAK PC 3007 DMSZQAK MW 135.21 DMSZQAK FM C9H13N DMSZQAK IC InChI=1S/C9H13N/c1-8(10)7-9-5-3-2-4-6-9/h2-6,8H,7,10H2,1H3 DMSZQAK CS CC(CC1=CC=CC=C1)N DMSZQAK IK KWTSXDURSIMDCE-UHFFFAOYSA-N DMSZQAK IU 1-phenylpropan-2-amine DMSZQAK CA CAS 300-62-9 DMSZQAK CB CHEBI:2679 DMSZQAK DE Attention deficit hyperactivity disorder DMTAJQE ID DMTAJQE DMTAJQE DN Amphotericin B DMTAJQE HS Approved DMTAJQE SN ABLC; Abelcet; Abelecet; Ambisome; Amphocin; Amphomoronal; Amphotec; Amphotericin; Amphotericinum; Amphotherizin; Amphozone; Fungilin; Fungisome; Fungisone; Fungizone; Halizon; SinuNase; Amfotericina B; Amophotericin B; Amphortericin B; Amphotericin B Cholesterol Dispersion; Amphotericin B Colloidal Dispersion; Amphotericin B liposomal; Amphotericin BETA; Amphotericine B; Amphotericinum B; Amphotherizin [German]; Liposomal Amphotericin B; NCI527017; NS 718; AMPH-B; Abelcet (TN); AmBisome (TN); Amfotericina B [INN-Spanish]; Ampho-Moronal; Amphocil (TN); Amphotec (TN); Amphotericin-B; Amphotericine B [INN-French]; Amphotericinum B [INN-Latin]; Fungilin (TN); Fungisome (TN); Fungizone (TN); LNS-AmB; Mysteclin-F; NKTR-024; Amphotericin B [USAN:INN:JAN]; Amphotericin B, Lipid-based; Amphotericin B, Streptomyces sp.; Amphotericin B (JP15/USP/INN) DMTAJQE TC Antifungal Agents DMTAJQE DT Small molecular drug DMTAJQE PC 5280965 DMTAJQE MW 924.1 DMTAJQE FM C47H73NO17 DMTAJQE IC InChI=1S/C47H73NO17/c1-27-17-15-13-11-9-7-5-6-8-10-12-14-16-18-34(64-46-44(58)41(48)43(57)30(4)63-46)24-38-40(45(59)60)37(54)26-47(61,65-38)25-33(51)22-36(53)35(52)20-19-31(49)21-32(50)23-39(55)62-29(3)28(2)42(27)56/h5-18,27-38,40-44,46,49-54,56-58,61H,19-26,48H2,1-4H3,(H,59,60)/b6-5+,9-7+,10-8+,13-11+,14-12+,17-15+,18-16+/t27-,28-,29-,30+,31+,32+,33-,34-,35+,36+,37-,38-,40+,41-,42+,43+,44-,46-,47+/m0/s1 DMTAJQE CS C[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@@H](C[C@H]2[C@@H]([C@H](C[C@](O2)(C[C@H](C[C@H]([C@@H](CC[C@H](C[C@H](CC(=O)O[C@H]([C@@H]([C@@H]1O)C)C)O)O)O)O)O)O)O)C(=O)O)O[C@H]3[C@H]([C@H]([C@@H]([C@H](O3)C)O)N)O DMTAJQE IK APKFDSVGJQXUKY-INPOYWNPSA-N DMTAJQE IU (1R,3S,5R,6R,9R,11R,15S,16R,17R,18S,19E,21E,23E,25E,27E,29E,31E,33R,35S,36R,37S)-33-[(2R,3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-1,3,5,6,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-14,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,23,25,27,29,31-heptaene-36-carboxylic acid DMTAJQE CA CAS 1397-89-3 DMTAJQE DE Fungal infection; Mycoses DMHWE7P ID DMHWE7P DMHWE7P DN Ampicillin DMHWE7P HS Approved DMHWE7P SN ABPC; Acillin; Adobacillin; Alpen; Amblosin; Amcill; Amfipen; Aminobenzylpenicillin; Ampen; Ampichel; Ampicil; Ampicilina; Ampicillanyl; Ampicillina; Ampicilline; Ampicillinum; Ampicin; Ampifarm; Ampikel; Ampimed; Ampipenin; Ampiscel; Ampisyn; Ampivax; Ampivet; Amplacilina; Amplin; Amplipenyl; Amplisom; Amplital; Austrapen; Binotal; Bonapicillin; Britacil; Campicillin; Cimex; Copharcilin; Delcillin; Deripen; Divercillin; Doktacillin; Duphacillin; Grampenil; Guicitrina; Guicitrine; Lifeampil; Morepen; Norobrittin; Nuvapen; Omnipen; Orbicilina; Penbristol; Penbritin; Penbrock; Penicline; Penimic; Pensyn; Pentrex; Pentrexl; Pentrexyl; Polycillin; Ponecil; Princillin; Principen; QIDamp; Racenacillin; Rosampline;Roscillin; Semicillin; Servicillin; Sumipanto; Supen; Synpenin; Texcillin; Tokiocillin; Tolomol; Totacillin; Totalciclina; Totapen; Trifacilina; Ukapen; Ultrabion; Ultrabron; Vampen; Viccillin; Wypicil; Amfipen V; Amipenix S; Ampicillin A; Ampicillin Anhydrous; Ampicillin Base; Ampicillin acid; Ampicillin anhydrate; Ampicillina [DCIT]; Anhydrous ampicillin; Olin Kid; Pen A; Pen A Oral; Pen Ampil;Penbritin paediatric; Penbritin syrup; Pfizerpen A; Semicillin R; Viccillin S; AY 6108; BA 7305; BRL 1341; Bayer 5427; HI 63; P 50; Principen 125; Principen 250; Principen 500; SQ 17382; AB-PC; AB-PCSol; AY-6108; Ambidrin (TN); Ampi-Co; Ampi-Tab; Ampi-bol; Ampicilina [INN-Spanish]; Ampicilline [INN-French]; Ampicillinum [INN-Latin]; Ampipenin, nt3; Ampy-Penyl; Anhydrous ampicillin (JP15); BRL-1341; D-Ampicillin; D-Cillin; KS-R1; Novo-ampicillin; OMNIPEN (AMPICILLIN); Omnipen (TN); Omnipen-N; P-50; Penbritin-S; Penicillin, Aminobenzyl; Pfizerpen-A; Polycillin-N; Polyflex (Veterinary); Ro-Ampen; SK-Ampicillin; Totacillin (sodium); Totacillin-N; WY-5103; Ampicillin (USP/INN); AMPICILLIN (SEE ALSO AMPICILLIN TRIHYDRATE 7177-48-2); Ampicillin [USAN:BAN:INN:JAN]; Ampicillin [USAN:INN:BAN:JAN];D-(-)-Ampicillin; D-(-)-alpha-Aminobenzylpenicillin; D-(-)-alpha-Aminopenicillin; D-(-)-6-(alpha-Aminophenylacetamido)penicillanic acid; 6-(D(-)-alpha-Aminophenylacetamido)penicillanic acid; 6beta-[(2R)-2-amino-2-phenylacetamido]-2,2-dimethylpenam-3alpha-carbonyl; 6beta-[(2R)-2-amino-2-phenylacetamido]-2,2-dimethylpenam-3alpha-carboxylic acid DMHWE7P CP Stadapharm GmbH DMHWE7P TC Antibiotics DMHWE7P DT Small molecular drug DMHWE7P PC 6249 DMHWE7P MW 349.4 DMHWE7P FM C16H19N3O4S DMHWE7P IC InChI=1S/C16H19N3O4S/c1-16(2)11(15(22)23)19-13(21)10(14(19)24-16)18-12(20)9(17)8-6-4-3-5-7-8/h3-7,9-11,14H,17H2,1-2H3,(H,18,20)(H,22,23)/t9-,10-,11+,14-/m1/s1 DMHWE7P CS CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)N)C(=O)O)C DMHWE7P IK AVKUERGKIZMTKX-NJBDSQKTSA-N DMHWE7P IU (2S,5R,6R)-6-[[(2R)-2-amino-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid DMHWE7P CA CAS 69-53-4 DMHWE7P CB CHEBI:28971 DMHWE7P DE Bacterial infection DM5BS98 ID DM5BS98 DM5BS98 DN Ampiroxicam DM5BS98 HS Approved DM5BS98 SN Flucam; Nacyl; Nasil; CP-65703 DM5BS98 CP Pfizer Inc DM5BS98 DT Small molecular drug DM5BS98 PC 2176 DM5BS98 MW 447.5 DM5BS98 FM C20H21N3O7S DM5BS98 IC InChI=1S/C20H21N3O7S/c1-4-28-20(25)30-13(2)29-18-14-9-5-6-10-15(14)31(26,27)23(3)17(18)19(24)22-16-11-7-8-12-21-16/h5-13H,4H2,1-3H3,(H,21,22,24) DM5BS98 CS CCOC(=O)OC(C)OC1=C(N(S(=O)(=O)C2=CC=CC=C21)C)C(=O)NC3=CC=CC=N3 DM5BS98 IK LSNWBKACGXCGAJ-UHFFFAOYSA-N DM5BS98 IU ethyl 1-[[2-methyl-1,1-dioxo-3-(pyridin-2-ylcarbamoyl)-1lambda6,2-benzothiazin-4-yl]oxy]ethyl carbonate DM5BS98 CA CAS 99464-64-9 DM5BS98 CB CHEBI:31210 DM5BS98 DE Inflammation DMLMXE0 ID DMLMXE0 DMLMXE0 DN Amprenavir DMLMXE0 HS Approved DMLMXE0 SN AMV; Agenerase; Amprenavir[usan]; Prozei; Vertex; Amprenavir [USAN]; VX 478; VX478; Vertex VX478; Agenerase (TM); Agenerase (TN); DRG-0258; GNA & Amprenavir; HHA & Amprenavir; KVX-478; VX-478; Amprenavir (JAN/USAN/INN); Tetrahydro-3-furyl N-(3-(4-amino-N-isobutylbenzenesulfonamido)-1-benzyl-2-hydroxypropyl)carbamate; {3-[(4-AMINO-BENZENESULFONYL)-ISOBUTYL-AMINO]-1-BENZYL-2-HYDROXY-PROPYL}-CARBAMIC ACID TETRAHYDRO-FURAN-3-YL ESTER; [(3S)-oxolan-3-yl] N-[(2S,3R)-4-[(4-aminophenyl)sulfonyl-(2-methylpropyl)amino]-3-hydroxy-1-phenylbutan-2-yl]carbamate; Carbamic acid, ((1S,2R)-3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)-, (3S)-tetrahydro-3-furanyl ester; Carbamic acid, ((1S,2R)-3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)-, (3S)-tetrahydro-3-furanyl ester & Galanthus nivalis agglutinin (GNA); Carbamic acid, ((1S,2R)-3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)-, (3S)-tetrahydro-3-furanyl ester & Hippeastrum hybrid agglutinin(HHA); (3S)-Tetrahydro-3-furanyl ((1S,2R)-3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)carbamate; (3S)-Tetrahydro-3-furyl ((alphaS)-alpha-((1R-1-hydroxy-2-(N(sup 1)-isobutylsulfanilamido)ethyl)phenethyl)carbamate; (3S)-tetrahydro-3-furyl N-[(1S,2R)-3-(4-amino-N-isobutylbenzenesulfonamido)-1-benzyl-2-hydroxy-propyl]carbamate; (3S-(3R*(1R*,2S*)))-(3-(((4-Aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl) tetrahydro-3-furanyl carbamate; 4-Amino-N-((2 syn,3S)-2-hydroxy-4-phenyl-3-((S)-tetrahydrofuran-3-yloxycarbonylamino)-butyl)-N-isobutyl-benzenesulfonamide DMLMXE0 CP GlaxoSmithKline DMLMXE0 TC Anti-HIV Agents DMLMXE0 DT Small molecular drug DMLMXE0 PC 65016 DMLMXE0 MW 505.6 DMLMXE0 FM C25H35N3O6S DMLMXE0 IC InChI=1S/C25H35N3O6S/c1-18(2)15-28(35(31,32)22-10-8-20(26)9-11-22)16-24(29)23(14-19-6-4-3-5-7-19)27-25(30)34-21-12-13-33-17-21/h3-11,18,21,23-24,29H,12-17,26H2,1-2H3,(H,27,30)/t21-,23-,24+/m0/s1 DMLMXE0 CS CC(C)CN(C[C@H]([C@H](CC1=CC=CC=C1)NC(=O)O[C@H]2CCOC2)O)S(=O)(=O)C3=CC=C(C=C3)N DMLMXE0 IK YMARZQAQMVYCKC-OEMFJLHTSA-N DMLMXE0 IU [(3S)-oxolan-3-yl] N-[(2S,3R)-4-[(4-aminophenyl)sulfonyl-(2-methylpropyl)amino]-3-hydroxy-1-phenylbutan-2-yl]carbamate DMLMXE0 CA CAS 161814-49-9 DMLMXE0 CB CHEBI:40050 DMLMXE0 DE Human immunodeficiency virus infection DMZKYIV ID DMZKYIV DMZKYIV DN Amsacrine DMZKYIV HS Approved DMZKYIV SN Acridinylanisidide; Amecrin; Amekrin; Amsacrina; Amsacrinum; Amsidine; Amsidyl; Amsine; Lamasine; MAMSA; NAMSA; Acridinyl Anisidide; SN 21429; SN11841; AMSA P-D; Acridinyl anisidide (TN); Amsacrina [INN-Spanish]; Amsacrinum [INN-Latin]; Amsidyl (TN); Cain's Acridine; M-AMSA; Meta-AMSA; Meta-Amsacrine; SN-11841; Amsacrine (USAN/INN); Amsacrine [USAN:BAN:INN]; M-AMSA (TN); N-[4-(9-Acridinylamino)-3-methoxyphenyl]methanesulfonamide; N-(4-(9-Acridinylamino)-3-methoxyphenyl)methanesulfonamide; N-[4-(9-Acridinylamino)-3-methoxy-phenyl]methanesulfonamide; N-[4-(acridin-9-ylamino)-3-methoxyphenyl]methanesulfonamide; N-[4-(acridin-9-ylmethyl)-3-methoxyphenyl]methanesulfonamide; N-(4-(Acridin-9-ylamino)-3-methoxyphenyl)methanesulfonamide; N-[4-(Acridin-9-ylamino)-3-(methyloxy)phenyl]methanesulfonamide; N-[4-(acridin-9-ylamino)-3-(methyloxy)phenyl]methanesulfonamide; 4'-(9-Acridinylamino)-3'-methoxymethanesulfonanilide; 4'-(9-Acridinylamino)methanesulfon-m-anisidide; 4'-(9-Acridinylamino)methanesulfon-meta-anisidide; 4'-(9-Acridinylamino)methanesulphon-m-anisidide DMZKYIV CP Travenol Laboratories Inc DMZKYIV TC Anticancer Agents DMZKYIV DT Small molecular drug DMZKYIV PC 2179 DMZKYIV MW 393.5 DMZKYIV FM C21H19N3O3S DMZKYIV IC InChI=1S/C21H19N3O3S/c1-27-20-13-14(24-28(2,25)26)11-12-19(20)23-21-15-7-3-5-9-17(15)22-18-10-6-4-8-16(18)21/h3-13,24H,1-2H3,(H,22,23) DMZKYIV CS COC1=C(C=CC(=C1)NS(=O)(=O)C)NC2=C3C=CC=CC3=NC4=CC=CC=C42 DMZKYIV IK XCPGHVQEEXUHNC-UHFFFAOYSA-N DMZKYIV IU N-[4-(acridin-9-ylamino)-3-methoxyphenyl]methanesulfonamide DMZKYIV CA CAS 51264-14-3 DMZKYIV CB CHEBI:2687 DMZKYIV DE Acute lymphoblastic leukaemia DMAWU35 ID DMAWU35 DMAWU35 DN Amtolmetin guacil DMAWU35 HS Approved DMAWU35 SN Artromed; Atromed; Eufans; Amtolmetin guacyl; MED-15; ST-679 DMAWU35 CP Sigma-Tau Ind Farm Riunite SpA DMAWU35 DT Small molecular drug DMAWU35 PC 65655 DMAWU35 MW 420.5 DMAWU35 FM C24H24N2O5 DMAWU35 IC InChI=1S/C24H24N2O5/c1-16-8-10-17(11-9-16)24(29)19-13-12-18(26(19)2)14-22(27)25-15-23(28)31-21-7-5-4-6-20(21)30-3/h4-13H,14-15H2,1-3H3,(H,25,27) DMAWU35 CS CC1=CC=C(C=C1)C(=O)C2=CC=C(N2C)CC(=O)NCC(=O)OC3=CC=CC=C3OC DMAWU35 IK CWJNMKKMGIAGDK-UHFFFAOYSA-N DMAWU35 IU (2-methoxyphenyl) 2-[[2-[1-methyl-5-(4-methylbenzoyl)pyrrol-2-yl]acetyl]amino]acetate DMAWU35 CA CAS 87344-06-7 DMAWU35 CB CHEBI:135678 DMAWU35 DE Inflammation DMJKO05 ID DMJKO05 DMJKO05 DN Amyl nitrite DMJKO05 HS Approved DMJKO05 SN Amyl nitrite; Pentyl nitrite; n-Amyl nitrite; 463-04-7; Nitramyl; n-Pentyl nitrite; Nitrous acid, pentyl ester; Pentyl alcohol, nitrite; UNII-H2HUX79FYK; CCRIS 763; EINECS 207-332-7; H2HUX79FYK; BRN 1701241; AI3-25184; CHEBI:55344; CSDTZUBPSYWZDX-UHFFFAOYSA-N; Pentylnitrite; n-pentylnitrite; amyl 1 nitrite; N-Phenyl nitrile; ACMC-1ACPW; nitrous acid pentyl ester; Nitrousacid, pentyl ester; DSSTox_CID_4522; UN 1113 (Related); Pentyl nitrite, AldrichCPR; AC1L1UC5; DSSTox_RID_77442; SCHEMBL34065; DSSTox_GSID_24522; KSC492M8F; 4-01-00-01644 DMJKO05 DT Small molecular drug DMJKO05 PC 10026 DMJKO05 MW 117.15 DMJKO05 FM C5H11NO2 DMJKO05 IC InChI=1S/C5H11NO2/c1-2-3-4-5-8-6-7/h2-5H2,1H3 DMJKO05 CS CCCCCON=O DMJKO05 IK CSDTZUBPSYWZDX-UHFFFAOYSA-N DMJKO05 IU pentyl nitrite DMJKO05 CA CAS 463-04-7 DMJKO05 CB CHEBI:55344 DMJKO05 DE Angina pectoris DMJXIC9 ID DMJXIC9 DMJXIC9 DN Anagliptin DMJXIC9 HS Approved DMJXIC9 SN Anagliptin; 739366-20-2; UNII-K726J96838; suiny; CHEMBL1929396; (S)-N-(2-((2-(2-Cyanopyrrolidin-1-yl)-2-oxoethyl)amino)-2-methylpropyl)-2-methylpyrazolo[1,5-a]pyrimidine-6-carboxamide; K726J96838; CHEMBL1929387; N-[2-[[2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl]amino]-2-methylpropyl]-2-methylpyrazolo[1,5-a]pyrimidine-6-carboxamide; Anagliptin [INN]; N-[2-({2-[(2s)-2-Cyanopyrrolidin-1-Yl]-2-Oxoethyl}amino)-2-Methylpropyl]-2-Methylpyrazolo[1,5-A]pyrimidine-6-Carboxamide; Anagliptin (JAN/INN); SCHEMBL905393; sk-0403 DMJXIC9 CP Kowa Research Institute DMJXIC9 DT Small molecular drug DMJXIC9 PC 44513473 DMJXIC9 MW 383.4 DMJXIC9 FM C19H25N7O2 DMJXIC9 IC InChI=1S/C19H25N7O2/c1-13-7-16-21-9-14(11-26(16)24-13)18(28)22-12-19(2,3)23-10-17(27)25-6-4-5-15(25)8-20/h7,9,11,15,23H,4-6,10,12H2,1-3H3,(H,22,28)/t15-/m0/s1 DMJXIC9 CS CC1=NN2C=C(C=NC2=C1)C(=O)NCC(C)(C)NCC(=O)N3CCC[C@H]3C#N DMJXIC9 IK LDXYBEHACFJIEL-HNNXBMFYSA-N DMJXIC9 IU N-[2-[[2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl]amino]-2-methylpropyl]-2-methylpyrazolo[1,5-a]pyrimidine-6-carboxamide DMJXIC9 CA CAS 739366-20-2 DMJXIC9 CB CHEBI:136043 DMJXIC9 DE Type-2 diabetes DMSQ8MD ID DMSQ8MD DMSQ8MD DN Anagrelide DMSQ8MD HS Approved DMSQ8MD SN Anagrelida; Anagrelidum; BL 416201; Agrylin (TN); Anagrelida [INN-Spanish]; Anagrelide [BAN:INN]; Anagrelide [INN:BAN]; Anagrelidum [INN-Latin]; Xagrid (TN); Anagrelide (INN/BAN); 6,7-Dichlor-1,5-dihydroimidazo(2,1-b)chinazolin-2(3H)-on; 6,7-Dichloro-1,5-dihydroimidazo(2,1-b)quinazolin-2(3H)-one; 6,7-dichloro-1,5-dihydroimidazo[2,1-]quinazolin-2(3H)-one; 6,7-dichloro-5,10-dihydro-3H-imidazo[2,1-b]quinazolin-2-one DMSQ8MD CP Shire Phamaceuticals DMSQ8MD TC Antithrombotic Agents DMSQ8MD DT Small molecular drug DMSQ8MD PC 135409400 DMSQ8MD MW 256.079 DMSQ8MD FM C10H7Cl2N3O DMSQ8MD IC InChI=1S/C10H7Cl2N3O/c11-6-1-2-7-5(9(6)12)3-15-4-8(16)14-10(15)13-7/h1-2H,3-4H2,(H,13,14,16) DMSQ8MD CS C1C2=C(C=CC(=C2Cl)Cl)N=C3N1CC(=O)N3 DMSQ8MD IK OTBXOEAOVRKTNQ-UHFFFAOYSA-N DMSQ8MD IU 6,7-dichloro-3,5-dihydro-1H-imidazo[2,1-b]quinazolin-2-one DMSQ8MD CA CAS 68475-42-3 DMSQ8MD CB CHEBI:142290 DMSQ8MD DE Thrombocythemia; Essential thrombocythemia DMU8KOD ID DMU8KOD DMU8KOD DN Anakinra DMU8KOD HS Approved DMU8KOD SN Kineret; Kineret (TN); Anakinra (USAN/INN) DMU8KOD CP Amgen Inc DMU8KOD TC Antiinflammatory Agents DMU8KOD SQ DB00026 sequence: MRPSGRKSSKMQAFRIWDVNQKTFYLRNNQLVAGYLQGPNVNLEEKIDVVPIEPHALFLGIHGGKMCLSCVKSGDETRLQLEAVNITDLSENRKQDKRFAFIRSDSGPTTSFESAACPGWFLCTAMEADQPVSLTNMPDEGVMVTKFYFQEDE DMU8KOD DE Rheumatoid arthritis DMV96ZH ID DMV96ZH DMV96ZH DN Anapsos DMV96ZH HS Approved DMV96ZH SN Psoriacen; EQA-00; Polypodium leucotomos extract, ASAC DMV96ZH CP ASAC Pharmaceutical International AIE DMV96ZH DE Atopic dermatitis DMNP60F ID DMNP60F DMNP60F DN Anastrozole DMNP60F HS Approved DMNP60F SN Anastrazole; Anastrole; Anastrozol; Arimidex; Asiolex; Astra brand of anastrozole; AstraZeneca brand of anastrozole; Zeneca brand of anastrozole; ZD 1033; ZD1033; Zeneca ZD 1033; Arimidex (TN); Arimidex (Zeneca); Arimidex, Anastrozole; ZD-1033; Anastrozole [USAN:INN:BAN]; Anastrozole (JAN/USAN/INN); Alpha,alpha,alpha',alpha'-tetramethyl-5(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile; Alpha,alpha,alpha',alpha'-Tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile; 1,3-benzenediacetonitrile, a, a,a', a'-tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl); 2,2'-(5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-phenylene)bis(2-methylpropionitrile); 2,2'-[5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-phenylene]bis(2-methylpropanenitrile); 2,2'-[5-(1H-1,2,4-triazol-1-ylmethyl)benzene-1,3-diyl]bis(2-methylpropanenitrile); 2-[3-(2-cyanopropan-2-yl)-5-(1,2,4-triazol-1-ylmethyl)phenyl]-2-methylpropanenitrile DMNP60F CP AstraZeneca DMNP60F TC Anticancer Agents DMNP60F DT Small molecular drug DMNP60F PC 2187 DMNP60F MW 293.4 DMNP60F FM C17H19N5 DMNP60F IC InChI=1S/C17H19N5/c1-16(2,9-18)14-5-13(8-22-12-20-11-21-22)6-15(7-14)17(3,4)10-19/h5-7,11-12H,8H2,1-4H3 DMNP60F CS CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N DMNP60F IK YBBLVLTVTVSKRW-UHFFFAOYSA-N DMNP60F IU 2-[3-(2-cyanopropan-2-yl)-5-(1,2,4-triazol-1-ylmethyl)phenyl]-2-methylpropanenitrile DMNP60F CA CAS 120511-73-1 DMNP60F CB CHEBI:2704 DMNP60F DE Breast cancer DMLWQ27 ID DMLWQ27 DMLWQ27 DN Angiotensin Ii DMLWQ27 HS Approved DMLWQ27 SN Human angiotensin II; Angiotensin II human; 4474-91-3; Angiotensin II (mouse); Angiotensin II (human); Giapreza; Ang II; 5-Isoleucine-angiotensin II; 5-L-Isoleucineangiotensin II; Ile(5)-angiotensin II; 1-8-Angiotensin I; isoleucine(5)-angiotensin II;Angiotensin II, human; Isoleucine5-angiotensin II; Angiotensin II, ile(5)-; Angiotensin ii [INN:JAN] DMLWQ27 CP La Jolla Pharmaceutical Company DMLWQ27 DT Small molecular drug DMLWQ27 PC 172198 DMLWQ27 MW 1046.2 DMLWQ27 FM C50H71N13O12 DMLWQ27 IC InChI=1S/C50H71N13O12/c1-5-28(4)41(47(72)59-36(23-31-25-54-26-56-31)48(73)63-20-10-14-38(63)45(70)60-37(49(74)75)22-29-11-7-6-8-12-29)62-44(69)35(21-30-15-17-32(64)18-16-30)58-46(71)40(27(2)3)61-43(68)34(13-9-19-55-50(52)53)57-42(67)33(51)24-39(65)66/h6-8,11-12,15-18,25-28,33-38,40-41,64H,5,9-10,13-14,19-24,51H2,1-4H3,(H,54,56)(H,57,67)(H,58,71)(H,59,72)(H,60,70)(H,61,68)(H,62,69)(H,65,66)(H,74,75)(H4,52,53,55)/t28-,33-,34-,35-,36-,37-,38-,40-,41-/m0/s1 DMLWQ27 CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)O)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(=O)O)N DMLWQ27 IK CZGUSIXMZVURDU-JZXHSEFVSA-N DMLWQ27 IU (3S)-3-amino-4-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[(2S)-2-[[(1S)-1-carboxy-2-phenylethyl]carbamoyl]pyrrolidin-1-yl]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-oxobutanoic acid DMLWQ27 CA CAS 4474-91-3 DMLWQ27 CB CHEBI:2719 DMLWQ27 DE Increase blood pressure DM8QM5U ID DM8QM5U DM8QM5U DN Anidulafungin DM8QM5U HS Approved DM8QM5U SN Ecalta; Eraxis; Anidulafungin [USAN:INN]; Ecalta (TN); Eraxis (TN); LY-303366; V-Echinocandin; VER-002 DM8QM5U CP Pfizer Pharmaceuticals DM8QM5U TC Antifungal Agents DM8QM5U DT Small molecular drug DM8QM5U PC 166548 DM8QM5U MW 1140.2 DM8QM5U FM C58H73N7O17 DM8QM5U IC InChI=1S/C58H73N7O17/c1-5-6-7-24-82-40-22-18-35(19-23-40)33-10-8-32(9-11-33)34-12-14-37(15-13-34)51(74)59-41-26-43(70)54(77)63-56(79)47-48(71)29(2)27-65(47)58(81)45(31(4)67)61-55(78)46(50(73)49(72)36-16-20-38(68)21-17-36)62-53(76)42-25-39(69)28-64(42)57(80)44(30(3)66)60-52(41)75/h8-23,29-31,39,41-50,54,66-73,77H,5-7,24-28H2,1-4H3,(H,59,74)(H,60,75)(H,61,78)(H,62,76)(H,63,79)/t29-,30+,31+,39+,41-,42-,43+,44-,45-,46-,47-,48-,49-,50-,54+/m0/s1 DM8QM5U CS CCCCCOC1=CC=C(C=C1)C2=CC=C(C=C2)C3=CC=C(C=C3)C(=O)N[C@H]4C[C@H]([C@H](NC(=O)[C@@H]5[C@H]([C@H](CN5C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]6C[C@H](CN6C(=O)[C@@H](NC4=O)[C@@H](C)O)O)[C@@H]([C@H](C7=CC=C(C=C7)O)O)O)[C@@H](C)O)C)O)O)O DM8QM5U IK JHVAMHSQVVQIOT-MFAJLEFUSA-N DM8QM5U IU N-[(3S,6S,9S,11R,15S,18S,20R,21R,24S,25S,26S)-6-[(1S,2S)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-11,20,21,25-tetrahydroxy-3,15-bis[(1R)-1-hydroxyethyl]-26-methyl-2,5,8,14,17,23-hexaoxo-1,4,7,13,16,22-hexazatricyclo[22.3.0.09,13]heptacosan-18-yl]-4-[4-(4-pentoxyphenyl)phenyl]benzamide DM8QM5U CA CAS 166663-25-8 DM8QM5U CB CHEBI:55346 DM8QM5U DE Convulsion DMBAUED ID DMBAUED DMBAUED DN Anileridine DMBAUED HS Approved DMBAUED SN Adopol; Alidine; Anileridina; Anileridinum; Apidol; Apodol; Leritin; Nipecotan; Anileridina [INN-Spanish]; Anileridine [INN:BAN]; Anileridinum [INN-Latin]; Leritine (TN); Anileridine (USP/INN); N-beta-(p-Aminophenyl)ethylnormeperidine; Ethyl 1-(4-aminophenethyl)-4-phenylisonipecotate; Ethyl 1-(p-aminophenethyl)-4-phenylisonipecotate; Ethyl 1-[2-(4-aminophenyl)ethyl]-4-phenylpiperidine-4-carboxylate; Isonipecotic acid, 1-(p-aminophenethyl)-4-phenyl-, ethyl ester; Ethyl 1-(2-(4-aminophenyl)ethyl)-4-phenyl-4-piperidinecarboxylate; N-(beta-(p-Aminophenyl)ethyl)-4-phenyl-4-carbethoxypiperidine; 1-(2-(4-Aminophenyl)ethyl)-4-phenyl-4-piperidinecarboxylic acid ethyl ester; 1-(p-Aminophenethyl)-4-phenylisonipecotic acid ethyl ester; 1-(p-Aminophenethyl)-4-phenylpiperidine-4-carboxylic acid ethyl ester; 1-[2-(4-Aminophenyl)ethyl]-4-phenyl-4-piperidinecarboxlic acid ethyl ester; 4-Piperidinecarboxylic acid, 1-(2-(4-aminophenyl)ethyl)-4-phenyl-, ethyl ester; 4-Piperidinecarboxylic acid, 1-[2-(4-aminophenyl)ethyl]-4-phenyl-, ethyl ester DMBAUED TC Analgesics DMBAUED DT Small molecular drug DMBAUED PC 8944 DMBAUED MW 352.5 DMBAUED FM C22H28N2O2 DMBAUED IC InChI=1S/C22H28N2O2/c1-2-26-21(25)22(19-6-4-3-5-7-19)13-16-24(17-14-22)15-12-18-8-10-20(23)11-9-18/h3-11H,2,12-17,23H2,1H3 DMBAUED CS CCOC(=O)C1(CCN(CC1)CCC2=CC=C(C=C2)N)C3=CC=CC=C3 DMBAUED IK LKYQLAWMNBFNJT-UHFFFAOYSA-N DMBAUED IU ethyl 1-[2-(4-aminophenyl)ethyl]-4-phenylpiperidine-4-carboxylate DMBAUED CA CAS 144-14-9 DMBAUED CB CHEBI:61203 DMBAUED DE Pain DMC128O ID DMC128O DMC128O DN Anileridine Hydrochloride DMC128O HS Approved DMC128O SN Anileridine Phosphate; Leritine DMC128O CP Merck And Co Inc DMC128O TC Neurology Agents DMC128O DT Small molecular drug DMC128O PC 31338 DMC128O MW 425.4 DMC128O FM C22H30Cl2N2O2 DMC128O IC InChI=1S/C22H28N2O2.2ClH/c1-2-26-21(25)22(19-6-4-3-5-7-19)13-16-24(17-14-22)15-12-18-8-10-20(23)11-9-18;;/h3-11H,2,12-17,23H2,1H3;2*1H DMC128O CS CCOC(=O)C1(CCN(CC1)CCC2=CC=C(C=C2)N)C3=CC=CC=C3.Cl.Cl DMC128O IK ZYTHLJLPPSSDIP-UHFFFAOYSA-N DMC128O IU ethyl 1-[2-(4-aminophenyl)ethyl]-4-phenylpiperidine-4-carboxylate;dihydrochloride DMC128O CA CAS 126-12-5 DMC128O CB CHEBI:61208 DMC128O DE Pain DMOIFW0 ID DMOIFW0 DMOIFW0 DN Aniracetam DMOIFW0 HS Approved DMOIFW0 SN aniracetam; 72432-10-1; Draganon; Sarpul; 1-(4-Methoxybenzoyl)-2-pyrrolidinone; Ampamet; 1-(4-methoxybenzoyl)pyrrolidin-2-one; 1-p-Anisoyl-2-pyrrolidinone; Ro 13-5057; Aniracetamun [INN-Latin]; Aniracetam [USAN:INN:JAN]; UNII-5L16LKN964; Ro 135057; BRN 4807205; Ro-13-5057; 1-p-anisoylpyrrolidin-2-one; 2-Pyrrolidinone, 1-(4-methoxybenzoyl)-; CHEMBL36994; MLS000079240; CHEBI:47943; 1-(p-Methoxybenzoyl)-2-pyrrolidinon [German]; ZXNRTKGTQJPIJK-UHFFFAOYSA-N; 5L16LKN964; NCGC00015116-10; SMR000038438 DMOIFW0 DT Small molecular drug DMOIFW0 PC 2196 DMOIFW0 MW 219.24 DMOIFW0 FM C12H13NO3 DMOIFW0 IC InChI=1S/C12H13NO3/c1-16-10-6-4-9(5-7-10)12(15)13-8-2-3-11(13)14/h4-7H,2-3,8H2,1H3 DMOIFW0 CS COC1=CC=C(C=C1)C(=O)N2CCCC2=O DMOIFW0 IK ZXNRTKGTQJPIJK-UHFFFAOYSA-N DMOIFW0 IU 1-(4-methoxybenzoyl)pyrrolidin-2-one DMOIFW0 CA CAS 72432-10-1 DMOIFW0 CB CHEBI:47943 DMOIFW0 DE Cerebrovascular ischaemia DM2C48U ID DM2C48U DM2C48U DN Anisindione DM2C48U HS Approved DM2C48U SN Anisindiona; Anisindionum; Miradon; Unidone; Anisin indandione; SPE 2792; Anisindiona [INN-Spanish]; Anisindione (INN); Anisindione [INN:BAN]; Anisindionum [INN-Latin]; Miradon (TN); 2-(4-Methoxy-phenyl)-indan-1,3-dione; 2-(4-Methoxyphenyl)-1H-indene-1,3(2H)-dione; 2-(4-Methoxyphenyl)indan-1,3-dione; 2-(4-methoxyphenyl)indene-1,3-dione; 2-(p-Methoxyphenyl)-1,3-indandione; 2-(p-Methoxyphenyl)indane-1,3-dione; 2-[4-(methyloxy)phenyl]-1H-indene-1,3(2H)-dione; 2-p-Anisyl-1,3-indandione; 2-para-Anisyl-1,3-indandione DM2C48U TC Anticoagulants DM2C48U DT Small molecular drug DM2C48U PC 2197 DM2C48U MW 252.26 DM2C48U FM C16H12O3 DM2C48U IC InChI=1S/C16H12O3/c1-19-11-8-6-10(7-9-11)14-15(17)12-4-2-3-5-13(12)16(14)18/h2-9,14H,1H3 DM2C48U CS COC1=CC=C(C=C1)C2C(=O)C3=CC=CC=C3C2=O DM2C48U IK XRCFXMGQEVUZFC-UHFFFAOYSA-N DM2C48U IU 2-(4-methoxyphenyl)indene-1,3-dione DM2C48U CA CAS 117-37-3 DM2C48U CB CHEBI:133809 DM2C48U DE Coagulation defect DMW51AX ID DMW51AX DMW51AX DN Anisodamine DMW51AX HS Approved DMW51AX SN anisodamine; racanisodamine; 55869-99-3; (6S)-6-Hydroxyhyoscyamine; (-)-Anisodamine; AC1O6SQS; AC1L4C7W; SCHEMBL620576; ZINC2112569; 8053AH; API0000388; 869A993; Q-100648; [(1S,3S,5S,6S)-6-hydroxy-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] (2S)-3-hydroxy-2-phenylpropanoate; (S)-((1S,3S,5S,6S)-6-hydroxy-8-methyl-8-azabicyclo[3.2.1]octan-3-yl) 3-hydroxy-2-phenylpropanoate; [(1R,3S,5R,6R)-6-hydroxy-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] (2R)-3-hydroxy-2-phenylpropanoate DMW51AX DT Small molecular drug DMW51AX PC 6918612 DMW51AX MW 305.4 DMW51AX FM C17H23NO4 DMW51AX IC InChI=1S/C17H23NO4/c1-18-12-7-13(9-15(18)16(20)8-12)22-17(21)14(10-19)11-5-3-2-4-6-11/h2-6,12-16,19-20H,7-10H2,1H3/t12-,13-,14+,15+,16-/m0/s1 DMW51AX CS CN1[C@H]2C[C@@H](C[C@@H]1[C@H](C2)O)OC(=O)[C@H](CO)C3=CC=CC=C3 DMW51AX IK WTQYWNWRJNXDEG-RBZJEDDUSA-N DMW51AX IU [(1R,3S,5R,6S)-6-hydroxy-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] (2S)-3-hydroxy-2-phenylpropanoate DMW51AX CA CAS 55869-99-3 DMW51AX DE Central and peripheral nervous disease DMNOSWU ID DMNOSWU DMNOSWU DN Anisodine DMNOSWU HS Approved DMNOSWU SN anisodine; 52646-92-1; SCHEMBL474045; AC1N31M8; 2,3-Dihydroxy-2-phenylpropanoic acid 9-methyl-3-oxa-9-azatricyclo[3.3.1.02,4]nonane-7alpha-yl ester DMNOSWU DT Small molecular drug DMNOSWU PC 11616712 DMNOSWU MW 319.4 DMNOSWU FM C17H21NO5 DMNOSWU IC InChI=1S/C17H21NO5/c1-18-12-7-11(8-13(18)15-14(12)23-15)22-16(20)17(21,9-19)10-5-3-2-4-6-10/h2-6,11-15,19,21H,7-9H2,1H3/t11?,12-,13+,14-,15+,17-/m1/s1 DMNOSWU CS CN1[C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@@](CO)(C4=CC=CC=C4)O DMNOSWU IK JEJREKXHLFEVHN-QDXGGTILSA-N DMNOSWU IU [(1S,2S,4R,5R)-9-methyl-3-oxa-9-azatricyclo[3.3.1.02,4]nonan-7-yl] (2S)-2,3-dihydroxy-2-phenylpropanoate DMNOSWU CA CAS 52646-92-1 DMNOSWU DE Central and peripheral nervous disease DMIJRF0 ID DMIJRF0 DMIJRF0 DN Anisotropine Methylbromide DMIJRF0 HS Approved DMIJRF0 SN Anisotropine; Endovalpin; Lytispasm; Valpin; Anisotropine methobromide; Anisotropine methyl bromide;Methyloctatropine bromide; Metilbromuro de octatropina; Octatropine methylbromide; Octatropini methylbromidum; Octatropone Bromide; Valpin 50; Anisotropine methylbromide (USAN); Anisotropine methylbromide [USAN:JAN]; Endovalpin (TN); Lytispasm (TN); Methylbromure d'octatropine; Methyloctatropine bromide (JAN); Metilbromuro de octatropina [INN-Spanish]; Octatropine methylbromide (INN); Octatropinimethylbromidum [INN-Latin]; Valpin (TN); Valpin 50 (TN); Methylbromure d'octatropine [INN-French]; Anisotropine methylbromide, (endo)-isomer; [(1R,5R)-8,8-dimethyl-8-azoniabicyclo[3.2.1]octan-3-yl] 2-propylpentanoate bromide; [(1R,5S)-8,8-dimethyl-8-azoniabicyclo[3.2.1]octan-3-yl] 2-propylpentanoate bromide; Endo-8,8-Dimethyl-3-((1-oxo-2-propylpentyl)oxy)-8-azoniabicyclo(3.2.1)octane bromide; (1r,5r)-8,8-dimethyl-3-[(2-propylpentanoyl)oxy]-8-azoniabicyclo[3.2.1]octane bromide; (3-endo)-8,8-dimethyl-3-[(2-propylpentanoyl)oxy]-8-azoniabicyclo[3.2.1]octane bromide; 1-alpha-H,5-alpha-H-Tropanium,3-alpha-hydroxy-8-methyl-, bromide, 2-propylvalerate; 1alphaH,5alphaH-Tropanium, 3alpha-hydroxy-8-methyl-, bromide, 2-propylvalerate; 2-Propylpentanoyltropinium methylbromide; 3-alpha-Hydroxy-8-methyl-1-alpha-H,5-alpha-H-tropanium bromide 2-propylvalerate; 3alpha-Hydroxy-8-methyl-1alphaH,5alphaH-tropanium bromide 2-propylvalerate; 8,8-dimethyl-3-[(2-propylpentanoyl)oxy]-8-azoniabicyclo[3.2.1]octane bromide; 8-Methyl-3-(2-propylpentanoyloxy)tropinium bromide; 8-Methyltropinium bromide 2-propylpentanoate; 8-Methyltropinium bromide 2-propylvalerate DMIJRF0 TC Anticholinergic Agents DMIJRF0 DT Small molecular drug DMIJRF0 PC 657201 DMIJRF0 MW 362.3 DMIJRF0 FM C17H32BrNO2 DMIJRF0 IC InChI=1S/C17H32NO2.BrH/c1-5-7-13(8-6-2)17(19)20-16-11-14-9-10-15(12-16)18(14,3)4;/h13-16H,5-12H2,1-4H3;1H/q+1;/p-1/t14-,15+,16?; DMIJRF0 CS CCCC(CCC)C(=O)OC1C[C@H]2CC[C@@H](C1)[N+]2(C)C.[Br-] DMIJRF0 IK QSFKGMJOKUZAJM-JXMYBXCISA-M DMIJRF0 IU [(1S,5R)-8,8-dimethyl-8-azoniabicyclo[3.2.1]octan-3-yl] 2-propylpentanoate;bromide DMIJRF0 CA CAS 80-50-2 DMIJRF0 DE Peptic ulcer DM6Q4B0 ID DM6Q4B0 DM6Q4B0 DN Anistreplase DM6Q4B0 HS Approved DM6Q4B0 TC Thrombolytic Agents DM6Q4B0 SQ DB00029 sequence: SYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP DM6Q4B0 DE Acute coronary syndrome DMUMOEV ID DMUMOEV DMUMOEV DN Ansuvimab DMUMOEV HS Approved DMUMOEV DT Antibody DMUMOEV DE Ebola virus infection DMA04JS ID DMA04JS DMA04JS DN Antazoline DMA04JS HS Approved DMA04JS SN Analergine; Antastan; Antasten; Antazolin; Antazolina; Antazolinum; Antihistal; Antistin; Antistine; Azalone; Histostab;Imidamin; Imidamine; Phenazolin; Phenazoline; Antazolina [Spanish]; Antazolinum [Latin]; Antazolina [INN-Spanish]; Antazoline (INN); Antazoline [INN:BAN]; Antazolinum [INN-Latin]; Ben-A-hist; N-Benzyl-N-(4,5-dihydro-1H-imidazol-2-ylmethyl)aniline; N-(4,5-dihydro-1H-imidazol-2-ylmethyl)-N-(phenylmethyl)aniline; 2-(N-Benzylanilinomethyl)-2-imidazoline; 2-(N-Phenyl-N-benzylaminomethyl)imidazoline; 2-Phenyl-benzyl-amino-methylimidazolin; 2-Phenyl-benzyl-amino-methylimidazolin [German]; 4,5-Dihydro-N-phenyl-N-phenylmethyl-1H-imidazole-2-methanamine; 5512-M DMA04JS DT Small molecular drug DMA04JS PC 2200 DMA04JS MW 265.35 DMA04JS FM C17H19N3 DMA04JS IC InChI=1S/C17H19N3/c1-3-7-15(8-4-1)13-20(14-17-18-11-12-19-17)16-9-5-2-6-10-16/h1-10H,11-14H2,(H,18,19) DMA04JS CS C1CN=C(N1)CN(CC2=CC=CC=C2)C3=CC=CC=C3 DMA04JS IK REYFJDPCWQRWAA-UHFFFAOYSA-N DMA04JS IU N-benzyl-N-(4,5-dihydro-1H-imidazol-2-ylmethyl)aniline DMA04JS CA CAS 91-75-8 DMA04JS CB CHEBI:84115 DMA04JS DE Nasal congestion DMNC64R ID DMNC64R DMNC64R DN Antegren DMNC64R HS Approved DMNC64R DT Antibody DMNC64R DE Multiple sclerosis DMH4CFE ID DMH4CFE DMH4CFE DN Antithymocyte globulin DMH4CFE HS Approved DMH4CFE SN Atgam (TN); Thymoglobulin (TN) DMH4CFE CP Pfizer Pharmaceuticals DMH4CFE TC Immunomodulatory Agents DMH4CFE DE Aplastic anemia DM89JLN ID DM89JLN DM89JLN DN Apixaban DM89JLN HS Approved DM89JLN SN GG2; BMS 562247-01; BMS-562247; Eliquis (TN); BMS-562247-01; Apixaban (JAN/USAN/INN); BMS-562247-01, Apixaban; Ro-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid amide; 1-(4-Methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5,6,7-tetrahyd DM89JLN CP Pfizer DM89JLN DT Small molecular drug DM89JLN PC 10182969 DM89JLN MW 459.5 DM89JLN FM C25H25N5O4 DM89JLN IC InChI=1S/C25H25N5O4/c1-34-19-11-9-18(10-12-19)30-23-20(22(27-30)24(26)32)13-15-29(25(23)33)17-7-5-16(6-8-17)28-14-3-2-4-21(28)31/h5-12H,2-4,13-15H2,1H3,(H2,26,32) DM89JLN CS COC1=CC=C(C=C1)N2C3=C(CCN(C3=O)C4=CC=C(C=C4)N5CCCCC5=O)C(=N2)C(=O)N DM89JLN IK QNZCBYKSOIHPEH-UHFFFAOYSA-N DM89JLN IU 1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5-dihydropyrazolo[3,4-c]pyridine-3-carboxamide DM89JLN CA CAS 503612-47-3 DM89JLN CB CHEBI:72296 DM89JLN DE Thrombosis DMX38HQ ID DMX38HQ DMX38HQ DN Apomorphine DMX38HQ HS Approved DMX38HQ SN Apomorphine (intranasal, Parkinson's disease) DMX38HQ CP Archimedes Pharma Ltd DMX38HQ DT Small molecular drug DMX38HQ PC 6005 DMX38HQ MW 267.32 DMX38HQ FM C17H17NO2 DMX38HQ IC InChI=1S/C17H17NO2/c1-18-8-7-10-3-2-4-12-15(10)13(18)9-11-5-6-14(19)17(20)16(11)12/h2-6,13,19-20H,7-9H2,1H3/t13-/m1/s1 DMX38HQ CS CN1CCC2=C3[C@H]1CC4=C(C3=CC=C2)C(=C(C=C4)O)O DMX38HQ IK VMWNQDUVQKEIOC-CYBMUJFWSA-N DMX38HQ IU (6aR)-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol DMX38HQ CA CAS 58-00-4 DMX38HQ CB CHEBI:48538 DMX38HQ DE Parkinson disease; Sexual dysfunction; Idiopathic parkinson disease DMO4PVE ID DMO4PVE DMO4PVE DN Apraclonidine DMO4PVE HS Approved DMO4PVE SN Aplonidine; Apraclonidina; Apraclonidinum; Iopidine; Iopidine Eye; ALO 2145; Apraclonidina [INN-Spanish]; Apraclonidine (INN); Apraclonidine [INN:BAN]; Apraclonidinum [INN-Latin]; Iopidine (TN); P-aminoclonidine; Para-aminoclonidine; 2,6-dichloro-1-N-(4,5-dihydro-1H-imidazol-2-yl)benzene-1,4-diamine; 2,6-dichloro-N(1)-(4,5-dihydro-1H-imidazol-2-yl)benzene-1,4-diamine; 2-(4-Amino-2,6-dichloroanilino)-2-imidazoline hydrochloride; 2-(4-amino-2,6-dichloro)phenyliminoimidazolidine; 4-Aminoclonidine DMO4PVE CP Alcon Canada Inc DMO4PVE TC Antiglaucomic Agents DMO4PVE DT Small molecular drug DMO4PVE PC 2216 DMO4PVE MW 245.11 DMO4PVE FM C9H10Cl2N4 DMO4PVE IC InChI=1S/C9H10Cl2N4/c10-6-3-5(12)4-7(11)8(6)15-9-13-1-2-14-9/h3-4H,1-2,12H2,(H2,13,14,15) DMO4PVE CS C1CN=C(N1)NC2=C(C=C(C=C2Cl)N)Cl DMO4PVE IK IEJXVRYNEISIKR-UHFFFAOYSA-N DMO4PVE IU 2,6-dichloro-1-N-(4,5-dihydro-1H-imidazol-2-yl)benzene-1,4-diamine DMO4PVE CA CAS 66711-21-5 DMO4PVE CB CHEBI:2788 DMO4PVE DE Intra ocular pressure reduction DMTWS9E ID DMTWS9E DMTWS9E DN Apremilast DMTWS9E HS Approved DMTWS9E SN Apremilast (USAN); CC-10004; N-[2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methylsulfonyl-ethyl]-1,3-dioxo-isoindol-4-yl]acetamide DMTWS9E CP Celgene DMTWS9E DT Small molecular drug DMTWS9E PC 11561674 DMTWS9E MW 460.5 DMTWS9E FM C22H24N2O7S DMTWS9E IC InChI=1S/C22H24N2O7S/c1-5-31-19-11-14(9-10-18(19)30-3)17(12-32(4,28)29)24-21(26)15-7-6-8-16(23-13(2)25)20(15)22(24)27/h6-11,17H,5,12H2,1-4H3,(H,23,25)/t17-/m1/s1 DMTWS9E CS CCOC1=C(C=CC(=C1)[C@@H](CS(=O)(=O)C)N2C(=O)C3=C(C2=O)C(=CC=C3)NC(=O)C)OC DMTWS9E IK IMOZEMNVLZVGJZ-QGZVFWFLSA-N DMTWS9E IU N-[2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-1,3-dioxoisoindol-4-yl]acetamide DMTWS9E CA CAS 608141-41-9 DMTWS9E CB CHEBI:78540 DMTWS9E DE Psoriasis vulgaris DM053KT ID DM053KT DM053KT DN Aprepitant DM053KT HS Approved DM053KT SN Aprepitant [USAN]; L 754030; MK 0869; Emend (TN); L-754030; MK-0869; ONO-7436; Aprepitant (JAN/USAN/INN); MK-869, L-754030, Emend, Aprepitant; 3-(((2R,3S)-3-(p-Fluorophenyl)-2-(((alphaR)-alpha-methyl-3,5-bis(trifluoromethyl)benzyl)oxy)morpholino)methyl)-Delta(2)-1,2,4-triazolin-5-one; 3-(((2R,3S)-3-(p-Fluorophenyl)-2-(((alphaR)-alpha-methyl-3,5-bis(trifluoromethyl)benzyl)oxy)morpholino)methyl)-delta(sup 2)-1,2,4-triazolin-5-one; 5-[[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)morpholin-4-yl]methyl]-1,2-dihydro-1,2,4-triazol-3-one; 5-[[(2S,3R)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)morpholin-4-yl]methyl]-1,2-dihydro-1,2,4-triazol-3-one; 5-{[(2R,3S)-2-{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy}-3-(4-fluorophenyl)morpholin-4-yl]methyl}-2,4-dihydro-3H-1,2,4-triazol-3-one DM053KT CP Merck & Co DM053KT TC Antiemetics DM053KT DT Small molecular drug DM053KT PC 135413536 DM053KT MW 534.4 DM053KT FM C23H21F7N4O3 DM053KT IC InChI=1S/C23H21F7N4O3/c1-12(14-8-15(22(25,26)27)10-16(9-14)23(28,29)30)37-20-19(13-2-4-17(24)5-3-13)34(6-7-36-20)11-18-31-21(35)33-32-18/h2-5,8-10,12,19-20H,6-7,11H2,1H3,(H2,31,32,33,35)/t12-,19+,20-/m1/s1 DM053KT CS C[C@H](C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)O[C@@H]2[C@@H](N(CCO2)CC3=NNC(=O)N3)C4=CC=C(C=C4)F DM053KT IK ATALOFNDEOCMKK-OITMNORJSA-N DM053KT IU 3-[[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)morpholin-4-yl]methyl]-1,4-dihydro-1,2,4-triazol-5-one DM053KT CA CAS 170729-80-3 DM053KT CB CHEBI:499361 DM053KT DE Depression; Nausea; Solid tumour/cancer DMBXWU8 ID DMBXWU8 DMBXWU8 DN Aprindine DMBXWU8 HS Approved DMBXWU8 SN Aprindin; Aprindina; Aprindinum; Aprinidine; Fibocil; AC 1802; Aprindina [INN-Spanish]; Aprindinum [INN-Latin]; Aprindine (USAN/INN); Aprindine [USAN:BAN:INN]; N-(3-(Diethylamino)propyl)-N-phenyl-2-indanamine; N,N-Diethyl-N'-2-indanyl-N'-phenyl-1,3-propanediamine; N,N-Diethyl-N'-2-indanyl-N'-phenyl-1,3-propanediaminemonohydrochloride; N'-(2,3-dihydro-1H-inden-2-yl)-N,N-diethyl-N'-phenylpropane-1,3-diamine; N-(2,3-Dihydro-1H-inden-2-yl)-N',N'-diethyl-N-phenyl-1,3-propanediamine; N-(2,3-dihydro-1H-inden-2-yl)-N',N'-diethyl-N-phenylpropane-1,3-diamine DMBXWU8 TC Antiarrhythmic Agents DMBXWU8 DT Small molecular drug DMBXWU8 PC 2218 DMBXWU8 MW 322.5 DMBXWU8 FM C22H30N2 DMBXWU8 IC InChI=1S/C22H30N2/c1-3-23(4-2)15-10-16-24(21-13-6-5-7-14-21)22-17-19-11-8-9-12-20(19)18-22/h5-9,11-14,22H,3-4,10,15-18H2,1-2H3 DMBXWU8 CS CCN(CC)CCCN(C1CC2=CC=CC=C2C1)C3=CC=CC=C3 DMBXWU8 IK NZLBHDRPUJLHCE-UHFFFAOYSA-N DMBXWU8 IU N'-(2,3-dihydro-1H-inden-2-yl)-N,N-diethyl-N'-phenylpropane-1,3-diamine DMBXWU8 CA CAS 37640-71-4 DMBXWU8 CB CHEBI:135370 DMBXWU8 DE Cardiac arrhythmias DMOWK6B ID DMOWK6B DMOWK6B DN Aprobarbital DMOWK6B HS Approved DMOWK6B SN Allional; Allonal; Allylisopropylmalonylurea; Allylpropymal; Allypropymal; Allypropymalum; Alurate; Aprobarbita; Aprobarbitale; Aprobarbitalum; Aprobarbitone; Aprozal; Numal; Allylisopropylbarbituric acid; Alurate elixir verdum; Aprobarbitale [DCIT]; Isopropylallylbarbituric acid; Alurate (TN); Aprobarbital (INN); Aprobarbital [INN:DCF]; Aprobarbitalum [INN-Latin]; Isonal (swedish); 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-(1-methylethyl)-5-(2-propenyl)-(9CI); 5-(1-Methylethyl)-5-(2-propenyl)-2,4,6(1H,3H,5H)-pyrimidinetrione;5-(1-methylethyl)-5-prop-2-en-1-ylpyrimidine-2,4,6(1H,3H,5H)-trione; 5-(propan-2-yl)-5-(prop-2-en-1-yl)pyrimidine-2,4,6(1H,3H,5H)-trione; 5-Allyl-5-isopropylbarbiturate; 5-Allyl-5-isopropylbarbituricacid; 5-Isopropyl-5-allylbarbituric acid; 5-allyl-5-isopropylpyrimidine-2,4,6(1H,3H,5H)-trione; 5-propan-2-yl-5-prop-2-enyl-1,3-diazinane-2,4,6-trione DMOWK6B TC Anticonvulsants DMOWK6B DT Small molecular drug DMOWK6B PC 6464 DMOWK6B MW 210.23 DMOWK6B FM C10H14N2O3 DMOWK6B IC InChI=1S/C10H14N2O3/c1-4-5-10(6(2)3)7(13)11-9(15)12-8(10)14/h4,6H,1,5H2,2-3H3,(H2,11,12,13,14,15) DMOWK6B CS CC(C)C1(C(=O)NC(=O)NC1=O)CC=C DMOWK6B IK UORJNBVJVRLXMQ-UHFFFAOYSA-N DMOWK6B IU 5-propan-2-yl-5-prop-2-enyl-1,3-diazinane-2,4,6-trione DMOWK6B CA CAS 77-02-1 DMOWK6B CB CHEBI:2791 DMOWK6B DE Anaesthesia; Insomnia DM0QD4W ID DM0QD4W DM0QD4W DN Aprotinin DM0QD4W HS Approved DM0QD4W SN Trasylol; Zymofren; Trazinin; Iniprol; Riker 52G; Bayer A 128; UNII-04XPW8C0FL; 04XPW8C0FL; APROTININ; RP-9921; Aprotininum; Aprotinina; Aprotinine; Antilysine; Repulson; Antagosan; Pantinol; Onquinin; Trascolan; Protimbin; Inhibin; Contrykal; Antilysin; Antikrein; Fosten; Tzalol; Gordox; Kir richter; Trypsin inhibitor; Aprotinin solution; 9087-70-1; BPTI; APROTININ BOVINE; Basic protease inhibitor; Aprotininum [INN-Latin]; Aprotinine [INN-French]; Aprotinina [INN-Spanish]; Pancreatic trypsin inhibitor; Kunitz and Northrop inhibitor DM0QD4W CP Novo Nordisk A/S DM0QD4W DT Small molecular drug DM0QD4W SQ Aprotinin (bovine pancreatic trypsin inhibitor): RPDFCLEPPYTGPCKARIIRYFYNAKAGLCQTFVYGGCRAKRNNFKSAEDCMRTCGGA DM0QD4W PC 146027575 DM0QD4W MW 6511 DM0QD4W FM C284H432N84O79S7 DM0QD4W IC InChI=1S/C284H432N84O79S7/c1-21-144(9)222-271(439)337-174(68-46-105-309-282(300)301)239(407)340-187(120-160-77-85-164(374)86-78-160)251(419)341-185(116-156-55-29-24-30-56-156)250(418)342-188(121-161-79-87-165(375)88-80-161)252(420)346-191(123-208(291)378)246(414)322-149(14)230(398)326-168(62-35-39-98-285)234(402)319-146(11)227(395)314-132-215(385)324-181(113-141(3)4)247(415)354-199-137-452-453-138-200-263(431)336-179(97-112-448-20)242(410)331-176(70-48-107-311-284(304)305)244(412)363-226(154(19)372)274(442)358-197(233(401)316-129-212(382)312-130-213(383)318-151(16)278(446)447)135-449-451-139-201(355-253(421)186(117-157-57-31-25-32-58-157)344-256(424)195(127-220(393)394)350-267(435)204-72-50-109-366(204)275(443)167(289)61-43-102-306-279(294)295)265(433)339-182(114-142(5)6)248(416)338-180(93-96-218(389)390)276(444)368-111-52-74-206(368)277(445)367-110-51-73-205(367)268(436)349-189(122-162-81-89-166(376)90-82-162)259(427)362-224(152(17)370)269(437)317-133-216(386)365-108-49-71-203(365)266(434)357-202(264(432)333-169(63-36-40-99-286)235(403)320-148(13)229(397)328-175(69-47-106-310-283(302)303)243(411)360-223(145(10)22-2)272(440)361-222)140-454-450-136-198(325-214(384)131-313-211(381)128-315-232(400)183(119-159-75-83-163(373)84-76-159)351-270(438)221(143(7)8)359-258(426)190(118-158-59-33-26-34-60-158)352-273(441)225(153(18)371)364-245(413)177(335-262(199)430)91-94-207(290)377)261(429)334-172(66-44-103-307-280(296)297)236(404)321-147(12)228(396)327-170(64-37-41-100-287)237(405)330-173(67-45-104-308-281(298)299)238(406)345-192(124-209(292)379)255(423)347-193(125-210(293)380)254(422)343-184(115-155-53-27-23-28-54-155)249(417)332-171(65-38-42-101-288)240(408)353-196(134-369)260(428)323-150(15)231(399)329-178(92-95-217(387)388)241(409)348-194(126-219(391)392)257(425)356-200/h23-34,53-60,75-90,141-154,167-206,221-226,369-376H,21-22,35-52,61-74,91-140,285-289H2,1-20H3,(H2,290,377)(H2,291,378)(H2,292,379)(H2,293,380)(H,312,382)(H,313,381)(H,314,395)(H,315,400)(H,316,401)(H,317,437)(H,318,383)(H,319,402)(H,320,403)(H,321,404)(H,322,414)(H,323,428)(H,324,385)(H,325,384)(H,326,398)(H,327,396)(H,328,397)(H,329,399)(H,330,405)(H,331,410)(H,332,417)(H,333,432)(H,334,429)(H,335,430)(H,336,431)(H,337,439)(H,338,416)(H,339,433)(H,340,407)(H,341,419)(H,342,418)(H,343,422)(H,344,424)(H,345,406)(H,346,420)(H,347,423)(H,348,409)(H,349,436)(H,350,435)(H,351,438)(H,352,441)(H,353,408)(H,354,415)(H,355,421)(H,356,425)(H,357,434)(H,358,442)(H,359,426)(H,360,411)(H,361,440)(H,362,427)(H,363,412)(H,364,413)(H,387,388)(H,389,390)(H,391,392)(H,393,394)(H,446,447)(H4,294,295,306)(H4,296,297,307)(H4,298,299,308)(H4,300,301,309)(H4,302,303,310)(H4,304,305,311)/t144-,145-,146-,147+,148-,149-,150+,151-,152-,153+,154+,167+,168-,169+,170+,171+,172+,173+,174-,175-,176+,177-,178+,179-,180+,181-,182+,183-,184+,185+,186+,187+,188+,189+,190-,191+,192+,193+,194+,195-,196+,197+,198+,199-,200+,201+,202-,203-,204+,205+,206+,221-,222+,223+,224-,225-,226-/m1/s1 DM0QD4W CS CC[C@@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)NCC(=O)N[C@@H](C(=O)N[C@@H]2CSSC[C@H]3C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N4CCC[C@H]4C(=O)N5CCC[C@H]5C(=O)N[C@H](C(=O)N[C@@H](C(=O)NCC(=O)N6CCC[C@@H]6C(=O)N[C@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N3)CC(=O)O)CCC(=O)O)C)CO)CCCCN)CC7=CC=CC=C7)CC(=O)N)CC(=O)N)CCCNC(=N)N)CCCCN)C)CCCNC(=N)N)NC(=O)CNC(=O)CNC(=O)[C@H](NC(=O)[C@H](NC(=O)[C@H](NC(=O)[C@H](NC(=O)[C@H](NC2=O)CCC(=O)N)[C@H](C)O)CC8=CC=CC=C8)C(C)C)CC9=CC=C(C=C9)O)C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N1)CCCNC(=N)N)C)CCCCN)[C@@H](C)O)CC1=CC=C(C=C1)O)CCC(=O)O)CC(C)C)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)N)C(=O)NCC(=O)NCC(=O)N[C@H](C)C(=O)O)[C@H](C)O)CCCNC(=N)N)CCSC)CC(C)C)C)CCCCN)C)CC(=O)N)CC1=CC=C(C=C1)O)CC1=CC=CC=C1)CC1=CC=C(C=C1)O)CCCNC(=N)N)[C@H](C)CC DM0QD4W IK ZPNFWUPYTFPOJU-VKTQZXOTSA-N DM0QD4W IU (3R)-4-[[(2S)-1-[[(1S,2aR,4R,5aR,8aR,11aR,13R,14aR,16S,17aS,19S,20aR,25S,26aR,29aR,31S,32aR,34S,35aS,37R,38aS,41aS,42R,44aS,45R,47aR,48S,50aS,51R,53aS,54R,56aR,57S,59aR,60S,62aS,63S,66S,69S,72S,75S,78S,81S,84S,87S,90S,93R)-29a,62a,69,84-tetrakis(4-aminobutyl)-35a,75,78-tris(2-amino-2-oxoethyl)-14a-(3-amino-3-oxopropyl)-8a,41a,72-tribenzyl-50a,53a-bis[(2R)-butan-2-yl]-47a,48,56a,81,90-pentakis(3-carbamimidamidopropyl)-31,60-bis(2-carboxyethyl)-42-[[2-[[2-[[(1R)-1-carboxyethyl]amino]-2-oxoethyl]amino]-2-oxoethyl]carbamoyl]-57-(carboxymethyl)-11a,45-bis[(1S)-1-hydroxyethyl]-13-[(1R)-1-hydroxyethyl]-66-(hydroxymethyl)-2a,16,38a,44a-tetrakis[(4-hydroxyphenyl)methyl]-26a,32a,59a,63,87-pentamethyl-20a,34-bis(2-methylpropyl)-51-(2-methylsulfanylethyl)-1a,3,4a,7a,9,10a,12,13a,15,16a,18,19a,22a,24,25a,28a,30,31a,33,34a,36,37a,40a,43a,44,46a,47,49a,50,52a,53,55a,56,58a,59,61a,62,64a,65,68,71,74,77,80,83,86,89,92,95,98-pentacontaoxo-5a-propan-2-yl-39,40,66a,67a,70a,71a-hexathia-a,2,3a,6a,8,9a,11,12a,14,15a,17,18a,21a,23,24a,27a,29,30a,32,33a,35,36a,39a,42a,43,45a,46,48a,49,51a,52,54a,55,57a,58,60a,61,63a,64,67,70,73,76,79,82,85,88,91,94,97-pentacontazahexacyclo[91.71.4.454,117.04,8.019,23.025,29]doheptacontahectan-37-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-[[(2S)-1-[(2S)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]-4-oxobutanoic acid DM0QD4W CA CAS 9087-70-1 DM0QD4W DE Bleeding disorder DMHTXSL ID DMHTXSL DMHTXSL DN Arbekacin DMHTXSL HS Approved DMHTXSL SN Habekacin (TN) DMHTXSL CP Meiji Seika DMHTXSL DT Small molecular drug DMHTXSL PC 68682 DMHTXSL MW 552.6 DMHTXSL FM C22H44N6O10 DMHTXSL IC InChI=1S/C22H44N6O10/c23-4-3-12(30)20(34)28-11-5-10(26)18(37-21-9(25)2-1-8(6-24)35-21)17(33)19(11)38-22-16(32)14(27)15(31)13(7-29)36-22/h8-19,21-22,29-33H,1-7,23-27H2,(H,28,34)/t8-,9+,10-,11+,12-,13+,14-,15+,16+,17-,18+,19-,21+,22+/m0/s1 DMHTXSL CS C1C[C@H]([C@H](O[C@@H]1CN)O[C@@H]2[C@H](C[C@H]([C@@H]([C@H]2O)O[C@@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)N)O)NC(=O)[C@H](CCN)O)N)N DMHTXSL IK MKKYBZZTJQGVCD-XTCKQBCOSA-N DMHTXSL IU (2S)-4-amino-N-[(1R,2S,3S,4R,5S)-5-amino-4-[(2R,3R,6S)-3-amino-6-(aminomethyl)oxan-2-yl]oxy-2-[(2S,3R,4S,5S,6R)-4-amino-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-hydroxycyclohexyl]-2-hydroxybutanamide DMHTXSL CA CAS 51025-85-5 DMHTXSL CB CHEBI:37922 DMHTXSL DE Bacterial infection DMOQK8Z ID DMOQK8Z DMOQK8Z DN Arbidol DMOQK8Z HS Approved DMOQK8Z SN Umifenovir; Arbidole; MC-101 DMOQK8Z CP Good Earth Medicine DMOQK8Z DT Small molecular drug DMOQK8Z PC 131411 DMOQK8Z MW 477.4 DMOQK8Z FM C22H25BrN2O3S DMOQK8Z IC InChI=1S/C22H25BrN2O3S/c1-5-28-22(27)20-18(13-29-14-9-7-6-8-10-14)25(4)17-11-16(23)21(26)15(19(17)20)12-24(2)3/h6-11,26H,5,12-13H2,1-4H3 DMOQK8Z CS CCOC(=O)C1=C(N(C2=CC(=C(C(=C21)CN(C)C)O)Br)C)CSC3=CC=CC=C3 DMOQK8Z IK KCFYEAOKVJSACF-UHFFFAOYSA-N DMOQK8Z IU ethyl 6-bromo-4-[(dimethylamino)methyl]-5-hydroxy-1-methyl-2-(phenylsulfanylmethyl)indole-3-carboxylate DMOQK8Z CA CAS 131707-25-0 DMOQK8Z CB CHEBI:134730 DMOQK8Z DE Virus infection DMCY8AF ID DMCY8AF DMCY8AF DN Arbutamine DMCY8AF HS Approved DMCY8AF SN Arbutamina; Arbutaminum; Genesa; Arbutamina [INN-Spanish]; Arbutamine [INN:BAN]; Arbutaminum [INN-Latin]; 4-[(1R)-1-hydroxy-2-[4-(4-hydroxyphenyl)butylamino]ethyl]benzene-1,2-diol; 4-[(1R)-1-hydroxy-2-{[4-(4-hydroxyphenyl)butyl]amino}ethyl]benzene-1,2-diol; 4-[1-hydroxy-2-[4-(4-hydroxyphenyl)butylamino]ethyl]benzene-1,2-diol DMCY8AF TC Cardiotonic Agents DMCY8AF DT Small molecular drug DMCY8AF PC 60789 DMCY8AF MW 317.4 DMCY8AF FM C18H23NO4 DMCY8AF IC InChI=1S/C18H23NO4/c20-15-7-4-13(5-8-15)3-1-2-10-19-12-18(23)14-6-9-16(21)17(22)11-14/h4-9,11,18-23H,1-3,10,12H2/t18-/m0/s1 DMCY8AF CS C1=CC(=CC=C1CCCCNC[C@@H](C2=CC(=C(C=C2)O)O)O)O DMCY8AF IK IIRWWTKISYTTBL-SFHVURJKSA-N DMCY8AF IU 4-[(1R)-1-hydroxy-2-[4-(4-hydroxyphenyl)butylamino]ethyl]benzene-1,2-diol DMCY8AF CA CAS 128470-16-6 DMCY8AF CB CHEBI:50580 DMCY8AF DE Coronary artery disease DM9GH25 ID DM9GH25 DM9GH25 DN Arcitumomab DM9GH25 HS Approved DM9GH25 SN CEA-Scan; Arcitumomab (USAN/INN); Cea-Scan (TN) DM9GH25 TC Diagnostic Agents DM9GH25 DT Antibody DM9GH25 DE Breast cancer DMYRX8B ID DMYRX8B DMYRX8B DN Ardeparin DMYRX8B HS Approved DMYRX8B SN Arteven; Bemiparin; Certoparin; Clivarine; Dalteparin; Eparina; Fluxum; Fraxiparin; Heparina; Heparinate; Heparine; Heparinum; Hepathrom; Innohep; Liquaemin; Liquemin; Logiparin; Multiparin; Nadroparin; Nadroparine; Novoheparin; Pabyrin; Parnaparin; Parvoparin; Pularin; Sandoparin; Subeparin; Sublingula; Thromboliquine; Tinzaparin; Triofiban; Vetren; Allocinnamic acid; Ardeparin sodium; Bemiparin sodium; Enoxaparin sodium; Eparina [DCIT]; Fragmin A; Fragmin B; Fragmin IV; Hep Flush Kit in plastic container; Heparin Lock Flush in plastic container; Heparin Lock Flush preservative free; Heparin Lock Flush preservative free in plastic container; Heparin natrium; Heparin sulfate; Heparinic acid; Heparinum natricum; Isocinnamic acid; Minolteparin sodium; Parnaparin sodium; Reviparin sodium; Sodium acid heparin; Sodium heparinate; Tinzaparin sodium; Vitrum AB; CY 216; Cy 222; FR 860; H 2149; Heparin CY 216; KB 101; Kabi 2165; LHN 1; Lioton 1000; OP 386; OP 622; Ro 11; WY 90493RD; ALFA 87-120; ALFA 87-163; ALFA 87-198; ALFA 87-81; ALFA 88-247; Alpha-Heparin; Cis-Cinnamic acid; Depo-Heparin; Hed-heparin; Hep-Lock; Heparin, sodium salt; Heparina [INN-Spanish]; Heparine [INN-French]; Heparinum [INN-Latin]; Hepflush-10; Inno-Hep; Normiflo (TN); Hep-Lock U/P; Cis-.beta.-Carboxystyrene DMYRX8B CP Celcius Laboratories DMYRX8B TC Anticoagulants DMYRX8B DT Small molecular drug DMYRX8B PC 772 DMYRX8B MW 1134.9 DMYRX8B FM C26H42N2O37S5 DMYRX8B IC InChI=1S/C26H42N2O37S5/c1-4(30)27-7-9(31)13(6(56-23(7)39)3-55-67(43,44)45)58-26-19(65-70(52,53)54)12(34)16(20(62-26)22(37)38)60-24-8(28-66(40,41)42)15(63-68(46,47)48)14(5(2-29)57-24)59-25-18(64-69(49,50)51)11(33)10(32)17(61-25)21(35)36/h5-20,23-26,28-29,31-34,39H,2-3H2,1H3,(H,27,30)(H,35,36)(H,37,38)(H,40,41,42)(H,43,44,45)(H,46,47,48)(H,49,50,51)(H,52,53,54) DMYRX8B CS CC(=O)NC1C(C(C(OC1O)COS(=O)(=O)O)OC2C(C(C(C(O2)C(=O)O)OC3C(C(C(C(O3)CO)OC4C(C(C(C(O4)C(=O)O)O)O)OS(=O)(=O)O)OS(=O)(=O)O)NS(=O)(=O)O)O)OS(=O)(=O)O)O DMYRX8B IK HTTJABKRGRZYRN-UHFFFAOYSA-N DMYRX8B IU 6-[6-[6-[5-acetamido-4,6-dihydroxy-2-(sulfooxymethyl)oxan-3-yl]oxy-2-carboxy-4-hydroxy-5-sulfooxyoxan-3-yl]oxy-2-(hydroxymethyl)-5-(sulfoamino)-4-sulfooxyoxan-3-yl]oxy-3,4-dihydroxy-5-sulfooxyoxane-2-carboxylic acid DMYRX8B CA CAS 9005-49-6 DMYRX8B DE Venous thrombosis; Thrombosis; Deep vein thrombosis; Venous thromboembolism DMVMY7K ID DMVMY7K DMVMY7K DN Arepanrix DMVMY7K HS Approved DMVMY7K SN H1N1 pandemic influenza vaccine (AS03 adjuvanted) 2, GlaxoSmithKline; H1N1 pandemic influenza vaccine2 (AS03 adjuvanted), GSK DMVMY7K CP GlaxoSmithKline plc DMVMY7K DT Vaccine DMVMY7K DE Influenza virus infection DMYM974 ID DMYM974 DMYM974 DN Arformoterol DMYM974 HS Approved DMYM974 SN 67346-49-0; Brovana; UNII-F91H02EBWT; Arformoterol tartrate; CHEMBL1363; F91H02EBWT; CHEBI:408174; Brovana (TN); Formoterol/fluticasone propionate DMYM974 CP Sepracor phamaceuticals DMYM974 TC Bronchodilator Agents DMYM974 DT Small molecular drug DMYM974 PC 3083544 DMYM974 MW 344.4 DMYM974 FM C19H24N2O4 DMYM974 IC InChI=1S/C19H24N2O4/c1-13(9-14-3-6-16(25-2)7-4-14)20-11-19(24)15-5-8-18(23)17(10-15)21-12-22/h3-8,10,12-13,19-20,23-24H,9,11H2,1-2H3,(H,21,22)/t13-,19+/m1/s1 DMYM974 CS C[C@H](CC1=CC=C(C=C1)OC)NC[C@@H](C2=CC(=C(C=C2)O)NC=O)O DMYM974 IK BPZSYCZIITTYBL-YJYMSZOUSA-N DMYM974 IU N-[2-hydroxy-5-[(1R)-1-hydroxy-2-[[(2R)-1-(4-methoxyphenyl)propan-2-yl]amino]ethyl]phenyl]formamide DMYM974 CA CAS 67346-49-0 DMYM974 CB CHEBI:408174 DMYM974 DE Chronic obstructive pulmonary disease; Asthma DMFI46A ID DMFI46A DMFI46A DN Argatroban DMFI46A HS Approved DMFI46A SN Acova; Argatrobanum; MMTQAP; MPQA; Novastan; Argatrobanum [Latin]; MITSUBISHI INHIBITOR; MCI 9038; MD 805; MD805; Argatroban (anhydrous); Argatroban [INN:JAN]; GN-1600; MCI-9038; MD-805; MQI-ARG-MCP; (2R,4R)-1-[(2S)-5-(diaminomethylideneamino)-2-[(3-methyl-1,2,3,4-tetrahydroquinolin-8-yl)sulfonylamino]pentanoyl]-4-methylpiperidine-2-carboxylic acid; (2R,4R)-1-[(2S)-5-(diaminomethylideneamino)-2-[[(3R)-3-methyl-1,2,3,4-tetrahydroquinolin-8-yl]sulfonylamino]pentanoyl]-4-methylpiperidine-2-carboxylic acid; (2R,4R)-1-[(2S)-5-(diaminomethylideneamino)-2-[[(3S)-3-methyl-1,2,3,4-tetrahydroquinolin-8-yl]sulfonylamino]pentanoyl]-4-methylpiperidine-2-carboxylic acid; (2R,4R)-1-[5-(diaminomethylideneamino)-2-[(3-methyl-1,2,3,4-tetrahydroquinolin-8-yl)sulfonylamino]pentanoyl]-4-methylpiperidine-2-carboxylic acid; (2R,4R)-4-Methyl-1-((S)-N(sup 2)-(((RS)-1,2,3,4-tetrahydro-3-methyl-8-quinolyl)sulfonyl)arginyl)pipecolic acid; (2R,4R)-4-Methyl-1[Nalpha-[(3-methyl-1,2,3,4-tetrahydro-8-quinolinyl)sulfonyl]-L-arginyl)]-2-piperadinecarboxylic acid; (2r,4r)-4-methyl-1-[n2-(3-methyl-1,2,3,4-tetrahydro-8-quinolinesulfonyl)-l-arginyl]-2-piperidinecarboxylic acid; 21R-Argatroban; 4-methyl-1-(N(2)-(3-methyl-1,2,3,4-tetrahydro-8-quinolinesulfonyl)-L-arginyl)-2-piperidinecarboxylic acid DMFI46A TC Anticoagulants DMFI46A DT Small molecular drug DMFI46A PC 92722 DMFI46A MW 508.6 DMFI46A FM C23H36N6O5S DMFI46A IC InChI=1S/C23H36N6O5S/c1-14-8-10-29(18(12-14)22(31)32)21(30)17(6-4-9-26-23(24)25)28-35(33,34)19-7-3-5-16-11-15(2)13-27-20(16)19/h3,5,7,14-15,17-18,27-28H,4,6,8-13H2,1-2H3,(H,31,32)(H4,24,25,26)/t14-,15?,17+,18-/m1/s1 DMFI46A CS C[C@@H]1CCN([C@H](C1)C(=O)O)C(=O)[C@H](CCCN=C(N)N)NS(=O)(=O)C2=CC=CC3=C2NCC(C3)C DMFI46A IK KXNPVXPOPUZYGB-IOVMHBDKSA-N DMFI46A IU (2R,4R)-1-[(2S)-5-(diaminomethylideneamino)-2-[(3-methyl-1,2,3,4-tetrahydroquinolin-8-yl)sulfonylamino]pentanoyl]-4-methylpiperidine-2-carboxylic acid DMFI46A CA CAS 74863-84-6 DMFI46A CB CHEBI:94385 DMFI46A DE Thrombosis DMRE4FC ID DMRE4FC DMRE4FC DN Arginine DMRE4FC HS Approved DMRE4FC SN DL-Arginine hydrochloride; 32042-43-6; 2-Amino-5-guanidinopentanoic acid hydrochloride; argininhydrochlorid; DL-Arginine HCl; 220144-84-3; H-DL-Arg-OH.xHCl; DL-(+/-)-Arginine Hydrochloride; 1-Hydrochloride arginine; NSC7914; Arginine monochloride; 2-Amino-5-guanidinovaleric acid monohydrochloride; WLN: MUYZM3YZVQ & DL-Arginine hydrochloride, 98%, anhydrous; Arginine monohydrochloride, L-(+)-; ARGININE, (L); L(+)-Arginine hydrochloride; D-Arginine, hydrochloride (1:1); EINECS 250-903-0; EINECS 239-674-8 DMRE4FC DT Small molecular drug DMRE4FC PC 6322 DMRE4FC MW 174.2 DMRE4FC FM C6H14N4O2 DMRE4FC IC InChI=1S/C6H14N4O2/c7-4(5(11)12)2-1-3-10-6(8)9/h4H,1-3,7H2,(H,11,12)(H4,8,9,10)/t4-/m0/s1 DMRE4FC CS C(C[C@@H](C(=O)O)N)CN=C(N)N DMRE4FC IK ODKSFYDXXFIFQN-BYPYZUCNSA-N DMRE4FC IU (2S)-2-amino-5-(diaminomethylideneamino)pentanoic acid DMRE4FC CA CAS 74-79-3 DMRE4FC CB CHEBI:16467 DMRE4FC DE Growth hormone deficiency DM3NUMH ID DM3NUMH DM3NUMH DN Aripiprazole DM3NUMH HS Approved DM3NUMH SN 129722-12-9; Abilify; Abilitat; Abilify Discmelt; OPC-14597; Discmelt; Opc 14597; OPC 31; OPC-31; 7-[4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butoxy]-3,4-dihydrocarbostyril; UNII-82VFR53I78; C23H27Cl2N3O2; HSDB 7320; 7-(4-(4-(2,3-DICHLOROPHENYL)PIPERAZIN-1-YL)BUTOXY)-3,4-DIHYDROQUINOLIN-2(1H)-ONE; CHEMBL1112; 7-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy}-1,2,3,4-tetrahydroquinolin-2-one; 7-(4-(4-(2,3-Dichlorophenyl)-1-piperazinyl)butyloxy)-3,4-dihydro-2(1H)-quinolinone; CHEBI:31236; Abilify; Aripiprazol; Aripiprazolum; Aripirazole; Arpizol; Asprito; Pripiprazole; Aripiprazole [USAN]; Otsuka brand of aripiprazole; OPC 14597; ALKS-9070; Abilify (TN); BMS-337039; Bristol-Myers Squibb brand of aripiprazole; Discmelt (TN); KS-1030; S06-0010; Aripiprazole (JAN/USAN/INN); 7-(4-(4-(2,3-Dichlorophenyl)-1-piperazinyl)butoxy)-3,4-dihydro-2(1H)-quinolinone; 7-(4-(4-(2,3-Dichlorophenyl)-1-piperazinyl)butoxy)-3,4-dihydrocarbostyril; 7-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy]-3,4-dihydro-1H-quinolin-2-one; 7-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy}-3,4-dihydroquinolin-2(1H)-one; ALKS9070/ALKS9072; Aripiprazole/escitalopram fixed-dose combination DM3NUMH CP Bristol-Myers Squibb; Otsuka Pharmaceutical Co., Ltd DM3NUMH TC Antipsychotic Agents DM3NUMH DT Small molecular drug DM3NUMH PC 60795 DM3NUMH MW 448.4 DM3NUMH FM C23H27Cl2N3O2 DM3NUMH IC InChI=1S/C23H27Cl2N3O2/c24-19-4-3-5-21(23(19)25)28-13-11-27(12-14-28)10-1-2-15-30-18-8-6-17-7-9-22(29)26-20(17)16-18/h3-6,8,16H,1-2,7,9-15H2,(H,26,29) DM3NUMH CS C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl DM3NUMH IK CEUORZQYGODEFX-UHFFFAOYSA-N DM3NUMH IU 7-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy]-3,4-dihydro-1H-quinolin-2-one DM3NUMH CA CAS 129722-12-9 DM3NUMH CB CHEBI:31236 DM3NUMH DE Major depressive disorder; Schizophrenia; Bipolar disorder; Erythropoietic porphyrias DMGB035 ID DMGB035 DMGB035 DN Armodafinil DMGB035 HS Approved DMGB035 SN Nuvigil; 112111-43-0; (R)-Modafinil; (R)-(-)-Modafinil; CEP-10953; UNII-V63XWA605I; CRL 40982; CEP 10953; V63XWA605I; CHEMBL1201192; CHEBI:77590; 2-[(R)-(Diphenylmethyl)sulfinyl]acetamide; (-)-2-((R)-(Diphenylmethyl)sulfinyl)acetamide; (-)-2-[(r)-(diphenylmethyl)sulfinyl]acetamide; Armodafinil [USAN:INN]; armodafinilo; armodafinilum; l-Modafinil; Nuvigil (TN); (-)-(R)-modafinil; Armodafinil (USAN/INN); SCHEMBL34489; ZINC6156; ACE037; Armodafinil, > YFGHCGITMMYXAQ-LJQANCHMSA-N DMGB035 CP Cephalon DMGB035 DT Small molecular drug DMGB035 PC 9690109 DMGB035 MW 273.4 DMGB035 FM C15H15NO2S DMGB035 IC InChI=1S/C15H15NO2S/c16-14(17)11-19(18)15(12-7-3-1-4-8-12)13-9-5-2-6-10-13/h1-10,15H,11H2,(H2,16,17)/t19-/m1/s1 DMGB035 CS C1=CC=C(C=C1)C(C2=CC=CC=C2)[S@](=O)CC(=O)N DMGB035 IK YFGHCGITMMYXAQ-LJQANCHMSA-N DMGB035 IU 2-[(R)-benzhydrylsulfinyl]acetamide DMGB035 CA CAS 112111-43-0 DMGB035 CB CHEBI:77590 DMGB035 DE Pediatric cancer DMT81LZ ID DMT81LZ DMT81LZ DN Arn-509 DMT81LZ HS Approved DMT81LZ SN Arn-509 (AR inhibitor) DMT81LZ CP Johnson & Johnson DMT81LZ DT Small molecular drug DMT81LZ PC 24872560 DMT81LZ MW 477.4 DMT81LZ FM C21H15F4N5O2S DMT81LZ IC InChI=1S/C21H15F4N5O2S/c1-27-17(31)13-4-3-11(8-15(13)22)30-19(33)29(18(32)20(30)5-2-6-20)12-7-14(21(23,24)25)16(9-26)28-10-12/h3-4,7-8,10H,2,5-6H2,1H3,(H,27,31) DMT81LZ CS CNC(=O)C1=C(C=C(C=C1)N2C(=S)N(C(=O)C23CCC3)C4=CC(=C(N=C4)C#N)C(F)(F)F)F DMT81LZ IK HJBWBFZLDZWPHF-UHFFFAOYSA-N DMT81LZ IU 4-[7-[6-cyano-5-(trifluoromethyl)pyridin-3-yl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-5-yl]-2-fluoro-N-methylbenzamide DMT81LZ CA CAS 956104-40-8 DMT81LZ DE Acute myeloid leukaemia; Prostate cancer DM1P6FR ID DM1P6FR DM1P6FR DN Arry-162 DM1P6FR HS Approved DM1P6FR SN 606143-89-9; Binimetinib; MEK162; MEK-162; ARRY-438162; 5-[(4-Bromo-2-fluorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzimidazole-6-carboxamide; ARRY 162; UNII-181R97MR71; Binimetinib (MEK162, ARRY-162, ARRY-438162); 181R97MR71; MEK162 (ARRY-162, ARRY-438162); 6-(4-bromo-2-fluorophenylamino)-7-fluoro-N-(2-hydroxyethoxy)-3-methyl-3H-benzo[d]imidazole-5-carboxamide; Binimetinib [USAN:INN]; MEK 162; ARRY 438162; MEK162(Binimetinib); Binimetinib (JAN/USAN); D0C4LF; NVP-ME DM1P6FR CP Array BioPharma DM1P6FR DT Small molecular drug DM1P6FR PC 10288191 DM1P6FR MW 441.2 DM1P6FR FM C17H15BrF2N4O3 DM1P6FR IC InChI=1S/C17H15BrF2N4O3/c1-24-8-21-16-13(24)7-10(17(26)23-27-5-4-25)15(14(16)20)22-12-3-2-9(18)6-11(12)19/h2-3,6-8,22,25H,4-5H2,1H3,(H,23,26) DM1P6FR CS CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO DM1P6FR IK ACWZRVQXLIRSDF-UHFFFAOYSA-N DM1P6FR IU 6-(4-bromo-2-fluoroanilino)-7-fluoro-N-(2-hydroxyethoxy)-3-methylbenzimidazole-5-carboxamide DM1P6FR CA CAS 606143-89-9 DM1P6FR CB CHEBI:145371 DM1P6FR DE Melanoma DMTL2Y1 ID DMTL2Y1 DMTL2Y1 DN Arsenic DMTL2Y1 HS Approved DMTL2Y1 SN Agent SA; Arsen [German,Polish]; Arsenic; Arsenic Black; Arsenic Lump (Metals Basis); Arsenic and arsenic compounds; Arsenic compounds; Arsenic hydride (AsH3); Arsenic, elemental; Arsenic, inorganic; Arsenic, organic compounds; Arsenic-75; Arsenicals; Arsenowodor [Polish]; Arsenwasserstoff [German]; Colloidal arsenic; Gray arsenic; Grey arsenic; Metallic arsenic; UN 2188; UN1558; UN2188; V1I29R0RJQ; 7440-38-2; Arsen; As; CCRIS 55; EINECS 231-148-6; EINECS 232-066-3; HSDB 509; HSDB 510; N712M78A8G; UNII-N712M78A8G; UNII-V1I29R0RJQ DMTL2Y1 PC 5359596 DMTL2Y1 MW 74.921 DMTL2Y1 FM As DMTL2Y1 IC RQNWIZPPADIBDY-UHFFFAOYSA-N DMTL2Y1 CS [As] DMTL2Y1 IK 1S/As DMTL2Y1 IU arsenic DMTL2Y1 CA CAS 7440-38-2 DMTL2Y1 CB CHEBI:27563 DMTL2Y1 DE Acute myeloid leukaemia DM61TA4 ID DM61TA4 DM61TA4 DN Arsenic trioxide DM61TA4 HS Approved DM61TA4 SN Arsenox; Arsentrioxide; Naonobin; Trisenox; Trixenox; Acide arsenieux [French]; Anhydride arsenieux [French]; Arseni trioxydum; Arsenic blanc [French]; Arsenic trioxide [JAN]; Arsenigen saure [German]; Arsenious Acid Anhydride; Arsenious trioxide; Arsenous oxide [ISO]; Oxyde Arsenieux; Arsenic trioxide [UN1561] [Poison]; Arsenic oxide (As2O3); Arsenic(III) trioxide; Oxyde Arsenieux [ISO-French]; Trisenox (TN); Arsenic trioxide (JP15/USAN); Arsenic(3+) DM61TA4 TC Anticancer Agents DM61TA4 DT Small molecular drug DM61TA4 PC 14888 DM61TA4 MW 197.841 DM61TA4 FM As2O3 DM61TA4 IC InChI=1S/2As.3O/q2*+3;3*-2 DM61TA4 CS [O-2].[O-2].[O-2].[As+3].[As+3] DM61TA4 IK QTLQKAJBUDWPIB-UHFFFAOYSA-N DM61TA4 IU arsenic(3+);oxygen(2-) DM61TA4 CA CAS 1327-53-3 DM61TA4 DE Acute lymphoblastic leukaemia DMQLX7O ID DMQLX7O DMQLX7O DN Arteether DMQLX7O HS Approved DMQLX7O SN Beta arteether; Artecef (TN); Artemotil (TN) DMQLX7O CP Artecef BV DMQLX7O DT Small molecular drug DMQLX7O PC 3000469 DMQLX7O MW 312.4 DMQLX7O FM C17H28O5 DMQLX7O IC InChI=1S/C17H28O5/c1-5-18-14-11(3)13-7-6-10(2)12-8-9-16(4)20-15(19-14)17(12,13)22-21-16/h10-15H,5-9H2,1-4H3/t10-,11-,12+,13+,14+,15-,16-,17-/m1/s1 DMQLX7O CS CCO[C@@H]1[C@@H]([C@@H]2CC[C@H]([C@H]3[C@]24[C@H](O1)O[C@@](CC3)(OO4)C)C)C DMQLX7O IK NLYNIRQVMRLPIQ-XQLAAWPRSA-N DMQLX7O IU (1R,4S,5R,8S,9R,10S,12R,13R)-10-ethoxy-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecane DMQLX7O CA CAS 75887-54-6 DMQLX7O CB CHEBI:135335 DMQLX7O DE Malaria DM48QOT ID DM48QOT DM48QOT DN Artemether DM48QOT HS Approved DM48QOT SN Artemetero; Artemether[inn]; Artemetheri; Artemetherum; Artemos; Artenam; Artesaph; Artesian; Artimist; Artmether; Falcidol; Gvither; Malartem; Paluther; Rither; Arteannuin ether; Artemether [INN]; Artemisininelactol methyl ether; Dihydroartemisinin methyl ether; Dihydroquinghaosu methyl ether; SM 224; SM 229; Alpha-Artemether; Alpha-Dihydroartemisinin methyl ether; Artemetero [INN-Spanish]; Artemether (INN); Artemetherum [INN-Latin]; Beta-Artemether; Beta-Dihydroartemisinin methyl ether; Methyl-dihydroartemisinine; O-Methyldihydroartemisinine; SM-224; Beta-Methylether of 11-epi-dihydroartemisinin; Artemether, (3R-(3alpha,5abeta,6beta,8abeta,9alpha,10alpha,12beta,12aR*))-isomer; (3R,5aS,6R,8aS,9R,10S,12R,12aR)-10-methoxy-3,6,9-trimethyldecahydro-3,12-epoxypyrano[4,3-j][1,2]benzodioxepine; (3R,5aS,6R,8aS,9R,10S,12R,12aR)-Decahydro-10-methoxy-3,6,9-trimethyl-3,12-epoxy-12H-pyrano(4,3-j)-1,2-benzodioxepin; (3alpha,5abeta,6beta,8abeta,9alpha,10beta,12beta,12aR*)-isomer of artemether; (3r,5as,6r,8as,9r,10r,12r,12ar)-10-methoxy-3,6,9-trimethyldecahydro-3,12-epoxy[1,2]dioxepino[4,3-i]isochromene; (5aS,6R,8aS,9R,10S,12R,12aR)-10-methoxy-3,6,9-trimethyldecahydro-3,12-epoxy[1,2]dioxepino[4,3-i]isochromene; 10-methoxy-1,5,9-trimethyl-(1R,4S,5R,8S,9R,10S,12R,13R)-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecane; 3,12-Epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin, decahydro-10-methoxy-3,6,9-tri DM48QOT DT Small molecular drug DM48QOT PC 68911 DM48QOT MW 298.37 DM48QOT FM C16H26O5 DM48QOT IC InChI=1S/C16H26O5/c1-9-5-6-12-10(2)13(17-4)18-14-16(12)11(9)7-8-15(3,19-14)20-21-16/h9-14H,5-8H2,1-4H3/t9-,10-,11+,12+,13+,14-,15-,16-/m1/s1 DM48QOT CS C[C@@H]1CC[C@H]2[C@H]([C@H](O[C@H]3[C@@]24[C@H]1CC[C@](O3)(OO4)C)OC)C DM48QOT IK SXYIRMFQILZOAM-HVNFFKDJSA-N DM48QOT IU (1R,4S,5R,8S,9R,10S,12R,13R)-10-methoxy-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecane DM48QOT CA CAS 71963-77-4 DM48QOT CB CHEBI:195280 DM48QOT DE Malaria DMOY7W3 ID DMOY7W3 DMOY7W3 DN Artemisinin DMOY7W3 HS Approved DMOY7W3 SN Arteannuin; Artemisine; Artemisinina; Artemisinine; Artemisininum; Artesin; Huanghuahaosu; Qinghaosu; Qinghosu; Quinghaosu; Artemisinin [INN]; Artemisinina [Spanish]; Artemisinine [French]; Artemisininum [Latin]; Qing Hau SU; Qing Hau Sau; Qing Hau Sau [Chinese]; Qinghaosu [Chinese]; Quing Hau Sau; Artemisinin (INN); Coartem, Artemisinin; Artemisia annua L., extract; GNF-PF-5671; GNF-Pf-5341; Octahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano(4,3-j)-1,2-benzodioxepin-10(3H)-one; (+)-Arteannuin; (+)-Artemisinin; (3R,5aS,6R,8aS,9R,12S,12aR)-3,6,9-trimethyloctahydro-3,12-epoxypyrano[4,3-j][1,2]benzodioxepin-10(3H)-one; (3R,5aS,6R,8aS,9R,12S,12aR)-Octahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano(4,3-j)-1,2-benzodioxepin-10(3H)-one; (5aS,6R,8aS,9R,12S,12aR)-3,6,9-trimethyloctahydro-3,12-epoxy[1,2]dioxepino[4,3-i]isochromen-10(3H)-one; 1,5,9-trimethyl-(1R,4S,5R,9R,12S,13R)-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-10-one; 3,6,9-trimethyloctahydro-3,12-epoxy[1,2]dioxepino[4,3-i]isochromen-10(3H)-one DMOY7W3 DT Small molecular drug DMOY7W3 PC 68827 DMOY7W3 MW 282.33 DMOY7W3 FM C15H22O5 DMOY7W3 IC InChI=1S/C15H22O5/c1-8-4-5-11-9(2)12(16)17-13-15(11)10(8)6-7-14(3,18-13)19-20-15/h8-11,13H,4-7H2,1-3H3/t8-,9-,10+,11+,13-,14-,15-/m1/s1 DMOY7W3 CS C[C@@H]1CC[C@H]2[C@H](C(=O)O[C@H]3[C@@]24[C@H]1CC[C@](O3)(OO4)C)C DMOY7W3 IK BLUAFEHZUWYNDE-NNWCWBAJSA-N DMOY7W3 IU (1R,4S,5R,8S,9R,12S,13R)-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-10-one DMOY7W3 CA CAS 63968-64-9 DMOY7W3 CB CHEBI:223316 DMOY7W3 DE Malaria DMFETDK ID DMFETDK DMFETDK DN Artemisinin SP DMFETDK HS Approved DMFETDK SN Isoguvacine; isoguvacine; 1,2,3,6-tetrahydropyridine-4-carboxylic acid; 64603-90-3; 1,2,3,6-Tetrahydro-pyridine-4-carboxylic acid; 1,2,3,6-Tetrahydro-4-pyridinecarboxylic acid; UNII-YTF580771Y; CHEMBL39071; CHEBI:34799; YTF580771Y; 4-Pyridinecarboxylic acid, 1,2,3,6-tetrahydro-; AC1OEMUS; 1,2,3,6-tetrahydropyridinium-4-carboxylate; 1,2,3,6-tetrahydropyridin-1-ium-4-carboxylate; Tocris-0235; Spectrum_001974; Lopac-G-002; AC1L1GNT; Spectrum3_001869; Biomol-NT_000254; AC1Q5QG1; Lopac0_000561; KBioSS_002540; BSPBio_003318; DivK1c_000115 DMFETDK DT Small molecular drug DMFETDK PC 3765 DMFETDK MW 127.14 DMFETDK FM C6H9NO2 DMFETDK IC InChI=1S/C6H9NO2/c8-6(9)5-1-3-7-4-2-5/h1,7H,2-4H2,(H,8,9) DMFETDK CS C1CNCC=C1C(=O)O DMFETDK IK KRVDMABBKYMBHG-UHFFFAOYSA-N DMFETDK IU 1,2,3,6-tetrahydropyridine-4-carboxylic acid DMFETDK CA CAS 64603-90-3 DMFETDK CB CHEBI:34799 DMFETDK DE Malaria DMR27C8 ID DMR27C8 DMR27C8 DN Artesunate DMR27C8 HS Approved DMR27C8 SN Arinate; Arsumax; Artesunato; Artesunatum; Artsuna; Dihydroqinghaosusuccinate; Nuartez; Plasmotrim; Plasmotrin; Qinghaozhi; Artesunic acid; Dihydroqinghasu hemsuccinate; Quinghaosu reduced succinate ester; Succinyl dihydroartemisinin; SM 804; WR 256283; Arsumax (TN); Artesunate (USAN); Artesunate (superseded RN); Artesunato [INN-Spanish]; Artesunatum [INN-Latin]; WR-256283; Dihydroartemisinine-12-alpha-succinate; Butanedioic acid, mono(decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano(4,3-j)-1,2-benzodioxepin-10-yl) ester; Butanedioic acid, mono((3R,5aS,6R,8aS,9R,10S,12R,12aR)-decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano(4,3-j)-1,2-benzodioxepin-10-yl) ester; (3R,5aS,6R,8aS,9R,10S,12R,12aR)-Decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano(4,3-j)-1,2-benzodioxepin-10-ol, hydrogen succinate; 4-Oxo-4-(((3R,5aS,6R,8aS,9R,10S,12R,12aR)-3,6,9-trimethyldecahydro-3,12-epoxypyrano(4,3-j)-1,2-benzodioxepin-10-yl hydrogen butanedioate; 4-oxo-4-{[(3r,5as,6r,8as,9r,10r,12r,12ar)-3,6,9-trimethyldecahydro-3,12-epoxy[1,2]dioxepino[4,3-i]isochromen-10-yl]oxy}butanoic acid; 4-oxo-4-{[(5aS,6R,8aS,9R,10S,12R,12aR)-3,6,9-trimethyldecahydro-3,12-epoxy[1,2]dioxepino[4,3-i]isochromen-10-yl]oxy}butanoic acid DMR27C8 DT Small molecular drug DMR27C8 PC 6917864 DMR27C8 MW 384.4 DMR27C8 FM C19H28O8 DMR27C8 IC InChI=1S/C19H28O8/c1-10-4-5-13-11(2)16(23-15(22)7-6-14(20)21)24-17-19(13)12(10)8-9-18(3,25-17)26-27-19/h10-13,16-17H,4-9H2,1-3H3,(H,20,21)/t10-,11-,12+,13+,16-,17-,18-,19-/m1/s1 DMR27C8 CS C[C@@H]1CC[C@H]2[C@H]([C@@H](O[C@H]3[C@@]24[C@H]1CC[C@](O3)(OO4)C)OC(=O)CCC(=O)O)C DMR27C8 IK FIHJKUPKCHIPAT-AHIGJZGOSA-N DMR27C8 IU 4-oxo-4-[[(1R,4S,5R,8S,9R,10S,12R,13R)-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-10-yl]oxy]butanoic acid DMR27C8 CA CAS 88495-63-0 DMR27C8 CB CHEBI:63918 DMR27C8 DE Malaria DMOKCVI ID DMOKCVI DMOKCVI DN ARZOXIFENE DMOKCVI HS Approved DMOKCVI SN Arzoxifene; 182133-25-1; UNII-E569WG6E60; LY 353381; E569WG6E60; 2-(4-methoxyphenyl)-3-[4-(2-piperidin-1-ylethoxy)phenoxy]-1-benzothiophen-6-ol; 2-(4-methoxyphenyl)-3-(4-(2-(piperidin-1-yl)ethoxy)phenoxy)benzo[b]thiophen-6-ol; Arzoxifene [INN]; LY-353381; SCHEMBL285277; CHEMBL226267; BDBM19442; DTXSID10171255; ZINC1544683; AC1L4522; AN-538; AKOS030631785; SB19713; KB-05502; FT-0751607; 124708-EP2295426A1; 124708-EP2295427A1; 124708-EP2292592A1; 124708-EP2292576A2; Benzo(b)thiophene-6-ol, 2-(4-methoxyphenyl)-3-(4-(2-(1-piperidinyl) DMOKCVI DT Small molecular drug DMOKCVI PC 179337 DMOKCVI MW 475.6 DMOKCVI FM C28H29NO4S DMOKCVI IC InChI=1S/C28H29NO4S/c1-31-22-8-5-20(6-9-22)28-27(25-14-7-21(30)19-26(25)34-28)33-24-12-10-23(11-13-24)32-18-17-29-15-3-2-4-16-29/h5-14,19,30H,2-4,15-18H2,1H3 DMOKCVI CS COC1=CC=C(C=C1)C2=C(C3=C(S2)C=C(C=C3)O)OC4=CC=C(C=C4)OCCN5CCCCC5 DMOKCVI IK MCGDSOGUHLTADD-UHFFFAOYSA-N DMOKCVI IU 2-(4-methoxyphenyl)-3-[4-(2-piperidin-1-ylethoxy)phenoxy]-1-benzothiophen-6-ol DMOKCVI CA CAS 182133-25-1 DMOKCVI DE Breast cancer DMV05SW ID DMV05SW DMV05SW DN As-1670542 DMV05SW HS Approved DMV05SW SN AVATROMBOPAG; 570406-98-3; AKR-501; UNII-3H8GSZ4SQL; 3H8GSZ4SQL; AKR 501; Avatrombopag [USAN:INN]; Doptelet; AS 1670542; Avatrombopag (USAN/INN); GTPL9953; DTXSID30205667; ZINC72190218; AKOS027323962; CS-3397; HY-13463; FT-0728753; D10306; AS1670542 DMV05SW CP Dova Pharmaceuticals DMV05SW DT Small molecular drug DMV05SW PC 9852519 DMV05SW MW 649.7 DMV05SW FM C29H34Cl2N6O3S2 DMV05SW IC InChI=1S/C29H34Cl2N6O3S2/c30-20-15-23(41-17-20)24-27(37-12-10-35(11-13-37)21-4-2-1-3-5-21)42-29(33-24)34-26(38)19-14-22(31)25(32-16-19)36-8-6-18(7-9-36)28(39)40/h14-18,21H,1-13H2,(H,39,40)(H,33,34,38) DMV05SW CS C1CCC(CC1)N2CCN(CC2)C3=C(N=C(S3)NC(=O)C4=CC(=C(N=C4)N5CCC(CC5)C(=O)O)Cl)C6=CC(=CS6)Cl DMV05SW IK OFZJKCQENFPZBH-UHFFFAOYSA-N DMV05SW IU 1-[3-chloro-5-[[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)-1,3-thiazol-2-yl]carbamoyl]pyridin-2-yl]piperidine-4-carboxylic acid DMV05SW CA CAS 570406-98-3 DMV05SW DE Thrombocytopenia; Idiopathic thrombocytopenic purpura DMCZIHT ID DMCZIHT DMCZIHT DN Asasantin DMCZIHT HS Approved DMCZIHT SN Aggrenox; Aspirin mixture with Dipyridamole; 87653-67-6; Asasantin Retard; Aspirin / Dipyridamole; aspirin, dipyridamole drug combination; TX-3301; TX 3301; C24H40N8O4.C9H8O4; Aspirin/extended-release dipyridamole; AC1L3AE0; SCHEMBL456521; DTXSID40236543; LS-178622; Benzoic acid, 2-(acetyloxy)-, mixt. with 2,2',2'',2'''-((4,8-di-1-piperidinylpyrimido(5,4-d)pyrimidine-2,6-diyl)dinitrilo)tetrakis(ethanol) DMCZIHT CP Boehringer Ingelheim Corp DMCZIHT DT Small molecular drug DMCZIHT PC 137329 DMCZIHT MW 684.8 DMCZIHT FM C33H48N8O8 DMCZIHT IC InChI=1S/C24H40N8O4.C9H8O4/c33-15-11-31(12-16-34)23-26-20-19(21(27-23)29-7-3-1-4-8-29)25-24(32(13-17-35)14-18-36)28-22(20)30-9-5-2-6-10-30;1-6(10)13-8-5-3-2-4-7(8)9(11)12/h33-36H,1-18H2;2-5H,1H3,(H,11,12) DMCZIHT CS CC(=O)OC1=CC=CC=C1C(=O)O.C1CCN(CC1)C2=NC(=NC3=C2N=C(N=C3N4CCCCC4)N(CCO)CCO)N(CCO)CCO DMCZIHT IK NOHUXXDTQJPXSB-UHFFFAOYSA-N DMCZIHT IU 2-acetyloxybenzoic acid;2-[[2-[bis(2-hydroxyethyl)amino]-4,8-di(piperidin-1-yl)pyrimido[5,4-d]pyrimidin-6-yl]-(2-hydroxyethyl)amino]ethanol DMCZIHT CA CAS 87653-67-6 DMCZIHT DE Cerebrovascular ischaemia DMSQZE2 ID DMSQZE2 DMSQZE2 DN Asenapine DMSQZE2 HS Approved DMSQZE2 SN Asenapi; Asenapine [INN:BAN]; Saphris (TN); [13C,2H3]-Asenipine; Trans-5-Chloro-2,3,3a,12b-tetrahydro-2-methyl-1H-dibenz(2,3:6,7)oxepino(4,5-c)pyrrole; 1H-Dibenz[2,3:6,7]oxepino[4,5-c]pyrrole, 5-chloro-2,3,3a,12b-tetrahydro-2-met; 5-chloro-2,3,3a,12b-tetrahydro-2-methyl-1H-dibenz(2,3-6,7)oxepino(4,5-c)pyrrole DMSQZE2 CP Organon BioSciences DMSQZE2 DT Small molecular drug DMSQZE2 PC 3036780 DMSQZE2 MW 285.8 DMSQZE2 FM C17H16ClNO DMSQZE2 IC InChI=1S/C17H16ClNO/c1-19-9-14-12-4-2-3-5-16(12)20-17-7-6-11(18)8-13(17)15(14)10-19/h2-8,14-15H,9-10H2,1H3/t14-,15-/m0/s1 DMSQZE2 CS CN1C[C@@H]2[C@@H](C1)C3=C(C=CC(=C3)Cl)OC4=CC=CC=C24 DMSQZE2 IK VSWBSWWIRNCQIJ-GJZGRUSLSA-N DMSQZE2 IU (2R,6R)-9-chloro-4-methyl-13-oxa-4-azatetracyclo[12.4.0.02,6.07,12]octadeca-1(18),7(12),8,10,14,16-hexaene DMSQZE2 CA CAS 65576-45-6 DMSQZE2 CB CHEBI:71246 DMSQZE2 DE Schizophrenia DMM4FXA ID DMM4FXA DMM4FXA DN Asfotase alfa DMM4FXA HS Approved DMM4FXA SN SPHEX, BioMep; SPHEX, Enobia; PHEX-based enzyme replacement therapy, BioMep; PHEX-based enzyme replacement therapy, Enobia; X-linked hypophosphatemic rickets therapy, BioMep; X-linked hypophosphatemic rickets therapy, Enobia DMM4FXA CP Enobia Pharma Inc DMM4FXA SQ Asfotase Alfa Sequence: LVPEKEKDPKYWRDQAQETLKYALELQKLNTNVAKNVIMFLGDGMGVSTVTAARILKGQLHHNPGEETRLEMDKFPFVALSKTYNTNAQVPDSAGTATAYLCGVKANEGTVGVSAATERSRCNTTQGNEVTSILRWAKDAGKSVGIVTTTRVNHATPSAAYAHSADRDWYSDNEMPPEALSQGCKDIAYQLMHNIRDIDVIMGGGRKYMYPKNKTDVEYESDEKARGTRLDGLDLVDTWKSFKPRYKHSHFIWNRTELLTLDPHNVDYLLGLFEPGDMQYELNRNNVTDPSLSEMVVVAIQILRKNPKGFFLLVEGGRIDHGHHEGKAKQALHEAVEMDRAIGQAGSLTSSEDTLTVVTADHSHVFTFGGYTPRGNSIFGLAPMLSDTDKKPFTAILYGNGPGYKVVGGERENVSMVDYAHNNYQAQSAVPLRHETHGGEDVAVFSKGPMAHLLHGVHEQNYVPHVMAYAACIGANLGHCAPASSLKDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKDIDDDDDDDDDD DMM4FXA DE Genetic disease DM672AH ID DM672AH DM672AH DN Aspirin DM672AH HS Approved DM672AH SN ACETYLSALICYLIC ACID; 50-78-2; 2-Acetoxybenzoic acid; o-Acetoxybenzoic acid; O-Acetylsalicylic acid; Polopiryna; Acylpyrin; Ecotrin; Easprin; Acetylsalicylate; Acetophen; Acenterine; Acetosal; Colfarit; Salicylic acid acetate; o-Carboxyphenyl acetate; Enterosarein; Aspergum; Salcetogen; Pharmacin; Acetosalin; Premaspin; Micristin; Benaspir; Aspirdrops; Acetonyl; Aceticyl; Temperal; Acetylin; Empirin; Ecolen; Rhodine; Endydol; Saletin; Rheumintabletten; Solprin acid; Acidum acetylsalicylicum; Globentyl; Pravigard DM672AH CP Bayer Pharmaceuticals Corporation DM672AH TC Analgesics DM672AH DT Small molecular drug DM672AH PC 2244 DM672AH MW 180.16 DM672AH FM C9H8O4 DM672AH IC InChI=1S/C9H8O4/c1-6(10)13-8-5-3-2-4-7(8)9(11)12/h2-5H,1H3,(H,11,12) DM672AH CS CC(=O)OC1=CC=CC=C1C(=O)O DM672AH IK BSYNRYMUTXBXSQ-UHFFFAOYSA-N DM672AH IU 2-acetyloxybenzoic acid DM672AH CA CAS 50-78-2 DM672AH CB CHEBI:15365 DM672AH DE Pain; Myocardial infarction; Cardiovascular disease DMSYRBX ID DMSYRBX DMSYRBX DN Atazanavir DMSYRBX HS Approved DMSYRBX SN 198904-31-3; Latazanavir; Zrivada; Reyataz; BMS-232632; BMS 232632; Atazanavir [INN:BAN]; CGP 73547; Atazanavir Base; UNII-QZU4H47A3S; CGP-73547; HSDB 7339; Reyataz (TN); ATV; QZU4H47A3S; CHEMBL1163; CHEBI:37924; (3S,8S,9S,12S)-3,12-BIS(1,1-DIMETHYLETHYL)-8-HYDROXY-4,11-DIOXO-9-(PHENYLMETHYL)-6-[[4-(2-PYRIDINYL)PHENYL]METHYL]-2,5,6,10,13-PENTAAZATETRADECANEDIOIC ACID DIMETHYL ESTER; NCGC00182552-01; AK174307; DSSTox_CID_28617; DSSTox_RID_82887; DSSTox_GSID_48691; DR7; atazanavirum; ATZ; Atazanavirum; Atazanavir (INN); Reyataz, BMS-232632, Atazanavir; Reyataz(TM) (*1:1 sulfate*); Dimethyl (3S,8S,9S,12S)-9-benzyl-3,12-di-tert-butyl-8-hydroxy-4,11-dioxo-6-[4-(2-pyridyl)benzyl]-2,5,6,10,13-pentaazatetradecanedioate; METHYL [(1S,4S,5S,10S)-4-BENZYL-1,10-DI-TERT-BUTYL-5-HYDROXY-2,9,12-TRIOXO-7-(4-PYRIDIN-2-YLBENZYL)-13-OXA-3,7,8,11-TETRAAZATETRADEC-1-YL]CARBAMATE; Methyl N-[(2S)-1-[2-[(2S,3S)-2-hydroxy-3-[[(2S)-2-(methoxycarbonylamino)-3,3-dimethylbutanoyl]amino]-4-phenylbutyl]-2-[(4-pyridin-2-ylphenyl)methyl]hydrazinyl]-3,3-dimethyl-1-oxobutan-2-yl]carbamate; (2S)-N-(3-{[(2S)-2-(Methoxycarbonylamino)-3,3-dimethylbutanoylamino][(4-(2-pyridyl)phenyl)methyl]amino}(1S,2S)-2-hydroxy-1-benzylpropyl)-2-(methoxycarbonylamino)-3,3-dimethylbutanamide DMSYRBX CP Bristol-Myers Squibb DMSYRBX TC Anti-HIV Agents DMSYRBX DT Small molecular drug DMSYRBX PC 148192 DMSYRBX MW 704.9 DMSYRBX FM C38H52N6O7 DMSYRBX IC InChI=1S/C38H52N6O7/c1-37(2,3)31(41-35(48)50-7)33(46)40-29(22-25-14-10-9-11-15-25)30(45)24-44(43-34(47)32(38(4,5)6)42-36(49)51-8)23-26-17-19-27(20-18-26)28-16-12-13-21-39-28/h9-21,29-32,45H,22-24H2,1-8H3,(H,40,46)(H,41,48)(H,42,49)(H,43,47)/t29-,30-,31+,32+/m0/s1 DMSYRBX CS CC(C)(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@H](CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)[C@H](C(C)(C)C)NC(=O)OC)O)NC(=O)OC DMSYRBX IK AXRYRYVKAWYZBR-GASGPIRDSA-N DMSYRBX IU methyl N-[(2S)-1-[2-[(2S,3S)-2-hydroxy-3-[[(2S)-2-(methoxycarbonylamino)-3,3-dimethylbutanoyl]amino]-4-phenylbutyl]-2-[(4-pyridin-2-ylphenyl)methyl]hydrazinyl]-3,3-dimethyl-1-oxobutan-2-yl]carbamate DMSYRBX CA CAS 198904-31-3 DMSYRBX CB CHEBI:37924 DMSYRBX DE Human immunodeficiency virus infection DMNKG1Z ID DMNKG1Z DMNKG1Z DN Atenolol DMNKG1Z HS Approved DMNKG1Z SN Aircrit; Alinor; Altol; Anselol; Antipressan; Atcardil; Atecard; Atehexal; Atenblock; Atendol; Atenet; Ateni; Atenil; Atenol; Atenolin; Atenololum; Atenomel; Atereal; Aterol; Betablok; Betacard; Betasyn; Blocotenol; Blokium; Cardaxen; Cardiopress; Corotenol; Cuxanorm; Duraatenolol; Duratenol; Evitocor; Farnormin; Hipres; Hypoten; Ibinolo; Internolol; Jenatenol; Juvental; Loten; Lotenal; Myocord; Neatenol; Normalol; Normiten; Noten; Oraday; Ormidol; Panapres; Plenacor; Premorine; Prenolol; Prenormine; Prinorm; Selobloc; Serten; Servitenol; Stermin; Tenidon; Tenobloc; Tenoblock; Tenolol; Tenoprin; Tenormin; Tenormine; Tensimin; Tensotin; Tredol; Unibloc; Uniloc; Vascoten; Vericordin; Wesipin; Xaten; Atenol AL; Atenol Atid; Atenol Cophar; Atenol Fecofar; Atenol GNR; Atenol Gador; Atenol Genericon; Atenol Heumann; Atenol MSD; Atenol NM Pharma; Atenol Nordic; Atenol PB; Atenol Quesada; Atenol Stada; Atenol Tika; Atenol Trom; Atenol acis; Atenol ct; Atenol von ct; Betatop Ge; Scheinpharm Atenol; Seles beta; Tenormine [French]; A 7655; Atenol 1A pharma; Apo-Atenolol; Atenol-Mepha; Atenol-Wolff; Atenol-ratiopharm; Atenololum [INN-Latin]; Felo-Bits; Lo-ten; Teno-basan; Tenormin (TN); Atenolol (JP15/USP/INN); Atenolol [USAN:INN:BAN:JAN]; Acetamide,2-(p-(2-hydroxy-3-(isopropylamino)propoxy)phenyl); (+-)-4-(2-Hydroxy-3-isopropylaminopropoxy)phenylacetamide; (+-)-Atenolol; (+/-)-4-[2-Hydroxy-3-[(1-methylethyl)amino]propoxy]benzeneacetamide; (1)-2-(4-(2-Hydroxy-3-(isopropylamino)propoxy)phenyl)acetamide; (inverted question mark)-Atenolol; 1-p-Carbamoylmethylphenoxy-3-isopropylamino-2-propanol; 2-(4-(2-Hydroxy-3-isopropylaminopropoxy)phenyl)acetamid; 2-(4-{2-hydroxy-3-[(propan-2-yl)amino]propoxy}phenyl)acetamide; 2-(p-(2-Hydroxy-3-(isopropylamino)propoxy)phenyl)acetamide; 2-[4-(2-Hydroxy-3-isopropylaminopropoxy)phenyl]acetamide; 2-[4-({2-hydroxy-3-[(1-methylethyl)amino]propyl}oxy)phenyl]acetamide; 2-[4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]acetamide; 2-{4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl}acetamide; 4-(2-Hydroxy-3-((1-methylethyl)amino)propoxy)benzeneacetamide; 4-[2'-Hydroxy-3'-(isopropylamino)propoxy]phenylacetamide; 4-[2-Hydroxy-3-(isopropylamino)-propoxy]phenylacetamide DMNKG1Z TC Antihypertensive Agents DMNKG1Z DT Small molecular drug DMNKG1Z PC 2249 DMNKG1Z MW 266.34 DMNKG1Z FM C14H22N2O3 DMNKG1Z IC InChI=1S/C14H22N2O3/c1-10(2)16-8-12(17)9-19-13-5-3-11(4-6-13)7-14(15)18/h3-6,10,12,16-17H,7-9H2,1-2H3,(H2,15,18) DMNKG1Z CS CC(C)NCC(COC1=CC=C(C=C1)CC(=O)N)O DMNKG1Z IK METKIMKYRPQLGS-UHFFFAOYSA-N DMNKG1Z IU 2-[4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]acetamide DMNKG1Z CA CAS 29122-68-7 DMNKG1Z CB CHEBI:2904 DMNKG1Z DE Hypertension DMMF8U0 ID DMMF8U0 DMMF8U0 DN Atezolizumab DMMF8U0 HS Approved DMMF8U0 CP Genentech South San Francisco, CA DMMF8U0 DT Monoclonal antibody DMMF8U0 DE Melanoma; Breast cancer; Bladder cancer; Colorectal cancer; Haematological malignancy; Myelodysplastic syndrome; Renal cell carcinoma; Squamous cell carcinoma; Urothelial carcinoma; Hepatocellular carcinoma; Ovarian cancer; Prostate cancer; Acute myeloid leukaemia; Follicular lymphoma; Gastric adenocarcinoma; Multiple myeloma; Pancreatic cancer; Small-cell lung cancer; Solid tumour/cancer; Bronchioalveolar carcinoma; Ulcer; Non-small cell lung cancer DM5L6HI ID DM5L6HI DM5L6HI DN Atomoxetine DM5L6HI HS Approved DM5L6HI SN Tomoxetina; Tomoxetine; Tomoxetinum; Tomoxetina [Spanish]; Tomoxetine [INN]; Tomoxetinum [Latin]; Atomoxetine (INN); Attentin (TN); Strattera (TN); Tomoxetin (TN); (-)-Tomoxetine; (3R)-N-methyl-3-(2-methylphenoxy)-3-phenylpropan-1-amine DM5L6HI CP Eli Lilly DM5L6HI DT Small molecular drug DM5L6HI PC 54841 DM5L6HI MW 255.35 DM5L6HI FM C17H21NO DM5L6HI IC InChI=1S/C17H21NO/c1-14-8-6-7-11-16(14)19-17(12-13-18-2)15-9-4-3-5-10-15/h3-11,17-18H,12-13H2,1-2H3/t17-/m1/s1 DM5L6HI CS CC1=CC=CC=C1O[C@H](CCNC)C2=CC=CC=C2 DM5L6HI IK VHGCDTVCOLNTBX-QGZVFWFLSA-N DM5L6HI IU (3R)-N-methyl-3-(2-methylphenoxy)-3-phenylpropan-1-amine DM5L6HI CA CAS 83015-26-3 DM5L6HI CB CHEBI:127342 DM5L6HI DE Attention deficit hyperactivity disorder DMF28YC ID DMF28YC DMF28YC DN Atorvastatin DMF28YC HS Approved DMF28YC SN Atogal; Atorlip; Atorpic; Atorvastatina; Atorvastatine; Atorvastatinium; Atrovastin; Cardyl; Faboxim; Lipotropic; Lipovastatinklonal; Liprimar; Lowden; Sincol; Sortis; Sotis; Torvacard; Torvast; Totalip; Tozalip; Tulip; Vastina; Xanator; Xarator; Xavator; Zurinel; Atorvastatin (INN); Atorvastatin [INN:BAN]; Lipitor (TN); Lipitor(TM); Sortis (TN); (3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid; (3R,5R)-7-[3-(anilinocarbonyl)-5-(4-fluorophenyl)-2-isopropyl-4-phenyl-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid; (R-(R*,R*))-2-(4-Fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoic acid; (betaR,deltaR)-2-(p-Fluorophenyl)-beta,delta-dihydroxy-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)pyrrole-1-heptanoic acid; 7-[2-(4-FLUORO-PHENYL)-5-ISOPROPYL-3-PHENYL-4-PHENYLCARBAMOYL-PYRROL-1-YL]-3,5-DIHYDROXY-HEPTANOIC ACID DMF28YC CP Pfizer Pharmaceuticals DMF28YC TC Anticholesteremic Agents DMF28YC DT Small molecular drug DMF28YC PC 60823 DMF28YC MW 558.6 DMF28YC FM C33H35FN2O5 DMF28YC IC InChI=1S/C33H35FN2O5/c1-21(2)31-30(33(41)35-25-11-7-4-8-12-25)29(22-9-5-3-6-10-22)32(23-13-15-24(34)16-14-23)36(31)18-17-26(37)19-27(38)20-28(39)40/h3-16,21,26-27,37-38H,17-20H2,1-2H3,(H,35,41)(H,39,40)/t26-,27-/m1/s1 DMF28YC CS CC(C)C1=C(C(=C(N1CC[C@H](C[C@H](CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4 DMF28YC IK XUKUURHRXDUEBC-KAYWLYCHSA-N DMF28YC IU (3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid DMF28YC CA CAS 134523-00-5 DMF28YC CB CHEBI:39548 DMF28YC DE Cardiovascular disease DMY4UMW ID DMY4UMW DMY4UMW DN Atovaquone DMY4UMW HS Approved DMY4UMW SN Acuvel; Atavaquone; Mepron; Pron; Wellvone; Atovaquone GlaxoSmithKline brand; Glaxo Wellcome brand of atovaquone; GlaxoSmithKline brand of atovaquone; Malarone Pediatric; BW 566C; BW 566C80; Hydroxynaphthoquinone 566C80; Atovaquone & Interleukin 12; BW 556C-80; BW 566C-80; BW-A 566C; DRG-0084; Hydroxynaphthoquinone, 566C80; Mepron (TN); Mepron (antipneumocystic); ATO & IL-12; Atovaquone (USP/INN); Atovaquone [USAN:BAN:INN]; CRL-8131 & Atovaquone; 2-(4-(4'-chlorophenyl)cyclohexyl)-3-hydroxy-1,4-naphthoquinone; 2-(4-(4-Chlorophenyl)cyclohexyl)-3-hydroxy-1,4-naphthoquinone; 2-(trans-4-(4-chlorophenyl)cyclohexyl)-3-hydroxy-1,4-naphthoquinone; 2-(trans-4-(p-Chlorophenyl)cyclohexyl)-3-hydroxy-1,4-naphthoquinone; 2-[trans-4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphthoquinone; 2-[trans-4-(4-chlorophenyl)cyclohexyl]-3-hydroxynaphthalene-1,4-dione; 2-[trans-4-(p-Chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphthoquinone; 3-(4-(4-chlorophenyl)cyclohexyl)-4-hydroxy-naphthalene-1,2-dione; 3-[4-(4-chlorophenyl)cyclohexyl]-4-hydroxynaphthalene-1,2-dione; 566C80 hydroxynaphthoquinone; 566C80, hydroxynaphthoquinone; ATQ DMY4UMW CP GlaxoSmithKline DMY4UMW TC Antifungal Agents DMY4UMW DT Small molecular drug DMY4UMW PC 74989 DMY4UMW MW 366.8 DMY4UMW FM C22H19ClO3 DMY4UMW IC InChI=1S/C22H19ClO3/c23-16-11-9-14(10-12-16)13-5-7-15(8-6-13)19-20(24)17-3-1-2-4-18(17)21(25)22(19)26/h1-4,9-13,15,24H,5-8H2 DMY4UMW CS C1CC(CCC1C2=CC=C(C=C2)Cl)C3=C(C4=CC=CC=C4C(=O)C3=O)O DMY4UMW IK BSJMWHQBCZFXBR-UHFFFAOYSA-N DMY4UMW IU 3-[4-(4-chlorophenyl)cyclohexyl]-4-hydroxynaphthalene-1,2-dione DMY4UMW CA CAS 94015-53-9 DMY4UMW CB CHEBI:575568 DMY4UMW DE Fungal infection DM42HXN ID DM42HXN DM42HXN DN Atracurium DM42HXN HS Approved DM42HXN SN Atracurium Dibesylate; Tracrium (TN); 2,2'-{pentane-1,5-diylbis[oxy(3-oxopropane-3,1-diyl)]}bis[1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolinium]; 5-[3-[1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propanoyloxy]pentyl 3-[1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propanoate DM42HXN CP Burroughs Wellcome Co DM42HXN TC Neuromuscular Nondepolarizing Agents DM42HXN DT Small molecular drug DM42HXN PC 47319 DM42HXN MW 929.1 DM42HXN FM C53H72N2O12+2 DM42HXN IC InChI=1S/C53H72N2O12/c1-54(22-18-38-32-48(62-7)50(64-9)34-40(38)42(54)28-36-14-16-44(58-3)46(30-36)60-5)24-20-52(56)66-26-12-11-13-27-67-53(57)21-25-55(2)23-19-39-33-49(63-8)51(65-10)35-41(39)43(55)29-37-15-17-45(59-4)47(31-37)61-6/h14-17,30-35,42-43H,11-13,18-29H2,1-10H3/q+2 DM42HXN CS C[N+]1(CCC2=CC(=C(C=C2C1CC3=CC(=C(C=C3)OC)OC)OC)OC)CCC(=O)OCCCCCOC(=O)CC[N+]4(CCC5=CC(=C(C=C5C4CC6=CC(=C(C=C6)OC)OC)OC)OC)C DM42HXN IK YXSLJKQTIDHPOT-UHFFFAOYSA-N DM42HXN IU 5-[3-[1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propanoyloxy]pentyl 3-[1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propanoate DM42HXN CA CAS 64228-79-1 DM42HXN CB CHEBI:2914 DM42HXN DE Anaesthesia DMEN6X7 ID DMEN6X7 DMEN6X7 DN Atropine DMEN6X7 HS Approved DMEN6X7 SN dl-Hyoscyamine; Atropin; Atropen; dl-Tropyltropate; Atropinol; Atropina; Eyesules; Troyl tropate; Isopto-atropine; Atropin [German]; Atropina [Italian]; Atropin-flexiolen; (+,-)-Tropyl tropate; 51-55-8; DL-Tropyl tropate; Tropine, tropate (ester); Tropic acid, ester with tropine; Atropine sulfate; CCRIS 3080; Atropine (USP); Isopto Atropine; Tropic acid, 3-alpha-tropanyl ester; Atropt; HSDB 2199; DL-Tropanyl; Anaspaz; Atropair; Atrosulf; Belladenal; Cytospaz; Minims; Tropanol; Urised; Atropine Care; Atropine [BAN]; Atropinium cation; Hyoscyamine sulfate; Minims Atropine; OR22908; Atropen (TN); Bellergal-S; D1-hyoscyamine; Dl-Hyoscyamine; Dl-Tropyltropate; I-Tropine; NP-010662; Neo-Diophen; Ocu-Tropine; Protamine & Atropine; Atropinium(1+); Tropan-3alpha-ol; Tropan-3beta-ol; Atropine Sulfate SOP; DL-Tropanyl 2-hydroxy-1-phenylpropionate; Beta-Phenyl-gamma-oxypropionsaeure-tropyl-ester [German]; Beta-Phenyl-gamma-oxypropionsaure-tropyl-ester [German]; Tropan-3alpha-yl 3-hydroxy-2-phenylpropanoate; Endo-8-methyl-8-azabicyclo[321]octan-3-ol; B eta-(Hydroxymethyl)benzeneacetic acid 8-methyl-8-azabicyclo[321]oct-3-yl ester; [(1R,5S)-8-methyl-8-azabicyclo[321]octan-3-yl] 3-hydroxy-2-phenylpropanoate; [(1S,5R)-8-methyl-8-azabicyclo[321]oct-3-yl] 3-hydroxy-2-phenyl-propanoate; Endo-(+/-)-alpha-(Hydroxymethyl)benzeneacetic acid 8-methyl-8-azabicyclo[321]oct-3-yl ester; Benzeneacetic acid, alpha-(hydroxymethyl)-, (3-endo)-8-methyl-8-azabicyclo(321)oct-3-yl ester; (3-endo)-8-methyl-8-azabicyclo[321]oct-3-yl (2S)-3-hydroxy-2-phenylpropanoate; (3-endo)-8-methyl-8-azabicyclo[321]oct-3-yl 3-hydroxy-2-phenylpropanoate; (3-endo)-8-methyl-8-azabicyclo[321]oct-3-yl tropate; (3-endo)-8-methyl-8-azabicyclo[321]octan-3-ol; (3-endo,8-syn)-3-[(3-hydroxy-2-phenylpropanoyl)oxy]-8-methyl-8-azoniabicyclo[321]octane; (3-exo)-8-methyl-8-azabicyclo[321]octan-3-ol; 1-alpha-H,5-alpha-H-Tropan-3-alpha-ol (+-)-tropate (ester); 1-alpha-H,5-alpha-H-Tropan-3-alpha-ol (+-)-tropate (ester) (8CI); 1alphaH,5alphaH-Tropan-3alpha-ol; 1alphaH,5alphaH-Tropan-3alpha-ol (+-)-tropate (ester); 1alphaH,5alphaH-Tropan-3beta-ol; 2-Phenylhydracrylic acid 3-alpha-tropanyl ester; 8-Methyl-8-azabicyclo[321]oct-3-yl 3-hydroxy-2-phenylpropanoate; 8-Methyl-8-azabicyclo[321]oct-3-yl tropate; 8-Methyl-8-azabicyclo[321]octan-3-yl 3-hydroxy-2-phenylpropionate DMEN6X7 CP Pfizer Pharmaceuticals DMEN6X7 TC Antiarrhythmic Agents DMEN6X7 DT Small molecular drug DMEN6X7 PC 174174 DMEN6X7 MW 289.4 DMEN6X7 FM C17H23NO3 DMEN6X7 IC InChI=1S/C17H23NO3/c1-18-13-7-8-14(18)10-15(9-13)21-17(20)16(11-19)12-5-3-2-4-6-12/h2-6,13-16,19H,7-11H2,1H3/t13-,14+,15?,16? DMEN6X7 CS CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C(CO)C3=CC=CC=C3 DMEN6X7 IK RKUNBYITZUJHSG-PJPHBNEVSA-N DMEN6X7 IU [(1R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate DMEN6X7 CA CAS 51-55-8 DMEN6X7 CB CHEBI:16684 DMEN6X7 DE Organophosphate poisoning; Poison intoxication DM79Y2T ID DM79Y2T DM79Y2T DN ATryn antithrombin DM79Y2T HS Approved DM79Y2T CP Revo biologics DM79Y2T DE Multiple sclerosis DMWE2N4 ID DMWE2N4 DMWE2N4 DN Auranofin DMWE2N4 HS Approved DMWE2N4 SN Ridaura; Ridauran; Ridaura (TN); SK&F 39162; SK&F-39162; Gold, (1-thio-.beta.-D-glucopyranosato)(triethylphosphine)-, 2,3,4,6-tetraacetate; (1-Thio-.beta.-D-glucopyranosato)(triethylphosphine)gold 2,3,4,6-tetraacetate DMWE2N4 TC Antirheumatic Agents DMWE2N4 DT Small molecular drug DMWE2N4 PC 24199313 DMWE2N4 MW 678.5 DMWE2N4 FM C20H34AuO9PS DMWE2N4 IC InChI=1S/C14H20O9S.C6H15P.Au/c1-6(15)19-5-10-11(20-7(2)16)12(21-8(3)17)13(14(24)23-10)22-9(4)18;1-4-7(5-2)6-3;/h10-14,24H,5H2,1-4H3;4-6H2,1-3H3;/q;;+1/p-1 DMWE2N4 CS CCP(CC)CC.CC(=O)OCC1C(C(C(C(O1)[S-])OC(=O)C)OC(=O)C)OC(=O)C.[Au+] DMWE2N4 IK AUJRCFUBUPVWSZ-UHFFFAOYSA-M DMWE2N4 IU gold(1+);3,4,5-triacetyloxy-6-(acetyloxymethyl)oxane-2-thiolate;triethylphosphane DMWE2N4 CA CAS 34031-32-8 DMWE2N4 DE Inflammatory arthritis DM75CXN ID DM75CXN DM75CXN DN Avanafil DM75CXN HS Approved DM75CXN SN Stendra (TN) DM75CXN CP Vivus DM75CXN DT Small molecular drug DM75CXN PC 9869929 DM75CXN MW 483.9 DM75CXN FM C23H26ClN7O3 DM75CXN IC InChI=1S/C23H26ClN7O3/c1-34-19-6-5-15(10-18(19)24)11-27-21-17(22(33)28-13-20-25-7-3-8-26-20)12-29-23(30-21)31-9-2-4-16(31)14-32/h3,5-8,10,12,16,32H,2,4,9,11,13-14H2,1H3,(H,28,33)(H,27,29,30)/t16-/m0/s1 DM75CXN CS COC1=C(C=C(C=C1)CNC2=NC(=NC=C2C(=O)NCC3=NC=CC=N3)N4CCC[C@H]4CO)Cl DM75CXN IK WEAJZXNPAWBCOA-INIZCTEOSA-N DM75CXN IU 4-[(3-chloro-4-methoxyphenyl)methylamino]-2-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-N-(pyrimidin-2-ylmethyl)pyrimidine-5-carboxamide DM75CXN CA CAS 330784-47-9 DM75CXN CB CHEBI:66876 DM75CXN DE Erectile dysfunction DMK2GZX ID DMK2GZX DMK2GZX DN Avapritinib DMK2GZX HS Approved DMK2GZX SN 1703793-34-3; UNII-513P80B4YJ; 513P80B4YJ; (1S)-1-(4-fluorophenyl)-1-[2-[4-[6-(1-methylpyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]piperazin-1-yl]pyrimidin-5-yl]ethanamine; Avapritinib [INN]; BLU-285 (Avapritinib); SCHEMBL16652297; EX-A1366; BCP20175; CS-7577; ACN-051245; HY-101561; (S)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazin-1-yl)pyrimidin-5-yl)ethanamine DMK2GZX CP Blueprint Medicines Cambridge, MA DMK2GZX PC 118023034 DMK2GZX MW 498.6 DMK2GZX FM C26H27FN10 DMK2GZX IC InChI=1S/C26H27FN10/c1-26(28,20-3-5-22(27)6-4-20)21-13-29-25(30-14-21)36-9-7-35(8-10-36)24-23-11-18(16-37(23)33-17-31-24)19-12-32-34(2)15-19/h3-6,11-17H,7-10,28H2,1-2H3/t26-/m0/s1 DMK2GZX CS C[C@](C1=CC=C(C=C1)F)(C2=CN=C(N=C2)N3CCN(CC3)C4=NC=NN5C4=CC(=C5)C6=CN(N=C6)C)N DMK2GZX IK DWYRIWUZIJHQKQ-SANMLTNESA-N DMK2GZX IU (1S)-1-(4-fluorophenyl)-1-[2-[4-[6-(1-methylpyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]piperazin-1-yl]pyrimidin-5-yl]ethanamine DMK2GZX CA CAS 1703793-34-3 DMK2GZX DE Mast cell leukaemia; Systemic mastocytosis; Gastrointestinal stromal tumour DMSZLJR ID DMSZLJR DMSZLJR DN Avelumab DMSZLJR HS Approved DMSZLJR CP Merck KGaA/Pfizer DMSZLJR DT Monoclonal antibody DMSZLJR SQ Heavy chain: EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYIMMWVRQAPGKGLEWVSSIYPSGGITFYADTVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARIKLGTVTTVDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK >Light chainQSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTRVFGTGTKVTVLGQPKANPTVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADGSPVKAGVETTKPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS DMSZLJR DE Melanoma; Ovarian cancer; Solid tumour/cancer; Renal cell carcinoma; Merkel cell carcinoma DM1AEH4 ID DM1AEH4 DM1AEH4 DN Avibactam DM1AEH4 HS Approved DM1AEH4 SN Avibactam; Avibactam (free acid); Avibactam [USAN:INN]; Avibactam free acid; AVE-1330A free acid; NXL 104; NXL104; Q15410251; SCHEMBL1666807; ZINC9302239; (2S,5R)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide; 1,6-Diazabicyclo(3.2.1)octane-2-carboxamide, 7-oxo-6-(sulfooxy)-, (1R,2S,5R)-rel-; 1192500-31-4; 396731-14-9; BDBM50339145; CHEBI:85984; CHEMBL1689063; CS-0593; DB09060; HY-14879; UNII-06MFO7817I component NDCUAPJVLWFHHB-UHNVWZDZSA-N; UNII-7352665165 DM1AEH4 PC 9835049 DM1AEH4 MW 265.25 DM1AEH4 FM C7H11N3O6S DM1AEH4 IC NDCUAPJVLWFHHB-UHNVWZDZSA-N DM1AEH4 CS C1CC(N2CC1N(C2=O)OS(=O)(=O)O)C(=O)N DM1AEH4 IK 1S/C7H11N3O6S/c8-6(11)5-2-1-4-3-9(5)7(12)10(4)16-17(13,14)15/h4-5H,1-3H2,(H2,8,11)(H,13,14,15)/t4-,5+/m1/s1 DM1AEH4 IU [(2S,5R)-2-carbamoyl-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl] hydrogen sulfate DM1AEH4 CA CAS 396731-14-9 DM1AEH4 CB CHEBI:85984 DM1AEH4 DE Infectious cystitis DMYHN59 ID DMYHN59 DMYHN59 DN Axicabtagene ciloleucel DMYHN59 HS Approved DMYHN59 CP Masonic Cancer Center, University of Minnesota DMYHN59 DT CAR T Cell Therapy DMYHN59 DE Acute lymphoblastic leukaemia; Mantle cell lymphoma; Non-hodgkin lymphoma; Diffuse large B-cell lymphoma; Follicular lymphoma; Primary mediastinal B-cell lymphoma; Large B-cell lymphoma DMGVH6N ID DMGVH6N DMGVH6N DN Axitinib DMGVH6N HS Approved DMGVH6N SN AG 013736; AG013736; AG-013736; AG-13736; AG-013736, Axitinib; N-methyl-2-[[3-[(E)-2-pyridin-2-ylethenyl]-1H-indazol-6-yl]sulfanyl]benzamide; N-methyl-2-((3-((1E)-2-(pyridin-2-yl)ethenyl)-1H-indazol-6-yl)sulfanyl)benzamide; Axitinib (VEGFR inhibitor) DMGVH6N CP Pfizer DMGVH6N TC Anticancer Agents DMGVH6N DT Small molecular drug DMGVH6N PC 6450551 DMGVH6N MW 386.5 DMGVH6N FM C22H18N4OS DMGVH6N IC InChI=1S/C22H18N4OS/c1-23-22(27)18-7-2-3-8-21(18)28-16-10-11-17-19(25-26-20(17)14-16)12-9-15-6-4-5-13-24-15/h2-14H,1H3,(H,23,27)(H,25,26)/b12-9+ DMGVH6N CS CNC(=O)C1=CC=CC=C1SC2=CC3=C(C=C2)C(=NN3)/C=C/C4=CC=CC=N4 DMGVH6N IK RITAVMQDGBJQJZ-FMIVXFBMSA-N DMGVH6N IU N-methyl-2-[[3-[(E)-2-pyridin-2-ylethenyl]-1H-indazol-6-yl]sulfanyl]benzamide DMGVH6N CA CAS 319460-85-0 DMGVH6N CB CHEBI:66910 DMGVH6N DE Renal cell carcinoma DMTA5OE ID DMTA5OE DMTA5OE DN Azacitidine DMTA5OE HS Approved DMTA5OE SN Azacitidina; Azacitidinum; Azacytidine; Ladakamycin; Mylosar; Vidaza; Mylo sar; Pharmion Brand of Azacitidine;A 2385; Antibiotic U 18496; U 18496; Wr 183027; Azacitidina [INN-Spanish]; Azacitidine [USAN:INN]; Azacitidinum [INN-Latin]; NS-17; Pyrimidine antimetabolite: inhibits nucleic acid replication; U-18496; Vidaz (TN); Vidaza (TN); WR-183027; Azacitidine (JAN/USAN/INN); S-Triazin-2(1H)-one, 4-amino-1-beta-D-ribofuranosyl-(8CI); 2-(beta-D-Ribofuranosyl)-4-amino-1,3,5-triazin-2-one; 4-Amino-1-(beta-D-ribofuranosyl)-1,3,5-triazin-2(1H)-one; 4-Amino-1-beta-D-ribofuranosyl-1,3,5-traizin-2(1H)-one; 4-Amino-1-beta-D-ribofuranosyl-1,3,5-triazine-2(1H)-one; 4-Amino-1-beta-D-ribofuranosyl-s-triazin-2(1H)-one; 4-Amino-1-beta-d-ribofuranosyl-1,3,5-triazin-2(1H)-one; 4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triaz; 4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one; 4-amino-1-beta-L-ribofuranosyl-1,3,5-triazin-2(1H)-one; 5 AZC; 5 Azacytidine; 5-AC; 5-AZAC; 5-AZCR; 5-aza-CR; 5-azacitidine; 5-azacytidine; 5-azacytidine, Mylosar, Ladakamycin, Vidaza, Azacitidine; 5AzaC DMTA5OE CP Celgene DMTA5OE TC Anticancer Agents DMTA5OE DT Small molecular drug DMTA5OE PC 9444 DMTA5OE MW 244.2 DMTA5OE FM C8H12N4O5 DMTA5OE IC InChI=1S/C8H12N4O5/c9-7-10-2-12(8(16)11-7)6-5(15)4(14)3(1-13)17-6/h2-6,13-15H,1H2,(H2,9,11,16)/t3-,4-,5-,6-/m1/s1 DMTA5OE CS C1=NC(=NC(=O)N1[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O)N DMTA5OE IK NMUSYJAQQFHJEW-KVTDHHQDSA-N DMTA5OE IU 4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one DMTA5OE CA CAS 320-67-2 DMTA5OE CB CHEBI:2038 DMTA5OE DE Myelodysplastic syndrome DMZ80SB ID DMZ80SB DMZ80SB DN Azatadine DMZ80SB HS Approved DMZ80SB SN Azatadina; Azatadinum; Azatidine; Azatadine maleate; Azatadina [INN-Spanish]; Azatadine (INN); Azatadine [INN:BAN]; Azatadinum [INN-Latin]; 11-(1-Methyl-4-piperidinylidene)-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine; 11-(1-methylpiperidin-4-ylidene)-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine; 6,11-Dihydro-11-(1-methyl-4-piperidylidene)-5H-benzo(5,6)cyclohepta(1,2-b)pyridine DMZ80SB TC Antihistamines DMZ80SB DT Small molecular drug DMZ80SB PC 19861 DMZ80SB MW 290.4 DMZ80SB FM C20H22N2 DMZ80SB IC InChI=1S/C20H22N2/c1-22-13-10-16(11-14-22)19-18-7-3-2-5-15(18)8-9-17-6-4-12-21-20(17)19/h2-7,12H,8-11,13-14H2,1H3 DMZ80SB CS CN1CCC(=C2C3=CC=CC=C3CCC4=C2N=CC=C4)CC1 DMZ80SB IK SEBMTIQKRHYNIT-UHFFFAOYSA-N DMZ80SB IU 2-(1-methylpiperidin-4-ylidene)-4-azatricyclo[9.4.0.03,8]pentadeca-1(15),3(8),4,6,11,13-hexaene DMZ80SB CA CAS 3964-81-6 DMZ80SB CB CHEBI:2946 DMZ80SB DE Allergic rhinitis DMMZSXQ ID DMMZSXQ DMMZSXQ DN Azathioprine DMMZSXQ HS Approved DMMZSXQ SN Azamun; Azanin; Azasan; Azathioprin; Azathioprinum; Azathiopurine; Azatioprin; Azatioprina; Azothioprine; Ccucol; Cytostatics; Immuran; Imuran; Imurek; Imurel; Methylnitroimidazolylmercaptopurine; Muran; Azamun [Czech]; Azathioprine sodium; Azatiopr in; A 4638; BW 57322; Azamun (TN); Azasan (TN); Azathioprinum [INN-Latin]; Azatioprina [INN-Spanish]; BW 57-322; Imuran (TN); Imurel (TN); [Methyl(nitroimidazolyl)mercaptopurine]; AI-981/34845012; BW-57-322; Azathioprine (JP15/USP/INN); Azathioprine [USAN:INN:BAN:JAN]; B. W. 57-322; Thiopurine 6-(1-methyl-4-nitroimidazol-5-yl); Azasan, Imuran, Azamun, BW-57-322, NSC-39084, Azathioprine; 6-((1-Methyl-4-nitro-1H-imidazol-5-yl)thio)-1H-purine; 6-((1-Methyl-4-nitroimidazol-5-yl)thio)purine; 6-(1'-Methyl-4'-nitro-5'-imidazolyl)-mercaptopurine; 6-(1'-Methyl-4'-nitro-5'-imidazolyl)mercaptopurine; 6-(1-Methyl-4-nitroimidazol-5-yl)thiopurine; 6-(1-Methyl-4-nitroimidazol-5-ylthio)purin; 6-(1-Methyl-4-nitroimidazol-5-ylthio)purin [Czech]; 6-(1-Methyl-p-nitro-5-imidazolyl)-thiopurine; 6-(1-Methyl-p-nitro-5-imidazolyl)thiopurine; 6-(3-Methyl-5-nitro-3H-imidazol-4-ylsulfanyl)-7H-purine; 6-(3-methyl-5-nitroimidazol-4-yl)sulfanyl-7H-purine; 6-(Methyl-p-nitro-5-imidazolyl)-thiopurine; 6-(Methyl-p-nitro-5-imidazolyl)thiopurine; 6-({4-nitro-1-methyl-1H-imidazol-5-yl}sulfanyl)-7H-purine; 6-1'-Methyl,4'-nitro,5'-imidazolyl mercaptopurine; 6-[(1-Methyl-4-nitroimidazol-5-yl)-thio] purine; 6-[(1-Methyl-4-nitroimidazol-5-yl)thio]purine; 6-[(1-methyl-4-nitro-1H-imidazol-5-yl)sulfanyl]-7H-purine; 6-[(1-methyl-4-nitro-1H-imidazol-5-yl)thio]-1H-Purine; 6-[(1-methyl-4-nitro-1H-imidazol-5-yl)thio]-7H-purine; 6-[(1-methyl-4-nitro-1H-imidazol-5-yl)thio]-9H-purine DMMZSXQ CP GlaxoSmithKline DMMZSXQ TC Immunosuppressive Agents DMMZSXQ DT Small molecular drug DMMZSXQ PC 2265 DMMZSXQ MW 277.27 DMMZSXQ FM C9H7N7O2S DMMZSXQ IC InChI=1S/C9H7N7O2S/c1-15-4-14-7(16(17)18)9(15)19-8-5-6(11-2-10-5)12-3-13-8/h2-4H,1H3,(H,10,11,12,13) DMMZSXQ CS CN1C=NC(=C1SC2=NC=NC3=C2NC=N3)[N+](=O)[O-] DMMZSXQ IK LMEKQMALGUDUQG-UHFFFAOYSA-N DMMZSXQ IU 6-(3-methyl-5-nitroimidazol-4-yl)sulfanyl-7H-purine DMMZSXQ CA CAS 446-86-6 DMMZSXQ CB CHEBI:2948 DMMZSXQ DE Organ transplant rejection DMHVL0J ID DMHVL0J DMHVL0J DN Azelaic Acid DMHVL0J HS Approved DMHVL0J SN AZA; Azelaic; Azelex; Finacea; Finevin; Skinorem; Skinoren; Acide azelaique; Acide azelaique [French]; Acido azelaico; Acido azelaico [Spanish]; Acidum azelaicum; Acidum azelaicum [Latin]; Anchoic acid; Azalaic Acid; Azelaic acid polyanhydride; Azelaic polyanhydride; Azelainic acid; Azleaic Acid; Heptanedicarboxylic acid; Lepargylic acid; NONANEDIOIC ACID; Nonanedioic acid; Polyazelaic anhydride; AZ1; Dicarboxylic acid C9; Emerox 1110; Emerox 1144; ZK 62498; A-9800; AGN-191861; Azelaic acid [USAN:INN]; Azelaic acid,technical grade; Azelex (TN); Finacea (TN); Finevin (TN); N-Nonanedioic acid; Nonanedioic acid, homopolymer; Poly(azelaic anhydride); SH-441; Skinoren (TN); ZK-62498; AZELAIC ACID, 95%; Azelaic acid (USAN/INN); Emery's L-110; 1,7-Heptanedicarboxylic acid; 1,9-Nonanedioic acid DMHVL0J TC Dermatologic Agents DMHVL0J DT Small molecular drug DMHVL0J PC 2266 DMHVL0J MW 188.22 DMHVL0J FM C9H16O4 DMHVL0J IC InChI=1S/C9H16O4/c10-8(11)6-4-2-1-3-5-7-9(12)13/h1-7H2,(H,10,11)(H,12,13) DMHVL0J CS C(CCCC(=O)O)CCCC(=O)O DMHVL0J IK BDJRBEYXGGNYIS-UHFFFAOYSA-N DMHVL0J IU nonanedioic acid DMHVL0J CA CAS 123-99-9 DMHVL0J CB CHEBI:48131 DMHVL0J DE Acne vulgaris DMXTMBJ ID DMXTMBJ DMXTMBJ DN Azelastine DMXTMBJ HS Approved DMXTMBJ SN Azelastina; Azelastinum; Optivar; Astelin (TN); Astepro (TN); Azelastina [INN-Spanish]; Azelastine (INN); Azelastine [INN:BAN]; Azelastinum [INN-Latin]; Optivar (TN); 4-((4-Chlorophenyl)methyl)-2-(hexahydro-1-methyl-1H-azepin-4-yl)-1(2H)-phthalazinone hydrochloride; 4-((4-chlorophenyl)methyl)-2-(hexahydro-1-methyl-1H-azepin-4-yl)-1(2H)-phthalazinone HCl; 4-(4-chlorobenzyl)-2-(1-methylazepan-4-yl)phthalazin-1(2H)-one; 4-(p-Chlorobenzyl)-2-(hexahydro-1-methyl-1H-azepin-4-yl)-1-(2H)-phthalazinone; 4-(p-chlorobenzyl)-2-(N-methylperhydroazepinyl-(4))-1-(2H)-phthalazinone; 4-[(4-chlorophenyl)methyl]-2-(1-methylazepan-4-yl)phthalazin-1(2H)-one; 4-[(4-chlorophenyl)methyl]-2-(1-methylazepan-4-yl)phthalazin-1-one DMXTMBJ CP Meda Pharmaceuticals Inc DMXTMBJ TC Antiallergic Agents DMXTMBJ DT Small molecular drug DMXTMBJ PC 2267 DMXTMBJ MW 381.9 DMXTMBJ FM C22H24ClN3O DMXTMBJ IC InChI=1S/C22H24ClN3O/c1-25-13-4-5-18(12-14-25)26-22(27)20-7-3-2-6-19(20)21(24-26)15-16-8-10-17(23)11-9-16/h2-3,6-11,18H,4-5,12-15H2,1H3 DMXTMBJ CS CN1CCCC(CC1)N2C(=O)C3=CC=CC=C3C(=N2)CC4=CC=C(C=C4)Cl DMXTMBJ IK MBUVEWMHONZEQD-UHFFFAOYSA-N DMXTMBJ IU 4-[(4-chlorophenyl)methyl]-2-(1-methylazepan-4-yl)phthalazin-1-one DMXTMBJ CA CAS 58581-89-8 DMXTMBJ CB CHEBI:2950 DMXTMBJ DE Allergic conjunctivitis DMOIX5S ID DMOIX5S DMOIX5S DN Azilsartan DMOIX5S HS Approved DMOIX5S SN TAK 536; TAK-536; Azilsartan (INN/USAN) DMOIX5S CP Takeda DMOIX5S DT Small molecular drug DMOIX5S PC 135415867 DMOIX5S MW 456.4 DMOIX5S FM C25H20N4O5 DMOIX5S IC InChI=1S/C25H20N4O5/c1-2-33-24-26-20-9-5-8-19(23(30)31)21(20)29(24)14-15-10-12-16(13-11-15)17-6-3-4-7-18(17)22-27-25(32)34-28-22/h3-13H,2,14H2,1H3,(H,30,31)(H,27,28,32) DMOIX5S CS CCOC1=NC2=CC=CC(=C2N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NOC(=O)N5)C(=O)O DMOIX5S IK KGSXMPPBFPAXLY-UHFFFAOYSA-N DMOIX5S IU 2-ethoxy-3-[[4-[2-(5-oxo-4H-1,2,4-oxadiazol-3-yl)phenyl]phenyl]methyl]benzimidazole-4-carboxylic acid DMOIX5S CA CAS 147403-03-0 DMOIX5S CB CHEBI:68850 DMOIX5S DE Hypertension DMIR5QP ID DMIR5QP DMIR5QP DN Azlocillin DMIR5QP HS Approved DMIR5QP SN Azlocilina; Azlocilline; Azlocillinum; Securopen; Bayer Brand of Azlocillin; Azlocilina [INN-Spanish]; Azlocillin Sodium (Sterile); Azlocilline [INN-French]; Azlocillinum [INN-Latin]; Bay-e 6905; Azlocillin (USAN/INN); Azlocillin [USAN:BAN:INN]; (2R,5R,6S)-3,3-dimethyl-7-oxo-6-[[(2R)-2-[(2-oxoimidazolidine-1-carbonyl)amino]-2-phenylacetyl]amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2R,5S,6S)-3,3-dimethyl-7-oxo-6-[[(2R)-2-[(2-oxoimidazolidine-1-carbonyl)amino]-2-phenylacetyl]amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-3,3-Dimethyl-7-oxo-6-((R)-2-(2-oxo-1-imidazolidinecarboxamido)-2-phenylacetamido)-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid; (2S,5R,6R)-3,3-dimethyl-7-oxo-6-[[(2R)-2-[(2-oxoimidazolidine-1-carbonyl)amino]-2-phenylacetyl]amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-3,3-dimethyl-7-oxo-6-[[(2S)-2-[(2-oxoimidazolidine-1-carbonyl)amino]-2-phenylacetyl]amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-3,3-dimethyl-7-oxo-6-[[2-[(2-oxoimidazolidine-1-carbonyl)amino]-2-phenylacetyl]amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-3,3-dimethyl-7-oxo-6-{[(2R)-2-{[(2-oxoimidazolidin-1-yl)carbonyl]amino}-2-phenylacetyl]amino}-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-3,3-dimethyl-7-oxo-6-{[(2S)-2-{[(2-oxoimidazolidin-1-yl)carbonyl]amino}-2-phenylacetyl]amino}-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5S,6R)-3,3-dimethyl-7-oxo-6-[[(2R)-2-[(2-oxoimidazolidine-1-carbonyl)amino]-2-phenylacetyl]amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2r,5s,6s)-3,3-dimethyl-7-oxo-6-{[(2r)-2-{[(2-oxoimidazolidin-1-yl)carbonyl]amino}-2-phenylacetyl]amino}-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (5R,6R)-3,3-dimethyl-7-oxo-6-[[(2R)-2-[(2-oxoimidazolidine-1-carbonyl)amino]-2-phenylacetyl]amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (6R)-3,3-dimethyl-7-oxo-6-[[2-[(2-oxoimidazolidine-1-carbonyl)amino]-2-phenylacetyl]amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 2,2-dimethyl-6beta-[(2R)-2-{[(2-oxoimidazolidin-1-yl)carbonyl]amino}-2-phenylacetamido]penam-3alpha-carboxylic acid; 3,3-dimethyl-7-oxo-6-[[2-[(2-oxoimidazolidine-1-carbonyl)amino]-2-phenylacetyl]amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 3,3-dimethyl-7-oxo-6-{[{[(2-oxoimidazolidin-1-yl)carbonyl]amino}(phenyl)acetyl]amino}-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 6-((R)-2-(2-Oxoimidazolidin-1-carboxamido)-2-phenylacetamido)penicillansaeure DMIR5QP CP Bayer Pharmaceuticals Corp DMIR5QP TC Antibiotics DMIR5QP DT Small molecular drug DMIR5QP PC 6479523 DMIR5QP MW 461.5 DMIR5QP FM C20H23N5O6S DMIR5QP IC InChI=1S/C20H23N5O6S/c1-20(2)13(17(28)29)25-15(27)12(16(25)32-20)22-14(26)11(10-6-4-3-5-7-10)23-19(31)24-9-8-21-18(24)30/h3-7,11-13,16H,8-9H2,1-2H3,(H,21,30)(H,22,26)(H,23,31)(H,28,29)/t11-,12-,13+,16-/m1/s1 DMIR5QP CS CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)NC(=O)N4CCNC4=O)C(=O)O)C DMIR5QP IK JTWOMNBEOCYFNV-NFFDBFGFSA-N DMIR5QP IU (2S,5R,6R)-3,3-dimethyl-7-oxo-6-[[(2R)-2-[(2-oxoimidazolidine-1-carbonyl)amino]-2-phenylacetyl]amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid DMIR5QP CA CAS 37091-66-0 DMIR5QP CB CHEBI:2956 DMIR5QP DE Pseudomonas infection DMDNJHG ID DMDNJHG DMDNJHG DN Aztreonam DMDNJHG HS Approved DMDNJHG SN Azactam; Primbactam; Azactam (TN); SQ-26776; Monobactam, SQ 26776, Squibb 26776, Aztreonam; [2S-[2alpha,3beta(Z)]]-2-[[[1-(2-Amino-4-thiazolyl)-2-[(2-methyl-4-oxo-1-sulfo-3-azetidinyl)amino]-2-oxoethylidene]amino]oxy]-2-methylpropanoic acid; 2-({[(1Z)-1-(2-amino-1,3-thiazol-4-yl)-2-{[(2S,3S)-2-methyl-4-oxo-1-sulfoazetidin-3-yl]amino}-2-oxoethylidene]amino}oxy)-2-methylpropanoic acid; 2-[(Z)-[1-(2-amino-1,3-thiazol-4-yl)-2-[[(2S,3S)-2-methyl-4-oxo-1-sulfoazetidin-3-yl]amino]-2-oxoethylidene]amino]oxy-2-methylpropanoic acid DMDNJHG CP Bristol-Myers Squibb Company DMDNJHG TC Antibiotics DMDNJHG DT Small molecular drug DMDNJHG PC 5742832 DMDNJHG MW 435.4 DMDNJHG FM C13H17N5O8S2 DMDNJHG IC InChI=1S/C13H17N5O8S2/c1-5-7(10(20)18(5)28(23,24)25)16-9(19)8(6-4-27-12(14)15-6)17-26-13(2,3)11(21)22/h4-5,7H,1-3H3,(H2,14,15)(H,16,19)(H,21,22)(H,23,24,25)/b17-8-/t5-,7-/m0/s1 DMDNJHG CS C[C@H]1[C@@H](C(=O)N1S(=O)(=O)O)NC(=O)/C(=N\\OC(C)(C)C(=O)O)/C2=CSC(=N2)N DMDNJHG IK WZPBZJONDBGPKJ-VEHQQRBSSA-N DMDNJHG IU 2-[(Z)-[1-(2-amino-1,3-thiazol-4-yl)-2-[[(2S,3S)-2-methyl-4-oxo-1-sulfoazetidin-3-yl]amino]-2-oxoethylidene]amino]oxy-2-methylpropanoic acid DMDNJHG CA CAS 78110-38-0 DMDNJHG CB CHEBI:161680 DMDNJHG DE Bacterial infection DMP54C7 ID DMP54C7 DMP54C7 DN Bacampicillin DMP54C7 HS Approved DMP54C7 SN Bacampicilina; Bacampicilline; Bacampicillinum; Penglobe; Bacampicillin hydrochloride; Bacampicilina [INN-Spanish]; Bacampicillin (INN); Bacampicillin [INN:BAN]; Bacampicilline [INN-French]; Bacampicillinum [INN-Latin]; Penglobe (TN); Spectrobid (TN); (2S,5R,6R)-6((R)-(2-Amino-2-phenylacetamido))-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid ester with ethyl 1-hydroxyethylcarbonate; 1'-Ethoxycarbonyloxyethyl-(6-D-alpha-aminophenylacetamido)penicillanate; 1-Ethoxycarbonyloxyethyl (2S,5R,6R)-6((R)-(2-amino-2-phenylacetamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptan-2-carboxylat; 1-[(ethoxycarbonyl)oxy]ethyl (2S,5R,6R)-6-{[(2R)-2-amino-2-phenylacetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate; 1-[(ethoxycarbonyl)oxy]ethyl 6beta-[(2R)-2-amino-2-phenylacetamido]-2,2-dimethylpenam-3alpha-carboxylate; 1-ethoxycarbonyloxyethyl (2S,5R)-6-[[(2R)-2-amino-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate; 1-ethoxycarbonyloxyethyl (2S,5R,6R)-6-[[(2R)-2-amino-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate; 1-ethoxycarbonyloxyethyl (2S,5R,6R)-6-[[(2S)-2-amino-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate; 6-((R)-2-Amino-2-phenylacetamido)penicillansaeure-(1-(ethoxycarbonyloxy)ethylester DMP54C7 CP Pfizer Pharmaceuticals DMP54C7 TC Antibiotics DMP54C7 DT Small molecular drug DMP54C7 PC 441397 DMP54C7 MW 465.5 DMP54C7 FM C21H27N3O7S DMP54C7 IC InChI=1S/C21H27N3O7S/c1-5-29-20(28)31-11(2)30-19(27)15-21(3,4)32-18-14(17(26)24(15)18)23-16(25)13(22)12-9-7-6-8-10-12/h6-11,13-15,18H,5,22H2,1-4H3,(H,23,25)/t11?,13-,14-,15+,18-/m1/s1 DMP54C7 CS CCOC(=O)OC(C)OC(=O)[C@H]1C(S[C@H]2N1C(=O)[C@H]2NC(=O)[C@@H](C3=CC=CC=C3)N)(C)C DMP54C7 IK PFOLLRNADZZWEX-FFGRCDKISA-N DMP54C7 IU 1-ethoxycarbonyloxyethyl (2S,5R,6R)-6-[[(2R)-2-amino-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate DMP54C7 CA CAS 50972-17-3 DMP54C7 CB CHEBI:2968 DMP54C7 DE Bacterial infection DM5OHYE ID DM5OHYE DM5OHYE DN Bacitracin DM5OHYE HS Approved DM5OHYE SN Altracin; Baciguent; Baciquent; Citracin; Fortracin; Bacitracin A; Bacitracin A1; Bacitracin A2a; Neosporin (TN); Solu-Tracin 50; Partyl-, (10.4)-lactam; L-Asparagine, N-[[(4R)-2-[(1S,2S)-1-amino-2-methylbutyl]-4,5-dihydro-4-thiazolyl]carbonyl]-L-leucyl-D-.alpha.-glutamyl-L-isoleucyl-L-lysyl-D-ornithyl-L-isoleucyl-D-phenylalanyl-L-histidyl-D-.alpha.-as; 11702_FLUKA; 11702_SIGMA DM5OHYE TC Antibiotics DM5OHYE DT Small molecular drug DM5OHYE PC 10909430 DM5OHYE MW 1422.7 DM5OHYE FM C66H103N17O16S DM5OHYE IC InChI=1S/C66H103N17O16S/c1-9-35(6)52(69)66-81-48(32-100-66)63(97)76-43(26-34(4)5)59(93)74-42(22-23-50(85)86)58(92)83-53(36(7)10-2)64(98)75-40-20-15-16-25-71-55(89)46(29-49(68)84)78-62(96)47(30-51(87)88)79-61(95)45(28-39-31-70-33-72-39)77-60(94)44(27-38-18-13-12-14-19-38)80-65(99)54(37(8)11-3)82-57(91)41(21-17-24-67)73-56(40)90/h12-14,18-19,31,33-37,40-48,52-54H,9-11,15-17,20-30,32,67,69H2,1-8H3,(H2,68,84)(H,70,72)(H,71,89)(H,73,90)(H,74,93)(H,75,98)(H,76,97)(H,77,94)(H,78,96)(H,79,95)(H,80,99)(H,82,91)(H,83,92)(H,85,86)(H,87,88)/t35-,36-,37-,40-,41+,42+,43-,44+,45-,46-,47+,48-,52-,53-,54-/m0/s1 DM5OHYE CS CC[C@H](C)[C@H]1C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)NCCCC[C@@H](C(=O)N[C@@H](C(=O)N1)CCCN)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CSC(=N2)[C@H]([C@@H](C)CC)N)CC(=O)N)CC(=O)O)CC3=CN=CN3)CC4=CC=CC=C4 DM5OHYE IK CLKOFPXJLQSYAH-ABRJDSQDSA-N DM5OHYE IU (4R)-4-[[(2S)-2-[[(4R)-2-[(1S,2S)-1-amino-2-methylbutyl]-4,5-dihydro-1,3-thiazole-4-carbonyl]amino]-4-methylpentanoyl]amino]-5-[[(2S,3S)-1-[[(3S,6R,9S,12R,15S,18R,21S)-3-(2-amino-2-oxoethyl)-18-(3-aminopropyl)-12-benzyl-15-[(2S)-butan-2-yl]-6-(carboxymethyl)-9-(1H-imidazol-5-ylmethyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclopentacos-21-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-5-oxopentanoic acid DM5OHYE CA CAS 1405-87-4 DM5OHYE CB CHEBI:35862 DM5OHYE DE Skin infection DMD2871 ID DMD2871 DMD2871 DN Bacitracin DMD2871 HS Approved DMD2871 SN Bacillus subtilis; Bacitracin Zinc free sample; Bacitracin zinc [USP]; Bacitracins zinc complex; Bacitracins, zinc complex; EPA Pesticide Chemical Code 006309; SC-18930; SCHEMBL543112; Ziba-RX; Zinc bacitracin; 5-((1-((9-((4H-imidazol-4-yl)methyl)-3-(2-amino-2-oxoethyl)-18-(3-aminopropyl)-12-benzyl-15-(sec-butyl)-6-(carboxymethyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptaazacyclopent; AKOS015896384; Albac; Caswell No. 909A; EINECS 215-787-8; FT-0622546; FT-0654564 DMD2871 PC 3083711 DMD2871 MW 1488.1 DMD2871 FM C66H103N17O16SZn DMD2871 IC QSNOBVJFKSQBBD-UHFFFAOYSA-N DMD2871 CS CCC(C)C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NCCCCC(C(=O)NC(C(=O)N1)CCCN)NC(=O)C(C(C)CC)NC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C2CSC(=N2)C(C(C)CC)N)CC(=O)N)CC(=O)O)CC3C=NC=N3)CC4=CC=CC=C4.[Zn] DMD2871 IK 1S/C66H103N17O16S.Zn/c1-9-35(6)52(69)66-81-48(32-100-66)63(97)76-43(26-34(4)5)59(93)74-42(22-23-50(85)86)58(92)83-53(36(7)10-2)64(98)75-40-20-15-16-25-71-55(89)46(29-49(68)84)78-62(96)47(30-51(87)88)79-61(95)45(28-39-31-70-33-72-39)77-60(94)44(27-38-18-13-12-14-19-38)80-65(99)54(37(8)11-3)82-57(91)41(21-17-24-67)73-56(40)90;/h12-14,18-19,31,33-37,39-48,52-54H,9-11,15-17,20-30,32,67,69H2,1-8H3,(H2,68,84)(H,71,89)(H,73,90)(H,74,93)(H,75,98)(H,76,97)(H,77,94)(H,78,96)(H,79,95)(H,80,99)(H,82,91)(H,83,92)(H,85,86)(H,87,88); DMD2871 IU 4-[[2-[[2-(1-amino-2-methylbutyl)-4,5-dihydro-1,3-thiazole-4-carbonyl]amino]-4-methylpentanoyl]amino]-5-[[1-[[3-(2-amino-2-oxoethyl)-18-(3-aminopropyl)-12-benzyl-15-butan-2-yl-6-(carboxymethyl)-9-(4H-imidazol-4-ylmethyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclopentacos-21-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-5-oxopentanoic acid;zinc DMD2871 CA CAS 1405-89-6 DMD2871 DE Pyothorax DM0QV1J ID DM0QV1J DM0QV1J DN Baclofen DM0QV1J HS Approved DM0QV1J SN Arbaclofen; (R)-Baclofen; 69308-37-8; (R)-4-Amino-3-(4-chlorophenyl)butanoic acid; d-Baclofen; (-)-Baclofen; (R)-(-)-Baclofen; R-Baclofen; R-(-)-Baclofen; STX209; (3R)-4-amino-3-(4-chlorophenyl)butanoic acid; UNII-NYU6UTW25B; l-Baclofen; STX 209; (R)-4-Amino-3-(4-chlorophenyl)butyric Acid; NYU6UTW25B; CHEMBL301742; AK109161; Benzenepropanoic acid, beta-(aminomethyl)-4-chloro-, (R)-; Benzeneporopanoic acid, (beta-(aminomethyl)-4-chloro-, (betaR)-; Arbaclofen [USAN:INN]; R-Baclofen RS; Arbaclofen (USAN); p-chlorophenyl GABA; ApoBaclofen; Atrofen; Baclofene; BaclofeneIrex; Baclofeno; Baclofenum; Baclon; Baclophen; Baclospas; Clofen; Gabalon; GenBaclofen; Genpharm; Kemstro; Lebic; Lioresal; NuBaclo; PMSBaclofen; ASTA Medica Brand of Baclofen; Alphapharm Brand of Baclofen; Apo Baclofen; Apotex Brand of Baclofen; Ashbourne Brand of Baclofen; Athena Brand of Baclofen; Baclofen AWD; Baclofen Alphapharm Brand; Baclofen Apotex Brand; Baclofen Ashbourne Brand; Baclofen Athena Brand; Baclofen Irex Brand; Baclofen Isis Brand; Baclofen Medtronic Brand; Baclofen Novartis Brand; Baclofen Pharmascience Brand; Baclofene Irex; Chlorophenyl GABA; Ciba Geigy Brand of Baclofen; Gen Baclofen; Irex Brand of Baclofen; Isis Brand of Baclofen; Lioresal Intrathecal; Medtronic Brand of Baclofen; Novartis Brand of Baclofen; Nu Baclo; Nu Pharm Brand of Baclofen; PMS Baclofen; Pharmascience Brand of Baclofen; B 5399; Ba 34647; Ba34647; C 34647Ba; AWD, Baclofen; Apo-Baclofen; Ba-34647; Ba34,647; Baclofen Ciba-Geigy Brand; Baclofen Nu-Pharm Brand; Baclofene [INN-French]; Baclofene-Irex; Baclofeno [INN-Spanish]; Baclofenum [INN-Latin]; CIBA34,647BA; Ciba-Geigy Brand of Baclofen; DL-Baclofen; GABA, Chlorophenyl; Gen-Baclofen; Kemstro (TN); Lioresal (TN); Nu-Baclo; Nu-Baclofen; Nu-Pharm Brand of Baclofen; PCP-GABA; Pms-Baclofen; Ba-34,647; Baclofen (R,S); Ciba 34,647-Ba; Baclofen (JP15/USP/INN); Baclofen [USAN:INN:BAN:JAN]; Beta-(4-Chlorophenyl)gaba; CIBA-34,647-BA; Beta-(Aminomethyl)-4-chlorobenzenepropanoic acid; Beta-(Aminomethyl)-p-chlorohydrocinnamic acid; Beta-(p-Chlorophenyl)-gamma-aminobutyric acid; DL-4-Amino-3-p-chlorophenylbutanoic acid; Gamma-Amino-beta-(p-chlorophenyl)butyric acid; Benzenepropanoic acid, beta-(aminomethyl)-4-chloro-(9CI); (+-)-Baclofen; (+/-)-BACLOFEN; (+/-)-beta-(Aminoethyl)-4-chlorobenzenepropanoic acid; (+/-)-beta-(Aminomethyl)-4-chlorobenzenepropanoic acid; (inverted question mark)-Baclofen; 4-Amino-3-(4-chlorophenyl)butanoic acid; 4-Amino-3-(4-chlorophenyl)butyric acid; (R)-4-Amino-3-(4-chloro-phenyl)-butyric acid DM0QV1J CP Norvatis Phamaceuticals Corporation DM0QV1J TC Muscle Relaxants DM0QV1J DT Small molecular drug DM0QV1J PC 2284 DM0QV1J MW 213.66 DM0QV1J FM C10H12ClNO2 DM0QV1J IC InChI=1S/C10H12ClNO2/c11-9-3-1-7(2-4-9)8(6-12)5-10(13)14/h1-4,8H,5-6,12H2,(H,13,14) DM0QV1J CS C1=CC(=CC=C1C(CC(=O)O)CN)Cl DM0QV1J IK KPYSYYIEGFHWSV-UHFFFAOYSA-N DM0QV1J IU 4-amino-3-(4-chlorophenyl)butanoic acid DM0QV1J CA CAS 1134-47-0 DM0QV1J CB CHEBI:2972 DM0QV1J DE Multiple sclerosis; Fragile X syndrome DMPWNDB ID DMPWNDB DMPWNDB DN Balofloxacin DMPWNDB HS Approved DMPWNDB SN Baloxin; Balofloxacin [INN]; Q 35; (+-)-1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-(methylamino)piperidino)-4-oxo-3-quinoline arboxylic acid; (+-)-1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-(methylamino)piperidino)-4-oxo-3-quinolinecarboxylic acid; 1-cyclopropyl-6-fluoro-8-methoxy-7-[3-(methylamino)piperidin-1-yl]-4-oxoquinoline-3-carboxylic acid DMPWNDB CP Chugai DMPWNDB DT Small molecular drug DMPWNDB PC 65958 DMPWNDB MW 389.4 DMPWNDB FM C20H24FN3O4 DMPWNDB IC InChI=1S/C20H24FN3O4/c1-22-11-4-3-7-23(9-11)17-15(21)8-13-16(19(17)28-2)24(12-5-6-12)10-14(18(13)25)20(26)27/h8,10-12,22H,3-7,9H2,1-2H3,(H,26,27) DMPWNDB CS CNC1CCCN(C1)C2=C(C=C3C(=C2OC)N(C=C(C3=O)C(=O)O)C4CC4)F DMPWNDB IK MGQLHRYJBWGORO-UHFFFAOYSA-N DMPWNDB IU 1-cyclopropyl-6-fluoro-8-methoxy-7-[3-(methylamino)piperidin-1-yl]-4-oxoquinoline-3-carboxylic acid DMPWNDB CA CAS 127294-70-6 DMPWNDB DE Gram-positive bacterial infection DM1UV7F ID DM1UV7F DM1UV7F DN Baloxavir marboxil DM1UV7F HS Approved DM1UV7F SN UNII-505CXM6OHG; 505CXM6OHG; Xofluza (TN); Baloxavir marboxil [INN]; Baloxavir marboxil (JAN/INN); SCHEMBL20108731; EX-A1867; HY-109025; CS-0030527 DM1UV7F CP Shionogi/Roche DM1UV7F PC 124081896 DM1UV7F MW 571.6 DM1UV7F FM C27H23F2N3O7S DM1UV7F IC InChI=1S/C27H23F2N3O7S/c1-36-27(35)39-14-38-25-19(33)8-9-31-24(25)26(34)30-10-11-37-12-21(30)32(31)23-15-6-7-18(28)22(29)17(15)13-40-20-5-3-2-4-16(20)23/h2-9,21,23H,10-14H2,1H3/t21-,23+/m1/s1 DM1UV7F CS COC(=O)OCOC1=C2C(=O)N3CCOC[C@H]3N(N2C=CC1=O)[C@H]4C5=C(CSC6=CC=CC=C46)C(=C(C=C5)F)F DM1UV7F IK RZVPBGBYGMDSBG-GGAORHGYSA-N DM1UV7F IU [(3R)-2-[(11S)-7,8-difluoro-6,11-dihydrobenzo[c][1]benzothiepin-11-yl]-9,12-dioxo-5-oxa-1,2,8-triazatricyclo[8.4.0.03,8]tetradeca-10,13-dien-11-yl]oxymethyl methyl carbonate DM1UV7F CA CAS 1985606-14-1 DM1UV7F DE Influenza virus infection DMRJ9EN ID DMRJ9EN DMRJ9EN DN Baloxavir marboxil DMRJ9EN HS Approved DMRJ9EN SN (((R)-12-((S)-7,8-difluoro-6,11-dihydrodibenzo[b,e]thiepin-11-yl)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H-[1,4]oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazin-7-yl)oxy)methyl methyl carbonate; Baloxavir marboxil; Baloxavir marboxil (JAN/INN); Baloxavir marboxil [INN]; Xofluza (TN) DMRJ9EN TC Antiviral Agents DMRJ9EN DT Small molecular drug DMRJ9EN PC 124081896 DMRJ9EN MW 571.552 DMRJ9EN FM C27H23F2N3O7S DMRJ9EN IC InChI=1S/C27H23F2N3O7S/c1-36-27(35)39-14-38-25-19(33)8-9-31-24(25)26(34)30-10-11-37-12-21(30)32(31)23-15-6-7-18(28)22(29)17(15)13-40-20-5-3-2-4-16(20)23/h2-9,21,23H,10-14H2,1H3/t21-,23+/m1/s1 DMRJ9EN CS COC(=O)OCOC1=C2C(=O)N3CCOCC3N(N2C=CC1=O)C4C5=C(CSC6=CC=CC=C46)C(=C(C=C5)F)F DMRJ9EN IK RZVPBGBYGMDSBG-GGAORHGYSA-N DMRJ9EN IU [(3R)-2-[(11S)-7,8-difluoro-6,11-dihydrobenzo[c][1]benzothiepin-11-yl]-9,12-dioxo-5-oxa-1,2,8-triazatricyclo[8.4.0.03,8]tetradeca-10,13-dien-11-yl]oxymethyl methyl carbonate DMRJ9EN CA CAS 1985606-14-1 DMRJ9EN DE Influenza A infection DM7I1T9 ID DM7I1T9 DM7I1T9 DN Balsalazide DM7I1T9 HS Approved DM7I1T9 SN Balsalazida; Balsalazida [Spanish]; Balsalazide Disodium; Balsalazide [INN:BAN]; Balsalazido; Balsalazido [Spanish]; Balsalazidum; Balsalazidum [Latin]; BX-661A; Colazide; BALSALAZIDE; P80AL8J7ZP; (E)-5-((4-(((2-Carboxyethyl)amino)carbonyl)phenyl)azo)-2-hydroxybenzoic acid; (E)-5-((4-((2-Carboxyethyl)carbamoyl)phenyl)diazenyl)-2-hydroxybenzoic acid; (E)-5-({p-[(2-carboxyethyl)carbamoyl]phenyl}azo)-2-salicylic acid; 80573-04-2; C17H15N3O6; CHEBI:267413; UNII-P80AL8J7ZP DM7I1T9 PC 54585 DM7I1T9 MW 357.32 DM7I1T9 FM C17H15N3O6 DM7I1T9 IC IPOKCKJONYRRHP-UHFFFAOYSA-N DM7I1T9 CS C1=CC(=CC=C1C(=O)NCCC(=O)O)N=NC2=CC(=C(C=C2)O)C(=O)O DM7I1T9 IK 1S/C17H15N3O6/c21-14-6-5-12(9-13(14)17(25)26)20-19-11-3-1-10(2-4-11)16(24)18-8-7-15(22)23/h1-6,9,21H,7-8H2,(H,18,24)(H,22,23)(H,25,26) DM7I1T9 IU 5-[[4-(2-carboxyethylcarbamoyl)phenyl]diazenyl]-2-hydroxybenzoic acid DM7I1T9 CA CAS 80573-04-2 DM7I1T9 CB CHEBI:267413 DM7I1T9 DE Ulcerative colitis DMO091F ID DMO091F DMO091F DN Balsalazide DMO091F HS Approved DMO091F SN Balsalazida; Balsalazido; Balsalazidum; Colazal; Balsalazida [Spanish]; Balsalazide Disodium; Balsalazido [Spanish]; Balsalazidum [Latin]; Balsalazide (INN); Balsalazide [INN:BAN]; Colazal (TN); Colazide (TN); (3Z)-3-[[4-(2-carboxyethylcarbamoyl)phenyl]hydrazinylidene]-6-oxocyclohexa-1,4-diene-1-carboxylic acid; (E)-5-((4-(((2-Carboxyethyl)amino)carbonyl)phenyl)azo)-2-hydroxybenzoic acid; (E)-5-({p-[(2-carboxyethyl)carbamoyl]phenyl}azo)-2-salicylic acid; 3-(2-{4-[(2-carboxyethyl)carbamoyl]phenyl}hydrazinylidene)-6-oxocyclohexa-1,4-diene-1-carboxylic acid; 5-[(E)-{4-[(2-carboxyethyl)carbamoyl]phenyl}diazenyl]-2-hydroxybenzoic acid; 5-[4-(2-carboxy-ethylcarbamoyl)-phenylazo]-2-hydroxy-benzoic acid DMO091F TC Antiinflammatory Agents DMO091F DT Small molecular drug DMO091F PC 54585 DMO091F MW 357.32 DMO091F FM C17H15N3O6 DMO091F IC InChI=1S/C17H15N3O6/c21-14-6-5-12(9-13(14)17(25)26)20-19-11-3-1-10(2-4-11)16(24)18-8-7-15(22)23/h1-6,9,21H,7-8H2,(H,18,24)(H,22,23)(H,25,26) DMO091F CS C1=CC(=CC=C1C(=O)NCCC(=O)O)N=NC2=CC(=C(C=C2)O)C(=O)O DMO091F IK IPOKCKJONYRRHP-UHFFFAOYSA-N DMO091F IU 5-[[4-(2-carboxyethylcarbamoyl)phenyl]diazenyl]-2-hydroxybenzoic acid DMO091F CA CAS 80573-04-2 DMO091F CB CHEBI:267413 DMO091F DE Inflammatory bowel disease DMKLSHF ID DMKLSHF DMKLSHF DN Bambuterol DMKLSHF HS Approved DMKLSHF SN Bambec; Bambuterolum; Oxeol; Bambuterolum [Latin]; Terbutaline bisdimethylcarbamate; Bambec (TN); Bambuterol (INN); Bambuterol [BAN:INN]; KWD-2183; Oxeol (TN); Terbutaline bis(dimethylcarbamate); [3-[2-(tert-butylamino)-1-hydroxyethyl]-5-(dimethylcarbamoyloxy)phenyl] N,N-dimethylcarbamate; (+-)-5-(2-(tert-Butylamino)-1-hydroxyethyl)-m-phenylene bis(dimethylcarbamate); 5-(2-(tert-butylamino)-1-hydroxyethyl)-3-phenylene bis(dimethylcarbamate); 5-[2-(tert-butylamino)-1-hydroxyethyl]benzene-1,3-diyl bis(dimethylcarbamate) DMKLSHF CP AstraZeneca DMKLSHF TC Bronchodilator Agents DMKLSHF DT Small molecular drug DMKLSHF PC 54766 DMKLSHF MW 367.4 DMKLSHF FM C18H29N3O5 DMKLSHF IC InChI=1S/C18H29N3O5/c1-18(2,3)19-11-15(22)12-8-13(25-16(23)20(4)5)10-14(9-12)26-17(24)21(6)7/h8-10,15,19,22H,11H2,1-7H3 DMKLSHF CS CC(C)(C)NCC(C1=CC(=CC(=C1)OC(=O)N(C)C)OC(=O)N(C)C)O DMKLSHF IK ANZXOIAKUNOVQU-UHFFFAOYSA-N DMKLSHF IU [3-[2-(tert-butylamino)-1-hydroxyethyl]-5-(dimethylcarbamoyloxy)phenyl] N,N-dimethylcarbamate DMKLSHF CA CAS 81732-65-2 DMKLSHF CB CHEBI:553827 DMKLSHF DE Asthma DMXLHYN ID DMXLHYN DMXLHYN DN Bamifylline DMXLHYN HS Approved DMXLHYN SN Bamifylline hydrochloride; Trentadil; Pulmac; Bamifylline HCl; Bamiphylline hydrochloride; 20684-06-4; mono-HCl; Benzetamophylline hydrochloride; UNII-66466QLM3S; 8102 CB; BAX 2793Z; Bamifylline hydrochloride [USAN]; EINECS 243-967-6; AC 3810; CB 8102; 66466QLM3S; 8-Benzyl-7-(2-(ethyl(2-hydroxyethyl)amino)ethyl)theophylline monohydrochloride; 8'-Benzyl-7-(2-(ethyl(2-hydroxyethyl)amino)ethyl)theophylline hydrochloride; 8-Benzyl-7-(N-ethyl-N-(beta-hydroxyethyl)aminoethyl)theophylline hydrochloride DMXLHYN DT Small molecular drug DMXLHYN PC 16229 DMXLHYN MW 385.5 DMXLHYN FM C20H27N5O3 DMXLHYN IC InChI=1S/C20H27N5O3/c1-4-24(12-13-26)10-11-25-16(14-15-8-6-5-7-9-15)21-18-17(25)19(27)23(3)20(28)22(18)2/h5-9,26H,4,10-14H2,1-3H3 DMXLHYN CS CCN(CCN1C(=NC2=C1C(=O)N(C(=O)N2C)C)CC3=CC=CC=C3)CCO DMXLHYN IK VVUYEFBRTFASAH-UHFFFAOYSA-N DMXLHYN IU 8-benzyl-7-[2-[ethyl(2-hydroxyethyl)amino]ethyl]-1,3-dimethylpurine-2,6-dione DMXLHYN CA CAS 2016-63-9 DMXLHYN CB CHEBI:135605 DMXLHYN DE Chronic obstructive pulmonary disease DME1DJX ID DME1DJX DME1DJX DN Baquting DME1DJX HS Approved DME1DJX CP China Nuokang Bio-Pharmaceutical Inc DME1DJX DE Bleeding disorder DMJ8NMC ID DMJ8NMC DMJ8NMC DN Barbital DMJ8NMC HS Approved DMJ8NMC SN Barbitale; Barbitalum; Barbitone; Barbitonum; DEBA; Diemal; Diemalum; Diethylbarbitone; Diethylmalonylurea; Dormileno; Dormonal; Ethylbarbital; Hypnogene; Malonal; Medinal; Sedeval; Uronal; Veroletten; Verolettin; Veronal; Vesperal; Barbital Faes Brand; Barbitale [DCIT]; Diethylbarbituric acid; Faes Brand of Barbital; Barbital (TN); Barbital (VAN); Barbital [INN:JAN]; Barbitalum [INN-Latin]; Veronal (TN); Barbital (JP15/INN); Kyselina 5,5-diethylbarbiturova; Kyselina 5,5-diethylbarbiturova [Czech]; 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5,5-diethyl-(9CI); 5,5-Diethyl-2,4,6(1H,3H,5H)-pyrimidinetrione; 5,5-Diethylbarbituric acid; 5,5-diethyl-1,3-diazinane-2,4,6-trione; 5,5-diethylpyrimidine-2,4,6(1H,3H,5H)-trione; 7979P DMJ8NMC CP Schering-Plough DMJ8NMC TC Hypnotics and Sedatives DMJ8NMC DT Small molecular drug DMJ8NMC PC 2294 DMJ8NMC MW 184.19 DMJ8NMC FM C8H12N2O3 DMJ8NMC IC InChI=1S/C8H12N2O3/c1-3-8(4-2)5(11)9-7(13)10-6(8)12/h3-4H2,1-2H3,(H2,9,10,11,12,13) DMJ8NMC CS CCC1(C(=O)NC(=O)NC1=O)CC DMJ8NMC IK FTOAOBMCPZCFFF-UHFFFAOYSA-N DMJ8NMC IU 5,5-diethyl-1,3-diazinane-2,4,6-trione DMJ8NMC CA CAS 57-44-3 DMJ8NMC CB CHEBI:31252 DMJ8NMC DE Insomnia DMJIA6T ID DMJIA6T DMJIA6T DN Barbiturate DMJIA6T HS Approved DMJIA6T SN Barbituric acid; BARBITURIC ACID; 67-52-7; Malonylurea; 6-Hydroxyuracil; 2,4,6(1H,3H,5H)-Pyrimidinetrione; Pyrimidinetrione; pyrimidine-2,4,6(1H,3H,5H)-trione; 2,4,6-Pyrimidinetrione; Malonylharnstoff; 2,4,6-Trioxohexahydropyrimidine; 1,3-diazinane-2,4,6-trione; Barbitursaeure; Hexahydropyrimidine-2,4,6-trione; Hydrouracil, 6-hydroxy-; Barbituric acid (VAN); Urea, N,N'-(1,3-dioxo-1,3-propanediyl)-; NSC 7889; UNII-WQ92Y2793G; 2,4,6-Pyrimidinetrione(1H,3H,5H); Barbituric acid (VAN) (8CI); CHEBI:16294; EINECS 200-658-0; Barbitursaeure; Pyrimidinetriol; Barbiturate anion; Sodiumbarbiturate; AG-670/31547005; Hexahydro-pyrimidine-2,4,6-trione; Pyrimidine-2,4,6(1H,3H,5H)-trione; 1,2,3,4,5,6-Hexahydro-2,4,6-pyrimidinetrione; 11709_FLUKA; 2,4,6-(1H,3H,5H)-Pyrimidinetrione; 2,4,6-Pyrimidinetriol; 2,4,6-Trihydroxypyrimidine; 2,4,6-trioxotetrahydro-2H-pyrimidin-1-ide; 4,6-dioxo-1H-pyrimidin-2-olate DMJIA6T DT Small molecular drug DMJIA6T PC 6211 DMJIA6T MW 128.09 DMJIA6T FM C4H4N2O3 DMJIA6T IC InChI=1S/C4H4N2O3/c7-2-1-3(8)6-4(9)5-2/h1H2,(H2,5,6,7,8,9) DMJIA6T CS C1C(=O)NC(=O)NC1=O DMJIA6T IK HNYOPLTXPVRDBG-UHFFFAOYSA-N DMJIA6T IU 1,3-diazinane-2,4,6-trione DMJIA6T CA CAS 67-52-7 DMJIA6T CB CHEBI:16294 DMJIA6T DE Depression; Anaesthesia DM4ONW5 ID DM4ONW5 DM4ONW5 DN Baricitinib DM4ONW5 HS Approved DM4ONW5 SN Baricitinib (LY3009104, INCB028050); Baricitinib [USAN:INN]; C16H17N7O2S; INCB 028050; INCB-028050; INCB028050; ISP4442I3Y; J-503551; LY-3009104; LY3009104; Olumiant (TN); UNII-ISP4442I3Y; olumiant DM4ONW5 CP Incyte/Eli Lilly DM4ONW5 DT Small molecular drug DM4ONW5 PC 44205240 DM4ONW5 MW 371.4 DM4ONW5 FM C16H17N7O2S DM4ONW5 IC InChI=1S/C16H17N7O2S/c1-2-26(24,25)22-9-16(10-22,4-5-17)23-8-12(7-21-23)14-13-3-6-18-15(13)20-11-19-14/h3,6-8,11H,2,4,9-10H2,1H3,(H,18,19,20) DM4ONW5 CS CCS(=O)(=O)N1CC(C1)(CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3 DM4ONW5 IK XUZMWHLSFXCVMG-UHFFFAOYSA-N DM4ONW5 IU 2-[1-ethylsulfonyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile DM4ONW5 CA CAS 1187594-09-7 DM4ONW5 CB CHEBI:95341 DM4ONW5 DE Rheumatoid arthritis DMWNRZT ID DMWNRZT DMWNRZT DN Basiliximab DMWNRZT HS Approved DMWNRZT SN Simulect (TN) DMWNRZT CP Norvatis Phamaceuticals Corporation DMWNRZT TC Immunomodulatory Agents DMWNRZT DT Monoclonal antibody DMWNRZT SQ Basiliximab heavy chain: QLQQSGTVLARPGASVKMSCKASGYSFTRYWMHWIKQRPGQGLEWIGAIYPGNSDTSYNQKFEGKAKLTAVTSASTAYMELSSLTHEDSAVYYCSRDYGYYFDFWGQGTTLTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK >Basiliximab light chainQIVSTQSPAIMSASPGEKVTMTCSASSSRSYMQWYQQKPGTSPKRWIYDTSKLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCHQRSSYTFGGGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGE DMWNRZT DE Organ transplant rejection DMU9C8F ID DMU9C8F DMU9C8F DN Bavencio DMU9C8F HS Approved DMU9C8F CP EMD Serono Rockland, MA Pfizer New York, NY DMU9C8F DT Monoclonal antibody DMU9C8F DE Melanoma; Merkel cell carcinoma; Breast cancer; Gastric adenocarcinoma; Haematological malignancy; Head and neck cancer; Squamous cell carcinoma; Urothelial carcinoma; Colon cancer; Testicular cancer DMLOS5R ID DMLOS5R DMLOS5R DN Bay 80-6946 DMLOS5R HS Approved DMLOS5R SN Copanlisib; BAY-80-6946; Aliqopa; UNII-WI6V529FZ9; BAY80-6946; WI6V529FZ9; AK172384; BAY 80-6946 (Copanlisib); Copanlisib [USAN:INN]; Copanlisib (USAN/INN); GTPL7875; SCHEMBL1655478; SCHEMBL13084037; Copanlisib (BAY 80-6946); DTXS DMLOS5R CP Bayer HealthCare Pharmaceuticals DMLOS5R DT Small molecular drug DMLOS5R PC 135565596 DMLOS5R MW 480.5 DMLOS5R FM C23H28N8O4 DMLOS5R IC InChI=1S/C23H28N8O4/c1-33-19-17(35-10-2-6-30-8-11-34-12-9-30)4-3-16-18(19)28-23(31-7-5-25-20(16)31)29-21(32)15-13-26-22(24)27-14-15/h3-4,13-14,25H,2,5-12H2,1H3,(H2,24,26,27) DMLOS5R CS COC1=C(C=CC2=C3NCCN3C(=NC(=O)C4=CN=C(N=C4)N)N=C21)OCCCN5CCOCC5 DMLOS5R IK MWYDSXOGIBMAET-UHFFFAOYSA-N DMLOS5R IU 2-amino-N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydro-1H-imidazo[1,2-c]quinazolin-5-ylidene]pyrimidine-5-carboxamide DMLOS5R CA CAS 1032568-63-0 DMLOS5R DE Follicular lymphoma; Non-hodgkin lymphoma DMY85QW ID DMY85QW DMY85QW DN Bazedoxifene DMY85QW HS Approved DMY85QW SN Brilence; Conbriza; Viviant; Bazedoxifene acetate; TSE-424; WAY-140424; WAY-TES 424 DMY85QW CP Ligand Pharmaceuticals Inc DMY85QW DT Small molecular drug DMY85QW PC 154257 DMY85QW MW 470.6 DMY85QW FM C30H34N2O3 DMY85QW IC InChI=1S/C30H34N2O3/c1-22-28-20-26(34)12-15-29(28)32(30(22)24-8-10-25(33)11-9-24)21-23-6-13-27(14-7-23)35-19-18-31-16-4-2-3-5-17-31/h6-15,20,33-34H,2-5,16-19,21H2,1H3 DMY85QW CS CC1=C(N(C2=C1C=C(C=C2)O)CC3=CC=C(C=C3)OCCN4CCCCCC4)C5=CC=C(C=C5)O DMY85QW IK UCJGJABZCDBEDK-UHFFFAOYSA-N DMY85QW IU 1-[[4-[2-(azepan-1-yl)ethoxy]phenyl]methyl]-2-(4-hydroxyphenyl)-3-methylindol-5-ol DMY85QW CA CAS 198481-32-2 DMY85QW CB CHEBI:135947 DMY85QW DE Osteopetrosis DM1R5X4 ID DM1R5X4 DM1R5X4 DN Becaplermin DM1R5X4 HS Approved DM1R5X4 SN Regranex; Regranex (TN); Becaplermin (USAN/INN) DM1R5X4 CP Ortho-McNeil Pharmaceutical DM1R5X4 TC Antiulcer Agents DM1R5X4 SQ DB00102 sequence: SLGSLTIAEPAMIAECKTRTEVFEISRRLIDRTNANFLVWPPCVEVQRCSGCCNNRNVQCRPTQVQLRPVQVRKIEIVRKKPIFKKATVTLEDHLACKCETVAAARPVT DM1R5X4 DE Diabetic complication DMZPHIK ID DMZPHIK DMZPHIK DN Beclomethasone DMZPHIK HS Approved DMZPHIK SN Anceron; Beclocort; Beclometason; Beclometasona; Beclometasonum; Becloval; Becodisks; Beconasol; Becotide; Inalone; Viarex; Beclometasondipropionat Mikron; Beclometasone [INN]; Vancenase AQ; B 0385; BMJ 5800; Beclometason (TN); Beclometasona [INN-Spanish]; Beclometasone (INN); Beclometasonum [INN-Latin]; Beconase (TN); Clipper (TN); Propaderm (TN); Vancenase (TN); (11beta,16beta)-9-chloro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione; (8R,9S,10S,11S,13R,14R,16R,17R)-9-chloro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; (8S,9R,10S,11S,13S,14S,16S,17R)-9-chloro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; 9-Chloro-11beta,17,21-trihydroxy-16beta-methylpregna-1,4-diene-3,20-dione; 9-chloro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; 9alpha-Chloro-11beta,17alpha,21-trihydroxy-16beta-methylpregna-1,4-diene-3,20-dione; 9alpha-Chloro-16beta-methyl-1,4-pregnadiene-11beta,17alpha,21-triol-3,20-dione; 9alpha-Chloro-16beta-methylprednisolone DMZPHIK CP Shire Pharmaceuticals DMZPHIK TC Antiasthmatic Agents DMZPHIK DT Small molecular drug DMZPHIK PC 20469 DMZPHIK MW 408.9 DMZPHIK FM C22H29ClO5 DMZPHIK IC InChI=1S/C22H29ClO5/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,23)17(26)10-20(16,3)22(12,28)18(27)11-24/h6-7,9,12,15-17,24,26,28H,4-5,8,10-11H2,1-3H3/t12-,15-,16-,17-,19-,20-,21-,22-/m0/s1 DMZPHIK CS C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)Cl)C DMZPHIK IK NBMKJKDGKREAPL-DVTGEIKXSA-N DMZPHIK IU (8S,9R,10S,11S,13S,14S,16S,17R)-9-chloro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one DMZPHIK CA CAS 4419-39-0 DMZPHIK CB CHEBI:3001 DMZPHIK DE Allergic rhinitis; Asthma DM3906J ID DM3906J DM3906J DN Bedaquiline DM3906J HS Approved DM3906J SN SIRTURO (TN) DM3906J CP Johnson & Johnson DM3906J DT Small molecular drug DM3906J PC 5388906 DM3906J MW 555.5 DM3906J FM C32H31BrN2O2 DM3906J IC InChI=1S/C32H31BrN2O2/c1-35(2)19-18-32(36,28-15-9-13-22-10-7-8-14-26(22)28)30(23-11-5-4-6-12-23)27-21-24-20-25(33)16-17-29(24)34-31(27)37-3/h4-17,20-21,30,36H,18-19H2,1-3H3/t30-,32-/m1/s1 DM3906J CS CN(C)CC[C@@](C1=CC=CC2=CC=CC=C21)([C@H](C3=CC=CC=C3)C4=C(N=C5C=CC(=CC5=C4)Br)OC)O DM3906J IK QUIJNHUBAXPXFS-XLJNKUFUSA-N DM3906J IU (1R,2S)-1-(6-bromo-2-methoxyquinolin-3-yl)-4-(dimethylamino)-2-naphthalen-1-yl-1-phenylbutan-2-ol DM3906J CA CAS 843663-66-1 DM3906J CB CHEBI:72292 DM3906J DE Multi-drug resistant tuberculosis DM8WCXM ID DM8WCXM DM8WCXM DN Befunolol hci DM8WCXM HS Approved DM8WCXM SN Bentox (TN) DM8WCXM DT Small molecular drug DM8WCXM PC 38286 DM8WCXM MW 327.8 DM8WCXM FM C16H22ClNO4 DM8WCXM IC InChI=1S/C16H21NO4.ClH/c1-10(2)17-8-13(19)9-20-14-6-4-5-12-7-15(11(3)18)21-16(12)14;/h4-7,10,13,17,19H,8-9H2,1-3H3;1H DM8WCXM CS CC(C)[NH2+]CC(COC1=CC=CC2=C1OC(=C2)C(=O)C)O.[Cl-] DM8WCXM IK TVVTWOGRPVJKDJ-UHFFFAOYSA-N DM8WCXM IU [3-[(2-acetyl-1-benzofuran-7-yl)oxy]-2-hydroxypropyl]-propan-2-ylazanium;chloride DM8WCXM CA CAS 39543-79-8 DM8WCXM CB CHEBI:31254 DM8WCXM DE Glaucoma/ocular hypertension DMBT3AI ID DMBT3AI DMBT3AI DN Belantamab mafodotin DMBT3AI HS Approved DMBT3AI DT Antibody drug conjugate DMBT3AI DE Multiple myeloma DMXLYQF ID DMXLYQF DMXLYQF DN Belatacept DMXLYQF HS Approved DMXLYQF SN Nulojix (TN); Belatacept (USAN/INN) DMXLYQF CP Bristol-Myers Squibb DMXLYQF SQ sequence for belatacept: MHVAQPAVVLASSRGIASFVCEYASPGKYTEVRVTVLRQADSQVTEVCAATYMMGNELTFLDDSICTGTSSGNQVNLTIQGLRAMDTGLYICKVELMYPPPYYEGIGNGTQIYVIDPEPCPDSDQEPKSSDKTHTSPPSPAPELLGGSSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK DMXLYQF DE Kidney transplant rejection; Heart transplant rejection DM3OBQF ID DM3OBQF DM3OBQF DN Belimumab DM3OBQF HS Approved DM3OBQF SN Belimumab (USAN); LymphoStat-B; LymphoStat-B (TN) DM3OBQF CP GSK DM3OBQF DT Antibody DM3OBQF DE Systemic lupus erythematosus DM2RBWK ID DM2RBWK DM2RBWK DN Belladonna DM2RBWK HS Approved DM2RBWK DE Colitis DM3SRJZ ID DM3SRJZ DM3SRJZ DN Belotecan hydrocholoride DM3SRJZ HS Approved DM3SRJZ DE Small-cell lung cancer DM1CI9R ID DM1CI9R DM1CI9R DN Bempedoic acid DM1CI9R HS Approved DM1CI9R SN ETC-1002; bempedoic acid; 738606-46-7; 8-Hydroxy-2,2,14,14-tetramethylpentadecanedioic acid; ESP-55016; UNII-1EJ6Z6Q368; ETC 1002; Bempedoic acid; ESP-55016; 1EJ6Z6Q368; Bempedoate; Bempedoic acid [USAN:INN]; ETC1002; ESP 55016; Bempedoic acid (USAN/INN); SCHEMBL185768; GTPL8321; CHEMBL3545313; HYHMLYSLQUKXKP-UHFFFAOYSA-N; EX-A1243; ZINC3948738; BCP16083; s7953; AKOS027439916; CS-3952; DB11936; AK499358; AC-29040; AS-49804; HY-12357; Bempedoic Acid(ETC-1002;ESP-55016); D10691; Pentadecanedioic acid, 8-hydroxy-2,2,14,14-tetramethyl- DM1CI9R CP Esperion Therapeutics DM1CI9R DT Small molecular drug DM1CI9R PC 10472693 DM1CI9R MW 344.5 DM1CI9R FM C19H36O5 DM1CI9R IC InChI=1S/C19H36O5/c1-18(2,16(21)22)13-9-5-7-11-15(20)12-8-6-10-14-19(3,4)17(23)24/h15,20H,5-14H2,1-4H3,(H,21,22)(H,23,24) DM1CI9R CS CC(C)(CCCCCC(CCCCCC(C)(C)C(=O)O)O)C(=O)O DM1CI9R IK HYHMLYSLQUKXKP-UHFFFAOYSA-N DM1CI9R IU 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid DM1CI9R CA CAS 738606-46-7 DM1CI9R CB CHEBI:149601 DM1CI9R DE Cardiovascular disease; Familial hypercholesterolemia DMH1M9B ID DMH1M9B DMH1M9B DN Benazepril DMH1M9B HS Approved DMH1M9B SN Benazapril; Benazeprilum; Benzazepril; Benazepril Sandoz; Benazeprilum [Latin]; Forteekor [veterinary]; Benazepril (INN); Benazepril Sandoz (TN); Benazepril [INN:BAN]; Forteekor [veterinary] (TN); Fortekor (TN); Lotensin (TN); CGS-14824-A; [(3S)-3-{[(1S)-1-(ethoxycarbonyl)-3-phenylpropyl]amino}-2-oxo-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl]acetic acid; [(3S)-3-({(1S)-1-[(ethyloxy)carbonyl]-3-phenylpropyl}amino)-2-oxo-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl]acetic acid; [(3S)-3-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}-2-oxo-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl]acetic acid; 2-[(3S)-3-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]-2-oxo-4,5-dihydro-3H-1-benzazepin-1-yl]acetic acid DMH1M9B CP Norvatis Phamaceuticals Corporation DMH1M9B TC Antihypertensive Agents DMH1M9B DT Small molecular drug DMH1M9B PC 5362124 DMH1M9B MW 424.5 DMH1M9B FM C24H28N2O5 DMH1M9B IC InChI=1S/C24H28N2O5/c1-2-31-24(30)20(14-12-17-8-4-3-5-9-17)25-19-15-13-18-10-6-7-11-21(18)26(23(19)29)16-22(27)28/h3-11,19-20,25H,2,12-16H2,1H3,(H,27,28)/t19-,20-/m0/s1 DMH1M9B CS CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@H]2CCC3=CC=CC=C3N(C2=O)CC(=O)O DMH1M9B IK XPCFTKFZXHTYIP-PMACEKPBSA-N DMH1M9B IU 2-[(3S)-3-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]-2-oxo-4,5-dihydro-3H-1-benzazepin-1-yl]acetic acid DMH1M9B CA CAS 86541-75-5 DMH1M9B CB CHEBI:3011 DMH1M9B DE Hypertension DMFH15Z ID DMFH15Z DMFH15Z DN Bendamustine hydrochloride DMFH15Z HS Approved DMFH15Z SN Treanda (TN) DMFH15Z CP Cephalon DMFH15Z DT Small molecular drug DMFH15Z PC 77082 DMFH15Z MW 394.7 DMFH15Z FM C16H22Cl3N3O2 DMFH15Z IC InChI=1S/C16H21Cl2N3O2.ClH/c1-20-14-6-5-12(21(9-7-17)10-8-18)11-13(14)19-15(20)3-2-4-16(22)23;/h5-6,11H,2-4,7-10H2,1H3,(H,22,23);1H DMFH15Z CS CN1C2=C(C=C(C=C2)N(CCCl)CCCl)N=C1CCCC(=O)O.Cl DMFH15Z IK ZHSKUOZOLHMKEA-UHFFFAOYSA-N DMFH15Z IU 4-[5-[bis(2-chloroethyl)amino]-1-methylbenzimidazol-2-yl]butanoic acid;hydrochloride DMFH15Z CA CAS 3543-75-7 DMFH15Z DE leukaemia DM7EVLC ID DM7EVLC DM7EVLC DN Bendroflumethiazide DM7EVLC HS Approved DM7EVLC SN Aprinox; BHFT; Bendrofluazide; Bendroflumethazide; Bendroflumethiazidum; Bendroflumetiazida; Bendroflumetiazide; Bendrofumethiazide; Bentride; Benuron; Benzhydroflumethiazide; Benzydroflumethiazide; Benzylhydroflumethiazide; Benzylrodiuran; Berkozide; Bristuric; Bristuron; Centyl; Corzide; Flumersil; Flumesil; Intolex; Livesan; Naigaril; Nateretin; Naturetin; Naturine; Niagaril; Nikion; Orsile; Pluryl; Pluryle; Plusuril; Poliuron; Rauzide; Repicin; Salural; Salures; Sinesalin; Sodiuretic; Thiazidico; Urlea; Bendroflumethiazide [USP]; Bendroflumetiazide [DCIT]; Rautrax N; Relan beta; BL H368; FT 8; FT 81; Be 724-A; Bendroflumethiazidum [INN-Latin]; Bendroflumetiazida [INN-Spanish]; Benzy-rodiuran; NATURETIN-10; NATURETIN-5; Naturetin (TN); Neo-naclex; Neo-rontyl; Naturetin-2.5; Bendroflumethiazide (JAN/USP/INN); (+-)-3-Benzyl-3,4-dihydro-6-(trifluoromethyl)-2H-1,2,4-benzothiadiazine-7-sulfonamide1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 3,4-dihydro-3-(phenylmethyl)-6-(trifluoromethyl)-, 1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 3-benzyl-3,4-dihydro-6-(trifluoromethyl)-, 1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 3-benzyl-3,4-dihydro-6-(trifluoromethyl)-,1,1-dioxide; 3,4-Dihydro-3-(phenylmethyl)-6-(trifluoromethyl)-2H-1,2,4-benzothiadiazine-7-sulfonamide1,1-dioxide; 3-(phenylmethyl)-6-(trifluoromethyl)-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 3-Benzyl-3,4-dihydro-6-(trifluoromethyl)-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 3-Benzyl-6-(trifluoromethyl)-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 3-Benzyl-6-trifluoromethyl-7-sulfamoyl-3,4-dihydro-1,2,4-benzothiadiazine, 1,1-dioxide; 3-Benzyl-6-trifluoromethyl-7-sulfamoyl-3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide; 6-Trifluoromethyl-3-benzyl-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine, 1,1-dioxide; 6-trifluoromethyl-3-benzyl-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine 1,1-dioxide DM7EVLC CP Crescent Pharmaceuticals DM7EVLC TC Antihypertensive Agents DM7EVLC DT Small molecular drug DM7EVLC PC 2315 DM7EVLC MW 421.4 DM7EVLC FM C15H14F3N3O4S2 DM7EVLC IC InChI=1S/C15H14F3N3O4S2/c16-15(17,18)10-7-11-13(8-12(10)26(19,22)23)27(24,25)21-14(20-11)6-9-4-2-1-3-5-9/h1-5,7-8,14,20-21H,6H2,(H2,19,22,23) DM7EVLC CS C1=CC=C(C=C1)CC2NC3=C(C=C(C(=C3)C(F)(F)F)S(=O)(=O)N)S(=O)(=O)N2 DM7EVLC IK HDWIHXWEUNVBIY-UHFFFAOYSA-N DM7EVLC IU 3-benzyl-1,1-dioxo-6-(trifluoromethyl)-3,4-dihydro-2H-1lambda6,2,4-benzothiadiazine-7-sulfonamide DM7EVLC CA CAS 73-48-3 DM7EVLC CB CHEBI:3013 DM7EVLC DE High blood pressure DM7P1J4 ID DM7P1J4 DM7P1J4 DN Benralizumab DM7P1J4 HS Approved DM7P1J4 CP AstraZeneca DM7P1J4 DT Monoclonal antibody DM7P1J4 DE Asthma; Chronic obstructive pulmonary disease DMRVBWU ID DMRVBWU DMRVBWU DN Bentazepam DMRVBWU HS Approved DMRVBWU DT Small molecular drug DMRVBWU PC 135412795 DMRVBWU MW 296.4 DMRVBWU FM C17H16N2OS DMRVBWU IC InChI=1S/C17H16N2OS/c20-14-10-18-16(11-6-2-1-3-7-11)15-12-8-4-5-9-13(12)21-17(15)19-14/h1-3,6-7H,4-5,8-10H2,(H,19,20) DMRVBWU CS C1CCC2=C(C1)C3=C(S2)NC(=O)CN=C3C4=CC=CC=C4 DMRVBWU IK AIZFEOPQVZBNGH-UHFFFAOYSA-N DMRVBWU IU 5-phenyl-1,3,6,7,8,9-hexahydro-[1]benzothiolo[2,3-e][1,4]diazepin-2-one DMRVBWU CA CAS 29462-18-8 DMRVBWU CB CHEBI:135252 DMRVBWU DE Anxiety disorder DMF7EXL ID DMF7EXL DMF7EXL DN Benzatropine DMF7EXL HS Approved DMF7EXL SN Benzatropina; Benzatropina [INN-Spanish]; Benzatropine; Benzatropinum; Benzatropinum [INN-Latin]; Benztropinum; Cobrentin; Cogentin; Cogentine; Akitan; Cogentinol; Tropine benzohydryl ether; benztropine; (3-endo)-3-(diphenylmethoxy)-8-methyl-8-azabicyclo[3.2.1]octane; 1NHL2J4X8K; 3alpha-(Diphenylmethoxy)-1alphaH,5alphaH-tropane; 3alpha-(diphenylmethoxy)tropane; 3alpha-benzhydryloxy-8-methyl-8-azabicyclo[3.2.1]octane; 3endo-benzhydryloxytropane; 86-13-5; CHEBI:3048; HSDB 3014; NCGC00159471-02; NK 02; UNII-1NHL2J4X8K DMF7EXL PC 1201549 DMF7EXL MW 307.4 DMF7EXL FM C21H25NO DMF7EXL IC GIJXKZJWITVLHI-YOFSQIOKSA-N DMF7EXL CS CN1C2CCC1CC(C2)OC(C3=CC=CC=C3)C4=CC=CC=C4 DMF7EXL IK 1S/C21H25NO/c1-22-18-12-13-19(22)15-20(14-18)23-21(16-8-4-2-5-9-16)17-10-6-3-7-11-17/h2-11,18-21H,12-15H2,1H3/t18-,19+,20? DMF7EXL IU (1R,5S)-3-benzhydryloxy-8-methyl-8-azabicyclo[3.2.1]octane DMF7EXL CA CAS 86-13-5 DMF7EXL CB CHEBI:3048 DMF7EXL DE Agitation/aggression DMC3YUA ID DMC3YUA DMC3YUA DN Benzbromarone DMC3YUA HS Approved DMC3YUA SN Acifugan; Azubromaron; Benzbromaron; Benzbromaronratiopharm; Benzbromaronum; Benzobromarona; Besuric; Desuric; Exurate; Harolan; Hipurik; Minuric; Narcaricin; Normurat; Uricovac; Urinorm; Uroleap; Aliud Brand of Benzbromarone; Benzbromaron AL; Benzbromaron ratiopharm; Benzbromarone Aliud Brand; Benzbromarone Heumann Brand; Benzbromarone Sanfer Brand; Benzbromarone ratiopharm Brand; Heumann Brand of Benzbromarone; Ratiopharm Brand of Benzbromarone; Sanfer Brand of Benzbromarone; Sanofi Winthrop Brand of Benzbromarone; L 2214; L2214; MJ 10061; NCI85433; AL, Benzbromaron; Benzbromaron-ratiopharm; Benzbromaronum [INN-Latin]; Benzobromarona [INN-Spanish]; L 2214-Labaz; L-2214; Uroleap (TN); Benzbromarone [USAN:INN:BAN]; Methanone, (3; Benzbromarone (JP15/USAN/INN); KETONE, 3,5-DIBROMO-4-HYDROXYPHENYL 2-ETHYL-3-BENZOFURANYL; Ketone, 3,5-dibromo-4-hydroxyphenyl 2-ethyl-3-benzofuranyl; (2-Ethyl-3-benzofuranyl)-(3,5-dibrom-4-hydroxyphenyl)keton; (3,5-Dibromo-4-hydroxyphenyl)(2-ethyl-1-benzofuran-3-yl)methanone; (3,5-dibromo-4-hydroxyphenyl)-(2-ethyl-1-benzofuran-3-yl)methanone; 2-Ethyl-3-(3,5-dibrom-4-hydroxybenzoyl)benzofuran; 3, 5-Dibromo-4-hydroxyphenyl-2-ethyl-3-benzofuranyl ketone; 3,5-Dibromo-4-hydroxyphenyl-2-ethyl-3-benzofuranyl ketone; 3-(3,5-Dibromo-4-hydroxybenzoyl)-2-ethylbenzofuran; 3-[3,5-DIBROMO-4-HYDROXYBENZOYL]-2-ETHYLBENZOFURAN DMC3YUA CP Labaz Laboratories DMC3YUA DT Small molecular drug DMC3YUA PC 2333 DMC3YUA MW 424.1 DMC3YUA FM C17H12Br2O3 DMC3YUA IC InChI=1S/C17H12Br2O3/c1-2-13-15(10-5-3-4-6-14(10)22-13)16(20)9-7-11(18)17(21)12(19)8-9/h3-8,21H,2H2,1H3 DMC3YUA CS CCC1=C(C2=CC=CC=C2O1)C(=O)C3=CC(=C(C(=C3)Br)O)Br DMC3YUA IK WHQCHUCQKNIQEC-UHFFFAOYSA-N DMC3YUA IU (3,5-dibromo-4-hydroxyphenyl)-(2-ethyl-1-benzofuran-3-yl)methanone DMC3YUA CA CAS 3562-84-3 DMC3YUA CB CHEBI:3023 DMC3YUA DE Gout DMI18HW ID DMI18HW DMI18HW DN Benzocaine DMI18HW HS Approved DMI18HW SN Aethoform; Americaine; Anaesthesin; Anaesthesinum; Anaesthin; Anestezin; Anesthesin; Anesthesine; Anesthone; Bensokain; Benzocaina; Benzocainum; Chloraseptic; Dermoplast; Ethoform; Ethoforme; Hurricaine; Identhesin; Keloform; Norcain; Norcaine; Norcainum; Orthesin; Otocain; Outgro; Parathesin; Parathesine; Solarcaine; Topcaine; Aethylium paraminobenzoicum; Amben ethyl ester; Anestezin [Russian]; Baby Anbesol; Benzocaine Acetate; Benzocaine Formate; Benzocaine Hydrobromide; Benzocaine Hydrochloride; Benzocaine Methanesulfonate; Ethyl PABA; Ethyl aminobenzoate; Ethylis aminobenzoas; Solu H; Acetate, Benzocaine; Anaesthan-syngala; Auralgan (TN); Benzocaina [INN-Spanish]; Benzocaine [INN:BAN]; Benzocainum [INN-Latin]; Ethyl 4-aminobenzoate; Ethyl 4-aminobenzoate hydrochloride; Ethyl aminobenzoate (JP15); Ethyl aminobenzoate (VAN); Ethyl p-aminobenzoate; Ethyl p-aminophenylcarboxylate; Ethylaminobenzoate-4; Ethylesterkyseliny p-aminobenzoove; Ethylester kyseliny p-aminobenzoove [Czech]; Formate, Benzocaine; Hydrobromide, Benzocaine; Hydrochloride, Benzocaine; Methanesulfonate, Benzocaine; Ora-jel; P-Aminobenzoic acid ethyl ester; P-Aminobenzoic ethyl ester; P-Carbethoxyaniline; P-Ethoxycarboxylic aniline; Parathesin (TN); AE-562/40377256; Benzocaine (USP/INN); ETHYL-P-AMINOBENZOATE; P-(Ethoxycarbonyl)aniline;P-Aminobenzoic acid, ethyl ester; Benzoic acid, amino-, ethyl ester; H-4-abz-oet; Benzoic acid, 4-amino-, ethyl ester; Benzoic acid, p-amino-, ethyl ester; Benzoic acid, 4-amino-, ethyl ester, hydrochloride; 112909_ALDRICH; 112909_SIAL; 4 Aminobenzoic Acid Ethyl Ester; 4-(Ethoxycarbonyl)aniline; 4-Aminobenzoic acid ethyl ester; 4-Aminobenzoic acid, ethyl ester; 4-Carbethoxyaniline; 4-amino-benzoic acid ethyl ester DMI18HW CP Wyeth Pharmaceuticals DMI18HW TC Anesthetics DMI18HW DT Small molecular drug DMI18HW PC 2337 DMI18HW MW 165.19 DMI18HW FM C9H11NO2 DMI18HW IC InChI=1S/C9H11NO2/c1-2-12-9(11)7-3-5-8(10)6-4-7/h3-6H,2,10H2,1H3 DMI18HW CS CCOC(=O)C1=CC=C(C=C1)N DMI18HW IK BLFLLBZGZJTVJG-UHFFFAOYSA-N DMI18HW IU ethyl 4-aminobenzoate DMI18HW CA CAS 94-09-7 DMI18HW CB CHEBI:116735 DMI18HW DE Anaesthesia DMKB9FI ID DMKB9FI DMKB9FI DN Benzoic acid DMKB9FI HS Approved DMKB9FI SN Phenylformate; benzoate anion; Benzoic acid, ion(1-); 766-76-7; Benzeneformate; Tennplas; Phenylcarboxylate; Benzenemethanoate; Retarded BA; Benzenecarboxylate; Phenyl carboxylic acid; benzoic acid anion; Oracyclic acid; 4-Carboxybenzenide; Benzene formic acid; AC1Q1HDY; AC1Q22CA; AC1L18SS; GTPL4565; DTXSID4043771; CHEBI:16150; BDBM36181; CTK2H9612; WPYMKLBDIGXBTP-UHFFFAOYSA-M; STL483236; ZINC328578076; NCGC00247905-01; ZB000218; CJ-00025; LS-190261; 3230-EP2374454A1; 3230-EP2372017A1; 3230-EP2316825A1; 3230-EP2316457A1 DMKB9FI DT Small molecular drug DMKB9FI PC 243 DMKB9FI MW 122.12 DMKB9FI FM C7H6O2 DMKB9FI IC InChI=1S/C7H6O2/c8-7(9)6-4-2-1-3-5-6/h1-5H,(H,8,9) DMKB9FI CS C1=CC=C(C=C1)C(=O)O DMKB9FI IK WPYMKLBDIGXBTP-UHFFFAOYSA-N DMKB9FI IU benzoic acid DMKB9FI CA CAS 65-85-0 DMKB9FI CB CHEBI:30746 DMKB9FI DE Fungal infection DM9U4FO ID DM9U4FO DM9U4FO DN Benzonatate DM9U4FO HS Approved DM9U4FO SN Benzonatato; Benzonatatum; Benzononantin; Benzononatine; Exangit; Tesalon; Tessalin; Tessalon; Ventussin; Tessalon Perles; KM65; Benzonatato [INN-Spanish]; Benzonatatum [INN-Latin]; Tessalon Capsules (TN); Tessalon Perles (TN); Tessalon perles (TN); Tessalon-ciba; Ventussin-loz; Benzonatate (USP/INN); Benzonatate [USAN:INN:BAN];Nonaethyleneglycol monomethyl ether p-n-butylaminobenzoate; P-butylaminobenzoic acid omega-O-methylnonaethyleneglycol ester; Polyethyleneglycol-p-n-butylaminobenzoate methyl ester; P-(n)-Butylaminobenzoesaeure-(nonaaethylenglykol-monomethylaether)-ester; P-(n)-Butylaminobenzoesaeure-(nonaaethylenglykol-monomethylaether)-ester [German]; Benzoic acid, 4-(butylamino)-, 2,5,8,11,14,17,20,23,26-nonaoxaoctacos-28-yl ester; Benzoic acid, 4-(butylamino)-, 3,6,9,12,15,18,21,24,27-nonaoxaoctacos-1-yl ester; Benzoic acid, 4-(butylamino)-, 3,6,9,12,15,18,21,24,27-nonaoxaoctacos-1-yl ester (9CI); Benzoic acid, p-(butylamino)-, 2-(2-(2-(2-(2-(2-(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethyl ester; 2,5,8,11,14,17,20,23,26-Nonaoxaoctacosan-28-yl p-(butylamino)benzoate; 2,5,8,11,14,17,20,23,26-nonaoxaoctacosan-28-yl 4-(butylamino)benzoate; 2-[2-[2-[2-[2-[2-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethyl 4-(butylamino)benzoate; 2-[2-[2-[2-[2-[2-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethyl 4-butylaminobenzoate; 3,6,9,12,15,18,21,24,27-Nonaoxaoctacos-1-yl 4-(butylamino)benzoate; 3,6,9,12,15,18,21,24,27-nonaoxaoctacosyl 4-butylaminobenzoate; 4-(butylamino)benzoic acid 3,6,9,12,15,18,21,24,27-nonaoxaoctacos-1-yl ester DM9U4FO TC Antitussives DM9U4FO DT Small molecular drug DM9U4FO PC 7699 DM9U4FO MW 603.7 DM9U4FO FM C30H53NO11 DM9U4FO IC InChI=1S/C30H53NO11/c1-3-4-9-31-29-7-5-28(6-8-29)30(32)42-27-26-41-25-24-40-23-22-39-21-20-38-19-18-37-17-16-36-15-14-35-13-12-34-11-10-33-2/h5-8,31H,3-4,9-27H2,1-2H3 DM9U4FO CS CCCCNC1=CC=C(C=C1)C(=O)OCCOCCOCCOCCOCCOCCOCCOCCOCCOC DM9U4FO IK MAFMQEKGGFWBAB-UHFFFAOYSA-N DM9U4FO IU 2-[2-[2-[2-[2-[2-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethyl 4-(butylamino)benzoate DM9U4FO CA CAS 104-31-4 DM9U4FO CB CHEBI:3032 DM9U4FO DE Cough DMIJATC ID DMIJATC DMIJATC DN Benzphetamine DMIJATC HS Approved DMIJATC SN Benzaphetamine; Benzfetamina; Benzfetamine; Benzfetaminum; Benzofetamina; Benzphetaminum; Benzylamphetamine; Benzfetamina [DCIT]; Benzfetamina [Spanish]; Benzfetaminum [Latin]; U 0441; Benzfetamina [INN-Spanish]; Benzfetamine (INN); Benzfetamine [INN:BAN]; Benzfetaminum [INN-Latin]; Benzofetamina [INN-Spanish]; Benzphetaminum [INN-Latin]; D-Benzphetamine; Didrex (TN); N-Benzylmethamphetamin; N-Benzyl-N,alpha-dimethylphenethylamine; N,alpha-Dimethyl-N-(phenylmethyl)benzeneethanamine; D-N-Methyl-N-benzyl-beta-phenylisopropylamine; N,alpha-Dimethyl-N-(phenylmethyl)-benzeneethanamine; N-Benzyl-N-methyl-1-phenyl-2-propanamine; N-benzyl-N-methyl-1-phenylpropan-2-amine; N-methyl-1-phenyl-N-(phenylmethyl)propan-2-amine; Benzeneethanamine, N,alpha-dimethyl-N-(phenylmethyl)-, (+)-(9CI); (+)-N,alpha-dimethyl-N-(phenylmethyl)-benzeneethanamine; (+)-N-benzyl-N,alpha-dimethylphenethylamine; (+)-benzphetamine; (2S)-N-benzyl-N-methyl-1-phenylpropan-2-amine; (R,S)-N-Benzyl-alpha,N-dimethylphenethylamin; (S)-(+)-N-benzyl-N,alpha-dimethylphenethylamine; (S)-(+)-benzphetamine; (S)-benzphetamine; (alphaS)-N,alpha-dimethylphenethylamine DMIJATC CP Pharmacia DMIJATC DT Small molecular drug DMIJATC PC 5311017 DMIJATC MW 239.35 DMIJATC FM C17H21N DMIJATC IC InChI=1S/C17H21N/c1-15(13-16-9-5-3-6-10-16)18(2)14-17-11-7-4-8-12-17/h3-12,15H,13-14H2,1-2H3/t15-/m0/s1 DMIJATC CS C[C@@H](CC1=CC=CC=C1)N(C)CC2=CC=CC=C2 DMIJATC IK YXKTVDFXDRQTKV-HNNXBMFYSA-N DMIJATC IU (2S)-N-benzyl-N-methyl-1-phenylpropan-2-amine DMIJATC CA CAS 156-08-1 DMIJATC CB CHEBI:3044 DMIJATC DE Obesity DMU4D5Y ID DMU4D5Y DMU4D5Y DN Benzquinamide DMU4D5Y HS Approved DMU4D5Y SN Benzchinamid; Benzchinamide; Benzchinamidum; Benzochinamide; Benzoquinamida; Benzoquinamide; Benzquinamid; Benzquinamida; Benzquinamidum; Emeticon; Promecon; Quantril; Quantryl; P 2647; Benzoquinamida [INN-Spanish]; Benzquinamide (USAN); Benzquinamidum [INN-Latin]; Emete-con; P-2647; Benzquinamide [USAN:INN:BAN]; [3-(diethylcarbamoyl)-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-benzo[a]quinolizin-2-yl] acetate; N,N-Diethyl-1,3,4,6,7,11b-hexahydro-2-hydroxy-9,10-dimethoxy-2H-benzo(a)quinolizine-3-carboxamideacetate; N,N-Diethyl-1,3,4,6,7,11b-hexahydro-2-hydroxy-9,10-dimethoxy-2H-benzo(a)quinolizine-3-carboxamide acetate (ester); N,N-Diethyl-1,3alpha,4,6,7,11bbeta-hexahydro-2beta-hydroxy-9,10-dimethoxy-2H-benzo(a)quinolizine-3-carboxamide acetate (ester); 2-(Acetyloxy)-N,N-diethyl-1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-2H-benzo(a)quinolizine-3-carboxamide; 2-(acetoxy)-N,N-diethyl-1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-2H-benzo[a]quinolizine-3-carboxamide; 2-(acetyloxy)-N,N-diethyl-1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-2H-benzo[a]quinolizine-3-carboxamide; 2-Acetoxy-3-(N,N-diethylcarboxamido)-9,10-dimethoxy-1,2,3,4,6,7-hexahydro-11bH-benzopyridocoline; 2-Acetoxy-3-diethylcarbamyl-9,10-dimethoxy-1,2,3,4,6,7-hexahydro-11b-benzo(a)quinolizine; 2-Hydroxy-3-diethylcarbamyl-9,10-dimethoxy-1,2,3,4,6,7-hexahydro-11bH-benzoquinolizine acetate; 2H-Benzo(a)quinolizine-3-carboxamide, 2-(acetyloxy)-N,N-diethyl-1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-, (2alpha,3beta,11balpha)-(9CI); 2H-Benzo(a)quinolizine-3-carboxamide, N,N-diethyl-1,3,4,6,7,11b-hexahydro-2-hydroxy-9,10-dimethoxy-, acetate (ester); 2H-Benzo(a)quinolizine-3-carboxamide, N,N-diethyl-1,3alpha,4,6,7,11bbeta-hexahydro-2beta-hydroxy-9,10-dimethoxy-, acetate (ester); 2H-Benzo[a]quinolizine-3-carboxamide, N,N-diethyl-1,3.alpha.,4,6,7,11b.beta.-hexahydro-2.beta.-hydroxy-9,10-dimethoxy-, acetate (ester); 3-(diethylcarbamoyl)-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl acetate; 3-Diethylcarbamoyl-2,3,4,6,7,11b-hexahydro-9,10-dimethoxy-1H-benzo(a)chinolizin-2-yl acetat; 3-[(diethylamino)carbonyl]-9,10-bis(methyloxy)-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl acetate DMU4D5Y TC Antiemetics DMU4D5Y DT Small molecular drug DMU4D5Y PC 2342 DMU4D5Y MW 404.5 DMU4D5Y FM C22H32N2O5 DMU4D5Y IC InChI=1S/C22H32N2O5/c1-6-23(7-2)22(26)17-13-24-9-8-15-10-20(27-4)21(28-5)11-16(15)18(24)12-19(17)29-14(3)25/h10-11,17-19H,6-9,12-13H2,1-5H3 DMU4D5Y CS CCN(CC)C(=O)C1CN2CCC3=CC(=C(C=C3C2CC1OC(=O)C)OC)OC DMU4D5Y IK JSZILQVIPPROJI-UHFFFAOYSA-N DMU4D5Y IU [3-(diethylcarbamoyl)-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-benzo[a]quinolizin-2-yl] acetate DMU4D5Y CA CAS 63-12-7 DMU4D5Y CB CHEBI:27662 DMU4D5Y DE Nausea DMQWZ0H ID DMQWZ0H DMQWZ0H DN Benzthiazide DMQWZ0H HS Approved DMQWZ0H SN Aquapres; Aquasec; Aquatag; Benzothiazide; Benzotiazida; Benzthazide; Benzthiazidum; Benztiazide; Dihydrex; Diucen;Diucene; Edemex; Exna; Exosalt; Fouane; Fovane; Freeuril; HyDrine; Lemazide; Proaqua; Regulon; Urazide; Urese; Benztiazide [DCIT]; P 1393; Pfizer 1393; Aqua-Scrip; Aquatag (TN); Benzotiazida [INN-Spanish]; Benzthiazidum [INN-Latin]; Dihydrex (TN); Diucen (TN); Edemax (TN); Exna (TN); Foven (TN); Hy-drine; Pro-aqua; Rid-ema; S-Aqua; Benzthiazide (JAN/INN); Benzthiazide [USAN:INN:BAN]; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 3-((benzylthio)menthyl)-6-chloro-, 1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 3-((benzylthio)methyl)-6-chloro-, 1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3-(((phenylmethyl)thio)methyl)-, 1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3-[[(phenylmethyl)thio]methyl]-, 1,1-dioxide; 3-((Benzylthio)methyl)-6-chloro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 3-((Benzylthio)methyl)-6-chloro-2H-1,2,4-benzothiadiazine-7-sulfonamide1,1-dioxide; 3-((Benzylthio)methyl)-6-chloro-7-sulfamoyl-2H-benzo-1,2,4-thiadiazine 1,1-dioxide; 3-((Benzylthio)methyl)-6-chloro-7-sulfamoyl-2H-benzo-1,2,4-thiadiazine-1,1-dioxide; 3-(benzylsulfanylmethyl)-6-chloro-1,1-dioxo-4H-1; 3-Benzylthiomethyl-6-chloro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 3-Benzylthiomethyl-6-chloro-7-sulfamoyl-1,2,4-benzothiadiazine 1,1-dioxide; 3-[(Benzylsulfanyl)methyl]-6-chloro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 6-Chloro-3-(((phenylmethyl)thio)methyl)-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 6-Chloro-7-sulfamoyl-3-benzylthiomethyl-2H-1,2,4-benzothiadiazine 1,1-dioxide; 6-chloro-1,1-dioxo-3-(phenylmethylsulfanylmethyl)-4H-benzo[e][1,2,4]thiadiazine-7-sulfonamide; 6-chloro-3-{[(phenylmethyl)thio]methyl}-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide DMQWZ0H TC Antihypertensive Agents DMQWZ0H DT Small molecular drug DMQWZ0H PC 2343 DMQWZ0H MW 431.9 DMQWZ0H FM C15H14ClN3O4S3 DMQWZ0H IC InChI=1S/C15H14ClN3O4S3/c16-11-6-12-14(7-13(11)25(17,20)21)26(22,23)19-15(18-12)9-24-8-10-4-2-1-3-5-10/h1-7H,8-9H2,(H,18,19)(H2,17,20,21) DMQWZ0H CS C1=CC=C(C=C1)CSCC2=NS(=O)(=O)C3=CC(=C(C=C3N2)Cl)S(=O)(=O)N DMQWZ0H IK NDTSRXAMMQDVSW-UHFFFAOYSA-N DMQWZ0H IU 3-(benzylsulfanylmethyl)-6-chloro-1,1-dioxo-4H-1lambda6,2,4-benzothiadiazine-7-sulfonamide DMQWZ0H CA CAS 91-33-8 DMQWZ0H CB CHEBI:3047 DMQWZ0H DE High blood pressure DMGZOVN ID DMGZOVN DMGZOVN DN Benztropine DMGZOVN HS Approved DMGZOVN SN Akitan; Benzatropina; Benzatropine; Benzatropinum; Benztropinum; Cobrentin; Cogentine; Cogentinol; Benzatropine [INN]; Benzatropine mesilate; Pms Benztropine; Tropine benzohydryl ether; NK 02; Apo-Benztropine; Benzatropina [INN-Spanish]; Benzatropine (INN); Benzatropine [INN:BAN]; Benzatropinum [INN-Latin]; Cogentin (TN); Benzhydryl 8-methyl-8-azabicyclo[3.2.1]oct-3-yl ether; (1R,5R)-3-benzhydryloxy-8-methyl-8-azabicyclo[3.2.1]octane; (1r,5r)-3-(diphenylmethoxy)-8-methyl-8-azabicyclo[3.2.1]octane; (3-endo)-3-(diphenylmethoxy)-8-methyl-8-azabicyclo[3.2.1]octane; (3-endo)-3-[(diphenylmethyl)oxy]-8-methyl-8-azabicyclo[3.2.1]octane; (5R)-3-benzhydryloxy-8-methyl-8-azabicyclo[3.2.1]octane; 3-(diphenylmethoxy)-8-methyl-8-azabicyclo[3.2.1]octane; 3-benzhydryloxy-8-methyl-8-azabicyclo[3.2.1]octane; 3alpha-(Diphenylmethoxy)-1alphaH,5alphaH-tropane; 3alpha-(diphenylmethoxy)tropane; 3alpha-benzhydryloxy-8-methyl-8-azabicyclo[3.2.1]octane; 3endo-benzhydryloxytropane; 8-Azabicyclo(3.2.1)octane, 3-(diphenylmethoxy)-8-methyl-, endo-(9CI) DMGZOVN CP Oak Pharmaceuticals Inc Sub Akorn Inc DMGZOVN TC Antiparkinson Agents DMGZOVN DT Small molecular drug DMGZOVN PC 1201549 DMGZOVN MW 307.4 DMGZOVN FM C21H25NO DMGZOVN IC InChI=1S/C21H25NO/c1-22-18-12-13-19(22)15-20(14-18)23-21(16-8-4-2-5-9-16)17-10-6-3-7-11-17/h2-11,18-21H,12-15H2,1H3/t18-,19+,20? DMGZOVN CS CN1[C@@H]2CC[C@H]1CC(C2)OC(C3=CC=CC=C3)C4=CC=CC=C4 DMGZOVN IK GIJXKZJWITVLHI-YOFSQIOKSA-N DMGZOVN IU (1R,5S)-3-benzhydryloxy-8-methyl-8-azabicyclo[3.2.1]octane DMGZOVN CA CAS 86-13-5 DMGZOVN CB CHEBI:3048 DMGZOVN DE Parkinson disease DMBVYDI ID DMBVYDI DMBVYDI DN Benzyl alcohol DMBVYDI HS Approved DMBVYDI SN Ulesfia (TN) DMBVYDI CP Sciele Pharma DMBVYDI DT Small molecular drug DMBVYDI PC 244 DMBVYDI MW 108.14 DMBVYDI FM C7H8O DMBVYDI IC InChI=1S/C7H8O/c8-6-7-4-2-1-3-5-7/h1-5,8H,6H2 DMBVYDI CS C1=CC=C(C=C1)CO DMBVYDI IK WVDDGKGOMKODPV-UHFFFAOYSA-N DMBVYDI IU phenylmethanol DMBVYDI CA CAS 100-51-6 DMBVYDI CB CHEBI:17987 DMBVYDI DE Head and body lice DMDPYI5 ID DMDPYI5 DMDPYI5 DN Benzyl benzoate DMDPYI5 HS Approved DMDPYI5 SN BENZYL BENZOATE; 120-51-4; Benylate; Ascabiol; Novoscabin; Benzoic acid, phenylmethyl ester; Benzoic acid benzyl ester; Scobenol; Scabitox; Ascabin; Benzyl phenylformate; Phenylmethyl benzoate; Scabiozon; Scabagen; Peruscabin; Colebenz; Scabanca; Benzylets; Benzoic acid, benzyl ester; Vanzoate; Scabide; Benzyl benzenecarboxylate; benzylbenzoate; Antiscabiosum; Benzylis benzoas; Benzyl alcohol benzoic ester; Peruscabina; Venzonate; Spasmodin; Benzylum benzoicum; Benzylester kyseliny benzoove; Benzoesaeurebenzylester; Caswell No. 082 DMDPYI5 DT Small molecular drug DMDPYI5 PC 2345 DMDPYI5 MW 212.24 DMDPYI5 FM C14H12O2 DMDPYI5 IC InChI=1S/C14H12O2/c15-14(13-9-5-2-6-10-13)16-11-12-7-3-1-4-8-12/h1-10H,11H2 DMDPYI5 CS C1=CC=C(C=C1)COC(=O)C2=CC=CC=C2 DMDPYI5 IK SESFRYSPDFLNCH-UHFFFAOYSA-N DMDPYI5 IU benzyl benzoate DMDPYI5 CA CAS 120-51-4 DMDPYI5 CB CHEBI:41237 DMDPYI5 DE Infestations of lice and scabies DMQHM2D ID DMQHM2D DMQHM2D DN Benzylpenicilloyl Polylysine DMQHM2D HS Approved DMQHM2D SN Benzylpenicilloyl; Benzylpenicilloyl G; Benzylpenicilloyl G polylysine; Benzylpenicilloyl-polylysine; Penicilloyl-polylysine; 2-(2-((5-Carboxypentyl)amino)-2-oxo-1-((phenylacetyl)amino)ethyl)-5,5-dimethyl-4-thiazolidinecarboxylic acid; 2-[2-[(6-hydroxy-6-oxohexyl)amino]-2-oxo-1-[(2-phenylacetyl)amino]ethyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid DMQHM2D TC Analgesics DMQHM2D DT Small molecular drug DMQHM2D PC 45266800 DMQHM2D MW 626.8 DMQHM2D FM C28H46N6O8S DMQHM2D IC InChI=1S/C22H32N4O6S.C6H14N2O2/c1-22(2)17(21(31)32)26-19(33-22)16(25-15(27)12-13-8-4-3-5-9-13)18(28)24-11-7-6-10-14(23)20(29)30;7-4-2-1-3-5(8)6(9)10/h3-5,8-9,14,16-17,19,26H,6-7,10-12,23H2,1-2H3,(H,24,28)(H,25,27)(H,29,30)(H,31,32);5H,1-4,7-8H2,(H,9,10)/t14-,16?,17+,19-;5-/m11/s1 DMQHM2D CS CC1([C@@H](N[C@H](S1)C(C(=O)NCCCC[C@H](C(=O)O)N)NC(=O)CC2=CC=CC=C2)C(=O)O)C.C(CCN)C[C@H](C(=O)O)N DMQHM2D IK IMPVZRLKKKXMKQ-SGDOCVTFSA-N DMQHM2D IU (2R,4S)-2-[2-[[(5R)-5-amino-5-carboxypentyl]amino]-2-oxo-1-[(2-phenylacetyl)amino]ethyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid;(2R)-2,6-diaminohexanoic acid DMQHM2D CA CAS 31855-75-1 DMQHM2D CB CHEBI:59297 DMQHM2D DE Bacterial infection DMXDZAQ ID DMXDZAQ DMXDZAQ DN Bepotastine DMXDZAQ HS Approved DMXDZAQ SN Betotastine; Tau 284; TAU-284DS; Talion (TN); (S)-4-(4-((4-Chlorophenyl)(2-pyridil)methoxy)piperidino)butylic acid; 4-((4-Chlorophenyl)-2-pyridinylmethoxy)-1-piperidinebutanoic acid; 4-[4-[(4-chlorophenyl)-pyridin-2-ylmethoxy]piperidin-1-yl]butanoic acid DMXDZAQ CP Tanabe Seiyaku Co DMXDZAQ TC Antiallergic Agents DMXDZAQ DT Small molecular drug DMXDZAQ PC 164522 DMXDZAQ MW 388.9 DMXDZAQ FM C21H25ClN2O3 DMXDZAQ IC InChI=1S/C21H25ClN2O3/c22-17-8-6-16(7-9-17)21(19-4-1-2-12-23-19)27-18-10-14-24(15-11-18)13-3-5-20(25)26/h1-2,4,6-9,12,18,21H,3,5,10-11,13-15H2,(H,25,26)/t21-/m0/s1 DMXDZAQ CS C1CN(CCC1O[C@@H](C2=CC=C(C=C2)Cl)C3=CC=CC=N3)CCCC(=O)O DMXDZAQ IK YWGDOWXRIALTES-NRFANRHFSA-N DMXDZAQ IU 4-[4-[(S)-(4-chlorophenyl)-pyridin-2-ylmethoxy]piperidin-1-yl]butanoic acid DMXDZAQ CA CAS 125602-71-3 DMXDZAQ CB CHEBI:71204 DMXDZAQ DE Allergic rhinitis DM0RKS4 ID DM0RKS4 DM0RKS4 DN Bepridil DM0RKS4 HS Approved DM0RKS4 SN Bepadin; Vascor; CERM 1978; Bepadin (TN); Bepridil (INN); Vascor (TN); N-benzyl-N-[3-(2-methylpropoxy)-2-pyrrolidin-1-ylpropyl]aniline; Beta-((2-Methylpropoxy)methyl)-N-phenyl-N-(phenylmethyl)-1-pyrrolidineethanamine; N-Benzyl-N-[3-(2-methylpropoxy)-2-pyrrolidin-1-yl-propyl]aniline hydrochloride; N-benzyl-N-[3-(2-methylpropoxy)-2-(pyrrolidin-1-yl)propyl]aniline; N-{3-[(2-methylpropyl)oxy]-2-pyrrolidin-1-ylpropyl}-N-(phenylmethyl)aniline DM0RKS4 TC Antiarrhythmic Agents DM0RKS4 DT Small molecular drug DM0RKS4 PC 2351 DM0RKS4 MW 366.5 DM0RKS4 FM C24H34N2O DM0RKS4 IC InChI=1S/C24H34N2O/c1-21(2)19-27-20-24(25-15-9-10-16-25)18-26(23-13-7-4-8-14-23)17-22-11-5-3-6-12-22/h3-8,11-14,21,24H,9-10,15-20H2,1-2H3 DM0RKS4 CS CC(C)COCC(CN(CC1=CC=CC=C1)C2=CC=CC=C2)N3CCCC3 DM0RKS4 IK UIEATEWHFDRYRU-UHFFFAOYSA-N DM0RKS4 IU N-benzyl-N-[3-(2-methylpropoxy)-2-pyrrolidin-1-ylpropyl]aniline DM0RKS4 CA CAS 64706-54-3 DM0RKS4 CB CHEBI:3061 DM0RKS4 DE Chronic/stable angina DMEBY2D ID DMEBY2D DMEBY2D DN Beriplast-P DMEBY2D HS Approved DMEBY2D SN Fibrin sealant, Aventis Behring DMEBY2D CP Aventis Behring LLC DMEBY2D DE Wound healing DMWA2DZ ID DMWA2DZ DMWA2DZ DN Berotralstat DMWA2DZ HS Approved DMWA2DZ SN UNII-XZA0KB1BDQ; XZA0KB1BDQ; 1809010-50-1; BCX7353; BCX-7353; Berotralstat (USAN); Berotralstat [USAN]; 1-[3-(aminomethyl)phenyl]-N-(5-{(R)-(3-; cyanophenyl)[(cyclopropylmethyl)amino]methyl}-2-; fluorophenyl)-3-(trifluoromethyl)-1H-pyrazole-5-; Orladeyo; Berotralstat [INN]; Berotralstat [USAN:INN]; SCHEMBL21974728; GTPL11347; WHO 10907; D11673; 1-(3-(Aminomethyl)phenyl)-N-(5-((R)-(3-cyanophenyl)((cyclopropylmethyl)amino)methyl)-2-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide; 1H-pyrazole-5-carboxamide, 1-(3-(aminomethyl)phenyl)-N-(5-((R)-(3-cyanophenyl)((cyclopropylmethyl); 1H-Pyrazole-5-carboxamide, 1-(3-(aminomethyl)phenyl)-N-(5-((R)-(3-cyanophenyl)((cyclopropylmethyl)amino)methyl)-2-fluorophenyl)-3-(trifluoromethyl)-; 2-[3-(aminomethyl)phenyl]-N-[5-[(R)-(3-cyanophenyl)-(cyclopropylmethylamino)methyl]-2-fluorophenyl]-5-(trifluoromethyl)pyrazole-3-carboxamide DMWA2DZ CP BioCryst Pharmaceuticals DMWA2DZ DT Small molecular drug DMWA2DZ PC 137528262 DMWA2DZ MW 562.6 DMWA2DZ FM C30H26F4N6O DMWA2DZ IC InChI=1S/C30H26F4N6O/c31-24-10-9-22(28(37-17-18-7-8-18)21-5-1-3-19(11-21)15-35)13-25(24)38-29(41)26-14-27(30(32,33)34)39-40(26)23-6-2-4-20(12-23)16-36/h1-6,9-14,18,28,37H,7-8,16-17,36H2,(H,38,41)/t28-/m1/s1 DMWA2DZ CS C1CC1CN[C@@H](C2=CC(=C(C=C2)F)NC(=O)C3=CC(=NN3C4=CC=CC(=C4)CN)C(F)(F)F)C5=CC=CC(=C5)C#N DMWA2DZ IK UXNXMBYCBRBRFD-MUUNZHRXSA-N DMWA2DZ IU 2-[3-(aminomethyl)phenyl]-N-[5-[(R)-(3-cyanophenyl)-(cyclopropylmethylamino)methyl]-2-fluorophenyl]-5-(trifluoromethyl)pyrazole-3-carboxamide DMWA2DZ CA CAS 1809010-50-1 DMWA2DZ DE Hereditary angioedema DMPHXMI ID DMPHXMI DMPHXMI DN Besifloxacin DMPHXMI HS Approved DMPHXMI SN Besivance (TN) DMPHXMI CP Bausch & Lomb DMPHXMI DT Small molecular drug DMPHXMI PC 10178705 DMPHXMI MW 393.8 DMPHXMI FM C19H21ClFN3O3 DMPHXMI IC InChI=1S/C19H21ClFN3O3/c20-15-16-12(18(25)13(19(26)27)9-24(16)11-4-5-11)7-14(21)17(15)23-6-2-1-3-10(22)8-23/h7,9-11H,1-6,8,22H2,(H,26,27)/t10-/m1/s1 DMPHXMI CS C1CCN(C[C@@H](C1)N)C2=C(C=C3C(=C2Cl)N(C=C(C3=O)C(=O)O)C4CC4)F DMPHXMI IK QFFGVLORLPOAEC-SNVBAGLBSA-N DMPHXMI IU 7-[(3R)-3-aminoazepan-1-yl]-8-chloro-1-cyclopropyl-6-fluoro-4-oxoquinoline-3-carboxylic acid DMPHXMI CA CAS 141388-76-3 DMPHXMI CB CHEBI:135622 DMPHXMI DE Ocular inflammation DM8L9D4 ID DM8L9D4 DM8L9D4 DN Bestatin DM8L9D4 HS Approved DM8L9D4 SN Bestatin (TN); CHEBI:3070; UPCMLD-DP116; CHEMBL476869; SureCN25971; Ubenimex (JP16/INN); Ubenimex (JP17/INN); SCHEMBL25971; GTPL5151; AC1L972Z; UPCMLD-DP116:001; DTXSID4048430; CHEBI:140702; ZINC1532730; ZINC01532730; BDBM50010142; AKOS026750073; NCGC00161660-01; C00732; D00087; ((2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl)-D-leucine; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl]amino]-4-methylpentanoic acid; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenyl-butanoyl]amino]-4-methyl-pentanoic acid DM8L9D4 DT Small molecular drug DM8L9D4 PC 72172 DM8L9D4 MW 308.37 DM8L9D4 FM C16H24N2O4 DM8L9D4 IC InChI=1S/C16H24N2O4/c1-10(2)8-13(16(21)22)18-15(20)14(19)12(17)9-11-6-4-3-5-7-11/h3-7,10,12-14,19H,8-9,17H2,1-2H3,(H,18,20)(H,21,22)/t12-,13+,14+/m1/s1 DM8L9D4 CS CC(C)C[C@@H](C(=O)O)NC(=O)[C@H]([C@@H](CC1=CC=CC=C1)N)O DM8L9D4 IK VGGGPCQERPFHOB-RDBSUJKOSA-N DM8L9D4 IU (2S)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl]amino]-4-methylpentanoic acid DM8L9D4 CA CAS 58970-76-6 DM8L9D4 DE Acute myeloid leukaemia DMI6GKT ID DMI6GKT DMI6GKT DN Beta-acetyldigoxin DMI6GKT HS Approved DMI6GKT SN Novodigal (TN) DMI6GKT DT Small molecular drug DMI6GKT PC 10350481 DMI6GKT MW 823 DMI6GKT FM C43H66O15 DMI6GKT IC InChI=1S/C43H66O15/c1-20-38(55-23(4)44)30(45)17-36(53-20)57-40-22(3)54-37(18-32(40)47)58-39-21(2)52-35(16-31(39)46)56-26-9-11-41(5)25(14-26)7-8-28-29(41)15-33(48)42(6)27(10-12-43(28,42)50)24-13-34(49)51-19-24/h13,20-22,25-33,35-40,45-48,50H,7-12,14-19H2,1-6H3/t20-,21-,22-,25-,26+,27-,28-,29+,30+,31+,32+,33-,35+,36+,37+,38-,39-,40-,41+,42+,43+/m1/s1 DMI6GKT CS C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2CC[C@]3([C@@H](C2)CC[C@@H]4[C@@H]3C[C@H]([C@]5([C@@]4(CC[C@@H]5C6=CC(=O)OC6)O)C)O)C)O)O[C@H]7C[C@@H]([C@@H]([C@H](O7)C)O[C@H]8C[C@@H]([C@@H]([C@H](O8)C)OC(=O)C)O)O DMI6GKT IK NREAGDHHMSOWKZ-DXJNJSHLSA-N DMI6GKT IU [(2R,3S,4S,6S)-6-[(2R,3S,4S,6S)-6-[(2R,3S,4S,6R)-6-[[(3S,5R,8R,9S,10S,12R,13S,14S,17R)-12,14-dihydroxy-10,13-dimethyl-17-(5-oxo-2H-furan-3-yl)-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-yl]oxy]-4-hydroxy-2-methyloxan-3-yl]oxy-4-hydroxy-2-methyloxan-3-yl]oxy-4-hydroxy-2-methyloxan-3-yl] acetate DMI6GKT CA CAS 5355-48-6 DMI6GKT CB CHEBI:135892 DMI6GKT DE Cardiovascular disease DM0RXBT ID DM0RXBT DM0RXBT DN Beta-carotene DM0RXBT HS Approved DM0RXBT SN beta-carotene; 7235-40-7; beta Carotene; beta,beta-Carotene; Betacarotene; Provitamin A; Solatene; Carotaben; Provatene; all-trans-beta-Carotene; Serlabo; Natural Yellow 26; Karotin; KPMK; C.I. Food Orange 5; Solatene (caps); Karotin [Czech]; Food orange 5; Zlut prirodni 26; Betacarotenum [Latin]; Betacaroteno [Spanish]; Lucaratin; BetaVit; beta-Karotin; beta-Carotin; beta;-Carotene; beta-Carotene, all-trans-; .beta. Carotene; .beta.-Carotene; Betacarotenum [INN-Latin]; C.I. 75130; Betacaroteno [INN-Spanish]; Zlut prirodni 26 [Czech] DM0RXBT DT Small molecular drug DM0RXBT PC 5280489 DM0RXBT MW 536.9 DM0RXBT FM C40H56 DM0RXBT IC InChI=1S/C40H56/c1-31(19-13-21-33(3)25-27-37-35(5)23-15-29-39(37,7)8)17-11-12-18-32(2)20-14-22-34(4)26-28-38-36(6)24-16-30-40(38,9)10/h11-14,17-22,25-28H,15-16,23-24,29-30H2,1-10H3/b12-11+,19-13+,20-14+,27-25+,28-26+,31-17+,32-18+,33-21+,34-22+ DM0RXBT CS CC1=C(C(CCC1)(C)C)/C=C/C(=C/C=C/C(=C/C=C/C=C(/C=C/C=C(/C=C/C2=C(CCCC2(C)C)C)\\C)\\C)/C)/C DM0RXBT IK OENHQHLEOONYIE-JLTXGRSLSA-N DM0RXBT IU 1,3,3-trimethyl-2-[(1E,3E,5E,7E,9E,11E,13E,15E,17E)-3,7,12,16-tetramethyl-18-(2,6,6-trimethylcyclohexen-1-yl)octadeca-1,3,5,7,9,11,13,15,17-nonaenyl]cyclohexene DM0RXBT CA CAS 7235-40-7 DM0RXBT CB CHEBI:17579 DM0RXBT DE Vitamin deficiency DMGRZW2 ID DMGRZW2 DMGRZW2 DN Betaine DMGRZW2 HS Approved DMGRZW2 SN Cystadane DMGRZW2 CP Rare Disease Therapeutics Inc DMGRZW2 DT Small molecular drug DMGRZW2 PC 247 DMGRZW2 MW 117.15 DMGRZW2 FM C5H11NO2 DMGRZW2 IC InChI=1S/C5H11NO2/c1-6(2,3)4-5(7)8/h4H2,1-3H3 DMGRZW2 CS C[N+](C)(C)CC(=O)[O-] DMGRZW2 IK KWIUHFFTVRNATP-UHFFFAOYSA-N DMGRZW2 IU 2-(trimethylazaniumyl)acetate DMGRZW2 CA CAS 107-43-7 DMGRZW2 CB CHEBI:17750 DMGRZW2 DE Inborn error of metabolism DMAHJEF ID DMAHJEF DMAHJEF DN Betamethasone DMAHJEF HS Approved DMAHJEF SN betamethasone; 378-44-9; Betadexamethasone; Flubenisolone; Betamethazone; Rinderon; Visubeta; Celestene; Betnelan; Betapredol; Betacortril; Betacorlan; Methazon; Betsolan; Betamamallet; Hormezon; Betasolon; Betametasone; Cidoten; Bebate; Bedifos; Becort; beta-Methasone; Desacort-Beta; Rinderon A; beta-Methasone alcohol; Betametasona; Betafluorene; Betamethasonum; Celestone; Betamethasone cream; Betamethasone alcohol; Betametasone [DCIT]; 9alpha-Fluoro-16beta-methylprednisolone; Celestone Syrup and Tablets; Celeston; Celestona; Cellestoderm; Luxiqo; Betamethasone Base; Betamethasone Valearate; Betamethasonvalerat Mikron; LT00441022; SCH 4831; Beta-Methasone; Beta-Methasone alcohol; Betametasona [INN-Spanish]; Betamethasonum [INN-Latin]; Betnovate (TN); Celestone (TN); Diprolene (TN); Diprosone (TN); Lotrisone (TN); Rinderon (TN); SCH-4831; Betamethasone (JP15/USP/INN); Betamethasone [USAN:BAN:INN:JAN]; Betamethasone [USAN:INN:BAN:JAN]; Celestone, Betadexamethasone, Flubenisolone, Sch-4831, NCS-39470, Betamethasone; 1,4-Pregnadiene-3,20-dione-9alpha-fluoro-16 beta-methyl-11 beta,17alpha,21-triol; 16beta-Methyl-1,4-pregnadiene-9alpha-fluoro-11beta,17alpha,21-triol-3,20-dione; 9-Fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione; 9-Fluoro-11-beta,17,21-trihydroxy-16-beta-methylpregna-1,4-diene-3,20-dione; 9-Fluoro-11beta,17,21-trihydroxy-16beta-methylpregna-1,4-diene-3,20-dione; 9-Fluoro-16beta-methylprednisolone; 9-alpha-Fluoro-16-beta-methylprednisolone; 9alpha-Fluoro-16 beta-methyl-prednisolone; Betamethasone sodium phosphate DMAHJEF TC Antiinflammatory Agents DMAHJEF DT Small molecular drug DMAHJEF PC 9782 DMAHJEF MW 392.5 DMAHJEF FM C22H29FO5 DMAHJEF IC InChI=1S/C22H29FO5/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,23)17(26)10-20(16,3)22(12,28)18(27)11-24/h6-7,9,12,15-17,24,26,28H,4-5,8,10-11H2,1-3H3/t12-,15-,16-,17-,19-,20-,21-,22-/m0/s1 DMAHJEF CS C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)F)C DMAHJEF IK UREBDLICKHMUKA-DVTGEIKXSA-N DMAHJEF IU (8S,9R,10S,11S,13S,14S,16S,17R)-9-fluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one DMAHJEF CA CAS 378-44-9 DMAHJEF CB CHEBI:3077 DMAHJEF DE Inflammation DMRMS1A ID DMRMS1A DMRMS1A DN Betamethasone Benzoate DMRMS1A HS Approved DMRMS1A SN Uticort DMRMS1A CP Parke Davis Div Warner Lambert Co DMRMS1A DT Small molecular drug DMRMS1A PC 5282492 DMRMS1A MW 496.6 DMRMS1A FM C29H33FO6 DMRMS1A IC InChI=1S/C29H33FO6/c1-17-13-22-21-10-9-19-14-20(32)11-12-26(19,2)28(21,30)23(33)15-27(22,3)29(17,24(34)16-31)36-25(35)18-7-5-4-6-8-18/h4-8,11-12,14,17,21-23,31,33H,9-10,13,15-16H2,1-3H3/t17-,21-,22-,23-,26-,27-,28-,29-/m0/s1 DMRMS1A CS C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)OC(=O)C5=CC=CC=C5)C)O)F)C DMRMS1A IK SOQJPQZCPBDOMF-YCUXZELOSA-N DMRMS1A IU [(8S,9R,10S,11S,13S,14S,16S,17R)-9-fluoro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] benzoate DMRMS1A CA CAS 22298-29-9 DMRMS1A CB CHEBI:135798 DMRMS1A DE Inflammation DMMIAXO ID DMMIAXO DMMIAXO DN Betamethasone valerate DMMIAXO HS Approved DMMIAXO SN Beta-val; Betaderm; Betatrex; Dermabet; Valnac DMMIAXO CP Schering Corp Sub Schering Plough Corp DMMIAXO DT Small molecular drug DMMIAXO PC 16533 DMMIAXO MW 476.6 DMMIAXO FM C27H37FO6 DMMIAXO IC InChI=1S/C27H37FO6/c1-5-6-7-23(33)34-27(22(32)15-29)16(2)12-20-19-9-8-17-13-18(30)10-11-24(17,3)26(19,28)21(31)14-25(20,27)4/h10-11,13,16,19-21,29,31H,5-9,12,14-15H2,1-4H3/t16-,19-,20-,21-,24-,25-,26-,27-/m0/s1 DMMIAXO CS CCCCC(=O)O[C@@]1([C@H](C[C@@H]2[C@@]1(C[C@@H]([C@]3([C@H]2CCC4=CC(=O)C=C[C@@]43C)F)O)C)C)C(=O)CO DMMIAXO IK SNHRLVCMMWUAJD-SUYDQAKGSA-N DMMIAXO IU [(8S,9R,10S,11S,13S,14S,16S,17R)-9-fluoro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] pentanoate DMMIAXO CA CAS 2152-44-5 DMMIAXO CB CHEBI:31277 DMMIAXO DE Dermatological disease DM6EUL5 ID DM6EUL5 DM6EUL5 DN Betaxolol DM6EUL5 HS Approved DM6EUL5 SN Betaxololum; Betazolol; KERLEDEX; Kerlone; Betaxolol HCL; SL 75212; Betaxolol (INN); Betaxolol (TN); Betaxolol [INN:BAN]; Betaxololum [INN-Latin]; Betoptic (TN); Betoptic S (TN); Kerlone (TN); Lokren (TN); SL-75212; ALO-1401-02; (+/-)-1-[p-[2-(Cyclopropylmethoxy)ethyl]phenoxy]-3-(isopropylamino)-2-propanol; 1-(4-(2-(Cyclopropylmethoxy)ethyl)phenoxy)-3-((1-methylethyl)amino)-2-propanol; 1-(isopropylamino)-3-[p-(cyclopropylmethoxyethyl)phenoxy]-2-propanol; 1-[(4-{2-[(cyclopropylmethyl)oxy]ethyl}phenyl)oxy]-3-[(1-methylethyl)amino]propan-2-ol; 1-[4-[2-(cyclopropylmethoxy)ethyl]phenoxy]-3-(propan-2-ylamino)propan-2-ol; 1-{4-[2-(cyclopropylmethoxy)ethyl]phenoxy}-3-(propan-2-ylamino)propan-2-ol DM6EUL5 CP Lorex Pharmaceuticals DM6EUL5 TC Antihypertensive Agents DM6EUL5 DT Small molecular drug DM6EUL5 PC 2369 DM6EUL5 MW 307.4 DM6EUL5 FM C18H29NO3 DM6EUL5 IC InChI=1S/C18H29NO3/c1-14(2)19-11-17(20)13-22-18-7-5-15(6-8-18)9-10-21-12-16-3-4-16/h5-8,14,16-17,19-20H,3-4,9-13H2,1-2H3 DM6EUL5 CS CC(C)NCC(COC1=CC=C(C=C1)CCOCC2CC2)O DM6EUL5 IK NWIUTZDMDHAVTP-UHFFFAOYSA-N DM6EUL5 IU 1-[4-[2-(cyclopropylmethoxy)ethyl]phenoxy]-3-(propan-2-ylamino)propan-2-ol DM6EUL5 CA CAS 63659-18-7 DM6EUL5 CB CHEBI:3082 DM6EUL5 DE Hypertension DMUFGAY ID DMUFGAY DMUFGAY DN Betazole DMUFGAY HS Approved DMUFGAY SN Ametazole; Betazol; Betazolo; Betazolum; Betazole [INN]; Betazolo [DCIT]; Lilly 96791; Betazol [INN-Spanish]; Betazolum [INN-Latin]; 1H-Pyrazole-3-ethanamine; 2-(1H-Pyrazol-3-yl)ethanamine; 2-(1H-pyrazol-5-yl)ethanamine; 2-(3-Pyrazolyl)ethylamine; 3-(2-Aminoethyl)pyrazole; 3-(beta-aminoethyl)pyrazole DMUFGAY CP Eli Lilly And Co DMUFGAY TC Antihistamines DMUFGAY DT Small molecular drug DMUFGAY PC 7741 DMUFGAY MW 111.15 DMUFGAY FM C5H9N3 DMUFGAY IC InChI=1S/C5H9N3/c6-3-1-5-2-4-7-8-5/h2,4H,1,3,6H2,(H,7,8) DMUFGAY CS C1=C(NN=C1)CCN DMUFGAY IK JXDFEQONERDKSS-UHFFFAOYSA-N DMUFGAY IU 2-(1H-pyrazol-5-yl)ethanamine DMUFGAY CA CAS 105-20-4 DMUFGAY CB CHEBI:59170 DMUFGAY DE Gastric secretory disorder DMCLHO0 ID DMCLHO0 DMCLHO0 DN Bethanechol DMCLHO0 HS Approved DMCLHO0 SN Amidopropyldimethylbetaine; Bethanecol; Urabeth; Myotonine chloride; Duvoid (TN); Myotonachol (TN); Urecholine (TN); Carbamoyl-beta-methylcholine; Carbamyl-beta-methylcholine; Ammonium, (2-hydroxypropyl)trimethyl-, carbamate (ester); (2-Hydroxypropyl)trimethylammonium carbamate; 1-Propanaminium, 2-((aminocarbonyl)oxy)-N,N,N-trimethyl-(9CI); 2-((Aminocarbonyl)oxy)-N,N,N-trimethyl-1-propanaminium; 2-(carbamoyloxy)-N,N,N-trimethylpropan-1-aminium; 2-carbamoyloxypropyl(trimethyl)azanium; 2-carbamoyloxypropyl-trimethylazanium DMCLHO0 CP Merck & Co DMCLHO0 TC Parasympathomimetics DMCLHO0 DT Small molecular drug DMCLHO0 PC 2370 DMCLHO0 MW 161.22 DMCLHO0 FM C7H17N2O2+ DMCLHO0 IC InChI=1S/C7H16N2O2/c1-6(11-7(8)10)5-9(2,3)4/h6H,5H2,1-4H3,(H-,8,10)/p+1 DMCLHO0 CS CC(C[N+](C)(C)C)OC(=O)N DMCLHO0 IK NZUPCNDJBJXXRF-UHFFFAOYSA-O DMCLHO0 IU 2-carbamoyloxypropyl(trimethyl)azanium DMCLHO0 CA CAS 674-38-4 DMCLHO0 CB CHEBI:3084 DMCLHO0 DE Urinary retention DM2C4RF ID DM2C4RF DM2C4RF DN Betrixaban DM2C4RF HS Approved DM2C4RF SN Betrixaban; 330942-05-7; Bevyxxa; PRT054021; UNII-74RWP7W0J9; PRT 054021; 74RWP7W0J9; betrixaban maleate; Betrixaban [USAN:INN]; betrixaban/; Betrixaban (USAN); D0J0BU; SCHEMBL158591; QCR-99; GTPL9602; EX-A358; MolPort-009-682-948; ZINC3 DM2C4RF CP Portola Pharmaceuticals DM2C4RF DT Small molecular drug DM2C4RF PC 10275777 DM2C4RF MW 451.9 DM2C4RF FM C23H22ClN5O3 DM2C4RF IC InChI=1S/C23H22ClN5O3/c1-29(2)21(25)14-4-6-15(7-5-14)22(30)27-19-10-9-17(32-3)12-18(19)23(31)28-20-11-8-16(24)13-26-20/h4-13,25H,1-3H3,(H,27,30)(H,26,28,31) DM2C4RF CS CN(C)C(=N)C1=CC=C(C=C1)C(=O)NC2=C(C=C(C=C2)OC)C(=O)NC3=NC=C(C=C3)Cl DM2C4RF IK XHOLNRLADUSQLD-UHFFFAOYSA-N DM2C4RF IU N-(5-chloropyridin-2-yl)-2-[[4-(N,N-dimethylcarbamimidoyl)benzoyl]amino]-5-methoxybenzamide DM2C4RF CA CAS 330942-05-7 DM2C4RF CB CHEBI:140421 DM2C4RF DE Venous thromboembolism; Cerebrovascular ischaemia DMSD1UN ID DMSD1UN DMSD1UN DN Bevacizumab DMSD1UN HS Approved DMSD1UN SN Bevacizumab (ophthalmic slow-release tissue tablet) DMSD1UN CP University of London DMSD1UN DT Monoclonal antibody DMSD1UN SQ Bevacizumab light chain: DIQMTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSTVPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC >"Bevacizumab heavy chain"EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYYGSSHWYFDVWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK DMSD1UN DE Solid tumour/cancer; Colorectal cancer; Lung cancer; Metastatic colorectal cancer; Brain metastases; Ovarian cancer DMZFICR ID DMZFICR DMZFICR DN Bevantolol DMZFICR HS Approved DMZFICR SN Bevantololum; Bevantolol [INN:BAN]; Bevantololum [INN-Latin]; (+-)-bevantolol; 1-((2-(3,4-Dimethoxyphenyl)ethyl)amino)-3-(3-methylphenoxy)-2-propanol; 1-((2-(3,4-dimethoxyphenyl)ethyl)amino)-3-(3-methylphenoxy)-2-propanol; 1-(3,4-Dimethoxyphenethylamino)-3-(m-tolyloxy)-2-propanol; 1-(3,4-dimethoxyphenethylamino)-3-m-tolyloxy-propan-2-ol; 1-[2-(3,4-Dimethoxy-phenyl)-ethylamino]-3-m-tolyloxy-propan-2-ol; 1-[2-(3,4-dimethoxyphenyl)ethylamino]-3-(3-methylphenoxy)propan-2-ol; 1-{[2-(3,4-dimethoxyphenyl)ethyl]amino}-3-(3-methylphenoxy)propan-2-ol DMZFICR TC Antihypertensive Agents DMZFICR DT Small molecular drug DMZFICR PC 2372 DMZFICR MW 345.4 DMZFICR FM C20H27NO4 DMZFICR IC InChI=1S/C20H27NO4/c1-15-5-4-6-18(11-15)25-14-17(22)13-21-10-9-16-7-8-19(23-2)20(12-16)24-3/h4-8,11-12,17,21-22H,9-10,13-14H2,1-3H3 DMZFICR CS CC1=CC(=CC=C1)OCC(CNCCC2=CC(=C(C=C2)OC)OC)O DMZFICR IK HXLAFSUPPDYFEO-UHFFFAOYSA-N DMZFICR IU 1-[2-(3,4-dimethoxyphenyl)ethylamino]-3-(3-methylphenoxy)propan-2-ol DMZFICR CA CAS 59170-23-9 DMZFICR CB CHEBI:238698 DMZFICR DE Hypertension DMOBIKY ID DMOBIKY DMOBIKY DN Bexarotene DMOBIKY HS Approved DMOBIKY SN Bexaroteno; Bexarotenum; Targret; Targretin; Targretyn; Targrexin; Bexarotene [USAN]; Elan brand of bexarotene;Ligand brand of bexarotene; LG 1069; LG100069; LG1069; LG69 compound; LGD 1069; LGD1069; LG-100069; LGD-1069; Targretin (TN); Targretin-gel; Bexarotene (USAN/INN); P-(1-(5,6,7,8-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphthyl)vinyl)benzoic acid; 3-methyl-TTNEB; 4-(1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethenyl)benzoic acid; 4-(1-(5,6,7,8-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)ethenyl)benzoic acid; 4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)ethenyl]benzoic acid; 4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)vinyl]benzoic acid; 4-[1-(3,5,5,8,8-pentamethyl-6,7-dihydronaphthalen-2-yl)ethenyl]benzoic acid; 4-[1-3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthaleneyl)vinyl]benzene carboxylic acid; 9RA DMOBIKY CP Eisai Inc DMOBIKY TC Anticancer Agents DMOBIKY DT Small molecular drug DMOBIKY PC 82146 DMOBIKY MW 348.5 DMOBIKY FM C24H28O2 DMOBIKY IC InChI=1S/C24H28O2/c1-15-13-20-21(24(5,6)12-11-23(20,3)4)14-19(15)16(2)17-7-9-18(10-8-17)22(25)26/h7-10,13-14H,2,11-12H2,1,3-6H3,(H,25,26) DMOBIKY CS CC1=CC2=C(C=C1C(=C)C3=CC=C(C=C3)C(=O)O)C(CCC2(C)C)(C)C DMOBIKY IK NAVMQTYZDKMPEU-UHFFFAOYSA-N DMOBIKY IU 4-[1-(3,5,5,8,8-pentamethyl-6,7-dihydronaphthalen-2-yl)ethenyl]benzoic acid DMOBIKY CA CAS 153559-49-0 DMOBIKY CB CHEBI:50859 DMOBIKY DE Cutaneous T-cell lymphoma DMZDCS0 ID DMZDCS0 DMZDCS0 DN Bezafibrate DMZDCS0 HS Approved DMZDCS0 SN Azufibrat; Befibrat; Befizal; BezaLande; BezaPuren; Bezabeta; Bezacur; Bezafibrat; Bezafibrato; Bezafibratum; Bezafisal;Bezalip; Bezamerck; Bezatol; Cedur; Difaterol; Durabezur; Eulitop; Lipox; Reducterol; Sklerofibrat; Solibay; Azupharma Brand of Bezafibrate; Bayer Brand of Bezafibrate; Berlin Chemie Brand of Bezafibrate; Betapharm Brand of Bezafibrate; Beza Lande; Beza Puren; Bezafibrat PB; Bezafibrate Azupharma Brand; Bezafibrate Bayer Brand; Bezafibrate Betapharm Brand; Bezafibrate Cryopharma Brand; Bezafibrate Elfar Brand; Bezafibrate Hennig Brand; Bezafibrate Hexal Brand; Bezafibrate Isis Brand; Bezafibrate Lakeside Brand; Bezafibrate Merckle Brand; Bezafibrate Roche Brand; Bezafibrate Synthelabo Brand; Bezafibrate TAD Brand; Bezafibrate Teva Brand; Bezafibrato [Spanish]; Bezalip Retard; Bezatol SR; Boehringer Mannheim Brand of Bezafibrate; Cryopharma Brand of Bezafibrate; Elfar Brand of Bezafibrate;Hennig Brand of Bezafibrate; Hexal Brand of Bezafibrate; Isis Brand of Bezafibrate; Lakeside Brand of Bezafibrate; Merckle Brand of Bezafibrate; Regadrin B; Roche Brand of Bezafibrate; Synthelabo Brand of Bezafibrate; TAD Brand of Bezafibrate; Teva Brand of Bezafibrate; BM 15075; LO 44; BF-759; BM 15.075; BM-15075; BM15.075; Berlin-Chemie Brand of Bezafibrate; Beza-Lande; Beza-Puren; Bezafibrate Berlin-Chemie Brand; Bezafibrato [INN-Spanish]; Bezafibratum [INN-Latin]; Bezalip (TN); Bezatol SR (TN); PB, Bezafibrat; BM-15.075; Bezafibrate (JP15/USAN/INN); Bezafibrate [USAN:BAN:INN:JAN]; A-[4-(4-chlorobenzoylaminoethyl)phenoxy]isobutyric acid; 2-(4-{2-[(4-chlorobenzoyl)amino]ethyl}phenoxy)-2-methylpropanoic acid; 2-(p-(2-(p-Chlorobenzamido)ethyl)phenoxy)-2-methylpropionic acid; 2-[4-(2-[4-Chlorobenzamido]ethyl)-phenoxy]-2-methylpropanoic acid; 2-[4-[2-(4-Chlorobenzamido)ethyl]phenoxy]-2-methylpropanoic acid; 2-[4-[2-(4-Chlorobenzamido)ethyl]phenoxy]isobutyric Acid; 2-[4-[2-[(4-chlorobenzoyl)amino]ethyl]phenoxy]-2-methylpropanoic acid DMZDCS0 TC Antilipemic Agents DMZDCS0 DT Small molecular drug DMZDCS0 PC 39042 DMZDCS0 MW 361.8 DMZDCS0 FM C19H20ClNO4 DMZDCS0 IC InChI=1S/C19H20ClNO4/c1-19(2,18(23)24)25-16-9-3-13(4-10-16)11-12-21-17(22)14-5-7-15(20)8-6-14/h3-10H,11-12H2,1-2H3,(H,21,22)(H,23,24) DMZDCS0 CS CC(C)(C(=O)O)OC1=CC=C(C=C1)CCNC(=O)C2=CC=C(C=C2)Cl DMZDCS0 IK IIBYAHWJQTYFKB-UHFFFAOYSA-N DMZDCS0 IU 2-[4-[2-[(4-chlorobenzoyl)amino]ethyl]phenoxy]-2-methylpropanoic acid DMZDCS0 CA CAS 41859-67-0 DMZDCS0 CB CHEBI:47612 DMZDCS0 DE Hyperlipidaemia DMTZC5G ID DMTZC5G DMTZC5G DN Bezlotoxumab DMTZC5G HS Approved DMTZC5G SN CDB1; Clostridium difficile toxin B monoclonal antibody; MBL-CDB1; MDX-1388; MK 6072; Zinplava DMTZC5G CP Merck & Co. DMTZC5G DT Monoclonal antibody DMTZC5G DE C. difficile infection DMTKD7Q ID DMTKD7Q DMTKD7Q DN BIBW 2992 DMTKD7Q HS Approved DMTKD7Q SN Afatinib; Tomtovok; Tovok; BIBW-2992; Tovok (TN); Tovok, BIBW2992; (2E)-N-{4-[(3-chloro-4-fluorophenyl)amino]-7-[(3S)-tetrahydrofuran-3-yloxy]quinazolin-6-yl}-4-(dimethylamino)but-2-enamide; EGFR inhibitor 2nd gens DMTKD7Q CP Boehringer Ingelheim DMTKD7Q DT Small molecular drug DMTKD7Q PC 10184653 DMTKD7Q MW 485.9 DMTKD7Q FM C24H25ClFN5O3 DMTKD7Q IC InChI=1S/C24H25ClFN5O3/c1-31(2)8-3-4-23(32)30-21-11-17-20(12-22(21)34-16-7-9-33-13-16)27-14-28-24(17)29-15-5-6-19(26)18(25)10-15/h3-6,10-12,14,16H,7-9,13H2,1-2H3,(H,30,32)(H,27,28,29)/b4-3+/t16-/m0/s1 DMTKD7Q CS CN(C)C/C=C/C(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)O[C@H]4CCOC4 DMTKD7Q IK ULXXDDBFHOBEHA-CWDCEQMOSA-N DMTKD7Q IU (E)-N-[4-(3-chloro-4-fluoroanilino)-7-[(3S)-oxolan-3-yl]oxyquinazolin-6-yl]-4-(dimethylamino)but-2-enamide DMTKD7Q CA CAS 850140-72-6 DMTKD7Q CB CHEBI:61390 DMTKD7Q DE Non-small-cell lung cancer DMZMSPF ID DMZMSPF DMZMSPF DN Bicalutamide DMZMSPF HS Approved DMZMSPF SN Casodex; Cosudex; Propanamide; Raffolutil; Astra brand of bicalutamide; AstraZeneca brand of bicalutamide; Zeneca brand of bicalutamide; Calutide (TN); Casodex (TN); Cosudex (TN); KS-1161; Kalumid (TN); Bicalutamide [USAN:INN:BAN]; Bicalutamide (JAN/USP/INN); Casodex, Cosudex, Calutide, Kalumid, Bicalutamide; N-[4-cyano-3-(trifluoromethyl)phenyl]-3-(4-fluorophenyl)sulfonyl-2-hydroxy-2-methylpropanamide; (+-)-4'-Cyano-alpha,alpha,alpha-trifluoro-3-((p-fluorophenyl)sulfonyl)-2-methyl-m-lactotoluidide; 4'-cyano-3-(4-fluorophenylsulfonyl)-2-hydroxy-2-methyl-3'-(trifluoromethyl)propionanilide DMZMSPF CP AstraZeneca plc DMZMSPF TC Anticancer Agents DMZMSPF DT Small molecular drug DMZMSPF PC 2375 DMZMSPF MW 430.4 DMZMSPF FM C18H14F4N2O4S DMZMSPF IC InChI=1S/C18H14F4N2O4S/c1-17(26,10-29(27,28)14-6-3-12(19)4-7-14)16(25)24-13-5-2-11(9-23)15(8-13)18(20,21)22/h2-8,26H,10H2,1H3,(H,24,25) DMZMSPF CS CC(CS(=O)(=O)C1=CC=C(C=C1)F)(C(=O)NC2=CC(=C(C=C2)C#N)C(F)(F)F)O DMZMSPF IK LKJPYSCBVHEWIU-UHFFFAOYSA-N DMZMSPF IU N-[4-cyano-3-(trifluoromethyl)phenyl]-3-(4-fluorophenyl)sulfonyl-2-hydroxy-2-methylpropanamide DMZMSPF CA CAS 90357-06-5 DMZMSPF CB CHEBI:91617 DMZMSPF DE Prostate cancer DMG0H8K ID DMG0H8K DMG0H8K DN Bictegravir, emtricitabine and tenofovir alafenamide DMG0H8K HS Approved DMG0H8K SN S900007760; Bictegravir mixture with emtricitabine and tenofovir alafenamide DMG0H8K CP Gilead Sciences DMG0H8K PC 129626368 DMG0H8K MW 1173.1 DMG0H8K FM C50H57F4N12O13PS DMG0H8K IC InChI=1S/C21H18F3N3O5.C21H29N6O5P.C8H10FN3O3S/c22-9-3-14(23)12(15(24)4-9)6-25-20(30)13-7-26-8-16-27(10-1-2-11(5-10)32-16)21(31)17(26)19(29)18(13)28;1-14(2)31-21(28)16(4)26-33(29,32-17-8-6-5-7-9-17)13-30-15(3)10-27-12-25-18-19(22)23-11-24-20(18)27;9-4-1-12(8(14)11-7(4)10)5-3-16-6(2-13)15-5/h3-4,7,10-11,16,29H,1-2,5-6,8H2,(H,25,30);5-9,11-12,14-16H,10,13H2,1-4H3,(H,26,29)(H2,22,23,24);1,5-6,13H,2-3H2,(H2,10,11,14)/t10-,11+,16+;15-,16+,33+;5-,6+/m010/s1 DMG0H8K CS C[C@H](CN1C=NC2=C(N=CN=C21)N)OC[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3.C1C[C@@H]2C[C@H]1N3[C@H](O2)CN4C=C(C(=O)C(=C4C3=O)O)C(=O)NCC5=C(C=C(C=C5F)F)F.C1[C@H](O[C@H](S1)CO)N2C=C(C(=NC2=O)N)F DMG0H8K IK GMIGIKGMWTUBHA-UKQLQXPXSA-N DMG0H8K IU 4-amino-5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one;(1S,11R,13R)-5-hydroxy-3,6-dioxo-N-[(2,4,6-trifluorophenyl)methyl]-12-oxa-2,9-diazatetracyclo[11.2.1.02,11.04,9]hexadeca-4,7-diene-7-carboxamide;propan-2-yl (2S)-2-[[[(2R)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethyl-phenoxyphosphoryl]amino]propanoate DMG0H8K DE Human immunodeficiency virus infection DM3KN7V ID DM3KN7V DM3KN7V DN Bifonazole DM3KN7V HS Approved DM3KN7V SN Amycor; Azolmen; Bifokey; Bifomyk; Bifon; Bifonazol; Bifonazolum; Moldina; Mycospor; Trifonazole; Bayer brand of bifonazole; Bioglan brand of bifonazole; Canesten Extra Bifonazol; Canesten brand of bifonazole; Dermapharm brand of bifonazole; Inkeysa brand of bifonazole; Juventus brand of bifonazole; Merck Lipha Sante brand of bifonazole; Bay H-4502; Bifonazol [INN-Spanish]; Bifonazolum [INN-Latin]; Canespor (TN); Mycospor (TN); Bay-h-4502; Bifonazole (JP15/USAN/INN); Bifonazole [USAN:BAN:INN:JAN]; (+-)-1-([1,1'-Biphenyl]-4-ylphenylmethyl)-1H-imidazole; (+-)-1-(p,alpha-Diphenylbenzyl)imidazole; 1-((4-Biphenylyl)phenylmethyl)-1H-imidazole; 1-(alpha-(4-Biphenylyl)benzyl)imidazole; 1-(p,alpha-Diphenylbenzyl)imidazole; 1-[4,alpha-Diphenylbenzyl]-imidazole; 1-[biphenyl-4-yl(phenyl)methyl]-1H-imidazole; 1-[phenyl-(4-phenylphenyl)methyl]imidazole DM3KN7V CP Bayer Pharmaceuticals Corporation DM3KN7V TC Antifungal Agents DM3KN7V DT Small molecular drug DM3KN7V PC 2378 DM3KN7V MW 310.4 DM3KN7V FM C22H18N2 DM3KN7V IC InChI=1S/C22H18N2/c1-3-7-18(8-4-1)19-11-13-21(14-12-19)22(24-16-15-23-17-24)20-9-5-2-6-10-20/h1-17,22H DM3KN7V CS C1=CC=C(C=C1)C2=CC=C(C=C2)C(C3=CC=CC=C3)N4C=CN=C4 DM3KN7V IK OCAPBUJLXMYKEJ-UHFFFAOYSA-N DM3KN7V IU 1-[phenyl-(4-phenylphenyl)methyl]imidazole DM3KN7V CA CAS 60628-96-8 DM3KN7V CB CHEBI:78692 DM3KN7V DE Fungal infection DMX0E5B ID DMX0E5B DMX0E5B DN Bimatoprost DMX0E5B HS Approved DMX0E5B SN Bimatoprost (topical, alopecia) DMX0E5B CP Allergan Inc DMX0E5B DT Small molecular drug DMX0E5B PC 5311027 DMX0E5B MW 415.6 DMX0E5B FM C25H37NO4 DMX0E5B IC InChI=1S/C25H37NO4/c1-2-26-25(30)13-9-4-3-8-12-21-22(24(29)18-23(21)28)17-16-20(27)15-14-19-10-6-5-7-11-19/h3,5-8,10-11,16-17,20-24,27-29H,2,4,9,12-15,18H2,1H3,(H,26,30)/b8-3-,17-16+/t20-,21+,22+,23-,24+/m0/s1 DMX0E5B CS CCNC(=O)CCC/C=C\\C[C@H]1[C@H](C[C@H]([C@@H]1/C=C/[C@H](CCC2=CC=CC=C2)O)O)O DMX0E5B IK AQOKCDNYWBIDND-FTOWTWDKSA-N DMX0E5B IU (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3S)-3-hydroxy-5-phenylpent-1-enyl]cyclopentyl]-N-ethylhept-5-enamide DMX0E5B CA CAS 155206-00-1 DMX0E5B CB CHEBI:51230 DMX0E5B DE Alopecia; Glaucoma/ocular hypertension DME78OA ID DME78OA DME78OA DN Biperiden DME78OA HS Approved DME78OA SN Akineton; Beperiden; Biperidene; Biperideno; Biperidenum; Biperidine; Biperidene hydrochloride; KL 373; Akineton (TN);Biperidene [INN-French]; Biperideno [INN-Spanish]; Biperidenum [INN-Latin]; Biperiden (JAN/USP/INN); Biperiden [USAN:BAN:INN:JAN]; Biperiden [USAN:INN:BAN:JAN]; Alpha-5-Norbornen-2-yl-alpha-phenyl-1-piperidinepropanol; Alpha-bicyclo[2.2.1]hept-5-en-2-yl-alpha-phenyl-1-piperidinepropanol; Alpha-Bicyclo(2.2.1)hept-5-en-2-yl-alpha-phenyl-1-piperidinepropanol; Alpha-(Bicyclo(2.2.1)hept-5-en-2-yl)-alpha-phenyl-1-piperidino propanol; 1-(5-bicyclo[2.2.1]hept-2-enyl)-1-phenyl-3-piperidin-1-ylpropan-1-ol; 1-(Bicyclo(2.2.1)hept-5-en-2alpha-yl)-1-phenyl-3-piperidinopropanol; 1-(bicyclo[2.2.1]hept-5-en-2-yl)-1-phenyl-3-(piperidin-1-yl)propan-1-ol; 1-Bicycloheptenyl-1-phenyl-3-piperidino-propanol-1; 1-Piperidinepropanol, .alpha.-bicyclo[2.2.1]hept-5-en-2-yl-.alpha.-phenyl-, hydrochloride; 3-Piperidino-1-phenyl-1-bicyclo(2.2.1)hepten-(5)-yl-propanol-(1); 3-Piperidino-1-phenyl-1-bicyclo(2.2.1)hepten-(5)-yl-propanol-(1) [German]; 3-Piperidino-1-phenyl-1-bicycloheptenyl-1-propanol DME78OA CP Knoll Pharma DME78OA TC Antiparkinson Agents DME78OA DT Small molecular drug DME78OA PC 2381 DME78OA MW 311.5 DME78OA FM C21H29NO DME78OA IC InChI=1S/C21H29NO/c23-21(19-7-3-1-4-8-19,11-14-22-12-5-2-6-13-22)20-16-17-9-10-18(20)15-17/h1,3-4,7-10,17-18,20,23H,2,5-6,11-16H2 DME78OA CS C1CCN(CC1)CCC(C2CC3CC2C=C3)(C4=CC=CC=C4)O DME78OA IK YSXKPIUOCJLQIE-UHFFFAOYSA-N DME78OA IU 1-(2-bicyclo[2.2.1]hept-5-enyl)-1-phenyl-3-piperidin-1-ylpropan-1-ol DME78OA CA CAS 514-65-8 DME78OA CB CHEBI:3112 DME78OA DE Parkinson disease DMTKU46 ID DMTKU46 DMTKU46 DN Bismuth DMTKU46 HS Approved DMTKU46 SN Bismut; Bismuto; Wismut; Bismuth standard for AAS; Bismuth standard for ICP; LTBB002773; Bismuth(III) nitrate solution; Bismuth, elemental; Bismuth-209; BISMUTH, 99.95%; BISMUTH, 99.999%; 83Bi DMTKU46 TC Antidiarrheals DMTKU46 DT Small molecular drug DMTKU46 PC 5359367 DMTKU46 MW 208.98 DMTKU46 FM Bi DMTKU46 IC InChI=1S/Bi DMTKU46 CS [Bi] DMTKU46 IK JCXGWMGPZLAOME-UHFFFAOYSA-N DMTKU46 IU bismuth DMTKU46 CA CAS 7440-69-9 DMTKU46 CB CHEBI:33301 DMTKU46 DE Diarrhea DM3UZ95 ID DM3UZ95 DM3UZ95 DN Bisoprolol DM3UZ95 HS Approved DM3UZ95 SN Bisocor; Bisoprololum; Cardicor; Concor; Detensiel; Emconcor; Emcor; Euradal; Isoten; Monocor; Soloc; Soprol; Zebeta; Bisoprolol fumerate; Bisoprolol hemifumarate; Bisoprololum [Latin]; CL-297939; Concor (TN); Concore (TN); EMD-33512; Monocor (TN); Zebeta (TN); Bisoprolol (USAN/INN); Bisoprolol [USAN:BAN:INN]; EMD-33-512; (+-)-1-((alpha-(2-Isopropoxyethoxy)-p-tolyl)oxy)-3-(isopropylamino)-2-propanol; (RS)-1-(4-(2-Isopropoxyethoxymethyl)phenoxy)-3-(isopropylamino)-2-propanol; 1-(propan-2-ylamino)-3-[4-(2-propan-2-yloxyethoxymethyl)phenoxy]propan-2-ol; 1-[(1-methylethyl)amino]-3-({4-[({2-[(1-methylethyl)oxy]ethyl}oxy)methyl]phenyl}oxy)propan-2-ol; 1-{4-[(2-isopropoxyethoxy)methyl]phenoxy}-3-(isopropylamino)propan-2-ol DM3UZ95 TC Antihypertensive Agents DM3UZ95 DT Small molecular drug DM3UZ95 PC 2405 DM3UZ95 MW 325.4 DM3UZ95 FM C18H31NO4 DM3UZ95 IC InChI=1S/C18H31NO4/c1-14(2)19-11-17(20)13-23-18-7-5-16(6-8-18)12-21-9-10-22-15(3)4/h5-8,14-15,17,19-20H,9-13H2,1-4H3 DM3UZ95 CS CC(C)NCC(COC1=CC=C(C=C1)COCCOC(C)C)O DM3UZ95 IK VHYCDWMUTMEGQY-UHFFFAOYSA-N DM3UZ95 IU 1-(propan-2-ylamino)-3-[4-(2-propan-2-yloxyethoxymethyl)phenoxy]propan-2-ol DM3UZ95 CA CAS 66722-44-9 DM3UZ95 CB CHEBI:3127 DM3UZ95 DE Hypertension DMK6XAV ID DMK6XAV DMK6XAV DN Bitolterol DMK6XAV HS Approved DMK6XAV SN Tornalate DMK6XAV CP Sanofi Aventis Us Llc DMK6XAV DT Small molecular drug DMK6XAV PC 35330 DMK6XAV MW 461.5 DMK6XAV FM C28H31NO5 DMK6XAV IC InChI=1S/C28H31NO5/c1-18-6-10-20(11-7-18)26(31)33-24-15-14-22(23(30)17-29-28(3,4)5)16-25(24)34-27(32)21-12-8-19(2)9-13-21/h6-16,23,29-30H,17H2,1-5H3 DMK6XAV CS CC1=CC=C(C=C1)C(=O)OC2=C(C=C(C=C2)C(CNC(C)(C)C)O)OC(=O)C3=CC=C(C=C3)C DMK6XAV IK FZGVEKPRDOIXJY-UHFFFAOYSA-N DMK6XAV IU [4-[2-(tert-butylamino)-1-hydroxyethyl]-2-(4-methylbenzoyl)oxyphenyl] 4-methylbenzoate DMK6XAV CA CAS 30392-40-6 DMK6XAV CB CHEBI:3133 DMK6XAV DE Chronic obstructive pulmonary disease; Asthma DMECRX1 ID DMECRX1 DMECRX1 DN Bivalirudin DMECRX1 HS Approved DMECRX1 SN 128270-60-0; Angiomax; Hirulog; bivalirudinum; bivalirudina; Bivalirudin Trifluoroacetate; BG-8967; UNII-TN9BEX005G; BG8967; Bivalirudin Trifluoacetate; TN9BEX005G; D-Phenylalanyl-L-prolyl-L-arginyl-L-prolylglycylglycylglycylglycyl-L-asparaginylglycyl-L-alpha-aspartyl-L-phenylalanyl-L-alpha-glutamyl-L-alpha-glutamyl-L-isoleucyl-L-prolyl-L-alpha-glutamyl-L-alpha-glutamyl-L-tyrosyl-L-leucine; CHEBI:59173; Hirulog-1; Angiox; Bivalirudina; Bivalirudine; Bivalirudinum; The Medicines Company brand of bivalirudin; BG 8967; Angiomax (TN); HS-2004; Bivalirudin [USAN:BAN:INN]; Phe-Pro-Arg-Pro-(Gly)4 desulfato-Tyr63'-hirugen; Phe-Pro-Arg-Pro-(Gly)4-desulfohirudin-(53-64); Phe-Pro-Arg-Pro-(Gly)4-Asn-Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu DMECRX1 TC Antithrombotic Agents DMECRX1 DT Small molecular drug DMECRX1 PC 16129704 DMECRX1 MW 2180.3 DMECRX1 FM C98H138N24O33 DMECRX1 IC InChI=1S/C98H138N24O33/c1-5-52(4)82(96(153)122-39-15-23-70(122)92(149)114-60(30-34-79(134)135)85(142)111-59(29-33-78(132)133)86(143)116-64(43-55-24-26-56(123)27-25-55)89(146)118-67(97(154)155)40-51(2)3)119-87(144)61(31-35-80(136)137)112-84(141)58(28-32-77(130)131)113-88(145)63(42-54-18-10-7-11-19-54)117-90(147)66(45-81(138)139)110-76(129)50-107-83(140)65(44-71(100)124)109-75(128)49-106-73(126)47-104-72(125)46-105-74(127)48-108-91(148)68-21-13-38-121(68)95(152)62(20-12-36-103-98(101)102)115-93(150)69-22-14-37-120(69)94(151)57(99)41-53-16-8-6-9-17-53/h6-11,16-19,24-27,51-52,57-70,82,123H,5,12-15,20-23,28-50,99H2,1-4H3,(H2,100,124)(H,104,125)(H,105,127)(H,106,126)(H,107,140)(H,108,148)(H,109,128)(H,110,129)(H,111,142)(H,112,141)(H,113,145)(H,114,149)(H,115,150)(H,116,143)(H,117,147)(H,118,146)(H,119,144)(H,130,131)(H,132,133)(H,134,135)(H,136,137)(H,138,139)(H,154,155)(H4,101,102,103)/t52-,57+,58-,59-,60-,61-,62-,63-,64-,65-,66-,67-,68-,69-,70-,82-/m0/s1 DMECRX1 CS CC[C@H](C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CC(C)C)C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)O)NC(=O)CNC(=O)[C@H](CC(=O)N)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@@H]4CCCN4C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]5CCCN5C(=O)[C@@H](CC6=CC=CC=C6)N DMECRX1 IK OIRCOABEOLEUMC-GEJPAHFPSA-N DMECRX1 IU (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-4-amino-2-[[2-[[2-[[2-[[2-[[(2S)-1-[(2S)-2-[[(2S)-1-[(2R)-2-amino-3-phenylpropanoyl]pyrrolidine-2-carbonyl]amino]-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]acetyl]amino]acetyl]amino]acetyl]amino]-4-oxobutanoyl]amino]acetyl]amino]-3-carboxypropanoyl]amino]-3-phenylpropanoyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbonyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoic acid DMECRX1 CA CAS 128270-60-0 DMECRX1 CB CHEBI:59173 DMECRX1 DE Thrombocytopenia DMR8YD6 ID DMR8YD6 DMR8YD6 DN B-Lactams DMR8YD6 HS Approved DMR8YD6 SN Luteolin; luteolin; 491-70-3; Luteolol; 2-(3,4-Dihydroxyphenyl)-5,7-dihydroxy-4H-chromen-4-one; Luteoline; Digitoflavone; Flacitran; Weld Lake; Cyanidenon 1470; Salifazide; Yama kariyasu; 5,7,3',4'-Tetrahydroxyflavone; UNII-KUX1ZNC9J2; CI Natural Yellow 2; 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-; 7-Tetrahydroxyflavone; CCRIS 3790; EINECS 207-741-0; KUX1ZNC9J2; CHEMBL151; BRN 0292084; 2-(3,4-dihydroxyphenyl)-5,7-dihydroxychromen-4-one DMR8YD6 DT Small molecular drug DMR8YD6 PC 5280445 DMR8YD6 MW 286.24 DMR8YD6 FM C15H10O6 DMR8YD6 IC InChI=1S/C15H10O6/c16-8-4-11(19)15-12(20)6-13(21-14(15)5-8)7-1-2-9(17)10(18)3-7/h1-6,16-19H DMR8YD6 CS C1=CC(=C(C=C1C2=CC(=O)C3=C(C=C(C=C3O2)O)O)O)O DMR8YD6 IK IQPNAANSBPBGFQ-UHFFFAOYSA-N DMR8YD6 IU 2-(3,4-dihydroxyphenyl)-5,7-dihydroxychromen-4-one DMR8YD6 CA CAS 491-70-3 DMR8YD6 CB CHEBI:15864 DMR8YD6 DE Bacterial infection DMNER5S ID DMNER5S DMNER5S DN Bleomycin DMNER5S HS Approved DMNER5S SN BLM; Blenoxane; Bleo; Bleocin; Bleogin; Bleomicin; Bleomicina; Bleomycine; Bleomycins; Bleomycinum; Bleomycin sulfate; Bleomycin a2; Pingyangmyvin A2; Zhengguangmycin A2; Zhengguangmycin A2 [Chinese]; Blenoxane (TN); Bleomicina [INN-Spanish]; Bleomycin A(2); Bleomycin A2 & Bleomycin B2; Bleomycin B(2); Bleomycine [INN-French]; Bleomycinum [INN-Latin]; NDC 0015-3010; N(1)-[3-(dimethylsulfonio)propyl]bleomycinamide; N1-(3-(Dimethylsulfonio)propyl)bleomycinamide DMNER5S CP Bristol-Myers Squibb DMNER5S TC Anticancer Agents DMNER5S DT Small molecular drug DMNER5S PC 5360373 DMNER5S MW 1415.6 DMNER5S FM C55H84N17O21S3+ DMNER5S IC InChI=1S/C55H83N17O21S3/c1-20-33(69-46(72-44(20)58)25(12-31(57)76)64-13-24(56)45(59)82)50(86)71-35(41(26-14-61-19-65-26)91-54-43(39(80)37(78)29(15-73)90-54)92-53-40(81)42(93-55(60)88)38(79)30(16-74)89-53)51(87)66-22(3)36(77)21(2)47(83)70-34(23(4)75)49(85)63-10-8-32-67-28(18-94-32)52-68-27(17-95-52)48(84)62-9-7-11-96(5)6/h14,17-19,21-25,29-30,34-43,53-54,64,73-75,77-81H,7-13,15-16,56H2,1-6H3,(H13-,57,58,59,60,61,62,63,65,66,69,70,71,72,76,82,83,84,85,86,87,88)/p+1/t21-,22+,23+,24-,25-,29?,30?,34-,35-,36-,37?,38?,39?,40?,41-,42?,43?,53?,54?/m0/s1 DMNER5S CS CC1=C(N=C(N=C1N)[C@H](CC(=O)N)NC[C@@H](C(=O)N)N)C(=O)N[C@@H]([C@H](C2=CN=CN2)OC3C(C(C(C(O3)CO)O)O)OC4C(C(C(C(O4)CO)O)OC(=O)N)O)C(=O)N[C@H](C)[C@H]([C@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCCC5=NC(=CS5)C6=NC(=CS6)C(=O)NCCC[S+](C)C)O DMNER5S IK OYVAGSVQBOHSSS-WXFSZRTFSA-O DMNER5S IU 3-[[2-[2-[2-[[(2S,3R)-2-[[(2S,3S,4R)-4-[[(2S,3R)-2-[[6-amino-2-[(1S)-3-amino-1-[[(2S)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[3-[4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-(1H-imidazol-5-yl)propanoyl]amino]-3-hydroxy-2-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]ethyl]-1,3-thiazol-4-yl]-1,3-thiazole-4-carbonyl]amino]propyl-dimethylsulfanium DMNER5S CA CAS 11056-06-7 DMNER5S DE Hodgkin lymphoma DMGECIJ ID DMGECIJ DMGECIJ DN Blinatumomab DMGECIJ HS Approved DMGECIJ SN AMG 103; Blincyto DMGECIJ CP Amgen DMGECIJ DT Monoclonal antibody DMGECIJ SQ single chain variable fragment fusion protein : DIQLTQSPASLAVSLGQRATISCKASQSVDYDGDSYLNWYQQIPGQPPKLLIYDASNLVSGIPPRFSGSGSGTDFTLNIHPVEKVDAATYHCQQSTEDPWTFGGGTKLEIKGGGGSGGGGSGGGGSQVQLQQSGAELVRPGSSVKISCKASGYAFSSYWMNWVKQRPGQGLEWIGQIWPGDGDTNYNGKFKGKATLTADESSSTAYMQLSSLASEDSAVYFCARRETTTVGRYYYAMDYWGQGTTVTVSSGGGGSDIKLQQSGAELARPGASVKMSCKTSGYTFTRYTMHWVKQRPGQGLEWIGYINPSRGYTNYNQKFKDKATLTTDKSSSTAYMQLSSLTSEDSAVYYCARYYDDHYCLDYWGQGTTLTVSSVEGGSGGSGGSGGSGGVDDIQLTQSPAIMSASPGEKVTMTCRASSSVSYMNWYQQKSGTSPKRWIYDTSKVASGVPYRFSGSGSGTSYSLTISSMEAEDAATYYCQQWSSNPLTFGAGTKLELKHHHHHH DMGECIJ DE Acute lymphoblastic leukaemia; Diffuse large B-cell lymphoma DMQTAGO ID DMQTAGO DMQTAGO DN BMS-201038 DMQTAGO HS Approved DMQTAGO SN AEGR 733; AEGR733; BMS 201038; BMS 201238; BMS201038; AEGR-733; BMS 201038-01 DMQTAGO CP Bristol-Myers Squibb DMQTAGO DT Small molecular drug DMQTAGO PC 9853053 DMQTAGO MW 693.7 DMQTAGO FM C39H37F6N3O2 DMQTAGO IC InChI=1S/C39H37F6N3O2/c40-38(41,42)25-46-36(50)37(33-13-5-3-10-30(33)31-11-4-6-14-34(31)37)21-7-8-22-48-23-19-28(20-24-48)47-35(49)32-12-2-1-9-29(32)26-15-17-27(18-16-26)39(43,44)45/h1-6,9-18,28H,7-8,19-25H2,(H,46,50)(H,47,49) DMQTAGO CS C1CN(CCC1NC(=O)C2=CC=CC=C2C3=CC=C(C=C3)C(F)(F)F)CCCCC4(C5=CC=CC=C5C6=CC=CC=C64)C(=O)NCC(F)(F)F DMQTAGO IK MBBCVAKAJPKAKM-UHFFFAOYSA-N DMQTAGO IU N-(2,2,2-trifluoroethyl)-9-[4-[4-[[2-[4-(trifluoromethyl)phenyl]benzoyl]amino]piperidin-1-yl]butyl]fluorene-9-carboxamide DMQTAGO CA CAS 182431-12-5 DMQTAGO CB CHEBI:72297 DMQTAGO DE Familial hypercholesterolemia DMBSHMF ID DMBSHMF DMBSHMF DN Boceprevir DMBSHMF HS Approved DMBSHMF SN Boceprevir; Victrelis; 394730-60-0; SCH 503034; EBP 520; UNII-89BT58KELH; SCH-503034; 89BT58KELH; CHEBI:68621; (1R,2S,5S)-N-(4-amino-1-cyclobutyl-3,4-dioxobutan-2-yl)-3-[N-(tert-butylcarbamoyl)-3-methyl-L-valyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide; 3-{[(1R,2S,5S)-3-[(2S)-2-[(tert-butylcarbamoyl)amino]-3,3-dimethylbutanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2-yl]formamido}-4-cyclobutyl-2-oxobutanamide DMBSHMF DT Small molecular drug DMBSHMF PC 10324367 DMBSHMF MW 519.7 DMBSHMF FM C27H45N5O5 DMBSHMF IC InChI=1S/C27H45N5O5/c1-25(2,3)20(30-24(37)31-26(4,5)6)23(36)32-13-15-17(27(15,7)8)18(32)22(35)29-16(19(33)21(28)34)12-14-10-9-11-14/h14-18,20H,9-13H2,1-8H3,(H2,28,34)(H,29,35)(H2,30,31,37)/t15-,16?,17-,18-,20+/m0/s1 DMBSHMF CS CC1([C@@H]2[C@H]1[C@H](N(C2)C(=O)[C@H](C(C)(C)C)NC(=O)NC(C)(C)C)C(=O)NC(CC3CCC3)C(=O)C(=O)N)C DMBSHMF IK LHHCSNFAOIFYRV-DOVBMPENSA-N DMBSHMF IU (1R,2S,5S)-N-(4-amino-1-cyclobutyl-3,4-dioxobutan-2-yl)-3-[(2S)-2-(tert-butylcarbamoylamino)-3,3-dimethylbutanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide DMBSHMF CA CAS 394730-60-0 DMBSHMF CB CHEBI:68621 DMBSHMF DE Hepatitis C virus infection DM2EXC5 ID DM2EXC5 DM2EXC5 DN BOL-303259-X DM2EXC5 HS Approved DM2EXC5 SN Latanoprostene bunod; Latanoprostene bunod); NCX-116; PF-03187207; PF-3187207; BOL-303259-X1; NO donors (glaucoma), NicOx/Pfizer; NO-donating prostaglandin F2-alpha analogs (glaucoma), Pfizer; NO-donating prostaglandin F2-alpha analogs (glaucoma), NicOx/Pfizer; Nitric oxide-donating prostaglandin F2-alpha analogs (eye disease), NicOx/Pfizer; NO-donating prostaglandin F2-alpha analogs (glaucoma), NicOx/ Bausch & Lomb DM2EXC5 CP Bausch and Lomb/Valeant Pharmaceuticals DM2EXC5 DT Small molecular drug DM2EXC5 PC 11156438 DM2EXC5 MW 507.6 DM2EXC5 FM C27H41NO8 DM2EXC5 IC InChI=1S/C27H41NO8/c29-22(15-14-21-10-4-3-5-11-21)16-17-24-23(25(30)20-26(24)31)12-6-1-2-7-13-27(32)35-18-8-9-19-36-28(33)34/h1,3-6,10-11,22-26,29-31H,2,7-9,12-20H2/b6-1-/t22-,23+,24+,25-,26+/m0/s1 DM2EXC5 CS C1[C@H]([C@@H]([C@H]([C@H]1O)C/C=C\\CCCC(=O)OCCCCO[N+](=O)[O-])CC[C@H](CCC2=CC=CC=C2)O)O DM2EXC5 IK LOVMMUBRQUFEAH-UIEAZXIASA-N DM2EXC5 IU 4-nitrooxybutyl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]hept-5-enoate DM2EXC5 CA CAS 860005-21-6 DM2EXC5 DE Open-angle glaucoma; Renal cell carcinoma DMIFYLX ID DMIFYLX DMIFYLX DN Bopindolol DMIFYLX HS Approved DMIFYLX SN BOPINDOLOL; 62658-63-3; Sandonorm; (+-)-Bopindolol; 1-(tert-Butylamino)-3-((2-methyl-1H-indol-4-yl)oxy)propan-2-yl benzoate; Bopindololum [INN-Latin]; Bopindolol [INN]; UUOJIACWOAYWEZ-UHFFFAOYSA-N; Bopindolol (INN); Wandonorm; 69010-88-4; NCGC00163155-01; Sandonorm (TN); (+-)-4-(2-Benzoyloxy-3-tert-butylaminopropoxy)-2-methylindole; DSSTox_CID_2684; DSSTox_RID_76690; (+-)-1-(tert-Butylamino)-3-((2-methylindol-4-yl)oxy)-2-propanol benzoate (ester); DSSTox_GSID_22684 DMIFYLX DT Small molecular drug DMIFYLX PC 44112 DMIFYLX MW 380.5 DMIFYLX FM C23H28N2O3 DMIFYLX IC InChI=1S/C23H28N2O3/c1-16-13-19-20(25-16)11-8-12-21(19)27-15-18(14-24-23(2,3)4)28-22(26)17-9-6-5-7-10-17/h5-13,18,24-25H,14-15H2,1-4H3 DMIFYLX CS CC1=CC2=C(N1)C=CC=C2OCC(CNC(C)(C)C)OC(=O)C3=CC=CC=C3 DMIFYLX IK UUOJIACWOAYWEZ-UHFFFAOYSA-N DMIFYLX IU [1-(tert-butylamino)-3-[(2-methyl-1H-indol-4-yl)oxy]propan-2-yl] benzoate DMIFYLX CA CAS 62658-63-3 DMIFYLX CB CHEBI:143782 DMIFYLX DE Hypertension DMNO38U ID DMNO38U DMNO38U DN Bortezomib DMNO38U HS Approved DMNO38U SN 179324-69-7; Velcade; Bortezomib (PS-341); UNII-69G8BD63PP; N-[(1R)-1-(DIHYDROXYBORYL)-3-METHYLBUTYL]-N-(PYRAZIN-2-YLCARBONYL)-L-PHENYLALANINAMIDE; MLN-341; [(1R)-3-methyl-1-[[(2S)-3-phenyl-2-(pyrazine-2-carbonylamino)propanoyl]amino]butyl]boronic acid; [(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic acid; CHEMBL325041; 69G8BD63PP; Boronic acid,; DPBA; PROSCRIPT BORONIC ACID; LPD 341; LPD-341; VELCADE (TN); Velcade (TN); Pyz-Phe-boroLeu; Bortezomib(JAN/USAN/INN); Velcade, MG-341, PS-341, Bortezomib; N-[(1R)-1-(dihydroxyboranyl)-3-methylbutyl]-Nalpha-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide; Bortezomib (Proteasome inhibitor); Peptide boronate DMNO38U CP Takeda DMNO38U TC Anticancer Agents DMNO38U DT Small molecular drug DMNO38U PC 387447 DMNO38U MW 384.2 DMNO38U FM C19H25BN4O4 DMNO38U IC InChI=1S/C19H25BN4O4/c1-13(2)10-17(20(27)28)24-18(25)15(11-14-6-4-3-5-7-14)23-19(26)16-12-21-8-9-22-16/h3-9,12-13,15,17,27-28H,10-11H2,1-2H3,(H,23,26)(H,24,25)/t15-,17-/m0/s1 DMNO38U CS B([C@H](CC(C)C)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O DMNO38U IK GXJABQQUPOEUTA-RDJZCZTQSA-N DMNO38U IU [(1R)-3-methyl-1-[[(2S)-3-phenyl-2-(pyrazine-2-carbonylamino)propanoyl]amino]butyl]boronic acid DMNO38U CA CAS 179324-69-7 DMNO38U CB CHEBI:52717 DMNO38U DE Multiple myeloma; Non-hodgkin lymphoma; Mantle cell lymphoma DMIOGBU ID DMIOGBU DMIOGBU DN Bosentan DMIOGBU HS Approved DMIOGBU SN Actelion; Bosentanum; Tracleer; Bosentan (INN); KS-5062; Ro 47-0203; Tracleer (TN); Bosentan [USAN:INN:BAN]; Ro 47-0203/039; Ro-47-0203; Ro-47-0203/029; Ro-47-0203/039; P-tert-Butyl-N-[6-(2-hydroxyethoxy); P-tert-Butyl-N-(6-(2-hydroxyethoxy)-5-(o-methoxyphenoxy)-2-(2-pyrimidinyl)-4-pyrimidinyl)benzenesulfonamide; 4-(1,1-Dimethylethyl)-N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-(2,2'-bipyrimidin)-4-yl) benzenesulfornamide; 4-(1,1-Dimethylethyl)-N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-(2,2'-bipyrimidin)-4-yl)benzenesulfornamide; 4-t-butyl-N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2,2'-bipyrimidin-4-yl)benzenesulfonamide; 4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2,2'-bipyrimidin-4-yl]benzenesulfonamide; 4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-pyrimidin-2-ylpyrimidin-4-yl]benzenesulfonamide DMIOGBU CP Actelion Pharmaceuticals DMIOGBU TC Antihypertensive Agents DMIOGBU DT Small molecular drug DMIOGBU PC 104865 DMIOGBU MW 551.6 DMIOGBU FM C27H29N5O6S DMIOGBU IC InChI=1S/C27H29N5O6S/c1-27(2,3)18-10-12-19(13-11-18)39(34,35)32-23-22(38-21-9-6-5-8-20(21)36-4)26(37-17-16-33)31-25(30-23)24-28-14-7-15-29-24/h5-15,33H,16-17H2,1-4H3,(H,30,31,32) DMIOGBU CS CC(C)(C)C1=CC=C(C=C1)S(=O)(=O)NC2=C(C(=NC(=N2)C3=NC=CC=N3)OCCO)OC4=CC=CC=C4OC DMIOGBU IK GJPICJJJRGTNOD-UHFFFAOYSA-N DMIOGBU IU 4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-pyrimidin-2-ylpyrimidin-4-yl]benzenesulfonamide DMIOGBU CA CAS 147536-97-8 DMIOGBU CB CHEBI:51450 DMIOGBU DE Pulmonary arterial hypertension DMTI8YE ID DMTI8YE DMTI8YE DN Bosutinib DMTI8YE HS Approved DMTI8YE SN SKI 606; SKI606; Bosutinib (USAN); PF-5208763; SKI-606; Xy]-3-quinolinecarbonitrile; 4-((2,4-dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methyl-1-piperazinyl)propoxy)-3-quinolinecarbonitrile; 4-((2,4-dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile; 4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile; 4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propo; 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile; Bosutinib (BCR-ABL inhibitor 3rd gen) DMTI8YE CP Wyeth Research DMTI8YE TC Anticancer Agents DMTI8YE DT Small molecular drug DMTI8YE PC 5328940 DMTI8YE MW 530.4 DMTI8YE FM C26H29Cl2N5O3 DMTI8YE IC InChI=1S/C26H29Cl2N5O3/c1-32-6-8-33(9-7-32)5-4-10-36-25-13-21-18(11-24(25)35-3)26(17(15-29)16-30-21)31-22-14-23(34-2)20(28)12-19(22)27/h11-14,16H,4-10H2,1-3H3,(H,30,31) DMTI8YE CS CN1CCN(CC1)CCCOC2=C(C=C3C(=C2)N=CC(=C3NC4=CC(=C(C=C4Cl)Cl)OC)C#N)OC DMTI8YE IK UBPYILGKFZZVDX-UHFFFAOYSA-N DMTI8YE IU 4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile DMTI8YE CA CAS 380843-75-4 DMTI8YE CB CHEBI:39112 DMTI8YE DE Breast cancer DMW67MU ID DMW67MU DMW67MU DN Botulinum Toxin Type A DMW67MU HS Approved DMW67MU SN Botox; Botulinum toxin type A (JAN) DMW67MU SQ Botulinum Toxin Type A Sequence: MPFVNKQFNYKDPVNGVDIAYIKIPNVGQMQPVKAFKIHNKIWVIPERDTFTNPEEGDLNPPPEAKQVPVSYYDSTYLSTDNEKDNYLKGVTKLFERIYSTDLGRMLLTSIVRGIPFWGGSTIDTELKVIDTNCINVIQPDGSYRSEELNLVIIGPSADIIQFECKSFGHEVLNLTRNGYGSTQYIRFSPDFTFGFEESLEVDTNPLLGAGKFATDPAVTLAHELIHAGHRLYGIAINPNRVFKVNTNAYYEMSGLEVSFEELRTFGGHDAKFIDSLQENEFRLYYYNKFKDIASTLNKAKSIVGTTASLQYMKNVFKEKYLLSEDTSGKFSVDKLKFDKLYKMLTEIYTEDNFVKFFKVLNRKTYLNFDKAVFKINIVPKVNYTIYDGFNLRNTNLAANFNGQNTEINNMNFTKLKNFTGLFEFYKLLCVRGIITSKTKSLDKGYNKALNDLCIKVNNWDLFFSPSEDNFTNDLNKGEEITSDTNIEAAEENISLDLIQQYYLTFNFDNEPENISIENLSSDIIGQLELMPNIERFPNGKKYELDKYTMFHYLRAQEFEHGKSRIALTNSVNEALLNPSRVYTFFSSDYVKKVNKATEAAMFLGWVEQLVYDFTDETSEVSTTDKIADITIIIPYIGPALNIGNMLYKDDFVGALIFSGAVILLEFIPEIAIPVLGTFALVSYIANKVLTVQTIDNALSKRNEKWDEVYKYIVTNWLAKVNTQIDLIRKKMKEALENQAEATKAIINYQYNQYTEEEKNNINFNIDDLSSKLNESINKAMININKFLNQCSVSYLMNSMIPYGVKRLEDFDASLKDALLKYIYDNRGTLIGQVDRLKDKVNNTLSTDIPFQLSKYVDNQRLLSTFTEYIKNIINTSILNLRYESNHLIDLSRYASKINIGSKVNFDPIDKNQIQLFNLESSKIEVILKNAIVYNSMYENFSTSFWIRIPKYFNSISLNNEYTIINCMENNSGWKVSLNYGEIIWTLQDTQEIKQRVVFKYSQMINISDYINRWIFVTITNNRLNNSKIYINGRLIDQKPISNLGNIHASNNIMFKLDGCRDTHRYIWIKYFNLFDKELNEKEIKDLYDNQSNSGILKDFWGDYLQYDKPYYMLNLYDPNKYVDVNNVGIRGYMYLKGPRGSVMTTNIYLNSSLYRGTKFIIKKYASGNKDNIVRNNDRVYINVVVKNKEYRLATNASQAGVEKILSALEIPDVGNLSQVVVMKSKNDQGITNKCKMNLQDNNGNDIGFIGFHQFNNIAKLVASNWYNRQIERSSRTLGCSWEFIPVDDGWGERPL DMW67MU DE Blepharospasm DM58QS1 ID DM58QS1 DM58QS1 DN Botulinum Toxin Type B DM58QS1 HS Approved DM58QS1 SN BTXA (TN); Dysport (TN); Myobloc (TN); Neurobloc (TN); Xeomin (TN) DM58QS1 CP Allergan Inc DM58QS1 TC Antidystonic Agents DM58QS1 SQ Botulinum neurotoxin type B - Clostridium botulinum: MPVTINNFNYNDPIDNNNIIMMEPPFARGTGRYYKAFKITDRIWIIPERYTFGYKPEDFNKSSGIFNRDVCEYYDPDYLNTNDKKNIFLQTMIKLFNRIKSKPLGEKLLEMIINGIPYLGDRRVPLEEFNTNIASVTVNKLISNPGEVERKKGIFANLIIFGPGPVLNENETIDIGIQNHFASREGFGGIMQMKFCPEYVSVFNNVQENKGASIFNRRGYFSDPALILMHELIHVLHGLYGIKVDDLPIVPNEKKFFMQSTDAIQAEELYTFGGQDPSIITPSTDKSIYDKVLQNFRGIVDRLNKVLVCISDPNININIYKNKFKDKYKFVEDSEGKYSIDVESFDKLYKSLMFGFTETNIAENYKIKTRASYFSDSLPPVKIKNLLDNEIYTIEEGFNISDKDMEKEYRGQNKAINKQAYEEISKEHLAVYKIQMCKSVKAPGICIDVDNEDLFFIADKNSFSDDLSKNERIEYNTQSNYIENDFPINELILDTDLISKIELPSENTESLTDFNVDVPVYEKQPAIKKIFTDENTIFQYLYSQTFPLDIRDISLTSSFDDALLFSNKVYSFFSMDYIKTANKVVEAGLFAGWVKQIVNDFVIEANKSNTMDKIADISLIVPYIGLALNVGNETAKGNFENAFEIAGASILLEFIPELLIPVVGAFLLESYIDNKNKIIKTIDNALTKRNEKWSDMYGLIVAQWLSTVNTQFYTIKEGMYKALNYQAQALEEIIKYRYNIYSEKEKSNINIDFNDINSKLNEGINQAIDNINNFINGCSVSYLMKKMIPLAVEKLLDFDNTLKKNLLNYIDENKLYLIGSAEYEKSKVNKYLKTIMPFDLSIYTNDTILIEMFNKYNSEILNNIILNLRYKDNNLIDLSGYGAKVEVYDGVELNDKNQFKLTSSANSKIRVTQNQNIIFNSVFLDFSVSFWIRIPKYKNDGIQNYIHNEYTIINCMKNNSGWKISIRGNRIIWTLIDINGKTKSVFFEYNIREDISEYINRWFFVTITNNLNNAKIYINGKLESNTDIKDIREVIANGEIIFKLDGDIDRTQFIWMKYFSIFNTELSQSNIEERYKIQSYSEYLKDFWGNPLMYNKEYYMFNAGNKNSYIKLKKDSPVGEILTRSKYNQNSKYINYRDLYIGEKFIIRRKSNSQSINDDIVRKEDYIYLDFFNLNQEWRVYTYKYFKKEEEKLFLAPISDSDEFYNTIQIKEYDEQPTYSCQLLFKKDEESTDEIGLIGIHRFYESGIVFEEYKDYFCISKWYLKEVKRKPYNLKLGCNWQFIPKDEGWTE DM58QS1 DE Parkinson disease DM20LIM ID DM20LIM DM20LIM DN Bremelanotide DM20LIM HS Approved DM20LIM SN Bremelanotide (USAN/INN); PT-141; Rekynda DM20LIM CP Palatin Technol DM20LIM DT Small molecular drug DM20LIM PC 9941379 DM20LIM MW 1025.2 DM20LIM FM C50H68N14O10 DM20LIM IC InChI=1S/C50H68N14O10/c1-3-4-16-35(58-29(2)65)43(67)64-41-25-42(66)54-20-11-10-18-37(49(73)74)60-46(70)39(23-31-26-56-34-17-9-8-15-33(31)34)62-44(68)36(19-12-21-55-50(51)52)59-45(69)38(22-30-13-6-5-7-14-30)61-47(71)40(63-48(41)72)24-32-27-53-28-57-32/h5-9,13-15,17,26-28,35-41,56H,3-4,10-12,16,18-25H2,1-2H3,(H,53,57)(H,54,66)(H,58,65)(H,59,69)(H,60,70)(H,61,71)(H,62,68)(H,63,72)(H,64,67)(H,73,74)(H4,51,52,55)/t35-,36-,37-,38+,39-,40-,41-/m0/s1 DM20LIM CS CCCC[C@@H](C(=O)N[C@H]1CC(=O)NCCCC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC1=O)CC2=CN=CN2)CC3=CC=CC=C3)CCCN=C(N)N)CC4=CNC5=CC=CC=C54)C(=O)O)NC(=O)C DM20LIM IK FFHBJDQSGDNCIV-MFVUMRCOSA-N DM20LIM IU (3S,6S,9R,12S,15S,23S)-15-[[(2S)-2-acetamidohexanoyl]amino]-9-benzyl-6-[3-(diaminomethylideneamino)propyl]-12-(1H-imidazol-5-ylmethyl)-3-(1H-indol-3-ylmethyl)-2,5,8,11,14,17-hexaoxo-1,4,7,10,13,18-hexazacyclotricosane-23-carboxylic acid DM20LIM CA CAS 189691-06-3 DM20LIM DE Erectile dysfunction; Hypoactive sexual desire dysfunction DMWLC57 ID DMWLC57 DMWLC57 DN Brentuximab vedotin DMWLC57 HS Approved DMWLC57 SN Adcetris (TN) DMWLC57 CP Millennium Pharmaceuticals; Seattle Genetics DMWLC57 DT Monoclonal antibody DMWLC57 DE Hodgkin lymphoma DM1FX74 ID DM1FX74 DM1FX74 DN Bretylium DM1FX74 HS Approved DM1FX74 SN Bretylum; Bretylium tolsylate; Bretylium tosylate(USAN); N-(2-bromobenzyl)-N,N-dimethylethanaminium; N-ethyl-N,N-dimethyl-2-bromobenzenemethanaminium; Benzenemethanaminium, 2-bromo-N-ethyl-N,N-dimethyl-, salt with 4-methylbenzenesulfonic acid (1:1); (2-bromobenzyl)ethyldimethylaminium; (2-bromophenyl)methyl-ethyl-dimethylazanium; (o-Bromobenzyl)ethyldimethylammonium p-toluenesulfonate; 2-bromo-N-ethyl-N,N-dimethylbenzenemethanaminium DM1FX74 CP Hospira Inc DM1FX74 TC Antiarrhythmic Agents DM1FX74 DT Small molecular drug DM1FX74 PC 2431 DM1FX74 MW 243.16 DM1FX74 FM C11H17BrN+ DM1FX74 IC InChI=1S/C11H17BrN/c1-4-13(2,3)9-10-7-5-6-8-11(10)12/h5-8H,4,9H2,1-3H3/q+1 DM1FX74 CS CC[N+](C)(C)CC1=CC=CC=C1Br DM1FX74 IK AAQOQKQBGPPFNS-UHFFFAOYSA-N DM1FX74 IU (2-bromophenyl)methyl-ethyl-dimethylazanium DM1FX74 CA CAS 59-41-6 DM1FX74 CB CHEBI:3172 DM1FX74 DE Ventricular fibrillation DM7W94S ID DM7W94S DM7W94S DN Brigatinib DM7W94S HS Approved DM7W94S SN 1197953-54-0; UNII-HYW8DB273J; Brigatinib [USAN]; ALUNBRIG; HYW8DB273J; Brigatinib (USAN); Brigatiib; Alunbrig (TN); Brigatinib [USAN:INN]; Brigatinib (AP26113); SCHEMBL11916361; KS-00000TSQ; EX-A775; MolPort-044-561-640; BDBM50185140; ZINC148723177; AKOS030257612; CS-4278; DB12267; HY-12857; AC-29958 DM7W94S CP Ariad Pharmaceuticals/Takeda DM7W94S DT Small molecular drug DM7W94S PC 68165256 DM7W94S MW 584.1 DM7W94S FM C29H39ClN7O2P DM7W94S IC InChI=1S/C29H39ClN7O2P/c1-35-15-17-37(18-16-35)21-11-13-36(14-12-21)22-9-10-24(26(19-22)39-2)33-29-31-20-23(30)28(34-29)32-25-7-5-6-8-27(25)40(3,4)38/h5-10,19-21H,11-18H2,1-4H3,(H2,31,32,33,34) DM7W94S CS CN1CCN(CC1)C2CCN(CC2)C3=CC(=C(C=C3)NC4=NC=C(C(=N4)NC5=CC=CC=C5P(=O)(C)C)Cl)OC DM7W94S IK AILRADAXUVEEIR-UHFFFAOYSA-N DM7W94S IU 5-chloro-4-N-(2-dimethylphosphorylphenyl)-2-N-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]pyrimidine-2,4-diamine DM7W94S CA CAS 1197953-54-0 DM7W94S DE Non-small-cell lung cancer; Anaplastic large cell lymphoma DMBR01X ID DMBR01X DMBR01X DN Brilinta DMBR01X HS Approved DMBR01X SN Ticagrelor; 274693-27-5; Brilique; AZD-6140; AZD6140; AZD 6140; AR-C126532XX; UNII-GLH0314RVC; [14C]-Ticagrelor; GLH0314RVC; CHEBI:68558; (1S,2S,3R,5S)-3-[7-[[(1R,2S)-2-(3,4-DIFLUOROPHENYL)CYCLOPROPYL]AMINO]-5-(PROPYLTHIO)-3H-1,2,3-TRIAZOLO[4,5-D]PYRIMIDIN-3-YL]-5-(2-HYDROXYETHOXY)-1,2-CYCLOPENTANEDIOL; (1S,2S,3R,5S)-3-(7-(((1R,2S)-2-(3,4-difluorophenyl)cyclopropyl)amino)-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol; Brilique; AR-C126532; Ticagrelor (USAN/INN); Brilinta/Brilique DMBR01X CP AstraZeneca DMBR01X DT Small molecular drug DMBR01X PC 9871419 DMBR01X MW 522.6 DMBR01X FM C23H28F2N6O4S DMBR01X IC InChI=1S/C23H28F2N6O4S/c1-2-7-36-23-27-21(26-15-9-12(15)11-3-4-13(24)14(25)8-11)18-22(28-23)31(30-29-18)16-10-17(35-6-5-32)20(34)19(16)33/h3-4,8,12,15-17,19-20,32-34H,2,5-7,9-10H2,1H3,(H,26,27,28)/t12-,15+,16+,17-,19-,20+/m0/s1 DMBR01X CS CCCSC1=NC(=C2C(=N1)N(N=N2)[C@@H]3C[C@@H]([C@H]([C@H]3O)O)OCCO)N[C@@H]4C[C@H]4C5=CC(=C(C=C5)F)F DMBR01X IK OEKWJQXRCDYSHL-FNOIDJSQSA-N DMBR01X IU (1S,2S,3R,5S)-3-[7-[[(1R,2S)-2-(3,4-difluorophenyl)cyclopropyl]amino]-5-propylsulfanyltriazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)cyclopentane-1,2-diol DMBR01X CA CAS 274693-27-5 DMBR01X CB CHEBI:68558 DMBR01X DE Myocardial infarction; Arterial thrombosis; Thrombosis DMQLT4N ID DMQLT4N DMQLT4N DN Brimonidine DMQLT4N HS Approved DMQLT4N SN brimonidine; 59803-98-4; Bromoxidine; UK 14,304; 5-Bromo-N-(4,5-dihydro-1H-imidazol-2-yl)-6-quinoxalinamine; 5-Bromo-6-(2-imidazolin-2-ylamino)quinoxaline; UK-14304; AGN 190342; UNII-E6GNX3HHTE; Brimonidine [INN:BAN]; UK 14304; C11H10BrN5; MLS000069370; 6-Quinoxalinamine, 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)-; E6GNX3HHTE; CHEMBL844; AGN-190342; BRN 0751629; SMR000058355; CHEBI:3175; LK 14304-18; Brimonidine, 98%; NCGC00016069-09; EN300-50880; DSSTox_RID_80758; Brimonidine (bioerodible, extended release); [3H]brimonidine DMQLT4N CP PSivida Corp DMQLT4N DT Small molecular drug DMQLT4N PC 2435 DMQLT4N MW 292.13 DMQLT4N FM C11H10BrN5 DMQLT4N IC InChI=1S/C11H10BrN5/c12-9-7(17-11-15-5-6-16-11)1-2-8-10(9)14-4-3-13-8/h1-4H,5-6H2,(H2,15,16,17) DMQLT4N CS C1CN=C(N1)NC2=C(C3=NC=CN=C3C=C2)Br DMQLT4N IK XYLJNLCSTIOKRM-UHFFFAOYSA-N DMQLT4N IU 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine DMQLT4N CA CAS 59803-98-4 DMQLT4N CB CHEBI:3175 DMQLT4N DE Ocular hypertension; Glaucoma/ocular hypertension DMBAPFG ID DMBAPFG DMBAPFG DN Brinzolamide DMBAPFG HS Approved DMBAPFG SN Azopt; Birnzolamide; Alcon brand of brinzolamide; Allphar brand of brinzolamide; Brinzolamide [USAN]; AL 4862; AL04862; BZ1; AL-4862; Azopt (TN); Brinzolamide (BRZ); Brinzolamide (JAN/USP/INN); (+)-4-ETHYLAMINO-3,4-DIHYDRO-2-(METHOXY)PROPYL-2H-THIENO[3,2-E]-1,2-THIAZINE-6-SULFONAMIDE-1,1-DIOXIDE; (4R)-4-(ethylamino)-2-(3-methoxypropyl)-1,1-dioxo-3,4-dihydrothieno[3,2-e]thiazine-6-sulfonamide; (4R)-4-(ethylamino)-2-(3-methoxypropyl)-3,4-dihydro-2H-thieno[3,2-e][1,2]thiazine-6-sulfonamide 1,1-dioxide; (R)-4-(Ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-2H-thieno(3,2-e)-1,2-thiazine-6-sulfonamide 1,1-dioxide; (R)-4-(ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-2H-thieno(3,2-e)-1,2-thiazine-6-sulfonamide; 2H-Thieno(3,2-e)-1,2-thiazine-6-sulfonamide,4-(ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-,1,1-dioxide,R DMBAPFG CP Alcon Laboratories DMBAPFG TC Antiglaucomic Agents DMBAPFG DT Small molecular drug DMBAPFG PC 68844 DMBAPFG MW 383.5 DMBAPFG FM C12H21N3O5S3 DMBAPFG IC InChI=1S/C12H21N3O5S3/c1-3-14-10-8-15(5-4-6-20-2)23(18,19)12-9(10)7-11(21-12)22(13,16)17/h7,10,14H,3-6,8H2,1-2H3,(H2,13,16,17)/t10-/m0/s1 DMBAPFG CS CCN[C@H]1CN(S(=O)(=O)C2=C1C=C(S2)S(=O)(=O)N)CCCOC DMBAPFG IK HCRKCZRJWPKOAR-JTQLQIEISA-N DMBAPFG IU (4R)-4-(ethylamino)-2-(3-methoxypropyl)-1,1-dioxo-3,4-dihydrothieno[3,2-e]thiazine-6-sulfonamide DMBAPFG CA CAS 138890-62-7 DMBAPFG CB CHEBI:3176 DMBAPFG DE Open-angle glaucoma DMSEPK8 ID DMSEPK8 DMSEPK8 DN Brivaracetam DMSEPK8 HS Approved DMSEPK8 SN Rikelta; UCB-34714; Brivaracetam (USAN/INN) DMSEPK8 CP UCB DMSEPK8 DT Small molecular drug DMSEPK8 PC 9837243 DMSEPK8 MW 212.29 DMSEPK8 FM C11H20N2O2 DMSEPK8 IC InChI=1S/C11H20N2O2/c1-3-5-8-6-10(14)13(7-8)9(4-2)11(12)15/h8-9H,3-7H2,1-2H3,(H2,12,15)/t8-,9+/m1/s1 DMSEPK8 CS CCC[C@@H]1CC(=O)N(C1)[C@@H](CC)C(=O)N DMSEPK8 IK MSYKRHVOOPPJKU-BDAKNGLRSA-N DMSEPK8 IU (2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl]butanamide DMSEPK8 CA CAS 357336-20-0 DMSEPK8 CB CHEBI:133013 DMSEPK8 DE Epilepsy; Pain; Complex partial seizure DMASDQ6 ID DMASDQ6 DMASDQ6 DN Brodalumab DMASDQ6 HS Approved DMASDQ6 SN AMG 827 DMASDQ6 CP Valeant Pharmaceuticals DMASDQ6 DT Monoclonal antibody DMASDQ6 DE Plaque psoriasis; Asthma; Psoriasis vulgaris DMW8QNG ID DMW8QNG DMW8QNG DN Brolucizumab DMW8QNG HS Approved DMW8QNG CP Alcon DMW8QNG DT Antibody DMW8QNG DE Wet age-related macular degeneration; Diabetic macular edema DMY9TCW ID DMY9TCW DMY9TCW DN Bromazepam DMY9TCW HS Approved DMY9TCW SN Bromazepamum; Calmepam; Compedium; Compendium; Creosedin; Durazanil; Lectopam; Lekotam; Lexaurin; Lexilium; Lexomil; Lexotan; Lexotanil; Normoc; Somalium; Ultramidol; Bromazepamum [Latin]; LA Xvii; KL 001; Ro 53350; Apo-Bromazepam; Brazepam (TN); Bromaze (TN); Bromazepam(USAN; Bromazepamum [INN-Latin]; Gen-Bromazepam; KL-001; Lectopam (TN); Lexotan (TN); Novo-bromazepam; Nu-Bromazepam; Ro 4-9253; Ro 5-3350; Bromazepam (JP15/USAN/INN); Bromazepam [USAN:INN:BAN:JAN]; 1,3-Dihydro-7-bromo-5-(2-pyridyl)-2H-1,4-benzodiazepin-2-one; 7-Bromo-1,3-dihydro-5-(2-pyridyl)-2H-1,4-benzdiazepin-2-one; 7-Bromo-1,3-dihydro-5-(2-pyridyl)-2H-1,4-benzodiazepin-2-one; 7-Bromo-5-(2-pyridyl)-3H-1,4-benzodiaxepin-2(1H)-one; 7-Bromo-5-(2-pyridyl)-3H-1,4-benzodiazepin-2(1H)-one; 7-bromo-5-pyridin-2-yl-1,3-dihydro-1,4-benzodiazepin-2-one DMY9TCW CP Hoffmann-La Roche pharmaceutical company DMY9TCW TC Hypnotics and Sedatives DMY9TCW DT Small molecular drug DMY9TCW PC 2441 DMY9TCW MW 316.15 DMY9TCW FM C14H10BrN3O DMY9TCW IC InChI=1S/C14H10BrN3O/c15-9-4-5-11-10(7-9)14(17-8-13(19)18-11)12-3-1-2-6-16-12/h1-7H,8H2,(H,18,19) DMY9TCW CS C1C(=O)NC2=C(C=C(C=C2)Br)C(=N1)C3=CC=CC=N3 DMY9TCW IK VMIYHDSEFNYJSL-UHFFFAOYSA-N DMY9TCW IU 7-bromo-5-pyridin-2-yl-1,3-dihydro-1,4-benzodiazepin-2-one DMY9TCW CA CAS 1812-30-2 DMY9TCW CB CHEBI:31302 DMY9TCW DE Panic attacks; Anxiety disorder DMKB79O ID DMKB79O DMKB79O DN Bromfenac DMKB79O HS Approved DMKB79O SN Bromfenaco; Bromfenacum; Duract; Xibrom; BROMFENAC SODIUM; Bromfenac [INN]; Bromfenaco [Spanish]; Bromfenacum [Latin]; AHR-10282; Bromfenac (INN); Duract (TN); Xibrom (TN); Sodium 2-amino-3-(4-bromobenzoyl) phenylacetate sesquihydrate; [2-amino-3-(4-bromobenzoyl)phenyl]acetic acid; {2-amino-3-[(4-bromophenyl)carbonyl]phenyl}acetic acid; [2-Amino-3-(4-bromo-benzoyl)-phenyl]-acetic acid; 2-Amino-3-(4-bromobenzoyl)benzeneacetic acid; 2-[2-amino-3-(4-bromobenzoyl)phenyl]acetic acid DMKB79O TC Antiinflammatory Agents DMKB79O DT Small molecular drug DMKB79O PC 60726 DMKB79O MW 334.16 DMKB79O FM C15H12BrNO3 DMKB79O IC InChI=1S/C15H12BrNO3/c16-11-6-4-9(5-7-11)15(20)12-3-1-2-10(14(12)17)8-13(18)19/h1-7H,8,17H2,(H,18,19) DMKB79O CS C1=CC(=C(C(=C1)C(=O)C2=CC=C(C=C2)Br)N)CC(=O)O DMKB79O IK ZBPLOVFIXSTCRZ-UHFFFAOYSA-N DMKB79O IU 2-[2-amino-3-(4-bromobenzoyl)phenyl]acetic acid DMKB79O CA CAS 91714-94-2 DMKB79O CB CHEBI:240107 DMKB79O DE Postoperative inflammation; Inflammation DMVE3TK ID DMVE3TK DMVE3TK DN Bromocriptine DMVE3TK HS Approved DMVE3TK SN Bagren; Bromergocryptine; Bromocriptin; Bromocriptina; Bromocriptinum; Bromocryptin; Bromocryptine; Bromoergocriptine; Bromoergocryptine; Ergoset; Parlodel; Bromocriptine [BAN]; Bromocriptine methanesulfonate; Parlodel Snaptabs; Alti-Bromocriptine; Apo-Bromocriptine; Bromocriptina [INN-Spanish]; Bromocriptinum [INN-Latin]; CB-154; Parlodel (TN); Bromocriptine (USAN/INN); Bromocriptine [USAN:BAN:INN]; Ergocryptine, 2-bromo-(8CI); (5'alpha)-2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)-3',6',18-trioxoergotaman; (5'alpha)-2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)ergotaman-3',6',18-trione; (5'alpha)-2-bromo-12'-hydroxy-5'-(2-methylpropyl)-2'-(propan-2-yl)-3',6',18-trioxoergotaman; (5'alpha)-2-bromo-12'-hydroxy-5'-isobutyl-2'-isopropyl-3',6',18-trioxoergotaman; (6aR,9R)-5-Bromo-N-((2R,5S,10aS,10bS)-10b-hydroxy-5-isobutyl-2-isopropyl-3,6-dioxooctahydro-2H-oxazolo[3,2-a]pyrrolo[2,1-c]pyrazin-2-yl)-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide; 2-Bromo-12'-hydroxy-2'-(1-methylethyl)-5'-alpha-(2-methylpropyl)ergotamin-3',6',18-trione; 2-Bromo-alpha-ergocryptine; 2-Bromo-alpha-ergokryptin; 2-Bromo-alpha-ergokryptine; 2-Bromoergocryptine Methanesulfonate; 2-Bromoergokryptine DMVE3TK CP Norvatis Phamaceuticals Corporation DMVE3TK TC Antiparkinson Agents DMVE3TK DT Small molecular drug DMVE3TK PC 31101 DMVE3TK MW 654.6 DMVE3TK FM C32H40BrN5O5 DMVE3TK IC InChI=1S/C32H40BrN5O5/c1-16(2)12-24-29(40)37-11-7-10-25(37)32(42)38(24)30(41)31(43-32,17(3)4)35-28(39)18-13-20-19-8-6-9-22-26(19)21(27(33)34-22)14-23(20)36(5)15-18/h6,8-9,13,16-18,23-25,34,42H,7,10-12,14-15H2,1-5H3,(H,35,39)/t18-,23-,24+,25+,31-,32+/m1/s1 DMVE3TK CS CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]3(N1C(=O)[C@](O3)(C(C)C)NC(=O)[C@H]4CN([C@@H]5CC6=C(NC7=CC=CC(=C67)C5=C4)Br)C)O DMVE3TK IK OZVBMTJYIDMWIL-AYFBDAFISA-N DMVE3TK IU (6aR,9R)-5-bromo-N-[(1S,2S,4R,7S)-2-hydroxy-7-(2-methylpropyl)-5,8-dioxo-4-propan-2-yl-3-oxa-6,9-diazatricyclo[7.3.0.02,6]dodecan-4-yl]-7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide DMVE3TK CA CAS 25614-03-3 DMVE3TK CB CHEBI:3181 DMVE3TK DE Parkinson disease DMNDJT5 ID DMNDJT5 DMNDJT5 DN Bromodiphenhydramine DMNDJT5 HS Approved DMNDJT5 SN Amodryl; Bromanautine; Bromazin; Bromazina; Bromazine; Bromazinum; Bromdiphenhydramine; Bromdiphenhydraminum; Deserol; Histabromamine; Ambodryl hydrochloride; Bromdiphenhydramine hydrochloride; Bromdiphenylhydramine hydrochloride; Bromodiphenhydramine hydrochloride; Ambrodyl (TN); Bromazina [INN-Spanish]; Bromazine [INN:BAN]; Bromazinum [INN-Latin]; Bromo-Benadryl; Bromo-Benzdryl; Neo-Benadryl; Beta-dimethylaminoethyl p-bromobenzhydryl ether; Beta-(p-Bromobenzhydryloxy)ethyldimethylamine; 2-(p-bromo-alpha-phenylbenzyloxy)-N,N-dimethylethylamine; 2-[(4-Bromophenyl)(phenyl)methoxy]-N,N-dimethylethanamine; 2-[(4-bromophenyl)-phenylmethoxy]-N,N-dimethylethanamine; 2-{[(4-bromophenyl)(phenyl)methyl]oxy}-N,N-dimethylethanamine DMNDJT5 TC Antihistamines DMNDJT5 DT Small molecular drug DMNDJT5 PC 2444 DMNDJT5 MW 334.2 DMNDJT5 FM C17H20BrNO DMNDJT5 IC InChI=1S/C17H20BrNO/c1-19(2)12-13-20-17(14-6-4-3-5-7-14)15-8-10-16(18)11-9-15/h3-11,17H,12-13H2,1-2H3 DMNDJT5 CS CN(C)CCOC(C1=CC=CC=C1)C2=CC=C(C=C2)Br DMNDJT5 IK NUNIWXHYABYXKF-UHFFFAOYSA-N DMNDJT5 IU 2-[(4-bromophenyl)-phenylmethoxy]-N,N-dimethylethanamine DMNDJT5 CA CAS 118-23-0 DMNDJT5 CB CHEBI:59177 DMNDJT5 DE Hay fever DM24XYQ ID DM24XYQ DM24XYQ DN Bromperidol DM24XYQ HS Approved DM24XYQ SN bromperidol; 10457-90-6; Impromen; Bromoperidol; Tesoprel; Azurene; 4-(4-(4-bromophenyl)-4-hydroxypiperidin-1-yl)-1-(4-fluorophenyl)butan-1-one; UNII-LYH6F7I22E; Bromperidolum [INN-Latin]; R 11333; EINECS 233-943-3; 4-(4-(4-Bromophenyl)-4-hydroxypiperidino)-4'-fluorobutyrophenone; CC 2489; BRN 1552256; LYH6F7I22E; 4-(4-(p-Bromophenyl)-4-hydroxypiperidino)-4'-fluorobutyrophenone; RKLNONIVDFXQRX-UHFFFAOYSA-N; 4-(4-(4-Bromophenyl)-4-hydroxy-1-piperidinyl)-1-(4-fluorophenyl)-1-butanone; NCGC00016692-01; CAS-10457-90-6 DM24XYQ DT Small molecular drug DM24XYQ PC 2448 DM24XYQ MW 420.3 DM24XYQ FM C21H23BrFNO2 DM24XYQ IC InChI=1S/C21H23BrFNO2/c22-18-7-5-17(6-8-18)21(26)11-14-24(15-12-21)13-1-2-20(25)16-3-9-19(23)10-4-16/h3-10,26H,1-2,11-15H2 DM24XYQ CS C1CN(CCC1(C2=CC=C(C=C2)Br)O)CCCC(=O)C3=CC=C(C=C3)F DM24XYQ IK RKLNONIVDFXQRX-UHFFFAOYSA-N DM24XYQ IU 4-[4-(4-bromophenyl)-4-hydroxypiperidin-1-yl]-1-(4-fluorophenyl)butan-1-one DM24XYQ CA CAS 10457-90-6 DM24XYQ CB CHEBI:31305 DM24XYQ DE Schizophrenia DMFOVSD ID DMFOVSD DMFOVSD DN Brompheniramine DMFOVSD HS Approved DMFOVSD SN Bromfed; Bromfenex; Bromfeniramina; Brotane; Parabromdylamine; BROMFED-DM; Bromfeniramina [INN-Spanish]; Brompheniramine (INN); Brompheniramine [INN:BAN]; Brompheniraminum [INN-Latin]; Brotane (TN); DIMETANE-DX; P-Bromdylamine; Para-Bromdylamine; Brompheniramine Maleate (1:1); [3-(4-Bromophenyl)-3-(2-pyridyl)propyl]dimethylamine; Gamma-(4-Bromophenyl)-N,N-dimethyl-2-pyridinepropanamine; 1-(p-Bromophenyl)-1-(2-pyridyl)-3-dimethylaminopropane; 2-(p-Bromo-alpha-(2-dimethylaminoethyl)benzyl)pyridine; 3-(4-Bromophenyl)-N,N-dimethyl-3-(2-pyridinyl)-1-propanamine; 3-(4-bromophenyl)-N,N-dimethyl-3-(pyridin-2-yl)propan-1-amine; 3-(4-bromophenyl)-N,N-dimethyl-3-pyridin-2-ylpropan-1-amine; 3-(p-Bromophenyl)-3-(2-pyridyl)-N,N-dimethylpropylamine DMFOVSD CP Alpharma Us Pharmaceuticals Division DMFOVSD TC Antiallergic Agents DMFOVSD DT Small molecular drug DMFOVSD PC 6834 DMFOVSD MW 319.24 DMFOVSD FM C16H19BrN2 DMFOVSD IC InChI=1S/C16H19BrN2/c1-19(2)12-10-15(16-5-3-4-11-18-16)13-6-8-14(17)9-7-13/h3-9,11,15H,10,12H2,1-2H3 DMFOVSD CS CN(C)CCC(C1=CC=C(C=C1)Br)C2=CC=CC=N2 DMFOVSD IK ZDIGNSYAACHWNL-UHFFFAOYSA-N DMFOVSD IU 3-(4-bromophenyl)-N,N-dimethyl-3-pyridin-2-ylpropan-1-amine DMFOVSD CA CAS 86-22-6 DMFOVSD CB CHEBI:3183 DMFOVSD DE Allergic rhinitis DMXKZT3 ID DMXKZT3 DMXKZT3 DN Buclizine DMXKZT3 HS Approved DMXKZT3 SN Bucladin; Buclifen; Buclina; Buclizina; Buclizinum; Buclodin; Histabuticine; Histabutizine; Histabutyzine; Hitabutyzyne; Posdel; Softran; Vibazine; Aphilan R; Buclizine dihydrochloride; Buclizine hydrochloride; Component of Softran; Histabutyzine dihydrochloride; Histabutyzine hydrochloride; Vibazine hydrochloride; AH 2526; UCB 4445; Aphilan-R base; Buclina (TN); Buclizina [INN-Spanish]; Buclizine (INN); Buclizine [INN:BAN]; Buclizine, hydrochloride; Buclizinum [INN-Latin]; Component of Bucladin-S; Migraleve (TN); Buclizine Hydrochloride (*dihydrochloride*); Piperazine, 1-[(4-chlorophenyl)phenylmethyl]-4-[[4-(1,1-dimethylethyl)phenyl]methyl]-, dihydrochloride; Piperazine, 1-((4-chlorophenyl)phenylmethyl)-4-((4-(1,1-dimethylethyl)phenyl)methyl)-(9CI); 1-(4-Tert-butylbenzyl)-4-((4-chlorophenyl)(phenyl)methyl)piperazine; 1-(4-tert-Butylbenzyl)-4-[(4-chlorophenyl)(phenyl)methyl]piperazine; 1-(p-tert-Butylbenzyl)-4-(4-chloro-alpha-phenylbenzyl)piperazine; 1-[(4-chlorophenyl)(phenyl)methyl]-4-{[4-(1,1-dimethylethyl)phenyl]methyl}piperazine; 1-[(4-tert-butylphenyl)methyl]-4-[(4-chlorophenyl)-phenylmethyl]piperazine DMXKZT3 CP McNeil Laboratories DMXKZT3 TC Antihistamines DMXKZT3 DT Small molecular drug DMXKZT3 PC 6729 DMXKZT3 MW 433 DMXKZT3 FM C28H33ClN2 DMXKZT3 IC InChI=1S/C28H33ClN2/c1-28(2,3)25-13-9-22(10-14-25)21-30-17-19-31(20-18-30)27(23-7-5-4-6-8-23)24-11-15-26(29)16-12-24/h4-16,27H,17-21H2,1-3H3 DMXKZT3 CS CC(C)(C)C1=CC=C(C=C1)CN2CCN(CC2)C(C3=CC=CC=C3)C4=CC=C(C=C4)Cl DMXKZT3 IK MOYGZHXDRJNJEP-UHFFFAOYSA-N DMXKZT3 IU 1-[(4-tert-butylphenyl)methyl]-4-[(4-chlorophenyl)-phenylmethyl]piperazine DMXKZT3 CA CAS 82-95-1 DMXKZT3 CB CHEBI:3205 DMXKZT3 DE Nausea DMJIBAW ID DMJIBAW DMJIBAW DN Budesonide DMJIBAW HS Approved DMJIBAW SN Bidien; Budenofalk; Budeson; Budesonido; Budesonidum; Budiair; Cortivent; Entocort; Horacort; Inflammide; Micronyl; Miflonide; Preferid; Pulmaxan; Respules; Rhinocort; Spirocort; UDB; Budecort Inhaler; Budesonide Easyhaler; Budesonide MMX; Entocort EC; GionaEasyhaler; Pulmaxan turbohaler; Pulmicort Flexhaler; Pulmicort Nebuamp; Pulmicort Respules; Pulmicort Topinasal; Pulmicort turbuhaler; Rhinocort Aqua; Rhinocort Turbuhaler; Rhinocort alpha; Unit dosebudesonide; B 7777; S 1320; Budesonido [INN-Spanish]; Budesonidum [INN-Latin]; Entocort (TN); Entocort EC (TN); MAP-0010; Noex (TN); Pulmicort (TN); Rhinocort (TN); S-1320; Budesonide (JAN/USAN/INN); Budesonide [USAN:INN:BAN:JAN]; Rhinocort, Pulmicort , Entocort, Symbicort, Noex. Entocort EC, Budesonide; Pregna-1,4-diene-3,20-dione, 16,17-butylidenebis(oxy)-11,21-dihydroxy-, (11beta,16alpha(R))-,and 16alpha,17-((S)-Butylidenebis(oxy))-11beta,21-dihydroxypregna-1,4-diene-3,20-dione; (11-beta,16-alpha)-16,17-(Butylidenebis(oxy))-11,21-dihydroxypregna-1,4-diene-3,20-dione; (11beta,16alpha)-16,17-(Butylidenebis(oxy))-11,21-dihydroxypregna-1,4-diene-3,20-dione; (4aR,4bS,5S,6aS,6bS,8R,9aR,10aS,10bS)-5-hydroxy-6b-(hydroxyacetyl)-4a,6a-dimethyl-8-propyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one; (4aR,4bS,5S,6aS,6bS,9aR,10aS,10bS)-5-hydroxy-6b-(hydroxyacetyl)-4a,6a-dimethyl-8-propyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one; (R,S)-11b,16a,17,21,tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with buty raldehyde; (RS)-(11beta,16alpha)-16,17-[Butylidenebis(oxy)]-11,21-dihydroxypregna-1,4-diene-3,20-dione; (RS)-11beta,16alpha,17,21-Tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with butyraldehyde; (S)-16alpha,17-(Butylidenedioxy)-11beta,21-dihydroxypregna-1,4-diene-3,20-dione; 11beta,21-dihydroxy-16alpha,17alpha-(butane-1,1-diyldioxy)pregna-1,4-diene-3,20-dione; 16,17-Butylidenebis(oxy)-11,21-dihydroxypregna-1,4-diene-3,20-dione; 16,17-Butylidenebis(oxy)-11-,21-dihydroxypregna-1,4-diene-3,20-dione; 16-alpha,17-alpha-Butylidenedioxy-11-beta,21-dihydroxy-1,4-pregnadiene-3,20-dione; 16alpha(R),17-(Butylidenebis(oxy))-11beta,21-dihydroxypregna-1,4-diene-3,20-dione; 16alpha-,17alpha-butylidenedioxypregna-1,4-diene-11beta-,21-diol-3,20-dione DMJIBAW CP AstraZeneca DMJIBAW TC Antiinflammatory Agents DMJIBAW DT Small molecular drug DMJIBAW PC 5281004 DMJIBAW MW 430.5 DMJIBAW FM C25H34O6 DMJIBAW IC InChI=1S/C25H34O6/c1-4-5-21-30-20-11-17-16-7-6-14-10-15(27)8-9-23(14,2)22(16)18(28)12-24(17,3)25(20,31-21)19(29)13-26/h8-10,16-18,20-22,26,28H,4-7,11-13H2,1-3H3/t16-,17-,18-,20+,21?,22+,23-,24-,25+/m0/s1 DMJIBAW CS CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@@]5([C@H]4[C@H](C[C@@]3([C@@]2(O1)C(=O)CO)C)O)C DMJIBAW IK VOVIALXJUBGFJZ-KWVAZRHASA-N DMJIBAW IU (1S,2S,4R,8S,9S,11S,12S,13R)-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-propyl-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one DMJIBAW CA CAS 51333-22-3 DMJIBAW CB CHEBI:3207 DMJIBAW DE Asthma DMODHQI ID DMODHQI DMODHQI DN Budipine DMODHQI HS Approved DMODHQI SN Parkinsan; BY-701 DMODHQI CP ALTANA Pharma AG DMODHQI DT Small molecular drug DMODHQI PC 68778 DMODHQI MW 293.4 DMODHQI FM C21H27N DMODHQI IC InChI=1S/C21H27N/c1-20(2,3)22-16-14-21(15-17-22,18-10-6-4-7-11-18)19-12-8-5-9-13-19/h4-13H,14-17H2,1-3H3 DMODHQI CS CC(C)(C)N1CCC(CC1)(C2=CC=CC=C2)C3=CC=CC=C3 DMODHQI IK QIHLUZAFSSMXHQ-UHFFFAOYSA-N DMODHQI IU 1-tert-butyl-4,4-diphenylpiperidine DMODHQI CA CAS 57982-78-2 DMODHQI CB CHEBI:135228 DMODHQI DE Migraine DMG1OPF ID DMG1OPF DMG1OPF DN Buflomedil DMG1OPF HS Approved DMG1OPF SN Loftyl; Buflomedil hydrochloride DMG1OPF CP Laboratoire L Lafon SA DMG1OPF DT Small molecular drug DMG1OPF PC 2467 DMG1OPF MW 307.4 DMG1OPF FM C17H25NO4 DMG1OPF IC InChI=1S/C17H25NO4/c1-20-13-11-15(21-2)17(16(12-13)22-3)14(19)7-6-10-18-8-4-5-9-18/h11-12H,4-10H2,1-3H3 DMG1OPF CS COC1=CC(=C(C(=C1)OC)C(=O)CCCN2CCCC2)OC DMG1OPF IK OWYLAEYXIQKAOL-UHFFFAOYSA-N DMG1OPF IU 4-pyrrolidin-1-yl-1-(2,4,6-trimethoxyphenyl)butan-1-one DMG1OPF CA CAS 55837-25-7 DMG1OPF CB CHEBI:94538 DMG1OPF DE Peripheral vascular disease DMX82DO ID DMX82DO DMX82DO DN Buformin DMX82DO HS Approved DMX82DO SN Buformin; 1-Butylbiguanide; Buformine; Butyldiguanide; Butylbiguanide; Butformin; Butylbiguanidum; Glybigid; 1-Butyldiguanide; Glybigidum; N-Butylbiguanide; Buformina; Buforminum; Buformine [INN-French]; Buforminum [INN-Latin]; Buformina [INN-Spanish]; Silubin; Adebit; BIGUANIDE, 1-BUTYL-; Buformin [USAN:INN]; W 37; Buformin HCl; Imidodicarbonimidic diamide, N-butyl-; Sindiatil; Panformin; Diabrin; Biforon; Andere; UNII-W2115E9C7B; Buformine HCl; N-butylimidodicarbonimidic diamide; DBV hydrochloride; H 224 DMX82DO PC 2468 DMX82DO MW 157.22 DMX82DO FM C6H15N5 DMX82DO IC InChI=1S/C6H15N5/c1-2-3-4-10-6(9)11-5(7)8/h2-4H2,1H3,(H6,7,8,9,10,11) DMX82DO CS CCCCN=C(N)N=C(N)N DMX82DO IK XSEUMFJMFFMCIU-UHFFFAOYSA-N DMX82DO IU 2-butyl-1-(diaminomethylidene)guanidine DMX82DO CA CAS 692-13-7 DMX82DO CB CHEBI:3209 DMX82DO DE Type 2 diabetes DMJUVE6 ID DMJUVE6 DMJUVE6 DN Bulevirtide DMJUVE6 HS Approved DMJUVE6 SN Lipopeptide DMJUVE6 CP MYR Pharma DMJUVE6 DT Peptide DMJUVE6 DE Hepatitis D virus infection DMRV7H0 ID DMRV7H0 DMRV7H0 DN Bumetanide DMRV7H0 HS Approved DMRV7H0 SN Aquazone; Bumedyl; Bumetanida; Bumetanidum; Bumethanide; Bumex; Burine; Burinex; Butinat; Cambiex; Diurama; Drenural; Fontego; Fordiuran; Lixil; Lunetoron; Miccil; Segurex; Yurinex; AstraZeneca Brand of Bumetanide; Atlantis Brand of Bumetanide; Bumetanide AstraZeneca Brand; Bumetanide Atlantis Brand; Bumetanide Farmacusi Brand; Bumetanide Grossmann Brand; Bumetanide Leo Brand; Bumetanide Roche Brand; Bumetanide Senosiain Brand; Farmacusi Brand of Bumetanide; Grossmann Brand of Bumetanide; Leo Brand of Bumetanide; Roche Brand of Bumetanide; Senosiain Brand of Bumetanide; B 3023; PF 1593; PF1593; Bumetanida [INN-Spanish]; Bumetanidum [INN-Latin]; Bumex (TN); Bumex, Bumetanide; Lixil-Leo; PF-1593; Ro 10-6338; Bumetanide (JP15/USP); Ro-10-6338; Bumetanide (JP15/USP/INN); Bumetanide [USAN:BAN:INN:JAN]; 3-(Aminosulfonyl)-5-(butylamino)-4-phenoxybenzoic acid; 3-(Butylamino)-4-phenoxy-5-sulfamoylbenzoic acid; 3-(aminosulfonyl)-5-(butylamino)-4-(phenyloxy)benzoic acid; 3-butylamino-4-(phenoxy)-5-sulfamoylbenzoic acid DMRV7H0 CP Hoffmann-La Roche pharmaceutical company DMRV7H0 TC Diuretics DMRV7H0 DT Small molecular drug DMRV7H0 PC 2471 DMRV7H0 MW 364.4 DMRV7H0 FM C17H20N2O5S DMRV7H0 IC InChI=1S/C17H20N2O5S/c1-2-3-9-19-14-10-12(17(20)21)11-15(25(18,22)23)16(14)24-13-7-5-4-6-8-13/h4-8,10-11,19H,2-3,9H2,1H3,(H,20,21)(H2,18,22,23) DMRV7H0 CS CCCCNC1=C(C(=CC(=C1)C(=O)O)S(=O)(=O)N)OC2=CC=CC=C2 DMRV7H0 IK MAEIEVLCKWDQJH-UHFFFAOYSA-N DMRV7H0 IU 3-(butylamino)-4-phenoxy-5-sulfamoylbenzoic acid DMRV7H0 CA CAS 28395-03-1 DMRV7H0 CB CHEBI:3213 DMRV7H0 DE Congestive heart failure DM4I8O7 ID DM4I8O7 DM4I8O7 DN Bunazosin DM4I8O7 HS Approved DM4I8O7 SN Andante; E 015; DE-070; Detantol-R; E-1015; E-643 DM4I8O7 CP Eisai Co Ltd DM4I8O7 DT Small molecular drug DM4I8O7 PC 2472 DM4I8O7 MW 373.4 DM4I8O7 FM C19H27N5O3 DM4I8O7 IC InChI=1S/C19H27N5O3/c1-4-6-17(25)23-7-5-8-24(10-9-23)19-21-14-12-16(27-3)15(26-2)11-13(14)18(20)22-19/h11-12H,4-10H2,1-3H3,(H2,20,21,22) DM4I8O7 CS CCCC(=O)N1CCCN(CC1)C2=NC3=CC(=C(C=C3C(=N2)N)OC)OC DM4I8O7 IK RHLJLALHBZGAFM-UHFFFAOYSA-N DM4I8O7 IU 1-[4-(4-amino-6,7-dimethoxyquinazolin-2-yl)-1,4-diazepan-1-yl]butan-1-one DM4I8O7 CA CAS 80755-51-7 DM4I8O7 CB CHEBI:135576 DM4I8O7 DE Glaucoma/ocular hypertension DM4PRFC ID DM4PRFC DM4PRFC DN Bupivacaine DM4PRFC HS Approved DM4PRFC SN Anekain; Bloqueina; Bucaine; Bupivacaina; Bupivacainum; Bupivan; CBupivacaine; Carbostesin; DepoBupivacaine; Marcaina; Marcaine; Sensorcaine; Bupivacaine Carbonate; Bupivacaine HCL; Bupivacaine HCL KIT; Marcaine HCL; Marcaine Spinal; AH 250; Win 11318; Win 11318 HCl; Bucaine (TN); Bupivacaina [INN-Spanish]; Bupivacaine (INN); Bupivacaine Monohydrochloride, Monohydrate; Bupivacaine [INN:BAN]; Bupivacainum [INN-Latin]; DL-Bupivacaine; DUR-843; Marcain (TN); Marcaine (TN); Sensorcaine (TN); Sensorcaine-MPF; Sensorcaine-MPFSpinal; Transdur-Bupivacaine; Vivacaine (TN); Dl-1-Butyl-2',6'-pipecoloxylidide; (1)-1-Butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide; (inverted exclamation markA)-bupivacaine; 1-Butyl-2',6'-pipecoloxylidide; 1-Butyl-N-(2,6-dimethylphenyl)-2-piperidinecarboxamide; 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide DM4PRFC CP AstraZeneca DM4PRFC TC Anesthetics DM4PRFC DT Small molecular drug DM4PRFC PC 2474 DM4PRFC MW 288.4 DM4PRFC FM C18H28N2O DM4PRFC IC InChI=1S/C18H28N2O/c1-4-5-12-20-13-7-6-11-16(20)18(21)19-17-14(2)9-8-10-15(17)3/h8-10,16H,4-7,11-13H2,1-3H3,(H,19,21) DM4PRFC CS CCCCN1CCCCC1C(=O)NC2=C(C=CC=C2C)C DM4PRFC IK LEBVLXFERQHONN-UHFFFAOYSA-N DM4PRFC IU 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide DM4PRFC CA CAS 38396-39-3 DM4PRFC CB CHEBI:77431 DM4PRFC DE Anaesthesia; Pain DMPRI8G ID DMPRI8G DMPRI8G DN Buprenorphine DMPRI8G HS Approved DMPRI8G SN Buprel; Buprenex; Buprenophine; Buprenorfina; Buprenorphinum; Probuphine; Temgesic; Buprenorphine Hcl; RX 6029M; Buprenex (TN); Buprenorfina [INN-Spanish]; Buprenorphine [INN:BAN]; Buprenorphinum [INN-Latin]; Subutex (TN); Temgesic (TN); Buprenorphine (JAN/INN); RX-6029-M; Suboxone (TN); [5alpha,7alpha(S)]-17-(Cyclopropylmethyl)-alpha-(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-alpha-methyl-6,14-ethenomorphinan-7-methanol; (-)-buprenorphine; (5alpha,6beta,14beta,18R)-17-(cyclopropylmethyl)-18-[(1S)-1-hydroxy-1,2,2-trimethylpropyl]-6-(methyloxy)-18,19-dihydro-4,5-epoxy-6,14-ethenomorphinan-3-ol; (5alpha,6beta,14beta,18R)-17-(cyclopropylmethyl)-18-[(2S)-2-hydroxy-3,3-dimethylbutan-2-yl]-6-methoxy-18,19-dihydro-4,5-epoxy-6,14-ethenomorphinan-3-ol; 17-Cyclopropylmethyl-4,5alpha-epoxy-7alpha-((S)-1-hydroxy-1,2,2-trimethylpropyl-6-methoxy-6,14-endo-ethanomorphinan-3-ol; 17-cyclopropylmethyl-4,5alpha-epoxy-7alpha-((S)-1-hydroxy-1,2,2-trimethylpropyl)-6-methoxy-6,14-endo-ethanomorphinan-3-ol; 2-(N-Cyclopropylmethyl-4,5alpha-epoxy-3-hydroxy-6-methoxy-6,14-endo-ethanomorphinan-7alpha-yl)-3,3-dimethyl-2-butanol; 2-(N-cyclopropylmethyl-4,5alpha-epoxy-3-hydroxy-6-methoxy-6,14-endo-ethanomorphinan-6alpha-yl)-3,3-dimethyl-2-butanol; 21-(Cyclopropyl-7alpha-((S)-1-hydroxy-1,2,2-trimethylpropyl-6,14-endo-ethano-6,7,8,14-tetrahydrooripavine; 21-cyclopropyl-7alpha-(2-hydroxy-3,3-dimethyl-2-butyl)-6,14-endo-ethano-6,7,8,14-tetrahydrooripavine; 21-cyclopropyl-7alpha-[(S)-1-hydroxy-1,2,2-trimethylpropyl]-6,14-endo-ethano-6,7,8,14-tetrahydrooripavine; 6,14-Ethenomorphinan-7-methanol; 6,14-Ethenomorphinan-7-methanol, 17-(cyclopropylmethyl)-alpha-(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-alpha-methyl-, (alphaS,5alpha,7alpha)-(9CI); 6029-M DMPRI8G CP Reckitt; Colman DMPRI8G TC Analgesics DMPRI8G DT Small molecular drug DMPRI8G PC 644073 DMPRI8G MW 467.6 DMPRI8G FM C29H41NO4 DMPRI8G IC InChI=1S/C29H41NO4/c1-25(2,3)26(4,32)20-15-27-10-11-29(20,33-5)24-28(27)12-13-30(16-17-6-7-17)21(27)14-18-8-9-19(31)23(34-24)22(18)28/h8-9,17,20-21,24,31-32H,6-7,10-16H2,1-5H3/t20-,21-,24-,26+,27-,28+,29-/m1/s1 DMPRI8G CS C[C@]([C@H]1C[C@@]23CC[C@@]1([C@H]4[C@@]25CCN([C@@H]3CC6=C5C(=C(C=C6)O)O4)CC7CC7)OC)(C(C)(C)C)O DMPRI8G IK RMRJXGBAOAMLHD-IHFGGWKQSA-N DMPRI8G IU (1S,2S,6R,14R,15R,16R)-5-(cyclopropylmethyl)-16-[(2S)-2-hydroxy-3,3-dimethylbutan-2-yl]-15-methoxy-13-oxa-5-azahexacyclo[13.2.2.12,8.01,6.02,14.012,20]icosa-8(20),9,11-trien-11-ol DMPRI8G CA CAS 52485-79-7 DMPRI8G CB CHEBI:3216 DMPRI8G DE Pain; Migraine; Psychiatric disorder DMBQEGT ID DMBQEGT DMBQEGT DN Buprenorphine + naloxone DMBQEGT HS Approved DMBQEGT SN Buprenorphine/naloxone; [5 ,7 (S)]-17-(Cyclopropylmethyl)- -(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy- -methyl-6,14-ethenomorphinan-7-methanol; SCHEMBL18085614; Buprenorphine 10 mg/ml in Methanol; Buprenorphine 01 mg/ml in Methanol; ALKS5461 DMBQEGT CP Orexo DMBQEGT DT Small molecular drug DMBQEGT PC 6321408 DMBQEGT MW 467.6 DMBQEGT FM C29H41NO4 DMBQEGT IC InChI=1S/C29H41NO4/c1-25(2,3)26(4,32)20-15-27-10-11-29(20,33-5)24-28(27)12-13-30(16-17-6-7-17)21(27)14-18-8-9-19(31)23(34-24)22(18)28/h8-9,17,20-21,24,31-32H,6-7,10-16H2,1-5H3/t20-,21-,24-,26+,27-,28+,29?/m1/s1 DMBQEGT CS C[C@]([C@H]1C[C@@]23CCC1([C@H]4[C@@]25CCN([C@@H]3CC6=C5C(=C(C=C6)O)O4)CC7CC7)OC)(C(C)(C)C)O DMBQEGT IK RMRJXGBAOAMLHD-MLLHIGKASA-N DMBQEGT IU (1S,2S,6R,14R,16R)-5-(cyclopropylmethyl)-16-[(2S)-2-hydroxy-3,3-dimethylbutan-2-yl]-15-methoxy-13-oxa-5-azahexacyclo[13.2.2.12,8.01,6.02,14.012,20]icosa-8(20),9,11-trien-11-ol DMBQEGT CA CAS 52485-79-7 DMBQEGT DE Opioid dependence; Major depressive disorder DM5PCS7 ID DM5PCS7 DM5PCS7 DN Bupropion DM5PCS7 HS Approved DM5PCS7 SN bupropion; Amfebutamone; 34911-55-2; Amfebutamon; 2-(tert-butylamino)-1-(3-chlorophenyl)propan-1-one; amfebutamonum; Amfebutamona; (+-)-Bupropion; Wellbatrin; Bupropion [INN:BAN]; 34841-39-9; Elontril; Amfebutamonum [INN-Latin]; Zyban; Amfebutamona [INN-Spanish]; Bupropion SR; AMFEBUTAMONE HCl; alpha-(tert-butylamino)-m-chloropropiophenone; CHEMBL894; BRN 2101062; (+-)-1-(3-chlorophenyl)-2-((1,1-dimethylethyl)amino)-1-propanone; CHEBI:3219; SNPPWIUOZRMYNY-UHFFFAOYSA-N; 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]propan-1-one; Amfebutamon; Amfebutamonum; Elont; Bupropion Hcl; Bupropion hydrocloride; Bupropion (INN); Bupropion (Old RN); Bupropion (USAN); Alpha-(tert-Butylamino)-m-chloropropiophenone; Alpha-(tert-butylamino)-m-chloropropiophenone; (-)-2-(tert-Butylamino)-3'-chloropropiophenone; (-)-2-(tert-Butylamino)-3'-chlorpropiophenon; 1-Propanone; 2-(Tert-Butylamino)-3'-chloropropiophenone DM5PCS7 CP GlaxoSmithKline plc DM5PCS7 DT Small molecular drug DM5PCS7 PC 444 DM5PCS7 MW 239.74 DM5PCS7 FM C13H18ClNO DM5PCS7 IC InChI=1S/C13H18ClNO/c1-9(15-13(2,3)4)12(16)10-6-5-7-11(14)8-10/h5-9,15H,1-4H3 DM5PCS7 CS CC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C DM5PCS7 IK SNPPWIUOZRMYNY-UHFFFAOYSA-N DM5PCS7 IU 2-(tert-butylamino)-1-(3-chlorophenyl)propan-1-one DM5PCS7 CA CAS 34911-55-2 DM5PCS7 CB CHEBI:3219 DM5PCS7 DE Smoking dependence DMKUOQV ID DMKUOQV DMKUOQV DN Burosumab DMKUOQV HS Approved DMKUOQV SN Burosumab [USAN]; UNII-G9WJT6RD29; G9WJT6RD29 DMKUOQV CP Ultragenyx Pharmaceutical/Kyowa Hakko Kirin DMKUOQV DT Antibody DMKUOQV DE X-linked hypophosphataemia DMBS632 ID DMBS632 DMBS632 DN Buspirone DMBS632 HS Approved DMBS632 SN Ansial; Ansiced; Anxiron; Axoren; Bespar; Buspirona; Buspironum; Buspisal; Ansial (TN); Ansiced (TN); Anxiron (TN); Axoren (TN); Bespar (TN); BuSpar (TN); Buspimen (TN); Buspinol (TN); Buspiron (TN); Buspirona [INN-Spanish]; Buspirone (INN); Buspirone [INN:BAN]; Buspirone-MDTS; Buspironum [INN-Latin]; Buspisal (TN); Gen-Buspirone; Narol (TN); Sorbon (TN); Spamilan (TN); Spitomin (TN); Gen-Buspirone (TN); MJ-9022-1; N-(4-(4-(2-pyrimidinyl)-1-piperazinyl)butyl)-1-cyclopentanediacetamide; 8-(4-(4-(2-Pyrimidinyl)-1-piperizinyl)butyl)-8-azaspiro(4,5)decane-7,9-dione; 8-[4-(4-Pyrimidin-2-yl-piperazin-1-yl)-butyl]-8-aza-spiro[4.5]decane-7,9-dione; 8-[4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]-8-azaspiro[4.5]decane-7,9-dione; 8-{4-[4-(pyrimidin-2-yl)piperazin-1-yl]butyl}-8-azaspiro[4.5]decane-7,9-dione DMBS632 CP Bristol-Myers Squibb DMBS632 TC Antianxiety Agents DMBS632 DT Small molecular drug DMBS632 PC 2477 DMBS632 MW 385.5 DMBS632 FM C21H31N5O2 DMBS632 IC InChI=1S/C21H31N5O2/c27-18-16-21(6-1-2-7-21)17-19(28)26(18)11-4-3-10-24-12-14-25(15-13-24)20-22-8-5-9-23-20/h5,8-9H,1-4,6-7,10-17H2 DMBS632 CS C1CCC2(C1)CC(=O)N(C(=O)C2)CCCCN3CCN(CC3)C4=NC=CC=N4 DMBS632 IK QWCRAEMEVRGPNT-UHFFFAOYSA-N DMBS632 IU 8-[4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]-8-azaspiro[4.5]decane-7,9-dione DMBS632 CA CAS 36505-84-7 DMBS632 CB CHEBI:3223 DMBS632 DE Anxiety disorder DMXYJ9C ID DMXYJ9C DMXYJ9C DN Busulfan DMXYJ9C HS Approved DMXYJ9C SN Busulfano; Busulfanum; Busulfex; Busulphan; Busulphane; Butanedioldimethanesulfonate; Buzulfan; Citosulfan; Glyzophrol; Leucosulfan; Mablin; Methanesulfonic; Mielevcin; Mielosan; Mielucin; Milecitan; Mileran; Misulban; Mitosan; Mitostan; Myeleukon; Myeloleukon; Myelosan; Myelosanum; Mylecytan; Myleran; Mylerlan; Sulfabutin; Sulphabutin; Busulfan GlaxoSmithKline Brand; Busulfan Orphan Brand; Busulfan Wellcome; Busulfan Wellcome Brand; Glaxo Wellcome Brand of Busulfan; GlaxoSmithKline Brand of Busulfan; Myleran tablets; Orphan Brand of Busulfan; Tetramethylene bis[methanesulfonate]; Tetramethylene dimethane sulfonate; Tetramethylenester kyseliny methansulfonove; Tetramethylenester kyseliny methansulfonove[Czech]; Wellcome Brand of Busulfan; AN 33501; CB 2041; GT 2041; GT 41; X 149; Acid, tetramethylene ester; Alkylating agent: crosslinks guanine residues; Busulfan [INN:JAN]; Busulfano [INN-Spanish]; Busulfanum [INN-Latin]; MYLERAN (TN); Methanesulfonic acid, tetram ethylene ester; Methanesulfonic acid, tetramethylene ester; Myleran (TN); Sulfabutin (VAN); Tetramethylene bis(methanesulfonate); Tetramethylene {bis[methanesulfonate]}; Wellcome, Busulfan; C.B. 2041; G.T. 41; Myleran, Busulfex, Busulfan; Busulfan (JP15/USP/INN); Butane-1,4-diyl dimethanesulfonate; BUSULFAN (1,4-BUTANEDIOL, DIMETHANESULFONATE); N-Butane-1,3-di(methylsulfonate); 1,4-BUTANEDIOL DIMETHANESULFONATE; 1,4-Bis(methanesulfonoxy)butane; 1,4-Bis(methanesulfonyloxy)butane; 1,4-Bis[methanesulfonoxy]butane; 1,4-Butanedi yl dimethanesulfonate; 1,4-Butanediol dimethanesulphonate; 1,4-Butanediol dimethylsulfonate; 1,4-Butanediol, dimethanesulfonate; 1,4-Butanediol, dimethanesulphonate; 1,4-Butanediyl dimethanesulfonate; 1,4-Di(methylsulfonoxy)butane; 1,4-Dimesyloxybutane; 1,4-Dimethane sulfonyl oxybutane; 1,4-Dimethanesulfonoxybutane; 1,4-Dimethanesulfonoxylbutane; 1,4-Dimethanesulfonyloxybutane; 1,4-Dimethanesulphonyloxybutane; 1,4-Dimethylsulfonoxybutane; 1,4-Dimethylsulfonyloxybutane; 1,{4-Bis[methanesulfonoxy]butane}; 4-((Methylsulfonyl)oxy)butyl methanesulfonate; 4-methylsulfonyloxybutyl methanesulfonate DMXYJ9C CP GlaxoSmithKline DMXYJ9C TC Anticancer Agents DMXYJ9C DT Small molecular drug DMXYJ9C PC 2478 DMXYJ9C MW 246.3 DMXYJ9C FM C6H14O6S2 DMXYJ9C IC InChI=1S/C6H14O6S2/c1-13(7,8)11-5-3-4-6-12-14(2,9)10/h3-6H2,1-2H3 DMXYJ9C CS CS(=O)(=O)OCCCCOS(=O)(=O)C DMXYJ9C IK COVZYZSDYWQREU-UHFFFAOYSA-N DMXYJ9C IU 4-methylsulfonyloxybutyl methanesulfonate DMXYJ9C CA CAS 55-98-1 DMXYJ9C CB CHEBI:28901 DMXYJ9C DE Myeloproliferative syndrome DMC5AST ID DMC5AST DMC5AST DN Butabarbital DMC5AST HS Approved DMC5AST SN Butabarb; Butabarbitone; Butalan; Butatab; Butatal; Buticaps; Butisol; Butrate; Medarsed; Nilox; Sarisol; Secbubarbital; Secbutabarbital; Secbutabarbitale; Secbutabarbitalum; Secbutobarbital; Secbutobarbitone; Unicelles; Butabarbital [USAN]; Butisol sodium; Secbutabarbital [INN]; Secbutabarbitale [DCIT]; Sodium butabarbital;Butabarbital (USP); Butabarbital (VAN); Butisol (TN); Sec-Butobarbitone; Secbutabarbitalum [INN-Latin]; 5-(butan-2-yl)-5-ethylpyrimidine-2,4,6(1H,3H,5H)-trione; 5-Ethyl-5-(1-methylpropyl)-2,4,6(1H,3H,5H)-pyrimidinetrione; 5-Ethyl-5-(1-methylpropyl)barbiturate; 5-Ethyl-5-(1-methylpropyl)barbituric acid; 5-Ethyl-5-isobutylbarbituric acid; 5-SEC-BUTYL-5-ETHYL-BARBITURIC ACID; 5-Sec-butyl-5-ethyl-2,4,6(1H,3H,5H)-pyrimidinetrione; 5-butan-2-yl-5-ethyl-1,3-diazinane-2,4,6-trione; 5-ethyl-5-(1-methylpropyl)pyrimidine-2,4,6(1H,3H,5H)-trione; 5-sec-Butyl-5-ethylbarbituric acid; 5-sec-Butyl-5-ethylmalonyl urea; 5-sec-butyl-5-ethylpyrimidine-2,4,6(1H,3H,5H)-trione DMC5AST TC Antianxiety Agents DMC5AST DT Small molecular drug DMC5AST PC 2479 DMC5AST MW 212.25 DMC5AST FM C10H16N2O3 DMC5AST IC InChI=1S/C10H16N2O3/c1-4-6(3)10(5-2)7(13)11-9(15)12-8(10)14/h6H,4-5H2,1-3H3,(H2,11,12,13,14,15) DMC5AST CS CCC(C)C1(C(=O)NC(=O)NC1=O)CC DMC5AST IK ZRIHAIZYIMGOAB-UHFFFAOYSA-N DMC5AST IU 5-butan-2-yl-5-ethyl-1,3-diazinane-2,4,6-trione DMC5AST CA CAS 125-40-6 DMC5AST CB CHEBI:3228 DMC5AST DE Insomnia DM584TM ID DM584TM DM584TM DN Butacaine DM584TM HS Approved DM584TM SN Butacaine sulfate; Butelline; Butyn; 149-15-5; Butacaine sulphate; Butacaine sulfate [USP]; UNII-PAU39W3CVB; EINECS 205-733-1; PAU39W3CVB; p-Aminobenzoyldibutylaminopropanol sulfate; Dibutylaminopropyl p-aminobenzoate sulfate; AI3-02405; 3'-Dibutylaminopropyl 4-aminobenzoate sulfate; 1-Propanol, 3-(dibutylamino)-, 4-aminobenzoate (ester), sulfate (2:1) (salt); 3-(p-Aminobenzoxy)-1-di-N-butylaminopropane sulfate; 3-(Dibutylamino)-1-propanol p-aminobenzoate (ester) sulfate (2:1) DM584TM DT Small molecular drug DM584TM PC 2480 DM584TM MW 306.4 DM584TM FM C18H30N2O2 DM584TM IC InChI=1S/C18H30N2O2/c1-3-5-12-20(13-6-4-2)14-7-15-22-18(21)16-8-10-17(19)11-9-16/h8-11H,3-7,12-15,19H2,1-2H3 DM584TM CS CCCCN(CCCC)CCCOC(=O)C1=CC=C(C=C1)N DM584TM IK HQFWVSGBVLEQGA-UHFFFAOYSA-N DM584TM IU 3-(dibutylamino)propyl 4-aminobenzoate DM584TM CA CAS 149-16-6 DM584TM CB CHEBI:94820 DM584TM DE Pain DM9J04X ID DM9J04X DM9J04X DN Butalbital DM9J04X HS Approved DM9J04X SN Alisobumal; Alisobumalum; Allylbarbital; Allylbarbitone; Allylisobutylbarbital; Allylisobutylbarbiturate; Butalbarbital;Butalbitale; Butalbitalum; Itobarbital; Profundal; Sandoptal; Tetrallobarbital; Butalbitale [DCIT]; Axocet (TN); Axotal (TN); Bucet (TN); Bupap (TN); Butalbital [USAN:INN]; Butalbitalum [INN-Latin]; Cephadyn (TN); Dolgic (TN); Esgic (TN); Fioricet (TN); Fiorinal (TN); Fiormor (TN); Fiortal (TN); Fortabs (TN); IBS-L0126512; Iso-butylallylbarbituric acid; Laniroif (TN); Phrenilin (TN); Phrenilin Forte (TN); Sandoptal (TN); Sedapap (TN); Butalbital (USP/INN); Esgic-Plus (TN); 5-(2-methylpropyl)-5-(prop-2-en-1-yl)pyrimidine-2,4,6(1H,3H,5H)-trione; 5-(2-methylpropyl)-5-prop-2-en-1-ylpyrimidine-2,4,6(1H,3H,5H)-trione; 5-(2-methylpropyl)-5-prop-2-enyl-1,3-diazinane-2,4,6-trione; 5-Allyl-5-(2'-methyl-n-propyl) barbituric acid; 5-Allyl-5-(2-methylpropyl)barbituric acid; 5-Allyl-5-isobutyl-2,4,6(1H,3H,5H)-pyrimidinetrione; 5-Allyl-5-isobutyl-pyrimidine-2,4,6-trione; 5-Allyl-5-isobutylbarbituric acid DM9J04X TC Analgesics DM9J04X DT Small molecular drug DM9J04X PC 2481 DM9J04X MW 224.26 DM9J04X FM C11H16N2O3 DM9J04X IC InChI=1S/C11H16N2O3/c1-4-5-11(6-7(2)3)8(14)12-10(16)13-9(11)15/h4,7H,1,5-6H2,2-3H3,(H2,12,13,14,15,16) DM9J04X CS CC(C)CC1(C(=O)NC(=O)NC1=O)CC=C DM9J04X IK UZVHFVZFNXBMQJ-UHFFFAOYSA-N DM9J04X IU 5-(2-methylpropyl)-5-prop-2-enyl-1,3-diazinane-2,4,6-trione DM9J04X CA CAS 77-26-9 DM9J04X CB CHEBI:102524 DM9J04X DE Anxiety disorder; Headache DMOJ4ZI ID DMOJ4ZI DMOJ4ZI DN Butenafine DMOJ4ZI HS Approved DMOJ4ZI SN Butenafina; Butenafinum; Mentax; Butenafine HCL; Butenafine [INN]; Butenafine hydrochloride; KP 363; Butenafina [INN-Spanish]; Butenafine (INN); Butenafinum [INN-Latin]; Butop (TN); KP-363; Mentax (TN); N-4-tert-butylbenzyl-N-methyl-1-naphthalene methylamine hydrochloride; N-p-tert-Butylbenzyl-N-methyl-1-naphthalenemethylamine; N-(p-tert-Butylbenzyl)-N-methyl-1-naphthalenemethylamine; 1-(4-tert-butylphenyl)-N-methyl-N-(naphthalen-1-ylmethyl)methanamine; 4-tert-butylbenzyl(methyl)(1-naphthalenemethyl)amine DMOJ4ZI CP Schering-Plough DMOJ4ZI TC Antifungal Agents DMOJ4ZI DT Small molecular drug DMOJ4ZI PC 2484 DMOJ4ZI MW 317.5 DMOJ4ZI FM C23H27N DMOJ4ZI IC InChI=1S/C23H27N/c1-23(2,3)21-14-12-18(13-15-21)16-24(4)17-20-10-7-9-19-8-5-6-11-22(19)20/h5-15H,16-17H2,1-4H3 DMOJ4ZI CS CC(C)(C)C1=CC=C(C=C1)CN(C)CC2=CC=CC3=CC=CC=C32 DMOJ4ZI IK ABJKWBDEJIDSJZ-UHFFFAOYSA-N DMOJ4ZI IU 1-(4-tert-butylphenyl)-N-methyl-N-(naphthalen-1-ylmethyl)methanamine DMOJ4ZI CA CAS 101828-21-1 DMOJ4ZI CB CHEBI:3238 DMOJ4ZI DE Dermatologic infection DM7JHX0 ID DM7JHX0 DM7JHX0 DN Butethal DM7JHX0 HS Approved DM7JHX0 SN Aethylbutylbarbitursaeure; Budorm; Butabarbitol; Butobarbital; Butobarbitalum; Butobarbitone; Butobarbitural; Etoval; Hyperbutal; Longanoct; Meonal; Monodorm; Neonal; Sonerile; Soneryl; Butobarbital [BAN]; Butobarbital (BAN); Neonal (TN); Butyl,5-ethylbarbituric acid; 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-butyl-5-ethyl-(9CI); 5-BUTYL-5-ETHYLBARBITURIC ACID; 5-Butyl-5-ethyl-2,4,6(1H,3H,5H)-pyrimidinetrione; 5-Ethyl-5-butylbarbituric acid; 5-Ethyl-5-n-butylbarbituric acid; 5-butyl-5-ethyl-1,3-diazinane-2,4,6-trione DM7JHX0 TC Hypnotics and Sedatives DM7JHX0 DT Small molecular drug DM7JHX0 PC 6473 DM7JHX0 MW 212.25 DM7JHX0 FM C10H16N2O3 DM7JHX0 IC InChI=1S/C10H16N2O3/c1-3-5-6-10(4-2)7(13)11-9(15)12-8(10)14/h3-6H2,1-2H3,(H2,11,12,13,14,15) DM7JHX0 CS CCCCC1(C(=O)NC(=O)NC1=O)CC DM7JHX0 IK STDBAQMTJLUMFW-UHFFFAOYSA-N DM7JHX0 IU 5-butyl-5-ethyl-1,3-diazinane-2,4,6-trione DM7JHX0 CA CAS 77-28-1 DM7JHX0 CB CHEBI:134884 DM7JHX0 DE Insomnia DM8SY60 ID DM8SY60 DM8SY60 DN Butoconazole DM8SY60 HS Approved DM8SY60 SN Butaconazole; Butoconazol; Butoconazolum; Femstat; Gynofort; Duplicate RN for parent cpd; RS 35887; Butoconazol [INN-Spanish]; Butoconazole (INN); Butoconazole [INN:BAN]; Butoconazolum [INN-Latin]; Gynofort (TN); RS 35887-10-3; (+-)-1-[4-(4-Chlorophenyl)-2-[(2,6-dichlorophenyl)thio]butyl]-1H-imidazole; (+/-)-1-[4-(p-Chlorophenyl)-2-[(2,6-dichlorophenyl)thio]butyl]imidazole; (-)-1-((4-(p-Chlorophenyl)-2-((2,6-dichlorophenyl)thio)imidazole; 1-(4-(4-Chlorophenyl)-2-(2,6-dichlorophenylthio)-n-butyl)-1H-imidazole; 1-[4-(4-chlorophenyl)-2-(2,6-dichlorophenyl)sulfanylbutyl]imidazole; 1-{4-(4-chlorophenyl)-2-[(2,6-dichlorophenyl)sulfanyl]butyl}-1H-imidazole; 1H-Imidazole; 1H-Imidazole, 1-(4-(4-chlorophenyl)-2-((2,6-dichlorophenyl)thio)butyl)-, nitrate DM8SY60 CP Roche Palo Alto Llc DM8SY60 TC Antifungal Agents DM8SY60 DT Small molecular drug DM8SY60 PC 47472 DM8SY60 MW 411.8 DM8SY60 FM C19H17Cl3N2S DM8SY60 IC InChI=1S/C19H17Cl3N2S/c20-15-7-4-14(5-8-15)6-9-16(12-24-11-10-23-13-24)25-19-17(21)2-1-3-18(19)22/h1-5,7-8,10-11,13,16H,6,9,12H2 DM8SY60 CS C1=CC(=C(C(=C1)Cl)SC(CCC2=CC=C(C=C2)Cl)CN3C=CN=C3)Cl DM8SY60 IK SWLMUYACZKCSHZ-UHFFFAOYSA-N DM8SY60 IU 1-[4-(4-chlorophenyl)-2-(2,6-dichlorophenyl)sulfanylbutyl]imidazole DM8SY60 CA CAS 64872-76-0 DM8SY60 CB CHEBI:3240 DM8SY60 DE Candidiasis DM5KYPJ ID DM5KYPJ DM5KYPJ DN Butorphanol DM5KYPJ HS Approved DM5KYPJ SN Beforal; Butorfanol; Butorphanolum; Moradol; Stadol; Butorphanol tartrate; BC-2627; Beforal (TN); Butorfanol [INN-Spanish]; Butorphanolum [INN-Latin]; L-BC 2627; Moradol (TN); Butorphanol (USAN/INN); Butorphanol [USAN:BAN:INN]; Levo-BC-2627; (-)-17-(Cyclobutylmethyl)morphinan-3,14-diol; (-)-N-cyclobutylmethyl-3,14-dihydroxymorphinan; (-)-butorphanol; 17-(CYCLOBUTYLMETHYL)MORPHINAN-3,14-DIOL DM5KYPJ CP Apotex Inc DM5KYPJ TC Analgesics DM5KYPJ DT Small molecular drug DM5KYPJ PC 5361092 DM5KYPJ MW 327.5 DM5KYPJ FM C21H29NO2 DM5KYPJ IC InChI=1S/C21H29NO2/c23-17-7-6-16-12-19-21(24)9-2-1-8-20(21,18(16)13-17)10-11-22(19)14-15-4-3-5-15/h6-7,13,15,19,23-24H,1-5,8-12,14H2/t19-,20+,21-/m1/s1 DM5KYPJ CS C1CC[C@]2([C@H]3CC4=C([C@]2(C1)CCN3CC5CCC5)C=C(C=C4)O)O DM5KYPJ IK IFKLAQQSCNILHL-QHAWAJNXSA-N DM5KYPJ IU (1S,9R,10S)-17-(cyclobutylmethyl)-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-triene-4,10-diol DM5KYPJ CA CAS 42408-82-2 DM5KYPJ CB CHEBI:3242 DM5KYPJ DE Pain DMZKXB7 ID DMZKXB7 DMZKXB7 DN Butylscopolamine DMZKXB7 HS Approved DMZKXB7 SN AC1LCV8Y DMZKXB7 DT Small molecular drug DMZKXB7 PC 160883 DMZKXB7 MW 360.5 DMZKXB7 FM C21H30NO4+ DMZKXB7 IC InChI=1S/C21H30NO4/c1-3-4-10-22(2)17-11-15(12-18(22)20-19(17)26-20)25-21(24)16(13-23)14-8-6-5-7-9-14/h5-9,15-20,23H,3-4,10-13H2,1-2H3/q+1/t15?,16-,17-,18+,19-,20+,22?/m1/s1 DMZKXB7 CS CCCC[N+]1([C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4)C DMZKXB7 IK YBCNXCRZPWQOBR-MWGADRMYSA-N DMZKXB7 IU [(1S,2S,4R,5R)-9-butyl-9-methyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonan-7-yl] (2S)-3-hydroxy-2-phenylpropanoate DMZKXB7 CA CAS 7182-53-8 DMZKXB7 CB CHEBI:145701 DMZKXB7 DE Dysmenorrhea DMPAZHC ID DMPAZHC DMPAZHC DN Cabazitaxel DMPAZHC HS Approved DMPAZHC SN Jevtana; Taxoid XRP6258; Jevtana (TN) DMPAZHC CP Sanofi-Aventis DMPAZHC DT Small molecular drug DMPAZHC PC 9854073 DMPAZHC MW 835.9 DMPAZHC FM C45H57NO14 DMPAZHC IC InChI=1S/C45H57NO14/c1-24-28(57-39(51)33(48)32(26-17-13-11-14-18-26)46-40(52)60-41(3,4)5)22-45(53)37(58-38(50)27-19-15-12-16-20-27)35-43(8,36(49)34(55-10)31(24)42(45,6)7)29(54-9)21-30-44(35,23-56-30)59-25(2)47/h11-20,28-30,32-35,37,48,53H,21-23H2,1-10H3,(H,46,52)/t28-,29-,30+,32-,33+,34+,35-,37-,43+,44-,45+/m0/s1 DMPAZHC CS CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)OC)C)OC DMPAZHC IK BMQGVNUXMIRLCK-OAGWZNDDSA-N DMPAZHC IU [(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4-acetyloxy-1-hydroxy-15-[(2R,3S)-2-hydroxy-3-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylpropanoyl]oxy-9,12-dimethoxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl] benzoate DMPAZHC CA CAS 183133-96-2 DMPAZHC CB CHEBI:63584 DMPAZHC DE Breast cancer; Solid tumour/cancer DMQ4HIN ID DMQ4HIN DMQ4HIN DN Cabergoline DMQ4HIN HS Approved DMQ4HIN SN Cabaser; Cabaseril; Cabergolina; Cabergolinum; Dostinex; Galastop; Sogilen; Cabergolina [Spanish]; Cabergolinum [Latin]; CG-101; Cabaser (TN); Dostinex (TN); FCE-21336; Cabergoline [USAN:BAN:INN]; Cabergoline (JAN/USAN/INN); (8R)-6-allyl-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)ergoline-8-carboxamide; (8beta)-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)-6-(prop-2-en-1-yl)ergoline-8-carboxamide; (8beta)-N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-(2-propenyl)-ergoline-8-carboxamide; (8beta)-N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-prop-2-en-1-ylergoline-8-carboxamide; 1-((6-Allylergolin-8beta-yl)carbonyl)-1-(3-(dimethylamino)propyl)-3-ethylurea; 1-[(6-allylergoline-8beta-yl)carbonyl]-1-[3-(dimethylamino)propyl]-3-ethylurea; 1-ethyl-2-(3'-dimethylaminopropyl)-3-(6'-allylergoline-8'-beta-carbonyl)urea diphosphate; 1-ethyl-3-(3'-dimethylamionpropyl)-2-(6'-allylergoline-8'beta-carbonyl)urea DMQ4HIN CP Pfizer Pharmaceuticals DMQ4HIN TC Anticancer Agents DMQ4HIN DT Small molecular drug DMQ4HIN PC 54746 DMQ4HIN MW 451.6 DMQ4HIN FM C26H37N5O2 DMQ4HIN IC InChI=1S/C26H37N5O2/c1-5-11-30-17-19(25(32)31(26(33)27-6-2)13-8-12-29(3)4)14-21-20-9-7-10-22-24(20)18(16-28-22)15-23(21)30/h5,7,9-10,16,19,21,23,28H,1,6,8,11-15,17H2,2-4H3,(H,27,33)/t19-,21-,23-/m1/s1 DMQ4HIN CS CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@H]2[C@@H](CC3=CNC4=CC=CC2=C34)N(C1)CC=C DMQ4HIN IK KORNTPPJEAJQIU-KJXAQDMKSA-N DMQ4HIN IU (6aR,9R,10aR)-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)-7-prop-2-enyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide DMQ4HIN CA CAS 81409-90-7 DMQ4HIN CB CHEBI:3286 DMQ4HIN DE Hyperprolactinaemia DMIYDT4 ID DMIYDT4 DMIYDT4 DN Cabozantinib DMIYDT4 HS Approved DMIYDT4 SN Cabometyx; Cometriq DMIYDT4 CP Exelixis DMIYDT4 DT Small molecular drug DMIYDT4 PC 25102847 DMIYDT4 MW 501.5 DMIYDT4 FM C28H24FN3O5 DMIYDT4 IC InChI=1S/C28H24FN3O5/c1-35-24-15-21-22(16-25(24)36-2)30-14-11-23(21)37-20-9-7-19(8-10-20)32-27(34)28(12-13-28)26(33)31-18-5-3-17(29)4-6-18/h3-11,14-16H,12-13H2,1-2H3,(H,31,33)(H,32,34) DMIYDT4 CS COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F DMIYDT4 IK ONIQOQHATWINJY-UHFFFAOYSA-N DMIYDT4 IU 1-N-[4-(6,7-dimethoxyquinolin-4-yl)oxyphenyl]-1-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide DMIYDT4 CA CAS 849217-68-1 DMIYDT4 CB CHEBI:72317 DMIYDT4 DE Thyroid cancer; Ovarian cancer DMKBJWP ID DMKBJWP DMKBJWP DN Caffeine DMKBJWP HS Approved DMKBJWP SN CFF; Cafamil; Cafecon; Cafeina; Cafeine; Caffedrine; Caffein; Caffeina; Caffenium; Caffine; Cafipel; Coffein; Coffeine; Coffeinum; DHCplus; Dasin; Dexitac; Diurex; Durvitan; Enerjets; Ercatab; Guaranine; Hycomine; Kofein; Koffein; Mateina; Methyltheobromide; Methyltheobromine; Miudol; Nodaca; Organex; Percutafeine; Phensal; Stim; Teina; Thein; Theine; Tirend; Vivarin; Anacin Maximum Strength; Anhydrous caffeine; Caffedrine Caplets; Caffeina [Italian]; Caffeine Pure; Caffeine solution; Coffein [German]; Coffeinum N; Coffeinum Purrum; Component of Cafergot; DHC Plus; Dexitac Stay Alert Stimulant; Eldiatric C; GlaxoSmithKline Brand of Caffeine; Hycomine Compound; Keep Alert; Kofein [Czech]; Koffein [German]; Merck dura Brand of Caffeine; Methylxanthine theophylline; Midol Maximum Strength; Monomethyl derivative of Theophylline; Natural Caffeinum; Nix Nap; No Doz; Nodoz Maximum Strength Caplets; Passauer Brand of Caffeine; Percoffedrinol N; Pierre Fabre Brand of Caffeine; Quick Pep; Republic Drug Brand of Caffeine; Seid Brand of Caffeine; Theobromine Me; Theophylline Me; C 0750; Propoxyphene Compound 65; SK 65 Compound; TNP00310; Thompson Brand 1 of Caffeine; Thompson Brand 2 of Caffeine; Alert-pep; Anhydrous caffeine (JP15); Anhydrous caffeine (TN); Berlin-Chemie Brand of Caffeine; Bristol-Myers Squibb Brand of Caffeine; Cafcit (TN); Caffeine (USP); Caffeine (natural); Caffeine [BAN:JAN]; Caffeine, Monohydrate; Caffeine, anhydrous; Caffeine, synthetic; No-Doz; Pep-Back; Propoxyphene Compound-65; Quick-Pep; Refresh'n; SK-65 Compound; Tri-Aqua; Ultra Pep-Back; Wake-Up; CU-01000012617-3; P-A-C Analgesic Tablets; Theophylline, 7-methyl; Xanthine, 1,3,7-trimethyl; 1,3,7-Trimethyl-2,6-dioxopurine; 1,3,7-Trimethylpurine-2,6-dione; 1,3,7-Trimethylxanthine; 1-3-7-TRIMETHYLXANTHINE; 1-methyltheobromine; 3,7-dihydro-1,3,7-trimethyl-1H-purine; 7-Methyltheophylline DMKBJWP CP Ben Venue Laboratories DMKBJWP TC Antihypertensive Agents DMKBJWP DT Small molecular drug DMKBJWP PC 2519 DMKBJWP MW 194.19 DMKBJWP FM C8H10N4O2 DMKBJWP IC InChI=1S/C8H10N4O2/c1-10-4-9-6-5(10)7(13)12(3)8(14)11(6)2/h4H,1-3H3 DMKBJWP CS CN1C=NC2=C1C(=O)N(C(=O)N2C)C DMKBJWP IK RYYVLZVUVIJVGH-UHFFFAOYSA-N DMKBJWP IU 1,3,7-trimethylpurine-2,6-dione DMKBJWP CA CAS 58-08-2 DMKBJWP CB CHEBI:27732 DMKBJWP DE Orthostatic hypotension DMQZBXI ID DMQZBXI DMQZBXI DN Calaspargase pegol DMQZBXI HS Approved DMQZBXI SN UNII-T9FVH03HMZ; T9FVH03HMZ; Calaspargase pegol [USAN:INN]; EZN-2285 DMQZBXI CP Servier DMQZBXI DT Antibody DMQZBXI DE Acute lymphoblastic leukaemia; Acute lymphocytic leukaemia DMN4CV5 ID DMN4CV5 DMN4CV5 DN Calcidiol DMN4CV5 HS Approved DMN4CV5 SN Calcifediolum; Calcifidiol; Delakmin; VDY; Calcifediol anhydrous; BML2-E02; Calcifediolum [INN-Latin]; Ro 8-8892; U-32070E; (1R,3Z)-3-[(2E)-2-[(1R,7aR)-1-[(2R)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol; (1S,3Z)-3-[(2E)-2-[(1R,3aS,7aR)-1-[(2R)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol; (3S,5Z,7E)-9,10-secocholesta-5,7,10(19)-triene-3,25-diol; (3S,5Z,7E)-9,10-secocholesta-5,7,10-triene-3,25-diol; (3beta,5Z,7E)-9,10-secocholesta-5,7,10(19)-triene-3,25-diol; (5Z,7E)-(3S)-9,10-secocholesta-5,7,10(19)-triene-3,25-diol; (5Z,7E)-9,10-Seco-5,7,10(19)-cholestatrien-3beta,25-diol; 25(OH)D3; 25-(OH)Vitamin D3; 25-Hydroxycholecalciferol; 25-Hydroxycholecalciferol (Calcifediol); 25-Hydroxycholescalciferol; 25-Hydroxyvitamin D; 25-Hydroxyvitamin D3 monohydrate; 25-hydroxyvitamin D3; 3-{2-[1-(5-HYDROXY-1,5-DIMETHYL-HEXYL)-7A-METHYL-OCTAHYDRO-INDEN-4-YLIDENE]-ETHYLIDENE}-4-METHYLENE-CYCLOHEXANOL; 5,6-cis-25-Hydroxyvitamin D3; 5,6-trans-25-Hydroxycholescalciferol; 5,6-trans-9,10-Seco-5,7,10(19)-cholestatrien-3beta,25-diol; 9,10-Secocholesta-5,7,10(19)-triene-3beta,25-diol DMN4CV5 CP United Research Laboratories DMN4CV5 TC Vitamins DMN4CV5 DT Small molecular drug DMN4CV5 PC 5283731 DMN4CV5 MW 400.6 DMN4CV5 FM C27H44O2 DMN4CV5 IC InChI=1S/C27H44O2/c1-19-10-13-23(28)18-22(19)12-11-21-9-7-17-27(5)24(14-15-25(21)27)20(2)8-6-16-26(3,4)29/h11-12,20,23-25,28-29H,1,6-10,13-18H2,2-5H3/b21-11+,22-12-/t20-,23+,24-,25+,27-/m1/s1 DMN4CV5 CS C[C@H](CCCC(C)(C)O)[C@H]1CC[C@@H]\\2[C@@]1(CCC/C2=C\\C=C/3\\C[C@H](CCC3=C)O)C DMN4CV5 IK JWUBBDSIWDLEOM-DTOXIADCSA-N DMN4CV5 IU (1S,3Z)-3-[(2E)-2-[(1R,3aS,7aR)-1-[(2R)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol DMN4CV5 CA CAS 19356-17-3 DMN4CV5 CB CHEBI:17933 DMN4CV5 DE Vitamin D deficiency DM03CP7 ID DM03CP7 DM03CP7 DN Calcipotriol DM03CP7 HS Approved DM03CP7 SN Calcipotriene; Divonex; Dovonex; BMS-181161; Daivonex (TN); Dovonex (TN); MC-903; (1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5S)-5-cyclopropyl-5-hydroxypent-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol; (1S,5Z,7Z,17ALPHA,22E)-24-CYCLOPROPYL-9,10-SECOCHOLA-5,7,10,22-TETRAENE-1,3,24-TRIOL; 1-ALPHA,24S-(OH)2-22-ENE-26,27-DEHYDROVITAMIN D3 DM03CP7 CP LEO Pharma Inc DM03CP7 TC Antipsoriatic Agents DM03CP7 DT Small molecular drug DM03CP7 PC 5288783 DM03CP7 MW 412.6 DM03CP7 FM C27H40O3 DM03CP7 IC InChI=1S/C27H40O3/c1-17(6-13-25(29)20-8-9-20)23-11-12-24-19(5-4-14-27(23,24)3)7-10-21-15-22(28)16-26(30)18(21)2/h6-7,10,13,17,20,22-26,28-30H,2,4-5,8-9,11-12,14-16H2,1,3H3/b13-6+,19-7+,21-10-/t17-,22-,23-,24+,25-,26+,27-/m1/s1 DM03CP7 CS C[C@H](/C=C/[C@H](C1CC1)O)[C@H]2CC[C@@H]\\3[C@@]2(CCC/C3=C\\C=C/4\\C[C@H](C[C@@H](C4=C)O)O)C DM03CP7 IK LWQQLNNNIPYSNX-UROSTWAQSA-N DM03CP7 IU (1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5S)-5-cyclopropyl-5-hydroxypent-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol DM03CP7 CA CAS 112965-21-6 DM03CP7 CB CHEBI:50749 DM03CP7 DE Psoriasis vulgaris DM0N9WA ID DM0N9WA DM0N9WA DN Calcitonin Human DM0N9WA HS Approved DM0N9WA CP Novartis Pharmaceuticals Corp DM0N9WA TC Anticancer Agents DM0N9WA PC 45055432 DM0N9WA MW 3417.9 DM0N9WA FM C151H226N40O45S3 DM0N9WA IC InChI=1S/C151H226N40O45S3/c1-17-75(8)118(144(229)163-67-114(205)183-117(74(6)7)143(228)162-64-112(203)165-77(10)150(235)190-50-29-38-106(190)124(158)209)185-125(210)76(9)166-145(230)120(79(12)194)186-131(216)92(45-47-109(155)200)170-142(227)107-39-30-51-191(107)151(236)103(58-85-35-25-20-26-36-85)180-148(233)122(81(14)196)188-139(224)99(59-87-63-159-71-164-87)176-133(218)96(55-83-31-21-18-22-32-83)174-128(213)90(37-27-28-49-152)168-136(221)101(61-111(157)202)177-134(219)97(56-84-33-23-19-24-34-84)175-137(222)102(62-116(207)208)178-129(214)91(44-46-108(154)199)171-147(232)121(80(13)195)187-138(223)98(57-86-40-42-88(198)43-41-86)179-146(231)119(78(11)193)184-115(206)66-161-127(212)94(53-72(2)3)172-130(215)93(48-52-237-16)169-141(226)105-70-239-238-69-89(153)126(211)160-65-113(204)167-100(60-110(156)201)135(220)173-95(54-73(4)5)132(217)181-104(68-192)140(225)189-123(82(15)197)149(234)182-105/h18-26,31-36,40-43,63,71-82,89-107,117-123,192-198H,17,27-30,37-39,44-62,64-70,152-153H2,1-16H3,(H2,154,199)(H2,155,200)(H2,156,201)(H2,157,202)(H2,158,209)(H,159,164)(H,160,211)(H,161,212)(H,162,228)(H,163,229)(H,165,203)(H,166,230)(H,167,204)(H,168,221)(H,169,226)(H,170,227)(H,171,232)(H,172,215)(H,173,220)(H,174,213)(H,175,222)(H,176,218)(H,177,219)(H,178,214)(H,179,231)(H,180,233)(H,181,217)(H,182,234)(H,183,205)(H,184,206)(H,185,210)(H,186,216)(H,187,223)(H,188,224)(H,189,225)(H,207,208)/t75-,76-,77-,78+,79+,80+,81+,82+,89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,117-,118-,119-,120-,121-,122-,123-/m0/s1 DM0N9WA CS CC[C@H](C)[C@@H](C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N)NC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC4=CNC=N4)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC6=CC=CC=C6)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC7=CC=C(C=C7)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@@H]8CSSC[C@@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N8)[C@@H](C)O)CO)CC(C)C)CC(=O)N)N DM0N9WA IK LDVRMNJZLWXJPL-JKQNMTHDSA-N DM0N9WA IU (3S)-4-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-1-[(2S)-2-[[(2S)-5-amino-1-[[(2S,3R)-1-[[(2S)-1-[[(2S,3S)-1-[[2-[[(2S)-1-[[2-[[(2S)-1-[(2S)-2-carbamoylpyrrolidin-1-yl]-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1,5-dioxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxohexan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-[[(2S)-5-amino-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-2-[[(2S)-2-[[(4R,7S,10S,13S,16S,22R)-22-amino-16-(2-amino-2-oxoethyl)-7-[(1R)-1-hydroxyethyl]-10-(hydroxymethyl)-13-(2-methylpropyl)-6,9,12,15,18,21-hexaoxo-1,2-dithia-5,8,11,14,17,20-hexazacyclotricosane-4-carbonyl]amino]-4-methylsulfanylbutanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxybutanoyl]amino]-5-oxopentanoyl]amino]-4-oxobutanoic acid DM0N9WA CB CHEBI:135973 DM0N9WA DE Postmenopausal osteoporosis; Pain; Paget's disease DM8ZVJ7 ID DM8ZVJ7 DM8ZVJ7 DN Calcitriol DM8ZVJ7 HS Approved DM8ZVJ7 SN calcitriol; Rocaltrol; 32222-06-3; Calcijex; Topitriol; 1alpha,25-Dihydroxyvitamin D3; Silkis; Soltriol; 1alpha,25-Dihydroxycholecalciferol; Calcitriolum; Dihydroxyvitamin D3; 1,25-DHCC; 1,25-Dihydroxyvitamin D; Vectical; 1,25-DIHYDROXYCHOLECALCIFEROL; 1,25-Dihydroxyvitamin D3; 1alpha,25-Dihydroxyvitamin D; 1-alpha,25-Dihydroxyvitamin D3; Calcitriolum [INN-Latin]; UNII-FXC9231JVH; 1alpha,25(OH)2D3; DN-101; 1,25-Dihydroxycholecaliferol; CCRIS 5522; Ro 21-5535; HSDB 3482; 1-alpha,25-Dihydroxycholecalciferol; EINECS 250-963-8; DN 101; Calcitriol (chemotherapy-induced alopecia); Calcitriol (chemotherapy-induced alopecia), Cytotech Labs; Calcitriol (API-31543, drug-induced alopecia), Cytotech Labs; 1alpha,25 dihydroxyvitamin D(3) DM8ZVJ7 CP Cytotech Labs LLC DM8ZVJ7 DT Small molecular drug DM8ZVJ7 PC 5280453 DM8ZVJ7 MW 416.6 DM8ZVJ7 FM C27H44O3 DM8ZVJ7 IC InChI=1S/C27H44O3/c1-18(8-6-14-26(3,4)30)23-12-13-24-20(9-7-15-27(23,24)5)10-11-21-16-22(28)17-25(29)19(21)2/h10-11,18,22-25,28-30H,2,6-9,12-17H2,1,3-5H3/b20-10+,21-11-/t18-,22-,23-,24+,25+,27-/m1/s1 DM8ZVJ7 CS C[C@H](CCCC(C)(C)O)[C@H]1CC[C@@H]\\2[C@@]1(CCC/C2=C\\C=C/3\\C[C@H](C[C@@H](C3=C)O)O)C DM8ZVJ7 IK GMRQFYUYWCNGIN-NKMMMXOESA-N DM8ZVJ7 IU (1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(2R)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol DM8ZVJ7 CA CAS 32222-06-3 DM8ZVJ7 CB CHEBI:17823 DM8ZVJ7 DE Congenital alopecia DM3W15N ID DM3W15N DM3W15N DN Calcium carbimide DM3W15N HS Approved DM3W15N SN Nitrolime; Alzodef; Aero cyanamid granular; USAF CY-2; Aero cyanamid special grade; Nitrolim; Cyanamid; Calcium cyanamid; Lime Nitroget; Cyanamid granular; NCI-C02937; CY-L 500; Cyanamid special grade; UN 1403, Nitrolime; WLN: CA NCN; NSC7078; NSC-7078 DM3W15N DT Small molecular drug DM3W15N PC 56955933 DM3W15N MW 80.1 DM3W15N FM CCaN2 DM3W15N IC InChI=1S/CN2.Ca/c2-1-3;/q-2;+2 DM3W15N CS C(=[N-])=[N-].[Ca+2] DM3W15N IK MYFXBBAEXORJNB-UHFFFAOYSA-N DM3W15N IU calcium;azanidylidenemethylideneazanide DM3W15N CA CAS 156-62-7 DM3W15N CB CHEBI:64301 DM3W15N DE Alcohol dependence DMJ3CFY ID DMJ3CFY DMJ3CFY DN Calcium phosphate dihydrate DMJ3CFY HS Approved DMJ3CFY SN Calcium phosphate dihydrate DMJ3CFY DT Small molecular drug DMJ3CFY PC 22340838 DMJ3CFY MW 346.204 DMJ3CFY FM Ca3H4O10P2 DMJ3CFY IC InChI=1S/3Ca.2H3O4P.2H2O/c;;;2*1-5(2,3)4;;/h;;;2*(H3,1,2,3,4);2*1H2/q3*+2;;;;/p-6 DMJ3CFY CS O.O.[O-]P(=O)([O-])[O-].[O-]P(=O)([O-])[O-].[Ca+2].[Ca+2].[Ca+2] DMJ3CFY IK WKMXOPXIVBEXRR-UHFFFAOYSA-H DMJ3CFY IU tricalcium;diphosphate;dihydrate DMJ3CFY DE Dental Caries DMWIO46 ID DMWIO46 DMWIO46 DN Camphor DMWIO46 HS Approved DMWIO46 SN camphor; 76-22-2; 2-Camphanone; 2-Bornanone; DL-Camphor; (+)-Camphor; l-(-)-Camphor; (+/-)-Camphor; Root bark oil; 1,7,7-Trimethylbicyclo[2.2.1]heptan-2-one; Bornan-2-one; Alphanon; Kampfer; Gum camphor; Spirit of camphor; Formosa camphor; Laurel camphor; 2-Camphonone; Matricaria camphor; Camphor, synthetic; Bornane, 2-oxo-; 1,7,7-Trimethylnorcamphor; Root bark spirit; 2-Keto-1,7,7-trimethylnorcamphane; DL-Bornan-2-one; D-(+)-Camphor; Norcamphor, 1,7,7-trimethyl-; 21368-68-3; Camphor, (1R,4R)-(+)-; Bicyclo[2.2.1]heptan-2-one, 1,7,7-tri DMWIO46 DT Small molecular drug DMWIO46 PC 2537 DMWIO46 MW 152.23 DMWIO46 FM C10H16O DMWIO46 IC InChI=1S/C10H16O/c1-9(2)7-4-5-10(9,3)8(11)6-7/h7H,4-6H2,1-3H3 DMWIO46 CS CC1(C2CCC1(C(=O)C2)C)C DMWIO46 IK DSSYKIVIOFKYAU-UHFFFAOYSA-N DMWIO46 IU 1,7,7-trimethylbicyclo[2.2.1]heptan-2-one DMWIO46 CA CAS 76-22-2 DMWIO46 CB CHEBI:36773 DMWIO46 DE Acute or chronic pain DMFRM1I ID DMFRM1I DMFRM1I DN Canagliflozin DMFRM1I HS Approved DMFRM1I SN 842133-18-0; Invokana; Canagliflozin anhydrous; canagliflozin hemihydrate; UNII-6S49DGR869; JNJ-28431754; JNJ 24831754ZAE; Canagliflozin hydrate; TA-7284; 1-(Glucopyranosyl)-4-methyl-3-(5-(4-fluorophenyl)-2-thienylmethyl)benzene; CHEBI:73274; 6S49DGR869; (2S,3R,4R,5S,6R)-2-(3-((5-(4-FLUOROPHENYL)THIOPHEN-2-YL)METHYL)-4-METHYLPHENYL)-6-(HYDROXYMETHYL)TETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; TA 7284; (1S)-1,5-anhydro-1-(3-{[5-(4-fluorophenyl)-2-thienyl]methyl}-4-methylphenyl)-D-glucitol; 928672-86-0 DMFRM1I CP Johnson & Johnson DMFRM1I DT Small molecular drug DMFRM1I PC 24812758 DMFRM1I MW 444.5 DMFRM1I FM C24H25FO5S DMFRM1I IC InChI=1S/C24H25FO5S/c1-13-2-3-15(24-23(29)22(28)21(27)19(12-26)30-24)10-16(13)11-18-8-9-20(31-18)14-4-6-17(25)7-5-14/h2-10,19,21-24,26-29H,11-12H2,1H3/t19-,21-,22+,23-,24+/m1/s1 DMFRM1I CS CC1=C(C=C(C=C1)[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)CC3=CC=C(S3)C4=CC=C(C=C4)F DMFRM1I IK XTNGUQKDFGDXSJ-ZXGKGEBGSA-N DMFRM1I IU (2S,3R,4R,5S,6R)-2-[3-[[5-(4-fluorophenyl)thiophen-2-yl]methyl]-4-methylphenyl]-6-(hydroxymethyl)oxane-3,4,5-triol DMFRM1I CA CAS 842133-18-0 DMFRM1I CB CHEBI:73274 DMFRM1I DE Type-2 diabetes; Diabetic nephropathy; Type-1 diabetes DM8HLO5 ID DM8HLO5 DM8HLO5 DN Canakinumab DM8HLO5 HS Approved DM8HLO5 SN Ilaris (TN) DM8HLO5 CP Novartis DM8HLO5 DT Antibody DM8HLO5 SQ 8836_H|canakinumab|Homo sapiens||H-GAMMA-1 (VH(1-118)+CH1(119-216)+HINGE-REGION(217-231)+CH2(232-341)+CH3(342-448))|||||||448||||MW 49253.6|MW 49253.6|: QVQLVESGGGVVQPGRSLRLSCAASGFTFSVYGMNWVRQAPGKGLEWVAIIWYDGDNQYYADSVKGRFTISRDNSKNTLYLQMNGLRAEDTAVYYCARDLRTGPFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK >8836_L|canakinumab|Homo sapiens||L-KAPPA (V-KAPPA(1-107)+C-KAPPA(108-214))|||||||214||||MW 23357.9|MW 23357.9|QVQLVESGGGVVQPGRSLRLSCAASGFTFSVYGMNWVRQAPGKGLEWVAIIWYDGDNQYYADSVKGRFTISRDNSKNTLYLQMNGLRAEDTAVYYCARDLRTGPFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLEIVLTQSPDFQSVTPKEKVTITCRASQSIGSSLHWYQQKPDQSPKLLIKYASQSFSGVPSRFSGSGSGTDFTLTINSLEAEDAAAYYCHQSSSLPFTFGPGTKVDIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC DM8HLO5 DE Vasculitis; Urticaria; Rheumatoid arthritis; Cryopyrin-associated periodic syndromes DMRK8OT ID DMRK8OT DMRK8OT DN Candesartan DMRK8OT HS Approved DMRK8OT SN candesartan; 139481-59-7; Blopress; Ratacand; CV-11974; 1-((2'-(1H-Tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylic acid; CV 11974; UNII-S8Q36MD2XX; 2-ethoxy-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]benzimidazole-4-carboxylic acid; CHEMBL1016; S8Q36MD2XX; 2-Ethoxy-1-(p-(o-1H-tetrazol-5-ylphenyl)benzyl)-7-benzimidazolecarboxylic acid; CHEBI:3347; C24H20N6O3; 2-ethoxy-3-[[4-[2-(1h-tetrazol-5-yl)phenyl]phenyl]methyl]-3h-benzoimidazole-4-carboxylic acid; NCGC00167474-01; AK-57139; Blopress; Candesartan [BAN]; CV11974; Amias (TN); Atacand (TN); Blopress (TN); Candesartan [USAN:INN]; KS-5003; Ratacand (TN); Candesartan (USAN/INN); Atacand, Blopress, Amias, Ratacand,Candesartan; 2-(ethyloxy)-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-benzimidazole-7-carboxylic acid; 2-Ethoxy-3-[[4-[2-(1H-tetrazol-5-yl)phenyl]phenyl] methyl]-3H-benzoimidazole-4-carboxylic acid; 2-ethoxy-1-({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl)-1H-benzimidazole-7-carboxylic acid; 2-ethoxy-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-benzimidazole-7-carboxylic acid; 2-ethoxy-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4ethyl}-1H-benzimidazole-7-carboxylic acid; 2-ethoxy-7-carboxy-1-(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methylbenzimidazole; [3H]candesartan DMRK8OT CP AstraZeneca DMRK8OT TC Antihypertensive Agents DMRK8OT DT Small molecular drug DMRK8OT PC 2541 DMRK8OT MW 440.5 DMRK8OT FM C24H20N6O3 DMRK8OT IC InChI=1S/C24H20N6O3/c1-2-33-24-25-20-9-5-8-19(23(31)32)21(20)30(24)14-15-10-12-16(13-11-15)17-6-3-4-7-18(17)22-26-28-29-27-22/h3-13H,2,14H2,1H3,(H,31,32)(H,26,27,28,29) DMRK8OT CS CCOC1=NC2=CC=CC(=C2N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5)C(=O)O DMRK8OT IK HTQMVQVXFRQIKW-UHFFFAOYSA-N DMRK8OT IU 2-ethoxy-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]benzimidazole-4-carboxylic acid DMRK8OT CA CAS 139481-59-7 DMRK8OT CB CHEBI:3347 DMRK8OT DE Hypertension DMNZSC1 ID DMNZSC1 DMNZSC1 DN Candicidin DMNZSC1 HS Approved DMNZSC1 SN (23E,25E,27E,29E,31E,33E,35E)-22-(4-amino-3,5-dihydroxy-6-methyloxan-2-yl)oxy-10,12,14,18,20-pentahydroxy-37-methyl-2,4,8,16-tetraoxo-1-oxacyclooctatriaconta-23,25,27,29,31,33,35-heptaene-19-carboxylic acid DMNZSC1 TC Antibiotics DMNZSC1 DT Small molecular drug DMNZSC1 PC 10079874 DMNZSC1 MW 1109.3 DMNZSC1 FM C59H84N2O18 DMNZSC1 IC InChI=1S/C59H84N2O18/c1-35-18-15-13-11-9-7-5-6-8-10-12-14-16-21-47(78-59-56(74)54(61)55(73)38(4)77-59)33-51(71)53(58(75)76)50(70)31-46(67)30-45(66)29-44(65)28-43(64)27-41(62)19-17-20-42(63)32-52(72)79-57(35)37(3)26-36(2)48(68)34-49(69)39-22-24-40(60)25-23-39/h5-16,18,21-25,35-38,43-45,47-48,50-51,53-57,59,64-66,68,70-71,73-74H,17,19-20,26-34,60-61H2,1-4H3,(H,75,76)/b6-5+,9-7+,10-8+,13-11+,14-12+,18-15+,21-16+/t35?,36?,37?,38-,43?,44?,45?,47?,48?,50?,51?,53?,54+,55-,56+,57?,59?/m1/s1 DMNZSC1 CS C[C@@H]1[C@H]([C@@H]([C@@H](C(O1)OC\\2CC(C(C(CC(=O)CC(CC(CC(CC(=O)CCCC(=O)CC(=O)OC(C(/C=C/C=C/C=C/C=C/C=C/C=C/C=C2)C)C(C)CC(C)C(CC(=O)C3=CC=C(C=C3)N)O)O)O)O)O)C(=O)O)O)O)N)O DMNZSC1 IK OPGSFDUODIJJGF-JBUZINEHSA-N DMNZSC1 IU (23E,25E,27E,29E,31E,33E,35E)-22-[(3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-38-[7-(4-aminophenyl)-5-hydroxy-4-methyl-7-oxoheptan-2-yl]-10,12,14,18,20-pentahydroxy-37-methyl-2,4,8,16-tetraoxo-1-oxacyclooctatriaconta-23,25,27,29,31,33,35-heptaene-19-carboxylic acid DMNZSC1 CA CAS 1403-17-4 DMNZSC1 CB CHEBI:3349 DMNZSC1 DE Bacterial infection DM8JRH0 ID DM8JRH0 DM8JRH0 DN Cangrelor DM8JRH0 HS Approved DM8JRH0 SN Cangrelor; 163706-06-7; Kengreal; UNII-6AQ1Y404U7; AR-C69931XX; CHEMBL334966; 6AQ1Y404U7; kengrexal; 5'-O-[({[dichloro(phosphono)methyl](hydroxy)phosphoryl}oxy)(hydroxy)phosphoryl]-N-[2-(methylsulfanyl)ethyl]-2-[(3,3,3-trifluoropropyl)sulfanyl]adenosine; 5'-Adenylicacid,N-[2-(methylthio)ethyl]-2-[(3,3,3-trifluoropropyl)thio]-,anhydridewithP,P'-(dichloromethylene)bis[phosphonicacid](1:1) DM8JRH0 CP The Medicines Company DM8JRH0 DT Small molecular drug DM8JRH0 PC 9854012 DM8JRH0 MW 776.4 DM8JRH0 FM C17H25Cl2F3N5O12P3S2 DM8JRH0 IC InChI=1S/C17H25Cl2F3N5O12P3S2/c1-43-5-3-23-12-9-13(26-15(25-12)44-4-2-16(20,21)22)27(7-24-9)14-11(29)10(28)8(38-14)6-37-42(35,36)39-41(33,34)17(18,19)40(30,31)32/h7-8,10-11,14,28-29H,2-6H2,1H3,(H,33,34)(H,35,36)(H,23,25,26)(H2,30,31,32)/t8-,10-,11-,14-/m1/s1 DM8JRH0 CS CSCCNC1=C2C(=NC(=N1)SCCC(F)(F)F)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(C(P(=O)(O)O)(Cl)Cl)O)O)O DM8JRH0 IK PAEBIVWUMLRPSK-IDTAVKCVSA-N DM8JRH0 IU [dichloro-[[[(2R,3S,4R,5R)-3,4-dihydroxy-5-[6-(2-methylsulfanylethylamino)-2-(3,3,3-trifluoropropylsulfanyl)purin-9-yl]oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]methyl]phosphonic acid DM8JRH0 CA CAS 163706-06-7 DM8JRH0 CB CHEBI:90841 DM8JRH0 DE Thrombosis DM0659E ID DM0659E DM0659E DN Cannabidiol DM0659E HS Approved DM0659E SN cannabidiol; 13956-29-1; (-)-Cannabidiol; (-)-trans-Cannabidiol; Epidiolex; UNII-19GBJ60SN5; (-)-trans-2-p-Mentha-1,8-dien-3-yl-5-pentylresorcinol; delta1(2)-trans-Cannabidiol; (-)-CBD; GWP42003-P; CBD; 19GBJ60SN5; QHMBSVQNZZTUGM-ZWKOTPCHSA-N DM0659E CP GW Pharmaceuticals DM0659E DT Small molecular drug DM0659E PC 644019 DM0659E MW 314.5 DM0659E FM C21H30O2 DM0659E IC InChI=1S/C21H30O2/c1-5-6-7-8-16-12-19(22)21(20(23)13-16)18-11-15(4)9-10-17(18)14(2)3/h11-13,17-18,22-23H,2,5-10H2,1,3-4H3/t17-,18+/m0/s1 DM0659E CS CCCCCC1=CC(=C(C(=C1)O)[C@@H]2C=C(CC[C@H]2C(=C)C)C)O DM0659E IK QHMBSVQNZZTUGM-ZWKOTPCHSA-N DM0659E IU 2-[(1R,6R)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]-5-pentylbenzene-1,3-diol DM0659E CA CAS 13956-29-1 DM0659E CB CHEBI:69478 DM0659E DE LennoxGastaut syndrome; Dravet syndrome; Epilepsy; Infantile spasm DMBP5N3 ID DMBP5N3 DMBP5N3 DN Cantharidin DMBP5N3 HS Approved DMBP5N3 SN DSSTox_CID_21752; DSSTox_RID_79835; DSSTox_GSID_41752; CAS-56-25-7; NCGC00016247-01; Spectrum_001114; SpecPlus_000537; Spectrum4_000920; Spectrum2_000630; Prestwick0_000885; Spectrum3_000621; Prestwick1_000885; Spectrum5_001618; Prestwick2_000885; KBioSS_001594; KBioGR_001420; BSPBio_002182; MLS002153505; SCHEMBL152261; DivK1c_006633; SPBio_002889; SPBio_000600; CHEMBL299846; DTXSID7041752; KBio2_006730; KBio3_001682; KBio2_004162; KBio2_001594; KBio1_001577; MolPort-003-665-556; HMS1570B12; Tox21_110326; CCG-39927; Tox21_110326_1 DMBP5N3 DT Small molecular drug DMBP5N3 PC 5944 DMBP5N3 MW 196.2 DMBP5N3 FM C10H12O4 DMBP5N3 IC InChI=1S/C10H12O4/c1-9-5-3-4-6(13-5)10(9,2)8(12)14-7(9)11/h5-6H,3-4H2,1-2H3/t5-,6+,9+,10- DMBP5N3 CS C[C@@]12[C@H]3CC[C@@H]([C@@]1(C(=O)OC2=O)C)O3 DMBP5N3 IK DHZBEENLJMYSHQ-XCVPVQRUSA-N DMBP5N3 IU (1S,2R,6S,7R)-2,6-dimethyl-4,10-dioxatricyclo[5.2.1.02,6]decane-3,5-dione DMBP5N3 CA CAS 56-25-7 DMBP5N3 CB CHEBI:64213 DMBP5N3 DE Molluscum contagiosum infection DMTS85L ID DMTS85L DMTS85L DN Capecitabine DMTS85L HS Approved DMTS85L SN Capecitabin; Capecitabina; Capecitabinum; Capecitibine; Capiibine; Caxeta; Xabine; Xeloda; Capecitabine [USAN]; R340;R-340; RG-340; Ro 09-1978; Xeloda (TN); Ro 09-1978/000; Ro-09-1978; Xeloda, Captabin, Capecitabine; Capecitabine (JAN/USAN/INN); Ro-09-1978/000; N(4)-Pentyloxycarbonyl-5'-deoxy-5-fluorocytidine; Pentyl 1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate; Pentyl [1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamate; Carbamic acid, (1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-, pentyl ester; Pentyl N-[1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-2-oxopyrimidin-4-yl]carbamate; (1-(5-Deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamic acid pentyl ester; 5'-Deoxy-5-fluoro-N-((pentyloxy)carbonyl)cytidine; 5'-deoxy-5-fluoro-N-[(pentyloxy)carbonyl]cytidine; Capecitabine (Fluoropyrimidine) DMTS85L CP Roche DMTS85L TC Anticancer Agents DMTS85L DT Small molecular drug DMTS85L PC 60953 DMTS85L MW 359.35 DMTS85L FM C15H22FN3O6 DMTS85L IC InChI=1S/C15H22FN3O6/c1-3-4-5-6-24-15(23)18-12-9(16)7-19(14(22)17-12)13-11(21)10(20)8(2)25-13/h7-8,10-11,13,20-21H,3-6H2,1-2H3,(H,17,18,22,23)/t8-,10-,11-,13-/m1/s1 DMTS85L CS CCCCCOC(=O)NC1=NC(=O)N(C=C1F)[C@H]2[C@@H]([C@@H]([C@H](O2)C)O)O DMTS85L IK GAGWJHPBXLXJQN-UORFTKCHSA-N DMTS85L IU pentyl N-[1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-2-oxopyrimidin-4-yl]carbamate DMTS85L CA CAS 154361-50-9 DMTS85L CB CHEBI:31348 DMTS85L DE Colorectal cancer; Breast cancer DMPUKA7 ID DMPUKA7 DMPUKA7 DN Caplacizumab DMPUKA7 HS Approved DMPUKA7 DT Antibody DMPUKA7 DE Thrombotic thrombocytopenic purpura DMYCXKL ID DMYCXKL DMYCXKL DN Capmatinib DMYCXKL HS Approved DMYCXKL SN 1029712-80-8; INCB28060; INC-280; INC280; UNII-TY34L4F9OZ; 2-fluoro-N-methyl-4-(7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl)benzamide; INC28060; INCB-28060; INCB28060(Capmatinib); NVP-INC280; TY34L4F9OZ; Capmatinib (INCB28060); INCB 28060; 2-Fluoro-N-methyl-4-[7-[(quinolin-6-yl)methyl]imidazo[1,2-b]-[1,2,4]triazin-2-yl]benzamide; BenzaMide, 2-fluoro-N-Methyl-4-[7-(6-quinolinylMethyl)iMidazo[1,2-b][1,2,4]triazin-2-yl]-; C23H17FN6O DMYCXKL CP Incyte DMYCXKL DT Small molecular drug DMYCXKL PC 25145656 DMYCXKL MW 412.4 DMYCXKL FM C23H17FN6O DMYCXKL IC InChI=1S/C23H17FN6O/c1-25-22(31)18-6-5-16(11-19(18)24)21-13-28-23-27-12-17(30(23)29-21)10-14-4-7-20-15(9-14)3-2-8-26-20/h2-9,11-13H,10H2,1H3,(H,25,31) DMYCXKL CS CNC(=O)C1=C(C=C(C=C1)C2=NN3C(=CN=C3N=C2)CC4=CC5=C(C=C4)N=CC=C5)F DMYCXKL IK LIOLIMKSCNQPLV-UHFFFAOYSA-N DMYCXKL IU 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide DMYCXKL CA CAS 1029712-80-8 DMYCXKL DE Hepatocellular carcinoma; Recurrent glioblastoma; Non-small-cell lung cancer DMNZBRY ID DMNZBRY DMNZBRY DN Capreomycin DMNZBRY HS Approved DMNZBRY SN Capreomycin Sulfate Standard; Capreomycin sulphate; Caprocin (Disulfate); Ogostal (Disulfate); (3S)-3,6-diamino-N-[[(2S,5S,8E,11S,15S)-15-amino-11-[(6R)-2-amino-1,4,5,6-tetrahydropyrimidin-6-yl]-8-[(carbamoylamino)methylidene]-2-(hydroxymethyl)-3,6,9,12,16-pentaoxo-1,4,7,10,13-pentazacyclohexadec-5-yl]methyl]hexanamide; (3S)-3,6-diamino-N-[[(2S,5S,8E,11S,15S)-15-amino-11-[(6R)-2-amino-1,4,5,6-tetrahydropyrimidin-6-yl]-8-[(carbamoylamino)methylidene]-2-methyl-3,6,9,12,16-pentaoxo-1,4,7,10,13-pentazacyclohexadec-5-yl]methyl]hexanamide DMNZBRY TC Antibiotics DMNZBRY DT Small molecular drug DMNZBRY PC 3000502 DMNZBRY MW 1321.4 DMNZBRY FM C50H88N28O15 DMNZBRY IC InChI=1S/C25H44N14O8.C25H44N14O7/c26-4-1-2-11(27)6-17(41)32-8-14-20(43)35-15(9-34-25(30)47)21(44)39-18(13-3-5-31-24(29)38-13)23(46)33-7-12(28)19(42)37-16(10-40)22(45)36-14;1-11-19(41)36-15(9-32-17(40)7-12(27)3-2-5-26)21(43)37-16(10-34-25(30)46)22(44)39-18(14-4-6-31-24(29)38-14)23(45)33-8-13(28)20(42)35-11/h9,11-14,16,18,40H,1-8,10,26-28H2,(H,32,41)(H,33,46)(H,35,43)(H,36,45)(H,37,42)(H,39,44)(H3,29,31,38)(H3,30,34,47);10-15,18H,2-9,26-28H2,1H3,(H,32,40)(H,33,45)(H,35,42)(H,36,41)(H,37,43)(H,39,44)(H3,29,31,38)(H3,30,34,46)/b15-9+;16-10+/t11-,12-,13+,14-,16-,18-;11-,12-,13-,14+,15-,18-/m00/s1 DMNZBRY CS C[C@H]1C(=O)N[C@H](C(=O)N/C(=C/NC(=O)N)/C(=O)N[C@H](C(=O)NC[C@@H](C(=O)N1)N)[C@H]2CCN=C(N2)N)CNC(=O)C[C@H](CCCN)N.C1CN=C(N[C@H]1[C@H]2C(=O)NC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N/C(=C/NC(=O)N)/C(=O)N2)CNC(=O)C[C@H](CCCN)N)CO)N)N DMNZBRY IK VCOPTHOUUNAYKQ-WBTCAYNUSA-N DMNZBRY IU (3S)-3,6-diamino-N-[[(2S,5S,8E,11S,15S)-15-amino-11-[(6R)-2-amino-1,4,5,6-tetrahydropyrimidin-6-yl]-8-[(carbamoylamino)methylidene]-2-(hydroxymethyl)-3,6,9,12,16-pentaoxo-1,4,7,10,13-pentazacyclohexadec-5-yl]methyl]hexanamide;(3S)-3,6-diamino-N-[[(2S,5S,8E,11S,15S)-15-amino-11-[(6R)-2-amino-1,4,5,6-tetrahydropyrimidin-6-yl]-8-[(carbamoylamino)methylidene]-2-methyl-3,6,9,12,16-pentaoxo-1,4,7,10,13-pentazacyclohexadec-5-yl]methyl]hexanamide DMNZBRY CA CAS 11003-38-6 DMNZBRY DE Bacterial infection; Mycobacterium infection DM346QI ID DM346QI DM346QI DN Capreomycin Sulfate DM346QI HS Approved DM346QI SN Capastat Sulfate DM346QI CP Akorn Inc DM346QI DE Tuberculosis DMHERIJ ID DMHERIJ DMHERIJ DN Capromab DMHERIJ HS Approved DMHERIJ SN Prostascint (TN) DMHERIJ TC Imaging Agents DMHERIJ DT Antibody DMHERIJ DE Prostate cancer DMGMF6V ID DMGMF6V DMGMF6V DN Capsaicin DMGMF6V HS Approved DMGMF6V SN Capsaicin (transdermal patch formulation, neuropathic pain) DMGMF6V CP Samyang Corp DMGMF6V DT Small molecular drug DMGMF6V PC 1548943 DMGMF6V MW 305.4 DMGMF6V FM C18H27NO3 DMGMF6V IC InChI=1S/C18H27NO3/c1-14(2)8-6-4-5-7-9-18(21)19-13-15-10-11-16(20)17(12-15)22-3/h6,8,10-12,14,20H,4-5,7,9,13H2,1-3H3,(H,19,21)/b8-6+ DMGMF6V CS CC(C)/C=C/CCCCC(=O)NCC1=CC(=C(C=C1)O)OC DMGMF6V IK YKPUWZUDDOIDPM-SOFGYWHQSA-N DMGMF6V IU (E)-N-[(4-hydroxy-3-methoxyphenyl)methyl]-8-methylnon-6-enamide DMGMF6V CA CAS 404-86-4 DMGMF6V CB CHEBI:3374 DMGMF6V DE Neuropathic pain DM458UM ID DM458UM DM458UM DN Captopril DM458UM HS Approved DM458UM SN Acediur; Aceplus; Acepress; Acepril; Alopresin; Apopril; Asisten; Capoten; Captolane; Captoprilum; Captopryl; Captoril; Captril; Cesplon; Dilabar; Garranil; Hipertil; Hypertil; Isopresol; Lopirin; Lopril; MCO; Tenosbon; Tensiomin; Tensobon; Tensoprel; Lopirin [Switzerland]; C 4042; SA 333; SQ 14225; X8Z; Apopril (TN); Capoten (TN); Captoprilum [INN-Latin]; Garranil (discontinued); L-Captopril; SQ 14,225; SQ-14225; SQ-14534; SQ-14,225; SQ-14,534; Captopril (JP15/USP/INN); Captopril [USAN:INN:BAN:JAN]; D-3-Mercapto-2-methylpropionylproline; D-2-Methyl-3-mercaptopropanoyl-L-proline; D-3-Mercapto-2-methylpropanoyl-L-proline; [2S]-1-[3-Mercapto-2-methylpropionyl]-L-proline; N-[(S)-3-Mercapto-2-methylpropionyl]-L-proline;(2S)-1-(3-Mercapto-2-methylpropionyl)-L-proline; (2S)-1-[(2S)-2-methyl-3-sulfanylpropanoyl]pyrrolidine-2-carboxylic acid; (S)-1-(3-Mercapto-2-methyl-1-oxo-propyl)-L-proline; (S)-1-(3-Mercapto-2-methyl-1-oxopropyl)-L-proline; 1-((2S)-3-Mercapto-2-methylpropionyl)-L-proline; 1-(3-Mercapto-2-methyl-1-oxopropyl)-L-proline; 1-(D-3-Mercapto-2-methyl-1-oxopropyl)-L-proline (S,S); 1-[(2S)-2-methyl-3-sulfanylpropanoyl]-L-proline; 3-Mercapto-2-methylpropionyl-proline DM458UM CP Bristol-Myers Squibb DM458UM TC Antihypertensive Agents DM458UM DT Small molecular drug DM458UM PC 44093 DM458UM MW 217.29 DM458UM FM C9H15NO3S DM458UM IC InChI=1S/C9H15NO3S/c1-6(5-14)8(11)10-4-2-3-7(10)9(12)13/h6-7,14H,2-5H2,1H3,(H,12,13)/t6-,7+/m1/s1 DM458UM CS C[C@H](CS)C(=O)N1CCC[C@H]1C(=O)O DM458UM IK FAKRSMQSSFJEIM-RQJHMYQMSA-N DM458UM IU (2S)-1-[(2S)-2-methyl-3-sulfanylpropanoyl]pyrrolidine-2-carboxylic acid DM458UM CA CAS 62571-86-2 DM458UM CB CHEBI:3380 DM458UM DE Hypertension DMX9K8F ID DMX9K8F DMX9K8F DN Carbachol DMX9K8F HS Approved DMX9K8F SN Carbach; Carbacholin; Carbacholine; Carbacholinum; Carbacholum; Carbacol; Carbacolina; Carbacolo; Carbamiotin; Carbamoylcholine; Carbastat; Carbochol; Carbocholin; Carbocholine; Carbyl; Carcholin; Coletyl; Doryl; Jestryl; Karbachol; Lentin; Lentine; Miostat; Moryl; Rilentol; Vasoperif; CARBACHOL CHLORIDE; Carbachol hydrochloride; Carbacholine chloride; Carbacholini chloridum; Carbacholinium chloratum; Carbacholum chloratum; Carbacolo [DCIT]; Carbaminocholine chloride; Carbaminoylcholine chloride; Carbamoylcholine chloride; Carbamylcholine chloride; Choline carbamate chloride; Choline chloride carbamate; Choline chlorine carbamate; Isopto Carbachol; Karbachol [Czech]; Karbamoylcholin chlorid; Karbamoylcholin chlorid [Czech]; Lentine [French]; Mistura C; C 4382; TL 457; C-1770; Carbacholum [INN-Latin]; Carbacol [INN-Spanish]; Carbamic acid, ester with choline chloride; Carbamoylcholine-hydrochloride; Carbastat (TN); Carboptic (TN); Choline chloride, carbamate; Doryl (VAN); Doryl (pharmaceutical); Gamma-Carbamoyl choline chloride; Isopto Carbachol (TN); Miostat (TN); Carbachol [INN:BAN:JAN]; Choline, chloride carbamate(ester); Choline, chloride, carbamate; P. V. Carbachol; Carbachol (JAN/USP/INN); Choline, chloride, carbamate, hydrochloride; Ethanaminium, 2-(aminocarbonyl)oxy-N,N,N-trimethyl-, chloride; Ethanaminium, 2-[(aminocarbonyl)oxy]-N,N,N-trimethyl-, chloride; Ethanaminium, 2-((aminocarbonyl)oxy)-N,N,N-trimethyl-, chloride; Ethanaminium, 2-((aminocarbonyl)oxy)-N,N,N-trimethyl-, chloride (1:1); (2-Carbamoyloxy-ethyl)-trimethyl-ammonium; (2-Carbamoyloxy-ethyl)-trimethyl-ammonium(Carbachol); (2-Carbamoyloxyethyl)trimethylammonium chloride; (2-Hydroxyethyl)trimethyl ammonium chloride carbamate; (2-Hydroxyethyl)trimethylammonium chloride carbamate; (carbachol)(2-Carbamoyloxy-ethyl)-trimethyl-ammonium; 2-((Aminocarbonyl)oxy)-N,N,N-trimethylethanaminium chloride; 2-((Aminocarbonyl)oxy)-N,N,N-trimethylethanaminum chloride; 2-(carbamoyloxy)-N,N,N-trimethylethanaminium chloride; 2-[(aminocarbonyl)oxy]-N,N,N-trimethylethanaminium chloride; 2-carbamoyloxyethyl(trimethyl)azanium chloride DMX9K8F CP Norvatis Phamaceuticals Corporation DMX9K8F TC Cardiotonic Agents DMX9K8F DT Small molecular drug DMX9K8F PC 5831 DMX9K8F MW 182.65 DMX9K8F FM C6H15ClN2O2 DMX9K8F IC InChI=1S/C6H14N2O2.ClH/c1-8(2,3)4-5-10-6(7)9;/h4-5H2,1-3H3,(H-,7,9);1H DMX9K8F CS C[N+](C)(C)CCOC(=O)N.[Cl-] DMX9K8F IK AIXAANGOTKPUOY-UHFFFAOYSA-N DMX9K8F IU 2-carbamoyloxyethyl(trimethyl)azanium;chloride DMX9K8F CA CAS 51-83-2 DMX9K8F CB CHEBI:3385 DMX9K8F DE Glaucoma/ocular hypertension DMZOLBI ID DMZOLBI DMZOLBI DN Carbamazepine DMZOLBI HS Approved DMZOLBI SN Carbamazepine (iv, epilepsy); Carbamazepine (iv, epilepsy), Lundbeck; Carbamazepine (iv, epilepsy), Ovation Pharmaceuticals DMZOLBI CP Lundbeck Inc DMZOLBI DT Small molecular drug DMZOLBI PC 2554 DMZOLBI MW 236.27 DMZOLBI FM C15H12N2O DMZOLBI IC InChI=1S/C15H12N2O/c16-15(18)17-13-7-3-1-5-11(13)9-10-12-6-2-4-8-14(12)17/h1-10H,(H2,16,18) DMZOLBI CS C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N DMZOLBI IK FFGPTBGBLSHEPO-UHFFFAOYSA-N DMZOLBI IU benzo[b][1]benzazepine-11-carboxamide DMZOLBI CA CAS 298-46-4 DMZOLBI CB CHEBI:3387 DMZOLBI DE Gastric adenocarcinoma; Epilepsy; Type-1 diabetes DMLEDNK ID DMLEDNK DMLEDNK DN Carbenicillin DMLEDNK HS Approved DMLEDNK SN CBPC; Carbenicilina; Carbenicillina; Carbenicilline; Carbenicillinum; Carboxybenzylpenicillin; Pyopen; Carbenicillina [DCIT]; Carboxybenzyl Penicillin; Carboxybenzylpenicillin acid; Alpha-Carboxybenzylpencillin; Alpha-Carboxybenzylpenicillin solution; Carbenicilina [INN-Spanish]; Carbenicillin (INN); Carbenicillin [INN:BAN]; Carbenicilline [INN-French]; Carbenicillinum [INN-Latin]; Alpha-Phenyl(carboxymethylpenicillin); N-(2-Carboxy-3,3-dimethyl-7-oxo-4-thia-azabicyclo(3.2.0)hept-6-yl)-2-phenylmalonamic acid;N-(2-carboxy-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)hept-6-yl)-2-phenylmalonamic acid; (2S,5R,6R)-6-[(3-hydroxy-3-oxo-2-phenylpropanoyl)amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-{[carboxy(phenyl)acetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 6-(alpha-Carboxyphenylacetamido)penicillanic acid; 6beta-(2-carboxy-2-phenylacetamido)-2,2-dimethylpenam-3alpha-carboxylic acid DMLEDNK CP Roerig Div Pfizer Inc DMLEDNK TC Antibiotics DMLEDNK DT Small molecular drug DMLEDNK PC 20824 DMLEDNK MW 378.4 DMLEDNK FM C17H18N2O6S DMLEDNK IC InChI=1S/C17H18N2O6S/c1-17(2)11(16(24)25)19-13(21)10(14(19)26-17)18-12(20)9(15(22)23)8-6-4-3-5-7-8/h3-7,9-11,14H,1-2H3,(H,18,20)(H,22,23)(H,24,25)/t9?,10-,11+,14-/m1/s1 DMLEDNK CS CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)C(C3=CC=CC=C3)C(=O)O)C(=O)O)C DMLEDNK IK FPPNZSSZRUTDAP-UWFZAAFLSA-N DMLEDNK IU (2S,5R,6R)-6-[(2-carboxy-2-phenylacetyl)amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid DMLEDNK CA CAS 4697-36-3 DMLEDNK CB CHEBI:3393 DMLEDNK DE Infection of the upper and lower urinary tract DME2XG3 ID DME2XG3 DME2XG3 DN Carbenicillin Indanyl Sodium DME2XG3 HS Approved DME2XG3 SN Geocillin DME2XG3 CP Pfizer Laboratories Div Pfizer Inc DME2XG3 TC Antiinfective Agents DME2XG3 DT Small molecular drug DME2XG3 PC 23676503 DME2XG3 MW 516.5 DME2XG3 FM C26H25N2NaO6S DME2XG3 IC InChI=1S/C26H26N2O6S.Na/c1-26(2)20(24(31)32)28-22(30)19(23(28)35-26)27-21(29)18(15-7-4-3-5-8-15)25(33)34-17-12-11-14-9-6-10-16(14)13-17;/h3-5,7-8,11-13,18-20,23H,6,9-10H2,1-2H3,(H,27,29)(H,31,32);/q;+1/p-1/t18?,19-,20+,23-;/m1./s1 DME2XG3 CS CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)C(C3=CC=CC=C3)C(=O)OC4=CC5=C(CCC5)C=C4)C(=O)[O-])C.[Na+] DME2XG3 IK QFWPXOXWAUAYAB-XZVIDJSISA-M DME2XG3 IU sodium;(2S,5R,6R)-6-[[3-(2,3-dihydro-1H-inden-5-yloxy)-3-oxo-2-phenylpropanoyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate DME2XG3 CA CAS 26605-69-6 DME2XG3 CB CHEBI:31358 DME2XG3 DE Bacterial infection DMUSLW3 ID DMUSLW3 DMUSLW3 DN Carbetocin DMUSLW3 HS Approved DMUSLW3 SN Carbetocino [INN-Spanish]; Carbetocinum [INN-Latin]; Duratocin (TN); 1-Buttersaeure-2-(3-(4-methoxyphenyl)-L-alanin)oxytocin; 1-{[(3r,6s,9s,12s,15s)-6-(2-amino-2-oxoethyl)-9-(3-amino-3-oxopropyl)-12-[(2s)-butan-2-yl]-15-(4-hydroxybenzyl)-16-methyl-5,8,11,14,17-pentaoxo-1-thia-4,7,10,13,16-pentaazacycloicosan-3-yl]carbonyl}-l-prolyl-l-leucylglycinamide DMUSLW3 CP Pfizer Pharmaceuticals DMUSLW3 TC Antitocolytic Agents DMUSLW3 DT Small molecular drug DMUSLW3 PC 16681432 DMUSLW3 MW 988.2 DMUSLW3 FM C45H69N11O12S DMUSLW3 IC InChI=1S/C45H69N11O12S/c1-6-25(4)38-44(66)51-28(15-16-34(46)57)40(62)52-31(21-35(47)58)41(63)54-32(23-69-18-8-10-37(60)50-30(42(64)55-38)20-26-11-13-27(68-5)14-12-26)45(67)56-17-7-9-33(56)43(65)53-29(19-24(2)3)39(61)49-22-36(48)59/h11-14,24-25,28-33,38H,6-10,15-23H2,1-5H3,(H2,46,57)(H2,47,58)(H2,48,59)(H,49,61)(H,50,60)(H,51,66)(H,52,62)(H,53,65)(H,54,63)(H,55,64)/t25-,28-,29-,30-,31-,32-,33-,38-/m0/s1 DMUSLW3 CS CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSCCCC(=O)N[C@H](C(=O)N1)CC2=CC=C(C=C2)OC)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N DMUSLW3 IK NSTRIRCPWQHTIA-DTRKZRJBSA-N DMUSLW3 IU (2S)-N-[(2S)-1-[(2-amino-2-oxoethyl)amino]-4-methyl-1-oxopentan-2-yl]-1-[(3R,6S,9S,12S,15S)-6-(2-amino-2-oxoethyl)-9-(3-amino-3-oxopropyl)-12-[(2S)-butan-2-yl]-15-[(4-methoxyphenyl)methyl]-5,8,11,14,17-pentaoxo-1-thia-4,7,10,13,16-pentazacycloicosane-3-carbonyl]pyrrolidine-2-carboxamide DMUSLW3 CA CAS 37025-55-1 DMUSLW3 CB CHEBI:59204 DMUSLW3 DE Postpartum haemorrhage DMHRG8Q ID DMHRG8Q DMHRG8Q DN Carbidopa DMHRG8Q HS Approved DMHRG8Q SN Atamet; Carbidopum; Lodosin; Lodosyn; Methyldopahydrazine; Stalevo; Carbidopa Monohydrate; Carbidopa anhydrous; Carbidopa hydrate; Carbidopum monohydricum; MK 486; Alpha-Methyldopahydrazine; C-126; C-DOPA; Carbidopa (anhydrous); Carbidopum [INN-Latin]; Lodosyn (TN); Lodosyn, Carbidopa; MK-485; MK-486; N-Aminomethyldopa; Carbidopa [USAN:INN:BAN]; Carbidopa-1-wasser; Hadrazino-alpha-methyldopa; L-alpha-Methyldopahydrazine; Carbidopa, (S)-Isomer; Carbidopa, Entacapone, & Levodopa; S(-)-CARBIDOPA; S-(-)-Carbidopa; L-alpha-(3,4-dihydroxybenzyl)-alpha-hydrazinopropionic acid monohydrate; Alpha-Hydrazino-alpha-methyl-beta-(3,4-dihydroxyphenyl)propionic acid; L-3-(3,4-Dihydroxyphenyl)-2-methyl-2-hydrazinopropionic acid; L-alpha-Methyl-alpha-hydrazino-beta-(3,4-dihydroxyphenylpropionic acid; L-alpha-Methyl-beta-(3,4-dihydroxyphenyl)-alpha-hydrazinopropionic acid; S(-)-alpha-Hydrazino-3,4-dihydroxy-alpha-methylhydrocinnamic acid monohydrate; S-(-)-alpha-Hydrazino-3,4-dihydroxy-2-methylbenzenepropanoic acid; Benzenepropanoic acid, alpha-hydrazino-3,4-dihydroxy-alpha-methyl-, monohydrate, (S); KINSON, 3-(3,4-DIHYDROXY-PHENYL)-2-HYDRAZINO-2-METHYL-PROPIONIC ACID; Hydrocinnamic acid, (-)-L-alpha-hydrazino-3,4-dihydroxy-alpha-methyl-, monohydrate; (-)-L-alpha-Hydrazino-3,4-dihydroxy-alpha-methylhydrocinnamic acid; (-)-L-alpha-Hydrazino-3,4-dihydroxy-alpha-methylhydrocinnamic acid monohydrate; (2S)-3-(3,4-dihydroxyphenyl)-2-hydrazino-2-methylpropanoic acid; (2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid; (2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid hydrate; (2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid monohydrate; (2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid-water (1/1); (S)-(-)-carbidopa; (S)-(-)-carbidopa hydrate; (S)-alpha-Hydrazino-3,4-dihydroxy-alpha-methyl-benzenepropanoic acid monohydrate; (S)-carbidopa; (S)-carbidopahydrate; (alphaS)-alpha-hydrazino-3,4-dihydroxy-alpha-methylbenzenepropanoic acid; (alphaS)-alpha-hydrazino-3,4-dihydroxy-alpha-methylbenzenepropanoic acid monohydrate DMHRG8Q TC Antiparkinson Agents DMHRG8Q DT Small molecular drug DMHRG8Q PC 34359 DMHRG8Q MW 226.23 DMHRG8Q FM C10H14N2O4 DMHRG8Q IC InChI=1S/C10H14N2O4/c1-10(12-11,9(15)16)5-6-2-3-7(13)8(14)4-6/h2-4,12-14H,5,11H2,1H3,(H,15,16)/t10-/m0/s1 DMHRG8Q CS C[C@](CC1=CC(=C(C=C1)O)O)(C(=O)O)NN DMHRG8Q IK TZFNLOMSOLWIDK-JTQLQIEISA-N DMHRG8Q IU (2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid DMHRG8Q CA CAS 28860-95-9 DMHRG8Q CB CHEBI:39585 DMHRG8Q DE Parkinson disease DMULAI4 ID DMULAI4 DMULAI4 DN Carbimazole DMULAI4 HS Approved DMULAI4 SN Athyromazole; Atirozidina; Basolest; Carbethoxymethimazole; Carbimazol; Carbimazolum; Carbinazole; Carbotiroid; Mertiran; Neomercazole; TYRAZOL; Thyrostat; Carbimazol henning; Carbimazol spofa; CG1; Cg 1; Carbimazol henning (TN); Carbimazole (INN); Carbimazolum [INN-Latin]; Neo-Mercazole; Neo-Thyreostat; Neo-Tireol; Carbimazol [INN-Spanish, French]; Carbimazole [INN:BAN:DCF]; Ethyl 3-methyl-2-sulfanylideneimidazole-1-carboxylate; Ethyl 3-methyl-2-thioimidazoline-1-carboxylate; Ethyl 3-methyl-2-thioxo-2,3-dihydro-1H-imidazole-1-carboxylate; 1-Ethoxycarbonyl-3-methyl-2-thioimidazol; 1-Ethoxycarbonyl-3-methyl-2-thioxo-4-imidazoline; 1H-Imidazole-1-carboxylic acid, 2,3-dihydro-3-methyl-2-thioxo, ethyl ester; 1H-Imidazole-1-carboxylic acid, 2,3-dihydro-3-methyl-2-thioxo-, ethyl ester; 3-Methyl-2-thioxo-4-imidazoline-1-carboxylic acid ethyl ester; 4-Imidazoline-1-carboxylic acid, 3-methyl-2-thioxo-, ethyl ester DMULAI4 TC Antithyroid Agents DMULAI4 DT Small molecular drug DMULAI4 PC 31072 DMULAI4 MW 186.23 DMULAI4 FM C7H10N2O2S DMULAI4 IC InChI=1S/C7H10N2O2S/c1-3-11-7(10)9-5-4-8(2)6(9)12/h4-5H,3H2,1-2H3 DMULAI4 CS CCOC(=O)N1C=CN(C1=S)C DMULAI4 IK CFOYWRHIYXMDOT-UHFFFAOYSA-N DMULAI4 IU ethyl 3-methyl-2-sulfanylideneimidazole-1-carboxylate DMULAI4 CA CAS 22232-54-8 DMULAI4 CB CHEBI:617099 DMULAI4 DE Hyperthyroidism DMCT31R ID DMCT31R DMCT31R DN Carbinoxamine DMCT31R HS Approved DMCT31R SN Allergefon; Carbinoxamina; Carbinoxaminum; Clistin; Clistine; Paracarbinoxamine; Paracarinoxamine; Rotoxamine; Carbinoxamine base; Carbinoxamina [INN-Spanish]; Carbinoxamine (INN); Carbinoxamine [INN:BAN]; Carbinoxaminum [INN-Latin]; Clistin (TN); McN-R 73Z; Palgic (TN); {2-[(4-Chlorophenyl)-2-pyridylmethoxy]ethyl}dimethylamine; N,N-Dimethyl-2-(p-chloro-alpha-(2-pyridyl)benzyloxy)ethylamine; Ethanamine, 2-((4-chlorophenyl)-2-pyridinylmethoxy)-N,N-dimethyl-(9CI); (+-)-Carbinoxamine; 2-(p-Chloro-alpha-(2-(dimethylamino)ethoxy)benzyl)pyridine; 2-[(4-chlorophenyl)(pyridin-2-yl)methoxy]-N,N-dimethylethanamine; 2-[(4-chlorophenyl)-pyridin-2-ylmethoxy]-N,N-dimethylethanamine; 2-{[(4-chlorophenyl)(pyridin-2-yl)methyl]oxy}-N,N-dimethylethanamine DMCT31R CP McNeil Laboratories DMCT31R TC Antihistamines DMCT31R DT Small molecular drug DMCT31R PC 2564 DMCT31R MW 290.79 DMCT31R FM C16H19ClN2O DMCT31R IC InChI=1S/C16H19ClN2O/c1-19(2)11-12-20-16(15-5-3-4-10-18-15)13-6-8-14(17)9-7-13/h3-10,16H,11-12H2,1-2H3 DMCT31R CS CN(C)CCOC(C1=CC=C(C=C1)Cl)C2=CC=CC=N2 DMCT31R IK OJFSXZCBGQGRNV-UHFFFAOYSA-N DMCT31R IU 2-[(4-chlorophenyl)-pyridin-2-ylmethoxy]-N,N-dimethylethanamine DMCT31R CA CAS 486-16-8 DMCT31R CB CHEBI:3398 DMCT31R DE Vasomotor/allergic rhinitis DMG281S ID DMG281S DMG281S DN Carboplatin DMG281S HS Approved DMG281S SN Azanide; Carbopaltin; Carboplatine; Carboplatino; Carboplatinum; Cbdca; Ercar; Paraplatin; Carboplatine [French]; Carboplatino [Spanish]; Carboplatinum [Latin]; C 2538; JM 8; Carboplatin (USAN); IUPAC: Azane; JM-8; Paraplatin (TN); Paraplatin, Carboplatin; Paraplatin-AQ; Cis-Diammine(cyclobutanedicarboxylato)platinumII; Platinum(+2) Cation; Carboplatin (JAN/USP/INN); Carboplatin [USAN:INN:BAN:JAN]; Cyclobutane-1,1-dicarboxylate; Cyclobutane-1,1-dicarboxylic acid; Diammine-1,1-cyclobutane dicarboxylate platinum II; Cis-Diamine[1,1-cyclobutanedicarboxylato]platinum(II); Cis-Diammine(1,1-cyclobutanedicarboxylato) platinum; Cis-Diammine(1,1-cyclobutanedicarboxylato)platinum; Cis-Diammine[1,1-cyclobutane-dicarboxylato] platinum; Diammine(1,1-cyclobutanedicarboxylato)platinum (II); Platinum, {diammine[1,1-cyclobut; Cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II); Cis-Diamine(1,1-cyclobutanedicarboxylato)platinum(II); Cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II); Platinum(II), (1, 1-cyclobutanedicar; Diammine[cyclobutane-1,1-dicarboxylato(2-)-k2O1,O1]platinum; Diammine(cyclobutane-1,1-dicarboxylato(2-)-O,O')platinum; Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2); (SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)-kappa(2)O,O']platinum; 1,1-Cyclobutanedicarboxylate diammine platinum (II); 1,1-Cyclobutanedicarboxylate diammine platinum(II) DMG281S CP Bristol-Myers Squibb DMG281S TC Anticancer Agents DMG281S DT Small molecular drug DMG281S PC 426756 DMG281S MW 371.25 DMG281S FM C6H12N2O4Pt DMG281S IC InChI=1S/C6H8O4.2H2N.Pt/c7-4(8)6(5(9)10)2-1-3-6;;;/h1-3H2,(H,7,8)(H,9,10);2*1H2;/q;2*-1;+2 DMG281S CS C1CC(C1)(C(=O)O)C(=O)O.[NH2-].[NH2-].[Pt+2] DMG281S IK VSRXQHXAPYXROS-UHFFFAOYSA-N DMG281S IU azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) DMG281S CA CAS 41575-94-4 DMG281S CB CHEBI:31355 DMG281S DE Ovarian cancer DMS3508 ID DMS3508 DMS3508 DN Carboprost tromethamine DMS3508 HS Approved DMS3508 SN Hemabate; Carboprost Trometanol; Carboprost trometamol; Carboprost tromethamine [USAN]; U 32921E; Hemabate (TN); Prostin / 15M; U-32921E; Prosta-5,13-dien-1-oic acid, 9,11,15-trihydroxy-15-methyl-, (5Z,9-alpha,11-alpha,13E,15S)-, compd. with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1); Prosta-5,13-dien-1-oic acid, 9,11,15-trihydroxy-15-methyl-, (5Z,9-alpha,11-alpha,13E,15S)-,compd. with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1); (15S)-15-Methylprostaglandin F(sub 2alpha) tromethamine; (15S)-15-Methylprostaglandin F2alpha tromethamine; (E)-7-[(1S,3S,5R)-3,5-dihydroxy-2-[(Z,3S)-3-hydroxy-3-methyloct-1-enyl]cyclopentyl]hept-5-enoic acid; (Z)-7-((1R,2R,3R,5S)-3,5-Dihydroxy-2-((E)-(3S)-3-hydroxy-3-methyl-1-octenyl)cyclopentyl)-5-heptenoic acid compound with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1); 15(S)15-Methyl pgf2-alpha tromethaminesalt; 15(S)15-Methyl prostaglandin F2-alpha tromethamine; 15-methylprostaglandin F2alpha-tromethamine DMS3508 TC Abortifacient Agents DMS3508 DT Small molecular drug DMS3508 PC 5281074 DMS3508 MW 489.6 DMS3508 FM C25H47NO8 DMS3508 IC InChI=1S/C21H36O5.C4H11NO3/c1-3-4-9-13-21(2,26)14-12-17-16(18(22)15-19(17)23)10-7-5-6-8-11-20(24)25;5-4(1-6,2-7)3-8/h5,7,12,14,16-19,22-23,26H,3-4,6,8-11,13,15H2,1-2H3,(H,24,25);6-8H,1-3,5H2/b7-5-,14-12+;/t16-,17-,18+,19-,21+;/m1./s1 DMS3508 CS CCCCC[C@@](C)(/C=C/[C@H]1[C@@H](C[C@@H]([C@@H]1C/C=C\\CCCC(=O)O)O)O)O.C(C(CO)(CO)N)O DMS3508 IK UMMADZJLZAPZAW-XOWPVRJPSA-N DMS3508 IU 2-amino-2-(hydroxymethyl)propane-1,3-diol;(Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3S)-3-hydroxy-3-methyloct-1-enyl]cyclopentyl]hept-5-enoic acid DMS3508 CA CAS 58551-69-2 DMS3508 DE Abortion DM48K0X ID DM48K0X DM48K0X DN Carfilzomib DM48K0X HS Approved DM48K0X SN Carfilzomib; 868540-17-4; Kyprolis; Carfilzomib (PR-171); PR-171; UNII-72X6E3J5AR; 72X6E3J5AR; CHEMBL451887; CHEBI:65347; NCGC00249613-01; DSSTox_RID_82886; DSSTox_CID_28616; DSSTox_GSID_48690; (S)-4-methyl-N-((S)-1-(((S)-4-methyl-1-((R)-2-methyloxiran-2-yl)-1-oxopentan-2-yl)amino)-1-oxo-3-phenylpropan-2-yl)-2-((S)-2-(2-morpholinoacetamido)-4-phenylbutanamido)pentanamide; N-{(2S)-2-[(morpholin-4-ylacetyl)amino]-4-phenylbutanoyl}-L-leucyl-N-{(2S)-4-methyl-1-[(2R)-2-methyloxiran-2-yl]-1-oxopentan-2-yl}-L-phenylalaninamide DM48K0X CP Onyx Pharmaceuticals DM48K0X DT Small molecular drug DM48K0X PC 11556711 DM48K0X MW 719.9 DM48K0X FM C40H57N5O7 DM48K0X IC InChI=1S/C40H57N5O7/c1-27(2)22-32(36(47)40(5)26-52-40)42-39(50)34(24-30-14-10-7-11-15-30)44-38(49)33(23-28(3)4)43-37(48)31(17-16-29-12-8-6-9-13-29)41-35(46)25-45-18-20-51-21-19-45/h6-15,27-28,31-34H,16-26H2,1-5H3,(H,41,46)(H,42,50)(H,43,48)(H,44,49)/t31-,32-,33-,34-,40+/m0/s1 DM48K0X CS CC(C)C[C@@H](C(=O)[C@]1(CO1)C)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC3=CC=CC=C3)NC(=O)CN4CCOCC4 DM48K0X IK BLMPQMFVWMYDKT-NZTKNTHTSA-N DM48K0X IU (2S)-4-methyl-N-[(2S)-1-[[(2S)-4-methyl-1-[(2R)-2-methyloxiran-2-yl]-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]-4-phenylbutanoyl]amino]pentanamide DM48K0X CA CAS 868540-17-4 DM48K0X CB CHEBI:65347 DM48K0X DE Multiple myeloma; Small-cell lung cancer DMCY0TI ID DMCY0TI DMCY0TI DN Carglumic acid DMCY0TI HS Approved DMCY0TI SN Carbaglu (TN) DMCY0TI CP Orphan Europe DMCY0TI DT Small molecular drug DMCY0TI PC 121396 DMCY0TI MW 190.15 DMCY0TI FM C6H10N2O5 DMCY0TI IC InChI=1S/C6H10N2O5/c7-6(13)8-3(5(11)12)1-2-4(9)10/h3H,1-2H2,(H,9,10)(H,11,12)(H3,7,8,13)/t3-/m0/s1 DMCY0TI CS C(CC(=O)O)[C@@H](C(=O)O)NC(=O)N DMCY0TI IK LCQLHJZYVOQKHU-VKHMYHEASA-N DMCY0TI IU (2S)-2-(carbamoylamino)pentanedioic acid DMCY0TI CA CAS 1188-38-1 DMCY0TI CB CHEBI:71028 DMCY0TI DE Acute hyperammonaemia DMJYDVK ID DMJYDVK DMJYDVK DN Cariprazine DMJYDVK HS Approved DMJYDVK SN Cariprazine; 839712-12-8; RGH-188; RGH 188; Cariprazine(RGH188); UNII-F6RJL8B278; F6RJL8B278; CHEMBL3085826; 3-[4-[2-[4-(2,3-dichlorophenyl)piperazin-1-yl]ethyl]cyclohexyl]-1,1-dimethylurea; Cariprazine [USAN:INN]; Reagila; MP-214; MP 214; Cariprazine (USAN/INN); Cariprazine (RGH-188); C21H32Cl2N4O; SCHEMBL184342; SCHEMBL184343; GTPL7671; SCHEMBL7861573; CHEMBL2028019; CHEBI:90933; HSDB 8310; DTXSID80232867; KPWSJANDNDDRMB-QAQDUYKDSA-N; MolPort-039-139-594; BDBM263449; BCP14691; BDBM50443101; BDBM50382290; ZINC38309313; 3526AH DMJYDVK CP Forest Laboratories; Gedeon Richter DMJYDVK DT Small molecular drug DMJYDVK PC 11154555 DMJYDVK MW 427.4 DMJYDVK FM C21H32Cl2N4O DMJYDVK IC InChI=1S/C21H32Cl2N4O/c1-25(2)21(28)24-17-8-6-16(7-9-17)10-11-26-12-14-27(15-13-26)19-5-3-4-18(22)20(19)23/h3-5,16-17H,6-15H2,1-2H3,(H,24,28) DMJYDVK CS CN(C)C(=O)NC1CCC(CC1)CCN2CCN(CC2)C3=C(C(=CC=C3)Cl)Cl DMJYDVK IK KPWSJANDNDDRMB-UHFFFAOYSA-N DMJYDVK IU 3-[4-[2-[4-(2,3-dichlorophenyl)piperazin-1-yl]ethyl]cyclohexyl]-1,1-dimethylurea DMJYDVK CA CAS 839712-12-8 DMJYDVK CB CHEBI:90933 DMJYDVK DE Bipolar disorder DMWR1JC ID DMWR1JC DMWR1JC DN Carisoprodol DMWR1JC HS Approved DMWR1JC SN carisoprodol; 78-44-4; Isomeprobamate; Carisoprodate; Carisoprodatum; Isoprotane; Isobamate; Isoprothane; Carisoma; Sanoma; Isopropyl meprobamate; SOMA; Somalgit; Atonalyt; Mioratrina; Mioartrina; Flexartal; Skutamil; Miolisodal; Mioril; Apesan; Relasom; Nospasm; Flexal; Arusal; Somanil; Carlsoprol; Carisoprodolum; Domarax; Stialgin; Somadril; Carsodal; Mioriodol; Mediquil; Izoprotan; Isoprotan; Carisol; Caprodat; Calenfa; Diolene; Carlsoma; Carlsodol; Brianil; Flexidon; Flexagilt; Caridolin; Meprodat; Listaflex; Flexagit; Fibrosona; Chinchen; Carsodol DMWR1JC DT Small molecular drug DMWR1JC PC 2576 DMWR1JC MW 260.329 DMWR1JC FM C12H24N2O4 DMWR1JC IC InChI=1S/C12H24N2O4/c1-5-6-12(4,7-17-10(13)15)8-18-11(16)14-9(2)3/h9H,5-8H2,1-4H3,(H2,13,15)(H,14,16) DMWR1JC CS CCCC(C)(COC(=O)N)COC(=O)NC(C)C DMWR1JC IK OFZCIYFFPZCNJE-UHFFFAOYSA-N DMWR1JC IU [2-(carbamoyloxymethyl)-2-methylpentyl] N-propan-2-ylcarbamate DMWR1JC CA CAS 78-44-4 DMWR1JC CB CHEBI:3419 DMWR1JC DE Musculoskeletal disorder DMHTB31 ID DMHTB31 DMHTB31 DN Carphenazine DMHTB31 HS Approved DMHTB31 SN Carfenazine; Carphenazin; Procethazine; Proketazin; Carfenazina [INN-Spanish]; Carfenazine [INN:BAN]; Carfenazinum [INN-Latin]; 1-(10-(3-(4-(2-Hydroxyethyl)-1-piperazinyl)propyl)phenothiazin-2-yl)-1-propanone; 1-(10-{3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl}-10H-phenothiazin-2-yl)propan-1-one; 1-[10-[3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl]phenothiazin-2-yl]propan-1-one DMHTB31 CP Wyeth Ayerst Laboratories DMHTB31 TC Antipsychotic Agents DMHTB31 DT Small molecular drug DMHTB31 PC 18104 DMHTB31 MW 425.6 DMHTB31 FM C24H31N3O2S DMHTB31 IC InChI=1S/C24H31N3O2S/c1-2-22(29)19-8-9-24-21(18-19)27(20-6-3-4-7-23(20)30-24)11-5-10-25-12-14-26(15-13-25)16-17-28/h3-4,6-9,18,28H,2,5,10-17H2,1H3 DMHTB31 CS CCC(=O)C1=CC2=C(C=C1)SC3=CC=CC=C3N2CCCN4CCN(CC4)CCO DMHTB31 IK XZSMZRXAEFNJCU-UHFFFAOYSA-N DMHTB31 IU 1-[10-[3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl]phenothiazin-2-yl]propan-1-one DMHTB31 CA CAS 2622-30-2 DMHTB31 DE Insomnia; Schizophrenia DMHMP05 ID DMHMP05 DMHMP05 DN Carprofen DMHMP05 HS Approved DMHMP05 SN Carprofene; Carprofeno; Carprofenum; Imadyl; Ridamyl; Rimadyl; Carprofeno [Spanish]; C 5720; Ro 205720; C-5720; Carprofene [INN-French]; Carprofeno [INN-Spanish]; Carprofenum [INN-Latin]; Rimadyl (TN); Ro 20-5720; Carprofen (USAN/INN); Carprofen [USAN:INN:BAN]; Ro 20-5720/000; Ro-20-5720; Ro-20-5720/000; (+-)-6-Chloro-alpha-methylcarbazole-2-acetic acid; (+-)-isomer of carprofen; (+/-)-2-(3-chloro-9H-carbazol-7-yl)propanoic acid; (+/-)-6-Chloro-.alpha.-methylcarbazole-2-acetic acid; (-)-6-Chlor-alpha-methyl-2-carbazolessigsaeure; 2-(6-Chloro-9H-carbazol-2-yl)-propionic acid; 2-(6-Chloro-9H-carbazol-2-yl)propanoic acid; 6-Chlor-alpha-methyl-carbazol-2-essigsaeure; 6-Chlor-alpha-methyl-carbazol-2-essigsaeure [German]; 6-Chloro-alpha-methyl-9H-carbazole-2-acetic acid; 6-Chloro-alpha-methylcarbazole-2-acetic acid; 9H-Carbazole-2-acetic acid, 6-chloro-.al DMHMP05 CP Pfizer Pharmaceuticals DMHMP05 TC Analgesics DMHMP05 DT Small molecular drug DMHMP05 PC 2581 DMHMP05 MW 273.71 DMHMP05 FM C15H12ClNO2 DMHMP05 IC InChI=1S/C15H12ClNO2/c1-8(15(18)19)9-2-4-11-12-7-10(16)3-5-13(12)17-14(11)6-9/h2-8,17H,1H3,(H,18,19) DMHMP05 CS CC(C1=CC2=C(C=C1)C3=C(N2)C=CC(=C3)Cl)C(=O)O DMHMP05 IK PUXBGTOOZJQSKH-UHFFFAOYSA-N DMHMP05 IU 2-(6-chloro-9H-carbazol-2-yl)propanoic acid DMHMP05 CA CAS 53716-49-7 DMHMP05 CB CHEBI:364453 DMHMP05 DE Pain DMFMDOB ID DMFMDOB DMFMDOB DN Carteolol DMFMDOB HS Approved DMFMDOB SN Carteololum; Carteolol HCl; Carteolol Monohydrochloride; Arteolol (TN); Arteoptic (TN); Calte (TN); Carteol (TN); Carteolol (INN); Carteolol [INN:BAN]; Carteololum [INN-Latin]; Cartrol (TN); Elebloc (TN); Endak (TN); Glauteolol (TN); Mikelan (TN); Ocupress (TN); Poenglaucol (TN); Singlauc (TN); Teoptic (TN); 5-({3-[(1,1-dimethylethyl)amino]-2-hydroxypropyl}oxy)-3,4-dihydroquinolin-2(1H)-one; 5-[3-(tert-butylamino)-2-hydroxypropoxy]-3,4-dihydro-1H-quinolin-2-one; 5-[3-(tert-butylamino)-2-hydroxypropoxy]-3,4-dihydroquinolin-2(1H)-one DMFMDOB CP CIBA Vision Sterile Mfg DMFMDOB TC Antihypertensive Agents DMFMDOB DT Small molecular drug DMFMDOB PC 2583 DMFMDOB MW 292.37 DMFMDOB FM C16H24N2O3 DMFMDOB IC InChI=1S/C16H24N2O3/c1-16(2,3)17-9-11(19)10-21-14-6-4-5-13-12(14)7-8-15(20)18-13/h4-6,11,17,19H,7-10H2,1-3H3,(H,18,20) DMFMDOB CS CC(C)(C)NCC(COC1=CC=CC2=C1CCC(=O)N2)O DMFMDOB IK LWAFSWPYPHEXKX-UHFFFAOYSA-N DMFMDOB IU 5-[3-(tert-butylamino)-2-hydroxypropoxy]-3,4-dihydro-1H-quinolin-2-one DMFMDOB CA CAS 51781-06-7 DMFMDOB CB CHEBI:3437 DMFMDOB DE Glaucoma/ocular hypertension DMHTEAO ID DMHTEAO DMHTEAO DN Carvedilol DMHTEAO HS Approved DMHTEAO SN Artist; Carvedilolum; Coreg; Coropres; Coropress; Dibloc; Dilatrend; Eucardic; Kredex; Querto; Atlana Pharma brand of carvedilol; Carvedilolum [Latin]; Coreg CR; GlaxoSmithKline brand of carvedilol; Lakeside brand of carvedilol; Roche brand of carvedilol; BM 14190; DQ 2466; SKF 105517; Artist (TN); BM-14190; Carloc (TN); Coreg (TN); DQ-2466; Dilatrend (TN); EG-P042; Eucardic (TN); BM-14-190; BM-14.190; Carvedilol, 14C-labeled; SK&F-105517; Carvedilol (JAN/USAN/INN); Carvedilol [USAN:INN:BAN:JAN]; Carvedilol, (R)-isomer; Carvedilol, (S)-isomer; Carvedilol, (+-)-isomer; (+-)-1-(Carbazol-4-yloxy)-3-((2-(o-methoxyphenoxy)ethyl)amino)-2-propanol; (+-)-1-Carbazol-4-yloxy)-3-((2-(o-methoxyphenoxy)ethyl)amino)-2-propanol; (+/-)-1-(Carbazol-4-yloxy)-3-[[2-(o-methoxyphenoxy)ethyl]amino]-2-propanol; 1-(9H-Carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]-2-propanol; 1-(9H-carbazol-4-yloxy)-3-[(2-{[2-(methyloxy)phenyl]oxy}ethyl)amino]propan-2-ol; 1-(9H-carbazol-4-yloxy)-3-[2-(2-methoxyphenoxy)ethylamino]propan-2-ol; 1-(9H-carbazol-4-yloxy)-3-{[2-(2-methoxyphenoxy)ethyl]amino}propan-2-ol DMHTEAO CP GlaxoSmithKline plc DMHTEAO TC Vasodilator Agents DMHTEAO DT Small molecular drug DMHTEAO PC 2585 DMHTEAO MW 406.5 DMHTEAO FM C24H26N2O4 DMHTEAO IC InChI=1S/C24H26N2O4/c1-28-21-10-4-5-11-22(21)29-14-13-25-15-17(27)16-30-23-12-6-9-20-24(23)18-7-2-3-8-19(18)26-20/h2-12,17,25-27H,13-16H2,1H3 DMHTEAO CS COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O DMHTEAO IK OGHNVEJMJSYVRP-UHFFFAOYSA-N DMHTEAO IU 1-(9H-carbazol-4-yloxy)-3-[2-(2-methoxyphenoxy)ethylamino]propan-2-ol DMHTEAO CA CAS 72956-09-3 DMHTEAO CB CHEBI:3441 DMHTEAO DE Congestive heart failure DMZPXRC ID DMZPXRC DMZPXRC DN Carzinophilin DMZPXRC HS Approved DMZPXRC SN CARZINOPHILIN; Cardinophyllin; Cardinophillin; Azinomycin; CARZINOPHILIN A; Carzinophyllin; NSC 20088; Antibiotic from Streptomyces Sahachiroi; BRN 5721373; C31H33N3O11; 1403-28-7; Carzinophilin (8CI); AC1MHU1X; Carzinophilin (8CI)(9CI); LS-52587; LS-52588; 11002-20-3; [(1S)-2-[[(1E)-1-[(3R,4R,5S)-3-acetyloxy-4-hydroxy-1-azabicyclo[3.1.0]hexan-2-ylidene]-2-[[(E)-1-hydroxy-3-oxobut-1-en-2-yl]amino]-2-oxoethyl]amino]-1-[(2S)-2-methyloxiran-2-yl]-2-oxoethyl] 3-methoxy-5-methylnaphthalene-1-carboxylate DMZPXRC DT Small molecular drug DMZPXRC PC 227922 DMZPXRC MW 639.6 DMZPXRC FM C31H33N3O12 DMZPXRC IC InChI=1S/C31H33N3O12/c1-14-7-6-8-18-19(14)9-17(43-5)10-20(18)26(40)32-13-30(4)24(39)28(41)45-31(46-30)25(23(38)22-11-34(22)16(3)37)44-27(33-29(31)42)21(12-35)15(2)36/h6-10,12,22-25,38-39H,11,13H2,1-5H3,(H,32,40)(H,33,42) DMZPXRC CS CC1=C2C=C(C=C(C2=CC=C1)C(=O)NCC3(C(C(=O)OC4(O3)C(OC(=C(C=O)C(=O)C)NC4=O)C(C5CN5C(=O)C)O)O)C)OC DMZPXRC IK GNGRYODSYNVRFD-UHFFFAOYSA-N DMZPXRC IU N-[[7-[(1-acetylaziridin-2-yl)-hydroxymethyl]-9-(1,3-dioxobutan-2-ylidene)-3-hydroxy-4-methyl-2,11-dioxo-1,5,8-trioxa-10-azaspiro[5.5]undecan-4-yl]methyl]-3-methoxy-5-methylnaphthalene-1-carboxamide DMZPXRC DE Solid tumour/cancer DMGQIPT ID DMGQIPT DMGQIPT DN Caspofungin DMGQIPT HS Approved DMGQIPT SN CASPO; Cancidas; Capsofungin; Caspofungin [INN]; M991; Cancidas (TM); Cancidas (TN); Caspofungin (INN); MK-0991; L-743,872; [1(R)-hydroxyethyl]-1,4,7,13,16,22-hexaazatricyclo[22.3.0.0(9,13)]heptacosane-2,5,8,14,17,23-hexaone diacetate; Pneumocandin B0, 1-[(4R,5S)-5-[(2-aminoethyl)amino]-N2-(10,12-dimethyl-1-oxotetradecyl)-4-hydroxy-L-ornithine]-5-[(3R)-3-hydroxy-L-ornithine]-(9CI); (4R,5S)-5-((2-Aminoethyl)amino)-N(sup 2)-(10,12-dimethyltetradecanoyl)-4-hydroxy-L-ornithyl-L-threonyl-trans-4-hydroxy-L-prolyl-(S)-4-hydroxy-4-(p-hydroxyphenyl)-L-threonyl-threo-3-hydroxy-L-ornithyl-trans-3-hydroxy-L-proline cyclic (6-1)-peptide; (4R,5S)-5-((2-aminoethyl)amino)-N(2)-(10,12-dimethyltetradecanoyl)-4-hydroxy-L-ornithyl-L-threonyl-trans-4-hydroxy-L-prolyl-(S)-4-hydroxy-4-(p-hydroxyphenyl)-L-threonyl-threo-3-hydroxy-L-ornithyl-trans-3-hydroxy-L-proline cyclic (6-1)-peptide; 1-[(4R,5S)-5-[(2-aminoethyl)amino]-N(2)-(10,12-dimethyl-1-oxotetradecyl)-4-hydroxy-L-ornithine]-5-[(3R)-3-hydroxy-L-ornithine]-pneumocandin B0 DMGQIPT CP Merck & Co DMGQIPT TC Antifungal Agents DMGQIPT DT Small molecular drug DMGQIPT PC 2826718 DMGQIPT MW 1093.3 DMGQIPT FM C52H88N10O15 DMGQIPT IC InChI=1S/C52H88N10O15/c1-5-28(2)24-29(3)12-10-8-6-7-9-11-13-39(69)56-34-26-38(68)46(55-22-21-54)60-50(75)43-37(67)19-23-61(43)52(77)41(36(66)18-20-53)58-49(74)42(45(71)44(70)31-14-16-32(64)17-15-31)59-48(73)35-25-33(65)27-62(35)51(76)40(30(4)63)57-47(34)72/h14-17,28-30,33-38,40-46,55,63-68,70-71H,5-13,18-27,53-54H2,1-4H3,(H,56,69)(H,57,72)(H,58,74)(H,59,73)(H,60,75)/t28?,29?,30-,33-,34+,35+,36-,37+,38-,40+,41+,42+,43+,44+,45+,46+/m1/s1 DMGQIPT CS CCC(C)CC(C)CCCCCCCCC(=O)N[C@H]1C[C@H]([C@H](NC(=O)[C@@H]2[C@H](CCN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@@H](NC1=O)[C@@H](C)O)O)[C@@H]([C@H](C4=CC=C(C=C4)O)O)O)[C@@H](CCN)O)O)NCCN)O DMGQIPT IK JYIKNQVWKBUSNH-OGZDCFRISA-N DMGQIPT IU N-[(3S,6S,9S,11R,15S,18S,20R,21S,24S,25S)-21-(2-aminoethylamino)-3-[(1R)-3-amino-1-hydroxypropyl]-6-[(1S,2S)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-11,20,25-trihydroxy-15-[(1R)-1-hydroxyethyl]-2,5,8,14,17,23-hexaoxo-1,4,7,13,16,22-hexazatricyclo[22.3.0.09,13]heptacosan-18-yl]-10,12-dimethyltetradecanamide DMGQIPT CA CAS 162808-62-0 DMGQIPT CB CHEBI:474180 DMGQIPT DE Fungal infection DMRSZA5 ID DMRSZA5 DMRSZA5 DN Cefacetrile DMRSZA5 HS Approved DMRSZA5 SN Cefacetril; Cefacetrilo; Cefacetrilum; Celospor; Cephacetrile; Vetrimast [veterinary]; Cefacetrile (INN); Cefacetrilo [INN-Spanish]; Cefacetrilum [INN-Latin]; Celospor (TN); Celtol (TN); Cristacef (TN); Vetrimast [veterinary] (TN); C-36278-Ba; (6R,7R)-3-(acetyloxymethyl)-7-[(2-cyanoacetyl)amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-3-Acetoxymethyl-7-(2-cyanacetamido)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-2-carbonsaeure; (6R,7R)-3-[(acetyloxy)methyl]-7-[(cyanoacetyl)amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7-(2-Cyanacetamido)-3-(hydroxymethyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-2-carboxylat acetat (ester); 7-Cyanacetylamino-cephalosporansaeure DMRSZA5 TC Antibiotics DMRSZA5 DT Small molecular drug DMRSZA5 PC 91562 DMRSZA5 MW 339.33 DMRSZA5 FM C13H13N3O6S DMRSZA5 IC InChI=1S/C13H13N3O6S/c1-6(17)22-4-7-5-23-12-9(15-8(18)2-3-14)11(19)16(12)10(7)13(20)21/h9,12H,2,4-5H2,1H3,(H,15,18)(H,20,21)/t9-,12-/m1/s1 DMRSZA5 CS CC(=O)OCC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)CC#N)SC1)C(=O)O DMRSZA5 IK RRYMAQUWDLIUPV-BXKDBHETSA-N DMRSZA5 IU (6R,7R)-3-(acetyloxymethyl)-7-[(2-cyanoacetyl)amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid DMRSZA5 CA CAS 10206-21-0 DMRSZA5 CB CHEBI:135437 DMRSZA5 DE Bacterial infection DMJXDGC ID DMJXDGC DMJXDGC DN Cefaclor DMJXDGC HS Approved DMJXDGC SN Alenfral; Alfacet; Alfatil; CCL; Ceclor; Cefaclorum; Distaclor; Kefolor; Panacef; Panoral; Alfatil Kapseln; Cefaclor anhydrous; Cefaclor hydrate; Cefaclor monohydrate; Dystaclor MR; Kefolor Suspension; Muco Panoral; Lilly 99638 hydrate; Alenfral (TN); Ceclor (TN); Cefaclor (JP15); Cefaclor (USP); Distaclor (TN); Keflor (TN); L-Kefral; Raniclor (TN); S-6472; Cefaclor-1-wasser; Cefaclor [USAN:INN:BAN:JAN]; Ceclor, Distaclor, Keflor, Raniclor, Cefaclor; (6R,7R)-7-((R)-2-Amino-2-phenylacetamido)-3-chloro-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid monohydrate; (6R,7R)-7-[[(2R)-2-amino-2-phenylacetyl]amino]-3-chloro-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[(2R)-2-amino-2-phenylacetyl]amino]-3-chloro-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid hydrate; (6R,7R)-7-{[(2R)-2-amino-2-phenylacetyl]amino}-3-chloro-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 3-Chloro-7-D-(2-phenylglycinamido)-3-cephem-4-carboxylic acid; 3-Chloro-7-D-(2-phenylglycinamido)-3-cephem-4-carboxylic acid monohydrate; 7-(2-Amino-2-phenyl-acetylamino)-3-chloro-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7beta-{[(2R)-2-amino-2-phenylacetyl]amino}-3-chloro-3,4-didehydrocepham-4-carboxylic acid DMJXDGC CP Eli Lilly DMJXDGC TC Antibiotics DMJXDGC DT Small molecular drug DMJXDGC PC 51039 DMJXDGC MW 367.8 DMJXDGC FM C15H14ClN3O4S DMJXDGC IC InChI=1S/C15H14ClN3O4S/c16-8-6-24-14-10(13(21)19(14)11(8)15(22)23)18-12(20)9(17)7-4-2-1-3-5-7/h1-5,9-10,14H,6,17H2,(H,18,20)(H,22,23)/t9-,10-,14-/m1/s1 DMJXDGC CS C1C(=C(N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)N)C(=O)O)Cl DMJXDGC IK QYIYFLOTGYLRGG-GPCCPHFNSA-N DMJXDGC IU (6R,7R)-7-[[(2R)-2-amino-2-phenylacetyl]amino]-3-chloro-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid DMJXDGC CA CAS 53994-73-3 DMJXDGC CB CHEBI:3478 DMJXDGC DE Bacterial infection DMMC345 ID DMMC345 DMMC345 DN Cefadroxil DMMC345 HS Approved DMMC345 SN CDX; Cefadroxilo; Cefadroxilum; Cephadroxil; Sumacef; Cefadroxil anhydrous; S 578; BL-S 578; BL-S578; Cefadroxil (JP15); Cefadroxilo [INN-Spanish]; Cefadroxilum [INN-Latin]; Curisafe (TN); D-Cefadroxil; S-578; Sumacef (TN); MJF-11567-3; (6R,7R)-7-((R)-2-Amino-2-(p-hydroxyphenyl)acetamido)-3-methyl-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino}-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7beta-{[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino}-3,4-didehydrocepham-4-carboxylic acid DMMC345 CP Pharco B international DMMC345 TC Antibiotics DMMC345 DT Small molecular drug DMMC345 PC 47965 DMMC345 MW 363.4 DMMC345 FM C16H17N3O5S DMMC345 IC InChI=1S/C16H17N3O5S/c1-7-6-25-15-11(14(22)19(15)12(7)16(23)24)18-13(21)10(17)8-2-4-9(20)5-3-8/h2-5,10-11,15,20H,6,17H2,1H3,(H,18,21)(H,23,24)/t10-,11-,15-/m1/s1 DMMC345 CS CC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)[C@@H](C3=CC=C(C=C3)O)N)SC1)C(=O)O DMMC345 IK BOEGTKLJZSQCCD-UEKVPHQBSA-N DMMC345 IU (6R,7R)-7-[[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid DMMC345 CA CAS 50370-12-2 DMMC345 CB CHEBI:3479 DMMC345 DE Bacterial infection DMVYSLE ID DMVYSLE DMVYSLE DN Cefalotin DMVYSLE HS Approved DMVYSLE SN Cefalothin; Cefalotina; Cefalotine; Cefalotinum; Cemastin; Cephalothinum; Cephalotin; Coaxin; Cefalotina fabra; Cephalothin Monosodium Salt; Averon-1; Cefalotin (BAN); Cefalotina [INN-Spanish]; Cefalotina fabra (TN); Cefalotine [INN-French]; Cefalotinum [INN-Latin]; Keflin (TN); (6R,7R)-3-(acetyloxymethyl)-8-oxo-7-[(2-thiophen-2-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-3-[(acetyloxy)methyl]-8-oxo-7-[(2-thienylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 3-(Acetoxymethyl)-8-oxo-7-(2-(2-thienyl)acetamido)-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid; 3-(Hydroxymethyl)-8-oxo-7-(2-(2-thienyl)acetamido)-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid acetate; 3-ACETOXYMETHYL-8-OXO-7-(2-THIOPHEN-2-YL-ACETYLAMINO)-5-THIA-1-AZA-BICYCLO[4.2.0]OCT-2-ENE-2-CARBOXYLIC ACID; 3-Acetoxymethyl-7-(2-thienylacetamido)-3-cephem-4-carboxylic acid; 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 3-(hydroxymethyl)-8-oxo-7-(2-(2-thienyl)acetamido)-, acetate (ester); 6R-trans-3-((Acetyloxy)methyl)-8-oxo-7-((2-thienylacetyl)amino)-5-thia-1-azabicyclo(4.2.0)-oct-2-ene-2-carboxylic acid; 7-(2-(2-Thienyl)acetylamido)cephalosporanic acid; 7-(2-Thienylacetamido)cephalosporanic acid; 7-(Thiophene-2-acetamido)cephalosporanic acid; 7-(Thiophene-2-acetamido)cephalosporin; 7beta-(thiophen-2-ylacetamido)-3-acetoxymethyl-3,4-didehydrocepham-4-carboxylic acid DMVYSLE CP Eli Lilly DMVYSLE TC Antibiotics DMVYSLE DT Small molecular drug DMVYSLE PC 6024 DMVYSLE MW 396.4 DMVYSLE FM C16H16N2O6S2 DMVYSLE IC InChI=1S/C16H16N2O6S2/c1-8(19)24-6-9-7-26-15-12(14(21)18(15)13(9)16(22)23)17-11(20)5-10-3-2-4-25-10/h2-4,12,15H,5-7H2,1H3,(H,17,20)(H,22,23)/t12-,15-/m1/s1 DMVYSLE CS CC(=O)OCC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)CC3=CC=CS3)SC1)C(=O)O DMVYSLE IK XIURVHNZVLADCM-IUODEOHRSA-N DMVYSLE IU (6R,7R)-3-(acetyloxymethyl)-8-oxo-7-[(2-thiophen-2-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid DMVYSLE CA CAS 153-61-7 DMVYSLE CB CHEBI:124991 DMVYSLE DE Bacterial infection DMNEXZF ID DMNEXZF DMNEXZF DN Cefamandole DMNEXZF HS Approved DMNEXZF SN Cefadole; Cefamandolum; Cefamandole (USAN/INN); (6R,7R)-7-(R)-Mandelamido-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-carboxylic acid; (6R,7R)-7-[[(2R)-2-hydroxy-2-phenylacetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2R)-2-hydroxy-2-phenylacetyl]amino}-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2R)-2-hydroxy-2-phenylacetyl]amino}-3-{[(1-methyl-1H-tetrazol-5-yl)thio]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7beta-[(2R)-2-hydroxy-2-phenylacetamido]-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}ceph-3-em-4-carboxylic acid DMNEXZF CP Eli Lilly DMNEXZF TC Antibiotics DMNEXZF DT Small molecular drug DMNEXZF PC 456255 DMNEXZF MW 462.5 DMNEXZF FM C18H18N6O5S2 DMNEXZF IC InChI=1S/C18H18N6O5S2/c1-23-18(20-21-22-23)31-8-10-7-30-16-11(15(27)24(16)12(10)17(28)29)19-14(26)13(25)9-5-3-2-4-6-9/h2-6,11,13,16,25H,7-8H2,1H3,(H,19,26)(H,28,29)/t11-,13-,16-/m1/s1 DMNEXZF CS CN1C(=NN=N1)SCC2=C(N3[C@@H]([C@@H](C3=O)NC(=O)[C@@H](C4=CC=CC=C4)O)SC2)C(=O)O DMNEXZF IK OLVCFLKTBJRLHI-AXAPSJFSSA-N DMNEXZF IU (6R,7R)-7-[[(2R)-2-hydroxy-2-phenylacetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid DMNEXZF CA CAS 34444-01-4 DMNEXZF CB CHEBI:3480 DMNEXZF DE Microorganisms infection DMPDYFR ID DMPDYFR DMPDYFR DN Cefazolin DMPDYFR HS Approved DMPDYFR SN CEZ; Cefamezin; Cefamezine; Cefazolina; Cefazoline; Cefazolinum; Cephamezine; Cephazolidin; Cephazolin; Cephazoline; Elzogram; Cephazolin Sodium; Ancef (TN); Cefacidal (TN); Cefamezin (TN); Cefazolin (USP); Cefazolin [USAN:INN]; Cefazolin(usp); Cefazolina [INN-Spanish]; Cefazoline [INN-French]; Cefazolinum [INN-Latin]; Cefrina (TN); Elzogram (TN); Faxilen (TN); Gramaxin (TN); Kefazol (TN); Kefol (TN); Kefzol (TN); Kefzolan (TN); Kezolin (TN); Novaporin (TN); Zolicef (TN); (6R, 7R)-3-[[(5-Methyl-1,3,4-thiadiazol-2-yl)thio]methyl]-8-oxo-7-[[1H-tetrazol-1-yl)acetyl]amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-3-(((5-Methyl-1,3,4-thiadiazol-2-yl)thio)methyl)-8-oxo-7-(2-(1H-tetrazol-1-yl)acetamido)-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid; (6R,7R)-3-[(5-methyl-1,3,4-thiadiazol-2-yl)sulfanylmethyl]-8-oxo-7-[[2-(tetrazol-1-yl)acetyl]amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-3-{[(5-methyl-1,3,4-thiadiazol-2-yl)sulfanyl]methyl}-8-oxo-7-[(1H-tetrazol-1-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-3-{[(5-methyl-1,3,4-thiadiazol-2-yl)thio]methyl}-8-oxo-7-[(1H-tetrazol-1-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R-trans)-3-(((5-Methyl-1,3,4-thiadiazol-2-yl)thio)methyl)-8-oxo-7-(((1H-tetrazol-1-yl)acetyl)-amino)-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid; 3-{[(5-methyl-1,3,4-thiadiazol-2-yl)sulfanyl]methyl}-7beta-[(1H-tetrazol-1-ylacetyl)amino]-3,4-didehydrocepham-4-carboxylic acid; 7-(1-(1H-)-Tetrazolylacetamido)-3-(2-(5-methyl-1,3,4-thiadiazolyl)thiomethyl)delta3-cephem-4-carboxylic acid DMPDYFR CP Fujisawa Pharmaceutical Co DMPDYFR TC Antibiotics DMPDYFR DT Small molecular drug DMPDYFR PC 33255 DMPDYFR MW 454.5 DMPDYFR FM C14H14N8O4S3 DMPDYFR IC InChI=1S/C14H14N8O4S3/c1-6-17-18-14(29-6)28-4-7-3-27-12-9(11(24)22(12)10(7)13(25)26)16-8(23)2-21-5-15-19-20-21/h5,9,12H,2-4H2,1H3,(H,16,23)(H,25,26)/t9-,12-/m1/s1 DMPDYFR CS CC1=NN=C(S1)SCC2=C(N3[C@@H]([C@@H](C3=O)NC(=O)CN4C=NN=N4)SC2)C(=O)O DMPDYFR IK MLYYVTUWGNIJIB-BXKDBHETSA-N DMPDYFR IU (6R,7R)-3-[(5-methyl-1,3,4-thiadiazol-2-yl)sulfanylmethyl]-8-oxo-7-[[2-(tetrazol-1-yl)acetyl]amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid DMPDYFR CA CAS 25953-19-9 DMPDYFR CB CHEBI:474053 DMPDYFR DE Bacterial infection DMJ7A0H ID DMJ7A0H DMJ7A0H DN Cefdinir DMJ7A0H HS Approved DMJ7A0H SN CFDN; Cefdinirum; Cefdinyl; Cefdirnir; Cefzon; Omnicef; BMY 28488; FK 482; PD 134393; Cefdinir [USAN:INN]; Cefdinirum [INN-Latin]; Cefzon (TN); FK-482; FR-80482; KS-1038; Omnicef (TN); PD-134393; Cefdinir (JP15/USAN/INN); Omnicef, FK-482, BMY-28488, PD 134393, CI-983, Cefdinir; (-)-(6R,7R)-7-(2-(2-Amino-4-thiazolyl)glyoxylamido)-8-oxo-3-vinyl-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7(sup 2)-(Z)-oxime; (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-hydroxyiminoacetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(hydroxyimino)acetyl]amino}-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7-(2 (2-aminothiazol-4-yl)-2-hydroxyiminoacetamido)-3-vinyl-3-cephem-4-carboxylic acid; 7beta-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(hydroxyimino)acetamido]-3-ethenyl-3,4-didehydrocepham-4-carboxylic acid DMJ7A0H CP Abbott Laboratories DMJ7A0H TC Antibiotics DMJ7A0H DT Small molecular drug DMJ7A0H PC 6915944 DMJ7A0H MW 395.4 DMJ7A0H FM C14H13N5O5S2 DMJ7A0H IC InChI=1S/C14H13N5O5S2/c1-2-5-3-25-12-8(11(21)19(12)9(5)13(22)23)17-10(20)7(18-24)6-4-26-14(15)16-6/h2,4,8,12,24H,1,3H2,(H2,15,16)(H,17,20)(H,22,23)/b18-7-/t8-,12-/m1/s1 DMJ7A0H CS C=CC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)/C(=N\\O)/C3=CSC(=N3)N)SC1)C(=O)O DMJ7A0H IK RTXOFQZKPXMALH-GHXIOONMSA-N DMJ7A0H IU (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-hydroxyiminoacetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid DMJ7A0H CA CAS 91832-40-5 DMJ7A0H CB CHEBI:3485 DMJ7A0H DE Bacterial infection DMSUVM1 ID DMSUVM1 DMSUVM1 DN Cefditoren DMSUVM1 HS Approved DMSUVM1 SN Cefditoren [USAN:INN]; Meiact (TN); Spectracef (TN); (+)-(6R,7R)-7-(2-(2-Amino-4-thiazolyl)glyoxylamido)-3-((Z)-2-(4-methyl-5-thiazolyl)vinyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7(sup 2)-(Z)-(O-methyloxime); (6R-(3(Z),6alpha,7beta(Z)))-7-((2-Amino-4-thiazolyl)(methoxyimino)acetyl)amino-3-(2-(4-methyl-5-thiazolyl)ethenyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid DMSUVM1 CP Cornerstone BioPharma DMSUVM1 TC Antibiotics DMSUVM1 DT Small molecular drug DMSUVM1 PC 9870843 DMSUVM1 MW 506.6 DMSUVM1 FM C19H18N6O5S3 DMSUVM1 IC InChI=1S/C19H18N6O5S3/c1-8-11(33-7-21-8)4-3-9-5-31-17-13(16(27)25(17)14(9)18(28)29)23-15(26)12(24-30-2)10-6-32-19(20)22-10/h3-4,6-7,13,17H,5H2,1-2H3,(H2,20,22)(H,23,26)(H,28,29)/b4-3-,24-12-/t13-,17-/m1/s1 DMSUVM1 CS CC1=C(SC=N1)/C=C\\C2=C(N3[C@@H]([C@@H](C3=O)NC(=O)/C(=N\\OC)/C4=CSC(=N4)N)SC2)C(=O)O DMSUVM1 IK KMIPKYQIOVAHOP-YLGJWRNMSA-N DMSUVM1 IU (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(Z)-2-(4-methyl-1,3-thiazol-5-yl)ethenyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid DMSUVM1 CA CAS 104145-95-1 DMSUVM1 CB CHEBI:59343 DMSUVM1 DE Bacterial infection DMHVWIK ID DMHVWIK DMHVWIK DN Cefepime DMHVWIK HS Approved DMHVWIK SN Axepim; CFPM; Cefepima; Cefepimum; Cepimax; Cepimex; Maxcef; Maxipime; Cefepima [Spanish]; Cefepimum [Latin]; BMY 28142; Axepim (TN); BMY-28142; Cefepime [USAN:INN]; Cepimax (TN); Cepimex (TN); Maxcef (TN); Maxipime (TN); Cefepime (USAN/INN); (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(1-methylpyrrolidin-1-ium-1-yl)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; (6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-[(1-methylpyrrolidinium-1-yl)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; 1-(((6R,7R)-7-(2-(2-Amino-4-thiazolyl)glyoxylamido)-2-carboxy-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-1-methylpyrrolidinium hydroxide, inner salt, 7(sup 2)-(Z)-(O-methyloxime); 7beta-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido]-3-[(1-methylpyrrolidinium-1-yl)methyl]-3,4-didehydrocepham-4-carboxylate DMHVWIK CP Bristol-Myers Squibb DMHVWIK TC Antibiotics DMHVWIK DT Small molecular drug DMHVWIK PC 5479537 DMHVWIK MW 480.6 DMHVWIK FM C19H24N6O5S2 DMHVWIK IC InChI=1S/C19H24N6O5S2/c1-25(5-3-4-6-25)7-10-8-31-17-13(16(27)24(17)14(10)18(28)29)22-15(26)12(23-30-2)11-9-32-19(20)21-11/h9,13,17H,3-8H2,1-2H3,(H3-,20,21,22,26,28,29)/b23-12-/t13-,17-/m1/s1 DMHVWIK CS C[N+]1(CCCC1)CC2=C(N3[C@@H]([C@@H](C3=O)NC(=O)/C(=N\\OC)/C4=CSC(=N4)N)SC2)C(=O)[O-] DMHVWIK IK HVFLCNVBZFFHBT-ZKDACBOMSA-N DMHVWIK IU (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(1-methylpyrrolidin-1-ium-1-yl)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate DMHVWIK CA CAS 88040-23-7 DMHVWIK CB CHEBI:478164 DMHVWIK DE Bacterial infection DMY60I8 ID DMY60I8 DMY60I8 DN Cefixime DMY60I8 HS Approved DMY60I8 SN CFIX; Cefixima; Cefiximum; Denvar; Necopen; Tricef; CL-284635; FK-027; FR-17027; Ofex (TN); Suprax (TN); Cefixime (JP15/USP/INN); (6R,7R)-7-({(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(carboxymethoxy)imino]acetyl}amino)-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(carboxymethyloxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-{[(carboxymethyl)oxy]imino}acetyl]amino}-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6r,7r)-7-[-2-(2-amino-thiazol-4-yl)-2-carboxymethoxyimino-acetylamino]-8-oxo-3-vinyl-5-thia-1-aza-b; 7beta-{(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(carboxymethoxy)imino]acetamido}-3-ethenyl-3,4-didehydrocepham-4-carboxylic acid DMY60I8 CP Wyeth Pharmaceuticals DMY60I8 TC Antibiotics DMY60I8 DT Small molecular drug DMY60I8 PC 5362065 DMY60I8 MW 453.5 DMY60I8 FM C16H15N5O7S2 DMY60I8 IC InChI=1S/C16H15N5O7S2/c1-2-6-4-29-14-10(13(25)21(14)11(6)15(26)27)19-12(24)9(20-28-3-8(22)23)7-5-30-16(17)18-7/h2,5,10,14H,1,3-4H2,(H2,17,18)(H,19,24)(H,22,23)(H,26,27)/b20-9-/t10-,14-/m1/s1 DMY60I8 CS C=CC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)/C(=N\\OCC(=O)O)/C3=CSC(=N3)N)SC1)C(=O)O DMY60I8 IK OKBVVJOGVLARMR-QSWIMTSFSA-N DMY60I8 IU (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(carboxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid DMY60I8 CA CAS 79350-37-1 DMY60I8 CB CHEBI:472657 DMY60I8 DE Bacterial infection DMPLY7B ID DMPLY7B DMPLY7B DN Cefmenoxime DMPLY7B HS Approved DMPLY7B SN Cefmax; Cefmenoxima; Cefmenoximum; Tacef; Cefmenoxime [INN]; A 50912; AB 50912; SCE 1365; Abbott-50192; Cefmenoxima [INN-Spanish]; Cefmenoxime (INN); Cefmenoximum [INN-Latin]; Cefmenoxime Hydrochloride (2:1); (6R,7R)-(2-(2-Amino-4-thiazolyl)glyoxylamido)-3-(1-methyl-1H-tetrazol-5-yl)thiomethyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-2-carbonsaeure-7-(Z)-(O-methyloxim); (6R,7R)-7-((Z)-2-(2-Amino-4-thiazolyl)-2-methoxyiminoacetamido)-3-((1-methyl-1H-5-tetraazolylthio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-2-carbonsaeure; (6R,7R)-7-({(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(methyloxy)imino]acetyl}amino)-3-{[(1-methyl-1H-tetrazol-5-yl)thio]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[(2E)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid (IUPAC); (6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7beta-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}-3,4-didehydrocepham-4-carboxylic acid DMPLY7B TC Antibiotics DMPLY7B DT Small molecular drug DMPLY7B PC 9570757 DMPLY7B MW 511.6 DMPLY7B FM C16H17N9O5S3 DMPLY7B IC InChI=1S/C16H17N9O5S3/c1-24-16(20-22-23-24)33-4-6-3-31-13-9(12(27)25(13)10(6)14(28)29)19-11(26)8(21-30-2)7-5-32-15(17)18-7/h5,9,13H,3-4H2,1-2H3,(H2,17,18)(H,19,26)(H,28,29)/b21-8-/t9-,13-/m1/s1 DMPLY7B CS CN1C(=NN=N1)SCC2=C(N3[C@@H]([C@@H](C3=O)NC(=O)/C(=N\\OC)/C4=CSC(=N4)N)SC2)C(=O)O DMPLY7B IK HJJDBAOLQAWBMH-YCRCPZNHSA-N DMPLY7B IU (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid DMPLY7B CA CAS 65085-01-0 DMPLY7B CB CHEBI:55490 DMPLY7B DE Bacterial infection DM42W1B ID DM42W1B DM42W1B DN Cefmetazole DM42W1B HS Approved DM42W1B SN CMZ; Cefmetazolo; Cefmetazolum; Cefmetazole Monosodium Salt; CS 1170; SKF 83088; U 72791; CS-1170; Cefmetazole [USAN:INN]; Cefmetazolo [INN-Spanish]; Cefmetazolum [INN-Latin]; U-72791A; Cefmetazole (USP/INN); (6R,7S)-7-(2-((Cyanomethyl)thio)acetamido)-7-methoxy-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid; (6R,7S)-7-(2-((Cyanomethyl)thio)acetamido)-7-methoxy-3-(((1-methyl-1H-tetrazol-5-yl)thiomethyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, sodium salt; (6R,7S)-7-({[(cyanomethyl)sulfanyl]acetyl}amino)-7-methoxy-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7S)-7-({[(cyanomethyl)thio]acetyl}amino)-7-(methyloxy)-3-{[(1-methyl-1H-tetrazol-5-yl)thio]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7S)-7-[[2-(cyanomethylsulfanyl)acetyl]amino]-7-methoxy-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 6beta-{[(cyanomethyl)sulfanyl]acetamido}-6alpha-methoxy-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}ceph-3-em-4-carboxylic acid DM42W1B CP Pharmacia And Upjohn Co DM42W1B TC Antibiotics DM42W1B DT Small molecular drug DM42W1B PC 42008 DM42W1B MW 471.5 DM42W1B FM C15H17N7O5S3 DM42W1B IC InChI=1S/C15H17N7O5S3/c1-21-14(18-19-20-21)30-6-8-5-29-13-15(27-2,17-9(23)7-28-4-3-16)12(26)22(13)10(8)11(24)25/h13H,4-7H2,1-2H3,(H,17,23)(H,24,25)/t13-,15+/m1/s1 DM42W1B CS CN1C(=NN=N1)SCC2=C(N3[C@@H]([C@@](C3=O)(NC(=O)CSCC#N)OC)SC2)C(=O)O DM42W1B IK SNBUBQHDYVFSQF-HIFRSBDPSA-N DM42W1B IU (6R,7S)-7-[[2-(cyanomethylsulfanyl)acetyl]amino]-7-methoxy-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid DM42W1B CA CAS 56796-20-4 DM42W1B CB CHEBI:3489 DM42W1B DE Bacterial infection DMORSGU ID DMORSGU DMORSGU DN Cefodizime DMORSGU HS Approved DMORSGU SN AC1NSFIB; CDZM; CHEBI:63214; CHEMBL2303613; Cefodizima; Cefodizima [INN-Spanish]; Cefodizime; Cefodizime (INN); Cefodizime Acid; Cefodizime [INN:BAN]; Cefodizimum; Cefodizimum [INN-Latin]; Cefodizme; DTXSID2022757; Diezime; EC 700-301-3; EX-A1379; HR 221 [AS SODIUM]; HR-221; HR-221 [As Sodium]; J-700161; Modivid; Neucef; S-771221B [As Sodium]; SCHEMBL151101; THR 221 [AS SODIUM]; THR-221; THR-221 [As Sodium]; Timecef; UNII-Z31298J4HQ; Z31298J4HQ DMORSGU TC Anti-Bacterial Agents DMORSGU DT Small molecular drug DMORSGU PC 5361871 DMORSGU MW 584.655 DMORSGU FM C20H20N6O7S4 DMORSGU IC InChI=1S/C20H20N6O7S4/c1-7-10(3-11(27)28)37-20(22-7)36-5-8-4-34-17-13(16(30)26(17)14(8)18(31)32)24-15(29)12(25-33-2)9-6-35-19(21)23-9/h6,13,17H,3-5H2,1-2H3,(H2,21,23)(H,24,29)(H,27,28)(H,31,32)/b25-12-/t13-,17-/m1/s1 DMORSGU CS CC1=C(SC(=N1)SCC2=C(N3C(C(C3=O)NC(=O)C(=NOC)C4=CSC(=N4)N)SC2)C(=O)O)CC(=O)O DMORSGU IK XDZKBRJLTGRPSS-BGZQYGJUSA-N DMORSGU IU (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[[5-(carboxymethyl)-4-methyl-1,3-thiazol-2-yl]sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid DMORSGU CA CAS 69739-16-8 DMORSGU CB CHEBI:63214 DMORSGU DE Bacterial infections DMTX2BH ID DMTX2BH DMTX2BH DN Cefonicid DMTX2BH HS Approved DMTX2BH SN Cefonicido; Cefonicidum; Monocef; Praticef; Cefonicid Monosodium Salt; Sodium Cefonicid; Cefonicid (INN); Cefonicid [INN:BAN]; Cefonicido [INN-Spanish]; Cefonicidum [INN-Latin]; Monocef (TN); SK&F-75073; SKF-75073-2; (6R,7R)-7-[(2-hydroxy-2-phenylacetyl)amino]-8-oxo-3-[[1-(sulfomethyl)tetrazol-5-yl]sulfanylmethyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[(2R)-2-hydroxy-2-phenylacetyl]amino]-8-oxo-3-[[1-(sulfomethyl)tetrazol-5-yl]sulfanylmethyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2R)-2-hydroxy-2-phenylacetyl]amino}-8-oxo-3-({[1-(sulfomethyl)-1H-tetrazol-5-yl]sulfanyl}methyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2R)-2-hydroxy-2-phenylacetyl]amino}-8-oxo-3-({[1-(sulfomethyl)-1H-tetrazol-5-yl]thio}methyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (7R)-7-(2-Hydroxy-2-phenylacetylamino)-6-oxo-3-{[1-(sulfomethyl)(1,2,3,4-tetraazol-5-ylthio)]methyl}-2H,7H,7aH-azetidino[2,1-b]1,3-thiazine-4-carboxylic acid; 6beta-[(2R)-2-hydroxy-2-phenylacetamido]-3-({[1-(sulfomethyl)-1H-tetrazol-5-yl]sulfanyl}methyl)ceph-3-em-4-carboxylic acid; 7-[(2-hydroxy-2-phenylacetyl)amino]-8-oxo-3-[[1-(sulfomethyl)tetrazol-5-yl]sulfanylmethyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid DMTX2BH CP Glaxosmithkline DMTX2BH TC Antibiotics DMTX2BH DT Small molecular drug DMTX2BH PC 43594 DMTX2BH MW 542.6 DMTX2BH FM C18H18N6O8S3 DMTX2BH IC InChI=1S/C18H18N6O8S3/c25-13(9-4-2-1-3-5-9)14(26)19-11-15(27)24-12(17(28)29)10(6-33-16(11)24)7-34-18-20-21-22-23(18)8-35(30,31)32/h1-5,11,13,16,25H,6-8H2,(H,19,26)(H,28,29)(H,30,31,32)/t11-,13-,16-/m1/s1 DMTX2BH CS C1C(=C(N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)O)C(=O)O)CSC4=NN=NN4CS(=O)(=O)O DMTX2BH IK DYAIAHUQIPBDIP-AXAPSJFSSA-N DMTX2BH IU (6R,7R)-7-[[(2R)-2-hydroxy-2-phenylacetyl]amino]-8-oxo-3-[[1-(sulfomethyl)tetrazol-5-yl]sulfanylmethyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid DMTX2BH CA CAS 61270-58-4 DMTX2BH CB CHEBI:3491 DMTX2BH DE Bacterial infection DM53PV8 ID DM53PV8 DM53PV8 DN Cefoperazone DM53PV8 HS Approved DM53PV8 SN Cefobid; Cefoperazon; Cefoperazono; Cefoperazonum; Cefoperazone sodium salt; Peracef [veterinary]; CP 52640; Cefazone (TN); Cefobid (TN); Cefoperazone (INN); Cefoperazone [INN:BAN]; Cefoperazono [INN-Spanish]; Cefoperazonum [INN-Latin]; Peracef [veterinary] (TN); (6R,7R)-7-((R)-2-(4-Ethyl-2,3-dioxo-1-piperazinylcarboxamido)-2-(4-hydroxyphenyl)acetamido)-3-((1-methyl-1H-tetrazol-5-yl)thiomethyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-2-carbonsaeure; (6R,7R)-7-[[(2R)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-(4-hydroxyphenyl)acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[(2S)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-(4-hydroxyphenyl)acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-(4-hydroxyphenyl)acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2R)-2-{[(4-ethyl-2,3-dioxopiperazin-1-yl)carbonyl]amino}-2-(4-hydroxyphenyl)acetyl]amino}-3-{[(1-methyl-1H-tetrazol-5-yl)thio]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[{[(4-ethyl-2,3-dioxopiperazin-1-yl)carbonyl]amino}(4-hydroxyphenyl)acetyl]amino}-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7S)-7-[[(2R)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-(4-hydroxyphenyl)acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7S)-7-[[(2S)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-(4-hydroxyphenyl)acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6S,7R)-7-[[(2S)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-(4-hydroxyphenyl)acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7-[[2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-(4-hydroxyphenyl)acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7beta-{[{[(4-ethyl-2,3-dioxopiperazin-1-yl)carbonyl]amino}(4-hydroxyphenyl)acetyl]amino}-3-[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl-3,4-didehydrocepham-4-carboxylic acid DM53PV8 CP Pfizer Pharmaceuticals DM53PV8 TC Antibiotics DM53PV8 DT Small molecular drug DM53PV8 PC 44187 DM53PV8 MW 645.7 DM53PV8 FM C25H27N9O8S2 DM53PV8 IC InChI=1S/C25H27N9O8S2/c1-3-32-8-9-33(21(39)20(32)38)24(42)27-15(12-4-6-14(35)7-5-12)18(36)26-16-19(37)34-17(23(40)41)13(10-43-22(16)34)11-44-25-28-29-30-31(25)2/h4-7,15-16,22,35H,3,8-11H2,1-2H3,(H,26,36)(H,27,42)(H,40,41)/t15-,16-,22-/m1/s1 DM53PV8 CS CCN1CCN(C(=O)C1=O)C(=O)N[C@H](C2=CC=C(C=C2)O)C(=O)N[C@H]3[C@@H]4N(C3=O)C(=C(CS4)CSC5=NN=NN5C)C(=O)O DM53PV8 IK GCFBRXLSHGKWDP-XCGNWRKASA-N DM53PV8 IU (6R,7R)-7-[[(2R)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-(4-hydroxyphenyl)acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid DM53PV8 CA CAS 62893-19-0 DM53PV8 CB CHEBI:3493 DM53PV8 DE Bacterial infection DMSQVD6 ID DMSQVD6 DMSQVD6 DN Ceforanide DMSQVD6 HS Approved DMSQVD6 SN Ceforanido; Ceforanidum; Precef; Radacef; Bl s786; BL-S 786; BL-S786; Ceforanido [INN-Spanish]; Ceforanidum [INN-Latin]; Precef (TN); Ceforanide (USP/INN); Ceforanide [USAN:INN:BAN]; (6R,7R)-7-(2-(alpha-Amino-o-tolyl)acetamido)-3-(((1-(carboxymethyl)-1H-tetrazol-5-yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid; (6R,7R)-7-({[2-(aminomethyl)phenyl]acetyl}amino)-3-({[1-(carboxymethyl)-1H-tetrazol-5-yl]sulfanyl}methyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-({[2-(aminomethyl)phenyl]acetyl}amino)-3-({[1-(carboxymethyl)-1H-tetrazol-5-yl]thio}methyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[2-[2-(aminomethyl)phenyl]acetyl]amino]-3-[[1-(carboxymethyl)tetrazol-5-yl]sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R-trans)-7-(((2-(Aminomethyl)phenyl)acetyl)amino)-3-(((1-(carboxymethyl)-1H-tetrazol-5-yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid; 7-(o-(Aminomethyl)phenylacetamido)-3-(((1-(carboxymethyl)-1H-tetrazol-5-yl)thio)methyl)-3-cephem-4-carboxylic acid; 7-[O-(aminomethyl)phenylacetamido]-3-[[[1-(carboxymethyl)-1H-tetrazol-5-yl]thio]methyl]-3-cephem-4-carboxylic acid; 7beta-[2-(aminomethyl)phenyl]acetamido-3-{[1-(carboxymethyl)-1H-tetrazol-5-yl]sulfanyl}methyl-3,4-didehydrocepham-4-carboxylic acid DMSQVD6 TC Antibiotics DMSQVD6 DT Small molecular drug DMSQVD6 PC 43507 DMSQVD6 MW 519.6 DMSQVD6 FM C20H21N7O6S2 DMSQVD6 IC InChI=1S/C20H21N7O6S2/c21-6-11-4-2-1-3-10(11)5-13(28)22-15-17(31)27-16(19(32)33)12(8-34-18(15)27)9-35-20-23-24-25-26(20)7-14(29)30/h1-4,15,18H,5-9,21H2,(H,22,28)(H,29,30)(H,32,33)/t15-,18-/m1/s1 DMSQVD6 CS C1C(=C(N2[C@H](S1)[C@@H](C2=O)NC(=O)CC3=CC=CC=C3CN)C(=O)O)CSC4=NN=NN4CC(=O)O DMSQVD6 IK SLAYUXIURFNXPG-CRAIPNDOSA-N DMSQVD6 IU (6R,7R)-7-[[2-[2-(aminomethyl)phenyl]acetyl]amino]-3-[[1-(carboxymethyl)tetrazol-5-yl]sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid DMSQVD6 CA CAS 60925-61-3 DMSQVD6 CB CHEBI:3495 DMSQVD6 DE Bacterial infection DMEB837 ID DMEB837 DMEB837 DN Cefotaxime DMEB837 HS Approved DMEB837 SN Cefotaxima; Cefotaxima [INN-Spanish]; Cefotaxime [INN:BAN]; Cefotaxime acid; Cefotaximum; Cefotaximum [INN-Latin]; Cephotaxime; E-cefotaxime; Omnatax; RU 24662; RU 24756; cefotaxime; 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 3-((acetyloxy)methyl)-7-(((2Z)-(2-amino-4-thiazolyl)(methoxyimino)acetyl)amino)-8-oxo-, (6R,7R)-; 60846-21-1; 63527-52-6; C16H17N5O7S2; CHEBI:204928; EINECS 264-299-1; HR 756; N2GI8B1GK7; Taxim; UNII-N2GI8B1GK7 DMEB837 PC 5742673 DMEB837 MW 455.5 DMEB837 FM C16H17N5O7S2 DMEB837 IC GPRBEKHLDVQUJE-QSWIMTSFSA-N DMEB837 CS CC(=O)OCC1=C(N2C(C(C2=O)NC(=O)C(=NOC)C3=CSC(=N3)N)SC1)C(=O)O DMEB837 IK 1S/C16H17N5O7S2/c1-6(22)28-3-7-4-29-14-10(13(24)21(14)11(7)15(25)26)19-12(23)9(20-27-2)8-5-30-16(17)18-8/h5,10,14H,3-4H2,1-2H3,(H2,17,18)(H,19,23)(H,25,26)/b20-9-/t10-,14-/m1/s1 DMEB837 IU (6R,7R)-3-(acetyloxymethyl)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid DMEB837 CA CAS 60846-21-1 DMEB837 CB CHEBI:204928 DMEB837 DE Meningitis DMMKHBJ ID DMMKHBJ DMMKHBJ DN Cefotaxime DMMKHBJ HS Approved DMMKHBJ SN Cefotaxim; Cefotaxima; Cefotaximum; Cephotaxim; Cephotaxime; Claforan; Klaforan; Cefotaxim Hikma; Cefotaxime acid; CE3; RU 24662; Cefotaxim Hikma (TN); Cefotaxima [INN-Spanish]; Cefotaxime (INN); Cefotaxime [INN:BAN]; Cefotaximum [INN-Latin]; Claforan (TN); Ru-24756; Claforan (*Sodium salt*) DMMKHBJ CP Roussel Uclaf DMMKHBJ TC Antibiotics DMMKHBJ DT Small molecular drug DMMKHBJ PC 5742673 DMMKHBJ MW 455.5 DMMKHBJ FM C16H17N5O7S2 DMMKHBJ IC InChI=1S/C16H17N5O7S2/c1-6(22)28-3-7-4-29-14-10(13(24)21(14)11(7)15(25)26)19-12(23)9(20-27-2)8-5-30-16(17)18-8/h5,10,14H,3-4H2,1-2H3,(H2,17,18)(H,19,23)(H,25,26)/b20-9-/t10-,14-/m1/s1 DMMKHBJ CS CC(=O)OCC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)/C(=N\\OC)/C3=CSC(=N3)N)SC1)C(=O)O DMMKHBJ IK GPRBEKHLDVQUJE-QSWIMTSFSA-N DMMKHBJ IU (6R,7R)-3-(acetyloxymethyl)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid DMMKHBJ CA CAS 63527-52-6 DMMKHBJ CB CHEBI:204928 DMMKHBJ DE Bacterial infection DM07TX3 ID DM07TX3 DM07TX3 DN Cefotetan DM07TX3 HS Approved DM07TX3 SN Cefotetanum; Apatef (TN); Cefotan (TN); Cefotetan (JP15/USP/INN); (6R,7S)-7-(4-(carbamoylcarboxymethylene)-1,3-dithiethane-2-carboxamido)-7-methoxy-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid; (6R,7S)-7-({[4-(2-amino-1-carboxy-2-oxoethylidene)-1,3-dithietan-2-yl]carbonyl}amino)-7-methoxy-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7S)-7-[[4-(1-amino-3-hydroxy-1,3-dioxopropan-2-ylidene)-1,3-dithietane-2-carbonyl]amino]-7-methoxy-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7beta-({[4-(2-amino-1-carboxy-2-oxoethylidene)-1,3-dithietan-2-yl]carbonyl}amino)-7alpha-methoxy-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}-3,4-didehydrocepham-4-carboxylic acid DM07TX3 CP AstraZeneca DM07TX3 TC Antibiotics DM07TX3 DT Small molecular drug DM07TX3 PC 53025 DM07TX3 MW 575.6 DM07TX3 FM C17H17N7O8S4 DM07TX3 IC InChI=1S/C17H17N7O8S4/c1-23-16(20-21-22-23)34-4-5-3-33-15-17(32-2,14(31)24(15)7(5)11(29)30)19-9(26)13-35-12(36-13)6(8(18)25)10(27)28/h13,15H,3-4H2,1-2H3,(H2,18,25)(H,19,26)(H,27,28)(H,29,30)/t13?,15-,17+/m1/s1 DM07TX3 CS CN1C(=NN=N1)SCC2=C(N3[C@@H]([C@@](C3=O)(NC(=O)C4SC(=C(C(=O)N)C(=O)O)S4)OC)SC2)C(=O)O DM07TX3 IK SRZNHPXWXCNNDU-RHBCBLIFSA-N DM07TX3 IU (6R,7S)-7-[[4-(2-amino-1-carboxy-2-oxoethylidene)-1,3-dithietane-2-carbonyl]amino]-7-methoxy-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid DM07TX3 CA CAS 69712-56-7 DM07TX3 CB CHEBI:3499 DM07TX3 DE Bacterial infection DMF5HU6 ID DMF5HU6 DMF5HU6 DN Cefotiam DMF5HU6 HS Approved DMF5HU6 SN Aspil; CTM; Cefotiamum; Ceradolan; Haloapor; CEFOTIAM HYDROCHLORIDE; CGP 14221E; Abbott-48999; Aspil (TN); Cefotiam (INN); Cefotiam [INN:BAN]; Cefotiamum [INN-Latin]; SCE-963; CGP-14221-E; (6R,7R)-7-[2-(2-Amino-thiazol-4-yl)-acetylamino]-3-[1-(2-dimethylamino-ethyl)-1H-tetrazol-5-ylsulfanylmethyl]-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[2-(2-amino-1,3-thiazol-4-yl)acetyl]amino]-3-[[1-(2-dimethylaminoethyl)tetrazol-5-yl]sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2-amino-1,3-thiazol-4-yl)acetyl]amino}-3-[({1-[2-(dimethylamino)ethyl]-1H-tetrazol-5-yl}sulfanyl)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2-amino-1,3-thiazol-4-yl)acetyl]amino}-3-[({1-[2-(dimethylamino)ethyl]-1H-tetrazol-5-yl}thio)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7b-[2-(aminothiazol-4-yl)acetamido]-3-[[[1-(2-dimethylaminoethyl)-1h-tetrazol-5-yl]thio]methyl]ceph-3-em-4-carboxylic acid; 7beta-(2-amino-1,3-thiazol-4-yl)acetamido-3-[({1-[2-(dimethylamino)ethyl]-1H-tetrazol-5-yl}sulfanyl)methyl]-3,4-didehydrocepham-4-carboxylic acid DMF5HU6 CP Takeda DMF5HU6 TC Antibiotics DMF5HU6 DT Small molecular drug DMF5HU6 PC 43708 DMF5HU6 MW 525.6 DMF5HU6 FM C18H23N9O4S3 DMF5HU6 IC InChI=1S/C18H23N9O4S3/c1-25(2)3-4-26-18(22-23-24-26)34-7-9-6-32-15-12(14(29)27(15)13(9)16(30)31)21-11(28)5-10-8-33-17(19)20-10/h8,12,15H,3-7H2,1-2H3,(H2,19,20)(H,21,28)(H,30,31)/t12-,15-/m1/s1 DMF5HU6 CS CN(C)CCN1C(=NN=N1)SCC2=C(N3[C@@H]([C@@H](C3=O)NC(=O)CC4=CSC(=N4)N)SC2)C(=O)O DMF5HU6 IK QYQDKDWGWDOFFU-IUODEOHRSA-N DMF5HU6 IU (6R,7R)-7-[[2-(2-amino-1,3-thiazol-4-yl)acetyl]amino]-3-[[1-[2-(dimethylamino)ethyl]tetrazol-5-yl]sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid DMF5HU6 CA CAS 61622-34-2 DMF5HU6 CB CHEBI:355510 DMF5HU6 DE Respiratory tract infection DMY8NC4 ID DMY8NC4 DMY8NC4 DN Cefoxitin DMY8NC4 HS Approved DMY8NC4 SN Cefoxitina; Cefoxitine; Cefoxitinum; Cefoxotin; Cenomycin; Mefoxin; Mefoxitin; Rephoxitin; cefoxitin; ceftoxitin; 35607-66-0; CEPHOXITIN; 4kow; 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 3-[[(aminocarbonyl)oxy]methyl]-7-methoxy-8-oxo-7-[(2-thienylacetyl)amino]-, (6R,7S)-; 6OEV9DX57Y; AK118716; CAS-35607-66-0; CFX; CHEBI:209807; CHEMBL996; DSSTox_CID_2764; DSSTox_GSID_22764; DSSTox_RID_76721; NCGC00183034-01; UNII-6OEV9DX57Y DMY8NC4 PC 441199 DMY8NC4 MW 427.5 DMY8NC4 FM C16H17N3O7S2 DMY8NC4 IC WZOZEZRFJCJXNZ-ZBFHGGJFSA-N DMY8NC4 CS COC1(C2N(C1=O)C(=C(CS2)COC(=O)N)C(=O)O)NC(=O)CC3=CC=CS3 DMY8NC4 IK 1S/C16H17N3O7S2/c1-25-16(18-10(20)5-9-3-2-4-27-9)13(23)19-11(12(21)22)8(6-26-15(17)24)7-28-14(16)19/h2-4,14H,5-7H2,1H3,(H2,17,24)(H,18,20)(H,21,22)/t14-,16+/m1/s1 DMY8NC4 IU (6R,7S)-3-(carbamoyloxymethyl)-7-methoxy-8-oxo-7-[(2-thiophen-2-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid DMY8NC4 CA CAS 35607-66-0 DMY8NC4 CB CHEBI:209807 DMY8NC4 DE Peritonitis DMYTXVR ID DMYTXVR DMYTXVR DN Cefoxitin DMYTXVR HS Approved DMYTXVR SN Mefoxin; Mefoxitin; CEFOXITIN SODIUM; Cefoxitin sodium salt; Mefoxin (TN); Cefoxitin (USAN/INN); Cefoxitin sodium (JAN/USP); (6R,7S)-3-(carbamoyloxymethyl)-7-methoxy-8-oxo-7-[(2-thiophen-2-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; (6R,7S)-3-(carbamoyloxymethyl)-7-methoxy-8-oxo-7-[(2-thiophen-2-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7S)-3-[(carbamoyloxy)methyl]-7-methoxy-8-oxo-7-[(2-thienylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; (6R,7S)-3-{[(aminocarbonyl)oxy]methyl}-7-(methyloxy)-8-oxo-7-[(2-thienylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 3-[(carbamoyloxy)methyl]-7alpha-methoxy-7beta-[(2-thienylacetyl)amino]-3,4-didehydrocepham-4-carboxylate; 3-[(carbamoyloxy)methyl]-7alpha-methoxy-7beta-[(thiophen-2-yl)acetamido]-3,4-didehydrocepham-4-carboxylic acid DMYTXVR CP Merck & Co DMYTXVR TC Antibiotics DMYTXVR DT Small molecular drug DMYTXVR PC 441199 DMYTXVR MW 427.5 DMYTXVR FM C16H17N3O7S2 DMYTXVR IC InChI=1S/C16H17N3O7S2/c1-25-16(18-10(20)5-9-3-2-4-27-9)13(23)19-11(12(21)22)8(6-26-15(17)24)7-28-14(16)19/h2-4,14H,5-7H2,1H3,(H2,17,24)(H,18,20)(H,21,22)/t14-,16+/m1/s1 DMYTXVR CS CO[C@@]1([C@@H]2N(C1=O)C(=C(CS2)COC(=O)N)C(=O)O)NC(=O)CC3=CC=CS3 DMYTXVR IK WZOZEZRFJCJXNZ-ZBFHGGJFSA-N DMYTXVR IU (6R,7S)-3-(carbamoyloxymethyl)-7-methoxy-8-oxo-7-[(2-thiophen-2-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid DMYTXVR CA CAS 35607-66-0 DMYTXVR CB CHEBI:209807 DMYTXVR DE Bacterial infection DMKBTFG ID DMKBTFG DMKBTFG DN Cefozopran DMKBTFG HS Approved DMKBTFG SN CZOP; Cefozopran [INN]; SCE 2787; Cefozopran (INN); (-)-1-(((6R,7R)-7-(2-(5-Amino-1,2,4-thiadiazol-3-yl)glyoxylamido)-2-carboxy-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-1H-imidazo(1,2-b)pyridazin-4-ium hydroxide inner salt, 7(sup 2)-(Z)-(O-methyloxime); Imidazo(1,2-b)pyridazinium, 1-((6R,7R)-7-(((2Z)-(5-amino-1,2,4-thiadiazol-3-yl)(methoxyimino)acetyl)amino)-2-carboxy-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-, inner salt DMKBTFG CP Takeda DMKBTFG DT Small molecular drug DMKBTFG PC 9571080 DMKBTFG MW 515.5 DMKBTFG FM C19H17N9O5S2 DMKBTFG IC InChI=1S/C19H17N9O5S2/c1-33-24-11(14-23-19(20)35-25-14)15(29)22-12-16(30)28-13(18(31)32)9(8-34-17(12)28)7-26-5-6-27-10(26)3-2-4-21-27/h2-6,12,17H,7-8H2,1H3,(H3-,20,22,23,25,29,31,32)/b24-11-/t12-,17-/m1/s1 DMKBTFG CS CO/N=C(/C1=NSC(=N1)N)\\C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C[N+]4=C5C=CC=NN5C=C4)C(=O)[O-] DMKBTFG IK QDUIJCOKQCCXQY-WHJQOFBOSA-N DMKBTFG IU (6R,7R)-7-[[(2Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-methoxyiminoacetyl]amino]-3-(imidazo[1,2-b]pyridazin-1-ium-1-ylmethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate DMKBTFG CA CAS 113359-04-9 DMKBTFG CB CHEBI:3502 DMKBTFG DE Gram-positive bacterial infection DMZ2WL4 ID DMZ2WL4 DMZ2WL4 DN Cefpiramide DMZ2WL4 HS Approved DMZ2WL4 SN Cefpiramido; Cefpiramidum; WY 44635; Cefpiramide [USAN:INN]; Cefpiramido [INN-Spanish]; Cefpiramidum [INN-Latin]; WY44,635; Cefpiramide (USP/INN); (6R)-7-[[(2R)-2-(4-hydroxyphenyl)-2-[(6-methyl-4-oxo-1H-pyridine-3-carbonyl)amino]acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-((R)-2-(4-Hydroxy-6-methylnicotinamido)-2-(p-hydroxyphe-nyl)acetamido)-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[(2R)-2-(4-hydroxyphenyl)-2-[(6-methyl-4-oxo-1H-pyridine-3-carbonyl)amino]acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[2-(4-hydroxyphenyl)-2-[(6-methyl-4-oxo-1H-pyridine-3-carbonyl)amino]acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2R)-2-{[(4-hydroxy-6-methylpyridin-3-yl)carbonyl]amino}-2-(4-hydroxyphenyl)acetyl]amino}-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6r)-7-{[(2r)-2-(4-hydroxyphenyl)-2-{[(6-methyl-4-oxo-1,4-dihydropyridin-3-yl)carbonyl]amino}acetyl]amino}-3-{[(1-methyl-1h-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7-[[2-(4-hydroxyphenyl)-2-[(6-methyl-4-oxo-1H-pyridine-3-carbonyl)amino]acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7beta-[(2R)-2-{[(4-hydroxy-6-methylpyridin-3-yl)carbonyl]amino}-2-(4-hydroxyphenyl)acetamido]-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}-3,4-didehydrocepham-4-carboxylic acid DMZ2WL4 CP Wyeth Ayerst Laboratories DMZ2WL4 TC Antibiotics DMZ2WL4 DT Small molecular drug DMZ2WL4 PC 636405 DMZ2WL4 MW 612.6 DMZ2WL4 FM C25H24N8O7S2 DMZ2WL4 IC InChI=1S/C25H24N8O7S2/c1-11-7-16(35)15(8-26-11)20(36)27-17(12-3-5-14(34)6-4-12)21(37)28-18-22(38)33-19(24(39)40)13(9-41-23(18)33)10-42-25-29-30-31-32(25)2/h3-8,17-18,23,34H,9-10H2,1-2H3,(H,26,35)(H,27,36)(H,28,37)(H,39,40)/t17-,18-,23-/m1/s1 DMZ2WL4 CS CC1=CC(=O)C(=CN1)C(=O)N[C@H](C2=CC=C(C=C2)O)C(=O)N[C@H]3[C@@H]4N(C3=O)C(=C(CS4)CSC5=NN=NN5C)C(=O)O DMZ2WL4 IK PWAUCHMQEXVFJR-PMAPCBKXSA-N DMZ2WL4 IU (6R,7R)-7-[[(2R)-2-(4-hydroxyphenyl)-2-[(6-methyl-4-oxo-1H-pyridine-3-carbonyl)amino]acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid DMZ2WL4 CA CAS 70797-11-4 DMZ2WL4 CB CHEBI:59213 DMZ2WL4 DE Bacterial infection DMJUNY5 ID DMJUNY5 DMJUNY5 DN Cefpodoxime DMJUNY5 HS Approved DMJUNY5 SN CPDX; Cefpodoxima; Cefpodoximum; Epoxim; Cefpodoxim acid; Cefpodoxima [Spanish]; Cefpodoximum [Latin]; RU 51807; Cefpodoxime (INN); Cefpodoxime [INN:BAN]; Epoxim (TN); Vantin (TN); (6R,7R)-7-({(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(methyloxy)imino]acetyl}amino)-3-[(methyloxy)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[(2E)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-(methoxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-(methoxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7-{[(2-amino-1,3-thiazol-4-yl)(methoxyimino)acetyl]amino}-3-(methoxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid DMJUNY5 CP Pfizer Pharmaceuticals DMJUNY5 TC Antibiotics DMJUNY5 DT Small molecular drug DMJUNY5 PC 6335986 DMJUNY5 MW 427.5 DMJUNY5 FM C15H17N5O6S2 DMJUNY5 IC InChI=1S/C15H17N5O6S2/c1-25-3-6-4-27-13-9(12(22)20(13)10(6)14(23)24)18-11(21)8(19-26-2)7-5-28-15(16)17-7/h5,9,13H,3-4H2,1-2H3,(H2,16,17)(H,18,21)(H,23,24)/b19-8-/t9-,13-/m1/s1 DMJUNY5 CS COCC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)/C(=N\\OC)/C3=CSC(=N3)N)SC1)C(=O)O DMJUNY5 IK WYUSVOMTXWRGEK-HBWVYFAYSA-N DMJUNY5 IU (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-(methoxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid DMJUNY5 CA CAS 80210-62-4 DMJUNY5 CB CHEBI:3504 DMJUNY5 DE Bacterial infection DM7DSYP ID DM7DSYP DM7DSYP DN Cefprozil DM7DSYP HS Approved DM7DSYP SN Arzimol; Brisoral; Cefprozilo; Cefprozilum; Cefzil; Cronocef; Procef; Serozil; Cefprozil anhydrous; BMY 28100; Cefprozil (INN); Cefprozil (TN); Cefprozilo [INN-Spanish]; Cefprozilum [INN-Latin]; Cefzil (TN); Procef (TN); (6R,7R)-7-[[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino]-8-oxo-3-[(E)-prop-1-enyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino}-8-oxo-3-(prop-1-en-1-yl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid DM7DSYP CP Bristol-Myers Squibb DM7DSYP TC Antibiotics DM7DSYP DT Small molecular drug DM7DSYP PC 5281006 DM7DSYP MW 389.4 DM7DSYP FM C18H19N3O5S DM7DSYP IC InChI=1S/C18H19N3O5S/c1-2-3-10-8-27-17-13(16(24)21(17)14(10)18(25)26)20-15(23)12(19)9-4-6-11(22)7-5-9/h2-7,12-13,17,22H,8,19H2,1H3,(H,20,23)(H,25,26)/b3-2+/t12-,13-,17-/m1/s1 DM7DSYP CS C/C=C/C1=C(N2[C@@H]([C@@H](C2=O)NC(=O)[C@@H](C3=CC=C(C=C3)O)N)SC1)C(=O)O DM7DSYP IK WDLWHQDACQUCJR-ZAMMOSSLSA-N DM7DSYP IU (6R,7R)-7-[[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino]-8-oxo-3-[(E)-prop-1-enyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid DM7DSYP CA CAS 92676-86-3 DM7DSYP CB CHEBI:3506 DM7DSYP DE Bacterial infection DMUNSWV ID DMUNSWV DMUNSWV DN Cefradine DMUNSWV HS Approved DMUNSWV SN Anspor; Cefradin; Cefradina; Cefradinum; Cephradin; Cephradine; Eskacef; Sefril; Velosef; CEPHRADINE SODIUM; SKF D 39304; SQ 11436; VELOSEF 125; VELOSEF 250; VELOSEF 500; Anspor (TN); Cefradina [INN-Spanish]; Cefradinum [INN-Latin]; Cephradine (USP); Cephradine (anhydrous); Cephradine [USAN:BAN]; SQ-11436; SQ-22022; Velosef (TN); Cefradine (JAN/INN); SK&F D-39304; SK-D-39304; (6R,7R)-7-((R)-2-Amino-2-(1,4-cyclohexadien-1-yl)acetamido)-3-methyl-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[(2R)-2-amino-2-cyclohexa-1,4-dien-1-ylacetyl]amino]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2R)-2-amino-2-cyclohexa-1,4-dien-1-ylacetyl]amino}-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7-(D-2-Amino-2-(1,4-cyclohexadien-1-yl)acetamido)-3-methyl-8-oxo-5-thia-1-azabicyclo(4.2.0)-oct-2-ene-2-caboxylic acid; 7-(D-2-Amino-2-(1,4-cyclohexadienyl)acetamide)desacetoxycephalosporanicacid; 7beta-[(2R)-2-(cyclohexa-1,4-dienyl)-2-phenylacetamido]-3-methyl-3,4-didehydrocepham-4-carboxylic acid DMUNSWV CP Kent Pharms DMUNSWV TC Antibiotics DMUNSWV DT Small molecular drug DMUNSWV PC 38103 DMUNSWV MW 349.4 DMUNSWV FM C16H19N3O4S DMUNSWV IC InChI=1S/C16H19N3O4S/c1-8-7-24-15-11(14(21)19(15)12(8)16(22)23)18-13(20)10(17)9-5-3-2-4-6-9/h2-3,6,10-11,15H,4-5,7,17H2,1H3,(H,18,20)(H,22,23)/t10-,11-,15-/m1/s1 DMUNSWV CS CC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)[C@@H](C3=CCC=CC3)N)SC1)C(=O)O DMUNSWV IK RDLPVSKMFDYCOR-UEKVPHQBSA-N DMUNSWV IU (6R,7R)-7-[[(2R)-2-amino-2-cyclohexa-1,4-dien-1-ylacetyl]amino]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid DMUNSWV CA CAS 38821-53-3 DMUNSWV CB CHEBI:3547 DMUNSWV DE Bacterial infection DMQXLF3 ID DMQXLF3 DMQXLF3 DN Cefsulodin DMQXLF3 HS Approved DMQXLF3 SN cefsulodin; (6R,7R)-3-{[4-(aminocarbonyl)pyridinium-1-yl]methyl}-8-oxo-7-{[phenyl(sulfo)acetyl]amino}-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; AC1NR4MP; SCHEMBL65524; DTXSID6022769; Cefsulodin free acid (SCE-129), Antibiotic for Culture Media Use Only DMQXLF3 DT Small molecular drug DMQXLF3 PC 656575 DMQXLF3 MW 532.6 DMQXLF3 FM C22H20N4O8S2 DMQXLF3 IC InChI=1S/C22H20N4O8S2/c23-18(27)13-6-8-25(9-7-13)10-14-11-35-21-15(20(29)26(21)16(14)22(30)31)24-19(28)17(36(32,33)34)12-4-2-1-3-5-12/h1-9,15,17,21H,10-11H2,(H4-,23,24,27,28,30,31,32,33,34)/t15-,17-,21-/m1/s1 DMQXLF3 CS C1C(=C(N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)S(=O)(=O)O)C(=O)[O-])C[N+]4=CC=C(C=C4)C(=O)N DMQXLF3 IK SYLKGLMBLAAGSC-QLVMHMETSA-N DMQXLF3 IU (6R,7R)-3-[(4-carbamoylpyridin-1-ium-1-yl)methyl]-8-oxo-7-[[(2R)-2-phenyl-2-sulfoacetyl]amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate DMQXLF3 CA CAS 62587-73-9 DMQXLF3 CB CHEBI:3507 DMQXLF3 DE Pseudomonas infection DM41GRA ID DM41GRA DM41GRA DN Ceftazidime DM41GRA HS Approved DM41GRA SN Ceftazidima; Ceftazidimum; Ceptaz; Fortaz; Ceftazidime Sodium In Plastic Container; Ceftazidime anhydrous; Ceftazidime pentahydrate; Fortaz In Plastic Container; SN 401; CEFTAZIDIME (ARGININE FORMULATION); Ceftazidima [INN-Spanish]; Ceftazidime (INN); Ceftazidime (TN); Ceftazidimum [INN-Latin]; Cefzim (TN); Ceptaz (TN); Fortaz (TN); Fortum (TN); (6R,7R)-7-({(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(1-carboxy-1-methylethoxy)imino]acetyl}amino)-8-oxo-3-(pyridinium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; (6R,7R)-7-[[(2E)-2-(2-amino-1,3-thiazol-4-yl)-2-(1-hydroxy-2-methyl-1-oxopropan-2-yl)oxyiminoacetyl]amino]-8-oxo-3-(pyridin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(1-hydroxy-2-methyl-1-oxopropan-2-yl)oxyiminoacetyl]amino]-8-oxo-3-(pyridin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; (6R,7R)-7-[[2-(2-amino-1,3-thiazol-4-yl)-2-(1-hydroxy-2-methyl-1-oxopropan-2-yl)oxyiminoacetyl]amino]-8-oxo-3-(pyridin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; (6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-{[(2-carboxypropan-2-yl)oxy]imino}acetyl]amino}-8-oxo-3-(pyridinium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; 7-[[2-(2-amino-1,3-thiazol-4-yl)-2-(1-hydroxy-2-methyl-1-oxopropan-2-yl)oxyiminoacetyl]amino]-8-oxo-3-(pyridin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; 7beta-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-{[(2-carboxypropan-2-yl)oxy]imino}acetyl]amino}-3-(pyridinium-1-ylmethyl)-3,4-didehydrocepham-4-carboxylate DM41GRA CP GlaxoSmithKline DM41GRA TC Antibiotics DM41GRA DT Small molecular drug DM41GRA PC 5481173 DM41GRA MW 546.6 DM41GRA FM C22H22N6O7S2 DM41GRA IC InChI=1S/C22H22N6O7S2/c1-22(2,20(33)34)35-26-13(12-10-37-21(23)24-12)16(29)25-14-17(30)28-15(19(31)32)11(9-36-18(14)28)8-27-6-4-3-5-7-27/h3-7,10,14,18H,8-9H2,1-2H3,(H4-,23,24,25,29,31,32,33,34)/b26-13-/t14-,18-/m1/s1 DM41GRA CS CC(C)(C(=O)O)O/N=C(/C1=CSC(=N1)N)\\C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C[N+]4=CC=CC=C4)C(=O)[O-] DM41GRA IK ORFOPKXBNMVMKC-DWVKKRMSSA-N DM41GRA IU (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2-carboxypropan-2-yloxyimino)acetyl]amino]-8-oxo-3-(pyridin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate DM41GRA CA CAS 72558-82-8 DM41GRA CB CHEBI:3508 DM41GRA DE Bacterial infection DMWV2AG ID DMWV2AG DMWV2AG DN Ceftibuten DMWV2AG HS Approved DMWV2AG SN CETB; Cedax; Ceftem; Ceftibutene; Ceftibuteno; Ceftibutenum; Cephem; Ceprifran; Isocef; Keimax; Antibiotic 7432S; S 7432; Sch 39720; Cedax (TN); Ceftibutene [INN-French]; Ceftibuteno [INN-Spanish]; Ceftibutenum [INN-Latin]; Cephalosporin 7432-S; Cis-Ceftibutin; Cis-ceftibuten; Sch-39720; Trans-Ceftibuten; Ceftibuten(USAN/INN); Ceftibuten [USAN:INN:BAN]; (+)-(6R,7R)-7-((Z)-2-(2-Amino-4-thiazolyl)-4-carboxycrotonamido)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[(E)-2-(2-amino-1,3-thiazol-4-yl)-5-hydroxy-5-oxopent-2-enoyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[(Z)-2-(2-amino-1,3-thiazol-4-yl)-5-hydroxy-5-oxopent-2-enoyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[2-(2-amino-1,3-thiazol-4-yl)-5-hydroxy-5-oxopent-2-enoyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-4-carboxybut-2-enoyl]amino}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7-[[(E)-2-(2-amino-1,3-thiazol-4-yl)-5-hydroxy-5-oxopent-2-enoyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7-[[(Z)-2-(2-amino-1,3-thiazol-4-yl)-5-hydroxy-5-oxopent-2-enoyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7-[[2-(2-amino-1,3-thiazol-4-yl)-5-hydroxy-5-oxopent-2-enoyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7432-S; 7beta-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-4-carboxybut-2-enoyl]amino}-3,4-didehydrocepham-4-carboxylic acid DMWV2AG CP Shionogi USA DMWV2AG TC Antibiotics DMWV2AG DT Small molecular drug DMWV2AG PC 5282242 DMWV2AG MW 410.4 DMWV2AG FM C15H14N4O6S2 DMWV2AG IC InChI=1S/C15H14N4O6S2/c16-15-17-7(5-27-15)6(1-2-9(20)21)11(22)18-10-12(23)19-8(14(24)25)3-4-26-13(10)19/h1,3,5,10,13H,2,4H2,(H2,16,17)(H,18,22)(H,20,21)(H,24,25)/b6-1-/t10-,13-/m1/s1 DMWV2AG CS C1C=C(N2[C@H](S1)[C@@H](C2=O)NC(=O)/C(=C\\CC(=O)O)/C3=CSC(=N3)N)C(=O)O DMWV2AG IK UNJFKXSSGBWRBZ-BJCIPQKHSA-N DMWV2AG IU (6R,7R)-7-[[(Z)-2-(2-amino-1,3-thiazol-4-yl)-4-carboxybut-2-enoyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid DMWV2AG CA CAS 97519-39-6 DMWV2AG CB CHEBI:3510 DMWV2AG DE Chronic bronchitis DMR2SOZ ID DMR2SOZ DMR2SOZ DN Ceftiofur DMR2SOZ HS Approved DMR2SOZ SN Excede (TN) DMR2SOZ CP Pfizer DMR2SOZ DT Small molecular drug DMR2SOZ PC 6328657 DMR2SOZ MW 523.6 DMR2SOZ FM C19H17N5O7S3 DMR2SOZ IC InChI=1S/C19H17N5O7S3/c1-30-23-11(9-7-34-19(20)21-9)14(25)22-12-15(26)24-13(17(27)28)8(5-32-16(12)24)6-33-18(29)10-3-2-4-31-10/h2-4,7,12,16H,5-6H2,1H3,(H2,20,21)(H,22,25)(H,27,28)/b23-11-/t12-,16-/m1/s1 DMR2SOZ CS CO/N=C(/C1=CSC(=N1)N)\\C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)CSC(=O)C4=CC=CO4)C(=O)O DMR2SOZ IK ZBHXIWJRIFEVQY-IHMPYVIRSA-N DMR2SOZ IU (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-(furan-2-carbonylsulfanylmethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid DMR2SOZ CA CAS 80370-57-6 DMR2SOZ DE Bacterial infection DM3VOGS ID DM3VOGS DM3VOGS DN Ceftizoxime DM3VOGS HS Approved DM3VOGS SN Ceftix; Ceftizoxima; Ceftizoximum; Eposerin; Ceftizoxime Monosodium Salt; FK749; FR 13749; Cefizox (TN); Ceftizoxima[INN-Spanish]; Ceftizoxime (INN); Ceftizoxime [INN:BAN]; Ceftizoximum [INN-Latin]; FK-749; FR-13479; FR-13749; SKF-88373; SK&F 88373-2; Syn-7-(2-(2-Amino-4-thiazolyl)-2-methoxyiminoacetamido)-3-cephem-4-carboxylic acid; (6R,7R)-7-(2-(2-Amino-4-thiazolyl)-2Z-(methoxyimino)acetamido)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-2-carbonsaeure; (6R,7R)-7-(2-(2-Amino-4-thiazolyl)glyoxyamido)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-carbonsaeure-7-(Z)-(O-methyloxim); (6R,7R)-7-({(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(methyloxy)imino]acetyl}amino)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7beta-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-2,3-didehydropenam-2-carboxylic acid DM3VOGS CP Fujisawa Pharmaceutical Co DM3VOGS TC Antibiotics DM3VOGS DT Small molecular drug DM3VOGS PC 6533629 DM3VOGS MW 383.4 DM3VOGS FM C13H13N5O5S2 DM3VOGS IC InChI=1S/C13H13N5O5S2/c1-23-17-7(5-4-25-13(14)15-5)9(19)16-8-10(20)18-6(12(21)22)2-3-24-11(8)18/h2,4,8,11H,3H2,1H3,(H2,14,15)(H,16,19)(H,21,22)/b17-7-/t8-,11-/m1/s1 DM3VOGS CS CO/N=C(/C1=CSC(=N1)N)\\C(=O)N[C@H]2[C@@H]3N(C2=O)C(=CCS3)C(=O)O DM3VOGS IK NNULBSISHYWZJU-LLKWHZGFSA-N DM3VOGS IU (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid DM3VOGS CA CAS 68401-81-0 DM3VOGS CB CHEBI:553473 DM3VOGS DE Bacterial infection DM9QWAH ID DM9QWAH DM9QWAH DN Ceftolozane/tazobactam DM9QWAH HS Approved DM9QWAH SN CXA-101/tazobactam; CXA-201; Tazobactam/ceftolozane; Tazobactam/CXA-101; Zerbaxa DM9QWAH TC Antiinfective Agents DM9QWAH DE Discovery agent DMCEW64 ID DMCEW64 DMCEW64 DN Ceftriaxone DMCEW64 HS Approved DMCEW64 SN Biotrakson; CTRX; Cefatriaxone; Ceftriaxon; Ceftriaxona; Ceftriaxonum; Ceftriazone; Longacef; Longaceph; Rocefin; Rocephin; Rocephine; CEFTRIAXONE SODIUM; Ceftriaxone intravenous; Ro 139904; Ceftriaxona [INN-Spanish]; Ceftriaxone (INN); Ceftriaxone (TN); Ceftriaxone [USAN:JAN]; Ceftriaxone, Disodium Salt; Ceftriaxonum [INN-Latin]; DRG-0071; Ro13-9904; Rocephin (TN); Ceftriaxone, Disodium Salt, Hemiheptahydrate; Ro-13-9904; (6R,7R)-7-(2-(2-Amino-4-thiazolyl)glyoxylamido)-8-oxo-3-(((1,2,5,6-tetrahydro-2-methyl-5,6-dioxo-as-triazin-3-yl)thio)methyl)-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7(sup 2)-(Z)-(O-methyloxime), sesquaterhydrate; (6R,7R)-7-({(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(methyloxy)imino]acetyl}amino)-3-{[(6-hydroxy-2-methyl-5-oxo-2,5-dihydro-1,2,4-triazin-3-yl)thio]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(2-methyl-5,6-dioxo-1H-1,2,4-triazin-3-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-{[(2-methyl-5,6-dioxo-1,2,5,6-tetrahydro-1,2,4-triazin-3-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7beta-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-{[(2-methyl-5,6-dioxo-1,2,5,6-tetrahydro-1,2,4-triazin-3-yl)sulfanyl]methyl}-3,4-didehydrocepham-4-carboxylic acid DMCEW64 CP Hoffmann-La Roche pharmaceutical company DMCEW64 TC Antibiotics DMCEW64 DT Small molecular drug DMCEW64 PC 5479530 DMCEW64 MW 554.6 DMCEW64 FM C18H18N8O7S3 DMCEW64 IC InChI=1S/C18H18N8O7S3/c1-25-18(22-12(28)13(29)23-25)36-4-6-3-34-15-9(14(30)26(15)10(6)16(31)32)21-11(27)8(24-33-2)7-5-35-17(19)20-7/h5,9,15H,3-4H2,1-2H3,(H2,19,20)(H,21,27)(H,23,29)(H,31,32)/b24-8-/t9-,15-/m1/s1 DMCEW64 CS CN1C(=NC(=O)C(=O)N1)SCC2=C(N3[C@@H]([C@@H](C3=O)NC(=O)/C(=N\\OC)/C4=CSC(=N4)N)SC2)C(=O)O DMCEW64 IK VAAUVRVFOQPIGI-SPQHTLEESA-N DMCEW64 IU (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(2-methyl-5,6-dioxo-1H-1,2,4-triazin-3-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid DMCEW64 CA CAS 73384-59-5 DMCEW64 CB CHEBI:29007 DMCEW64 DE Bacterial infection DMSIMD8 ID DMSIMD8 DMSIMD8 DN Cefuroxime DMSIMD8 HS Approved DMSIMD8 SN Anaptivan; Biociclin; Biofuroksym; Bioxima; CXM; Cefofix; Cefumax; Cefurex; Cefuril; Cefuroxim; Cefuroximesodium; Cefuroximine; Cefuroximo; Cefuroximum; Cephuroxime; Cetroxil; Colifossim; Curocef; Curoxim; Curoxima; Curoxime; Froxal; Furoxil; Kesint; Ketocef; Lifurox; Medoxim; Sharox; Spectrazolr; Ultroxim; Zinacef;CEFUROXIME AND DEXTROSE IN DUPLEX CONTAINER; CEFUROXIME SODIUM; Cefuroxim AJ; Cefuroxim Fresenius; Cefuroxim Genericsn; Cefuroxim Hexal; Cefuroxim Lilly; Cefuroxim MN; Cefuroxim Norcox; Cefuroxim curasan; Cefuroxima Fabra; Cefuroxima Richet; Cefuroxime for Injection and Dextrose for Injection in Duplex Container; Cefuroxime na; Cefuroxime sodium salt; KEFUROX IN PLASTIC CONTAINER; Sodium cefuroxime; ZINACEF IN PLASTIC CONTAINER; Zinacef Danmark; Ceftin (TN); Cefuroxim Norcox [inj.]; Cefuroxime (TN); Cefuroximo [INN-Spanish]; Cefuroximum [INN-Latin]; Cetroxil [inj.]; Froxal [inj.]; KS-1040; Sharox [inj.]; Zinacef (TN); Zinnat (TN); Zinnat [inj.]; Cefuroxime (USAN/INN); Cefuroxime [USAN:INN:BAN]; Cefuroxime sodium (JP15/USP); Cefuroxime sodium [USAN:BAN:JAN]; Sodium (6R-(6alpha,7beta(Z)))-3-(((aminocarbonyl)oxy)methyl)-7-(2-furyl(methoxyimino)acetamido)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylate; Sodium (6R,7R)-7-(2-(2-furyl)glyoxylamido)-3-(hydroxymethyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylate, 7(sup 2)-(Z)-(O-methyloxime), carbamate (ester); (6R,7R)-3-(carbamoyloxymethyl)-7-[[(2Z)-2-(furan-2-yl)-2-methoxyiminoacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-3-[(carbamoyloxy)methyl]-7-[(2Z)-2-(furan-2-yl)-2-(methoxyimino)acetamido]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-3-[(carbamoyloxy)methyl]-7-{[(2Z)-2-furan-2-yl-2-(methoxyimino)acetyl]amino}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-(2-(2-Furyl)glyoxylamido)-3-(hydroxymethyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid 7(sup 2)-(Z)-(O-methyloxime) carbamate (ester); 3-[(carbamoyloxy)methyl]-7beta-[(2Z)-2-(furan-2-yl)-2-(methoxyimino)acetamido]-3,4-didehydrocepham-4-carboxylic acid DMSIMD8 CP GlaxoSmithKline DMSIMD8 TC Antibiotics DMSIMD8 DT Small molecular drug DMSIMD8 PC 5479529 DMSIMD8 MW 424.4 DMSIMD8 FM C16H16N4O8S DMSIMD8 IC InChI=1S/C16H16N4O8S/c1-26-19-9(8-3-2-4-27-8)12(21)18-10-13(22)20-11(15(23)24)7(5-28-16(17)25)6-29-14(10)20/h2-4,10,14H,5-6H2,1H3,(H2,17,25)(H,18,21)(H,23,24)/b19-9-/t10-,14-/m1/s1 DMSIMD8 CS CO/N=C(/C1=CC=CO1)\\C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)COC(=O)N)C(=O)O DMSIMD8 IK JFPVXVDWJQMJEE-IZRZKJBUSA-N DMSIMD8 IU (6R,7R)-3-(carbamoyloxymethyl)-7-[[(2Z)-2-(furan-2-yl)-2-methoxyiminoacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid DMSIMD8 CA CAS 55268-75-2 DMSIMD8 CB CHEBI:3515 DMSIMD8 DE Acute bronchitis DM4CHN0 ID DM4CHN0 DM4CHN0 DN Cefuroxime axetil DM4CHN0 HS Approved DM4CHN0 SN cefuroxime axetil; Ceftin; Zinnat; Elobact; Zinat; Cefuroxime 1-acetoxyethyl ester; Bioracef; CXM-AX; Coliofossim; Furoxime; Cetoxil; Celocid; Cethixim; Nivador; Medoxm; Kalcef; Zoref; Sharox-500; UNII-Z49QDT0J8Z; DRG-0157; SN 407; CCI 15641; CCI-15641; Cepazine; CCI 1564; BRN 6854419; Z49QDT0J8Z; CHEBI:3516; (RS)-1-Hydroxyethyl (6R,7R)-7-(2-(2-furyl)glyoxylamido)-3-(hydroxymethyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylate, 7(sup 2)-(Z)-(O-methyloxime), 1-acetate 3-carbamate; C20H22N4O10S; Cefazine; Altacef DM4CHN0 PC 6321416 DM4CHN0 MW 510.5 DM4CHN0 FM C20H22N4O10S DM4CHN0 IC InChI=1S/C20H22N4O10S/c1-9(25)33-10(2)34-19(28)15-11(7-32-20(21)29)8-35-18-14(17(27)24(15)18)22-16(26)13(23-30-3)12-5-4-6-31-12/h4-6,10,14,18H,7-8H2,1-3H3,(H2,21,29)(H,22,26)/b23-13-/t10?,14-,18-/m1/s1 DM4CHN0 CS CC(OC(=O)C)OC(=O)C1=C(CSC2N1C(=O)C2NC(=O)C(=NOC)C3=CC=CO3)COC(=O)N DM4CHN0 IK KEJCWVGMRLCZQQ-YJBYXUATSA-N DM4CHN0 IU 1-acetyloxyethyl (6R,7R)-3-(carbamoyloxymethyl)-7-[[(2Z)-2-(furan-2-yl)-2-methoxyiminoacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate DM4CHN0 CA CAS 64544-07-6 DM4CHN0 CB CHEBI:3516 DM4CHN0 DE Bacterial infections DM6LOQU ID DM6LOQU DM6LOQU DN Celecoxib DM6LOQU HS Approved DM6LOQU SN CEL; Celebra; Celebrex; Celecox; Celecoxi; Celocoxib; Eurocox; Medicoxib; Onsenal; Solexa; Xilebao; Celecoxib [Old RN]; Celecoxib [USAN]; Pfizer brand of celecoxib; SC 58635; SC58635; YM 177; YM177; AI-525; CEP-33222; Celebra (TN); Celebrex (TN); SC-58635; TPI-336; YM-177; Celebrex, Celebra, Celecoxib; Celecoxib (SC-58635); Celecoxib (JAN/USAN/INN); SC-58553, SC-58635; P-(5-p-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide; Benzenesulfonamide,4-(5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl); 4-(5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide; 4-[5-(4-METHYLPHENYL)-3-(TRIFLUOROMETHYL)-1H-PYRAZOL-1-YL]BENZENESULFONAMIDE; 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1Hpyrazol-1-yl] benzenesulfonamide; 4-[5-(4-methylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide DM6LOQU CP Pfizer DM6LOQU TC Analgesics DM6LOQU DT Small molecular drug DM6LOQU PC 2662 DM6LOQU MW 381.4 DM6LOQU FM C17H14F3N3O2S DM6LOQU IC InChI=1S/C17H14F3N3O2S/c1-11-2-4-12(5-3-11)15-10-16(17(18,19)20)22-23(15)13-6-8-14(9-7-13)26(21,24)25/h2-10H,1H3,(H2,21,24,25) DM6LOQU CS CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F DM6LOQU IK RZEKVGVHFLEQIL-UHFFFAOYSA-N DM6LOQU IU 4-[5-(4-methylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide DM6LOQU CA CAS 169590-42-5 DM6LOQU CB CHEBI:41423 DM6LOQU DE Rheumatoid arthritis; Pain DMD5LBX ID DMD5LBX DMD5LBX DN Celiprolol HCL DMD5LBX HS Approved DMD5LBX SN Selectol (TN) DMD5LBX DT Small molecular drug DMD5LBX PC 42373 DMD5LBX MW 416 DMD5LBX FM C20H34ClN3O4 DMD5LBX IC InChI=1S/C20H33N3O4.ClH/c1-7-23(8-2)19(26)22-15-9-10-18(17(11-15)14(3)24)27-13-16(25)12-21-20(4,5)6;/h9-11,16,21,25H,7-8,12-13H2,1-6H3,(H,22,26);1H DMD5LBX CS CCN(CC)C(=O)NC1=CC(=C(C=C1)OCC(CNC(C)(C)C)O)C(=O)C.Cl DMD5LBX IK VKJHTUVLJYWAEY-UHFFFAOYSA-N DMD5LBX IU 3-[3-acetyl-4-[3-(tert-butylamino)-2-hydroxypropoxy]phenyl]-1,1-diethylurea;hydrochloride DMD5LBX CA CAS 57470-78-7 DMD5LBX CB CHEBI:31385 DMD5LBX DE Hypertension DMYT2FP ID DMYT2FP DMYT2FP DN Cellulose Sodium Phosphate DMYT2FP HS Approved DMYT2FP SN Calcibind DMYT2FP CP Mission Pharmacal Co DMYT2FP DE Hypercalciuria DMTIUFA ID DMTIUFA DMTIUFA DN Celtura DMTIUFA HS Approved DMTIUFA SN A/H1N1v; A/H1N1v vaccine (influenza virus infection), Novartis; H1N1 pandemic influenza A vaccine (MF59-adjuvanted, cell culture), Novartis DMTIUFA CP Novartis AG DMTIUFA DT Vaccine DMTIUFA DE Influenza virus infection DMKMJHE ID DMKMJHE DMKMJHE DN Cemiplimab DMKMJHE HS Approved DMKMJHE SN REGN2810; REGN-2810; REGN 2810 DMKMJHE CP Regeneron/Sanofi DMKMJHE DT Monoclonal antibody DMKMJHE DE Cutaneous squamous cell carcinoma DM8Y2RU ID DM8Y2RU DM8Y2RU DN Cenegermin DM8Y2RU HS Approved DM8Y2RU SN cenegermin; Cenegermin [INN]; UNII-B6E7K36KT8; B6E7K36KT8; Human beta-nerve growth factor (beta-ngf)-(1-118)- peptide (non-covalent dimer) produced in escherichia coli nerve growth factor DM8Y2RU CP Domp DM8Y2RU DT Antibody DM8Y2RU DE Neurotrophic keratitis DMXQS7K ID DMXQS7K DMXQS7K DN Cenestin DMXQS7K HS Approved DMXQS7K SN Sodium equilin sulfate; Equilin sodium sulfate; Climopax; Estratab; 16680-47-0; Sodium equilin 3-monosulfate; Emopremarin; Novoconestron; Climestrone; Promarit; Primarin; Premarose; Premaril; Menotrol; Ganeake; Estropan; Estrifol; Premarina; Palopause; Menogen; Mannest; Hyphorin; Formatrix; Estromed; Equigyne; Prempak; Oestrilin; Menotab; Kestrin; Glyestrin; Estroate; Equilin 3-Sulfate Sodium Salt; Conjugen; Conestron; Ayerogen; Theogen; Sukingpo DMXQS7K CP Duramed Pharmaceuticals Inc DMXQS7K DT Small molecular drug DMXQS7K PC 23676225 DMXQS7K MW 370.4 DMXQS7K FM C18H19NaO5S DMXQS7K IC InChI=1S/C18H20O5S.Na/c1-18-9-8-14-13-5-3-12(23-24(20,21)22)10-11(13)2-4-15(14)16(18)6-7-17(18)19;/h3-5,10,14,16H,2,6-9H2,1H3,(H,20,21,22);/q;+1/p-1/t14-,16+,18+;/m1./s1 DMXQS7K CS C[C@]12CC[C@H]3C(=CCC4=C3C=CC(=C4)OS(=O)(=O)[O-])[C@@H]1CCC2=O.[Na+] DMXQS7K IK QTTMOCOWZLSYSV-QWAPEVOJSA-M DMXQS7K IU sodium;[(9S,13S,14S)-13-methyl-17-oxo-9,11,12,14,15,16-hexahydro-6H-cyclopenta[a]phenanthren-3-yl] sulfate DMXQS7K CA CAS 12126-59-9 DMXQS7K CB CHEBI:32143 DMXQS7K DE Menopause symptom; Osteoporosis DM8KLU9 ID DM8KLU9 DM8KLU9 DN Cenobamate DM8KLU9 HS Approved DM8KLU9 SN Cenobamate; Cenobamate (USAN/INN); Cenobamate [INN]; Cenobamate [USAN:INN]; P85X70RZWS; SCHEMBL1682643; YKP3089; 2H-Tetrazole-2-ethanol, alpha-(2-chlorophenyl)-, 2-carbamate, (alphaR)-; 2H-Tetrazole-2-ethanol, alpha-(2-chlorophenyl)-, carbamate (ester), (alphaR)-; 913088-80-9; CHEMBL3989949; CS-0014686; Carbamic acid (R)-(+)-1-(2-chlorophenyl)-2-(2H-tetrazol-2-yl)ethyl ester; HY-17607; UNII-P85X70RZWS DM8KLU9 PC 11962412 DM8KLU9 MW 267.67 DM8KLU9 FM C10H10ClN5O2 DM8KLU9 IC GFHAXPJGXSQLPT-VIFPVBQESA-N DM8KLU9 CS C1=CC=C(C(=C1)C(CN2N=CN=N2)OC(=O)N)Cl DM8KLU9 IK 1S/C10H10ClN5O2/c11-8-4-2-1-3-7(8)9(18-10(12)17)5-16-14-6-13-15-16/h1-4,6,9H,5H2,(H2,12,17)/t9-/m0/s1 DM8KLU9 IU [(1R)-1-(2-chlorophenyl)-2-(tetrazol-2-yl)ethyl] carbamate DM8KLU9 CA CAS 913088-80-9 DM8KLU9 DE Focal seizure DMGOVHA ID DMGOVHA DMGOVHA DN Cenobamate DMGOVHA HS Approved DMGOVHA SN Xcopri; UNII-P85X70RZWS; 913088-80-9; YKP3089; YKP-3089; P85X70RZWS; [(1R)-1-(2-chlorophenyl)-2-(tetrazol-2-yl)ethyl] Carbamate; (R)-1-(2-chlorophenyl)-2-(2H-tetrazol-2-yl)ethyl carbamate; Cenobamate [INN]; Xcopri (TN); YKP-3089 Cenobamate; Cenobamate (USAN/INN); Cenobamate [USAN:INN]; SCHEMBL1682643; CHEMBL3989949; GTPL10773; EX-A3604; 2H-Tetrazole-2-ethanol, alpha-(2-chlorophenyl)-, 2-carbamate, (alphaR)-; Carbamic acid (R)-(+)-1-(2-chlorophenyl)-2-(2H-tetrazol-2-yl)ethyl ester; DB06119; 2H-Tetrazole-2-ethanol, alpha-(2-chlorophenyl)-, carbamate (ester), (alphaR)-; HY-17607; CS-0014686; D11150; Q27286352 DMGOVHA DT Small molecular drug DMGOVHA PC 11962412 DMGOVHA MW 267.67 DMGOVHA FM C10H10ClN5O2 DMGOVHA IC InChI=1S/C10H10ClN5O2/c11-8-4-2-1-3-7(8)9(18-10(12)17)5-16-14-6-13-15-16/h1-4,6,9H,5H2,(H2,12,17)/t9-/m0/s1 DMGOVHA CS C1=CC=C(C(=C1)[C@H](CN2N=CN=N2)OC(=O)N)Cl DMGOVHA IK GFHAXPJGXSQLPT-VIFPVBQESA-N DMGOVHA IU [(1R)-1-(2-chlorophenyl)-2-(tetrazol-2-yl)ethyl] carbamate DMGOVHA CA CAS 913088-80-9 DMGOVHA DE Complex partial seizure DMD5JU8 ID DMD5JU8 DMD5JU8 DN Cephalexin DMD5JU8 HS Approved DMD5JU8 SN Adcadina; Ades[prex; Alcephin; Alexin; Alsporin; Ambal; Aristosporin; Azabort; Bactopenor; Beliam; Biocef; CEX; Carnosporin; Cefablan; Cefacet; Cefadal; Cefadin; Cefadina; Cefalekey; Cefaleksin; Cefalessina; Cefalexgobens; Cefalexin; Cefalexina; Cefalexine; Cefalexinum; Cefalin; Cefalival; Cefaloto; Cefaseptin; Cefax; Ceffanex; Cefibacter; Ceflax; Ceforal; Cefovit; Celexin; Cepastar; Cepexin; Cephacillin; Cephalexine; Cephalexinum; Cephalobene; Cephanasten; Cephaxin; Cephin; Cepol; Ceporex; Ceporexin; Ceporexine; Check; Cophalexin; Domucef; Doriman; Durantel; Efemida; Erocetin; Factagard; Felexin; Fexin; Ibilex; Ibrexin; Inphalex; Karilexina; Kefalospes; Keflet; Keflex; Kefolan; Keforal; Keftab; Kekrinal; Kidolex; Lafarine; Larixin; Lenocef; Lexibiotico; Loisine; Lonflex; Lopilexin; Losporal; Madlexin; Maksipor; Mamalexin; Mamlexin; Medolexin; Medoxine; Neokef; Neolexina; Noveol; Novolexin; Nufex; Oracef; Oriphex; Oroxin; Ortisporina; Ospexin; Palitrex; Pectril; Prindex; Pyassan; Rilexine; Roceph; Rogevil; Sanaxin; Sartosona; Sencephalin; Sepexin; Servicef; Servispor; Sialexin; Sinthecillin; Sintolexyn; Sporicef; Sporidex; Syncl; Syncle; Synecl; Tepaxin; Theratrex; Tokiolexin; Uphalexin; Viosporine; Voxxim; Winlex; Zabytrex; Zozarine; Cefalessina [DCIT]; Cefalexin Scand Pharm; Cefalexin Sodium; Cefalexin generics; Cefalexin hydrate; Cefalexin monohydrate; Cefalexina Northia; Cefalexina Richet; Cephalex von ct; Cephalexin hydrate; Cephalexin monohydrate; Ceporex Forte; Durantel DS; Henina Oral; Panixine Disperdose; Roceph Distab; Lilly 66873; S 6437; SQ 20248; Cefa-iskia; Cefalexin (JP15); Cefalexin.H2O; Cefalexina [INN-Spanish]; Cefalexine [INN-French]; Cefalexinum [INN-Latin]; Cephalexin(USP); Cephalexin (anhydrous); Cephalexin 1-hydrate; Cephalexin 1-wasser; Cephalexin [USAN:BAN]; Cephalexin.H2O; Ceporexin-E; Cusisporina-Cefalox; Ed A-Ceph; KS-1134; Keflex (TN); Keftab (TN); L-Keflex; Panixine disperdose (TN); Sporidex (TN); Cephalexin, (6R-(6alpha,7beta))-Isomer; 7-(D-2-Amino-2-phenylacetamido)-3-methyl-delta (sup 3)-cephem-4-carboxylic acid; 7-(D-2-Amino-2-phenylacetamido)-3-methyl-delta3-cephem-4-carboxylic acid; 7-(D-alpha-Aminophenylacetamido)desacetoxycephalosporanic acid DMD5JU8 CP Eli Lilly DMD5JU8 TC Antibiotics DMD5JU8 DT Small molecular drug DMD5JU8 PC 27447 DMD5JU8 MW 347.4 DMD5JU8 FM C16H17N3O4S DMD5JU8 IC InChI=1S/C16H17N3O4S/c1-8-7-24-15-11(14(21)19(15)12(8)16(22)23)18-13(20)10(17)9-5-3-2-4-6-9/h2-6,10-11,15H,7,17H2,1H3,(H,18,20)(H,22,23)/t10-,11-,15-/m1/s1 DMD5JU8 CS CC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)N)SC1)C(=O)O DMD5JU8 IK ZAIPMKNFIOOWCQ-UEKVPHQBSA-N DMD5JU8 IU (6R,7R)-7-[[(2R)-2-amino-2-phenylacetyl]amino]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid DMD5JU8 CA CAS 15686-71-2 DMD5JU8 CB CHEBI:3534 DMD5JU8 DE Bacterial infection DMYZITL ID DMYZITL DMYZITL DN Cephaloglycin DMYZITL HS Approved DMYZITL SN CEG; Cefaloglicina; Cefaloglycin; Cefaloglycine; Cefaloglycinum; Cephaloglycine; Kafocin; Kefglycin; Cephaloglycinanhdyous; Cephaloglycin anhydrous; Cephaoglycin acid; Lilly 39435; Cefaloglicina [INN-Spanish]; Cefaloglycin (JAN); Cefaloglycine [INN-French]; Cefaloglycinum [INN-Latin]; Cephaloglycin (anhydrous); D-Cephaloglycine; D-(-)-Cephaloglycin; (6R,7R)-3-(acetoxymethyl)-7-{[(2R)-2-amino-2-phenylacetyl]amino}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-3-(acetyloxymethyl)-7-[[(2R)-2-amino-2-phenylacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-3-[(acetyloxy)methyl]-7-{[(2R)-2-amino-2-phenylacetyl]amino}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 3-((Acetyloxy)methyl)-7-((aminophenylacetyl)amino)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid; 3-acetoxymethyl-7beta-[(2R)-2-amino-2-phenylacetamido]-3,4-didehydrocepham-4-carboxylic acid; 7-(2-Amino-2-phenylacetamido)-3-(hydroxymethyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid acetate (ester); 7-(2-Amino-2-phenylacetamido)-3-(hydroxymethyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)octane-2-carboxylic acid, acetate inner salt; 7-(2-D-alpha-Aminophenylacetamido)cephalosporanic acid; 7-(D-2-Amino-2-phenylacetamido)-3-acetoxymethyl-delta(sup 3)-cephem-4-carboxylic acid; 7-(D-2-Amino-2-phenylacetamido)-3-acetoxymethyl-delta(sup3)-cephem-4-carboxylic acid; 7-(D-alpha-Aminophenyl-acetamido)cephalosporanic acid DMYZITL TC Antibiotics DMYZITL DT Small molecular drug DMYZITL PC 19150 DMYZITL MW 405.4 DMYZITL FM C18H19N3O6S DMYZITL IC InChI=1S/C18H19N3O6S/c1-9(22)27-7-11-8-28-17-13(16(24)21(17)14(11)18(25)26)20-15(23)12(19)10-5-3-2-4-6-10/h2-6,12-13,17H,7-8,19H2,1H3,(H,20,23)(H,25,26)/t12-,13-,17-/m1/s1 DMYZITL CS CC(=O)OCC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)N)SC1)C(=O)O DMYZITL IK FUBBGQLTSCSAON-PBFPGSCMSA-N DMYZITL IU (6R,7R)-3-(acetyloxymethyl)-7-[[(2R)-2-amino-2-phenylacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid DMYZITL CA CAS 3577-01-3 DMYZITL CB CHEBI:34613 DMYZITL DE Bacterial infection DM79XDW ID DM79XDW DM79XDW DN Cephalosporin DM79XDW HS Approved DM79XDW SN Cephalothin (TN) DM79XDW CP Eli Lilly DM79XDW TC Antibiotics DM79XDW DT Small molecular drug DM79XDW PC 25058126 DM79XDW MW 387.4 DM79XDW FM C15H21N3O7S DM79XDW IC InChI=1S/C15H21N3O7S/c1-7-6-26-12(18-10(7)14(22)23)11(15(24)25)17-9(19)5-3-2-4-8(16)13(20)21/h8,11-12H,1-6,16H2,(H,17,19)(H,20,21)(H,22,23)(H,24,25)/t8-,11+,12-/m1/s1 DM79XDW CS C=C1CS[C@@H](N=C1C(=O)O)[C@@H](C(=O)O)NC(=O)CCCC[C@H](C(=O)O)N DM79XDW IK JGKXEMYIHDYWCZ-JFUSQASVSA-N DM79XDW IU (2R)-2-[(R)-[[(6R)-6-amino-6-carboxyhexanoyl]amino]-carboxymethyl]-5-methylidene-2H-1,3-thiazine-4-carboxylic acid DM79XDW DE Bacterial infection DM51Z9E ID DM51Z9E DM51Z9E DN Cephalothin sodium DM51Z9E HS Approved DM51Z9E SN Cephalothin Sodium W/ Dextrose In Plastic Container; Cephalothin Sodium W/ Sodium Chloride In Plastic Container; Keflin In Plastic Container DM51Z9E CP Eli Lilly And Co DM51Z9E TC Antiinfective Agents DM51Z9E DT Small molecular drug DM51Z9E PC 23675321 DM51Z9E MW 418.4 DM51Z9E FM C16H15N2NaO6S2 DM51Z9E IC InChI=1S/C16H16N2O6S2.Na/c1-8(19)24-6-9-7-26-15-12(14(21)18(15)13(9)16(22)23)17-11(20)5-10-3-2-4-25-10;/h2-4,12,15H,5-7H2,1H3,(H,17,20)(H,22,23);/q;+1/p-1/t12-,15-;/m1./s1 DM51Z9E CS CC(=O)OCC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)CC3=CC=CS3)SC1)C(=O)[O-].[Na+] DM51Z9E IK VUFGUVLLDPOSBC-XRZFDKQNSA-M DM51Z9E IU sodium;(6R,7R)-3-(acetyloxymethyl)-8-oxo-7-[(2-thiophen-2-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate DM51Z9E CA CAS 58-71-9 DM51Z9E CB CHEBI:3542 DM51Z9E DE Bacterial infection DMV2JNY ID DMV2JNY DMV2JNY DN Cephapirin DMV2JNY HS Approved DMV2JNY SN CEPR; Cefa; Cefadyl; Cefapirin; Cefapirina; Cefapirine; Cefapirinum; Cefaprin; Cephapirine; Metricure; CEPHAPIRIN SODIUM; Cefaprinsodium; Cephapirin Monosodium Salt; ANTIBIOTIC BL-P1322; BL-P 1322; Cefa-ak; Cefadyl (TN); Cefapirin (BAN); Cefapirin [INN:BAN]; Cefapirina [INN-Spanish]; Cefapirine [INN-French]; Cefapirinum [INN-Latin]; Metricure (TN); (6R,7R)-3-(Acetoxymethyl)-8-oxo-7-(2-(4-pyridylthio)acetamido)-5-thia-1-azabicyclo(4.2.0)oct-2-en-2-carbonsaeure; (6R,7R)-3-(acetyloxymethyl)-8-oxo-7-[(2-pyridin-4-ylsulfanylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-3-[(acetyloxy)methyl]-8-oxo-7-{[(pyridin-4-ylthio)acetyl]amino}-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-3-acetoxymethyl-7-[(pyridin-4-ylsulfanyl)acetamido]-3,4-didehydrocepham-4-carboxylic acid; 3-(Hydroxymethyl)-8-oxo-7-(2-(4-pyridylthio)acetamidol-5-thia-1-azabicyclo(4.2.0)oct-2-en-2carbonsaeure acetat; 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 3-(hydroxymethyl)-8-oxo-7-(2-(4-pyridylthio)acetamido)-, acetate (ester); 7-(2-(4-Pyridylthio)acetamido)cephalosporanic acid DMV2JNY TC Antibiotics DMV2JNY DT Small molecular drug DMV2JNY PC 30699 DMV2JNY MW 423.5 DMV2JNY FM C17H17N3O6S2 DMV2JNY IC InChI=1S/C17H17N3O6S2/c1-9(21)26-6-10-7-28-16-13(15(23)20(16)14(10)17(24)25)19-12(22)8-27-11-2-4-18-5-3-11/h2-5,13,16H,6-8H2,1H3,(H,19,22)(H,24,25)/t13-,16-/m1/s1 DMV2JNY CS CC(=O)OCC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)CSC3=CC=NC=C3)SC1)C(=O)O DMV2JNY IK UQLLWWBDSUHNEB-CZUORRHYSA-N DMV2JNY IU (6R,7R)-3-(acetyloxymethyl)-8-oxo-7-[(2-pyridin-4-ylsulfanylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid DMV2JNY CA CAS 21593-23-7 DMV2JNY CB CHEBI:554446 DMV2JNY DE Sepsis DM9Y5JB ID DM9Y5JB DM9Y5JB DN Cepharanthine DM9Y5JB HS Approved DM9Y5JB SN CEPHARANTHINE; Cepharanthin; (+)-Cepharanthine; O-Methylcepharanoline; Cepharantin; Cepharanthine [JAN]; UNII-7592YJ0J6T; CCRIS 6539; NSC 623442; BRN 0075231; 6',12'-Dimethoxy-2,2'-dimethyl-6,7-(methylenebis(oxy))oxyacanthan; CHEBI:3546; 7592YJ0J6T; NSC623442; Cepharanthine (JAN); NSC-623442; ecaene (non-preferred name); DSSTox_RID_81253; DSSTox_CID_25957; DSSTox_GSID_45957; Oxyacanthan, 6',12'-dimethoxy-2,2'-dimethyl-6,7-(methylenebis(oxy))-; CAS-481-49-2; SR-01000779734; Cepharanthin,(S) DM9Y5JB PC 10206 DM9Y5JB MW 606.7 DM9Y5JB FM C37H38N2O6 DM9Y5JB IC InChI=1S/C37H38N2O6/c1-38-13-11-24-18-31(41-4)33-20-27(24)28(38)16-23-7-10-30(40-3)32(17-23)44-26-8-5-22(6-9-26)15-29-35-25(12-14-39(29)2)19-34-36(37(35)45-33)43-21-42-34/h5-10,17-20,28-29H,11-16,21H2,1-4H3/t28-,29+/m1/s1 DM9Y5JB CS CN1CCC2=CC3=C(C4=C2C1CC5=CC=C(C=C5)OC6=C(C=CC(=C6)CC7C8=CC(=C(C=C8CCN7C)OC)O4)OC)OCO3 DM9Y5JB IK YVPXVXANRNDGTA-WDYNHAJCSA-N DM9Y5JB IU (14S,27R)-22,33-dimethoxy-13,28-dimethyl-2,5,7,20-tetraoxa-13,28-diazaoctacyclo[25.6.2.216,19.13,10.121,25.04,8.031,35.014,39]nonatriaconta-1(33),3(39),4(8),9,16(38),17,19(37),21,23,25(36),31,34-dodecaene DM9Y5JB CA CAS 481-49-2 DM9Y5JB CB CHEBI:3546 DM9Y5JB DE Thrombocytopenia DMB920Z ID DMB920Z DMB920Z DN Ceritinib DMB920Z HS Approved DMB920Z SN ceritinib; LDK378; 1032900-25-6; ZYKADIA; NVP-LDK378-NX; LDK-378; UNII-K418KG2GET; LDK378(Ceritinib); LDK 378; Eritinib (LDK378); 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; K418KG2GET; CHEMBL2403108; CHEBI:78432; AK174337; ceritinib; C28H36ClN5O3S; 5-Chloro-N2-[2-isopropoxy-5-Methyl-4-(4-piperidyl)phenyl]-N4-(2-isopropylsulfonylphenyl)pyriMidine-2,4-diaMine; 5-Chloro-N2-(5-methyl-4-(piperidin-4-yl)-2-(propan-2-yloxy)phenyl)-N4-(2-(propane-2-sulfonyl)phenyl)pyrim DMB920Z DT Small molecular drug DMB920Z PC 57379345 DMB920Z MW 558.1 DMB920Z FM C28H36ClN5O3S DMB920Z IC InChI=1S/C28H36ClN5O3S/c1-17(2)37-25-15-21(20-10-12-30-13-11-20)19(5)14-24(25)33-28-31-16-22(29)27(34-28)32-23-8-6-7-9-26(23)38(35,36)18(3)4/h6-9,14-18,20,30H,10-13H2,1-5H3,(H2,31,32,33,34) DMB920Z CS CC1=CC(=C(C=C1C2CCNCC2)OC(C)C)NC3=NC=C(C(=N3)NC4=CC=CC=C4S(=O)(=O)C(C)C)Cl DMB920Z IK VERWOWGGCGHDQE-UHFFFAOYSA-N DMB920Z IU 5-chloro-2-N-(5-methyl-4-piperidin-4-yl-2-propan-2-yloxyphenyl)-4-N-(2-propan-2-ylsulfonylphenyl)pyrimidine-2,4-diamine DMB920Z CA CAS 1032900-25-6 DMB920Z CB CHEBI:78432 DMB920Z DE Non-small-cell lung cancer DMXCM7H ID DMXCM7H DMXCM7H DN Cerivastatin DMXCM7H HS Approved DMXCM7H SN cerivastatin; Baycol; cerivastatin acid; Lipobay; 145599-86-6; Cerivastatin [INN:BAN]; UNII-AM91H2KS67; CHEBI:3558; AM91H2KS67; HSDB 7357; (3R,5S,6E)-7-(4-(p-Fluorophenyl)-2,6-diisopropyl-5-(methoxymethyl)-3-pyridyl)-3,5-dihydroxy-6-heptenoic acid; (3R,5S,6E)-7-(4-(4-Fluorophenyl)-5-(methoxymethyl)-2,6-bis(1-methylethyl)-3-pyridinyl)-3,5-dihydroxy-6-heptenoic acid; 143201-11-0; 6-Heptenoic acid, 7-(4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-bis(1-methylethyl)-3-pyridinyl)-3,5-dihydroxy-, (3R,5S,6E)-; Statins DMXCM7H DT Small molecular drug DMXCM7H PC 446156 DMXCM7H MW 459.5 DMXCM7H FM C26H34FNO5 DMXCM7H IC InChI=1S/C26H34FNO5/c1-15(2)25-21(11-10-19(29)12-20(30)13-23(31)32)24(17-6-8-18(27)9-7-17)22(14-33-5)26(28-25)16(3)4/h6-11,15-16,19-20,29-30H,12-14H2,1-5H3,(H,31,32)/b11-10+/t19-,20-/m1/s1 DMXCM7H CS CC(C)C1=C(C(=C(C(=N1)C(C)C)COC)C2=CC=C(C=C2)F)/C=C/[C@H](C[C@H](CC(=O)O)O)O DMXCM7H IK SEERZIQQUAZTOL-ANMDKAQQSA-N DMXCM7H IU (E,3R,5S)-7-[4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-di(propan-2-yl)pyridin-3-yl]-3,5-dihydroxyhept-6-enoic acid DMXCM7H CA CAS 145599-86-6 DMXCM7H CB CHEBI:3558 DMXCM7H DE Hyperlipidaemia; Multiple myeloma DM0HAC8 ID DM0HAC8 DM0HAC8 DN Cerliponase Alfa DM0HAC8 HS Approved DM0HAC8 SN Brineura DM0HAC8 CP BioMarin Pharmaceutical DM0HAC8 DT Recombinant protein DM0HAC8 SQ Cerliponase alfa Sequence: SYSPEPDQRRTLPPGWVSLGRADPEEELSLTFALRQQNVERLSELVQAVSDPSSPQYGKYLTLENVADLVRPSPLTLHTVQKWLLAAGAQKCHSVITQDFLTCWLSIRQAELLLPGAEFHHYVGGPTETHVVRSPHPYQLPQALAPHVDFVGGLHRFPPTSSLRQRPEPQVTGTVGLHLGVTPSVIRKRYNLTSQDVGSGTSNNSQACAQFLEQYFHDSDLAQFMRLFGGNFAHQASVARVVGQQGRGRAGIEASLDVQYLMSAGANISTWVYSSPGRHEGQEPFLQWLMLLSNESALPHVHTVSYGDDEDSLSSAYIQRVNTELMKAAARGLTLLFASGDSGAGCWSVSGRHQFRPTFPASSPYVTTVGGTSFQEPFLITNEIVDYISGGGFSNVFPRPSYQEEAVTKFLSSSPHLPPSSYFNASGRAYPDVAALSDGYWVVSNRVPIPWVSGTSASTPVFGGILSLINEHRILSGRPPLGFLNPRLYQQHGAGLFDVTRGCHESCLDEEVEGQGFCSGPGWDPVTGWGTPNFPALLKTLLNP DM0HAC8 DE Tripeptidyl peptidase 1 deficiency; Neuronal ceroid lipofuscinosis DM5CL9Z ID DM5CL9Z DM5CL9Z DN Certolizumab DM5CL9Z HS Approved DM5CL9Z SN CDP-870; Cimzia; PHA-738144; Simziya DM5CL9Z CP UCB DM5CL9Z DT Monoclonal antibody DM5CL9Z DE Rheumatoid arthritis DMUR94J ID DMUR94J DMUR94J DN Certoparin sodium DMUR94J HS Approved DMUR94J SN Alphaparin (TN) DMUR94J DE Deep vein thrombosis DM6N4PR ID DM6N4PR DM6N4PR DN Cerulenin DM6N4PR HS Approved DM6N4PR SN Helicocerin; Cerulenin, Cephalosporium caerulens; Oxiranecarboxamide, 3-(1-oxo-4,7-nonadienyl)-, (2R-(2-alpha,3-alpha(4E,7E)))-(9CI); (2R,3S)-2,3-Epoxy-4-oxo-7E,10E-dodecadienamide; (2R,3S)-3-((4E,7E)-Nona-4,7-dienoyl)-oxirane-2-carboxylic acid amide; (2R,3S)-3-((4E,7E)-nona-4,7-dienoyl)oxirane-2-carboxamide; (2R,3S)-3-[(4E,7E)-nona-4,7-dienoyl]oxirane-2-carboxamide; (2R,3S)-3-nona-4,7-dienoyloxirane-2-carboxamide; (2R,3S,E,E)-2,3-Epoxy-4-oxo-7,10-dodecadienamide; (2R-(2alpha,3alpha(4E,7E)))-3-(1-Oxonona-4,7-dienyl)oxirane-2-carboxamide; (2S)(3R)-2,3-Epoxy-4-oxo-7,10-dodecadienoylamide; (2S,3R)-2,3-epoxy-4-oxy-7,10-dodecadienoylamide; (2r,3s)-3-(nona-4,7-dienoyl)oxirane-2-carboxamide; 2,3-Epoxy-4-oxo-7,10-dodecadienamide; 2,3-Epoxy-4-oxo-7,10-dodecadienoylamide; 3-(1-Oxo-4,7-nonadienyl)oxiranecarboxamide; 3-[(4E,7E)-nona-4,7-dienoyl]oxirane-2-carboxamide; 3-nona-4,7-dienoyloxirane-2-carboxamide DM6N4PR TC Antiinfective Agents DM6N4PR DT Small molecular drug DM6N4PR PC 5282054 DM6N4PR MW 223.27 DM6N4PR FM C12H17NO3 DM6N4PR IC InChI=1S/C12H17NO3/c1-2-3-4-5-6-7-8-9(14)10-11(16-10)12(13)15/h2-3,5-6,10-11H,4,7-8H2,1H3,(H2,13,15)/b3-2+,6-5+/t10-,11-/m1/s1 DM6N4PR CS C/C=C/C/C=C/CCC(=O)[C@@H]1[C@@H](O1)C(=O)N DM6N4PR IK GVEZIHKRYBHEFX-NQQPLRFYSA-N DM6N4PR IU (2R,3S)-3-[(4E,7E)-nona-4,7-dienoyl]oxirane-2-carboxamide DM6N4PR CA CAS 17397-89-6 DM6N4PR CB CHEBI:171741 DM6N4PR DE Weight loss DM2WE5K ID DM2WE5K DM2WE5K DN Ceruletide DM2WE5K HS Approved DM2WE5K SN Caerulein; Cerulein; Ceruletida; Ceruletidum; Ceruletida [INN-Spanish]; Ceruletidum [INN-Latin]; Ceruletide (USAN/INN); Ceruletide [USAN:INN:BAN]; 5-Oxo-L-prolyl-L-glutaminyl-L-alpha-aspartyl-O-sulfo-L-tyrosyl-L-threonylglycyl-L-tryptophyl-L-methionyl-L-alpha-aspartyl-L-phenylalaninamide; 5-Oxo-L-prolyl-L-glutaminyl-L-aspartyl-L-tyrosyl-L-threonylglycyl-L-tryptophyl-L-methionyl-L-aspartylphenyl-L-alaninamide 4-(hydrogen sulfate) (ester); 5-oxo-L-prolyl-L-glutaminyl-L-a-aspartyl-O-sulfo-L-tyrosyl-L-threonylglycyl-L-tryptophyl-L-methionyl-L-a-aspartyl-L-phenylalaninamide DM2WE5K CP Pharmacia And Upjohn Co DM2WE5K TC Diagnostic Agents DM2WE5K DT Small molecular drug DM2WE5K PC 16129675 DM2WE5K MW 1352.4 DM2WE5K FM C58H73N13O21S2 DM2WE5K IC InChI=1S/C58H73N13O21S2/c1-29(72)49(71-57(87)40(23-31-12-14-33(15-13-31)92-94(89,90)91)68-56(86)43(26-48(78)79)69-52(82)37(16-18-44(59)73)65-51(81)36-17-19-45(74)63-36)58(88)62-28-46(75)64-41(24-32-27-61-35-11-7-6-10-34(32)35)54(84)66-38(20-21-93-2)53(83)70-42(25-47(76)77)55(85)67-39(50(60)80)22-30-8-4-3-5-9-30/h3-15,27,29,36-43,49,61,72H,16-26,28H2,1-2H3,(H2,59,73)(H2,60,80)(H,62,88)(H,63,74)(H,64,75)(H,65,81)(H,66,84)(H,67,85)(H,68,86)(H,69,82)(H,70,83)(H,71,87)(H,76,77)(H,78,79)(H,89,90,91)/t29-,36+,37+,38+,39+,40+,41+,42+,43+,49+/m1/s1 DM2WE5K CS C[C@H]([C@@H](C(=O)NCC(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N)NC(=O)[C@H](CC4=CC=C(C=C4)OS(=O)(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@@H]5CCC(=O)N5)O DM2WE5K IK YRALAIOMGQZKOW-HYAOXDFASA-N DM2WE5K IU (3S)-3-[[(2S)-5-amino-5-oxo-2-[[(2S)-5-oxopyrrolidine-2-carbonyl]amino]pentanoyl]amino]-4-[[(2S)-1-[[(2S,3R)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxo-3-(4-sulfooxyphenyl)propan-2-yl]amino]-4-oxobutanoic acid DM2WE5K CA CAS 17650-98-5 DM2WE5K CB CHEBI:59219 DM2WE5K DE Caerulein stimulated gastric and pancreatic secretion; Solid tumour/cancer DMOMP9U ID DMOMP9U DMOMP9U DN Cetirizine DMOMP9U HS Approved DMOMP9U SN Cetiderm; Cetirizin; Cetirizina; Cetirizinum; Cetryn; Setir; Virlix; Ziptek; Zirtek; Zyrlex; Cetirizina [Spanish]; Cetirizinum [Latin]; Cetrizine Hcl; Hitrizin Film Tablet; Cetiderm (TN); Cetirizine (INN); Cetirizine [INN:BAN]; P-071; Reactine (TN); Zyrtec (TN); [(2-{4-[(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl}ethyl)oxy]acetic acid; (2-(4-((4-Chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)acetic acid; (2-{4-[(4-Chloro-phenyl)-phenyl-methyl]-piperazin-1-yl}-ethoxy)-acetic acid; (2-{4-[(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl}ethoxy)acetic acid; 2-(2-{4-[(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl}ethoxy)acetic acid; 2-[2-[4-[(4-chlorophenyl)-phenylmethyl]piperazin-1-yl]ethoxy]acetic acid DMOMP9U CP Pfizer Pharmaceuticals DMOMP9U TC Antiallergic Agents DMOMP9U DT Small molecular drug DMOMP9U PC 2678 DMOMP9U MW 388.9 DMOMP9U FM C21H25ClN2O3 DMOMP9U IC InChI=1S/C21H25ClN2O3/c22-19-8-6-18(7-9-19)21(17-4-2-1-3-5-17)24-12-10-23(11-13-24)14-15-27-16-20(25)26/h1-9,21H,10-16H2,(H,25,26) DMOMP9U CS C1CN(CCN1CCOCC(=O)O)C(C2=CC=CC=C2)C3=CC=C(C=C3)Cl DMOMP9U IK ZKLPARSLTMPFCP-UHFFFAOYSA-N DMOMP9U IU 2-[2-[4-[(4-chlorophenyl)-phenylmethyl]piperazin-1-yl]ethoxy]acetic acid DMOMP9U CA CAS 83881-51-0 DMOMP9U CB CHEBI:3561 DMOMP9U DE Allergic rhinitis DMSP4JX ID DMSP4JX DMSP4JX DN Cetraxate DMSP4JX HS Approved DMSP4JX SN Neuer; NeuerCap; NeuerS; Cetraxate hydrochloride; DV-1006 DMSP4JX CP Daiichi Seiyaku Co Ltd DMSP4JX DT Small molecular drug DMSP4JX PC 2680 DMSP4JX MW 305.4 DMSP4JX FM C17H23NO4 DMSP4JX IC InChI=1S/C17H23NO4/c18-11-13-1-6-14(7-2-13)17(21)22-15-8-3-12(4-9-15)5-10-16(19)20/h3-4,8-9,13-14H,1-2,5-7,10-11,18H2,(H,19,20) DMSP4JX CS C1CC(CCC1CN)C(=O)OC2=CC=C(C=C2)CCC(=O)O DMSP4JX IK FHRSHSOEWXUORL-UHFFFAOYSA-N DMSP4JX IU 3-[4-[4-(aminomethyl)cyclohexanecarbonyl]oxyphenyl]propanoic acid DMSP4JX CA CAS 34675-84-8 DMSP4JX CB CHEBI:17340 DMSP4JX DE Peptic ulcer DMFD9Q6 ID DMFD9Q6 DMFD9Q6 DN Cetrorelix DMFD9Q6 HS Approved DMFD9Q6 SN Cetrorelixum; Cetrorelix (INN); Cetrotide (TN); HS-2008; Ac-D-Nal(2)-D-Phe(pCl)-D-Pal(3)-Ser-Tyr-D-Cit-Leu-Arg-Pro-D-Ala-NH2; N-acetyl-3-(2-naphthyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridyl)-D-alanyl-L-seryl-L-tyrosyl-N5-carbomoyl-D-ornithyl-L-leucyl-L-prolyl-D-alaninamide; N-acetyl-3-(naphthalen-2-yl)-D-alanyl-4-chloro-D-phenylalanyl-3-(pyridin-3-yl)-D-alanyl-L-seryl-L-tyrosyl-N(5)-carbamoyl-D-ornithyl-L-leucyl-L-arginyl-L-prolyl-D-alaninamide DMFD9Q6 CP Merck Serono DMFD9Q6 TC Infertility Agents DMFD9Q6 DT Small molecular drug DMFD9Q6 PC 25074887 DMFD9Q6 MW 1431 DMFD9Q6 FM C70H92ClN17O14 DMFD9Q6 IC InChI=1S/C70H92ClN17O14/c1-39(2)31-52(61(94)82-51(15-9-28-77-69(73)74)68(101)88-30-10-16-58(88)67(100)79-40(3)59(72)92)83-60(93)50(14-8-29-78-70(75)102)81-63(96)54(34-43-20-25-49(91)26-21-43)86-66(99)57(38-89)87-65(98)56(36-45-11-7-27-76-37-45)85-64(97)55(33-42-18-23-48(71)24-19-42)84-62(95)53(80-41(4)90)35-44-17-22-46-12-5-6-13-47(46)32-44/h5-7,11-13,17-27,32,37,39-40,50-58,89,91H,8-10,14-16,28-31,33-36,38H2,1-4H3,(H2,72,92)(H,79,100)(H,80,90)(H,81,96)(H,82,94)(H,83,93)(H,84,95)(H,85,97)(H,86,99)(H,87,98)(H4,73,74,77)(H3,75,78,102)/t40-,50-,51+,52+,53-,54+,55-,56-,57+,58+/m1/s1 DMFD9Q6 CS C[C@H](C(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CCCNC(=O)N)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC3=CN=CC=C3)NC(=O)[C@@H](CC4=CC=C(C=C4)Cl)NC(=O)[C@@H](CC5=CC6=CC=CC=C6C=C5)NC(=O)C DMFD9Q6 IK SBNPWPIBESPSIF-MHWMIDJBSA-N DMFD9Q6 IU (2S)-1-[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-5-(carbamoylamino)pentanoyl]amino]-4-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]-N-[(2R)-1-amino-1-oxopropan-2-yl]pyrrolidine-2-carboxamide DMFD9Q6 CA CAS 120287-85-6 DMFD9Q6 CB CHEBI:59224 DMFD9Q6 DE Ovarian stimulation DMLNCE0 ID DMLNCE0 DMLNCE0 DN Cetuximab DMLNCE0 HS Approved DMLNCE0 SN Erbitux; Cetuximab (genetical recombination); Erbitux (TN); Cetuximab (USAN/INN); Cetuximab (genetical recombination) (JAN); novel EGFR mAb inhibitors DMLNCE0 CP Bristol-Myers Squibb DMLNCE0 TC Anticancer Agents DMLNCE0 DT Antibody DMLNCE0 SQ Cetuximab heavy chain: QVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGVHWVRQSPGKGLEWLGVIWSGGNTDYNTPFTSRLSINKDNSKSQVFFKMNSLQSNDTAIYYCARALTYYDYEFAYWGQGTLVTVSAASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK >Cetuximab light chainDILLTQSPVILSVSPGERVSFSCRASQSIGTNIHWYQQRTNGSPRLLIKYASESISGIPSRFSGSGSGTDFTLSINSVESEDIADYYCQQNNNWPTTFGAGTKLELKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC DMLNCE0 DE Colorectal cancer DMWSMND ID DMWSMND DMWSMND DN Cevimeline DMWSMND HS Approved DMWSMND SN Evoxac; Saligren; Cevimeline [INN]; Cevimeline hydrochloride; Cevimeline hydrochloride [USAN]; Cevimeline hydrochloride hemihydrate; Cevimeline hydrochloride hydrate; AF 102B; AF102B; Fks 508; AF-102B; Cevimeline (INN); Cevimeline HCl 1/2H2O; Cevimeline hydrochloride (USAN); Cevimeline hydrochloride hydrate (JAN); Cevimeline.HCl; Evoxac (TN); FKS-508; SND-5008; SNI-2011; SNK-508; Saligren (TN); SND 5008, AF-102B, FKS-508; Cis-2-Methylspiro(1,3-oxathiolane-5,3')quinuclidine hydrochloride hydrate (2:2:1); (+-)-cis-2-Methylspiro(1,3-oxathiolane-5,3'-quinuclidine) hydrochloride, hemihydrate; (+/-)-cis-2-methylspiro(1-azabicyclo[2.2.2]octance-3,5'-(1,3)oxathiolane) hydrochloride hemihydrate; (2R,2'R)-2'-methylspiro[4-azabicyclo[2.2.2]octane-2,5'-[1,3]oxathiolane] dihydrochloride hydrate; (2R,5R)-2-methylspiro[1,3-oxathiolane-5,3'-1-azabicyclo[2.2.2]octane]; (2R,5R)-2-methylspiro[1,3-oxathiolane-5,3'-1-azabicyclo[2.2.2]octane] dihydrate hydrochloride; (2R,5R)-2-methylspiro[1,3-oxathiolane-5,3'-1-azabicyclo[2.2.2]octane] hydrate dihydrochloride; (2R,5R)-2-methylspiro[1,3-oxathiolane-5,3'-1-azabicyclo[2.2.2]octane] hydrate hydrochloride; 2-Methyspiro(1,3-oxathiolane-5,3)quinuclidine DMWSMND CP Daiichi Sankyo Pharma Development DMWSMND TC Parasympathomimetics DMWSMND DT Small molecular drug DMWSMND PC 83898 DMWSMND MW 199.32 DMWSMND FM C10H17NOS DMWSMND IC InChI=1S/C10H17NOS/c1-8-12-10(7-13-8)6-11-4-2-9(10)3-5-11/h8-9H,2-7H2,1H3/t8-,10-/m1/s1 DMWSMND CS C[C@@H]1O[C@]2(CN3CCC2CC3)CS1 DMWSMND IK WUTYZMFRCNBCHQ-PSASIEDQSA-N DMWSMND IU (2R,5R)-2-methylspiro[1,3-oxathiolane-5,3'-1-azabicyclo[2.2.2]octane] DMWSMND CA CAS 107233-08-9 DMWSMND DE Sjogren syndrome DMKN345 ID DMKN345 DMKN345 DN Charybdotoxin DMKN345 HS Approved DMKN345 SN ChTX; CTX Toxin; Quinquestriatus Toxin; Charybdotoxin (reduced); Toxin, CTX; Toxin, Quinquestriatus DMKN345 DT Small molecular drug DMKN345 PC 56842037 DMKN345 MW 4296 DMKN345 FM C176H277N57O55S7 DMKN345 IC InChI=1S/C176H277N57O55S7/c1-81(2)58-106-149(263)213-110(62-91-67-191-80-197-91)152(266)215-112(64-127(183)246)156(270)231-135(85(8)240)170(284)219-114(69-234)157(271)200-95(36-25-54-192-174(185)186)138(252)196-68-130(249)199-96(32-17-21-50-177)139(253)222-120-75-291-295-79-124(226-159(273)116(71-236)218-167(281)132(82(3)4)228-155(269)113(65-128(184)247)216-169(283)134(84(7)239)230-154(268)108(59-88-28-13-12-14-29-88)210-145(259)102-44-47-129(248)198-102)166(280)232-137(87(10)242)172(286)233-136(86(9)241)171(285)220-115(70-235)158(272)204-98(34-19-23-52-179)141(255)206-104(45-48-131(250)251)147(261)225-122-77-292-290-74-119(223-143(257)99(35-20-24-53-180)201-140(254)97(33-18-22-51-178)203-153(267)111(63-126(182)245)214-148(262)105(49-57-289-11)208-162(120)276)161(275)205-101(38-27-56-194-176(189)190)144(258)224-121(164(278)211-107(60-89-39-41-92(243)42-40-89)150(264)221-118(73-238)173(287)288)76-293-294-78-123(163(277)207-103(43-46-125(181)244)146(260)202-100(142(256)209-106)37-26-55-193-175(187)188)227-168(282)133(83(5)6)229-160(274)117(72-237)217-151(265)109(212-165(122)279)61-90-66-195-94-31-16-15-30-93(90)94/h12-16,28-31,39-42,66-67,80-87,95-124,132-137,195,234-243H,17-27,32-38,43-65,68-79,177-180H2,1-11H3,(H2,181,244)(H2,182,245)(H2,183,246)(H2,184,247)(H,191,197)(H,196,252)(H,198,248)(H,199,249)(H,200,271)(H,201,254)(H,202,260)(H,203,267)(H,204,272)(H,205,275)(H,206,255)(H,207,277)(H,208,276)(H,209,256)(H,210,259)(H,211,278)(H,212,279)(H,213,263)(H,214,262)(H,215,266)(H,216,283)(H,217,265)(H,218,281)(H,219,284)(H,220,285)(H,221,264)(H,222,253)(H,223,257)(H,224,258)(H,225,261)(H,226,273)(H,227,282)(H,228,269)(H,229,274)(H,230,268)(H,231,270)(H,232,280)(H,233,286)(H,250,251)(H,287,288)(H4,185,186,192)(H4,187,188,193)(H4,189,190,194)/t84-,85-,86-,87-,95+,96+,97+,98+,99+,100+,101+,102+,103+,104+,105+,106+,107+,108+,109+,110+,111+,112+,113+,114+,115+,116+,117+,118+,119+,120+,121+,122+,123+,124+,132+,133+,134+,135+,136+,137+/m1/s1 DMKN345 CS C[C@H]([C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC4=CC=CC=C4)NC(=O)[C@@H]5CCC(=O)N5)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N3)CCCCN)CCCCN)CC(=O)N)CCSC)CCCCN)CCCNC(=N)N)CO)[C@@H](C)O)CC(=O)N)CC6=CN=CN6)CC(C)C)CCCNC(=N)N)CCC(=O)N)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC2=O)CC7=CNC8=CC=CC=C87)CO)C(C)C)C(=O)N[C@@H](CC9=CC=C(C=C9)O)C(=O)N[C@@H](CO)C(=O)O)CCCNC(=N)N)CCC(=O)O)CCCCN)CO)[C@@H](C)O)O DMKN345 IK CNVQLPPZGABUCM-LIGYZCPXSA-N DMKN345 IU (2S)-3-hydroxy-2-[[(2S)-3-(4-hydroxyphenyl)-2-[[(1R,4S,7R,12R,15S,18S,21S,24S,27S,30S,33S,36S,42S,45R,50R,53S,56S,59S,62S,65S,68R,75S,78S,81S,84S,89S,92S,95S)-42,62,75,78-tetrakis(4-aminobutyl)-50-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S,3R)-3-hydroxy-2-[[(2S)-2-[[(2S)-5-oxopyrrolidine-2-carbonyl]amino]-3-phenylpropanoyl]amino]butanoyl]amino]-4-oxobutanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-27,81-bis(2-amino-2-oxoethyl)-15-(3-amino-3-oxopropyl)-4,18,36-tris(3-carbamimidamidopropyl)-65-(2-carboxyethyl)-30,53,56-tris[(1R)-1-hydroxyethyl]-33,59,92-tris(hydroxymethyl)-24-(1H-imidazol-5-ylmethyl)-89-(1H-indol-3-ylmethyl)-21-(2-methylpropyl)-84-(2-methylsulfanylethyl)-2,5,13,16,19,22,25,28,31,34,37,40,43,51,54,57,60,63,66,74,77,80,83,86,87,90,93,96-octacosaoxo-95-propan-2-yl-9,10,47,48,70,71-hexathia-3,6,14,17,20,23,26,29,32,35,38,41,44,52,55,58,61,64,67,73,76,79,82,85,88,91,94,97-octacosazatricyclo[43.27.14.1112,68]heptanonacontane-7-carbonyl]amino]propanoyl]amino]propanoic acid DMKN345 CA CAS 95751-30-7 DMKN345 DE Scorpion envenoming syndrome DMQ8JIK ID DMQ8JIK DMQ8JIK DN Chenodiol DMQ8JIK HS Approved DMQ8JIK SN 474-25-9; Chenix; Chenic acid; Chenodeoxycholate; Gallodesoxycholic acid; Chendol; Chenodesoxycholic acid; Cdca; Chenofalk; Anthropodeoxycholic acid; Anthropodesoxycholic acid; Anthropododesoxycholic acid; Chenodesoxycholsaeure; Xenbilox; Henohol; Chenique Acid; Chenodiol [USAN]; 3alpha,7alpha-Dihydroxy-5beta-cholan-24-oic acid; Sodium chenodeoxycholate; Acido chenodeoxicholico; Chenodesoxycholsaeure [German]; Acide chenodeoxycholique; 7-alpha-Hydroxylithocholic acid; Acidum chenodeoxycholicum DMQ8JIK CP Sigma Tau Pharmaceuticals Inc DMQ8JIK DT Small molecular drug DMQ8JIK PC 10133 DMQ8JIK MW 392.6 DMQ8JIK FM C24H40O4 DMQ8JIK IC InChI=1S/C24H40O4/c1-14(4-7-21(27)28)17-5-6-18-22-19(9-11-24(17,18)3)23(2)10-8-16(25)12-15(23)13-20(22)26/h14-20,22,25-26H,4-13H2,1-3H3,(H,27,28)/t14-,15+,16-,17-,18+,19+,20-,22+,23+,24-/m1/s1 DMQ8JIK CS C[C@H](CCC(=O)O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2[C@@H](C[C@H]4[C@@]3(CC[C@H](C4)O)C)O)C DMQ8JIK IK RUDATBOHQWOJDD-BSWAIDMHSA-N DMQ8JIK IU (4R)-4-[(3R,5S,7R,8R,9S,10S,13R,14S,17R)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid DMQ8JIK CA CAS 474-25-9 DMQ8JIK CB CHEBI:16755 DMQ8JIK DE Cholelithiasis DMXGJEI ID DMXGJEI DMXGJEI DN Chlophedianol DMXGJEI HS Approved DMXGJEI SN Abehol; Antitussin; Calmotusin; Chlofedanol; Clofedano; Clofedanol; Clofedanolum; Clofedianolo; Dencyl; Eutus; Tussistop; Clofedianolo [Italian]; Clophedianol base; Ulo base; SL 501 base; Antitussin (TN); Clofedanol (INN); Clofedanol [INN:BAN]; Clofedanolum [INN-Latin]; Ulone (TN); Alpha-(Dimethylaminoethyl)-o-chlorobenzhydrol; Benzenemethanol, 2-chloro-alpha-(2-(dimethylamino)ethyl)-alpha-phenyl-(9CI); 1-(2-Chlorophenyl)-1-phenyl-3-dimethylaminopropanol; 1-(2-Chlorophenyl)-3-(dimethylamino)-1-phenyl-1-propanol; 1-(2-chlorophenyl)-3-(dimethylamino)-1-phenylpropan-1-ol; 1-(2-chlorophenyl)-3-dimethylamino-1-phenylpropan-1-ol; 1-Phenyl-1-(o-chlorophenyl)-3-dimethylaminopropanol; 2-Chloro-.alpha.-(2-dimethylaminoethyl)benzhydrol; 2-Chloro-alpha-(2-(dimethylamino)ethyl)benzhydrol; 2-Cloro-alpha-(2-dimetilaminoetil)-benzidrolo; 2-Cloro-alpha-(2-dimetilaminoetil)-benzidrolo [Italian] DMXGJEI CP 3m Pharmaceuticals Inc DMXGJEI TC Anesthetics DMXGJEI DT Small molecular drug DMXGJEI PC 2795 DMXGJEI MW 289.8 DMXGJEI FM C17H20ClNO DMXGJEI IC InChI=1S/C17H20ClNO/c1-19(2)13-12-17(20,14-8-4-3-5-9-14)15-10-6-7-11-16(15)18/h3-11,20H,12-13H2,1-2H3 DMXGJEI CS CN(C)CCC(C1=CC=CC=C1)(C2=CC=CC=C2Cl)O DMXGJEI IK WRCHFMBCVFFYEQ-UHFFFAOYSA-N DMXGJEI IU 1-(2-chlorophenyl)-3-(dimethylamino)-1-phenylpropan-1-ol DMXGJEI CA CAS 791-35-5 DMXGJEI CB CHEBI:135207 DMXGJEI DE Dry cough; Anaesthesia DMRKE63 ID DMRKE63 DMRKE63 DN Chlorambucil DMRKE63 HS Approved DMRKE63 SN Ambochlorin; Amboclorin; Chlocambucil; Chloorambucol; Chlorambucilum; Chloraminophen; Chloraminophene; Chlorbutin; Chlorbutine; Chlorbutinum; Chloroambucil; Chlorobutin; Chlorobutine; Clorambucile; Clorambucilo; Ecloril; Elcoril; Elcorin; Leukeran; Leukersan; Leukoran; Linfolizin; Linfolysin; Lympholysin; Clorambucile [DCIT]; Glaxo Wellcome Brand of Chlorambucil; GlaxoSmithKline Brand of Chlorambucil; Leuk ersan; Leukeran tablets; Phenylbutyric acid nitrogen mustard; Wellcome Brand of Chlorambucil; C0253; CB 1348; CB1348; Cb l348; CB-1348; Chlorambucil [INN:BAN]; Chlorambucilum [INN-Latin]; Clorambucilo [INN-Spanish]; LEUKERAN (TN); Leukeran (TN); Phenylbuttersaeure-lost; Phenylbuttersaeure-lost[German]; Chlorambucil (USP/INN) DMRKE63 CP GlaxoSmithKline DMRKE63 TC Anticancer Agents DMRKE63 DT Small molecular drug DMRKE63 PC 2708 DMRKE63 MW 304.2 DMRKE63 FM C14H19Cl2NO2 DMRKE63 IC InChI=1S/C14H19Cl2NO2/c15-8-10-17(11-9-16)13-6-4-12(5-7-13)2-1-3-14(18)19/h4-7H,1-3,8-11H2,(H,18,19) DMRKE63 CS C1=CC(=CC=C1CCCC(=O)O)N(CCCl)CCCl DMRKE63 IK JCKYGMPEJWAADB-UHFFFAOYSA-N DMRKE63 IU 4-[4-[bis(2-chloroethyl)amino]phenyl]butanoic acid DMRKE63 CA CAS 305-03-3 DMRKE63 CB CHEBI:28830 DMRKE63 DE Chronic lymphocytic leukaemia DMFXEWT ID DMFXEWT DMFXEWT DN Chloramphenicol DMFXEWT HS Approved DMFXEWT SN Alficetyn; Ambofen; Amphenicol; Amphicol; Amseclor; Anacetin; Aquamycetin; Austracil; Austracol; Biocetin; Biophenicol; CAF; CLM; Catilan; Chemiceticol; Chemicetin; Chemicetina; Chlomin; Chlomycol; Chloramex; Chloramfenikol; Chloramficin; Chloramfilin; Chloramphenicolum; Chloramsaar; Chlorasol; Chloricol; Chlornitromycin; Chloroamphenicol; Chlorocaps; Chlorocid; Chlorocide; Chlorocol; Chlorofair; Chloromax; Chloromycetin; Chloromycetny; Chloromyxin; Chloronitrin; Chloroptic; Chlorovules; Chlorsig; Cidocetine; Ciplamycetin; Cloramfen; Cloramfenicol; Cloramfenicolo; Cloramficin; Cloramical; Cloramicol; Cloramidina; Cloranfenicol; Cloroamfenicolo; Clorocyn; Cloromisan; Cloromissan; Clorosintex; Comycetin; Cylphenicol; Desphen; Detreomycin; Detreomycine; Dextromycetin; Doctamicina; Duphenicol; Econochlor; Embacetin; Emetren; Enicol; Enteromycetin; Erbaplast; Ertilen; Farmicetina; Fenicol; Globenicol; Glorous; Halomycetin; Hortfenicol; Interomycetine; Intramycetin; Intramyctin; Isicetin; Ismicetina; Isophenicol; Juvamycetin; Kamaver; Kemicetina; Kemicetine; Kloramfenikol; Klorita; Laevomycetinum; Leukamycin; Leukomyan; Leukomycin; Levomicetina; Levomitsetin; Levomycetin; Loromicetina; Loromisan; Loromisin; Mastiphen; Mediamycetine; Medichol; Micloretin; Micochlorine; Micoclorina; Microcetina; Mychel; Mycinol; Myscel; Novochlorocap; Novomycetin; Novophenicol; Oftalent; Oleomycetin; Opclor; Opelor; Ophthochlor; Ophtochlor; Optomycin; Otachron; Otophen; Pantovernil; Paraxin; Pentamycetin; Quemicetina; Rivomycin; Romphenil; Ronfenil; Ronphenil; Septicol; Sificetina; Sintomicetina; Stanomycetin; Synthomycetin; Synthomycetine; Synthomycine; Syntomycin; Tevcocin; Tevcosin; Tifomycin; Tifomycine;Tiromycetin; Treomicetina; Unimycetin; Veticol; Viceton; Ch loramex; Chloramfenikol [Czech]; Chloramphenicol crystalline; Chlormycetin R; Chlorocid S; Chlorocidin C; Chlorocidin C tetran; Chloroject L; Chloromycetny [Polish]; Cloramfenicolo [DCIT]; Cloroamfenicolo [Italian]; F armicetina; Isopto fenicol; Klorocid S; Normimycin V; Sintomicetine R; Sno Phenicol; Vice ton; I 337A; Ak-chlor; Alficetyn (TN); Amphicol (TN); Biomicin (TN); Brochlor (TN); CAF (pharmaceutical); Cedoctine (TN); Chlora-tabs; Chloramex (TN); Chloramphenicol & VRC3375; Chloramphenicolum [INN-Latin]; Chlorbiotic (Veterinary); Chlornitromycin (TN); Chloro-25 vetag; Chloromycetin (TN); Chlorsig (TN); Cloramfenicol [INN-Spanish]; D-Chloramphenicol; Dispersadron C (TN); Econochlor (TN); Elase-Chloromycetin; Fenicol (TN); Golden Eye (TN); Isoptophenicol (TN); Kemicetine (TN); Laevomycetin (TN); Medicom (TN); Mychel-Vet; Nevimycin (TN); Oftan Chlora (TN); Optrex Infected Eyes (TN); Orchadexoline (TN); Phenicol (TN); Renicol (TN); Silmycetin (TN); Sno-Phenicol; Synthomycine (TN); Tea-Cetin; Tega-Cetin; Tifomycine (TN); U-6062; Vernacetin (TN); Veticol (TN); C.A.F; CHLOROPTIC S.O.P; Chloramphenicol [INN:BAN:JAN]; Chloromycetin® D-threo-Chloramphenicol; Alficetyn, Chlornitromycin, Chloromycetin, Chloramphenicol; Chloramphenicol (JP15/USP/INN); Chloroptic S.O.P.; D(-)-threo-Chloramphenicol; D-(-)-Chloramphenicol; D-(-)-threo-Chloramphenicol; D(-)-threo-2-dichloroacetamido-1-p-nitrophen yl-propanediol; D(-)-threo-2-dichloroacetamido-1-p-nitrophenyl-propanediol DMFXEWT CP Aventis Pharmaceuticals Inc. DMFXEWT TC Antibiotics DMFXEWT DT Small molecular drug DMFXEWT PC 5959 DMFXEWT MW 323.13 DMFXEWT FM C11H12Cl2N2O5 DMFXEWT IC InChI=1S/C11H12Cl2N2O5/c12-10(13)11(18)14-8(5-16)9(17)6-1-3-7(4-2-6)15(19)20/h1-4,8-10,16-17H,5H2,(H,14,18)/t8-,9-/m1/s1 DMFXEWT CS C1=CC(=CC=C1[C@H]([C@@H](CO)NC(=O)C(Cl)Cl)O)[N+](=O)[O-] DMFXEWT IK WIIZWVCIJKGZOK-RKDXNWHRSA-N DMFXEWT IU 2,2-dichloro-N-[(1R,2R)-1,3-dihydroxy-1-(4-nitrophenyl)propan-2-yl]acetamide DMFXEWT CA CAS 56-75-7 DMFXEWT CB CHEBI:17698 DMFXEWT DE Bacterial infection DMTN5XI ID DMTN5XI DMTN5XI DN Chlordiazepoxide DMTN5XI HS Approved DMTN5XI SN Abboxide; Balance; Chloradiazepoxide; Chlordiazachel; Chlordiazepoxid; Chlordiazepoxidum; Chlordiazepoxydum; Chloridazepoxide; Chloridiazepide; Chloridiazepoxide; Chlorodiazepoxide; Chlozepid; Clopoxide; Clordiazepossido; Clordiazepoxido; Control; Decacil; Disarim; Eden; Elenium; Helogaphen; Ifibrium; Kalmocaps; Librelease; Librinin; Libritabs; Librium; Lygen; Menrium; Mesural; Methaminodiazepoxide; Mildmen; Multum; Napoton; Napton; Psicosan; Radepur; Risolid; Silibrin; Sonimen; Tropium; Viopsicol; Zeisin; Zetran; Chlordiazepoxide Base; Clordiazepossido [Italian]; A-Poxide; Apo-Chlordiazepoxide; Balance (pharmaceutical); Chlordiazepoxidum [INN-Latin]; Clordiazepoxido [INN-Spanish]; Eden-psich; Libritabs (TN); Librium (TN); MENRIUM 10-4; MENRIUM 5-4; Novapam (TN); Novo-Poxide; Tropium (TN); Chlordiazepoxide (JP15/USP/INN); Chlordiazepoxide [USAN:INN:BAN:JAN]; 3H-1,4-Benzodiazepin-2-amine, 7-chloro-N-methyl-5-phenyl, 4-oxide; 3H-1,4-Benzodiazepin-2-amine, 7-chloro-N-methyl-5-phenyl-, 4-oxide; 3H-1,4-Benzodiazepine, 7-chloro-2-(methylamino)-5-phenyl-, 4-oxide; 3H-1,4-benzodiazepin-2-amine,7-chloro-N-methyl-5-phenyl-,4-oxide; 7-Chlor-2-methylamino-5-phenyl-3H-1,4-benzodiazepin-4-oxid; 7-Chlor-2-methylamino-5-phenyl-3H-1,4-benzodiazepin-4-oxid [German]; 7-Chloro-2-(methylamino)-5-phenyl-3H-1,4-benzodiazepine 4-oxide; 7-Chloro-N-methyl-5-phenyl-3H-1,4-benzodiazepin-2-amine 4-oxide; 7-Cloro-2-metilamino-5-fenil-3H-1,4-benzodiazepina 4-ossido; 7-Cloro-2-metilamino-5-fenil-3H-1,4-benzodiazepina 4-ossido [Italian]; 7-chloro-4-hydroxy-N-methyl-5-phenyl-3H-1,4-benzodiazepin-2-imine DMTN5XI CP Patheon Pharmaceuticals Inc DMTN5XI TC Antianxiety Agents DMTN5XI DT Small molecular drug DMTN5XI PC 2712 DMTN5XI MW 299.75 DMTN5XI FM C16H14ClN3O DMTN5XI IC InChI=1S/C16H14ClN3O/c1-18-15-10-20(21)16(11-5-3-2-4-6-11)13-9-12(17)7-8-14(13)19-15/h2-9,21H,10H2,1H3 DMTN5XI CS CN=C1CN(C(=C2C=C(C=CC2=N1)Cl)C3=CC=CC=C3)O DMTN5XI IK BUCORZSTKDOEKQ-UHFFFAOYSA-N DMTN5XI IU 7-chloro-4-hydroxy-N-methyl-5-phenyl-3H-1,4-benzodiazepin-2-imine DMTN5XI CA CAS 58-25-3 DMTN5XI CB CHEBI:3611 DMTN5XI DE Anxiety disorder DMQ9MVG ID DMQ9MVG DMQ9MVG DN Chlorhexidine DMQ9MVG HS Approved DMQ9MVG SN AVAGARD; Chlorhexidin; Chlorhexidinum; Cloresidina; Clorhexidina; Fimeil; Hexadol; Hibiclens; Hibispray; Hibistat;Nolvasan; Novalsan; Peridex; Periogard; Rotersept; Savloclens; Soretol; Sterido; Sterilon; Superspray; Tubulicid; Chlorhexidin [Czech]; Chlorhexidine Base; Chlorhexidine gluconate; Cloresidina [DCIT]; Decanoylacetaldehyde Sodium Sulfide; Dentisept [veterinary]; Savlon babycare; Sebidin A; Sodium Houttuyfonamide; Avagard (TN); BIOPATCH (TN); ChloraPrep (TN); Chlorhexamed (TN); Chlorhexidine (INN);Chlorhexidine [INN:BAN]; Chlorhexidinum [INN-Latin]; Chlorohex (TN); Clohex (TN); Clorexil (TN); Clorhexidina [INN-Spanish]; Corsodyl (TN); Dentisept [veterinary] (TN); Dexidin (TN); Exidine (TN); Hibiclens (TN); Hibiscrub (TN); MK-412A; Merfen-incolore; Oro-Clense; Oronine (TN); Perichlor (TN); Peridex (TN); Peridont (TN); Periochip (TN); Periogard Oral Rinse (TN); Perioxidina (TN); Savacol (TN); Suthol (TN); Dejavu-MW (TN); Merfen-incolore (TN); Lisium (*Dihydrochloride*); Nolvasan (*Diacetate*); SOLU-I.V (TN); N,N'-Bis(4-chlorophenyl)-3,12-diimino-2,4,11,13-tetraazatetradecanediimidamide; N,N''''-hexane-1,6-diylbis[N'-(4-chlorophenyl)(imidodicarbonimidic diamide)]; N,N'-Bis(4-chlorophenyl)-3,12-diimino-2,4,11,13-tetraazatetradeca-nediimidamide; N',N'''''-hexane-1,6-diylbis[N-(4-chlorophenyl)(imidodicarbonimidic diamide)]; 1,1 inverted exclamation marka-Hexamethylenebis[5-(4-chlorophenyl)biguanide]; 1,1'-Hexamethylene bis(5-(p-chlorophenyl)biguanide); 1,1'-Hexamethylenebis(5-(p-chlorophenyl)biguanide); 1,1'-Hexamethylenebis[5-(4-chlorophenyl)biguanide; 1,6-Bis(5-(p-chlorophenyl)biguandino)hexane; 1,6-Bis(p-chlorophenyldiguanido)hexane; 1,6-Di(4'-chlorophenyldiguanido)hexane; 1,6-Di(N-p-chlorophenyldiguanido)hexane DMQ9MVG CP G. D. Pharmaceuticals DMQ9MVG TC Antibiotics DMQ9MVG DT Small molecular drug DMQ9MVG PC 9552079 DMQ9MVG MW 505.4 DMQ9MVG FM C22H30Cl2N10 DMQ9MVG IC InChI=1S/C22H30Cl2N10/c23-15-5-9-17(10-6-15)31-21(27)33-19(25)29-13-3-1-2-4-14-30-20(26)34-22(28)32-18-11-7-16(24)8-12-18/h5-12H,1-4,13-14H2,(H5,25,27,29,31,33)(H5,26,28,30,32,34) DMQ9MVG CS C1=CC(=CC=C1N/C(=N/C(=NCCCCCCN=C(/N=C(/NC2=CC=C(C=C2)Cl)\\N)N)N)/N)Cl DMQ9MVG IK GHXZTYHSJHQHIJ-UHFFFAOYSA-N DMQ9MVG IU (1E)-2-[6-[[amino-[(E)-[amino-(4-chloroanilino)methylidene]amino]methylidene]amino]hexyl]-1-[amino-(4-chloroanilino)methylidene]guanidine DMQ9MVG CA CAS 55-56-1 DMQ9MVG CB CHEBI:3614 DMQ9MVG DE Bacterial infection DMSF4PR ID DMSF4PR DMSF4PR DN Chlormerodrin DMSF4PR HS Approved DMSF4PR SN Chlormerodrina; Chloromeridin; Neogidrin; Chlormerodrin Hg 197; Chlormerodrin Hg 203; Chlormerodrin (197Hg); Chlormerodrin (203Hg); Chlormerodrin Hg 197 (TN); Chlormerodrin Hg 197 (USAN); Chlormerodrin Hg 197 [USAN:USP XX]; Chlormerodrin Hg 203 (USAN); Hg-203 chlormerodrin; Loro-}; Neohydrin-203; Chlormerodrin (197Hg) (INN); Neohydrin-203 (TN); Mercury, [3-[(aminocarbonyl)amino]-2-methoxypropyl]chloro; Urea, (2-methoxypropyl)-, mercury complex; [3-(carbamoylamino)-2-methoxypropyl](chloro)mercury; [3-(carbamoylamino)-2-methoxypropyl]-chloromercury; {[3-(Chloromercuri)-2-methoxypropyl]urea}; {[3-[(Aminocarbonyl)amino]-2-hydroxypropyl]chloromercury}; [3-(carbamoylamino)-2-methoxypropyl](chloro)(203hg)mercury; [3-(carbamoylamino)-2-methoxypropyl]-chloromercury-203; Chloro(2-methoxy-3-ureidopropyl)((203)Hg)mercury(II); Mercury, {[3-[(aminocarbonyl)amino]-2-methoxypropyl]chloro-}; [3-(carbamoylamino)-2-methoxypropyl](chloro)((203)Hg)mercury; Mercury, {[3-[(aminocarbonyl)amino]-2-methoxypropyl-C1,O3]ch; (3-(Chloromercuri)-2-methoxypropyl)urea; 3-Chloromercuri-2-methoxypropylurea; 3-ureido-2-methoxypropyl((203)Hg)mercury(II) chloride DMSF4PR TC Diagnostic Agents DMSF4PR DT Small molecular drug DMSF4PR PC 25210 DMSF4PR MW 367.2 DMSF4PR FM C5H11ClHgN2O2 DMSF4PR IC InChI=1S/C5H11N2O2.ClH.Hg/c1-4(9-2)3-7-5(6)8;;/h4H,1,3H2,2H3,(H3,6,7,8);1H;/q;;+1/p-1 DMSF4PR CS COC(CNC(=O)N)C[Hg]Cl DMSF4PR IK BJFGVYCULWBXKF-UHFFFAOYSA-M DMSF4PR IU [3-(carbamoylamino)-2-methoxypropyl]-chloromercury DMSF4PR CA CAS 10375-56-1 DMSF4PR CB CHEBI:59445 DMSF4PR DE Diagnostic imaging DMTWUXR ID DMTWUXR DMTWUXR DN Chlormezanone DMTWUXR HS Approved DMTWUXR SN Alinam; Banabin; Bisina; Chlomedinon; Chlormethazanone; Chlormethazone; Chlormezanon; Chlormezanona; Chlormezanonum; Clorilax; Clormetazanone; Clormetazon; Clormezanona; Clormezanone; Dichloromethazanone; Dichloromezanone; Lobak; Miorilax; Muskel; Myolespen; Phenarol; Rexan; Rilansyl; Rilaquil; Rilasol; Rilassol; Rilax; Rillasol; Supotran; Suprotan; Tanafol; Trancopal; Trancote; Tranrilax; Transanate; Clormezanone [DCIT]; WIN 4692; Banabil-sintyal; Banabin-sintyal; Banabin-syntyal; C-192; Chlormezanonum [INN-Latin]; Clormezanona [INN-Spanish]; Dl-Chlormezanone; Mio-sed; Muskel-Trancopal; TRANCOPAL (TN); Trancopal (TN); Chlormezanone (JAN/INN); Chlormezanone [BAN:INN:JAN]; Chlormezanone [INN:BAN:JAN]; (+-)-Chlormezanone; 2-(4-Chlorophenyl)-3-methyl-1,3-thiazinan-4-one 1,1-dioxide; 2-(4-Chlorophenyl)-3-methyl-4-metathiazanone-1,1-dioxide; 2-(4-Chlorophenyl)tetrahydro-3-methyl-4H,1,3-thiazin-4-one 1,1-Dioxide; 2-(4-Chlorophenyl)tetrahydro-3-methyl-4H-1,3-thiazin-4-one 1,1-dioxide; 2-(4-Chlorphenyl)-3-methyl-4-metathiazanon-1,1-dioxid; 2-(4-chlorophenyl)-3-methyl-1,1-dioxo-1,3-thiazinan-4-one; 2-(p-Chlorophenyl)tetrahydro-3-methyl-4H-1,3-thiazin-4-one 1,1-dioxide; 2-(p-Chlorphenyl)-3-methyl-1,3-perhydrothiazin-4-on-1,1-dioxide; 2-(para-Chlorophenyl)tetrahydro-3-methyl-4H-1,3-thiazin-4-one, 1,1-dioxide; 4H-1,3-Thiazin-4-one, 2-(4-chlorophenyl)tetrahydro-3-methyl-, 1,1-dioxide; 4H-1,3-Thiazin-4-one, 2-(4-chlorophenyl)tetrahydro-3-methyl-1,1-dioxide; 4H-1,3-Thiazin-4-one, 2-(p-chlorophenyl)tetrahydro-3-methyl-, 1,1,-dioxide; 4H-1,3-Thiazin-4-one, 2-(p-chlorophenyl)tetrahydro-3-methyl-, 1,1-dioxide; 4H-1,3-Thiazin-4-one, 2-(p-chlorophenyl)tetrahydro-3-methyl-1,1-dioxide; 4H-1,3-Thiazin-4-one, tetrahydro-2-(p-chlorophenyl)-3-methyl-, 1,1-dioxide DMTWUXR TC Analgesics DMTWUXR DT Small molecular drug DMTWUXR PC 2717 DMTWUXR MW 273.74 DMTWUXR FM C11H12ClNO3S DMTWUXR IC InChI=1S/C11H12ClNO3S/c1-13-10(14)6-7-17(15,16)11(13)8-2-4-9(12)5-3-8/h2-5,11H,6-7H2,1H3 DMTWUXR CS CN1C(S(=O)(=O)CCC1=O)C2=CC=C(C=C2)Cl DMTWUXR IK WEQAYVWKMWHEJO-UHFFFAOYSA-N DMTWUXR IU 2-(4-chlorophenyl)-3-methyl-1,1-dioxo-1,3-thiazinan-4-one DMTWUXR CA CAS 80-77-3 DMTWUXR CB CHEBI:3619 DMTWUXR DE Anxiety disorder DMSOQK1 ID DMSOQK1 DMSOQK1 DN Chloroprocaine DMSOQK1 HS Approved DMSOQK1 SN Chloroprocain; Chloroprocainum; Chlorprocaine; Chlorprocainum; Cloroprocaina; Halestyn; Nesacaine; Piocaine; Chloroprocaine [INN]; Chloroprocaine hydrochloride; Nesacaine MPF; Chlor-procaine; Chloroprocaine (INN); Chloroprocainum [INN-Latin]; Cloroprocaina [INN-Spanish]; Nesacaine (TN); Nesacaine-Ce; Nesacaine-MPF (TN); Benzoic acid, 4-amino-2-chloro-, 2-(diethylamino)ethyl ester; 2-(Diethylamino)ethyl 4-amino-2-chlorobenzoate; 2-(Diethylaminoethyl)-4-amino-2-chlorobenzoate; 2-Chloroprocaine; 2-diethylaminoethyl 4-amino-2-chlorobenzoate; 4-amino-2-chlorobenzoic acid 2-(diethylamino)ethyl ester DMSOQK1 CP Abbott Laboratories DMSOQK1 TC Anesthetics DMSOQK1 DT Small molecular drug DMSOQK1 PC 8612 DMSOQK1 MW 270.75 DMSOQK1 FM C13H19ClN2O2 DMSOQK1 IC InChI=1S/C13H19ClN2O2/c1-3-16(4-2)7-8-18-13(17)11-6-5-10(15)9-12(11)14/h5-6,9H,3-4,7-8,15H2,1-2H3 DMSOQK1 CS CCN(CC)CCOC(=O)C1=C(C=C(C=C1)N)Cl DMSOQK1 IK VDANGULDQQJODZ-UHFFFAOYSA-N DMSOQK1 IU 2-(diethylamino)ethyl 4-amino-2-chlorobenzoate DMSOQK1 CA CAS 133-16-4 DMSOQK1 CB CHEBI:3636 DMSOQK1 DE Anaesthesia DMSI5CB ID DMSI5CB DMSI5CB DN Chloroquine DMSI5CB HS Approved DMSI5CB SN Amokin; Aralen; Aralen HCl; Arechin; Arechine; Arequin; Arolen; Arthrochin; Artrichin; Avlochlor; Avloclor; Bemaco; Bemaphate; Bemasulph; Benaquin; Bipiquin; CU-01000012392-2; Capquin; Chemochin; Chingamin; Chloraquine; Chlorochin; Chlorochine; Chlorochinum; Chloroin; Chloroquin; Chloroquina; Chloroquine (USP/INN); Chloroquine (VAN); Chloroquine Bis-Phosphoric Acid; Chloroquine FNA (TN); Chloroquine [USAN:INN:BAN]; Chloroquine phosphate; Chloroquinium; Chloroquinum; Chloroquinum [INN-Latin]; Chlorquin; Cidanchin; Clorochina; Clorochina [DCIT]; Cloroquina; Cloroquina [INN-Spanish]; Cocartrit; Dawaquin (TN); Delagil; Dichinalex; Elestol; Gontochin; Gontochin phosphate; Heliopar; Imagon; Ipsen 225; Iroquine; Khingamin; Klorokin; Lapaquin; Malaquin; Malaquin (*Diphosphate*); Malaren; Malarex; Mesylith; Miniquine; Neochin; Nivachine; Nivaquine B; Pfizerquine; Quinachlor; Quinagamin; Quinagamine; Quinercyl; Quingamine; Quinilon; Quinoscan; RP 3377; RP-3377; Resochen; Resochin; Resochin (TN); Resoquina; Resoquine; Reumachlor; Reumaquin; Rivoquine; Ro 01-6014/N2; Ronaquine; Roquine; SN 6718; SN-7618; ST 21; ST 21 (pharmaceutical); Sanoquin; Silbesan;Siragan; Solprina; Sopaquin; Tanakan; Tanakene; Tresochin; Trochin; W 7618;WIN 244 DMSI5CB CP Medreich Sterilab Ltd DMSI5CB TC Antimalarials DMSI5CB DT Small molecular drug DMSI5CB PC 2719 DMSI5CB MW 319.9 DMSI5CB FM C18H26ClN3 DMSI5CB IC InChI=1S/C18H26ClN3/c1-4-22(5-2)12-6-7-14(3)21-17-10-11-20-18-13-15(19)8-9-16(17)18/h8-11,13-14H,4-7,12H2,1-3H3,(H,20,21) DMSI5CB CS CCN(CC)CCCC(C)NC1=C2C=CC(=CC2=NC=C1)Cl DMSI5CB IK WHTVZRBIWZFKQO-UHFFFAOYSA-N DMSI5CB IU 4-N-(7-chloroquinolin-4-yl)-1-N,1-N-diethylpentane-1,4-diamine DMSI5CB CA CAS 54-05-7 DMSI5CB CB CHEBI:3638 DMSI5CB DE Malaria DMLHESP ID DMLHESP DMLHESP DN Chlorothiazide DMLHESP HS Approved DMLHESP SN Aldoclor; Alurene; Chloriazid; Chlorosal; Chlorothiazid; Chlorothiazidum; Chlorotiazida; Chlorthiazid; Chlorthiazide; Chlorthiazidum; Chlortiazid; Chlorurit; Chlotride; Chlrosal; Clorotiazida; Clorotiazide; Clotride; Diupres; Diuresal; Diuril; Diurilix; Diurite; Diutrid; Flumen; Minzil; Salisan; Salunil; Saluretil; Saluric; Thiazide; Urinex; Warduzide; Yadalan; Clorotiazide [DCIT]; Component of Aldoclor; Diuril Boluses; C 4911; Chlorothiazidum [INN-Latin]; Clorotiazida [INN-Spanish]; Diuril (TN); Diuril Boluses, Veterinary; Neo-Dema; Sk-chlorothiazide; Chlorothiazide [USAN:INN:BAN]; Diuril, Chlotride, Chlorothiazide; Chlorothiazide (JAN/USP/INN); 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-, 1,1-dioxide; 6-Chloro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 6-Chloro-7-sulfamoyl-2H-1,2,4-benzothiadiazine 1,1-dioxide; 6-chloro-4H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide DMLHESP CP Oak Pharmaceuticals Inc Sub Akorn Inc DMLHESP TC Antihypertensive Agents DMLHESP DT Small molecular drug DMLHESP PC 2720 DMLHESP MW 295.7 DMLHESP FM C7H6ClN3O4S2 DMLHESP IC InChI=1S/C7H6ClN3O4S2/c8-4-1-5-7(2-6(4)16(9,12)13)17(14,15)11-3-10-5/h1-3H,(H,10,11)(H2,9,12,13) DMLHESP CS C1=C2C(=CC(=C1Cl)S(=O)(=O)N)S(=O)(=O)N=CN2 DMLHESP IK JBMKAUGHUNFTOL-UHFFFAOYSA-N DMLHESP IU 6-chloro-1,1-dioxo-4H-1lambda6,2,4-benzothiadiazine-7-sulfonamide DMLHESP CA CAS 58-94-6 DMLHESP CB CHEBI:3640 DMLHESP DE Congestive heart failure DMFZBMQ ID DMFZBMQ DMFZBMQ DN Chloroxine DMFZBMQ HS Approved DMFZBMQ SN chloroxine; 5,7-Dichloroquinolin-8-ol; 773-76-2; 5,7-Dichloro-8-hydroxyquinoline; Chlorquinol; Quixalin; Capitrol; Dichloroxin; Chloroxyquinoline; Dichloroquinolinol; Dikhloroskin; 5,7-Dichloro-8-quinolinol; Endiaron; Clofuzid; Quinolor; Dichlorohydroxyquinoline; Chlofucid; Quesyl; 5,7-Dichloroxine; 5,7-Dichlorooxine; Chlorohydroxyquinoline; 8-QUINOLINOL, 5,7-DICHLORO-; 5,7-Dichloro-8-oxyquinoline; Chloroxine [USAN]; 5,7-Dichlor-8-hydroxychinolin; C9H5Cl2NO; NSC 3904; UNII-2I8BD50I8B; CCRIS 5751; CHQ; Capitrol Cream Shampoo; EINECS 212-2 DMFZBMQ DT Small molecular drug DMFZBMQ PC 2722 DMFZBMQ MW 214.04 DMFZBMQ FM C9H5Cl2NO DMFZBMQ IC InChI=1S/C9H5Cl2NO/c10-6-4-7(11)9(13)8-5(6)2-1-3-12-8/h1-4,13H DMFZBMQ CS C1=CC2=C(C(=C(C=C2Cl)Cl)O)N=C1 DMFZBMQ IK WDFKMLRRRCGAKS-UHFFFAOYSA-N DMFZBMQ IU 5,7-dichloroquinolin-8-ol DMFZBMQ CA CAS 773-76-2 DMFZBMQ CB CHEBI:59477 DMFZBMQ DE Erythema DM5URA2 ID DM5URA2 DM5URA2 DN Chlorpheniramine DM5URA2 HS Approved DM5URA2 SN Allergican; Allergisan; Antagonate; Chloropheniramine; Chlorophenylpyridamin; Chlorophenylpyridamine; Chloropiril; Chloroprophenpyridamine; Chlorphenamine; Chlorphenaminum; Chlorpheniraminum; Chlorprophenpyridamine; Clofeniramina; Clorfenamina; Clorfeniramina; Cloropiril; Haynon; Hayon; Histadur; ISOCLOR; Kloromin; Phenetron; PiriIton; Piriton; Polaronil; Telachlor; Teldrin; Chlorphenamine [INN]; Clorfeniramina [Italian]; Pediacare Allergy Formula; [3H]Chlorpheniramine; Aller-Chlor; Chlo-amine; Chlor-Pro; Chlor-Trimeton Repetabs; Chlor-trimeton; Chlorphenamine (INN); Chlorphenaminum [INN-Latin]; Clofeniramina (TN); Clorfenamina [INN-Spanish]; Comakin (TN); Gen-Allerate; Novo-Pheniram; Piriton (TN); Chlor-Trimeton (TN); Chlor-Tripolon (TN); CHLORPHENIRAMINE (SEE ALSO: CHLORPHENIRAMINE MALEATE (CAS113-92-8)); Gamma-(4-Chlorophenyl)-gamma-(2-pyridyl)propyldimethylamine; Gamma-(4-Chlorophenyl)-N,N-dimethyl-2-pyridinepropanamine; 1-(p-Chlorophenyl)-1-(2-pyridyl)-3-N,N-dimethylpropylamine; 1-(p-Chlorophenyl)-1-(2-pyridyl)-3-dimethylaminopropane; 2-(p-Chloro-alpha-(2-(dimethylamino)ethyl)benzyl)pyridine; 3-(4-chlorophenyl)-N,N-dimethyl-3-(pyridin-2-yl)propan-1-amine; 3-(4-chlorophenyl)-N,N-dimethyl-3-pyridin-2-ylpropan-1-amine; 3-(p-Chlorophenyl)-3-(2-pyridyl)-N,N-dimethylpropylamine; 4-Chloropheniramine DM5URA2 CP Schering-Plough Corporation DM5URA2 TC Antiallergic Agents DM5URA2 DT Small molecular drug DM5URA2 PC 2725 DM5URA2 MW 274.79 DM5URA2 FM C16H19ClN2 DM5URA2 IC InChI=1S/C16H19ClN2/c1-19(2)12-10-15(16-5-3-4-11-18-16)13-6-8-14(17)9-7-13/h3-9,11,15H,10,12H2,1-2H3 DM5URA2 CS CN(C)CCC(C1=CC=C(C=C1)Cl)C2=CC=CC=N2 DM5URA2 IK SOYKEARSMXGVTM-UHFFFAOYSA-N DM5URA2 IU 3-(4-chlorophenyl)-N,N-dimethyl-3-pyridin-2-ylpropan-1-amine DM5URA2 CA CAS 113-92-8 DM5URA2 CB CHEBI:52010 DM5URA2 DE Allergic rhinitis DMQRPOS ID DMQRPOS DMQRPOS DN Chlorphentermine hydrochloride DMQRPOS HS Approved DMQRPOS SN Pre-sate DMQRPOS CP Parke Davis Div Warner Lambert Co DMQRPOS DT Small molecular drug DMQRPOS PC 65477 DMQRPOS MW 220.14 DMQRPOS FM C10H15Cl2N DMQRPOS IC InChI=1S/C10H14ClN.ClH/c1-10(2,12)7-8-3-5-9(11)6-4-8;/h3-6H,7,12H2,1-2H3;1H DMQRPOS CS CC(C)(CC1=CC=C(C=C1)Cl)N.Cl DMQRPOS IK WEJDYJKJPUPMLH-UHFFFAOYSA-N DMQRPOS IU 1-(4-chlorophenyl)-2-methylpropan-2-amine;hydrochloride DMQRPOS CA CAS 151-06-4 DMQRPOS DE Appetite suppressant DM1IFGT ID DM1IFGT DM1IFGT DN Chlorproguanil DM1IFGT HS Approved DM1IFGT SN Chlorproguanilum; Clorpreguanile; Clorproguanil; Lapudrine; Clorpreguanile [DCIT]; Unspecified HCl of chlorproguanil; Chlorproguanil [INN:BAN]; Chlorproguanilum [INN-Latin]; Clorproguanil [INN-Spanish]; N-(3,4-dichlorophenyl)-N'-(1-methylethyl)imidodicarbonimidic diamide; 1-(3,4-Dichlorophenyl)-5-isopropylbiguanide DM1IFGT DT Small molecular drug DM1IFGT PC 9571037 DM1IFGT MW 288.17 DM1IFGT FM C11H15Cl2N5 DM1IFGT IC InChI=1S/C11H15Cl2N5/c1-6(2)16-10(14)18-11(15)17-7-3-4-8(12)9(13)5-7/h3-6H,1-2H3,(H5,14,15,16,17,18) DM1IFGT CS CC(C)N=C(N)/N=C(\\N)/NC1=CC(=C(C=C1)Cl)Cl DM1IFGT IK ISZNZKHCRKXXAU-UHFFFAOYSA-N DM1IFGT IU (1E)-1-[amino-(3,4-dichloroanilino)methylidene]-2-propan-2-ylguanidine DM1IFGT CA CAS 537-21-3 DM1IFGT CB CHEBI:135192 DM1IFGT DE Malaria DMBGZI3 ID DMBGZI3 DMBGZI3 DN Chlorpromazine DMBGZI3 HS Approved DMBGZI3 SN Aminasine; Aminazin; Aminazine; Ampliactil; Amplicitil; Amplictil; BC 135; Chlor-PZ; Chlor-Promanyl; Chlordelazine; Chlorderazin; Chloropromazine; Chlorpromados; Chlorpromanyl (discontinued); Chlorpromazin; Chlorpromazine (USP/INN); Chlorpromazine Tannate; Chlorpromazine [USAN:INN:BAN]; Chlorpromazinum; Chlorpromazinum [INN-Latin]; Clorpromazina; Clorpromazina [INN-Spanish]; Clorpromazina [Italian]; Contomin; Cromedazine; Elmarin; Esmind; Fenactil; Fenaktyl; Fraction AB; HL 5746; JHICC02042; Largactil; Largactil (TN); Largactil Liquid; Largactil Oral Drops; Largactilothiazine; Largactyl; Megaphen; Novo-Chlorpromazine; Novomazina; Phenactyl; Phenathyl; Phenothiazine hydrochloride; Plegomasine; Plegomazin; Prazilpromactil; Proma; Promactil; Promazil; Propaphen; Propaphenin; Prozil; Psychozine; SKF 2601-A; SKF 2601A; SKF-2601; Sanopron; Thorazine; Thorazine (TN); Thorazine Spansule; Thorazine Suppositories; Thorazine hydrochloride; Torazina; Wintermin; Z80 DMBGZI3 CP GlaxoSmithKline DMBGZI3 TC Antipsychotic Agents DMBGZI3 DT Small molecular drug DMBGZI3 PC 2726 DMBGZI3 MW 318.9 DMBGZI3 FM C17H19ClN2S DMBGZI3 IC InChI=1S/C17H19ClN2S/c1-19(2)10-5-11-20-14-6-3-4-7-16(14)21-17-9-8-13(18)12-15(17)20/h3-4,6-9,12H,5,10-11H2,1-2H3 DMBGZI3 CS CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl DMBGZI3 IK ZPEIMTDSQAKGNT-UHFFFAOYSA-N DMBGZI3 IU 3-(2-chlorophenothiazin-10-yl)-N,N-dimethylpropan-1-amine DMBGZI3 CA CAS 34468-21-8 DMBGZI3 CB CHEBI:3647 DMBGZI3 DE Schizophrenia DMPHZQE ID DMPHZQE DMPHZQE DN Chlorpropamide DMPHZQE HS Approved DMPHZQE SN Adiaben; Asucrol; Bioglumin; Catanil; Chlorodiabina; Chloronase; Chloropropamide; Chlorporpamide; Chlorpropamid; Chlorpropamidum; Clorpropamid; Clorpropamida; Clorpropamide; Diabaril; Diabechlor; Diabenal; Diabenese; Diabeneza; Diabetoral; Diabexan; Diabinese; Dynalase; Glisema; Glucamide; Insogen; Insulase; Meldian; Melitase; Mellinese; Millinese; Oradian; Prodiaben; Stabinol; Apotex Brand of Chlorpropamide; Byk Gulden Brand of Chlorpropamide; CHLORPROPAMIDE USP; Clorpropamide [DCIT]; Clorpropamide [Italian];Dia benese; Diamel Ex; Farmasierra Brand of Chlorpropamide; Pfizer Brand of Chlorpropamide; C 1290; P 607; Apo-Chlorpropamide; Chlorpropamide Bp/ Usp; Chlorpropamidum [INN-Latin]; Clorpropamida [INN-Spanish]; Diabet-Pages; Diabinese (TN); Novo-Propamide; U-3818; U-9818; Chlorpropamide [INN:BAN:JAN]; Chlorpropamide (JP15/USP/INN); N3-Butyl-N1-p-chlorobenzenesulfonylure a; N3-Butyl-N1-p-chlorobenzenesulfonylurea; N-Propyl-N'-p-chlorophenylsulfonylcarbamide; N-Propyl-N'-p-chlorphenylsulfonylcarbamide; N-propyl-N'-p-chlorophenylsu lfonylcarbamide; N-(4-Chlorophenylsulfonyl)-N'-propylurea; N-(p-Chlorobenzenesulfonyl)-N'-propylurea; N-Propyl-N'-(p-chlorobenzenesulfonyl)urea; 1-((p-Chlorophenyl)sulfonyl)-3-propylurea; 1-(4-Chlorophenylsulfonyl)-3-propylurea; 1-(4-chlorophenyl)sulfonyl-3-propylurea; 1-(p-Chlorobenzenesulfonyl)-3-propylurea; 1-(p-Chlorobenzensulfonyl)-3-propylurea; 1-(p-Chlorophenylsulfonyl)-3-propylurea; 1-(para-Chlorophenylsulfonyl)-3-propylurea; 1-Propyl-3-(p-chlorobenzenesulfonyl)urea; 1-[(4-chlorobenzene)sulfonyl]-3-propylurea; 1-[p-Chlorobenzenesulfonyl]-3-propylurea; 1-p-Chlorophenyl-3-(propylsulfonyl)urea; 4-Chloro-4-((propylamino)carbonyl)benzenesulfonamide; 4-Chloro-N-((propylamino)carbonyl)benzenesulfonamide; 4-chloro-N-(propylcarbamoyl)benzenesulfonamide; 4-chloro-N-[(propylamino)carbonyl]benzenesulfonamide DMPHZQE TC Hypoglycemic Agents DMPHZQE DT Small molecular drug DMPHZQE PC 2727 DMPHZQE MW 276.74 DMPHZQE FM C10H13ClN2O3S DMPHZQE IC InChI=1S/C10H13ClN2O3S/c1-2-7-12-10(14)13-17(15,16)9-5-3-8(11)4-6-9/h3-6H,2,7H2,1H3,(H2,12,13,14) DMPHZQE CS CCCNC(=O)NS(=O)(=O)C1=CC=C(C=C1)Cl DMPHZQE IK RKWGIWYCVPQPMF-UHFFFAOYSA-N DMPHZQE IU 1-(4-chlorophenyl)sulfonyl-3-propylurea DMPHZQE CA CAS 94-20-2 DMPHZQE CB CHEBI:3650 DMPHZQE DE Non-insulin dependent diabetes DMY0KGJ ID DMY0KGJ DMY0KGJ DN Chlorprothixene DMY0KGJ HS Approved DMY0KGJ SN Chloroprothixene; Chlorprothixen; Chlorprothixenum; Chlorprothixine; Chlorprotixen; Chlorprotixene; Chlorprotixine; Chlothixen; Clorprotisene; Clorprotixeno; Iaractan; Paxyl; Rentovet; Tactaran; Taractan; Tarasan; Tardan; Traquilan; Trictal; Truxal; Truxaletten; Truxil; Vetacalm; Clorprotisene [DCIT]; MK 184; N 714; N 714C; NCI56378; Alpha-Chlorprothixene; Chlorprothixenum [INN-Latin]; Cis-Chlorprothixene; Clorprotixeno [INN-Spanish]; N-714; Ro 4-0403; Taractan (TN); Truxal (TN); Ro-4-0403;Trans(E)-Chlorprothixen; Chlorprothixene (JAN/USAN/INN); Chlorprothixene [USAN:INN:BAN:JAN]; Cloxan, Taractan, Truxal, Chlorprothixene; Cis-2-Chloro-9-(3-dimethylaminopropylidene)thioxanthene; {3-[2-Chloro-thioxanthen-(9Z)-ylidene]-propyl}-dimethyl-amine; Thioxanthene-delta9,gamma-propylamine, 2-chloro-N,N-dimethyl-, (Z)-(8CI); (3E)-3-(2-chloro-9H-thioxanthen-9-ylidene)-N,N-dimethylpropan-1-amine; (3E)-3-(2-chlorothioxanthen-9-ylidene)-N,N-dimethylpropan-1-amine; (3Z)-3-(2-chloro-9H-thioxanthen-9-ylidene)-N,N-dimethylpropan-1-amine; (3Z)-3-(2-chlorothioxanthen-9-ylidene)-N,N-dimethylpropan-1-amine; (Z)-2-Chloro-9-(omega-dimethylaminopropylidene)thioxanthene; (Z)-2-Chloro-N,N-dimethylthioxanthene-.DELTA.(sup9),(sup.gamma.)-propylamine; (Z)-2-Chloro-N,N-dimethylthioxanthene-delta(sup 9,gamma)-propylamine; (alpha.-2-Chloro-9-.omega.-dimethylamino-propylamine)thioxanthene; 2-Chloro-9-[.omega.-(dimethylamino)propylidene]thioxanthene; 2-Chloro-9-[3-(dimethylamino)propylidene]thioxanthene; 2-Chloro-N,N-dimethylthioxanthene-.delta.(sup 9), .gamma.-propylamine; 3-(2-chloro-9H-thioxanthen-9-ylidene)-N,N-dimethyl-1-propanamine; 3-(2-chloro-9H-thioxanthen-9-ylidene)-N,N-dimethylpropan-1-amine; 3-(2-chlorothioxanthen-9-ylidene)-N,N-dimethylpropan-1-amine DMY0KGJ TC Antipsychotic Agents DMY0KGJ DT Small molecular drug DMY0KGJ PC 667467 DMY0KGJ MW 315.9 DMY0KGJ FM C18H18ClNS DMY0KGJ IC InChI=1S/C18H18ClNS/c1-20(2)11-5-7-14-15-6-3-4-8-17(15)21-18-10-9-13(19)12-16(14)18/h3-4,6-10,12H,5,11H2,1-2H3/b14-7- DMY0KGJ CS CN(C)CC/C=C\\1/C2=CC=CC=C2SC3=C1C=C(C=C3)Cl DMY0KGJ IK WSPOMRSOLSGNFJ-AUWJEWJLSA-N DMY0KGJ IU (3Z)-3-(2-chlorothioxanthen-9-ylidene)-N,N-dimethylpropan-1-amine DMY0KGJ CA CAS 113-59-7 DMY0KGJ CB CHEBI:50931 DMY0KGJ DE Psychotic disorder DM4DMBT ID DM4DMBT DM4DMBT DN Chlorthalidone DM4DMBT HS Approved DM4DMBT SN Chlorothalidone; Chlorphthalidolone; Chlorphthalidone; Chlortalidone; Chlortalidonum; Chlorthalidon; Clortalidona; Clortalidone; Famolin; Higroton; Hygroton; Igroton; Isoren; Natriuran; Oradil; Oxodolin; Oxodoline; Phthalamodine; Phthalamudine; Renon; Saluretin; Thalitone; Urolin; Zambesil; Clortalidone [DCIT]; Racemic chlorthalidone; G 33182; Chlortalidonum [INN-Latin]; Chlorthalidone (USP); Clortalidona [INN-Spanish]; G-33182; Hydro-Long; Hygroton (TN); Oksodolin (oxodolin); Thalitone (TN); Chlortalidone (JAN/INN); Chlorthalidone [USAN:INN:BAN]; (+-)-Chlorthalidone; (+-)-Hygroton; 1-Keto-3-(3'-sulfamyl-4'-chlorophenyl)-3-hydroxyisoindoline; 1-Oxo-3-(3-sulfamyl-4-chlorophenyl)-3-hydroxyisoindoline; 2-Chloro-5-(1-hydroxy-3-oxo-1-isoindolinyl)benzenesulfonamide; 2-Chloro-5-(1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl)benzenesulfonamide; 2-chloro-5-(1-hydroxy-3-oxo-2H-isoindol-1-yl)benzenesulfonamide; 2-chloro-5-(2,3-dihydro-1-hydroxy-3-oxo-1H-isoindol-1-yl)benzenesulfonamide; 3-(4'-Chloro-3'-sulfamoylphenyl)-3-hydroxyphthalimidine; 3-Hydroxy-3-(4-chloro-3-sulfamylphenyl)phthalimidine DM4DMBT TC Antihypertensive Agents DM4DMBT DT Small molecular drug DM4DMBT PC 2732 DM4DMBT MW 338.8 DM4DMBT FM C14H11ClN2O4S DM4DMBT IC InChI=1S/C14H11ClN2O4S/c15-11-6-5-8(7-12(11)22(16,20)21)14(19)10-4-2-1-3-9(10)13(18)17-14/h1-7,19H,(H,17,18)(H2,16,20,21) DM4DMBT CS C1=CC=C2C(=C1)C(=O)NC2(C3=CC(=C(C=C3)Cl)S(=O)(=O)N)O DM4DMBT IK JIVPVXMEBJLZRO-UHFFFAOYSA-N DM4DMBT IU 2-chloro-5-(1-hydroxy-3-oxo-2H-isoindol-1-yl)benzenesulfonamide DM4DMBT CA CAS 77-36-1 DM4DMBT CB CHEBI:3654 DM4DMBT DE Edema; Hypertension DMCYVDT ID DMCYVDT DMCYVDT DN Chlorzoxazone DMCYVDT HS Approved DMCYVDT SN Biomioran; CLW; Chloroxazone; Chlorsoxazone; Chlorzoxane; Chlorzoxazon; Chlorzoxazona; Chlorzoxazonum; Clorzoxazona; Escoflex; Klorzoxazon; Mioran; Miotran; Myoflexin; Myoflexine; Neoflex; Nyoflex; Paraflex; Parafon; Pathorysin; Relaxazone; Remofleks; Remular; Solaxin; Component of Parafon Forte; McNeil Brand of Chlorzoxazone; Ortho Brand of Chlorzoxazone; Parafon Forte; Parafon Forte DSC; Strifon Forte Dsc; C 4397; Chlorzoxazonum [INN-Latin]; Clorzoxazona [INN-Spanish]; EZE-DS; Muscol (TN); Paraflex (TN); Parafon Forte (TN); Remular-S; Usaf ma-10; Chlorzoxazone [INN:BAN:JAN]; Chlorzoxazone (JAN/USP/INN); 2-Hydroxy-5-chlorobenzoxazole; 5-Chlorbenzoxazolin-2-on; 5-Chloro-1,3-benzoxazol-2(3H)-one; 5-Chloro-2(3H)-benzoxazolone; 5-Chloro-2-benzoxazolinone; 5-Chloro-2-benzoxazolol; 5-Chloro-2-benzoxazolone; 5-Chloro-2-hydroxybenzoxazole; 5-Chloro-3(H)-2-benzoxazolone; 5-Chlorobenzoksazolinon-2; 5-Chlorobenzoksazolinon-2 [Polish]; 5-Chlorobenzoksazolon-2; 5-Chlorobenzoksazolon-2 [Polish]; 5-Chlorobenzoxazol-2-one; 5-Chlorobenzoxazolidone; 5-Chlorobenzoxazolone; 5-chloro-1,3-benzoxazol-2-ol; 5-chloro-3H-1,3-benzoxazol-2-one; 5-chlorobenzoxazolin-2-one DMCYVDT TC Analgesics DMCYVDT DT Small molecular drug DMCYVDT PC 2733 DMCYVDT MW 169.56 DMCYVDT FM C7H4ClNO2 DMCYVDT IC InChI=1S/C7H4ClNO2/c8-4-1-2-6-5(3-4)9-7(10)11-6/h1-3H,(H,9,10) DMCYVDT CS C1=CC2=C(C=C1Cl)NC(=O)O2 DMCYVDT IK TZFWDZFKRBELIQ-UHFFFAOYSA-N DMCYVDT IU 5-chloro-3H-1,3-benzoxazol-2-one DMCYVDT CA CAS 95-25-0 DMCYVDT CB CHEBI:3655 DMCYVDT DE Acute pain DMGU74E ID DMGU74E DMGU74E DN Cholecalciferol DMGU74E HS Approved DMGU74E SN Arachitol; Calciol; Cholecalciferolum; Colecalciferol; Colecalciferolo; Colecalciferolum; Colecalcipherol; Delsterol; Deparal; Ebivit; FeraCol; Provitamine; Provitina; Rampage; Ricketon; Trivitan; Vigorsan; Colecalciferolo [DCIT]; VITAMIN D; Duphafral D3 1000; LT00244775; NEO Dohyfral D3; Oleovitamin D3; TNP00266; VITAMIN D3 POWDER; VITAMIN_D3; Vitamin D3; Vitamin D3 emulsifiable; Activated 7-dehydrocholesterol; Cholecalciferol (D3); Cholecalciferol, D3; Colecalciferol (INN); Colecalciferolum [INN-Latin]; D3-Vicotrat; D3-Vigantol; Delta-D; Irradiated 7-dehydrocholesterol; Micro-dee; Vitamin d-3; Cholecalciferol (JP15/USP); Cholecalciferol [USAN:BAN:JAN]; Delta-D (TN); Vitinc Dan-Dee-3; Vi-de-3-hydrosol; (+)-Vitamin D3; (3S,5Z,7E)-9,10-secocholesta-5,7,10(19)-trien-3-ol; (3beta,5Z,7E)-9,10-secocholesta-5,7,10(19)-trien-3-ol; (5Z,7E)-(3S)-9,10-seco-5,7,10(19)-cholestatrien-3-ol; (5Z,7E)-(3S)-9,10-secocholesta-5,7,10(19)-trien-3-ol; 25(OH)D; 7-Dehydrocholesterol activated; 7-Dehydrocholesterol, Activated; 7-Dehydrocholesterol, irradiated; 7-Dehydrocholestrol, activated; 9,10-Seco(5Z,7E)-5,7,10(19)-cholestatrien-3-ol; 9,10-Seco(5Z,7E)-5,7,10(19)-cholestatrien-3beta-ol; 9,10-Secocholesta-5(Z),7(E),10(19)-trien-3(beta.)-ol; 9,10-Secocholesta-5,7,10(19)-trien-3-beta-ol DMGU74E TC Vitamins DMGU74E DT Small molecular drug DMGU74E PC 5280795 DMGU74E MW 384.6 DMGU74E FM C27H44O DMGU74E IC InChI=1S/C27H44O/c1-19(2)8-6-9-21(4)25-15-16-26-22(10-7-17-27(25,26)5)12-13-23-18-24(28)14-11-20(23)3/h12-13,19,21,24-26,28H,3,6-11,14-18H2,1-2,4-5H3/b22-12+,23-13-/t21-,24+,25-,26+,27-/m1/s1 DMGU74E CS C[C@H](CCCC(C)C)[C@H]1CC[C@@H]\\2[C@@]1(CCC/C2=C\\C=C/3\\C[C@H](CCC3=C)O)C DMGU74E IK QYSXJUFSXHHAJI-YRZJJWOYSA-N DMGU74E IU (1S,3Z)-3-[(2E)-2-[(1R,3aS,7aR)-7a-methyl-1-[(2R)-6-methylheptan-2-yl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol DMGU74E CA CAS 67-97-0 DMGU74E CB CHEBI:28940 DMGU74E DE Vitamin D deficiency DM7OKQV ID DM7OKQV DM7OKQV DN Cholic acid DM7OKQV HS Approved DM7OKQV SN cholic acid; 81-25-4; Cholalic acid; cholate; Cholalin; Colalin; Cholsaeure; NSC-6135; Cholic acid, 5beta-; 3alpha,7alpha,12alpha-Trihydroxy-5beta-cholanic acid; 3alpha,7alpha,12alpha-Trihydroxy-5beta-cholan-24-oic acid; UNII-G1JO7801AE; HSDB 982; (R)-4-((3R,5S,7R,8R,9S,10S,12S,13R,14S,17R)-3,7,12-Trihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoic acid; Cholic acid [USAN]; 3,7,12-Trihydroxycholanic acid; G1JO7801AE; CHEMBL205596; CHEBI:16359; NSC6135; BHQCQFFYRZLCQQ-OELDTZBJSA-N DM7OKQV DT Small molecular drug DM7OKQV PC 221493 DM7OKQV MW 408.6 DM7OKQV FM C24H40O5 DM7OKQV IC InChI=1S/C24H40O5/c1-13(4-7-21(28)29)16-5-6-17-22-18(12-20(27)24(16,17)3)23(2)9-8-15(25)10-14(23)11-19(22)26/h13-20,22,25-27H,4-12H2,1-3H3,(H,28,29)/t13-,14+,15-,16-,17+,18+,19-,20+,22+,23+,24-/m1/s1 DM7OKQV CS C[C@H](CCC(=O)O)[C@H]1CC[C@@H]2[C@@]1([C@H](C[C@H]3[C@H]2[C@@H](C[C@H]4[C@@]3(CC[C@H](C4)O)C)O)O)C DM7OKQV IK BHQCQFFYRZLCQQ-OELDTZBJSA-N DM7OKQV IU (4R)-4-[(3R,5S,7R,8R,9S,10S,12S,13R,14S,17R)-3,7,12-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid DM7OKQV CA CAS 81-25-4 DM7OKQV CB CHEBI:16359 DM7OKQV DE Synthesis disorder; Peroxisomal disorder DMOI1ZF ID DMOI1ZF DMOI1ZF DN Choline alfoscerate DMOI1ZF HS Approved DMOI1ZF SN Delecit (TN) DMOI1ZF DT Small molecular drug DMOI1ZF PC 657272 DMOI1ZF MW 257.22 DMOI1ZF FM C8H20NO6P DMOI1ZF IC InChI=1S/C8H20NO6P/c1-9(2,3)4-5-14-16(12,13)15-7-8(11)6-10/h8,10-11H,4-7H2,1-3H3/t8-/m1/s1 DMOI1ZF CS C[N+](C)(C)CCOP(=O)([O-])OC[C@@H](CO)O DMOI1ZF IK SUHOQUVVVLNYQR-MRVPVSSYSA-N DMOI1ZF IU [(2R)-2,3-dihydroxypropyl] 2-(trimethylazaniumyl)ethyl phosphate DMOI1ZF CA CAS 28319-77-9 DMOI1ZF CB CHEBI:16870 DMOI1ZF DE Amnesia DM8P137 ID DM8P137 DM8P137 DN Choline salicylate DM8P137 HS Approved DM8P137 SN 2016-36-6; Arthropan; Syrap; Mundisal; Satibon; Actasal; Salicol; Artrobione; Arret; Choline salicylate B; (2-Hydroxyethyl)trimethylammonium salicylate; UNII-KD510K1IQW; Choline salicylic acid salt; Salicylic acid choline salt; Cholini salicylas [INN-Latin]; Salicylic acid, ion(1-), choline; Salicylate de choline [INN-French]; Salicilato de colina [INN-Spanish]; EINECS 217-948-8; KD510K1IQW; Choline salicylate [USAN:INN:BAN:JAN]; Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with 2-hydroxybenzoic acid (1:1) DM8P137 DT Small molecular drug DM8P137 PC 54686350 DM8P137 MW 241.28 DM8P137 FM C12H19NO4 DM8P137 IC InChI=1S/C7H6O3.C5H14NO/c8-6-4-2-1-3-5(6)7(9)10;1-6(2,3)4-5-7/h1-4,8H,(H,9,10);7H,4-5H2,1-3H3/q;+1/p-1 DM8P137 CS C[N+](C)(C)CCO.C1=CC=C(C(=C1)C(=O)O)[O-] DM8P137 IK UDKCHVLMFQVBAA-UHFFFAOYSA-M DM8P137 IU 2-carboxyphenolate;2-hydroxyethyl(trimethyl)azanium DM8P137 CA CAS 2016-36-6 DM8P137 CB CHEBI:3668 DM8P137 DE Inflammation DMFMZ3G ID DMFMZ3G DMFMZ3G DN Choriogonadotropin alfa DMFMZ3G HS Approved DMFMZ3G TC Fertility Agents DMFMZ3G SQ Alpha chain: APDVQDCPECTLQENPFFSQPGAPILQCMGCCFSRAYPTPLRSKKTMLVQKNVTSESTCCVAKSYNRVTVMGGFKVENHTACHCSTCYYHKS >Beta chainSKEPLRPRCRPINATLAVEKEGCPVCITVNTTICAGYCPTMTRVLQGVLPALPQVVCNYRDVRFESIRLPGCPRGVNPVVSYAVALSCQCALCRRSTTDCGGPKDHPLTCDDPRFQDSSSSKAPPPSLPSPSRLPGPSDTPILPQ DMFMZ3G DE Female infertility DMFT73E ID DMFT73E DMFT73E DN Chorionic Gonadotropin DMFT73E HS Approved DMFT73E SN A.P.L.; Chorionic Gonadotropin; Follutein; Pregnyl DMFT73E CP Ferring Pharmaceuticals Inc DMFT73E DE Fertility problem DM2NA4K ID DM2NA4K DM2NA4K DN Ciclesonide DM2NA4K HS Approved DM2NA4K SN Alvesco; Omnair; Omnaris; Osonase; Osonide; Alvesco HFA; Ciclesonide [INN]; Omnaris HFA; RPR 251526; Alvesco (TN); BTR-15; BTR-15K; BY-9010; BYK-20426; KS-1165; Omnaris (TN); Omniair (TN); TBN-15; B-9207-015; Ciclesonide (JAN/USAN/INN); (R)-11beta,16alpha,17,21-Tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with cyclohexanecarboxaldehyde, 21-isobutyrate DM2NA4K CP Altana Pharma DM2NA4K TC Antiallergic Agents DM2NA4K DT Small molecular drug DM2NA4K PC 6918155 DM2NA4K MW 540.7 DM2NA4K FM C32H44O7 DM2NA4K IC InChI=1S/C32H44O7/c1-18(2)28(36)37-17-25(35)32-26(38-29(39-32)19-8-6-5-7-9-19)15-23-22-11-10-20-14-21(33)12-13-30(20,3)27(22)24(34)16-31(23,32)4/h12-14,18-19,22-24,26-27,29,34H,5-11,15-17H2,1-4H3/t22-,23-,24-,26+,27+,29+,30-,31-,32+/m0/s1 DM2NA4K CS CC(C)C(=O)OCC(=O)[C@@]12[C@@H](C[C@@H]3[C@@]1(C[C@@H]([C@H]4[C@H]3CCC5=CC(=O)C=C[C@]45C)O)C)O[C@H](O2)C6CCCCC6 DM2NA4K IK LUKZNWIVRBCLON-GXOBDPJESA-N DM2NA4K IU [2-[(1S,2S,4R,6R,8S,9S,11S,12S,13R)-6-cyclohexyl-11-hydroxy-9,13-dimethyl-16-oxo-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-8-yl]-2-oxoethyl] 2-methylpropanoate DM2NA4K CA CAS 126544-47-6 DM2NA4K CB CHEBI:31397 DM2NA4K DE Obstructive airway disease; Asthma DMN5T2A ID DMN5T2A DMN5T2A DN Ciclopirox DMN5T2A HS Approved DMN5T2A SN Ciclopiroxum; Cyclopirox; Cyclopyroxolamine; Loprox; Penlac; Stieprox; Terit; Ciclopirox Olamin; Ciclopirox gel; Loprox Gel; Loprox Shampoo; Loprox cream; Penlac nail lacquer; HOE 296b; Batrafen (TN); Ciclopirox-Olamin; Ciclopiroxum [INN-Latin]; Dafnegin-CSC; HOE-296; HOE-296b; Loprox (TN); Penlac (TN); Stieprox (TN); Ciclopirox (USP/INN); Ciclopirox [USAN:BAN:INN]; (6-Cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridone); 6-Cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridinone; 6-Cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridone; 6-Cyclohexyl-1-hydroxy-4-methyl-2-(1H)-pyridone; 6-cyclohexyl-1-hydroxy-4-methyl-2(1 H)-pyridinone; 6-cyclohexyl-1-hydroxy-4-methylpyridin-2(1H)-one; 6-cyclohexyl-1-hydroxy-4-methylpyridin-2-one DMN5T2A TC Antifungal Agents DMN5T2A DT Small molecular drug DMN5T2A PC 2749 DMN5T2A MW 207.27 DMN5T2A FM C12H17NO2 DMN5T2A IC InChI=1S/C12H17NO2/c1-9-7-11(13(15)12(14)8-9)10-5-3-2-4-6-10/h7-8,10,15H,2-6H2,1H3 DMN5T2A CS CC1=CC(=O)N(C(=C1)C2CCCCC2)O DMN5T2A IK SCKYRAXSEDYPSA-UHFFFAOYSA-N DMN5T2A IU 6-cyclohexyl-1-hydroxy-4-methylpyridin-2-one DMN5T2A CA CAS 29342-05-0 DMN5T2A CB CHEBI:453011 DMN5T2A DE Fungal infection DMAZJFX ID DMAZJFX DMAZJFX DN Ciclosporin DMAZJFX HS Approved DMAZJFX SN Ciclosporin; Ciclosporin (Ciclosporin A); Ciclosporina; Ciclosporina [INN-Spanish]; Ciclosporine; Ciclosporine [INN-French]; Ciclosporinum; Ciclosporinum [INN-Latin]; Cipol N; Consupren; Cyclosporin; Cyclosporine A; Equoral; Antibiotic S 7481F1; Gengraf; Neoplanta; Neoral; Ramihyphin A; Restasis; S-Neoral; Sandimmun; Sandimmun Neoral; Sandimmune; Sang 35; Sang-35; SangCyA; Sigmasporin Microoral; cyclosporin A; cyclosporine; 59865-13-3; 83HN0GTJ6D; CHEBI:4031; CSA; DSSTox_CID_365; DSSTox_RID_75541; MFCD00274558; MLS001333756; UNII-83HN0GTJ6D DMAZJFX PC 5284373 DMAZJFX MW 1202.6 DMAZJFX FM C62H111N11O12 DMAZJFX IC PMATZTZNYRCHOR-CGLBZJNRSA-N DMAZJFX CS CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C DMAZJFX IK 1S/C62H111N11O12/c1-25-27-28-40(15)52(75)51-56(79)65-43(26-2)58(81)67(18)33-48(74)68(19)44(29-34(3)4)55(78)66-49(38(11)12)61(84)69(20)45(30-35(5)6)54(77)63-41(16)53(76)64-42(17)57(80)70(21)46(31-36(7)8)59(82)71(22)47(32-37(9)10)60(83)72(23)50(39(13)14)62(85)73(51)24/h25,27,34-47,49-52,75H,26,28-33H2,1-24H3,(H,63,77)(H,64,76)(H,65,79)(H,66,78)/b27-25+/t40-,41+,42-,43+,44+,45+,46+,47+,49+,50+,51+,52-/m1/s1 DMAZJFX IU (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(E,1R,2R)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone DMAZJFX CA CAS 59865-13-3 DMAZJFX CB CHEBI:4031 DMAZJFX DE Viral hepatitis DMT2KRV ID DMT2KRV DMT2KRV DN Ciclosporin DMT2KRV HS Approved DMT2KRV SN Cyclosporine A; CSA; CsA; Antibiotic S 7481F1; BMT-ABA-SAR-MLE-VAL-MLE-ALA-ALA-MLE-MLE-MVA; BMT-ABA-SAR-MLE-VAL-MLE-ALA-DAL-MLE-MLE-MVA; C 3662; CB-01-09 MMX; CYCLOSPORIN A (SEE ALSO TRANSGENIC MODEL EVALUATION (CYCLOSPORIN A)); Cicloral (TN); Ciclosporin; Ciclosporin (JP15); Cipol N; Cipol-N; Consupren; Consupren S; CsA & IFN-alpha; Cyclokat; Cyclophorine; Cyclosporin; Cyclosporin A; Cyclosporin A & IFN-alpha; Cyclosporin A Implant; Cyclosporin A, Tolypocladium inflatum; Cyclosporine (USP); Cyclosporine A; Cyclosporine [USAN]; DE-076; Equoral; From Tolypocladium inflatum (Trichoderma polysporin); GNF-Pf-2808; Gengraf; Gengraf (TN); Helv Chim Acta 60: 1568 (1977); Mitogard; Modusik-A; Neoplanta; Neoral; Neoral (TN); NeuroSTAT; Nova-22007; OL 27-400; OL-27400; OLO-400; Papilock; Pulminiq; RamihyphinA; Restasis; Restasis (TN); S-Neoral; SDZ-OXL 400; ST-603; Sandimmun; Sandimmun Neoral; Sandimmune; Sandimmune (TN); Sandimmune, Gengraf, Restasis, Atopica, Sangcya, Cyclosporine; Sang-2000; Sang-35; SangCyA; Sigmasporin; Sigmasporin Microoral; TRANSGENIC MODEL EVALUATION (CYCLOSPORIN A); Vekacia; Zyclorin DMT2KRV CP Sandoz DMT2KRV TC Immunosuppressive Agents DMT2KRV DT Protein/peptide drug DMT2KRV PC 24883466 DMT2KRV MW 1202.6 DMT2KRV FM C62H111N11O12 DMT2KRV IC InChI=1S/C62H111N11O12/c1-25-27-28-40(15)52(75)51-56(79)65-43(26-2)58(81)67(18)33-48(74)68(19)44(29-34(3)4)55(78)66-49(38(11)12)61(84)69(20)45(30-35(5)6)54(77)63-41(16)53(76)64-42(17)57(80)70(21)46(31-36(7)8)59(82)71(22)47(32-37(9)10)60(83)72(23)50(39(13)14)62(85)73(51)24/h25,27,34-47,49-52,75H,26,28-33H2,1-24H3,(H,63,77)(H,64,76)(H,65,79)(H,66,78)/b27-25+/t40-,41+,42+,43-,44+,45-,46+,47+,49+,50-,51+,52-/m1/s1 DMT2KRV CS CC[C@@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C DMT2KRV IK PMATZTZNYRCHOR-VJRYSDSKSA-N DMT2KRV IU (3R,6S,9S,12S,15S,18R,21S,24S,30R,33S)-30-ethyl-33-[(E,1R,2R)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone DMT2KRV CA CAS 59865-13-3 DMT2KRV DE Psoriasis vulgaris; Xerophthalmia; Brain injury DMA13GD ID DMA13GD DMA13GD DN Cidofovir DMA13GD HS Approved DMA13GD SN CDV; Cidofovirum; Forvade; HPMPC; Vistide; Cidofovir anhydrous; GS 0504; GS 504; GS504; Cidofovir (Vistide); Cidofovir (anhydrous); GS-0504; GS-504; Vistide (TN); Vistide, Cidofovir; [(2S)-1-(4-amino-2-oxopyrimidin-1-yl)-3-hydroxypropan-2-yl]oxymethylphosphonic acid; (2S)-3-Hydroxy-2-phosphonylmethoxypropyl-cytosine; (S)-1-(3-Hydroxy-2-phosphonomethoxypropyl)cytosine; (S)-1-[3-hydroxy-2-(phosphonylmethoxy)-propyl]cytosine; (S)-2-(4-Amino-2-oxo-1(2H)-pyrimidinyl-1-(hydroxymethyl)ethoxy)methyl phosphonic acid; (S)-HPMPC; (s)-[[2-(4-amino-2-oxo-1(2h)-pyrimidinyl)-1-(hydroxymethyl)ethoxy]methyl]phosphonic acid; ({[(2S)-1-(4-amino-2-oxopyrimidin-1(2H)-yl)-3-hydroxypropan-2-yl]oxy}methyl)phosphonic acid; 1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine; 1-[(S)-3-Hydroxy-2-(phosphonomethoxy)propyl]-cytosine dihydrate DMA13GD CP Pfizer Pharmaceuticals DMA13GD TC Anti-HIV Agents DMA13GD DT Small molecular drug DMA13GD PC 60613 DMA13GD MW 279.19 DMA13GD FM C8H14N3O6P DMA13GD IC InChI=1S/C8H14N3O6P/c9-7-1-2-11(8(13)10-7)3-6(4-12)17-5-18(14,15)16/h1-2,6,12H,3-5H2,(H2,9,10,13)(H2,14,15,16)/t6-/m0/s1 DMA13GD CS C1=CN(C(=O)N=C1N)C[C@@H](CO)OCP(=O)(O)O DMA13GD IK VWFCHDSQECPREK-LURJTMIESA-N DMA13GD IU [(2S)-1-(4-amino-2-oxopyrimidin-1-yl)-3-hydroxypropan-2-yl]oxymethylphosphonic acid DMA13GD CA CAS 113852-37-2 DMA13GD CB CHEBI:3696 DMA13GD DE Cytomegalovirus infection DME2H5T ID DME2H5T DME2H5T DN Cilastatin DME2H5T HS Approved DME2H5T SN Cilastatina; Cilastatine; Cilastatinum; Cilastatin Monosodium Salt; Cilastatin acid; Cilastatina [Spanish]; Cilastatine [French]; Cilastatinum [Latin]; MK0791; Cilastatin (INN); Cilastatin [INN:BAN]; MK-791; (2Z)-7-{[(2R)-2-amino-2-carboxyethyl]sulfanyl}-2-({[(1S)-2,2-dimethylcyclopropyl]carbonyl}amino)hept-2-enoic acid; (Z)-(S)-6-carboxy-6-[(S)-2,2-dimethylcyclopropanecarboxamido]hex-5-enyl-L-cysteine; (Z)-7-[(2R)-2-amino-3-hydroxy-3-oxopropyl]sulfanyl-2-[[(1S)-2,2-dimethylcyclopropanecarbonyl]amino]hept-2-enoic acid DME2H5T CP Merck DME2H5T TC Antibiotics DME2H5T DT Small molecular drug DME2H5T PC 6435415 DME2H5T MW 358.5 DME2H5T FM C16H26N2O5S DME2H5T IC InChI=1S/C16H26N2O5S/c1-16(2)8-10(16)13(19)18-12(15(22)23)6-4-3-5-7-24-9-11(17)14(20)21/h6,10-11H,3-5,7-9,17H2,1-2H3,(H,18,19)(H,20,21)(H,22,23)/b12-6-/t10-,11+/m1/s1 DME2H5T CS CC1(C[C@@H]1C(=O)N/C(=C\\CCCCSC[C@@H](C(=O)O)N)/C(=O)O)C DME2H5T IK DHSUYTOATWAVLW-WFVMDLQDSA-N DME2H5T IU (Z)-7-[(2R)-2-amino-2-carboxyethyl]sulfanyl-2-[[(1S)-2,2-dimethylcyclopropanecarbonyl]amino]hept-2-enoic acid DME2H5T CA CAS 82009-34-5 DME2H5T CB CHEBI:3697 DME2H5T DE Bacterial infection DM4V6JA ID DM4V6JA DM4V6JA DN Cilazapril DM4V6JA HS Approved DM4V6JA SN Cilazaprilum; Cilazil; Dynorm; Inhibace; Inibace; Justor; Vascace; CILAZAPRIL MONOHYDRATE; Cilazapril anhydrous;Cilazapril hydrate; Cilazaprilum [Latin]; Cilazapril (INN); Cilazapril (USAN); Cilazapril (anhydrous); Cilazapril hydrate (JAN); Cilazapril, Anhydrous; Inhibace (TN); Ro 31-2848; Ro 31-2848 monohydrate; Ro 34-2848; Ro-312848; Ro-31-2848; Cilazapril [USAN:INN:BAN:JAN]; (1S,9S)-9-(((S)-1-Carboxy-3-phenylpropyl)amino)octahydro-10-oxo-6H-pyridazino(1,2-a)(1,2)diazepine-1-carboxylic acid 9-ethyl estermonohydrate; (4S,7S)-7-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]-6-oxo-1,2,3,4,7,8,9,10-octahydropyridazino[1,2-a]diazepine-4-carboxylic acid; (4S,7S)-7-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]-6-oxo-1,2,3,4,7,8,9,10-octahydropyridazino[1,2-a]diazepine-4-carboxylic acid hydrate DM4V6JA TC Antihypertensive Agents DM4V6JA DT Small molecular drug DM4V6JA PC 56330 DM4V6JA MW 417.5 DM4V6JA FM C22H31N3O5 DM4V6JA IC InChI=1S/C22H31N3O5/c1-2-30-22(29)18(13-12-16-8-4-3-5-9-16)23-17-10-6-14-24-15-7-11-19(21(27)28)25(24)20(17)26/h3-5,8-9,17-19,23H,2,6-7,10-15H2,1H3,(H,27,28)/t17-,18-,19-/m0/s1 DM4V6JA CS CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@H]2CCCN3CCC[C@H](N3C2=O)C(=O)O DM4V6JA IK HHHKFGXWKKUNCY-FHWLQOOXSA-N DM4V6JA IU (4S,7S)-7-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]-6-oxo-1,2,3,4,7,8,9,10-octahydropyridazino[1,2-a]diazepine-4-carboxylic acid DM4V6JA CA CAS 88768-40-5 DM4V6JA CB CHEBI:3698 DM4V6JA DE Congestive heart failure DMZMSCT ID DMZMSCT DMZMSCT DN Cilostazol DMZMSCT HS Approved DMZMSCT SN cilostazol; 73963-72-1; Pletal; Cilostazole; Pletaal; Cilostazolum; OPC-13013; Cilostazolum [INN-Latin]; OPC-21; OPC 13013; OPC 21; UNII-N7Z035406B; CHEBI:31401; C20H27N5O2; 6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydro-2(1H)-quinolinone; BRN 3632107; 6-[4-(1-cyclohexyltetrazol-5-yl)butoxy]-3,4-dihydro-1H-quinolin-2-one; 6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydroquinolin-2(1H)-one; 3,4-Dihydro-6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)-2(1H)-quinolinone; MLS000028470; Cilostazole; Otsuka brand of cilostazol; C 0737; CL23867; Cilostazol [INN:JAN]; Pleta (TN); Pletal (TN); Pletal, Cilostazol; Cilostazol (JP15/USAN/INN); 6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydrocarbostyril; 6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxyl)-3,4-dihydrocarobostyril; 6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)-butoxy]-3,4-dihydro-2(1H)-quinolinone; 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydroquinolin-2(1H)-one DMZMSCT CP Otsuka Pharmaceutical Co DMZMSCT TC Vasodilator Agents DMZMSCT DT Small molecular drug DMZMSCT PC 2754 DMZMSCT MW 369.5 DMZMSCT FM C20H27N5O2 DMZMSCT IC InChI=1S/C20H27N5O2/c26-20-12-9-15-14-17(10-11-18(15)21-20)27-13-5-4-8-19-22-23-24-25(19)16-6-2-1-3-7-16/h10-11,14,16H,1-9,12-13H2,(H,21,26) DMZMSCT CS C1CCC(CC1)N2C(=NN=N2)CCCCOC3=CC4=C(C=C3)NC(=O)CC4 DMZMSCT IK RRGUKTPIGVIEKM-UHFFFAOYSA-N DMZMSCT IU 6-[4-(1-cyclohexyltetrazol-5-yl)butoxy]-3,4-dihydro-1H-quinolin-2-one DMZMSCT CA CAS 73963-72-1 DMZMSCT CB CHEBI:31401 DMZMSCT DE Intermittent claudication DMH61ZB ID DMH61ZB DMH61ZB DN Cimetidine DMH61ZB HS Approved DMH61ZB SN Acibilin; Acinil; Altramet; Brumetidina; Cimal; Cimetadine; Cimetag; Cimetidina; Cimetidinum; Cimetum; Dyspamet; Edalene; Eureceptor; Evicer; Gastrobitan; Gastromet; Histodil; Magicul; Metracin; Peptol; Sigmetadine; Tagamet; Tametin; Tratul; Ulcedin; Ulcedine; Ulcestop; Ulcimet; Ulcofalk; Ulcomedina; Ulcomet; Ulhys; Valmagen; Venopex; Ci metum; Cimetidine Hcl; Tagamet Hb; Biomet400; C 4522; FPF 1002; SKF 92334; Tagamet Hb 200; CIMETIDINE A/AB; Cimetidina [INN-Spanish]; Cimetidinum [INN-Latin]; DRG-0150; SKF-92334; Tagamet (TN); Tagamet HB (TN); Tagamet HB200 (TN); SK&F-92334; Cimetidine (JP15/USP/INN); Cimetidine [USAN:INN:BAN:JAN]; Tagamet, SKF-92334, Tratul, Tametin, Dyspamet, Acinil, Cimetidine; N-Cyano-N'-methyl-[2-[[[5-methyl-1H-imidazol-4-yl]methyl]thio]ethyl]guanidine; N''-Cyano-N-methyl-N'-[2-[(5-methyl-1H-imidazol-4-yl)methylthio]ethyl]guanidine; N''-cyano-N-methyl-N'-(2-{[(5-methyl-1H-imidazol-4-yl)methyl]thio}ethyl)guanidine; N-cyano-N'-methyl-N''-(2-([(5-methyl-1H-imidazol-4-yl)methyl]sulfanyl)ethyl)guanidine; N-cyano-N'-methyl-N''-(2-{[(5-methyl-1H-imidazol-4-yl)methyl]thio}ethyl)guanidine; N-Cyano-N'-Methyl-N''-(2-(((5-Methyl-1H-Imidazol-4-YL)Methyl)Thio)Ethyl) Guanidine; N-Cyano-N'-methyl-N''-(2-(((5-methyl-1 H-imidazol-4-yl) methyl)thio)ethyl)guanidine; N-Cyano-N'-methyl-N''-(2-(((5-methyl-1H-imidazol-4-yl)methyl)thio)ethyl)guanidine; N''-cyano-N-methyl-N'-(2-(((5-methyl-1H-imidazol-4-yl)methyl)thio)-ethyl)guanidine; 1-Cyano-2-methyl-3-(2-(((5-methyl-4-imidazolyl)methyl)thio)ethyl)guanidine; 1-Cyano-2-methyl-3-[2-[[(5-methylimidazol-4-yl)methyl]thio]ethyl]guanidine; 1-cyano-2-methyl-3-[2-[(5-methyl-1H-imidazol-4-yl)methylsulfanyl]ethyl]guanidine; 2-Cyano-1-methyl-3-(2-(((5-methylimidazol-4-yl)methyl)thio)ethyl)guanidine; 2-Cyano-1-methyl-3-[2-(5-methyl-1H-imidazol-4-yl-methylthio)ethyl]guanidine; 2-cyano-1-methyl-3-(2-{[(5-methyl-1H-imidazol-4-yl)methyl]sulfanyl}ethyl)guanidine; 2-cyano-1-methyl-3-(2-{[(5-methyl-1H-imidazol-4-yl)methyl]thio}ethyl)guanidine DMH61ZB CP GlaxoSmithKline DMH61ZB TC Antiulcer Agents DMH61ZB DT Small molecular drug DMH61ZB PC 2756 DMH61ZB MW 252.34 DMH61ZB FM C10H16N6S DMH61ZB IC InChI=1S/C10H16N6S/c1-8-9(16-7-15-8)5-17-4-3-13-10(12-2)14-6-11/h7H,3-5H2,1-2H3,(H,15,16)(H2,12,13,14) DMH61ZB CS CC1=C(N=CN1)CSCCNC(=NC)NC#N DMH61ZB IK AQIXAKUUQRKLND-UHFFFAOYSA-N DMH61ZB IU 1-cyano-2-methyl-3-[2-[(5-methyl-1H-imidazol-4-yl)methylsulfanyl]ethyl]guanidine DMH61ZB CA CAS 51481-61-9 DMH61ZB CB CHEBI:3699 DMH61ZB DE Acid-reflux disorder DMZHPNE ID DMZHPNE DMZHPNE DN Cimetropium bromide DMZHPNE HS Approved DMZHPNE SN Alginor (TN) DMZHPNE CP DeAngelini DMZHPNE DT Small molecular drug DMZHPNE PC 20054870 DMZHPNE MW 438.4 DMZHPNE FM C21H28BrNO4 DMZHPNE IC InChI=1S/C21H28NO4.BrH/c1-22(11-13-7-8-13)17-9-15(10-18(22)20-19(17)26-20)25-21(24)16(12-23)14-5-3-2-4-6-14;/h2-6,13,15-20,23H,7-12H2,1H3;1H/q+1;/p-1/t15?,16-,17-,18+,19-,20+,22?;/m1./s1 DMZHPNE CS C[N+]1([C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4)CC5CC5.[Br-] DMZHPNE IK WDURTRGFUGAJHA-HNHWXVNLSA-M DMZHPNE IU [(1R,2R,4S,5S)-9-(cyclopropylmethyl)-9-methyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonan-7-yl] (2S)-3-hydroxy-2-phenylpropanoate;bromide DMZHPNE CA CAS 51598-60-8 DMZHPNE DE Spasm; Gastric motility disorder DMCX0K3 ID DMCX0K3 DMCX0K3 DN Cinacalcet DMCX0K3 HS Approved DMCX0K3 SN Cinacalcet [INN]; AMG 073; AMG073; Cinacalcet (USAN); Mimpara (TN); Sensipar (TN); N-[(1R)-1-(1-naphthyl)ethyl]-3-[3-(trifluoromethyl)phenyl]propan-1-amine; N-[(1R)-1-naphthalen-1-ylethyl]-3-[3-(trifluoromethyl)phenyl]propan-1-amine; N-((1R)-1-(1-Naphthyl)ethyl)-3-(3-(trifluoromethyl)phenyl)propan-1-amine; N-((1R)-1-(Naphthalen-1-yl)ethyl)-3-(3-(trifluoromethyl)phenyl)propan-1-amine; (R)-N-(1-(Naphthalen-1-yl)ethyl)-3-(3-(trifluoromethyl)phenyl)propan-1-amine; (R)-alpha-methyl-N-[3-[3-(trifluoromethyl)phenyl]propyl]-1-naphthalenemethane amine DMCX0K3 CP Amgen DMCX0K3 TC Calcimimetics DMCX0K3 DT Small molecular drug DMCX0K3 PC 156419 DMCX0K3 MW 357.4 DMCX0K3 FM C22H22F3N DMCX0K3 IC InChI=1S/C22H22F3N/c1-16(20-13-5-10-18-9-2-3-12-21(18)20)26-14-6-8-17-7-4-11-19(15-17)22(23,24)25/h2-5,7,9-13,15-16,26H,6,8,14H2,1H3/t16-/m1/s1 DMCX0K3 CS C[C@H](C1=CC=CC2=CC=CC=C21)NCCCC3=CC(=CC=C3)C(F)(F)F DMCX0K3 IK VDHAWDNDOKGFTD-MRXNPFEDSA-N DMCX0K3 IU N-[(1R)-1-naphthalen-1-ylethyl]-3-[3-(trifluoromethyl)phenyl]propan-1-amine DMCX0K3 CA CAS 226256-56-0 DMCX0K3 CB CHEBI:48390 DMCX0K3 DE Hyperparathyroidism; Kidney disease DMFIC0M ID DMFIC0M DMFIC0M DN Cinalukast DMFIC0M HS Approved DMFIC0M SN Cinalukast [USAN:INN]; Ro 24-5913; Cinalukast (USAN/INN); Ro-24-5913; (E)-4-[[3-(2-(4-Cyclobutyl-2-thiazolyl)ethenyl)phenyl]amino]-2,2-diethyl-4-oxobutanoic acid; 3'-((E)-2-(4-Cyclobutyl-2-thiazolyl)vinyl)-2,2-diethylsuccinanilic acid; 4-({3-[(E)-2-(4-cyclobutyl-1,3-thiazol-2-yl)ethenyl]phenyl}amino)-2,2-diethyl-4-oxobutanoic acid; 4-[3-[(E)-2-(4-cyclobutyl-1,3-thiazol-2-yl)ethenyl]anilino]-2,2-diethyl-4-oxobutanoic acid DMFIC0M TC Antiarrhythmic Agents DMFIC0M DT Small molecular drug DMFIC0M PC 6436135 DMFIC0M MW 412.5 DMFIC0M FM C23H28N2O3S DMFIC0M IC InChI=1S/C23H28N2O3S/c1-3-23(4-2,22(27)28)14-20(26)24-18-10-5-7-16(13-18)11-12-21-25-19(15-29-21)17-8-6-9-17/h5,7,10-13,15,17H,3-4,6,8-9,14H2,1-2H3,(H,24,26)(H,27,28)/b12-11+ DMFIC0M CS CCC(CC)(CC(=O)NC1=CC=CC(=C1)/C=C/C2=NC(=CS2)C3CCC3)C(=O)O DMFIC0M IK BZMKNPGKXJAIDV-VAWYXSNFSA-N DMFIC0M IU 4-[3-[(E)-2-(4-cyclobutyl-1,3-thiazol-2-yl)ethenyl]anilino]-2,2-diethyl-4-oxobutanoic acid DMFIC0M CA CAS 128312-51-6 DMFIC0M CB CHEBI:126598 DMFIC0M DE Asthma DM7U5QJ ID DM7U5QJ DM7U5QJ DN Cinnarizine DM7U5QJ HS Approved DM7U5QJ SN Aplactan; Aplexal; Apotomin; Artate; Carecin; Cerebolan; Cinaperazine; Cinarizina; Cinarizine; Cinazyn; Cinnacet; Cinnageron; Cinnarizinum; Corathiem; Denapol; Dimitron; Dimitronal; Eglen; Folcodal; Giganten; Glanil; Hilactan; Ixertol; Katoseran; Labyrin; Lazeta; Libotasin; Marisan; Midronal; Mitronal; Olamin; Processine; Sedatromin; Senoger; Sepan; Siptazin; Spaderizine; Stugeron; Stutgeron; Stutgin; Toliman; Votegol; Zepamol; Cinnarizine Stugeron; C 5270; MD 516; R 1575; R 516; Cero-Aterin; Cinarizina [INN-Spanish]; Cinnarizinum [INN-Latin]; R-516; Stugeron (TN); Stunarone (TN); Cinnarizine (JAN/USAN/INN); Cinnarizine [USAN:INN:BAN:JAN]; N-Benzhydryl-N'-cinnamylpiperazine; 1-(Diphenylmethyl)-4-(3-phenyl-2-propenyl)piperazine; 1-(diphenylmethyl)-4-(3-phenyl-2-propenyl)-piperazine; 1-(diphenylmethyl)-4-[(2E)-3-phenylprop-2-en-1-yl]piperazine; 1-Benzhydryl-4-cinnamylpiperazin; 1-Cinnamyl-4-(diphenylmethyl)piperazine; 1-benzhydryl-4-[(E)-3-phenylprop-2-enyl]piperazine; 1-trans-Cinnamyl-4-diphenylmethylpiperazine DM7U5QJ CP Janssen Pharmaceutica DM7U5QJ TC Antiallergic Agents DM7U5QJ DT Small molecular drug DM7U5QJ PC 1547484 DM7U5QJ MW 368.5 DM7U5QJ FM C26H28N2 DM7U5QJ IC InChI=1S/C26H28N2/c1-4-11-23(12-5-1)13-10-18-27-19-21-28(22-20-27)26(24-14-6-2-7-15-24)25-16-8-3-9-17-25/h1-17,26H,18-22H2/b13-10+ DM7U5QJ CS C1CN(CCN1C/C=C/C2=CC=CC=C2)C(C3=CC=CC=C3)C4=CC=CC=C4 DM7U5QJ IK DERZBLKQOCDDDZ-JLHYYAGUSA-N DM7U5QJ IU 1-benzhydryl-4-[(E)-3-phenylprop-2-enyl]piperazine DM7U5QJ CA CAS 16699-20-0 DM7U5QJ CB CHEBI:31403 DM7U5QJ DE Vertigo meniere disease DMDX1ZC ID DMDX1ZC DMDX1ZC DN Cinolazepam DMDX1ZC HS Approved DMDX1ZC SN Cinolazepamum; Gerodorm; Cinolazepam [INN]; OX 373; Cinolazepam (INN); Cinolazepamum [INN-Latin]; Gerodorm (TN); OX-373;1-(2-cyanoethyl)-7-chloro-3-hydroxy-5-(2'-fluorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one; 3-[7-chloro-5-(2-fluorophenyl)-3-hydroxy-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-1-yl]propanenitrile; 3-[7-chloro-5-(2-fluorophenyl)-3-hydroxy-2-oxo-3H-1,4-benzodiazepin-1-yl]propanenitrile; 7-Chloro-5-(o-fluorophenyl)-2,3-dihydro-3-hydroxy-2-oxo-1H-1,4-benzodiazepine-1-propionitrile; 7-chloro-5-(2-fluorophenyl)-2,3-dihydro-3-hydroxy-2-oxo-1H-1,4-benzodiazepine-1-propanenitrile DMDX1ZC TC Anticonvulsants DMDX1ZC DT Small molecular drug DMDX1ZC PC 3033621 DMDX1ZC MW 357.8 DMDX1ZC FM C18H13ClFN3O2 DMDX1ZC IC InChI=1S/C18H13ClFN3O2/c19-11-6-7-15-13(10-11)16(12-4-1-2-5-14(12)20)22-17(24)18(25)23(15)9-3-8-21/h1-2,4-7,10,17,24H,3,9H2 DMDX1ZC CS C1=CC=C(C(=C1)C2=NC(C(=O)N(C3=C2C=C(C=C3)Cl)CCC#N)O)F DMDX1ZC IK XAXMYHMKTCNRRZ-UHFFFAOYSA-N DMDX1ZC IU 3-[7-chloro-5-(2-fluorophenyl)-3-hydroxy-2-oxo-3H-1,4-benzodiazepin-1-yl]propanenitrile DMDX1ZC CA CAS 75696-02-5 DMDX1ZC CB CHEBI:59514 DMDX1ZC DE Muscle spasm DM4EWNS ID DM4EWNS DM4EWNS DN Cinoxacin DM4EWNS HS Approved DM4EWNS SN Cinobac; Cinobactin; Cinoxacine; Cinoxacino; Cinoxacinum; Cinx; Clinoxacin; Uronorm; Azolinic Acid; C 8645; Lilly 64716; TNP00246; Cinobac (TN); Cinoxacine [INN-French]; Cinoxacino [INN-Spanish]; Cinoxacinum [INN-Latin]; Cinoxacin (JAN/USP/INN); Cinoxacin [USAN:BAN:INN:JAN]; 1-Ethyl-1,4-dihydro-4-oxo(1,3)dioxolo(4,5-g)cinnoline-3-carboxylic acid; 1-Ethyl-1,4-dihydro-4-oxo[1,3]dioxolo[4,5-g]cinnoline-3-carboxylic acid; 1-Ethyl-4-oxo-1,4-dihydro[1,3]dioxolo[4,5-g]cinnoline-3-carboxylic acid; 1-Ethyl-6,7-methylenedioxy-4(1H)-oxocinnoline-3-carboxylic acid; 1-ethyl-4-oxo-[1,3]dioxolo[4,5-g]cinnoline-3-carboxylic acid DM4EWNS TC Antiinfective Agents DM4EWNS DT Small molecular drug DM4EWNS PC 2762 DM4EWNS MW 262.22 DM4EWNS FM C12H10N2O5 DM4EWNS IC InChI=1S/C12H10N2O5/c1-2-14-7-4-9-8(18-5-19-9)3-6(7)11(15)10(13-14)12(16)17/h3-4H,2,5H2,1H3,(H,16,17) DM4EWNS CS CCN1C2=CC3=C(C=C2C(=O)C(=N1)C(=O)O)OCO3 DM4EWNS IK VDUWPHTZYNWKRN-UHFFFAOYSA-N DM4EWNS IU 1-ethyl-4-oxo-[1,3]dioxolo[4,5-g]cinnoline-3-carboxylic acid DM4EWNS CA CAS 28657-80-9 DM4EWNS CB CHEBI:3716 DM4EWNS DE Urinary tract infection DMVIKJZ ID DMVIKJZ DMVIKJZ DN Cinryze DMVIKJZ HS Approved DMVIKJZ DE Hereditary angioedema DMGC5DB ID DMGC5DB DMGC5DB DN Ciprofibrate DMGC5DB HS Approved DMGC5DB SN Ciprofibrato; Ciprofibratum; Ciprol; Hiperlipen; Hyperlipen; Lipanor; Modalim; Oroxadin; Sanofi Synthelabo brand of ciprofibrate; Sanofi Winthrop brand of ciprofibrate; C 0330; WIN 35833; Ciprofibrato [INN-Spanish]; Ciprofibratum [INN-Latin]; Win 35,833; Win-35833; Ciprofibrate (USAN/INN); Ciprofibrate [USAN:BAN:INN]; 2-(4-(2,2-Dichlorocyclopropyl)phenoxy)2-methylpropanoic acid; 2-(p-(2,2-Dichlorocyclopropyl)phenoxy)-2-methylpropionic acid; 2-[4-(2,2-Dichlorocyclopropyl)phenoxy]-2-methylpropanoic acid; 2-[p-(2,2-Dichlorocyclopropyl)phenoxy]-2-methylpropanoic acid; 2-{4-[2,2-dichlorocyclopropyl]phenoxy}-2-methylpropanoic acid; 2-{[4-(2,2-dichlorocyclopropyl)phenyl]oxy}-2-methylpropanoic acid DMGC5DB TC Anticancer Agents DMGC5DB DT Small molecular drug DMGC5DB PC 2763 DMGC5DB MW 289.15 DMGC5DB FM C13H14Cl2O3 DMGC5DB IC InChI=1S/C13H14Cl2O3/c1-12(2,11(16)17)18-9-5-3-8(4-6-9)10-7-13(10,14)15/h3-6,10H,7H2,1-2H3,(H,16,17) DMGC5DB CS CC(C)(C(=O)O)OC1=CC=C(C=C1)C2CC2(Cl)Cl DMGC5DB IK KPSRODZRAIWAKH-UHFFFAOYSA-N DMGC5DB IU 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanoic acid DMGC5DB CA CAS 52214-84-3 DMGC5DB CB CHEBI:50867 DMGC5DB DE Hyperlipoproteinemia DM2NLS9 ID DM2NLS9 DM2NLS9 DN Ciprofloxacin XR DM2NLS9 HS Approved DM2NLS9 SN ciprofloxacin; 85721-33-1; Ciprofloxacine; Ciprobay; Ciproxan; Ciprofloxacina; Ciprofloxacinum; Ciprofloxacino; Cipro IV; Ciproxina; Ciprinol; Bernoflox; Ciprodar; Cifloxin; Septicide; Bacquinor; Ciproquinol; Cipromycin; Ciprocinol; Cipro XR; Superocin; Ciprowin; Ciprolon; Ciproflox; Ciprecu; BAY q 3939; Spitacin; Quintor; Quinolid; Proflaxin; Probiox; Ipiflox; Zumaflox; Ciproxine; Ciprolin; Roxytal; Italnik; Fimoflox; Corsacin; Citopcin; Ciprogis; Rancif; Ciriax; Ciplus; Baflox; Loxan; Cilab; Cycin; Cixan; Unex; GW1843; Ciprofloxacin Hydrochloride; Ciprofloxacin intratympanic - Otonomy DM2NLS9 CP Depomed Bayer DM2NLS9 DT Small molecular drug DM2NLS9 PC 2764 DM2NLS9 MW 331.34 DM2NLS9 FM C17H18FN3O3 DM2NLS9 IC InChI=1S/C17H18FN3O3/c18-13-7-11-14(8-15(13)20-5-3-19-4-6-20)21(10-1-2-10)9-12(16(11)22)17(23)24/h7-10,19H,1-6H2,(H,23,24) DM2NLS9 CS C1CC1N2C=C(C(=O)C3=CC(=C(C=C32)N4CCNCC4)F)C(=O)O DM2NLS9 IK MYSWGUAQZAJSOK-UHFFFAOYSA-N DM2NLS9 IU 1-cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-ylquinoline-3-carboxylic acid DM2NLS9 CA CAS 85721-33-1 DM2NLS9 CB CHEBI:100241 DM2NLS9 DE Bacterial infection; Gram-positive bacterial infection; Biliary cancer; Cystic fibrosis DMZR26N ID DMZR26N DMZR26N DN Ciprofloxacin+dexamethasone DMZR26N HS Approved DMZR26N SN CIPRODEX; Ciprofloxacin mixture with dexamethasone; 130244-48-3; Ciprodex Otic; Ciprofloxacin / dexamethasone; Ciprofloxacin and dexamethasone; Ciprofloxacin-dexamethasone Mixt.; SCHEMBL2523572; DTXSID50156420; NTRHYMXQWWPZDD-WKSAPEMMSA-N; Pregna-1,4-diene-3,20-dione, 9-fluoro-11,17,21-trihydroxy-16-methyl-, (11beta,16alpha)-, mixt. with 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid DMZR26N CP Alcon DMZR26N DT Small molecular drug DMZR26N PC 9961920 DMZR26N MW 723.8 DMZR26N FM C39H47F2N3O8 DMZR26N IC InChI=1S/C22H29FO5.C17H18FN3O3/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,23)17(26)10-20(16,3)22(12,28)18(27)11-24;18-13-7-11-14(8-15(13)20-5-3-19-4-6-20)21(10-1-2-10)9-12(16(11)22)17(23)24/h6-7,9,12,15-17,24,26,28H,4-5,8,10-11H2,1-3H3;7-10,19H,1-6H2,(H,23,24)/t12-,15+,16+,17+,19+,20+,21+,22+;/m1./s1 DMZR26N CS C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)F)C.C1CC1N2C=C(C(=O)C3=CC(=C(C=C32)N4CCNCC4)F)C(=O)O DMZR26N IK NTRHYMXQWWPZDD-WKSAPEMMSA-N DMZR26N IU 1-cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-ylquinoline-3-carboxylic acid;(8S,9R,10S,11S,13S,14S,16R,17R)-9-fluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one DMZR26N CA CAS 130244-48-3 DMZR26N DE Otitis externa; Acute otitis media DMY7PED ID DMY7PED DMY7PED DN Cisapride DMY7PED HS Approved DMY7PED SN cisapride; Propulsid; Prepulsid; Syspride; Pridesia; Risamal; Acenalin; Alimix; Propulsin; Propulsid Quicksolv; Enteropride; Kinestase; 81098-60-4; Cisawal; Vomiprid; Colinorm; Cisapron; Vomipride; Unipride; Kaudalit; Alipride; Acpulsif; Rapulid; Cipride; Pulsid; Esorid; Dispep; Presid; Unamol; Guptro; Alimix Forte; Cisapridum [Latin]; Cisaprida [Spanish]; R-51619; Cisapridum [INN-Latin]; R 51619; Cisaprida [INN-Spanish]; 104860-73-3; DCSUBABJRXZOMT-UHFFFAOYSA-N; T 1341; DSSTox_CID_2825; Acenalin; Cisaprida; Cisapridum; Risamol; Prepulsid (TN); Propulsid (TN); Cisapride (USAN/INN); Cisapride [USAN:BAN:INN:JAN]; Cis-4-Amino-5-chloro-N-(1-(3-(p-fluorophenoxy)propyl)-3-methoxy-4-piperidyl)-o-anisamide; (+-)-Cisapride; 4-amino-5-chloro-N-[1-[3-(4-fluorophenoxy)propyl]-3-methoxypiperidin-4-yl]-2-methoxybenzamide; 4-amino-5-chloro-N-[1-{3-[(4-fluorophenyl)oxy]propyl}-3-(methyloxy)piperidin-4-yl]-2-(methyloxy)benzamide; 4-amino-5-chloro-N-{1-[3-(4-fluorophenoxy)propyl]-3-methoxypiperidin-4-yl}-2-methoxybenzamide; E-1454 DMY7PED CP Janssen Pharmaceutica DMY7PED TC Gastrointestinal Agents DMY7PED DT Small molecular drug DMY7PED PC 6917698 DMY7PED MW 465.9 DMY7PED FM C23H29ClFN3O4 DMY7PED IC InChI=1S/C23H29ClFN3O4/c1-30-21-13-19(26)18(24)12-17(21)23(29)27-20-8-10-28(14-22(20)31-2)9-3-11-32-16-6-4-15(25)5-7-16/h4-7,12-13,20,22H,3,8-11,14,26H2,1-2H3,(H,27,29)/t20-,22+/m1/s1 DMY7PED CS CO[C@H]1CN(CC[C@H]1NC(=O)C2=CC(=C(C=C2OC)N)Cl)CCCOC3=CC=C(C=C3)F DMY7PED IK DCSUBABJRXZOMT-IRLDBZIGSA-N DMY7PED IU 4-amino-5-chloro-N-[(3S,4R)-1-[3-(4-fluorophenoxy)propyl]-3-methoxypiperidin-4-yl]-2-methoxybenzamide DMY7PED CA CAS 81098-60-4 DMY7PED CB CHEBI:3720 DMY7PED DE Gastroesophageal reflux disease; Gastrointestinal disease DMUZPJ5 ID DMUZPJ5 DMUZPJ5 DN Cisatracurium DMUZPJ5 HS Approved DMUZPJ5 SN Cisatracurium Besylate; Cisatracurium Besylate Preservative Free; Nimbex; Nimbex Preservative Free DMUZPJ5 CP Abbvie Inc DMUZPJ5 DT Small molecular drug DMUZPJ5 PC 62887 DMUZPJ5 MW 929.1 DMUZPJ5 FM C53H72N2O12+2 DMUZPJ5 IC InChI=1S/C53H72N2O12/c1-54(22-18-38-32-48(62-7)50(64-9)34-40(38)42(54)28-36-14-16-44(58-3)46(30-36)60-5)24-20-52(56)66-26-12-11-13-27-67-53(57)21-25-55(2)23-19-39-33-49(63-8)51(65-10)35-41(39)43(55)29-37-15-17-45(59-4)47(31-37)61-6/h14-17,30-35,42-43H,11-13,18-29H2,1-10H3/q+2/t42-,43-,54-,55-/m1/s1 DMUZPJ5 CS C[N@@+]1(CCC2=CC(=C(C=C2[C@H]1CC3=CC(=C(C=C3)OC)OC)OC)OC)CCC(=O)OCCCCCOC(=O)CC[N@+]4(CCC5=CC(=C(C=C5[C@H]4CC6=CC(=C(C=C6)OC)OC)OC)OC)C DMUZPJ5 IK YXSLJKQTIDHPOT-LJCJQEJUSA-N DMUZPJ5 IU 5-[3-[(1R,2R)-1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propanoyloxy]pentyl 3-[(1R,2R)-1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propanoate DMUZPJ5 CA CAS 96946-41-7 DMUZPJ5 CB CHEBI:140621 DMUZPJ5 DE Muscle spasm DMRHGI9 ID DMRHGI9 DMRHGI9 DN Cisplatin DMRHGI9 HS Approved DMRHGI9 SN Abiplatin; Biocisplatinum; Briplatin; Cismaplat; Cisplatine; Cisplatino; Cisplatinum; Cisplatyl; Citoplationo; Lederplatin; Neoplatin; Plastin; Platamine; Platidiam; Platinoxan; Randa; Cis-DDP; Cis-Diamminedichloroplatinum; Peyrone's chloride; Peyrone's salt; Cis-Dichlorodiammineplatinum(II); Cis-[PtCl2(NH3)2]; Cis-diamminedichloridoplatinum(II); Trans-diamminedichloridoplatinum(II); (SP-4-1)-diamminedichloridoplatinum; (SP-4-1)-diamminedichloroplatinum; (SP-4-2)-diamminedichloridoplatinum; (SP-4-2)-diamminedichloroplatinum; Cisplatin (Chemotherapy) DMRHGI9 CP Bristol-Myers Squibb DMRHGI9 TC Anticancer Agents DMRHGI9 DT Small molecular drug DMRHGI9 PC 5702198 DMRHGI9 MW 300.05 DMRHGI9 FM Cl2H6N2Pt DMRHGI9 IC InChI=1S/2ClH.2H3N.Pt/h2*1H;2*1H3;/q;;;;+2/p-2 DMRHGI9 CS N.N.Cl[Pt]Cl DMRHGI9 IK LXZZYRPGZAFOLE-UHFFFAOYSA-L DMRHGI9 IU azane;dichloroplatinum DMRHGI9 CA CAS 15663-27-1 DMRHGI9 DE Solid tumour/cancer; Osteosarcoma DM2G9AE ID DM2G9AE DM2G9AE DN Citalopram DM2G9AE HS Approved DM2G9AE SN Akarin; Celapram; Celexa; Celius; Ciazil; Cilift; Cipram; Ciprapine; Citabax; Citadur; Citalec; Citalopramum; Citopam; Cytalopram; Dalsan; Humorup; Nitalapram; Oropram; Pramcit; Recital; Seropram; Talam; Talohexal; Temperax; Vodelax; Zentius; Zetalo; Citalopram [Celexa]; [3H]Citalopram; Akarin (TN); Celapram (TN); Celexa (TN); Celius (TN); Ciazil (TN); Cilift (TN); Cipram (TN); Cipramil (TN); Ciprapine (TN); Citabax (TN); Citadur (TN); Citalec (TN); Citalopram [INN:BAN]; Citalopramum [INN-Latin]; Citaxin (TN); Citol (TN); Citopam (TN); Citox (TN); Citrol (TN); Dalsan (TN); Lu 10-171; Recital (TN); Seropram (TN); Talam (TN); Zentius (TN); Zetalo (TN); AE-641/00603021; Citalopram (USP/INN); Lu-10-171; 1,3-Dihydro-1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-5-isobenzofurancarbonitrile; 1,3-dihydro[3,4]benzofuran-5-carbonitrile; 1-(3-(Dimethylamino)propyl)-1-(p-fluorophenyl)-5-phthalancarbonitrile; 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile; 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3H-2-benzofuran-5-carbonitrile DM2G9AE CP Forest Laboratories, Inc DM2G9AE TC Antidepressants DM2G9AE DT Small molecular drug DM2G9AE PC 2771 DM2G9AE MW 324.4 DM2G9AE FM C20H21FN2O DM2G9AE IC InChI=1S/C20H21FN2O/c1-23(2)11-3-10-20(17-5-7-18(21)8-6-17)19-9-4-15(13-22)12-16(19)14-24-20/h4-9,12H,3,10-11,14H2,1-2H3 DM2G9AE CS CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F DM2G9AE IK WSEQXVZVJXJVFP-UHFFFAOYSA-N DM2G9AE IU 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3H-2-benzofuran-5-carbonitrile DM2G9AE CA CAS 59729-33-8 DM2G9AE CB CHEBI:77397 DM2G9AE DE Depression DMI4XBM ID DMI4XBM DMI4XBM DN Citicoline DMI4XBM HS Approved DMI4XBM SN Alphcolin; CerAxon; Citicholine; Hipercol; Neurex; Nicholin; Somazina; Trausan; Citicoline sodium; Cytidil diphosphocholine; CDP-choline; IP-302; Cytidine-5-diphosphocholine DMI4XBM CP Ferrer Internacional SA DMI4XBM DT Small molecular drug DMI4XBM PC 13804 DMI4XBM MW 488.32 DMI4XBM FM C14H26N4O11P2 DMI4XBM IC InChI=1S/C14H26N4O11P2/c1-18(2,3)6-7-26-30(22,23)29-31(24,25)27-8-9-11(19)12(20)13(28-9)17-5-4-10(15)16-14(17)21/h4-5,9,11-13,19-20H,6-8H2,1-3H3,(H3-,15,16,21,22,23,24,25)/t9-,11-,12-,13-/m1/s1 DMI4XBM CS C[N+](C)(C)CCOP(=O)([O-])OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=CC(=NC2=O)N)O)O DMI4XBM IK RZZPDXZPRHQOCG-OJAKKHQRSA-N DMI4XBM IU [[(2R,3S,4R,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] 2-(trimethylazaniumyl)ethyl phosphate DMI4XBM CA CAS 987-78-0 DMI4XBM CB CHEBI:16436 DMI4XBM DE Cerebrovascular ischaemia DMMEBWR ID DMMEBWR DMMEBWR DN Citric acid, magnesium oxide, sodium picosulfate DMMEBWR HS Approved DMMEBWR SN Prepopik (TN) DMMEBWR CP Ferring Pharmaceuticals DMMEBWR DT Small molecular drug DMMEBWR PC 68654 DMMEBWR MW 481.4 DMMEBWR FM C18H13NNa2O8S2 DMMEBWR IC InChI=1S/C18H15NO8S2.2Na/c20-28(21,22)26-15-8-4-13(5-9-15)18(17-3-1-2-12-19-17)14-6-10-16(11-7-14)27-29(23,24)25;;/h1-12,18H,(H,20,21,22)(H,23,24,25);;/q;2*+1/p-2 DMMEBWR CS C1=CC=NC(=C1)C(C2=CC=C(C=C2)OS(=O)(=O)[O-])C3=CC=C(C=C3)OS(=O)(=O)[O-].[Na+].[Na+] DMMEBWR IK GOZDTZWAMGHLDY-UHFFFAOYSA-L DMMEBWR IU disodium;[4-[pyridin-2-yl-(4-sulfonatooxyphenyl)methyl]phenyl] sulfate DMMEBWR CA CAS 10040-45-6 DMMEBWR CB CHEBI:32147 DMMEBWR DE Crohn disease DM3JDRP ID DM3JDRP DM3JDRP DN Cladribine DM3JDRP HS Approved DM3JDRP SN Chlorodeoxyadenosine; Cladarabine; Cladaribine; Cladribina; Cladribinum; CldAdo; Leustat; Leustatin; Litak; Movectro;Mylinax; CL9; RWJ 26251; Leustatin (TN); RWJ-26251; Cladribine [USAN:INN:BAN]; RWJ-26251-000; Cladribine (JAN/USAN/INN); Leustatin, 2-chlorodeoxyadenosine, Cladribine; Adenosine, 2-chloro-2'-deoxy; (2R,3S,5R)-5-(6-amino-2-chloropurin-9-yl)-2-(hydroxymethyl)oxolan-3-ol; 2 Chlorodeoxyadenosine; 2'-Deoxy-2-chloroadenosine; 2-CdA; 2-Chloro-2'-deoxy-beta-adenosine; 2-Chloro-2'-deoxyadenosine; 2-Chloro-6-amino-9-(2-deoxy-beta-D-erythropentofuranosyl)purine; 2-Chlorodeoxyadenosine; 2-chloro-6-amino-9-(2-deoxy-beta-D-erythro-pentofuranosyl)purine; 2-chloro-deoxyadenosine DM3JDRP CP EMD Serono Rockland, MA DM3JDRP TC Anticancer Agents DM3JDRP DT Small molecular drug DM3JDRP PC 20279 DM3JDRP MW 285.69 DM3JDRP FM C10H12ClN5O3 DM3JDRP IC InChI=1S/C10H12ClN5O3/c11-10-14-8(12)7-9(15-10)16(3-13-7)6-1-4(18)5(2-17)19-6/h3-6,17-18H,1-2H2,(H2,12,14,15)/t4-,5+,6+/m0/s1 DM3JDRP CS C1[C@@H]([C@H](O[C@H]1N2C=NC3=C(N=C(N=C32)Cl)N)CO)O DM3JDRP IK PTOAARAWEBMLNO-KVQBGUIXSA-N DM3JDRP IU (2R,3S,5R)-5-(6-amino-2-chloropurin-9-yl)-2-(hydroxymethyl)oxolan-3-ol DM3JDRP CA CAS 4291-63-8 DM3JDRP CB CHEBI:567361 DM3JDRP DE Multiple sclerosis; Relapsing-remitting multiple sclerosis; Hairy cell leukaemia DM4M1SG ID DM4M1SG DM4M1SG DN Clarithromycin DM4M1SG HS Approved DM4M1SG SN Abbotic; Adel; Astromen; Biaxin; Bicrolid; CTY; Clacine; Clambiotic; Claribid; Claricide; Clarith; Clarithromycina; Clarithromycine; Clarithromycinum; Claritromicina; Clathromycin; Cyllid; Cyllind; Helas; Heliclar; Klacid; Klaciped; Klaricid; Klarid; Klarin; Klax; Kofron; Mabicrol; Macladin; Maclar; Mavid; Naxy;Veclam; Zeclar; Biaxin HP; Biaxin XL; Biaxin filmtab; Biaxin xl filmtab; Clarithromycin extended release; Clarithromycin suspension or tablets; Klaricid Pediatric; Klaricid XL; TE031; A-56268; ANX-015; Abbott-56268; Biaxin (TN); Clacid (TN); Claridar (TN); Claripen (TN); Clarithromycine [INN-French]; Clarithromycinum [INN-Latin]; Claritromicina [INN-Spanish]; Crixan (TN); DRG-0099; Fromilid (TN);Infex (TN); Klabax (TN); Klaricid (TN); Klaricid H.P; Lactoferrin B & Clarithromycin; Lactoferrin H & Clarithromycin; SDP-015; TE-031; Vikrol (TN); CLM & IL-12; CRL-1605 & Clarithromycin; Clarithromycin & Interleukin-12; Klaricid H.P.; O(6)-methylerythromycin; Clarithromycin (JP15/USP/INN); Clarithromycin [USAN:INN:BAN:JAN]; Hydro-2H-pyran-2-yl]oxy}-7-methoxy-3,5,7,9,11,13-hexame; (14R)-14-Hydroxyclarithromycin; 6-O-Methylerythromycin; 6-O-Methylerythromycin a DM4M1SG CP Abbott Laboratories DM4M1SG TC Antibiotics DM4M1SG DT Small molecular drug DM4M1SG PC 84029 DM4M1SG MW 748 DM4M1SG FM C38H69NO13 DM4M1SG IC InChI=1S/C38H69NO13/c1-15-26-38(10,45)31(42)21(4)28(40)19(2)17-37(9,47-14)33(52-35-29(41)25(39(11)12)16-20(3)48-35)22(5)30(23(6)34(44)50-26)51-27-18-36(8,46-13)32(43)24(7)49-27/h19-27,29-33,35,41-43,45H,15-18H2,1-14H3/t19-,20-,21+,22+,23-,24+,25+,26-,27+,29-,30+,31-,32+,33-,35+,36-,37-,38-/m1/s1 DM4M1SG CS CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O DM4M1SG IK AGOYDEPGAOXOCK-KCBOHYOISA-N DM4M1SG IU (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-12,13-dihydroxy-4-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-7-methoxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecane-2,10-dione DM4M1SG CA CAS 81103-11-9 DM4M1SG CB CHEBI:3732 DM4M1SG DE Bacterial infection DMPGR1E ID DMPGR1E DMPGR1E DN Clascoterone DMPGR1E HS Approved DMPGR1E SN CB-03-01 DMPGR1E CP Cosmo Pharmaceuticals SpA DMPGR1E DT Small molecular drug DMPGR1E PC 11750009 DMPGR1E MW 402.5 DMPGR1E FM C24H34O5 DMPGR1E IC InChI=1S/C24H34O5/c1-4-21(28)29-24(20(27)14-25)12-9-19-17-6-5-15-13-16(26)7-10-22(15,2)18(17)8-11-23(19,24)3/h13,17-19,25H,4-12,14H2,1-3H3/t17-,18+,19+,22+,23+,24+/m1/s1 DMPGR1E CS CCC(=O)O[C@@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C)C(=O)CO DMPGR1E IK GPNHMOZDMYNCPO-PDUMRIMRSA-N DMPGR1E IU [(8R,9S,10R,13S,14S,17R)-17-(2-hydroxyacetyl)-10,13-dimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-17-yl] propanoate DMPGR1E CA CAS 19608-29-8 DMPGR1E DE Acne vulgaris DM2FGRT ID DM2FGRT DM2FGRT DN Clavulanate DM2FGRT HS Approved DM2FGRT SN Clavulansaeure; Clavulox; Acide clavulanique; Acido clavulanico; Acidum clavulanicum; CLAVULANIC ACID; Clavulansaeure [INN]; Clavulinic Acid; Sodium Clavulanate; Antibiotic MM 14151; MM 14151; Acide clavulanique [INN-French]; Acido clavulanico [INN-Spanish]; Acidum clavulanicum [INN-Latin]; BRL-14151; Clavulanic acid (INN); Clavulanic acid [BAN:INN]; Clavulox (TN); MM-14151; (2R,3Z,5R)-3-(2-hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (Z)-(2R,5R)-3-(2-Hydroxyethyliden)-7-oxo-4-oxa-1-azabicyclo(3.2.0)heptan-2-carbonsaeure; (Z)-(2R,5R)-3-(2-Hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo(3.2.0)heptane-2-carboxylic acid; 3008-B; 4-Oxa-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 3-(2-hydroxyethylidene)-7-oxo-, (2R-(2alpha,3Z,5alpha)) DM2FGRT CP GlaxoSmithKline DM2FGRT TC Antibiotics DM2FGRT DT Small molecular drug DM2FGRT PC 5280980 DM2FGRT MW 199.16 DM2FGRT FM C8H9NO5 DM2FGRT IC InChI=1S/C8H9NO5/c10-2-1-4-7(8(12)13)9-5(11)3-6(9)14-4/h1,6-7,10H,2-3H2,(H,12,13)/b4-1-/t6-,7-/m1/s1 DM2FGRT CS C1[C@@H]2N(C1=O)[C@H](/C(=C/CO)/O2)C(=O)O DM2FGRT IK HZZVJAQRINQKSD-PBFISZAISA-N DM2FGRT IU (2R,3Z,5R)-3-(2-hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo[3.2.0]heptane-2-carboxylic acid DM2FGRT CA CAS 58001-44-8 DM2FGRT CB CHEBI:48947 DM2FGRT DE Bacterial infection DMBZWQL ID DMBZWQL DMBZWQL DN Clemastine DMBZWQL HS Approved DMBZWQL SN Clemastina; Clemastinum; Meclastin; Meclastine; Mecloprodin; Tavegyl; Tavist; CLEMASTINE FUMARATE; HS 592; Clemastina [INN-Spanish]; Clemastine [USAN:BAN]; Clemastinum [INN-Latin]; HS-592; Tavegyl (TN); Tavist (TN); Tavist (*Fumarate*); (+)-(2R)-2-(2-(((R)-p-Chloro-alpha-methyl-alpha-phenylbenzyl)oxy)ethyl)-1-methylpyrrolidine; (+)-(2R)-2-[2-[[(R)-p-Chloro-alpha-methyl-alpha-phenylbenzyl]oxy]ethyl]-1-methylpyrrolidine; (2R)-2-(2-{[(1R)-1-(4-chlorophenyl)-1-phenylethyl]oxy}ethyl)-1-methylpyrrolidine; (2R)-2-[2-[(1R)-1-(4-chlorophenyl)-1-phenylethoxy]ethyl]-1-methylpyrrolidine; (2R)-2-{2-[(1R)-1-(4-chlorophenyl)-1-phenylethoxy]ethyl}-1-methylpyrrolidine; 2(R)-[2-[(1R)-(4-Chlorophenyl)-1-phenyl-ethoxy]ethyl-1-methylpyrrolidine; 2-(2-(4-Chlor-alpha-methylbenzhydryloxy)ethyl)-1-methylpyrrolidin DMBZWQL CP Norvatis Phamaceuticals Corporation DMBZWQL TC Antiallergic Agents DMBZWQL DT Small molecular drug DMBZWQL PC 26987 DMBZWQL MW 343.9 DMBZWQL FM C21H26ClNO DMBZWQL IC InChI=1S/C21H26ClNO/c1-21(17-7-4-3-5-8-17,18-10-12-19(22)13-11-18)24-16-14-20-9-6-15-23(20)2/h3-5,7-8,10-13,20H,6,9,14-16H2,1-2H3/t20-,21-/m1/s1 DMBZWQL CS C[C@@](C1=CC=CC=C1)(C2=CC=C(C=C2)Cl)OCC[C@H]3CCCN3C DMBZWQL IK YNNUSGIPVFPVBX-NHCUHLMSSA-N DMBZWQL IU (2R)-2-[2-[(1R)-1-(4-chlorophenyl)-1-phenylethoxy]ethyl]-1-methylpyrrolidine DMBZWQL CA CAS 15686-51-8 DMBZWQL CB CHEBI:3738 DMBZWQL DE Allergic rhinitis DMCKYZ5 ID DMCKYZ5 DMCKYZ5 DN Clenbuterol DMCKYZ5 HS Approved DMCKYZ5 SN Clenbuterolum; Contraspasmin; Planipart; Planipart [veterinary]; Clenbuterol (INN); Clenbuterol [BAN:INN]; Clenbuterolum [INN-Latin]; Contraspasmin (TN); NAB-365; Planipart [veterinary] (TN); (+)-4-Amino-alpha-((tert-butylamino)methyl)-3,5-dichlorobenzyl alcohol; (+-)-clenbuterol; (-)-4-Amino-alpha-((tert-butylamino)methyl)-3,5-dichlorobenzyl alcohol; 1-(4-Amino-3,5-dichloro-phenyl)-2-tert-butylamino-ethanol; 1-(4-Amino-3,5-dichlorophenyl)-2-(tert-butylamino)ethanol; 1-(4-amino-3,5-dichlorophenyl)-2-[(1,1-dimethylethyl)amino]ethanol; 4-Amino-3,5-dichloro-alpha-(((1,1-dimethylethyl)amino)methyl)benzenemethanol; 4-Amino-alpha-((tert-butylamino)methyl)-3,5-dichlorobenzyl alcohol DMCKYZ5 TC Bronchodilator Agents DMCKYZ5 DT Small molecular drug DMCKYZ5 PC 2783 DMCKYZ5 MW 277.19 DMCKYZ5 FM C12H18Cl2N2O DMCKYZ5 IC InChI=1S/C12H18Cl2N2O/c1-12(2,3)16-6-10(17)7-4-8(13)11(15)9(14)5-7/h4-5,10,16-17H,6,15H2,1-3H3 DMCKYZ5 CS CC(C)(C)NCC(C1=CC(=C(C(=C1)Cl)N)Cl)O DMCKYZ5 IK STJMRWALKKWQGH-UHFFFAOYSA-N DMCKYZ5 IU 1-(4-amino-3,5-dichlorophenyl)-2-(tert-butylamino)ethanol DMCKYZ5 CA CAS 37148-27-9 DMCKYZ5 CB CHEBI:174690 DMCKYZ5 DE Chronic breathing disorder DMW4M97 ID DMW4M97 DMW4M97 DN Clevidipine butyrate DMW4M97 HS Approved DMW4M97 SN Clevidipine; Cleviprex; 167221-71-8; Clevelox; rac-Clevidipine; H 324/38; Methyl (1-oxobutoxy)methyl 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dime thyl-3,5-pyridinedicarboxylate; Methyl (1-oxobutoxy)methyl 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate; Cleviprex (TN); 3-((butyryloxy)methyl) 5-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate; METHYL 5-{[(BUTANOYLOXY)METHOXY]CARBONYL}-4-(2,3-DICHLOROPHENYL)-2,6-DIMETHYL-1,4-DIHYDROPYRIDINE-3 DMW4M97 CP The Medicines Company DMW4M97 DT Small molecular drug DMW4M97 PC 153994 DMW4M97 MW 456.3 DMW4M97 FM C21H23Cl2NO6 DMW4M97 IC InChI=1S/C21H23Cl2NO6/c1-5-7-15(25)29-10-30-21(27)17-12(3)24-11(2)16(20(26)28-4)18(17)13-8-6-9-14(22)19(13)23/h6,8-9,18,24H,5,7,10H2,1-4H3 DMW4M97 CS CCCC(=O)OCOC(=O)C1=C(NC(=C(C1C2=C(C(=CC=C2)Cl)Cl)C(=O)OC)C)C DMW4M97 IK KPBZROQVTHLCDU-UHFFFAOYSA-N DMW4M97 IU 5-O-(butanoyloxymethyl) 3-O-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate DMW4M97 CA CAS 167221-71-8 DMW4M97 CB CHEBI:135738 DMW4M97 DE Hypertension DMUMQZ0 ID DMUMQZ0 DMUMQZ0 DN Clidinium DMUMQZ0 HS Approved DMUMQZ0 SN clidinium; N-Methyl quinuclidinyl benzilate; 7020-55-5; 3-hydroxy-1-methylquinuclidinium benzilate ester; 3-{[hydroxy(diphenyl)acetyl]oxy}-1-methyl-1-azoniabicyclo[222]octane; Ro-23773; 3-(2-Hydroxy-2,2-diphenyl-acetoxy)-1-methyl-1-azonia-bicyclo[222]octane; 1-Azoniabicyclo(222)octane, 3-((hydroxydiphenylacetyl)oxy)-1-methyl-; [3H]clidinium; (-)MQNB; Clidinium bromid; (1-methyl-1-azoniabicyclo[222]octan-8-yl) 2-hydroxy-2,2-di(phenyl)acetate; 3-Hydroxy-1-methylquinuclidinium benzilate (ester); Quinuclidinium,; Librax (TN); Benzilic acid, ester with 3-hydroxy-1-methylquinuclidinium; Quinuclidinium, 3-hydroxy-1-methyl-, benzilate (ester); (1-methyl-1-azoniabicyclo[222]octan-3-yl) 2-hydroxy-2,2-diphenylacetate DMUMQZ0 CP Hoffmann La Roche Inc DMUMQZ0 TC Analgesics DMUMQZ0 DT Small molecular drug DMUMQZ0 PC 2784 DMUMQZ0 MW 352.4 DMUMQZ0 FM C22H26NO3+ DMUMQZ0 IC InChI=1S/C22H26NO3/c1-23-14-12-17(13-15-23)20(16-23)26-21(24)22(25,18-8-4-2-5-9-18)19-10-6-3-7-11-19/h2-11,17,20,25H,12-16H2,1H3/q+1 DMUMQZ0 CS C[N+]12CCC(CC1)C(C2)OC(=O)C(C3=CC=CC=C3)(C4=CC=CC=C4)O DMUMQZ0 IK HOOSGZJRQIVJSZ-UHFFFAOYSA-N DMUMQZ0 IU (1-methyl-1-azoniabicyclo[2.2.2]octan-3-yl) 2-hydroxy-2,2-diphenylacetate DMUMQZ0 CA CAS 7020-55-5 DMUMQZ0 CB CHEBI:3743 DMUMQZ0 DE Irritable bowel syndrome; Abdominal stomach pain DM15HL8 ID DM15HL8 DM15HL8 DN Clindamycin DM15HL8 HS Approved DM15HL8 SN Antirobe; CLDM; CLY; Chlolincocin; Chlorlincocin; Chlorodeoxylincomycin; Chlorolincomycin; Cleocin; ClindaDerm; Clindamicina; Clindamycine; Clindamycinum; Clinimycin; Dalacine; Klimicin; Sobelin; Zindaclin; Cleocin HCl; Cleocin T Gel; Cleocin T Lotion; Cleocin T Topical Solution; Clindamycine [French]; Dalacin C; Dalacin C Flavored Granules; Dalacin C Phosphate; Dalacin T Topical Solution; ResiDerm A; Klindan 300; U 21251; Cleocin (TN); Clindacin (TN); Clindamicina [INN-Spanish]; Clindamycin & Interleukin 12; Clindamycin & VRC3375; Clindamycine [INN-French]; Clindamycinum [INN-Latin]; Dalacin (TN); Evoclin (TN); U-21251; CLINDA & IL-12; Clindamycin (USAN/INN); Clindamycin [USAN:BAN:INN]; U-21,251; 7(S)-Chloro-7-deoxylincomycin; 7-CDL; 7-Chloro-7-deoxylincomycin; 7-Chlorolincomycin; 7-Deoxy-7(S)-chlorolincomycin DM15HL8 CP Pharmacia And Upjohn Co DM15HL8 TC Antibiotics DM15HL8 DT Small molecular drug DM15HL8 PC 446598 DM15HL8 MW 425 DM15HL8 FM C18H33ClN2O5S DM15HL8 IC InChI=1S/C18H33ClN2O5S/c1-5-6-10-7-11(21(3)8-10)17(25)20-12(9(2)19)16-14(23)13(22)15(24)18(26-16)27-4/h9-16,18,22-24H,5-8H2,1-4H3,(H,20,25)/t9-,10+,11-,12+,13-,14+,15+,16+,18+/m0/s1 DM15HL8 CS CCC[C@@H]1C[C@H](N(C1)C)C(=O)N[C@@H]([C@@H]2[C@@H]([C@@H]([C@H]([C@H](O2)SC)O)O)O)[C@H](C)Cl DM15HL8 IK KDLRVYVGXIQJDK-AWPVFWJPSA-N DM15HL8 IU (2S,4R)-N-[(1S,2S)-2-chloro-1-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-methylsulfanyloxan-2-yl]propyl]-1-methyl-4-propylpyrrolidine-2-carboxamide DM15HL8 CA CAS 18323-44-9 DM15HL8 DE Acne vulgaris DMW1OQ0 ID DMW1OQ0 DMW1OQ0 DN Clobazam - Lundbeck DMW1OQ0 HS Approved DMW1OQ0 SN Clobazam; Chlorepin; Urbanyl; Frisium; Clorepin; Urbadan; 22316-47-8; Clobazamum; Onfi; LM-2717; HR 376; RU-4723; Clobazamum [INN-Latin]; LM 2717; H-4723; H 4723; 7-Chloro-1-methyl-5-phenyl-1H-1,5-benzodiazepine-2,4(3H,5H)-dione; UNII-2MRO291B4U; 1H-1,5-Benzodiazepine-2,4(3H,5H)-dione, 7-chloro-1-methyl-5-phenyl-; NSC 336279; 1-Phenyl-5-methyl-8-chloro-1,2,4,5-tetrahydro-2,4-dioxo-3H-1,5-benzodiazepine; CCRIS 7506; 7-chloro-1-methyl-5-phenyl-1,5-benzodiazepine-2,4-dione; EINECS 244-908-7; BRN 0758410; Onfi DMW1OQ0 TC Neurology Agents DMW1OQ0 DT Small molecular drug DMW1OQ0 PC 2789 DMW1OQ0 MW 300.74 DMW1OQ0 FM C16H13ClN2O2 DMW1OQ0 IC InChI=1S/C16H13ClN2O2/c1-18-13-8-7-11(17)9-14(13)19(16(21)10-15(18)20)12-5-3-2-4-6-12/h2-9H,10H2,1H3 DMW1OQ0 CS CN1C(=O)CC(=O)N(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3 DMW1OQ0 IK CXOXHMZGEKVPMT-UHFFFAOYSA-N DMW1OQ0 IU 7-chloro-1-methyl-5-phenyl-1,5-benzodiazepine-2,4-dione DMW1OQ0 CA CAS 22316-47-8 DMW1OQ0 CB CHEBI:31413 DMW1OQ0 DE Anxiety disorder; Epilepsy DMUXP52 ID DMUXP52 DMUXP52 DN Clobetasol DMUXP52 HS Approved DMUXP52 SN Clobetasolum; Clofenazon; Clobecort Amex; Butavate (TN); Clobecort Amex (TN); Clobetasol (INN); Clobetasol [INN:BAN]; Clobetasolum [INN-Latin]; Clobex (TN); Dermatovate (TN); Dermovate (TN); Movate (TN); Olux (TN); Temovate (TN); Tenovate (TN); (11beta,16beta)-21-chloro-9-fluoro-11,17-dihydroxy-16-methylpregna-1,4-diene-3,20-dione; (8S,9R,10S,11S,13S,14S,16S,17R)-17-(2-chloroacetyl)-9-fluoro-11,17-dihydroxy-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; (9R,17R)-17-(2-chloroacetyl)-9-fluoro-11,17-dihydroxy-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; 17-(2-chloroacetyl)-9-fluoro-11,17-dihydroxy-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; 21-Chloro-9-fluoro-11beta,17-dihydroxy-16beta-methylpregna-1,4-diene-3,20-dione; 21-chloro-9-fluoro-11,17-dihydroxy-16-methylpregna-1,4-diene-3,20-dione DMUXP52 CP Fougera Pharmaceuticals Inc DMUXP52 TC Antiinflammatory Agents DMUXP52 DT Small molecular drug DMUXP52 PC 5311051 DMUXP52 MW 410.9 DMUXP52 FM C22H28ClFO4 DMUXP52 IC InChI=1S/C22H28ClFO4/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,24)17(26)10-20(16,3)22(12,28)18(27)11-23/h6-7,9,12,15-17,26,28H,4-5,8,10-11H2,1-3H3/t12-,15-,16-,17-,19-,20-,21-,22-/m0/s1 DMUXP52 CS C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CCl)O)C)O)F)C DMUXP52 IK FCSHDIVRCWTZOX-DVTGEIKXSA-N DMUXP52 IU (8S,9R,10S,11S,13S,14S,16S,17R)-17-(2-chloroacetyl)-9-fluoro-11,17-dihydroxy-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one DMUXP52 CA CAS 25122-41-2 DMUXP52 CB CHEBI:205919 DMUXP52 DE Rosacea; Oral lichen planus DM9ZMQH ID DM9ZMQH DM9ZMQH DN Clocortolone DM9ZMQH HS Approved DM9ZMQH SN Clocortolona; Clocortolonum; Clocortolone (INN); (6S,8S,9R,10S,11S,13S,14S,16R,17S)-9-chloro-6-fluoro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-7,8,11,12,14,15,16,17-octahydro-6H-cyclopenta[a]phenanthren-3-one; 9-chloro-6alpha-fluoro-11beta,21-dihydroxy-16alpha-methyl-1,4-pregnadien-3,20-dione; 9-chloro-6alpha-fluoro-11beta,21-dihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione; 9-chloro-6alpha-fluoro-16alpha-methyl-1,4-pregnadiene-11beta,21-diol-3,20-dione DM9ZMQH CP Promius Pharma Llc DM9ZMQH DT Small molecular drug DM9ZMQH PC 5311052 DM9ZMQH MW 410.9 DM9ZMQH FM C22H28ClFO4 DM9ZMQH IC InChI=1S/C22H28ClFO4/c1-11-6-13-14-8-16(24)15-7-12(26)4-5-21(15,3)22(14,23)18(28)9-20(13,2)19(11)17(27)10-25/h4-5,7,11,13-14,16,18-19,25,28H,6,8-10H2,1-3H3/t11-,13+,14+,16+,18+,19-,20+,21+,22+/m1/s1 DM9ZMQH CS C[C@@H]1C[C@H]2[C@@H]3C[C@@H](C4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@H]1C(=O)CO)C)O)Cl)C)F DM9ZMQH IK YMTMADLUXIRMGX-RFPWEZLHSA-N DM9ZMQH IU (6S,8S,9R,10S,11S,13S,14S,16R,17S)-9-chloro-6-fluoro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-7,8,11,12,14,15,16,17-octahydro-6H-cyclopenta[a]phenanthren-3-one DM9ZMQH CA CAS 4828-27-7 DM9ZMQH CB CHEBI:59582 DM9ZMQH DE Rosacea DM9Y6X7 ID DM9Y6X7 DM9Y6X7 DN Clodronate DM9Y6X7 HS Approved DM9Y6X7 SN Bonefos; Clodronsaeure; Dichloromethanediphosphonate; Dichloromethylenebisphosphonate; Methanedichlorodiphosphonate; Acide clodronique; Acido clodronico; Acidum clodronicum; Clodronic Acid; Dichloromethanediphosphonic acid; Dichloromethylene Biphosphonate; Dichloromethylene Diphosphonate; Dichloromethylidene diphosphonate; Liposomes containing clodronic acid; Methanedichlorodiphosphonic acid; Acid, Clodronic; Acid, Dichloromethanediphosphonic; Acide clodronique [INN-French]; Acido clodronico [INN-Spanish]; Acidum clodronicum [INN-Latin]; Biphosphonate, Dichloromethylene; Bonefos (TN); Clodron (TN); Diphosphonate, Dichloromethane; Diphosphonate, Dichloromethylene; Disodium, Clodronate; Loron (TN); Sodium, Clodronate; [dichloro(phosphono)methyl]phosphonic acid; Clodronic acid (USAN/INN); Clodronic acid [USAN:BAN:INN]; Dichlormethylen-bis(phosphonsaeure); Dichloromethylene-1,1-bisphosphonic acid; Dichloromethylene-1,1-diphosphonic acid; Phosphonic acid, (dichloromethylene)di-(8CI); (Dichloro-phosphono-methyl)-phosphonic acid; (Dichloromethylene)bisphosphonic acid; (Dichloromethylene)diphosphonic acid; (Lip-C); (dichloromethanediyl)bis(phosphonic acid) DM9Y6X7 TC Antihypocalcemic Agents DM9Y6X7 DT Small molecular drug DM9Y6X7 PC 25419 DM9Y6X7 MW 244.89 DM9Y6X7 FM CH4Cl2O6P2 DM9Y6X7 IC InChI=1S/CH4Cl2O6P2/c2-1(3,10(4,5)6)11(7,8)9/h(H2,4,5,6)(H2,7,8,9) DM9Y6X7 CS C(P(=O)(O)O)(P(=O)(O)O)(Cl)Cl DM9Y6X7 IK ACSIXWWBWUQEHA-UHFFFAOYSA-N DM9Y6X7 IU [dichloro(phosphono)methyl]phosphonic acid DM9Y6X7 CA CAS 10596-23-3 DM9Y6X7 CB CHEBI:110423 DM9Y6X7 DE Hypercalcaemia DMCVJ86 ID DMCVJ86 DMCVJ86 DN Clofarabine DMCVJ86 HS Approved DMCVJ86 SN CAFdA; CFB; Clofarabina; Clofarabinum; Clofarex; Clolar; Evoltra; Clofarabine [USAN]; Clolar (TN); Evoltra (TN); Clofarabine (USAN/INN); Clolar, Evoltra, Clofarabine; Cl-F-Ara-A; (2R,3R,4S,5R)-5-(6-amino-2-chloropurin-9-yl)-4-fluoro-2-(hydroxymethyl)oxolan-3-ol; 2-Chloro-9-(2-deoxy-2-fluoro-b-D-arabinofuranosyl)-9H-purin-6-amine; 2-Chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-9H-purin-6-amine; 2-Chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)adenine; 2-Cl-2'-F-araA; 2-chloro-9-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)adenine; 3S211048 DMCVJ86 TC Anticancer Agents DMCVJ86 DT Small molecular drug DMCVJ86 PC 119182 DMCVJ86 MW 303.68 DMCVJ86 FM C10H11ClFN5O3 DMCVJ86 IC InChI=1S/C10H11ClFN5O3/c11-10-15-7(13)5-8(16-10)17(2-14-5)9-4(12)6(19)3(1-18)20-9/h2-4,6,9,18-19H,1H2,(H2,13,15,16)/t3-,4+,6-,9-/m1/s1 DMCVJ86 CS C1=NC2=C(N=C(N=C2N1[C@H]3[C@H]([C@@H]([C@H](O3)CO)O)F)Cl)N DMCVJ86 IK WDDPHFBMKLOVOX-AYQXTPAHSA-N DMCVJ86 IU (2R,3R,4S,5R)-5-(6-amino-2-chloropurin-9-yl)-4-fluoro-2-(hydroxymethyl)oxolan-3-ol DMCVJ86 CA CAS 123318-82-1 DMCVJ86 CB CHEBI:681569 DMCVJ86 DE Acute lymphoblastic leukaemia; Myelodysplastic syndrome DMEBOFW ID DMEBOFW DMEBOFW DN Clofazimine DMEBOFW HS Approved DMEBOFW SN clofazimine; 2030-63-9; Lamprene; Lampren; Chlofazimine; Clofazimina; Clofaziminum; Clofaziminum [INN-Latin]; B 663 (Pharmaceutical); Clofazimina [INN-Spanish]; B-663; NSC-141046; G 30320; UNII-D959AE5USF; B 663 (VAN); C27H22Cl2N4; 3-(p-Chloranilino)-10-(p-chlorphenyl)-2,10-dihydro-2-(isopropylimino)-phenazin; B 663; 3-(p-Chloroanilino)-10-(p-chlorophenyl)-2,10-dihydro-2-(isopropylimino)phenazine; 3-(p-Chloranilino)-10-(p-chlorophenyl)-2,10-dihydro-2-(isopropylimino)-phenazine; EINECS 217-980-2; CFZ; SMP2_000339; B 663, pharmaceutical; G-30320; Lamprene (TN); Liposome-encapsulated clofazimine; Clofazimine [USAN:INN:BAN]; G-30,320; Clofazimine (JAN/USP/INN); N,5-bis(4-chlorophenyl)-3-propan-2-yliminophenazin-2-amine; N,5-Bis(4-chlorophenyl)-3,5-dihydro-3-(isopropylimino)phenazin-2-amine; N,5-Bis(4-chlorophenyl)-3,5-dihydro-3-(1-methylethyl)imino)-2-phenazinamine; N,5-Bis(4-chlorophenyl)-3,5-dihydro-3-[(1-methylethyl)imino]-2-phenazinamine; N,5-bis(4-chlorophenyl)-3-(propan-2-ylimino)-3,5-dihydrophenazin-2-amine; (3Z)-N,5-bis(4-chlorophenyl)-3-[(1-methylethyl)imino]-3,5-dihydrophenazin-2-amine; 3-(p-Chloranilino)-10-(p-chlorophenyl)-2,10-dihydro-2-(isopropylimino)phenazine; 3-(p-Chloranilino)-10-(p-chlorphenyl)-2,10-dihydro-2-(isopropylimino)-phenazin [German]; Riminophenazine DMEBOFW CP Norvatis Phamaceuticals Corporation DMEBOFW TC Antiinflammatory Agents DMEBOFW DT Small molecular drug DMEBOFW PC 2794 DMEBOFW MW 473.4 DMEBOFW FM C27H22Cl2N4 DMEBOFW IC InChI=1S/C27H22Cl2N4/c1-17(2)30-24-16-27-25(15-23(24)31-20-11-7-18(28)8-12-20)32-22-5-3-4-6-26(22)33(27)21-13-9-19(29)10-14-21/h3-17,31H,1-2H3 DMEBOFW CS CC(C)N=C1C=C2C(=NC3=CC=CC=C3N2C4=CC=C(C=C4)Cl)C=C1NC5=CC=C(C=C5)Cl DMEBOFW IK WDQPAMHFFCXSNU-UHFFFAOYSA-N DMEBOFW IU N,5-bis(4-chlorophenyl)-3-propan-2-yliminophenazin-2-amine DMEBOFW CA CAS 2030-63-9 DMEBOFW CB CHEBI:3749 DMEBOFW DE Crohn disease; Mycobacterium infection DMPC1J7 ID DMPC1J7 DMPC1J7 DN Clofibrate DMPC1J7 HS Approved DMPC1J7 SN Amotril; Angiokapsul; Anparton; Antilipid; Antilipide; Apolan; Arterioflexin; Arterosol; Artevil; Ateculon; Ateriosan; Athebrate; Atheromide; Atheropront; Athromidin; Atrolen; Atromid; Atromida; Atromidin; Atrovis; Azionyl; Bioscleran; Bresit; CPIB; Cartagyl; Chlorfenisate; Chlorphenisate; Cinnarizin; Citiflus; Claripex; Cloberat; Clobrat; Clofar; Clofibate; Clofibram; Clofibrat; Clofibrato; Clofibratum; Clofinit; Clofipront; Delipid; Deliva; ELPI; EPIB; Fibralem; Gerastop; Hyclorate; Klofibrat; Klofiran; Levatrom; Lipamid; Lipavil; Lipavlon; Lipidsenker; Lipofacton; Lipomid; Liponorm; Liporeduct; Liporil; Liposid; Liprin; Liprinal; Lobetrin; Miscleron; Misclerone; Miskleron; Negalip; Normalip; Normat; Normet; Normolipol; Novofibrate; Persantinat; Recolip; Regardin; Regelan; Robigram; Scrobin; Serofinex; Serotinex; Skerolip; Sklerepmexe; Sklero; Sklerolip; Skleromex; Skleromexe; Ticlobran; Xyduril; Yoclo; Amotril S; Atromid S; Claripex CPIB; Clofibrato [Spanish]; Dura clofibrat; Ethyl chlorophenoxyisobutyrate; Ethyl clofibrate; Regelan N; Vincamin compositum; AY 61123; C 6643; Lipide 500; Oxan 600; AY-61123; Athranid-wirkstoff; Atromid-S; BML2-F02; Chlorophenoxyisobutyrate, Ethyl; Clobren-5F; Clobren-SF; Clofibrate (CLOF); Clofibrato [INN-Spanish]; Clofibratum [INN-Latin]; Clofibric Acid, Ethyl Ester; Ethyl p-chlorophenoxyisobutyrate; Ethyl para-chlorophenoxyisobutyrate; Neo-Atomid; Neo-Atromid; Sklero-Tablinen; Sklero-tablinene; Sklero-tabuls; ATROMID-S (TN); Atromid-S (TN); Atromid-S, Clofibrate; Ethyl alpha-p-chlorophenoxyisobutyrate; Clofibrate (JP15/USP/INN); Clofibrate [USAN:INN:BAN:JAN]; Ethyl 2-(4-chlorophenoxy)isobutyrate; Ethyl 2-(p-chlorophenoxy)isobutyrate; Ethyl alpha-(4-chlorophenoxy)isobutyrate; Ethyl alpha-(p-chlorophenoxy)isobutyrate; Ethyl-alpha-p-chlorophenoxy-isobutyrate DMPC1J7 CP Ayerst Laboratories Inc DMPC1J7 TC Antilipemic Agents DMPC1J7 DT Small molecular drug DMPC1J7 PC 2796 DMPC1J7 MW 242.7 DMPC1J7 FM C12H15ClO3 DMPC1J7 IC InChI=1S/C12H15ClO3/c1-4-15-11(14)12(2,3)16-10-7-5-9(13)6-8-10/h5-8H,4H2,1-3H3 DMPC1J7 CS CCOC(=O)C(C)(C)OC1=CC=C(C=C1)Cl DMPC1J7 IK KNHUKKLJHYUCFP-UHFFFAOYSA-N DMPC1J7 IU ethyl 2-(4-chlorophenoxy)-2-methylpropanoate DMPC1J7 CA CAS 637-07-0 DMPC1J7 CB CHEBI:3750 DMPC1J7 DE Dysbetalipoproteinemia DMKI7RB ID DMKI7RB DMKI7RB DN Clomifene DMKI7RB HS Approved DMKI7RB SN Androxal; Chlomaphene; Chloramifene; Cisclomifenum; Cisclomiphene; Clomifen; Clomifeno; Clomifenum; Clomifert; Clomiphene; Clostilbegit; Enclomifene; Enclomifeno; Enclomifenum; Enclomiphen; Enclomiphene; Klostilbegit; Transclomifenum; Transclomiphene; Zuclomifene; Zuclomifeno; Zuclomifenum; Zuclomiphene; Clomiphene B;Enclomiphene [USAN]; ISOMER B; Zuclomiphene [USAN]; Cis-Clomifene; Cis-Clomiphene; Clomid (TN); Clomifene (INN); Clomifene (TN); Clomifene [INN:BAN]; Clomifeno [INN-Spanish]; Clomifenum [INN-Latin]; En-Clomiphene; Enclomifeno [INN-Spanish]; Enclomifenum [INN-Latin]; Enclomiphene (USAN); Milophene (TN); RMI 16,289; RMI-16289; RMI-16312; Serophene (TN); Trans-Clomifene; Trans-Clomiphene; Zuclomifeno [INN-Spanish]; Zuclomifenum [INN-Latin]; Zuclomiphene (USAN); Cis-2-(p-(2-Chloro-1,2-diphenylvinyl)phenoxy)triethylamine; Trans-2-(p-(2-Chloro-1,2-diphenylvinyl)phenoxy)triethylamine; Cis-2-(4-(2-Chloro-1,2-diphenylethenyl)phenoxy)-N,N-diethylethanamine; Trans-2-(4-(2-Chloro-1,2-diphenylethenyl)phenoxy)-N,N-diethylethanamine; (E)-2-(p-(2-Chloro-1,2-diphenylvinyl)phenoxy)triethylamine; (Z)-2-(p-(2-Chloro-1,2-diphenylvinyl)phenoxy)triethylamine; (Z)-isomer; 1-(p-(beta-Diethylaminoethoxy)-phenyl)-1,2-diphenylchloroethylene; 2-(4-(2-Chloro-1,2-diphenylethenyl)phenoxy)-N,N-diethylethanamine; 2-(p-(2-Chloro-1,2-diphenylvinyl)phenoxy)triethylamine; 2-(p-(beta-Chloro-alpha-phenylstyryl)phenoxy)-triethylamine; 2-(p-(beta-chloro-alpha-phenylstyryl)phenoxy)triethylamine; 2-({4-[(Z)-2-chloro-1,2-diphenylethenyl]phenyl}oxy)-N,N-diethylethanamine; 2-[4-(2-chloro-1,2-diphenylethenyl)phenoxy]-N,N-diethylethanamine; 2-[4-[(E)-2-chloro-1,2-diphenylethenyl]phenoxy]-N,N-diethylethanamine; 2-[4-[(Z)-2-chloro-1,2-diphenylethenyl]phenoxy]-N,N-diethylethanamine; 2-{4-[(E)-2-chloro-1,2-diphenylethenyl]phenoxy}-N,N-diethylethanamine DMKI7RB TC Fertility Agents DMKI7RB DT Small molecular drug DMKI7RB PC 1548953 DMKI7RB MW 406 DMKI7RB FM C26H28ClNO DMKI7RB IC InChI=1S/C26H28ClNO/c1-3-28(4-2)19-20-29-24-17-15-22(16-18-24)25(21-11-7-5-8-12-21)26(27)23-13-9-6-10-14-23/h5-18H,3-4,19-20H2,1-2H3/b26-25+ DMKI7RB CS CCN(CC)CCOC1=CC=C(C=C1)/C(=C(\\C2=CC=CC=C2)/Cl)/C3=CC=CC=C3 DMKI7RB IK GKIRPKYJQBWNGO-OCEACIFDSA-N DMKI7RB IU 2-[4-[(E)-2-chloro-1,2-diphenylethenyl]phenoxy]-N,N-diethylethanamine DMKI7RB CA CAS 15690-57-0 DMKI7RB CB CHEBI:3752 DMKI7RB DE Female infertility DMS51VC ID DMS51VC DMS51VC DN Clomiphene citrate DMS51VC HS Approved DMS51VC SN Clomid; Milophene; Serophene DMS51VC CP Sanofi Aventis Us Llc DMS51VC DT Small molecular drug DMS51VC PC 3033832 DMS51VC MW 598.1 DMS51VC FM C32H36ClNO8 DMS51VC IC InChI=1S/C26H28ClNO.C6H8O7/c1-3-28(4-2)19-20-29-24-17-15-22(16-18-24)25(21-11-7-5-8-12-21)26(27)23-13-9-6-10-14-23;7-3(8)1-6(13,5(11)12)2-4(9)10/h5-18H,3-4,19-20H2,1-2H3;13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)/b26-25-; DMS51VC CS CCN(CC)CCOC1=CC=C(C=C1)/C(=C(/C2=CC=CC=C2)\\Cl)/C3=CC=CC=C3.C(C(=O)O)C(CC(=O)O)(C(=O)O)O DMS51VC IK PYTMYKVIJXPNBD-OQKDUQJOSA-N DMS51VC IU 2-[4-[(Z)-2-chloro-1,2-diphenylethenyl]phenoxy]-N,N-diethylethanamine;2-hydroxypropane-1,2,3-tricarboxylic acid DMS51VC CA CAS 7619-53-6 DMS51VC DE Female infertility DMINRKW ID DMINRKW DMINRKW DN Clomipramine DMINRKW HS Approved DMINRKW SN Chlomipramine; Chlorimipramine; Clomicalm; Clomipramina; Clomipraminum; Hydiphen; Monochlorimipramine; Anafranil base; G 34586; Anafranil (TN); Anafranil (free base); Clomipramina [INN-Spanish]; Clomipramine (INN); Clomipramine [INN:BAN]; Clomipraminum [INN-Latin]; 10,11-dihydro-3-chloro-5-(3-(dimethylamino)propyl)-5H-dibenz(b,f)azepine; 3-(2-chloro-5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N,N-dimethylpropan-1-amine; 3-(3-Chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N-dimethyl-1-propanamine; 3-(3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N-dimethylpropan-1-amine; 3-Chloro-5-(3-(dimethylamino)propyl)-10,11-dihydro-5H-dibenz(b,f)azepine; 3-Chloro-5-[3-(dimethylamino)propyl]-10,11-dihydro-5H-dibenz[b,f]azepine; 3-Chloroimipramine; 3-chloro-10,11-dihydro-N,N-dimethyl-5H-Dibenz(b,f)azepine-5-propanamine; 5H-Dibenz(b,f)azepine, 3-chloro-5-(3-(dimethylamino)propyl)-10,11-dihydro-(8CI) DMINRKW CP Norvatis Phamaceuticals Corporation DMINRKW TC Antidepressants DMINRKW DT Small molecular drug DMINRKW PC 2801 DMINRKW MW 314.9 DMINRKW FM C19H23ClN2 DMINRKW IC InChI=1S/C19H23ClN2/c1-21(2)12-5-13-22-18-7-4-3-6-15(18)8-9-16-10-11-17(20)14-19(16)22/h3-4,6-7,10-11,14H,5,8-9,12-13H2,1-2H3 DMINRKW CS CN(C)CCCN1C2=CC=CC=C2CCC3=C1C=C(C=C3)Cl DMINRKW IK GDLIGKIOYRNHDA-UHFFFAOYSA-N DMINRKW IU 3-(2-chloro-5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N,N-dimethylpropan-1-amine DMINRKW CA CAS 303-49-1 DMINRKW CB CHEBI:47780 DMINRKW DE Depression DM0ZRMQ ID DM0ZRMQ DM0ZRMQ DN Clomocycline DM0ZRMQ HS Approved DM0ZRMQ SN Chlormethylenecycline; Clomociclina; Clomocyclina; Clomocyclinum; Clomociclina [INN-Spanish]; Clomocycline (INN); Clomocycline [INN:BAN]; Clomocyclinum [INN-Latin]; N-2-Hydroxymethylchlortetracycline; N'-Methylolo-chlortetracycline; (2Z,4S,4aS,5aS,6S,12aS)-7-chloro-4-(dimethylamino)-6,10,11,12a-tetrahydroxy-2-[hydroxy-(hydroxymethylamino)methylidene]-6-methyl-4,4a,5,5a-tetrahydrotetracene-1,3,12-trione; (4S,4aS,5aS,6S,12aS)-7-chloro-4-(dimethylamino)-3,6,10,12,12a-pentahydroxy-N-(hydroxymethyl)-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide; 7-Chloro-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-N-(hydroxymethyl)-6-methyl-1,11-dioxo-2-naphthacenecarboxamide DM0ZRMQ TC Antibiotics DM0ZRMQ DT Small molecular drug DM0ZRMQ PC 54680675 DM0ZRMQ MW 508.9 DM0ZRMQ FM C23H25ClN2O9 DM0ZRMQ IC InChI=1S/C23H25ClN2O9/c1-22(34)8-6-9-16(26(2)3)18(30)14(21(33)25-7-27)20(32)23(9,35)19(31)12(8)17(29)13-11(28)5-4-10(24)15(13)22/h4-5,8-9,16,27-29,32,34-35H,6-7H2,1-3H3,(H,25,33)/t8-,9-,16-,22-,23-/m0/s1 DM0ZRMQ CS C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C(C=CC(=C41)Cl)O)O)O)O)C(=O)NCO)N(C)C)O DM0ZRMQ IK BXTHDFJCJQJHKD-KMVLDZISSA-N DM0ZRMQ IU (4S,4aS,5aS,6S,12aR)-7-chloro-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-N-(hydroxymethyl)-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide DM0ZRMQ CA CAS 1181-54-0 DM0ZRMQ CB CHEBI:59589 DM0ZRMQ DE Bacterial infection DMTO13J ID DMTO13J DMTO13J DN Clonazepam DMTO13J HS Approved DMTO13J SN Antelepsin; Antilepsin; Chlonazepam; Cloazepam; Clonazepamum; Clonex; Clonopin; Iktorivil; Kenoket; Klonopin; Landsen; Lktorivil; Lonazep; Melzap; Paxam; Ravotril; Rivatril; Rivoril; Rivotril; Solfidin; Klonopin Rapidly Disintegrating; DF2374250; RO4023; Ro 4023; Ro 54023; Alti-Clonazepam; Clonazepamum [INN-Latin]; Klonopin (TN); Ravotril (TN); Rivatril (TN); Rivotril (TN); Ro 4-8180; Ro 5-4023; Ro-5-4023; Clonazepam (JP15/USP/INN); Clonazepam [USAN:INN:BAN:JAN]; Ro 5-4023/B-7; 1,3-Dihydro-5-(o-chlorophenyl)-7-nitro-3H-1,4-benzodiazepin-2-one; 1,3-Dihydro-7-nitro-5-(2-chlorophenyl)-2H-1,4.benzodiazepin-2-one; 5-(2-Chloro-phenyl)-7-nitro-1,3-dihydro-benzo[e][1,4]diazepin-2-one; 5-(2-Chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one; 5-(2-Chlorophenyl)-7-nitro-1,3-dihydro-2H-1,4-benzodiazepin-2-one; 5-(2-Chlorophenyl)-7-nitro-3H-1,4-benzodiazepin-2(1H)-one; 5-(2-chlorophenyl)-7-nitro-1,3-dihydro-1,4-benzodiazepin-2-one; 5-(o-Chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one; 5-(o-Chlorophenyl)-7-nitro-1H-1,4-benzodiazepin-2(3H)-one; 5-(o-chlorophenyl)-7-nitro-1,3-dihydro-2H-1,4-benzodiazepin-2-one; 7-Nitro-5-(2-chlorophenyl)-3H-1,4-benzodiazepin-2(1H)-one DMTO13J CP Roche Pharmaceuticals DMTO13J TC Anticonvulsants DMTO13J DT Small molecular drug DMTO13J PC 2802 DMTO13J MW 315.71 DMTO13J FM C15H10ClN3O3 DMTO13J IC InChI=1S/C15H10ClN3O3/c16-12-4-2-1-3-10(12)15-11-7-9(19(21)22)5-6-13(11)18-14(20)8-17-15/h1-7H,8H2,(H,18,20) DMTO13J CS C1C(=O)NC2=C(C=C(C=C2)[N+](=O)[O-])C(=N1)C3=CC=CC=C3Cl DMTO13J IK DGBIGWXXNGSACT-UHFFFAOYSA-N DMTO13J IU 5-(2-chlorophenyl)-7-nitro-1,3-dihydro-1,4-benzodiazepin-2-one DMTO13J CA CAS 1622-61-3 DMTO13J CB CHEBI:3756 DMTO13J DE Epilepsy; Seizure disorder DM6RZ9Q ID DM6RZ9Q DM6RZ9Q DN Clonidine DM6RZ9Q HS Approved DM6RZ9Q SN clonidine; Clonidin; Duraclon; Chlornidinum; 4205-90-7; Catapres-TTS; Catarpresan; Catarpres; Adesipress; Catapres; Catapressan; Catapresan; ST 155BS; ST-155-BS; Clonidinum; Clonidina; Clonidinum [INN-Latin]; Clonidinhydrochlorid; CATAPRES-TTS-3; CATAPRES-TTS-1; CATAPRES-TTS-2; N-(2,6-Dichlorophenyl)-4,5-dihydro-1H-imidazol-2-amine; Isoglaucon; 2-(2,6-Dichloroanilino)-2-imidazoline; Dixarit; SKF 34427; Catapres- TTS; Clonidina [INN-Spanish]; M-5041T; Hemiton; CLORPRES; clonidine (amino form); Adesipress; Clofenil; Clopheline; Duraclont; Gemiton; Klofelin; Klofenil; M 5041T; Catapres (TN); Catarpres-TTS; ST-155BS; Tenso-Timelets; Catarpres-TTS (TN); Clonidine [USAN:BAN:INN]; Clonidine (JAN/USAN/INN); 1H-Imidazol-2-amine, N-(2,6-dichlorophenyl)-4,5-dihydro-(9CI); 2,6-Dichloro-N-2-imidazolidinylidenebenzenamine; 2,6-dichloro-N-(2-imidazolidinylidene)aniline; 2,6-dichloro-N-2-imidazolidinylidenebenzenamide; 2,6-dichloro-N-imidazolidin-2-ylideneaniline; 2-((2,6-Dichlorophenyl)imino)imidazolidine; 2-(2,6-Dichloroanilino)-1,3-diazacyclopentene-(2);2-(2,6-Dichloroanilino)-2-imidazoline; 2-(2,6-Dichlorophenylamino)-2-imidazoline; 2-(2,6-Dichlorophenylimino)imidazolidine; 2-Imidazoline, 2-(2,6-dichloroanilino)-(7CI,8CI); 2-[(2,6-Dichlorophenyl)imino]imidazoline; 2-[(2,6-dichlorophenyl)imino]-2-imidazoline; 734571A; 2,6-DICHLORO-N-IMIDAZOLIDIN-2-YLIDENEANILINE DM6RZ9Q CP Intas Pharmaceuticals DM6RZ9Q TC Antihypertensive Agents DM6RZ9Q DT Small molecular drug DM6RZ9Q PC 2803 DM6RZ9Q MW 230.09 DM6RZ9Q FM C9H9Cl2N3 DM6RZ9Q IC InChI=1S/C9H9Cl2N3/c10-6-2-1-3-7(11)8(6)14-9-12-4-5-13-9/h1-3H,4-5H2,(H2,12,13,14) DM6RZ9Q CS C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl DM6RZ9Q IK GJSURZIOUXUGAL-UHFFFAOYSA-N DM6RZ9Q IU N-(2,6-dichlorophenyl)-4,5-dihydro-1H-imidazol-2-amine DM6RZ9Q CA CAS 4205-90-7 DM6RZ9Q CB CHEBI:3757 DM6RZ9Q DE Hypertension; Diabetic neuropathy DMOL54H ID DMOL54H DMOL54H DN Clopidogrel DMOL54H HS Approved DMOL54H SN clopidogrel; 113665-84-2; (S)-Clopidogrel; Plavix; Clopidogrel [INN:BAN]; (+)-(S)-Clopidogrel; (+)-Clopidogrel; UNII-A74586SNO7; HSDB 7430; CLOPIDOGREL SULFATE; CHEBI:37941; GKTWGGQPFAXNFI-HNNXBMFYSA-N; A74586SNO7; CPD000550475; Zyllt; Clopidogrel (TN); SR-25990C; Plavix (TN); methyl (2S)-(2-chlorophenyl)(6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl)ethanoate; Clopidogrelum; Thrombo; Clopidogrel BMS; Clopidogrel Hexal; Clopidogrel Acino; methyl (2S)-2-(2-chlorophenyl)-2-{4H,5H,6H,7H-thieno[3,2-c]pyridin-5-yl}acetate; PM-103; Clopidogrel (captisol-enabled); Clopidogrel (captisol-enabled), The Medicines Co; Clopidogrel (captisol-enabled, cardiovascular disease), Cydex; Clopidogrel (captisol-enabled, cardiovascular disease), Prism Pharmaceuticals DMOL54H CP Prism Pharmaceuticals Inc DMOL54H DT Small molecular drug DMOL54H PC 60606 DMOL54H MW 321.8 DMOL54H FM C16H16ClNO2S DMOL54H IC InChI=1S/C16H16ClNO2S/c1-20-16(19)15(12-4-2-3-5-13(12)17)18-8-6-14-11(10-18)7-9-21-14/h2-5,7,9,15H,6,8,10H2,1H3/t15-/m0/s1 DMOL54H CS COC(=O)[C@H](C1=CC=CC=C1Cl)N2CCC3=C(C2)C=CS3 DMOL54H IK GKTWGGQPFAXNFI-HNNXBMFYSA-N DMOL54H IU methyl (2S)-2-(2-chlorophenyl)-2-(6,7-dihydro-4H-thieno[3,2-c]pyridin-5-yl)acetate DMOL54H CA CAS 113665-84-2 DMOL54H CB CHEBI:37941 DMOL54H DE Thrombosis DMC3JST ID DMC3JST DMC3JST DN Clorazepate DMC3JST HS Approved DMC3JST SN Chlorazepate; Tranxene; Cchlorazepic acid; Chlorazepic acid; Clorazepate dipotassium; Clorazepic acid; Clorazepic acid [BAN]; Gen-xene; Novo-Clopate; Tranxene (Cherazepate dipotasium); Tranxene (TN); Novo-Clopate (TN); (Chloromethyl)(dimethyl)(tridecyloxy)silane; 7-Chloro-2,3-dihydro-2,2-dihydroxy-5-phenyl-1H-1,4-benzodiazepine-3-carboxylic acid; 7-chloro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine-3-carboxylic acid; 7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepine-3-carboxylic acid DMC3JST CP Taro Pharmaceutical Industries Ltd DMC3JST TC Hypnotics and Sedatives DMC3JST DT Small molecular drug DMC3JST PC 2809 DMC3JST MW 314.72 DMC3JST FM C16H11ClN2O3 DMC3JST IC InChI=1S/C16H11ClN2O3/c17-10-6-7-12-11(8-10)13(9-4-2-1-3-5-9)19-14(16(21)22)15(20)18-12/h1-8,14H,(H,18,20)(H,21,22) DMC3JST CS C1=CC=C(C=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)C(=O)O DMC3JST IK XDDJGVMJFWAHJX-UHFFFAOYSA-N DMC3JST IU 7-chloro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine-3-carboxylic acid DMC3JST CA CAS 23887-31-2 DMC3JST CB CHEBI:3761 DMC3JST DE Anxiety disorder DMCEUJD ID DMCEUJD DMCEUJD DN Clorgyline DMCEUJD HS Approved DMCEUJD SN Chlorgyline; Clorgilin; Clorgilina; Clorgiline; Clorgilinum; Clorgiline [INN]; M and B 9302; Clorgilina [INN-Spanish]; Clorgiline (INN); Clorgilinum [INN-Latin]; M & B 9302; N-methyl-n-propargyl-3-(2,4-dichlorophenoxy)propylamine; N-(3-(2,4-Dichlorophenoxy)propyl)-N-methyl-2-propynylamine; N-[3-(2,4-DICHLOROPHENOXY)PROPYL]-N-METHYL-N-PROP-2-YNYLAMINE; 2-Propyn-1-amine, N-(3-(2,4-dichlorophenoxy)propyl)-N-methyl-(9CI); 3-(2,4-dichlorophenoxy)-N-methyl-N-prop-2-ynylpropan-1-amine DMCEUJD TC Antiparkinson Agents DMCEUJD DT Small molecular drug DMCEUJD PC 4380 DMCEUJD MW 272.17 DMCEUJD FM C13H15Cl2NO DMCEUJD IC InChI=1S/C13H15Cl2NO/c1-3-7-16(2)8-4-9-17-13-6-5-11(14)10-12(13)15/h1,5-6,10H,4,7-9H2,2H3 DMCEUJD CS CN(CCCOC1=C(C=C(C=C1)Cl)Cl)CC#C DMCEUJD IK BTFHLQRNAMSNLC-UHFFFAOYSA-N DMCEUJD IU 3-(2,4-dichlorophenoxy)-N-methyl-N-prop-2-ynylpropan-1-amine DMCEUJD CA CAS 17780-72-2 DMCEUJD CB CHEBI:3763 DMCEUJD DE Skin imperfections; Parkinson disease DM6K1OA ID DM6K1OA DM6K1OA DN Clothiapine DM6K1OA HS Approved DM6K1OA SN Clothiapine; Clotiapine; 2058-52-8; Entumine; Entumin; Etumine; HF 2159; Clotiapinum [INN-Latin]; Clotiapina [INN-Spanish]; UNII-Z05HCY0X1T; S-805C; Clothiapine [USAN]; EINECS 218-162-8; LW 2159; C18H18ClN3S; BRN 0568276; Z05HCY0X1T; CHEMBL304902; 2-Chloro-11-(4-methylpiperazino)dibenzo(b,f)(1,4)thiazepine; KAAZGXDPUNNEFN-UHFFFAOYSA-N; 2-Chloro-11-(4-methyl-1-piperazinyl)dibenzo(b,f)(1,4)thiazepine; DIBENZO(b,f)(1,4)THIAZEPINE, 2-CHLORO-11-(4-METHYL-1-PIPERAZINYL)-; Clothiapine (USAN); HF-2159; NCGC00160387-01 DM6K1OA DT Small molecular drug DM6K1OA PC 16351 DM6K1OA MW 343.9 DM6K1OA FM C18H18ClN3S DM6K1OA IC InChI=1S/C18H18ClN3S/c1-21-8-10-22(11-9-21)18-14-12-13(19)6-7-16(14)23-17-5-3-2-4-15(17)20-18/h2-7,12H,8-11H2,1H3 DM6K1OA CS CN1CCN(CC1)C2=NC3=CC=CC=C3SC4=C2C=C(C=C4)Cl DM6K1OA IK KAAZGXDPUNNEFN-UHFFFAOYSA-N DM6K1OA IU 8-chloro-6-(4-methylpiperazin-1-yl)benzo[b][1,4]benzothiazepine DM6K1OA CA CAS 2058-52-8 DM6K1OA CB CHEBI:31424 DM6K1OA DE Schizophrenia DM59AZT ID DM59AZT DM59AZT DN Clotiazepam DM59AZT HS Approved DM59AZT SN Clotiazepamum; Clozan; Distensan; Rise; Rize; Rizen; Tienor; Trecalmo; Veratran; Y 6047; Clotiazepam [INN:JAN]; Clotiazepamum [INN-Latin]; Clozan (TN); Distensan (TN); Rize (TN); Rizen (TN); Trecalmo (TN); Veratran (TN); Y-6047; Clotiazepam (JP15/INN); 2H-Thieno(2,3e)(1,4)-diazepin-2-one, 5-(o-chlorophenyl)-7-ethyl-1,3-dihydro-1-methyl-(8CI); 5-(2-Chlorophenyl)-7-ethyl-1-methyl-1,3-dihydro-2H-thieno(2,3-e)(1,4)diazepin-2-one; 5-(2-chlorophenyl)-7-ethyl-1-methyl-1,3-dihydro-2H-thieno[2,3-e][1,4]diazepin-2-one; 5-(2-chlorophenyl)-7-ethyl-1-methyl-3H-thieno[2,3-e][1,4]diazepin-2-one; 5-(o-Chlorophenyl)-7-ethyl-1,3-dihydro-1-methyl-2H-thieno(2,3-e)-1,4-diazepin-2-one DM59AZT TC Hypnotics and Sedatives DM59AZT DT Small molecular drug DM59AZT PC 2811 DM59AZT MW 318.8 DM59AZT FM C16H15ClN2OS DM59AZT IC InChI=1S/C16H15ClN2OS/c1-3-10-8-12-15(11-6-4-5-7-13(11)17)18-9-14(20)19(2)16(12)21-10/h4-8H,3,9H2,1-2H3 DM59AZT CS CCC1=CC2=C(S1)N(C(=O)CN=C2C3=CC=CC=C3Cl)C DM59AZT IK CHBRHODLKOZEPZ-UHFFFAOYSA-N DM59AZT IU 5-(2-chlorophenyl)-7-ethyl-1-methyl-3H-thieno[2,3-e][1,4]diazepin-2-one DM59AZT CA CAS 33671-46-4 DM59AZT CB CHEBI:31425 DM59AZT DE Anxiety disorder DMMFCIH ID DMMFCIH DMMFCIH DN Clotrimazole DMMFCIH HS Approved DMMFCIH SN Canesten; Canestene; Canestine; Canifug; Chlotrimazole; Cimitidine; Clomatin; Clotrimaderm; Clotrimazol; Clotrimazolum; Clotrimeizol; Cutistad; Empecid; Esparol; FemCare; Gynix; Kanesten; Klotrimazole; Lotrimax; Lotrimin; Monobaycuten; Mycelax; Mycelex; Mycofug; Mycosporin; Mykosporin; Nalbix; Pedisafe; Rimazole; Stiemazol; Tibatin; Trimysten; Canesten Cream; Canesten Solution; Clotrimazole Schering Brand; Desamix F; Fem Care; Gyne lotrimin; Lotrimin AF Cream; Lotrimin AF Lotion; Lotrimin AF Solution; Lotrimin Af; Lotrimin Cream; Lotrimin Lotion; Lotrimin Solution; Mycelex Cream; Mycelex G; Mycelex OTC; Mycelex Solution; Mycelex Troches; Mycelex Twin Pack; Myclo Cream; Myclo Solution; Myclo Spray Solution; Schering Brand of Clotrimazole; B 5097; Bay b 9057; Bayer Brand 1 of Clotrimazole; Bayer Brand 2 of Clotrimazole; C 6019; FB 5097; FB b 5097; Mycelex 7; Trivagizole 3; Bay-B 5097; Candid Vaginal (TN); Candinil (TN); Canesten (TN); Canesten 1-Day Therapy; Canesten 3-Day Therapy; Canesten 6-Day Therapy; Clobrate VT (TN); Clotrimazol [INN-Spanish]; Clotrimazolum [INN-Latin]; DRG-0072; Gino-Lotremine; Gyne-Lotrimin; Gyne-Lotrimin 3; Gyne-Lotrimin 3 Combination Pack; Gyne-Lotrimin Combination Pack; Lotrimin (TN); Lotrimin AF Jock-Itch Cream; Mono-baycuten; Mycelex (TN); Mycelex-7; Mycelex-7 Combination Pack; Mycelex-G; Mycelex: MycosporinRimazole; Myclo-Gyne; Neo-Zol Cream; Pan-Fungex; Cancap-VT (TN); Candid - V Gel (TN); Canesten 1-Day Cream Combi-Pak; Canesten Combi-Pak 1-Day Therapy; Canesten Combi-Pak 3-Day Therapy; Clotrimazole (JP15/USP/INN); Clotrimazole [USAN:INN:BAN:JAN]; (Chlorotrityl)imidazole; 1-(o-Chlorotrityl)imidazole DMMFCIH CP Bayer Pharmaceuticals Corporation DMMFCIH TC Antifungal Agents DMMFCIH DT Small molecular drug DMMFCIH PC 2812 DMMFCIH MW 344.8 DMMFCIH FM C22H17ClN2 DMMFCIH IC InChI=1S/C22H17ClN2/c23-21-14-8-7-13-20(21)22(25-16-15-24-17-25,18-9-3-1-4-10-18)19-11-5-2-6-12-19/h1-17H DMMFCIH CS C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3Cl)N4C=CN=C4 DMMFCIH IK VNFPBHJOKIVQEB-UHFFFAOYSA-N DMMFCIH IU 1-[(2-chlorophenyl)-diphenylmethyl]imidazole DMMFCIH CA CAS 23593-75-1 DMMFCIH CB CHEBI:3764 DMMFCIH DE Fungal infection DMUTL7O ID DMUTL7O DMUTL7O DN Cloxacillin DMUTL7O HS Approved DMUTL7O SN Chloroxacillin; Clossacillina; Cloxacilina; Cloxacilline; Cloxacillinum; MCIPC; Orbenin; Syntarpen; Tegopen; Clossacillina [DCIT]; Cloxacillin sodium; Methocillin S; BRL 1621; Cloxacilina [INN-Spanish]; Cloxacillin (INN); Cloxacillin [INN:BAN]; Cloxacilline [INN-French]; Cloxacillinum [INN-Latin]; Cloxapen (TN); Cloxapen (sodium monohydrate); Methylchlorphenylisoxazoryl-penicillin; Novo-Cloxin; Nu-Cloxi; Orbenin (TN); Tegopen (sodium monohydrate); BRL-1621 (sodium monohydrate); P-25 (sodium monohydrate); [3-(O-CHLOROPHENYL)-5-METHYL-4-ISOXAZOLYL]PENICILLIN; (2S,5R,6R)-6-({[3-(2-chlorophenyl)-5-methylisoxazol-4-yl]carbonyl}amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-[[3-(2-chlorophenyl)-5-methyl-1,2-oxazole-4-carbonyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (3-(o-Chlorophenyl)-5-methyl-4-isoxazolyl)penicillin; 6-(((3-(2-Chlorophenyl)-5-methyl-4-isoxazolyl)carbonyl)amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid; 6-(3-(o-Chlorophenyl)-5-methyl-4-isoxazolecarboxamido)penicillanic acid DMUTL7O CP Beecham phamaceuticals DMUTL7O TC Antibiotics DMUTL7O DT Small molecular drug DMUTL7O PC 6098 DMUTL7O MW 435.9 DMUTL7O FM C19H18ClN3O5S DMUTL7O IC InChI=1S/C19H18ClN3O5S/c1-8-11(12(22-28-8)9-6-4-5-7-10(9)20)15(24)21-13-16(25)23-14(18(26)27)19(2,3)29-17(13)23/h4-7,13-14,17H,1-3H3,(H,21,24)(H,26,27)/t13-,14+,17-/m1/s1 DMUTL7O CS CC1=C(C(=NO1)C2=CC=CC=C2Cl)C(=O)N[C@H]3[C@@H]4N(C3=O)[C@H](C(S4)(C)C)C(=O)O DMUTL7O IK LQOLIRLGBULYKD-JKIFEVAISA-N DMUTL7O IU (2S,5R,6R)-6-[[3-(2-chlorophenyl)-5-methyl-1,2-oxazole-4-carbonyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid DMUTL7O CA CAS 61-72-3 DMUTL7O CB CHEBI:49566 DMUTL7O DE Bacterial infection DMFC71L ID DMFC71L DMFC71L DN Clozapine DMFC71L HS Approved DMFC71L SN Asaleptin; CLOZARIL; Clorazil; Clozapin; Clozapina; Clozapinum; Fazaclo; Iprox; Leponex; Lepotex; Fazaclo ODT; C 6305; HF1854; Clopine (TN); Clozapina [INN-Spanish]; Clozapine(tautomer); Clozapinum [INN-Latin]; Clozaril (TN); Denzapine (TN); Fazaclo (TN); Froidir (TN); HF-1854; KS-1166; Klozapol (TN); LEX-123; LX 100-129; Leponex (TN); W-801; Zaponex (TN); Clozapine [USAN:INN:BAN]; Clozapine (JAN/USP/INN); 3-chloro-6-(4-methylpiperazin-1-yl)-5H-benzo[b][1,4]benzodiazepine; 8-Chloro-11-(4-methyl)-1-piperazinyl)-5H-dibenzo[b,e][1,4]diazepine; 8-Chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo (b,e)(1,4)diazepine; 8-Chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo(b,e)(1,4)diazepine; 8-Chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo[b,e][1,4]-diazepine; 8-Chloro-11-(4-methyl-piperazin-1-yl)-5H-dibenzo[b,e][1,4]diazepine; 8-chloro-11-(4-methylpiperazin-1-yl)-5H-dibenzo[b,e][1,4]diazepine DMFC71L CP Sandoz DMFC71L TC Antipsychotic Agents DMFC71L DT Small molecular drug DMFC71L PC 135398737 DMFC71L MW 326.8 DMFC71L FM C18H19ClN4 DMFC71L IC InChI=1S/C18H19ClN4/c1-22-8-10-23(11-9-22)18-14-4-2-3-5-15(14)20-16-7-6-13(19)12-17(16)21-18/h2-7,12,20H,8-11H2,1H3 DMFC71L CS CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42 DMFC71L IK QZUDBNBUXVUHMW-UHFFFAOYSA-N DMFC71L IU 3-chloro-6-(4-methylpiperazin-1-yl)-11H-benzo[b][1,4]benzodiazepine DMFC71L CA CAS 5786-21-0 DMFC71L CB CHEBI:3766 DMFC71L DE Schizophrenia DMPC2QY ID DMPC2QY DMPC2QY DN CNTO-1959 DMPC2QY HS Approved DMPC2QY SN Guselkumab DMPC2QY CP Janssen/Johnson & Johnson DMPC2QY DT Antibody DMPC2QY SQ Heavy chain: EVQLVQSGAEVKKPGESLKISCKGSGYSFSNYWIGWVRQMPGKGLEWMGIIDPSNSYTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARWYYKPFDVWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK >Light chainQSVLTQPPSVSGAPGQRVTISCTGSSSNIGSGYDVHWYQQLPGTAPKLLIYGNSKRPSGVPDRFSGSKSGTSASLAITGLQSEDEADYYCASWTDGLSLVVFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS DMPC2QY DE Plaque psoriasis; Asthma DM8HBJI ID DM8HBJI DM8HBJI DN Coagulation Factor IX DM8HBJI HS Approved DM8HBJI TC Anticoagulants DM8HBJI DE Haemophilia B DM6L4H2 ID DM6L4H2 DM6L4H2 DN Cobicistat DM6L4H2 HS Approved DM6L4H2 SN 1004316-88-4; Cobicistat (GS-9350); GS 9350; GS-9350; UNII-LW2E03M5PG; Cobicistat,GS-9350; CHEBI:72291; LW2E03M5PG; Tybost; thiazol-5-ylmethyl (2R,5R)-5-((S)-2-(3-((2-isopropylthiazol-4-yl)methyl)-3-methylureido)-4-morpholinobutanamido)-1,6-diphenylhexan-2-ylcarbamate; 1,3-thiazol-5-ylmethyl [(2R,5R)-5-{[(2S)-2-({[(2-isopropyl-1,3-thiazol-4-yl)methyl](methyl)carbamoyl}amino)-4-(morpholin-4-yl)butanoyl]amino}-1,6-diphenylhexan-2-yl]carbamate; 1,3-thiazol-5-ylmethyl DM6L4H2 CP GILEAD DM6L4H2 DT Small molecular drug DM6L4H2 PC 25151504 DM6L4H2 MW 776 DM6L4H2 FM C40H53N7O5S2 DM6L4H2 IC InChI=1S/C40H53N7O5S2/c1-29(2)38-43-34(27-53-38)25-46(3)39(49)45-36(16-17-47-18-20-51-21-19-47)37(48)42-32(22-30-10-6-4-7-11-30)14-15-33(23-31-12-8-5-9-13-31)44-40(50)52-26-35-24-41-28-54-35/h4-13,24,27-29,32-33,36H,14-23,25-26H2,1-3H3,(H,42,48)(H,44,50)(H,45,49)/t32-,33-,36+/m1/s1 DM6L4H2 CS CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)CC5=CC=CC=C5 DM6L4H2 IK ZCIGNRJZKPOIKD-CQXVEOKZSA-N DM6L4H2 IU 1,3-thiazol-5-ylmethyl N-[(2R,5R)-5-[[(2S)-2-[[methyl-[(2-propan-2-yl-1,3-thiazol-4-yl)methyl]carbamoyl]amino]-4-morpholin-4-ylbutanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate DM6L4H2 CA CAS 1004316-88-4 DM6L4H2 CB CHEBI:72291 DM6L4H2 DE Human immunodeficiency virus infection DMDKXTO ID DMDKXTO DMDKXTO DN Cobicistat/darunavir DMDKXTO HS Approved DMDKXTO SN Prezcobix; Cobicistat / darunavir; Darunavir / Cobicistat; Cobicistat and darunavir; Cobicistat mixture with darunavir; Darunavir and cobicistat DMDKXTO CP Gilead Sciences DMDKXTO DT Small molecular drug DMDKXTO PC 57327017 DMDKXTO MW 1323.7 DMDKXTO FM C67H90N10O12S3 DMDKXTO IC InChI=1S/C40H53N7O5S2.C27H37N3O7S/c1-29(2)38-43-34(27-53-38)25-46(3)39(49)45-36(16-17-47-18-20-51-21-19-47)37(48)42-32(22-30-10-6-4-7-11-30)14-15-33(23-31-12-8-5-9-13-31)44-40(50)52-26-35-24-41-28-54-35;1-18(2)15-30(38(33,34)21-10-8-20(28)9-11-21)16-24(31)23(14-19-6-4-3-5-7-19)29-27(32)37-25-17-36-26-22(25)12-13-35-26/h4-13,24,27-29,32-33,36H,14-23,25-26H2,1-3H3,(H,42,48)(H,44,50)(H,45,49);3-11,18,22-26,31H,12-17,28H2,1-2H3,(H,29,32)/t32-,33-,36+;22-,23-,24+,25-,26+/m10/s1 DMDKXTO CS CC(C)CN(C[C@H]([C@H](CC1=CC=CC=C1)NC(=O)O[C@H]2CO[C@@H]3[C@H]2CCO3)O)S(=O)(=O)C4=CC=C(C=C4)N.CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)CC5=CC=CC=C5 DMDKXTO IK CXORHDVSJFELCV-HWDLLDTBSA-N DMDKXTO IU [(3aS,4R,6aR)-2,3,3a,4,5,6a-hexahydrofuro[2,3-b]furan-4-yl] N-[(2S,3R)-4-[(4-aminophenyl)sulfonyl-(2-methylpropyl)amino]-3-hydroxy-1-phenylbutan-2-yl]carbamate;1,3-thiazol-5-ylmethyl N-[(2R,5R)-5-[[(2S)-2-[[methyl-[(2-propan-2-yl-1,3-thiazol-4-yl)methyl]carbamoyl]amino]-4-morpholin-4-ylbutanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate DMDKXTO DE Human immunodeficiency virus infection DMSOX7I ID DMSOX7I DMSOX7I DN Cocaine DMSOX7I HS Approved DMSOX7I SN Allococaine; Allopseudococaine; Badrock; Bazooka; Benzoylethylecgonine; Benzoylmethylecgonine; Bernice; Bernies; Blast; Blizzard; Blow; Burese; COC; Cabello; Candy; Carrie; Caviar; Cecil; Charlie; Cholly; Coca; Cocain; Cocaina; Cocainum; Cocktail; Coke; Cola; Corine; Crack; Eritroxilina; Erytroxylin; Flake; Flex; Freeze; Girl; Goofball; Heaven; Hell; Jam; Kokain; Kokan; Kokayeen; Lady; Leaf; Moonrocks; Neurocaine; Pseudoallococaine; Rock; Sleighride; Snort; Snow; Toke; Toot; Trails; Yeyo; Bernice [Street Name]; Blow [Street Name]; Bouncing Powder; Cecil [Street Name]; Chicken Scratch; Cocaine [BAN]; Cocaine free base; Cocaine solution; Crack cocaine; Dama blanca; Ecgonine methyl ester benzoate; Ecgonine methyl ester benzoate solution; Flake [Street Name]; Florida Snow; Foo Foo; Girl [Street Name]; Gold dust; Gold dust [Street Name]; Green gold; Happy dust; Happy dust [Street Name]; Happy powder; Happy trails; Lady [Street Name]; Methyl Benzoylecgonine; Nose candy; Prime Time; Rock [Street Name]; Sweet Stuff; Toot [Street Name]; White girl or lady; Beta-Cocain; C" Carrie; Cocaine (TN); Cocaine (USP); Cocaine-M; G-Rock; Kibbles n' Bits; L-Cocain; L-Cocaine; Pimp's drug; Snow (birds); Star-spangled powder; Ecgonine, methyl ester, benzoate (ester); Methyl 3beta-hydroxy-1alphaH,5alphaH-tropane-2beta-carboxylate benzoate (ester); Methyl 3-benzoyloxy-8-methyl-8-azabicyclo[3.2.1]octane-4-carboxylate; Methyl 3-(benzoyloxy)-8-methyl-8-azabicyclo[3.2.1]octane-2-carboxylate; Methyl (3S,4R)-3-benzoyloxy-8-methyl-8-azabicyclo[3.2.1]octane-4-carboxylate; Methyl (1S,4R,5R)-3-benzoyloxy-8-methyl-8-azabicyclo[3.2.1]octane-4-carboxylate; (-)-Cocaine; (-)-Cocaine base; (1R,2R,3S,5S)-2-(methoxycarbonyl)tropan-3-yl benzoate; (1R,2R,3S,5S)-2-Methoxycarbonyltropan-3-yl benzoate; (R)-Cocaine; 1-Cocaine; 2-beta-Carbomethoxy-3-beta-benzoxytropane; 2-beta-Tropanecarboxylic acid, 3-beta-hydroxy-, methyl ester, benzoate (ester); 2beta-Carbomethoxy-3beta-benzoxytropane; 3-Tropanylbenzoate-2-carboxylic acid methyl ester; 3beta-Hydroxy-2beta-tropanecarboxylic acid methyl ester benzoate (ester) DMSOX7I TC Anesthetics DMSOX7I DT Small molecular drug DMSOX7I PC 446220 DMSOX7I MW 303.35 DMSOX7I FM C17H21NO4 DMSOX7I IC InChI=1S/C17H21NO4/c1-18-12-8-9-13(18)15(17(20)21-2)14(10-12)22-16(19)11-6-4-3-5-7-11/h3-7,12-15H,8-10H2,1-2H3/t12-,13+,14-,15+/m0/s1 DMSOX7I CS CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)OC(=O)C3=CC=CC=C3)C(=O)OC DMSOX7I IK ZPUCINDJVBIVPJ-LJISPDSOSA-N DMSOX7I IU methyl (1R,2R,3S,5S)-3-benzoyloxy-8-methyl-8-azabicyclo[3.2.1]octane-2-carboxylate DMSOX7I CA CAS 50-36-2 DMSOX7I CB CHEBI:27958 DMSOX7I DE Anaesthesia DMJX6ZG ID DMJX6ZG DMJX6ZG DN Codeine DMJX6ZG HS Approved DMJX6ZG SN codeine; Methylmorphine; Codeine anhydrous; Codicept; l-Codeine; Coducept; Morphine monomethyl ether; Morphine 3-methyl ether; 76-57-3; (-)-Codeine; O3-Methylmorphine; codeinum; Morphine-3-methyl ether; Codein; Norcodine, N-methyl; Norcodeine, N-methyl; CODEINE BASE; Codeine polistirex; codeina; O(3)-methylmorphine; CCRIS 7555; Morphine-3-methyl ester; HSDB 3043; UNII-UX6OWY2V7J; CHEBI:16714; EINECS 200-969-1; UX6OWY2V7J; Morphinan-6-ol, 7,8-didehydro-4,5-epoxy-3-methoxy-17-methyl-, (5alpha,6alpha)-; Codeine Anhydrate DMJX6ZG CP Forest Pharmaceuticals DMJX6ZG TC Analgesics DMJX6ZG DT Small molecular drug DMJX6ZG PC 5284371 DMJX6ZG MW 299.4 DMJX6ZG FM C18H21NO3 DMJX6ZG IC InChI=1S/C18H21NO3/c1-19-8-7-18-11-4-5-13(20)17(18)22-16-14(21-2)6-3-10(15(16)18)9-12(11)19/h3-6,11-13,17,20H,7-9H2,1-2H3/t11-,12+,13-,17-,18-/m0/s1 DMJX6ZG CS CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)OC)O[C@H]3[C@H](C=C4)O DMJX6ZG IK OROGSEYTTFOCAN-DNJOTXNNSA-N DMJX6ZG IU (4R,4aR,7S,7aR,12bS)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-ol DMJX6ZG CA CAS 76-57-3 DMJX6ZG CB CHEBI:16714 DMJX6ZG DE Pain; Cough DM2POTE ID DM2POTE DM2POTE DN Colchicine DM2POTE HS Approved DM2POTE SN Colchicin; Colchicina; Colchicinum; Colchineos; Colchisol; Colchysat; Colcin; Colcrys; Colsaloid; Colstat; Condylon; Goutnil; Kolkicin; LOC; Binds to tubulin; Colchicin [German]; Colchicina [Italian]; Colchicine [JAN]; Inhibits microtubular assembly; Spindle poison; C 9754; Colchicine (TN); Colchicine, Colchicum autumnale; MPC-004; N-Acetyl trimethylcolchicinic acid methylether; Colchicine (JP15/USP); Colchicine, (R)-Isomer; Benzo(a)heptalen-9(5H)-one; Colchicine, (+-)-Isomer; N-(5,6,7,9-Tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo(a)heptalen-7-yl)acetamide; N-[(7S)-1,2,3,10-tetramethoxy-9-oxo-5,6,7,9-tetrahydrobenzo[a]heptalen-7-yl]acetamide; N-[(7S)-1,2,3,10-tetramethoxy-9-oxo-6,7-dihydro-5H-benzo[a]heptalen-7-yl]acetamide; N-[(7S)-5,6,7,9-tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo[a]heptalen-7-yl]acetamide; N-(5,6,7,9-Tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo[.alpha.]heptalen-7-yl)-acetamide; N-((7S)-5,6,7,9-tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo(a)heptalen-7-yl)-acetamide; (S)-N-(5,6,7,9-Tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo[a]heptalen-7-yl)acetamide; 7-alpha-H-Colchicine; 7.alpha.H-Colchicine; 7alphaH-Colchicine DM2POTE TC Gout Suppressants DM2POTE DT Small molecular drug DM2POTE PC 6167 DM2POTE MW 399.4 DM2POTE FM C22H25NO6 DM2POTE IC InChI=1S/C22H25NO6/c1-12(24)23-16-8-6-13-10-19(27-3)21(28-4)22(29-5)20(13)14-7-9-18(26-2)17(25)11-15(14)16/h7,9-11,16H,6,8H2,1-5H3,(H,23,24)/t16-/m0/s1 DM2POTE CS CC(=O)N[C@H]1CCC2=CC(=C(C(=C2C3=CC=C(C(=O)C=C13)OC)OC)OC)OC DM2POTE IK IAKHMKGGTNLKSZ-INIZCTEOSA-N DM2POTE IU N-[(7S)-1,2,3,10-tetramethoxy-9-oxo-6,7-dihydro-5H-benzo[a]heptalen-7-yl]acetamide DM2POTE CA CAS 64-86-8 DM2POTE CB CHEBI:27882 DM2POTE DE Acute gouty arthritis DMJ01D8 ID DMJ01D8 DMJ01D8 DN Colforsin daropate hci DMJ01D8 HS Approved DMJ01D8 SN Adehl (TN); Adele (TN) DMJ01D8 CP Nippon Kayaku DMJ01D8 DT Small molecular drug DMJ01D8 PC 444028 DMJ01D8 MW 546.1 DMJ01D8 FM C27H44ClNO8 DMJ01D8 IC InChI=1S/C27H43NO8.ClH/c1-10-24(5)15-18(31)27(33)25(6)17(30)11-13-23(3,4)21(25)20(35-19(32)12-14-28(8)9)22(34-16(2)29)26(27,7)36-24;/h10,17,20-22,30,33H,1,11-15H2,2-9H3;1H/t17-,20-,21-,22-,24-,25-,26+,27-;/m0./s1 DMJ01D8 CS CC(=O)O[C@H]1[C@H]([C@@H]2[C@]([C@H](CCC2(C)C)O)([C@@]3([C@@]1(O[C@@](CC3=O)(C)C=C)C)O)C)OC(=O)CCN(C)C.Cl DMJ01D8 IK VIRRLEDAYYYTOD-YHEOSNBFSA-N DMJ01D8 IU [(3R,4aR,5S,6S,6aS,10S,10aR,10bS)-5-acetyloxy-3-ethenyl-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-5,6,6a,8,9,10-hexahydro-2H-benzo[f]chromen-6-yl] 3-(dimethylamino)propanoate;hydrochloride DMJ01D8 CA CAS 138605-00-2 DMJ01D8 CB CHEBI:31429 DMJ01D8 DE Asthma DMZ9BMU ID DMZ9BMU DMZ9BMU DN Colistimethate DMZ9BMU HS Approved DMZ9BMU SN Colimicina; Colimyscine; Colimycin M; Colistimethale Sodium; Colistimethate sodium; Colistin Sulfomethate; Colistin methanesulfonate sodium salt; Colistin sodium methanesulfonate; Colistin sodium methanesulfonate from bacillus colistinus; Colistin sulfomethate sodium; Colistinemethanesulfonate sodique; Colistrimethate sodium; Colymycin M; Pentasodium colistinmethanesulfonate; Sodium colistimethate; Sodium colistin methanesulfonate; Sodium colistinemethanesulfonate; W 1929; Colistimethate sodium [USAN:INN]; Colistinmethanesulfonic acid, sodium salt; Coly-Mycin M; Coly-Mycin M Parenteral; Coly-mycin injectable DMZ9BMU TC Antibiotics DMZ9BMU DT Small molecular drug DMZ9BMU PC 216258 DMZ9BMU MW 1749.8 DMZ9BMU FM C58H105N16Na5O28S5 DMZ9BMU IC InChI=1S/C58H110N16O28S5.5Na/c1-9-35(6)12-10-11-13-46(77)65-38(14-20-59-28-103(88,89)90)53(82)74-48(37(8)76)58(87)70-41(17-23-62-31-106(97,98)99)50(79)68-43-19-25-64-57(86)47(36(7)75)73-54(83)42(18-24-63-32-107(100,101)102)67-49(78)39(15-21-60-29-104(91,92)93)69-55(84)44(26-33(2)3)72-56(85)45(27-34(4)5)71-52(81)40(66-51(43)80)16-22-61-30-105(94,95)96;;;;;/h33-45,47-48,59-63,75-76H,9-32H2,1-8H3,(H,64,86)(H,65,77)(H,66,80)(H,67,78)(H,68,79)(H,69,84)(H,70,87)(H,71,81)(H,72,85)(H,73,83)(H,74,82)(H,88,89,90)(H,91,92,93)(H,94,95,96)(H,97,98,99)(H,100,101,102);;;;;/q;5*+1/p-5 DMZ9BMU CS CCC(C)CCCCC(=O)NC(CCNCS(=O)(=O)[O-])C(=O)NC(C(C)O)C(=O)NC(CCNCS(=O)(=O)[O-])C(=O)NC1CCNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC1=O)CCNCS(=O)(=O)[O-])CC(C)C)CC(C)C)CCNCS(=O)(=O)[O-])CCNCS(=O)(=O)[O-])C(C)O.[Na+].[Na+].[Na+].[Na+].[Na+] DMZ9BMU IK IQWHCHZFYPIVRV-UHFFFAOYSA-I DMZ9BMU IU pentasodium;[2-[17-(1-hydroxyethyl)-22-[[2-[[3-hydroxy-2-[[2-(6-methyloctanoylamino)-4-(sulfonatomethylamino)butanoyl]amino]butanoyl]amino]-4-(sulfonatomethylamino)butanoyl]amino]-5,8-bis(2-methylpropyl)-3,6,9,12,15,18,23-heptaoxo-11,14-bis[2-(sulfonatomethylamino)ethyl]-1,4,7,10,13,16,19-heptazacyclotricos-2-yl]ethylamino]methanesulfonate DMZ9BMU CA CAS 8068-28-8 DMZ9BMU DE Respiratory tract infection DMMD9QE ID DMMD9QE DMMD9QE DN Colistin DMMD9QE HS Approved DMMD9QE SN Colistin sulphate; Polymyxin E; Colistin sulfate, nonsterile; Polymyxin E. Sulfate; Coly-Mycin M Parenteral (TN) DMMD9QE CP Parkdale Pharmaceuticals DMMD9QE TC Antibiotics DMMD9QE DT Small molecular drug DMMD9QE PC 5311054 DMMD9QE MW 1155.4 DMMD9QE FM C52H98N16O13 DMMD9QE IC InChI=1S/C52H98N16O13/c1-9-29(6)11-10-12-40(71)59-32(13-19-53)47(76)68-42(31(8)70)52(81)64-35(16-22-56)44(73)63-37-18-24-58-51(80)41(30(7)69)67-48(77)36(17-23-57)61-43(72)33(14-20-54)62-49(78)38(25-27(2)3)66-50(79)39(26-28(4)5)65-45(74)34(15-21-55)60-46(37)75/h27-39,41-42,69-70H,9-26,53-57H2,1-8H3,(H,58,80)(H,59,71)(H,60,75)(H,61,72)(H,62,78)(H,63,73)(H,64,81)(H,65,74)(H,66,79)(H,67,77)(H,68,76)/t29?,30-,31-,32+,33+,34+,35+,36+,37+,38+,39-,41+,42+/m1/s1 DMMD9QE CS CCC(C)CCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC1=O)CCN)CC(C)C)CC(C)C)CCN)CCN)[C@@H](C)O DMMD9QE IK YKQOSKADJPQZHB-QNPLFGSASA-N DMMD9QE IU N-[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-4-amino-1-oxo-1-[[(3S,6S,9S,12S,15R,18S,21S)-6,9,18-tris(2-aminoethyl)-3-[(1R)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-5-methylheptanamide DMMD9QE CA CAS 1066-17-7 DMMD9QE DE Pseudomonas infection DMFJ2OG ID DMFJ2OG DMFJ2OG DN Collagenase DMFJ2OG HS Approved DMFJ2OG TC Antiulcer Agents DMFJ2OG DE Skin burns; Dermal ulcers DM1V329 ID DM1V329 DM1V329 DN Conivaptan DM1V329 HS Approved DM1V329 SN Conivaptan [INN]; YM 087; YM087; Conivaptan (INN); Vaprisol (TN); YM-087; N-[4-(2-methyl-4,5-dihydro-3H-imidazo[4,5-d][1]benzazepine-6-carbonyl)phenyl]-2-phenylbenzamide; N-{4-[(2-methyl-4,5-dihydroimidazo[4,5-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl}biphenyl-2-carboxamide; 4'-((4,5-dihydro-2-methylimidazo(4,5-d)(1)benzazepin-6(1H)-yl)carbonyl)-2-biphenylcarboxanilide DM1V329 CP Astellas Pharma Inc DM1V329 DT Small molecular drug DM1V329 PC 151171 DM1V329 MW 498.6 DM1V329 FM C32H26N4O2 DM1V329 IC InChI=1S/C32H26N4O2/c1-21-33-28-19-20-36(29-14-8-7-13-27(29)30(28)34-21)32(38)23-15-17-24(18-16-23)35-31(37)26-12-6-5-11-25(26)22-9-3-2-4-10-22/h2-18H,19-20H2,1H3,(H,33,34)(H,35,37) DM1V329 CS CC1=NC2=C(N1)CCN(C3=CC=CC=C32)C(=O)C4=CC=C(C=C4)NC(=O)C5=CC=CC=C5C6=CC=CC=C6 DM1V329 IK IKENVDNFQMCRTR-UHFFFAOYSA-N DM1V329 IU N-[4-(2-methyl-4,5-dihydro-3H-imidazo[4,5-d][1]benzazepine-6-carbonyl)phenyl]-2-phenylbenzamide DM1V329 CA CAS 210101-16-9 DM1V329 CB CHEBI:681850 DM1V329 DE Euvolemic hyponatremia DMLT0E1 ID DMLT0E1 DMLT0E1 DN Conjugated estrogens DMLT0E1 HS Approved DMLT0E1 SN Par Estro; evex; Premarin; Conestoral; NSC18313; Sodium estrone 3-monosulfate; Estrone, hydrogen sulfate sodium salt; AC1NS0NL; NSC-18313; sodium [(8R,9S,13S,14S)-13-methyl-17-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-yl] hydrogen sulfate; Estra-1,5(10)-trien-17-one, 3-(sulfooxy)-, sodium; Carentil; Congest; Estroplus; Evex; Menotabs; Oestrogen; Prelestrin; Presomil; Progens; Conjugated Equine Estrogens; Conjugated Estrogenic Substances; Conjugated estrogenic hormones; Conjugated oestrogens; Conjugated oestrogens [Steroidal oestrogens]; Steroidal estrogens; ASTA Medica Brand of Estrogens, Conjugated; Almirall Brand of Estrogens, Conjugated; Equine Estrogens, Conjugated; Estro-Feminal; Estrogenic Hormones, Conjugated; Estrogenic substances, conjugated; Estrogens, conjugated USP; Estrogens, conjugated [USP]; Estrogens, conjugated synthetic A; Estrogens, steroidal; Solvay Brand of Estrogens, Conjugated; Trianon Brand of Estrogens, Conjugated; Wyeth Brand of Estrogens, Conjugated; Estrogens, conjugated (USP); Estrogens, conjugated-equine; Mack Brand of Estrogens, Conjugated (USP); Major Brand of Estrogens, Conjugated (USP); Pasadena Brand of Estrogens, Conjugated (USP); Pharmacia Brand of Estrogens, Conjugated (USP); CES; Estra-1,3,5(10)-trien-17-one, 3-(sulfooxy)-, sodium salt; Sodium [(8R,9S,13S,14S)-13-methyl-17-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-yl] hydrogen sulfate DMLT0E1 CP Wyeth Pharmaceuticals DMLT0E1 TC Estrogens DMLT0E1 DT Small molecular drug DMLT0E1 PC 45357473 DMLT0E1 MW 372.4 DMLT0E1 FM C18H21NaO5S DMLT0E1 IC InChI=1S/C18H22O5S.Na/c1-18-9-8-14-13-5-3-12(23-24(20,21)22)10-11(13)2-4-15(14)16(18)6-7-17(18)19;/h3,5,10,14-16H,2,4,6-9H2,1H3,(H,20,21,22);/q;+1/p-1/t14?,15?,16?,18-;/m0./s1 DMLT0E1 CS C[C@]12CCC3C(C1CCC2=O)CCC4=C3C=CC(=C4)OS(=O)(=O)[O-].[Na+] DMLT0E1 IK VUCAHVBMSFIGAI-TWCWWGPMSA-M DMLT0E1 IU sodium;[(13S)-13-methyl-17-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-yl] sulfate DMLT0E1 DE Menopause symptom; Vasomotor symptom DMTPIZC ID DMTPIZC DMTPIZC DN Conjugated estrogens a DMTPIZC HS Approved DMTPIZC SN Conestin (TN) DMTPIZC DE Hormone replacement therapy DMU7SF8 ID DMU7SF8 DMU7SF8 DN Conjugated estrogens b DMU7SF8 HS Approved DMU7SF8 SN Enjuvia (TN) DMU7SF8 DE Hormone replacement therapy DMF29Q5 ID DMF29Q5 DMF29Q5 DN Connexyn DMF29Q5 HS Approved DMF29Q5 SN Estulic; Intuniv; Tenex; GUANFACINE HCL; Guanfacine hydrochloride; G 1043; LON 798; BS 100-141; Guanfacine hydrochloride [USAN:JAN]; SPD-503; Tenex (TN); BS-100-141; Guanfacine hydrochloride (JAN/USP); N-(Aminoiminomethyl)-2,6-dichlorobenzeneacetamide hydrochloride; N-(Aminoiminomethyl)-2,6-dichlorophenylacetamide monohydrochloride; N-(aminoiminomethyl)-2,6-dichloro-benzeneacetamide hydrochloride; N-Amidino-2-(2,6-dichlorophenyl)acetamide hydrochloride; N-Amidino-2-(2,6-dichlorophenyl)acetamide monohydrochloride; N-carbamimidoyl-2-(2,6-dichlorphenyl)acetamidhydrochlorid; N-(diaminomethylidene)-2-(2,6-dichlorophenyl)acetamide hydrochloride; Benzeneacetamide, N-(aminoiminomethyl)-2,6-dichloro-, monohydrochloride; Benzeneacetamide, N-(aminoiminomethyl)-2,6-dichloro-, hydrochloride (1:1) DMF29Q5 DT Small molecular drug DMF29Q5 PC 71401 DMF29Q5 MW 282.5 DMF29Q5 FM C9H10Cl3N3O DMF29Q5 IC InChI=1S/C9H9Cl2N3O.ClH/c10-6-2-1-3-7(11)5(6)4-8(15)14-9(12)13;/h1-3H,4H2,(H4,12,13,14,15);1H DMF29Q5 CS C1=CC(=C(C(=C1)Cl)CC(=O)N=C(N)N)Cl.Cl DMF29Q5 IK DGFYECXYGUIODH-UHFFFAOYSA-N DMF29Q5 IU N-(diaminomethylidene)-2-(2,6-dichlorophenyl)acetamide;hydrochloride DMF29Q5 CA CAS 29110-48-3 DMF29Q5 CB CHEBI:5559 DMF29Q5 DE Attention deficit hyperactivity disorder DM26KR1 ID DM26KR1 DM26KR1 DN Copper dotatate Cu-64 DM26KR1 HS Approved DM26KR1 SN UNII-N3858377KC; N3858377KC; Copper 64-DOTA-tate; Copper Cu-64 dotatate; 1426155-87-4; Cuprate(2-)-64Cu, (N-(2-(4,10-bis((carboxy-kappaO)methyl)-7-(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl-kappaN1,kappaN4,kappaN7,kappaN10)acetyl)-D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-threonyl-L-cysteinyl-L-threoni DM26KR1 DT Radioactive diagnostic agent DM26KR1 PC 124220636 DM26KR1 MW 1497.5 DM26KR1 FM C65H88CuN14O19S2 DM26KR1 IC InChI=1S/C65H90N14O19S2.Cu/c1-38(80)56-64(96)73-51(63(95)75-57(39(2)81)65(97)98)37-100-99-36-50(72-59(91)47(28-40-10-4-3-5-11-40)68-52(83)32-76-20-22-77(33-53(84)85)24-26-79(35-55(88)89)27-25-78(23-21-76)34-54(86)87)62(94)70-48(29-41-15-17-43(82)18-16-41)60(92)71-49(30-42-31-67-45-13-7-6-12-44(42)45)61(93)69-46(58(90)74-56)14-8-9-19-66;/h3-7,10-13,15-18,31,38-39,46-51,56-57,67,80-82H,8-9,14,19-30,32-37,66H2,1-2H3,(H,68,83)(H,69,93)(H,70,94)(H,71,92)(H,72,91)(H,73,96)(H,74,90)(H,75,95)(H,84,85)(H,86,87)(H,88,89)(H,97,98);/q;+2/p-2/t38-,39-,46+,47-,48+,49-,50+,51+,56+,57+;/m1./s1/i;1+0 DM26KR1 CS C[C@H]([C@H]1C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@@H](CC5=CC=CC=C5)NC(=O)CN6CCN(CCN(CCN(CC6)CC(=O)[O-])CC(=O)[O-])CC(=O)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)O.[64Cu+2] DM26KR1 IK IJRLLVFQGCCPPI-NVGRTJHCSA-L DM26KR1 IU 2-[4-[2-[[(2R)-1-[[(4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-4-[[(1S,2R)-1-carboxy-2-hydroxypropyl]carbamoyl]-7-[(1R)-1-hydroxyethyl]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicos-19-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]-10-(carboxylatomethyl)-7-(carboxymethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetate;copper-64(2+) DM26KR1 CA CAS 1426155-87-4 DM26KR1 DE Diagnostic imaging DMP9TWZ ID DMP9TWZ DMP9TWZ DN Corticotropin DMP9TWZ HS Approved DMP9TWZ SN corticotropin; ACTH; Cortrophin; Corticotrophin; Adrenocorticotropic hormone; Corticotrophine; Corticotrofina; Acthargel; Corticotrophinum; beta-Corticotropin; Adrenocorticotrophin; Purified Cortrophin gel; Corticotropin [USP:INN]; 9002-60-2; CHEBI:3892; BDBM82408; ACTH-(1-39); 25-Asp-30-Gln-corticotropin porcine; NCGC00167127-01; CAS_12279-41-3; Adrenocorticotropic Hormone (1-39), human; LS-187380; SYSMEHFRWGKPVGKKRRPVKVYPDGAEDQLAEAFPLEF; J-004856; alpha1-39-Corticotropin (swine), 25-L-aspartic acid-30-L-glutamine DMP9TWZ CP Questcor pharmaceuticals DMP9TWZ SQ ACTH(1-39): SYSMEHFRWGKPVGKKRRPVKVYPDGAEDQLAEAFPLEF DMP9TWZ PC 16132265 DMP9TWZ MW 4541 DMP9TWZ FM C207H308N56O58S DMP9TWZ IC InChI=1S/C207H308N56O58S/c1-108(2)89-140(186(302)240-135(69-74-163(279)280)182(298)254-149(204(320)321)94-117-43-20-15-21-44-117)250-193(309)152-54-35-86-262(152)202(318)147(92-116-41-18-14-19-42-116)252-171(287)114(11)230-175(291)132(66-71-160(273)274)234-170(286)113(10)231-191(307)150(105-265)255-183(299)136(70-75-164(281)282)241-190(306)146(98-165(283)284)249-180(296)133(67-72-161(275)276)235-169(285)112(9)229-157(270)101-225-174(290)145(97-156(213)269)251-194(310)153-55-36-87-263(153)203(319)148(93-119-60-64-123(268)65-61-119)253-199(315)167(110(5)6)257-185(301)129(49-26-30-79-210)243-198(314)168(111(7)8)259-196(312)155-57-38-85-261(155)201(317)139(53-34-83-223-207(218)219)244-178(294)130(51-32-81-221-205(214)215)237-177(293)128(48-25-29-78-209)236-176(292)127(47-24-28-77-208)232-158(271)103-227-197(313)166(109(3)4)258-195(311)154-56-37-84-260(154)200(316)138(50-27-31-80-211)233-159(272)102-226-173(289)143(95-120-99-224-126-46-23-22-45-124(120)126)247-179(295)131(52-33-82-222-206(216)217)238-187(303)142(90-115-39-16-13-17-40-115)246-189(305)144(96-121-100-220-107-228-121)248-181(297)134(68-73-162(277)278)239-184(300)137(76-88-322-12)242-192(308)151(106-266)256-188(304)141(245-172(288)125(212)104-264)91-118-58-62-122(267)63-59-118/h13-23,39-46,58-65,99-100,107-114,125,127-155,166-168,224,264-268H,24-38,47-57,66-98,101-106,208-212H2,1-12H3,(H2,213,269)(H,220,228)(H,225,290)(H,226,289)(H,227,313)(H,229,270)(H,230,291)(H,231,307)(H,232,271)(H,233,272)(H,234,286)(H,235,285)(H,236,292)(H,237,293)(H,238,303)(H,239,300)(H,240,302)(H,241,306)(H,242,308)(H,243,314)(H,244,294)(H,245,288)(H,246,305)(H,247,295)(H,248,297)(H,249,296)(H,250,309)(H,251,310)(H,252,287)(H,253,315)(H,254,298)(H,255,299)(H,256,304)(H,257,301)(H,258,311)(H,259,312)(H,273,274)(H,275,276)(H,277,278)(H,279,280)(H,281,282)(H,283,284)(H,320,321)(H4,214,215,221)(H4,216,217,222)(H4,218,219,223)/t112-,113-,114-,125-,127-,128-,129-,130-,131-,132-,133-,134-,135-,136-,137-,138-,139-,140-,141-,142-,143-,144-,145-,146-,147-,148-,149-,150-,151-,152-,153-,154-,155-,166-,167-,168-/m0/s1 DMP9TWZ CS C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)O)NC(=O)CNC(=O)[C@H](CC(=O)N)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CC5=CC=C(C=C5)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]6CCCN6C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](C(C)C)NC(=O)[C@@H]7CCCN7C(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CC8=CNC9=CC=CC=C98)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CO)N DMP9TWZ IK IDLFZVILOHSSID-OVLDLUHVSA-N DMP9TWZ IU (4S)-4-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-4-amino-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-6-amino-2-[[2-[[(2S)-2-[[(2S)-1-[(2S)-6-amino-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-4-carboxybutanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]acetyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]acetyl]amino]hexanoyl]amino]hexanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]hexanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carbonyl]amino]-4-oxobutanoyl]amino]acetyl]amino]propanoyl]amino]-4-carboxybutanoyl]amino]-3-carboxypropanoyl]amino]-4-carboxybutanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]-5-[[(2S)-1-[[(2S)-1-[(2S)-2-[[(2S)-1-[[(2S)-4-carboxy-1-[[(1S)-1-carboxy-2-phenylethyl]amino]-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-oxopentanoic acid DMP9TWZ CA CAS 12427-33-7 DMP9TWZ CB CHEBI:3892 DMP9TWZ DE Diabetic nephropathy; Cushing disease DMU5QZX ID DMU5QZX DMU5QZX DN Cortisone DMU5QZX HS Approved DMU5QZX SN 11-dehydro-17-hydroxycorticosterone; 17-hydroxy-11-dehydrocorticosterone DMU5QZX DT Small molecular drug DMU5QZX PC 222786 DMU5QZX MW 360.4 DMU5QZX FM C21H28O5 DMU5QZX IC InChI=1S/C21H28O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h9,14-15,18,22,26H,3-8,10-11H2,1-2H3/t14-,15-,18+,19-,20-,21-/m0/s1 DMU5QZX CS C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@H]2C(=O)C[C@]4([C@H]3CC[C@@]4(C(=O)CO)O)C DMU5QZX IK MFYSYFVPBJMHGN-ZPOLXVRWSA-N DMU5QZX IU (8S,9S,10R,13S,14S,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-1,2,6,7,8,9,12,14,15,16-decahydrocyclopenta[a]phenanthrene-3,11-dione DMU5QZX CA CAS 53-06-5 DMU5QZX CB CHEBI:16962 DMU5QZX DE Atopic dermatitis DMG8K57 ID DMG8K57 DMG8K57 DN Cortisone acetate DMG8K57 HS Approved DMG8K57 SN Cortone DMG8K57 CP Pharmacia And Upjohn Co DMG8K57 TC Anticancer Agents DMG8K57 DT Small molecular drug DMG8K57 PC 5745 DMG8K57 MW 402.5 DMG8K57 FM C23H30O6 DMG8K57 IC InChI=1S/C23H30O6/c1-13(24)29-12-19(27)23(28)9-7-17-16-5-4-14-10-15(25)6-8-21(14,2)20(16)18(26)11-22(17,23)3/h10,16-17,20,28H,4-9,11-12H2,1-3H3/t16-,17-,20+,21-,22-,23-/m0/s1 DMG8K57 CS CC(=O)OCC(=O)[C@]1(CC[C@@H]2[C@@]1(CC(=O)[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C)O DMG8K57 IK ITRJWOMZKQRYTA-RFZYENFJSA-N DMG8K57 IU [2-[(8S,9S,10R,13S,14S,17R)-17-hydroxy-10,13-dimethyl-3,11-dioxo-1,2,6,7,8,9,12,14,15,16-decahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] acetate DMG8K57 CA CAS 50-04-4 DMG8K57 CB CHEBI:3897 DMG8K57 DE Solid tumour/cancer DMUIASK ID DMUIASK DMUIASK DN Cosyntropin DMUIASK HS Approved DMUIASK SN Cortrosyn; Tetracosactide; Cortrosyn (TN); Cosyntropin (USAN); Tetracosactide (INN) DMUIASK CP Sandoz DMUIASK TC Diagnostic Agents DMUIASK PC 16129617 DMUIASK MW 2933.4 DMUIASK FM C136H210N40O31S DMUIASK IC InChI=1S/C136H210N40O31S/c1-75(2)109(127(200)154-71-106(181)156-88(31-13-17-52-137)114(187)158-89(32-14-18-53-138)115(188)159-91(35-21-56-149-134(142)143)116(189)164-96(37-23-58-151-136(146)147)131(204)175-60-25-39-104(175)126(199)173-111(77(5)6)128(201)163-90(33-15-19-54-139)120(193)171-110(76(3)4)129(202)169-101(65-80-43-47-84(180)48-44-80)132(205)176-61-26-40-105(176)133(206)207)172-125(198)103-38-24-59-174(103)130(203)95(34-16-20-55-140)157-107(182)70-153-113(186)99(66-81-68-152-87-30-12-11-29-85(81)87)167-117(190)92(36-22-57-150-135(144)145)160-121(194)98(63-78-27-9-8-10-28-78)166-123(196)100(67-82-69-148-74-155-82)168-118(191)93(49-50-108(183)184)161-119(192)94(51-62-208-7)162-124(197)102(73-178)170-122(195)97(165-112(185)86(141)72-177)64-79-41-45-83(179)46-42-79/h8-12,27-30,41-48,68-69,74-77,86,88-105,109-111,152,177-180H,13-26,31-40,49-67,70-73,137-141H2,1-7H3,(H,148,155)(H,153,186)(H,154,200)(H,156,181)(H,157,182)(H,158,187)(H,159,188)(H,160,194)(H,161,192)(H,162,197)(H,163,201)(H,164,189)(H,165,185)(H,166,196)(H,167,190)(H,168,191)(H,169,202)(H,170,195)(H,171,193)(H,172,198)(H,173,199)(H,183,184)(H,206,207)(H4,142,143,149)(H4,144,145,150)(H4,146,147,151)/t86?,88-,89-,90+,91-,92+,93+,94+,95+,96-,97+,98+,99+,100+,101+,102+,103+,104+,105+,109+,110+,111+/m1/s1 DMUIASK CS CC(C)[C@@H](C(=O)NCC(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N3CCC[C@H]3C(=O)O)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CC5=CNC6=CC=CC=C65)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC7=CC=CC=C7)NC(=O)[C@H](CC8=CNC=N8)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CO)NC(=O)[C@H](CC9=CC=C(C=C9)O)NC(=O)C(CO)N DMUIASK IK ZOEFCCMDUURGSE-CQVUSSRSSA-N DMUIASK IU (2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-1-[(2R)-2-[[(2R)-2-[[(2R)-6-amino-2-[[(2R)-6-amino-2-[[2-[[(2S)-2-[[(2S)-1-[(2S)-6-amino-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[(2-amino-3-hydroxypropanoyl)amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-4-carboxybutanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]acetyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]acetyl]amino]hexanoyl]amino]hexanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]hexanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carboxylic acid DMUIASK CA CAS 16960-16-0 DMUIASK DE Adrenocortical insufficiency DMCEZ1B ID DMCEZ1B DMCEZ1B DN Cotinine DMCEZ1B HS Approved DMCEZ1B SN cotinine; (-)-Cotinine; 486-56-6; Cotinina; Cotininum; (S)-(-)-Cotinine; (5S)-1-methyl-5-(pyridin-3-yl)pyrrolidin-2-one; Cotinine (-); (S)-Cotinine; UNII-K5161X06LL; (S)-1-Methyl-5-(3-pyridinyl)-2-pyrrolidinone; 2-Pyrrolidinone, 1-methyl-5-(3-pyridinyl)-, (5S)-; CHEBI:68641; (S)-1-Methyl-5-(3-pyridyl)-2-pyrrolidinone; UIKROCXWUNQSPJ-VIFPVBQESA-N; K5161X06LL; Cotinine [INN]; MFCD00077696; Cotininum [INN-Latin]; Cotinina [INN-Spanish]; S(-)-1-Methyl-5-(3-pyridyl)-2-pyrrolidone; (5S)-1-methyl-5-pyridin-3-ylpyrrolidin-2-one DMCEZ1B DT Small molecular drug DMCEZ1B PC 854019 DMCEZ1B MW 176.21 DMCEZ1B FM C10H12N2O DMCEZ1B IC InChI=1S/C10H12N2O/c1-12-9(4-5-10(12)13)8-3-2-6-11-7-8/h2-3,6-7,9H,4-5H2,1H3/t9-/m0/s1 DMCEZ1B CS CN1[C@@H](CCC1=O)C2=CN=CC=C2 DMCEZ1B IK UIKROCXWUNQSPJ-VIFPVBQESA-N DMCEZ1B IU (5S)-1-methyl-5-pyridin-3-ylpyrrolidin-2-one DMCEZ1B CA CAS 486-56-6 DMCEZ1B CB CHEBI:68641 DMCEZ1B DE Insecticide DMJ7IQX ID DMJ7IQX DMJ7IQX DN Crestor/TriLipix DMJ7IQX HS Approved DMJ7IQX CP AstraZeneca DMJ7IQX DE Dyslipidemia DMNVKU6 ID DMNVKU6 DMNVKU6 DN Crisaborole DMNVKU6 HS Approved DMNVKU6 SN Crisaborole ointment 2%; PF-06930164 DMNVKU6 CP Pfizer/Anacor Pharmaceuticals DMNVKU6 DT Small molecular drug DMNVKU6 PC 44591583 DMNVKU6 MW 251.05 DMNVKU6 FM C14H10BNO3 DMNVKU6 IC InChI=1S/C14H10BNO3/c16-8-10-1-3-12(4-2-10)19-13-5-6-14-11(7-13)9-18-15(14)17/h1-7,17H,9H2 DMNVKU6 CS B1(C2=C(CO1)C=C(C=C2)OC3=CC=C(C=C3)C#N)O DMNVKU6 IK USZAGAREISWJDP-UHFFFAOYSA-N DMNVKU6 IU 4-[(1-hydroxy-3H-2,1-benzoxaborol-5-yl)oxy]benzonitrile DMNVKU6 CA CAS 906673-24-3 DMNVKU6 CB CHEBI:134677 DMNVKU6 DE Atopic dermatitis DMAHOVJ ID DMAHOVJ DMAHOVJ DN Crizanlizumab DMAHOVJ HS Approved DMAHOVJ SN SEG101 DMAHOVJ CP Novartis DMAHOVJ DT Antibody DMAHOVJ DE Vaso-occlusive crisis; Sickle-cell disorder DM4F29C ID DM4F29C DM4F29C DN Crizotinib DM4F29C HS Approved DM4F29C SN Xalkori (TN); novel ALK inhibitors DM4F29C CP Pfizer New York, NY DM4F29C DT Small molecular drug DM4F29C PC 11626560 DM4F29C MW 450.3 DM4F29C FM C21H22Cl2FN5O DM4F29C IC InChI=1S/C21H22Cl2FN5O/c1-12(19-16(22)2-3-17(24)20(19)23)30-18-8-13(9-27-21(18)25)14-10-28-29(11-14)15-4-6-26-7-5-15/h2-3,8-12,15,26H,4-7H2,1H3,(H2,25,27)/t12-/m1/s1 DM4F29C CS C[C@H](C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N DM4F29C IK KTEIFNKAUNYNJU-GFCCVEGCSA-N DM4F29C IU 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine DM4F29C CA CAS 877399-52-5 DM4F29C CB CHEBI:64310 DM4F29C DE Non-small-cell lung cancer DM4AMQZ ID DM4AMQZ DM4AMQZ DN Crofelemer DM4AMQZ HS Approved DM4AMQZ SN Fulyzaq (TN) DM4AMQZ CP Salix DM4AMQZ DT Small molecular drug DM4AMQZ PC 17397714 DM4AMQZ MW 308.3 DM4AMQZ FM C18H16N2O3 DM4AMQZ IC InChI=1S/C18H16N2O3/c1-22-16-10-6-5-9-14(16)12-19-18(21)15-11-17(23-20-15)13-7-3-2-4-8-13/h2-11H,12H2,1H3,(H,19,21) DM4AMQZ CS COC1=CC=CC=C1CNC(=O)C2=NOC(=C2)C3=CC=CC=C3 DM4AMQZ IK JDNAIBCYTQGWFC-UHFFFAOYSA-N DM4AMQZ IU N-[(2-methoxyphenyl)methyl]-5-phenyl-1,2-oxazole-3-carboxamide DM4AMQZ DE HIV-associated diarrhoea DM74LZK ID DM74LZK DM74LZK DN Cromoglicate DM74LZK HS Approved DM74LZK SN Crolom (TN); Intal (TN); Nasalcrom (TN); Opticrom (TN); Optrex Allergy (TN); Prevalin (TN); Rynacrom (TN) DM74LZK CP Zambon Group DM74LZK TC Antiasthmatic Agents DM74LZK DT Small molecular drug DM74LZK PC 2882 DM74LZK MW 468.4 DM74LZK FM C23H16O11 DM74LZK IC InChI=1S/C23H16O11/c24-11(9-31-14-3-1-5-16-20(14)12(25)7-18(33-16)22(27)28)10-32-15-4-2-6-17-21(15)13(26)8-19(34-17)23(29)30/h1-8,11,24H,9-10H2,(H,27,28)(H,29,30) DM74LZK CS C1=CC2=C(C(=C1)OCC(COC3=CC=CC4=C3C(=O)C=C(O4)C(=O)O)O)C(=O)C=C(O2)C(=O)O DM74LZK IK IMZMKUWMOSJXDT-UHFFFAOYSA-N DM74LZK IU 5-[3-(2-carboxy-4-oxochromen-5-yl)oxy-2-hydroxypropoxy]-4-oxochromene-2-carboxylic acid DM74LZK CA CAS 16110-51-3 DM74LZK CB CHEBI:59773 DM74LZK DE Asthma; Allergic rhinitis DMHCTAL ID DMHCTAL DMHCTAL DN Cryptenamine Acetates DMHCTAL HS Approved DMHCTAL SN Unitensen; Cryptenamine Tannates DMHCTAL CP Medpointe Pharmaceuticals Medpointe Healthcare Inc DMHCTAL TC Cardiovascular Agents DMHCTAL DE Hypertension DMB8PF3 ID DMB8PF3 DMB8PF3 DN CT-102 DMB8PF3 HS Approved DMB8PF3 CP Curative Health Services DMB8PF3 DE Diabetic foot ulcer DMP0NFQ ID DMP0NFQ DMP0NFQ DN Cupric Sulfate DMP0NFQ HS Approved DMP0NFQ SN Copper sulfate; 7758-98-7; CUPRIC SULFATE; Copper(II) sulfate; Cupric sulfate anhydrous; Copper sulphate; Copper(2+) sulfate; Cupricsulfate; Blue stone; Copper monosulfate; Copper II sulfate; Trinagle; Hylinec; Delcup; Cupric sulphate; Copper(ii) sulfate, anhydrous; Monocopper sulfate; Copper sulfate (1:1); Incracide 10A; Incracide E 51; Sulfuric acid copper(2+) salt (1:1); BCS copper fungicide; Blue copper (VAN); Copper Sulfate Powder; Bonide Root Destroyer; CuSO4; Kupfersulfat [German]; All Clear Root Destroyer; Copper sulfate (CuSO DMP0NFQ CP Abraxis Pharmaceutical Products DMP0NFQ TC Antiinfective Agents DMP0NFQ DT Small molecular drug DMP0NFQ PC 24462 DMP0NFQ MW 159.61 DMP0NFQ FM CuO4S DMP0NFQ IC InChI=1S/Cu.H2O4S/c;1-5(2,3)4/h;(H2,1,2,3,4)/q+2;/p-2 DMP0NFQ CS [O-]S(=O)(=O)[O-].[Cu+2] DMP0NFQ IK ARUVKPQLZAKDPS-UHFFFAOYSA-L DMP0NFQ IU copper;sulfate DMP0NFQ CA CAS 7758-98-7 DMP0NFQ CB CHEBI:23414 DMP0NFQ DE Pest attack; Fungal infection; Herbicide DMHSJB4 ID DMHSJB4 DMHSJB4 DN Cyclacillin DMHSJB4 HS Approved DMHSJB4 SN Aminocyclohexylpenicillin; Bastcillin; Calthor; Ciclacilina; Ciclacillin; Ciclacilline; Ciclacillinum; Ciclacillum; Citosarin; Cyclapen; Noblicil; Orfilina; Peamezin; Syngacillin; Ultracillin; Vastcillin; Vipicil; Wyvital; Aminocyclohexyl penicillin; Cyclacillin [USAN]; AC 98; WY 4508; WY4508; C-12104; Ciclacilina [INN-Spanish]; Ciclacilline [INN-French]; Ciclacillinum [INN-Latin]; Cyclacillin (USAN); Cyclapen (TN); Cyclapen-W; Vastcillin (TN); Wy-4508; Ciclacillin (JP15/INN); Cyclapen-W (TN); (1-Aminocyclohexyl)penicillin; (2S,5R,6R)-6-[(1-aminocyclohexanecarbonyl)amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-{[(1-aminocyclohexyl)carbonyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-(1-aminocyclohexanecarboxamido)-3,3-dimethyl-7-oxo-(8CI); 6-(1-Aminocyclohexanecarboxamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid; 6-(1-Aminocyclohexanecarboxamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 6-(1-Aminocyclohexanecarboxamido)penicillanic acid; 6-(1-Aminocyclohexylcarboxamido)penicillanic acid; 6beta-(1-aminocyclohexanecarboxamido)-2,2-dimethylpenam-3alpha-carboxylic acid DMHSJB4 TC Antibiotics DMHSJB4 DT Small molecular drug DMHSJB4 PC 19003 DMHSJB4 MW 341.4 DMHSJB4 FM C15H23N3O4S DMHSJB4 IC InChI=1S/C15H23N3O4S/c1-14(2)9(12(20)21)18-10(19)8(11(18)23-14)17-13(22)15(16)6-4-3-5-7-15/h8-9,11H,3-7,16H2,1-2H3,(H,17,22)(H,20,21)/t8-,9+,11-/m1/s1 DMHSJB4 CS CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)C3(CCCCC3)N)C(=O)O)C DMHSJB4 IK HGBLNBBNRORJKI-WCABBAIRSA-N DMHSJB4 IU (2S,5R,6R)-6-[(1-aminocyclohexanecarbonyl)amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid DMHSJB4 CA CAS 3485-14-1 DMHSJB4 CB CHEBI:31444 DMHSJB4 DE Bacterial infection DMO0R76 ID DMO0R76 DMO0R76 DN Cyclandelate DMO0R76 HS Approved DMO0R76 SN cyclandelate; 456-59-7; Cyclolyt; Cyclomandol; Cyclospasmol; Spasmocyclon; Spasmocyclone; Ciclospasmol; Ciclandelato; Sancyclan; Saiclate; Sepyron; Perebral; Dilatan; Clandilon; Capilan; Spasmione; Arto-espasmol; 3,3,5-Trimethylcyclohexyl mandelate; Cyclandelatum; 3,5,5-Trimethylcyclohexyl amygdalate; Cyclobral; Cyclergine; Cyclandelatum [INN-Latin]; Ciclandelato [INN-Spanish]; 3,5,5-Trimethylcyclohexyl mandelate; Novodil; Natil; Mandelic Acid 3,3,5-Trimethylcyclohexyl Ester; Cyclandelic acid; BS 572; UNII-4139O1OAY2; HSDB 3046; EINECS 207 DMO0R76 DT Small molecular drug DMO0R76 PC 2893 DMO0R76 MW 276.4 DMO0R76 FM C17H24O3 DMO0R76 IC InChI=1S/C17H24O3/c1-12-9-14(11-17(2,3)10-12)20-16(19)15(18)13-7-5-4-6-8-13/h4-8,12,14-15,18H,9-11H2,1-3H3 DMO0R76 CS CC1CC(CC(C1)(C)C)OC(=O)C(C2=CC=CC=C2)O DMO0R76 IK WZHCOOQXZCIUNC-UHFFFAOYSA-N DMO0R76 IU (3,3,5-trimethylcyclohexyl) 2-hydroxy-2-phenylacetate DMO0R76 CA CAS 456-59-7 DMO0R76 CB CHEBI:3988 DMO0R76 DE Dementia DM9G7BS ID DM9G7BS DM9G7BS DN Cyclizine DM9G7BS HS Approved DM9G7BS SN Ciclizina; Cyclizinum; Emoquil; Marezine; Nautazine; Valoid; Wellcome; Cyclizine chloride; Cyclizine hydrochloride; Marezine hydrochloride; BW 47-83; Ciclizina [INN-Spanish]; Cyclizine (INN); Cyclizinum [INN-Latin]; Emoquil (TN); Marezine (TN); Marzine (TN); Ne-devomit; Neo-devomit; Reis-fit; Valoid (TN); Wellcome preparation 47-83; Wellcome prepn 47-83; Cyclizine [INN:BAN:DCF]; Wellcome prepn. 47-83; N-Benzhydryl-N'-methylpiperazine; N-Methyl-N'-benzhydrylpiperazine; N-Methyl-N'-benzyhydrylpiperazine; (+-)-1-diphenylmethyl-4-methylpiperazine; (-)-1-Diphenylmethyl-4-methylpiperazine; (N-Benzhydryl)(N'-methyl)diethylenediamine; 1-(Diphenylmethyl)-4-methylpiperazine; 1-Benzhydryl-4-methylpiperazin; 1-Benzhydryl-4-methylpiperazine; 1-Diphenylmethyl-4-methylpiperazine DM9G7BS CP Seatrace Pharmaceuticals DM9G7BS TC Antiemetics DM9G7BS DT Small molecular drug DM9G7BS PC 6726 DM9G7BS MW 266.4 DM9G7BS FM C18H22N2 DM9G7BS IC InChI=1S/C18H22N2/c1-19-12-14-20(15-13-19)18(16-8-4-2-5-9-16)17-10-6-3-7-11-17/h2-11,18H,12-15H2,1H3 DM9G7BS CS CN1CCN(CC1)C(C2=CC=CC=C2)C3=CC=CC=C3 DM9G7BS IK UVKZSORBKUEBAZ-UHFFFAOYSA-N DM9G7BS IU 1-benzhydryl-4-methylpiperazine DM9G7BS CA CAS 82-92-8 DM9G7BS CB CHEBI:3994 DM9G7BS DE Nausea DM1YBRM ID DM1YBRM DM1YBRM DN Cyclobenzaprine DM1YBRM HS Approved DM1YBRM SN Ciclobenzaprina; Cyclobenz; Cyclobenzaprinum; Fexmid; Flexeril; Lisseril; Proeptatriene; Proheptatrien; Proheptatriene; Yurelax; Cyclobenzaprine [INN]; Flexeril hydrochloride; Proeptatriene [Italian]; MK 130; NCI78206; Amrix (TN); Ciclobenzaprina [INN-Spanish]; Cyclobenzaprine (INN); Cyclobenzaprinum [INN-Latin]; Fexmid(TN); Flexeril (TN); MK-130 HCl; Ro 4-1577; Apo-Cyclobenzaprine (TN); N,N-Dimethyl-3-(dibenzo(a,d)cycloheptene-4-ylidene)propylamine; N,N-Dimethyl-5H-dibenzo(a,d)cycloheptene-delta(sup 5),gamma-propylamine; N,N-dimethyl-5H-dibenzo(a,d)cycloheptene-Delta(5,gamma)-propylamine; 1-Propanamine, 3-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-N,N-dimethyl-(9CI); 10,11-Dehydroamitriptyline; 3-(5H-Dibenzo[a,d]cyclohepten-5-ylidene)-N,N-dimethyl-1-propanamine; 3-(5H-dibenzo[a,d][7]annulen-5-ylidene)-N,N-dimethylpropan-1-amine; 3-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-N,N-dimethylpropan-1-amine; 5-(3-Dimetilaminopropiliden)-5H-dibenzo-(a,d)-ciclopentene; 5-(3-Dimetilaminopropiliden)-5H-dibenzo-(a,d)-ciclopentene [Italian]; 9715 R.P; 9715 R.P. DM1YBRM CP Janssen Research And Development Llc DM1YBRM TC Antidepressants DM1YBRM DT Small molecular drug DM1YBRM PC 2895 DM1YBRM MW 275.4 DM1YBRM FM C20H21N DM1YBRM IC InChI=1S/C20H21N/c1-21(2)15-7-12-20-18-10-5-3-8-16(18)13-14-17-9-4-6-11-19(17)20/h3-6,8-14H,7,15H2,1-2H3 DM1YBRM CS CN(C)CCC=C1C2=CC=CC=C2C=CC3=CC=CC=C31 DM1YBRM IK JURKNVYFZMSNLP-UHFFFAOYSA-N DM1YBRM IU N,N-dimethyl-3-(2-tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,9,11,13-heptaenylidene)propan-1-amine DM1YBRM CA CAS 303-53-7 DM1YBRM CB CHEBI:3996 DM1YBRM DE Depression DMT5RMB ID DMT5RMB DMT5RMB DN Cyclofenil DMT5RMB HS Approved DMT5RMB SN cyclofenil; 2624-43-3; Ondogyne; Cyclofenyl; Cyclophenyl; Cyclopenil; Fertodur; Sanocrisin; Cyclophenil; Sexovar; Rehibin; Sexadieno; Sexovid; Ondonid; Oginex; (Cyclohexylidenemethylene)bis(4,1-phenylene) diacetate; Neoclym; ICI 48213; Cyclofenilum [INN-Latin]; Ciclofenilo [INN-Spanish]; NSC 86464; H 3452; F 6066; UNII-J468V64WZ1; Cyclofenil [INN:BAN:DCF:JAN]; 4,4'-(Cyclohexylidenemethylene)diphenol diacetate ester; C23H24O4; EINECS 220-089-1; Bis(p-hydroxyphenyl)cyclohexyldienemethane diacetate; BRN 2014687; AI3-52271; F-6066 DMT5RMB DT Small molecular drug DMT5RMB PC 2898 DMT5RMB MW 364.4 DMT5RMB FM C23H24O4 DMT5RMB IC InChI=1S/C23H24O4/c1-16(24)26-21-12-8-19(9-13-21)23(18-6-4-3-5-7-18)20-10-14-22(15-11-20)27-17(2)25/h8-15H,3-7H2,1-2H3 DMT5RMB CS CC(=O)OC1=CC=C(C=C1)C(=C2CCCCC2)C3=CC=C(C=C3)OC(=O)C DMT5RMB IK GVOUFPWUYJWQSK-UHFFFAOYSA-N DMT5RMB IU [4-[(4-acetyloxyphenyl)-cyclohexylidenemethyl]phenyl] acetate DMT5RMB CA CAS 2624-43-3 DMT5RMB CB CHEBI:31446 DMT5RMB DE Infertility DMA8LM5 ID DMA8LM5 DMA8LM5 DN Cyclopentolate DMA8LM5 HS Approved DMA8LM5 SN Ciclopentolato; Cyclopentoiate; Cyclopentolatum; Cyclopentylate; Cylate; Diopentolate; Mydrilate; Bell Pentolate; Minims Cyclopentolate; Bell Pentolate (TN); Ciclopentolato [INN-Spanish]; Cyclopentolate (INN); Cyclopentolate [INN:BAN]; Cyclopentolatum [INN-Latin]; Ocu-Pentolate; B-dimethylaminoethyl(1-hydroxycyclopentyl)phenylacetate; Beta-dimethylaminoethyl (1-hydroxycyclopentyl)phenylacetate; Beta-(Dimethylamino)ethyl (1-hydroxycyclopentyl)phenylacetate; Alpha-(1-hydroxycyclopentyl)benzeneacetic acid 2-(dimethylamino)ethyl ester; Benzeneacetic acid, alpha-(1-hydroxycyclopentyl)-, 2-(dimethylamino)ethyl ester; Benzeneacetic acid, .alpha.-(1-hydroxycyclopentyl)-, 2-(dimethylamino)ethyl ester; (+-)-cyclopentolate; 1-hydroxy-alpha-phenylcyclopentaneacetic acid 2-(dimethylamino)ethyl ester; 2-(Dimethylamino)ethyl (1-hydroxycyclopentyl)(phenyl)acetate; 2-(Dimethylamino)ethyl 1-hydroxy-alpha-phenylcyclopentaneacetate; 2-(dimethylamino)ethyl 2-(1-hydroxycyclopentyl)-2-phenylacetate; 2-Dimethylaminoethyl 2-(1-hydroxycyclopentyl)-2-phenylacetat; 2-dimethylaminoethyl 2-(1-hydroxycyclopentyl)-2-phenylacetate; 2-phenyl-2-(1-hydroxycyclopentyl)ethanoic acid beta-(dimethylamino)ethyl ester DMA8LM5 CP Akorn Inc DMA8LM5 TC Parasympatholytics DMA8LM5 DT Small molecular drug DMA8LM5 PC 2905 DMA8LM5 MW 291.4 DMA8LM5 FM C17H25NO3 DMA8LM5 IC InChI=1S/C17H25NO3/c1-18(2)12-13-21-16(19)15(14-8-4-3-5-9-14)17(20)10-6-7-11-17/h3-5,8-9,15,20H,6-7,10-13H2,1-2H3 DMA8LM5 CS CN(C)CCOC(=O)C(C1=CC=CC=C1)C2(CCCC2)O DMA8LM5 IK SKYSRIRYMSLOIN-UHFFFAOYSA-N DMA8LM5 IU 2-(dimethylamino)ethyl 2-(1-hydroxycyclopentyl)-2-phenylacetate DMA8LM5 CA CAS 512-15-2 DMA8LM5 CB CHEBI:4024 DMA8LM5 DE Examination of eyes or vision DM4O2Z7 ID DM4O2Z7 DM4O2Z7 DN Cyclophosphamide DM4O2Z7 HS Approved DM4O2Z7 SN ASTA; Ciclofosfamida; Ciclophosphamide; Clafen; Claphene; Cycloblastin; Cyclophosphamid; Cyclophosphamides; Cyclophosphamidum; Cyclophosphan; Cyclophosphane; Cyclophosphanum; Cyclophosphoramide; Cyclostin; Cyklofosfamid; Cytophosphan; Cytophosphane; Cytoxan; Endoxan; Endoxana; Endoxanal; Endoxane; Enduxan; Genoxal; Mitoxan; Neosar; Procytox; Revimmune; Semdoxan; Sendoxan; Senduxan; Zyklophosphamid; Ciclophosphamide [INN]; Cyclophosphamide Sterile; Cyclophosphamide anhydrous; Cyklofosfamid [Czech]; Cytoxan Lyoph; Endoxan R; Lyophilized Cytoxan; Zyklophosphamid [German]; ASTA B518; Asta B 518; B 518; C 0768; CB 4564; SK 20501; B-518; CB-4564; Ciclofosfamida [INN-Spanish]; Cyclophosphamide (INN); Cyclophosphamide (TN); Cyclophosphamide (anhydrous form); Cyclophosphamide (anhydrous); Cyclophosphamidum [INN-Latin]; Cytoxan (TN); Endoxan (TN); Endoxan-Asta; Neosar (TN); Occupation, cyclophosphamide exposure; Procytox (TN); Revimmune (TN); Bis(2-Chloroethyl)phosphami de cyclic propanolamide; Bis(2-Chloroethyl)phosphamide cyclic propanolamide ester; Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester; D,L-Cyclophosphamide; Cyclophosphamide, (+-)-Isomer; N,N-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide; (+-)-Cyclophosphamide; (-)-Cyclophosphamide; (RS)-Cyclophosphamide; 1-(bis(2-chloroethyl)amino)-1-oxo-2-aza-5-oxaphosphoridine; 1-Bis(2-chloroethyl)amino-1-oxo-2-aza-5-oxaphosphoridin; 4-Hydroxy-cyclophosphan-mamophosphatide DM4O2Z7 CP Baxter International Inc DM4O2Z7 TC Anticancer Agents DM4O2Z7 DT Small molecular drug DM4O2Z7 PC 2907 DM4O2Z7 MW 261.079 DM4O2Z7 FM C7H15Cl2N2O2P DM4O2Z7 IC InChI=1S/C7H15Cl2N2O2P/c8-2-5-11(6-3-9)14(12)10-4-1-7-13-14/h1-7H2,(H,10,12) DM4O2Z7 CS C1CNP(=O)(OC1)N(CCCl)CCCl DM4O2Z7 IK CMSMOCZEIVJLDB-UHFFFAOYSA-N DM4O2Z7 IU N,N-bis(2-chloroethyl)-2-oxo-1,3,2lambda5-oxazaphosphinan-2-amine DM4O2Z7 CA CAS 50-18-0 DM4O2Z7 CB CHEBI:4027 DM4O2Z7 DE Solid tumour/cancer DMT1I52 ID DMT1I52 DMT1I52 DN Cycloserine DMT1I52 HS Approved DMT1I52 SN D-cycloserine; cycloserine; 68-41-7; Seromycin; orientomycin; Oxamycin; Cyclorin; Cyclo-D-serine; Wasserina; Farmiserina; Tisomycin; Cicloserina; Miroseryn; Closina; D-4-amino-3-isoxazolidinone; (R)-4-AMINOISOXAZOLIDIN-3-ONE; alpha-Cycloserine; (+)-4-Amino-3-isoxazolidinone; Miroserina; Cycloserinum; D-4-amino-3-isoxazolidone; Oxamicina; (4R)-4-aminoisoxazolidin-3-one; PA 94; (+)-Cycloserine; (4R)-4-amino-1,2-oxazolidin-3-one; Oxamicina [Italian]; Cycloserin; Micoserina; Cicloserina [Italian]; PA-94; Tebemicina; Novoserin; D-Oxamycin; Cicloserina; Closerin; Orientomycin; C 3909; Alpha-Cycloserine; C-9390; C-9400; Cicloserina [INN-Spanish]; Cycloserinum [INN-Latin]; D-CS; DRG-0195; I-1431; K-300; SC-49088; Seromycin (TN); Cycloserine [INN:BAN:JAN]; E-733-A; RO-1-9213; Cycloserine (JP15/USP/INN); D-amino-3-isoxazolidinone; D-(+)-Cycloserine; D-4-Amino-3-isossazolidone; D-4-Amino-3-isossazolidone [Italian]; FA6C7F8B-D080-4EA3-978F-1ECFB5A29D09; R-(+)-Cycloserine; R-4-Amino-3-isoxazolidinone; R(+)-4-Amino-3-isoxazolidinone; (4R)-4-Amino-3-isoxazolidinone; (R)-(+)-4-Amino-3-isoxazolidinone; (R)-(+)-Cycloserine; (R)-4-AMINO-ISOXAZOLIDIN-3-ONE; (R)-4-Amino-3-isoxazolidinone; (R)-4-Amino-3-isoxazolidone; (R)-Cycloserine; 3-Isoxazolidinone, 4-amino-, (+)-(8CI); 3-Isoxazolidinone, 4-amino-, (4R)-(9CI); 3-Isoxazolidinone, 4-amino-, (R); 3-Isoxazolidinone, 4-amino-, D; (R)-4-Amino-Isoxazolidin-3-One DMT1I52 TC Antiinfective Agents DMT1I52 DT Small molecular drug DMT1I52 PC 6234 DMT1I52 MW 102.09 DMT1I52 FM C3H6N2O2 DMT1I52 IC InChI=1S/C3H6N2O2/c4-2-1-7-5-3(2)6/h2H,1,4H2,(H,5,6)/t2-/m1/s1 DMT1I52 CS C1[C@H](C(=O)NO1)N DMT1I52 IK DYDCUQKUCUHJBH-UWTATZPHSA-N DMT1I52 IU (4R)-4-amino-1,2-oxazolidin-3-one DMT1I52 CA CAS 68-41-7 DMT1I52 CB CHEBI:40009 DMT1I52 DE Tuberculosis; Bacterial infection; Obsessive compulsive disorder DMJ4AWC ID DMJ4AWC DMJ4AWC DN Cyclothiazide DMJ4AWC HS Approved DMJ4AWC SN Anhydron; Aquirel; Ciclotiazida; Ciclotiazide; Cyclothiazidum; Doburil; Fluidil; Renazide; Valmiran; Ciclotiazide [DCIT]; C 9847; MDi 193; Anhydron (TN); Ciclotiazida [INN-Spanish]; Cyclothiazidum [INN-Latin]; Lilly 35,483; Cyclothiazide [USAN:INN:BAN]; Cyclothiazide (JAN/USAN/INN); 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 3,4-dihydro-6-chloro-3-(5-norbornen-2-yl)-, 1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 3,4-dihydro-6-chloro-3-(5-norbornen-2-yl)-,1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 3-bicyclo(2.2.1)hept-5-en-2-yl-6-chloro-3,4-dihydro-, 1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 3-bicyclo[2.2.1]hept-5-en-2-yl-6-chloro-3,4-dihydro-, 1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3,4-dihydro-3-(5-norbornen-2-yl)-, 1,1-dioxide; 3-(bicyclo[2.2.1]hept-5-en-2-yl)-6-chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 3-Bicyclo(2.2.1)hept-5-en-2-yl-6-chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 3-Bicyclo[2.2.1]hept-5-en-2-yl-6-chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 6-Chloro-3,4-dihydro-3-(2-norbornen-5-yl)-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 6-Chloro-3,4-dihydro-3-(2-norbornen-5-yl)-2H-1,2-4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 6-Chloro-3,4-dihydro-3-(2-norbornen-5-yl)-7-sulfamoyl-1,2,4-benzothiadiazine 1,1-dioxide; 6-Chloro-3,4-dihydro-3-(5-norbornen-2-yl)-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 6-Chloro-3,4-dihydro-3-(norbornen-2-yl)-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 6-Chloro-3-(2-norbornen-5-yl)-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine 1,1-dioxide; 6-chloro-3,4-dihydro-3-(norbornen-2-yl)-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide DMJ4AWC TC Antihypertensive Agents DMJ4AWC DT Small molecular drug DMJ4AWC PC 2910 DMJ4AWC MW 389.9 DMJ4AWC FM C14H16ClN3O4S2 DMJ4AWC IC InChI=1S/C14H16ClN3O4S2/c15-10-5-11-13(6-12(10)23(16,19)20)24(21,22)18-14(17-11)9-4-7-1-2-8(9)3-7/h1-2,5-9,14,17-18H,3-4H2,(H2,16,19,20) DMJ4AWC CS C1C2CC(C1C=C2)C3NC4=CC(=C(C=C4S(=O)(=O)N3)S(=O)(=O)N)Cl DMJ4AWC IK BOCUKUHCLICSIY-UHFFFAOYSA-N DMJ4AWC IU 3-(2-bicyclo[2.2.1]hept-5-enyl)-6-chloro-1,1-dioxo-3,4-dihydro-2H-1lambda6,2,4-benzothiadiazine-7-sulfonamide DMJ4AWC CA CAS 2259-96-3 DMJ4AWC CB CHEBI:31448 DMJ4AWC DE Congestive heart failure DM8C43Q ID DM8C43Q DM8C43Q DN Cycrimine DM8C43Q HS Approved DM8C43Q SN Cicrimina; Cycriminum; Pagitane; Cicrimina [INN-Spanish]; Cycriminum [INN-Latin]; Alpha-Cyclopentyl-alpha-phenyl-1-Piperidinepropanol; (+-)-cycrimine; 1-Phenyl-1-cyclopentyl-3-piperidino-1-propanol; 1-cyclopentyl-1-phenyl-3-(piperidin-1-yl)propan-1-ol; 1-cyclopentyl-1-phenyl-3-piperidin-1-ylpropan-1-ol DM8C43Q TC Antiparkinson Agents DM8C43Q DT Small molecular drug DM8C43Q PC 2911 DM8C43Q MW 287.4 DM8C43Q FM C19H29NO DM8C43Q IC InChI=1S/C19H29NO/c21-19(18-11-5-6-12-18,17-9-3-1-4-10-17)13-16-20-14-7-2-8-15-20/h1,3-4,9-10,18,21H,2,5-8,11-16H2 DM8C43Q CS C1CCN(CC1)CCC(C2CCCC2)(C3=CC=CC=C3)O DM8C43Q IK SWRUZBWLEWHWRI-UHFFFAOYSA-N DM8C43Q IU 1-cyclopentyl-1-phenyl-3-piperidin-1-ylpropan-1-ol DM8C43Q CA CAS 77-39-4 DM8C43Q CB CHEBI:59692 DM8C43Q DE Parkinson disease DMUY2OR ID DMUY2OR DMUY2OR DN Cynarin DMUY2OR HS Approved DMUY2OR SN 1,3-O-Dicaffeoylquinic acid; 19870-46-3; 1,3-Dicaffeoylquinic acid; Cynarin; 1,5-Dicaffeoylquinic acid; Cynarine; 1,5-di-O-Caffeoylquinic acid; 1,3-di-O-Caffeoylquinic acid; 30964-13-7; (1S,3R,4R,5R)-1,3-Bis[3-(3,4-dihydroxyphenyl)acryloyloxy]-4,5-dihydroxycyclohexanecarboxylic acid; (1S,3R,4R,5R)-1,3-bis[[(E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy]-4,5-dihydroxy-cyclohexanecarboxylic acid; AC1O6FEM; 1,5-Dicaffeoylquinic-acid; 1,3-Dicaffeoyl quinic acid; 1,5-Dicaffeoylquinic acid ; CHEMBL478574; 1,5-DCQA DMUY2OR DT Small molecular drug DMUY2OR PC 5281769 DMUY2OR MW 516.4 DMUY2OR FM C25H24O12 DMUY2OR IC InChI=1S/C25H24O12/c26-15-5-1-13(9-17(15)28)3-7-21(31)36-20-12-25(24(34)35,11-19(30)23(20)33)37-22(32)8-4-14-2-6-16(27)18(29)10-14/h1-10,19-20,23,26-30,33H,11-12H2,(H,34,35)/b7-3+,8-4+/t19-,20-,23+,25-/m1/s1 DMUY2OR CS C1[C@H]([C@@H]([C@@H](C[C@]1(C(=O)O)OC(=O)/C=C/C2=CC(=C(C=C2)O)O)OC(=O)/C=C/C3=CC(=C(C=C3)O)O)O)O DMUY2OR IK YDDUMTOHNYZQPO-RVXRWRFUSA-N DMUY2OR IU (1R,3R,4S,5R)-1,3-bis[[(E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy]-4,5-dihydroxycyclohexane-1-carboxylic acid DMUY2OR CA CAS 212891-05-9 DMUY2OR CB CHEBI:520 DMUY2OR DE Vibrio cholerae infection DM92AH3 ID DM92AH3 DM92AH3 DN Cyproheptadine DM92AH3 HS Approved DM92AH3 SN Ciproheptadina; Ciprovit; Cypoheptadine; Cyproheptadiene; Cyproheptadinum; Dihexazin; Dronactin; Eiproheptadine; Periactin; Periactine; Periactinol; Viternum; Cyproheptadine Hcl; MK 141; Ciproheptadina [INN-Spanish]; Ciprovit (TN); Cyproheptadine (INN); Cyproheptadine [INN:BAN]; Cyproheptadinum [INN-Latin]; Dibenzosuberonone/Cyproheptadine; Periactin (TN); 1-Methyl-4-(5-dibenzo(a,e)cycloheptatrienylidene)piperidine; 1-Methyl-4-(5H-dibenzo(a,d)cycloheptenylidene)piperidine; 4-(5-Dibenzo(a,d)cyclohepten-5-ylidine)-1-methylpiperidine; 4-(5H-Dibenzo(a,d)cyclohepten-5-ylidene)-1-methylpiperidene; 4-(5H-Dibenzo(a,d)cyclohepten-5-ylidene)-1-methylpiperidine; 4-(5H-Dibenzo[a,d]cyclohepten-5-ylidene)-1-methylpiperidine; 4-(5H-dibenzo[a,d][7]annulen-5-ylidene)-1-methylpiperidine; 5-(1-Methylpiperidylidene-4)-5H-dibenzo(a,d)cyclopheptene DM92AH3 CP Merck & Co DM92AH3 TC Antihistamines DM92AH3 DT Small molecular drug DM92AH3 PC 2913 DM92AH3 MW 287.4 DM92AH3 FM C21H21N DM92AH3 IC InChI=1S/C21H21N/c1-22-14-12-18(13-15-22)21-19-8-4-2-6-16(19)10-11-17-7-3-5-9-20(17)21/h2-11H,12-15H2,1H3 DM92AH3 CS CN1CCC(=C2C3=CC=CC=C3C=CC4=CC=CC=C42)CC1 DM92AH3 IK JJCFRYNCJDLXIK-UHFFFAOYSA-N DM92AH3 IU 1-methyl-4-(2-tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,9,11,13-heptaenylidene)piperidine DM92AH3 CA CAS 129-03-3 DM92AH3 CB CHEBI:4046 DM92AH3 DE Rhinitis DMQXLD2 ID DMQXLD2 DMQXLD2 DN Cyproterone DMQXLD2 HS Approved DMQXLD2 SN Ciproterona; Ciproterone; CyPat; Cyproteron; Cyproteronum; Ciproterona Servycal; Ciproterone [DCIT]; SH 80881; Apo-cyproterone; Ciproterona Servycal (TN); Ciproterona [INN-Spanish]; Cyproterone (INN); Cyproterone [INN:BAN]; Cyproteronum [INN-Latin]; Dianette (TN); Gen-Cyproterone; Novo-cyproterone; Diane-35 (TN); (1R,3aS,3bR,7aR,8aS,8bS,8cS,10aS)-1-acetyl-5-chloro-1-hydroxy-8b,10a-dimethyl-2,3,3a,3b,7a,8,8a,8b,8c,9,10,10a-dodecahydrocyclopenta[a]cyclopropa[g]phenanthren-7(1H)-one; 6-Chlor-delta(6)-1,2-alpha-methylen-17-alpha-hydroxyprogesteron; 6-Chlor-delta(sup 6)-1,2-alpha-methylen-17-alpha-hydroxyprogesteron; 6-Chlor-delta(sup 6)-1,2-alpha-methylen-17-alpha-hydroxyprogesteron [German]; 6-chloro-17-hydroxy-1beta,2beta-dihydro-3'H-cyclopropa[1,2]pregna-4,6-diene-3,20-dione DMQXLD2 CP Schering-Plough DMQXLD2 TC Anticancer Agents DMQXLD2 DT Small molecular drug DMQXLD2 PC 5284537 DMQXLD2 MW 374.9 DMQXLD2 FM C22H27ClO3 DMQXLD2 IC InChI=1S/C22H27ClO3/c1-11(24)22(26)7-5-14-12-9-18(23)17-10-19(25)13-8-16(13)21(17,3)15(12)4-6-20(14,22)2/h9-10,12-16,26H,4-8H2,1-3H3/t12-,13+,14-,15-,16-,20-,21-,22-/m0/s1 DMQXLD2 CS CC(=O)[C@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2C=C(C4=CC(=O)[C@@H]5C[C@@H]5[C@]34C)Cl)C)O DMQXLD2 IK DUSHUSLJJMDGTE-ZJPMUUANSA-N DMQXLD2 IU (1S,2S,3S,5R,11R,12S,15R,16S)-15-acetyl-9-chloro-15-hydroxy-2,16-dimethylpentacyclo[9.7.0.02,8.03,5.012,16]octadeca-7,9-dien-6-one DMQXLD2 CA CAS 2098-66-0 DMQXLD2 CB CHEBI:50742 DMQXLD2 DE Prostate cancer DMSYFM8 ID DMSYFM8 DMSYFM8 DN Cysteamine DMSYFM8 HS Approved DMSYFM8 SN Becaptan; Cisteamina; Cystavision; Cysteamide; Cysteamin; Cysteinamine; Decarboxycysteine; Ethanethiolamine; Lambraten; Lambratene; MEA; Mecramine; Mercamin; Mercamine; Mercaptamin; Mercaptamina; Mercaptamine; Mercaptaminum; Mercaptoethylamine; Merkamin; Riacon; Thioethanolamine; Aminoethyl mercaptan; Cisteamina [Italian]; Cysteamine bitartate; L 1573; WR 347; Beta-Aminoethanethiol; Beta-Aminoethylthiol; Beta-MEA; Beta-Mercaptoethylamine; C-9500; Cysteamine (USAN); Cysteamine [USAN:BAN]; L-1573; MEA (mercaptan); Mercaptamina [INN-Spanish]; Mercaptamine (INN); Mercaptaminum [INN-Latin]; (2-Mercaptoethyl)amine; (Mercaptoethyl)ammonium toluene-p-sulphonate; 1-Amino-2-mercaptoethylamine; 2-AMINO-ETHANETHIOL; 2-Amino-1-ethanethiol; 2-Aminoethanethiol; 2-Aminoethyl mercaptan; 2-Mercaptoethanamine; 2-Mercaptoethylamine; 2-Mercaptoethylamine, polymer-bound; 641022_ALDRICH DMSYFM8 CP Mylan Pharmaceuticals Inc DMSYFM8 TC Nephropathic cystinosis therapy DMSYFM8 DT Small molecular drug DMSYFM8 PC 6058 DMSYFM8 MW 77.15 DMSYFM8 FM C2H7NS DMSYFM8 IC InChI=1S/C2H7NS/c3-1-2-4/h4H,1-3H2 DMSYFM8 CS C(CS)N DMSYFM8 IK UFULAYFCSOUIOV-UHFFFAOYSA-N DMSYFM8 IU 2-aminoethanethiol DMSYFM8 CA CAS 60-23-1 DMSYFM8 CB CHEBI:17141 DMSYFM8 DE Nephropathic cystinosis DMZD5QR ID DMZD5QR DMZD5QR DN Cytarabine DMZD5QR HS Approved DMZD5QR SN Alexan; AraC; Arabinocytidine; Arabinofuranosylcytosine; Arabinosylcytosine; Arabitin; Aracytidine; Aracytin; Aracytine; Arafcyt; Citarabina; Cytarabin; Cytarabina; Cytarabinoside; Cytarabinum; Cytarbel; Cytonal; Cytosar; Cytosinearabinoside; DepoCyte; Depocyt; Erpalfa; Iretin; Spongocytidine; Tarabine; Udicil; Arabinosyl Cytosine; Cytarabine liposome injection; Cytosine arabinofuranoside; Cytosine arabinose; Cytosine arabinoside; AR3; BTB15125; CHX 3311; U 19920A; Ara-C; Ara-Cytidine; Beta-Ara C; Beta-Arabinosylcytosine; Beta-cytosine arabinoside; Citarabina [INN-Spanish]; Cytarabinum [INN-Latin]; Cytosar-U; Cytosine arabinoside (VAN); Depocyt (TN); Depocyt (liposomal); Intrathecal (injected into the spinal fluid) DepoCyt; U-19920; Beta-D-Arabinosylcytosine; Cytosar-U (TN); Cytosine beta-D-arabinofuranoside; Cytosine beta-D-arabinofuranoside hydrochloride; Cytosine beta-D-arabinoside; Cytosine-beta-arabinoside; Intrathecal cytarabine (also known as ara-C); U-19,920; CYTARABINE (SEE ALSO CYTARABINE HYDROCHLORIDE 69-74-9); Cytarabine (JP15/USP/INN); Cytarabine [USAN:INN:BAN:JAN]; Cytosine 1-beta-D-arabinofuranoside; Cytosine, beta-D-arabinoside; Cytosine-beta-D-arabinofuranoside; Cytosine-1-beta-D-arabinofuranoside; Ara-C, Cytosine Arabinoside, Cytosar-U, Cytarabine; (beta-D-Arabinofuranosyl)cytosine; 1-.beta.-D-arabinofuranosyl-cytosine; 1-Arabinofuranosylcytosine; 1-beta-D-Arabinofaranosylcytosine; 1-beta-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone; 1-beta-D-Arabinofuranosylcytosine; 1-beta-D-Arabinofuranosylcytosine, Cytosine Arabinoside; 1-beta-D-Arabinosylcytosine; 1beta-Arabinofuranasylcytosine; 1beta-D-Arabinofuranosylcytosine; 1beta-D-Arabinosylcytosine; 2(1H)-Pyrimidinone, 4-amino-1-D-arabinofuranosyl-[CAS]; 4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin; 4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin [Czech]; 4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidine; 4-Amino-1-b-D-arabinofuranosyl-2-(1H)-pyrimidinone; 4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinon; 4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinon [Czech]; 4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone; 4-amino-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one; 4-amino-1-beta-D-arabinofuranosylpyrimidin-2(1H)-one DMZD5QR CP Upjohn Corporation DMZD5QR TC Anticancer Agents DMZD5QR DT Small molecular drug DMZD5QR PC 6253 DMZD5QR MW 243.22 DMZD5QR FM C9H13N3O5 DMZD5QR IC InChI=1S/C9H13N3O5/c10-5-1-2-12(9(16)11-5)8-7(15)6(14)4(3-13)17-8/h1-2,4,6-8,13-15H,3H2,(H2,10,11,16)/t4-,6-,7+,8-/m1/s1 DMZD5QR CS C1=CN(C(=O)N=C1N)[C@H]2[C@H]([C@@H]([C@H](O2)CO)O)O DMZD5QR IK UHDGCWIWMRVCDJ-CCXZUQQUSA-N DMZD5QR IU 4-amino-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one DMZD5QR CA CAS 147-94-4 DMZD5QR CB CHEBI:28680 DMZD5QR DE Acute lymphoblastic leukaemia DMDI6R4 ID DMDI6R4 DMDI6R4 DN Dabigatran DMDI6R4 HS Approved DMDI6R4 SN Pradaxa (TN) DMDI6R4 CP Boehringer Ingelheim DMDI6R4 DT Small molecular drug DMDI6R4 PC 216210 DMDI6R4 MW 471.5 DMDI6R4 FM C25H25N7O3 DMDI6R4 IC InChI=1S/C25H25N7O3/c1-31-20-10-7-17(25(35)32(13-11-23(33)34)21-4-2-3-12-28-21)14-19(20)30-22(31)15-29-18-8-5-16(6-9-18)24(26)27/h2-10,12,14,29H,11,13,15H2,1H3,(H3,26,27)(H,33,34) DMDI6R4 CS CN1C2=C(C=C(C=C2)C(=O)N(CCC(=O)O)C3=CC=CC=N3)N=C1CNC4=CC=C(C=C4)C(=N)N DMDI6R4 IK YBSJFWOBGCMAKL-UHFFFAOYSA-N DMDI6R4 IU 3-[[2-[(4-carbamimidoylanilino)methyl]-1-methylbenzimidazole-5-carbonyl]-pyridin-2-ylamino]propanoic acid DMDI6R4 CA CAS 211914-51-1 DMDI6R4 CB CHEBI:70752 DMDI6R4 DE Stroke DMX6OE3 ID DMX6OE3 DMX6OE3 DN Dabrafenib DMX6OE3 HS Approved DMX6OE3 SN 1195765-45-7; Dabrafenib (GSK2118436); Tafinlar; GSK2118436A; UNII-QGP4HA4G1B; GSK 2118436; QGP4HA4G1B; N-(3-(5-(2-aminopyrimidin-4-yl)-2-tert-butylthiazol-4-yl)-2-fluorophenyl)-2,6-difluorobenzenesulfonamide; CHEBI:75045; N-[3-[5-(2-Amino-4-pyrimidinyl)-2-(tert-butyl)-4-thiazolyl]-2-fluorophenyl]-2,6-difluorobenzenesulfonamide; N-{3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide; GSK-2118436A; Dabrafenib [USAN:INN]; GSK2118436 DMX6OE3 DT Small molecular drug DMX6OE3 PC 44462760 DMX6OE3 MW 519.6 DMX6OE3 FM C23H20F3N5O2S2 DMX6OE3 IC InChI=1S/C23H20F3N5O2S2/c1-23(2,3)21-30-18(19(34-21)16-10-11-28-22(27)29-16)12-6-4-9-15(17(12)26)31-35(32,33)20-13(24)7-5-8-14(20)25/h4-11,31H,1-3H3,(H2,27,28,29) DMX6OE3 CS CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F DMX6OE3 IK BFSMGDJOXZAERB-UHFFFAOYSA-N DMX6OE3 IU N-[3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1,3-thiazol-4-yl]-2-fluorophenyl]-2,6-difluorobenzenesulfonamide DMX6OE3 CA CAS 1195765-45-7 DMX6OE3 CB CHEBI:75045 DMX6OE3 DE Melanoma DMNPZL4 ID DMNPZL4 DMNPZL4 DN Dacarbazine DMNPZL4 HS Approved DMNPZL4 SN Biocarbazin; Biocarbazine; DTIC; DTICDome; DTIE; Dacarbazino; Dacarbazinum; Dacatic; Decarbazine; Deticene; Dimethyltriazenoimidazolecarboxamide; ICDMT; ICDT; Biocarbazine R; DTIC Dome; Dimethyl Imidazole Carboxamide; Dimethyl Triazeno Imidazole Carboxamide; Imidazole carboxamide; HE1150000; Carboxamide (TN); Carboxamide, Dimethyl Imidazole; DIC (TN); DTIC (TN); DTIC-Dome; Dacarbazino [INN-Spanish]; Dacarbazinum [INN-Latin]; Imidazole (TN); Imidazole Carboxamide, Dimethyl; NPFAPI-05; DTIC-Dome (TN); Di-me-triazenoimidazolecarboxamide; Di-methyl-triazenoimidazolecarboxamide; Dtic-Dome (TN); DTIC, DTIC-Dome, Dacarbazine; Dacarbazine (JAN/USP/INN); Dacarbazine [USAN:INN:BAN:JAN]; (5E)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide; (5Z)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide; (Dimethyltriazeno)imidazolecarboxamide; 4(5)-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide; 4(5)-(3,3-Dimethyl-1-triazeno)imidazole-5(4)-carboxamide; 4-(3,3-Dimethyl-1-triazeno)imidazole-5-carboxamide; 4-(3,3-Dimethyltriazeno)imidazole-5-carboxamide; 4-(5)-(3,3-Dimethyl-1-triazeno)imidazole-5(4)-carboxamide; 4-(Dimethyltriazeno)imidazole-5-c arboxamide; 4-(Dimethyltriazeno)imidazole-5-carboxamide; 4-(or 5)-(3,3-Dimethyl-1-triazeno)imidazole-5(or 4)-carboxamide; 4-[(1E)-3,3-Dimethyltriaz-1-en-1-yl]-1H-imidazole-5-carboxamide; 4-[3,3-dimethyltriaz-1-en-1-yl]-1H-imidazole-5-carboxamide; 5(or 4)-(dimethyltriazeno)imidazol e-4(or 5)-carboxamide; 5(or 4)-(dimethyltriazeno)imidazole-4(or 5)-carboxamide; 5-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide; 5-(3,3-Dimethyl-1-triazenyl)-1H-imidazole-4-carboxamide; 5-(3,3-Dimethyl-1-triazenyl)imidazole-4-carboxamide; 5-(3,3-Dimethyltri azeno)imidazole-4-carboxamide; 5-(3,3-Dimethyltriazeno)-imidazole-4-carbamide; 5-(3,3-Dimethyltriazeno)imidazole-4-carboxamide; 5-(3,3-dimethyltriaz-1-en-1-yl)-1H-imidazole-4-carboxamide; 5-(Dimethyltriazeno)-4-imidazolecarboxamide; 5-(Dimethyltriazeno)imidazole-4-carboxamide; 5-(Dimethyltriazeno)imidazole-4-carboximide; 5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide; 5-[3,3-Dimethyl-1-triazenyl]imidazole-4-carboxamide DMNPZL4 CP Bayer Pharmaceuticals Corporation DMNPZL4 TC Anticancer Agents DMNPZL4 DT Small molecular drug DMNPZL4 PC 135398738 DMNPZL4 MW 182.18 DMNPZL4 FM C6H10N6O DMNPZL4 IC InChI=1S/C6H10N6O/c1-12(2)11-10-6-4(5(7)13)8-3-9-6/h3H,1-2H3,(H2,7,13)(H,8,9)/b11-10+ DMNPZL4 CS CN(C)/N=N/C1=C(NC=N1)C(=O)N DMNPZL4 IK FDKXTQMXEQVLRF-ZHACJKMWSA-N DMNPZL4 IU 4-[(E)-dimethylaminodiazenyl]-1H-imidazole-5-carboxamide DMNPZL4 CA CAS 4342-03-4 DMNPZL4 CB CHEBI:94587 DMNPZL4 DE Melanoma DMSFK9V ID DMSFK9V DMSFK9V DN Daclatasvir DMSFK9V HS Approved DMSFK9V SN 1009119-64-5; Daclatasvir (BMS-790052); 1214735-16-6; CHEBI:82977; C40H50N8O6; methyl N-[(1S)-1-[(2S)-2-[5-[4-[4-[2-[(2S)-1-[(2S)-2-(methoxycarbonylamino)-3-methyl-butanoyl]pyrrolidin-2-yl]-1H-imidazol-5-yl]phenyl]phenyl]-1H-imidazol-2-yl]pyrrolidine-1-carbonyl]-2-methyl-propyl]carbamate; Daclatasvir (USAN); cc-39; Daclatasvir BMS 790052; MLS006011140; SCHEMBL2756027; CHEMBL2023898; SCHEMBL17897804; KS-00000XPC; EX-A410 DMSFK9V CP Bristol-Myers Squibb DMSFK9V DT Small molecular drug DMSFK9V PC 25154714 DMSFK9V MW 738.9 DMSFK9V FM C40H50N8O6 DMSFK9V IC InChI=1S/C40H50N8O6/c1-23(2)33(45-39(51)53-5)37(49)47-19-7-9-31(47)35-41-21-29(43-35)27-15-11-25(12-16-27)26-13-17-28(18-14-26)30-22-42-36(44-30)32-10-8-20-48(32)38(50)34(24(3)4)46-40(52)54-6/h11-18,21-24,31-34H,7-10,19-20H2,1-6H3,(H,41,43)(H,42,44)(H,45,51)(H,46,52)/t31-,32-,33-,34-/m0/s1 DMSFK9V CS CC(C)[C@@H](C(=O)N1CCC[C@H]1C2=NC=C(N2)C3=CC=C(C=C3)C4=CC=C(C=C4)C5=CN=C(N5)[C@@H]6CCCN6C(=O)[C@H](C(C)C)NC(=O)OC)NC(=O)OC DMSFK9V IK FKRSSPOQAMALKA-CUPIEXAXSA-N DMSFK9V IU methyl N-[(2S)-1-[(2S)-2-[5-[4-[4-[2-[(2S)-1-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]pyrrolidin-2-yl]-1H-imidazol-5-yl]phenyl]phenyl]-1H-imidazol-2-yl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate DMSFK9V CA CAS 1009119-64-5 DMSFK9V CB CHEBI:82977 DMSFK9V DE Hepatitis C virus infection DM6OZQV ID DM6OZQV DM6OZQV DN Daclizumab DM6OZQV HS Approved DM6OZQV SN DAC HYP; Daclizumab HYP; Daclizumab High Yield Process; Daclizumab (subcutaneous, multiple sclerosis); Daclizumab (subcutaneous, multiple sclerosis), Abbott/Biogen Idec DM6OZQV CP Biogen DM6OZQV DT Monoclonal antibody DM6OZQV SQ Humanized Anti-CD25 Heavy Chain 1: QVQLVQSGAEVKKPGSSVKVSCKASGYTFTSYRMHWVRQAPGQGLEWIGYINPSTGYTEYNQKFKDKATITADESTNTAYMELSSLRSEDTAVYYCARGGGVFDYWGQGTTLTVSSGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKAEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK >Humanized Anti-CD25 Light Chain 1DIQMTQSPSTLSASVGDRVTITCSASSSISYMHWYQQKPGKAPKLLIYTTSNLASGVPARFSGSGSGTEFTLTISSLQPDDFATYYCHQRSTYPLTFGSGTKVEVKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR DM6OZQV DE Multiple sclerosis DMOH8VY ID DMOH8VY DMOH8VY DN Dacomitinib DMOH8VY HS Approved DMOH8VY SN PF-00299804 DMOH8VY CP Pfizer DMOH8VY DT Small molecular drug DMOH8VY PC 11511120 DMOH8VY MW 469.9 DMOH8VY FM C24H25ClFN5O2 DMOH8VY IC InChI=1S/C24H25ClFN5O2/c1-33-22-14-20-17(24(28-15-27-20)29-16-7-8-19(26)18(25)12-16)13-21(22)30-23(32)6-5-11-31-9-3-2-4-10-31/h5-8,12-15H,2-4,9-11H2,1H3,(H,30,32)(H,27,28,29)/b6-5+ DMOH8VY CS COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)NC(=O)/C=C/CN4CCCCC4 DMOH8VY IK LVXJQMNHJWSHET-AATRIKPKSA-N DMOH8VY IU (E)-N-[4-(3-chloro-4-fluoroanilino)-7-methoxyquinazolin-6-yl]-4-piperidin-1-ylbut-2-enamide DMOH8VY CA CAS 1110813-31-4 DMOH8VY CB CHEBI:91466 DMOH8VY DE Non-small-cell lung cancer DM2YGNW ID DM2YGNW DM2YGNW DN Dactinomycin DM2YGNW HS Approved DM2YGNW SN Cosmegen; Dactinomicina; Dactinomycine; Dactinomycinum; Meractinomycin; ACT D; ACTINOMYCIN D AMP; Actactinomycin A IV; Actinomycin A IV; Actinomycin Aiv; Actinomycin I; Actinomycin IV; Actinomycin cl; Actinomycin x i; Antibiotic from Streptomyces parvullus; Chounghwamycin B; D Actinomycin; Dactinomycin D; Dactinomyein d; Dilactone actin omycindioic D acid; Dilactone actinomycin D acid; Dilactone actinomycindioic D acid; Lyovac cosmegen; Oncostatin K; Actinomycin 11 cosmegen; Actinomycin 7; Actinomycin C1; Actinomycin I1; Actinomycin X 1; Actinomycin X1; HBF 386; HBF 386 meractinomycin; X 97; AD (VAN); Actinomycin C (sub1); Actinomycin C(sub1); Actinomycin D (JP15); Actinomycin D, sodium deoxyribonucleic acid complex; Actinomycin I (sub1); Actinomycin I(sub 1); Actinomycin I(sub1); Actinomycin-IV; Actinomycindioic D acid, dilactone; Acto-D; COSMEGEN (TN); Dactinomicina [INN-Spanish]; Dactinomycin (USP); Dactinomycin [USAN:BAN]; Dactinomycine [INN-French]; Dactinomycinum [INN-Latin]; NP-005932; Actinomycin D deriv. of 3H-phenoxaocardazine; GNF-PF-1977; Actinomycin-[threo-val-pro-sar-meval]; Actinomyein-theo-val-pro-sar-meval; Actinomycin-(threo-val-pro-sar-meval); O)-(1-oxo-1,2-ethanediyl)]bis(N-methyl)L-valine; PXZ-THR-DVA-PRO-SAR-MVA-THR-DVA-PRO-SAR-MVA; DVA-DPR-SAR-MVA-(c1)DTH-PXZ-(c11)DTH-DVA-DPR-SAR-MVA; 1H-Pyrrolo(2,1-1)-(1,4,7,10,13)oxatetraazacyclohexadecine; 4,6-dimethyl-3-oxo-3H-phenoxazine-1,9-dicarboxamide DM2YGNW TC Anticancer Agents DM2YGNW DT Small molecular drug DM2YGNW PC 457193 DM2YGNW MW 1255.4 DM2YGNW FM C62H86N12O16 DM2YGNW IC InChI=1S/C62H86N12O16/c1-27(2)42-59(84)73-23-17-19-36(73)57(82)69(13)25-38(75)71(15)48(29(5)6)61(86)88-33(11)44(55(80)65-42)67-53(78)35-22-21-31(9)51-46(35)64-47-40(41(63)50(77)32(10)52(47)90-51)54(79)68-45-34(12)89-62(87)49(30(7)8)72(16)39(76)26-70(14)58(83)37-20-18-24-74(37)60(85)43(28(3)4)66-56(45)81/h21-22,27-30,33-34,36-37,42-45,48-49H,17-20,23-26,63H2,1-16H3,(H,65,80)(H,66,81)(H,67,78)(H,68,79)/t33-,34-,36+,37+,42-,43-,44+,45+,48+,49+/m1/s1 DM2YGNW CS C[C@@H]1[C@@H](C(=O)N[C@@H](C(=O)N2CCC[C@H]2C(=O)N(CC(=O)N([C@H](C(=O)O1)C(C)C)C)C)C(C)C)NC(=O)C3=C4C(=C(C=C3)C)OC5=C(C(=O)C(=C(C5=N4)C(=O)N[C@H]6[C@H](OC(=O)[C@@H](N(C(=O)CN(C(=O)[C@@H]7CCCN7C(=O)[C@H](NC6=O)C(C)C)C)C)C(C)C)C)N)C DM2YGNW IK RJURFGZVJUQBHK-IIXSONLDSA-N DM2YGNW IU 2-amino-4,6-dimethyl-3-oxo-1-N,9-N-bis[(3R,6S,7R,10S,16S)-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-3,10-di(propan-2-yl)-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]phenoxazine-1,9-dicarboxamide DM2YGNW CA CAS 50-76-0 DM2YGNW CB CHEBI:27666 DM2YGNW DE Solid tumour/cancer DMGMNH3 ID DMGMNH3 DMGMNH3 DN Dalbavancin DMGMNH3 HS Approved DMGMNH3 SN Zeven; Zeven (TN); Dalbavancin (USAN/INN); Dalvance; Xydalba DMGMNH3 CP Pfizer DMGMNH3 DT Small molecular drug DMGMNH3 PC 16134627 DMGMNH3 MW 1816.7 DMGMNH3 FM C88H100Cl2N10O28 DMGMNH3 IC InChI=1S/C88H100Cl2N10O28/c1-38(2)13-10-8-6-7-9-11-14-61(106)94-70-73(109)75(111)78(86(120)121)128-87(70)127-77-58-31-43-32-59(77)124-55-24-19-42(29-50(55)89)71(107)69-85(119)98-67(80(114)92-25-12-26-100(4)5)48-33-44(102)34-57(125-88-76(112)74(110)72(108)60(37-101)126-88)62(48)47-28-40(17-22-52(47)103)65(82(116)99-69)95-83(117)66(43)96-84(118)68-49-35-46(36-54(105)63(49)90)123-56-30-41(18-23-53(56)104)64(91-3)81(115)93-51(79(113)97-68)27-39-15-20-45(122-58)21-16-39/h15-24,28-36,38,51,60,64-76,78,87-88,91,101-105,107-112H,6-14,25-27,37H2,1-5H3,(H,92,114)(H,93,115)(H,94,106)(H,95,117)(H,96,118)(H,97,113)(H,98,119)(H,99,116)(H,120,121)/t51-,60-,64-,65-,66-,67+,68+,69+,70-,71-,72-,73-,74+,75+,76+,78+,87-,88+/m1/s1 DMGMNH3 CS CC(C)CCCCCCCCC(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@H]1OC2=C3C=C4C=C2OC5=C(C=C(C=C5)[C@H]([C@H]6C(=O)N[C@@H](C7=C(C(=CC(=C7)O)O[C@@H]8[C@H]([C@H]([C@@H]([C@H](O8)CO)O)O)O)C9=C(C=CC(=C9)[C@H](C(=O)N6)NC(=O)[C@@H]4NC(=O)[C@@H]1C2=C(C(=CC(=C2)OC2=C(C=CC(=C2)[C@H](C(=O)N[C@H](CC2=CC=C(O3)C=C2)C(=O)N1)NC)O)O)Cl)O)C(=O)NCCCN(C)C)O)Cl)C(=O)O)O)O DMGMNH3 IK KGPGQDLTDHGEGT-SZUNQUCBSA-N DMGMNH3 IU (2S,3S,4R,5R,6S)-6-[[(1S,2R,19R,22R,34S,37R,40R,52S)-5,32-dichloro-52-[3-(dimethylamino)propylcarbamoyl]-2,26,31,44,49-pentahydroxy-22-(methylamino)-21,35,38,54,56,59-hexaoxo-47-[(2R,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-7,13,28-trioxa-20,36,39,53,55,58-hexazaundecacyclo[38.14.2.23,6.214,17.219,34.18,12.123,27.129,33.141,45.010,37.046,51]hexahexaconta-3,5,8,10,12(64),14(63),15,17(62),23(61),24,26,29(60),30,32,41(57),42,44,46(51),47,49,65-henicosaen-64-yl]oxy]-3,4-dihydroxy-5-(10-methylundecanoylamino)oxane-2-carboxylic acid DMGMNH3 CA CAS 171500-79-1 DMGMNH3 CB CHEBI:82721 DMGMNH3 DE Bacterial infection DMM0PDO ID DMM0PDO DMM0PDO DN Dalfampridine DMM0PDO HS Approved DMM0PDO SN Ampyra (TN) DMM0PDO CP Acorda Therapeutics DMM0PDO DT Small molecular drug DMM0PDO PC 1727 DMM0PDO MW 94.11 DMM0PDO FM C5H6N2 DMM0PDO IC InChI=1S/C5H6N2/c6-5-1-3-7-4-2-5/h1-4H,(H2,6,7) DMM0PDO CS C1=CN=CC=C1N DMM0PDO IK NUKYPUAOHBNCPY-UHFFFAOYSA-N DMM0PDO IU pyridin-4-amine DMM0PDO CA CAS 504-24-5 DMM0PDO CB CHEBI:34385 DMM0PDO DE Multiple sclerosis DM4LTKV ID DM4LTKV DM4LTKV DN Dalfopristin DM4LTKV HS Approved DM4LTKV SN 5-(2-DIETHYLAMINO-ETHANESULFONYL)-21-HYDROXY-10-ISOPROPYL-11,19-DIMETHYL-9,26-DIOXA-3,15,28-TRIAZA-TRICYCLO[23.2.1.00,255]OCTACOSA-1(27),12,17,19,25(28)-PENTAENE-2,8,14,23-TETRAONE DM4LTKV TC Antibiotics DM4LTKV DT Small molecular drug DM4LTKV PC 6323289 DM4LTKV MW 690.8 DM4LTKV FM C34H50N4O9S DM4LTKV IC InChI=1S/C34H50N4O9S/c1-7-37(8-2)16-17-48(44,45)28-13-15-38-31(28)34(43)47-32(22(3)4)24(6)11-12-29(41)35-14-9-10-23(5)18-25(39)19-26(40)20-30-36-27(21-46-30)33(38)42/h9-12,18,21-22,24-25,28,31-32,39H,7-8,13-17,19-20H2,1-6H3,(H,35,41)/b10-9+,12-11+,23-18+/t24-,25-,28-,31-,32-/m1/s1 DM4LTKV CS CCN(CC)CCS(=O)(=O)[C@@H]1CCN2[C@H]1C(=O)O[C@@H]([C@@H](/C=C/C(=O)NC/C=C/C(=C/[C@H](CC(=O)CC3=NC(=CO3)C2=O)O)/C)C)C(C)C DM4LTKV IK SUYRLXYYZQTJHF-VMBLUXKRSA-N DM4LTKV IU (6R,7S,10R,11R,12E,17E,19E,21S)-6-[2-(diethylamino)ethylsulfonyl]-21-hydroxy-11,19-dimethyl-10-propan-2-yl-9,26-dioxa-3,15,28-triazatricyclo[23.2.1.03,7]octacosa-1(27),12,17,19,25(28)-pentaene-2,8,14,23-tetrone DM4LTKV CA CAS 112362-50-2 DM4LTKV CB CHEBI:4309 DM4LTKV DE Bacterial infection DM6CLBN ID DM6CLBN DM6CLBN DN Danaparoid DM6CLBN HS Approved DM6CLBN SN Orgaran (TN) DM6CLBN CP Schering-Plough DM6CLBN TC Anticoagulants DM6CLBN DE Deep venous clot DML8KTN ID DML8KTN DML8KTN DN Danazol DML8KTN HS Approved DML8KTN SN Anatrol; Chronogyn; Cyclomen; Danatrol; Danazant; Danazole; Danazolum; Danocrine; Danogen; Danokrin; Danol; Danoval; Danzol; Ladogal; Norciden; Panacrine; Winobanin; Alphapharm Brand of Danazol; Antigen Brand of Danazol; Kendrick Brand of Danazol; Ratiopharm Brand of Danazol; Sanofi Brand of Danazol; Sanofi Synthelabo Brand ofDanazol; Sanofi Winthrop Brand of Danazol; WIN 17757; Danazol-ratiopharm; Danazolum [INN-Latin]; Danocrine (TN); WIN 17,757; WIN-17757; Win 17, 757; Danazol (JAN/USP/INN); Danazol [USAN:BAN:INN:JAN];[1,2]oxazolo[4',5':2,3]-17alpha-pregn-4-en-20-yn-17-ol; (1R,3aS,3bR,10aR,10bS,12aS)-1-ethynyl-10a,12a-dimethyl-2,3,3a,3b,4,5,10,10a,10b,11,12,12a-dodecahydro-1H-cyclopenta[7,8]phenanthro[3,2-d]isoxazol-1-ol; (1S,2R,13R,14S,17R,18S)-17-ethynyl-2,18-dimethyl-7-oxa-6-azapentacyclo[11.7.0.0^{2,10}.0^{4,8}.0^{14,18}]icosa-4(8),5,9-trien-17-ol; 1-Ethynyl-10a,12a-dimethyl-2,3,3a,3b,4,5,10,10a,10b,11,12,12a-dodecahydro-1H-cyclopenta[7,8]phenanthro[3,2-d]isoxazol-1-ol; 17-alpha-2,4-Pregnadien-20-yno(2,3-d)isoxazol-17-ol; 17-alpha-Pregn-4-en-20-yno(2,3-d)isoxazol-17-ol; 17-alpha-Pregna-2,4-dien-20-yno(2,3-d)isoxazol-17-ol; 17.Alpha.-Pregna-2, {4-dien-20-yno[2,3-d]isoxazol-17-ol}; 17alpha-Pregna-2,4-dien-20-yno(2,3-d)isoxazol-17-ol DML8KTN TC Fertility Agents DML8KTN DT Small molecular drug DML8KTN PC 28417 DML8KTN MW 337.5 DML8KTN FM C22H27NO2 DML8KTN IC InChI=1S/C22H27NO2/c1-4-22(24)10-8-18-16-6-5-15-11-19-14(13-23-25-19)12-20(15,2)17(16)7-9-21(18,22)3/h1,11,13,16-18,24H,5-10,12H2,2-3H3/t16-,17+,18+,20+,21+,22+/m1/s1 DML8KTN CS C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC5=C(C[C@]34C)C=NO5 DML8KTN IK POZRVZJJTULAOH-LHZXLZLDSA-N DML8KTN IU (1S,2R,13R,14S,17R,18S)-17-ethynyl-2,18-dimethyl-7-oxa-6-azapentacyclo[11.7.0.02,10.04,8.014,18]icosa-4(8),5,9-trien-17-ol DML8KTN CA CAS 17230-88-5 DML8KTN CB CHEBI:4315 DML8KTN DE Menorrhagia; Breast cancer DM1D8XY ID DM1D8XY DM1D8XY DN Dantrolene DM1D8XY HS Approved DM1D8XY SN Dantrium; Dantroleno; Dantrolenum; DANTROLENE SODIUM; Dantrium Intravenous; Dantrium (TN); Dantrolen (TN); Dantroleno [INN-Spanish]; Dantrolenum [INN-Latin]; F-368; Dantrolene (USAN/INN); Dantrolene [USAN:BAN:INN]; 1-(((5-(4-Nitrophenyl)-2-furanyl)methylene)amino)-2,4-imidazolidinedione; 1-((5-(p-Nitrophenyl)furfurylidene)amino)hydantoin; 1-({(1E)-[5-(4-nitrophenyl)furan-2-yl]methylidene}amino)imidazolidine-2,4-dione; 1-({[5-(4-nitrophenyl)furan-2-yl]methylidene}amino)imidazolidine-2,4-dione; 1-[(E)-[5-(4-nitrophenyl)furan-2-yl]methylideneamino]imidazolidine-2,4-dione DM1D8XY CP Procter & Gamble DM1D8XY TC Muscle Relaxants DM1D8XY DT Small molecular drug DM1D8XY PC 6914273 DM1D8XY MW 314.25 DM1D8XY FM C14H10N4O5 DM1D8XY IC InChI=1S/C14H10N4O5/c19-13-8-17(14(20)16-13)15-7-11-5-6-12(23-11)9-1-3-10(4-2-9)18(21)22/h1-7H,8H2,(H,16,19,20)/b15-7+ DM1D8XY CS C1C(=O)NC(=O)N1/N=C/C2=CC=C(O2)C3=CC=C(C=C3)[N+](=O)[O-] DM1D8XY IK OZOMQRBLCMDCEG-VIZOYTHASA-N DM1D8XY IU 1-[(E)-[5-(4-nitrophenyl)furan-2-yl]methylideneamino]imidazolidine-2,4-dione DM1D8XY CA CAS 7261-97-4 DM1D8XY DE Hyperthermia DM28UJG ID DM28UJG DM28UJG DN Dapagliflozin DM28UJG HS Approved DM28UJG SN BMS 512148; BMS-512148; BMS-512148, Dapagliflozin; Dapagliflozin (INN/USAN); 2-(3-(4-Ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol DM28UJG CP AstraZeneca DM28UJG DT Small molecular drug DM28UJG PC 9887712 DM28UJG MW 408.9 DM28UJG FM C21H25ClO6 DM28UJG IC InChI=1S/C21H25ClO6/c1-2-27-15-6-3-12(4-7-15)9-14-10-13(5-8-16(14)22)21-20(26)19(25)18(24)17(11-23)28-21/h3-8,10,17-21,23-26H,2,9,11H2,1H3/t17-,18-,19+,20-,21+/m1/s1 DM28UJG CS CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O)Cl DM28UJG IK JVHXJTBJCFBINQ-ADAARDCZSA-N DM28UJG IU (2S,3R,4R,5S,6R)-2-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol DM28UJG CA CAS 461432-26-8 DM28UJG CB CHEBI:85078 DM28UJG DE Type-2 diabetes DM34TXO ID DM34TXO DM34TXO DN Dapagliflozin Propanediol; Saxagliptin Hydrochloride DM34TXO HS Approved DM34TXO SN Saxagliptin Hydrochloride; Qtern DM34TXO CP Astrazeneca DM34TXO DT Small molecular drug DM34TXO DE Type-2 diabetes DMOXJKF ID DMOXJKF DMOXJKF DN Dapiprazole DMOXJKF HS Approved DMOXJKF SN Dapiprazol; Dapiprazolum; Dapirazol; Dapirazolum; Glamidolo; Remydrial; Reversil; Dapiprazol [German]; Dapiprazole [INN]; Dapiprazole (INN); Dapirazol [INN-Spanish]; Dapirazolum [INN-Latin]; Rev-Eyes; Rev-Eyes (TN); S-Triazolo(4,3-a)pyridine, 5,6,7,8-tetrahydro-3-(2-(4-(o-tolyl)-1-piperazinyl)ethyl)-,hydrochloride; 3-(2-(4-(2-methylphenyl)-1-piperazinyl)ethyl)-5,6,7,8,-tetrahydro-1,2,4-triazolo(4,3-a)pyridine hydrochloride; 3-[2-[4-(2-methylphenyl)piperazin-1-yl]ethyl]-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyridine; 3-{2-[4-(2-methylphenyl)piperazin-1-yl]ethyl}-5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyridine; 5,6,7,8-Tetrahydro-3-(2-(4-(o-tolyl)-1-piperazinyl)ethyl)-s-triazolo(4,3-a)pyridine DMOXJKF CP Abbott Laboratories DMOXJKF TC Ophthalmologicals DMOXJKF DT Small molecular drug DMOXJKF PC 3033538 DMOXJKF MW 325.5 DMOXJKF FM C19H27N5 DMOXJKF IC InChI=1S/C19H27N5/c1-16-6-2-3-7-17(16)23-14-12-22(13-15-23)11-9-19-21-20-18-8-4-5-10-24(18)19/h2-3,6-7H,4-5,8-15H2,1H3 DMOXJKF CS CC1=CC=CC=C1N2CCN(CC2)CCC3=NN=C4N3CCCC4 DMOXJKF IK RFWZESUMWJKKRN-UHFFFAOYSA-N DMOXJKF IU 3-[2-[4-(2-methylphenyl)piperazin-1-yl]ethyl]-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyridine DMOXJKF CA CAS 72822-12-9 DMOXJKF CB CHEBI:51066 DMOXJKF DE Glaucoma/ocular hypertension DM4LT8A ID DM4LT8A DM4LT8A DN Dapsone DM4LT8A HS Approved DM4LT8A SN Aczone; Atrisone; Avlosulfon; Avlosulfone; Avlosulphone; Avsulfor; Croysulfone; Croysulphone; DADPS; DDS; Dapson; Dapsona; Dapsonum; Diaminodifenilsulfona; Diaminodiphenylsulfone; Diaphenylsulfon; Diaphenylsulfone; Diaphenylsulphon; Diaphenylsulphone; Diphenasone; Diphone; Disulone; Dubronax; Dubronaz; Dumitone; Eporal; Novophone; Protogen; Sulfadione; Sulfona; Sulfonyldianiline; Sulphadione; Sulphonyldianiline; Tarimyl; Udolac; Araldite HT; D SS; Diaminodifenilsulfona [Spanish]; Diaminodiphenyl sulfone;Fatol Brand of Dapsone; Metabolite C; Orsade Brand of Dapsone; Sulfone ucb; Sumicure S; Araldite HT 976; F 1358; HT 976; HY 976; Hardener HT 976; W R 448; WR 448; ALBB-005917; AZT + Dapsone cominbation; Aczone (TN); DDS (pharmaceutical); DDS, diaphenylsulfone; DDS, pharmaceutical; DSS (VAN); Dapsoderm-X; Dapson-Fatol; Dapsona [INN-Spanish]; Dapsone (USP); Dapsone [USAN:BAN]; Dapsonum [INN-Latin];Diamino-diphenyl sulphone; Diaphenylsulfone (JAN); IN-201; Mex-America Brand of Dapsone; P-Aminophenyl sulfone; Sulfanona-mae; Sulfon-mere; Sulfona-MAE; Sulphon-mere; Bis(4-aminophenyl) sulfone; Bis(4-aminophenyl)sulfone; Bis(4-aminophenyl)sulphone; Bis(p-aminophenyl) sulfone; Bis(p-aminophenyl)sulphone; Di(4-aminophenyl) sulfone; Di(4-aminophenyl)sulfone; Di(4-aminophenyl)sulphone; Di(p-aminophenyl) sulfone; Di(p-aminophenyl)sulphone; P,p-Diaminodiphenyl sulphone; P,p-Sulfonylbisbenzamine; P,p-Sulfonylbisbenzenamine; P,p-Sulphonylbisbenzamine; P,p-Sulphonylbisbenzenamine; P,p-Sulphonyldianiline; N, N'-Diphenyl sulfondiamide; N,N'-Diphenyl sulfondiamide; P, p'-Sulfonyldianiline; P,p'-Diaminodiphenyl sulfone; P,p'-sulfonyldianiline; Diamino-4,4'-diphenyl sulfone; Diamino-4,4'-diphenyl sulphone; Sulfone, 4,4'-Diaminophenyl; (4-sulfanilylphenyl)amine; 1,1'-Sulfonylbis(4-aminobenzene); 1,1'-Sulfonylbis[4-aminobenzene]; 1,1'-Sulphonylbis(4-aminobenzene); 4,4' Diaminophenyl Sulfone; 4,4'-Dapsone; 4,4'-Diaminodiphenyl sulfone; 4,4'-Diaminodiphenyl suphone; 4,4'-Diaminodiphenylsulfone; 4,4'-Sulfonylbisaniline; 4,4'-Sulfonylbisbenzamine; 4,4'-Sulfonylbisbenzenamine; 4,4'-Sulfonyldianiline;4,4'-Sulfonyldianiline (Dapsone); 4,4'-Sulphonylbisbenzamine; 4,4'-Sulphonylbisbenzenamine; 4,4'-Sulphonyldianiline; 4,4'-diaminophenyl sulfone; 4,4-Diaminodifenylsulfon; 4,4-Diaminodifenylsulfon [Czech]; 4,4-Sulfonyldianiline; 4-(4-aminophenyl)sulfonylaniline; 4-Aminop henyl sulfone; 4-Aminophenyl sulfone; 4-Aminophenylsulfone; 4-[(4-aminobenzene)sulfonyl]aniline; 4-[(4-aminophenyl)sulfonyl]aniline DM4LT8A TC Antiinflammatory Agents DM4LT8A DT Small molecular drug DM4LT8A PC 2955 DM4LT8A MW 248.3 DM4LT8A FM C12H12N2O2S DM4LT8A IC InChI=1S/C12H12N2O2S/c13-9-1-5-11(6-2-9)17(15,16)12-7-3-10(14)4-8-12/h1-8H,13-14H2 DM4LT8A CS C1=CC(=CC=C1N)S(=O)(=O)C2=CC=C(C=C2)N DM4LT8A IK MQJKPEGWNLWLTK-UHFFFAOYSA-N DM4LT8A IU 4-(4-aminophenyl)sulfonylaniline DM4LT8A CA CAS 80-08-0 DM4LT8A CB CHEBI:4325 DM4LT8A DE Pneumocystis pneumonia DMFDQ3I ID DMFDQ3I DMFDQ3I DN Daptomycin DMFDQ3I HS Approved DMFDQ3I SN Dapcin; Daptomicina; Daptomycine; Daptomycinum; LY 146032; LY-146032; LY146032; (2S)-daptomycin; 103060-53-3; C72H101N17O26; Cidecin; Cubicin; DAPTOMYCIN; CHEBI:600103; N-decanoyl-L-tryptophyl-L-asparaginyl-N-[(3S,6S,9R,15S,18R,21S,24S,30S,31R)-3-[2-(2-aminophenyl)-2-oxoethyl]-24-(3-aminopropyl)-15,21-bis(carboxymethyl)-6-[(2R)-1-carboxypropan-2-yl]-9-(hydroxymethyl)-18,31-dimethyl-2,5,8,11,14,17,20,23,26,29-decaoxo-1-oxa-4,7,10,13,16,19,22,25,28-nonaazacyclohentriacontan-30-yl]-L-alpha-asparagine; SCHEMBL28102 DMFDQ3I PC 16134395 DMFDQ3I MW 1620.7 DMFDQ3I FM C72H101N17O26 DMFDQ3I IC DOAKLVKFURWEDJ-RWDRXURGSA-N DMFDQ3I CS CCCCCCCCCC(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(=O)N)C(=O)NC(CC(=O)O)C(=O)NC3C(OC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC3=O)CCCN)CC(=O)O)C)CC(=O)O)CO)C(C)CC(=O)O)CC(=O)C4=CC=CC=C4N)C DMFDQ3I IK 1S/C72H101N17O26/c1-5-6-7-8-9-10-11-22-53(93)81-44(25-38-31-76-42-20-15-13-17-39(38)42)66(108)84-45(27-52(75)92)67(109)86-48(30-59(102)103)68(110)89-61-37(4)115-72(114)49(26-51(91)40-18-12-14-19-41(40)74)87-71(113)60(35(2)24-56(96)97)88-69(111)50(34-90)82-55(95)32-77-63(105)46(28-57(98)99)83-62(104)36(3)79-65(107)47(29-58(100)101)85-64(106)43(21-16-23-73)80-54(94)33-78-70(61)112/h12-15,17-20,31,35-37,43-50,60-61,76,90H,5-11,16,21-30,32-34,73-74H2,1-4H3,(H2,75,92)(H,77,105)(H,78,112)(H,79,107)(H,80,94)(H,81,93)(H,82,95)(H,83,104)(H,84,108)(H,85,106)(H,86,109)(H,87,113)(H,88,111)(H,89,110)(H,96,97)(H,98,99)(H,100,101)(H,102,103)/t35-,36-,37-,43+,44+,45+,46+,47+,48+,49+,50-,60+,61+/m1/s1 DMFDQ3I IU (3S)-3-[[(2S)-4-amino-2-[[(2S)-2-(decanoylamino)-3-(1H-indol-3-yl)propanoyl]amino]-4-oxobutanoyl]amino]-4-[[(3S,6S,9R,15S,18R,21S,24S,30S,31R)-3-[2-(2-aminophenyl)-2-oxoethyl]-24-(3-aminopropyl)-15,21-bis(carboxymethyl)-6-[(2R)-1-carboxypropan-2-yl]-9-(hydroxymethyl)-18,31-dimethyl-2,5,8,11,14,17,20,23,26,29-decaoxo-1-oxa-4,7,10,13,16,19,22,25,28-nonazacyclohentriacont-30-yl]amino]-4-oxobutanoic acid DMFDQ3I CA CAS 103060-53-3 DMFDQ3I CB CHEBI:600103 DMFDQ3I DE Methicillin-resistant staphylococcus infection DMKDU16 ID DMKDU16 DMKDU16 DN Daptomycin DMKDU16 HS Approved DMKDU16 SN Cidecin; Cubicin; Dapcin; Daptomicina; Daptomycine; Daptomycinum; Deptomycin; Daptomicina [Spanish]; Daptomycine [French]; Daptomycinum [Latin]; LY146032; Cubicin (TN); LY-146032; MK-3009; Daptomycin [USAN:INN:BAN]; Daptomycin (JAN/USAN/INN); N-Decanoyl-L-tryptophyl-L-asparaginyl-L-aspartyl-L-threonylglycyl-L-ornithyl-L-aspartyl-D-alanyl-L-aspartylglycyl-D-seryl-threo-3-methyl-L-glutamyl-3-anthraniloyl-L-alanine epsilon1-lactone; N-decanoyl-L-tryptophyl-D-asparaginyl-L-aspartyl-L-threonylglycyl-L-ornithyl-L-aspartyl-D-alanyl-L-aspartylglycyl-D-seryl-threo-3-methyl-L-glutamyl-3-anthraniloyl-L-alanine epsilon(1)-lactone; N-decanoyl-L-tryptophyl-D-asparaginyl-L-aspartyl-L-threonylglycyl-L-ornithyl-L-aspartyl-D-alanyl-L-aspartylglycyl-D-seryl-threo-3-methyl-L-glutamyl-3-anthraniloyl-L-alanine 1.13-3.4-lactone; N-decanoyl-L-tryptophyl-L-asparaginyl-N-[(3S,6S,9R,15S,18R,21S,24S,30S,31R)-3-[2-(2-aminophenyl)-2-oxoethyl]-24-(3-aminopropyl)-15,21-bis(carboxymethyl)-6-[(2R)-1-carboxypropan-2-yl]-9-(hydroxymethyl)-18,31-dimethyl-2,5,8,11,14,17,20,23,26,29-decaoxo-1-ox DMKDU16 CP Cubist Pharmaceuticals DMKDU16 TC Antibiotics DMKDU16 DT Small molecular drug DMKDU16 PC 16134395 DMKDU16 MW 1620.7 DMKDU16 FM C72H101N17O26 DMKDU16 IC InChI=1S/C72H101N17O26/c1-5-6-7-8-9-10-11-22-53(93)81-44(25-38-31-76-42-20-15-13-17-39(38)42)66(108)84-45(27-52(75)92)67(109)86-48(30-59(102)103)68(110)89-61-37(4)115-72(114)49(26-51(91)40-18-12-14-19-41(40)74)87-71(113)60(35(2)24-56(96)97)88-69(111)50(34-90)82-55(95)32-77-63(105)46(28-57(98)99)83-62(104)36(3)79-65(107)47(29-58(100)101)85-64(106)43(21-16-23-73)80-54(94)33-78-70(61)112/h12-15,17-20,31,35-37,43-50,60-61,76,90H,5-11,16,21-30,32-34,73-74H2,1-4H3,(H2,75,92)(H,77,105)(H,78,112)(H,79,107)(H,80,94)(H,81,93)(H,82,95)(H,83,104)(H,84,108)(H,85,106)(H,86,109)(H,87,113)(H,88,111)(H,89,110)(H,96,97)(H,98,99)(H,100,101)(H,102,103)/t35-,36-,37-,43+,44+,45+,46+,47+,48+,49+,50-,60+,61+/m1/s1 DMKDU16 CS CCCCCCCCCC(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H]3[C@H](OC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC3=O)CCCN)CC(=O)O)C)CC(=O)O)CO)[C@H](C)CC(=O)O)CC(=O)C4=CC=CC=C4N)C DMKDU16 IK DOAKLVKFURWEDJ-RWDRXURGSA-N DMKDU16 IU (3S)-3-[[(2S)-4-amino-2-[[(2S)-2-(decanoylamino)-3-(1H-indol-3-yl)propanoyl]amino]-4-oxobutanoyl]amino]-4-[[(3S,6S,9R,15S,18R,21S,24S,30S,31R)-3-[2-(2-aminophenyl)-2-oxoethyl]-24-(3-aminopropyl)-15,21-bis(carboxymethyl)-6-[(2R)-1-carboxypropan-2-yl]-9-(hydroxymethyl)-18,31-dimethyl-2,5,8,11,14,17,20,23,26,29-decaoxo-1-oxa-4,7,10,13,16,19,22,25,28-nonazacyclohentriacont-30-yl]amino]-4-oxobutanoic acid DMKDU16 CA CAS 103060-53-3 DMKDU16 CB CHEBI:600103 DMKDU16 DE Bacterial infection DMKCIUZ ID DMKCIUZ DMKCIUZ DN Daratumumab DMKCIUZ HS Approved DMKCIUZ CP Genmab Princeton, NJ DMKCIUZ DT Antibody DMKCIUZ DE Multiple myeloma DMMJTYW ID DMMJTYW DMMJTYW DN Darbepoetin alfa DMMJTYW HS Approved DMMJTYW SN Aranesp (TN) DMMJTYW CP Amgen Inc DMMJTYW TC Antianemic Agents DMMJTYW SQ DB00012 sequence: APPRLICDSRVLERYLLEAKEAENITTGCAEHCSLNENITVPDTKVNFYAWKRMEVGQQAVEVWQGLALLSEAVLRGQALLVNSSQPWEPLQLHVDKAVSGLRSLTTLLRALGAQKEAISPPDAASAAPLRTITADTFRKLFRVYSNFLRGKLKLYTGEACRTGDR DMMJTYW DE Anemia DMWXLYZ ID DMWXLYZ DMWXLYZ DN Darifenacin DMWXLYZ HS Approved DMWXLYZ SN Enablex; Emselex; 133099-04-4; UNII-APG9819VLM; UK-88525; APG9819VLM; CHEMBL1346; CHEBI:391960; (S)-1-(2-(2,3-Dihydro-5-benzofuranyl)ethyl)-alpha,alpha-diphenyl-3-pyrrolidineacetamide; 2-[(3S)-1-[2-(2,3-dihydro-1-benzofuran-5-yl)ethyl]pyrrolidin-3-yl]-2,2-diphenylacetamide; darifenacine; [3H]darifenacin; 2-{(3S)-1-[2-(2,3-dihydro-1-benzofuran-5-yl)ethyl]pyrrolidin-3-yl}-2,2-diphenylacetamide; NCGC00168775-01; Darifenacin (USAN/INN); Darifenacinum; Darifenacina; Darifenacin [USAN:INN:BAN]; Emselex; Emselex (TN); Enablex (TN) DMWXLYZ CP Norvatis Phamaceuticals Corporation DMWXLYZ TC Urinary antispasmodics DMWXLYZ DT Small molecular drug DMWXLYZ PC 444031 DMWXLYZ MW 426.5 DMWXLYZ FM C28H30N2O2 DMWXLYZ IC InChI=1S/C28H30N2O2/c29-27(31)28(23-7-3-1-4-8-23,24-9-5-2-6-10-24)25-14-17-30(20-25)16-13-21-11-12-26-22(19-21)15-18-32-26/h1-12,19,25H,13-18,20H2,(H2,29,31)/t25-/m1/s1 DMWXLYZ CS C1CN(C[C@@H]1C(C2=CC=CC=C2)(C3=CC=CC=C3)C(=O)N)CCC4=CC5=C(C=C4)OCC5 DMWXLYZ IK HXGBXQDTNZMWGS-RUZDIDTESA-N DMWXLYZ IU 2-[(3S)-1-[2-(2,3-dihydro-1-benzofuran-5-yl)ethyl]pyrrolidin-3-yl]-2,2-diphenylacetamide DMWXLYZ CA CAS 133099-04-4 DMWXLYZ CB CHEBI:391960 DMWXLYZ DE Overactive bladder DMV7YFT ID DMV7YFT DMV7YFT DN Darolutamide DMV7YFT HS Approved DMV7YFT SN 1297538-32-9; BAY-1841788; N-((S)-1-(3-(3-Chloro-4-cyanophenyl)-1H-pyrazol-1-yl)propan-2-yl)-5-(1-hydroxyethyl)-1H-pyrazole-3-carboxamide; Darolutamide [USAN]; Darolutamide (JAN/USAN/INN); SCHEMBL1814935; SCHEMBL13733117; KS-00000TSX; EX-A759; BLIJXOOIHRSQRB-PXYINDEMSA-N; MolPort-046-033-692; MolPort-044-560-277; AKOS030526387; CS-5174; BAY1841788; DB12941; BAY 1841788; HY-16985; S7559; FT-0700158; J3.501.129C; D11045; J-690121; 1H-Pyrazole-3-carboxamide, N-((1S)-2-(3-(3-chloro-4-cyanophen DMV7YFT CP Bayer Pharmaceuticals Whippany, NJ DMV7YFT PC 67171867 DMV7YFT MW 398.8 DMV7YFT FM C19H19ClN6O2 DMV7YFT IC InChI=1S/C19H19ClN6O2/c1-11(22-19(28)18-8-17(12(2)27)23-24-18)10-26-6-5-16(25-26)13-3-4-14(9-21)15(20)7-13/h3-8,11-12,27H,10H2,1-2H3,(H,22,28)(H,23,24)/t11-,12?/m0/s1 DMV7YFT CS C[C@@H](CN1C=CC(=N1)C2=CC(=C(C=C2)C#N)Cl)NC(=O)C3=NNC(=C3)C(C)O DMV7YFT IK BLIJXOOIHRSQRB-PXYINDEMSA-N DMV7YFT IU N-[(2S)-1-[3-(3-chloro-4-cyanophenyl)pyrazol-1-yl]propan-2-yl]-5-(1-hydroxyethyl)-1H-pyrazole-3-carboxamide DMV7YFT CA CAS 1297538-32-9 DMV7YFT DE Prostate cancer DMN3GCH ID DMN3GCH DMN3GCH DN Darunavir DMN3GCH HS Approved DMN3GCH SN 206361-99-1; TMC114; Prezista; TMC-114; UIC-94017; Darunavirum; TMC 114; Darunavirum [INN-Latin]; UNII-YO603Y8113; AIDS073035; CHEMBL1323; (3R,3AS,6AR)-HEXAHYDROFURO[2,3-B]FURAN-3-YL(1S,2R)-3-[[(4-AMINOPHENYL)SULFONYL](ISOBUTYL)AMINO]-1-BENZYL-2-HYDROXYPROPYLCARBAMATE; CHEBI:367163; Darunavir-d9; YO603Y8113; (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ((2S,3R)-4-(4-amino-N-isobutylphenylsulfonamido)-3-hydroxy-1-phenylbutan-2-yl)carbamate; NCGC00168773-01; (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl; Darunavirum; Darunavir [USAN]; UIC 94017; Prezista(TM); UIC-96017; Darunavir (USAN/INN); Carbamic acid, [(1S,2R)-3-[[(4-aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester; {(1S,2R)-3-[(4-Amino-benzenesulfonyl)-isobutyl-amino]-1-benzyl-2-hydroxy-propyl}-carbamic acid (3R,3aS,6aR)-(hexahydro-furo[2,3-b]furan-3-yl) ester; [(S)-3-[(4-Amino-benzenesulfonyl)-isobutyl-amino]-2-hydroxy-1-((R)-phenylmethyl)-propyl]-carbamic acid (3R,3aS,6aR)-(hexahydro-furo[2,3-b]furan-3-yl) ester; N-((1S,2R)-3-(((4-Aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-benzylpropyl)((1S,2R,5R)-4,6-dioxabicyclo(330)oct-2-yloxy)carboxamide; [(3aS,4R,6aR)-2,3,3a,4,5,6a-hexahydrofuro[2,3-b]furan-4-yl] N-[(2S,3R)-4-[(4-aminophenyl)sulfonyl-(2-methylpropyl)amino]-3-hydroxy-1-phenylbutan-2-yl]carbamate; (3-((4-aminobenzenesulfonyl)isobutylamino)-1-benzyl-2-hydroxypropyl)carbamic acid hexahydrofuro(2,3-b)furan-3-yl ester; (3R,3aS,6aR)-Hexahydrofuro(2,3-b)furan-3-yl N-((1S,2R)-1-benzyl-2-hydroxy-3-(N1-isobutylsulfanilamido)propyl)carbamate; (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl N-((1S,2R)-1-benzyl-2-hydroxy-3-(N(1)-isobutylsulfanilamido)propyl)carbamate; (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl [(2S,3R)-4-{[(4-aminophenyl)sulfonyl](2-methylpropyl)amino}-3-hydroxy-1-phenylbutan-2-yl]carbamate; (3R,3aS,6aR)-tetrahydro-2H-furo[2,3-b]furan-3-yl (2S,3R)-4-(4-amino-N-isobutylphenylsulfonamido)-3-hydroxy-1-phenylbutan-2-ylcarbamate; (3R,3aS,6aR)-tetrahydro-2H-furo[2,3-b]furan-3-yl (2S,3R)-4-(4-amino-N-neopentylphenylsulfonamido)-3-hydroxy-1-phenylbutan-2-ylcarbamate DMN3GCH CP Tibotec DMN3GCH TC Antiviral Agents DMN3GCH DT Small molecular drug DMN3GCH PC 213039 DMN3GCH MW 547.7 DMN3GCH FM C27H37N3O7S DMN3GCH IC InChI=1S/C27H37N3O7S/c1-18(2)15-30(38(33,34)21-10-8-20(28)9-11-21)16-24(31)23(14-19-6-4-3-5-7-19)29-27(32)37-25-17-36-26-22(25)12-13-35-26/h3-11,18,22-26,31H,12-17,28H2,1-2H3,(H,29,32)/t22-,23-,24+,25-,26+/m0/s1 DMN3GCH CS CC(C)CN(C[C@H]([C@H](CC1=CC=CC=C1)NC(=O)O[C@H]2CO[C@@H]3[C@H]2CCO3)O)S(=O)(=O)C4=CC=C(C=C4)N DMN3GCH IK CJBJHOAVZSMMDJ-HEXNFIEUSA-N DMN3GCH IU [(3aS,4R,6aR)-2,3,3a,4,5,6a-hexahydrofuro[2,3-b]furan-4-yl] N-[(2S,3R)-4-[(4-aminophenyl)sulfonyl-(2-methylpropyl)amino]-3-hydroxy-1-phenylbutan-2-yl]carbamate DMN3GCH CA CAS 206361-99-1 DMN3GCH CB CHEBI:367163 DMN3GCH DE Human immunodeficiency virus infection; Human immunodeficiency virus-1 infection DMJV2EK ID DMJV2EK DMJV2EK DN Dasatinib DMJV2EK HS Approved DMJV2EK SN Sprycel (TN); BMS 354825; BMS-354825; BMS-354825, Sprycel, BMS354825, Dasatinib; BMS354825; Dasatinib (USAN); Dasatinib [USAN]; Dasatinib anhydrous; Dasatinib, BMS 354825; Dasatinibum; Sprycel; Spyrcel DMJV2EK CP Bristol Myers Squibb DMJV2EK TC Anticancer Agents DMJV2EK DT Small molecular drug DMJV2EK PC 3062316 DMJV2EK MW 488 DMJV2EK FM C22H26ClN7O2S DMJV2EK IC InChI=1S/C22H26ClN7O2S/c1-14-4-3-5-16(23)20(14)28-21(32)17-13-24-22(33-17)27-18-12-19(26-15(2)25-18)30-8-6-29(7-9-30)10-11-31/h3-5,12-13,31H,6-11H2,1-2H3,(H,28,32)(H,24,25,26,27) DMJV2EK CS CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO DMJV2EK IK ZBNZXTGUTAYRHI-UHFFFAOYSA-N DMJV2EK IU N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-1,3-thiazole-5-carboxamide DMJV2EK CA CAS 302962-49-8 DMJV2EK CB CHEBI:49375 DMJV2EK DE Chronic myelogenous leukaemia; Multiple myeloma DM74SVE ID DM74SVE DM74SVE DN Dasiglucagon DM74SVE HS Approved DM74SVE SN UNII-AD4J2O47FQ; AD4J2O47FQ; Dasiglucagon [INN]; Dasiglucagon [USAN]; Dasiglucagon [WHO-DD]; Dasiglucagon [USAN:INN]; ZP-GA-1; ZP4207; ZP-4207; 1544300-84-6; His-Ser-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-Asp-aib-Ala-Arg-Ala-Glu-Glu-Phe-Val-Lys-Trp-Leu-Glu-Ser-Thr; L-Threonine, L-histidyl-L-seryl-L-glutaminylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-alpha-aspartyl-L-tyrosyl-L-seryl-L-lysyl-L-tyrosyl-L-leucyl-L-alpha-aspartyl-2-methylalanyl-L-alanyl-L-arginyl-L-alanyl-L-alpha-glutamyl-L-alpha DM74SVE CP Zealand Pharma DM74SVE DT Peptide DM74SVE PC 126961379 DM74SVE MW 3381.6 DM74SVE FM C152H222N38O50 DM74SVE IC InChI=1S/C152H222N38O50/c1-73(2)55-99(133(222)171-98(47-51-116(206)207)132(221)183-111(71-194)144(233)189-122(80(11)197)149(238)239)174-137(226)105(61-85-65-161-91-32-21-20-31-89(85)91)178-129(218)93(34-23-25-53-154)172-146(235)119(75(5)6)187-139(228)103(57-81-27-16-14-17-28-81)176-131(220)97(46-50-115(204)205)170-130(219)96(45-49-114(202)203)167-123(212)76(7)164-127(216)94(35-26-54-160-151(157)158)166-124(213)77(8)165-150(240)152(12,13)190-145(234)107(64-118(210)211)180-134(223)100(56-74(3)4)173-135(224)101(59-83-36-40-87(198)41-37-83)175-128(217)92(33-22-24-52-153)168-142(231)109(69-192)184-136(225)102(60-84-38-42-88(199)43-39-84)177-138(227)106(63-117(208)209)179-143(232)110(70-193)185-148(237)121(79(10)196)188-140(229)104(58-82-29-18-15-19-30-82)181-147(236)120(78(9)195)186-113(201)67-162-126(215)95(44-48-112(156)200)169-141(230)108(68-191)182-125(214)90(155)62-86-66-159-72-163-86/h14-21,27-32,36-43,65-66,72-80,90,92-111,119-122,161,191-199H,22-26,33-35,44-64,67-71,153-155H2,1-13H3,(H2,156,200)(H,159,163)(H,162,215)(H,164,216)(H,165,240)(H,166,213)(H,167,212)(H,168,231)(H,169,230)(H,170,219)(H,171,222)(H,172,235)(H,173,224)(H,174,226)(H,175,217)(H,176,220)(H,177,227)(H,178,218)(H,179,232)(H,180,223)(H,181,236)(H,182,214)(H,183,221)(H,184,225)(H,185,237)(H,186,201)(H,187,228)(H,188,229)(H,189,233)(H,190,234)(H,202,203)(H,204,205)(H,206,207)(H,208,209)(H,210,211)(H,238,239)(H4,157,158,160)/t76-,77-,78+,79+,80+,90-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,119-,120-,121-,122-/m0/s1 DM74SVE CS C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)NC(C)(C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC4=CC=CC=C4)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC5=CNC6=CC=CC=C65)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)CNC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC7=CNC=N7)N)O DM74SVE IK RZRMFQMNPDPAIX-AJTOSFMRSA-N DM74SVE IU (4S)-4-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-amino-3-(1H-imidazol-4-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-3-carboxypropanoyl]amino]-2-methylpropanoyl]amino]propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-carboxy-1-[[(2S)-1-[[(1S,2R)-1-carboxy-2-hydroxypropyl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-5-oxopentanoic acid DM74SVE CA CAS 1544300-84-6 DM74SVE DE Hypoglycemia; Hyperinsulinemia DMLDQFV ID DMLDQFV DMLDQFV DN Dasotraline DMLDQFV HS Approved DMLDQFV SN SEP-225289; SEP-289; Triple reuptake inhibitors (depression), Sepracor DMLDQFV CP Sunovion pharmaceuticals DMLDQFV DT Small molecular drug DMLDQFV PC 9947999 DMLDQFV MW 292.2 DMLDQFV FM C16H15Cl2N DMLDQFV IC InChI=1S/C16H15Cl2N/c17-14-7-5-10(9-15(14)18)11-6-8-16(19)13-4-2-1-3-12(11)13/h1-5,7,9,11,16H,6,8,19H2/t11-,16+/m0/s1 DMLDQFV CS C1C[C@H](C2=CC=CC=C2[C@@H]1C3=CC(=C(C=C3)Cl)Cl)N DMLDQFV IK SRPXSILJHWNFMK-MEDUHNTESA-N DMLDQFV IU (1R,4S)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-amine DMLDQFV CA CAS 675126-05-3 DMLDQFV DE Mood disorder; Attention deficit hyperactivity disorder; Eating disorder DMQUSBT ID DMQUSBT DMQUSBT DN Daunorubicin DMQUSBT HS Approved DMQUSBT SN daunorubicin; Daunomycin; 20830-81-3; Rubidomycin; Cerubidine; Daunorubicine; Acetyladriamycin; Leukaemomycin C; Daunorubicinum; Daunarubicinum; Daunorrubicina; Daunamycin; Cerubidin; DaunoXome; Rubomycin C; (+)-Daunomycin; Daunoblastin; Anthracyline; Rubomycin; Daunorubicinum [INN-Latin]; RP 13057; Daunorubicin [INN:BAN]; RCRA waste no U059; FI6339; NSC-82151; DAUNORUBICIN HCL; DaunoXome (TN); UNII-ZS7284E0ZP; CCRIS 914; ZS7284E0ZP; CHEBI:41977; HSDB 5095; C27H29NO10; NCI-C04693; EINECS 244-069-7; Ondena; NSC 83142; Acetyladriamycin; Daunoblastine; Antibiotics from Streptomyces coeruleorubidus; DM1; FI 6339; Dauno-Rubidomycine; Daunorubicin (INN); Daunorubicin (liposomal); Daunorubicin, Hydrochloride; VS-103; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside; (7S,9R)-9-Acetyl-7-[(2S,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (8S-cis)-8-Acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione; (8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione; Anthracycline DMQUSBT TC Anticancer Agents DMQUSBT DT Small molecular drug DMQUSBT PC 30323 DMQUSBT MW 527.5 DMQUSBT FM C27H29NO10 DMQUSBT IC InChI=1S/C27H29NO10/c1-10-22(30)14(28)7-17(37-10)38-16-9-27(35,11(2)29)8-13-19(16)26(34)21-20(24(13)32)23(31)12-5-4-6-15(36-3)18(12)25(21)33/h4-6,10,14,16-17,22,30,32,34-35H,7-9,28H2,1-3H3/t10-,14-,16-,17-,22+,27-/m0/s1 DMQUSBT CS C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)C)O)N)O DMQUSBT IK STQGQHZAVUOBTE-VGBVRHCVSA-N DMQUSBT IU (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione DMQUSBT CA CAS 20830-81-3 DMQUSBT CB CHEBI:41977 DMQUSBT DE Acute myeloid leukaemia; Solid tumour/cancer; Kaposi sarcoma DMC50ME ID DMC50ME DMC50ME DN Debrisoquin DMC50ME HS Approved DMC50ME SN Debrisochinum; Debrisoquina; Debrisoquine; Debrisoquinum; Declinax; Equitonil; Isocaramidine; Tendor; DEBRISOQUIN SULFATE; Debrisoquin hemisulfate; Debrisoquine sulfate; Isocaramidine sulfate; Debrisoquina [INN-Spanish]; Debrisoquine [INN:BAN]; Debrisoquinum [INN-Latin]; Ro 5-3307/1; Sulfuric acid compound with 3,4-dihydro-2(1H)-isoquinolinecarboximidamide (1:1); 1,2,3, 4-Tetrahydro-isoquinoline-2-carboxamidine sulfate; 2(1H)-Isoquinolinecarboxamidine, 3,4-dihydro-(7CI,8CI); 2(1H)-Isoquinolinecarboxamidine, 3,4-dihydro-, sulfate (2:1); 2(1H)-Isoquinolinecarboximidamide, 3,4-dihydro-, sulfate (2:1); 2-Amidino-1,2,3,4-tetrahydroisoquinoline; 3,4-Dihydro-2(1H)-isoquinolinecarboxamidine; 3,4-Dihydro-2(1H)-isoquinolinecarboxamidine sulfate (2:1); 3,4-Dihydro-2(1H)-isoquinolinecarboximidamide; 3,4-Dihydro-2(1H;)-isoquinoline carboxamidine sulfate; 3,4-dihydro-1H-isoquinoline-2-carboximidamide; 3,4-dihydroisoquinoline-2(1H)-carboximidamide DMC50ME TC Antihypertensive Agents DMC50ME DT Small molecular drug DMC50ME PC 2966 DMC50ME MW 175.23 DMC50ME FM C10H13N3 DMC50ME IC InChI=1S/C10H13N3/c11-10(12)13-6-5-8-3-1-2-4-9(8)7-13/h1-4H,5-7H2,(H3,11,12) DMC50ME CS C1CN(CC2=CC=CC=C21)C(=N)N DMC50ME IK JWPGJSVJDAJRLW-UHFFFAOYSA-N DMC50ME IU 3,4-dihydro-1H-isoquinoline-2-carboximidamide DMC50ME CA CAS 1131-64-2 DMC50ME CB CHEBI:34665 DMC50ME DE Hypertension DMSBRUW ID DMSBRUW DMSBRUW DN Decamethonium DMSBRUW HS Approved DMSBRUW SN Decamethonum; Syncurine; DECAMETHONIUM ION; AIDS351484; AIDS-351484; Decamethylenebis(trimethylammonium)bromide; Syncurine (TN); Syncurine (*dibromide salt*); Trimethyl-[10-(trimethylazaniumyl)decyl]azanium; C 10 (VAN) (*dibromide salt*); N,N,N,N',N',N'-hexamethyldecane-1,10-diaminium; (DM)Br2; 1,10-Decanediaminium, N,N,N,N',N',N'-hexamethyl-(9CI); 1,10-Decanediaminium, N,N,N,N',N',N'-hexamethyl-, dibromide DMSBRUW TC Neuromuscular Depolarizing Agents DMSBRUW DT Small molecular drug DMSBRUW PC 2968 DMSBRUW MW 258.49 DMSBRUW FM C16H38N2+2 DMSBRUW IC InChI=1S/C16H38N2/c1-17(2,3)15-13-11-9-7-8-10-12-14-16-18(4,5)6/h7-16H2,1-6H3/q+2 DMSBRUW CS C[N+](C)(C)CCCCCCCCCC[N+](C)(C)C DMSBRUW IK MTCUAOILFDZKCO-UHFFFAOYSA-N DMSBRUW IU trimethyl-[10-(trimethylazaniumyl)decyl]azanium DMSBRUW CA CAS 156-74-1 DMSBRUW CB CHEBI:41934 DMSBRUW DE Muscle spasm DMQL8XJ ID DMQL8XJ DMQL8XJ DN Decitabine DMQL8XJ HS Approved DMQL8XJ SN AzadC; Dacogen; Dezocitidine; NCGC_5ADOC; Dacogen (TN); E-7373; Decitabine (USAN/INN); Dacogen, 5-aza-2'-deoxycytidine,NSC 127716, Dacogen, DAC, Decitabine; 2'-Deoxy-5-azacytidine; 4-Amino-1-(2-deoxy-beta-D-erythro-pentofuranosyl)-1,3,5-triazin-2(1H)-one; 4-Amino-1-(2-deoxy-beta-D-erythro-pentofuranosyl)-s-triazin-2(1H)-one; 4-Amino-1-(2-deoxy-beta-D-ribofuranosyl)-1,3,5-triazin-2(1H)-one; 4-amino-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one; 5-AZAdC; 5-Aza-2′-Deoxycytidine; 5-Aza-2'-deoxycytidine; 5-Azadeoxycytidine; 5-Deoxy-2′-azacytidine; 5-aza-2-deoxycytidine; 5-aza-CdR; 5-aza-dC; 5A2dc DMQL8XJ TC Anticancer Agents DMQL8XJ DT Small molecular drug DMQL8XJ PC 451668 DMQL8XJ MW 228.21 DMQL8XJ FM C8H12N4O4 DMQL8XJ IC InChI=1S/C8H12N4O4/c9-7-10-3-12(8(15)11-7)6-1-4(14)5(2-13)16-6/h3-6,13-14H,1-2H2,(H2,9,11,15)/t4-,5+,6+/m0/s1 DMQL8XJ CS C1[C@@H]([C@H](O[C@H]1N2C=NC(=NC2=O)N)CO)O DMQL8XJ IK XAUDJQYHKZQPEU-KVQBGUIXSA-N DMQL8XJ IU 4-amino-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one DMQL8XJ CA CAS 2353-33-5 DMQL8XJ CB CHEBI:50131 DMQL8XJ DE Myelodysplastic syndrome DM6ETS0 ID DM6ETS0 DM6ETS0 DN Deferasirox DM6ETS0 HS Approved DM6ETS0 SN Deferasirox; Deferasirox (Exjade); Deferasiroxum; Deferasiroxum [INN-Latin]; Exjade; V8G4MOF2V9; 201530-41-8; 4-(3,5-Bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl)benzoic acid; 4-[3,5-Bis(2-hydroxyphenyl)-1,2,4-triazol-1-yl]benzoic acid; 4-[3,5-bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl]benzoic acid; Benzoic acid, 4-[3,5-bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl]-; C21H15N3O4; CGP-72670; CHEBI:49005; DSSTox_CID_28522; DSSTox_RID_82794; ICL 670; ICL 670A; ICL-670; ICL-670A; ICL670; ICL670A; NCGC00181754-01; UNII-V8G4MOF2V9 DM6ETS0 PC 214348 DM6ETS0 MW 373.4 DM6ETS0 FM C21H15N3O4 DM6ETS0 IC BOFQWVMAQOTZIW-UHFFFAOYSA-N DM6ETS0 CS C1CCC(C(C1)CN2CCN(CC2)C3=NSC4=CC=CC=C43)CN5C(=O)C6C7CCC(C7)C6C5=O DM6ETS0 IK C1CCC(C(C1)CN2CCN(CC2)C3=NSC4=CC=CC=C43)CN5C(=O)C6C7CCC(C7)C6C5=O DM6ETS0 IU 4-[3,5-bis(2-hydroxyphenyl)-1,2,4-triazol-1-yl]benzoic acid DM6ETS0 CA C1CCC(C(C1)CN2CCN(CC2)C3=NSC4=CC=CC=C43)CN5C(=O)C6C7CCC(C7)C6C5=O DM6ETS0 CB CHEBI:49005 DM6ETS0 DE Hyperphosphatemia DMS2M7O ID DMS2M7O DMS2M7O DN Deferiprone DMS2M7O HS Approved DMS2M7O SN Ferriprox (TN) DMS2M7O CP ApoPharma DMS2M7O DT Small molecular drug DMS2M7O PC 2972 DMS2M7O MW 139.15 DMS2M7O FM C7H9NO2 DMS2M7O IC InChI=1S/C7H9NO2/c1-5-7(10)6(9)3-4-8(5)2/h3-4,10H,1-2H3 DMS2M7O CS CC1=C(C(=O)C=CN1C)O DMS2M7O IK TZXKOCQBRNJULO-UHFFFAOYSA-N DMS2M7O IU 3-hydroxy-1,2-dimethylpyridin-4-one DMS2M7O CA CAS 30652-11-0 DMS2M7O CB CHEBI:68554 DMS2M7O DE Thalassemia DMTUKZH ID DMTUKZH DMTUKZH DN Deferoxamine mesylate DMTUKZH HS Approved DMTUKZH SN Desferal DMTUKZH CP Novartis Pharmaceuticals Corp DMTUKZH DT Small molecular drug DMTUKZH PC 62881 DMTUKZH MW 656.8 DMTUKZH FM C26H52N6O11S DMTUKZH IC InChI=1S/C25H48N6O8.CH4O3S/c1-21(32)29(37)18-9-3-6-16-27-22(33)12-14-25(36)31(39)20-10-4-7-17-28-23(34)11-13-24(35)30(38)19-8-2-5-15-26;1-5(2,3)4/h37-39H,2-20,26H2,1H3,(H,27,33)(H,28,34);1H3,(H,2,3,4) DMTUKZH CS CC(=O)N(CCCCCNC(=O)CCC(=O)N(CCCCCNC(=O)CCC(=O)N(CCCCCN)O)O)O.CS(=O)(=O)O DMTUKZH IK IDDIJAWJANBQLJ-UHFFFAOYSA-N DMTUKZH IU N-[5-[[4-[5-[acetyl(hydroxy)amino]pentylamino]-4-oxobutanoyl]-hydroxyamino]pentyl]-N'-(5-aminopentyl)-N'-hydroxybutanediamide;methanesulfonic acid DMTUKZH CA CAS 138-14-7 DMTUKZH CB CHEBI:31460 DMTUKZH DE Acute iron or aluminum toxicity DMV0RNS ID DMV0RNS DMV0RNS DN Deflazacort DMV0RNS HS Approved DMV0RNS SN C25H33NO6; Deflazacort (Calcort); Deflazacortum [INN-Latin]; EINECS 238-483-7; Deflan (TN); D09WYX; AC1L1BQ2; Deflazacort [USAN:BAN:INN]; CTK8F9001; MolPort-035-394-927 DMV0RNS CP PTC Therapeutics DMV0RNS DT Small molecular drug DMV0RNS PC 189821 DMV0RNS MW 441.5 DMV0RNS FM C25H31NO6 DMV0RNS IC InChI=1S/C25H31NO6/c1-13-26-25(20(30)12-31-14(2)27)21(32-13)10-18-17-6-5-15-9-16(28)7-8-23(15,3)22(17)19(29)11-24(18,25)4/h7-9,17-19,21-22,29H,5-6,10-12H2,1-4H3/t17-,18-,19-,21+,22+,23-,24-,25+/m0/s1 DMV0RNS CS CC1=N[C@@]2([C@H](O1)C[C@@H]3[C@@]2(C[C@@H]([C@H]4[C@H]3CCC5=CC(=O)C=C[C@]45C)O)C)C(=O)COC(=O)C DMV0RNS IK FBHSPRKOSMHSIF-GRMWVWQJSA-N DMV0RNS IU [2-[(1S,2S,4R,8S,9S,11S,12S,13R)-11-hydroxy-6,9,13-trimethyl-16-oxo-5-oxa-7-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-6,14,17-trien-8-yl]-2-oxoethyl] acetate DMV0RNS CA CAS 14484-47-0 DMV0RNS CB CHEBI:135720 DMV0RNS DE Duchenne dystrophy DM3O8QY ID DM3O8QY DM3O8QY DN Degarelix DM3O8QY HS Approved DM3O8QY SN Degarelix; 214766-78-6; UNII-SX0XJI3A11; SX0XJI3A11; CHEMBL415606; Uglypeptide1; Degarelix (INN/USAN); Degarelix [USAN:INN:BAN]; SCHEMBL1397034; GTPL5585; HSDB 7817; CHEBI:135961; HY-16168A; BDBM50102450; AKOS030526717; AN-5181; RL02641; DB06699; CS-5350; FE200486 (AS ACETATE SALT); QC-10170; Z-3147; D08901; 766D786; Ac-D-Nal-[D-(pCl)Phe]-D-Pal-Ser-[Aph(DHor)]-D-[Aph(Cbm)]-Leu-ILys-Pro-DAla-NH2 DM3O8QY DT Small molecular drug DM3O8QY PC 16136245 DM3O8QY MW 1632.3 DM3O8QY FM C82H103ClN18O16 DM3O8QY IC InChI=1S/C82H103ClN18O16/c1-45(2)35-60(72(107)92-59(16-9-10-33-87-46(3)4)80(115)101-34-12-17-68(101)79(114)88-47(5)70(84)105)93-74(109)63(38-51-23-30-58(31-24-51)91-81(85)116)95-76(111)64(39-50-21-28-57(29-22-50)90-71(106)66-42-69(104)100-82(117)99-66)97-78(113)67(44-102)98-77(112)65(41-53-13-11-32-86-43-53)96-75(110)62(37-49-19-26-56(83)27-20-49)94-73(108)61(89-48(6)103)40-52-18-25-54-14-7-8-15-55(54)36-52/h7-8,11,13-15,18-32,36,43,45-47,59-68,87,102H,9-10,12,16-17,33-35,37-42,44H2,1-6H3,(H2,84,105)(H,88,114)(H,89,103)(H,90,106)(H,92,107)(H,93,109)(H,94,108)(H,95,111)(H,96,110)(H,97,113)(H,98,112)(H3,85,91,116)(H2,99,100,104,117)/t47-,59+,60+,61-,62-,63-,64+,65-,66+,67+,68+/m1/s1 DM3O8QY CS C[C@H](C(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCNC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=C(C=C2)NC(=O)N)NC(=O)[C@H](CC3=CC=C(C=C3)NC(=O)[C@@H]4CC(=O)NC(=O)N4)NC(=O)[C@H](CO)NC(=O)[C@@H](CC5=CN=CC=C5)NC(=O)[C@@H](CC6=CC=C(C=C6)Cl)NC(=O)[C@@H](CC7=CC8=CC=CC=C8C=C7)NC(=O)C DM3O8QY IK MEUCPCLKGZSHTA-XYAYPHGZSA-N DM3O8QY IU (4S)-N-[4-[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-[[(2R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[[(2R)-1-amino-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-6-(propan-2-ylamino)hexan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[4-(carbamoylamino)phenyl]-1-oxopropan-2-yl]amino]-3-oxopropyl]phenyl]-2,6-dioxo-1,3-diazinane-4-carboxamide DM3O8QY CA CAS 214766-78-6 DM3O8QY CB CHEBI:135961 DM3O8QY DE Prostate cancer DM4Q80H ID DM4Q80H DM4Q80H DN Dehydroepiandrosterone sulfate DM4Q80H HS Approved DM4Q80H SN Prasterone sulfate; DHEA sulfate; DEHYDROEPIANDROSTERONE SULFATE; Dehydroisoandrosterone sulfate; DHEAS; Dehydroepiandrosterone sulphate; Dehydroepiandrosterone monosulfate; 3-O-Sulfodehydroepiandrosterone; Dehydroepiandrosterone 3-sulfate; Dehydroandrosterone sulfate; Dehydroisoandrosterone-3-sulfate; 17-Ketoandrost-5-en-3beta-yl sulfate; DHEA-S; Androst-5-en-17-on-3beta-yl sulfuric acid; 3beta-Hydroxyandrost-5-en-17-one 3-sulfate; CCRIS 6746; (3-beta)-3-(Sulfooxy)androst-5-en-17-one; DHEA sulphate DM4Q80H PC 12594 DM4Q80H MW 368.5 DM4Q80H FM C19H28O5S DM4Q80H IC InChI=1S/C19H28O5S/c1-18-9-7-13(24-25(21,22)23)11-12(18)3-4-14-15-5-6-17(20)19(15,2)10-8-16(14)18/h3,13-16H,4-11H2,1-2H3,(H,21,22,23)/t13-,14-,15-,16-,18-,19-/m0/s1 DM4Q80H CS CC12CCC3C(C1CCC2=O)CC=C4C3(CCC(C4)OS(=O)(=O)O)C DM4Q80H IK CZWCKYRVOZZJNM-USOAJAOKSA-N DM4Q80H IU [(3S,8R,9S,10R,13S,14S)-10,13-dimethyl-17-oxo-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-yl] hydrogen sulfate DM4Q80H CA CAS 651-48-9 DM4Q80H CB CHEBI:16814 DM4Q80H DE Dyspareunia DMVTU5Q ID DMVTU5Q DMVTU5Q DN Delafloxacin Meglumine DMVTU5Q HS Approved DMVTU5Q SN Baxdela DMVTU5Q CP Melinta Therapeutics DMVTU5Q DT Small molecular drug DMVTU5Q PC 11578213 DMVTU5Q MW 636 DMVTU5Q FM C25H29ClF3N5O9 DMVTU5Q IC InChI=1S/C18H12ClF3N4O4.C7H17NO5/c19-12-13-7(1-9(20)14(12)25-3-6(27)4-25)15(28)8(18(29)30)5-26(13)17-11(22)2-10(21)16(23)24-17;1-8-2-4(10)6(12)7(13)5(11)3-9/h1-2,5-6,27H,3-4H2,(H2,23,24)(H,29,30);4-13H,2-3H2,1H3/t;4-,5+,6+,7+/m.0/s1 DMVTU5Q CS CNC[C@@H]([C@H]([C@@H]([C@@H](CO)O)O)O)O.C1C(CN1C2=C(C=C3C(=C2Cl)N(C=C(C3=O)C(=O)O)C4=C(C=C(C(=N4)N)F)F)F)O DMVTU5Q IK AHJGUEMIZPMAMR-WZTVWXICSA-N DMVTU5Q IU 1-(6-amino-3,5-difluoropyridin-2-yl)-8-chloro-6-fluoro-7-(3-hydroxyazetidin-1-yl)-4-oxoquinoline-3-carboxylic acid;(2R,3R,4R,5S)-6-(methylamino)hexane-1,2,3,4,5-pentol DMVTU5Q CA CAS 352458-37-8 DMVTU5Q DE Acute bacterial skin infection; Skin infection DMXE76K ID DMXE76K DMXE76K DN Delamanid DMXE76K HS Approved DMXE76K SN OPC-67683; Nitro-dihydroimidazo-oxazole derivatives (tuberculosis), Otsuka; 2-nitroimidazole derivatives (tuberculosis), Otsuka DMXE76K CP Otsuka pharmaceutical DMXE76K DT Small molecular drug DMXE76K PC 6480466 DMXE76K MW 534.5 DMXE76K FM C25H25F3N4O6 DMXE76K IC InChI=1S/C25H25F3N4O6/c1-24(15-31-14-22(32(33)34)29-23(31)38-24)16-35-18-4-2-17(3-5-18)30-12-10-20(11-13-30)36-19-6-8-21(9-7-19)37-25(26,27)28/h2-9,14,20H,10-13,15-16H2,1H3/t24-/m1/s1 DMXE76K CS C[C@@]1(CN2C=C(N=C2O1)[N+](=O)[O-])COC3=CC=C(C=C3)N4CCC(CC4)OC5=CC=C(C=C5)OC(F)(F)F DMXE76K IK XDAOLTSRNUSPPH-XMMPIXPASA-N DMXE76K IU (2R)-2-methyl-6-nitro-2-[[4-[4-[4-(trifluoromethoxy)phenoxy]piperidin-1-yl]phenoxy]methyl]-3H-imidazo[2,1-b][1,3]oxazole DMXE76K CA CAS 681492-22-8 DMXE76K CB CHEBI:134742 DMXE76K DE Mycobacterium infection; Multi-drug resistant tuberculosis DM7EUK3 ID DM7EUK3 DM7EUK3 DN Delapril DM7EUK3 HS Approved DM7EUK3 SN Adecut (TN) DM7EUK3 CP Takeda DM7EUK3 DT Small molecular drug DM7EUK3 PC 5362116 DM7EUK3 MW 452.5 DM7EUK3 FM C26H32N2O5 DM7EUK3 IC InChI=1S/C26H32N2O5/c1-3-33-26(32)23(14-13-19-9-5-4-6-10-19)27-18(2)25(31)28(17-24(29)30)22-15-20-11-7-8-12-21(20)16-22/h4-12,18,22-23,27H,3,13-17H2,1-2H3,(H,29,30)/t18-,23-/m0/s1 DM7EUK3 CS CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N(CC(=O)O)C2CC3=CC=CC=C3C2 DM7EUK3 IK WOUOLAUOZXOLJQ-MBSDFSHPSA-N DM7EUK3 IU 2-[2,3-dihydro-1H-inden-2-yl-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]amino]acetic acid DM7EUK3 CA CAS 83435-66-9 DM7EUK3 CB CHEBI:135735 DM7EUK3 DE Cardiovascular disease DM3NF5G ID DM3NF5G DM3NF5G DN Delavirdine DM3NF5G HS Approved DM3NF5G SN DLV; Rescriptor; SPP; DELAVIRDINE MESYLATE; Delavirdine [INN]; U 90152; BHAP-U 90152; Delavirdine (INN); Rescriptor (TM);Rescriptor (TN); U-90152; U-90152S; PNU-90152-T; Delavirdine (*Mesylate salt*); U90152S (*Mesylate salt*); Delavirdine(U-90152) & .a.IFN; N-[2-[4-[3-(propan-2-ylamino)pyridin-2-yl]piperazine-1-carbonyl]-1H-indol-5-yl]methanesulfonamide; N-(2-(1-(3-(isopropylamino)pyridin-2-yl)piperazine-4-carbonyl)-1H-indol-5-yl)methanesulfonamide; N-[2-({4-[3-(propan-2-ylamino)pyridin-2-yl]piperazin-1-yl}carbonyl)-1H-indol-5-yl]methanesulfonamide; N-{2-[(4-{3-[(1-methylethyl)amino]pyridin-2-yl}piperazin-1-yl)carbonyl]-1H-indol-5-yl}methanesulfonamide; N-{2-[4-(3-Isopropylamino-pyridin-2-yl)-piperazine-1-carbonyl]-1H-indol-5-yl}-methanesulfonamide; Piperazine, 1-[3-[(1-methylethyl)amino]-2-pyridinyl]-4-[[5-[(methylsulfonyl)amino]-1H-indol-2-yl]carbonyl]-& alpha-Interferon; (1-(5-METHANSULPHONAMIDO-1H-INDOL-2-YL-CARBONYL)4-[METHYLAMINO)PYRIDINYL]PIPERAZINE; (N-[2-[4-[3-(1-methylethylamino)pyridin-2-yl]piperazin-1-yl]carbonyl-1H-indol-5-yl] methanesulfonamide); 1-(3-((1-Methylethyl)amino)-2-pyridinyl)-4-((5-((methylsulfonyl)amino)-1H-indol-2-yl)carbonyl)piperazine; 1-(5-Methanesulphonamido)-1H-indol-2-yl-carbonyl)-4-[3-(isopropylamino)-2-pyridinyl]piperaz; 2-(4-(5-Methanesulfonamido-1H-indol-2-ylcarbonyl)-1-piperazinyl)-N-(1-methylethyl)-3-pyridinamine DM3NF5G CP Pfizer Pharmaceuticals DM3NF5G TC Anti-HIV Agents DM3NF5G DT Small molecular drug DM3NF5G PC 5625 DM3NF5G MW 456.6 DM3NF5G FM C22H28N6O3S DM3NF5G IC InChI=1S/C22H28N6O3S/c1-15(2)24-19-5-4-8-23-21(19)27-9-11-28(12-10-27)22(29)20-14-16-13-17(26-32(3,30)31)6-7-18(16)25-20/h4-8,13-15,24-26H,9-12H2,1-3H3 DM3NF5G CS CC(C)NC1=C(N=CC=C1)N2CCN(CC2)C(=O)C3=CC4=C(N3)C=CC(=C4)NS(=O)(=O)C DM3NF5G IK WHBIGIKBNXZKFE-UHFFFAOYSA-N DM3NF5G IU N-[2-[4-[3-(propan-2-ylamino)pyridin-2-yl]piperazine-1-carbonyl]-1H-indol-5-yl]methanesulfonamide DM3NF5G CA CAS 136817-59-9 DM3NF5G CB CHEBI:119573 DM3NF5G DE Human immunodeficiency virus infection DMAYEU1 ID DMAYEU1 DMAYEU1 DN Demecarium bromide DMAYEU1 HS Approved DMAYEU1 SN Demecarium; Demecastigmine; Frumtosnil; Humorsol; Tonilen; Tosmicil; Tosmilen; Tosmilene; Visumatic; Visumiotic;Bromure de demecarium; Bromuro de demecario; Demecarii bromidum; Demekarium bromide; Demekastigmine bromide; BC 48; Bromure de demecarium [INN-French]; Bromuro de demecario [INN-Spanish]; Demecarii bromidum [INN-Latin]; Demecarium bromide [INN:BAN]; Humorsol (TN); Decamethylenebis[m-dimethylaminophenyl n-methylcarbamate] dimethobromide; Demecarium bromide (USP/INN); Decamethylenebis(N-methylcarbamic acid m-dimethylaminophenyl ester) bromomethylate; Decamethylenebis(m-dimethylaminophenyl-N-methylcarbamate) dimethobromide; Decamethylenebis(m-dimethylaminophenyl-N-methylcarbamate)dimethobromide;Ammonium, (m-hydroxyphenyl)trimethyl-, bromide, decamethylenebis(methylcarbamate); Trimethyl-[3-[methyl-[10-[methyl-[3-(trimethylazaniumyl)phenoxy]carbonylamino]decyl]carbamoyl]oxyphenyl]azanium dibromide; Ammonium, (m-hydroxyphenyl)trimethyl-, bromide, decamethylenebis(methylcarbamate) (2:1); N,N'-Bis(3-trimethylammoniumphenoxycarbonyl)-N,N'-dimethyldecamethylenediamine dibromide; Benzenaminium,3,3'-(1,10-decanediylbis((methylimino)carbonyloxy))bis(N,N,N-trimethyl-, dibromide; (m-Hydroxyphenyl)trimethylammonium bromide decamethylenebis(methylcarbamate); (m-Hydroxyphenyl)trimethylammonium bromide decamethylenebis(methylcarbamate) (2:1); (m-Hydroxyphenyl)trimethylammonium bromide decamethylenebis(methylcarbamate) (7CI); 3,3'-{decane-1,10-diylbis[(methylcarbamoyl)oxy]}bis(N,N,N-trimethylanilinium) dibromide DMAYEU1 TC Parasympathomimetics DMAYEU1 DT Small molecular drug DMAYEU1 PC 5965 DMAYEU1 MW 716.6 DMAYEU1 FM C32H52Br2N4O4 DMAYEU1 IC InChI=1S/C32H52N4O4.2BrH/c1-33(31(37)39-29-21-17-19-27(25-29)35(3,4)5)23-15-13-11-9-10-12-14-16-24-34(2)32(38)40-30-22-18-20-28(26-30)36(6,7)8;;/h17-22,25-26H,9-16,23-24H2,1-8H3;2*1H/q+2;;/p-2 DMAYEU1 CS CN(CCCCCCCCCCN(C)C(=O)OC1=CC=CC(=C1)[N+](C)(C)C)C(=O)OC2=CC=CC(=C2)[N+](C)(C)C.[Br-].[Br-] DMAYEU1 IK YHKBUDZECQDYBR-UHFFFAOYSA-L DMAYEU1 IU trimethyl-[3-[methyl-[10-[methyl-[3-(trimethylazaniumyl)phenoxy]carbonylamino]decyl]carbamoyl]oxyphenyl]azanium;dibromide DMAYEU1 CA CAS 56-94-0 DMAYEU1 CB CHEBI:4391 DMAYEU1 DE Open-angle glaucoma DMZEPFJ ID DMZEPFJ DMZEPFJ DN Demeclocycline DMZEPFJ HS Approved DMZEPFJ SN Bioterciclin; Clortetrin; DMCT; DMCTC; Declomycin; Deganol; Demeclociclina; Demeclocyclinum; Demeclor; Demethylchlorotetracycline; Demethylchlortetracyclin; Demethylchlortetracycline; Demethylchlortetracyclinum; Demetraclin; Diuciclin; Ledermycin; Methylchlorotetracycline; Mexocine; Novotriclina; Perciclina; Sumaclina; Demeclocycline Monohydrochloride; Demethylchlortetracycline base; Ledermycin hydrochloride; RP 10192; DMCT (antibiotic); Declomycin (TN); Declostatin (TN); Demeclociclina [INN-Spanish]; Demeclocycline (USP); Demeclocycline [USAN:BAN]; Demeclocyclinum [INN-Latin]; Demethylchlortetracycline (JAN); Ledermycin (TN); Tri-demethylchlortetracycline; [4S-(4alpha,4aalpha,5aalpha,6beta,12aalpha)]-7-chloro-4-(dimethylamino)1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-1,11-dioxo-2-naphthacenecarboxamide; (2E)-2-[amino(hydroxy)methylidene]-7-chloro-4-(dimethylamino)-6,10,11,12a-tetrahydroxy-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione; (2E,4S,4aS,5aS,6R,12aR)-2-[amino(hydroxy)methylidene]-7-chloro-4-(dimethylamino)-6,10,11,12a-tetrahydroxy-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione; (2E,4S,4aS,5aS,6S,12aS)-2-[amino(hydroxy)methylidene]-7-chloro-4-(dimethylamino)-6,10,11,12a-tetrahydroxy-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione; (2Z,4S,4aS,5aS,6S,12aS)-2-[amino(hydroxy)methylidene]-7-chloro-4-(dimethylamino)-6,10,11,12a-tetrahydroxy-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione; (4S,4aS,5aS,6S,12aS)-7-chloro-4-(dimethylamino)-3,6,10,12,12a-pentahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide; 2-[amino(hydroxy)methylidene]-7-chloro-4-(dimethylamino)-6,10,11,12a-tetrahydroxy-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione; 6-Demethyl-7-chlorotetracycline; 6-Demethyl-7-chlortetracycline; 6-Demethylchlorotetracycline; 6-Demethylchlortetracycline; 6-Demetil-7-clorotetraciclina; 6-Demetil-7-clorotetraciclina [Italian]; 7-Chloro-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-1,11-dioxo-2-naphthacenecarboxamide; 7-Chloro-4-dimethylamino-3,6,10,12,12a-pentahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydro-naphthacene-2-carboxylic acid amide; 7-Chloro-6-demethyltetracycline DMZEPFJ CP Patheon Pharmaceuticals Inc DMZEPFJ TC Antibiotics DMZEPFJ DT Small molecular drug DMZEPFJ PC 54680690 DMZEPFJ MW 464.9 DMZEPFJ FM C21H21ClN2O8 DMZEPFJ IC InChI=1S/C21H21ClN2O8/c1-24(2)14-7-5-6-10(16(27)12-9(25)4-3-8(22)11(12)15(6)26)18(29)21(7,32)19(30)13(17(14)28)20(23)31/h3-4,6-7,14-15,25-27,30,32H,5H2,1-2H3,(H2,23,31)/t6-,7-,14-,15-,21-/m0/s1 DMZEPFJ CS CN(C)[C@H]1[C@@H]2C[C@@H]3[C@@H](C4=C(C=CC(=C4C(=C3C(=O)[C@@]2(C(=C(C1=O)C(=O)N)O)O)O)O)Cl)O DMZEPFJ IK GUXHBMASAHGULD-SEYHBJAFSA-N DMZEPFJ IU (4S,4aS,5aS,6S,12aR)-7-chloro-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4H-tetracene-2-carboxamide DMZEPFJ CA CAS 127-33-3 DMZEPFJ CB CHEBI:4392 DMZEPFJ DE Bronchitis; Acne vulgaris; Lyme disease DMCZQGK ID DMCZQGK DMCZQGK DN Demecolcine DMCZQGK HS Approved DMCZQGK SN colcemid; 1,2,3,10-tetramethoxy-7-(methylamino)-6,7-dihydro-5H-benzo[a]heptalen-9-one; demecolcine,colcemid, n-deacetyl-n-methylcolchicine, n-methyl-n-desacetylcolchicine; Demicolcine; NSC3096; 1,2,3,10-Tetramethoxy-7-(methylamino)-6,7-dihydrobenzo[a]heptalen-9(5H)-one; NCGC00166035-01; AC1L1EKK; MolMap_000011; SCHEMBL8160; AC1Q698E; CHEMBL433632; CTK8E8505; MolPort-003-846-192; 6,7-Dihydro-1,2,3,10-Tetramethoxy-7-(Methylamino) Benzo (alpha) Heptalen-9(5H)-one; HMS3374M04; HSCI1_000384; BBL027927; STL377913; CD0013 DMCZQGK DT Small molecular drug DMCZQGK PC 220401 DMCZQGK MW 371.4 DMCZQGK FM C21H25NO5 DMCZQGK IC InChI=1S/C21H25NO5/c1-22-15-8-6-12-10-18(25-3)20(26-4)21(27-5)19(12)13-7-9-17(24-2)16(23)11-14(13)15/h7,9-11,15,22H,6,8H2,1-5H3/t15-/m0/s1 DMCZQGK CS CN[C@H]1CCC2=CC(=C(C(=C2C3=CC=C(C(=O)C=C13)OC)OC)OC)OC DMCZQGK IK NNJPGOLRFBJNIW-HNNXBMFYSA-N DMCZQGK IU (7S)-1,2,3,10-tetramethoxy-7-(methylamino)-6,7-dihydro-5H-benzo[a]heptalen-9-one DMCZQGK CA CAS 477-30-5 DMCZQGK CB CHEBI:4393 DMCZQGK DE Solid tumour/cancer DMMHR1U ID DMMHR1U DMMHR1U DN Denileukin diftitox DMMHR1U HS Approved DMMHR1U CP Louisville DMMHR1U TC Anticancer Agents DMMHR1U SQ DB00004 sequence: MGADDVVDSSKSFVMENFSSYHGTKPGYVDSIQKGIQKPKSGTQGNYDDDWKGFYSTDNKYDAAGYSVDNENPLSGKAGGVVKVTYPGLTKVLALKVDNAETIKKELGLSLTEPLMEQVGTEEFIKRFGDGASRVVLSLPFAEGSSSVEYINNWEQAKALSVELEINFETRGKRGQDAMYEYMAQACAGNRVRRSVGSSLSCINLDWDVIRDKTKTKIESLKEHGPIKNKMSESPNKTVSEEKAKQYLEEFHQTALEHPELSELKTVTGTNPVFAGANYAAWAVNVAQVIDSETADNLEKTTAALSILPGIGSVMGIADGAVHHNTEEIVAQSIALSSLMVAQAIPLVGELVDIGFAAYNFVESIINLFQVVHNSYNRPAYSPGHKTHAPTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTRMLTFKFYMPKKATELKHLQCLEEELKPLEEVLNLAQSKNFHLRPRDLISNINVIVLELKGSETTFMCEYADETATIVEFLNRWITFCQSIISTLT DMMHR1U DE leukaemia; Non-small-cell lung cancer DM8C3GN ID DM8C3GN DM8C3GN DN Denopamine DM8C3GN HS Approved DM8C3GN SN Kalgut (TN) DM8C3GN DT Small molecular drug DM8C3GN PC 5311064 DM8C3GN MW 317.4 DM8C3GN FM C18H23NO4 DM8C3GN IC InChI=1S/C18H23NO4/c1-22-17-8-3-13(11-18(17)23-2)9-10-19-12-16(21)14-4-6-15(20)7-5-14/h3-8,11,16,19-21H,9-10,12H2,1-2H3/t16-/m0/s1 DM8C3GN CS COC1=C(C=C(C=C1)CCNC[C@@H](C2=CC=C(C=C2)O)O)OC DM8C3GN IK VHSBBVZJABQOSG-INIZCTEOSA-N DM8C3GN IU 4-[(1R)-2-[2-(3,4-dimethoxyphenyl)ethylamino]-1-hydroxyethyl]phenol DM8C3GN CA CAS 71771-90-9 DM8C3GN CB CHEBI:135359 DM8C3GN DE Cardiac disease DMNI0KO ID DMNI0KO DMNI0KO DN Denosumab DMNI0KO HS Approved DMNI0KO SN Denosumab (USAN); Denosumab (genetical recombination); Prolia (TN); Denosumab (genetical recombination) (JAN) DMNI0KO CP Amgen DMNI0KO DT Antibody DMNI0KO SQ Denosumab OPGL-1 heavy chain sequence: EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSGITGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDPGTTVIMSWFDPWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK > Denosumab OPGL-1 light chain sequenceEIVLTQSPGTLSLSPGERATLSCRASQSVRGRYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVFYCQQYGSSPRTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC DMNI0KO DE Postmenopausal osteoporosis; Rheumatoid arthritis; Prostate cancer DM3GYAL ID DM3GYAL DM3GYAL DN Deoxycholic acid DM3GYAL HS Approved DM3GYAL SN (3alpha,5beta,12alpha)-3,12-Dihydroxycholan-24-oic acid; 3,12-Dihydroxycholanic acid; 3alpha,12alpha-Dihydroxy-5beta-cholan-24-oic acid; 3alpha,12alpha-Dihydroxy-5beta-cholanic acid; 5-beta-Deoxycholic acid; 7-Deoxycholic acid; 7alpha-Deoxycholic acid; ATX-101; Choleic acid; Cholerebic; Cholic acid, deoxy-; Cholorebic; DEOXYCHOLIC ACID; Degalol; Deoxy cholic acid; Deoxycholatic acid; Desoxycholic acid; Desoxycholsaeure; Dihydroxycholanoic acid; Droxolan; Pyrochol; Septochol; Sodium deoxycholate; deoxycholate DM3GYAL DT Small molecular drug DM3GYAL PC 222528 DM3GYAL MW 392.58 DM3GYAL FM C24H40O4 DM3GYAL IC InChI=1S/C24H40O4/c1-14(4-9-22(27)28)18-7-8-19-17-6-5-15-12-16(25)10-11-23(15,2)20(17)13-21(26)24(18,19)3/h14-21,25-26H,4-13H2,1-3H3,(H,27,28)/t14-,15-,16-,17+,18-,19+,20+,21+,23+,24-/m1/s1 DM3GYAL CS CC(CCC(=O)O)C1CCC2C1(C(CC3C2CCC4C3(CCC(C4)O)C)O)C DM3GYAL IK KXGVEGMKQFWNSR-LLQZFEROSA-N DM3GYAL IU (4R)-4-[(3R,5R,8R,9S,10S,12S,13R,14S,17R)-3,12-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid DM3GYAL CA CAS 83-44-3 DM3GYAL CB CHEBI:28834 DM3GYAL DE Fat below the chin DMYE5LJ ID DMYE5LJ DMYE5LJ DN DEOXYCYTIDINE DMYE5LJ HS Approved DMYE5LJ SN Cytosine deoxyribonucleoside; 2'-dC; bmse000323; ACMC-209rv6; CYTIDINE, 2'-DEOXY-; Cytosine deoxy nucleoside hydrochloride; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2(1H)-one; Desoxycytidine; 4-amino-1-(2-deoxypentofuranosyl)pyrimidin-2(1H)-one; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2-one; 3h-deoxycytidine; 4-amino-1-(4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one; 40093-94-5; AC1L19OG; TimTec1_003892; NCIOpen2_004589; Oprea1_817993 DMYE5LJ DT Small molecular drug DMYE5LJ PC 13711 DMYE5LJ MW 227.22 DMYE5LJ FM C9H13N3O4 DMYE5LJ IC InChI=1S/C9H13N3O4/c10-7-1-2-12(9(15)11-7)8-3-5(14)6(4-13)16-8/h1-2,5-6,8,13-14H,3-4H2,(H2,10,11,15)/t5-,6+,8+/m0/s1 DMYE5LJ CS C1[C@@H]([C@H](O[C@H]1N2C=CC(=NC2=O)N)CO)O DMYE5LJ IK CKTSBUTUHBMZGZ-SHYZEUOFSA-N DMYE5LJ IU 4-amino-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one DMYE5LJ CA CAS 951-77-9 DMYE5LJ CB CHEBI:15698 DMYE5LJ DE Acute myeloid leukaemia DMRH7CV ID DMRH7CV DMRH7CV DN Deserpidine DMRH7CV HS Approved DMRH7CV SN Canescin; Canescine; Deresperine; Desepridine; Deserpidin; Deserpidina; Deserpidinum; Desmethoxyreserpine; Halmonyl; Harmonyl; Raunormin; Raunormine; Recanescin; Recanescine; Reserpidine; Tranquinil; Lilly 22641; ORETICYL 50; A-11025; Deserpidina [INN-Spanish]; Deserpidine (INN); Deserpidine [INN:BAN]; Deserpidinum [INN-Latin]; Halmonyl (TN); MD-0232; Deserpidic acid, methyl ester, 3,4,5-trimethoxybenzoate; Methyl 17alpha-methoxy-18beta-(3,4,5-trimethoxybenzoyloxy)-3beta,20alpha-yohimban-16beta-carboxylat; Methyl 17alpha-methoxy-18beta-((3,4,5-trimethoxybenzoyl)oxy)-3beta,20alpha-yohimban-16beta-carboxylate; Methyl 18beta-hydroxy-17alpha-methoxy-3beta,20alpha-yohimban-16beta-carboxylate, 3,4,5-trimethoxybenzoate (ester); Methyl (3beta,16beta,17alpha,18beta,20alpha)-17-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]yohimban-16-carboxylate; Methyl (3beta,16beta,17alpha,18beta,20alpha)-17-(methyloxy)-18-({[3,4,5-tris(methyloxy)phenyl]carbonyl}oxy)yohimban-16-carboxylate; Benz[g]indolo[2,3-a]quinolizine-1-carboxylic acid, 1,2,3,4,4a,5,7,8,-13,13b,14,14a-dodecahydro-3-hydroxy-2-methoxy-, methyl ester, 3,4,5-trimethoxybenzoate; (3beta,16beta,17alpha,18beta,20alpha)-17-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]yohimban-16-carboxylic acid methyl ester; 11-Demethoxyreserpine; 11-Desmethoxyreserpine; 17.alpha.-Methoxy-18.beta.-[(3,4,5-trimethoxybenzoyl)oxy]-3.beta.,20.alpha.-yohimban-16.beta.-carboxylic acid methyl ester; 3-beta,20-alpha-Yohimban-16-beta-carboxylic acid, 18-beta-hydroxy-17-alpha-methoxy-, methyl ester, 3,4,5-trimethoxybenzoate (ester); 3-beta,20-alpha-Yohimban-16-beta-carboxylic acid, 18-beta-hydroxy-17-alpha-methoxy-,methyl ester, 3,4,5-trimethoxybenzoate (ester) DMRH7CV TC Antihypertensive Agents DMRH7CV DT Small molecular drug DMRH7CV PC 8550 DMRH7CV MW 578.7 DMRH7CV FM C32H38N2O8 DMRH7CV IC InChI=1S/C32H38N2O8/c1-37-24-12-17(13-25(38-2)29(24)39-3)31(35)42-26-14-18-16-34-11-10-20-19-8-6-7-9-22(19)33-28(20)23(34)15-21(18)27(30(26)40-4)32(36)41-5/h6-9,12-13,18,21,23,26-27,30,33H,10-11,14-16H2,1-5H3/t18-,21+,23-,26-,27+,30+/m1/s1 DMRH7CV CS CO[C@H]1[C@@H](C[C@@H]2CN3CCC4=C([C@H]3C[C@@H]2[C@@H]1C(=O)OC)NC5=CC=CC=C45)OC(=O)C6=CC(=C(C(=C6)OC)OC)OC DMRH7CV IK CVBMAZKKCSYWQR-WCGOZPBSSA-N DMRH7CV IU methyl (1R,15S,17R,18R,19S,20S)-18-methoxy-17-(3,4,5-trimethoxybenzoyl)oxy-1,3,11,12,14,15,16,17,18,19,20,21-dodecahydroyohimban-19-carboxylate DMRH7CV CA CAS 131-01-1 DMRH7CV CB CHEBI:27478 DMRH7CV DE Hypertension DM2TO9R ID DM2TO9R DM2TO9R DN Desflurane DM2TO9R HS Approved DM2TO9R SN Desflurano; Desfluranum; Suprane; I 653; I653; PC6781E; Desflurane [USAN:INN]; Desflurano [INN-Spanish]; Desfluranum [INN-Latin]; I-653; R-e 236ea1; Suprane (TN); Desflurane (JAN/USP/INN); Difluoromethyl 1,2,2,2-tetrafluoroethyl ether; (+-)-2-Difluoromethyl 1,2,2,2-tetrafluoroethyl ether; 1,1,1,2-tetrafluoro-2-(difluoromethoxy)ethane; 2-(difluoromethoxy)-1,1,1,2-tetrafluoroethane DM2TO9R TC Anesthetics DM2TO9R DT Small molecular drug DM2TO9R PC 42113 DM2TO9R MW 168.04 DM2TO9R FM C3H2F6O DM2TO9R IC InChI=1S/C3H2F6O/c4-1(3(7,8)9)10-2(5)6/h1-2H DM2TO9R CS C(C(F)(F)F)(OC(F)F)F DM2TO9R IK DPYMFVXJLLWWEU-UHFFFAOYSA-N DM2TO9R IU 2-(difluoromethoxy)-1,1,1,2-tetrafluoroethane DM2TO9R CA CAS 57041-67-5 DM2TO9R CB CHEBI:4445 DM2TO9R DE Anaesthesia DMT2FDC ID DMT2FDC DMT2FDC DN Desipramine DMT2FDC HS Approved DMT2FDC SN Demethylimipramine; Desimipramine; Desimpramine; Desipramin; Desipramina; Desipraminum; Desmethylimipramine; Dezipramine; Dimethylimipramine; Methylaminopropyliminodibenzyl; Monodemethylimipramine; Norimipramine; Norpramine; Pentofran; Pertrofane; Sertofran; Desipramine Hcl; DMI 50475; DMI (pharmaceutical); Desipramina [INN-Spanish]; Desipramine (D4); Desipramine (INN); Desipramine [INN:BAN]; Desipraminum [INN-Latin]; Norpramin (TN); Pertofrane (TN); ZERO/006017; N-(3-Methylaminopropyl)iminobibenzyl; (3-(10H,11H-Dibenzo[b,f]azepin-5-yl)propyl)methylamine; 10, 11-Dihydro-N-methyl-5H-dibez[b,f]azepine-5-propanamine; 10,11-Dihydro-5-(3-methylaminopropyl)-5H-dibenz(b,f)azepine; 3-(10,11-DIHYDRO-5H-DIBENZO[B,F]AZEPIN-5-YL)-N-METHYLPROPAN-1-AMINE; 3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N-methylpropan-1-amine; 5-(gamma-Methylaminopropyl)iminodibenzyl DMT2FDC CP Sanofi Aventis Us Llc DMT2FDC TC Antidepressants DMT2FDC DT Small molecular drug DMT2FDC PC 2995 DMT2FDC MW 266.4 DMT2FDC FM C18H22N2 DMT2FDC IC InChI=1S/C18H22N2/c1-19-13-6-14-20-17-9-4-2-7-15(17)11-12-16-8-3-5-10-18(16)20/h2-5,7-10,19H,6,11-14H2,1H3 DMT2FDC CS CNCCCN1C2=CC=CC=C2CCC3=CC=CC=C31 DMT2FDC IK HCYAFALTSJYZDH-UHFFFAOYSA-N DMT2FDC IU 3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N-methylpropan-1-amine DMT2FDC CA CAS 50-47-5 DMT2FDC CB CHEBI:47781 DMT2FDC DE Attention deficit hyperactivity disorder; Depression DM2BTFN ID DM2BTFN DM2BTFN DN Desirudin Recombinant DM2BTFN HS Approved DM2BTFN SN Iprivask DM2BTFN CP Valeant Pharmaceuticals North America Llc DM2BTFN TC Cardiovascular Agents DM2BTFN DE Coagulation defect DMB3ZSK ID DMB3ZSK DMB3ZSK DN Deslanoside DMB3ZSK HS Approved DMB3ZSK SN Ceglunat; Desace; Deslanosido; Deslanosidum; Glucodigoxin; Lekozid; Sediranido; Deacetyllanatoside C; DesacetylLanatoside; Desacetyldigilanide C; Desacetyllanatoside C; Deslanatoside C; Deslanosidum C; Lanatosid C; Cedilanid-D; Desacetyl-Lanatoside C; Deslanosido [INN-Spanish]; Deslanosidum [INN-Latin]; Cedilanid-d (TN); Deslanoside (JP15/USP/INN); Deslanoside [USAN:BAN:INN:JAN]; (3beta,5beta,12beta)-3-{[beta-D-glucopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl]oxy}-12,14-dihydroxycard-20(22)-enolide; 3-[(O-beta-D-glucopyranosyl-(1->4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl)oxy]-12,14-dihydroxy-3beta,5beta,12beta-card-20(22)-enolide; 3beta-(O-beta-D-Glucopyranosyl-(1-4)-O-beta-D-digitoxosyl-(1-4)-O-beta-D-digitoxosyl-(1-4)-beta-D-digitoxosyloxy-12beta,14-dihydroxy-5beta,14beta-card-20(22)-enolid; 3beta-(O-beta-D-Glucopyranosyl-(1-4)-O-beta-D-digitoxosyl-(1-4)-O-beta-D-digitoxosyl-(1-4)-beta-D-digitoxosyloxy=12beta.14=dihydroxy-5beta,14beta-card-20(22)-enolid; 3beta-{[beta-D-glucopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl]oxy}-12beta,14-dihydroxy-5beta-card-20(22)-enolide DMB3ZSK TC Antiarrhythmic Agents DMB3ZSK DT Small molecular drug DMB3ZSK PC 28620 DMB3ZSK MW 943.1 DMB3ZSK FM C47H74O19 DMB3ZSK IC InChI=1S/C47H74O19/c1-20-41(64-36-16-30(50)42(21(2)60-36)65-37-17-31(51)43(22(3)61-37)66-44-40(56)39(55)38(54)32(18-48)63-44)29(49)15-35(59-20)62-25-8-10-45(4)24(13-25)6-7-27-28(45)14-33(52)46(5)26(9-11-47(27,46)57)23-12-34(53)58-19-23/h12,20-22,24-33,35-44,48-52,54-57H,6-11,13-19H2,1-5H3/t20-,21-,22-,24-,25+,26-,27-,28+,29+,30+,31+,32-,33-,35+,36+,37+,38-,39+,40-,41-,42-,43-,44+,45+,46+,47+/m1/s1 DMB3ZSK CS C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2CC[C@]3([C@@H](C2)CC[C@@H]4[C@@H]3C[C@H]([C@]5([C@@]4(CC[C@@H]5C6=CC(=O)OC6)O)C)O)C)O)O[C@H]7C[C@@H]([C@@H]([C@H](O7)C)O[C@H]8C[C@@H]([C@@H]([C@H](O8)C)O[C@H]9[C@@H]([C@H]([C@@H]([C@H](O9)CO)O)O)O)O)O DMB3ZSK IK OBATZBGFDSVCJD-LALPQLPRSA-N DMB3ZSK IU 3-[(3S,5R,8R,9S,10S,12R,13S,14S,17R)-12,14-dihydroxy-3-[(2R,4S,5S,6R)-4-hydroxy-5-[(2S,4S,5S,6R)-4-hydroxy-5-[(2S,4S,5S,6R)-4-hydroxy-6-methyl-5-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-6-methyloxan-2-yl]oxy-6-methyloxan-2-yl]oxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2H-furan-5-one DMB3ZSK CA CAS 17598-65-1 DMB3ZSK CB CHEBI:31468 DMB3ZSK DE Heart failure; Arrhythmia; Congestive cardiac insufficiency DM56YN7 ID DM56YN7 DM56YN7 DN Desloratadine DM56YN7 HS Approved DM56YN7 SN Aerius; Allex; Azomyr; Claramax; Clarinex; Denosin; Desalex; Descarboethoxyloratadine; Descarboethoxyoratidine; Desloratidine; Neoclarityn; Opulis; Clarinex RediTabs; Desloratadine [USAN]; Essex brand of desloratadine; Schering brand of desloratadine; Sch 34117; Aerius (TN); Claramax (TN); Clarinex (TN); NeoClarityn (TN); Sch-34117; Schering-Plough brand of desloratadine; Desloratadine (USAN/INN); 8-Chloro-11-piperidin-4-ylidene-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine; 8-Chloro-6,11-dihydro-11-(4-piperidinylidene)-5H-benzo(5,6)cyclohepta(1,2-b)pyridine; 8-chloro-11-(piperidin-4-ylidene)-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine DM56YN7 CP Schering-Plough DM56YN7 TC Antiallergic Agents DM56YN7 DT Small molecular drug DM56YN7 PC 124087 DM56YN7 MW 310.8 DM56YN7 FM C19H19ClN2 DM56YN7 IC InChI=1S/C19H19ClN2/c20-16-5-6-17-15(12-16)4-3-14-2-1-9-22-19(14)18(17)13-7-10-21-11-8-13/h1-2,5-6,9,12,21H,3-4,7-8,10-11H2 DM56YN7 CS C1CC2=C(C=CC(=C2)Cl)C(=C3CCNCC3)C4=C1C=CC=N4 DM56YN7 IK JAUOIFJMECXRGI-UHFFFAOYSA-N DM56YN7 IU 13-chloro-2-piperidin-4-ylidene-4-azatricyclo[9.4.0.03,8]pentadeca-1(11),3(8),4,6,12,14-hexaene DM56YN7 CA CAS 100643-71-8 DM56YN7 CB CHEBI:291342 DM56YN7 DE Allergic rhinitis DMS3GVE ID DMS3GVE DMS3GVE DN Desmopressin DMS3GVE HS Approved DMS3GVE SN Ddavp; DESMOPRESSIN; DDAVP; dAVP; Minirin; Adiuretin SD; Noctiva; Adiuretin; Deamino Arginine Vasopressin; Desmopressinum; deamino-vasopressin; [deamino1]AVP; Desmopressin [INN:BAN]; [deamino-Cys1]AVP; Desmopressinum [INN-Latin]; Desmopressine [INN-French]; Desmopresina [INN-Spanish]; Vasopressin, 1-(3-mercaptopropanoic acid)-8-D-arginine-; desnopressin; Vasopressin, Deamino Arginine; EINECS 240-726-7; 1-Desamino-8-D-arginine vasopressin; Desamino-8-D-arginine vasopressin, l-; Deamino-8-D-arginine, l-, vasopressin; Desmopressin Melt; Minrin Melt; FE-992026; Desmopressin (fast-dissolving, nocturia/diabetes insipidus); Desmopressin (fast-dissolving, nocturia/diabetes insipidus), Ferring Pharmaceuticals DMS3GVE CP Ferring Pharmaceuticals Inc DMS3GVE DT Small molecular drug DMS3GVE PC 5311065 DMS3GVE MW 1069.2 DMS3GVE FM C46H64N14O12S2 DMS3GVE IC InChI=1S/C46H64N14O12S2/c47-35(62)15-14-29-40(67)58-32(22-36(48)63)43(70)59-33(45(72)60-18-5-9-34(60)44(71)56-28(8-4-17-52-46(50)51)39(66)53-23-37(49)64)24-74-73-19-16-38(65)54-30(21-26-10-12-27(61)13-11-26)41(68)57-31(42(69)55-29)20-25-6-2-1-3-7-25/h1-3,6-7,10-13,28-34,61H,4-5,8-9,14-24H2,(H2,47,62)(H2,48,63)(H2,49,64)(H,53,66)(H,54,65)(H,55,69)(H,56,71)(H,57,68)(H,58,67)(H,59,70)(H4,50,51,52)/t28-,29+,30+,31+,32+,33+,34+/m1/s1 DMS3GVE CS C1C[C@H](N(C1)C(=O)[C@@H]2CSSCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N DMS3GVE IK NFLWUMRGJYTJIN-PNIOQBSNSA-N DMS3GVE IU (2S)-N-[(2R)-1-[(2-amino-2-oxoethyl)amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]-1-[(4R,7S,10S,13S,16S)-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]pyrrolidine-2-carboxamide DMS3GVE CA CAS 16679-58-6 DMS3GVE CB CHEBI:4450 DMS3GVE DE Diabetic complication DM27U4Y ID DM27U4Y DM27U4Y DN Desogestrel DM27U4Y HS Approved DM27U4Y SN Cerazette; Desogen; Desogestrelum; Organon Brand of Desogestrel; ORG 2969; Desogestrelum [INN-Latin]; Desogestrel (USAN/INN); Desogestrel [USAN:BAN:INN]; Alpha-pregn-4-en-20-yn-17-ol, 13-Ethyl-11-methylene-18,19-dinor-17; (17alpha)-13-Ethyl-11-methylene-18,19-dinorpregn-4-en-20-yn-17-ol; (8S,9S,10R,13S,14S,17R)-13-ethyl-17-ethynyl-11-methylidene-1,2,3,6,7,8,9,10,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-ol; 13 Ethyl 11 methylene 18,19 dinor 17 alpha pregn 4 en 20 yn 17 ol; 13-Ethyl-11-methylene-18,19-dinor-17 alpha-pregn-4-en-20-yn-17-ol; 13-Ethyl-11-methylene-18,19-dinor-17alpha-pregn-4-en-20-yn-17-ol; 17alpha-ethynyl-11-methylidene-18a-homo-estr-4-en-17beta-ol DM27U4Y TC Contraceptive Agents DM27U4Y DT Small molecular drug DM27U4Y PC 40973 DM27U4Y MW 310.5 DM27U4Y FM C22H30O DM27U4Y IC InChI=1S/C22H30O/c1-4-21-14-15(3)20-17-9-7-6-8-16(17)10-11-18(20)19(21)12-13-22(21,23)5-2/h2,8,17-20,23H,3-4,6-7,9-14H2,1H3/t17-,18-,19-,20+,21-,22-/m0/s1 DM27U4Y CS CC[C@]12CC(=C)[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CCCC[C@H]34 DM27U4Y IK RPLCPCMSCLEKRS-BPIQYHPVSA-N DM27U4Y IU (8S,9S,10R,13S,14S,17R)-13-ethyl-17-ethynyl-11-methylidene-1,2,3,6,7,8,9,10,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-ol DM27U4Y CA CAS 54024-22-5 DM27U4Y CB CHEBI:4453 DM27U4Y DE Contraception DMTP2NJ ID DMTP2NJ DMTP2NJ DN Desonide DMTP2NJ HS Approved DMTP2NJ SN Apolar; DesOwen; Desilux; Desonate; Desonida; Desonidum; Flusemidon; Hamiltoderm; Locapred; Prednacinolone; Prenacid; Reticus; Sterax; Steroderm; Topifug; Tridesilon; Tridesonit; Verdeso; Zotinar; Desfluorotriamcinolone acetonide; D 2083; D-2083; Desonida [INN-Spanish]; Desonidum [INN-Latin]; Desowen (TN); Verdeso (TN);Verdeso Foam (TN); Desonide (USAN/INN); Desonide [USAN:INN:BAN]; Locapred, Topifug, Tridesilon, Desonide; (4aR,4bS,5S,6aS,6bS,9aR,10aS,10bS)-5-hydroxy-6b-(hydroxyacetyl)-4a,6a,8,8-tetramethyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one; 11beta,16alpha,17,21-Tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with acetone; 11beta,21-dihydroxy-16alpha,17-[(1-methylethylidene)bis(oxy)]pregna-1,4-diene-3,20-dione; 11beta,21-dihydroxy-16alpha,17-isopropylidenedioxypregna-1,4-diene-3,20-dione; 11beta,21-dihydroxy-16alpha,17alpha-isopropylidenedioxypregna-1,4-diene-3,20-dione; 16-alpha-Hydroxyprednisole-16,17-acetonide; 16alpha,17alpha-isopropylidenedioxyprednisolone; 16alpha-hydroxyprednisole-16,17-acetonide; 16alpha-hydroxyprednisolone-16alpha,17-acetonide DMTP2NJ TC Antiinflammatory Agents DMTP2NJ DT Small molecular drug DMTP2NJ PC 5311066 DMTP2NJ MW 416.5 DMTP2NJ FM C24H32O6 DMTP2NJ IC InChI=1S/C24H32O6/c1-21(2)29-19-10-16-15-6-5-13-9-14(26)7-8-22(13,3)20(15)17(27)11-23(16,4)24(19,30-21)18(28)12-25/h7-9,15-17,19-20,25,27H,5-6,10-12H2,1-4H3/t15-,16-,17-,19+,20+,22-,23-,24+/m0/s1 DMTP2NJ CS C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1C[C@@H]4[C@]2(OC(O4)(C)C)C(=O)CO)CCC5=CC(=O)C=C[C@]35C)O DMTP2NJ IK WBGKWQHBNHJJPZ-LECWWXJVSA-N DMTP2NJ IU (1S,2S,4R,8S,9S,11S,12S,13R)-11-hydroxy-8-(2-hydroxyacetyl)-6,6,9,13-tetramethyl-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one DMTP2NJ CA CAS 638-94-8 DMTP2NJ CB CHEBI:204734 DMTP2NJ DE Atopic dermatitis DM4PXF6 ID DM4PXF6 DM4PXF6 DN Desoximetasone DM4PXF6 HS Approved DM4PXF6 SN Desoximetasona; Desoximetasonum; Topicort; HOE-304; R-2113; Topicort (TN); Topicort Emollient (TN); A-41-304; Desoximetasone (USP/INN); (11beta,16alpha)-9-Fluoro-11,21-dihydroxy-16-methylpregna-1,4-diene-3,20-dione; (8S,9R,10S,11S,13S,14S,16R,17S)-9-fluoro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-7,8,11,12,14,15,16,17-octahydro-6H-cyclopenta[a]phenanthren-3-one; 9-Fluoro-11beta,21-dihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione; 9alpha-fluoro-16alpha-methyl-Delta(1)-corticosterone DM4PXF6 TC Antiinflammatory Agents DM4PXF6 DT Small molecular drug DM4PXF6 PC 5311067 DM4PXF6 MW 376.5 DM4PXF6 FM C22H29FO4 DM4PXF6 IC InChI=1S/C22H29FO4/c1-12-8-16-15-5-4-13-9-14(25)6-7-21(13,3)22(15,23)18(27)10-20(16,2)19(12)17(26)11-24/h6-7,9,12,15-16,18-19,24,27H,4-5,8,10-11H2,1-3H3/t12-,15+,16+,18+,19-,20+,21+,22+/m1/s1 DM4PXF6 CS C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@H]1C(=O)CO)C)O)F)C DM4PXF6 IK VWVSBHGCDBMOOT-IIEHVVJPSA-N DM4PXF6 IU (8S,9R,10S,11S,13S,14S,16R,17S)-9-fluoro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-7,8,11,12,14,15,16,17-octahydro-6H-cyclopenta[a]phenanthren-3-one DM4PXF6 CA CAS 140218-14-0 DM4PXF6 CB CHEBI:691037 DM4PXF6 DE Inflammation DMS0AFE ID DMS0AFE DMS0AFE DN Desoxycorticosterone acetate DMS0AFE HS Approved DMS0AFE SN Doca DMS0AFE CP Organon Usa Inc DMS0AFE DT Small molecular drug DMS0AFE PC 5952 DMS0AFE MW 372.5 DMS0AFE FM C23H32O4 DMS0AFE IC InChI=1S/C23H32O4/c1-14(24)27-13-21(26)20-7-6-18-17-5-4-15-12-16(25)8-10-22(15,2)19(17)9-11-23(18,20)3/h12,17-20H,4-11,13H2,1-3H3/t17-,18-,19-,20+,22-,23-/m0/s1 DMS0AFE CS CC(=O)OCC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C DMS0AFE IK VPGRYOFKCNULNK-ACXQXYJUSA-N DMS0AFE IU [2-[(8S,9S,10R,13S,14S,17S)-10,13-dimethyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] acetate DMS0AFE CA CAS 56-47-3 DMS0AFE CB CHEBI:34671 DMS0AFE DE Discovery agent DMSA4B3 ID DMSA4B3 DMSA4B3 DN Desoxycorticosterone pivalate DMSA4B3 HS Approved DMSA4B3 SN DOCP; DTMA; Cortexone M; Deoxycorticosterone pivalate; Deoxycorticosterone trimethylacetate; Deoxycortolone Pivalate; Deoxycortone pivalate; Deoxycortone trimethylacetate; Desoxycorticosterone trimethylacetate; Desoxycortone pivalate; Percorten M; Percorten Pivalate; Desoxycorticosterone pivalate (USP); Neodin-depositum; Percorten (TN); Corticosterone, deoxy-, pivalate (6CI,7CI); [2-(10,13-dimethyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl)-2-oxoethyl] 2,2-dimethylpropanoate; 11-Deoxycorticosterone pivalate; 11-Deoxycorticosterone, pivalate; 11-Deoxycorticosterone, pivalate (8CI); 21-(2,2-Dimethyl-1-oxopropoxy)pregn-4-ene-3,20-dione; 3,20-dioxopregn-4-en-21-yl 2,2-dimethylpropanoate DMSA4B3 TC Antiaddison Agents DMSA4B3 DT Small molecular drug DMSA4B3 PC 11876263 DMSA4B3 MW 414.6 DMSA4B3 FM C26H38O4 DMSA4B3 IC InChI=1S/C26H38O4/c1-24(2,3)23(29)30-15-22(28)21-9-8-19-18-7-6-16-14-17(27)10-12-25(16,4)20(18)11-13-26(19,21)5/h14,18-21H,6-13,15H2,1-5H3/t18-,19-,20-,21+,25-,26-/m0/s1 DMSA4B3 CS C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2C(=O)COC(=O)C(C)(C)C)CCC4=CC(=O)CC[C@]34C DMSA4B3 IK VVOIQBFMTVCINR-WWMZEODYSA-N DMSA4B3 IU [2-[(8S,9S,10R,13S,14S,17S)-10,13-dimethyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] 2,2-dimethylpropanoate DMSA4B3 CA CAS 808-48-0 DMSA4B3 CB CHEBI:50782 DMSA4B3 DE Addison disease DMEZFXR ID DMEZFXR DMEZFXR DN Desoxyribonuclease DMEZFXR HS Approved DMEZFXR DE Female genital tract inflammation DMJE6KO ID DMJE6KO DMJE6KO DN Desvenalfaxine succinate DMJE6KO HS Approved DMJE6KO SN 386750-22-7; Desvenlafaxine succinate monohydrate; Desvenlafaxine (succinate hydrate); Desvenlafaxine succinate hydrate; Desvenlafaxine Succinate [USAN]; Desvenlafaxine succinate (USAN); O-desmethylvenlafaxine Succinate Monohydrate; Desvenlafaxine Succinate Monohydrate (O-Desmethylvenlafaxine Succinate Monohydrate); Pristiq (TN); AC1OCFPN; Desvenlafaxine(succinatehydrate); SCHEMBL1278407; CTK8E8387; HY-B0602A; MolPort-021-783-032 DMJE6KO CP Wyeth DMJE6KO DT Small molecular drug DMJE6KO PC 6918664 DMJE6KO MW 399.5 DMJE6KO FM C20H33NO7 DMJE6KO IC InChI=1S/C16H25NO2.C4H6O4.H2O/c1-17(2)12-15(13-6-8-14(18)9-7-13)16(19)10-4-3-5-11-16;5-3(6)1-2-4(7)8;/h6-9,15,18-19H,3-5,10-12H2,1-2H3;1-2H2,(H,5,6)(H,7,8);1H2 DMJE6KO CS CN(C)CC(C1=CC=C(C=C1)O)C2(CCCCC2)O.C(CC(=O)O)C(=O)O.O DMJE6KO IK PWPDEXVGKDEKTE-UHFFFAOYSA-N DMJE6KO IU butanedioic acid;4-[2-(dimethylamino)-1-(1-hydroxycyclohexyl)ethyl]phenol;hydrate DMJE6KO CA CAS 386750-22-7 DMJE6KO DE Fibromyalgia DMHD4PE ID DMHD4PE DMHD4PE DN Desvenlafaxine DMHD4PE HS Approved DMHD4PE SN Norvenlafaxine; Desvenlafaxine (INN); Desvenlafaxine [INN:BAN]; O-Desmethylvenlafaxine; WY 45,233; O-DESMETHYLVENLAFAXINE (ODV); WY-45,233 DMHD4PE CP Wyeth DMHD4PE DT Small molecular drug DMHD4PE PC 125017 DMHD4PE MW 263.37 DMHD4PE FM C16H25NO2 DMHD4PE IC InChI=1S/C16H25NO2/c1-17(2)12-15(13-6-8-14(18)9-7-13)16(19)10-4-3-5-11-16/h6-9,15,18-19H,3-5,10-12H2,1-2H3 DMHD4PE CS CN(C)CC(C1=CC=C(C=C1)O)C2(CCCCC2)O DMHD4PE IK KYYIDSXMWOZKMP-UHFFFAOYSA-N DMHD4PE IU 4-[2-(dimethylamino)-1-(1-hydroxycyclohexyl)ethyl]phenol DMHD4PE CA CAS 93413-62-8 DMHD4PE CB CHEBI:83527 DMHD4PE DE Major depressive disorder; Menopause symptom DMUPFLI ID DMUPFLI DMUPFLI DN Deutetrabenazine DMUPFLI HS Approved DMUPFLI SN Dutetrabenazine; Austedo; SD809; SD-809; SD 809; 1392826-25-3; Deutetrabenazine [USAN:INN] DMUPFLI CP Teva DMUPFLI DT Small molecular drug DMUPFLI PC 73437646 DMUPFLI MW 323.5 DMUPFLI FM C19H27NO3 DMUPFLI IC InChI=1S/C19H27NO3/c1-12(2)7-14-11-20-6-5-13-8-18(22-3)19(23-4)9-15(13)16(20)10-17(14)21/h8-9,12,14,16H,5-7,10-11H2,1-4H3/t14-,16-/m1/s1/i3D3,4D3 DMUPFLI CS [2H]C([2H])([2H])OC1=C(C=C2[C@H]3CC(=O)[C@@H](CN3CCC2=C1)CC(C)C)OC([2H])([2H])[2H] DMUPFLI IK MKJIEFSOBYUXJB-VFJJUKLQSA-N DMUPFLI IU (3R,11bR)-3-(2-methylpropyl)-9,10-bis(trideuteriomethoxy)-1,3,4,6,7,11b-hexahydrobenzo[a]quinolizin-2-one DMUPFLI CA CAS 1392826-25-3 DMUPFLI DE Tardive dyskinesia; Huntington disease DMMWZET ID DMMWZET DMMWZET DN Dexamethasone DMMWZET HS Approved DMMWZET SN Adexone; Anaflogistico; Aphtasolon; Aphthasolone; Auxiron; Azium; Calonat; Corson; Corsone; Cortisumman; DXM; Decacort; Decacortin; Decaderm; Decadron; Decagel; Decaject; Decalix; Decameth; Decasone; Decaspray; Dectancyl; Dekacort; Deltafluorene; Dergramin; Deronil; Desadrene; Desametasone; Desamethasone; Desameton; Deseronil; Dexacort; Dexacortal; Dexacortin; Dexadeltone; Dexafarma; Dexair; Dexalona; Dexaltin; Dexametasona; Dexameth; Dexamethansone; Dexamethasonum; Dexamethazone; Dexamonozon; Dexapolcort; Dexaprol; Dexason; Dexasone; Dexinolon; Dexinoral; Dexone; Dexonium; Dexpak; Dextelan; Dezone; Dinormon; Dxms; Fluormethylprednisolone; Fluormone; Fluorocort; Fortecortin; Gammacorten; Hexadecadrol; Hexadrol; IontoDex; Loverine; Luxazone; Maxidex; Mediamethasone; Methylfluorprednisolone; Mexidex; Millicorten; Mymethasone; Oradexon; Policort; Posurdex; Prodex; Spoloven; Superprednol; Turbinaire; Visumetazone; Alcon Brand of Dexamethasone; Bisu DS; Desametasone [DCIT]; Dexa Mamallet; Dexamethasone Base; Dexamethasone Intensol; Dexamethasone alcohol; ECR Brand of Dexamethasone; Foy Brand of Dexamethasone; Hexadrol Elixir; Hexadrol Tablets; ICN Brand of Dexamethasone; Lokalison F; Merck Brand of Dexamethasone; Pet Derm III; Prednisolon F; Prednisolone F; Sunia Sol D; Dexone 4; MK 125; Merz Brand 1 of Dexamethasone; Merz Brand 2 of Dexamethasone; Aeroseb-D; Aeroseb-Dex; Azium (Veterinary); Decadron (TN); Decadron Tablets, Elixir; Decadron, Dexamethasone; Decadron-LA; Dex-ide; Dexa-Cortidelt;Dexa-Cortisyl; Dexa-Mamallet; Dexa-Scheroson; Dexa-sine; Dexacen-4; Dexametasona [INN-Spanish]; Dexamethasonum [INN-Latin]; Dexone 0.5; Dexone 0.75; Dexone 1.5; Hl-dex; Isopto-Dex; OTO-104; Ocu-trol;Pet-Derm Iii; SK-Dexamethasone; Decaject L.A.; Dexamethasone [INN:BAN:JAN]; Decaject-L.A.; Dexamethasone (JP15/USP/INN); Delta1-9alpha-Fluoro-16alpha-methylcortisol; Delta(sup 1)-9-alpha-Fluoro-16-alpha-methylcortisol; (3H)-Dexamethasone; 1-Dehydro-16.alpha.-methyl-9.alpha.-fluorohydrocortisone; 1-Dehydro-16alpha-methyl-9alpha-fluorohydrocortisone; 16-alpha-Methyl-9-alpha-fluoro-1-dehydrocortisol; 16-alpha-Methyl-9-alpha-fluoro-delta(sup 1)-hydrocortisone; 16-alpha-Methyl-9-alpha-fluoro-delta1-hydrocortisone; 16-alpha-Methyl-9-alpha-fluoroprednisolone; 16.alpha.-Methyl-9.alpha.-fluoro-1-dehydrocortisol; 16.alpha.-Methyl-9.alpha.-fluoroprednisolone; 16alpha-Methyl-9alpha-fluoro-1-dehydrocortisol; 16alpha-Methyl-9alpha-fluoro-delta(sup 1)-hydrocortisone; 16alpha-Methyl-9alpha-fluoroprednisolone; 9-alpha-Fluoro-16-alpha-methylprednisolone; 9.alpha.-Fluoro-16.alpha.-methylprednisolone; 9A-FLUORO-16BETA-METHYLPREDNISOLONE; 9alpha-Fluoro-16alpha-methylprednisolone DMMWZET CP Swiss Pharma DMMWZET TC Antiinflammatory Agents DMMWZET DT Small molecular drug DMMWZET PC 5743 DMMWZET MW 392.5 DMMWZET FM C22H29FO5 DMMWZET IC InChI=1S/C22H29FO5/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,23)17(26)10-20(16,3)22(12,28)18(27)11-24/h6-7,9,12,15-17,24,26,28H,4-5,8,10-11H2,1-3H3/t12-,15+,16+,17+,19+,20+,21+,22+/m1/s1 DMMWZET CS C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)F)C DMMWZET IK UREBDLICKHMUKA-CXSFZGCWSA-N DMMWZET IU (8S,9R,10S,11S,13S,14S,16R,17R)-9-fluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one DMMWZET CA CAS 50-02-2 DMMWZET CB CHEBI:41879 DMMWZET DE Rheumatoid arthritis DMIG8DW ID DMIG8DW DMIG8DW DN Dexamethasone sodium phosphate DMIG8DW HS Approved DMIG8DW SN EryDex; Dexamethasone sodium phosphate (erythrocyte encapsulated); Dexamethasone sodium phosphate (erythrocyte encapsulated), Urbino University/EryDel; Dex 21-P (red blood cell encapsulated), Urbino University/EryDel; Intra-erythrocyte dexamethasone (inflammatory diseases), Urbino University/EryDel DMIG8DW CP Universita' Degli Studi Di Urbino DMIG8DW DT Small molecular drug DMIG8DW PC 16961 DMIG8DW MW 516.4 DMIG8DW FM C22H28FNa2O8P DMIG8DW IC InChI=1S/C22H30FO8P.2Na/c1-12-8-16-15-5-4-13-9-14(24)6-7-19(13,2)21(15,23)17(25)10-20(16,3)22(12,27)18(26)11-31-32(28,29)30;;/h6-7,9,12,15-17,25,27H,4-5,8,10-11H2,1-3H3,(H2,28,29,30);;/q;2*+1/p-2/t12-,15+,16+,17+,19+,20+,21+,22+;;/m1../s1 DMIG8DW CS C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)COP(=O)([O-])[O-])O)C)O)F)C.[Na+].[Na+] DMIG8DW IK PLCQGRYPOISRTQ-FCJDYXGNSA-L DMIG8DW IU disodium;[2-[(8S,9R,10S,11S,13S,14S,16R,17R)-9-fluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] phosphate DMIG8DW CA CAS 2392-39-4 DMIG8DW CB CHEBI:4462 DMIG8DW DE Ataxia-telangiectasia DMKVWGE ID DMKVWGE DMKVWGE DN Dexbrompheniramine DMKVWGE HS Approved DMKVWGE SN Dexbromfeniramina; Dexbrompheniraminum; Ilvin; Parabromodylamine; D-Brompheniramine; Dexbromfeniramina [INN-Spanish]; Dexbrompheniramine [INN:BAN]; Dexbrompheniraminum [INN-Latin]; N,N-Dimethyl-(3-(4-bromphenyl)-3-(2-pyridyl)propyl)amin; (3-p-Bromphenyl-3-pyrid-2'-ylpropyl)dimethylamin; (3S)-3-(4-bromophenyl)-N,N-dimethyl-3-(pyridin-2-yl)propan-1-amine; (3S)-3-(4-bromophenyl)-N,N-dimethyl-3-pyridin-2-ylpropan-1-amine; (S)-(+)-brompheniramine; (S)-brompheniramine DMKVWGE CP Schering Corp Sub Schering Plough Corp DMKVWGE TC Antihistamines DMKVWGE DT Small molecular drug DMKVWGE PC 16960 DMKVWGE MW 319.24 DMKVWGE FM C16H19BrN2 DMKVWGE IC InChI=1S/C16H19BrN2/c1-19(2)12-10-15(16-5-3-4-11-18-16)13-6-8-14(17)9-7-13/h3-9,11,15H,10,12H2,1-2H3/t15-/m0/s1 DMKVWGE CS CN(C)CC[C@@H](C1=CC=C(C=C1)Br)C2=CC=CC=N2 DMKVWGE IK ZDIGNSYAACHWNL-HNNXBMFYSA-N DMKVWGE IU (3S)-3-(4-bromophenyl)-N,N-dimethyl-3-pyridin-2-ylpropan-1-amine DMKVWGE CA CAS 132-21-8 DMKVWGE CB CHEBI:59269 DMKVWGE DE Hay fever DMA8DPN ID DMA8DPN DMA8DPN DN Dexchlorpheniramine maleate DMA8DPN HS Approved DMA8DPN SN Polaramine DMA8DPN CP Schering Corp Sub Schering Plough Corp DMA8DPN DT Small molecular drug DMA8DPN PC 5281070 DMA8DPN MW 390.9 DMA8DPN FM C20H23ClN2O4 DMA8DPN IC InChI=1S/C16H19ClN2.C4H4O4/c1-19(2)12-10-15(16-5-3-4-11-18-16)13-6-8-14(17)9-7-13;5-3(6)1-2-4(7)8/h3-9,11,15H,10,12H2,1-2H3;1-2H,(H,5,6)(H,7,8)/b;2-1-/t15-;/m0./s1 DMA8DPN CS CN(C)CC[C@@H](C1=CC=C(C=C1)Cl)C2=CC=CC=N2.C(=C\\C(=O)O)\\C(=O)O DMA8DPN IK DBAKFASWICGISY-DASCVMRKSA-N DMA8DPN IU (Z)-but-2-enedioic acid;(3S)-3-(4-chlorophenyl)-N,N-dimethyl-3-pyridin-2-ylpropan-1-amine DMA8DPN CA CAS 2438-32-6 DMA8DPN CB CHEBI:4465 DMA8DPN DE Rhinitis DMFYBD0 ID DMFYBD0 DMFYBD0 DN Dexibuprofen DMFYBD0 HS Approved DMFYBD0 SN (S)-(+)-Ibuprofen; 51146-56-6; DEXIBUPROFEN; S(+)-Ibuprofen; (S)-2-(4-Isobutylphenyl)propanoic acid; (S)-Ibuprofen; d-Ibuproten; (S)-(+)-2-(4-Isobutylphenyl)propionic acid; (+)-(S)-p-Isobutylhydratropic acid; Seractil; (2S)-2-[4-(2-methylpropyl)phenyl]propanoic acid; (S)-(+)-4-Isobutyl-alpha-methylphenylacetic acid; UNII-671DKG7P5S; S-(+)-ibuprofen; (2S)-2-(4-isobutylphenyl)propanoic acid; CHEMBL175; 671DKG7P5S; CHEBI:43415; (S)-alpha-methyl-4-(2-methylpropyl)benzeneacetic acid; NCGC00016861-05 DMFYBD0 DT Small molecular drug DMFYBD0 PC 39912 DMFYBD0 MW 206.28 DMFYBD0 FM C13H18O2 DMFYBD0 IC InChI=1S/C13H18O2/c1-9(2)8-11-4-6-12(7-5-11)10(3)13(14)15/h4-7,9-10H,8H2,1-3H3,(H,14,15)/t10-/m0/s1 DMFYBD0 CS C[C@@H](C1=CC=C(C=C1)CC(C)C)C(=O)O DMFYBD0 IK HEFNNWSXXWATRW-JTQLQIEISA-N DMFYBD0 IU (2S)-2-[4-(2-methylpropyl)phenyl]propanoic acid DMFYBD0 CA CAS 51146-56-6 DMFYBD0 CB CHEBI:43415 DMFYBD0 DE Ankylosing spondylitis DM1DBV5 ID DM1DBV5 DM1DBV5 DN Dexlansoprazole DM1DBV5 HS Approved DM1DBV5 SN dexlansoprazole; (R)-Lansoprazole; 138530-94-6; Kapidex; dexilant; R-(+)-LANSOPRAZOLE; Dexilant Solutab; TAK 390; UNII-UYE4T5I70X; TAK-390; (r)-(+)-lansoprazole; T 168390; UYE4T5I70X; AK170558; TAK-390MR; T-168390; 2-((R)-((3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl)methyl)sulfinyl)-1H-benzimidazole; 2-[(R)-[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methylsulfinyl]-1H-benzimidazole; (R)-2-(((3-Methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazole; Dexlansoprazole (INN/USAN); Kapidex; KS-1075; Lansoprazole DM1DBV5 CP Takeda DM1DBV5 DT Small molecular drug DM1DBV5 PC 9578005 DM1DBV5 MW 369.4 DM1DBV5 FM C16H14F3N3O2S DM1DBV5 IC InChI=1S/C16H14F3N3O2S/c1-10-13(20-7-6-14(10)24-9-16(17,18)19)8-25(23)15-21-11-4-2-3-5-12(11)22-15/h2-7H,8-9H2,1H3,(H,21,22)/t25-/m1/s1 DM1DBV5 CS CC1=C(C=CN=C1C[S@@](=O)C2=NC3=CC=CC=C3N2)OCC(F)(F)F DM1DBV5 IK MJIHNNLFOKEZEW-RUZDIDTESA-N DM1DBV5 IU 2-[(R)-[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methylsulfinyl]-1H-benzimidazole DM1DBV5 CA CAS 138530-94-6 DM1DBV5 CB CHEBI:135931 DM1DBV5 DE Non-erosive gastro-esophageal reflux disease; Erosive esophagitis; Peptic ulcer; NSAID-associated gastric ulcer DM93L4X ID DM93L4X DM93L4X DN Dexmedetomidine DM93L4X HS Approved DM93L4X SN Dexmedetomidina; Dexmedetomidinum; MPV 1440; MPV-1440; Precedex (TN); Dexmedetomidine (USAN/INN); (+)-4-((S)-alpha,2,3-Trimethylbenzyl)imidazole; 4-[(1S)-1-(2,3-dimethylphenyl)ethyl]-1H-imidazole; 5-[(1S)-1-(2,3-dimethylphenyl)ethyl]-1H-imidazole DM93L4X CP Hospira DM93L4X TC Hypnotics and Sedatives DM93L4X DT Small molecular drug DM93L4X PC 5311068 DM93L4X MW 200.28 DM93L4X FM C13H16N2 DM93L4X IC InChI=1S/C13H16N2/c1-9-5-4-6-12(10(9)2)11(3)13-7-14-8-15-13/h4-8,11H,1-3H3,(H,14,15)/t11-/m0/s1 DM93L4X CS CC1=C(C(=CC=C1)[C@H](C)C2=CN=CN2)C DM93L4X IK CUHVIMMYOGQXCV-NSHDSACASA-N DM93L4X IU 5-[(1S)-1-(2,3-dimethylphenyl)ethyl]-1H-imidazole DM93L4X CA CAS 113775-47-6 DM93L4X CB CHEBI:4466 DM93L4X DE Irritability DMUQE2A ID DMUQE2A DMUQE2A DN Dexmethylphenidate DMUQE2A HS Approved DMUQE2A SN Dexmethylphenidate; Dexmethylphenidate (INN); Dexmethylphenidate [INN]; Focalin; Focalin XR; M32RH9MFGP; Methyl D-phenidate; d-Methylphenidate; Attenade; Dex methylphenidate; d-threo-Methylphenidate; dex-methylphenidate; dexmethylphenidatum; dexmetilfenidato; threo-(+)-Methylphenidate; (+)-threo-Methylphenidate; 40431-64-9; CHEBI:51860; CHEMBL827; D-MPH; D-TMP; UNII-M32RH9MFGP; methyl (2R)-2-phenyl-2-[(2R)-piperidin-2-yl]acetate; methyl (2R)-phenyl[(2R)-piperidin-2-yl]acetate; methyl (R)-phenyl[(R)-piperidin-2-yl]acetate DMUQE2A PC 154101 DMUQE2A MW 233.31 DMUQE2A FM C14H19NO2 DMUQE2A IC DUGOZIWVEXMGBE-CHWSQXEVSA-N DMUQE2A CS COC(=O)C(C1CCCCN1)C2=CC=CC=C2 DMUQE2A IK 1S/C14H19NO2/c1-17-14(16)13(11-7-3-2-4-8-11)12-9-5-6-10-15-12/h2-4,7-8,12-13,15H,5-6,9-10H2,1H3/t12-,13-/m1/s1 DMUQE2A IU methyl (2R)-2-phenyl-2-[(2R)-piperidin-2-yl]acetate DMUQE2A CA CAS 40431-64-9 DMUQE2A CB CHEBI:51860 DMUQE2A DE Attention deficit hyperactivity disorder DM8WBAH ID DM8WBAH DM8WBAH DN Dexmethylphenidate hydrochloride DM8WBAH HS Approved DM8WBAH SN Dexmethylphenidate hydrochloride; Focalin; D-threo-Methylphenidate hydrochloride; Dexmethylphenidate HCl; Focalin XR; UNII-1678OK0E08; Dexmethylphenidate hydrochloride [USAN]; 19262-68-1; 1678OK0E08; 23655-65-4; CHEMBL904; Methyl (2R)-phenyl((2R)-piperidin-2-yl)acetate hydrochloride; dl-threo-Methylphenidate Hydrochloride; 2-Piperidineacetic acid, alpha-phenyl-, methyl ester, hydrochloride, (R-(R*,R*))-; 2-Piperidineacetic acid, alpha-phenyl-, methyl ester, hydrochloride, (alphaR,2R)-; Dexmethylphenidate; NWP06 DM8WBAH DT Small molecular drug DM8WBAH PC 154100 DM8WBAH MW 269.77 DM8WBAH FM C14H20ClNO2 DM8WBAH IC InChI=1S/C14H19NO2.ClH/c1-17-14(16)13(11-7-3-2-4-8-11)12-9-5-6-10-15-12;/h2-4,7-8,12-13,15H,5-6,9-10H2,1H3;1H/t12-,13-;/m1./s1 DM8WBAH CS COC(=O)[C@@H]([C@H]1CCCCN1)C2=CC=CC=C2.Cl DM8WBAH IK JUMYIBMBTDDLNG-OJERSXHUSA-N DM8WBAH IU methyl (2R)-2-phenyl-2-[(2R)-piperidin-2-yl]acetate;hydrochloride DM8WBAH CA CAS 19262-68-1 DM8WBAH DE Attention deficit hyperactivity disorder DMD7X1O ID DMD7X1O DMD7X1O DN Dexrazoxane DMD7X1O HS Approved DMD7X1O SN 24584-09-6; Zinecard; (S)-4,4'-(Propane-1,2-diyl)bis(piperazine-2,6-dione); Cardioxane; ICRF-187; Dexrazoxano; Dexrazoxanum; Dextrorazoxane; Dexrazoxanum [INN-Latin]; Dexrazoxano [INN-Spanish]; Desrazoxane; Eucardion; ADR 529; ICRF 187; (+)-(S)-4,4'-Propylenedi-2,6-piperazinedione; Dexrazone; ADR-529; (+)-1,2-Bis(3,5-dioxo-1-piperazinyl)propane; HSDB 7319; UNII-048L81261F; NSC169780; dyzoxane; BRN 5759131; CHEBI:50223; 4-[(2S)-2-(3,5-dioxopiperazin-1-yl)propyl]piperazine-2,6-dione; NSC 169780; AK-72797; Razoxanum; Cardioxane; Dyzoxane; Savene; TopoTect; Totect; Dexrazoxane HCl; Dexrazoxane hydrochloride; ICRF 187 hydrochloride; Cardioxane (TN); Dexrazoxane (TN); Totect (TN); Zinecard (TN); Dexrazoxane (USAN/INN); Dexrazoxane [USAN:BAN:INN]; Soluble ICRF (L-isosomer); Razoxane, (S)-Isomer; Totect, ICRF-187, Zinecard, Cardioxane, Dexrazoxane Hydrochloride;(+)-(S)-4,4'-Propylenedi-2,6-piperazinedione; (+)-1,2-Bis(3,5-dioxopiperazin-1-yl)propane; (S)-(+)-1,2-Bis(3,5-dioxopiperazin-1-yl)propane; 2,6-Piperazinedione, 4,4'-(1-methyl-1,2-ethanediyl)bis-, (+)-(9CI); 4,4'-(2S)-propane-1,2-diyldipiperazine-2,6-dione; 4-[(2S)-2-(3,5-dioxopiperazin-1-yl)propyl]piperazine-2,6-dione hydrochloride; Icrf-187 DMD7X1O CP Pfizer Pharmaceuticals DMD7X1O TC Anticancer Agents DMD7X1O DT Small molecular drug DMD7X1O PC 71384 DMD7X1O MW 268.27 DMD7X1O FM C11H16N4O4 DMD7X1O IC InChI=1S/C11H16N4O4/c1-7(15-5-10(18)13-11(19)6-15)2-14-3-8(16)12-9(17)4-14/h7H,2-6H2,1H3,(H,12,16,17)(H,13,18,19)/t7-/m0/s1 DMD7X1O CS C[C@@H](CN1CC(=O)NC(=O)C1)N2CC(=O)NC(=O)C2 DMD7X1O IK BMKDZUISNHGIBY-ZETCQYMHSA-N DMD7X1O IU 4-[(2S)-2-(3,5-dioxopiperazin-1-yl)propyl]piperazine-2,6-dione DMD7X1O CA CAS 24584-09-6 DMD7X1O CB CHEBI:50223 DMD7X1O DE Breast cancer; Chemoprotection; Respiratory tract disease DMMIHVP ID DMMIHVP DMMIHVP DN Dextroamphetamine DMMIHVP HS Approved DMMIHVP SN D-Amphetamine; dextroamphetamine; Dexamphetamine; Dexamfetamine; (S)-Amphetamine; Dexadrine; (+)-(S)-Amphetamine; Dexedrine; (2S)-1-phenylpropan-2-amine; (S)-(+)-Amphetamine; Dextrostat; Desamfetamina; (S)-1-Phenyl-2-propylamine; Dexidrine; Sympamin; Dephadren; Amsustain; (+)-Phenaminum; (+)-alpha-Methylphenethylamine; (S)-1-Phenyl-2-aminopropane; (+)-alpha-Methylphenylethylamine; D-(S)-Amphetamine; (S)-(+)-beta-Phenylisopropylamine; 51-64-9; (S)-alpha-Phenylethylamine; (2S)-(+)-Amphetamine; Benzedrine; Dexacaps; Dexamfetamina; Dexamfetaminum; Dexamphetaminum; Dexanfetamina; Isoamycin; Propisamine; Psychedrine; Raphetamine; Rhinalator; Simpatedrin; Sympamine; Sympatedrine; Weckamine; Desamfetamina [DCIT]; Dexedrine Spansule; Dextroamphetamine [USAN]; Dextroamphetamine resin complex; D-AM; Dexamfetamina [INN-Spanish]; Dexamfetamine (INN); Dexamfetaminum [INN-Latin]; Dexamphetaminum [INN-Latin]; Dexanfetamina [INN-Spanish]; Dexedrine (TN); Dextro-Amphetamine; Dextro-Amphetamine Sulfate; Dextroamphetamine (USAN); Dextrostat (TN); Dl-Amphetamine; Dl-Benzedrine; Fenylo-izopropylaminyl; Beta-phenyl-isopropylamine; D-alpha-methylphenethylamine; Alpha-Methylphenethylamine, d-form; S(+)-Amphetamine; D-(+)-Amphetamine; D-1-Phenyl-2-aminopropan; D-1-Phenyl-2-aminopropan [German]; D-1-Phenyl-2-aminopropane; D-2-Amino-1-phenylpropane; Dl-1-Phenyl-2-aminopropane; Benzeneethanamine, alpha-methyl-, (aS)-(9CI); Phenethylamine, alpha-methyl-, (+)-(8CI); (+/-)-Benzedrine; (+/-)-Desoxynorephedrine; (+/-)-beta-Phenylisopropylamine; (S)-1-Phenyl-2-propanamine; (S)-alpha-Methylphenethylamine; (S)-alpha-methylbenzeneethanamine; (alphaS)-alpha-methylbenzeneethanamine; dextroamphetamine sulfate (oral liquid, ADHD), Auriga DMMIHVP CP GlaxoSmithKline DMMIHVP TC Central Nervous System Stimulants DMMIHVP DT Small molecular drug DMMIHVP PC 5826 DMMIHVP MW 135.21 DMMIHVP FM C9H13N DMMIHVP IC InChI=1S/C9H13N/c1-8(10)7-9-5-3-2-4-6-9/h2-6,8H,7,10H2,1H3/t8-/m0/s1 DMMIHVP CS C[C@@H](CC1=CC=CC=C1)N DMMIHVP IK KWTSXDURSIMDCE-QMMMGPOBSA-N DMMIHVP IU (2S)-1-phenylpropan-2-amine DMMIHVP CA CAS 51-64-9 DMMIHVP CB CHEBI:4469 DMMIHVP DE Narcolepsy; Attention deficit hyperactivity disorder DMUDJZM ID DMUDJZM DMUDJZM DN Dextromethorphan DMUDJZM HS Approved DMUDJZM SN Albutussin; Canfodion; Cosylan; Demorphine; Destrometerfano; Dextromethorfan; Dextromethorphane; Dextromethorphanum; Dextrometorfano; Dextrometorphan; Dextromorphan; Dexyromethorphan; Dormetan; Levomethorphan; Levomethorphane; Levomethorphanum; Levometorfano; Methorphan; RACEMETHORPHAN; Trocal; Balminil DM; Balminil DM Children; Benylin Adult Formula Cough Suppressant; Benylin DM for Children; Benylin Pediatric Cough Suppressant; Delsym Cough Formula; Demorphan hydrobromide; Destrometerfano [DCIT]; Dextromethorfan [Czech]; Dextromethorphan Bromhydrate; Hold DM; Koffex DM; Novahistex DM; Novahistine DM; Pertussin DM Extra Strength; Robitussin Maximum Strength Cough Suppressant; Robitussin Pediatric; Robitussin Pediatric Cough Suppressant; Triaminic DM Long Lasting for Children; BA 2666; Benylin DM 12 Hour; Benylin DM for Children 12 Hour; Sucrets 4 Hour Cough Suppressant; Vicks 44 Cough Relief; Calmylin #1; Cough-X; Creo-Terpin; D-Methorphan; Delta-Methorphan; Dextromethorphan (USP); Dextromethorphane [INN-French]; Dextromethorphanum [INN-Latin]; Dextrometorfano [INN-Spanish]; Diabe-Tuss DM Syrup; Hihustan M.; L-Methorphan; Levomethorphane [INN-French]; Levomethorphanum [INN-Latin]; Levometorfano [INN-Spanish]; Neurodex (TN); Pertussin CS Children's Strength; Romilar (TN); Dextromethorphan [USP:INN:BAN]; Levomethorphan [BAN:DCF:INN]; Levomethorphan [INN:BAN:DCF]; Morphinan, 3-methoxy-17-methyl-, (9-alpha,13-alpha,14-alpha)-(9CI); Cis-1,3,4,9,10,10a-Hexahydro-6-methoxy-11-methyl-2H-10,4alpha-iminoethanophenanthren; (+)-3-Methoxy-17-methylmorphinan; (-)-3-Methoxy-N-methylmorphinan; (9alpha,13alpha,14alpha)-17-methyl-3-(methyloxy)morphinan; 3-Methoxy-17-methyl-9alpha,13alpha,14alpha-morphinan; 3-Methoxy-17-methylmorphinan; 3-Methoxy-N-methylmorphinon; 9alpha,13alpha,14alpha-Morphinan, 3-methoxy-17-methyl-(8CI) DMUDJZM TC Analgesics DMUDJZM DT Small molecular drug DMUDJZM PC 5360696 DMUDJZM MW 271.4 DMUDJZM FM C18H25NO DMUDJZM IC InChI=1S/C18H25NO/c1-19-10-9-18-8-4-3-5-15(18)17(19)11-13-6-7-14(20-2)12-16(13)18/h6-7,12,15,17H,3-5,8-11H2,1-2H3/t15-,17+,18+/m1/s1 DMUDJZM CS CN1CC[C@@]23CCCC[C@@H]2[C@@H]1CC4=C3C=C(C=C4)OC DMUDJZM IK MKXZASYAUGDDCJ-NJAFHUGGSA-N DMUDJZM IU (1S,9S,10S)-4-methoxy-17-methyl-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-triene DMUDJZM CA CAS 125-71-3 DMUDJZM CB CHEBI:4470 DMUDJZM DE Cough DMEHCY5 ID DMEHCY5 DMEHCY5 DN Dextromethorphan polistirex DMEHCY5 HS Approved DMEHCY5 CP Reckitt Benckiser Llc DMEHCY5 PC 5464025 DMEHCY5 MW 352.3 DMEHCY5 FM C18H26BrNO DMEHCY5 IC InChI=1S/C18H25NO.BrH/c1-19-10-9-18-8-4-3-5-15(18)17(19)11-13-6-7-14(20-2)12-16(13)18;/h6-7,12,15,17H,3-5,8-11H2,1-2H3;1H/t15-,17+,18+;/m1./s1 DMEHCY5 CS CN1CC[C@@]23CCCC[C@@H]2[C@@H]1CC4=C3C=C(C=C4)OC.Br DMEHCY5 IK MISZALMBODQYFT-URVXVIKDSA-N DMEHCY5 IU (1S,9S,10S)-4-methoxy-17-methyl-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-triene;hydrobromide DMEHCY5 CA CAS 125-69-9 DMEHCY5 DE Dry cough DM23HCX ID DM23HCX DM23HCX DN Dextropropoxyphene DM23HCX HS Approved DM23HCX SN Algafan; Antalvic; Destropropossifene; Dextropropoxifeno; Dextropropoxyphen; Dextropropoxyphenum; Dextroproxifeno; Femadol; Levopropoxyphene; Propoxyphene; Proxagesic; Proxyphen; Destropropossifene [DCIT]; Dextroproxifeno [Spanish]; SK 65; D-Propoxyphene; Dextropropoxifeno [INN-Spanish]; Dextropropoxyphene[INN:BAN]; Dextropropoxyphenum [INN-Latin]; Bulk dextropropoxyphene (non-dosage forms); Alpha-4-Dimethylamino-1,2-diphenyl-3-methyl-2-butanol propionate; Alpha-D-4-Dimethylamino-3-methyl-1,2-diphenyl-2-butanol propionate; Alpha-D-4-Dimethylamino-3-methyl-1,2-diphenyl-2-butanol-propionat; Alpha-D-4-Dimethylamino-3-methyl-1,2-diphenyl-2-butanol-propionat [German]; Alpha-(+)-4-Dimethylamino-1,2-diphenyl-3-methyl-2-butanol propionate ester; Alpha-(+)-4-Dimethylamino-1,2-diphenyl-3-methyl-2-propionoxybutane; [(2S,3R)-4-(dimethylamino)-3-methyl-1,2-diphenylbutan-2-yl] propanoate; (+)-1,2-Diphenyl-2-propionoxy-3-methyl-4-dimethylaminobutane; (+)-4-Dimethylamino-1,2-diphenyl-3-methyl-2-propionyloxybutane; (1S,2R)-1-benzyl-3-(dimethylamino)-2-methyl-1-phenylpropyl propanoate; (D)-PROPOXYPHENE; (S)-alpha-(2-(Dimethylamino)-1-methylethyl)-alpha-phenylbenzeneethanol propanoate; 4-Dimethylamino-3-methyl-1,2-diphenyl-2-propoxybutane DM23HCX TC Analgesics DM23HCX DT Small molecular drug DM23HCX PC 10100 DM23HCX MW 339.5 DM23HCX FM C22H29NO2 DM23HCX IC InChI=1S/C22H29NO2/c1-5-21(24)25-22(18(2)17-23(3)4,20-14-10-7-11-15-20)16-19-12-8-6-9-13-19/h6-15,18H,5,16-17H2,1-4H3/t18-,22+/m1/s1 DM23HCX CS CCC(=O)O[C@](CC1=CC=CC=C1)(C2=CC=CC=C2)[C@H](C)CN(C)C DM23HCX IK XLMALTXPSGQGBX-GCJKJVERSA-N DM23HCX IU [(2S,3R)-4-(dimethylamino)-3-methyl-1,2-diphenylbutan-2-yl] propanoate DM23HCX CA CAS 469-62-5 DM23HCX CB CHEBI:51173 DM23HCX DE Pain DMBVEC7 ID DMBVEC7 DMBVEC7 DN Dextrothyroxine Sodium DMBVEC7 HS Approved DMBVEC7 SN Choloxin DMBVEC7 CP Abbvie Inc DMBVEC7 DT Small molecular drug DMBVEC7 PC 23690433 DMBVEC7 MW 798.85 DMBVEC7 FM C15H10I4NNaO4 DMBVEC7 IC InChI=1S/C15H11I4NO4.Na/c16-8-4-7(5-9(17)13(8)21)24-14-10(18)1-6(2-11(14)19)3-12(20)15(22)23;/h1-2,4-5,12,21H,3,20H2,(H,22,23);/q;+1/p-1/t12-;/m1./s1 DMBVEC7 CS C1=C(C=C(C(=C1I)OC2=CC(=C(C(=C2)I)O)I)I)C[C@H](C(=O)[O-])N.[Na+] DMBVEC7 IK YDTFRJLNMPSCFM-UTONKHPSSA-M DMBVEC7 IU sodium;(2R)-2-amino-3-[4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]propanoate DMBVEC7 CA CAS 137-53-1 DMBVEC7 DE High blood cholesterol level DMJDB0Y ID DMJDB0Y DMJDB0Y DN Dezocine DMJDB0Y HS Approved DMJDB0Y SN SCHEMBL1369581; (5R,11S,13S)-13-amino-5-methyl-5,6,7,8,9,10,11,12-octahydro-5,11-methanobenzo[10]annulen-3-ol DMJDB0Y TC Analgesics DMJDB0Y DT Small molecular drug DMJDB0Y PC 3033053 DMJDB0Y MW 245.36 DMJDB0Y FM C16H23NO DMJDB0Y IC InChI=1S/C16H23NO/c1-16-8-4-2-3-5-12(15(16)17)9-11-6-7-13(18)10-14(11)16/h6-7,10,12,15,18H,2-5,8-9,17H2,1H3/t12-,15-,16+/m0/s1 DMJDB0Y CS C[C@]12CCCCC[C@H]([C@@H]1N)CC3=C2C=C(C=C3)O DMJDB0Y IK VTMVHDZWSFQSQP-VBNZEHGJSA-N DMJDB0Y IU (1R,9S,15S)-15-amino-1-methyltricyclo[7.5.1.02,7]pentadeca-2(7),3,5-trien-4-ol DMJDB0Y CA CAS 53648-55-8 DMJDB0Y CB CHEBI:4474 DMJDB0Y DE Pain DMU3FGB ID DMU3FGB DMU3FGB DN Dhaq diacetate DMU3FGB HS Approved DMU3FGB SN Mitoxantrone diacetate; Anthraquinone, 5,8-bis((2-((2-hydroxyethyl)amino)ethyl)amino)-1,4-dihydroxy-, 1,4-diacetate (salt); 1,4-Dihydroxy-5,8-bis(2-((2-hydroxyethyl)amino)ethylamino)-9,10-anthracenedione diacetate; 2-[[5,8-dihydroxy-4-[2-(2-hydroxyethylazaniumyl)ethylamino]-9,10-dioxoanthracen-1-yl]amino]ethyl-(2-hydroxyethyl)azanium diacetate; 5,8-Bis((2-((2-hydroxyethyl)amino)ethyl)amino)-1,4-dihydroxy-9,10-anthracenedione diacetate; 5,8-Bis((2-((2-hydroxyethyl)amino)ethyl)amino)-1,4-dihydroxyanthraquinone 1,4-diaceate DMU3FGB TC Anticancer Agents DMU3FGB DT Small molecular drug DMU3FGB PC 51151 DMU3FGB MW 564.6 DMU3FGB FM C26H36N4O10 DMU3FGB IC InChI=1S/C22H28N4O6.2C2H4O2/c27-11-9-23-5-7-25-13-1-2-14(26-8-6-24-10-12-28)18-17(13)21(31)19-15(29)3-4-16(30)20(19)22(18)32;2*1-2(3)4/h1-4,23-30H,5-12H2;2*1H3,(H,3,4) DMU3FGB CS CC(=O)[O-].CC(=O)[O-].C1=CC(=C2C(=C1NCC[NH2+]CCO)C(=O)C3=C(C=CC(=C3C2=O)O)O)NCC[NH2+]CCO DMU3FGB IK ZWCKUVMZBKQQRG-UHFFFAOYSA-N DMU3FGB IU 2-[[5,8-dihydroxy-4-[2-(2-hydroxyethylazaniumyl)ethylamino]-9,10-dioxoanthracen-1-yl]amino]ethyl-(2-hydroxyethyl)azanium;diacetate DMU3FGB CA CAS 70711-41-0 DMU3FGB DE Solid tumour/cancer DM08E9O ID DM08E9O DM08E9O DN Diazepam DM08E9O HS Approved DM08E9O SN diazepam; Valium; 439-14-5; Diazemuls; Ansiolisina; Sibazon; Relanium; Faustan; Apaurin; Stesolid; Seduxen; Methyldiazepinone; Valitran; Tranqdyn; Seduksen; Relaminal; Quiatril; Quetinil; Dipezona; Diazetard; Diazepan; Calmpose; Tranimul; Tensopam; Serenack; Paranten; Kiatrium; Domalium; Condition; Bialzepam; Ansiolin; Unisedil; Stesolin; Serenamin; Ruhsitus; Renborin; Quievita; Tranquirit; Serenzin; Neurolytril; Liberetas; Diacepan; Ceregulart; Calmocitene; Bensedin; Atensine; Apozepam; Umbrium; Sonacon; Sedipam; Levium; Diapam; Atilen; Assival; Amiprol; Diazepam (intranasal, epilepsy) DM08E9O CP Archimedes Pharma Ltd DM08E9O DT Small molecular drug DM08E9O PC 3016 DM08E9O MW 284.74 DM08E9O FM C16H13ClN2O DM08E9O IC InChI=1S/C16H13ClN2O/c1-19-14-8-7-12(17)9-13(14)16(18-10-15(19)20)11-5-3-2-4-6-11/h2-9H,10H2,1H3 DM08E9O CS CN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3 DM08E9O IK AAOVKJBEBIDNHE-UHFFFAOYSA-N DM08E9O IU 7-chloro-1-methyl-5-phenyl-3H-1,4-benzodiazepin-2-one DM08E9O CA CAS 439-14-5 DM08E9O CB CHEBI:49575 DM08E9O DE Epilepsy DML1538 ID DML1538 DML1538 DN Diazoxide DML1538 HS Approved DML1538 SN Aroglycem; Diazossido; Diazoxido; Diazoxidum; Dizoxide; Eudemine; Hyperstat; Hypertonalum; Mutabase; Proglicem; Proglycem; Diazossido [DCIT]; Diazossido [Italian]; D 9035; SRG 95213; Sch 6783; Diazoxido [INN-Spanish]; Diazoxidum [INN-Latin]; Hyperstat (TN); SRG-95213; Sch-6783; Diazoxide [USAN:INN:BAN]; Diazoxide (JAN/USP/INN); 2H-1,2, 4-Benzothiadiazine, 7-chloro-3-methyl-, 1,1-dioxide; 2H-1,2,4-Benzothiadiazine, 7-chloro-3-methyl-, 1,1-dioxide; 7-Chloro-3-methyl-1lambda~4~,2,4-benzothiadiazin-1-ol 1-oxide; 7-Chloro-3-methyl-2H-1,2,4-benzothiadiazine 1,1-dioxide; 7-Cloro-3-metil-2H-1,2,4-benzotiodiazina-1,1-diossido; 7-Cloro-3-metil-2H-1,2,4-benzotiodiazina-1,1-diossido [Italian]; 7-chloro-3-methyl-4H-1 DML1538 TC Antihypertensive Agents DML1538 DT Small molecular drug DML1538 PC 3019 DML1538 MW 230.67 DML1538 FM C8H7ClN2O2S DML1538 IC InChI=1S/C8H7ClN2O2S/c1-5-10-7-3-2-6(9)4-8(7)14(12,13)11-5/h2-4H,1H3,(H,10,11) DML1538 CS CC1=NS(=O)(=O)C2=C(N1)C=CC(=C2)Cl DML1538 IK GDLBFKVLRPITMI-UHFFFAOYSA-N DML1538 IU 7-chloro-3-methyl-4H-1lambda6,2,4-benzothiadiazine 1,1-dioxide DML1538 CA CAS 364-98-7 DML1538 CB CHEBI:4495 DML1538 DE Hypertension DMF9G7L ID DMF9G7L DMF9G7L DN Dibucaine DMF9G7L HS Approved DMF9G7L SN Cincainum; Cinchocaine; Cinchocainum; Cincocaina; Cincocainio; Dermacaine; Dibucain; Dibucainum; Nupercainal; Nupercaine; Percamine; Sovcaine; Cinchocaine HCL; Cinchocaine hydrochloride; Cincocaina [DCIT]; Dibucaine Base; Dibucaine [USP]; Alpha-Butyloxycinchoninic acid diethylethylenediamide; Cincain (TN); Cinchocaine (INN);Cinchocainum [INN-Latin]; Cincocainio [INN-Spanish]; Dibucaine (USP); Nupercainal (TN); Nupercainal (VAN); Nupercaine (TN); Sovcaine (TN); Alpha-Butyloxycinchonic acid-gamma-diethylethylenediamine; N-[2-(Diethylamino)ethyl]-2-butoxycinchoninamide; N-(2-(Diethylamino)ethyl)-2-butoxycinchoninamide; QUINOLINE,2-BUTOXY,4-CARBOXY,(N-TRIETHYLAMINO) AMIDE CINCHOCAIN; 2-Butoxy-N-(2-(diethylamino)ethyl)cinchoninamide; 2-Butoxy-N-(beta-diethylaminoethyl)cinchoninamide; 2-Butoxy-N-(beta.-diethylaminoethyl)cinchoninamide; 2-Butoxy-N-[2-(diethylamino)ethyl]-4-quinolinecarboxamide; 2-Butoxy-N-[2-(diethylamino)ethyl]cinchoninamide; 2-Butoxy-quinoline-4-carboxylic acid (2-diethylamino-ethyl)-amide; 2-Butoxyquinoline-4-carboxylic acid diethylaminoethylamide; 2-N-Butoxy-N-(2-diethylaminoethyl)cinchoninamide; 2-butoxy-N-(2-diethylaminoethyl)quinoline-4-carboxamide; 2-butoxy-N-(alpha-diethylaminoethyl)cinchoninamide; 2-butoxy-N-[2-(diethylamino)ethyl]quinoline-4-carboxamide DMF9G7L CP Novartis Pharmaceuticals Corp DMF9G7L TC Anesthetics DMF9G7L DT Small molecular drug DMF9G7L PC 3025 DMF9G7L MW 343.5 DMF9G7L FM C20H29N3O2 DMF9G7L IC InChI=1S/C20H29N3O2/c1-4-7-14-25-19-15-17(16-10-8-9-11-18(16)22-19)20(24)21-12-13-23(5-2)6-3/h8-11,15H,4-7,12-14H2,1-3H3,(H,21,24) DMF9G7L CS CCCCOC1=NC2=CC=CC=C2C(=C1)C(=O)NCCN(CC)CC DMF9G7L IK PUFQVTATUTYEAL-UHFFFAOYSA-N DMF9G7L IU 2-butoxy-N-[2-(diethylamino)ethyl]quinoline-4-carboxamide DMF9G7L CA CAS 85-79-0 DMF9G7L CB CHEBI:247956 DMF9G7L DE Anaesthesia DMH7IDQ ID DMH7IDQ DMH7IDQ DN Dichlorphenamide DMH7IDQ HS Approved DMH7IDQ SN dichlorphenamide; Diclofenamide; 120-97-8; 4,5-dichlorobenzene-1,3-disulfonamide; Dichlofenamide; Dichlorophenamide; Daranide; Dichlorphenamid; Glauconide; Antidrasi; Glaucol; Oratrol; Diclofenamidum; Diclofenamida; Diclofenamid; Barastonin; Glaumid; Glafco; Glajust; 4,5-Dichloro-m-benzenedisulfonamide; 1,3-Benzenedisulfonamide, 4,5-dichloro-; Diclofenamidum [INN-Latin]; 4,5-Dichloro-1,3-disulfamoylbenzene; 1,3-Disulfamoyl-4,5-dichlorobenzene; Diclofenamida [INN-Spanish]; 1,3-Disulfamyl-4,5-dichlorobenzene; Dasanide; Keveyis; Antidrasi; Dichlorphenamide [BAN]; Llorens Brand of Dichlorphenamide; Merck Brand of Dichlorphenamide; CB 8000; I7A; Daranide (TN); Dichlorophenamide (DCP); Dichlorphenamide (USP); Diclofenamide (JP15/INN); 3,4-Dichloro-5-sulfamylbenzenesulfonamide; 4,5-Dichloro-1,3-benzenedisulfonamide; 4,5-Dichloro-benzene-1,3-disulfonic acid diamide; 4,5-DICHLOROBENZENE-1,3-DISULFONAMIDE DMH7IDQ TC Antiglaucomic Agents DMH7IDQ DT Small molecular drug DMH7IDQ PC 3038 DMH7IDQ MW 305.2 DMH7IDQ FM C6H6Cl2N2O4S2 DMH7IDQ IC InChI=1S/C6H6Cl2N2O4S2/c7-4-1-3(15(9,11)12)2-5(6(4)8)16(10,13)14/h1-2H,(H2,9,11,12)(H2,10,13,14) DMH7IDQ CS C1=C(C=C(C(=C1S(=O)(=O)N)Cl)Cl)S(=O)(=O)N DMH7IDQ IK GJQPMPFPNINLKP-UHFFFAOYSA-N DMH7IDQ IU 4,5-dichlorobenzene-1,3-disulfonamide DMH7IDQ CA CAS 120-97-8 DMH7IDQ CB CHEBI:101085 DMH7IDQ DE Chronic glaucoma DMPIHLS ID DMPIHLS DMPIHLS DN Diclofenac DMPIHLS HS Approved DMPIHLS SN Diclofenac (sodium matrix patch, pain) DMPIHLS CP Novartis Pharmaceuticals Corp DMPIHLS TC Neurology Agents DMPIHLS DT Small molecular drug DMPIHLS PC 3033 DMPIHLS MW 296.1 DMPIHLS FM C14H11Cl2NO2 DMPIHLS IC InChI=1S/C14H11Cl2NO2/c15-10-5-3-6-11(16)14(10)17-12-7-2-1-4-9(12)8-13(18)19/h1-7,17H,8H2,(H,18,19) DMPIHLS CS C1=CC=C(C(=C1)CC(=O)O)NC2=C(C=CC=C2Cl)Cl DMPIHLS IK DCOPUUMXTXDBNB-UHFFFAOYSA-N DMPIHLS IU 2-[2-(2,6-dichloroanilino)phenyl]acetic acid DMPIHLS CA CAS 15307-86-5 DMPIHLS CB CHEBI:47381 DMPIHLS DE Osteoarthritis DM8EU0Z ID DM8EU0Z DM8EU0Z DN Dicloxacillin DM8EU0Z HS Approved DM8EU0Z SN Dichloroxacillin; Diclossacillina; Dicloxaciclin; Dicloxacilin; Dicloxacilina; Dicloxacilline; Dicloxacillinum; Dicloxacycline; Dycill; Dynapen; Maclicine; Methyldichlorophenylisoxazolylpenicillin; Pathocil; Diclossacillina [DCIT]; Dicloxacillin sodium; BRL 1702; Diclocil (TN); Dicloxacilina [INN-Spanish]; Dicloxacilline [INN-French]; Dicloxacillinum [INN-Latin]; R-13423; Dicloxacillin (USAN/INN); Dicloxacillin [USAN:INN:BAN]; Dicloxacillin, Monosodium Salt, Mono-Hydrate; (2S,5R,6R)-6-({[3-(2,6-dichlorophenyl)-5-methyl-1,2-oxazol-4-yl]carbonyl}amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-({[3-(2,6-dichlorophenyl)-5-methylisoxazol-4-yl]carbonyl}amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-[[3-(2,6-dichlorophenyl)-5-methyl-1,2-oxazole-4-carbonyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 3-(2,6-Dichlorophenyl)-5-methyl-4-isoxazolylpenicillin; 6-(3-(2,6-Dichlorophenyl)-5-methyl-4-isoxazolecarboxamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid; 6-(3-(2,6-Dichlorophenyl)-5-methyl-4-isoxazolecarboxamido)penicillanic acid; 6beta-{[3-(2,6-dichlorophenyl)-5-methyl-1,2-oxazol-4-yl]carboxamido}-2,2-dimethylpenam-3alpha-carboxylic acid DM8EU0Z CP Sandoz Inc DM8EU0Z TC Antibiotics DM8EU0Z DT Small molecular drug DM8EU0Z PC 18381 DM8EU0Z MW 470.3 DM8EU0Z FM C19H17Cl2N3O5S DM8EU0Z IC InChI=1S/C19H17Cl2N3O5S/c1-7-10(12(23-29-7)11-8(20)5-4-6-9(11)21)15(25)22-13-16(26)24-14(18(27)28)19(2,3)30-17(13)24/h4-6,13-14,17H,1-3H3,(H,22,25)(H,27,28)/t13-,14+,17-/m1/s1 DM8EU0Z CS CC1=C(C(=NO1)C2=C(C=CC=C2Cl)Cl)C(=O)N[C@H]3[C@@H]4N(C3=O)[C@H](C(S4)(C)C)C(=O)O DM8EU0Z IK YFAGHNZHGGCZAX-JKIFEVAISA-N DM8EU0Z IU (2S,5R,6R)-6-[[3-(2,6-dichlorophenyl)-5-methyl-1,2-oxazole-4-carbonyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid DM8EU0Z CA CAS 3116-76-5 DM8EU0Z CB CHEBI:4511 DM8EU0Z DE Bacterial infection DMFQCB1 ID DMFQCB1 DMFQCB1 DN Dicumarol DMFQCB1 HS Approved DMFQCB1 SN Acadyl; Acavyl; Anathrombase; Antitrombosin; Apekumarol; Baracoumin; Bishydroxycoumarin; Cuma; Cumid; Dicoumal; Dicoumarin; Dicoumarol; Dicoumarolum; Dicoumerol; Dicuman; Dicumarine; Dicumarinum; Dicumarolo; Dicumarolum; Dicumol; Dikumarol; Dufalone; Dwukumarol; Kumoran; Melitoxin; Temparin; Trombosan; Dicumaol R; Dicumarol [USAN]; Dicumarolo [DCIT]; Dwukumarol [Polish]; Uncoupler of oxidative respiration; M0216; NC 034; Bis-hydroxycoumarin; Dicoumarol (INN); Dicoumarolum [INN-Latin]; Dicumarol (TN); Dicumarol (USAN); Dicumarol [INN-Spanish]; Symmetric dicoumarol analogue, 1; Bis(4-hydroxycoumarin-3-yl)methane; Di-(4-hydroxy-3-coumarinyl)methane; Bis-3,3'-(4-hydroxycoumarinyl)methane; Bis-3,3'-(4-oxycoumarinyl)ethylacetate; Di-4-hydroxy-3,3'-methylenedicoumarin; Coumarin, 3,3'-methylenebis[4-hydroxy-(8CI); 2-hydroxy-3-[(2-hydroxy-4-oxochromen-3-yl)methyl]chromen-4-one; 2H-1-Benzopyran-2-one, 3,3'-methylenebis[4-hydroxy-(9CI); 3,3′-Methylenebis(4-hydroxycoumarin); 3,3'-Methyleen-bis(4-hydroxy-cumarine); 3,3'-Methyleen-bis(4-hydroxy-cumarine) [Dutch]; 3,3'-Methylen-bis(4-hydroxy-cumarin); 3,3'-Methylen-bis(4-hydroxy-cumarin) [German]; 3,3'-Methylene-bis(4-hydroxycoumarin); 3,3'-Methylene-bis(4-hydroxycoumarine); 3,3'-Methylene-bis(4-hydroxycoumarine) [French]; 3,3'-Methylenebis(4-hydroxy-1,2-benzopyrone); 3,3'-Methylenebis(4-hydroxy-2H-1-benzopyran-2-one); 3,3'-Methylenebis(4-hydroxycoumarin); 3,3'-Methylenebis[4-hydroxy-1,2-benzopyrone]; 3,3'-Methylenebis[4-hydroxy-2H-1-benzopyran-2-one]; 3,3'-Methylenebis[4-hydroxycoumarin]; 3,3'-Metilen-bis(4-idrossi-cumarina); 3,3'-Metilen-bis(4-idrossi-cumarina) [Italian]; 3,3'-methanediylbis(4-hydroxy-2H-chromen-2-one); 3,3'-methylenebis(2-hydroxy-4h-chromen-4-one); 3,3'-methylenebis(4-hydroxy-2H-chromen-2-one); 3,3-Methylene-bis[4-hydroxycoumarin]; 4,4'-Dihydroxy-3,3'-methylene bis coumarin DMFQCB1 TC Anticoagulants DMFQCB1 DT Small molecular drug DMFQCB1 PC 54676038 DMFQCB1 MW 336.3 DMFQCB1 FM C19H12O6 DMFQCB1 IC InChI=1S/C19H12O6/c20-16-10-5-1-3-7-14(10)24-18(22)12(16)9-13-17(21)11-6-2-4-8-15(11)25-19(13)23/h1-8,20-21H,9H2 DMFQCB1 CS C1=CC=C2C(=C1)C(=C(C(=O)O2)CC3=C(C4=CC=CC=C4OC3=O)O)O DMFQCB1 IK DOBMPNYZJYQDGZ-UHFFFAOYSA-N DMFQCB1 IU 4-hydroxy-3-[(4-hydroxy-2-oxochromen-3-yl)methyl]chromen-2-one DMFQCB1 CA CAS 66-76-2 DMFQCB1 CB CHEBI:4513 DMFQCB1 DE Thrombosis; Bleeding disorder DMZSDGX ID DMZSDGX DMZSDGX DN Dicyclomine DMZSDGX HS Approved DMZSDGX SN Atumin; Bentomine; Bentylol; Dicicloverina; Dicycloverin; Dicycloverine; Dicycloverinum; Dicymine; Diocyl; Dyspas; Formulex; Mamiesan; Merbentyl; Procyclomin; Sawamin; Spasmoban; Wyovin; Bentyl hydrochloride; Bentylol hydrochloride; Dicyclomine Hcl; Dicycloverin hydrochloride; Diethylaminocarbethoxybicyclohexyl hydrochloride; Diocyl hydrochloride; Kolantyl hydrochloride; Wyovin hydrochloride; GU8471000; Bentyl (TN); Bentylol (TN); Byclomine (TN); Di-syntramine; Dibent (TN); Dicicloverina [INN-Spanish]; Dicycloverine (INN); Dicycloverine [INN:BAN]; Dicycloverinum [INN-Latin]; Dicymine (TN); Dilomine (TN); Formulex (TN); Lomine (TN); Merbentyl (TN); Oxityl-P; Beta-Diethylaminoethyl 1-cyclohexylcyclohexanecarboxylate hydrochloride; Di-Spaz (TN); J.L. 998; Beta-Diethylaminoethyl-1-cyclohexylhexahydrobenzoate hydrochloride; Bicyclohexyl-1-carbonsaeure-2'diethylaminoethylester; [Bicyclohexyl]-1-carboxylic acid, 2-(diethylamino)ethyl ester hydrochloride; Cyclohexanecarboxylic acid, 1-cyclohexyl-, 2-(diethylamino)ethyl ester; [1,1'-Bicyclohexyl]-1-carboxylic acid, 2-(diethylamino)ethyl ester; (1,1'-Bicyclohexyl)-1-carboxylic acid, 2-(diethylamino)ethyl ester; (BICYCLOHEXYL)-1-CARBOXYLIC ACID, 2-(DIETHYLAMINO)ETHYL ESTER, HYDROCHLORIDE; (Bicyclohexyl)-1-carboxylic acid, 2-(diethylamino)ethyl ester; 1-Cyclohexylcyclohexanecarboxylic acid 2-(diethylamino)ethyl ester; 2-(diethylamino)ethyl 1,1'-bi(cyclohexyl)-1-carboxylate; 2-(diethylamino)ethyl 1-cyclohexylcyclohexane-1-carboxylate; 2-diethylaminoethyl 1-cyclohexylcyclohexane-1-carboxylate; 2-diethylaminoethyl 1-cyclohexylcyclohexane-1-carboxylate hydrochloride DMZSDGX CP Peckforton Pharmaceuticals DMZSDGX TC Anticholinergic Agents DMZSDGX DT Small molecular drug DMZSDGX PC 3042 DMZSDGX MW 309.5 DMZSDGX FM C19H35NO2 DMZSDGX IC InChI=1S/C19H35NO2/c1-3-20(4-2)15-16-22-18(21)19(13-9-6-10-14-19)17-11-7-5-8-12-17/h17H,3-16H2,1-2H3 DMZSDGX CS CCN(CC)CCOC(=O)C1(CCCCC1)C2CCCCC2 DMZSDGX IK CURUTKGFNZGFSE-UHFFFAOYSA-N DMZSDGX IU 2-(diethylamino)ethyl 1-cyclohexylcyclohexane-1-carboxylate DMZSDGX CA CAS 77-19-0 DMZSDGX CB CHEBI:4514 DMZSDGX DE Functional bowel syndrome DMI2QPE ID DMI2QPE DMI2QPE DN Didanosine DMI2QPE HS Approved DMI2QPE SN didanosine; 69655-05-6; DIDEOXYINOSINE; Videx; Videx EC; Inosine, 2',3'-dideoxy-; ddIno; Didanosina; Didanosinum; DDI; BMY-40900; UNII-K3GDH6OH08; K3GDH6OH08; Didanosinum [INN-Latin]; Didanosina [INN-Spanish]; CHEBI:490877; 9-(2,3-Dideoxy-beta-D-ribofuranosyl)-6-oxopurine; NSC 612049; 9-[(2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl]-1,9-dihydro-6H-purin-6-one; 9-[(2R,5R)-5-(HYDROXYMETHYL)TETRAHYDROFURAN-2-YL]-1,9-DIHYDRO-6H-PURIN-6-ONE; NCGC00159514-02; NCGC00090691-03; DRG-0016; BMY 40900; DSSTox_CID_2927 DMI2QPE CP Bristol-Myers Squibb DMI2QPE TC Anti-HIV Agents DMI2QPE DT Small molecular drug DMI2QPE PC 135398739 DMI2QPE MW 236.23 DMI2QPE FM C10H12N4O3 DMI2QPE IC InChI=1S/C10H12N4O3/c15-3-6-1-2-7(17-6)14-5-13-8-9(14)11-4-12-10(8)16/h4-7,15H,1-3H2,(H,11,12,16)/t6-,7+/m0/s1 DMI2QPE CS C1C[C@@H](O[C@@H]1CO)N2C=NC3=C2N=CNC3=O DMI2QPE IK BXZVVICBKDXVGW-NKWVEPMBSA-N DMI2QPE IU 9-[(2R,5S)-5-(hydroxymethyl)oxolan-2-yl]-1H-purin-6-one DMI2QPE CA CAS 69655-05-6 DMI2QPE CB CHEBI:490877 DMI2QPE DE Human immunodeficiency virus infection DMBSXI0 ID DMBSXI0 DMBSXI0 DN Dienestrol DMBSXI0 HS Approved DMBSXI0 SN Agaldog; Cycladiene; Dehydrostilbestrol; Dehydrostilboestrol; Dienesterol; Dienestrolo; Dienestrolum; Dienoestrol; Dienol; Dinestrol; Dinovex; Estragard; Estraguard; Estrodienol; Estroral; Follidiene; Follormon; Gynefollin; Hormofemin; Isodienestrol; Oestrasid; Oestrodiene; Oestrodienol; Oestroral; Oestrovis; Restrol; Retalon; Sexadien; Synestrol; Teserene; Willnestrol; Dienestrolo [DCIT]; Dienoestrol [Nonsteroidal oestrogens]; Dienoestrol bp; Alpha-Dienestrol; DV (TN); Dienestrolum [INN-Latin]; Para-Dien; Restrol, Dienestrol; Dienestrol (E,E); Dienestrol (USP/INN); Dienestrol, (E,E)-Isomer; P,p'-(Diethylideneethylene)diphenol; Para,para'-(Diethylideneethylene)diphenol; Di(p-oxyphenyl)-2,4-hexadiene; Di(para-oxyphenyl)-2,4-hexadiene; Phenol, 4,4'-(1,2-diethylidene-1,2-ethanediyl)bis-, (E,E-(9CI); (E,E)-Dienestrol; 3,4-Bis(4-hydroxyphenyl)-2,4-hexadiene; 3,4-Bis(p-hydroxyphenyl)-2,4-hexadiene; 3,4-Bis(para-hydroxyphenyl)-2,4-hexadiene; 4,4'-(1,2-Diethylidene-1,2-ethanediyl)bisphenol; 4,4'-(2E,4E)-hexa-2,4-diene-3,4-diyldiphenol; 4,4'-(Diethylideneethylene)diphenol; 4,4'-Dihydroxy-gamma,delta-diphenyl-beta,delta-hexadiene; 4,4'-Hydroxy-gamma,delta-diphenyl-beta,delta-hexadiene; 4,4'-hexa-2,4-diene-3,4-diyldiphenol; 4-[(2E,4E)-4-(4-hydroxyphenyl)hexa-2,4-dien-3-yl]phenol DMBSXI0 TC Estrogens DMBSXI0 DT Small molecular drug DMBSXI0 PC 667476 DMBSXI0 MW 266.3 DMBSXI0 FM C18H18O2 DMBSXI0 IC InChI=1S/C18H18O2/c1-3-17(13-5-9-15(19)10-6-13)18(4-2)14-7-11-16(20)12-8-14/h3-12,19-20H,1-2H3/b17-3+,18-4+ DMBSXI0 CS C/C=C(/C(=C/C)/C1=CC=C(C=C1)O)\\C2=CC=C(C=C2)O DMBSXI0 IK NFDFQCUYFHCNBW-SCGPFSFSSA-N DMBSXI0 IU 4-[(2E,4E)-4-(4-hydroxyphenyl)hexa-2,4-dien-3-yl]phenol DMBSXI0 CA CAS 13029-44-2 DMBSXI0 CB CHEBI:4518 DMBSXI0 DE Atrophic vaginitis DM1TJ8F ID DM1TJ8F DM1TJ8F DN Diethylcarbamazine DM1TJ8F HS Approved DM1TJ8F SN Bitirazine; Camin; Caracide; Carbamazine; Carbilazine; Caricide; Cypip; Decacide; Diaethylcarbamazinum; Diethylcarbamazinum; Dietilcarbamazina; Ethodryl; Luxuran; Notezine; Spatonin; Diethyl carbamazine; Ditrazine Base; Banocide (TN); Camin (TN); Carbilazine (TN); Caricide (TN); Cypip (TN); Diethylcarbamazine (INN); Diethylcarbamazine [INN:BAN]; Diethylcarbamazinum [INN-Latin]; Dietilcarbamazina [INN-Spanish]; Ethodryl (TN); FR-1031; Filaribits (TN); Forte (TN); Hetrazan (TN); Spatonin (TN); N,N-Diethyl-4-methyl-1-piperazinecarboxamide; N,N-diethyl-4-methylpiperazine-1-carboxamide; 1-Diethylcarbamyl-4-methylpiperazine; 84L DM1TJ8F CP Lederle Laboratories Div American Cyanamid Co DM1TJ8F TC Anthelmintics DM1TJ8F DT Small molecular drug DM1TJ8F PC 3052 DM1TJ8F MW 199.29 DM1TJ8F FM C10H21N3O DM1TJ8F IC InChI=1S/C10H21N3O/c1-4-12(5-2)10(14)13-8-6-11(3)7-9-13/h4-9H2,1-3H3 DM1TJ8F CS CCN(CC)C(=O)N1CCN(CC1)C DM1TJ8F IK RCKMWOKWVGPNJF-UHFFFAOYSA-N DM1TJ8F IU N,N-diethyl-4-methylpiperazine-1-carboxamide DM1TJ8F CA CAS 90-89-1 DM1TJ8F CB CHEBI:4527 DM1TJ8F DE Lymphatic filariasis DMN3UXQ ID DMN3UXQ DMN3UXQ DN Diethylstilbestrol DMN3UXQ HS Approved DMN3UXQ SN Acnestrol; Agostilben; Antigestil; Apstil; Bufon; Climaterine; Comestrol; Cyren; DES; Desma; Destrol; Diaethylstilboestrolum; Diastyl; Dibestrol; Dicorvin; Diethylstilbesterol; Diethylstilbestrolum; Diethylstilboesterol; Dietilestilbestrol; Dietilstilbestrolo; Distilbene; Domestrol; Dyestrol; Estril; Estrobene; Estrogenine; Estromenin; Estrosyn; Fonatol; Grafestrol; Gynopharm; Hibestrol; Idroestril; Iscovesco; Makarol; Menostilbeen; Micrest; Microest; Milestrol; OeKolp; Oestrogenine; Oestrolmensil; Oestromenin; Oestromensil; Oestromensyl; Oestromienin; Oestromon; Pabestrol; Palestrol; Protectona; Sedestran; Serral; Sexocretin; Sibol; Sintestrol; Stibilium; Stilbestroform; Stilbestrol; Stilbestrone; Stilbetin; Stilboefral; Stilboestroform; Stilboestrol; Stilbofolin; Stilbofollin; Stilbol; Stilkap; Strobene; Synestrin; Synthestrin; Synthoestrin; Synthofolin; Syntofolin; Tampovagan; Tylosterone; Vagestrol; APS Brand of Diethylstilbestrol; Anti gestil; Co Pharma Brand of Diethylstilbestrol; Comestrol estrobene; Cyren A; Diethylstilbestrol BP; Dietilestilbestrol [Spanish]; Dietilstilbestrolo [DCIT]; Estilbin MCO; Gerda Brand of Diethylstilbestrol; Oestrol vetag; Percutatrine oestrogenique iscovesco; ST IL; Stilbene Estrogen; Tampovagan stilboestrol; DiBestrol 2 Premix; MG 137; Rumestrol 1; Rumestrol 2; Cis-Des; Cis-Diethylstilbesterol; Cis-Diethylstilbestrol; Co-Pharma Brand of Diethylstilbestrol; DES (synthetic estrogen); Dawe's destrol; Di-Estryl; Diethylstilbestrol (DES); Diethylstilbestrol [USAN:INN]; Diethylstilbestrol, Disodium Salt; Diethylstilbestrolum [INN-Latin]; Dietilestilbestrol [INN-Spanish]; E-Diethylstilbestrol; Estilbin (MCO); Estrogen, Stilbene; Hi-Bestrol; Neo-Oestranol 1; Neo-Oestranol I; Neo-oe stranol 1; New-Estranol 1; Stil-Rol; Stilbestrol (TN); TRANS-DIETHYSTILBESTEROL; TRANSGENIC MODEL EVALUATION (DES); Trans-Diethylstilbesterol; Trans-Diethylstilbestrol; Trans-Diethylstilboesterol; DiBestrol "2" Premix; Dibestrol '2' premix; Diethylstilbestrol (USP/INN); Alpha,alpha'-Diethylstilbenediol; Diethylstilbestrol, (Z)-Isomer; Alpha,alpha'-Diethyl-4,4'-stilbenediol; (E)-3,4-Bis(4-hydroxyphenyl)-3-hexene; (E)-4,4'-(hex-3-ene-3,4-diyl)diphenol; (E)-Diethylstilbestrol; 3,4'(4,4'-Dihydroxyphenyl)hex-3-ene; 3,4-Bis(p-hydroxyphenyl)-3-hexene; 3,4-bis(4-hydroxyphenyl)hex-3-ene; 4,4'-(3E)-hex-3-ene-3,4-diyldiphenol; 4,4'-Dihydroxydiethylstilbene; 4,4'-hex-3-ene-3,4-diyldiphenol DMN3UXQ CP Bayer Pharmaceuticals Corp DMN3UXQ TC Anticancer Agents DMN3UXQ DT Small molecular drug DMN3UXQ PC 448537 DMN3UXQ MW 268.3 DMN3UXQ FM C18H20O2 DMN3UXQ IC InChI=1S/C18H20O2/c1-3-17(13-5-9-15(19)10-6-13)18(4-2)14-7-11-16(20)12-8-14/h5-12,19-20H,3-4H2,1-2H3/b18-17+ DMN3UXQ CS CC/C(=C(/CC)\\C1=CC=C(C=C1)O)/C2=CC=C(C=C2)O DMN3UXQ IK RGLYKWWBQGJZGM-ISLYRVAYSA-N DMN3UXQ IU 4-[(E)-4-(4-hydroxyphenyl)hex-3-en-3-yl]phenol DMN3UXQ CA CAS 56-53-1 DMN3UXQ CB CHEBI:41922 DMN3UXQ DE Gonorrheal vaginitis DMI9PRJ ID DMI9PRJ DMI9PRJ DN Diflorasone DMI9PRJ HS Approved DMI9PRJ SN Diflorasona; Diflorasonum; Maxiflor; Murode; U 34865; Diflorasona [INN-Spanish]; Diflorasone (INN); Diflorasone [INN:BAN]; Diflorasonum [INN-Latin]; Murode (TN); (6S,8S,9R,10S,11S,13S,14S,16S,17R)-6,9-difluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; (6alpha,11beta,16beta)-6,9-difluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione; 6a,9a-difluoro-16b-methylprednisolone; 6alpha,9-Difluoro-11beta,17,21-trihydroxy-16beta-methylpregna-1,4-diene-3,20-dione DMI9PRJ CP Pharmacia And Upjohn Co DMI9PRJ TC Antiinflammatory Agents DMI9PRJ DT Small molecular drug DMI9PRJ PC 71415 DMI9PRJ MW 410.5 DMI9PRJ FM C22H28F2O5 DMI9PRJ IC InChI=1S/C22H28F2O5/c1-11-6-13-14-8-16(23)15-7-12(26)4-5-19(15,2)21(14,24)17(27)9-20(13,3)22(11,29)18(28)10-25/h4-5,7,11,13-14,16-17,25,27,29H,6,8-10H2,1-3H3/t11-,13-,14-,16-,17-,19-,20-,21-,22-/m0/s1 DMI9PRJ CS C[C@H]1C[C@H]2[C@@H]3C[C@@H](C4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)F)C)F DMI9PRJ IK WXURHACBFYSXBI-XHIJKXOTSA-N DMI9PRJ IU (6S,8S,9R,10S,11S,13S,14S,16S,17R)-6,9-difluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one DMI9PRJ CA CAS 2557-49-5 DMI9PRJ CB CHEBI:59750 DMI9PRJ DE Rosacea DM7EN8I ID DM7EN8I DM7EN8I DN Diflunisal DM7EN8I HS Approved DM7EN8I SN Adomal; Algobid; Citidol; Difludol; Diflunisalum; Dolisal; Dolobid; Dolobil; Dolobis; Dolocid; Flovacil; Fluniget; Fluodonil; Flustar; Noaldol; Reuflos; Unisal; Apotex Brand of Diflunisal; Cahill May Roberts Brand of Diflunisal; Diflunisal Novopharm Brand; Frosst SA Brand of Diflunisal; Merck Brand of Diflunisal; Novopharm Brand of Diflunisal; Nu Pharm Brand of Diflunisal; MK 647; MK647; Apo-Diflunisal; Diflunisalum [INN-Latin]; Dolobid (TN); MK-647; Merck Sharp & Dohme Brand of Diflunisal; Novo-Diflunisal; Nu-Diflunisal; Nu-Pharm Brand of Diflunisal; Diflunisal (JAN/USP/INN); Diflunisal [USAN:INN:BAN:JAN]; 2',4'-Difluoro-4-hydroxy-(1,1'-biphenyl)-3-carboxylic acid; 2',4'-Difluoro-4-hydroxy-3-biphenylcarboxylic acid; 2',4'-difluoro-4-hydroxybiphenyl-3-carboxylic acid; 2-(Hydroxy)-5-(2,4-difluorophenyl)benzoic acid; 5-(2,4-DIFLUOROPHENYL)-2-HYDROXY-BENZOIC ACID; 5-(2,4-Difluorophenyl)salicylic acid; 5-(2,4-difluorophenyl)-2-hydroxybenzoic acid; 5-[2,4-Difluorophenyl]salicylic acid DM7EN8I CP Merck & Co DM7EN8I TC Analgesics DM7EN8I DT Small molecular drug DM7EN8I PC 3059 DM7EN8I MW 250.2 DM7EN8I FM C13H8F2O3 DM7EN8I IC InChI=1S/C13H8F2O3/c14-8-2-3-9(11(15)6-8)7-1-4-12(16)10(5-7)13(17)18/h1-6,16H,(H,17,18) DM7EN8I CS C1=CC(=C(C=C1C2=C(C=C(C=C2)F)F)C(=O)O)O DM7EN8I IK HUPFGZXOMWLGNK-UHFFFAOYSA-N DM7EN8I IU 5-(2,4-difluorophenyl)-2-hydroxybenzoic acid DM7EN8I CA CAS 22494-42-4 DM7EN8I CB CHEBI:39669 DM7EN8I DE Pain DMMFVB3 ID DMMFVB3 DMMFVB3 DN Difluprednate DMMFVB3 HS Approved DMMFVB3 SN Durezol (TN) DMMFVB3 CP Sirion DMMFVB3 DT Small molecular drug DMMFVB3 PC 443936 DMMFVB3 MW 508.5 DMMFVB3 FM C27H34F2O7 DMMFVB3 IC InChI=1S/C27H34F2O7/c1-5-6-23(34)36-26(22(33)14-35-15(2)30)10-8-17-18-12-20(28)19-11-16(31)7-9-24(19,3)27(18,29)21(32)13-25(17,26)4/h7,9,11,17-18,20-21,32H,5-6,8,10,12-14H2,1-4H3/t17-,18-,20-,21-,24-,25-,26-,27-/m0/s1 DMMFVB3 CS CCCC(=O)O[C@@]1(CC[C@@H]2[C@@]1(C[C@@H]([C@]3([C@H]2C[C@@H](C4=CC(=O)C=C[C@@]43C)F)F)O)C)C(=O)COC(=O)C DMMFVB3 IK WYQPLTPSGFELIB-JTQPXKBDSA-N DMMFVB3 IU [(6S,8S,9R,10S,11S,13S,14S,17R)-17-(2-acetyloxyacetyl)-6,9-difluoro-11-hydroxy-10,13-dimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] butanoate DMMFVB3 CA CAS 23674-86-4 DMMFVB3 CB CHEBI:31485 DMMFVB3 DE Ocular pain DMWVIGP ID DMWVIGP DMWVIGP DN Digitoxin DMWVIGP HS Approved DMWVIGP SN Acedoxin; Asthenthilo; Cardidigin; Cardigin; Cardiolanata; Carditalin; Carditoxin; Coramedan; Cristapurat; Crystodigin; Digicor; Digilanid; Digilong; Digimed; Digimerck; Digipural; Digisidin; Digitoksim; Digitoksin; Digitophyllin; Digitossina; Digitoxina; Digitoxine; Digitoxinum; Digitoxoside; Digitoxosidum; Digitrin; Ditaven; Glucodigin; Lanatoxin; Lanostabil; Monodigitoxoside; Myodigin; Natigal; Pandigal; Panlanat; Purodigin; Purpurid; Tardigal; Unidigin; Crystalline digitalin; Digitaline cristallisee; Digitaline nativelle; Digitalinum verum; Digitossina [DCIT]; Digitoxigenin tridigitoxoside; LT00244784; Crystodigin (TN); De-Tone; Digitalin, crystalline; Digitaline (TN); Digitoxigenin-tridigitoxosid; Digitoxigenin-tridigitoxosid [German]; Digitoxina [INN-Spanish]; Digitoxine [INN-French]; Digitoxinum [INN-Latin]; Mono-digitoxid; Mono-digitoxid [German]; Mono-glycocard; Purodigin, crystalline; Tri-digitoxoside; Tri-digitoxoside [German]; Digitoxin [INN:BAN:JAN]; Digitoxin (JP15/USP/INN); Inhibits Na+/K+ ATPase; 5.beta.-Card-20(22)-enolide, 3.beta.,14-dihydroxy-, 3-[tris-(digitoxoside)] DMWVIGP TC Antiarrhythmic Agents DMWVIGP DT Small molecular drug DMWVIGP PC 441207 DMWVIGP MW 764.9 DMWVIGP FM C41H64O13 DMWVIGP IC InChI=1S/C41H64O13/c1-20-36(46)29(42)16-34(49-20)53-38-22(3)51-35(18-31(38)44)54-37-21(2)50-33(17-30(37)43)52-25-8-11-39(4)24(15-25)6-7-28-27(39)9-12-40(5)26(10-13-41(28,40)47)23-14-32(45)48-19-23/h14,20-22,24-31,33-38,42-44,46-47H,6-13,15-19H2,1-5H3/t20-,21-,22-,24-,25+,26-,27+,28-,29+,30+,31+,33+,34+,35+,36-,37-,38-,39+,40-,41+/m1/s1 DMWVIGP CS C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5CC[C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)C)C)C)O)O DMWVIGP IK WDJUZGPOPHTGOT-XUDUSOBPSA-N DMWVIGP IU 3-[(3S,5R,8R,9S,10S,13R,14S,17R)-3-[(2R,4S,5S,6R)-5-[(2S,4S,5S,6R)-5-[(2S,4S,5S,6R)-4,5-dihydroxy-6-methyloxan-2-yl]oxy-4-hydroxy-6-methyloxan-2-yl]oxy-4-hydroxy-6-methyloxan-2-yl]oxy-14-hydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2H-furan-5-one DMWVIGP CA CAS 71-63-6 DMWVIGP CB CHEBI:28544 DMWVIGP DE Heart failure; Arrhythmia; Congestive cardiac insufficiency DMQCTIH ID DMQCTIH DMQCTIH DN Digoxin DMQCTIH HS Approved DMQCTIH SN digoxin; 20830-75-5; 12beta-Hydroxydigitoxin; Digoxine; Lanoxin; Lanoxicaps; Digossina; Digoxina; Digoxinum; Digosin; Lanicor; Digacin; Dilanacin; CHEBI:4551; MLS000069819; Lanacordin; Cardiogoxin; Eudigox; Davoxin; SMR000059217; Rougoxin; Mapluxin; Lenoxin; Lanacrist; Dynamos; Vanoxin; Neo-Lanicor; Lanoxin PG; Digoxin Pediatric; Digoxin Nativelle; SK-Digoxin; UNII-73K4184T59; Homolle's digitalin; Hemigoxine Nativelle; MFCD00003674; Digitek (TN); Lanoxicaps (TN); Lanoxin (TN); Digoxin (JP15/USP); (3beta,5beta,12beta)-3-{[2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl]oxy}-12,14-dihydroxycard-20(22)-enolide; 4-[(1S,2S,5S,7R,10R,11S,14R,15S,16R)-5-{[(2R,4S,5S,6R)-5-{[(2S,4S,5S,6R)-5-{[(2S,4S,5S,6R)-4,5-dihydroxy-6-methyloxan-2-yl]oxy}-4-hydroxy-6-methyloxan-2-yl]oxy}-4-hydroxy-6-methyloxan-2-yl]oxy}-11,16-dihydroxy-2,15-dimethyltetracyclo[8700^{2,7}; [3H]digoxin DMQCTIH CP GlaxoSmithKline DMQCTIH TC Antiarrhythmic Agents DMQCTIH DT Small molecular drug DMQCTIH PC 2724385 DMQCTIH MW 780.9 DMQCTIH FM C41H64O14 DMQCTIH IC InChI=1S/C41H64O14/c1-19-36(47)28(42)15-34(50-19)54-38-21(3)52-35(17-30(38)44)55-37-20(2)51-33(16-29(37)43)53-24-8-10-39(4)23(13-24)6-7-26-27(39)14-31(45)40(5)25(9-11-41(26,40)48)22-12-32(46)49-18-22/h12,19-21,23-31,33-38,42-45,47-48H,6-11,13-18H2,1-5H3/t19-,20-,21-,23-,24+,25-,26-,27+,28+,29+,30+,31-,33+,34+,35+,36-,37-,38-,39+,40+,41+/m1/s1 DMQCTIH CS C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O DMQCTIH IK LTMHDMANZUZIPE-PUGKRICDSA-N DMQCTIH IU 3-[(3S,5R,8R,9S,10S,12R,13S,14S,17R)-3-[(2R,4S,5S,6R)-5-[(2S,4S,5S,6R)-5-[(2S,4S,5S,6R)-4,5-dihydroxy-6-methyloxan-2-yl]oxy-4-hydroxy-6-methyloxan-2-yl]oxy-4-hydroxy-6-methyloxan-2-yl]oxy-12,14-dihydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2H-furan-5-one DMQCTIH CA CAS 20830-75-5 DMQCTIH CB CHEBI:4551 DMQCTIH DE Heart failure; Arrhythmia; Congestive cardiac insufficiency DMZIXU9 ID DMZIXU9 DMZIXU9 DN Dihydralazine DMZIXU9 HS Approved DMZIXU9 SN Dihydralazine sulfate; 7327-87-9; Dihydralazine sulphate; 1,4-Dihydrazinophthalazine sulfate; Depressan; Hydralazine sulfate; Ophthazin Sulfate; UNII-1C2B1W91NK; CCRIS 5386; Sulfate de dihydralazine [French]; 1,4-Dihydrazinylphthalazine Sulfate; EINECS 230-808-0; 1C2B1W91NK; Phthalazine, 1,4-dihydrazino-, sulfate (1:1); 1,4-Dihydrazinophthalazine hydrogen sulfate; W-104459; Sulfate de dihydralazine; 1,4-dihydrazinophthalazine sulfate(1:1); Dihydralazinsulfat; C8H10N6.H2O4S; Nepresol (TN); Dihydralazine Sulfate,(S); AC1Q6XE2 DMZIXU9 DT Small molecular drug DMZIXU9 PC 10230 DMZIXU9 MW 190.21 DMZIXU9 FM C8H10N6 DMZIXU9 IC InChI=1S/C8H10N6/c9-11-7-5-3-1-2-4-6(5)8(12-10)14-13-7/h1-4H,9-10H2,(H,11,13)(H,12,14) DMZIXU9 CS C1=CC=C2C(=C1)C(=NN=C2NN)NN DMZIXU9 IK VQKLRVZQQYVIJW-UHFFFAOYSA-N DMZIXU9 IU (4-hydrazinylphthalazin-1-yl)hydrazine DMZIXU9 CA CAS 484-23-1 DMZIXU9 CB CHEBI:134841 DMZIXU9 DE Hypertension DMBXVMZ ID DMBXVMZ DMBXVMZ DN Dihydroartemisinin DMBXVMZ HS Approved DMBXVMZ SN Artenimol; Cotecxin; Dihydroartemisinine; Dihydroqinghaosu; Dihydroquinghaosu; Dihydroquinghoasu; VM3352; Artenimol (INN); JAV-110; GNF-PF-5634; (3R,5aS,6R,8aS,9R,12R,12aR)-3,6,9-trimethyldecahydro-3,12-epoxypyrano[4,3-j][1,2]benzodioxepin-10-ol; [3R-(3.alpha.,5a.beta.,6.beta.,8a.beta.,9.alpha.,10.alpha.,12.beta.,12aR*)]-Decahydro-10-hydroxy-3,6,9-trimethyl-3,12-epoxy-12H-pyrano[4.3-j]-1,2-benzodioxepin; 1,5,9-trimethyl-(1R,4S,5R,8S,9R,10S,12R,13R)-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-10-ol(Dihydroartemisinin) DMBXVMZ DT Small molecular drug DMBXVMZ PC 3000518 DMBXVMZ MW 284.35 DMBXVMZ FM C15H24O5 DMBXVMZ IC InChI=1S/C15H24O5/c1-8-4-5-11-9(2)12(16)17-13-15(11)10(8)6-7-14(3,18-13)19-20-15/h8-13,16H,4-7H2,1-3H3/t8-,9-,10+,11+,12+,13-,14-,15-/m1/s1 DMBXVMZ CS C[C@@H]1CC[C@H]2[C@H]([C@H](O[C@H]3[C@@]24[C@H]1CC[C@](O3)(OO4)C)O)C DMBXVMZ IK BJDCWCLMFKKGEE-ISOSDAIHSA-N DMBXVMZ IU (1R,4S,5R,8S,9R,10S,12R,13R)-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-10-ol DMBXVMZ CA CAS 71939-50-9 DMBXVMZ CB CHEBI:135921 DMBXVMZ DE Malaria DM5SQ1G ID DM5SQ1G DM5SQ1G DN Dihydroergocristine DM5SQ1G HS Approved DM5SQ1G SN Nehydrin DM5SQ1G CP Sanochemia Pharmazeutika AG DM5SQ1G DT Small molecular drug DM5SQ1G PC 107715 DM5SQ1G MW 611.7 DM5SQ1G FM C35H41N5O5 DM5SQ1G IC InChI=1S/C35H41N5O5/c1-20(2)34(37-31(41)23-16-25-24-11-7-12-26-30(24)22(18-36-26)17-27(25)38(3)19-23)33(43)40-28(15-21-9-5-4-6-10-21)32(42)39-14-8-13-29(39)35(40,44)45-34/h4-7,9-12,18,20,23,25,27-29,36,44H,8,13-17,19H2,1-3H3,(H,37,41)/t23-,25-,27-,28+,29+,34-,35+/m1/s1 DM5SQ1G CS CC(C)[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@@H]5C[C@H]6[C@@H](CC7=CNC8=CC=CC6=C78)N(C5)C DM5SQ1G IK DEQITUUQPICUMR-HJPBWRTMSA-N DM5SQ1G IU (6aR,9R,10aR)-N-[(1S,2S,4R,7S)-7-benzyl-2-hydroxy-5,8-dioxo-4-propan-2-yl-3-oxa-6,9-diazatricyclo[7.3.0.02,6]dodecan-4-yl]-7-methyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide DM5SQ1G CA CAS 17479-19-5 DM5SQ1G CB CHEBI:59912 DM5SQ1G DE Alcohol dependence DM5IKUF ID DM5IKUF DM5IKUF DN Dihydroergotamine DM5IKUF HS Approved DM5IKUF SN Migranal (TN) DM5IKUF CP Pfizer Pharmaceuticals DM5IKUF TC Antimigraine Agents DM5IKUF DT Small molecular drug DM5IKUF PC 10531 DM5IKUF MW 583.7 DM5IKUF FM C33H37N5O5 DM5IKUF IC InChI=1S/C33H37N5O5/c1-32(35-29(39)21-15-23-22-10-6-11-24-28(22)20(17-34-24)16-25(23)36(2)18-21)31(41)38-26(14-19-8-4-3-5-9-19)30(40)37-13-7-12-27(37)33(38,42)43-32/h3-6,8-11,17,21,23,25-27,34,42H,7,12-16,18H2,1-2H3,(H,35,39)/t21-,23-,25-,26+,27+,32-,33+/m1/s1 DM5IKUF CS C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@@H]5C[C@H]6[C@@H](CC7=CNC8=CC=CC6=C78)N(C5)C DM5IKUF IK LUZRJRNZXALNLM-JGRZULCMSA-N DM5IKUF IU (6aR,9R,10aR)-N-[(1S,2S,4R,7S)-7-benzyl-2-hydroxy-4-methyl-5,8-dioxo-3-oxa-6,9-diazatricyclo[7.3.0.02,6]dodecan-4-yl]-7-methyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide DM5IKUF CA CAS 511-12-6 DM5IKUF CB CHEBI:4562 DM5IKUF DE Migraine DM5D6WZ ID DM5D6WZ DM5D6WZ DN Dihydroergotoxine DM5D6WZ HS Approved DM5D6WZ SN Ergotamine, dihydro, methanesulfonate (salt) DM5D6WZ TC Vasodilator Agents DM5D6WZ DT Small molecular drug DM5D6WZ PC 6420006 DM5D6WZ MW 679.8 DM5D6WZ FM C34H41N5O8S DM5D6WZ IC InChI=1S/C33H37N5O5.CH4O3S/c1-32(35-29(39)21-15-23-22-10-6-11-24-28(22)20(17-34-24)16-25(23)36(2)18-21)31(41)38-26(14-19-8-4-3-5-9-19)30(40)37-13-7-12-27(37)33(38,42)43-32;1-5(2,3)4/h3-6,8-11,17,21,23,25-27,34,42H,7,12-16,18H2,1-2H3,(H,35,39);1H3,(H,2,3,4)/t21-,23?,25-,26+,27+,32-,33+;/m1./s1 DM5D6WZ CS C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@@H]5CC6[C@@H](CC7=CNC8=CC=CC6=C78)N(C5)C.CS(=O)(=O)O DM5D6WZ IK ADYPXRFPBQGGAH-WVVAGBSPSA-N DM5D6WZ IU (6aR,9R)-N-[(1S,2S,4R,7S)-7-benzyl-2-hydroxy-4-methyl-5,8-dioxo-3-oxa-6,9-diazatricyclo[7.3.0.02,6]dodecan-4-yl]-7-methyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide;methanesulfonic acid DM5D6WZ CA CAS 11032-41-0 DM5D6WZ DE Alzheimer disease DMFB97P ID DMFB97P DMFB97P DN Dihydrotachysterol DMFB97P HS Approved DMFB97P SN Antitanil; Calcamine; Dichystrolum; Dihidrotaquisterol; Dihydral; Dihydrotachysterolum; Diidrotachisterolo; Dygratyl; Hytakerol; Parterol; Tachyrol; Tachystin; Dht Intensol; Diidrotachisterolo [DCIT]; AT 10; DHT2; Anti-tetany substance 10; Dht(sub 2); Dihidrotaquisterol [INN-Spanish]; Dihydrotachysterol(sub 2); Dihydrotachysterolum [INN-Latin]; Dihydrotachysterol [INN:BAN:JAN]; (1S,3E,4S)-3-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5R)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylcyclohexan-1-ol; (1S,3E,4S)-3-[(2E)-2-[(3aS,7aR)-1-[(E,2R,5R)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylcyclohexan-1-ol; (3E)-3-[(2E)-2-[1-[(E)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylcyclohexan-1-ol; (3S,5E,7E,10S,22E)-9,10-secoergosta-5,7,22-trien-3-ol; (3Z)-3-[(2E)-2-[1-[(E)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylcyclohexan-1-ol; 9,10-Secoergosta-5,7,22-trien-3beta-ol DMFB97P TC Antihypoparathyroid Agents DMFB97P DT Small molecular drug DMFB97P PC 5311071 DMFB97P MW 398.7 DMFB97P FM C28H46O DMFB97P IC InChI=1S/C28H46O/c1-19(2)20(3)9-10-22(5)26-15-16-27-23(8-7-17-28(26,27)6)12-13-24-18-25(29)14-11-21(24)4/h9-10,12-13,19-22,25-27,29H,7-8,11,14-18H2,1-6H3/b10-9+,23-12+,24-13+/t20-,21-,22+,25-,26+,27-,28+/m0/s1 DMFB97P CS C[C@H]\\1CC[C@@H](C/C1=C\\C=C\\2/CCC[C@]3([C@H]2CC[C@@H]3[C@H](C)/C=C/[C@H](C)C(C)C)C)O DMFB97P IK ILYCWAKSDCYMBB-OPCMSESCSA-N DMFB97P IU (1S,3E,4S)-3-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5R)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylcyclohexan-1-ol DMFB97P CA CAS 67-96-9 DMFB97P CB CHEBI:4591 DMFB97P DE Hypocalcemia DMM1LG2 ID DMM1LG2 DMM1LG2 DN Dihydroxyacetone DMM1LG2 HS Approved DMM1LG2 SN 1,3-dihydroxyacetone; Dihydroxyacetone; 96-26-4; 1,3-Dihydroxypropan-2-one; Chromelin; 1,3-Dihydroxy-2-propanone; glycerone; Triulose; Viticolor; Soleal; Oxatone; Dihyxal; Oxantin; Otan; 2-Propanone, 1,3-dihydroxy-; 1,3-Dihydroxypropanone; 1,3-Dihydroxydimethyl ketone; NSC-24343; Ketochromin; Bis(hydroxymethyl) ketone; UNII-O10DDW6JOO; dihydroxy-acetone; 2-Propanone, 1,3-dihydroxy; BRN 1740268; CCRIS 4899; AI3-24477; Dihydroxyacetone [USP]; EINECS 202-494-5; O10DDW6JOO; 1,2-Dihydroxy-2-propanone; CHEBI:16016; RXKJFZQQPQGTFL-UHFFFAOYSA-N DMM1LG2 DT Small molecular drug DMM1LG2 PC 670 DMM1LG2 MW 90.08 DMM1LG2 FM C3H6O3 DMM1LG2 IC InChI=1S/C3H6O3/c4-1-3(6)2-5/h4-5H,1-2H2 DMM1LG2 CS C(C(=O)CO)O DMM1LG2 IK RXKJFZQQPQGTFL-UHFFFAOYSA-N DMM1LG2 IU 1,3-dihydroxypropan-2-one DMM1LG2 CA CAS 96-26-4 DMM1LG2 CB CHEBI:16016 DMM1LG2 DE Sunburn DM8YXKW ID DM8YXKW DM8YXKW DN Dihydroxyaluminium DM8YXKW HS Approved DM8YXKW SN (2-Aminoacetoxy)dihydroxyaluminum; Dihydroxyaluminium glycinate; Dihydroxyaluminum aminoacetate; 41354-48-7; Robalate; Prodexin; Hyperacid; Alilac; (Glycinato)dihydroxyaluminum; Alminate; (T-4)-(Glycinato-N,O)dihydroxyaluminum; Dihydroxyaluminum aminoacetate [USAN:USP]; C2H6AlNO4; Dihydroxoaluminium glycinat; Aluminum glycinate, AldrichCPR; DTXSID3044546; (Glycinato-N,O)dihydroxyaluminum; 51484-68-5 (proacid); MolPort-023-220-319; 13682-92-3 (Parent); (Glycinato)dihydroxyaluminum hydrate; EINECS 237-193-8; Aluminum, (glycinato-N DM8YXKW TC Antiinflammatory Agents DM8YXKW DT Small molecular drug DM8YXKW PC 16683036 DM8YXKW MW 137.07 DM8YXKW FM C2H8AlNO4 DM8YXKW IC InChI=1S/C2H5NO2.Al.2H2O/c3-1-2(4)5;;;/h1,3H2,(H,4,5);;2*1H2/q;+1;;/p-1 DM8YXKW CS C(C(=O)O[Al])N.O.O DM8YXKW IK RBNPZEHAODHBPZ-UHFFFAOYSA-M DM8YXKW CA CAS 13682-92-3 DM8YXKW DE Skin inflammation DMAI7ZV ID DMAI7ZV DMAI7ZV DN Diltiazem DMAI7ZV HS Approved DMAI7ZV SN Acalix; Adizem; Aldizem; Anoheal; Cardil; Cardizem; Citizem; Dilacor; Dilcontin; Dilren; Diltia; Diltiazemum; Dilticard; Diltzac; Dilzen; Endrydil; Viazem; Cardizen LA; Incoril AP; Tiazac Tildiem; Tiazac XC; Adizem (TN); Altiazem (TN); Angiozem (TN); Angizem (TN); Angizem CD (TN); Apo-Diltiaz; Cardizem (Hydrochloride); Cardizem (TN); Cartia XT (TN); Dilacor-XR; Dilatam (TN); Dilatem (TN); Dilcardia (TN); Dilcontin SR (TN); Dilt-cd; Dilta-Hexal; Diltelan (TN); Diltiazem (INN); Diltiazem [INN:BAN]; Diltiazemum [INN-Latin]; Diltime (TN); Dilzem (TN); Dyalec (TN); Filazem (TN); Herben (TN); Nu-Diltiaz; Progor (TN); RG 83606 (Hydrochloride); Surazem (TN); Tiamate (TN); Tiazac (TN); Tiazac XC (TN); Tildiem (TN); Vasmulax (TN); Viazem (TN); Zandil (TN); Zemtrial (TN); D-cis-Diltiazem; MK-793 (Malate); [(2S,3S)-5-(2-dimethylaminoethyl)-2-(4-methoxyphenyl)-4-oxo-2,3-dihydro-1,5-benzothiazepin-3-yl] acetate; Acetic acid (2S,3S)-5-(2-dimethylamino-ethyl)-2-(4-methoxy-phenyl)-4-oxo-2,3,4,5-tetrahydro-benzo[b][1,4]thiazepin-3-yl ester; (+)-cis-5-[2-(dimethylamino)ethyl]-2,3-dihydro-3-hydroxy-2-(p-methoxyphenyl)-1,5-benzothiazepin-4(5H)-one acetate ester; (2S,3S)-5-(2-(dimethylamino)ethyl)-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepin-3-yl acetate; (2S,3S)-5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetate; (2S,3S)-5-[2-(dimethylamino)ethyl]-2-[4-(methyloxy)phenyl]-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetate; (2S-cis)-3-(acetyloxy)-5-[2-(dimethylamino)ethyl]-2,3-dihydro-2-(4-methoxyphenyl)-1,5-benzothiazepin-4(5H)-one DMAI7ZV CP Valeant International Barbados Srl DMAI7ZV TC Antihypertensive Agents DMAI7ZV DT Small molecular drug DMAI7ZV PC 39186 DMAI7ZV MW 414.5 DMAI7ZV FM C22H26N2O4S DMAI7ZV IC InChI=1S/C22H26N2O4S/c1-15(25)28-20-21(16-9-11-17(27-4)12-10-16)29-19-8-6-5-7-18(19)24(22(20)26)14-13-23(2)3/h5-12,20-21H,13-14H2,1-4H3/t20-,21+/m1/s1 DMAI7ZV CS CC(=O)O[C@@H]1[C@@H](SC2=CC=CC=C2N(C1=O)CCN(C)C)C3=CC=C(C=C3)OC DMAI7ZV IK HSUGRBWQSSZJOP-RTWAWAEBSA-N DMAI7ZV IU [(2S,3S)-5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3-dihydro-1,5-benzothiazepin-3-yl] acetate DMAI7ZV CA CAS 56209-45-1 DMAI7ZV CB CHEBI:101278 DMAI7ZV DE Hypertension DM264B3 ID DM264B3 DM264B3 DN Dimenhydrinate DM264B3 HS Approved DM264B3 SN Gravamin (TN); Gravol (TN); Vertirosan (TN); Dimenhydrinate (JP15/USP/INN); 2-(diphenylmethoxy)-N,N-dimethylethanaminium 8-chloro-1,3-dimethyl-2,6-dioxo-1,2,3,6-tetrahydropurin-7-ide; 2-benzhydryloxyethyl(dimethyl)azanium; 8-chloro-1,3-dimethyl-2-oxopurin-6-olate; 8-chloro-1,3-dimethyl-3,7-dihydro-1H-purine-2,6-dione-2-(diphenylmethoxy)-N,N-dimethylethanamine (1:1) DM264B3 CP Carter-Horner Corp. DM264B3 TC Antiemetics DM264B3 DT Small molecular drug DM264B3 PC 10660 DM264B3 MW 470 DM264B3 FM C24H28ClN5O3 DM264B3 IC InChI=1S/C17H21NO.C7H7ClN4O2/c1-18(2)13-14-19-17(15-9-5-3-6-10-15)16-11-7-4-8-12-16;1-11-4-3(9-6(8)10-4)5(13)12(2)7(11)14/h3-12,17H,13-14H2,1-2H3;1-2H3,(H,9,10) DM264B3 CS CN1C2=C(C(=O)N(C1=O)C)NC(=N2)Cl.CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2 DM264B3 IK NFLLKCVHYJRNRH-UHFFFAOYSA-N DM264B3 IU 2-benzhydryloxy-N,N-dimethylethanamine;8-chloro-1,3-dimethyl-7H-purine-2,6-dione DM264B3 CA CAS 523-87-5 DM264B3 CB CHEBI:94848 DM264B3 DE Nausea DM32YAI ID DM32YAI DM32YAI DN Dimethindene DM32YAI HS Approved DM32YAI SN Dimethpyrindene; Dimethylpyrindene; Dimetindene; Dimetindeno; Dimetindenum; Fengel; Fenistil; Forhistal; Foristal; Pecofenil; Triten; Z 2001; Dimetindene (INN); Dimetindene [INN:BAN]; Dimetindeno [INN-Spanish]; Dimetindenum [INN-Latin]; Fenistil (TN); Dimethyl{2-[3-(2-pyridylethyl)inden-2-yl]ethyl}amine; N,N-Dimethyl-3-(1-(2-pyridyl)ethyl)inden-2-ethylamin; N,N-Dimethyl-N-(3-(1-(2-pyridyl)ethyl)-2-indenylethyl)amin; N,N-dimethyl-2-[3-(1-pyridin-2-ylethyl)-1H-inden-2-yl]ethanamine; 1H-Indene-2-ethanamine, N,N-dimethyl-3-(1-(2-pyridinyl)ethyl)-(9CI); 2-(1-(2-(2-Dimethylaminoethyl)inden-3-yl)ethyl)pyridine DM32YAI TC Antiallergic Agents DM32YAI DT Small molecular drug DM32YAI PC 21855 DM32YAI MW 292.4 DM32YAI FM C20H24N2 DM32YAI IC InChI=1S/C20H24N2/c1-15(19-10-6-7-12-21-19)20-17(11-13-22(2)3)14-16-8-4-5-9-18(16)20/h4-10,12,15H,11,13-14H2,1-3H3 DM32YAI CS CC(C1=CC=CC=N1)C2=C(CC3=CC=CC=C32)CCN(C)C DM32YAI IK MVMQESMQSYOVGV-UHFFFAOYSA-N DM32YAI IU N,N-dimethyl-2-[3-(1-pyridin-2-ylethyl)-1H-inden-2-yl]ethanamine DM32YAI CA CAS 5636-83-9 DM32YAI CB CHEBI:135222 DM32YAI DE Respiratory allergy DMXQKSL ID DMXQKSL DMXQKSL DN Dinoprost Tromethamine DMXQKSL HS Approved DMXQKSL SN Dinolytic; Ensaprost; Lutalyse; Prostamate; Zinoprost; Panacelan F tromethamine salt; Pronalgon F; Prostalmon F; PGF2alpha THAM; PGF2alpha tromethamine; PROSTAGLANDIN F2ALPHA TRIS SALT; Prostaglandin F2a tromethamine; Prostaglandin F2alpha tham; Prostaglandin F2alpha tromethamine; Prostin F2 alpha; U 14585; Dinoprost tromethamine [USAN:JAN]; Dinoprost, trometamol salt; Enzaprost F compd. with trisamine; Lutalyse (Veterinary); PGF2-alpha tham; PGF2-alpha tris salt; PGF2-alpha tromethamine; PGF2-alpha tromethamine salt; PGF2alpha-Tris; Prostaglandin F(sub 2a) tromethamine; Prostaglandin F-2alpha tromethamine salt; Prostaglandin F2-alpha THAM; Prostaglandin F2-alpha THAM salt; Prostaglandin F2-alpha tromethamine; Prostin F2 alpha (TN); THAM PGF2-alpha; Tromethamine prostaglandin F2-alpha; U-14583E; Dinoprost tromethamine (JAN/USP); Protaglandin F2-alpha-tham salt; U-14,583E; Prosta-5,13-dien-1-oic acid, (5Z,9-alpha,11-alpha,13E,15S)-9,11,15-trihydroxy-, compd. with trimethylolaminomethane; Prosta-5,13-dien-1-oic acid, (5Z,9-alpha,11-alpha,13E,15S)-9,11,15-trihydroxy-,compd. with trimethylolaminomethane; Prosta-5,13-dien-1-oic acid, 9,11,15-trihydroxy-, (5Z,9alpha,11alpha,13E,15S)-, compd. with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1); (5Z,9alpha,11alpha,13E,15S)-9,11,15-Trihydroxyprosta-5,13-dienoic acid tris salt; (E,Z)-(1R,2R,3R,5S)-7-(3,5-Dihydroxy-2-((3S)-(3-hydroxy-1-octenyl))cyclopentyl)-5-heptenoic acid compound with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1); (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]cyclopentyl]hept-5-enoic acid; 1,3-Propanediol, 2-amino-2-(hydroxymethyl)-, (5Z,9alpha,11alpha,13E,15S)-9,11,15-trihydroxyprosta-5,13-dien-1-oate (salt); 5-Heptenoic acid, 7-(3,5-dihydroxy-2-(3-hydroxy-1-octenyl)cyclopentyl)-, tham; 7-(3,5-Dihydroxy-2-(3-hydroxy-1-octenyl)cyclopentyl)-5-heptenoic acid, tromethamine salt DMXQKSL TC Abortifacient Agents DMXQKSL DT Small molecular drug DMXQKSL PC 5282415 DMXQKSL MW 475.6 DMXQKSL FM C24H45NO8 DMXQKSL IC InChI=1S/C20H34O5.C4H11NO3/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25;5-4(1-6,2-7)3-8/h4,7,12-13,15-19,21-23H,2-3,5-6,8-11,14H2,1H3,(H,24,25);6-8H,1-3,5H2/b7-4-,13-12+;/t15-,16+,17+,18-,19+;/m0./s1 DMXQKSL CS CCCCC[C@@H](/C=C/[C@H]1[C@@H](C[C@@H]([C@@H]1C/C=C\\CCCC(=O)O)O)O)O.C(C(CO)(CO)N)O DMXQKSL IK IYGXEHDCSOYNKY-RZHHZEQLSA-N DMXQKSL IU 2-amino-2-(hydroxymethyl)propane-1,3-diol;(Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]cyclopentyl]hept-5-enoic acid DMXQKSL CA CAS 38562-01-5 DMXQKSL CB CHEBI:31502 DMXQKSL DE Abortion DMTYOPD ID DMTYOPD DMTYOPD DN Dinoprostone DMTYOPD HS Approved DMTYOPD SN Cervidil; Dinoproston; Dinoprostona; Dinoprostonum; Prepidil; Propess; Prostenon; Prostin; Prepidil Gel; Prostarmon E;Prostin E; Dinoprostone Prostaglandin E2; Minprositin E2; Minprostin E2; PGE2; PGE2 alpha; PGE2alpha; Prostaglandin E2; Prostaglandin E2 alpha; Prostaglandin E2alpha; Prostarmon E2; Prostin E2; U 12062; [3H]PGE2; Alpha, PGE2; Alpha, Prostaglandin E2; BML1-F07; Cervidil (TN); Dinoprostona [INN-Spanish]; Dinoprostone beta-Cyclodextrin Clathrate; Dinoprostonum [INN-Latin]; E2 alpha, Prostaglandin; E2, Prostaglandin; E2alpha, Prostaglandin; Gel, Prepidil; L-PGE2; L-Prostaglandin E2; Prepidil (TN); Propess (TN); Prostin E2 (TN); U-12062; BMS-279654 & PGE2; Dinoprostone (JAN/USP/INN); Dinoprostone [USAN:INN:BAN:JAN]; L-7-(3-Hydroxy-2-(3-hydroxy-1-octenyl)-5-oxocyclopentyl)-5-heptenoic acid; (15S)-Prostaglandin E2; (5Z,11-alpha,13E,15S)-11,15-Dihydroxy-9-oxoprosta-5,13-dien-1-oic acid; (5Z,11.alpha.,13E,15S)-11,15-Dihydroxy-9-oxoprosta-5,13-dien-1-oic acid; (5Z,11alpha,13E,15S)-11,15-Dihydroxy-9-oxoprosta-5,13-dien-1-oic; (5Z,11alpha,13E,15S)-11,15-Dihydroxy-9-oxoprosta-5,13-dienoic acid; (5Z,11alpha,13E,15S)-11,15-dihydroxy-9-oxoprosta-5,13-dien-1-oic acid; (5Z,13E)-(15S)-11alpha,15-Dihydroxy-9-oxoprost-13-enoate; (5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprosta-5,13-dienoate; (5Z,13E,15S)-11alpha,15-dihydroxy-9-oxoprosta-5,13-dien-1-oic acid; (E,Z)-(1R,2R,3R)-7-(3-Hydroxy-2-((3S)-(3-hydroxy-1-octenyl))-5-oxocyclopentyl)-5-heptenoic acid; (Z)-7-[(1R,2R,3R)-3-Hydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]-5-oxocyclopentyl]hept-5-enoic acid; 5-Heptenoic acid, 7-(3-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxocyclopentyl)-(8CI); 7-(3-Hydroxy-2-(3-hydroxy-1-octenyl)-5-oxocyclopentyl)-5-heptenoic acid DMTYOPD CP Pfizer Pharmaceuticals DMTYOPD TC Prostaglandins DMTYOPD DT Small molecular drug DMTYOPD PC 5280360 DMTYOPD MW 352.5 DMTYOPD FM C20H32O5 DMTYOPD IC InChI=1S/C20H32O5/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25/h4,7,12-13,15-17,19,21,23H,2-3,5-6,8-11,14H2,1H3,(H,24,25)/b7-4-,13-12+/t15-,16+,17+,19+/m0/s1 DMTYOPD CS CCCCC[C@@H](/C=C/[C@H]1[C@@H](CC(=O)[C@@H]1C/C=C\\CCCC(=O)O)O)O DMTYOPD IK XEYBRNLFEZDVAW-ARSRFYASSA-N DMTYOPD IU (Z)-7-[(1R,2R,3R)-3-hydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]-5-oxocyclopentyl]hept-5-enoic acid DMTYOPD CA CAS 363-24-6 DMTYOPD CB CHEBI:15551 DMTYOPD DE Medical abortion DMXVU6D ID DMXVU6D DMXVU6D DN Diphemanil Methylsulfate DMXVU6D HS Approved DMXVU6D SN Demotil; Diphemanil; Diphemanilum; Diphenatil; Diphenmethanil; Nivelon; Nivelona; Prantal; Prantil; Prentol; Talpran; Vagophemanil; Variton; Diphemanil methosulfate; Diphemanil methyl sulfate; Diphemanil methylsulphate; Diphemanil metilsulfate; Diphemanili metilsulfas; Diphenmanil methyl sulfate; Diphenmanil methylsulfate; Diphenmethanil methyl sulfate; Diphenmethanil methylsulfate; Metilsulfate de diphemanil; Metilsulfato de difemanilo; Prantal methylsulfate; Vagophemanil methyl sulfate; Ban-guard; Diphemanil methylsulfate [INN:BAN]; Diphemanil metilsulfate (INN); Diphemanili metilsulfas [INN-Latin]; Metilsulfate de diphemanil [INN-French]; Metilsulfato de difemanilo [INN-Spanish]; Prantal (TN); Ban-Guard (Veterinary); P-(alpha-Phenylbenzylidene)-1,1-dimethylpiperidinium methyl sulfate; N,N-Dimethyl-4-piperidylidene-1,1-diphenylmethane methylsulfate; P-(alpha.-Phenylbenzylidene)-1,1-dimethylpiperidinium methyl sulfate; Piperidinium, 4-(diphenylmethylene)-1,1-dimethyl-, methyl sulfate; 4-(Diphenylmethylene)-1,1-dimethylpiperidinium methyl sulfate; 4-(Diphenylmethylene)-1,1-dimethylpiperidinium methylsulfate; 4-(diphenylmethylidene)-1,1-dimethylpiperidinium methyl sulfate; 4-benzhydrylidene-1,1-dimethylpiperidin-1-ium DMXVU6D TC Parasympatholytics DMXVU6D DT Small molecular drug DMXVU6D PC 6126 DMXVU6D MW 389.5 DMXVU6D FM C21H27NO4S DMXVU6D IC InChI=1S/C20H24N.CH4O4S/c1-21(2)15-13-19(14-16-21)20(17-9-5-3-6-10-17)18-11-7-4-8-12-18;1-5-6(2,3)4/h3-12H,13-16H2,1-2H3;1H3,(H,2,3,4)/q+1;/p-1 DMXVU6D CS C[N+]1(CCC(=C(C2=CC=CC=C2)C3=CC=CC=C3)CC1)C.COS(=O)(=O)[O-] DMXVU6D IK BREMLQBSKCSNNH-UHFFFAOYSA-M DMXVU6D IU 4-benzhydrylidene-1,1-dimethylpiperidin-1-ium;methyl sulfate DMXVU6D CA CAS 62-97-5 DMXVU6D CB CHEBI:59782 DMXVU6D DE Peptic ulcer DMKQTBA ID DMKQTBA DMKQTBA DN Diphenhydramine DMKQTBA HS Approved DMKQTBA SN diphenhydramine; 58-73-1; Benadryl; Benzhydramine; Probedryl; Alledryl; Antistominum; Dihidral; 2-(Benzhydryloxy)-N,N-dimethylethanamine; Benzhydraminum; Benzhydroamina; Diphantine; Difenhydramin; Ibiodral; Difedryl; Dibondrin; Mephadryl; Desentol; Dermistina; Betramin; Benzhydril; Benzantine; Benachlor; Bagodryl; Syntedril; Novamina; Medidryl; Hyadrine; Histaxin; Etanautine; Drylistan; Diabylen; Diabenyl; Dermodrin; Benodine; Baramine; Allergical; Debendrin; Benadrin; Dabylen; Antomin; Nausen; Benapon; Dylamon; Benylin; Benylan; Benodin; Amidryl; Aleryl; Allerdryl; Allergeval; Allergina; Allergival; Antitussive; Automin; Banophen; Beldin; Belix; Bena; Benhydramin; Benzhydryl; Compoz; Dibendrin; Dibenil; Difenhidramina; Difenidramina; Dimedrol; Dimedryl; Dimehydrinate; Diphen; Diphenhist; Diphenhydraminum; Diphenylhydramin; Diphenylhydramine; Dryistan; Genahist; Hydramine; Hyrexin; Restamin; Rigidil; Siladryl; Silphen; Syntodril; Allergan B; Allermax Caplets; BENADRYL HCl; Banophen Caplets; Benadryl Allergy; Difenidramina [Italian]; Dimedrol base; Diphen Cough; Diphenhist Captabs; Diphenhydramine Base; Diphenhydramine HCl; Nytol Quickcaps; Nytol Quickgels;Twilite Caplets; Unisom Sleepgels Maximum Strength; Dormarex 2; FAR 90X2; PM 255; S51; Aller-Med; Ben-allergin; Benadryl (TN); Benadryl (hydrochloride); Beta-Dimethylaminoethanol diphenylmethyl ether; Beta-Dimethylaminoethylbenzhydrylether; Beta-dimethylaminoethyl benzhydryl ether; Difenhidramina [INN-Spanish]; Dimedrol (TN); Diphenhydraminum [INN-Latin]; Nervine Nighttime Sleep-Aid; Nytol (TN); O-Benzhydryldimethylaminoethanol; Restamin (TN); Sleep-Eze D; Sleep-Eze D Extra Strength; DIPHENHYDRAMINE, ANTISTOMINUM, BENZHYDRAMINE; Diphenhydramine (JP15/INN); Diphenhydramine [INN:BAN:JAN]; Alpha-(2-Dimethylaminoethoxy)diphenylmethane; N-(Benzhydryloksy-etylo)dwumetyloamina; N-(Benzhydryloksy-etylo)dwumetyloamina [Polish]; Beta-Dimethylamino-aethyl-benzhydryl-aether; Beta-Dimethylamino-aethyl-benzhydryl-aether [German]; N,N-Dimethyl-2-(diphenylmethoxy)-ethylamine hydrochloride; N-[2-(BENZHYDRYLOXY)ETHYL]-N,N-DIMETHYLAMINE; N-(2-(Diphenylmethoxy)ethyl)-N,N-dimethylamine; 2-(Benzhydryloxy)-N,N-dimethylethylamine; 2-(Benzhydryloxy)-N,N-dimethylethylamine, hydrochloride; 2-(Diphenylmethoxy)-N,N-dimethylethylamine; 2-(diphenylmethoxy)-N,N-dimethylethanamine; 2-Diphenylmethoxy-N,N-dimethylethylamine; 2-[(diphenylmethyl)oxy]-N,N-dimethylethanamine; 2-benzhydryloxy-N,N-dimethylethanamine; 2-benzhydryloxyethyl-N,N-dimethylammonium; 2-diphenylmethoxy-N,N-demthylethanamine; 2PM DMKQTBA CP Johnson & Johnson DMKQTBA TC Antiallergic Agents DMKQTBA DT Small molecular drug DMKQTBA PC 3100 DMKQTBA MW 255.35 DMKQTBA FM C17H21NO DMKQTBA IC InChI=1S/C17H21NO/c1-18(2)13-14-19-17(15-9-5-3-6-10-15)16-11-7-4-8-12-16/h3-12,17H,13-14H2,1-2H3 DMKQTBA CS CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2 DMKQTBA IK ZZVUWRFHKOJYTH-UHFFFAOYSA-N DMKQTBA IU 2-benzhydryloxy-N,N-dimethylethanamine DMKQTBA CA CAS 58-73-1 DMKQTBA CB CHEBI:4636 DMKQTBA DE Meniere disease DMHPWOM ID DMHPWOM DMHPWOM DN Diphenidol DMHPWOM HS Approved DMHPWOM SN Avomol; Defenidol; Difenidol; Difenidolo; Difenidolum; Nometic; Vontrol; Difenidol HCl; Difenidolo [DCIT]; SKF 478; Difenidolum [INN-Latin]; Diphenidol [USAN:BAN]; SK-478; Diphenidol (USAN/INN); SK&F-478; Alpha,alpha-Diphenyl-1-piperidinebutanol; Diphenyl(3-(1-piperidyl)propyl)carbinol; 1,1-diphenyl-4-piperidin-1-ylbutan-1-ol; 1,1-diphenyl-4-piperidin-1-ylbutan-1-ol hydrochloride DMHPWOM DT Small molecular drug DMHPWOM PC 3055 DMHPWOM MW 309.4 DMHPWOM FM C21H27NO DMHPWOM IC InChI=1S/C21H27NO/c23-21(19-11-4-1-5-12-19,20-13-6-2-7-14-20)15-10-18-22-16-8-3-9-17-22/h1-2,4-7,11-14,23H,3,8-10,15-18H2 DMHPWOM CS C1CCN(CC1)CCCC(C2=CC=CC=C2)(C3=CC=CC=C3)O DMHPWOM IK OGAKLTJNUQRZJU-UHFFFAOYSA-N DMHPWOM IU 1,1-diphenyl-4-piperidin-1-ylbutan-1-ol DMHPWOM CA CAS 972-02-1 DMHPWOM CB CHEBI:4638 DMHPWOM DE Nausea DMO5SZX ID DMO5SZX DMO5SZX DN Diphenoxylate DMO5SZX HS Approved DMO5SZX SN Difenossilato; Difenoxilato; Diphenoxalate; Diphenoxylatum; Difenossilato [DCIT]; Difenoxilato [Spanish]; Diphenoxylate HCl; Diphenoxylate Monohydrochloride; Diphenoxylate hydrochloride; Diphenoxylatum [Latin]; NIH 7562; R 1132; Difenoxilato [INN-Spanish]; Diphenoxylate (INN); Diphenoxylate [INN:BAN]; Diphenoxylate hydrochloride (USP); Diphenoxylate hydrochloride(usp); Diphenoxylatum [INN-Latin]; R 1132 (antiperistaltic); R-1132; Co-phenotrope (TN); Ethyl 1-(3-cyano-3,3-diphenylpropyl)-4-phenylisonipecotate; Ethyl 1-(3-cyano-3,3-diphenylpropyl)-4-phenylisonipecotate monohydrochloride; Ethyl 1-(3-cyano-3,3-diphenylpropyl)-4-phenyl-4-piperidinecarboxylate; Ethyl 1-(3-cyano-3,3-diphenylpropyl)-4-phenylpiperidine-4-carboxylate; Ethyl 1-(3-cyano-3,3-diphenylpropyl)-4-phenylpiperidine-4-carboxylate hydrochloride; Isonipecotic acid, 1-(3-cyano-3,3-diphenylpropyl)-4-phenyl-, ethyl ester; Ethyl 1-(3-cyano-3,3-diphenylpropyl)-4-phenylpiperidin-1-ium-4-carboxylate chloride; Isonipecotic acid, 1-(3-cyano-3,3-diphenylpropyl)-4-phenyl-, ethyl ester, hydrochloride; 1-(3-Cyano-3,3-diphenylpropyl)-4-phenyl-4-piperidinecarboxylic acid ethyl ester; 1-(3-Cyano-3,3-diphenylpropyl)-4-phenyl-isonipecotic acid ethyl ester; 1-(3-Cyano-3,3-diphenylpropyl)-4-phenylisonipecotic acid ethyl ester hydrochloride; 1-(3-cyano-3,3-diphenylpropyl)-4-(ethoxycarbonyl)-4-phenylpiperidinium chloride; 2,2-Diphenyl-4-(4-carbethoxy-4-phenylpiperidino)butyronitrile; 4-Ethoxycarbonyl-alpha,alpha,4-triphenyl-1-piperidinebutyronitrile, hydrochloride; 4-Piperidinecarboxylic acid, 1-(3-cyano-3,3-diphenylpropyl)-4-phenyl-, ethyl ester; 4-Piperidinecarboxylic acid, 1-(3-cyano-3,3-diphenylpropyl)-4-phenyl-, ethyl ester (9CI); 4-Piperidinecarboxylic acid, 1-(3-cyano-3,3-diphenylpropyl)-4-phenyl-, ethyl ester, monohydrochloride; 4-ethoxycarbonyl-alpha,alpha,4-triphenyl-1-piperidinebutyronitrile hydrochloride DMO5SZX CP Janssen Pharmaceutica DMO5SZX TC Analgesics DMO5SZX DT Small molecular drug DMO5SZX PC 13505 DMO5SZX MW 452.6 DMO5SZX FM C30H32N2O2 DMO5SZX IC InChI=1S/C30H32N2O2/c1-2-34-28(33)29(25-12-6-3-7-13-25)18-21-32(22-19-29)23-20-30(24-31,26-14-8-4-9-15-26)27-16-10-5-11-17-27/h3-17H,2,18-23H2,1H3 DMO5SZX CS CCOC(=O)C1(CCN(CC1)CCC(C#N)(C2=CC=CC=C2)C3=CC=CC=C3)C4=CC=CC=C4 DMO5SZX IK HYPPXZBJBPSRLK-UHFFFAOYSA-N DMO5SZX IU ethyl 1-(3-cyano-3,3-diphenylpropyl)-4-phenylpiperidine-4-carboxylate DMO5SZX CA CAS 915-30-0 DMO5SZX CB CHEBI:4639 DMO5SZX DE Diarrhea DMW4X37 ID DMW4X37 DMW4X37 DN Diphenylpyraline DMW4X37 HS Approved DMW4X37 SN Allergen; Belfene; Dafen; Dayfen; Diafen; Difenilpiralina; Diphenylpyralamine; Diphenylpyralinum; Diphenylpyrilene; Hispril; Histryl; Histyn; Hystryl; Lergobine; Lyssipoll; Mepiben; Neargal; AN 1041; Difenilpiralina [INN-Spanish]; Diphenylpyraline (INN); Diphenylpyraline [INN:BAN]; Diphenylpyralinum [INN-Latin];Diphenylpyraline maleate (2:1); N-Methylpiperidyl-(4)-benzhydrylaether salzsauren salze; N-Methylpiperidyl-(4)-benzhydrylaether salzsauren salze [German]; 1-Methyl-4-piperidyl benzhydryl ether; 1-methyl-4-hydroxypiperidine benzhydryl ether; 4-(Benzhydryloxy)-1-methylpiperidine; 4-(Diphenylmethoxy)-1-methylpiperidine; 4-(benzhydryloxy)-N-methylpiperidine; 4-DIPHENYLMETHOXY-1-METHYLPIPERIDINE; 4-[(diphenylmethyl)oxy]-1-methylpiperidine; 4-benzhydryloxy-1-methylpiperidine DMW4X37 TC Antihistamines DMW4X37 DT Small molecular drug DMW4X37 PC 3103 DMW4X37 MW 281.4 DMW4X37 FM C19H23NO DMW4X37 IC InChI=1S/C19H23NO/c1-20-14-12-18(13-15-20)21-19(16-8-4-2-5-9-16)17-10-6-3-7-11-17/h2-11,18-19H,12-15H2,1H3 DMW4X37 CS CN1CCC(CC1)OC(C2=CC=CC=C2)C3=CC=CC=C3 DMW4X37 IK OWQUZNMMYNAXSL-UHFFFAOYSA-N DMW4X37 IU 4-benzhydryloxy-1-methylpiperidine DMW4X37 CA CAS 147-20-6 DMW4X37 CB CHEBI:59788 DMW4X37 DE Allergic rhinitis DM0FSIM ID DM0FSIM DM0FSIM DN Diphtheria-tetanus vaccine DM0FSIM HS Approved DM0FSIM SN Diphtheria-tetanus vaccine (im suspension), Finlay Institute DM0FSIM CP Finlay Institute DM0FSIM DT Vaccine DM0FSIM DE Clostridium infection DMH5W0G ID DMH5W0G DMH5W0G DN Dipivefrin DMH5W0G HS Approved DMH5W0G SN AKPro; Dipivefrina; Dipivefrine; Dipivefrinum; Propine; Dipivalyl epinephrine; Dipivefrin HCL; Dipivefrin [USAN]; K 30081; Dipivefrin (USAN); Dipivefrina [INN-Spanish]; Dipivefrine (INN); Dipivefrinum [INN-Latin]; Ophtho-Dipivefrin; Propine C Cap B.I.D.; [2-(2,2-dimethylpropanoyloxy)-4-[1-hydroxy-2-(methylamino)ethyl]phenyl] 2,2-dimethylpropanoate; (+-)-3,4-Dihydroxy-alpha-((methylamino)methyl)benzyl alcohol 3,4-dipivalate; (+-)-4-[1-hydroxy-2-(methylamino)ethyl]-o-phenylene divavalate; (-)-2,2-Dimethylpropansaeure-4-(1-hydroxy-2-(methylamino)ethyl)-1,2-phenylenester; (-)-4-(1-Hydroxy-2-methylaminoethyl)-o-phenylendipivalat; (RS)-4-(1-Hydroxy-2-(methylamino)ethyl)-1,2-phenylen dipivalat; 1-(3',4'-dipivaloyloxyphenyl)-2-methylamino-1-ethanol; 2,2-Dimethylpropanoic acid 4-[1-hydroxy-2-(methylamino)ethyl]-1,2-phenylene ester; 4-(1-Hydroxy-2-(methylamino)ethyl)-1,2-phenylen dipivalat; 4-[1-hydroxy-2-(methylamino)ethyl]-o-phenylene divavalate; 4-[1-hydroxy-2-(methylamino)ethyl]benzene-1,2-diyl bis(2,2-dimethylpropanoate) DMH5W0G CP Allergan Pharmaceutical DMH5W0G TC Ophthalmologicals DMH5W0G DT Small molecular drug DMH5W0G PC 3105 DMH5W0G MW 351.4 DMH5W0G FM C19H29NO5 DMH5W0G IC InChI=1S/C19H29NO5/c1-18(2,3)16(22)24-14-9-8-12(13(21)11-20-7)10-15(14)25-17(23)19(4,5)6/h8-10,13,20-21H,11H2,1-7H3 DMH5W0G CS CC(C)(C)C(=O)OC1=C(C=C(C=C1)C(CNC)O)OC(=O)C(C)(C)C DMH5W0G IK OCUJLLGVOUDECM-UHFFFAOYSA-N DMH5W0G IU [2-(2,2-dimethylpropanoyloxy)-4-[1-hydroxy-2-(methylamino)ethyl]phenyl] 2,2-dimethylpropanoate DMH5W0G CA CAS 52365-63-6 DMH5W0G CB CHEBI:4646 DMH5W0G DE Chronic open-angle glaucoma DMXY30O ID DMXY30O DMXY30O DN Dipyridamole DMXY30O HS Approved DMXY30O SN Agilease; Anginal; Antistenocardin; Apricor; Cardioflux; Cardoxil; Cardoxin; Cerebrovase; Chilcolan; Cleridium; Coribon; Coridil; Coronarine; Corosan; Coroxin; Curantil; Curantyl; Dipiridamol; Dipyramidole; Dipyridamine; Dipyridamol; Dipyridamolum; Dipyridan; Dipyudamine; Dypyridamol; Gulliostin; Justpertin; Kurantil; Miosen; Natyl; Peridamol; Permiltin; Persantin; Persantine; Piroan; Prandiol; Protangix; Stenocardil; Stenocardiol; Stimolcardio; Apotex Brand of Dipyridamole; Ashbourne Brand of Dipyridamole; Belmac Brand of Dipyridamole; Berlin Chemie Brand of Dipyridamole; Boehringer Ingelheim Brand of Dipyridamole; IPRAD Brand of Dipyridamole; Iv Persantine; Novopharm Brand of Dipyridamole; Cleridium 150; D 9766; Prandiol 75; Apo-Dipyridamole; Apo-Dipyridamole Fc; Apo-Dipyridamole Sc; Berlin-Chemie Brand of Dipyridamole; Dipiridamol [INN-Spanish]; Dipyridamolum [INN-Latin]; Novo-Dipiradol; Persantine (TN); RA-8; Usaf Ge-12; Dipyridamole (JP15/USP/INN); Dipyridamole [USAN:INN:BAN:JAN]; Permole, Persantine, Dipyridan, Dipyridamole; 2,6-Bis(diethanolamine)-4,8-dipiperidinopyrimido[5,4-d]pyrimidine; 2,6-Bis(diethanolamino)-4,8-dipiperidinopyrimido(5,4-d)pyrimidine; 2,6-Bis(diethanolamino)-4,8-dipiperidinopyrimido[5,4-d]pyrimidine DMXY30O CP FISCHER and ROCH DMXY30O TC Vasodilator Agents DMXY30O DT Small molecular drug DMXY30O PC 3108 DMXY30O MW 504.6 DMXY30O FM C24H40N8O4 DMXY30O IC InChI=1S/C24H40N8O4/c33-15-11-31(12-16-34)23-26-20-19(21(27-23)29-7-3-1-4-8-29)25-24(32(13-17-35)14-18-36)28-22(20)30-9-5-2-6-10-30/h33-36H,1-18H2 DMXY30O CS C1CCN(CC1)C2=NC(=NC3=C2N=C(N=C3N4CCCCC4)N(CCO)CCO)N(CCO)CCO DMXY30O IK IZEKFCXSFNUWAM-UHFFFAOYSA-N DMXY30O IU 2-[[2-[bis(2-hydroxyethyl)amino]-4,8-di(piperidin-1-yl)pyrimido[5,4-d]pyrimidin-6-yl]-(2-hydroxyethyl)amino]ethanol DMXY30O CA CAS 58-32-2 DMXY30O CB CHEBI:4653 DMXY30O DE Hypertension DM0D9YJ ID DM0D9YJ DM0D9YJ DN Dirithromycin DM0D9YJ HS Approved DM0D9YJ SN Dirithromycine; Dirithromycinum; Diritromicina; Divitross; Dynabac; Noriclan; Valodin; Dirithromycine [French]; Dirithromycinum [Latin]; Diritromicina [Spanish]; LY 237216; AS-E 136; ASE-136; Dynabac (TN); LY-237216; Dirithromycin (USP/INN); Dirithromycin [USAN:BAN:INN]; (9S)-9-deoxo-11-deoxy-9,11-[imino[2-(2-methoxyethoxy)ethylidene]erythromycin DM0D9YJ TC Antibiotics DM0D9YJ DT Small molecular drug DM0D9YJ PC 6473883 DM0D9YJ MW 835.1 DM0D9YJ FM C42H78N2O14 DM0D9YJ IC InChI=1S/C42H78N2O14/c1-15-29-42(10,49)37-24(4)32(43-30(56-37)21-52-17-16-50-13)22(2)19-40(8,48)36(58-39-33(45)28(44(11)12)18-23(3)53-39)25(5)34(26(6)38(47)55-29)57-31-20-41(9,51-14)35(46)27(7)54-31/h22-37,39,43,45-46,48-49H,15-21H2,1-14H3/t22-,23-,24+,25+,26-,27+,28+,29-,30-,31+,32+,33-,34+,35+,36-,37-,39+,40-,41-,42-/m1/s1 DM0D9YJ CS CC[C@@H]1[C@@]([C@H]2[C@H]([C@H]([C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]3C[C@@]([C@H]([C@@H](O3)C)O)(C)OC)C)O[C@H]4[C@@H]([C@H](C[C@H](O4)C)N(C)C)O)(C)O)C)N[C@H](O2)COCCOC)C)(C)O DM0D9YJ IK WLOHNSSYAXHWNR-DWIOZXRMSA-N DM0D9YJ IU (1R,2R,3R,6R,7S,8S,9R,10R,12R,13S,15R,17S)-9-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-3-ethyl-2,10-dihydroxy-7-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-15-(2-methoxyethoxymethyl)-2,6,8,10,12,17-hexamethyl-4,16-dioxa-14-azabicyclo[11.3.1]heptadecan-5-one DM0D9YJ CA CAS 62013-04-1 DM0D9YJ CB CHEBI:474014 DM0D9YJ DE Bacterial infection DM5SYZP ID DM5SYZP DM5SYZP DN Disopyramide DM5SYZP HS Approved DM5SYZP SN Dicorantil; Disopiramida; Disopyramidum; Isorythm; Lispine; Ritmodan; Rythmodan; Disopyramide Free Base; Rythmodan P; D 7644; H 3292; SC 7031; Searle 703; Disopiramida [INN-Spanish]; Disopyramidum [INN-Latin]; Norpace (TN); Rythmodan (TN); Rythmodan P (TN); Rythmodan-La; SC-7031; Xi-Disopyramide; Disopyramide (JP15/USAN/INN); Disopyramide [USAN:BAN:INN:JAN]; Alpha-Diisopropylaminoethyl-alpha-phenylpyridine-2-acetamide; Gamma-Diisopropylamino-alpha-phenyl-alpha-(2-pyridyl)butyramide; Alpha-(2-(Diisopropylamino)ethyl)-alpha-phenyl-2-pyridineacetamide; Alpha-[2-[Bis(1-methylethyl)amino]ethyl]-alpha-phenyl-2-pyridine acetamide; 4-(diisopropylamino)-2-phenyl-2-pyridin-2-ylbutanamide; 4-[di(propan-2-yl)amino]-2-phenyl-2-pyridin-2-ylbutanamide DM5SYZP CP Gd Searle Llc DM5SYZP TC Antiarrhythmic Agents DM5SYZP DT Small molecular drug DM5SYZP PC 3114 DM5SYZP MW 339.5 DM5SYZP FM C21H29N3O DM5SYZP IC InChI=1S/C21H29N3O/c1-16(2)24(17(3)4)15-13-21(20(22)25,18-10-6-5-7-11-18)19-12-8-9-14-23-19/h5-12,14,16-17H,13,15H2,1-4H3,(H2,22,25) DM5SYZP CS CC(C)N(CCC(C1=CC=CC=C1)(C2=CC=CC=N2)C(=O)N)C(C)C DM5SYZP IK UVTNFZQICZKOEM-UHFFFAOYSA-N DM5SYZP IU 4-[di(propan-2-yl)amino]-2-phenyl-2-pyridin-2-ylbutanamide DM5SYZP CA CAS 3737-09-5 DM5SYZP CB CHEBI:4657 DM5SYZP DE Ventricular arrhythmias; Urinary incontinence DMCL2OK ID DMCL2OK DMCL2OK DN Disulfiram DMCL2OK HS Approved DMCL2OK SN Abstenisil; Abstinil; Abstinyl; Alcophobin; Antabus; Antabuse; Antadix; Antaenyl; Antaethan; Antaethyl; Antaetil; Antalcol; Antetan; Antethyl; Antetil; Anteyl; Anthethyl; Antiaethan; Anticol; Antietanol; Antiethanol; Antietil; Antikol; Antivitium; Aversan; Averzan; Bonibal; Contralin; Contrapot; Cronetal; Dicupral; Disetil; Disulfan; Disulfirame; Disulfiramo; Disulfiramum; Disulfirm; Disulfram; Disulfuram; Disulphuram; Ephorran; Espenal; Esperal; Etabus; Ethyldithiourame; Ethyldithiurame; Exhoran; Exhorran; Gababentin; Hoca; Krotenal; Nocbin; Nocceler; Noxal; Refusal; Stopaethyl; Stopethyl; Stopety; Stopetyl; TATD; TETD; THIOCID; TTD; TTS; Tenurid; Tenutex; Tetidis; Tetradin; Tetradine; Tetraethylthiuram; Tetraetil; Teturam; Teturamin; Thireranide; Thiuranide; Tillram; Tiuram; Accel TET; Akrochem TETD; Ancazide ET; Antab use; Disulfirame [DCIT]; Ekagom DTET; Ekagom TEDS; Ekagom TETDS; Ekaland TETD; Esperal [France]; Eta bus; Ethyl Thiram; Ethyl Thiudad; Ethyl Thiurad; Ethyl Tuads Rodform; Ethyl Tuex; Ethyl tuads; Etyl Tuex; Nocceler TET; Perkacit TETD; Perkait TETD; Robac TET; Sanceler TET; Soxinol TET; TTS x; Tet raethylthiuram; Thiuram E; Dupon 4472; T 1132; Accel TET-R; Alk-aubs; Antabus (TN); Antabuse (TN); Anti-ethyl; Antivitium (Spain); ENT 27,340; Nocceler TET-G; Noxal (VAN); Ro-sulfiram; Sanceler TET-G; Tuads, ethyl; Usaf B-33; Ro-Sulfram-500 (USA) DMCL2OK CP Odyssey Pharmaceuticals DMCL2OK TC Alcohol Deterrents DMCL2OK DT Small molecular drug DMCL2OK PC 3117 DMCL2OK MW 296.5 DMCL2OK FM C10H20N2S4 DMCL2OK IC InChI=1S/C10H20N2S4/c1-5-11(6-2)9(13)15-16-10(14)12(7-3)8-4/h5-8H2,1-4H3 DMCL2OK CS CCN(CC)C(=S)SSC(=S)N(CC)CC DMCL2OK IK AUZONCFQVSMFAP-UHFFFAOYSA-N DMCL2OK IU diethylcarbamothioylsulfanyl N,N-diethylcarbamodithioate DMCL2OK CA CAS 97-77-8 DMCL2OK CB CHEBI:4659 DMCL2OK DE Alcohol dependence DM4RK0G ID DM4RK0G DM4RK0G DN Divalproex sodium DM4RK0G HS Approved DM4RK0G SN Delepsine; Depakote; Divalproate; Divalproex; Epilex; Epival; Sprinkle; Valcote; Valdisoval; Valparin; Depakote CP; Depakote ER; Depakote Sprinkle; Divalproex sodium [USAN]; Sodium divalproate; Sodium hydrogen divalproate; Valproate semisodique; Valproate semisodique [French]; Valproate semisodium; Valproato semisodico; Valproato semisodico [Spanish]; Valproatum seminatricum; Valproatum seminatricum [Latin]; Abbott 50711; Abbott-50711; Depacon (TN); Depakote (TN); Depakote ER (TN); Divalproex sodium (USP); Epival (TN); Ergenyl Chrono (TN); Valance (TN); Valproate semisodium (INN); Divalproex sodium, Depakote, Epival; Natrium hydrogen bis(2-propylvalerat); Sodium hydrogen bis(2-propylpentanoate); Sodium hydrogen bis(2-propylvalerate); Valproic acid semisodium salt (2:1); Zalkote. (TN); Sodium hydrogen bis(2-propylvalerate), oligomer; Sodium 2-propylpentanoate-2-propylpentanoic acid (1:1); Pentanoic acid, 2-propyl-, sodium salt (2:1); Pentanoic acid, 2-propyl-, sodium salt(2:1); 2-propylpentanoate DM4RK0G CP Abbott Laboratories DM4RK0G TC Anticonvulsants DM4RK0G DT Small molecular drug DM4RK0G PC 23663956 DM4RK0G MW 310.4 DM4RK0G FM C16H31NaO4 DM4RK0G IC InChI=1S/2C8H16O2.Na/c2*1-3-5-7(6-4-2)8(9)10;/h2*7H,3-6H2,1-2H3,(H,9,10);/q;;+1/p-1 DM4RK0G CS CCCC(CCC)C(=O)O.CCCC(CCC)C(=O)[O-].[Na+] DM4RK0G IK MSRILKIQRXUYCT-UHFFFAOYSA-M DM4RK0G IU sodium;2-propylpentanoate;2-propylpentanoic acid DM4RK0G CA CAS 76584-70-8 DM4RK0G CB CHEBI:4667 DM4RK0G DE Seizure disorder DMD1B8Z ID DMD1B8Z DMD1B8Z DN Dobutamine DMD1B8Z HS Approved DMD1B8Z SN Dobutamina; Dobutaminum; Dobutamine Hcl; Dobutamine [USAN]; Dobutamine hydrobromide; LY 81929; Lilly 81929; DL-dobutamine; Dobutamina [INN-Spanish]; Dobutamine Hcl in Dextrose 5%; Dobutamine(usp); Dobutaminum [INN-Latin]; Rac-dobutamine; Racemic-Dobutamine; Dobutamine (USP/INN); Dobutamine [USAN:BAN:INN]; Dobutamine Tartrate (1:1), (S-(R*,R*))-Isomer; (+-)-4-(2-((3-(p-Hydroxyphenyl)-1-methylpropyl)amino)ethyl)pyrocatechol; 3,4-dihydroxy-N-[3-(4-hydroxyphenyl)-1-methylpropyl]-beta-phenylethylamine; 4-(2-{[3-(4-hydroxyphenyl)-1-methylpropyl]amino}ethyl)benzene-1,2-diol; 4-(2-{[4-(4-hydroxyphenyl)butan-2-yl]amino}ethyl)benzene-1,2-diol; 4-[2-[4-(4-hydroxyphenyl)butan-2-ylamino]ethyl]benzene-1,2-diol DMD1B8Z CP Ben Venue Laboratories DMD1B8Z TC Cardiotonic Agents DMD1B8Z DT Small molecular drug DMD1B8Z PC 36811 DMD1B8Z MW 301.4 DMD1B8Z FM C18H23NO3 DMD1B8Z IC InChI=1S/C18H23NO3/c1-13(2-3-14-4-7-16(20)8-5-14)19-11-10-15-6-9-17(21)18(22)12-15/h4-9,12-13,19-22H,2-3,10-11H2,1H3 DMD1B8Z CS CC(CCC1=CC=C(C=C1)O)NCCC2=CC(=C(C=C2)O)O DMD1B8Z IK JRWZLRBJNMZMFE-UHFFFAOYSA-N DMD1B8Z IU 4-[2-[4-(4-hydroxyphenyl)butan-2-ylamino]ethyl]benzene-1,2-diol DMD1B8Z CA CAS 34368-04-2 DMD1B8Z CB CHEBI:4670 DMD1B8Z DE Heart failure DMS5IEB ID DMS5IEB DMS5IEB DN Docarpamine DMS5IEB HS Approved DMS5IEB SN Tanadopa (TN) DMS5IEB DT Small molecular drug DMS5IEB PC 71137 DMS5IEB MW 470.5 DMS5IEB FM C21H30N2O8S DMS5IEB IC InChI=1S/C21H30N2O8S/c1-5-28-20(26)30-17-8-7-15(13-18(17)31-21(27)29-6-2)9-11-22-19(25)16(10-12-32-4)23-14(3)24/h7-8,13,16H,5-6,9-12H2,1-4H3,(H,22,25)(H,23,24)/t16-/m0/s1 DMS5IEB CS CCOC(=O)OC1=C(C=C(C=C1)CCNC(=O)[C@H](CCSC)NC(=O)C)OC(=O)OCC DMS5IEB IK ZLVMAMIPILWYHQ-INIZCTEOSA-N DMS5IEB IU [4-[2-[[(2S)-2-acetamido-4-methylsulfanylbutanoyl]amino]ethyl]-2-ethoxycarbonyloxyphenyl] ethyl carbonate DMS5IEB CA CAS 74639-40-0 DMS5IEB CB CHEBI:31513 DMS5IEB DE Hypertension DMDI269 ID DMDI269 DMDI269 DN Docetaxel DMDI269 HS Approved DMDI269 SN EmDOC; TXL; Taxotere; Docetaxel anhydrous; ANX-514; Docetaxel (INN); Docetaxel, Trihydrate; RP-56976; SDP-014; Taxotere (TN); Taxotere(R); XRP-6976L; Docetaxel 114977-28-5; N-debenzoyl-N-Boc-10-deacetyl taxol; N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel; N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol; (2alpha,5beta,7beta,10beta,13alpha)-4-(acetyloxy)-13-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7,10-trihydroxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate; 4-(acetyloxy)-13alpha-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7beta,10beta-trihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate DMDI269 CP Sanofi-Aventis DMDI269 TC Anticancer Agents DMDI269 DT Small molecular drug DMDI269 PC 148124 DMDI269 MW 807.9 DMDI269 FM C43H53NO14 DMDI269 IC InChI=1S/C43H53NO14/c1-22-26(55-37(51)32(48)30(24-15-11-9-12-16-24)44-38(52)58-39(3,4)5)20-43(53)35(56-36(50)25-17-13-10-14-18-25)33-41(8,34(49)31(47)29(22)40(43,6)7)27(46)19-28-42(33,21-54-28)57-23(2)45/h9-18,26-28,30-33,35,46-48,53H,19-21H2,1-8H3,(H,44,52)/t26-,27-,28+,30-,31+,32+,33-,35-,41+,42-,43+/m0/s1 DMDI269 CS CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O DMDI269 IK ZDZOTLJHXYCWBA-VCVYQWHSSA-N DMDI269 IU [(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4-acetyloxy-1,9,12-trihydroxy-15-[(2R,3S)-2-hydroxy-3-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylpropanoyl]oxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl] benzoate DMDI269 CA CAS 114977-28-5 DMDI269 CB CHEBI:4672 DMDI269 DE Solid tumour/cancer DMOHK1E ID DMOHK1E DMOHK1E DN Docosanol DMOHK1E HS Approved DMOHK1E SN Abreva; Debat; Doconsanol; Erazaban; Healip; Herepair; Lidakol; Lidavol; Tadenan; Behenic alcohol; Behenyl alcohol; Docosanol [USAN]; Docosyl alcohol; IK 2; Lanette 22; NAA 422; Stenol 1822; Stenol 1822A; Abreva (TN); Docosanol (USAN); Docosanol (VAN); Erazaban (TN); IK.2; N-Docosanol; Nacol 22-97; V-1326;BEHENYL ALCOHOL, 98%; Docosan-1-ol; Behenyl alcohol, Abreva, 1-Docosanol, Docosanol; Behenyl alcohol, AI3-36489, Behenic alcohol, 1-Docosanol, Docosyl alcohol, IK-2, Tadenan; 1-DOCOSANOL DMOHK1E CP Avanir Pharmaceuticals DMOHK1E TC Antiviral Agents DMOHK1E DT Small molecular drug DMOHK1E PC 12620 DMOHK1E MW 326.6 DMOHK1E FM C22H46O DMOHK1E IC InChI=1S/C22H46O/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23/h23H,2-22H2,1H3 DMOHK1E CS CCCCCCCCCCCCCCCCCCCCCCO DMOHK1E IK NOPFSRXAKWQILS-UHFFFAOYSA-N DMOHK1E IU docosan-1-ol DMOHK1E CA CAS 661-19-8 DMOHK1E CB CHEBI:31000 DMOHK1E DE Herpes simplex virus infection DMPN1TW ID DMPN1TW DMPN1TW DN Dofetilide DMPN1TW HS Approved DMPN1TW SN Dofetilida; Dofetilidum; Tikosyn; Xelide; UK 68798; Dofetilida [INN-Spanish]; Dofetilidum [INN-Latin];Tikosyn (TN); UK 68,798; UK-68798; Dofetilide [USAN:BAN:INN]; Tikosyn, UK68798, Dofetilide; UK-68,798; Dofetilide (JAN/USAN/INN); Beta-((p-Methanesulfonamidophenethyl)methylamino)methanesulfono-p-phenetidide; N-[4-[2-[2-[4-(methanesulfonamido)phenoxy]ethyl-methylamino]ethyl]phenyl]methanesulfonamide; N-(4-{2-[methyl(2-{4-[(methylsulfonyl)amino]phenoxy}ethyl)amino]ethyl}phenyl)methanesulfonamide; Methanesulfonamide, N-(4-(2-(methyl(2-(4-((methylsulfonyl)amino)phenoxy)ethyl)amino)ethyl)phenyl); 1-(4-methanesulfonamidophenoxy)-2-(N-(4-methanesulfonamidophenethyl)-N-methylamine)ethane; 1-MSPMPE DMPN1TW CP Pfizer Pharmaceuticals DMPN1TW TC Antiarrhythmic Agents DMPN1TW DT Small molecular drug DMPN1TW PC 71329 DMPN1TW MW 441.6 DMPN1TW FM C19H27N3O5S2 DMPN1TW IC InChI=1S/C19H27N3O5S2/c1-22(13-12-16-4-6-17(7-5-16)20-28(2,23)24)14-15-27-19-10-8-18(9-11-19)21-29(3,25)26/h4-11,20-21H,12-15H2,1-3H3 DMPN1TW CS CN(CCC1=CC=C(C=C1)NS(=O)(=O)C)CCOC2=CC=C(C=C2)NS(=O)(=O)C DMPN1TW IK IXTMWRCNAAVVAI-UHFFFAOYSA-N DMPN1TW IU N-[4-[2-[2-[4-(methanesulfonamido)phenoxy]ethyl-methylamino]ethyl]phenyl]methanesulfonamide DMPN1TW CA CAS 115256-11-6 DMPN1TW CB CHEBI:4681 DMPN1TW DE Sinus rhythm disorder DMMG26Z ID DMMG26Z DMMG26Z DN Dolasetron DMMG26Z HS Approved DMMG26Z SN Dolasetronum; Dolasteron; Anzemet (TN); Dolasetron (INN); Dolasetron [INN:BAN]; Dolasetronum [INN-Latin]; 3-oxooctahydro-2h-2,6-methanoquinolizin-8-yl 1h-indole-3-carboxylate DMMG26Z CP Aventis Pharmaceuticals Inc. DMMG26Z TC Antiemetics DMMG26Z DT Small molecular drug DMMG26Z PC 3033818 DMMG26Z MW 324.4 DMMG26Z FM C19H20N2O3 DMMG26Z IC InChI=1S/C19H20N2O3/c22-18-10-21-12-5-11(18)6-13(21)8-14(7-12)24-19(23)16-9-20-17-4-2-1-3-15(16)17/h1-4,9,11-14,20H,5-8,10H2/t11?,12-,13+,14? DMMG26Z CS C1[C@@H]2CC(C[C@H]3N2CC(=O)C1C3)OC(=O)C4=CNC5=CC=CC=C54 DMMG26Z IK UKTAZPQNNNJVKR-AKJUYKBHSA-N DMMG26Z IU [(3S,7R)-10-oxo-8-azatricyclo[5.3.1.03,8]undecan-5-yl] 1H-indole-3-carboxylate DMMG26Z CA CAS 115956-12-2 DMMG26Z CB CHEBI:94561 DMMG26Z DE Nausea DMCZGRE ID DMCZGRE DMCZGRE DN Dolutegravir DMCZGRE HS Approved DMCZGRE SN 1051375-16-6; GSK1349572; Tivicay; S/GSK1349572; Dolutegravir (GSK1349572); S-349572; GSK-1349572; GSK 1349572; UNII-DKO1W9H7M1; (4r,12as)-N-(2,4-Difluorobenzyl)-7-Hydroxy-4-Methyl-6,8-Dioxo-3,4,6,8,12,12a-Hexahydro-2h-Pyrido[1',2':4,5]pyrazino[2,1-B][1,3]oxazine-9-Carboxamide; CHEBI:76010; DKO1W9H7M1; Tivicay (TN); (4R,12aS)-N-[(2,4-Difluorophenyl)methyl]-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide; Dolutegravir Sodium ( DMCZGRE CP GlaxoSmithKline DMCZGRE DT Small molecular drug DMCZGRE PC 54726191 DMCZGRE MW 419.4 DMCZGRE FM C20H19F2N3O5 DMCZGRE IC InChI=1S/C20H19F2N3O5/c1-10-4-5-30-15-9-24-8-13(17(26)18(27)16(24)20(29)25(10)15)19(28)23-7-11-2-3-12(21)6-14(11)22/h2-3,6,8,10,15,27H,4-5,7,9H2,1H3,(H,23,28)/t10-,15+/m1/s1 DMCZGRE CS C[C@@H]1CCO[C@@H]2N1C(=O)C3=C(C(=O)C(=CN3C2)C(=O)NCC4=C(C=C(C=C4)F)F)O DMCZGRE IK RHWKPHLQXYSBKR-BMIGLBTASA-N DMCZGRE IU (3S,7R)-N-[(2,4-difluorophenyl)methyl]-11-hydroxy-7-methyl-9,12-dioxo-4-oxa-1,8-diazatricyclo[8.4.0.03,8]tetradeca-10,13-diene-13-carboxamide DMCZGRE CA CAS 1051375-16-6 DMCZGRE CB CHEBI:76010 DMCZGRE DE Human immunodeficiency virus infection DMBDPY0 ID DMBDPY0 DMBDPY0 DN Domperidone DMBDPY0 HS Approved DMBDPY0 SN Domperidon; Domperidona; Domperidonum; Motilium; Nauzelin; KW 5338; NCI299589; Costi (TN); D-122; Domperidona [INN-Spanish]; Domperidonum [INN-Latin]; HS-0067; KW-5338; Motilium (TN); Motillium (TN); Motinorm (TN); R 33,812; R-33812; R-33,812; Domperidone (JAN/USAN/INN); Domperidone [USAN:BAN:INN:JAN]; 4-(5-Chloro-2-oxo-1-benzimidazolinyl)-1-[3-(2-oxobenzimidazolinyl)propyl]piperidine; 5-Chloro-1-(1-(3-(2-oxo-1-benzimidazolinyl)propyl)-4-piperidyl)-2-benzimidazolinone; 5-Chloro-1-[1-[3-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)propyl]-4-piperidinyl]-1,3-dihydro-2H-benzimidazol-2-one; 5-Chloro-1-[1-[3-(2-oxo-1-benzimidazolinyl)propyl]-4-piperidyl]-2-benzimidazolinone; 5-chloro-1-(1-(3-(2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)propyl)-4-piperidinyl)-1,3-dihydro-2H-benzimidazol-2-one; 5-chloro-1-{1-[3-(2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)propyl]piperidin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one; 6-chloro-3-[1-[3-(2-oxo-3H-benzimidazol-1-yl)propyl]piperidin-4-yl]-1H-benzimidazol-2-one DMBDPY0 CP Janssen Pharmaceutica DMBDPY0 TC Antiemetics DMBDPY0 DT Small molecular drug DMBDPY0 PC 3151 DMBDPY0 MW 425.9 DMBDPY0 FM C22H24ClN5O2 DMBDPY0 IC InChI=1S/C22H24ClN5O2/c23-15-6-7-20-18(14-15)25-22(30)28(20)16-8-12-26(13-9-16)10-3-11-27-19-5-2-1-4-17(19)24-21(27)29/h1-2,4-7,14,16H,3,8-13H2,(H,24,29)(H,25,30) DMBDPY0 CS C1CN(CCC1N2C3=C(C=C(C=C3)Cl)NC2=O)CCCN4C5=CC=CC=C5NC4=O DMBDPY0 IK FGXWKSZFVQUSTL-UHFFFAOYSA-N DMBDPY0 IU 6-chloro-3-[1-[3-(2-oxo-3H-benzimidazol-1-yl)propyl]piperidin-4-yl]-1H-benzimidazol-2-one DMBDPY0 CA CAS 57808-66-9 DMBDPY0 CB CHEBI:31515 DMBDPY0 DE Gastrointestinal disease DMIYG7Z ID DMIYG7Z DMIYG7Z DN Donepezil DMIYG7Z HS Approved DMIYG7Z SN Donepezil (transdermal patch, Alzheimer's disease) DMIYG7Z CP Nitto Denko Corp DMIYG7Z TC Neurology Agents DMIYG7Z DT Small molecular drug DMIYG7Z PC 3152 DMIYG7Z MW 379.5 DMIYG7Z FM C24H29NO3 DMIYG7Z IC InChI=1S/C24H29NO3/c1-27-22-14-19-13-20(24(26)21(19)15-23(22)28-2)12-17-8-10-25(11-9-17)16-18-6-4-3-5-7-18/h3-7,14-15,17,20H,8-13,16H2,1-2H3 DMIYG7Z CS COC1=C(C=C2C(=C1)CC(C2=O)CC3CCN(CC3)CC4=CC=CC=C4)OC DMIYG7Z IK ADEBPBSSDYVVLD-UHFFFAOYSA-N DMIYG7Z IU 2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxy-2,3-dihydroinden-1-one DMIYG7Z CA CAS 120014-06-4 DMIYG7Z CB CHEBI:53289 DMIYG7Z DE Alzheimer disease DMPGUCF ID DMPGUCF DMPGUCF DN Dopamine DMPGUCF HS Approved DMPGUCF SN Dopamin; Dopamina; Dopaminum; Dophamine; Hydroxytyramin; Hydroxytyramine; Intropin; LDP; Oxytyramine; Revimine; ASL 279; IP 498; Dopamina [INN-Spanish]; Dopamine (INN); Dopamine [INN:BAN]; Dopaminum [INN-Latin]; L-DOPAMINE; M-Hydroxytyramine hydrochloride; Medopa (TN); Intropin [*hydrochloride*]; KW-3-060; Beta-(3,4-Dihydroxyphenyl)ethylamine hydrochloride; Dopamine (USAN)(*hydrochloride*); A-(3,4-Dihydroxyphenyl)-b-aminoethane; Alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane; Pyrocatechol, 4-(2-aminoethyl)-(8CI); Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride; (3H)-Dopamine; 1,2-Benzenediol, 4-(2-aminoethyl)-(9CI); 1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride; 1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium; 153C5321-5FEE-4B0B-8925-F388F0EEEBD1; 2-(3,4-dihydroxyphenyl)ethylamine; 2-benzenediol; 3,4-Dihydroxyphenethylamine hydrochloride; 3,4-Dihydroxyphenylethylamine; 3,4-dihydroxyphenethylamine; 3-Hydroxtyramine; 3-Hydroxytyramine; 3-Hydroxytyramine Hydrobromide; 3-Hydroxytyramine hydrochloride; 4-(2-Aminoethyl)-1; 4-(2-Aminoethyl)-1,2-benzenediol; 4-(2-Aminoethyl)-1,2-bezenediol; 4-(2-Aminoethyl)benzene-1,2-diol; 4-(2-Aminoethyl)catechol; 4-(2-Aminoethyl)pyrocatechol; 4-(2-Aminoethyl)pyrocatechol hydrochloride; 4-(2-aminoethyl)-pyrocatechol DMPGUCF CP Baxter Healthcare Corp Anesthesia And Critical Care DMPGUCF TC Cardiotonic Agents DMPGUCF DT Small molecular drug DMPGUCF PC 681 DMPGUCF MW 153.18 DMPGUCF FM C8H11NO2 DMPGUCF IC InChI=1S/C8H11NO2/c9-4-3-6-1-2-7(10)8(11)5-6/h1-2,5,10-11H,3-4,9H2 DMPGUCF CS C1=CC(=C(C=C1CCN)O)O DMPGUCF IK VYFYYTLLBUKUHU-UHFFFAOYSA-N DMPGUCF IU 4-(2-aminoethyl)benzene-1,2-diol DMPGUCF CA CAS 51-61-6 DMPGUCF CB CHEBI:18243 DMPGUCF DE Parkinson disease; Hypotension DMSCIKZ ID DMSCIKZ DMSCIKZ DN Dopexamine DMSCIKZ HS Approved DMSCIKZ SN Dopacard (TN) DMSCIKZ DT Small molecular drug DMSCIKZ PC 55483 DMSCIKZ MW 356.5 DMSCIKZ FM C22H32N2O2 DMSCIKZ IC InChI=1S/C22H32N2O2/c25-21-11-10-20(18-22(21)26)13-17-24-15-7-2-1-6-14-23-16-12-19-8-4-3-5-9-19/h3-5,8-11,18,23-26H,1-2,6-7,12-17H2 DMSCIKZ CS C1=CC=C(C=C1)CCNCCCCCCNCCC2=CC(=C(C=C2)O)O DMSCIKZ IK RYBJORHCUPVNMB-UHFFFAOYSA-N DMSCIKZ IU 4-[2-[6-(2-phenylethylamino)hexylamino]ethyl]benzene-1,2-diol DMSCIKZ CA CAS 86197-47-9 DMSCIKZ CB CHEBI:135507 DMSCIKZ DE Cardiac failure DM9UCJK ID DM9UCJK DM9UCJK DN Doripenem DM9UCJK HS Approved DM9UCJK SN Doribax; S 4661; S-4661; Doripenem (USAN/INN); (4R,5S,6S)-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-3-[(3S,5S)-5-[(sulfamoylamino)methyl]pyrrolidin-3-yl]sulfanyl-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid DM9UCJK CP Shionogi; penisula DM9UCJK DT Small molecular drug DM9UCJK PC 73303 DM9UCJK MW 420.5 DM9UCJK FM C15H24N4O6S2 DM9UCJK IC InChI=1S/C15H24N4O6S2/c1-6-11-10(7(2)20)14(21)19(11)12(15(22)23)13(6)26-9-3-8(17-5-9)4-18-27(16,24)25/h6-11,17-18,20H,3-5H2,1-2H3,(H,22,23)(H2,16,24,25)/t6-,7-,8+,9+,10-,11-/m1/s1 DM9UCJK CS C[C@@H]1[C@@H]2[C@H](C(=O)N2C(=C1S[C@H]3C[C@H](NC3)CNS(=O)(=O)N)C(=O)O)[C@@H](C)O DM9UCJK IK AVAACINZEOAHHE-VFZPANTDSA-N DM9UCJK IU (4R,5S,6S)-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-3-[(3S,5S)-5-[(sulfamoylamino)methyl]pyrrolidin-3-yl]sulfanyl-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid DM9UCJK CA CAS 148016-81-3 DM9UCJK CB CHEBI:135928 DM9UCJK DE Urinary tract infection; Gram-positive bacterial infection DM3XU74 ID DM3XU74 DM3XU74 DN Dornase Alfa DM3XU74 HS Approved DM3XU74 SN Pulmozyme (TN) DM3XU74 CP Genentech DM3XU74 TC Enzyme Replacement Agents DM3XU74 SQ Dornase alfa sequence: LKIAAFNIQTFGETKMSNATLVSYIVQILSRYDIALVQEVRDSHLTAVGKLLDNLNQDAPDTYHYVVSEPLGRNSYKERYLFVYRPDQVSAVDSYYYDDGCEPCGNDTFNREPAIVRFFSRFTEVREFAIVPLHAAPGDAVAEIDALYDVYLDVQEKWGLEDVMLMGDFNAGCSYVRPSQWSSIRLWTSPTFQWLIPDSADTTATPTHCAYDRIVVAGMLLRGAVVPDSALPFNFQAAYGLSDQLAQAISDHYPVEVMLK DM3XU74 DE Cystic fibrosis DMA17D0 ID DMA17D0 DMA17D0 DN Dorzolamide DMA17D0 HS Approved DMA17D0 SN Trusopt; Dorzolamide (DZA); Dorzolamide (INN); Trusopt (TN); (4S,6S)-4-(ethylamino)-6-methyl-5,6-dihydro-4H-thieno[2,3-b]thiopyran-2-sulfonamide 7,7-dioxide; (4S,6S)-4-(ethylamino)-6-methyl-7,7-dioxo-5,6-dihydro-4H-thieno[2,3-b]thiopyran-2-sulfonamide; (4S,6S)-4-Ethylamino-6-methyl-7,7-dioxo-4,5,6,7-tetrahydro-7lambda*6*-thieno[2,3-b]thiopyran-2-sulfonic acid amide; (4S,trans)-4-(ethylamino)-6-methyl-5,6-dihydro-4H-thieno[2,3-b]thiopyran-2-sulfonamide 7,7-dioxide; (4S-TRANS)-4-(ETHYLAMINO)-5,6-DIHYDRO-6-METHYL-4H-THIENO(2,3-B)THIOPYRAN-2-SULFONAMIDE-7,7-DIOXIDE DMA17D0 CP Merck & Co DMA17D0 TC Antihypertensive Agents DMA17D0 DT Small molecular drug DMA17D0 PC 5284549 DMA17D0 MW 324.4 DMA17D0 FM C10H16N2O4S3 DMA17D0 IC InChI=1S/C10H16N2O4S3/c1-3-12-8-4-6(2)18(13,14)10-7(8)5-9(17-10)19(11,15)16/h5-6,8,12H,3-4H2,1-2H3,(H2,11,15,16)/t6-,8-/m0/s1 DMA17D0 CS CCN[C@H]1C[C@@H](S(=O)(=O)C2=C1C=C(S2)S(=O)(=O)N)C DMA17D0 IK IAVUPMFITXYVAF-XPUUQOCRSA-N DMA17D0 IU (4S,6S)-4-(ethylamino)-6-methyl-7,7-dioxo-5,6-dihydro-4H-thieno[2,3-b]thiopyran-2-sulfonamide DMA17D0 CA CAS 120279-96-1 DMA17D0 CB CHEBI:4702 DMA17D0 DE Open-angle glaucoma DM78NWP ID DM78NWP DM78NWP DN Dostarlimab DM78NWP HS Approved DM78NWP CP AnaptysBio; GlaxoSmithKline DM78NWP DT Antibody DM78NWP DE Endometrial cancer; Multiple myeloma; Breast cancer; Neoplasm DMKE7L9 ID DMKE7L9 DMKE7L9 DN Doxacurium DMKE7L9 HS Approved DMKE7L9 SN Nuromax; Chlorure de doxacurium; Chlorure de doxacurium [French]; Cloruro de doxacurio; Cloruro de doxacurio [Spanish]; Doxacurii chloridum; Doxacurii chloridum [Latin]; Doxacurium chloride(no stereochemistry); Nuromax (TN); Doxacurium chloride (USAN/INN); Bis[3-[6,7,8-trimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propyl] butanedioate; Bis[3-[6,7,8-trimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propyl] butanedioate dichloride DMKE7L9 CP Abbott Laboratories DMKE7L9 TC Analgesics DMKE7L9 DT Small molecular drug DMKE7L9 PC 60169 DMKE7L9 MW 1035.2 DMKE7L9 FM C56H78N2O16+2 DMKE7L9 IC InChI=1S/C56H78N2O16/c1-57(23-19-37-33-45(65-7)53(69-11)55(71-13)49(37)39(57)27-35-29-41(61-3)51(67-9)42(30-35)62-4)21-15-25-73-47(59)17-18-48(60)74-26-16-22-58(2)24-20-38-34-46(66-8)54(70-12)56(72-14)50(38)40(58)28-36-31-43(63-5)52(68-10)44(32-36)64-6/h29-34,39-40H,15-28H2,1-14H3/q+2 DMKE7L9 CS C[N+]1(CCC2=CC(=C(C(=C2C1CC3=CC(=C(C(=C3)OC)OC)OC)OC)OC)OC)CCCOC(=O)CCC(=O)OCCC[N+]4(CCC5=CC(=C(C(=C5C4CC6=CC(=C(C(=C6)OC)OC)OC)OC)OC)OC)C DMKE7L9 IK GBLRQXKSCRCLBZ-UHFFFAOYSA-N DMKE7L9 IU bis[3-[6,7,8-trimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propyl] butanedioate DMKE7L9 CA CAS 133814-18-3 DMKE7L9 CB CHEBI:4706 DMKE7L9 DE Spasm DMCYANK ID DMCYANK DMCYANK DN Doxapram DMCYANK HS Approved DMCYANK SN Docatone; Dopram; Doxapramum; Doxapram HCL; Doxapram hydrochloride; Docatone (TN); Dopram (TN); Doxapram (INN); Doxapram [USP:JAN]; Doxapramum [INN-Latin]; (+-)-doxapram; 1-Ethyl-4-(2-morpholinoethyl)-3,3-diphenyl-2-pyrrolidinone; 1-ethyl-4-(2-morpholin-4-ylethyl)-3,3-diphenylpyrrolidin-2-one; 1-ethyl-4-[2-(morpholin-4-yl)ethyl]-3,3-diphenylpyrrolidin-2-one; 2-Pyrrolidinone, 1-ethyl-4-(2-(4-morpholinyl)ethyl)-3,3-diphenyl-(9CI) DMCYANK TC Central Nervous System Stimulants DMCYANK DT Small molecular drug DMCYANK PC 3156 DMCYANK MW 378.5 DMCYANK FM C24H30N2O2 DMCYANK IC InChI=1S/C24H30N2O2/c1-2-26-19-22(13-14-25-15-17-28-18-16-25)24(23(26)27,20-9-5-3-6-10-20)21-11-7-4-8-12-21/h3-12,22H,2,13-19H2,1H3 DMCYANK CS CCN1CC(C(C1=O)(C2=CC=CC=C2)C3=CC=CC=C3)CCN4CCOCC4 DMCYANK IK XFDJYSQDBULQSI-UHFFFAOYSA-N DMCYANK IU 1-ethyl-4-(2-morpholin-4-ylethyl)-3,3-diphenylpyrrolidin-2-one DMCYANK CA CAS 309-29-5 DMCYANK CB CHEBI:681848 DMCYANK DE Respiratory disease DM9PLRH ID DM9PLRH DM9PLRH DN Doxazosin DM9PLRH HS Approved DM9PLRH SN Doxazosina; Doxazosine; Doxazosinum; Normothen; Doxazosina [Spanish]; Doxazosine [French]; Doxazosinum [Latin]; UK 33274; Cardura (TN); Cardura XL (TN); Cardura-1; Cardura-2; Cardura-4; Carduran (TN); Doxazosin (INN); Doxazosin [INN:BAN]; UK-33274; [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(2,3-dihydro-1,4-benzodioxin-3-yl)methanone; 1-(4-Amino-6,7-Dimethoxy-2-quinazolinyl)-4-(1,4-benzodioxan-2-ylcarbonyl)piperazin; 1-(4-Amino-6,7-dimethoxy-2-chinazolinyl)-4-(2,3-dihydro-1,4-benzodioxixin-2-ylcarbonyl)piperazin; 1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-[4-(1,4-benzodioxan-2-yl)carpiperazin-1-yl)]-6,7-dimethoxyquinazoline mesylate; 2-[4-(2,3-dihydro-1,4-benzodioxin-2-ylcarbonyl)piperazin-1-yl]-6,7-bis(methyloxy)quinazolin-4-amine; 2-[4-(2,3-dihydro-1,4-benzodioxin-2-ylcarbonyl)piperazin-1-yl]-6,7-dimethoxyquinazolin-4-amine; 2-{4-[(2,3-dihydro-1,4-benzodioxin-2-yl)carbonyl]piperazin-1-yl}-6,7-dimethoxyquinazolin-4-amine DM9PLRH CP Pfizer Pharmaceuticals DM9PLRH TC Antihypertensive Agents DM9PLRH DT Small molecular drug DM9PLRH PC 3157 DM9PLRH MW 451.5 DM9PLRH FM C23H25N5O5 DM9PLRH IC InChI=1S/C23H25N5O5/c1-30-18-11-14-15(12-19(18)31-2)25-23(26-21(14)24)28-9-7-27(8-10-28)22(29)20-13-32-16-5-3-4-6-17(16)33-20/h3-6,11-12,20H,7-10,13H2,1-2H3,(H2,24,25,26) DM9PLRH CS COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4COC5=CC=CC=C5O4)N)OC DM9PLRH IK RUZYUOTYCVRMRZ-UHFFFAOYSA-N DM9PLRH IU [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(2,3-dihydro-1,4-benzodioxin-3-yl)methanone DM9PLRH CA CAS 74191-85-8 DM9PLRH CB CHEBI:4708 DM9PLRH DE Hypertension DMPI98T ID DMPI98T DMPI98T DN Doxepin DMPI98T HS Approved DMPI98T SN Zonalon; doxepin; Doxepine; Doxepinum [INN-Latin]; Doxepina [INN-Spanish]; Doxepin [USAN]; trans-doxepin; (e)-doxepin; 1668-19-5; Quitaxon; MF 10; UNII-851NLB57HQ; Sinequan; CCRIS 9176; HSDB 3069; Sinequan (TN); Cidoxepina; Cidoxepinum; 851NLB57HQ; 11-(3-(Dimethylamino)propylidene)-6H-dibenz(b,e)oxepine; 11-(3-Dimethylaminopropylidene)-6,11-dihydrodibenz(b,e)oxipin; 11-(3-Dimethylamino-propyliden)-6,11-dihydro-dibenz(b,e)oxipin; N,N-Dimethyldibenz(b,e)oxepin-delta(11(6H),gamma)-propylamine; Cidoxepin [INN]; Curatin; Adapin; Cidoxepin; Doxepina; Doxepinum; Triadapin; Doxepin Hydrochloride; MOLI001594; Adapine (TN); Aponal (TN); Cis-doxepin; Deptran (TN); Doxepin (INN); Doxepin, Hydrochloride; Sinquan (TN); Xepin (TN); Zonalon (TN); Doxepin (Z)-isomer; Cis-N-(3-(6H-Dibenz(b,e)oxepin-11-yliden)propyl)-N,N-dimethylamin; (3E)-3-(6H-benzo[c][1]benzoxepin-11-ylidene)-N,N-dimethylpropan-1-amine; (3E)-3-dibenzo[b,e]oxepin-11(6H)-ylidene-N,N-dimethylpropan-1-amine; (3Z)-3-(6H-benzo[c][1]benzoxepin-11-ylidene)-N,N-di(methyl)propan-1-amine; (3Z)-3-(6H-benzo[c][1]benzoxepin-11-ylidene)-N,N-dimethylpropan-1-amine; (3Z)-3-dibenzo[b,e]oxepin-11(6H)-ylidene-N,N-dimethylpropan-1-amine; (Z)-Doxepin; 3-(6H-benzo[c][1]benzoxepin-11-ylidene)-N,N-dimethylpropan-1-amine; 3-Dibenz[b,e]oxepin-11(6H)-ylidene-N,N-dimethyl-1-propanamine; 3-dibenzo[b,e]oxepin-11(6H)-ylidene-N,N-dimethylpropan-1-amine; [11C]doxepin DMPI98T CP Pfizer Pharmaceuticals DMPI98T TC Antidepressants DMPI98T DT Small molecular drug DMPI98T PC 667477 DMPI98T MW 279.4 DMPI98T FM C19H21NO DMPI98T IC InChI=1S/C19H21NO/c1-20(2)13-7-11-17-16-9-4-3-8-15(16)14-21-19-12-6-5-10-18(17)19/h3-6,8-12H,7,13-14H2,1-2H3/b17-11+ DMPI98T CS CN(C)CC/C=C/1\\C2=CC=CC=C2COC3=CC=CC=C31 DMPI98T IK ODQWQRRAPPTVAG-GZTJUZNOSA-N DMPI98T IU (3E)-3-(6H-benzo[c][1]benzoxepin-11-ylidene)-N,N-dimethylpropan-1-amine DMPI98T CA CAS 1668-19-5 DMPI98T DE Depression DM6FG1P ID DM6FG1P DM6FG1P DN Doxercalciferol DM6FG1P HS Approved DM6FG1P SN Doxcercalciferol; Hectorol; Doxercalciferol [INN]; TSA 840; BCI-101; Doxercalciferol (INN); Hectorol (TN); (1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5R)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol; (5Z,7E,22E)-9,10-Secoergosta-5,7,10(19),22-tetraene-1alpha,3beta-diol; 1-Hydroxyergocalciferol; 1-alpha-Hydroxyvitamin D2; 1alpha-Hydroxyergocalciferol; 1alpha-OH-D2; 9,10-Secoergosta-5,7,10(19),22-tetraene-1,3-diol,(1-alpha,3-beta,5Z,7E,22E) DM6FG1P CP Genzyme DM6FG1P DT Small molecular drug DM6FG1P PC 5281107 DM6FG1P MW 412.6 DM6FG1P FM C28H44O2 DM6FG1P IC InChI=1S/C28H44O2/c1-18(2)19(3)9-10-20(4)25-13-14-26-22(8-7-15-28(25,26)6)11-12-23-16-24(29)17-27(30)21(23)5/h9-12,18-20,24-27,29-30H,5,7-8,13-17H2,1-4,6H3/b10-9+,22-11+,23-12-/t19-,20+,24+,25+,26-,27-,28+/m0/s1 DM6FG1P CS C[C@H](/C=C/[C@H](C)C(C)C)[C@H]1CC[C@@H]\\2[C@@]1(CCC/C2=C\\C=C/3\\C[C@H](C[C@@H](C3=C)O)O)C DM6FG1P IK HKXBNHCUPKIYDM-CGMHZMFXSA-N DM6FG1P IU (1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5R)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol DM6FG1P CA CAS 54573-75-0 DM6FG1P CB CHEBI:4712 DM6FG1P DE Chronic kidney disease DMEDKZH ID DMEDKZH DMEDKZH DN Doxofylline DMEDKZH HS Approved DMEDKZH SN Ansimar (TN) DMEDKZH CP ABC S.p.A. DMEDKZH DT Small molecular drug DMEDKZH PC 50942 DMEDKZH MW 266.25 DMEDKZH FM C11H14N4O4 DMEDKZH IC InChI=1S/C11H14N4O4/c1-13-9-8(10(16)14(2)11(13)17)15(6-12-9)5-7-18-3-4-19-7/h6-7H,3-5H2,1-2H3 DMEDKZH CS CN1C2=C(C(=O)N(C1=O)C)N(C=N2)CC3OCCO3 DMEDKZH IK HWXIGFIVGWUZAO-UHFFFAOYSA-N DMEDKZH IU 7-(1,3-dioxolan-2-ylmethyl)-1,3-dimethylpurine-2,6-dione DMEDKZH CA CAS 69975-86-6 DMEDKZH CB CHEBI:94714 DMEDKZH DE Asthma DMVP5YE ID DMVP5YE DMVP5YE DN Doxorubicin DMVP5YE HS Approved DMVP5YE SN doxorubicin; 23214-92-8; Doxil; Doxorubicine; Adriablastin; Doxorubicinum; 14-Hydroxydaunomycin; 14-Hydroxydaunorubicine; Doxorubicina; Adriamycin semiquinone; Doxorubicinum [INN-Latin]; Doxorubicine [INN-French]; Doxorubicina [INN-Spanish]; Myocet; FI 106; Doxorubicin [USAN:INN:BAN]; CCRIS 739; NDC 38242-874; HSDB 3070; UNII-80168379AG; NCI-C01514; EINECS 245-495-6; CHEMBL53463; CHEBI:28748; 5,12-Naphthacenedione,; ADM; ADR; ThermoDox; Aerosolized Doxorubicin; Doxorubicin citrate; RDF Rubex; Conjugate of doxorubicin with humanized monoclonal antibody LL1 against CD74; DM2; JT9100000; Adiblastine (hydrochloride salt); Adr iablatina (hydrochloride salt); Adriablastine (hydrochloride salt); Adriablatina (hydrochloride salt); Adriacin (hydrochloride salt); Adriamycin PFS (TN); Adriamycin PFS (hydrochloride salt); Adriamycin RDF (TN); Adriamycin RDF (hydrochloride salt); Adriblastina (TN); Adriblastina (hydrochloride salt); Adriblatina (hydrochloride salt); Caelyx (TN); Conjugate of doxorubicin with monoclonal antibody P4/D10 against GP120; DOX-SL; Doxorubicin hydrochloride (hydrochloride salt); Doxorubicin-hLL1; Doxorubicin-hLL1 conjugate; Farmablastina (hydrochloride salt); Hydroxydaunomycin hydrochlor ide (hydrochloride salt); Hydroxydaunomycin hydrochloride (hydrochloride salt); Hydroxydaunorubicin hydrochloride (hydrochloride salt); Myocet (TN); Rubex (TN); Rubex (hydrochloride salt); TLC D-99; Doxorubicin (USAN/INN); Doxorubicin-P4/D10; Doxorubicin-P4/D10 conjugate; Cantide + adriamycin DMVP5YE CP Sequus Pharmaceuticals Inc DMVP5YE TC Anticancer Agents DMVP5YE DT Small molecular drug DMVP5YE PC 31703 DMVP5YE MW 543.5 DMVP5YE FM C27H29NO11 DMVP5YE IC InChI=1S/C27H29NO11/c1-10-22(31)13(28)6-17(38-10)39-15-8-27(36,16(30)9-29)7-12-19(15)26(35)21-20(24(12)33)23(32)11-4-3-5-14(37-2)18(11)25(21)34/h3-5,10,13,15,17,22,29,31,33,35-36H,6-9,28H2,1-2H3/t10-,13-,15-,17-,22+,27-/m0/s1 DMVP5YE CS C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O DMVP5YE IK AOJJSUZBOXZQNB-TZSSRYMLSA-N DMVP5YE IU (7S,9S)-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione DMVP5YE CA CAS 23214-92-8 DMVP5YE CB CHEBI:28748 DMVP5YE DE Solid tumour/cancer; Tumour; Breast cancer; Hepatocellular carcinoma DM7ICNU ID DM7ICNU DM7ICNU DN Doxycycline DM7ICNU HS Approved DM7ICNU SN Atridox; Azudoxat; DOXY; Deoxymykoin; Dossiciclina; Doxiciclina; Doxitard; Doxivetin; Doxycen; Doxychel; Doxycin; Doxycyclin; Doxycyclinum; Doxysol; Doxytec; Doxytetracycline; Hydramycin; Investin; Jenacyclin; Liviatin; Monodox; Oracea; Ronaxan; Spanor; Supracyclin; Vibramycin; Vibramycine; Vibravenos; DOXCYCLINE ANHYDROUS; DOXYCYCLINE CALCIUM; DOXYCYCLINE MONOHYDRATE; Dossiciclina [DCIT]; Doxiciclina [Italian]; Doxycycline anhydrous; Doxycycline hyclate; Vibramycin Novum; Alpha-Doxycycline; Alti-Doxycycline; Apo-Doxy; BMY-28689; BU-3839T; Doxiciclina [INN-Spanish]; Doxy-Caps; Doxy-Puren; Doxy-Tabs; Doxychel (TN); Doxycycline (INN); Doxycycline (TN); Doxycycline (anhydrous); Doxycycline (internal use); Doxycycline-Chinoin; Doxycyclinum [INN-Latin]; Novo-Doxylin; Nu-Doxycycline; Periostat (TN); Vibra-tabs; Alpha-6-Deoxyoxytetracycline; DMSC (*Fosfatex); Doxycycline (200mg/day) or Placebo; Monodox (*monohydrate); Vibramycin (*monohydrate); Vivox (*Hyclate); GS-3065 (*monohydrate); Alpha-6-Deoxy-5-hydroxytetracycline; (2E,4S,4aR,5S,5aR,6R,12aS)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methyl-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione; (2Z)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methyl-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione; (2Z,4S,4aR,5S,5aR,6R)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methyl-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione; (2Z,4S,4aR,5S,5aR,6R,12aS)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methyl-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione; (4S,4aR,5S,5aR,6R,12aS)-4-(dimethylamino)-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide; 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4S,4aR,5S,5aR,6R,12aS); 5-Hydroxy-alpha-6-deoxytetracycline; 6-Deoxyoxytetracycline; 6-Deoxytetracycline; 6-alpha-Deoxy-5-oxytetracycline; 6alpha-Deoxy-5-oxytetracycline DM7ICNU CP Collagenex DM7ICNU TC Antiinflammatory Agents DM7ICNU DT Small molecular drug DM7ICNU PC 54671203 DM7ICNU MW 444.4 DM7ICNU FM C22H24N2O8 DM7ICNU IC InChI=1S/C22H24N2O8/c1-7-8-5-4-6-9(25)11(8)16(26)12-10(7)17(27)14-15(24(2)3)18(28)13(21(23)31)20(30)22(14,32)19(12)29/h4-7,10,14-15,17,25-27,30,32H,1-3H3,(H2,23,31)/t7-,10+,14+,15-,17-,22-/m0/s1 DM7ICNU CS C[C@@H]1[C@H]2[C@@H]([C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O DM7ICNU IK SGKRLCUYIXIAHR-AKNGSSGZSA-N DM7ICNU IU (4S,4aR,5S,5aR,6R,12aR)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4H-tetracene-2-carboxamide DM7ICNU CA CAS 564-25-0 DM7ICNU CB CHEBI:50845 DM7ICNU DE Chronic periodontitis; Advanced gum disease; Diabetic foot ulcer DMKOXFE ID DMKOXFE DMKOXFE DN Doxylamine DMKOXFE HS Approved DMKOXFE SN Dossilamina; Doxilamina; Doxilminio; Doxylaminum; Dossilamina [DCIT]; Diclectin (TN); Dolased (TN); Donormyl (TN); Dormidina (TN); Doxilminio [INN-Spanish]; Doxylamine (INN); Doxylamine [INN:BAN]; Doxylaminum [INN-Latin]; Dozile (TN); Evanorm (TN); Mersyndol (TN); Restavit (TN); Somnil (TN); Syndol (TN); Unisom-2 (TN); Phenyl-2-pyridylmethyl-beta-N,N-dimethylaminoethyl ether; N,N-Dimethyl-2-(1-phenyl-1-(2-pyridinyl)ethoxy)ethanamine; N,N-dimethyl-2-(1-phenyl-1-pyridin-2-ylethoxy)ethanamine; N,N-dimethyl-2-[(1-phenyl-1-pyridin-2-ylethyl)oxy]ethanamine; N,N-dimethyl-2-[1-phenyl-1-(pyridin-2-yl)ethoxy]ethanamine; 2-(alpha-(2-(Dimethylamino)ethoxy)-alpha-methylbenzyl)pyridine; 2-Dimethylaminoethoxyphenylmethyl-2-picoline DMKOXFE CP Ion Healthcare DMKOXFE TC Hypnotics and Sedatives DMKOXFE DT Small molecular drug DMKOXFE PC 3162 DMKOXFE MW 270.37 DMKOXFE FM C17H22N2O DMKOXFE IC InChI=1S/C17H22N2O/c1-17(20-14-13-19(2)3,15-9-5-4-6-10-15)16-11-7-8-12-18-16/h4-12H,13-14H2,1-3H3 DMKOXFE CS CC(C1=CC=CC=C1)(C2=CC=CC=N2)OCCN(C)C DMKOXFE IK HCFDWZZGGLSKEP-UHFFFAOYSA-N DMKOXFE IU N,N-dimethyl-2-(1-phenyl-1-pyridin-2-ylethoxy)ethanamine DMKOXFE CA CAS 469-21-6 DMKOXFE CB CHEBI:51380 DMKOXFE DE Morning sickness DMGOXPQ ID DMGOXPQ DMGOXPQ DN DP-VPA DMGOXPQ HS Approved DMGOXPQ SN TVA; RAP-valproate; SPD-421; Valproic acid prodrug, Shire; RAP-valproate, D-Pharm DMGOXPQ CP D-Pharm Ltd DMGOXPQ DE Bipolar disorder DMF2JDG ID DMF2JDG DMF2JDG DN Dromostanolone DMF2JDG HS Approved DMF2JDG SN Drostanolo; Drostanolon; Drostanolona; Drostanolone; Drostanolonum; Medrosteron; Medrotestron; Methalone; Metholone; Prometholone; Drostanolo [DCIT]; SKI 27719; Drolban (TN); Drostanolona [INN-Spanish]; Drostanolone [INN:BAN]; Drostanolonum [INN-Latin]; Dihydro-2alpha-methyltestosterone; Dihydro-2-alpha-methyltestosterone; Dihydro-2.alpha.-methyltestosterone; Androstan-3-one, 17-hydroxy-2-methyl-, (2alpha,5alpha,17beta)-(9CI); (2R,5S,8R,9S,10S,13S,14S,17S)-17-hydroxy-2,10,13-trimethyl-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-one; (2alpha,5alpha,17beta)-17-hydroxy-2-methylandrostan-3-one; 17 beta-hydroxy-2 alpha-methyl-5 alpha-androstan-3-one; 17-beta-Hydroxy-2-alpha-methyl-5-alpha-androstan-3-one; 17beta-Hydroxy-2alpha-methyl-5alpha-androstan-3-one; 2-alpha-Methyl-17-beta-hydroxy-5-alpha-androstan-3-one; 2-alpha-Methyldihydrotestosterone; 2.alpha.-Methyldihydrotestosterone; 2a-methylandrostan-17b-ol-3-one; 2alpha-Methyldihydrotestosterone DMF2JDG CP Eli Lilly And Co DMF2JDG TC Anabolic Agents DMF2JDG DT Small molecular drug DMF2JDG PC 6011 DMF2JDG MW 304.5 DMF2JDG FM C20H32O2 DMF2JDG IC InChI=1S/C20H32O2/c1-12-11-20(3)13(10-17(12)21)4-5-14-15-6-7-18(22)19(15,2)9-8-16(14)20/h12-16,18,22H,4-11H2,1-3H3/t12-,13+,14+,15+,16+,18+,19+,20+/m1/s1 DMF2JDG CS C[C@@H]1C[C@]2([C@@H](CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC[C@@H]4O)C)CC1=O)C DMF2JDG IK IKXILDNPCZPPRV-RFMGOVQKSA-N DMF2JDG IU (2R,5S,8R,9S,10S,13S,14S,17S)-17-hydroxy-2,10,13-trimethyl-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-one DMF2JDG CA CAS 58-19-5 DMF2JDG CB CHEBI:34838 DMF2JDG DE Mammary tumour DMA8FS5 ID DMA8FS5 DMA8FS5 DN Dronedarone DMA8FS5 HS Approved DMA8FS5 SN Multaq; Dronedarone [INN]; SR 33589; SR 33589B; Dronedarone (INN); Sanofi-Aventis brand of dronedarone; N-[2-butyl-3-[4-[3-(dibutylamino)propoxy]benzoyl]-1-benzofuran-5-yl]methanesulfonamide; N-(2-Butyl-3-(p-(3-(dibutylamino)propoxy)benzoyl)-5-benzofuranyl)methanesulfonamide; N-[2-butyl-3-{4-[3-(dibutylamino)propoxy]benzoyl}-1-benzofuran-5-yl]methanesulfonamide; N-(2-butyl-3-(4-(3-(dibutylamino)propoxy)benzoyl)-5-benzofuranyl)-methanesulfonamide DMA8FS5 CP Sanofi-Synthelabo DMA8FS5 DT Small molecular drug DMA8FS5 PC 208898 DMA8FS5 MW 556.8 DMA8FS5 FM C31H44N2O5S DMA8FS5 IC InChI=1S/C31H44N2O5S/c1-5-8-12-29-30(27-23-25(32-39(4,35)36)15-18-28(27)38-29)31(34)24-13-16-26(17-14-24)37-22-11-21-33(19-9-6-2)20-10-7-3/h13-18,23,32H,5-12,19-22H2,1-4H3 DMA8FS5 CS CCCCC1=C(C2=C(O1)C=CC(=C2)NS(=O)(=O)C)C(=O)C3=CC=C(C=C3)OCCCN(CCCC)CCCC DMA8FS5 IK ZQTNQVWKHCQYLQ-UHFFFAOYSA-N DMA8FS5 IU N-[2-butyl-3-[4-[3-(dibutylamino)propoxy]benzoyl]-1-benzofuran-5-yl]methanesulfonamide DMA8FS5 CA CAS 141626-36-0 DMA8FS5 CB CHEBI:50659 DMA8FS5 DE Angina pectoris; Atrial fibrillation DM0DXA8 ID DM0DXA8 DM0DXA8 DN Droperidol DM0DXA8 HS Approved DM0DXA8 SN DHBP; Dehidrobenzperidol; Dehydrobenzoperidol; Dehydrobenzperidol; Deidrobenzperidolo; Dihidrobenzperidol; Dridol; Droleptan; Droperidolo; Droperidolum; Halkan; Inappin; Inapsin; Inapsine; Innovan; Inopsin; Inoval; Leptanal; Leptofen; Properidol; Sintodril; Sintosian; Thalamanol; Thalamonal; Vetkalm; Component of Innovar; Droperidolo [DCIT]; Janssen Brand of Droperidol; Kern Brand of Droperidol; Taylor Brand of Droperidol; R 4749; R4749; Dridol (TN); Droleptan (TN); Droperidolum [INN-Latin]; Dropletan (TN); HS-0065; INAPSINE (TN); Inapsine (TN); Innovar-vet; McN-JR 4749; R-4749; Ina.psi.n; Ina.psi.ne; Ino.psi.n; McN-JR-4749; Droperidol (JP15/USP/INN); Droperidol [USAN:INN:BAN:JAN]; Luorophenyl)-4-oxobutyl]-1,2,3,6-tetrahydro-4-pyridyl]-2-benzimidazolinone; 1-(1-(3-(p-Fluorobenzoyl)propyl)-1,2,3,6-tetrahydro-4-pyridyl)-2-benzimidazolinone; 1-(1-(4-(4-Fluorophenyl)-4-oxobutyl)-1,2,3,6-tetrahydro-4-pyridinyl)-1,3-dihydro-2H-benzimidazol-2-one; 1-(1-(4-(p-Fluorophenyl)-4-oxobutyl)-1,2,3,6-tetrahydro-4-pyridyl)-2-benzimidazolinone; 1-1-[3-(p-Fluorobenzoyl)propyl]-1,2,3,6-tetrahydro-4-pyridyl-2-benzimidazolinone; 1-[1-[3-(p-Fluorobenzoyl)propyl]-1,2,3,6-tetrahydro-4-pyridyl]-2-benzimidazolinone; 1-[1-[4-(p-F; 1-[1-[4-(p-Fluorophenyl)-4-oxobutyl]-1,2,3,6-tetrahydro-4-pyridyl]-2-benzimidazolinone; 1-{1-[4-(4-fluorophenyl)-4-oxobutyl]-1,2,3,6-tetrahydropyridin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one; 2-Benzimidazolinone, 1-[1-[3-(p-fluorobenz; 3-[1-[4-(4-fluorophenyl)-4-oxobutyl]-3,6-dihydro-2H-pyridin-4-yl]-1H-benzimidazol-2-one DM0DXA8 CP Janssen Pharmaceutica DM0DXA8 TC Antipsychotic Agents DM0DXA8 DT Small molecular drug DM0DXA8 PC 3168 DM0DXA8 MW 379.4 DM0DXA8 FM C22H22FN3O2 DM0DXA8 IC InChI=1S/C22H22FN3O2/c23-17-9-7-16(8-10-17)21(27)6-3-13-25-14-11-18(12-15-25)26-20-5-2-1-4-19(20)24-22(26)28/h1-2,4-5,7-11H,3,6,12-15H2,(H,24,28) DM0DXA8 CS C1CN(CC=C1N2C3=CC=CC=C3NC2=O)CCCC(=O)C4=CC=C(C=C4)F DM0DXA8 IK RMEDXOLNCUSCGS-UHFFFAOYSA-N DM0DXA8 IU 3-[1-[4-(4-fluorophenyl)-4-oxobutyl]-3,6-dihydro-2H-pyridin-4-yl]-1H-benzimidazol-2-one DM0DXA8 CA CAS 548-73-2 DM0DXA8 CB CHEBI:4717 DM0DXA8 DE Nausea DM1A9W3 ID DM1A9W3 DM1A9W3 DN Drospirenone DM1A9W3 HS Approved DM1A9W3 SN DRSP; Dehydrospirorenone; Dihydrospirorenone; Drospirenona; Drospirenonum; Drospirenone [INN]; ZK 30595; ZK30595; Angeliq, Drospirenone; Drospirenona [INN-Spanish]; Drospirenonum [INN-Latin]; SH-470; ZK-30595; Drospirenone (JAN/USAN/INN); (6R,7R,8R,9S,10R,13S,14S,15S,16S,17S)-1,3',4',6,6a,7,8,9,10,11,12,13,14,15,15a,16-Hexadecahydro-10,13-dimethylspiro-(17H-dicyclopropa(6,7:15,16)cyclopenta(a)phenanthrene-17,2'(5'H)-furan)-3,5'(2H)-dione; 1,2-Dihydrospirorenone; 1,2-dihydro-spirorenone; 17-Hydroxy-6beta,7beta:15beta,16beta-dimethylene-3-oxo-17alpha-pregn-4-ene-21-carboxylic acid, gamma-lactone; 3-oxo-6alpha,7alpha,15alpha,16alpha-tetrahydro-7'H,16'H-dicyclopropa[6,7;15,16]-17alpha-pregn-4-ene-21,17-carbolactone; 6-beta,7-beta;15-beta,16-beta-Dimethylene-3-oxo-17-alpha-pregn-4-ene-21,17-carbolactone; 6beta,7beta,15beta,16beta-dimethylen-3-oxo-17alpha-pregn-4-en-21,17-carbolacton; 6beta,7beta,15beta,16beta-dimethylene-3-oxo-17alpha-pregn-4-ene-21,17 carbolactone; 6beta,7beta;15beta,16beta-Dimethylene-3-oxo-17alpha-pregn-4-ene-21,17-carbolactone; Spiro(17H-dicyclopropa(6,7:15,16)cyclopenta(a)phenanthrene-17,2'(5'H)-furan)-3,5'(2H)-dione, 1,3',4',6,7,8,9,10,11,12,13,14,15,16,20,21-hexadecahydro-10,13-dimethyl-, (6R-(6alpha,7alpha,8beta,9alpha,10beta,13beta,14alpha,15alpha,16alpha,17beta DM1A9W3 TC Contraceptive Agents DM1A9W3 DT Small molecular drug DM1A9W3 PC 68873 DM1A9W3 MW 366.5 DM1A9W3 FM C24H30O3 DM1A9W3 IC InChI=1S/C24H30O3/c1-22-6-3-12(25)9-17(22)13-10-14(13)20-16(22)4-7-23(2)21(20)15-11-18(15)24(23)8-5-19(26)27-24/h9,13-16,18,20-21H,3-8,10-11H2,1-2H3/t13-,14+,15-,16+,18+,20-,21+,22-,23+,24+/m1/s1 DM1A9W3 CS C[C@]12CCC(=O)C=C1[C@@H]3C[C@@H]3[C@@H]4[C@@H]2CC[C@]5([C@H]4[C@@H]6C[C@@H]6[C@@]57CCC(=O)O7)C DM1A9W3 IK METQSPRSQINEEU-HXCATZOESA-N DM1A9W3 IU (1R,2R,4R,10R,11S,14S,15S,16S,18S,19S)-10,14-dimethylspiro[hexacyclo[9.8.0.02,4.05,10.014,19.016,18]nonadec-5-ene-15,5'-oxolane]-2',7-dione DM1A9W3 CA CAS 67392-87-4 DM1A9W3 CB CHEBI:50838 DM1A9W3 DE Contraception DM59JCN ID DM59JCN DM59JCN DN Drotrecogin alfa DM59JCN HS Approved DM59JCN SN Xigris; Drotrecogin alfa (activated); Xigris (TN); Drotrecogin alfa (activated) (USAN) DM59JCN CP Eli Lilly DM59JCN TC Antisepsis Agents DM59JCN SQ Heavy chain: LIDGKMTRRGDSPWQVVLLDSKKKLACGAVLIHPSWVLTAAHCMDESKKLLVRLGEYDLRRWEKWELDLDIKEVFVHPNYSKSTTDNDIALLHLAQPATLSQTIVPICLPDSGLAERELNQAGQETLVTGWGYHSSREKEAKRNRTFVLNFIKIPVVPHNECSEVMSNMVSENMLCAGILGDRQDACEGDSGGPMVASFHGTWFLVGLVSWGEGCGLLHNYGVYTKVSRYLDWIHGHIRDKEAPQKSWAP >Light chainSKHVDGDQCLVLPLEHPCASLCCGHGTCIXGIGSFSCDCRSGWEGRFCQREVSFLNCSLDNGGCTHYCLEEVGWRRCSCAPGYKLGDDLLQCHPAVKFPCGRPWKRMEKKRSHL DM59JCN DE Cerebrovascular ischaemia; Severe sepsis DM5YF4M ID DM5YF4M DM5YF4M DN Droxidopa DM5YF4M HS Approved DM5YF4M SN droxidopa; 23651-95-8; L-DOPS; Northera; (2S,3R)-2-amino-3-(3,4-dihydroxyphenyl)-3-hydroxypropanoic acid; threo-Dopaserine; 3916-18-5; DOPS; DL-threo-DOPS; L-Threodops; DL-threo-3,4-Dihydroxyphenylserine; DL-threo-Droxidopa; DL-threo-Dihydroxyphenylserine; UNII-J7A92W69L7; SM 5688; CHEBI:31524; Droxidopa (L-DOPS); threo-beta,3-Dihydroxy-DL-tyrosine; EINECS 223-480-5; beta,3-Dihydroxy-DL-tyrosine threo-; BRN 2852792; L-threo-dihydroxyphenylserine; DL-threo-3-(3,4-Dihydroxyphenyl)serine; Serine, 3-(3,4-dihydroxyphenyl)-, DL-threo- DM5YF4M CP Chelsea Therapeutics DM5YF4M DT Small molecular drug DM5YF4M PC 92974 DM5YF4M MW 213.19 DM5YF4M FM C9H11NO5 DM5YF4M IC InChI=1S/C9H11NO5/c10-7(9(14)15)8(13)4-1-2-5(11)6(12)3-4/h1-3,7-8,11-13H,10H2,(H,14,15)/t7-,8+/m0/s1 DM5YF4M CS C1=CC(=C(C=C1[C@H]([C@@H](C(=O)O)N)O)O)O DM5YF4M IK QXWYKJLNLSIPIN-JGVFFNPUSA-N DM5YF4M IU (2S,3R)-2-amino-3-(3,4-dihydroxyphenyl)-3-hydroxypropanoic acid DM5YF4M CA CAS 23651-95-8 DM5YF4M CB CHEBI:31524 DM5YF4M DE Neurogenic orthostatic hypotension DMXZRW0 ID DMXZRW0 DMXZRW0 DN DTI-015 DMXZRW0 HS Approved DMXZRW0 SN Carmustine; carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; BCNU; Injectable carmustine, Direct Therapeutics DMXZRW0 CP Direct Therapeutics Inc DMXZRW0 DT Small molecular drug DMXZRW0 PC 2578 DMXZRW0 MW 214.05 DMXZRW0 FM C5H9Cl2N3O2 DMXZRW0 IC InChI=1S/C5H9Cl2N3O2/c6-1-3-8-5(11)10(9-12)4-2-7/h1-4H2,(H,8,11) DMXZRW0 CS C(CCl)NC(=O)N(CCCl)N=O DMXZRW0 IK DLGOEMSEDOSKAD-UHFFFAOYSA-N DMXZRW0 IU 1,3-bis(2-chloroethyl)-1-nitrosourea DMXZRW0 CA CAS 154-93-8 DMXZRW0 CB CHEBI:3423 DMXZRW0 DE Liver cancer; Brain cancer DMCIJBH ID DMCIJBH DMCIJBH DN DU-176B DMCIJBH HS Approved DMCIJBH SN Edoxaban DMCIJBH CP Daiichi Sankyo DMCIJBH DT Small molecular drug DMCIJBH PC 25022378 DMCIJBH MW 738.3 DMCIJBH FM C31H40ClN7O8S2 DMCIJBH IC InChI=1S/C24H30ClN7O4S.C7H8O3S.H2O/c1-31(2)24(36)13-4-6-15(27-20(33)21(34)30-19-7-5-14(25)11-26-19)17(10-13)28-22(35)23-29-16-8-9-32(3)12-18(16)37-23;1-6-2-4-7(5-3-6)11(8,9)10;/h5,7,11,13,15,17H,4,6,8-10,12H2,1-3H3,(H,27,33)(H,28,35)(H,26,30,34);2-5H,1H3,(H,8,9,10);1H2/t13-,15-,17+;;/m0../s1 DMCIJBH CS CC1=CC=C(C=C1)S(=O)(=O)O.CN1CCC2=C(C1)SC(=N2)C(=O)N[C@@H]3C[C@H](CC[C@@H]3NC(=O)C(=O)NC4=NC=C(C=C4)Cl)C(=O)N(C)C.O DMCIJBH IK PSMMNJNZVZZNOI-SJILXJHISA-N DMCIJBH IU N'-(5-chloropyridin-2-yl)-N-[(1S,2R,4S)-4-(dimethylcarbamoyl)-2-[(5-methyl-6,7-dihydro-4H-[1,3]thiazolo[5,4-c]pyridine-2-carbonyl)amino]cyclohexyl]oxamide;4-methylbenzenesulfonic acid;hydrate DMCIJBH CA CAS 1229194-11-9 DMCIJBH CB CHEBI:85974 DMCIJBH DE Atrial fibrillation DMYXBV3 ID DMYXBV3 DMYXBV3 DN Dulaglutide DMYXBV3 HS Approved DMYXBV3 SN GLP-1 analog DMYXBV3 CP Eli Lilly DMYXBV3 SQ Dulaglutide Sequence: HGEGTFTSDVSSYLEEQAAKEFIAWLVKGGGGGGGSGGGGSGGGGSAESKYGPPCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLG DMYXBV3 DE Type-2 diabetes DM9BI7M ID DM9BI7M DM9BI7M DN Duloxetine DM9BI7M HS Approved DM9BI7M SN Yentreve; LY 248686; Cymbalta (TN); Duloxetine (INN); Duloxetine [INN:BAN]; Yentreve (TN); Duloxetine, (+)-isomer; (3S)-N-methyl-3-(1-naphthyloxy)-3-(2-thienyl)propan-1-amine; (3S)-N-methyl-3-(naphthalen-1-yloxy)-3-(2-thienyl)propan-1-amine; (3S)-N-methyl-3-naphthalen-1-yloxy-3-thiophen-2-ylpropan-1-amine; (S)-Duloxetine; (S)-N-Methyl-gamma-(1-naphthalenyloxy)-2-thiophenepropanamine DM9BI7M CP Eli Lilly DM9BI7M TC Antidepressants DM9BI7M DT Small molecular drug DM9BI7M PC 60835 DM9BI7M MW 297.4 DM9BI7M FM C18H19NOS DM9BI7M IC InChI=1S/C18H19NOS/c1-19-12-11-17(18-10-5-13-21-18)20-16-9-4-7-14-6-2-3-8-15(14)16/h2-10,13,17,19H,11-12H2,1H3/t17-/m0/s1 DM9BI7M CS CNCC[C@@H](C1=CC=CS1)OC2=CC=CC3=CC=CC=C32 DM9BI7M IK ZEUITGRIYCTCEM-KRWDZBQOSA-N DM9BI7M IU (3S)-N-methyl-3-naphthalen-1-yloxy-3-thiophen-2-ylpropan-1-amine DM9BI7M CA CAS 116539-59-4 DM9BI7M CB CHEBI:36795 DM9BI7M DE Depression DMOAD2Y ID DMOAD2Y DMOAD2Y DN Dupilumab DMOAD2Y HS Approved DMOAD2Y SN REGN-668; REGN-668); Anti-IL-4 monoclonal antibody (asthma/atopic dermatitis), sanofi-aventis; Anti-IL-4 receptor antibody (VelocImmune, allergy/immune disorder), Regeneron/sanofi-aventis DMOAD2Y CP Regeneron/Sanofi DMOAD2Y DT Antibody DMOAD2Y DE Atopic dermatitis; Asthma DM4PVDY ID DM4PVDY DM4PVDY DN Durvalumab DM4PVDY HS Approved DM4PVDY CP AstraZeneca DM4PVDY DT Monoclonal antibody DM4PVDY SQ Durvalumab heavy chain: EVQLVESGGGLVQPGGSLRLSCAASGFTFSRYWMSWVRQAPGKGLEWVANIKQDGSEKYYVDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREGGWFGELAFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEFEGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPASIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK >Durvalumab light chainEIVLTQSPGTLSLSPGERATLSCRASQRVSSSYLAWYQQKPGQAPRLLIYDASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSLPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC DM4PVDY DE Pancreatic ductal carcinoma; Solid tumour/cancer; Biliary tract cancer; Diffuse large B-cell lymphoma; Hepatocellular carcinoma; Melanoma; Urothelial carcinoma DMQ4TJK ID DMQ4TJK DMQ4TJK DN Dutasteride DMQ4TJK HS Approved DMQ4TJK SN Avodart; Avolve; Duagen; Dutasteride [USAN]; GG 745; GI 198745; Avidart (TN); Avodart (TN); Avodart, Dutasteride; Avolve (TN); Duagen (TN); Duprost (TN); Dutagen (TN); Dutas (TN); GG-745; GI-198745; GI-198745X; Dutasteride (JAN/USAN/INN); N-[2,5-bis(trifluoromethyl)phenyl]-3-oxo-4-aza-5alpha-androst-1-ene-17beta-carboxamide; Alpha,alpha,alpha,alpha',alpha',alpha'-Hexafluoro-3-oxo-4-aza-5alpha-androst-1-ene-17beta-carboxy-2',5'-xylidide; (1S,3aS,3bS,5aR,9aR,11aS)-N-[2,5-bis(trifluoromethyl)phenyl]-9a,11a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,5a,6,9b,10,11-dodecahydroindeno[5,4-f]quinoline-1-carboxamide; (1S,3aS,3bS,5aR,9aR,9bS,11aS)-N-[2,5-bis(trifluoromethyl)phenyl]-9a,11a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,5a,6,9b,10,11-dodecahydroindeno[5,4-f]quinoline-1-carboxamide; (5-alpha,17-beta)-N-{2,5 bis(trifluoromethyl)phenyl}-3-oxo-4-azaandrost-1-ene-17-carboxamide;dutasteride; (5alpha,17beta)-N-(2,5-Bis(trifluoromethyl)phenyl)-3-oxo-4-azaandrost-1-ene-17-carboxamide DMQ4TJK CP GSK DMQ4TJK TC Anticancer Agents DMQ4TJK DT Small molecular drug DMQ4TJK PC 6918296 DMQ4TJK MW 528.5 DMQ4TJK FM C27H30F6N2O2 DMQ4TJK IC InChI=1S/C27H30F6N2O2/c1-24-11-9-17-15(4-8-21-25(17,2)12-10-22(36)35-21)16(24)6-7-19(24)23(37)34-20-13-14(26(28,29)30)3-5-18(20)27(31,32)33/h3,5,10,12-13,15-17,19,21H,4,6-9,11H2,1-2H3,(H,34,37)(H,35,36)/t15-,16-,17-,19+,21+,24-,25+/m0/s1 DMQ4TJK CS C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2C(=O)NC4=C(C=CC(=C4)C(F)(F)F)C(F)(F)F)CC[C@@H]5[C@@]3(C=CC(=O)N5)C DMQ4TJK IK JWJOTENAMICLJG-QWBYCMEYSA-N DMQ4TJK IU (1S,3aS,3bS,5aR,9aR,9bS,11aS)-N-[2,5-bis(trifluoromethyl)phenyl]-9a,11a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,5a,6,9b,10,11-dodecahydroindeno[5,4-f]quinoline-1-carboxamide DMQ4TJK CA CAS 164656-23-9 DMQ4TJK CB CHEBI:521033 DMQ4TJK DE Benign prostatic hyperplasia; Prostate cancer DMU6OFP ID DMU6OFP DMU6OFP DN Dyclonine DMU6OFP HS Approved DMU6OFP SN Diclonia; Diclonina; Dyclocaine; Dyclocainum; Dyclonin; Dycloninum; Dyclothane; Tanaclone; Diclonina [INN-Spanish]; Dyclonine (INN); Dyclonine [INN:BAN]; Dycloninum [INN-Latin]; 1-(4-Butoxy-phenyl)-3-piperidin-1-yl-propan-1-one; 1-(4-Butoxyphenyl)-3-(1-piperidinyl)-1-propanone; 1-(4-butoxyphenyl)-3-(piperidin-1-yl)propan-1-one; 1-(4-butoxyphenyl)-3-piperidin-1-ylpropan-1-one; 1-Propanone, 1-(4-butoxyphenyl)-3-(1-piperidinyl)-(9CI); 2-(1-piperidyl)ethyl p-butoxyphenyl ketone; 3-Piperidino-4'-butoxypropiophenone; 4'-Butoxy-3-piperidinopropiophenone; 4-butoxy-beta-piperidinopropiophenone; 4-n-butoxy-beta-(1-piperidyl)propiophenone DMU6OFP CP Astrazeneca Lp DMU6OFP TC Anesthetics DMU6OFP DT Small molecular drug DMU6OFP PC 3180 DMU6OFP MW 289.4 DMU6OFP FM C18H27NO2 DMU6OFP IC InChI=1S/C18H27NO2/c1-2-3-15-21-17-9-7-16(8-10-17)18(20)11-14-19-12-5-4-6-13-19/h7-10H,2-6,11-15H2,1H3 DMU6OFP CS CCCCOC1=CC=C(C=C1)C(=O)CCN2CCCCC2 DMU6OFP IK BZEWSEKUUPWQDQ-UHFFFAOYSA-N DMU6OFP IU 1-(4-butoxyphenyl)-3-piperidin-1-ylpropan-1-one DMU6OFP CA CAS 586-60-7 DMU6OFP CB CHEBI:4724 DMU6OFP DE Pain DMAKIDV ID DMAKIDV DMAKIDV DN Dydrogesterone DMAKIDV HS Approved DMAKIDV SN Dehydrogesterone; Didrogesterona; Didrogesterone; Diphaston; Dufaston; Duphaston; Duvaron; Dydrogesterona; Dydrogesteronum; Gestatron; Gynorest; Hydrogesterone; Hydrogestrone; Isopregnenone; Prodel; Retrone; Terolut; Didrogesterone [DCIT]; Solvay Brand of Dydrogesterone; DELTA6-Retroprogesterone; Duphaston (TN); Dydrogesterona [INN-Spanish]; Dydrogesteronum [INN-Latin]; Gynorest (TN); Delta(6)-Retroprogesterone; Delta(sup 6)-Retroprogesterone; Retro-6-dehydroprogesterone; Dydrogesterone (JP15/USP/INN); Dydrogesterone [USAN:INN:BAN:JAN]; Pregna-4,6-diene-3,20-dione, (9-beta,10-alpha)-(9CI); (8S,9R,10S,13S,14S,17S)-17-acetyl-10,13-dimethyl-1,2,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-one; (9-beta,10-alpha)-Pregna-4,6-diene-3,20-dione; (9beta,10alpha)-pregna-4,6-diene-3,20-dione; 10alpha-Isopregnenone; 6 Dehydro 9 beta 10 alpha progesterone; 6-Dehydro-9 beta-10 alpha-progesterone; 6-Dehydro-9.beta.,10.alpha.-progesterone; 6-Dehydro-9beta,10alpha-progesterone; 6-Dehydro-retro-progesterone; 6-Dehydroretroprogesterone; 9-.beta.,10.alpha.-Pregna-4,6-diene-3,20-dione; 9-beta,10-alpha-Pregna-4,6-diene-3,20-dione; 9-beta,10alpha-Pregna-4,6-diene-3,20-dione; 9.beta.,10.alpha.-Pregna-4,6-diene-3,20-dione; 9beta,10alpha-Pregna-4,6-diene-3,20-dione; 9beta,10alpha-Pregna-4,6-diene-3,20-dione (8CI) DMAKIDV CP Solvay Pharmaceuticals DMAKIDV TC Progesterones DMAKIDV DT Small molecular drug DMAKIDV PC 9051 DMAKIDV MW 312.4 DMAKIDV FM C21H28O2 DMAKIDV IC InChI=1S/C21H28O2/c1-13(22)17-6-7-18-16-5-4-14-12-15(23)8-10-20(14,2)19(16)9-11-21(17,18)3/h4-5,12,16-19H,6-11H2,1-3H3/t16-,17+,18-,19+,20+,21+/m0/s1 DMAKIDV CS CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@@H]3[C@H]2C=CC4=CC(=O)CC[C@@]34C)C DMAKIDV IK JGMOKGBVKVMRFX-HQZYFCCVSA-N DMAKIDV IU (8S,9R,10S,13S,14S,17S)-17-acetyl-10,13-dimethyl-1,2,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-one DMAKIDV CA CAS 152-62-5 DMAKIDV CB CHEBI:31527 DMAKIDV DE Menstrual disorder DM8DZC1 ID DM8DZC1 DM8DZC1 DN Dyphylline DM8DZC1 HS Approved DM8DZC1 SN Aristophyllin; Asthmolysin; Astmamasit; Astrophyllin; Circain; Circair; Coronal; Coronarin; Corphyllin; Dihydroxypropyltheophylline; Diprofilina; Diprofillin; Diprofillina; Diprofilline; Diprophyllin; Diprophylline; Diprophyllinum; Dipropylline; Droxine; Dyflex; Glyfyllin; Glyphyllin; Glyphylline; Glyphyllinum; Hidroxiteofillina; Hiphyllin; Hyphylline; Iphyllin; Isophyllen; Liactemin; Lufyllin; Neophyl; Neophyllin; Neophylline; Neostenovasan; Neothylline; Neotilina; Neufil; Neutrafil; Neutrafillina; Neutraphyllin; Neutraphylline; Neutroxantina; Propyphyllin; Protheophylline; Purifilin; Silbephyllin; Silbephylline; Solufilin; Solufyllin; Soluphyllin; Synthophylline; Tefilan; Teofen; Tesfen; Theal; Thefylan; Dihydroxypropyl theophylline; Dihydroxypropyl theopylin; Dilor G; Diprofillina [DCIT]; Dyphylline [USAN]; Neophyllin M; Theal ampules; AFI-Phyllin; COR-theophylline; Dihydroxypropyl theopylin (german); Dilor-400; Diphyllin (VAN); Diprofilina [INN-Spanish]; Diprophyllinum [INN-Latin]; Dyphylline (USP); Lufyllin (TN); Neo-Vasophylline; Diprophylline (JAN/INN); Neothylline, Lufyllin, diprophylline,Dyphylline; (+-)-7-(2,3-Dihydroxypropyl)theophylline; (+-)-diprophylline; (+-)-dyphylline; (1,2-Dihydroxy-3-propyl)thiophyllin; 1,3-Dimethyl-7-(2,3-dihydroxypropyl)xanthine; 1H-Purine-2,6-dione, 7-(2,3-dihydroxypropyl)-3,7-dihydro-1,3-dimethyl; 7-(2,3-Dihydroxypropyl)-1,3-dimethyl-3,7-dihydro-1H-purine-2,6-dione; 7-(2,3-Dihydroxypropyl)-1,3-dimethylxanthine; 7-(2,3-Dihydroxypropyl)-3,7-dihydro-1,3-dimethyl-1H-purine-2,6-dione; 7-(2,3-Dihydroxypropyl)theophylline; 7-(2,3-Dioxypropyl)theophylline; 7-(2,3-dihydroxypropyl)-1,3-dimethyl-2,3,6,7-tetrahydro-1H-purine-2,6-dione; 7-(2,3-dihydroxypropyl)-1,3-dimethylpurine-2,6-dione; 7-(beta,gamma-Dihydroxypropyl)theophylline; 7-(beta.,.gamma.-Dihydroxypropyl)theophylline; 7-DIHYDROXYPROPYLTHEOPHYLLINE; 7-[2,3-Dihydroxypropyl]-theophylline DM8DZC1 TC Bronchodilator Agents DM8DZC1 DT Small molecular drug DM8DZC1 PC 3182 DM8DZC1 MW 254.24 DM8DZC1 FM C10H14N4O4 DM8DZC1 IC InChI=1S/C10H14N4O4/c1-12-8-7(9(17)13(2)10(12)18)14(5-11-8)3-6(16)4-15/h5-6,15-16H,3-4H2,1-2H3 DM8DZC1 CS CN1C2=C(C(=O)N(C1=O)C)N(C=N2)CC(CO)O DM8DZC1 IK KSCFJBIXMNOVSH-UHFFFAOYSA-N DM8DZC1 IU 7-(2,3-dihydroxypropyl)-1,3-dimethylpurine-2,6-dione DM8DZC1 CA CAS 479-18-5 DM8DZC1 CB CHEBI:4728 DM8DZC1 DE Acute bronchial asthma DMJDYNQ ID DMJDYNQ DMJDYNQ DN E-2007 DMJDYNQ HS Approved DMJDYNQ SN Perampanel; E 2007; Perampanel (USAN); 2-(2-oxo-1-phenyl-5-pyridin-2-yl-pyridin-3-yl)benzonitrile; 3-(2-Cyanophenyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one DMJDYNQ CP Eisai Co. Ltd. DMJDYNQ DT Small molecular drug DMJDYNQ PC 9924495 DMJDYNQ MW 349.4 DMJDYNQ FM C23H15N3O DMJDYNQ IC InChI=1S/C23H15N3O/c24-15-17-8-4-5-11-20(17)21-14-18(22-12-6-7-13-25-22)16-26(23(21)27)19-9-2-1-3-10-19/h1-14,16H DMJDYNQ CS C1=CC=C(C=C1)N2C=C(C=C(C2=O)C3=CC=CC=C3C#N)C4=CC=CC=N4 DMJDYNQ IK PRMWGUBFXWROHD-UHFFFAOYSA-N DMJDYNQ IU 2-(2-oxo-1-phenyl-5-pyridin-2-ylpyridin-3-yl)benzonitrile DMJDYNQ CA CAS 380917-97-5 DMJDYNQ CB CHEBI:71013 DMJDYNQ DE Diabetic neuropathy; Parkinson disease DMOF2C6 ID DMOF2C6 DMOF2C6 DN Ecallantide DMOF2C6 HS Approved DMOF2C6 SN FOV-2302; Retinal venous occlusion therapy, Fovea; Ecallantide (ophthalmic formulation/retinal disease); Ecallantide (ophthalmic formulation/retinal disease), Dyax/Fovea; DX-88 (ophthalmic formulation/retinal disease), Dyax/Fovea DMOF2C6 CP Dyax Corp DMOF2C6 DT Small molecular drug DMOF2C6 PC 44152182 DMOF2C6 MW 7054 DMOF2C6 FM C305H442N88O91S8 DMOF2C6 IC InChI=1S/C305H442N88O91S8/c1-16-152(5)241-295(478)377-195(124-168-80-82-172(398)83-81-168)252(435)334-137-227(404)333-138-228(405)345-214-143-487-491-147-218-291(474)351-179(73-47-107-327-301(315)316)255(438)341-154(7)245(428)339-155(8)249(432)379-210(127-171-136-326-150-338-171)299(482)393-113-53-79-221(393)294(477)361-181(75-49-109-329-303(319)320)260(443)372-203(125-169-134-332-175-69-40-39-68-173(169)175)277(460)370-198(119-163-58-29-20-30-59-163)274(457)369-199(120-164-60-31-21-32-61-164)275(458)375-207(130-226(314)403)284(467)389-242(153(6)17-2)296(479)378-202(123-167-66-37-24-38-67-167)283(466)390-243(159(12)396)297(480)362-182(76-50-110-330-304(321)322)258(441)353-186(86-94-223(311)400)267(450)383-217(290(473)359-188(89-98-234(414)415)263(446)354-189(90-99-235(416)417)265(448)368-201(282(465)388-241)122-166-64-35-23-36-65-166)146-490-489-145-216(384-268(451)191(92-101-237(420)421)355-262(445)187(88-97-233(412)413)357-271(454)194(116-151(3)4)366-285(468)212(141-394)381-266(449)190(91-100-236(418)419)358-273(456)197(118-162-56-27-19-28-57-162)367-259(442)180(74-48-108-328-302(317)318)349-280(463)206(129-225(313)402)374-264(447)185(85-93-222(310)399)356-279(462)205(128-224(312)401)344-229(406)139-335-251(434)184(352-288(214)471)87-96-232(410)411)289(472)350-178(72-43-46-106-308)256(439)347-177(71-42-45-105-307)257(440)360-193(103-115-486-15)270(453)385-219(292(475)391-244(160(13)397)298(481)363-183(77-51-111-331-305(323)324)261(444)380-211(300(483)484)133-240(426)427)148-492-488-144-215(386-276(459)200(121-165-62-33-22-34-63-165)371-286(469)213(142-395)382-278(461)204(126-170-135-325-149-337-170)373-269(452)192(102-114-485-14)346-246(429)156(9)340-250(433)174(309)84-95-231(408)409)287(470)343-158(11)247(430)364-196(117-161-54-25-18-26-55-161)272(455)348-176(70-41-44-104-306)254(437)342-157(10)248(431)365-209(132-239(424)425)281(464)376-208(131-238(422)423)253(436)336-140-230(407)392-112-52-78-220(392)293(476)387-218/h18-40,54-69,80-83,134-136,149-160,174,176-221,241-244,332,394-398H,16-17,41-53,70-79,84-133,137-148,306-309H2,1-15H3,(H2,310,399)(H2,311,400)(H2,312,401)(H2,313,402)(H2,314,403)(H,325,337)(H,326,338)(H,333,404)(H,334,435)(H,335,434)(H,336,436)(H,339,428)(H,340,433)(H,341,438)(H,342,437)(H,343,470)(H,344,406)(H,345,405)(H,346,429)(H,347,439)(H,348,455)(H,349,463)(H,350,472)(H,351,474)(H,352,471)(H,353,441)(H,354,446)(H,355,445)(H,356,462)(H,357,454)(H,358,456)(H,359,473)(H,360,440)(H,361,477)(H,362,480)(H,363,481)(H,364,430)(H,365,431)(H,366,468)(H,367,442)(H,368,448)(H,369,457)(H,370,460)(H,371,469)(H,372,443)(H,373,452)(H,374,447)(H,375,458)(H,376,464)(H,377,478)(H,378,479)(H,379,432)(H,380,444)(H,381,449)(H,382,461)(H,383,450)(H,384,451)(H,385,453)(H,386,459)(H,387,476)(H,388,465)(H,389,467)(H,390,466)(H,391,475)(H,408,409)(H,410,411)(H,412,413)(H,414,415)(H,416,417)(H,418,419)(H,420,421)(H,422,423)(H,424,425)(H,426,427)(H,483,484)(H4,315,316,327)(H4,317,318,328)(H4,319,320,329)(H4,321,322,330)(H4,323,324,331)/t152-,153-,154-,155-,156-,157-,158-,159-,160-,174-,176-,177-,178-,179-,180-,181-,182-,183-,184-,185-,186-,187-,188-,189-,190-,191-,192-,193-,194-,195-,196-,197-,198-,199-,200-,201-,202-,203-,204-,205-,206-,207-,208-,209-,210-,211-,212-,213-,214-,215-,216-,217-,218-,219-,220-,221-,241-,242-,243-,244-/m0/s1 DMOF2C6 CS CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N4CCC[C@H]4C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N5CCC[C@H]5C(=O)N3)CC(=O)O)CC(=O)O)C)CCCCN)CC6=CC=CC=C6)C)NC(=O)[C@H](CC7=CC=CC=C7)NC(=O)[C@H](CO)NC(=O)[C@H](CC8=CN=CN8)NC(=O)[C@H](CCSC)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)N)C(=O)N[C@@H]([C@H](C)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(=O)O)C(=O)O)CCSC)CCCCN)CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC2=O)CCC(=O)O)CC(=O)N)CCC(=O)N)CC(=O)N)CCCNC(=N)N)CC9=CC=CC=C9)CCC(=O)O)CO)CC(C)C)CCC(=O)O)CCC(=O)O)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CC1=CC=CC=C1)CCC(=O)O)CCC(=O)O)CCC(=O)N)CCCNC(=N)N)[C@H](C)O)CC1=CC=CC=C1)[C@@H](C)CC)CC(=O)N)CC1=CC=CC=C1)CC1=CC=CC=C1)CC1=CNC2=CC=CC=C21)CCCNC(=N)N)CC1=CN=CN1)C)C)CCCNC(=N)N)CC1=CC=C(C=C1)O DMOF2C6 IK VBGWSQKGUZHFPS-VGMMZINCSA-N DMOF2C6 IU (2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(1R,2aS,4S,5aS,8aS,11aR,13S,14aS,16S,17aS,19S,20aS,22S,23aS,25S,26aS,28S,29aS,31R,32aS,35aS,36R,38aS,39S,41aS,42S,44aS,45S,48R,50aS,51S,53aS,54S,56aS,57S,59aS,60S,63S,66S,69S,72S,75S,78S,84S,87R,96S,99S)-22,42,45-tris(4-aminobutyl)-31-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-carboxybutanoyl]amino]propanoyl]amino]-4-methylsulfanylbutanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-3-phenylpropanoyl]amino]-29a,72,78-tris(2-amino-2-oxoethyl)-14a,75-bis(3-amino-3-oxopropyl)-2a,23a,25,32a,35a,66-hexabenzyl-26a,99-bis[(2S)-butan-2-yl]-17a,41a,59a,69-tetrakis(3-carbamimidamidopropyl)-5a,8a,51,54,63,84-hexakis(2-carboxyethyl)-13,16-bis(carboxymethyl)-20a-[(1S)-1-hydroxyethyl]-60-(hydroxymethyl)-96-[(4-hydroxyphenyl)methyl]-50a-(1H-imidazol-5-ylmethyl)-38a-(1H-indol-3-ylmethyl)-19,28,53a,56a-tetramethyl-57-(2-methylpropyl)-39-(2-methylsulfanylethyl)-1a,3,4a,7a,9,10a,12,13a,15,16a,18,19a,21,22a,24,25a,27,28a,30,31a,34a,37a,38,40a,41,43a,44,47,49a,50,52a,53,55a,56,58a,59,61a,62,65,68,71,74,77,80,83,86,89,92,95,98-pentacontaoxo-33,34,63a,64a,67a,68a-hexathia-a,2,3a,6a,8,9a,11,12a,14,15a,17,18a,20,21a,23,24a,26,27a,29,30a,33a,36a,37,39a,40,42a,43,46,48a,49,51a,52,54a,55,57a,58,60a,61,64,67,70,73,76,79,82,85,88,91,94,97-pentacontazapentacyclo[85.74.4.448,111.04,8.0144,148]nonahexacontahectane-36-carbonyl]amino]-3-hydroxybutanoyl]amino]-5-carbamimidamidopentanoyl]amino]butanedioic acid DMOF2C6 CA CAS 460738-38-9 DMOF2C6 DE Retina venous occlusion DMSNVGB ID DMSNVGB DMSNVGB DN Echothiophate Iodide DMSNVGB HS Approved DMSNVGB SN Echodide; Phospholine; Diethoxyphosphinylthiocholine iodide; ECOTHIOPATE IODIDE; Ecostigmini jodidum; Ecothiopati iodidum; Ecothiophate iodide; Ioduro de ecotiopato; Phospholine iodide; Diethoxyphosphoryl-thiocholine iodide; Echothiophate iodide (USP); Ecothiopati iodidum [INN-Latin]; Iodide, Echothiophate; Iodide, Ecothiopate; Iodide, Ecothiophate; Iodide, Phospholine; Iodure d'ecothiopate; Ioduro de ecotiopato [INN-Spanish]; Phospholine (the pharmaceutical); Phospholine Iodide (TN); Phospholine iodide (TN); Ecothiopate iodide (JP15/INN); Iodure d'ecothiopate [INN-French]; N-(2-(Diethoxyphosphinylthio)ethyl)trimethylammonium iodide; O,O-Diethyl S-2-trimethylammonium ethylphosphonothiolate iodide; S-Ester of (2-mercaptoethyl)trimethylammonium iodide with O,O-diethyl phosphorothioate; S-beta-dimethylaminoethyl-O,O-diethylthionophosphate methiodide; S-(2-Dimethylaminoethyl)-O.O-diethylphosphorothioate methiodide; S-(2-dimethylaminoethyl)-O,O-diethylphosphorothioate methiodide; Ammonium, (2-(O,O-diethylphosphorothio)ethyl)trimethyl-, iodide; Ammonium, (2-mercaptoethyl)trimethyl-, iodide, S-ester with O,O-diethylphosphorothioate; S-(2-(N,N,N-Trimethylammonio)ethyl) O,O-diethylphosphorothiolate iodide; Ethanaminium, 2-((diethoxyphosphinyl)thio)-N,N,N-trimethyl-, iodide; (2-Mercaptoethyl)trimethylammonium iodide S-ester with O,O-diethyl phosphorothioate; (2-mercaptoethyl)trimethylammonium iodidie O,O-diethyl phosphorothioate; 2-((Diethoxyphosphinyl)thio)-N,N,N,-trimethylethanaminium iodide; 2-Diaethoxyphosphinyl-thioaethyl-trimethyl-ammonium-jodid; 2-Diaethoxyphosphinyl-thioaethyl-trimethyl-ammonium-jodid [German]; 2-Diethoxy-phosphinylthioethyl-trimethylammonium iodide; 2-[(diethoxyphosphinyl)thio]-N,N,N-trimethylethanaminium iodide; 2-[(diethoxyphosphoryl)sulfanyl]-N,N,N-trimethylethanaminium iodide; 2-diethoxyphosphorylsulfanylethyl(trimethyl)azanium iodide; 2-{[bis(ethyloxy)phosphoryl]thio}-N,N,N-trimethylethanaminium iodide; 217 MI; 217-mi DMSNVGB CP Wyeth Pharmaceuticals DMSNVGB TC Parasympathomimetics DMSNVGB DT Small molecular drug DMSNVGB PC 10547 DMSNVGB MW 383.23 DMSNVGB FM C9H23INO3PS DMSNVGB IC InChI=1S/C9H23NO3PS.HI/c1-6-12-14(11,13-7-2)15-9-8-10(3,4)5;/h6-9H2,1-5H3;1H/q+1;/p-1 DMSNVGB CS CCOP(=O)(OCC)SCC[N+](C)(C)C.[I-] DMSNVGB IK OVXQHPWHMXOFRD-UHFFFAOYSA-M DMSNVGB IU 2-diethoxyphosphorylsulfanylethyl(trimethyl)azanium;iodide DMSNVGB CA CAS 513-10-0 DMSNVGB CB CHEBI:59849 DMSNVGB DE Chronic glaucoma DMFSWGH ID DMFSWGH DMFSWGH DN Econazole DMFSWGH HS Approved DMFSWGH SN Ecostatin; Palavale; Pevaryl; Ecostatin Vaginal Ovules; Ecostatin cream; Spectazole cream; SQ 13050; Ecostatin (TN); Gyno-Pevaryl 150; Gyno-pevaryl; Pevaryl (TN); Spectazole (TN); Econazole (USAN/INN); 1-[2,4-Dichloro-.beta.-[(p-chlorobenzyl)oxy]phenethyl]imidazole; 1-[2-[(4-Chlorophenyl)methoxy]-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole; 1-[2-[(4-chlorophenyl)methoxy]-2-(2,4-dichlorophenyl)ethyl]imidazole; 1-{2-(4-chlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole; 1-{2-[(4-chlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole; 1-{2-[(4-chlorophenyl)methoxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole DMFSWGH CP Merz Pharmaceuticals Llc DMFSWGH TC Antifungal Agents DMFSWGH DT Small molecular drug DMFSWGH PC 3198 DMFSWGH MW 381.7 DMFSWGH FM C18H15Cl3N2O DMFSWGH IC InChI=1S/C18H15Cl3N2O/c19-14-3-1-13(2-4-14)11-24-18(10-23-8-7-22-12-23)16-6-5-15(20)9-17(16)21/h1-9,12,18H,10-11H2 DMFSWGH CS C1=CC(=CC=C1COC(CN2C=CN=C2)C3=C(C=C(C=C3)Cl)Cl)Cl DMFSWGH IK LEZWWPYKPKIXLL-UHFFFAOYSA-N DMFSWGH IU 1-[2-[(4-chlorophenyl)methoxy]-2-(2,4-dichlorophenyl)ethyl]imidazole DMFSWGH CA CAS 27220-47-9 DMFSWGH CB CHEBI:82873 DMFSWGH DE Tinea versicolor; Cutaneous candidiasis; Tinea corporis; Tinea cruris; Tinea pedis DMCRQHB ID DMCRQHB DMCRQHB DN Edrophonium DMCRQHB HS Approved DMCRQHB SN EDR; Edrophonum; Edroponium; Reversol; Tensilon; EDROPHONIUM ION; Edrophone Chloride; Enlon Plus; ENLON-PLUS; Enlon (TN); Reversol (TN); Tensilon (TN); Ethyl-(3-hydroxyphenyl)-dimethylazanium; Ethyl-(3-hydroxy-phenyl)-dimethyl-ammonium; N-ethyl-3-hydroxy-N,N-dimethylanilinium; N-ethyl-3-hydroxy-N,N-dimethylbenzenaminium; (3-hydroxyphenyl)dimethylethylammonium; 3-hydroxy-N,N-dimethyl-N-ethylanilinium DMCRQHB TC Antidotes DMCRQHB DT Small molecular drug DMCRQHB PC 3202 DMCRQHB MW 166.24 DMCRQHB FM C10H16NO+ DMCRQHB IC InChI=1S/C10H15NO/c1-4-11(2,3)9-6-5-7-10(12)8-9/h5-8H,4H2,1-3H3/p+1 DMCRQHB CS CC[N+](C)(C)C1=CC(=CC=C1)O DMCRQHB IK VWLHWLSRQJQWRG-UHFFFAOYSA-O DMCRQHB IU ethyl-(3-hydroxyphenyl)-dimethylazanium DMCRQHB CA CAS 312-48-1 DMCRQHB CB CHEBI:251408 DMCRQHB DE Myasthenia gravis DMCKL5V ID DMCKL5V DMCKL5V DN Efalizumab DMCKL5V HS Approved DMCKL5V SN Raptiva; Raptiva (TN); Efalizumab (USAN/INN) DMCKL5V CP Roche DMCKL5V TC Immunomodulatory Agents DMCKL5V DT Antibody DMCKL5V SQ Heavy Chain Variable Region: EVQLVESGGGLVQPGGSLRLSCAASGYSFTGHWMNWVRQAPGKGLEWVGIMIHPSDSETRYNQKFKDIRFTISVDKSKNTLYLQMNSLRAEDTAVYYCARIGIYFYGTTYFDYIWGQGTLVTVSS >Light Chain Variable RegionDIQMTQSPSSLSASVGDRVTITCRASKTISKYLAWXQQKPGKAPKLLIYSGSTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQHNEYPLTFGQGTKVEIKR DMCKL5V DE Psoriasis vulgaris; Renal transplantation DMC0GSJ ID DMC0GSJ DMC0GSJ DN Efavirenz DMC0GSJ HS Approved DMC0GSJ SN EFV; EFZ; Eravirenz; Stocrin; Sustiva; DMP 266; L 743726; DMP-266; L-741211; L-743725; L-743726; Stocrin (TN); Strocin (TM); Sustiva (TM); Sustiva (TN); Efavirenz (JAN/INN); L-743,726; Zoxazin-2-one; Efavirenz, (S)-isomer; Met-SDF-1.beta. & Efavirenz; Met-Stromal Cell-derived Factor-1.beta. (Human) & Efavirenz; (-)-Efavirenz; (4S)-6-Chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one; (4S)-6-Chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one; (4S)-6-chloro-4-(2-cyclopropylethynyl)-4-(trifluoromethyl)-1H-3,1-benzoxazin-2-one; (4S)-6-chloro-4-(cyclopropylethynyl)-4-(trifluoromethyl)-1,4-dihydro-2H-3,1-benzoxazin-2-one; (S)-6-Chloro-4-(2-cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-ben; (S)-6-Chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one; (S)-6-Chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one; 2H-3,1-Benzoxazin-2-one, 6-chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-, (4S)-(9; 6-chloro-4-(2-cyclopropyl-1-ethynyl)-4-trifluoromethyl-(4S)-1,4-dihydro-2H-benzo[d][1,3]oxazin-2-one DMC0GSJ TC Anti-HIV Agents DMC0GSJ DT Small molecular drug DMC0GSJ PC 64139 DMC0GSJ MW 315.67 DMC0GSJ FM C14H9ClF3NO2 DMC0GSJ IC InChI=1S/C14H9ClF3NO2/c15-9-3-4-11-10(7-9)13(14(16,17)18,21-12(20)19-11)6-5-8-1-2-8/h3-4,7-8H,1-2H2,(H,19,20)/t13-/m0/s1 DMC0GSJ CS C1CC1C#C[C@]2(C3=C(C=CC(=C3)Cl)NC(=O)O2)C(F)(F)F DMC0GSJ IK XPOQHMRABVBWPR-ZDUSSCGKSA-N DMC0GSJ IU (4S)-6-chloro-4-(2-cyclopropylethynyl)-4-(trifluoromethyl)-1H-3,1-benzoxazin-2-one DMC0GSJ CA CAS 154598-52-4 DMC0GSJ CB CHEBI:119486 DMC0GSJ DE Human immunodeficiency virus infection DMFA9MV ID DMFA9MV DMFA9MV DN Efinaconazole DMFA9MV HS Approved DMFA9MV SN IDP-108; KP-103 DMFA9MV CP Dow DMFA9MV DT Small molecular drug DMFA9MV PC 489181 DMFA9MV MW 348.4 DMFA9MV FM C18H22F2N4O DMFA9MV IC InChI=1S/C18H22F2N4O/c1-13-5-7-23(8-6-13)14(2)18(25,10-24-12-21-11-22-24)16-4-3-15(19)9-17(16)20/h3-4,9,11-12,14,25H,1,5-8,10H2,2H3/t14-,18-/m1/s1 DMFA9MV CS C[C@H]([C@](CN1C=NC=N1)(C2=C(C=C(C=C2)F)F)O)N3CCC(=C)CC3 DMFA9MV IK NFEZZTICAUWDHU-RDTXWAMCSA-N DMFA9MV IU (2R,3R)-2-(2,4-difluorophenyl)-3-(4-methylidenepiperidin-1-yl)-1-(1,2,4-triazol-1-yl)butan-2-ol DMFA9MV CA CAS 164650-44-6 DMFA9MV CB CHEBI:82718 DMFA9MV DE Fungal infection DMJOQM3 ID DMJOQM3 DMJOQM3 DN Eflornithine DMJOQM3 HS Approved DMJOQM3 SN EFLORNITHINE; Ornidyl; 70052-12-9; 2-(Difluoromethyl)ornithine; alpha-Difluoromethylornithine; Difluromethylornithine; Eflornitina [Spanish]; Eflornithinum [Latin]; 2,5-diamino-2-(difluoromethyl)pentanoic acid; alpha-(Difluoromethyl)-DL-ornithine; N-Difluoromethylornithine; DFMO (growth regulator); 67037-37-0; Eflornithine [INN:BAN]; 2-(Difluoromethyl)-DL-ornithine; DL-alpha-(Difluoromethyl)ornithine; MDL 71782; CCRIS 3295; Ornithine, 2-(difluoromethyl)-; Eflornithinum; Eflornitina; DFMO hydrochloride; DFMO hydrochloride hydrate; EFLORNITHINE HYDROCHLORIDE; BMS 203522; Alpha-DFMO HCl; Alpha-Difluoromethylornithine; Alpha-Difluoromethylornithine hydrochloride; CPP-1X; Eflornithine (INN); Ornidyl (TN); DL-alpha-Difluoromethylornithine; DL-alpha-Difluoromethylornithine hydrochloride hydrate; D,L-alpha-Difluoromethylornithine; Alpha-(Difluoromethyl)-DL-ornithine; Alpha,delta-Diamino-alpha-(difluoromethyl)valeric acid; Ornithine, 2-(difluoromethyl)-, monohydrochloride; DL-Ornithine, 2-(difluoromethyl)-, monohydrochloride; DL-Ornithine, 2-(difluoromethyl)-, monohydrochloride, monohydrate; 2,5-diamino-2-(difluoromethyl)pentanoic acid hydrochloride; 2-(Difluoromethyl)-DL-ornithine HCl; 2-(Difluoromethyl)-DL-ornithine hydrochloride; 2-(Difluoromethyl)-DL-ornithine monohydrochloride; 2-(Difluoromethyl)ornithine hydrochloride hydrate DMJOQM3 CP Sanofi-Aventis DMJOQM3 TC Anticancer Agents DMJOQM3 DT Small molecular drug DMJOQM3 PC 3009 DMJOQM3 MW 182.17 DMJOQM3 FM C6H12F2N2O2 DMJOQM3 IC InChI=1S/C6H12F2N2O2/c7-4(8)6(10,5(11)12)2-1-3-9/h4H,1-3,9-10H2,(H,11,12) DMJOQM3 CS C(CC(C(F)F)(C(=O)O)N)CN DMJOQM3 IK VLCYCQAOQCDTCN-UHFFFAOYSA-N DMJOQM3 IU 2,5-diamino-2-(difluoromethyl)pentanoic acid DMJOQM3 CA CAS 70052-12-9 DMJOQM3 CB CHEBI:41948 DMJOQM3 DE African trypanosomiasis; Trypanosomiasis DMMUCG4 ID DMMUCG4 DMMUCG4 DN Eicosapentaenoic acid/docosa-hexaenoic acid DMMUCG4 HS Approved DMMUCG4 SN Docosahexaenoic acid; Doconexent; Cervonic acid; 6217-54-5; all-cis-DHA; Doconexentum; Doconexento; Doxonexent; (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoic acid; AquaGrow Advantage; all-Z-Docosahexaenoic acid; Martek DHA HM; Ropufa 60; cis-4,7,10,13,16,19-Docosahexaenoic acid; Docosahexaenoate; UNII-ZAD9OKH9JC; (4Z,7Z,10Z,13Z,16Z,19Z)-Docosahexaenoic acid; Docosahexaenoic acid (all-Z); CCRIS 7670; all-cis-4,7,10,13,16,19-Docosahexaenoic acid; ZAD9OKH9JC; all-cis-docosa-4,7,10,13,16,19-hexaenoic acid; CHEMBL367149; Espanova (TN); DOCOSAHEXAENOIC ACID DMMUCG4 CP Omthera Pharmaceutials DMMUCG4 DT Small molecular drug DMMUCG4 PC 445580 DMMUCG4 MW 328.5 DMMUCG4 FM C22H32O2 DMMUCG4 IC InChI=1S/C22H32O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22(23)24/h3-4,6-7,9-10,12-13,15-16,18-19H,2,5,8,11,14,17,20-21H2,1H3,(H,23,24)/b4-3-,7-6-,10-9-,13-12-,16-15-,19-18- DMMUCG4 CS CC/C=C\\C/C=C\\C/C=C\\C/C=C\\C/C=C\\C/C=C\\CCC(=O)O DMMUCG4 IK MBMBGCFOFBJSGT-KUBAVDMBSA-N DMMUCG4 IU (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoic acid DMMUCG4 CA CAS 6217-54-5 DMMUCG4 CB CHEBI:28125 DMMUCG4 DE Hypertriglyceridemia; Alzheimer disease DMRDUC0 ID DMRDUC0 DMRDUC0 DN Elagolix sodium DMRDUC0 HS Approved DMRDUC0 SN Elagolix sodium salt; UNII-5948VUI423; Elagolix sodium [USAN]; 5948VUI423; Elagolix sodium (USAN); SCHEMBL1641994; NBI 56418NA; NBI-56418-NA; MolPort-003-984-965; NBI-56418 NA; DQYGXRQUFSRDCH-UQIIZPHYSA-M; AKOS030524154; VA12044; KS-0000063K; KB-76766; HY-14369; AC-29671; CS-0003317; D09336 DMRDUC0 CP AbbVie DMRDUC0 PC 24785956 DMRDUC0 MW 653.6 DMRDUC0 FM C32H29F5N3NaO5 DMRDUC0 IC InChI=1S/C32H30F5N3O5.Na/c1-19-28(21-11-6-14-26(45-2)29(21)34)30(43)40(18-25(20-9-4-3-5-10-20)38-16-8-15-27(41)42)31(44)39(19)17-22-23(32(35,36)37)12-7-13-24(22)33;/h3-7,9-14,25,38H,8,15-18H2,1-2H3,(H,41,42);/q;+1/p-1/t25-;/m0./s1 DMRDUC0 CS CC1=C(C(=O)N(C(=O)N1CC2=C(C=CC=C2F)C(F)(F)F)C[C@@H](C3=CC=CC=C3)NCCCC(=O)[O-])C4=C(C(=CC=C4)OC)F.[Na+] DMRDUC0 IK DQYGXRQUFSRDCH-UQIIZPHYSA-M DMRDUC0 IU sodium;4-[[(1R)-2-[5-(2-fluoro-3-methoxyphenyl)-3-[[2-fluoro-6-(trifluoromethyl)phenyl]methyl]-4-methyl-2,6-dioxopyrimidin-1-yl]-1-phenylethyl]amino]butanoate DMRDUC0 CA CAS 832720-36-2 DMRDUC0 DE Endometriosis DMS7OU8 ID DMS7OU8 DMS7OU8 DN Elapegademase DMS7OU8 HS Approved DMS7OU8 SN Elapegademase [INN]; UNII-9R3D3Y0UHS; Elapegademase [USAN:INN]; 9R3D3Y0UHS DMS7OU8 CP Leadiant Biosciences DMS7OU8 DE Immunodeficiency; Adenosine deaminase defciency DMJLE18 ID DMJLE18 DMJLE18 DN Elbasvir DMJLE18 HS Approved DMJLE18 SN Elbasvir; Elbasvir [USAN:INN]; Elbasvir(MK-8742); MK 8742; MK-8742; MK8742; SB16741; ZINC150588351; 1370468-36-2; 632L571YDK; A16855; CHEBI:132967; CHEMBL3039514; CS-5332; Carbamic acid, N,N'-(((6S)-6-phenyl-6H-indolo(1,2-c)(1,3)benzoxazine-3,10-diyl)bis(1H-imidazole-5,2-diyl-(2S)-2,1-pyrrolidinediyl((1S)-1-(1-methylethyl)-2-oxo-2,1-ethanediyl)))bis-, C,C'-dimethyl ester; DB11574; EX-A2889; HY-15789; SCHEMBL17429773; UNII-632L571YDK DMJLE18 PC 71661251 DMJLE18 MW 882 DMJLE18 FM C49H55N9O7 DMJLE18 IC BVAZQCUMNICBAQ-PZHYSIFUSA-N DMJLE18 CS CC(C)C(C(=O)N1CCCC1C2=NC=C(N2)C3=CC4=C(C=C3)N5C(OC6=C(C5=C4)C=CC(=C6)C7=CN=C(N7)C8CCCN8C(=O)C(C(C)C)NC(=O)OC)C9=CC=CC=C9)NC(=O)OC DMJLE18 IK 1S/C49H55N9O7/c1-27(2)41(54-48(61)63-5)45(59)56-20-10-14-37(56)43-50-25-34(52-43)30-17-19-36-32(22-30)23-39-33-18-16-31(24-40(33)65-47(58(36)39)29-12-8-7-9-13-29)35-26-51-44(53-35)38-15-11-21-57(38)46(60)42(28(3)4)55-49(62)64-6/h7-9,12-13,16-19,22-28,37-38,41-42,47H,10-11,14-15,20-21H2,1-6H3,(H,50,52)(H,51,53)(H,54,61)(H,55,62)/t37-,38-,41-,42-,47-/m0/s1 DMJLE18 IU methyl N-[(2S)-1-[(2S)-2-[5-[(6S)-3-[2-[(2S)-1-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]pyrrolidin-2-yl]-1H-imidazol-5-yl]-6-phenyl-6H-indolo[1,2-c][1,3]benzoxazin-10-yl]-1H-imidazol-2-yl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate DMJLE18 CA CAS 1370468-36-2 DMJLE18 CB CHEBI:132967 DMJLE18 DE Viral hepatitis DMW649X ID DMW649X DMW649X DN Eletriptan DMW649X HS Approved DMW649X SN Eletriptanum; Relpax; UK 116044; UK116044; Eletriptan (INN); Eletriptan [INN:BAN]; Relpax (TN); UK-116044; UK-116044-04; (R)-3-[(1-Methyl-2-pyrrolidinyl)methyl]-5-[2-(phenylsulfonyl)ethyl]-1H-Indole; (R)-5-[2-(Benzenesulfonyl)ethyl]-3-[(N-methylpyrrolidin-2-yl)methyl]-1H-indole; 3-(((R)-1-Methyl-2-pyrrolidinyl)methyl)-5-(2-(phenylsulfonyl)ethyl)indole; 3-{[(2R)-1-methylpyrrolidin-2-yl]methyl}-5-[2-(phenylsulfonyl)ethyl]-1H-indole; 5-[2-(benzenesulfonyl)ethyl]-3-[[(2R)-1-methylpyrrolidin-2-yl]methyl]-1H-indole DMW649X CP Pfizer Inc DMW649X TC Antimigraine Agents DMW649X DT Small molecular drug DMW649X PC 77993 DMW649X MW 382.5 DMW649X FM C22H26N2O2S DMW649X IC InChI=1S/C22H26N2O2S/c1-24-12-5-6-19(24)15-18-16-23-22-10-9-17(14-21(18)22)11-13-27(25,26)20-7-3-2-4-8-20/h2-4,7-10,14,16,19,23H,5-6,11-13,15H2,1H3/t19-/m1/s1 DMW649X CS CN1CCC[C@@H]1CC2=CNC3=C2C=C(C=C3)CCS(=O)(=O)C4=CC=CC=C4 DMW649X IK PWVXXGRKLHYWKM-LJQANCHMSA-N DMW649X IU 5-[2-(benzenesulfonyl)ethyl]-3-[[(2R)-1-methylpyrrolidin-2-yl]methyl]-1H-indole DMW649X CA CAS 143322-58-1 DMW649X CB CHEBI:50922 DMW649X DE Migraine DMSRZAO ID DMSRZAO DMSRZAO DN Eliglustat tartrate DMSRZAO HS Approved DMSRZAO SN Fabrazyme (TN) DMSRZAO CP Genzyme DMSRZAO DT Small molecular drug DMSRZAO PC 52918379 DMSRZAO MW 959.2 DMSRZAO FM C50H78N4O14 DMSRZAO IC InChI=1S/2C23H36N2O4.C4H6O6/c2*1-2-3-4-5-6-9-22(26)24-19(17-25-12-7-8-13-25)23(27)18-10-11-20-21(16-18)29-15-14-28-20;5-1(3(7)8)2(6)4(9)10/h2*10-11,16,19,23,27H,2-9,12-15,17H2,1H3,(H,24,26);1-2,5-6H,(H,7,8)(H,9,10)/t2*19-,23-;1-,2-/m111/s1 DMSRZAO CS CCCCCCCC(=O)N[C@H](CN1CCCC1)[C@@H](C2=CC3=C(C=C2)OCCO3)O.CCCCCCCC(=O)N[C@H](CN1CCCC1)[C@@H](C2=CC3=C(C=C2)OCCO3)O.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O DMSRZAO IK KUBARPMUNHKBIQ-VTHUDJRQSA-N DMSRZAO IU N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-pyrrolidin-1-ylpropan-2-yl]octanamide;(2R,3R)-2,3-dihydroxybutanedioic acid DMSRZAO CA CAS 928659-70-5 DMSRZAO CB CHEBI:83353 DMSRZAO DE Metabolic disorder DMZC6GT ID DMZC6GT DMZC6GT DN Elliptinium acetate DMZC6GT HS Approved DMZC6GT SN Celiptium (TN) DMZC6GT CP Sanofi DMZC6GT DT Small molecular drug DMZC6GT PC 42722 DMZC6GT MW 336.4 DMZC6GT FM C20H20N2O3 DMZC6GT IC InChI=1S/C18H16N2O.C2H4O2/c1-10-15-9-20(3)7-6-13(15)11(2)18-17(10)14-8-12(21)4-5-16(14)19-18;1-2(3)4/h4-9,21H,1-3H3;1H3,(H,3,4) DMZC6GT CS CC1=C2C=C[N+](=CC2=C(C3=C1NC4=C3C=C(C=C4)O)C)C.CC(=O)[O-] DMZC6GT IK BOMZMNZEXMAQQW-UHFFFAOYSA-N DMZC6GT IU 2,5,11-trimethyl-6H-pyrido[4,3-b]carbazol-2-ium-9-ol;acetate DMZC6GT CA CAS 58337-35-2 DMZC6GT DE Solid tumour/cancer DMRCX8K ID DMRCX8K DMRCX8K DN Eloctate DMRCX8K HS Approved DMRCX8K SN Recombinant human factor VIII-FC DMRCX8K CP Biogen Idec DMRCX8K DE Haemophilia A DMA9REV ID DMA9REV DMA9REV DN Elosulfase alfa DMA9REV HS Approved DMA9REV SN Vimizim DMA9REV CP Biomarin DMA9REV SQ Elosulfase-alfa: APQPPNILLLLMDDMGWGDLGVYGEPSRETPLCSPSRAALLTGRLPIRNGFYTTNAHARNLLKKAGYVSKIVGKWHLGHRPQFHPLKHGFNIPVYRDWEMVGRYYEEFPINLKTGEANLTFLYWAVDATHAPVYASKPFLGTSQRGRYGDVADNTFVFFTSDNGAALISAPEQGGSNGPFPGHVTAGQVSHQLGSIMDLFTTSLALAGLTLMDRPIFYYRGDTLMAATLGQHKAHFWTWTVTTHNLEDHTKLPLIFHLGRDPGERFPLSFEALVPAQPQLNVCNWAVMNWAPPGCEKLGKPNLDRMAAEGLLFPNFYSANAYTPQEIVGGIPDSEQLLPEDEWFGSPNCHFGPYDNKARPQIYLQEALDFIKRQARHHPFAVREIDDSIGKILELLQDLHLCGKQTTFEGGMREPALAWWPPSDRAIDGLNLLPTLLQGRNSWENFRQGIDFCPGQNVSGASAEYQEALSRITSVVQQHQCLTPPESIPKKCLWSH DMA9REV DE Mucopolysaccharidosis DMEYHG9 ID DMEYHG9 DMEYHG9 DN Elotuzumab DMEYHG9 HS Approved DMEYHG9 SN BMS-901608 DMEYHG9 CP Bristol-Myers Squibb DMEYHG9 DT Antibody DMEYHG9 SQ Elotuzumab heavy chain: EVQLVESGGGLVQPGGSLRLSCAASGFDFSRYWMSWVRQAPGKGLEWIGEINPDSSTINYAPSLKDKFIISRDNAKNSLYLQMNSLRAEDTAVYYCARPDGNYWYFDVWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK >Elotuzumab light chainDIQMTQSPSSLSASVGDRVTITCKASQDVGIAVAWYQQKPGKVPKLLIYWASTRHTGVPDRFSGSGSGTDFTLTISSLQPEDVATYYCQQYSSYPYTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC DMEYHG9 DE Multiple myeloma DMOGFIX ID DMOGFIX DMOGFIX DN Eltrombopag DMOGFIX HS Approved DMOGFIX SN Eltrombopag [INN]; SB 497115; SB497115; SB-497115; [1,1'-Biphenyl]-3-carboxylic acid, 3'-[(2Z)-[1-(3,4-dime; Thylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-(9CI); (E)-3\'-(2-(1-(3,4-Dimethylphenyl)-3-methyl-5-oxo-1H-pyrazol-4(5H)-ylidene)hydrazinyl)-2\'-hydroxybiphenyl-3-carboxylic acid DMOGFIX CP GlaxoSmithKline DMOGFIX DT Small molecular drug DMOGFIX PC 135449332 DMOGFIX MW 442.5 DMOGFIX FM C25H22N4O4 DMOGFIX IC InChI=1S/C25H22N4O4/c1-14-10-11-19(12-15(14)2)29-24(31)22(16(3)28-29)27-26-21-9-5-8-20(23(21)30)17-6-4-7-18(13-17)25(32)33/h4-13,28,30H,1-3H3,(H,32,33) DMOGFIX CS CC1=C(C=C(C=C1)N2C(=O)C(=C(N2)C)N=NC3=CC=CC(=C3O)C4=CC(=CC=C4)C(=O)O)C DMOGFIX IK SVOQIEJWJCQGDQ-UHFFFAOYSA-N DMOGFIX IU 3-[3-[[2-(3,4-dimethylphenyl)-5-methyl-3-oxo-1H-pyrazol-4-yl]diazenyl]-2-hydroxyphenyl]benzoic acid DMOGFIX CA CAS 496775-61-2 DMOGFIX CB CHEBI:85010 DMOGFIX DE Thrombocytopenia; Idiopathic thrombocytopenic purpura DMYZ0P1 ID DMYZ0P1 DMYZ0P1 DN Eluxadoline DMYZ0P1 HS Approved DMYZ0P1 SN MuDelta DMYZ0P1 CP Furiex pharmaceuticals DMYZ0P1 DT Small molecular drug DMYZ0P1 PC 11250029 DMYZ0P1 MW 569.6 DMYZ0P1 FM C32H35N5O5 DMYZ0P1 IC InChI=1S/C32H35N5O5/c1-18-12-23(29(34)38)13-19(2)24(18)15-26(33)31(39)37(17-21-10-11-28(42-4)25(14-21)32(40)41)20(3)30-35-16-27(36-30)22-8-6-5-7-9-22/h5-14,16,20,26H,15,17,33H2,1-4H3,(H2,34,38)(H,35,36)(H,40,41)/t20-,26-/m0/s1 DMYZ0P1 CS CC1=CC(=CC(=C1C[C@@H](C(=O)N(CC2=CC(=C(C=C2)OC)C(=O)O)[C@@H](C)C3=NC=C(N3)C4=CC=CC=C4)N)C)C(=O)N DMYZ0P1 IK QFNHIDANIVGXPE-FNZWTVRRSA-N DMYZ0P1 IU 5-[[[(2S)-2-amino-3-(4-carbamoyl-2,6-dimethylphenyl)propanoyl]-[(1S)-1-(5-phenyl-1H-imidazol-2-yl)ethyl]amino]methyl]-2-methoxybenzoic acid DMYZ0P1 CA CAS 864821-90-9 DMYZ0P1 CB CHEBI:85980 DMYZ0P1 DE Diarrhea-predominant irritable bowel syndrome DMG9B1U ID DMG9B1U DMG9B1U DN Elvitegravir DMG9B1U HS Approved DMG9B1U SN EVG DMG9B1U DT Small molecular drug DMG9B1U PC 5277135 DMG9B1U MW 447.9 DMG9B1U FM C23H23ClFNO5 DMG9B1U IC InChI=1S/C23H23ClFNO5/c1-12(2)19(11-27)26-10-16(23(29)30)22(28)15-8-14(20(31-3)9-18(15)26)7-13-5-4-6-17(24)21(13)25/h4-6,8-10,12,19,27H,7,11H2,1-3H3,(H,29,30)/t19-/m1/s1 DMG9B1U CS CC(C)[C@@H](CO)N1C=C(C(=O)C2=C1C=C(C(=C2)CC3=C(C(=CC=C3)Cl)F)OC)C(=O)O DMG9B1U IK JUZYLCPPVHEVSV-LJQANCHMSA-N DMG9B1U IU 6-[(3-chloro-2-fluorophenyl)methyl]-1-[(2S)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxoquinoline-3-carboxylic acid DMG9B1U CA CAS 697761-98-1 DMG9B1U CB CHEBI:72289 DMG9B1U DE Human immunodeficiency virus infection DMZG5WL ID DMZG5WL DMZG5WL DN Emapalumab DMZG5WL HS Approved DMZG5WL SN emapalumab; Emapalumab [INN]; Emapalumab [USAN:INN]; UNII-3S252O2Z4X; 3S252O2Z4X DMZG5WL CP Novimmune DMZG5WL DT Antibody DMZG5WL DE Primary haemophagocytic lymphohistiocytosis DM36LAJ ID DM36LAJ DM36LAJ DN Emedastine DM36LAJ HS Approved DM36LAJ SN Emadine; Emedastina; Emedastinum; Emedastine [INN]; Emedastine difumarate; KB 2413; KG 2413; Emadine (TN); Emedastina [INN-Spanish]; Emedastine (INN); Emedastine [INN:BAN]; Emedastinum [INN-Latin]; KB-2413; KG-2413; 1-(2-Ethoxyethyl)-2-(4-methyl-1-homopiperazinyl)benzimidazole difumarate; 1-(2-Ethoxyethyl)-2-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)benzimidazole; 1-(2-ethoxyethyl)-2-(4-methyl-1,4-diazepan-1-yl)-1H-benzimidazole; 1-(2-ethoxyethyl)-2-(4-methyl-1,4-diazepan-1-yl)benzimidazole; 1-Methyl-4-(1-(2-ethoxyethyl)-1H-benzimidazo)-2-yl)(1,4)diazepane; 1-[2-(ethoxy)ethyl]-2-(4-methyl-1-homopiperazinyl)benzimidazole DM36LAJ TC Antiallergic Agents DM36LAJ DT Small molecular drug DM36LAJ PC 3219 DM36LAJ MW 302.4 DM36LAJ FM C17H26N4O DM36LAJ IC InChI=1S/C17H26N4O/c1-3-22-14-13-21-16-8-5-4-7-15(16)18-17(21)20-10-6-9-19(2)11-12-20/h4-5,7-8H,3,6,9-14H2,1-2H3 DM36LAJ CS CCOCCN1C2=CC=CC=C2N=C1N3CCCN(CC3)C DM36LAJ IK KBUZBQVCBVDWKX-UHFFFAOYSA-N DM36LAJ IU 1-(2-ethoxyethyl)-2-(4-methyl-1,4-diazepan-1-yl)benzimidazole DM36LAJ CA CAS 87233-61-2 DM36LAJ CB CHEBI:4779 DM36LAJ DE Allergic conjunctivitis DMCOAVT ID DMCOAVT DMCOAVT DN Emepronium DMCOAVT HS Approved DMCOAVT SN Emepronium Bromide; Restenacht; Cetiprin; Emeprone bromide; Emepron bromide; 3614-30-0; Emeproniumbromid [German]; Emepronium bromide [INN:BAN]; Emepronii bromidum [INN-Latin]; Bromure d'emepronium [INN-French]; Bromuro de emepronio [INN-Spanish]; EINECS 222-786-6; Ethyldimethyl(1-methyl-3,3-diphenylpropyl)ammonium bromide; Dimethylethyl(beta-benzhydrylisopropyl)ammonium bromide; C20H28N; Ammonium, ethyldimethyl(1-methyl-3,3-diphenylpropyl)-, bromide; Emeproniumbromid; Emepronii bromidum; Bromure d'emepronium; Bromuro de emep DMCOAVT DT Small molecular drug DMCOAVT PC 34055 DMCOAVT MW 282.4 DMCOAVT FM C20H28N+ DMCOAVT IC InChI=1S/C20H28N/c1-5-21(3,4)17(2)16-20(18-12-8-6-9-13-18)19-14-10-7-11-15-19/h6-15,17,20H,5,16H2,1-4H3/q+1 DMCOAVT CS CC[N+](C)(C)C(C)CC(C1=CC=CC=C1)C2=CC=CC=C2 DMCOAVT IK JEJBJBKVPOWOQK-UHFFFAOYSA-N DMCOAVT IU 4,4-diphenylbutan-2-yl-ethyl-dimethylazanium DMCOAVT CA CAS 27892-33-7 DMCOAVT CB CHEBI:135169 DMCOAVT DE Urinary incontinence DMCT2YF ID DMCT2YF DMCT2YF DN Emetine DMCT2YF HS Approved DMCT2YF SN Emetine hydrochloride; EMETINE; 14198-59-5; MLS000028478; SMR000058444; NSC-33669; NSC33669; Emetine monohydrochloride; Opera_ID_1460; Cephaeline methyl ether HCl; AC1O7FP4; SCHEMBL636599; CHEMBL513000; DTXSID80424947; MolPort-004-964-890; Cephaeline methyl ether hydrochloride; NSC752340; AKOS024374935; NSC-752340; ST51014995; Emetan,7',10,11-tetramethoxy-, dihydrochloride; Q-100155; 10-[((1R)-6,7-dimethoxy(1,2,3,4-tetrahydroisoquinolyl))methyl](10S,11aS,9R)-9- ethyl-2,3-dimethoxy-5,6,7,11a-tetrahydropiperidino[2,1-a]isoquinolin DMCT2YF DT Small molecular drug DMCT2YF PC 10219 DMCT2YF MW 480.6 DMCT2YF FM C29H40N2O4 DMCT2YF IC InChI=1S/C29H40N2O4/c1-6-18-17-31-10-8-20-14-27(33-3)29(35-5)16-23(20)25(31)12-21(18)11-24-22-15-28(34-4)26(32-2)13-19(22)7-9-30-24/h13-16,18,21,24-25,30H,6-12,17H2,1-5H3/t18-,21-,24+,25-/m0/s1 DMCT2YF CS CC[C@H]1CN2CCC3=CC(=C(C=C3[C@@H]2C[C@@H]1C[C@@H]4C5=CC(=C(C=C5CCN4)OC)OC)OC)OC DMCT2YF IK AUVVAXYIELKVAI-CKBKHPSWSA-N DMCT2YF IU (2S,3R,11bS)-2-[[(1R)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-1-yl]methyl]-3-ethyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-benzo[a]quinolizine DMCT2YF CA CAS 483-18-1 DMCT2YF CB CHEBI:4781 DMCT2YF DE Hepatitis virus infection DM0AQ83 ID DM0AQ83 DM0AQ83 DN Emicizumab DM0AQ83 HS Approved DM0AQ83 CP Roche/Genentech DM0AQ83 DT Antibody DM0AQ83 DE Factor VIII deficiency DMRF9YK ID DMRF9YK DMRF9YK DN Empagliflozin DMRF9YK HS Approved DMRF9YK SN 864070-44-0; JARDIANCE; BI 10773; UNII-HDC1R2M35U; Empagliflozin (BI 10773); BI-10773; BI10773; HDC1R2M35U; CHEBI:82720; 1-chloro-4-(glucopyranos-1-yl)-2-(4-(tetrahydrofuran-3-yloxy)benzyl)benzene; AK160980; (1S)-1,5-anhydro-1-(4-chloro-3-{4-[(3S)-tetrahydrofuran-3-yloxy]benzyl}phenyl)-D-glucitol; (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-(((S)-tetrahydrofuran-3-yl)oxy)benzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol DMRF9YK CP Boehringer Ingelheim Pharmaceuticals; Eli Lilly DMRF9YK DT Small molecular drug DMRF9YK PC 11949646 DMRF9YK MW 450.9 DMRF9YK FM C23H27ClO7 DMRF9YK IC InChI=1S/C23H27ClO7/c24-18-6-3-14(23-22(28)21(27)20(26)19(11-25)31-23)10-15(18)9-13-1-4-16(5-2-13)30-17-7-8-29-12-17/h1-6,10,17,19-23,25-28H,7-9,11-12H2/t17-,19+,20+,21-,22+,23-/m0/s1 DMRF9YK CS C1COC[C@H]1OC2=CC=C(C=C2)CC3=C(C=CC(=C3)[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)Cl DMRF9YK IK OBWASQILIWPZMG-QZMOQZSNSA-N DMRF9YK IU (2S,3R,4R,5S,6R)-2-[4-chloro-3-[[4-[(3S)-oxolan-3-yl]oxyphenyl]methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol DMRF9YK CA CAS 864070-44-0 DMRF9YK CB CHEBI:82720 DMRF9YK DE Type-1 diabetes DMBMUWZ ID DMBMUWZ DMBMUWZ DN Emtricitabine DMBMUWZ HS Approved DMBMUWZ SN Coviracil; DOTFC; Emtriva; RCV; Racivir; BW 1592; BW 524W91; BW524W91; BW-524W91; Coviracil (TN); Coviracil(TM); DRG-0208; Emtriva(TM); Emtricitabine (JAN/USAN/INN); Beta-L-2',3'-dideoxy-5-fluoro-3'-thiacytidine; Beta-L-(-)-(2R,5S)-5-Fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine; (-)-(2R,5S)-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine; (-)-.beta.-L-FTC; (-)-2',3'-Dideoxy-5-fluoro-3'-thiacytidine; (-)-2'-Deoxy-5-fluoro-3'-thiacytidine; (-)-FTC; (-)-beta-2',3'-dideoxy-5-fluoro-3'-thiacytidine; (-)-cis-4-amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one; (2R-cis)-4-Amino-5-fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-2(1H)-pyrimidinone; 1-(2-(Hydroxymethyl)oxathiolan-5-yl)-5-fluorocytosine; 2',3',5-FTC; 2',3'-Dideoxy-5-fluoro-3'-thiacytidine; 2'-Deoxy-5-fluoro-3'-oxa-4'-thiocytidine; 2'-Deoxy-5-fluoro-3'-thiacytidine; 2-FTC; 3'-Thia-2'.3'-dideoxy-5-fluorocytidine; 4-Amino-5-fluoro-1-[(2R,5S)-(hydroxymethyl)-1,3-oxathiolan-5-yl]-2(1H)-pyrimidinone; 4-amino-5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2(1H)-one; 4-amino-5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one; 5-Fluoro-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine; 5-Fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine; 5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)[1,3]oxathiolan-5-yl]cytosine; 524W91; FTC DMBMUWZ CP Gilead; Bristol-Myers Squibb DMBMUWZ TC Anti-HIV Agents DMBMUWZ DT Small molecular drug DMBMUWZ PC 60877 DMBMUWZ MW 247.25 DMBMUWZ FM C8H10FN3O3S DMBMUWZ IC InChI=1S/C8H10FN3O3S/c9-4-1-12(8(14)11-7(4)10)5-3-16-6(2-13)15-5/h1,5-6,13H,2-3H2,(H2,10,11,14)/t5-,6+/m0/s1 DMBMUWZ CS C1[C@H](O[C@H](S1)CO)N2C=C(C(=NC2=O)N)F DMBMUWZ IK XQSPYNMVSIKCOC-NTSWFWBYSA-N DMBMUWZ IU 4-amino-5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one DMBMUWZ CA CAS 143491-57-0 DMBMUWZ CB CHEBI:31536 DMBMUWZ DE Human immunodeficiency virus infection; Hepatitis virus infection; Hepatitis B virus infection DMNFUZR ID DMNFUZR DMNFUZR DN Enalapril DMNFUZR HS Approved DMNFUZR SN Vasotec; Enalapril (INN); Enalapril (TN); N-{(1S)-1-[(ethyloxy)carbonyl]-3-phenylpropyl}-L-alanyl-L-proline; N-[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]-L-alanyl-L-proline; (2S)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]pyrrolidine-2-carboxylic acid DMNFUZR CP Merck & Co DMNFUZR TC Antihypertensive Agents DMNFUZR DT Small molecular drug DMNFUZR PC 5388962 DMNFUZR MW 376.4 DMNFUZR FM C20H28N2O5 DMNFUZR IC InChI=1S/C20H28N2O5/c1-3-27-20(26)16(12-11-15-8-5-4-6-9-15)21-14(2)18(23)22-13-7-10-17(22)19(24)25/h4-6,8-9,14,16-17,21H,3,7,10-13H2,1-2H3,(H,24,25)/t14-,16-,17-/m0/s1 DMNFUZR CS CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2CCC[C@H]2C(=O)O DMNFUZR IK GBXSMTUPTTWBMN-XIRDDKMYSA-N DMNFUZR IU (2S)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]pyrrolidine-2-carboxylic acid DMNFUZR CA CAS 75847-73-3 DMNFUZR CB CHEBI:4784 DMNFUZR DE Hypertension DMFYAM1 ID DMFYAM1 DMFYAM1 DN Enalaprilat DMFYAM1 HS Approved DMFYAM1 SN Extract of ginger root; Ginger extract; Ginger root extract; Ginger, ext; LS-3194; Zingiber officinale extract; Zingiber officinale root extract; CCRIS 7641; EINECS 283-634-2; FEMA No. 2520; FEMA No. 2521; FEMA No. 2523; Ginger extract (Zingiber officinale); ginger, extract (zingiber officinale rosc.) DMFYAM1 PC 6850776 DMFYAM1 MW 568.8 DMFYAM1 FM C35H52O6 DMFYAM1 IC QCVRFSPGUWEKFC-ILHSMLOTSA-N DMFYAM1 CS CCCCCC=CC(=O)CCC1=CC(=C(C=C1)O)OC.CCCCCC(C)CC(=O)CCC1=CC(=C(C=C1)O)OC DMFYAM1 IK 1S/C18H28O3.C17H24O3/c1-4-5-6-7-14(2)12-16(19)10-8-15-9-11-17(20)18(13-15)21-3;1-3-4-5-6-7-8-15(18)11-9-14-10-12-16(19)17(13-14)20-2/h9,11,13-14,20H,4-8,10,12H2,1-3H3;7-8,10,12-13,19H,3-6,9,11H2,1-2H3/b;8-7+ DMFYAM1 IU (E)-1-(4-hydroxy-3-methoxyphenyl)dec-4-en-3-one;1-(4-hydroxy-3-methoxyphenyl)-5-methyldecan-3-one DMFYAM1 CA CAS 84696-15-1 DMFYAM1 DE Essential hypertension DMPRBQV ID DMPRBQV DMPRBQV DN Enalaprilat DMPRBQV HS Approved DMPRBQV SN EAL; Enalaprilate; Enalaprilatum; ENALAPRILAT INHIBITOR; Enalapril acid; Enalapril diacid; Enalaprilat anhydrous; Enalaprilic acid; Enalprilat hydrate; Enalprilate hydrate; Enalaprilat (USP); MK-422; Vasotec I.V.; N-[(1S)-1-carboxy-3-phenylpropyl]-L-alanyl-L-proline; N-[(1S)-1-carboxy-3-phenylpropyl]-L-alanyl-L-proline-water (1/2); (2S)-1-[(2S)-2-[[(2S)-1-hydroxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]pyrrolidine-2-carboxylic acid; (2S)-1-[(2S)-2-[[(2S)-1-hydroxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]pyrrolidine-2-carboxylic acid dihydrate; 1-((2S)-2-{[(1S)-1-CARBOXY-3-PHENYLPROPYL]AMINO}PROPANOYL)-L-PROLINE; 1-(N-((S)-1-Carboxy-3-phenylpropyl)-L-alanyl)-L-proline dihydrate DMPRBQV CP Merck & Co DMPRBQV TC Antihypertensive Agents DMPRBQV DT Small molecular drug DMPRBQV PC 5462501 DMPRBQV MW 348.4 DMPRBQV FM C18H24N2O5 DMPRBQV IC InChI=1S/C18H24N2O5/c1-12(16(21)20-11-5-8-15(20)18(24)25)19-14(17(22)23)10-9-13-6-3-2-4-7-13/h2-4,6-7,12,14-15,19H,5,8-11H2,1H3,(H,22,23)(H,24,25)/t12-,14-,15-/m0/s1 DMPRBQV CS C[C@@H](C(=O)N1CCC[C@H]1C(=O)O)N[C@@H](CCC2=CC=CC=C2)C(=O)O DMPRBQV IK LZFZMUMEGBBDTC-QEJZJMRPSA-N DMPRBQV IU (2S)-1-[(2S)-2-[[(1S)-1-carboxy-3-phenylpropyl]amino]propanoyl]pyrrolidine-2-carboxylic acid DMPRBQV CA CAS 76420-72-9 DMPRBQV CB CHEBI:4786 DMPRBQV DE Hypertension DM8QXOC ID DM8QXOC DM8QXOC DN Enasidenib DM8QXOC HS Approved DM8QXOC SN Enasidenib; Enasidenib mesylate; IDHIFA; 1446502-11-9; 2-Methyl-1-(4-(6-(trifluoromethyl)pyridin-2-yl)-6-(2-(trifluoromethyl)pyridin-4-ylamino)-1,3,5-triazin-2-ylamino)propan-2-ol; 2-Propanol, 2-methyl-1-((4-(6-(trifluoromethyl)-2-pyridinyl)-6-((2-(trifluoromethyl)-4-pyridinyl)amino)-1,3,5-triazin-2-yl)amino)-; 2-methyl-1-((4-(6-(trifluoromethyl)pyridin-2-yl)-6-((2-(trifluoromethyl)pyridin-4-yl)amino)-1,3,5-triazin-2-yl)amino)propan-2-ol; 3T1SS4E7AG; AG-221; CC-90007; CC-90007 Free Base; UNII-3T1SS4E7AG DM8QXOC PC 89683805 DM8QXOC MW 473.4 DM8QXOC FM C19H17F6N7O DM8QXOC IC DYLUUSLLRIQKOE-UHFFFAOYSA-N DM8QXOC CS CC(C)(CNC1=NC(=NC(=N1)C2=NC(=CC=C2)C(F)(F)F)NC3=CC(=NC=C3)C(F)(F)F)O DM8QXOC IK 1S/C19H17F6N7O/c1-17(2,33)9-27-15-30-14(11-4-3-5-12(29-11)18(20,21)22)31-16(32-15)28-10-6-7-26-13(8-10)19(23,24)25/h3-8,33H,9H2,1-2H3,(H2,26,27,28,30,31,32) DM8QXOC IU 2-methyl-1-[[4-[6-(trifluoromethyl)pyridin-2-yl]-6-[[2-(trifluoromethyl)pyridin-4-yl]amino]-1,3,5-triazin-2-yl]amino]propan-2-ol DM8QXOC CA CAS 1446502-11-9 DM8QXOC CB CHEBI:145374 DM8QXOC DE Acute myeloid leukaemia DMPOU5H ID DMPOU5H DMPOU5H DN ENASIDENIB MESYLATE DMPOU5H HS Approved DMPOU5H SN UNII-UF6PC17XAV; AG-221 mesylate; Enasidenib (mesylate); UF6PC17XAV; Enasidenib mesylate [USAN]; Enasidenib mesylate (USAN); Enasidenib mesilate; Enasidenib methanesulfonate; Idhifa (TN); SCHEMBL16448052; HY-18690A; CS-7541 DMPOU5H CP Celgene/Agios DMPOU5H PC 90480031 DMPOU5H MW 569.5 DMPOU5H FM C20H21F6N7O4S DMPOU5H IC InChI=1S/C19H17F6N7O.CH4O3S/c1-17(2,33)9-27-15-30-14(11-4-3-5-12(29-11)18(20,21)22)31-16(32-15)28-10-6-7-26-13(8-10)19(23,24)25;1-5(2,3)4/h3-8,33H,9H2,1-2H3,(H2,26,27,28,30,31,32);1H3,(H,2,3,4) DMPOU5H CS CC(C)(CNC1=NC(=NC(=N1)C2=NC(=CC=C2)C(F)(F)F)NC3=CC(=NC=C3)C(F)(F)F)O.CS(=O)(=O)O DMPOU5H IK ORZHZQZYWXEDDL-UHFFFAOYSA-N DMPOU5H IU methanesulfonic acid;2-methyl-1-[[4-[6-(trifluoromethyl)pyridin-2-yl]-6-[[2-(trifluoromethyl)pyridin-4-yl]amino]-1,3,5-triazin-2-yl]amino]propan-2-ol DMPOU5H CA CAS 1650550-25-6 DMPOU5H DE Acute myeloid leukaemia DM7RNP3 ID DM7RNP3 DM7RNP3 DN Enbrel DM7RNP3 HS Approved DM7RNP3 DE Arthritis DM0YJSB ID DM0YJSB DM0YJSB DN Enflurane DM0YJSB HS Approved DM0YJSB SN Alyrane; Efrane; Enflurano; Enfluranum; Enfran; Enlirane; Ethrane; Etran; Methylflurether; Abbott Brand of Enflurane; AstraZeneca Brand of Enflurane; Baxter Anaesthesia Brand of Enflurane; Pisa Brand of Enflurane; Zeneca Brand of Enflurane; Anesthetic 347; C 347; OHIO 347; Anesthetic Compound No. 347; Enflurane [Anaesthetics,volatile]; Enflurano [INN-Spanish]; Enfluranum [INN-Latin]; Ethrane (TN); Enflurane (JP15/USP/INN); Enflurane [USAN:BAN:INN:JAN]; Ether, 2-chloro-1,1,2-trifluoroethyl difluoromethyl; (+-)-2-Chloro-1,1,2-trifluoroethyl difluoromethyl ether; 2-Chloro-1,1,2-trifluoroethyl difluoromethyl ether; 2-Chloro-1-(difluoromethoxy)-1,1,2-trifluoroethane DM0YJSB TC Anesthetics DM0YJSB DT Small molecular drug DM0YJSB PC 3226 DM0YJSB MW 184.49 DM0YJSB FM C3H2ClF5O DM0YJSB IC InChI=1S/C3H2ClF5O/c4-1(5)3(8,9)10-2(6)7/h1-2H DM0YJSB CS C(C(OC(F)F)(F)F)(F)Cl DM0YJSB IK JPGQOUSTVILISH-UHFFFAOYSA-N DM0YJSB IU 2-chloro-1-(difluoromethoxy)-1,1,2-trifluoroethane DM0YJSB CA CAS 13838-16-9 DM0YJSB CB CHEBI:4792 DM0YJSB DE Anaesthesia DMFS63G ID DMFS63G DMFS63G DN Enfortumab DMFS63G HS Approved DMFS63G SN ASG-2ME DMFS63G CP Astellas Northbrook, IL Seattle Genetics Bothell, WA DMFS63G DT Antibody drug conjugate DMFS63G DE Urothelial carcinoma DM7YPM1 ID DM7YPM1 DM7YPM1 DN Enfuvirtide DM7YPM1 HS Approved DM7YPM1 SN Fuzeon; Pentafuside; Enfuvirtide [USAN]; Roche brand of pentafuside; DP178; Dp 178; Peptide T20; T 20; T20 peptide; Fuzeon (TN); T 20 (peptide); T-20; T-20 cpd DM7YPM1 CP Hoffmann-La Roche pharmaceutical company DM7YPM1 TC Anti-HIV Agents DM7YPM1 DT Small molecular drug DM7YPM1 SQ DB00109 sequence: YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF DM7YPM1 PC 24847866 DM7YPM1 MW 4565 DM7YPM1 FM C206H304N52O66 DM7YPM1 IC InChI=1S/C206H304N52O66/c1-20-103(15)168(254-197(315)137(75-101(11)12)239-202(320)151(94-261)252-192(310)143(82-113-90-216-96-221-113)249-205(323)169(104(16)21-2)255-198(316)138(76-102(13)14)240-203(321)152(95-262)253-206(324)170(106(18)263)256-199(317)148(258-257-107(19)264)78-109-45-47-114(265)48-46-109)204(322)234-132(58-68-165(283)284)180(298)229-131(57-67-164(281)282)184(302)251-150(93-260)200(318)233-126(52-62-156(212)269)181(299)246-145(84-158(214)271)193(311)230-125(51-61-155(211)268)177(295)225-123(49-59-153(209)266)175(293)227-127(53-63-160(273)274)178(296)223-121(43-31-33-69-207)174(292)245-144(83-157(213)270)194(312)232-128(54-64-161(275)276)179(297)226-124(50-60-154(210)267)176(294)228-129(55-65-162(277)278)182(300)235-134(72-98(5)6)187(305)237-133(71-97(3)4)186(304)231-130(56-66-163(279)280)183(301)236-135(73-99(7)8)189(307)248-147(86-166(285)286)196(314)224-122(44-32-34-70-208)173(291)242-140(79-110-87-217-118-40-28-25-37-115(110)118)185(303)222-105(17)171(289)250-149(92-259)201(319)238-136(74-100(9)10)188(306)243-142(81-112-89-219-120-42-30-27-39-117(112)120)191(309)247-146(85-159(215)272)195(313)244-141(80-111-88-218-119-41-29-26-38-116(111)119)190(308)241-139(172(290)220-91-167(287)288)77-108-35-23-22-24-36-108/h22-30,35-42,45-48,87-90,96-106,121-152,168-170,217-219,258-263,265H,20-21,31-34,43-44,49-86,91-95,207-208H2,1-19H3,(H2,209,266)(H2,210,267)(H2,211,268)(H2,212,269)(H2,213,270)(H2,214,271)(H2,215,272)(H,216,221)(H,220,290)(H,222,303)(H,223,296)(H,224,314)(H,225,295)(H,226,297)(H,227,293)(H,228,294)(H,229,298)(H,230,311)(H,231,304)(H,232,312)(H,233,318)(H,234,322)(H,235,300)(H,236,301)(H,237,305)(H,238,319)(H,239,320)(H,240,321)(H,241,308)(H,242,291)(H,243,306)(H,244,313)(H,245,292)(H,246,299)(H,247,309)(H,248,307)(H,249,323)(H,250,289)(H,251,302)(H,252,310)(H,253,324)(H,254,315)(H,255,316)(H,256,317)(H,257,264)(H,273,274)(H,275,276)(H,277,278)(H,279,280)(H,281,282)(H,283,284)(H,285,286)(H,287,288)/t103-,104-,105-,106+,121-,122-,123-,124-,125-,126-,127-,128-,129-,130-,131-,132-,133-,134-,135-,136-,137-,138-,139-,140-,141-,142-,143-,144-,145-,146-,147-,148-,149-,150-,151-,152-,168-,169-,170-/m0/s1 DM7YPM1 CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC5=CNC6=CC=CC=C65)C(=O)N[C@@H](CC7=CC=CC=C7)C(=O)NCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CC8=CN=CN8)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC9=CC=C(C=C9)O)NNC(=O)C DM7YPM1 IK BWVBEUNZTQWGMR-CKVIKZOTSA-N DM7YPM1 IU (4S)-4-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-(2-acetylhydrazinyl)-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-methylpentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-methylpentanoyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-3-hydroxypropanoyl]amino]-5-amino-5-oxopentanoyl]amino]-4-amino-4-oxobutanoyl]amino]-5-amino-5-oxopentanoyl]amino]-5-amino-5-oxopentanoyl]amino]-5-[[(2S)-6-amino-1-[[(2S)-4-amino-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-1-[[(2S)-1-(carboxymethylamino)-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-oxopentanoic acid DM7YPM1 DE Human immunodeficiency virus infection DMYTE6L ID DMYTE6L DMYTE6L DN Enoxacin DMYTE6L HS Approved DMYTE6L SN Almitil; Bactidan; Comprecin; Enoram; Enoxacine; Enoxacino; Enoxacinum; Enoxin; Enoxor; Flumark; Penetrex; Enoxacin Sesquihydrate; Enoxacine [French]; Enoxacino [Spanish]; Enoxacinum [Latin]; Faulding Brand of Enoxacin; Pierre Fabre Brand of Enoxacin Sesquihydrate; Rhone Poulenc Rorer Brand of Enoxacin Sesquihydrate; AT 2266; AT2266; CI919; CL23362; E0762; PD 107779; PD107779; AT-2266; Almitil (TN); Bactidan (TN); Bactidron (TN); Comprecin (TN); Enoksetin (TN); Enoxen (TN); Enoxin (TN); Enoxor (TN); Enroxil (TN); Flumark (TN); Gyramid (TN); PD-107779; Penetrex (TN); Rhone-Poulenc Rorer Brand of Enoxacin Sesquihydrate; Sesquihydrate, Enoxacin; Vinone (TN); Enoxacin (USAN/INN); Enoxacin [USAN:BAN:INN:JAN]; 1,8-Naphthyridine-3-carboxylic acid, 6-fluoro-1,4-dihydro-4-oxo-7-piperazinyl; 1-Ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-1,8-naphthyridine-3-carboxylic acid; 1-Ethyl-6-fluoro-1,4-dihydro-4-oxo-7-[1-piperazinyl]-1,8-naphthyridine-3-carboxylic acid; 1-Ethyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid; 1-ethyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid; 1-ethyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid; 1-ethyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,8-naphthyridine-3-carboxylic acid DMYTE6L TC Antiinfective Agents DMYTE6L DT Small molecular drug DMYTE6L PC 3229 DMYTE6L MW 320.32 DMYTE6L FM C15H17FN4O3 DMYTE6L IC InChI=1S/C15H17FN4O3/c1-2-19-8-10(15(22)23)12(21)9-7-11(16)14(18-13(9)19)20-5-3-17-4-6-20/h7-8,17H,2-6H2,1H3,(H,22,23) DMYTE6L CS CCN1C=C(C(=O)C2=CC(=C(N=C21)N3CCNCC3)F)C(=O)O DMYTE6L IK IDYZIJYBMGIQMJ-UHFFFAOYSA-N DMYTE6L IU 1-ethyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,8-naphthyridine-3-carboxylic acid DMYTE6L CA CAS 74011-58-8 DMYTE6L CB CHEBI:157175 DMYTE6L DE Urinary tract infection DMQVZJD ID DMQVZJD DMQVZJD DN Enoximone DMQVZJD HS Approved DMQVZJD SN ENOXIMONE; Perfan; 77671-31-9; Fenoximone; Enoximonum [Latin]; MDL-17043; Enoximona [Spanish]; MDL 17,043; UNII-C7Z4ITI7L7; MDL-17,043; RMI-17043; 4-methyl-5-(4-methylsulfanylbenzoyl)-1,3-dihydroimidazol-2-one; C7Z4ITI7L7; 4-Methyl-5-(p-(methylthio)benzoyl)-4-imidazolin-2-one; CHEMBL249856; 2H-Imidazol-2-one, 1,3-dihydro-4-methyl-5-(4-(methylthio)benzoyl)-; NCGC00015400-02; Enoximonum; Enoximona; 1,3-Dihydro-4-methyl-5-[4-methylthiobenzoyl]-2H-imidazol-2-one; DSSTox_RID_80702; DSSTox_CID_25147; DSSTox_GSID_45147; Perfane; Enoximona; E 1279; Perfan (TN); Enoximone (USAN/INN); Enoximone [USAN:BAN:INN]; 1,3-Dihydro-4-methyl-5-(4-methylthiobenzoyl)-2H-imidazol-2-one; FENOXIMONE DMQVZJD TC Cardiotonic Agents DMQVZJD DT Small molecular drug DMQVZJD PC 53708 DMQVZJD MW 248.3 DMQVZJD FM C12H12N2O2S DMQVZJD IC InChI=1S/C12H12N2O2S/c1-7-10(14-12(16)13-7)11(15)8-3-5-9(17-2)6-4-8/h3-6H,1-2H3,(H2,13,14,16) DMQVZJD CS CC1=C(NC(=O)N1)C(=O)C2=CC=C(C=C2)SC DMQVZJD IK ZJKNESGOIKRXQY-UHFFFAOYSA-N DMQVZJD IU 4-methyl-5-(4-methylsulfanylbenzoyl)-1,3-dihydroimidazol-2-one DMQVZJD CA CAS 77671-31-9 DMQVZJD CB CHEBI:135010 DMQVZJD DE Congestive heart failure DMFYZKN ID DMFYZKN DMFYZKN DN Enprofylline DMFYZKN HS Approved DMFYZKN SN Enprofilina; Enprofyllinum; Nilyph; Oxeze; P 5679; D-4028; Enprofilina [INN-Spanish]; Enprofylline [USAN:INN]; Enprofyllinum [INN-Latin]; Enprofylline (USAN/INN); 3,7-Dihydro-3-propyl-1H-purine-2,6-dione; 3-Propyl-3,7-dihydro-purine-2,6-dione; 3-Propylxanthine; 3-n-Propylxanthine; 3-propyl-3,7-dihydro-1H-purine-2,6-dione; 3-propyl-7H-purine-2,6-dione DMFYZKN TC Antiinflammatory Agents DMFYZKN DT Small molecular drug DMFYZKN PC 1676 DMFYZKN MW 194.19 DMFYZKN FM C8H10N4O2 DMFYZKN IC InChI=1S/C8H10N4O2/c1-2-3-12-6-5(9-4-10-6)7(13)11-8(12)14/h4H,2-3H2,1H3,(H,9,10)(H,11,13,14) DMFYZKN CS CCCN1C2=C(C(=O)NC1=O)NC=N2 DMFYZKN IK SIQPXVQCUCHWDI-UHFFFAOYSA-N DMFYZKN IU 3-propyl-7H-purine-2,6-dione DMFYZKN CA CAS 41078-02-8 DMFYZKN CB CHEBI:126237 DMFYZKN DE Asthma DMLBVKQ ID DMLBVKQ DMLBVKQ DN Entacapone DMLBVKQ HS Approved DMLBVKQ SN Comtan; Comtess; Entacapona; Entacaponum; Novartis brand of entacapone; Orion brand of entacapone; KB475572; OR 611; COM-998; Comtan (TN); Entacapona [INN-Spanish]; Entacapone [USAN:INN]; Entacaponum [INN-Latin]; OR-611; Stalevo (TN); Entacapone (JAN/USAN/INN); N,N-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl) acrylamide; (2E)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethylprop-2-enamide; (E)-2-Cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethyl-2-propenamide; (E)-2-cyano-3-(3,4-dihydroxy-5-nitro-phenyl)-N,N-diethyl-prop-2-enamide; (E)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethylprop-2-enamide; (E)-alpha-Cyano-N,N-diethyl-3,4-dihydroxy-5-nitrocinnamamide; 2-Cyano-N,N-diethyl-3-(3,4-dihydroxy-5-nitrophenyl)propenamide DMLBVKQ CP Norvatis Phamaceuticals Corporation DMLBVKQ TC Antiparkinson Agents DMLBVKQ DT Small molecular drug DMLBVKQ PC 5281081 DMLBVKQ MW 305.29 DMLBVKQ FM C14H15N3O5 DMLBVKQ IC InChI=1S/C14H15N3O5/c1-3-16(4-2)14(20)10(8-15)5-9-6-11(17(21)22)13(19)12(18)7-9/h5-7,18-19H,3-4H2,1-2H3/b10-5+ DMLBVKQ CS CCN(CC)C(=O)/C(=C/C1=CC(=C(C(=C1)O)O)[N+](=O)[O-])/C#N DMLBVKQ IK JRURYQJSLYLRLN-BJMVGYQFSA-N DMLBVKQ IU (E)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethylprop-2-enamide DMLBVKQ CA CAS 130929-57-6 DMLBVKQ CB CHEBI:4798 DMLBVKQ DE Parkinson disease DM7VTQO ID DM7VTQO DM7VTQO DN Entecavir DM7VTQO HS Approved DM7VTQO SN Baraclude; ETV; Entecavir hydrate; Entecavir monohydrate; BMS-200475; Baraclude (TN); Entecavir (INN); Entecavir (USAN); Entecavir hydrate (JAN); SQ-34676; 2-amino-1,9-dihydro-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one; 2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl]-1,9-dihydro-6H-purin-6-one; 2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl]-1,9-dihydro-6H-purin-6-one-water (1/1); 2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl]-3H-purin-6-one; 6-H-Purin-6-one-,2-amino-1,9-dihydro-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]; 9-((1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl)guanine monohydrate DM7VTQO CP Bristol-Myers Squibb DM7VTQO TC Antiviral Agents DM7VTQO DT Small molecular drug DM7VTQO PC 135398508 DM7VTQO MW 277.28 DM7VTQO FM C12H15N5O3 DM7VTQO IC InChI=1S/C12H15N5O3/c1-5-6(3-18)8(19)2-7(5)17-4-14-9-10(17)15-12(13)16-11(9)20/h4,6-8,18-19H,1-3H2,(H3,13,15,16,20)/t6-,7-,8-/m0/s1 DM7VTQO CS C=C1[C@H](C[C@@H]([C@H]1CO)O)N2C=NC3=C2N=C(NC3=O)N DM7VTQO IK QDGZDCVAUDNJFG-FXQIFTODSA-N DM7VTQO IU 2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl]-1H-purin-6-one DM7VTQO CA CAS 142217-69-4 DM7VTQO CB CHEBI:473990 DM7VTQO DE Hepatitis B virus infection DMK659W ID DMK659W DMK659W DN Enteric-coated mycophenolate sodium DMK659W HS Approved DMK659W SN Myfortic; Mycophenolate sodium; ERL-080; Enteric-coated MPA, Novartis; Enteric-coated mycophenolate sodium, Novartis DMK659W CP Novartis AG DMK659W DE Transplant rejection DMMPTLH ID DMMPTLH DMMPTLH DN Entrectinib DMMPTLH HS Approved DMMPTLH SN 1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK DMMPTLH CP Ignyta DMMPTLH DT Small molecular drug DMMPTLH PC 25141092 DMMPTLH MW 560.6 DMMPTLH FM C31H34F2N6O2 DMMPTLH IC InChI=1S/C31H34F2N6O2/c1-38-8-10-39(11-9-38)25-3-4-26(29(19-25)34-24-6-12-41-13-7-24)31(40)35-30-27-17-20(2-5-28(27)36-37-30)14-21-15-22(32)18-23(33)16-21/h2-5,15-19,24,34H,6-14H2,1H3,(H2,35,36,37,40) DMMPTLH CS CN1CCN(CC1)C2=CC(=C(C=C2)C(=O)NC3=NNC4=C3C=C(C=C4)CC5=CC(=CC(=C5)F)F)NC6CCOCC6 DMMPTLH IK HAYYBYPASCDWEQ-UHFFFAOYSA-N DMMPTLH IU N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methylpiperazin-1-yl)-2-(oxan-4-ylamino)benzamide DMMPTLH CA CAS 1108743-60-7 DMMPTLH DE Solid tumour/cancer; Colorectal cancer; Neuroblastoma; Mammary analogue secretory carcinoma; Non-small cell lung cancer DMGL19D ID DMGL19D DMGL19D DN Enzalutamide DMGL19D HS Approved DMGL19D SN MDV3100; Enzalutamide (AR inhibitor) DMGL19D CP Astellas Pharma DMGL19D DT Small molecular drug DMGL19D SQ 5'-CTCCAACATCAAGGAAGATGGCATTTCTAG DMGL19D PC 15951529 DMGL19D MW 464.4 DMGL19D FM C21H16F4N4O2S DMGL19D IC InChI=1S/C21H16F4N4O2S/c1-20(2)18(31)28(12-5-4-11(10-26)15(8-12)21(23,24)25)19(32)29(20)13-6-7-14(16(22)9-13)17(30)27-3/h4-9H,1-3H3,(H,27,30) DMGL19D CS CC1(C(=O)N(C(=S)N1C2=CC(=C(C=C2)C(=O)NC)F)C3=CC(=C(C=C3)C#N)C(F)(F)F)C DMGL19D IK WXCXUHSOUPDCQV-UHFFFAOYSA-N DMGL19D IU 4-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-sulfanylideneimidazolidin-1-yl]-2-fluoro-N-methylbenzamide DMGL19D CA CAS 915087-33-1 DMGL19D CB CHEBI:68534 DMGL19D DE Prostate cancer DM5OGK0 ID DM5OGK0 DM5OGK0 DN Epalrestat DM5OGK0 HS Approved DM5OGK0 SN epalrestat; 82159-09-9; Kinedak; Epalrestatum; Ono 2235; Ono-2235; Epalrestat [INN]; Epalrestatum [Latin]; ONO-2; 2-((z)-5-((e)-2-methyl-3-phenylallylidene)-4-oxo-2-thioxothiazolidin-3-yl)acetic acid; ONO 2; UNII-424DV0807X; C15H13NO3S2; CHEMBL56337; 5-((1Z,2E)-2-Methyl-3-phenylpropenylidene)-4-oxo-2-thioxo-3-thiazolidineacetic acid; CHEBI:31539; 5-((Z,E)-beta-Methylcinnamylidene)-4-oxo-2-thioxo-3-thiazolidineacetic acid; 424DV0807X; Epalrestatum; Aldorin (TN); Kinedak (TN); Epalrestat (JAN/INN); {5-[(E)-2-Methyl-3-phenyl-prop-2-en-(Z)-ylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-acetic acid; {(5Z)-5-[(2E)-2-methyl-3-phenylprop-2-en-1-ylidene]-4-oxo-2-thioxo-1,3-thiazolidin-3-yl}acetic acid; 2-[(5Z)-5-[(E)-2-methyl-3-phenylprop-2-enylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]acetic acid; 3-carboxymethyl-5-(methyl-3-phenylpropenylidene)rhodanine; Ono 2 DM5OGK0 CP Eskayef Bangladesh Limited DM5OGK0 TC Hypoglycemic Agents DM5OGK0 DT Small molecular drug DM5OGK0 PC 1549120 DM5OGK0 MW 319.4 DM5OGK0 FM C15H13NO3S2 DM5OGK0 IC InChI=1S/C15H13NO3S2/c1-10(7-11-5-3-2-4-6-11)8-12-14(19)16(9-13(17)18)15(20)21-12/h2-8H,9H2,1H3,(H,17,18)/b10-7+,12-8- DM5OGK0 CS C/C(=C\\C1=CC=CC=C1)/C=C\\2/C(=O)N(C(=S)S2)CC(=O)O DM5OGK0 IK CHNUOJQWGUIOLD-NFZZJPOKSA-N DM5OGK0 IU 2-[(5Z)-5-[(E)-2-methyl-3-phenylprop-2-enylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]acetic acid DM5OGK0 CA CAS 82159-09-9 DM5OGK0 CB CHEBI:31539 DM5OGK0 DE Diabetic neuropathy; Pain DMHEAGL ID DMHEAGL DMHEAGL DN Epanova DMHEAGL HS Approved DMHEAGL SN Omefas; Anti-hypertriglycemic (oral/capsule, hypertriglyceridemia/crohn's disease), Omthera DMHEAGL CP Tillotts Pharma AG DMHEAGL DT Small molecular drug DMHEAGL PC 56842239 DMHEAGL MW 909.4 DMHEAGL FM C60H92O6 DMHEAGL IC InChI=1S/C22H32O2.C20H30O2.C18H30O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22(23)24;1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20(21)22;1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18(19)20/h3-4,6-7,9-10,12-13,15-16,18-19H,2,5,8,11,14,17,20-21H2,1H3,(H,23,24);3-4,6-7,9-10,12-13,15-16H,2,5,8,11,14,17-19H2,1H3,(H,21,22);3-4,6-7,9-10H,2,5,8,11-17H2,1H3,(H,19,20)/b4-3-,7-6-,10-9-,13-12-,16-15-,19-18-;4-3-,7-6-,10-9-,13-12-,16-15-;4-3-,7-6-,10-9- DMHEAGL CS CC/C=C\\C/C=C\\C/C=C\\CCCCCCCC(=O)O.CC/C=C\\C/C=C\\C/C=C\\C/C=C\\C/C=C\\CCCC(=O)O.CC/C=C\\C/C=C\\C/C=C\\C/C=C\\C/C=C\\C/C=C\\CCC(=O)O DMHEAGL IK QPEOIOLHJXXJFN-GNGJDXFDSA-N DMHEAGL IU (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoic acid;(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoic acid;(9Z,12Z,15Z)-octadeca-9,12,15-trienoic acid DMHEAGL DE Hypertriglyceridemia DMMV0KW ID DMMV0KW DMMV0KW DN Ephedrine DMMV0KW HS Approved DMMV0KW SN Biophedrin; Eciphin; Efedrin; Ephedral; Ephedremal; Ephedrin; Ephedrital; Ephedrol; Ephedrosan; Ephedrotal; Ephedsol; Ephendronal; Ephoxamin; Fedrin; Kratedyn; Lexofedrin; Manadrin; Mandrin; Nasol; Racephedrine; Sanedrine; Vencipon; Zephrol; CPDD 0049; D-Ephedrine; Ephedrine (TN); Ephedrine (USP); Ephedrine [USAN:BAN]; Ephedrine l-form; I-Sedrin; L-Ephedrine; L(-)-Ephedrine; L-(+)-Ephedrine; L-(-)-Ephedrine; (+)-Ephedrin; (1R,2R)-Ephedrine; (1S,2R)-Ephedrine; (L)-EPHEDRINE; 1-EPHEDRINE; 1-Sedrin DMMV0KW CP Ben Venue Laboratories Inc DMMV0KW TC Central Nervous System Stimulants DMMV0KW DT Small molecular drug DMMV0KW PC 9294 DMMV0KW MW 165.23 DMMV0KW FM C10H15NO DMMV0KW IC InChI=1S/C10H15NO/c1-8(11-2)10(12)9-6-4-3-5-7-9/h3-8,10-12H,1-2H3/t8-,10-/m0/s1 DMMV0KW CS C[C@@H]([C@@H](C1=CC=CC=C1)O)NC DMMV0KW IK KWGRBVOPPLSCSI-WPRPVWTQSA-N DMMV0KW IU (1R,2S)-2-(methylamino)-1-phenylpropan-1-ol DMMV0KW CA CAS 299-42-3 DMMV0KW CB CHEBI:15407 DMMV0KW DE Asthma DMVONE6 ID DMVONE6 DMVONE6 DN Epidermal growth factor DMVONE6 HS Approved DMVONE6 SN 62229-50-9; Urogastrone; Uroenterone; Uroanthelone; Urogastron; Kutrol; beta-Urogastrone; Anthelone U; Urogastrone [JAN]; Gastrone, gamma-uro-; Gastrone, beta-uro- (human); Epidermal growth factor (egf); CCRIS 7234; EINECS 263-468-7; EPIDERMAL GROWTH FACTOR-UROGASTRONE; Gastrone, uro- (9CI); 9010-53-1; Gentel (TN); EGF DMVONE6 DT Small molecular drug DMVONE6 PC 56841751 DMVONE6 MW 6046 DMVONE6 FM C257H381N73O83S7 DMVONE6 IC InChI=1S/C257H381N73O83S7/c1-20-123(15)203(245(404)283-103-192(351)285-157(80-127-42-52-135(339)53-43-127)222(381)313-171(104-331)210(369)281-101-191(350)287-167(92-198(360)361)228(387)290-146(37-27-70-273-255(265)266)213(372)318-177(110-414)238(397)292-148(62-65-185(259)344)217(376)327-205(125(17)337)249(408)294-147(38-28-71-274-256(267)268)212(371)309-168(93-199(362)363)229(388)298-153(76-117(3)4)218(377)289-145(36-26-69-272-254(263)264)211(370)303-162(86-133-96-277-144-35-25-23-33-141(133)144)226(385)304-161(85-132-95-276-143-34-24-22-32-140(132)143)225(384)291-149(63-66-195(354)355)214(373)297-154(77-118(5)6)219(378)296-152(253(412)413)39-29-72-275-257(269)270)326-247(406)202(122(13)14)324-242(401)181(114-418)320-227(386)165(90-188(262)347)307-241(400)180(113-417)322-250(409)206(126(18)338)328-231(390)160(83-130-48-58-138(342)59-49-130)302-234(393)174(107-334)315-230(389)169(94-200(364)365)310-221(380)155(78-119(7)8)299-233(392)173(106-333)314-215(374)150(64-67-196(356)357)295-248(407)204(124(16)21-2)325-232(391)163(87-134-97-271-116-284-134)305-216(375)151(68-75-420-19)293-239(398)179(112-416)321-246(405)201(121(11)12)323-194(353)99-278-189(348)98-279-208(367)164(89-187(261)346)306-220(379)156(79-120(9)10)300-240(399)178(111-415)319-223(382)158(81-128-44-54-136(340)55-45-128)286-190(349)100-280-209(368)166(91-197(358)359)308-224(383)159(82-129-46-56-137(341)57-47-129)301-235(394)175(108-335)316-237(396)176(109-336)317-244(403)184-41-31-74-330(184)252(411)182(115-419)288-193(352)102-282-243(402)183-40-30-73-329(183)251(410)170(84-131-50-60-139(343)61-51-131)311-236(395)172(105-332)312-207(366)142(258)88-186(260)345/h22-25,32-35,42-61,95-97,116-126,142,145-184,201-206,276-277,331-343,414-419H,20-21,26-31,36-41,62-94,98-115,258H2,1-19H3,(H2,259,344)(H2,260,345)(H2,261,346)(H2,262,347)(H,271,284)(H,278,348)(H,279,367)(H,280,368)(H,281,369)(H,282,402)(H,283,404)(H,285,351)(H,286,349)(H,287,350)(H,288,352)(H,289,377)(H,290,387)(H,291,384)(H,292,397)(H,293,398)(H,294,408)(H,295,407)(H,296,378)(H,297,373)(H,298,388)(H,299,392)(H,300,399)(H,301,394)(H,302,393)(H,303,370)(H,304,385)(H,305,375)(H,306,379)(H,307,400)(H,308,383)(H,309,371)(H,310,380)(H,311,395)(H,312,366)(H,313,381)(H,314,374)(H,315,389)(H,316,396)(H,317,403)(H,318,372)(H,319,382)(H,320,386)(H,321,405)(H,322,409)(H,323,353)(H,324,401)(H,325,391)(H,326,406)(H,327,376)(H,328,390)(H,354,355)(H,356,357)(H,358,359)(H,360,361)(H,362,363)(H,364,365)(H,412,413)(H4,263,264,272)(H4,265,266,273)(H4,267,268,274)(H4,269,270,275)/t123-,124-,125+,126+,142-,145-,146-,147-,148-,149-,150-,151-,152-,153-,154-,155-,156-,157-,158-,159-,160-,161-,162-,163-,164-,165-,166-,167-,168-,169-,170-,171-,172-,173-,174-,175-,176-,177-,178-,179-,180-,181-,182-,183-,184-,201-,202-,203-,204-,205-,206-/m0/s1 DMVONE6 CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N[C@@H](CC5=CNC6=CC=CC=C65)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)NC(=O)[C@H](CC7=CN=CN7)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)CNC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC8=CC=C(C=C8)O)NC(=O)CNC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC9=CC=C(C=C9)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CS)NC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)N)N DMVONE6 IK VBEQCZHXXJYVRD-GACYYNSASA-N DMVONE6 IU (4S)-4-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-4-amino-2-[[(2R)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[2-[[2-[[(2S)-4-amino-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[2-[[(2S)-3-carboxy-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2R)-2-[[2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2,4-diamino-4-oxobutanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]-3-sulfanylpropanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]acetyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]acetyl]amino]acetyl]amino]-3-methylbutanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-methylpentanoyl]amino]-4-carboxybutanoyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxybutanoyl]amino]-3-sulfanylpropanoyl]amino]-4-oxobutanoyl]amino]-3-sulfanylpropanoyl]amino]-3-methylbutanoyl]amino]-3-methylpentanoyl]amino]acetyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-carboxypropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-sulfanylpropanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-carboxypropanoyl]amino]-4-methylpentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-[[(2S)-1-[[(1S)-4-carbamimidamido-1-carboxybutyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-oxopentanoic acid DMVONE6 CA CAS 62229-50-9 DMVONE6 DE Vulnerary; Wound healing DMX0K3Q ID DMX0K3Q DMX0K3Q DN Epinastine DMX0K3Q HS Approved DMX0K3Q SN Epinastina; Epinastinum; Purivist; Epinastina [Spanish]; Epinastine [INN]; Epinastinum [Latin]; WAL 80; WAL 801; WAL 801CL; Elestat (TN); Epinastine (INN); Purivist (TN); Relestat (TN); WAL-80 Cl; (+-)-Epinastine; 3-Amino-9,13b-dihydro-1H-dibenz(c,f)imidazo(1,5-a)azepine; 3-amino-9,13b-dihydro-1H-benz(c,f)imidazo(1,5a)azepine; 9,13b-dihydro-1H-dibenzo[c,f]imidazo[1,5-a]azepin-3-amine DMX0K3Q CP Allergan Pharmaceuticals DMX0K3Q TC Antihistamines DMX0K3Q DT Small molecular drug DMX0K3Q PC 3241 DMX0K3Q MW 249.31 DMX0K3Q FM C16H15N3 DMX0K3Q IC InChI=1S/C16H15N3/c17-16-18-10-15-13-7-3-1-5-11(13)9-12-6-2-4-8-14(12)19(15)16/h1-8,15H,9-10H2,(H2,17,18) DMX0K3Q CS C1C2C3=CC=CC=C3CC4=CC=CC=C4N2C(=N1)N DMX0K3Q IK WHWZLSFABNNENI-UHFFFAOYSA-N DMX0K3Q IU 2,4-diazatetracyclo[12.4.0.02,6.07,12]octadeca-1(18),3,7,9,11,14,16-heptaen-3-amine DMX0K3Q CA CAS 80012-43-7 DMX0K3Q CB CHEBI:51032 DMX0K3Q DE Allergic conjunctivitis DM3KJBC ID DM3KJBC DM3KJBC DN Epinephrine DM3KJBC HS Approved DM3KJBC SN ADROP; Adnephrine; Adrenal; Adrenalin; Adrenalina; Adrenaline; Adrenalinum; Adrenamine; Adrenan; Adrenapax; Adrenasol; Adrenatrate; Adrenine; Adrenodis; Adrenohorma; Adrenosan; Adrenutol; Adrin; Adrine; Antiasthmatique; Asthmanefrin; Astmahalin; Astminhal; Balmadren; Bernarenin; Biorenine; Bosmin; Brevirenin; Bronkaid; Chelafrin; Corisol; Drenamist; Dylephrin; Epifrin; Epiglaufrin; Epinefrin; Epinefrina; Epinephran; Epinephrin; Epinephrinum; Epipen; Epirenamine; Epirenan; Epirenin; Epitrate; Eppy; Esphygmogenina; Exadrin; Glaucon; Glaucosan; Glauposine; Glycirenan; Haemostasin; Haemostatin; Hektalin; Hemisine; Hemostasin; Hemostatin; Hypernephrin; Hyporenin; IOP; Intranefrin; Iontocaine; Isoptoepinal; Kidoline; Levoadrenaline; Levoepinephrine; Levorenen; Levorenin; Levorenine; Lyophrin; Metanephrin; Methylaminoethanolcatechol; Methylarterenol; Micronefrin; Micronephrine; Mucidrina; Myosthenine; Mytrate; Nephridine; Nieraline; Paranephrin; Primatene; Racepinephrine; Renagladin; Renaglandin; Renaglandulin; Renaleptine; Renalina; Renoform; Renostypricin; Renostypticin; Renostyptin; Scurenaline; Septocaine; Simplene; Sindrenina; Soladren; Sphygmogenin; Stryptirenal; Styptirenal; Supracapsulin; Supradin; Supranefran; Supranephrane; Supranephrine; Supranol; Suprarenaline; Suprarenin; Suprel; Surenine; Surrenine; Susphrine; Takamina; Takamine; Tokamina; Tonogen; Twinject; Vaponefrin; Vasoconstrictine; Vasoconstrictor; Vasodrine; Vasoton; Vasotonin; ADR ADRENALINE; Adrenalin in Oil; Adrenalina [DCIT]; Asmatane Mist; Asthma meter mist; Asthmahaler Mist; Bronkaid Mist; Bronkaid Suspension Mist; Bupivacaine Hcl and Epinephrine; Citanest Forte; EPI E Z PEN JR; EPIPEN E Z PEN; EPIPEN JR; Epi EZ Pen Jr; Epinefrin [Czech]; Epinephrine hydrochloride; Epipen EZ Pen; Primatene Mist; Racemic Epinephrine; Sympathin I; Adrenalin (TN); Adrenalin-Medihaler; Adrenaline (JP15); Adrenaline/Epinephrine; Ana-Guard; Asthma-nefrin; D-Adrenaline; D-Epifrin; D-Epinephrine; Dyspne-Inhal; Epinefrina [INN-Spanish]; Epinephrine (USP); Epinephrinum [INN-Latin]; Epipen (TN); Epipen Auto-Injector; Epipen Jr.; L-Adrenalin; L-Adrenaline; L-Adrenaline Base; L-Epinehphrine; L-Epinephine; L-Epirenamine; L-Methylaminoethanolcatechol; L-epinephrine; Levo-Methylaminoethanolcatechol; Medihaler-Epi; R-Adrenaline; Sus-Phrine; Twinject 0.15; Twinject 0.3; Twinject 0.30; Epinephrine (USP/INN); Epinephrine [USAN:INN:JAN]; Epipen Jr. Auto-Injector; L-Epinephrine (synthetic); SUS-PHRINE SULFITE-FREE; R-(-)-Epinephrine; L-1-(3,4-Dihydroxyphenyl)-2-methylaminoethanol; (-)-(R)-Epinephrine; (-)-3,4-Dihydroxy-alpha-((methylamino)methyl)benzyl alcohol; (-)-Adrenalin; (-)-Adrenaline; (-)-R-Epinephrine; (R)-(-)-Adnephrine; (R)-(-)-Adrenaline; (R)-(-)-Epinephrine; (R)-(-)-Epirenamine; (R)-4-[1-Hydroxy-2-(methylamino)ethyl]-1,2-benzenediol; (R)-Adrenaline; (R)-Epinephrine; 1-1-(3,4-Dihydroxyphenyl)-2-methylaminoethanol; 1-Adrenalin; 1-Epinephrine; 4-(1-Hydroxy-2-(methylamino)ethyl)-1,2-benzenediol; 4-(1-hydroxy-2-methylamino-ethyl)benzene-1,2-diol; 4-[(1R)-1-Hydroxy-2-(methylamino)ethyl]-1,2-benzenediol; 4-[(1R)-1-hydroxy-2-(methylamino)ethyl]benzene-1,2-diol DM3KJBC TC Vasoconstrictor Agents DM3KJBC DT Small molecular drug DM3KJBC PC 5816 DM3KJBC MW 183.2 DM3KJBC FM C9H13NO3 DM3KJBC IC InChI=1S/C9H13NO3/c1-10-5-9(13)6-2-3-7(11)8(12)4-6/h2-4,9-13H,5H2,1H3/t9-/m0/s1 DM3KJBC CS CNC[C@@H](C1=CC(=C(C=C1)O)O)O DM3KJBC IK UCTWMZQNUQWSLP-VIFPVBQESA-N DM3KJBC IU 4-[(1R)-1-hydroxy-2-(methylamino)ethyl]benzene-1,2-diol DM3KJBC CA CAS 51-43-4 DM3KJBC CB CHEBI:28918 DM3KJBC DE Allergy DMPDW6T ID DMPDW6T DMPDW6T DN Epirubicin DMPDW6T HS Approved DMPDW6T SN Ellence; Epiadriamycin; Epidoxorubicin; Epirubicina; Epirubicine; Epirubicinum; Pidorubicin; Pidorubicina; Pidorubicine; Pidorubicinum; Ridorubicin; Epirubicina [Spanish]; Epirubicine [French]; Epirubicinum [Latin]; Pharmorubicin Pfs; IMI 28; WP 697; Ebewe (TN); Ellence (TN); Epi-DX; Epirubicin (INN); Epirubicin (TN); Epirubicin [INN:BAN]; Epirubicina [INN-Spanish]; Epirubicine [INN-French]; Epirubicinum [INN-Latin]; Farmorubicin (TN); Pharmorubicin (TN); Pidorubicina [INN-Spanish]; Pidorubicine [INN-French]; Pidorubicinum [INN-Latin]; (1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranoside; (1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranoside; (7S,9R)-7-[(2S,4S,5R,6S)-4-Amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S,9S)-7-[(2R,4S,5R,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; 10-((3-amino-2,3,6-trideoxy-beta-L-arabino-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-(8S-cis)-5,12-naphthacenedione; 4'-Epi-DXR; 4'-Epiadriamycin; 4'-epi-DX; 4'-epi-Doxorubicin; 4'-epidoxorubicin; 4-Epidoxorubicin DMPDW6T CP Pfizer Pharmaceuticals DMPDW6T TC Anticancer Agents DMPDW6T DT Small molecular drug DMPDW6T PC 41867 DMPDW6T MW 543.5 DMPDW6T FM C27H29NO11 DMPDW6T IC InChI=1S/C27H29NO11/c1-10-22(31)13(28)6-17(38-10)39-15-8-27(36,16(30)9-29)7-12-19(15)26(35)21-20(24(12)33)23(32)11-4-3-5-14(37-2)18(11)25(21)34/h3-5,10,13,15,17,22,29,31,33,35-36H,6-9,28H2,1-2H3/t10-,13-,15-,17-,22-,27-/m0/s1 DMPDW6T CS C[C@H]1[C@@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O DMPDW6T IK AOJJSUZBOXZQNB-VTZDEGQISA-N DMPDW6T IU (7S,9S)-7-[(2R,4S,5R,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione DMPDW6T CA CAS 56420-45-2 DMPDW6T CB CHEBI:47898 DMPDW6T DE Solid tumour/cancer DMF0NQR ID DMF0NQR DMF0NQR DN Eplerenone DMF0NQR HS Approved DMF0NQR SN Epoxymexrenone; Inspra; Selara; CGP-30083; Inspra (TN); SC-66110; Eplerenone (JAN/USAN/INN); Inspra, Epoxymexrenone, CGP30083, SC-66110,Eplerenone; 7alpha-methoxycarbonyl-3-oxo-9,11alpha-epoxy-17alpha-pregn-4-ene-21,17-carbolactone DMF0NQR CP Pfizer Pharmaceuticals DMF0NQR TC Antihypertensive Agents DMF0NQR DT Small molecular drug DMF0NQR PC 443872 DMF0NQR MW 414.5 DMF0NQR FM C24H30O6 DMF0NQR IC InChI=1S/C24H30O6/c1-21-7-4-14(25)10-13(21)11-15(20(27)28-3)19-16-5-8-23(9-6-18(26)30-23)22(16,2)12-17-24(19,21)29-17/h10,15-17,19H,4-9,11-12H2,1-3H3/t15-,16+,17-,19+,21+,22+,23-,24-/m1/s1 DMF0NQR CS C[C@]12CCC(=O)C=C1C[C@H]([C@@H]3[C@]24[C@H](O4)C[C@]5([C@H]3CC[C@@]56CCC(=O)O6)C)C(=O)OC DMF0NQR IK JUKPWJGBANNWMW-VWBFHTRKSA-N DMF0NQR IU methyl (1R,2S,9R,10R,11S,14R,15S,17R)-2,15-dimethyl-5,5'-dioxospiro[18-oxapentacyclo[8.8.0.01,17.02,7.011,15]octadec-6-ene-14,2'-oxolane]-9-carboxylate DMF0NQR CA CAS 107724-20-9 DMF0NQR CB CHEBI:31547 DMF0NQR DE Heart failure DMKWB73 ID DMKWB73 DMKWB73 DN Epoetin alfa DMKWB73 HS Approved DMKWB73 SN Epogen (TN); Procrit (TN) DMKWB73 CP Amgen Inc DMKWB73 TC Antianemic Agents DMKWB73 DE Anemia DMUTYR2 ID DMUTYR2 DMUTYR2 DN Epoprostenol DMUTYR2 HS Approved DMUTYR2 SN Epoprostanol; Epoprostenolum; Flolan; PGX; Prostacyclin; Prostacycline; Prostacyclins; Vasocyclin; ProstaglandinI; Prostaglandin X; Prostaglandins X; PGI2; Prostacyclin I2; Prostaglandin I2; TRY 200; Epoprostenol (TN); Epoprostenol [USAN:INN]; Epoprostenolum [INN-Latin]; PG-I2; PGI(sub 2); Prostaglandin I(2); Try-200; U 53,217; U-53217; Epoprostenol (USAN/INN); KB-IV-24; (5E)-5-[(3aR,4R,5R,6aS)-5-hydroxy-4-[(E,3R)-3-hydroxyoct-1-enyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]pentanoic acid; (5Z)-5-[(3aR,4R,5R,6aS)-5-hydroxy-4-[(E,3S)-3-hydroxyoct-1-enyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]pentanoic acid; (5Z)-5-[(4R,5R)-5-hydroxy-4-[(E,3S)-3-hydroxyoct-1-enyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]pentanoic acid; (5Z,13E)-(15S)-6,9alpha-Epoxy-11alpha,15-dihydroxyprosta-5,13-dienoate; (5Z,13E,15S)-6,9alpha-epoxy-11alpha,15-dihydroxyprosta-5,13-dienoic acid; (5Z,9alpha,11alpha,13E,15S)-11,15-dihydroxy-6,9-epoxyprosta-5,13-dien-1-oic acid; (5Z,9alpha,11alpha,13E,15S)-6,9-epoxy-11,15-dihydroxyprosta-5,13-dien-1-oic acid; (Z)-(3aR,4R,5R,6aS)-Hexahydro-5-hydroxy-4-((E)-(3S)-3-hydroxy-1-octenyl)-2H-cyclopenta(b)furan-delta(sup 2,delta)-valeric acid; 5-[(3aR,4R,5R,6aS)-5-hydroxy-4-[(3S)-3-hydroxyoct-1-enyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]pentanoic acid; 5-[(3aR,4R,5R,6aS)-5-hydroxy-4-[(E,3S)-3-hydroxyoct-1-enyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]pentanoic acid; 5-[5-hydroxy-4-(3-hydroxyoct-1-enyl)-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]pentanoic acid; 6,9-alpha-Epoxy-11-alpha,15(S)-dihydroxyprosta-5(Z),13(E)-dien-1-oic acid DMUTYR2 TC Antihypertensive Agents DMUTYR2 DT Small molecular drug DMUTYR2 PC 5282411 DMUTYR2 MW 352.5 DMUTYR2 FM C20H32O5 DMUTYR2 IC InChI=1S/C20H32O5/c1-2-3-4-7-14(21)10-11-16-17-12-15(8-5-6-9-20(23)24)25-19(17)13-18(16)22/h8,10-11,14,16-19,21-22H,2-7,9,12-13H2,1H3,(H,23,24)/b11-10+,15-8-/t14-,16+,17+,18+,19-/m0/s1 DMUTYR2 CS CCCCC[C@@H](/C=C/[C@H]1[C@@H](C[C@H]2[C@@H]1C/C(=C/CCCC(=O)O)/O2)O)O DMUTYR2 IK KAQKFAOMNZTLHT-OZUDYXHBSA-N DMUTYR2 IU (5Z)-5-[(3aR,4R,5R,6aS)-5-hydroxy-4-[(E,3S)-3-hydroxyoct-1-enyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]pentanoic acid DMUTYR2 CA CAS 35121-78-9 DMUTYR2 CB CHEBI:15552 DMUTYR2 DE Pulmonary hypertension DM07K2I ID DM07K2I DM07K2I DN Eprosartan DM07K2I HS Approved DM07K2I SN 133040-01-4; Teveten; F-108566; F 108566; UNII-2KH13Z0S0Y; (E)-4-((2-Butyl-5-(2-carboxy-3-(thiophen-2-yl)prop-1-en-1-yl)-1H-imidazol-1-yl)methyl)benzoic acid; (E)-2-Butyl-1-(p-carboxybenzyl)-alpha-2-thenylimidazole-5-acrylic acid; CHEMBL813; SK-108566; 2KH13Z0S0Y; CHEBI:4814; 4-({2-butyl-5-[(1E)-2-carboxy-3-(2-thienyl)prop-1-en-1-yl]-1H-imidazol-1-yl}methyl)benzoic acid; (E)-3-[2-n-butyl-1-{(4-carboxyphenyl)methyl}-1H-imidazol-5-yl]-2-(2-thienyl)methyl-2-propenoic acid; SK&F 108566; SKF-108566; Teveten (TN); Eprosartan (USAN/INN); Eprosartan [USAN:BAN:INN]; SK&F-108566; (4-carboxybenzyl)imidazole-5-acrylic acid; (E)-alpha{[2-butyl-1-[(4-carboxyphenyl)methyl]-1H-imidazole-5-yl]methylene}-2-thiopheneproprionic acid; 4-({2-butyl-5-[(1E)-2-carboxy-3-(thiophen-2-yl)prop-1-en-1-yl]-1H-imidazol-1-yl}methyl)benzoic acid; 4-[[2-butyl-5-[(E)-3-hydroxy-3-oxo-2-(thiophen-2-ylmethyl)prop-1-enyl]imidazol-1-yl]methyl]benzoic acid; [3H]eprosartan DM07K2I CP Abbott Laboratories DM07K2I TC Antihypertensive Agents DM07K2I DT Small molecular drug DM07K2I PC 5281037 DM07K2I MW 424.5 DM07K2I FM C23H24N2O4S DM07K2I IC InChI=1S/C23H24N2O4S/c1-2-3-6-21-24-14-19(12-18(23(28)29)13-20-5-4-11-30-20)25(21)15-16-7-9-17(10-8-16)22(26)27/h4-5,7-12,14H,2-3,6,13,15H2,1H3,(H,26,27)(H,28,29)/b18-12+ DM07K2I CS CCCCC1=NC=C(N1CC2=CC=C(C=C2)C(=O)O)/C=C(\\CC3=CC=CS3)/C(=O)O DM07K2I IK OROAFUQRIXKEMV-LDADJPATSA-N DM07K2I IU 4-[[2-butyl-5-[(E)-2-carboxy-3-thiophen-2-ylprop-1-enyl]imidazol-1-yl]methyl]benzoic acid DM07K2I CA CAS 133040-01-4 DM07K2I CB CHEBI:4814 DM07K2I DE Hypertension DMQXTJS ID DMQXTJS DMQXTJS DN Eptifibatide DMQXTJS HS Approved DMQXTJS SN Integrelin; Integrilin; Intrifiban; HS-2011; Integrilin (TN); SB-1; Sch-60936; N(6)-amidino-N(2)-(3-mercaptopropionyl)-L-lysylglycyl-L-alpha-aspartyl-L-tryptophyl-L-prolyl-L-cysteinamide, cyclic(1-6)-disulfide; N(sup 6)-Amidino-N(sup 2)-(3-mercaptopropionyl)-L-lysylglycyl-L-alpha-aspartyl-L-tryptophyl-L-prolyl-L-cysteinamide, cyclic(1-6)-disulfide; S(1),S(6)-cyclo[N(6)-carbamimidoyl-N(2)-(3-sulfanylpropanoyl)-L-lysylglycyl-L-alpha-aspartyl-L-tryptophyl-L-prolyl-L-cysteinamide]; L-Cysteinamide, N6-(aminoiminomethyl)-N2-(3-mercapto-1-oxopropyl)-L-lysylglycyl-L-alpha-aspartyl-L-tryptophy-L-prolyl-, cyclic (1-6)-disulfide; L-Cysteinamide,N6-(aminoiminomethyl)-N2-(3-mercapto-1-oxopropyl)-L-lysylglycyl-L-alpha-aspartyl-L-tryptophy-L-propyl-,cyclic (1-6)-disulfide; [(3R,11S,17S,20S,25aS)-11-(4-carbamimidamidobutyl)-3-carbamoyl-20-(1H-indol-3-ylmethyl)-1,9,12,15,18,21-hexaoxodocosahydro-7H-pyrrolo[2,1-g][1,2,5,8,11,14,17,20]dithiahexaazacyclotricosin-17-yl]acetic acid; 2-[(3S,6S,12S,20R,23S)-20-carbamoyl-12-[4-(diaminomethylideneamino)butyl]-3-(1H-indol-3-ylmethyl)-2,5,8,11,14,22-hexaoxo-17,18-dithia-1,4,7,10,13,21-hexazabicyclo[21.3.0]hexacosan-6-yl]acetic acid; 2-[20-carbamoyl-12-[4-(diaminomethylideneamino)butyl]-3-(1H-indol-3-ylmethyl)-2,5,8,11,14,22-hexaoxo-17,18-dithia-1,4,7,10,13,21-hexazabicyclo[21.3.0]hexacosan-6-yl]acetic acid DMQXTJS CP Millennium Pharmaceuticals DMQXTJS TC Anticoagulants DMQXTJS DT Small molecular drug DMQXTJS PC 448812 DMQXTJS MW 832 DMQXTJS FM C35H49N11O9S2 DMQXTJS IC InChI=1S/C35H49N11O9S2/c36-30(51)25-18-57-56-13-10-27(47)42-22(8-3-4-11-39-35(37)38)31(52)41-17-28(48)43-23(15-29(49)50)32(53)44-24(14-19-16-40-21-7-2-1-6-20(19)21)34(55)46-12-5-9-26(46)33(54)45-25/h1-2,6-7,16,22-26,40H,3-5,8-15,17-18H2,(H2,36,51)(H,41,52)(H,42,47)(H,43,48)(H,44,53)(H,45,54)(H,49,50)(H4,37,38,39)/t22-,23-,24-,25-,26-/m0/s1 DMQXTJS CS C1C[C@H]2C(=O)N[C@@H](CSSCCC(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N2C1)CC3=CNC4=CC=CC=C43)CC(=O)O)CCCCN=C(N)N)C(=O)N DMQXTJS IK CZKPOZZJODAYPZ-LROMGURASA-N DMQXTJS IU 2-[(3S,6S,12S,20R,23S)-20-carbamoyl-12-[4-(diaminomethylideneamino)butyl]-3-(1H-indol-3-ylmethyl)-2,5,8,11,14,22-hexaoxo-17,18-dithia-1,4,7,10,13,21-hexazabicyclo[21.3.0]hexacosan-6-yl]acetic acid DMQXTJS CA CAS 188627-80-7 DMQXTJS CB CHEBI:291902 DMQXTJS DE Acute cardiac ischemic events DM5LJCI ID DM5LJCI DM5LJCI DN Eptinezumab DM5LJCI HS Approved DM5LJCI CP Alder Biopharmaceuticals Bothell, WA DM5LJCI DE Migraine DMI782S ID DMI782S DMI782S DN Erdafitinib DMI782S HS Approved DMI782S SN 1346242-81-6; UNII-890E37NHMV; 890E37NHMV; Erdafitinib [USAN:INN]; Erdafitinib (USAN/INN); GTPL9039; SCHEMBL2583760; CHEMBL3545376; MolPort-044-560-398; JNJ-42756493 (Erdafitinib); s8401; compound 4 [WO2011135376]; ZINC168520308; AKOS030526429; CS-4988; DB12147; AC-30222; 1,2-Ethanediamine, N1-(3,5-dimethoxyphenyl)-N2-(1-methylethyl)-N1-(3-(1-methyl-1H-pyrazol-4-yl)-6-quinoxalinyl)-; HY-18708; AS-35040; KB-333716; D10927; N'-(3,5-dimethoxyphenyl)-N'-[3-(1-methylpyrazol-4-yl)quino DMI782S CP Janssen Research & Development Raritan, NJ DMI782S PC 67462786 DMI782S MW 446.5 DMI782S FM C25H30N6O2 DMI782S IC InChI=1S/C25H30N6O2/c1-17(2)26-8-9-31(20-10-21(32-4)13-22(11-20)33-5)19-6-7-23-24(12-19)29-25(15-27-23)18-14-28-30(3)16-18/h6-7,10-17,26H,8-9H2,1-5H3 DMI782S CS CC(C)NCCN(C1=CC2=NC(=CN=C2C=C1)C3=CN(N=C3)C)C4=CC(=CC(=C4)OC)OC DMI782S IK OLAHOMJCDNXHFI-UHFFFAOYSA-N DMI782S IU N'-(3,5-dimethoxyphenyl)-N'-[3-(1-methylpyrazol-4-yl)quinoxalin-6-yl]-N-propan-2-ylethane-1,2-diamine DMI782S CA CAS 1346242-81-6 DMI782S DE Lymphoma; Urothelial carcinoma; Bladder cancer; Solid tumour/cancer DM6QFSV ID DM6QFSV DM6QFSV DN Erdosteine DM6QFSV HS Approved DM6QFSV SN Asdigan; Biopulmin; Dostin; Dostol; Drupsan; Ectrin; Edirel; Erdomed; Erdopect; Erdos; Erdotin; Esteclin; Fluidasa; Flusten; Mucoflux; Mucofor; Mucotec; Mucothera; Mukial; Secresolv; Theovix; Tusselin; Vectrine; KW-9144; RV-144 DM6QFSV CP Edmond Pharma DM6QFSV DT Small molecular drug DM6QFSV PC 65632 DM6QFSV MW 249.3 DM6QFSV FM C8H11NO4S2 DM6QFSV IC InChI=1S/C8H11NO4S2/c10-6(3-14-4-7(11)12)9-5-1-2-15-8(5)13/h5H,1-4H2,(H,9,10)(H,11,12) DM6QFSV CS C1CSC(=O)C1NC(=O)CSCC(=O)O DM6QFSV IK QGFORSXNKQLDNO-UHFFFAOYSA-N DM6QFSV IU 2-[2-oxo-2-[(2-oxothiolan-3-yl)amino]ethyl]sulfanylacetic acid DM6QFSV CA CAS 84611-23-4 DM6QFSV CB CHEBI:135014 DM6QFSV DE Bronchitis DMWMCN0 ID DMWMCN0 DMWMCN0 DN Erenumab DMWMCN0 HS Approved DMWMCN0 SN Aimovig; Erenumab [USAN]; UNII-I5I8VB78VT; I5I8VB78VT DMWMCN0 CP Amgen/Novartis DMWMCN0 DE Hyperprolactinaemia DMHO0AR ID DMHO0AR DMHO0AR DN Ergocalciferol DMHO0AR HS Approved DMHO0AR SN Calciferol; Calciferolum; Condacaps; Condocaps; Condol; Crtron; Crystallina; Daral; Davitin; Decaps; Deltalin; Deratol; Detalup; Diactol; Drisdol; Ercalciol; Ergocalciferolo; Ergocalciferols; Ergocalciferolum; Ergorone; Ertron; Fortodyl; Geltabs; Haliver; Hyperkil; Infron; Metadee; Mulsiferol; Mykostin; Ostelin; Radiostol; Radstein; Radsterin; Rodinec; Sterogyl; Vigantol; Viostdrol; Viosterol; CALCIFEROL IN A GELATIN MATRIX; Component of Geltabs Vitamin D; Davitamon D; Divit urto; Ergocalciferolo [DCIT]; Ergosterol activated; Ergosterol irradiated; Geltabs Vitamin D; Irradiated ergosterol; Oleovitamin D; Rodine C; Synthetic Vitamin D; Viosterol in Oil; Calciferon 2; Mina D2; Oleovitamin D2; VITAMIN D2; VITAMIN_D2; Vitamina D2; Buco-D; Calciferol (TN); Calciferol (vitamin D2); D-Arthin; D-Tracetten; De-rat concentrate; Dee-Osterol; Dee-Ron; Dee-Ronal; Dee-Roual; Deltalin (TN); Drisdol (TN); Ergocalciferol (D2); Ergocalciferol: Vitamin D; Ergocalciferolum [INN-Latin]; Ergosterol, irradiated; Hi-Deratol; Novovitamin-D; Oleovitamin D, Synthetic; Shock-ferol; Shock-ferol sterogyl; Sorex C.R; Uvesterol-D; Vio-D; Vitamin d-2; Vitamin-D2; Vitavel-D; Ergocalciferol (JP15/USP); Ergocalciferol [INN:BAN:JAN]; Sorex C.R.; VITAMIN D2 WATER DISPERSABLE U.S.P.; CALCIFEROL, U.S.P.; Irradiated ergosta-5,7,22-trien-3-beta-ol; Irradiated ergosta-5,7,22-trien-3.beta.-ol; (+)-Vitamin D2; (3-beta,5Z,7E,22E)-9,10-Secoergosta-5,7,10,(19),22-tetraen-3-ol; (3S,5Z,7E,14xi,17alpha,22E)-9,10-secoergosta-5,7,10,22-tetraen-3-ol; (3S,5Z,7E,22E)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol; (3S,5Z,7E,22E)-9,10-secoergosta-5,7,10,22-tetraen-3-ol; (3beta,5Z,7E,22E)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol; (5Z,7E,22E)-(3S)-9,10-seco-5,7,10(19),22-ergostatetraen-3-ol; (5Z,7E,22E)-(3S)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol; 7E677DC1-E1C4-4FC5-8F4A-BCE1857F7E87; 9,10,Secoergosta-5,7,10(19),22-tetraen 3.beta.-ol;9,10-Seco(5Z,7E,22E)-5,7,10(19),22-ergostatetraen-3-ol; 9,10-Secoergosta-5,7,10(19),22-tetraen-3-beta-ol DMHO0AR CP Eli Lilly DMHO0AR TC Vitamins DMHO0AR DT Small molecular drug DMHO0AR PC 5280793 DMHO0AR MW 396.6 DMHO0AR FM C28H44O DMHO0AR IC InChI=1S/C28H44O/c1-19(2)20(3)9-10-22(5)26-15-16-27-23(8-7-17-28(26,27)6)12-13-24-18-25(29)14-11-21(24)4/h9-10,12-13,19-20,22,25-27,29H,4,7-8,11,14-18H2,1-3,5-6H3/b10-9+,23-12+,24-13-/t20-,22+,25-,26+,27-,28+/m0/s1 DMHO0AR CS C[C@H](/C=C/[C@H](C)C(C)C)[C@H]1CC[C@@H]\\2[C@@]1(CCC/C2=C\\C=C/3\\C[C@H](CCC3=C)O)C DMHO0AR IK MECHNRXZTMCUDQ-RKHKHRCZSA-N DMHO0AR IU (1S,3Z)-3-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5R)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol DMHO0AR CA CAS 50-14-6 DMHO0AR CB CHEBI:28934 DMHO0AR DE Hypoparathyroidism DMORPBA ID DMORPBA DMORPBA DN Ergoloid mesylate DMORPBA HS Approved DMORPBA SN Alkergot; Circanol; Gerimal; Hydergin; Ischelium; Redergin; Trigot; Dihydroergotoxin Mesilat; Dihydroergotoxinmesylate; Dihydroergotoxin methanesulfonate; Dihydroergotoxine methanesulfonate; Dihydroergotoxine methanesulphonate; Ergoloid Mesylates [USAN]; Hydergine LC; Hydrogenated Ergot Alkaloids; Alkergot (TN); Cicanol (TN); Deapril-ST; Gerimal (TN); Hydergina (TN); Hydergine (TN); Niloric (TN); Redergin (TN); Redizork (TN) DMORPBA CP Sandoz DMORPBA TC Vasodilator Agents DMORPBA DT Small molecular drug DMORPBA PC 592735 DMORPBA MW 591.7 DMORPBA FM C33H45N5O5 DMORPBA IC InChI=1S/C33H45N5O5/c1-7-31(4,5)27-29(40)37-13-9-12-25(37)33(42)38(27)30(41)32(43-33,18(2)3)35-28(39)20-14-22-21-10-8-11-23-26(21)19(16-34-23)15-24(22)36(6)17-20/h8,10-11,16,18,20,22,24-25,27,34,42H,7,9,12-15,17H2,1-6H3,(H,35,39) DMORPBA CS CCC(C)(C)C1C(=O)N2CCCC2C3(N1C(=O)C(O3)(C(C)C)NC(=O)C4CC5C(CC6=CNC7=CC=CC5=C67)N(C4)C)O DMORPBA IK YLXBZBPHTNJZQE-UHFFFAOYSA-N DMORPBA IU N-[2-hydroxy-7-(2-methylbutan-2-yl)-5,8-dioxo-4-propan-2-yl-3-oxa-6,9-diazatricyclo[7.3.0.02,6]dodecan-4-yl]-7-methyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide DMORPBA DE Alzheimer disease DM0VEC1 ID DM0VEC1 DM0VEC1 DN Ergonovine DM0VEC1 HS Approved DM0VEC1 SN Basergin; Ergobasin; Ergobasine; Ergoklinine; Ergometrin; Ergometrina; Ergometrine; Ergometrinum; Ergostetrine; Ergotocine; Ergotrate; Margonovine; Neofemergen; Secacornin; Secometrin; Ergotrate Maleate; Lysergic acid propanolamide; Ergometrina [INN-Spanish]; Ergometrine (INN); Ergometrine [INN:BAN]; Ergometrinum[INN-Latin]; D-Lysergic acid 1-hydroxymethylethylamide; D-Lysergic acid-L-propanolamide; L-Lysergic-L(beta-hydroxyisopropylamide); N-(1-(Hydroxymethyl)ethyl)-D-lysergamide; N-(alpha-(Hydroxymethyl)ethyl)-D-lysergamide; N-(2-Hydroxy-1-methylethyl)-D(+)-lysergamide; N-[(2S)-1-hydroxypropan-2-yl]-6-methyl-9,10-didehydroergoline-8beta-carboxamide; [8beta(S)]-9,10-didehydro-N-(2-hydroxy-1-methylethyl)-6-methylergoline-8-carboxamide; 9,10-Didehydro-N-(2-hydroxy-1-methylethyl)-6-methylergoline-8beta(S)-carboxamide; 9,10-Didehydro-N-(alpha-(hydroxymethyl)ethyl)-6-methylergoline-8-beta-carboxamide DM0VEC1 CP Pfizer Pharmaceuticals DM0VEC1 TC Oxytocics DM0VEC1 DT Small molecular drug DM0VEC1 PC 443884 DM0VEC1 MW 325.4 DM0VEC1 FM C19H23N3O2 DM0VEC1 IC InChI=1S/C19H23N3O2/c1-11(10-23)21-19(24)13-6-15-14-4-3-5-16-18(14)12(8-20-16)7-17(15)22(2)9-13/h3-6,8,11,13,17,20,23H,7,9-10H2,1-2H3,(H,21,24)/t11-,13+,17+/m0/s1 DM0VEC1 CS C[C@@H](CO)NC(=O)[C@H]1CN([C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1)C DM0VEC1 IK WVVSZNPYNCNODU-XTQGRXLLSA-N DM0VEC1 IU (6aR,9R)-N-[(2S)-1-hydroxypropan-2-yl]-7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide DM0VEC1 CA CAS 60-79-7 DM0VEC1 CB CHEBI:4822 DM0VEC1 DE Postpartum haemorrhage DMKR3C5 ID DMKR3C5 DMKR3C5 DN Ergotamine DMKR3C5 HS Approved DMKR3C5 SN Avetol; Cornutamin; Cornutamine; ETIN; Ergam; Ergate; Ergomar; Ergonsvine; Ergostat; Ergotamin; Ergotartrate; Exmigra; Femergin;Gynergen; Lingraine; Lingran; Migretamine; Rigetamin; Secagyn; Secupan; Temigran; Wigrettes; Ergotamine bitartrate; Ergotamine hemitartrate; Ergotamine tartrate; Gotamine tartrate; Medihaler ergotamine; Ergomar (TN); Ergotamina [INN-Spanish]; Ergotamine (INN); Ergotamine [INN:BAN]; Ergotamine tartrate (VAN); Ergotaminum [INN-Latin]; Ergoton-A; Neo-ergotin; Ergotamine, tartrate (2:1); Ergotamine tartrate, Avetol, Cornutamin, Ergam, Ergotartrate; ERGOTAMINE (SEE ALSO: ERGOTAMINE TARTRATE (CAS 379-79-3)); Ergotamine, tartrate (2:1) (salt) (8CI); Ergotaman-3',6',18-trione, 12'-hydroxy-2'-methyl-5'-(phenylmethyl)-, (5'-alpha)-(9CI); Ergotaman-3',6',18-trione, 12'-hydroxy-2'-methyl-5'-(phenylmethyl)-, (5alpha)-, (2R,3R)-2,3-dihydroxybutanedioate (2:1); Ergotaman-3',6',18-trione, 12'-hydroxy-2'-methyl-5'-(phenylmethyl)-, (5'alpha)-, (2R,3R)-2,3-dihydroxybutanedioate (2:1) (salt); (5'A)-5'-benzyl-12'-hydroxy-2'-methyl-3',6',18-trioxoergotaman 2,3-dihydroxybutanedioate(2:1); 12'-Hydroxy-2'-methyl-5'alpha-(phenylmethyl)ergotaman-3',6',18-trione DMKR3C5 CP Eli Lilly DMKR3C5 TC Analgesics DMKR3C5 DT Small molecular drug DMKR3C5 PC 8223 DMKR3C5 MW 581.7 DMKR3C5 FM C33H35N5O5 DMKR3C5 IC InChI=1S/C33H35N5O5/c1-32(35-29(39)21-15-23-22-10-6-11-24-28(22)20(17-34-24)16-25(23)36(2)18-21)31(41)38-26(14-19-8-4-3-5-9-19)30(40)37-13-7-12-27(37)33(38,42)43-32/h3-6,8-11,15,17,21,25-27,34,42H,7,12-14,16,18H2,1-2H3,(H,35,39)/t21-,25-,26+,27+,32-,33+/m1/s1 DMKR3C5 CS C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@H]5CN([C@@H]6CC7=CNC8=CC=CC(=C78)C6=C5)C DMKR3C5 IK XCGSFFUVFURLIX-VFGNJEKYSA-N DMKR3C5 IU (6aR,9R)-N-[(1S,2S,4R,7S)-7-benzyl-2-hydroxy-4-methyl-5,8-dioxo-3-oxa-6,9-diazatricyclo[7.3.0.02,6]dodecan-4-yl]-7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide DMKR3C5 CA CAS 379-79-3 DMKR3C5 CB CHEBI:64318 DMKR3C5 DE Headache DM78IME ID DM78IME DM78IME DN Ergotidine DM78IME HS Approved DM78IME SN Eramin; Ergamine; Histamine; Histaminum; Istamina; Theramine; Free histamine; Histamine Base; Histamine [USAN]; Istamina [Italian]; H7125_SIGMA; [3H]histamine; ALBB-005968; Beta-Aminoethylglyoxaline; Beta-Aminoethylimidazole; Beta-aminothethylglyoxaline; Histamine (DCF); Histamine, Free Base; Histaminum (TN); L-histamine; ZERO/004089; Imidazole-4-ethylamine; Beta-Imidazolyl-4-ethylamine; F411C768-A159-4FC0-A195-291A08BB03AA; 1H-Imidazole-4-ethanamine; 1H-Imidazole-5-ethanamine; 2-(1H-Imidazol-4-yl)ethanamine; 2-(1H-imidazol-4-yl)ethan-1-amine; 2-(1H-imidazol-5-yl)ethanamine; 2-(3H-Imidazol-4-yl)-ethylamine; 2-(4-Imidazolyl)ethylamine; 2-Imidazol-4-ylethylamine; 2-[4-Imidazolyl]ethylamine; 4-(2-Aminoethyl)-1H-imidazole; 4-Imidazoleethylamine; 5-Imidazoleethylamine DM78IME TC Antiallergic Agents DM78IME DT Small molecular drug DM78IME PC 774 DM78IME MW 111.15 DM78IME FM C5H9N3 DM78IME IC InChI=1S/C5H9N3/c6-2-1-5-3-7-4-8-5/h3-4H,1-2,6H2,(H,7,8) DM78IME CS C1=C(NC=N1)CCN DM78IME IK NTYJJOPFIAHURM-UHFFFAOYSA-N DM78IME IU 2-(1H-imidazol-5-yl)ethanamine DM78IME CA CAS 51-45-6 DM78IME CB CHEBI:18295 DM78IME DE Respiratory allergy DM1DX4Q ID DM1DX4Q DM1DX4Q DN Eribulin DM1DX4Q HS Approved DM1DX4Q CP Eisai DM1DX4Q DT Small molecular drug DM1DX4Q PC 11354606 DM1DX4Q MW 729.9 DM1DX4Q FM C40H59NO11 DM1DX4Q IC InChI=1S/C40H59NO11/c1-19-11-24-5-7-28-20(2)12-26(45-28)9-10-40-17-33-36(51-40)37-38(50-33)39(52-40)35-29(49-37)8-6-25(47-35)13-22(42)14-27-31(16-30(46-24)21(19)3)48-32(34(27)44-4)15-23(43)18-41/h19,23-39,43H,2-3,5-18,41H2,1,4H3/t19-,23+,24+,25-,26+,27+,28+,29+,30-,31+,32-,33-,34-,35+,36+,37+,38-,39+,40+/m1/s1 DM1DX4Q CS C[C@@H]1C[C@@H]2CC[C@H]3C(=C)C[C@@H](O3)CC[C@]45C[C@@H]6[C@H](O4)[C@H]7[C@@H](O6)[C@@H](O5)[C@@H]8[C@@H](O7)CC[C@@H](O8)CC(=O)C[C@H]9[C@H](C[C@H](C1=C)O2)O[C@@H]([C@@H]9OC)C[C@@H](CN)O DM1DX4Q IK UFNVPOGXISZXJD-JBQZKEIOSA-N DM1DX4Q IU (1S,3S,6S,9S,12S,14R,16R,18S,20R,21R,22S,26R,29S,31R,32S,33R,35R,36S)-20-[(2S)-3-amino-2-hydroxypropyl]-21-methoxy-14-methyl-8,15-dimethylidene-2,19,30,34,37,39,40,41-octaoxanonacyclo[24.9.2.13,32.13,33.16,9.112,16.018,22.029,36.031,35]hentetracontan-24-one DM1DX4Q CA CAS 253128-41-5 DM1DX4Q CB CHEBI:63587 DM1DX4Q DE Breast cancer DMCMBHA ID DMCMBHA DMCMBHA DN Erlotinib DMCMBHA HS Approved DMCMBHA SN Erlotinin; Tarceva; Erlotinib Base; OSI 744; R 1415; CP 358,774; CP-358774; Erlotinib(Tarceva); Tarceva (TN); CP-358,774; Erlotinib, OS-774; N-(3-ethynylphenyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine; N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-Quinazolinamine; [6,7-BIS(2-METHOXY-ETHOXY)QUINAZOLINE-4-YL]-(3-ETHYNYLPHENYL)AMINE; [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine; 4-[(3-Ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline; 4-[(3-ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline DMCMBHA CP OSI Pharma DMCMBHA TC Anticancer Agents DMCMBHA DT Small molecular drug DMCMBHA PC 176870 DMCMBHA MW 393.4 DMCMBHA FM C22H23N3O4 DMCMBHA IC InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25) DMCMBHA CS COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC DMCMBHA IK AAKJLRGGTJKAMG-UHFFFAOYSA-N DMCMBHA IU N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine DMCMBHA CA CAS 183321-74-6 DMCMBHA CB CHEBI:114785 DMCMBHA DE Non-small-cell lung cancer; Colon cancer; Pancreatic cancer DM4S3O8 ID DM4S3O8 DM4S3O8 DN Ertapenem DM4S3O8 HS Approved DM4S3O8 SN Ertapenem [INN]; Ertapenem (INN); Invanz (TN); (1R,5S,6S,8R,2'S,4'S)-2-(2-(3-carboxyphenylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylic acid; (4R,5S,6S)-3-((3S,5S)-5-((3-carboxyphenyl)carbamoyl)pyrrolidin-3-ylthio)-6-((R)-1-hydroxyethyl)-4-methyl-7-oxo-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylic acid; (4R,5S,6S)-3-({(3S,5S)-5-[(3-carboxyphenyl)carbamoyl]pyrrolidin-3-yl}sulfanyl)-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; (4R,5S,6S)-3-[(3S,5S)-5-[(3-carboxyphenyl)carbamoyl]pyrrolidin-3-yl]sulfanyl-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid DM4S3O8 CP Merck & Co DM4S3O8 TC Antibiotics DM4S3O8 DT Small molecular drug DM4S3O8 PC 150610 DM4S3O8 MW 475.5 DM4S3O8 FM C22H25N3O7S DM4S3O8 IC InChI=1S/C22H25N3O7S/c1-9-16-15(10(2)26)20(28)25(16)17(22(31)32)18(9)33-13-7-14(23-8-13)19(27)24-12-5-3-4-11(6-12)21(29)30/h3-6,9-10,13-16,23,26H,7-8H2,1-2H3,(H,24,27)(H,29,30)(H,31,32)/t9-,10-,13+,14+,15-,16-/m1/s1 DM4S3O8 CS C[C@@H]1[C@@H]2[C@H](C(=O)N2C(=C1S[C@H]3C[C@H](NC3)C(=O)NC4=CC=CC(=C4)C(=O)O)C(=O)O)[C@@H](C)O DM4S3O8 IK JUZNIMUFDBIJCM-ANEDZVCMSA-N DM4S3O8 IU (4R,5S,6S)-3-[(3S,5S)-5-[(3-carboxyphenyl)carbamoyl]pyrrolidin-3-yl]sulfanyl-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid DM4S3O8 CA CAS 153832-46-3 DM4S3O8 CB CHEBI:404903 DM4S3O8 DE Bacterial infection DMFGQ2S ID DMFGQ2S DMFGQ2S DN Erythrityl Tetranitrate DMFGQ2S HS Approved DMFGQ2S SN Cardilate; Cardiloid; Cardivell; Cardiwell; Erythritetranitrat; Nitroerythrit; Nitroerythrite; Nitroerythrol; Tetranitrin; Tetranitrol; Eritritile tetranitrato; Eritritile tetranitrato [DCIT]; Eritrityl tetranitrate; Eritrityli tetranitras; Erythritol tetranitrate; Erythrityl tetranitrate [USAN]; Erythrol tetranitrate; Tetranitrato de eritritilo; Eritrityli tetranitras [INN-Latin]; Erythritol, tetranitrate; Meso-Erythritol tetranitrate; Tetranitrate d'erithrityle; Tetranitrate d'eritrityle; Tetranitrato de eritritilo [INN-Spanish]; Erythritol, tetranitrate (8CI); Tetranitrate d'eritrityle [INN-French]; 1,2,3,4-Butanetetralyl tetranitrate; 1,3,4-trinitrooxybutan-2-yl nitrate DMFGQ2S TC Vasodilator Agents DMFGQ2S DT Small molecular drug DMFGQ2S PC 5284553 DMFGQ2S MW 302.11 DMFGQ2S FM C4H6N4O12 DMFGQ2S IC InChI=1S/C4H6N4O12/c9-5(10)17-1-3(19-7(13)14)4(20-8(15)16)2-18-6(11)12/h3-4H,1-2H2/t3-,4+ DMFGQ2S CS C([C@H]([C@H](CO[N+](=O)[O-])O[N+](=O)[O-])O[N+](=O)[O-])O[N+](=O)[O-] DMFGQ2S IK SNFOERUNNSHUGP-ZXZARUISSA-N DMFGQ2S IU [(2R,3S)-1,3,4-trinitrooxybutan-2-yl] nitrate DMFGQ2S CA CAS 7297-25-8 DMFGQ2S CB CHEBI:60072 DMFGQ2S DE Angina pectoris DM4K7GQ ID DM4K7GQ DM4K7GQ DN Erythromycin DM4K7GQ HS Approved DM4K7GQ SN Abboticin; Abomacetin; Acneryne; Acnesol; Aknemycin; Aknin; AustriaS; Benzamycin; Derimer; Deripil; Dotycin; Dumotrycin; ERY; ERYC; Emgel; Emuvin; Emycin; Endoeritrin; Erecin; Erisone; Eritomicina; Eritrocina; Eritromicina; Ermycin; Eros; Eryacne; Eryacnen; Erycen; Erycette; Erycin; Erycinum; Eryderm; Erydermer; Erygel; Eryhexal; Erymax; Erymed; Erysafe; Erytab; Erythro; Erythroderm; Erythrogran; Erythroguent; Erythromid; Erythromycine; Erythromycinum; Erytop; Erytrociclin; Ilocaps; Iloticina; Ilotycin; Inderm; IndermRetcin; Latotryd; Lederpax; Mephamycin; Mercina; Oftamolets; Paediathrocin; Pantoderm; Pantodrin; Pantomicina; Pharyngocin; Primacine; Propiocine; Proterytrin; Retcin; Robimycin; Romycin; Sansac; Staticin; Stiemicyn; Stiemycin; Tiloryth; Tiprocin; Torlamicina; Wemid; Akne Cordes Losung; Aknederm Ery Gel; Benzamycin Pak; ERYTHROMYCIN STEARATE; Eryc Sprinkles; Erythromycin A; Erythromycin Lactate; Erythromycin Ointment; Erythromycin base; Erythromycin intravenous; Erythromycin sodium lauryl sulfate; Inderm Gel; Oftalmolosa Cusi Eritromicina; Skid Gel E; Theramycin Z; Udima Ery Gel; E0751; Eryc 125; Erythromast 36; Ak-Mycin; Akne-Mycin; Del-Mycin; E-Base; E-Glades; E-Mycin; E-Solve 2; ERYC (base); Emu-V; Emu-Ve; Erimycin-T; Eritromicina [INN-Spanish]; Ery-B; Ery-Diolan; Ery-Sol; Ery-Tab; Ery-maxin; Eryc (TN); Eryc-125; Eryc-250; Erygel (TN); Erythra-Derm; Erythro-Statin; Erythro-Teva; Erythromycin & VRC3375; Erythromycine [INN-French]; Erythromycinum [INN-Latin]; Ilosone (TN); Ilosone (estolate); Ilotycin T.S; Kesso-Mycin; N-Methylerythromycin A; PCE Dispertab (base); Pce (TN); R-P Mycin; Sans-acne; Staticin (TN); T-Stat; Taimoxin-F; A/T/S; Akne-mycin (TN); C-Solve-2; E-Base (base); E-Mycin (base); Ery-Tab (base); Erythromycin [INN:BAN:JAN]; Ilotycin T.S.; T-stat (TN); E-mycin, Erycin, Robimysin; Erythromycin (JP15/USP/INN); Erythromycin, compd. with monododecyl sulfate, sodium salt; Sulfuric acid, monododecyl ester, sodium salt, compd. with erythromycin; Adecane-2,10-dione (non-preferred name); Erythromycin A, T-Stat, Pantomicina, HSDB 3074, Erytab, DRG-0279; Ery DM4K7GQ CP Eli Lilly DM4K7GQ TC Antibiotics DM4K7GQ DT Small molecular drug DM4K7GQ PC 12560 DM4K7GQ MW 733.9 DM4K7GQ FM C37H67NO13 DM4K7GQ IC InChI=1S/C37H67NO13/c1-14-25-37(10,45)30(41)20(4)27(39)18(2)16-35(8,44)32(51-34-28(40)24(38(11)12)15-19(3)47-34)21(5)29(22(6)33(43)49-25)50-26-17-36(9,46-13)31(42)23(7)48-26/h18-26,28-32,34,40-42,44-45H,14-17H2,1-13H3/t18-,19-,20+,21+,22-,23+,24+,25-,26+,28-,29+,30-,31+,32-,34+,35-,36-,37-/m1/s1 DM4K7GQ CS CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O DM4K7GQ IK ULGZDMOVFRHVEP-RWJQBGPGSA-N DM4K7GQ IU (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-4-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecane-2,10-dione DM4K7GQ CA CAS 114-07-8 DM4K7GQ CB CHEBI:42355 DM4K7GQ DE Bacterial infection DMFK9HG ID DMFK9HG DMFK9HG DN Escitalopram DMFK9HG HS Approved DMFK9HG SN Esertia; Escitalopram [INN]; Cipralex (TN); Escitalopram (INN); Esertia (TN); Lexapro (TN); S(+)-Citalopram; (+)-(S)-1-(3-(Dimethylamino)propyl)-1-(p-fluorophenyl)-5-phthalancarbonitrile; (1S)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile; (1S)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3H-2-benzofuran-5-carbonitrile; (S)-Citalopram DMFK9HG CP Forest Laboratories DMFK9HG TC Antidepressants DMFK9HG DT Small molecular drug DMFK9HG PC 146570 DMFK9HG MW 324.4 DMFK9HG FM C20H21FN2O DMFK9HG IC InChI=1S/C20H21FN2O/c1-23(2)11-3-10-20(17-5-7-18(21)8-6-17)19-9-4-15(13-22)12-16(19)14-24-20/h4-9,12H,3,10-11,14H2,1-2H3/t20-/m0/s1 DMFK9HG CS CN(C)CCC[C@@]1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F DMFK9HG IK WSEQXVZVJXJVFP-FQEVSTJZSA-N DMFK9HG IU (1S)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3H-2-benzofuran-5-carbonitrile DMFK9HG CA CAS 128196-01-0 DMFK9HG CB CHEBI:36791 DMFK9HG DE Major depressive disorder DMZREFQ ID DMZREFQ DMZREFQ DN Eslicarbazepine DMZREFQ HS Approved DMZREFQ SN Aptiom; BIA 2-093; Exalief; SEP-0002093; Sep-93; Stedesa; Zebinix DMZREFQ TC Neurology Agents DMZREFQ DT Small molecular drug DMZREFQ PC 9881504 DMZREFQ MW 254.28 DMZREFQ FM C15H14N2O2 DMZREFQ IC InChI=1S/C15H14N2O2/c16-15(19)17-12-7-3-1-5-10(12)9-14(18)11-6-2-4-8-13(11)17/h1-8,14,18H,9H2,(H2,16,19)/t14-/m0/s1 DMZREFQ CS C1[C@@H](C2=CC=CC=C2N(C3=CC=CC=C31)C(=O)N)O DMZREFQ IK BMPDWHIDQYTSHX-AWEZNQCLSA-N DMZREFQ IU (5S)-5-hydroxy-5,6-dihydrobenzo[b][1]benzazepine-11-carboxamide DMZREFQ CA CAS 104746-04-5 DMZREFQ DE Seizure disorder DMREUZV ID DMREUZV DMREUZV DN Eslicarbazepine acetate DMREUZV HS Approved DMREUZV SN Eslicarbazepine acetate; BIA 2-093; Aptiom; Zebinix; Stedesa; Exalief; Eslicarbazepine (acetate); UNII-BEA68ZVB2K; BIA-2-093; (S)-5-Carbamoyl-10,11-dihydro-5H-dibenzo[b,f]azepin-10-yl acetate; Sep 0002093; BIA 2093; BEA68ZVB2K; SEP-0002093; CHEMBL87992; Eslicarbazepine acetate [USAN]; CHEBI:87016; exelief; (S)-(-)-10-Acetoxy-10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide; [(5S)-11-carbamoyl-5,6-dihydrobenzo[b][1]benzazepin-5-yl] acetate; Eslicarbazepine acetate (USAN) DMREUZV PC 179344 DMREUZV MW 296.32 DMREUZV FM C17H16N2O3 DMREUZV IC InChI=1S/C17H16N2O3/c1-11(20)22-16-10-12-6-2-4-8-14(12)19(17(18)21)15-9-5-3-7-13(15)16/h2-9,16H,10H2,1H3,(H2,18,21)/t16-/m0/s1 DMREUZV CS CC(=O)OC1CC2=CC=CC=C2N(C3=CC=CC=C13)C(=O)N DMREUZV IK QIALRBLEEWJACW-INIZCTEOSA-N DMREUZV IU [(5S)-11-carbamoyl-5,6-dihydrobenzo[b][1]benzazepin-5-yl] acetate DMREUZV CA CAS 236395-14-5 DMREUZV CB CHEBI:87016 DMREUZV DE Partial seizures DM51TYR ID DM51TYR DM51TYR DN Esmolol DM51TYR HS Approved DM51TYR SN ASL 8052-001; Brevibloc (TN); Esmolol (INN); Esmolol [INN:BAN]; Methyl p-[2-hydroxy-3-(isopropylamino)propoxy]hydrocinnamate; Methyl p-(2-hydroxy-3-(isopropylamino)propoxy)hydrocinnamate; Methyl 3-[4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]propanoate; Methyl 4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)benzenepropanoate; Methyl 3-[4-({2-hydroxy-3-[(1-methylethyl)amino]propyl}oxy)phenyl]propanoate; Methyl 3-{4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl}propanoate; Benzenepropanoic acid, 4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)-, methyl ester; (+-)-Esmolol; (+-)-methyl p-(2-hydroxy-3-(isopropylamino)propoxy)hydrocinnamate DM51TYR CP Bedford Laboratories DM51TYR TC Antihypertensive Agents DM51TYR DT Small molecular drug DM51TYR PC 59768 DM51TYR MW 295.37 DM51TYR FM C16H25NO4 DM51TYR IC InChI=1S/C16H25NO4/c1-12(2)17-10-14(18)11-21-15-7-4-13(5-8-15)6-9-16(19)20-3/h4-5,7-8,12,14,17-18H,6,9-11H2,1-3H3 DM51TYR CS CC(C)NCC(COC1=CC=C(C=C1)CCC(=O)OC)O DM51TYR IK AQNDDEOPVVGCPG-UHFFFAOYSA-N DM51TYR IU methyl 3-[4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]propanoate DM51TYR CA CAS 81147-92-4 DM51TYR CB CHEBI:88206 DM51TYR DE Acute supraventricular tachycardia DM7BN0X ID DM7BN0X DM7BN0X DN Esomeprazole DM7BN0X HS Approved DM7BN0X SN Esomeprazolum; Nexiam; Inexium paranova; Axagon (TN); Esomeprazole (INN); Esomeprazole [INN:BAN]; Esopral (TN); Inexium paranova (TN); Lucen (TN); Nexiam (TN); Nexium (TN); Sompraz (TN); Zoleri (TN); (S)-(-)-Omeprazole; (S)-Omeprazole; 5-Methoxy-2-((S)-((4-methoxy-3,5-dimethyl-2-pyridyl)methyl)sulfinyl)benzimidazole; 5-methoxy-2-{(S)-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole; 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1-methyl-1H-benzimidazole DM7BN0X CP AstraZeneca DM7BN0X TC Antiulcer Agents DM7BN0X DT Small molecular drug DM7BN0X PC 9568614 DM7BN0X MW 345.4 DM7BN0X FM C17H19N3O3S DM7BN0X IC InChI=1S/C17H19N3O3S/c1-10-8-18-15(11(2)16(10)23-4)9-24(21)17-19-13-6-5-12(22-3)7-14(13)20-17/h5-8H,9H2,1-4H3,(H,19,20)/t24-/m0/s1 DM7BN0X CS CC1=CN=C(C(=C1OC)C)C[S@](=O)C2=NC3=C(N2)C=C(C=C3)OC DM7BN0X IK SUBDBMMJDZJVOS-DEOSSOPVSA-N DM7BN0X IU 6-methoxy-2-[(S)-(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]-1H-benzimidazole DM7BN0X CA CAS 119141-88-7 DM7BN0X CB CHEBI:50275 DM7BN0X DE Peptic ulcer DMZGXUM ID DMZGXUM DMZGXUM DN Estazolam DMZGXUM HS Approved DMZGXUM SN Cannoc; Esilgan; Estazolamum; Eurodin; Julodin; Nemurel; Nuctalon; ProSom; Somnatrol; Tasedan; Abbott Brand of Estazolam; HormonaBrand of Estazolam; Takeda Brand of Estazolam; Abbott 47631; D 40TA; D40TA; U 33737; D-40TA; Estazolamum [INN-Latin]; Eurodin (TN); ProSom (TN); Prosom (TN); Estazolam [USAN:INN:JAN]; Estazolam (JP15/USAN/INN); 4H-(1,2,4)Triazolo(4,3-a)(1,4)benzodiazepine, 8-chloro-6-phenyl; 8-Chloro-6-phenyl-4H-(1,2,4)triazolo-(4,3-a)(1,4)benzodiazepine; 8-Chloro-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine; 8-Chloro-6-phenyl-4H-s-triazolo(4,3-a)(1,4)benzodiazepine; 8-Chloro-6-phenyl-4H-s-triazolo(4,3-a)(1,4)benzodiazepine (IUPAC); 8-Chloro-6-phenyl-4H-s-triazolo[4,3-a][1,4]benzodiazepine; 8-chloro-6-phenyl-4H-s-triazolo[4,3-(alpha)] [1,4]benzodiazepine DMZGXUM TC Anticonvulsants DMZGXUM DT Small molecular drug DMZGXUM PC 3261 DMZGXUM MW 294.74 DMZGXUM FM C16H11ClN4 DMZGXUM IC InChI=1S/C16H11ClN4/c17-12-6-7-14-13(8-12)16(11-4-2-1-3-5-11)18-9-15-20-19-10-21(14)15/h1-8,10H,9H2 DMZGXUM CS C1C2=NN=CN2C3=C(C=C(C=C3)Cl)C(=N1)C4=CC=CC=C4 DMZGXUM IK CDCHDCWJMGXXRH-UHFFFAOYSA-N DMZGXUM IU 8-chloro-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine DMZGXUM CA CAS 29975-16-4 DMZGXUM CB CHEBI:4858 DMZGXUM DE Insomnia DM9KZDO ID DM9KZDO DM9KZDO DN Esterified estrogens DM9KZDO HS Approved DM9KZDO DE Breast cancer DMUNTE3 ID DMUNTE3 DMUNTE3 DN Estradiol DMUNTE3 HS Approved DMUNTE3 SN Aerodiol; Alora; Altrad; Aquadiol; Bardiol; Climaderm; Climara; Compudose; Corpagen; Dermestril; Destradiol; Dihydrofolliculin; Dihydromenformon; Dihydrotheelin; Dihydroxyesterin; Dihydroxyestrin; Dihydroxyoestrin; Dimenformon; Diogyn; Diogynets; Divigel; Elestrin; Encore; Esclim; Estrace; Estraderm; Estradiolo; Estradiolum; Estradot; Estraldine; Estrasorb; Estreva; Estrifam; Estring; Estroclim; Estrodiolum; Estrogel; Estrovite; Evamist; Evorel; Extrasorb; Femanest; Femestral; Femestrol; Fempatch; Femtran; Follicyclin; Gelestra; Ginedisc; Ginosedol; GynPolar; Gynergon; Gynestrel; Gynodiol; Gynoestryl; Innofem; Lamdiol; Macrodiol; Macrol; Menest; Menorest; Microdiol; Nordicol; Oesclim; Oestergon; Oestradiol; Oestradiolum; Oestrogel; Oestroglandol; Oestrogynal; Ovahormon; Ovasterol; Ovastevol; Ovociclina; Ovocyclin; Ovocycline; Ovocylin; Perlatanol; Polyestradiol; Primofol; Profoliol; Progynon; Syndiol; Systen; Tradelia; Trocosone; Vagifem; Vivelle; Zerella; Zesteem; Zesteen; Zumenon; Climara Forte; Component of Menrium; Estraderm MX; Estraderm TTS; Estradiolo [DCIT]; Estradiolum [INN]; Estring vaginal ring; Estrofem Forte; Oestradiol Berco; Oestradiol R; Progynon DH; Sandrena Gel; Sisare Gel; Trial SAT; CMC_11154; Compudose 200; Compudose 365; E 2; E 8875; E0025; Epiestriol 50; Estraderm TTS 100; Estraderm TTS 50; Estrapak 50; Estroclim 50; Estrofem 2; Sandrena 1; [3H]]estradiol; Activella (TN); Alora (TN); Alpha-Oestradiol; AngeliQ (TN); B-Estradiol; Beta-Estradiol; Beta-Oestradiol; Beta-estradiol; Cis-Estradiol; Cis-Oestradiol; Climara (TN); D-Estradiol; D-Oestradiol; Divigel (TN); E(sub 2); Elestrin (TN); Estrace (TN); Estraderm (TN); Estraderm TTS (TN); Estradiol [USAN:INN]; Estradiol acetate (TN); Estradiol cypionate (TN); Estradiol valerate (TN); Estradiol-17 beta; Estradiol-17beta; Estrasorb (TN); Estrasorb Topical (TN); Estring (TN); Estrofem (TN); Estrogel (TN); EvaMist (TN); Femring (TN); Innofem (TN); Menostar (TN); Oestradiol-17beta; Progynon-DH; Progynova (TN); S-21400; SK-Estrogens; SL-1100; VIVELLE-DOT; Vagifem (TN); Vivelle (TN); [3H]-estradiol; Estradiol-17-beta; Estradiol-3,17beta; Oestradiol-17-beta; Vivelle-Dot (TN); D-3,17beta-Estradiol; [2,4,6,7-3H]-E2; 17 beta-Estradiol; 17-.BETA.-Estradiol; 17-beta-OH-estradiol; 17-beta-estradiol; 17.beta.-Estradiol; 17.beta.-Oestradiol; 17b-Oestradiol; 17beta oestradiol; 17beta-Estradiol; 17beta-Oestradiol; 3,17-beta-Estradiol; 3,17-beta-Oestradiol; 3,17.beta.-Estradiol; 3,17beta-Estradiol DMUNTE3 TC Estrogens DMUNTE3 DT Small molecular drug DMUNTE3 PC 5757 DMUNTE3 MW 272.4 DMUNTE3 FM C18H24O2 DMUNTE3 IC InChI=1S/C18H24O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h3,5,10,14-17,19-20H,2,4,6-9H2,1H3/t14-,15-,16+,17+,18+/m1/s1 DMUNTE3 CS C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CCC4=C3C=CC(=C4)O DMUNTE3 IK VOXZDWNPVJITMN-ZBRFXRBCSA-N DMUNTE3 IU (8R,9S,13S,14S,17S)-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol DMUNTE3 CA CAS 17916-67-5 DMUNTE3 CB CHEBI:16469 DMUNTE3 DE Breast cancer DM07U2A ID DM07U2A DM07U2A DN Estradiol acetate DM07U2A HS Approved DM07U2A SN Femring DM07U2A CP Warner Chilcott Ireland Ltd DM07U2A DT Small molecular drug DM07U2A PC 9818306 DM07U2A MW 314.4 DM07U2A FM C20H26O3 DM07U2A IC InChI=1S/C20H26O3/c1-12(21)23-14-4-6-15-13(11-14)3-5-17-16(15)9-10-20(2)18(17)7-8-19(20)22/h4,6,11,16-19,22H,3,5,7-10H2,1-2H3/t16-,17-,18+,19+,20+/m1/s1 DM07U2A CS CC(=O)OC1=CC2=C(C=C1)[C@H]3CC[C@]4([C@H]([C@@H]3CC2)CC[C@@H]4O)C DM07U2A IK FHXBMXJMKMWVRG-SLHNCBLASA-N DM07U2A IU [(8R,9S,13S,14S,17S)-17-hydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-yl] acetate DM07U2A CA CAS 4245-41-4 DM07U2A CB CHEBI:135981 DM07U2A DE Hormone replacement therapy DM27Z5T ID DM27Z5T DM27Z5T DN Estradiol cypionate DM27Z5T HS Approved DM27Z5T SN Depo-estradiol DM27Z5T CP Pharmacia And Upjohn Co DM27Z5T DT Small molecular drug DM27Z5T PC 9403 DM27Z5T MW 396.6 DM27Z5T FM C26H36O3 DM27Z5T IC InChI=1S/C26H36O3/c1-26-15-14-21-20-10-8-19(27)16-18(20)7-9-22(21)23(26)11-12-24(26)29-25(28)13-6-17-4-2-3-5-17/h8,10,16-17,21-24,27H,2-7,9,11-15H2,1H3/t21-,22-,23+,24+,26+/m1/s1 DM27Z5T CS C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2OC(=O)CCC4CCCC4)CCC5=C3C=CC(=C5)O DM27Z5T IK UOACKFBJUYNSLK-XRKIENNPSA-N DM27Z5T IU [(8R,9S,13S,14S,17S)-3-hydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl] 3-cyclopentylpropanoate DM27Z5T CA CAS 313-06-4 DM27Z5T CB CHEBI:34745 DM27Z5T DE Hormone replacement therapy DM8MC6O ID DM8MC6O DM8MC6O DN Estradiol valerate DM8MC6O HS Approved DM8MC6O SN Delestrogen DM8MC6O CP Par Sterile Products Llc DM8MC6O DT Small molecular drug DM8MC6O PC 13791 DM8MC6O MW 356.5 DM8MC6O FM C23H32O3 DM8MC6O IC InChI=1S/C23H32O3/c1-3-4-5-22(25)26-21-11-10-20-19-8-6-15-14-16(24)7-9-17(15)18(19)12-13-23(20,21)2/h7,9,14,18-21,24H,3-6,8,10-13H2,1-2H3/t18-,19-,20+,21+,23+/m1/s1 DM8MC6O CS CCCCC(=O)O[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=C3C=CC(=C4)O)C DM8MC6O IK RSEPBGGWRJCQGY-RBRWEJTLSA-N DM8MC6O IU [(8R,9S,13S,14S,17S)-3-hydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl] pentanoate DM8MC6O CA CAS 979-32-8 DM8MC6O CB CHEBI:31561 DM8MC6O DE Hormone replacement therapy DMLNMEA ID DMLNMEA DMLNMEA DN Estradiol valerate/dienogest DMLNMEA HS Approved DMLNMEA SN Climodien; Climodiene; Dienogest/estradiol valerate; DNG/E2V; E2V/DNG; Klimodien; Lafamme DMLNMEA DT Small molecular drug DMLNMEA PC 9874560 DMLNMEA MW 667.9 DMLNMEA FM C43H57NO5 DMLNMEA IC InChI=1S/C23H32O3.C20H25NO2/c1-3-4-5-22(25)26-21-11-10-20-19-8-6-15-14-16(24)7-9-17(15)18(19)12-13-23(20,21)2;1-19-8-6-16-15-5-3-14(22)12-13(15)2-4-17(16)18(19)7-9-20(19,23)10-11-21/h7,9,14,18-21,24H,3-6,8,10-13H2,1-2H3;12,17-18,23H,2-10H2,1H3/t18-,19-,20+,21+,23+;17-,18+,19+,20-/m11/s1 DMLNMEA CS CCCCC(=O)O[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=C3C=CC(=C4)O)C.C[C@]12CCC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@]2(CC#N)O DMLNMEA IK LRHSUZNWLAJWRT-GAJBHWORSA-N DMLNMEA IU [(8R,9S,13S,14S,17S)-3-hydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl] pentanoate;2-[(8S,13S,14S,17R)-17-hydroxy-13-methyl-3-oxo-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-17-yl]acetonitrile DMLNMEA CA CAS 307334-58-3 DMLNMEA DE Discovery agent DMWTAOI ID DMWTAOI DMWTAOI DN Estramustine DMWTAOI HS Approved DMWTAOI SN Estramustina; Estramustinum; Emcyt (TN); Estramustine (USAN/INN); Estradiol 3-[bis(2-chloroethyl)carbamate]; Ro-22-2296/000; Estra-1,3,5(10)-triene-3,17-diol (17.beta.)-, 3-[bis(2-chloroethyl)carbamate]; [(8R,9S,13S,14S,17S)-17-hydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-yl] N,N-bis(2-chloroethyl)carbamate; (17beta)-17-hydroxyestra-1(10),2,4-trien-3-yl bis(2-chloroethyl)carbamate; 17.beta.-Estradiol 3-[bis(2-chloroethyl)carbamate] DMWTAOI CP Pfizer Pharmaceuticals DMWTAOI TC Anticancer Agents DMWTAOI DT Small molecular drug DMWTAOI PC 259331 DMWTAOI MW 440.4 DMWTAOI FM C23H31Cl2NO3 DMWTAOI IC InChI=1S/C23H31Cl2NO3/c1-23-9-8-18-17-5-3-16(29-22(28)26(12-10-24)13-11-25)14-15(17)2-4-19(18)20(23)6-7-21(23)27/h3,5,14,18-21,27H,2,4,6-13H2,1H3/t18-,19-,20+,21+,23+/m1/s1 DMWTAOI CS C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CCC4=C3C=CC(=C4)OC(=O)N(CCCl)CCCl DMWTAOI IK FRPJXPJMRWBBIH-RBRWEJTLSA-N DMWTAOI IU [(8R,9S,13S,14S,17S)-17-hydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-yl] N,N-bis(2-chloroethyl)carbamate DMWTAOI CA CAS 2998-57-4 DMWTAOI CB CHEBI:4868 DMWTAOI DE Prostate cancer DMOEM2I ID DMOEM2I DMOEM2I DN Estriol DMOEM2I HS Approved DMOEM2I SN Aacifemine; Destriol; Estratriol; Estriel; Estriolo; Gynaesan; Hemostyptanon; Holin; Hormomed; Hormonin; Klimoral; Oestratriol; Oestriol; Oestriolum; Orestin; Orgastyptin; Overstin; Ovestin; Ovestrion; Stiptanon; Synapause; Theelol; Thulol; Tridestrin; Trihydroxyestrin; Trihydroxyoestrin; Triodurin; Triovex; Deuslon A; Estriolo [Italian]; Folicular hormone; Follicular hormone hydrate; Oestriol [Steroidal oestrogens]; A 13610; E0218; OE3; Deuslon-A; Estriel (TN); Estriol [USAN:JAN]; Estriol, unconjugated; Ortho-Gynest; Estriol (JP15/USP); Estra-1,3,5(10)-trien-3,16alpha,17beta-triol; Estra-1,3,5(10)-triene-3,16,17-triol; Estra-1,3,5(10)-triene-3,16alpha,17beta-triol; Oestra-1,3,5(10)-triene-3,16alpha,17beta-triol; Oestra-1,3,5(10)-triene-3,16-alpha,17-beta-triol; Estra-1,3,5(10)-trien-3,16.alpha., 17.beta.-triol; Estra-1,3,5(10)-trien-3,16.alpha.,17.beta.-triol; Estra-1,3,5(10)-triene-3,16.alpha., 17.beta.-triol; Estra-1,3,5(10)-triene-3,16.alpha.,17.beta.-triol; Oestra-1,3,5(10)-triene-3,16.alpha., 17.beta.-triol; Oestra-1,3,5(10)-triene-3,16.alpha.,17.beta.-triol; (16.alpha.,17.beta.)-Estra-1,3,5(10)-triene-3,16,17-triol; (16.alpha.,17.beta.)-Oestra-1,3,5(10)-triene-3,16,17-triol; (16alpha,17beta)-Estra-1,3,5(10)-triene-3,16,17-triol; (16alpha,17beta)-Oestra-1,3,5(10)-triene-3,16,17-triol; 1,3,5(10)-ESTRATRIENE-3,16,17-TRIOL; 1,3,5(10)-Estratriene-3,16-alpha,17beta-triol; 1,3,5(10)-Estratriene-3,16.alpha., 17.beta.-triol; 1,3,5(10)-Estratriene-3,16.alpha.,17.beta.-triol; 1,3,5(10)-Estratriene-3,16alpha,17beta-Triol; 1,3,5-Estratriene-3.beta.,16-.alpha.,17-.beta.-triol; 1,3,5-Estratriene-3beta,16alpha,17beta-triol; 1,3,5-Oestratriene-3-.beta.,16.alpha.,17.beta.-triol; 1,3,5-Oestratriene-3beta,16alpha,17beta-triol; 16,17-Epiestriol; 16-Epiestriol; 16-Hydroxyestradiol; 16-alpha,17-beta-Estriol; 16-alpha,17-beta-Oestriol; 16-alpha-Hydroxyestradiol; 16-alpha-Hydroxyoestradiol; 16.alpha.,17.beta.-Estriol; 16.alpha.,17.beta.-Oestriol; 16.alpha.-Estriol; 16.alpha.-Hydroxy-17.beta.-estradiol; 16.alpha.-Hydroxyestradiol; 16.alpha.-Hydroxyoestradiol; 16alpha,17beta-Estriol; 16alpha,17beta-Oestriol; 16alpha-Hydroxy-17beta-estradiol; 16alpha-Hydroxyestradiol; 16alpha-Hydroxyoestradiol; 3,16-alpha,17-beta-Estriol; 3,16-alpha,17-beta-Oestriol; 3,16-alpha,17-beta-Trihydroxy-delta-1,3,5-estratriene; 3,16-alpha,17-beta-Trihydroxy-delta-1,3,5-oestratriene; 3,16-alpha,17-beta-Trihydroxyestra-1,3,5(10)-triene; 3,16-alpha,17-beta-Trihydroxyoestra-1,3,5(10)-triene; 3,16.alpha.,17.beta.-Estriol; 3,16.alpha.,17.beta.-Trihydroxy-.delta.-1,3,5-estratriene; 3,16.alpha.,17.beta.-Trihydroxy-.delta.-1,3,5-oestratriene; 3,16.alpha.,17.beta.-Trihydroxy-1,3,5(10)-estratriene; 3,16.alpha.,17.beta.-Trihydroxyestra-1,3,5(10)-triene; 3,16alpha,17beta-Estriol; 3,16alpha,17beta-Trihydroxy-1,3,5(10)-estratriene; 3,16alpha,17beta-Trihydroxy-delta-1,3,5-oestratriene; 3,16alpha,17beta-trihydroxy-Delta(1,3,5)-estratriene DMOEM2I CP Pipex Pharmaceuticals DMOEM2I TC Estrogens DMOEM2I DT Small molecular drug DMOEM2I PC 5756 DMOEM2I MW 288.4 DMOEM2I FM C18H24O3 DMOEM2I IC InChI=1S/C18H24O3/c1-18-7-6-13-12-5-3-11(19)8-10(12)2-4-14(13)15(18)9-16(20)17(18)21/h3,5,8,13-17,19-21H,2,4,6-7,9H2,1H3/t13-,14-,15+,16-,17+,18+/m1/s1 DMOEM2I CS C[C@]12CC[C@H]3[C@H]([C@@H]1C[C@H]([C@@H]2O)O)CCC4=C3C=CC(=C4)O DMOEM2I IK PROQIPRRNZUXQM-ZXXIGWHRSA-N DMOEM2I IU (8R,9S,13S,14S,16R,17R)-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,16,17-triol DMOEM2I CA CAS 50-27-1 DMOEM2I CB CHEBI:27974 DMOEM2I DE Hormone deficiency; Multiple sclerosis DMGY0UT ID DMGY0UT DMGY0UT DN Estrogen DMGY0UT HS Approved DMGY0UT DE Menopause symptom DM5T6US ID DM5T6US DM5T6US DN Estrone DM5T6US HS Approved DM5T6US SN Aquacrine; Crinovaryl; Cristallovar; Crystogen; Destrone; Disynformon; Endofolliculina; Esterone; Estrin; Estrol; Estron; Estrona; Estronum; Estrovarin; Estrugenone; Estrusol; Femidyn; Fermidyn; Folikrin; Folipex; Folisan; Follestrine; Follestrol; Folliculin; Folliculine; Follicunodis; Glandubolin; Hiestrone; Hormestrin; Hormofollin; Hormovarine; Kestrone; Ketodestrin; Ketohydroxyestrin; Ketohydroxyoestrin; Ketophydroxyestrin; Kolpon; Menagen; Menformon; Mestronaq; OESTRONE; Oestrin; Oestroform; Oestronum; Oestroperos; Ovifollin; Perlatan; Solliculin; Theelin; Thelestrin; Thelykinin; Thynestron; Tokokin; Unden; Unigen; Wehgen; Wynestron; Estrogenic Substance; Estrona [Spanish]; Femestrone injection; Follicular hormone; Folliculine benzoate; Hauck Brand of Estrone; Hyrex Brand of Estrone; Menformon A; Oestrone [Steroidal oestrogens]; Penncap M; Vortech Brand of Estrone; WynestronPencap M; CMC_13458; E 9750; E0026; E(sub 1); Estrona [INN-Spanish]; Estrone (E1); Estrone (TN); Estrone [USAN:INN]; Estrone-A; Estronum [INN-Latin]; Femestrone inj.; Ketohydroxy-Estratriene; NATURAL ESTROGENIC SUBSTANCE-ESTRONE; Oestrone, Estrone; Ovex (tablets); Unden (pharmaceutical); Unden (pharmaceutical) (VAN); Estrone (JAN/USP/INN); Estrone, (8 alpha)-Isomer; Estrone, (9 beta)-Isomer; Estrone, (+-)-Isomer; [2,4,6,7-3H]-E1; Delta-1,3,5-Estratrien-3beta-ol-17-one; Delta-1,3,5-Oestratrien-3beta-ol-17-one; Delta-1,3,5-estratrien-3-beta-ol-17-one; Delta-1,3,5-oestratrien-3-beta-ol-17-one; (13S)-3-hydroxy-13-methyl-7,8,9,11,12,13,15,16-octahydro-6H-cyclopenta[a]phenanthren-17(14H)-one; (8R,9S,13S,14S)-3-hydroxy-13-methyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-one; 1,3,5(10)-Estratrien-3-ol-17-one; 1,3,5(10)-Oestratrien-3-ol-17-one; 3-Hydroxy-1,3,5(10)-estratrien-17-one; 3-Hydroxy-17-keto-estra-1,3,5-triene; 3-Hydroxy-17-keto-oestra-1,3,5-triene; 3-Hydroxy-oestra-1,3,5(10)-trien-17-one; 3-Hydroxyestra-1,3,5(10)-trien-17-one; 3-Hydroxyestra-1,3,5(10)-triene-17-one; 3-hydroxy-estra-1,3,5(10)-trien-17-one DM5T6US TC Antimenopausal Agents DM5T6US DT Small molecular drug DM5T6US PC 5870 DM5T6US MW 270.4 DM5T6US FM C18H22O2 DM5T6US IC InChI=1S/C18H22O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h3,5,10,14-16,19H,2,4,6-9H2,1H3/t14-,15-,16+,18+/m1/s1 DM5T6US CS C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CCC4=C3C=CC(=C4)O DM5T6US IK DNXHEGUUPJUMQT-CBZIJGRNSA-N DM5T6US IU (8R,9S,13S,14S)-3-hydroxy-13-methyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-one DM5T6US CA CAS 53-16-7 DM5T6US CB CHEBI:17263 DM5T6US DE Menopausal and postmenopausal disorder DMVBIZL ID DMVBIZL DMVBIZL DN Estrone sulfate DMVBIZL HS Approved DMVBIZL SN Estrone 3-sulfate; Estrone hydrogen sulfate; Estrone sulphate; [3H]-estrone hydrogen sulfate; [3H]-estrone-3-sulphate; [3H]estrone-3-sulfate; [3H]estrone-3-sulphate DMVBIZL DT Small molecular drug DMVBIZL PC 3001028 DMVBIZL MW 350.429 DMVBIZL FM C18H22O5S DMVBIZL IC InChI=1S/C18H22O5S/c1-18-9-8-14-13-5-3-12(23-24(20,21)22)10-11(13)2-4-15(14)16(18)6-7-17(18)19/h3,5,10,14-16H,2,4,6-9H2,1H3,(H,20,21,22)/t14-,15-,16+,18+/m1/s1 DMVBIZL CS CC12CCC3C(C1CCC2=O)CCC4=C3C=CC(=C4)OS(=O)(=O)O DMVBIZL IK JKKFKPJIXZFSSB-CBZIJGRNSA-N DMVBIZL IU [(8R,9S,13S,14S)-13-methyl-17-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-yl] hydrogen sulfate DMVBIZL CA CAS 481-97-0 DMVBIZL CB CHEBI:17474 DMVBIZL DE Menopausal symptoms DMRMDWA ID DMRMDWA DMRMDWA DN Estropipate DMRMDWA HS Approved DMRMDWA SN Estropipate; 7280-37-7; Piperazine estrone sulfate; Harmogen; Ogen; Ortho-Est; UNII-SVI38UY019; Piperazine estronesulfate; Sulestrex; SVI38UY019; Estra-1,3,5(10)-trien-17-one, 3-(sulfooxy)-, compd. with piperazine (1:1); OGEN 2.5; Estropipate (USP); OGEN 5; Ogen (TN); OGEN .625; OGEN 1.25; EINECS 230-696-3; piperazine (8R,9S,13S,14S)-13-methyl-17-oxo-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl sulfate; Piperazine oestrone sulphate; Conjugated estrogens: piperazine estrone sulfate; Estrone hydrogen sulf DMRMDWA DT Small molecular drug DMRMDWA PC 5284555 DMRMDWA MW 436.6 DMRMDWA FM C22H32N2O5S DMRMDWA IC InChI=1S/C18H22O5S.C4H10N2/c1-18-9-8-14-13-5-3-12(23-24(20,21)22)10-11(13)2-4-15(14)16(18)6-7-17(18)19;1-2-6-4-3-5-1/h3,5,10,14-16H,2,4,6-9H2,1H3,(H,20,21,22);5-6H,1-4H2/t14-,15-,16+,18+;/m1./s1 DMRMDWA CS C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CCC4=C3C=CC(=C4)OS(=O)(=O)O.C1CNCCN1 DMRMDWA IK HZEQBCVBILBTEP-ZFINNJDLSA-N DMRMDWA IU [(8R,9S,13S,14S)-13-methyl-17-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-yl] hydrogen sulfate;piperazine DMRMDWA CA CAS 7280-37-7 DMRMDWA CB CHEBI:4873 DMRMDWA DE Hypogonadism DM8RZ9H ID DM8RZ9H DM8RZ9H DN Eszopiclone DM8RZ9H HS Approved DM8RZ9H SN Esopiclone; Estorra; Lunesta; Lunivia; Estorra (TN); Eszopiclone [USAN:INN]; KS-1055; SEP-0227018; SEP-0227108; SEP-190; SEP-225441; Eszopiclone (JAN/USAN/INN); [(7S)-6-(5-chloropyridin-2-yl)-5-oxo-7H-pyrrolo[3,4-b]pyrazin-7-yl] 4-methylpiperazine-1-carboxylate; (+)-(5S)-6-(5-Chloropyridin-2-yl)-7-oxo-6,7-dihydro-5H-pyrrolo(3,4-b)pyrazin-5-yl 4-methylpiperazine-1-carboxylate; (5S)-6-(5-Chloropyridin-2-yl)-7-oxo-6,7-dihydro-5H-pyrrolo(3,4-b)pyrazin-5-yl 4-methylpiperazine-1-carboxylate; (5S)-6-(5-chloropyridin-2-yl)-7-oxo-5H,6H,7H-pyrrolo[3,4-b]pyrazin-5-yl 4-methylpiperazine-1-carboxylate; (5S)-6-(5-chloropyridin-2-yl)-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazin-5-yl 4-methylpiperazine-1-carboxylate; (S)-Zopiclone; (plus)-Zopiclone; 1-Piperazinecarboxylic acid, 4-methyl-, (5S)-6-(5-chloro-2-pyridinyl)-6,7-dihydro-7-oxo-5H-pyrrolo(3,4-b)pyrazin-5-yl ester DM8RZ9H CP GSK DM8RZ9H TC Hypnotics and Sedatives DM8RZ9H DT Small molecular drug DM8RZ9H PC 969472 DM8RZ9H MW 388.8 DM8RZ9H FM C17H17ClN6O3 DM8RZ9H IC InChI=1S/C17H17ClN6O3/c1-22-6-8-23(9-7-22)17(26)27-16-14-13(19-4-5-20-14)15(25)24(16)12-3-2-11(18)10-21-12/h2-5,10,16H,6-9H2,1H3/t16-/m0/s1 DM8RZ9H CS CN1CCN(CC1)C(=O)O[C@H]2C3=NC=CN=C3C(=O)N2C4=NC=C(C=C4)Cl DM8RZ9H IK GBBSUAFBMRNDJC-INIZCTEOSA-N DM8RZ9H IU [(7S)-6-(5-chloropyridin-2-yl)-5-oxo-7H-pyrrolo[3,4-b]pyrazin-7-yl] 4-methylpiperazine-1-carboxylate DM8RZ9H CA CAS 138729-47-2 DM8RZ9H CB CHEBI:53760 DM8RZ9H DE Insomnia DMCV109 ID DMCV109 DMCV109 DN Etanercept DMCV109 HS Approved DMCV109 SN Etanercept (sciatica); Etanercept (sciatica), BioAssets Development; Etanercept (sciatica), Cephalon DMCV109 CP AstraZeneca DMCV109 DT Monoclonal antibody DMCV109 SQ Etanercept Sequence: LPAQVAFTPYAPEPGSTCRLREYYDQTAQMCCSKCSPGQHAKVFCTKTSDTVCDSCEDSTYTQLWNWVPECLSCGSRCSSDQVETQACTREQNRICTCRPGWYCALSKQEGCRLCAPLRKCRPGFGVARPGTETSDVVCKPCAPGTFSNTTSSTDICRPHQICNVVAIPGNASMDAVCTSTSPTRSMAPGAVHLPQPVSTRSQHTQPTPEPSTAPSTSFLLPMGPSPPAEGSTGDEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK DMCV109 DE Arthritis; Pemphigus vulgaris; Sciatica DMHP9BL ID DMHP9BL DMHP9BL DN Etelcalcetide DMHP9BL HS Approved DMHP9BL SN Velcalcetide; Parsabiv; UNII-60ME133FJB; 1262780-97-1; 60ME133FJB; etelcalcetide HCl; Etelcalcetide [USAN:INN]; Etelcalcetide (USAN/INN); Etelcalcetide Hydrochloride(AMG-416) DMHP9BL CP Amgen/Kai Pharmaceuticals DMHP9BL DT Small molecular drug DMHP9BL PC 71511839 DMHP9BL MW 1048.3 DMHP9BL FM C38H73N21O10S2 DMHP9BL IC InChI=1S/C38H73N21O10S2/c1-18(28(62)56-22(27(40)61)8-4-12-49-35(41)42)53-30(64)23(9-5-13-50-36(43)44)58-32(66)25(11-7-15-52-38(47)48)59-31(65)24(10-6-14-51-37(45)46)57-29(63)19(2)54-33(67)26(55-20(3)60)17-71-70-16-21(39)34(68)69/h18-19,21-26H,4-17,39H2,1-3H3,(H2,40,61)(H,53,64)(H,54,67)(H,55,60)(H,56,62)(H,57,63)(H,58,66)(H,59,65)(H,68,69)(H4,41,42,49)(H4,43,44,50)(H4,45,46,51)(H4,47,48,52)/t18-,19-,21+,22-,23-,24-,25-,26-/m1/s1 DMHP9BL CS C[C@H](C(=O)N[C@H](CCCN=C(N)N)C(=O)N)NC(=O)[C@@H](CCCN=C(N)N)NC(=O)[C@@H](CCCN=C(N)N)NC(=O)[C@@H](CCCN=C(N)N)NC(=O)[C@@H](C)NC(=O)[C@@H](CSSC[C@@H](C(=O)O)N)NC(=O)C DMHP9BL IK ANIAZGVDEUQPRI-ZJQCGQFWSA-N DMHP9BL IU (2R)-3-[[(2S)-2-acetamido-3-[[(2R)-1-[[(2R)-1-[[(2R)-1-[[(2R)-1-[[(2R)-1-[[(2R)-1-amino-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-oxopropyl]disulfanyl]-2-aminopropanoic acid DMHP9BL CA CAS 1262780-97-1 DMHP9BL CB CHEBI:134700 DMHP9BL DE Secondary hyperparathyroidism; Myelodysplastic syndrome DM2QBHP ID DM2QBHP DM2QBHP DN Eteplirsen DM2QBHP HS Approved DM2QBHP SN AVI-4658 DM2QBHP CP Sarepta Therapeutics DM2QBHP DE Duchenne dystrophy DM5M4NT ID DM5M4NT DM5M4NT DN Ethacrynate sodium DM5M4NT HS Approved DM5M4NT CP Aton Pharma Inc DM5M4NT TC Cardiovascular Agents DM5M4NT DT Small molecular drug DM5M4NT PC 23668825 DM5M4NT MW 325.12 DM5M4NT FM C13H11Cl2NaO4 DM5M4NT IC InChI=1S/C13H12Cl2O4.Na/c1-3-7(2)13(18)8-4-5-9(12(15)11(8)14)19-6-10(16)17;/h4-5H,2-3,6H2,1H3,(H,16,17);/q;+1/p-1 DM5M4NT CS CCC(=C)C(=O)C1=C(C(=C(C=C1)OCC(=O)[O-])Cl)Cl.[Na+] DM5M4NT IK CWCSCNSKBSCYCS-UHFFFAOYSA-M DM5M4NT IU sodium;2-[2,3-dichloro-4-(2-methylidenebutanoyl)phenoxy]acetate DM5M4NT CA CAS 6500-81-8 DM5M4NT DE High blood pressure DM60QMR ID DM60QMR DM60QMR DN Ethacrynic acid DM60QMR HS Approved DM60QMR SN Crinuryl; Edecril; Edecrina; Endecril; Ethacrynate; Hidromedin; Hydromedin; Mingit; Otacril; Reomax; Taladren; Uregit; Acide etacrynique; Acido etacrinico; Acidum etacrynicum; Etacrinic acid; Etacrynic Acid; Etakrinic acid; Ethacrinic acid; Ethacryinic Acid; Kyselina ethakrynova; Kyselina ethakrynova [Czech]; Methylenebutyryl phenoxyacetic acid; Methylenebutyrylphenoxyacetic acid; E0526; MK 595; Acide etacrynique [INN-French]; Acido etacrinico [INN-Spanish]; Acidum etacrynicum [INN-Latin]; Edecrin (TN); Ethacrinique (acide); Ethacrynic Acid, Sodium Salt; Ethacrynic acid (USP); Ethacrynic acid [USAN:BAN]; MK-595; Etacrynic acid (JP15/INN); [2,3-Dichloro-4-(2-methylenebutyryl)phenoxy]acetic acid; [2,3-dichloro-4-(2-methylenebutanoyl)phenoxy]acetic acid; [2,3-dichloro-4-(2-methylidenebutanoyl)phenoxy]acetic acid; [4-(2-Methylenebutyryl)-2,3-dichlorophenoxy]acetic acid; Kyselina 4-(2-(1-butenyl)karbonyl)-2,3-dichlorfenoxyoctova; Kyselina 4-(2-(1-butenyl)karbonyl)-2,3-dichlorfenoxyoctova [Czech]; [2,3-Dichloro-4-(2-methylene-1-oxobutyl)phenoxy]acetic acid; (2,3-Dichloro-4-(2-methylene-1-oxobutyl)phenoxy)acetic acid; (2,3-Dichloro-4-(2-methylenebutyryl)phenoxy)acetic acid; (2,3-Dichloro-4-[2-methylenebutyryl]phenoxy)acetic acid; (4-(2-Methylenebutyryl)-2,3-dichlorophenoxy)acetic acid; 2,3-Dichloro-4(2-methylene-butyryl)phenoxy] acetic acid; 2,3-Dichloro-4-(2-methylenebutyl)phenoxyacetic acid; 2,3-Dichloro-4-(2-methylenebutyryl)phenoxy acetic acid; 2,3-Dichloro-4-(2-methylenebutyryl)phenoxyacetic acid; 2-[2,3-dichloro-4-(2-methylidenebutanoyl)phenoxy]acetic acid DM60QMR TC Diuretics DM60QMR DT Small molecular drug DM60QMR PC 3278 DM60QMR MW 303.13 DM60QMR FM C13H12Cl2O4 DM60QMR IC InChI=1S/C13H12Cl2O4/c1-3-7(2)13(18)8-4-5-9(12(15)11(8)14)19-6-10(16)17/h4-5H,2-3,6H2,1H3,(H,16,17) DM60QMR CS CCC(=C)C(=O)C1=C(C(=C(C=C1)OCC(=O)O)Cl)Cl DM60QMR IK AVOLMBLBETYQHX-UHFFFAOYSA-N DM60QMR IU 2-[2,3-dichloro-4-(2-methylidenebutanoyl)phenoxy]acetic acid DM60QMR CA CAS 58-54-8 DM60QMR CB CHEBI:4876 DM60QMR DE High blood pressure DMR87LC ID DMR87LC DMR87LC DN Ethambutol DMR87LC HS Approved DMR87LC SN Aethambutolum; Diambutol; EMB; Etambutol; Etambutolo; Ethambutolum; Etibi; Miambutol; Myambutol; Purderal; Servambutol; Tibutol; Etambutolo [DCIT]; CL 40881 (dihydrochloride); D-Ethambutol; Etambutol [INN-Spanish]; Ethambutol & EEP; Ethambutol & Propolis; Ethambutol (INN); Ethambutol [INN:BAN]; Ethambutol, meso form; Ethambutol, racemic mixture; Ethambutolum [INN-Latin]; Myambutol (TN); Myambutol (dihydrochloride); Servambutol (TN); Ethambutol, (-)-isomer; D,N,N'-Bis(1-hydroxymethylpropyl)ethylenediamine; D-N,N'-Bis(1-hydroxymethylpropyl)ethylenediamine; D-2,2'-(Ethylenediimino)bis(1-butanol); D-2,2'-(Ethylenediimino)di-1-butanol; (+)-(S,S)-2,2'-(1,2-Ethylenediimino)-di-1-butanol; (+)-2,2'-(Ethylenediimino)di-1-butanol; (+)-N,N'-Bis(1-(hydroxymethyl)propyl)ethylenediamine; (+)-S,S-Ethambutol; (+)-ethambutol; (-)-(R,R)-2,2'-(1,2-Ethylenediimino)-di-1-butanol; (2'S)-2,2'-[Ethane-1,2-diyldi(imino)]dibutan-1-ol; (2R)-2-[2-(1-hydroxybutan-2-ylamino)ethylamino]butan-1-ol; (2R)-2-[2-[[(2R)-1-hydroxybutan-2-yl]amino]ethylamino]butan-1-ol; (2S)-2-[2-(1-hydroxybutan-2-ylamino)ethylamino]butan-1-ol; (2S)-2-[2-[[(2R)-1-hydroxybutan-2-yl]amino]ethylamino]butan-1-ol; (2S,2'S)-2,2'-(ethane-1,2-diyldiimino)dibutan-1-ol; (2S,7S)-2,7-diethyl-3,6-diazaoctane-1,8-diol; (R)-2,2'-(1,2-Ethanediyldiimino)bis-1-butanol; (S,R)-2,2'-(1,2-Ethylenediimino)-di-1-butanol; (S,S)-ethambutol; 2,2'-(1,2-Ethylenediimino)-di-1-butanol; 2,2'-(ethane-1,2-diyldiimino)dibutan-1-ol; 2-[2-(1-hydroxybutan-2-ylamino)ethylamino]butan-1-ol DMR87LC CP Macleods Pharmaceutical. Ltd DMR87LC TC Antitubercular Agents DMR87LC DT Small molecular drug DMR87LC PC 14052 DMR87LC MW 204.31 DMR87LC FM C10H24N2O2 DMR87LC IC InChI=1S/C10H24N2O2/c1-3-9(7-13)11-5-6-12-10(4-2)8-14/h9-14H,3-8H2,1-2H3/t9-,10-/m0/s1 DMR87LC CS CC[C@@H](CO)NCCN[C@@H](CC)CO DMR87LC IK AEUTYOVWOVBAKS-UWVGGRQHSA-N DMR87LC IU (2S)-2-[2-[[(2S)-1-hydroxybutan-2-yl]amino]ethylamino]butan-1-ol DMR87LC CA CAS 74-55-5 DMR87LC CB CHEBI:4877 DMR87LC DE Pulmonary tuberculosis DMDRQZU ID DMDRQZU DMDRQZU DN Ethanol DMDRQZU HS Approved DMDRQZU SN Aethanol; Aethylalkohol; Alcohol; Alcohols; Algrain; Alkohol; Anhydrol; EOH; EOX; EtOH; Etanol; Etanolo; Ethicap; Ethylalcohol; Ethylol; Hinetoless; Hydroxyethane; Jaysol; Methylcarbinol; QMHAIh; Sekundasprit; Spirit; Spirt; Synasol; Tecsol; Thanol; Absolute alcohol; Absolute ethanol; Aethanol [German]; Alcare Hand Degermer; Alcohol [USP]; Alcohol anhydrous; Alcohol dehydrated; Alcohol etilico; Alcool ethylique; Alcool etilico; Alkohol [German]; Alkoholu etylowego; Anhydrous alcohol; Anhydrous ethanol; Cologne Spirit; Colognespirits; Dehydrated alcohol; Dehydrated ethanol; Denatured alcohol; Denatured ethanol; Desinfektol EL; Distilled spirits; Etanolo [Italian]; Ethanol Absolute; Ethanol Absolute Bp; Ethanol Anhydrous; Ethanol Extra Pure; Ethanol Vapor; Ethanol [JAN]; Ethanol solution; Ethanolum anhydricum; Ethyl alc; Ethyl alcohol; Ethyl alcohol usp; Ethyl hydrate; Ethyl hydroxide; Ethylalcohol [Dutch]; Ethyloxy Group; Etylowy alkohol; Fermentation alcohol; Grain alcohol; HYDROXYETHYL GROUP; Infinity Pure; Jaysol S; Methylated spirit; Molasses alcohol; Oxydimethylene Group; Potato alcohol; Reagent Alcohol; SY Fresh M; Spirits of wine; Spiritus vini; Tecsol C; AHD 2000; Anhydrol PM 4085; CDA 19; E7148_ALDRICH; Esumiru WK 88; Ethanol 200 proof; IMS 99; LTBB002977; SDA 3A; Alcohol (USP); Alcohol, Absolute; Alcohol, Grain; Alcohol, anhydrous; Alcohol, dehydrated; Alcohol, diluted; Alcohol, ethyl; Alcohols, C30; CDA 19-200; Ethanol (9CI); Ethanol, undenatured; Ru-Tuss Expectorant; SDA 40-2; SDM No. 37; ALCOHOL 5% IN D5-W; Alcohols, C1-3; Alcohols, C6-9; (C6-C9)Alkyl alcohol; 1-Hydroxyethane; 100C.NPA DMDRQZU TC Analgesics DMDRQZU DT Small molecular drug DMDRQZU PC 702 DMDRQZU MW 46.07 DMDRQZU FM C2H6O DMDRQZU IC InChI=1S/C2H6O/c1-2-3/h3H,2H2,1H3 DMDRQZU CS CCO DMDRQZU IK LFQSCWFLJHTTHZ-UHFFFAOYSA-N DMDRQZU IU ethanol DMDRQZU CA CAS 64-17-5 DMDRQZU CB CHEBI:16236 DMDRQZU DE Cystitis; Chronic pain DM3B654 ID DM3B654 DM3B654 DN Ethanolamine oleate DM3B654 HS Approved DM3B654 SN Ethamolin (TN) DM3B654 DT Small molecular drug DM3B654 PC 5282489 DM3B654 MW 343.5 DM3B654 FM C20H41NO3 DM3B654 IC InChI=1S/C18H34O2.C2H7NO/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18(19)20;3-1-2-4/h9-10H,2-8,11-17H2,1H3,(H,19,20);4H,1-3H2/b10-9-; DM3B654 CS CCCCCCCC/C=C\\CCCCCCCC(=O)O.C(CO)N DM3B654 IK KGWDUNBJIMUFAP-KVVVOXFISA-N DM3B654 IU 2-aminoethanol;(Z)-octadec-9-enoic acid DM3B654 CA CAS 2272-11-9 DM3B654 DE Bleeding disorder DM53IP1 ID DM53IP1 DM53IP1 DN Ethchlorvynol DM53IP1 HS Approved DM53IP1 SN Alvinol; Arvynol; Etchlorvinolo; Etclorvinol; Ethchlorovynol; Ethchlorvinol; Ethchlorvinyl; Ethchlorvynolum;Ethclorvynol; Ethochlorvynol; Ethychlorvynol; Normonson; Normosan; Normoson; Nostel; Nromoson; Placidil; Placidyl; Roeridorm; Serenesil; Serenil; Serensil; Serensiloline; A 71; Aethyl-chlorvynol; Beta-Chlorovinyl ethyl ethynyl carbinol; Beta-Chlorvinyl ethyl ethynyl carbinol; Etclorvinol [INN-Spanish]; Ethchlorvynolum [INN-Latin]; Ethyl beta-chlorovinyl ethynyl carbinol; Placidyl (TN); Ethchlorvynol [USAN:INN:BAN]; Ethchlorvynol (JAN/USP/INN); (E)-1-chloro-3-ethylpent-1-en-4-yn-3-ol; 1-Chloro-3-ethyl-1-penten-4-yn-3-ol; 1-Chloro-3-ethylpent-1-4-yn-3-ol; 1-chloro-3-ethylpent-1-en-4-yn-3-ol; 3-(beta-Chlorovinyl)-1-pentyn-3-ol; 5-Chloro-3-ethylpent-1-yn-4-en-3-ol DM53IP1 CP Abbott Laboratories DM53IP1 TC Hypnotics and Sedatives DM53IP1 DT Small molecular drug DM53IP1 PC 5281077 DM53IP1 MW 144.6 DM53IP1 FM C7H9ClO DM53IP1 IC InChI=1S/C7H9ClO/c1-3-7(9,4-2)5-6-8/h1,5-6,9H,4H2,2H3/b6-5+ DM53IP1 CS CCC(/C=C/Cl)(C#C)O DM53IP1 IK ZEHYJZXQEQOSON-AATRIKPKSA-N DM53IP1 IU (E)-1-chloro-3-ethylpent-1-en-4-yn-3-ol DM53IP1 CA CAS 113-18-8 DM53IP1 CB CHEBI:4882 DM53IP1 DE Insomnia DMK57GB ID DMK57GB DMK57GB DN Ethinamate DMK57GB HS Approved DMK57GB SN Ethinamat; Ethinamatum; Ethinimate; Etinamate; Etinamato; Valamid; Valamin; Valaminetta; Valaminettae; Valaminetten; Valmid; Valmidate; Volamin; Ethynylcyclohexyl carbamate; Carbamate de L'ethinylcyclohexanol; Carbamate de l'ethinylcyclohexanol [French]; Ethinamatum [INN-Latin]; Etinamato [INN-Spanish]; USAF EL-42; Valamin (TN); Valmid (TN); Aethinyl-cyclohexyl-carbamat; Aethinyl-cyclohexyl-carbamat [German]; Carbamic acid, 1-ethynylcyclohexyl ester; Ethinamate (JAN/INN); Ethinamate [INN:BAN:JAN]; Cyclohexanol, 1-ethynyl-, carbamate; Cyclohexanol, 1-ethynyl-, 1-carbamate; (1-ethynylcyclohexyl) carbamate; 1-Ethinylcyclohexyl carbamate; 1-Ethinylcyclohexyl carbonate; 1-Ethynylcyclohexanol carbamate; 1-Ethynylcyclohexyl carbamate; 1-ethynylcyclohexylcarbamate DMK57GB TC Hypnotics and Sedatives DMK57GB DT Small molecular drug DMK57GB PC 3284 DMK57GB MW 167.2 DMK57GB FM C9H13NO2 DMK57GB IC InChI=1S/C9H13NO2/c1-2-9(12-8(10)11)6-4-3-5-7-9/h1H,3-7H2,(H2,10,11) DMK57GB CS C#CC1(CCCCC1)OC(=O)N DMK57GB IK GXRZIMHKGDIBEW-UHFFFAOYSA-N DMK57GB IU (1-ethynylcyclohexyl) carbamate DMK57GB CA CAS 126-52-3 DMK57GB CB CHEBI:4884 DMK57GB DE Insomnia DMODJ40 ID DMODJ40 DMODJ40 DN Ethinyl estradiol DMODJ40 HS Approved DMODJ40 SN Aethinyloestradiolum; Aethinyoestradiol; Amenoron; Amenorone; Anovlar; Certostat; Cyclosa; Dicromil; Diprol; Dyloform; Ertonyl; Esteed; Estigyn; Estinyl; Estopherol; Estoral; Estorals; Ethidol; Ethinoral; Ethinylestradiolum; Ethinylestriol; Ethinyloestradiol; Ethynylestradiol; Ethynyloestradiol; Eticyclin; Eticyclol; Eticylol; Etinestrol; Etinestryl; Etinilestradiol; Etinilestradiolo; Etinoestryl; Etistradiol; Etivex; Feminone; Follicoral; Ginestrene; Inestra; Kolpolyn; Linoral; Lynoral; Menolyn; Microfollin; Novestrol; Oradiol; Orestralyn; Orestrayln; Palonyl; Perovex; Primogyn; Prosexol; Spanestrin; Ylestrol; Aethinyoestradiol [German]; Component of Demulen; Component of Oracon; Component of Ortrel; Diogyn E; Effik Brand of Ethinyl Estradiol; Estoral [Orion]; Ethinyl Estradiol Hemihydrate; Ethinyl Estradiol [USP]; Ethinyl Oestradiol Effik; Ethinylestradiol Jenapharm; Ethinyloestradiol [Steroidal oestrogens]; Ethynyl estradiol; Etinilestradiolo [DCIT]; Jenapharm Brand of Ethinyl Estradiol; Microfollin Forte; Organon Brand of Ethinyl Estradiol; PUBERTAL ETHINYL ESTRADIOL STUDY; Primogyn C; Primogyn M; Progynon C; Progynon M; Schering Brand of Ethinyl Estradiol; EE2; Ethinyl E2; Ethy 11; Diognat-E; Diogyn-E; EE(sub 2); Estinyl (TN); Eston-E; Estoral (Orion); Estoral (VAN); Estradiol, Ethinyl; Estradiol, Ethynyl; Ethinyl estradiol (USP); Ethinyl-Oestradiol Effik; Ethinyl-oestranol; Ethinylestradiolum [INN-Latin]; Ethynylestradiol, Ethinyl Estradiol; Etinilestradiol [INN-Spanish]; Hemihydrate, Ethinyl Estradiol; Jenapharm, Ethinylestradiol; Neo-Estrone; Nogest-S; OVULEN-21; OVULEN-28; Ortho-Cyclen; Chee-O-Gen; Chee-O-Genf; Ethinylestradiol (JP15/INN); Ethinylestradiol [INN:BAN:JAN]; Ethinyl Estradiol, (8 alpha)-Isomer; 17 alpha-Ethinylestradiol; 17 alpha-Ethynylestradiol; 17 alpha-Ethynyloestradiol; 17 alpha-ethinyestradiol; 17-Ethinyl-3,17-estradiol; 17-Ethinyl-3,17-oestradiol; 17-Ethinylestradiol; 17-Ethynylestradiol; 17-Ethynyloestradiol; 17-alpha-Ethinyl-17-beta-estradiol; 17-alpha-Ethynyl-17-beta-oestradiol; 17-alpha-Ethynylestradiol; 17-alpha-Ethynylestradiol-17-beta; 17-alpha-Ethynylestradiol-l7-beta; 17-alpha-Ethynyloestradiol-17-beta; 17-alpha-ethynyl estradiol; 17.alpha.-Ethinyl-17.beta.-estradiol; 17.alpha.-Ethinylestradiol; 17.alpha.-Ethynyl-17.beta.-oestradiol; 17.alpha.-Ethynylestradiol; 17.alpha.-Ethynyloestradiol; 17a-Ethynylestradiol; 17alpha-Ethinyl estradiol; 17alpha-Ethinylestradiol; 17alpha-Ethinylestradiol-17beta; 17alpha-Ethynylestradiol; 17alpha-Ethynyloestradiol; 17alpha-Ethynyloestradiol-17beta DMODJ40 CP Schering-Plough DMODJ40 TC Estrogens DMODJ40 DT Small molecular drug DMODJ40 PC 5991 DMODJ40 MW 296.4 DMODJ40 FM C20H24O2 DMODJ40 IC InChI=1S/C20H24O2/c1-3-20(22)11-9-18-17-6-4-13-12-14(21)5-7-15(13)16(17)8-10-19(18,20)2/h1,5,7,12,16-18,21-22H,4,6,8-11H2,2H3/t16-,17-,18+,19+,20+/m1/s1 DMODJ40 CS C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)O DMODJ40 IK BFPYWIDHMRZLRN-SLHNCBLASA-N DMODJ40 IU (8R,9S,13S,14S,17R)-17-ethynyl-13-methyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthrene-3,17-diol DMODJ40 CA CAS 57-63-6 DMODJ40 CB CHEBI:4903 DMODJ40 DE Female hypogonadism DM8K3EI ID DM8K3EI DM8K3EI DN Ethionamide DM8K3EI HS Approved DM8K3EI SN Aethionamidum; Aetina; Aetiva; Amidazin; Amidazine; Atina; Ethatyl; Ethimide; Ethina; Ethinamide; Ethionamidum; Ethioniamide; Ethylisothiamide; Ethyonomide; Etimid; Etiocidan; Etionamid; Etionamida; Etionamide; Etioniamid; Etionid; Etionizin; Etionizina; Etionizine; Fatoliamid; Iridocin; Iridozin; Isothin; Isotiamida; Itiocide; Nicotion; Nisotin; Nizotin; Rigenicid; Sertinon; Teberus; Thianid; Thianide; Thioamide; Thiomid; Thioniden; Tianid; Tiomid; Trecator; Trekator; Trescatyl; Trescazide; Tubenamide; Tubermin; Tuberoid; Tuberoson; Ethionamid prothionamid; Etionamide [DCIT]; Iridocin Bayer; Trecator SC; Wyeth Brand of Ethionamide; Bayer 5312; Bayer5312; E0695; TH 1314; Alpha-Ethylisonicotinic acid thioamide; Alpha-Ethylisonicotinoylthioamide; Alpha-Ethylisothionicotinamide; Alpha-Ethylthioisonicotinamide; Alpha-ethylt hioisonicotinamide; Ethina (VAN); Ethionamidum [INN-Latin]; Etionamida [INN-Spanish]; Tio-Mid; Trecator-SC; Alpha-Ethyl-thioisonicotinamide; Trecator-SC (TN); Ethionamide (JP15/USP/INN); Ethionamide [USAN:INN:BAN:JAN]; 2-ETHYL-4-PYRIDINECARBOTHIOAMIDE; 2-Ethyl-4-thioamidylpyridine; 2-Ethyl-4-thiocarbamoylpyridine; 2-Ethyl-thioisonicotinamide; 2-Ethylisonicotinic acid thioamide; 2-Ethylisonicotinic thioamide; 2-Ethylisonicotinothioamide; 2-Ethylisonicotinoylthioamide; 2-Ethylisothionicotinamide; 2-Ethylthioisonicotinamide; 2-e thylisothionicotinamide; 2-ethyl-4-aminothiocarbonylpyridine; 2-ethylisonicotinic acid thiomide; 2-ethylpyridine-4-carbothioamide; 2-ethylthioisonicotinamide, Trecator SC, Amidazine, Ethionamide; 3-Ethylisothionicotinamide DM8K3EI TC Antituberculosis Agents DM8K3EI DT Small molecular drug DM8K3EI PC 2761171 DM8K3EI MW 166.25 DM8K3EI FM C8H10N2S DM8K3EI IC InChI=1S/C8H10N2S/c1-2-7-5-6(8(9)11)3-4-10-7/h3-5H,2H2,1H3,(H2,9,11) DM8K3EI CS CCC1=NC=CC(=C1)C(=S)N DM8K3EI IK AEOCXXJPGCBFJA-UHFFFAOYSA-N DM8K3EI IU 2-ethylpyridine-4-carbothioamide DM8K3EI CA CAS 536-33-4 DM8K3EI CB CHEBI:4885 DM8K3EI DE Tuberculosis DM0N3L7 ID DM0N3L7 DM0N3L7 DN Ethopropazine DM0N3L7 HS Approved DM0N3L7 SN Aethopropropazin; Athapropazine; Athopropazin; Ethapropazine; Ethopromazine; Etopropezina; Fempropazine; Fenpropazina; Isopthazine; Isotazin; Isothazine; Isothiazine; Lysivane; Parcidol; Pardidol; Parfezine; Parkin; Parkisol; Parsidan; Parsidol; Parsitan; Parsotil; Phenopropazine; Phenoprozine; Prodictazin; Prodierazine; Profenamina; Profenamine; Profenaminum; Prophenamine; Prophenaminum; Rochipel; Rocipel; Rodipal; Profenamina [Italian]; RP 3356; SC 2538; SKF 2538; W 483; Parkin (TN); Parsidan (TN); Parsidol(TN); Profenamina [INN-Spanish]; Profenamine (INN); Profenamine [INN:BAN]; Profenaminum [INN-Latin]; N,N-Diethyl-alpha-methyl-10H-phenothiazine-10-ethanamine; N,N-diethyl-1-phenothiazin-10-ylpropan-2-amine; N,N-Diethyl-1-(10H-phenothiazin-10-yl)-2-propanamine; N,N-diethyl-1-(10H-phenothiazin-10-yl)propan-2-amine; 10-(2-Diethylaminopropyl)phenothiazine; 10-[2-(Diethylamino)-1-Propyl]phenothiazine;10-[2-(Diethylamino)-2-methylethyl]phenothiazine; 10-[2-(Diethylamino)propyl]phenothiazine; 2-Diethylamino-1-propyl-N-dibenzoparathiazine DM0N3L7 TC Antiparkinson Agents DM0N3L7 DT Small molecular drug DM0N3L7 PC 3290 DM0N3L7 MW 312.5 DM0N3L7 FM C19H24N2S DM0N3L7 IC InChI=1S/C19H24N2S/c1-4-20(5-2)15(3)14-21-16-10-6-8-12-18(16)22-19-13-9-7-11-17(19)21/h6-13,15H,4-5,14H2,1-3H3 DM0N3L7 CS CCN(CC)C(C)CN1C2=CC=CC=C2SC3=CC=CC=C31 DM0N3L7 IK CDOZDBSBBXSXLB-UHFFFAOYSA-N DM0N3L7 IU N,N-diethyl-1-phenothiazin-10-ylpropan-2-amine DM0N3L7 CA CAS 522-00-9 DM0N3L7 CB CHEBI:313639 DM0N3L7 DE Parkinson disease DMDZ9LT ID DMDZ9LT DMDZ9LT DN Ethosuximide DMDZ9LT HS Approved DMDZ9LT SN Aethosuccimidum; Aethosuximide; Asamid; Atysmal; Capitus; Emeside; Ethosuccimid; Ethosuccimide; Ethosuccinimide; Ethosuxide; Ethosuximidum; Ethylmethylsuccimide; Ethymal; Etomal; Etosuccimide; Etosuximid; Etosuximida; Etosuximide; Mesentol; Pemal; Pemalin; Pentinimid; Peptinimid; Petinimid; Petnidan; Piknolepsin; Pyknolepsinum; Ronton; Simatin; Succimal; Succimitin; Suksilep; Suxilep; Suximal; Suxin; Suxinutin; Thetamid; Thilopemal; Zaraondan; Zarodan; Zarondan; Zarontin; Zartalin; Aethosuximide [German]; Desitin Brand of Ethosuximide; Epileo Petit MAL; Etosuccimide [DCIT]; Etosuximida Faes; Faes Brand of Ethosuximide; Fortbenton Brand of Ethosuximide; Jenapharm Brand of Ethosuximide; Katwijk Brand of Ethosuximide; LAB Brand of Ethosuximide; Parke Davis Brand of Ethosuximide; Pfizer Brand of Ethosuximide; United Drug Brand of Ethosuximide; Warner Lambert Brand of Ethosuximide; Wernigerode Brand of Ethosuximide; Cl 366; E 7138; E0746; H 940; PM 671; CN-10395; Ethosuximidum [INN-Latin]; Etosuximida [INN-Spanish]; Faes, Etosuximida; H-490; N-Ethyl methylsuccinimide; PM-671; Simatin(E); Warner-Lambert Brand of Ethosuximide; Zarondan-Saft; Zarontin (TN); C.I. 366; CN-10,395; Piknole.psi.n; Pyknole.psi.num; Alpha-Ethyl-alpha-methylsuccinimide; Alpha-Methyl-alpha-ethylsuccinimide; Ethosuximide (JP15/USP/INN); Ethosuximide [USAN:INN:BAN:JAN]; Gamma-Methyl-gamma-ethylsuccinimide; Gamma-Methyl-gamma-ethyl-succinimide; Gamma-ethyl-gamma-methyl-succinimide; (+-)-2-Ethyl-2-methylsuccinimide; 2-Ethyl-2-methylsuccinimide; 2-Methyl-2-ethylsuccinimide; 3-Ethyl-3-methyl-2, 5-pyrrolidinedion; 3-Ethyl-3-methyl-2,5-pyrrolidinedione; 3-Ethyl-3-methylpyrrolidine-2,5-dione; 3-Ethyl-3-methylpyrroline-2,5-dione; 3-Ethyl-3-methylsuccinimide; 3-Methyl-3-ethylpyrrolidine-2,5-dione; 3-Methyl-3-ethylsuccinimide DMDZ9LT CP Pfizer DMDZ9LT TC Analgesics DMDZ9LT DT Small molecular drug DMDZ9LT PC 3291 DMDZ9LT MW 141.17 DMDZ9LT FM C7H11NO2 DMDZ9LT IC InChI=1S/C7H11NO2/c1-3-7(2)4-5(9)8-6(7)10/h3-4H2,1-2H3,(H,8,9,10) DMDZ9LT CS CCC1(CC(=O)NC1=O)C DMDZ9LT IK HAPOVYFOVVWLRS-UHFFFAOYSA-N DMDZ9LT IU 3-ethyl-3-methylpyrrolidine-2,5-dione DMDZ9LT CA CAS 77-67-8 DMDZ9LT CB CHEBI:4887 DMDZ9LT DE Epilepsy DMXWOCP ID DMXWOCP DMXWOCP DN Ethotoin DMXWOCP HS Approved DMXWOCP SN Accenon; Ethotoine; Ethotoinum; Etotoina; Peganone; Pegoanone; Abbott brand of ethotoin; Accenon (TN); Ethotoine [INN-French]; Ethotoinum [INN-Latin]; Etotoina [INN-Spanish]; Peganone (TN); Ethotoin [INN:BAN:JAN]; Ethotoin (JAN/USP/INN); (+-)-3-Ethyl-5-phenylhydantoin; 1-Ethyl-2,5-dioxo-4-phenylimidazolidine; 3-Ethyl-5-phenyl-2,4-imidazolidinedione; 3-Ethyl-5-phenylhydantoin; 3-Ethyl-5-phenylimidazolidin-2,4-dione; 3-ethyl-5-phenylimidazolidine-2,4-dione DMXWOCP CP Ovation Pharmaceuticals DMXWOCP TC Anticonvulsants DMXWOCP DT Small molecular drug DMXWOCP PC 3292 DMXWOCP MW 204.22 DMXWOCP FM C11H12N2O2 DMXWOCP IC InChI=1S/C11H12N2O2/c1-2-13-10(14)9(12-11(13)15)8-6-4-3-5-7-8/h3-7,9H,2H2,1H3,(H,12,15) DMXWOCP CS CCN1C(=O)C(NC1=O)C2=CC=CC=C2 DMXWOCP IK SZQIFWWUIBRPBZ-UHFFFAOYSA-N DMXWOCP IU 3-ethyl-5-phenylimidazolidine-2,4-dione DMXWOCP CA CAS 86-35-1 DMXWOCP CB CHEBI:4888 DMXWOCP DE Complex partial seizure DMVO4ED ID DMVO4ED DMVO4ED DN Ethoxzolamide DMVO4ED HS Approved DMVO4ED SN ethoxzolamide; Ethoxyzolamide; Ethoxazolamide; Ethamide; Etoxzolamide; Cardrase; 6-Ethoxy-2-benzothiazolesulfonamide; 452-35-7; Glaucotensil; Diuretic C; 6-Ethoxy-1,3-benzothiazole-2-sulfonamide; Mingoral; 2-Benzothiazolesulfonamide, 6-ethoxy-; Redupresin; 6-Ethoxybenzo[d]thiazole-2-sulfonamide; 6-Ethoxyzolamide; 6-Ethoxybenzothiazole-2-sulfonamide; 6-Ethoxybenzothiazole-2-sulphonamide; U-4191; NSC 10679; UNII-Z52H4811WX; C9H10N2O3S2; HSDB 3268; CHEMBL18; EINECS 207-199-5; BRN 0212240; MLS000028637; AI3-50805; Cardrase; EZL; Cardrase (TN); Ethoxzolamide (EZA); 6-(ethyloxy)-1,3-benzothiazole-2-sulfonamide; 6-Ethoxy-benzothiazole-2-sulfonic acid amide; 6-ethoxy-1,3-benzothiazole-2-sulfonamide DMVO4ED TC Diuretics DMVO4ED DT Small molecular drug DMVO4ED PC 3295 DMVO4ED MW 258.3 DMVO4ED FM C9H10N2O3S2 DMVO4ED IC InChI=1S/C9H10N2O3S2/c1-2-14-6-3-4-7-8(5-6)15-9(11-7)16(10,12)13/h3-5H,2H2,1H3,(H2,10,12,13) DMVO4ED CS CCOC1=CC2=C(C=C1)N=C(S2)S(=O)(=O)N DMVO4ED IK OUZWUKMCLIBBOG-UHFFFAOYSA-N DMVO4ED IU 6-ethoxy-1,3-benzothiazole-2-sulfonamide DMVO4ED CA CAS 452-35-7 DMVO4ED CB CHEBI:101096 DMVO4ED DE Glaucoma/ocular hypertension; Duodenal ulcer DM20VMW ID DM20VMW DM20VMW DN Ethylestrenol DM20VMW HS Approved DM20VMW SN Maxibolin DM20VMW CP Organon Usa Inc DM20VMW DT Small molecular drug DM20VMW PC 13765 DM20VMW MW 288.5 DM20VMW FM C20H32O DM20VMW IC InChI=1S/C20H32O/c1-3-20(21)13-11-18-17-9-8-14-6-4-5-7-15(14)16(17)10-12-19(18,20)2/h6,15-18,21H,3-5,7-13H2,1-2H3/t15-,16+,17+,18-,19-,20-/m0/s1 DM20VMW CS CC[C@@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CCCC[C@H]34)C)O DM20VMW IK AOXRBFRFYPMWLR-XGXHKTLJSA-N DM20VMW IU (8R,9S,10R,13S,14S,17S)-17-ethyl-13-methyl-2,3,6,7,8,9,10,11,12,14,15,16-dodecahydro-1H-cyclopenta[a]phenanthren-17-ol DM20VMW CA CAS 965-90-2 DM20VMW CB CHEBI:31578 DM20VMW DE Testosterone deficiency DMZM84R ID DMZM84R DMZM84R DN Ethynodiol diacetate DMZM84R HS Approved DMZM84R SN Cervicundin; Continuin; Femulen; Luteonorm; Metrodiol; Ethinodiol diacetate; Ethyndiol Diacetate; Ethynodiol diacetate [Progestins]; Ethynodiol diacetate [USAN]; Etynodiol Acetate; Metrodiol diacetate; Ovulen 50; SC 11800; Etynodiol di(acetate); Luto-metrodiol; SC-11800; Ethynodiol diacetate (JAN/USP);[(3S,8R,9S,10R,13S,14S,17R)-17-acetyloxy-17-ethynyl-13-methyl-2,3,6,7,8,9,10,11,12,14,15,16-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl] acetate; (3 beta, 17 alpha)-19-Norpregn-4-en-20-yne-3,17 diolDiacetate; (3-beta,17-alpha)-19-Norpregn-4-en-20-yne-3,17-diol diacetate; (3beta,17beta)-17-ethynylestr-4-ene-3,17-diyl diacetate; 17-alpha-Ethynyl-19-norandrost-4-ene-3-beta,17-beta-diol diacetate; 17-alpha-Ethynyl-3,17-dihydroxy-4-estrene diacetate; 17-alpha-Ethynyl-4-estrene-3-beta,17-beta-diol diacetate; 17-alpha-Ethynylestr-4-ene-3-beta,17-beta-diol acetate; 17alpha-Ethynyl-19-norandrost-4-ene-3beta,17-beta-diol diacetate; 17alpha-Ethynyl-3,17-dihydroxy-4-estrene diacetate; 17alpha-Ethynyl-4-estrene-3beta,17beta-diol diacetate; 17alpha-Ethynylestr-4-ene-3beta,17beta-diol acetate; 17alpha-ethynylestr-4-ene-3beta,17beta-diyl diacetate; 19-Nor-17-alpha-pregn-4-en-20-yne-3-beta,17-diol diacetate; 19-Nor-17-alpha-pregn-4-en-20-yne-3-beta,17-diol, diacetate; 19-Nor-17alpha-pregn-4-en-20-yne-3beta,17-diol diacetate; 3-beta, 17-beta-Diacetoxy-17-alpha-ethynyl-4-oestrene; 3-beta,17-beta-Diacetoxy-19-nor-17-alpha-pregn-4-en-20-yne; 3beta, 17beta-Diacetoxy-17alpha-ethynyl-4-oestrene; 3beta,17beta-Diacetoxy-17alpha-ethynyl-4-estrene; 3beta,17beta-Diacetoxy-19-nor-17alpha-pregn-4-en-20-yne DMZM84R TC Contraceptive Agents DMZM84R DT Small molecular drug DMZM84R PC 9270 DMZM84R MW 384.5 DMZM84R FM C24H32O4 DMZM84R IC InChI=1S/C24H32O4/c1-5-24(28-16(3)26)13-11-22-21-8-6-17-14-18(27-15(2)25)7-9-19(17)20(21)10-12-23(22,24)4/h1,14,18-22H,6-13H2,2-4H3/t18-,19-,20+,21+,22-,23-,24-/m0/s1 DMZM84R CS CC(=O)O[C@H]1CC[C@@H]2[C@H]3CC[C@]4([C@H]([C@@H]3CCC2=C1)CC[C@]4(C#C)OC(=O)C)C DMZM84R IK ONKUMRGIYFNPJW-KIEAKMPYSA-N DMZM84R IU [(3S,8R,9S,10R,13S,14S,17R)-17-acetyloxy-17-ethynyl-13-methyl-2,3,6,7,8,9,10,11,12,14,15,16-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl] acetate DMZM84R CA CAS 297-76-7 DMZM84R CB CHEBI:31580 DMZM84R DE Contraception DMBIYNH ID DMBIYNH DMBIYNH DN ETI-204 DMBIYNH HS Approved DMBIYNH CP Elusys Therapeutics DMBIYNH DT Antibody DMBIYNH DE Anthrax DMAWJIN ID DMAWJIN DMAWJIN DN Etidronate Disodium DMAWJIN HS Approved DMAWJIN SN Didronel DMAWJIN CP Procter And Gamble Pharmaceuticals Inc Sub Procter And Gamble Co DMAWJIN DT Small molecular drug DMAWJIN PC 23894 DMAWJIN MW 249.99 DMAWJIN FM C2H6Na2O7P2 DMAWJIN IC InChI=1S/C2H8O7P2.2Na/c1-2(3,10(4,5)6)11(7,8)9;;/h3H,1H3,(H2,4,5,6)(H2,7,8,9);;/q;2*+1/p-2 DMAWJIN CS CC(O)(P(=O)(O)[O-])P(=O)(O)[O-].[Na+].[Na+] DMAWJIN IK GWBBVOVXJZATQQ-UHFFFAOYSA-L DMAWJIN IU disodium;hydroxy-[1-hydroxy-1-[hydroxy(oxido)phosphoryl]ethyl]phosphinate DMAWJIN CA CAS 7414-83-7 DMAWJIN CB CHEBI:4906 DMAWJIN DE Osteoporosis DM1XHYJ ID DM1XHYJ DM1XHYJ DN Etidronic acid DM1XHYJ HS Approved DM1XHYJ SN EHDP; Etidronate; Etidronsaeure; HEDP; Osteoscan; Acetodiphosphonic acid; Acide etidronique; Acido etidronico; Acidumetidronicum; Didronel IV; Etidronic acid monohydrate; Hydroxyethanediphosphonic acid; Oxyethylidenediphosphonic acid; Turpinal SL; Dequest2010; Dequest 2015; Dequest Z 010; Ferrofos 510; RP 61; Acide etidronique [INN-French]; Acido etidronico [INN-Spanish]; Acidum etidronicum [INN-Latin]; Diphosphonate (base); Etidronic acid (USAN/INN); Etidronic acid [USAN:INN:BAN]; Hydroxyethane-1,1-diphosphonic acid; Ethane-1-hydroxy-1,1-bisphosphonate; Ethane-1-hydroxy-1,1-bisphosphonic acid; Ethane-1-hydroxy-1,1-diphosphonate; Ethane-1-hydroxy-1,1-diphosphonic acid; Phosphonic acid, 1-hydroxy-1,1-ethanediyl ester; (1-Hydroxyethylene)diphosphonic acid; (1-Hydroxyethylidene)bis(phosphonic acid); (1-Hydroxyethylidene)bisphosphonic acid; (1-Hydroxyethylidene)diphoshonic acid; (1-Hydroxyethylidene)diphosphonic acid; (1-hydroxy-1-phosphonoethyl)phosphonic acid; (1-hydroxyethane-1,1-diyl)bis(phosphonic acid); (Hydroxyethylidene)diphosphonic acid; 1,1,1-Ethanetriol diphosphonate; 1-HYDROXY-1,1-DIPHOSPHONOETHANE; 1-Hydroxyethane-1,1,-diphosphonic acid; 1-Hydroxyethane-1,1-bisphosphonic acid; 1-Hydroxyethane-1,1-diphosphonate; 1-Hydroxyethane-1,1-diphosphonic acid; 1-Hydroxyethanediphosphonic acid; 1-Hydroxyethylidene 1,1-diphosphonic acid; 1-Hydroxyethylidene-1,1-biphosphonate; 1-Hydroxyethylidene-1,1-bisphosphonate; 1-Hydroxyethylidene-1,1-diphosphonic acid; 1-Hydroxyethylidenediphosphonic acid; 1000SL DM1XHYJ TC Bone Density Conservation Agents DM1XHYJ DT Small molecular drug DM1XHYJ PC 3305 DM1XHYJ MW 206.03 DM1XHYJ FM C2H8O7P2 DM1XHYJ IC InChI=1S/C2H8O7P2/c1-2(3,10(4,5)6)11(7,8)9/h3H,1H3,(H2,4,5,6)(H2,7,8,9) DM1XHYJ CS CC(O)(P(=O)(O)O)P(=O)(O)O DM1XHYJ IK DBVJJBKOTRCVKF-UHFFFAOYSA-N DM1XHYJ IU (1-hydroxy-1-phosphonoethyl)phosphonic acid DM1XHYJ CA CAS 2809-21-4 DM1XHYJ CB CHEBI:4907 DM1XHYJ DE Paget's disease DM6WJO9 ID DM6WJO9 DM6WJO9 DN Etodolac DM6WJO9 HS Approved DM6WJO9 SN etodolac; 41340-25-4; Etodolic acid; Lodine; Ultradol; Lodine XL; Etodolacum; Etodolaco; Ramodar; AY 24236; Etodolacum [INN-Latin]; Etodolaco [INN-Spanish]; AY-24236; AY-24,236; Edolan; CCRIS 3923; 2-(1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indol-1-yl)acetic acid; CHEMBL622; NSC 282126; 1,3,4,9-Tetrahydro-1,8-diethylpyrano(3,4-b)indole-1-acetic acid; 1,8-Diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indole-1-acetic acid; 1,8-Diethyl-1,3,4,9-tetrahydropyrano(3,4-b)indole-1-acetic acid; Pyrano[3,4-b]indole-1-acetic acid, 1,8-diethyl-1 DM6WJO9 CP Meda Pharmaceuticals DM6WJO9 TC Analgesics DM6WJO9 DT Small molecular drug DM6WJO9 PC 3308 DM6WJO9 MW 287.35 DM6WJO9 FM C17H21NO3 DM6WJO9 IC InChI=1S/C17H21NO3/c1-3-11-6-5-7-12-13-8-9-21-17(4-2,10-14(19)20)16(13)18-15(11)12/h5-7,18H,3-4,8-10H2,1-2H3,(H,19,20) DM6WJO9 CS CCC1=C2C(=CC=C1)C3=C(N2)C(OCC3)(CC)CC(=O)O DM6WJO9 IK NNYBQONXHNTVIJ-UHFFFAOYSA-N DM6WJO9 IU 2-(1,8-diethyl-4,9-dihydro-3H-pyrano[3,4-b]indol-1-yl)acetic acid DM6WJO9 CA CAS 41340-25-4 DM6WJO9 CB CHEBI:4909 DM6WJO9 DE Pain DMZI3WO ID DMZI3WO DMZI3WO DN Etomidate DMZI3WO HS Approved DMZI3WO SN Absele; Amidate; Ethnor; Ethomidate; Etomidato; Etomidatum; Hypnomidate; Radenarcon; Radenarkon; Etomidic acid; R 16659; R 26490; R26490; Amidate (TN); Amidate (pharmaceutical); Amidate, Etomidate; D-Etomidate; Etomidato [INN-Spanish]; Etomidatum [INN-Latin]; R-26490; Etomidate (USAN/INN); Etomidate [USAN:BAN:INN]; Ethyl 3-(1-phenylethyl)imidazole-4-carboxylate; Ethyl 1-(1-phenylethyl)-1H-imidazole-5-carboxylate; R-(+)-Ethyl 1-(1-phenylethyl)-1H-imidazole-5-carboxylate; (+)-Ethyl 1-(alpha-methylbenzyl)imidazole-5-carboxylate; (+)-Etomidate; (R)-(+)-1-(alpha-Methylbenzyl)imidazole-5-carboxylic acid ethyl ester; (d)-Etomidate; 1-(1-Phenylethyl)-1H-imidazole-5-carboxylic acid ethyl ester; 1-(1-Phenylethyl)-imidazole-5-carboxylic acid, ethyl ester; 1-(alpha-Methylbenzyl)-1H-imidazole-5-carboxylic acid ethyl ester; 1H-Imidazole-5-carboxylic acid, 1-((1R)-1-phenylethyl)-, ethyl ester; 3-(1-Phenyl-ethyl)-3H-imidazole-4-carboxylic acid ethyl ester DMZI3WO CP Janssen Pharmaceutica DMZI3WO TC Analgesics DMZI3WO DT Small molecular drug DMZI3WO PC 667484 DMZI3WO MW 244.29 DMZI3WO FM C14H16N2O2 DMZI3WO IC InChI=1S/C14H16N2O2/c1-3-18-14(17)13-9-15-10-16(13)11(2)12-7-5-4-6-8-12/h4-11H,3H2,1-2H3/t11-/m1/s1 DMZI3WO CS CCOC(=O)C1=CN=CN1[C@H](C)C2=CC=CC=C2 DMZI3WO IK NPUKDXXFDDZOKR-LLVKDONJSA-N DMZI3WO IU ethyl 3-[(1R)-1-phenylethyl]imidazole-4-carboxylate DMZI3WO CA CAS 33125-97-2 DMZI3WO CB CHEBI:4910 DMZI3WO DE Anaesthesia DMKA8J4 ID DMKA8J4 DMKA8J4 DN Etonogestrel DMKA8J4 HS Approved DMKA8J4 SN Etonogestrelum; Implanon; Implanon (TN); NuvaRing (TN); Etonogestrel (USAN/INN); (8S,9S,10R,13S,14S,17R)-13-ethyl-17-ethynyl-17-hydroxy-11-methylidene-2,6,7,8,9,10,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one; 17alpha-ethynyl-17beta-hydroxy-11-methylidene-18a-homo-estr-4-en-3-one; 3-Ketodesogestrel; 3-Oxodesogestrel DMKA8J4 TC Contraceptive Agents DMKA8J4 DT Small molecular drug DMKA8J4 PC 6917715 DMKA8J4 MW 324.5 DMKA8J4 FM C22H28O2 DMKA8J4 IC InChI=1S/C22H28O2/c1-4-21-13-14(3)20-17-9-7-16(23)12-15(17)6-8-18(20)19(21)10-11-22(21,24)5-2/h2,12,17-20,24H,3-4,6-11,13H2,1H3/t17-,18-,19-,20+,21-,22-/m0/s1 DMKA8J4 CS CC[C@]12CC(=C)[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC(=O)CC[C@H]34 DMKA8J4 IK GCKFUYQCUCGESZ-BPIQYHPVSA-N DMKA8J4 IU (8S,9S,10R,13S,14S,17R)-13-ethyl-17-ethynyl-17-hydroxy-11-methylidene-2,6,7,8,9,10,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one DMKA8J4 CA CAS 54048-10-1 DMKA8J4 CB CHEBI:50777 DMKA8J4 DE Contraception DMNH3PG ID DMNH3PG DMNH3PG DN Etoposide DMNH3PG HS Approved DMNH3PG SN etoposide; 33419-42-0; VePesid; Toposar; trans-Etoposide; Lastet; (-)-Etoposide; Zuyeyidal; Etoposidum; Etoposido; Vepesid J; Eposin; Etoposidum [INN-Latin]; Etoposide (VP16); VP 16-213; VP 16 (pharmaceutical); Etoposido [INN-Spanish]; Etopophos (phosphate salt); VP-16-213; 4-Demethylepipodophyllotoxin beta-D-ethylideneglucoside; VP 16213; UNII-6PLQ3CP4P3; NK 171; NSC 141540; CCRIS 2392; HSDB 6517; 4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-beta-D-glucopyranoside); EINECS 251-509-1; NSC-141540; Eposide; Etopol; Etosid; Vepeside; Demethyl EpipodophyllotoxinEthylidine Glucoside; E0675; Demethyl-epiodophyllotoxin ethylidene glucoside; Epipodophyllotoxin VP-16213; Eposin (TN); Etopophos (TN); Trans-Etoposide; VePESID (TN); Vepesid (TN); DEMETHY-EPIPODOPHYLLOTOXIN, ETHYLIDENE GLUCOSIDE; VP-16 (TN); Demethylepipodophyllotoxin-beta-D-ethylideneglucoside; Etoposide (JP15/USP/INN); Etoposide [USAN:INN:BAN:JAN]; Eposin, Vepesid, VP-16, Toposar, Etoposide; Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside; Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside (8CI); Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-beta-D-glucopyranoside); 4'-Demethyl-epipodophyllotoxin 9-[4,6-O-(R)-ethylidene-beta-D-glucopyranoside; 4'-Demethylepipodophyllotoxin 9-(4,6-O-ethylidene-beta-D-glucopyranoside); 4'-Demethylepipodophyllotoxin ethylidene-beta-D-glucoside; 4'-O-Demethyl-1-O-(4,6-O-ethylidene-beta-D-glucopyranosyl)epipodophyllotoxin; 4-Demethylepipodophyllotoxin-beta-D-ethylideneglucoside DMNH3PG CP Bristol Myers Squibb Co Pharmaceutical Research Institute DMNH3PG TC Anticancer Agents DMNH3PG DT Small molecular drug DMNH3PG PC 36462 DMNH3PG MW 588.6 DMNH3PG FM C29H32O13 DMNH3PG IC InChI=1S/C29H32O13/c1-11-36-9-20-27(40-11)24(31)25(32)29(41-20)42-26-14-7-17-16(38-10-39-17)6-13(14)21(22-15(26)8-37-28(22)33)12-4-18(34-2)23(30)19(5-12)35-3/h4-7,11,15,20-22,24-27,29-32H,8-10H2,1-3H3/t11-,15+,20-,21-,22+,24-,25-,26-,27-,29+/m1/s1 DMNH3PG CS C[C@@H]1OC[C@@H]2[C@@H](O1)[C@@H]([C@H]([C@@H](O2)O[C@H]3[C@H]4COC(=O)[C@@H]4[C@@H](C5=CC6=C(C=C35)OCO6)C7=CC(=C(C(=C7)OC)O)OC)O)O DMNH3PG IK VJJPUSNTGOMMGY-MRVIYFEKSA-N DMNH3PG IU (5S,5aR,8aR,9R)-5-[[(2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-methyl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-9-(4-hydroxy-3,5-dimethoxyphenyl)-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[6,5-f][1,3]benzodioxol-8-one DMNH3PG CA CAS 33419-42-0 DMNH3PG CB CHEBI:4911 DMNH3PG DE Solid tumour/cancer DM6A4NW ID DM6A4NW DM6A4NW DN Etoricoxib DM6A4NW HS Approved DM6A4NW SN Algix; Arcoxia; Etoricoxibe; Nucoxia; Tauxib; L791456; MK 0663; MK 663; Algix (TN); Arcoxia (TN); L-791456; MK-0663; MK-663; Merck Sharp & Dohme brand of etoricoxib; Tauxib (TN); Etoricoxib (USAN/INN); Etoricoxib [USAN:INN:BAN]; 5-Chloro-6'-methyl-3-(p-(methylsulfonyl)phenyl)-2,3'-bipyridine; 5-chloro-2-(6-methylpyridin-3-yl)-3-(4-methylsulfonylphenyl)pyridine; 5-chloro-6'-methyl-3-[4-(methylsulfonyl)phenyl]-2,3'-bipyridine; 5CH DM6A4NW CP Merck & Co DM6A4NW TC Antiinflammatory Agents DM6A4NW DT Small molecular drug DM6A4NW PC 123619 DM6A4NW MW 358.8 DM6A4NW FM C18H15ClN2O2S DM6A4NW IC InChI=1S/C18H15ClN2O2S/c1-12-3-4-14(10-20-12)18-17(9-15(19)11-21-18)13-5-7-16(8-6-13)24(2,22)23/h3-11H,1-2H3 DM6A4NW CS CC1=NC=C(C=C1)C2=C(C=C(C=N2)Cl)C3=CC=C(C=C3)S(=O)(=O)C DM6A4NW IK MNJVRJDLRVPLFE-UHFFFAOYSA-N DM6A4NW IU 5-chloro-2-(6-methylpyridin-3-yl)-3-(4-methylsulfonylphenyl)pyridine DM6A4NW CA CAS 202409-33-4 DM6A4NW CB CHEBI:6339 DM6A4NW DE Rheumatoid arthritis DMGV8QU ID DMGV8QU DMGV8QU DN Etravirine DMGV8QU HS Approved DMGV8QU SN Intelence; DAPY deriv; Diaminopyrimidine deriv; R 165335; R165335; TMC 125; TMC125; Intelence (TN); Intelence(TM); R-165335; R165335-TMC125; TMC-125; Etravirine (JAN/USAN/INN); TMC-125/R-165335; 4-((6-amino-5-bromo-2-((4-cyanophenyl)amino)-4-pyrimidinyl)oxy)-3,5-dimethyl-benzonitrile; 4-({6-AMINO-5-BROMO-2-[(4-CYANOPHENYL)AMINO]PYRIMIDIN-4-YL}OXY)-3,5-DIMETHYLBENZONITRILE; 4-[6-amino-5-bromo-2-(4-cyanoanilino)pyrimidin-4-yl]oxy-3,5-dimethylbenzonitrile; 65B; ETR DMGV8QU DT Small molecular drug DMGV8QU PC 193962 DMGV8QU MW 435.3 DMGV8QU FM C20H15BrN6O DMGV8QU IC InChI=1S/C20H15BrN6O/c1-11-7-14(10-23)8-12(2)17(11)28-19-16(21)18(24)26-20(27-19)25-15-5-3-13(9-22)4-6-15/h3-8H,1-2H3,(H3,24,25,26,27) DMGV8QU CS CC1=CC(=CC(=C1OC2=NC(=NC(=C2Br)N)NC3=CC=C(C=C3)C#N)C)C#N DMGV8QU IK PYGWGZALEOIKDF-UHFFFAOYSA-N DMGV8QU IU 4-[6-amino-5-bromo-2-(4-cyanoanilino)pyrimidin-4-yl]oxy-3,5-dimethylbenzonitrile DMGV8QU CA CAS 269055-15-4 DMGV8QU CB CHEBI:63589 DMGV8QU DE Human immunodeficiency virus-1 infection DM2CZFA ID DM2CZFA DM2CZFA DN Etretinate DM2CZFA HS Approved DM2CZFA SN etretinate; 54350-48-0; Tegison; Ethyl etrinoate; Retinoid; Etretinatum; Etretinato; Ro 10-9359; Etretinatum [INN-Latin]; Etretinato [INN-Spanish]; UNII-65M2UDR9AG; CCRIS 3615; HSDB 7185; EINECS 259-119-3; NSC 297936; 65M2UDR9AG; Ro-10-9359; Tigason; CHEBI:4913; C23H30O3; Ethyl all-trans-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoate; Ethyl (all-E)-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoate; 3,7-Dimethyl-9-(4-methoxy-2,3,6-trimethylphenyl)-2,4,6,8-nonanetetraenoic acid ethy DM2CZFA DT Small molecular drug DM2CZFA PC 5282375 DM2CZFA MW 354.5 DM2CZFA FM C23H30O3 DM2CZFA IC InChI=1S/C23H30O3/c1-8-26-23(24)14-17(3)11-9-10-16(2)12-13-21-18(4)15-22(25-7)20(6)19(21)5/h9-15H,8H2,1-7H3/b11-9+,13-12+,16-10+,17-14+ DM2CZFA CS CCOC(=O)/C=C(\\C)/C=C/C=C(\\C)/C=C/C1=C(C(=C(C=C1C)OC)C)C DM2CZFA IK HQMNCQVAMBCHCO-DJRRULDNSA-N DM2CZFA IU ethyl (2E,4E,6E,8E)-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoate DM2CZFA CA CAS 54350-48-0 DM2CZFA CB CHEBI:4913 DM2CZFA DE Keratosis DM5GT1M ID DM5GT1M DM5GT1M DN EVANS BLUE DM5GT1M HS Approved DM5GT1M SN tetrasodium (6E)-4-amino-6-[[4-[4-[(2Z)-2-(8-amino-1-oxo-5,7-disulfonatonaphthalen-2-ylidene)hydrazinyl]-3-methylphenyl]-2-methylphenyl]hydrazinylidene]-5-oxonaphthalene-1,3-disulfonate; AC1NUWHB; AC1O426Q; AN-23389; tetrasodium (6E)-4-amino-6-[[4-[4-[(2Z)-2-(8-amino-1-oxo-5,7-disulfonato-2-naphthylidene)hydrazino]-3-methyl-phenyl]-2-methyl-phenyl]hydrazono]-5-oxo-naphthalene-1,3-disulfonate; 6,6-[(3,3'-Dimethyl[1,1'-biphenyl]-4,4'-diyl)bis(azo)bis[4-amino-5-hydroxy-1,3-naphthalenedisulphonic acid]tetrasodium sa DM5GT1M DT Small molecular drug DM5GT1M PC 9409 DM5GT1M MW 960.8 DM5GT1M FM C34H24N6Na4O14S4 DM5GT1M IC InChI=1S/C34H28N6O14S4.4Na/c1-15-11-17(3-7-21(15)37-39-23-9-5-19-25(55(43,44)45)13-27(57(49,50)51)31(35)29(19)33(23)41)18-4-8-22(16(2)12-18)38-40-24-10-6-20-26(56(46,47)48)14-28(58(52,53)54)32(36)30(20)34(24)42;;;;/h3-14,41-42H,35-36H2,1-2H3,(H,43,44,45)(H,46,47,48)(H,49,50,51)(H,52,53,54);;;;/q;4*+1/p-4 DM5GT1M CS CC1=C(C=CC(=C1)C2=CC(=C(C=C2)N=NC3=C(C4=C(C=C3)C(=CC(=C4N)S(=O)(=O)[O-])S(=O)(=O)[O-])O)C)N=NC5=C(C6=C(C=C5)C(=CC(=C6N)S(=O)(=O)[O-])S(=O)(=O)[O-])O.[Na+].[Na+].[Na+].[Na+] DM5GT1M IK ATNOAWAQFYGAOY-UHFFFAOYSA-J DM5GT1M IU tetrasodium;4-amino-6-[[4-[4-[(8-amino-1-hydroxy-5,7-disulfonatonaphthalen-2-yl)diazenyl]-3-methylphenyl]-2-methylphenyl]diazenyl]-5-hydroxynaphthalene-1,3-disulfonate DM5GT1M CA CAS 314-13-6 DM5GT1M CB CHEBI:82467 DM5GT1M DE Abdominal aortic aneurysm DM8X2EH ID DM8X2EH DM8X2EH DN Everolimus DM8X2EH HS Approved DM8X2EH SN Afinitor; Afinitor (TN); CERTICAN(R); Certican; Certican (TN); Everolimus (JAN/USAN/INN); Everolimus [USAN]; MTOR kinase inhibitors; NVP-RAD-001; RAD 001; RAD-001; RAD-001C; RAD001; RAD001, SDZ-RAD, Certican, Zortress, Afinitor, Everolimus; SDZ-RAD; Zortress DM8X2EH CP Novartis DM8X2EH TC Anticancer Agents DM8X2EH DT Small molecular drug DM8X2EH PC 6442177 DM8X2EH MW 958.2 DM8X2EH FM C53H83NO14 DM8X2EH IC InChI=1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1 DM8X2EH CS C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)OCCO)C)/C)O)OC)C)C)/C)OC DM8X2EH IK HKVAMNSJSFKALM-GKUWKFKPSA-N DM8X2EH IU (1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-[(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl]-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone DM8X2EH CA CAS 159351-69-6 DM8X2EH CB CHEBI:68478 DM8X2EH DE Renal cell carcinoma; Kidney cancer DMBLX7U ID DMBLX7U DMBLX7U DN Evinacumab DMBLX7U HS Approved DMBLX7U SN REGN1500; ANGPTL-1 antibody DMBLX7U CP Regeneron Pharmaceuticals Tarrytown, NY DMBLX7U DE Elevated C-reactive protein; Familial hypercholesterolemia; Hypercholesterolaemia DM9HPW3 ID DM9HPW3 DM9HPW3 DN Exemestane DM9HPW3 HS Approved DM9HPW3 SN Aromasil; Aromasin; Aromasine; EXE; Exemestance; Exemestano; Exemestanum; Nikidess; Pfizer brand of exemestane; Curator_000009; Fce 24304; Aromasin (TN); Aromasin, Exemestane; Exemestano [INN-Spanish]; Exemestanum [INN-Latin]; FCE-24304; PNU-155971; Exemestane [USAN:INN:BAN]; Exemestane (JAN/USP/INN); (8R,9S,10R,13S,14S)-10,13-dimethyl-6-methylidene-7,8,9,11,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,17-dione; 6-Methylenandrosta-1,4-diene-3,17-dione; 6-Methyleneandrosta-1,4-diene-3,17-dione; 6-methylideneandrosta-1,4-diene-3,17-dione DM9HPW3 TC Anticancer Agents DM9HPW3 DT Small molecular drug DM9HPW3 PC 60198 DM9HPW3 MW 296.4 DM9HPW3 FM C20H24O2 DM9HPW3 IC InChI=1S/C20H24O2/c1-12-10-14-15-4-5-18(22)20(15,3)9-7-16(14)19(2)8-6-13(21)11-17(12)19/h6,8,11,14-16H,1,4-5,7,9-10H2,2-3H3/t14-,15-,16-,19+,20-/m0/s1 DM9HPW3 CS C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CC(=C)C4=CC(=O)C=C[C@]34C DM9HPW3 IK BFYIZQONLCFLEV-DAELLWKTSA-N DM9HPW3 IU (8R,9S,10R,13S,14S)-10,13-dimethyl-6-methylidene-7,8,9,11,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,17-dione DM9HPW3 CA CAS 107868-30-4 DM9HPW3 CB CHEBI:4953 DM9HPW3 DE Hormonally-responsive breast cancer DMYHBKN ID DMYHBKN DMYHBKN DN Exenatide DMYHBKN HS Approved DMYHBKN SN Exenatide Synthetic; AC 2993 LAR; Ex4 peptide; Byetta (TN); Exendin 4 (Heloderma suspectum); Extendin-4; L-Serinamide DMYHBKN CP Eli Lilly DMYHBKN TC Hypoglycemic Agents DMYHBKN DT Small molecular drug DMYHBKN SQ Exenatide: HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS DMYHBKN PC 45588096 DMYHBKN MW 4187 DMYHBKN FM C184H282N50O60S DMYHBKN IC InChI=1S/C184H282N50O60S/c1-16-94(10)147(178(289)213-114(52-58-144(257)258)163(274)218-121(73-101-77-195-105-39-24-23-38-103(101)105)168(279)215-116(68-90(2)3)165(276)205-107(41-26-28-61-186)158(269)219-122(75-134(189)243)154(265)198-79-135(244)196-83-139(248)231-63-30-43-129(231)175(286)225-127(87-238)174(285)223-125(85-236)155(266)200-80-136(245)202-96(12)181(292)233-65-32-45-131(233)183(294)234-66-33-46-132(234)182(293)232-64-31-44-130(232)176(287)222-124(84-235)150(190)261)229-170(281)119(71-99-34-19-17-20-35-99)217-166(277)117(69-91(4)5)214-159(270)108(42-29-62-194-184(191)192)212-177(288)146(93(8)9)228-151(262)95(11)203-156(267)111(49-55-141(251)252)208-161(272)112(50-56-142(253)254)209-162(273)113(51-57-143(255)256)210-164(275)115(59-67-295-15)211-160(271)110(47-53-133(188)242)207-157(268)106(40-25-27-60-185)206-172(283)126(86-237)224-167(278)118(70-92(6)7)216-169(280)123(76-145(259)260)220-173(284)128(88-239)226-180(291)149(98(14)241)230-171(282)120(72-100-36-21-18-22-37-100)221-179(290)148(97(13)240)227-138(247)82-199-153(264)109(48-54-140(249)250)204-137(246)81-197-152(263)104(187)74-102-78-193-89-201-102/h17-24,34-39,77-78,89-98,104,106-132,146-149,195,235-241H,16,25-33,40-76,79-88,185-187H2,1-15H3,(H2,188,242)(H2,189,243)(H2,190,261)(H,193,201)(H,196,244)(H,197,263)(H,198,265)(H,199,264)(H,200,266)(H,202,245)(H,203,267)(H,204,246)(H,205,276)(H,206,283)(H,207,268)(H,208,272)(H,209,273)(H,210,275)(H,211,271)(H,212,288)(H,213,289)(H,214,270)(H,215,279)(H,216,280)(H,217,277)(H,218,274)(H,219,269)(H,220,284)(H,221,290)(H,222,287)(H,223,285)(H,224,278)(H,225,286)(H,226,291)(H,227,247)(H,228,262)(H,229,281)(H,230,282)(H,249,250)(H,251,252)(H,253,254)(H,255,256)(H,257,258)(H,259,260)(H4,191,192,194)/t94-,95-,96-,97+,98+,104-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,127-,128-,129-,130-,131-,132-,146-,147-,148-,149-/m0/s1 DMYHBKN CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N)C(=O)NCC(=O)NCC(=O)N3CCC[C@H]3C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N4CCC[C@H]4C(=O)N5CCC[C@H]5C(=O)N6CCC[C@H]6C(=O)N[C@@H](CO)C(=O)N)NC(=O)[C@H](CC7=CC=CC=C7)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC8=CC=CC=C8)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@H](CC9=CNC=N9)N DMYHBKN IK HTQBXNHDCUEHJF-XWLPCZSASA-N DMYHBKN IU (4S)-5-[[2-[[(2S,3R)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-4-amino-1-[[2-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[(2S)-2-[(2S)-2-[(2S)-2-[[(2S)-1-amino-3-hydroxy-1-oxopropan-2-yl]carbamoyl]pyrrolidine-1-carbonyl]pyrrolidine-1-carbonyl]pyrrolidin-1-yl]-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-2-oxoethyl]amino]-1,4-dioxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-4-[[2-[[(2S)-2-amino-3-(1H-imidazol-4-yl)propanoyl]amino]acetyl]amino]-5-oxopentanoic acid DMYHBKN CA CAS 141758-74-9 DMYHBKN DE Cardiovascular disease; Type-2 diabetes DMHPRWG ID DMHPRWG DMHPRWG DN Exjade DMHPRWG HS Approved DMHPRWG SN Deferasirox DMHPRWG CP Novartis DMHPRWG DT Small molecular drug DMHPRWG PC 214348 DMHPRWG MW 373.4 DMHPRWG FM C21H15N3O4 DMHPRWG IC InChI=1S/C21H15N3O4/c25-17-7-3-1-5-15(17)19-22-20(16-6-2-4-8-18(16)26)24(23-19)14-11-9-13(10-12-14)21(27)28/h1-12,25-26H,(H,27,28) DMHPRWG CS C1=CC=C(C(=C1)C2=NN(C(=N2)C3=CC=CC=C3O)C4=CC=C(C=C4)C(=O)O)O DMHPRWG IK BOFQWVMAQOTZIW-UHFFFAOYSA-N DMHPRWG IU 4-[3,5-bis(2-hydroxyphenyl)-1,2,4-triazol-1-yl]benzoic acid DMHPRWG CA CAS 201530-41-8 DMHPRWG CB CHEBI:49005 DMHPRWG DE Iron overload disease DM7A8TW ID DM7A8TW DM7A8TW DN Ezetimibe DM7A8TW HS Approved DM7A8TW SN Ezedoc; Ezetimib; Ezetrol; Zetia; Zient; Essex brand of ezetimibe; MSD brand of ezetimibe; Merck brand of ezetimibe; SCH58235; Sch 58235; Ezetimibe [USAN:INN]; Inegy (TN); MK-0653; SCH-58235; Schering-Plough brand of ezetimibe; Vytorin (TN); Zetia (TN); Zetia , Ezetrol, Ezetimibe; Ezetimibe (JAN/USAN/INN); (-)-Sch 58235; (1-(4-fluorophenyl)-(3R)-(3-(4-fluorophenyl)-(3S)-hydroxypropyl)-(4S)-(4-hydroxyphenyl)-2-azetidinone); (3R,4S)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)azetidin-2-one; (3R,4S)-1-(p-Fluorophenyl)-3-((3S)-3-(p-fluorophenyl)-3-hydroxypropyl)-4-(p-hydroxyphenyl)-2-azetidinone; 1-(4-fluorophenyl)-3(R)-[3-(4-fluorophenyl)-3(S)-(4-hydroxyphenyl)-2-azetidione; 1-(4-fluorophenyl)-3(R)-[3-(4-fluorophenyl)-3(S)-hydroxypropyl]-4(S)-(4-hydroxyphenyl)-2-azetidinone DM7A8TW CP Schering-Plough DM7A8TW TC Anticholesteremic Agents DM7A8TW DT Small molecular drug DM7A8TW PC 150311 DM7A8TW MW 409.4 DM7A8TW FM C24H21F2NO3 DM7A8TW IC InChI=1S/C24H21F2NO3/c25-17-5-1-15(2-6-17)22(29)14-13-21-23(16-3-11-20(28)12-4-16)27(24(21)30)19-9-7-18(26)8-10-19/h1-12,21-23,28-29H,13-14H2/t21-,22+,23-/m1/s1 DM7A8TW CS C1=CC(=CC=C1[C@@H]2[C@H](C(=O)N2C3=CC=C(C=C3)F)CC[C@@H](C4=CC=C(C=C4)F)O)O DM7A8TW IK OLNTVTPDXPETLC-XPWALMASSA-N DM7A8TW IU (3R,4S)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)azetidin-2-one DM7A8TW CA CAS 163222-33-1 DM7A8TW CB CHEBI:49040 DM7A8TW DE Hypercholesterolaemia DMAB6PM ID DMAB6PM DMAB6PM DN Factor 8 DMAB6PM HS Approved DMAB6PM SN Wilate (TN) DMAB6PM DE Hemophilia DMZUW6P ID DMZUW6P DMZUW6P DN Factor viia DMZUW6P HS Approved DMZUW6P SN Novoseven (TN) DMZUW6P DE Hemophilia DM3C5GZ ID DM3C5GZ DM3C5GZ DN FADROZOLE DM3C5GZ HS Approved DM3C5GZ SN 102676-47-1; CGS-16949A; Fadrozole [INN]; Fadrozolum [INN-Latin]; Fadrozol [INN-Spanish]; CHEMBL9298; Fadrozole (INN); 5-p-cyanophenyl-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine; Benzonitrile, 4-(5,6,7,8-tetrahydroimidazo(1,5-a)pyridin-5-yl)-; Fadrozolum; Fadrozol; 4-{5H,6H,7H,8H-imidazo[1,5-a]pyridin-5-yl}benzonitrile; Benzonitrile, 4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)- DM3C5GZ DT Small molecular drug DM3C5GZ PC 59693 DM3C5GZ MW 223.27 DM3C5GZ FM C14H13N3 DM3C5GZ IC InChI=1S/C14H13N3/c15-8-11-4-6-12(7-5-11)14-3-1-2-13-9-16-10-17(13)14/h4-7,9-10,14H,1-3H2 DM3C5GZ CS C1CC(N2C=NC=C2C1)C3=CC=C(C=C3)C#N DM3C5GZ IK CLPFFLWZZBQMAO-UHFFFAOYSA-N DM3C5GZ IU 4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)benzonitrile DM3C5GZ CA CAS 102676-47-1 DM3C5GZ CB CHEBI:94355 DM3C5GZ DE Breast cancer DMBI9ZJ ID DMBI9ZJ DMBI9ZJ DN Falecalcitrol DMBI9ZJ HS Approved DMBI9ZJ SN Falecalcitriol; falecalcitriol; Flocalcitriol; 83805-11-2; calcitriol hexafluoride; Hornel, Fulstan; Falecalcitriol [INN]; ST-630; ST 630; Fulstan; Ro 23-4194; UNII-G70A8514T8; C27H38F6O3; Hornel; 26,26,26,27,27,27-Hexafluoro-1,25-dihydroxyvitamin D3; G70A8514T8; (1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-7a-methyl-1-[(2R)-7,7,7-trifluoro-6-hydroxy-6-(trifluoromethyl)heptan-2-yl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol; Hexafluorocalcitriol; 9,10-Secocholesta-5,7,10(19)-triene-1,3,25-triol,; Fulstan (TN); Horner (TN) DMBI9ZJ DT Small molecular drug DMBI9ZJ PC 5282190 DMBI9ZJ MW 524.6 DMBI9ZJ FM C27H38F6O3 DMBI9ZJ IC InChI=1S/C27H38F6O3/c1-16(6-4-13-25(36,26(28,29)30)27(31,32)33)21-10-11-22-18(7-5-12-24(21,22)3)8-9-19-14-20(34)15-23(35)17(19)2/h8-9,16,20-23,34-36H,2,4-7,10-15H2,1,3H3/b18-8+,19-9-/t16-,20-,21-,22+,23+,24-/m1/s1 DMBI9ZJ CS C[C@H](CCCC(C(F)(F)F)(C(F)(F)F)O)[C@H]1CC[C@@H]\\2[C@@]1(CCC/C2=C\\C=C/3\\C[C@H](C[C@@H](C3=C)O)O)C DMBI9ZJ IK XPYGGHVSFMUHLH-UUSULHAXSA-N DMBI9ZJ IU (1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-7a-methyl-1-[(2R)-7,7,7-trifluoro-6-hydroxy-6-(trifluoromethyl)heptan-2-yl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol DMBI9ZJ CA CAS 83805-11-2 DMBI9ZJ DE Hyperparathyroidism DMJHLSD ID DMJHLSD DMJHLSD DN Famciclovir DMJHLSD HS Approved DMJHLSD SN FCV; Famciclovirum; Famvir; Oravir; BRL 42810; IN1338; Anti-Farnesyl Rabbit pAb; BRL-42810; Famciclovirum [INN-Latin]; Famvir (TN); Famciclovir [USAN:BAN:INN]; Famciclovir (JAN/USAN/INN); [2-(acetyloxymethyl)-4-(2-aminopurin-9-yl)butyl] acetate; Diacetyl 6-deoxy-9-(4-hydroxy-3-hydroxymethyl-but-1-yl)guanine; 1,3-Propanediol, 2-(2-(2-amino-9H-purin-9-yl)ethyl)-, diacetate (ester); 2-(2-(2-Amino-9H-purin-9-yl)ethyl)-1,3-propanediol diacetate (ester); 2-(2-(2-amino-9H-purin-9-yl)ethyl)-1,3-propanediol diacetate; 2-(acetoxymethyl)-4-(2-amino-4,5-dihydro-9H-purin-9-yl)butyl acetate; 2-[(acetyloxy)methyl]-4-(2-amino-9H-purin-9-yl)butyl acetate; 2-[2-(2-amino-9H-purin-9-yl)ethyl]-1,3-propanediol diacetate; 9-(4-acetoxy-3-(acetoxymethyl)but-1-yl)-2-aminopurine; 9-[4-acetoxy-3-(acetoxymethyl)but-1-yl]-2-aminopurine DMJHLSD CP Schering-Plough DMJHLSD TC Antiviral Agents DMJHLSD DT Small molecular drug DMJHLSD PC 3324 DMJHLSD MW 321.33 DMJHLSD FM C14H19N5O4 DMJHLSD IC InChI=1S/C14H19N5O4/c1-9(20)22-6-11(7-23-10(2)21)3-4-19-8-17-12-5-16-14(15)18-13(12)19/h5,8,11H,3-4,6-7H2,1-2H3,(H2,15,16,18) DMJHLSD CS CC(=O)OCC(CCN1C=NC2=CN=C(N=C21)N)COC(=O)C DMJHLSD IK GGXKWVWZWMLJEH-UHFFFAOYSA-N DMJHLSD IU [2-(acetyloxymethyl)-4-(2-aminopurin-9-yl)butyl] acetate DMJHLSD CA CAS 104227-87-4 DMJHLSD CB CHEBI:4974 DMJHLSD DE Virus infection DMRL3AB ID DMRL3AB DMRL3AB DN Famotidine DMRL3AB HS Approved DMRL3AB SN Pepcid; famotidine; 76824-35-6; Pepcid AC; Pepcidine; Quamatel; Gastridin; Famodil; Dispromil; Pepdine; Digervin; Gaster; Fluxid; Pepdul; Pepcid RPD; Famulcer; Supertidine; Pepcidina; Fagastine; Whitidin; Farmotex; Peptifam; Ferotine; Dispronil; Tairal; Sigafam; Famtac; Durater; Yamarin; Pepzan; Famoxal; Evatin; Weimok; Pepdif; Fudone; Fanosin; Fanobel; Duovel; Fibonel; Fadine; Dipsin; Ganor; Fadin; Dinul; Fanox; Fadyn; Famox; Famo; Nu-Famotidine; Pepcidin Rapitab; Sedanium-R; Dibrit 40; Famotidinum [Latin]; PEPCID; Famotidina [Spanish]; Apogastine; Antodine; Bestidine; Amfamox; Blocacid; Brolin; Cepal; Confobos; Cronol; Cuantin; Famocid; Famodar; Famodin; Famodine; Famogard; Famonit; Famopsin; Famos; Famosan; Famotal; Famotep; Famotin; Famovane; Famowal; Gastridan; Gastrion; Gastro; Gastrodomina; Gastrofam; Gastropen; Gastrosidin; Hacip; Huberdina; Ingastri; Invigan; Lecedil; Logos; Mensoma; Midefam; Mosul; Motiax; Muclox; Neocidine; Nevofam; Notidin; Nulceran; Nulcerin; Panalba; Pepcidac; Pepcidin; Pepfamin; Peptan; Peptidin; Purifam; Quamtel; Renapepsa; Restadin; Rogasti; Rubacina; Tamin; Tipodex; Topcid; Ulcatif; Ulceprax; Ulcofam; Ulfagel; Ulfam; Ulfamid; Ulfinol; Ulgarine; Vagostal; FAMOTIDINE PRESERVATIVE FREE; FAMOTIDINE PRESERVATIVE FREE IN PLASTIC CONTAINER; Mylanta AR; PEPCID COMPLETE; PEPCID PRESERVATIVE FREE; PEPCID PRESERVATIVE FREE IN PLASTIC CONTAINER; Pepcid AC Gelcaps; PepcidRPD; F 6889; F0530; L 643341; MK 208; YM 11170; Apo-Famotidine; HS-0054; MK-208; Novo-Famotidine; Pepcid (TN); Pepcidine (TN); YM-11170; YM-1170; Famotidine [USAN:BAN:INN:JAN]; Propanimidamide, 3-[[[2-[aminoiminomethyl)amino]-4-thiazoyl]methyl]thio]-N-(aminosulfonyl); N'-(Aminosulfonyl)-3-([2-(diaminomethyleneamino)-4-thiazolyl]methylthio)propanamidine; (1-Amino-3-(((2-((diaminomethylene)amino)-4-thiazolyl)methyl)thio)propylidene)sulfamide; (1Z)-3-[({2-[(diaminomethylidene)amino]-1,3-thiazol-4-yl}methyl)sulfanyl]-N'-sulfamoylpropanimidamide; (1Z)-N'-(aminosulfonyl)-3-[({2-[(diaminomethylidene)amino]-1,3-thiazol-4-yl}methyl)thio]propanimidamide; 3-(2-Guanidinothiazol-4-ylmethylthio)-N1-sulfamoylpropionamide; 3-[({2-[(diaminomethylidene)amino]-1,3-thiazol-4-yl}methyl)sulfanyl]-N-sulfamoylpropanimidamide; 3-[[2-(diaminomethylideneamino)-1,3-thiazol-4-yl]methylsulfanyl]-N'-sulfamoylpro; 3-[[2-(diaminomethylideneamino)-1,3-thiazol-4-yl]methylsulfanyl]-N'-sulfamoylpropanimidamide DMRL3AB CP Astellas Pharma DMRL3AB TC Antiulcer Agents DMRL3AB DT Small molecular drug DMRL3AB PC 5702160 DMRL3AB MW 337.5 DMRL3AB FM C8H15N7O2S3 DMRL3AB IC InChI=1S/C8H15N7O2S3/c9-6(15-20(12,16)17)1-2-18-3-5-4-19-8(13-5)14-7(10)11/h4H,1-3H2,(H2,9,15)(H2,12,16,17)(H4,10,11,13,14) DMRL3AB CS C1=C(N=C(S1)N=C(N)N)CSCC/C(=N/S(=O)(=O)N)/N DMRL3AB IK XUFQPHANEAPEMJ-UHFFFAOYSA-N DMRL3AB IU 3-[[2-(diaminomethylideneamino)-1,3-thiazol-4-yl]methylsulfanyl]-N'-sulfamoylpropanimidamide DMRL3AB CA CAS 76824-35-6 DMRL3AB CB CHEBI:4975 DMRL3AB DE Peptic ulcer DMX7A5V ID DMX7A5V DMX7A5V DN Faropenem DMX7A5V HS Approved DMX7A5V SN FPM; Fropenem; (+)-(5R,6S)-6-((1R)-1-Hydroxyethyl)-7-oxo-3-((2R)-tetrahydro-2-furyl)-4-thia-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid; (5R,6S)-6-[(1R)-1-hydroxyethyl]-7-oxo-3-[(2R)-oxolan-2-yl]-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; (5R,6S)-6-[(1R)-1-hydroxyethyl]-7-oxo-3-[(2R)-tetrahydrofuran-2-yl]-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; 6alpha-[(1R)-1-hydroxyethyl]-2-[(2R)-tetrahydrofuran-2-yl]-2,3-didehydropenam-3-carboxylic acid DMX7A5V CP Suntory DMX7A5V TC Respiratory Agents DMX7A5V DT Small molecular drug DMX7A5V PC 65894 DMX7A5V MW 285.32 DMX7A5V FM C12H15NO5S DMX7A5V IC InChI=1S/C12H15NO5S/c1-5(14)7-10(15)13-8(12(16)17)9(19-11(7)13)6-3-2-4-18-6/h5-7,11,14H,2-4H2,1H3,(H,16,17)/t5-,6-,7+,11-/m1/s1 DMX7A5V CS C[C@H]([C@@H]1[C@@H]2N(C1=O)C(=C(S2)[C@H]3CCCO3)C(=O)O)O DMX7A5V IK HGGAKXAHAYOLDJ-FHZUQPTBSA-N DMX7A5V IU (5R,6S)-6-[(1R)-1-hydroxyethyl]-7-oxo-3-[(2R)-oxolan-2-yl]-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid DMX7A5V CA CAS 106560-14-9 DMX7A5V CB CHEBI:51257 DMX7A5V DE Gram-positive bacterial infection DMDEXQ0 ID DMDEXQ0 DMDEXQ0 DN Febuxostat DMDEXQ0 HS Approved DMDEXQ0 SN Adenuric; TEI; Uloric; Febuxostat [USAN]; S1547; TMX 67; Tei 6720; TMX-67; Tei-6720; Uloric (TN); Febuxostat (JAN/USAN/INN); TMX-67, Adenuric, Uloric, Febuxostat; 111GE013; 2-(3-CYANO-4-ISOBUTOXY-PHENYL)-4-METHYL-5-THIAZOLE-CARBOXYLIC ACID; 2-(3-Cyano-4-(2-methylpropoxy)phenyl)-4-methylthiazole-5-carboxylic acid;2-(3-Cyano-4-isobutoxyphenyl)-4-methyl-5-thiazolecarboxylic acid; 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methyl-1,3-thiazole-5-carboxylic acid DMDEXQ0 CP Takeda DMDEXQ0 DT Small molecular drug DMDEXQ0 PC 134018 DMDEXQ0 MW 316.4 DMDEXQ0 FM C16H16N2O3S DMDEXQ0 IC InChI=1S/C16H16N2O3S/c1-9(2)8-21-13-5-4-11(6-12(13)7-17)15-18-10(3)14(22-15)16(19)20/h4-6,9H,8H2,1-3H3,(H,19,20) DMDEXQ0 CS CC1=C(SC(=N1)C2=CC(=C(C=C2)OCC(C)C)C#N)C(=O)O DMDEXQ0 IK BQSJTQLCZDPROO-UHFFFAOYSA-N DMDEXQ0 IU 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methyl-1,3-thiazole-5-carboxylic acid DMDEXQ0 CA CAS 144060-53-7 DMDEXQ0 CB CHEBI:31596 DMDEXQ0 DE Hyperuricaemia DM4ZBK6 ID DM4ZBK6 DM4ZBK6 DN Fedratinib DM4ZBK6 HS Approved DM4ZBK6 SN TG101348 DM4ZBK6 CP Targen DM4ZBK6 DT Small molecular drug DM4ZBK6 PC 16722836 DM4ZBK6 MW 524.7 DM4ZBK6 FM C27H36N6O3S DM4ZBK6 IC InChI=1S/C27H36N6O3S/c1-20-19-28-26(30-21-10-12-23(13-11-21)36-17-16-33-14-5-6-15-33)31-25(20)29-22-8-7-9-24(18-22)37(34,35)32-27(2,3)4/h7-13,18-19,32H,5-6,14-17H2,1-4H3,(H2,28,29,30,31) DM4ZBK6 CS CC1=CN=C(N=C1NC2=CC(=CC=C2)S(=O)(=O)NC(C)(C)C)NC3=CC=C(C=C3)OCCN4CCCC4 DM4ZBK6 IK JOOXLOJCABQBSG-UHFFFAOYSA-N DM4ZBK6 IU N-tert-butyl-3-[[5-methyl-2-[4-(2-pyrrolidin-1-ylethoxy)anilino]pyrimidin-4-yl]amino]benzenesulfonamide DM4ZBK6 CA CAS 936091-26-8 DM4ZBK6 CB CHEBI:91408 DM4ZBK6 DE Myelofibrosis DML2DCR ID DML2DCR DML2DCR DN Fedratinib hydrochloride DML2DCR HS Approved DML2DCR SN Fedratinib hydrochloride (USAN); TG101348(2ClH.H2O); UH9J2HBQWJ; 1374744-69-0; BCP24783; D11296; Fedratinib dihydrochloride monohydrate; UNII-UH9J2HBQWJ DML2DCR PC 67517580 DML2DCR MW 615.6 DML2DCR FM C27H40Cl2N6O4S DML2DCR IC QAFZLTVOFJHYDF-UHFFFAOYSA-N DML2DCR CS CC1=CN=C(N=C1NC2=CC(=CC=C2)S(=O)(=O)NC(C)(C)C)NC3=CC=C(C=C3)OCCN4CCCC4.O.Cl.Cl DML2DCR IK 1S/C27H36N6O3S.2ClH.H2O/c1-20-19-28-26(30-21-10-12-23(13-11-21)36-17-16-33-14-5-6-15-33)31-25(20)29-22-8-7-9-24(18-22)37(34,35)32-27(2,3)4;;;/h7-13,18-19,32H,5-6,14-17H2,1-4H3,(H2,28,29,30,31);2*1H;1H2 DML2DCR IU N-tert-butyl-3-[[5-methyl-2-[4-(2-pyrrolidin-1-ylethoxy)anilino]pyrimidin-4-yl]amino]benzenesulfonamide;hydrate;dihydrochloride DML2DCR CA CAS 1374744-69-0 DML2DCR DE Myelofibrosis DM1V5ZS ID DM1V5ZS DM1V5ZS DN Felbamate DM1V5ZS HS Approved DM1V5ZS SN Felbamato; Felbamatum; Felbamyl; Felbatol; Taloxa; Essex brand of felbamate; Felbamato [Spanish]; Felbamatum [Latin]; Schering brand of felbamate; F 0778; W 554; Wallace brand 1 of felbamate; Wallace brand 2 of felbamate; ADD-03055; Carbamic acid 2-phenyltrimethylene ester; Felbamate [USAN:INN]; Felbatol (TN); Schering-Plough brand of felbamate; W-554; Carbamic acid, 2-phenyltrimethylene ester; Felbamate (USAN/INN); (3-carbamoyloxy-2-phenyl-propyl) carbamate; (3-carbamoyloxy-2-phenylpropyl) carbamate; 1,3-Propanediol, 2-phenyl-, dicarbamate; 2-Phenyl-1,3-propanediol dicarbamate; 2-Phenylpropane-1,3-diyl dicarbamate DM1V5ZS CP MedPointe DM1V5ZS TC Antiepileptic Agents DM1V5ZS DT Small molecular drug DM1V5ZS PC 3331 DM1V5ZS MW 238.24 DM1V5ZS FM C11H14N2O4 DM1V5ZS IC InChI=1S/C11H14N2O4/c12-10(14)16-6-9(7-17-11(13)15)8-4-2-1-3-5-8/h1-5,9H,6-7H2,(H2,12,14)(H2,13,15) DM1V5ZS CS C1=CC=C(C=C1)C(COC(=O)N)COC(=O)N DM1V5ZS IK WKGXYQFOCVYPAC-UHFFFAOYSA-N DM1V5ZS IU (3-carbamoyloxy-2-phenylpropyl) carbamate DM1V5ZS CA CAS 25451-15-4 DM1V5ZS CB CHEBI:4995 DM1V5ZS DE Epilepsy DMKZEIB ID DMKZEIB DMKZEIB DN Felbinac DMKZEIB HS Approved DMKZEIB SN Felbinac); Felbinac, Takeda Chemical Industries Ltd; Seltouch, Takeda DMKZEIB CP Takeda Pharmaceutical Co Ltd DMKZEIB DT Small molecular drug DMKZEIB PC 3332 DMKZEIB MW 212.24 DMKZEIB FM C14H12O2 DMKZEIB IC InChI=1S/C14H12O2/c15-14(16)10-11-6-8-13(9-7-11)12-4-2-1-3-5-12/h1-9H,10H2,(H,15,16) DMKZEIB CS C1=CC=C(C=C1)C2=CC=C(C=C2)CC(=O)O DMKZEIB IK QRZAKQDHEVVFRX-UHFFFAOYSA-N DMKZEIB IU 2-(4-phenylphenyl)acetic acid DMKZEIB CA CAS 5728-52-9 DMKZEIB CB CHEBI:31597 DMKZEIB DE Arthritis DMOSW35 ID DMOSW35 DMOSW35 DN Felodipine DMOSW35 HS Approved DMOSW35 SN Agon; Felobeta; Felocor; Feloday; Felodipina; Felodipinum; Felodur; Felogamma; Felogard; Fensel; Flodil; Hydac; Lexxel; Logimax; Modip; Munobal; Penedil; Perfudal; Plandil; Plendil; Preslow; Prevex; Renedil; Splendil; AGON SR; AbZ Brand of Felodipine; Aliud Brand of Felodipine; Alphapharm Brand of Felodipine; Alpharma Brand of Felodipine; Astra Brand of Felodipine; AstraZeneca Brand of Felodipine; Aventis Brand of Felodipine; Azupharma Brand of Felodipine; BC Brand of Felodipine; Betapharm Brand of Felodipine; Ct Arzneimittel Brand of Felodipine; Felo Biochemie; Felo Puren; Felodipin AL; Felodipin AZU; Felodipin AbZ; Felodipin Heumann; Felodipin Stada; Felodipin dura; Felodipin ratiopharm; Felodipin von ct; FelodurER; Heumann Brand of Felodipine; Hexal Brand of Felodipine; Hoechst Brand of Felodipine; Merck dura Brand of Felodipine; Munobal Retard; Pharmaceutica Astra Brand of Felodipine; Pharmacia Spain Brandof Felodipine; Plendil Depottab; Plendil ER; Plendil Retard; Promed Brand of Felodipine; Ratiopharm Brand of Felodipine; Stadapharm Brand of Felodipine; TheraPharm Brand of Felodipine; Worwag Brand of Felodipine; F 9677; Felodipin 1A Pharma; H 154 82; H 15482; CGH-869; Ct-Arzneimittel Brand of Felodipine; Dl-Felodipine; Felo-Puren; Felodipin-ratiopharm; Felodipina [INN-Spanish]; Felodipinum [INN-Latin]; H 154-82; H 154/82; Heumann, Felodipin; Plendil (TN); AE-641/11429675; Felodipine [USAN:BAN:INN]; Felodipine [USAN:INN:BAN]; H-154/82; Felodipine (JAN/USP/INN); Plendil, Renedil, Feloday, Felodipine; Ethyl methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate; (+-)-Ethyl methyl 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate; (+/-)-ethylmethyl 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate; 1A Brand of Felodipine; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-4-(2,3-dichlorophenyl)-2,6-dimethyl-, ethyl methylester; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-4-(2,3-dichlorophenyl)-2,6-dimethyl-,ethyl methyl ester; 3,5-Pyridinedicarboxylic acid, 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-, ethyl methyl ester; 3-Ethyl 5-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydro-3,5-pyridinedicarboxylate; 3-ethyl 5-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate; 4-(2,3-Dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinecarboxylic acid ethyl methyl ester; 4-(2,3-dichloro-phenyl)-2,6-dimethyl-1,4-dihydro-pyridine-3,5-dicarboxylic acid 3-ethyl ester 5-methyl ester; 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid ethyl methyl ester; 5-O-ethyl 3-O-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate DMOSW35 CP AstraZeneca DMOSW35 TC Antihypertensive Agents DMOSW35 DT Small molecular drug DMOSW35 PC 3333 DMOSW35 MW 384.2 DMOSW35 FM C18H19Cl2NO4 DMOSW35 IC InChI=1S/C18H19Cl2NO4/c1-5-25-18(23)14-10(3)21-9(2)13(17(22)24-4)15(14)11-7-6-8-12(19)16(11)20/h6-8,15,21H,5H2,1-4H3 DMOSW35 CS CCOC(=O)C1=C(NC(=C(C1C2=C(C(=CC=C2)Cl)Cl)C(=O)OC)C)C DMOSW35 IK RZTAMFZIAATZDJ-UHFFFAOYSA-N DMOSW35 IU 5-O-ethyl 3-O-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate DMOSW35 CA CAS 72509-76-3 DMOSW35 CB CHEBI:585948 DMOSW35 DE Hypertension DMHLP9C ID DMHLP9C DMHLP9C DN Felypressin DMHLP9C HS Approved DMHLP9C SN Felipresina; Felipressina; Felypressine; Felypressinum; Octapressin; Octopressin; Phelypressin; Felipressina [DCIT]; Phenylalanine Lysine Vasopressin; Felipresina [INN-Spanish]; Felypressine [INN-French]; Felypressinum [INN-Latin]; Octapressin (TN); PLV-2; Felypressin [USAN:INN:BAN]; Vasopressin, Phenylalanyl-Lysyl; L-Cysteinyl-L-phenylalanyl-L-phenylalanyl-L-glutaminyl-L-asparaginyl-L-cysteinyl-L-prolyl-L-lysylglycinamide cyclic (1-6)disulfide; L-Cysteinyl-L-phenylalanyl-L-phenylalanyl-L-glutaminyl-L-asparaginyl-L-cysteinyl-L-prolyl-L-lysylglycinamide cyclic (1->6)disulfide; 1-{[19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13,16-dibenzyl-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-4-yl]carbonyl}prolyllysylglycinamide; 2-(L-Phenylalanine)-8-L-lysinevasopressin; N-[6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]-1-[19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13,16-dibenzyl-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]pyrrolidine-2-carboxamide DMHLP9C CP AstraZeneca DMHLP9C TC Vasoconstrictor Agents DMHLP9C DT Small molecular drug DMHLP9C PC 14257662 DMHLP9C MW 1040.2 DMHLP9C FM C46H65N13O11S2 DMHLP9C IC InChI=1S/C46H65N13O11S2/c47-18-8-7-14-29(40(64)52-23-38(51)62)54-45(69)35-15-9-19-59(35)46(70)34-25-72-71-24-28(48)39(63)55-31(20-26-10-3-1-4-11-26)43(67)56-32(21-27-12-5-2-6-13-27)42(66)53-30(16-17-36(49)60)41(65)57-33(22-37(50)61)44(68)58-34/h1-6,10-13,28-35H,7-9,14-25,47-48H2,(H2,49,60)(H2,50,61)(H2,51,62)(H,52,64)(H,53,66)(H,54,69)(H,55,63)(H,56,67)(H,57,65)(H,58,68)/t28-,29-,30-,31-,32-,33-,34-,35-/m0/s1 DMHLP9C CS C1C[C@H](N(C1)C(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=CC=C4)N)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N DMHLP9C IK SFKQVVDKFKYTNA-DZCXQCEKSA-N DMHLP9C IU (2S)-N-[(2S)-6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]-1-[(4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13,16-dibenzyl-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]pyrrolidine-2-carboxamide DMHLP9C CA CAS 56-59-7 DMHLP9C CB CHEBI:60564 DMHLP9C DE Localisation DMXGDFK ID DMXGDFK DMXGDFK DN Fenbufen DMXGDFK HS Approved DMXGDFK SN fenbufen; 36330-85-5; Lederfen; Cinopal; Napanol; Bufemid; 4-(4-Biphenylyl)-4-oxobutyric acid; 3-(4-Phenylbenzoyl)propionic acid; 3-(4-Biphenylylcarbonyl)propionic acid; 4-(biphenyl-4-yl)-4-oxobutanoic acid; gamma-Oxo(1,1'-biphenyl)-4-butanoic acid; 3-(4-Biphenylcarbonyl)propionic acid; Cinopol; Fenbufenum [INN-Latin]; Fenbufene [INN-French]; 4-([1,1'-biphenyl]-4-yl)-4-oxobutanoic acid; CL-82204; CL 82204; 4-biphenyl-4-yl-4-oxobutanoic acid; Butyric acid 4-(4-biphenyl)-4-oxo-; UNII-9815R1WR9B; 4-oxo-4-(4-phenylphenyl)butanoic a DMXGDFK DT Small molecular drug DMXGDFK PC 3335 DMXGDFK MW 254.28 DMXGDFK FM C16H14O3 DMXGDFK IC InChI=1S/C16H14O3/c17-15(10-11-16(18)19)14-8-6-13(7-9-14)12-4-2-1-3-5-12/h1-9H,10-11H2,(H,18,19) DMXGDFK CS C1=CC=C(C=C1)C2=CC=C(C=C2)C(=O)CCC(=O)O DMXGDFK IK ZPAKPRAICRBAOD-UHFFFAOYSA-N DMXGDFK IU 4-oxo-4-(4-phenylphenyl)butanoic acid DMXGDFK CA CAS 36330-85-5 DMXGDFK CB CHEBI:31599 DMXGDFK DE Arthritis DM0LRU9 ID DM0LRU9 DM0LRU9 DN Fendrix DM0LRU9 HS Approved DM0LRU9 SN Fendrix Extra Strength; New hepatitis B prophylactic vaccine, GlaxoSmithKline; HBV prophylactic vaccine (new), GlaxoSmithKline; Hepatitis B prophylactic vaccine (extra strength), GlaxoSmithKline; MPL hepatitis B vaccine, GSK/Corixa; SBAS4-adjuvanted hepatitis B vaccine, GlaxoSmithKline; SBAS4-adjuvanted hepatitis B vaccine, SmithKline Beecham; SBAS4/MPL (HBV vaccine), GlaxoSmithKline/Ribi; SBAS4/MPL (HBV vaccine), SmithKline Beecham/Ribi DM0LRU9 CP GlaxoSmithKline Biologicals DM0LRU9 DT Vaccine DM0LRU9 DE Hepatitis B virus infection DMFKXDY ID DMFKXDY DMFKXDY DN Fenofibrate DMFKXDY HS Approved DMFKXDY SN Ankebin; Antara; Controlip; Durafenat; Elasterate; Elasterin; FNF; Fenobeta; Fenobrate; Fenofanton; Fenofibrato; Fenofibratum; Fenogal; Fenoglide; Fenomax; Fenotard; Finofibrate; Fulcro; Lipanthyl; Lipantil; Liparison; Lipidex; Lipidil; Lipifen; Lipirex; Lipoclar; Lipofen; Lipofene; Liposit; Lipsin; Lofibra; Luxacor; Nolipax; Pharmavit; Phenofibrate; Procetofen; Procetofene; Proctofene; Protolipan; Secalip; Sedufen; Supralip; Tricor; Triglide; AbZ Brand of Procetofen; Abbott Brand of Procetofen; Aliud Brand of Procetofen; Antara Micronized Procetofen; Anto Brand of Procetofen; Apo Feno Micro; Apo Fenofibrate; Apotex Brand of Procetofen; Azupharma Brand of Procetofen; Betapharm Brand of Procetofen; Bouchara Brand of Procetofen; Ct Arzneimittel Brand of Procetofen; Fenofibrat AL; Fenofibrat AZU; Fenofibrat AbZ; Fenofibrat FPh; Fenofibrat Heumann; Fenofibrat Hexal; Fenofibrat Stada; Fenofibrat ratiopharm; Fenofibrat von ct; Fenofibrate Debat; Fenofibrate MSD; Fournier Brand of Procetofen; GNR Pharma Brand of Procetofen; Gate Brand of Procetofen; Gen Fenofibrate; Genpharm Brand of Procetofen; Heumann Brand of Procetofen; Hexal Brand of Procetofen; Knoll Brand of Procetofen; Lichtenstein Brand of Procetofen; Lipidil Micro; Lipidil Supra; Lipidil Ter; MTW Brand of Procetofen; MTW Fenofibrat; Merck dura Brand of Procetofen; Novartis Brand of Procetofen; Novo Fenofibrate; Novopharm Brand of Procetofen; Nu Fenofibrate; Nu Pharm Brand of Procetofen; PMS Fenofibrate Micro;Pharmascience Brand of Procetofen; Procetofen Reliant Brand; Q Pharm Brand of Procetofen; Ratiopharm Brand of Procetofen; Reliant Brand of Procetofen; Schering Plough Brand of Procetofen; Stadapharm Brand of Procetofen; United Drug Brand of Procetofen; F 6020; LF 178; LF178; AZU, Fenofibrat; Antara (TN); Antara (micronized); Apo-Fenofibrate; CIP-Fenofibrate; Ct-Arzneimittel Brand of Procetofen; Debat, Fenofibrate; FENOFIBRATE (MICRONIZED); Fenofibrat-ratiopharm; Fenofibrate IDD-P; Fenofibrate [INN:BAN]; Fenofibrato [INN-Spanish]; Fenofibratum [INN-Latin]; Fenogal (TN); GNR-Pharma Brand of Procetofen; GRS-027; Gen-Fenofibrate; Heumann, Fenofibrat; Hexal, Fenofibrat; LCP-Feno; LCP-FenoChol; LF-178; Lipanthyl (TN); Lipantil (TN); Lipidil (TN); Lipidil-Ter; Lipofen (TN); Lofibra (TN); MTW-Fenofibrat; Micronized Procetofen, Antara; Novo-Fenofibrate; Nu-Fenofibrate; Nu-Pharm Brand of Procetofen; PMS-Fenofibrate Micro; Procetofen, Antara Micronized; Q-Pharm Brand of Procetofen; Schering-Plough Brand of Procetofen; Stada, Fenofibrat; TRICOR (MICRONIZED); Tricor (TN); Triglide (TN); Trilipix (TN); Apo-Feno-Micro; Fenocor-67 (TN); Fenofibrate (JAN/INN); Isopropyl 2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoate; Isopropyl 2-(4-(4-chlorobenzoyl)phenoxy)-2-methylpropionate; Isopropyl 2-(p-(p-chlorobenzoyl)phenoxy)-2-methylpropionate DMFKXDY CP Abbott Laboratories DMFKXDY TC Antilipemic Agents DMFKXDY DT Small molecular drug DMFKXDY PC 3339 DMFKXDY MW 360.8 DMFKXDY FM C20H21ClO4 DMFKXDY IC InChI=1S/C20H21ClO4/c1-13(2)24-19(23)20(3,4)25-17-11-7-15(8-12-17)18(22)14-5-9-16(21)10-6-14/h5-13H,1-4H3 DMFKXDY CS CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C2=CC=C(C=C2)Cl DMFKXDY IK YMTINGFKWWXKFG-UHFFFAOYSA-N DMFKXDY IU propan-2-yl 2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoate DMFKXDY CA CAS 49562-28-9 DMFKXDY CB CHEBI:5001 DMFKXDY DE High cholesterol level DMGO2MC ID DMGO2MC DMGO2MC DN Fenofibric acid DMGO2MC HS Approved DMGO2MC SN Fenofibric acid; 42017-89-0; Procetofenic acid; 2-(4-(4-Chlorobenzoyl)phenoxy)-2-methylpropanoic acid; alpha 1081; NSC 281318; LF 178 acid; UNII-BGF9MN2HU1; 2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoic acid; LF 153; FNF Acid; C17H15ClO4; Trilipix; CCRIS 7302; EINECS 255-626-9; BGF9MN2HU1; CHEMBL981; BRN 2058973; CHEBI:83469; 2-[4-(4-Chlorobenzoyl)phenoxy]-2-methylpropionic Acid; Propanoic acid, 2-(4-(4-chlorobenzoyl)phenoxy)-2-methyl-; AK117112; 2-{4-[(4-chlorophenyl)carbonyl]phenoxy}-2-methylpropanoic acid; W-106287 DMGO2MC DT Small molecular drug DMGO2MC PC 64929 DMGO2MC MW 318.7 DMGO2MC FM C17H15ClO4 DMGO2MC IC InChI=1S/C17H15ClO4/c1-17(2,16(20)21)22-14-9-5-12(6-10-14)15(19)11-3-7-13(18)8-4-11/h3-10H,1-2H3,(H,20,21) DMGO2MC CS CC(C)(C(=O)O)OC1=CC=C(C=C1)C(=O)C2=CC=C(C=C2)Cl DMGO2MC IK MQOBSOSZFYZQOK-UHFFFAOYSA-N DMGO2MC IU 2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoic acid DMGO2MC CA CAS 42017-89-0 DMGO2MC CB CHEBI:83469 DMGO2MC DE Cardiovascular disease DMFAOKP ID DMFAOKP DMFAOKP DN Fenoldopam DMFAOKP HS Approved DMFAOKP SN Carlacor; Fenoldopamum; Fenodopam mesylate; Fenoldopamum [Latin]; SKF 82526; Carlacor (TN); Corlopam (TN); Fenoldopam (INN);Fenoldopam [INN:BAN]; SKF 82526-J; SKF-82526J; SK&F-82526; 6-chloro-1-(4-hydroxyphenyl)-2,3,4,5-tetrahydro-1H-3-benzazepine-7,8-diol; 9-chloro-5-(4-hydroxyphenyl)-2,3,4,5-tetrahydro-1H-3-benzazepine-7,8-diol DMFAOKP CP Ben Venue Laboratories DMFAOKP TC Antihypertensive Agents DMFAOKP DT Small molecular drug DMFAOKP PC 3341 DMFAOKP MW 305.75 DMFAOKP FM C16H16ClNO3 DMFAOKP IC InChI=1S/C16H16ClNO3/c17-15-11-5-6-18-8-13(9-1-3-10(19)4-2-9)12(11)7-14(20)16(15)21/h1-4,7,13,18-21H,5-6,8H2 DMFAOKP CS C1CNCC(C2=CC(=C(C(=C21)Cl)O)O)C3=CC=C(C=C3)O DMFAOKP IK TVURRHSHRRELCG-UHFFFAOYSA-N DMFAOKP IU 9-chloro-5-(4-hydroxyphenyl)-2,3,4,5-tetrahydro-1H-3-benzazepine-7,8-diol DMFAOKP CA CAS 67227-56-9 DMFAOKP CB CHEBI:5002 DMFAOKP DE Hypertension DML5VQ0 ID DML5VQ0 DML5VQ0 DN Fenoprofen DML5VQ0 HS Approved DML5VQ0 SN Fenoprofene; Fenoprofeno; Fenoprofenum; Feprona; Nalfon; Nalgesic; Feneprofen calcium salt dihydrate; Fenoprofen calcium; Fenoprofen calcium hydrate; Lilly 53838; Fenoprofen Dihydrate, Calcium Salt; Fenoprofene [INN-French]; Fenoprofeno [INN-Spanish]; Fenoprofenum [INN-Latin]; Fenopron (TN); Fenoprofen (USAN/INN); Fenoprofen [USAN:BAN:INN]; Alpha-(m-phenoxyphenyl)propionic acid; Alpha-Methyl-3-phenoxybenzeneacetic acid; (+-)-2-(3-Phenoxyphenyl)propionic acid; (+-)-m-Phenoxyhydratropic acid; 2-(3-Phenoxyphenyl)propanoic acid; 2-(3-Phenoxyphenyl)propionic acid; 2-(m-phenoxyphenyl)propionic acid; 2-[3-(phenyloxy)phenyl]propanoic acid DML5VQ0 CP Typharm Limited DML5VQ0 TC Antiinflammatory Agents DML5VQ0 DT Small molecular drug DML5VQ0 PC 3342 DML5VQ0 MW 242.27 DML5VQ0 FM C15H14O3 DML5VQ0 IC InChI=1S/C15H14O3/c1-11(15(16)17)12-6-5-9-14(10-12)18-13-7-3-2-4-8-13/h2-11H,1H3,(H,16,17) DML5VQ0 CS CC(C1=CC(=CC=C1)OC2=CC=CC=C2)C(=O)O DML5VQ0 IK RDJGLLICXDHJDY-UHFFFAOYSA-N DML5VQ0 IU 2-(3-phenoxyphenyl)propanoic acid DML5VQ0 CA CAS 29679-58-1 DML5VQ0 CB CHEBI:5004 DML5VQ0 DE Rheumatoid arthritis DMIP3ZV ID DMIP3ZV DMIP3ZV DN Fenoterol DMIP3ZV HS Approved DMIP3ZV SN Berotec; Berotek; Fenoterolum; Phenoterol; TH 1165A; Berotec (TN); Fenoterolum [INN-Latin]; P-Hydroxyphenylorciprenaline; Th-1165a; Fenoterol (USAN/INN); Fenoterol [USAN:BAN:INN]; P-Hydroxyphenyl-orciprenaline; 1-(3,5-Dihydroxyphenyl)-1-hydroxy-2-((4-hydroxyphenyl)isopropylamino)ethane; 1-(p-Hydroxyphenyl)-2-((beta-hydroxy-beta-(3',5'-dihydroxyphenyl))ethyl)aminopropane; 3,5-Dihydroxy-alpha-(((p-hydroxy-alpha-methylphenethyl)amino)methyl)benzyl alcohol; 5-(1-hydroxy-2-{[1-(4-hydroxyphenyl)propan-2-yl]amino}ethyl)benzene-1,3-diol; 5-(1-hydroxy-2-{[2-(4-hydroxyphenyl)-1-methylethyl]amino}ethyl)benzene-1,3-diol; 5-[1-hydroxy-2-[1-(4-hydroxyphenyl)propan-2-ylamino]ethyl]benzene-1,3-diol; 5-{1-Hydroxy-2-[2-(4-hydroxy-phenyl)-1-methyl-ethylamino]-ethyl}-benzene-1,3-diol DMIP3ZV CP Boehriger Ingelheim DMIP3ZV TC Bronchodilator Agents DMIP3ZV DT Small molecular drug DMIP3ZV PC 3343 DMIP3ZV MW 303.35 DMIP3ZV FM C17H21NO4 DMIP3ZV IC InChI=1S/C17H21NO4/c1-11(6-12-2-4-14(19)5-3-12)18-10-17(22)13-7-15(20)9-16(21)8-13/h2-5,7-9,11,17-22H,6,10H2,1H3 DMIP3ZV CS CC(CC1=CC=C(C=C1)O)NCC(C2=CC(=CC(=C2)O)O)O DMIP3ZV IK LSLYOANBFKQKPT-UHFFFAOYSA-N DMIP3ZV IU 5-[1-hydroxy-2-[1-(4-hydroxyphenyl)propan-2-ylamino]ethyl]benzene-1,3-diol DMIP3ZV CA CAS 13392-18-2 DMIP3ZV CB CHEBI:149226 DMIP3ZV DE Asthma DM8WAHT ID DM8WAHT DM8WAHT DN Fentanyl DM8WAHT HS Approved DM8WAHT SN fentanyl; Fentanil; Phentanyl; Fentora; Sublimaze; Fentanila; Fentanest; Duragesic; Fentanylum; Durogesic; Sentonil; 437-38-7; Duragesic-100; IONSYS; Duragesic-25; Duragesic-75; Duragesic-50; Duragesic-12; Fentanyl-25; Fentanyl-75; Fentanyl-12; Fentanyl-50; Fentanylum [INN-Latin]; Fentanila [INN-Spanish]; Fentanyl-100; 1-Phenethyl-4-N-propionylanilinopiperidine; Matrifen; Sublimase; N-(1-Phenethylpiperidin-4-yl)-N-phenylpropionamide; N-(1-Phenethyl-4-piperidyl)propionanilide; N-Phenethyl-4-(N-propionylanilino)piperidine; Fentanil [DCIT]; Subsys; Fentanyl-37; Fentanyl-62; Fentanyl-87; Abstral; Actiq; Lazanda; Onsolis; Fentanyl Citrate; Fentanyl Citrate Preservative Free; Sublimaze Preservative Free; fentanyl (transmucosal film, pain), Auxilium Pharmaceuticals DM8WAHT CP Janssen Pharmaceuticals Inc DM8WAHT TC Neurology Agents DM8WAHT DT Small molecular drug DM8WAHT PC 3345 DM8WAHT MW 336.5 DM8WAHT FM C22H28N2O DM8WAHT IC InChI=1S/C22H28N2O/c1-2-22(25)24(20-11-7-4-8-12-20)21-14-17-23(18-15-21)16-13-19-9-5-3-6-10-19/h3-12,21H,2,13-18H2,1H3 DM8WAHT CS CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3 DM8WAHT IK PJMPHNIQZUBGLI-UHFFFAOYSA-N DM8WAHT IU N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide DM8WAHT CA CAS 437-38-7 DM8WAHT CB CHEBI:119915 DM8WAHT DE Analgesia; Pain; Cancer related pain; Chronic pain DM13495 ID DM13495 DM13495 DN Fesoterodine fumarate DM13495 HS Approved DM13495 SN Toviaz (TN) DM13495 CP Pfizer DM13495 DT Small molecular drug DM13495 PC 9849808 DM13495 MW 527.6 DM13495 FM C30H41NO7 DM13495 IC InChI=1S/C26H37NO3.C4H4O4/c1-18(2)26(29)30-25-13-12-21(17-28)16-24(25)23(22-10-8-7-9-11-22)14-15-27(19(3)4)20(5)6;5-3(6)1-2-4(7)8/h7-13,16,18-20,23,28H,14-15,17H2,1-6H3;1-2H,(H,5,6)(H,7,8)/b;2-1+/t23-;/m1./s1 DM13495 CS CC(C)C(=O)OC1=C(C=C(C=C1)CO)[C@H](CCN(C(C)C)C(C)C)C2=CC=CC=C2.C(=C/C(=O)O)\\C(=O)O DM13495 IK MWHXMIASLKXGBU-RNCYCKTQSA-N DM13495 IU (E)-but-2-enedioic acid;[2-[(1R)-3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl] 2-methylpropanoate DM13495 CA CAS 286930-03-8 DM13495 DE Overactive bladder DM17ONX ID DM17ONX DM17ONX DN Fexofenadine DM17ONX HS Approved DM17ONX SN Carboxyterfenadine; Fexofendine; Terfenadine acid metabolite; Terfenadine carboxylate; F 9427; MDL 16455; Allegra (TN); Fastofen (TN); Fexofenadine (INN); Fexofenadine [INN:BAN]; Telfast (TN); Terfenadine-COOH; Terfenidine carboxylate, MDL 16455; Tilfur (TN); 2-[4-(1-hydroxy-4-{4-[hydroxy(diphenyl)methyl]piperidin-1-yl}butyl)phenyl]-2-methylpropanoic acid; 2-[4-[1-hydroxy-4-[4-[hydroxy(diphenyl)methyl]piperidin-1-yl]butyl]phenyl]-2-methylpropanoic acid; 4-(1-Hydroxy-4-(4-(hydroxydiphenylmethyl)-1-piperidinyl)butyl)-alpha,alpha-dimethylbenzeneacetic acid DM17ONX CP Sanofi-Aventis DM17ONX TC Antiallergic Agents DM17ONX DT Small molecular drug DM17ONX PC 3348 DM17ONX MW 501.7 DM17ONX FM C32H39NO4 DM17ONX IC InChI=1S/C32H39NO4/c1-31(2,30(35)36)25-17-15-24(16-18-25)29(34)14-9-21-33-22-19-28(20-23-33)32(37,26-10-5-3-6-11-26)27-12-7-4-8-13-27/h3-8,10-13,15-18,28-29,34,37H,9,14,19-23H2,1-2H3,(H,35,36) DM17ONX CS CC(C)(C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O)C(=O)O DM17ONX IK RWTNPBWLLIMQHL-UHFFFAOYSA-N DM17ONX IU 2-[4-[1-hydroxy-4-[4-[hydroxy(diphenyl)methyl]piperidin-1-yl]butyl]phenyl]-2-methylpropanoic acid DM17ONX CA CAS 83799-24-0 DM17ONX CB CHEBI:5050 DM17ONX DE Allergic rhinitis DM9Q8SO ID DM9Q8SO DM9Q8SO DN Fibrinolysin DM9Q8SO HS Approved DM9Q8SO SQ Fibrinolysin heavy chain: DLLDDYVNTQGASLLSLSRKNLAGRSVEDCAAKCEEETDFVCRAFQYHSKEQQCVVMAENSKNTPVFRMRDVILYEKRIYLLECKTGNGQTYRGTTAETKSGVTCQKWSATSPHVPKFSPEKFPLAGLEENYCRNPDNDENGPWCYTTDPDKRYDYCDIPECEDKCMHCSGENYEGKIAKTMSGRDCQAWDSQSPHAHGYIPSKFPNKNLKMNYCRNPDGEPRPWCFTTDPQKRWEFCDIPRCTTPPPSSGPKYQCLKGTGKNYGGTVAVTESGHTCQRWSEQTPHKHNRTPENFPCKNLEENYCRNPNGEKAPWCYTTNSEVRWEYCTIPSCESSPLSTERMDVPVPPEQTPVPQDCYHGNGQSYRGTSSTTITGRKCQSWSSMTPHRHLKTPENYPNAGLTMNYCRNPDADKSPWCYTTDPRVRWEFCNLKKCSETPEQVPAAPQAPGVENPPEADCMIGTGKSYRGKKATTVAGVPCQEWAAQEPHQHSIFTPETNPQSGLERNYCRNPDGDVNGPWCYTMNPRKPFDYCDVPQCESSFDCGKPKVEPKKCSGR >Fibrinolysin light chainIVGGCVSKPHSWPWQVSLRRSSRHFCGGTLISPKWVLTAAHCLDNILALSFYKVILGAHNEKVREQSVQEIPVSRLFREPSQADIALLKLSRPAIITKEVIPACLPPPNYMVAARTECYITGWGETQGTFGEGLLKEAHLPVIENKVCNRNEYLDGRVKPTELCAGHLIGGTDSCQGDSGGPLVCFEKDKYILQGVTSWGLGCARPNKPGVYVRVSPYVPWIEETMRRN DM9Q8SO DE Wound healing DMFP6MV ID DMFP6MV DMFP6MV DN Fidaxomicin DMFP6MV HS Approved DMFP6MV SN Dificid (TN) DMFP6MV CP Astellas DMFP6MV DT Small molecular drug DMFP6MV PC 10034073 DMFP6MV MW 1058 DMFP6MV FM C52H74Cl2O18 DMFP6MV IC InChI=1S/C52H74Cl2O18/c1-13-30-22-26(6)33(56)18-16-15-17-31(23-66-51-45(65-12)42(61)44(29(9)67-51)69-49(64)35-32(14-2)36(53)39(58)37(54)38(35)57)48(63)68-34(28(8)55)20-19-25(5)21-27(7)43(30)70-50-41(60)40(59)46(52(10,11)72-50)71-47(62)24(3)4/h15-17,19,21-22,24,28-30,33-34,40-46,50-51,55-61H,13-14,18,20,23H2,1-12H3/b16-15+,25-19+,26-22+,27-21+,31-17+/t28-,29-,30+,33+,34+,40-,41+,42+,43+,44-,45+,46+,50-,51-/m1/s1 DMFP6MV CS CC[C@H]1/C=C(/[C@H](C/C=C/C=C(/C(=O)O[C@@H](C/C=C(/C=C(/[C@@H]1O[C@H]2[C@H]([C@H]([C@@H](C(O2)(C)C)OC(=O)C(C)C)O)O)\\C)\\C)[C@@H](C)O)\\CO[C@H]3[C@H]([C@H]([C@@H]([C@H](O3)C)OC(=O)C4=C(C(=C(C(=C4O)Cl)O)Cl)CC)O)OC)O)\\C DMFP6MV IK ZVGNESXIJDCBKN-UUEYKCAUSA-N DMFP6MV IU [(2R,3S,4S,5S,6R)-6-[[(3E,5E,8S,9E,11S,12R,13E,15E,18S)-12-[(2R,3S,4R,5S)-3,4-dihydroxy-6,6-dimethyl-5-(2-methylpropanoyloxy)oxan-2-yl]oxy-11-ethyl-8-hydroxy-18-[(1R)-1-hydroxyethyl]-9,13,15-trimethyl-2-oxo-1-oxacyclooctadeca-3,5,9,13,15-pentaen-3-yl]methoxy]-4-hydroxy-5-methoxy-2-methyloxan-3-yl] 3,5-dichloro-2-ethyl-4,6-dihydroxybenzoate DMFP6MV CA CAS 873857-62-6 DMFP6MV DE Clostridium difficile associated diarrhea DMZEONG ID DMZEONG DMZEONG DN Finafloxacin DMZEONG HS Approved DMZEONG SN Finafloxacin hydrochloride; Antibacterial (Helicobacter pylori infection/ bacterial urinary tract infection), Combinature; Finafloxacin (iv, bacterial infection), MerLion/Alcon; Finafloxacin (oral, bacterial infection), MerLion/Alcon DMZEONG CP Alcon DMZEONG DT Small molecular drug DMZEONG PC 11567473 DMZEONG MW 398.4 DMZEONG FM C20H19FN4O4 DMZEONG IC InChI=1S/C20H19FN4O4/c21-14-5-11-17(25(10-1-2-10)7-13(19(11)26)20(27)28)12(6-22)18(14)24-8-15-16(9-24)29-4-3-23-15/h5,7,10,15-16,23H,1-4,8-9H2,(H,27,28)/t15-,16-/m0/s1 DMZEONG CS C1CC1N2C=C(C(=O)C3=CC(=C(C(=C32)C#N)N4C[C@H]5[C@H](C4)OCCN5)F)C(=O)O DMZEONG IK FYMHQCNFKNMJAV-HOTGVXAUSA-N DMZEONG IU 7-[(4aS,7aS)-3,4,4a,5,7,7a-hexahydro-2H-pyrrolo[3,4-b][1,4]oxazin-6-yl]-8-cyano-1-cyclopropyl-6-fluoro-4-oxoquinoline-3-carboxylic acid DMZEONG CA CAS 209342-40-5 DMZEONG CB CHEBI:85176 DMZEONG DE Urinary tract infection DMWV3TZ ID DMWV3TZ DMWV3TZ DN Finasteride DMWV3TZ HS Approved DMWV3TZ SN Andozac; Eucoprost; FIT; Finasterida; Finasteridum; Finastid; Finpecia; Propecia; Propeshia; Proscar; Prostide; Cahill May Roberts Brand of Finasteride; Chibro Proscar; Frosst Iberica Brand of Finasteride; Lipha Brand of Finasteride; MSD Brand of Finasteride; MSD Chibropharm Brand of Finasteride; MK 0906; MK 906; MK906; Merck Brand 1 of Finasteride; Merck Brand 2 of Finasteride; Merck Frosst Brand 1 of Finasteride; Merck Frosst Brand 2 of Finasteride; Alternova (TN); Appecia (TN); Chibro-Proscar; Finalo (TN); Finara (TN); Finast (TN); Finasterid (TN); Finasterid IVAX (TN); Finasterida [INN-Spanish]; Finasteridum [INN-Latin]; Finax (TN); Fincar (TN); Finpecia (TN); Gefina (TN); KS-1058; MK-0906; MK-906; Merck Sharp & Dhome Brand 2 of Finasteride; Merck Sharp & Dohme Brand 1 of Finasteride; Propecia (TN); Proscar (TN); Prosteride (TN); YM-152; Finasteride (USP/INN); Finasteride [USAN:INN:BAN]; L-652,931; Proscar, Propecia, Finasteride; N-tert-Butyl-3-oxo-4-aza-5alpha-androst-1-en-17beta-carboxamide; N-tert-Butyl-3-oxo-4-aza-5alpha-androst-1-ene-17beta-carboxamide; N-(2-methyl-2-propyl)-3-oxo-4-aza-5alpha-androst-1-ene-17beta-carboxamide; N-(2-Methyl-2-propyl)-3-oxo-4-aza-5-alpha-androst-1-ene-17-beta-carboxamide; (1S,3aS,3bS,5aR,9aR,9bS,11aS)-N-tert-butyl-9a,11a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,5a,6,9b,10,11-dodecahydroindeno[5,4-f]quinoline-1-carboxamide; (4aR,4bS,6aS,7S,9aS,9bS,11aR)-N-(1,1-dimethylethyl)-4a,6a-dimethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide; (4aR,4bS,6aS,7S,9aS,9bS,11aR)-N-(tert-butyl)-4a,6a-dimethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide; (5alpha,17beta)-(1,1-Dimethylethyl)-3-oxo-4-azaandrost-1-ene-17-carboxamide; 17beta-(N-tert-butylcarbamoyl)-4-aza-5 alpha-androst-1-en-3-one DMWV3TZ CP Merck DMWV3TZ TC Antihyperplasia Agents DMWV3TZ DT Small molecular drug DMWV3TZ PC 57363 DMWV3TZ MW 372.5 DMWV3TZ FM C23H36N2O2 DMWV3TZ IC InChI=1S/C23H36N2O2/c1-21(2,3)25-20(27)17-8-7-15-14-6-9-18-23(5,13-11-19(26)24-18)16(14)10-12-22(15,17)4/h11,13-18H,6-10,12H2,1-5H3,(H,24,26)(H,25,27)/t14-,15-,16-,17+,18+,22-,23+/m0/s1 DMWV3TZ CS C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2C(=O)NC(C)(C)C)CC[C@@H]4[C@@]3(C=CC(=O)N4)C DMWV3TZ IK DBEPLOCGEIEOCV-WSBQPABSSA-N DMWV3TZ IU (1S,3aS,3bS,5aR,9aR,9bS,11aS)-N-tert-butyl-9a,11a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,5a,6,9b,10,11-dodecahydroindeno[5,4-f]quinoline-1-carboxamide DMWV3TZ CA CAS 98319-26-7 DMWV3TZ CB CHEBI:5062 DMWV3TZ DE Benign prostatic hyperplasia DM5JVAN ID DM5JVAN DM5JVAN DN Fingolimod DM5JVAN HS Approved DM5JVAN SN 2-Amino-2-(4-octylphenethyl)propane-1,3-diol DM5JVAN CP Novartis DM5JVAN DT Small molecular drug DM5JVAN PC 107970 DM5JVAN MW 307.5 DM5JVAN FM C19H33NO2 DM5JVAN IC InChI=1S/C19H33NO2/c1-2-3-4-5-6-7-8-17-9-11-18(12-10-17)13-14-19(20,15-21)16-22/h9-12,21-22H,2-8,13-16,20H2,1H3 DM5JVAN CS CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N DM5JVAN IK KKGQTZUTZRNORY-UHFFFAOYSA-N DM5JVAN IU 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol DM5JVAN CA CAS 162359-55-9 DM5JVAN CB CHEBI:63115 DM5JVAN DE Primary progressive multiple sclerosis DMKV4NL ID DMKV4NL DMKV4NL DN Flavoxate DMKV4NL HS Approved DMKV4NL SN Bladuril; Flavossato; Flavoxato; Flavoxatum; Urispas; Flavossato [DCIT]; Flavoxate HCI; Flavoxate HCL; Spasuret hydrochloride; AK 123; Bladderon (TN); Bladuril (TN); DW-61; Flavoxate (INN); Flavoxate [INN:BAN]; Flavoxato [INN-Spanish]; Flavoxatum [INN-Latin]; Urispas (TN); Uritac (TN); Zopyran-8-carboxylate; Beta-piperidinoethyl 3-methylflavone-8-carboxylate; Piperidinoethyl-3-methylflavone-8-carboxylate; 1-Piperidinoethanol, 3-methyl-4-oxo-2-phenyl-4H-1-benzopyran-8-carboxylate; 2-(1-Piperidinyl)ethyl 3-methyl-4-oxo-2-phenyl-4H-chromene-8-carboxylate; 2-(piperidin-1-yl)ethyl 3-methyl-4-oxo-2-phenyl-4H-chromene-8-carboxylate; 2-Piperidinoethyl 3-methyl-4-oxo-2-phenyl-4H-1-benzopyran-8-carboxylat; 2-Piperidinoethyl 3-methyl-4-oxo-2-phenyl-4H-1-benzopyran-8-carboxylate; 2-Piperidinoethyl-3-methyl-4-oxo-2-phenyl-4H-1-ben; 2-piperidin-1-ylethyl 3-methyl-4-oxo-2-phenyl-4H-chromene-8-carboxylate; 2-piperidin-1-ylethyl 3-methyl-4-oxo-2-phenylchromene-8-carboxylate; 2-piperidinoethyl 3-methylflavone-8-carboxylate; 4H-1-Benzopyran-8-carboxylic acid, 3-methyl-4-oxo-2-phenyl-, 2-(1-piperidinyl)ethyl ester DMKV4NL CP Nippon Shinyaku DMKV4NL TC Parasympatholytics DMKV4NL DT Small molecular drug DMKV4NL PC 3354 DMKV4NL MW 391.5 DMKV4NL FM C24H25NO4 DMKV4NL IC InChI=1S/C24H25NO4/c1-17-21(26)19-11-8-12-20(23(19)29-22(17)18-9-4-2-5-10-18)24(27)28-16-15-25-13-6-3-7-14-25/h2,4-5,8-12H,3,6-7,13-16H2,1H3 DMKV4NL CS CC1=C(OC2=C(C1=O)C=CC=C2C(=O)OCCN3CCCCC3)C4=CC=CC=C4 DMKV4NL IK SPIUTQOUKAMGCX-UHFFFAOYSA-N DMKV4NL IU 2-piperidin-1-ylethyl 3-methyl-4-oxo-2-phenylchromene-8-carboxylate DMKV4NL CA CAS 15301-69-6 DMKV4NL CB CHEBI:5088 DMKV4NL DE Suprapubic pain; Nocturia; Urgency; Dysuria DMSQDLE ID DMSQDLE DMSQDLE DN Flecainide DMSQDLE HS Approved DMSQDLE SN flecainide; 54143-55-4; Flecaine; Tambocor; Flecainida; Flecainidum; (+-)-Flecainide; Flecainidum [INN-Latin]; Flecainida [INN-Spanish]; N-(piperidin-2-ylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzamide; Flecainide [INN:BAN]; CCRIS 313; Benzamide, N-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)-; C17H20F6N2O3; CHEMBL652; N-(2-Piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzamide; CHEBI:75984; DJBNUMBKLMJRSA-UHFFFAOYSA-N; NCGC00015443-06; DSSTox_CID_3054; DSSTox_RID_76854; DSSTox_GSID_23054; (-)-Flecainide; Flecaine; Almarytm (TN); Apocard (TN); Ecrinal (TN); Flecainide (INN); Tambocor (TN); N-(piperidin-2-ylmethyl)-2,5-bis[(2,2,2-trifluoroethyl)oxy]benzamide; Ic Flecainide DMSQDLE CP 3M pharmaceuticals DMSQDLE TC Antiarrhythmic Agents DMSQDLE DT Small molecular drug DMSQDLE PC 3356 DMSQDLE MW 414.34 DMSQDLE FM C17H20F6N2O3 DMSQDLE IC InChI=1S/C17H20F6N2O3/c18-16(19,20)9-27-12-4-5-14(28-10-17(21,22)23)13(7-12)15(26)25-8-11-3-1-2-6-24-11/h4-5,7,11,24H,1-3,6,8-10H2,(H,25,26) DMSQDLE CS C1CCNC(C1)CNC(=O)C2=C(C=CC(=C2)OCC(F)(F)F)OCC(F)(F)F DMSQDLE IK DJBNUMBKLMJRSA-UHFFFAOYSA-N DMSQDLE IU N-(piperidin-2-ylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzamide DMSQDLE CA CAS 54143-55-4 DMSQDLE CB CHEBI:75984 DMSQDLE DE Tachyarrhythmias; Atrial fibrillation; Paroxysmal atrial fibrillation DMXGQYZ ID DMXGQYZ DMXGQYZ DN Fleroxacin DMXGQYZ HS Approved DMXGQYZ SN FLRX; Fleroxacine; Fleroxacino; Fleroxacinum; Fleroxicin; Megalocin; Megalone; Megalosin; Quinodis; Fleroxacine [French]; Fleroxacino [Spanish]; Fleroxacinum [Latin]; AM 833; F0646; AM-833; Megalocin (TN); Megalone (TN); Quinodis (TN); Ro 23-6240; Ro-236240; Ro 23-6240/000; Fleroxacin (JAN/USAN/INN); Fleroxacin [USAN:BAN:INN:JAN]; Ro-23-6240/000; 6,8-Difluoro-1-(2-fluoroethyl)-1,4-dihydro-7-(4-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid; 6,8-Difluoro-1-(2-fluoroethyl)-1,4-dihydro-7-(4-methylpiperazino)-4-oxo-3-quinolinecarboxylic acid; 6,8-Difluoro-1-(2-fluoroethyl)1,4-dihydro-7-(4-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid; 6,8-difluoro-1-(2-fluoroethyl)-7-(4-methyl-1-piperazinyl)-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid; 6,8-difluoro-1-(2-fluoroethyl)-7-(4-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid DMXGQYZ TC Antiinfective Agents DMXGQYZ DT Small molecular drug DMXGQYZ PC 3357 DMXGQYZ MW 369.34 DMXGQYZ FM C17H18F3N3O3 DMXGQYZ IC InChI=1S/C17H18F3N3O3/c1-21-4-6-22(7-5-21)15-12(19)8-10-14(13(15)20)23(3-2-18)9-11(16(10)24)17(25)26/h8-9H,2-7H2,1H3,(H,25,26) DMXGQYZ CS CN1CCN(CC1)C2=C(C=C3C(=C2F)N(C=C(C3=O)C(=O)O)CCF)F DMXGQYZ IK XBJBPGROQZJDOJ-UHFFFAOYSA-N DMXGQYZ IU 6,8-difluoro-1-(2-fluoroethyl)-7-(4-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid DMXGQYZ CA CAS 79660-72-3 DMXGQYZ CB CHEBI:31810 DMXGQYZ DE Bacterial infection DM70DTN ID DM70DTN DM70DTN DN Flibanserin DM70DTN HS Approved DM70DTN SN Flibanserin [USAN]; Bimt 17; Bimt-17; 1,3-Dihydro-1-(2-(4-(3-(trifluoromethyl)phenyl)-1-piperazinyl)ethyl)-2H-benzimidazol-2-one; 1-(2-(4-(3-Trifluoromethylphenyl)piperazin-1-yl)ethyl)benzimidazol(1H)-2-one; 1-(2-(4-(alpha,alpha,alpha-Trifluoro-m-tolyl)-1-piperazinyl)ethyl)-2-benzimidazolinone; 1-(2-(4-alpha,alpha,alpha-Trifluoro-m-tolyl)-1-piperazinyl)ethyl)-2-benzimidazolinone; 3-[2-[4-[4-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]-1H-benzimidazol-2-one DM70DTN CP Boehringer Ingelheim DM70DTN DT Small molecular drug DM70DTN PC 6918248 DM70DTN MW 390.4 DM70DTN FM C20H21F3N4O DM70DTN IC InChI=1S/C20H21F3N4O/c21-20(22,23)15-4-3-5-16(14-15)26-11-8-25(9-12-26)10-13-27-18-7-2-1-6-17(18)24-19(27)28/h1-7,14H,8-13H2,(H,24,28) DM70DTN CS C1CN(CCN1CCN2C3=CC=CC=C3NC2=O)C4=CC=CC(=C4)C(F)(F)F DM70DTN IK PPRRDFIXUUSXRA-UHFFFAOYSA-N DM70DTN IU 3-[2-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]-1H-benzimidazol-2-one DM70DTN CA CAS 167933-07-5 DM70DTN CB CHEBI:90865 DM70DTN DE Mood disorder; Female sexual arousal dysfunction DMJ8A3Z ID DMJ8A3Z DMJ8A3Z DN Florbetapir F-18 DMJ8A3Z HS Approved DMJ8A3Z SN Amyvid (TN) DMJ8A3Z CP Avid Radiopharmaceuticals DMJ8A3Z DT Small molecular drug DMJ8A3Z PC 24822371 DMJ8A3Z MW 359.4 DMJ8A3Z FM C20H25FN2O3 DMJ8A3Z IC InChI=1S/C20H25FN2O3/c1-22-19-7-4-17(5-8-19)2-3-18-6-9-20(23-16-18)26-15-14-25-13-12-24-11-10-21/h2-9,16,22H,10-15H2,1H3/b3-2+/i21-1 DMJ8A3Z CS CNC1=CC=C(C=C1)/C=C/C2=CN=C(C=C2)OCCOCCOCC[18F] DMJ8A3Z IK YNDIAUKFXKEXSV-CRYLGTRXSA-N DMJ8A3Z IU 4-[(E)-2-[6-[2-[2-(2-(18F)fluoranylethoxy)ethoxy]ethoxy]pyridin-3-yl]ethenyl]-N-methylaniline DMJ8A3Z CA CAS 956103-76-7 DMJ8A3Z CB CHEBI:66880 DMJ8A3Z DE Diagnostic imaging DM04LR2 ID DM04LR2 DM04LR2 DN Floxuridine DM04LR2 HS Approved DM04LR2 SN floxuridine; 50-91-9; 2'-Deoxy-5-fluorouridine; 5-Fluorodeoxyuridine; Fluorodeoxyuridine; Floxuridin; FUDR; Fluoruridine deoxyribose; Deoxyfluorouridine; 5-Fluoro-2'-deoxyuridine; FdUrd; Floxuridinum; Floxiridina; 5FdU; 5-fluoro-1-((2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidine-2,4(1h,3h)-dione; 5-Fluoro-2-desoxyuridine; 5 Fluorodeoxyuridine; Floxuridinum [INN-Latin]; FDUR; Floxiridina [INN-Spanish]; beta-5-Fluoro-2'-deoxyuridine; 5-Fluoro-2-deoxyuridine; 5-FdUrd; 5-Fluorouracil deoxyriboside; Sterile fudr (TN); Floxuridine/5-fluorouracil DM04LR2 CP Heidelberger DM04LR2 DT Small molecular drug DM04LR2 PC 5790 DM04LR2 MW 246.19 DM04LR2 FM C9H11FN2O5 DM04LR2 IC InChI=1S/C9H11FN2O5/c10-4-2-12(9(16)11-8(4)15)7-1-5(14)6(3-13)17-7/h2,5-7,13-14H,1,3H2,(H,11,15,16)/t5-,6+,7+/m0/s1 DM04LR2 CS C1[C@@H]([C@H](O[C@H]1N2C=C(C(=O)NC2=O)F)CO)O DM04LR2 IK ODKNJVUHOIMIIZ-RRKCRQDMSA-N DM04LR2 IU 5-fluoro-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione DM04LR2 CA CAS 50-91-9 DM04LR2 CB CHEBI:60761 DM04LR2 DE Solid tumour/cancer; Colorectal cancer DMNUWST ID DMNUWST DMNUWST DN Flucloxacillin DMNUWST HS Approved DMNUWST SN FLOXACILLIN; Floxapen; Fluclox; Flucloxacilina; Flucloxacilline; Flucloxacillinum; Fluorochloroxacillin; MFIPC; Floxacillin [USAN]; Flucloxacillin sodium; BRL 2039; Flopen (TN); Floxacillin (USAN); Floxapen (TN); Flucloxacilina [INN-Spanish]; Flucloxacillin (INN); Flucloxacillin-Sodium; Flucloxacilline [INN-French]; Flucloxacillinum [INN-Latin]; Rel-(2R,6S)-6-({[3-(2-chloro-6-fluorophenyl)-5-methylisoxazol-4-yl]carbonyl}amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylato; (2S,5R,6R)-6-({[3-(2-chloro-6-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]carbonyl}amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-({[3-(2-chloro-6-fluorophenyl)-5-methylisoxazol-4-yl]carbonyl}amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-[[3-(2-chloro-6-fluorophenyl)-5-methyl-1,2-oxazole-4-carbonyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 3-(2-Chloro-6-fluorophenyl)-5-methyl-4-isoxazolylpenicillin; 4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-(((3-(2-chloro-6-fluorophenyl)-5-methyl-4-isoxazolyl)carbonyl)amino)-3,3-dimethyl-7-oxo-, (2S(2alpha,5alpha,6beta)); 6beta-[3-(2-chloro-6-fluorophenyl)-5-methyl-1,2-oxazole-4-carboxamido]-2,2-dimethylpenam-3alpha-carboxylic acid DMNUWST CP GlaxoSmithKline DMNUWST TC Antibiotics DMNUWST DT Small molecular drug DMNUWST PC 21319 DMNUWST MW 453.9 DMNUWST FM C19H17ClFN3O5S DMNUWST IC InChI=1S/C19H17ClFN3O5S/c1-7-10(12(23-29-7)11-8(20)5-4-6-9(11)21)15(25)22-13-16(26)24-14(18(27)28)19(2,3)30-17(13)24/h4-6,13-14,17H,1-3H3,(H,22,25)(H,27,28)/t13-,14+,17-/m1/s1 DMNUWST CS CC1=C(C(=NO1)C2=C(C=CC=C2Cl)F)C(=O)N[C@H]3[C@@H]4N(C3=O)[C@H](C(S4)(C)C)C(=O)O DMNUWST IK UIOFUWFRIANQPC-JKIFEVAISA-N DMNUWST IU (2S,5R,6R)-6-[[3-(2-chloro-6-fluorophenyl)-5-methyl-1,2-oxazole-4-carbonyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid DMNUWST CA CAS 5250-39-5 DMNUWST CB CHEBI:5098 DMNUWST DE Bacterial infection DMOWZ6B ID DMOWZ6B DMOWZ6B DN Fluconazole DMOWZ6B HS Approved DMOWZ6B SN Afungil; Alflucoz; Baten; Beagyne; Biocanol; Biozolene; Canzol; Cryptal; Diflazon; Diflucan; Dimycon; Elazor; FCZ; FLCZ; Flucazol; FlucoLich; Flucobeta; Fluconazol; Fluconazolum; Flucostat; Flukezol; Flunazul; Flunizol; Fluzone; Forcan; Fuconal; Fungata; Lavisa; Loitin; Mutum; Neofomiral; Oxifugol; Oxifungol; Pritenzol; Solacap; Syscan; TPF; Triflucan; Zemyc; Zoltec; Zonal; AbZ Brand of Fluconazole; Aliud Brand of Fluconazole; Alpharma Brand of Fluconazole; Apo Fluconazole; Apotex Brand of Fluconazole; Armstrong Brand of Fluconazole; Betapharm Brand of Fluconazole; Chemia Brand of Fluconazole; Ct Arzneimittel Brand of Fluconazole; Effik Brand of Fluconazole; Fluc Hexal; Fluconazol AL; Fluconazol AbZ; Fluconazol Isis; Fluconazol Stada; Fluconazol [Spanish]; Fluconazol ratiopharm; Fluconazol von ct; Fluconazolum [Latin]; Hexal Brand of Fluconazole; Lesvi Brand of Fluconazole; Lichtenstein Brand of Fluconazole; Mack Brand of Fluconazole; Pfizer Brand of Fluconazole; Pfleger Brand of Fluconazole; Ratiopharm Brand of Fluconazole; SAT Brand of Fluconazole; Silanes Brand of Fluconazole; Stada Brand of Fluconazole; Vita Brand of Fluconazole; F0677; Fluconazole in combination with MGCD290; UK 49858; UK49858; Alfumet (TN); Apo-Fluconazole; Ct-Arzneimittel Brand of Fluconazole; DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER; DRG-0005; Diflucan (TN); Fluconazol-Isis; Fluconazol-ratiopharm; Fluconazole & Bovine Lactoferrin; Fluconazole & Human recombinant granulocyte colony stimulating factor; Fluconazole & hGCSF; Fluconazole in dextrose 5% in plastic container; Flucytosine & Nyotran; GL663142 & Fluconazole; KS-1059; Trican (TN); UK-49858; DIFLUCAN IN SODIUM CHLORIDE 0.9%; DIFLUCAN IN SODIUM CHLORIDE 0.9%IN PLASTIC CONTAINER; Fluconazole in sodium chloride 0.9%; Fluconazole in sodium chloride 0.9% in plastic container; Flucytosine & Nyotran(Liposomal Nystatin); XMP.284 & Fluconazole; XMP.366 & Fluconazole; XMP.391 & Fluconazole; Diflucan, Trican, Alfumet, Fluconazole; Fluconazole & MC-510,011; Fluconazole (JAN/USAN/INN); Fluconazole [USAN:INN:BAN:JAN]; 2,4-Difluoro-alpha,alpha-bis(1H-1,2,4-triazol-1-ylmethyl)benzyl alcohol; 2,4-difluoro-,1-bis(1H-1,2,4-triazol-1-ylmethyl)benzyl alcohol; 2-(2,4-DIFLUOROPHENYL)-1,3-DI(1H-1,2,4-TRIAZOL-1-YL)PROPAN-2-OL; 2-(2,4-Difluoro-phenyl)-1,3-bis-[1,2,4]triazol-1-yl-propan-2-ol; 2-(2,4-Difluorophenyl)-1,3-bis(1H-1,2,4-triazol-1-yl)-2-propanol; 2-(2,4-Difluorophenyl)-1,3-bis(1H-1,2,4-triazol-1-yl)propan-2-ol; 2-(2,4-Difluorophenyl)-1,3-di-1H-1,2,4-triazol-1-ylpropan-2-ol; 2-(2,4-difluorophenyl)-1,3-bis(1,2,4-triazol-1-yl)propan-2-ol DMOWZ6B CP Pfizer DMOWZ6B TC Antifungal Agents DMOWZ6B DT Small molecular drug DMOWZ6B PC 3365 DMOWZ6B MW 306.27 DMOWZ6B FM C13H12F2N6O DMOWZ6B IC InChI=1S/C13H12F2N6O/c14-10-1-2-11(12(15)3-10)13(22,4-20-8-16-6-18-20)5-21-9-17-7-19-21/h1-3,6-9,22H,4-5H2 DMOWZ6B CS C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O DMOWZ6B IK RFHAOTPXVQNOHP-UHFFFAOYSA-N DMOWZ6B IU 2-(2,4-difluorophenyl)-1,3-bis(1,2,4-triazol-1-yl)propan-2-ol DMOWZ6B CA CAS 86386-73-4 DMOWZ6B CB CHEBI:46081 DMOWZ6B DE Fungal infection DM13VTW ID DM13VTW DM13VTW DN Flucytosine DM13VTW HS Approved DM13VTW SN Alcobon; Ancobon; Ancotil; Ancotyl; Flucitosina; Flucystine; Flucytosin; Flucytosinum; Flucytosone; Fluocytosine; Fluorcytosine; Fluorocytosine; Flucitosina [DCIT]; F0321; LT00771985; Ancobon (TN); Flucytosinum [INN-Latin]; GL663142 & 5FC; Ro 2-9915; Ro 29915 E/265601; Ro-2-9915; Flucytosine (JP15/USP/INN); Flucytosine [USAN:INN:BAN:JAN]; Cytosine, 5-fluoro-(6CI,7CI,8CI); GL663142 & 4-Amino-5-fluoropyrimidin-2(1H)-one; 2(1H)-Pyrimidinone, 4-amino-5-fluoro-); 2-Hydroxy-4-amino-5-fluoropyrimidine; 4-Amino-5-fluoro-2(1H)-pyrimidinone; 4-Amino-5-fluoro-2-hydroxypyrimidine; 4-Amino-5-fluoro-2-hyroxypyrimidine; 4-Amino-5-fluoropyrimidin-2(1H)-one; 5-FC; 5-Flucytosine; 5-Fluorocystosine; 5-Fluorocytosin; 5-Fluorocytosine; 5-Fluorocytosine-6-3H; 5-Flurocytosine; 5-fluoro cytosine; 5987P; 6-Amino-2-oxo-5-fluoropyrimidine; 6-amino-5-fluoro-1H-pyrimidin-2-one; 9074P DM13VTW TC Antifungal Agents DM13VTW DT Small molecular drug DM13VTW PC 3366 DM13VTW MW 129.09 DM13VTW FM C4H4FN3O DM13VTW IC InChI=1S/C4H4FN3O/c5-2-1-7-4(9)8-3(2)6/h1H,(H3,6,7,8,9) DM13VTW CS C1=NC(=O)NC(=C1F)N DM13VTW IK XRECTZIEBJDKEO-UHFFFAOYSA-N DM13VTW IU 6-amino-5-fluoro-1H-pyrimidin-2-one DM13VTW CA CAS 2022-85-7 DM13VTW CB CHEBI:5100 DM13VTW DE Endocarditis DMVRLT7 ID DMVRLT7 DMVRLT7 DN Fludarabine DMVRLT7 HS Approved DMVRLT7 SN FaraA; Fludarabina; Fludarabinum; Fluradosa; Fludarabina [Spanish]; Fludarabine [INN]; Fludarabinum [Latin]; SQ Fludarabine; Fludara, Fludarabine; Fludarabine (INN); Fluradosa (TN); F-Ara-A; (2R,3S,4S,5R)-2-(6-amino-2-fluoro-9H-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol; (2R,3S,4S,5R)-2-(6-amino-2-fluoropurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol; 2-F-ara-A; 2-Fluoro Ara-A; 2-Fluoro-9-beta-D-arabinofuranosyladenine; 9-beta-D-Arabinofuranosyl-2-fluoroadenine; 9-beta-D-arabinofuranosyl-2-fluoro-9H-purin-6-amine; 9H-Purin-6-amine, 9-beta-D-arabinofuranosyl-2-fluoro-(9CI) DMVRLT7 CP Genzyme Corp DMVRLT7 TC Anticancer Agents DMVRLT7 DT Small molecular drug DMVRLT7 PC 657237 DMVRLT7 MW 285.23 DMVRLT7 FM C10H12FN5O4 DMVRLT7 IC InChI=1S/C10H12FN5O4/c11-10-14-7(12)4-8(15-10)16(2-13-4)9-6(19)5(18)3(1-17)20-9/h2-3,5-6,9,17-19H,1H2,(H2,12,14,15)/t3-,5-,6+,9-/m1/s1 DMVRLT7 CS C1=NC2=C(N=C(N=C2N1[C@H]3[C@H]([C@@H]([C@H](O3)CO)O)O)F)N DMVRLT7 IK HBUBKKRHXORPQB-FJFJXFQQSA-N DMVRLT7 IU (2R,3S,4S,5R)-2-(6-amino-2-fluoropurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol DMVRLT7 CA CAS 21679-14-1 DMVRLT7 CB CHEBI:94701 DMVRLT7 DE Haematological malignancy DMD2K4I ID DMD2K4I DMD2K4I DN Fludiazepam DMD2K4I HS Approved DMD2K4I SN Erispan; Fludiazepamum; ID 540; Erispan (TN); Fludiazepam [INN:JAN]; Fludiazepamum [INN-Latin]; ID-540; Fludiazepam (JP15/INN); 2H-1,4-Benzodiazepin-2-one, 7-chloro-5-(2-fluorophenyl)-1,3-dihydro-1-methyl-(9CI); 7-Chloro-5-(2-fluorophenyl)-1,3-dihydro-1-methyl-2H-1,4-benzodiazepin-2-one; 7-Chloro-5-(2-fluorophenyl)-1-methyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one; 7-Chloro-5-(2-fluorophenyl)-1-methyl-1H-1,4-benzodiazepin-2(3H)-one; 7-Chloro-5-(o-Fluorophenyl)-1,3-dihydro-1-methyl-2H-1,4-benzodiazepin-2-one; 7-chloro-5-(2-fluorophenyl)-1-methyl-3H-1,4-benzodiazepin-2-one DMD2K4I CP Dainippon Sumitomo Pharma DMD2K4I TC Antianxiety Agents DMD2K4I DT Small molecular drug DMD2K4I PC 3369 DMD2K4I MW 302.73 DMD2K4I FM C16H12ClFN2O DMD2K4I IC InChI=1S/C16H12ClFN2O/c1-20-14-7-6-10(17)8-12(14)16(19-9-15(20)21)11-4-2-3-5-13(11)18/h2-8H,9H2,1H3 DMD2K4I CS CN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3F DMD2K4I IK ROYOYTLGDLIGBX-UHFFFAOYSA-N DMD2K4I IU 7-chloro-5-(2-fluorophenyl)-1-methyl-3H-1,4-benzodiazepin-2-one DMD2K4I CA CAS 3900-31-0 DMD2K4I CB CHEBI:31618 DMD2K4I DE Anxiety disorder DMUDIR8 ID DMUDIR8 DMUDIR8 DN Fludrocortisone DMUDIR8 HS Approved DMUDIR8 SN fludrocortisone; Fluorocortisone; Fluorocortisol; Fluohydrisone; Florinef; Fluohydrocortisone; Astonin-H; Fludrocortone; Alflorone; Fludronef; Fludrone; Fluodrocortisone; 127-31-1; F-Cortef; 9alpha-Fluorocortisol; Fludrocortisona; Fludrocortisonum; F-COL; 9-Fluorocortisol; 9 alpha FF; 9-Fluorohydrocortisone; Cortisol, 9-fluoro-; StC 1400; 9alpha-Fludrocortisone; 9-AFH; 9-alpha-Fluorocortisol; 9-alpha-Fludrocortisone; Fludrocortisonum [INN-Latin]; Fludrocortisona [INN-Spanish]; 9-AF; Alflorone; Astonin; FCOL; Astonin H; Astonin Merck; Merck Brand of Fludrocortisone; U 5963; ZK5; F-Cortef;Florinef (TN); Fludrocortisone (INN); Fludrocortisone [INN:BAN]; Merck, Astonin; Astonin-H (TN); Hydrocortisone-9alpha-fluoro; Pregn-4-ene-3,20-dione, 9-fluoro-11beta,17,21-trihydroxy-(8CI); (11beta)-9-Fluoro-11,17,21-trihydroxypregn-4-ene-3,20-dione; (8S,9R,10S,11S,13S,14S,17R)-9-fluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one; 9 Fluoro 17 Hydroxycortisone; 9 Fluorocortisol; 9 Fluorohydrocortisone; 9 alpha Fludrohydrocortisone; 9 alpha Fluoro 17 Hydroxycorticosterone; 9 alpha Fluorohydrocortisone; 9 alpha-Fludrocortisone; 9 alpha-Fluoro-17-Hydroxycorticosterone; 9 alpha-Fluorocortisol; 9 alpha-Fluorohydrocortisone; 9-Fluoro-11-beta,17,21-trihydroxypregn-4-ene-3,20-dione; 9-Fluoro-11beta,17,21-trihydroxypregn-4-ene-3,20-dione; 9-Fluoro-17-Hydroxycortisone; 9-alpha-Fluoro-17-hydroxycorticosterone; 9-alpha-Fluorohydrocortisone; 9alpha-Fluoro-11beta,17alpha,21-trihydroxy-4-pregnene-3,20-dione; 9alpha-Fluoro-17-hydroxycorticosterone; 9alpha-Fluorohydrocortisone; 9alpha-Fluoro-hydrocortisone DMUDIR8 TC Antiinflammatory Agents DMUDIR8 DT Small molecular drug DMUDIR8 PC 31378 DMUDIR8 MW 380.4 DMUDIR8 FM C21H29FO5 DMUDIR8 IC InChI=1S/C21H29FO5/c1-18-7-5-13(24)9-12(18)3-4-15-14-6-8-20(27,17(26)11-23)19(14,2)10-16(25)21(15,18)22/h9,14-16,23,25,27H,3-8,10-11H2,1-2H3/t14-,15-,16-,18-,19-,20-,21-/m0/s1 DMUDIR8 CS C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@]2([C@H](C[C@]4([C@H]3CC[C@@]4(C(=O)CO)O)C)O)F DMUDIR8 IK AAXVEMMRQDVLJB-BULBTXNYSA-N DMUDIR8 IU (8S,9R,10S,11S,13S,14S,17R)-9-fluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one DMUDIR8 CA CAS 127-31-1 DMUDIR8 CB CHEBI:50885 DMUDIR8 DE Cerebral salt-wasting syndrome DMC8VNH ID DMC8VNH DMC8VNH DN Flufenamic Acid DMC8VNH HS Approved DMC8VNH SN flufenamic acid; 530-78-9; Fluphenamic acid; Nichisedan; Achless; Arlef; Tecramine; Paraflu; Lanceat; Flufacid; Plostene; Fullsafe; Parlef; Surika; Parlif; Flufenaminsaeure; Reumajust A; Acido flufenamico; N-(3-Trifluoromethylphenyl)anthranilic acid; Ristogen; Sastridex; Meralen; Ansatin; 2-((3-(Trifluoromethyl)phenyl)amino)benzoic acid; Fluore-200; 2-{[3-(trifluoromethyl)phenyl]amino}benzoic acid; ANT-1; Acide flufenamique; Acidum flufenamicum; TVX 916; INF 1837; 3'-Trifluoromethyldiphenylamine-2-carboxylic acid; NSC-82699; CI 440 DMC8VNH DT Small molecular drug DMC8VNH PC 3371 DMC8VNH MW 281.23 DMC8VNH FM C14H10F3NO2 DMC8VNH IC InChI=1S/C14H10F3NO2/c15-14(16,17)9-4-3-5-10(8-9)18-12-7-2-1-6-11(12)13(19)20/h1-8,18H,(H,19,20) DMC8VNH CS C1=CC=C(C(=C1)C(=O)O)NC2=CC=CC(=C2)C(F)(F)F DMC8VNH IK LPEPZBJOKDYZAD-UHFFFAOYSA-N DMC8VNH IU 2-[3-(trifluoromethyl)anilino]benzoic acid DMC8VNH CA CAS 530-78-9 DMC8VNH CB CHEBI:42638 DMC8VNH DE Dysmenorrhea DMPCG2L ID DMPCG2L DMPCG2L DN Flumazenil DMPCG2L HS Approved DMPCG2L SN flumazenil; 78755-81-4; Anexate; Flumazepil; Romazicon; Lanexat; Mazicon; Ro 15-1788; Flumazenilum; Flumazenilo; Flumazenilum [Latin]; Flumazenilo [Spanish]; Ethyl 8-fluoro-5-methyl-6-oxo-5,6-dihydro-4H-benzo[f]imidazo[1,5-a][1,4]diazepine-3-carboxylate; [11C]flumazenil; Ro 151788; Flumazenil (Ro 15-1788); Ro-15-1788; UNII-40P7XK9392; C15H14FN3O3; CHEMBL407; Ro15-1788; BRN 4763661; MLS000028850; Ethyl 8-fluoro-5-methyl-6-oxo-5,6-dihydro-4H-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylate; CHEBI:5103; OFBIFZUFASYYRE-UHFFFAOYSA-N; FlumUP TD; Flumazenil (transdermal patch formulation); Flumazenil (transdermal patch formulation), Coeruleus DMPCG2L CP Coeruleus Ltd DMPCG2L DT Small molecular drug DMPCG2L PC 3373 DMPCG2L MW 303.29 DMPCG2L FM C15H14FN3O3 DMPCG2L IC InChI=1S/C15H14FN3O3/c1-3-22-15(21)13-12-7-18(2)14(20)10-6-9(16)4-5-11(10)19(12)8-17-13/h4-6,8H,3,7H2,1-2H3 DMPCG2L CS CCOC(=O)C1=C2CN(C(=O)C3=C(N2C=N1)C=CC(=C3)F)C DMPCG2L IK OFBIFZUFASYYRE-UHFFFAOYSA-N DMPCG2L IU ethyl 8-fluoro-5-methyl-6-oxo-4H-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylate DMPCG2L CA CAS 78755-81-4 DMPCG2L CB CHEBI:5103 DMPCG2L DE Benzodiazepine overdose DMUNG4A ID DMUNG4A DMUNG4A DN Flumethasone DMUNG4A HS Approved DMUNG4A SN Flucorticin; Flumetasona; Flumetasona [INN-Spanish]; Flumetasone; Flumetasone [INN]; Flumetasonum; Flumetasonum [INN-Latin]; Flumethason; Flumethasonum; Fluvet; LR3CD8SX89; Methagon; RS 2177; RS-2177; U-10974; flumethasone; 2135-17-3; Anaprime; Aniprime; Cortexilar; Flucort (Veterinary); 6-alpha-Fluorodexamethasone; 6alpha,9-Difluoro-11beta,17,21-trihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione; 6alpha,9alpha-Difluoro-16alpha-methylprednisolone; 6alpha-Fluorodexamethasone; CHEBI:34764; MLS000028618; NSC 54702; UNII-LR3CD8SX89 DMUNG4A PC 16490 DMUNG4A MW 410.5 DMUNG4A FM C22H28F2O5 DMUNG4A IC WXURHACBFYSXBI-GQKYHHCASA-N DMUNG4A CS CC1CC2C3CC(C4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CO)O)C)O)F)C)F DMUNG4A IK 1S/C22H28F2O5/c1-11-6-13-14-8-16(23)15-7-12(26)4-5-19(15,2)21(14,24)17(27)9-20(13,3)22(11,29)18(28)10-25/h4-5,7,11,13-14,16-17,25,27,29H,6,8-10H2,1-3H3/t11-,13+,14+,16+,17+,19+,20+,21+,22+/m1/s1 DMUNG4A IU (6S,8S,9R,10S,11S,13S,14S,16R,17R)-6,9-difluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one DMUNG4A CA CAS 2135-17-3 DMUNG4A CB CHEBI:34764 DMUNG4A DE Atopic dermatitis DMU0YP6 ID DMU0YP6 DMU0YP6 DN Flumethasone Pivalate DMU0YP6 HS Approved DMU0YP6 SN Locacorten; Locorten; Lorinden; Flumetasone pivalate; Flumethasone pivalate (USP); KS-1138; Locorten (TN); Flumetasone pivalate (JAN/BAN); Lpha.-methylpregna-1,4-diene-3,20-dione 21-pivalate; [2-[(6S,8S,9R,10S,11S,13S,14S,16R,17R)-6,9-difluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] 2,2-dimethylpropanoate; 6,9-Difluoro-11,17-dihydroxy-16-methyl-3,20-dioxopregna-1,4-dien-21-yl pivalate; 6.Alpha.,9-Difluoro-11.beta.,17,21-trihydroxy-16.a; 6.Alpha.,9.alpha.-Difluoro-16.alpha.-methylprednisolone 21-pivalate; 6alpha,9-Difluoro-11beta,17,21-trihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione 21-(2,2-dimethylpropionate); 6alpha,9-difluoro-11beta,17-dihydroxy-16alpha-methyl-3,20-dioxopregna-1,4-dien-21-yl 2,2-dimethylpropanoate DMU0YP6 TC Antiinflammatory Agents DMU0YP6 DT Small molecular drug DMU0YP6 PC 443980 DMU0YP6 MW 494.6 DMU0YP6 FM C27H36F2O6 DMU0YP6 IC InChI=1S/C27H36F2O6/c1-14-9-16-17-11-19(28)18-10-15(30)7-8-24(18,5)26(17,29)20(31)12-25(16,6)27(14,34)21(32)13-35-22(33)23(2,3)4/h7-8,10,14,16-17,19-20,31,34H,9,11-13H2,1-6H3/t14-,16+,17+,19+,20+,24+,25+,26+,27+/m1/s1 DMU0YP6 CS C[C@@H]1C[C@H]2[C@@H]3C[C@@H](C4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)COC(=O)C(C)(C)C)O)C)O)F)C)F DMU0YP6 IK JWRMHDSINXPDHB-OJAGFMMFSA-N DMU0YP6 IU [2-[(6S,8S,9R,10S,11S,13S,14S,16R,17R)-6,9-difluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] 2,2-dimethylpropanoate DMU0YP6 CA CAS 2002-29-1 DMU0YP6 CB CHEBI:31620 DMU0YP6 DE Contact dermatitis DMZU5JP ID DMZU5JP DMZU5JP DN Flunarizine DMZU5JP HS Approved DMZU5JP SN Flufenal; Flunarizin; Flunarizina; Flunarizinum; Fluvert; Issium; Sibelium; Vertix; Zinasen; Apo-flunarizine capsules; Flunarizina [INN-Spanish]; Flunarizine (INN); Flunarizine [INN:BAN]; Flunarizinum [INN-Latin]; Novo-Flunarizine; R-14950; Sibelium (TN); (E)-1-(Bis(4-fluorophenyl)methyl)-4-(3-phenyl-2-propenyl)piperazine; (E)-1-[Bis-(p-fluorophenyl)methyl]-4-cinnamylpiperazine; 1-(Bis(4-fluorophenyl)methyl)-4-cinnamylpiperazine; 1-[bis(4-fluorophenyl)methyl]-4-(3-phenylprop-2-en-1-yl)piperazine; 1-[bis(4-fluorophenyl)methyl]-4-[(E)-3-phenylprop-2-enyl]piperazine DMZU5JP CP Janssen Pharmaceutica DMZU5JP TC Anticonvulsants DMZU5JP DT Small molecular drug DMZU5JP PC 941361 DMZU5JP MW 404.5 DMZU5JP FM C26H26F2N2 DMZU5JP IC InChI=1S/C26H26F2N2/c27-24-12-8-22(9-13-24)26(23-10-14-25(28)15-11-23)30-19-17-29(18-20-30)16-4-7-21-5-2-1-3-6-21/h1-15,26H,16-20H2/b7-4+ DMZU5JP CS C1CN(CCN1C/C=C/C2=CC=CC=C2)C(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F DMZU5JP IK SMANXXCATUTDDT-QPJJXVBHSA-N DMZU5JP IU 1-[bis(4-fluorophenyl)methyl]-4-[(E)-3-phenylprop-2-enyl]piperazine DMZU5JP CA CAS 52468-60-7 DMZU5JP CB CHEBI:92209 DMZU5JP DE Migraine DMZSWQC ID DMZSWQC DMZSWQC DN Flunisolide DMZSWQC HS Approved DMZSWQC SN Aerobid; Aerospan; Bronalide; Flunisolida; Flunisolidum; Lunis; Nasalide; Nasarel; Nisolid; Rhinalar; Rhinolar; Soluzione; Synaclyn; Syntaris; Aerobid M; Aerospan HFA; Flunisolide HFA; Flunisolide [INN]; Flunisolide [anhydrous]; Flunisolide anhydrous; F0437; RS 3999; AeroBid (TN); Flunisolida [INN-Spanish]; Flunisolide (anhydrous); Flunisolidum [INN-Latin]; Nasalide (TN); Nasarel (TN); RS-3999; AeroBid, Nasalide, Nasarel,Flunisolide; Pregna-1,4-diene-3,20-dione, 6-alpha-fluoro-11-beta,16-alpha,17,21-tetrahydroxy-, cyclic 16,17-acetal with acetone; Pregna-1,4-diene-3,20-dione, 6-alpha-fluoro-11-beta,16-alpha,17,21-tetrahydroxy-,cyclic 16,17-acetal with acetone; 6 alpha-fluoro-11 beta,16 alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16, 17-acetal with acetone; 6 alpha-fluorodihydroxy-16 alpha,17 alpha-isopropylidenedioxy-1,4-pregnadiene-3,20-dione; 6-Fluoro-11,21-dihydroxy-16,17-(isopropylidenedioxy)pregna-1,4-diene-3,20-dione; 6alpha-Fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16, 17-acetal with acetone; 6alpha-fluoro-11beta,21-dihydroxy-16alpha,17alpha-(isopropylidenedioxy)pregna-1,4-diene-3,20-dione DMZSWQC TC Antiasthmatic Agents DMZSWQC DT Small molecular drug DMZSWQC PC 82153 DMZSWQC MW 434.5 DMZSWQC FM C24H31FO6 DMZSWQC IC InChI=1S/C24H31FO6/c1-21(2)30-19-9-14-13-8-16(25)15-7-12(27)5-6-22(15,3)20(13)17(28)10-23(14,4)24(19,31-21)18(29)11-26/h5-7,13-14,16-17,19-20,26,28H,8-11H2,1-4H3/t13-,14-,16-,17-,19+,20+,22-,23-,24+/m0/s1 DMZSWQC CS C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1C[C@@H]4[C@]2(OC(O4)(C)C)C(=O)CO)C[C@@H](C5=CC(=O)C=C[C@]35C)F)O DMZSWQC IK XSFJVAJPIHIPKU-XWCQMRHXSA-N DMZSWQC IU (1S,2S,4R,8S,9S,11S,12S,13R,19S)-19-fluoro-11-hydroxy-8-(2-hydroxyacetyl)-6,6,9,13-tetramethyl-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one DMZSWQC CA CAS 3385-03-3 DMZSWQC CB CHEBI:5106 DMZSWQC DE Allergic rhinitis DMGR5Z3 ID DMGR5Z3 DMGR5Z3 DN Flunitrazepam DMGR5Z3 HS Approved DMGR5Z3 SN Flunibeta; Flunimerck; Fluninoc; Flunitrazepamum; Fluridrazepam; Narcozep; Primun; Rohipnol; Rohypnol; Roipnol; Betapharm Brand of Flunitrazepam; Ct Arzneimittel Brand of Flunitrazepam; Flunitrazepam Teva; Flunitrazepam neuraxpharm; Flunitrazepam ratiopharm; Flunizep von ct; Hexal Brand of Flunitrazepam; Merck dura Brand ofFlunitrazepam; Neuraxpharm Brand of Flunitrazepam; Ratiopharm Brand of Flunitrazepam; Roche Brand of Flunitrazepam; Teva Brand of Flunitrazepam; Fluni 1A Pharma; RO54200; [3H]flunitrazepam; Ct-Arzneimittel Brand of Flunitrazepam; Darkene (TN); Flunipam (TN); Flunitrazepam-Teva; Flunitrazepam-neuraxpharm; Flunitrazepam-ratiopharm; Flunitrazepamum [INN-Latin]; Hipnosedon (TN); Hypnodorm (TN); Ilman(TN); Insom (TN); Nilium (TN); Ro 5-4200; Rohypnol (TN); Rufinol (TN); Silece (TN); Vulbegal (TN); RO-5-4200; Flunitrazepam (JP15/USAN/INN); Flunitrazepam [USAN:INN:BAN:JAN]; 1,3-Dihydro-5-(o-fluorophenyl)-1-methyl-7-nitro-2H-1,4-benzodiazepin-2-one; 1-Methyl-7-nitro-5-(2-fluorophenyl)-3H-1,4-benzodiazepin-2(1H)-one; 1A Brand of Flunitrazepam; 5-(2-Fluorophenyl)-1-methyl-7-nitro-1,3-dihydro-2H-1,4-benzodiazepin-2-one; 5-(2-Fluorophenyl)-1-methyl-7-nitro-3H-1,4-benzodiazepin-2(1H)-one; 5-(2-fluorophenyl)-1-methyl-7-nitro-3H-1,4-benzodiazepin-2-one; 5-(o-Fluorophenyl)-1,3-dihydro-1-methyl-7-nitro-2H-1,4-benzodiazepin-2-one DMGR5Z3 CP Roche Laboratories Inc DMGR5Z3 TC Hypnotics and Sedatives DMGR5Z3 DT Small molecular drug DMGR5Z3 PC 3380 DMGR5Z3 MW 313.28 DMGR5Z3 FM C16H12FN3O3 DMGR5Z3 IC InChI=1S/C16H12FN3O3/c1-19-14-7-6-10(20(22)23)8-12(14)16(18-9-15(19)21)11-4-2-3-5-13(11)17/h2-8H,9H2,1H3 DMGR5Z3 CS CN1C(=O)CN=C(C2=C1C=CC(=C2)[N+](=O)[O-])C3=CC=CC=C3F DMGR5Z3 IK PPTYJKAXVCCBDU-UHFFFAOYSA-N DMGR5Z3 IU 5-(2-fluorophenyl)-1-methyl-7-nitro-3H-1,4-benzodiazepin-2-one DMGR5Z3 CA CAS 1622-62-4 DMGR5Z3 CB CHEBI:31622 DMGR5Z3 DE Insomnia DMG2KI4 ID DMG2KI4 DMG2KI4 DN Fluocinolone acetonide DMG2KI4 HS Approved DMG2KI4 SN Coriphate; Cortiplastol; Dermalar; Flucinar; Flucinolone; Flucort; Fluocet; Fluocinolonacetonidum; Fluonid; Fluotrex; Fluovitif; Flupollon; Jellin; Localyn; Medidur; Omniderm; Percutina; Prodermin; Radiocin; Retisert; Sinalar; Synalar; Synamol; Synandone; Synandrone; Synemol; Synotic; Synsac; Tefunote;Acetonida de fluocinolona; Acetonide de fluocinolone; Fluocinolone acetonide [DCIT]; Fluocinoloni acetonidum; Fluortriamcinolone Acetonide; Fs Shampoo; Localyn Syntex; F0657; RS 1401AT; Acetonida de fluocinolona [INN-Spanish]; Acetonide de fluocinolone [INN-French]; Component of Neo-Synalar; Dermatin (steroid); Fluocet (TN); Fluocinoloni acetonidum [INN-Latin]; Neo-Synalar; RS-1401 AT; Retisert (TN); Synalar (TN); Synalar-HP; Derma-smoothe/fs; Flucort-N (TN); Fluocinolone 16,17-acetonide; Fluocinolone acetonide [USAN:INN:JAN]; Ydroxyprednisolone 16,17-acetonide; Fluocinolone acetonide (JP15/USP/INN); Pregna-1,4-diene-3,20-dione, 6alpha,9-difluoro-11beta,16alpha,17,21-tetrahydroxy-, cyclic 16,17-acetal with acetone; Pregna-1,4-diene-3,20-dione, 6alpha,9-difluoro-11beta,16alpha,17,21-tetrahydroxy-, cyclic 16,17-acetal with acetone (8CI); Pregna-1,4-diene-3,20-dione, 6.alpha.,9-difluoro-11.beta.,16.alpha.,17,21-tetrahydroxy-, cyclic 16,17-acetal with acetone; (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-difluoro-5-hydroxy-6b-(hydroxyacetyl)-4a,6a,8,8-tetramethyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one; 4b,12-Difluoro-6b-glycoloyl-5-hydroxy-4a,6a,8,8-tetramethyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one; 6-alpha,9-alpha-Difluoro-16-alpha-hydroxyprednisolone 16,17-acetonide; 6.Alpha., 9.alpha.-Difluoro-16.alpha.-h; 6.Alpha.,9-Difluoro; 6.alpha.,9-Difluoro-11.beta.,16.alpha.,17,21-tetrahydroxypregna-1,4-diene-3,20-dione, cyclic 16,17-acetal with acetone; 6.alpha.,9.alpha.-Difluoro-16.alpha.-hydroxyprednisolone 16,17-acetonide; 6.alpha.-Fluorotriamcinolone acetonide; 6a,9a-difluoro-16a-hydroxyprednisolone 16,17-acetonide; 6alpha,9-Difluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione, cyclic 16,17-acetal with acetone; 6alpha,9alpha-Difluoro-11beta,16alpha,17alpha,21-tetrahydroxy-1,4-pregnadiene-3,20-dione; 6alpha,9alpha-Difluoro-11beta,16alpha,17alpha,21-tetrahydroxy-1,4-pregnadiene-3,20-dione 16,17-Acetonide; 6alpha,9alpha-Difluoro-16alpha-hydroxyprednisolone 16,17-acetonide; 6alpha-Fluorotriamcinolone acetonide DMG2KI4 TC Antiinflammatory Agents DMG2KI4 DT Small molecular drug DMG2KI4 PC 6215 DMG2KI4 MW 452.5 DMG2KI4 FM C24H30F2O6 DMG2KI4 IC InChI=1S/C24H30F2O6/c1-20(2)31-19-9-13-14-8-16(25)15-7-12(28)5-6-21(15,3)23(14,26)17(29)10-22(13,4)24(19,32-20)18(30)11-27/h5-7,13-14,16-17,19,27,29H,8-11H2,1-4H3/t13-,14-,16-,17-,19+,21-,22-,23-,24+/m0/s1 DMG2KI4 CS C[C@]12C[C@@H]([C@]3([C@H]([C@@H]1C[C@@H]4[C@]2(OC(O4)(C)C)C(=O)CO)C[C@@H](C5=CC(=O)C=C[C@@]53C)F)F)O DMG2KI4 IK FEBLZLNTKCEFIT-VSXGLTOVSA-N DMG2KI4 IU (1S,2S,4R,8S,9S,11S,12R,13S,19S)-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-6,6,9,13-tetramethyl-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one DMG2KI4 CA CAS 67-73-2 DMG2KI4 CB CHEBI:31623 DMG2KI4 DE Inflammation DM65KL8 ID DM65KL8 DM65KL8 DN Fluocinonide DM65KL8 HS Approved DM65KL8 SN Bestasone; Biscosal; Cortalar; Fluocinolide; Fluocinonido; Fluocinonidum; Fluonex; Fluzon; Lidex; Lonide; Lyderm;Metosyn; Straderm; Topsymin; Topsyn; Vanos; Fluocinolide acetate; Fluocinolone acetonide acetate; Fluocinonide Emulsified Base; Fluocinonide FAPG; Lidex E; Synalar acetate; Fluocinolone acetonide 21-acetate; Fluocinonido [INN-Spanish]; Fluocinonidum [INN-Latin]; Fluonex (TN); LIDEX (TN); LIDEX-E; Lidex (TN); Lonide (TN); Lyderm (TN); Vanos (TN); Lidex-E (TN); Fluocinonide (JP15/USP/INN); Fluocinonide [USAN:BAN:INN:JAN]; Fluocinonide [USAN:INN:BAN:JAN]; Pregna-1,4-diene-3,20-dione, 6alpha,9-difluoro-11beta,16alpha,17,21-tetrahydroxy-, cyclic 16,17-acetal with acetone, 21-acetate; Pregna-1,4-diene-3,20-dione, 6alpha,9-difluoro-11beta,16alpha,17,21-tetrahydroxy-, cyclic 16,17-acetal with acetone, 21-acetate (8CI); Pregna-1,4-diene-3,20-dione, 6-alpha, 9-difluoro-11-beta,16-alpha,17,21-tetrahydroxy-, cyclic17-acetal with acetone, 21-acetate; 6alpha,9-Difluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione, cyclic 16,17-acetal with acetone, 21-acetate DM65KL8 CP Taro Pharmaceuticals Inc DM65KL8 TC Antiinflammatory Agents DM65KL8 DT Small molecular drug DM65KL8 PC 9642 DM65KL8 MW 494.5 DM65KL8 FM C26H32F2O7 DM65KL8 IC InChI=1S/C26H32F2O7/c1-13(29)33-12-20(32)26-21(34-22(2,3)35-26)10-15-16-9-18(27)17-8-14(30)6-7-23(17,4)25(16,28)19(31)11-24(15,26)5/h6-8,15-16,18-19,21,31H,9-12H2,1-5H3/t15-,16-,18-,19-,21+,23-,24-,25-,26+/m0/s1 DM65KL8 CS CC(=O)OCC(=O)[C@@]12[C@@H](C[C@@H]3[C@@]1(C[C@@H]([C@]4([C@H]3C[C@@H](C5=CC(=O)C=C[C@@]54C)F)F)O)C)OC(O2)(C)C DM65KL8 IK WJOHZNCJWYWUJD-IUGZLZTKSA-N DM65KL8 IU [2-[(1S,2S,4R,8S,9S,11S,12R,13S,19S)-12,19-difluoro-11-hydroxy-6,6,9,13-tetramethyl-16-oxo-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-8-yl]-2-oxoethyl] acetate DM65KL8 CA CAS 356-12-7 DM65KL8 CB CHEBI:5109 DM65KL8 DE Inflammation DMQTFAO ID DMQTFAO DMQTFAO DN Fluorescein DMQTFAO HS Approved DMQTFAO SN Ful-Glo; Fluoreseptic; 41935-48-2; NSC5070 DMQTFAO DT Small molecular drug DMQTFAO PC 16850 DMQTFAO MW 332.3 DMQTFAO FM C20H12O5 DMQTFAO IC InChI=1S/C20H12O5/c21-11-5-7-15-17(9-11)24-18-10-12(22)6-8-16(18)20(15)14-4-2-1-3-13(14)19(23)25-20/h1-10,21-22H DMQTFAO CS C1=CC=C2C(=C1)C(=O)OC23C4=C(C=C(C=C4)O)OC5=C3C=CC(=C5)O DMQTFAO IK GNBHRKFJIUUOQI-UHFFFAOYSA-N DMQTFAO IU 3',6'-dihydroxyspiro[2-benzofuran-3,9'-xanthene]-1-one DMQTFAO CA CAS 2321-07-5 DMQTFAO CB CHEBI:31624 DMQTFAO DE Ocular disease DM2HKC4 ID DM2HKC4 DM2HKC4 DN Fluorometholone DM2HKC4 HS Approved DM2HKC4 SN Cortilet; Cortisdin; Delmeson; Efflumidex; FML; Fluaton; Flucon; Flumetholon; Fluormetholon; Fluormetholone; Fluormetholonum; Fluoromethalone; Fluorometholonum; Fluorometolona; Fluorometolone; Fluoropos; Loticort; Oxylone; Trilcin; Ursnon; Alcon Brand of Fluorometholone; FML Forte; FML Liquifilm; Fluor Op; Fluoro Ophtal; Fluorometolone [DCIT]; Isdin Brand of Fluorometholone; Isopto Flucon; Novartis Brand of Fluorometholone; PMS Fluorometholone; Pharm Allergan Brand of Fluorometholone; Pharmascience Brand of Fluorometholone; Ursapharm Brand of Fluorometholone; Winzer Brand of Fluorometholone; Allergan Brand 1 of Fluorometholone; Allergan Brand 2 of Fluorometholone; Allergan Brand 3 of Fluorometholone; F0414; U 8614; Component of Neo-Oxylone; FML (TN); FML-S Liquifilm; Flarex (TN); Flucon, Isopto; Fluor-Op; Fluoro-Ophtal; Fluorometholonum [INN-Latin]; Fluorometolona [INN-Spanish]; Fml (TN); Neo-Oxylone; Oxylone (TN); PMS-Fluorometholone; Pharm-Allergan Brand of Fluorometholone; FML S.O.P; Fluor-op (TN); Fluorometholone [INN:BAN:JAN]; Fluorometholone (JP15/USP/INN); Pregna-1,4-diene-3,20-dione, 9-fluoro-11.beta.,17; Pregna-1,4-diene-3,20-dione, 9-fluoro-11beta,17-dihydroxy-6alpha-methyl-(8CI); (6S,8S,9R,10S,11S,13S,14S,17R)-17-acetyl-9-fluoro-11,17-dihydroxy-6,10,13-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; 11beta,17alpha-Dihydroxy-9-fluoro-6-methyl-1,4-pregnadiene-3,20-dione; 9-Fluoro-11,17-dihydroxy-6-methylpregna-1,4-diene-3,20-dione; 9-Fluoro-11-beta,17-dihydroxy-6-alpha-methylpregna-1,4-diene-3,20-dione; 9-Fluoro-11beta,17-dihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione DM2HKC4 CP Alcon Laboratories DM2HKC4 TC Antiallergic Agents DM2HKC4 DT Small molecular drug DM2HKC4 PC 9878 DM2HKC4 MW 376.5 DM2HKC4 FM C22H29FO4 DM2HKC4 IC InChI=1S/C22H29FO4/c1-12-9-17-15-6-8-21(27,13(2)24)20(15,4)11-18(26)22(17,23)19(3)7-5-14(25)10-16(12)19/h5,7,10,12,15,17-18,26-27H,6,8-9,11H2,1-4H3/t12-,15-,17-,18-,19-,20-,21-,22-/m0/s1 DM2HKC4 CS C[C@H]1C[C@H]2[C@@H]3CC[C@@]([C@]3(C[C@@H]([C@@]2([C@@]4(C1=CC(=O)C=C4)C)F)O)C)(C(=O)C)O DM2HKC4 IK FAOZLTXFLGPHNG-KNAQIMQKSA-N DM2HKC4 IU (6S,8S,9R,10S,11S,13S,14S,17R)-17-acetyl-9-fluoro-11,17-dihydroxy-6,10,13-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one DM2HKC4 CA CAS 426-13-1 DM2HKC4 CB CHEBI:31625 DM2HKC4 DE Chronic obstructive pulmonary disease DMUM7HZ ID DMUM7HZ DMUM7HZ DN Fluorouracil DMUM7HZ HS Approved DMUM7HZ SN 5-Fluorouracil; 51-21-8; fluorouracil; 5-FU; Fluoroplex; Adrucil; Efudex; Carac; Fluracil; Fluoroblastin; 5-fluoropyrimidine-2,4(1H,3H)-dione; Kecimeton; Timazin; Carzonal; Efudix; Arumel; Fluril; Queroplex; Fluracilum; Ulup; 5-Fluoracil; Phthoruracil; Fluro Uracil; 5-Fluoro-2,4(1H,3H)-pyrimidinedione; Ftoruracil; Fluorouracilum; Efurix; Fluri; 5 Fluorouracil; Effluderm (free base); 5-fluoro-1H-pyrimidine-2,4-dione; Fluorouracilo; Fluroblastin; Phtoruracil; 2,4-Dihydroxy-5-fluoropyrimidine; 2,4(1H,3H)-Pyrimidinedione, 5-fluoro-; Adrucil; Effluderm; Fluorouracile; Fluoruracil; Fluracedyl; Flurodex; Neofluor; Onkofluor; Ribofluor; Tetratogen; URF; Allergan Brand of Fluorouracil; Biosyn Brand of Fluorouracil; CSP Brand of Fluorouracil; Cinco FU; Dakota Brand of Fluorouracil; Dermatech Brand of Fluorouracil; Dermik Brandof Fluorouracil; Ferrer Brand of Fluorouracil; Fluoro Uracile ICN; Fluorouracil GRY; Fluorouracil Mononitrate; Fluorouracil Monopotassium Salt; Fluorouracil Monosodium Salt; Fluorouracil Potassium Salt; Fluorouracil Teva Brand; Fluorouracile Dakota; Fluorouracile [DCIT]; Fluorouracilo Ferrer Far; Gry Brand of Fluorouracil; Haemato Brand of Fluorouracil; Haemato fu; Hexal Brand of Fluorouracil; ICN Brand of Fluorouracil; Inhibits thymilidate synthetase; Medac Brand of Fluorouracil; Neocorp Brand of Fluorouracil; Onkoworks Brand of Fluorouracil; Ribosepharm Brand of Fluorouracil; Riemser Brand of Fluorouracil; Roche Brand of Fluorouracil; Teva Brand of Fluorouracil; F 6627; F0151; IN1335; U 8953; Adrucil (TN); Carac (TN); Dakota, Fluorouracile; Efudex (TN); Fluoro-Uracile ICN; Fluoro-uracile; Fluoro-uracilo; Fluoroplex (TN); Fluorouracil-GRY; Fluorouracilo [INN-Spanish]; Fluorouracilum [INN-Latin]; Haemato-fu; Ro 2-9757; U-8953; Ro-2-9757; Fluorouracil (JP15/USP/INN); Fluorouracil [USAN:INN:BAN:JAN]; 1-fluoro-1h-pyrimidine-2,4-dione; 2,4-Dioxo-5-fluoropryimidine; 2,4-Dioxo-5-fluoropyrimidine; 5 FU Lederle; 5 FU medac; 5 Fluorouracil biosyn; 5 HU Hexal; 5-FU (TN); 5-FU Lederle; 5-FU medac; 5-Faracil; 5-Fluor-2,4(1H,3H)-pyrimidindion; 5-Fluor-2,4(1H,3H)-pyrimidindion [Czech]; 5-Fluor-2,4-dihydroxypyrimidin; 5-Fluor-2,4-dihydroxypyrimidin [Czech]; 5-Fluor-2,4-pyrimidindiol; 5-Fluor-2,4-pyrimidindiol [Czech]; 5-Fluoracil [German]; 5-Fluoracyl; 5-Fluoro-2,4-pyrimidinedione; 5-Fluoropyrimidin-2,4-diol; 5-Fluoropyrimidine-2,4-dione; 5-Fluorouracil-biosyn; 5-Fluoruracil; 5-Fluoruracil [German]; 5-Ftouracyl; 5-HU Hexal; 5-fluoro uracil; 5FU DMUM7HZ CP Hoffmann-La Roche pharmaceutical company DMUM7HZ TC Immunosuppressive Agents DMUM7HZ DT Small molecular drug DMUM7HZ PC 3385 DMUM7HZ MW 130.08 DMUM7HZ FM C4H3FN2O2 DMUM7HZ IC InChI=1S/C4H3FN2O2/c5-2-1-6-4(9)7-3(2)8/h1H,(H2,6,7,8,9) DMUM7HZ CS C1=C(C(=O)NC(=O)N1)F DMUM7HZ IK GHASVSINZRGABV-UHFFFAOYSA-N DMUM7HZ IU 5-fluoro-1H-pyrimidine-2,4-dione DMUM7HZ CA CAS 51-21-8 DMUM7HZ CB CHEBI:46345 DMUM7HZ DE Solid tumour/cancer; Tumour; Colorectal cancer DM3PD2C ID DM3PD2C DM3PD2C DN Fluoxetine DM3PD2C HS Approved DM3PD2C SN Eufor; Floxetine; Fluoxetin; Fluoxetina; Fluoxetinum; Fluval; Fontex; Portal; Pulvules; Reconcile; Reneuron; Fluoxetina [Spanish]; Fluoxetine Hcl; Prozac Weekly; Animex-On; Fluoxetina [INN-Spanish]; Fluoxetine (Prozac); Fluoxetine (TN); Fluoxetinum [INN-Latin]; Lilly-110140; Prozac (TN); Fluoxetine (USAN/INN); Fluoxetine [USAN:INN:BAN]; N-Methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine; Methyl({3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl})amine; N-Methyl-3-(p-trifluoromethylphenoxy)-3-phenylpropylamine; Dl-3-(p-Trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine; Methyl-[3-phenyl-3-(4-trifluoromethyl-phenoxy)-propyl]-amine; N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine; N-methyl-3-phenyl-3-{[4-(trifluoromethyl)phenyl]oxy}propan-1-amine; (+-)-N-Methyl-3-phenyl-3-((alpha,alpha,alpha-trifluoro-p-tolyl)oxy)propylamine; (+-)-N-Methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine;(+/-)-Fluoxetine; (+/-)-N-Methyl-3-(p-trifluoromethylphenoxy)-3-phenylpropylamine; (+/-)-N-Methyl-3-p-(p-trifluoromethylphenoxy)-3-phenylpropylamine; (+/-)-N-Methyl-3-phenyl-3-[(alpha,alpha,alpha-trifluoro-p-tolyl)oxy]propylamine; (+/-)-N-Methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propylamine]; (+/-)-N-Methyl-gamma-[4-(trifluoromethyl)phenoxy]benzenepropanamine; 3-(p-Trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine DM3PD2C CP Eli Lilly DM3PD2C TC Antidepressants DM3PD2C DT Small molecular drug DM3PD2C PC 3386 DM3PD2C MW 309.33 DM3PD2C FM C17H18F3NO DM3PD2C IC InChI=1S/C17H18F3NO/c1-21-12-11-16(13-5-3-2-4-6-13)22-15-9-7-14(8-10-15)17(18,19)20/h2-10,16,21H,11-12H2,1H3 DM3PD2C CS CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F DM3PD2C IK RTHCYVBBDHJXIQ-UHFFFAOYSA-N DM3PD2C IU N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine DM3PD2C CA CAS 54910-89-3 DM3PD2C CB CHEBI:86990 DM3PD2C DE Depression DMUHCF1 ID DMUHCF1 DMUHCF1 DN Fluoxymesterone DMUHCF1 HS Approved DMUHCF1 SN Androfluorene; Androfluorone; Androsterolo; Fluossimesterone; Fluosterone; Fluotestin; Fluoximesteron; Fluoximesterona; Fluoximesterone; Fluoximesteronum; Fluoxymesteronum; Fluoxymestrone; Flusteron; Flutestos; Halotestin; Oralsterone; Oratestin; Testoral; Ultandren; Ultandrene; Component of Halodrin; Fluossimesterone [DCIT]; Ora Testryl; U 6040; Anadroid-F; Android-f; Fluoximesterona [INN-Spanish]; Fluoxymesteronum [INN-Latin]; Halotestin (TN); Neo-Ormonal; Ora-Testryl; Fluoxymesterone [INN:BAN:JAN]; Fluoxymesterone (JP15/USP/INN); Fluoro-9-alpha dihydroxy-11-beta,17-beta methyl-17-alpha androstene-4 one-3; Fluoro-9-alpha dihydroxy-11-beta,17-beta methyl-17-alpha androstene-4 one-3 [French]; Androst-4-en-3-one, 9-fluoro-11beta,17beta-dihydroxy-17-methyl-(VAN); Androst-4-en-3-one, 9-fluoro-11beta,17beta-dihydroxy-17-methyl-(VAN) (8CI); (11beta,17beta)-9-fluoro-11,17-dihydroxy-17-methylandrost-4-en-3-one; (8S,9R,10S,11S,13S,14S,17S)-9-fluoro-11,17-dihydroxy-10,13,17-trimethyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one; 11-beta,17-beta-Dihydroxy-9-alpha-fluoro-17-alpha-methyl-4-androster-3-one; 11beta,17beta-Dihydroxy-9alpha-fluoro-17alpha-methyl-4-androsten-3-one; 11beta,17beta-Dihydroxy-9alpha-fluoro-17alpha-methyl-4-androster-3-one; 17-alpha-Methyl-9-alpha-fluoro-11-beta-hydroxytesterone; 17alpha-Methyl-9alpha-fluoro-11beta-hydroxytesterone; 9-Fluoro-11-beta,17-beta-dihydroxy-17-methylandrost-4-en-3-one; 9-Fluoro-11beta,17beta-dihydroxy-17-methylandrost-4-en-3-one; 9-alpha-Fluoro-11-beta,17-beta-dihydroxy-17-alpha-methyl-4-androstene-3-one; 9-alpha-Fluoro-11-beta-hydroxy-17-methyltestosterone; 9-alpha-Fluoro-17-alpha-methyl-11-beta,17-dihydroxy-4-androsten-3-one;9-fluoro-11beta,17beta-dihydroxy-17alpha-methylandrost-4-en-3-one; 9.alpha.-Fluoro-11.beta.,17.beta.-dihydroxy-17.alpha.-methyl-4-androstene-3-one; 9.alpha.-Fluoro-11.beta.-hydroxy-17-methyltestosterone; 9alpha-Fluoro-11beta,17beta-dihydroxy-17alpha-methyl-4-androstene-3-one; 9alpha-Fluoro-11beta,17beta-dihydroxy-17alpha-methylandrost-4-en-3-one; 9alpha-Fluoro-11beta-hydroxy-17-methyltestosterone; 9alpha-Fluoro-11beta-hydroxy-17alpha-methyltestosterone; 9alpha-Fluoro-17alpha-methyl-11beta,17-dihydroxy-4-androsten-3-one DMUHCF1 TC Anabolic Agents DMUHCF1 DT Small molecular drug DMUHCF1 PC 6446 DMUHCF1 MW 336.4 DMUHCF1 FM C20H29FO3 DMUHCF1 IC InChI=1S/C20H29FO3/c1-17-8-6-13(22)10-12(17)4-5-15-14-7-9-19(3,24)18(14,2)11-16(23)20(15,17)21/h10,14-16,23-24H,4-9,11H2,1-3H3/t14-,15-,16-,17-,18-,19-,20-/m0/s1 DMUHCF1 CS C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@]2([C@H](C[C@]4([C@H]3CC[C@]4(C)O)C)O)F DMUHCF1 IK YLRFCQOZQXIBAB-RBZZARIASA-N DMUHCF1 IU (8S,9R,10S,11S,13S,14S,17S)-9-fluoro-11,17-dihydroxy-10,13,17-trimethyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one DMUHCF1 CA CAS 76-43-7 DMUHCF1 CB CHEBI:5120 DMUHCF1 DE Breast cancer DM0DJ9O ID DM0DJ9O DM0DJ9O DN Flupentixol DM0DJ9O HS Approved DM0DJ9O SN 2-[4-[(3Z)-3-[2-(Trifluoromethyl)thioxanthen-9-ylidene]propyl]piperazin-1-yl]ethanol; 4-(3-(2-(Trifluoromethyl)thioxanthen-9-ylidene)propyl)-1-piperazineethanol; 53772-82-0; ALPHA-FLUPENTHIXOL; EINECS 220-304-9; EINECS 258-756-4; Emergil; FA0UYH6QUO; FLUPENTHIXOL; Fluanxol; Flupenthixole; Flupentixol; Flupentixolum [INN-Latin]; Fluphenthixol; Fluxanxol; LC 44; N 7009; Siplaril; Siplarol; UNII-FA0UYH6QUO; cis-(Z)-Flupenthixol; cis-(Z)-Flupenthixol dihydrochloride; cis-Flupenthixol; cis-Flupentixol; flupentixolum DM0DJ9O TC Antipsychotic Neuroleptic drug DM0DJ9O DT Small molecular drug DM0DJ9O PC 5281881 DM0DJ9O MW 434.521 DM0DJ9O FM C23H25F3N2OS DM0DJ9O IC InChI=1S/C23H25F3N2OS/c24-23(25,26)17-7-8-22-20(16-17)18(19-4-1-2-6-21(19)30-22)5-3-9-27-10-12-28(13-11-27)14-15-29/h1-2,4-8,16,29H,3,9-15H2/b18-5- DM0DJ9O CS C1CN(CCN1CCC=C2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F)CCO DM0DJ9O IK NJMYODHXAKYRHW-DVZOWYKESA-N DM0DJ9O IU 2-[4-[(3Z)-3-[2-(trifluoromethyl)thioxanthen-9-ylidene]propyl]piperazin-1-yl]ethanol DM0DJ9O CA CAS 2709-56-0 DM0DJ9O CB CHEBI:10454 DM0DJ9O DE Depression; Schizophrenia DMIT8LX ID DMIT8LX DMIT8LX DN Fluphenazine DMIT8LX HS Approved DMIT8LX SN FLUPHENAZINE; Triflumethazine; Fluorophenazine; Fluorphenazine; Fluorfenazine; Siqualon; Elinol; 69-23-8; Phthorphenazine; Vespazine; Ftorphenazine; Siqualine; Sevinol; Pacinol; Fluphenazinum; Flufenazina; Prolixin; Flufenazin; Dapotum; Flufenazina [DCIT]; Yespazine; SQ 4918; Fluphenazine [INN:BAN]; Moditen (Tabl or elixir); Fluphenazinum [INN-Latin]; 2-(4-(3-(2-(trifluoromethyl)-10H-phenothiazin-10-yl)propyl)piperazin-1-yl)ethanol; 10-(3-(2-Hydroxyethyl)piperazinopropyl)-2-(trifluoromethyl)phenothiazine; UNII-S79426A41Z; HSDB 3334; Dapotum; Prolixine; Fluphenazine hydrochloride; Moditen Hcl; Permitil Concentrate; Prolixin Concentrate; S94; Anatensol (TN); Apo-Fluphenazine; Dapotum (TN); Dapotum D (TN); Dapotum Injektion (TN); Decanoate (TN); Deconoate (TN); Enanthate (TN); Fludecate (TN); Flunanthate (TN); Fluphenazine (INN); Hydrochloride, Fluphenazine; Lyogen (TN); Modecate (TN); Moditen (TN); Moditen Enanthate Injection (TN); Omca (TN); Permitil (TN); Prolixin (TN); Sediten (TN); Selecten (TN); Sevinol (TN); Sinqualone (TN); Trancin (TN) DMIT8LX CP Bristol-Myers Squibb DMIT8LX TC Antipsychotic Agents DMIT8LX DT Small molecular drug DMIT8LX PC 3372 DMIT8LX MW 437.5 DMIT8LX FM C22H26F3N3OS DMIT8LX IC InChI=1S/C22H26F3N3OS/c23-22(24,25)17-6-7-21-19(16-17)28(18-4-1-2-5-20(18)30-21)9-3-8-26-10-12-27(13-11-26)14-15-29/h1-2,4-7,16,29H,3,8-15H2 DMIT8LX CS C1CN(CCN1CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F)CCO DMIT8LX IK PLDUPXSUYLZYBN-UHFFFAOYSA-N DMIT8LX IU 2-[4-[3-[2-(trifluoromethyl)phenothiazin-10-yl]propyl]piperazin-1-yl]ethanol DMIT8LX CA CAS 69-23-8 DMIT8LX CB CHEBI:5123 DMIT8LX DE Psychotic disorder DMZWBKG ID DMZWBKG DMZWBKG DN Fluprednisolone DMZWBKG HS Approved DMZWBKG SN Alphadrol DMZWBKG CP Pharmacia And Upjohn Co DMZWBKG DT Small molecular drug DMZWBKG PC 5876 DMZWBKG MW 378.4 DMZWBKG FM C21H27FO5 DMZWBKG IC InChI=1S/C21H27FO5/c1-19-5-3-11(24)7-14(19)15(22)8-12-13-4-6-21(27,17(26)10-23)20(13,2)9-16(25)18(12)19/h3,5,7,12-13,15-16,18,23,25,27H,4,6,8-10H2,1-2H3/t12-,13-,15-,16-,18+,19-,20-,21-/m0/s1 DMZWBKG CS C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)CO)O)C[C@@H](C4=CC(=O)C=C[C@]34C)F)O DMZWBKG IK MYYIMZRZXIQBGI-HVIRSNARSA-N DMZWBKG IU (6S,8S,9S,10R,11S,13S,14S,17R)-6-fluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one DMZWBKG CA CAS 53-34-9 DMZWBKG CB CHEBI:34474 DMZWBKG DE Asthma DMHCI9S ID DMHCI9S DMHCI9S DN Flurandrenolide DMHCI9S HS Approved DMHCI9S SN Cordran; Drenison; Drocort; Floudroxycortide; Fludrossicortide; Fludroxicortida; Fludroxicortidum; Fludroxycortide; Fludroxycortidum; Fluorandrenolone; Fluradrenolide; Flurandrenolone; Haelan; Sermaka; CORDRAN SP; Fludrossicortide [DCIT]; Fluorandrenolone acetonide; Flurandrenolide [USAN]; Flurandrenolone acetonide; L 33379; Alondra-F; CORDRAN (TN); Cordran tape (TN); Fludroxicortida [INN-Spanish]; Fludroxycortidum [INN-Latin]; Flurandrenolide (USP); Haldrone-F; Fludroxycortide (JAN/INN); Acetonide of 6alpha-fluoro-16alpha-hydroxyhydrocortisone; Pregn-4-ene-3,20-dione, 6alpha-fluoro-11beta,16alpha,17,21-tetrahydroxy-, cyclic 16,17-acetal with acetone; Pregn-4-ene-3,20-dione, 6-alpha-fluoro-11-beta,16-alpha,17,21-tetrahydroxy-, cyclic 16,17-acetal with acetone; 6alpha-Fluoro-11beta,16alpha,17,21-tetrahydroxypregn-4-ene-3,20-dione, cyclic 16,17-acetal with acetone; 6alpha-Fluoro-11beta,16alpha,17,21-tetrahydroxyprogesterone cyclic 16,17-acetal with acetone; 6alpha-Fluoro-16alpha-hydroxyhydrocortisone 16,17-acetonide DMHCI9S CP Watson Laboratories DMHCI9S TC Antiinflammatory Agents DMHCI9S DT Small molecular drug DMHCI9S PC 15209 DMHCI9S MW 436.5 DMHCI9S FM C24H33FO6 DMHCI9S IC InChI=1S/C24H33FO6/c1-21(2)30-19-9-14-13-8-16(25)15-7-12(27)5-6-22(15,3)20(13)17(28)10-23(14,4)24(19,31-21)18(29)11-26/h7,13-14,16-17,19-20,26,28H,5-6,8-11H2,1-4H3/t13-,14-,16-,17-,19+,20+,22-,23-,24+/m0/s1 DMHCI9S CS C[C@]12CCC(=O)C=C1[C@H](C[C@@H]3[C@@H]2[C@H](C[C@]4([C@H]3C[C@@H]5[C@]4(OC(O5)(C)C)C(=O)CO)C)O)F DMHCI9S IK POPFMWWJOGLOIF-XWCQMRHXSA-N DMHCI9S IU (1S,2S,4R,8S,9S,11S,12S,13R,19S)-19-fluoro-11-hydroxy-8-(2-hydroxyacetyl)-6,6,9,13-tetramethyl-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icos-17-en-16-one DMHCI9S CA CAS 1524-88-5 DMHCI9S CB CHEBI:5127 DMHCI9S DE Inflammation DMAL4G0 ID DMAL4G0 DMAL4G0 DN Flurazepam DMAL4G0 HS Approved DMAL4G0 SN Dalmadorm; Dalmane; Felison; Felmane; Flunox; Flurazepamum; Insumin; Noctosom; Paxane; Somnol; Stauroderm; Valdorm; Flurazepam HCL; Flurazepam hydrochloride; Dalmadorm (TN); Dalmane (TN); Dalmane-R; Flurazepamum [INN-Latin]; Insumin (TN); Flurazepam (JP15/INN); Flurazepam [INN:BAN:JAN]; Ro-5-6901/3; 2H-1,4-Benzodiazepin-2-one,7-chloro-1-[2-(diethylamino)ethyl]-5-(2-fluorophenyl)-1,3-dihydro-, dihydrochloride; 7-Chloro-1-(2-(diethylamino)ethyl)-5-(2-fluorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one; 7-Chloro-1-(2-(diethylamino)ethyl)-5-(2-fluorophenyl)-1H-1,4-benzodiazepin-2(3H)-one; 7-Chloro-1-[2-(diethylamino)ethyl]-5-(2-fluorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one; 7-chloro-1-(2-diethylaminoethyl)-5-(2-fluorophenyl)-3H-1,4-benzodiazepin-2-one DMAL4G0 CP West-ward Pharmaceutical Corp DMAL4G0 TC Hypnotics and Sedatives DMAL4G0 DT Small molecular drug DMAL4G0 PC 3393 DMAL4G0 MW 387.9 DMAL4G0 FM C21H23ClFN3O DMAL4G0 IC InChI=1S/C21H23ClFN3O/c1-3-25(4-2)11-12-26-19-10-9-15(22)13-17(19)21(24-14-20(26)27)16-7-5-6-8-18(16)23/h5-10,13H,3-4,11-12,14H2,1-2H3 DMAL4G0 CS CCN(CC)CCN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3F DMAL4G0 IK SAADBVWGJQAEFS-UHFFFAOYSA-N DMAL4G0 IU 7-chloro-1-[2-(diethylamino)ethyl]-5-(2-fluorophenyl)-3H-1,4-benzodiazepin-2-one DMAL4G0 CA CAS 17617-23-1 DMAL4G0 CB CHEBI:5128 DMAL4G0 DE Insomnia DMGN4BY ID DMGN4BY DMGN4BY DN Flurbiprofen DMGN4BY HS Approved DMGN4BY SN Adfeed; Adofeed; Anmetarin; Ansaid; Anside; Antadys; Cebutid; FLP; Flubiprofen; Flugalin; Flurbiprofene; Flurbiprofeno; Flurbiprofenum; Fluriproben; Flurofen; Froben; Ocufen; Ocuflur; Stayban; Yakuban; Zepolas; FLURBIPROFEN SODIUM; Froben Sr; BTS 18322; F0371; FP 70; IN1332; U 27182; Ansaid (TN); Apo-Flurbiprofen; BTS-18322; Flurbiprofene [INN-French]; Flurbiprofeno [INN-Spanish]; Flurbiprofenum [INN-Latin]; Froben (TN); MKS-11; Novo-Flurprofen; Nu-Flurbiprofen; U 27,182; U-27182; L-790,330; Flurbiprofen (JP15/USP/INN); Flurbiprofen [USAN:INN:BAN:JAN]; [+/-]-2-Fluoro-alpha-methyl-4-biphenylacetic acid; (+-)-2-(2-Fluoro-4-biphenylyl)propionic acid; (+-)-2-Fluoro-alpha-methyl-4-biphenylacetic acid; (+/-)-2-Fluoro-alpha-methyl-4-biphenylacetic acid; (+/-)-2-Fluoro-alpha-methyl[1,1′ -biphenyl]-4-acetic Acid; (1)-2-Fluoro-alpha-methyl(1,1'-biphenyl)-4-acetic acid; 2-(2-Fluorobiphenyl-4-yl)propionic Acid; 2-(2-fluoro-[1,1'-biphenyl-4-yl])propanoic acid; 2-(2-fluorobiphenyl-4-yl)propanoic acid; 2-(3-fluoro-4-phenylphenyl)propanoic acid; 2-Fluoro-alpha-methyl-(1,1'-biphenyl)-4-acetic acid; 2-Fluoro-alpha-methyl-4-biphenylacetic acid; 3-Fluoro-4-phenylhydratropic acid DMGN4BY CP Abbott Laboratories DMGN4BY TC Antiinflammatory Agents DMGN4BY DT Small molecular drug DMGN4BY PC 3394 DMGN4BY MW 244.26 DMGN4BY FM C15H13FO2 DMGN4BY IC InChI=1S/C15H13FO2/c1-10(15(17)18)12-7-8-13(14(16)9-12)11-5-3-2-4-6-11/h2-10H,1H3,(H,17,18) DMGN4BY CS CC(C1=CC(=C(C=C1)C2=CC=CC=C2)F)C(=O)O DMGN4BY IK SYTBZMRGLBWNTM-UHFFFAOYSA-N DMGN4BY IU 2-(3-fluoro-4-phenylphenyl)propanoic acid DMGN4BY CA CAS 5104-49-4 DMGN4BY CB CHEBI:5130 DMGN4BY DE Rheumatoid arthritis DMFO843 ID DMFO843 DMFO843 DN Fluspirilene DMFO843 HS Approved DMFO843 SN Fluspirilen; Fluspirileno; Fluspirilenum; Imap; Redeptin; Spirodiflamine; R 6218; F-100; Fluspirileno [INN-Spanish]; Fluspirilenum [INN-Latin]; Imap (TN); Spiropiperidine analogue, 1; Fluspirilene (USAN/INN); Fluspirilene [USAN:INN:BAN]; McN-JR-6218; 1-Phenyl-4-oxo-8-(4,4-bis(4-fluorophenyl)butyl)-1,3,8-triazaspiro(4,5)decane; 8-(4,4-Bis(p-fluorophenyl)butyl)-1-phenyl-1,3,8-triazaspiro-(4.5)decan-4-one; 8-[4,4-bis (p-fluorophenyl)butyl]-1-phenyl-1,3,8-triazino[4,5]decan-4-one; 8-[4,4-bis(4-fluorophenyl)butyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one; 8-[4,4-bis(4-fluorophenyl)butyl]-4-phenyl-2,4,8-triazaspiro[4.5]decan-1-one; 8-[4,4-bis(p-Fluorophenyl)butyl]-1-phenyl-1,3,8-triazino[4.5]decan-4-one DMFO843 CP Janssen Pharmaceutica DMFO843 TC Antipsychotic Agents DMFO843 DT Small molecular drug DMFO843 PC 3396 DMFO843 MW 475.6 DMFO843 FM C29H31F2N3O DMFO843 IC InChI=1S/C29H31F2N3O/c30-24-12-8-22(9-13-24)27(23-10-14-25(31)15-11-23)7-4-18-33-19-16-29(17-20-33)28(35)32-21-34(29)26-5-2-1-3-6-26/h1-3,5-6,8-15,27H,4,7,16-21H2,(H,32,35) DMFO843 CS C1CN(CCC12C(=O)NCN2C3=CC=CC=C3)CCCC(C4=CC=C(C=C4)F)C5=CC=C(C=C5)F DMFO843 IK QOYHHIBFXOOADH-UHFFFAOYSA-N DMFO843 IU 8-[4,4-bis(4-fluorophenyl)butyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one DMFO843 CA CAS 1841-19-6 DMFO843 CB CHEBI:93369 DMFO843 DE Schizophrenia DMK0O7U ID DMK0O7U DMK0O7U DN Flutamide DMK0O7U HS Approved DMK0O7U SN Apimid; ApoFlutamide; Cebatrol; Chimax; Cytamid; Drogenil; Eulexin; Eulexine; Fluken; Flulem; Flumid; FlutaGRY; Flutacell; Flutamida; Flutamidum; Flutamin; Flutandrona; Flutaplex; Flutexin; Fugerel; METHOXYCHLOR; NFBA; Niftholide; Niftolid; Niftolide; NovoFlutamide; Odyne; Oncosal; Prostacur; Prostandril; Prostica; Prostogenat; Testotard; Alphapharm Brand of Flutamide; Apo Flutamide; Apogepha Brand of Flutamide; Apotex Brand of Flutamide; Azupharma Brand of Flutamide; Cell pharm Brand of Flutamide; Chephasaar Brand of Flutamide; Chiron Brand of Flutamide; Ciclum Brand of Flutamide; Esparma Brand of Flutamide; Essex Brand of Flutamide; Fluta GRY; Fluta cell; Gry Brand of Flutamide; Hexal Brand of Flutamide; InibsaBrand of Flutamide; Ipsen Brand of Flutamide; Juta Brand of Flutamide; Kendrick Brand of Flutamide; Lemery Brand of Flutamide; Novo Flutamide; Novopharm Brand of Flutamide; PMS Flutamide; Pharmascience Brand of Flutamide; Prasfarma Brand of Flutamide; Q Pharm Brand of Flutamide; Schering Brand of Flutamide; Schering Plough Brand of Flutamide; TAD Brand of Flutamide; Tedec Meiji Brand of Flutamide; F 9397; F0663; Fluta 1A Pharma; Flutamide USP25; SCH13521; Sch 13521; Apo-Flutamide; Cebatrol, veterinary; Eulexin (TN); Fluta-GRY; Fluta-cell; Flutamida [INN-Spanish]; Flutamide(pubertal study); Flutamidum [INN-Latin]; NK-601; Novo-Flutamide; PMS-Flutamide; PUBERTAL FLUTAMIDE STUDY (PUBERTAL STUDIES OF VINCLOZOLIN; Q-Pharm Brand of Flutamide; Sch-13521; Schering-Plough Brand of Flutamide; Flutamide [USAN:BAN:INN]; Ham's F-12 medium; Eulexin, Flutamin, Drogenil,Flutamide; Flutamide (JAN/USP/INN); Alpha,alpha,alpha-Trifluoro-2-methyl-4'-nitro-m-propionotoluidide; M-propionotoluidide,alpha,alpha,alpha-trifluoro-2-methyl-4'-nitro; M-Propionotoluidide, alpha,alpha,alpha-trifluoro-2-methyl-4'-nitro-(8CI); 1A Brand of Flutamide; 2-Methyl-N-(4-nitro-3-[trifluoromethyl]phenyl)propanamide; 2-Methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide; 2-Methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propionamide; 4'-Nitro-3'-(trifluoromethyl)isobutyranilide; 4'-Nitro-3'-trifluoromethylisobutyramilide; 4'-Nitro-3'-trifluoromethylisobutyranilide; 4-Nitro-3-(trifluoromethyl)isobutyranilide; Flutamide (AR inhibitor) DMK0O7U CP Schering-Plough Corporation DMK0O7U TC Anticancer Agents DMK0O7U DT Small molecular drug DMK0O7U PC 3397 DMK0O7U MW 276.21 DMK0O7U FM C11H11F3N2O3 DMK0O7U IC InChI=1S/C11H11F3N2O3/c1-6(2)10(17)15-7-3-4-9(16(18)19)8(5-7)11(12,13)14/h3-6H,1-2H3,(H,15,17) DMK0O7U CS CC(C)C(=O)NC1=CC(=C(C=C1)[N+](=O)[O-])C(F)(F)F DMK0O7U IK MKXKFYHWDHIYRV-UHFFFAOYSA-N DMK0O7U IU 2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide DMK0O7U CA CAS 13311-84-7 DMK0O7U CB CHEBI:5132 DMK0O7U DE Prostate cancer DMGCSVF ID DMGCSVF DMGCSVF DN Fluticasone DMGCSVF HS Approved DMGCSVF SN Fluticaps; Fluticaps (TN); Fluticasone (INN); S-(fluoromethyl) (6S,8S,9R,10S,11S,13S,14S,16R,17R)-6,9-difluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthrene-17-carbothioate DMGCSVF CP Fougera Pharmaceuticals Inc DMGCSVF TC Antiinflammatory Agents DMGCSVF DT Small molecular drug DMGCSVF PC 5311101 DMGCSVF MW 444.5 DMGCSVF FM C22H27F3O4S DMGCSVF IC InChI=1S/C22H27F3O4S/c1-11-6-13-14-8-16(24)15-7-12(26)4-5-19(15,2)21(14,25)17(27)9-20(13,3)22(11,29)18(28)30-10-23/h4-5,7,11,13-14,16-17,27,29H,6,8-10H2,1-3H3/t11-,13+,14+,16+,17+,19+,20+,21+,22+/m1/s1 DMGCSVF CS C[C@@H]1C[C@H]2[C@@H]3C[C@@H](C4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)SCF)O)C)O)F)C)F DMGCSVF IK MGNNYOODZCAHBA-GQKYHHCASA-N DMGCSVF IU S-(fluoromethyl) (6S,8S,9R,10S,11S,13S,14S,16R,17R)-6,9-difluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthrene-17-carbothioate DMGCSVF CA CAS 90566-53-3 DMGCSVF CB CHEBI:5134 DMGCSVF DE Allergic rhinitis DMRWLB2 ID DMRWLB2 DMRWLB2 DN Fluticasone propionate DMRWLB2 HS Approved DMRWLB2 SN FLUTICASONE PROPIONATE; Flovent; Cutivate; Flixotide; Flonase; Flixonase; Flovent HFA; Flunase; Flutide; Fluspiral; Flusonal; atemur; Flutivate; Fluinol; Axotide; Asmatil; Brethal; Flovent Diskus 50; Flixotide Disks; Flixotide Disk; Flovent Diskus; Flovent Diskus 100; Flovent Diskus 250; Flixotide Inhaler; Trialona; Rinosone; Inalacor; Cultivate; Ubizol; Zoflut; Flixonase Nasal Spray; Flonase Aq; Fluticasonpropionat Allen; Fluticasone (propionate); UNII-O2GMZ0LF5W; CCI-18781; CCI 18781; MFCD00866007; O2GMZ0LF5W DMRWLB2 PC 444036 DMRWLB2 MW 500.6 DMRWLB2 FM C25H31F3O5S DMRWLB2 IC InChI=1S/C25H31F3O5S/c1-5-20(31)33-25(21(32)34-12-26)13(2)8-15-16-10-18(27)17-9-14(29)6-7-22(17,3)24(16,28)19(30)11-23(15,25)4/h6-7,9,13,15-16,18-19,30H,5,8,10-12H2,1-4H3/t13-,15+,16+,18+,19+,22+,23+,24+,25+/m1/s1 DMRWLB2 CS CCC(=O)OC1(C(CC2C1(CC(C3(C2CC(C4=CC(=O)C=CC43C)F)F)O)C)C)C(=O)SCF DMRWLB2 IK WMWTYOKRWGGJOA-CENSZEJFSA-N DMRWLB2 IU [(6S,8S,9R,10S,11S,13S,14S,16R,17R)-6,9-difluoro-17-(fluoromethylsulfanylcarbonyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] propanoate DMRWLB2 CA CAS 80474-14-2 DMRWLB2 CB CHEBI:31441 DMRWLB2 DE Asthma DMU54C3 ID DMU54C3 DMU54C3 DN Flutropium bromide DMU54C3 HS Approved DMU54C3 SN Flubron (TN) DMU54C3 DT Small molecular drug DMU54C3 PC 656602 DMU54C3 MW 478.4 DMU54C3 FM C24H29BrFNO3 DMU54C3 IC InChI=1S/C24H29FNO3.BrH/c1-26(15-14-25)20-12-13-21(26)17-22(16-20)29-23(27)24(28,18-8-4-2-5-9-18)19-10-6-3-7-11-19;/h2-11,20-22,28H,12-17H2,1H3;1H/q+1;/p-1/t20-,21+,22?,26?; DMU54C3 CS C[N+]1([C@@H]2CC[C@H]1CC(C2)OC(=O)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)CCF.[Br-] DMU54C3 IK FNUZASGZEHGWQM-QCERWEEGSA-M DMU54C3 IU [(1S,5R)-8-(2-fluoroethyl)-8-methyl-8-azoniabicyclo[3.2.1]octan-3-yl] 2-hydroxy-2,2-diphenylacetate;bromide DMU54C3 CA CAS 63516-07-4 DMU54C3 CB CHEBI:31630 DMU54C3 DE Cough DM4MDJY ID DM4MDJY DM4MDJY DN Fluvastatin DM4MDJY HS Approved DM4MDJY SN Canef; Cranoc; Fluindostatin; Fluvas; Fluvastatina; Fluvastatine; Fluvastatinum; Lescol; Lescol XL; XU 62320; Canef(TN); Fluvas (TN); Fluvastatin & Primycin; Fluvastatin (INN); Fluvastatin [INN:BAN]; Fluvastatina [INN-Spanish]; Fluvastatine [INN-French]; Fluvastatinum [INN-Latin]; Lescol (TN); Vastin (TN); XU-62320; (+)-(3R,5S)-fluvastatin; (-)-(3S,5R)-fluvastatin; (3R,5R,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (3R,5R,6E)-7-[3-(4-fluorophenyl)-1-isopropyl-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (3R,5S)-7-[3-(4-fluorophenyl)-1-propan-2-ylindol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (3R,5S,6E)-7-[3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (3R,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (3R,5S,6E)-7-[3-(4-fluorophenyl)-1-isopropyl-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (3R,5S,6E)-rel-7-[3-(4-Fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]-3,5-dihydroxy-6-heptenoic acid; (3S,5R,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (3S,5R,6E)-7-[3-(4-fluorophenyl)-1-isopropyl-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (6E)-7-[3-(4-fluorophenyl)-1-isopropyl-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (E)-7-[3-(4-fluorophenyl)-1-propan-2-ylindol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (E,3R,5S)-7-[3-(4-fluorophenyl)-1-propan-2-ylindol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (E,3S,5R)-7-[3-(4-fluorophenyl)-1-propan-2-ylindol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (Z,3R,5S)-7-[3-(4-fluorophenyl)-1-propan-2-ylindol-2-yl]-3,5-dihydroxyhept-6-enoic acid; 7-(3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl)-3,5-dihydroxy-6-heptenoate; 7-[3-(4-fluorophenyl)-1-propan-2-ylindol-2-yl]-3,5-dihydroxyhept-6-enoic acid DM4MDJY TC Anticholesteremic Agents DM4MDJY DT Small molecular drug DM4MDJY PC 446155 DM4MDJY MW 411.5 DM4MDJY FM C24H26FNO4 DM4MDJY IC InChI=1S/C24H26FNO4/c1-15(2)26-21-6-4-3-5-20(21)24(16-7-9-17(25)10-8-16)22(26)12-11-18(27)13-19(28)14-23(29)30/h3-12,15,18-19,27-28H,13-14H2,1-2H3,(H,29,30)/b12-11+/t18-,19-/m1/s1 DM4MDJY CS CC(C)N1C2=CC=CC=C2C(=C1/C=C/[C@H](C[C@H](CC(=O)O)O)O)C3=CC=C(C=C3)F DM4MDJY IK FJLGEFLZQAZZCD-MCBHFWOFSA-N DM4MDJY IU (E,3R,5S)-7-[3-(4-fluorophenyl)-1-propan-2-ylindol-2-yl]-3,5-dihydroxyhept-6-enoic acid DM4MDJY CA CAS 93957-54-1 DM4MDJY CB CHEBI:38565 DM4MDJY DE Hypercholesterolaemia DMQTJSX ID DMQTJSX DMQTJSX DN Fluvoxamine DMQTJSX HS Approved DMQTJSX SN Dumyrox; Fluvoxamina; Fluvoxaminum; Fluvoxamina [INN-Spanish]; Fluvoxamine (INN); Fluvoxamine [INN:BAN]; Fluvoxamine-CR; Fluvoxaminum [INN-Latin]; Luvox (TN); (1E)-5-methoxy-1-[4-(trifluoromethyl)phenyl]pentan-1-one O-(2-aminoethyl)oxime; 2-[(E)-[5-methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene]amino]oxyethanamine; 2-[({5-methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene}amino)oxy]ethanamine DMQTJSX CP IVAX Pharmaceuticals DMQTJSX TC Antidepressants DMQTJSX DT Small molecular drug DMQTJSX PC 5324346 DMQTJSX MW 318.33 DMQTJSX FM C15H21F3N2O2 DMQTJSX IC InChI=1S/C15H21F3N2O2/c1-21-10-3-2-4-14(20-22-11-9-19)12-5-7-13(8-6-12)15(16,17)18/h5-8H,2-4,9-11,19H2,1H3/b20-14+ DMQTJSX CS COCCCC/C(=N\\OCCN)/C1=CC=C(C=C1)C(F)(F)F DMQTJSX IK CJOFXWAVKWHTFT-XSFVSMFZSA-N DMQTJSX IU 2-[(E)-[5-methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene]amino]oxyethanamine DMQTJSX CA CAS 54739-18-3 DMQTJSX CB CHEBI:5138 DMQTJSX DE Depression DM2PSBE ID DM2PSBE DM2PSBE DN Focetria A(H1N1) DM2PSBE HS Approved DM2PSBE SN Focetria (H1N1); H1N1 pandemic influenza A vaccine (MF59-adjuvanted, egg-based), Novartis DM2PSBE CP Novartis AG DM2PSBE DT Vaccine DM2PSBE DE Influenza virus infection DMEMBJC ID DMEMBJC DMEMBJC DN Folic acid DMEMBJC HS Approved DMEMBJC SN folic acid; 59-30-3; Folate; Pteroylglutamic acid; Vitamin M; Folacin; Folacid; PteGlu; Vitamin B9; Folvite; Pteroyl-L-glutamic acid; Vitamin Bc; Acifolic; Cytofol; Incafolic; Foliamin; Folsaure; Folicet; Millafol; Folipac; Folettes; Folsan; Folbal; Folsav; Vitamin Be; Pteroyl-L-monoglutamic acid; Mittafol; Folan; Facid; Pteroylmonoglutamic acid; Antianemia factor; Factor U; Folico (Italy); Folina (Italy); Foldine [France]; Pteroylmonoglutamate; Acfol (Spain); Foldine; Folcysteine; Folasic (Australia); Folcidin; Folaemin [Netherlands]; Nifolin; [3H]folic acid DMEMBJC TC Vitamins DMEMBJC DT Small molecular drug DMEMBJC PC 135398658 DMEMBJC MW 441.4 DMEMBJC FM C19H19N7O6 DMEMBJC IC InChI=1S/C19H19N7O6/c20-19-25-15-14(17(30)26-19)23-11(8-22-15)7-21-10-3-1-9(2-4-10)16(29)24-12(18(31)32)5-6-13(27)28/h1-4,8,12,21H,5-7H2,(H,24,29)(H,27,28)(H,31,32)(H3,20,22,25,26,30)/t12-/m0/s1 DMEMBJC CS C1=CC(=CC=C1C(=O)N[C@@H](CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N DMEMBJC IK OVBPIULPVIDEAO-LBPRGKRZSA-N DMEMBJC IU (2S)-2-[[4-[(2-amino-4-oxo-3H-pteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid DMEMBJC CA CAS 59-30-3 DMEMBJC CB CHEBI:27470 DMEMBJC DE Vitamin deficiency; Folate-deficiency anemia DM2JTS5 ID DM2JTS5 DM2JTS5 DN Follitropin beta DM2JTS5 HS Approved DM2JTS5 TC Fertility Agents DM2JTS5 SQ Alpha chain: APDVQDCPECTLQENPFFSQPGAPILQCMGCCFSRAYPTPLRSKKTMLVQKNVTSESTCCVAKSYNRVTVMGGFKVENHTACHCSTCYYHKS >Beta chainNSCELTNITIAIEKEECRFCISINTTWCAGYCYTRDLVYKDPARPKIQKTCTFKELVYETVRVPGCAHHADSLYTYPVATQCHCGKCDSDSTDCTVRGLGPSYCSFGEMKE DM2JTS5 DE Female infertility DM6VOWQ ID DM6VOWQ DM6VOWQ DN Fomepizole DM6VOWQ HS Approved DM6VOWQ SN Antizol; Fomepizol; Fomepizolum; Orphan brand of fomepizole; Paladin brand of fomepizole; M0774; Antizol (TN); Fomepizol [INN-Spanish]; Fomepizole [USAN:INN]; Fomepizolum [INN-Latin]; S14-0570; Fomepizole (USAN/INN); 4-Methyl-1H-pyrazole; 4-Methylpyrazol; 4-Methylpyrazole; 4-methylpyrazole monohydrochloride DM6VOWQ TC Antidotes DM6VOWQ DT Small molecular drug DM6VOWQ PC 3406 DM6VOWQ MW 82.1 DM6VOWQ FM C4H6N2 DM6VOWQ IC InChI=1S/C4H6N2/c1-4-2-5-6-3-4/h2-3H,1H3,(H,5,6) DM6VOWQ CS CC1=CNN=C1 DM6VOWQ IK RIKMMFOAQPJVMX-UHFFFAOYSA-N DM6VOWQ IU 4-methyl-1H-pyrazole DM6VOWQ CA CAS 7554-65-6 DM6VOWQ CB CHEBI:5141 DM6VOWQ DE Athylene glycol or methanol poisoning DMBEP7G ID DMBEP7G DMBEP7G DN Fomivirsen sodium DMBEP7G HS Approved DMBEP7G SN Vitravene; Vitravene Preservative Free; DRG-0234; Vitravene (TN); DNA, d(P-thio)(G-C-G-T-T-T-G-C-T-C-T-T-C-T-T-C-T-T-G-C-G), eicosasodium salt DMBEP7G CP Novartis AG; Isis Pharmaceuticals DMBEP7G TC Antisense DMBEP7G DT Small molecular drug DMBEP7G PC 71587550 DMBEP7G MW 7122 DMBEP7G FM C204H243N63Na20O114P20S20 DMBEP7G IC InChI=1S/C204H263N63O114P20S20.20Na/c1-80-44-253(195(291)237-169(80)270)145-31-98(119(349-145)62-328-387(306,407)367-97-30-144(252-22-16-137(210)226-194(252)290)348-118(97)61-327-400(319,420)380-109-42-157(266-78-219-162-167(266)230-187(214)235-182(162)283)361-131(109)74-340-398(317,418)378-107-40-154(262-53-89(10)178(279)246-204(262)300)357-127(107)70-336-395(314,415)375-104-37-151(259-50-86(7)175(276)243-201(259)297)355-125(104)68-334-396(315,416)376-105-38-152(260-51-87(8)176(277)244-202(260)298)358-128(105)71-337-401(320,421)381-110-43-158(267-79-220-163-168(267)231-188(215)236-183(163)284)359-129(110)72-338-388(307,408)368-93-26-140(248-18-12-133(206)222-190(248)286)343-113(93)56-322-383(302,403)362-91-24-155(341-111(91)54-268)264-76-217-160-165(264)228-185(212)233-180(160)281)369-389(308,409)323-58-115-94(27-141(345-115)249-19-13-134(207)223-191(249)287)364-384(303,404)329-63-120-101(34-148(350-120)256-47-83(4)172(273)240-198(256)294)372-392(311,412)332-66-123-99(32-146(353-123)254-45-81(2)170(271)238-196(254)292)370-390(309,410)324-59-116-95(28-142(346-116)250-20-14-135(208)224-192(250)288)365-385(304,405)330-64-121-102(35-149(351-121)257-48-84(5)173(274)241-199(257)295)373-393(312,413)333-67-124-100(33-147(354-124)255-46-82(3)171(272)239-197(255)293)371-391(310,411)325-60-117-96(29-143(347-117)251-21-15-136(209)225-193(251)289)366-386(305,406)331-65-122-103(36-150(352-122)258-49-85(6)174(275)242-200(258)296)374-394(313,414)335-69-126-106(39-153(356-126)261-52-88(9)177(278)245-203(261)299)377-397(316,417)339-73-130-108(41-156(360-130)265-77-218-161-166(265)229-186(213)234-181(161)282)379-399(318,419)326-57-114-92(25-139(344-114)247-17-11-132(205)221-189(247)285)363-382(301,402)321-55-112-90(269)23-138(342-112)263-75-216-159-164(263)227-184(211)232-179(159)280;;;;;;;;;;;;;;;;;;;;/h11-22,44-53,75-79,90-131,138-158,268-269H,23-43,54-74H2,1-10H3,(H,301,402)(H,302,403)(H,303,404)(H,304,405)(H,305,406)(H,306,407)(H,307,408)(H,308,409)(H,309,410)(H,310,411)(H,311,412)(H,312,413)(H,313,414)(H,314,415)(H,315,416)(H,316,417)(H,317,418)(H,318,419)(H,319,420)(H,320,421)(H2,205,221,285)(H2,206,222,286)(H2,207,223,287)(H2,208,224,288)(H2,209,225,289)(H2,210,226,290)(H,237,270,291)(H,238,271,292)(H,239,272,293)(H,240,273,294)(H,241,274,295)(H,242,275,296)(H,243,276,297)(H,244,277,298)(H,245,278,299)(H,246,279,300)(H3,211,227,232,280)(H3,212,228,233,281)(H3,213,229,234,282)(H3,214,230,235,283)(H3,215,231,236,284);;;;;;;;;;;;;;;;;;;;/q;20*+1/p-20/t90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111+,112+,113+,114+,115+,116+,117+,118+,119+,120+,121+,122+,123+,124+,125+,126+,127+,128+,129+,130+,131+,138+,139+,140+,141+,142+,143+,144+,145+,146+,147+,148+,149+,150+,151+,152+,153+,154+,155+,156+,157+,158+,382?,383?,384?,385?,386?,387?,388?,389?,390?,391?,392?,393?,394?,395?,396?,397?,398?,399?,400?,401?;;;;;;;;;;;;;;;;;;;;/m0..................../s1 DMBEP7G CS CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)COP(=S)([O-])O[C@H]3C[C@@H](O[C@@H]3COP(=S)([O-])O[C@H]4C[C@@H](O[C@@H]4COP(=S)([O-])O[C@H]5C[C@@H](O[C@@H]5COP(=S)([O-])O[C@H]6C[C@@H](O[C@@H]6COP(=S)([O-])O[C@H]7C[C@@H](O[C@@H]7COP(=S)([O-])O[C@H]8C[C@@H](O[C@@H]8COP(=S)([O-])O[C@H]9C[C@@H](O[C@@H]9COP(=S)([O-])O[C@H]1C[C@@H](O[C@@H]1CO)N1C=NC2=C1N=C(NC2=O)N)N1C=CC(=NC1=O)N)N1C=NC2=C1N=C(NC2=O)N)N1C=C(C(=O)NC1=O)C)N1C=C(C(=O)NC1=O)C)N1C=C(C(=O)NC1=O)C)N1C=NC2=C1N=C(NC2=O)N)N1C=CC(=NC1=O)N)OP(=S)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=CC(=NC1=O)N)OP(=S)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=C(C(=O)NC1=O)C)OP(=S)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=C(C(=O)NC1=O)C)OP(=S)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=CC(=NC1=O)N)OP(=S)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=C(C(=O)NC1=O)C)OP(=S)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=C(C(=O)NC1=O)C)OP(=S)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=CC(=NC1=O)N)OP(=S)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=C(C(=O)NC1=O)C)OP(=S)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=C(C(=O)NC1=O)C)OP(=S)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=NC2=C1N=C(NC2=O)N)OP(=O)(OC[C@@H]1[C@H](C[C@@H](O1)N1C=CC(=NC1=O)N)OP(=S)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=NC2=C1N=C(NC2=O)N)O)[S-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+] DMBEP7G IK DLKYYJFLRUUGHJ-SSJCJZGYSA-A DMBEP7G IU icosasodium;1-[(2R,4S,5R)-5-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-2-(hydroxymethyl)oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]-4-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-oxidophosphinothioyl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-sulfidophosphoryl]oxyoxolan-2-yl]methoxy-oxidophosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-oxidophosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-oxidophosphinothioyl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-oxidophosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-oxidophosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-oxidophosphinothioyl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-oxidophosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-oxidophosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-oxidophosphinothioyl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-oxidophosphinothioyl]oxyoxolan-2-yl]-5-methylpyrimidine-2,4-dione DMBEP7G CA CAS 160369-77-7 DMBEP7G DE Cytomegalovirus retinitis DMWS3FH ID DMWS3FH DMWS3FH DN Fondaparinux sodium DMWS3FH HS Approved DMWS3FH SN Arixtra; Quixidar; Fondaparin sodium; Arixtra (TN); GSK-576428; SR-90107; SR-90107A; Fondaparinux sodium (JAN/USAN/INN) DMWS3FH CP GSK DMWS3FH TC Anticoagulants DMWS3FH DT Small molecular drug DMWS3FH PC 636380 DMWS3FH MW 1728.1 DMWS3FH FM C31H43N3Na10O49S8 DMWS3FH IC InChI=1S/C31H53N3O49S8.10Na/c1-69-27-9(33-85(48,49)50)13(37)17(6(74-27)3-71-88(57,58)59)76-31-22(83-91(66,67)68)16(40)21(24(81-31)26(43)44)79-29-10(34-86(51,52)53)19(82-90(63,64)65)18(7(75-29)4-72-89(60,61)62)77-30-15(39)14(38)20(23(80-30)25(41)42)78-28-8(32-84(45,46)47)12(36)11(35)5(73-28)2-70-87(54,55)56;;;;;;;;;;/h5-24,27-40H,2-4H2,1H3,(H,41,42)(H,43,44)(H,45,46,47)(H,48,49,50)(H,51,52,53)(H,54,55,56)(H,57,58,59)(H,60,61,62)(H,63,64,65)(H,66,67,68);;;;;;;;;;/q;10*+1/p-10/t5-,6-,7-,8-,9-,10-,11-,12-,13-,14-,15-,16+,17-,18-,19-,20+,21+,22-,23+,24-,27+,28-,29-,30-,31-;;;;;;;;;;/m1........../s1 DMWS3FH CS CO[C@@H]1[C@@H]([C@H]([C@@H]([C@H](O1)COS(=O)(=O)[O-])O[C@H]2[C@@H]([C@H]([C@@H]([C@@H](O2)C(=O)[O-])O[C@@H]3[C@@H]([C@H]([C@@H]([C@H](O3)COS(=O)(=O)[O-])O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)C(=O)[O-])O[C@@H]5[C@@H]([C@H]([C@@H]([C@H](O5)COS(=O)(=O)[O-])O)O)NS(=O)(=O)[O-])O)O)OS(=O)(=O)[O-])NS(=O)(=O)[O-])O)OS(=O)(=O)[O-])O)NS(=O)(=O)[O-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+] DMWS3FH IK XEKSTYNIJLDDAZ-JASSWCPGSA-D DMWS3FH IU decasodium;(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5R,6R)-6-[(2R,3S,4S,5R,6R)-2-carboxylato-4-hydroxy-6-[(2R,3S,4R,5R,6S)-4-hydroxy-6-methoxy-5-(sulfonatoamino)-2-(sulfonatooxymethyl)oxan-3-yl]oxy-5-sulfonatooxyoxan-3-yl]oxy-5-(sulfonatoamino)-4-sulfonatooxy-2-(sulfonatooxymethyl)oxan-3-yl]oxy-3-[(2R,3R,4R,5S,6R)-4,5-dihydroxy-3-(sulfonatoamino)-6-(sulfonatooxymethyl)oxan-2-yl]oxy-4,5-dihydroxyoxane-2-carboxylate DMWS3FH CA CAS 114870-03-0 DMWS3FH DE Venous thrombosis DMRBJNZ ID DMRBJNZ DMRBJNZ DN Forasartan DMRBJNZ HS Approved DMRBJNZ SN SC 52458; SC-52458; Forasartan (USAN/INN); 5-((3,5-Dibutyl-1H-1,2,4-triazol-1-yl)methyl)-2-(2-(1H-tetrazol-5-ylphenyl))pyridine; 5-[(3,5-dibutyl-1,2,4-triazol-1-yl)methyl]-2-[2-(2H-tetrazol-5-yl)phenyl]pyridine DMRBJNZ TC Antihypertensive Agents DMRBJNZ DT Small molecular drug DMRBJNZ PC 132706 DMRBJNZ MW 416.5 DMRBJNZ FM C23H28N8 DMRBJNZ IC InChI=1S/C23H28N8/c1-3-5-11-21-25-22(12-6-4-2)31(28-21)16-17-13-14-20(24-15-17)18-9-7-8-10-19(18)23-26-29-30-27-23/h7-10,13-15H,3-6,11-12,16H2,1-2H3,(H,26,27,29,30) DMRBJNZ CS CCCCC1=NN(C(=N1)CCCC)CC2=CN=C(C=C2)C3=CC=CC=C3C4=NNN=N4 DMRBJNZ IK YONOBYIBNBCDSJ-UHFFFAOYSA-N DMRBJNZ IU 5-[(3,5-dibutyl-1,2,4-triazol-1-yl)methyl]-2-[2-(2H-tetrazol-5-yl)phenyl]pyridine DMRBJNZ CA CAS 145216-43-9 DMRBJNZ CB CHEBI:141552 DMRBJNZ DE Hypertension DMSOURV ID DMSOURV DMSOURV DN Formoterol DMSOURV HS Approved DMSOURV SN Foradile; Formoterol tartrate; Oxeze Turbuhaler Foradil; MOLI000351; Atimos (TN); Atock (TN); Foradil (TN); Foradile (TN); Formoterol (INN); Modulite (TN); Oxeze (TN); Oxis (TN); Perforomist (TN); Formoterol, ((R*,R*)-(+-)-)-isomer; N-[2-hydroxy-5-[1-hydroxy-2-[1-(4-methoxyphenyl)propan-2-ylamino]ethyl]phenyl]formamide; N-[2-hydroxy-5-(1-hydroxy-2-{[1-(4-methoxyphenyl)propan-2-yl]amino}ethyl)phenyl]formamide; N-[2-hydroxy-5-[(1R)-1-hydroxy-2-[[(2S)-1-(4-methoxyphenyl)propan-2-yl]amino]ethyl]phenyl]formamide; (+-)-2'-Hydroxy-5'-((RS)-1-hydroxy-2-(((RS)-p-methoxy-alpha-methylphenethyl)amino)ethyl)formanilide; 3-formylamino-4-hydroxy-alpha-(N-1-methyl-2-p-methoxyphenethylaminomethyl)benzyl alcohol.hemifumarate DMSOURV CP Norvatis Phamaceuticals Corporation DMSOURV TC Sympathomimetics DMSOURV DT Small molecular drug DMSOURV PC 3410 DMSOURV MW 344.4 DMSOURV FM C19H24N2O4 DMSOURV IC InChI=1S/C19H24N2O4/c1-13(9-14-3-6-16(25-2)7-4-14)20-11-19(24)15-5-8-18(23)17(10-15)21-12-22/h3-8,10,12-13,19-20,23-24H,9,11H2,1-2H3,(H,21,22) DMSOURV CS CC(CC1=CC=C(C=C1)OC)NCC(C2=CC(=C(C=C2)O)NC=O)O DMSOURV IK BPZSYCZIITTYBL-UHFFFAOYSA-N DMSOURV IU N-[2-hydroxy-5-[1-hydroxy-2-[1-(4-methoxyphenyl)propan-2-ylamino]ethyl]phenyl]formamide DMSOURV CA CAS 73573-87-2 DMSOURV CB CHEBI:63082 DMSOURV DE Asthma DM4W9B3 ID DM4W9B3 DM4W9B3 DN Fosamprenavir DM4W9B3 HS Approved DM4W9B3 SN Telzir; Amprenavir phosphate; Fosamprenavir [INN]; GW 433908; GW433908; VX 175; Fosamprenavir (INN); Lexiva (TM); Lexiva (TN); Telzir (TN); Telzir(TM); VX-175; GW433908A (*Sodium Salt*); GW433908G (*Calcium Salt*); [(3S)-oxolan-3-yl] N-[(2S,3R)-4-[(4-aminophenyl)sulfonyl-(2-methylpropyl)amino]-1-phenyl-3-phosphonooxybutan-2-yl]carbamate; Carbamic acid, ((1S,2R)-3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-1-(phenylmethyl)-2-(phosphonooxy)propyl)-, C-((3S)-tetrahydro-3-furanyl) ester; ((3S)Oxolan-3-yloxy)-N-((1S,2R)-3-{[(4-aminophenyl)sulfonyl](2-methylpropyl)amino}-1-benzyl-2-(phosphonooxy)propyl)carboxamide; (3-(((4-Aminophenyl)sulfonyl)(2-methylpropyl)amino)-1-(phenylmethyl)-2-(phosphonooxy)propyl)carbamic acid C-(tetrahydro-3-furanyl) ester DM4W9B3 CP GlaxoSmithKline DM4W9B3 TC Anti-HIV Agents DM4W9B3 DT Small molecular drug DM4W9B3 PC 131536 DM4W9B3 MW 585.6 DM4W9B3 FM C25H36N3O9PS DM4W9B3 IC InChI=1S/C25H36N3O9PS/c1-18(2)15-28(39(33,34)22-10-8-20(26)9-11-22)16-24(37-38(30,31)32)23(14-19-6-4-3-5-7-19)27-25(29)36-21-12-13-35-17-21/h3-11,18,21,23-24H,12-17,26H2,1-2H3,(H,27,29)(H2,30,31,32)/t21-,23-,24+/m0/s1 DM4W9B3 CS CC(C)CN(C[C@H]([C@H](CC1=CC=CC=C1)NC(=O)O[C@H]2CCOC2)OP(=O)(O)O)S(=O)(=O)C3=CC=C(C=C3)N DM4W9B3 IK MLBVMOWEQCZNCC-OEMFJLHTSA-N DM4W9B3 IU [(3S)-oxolan-3-yl] N-[(2S,3R)-4-[(4-aminophenyl)sulfonyl-(2-methylpropyl)amino]-1-phenyl-3-phosphonooxybutan-2-yl]carbamate DM4W9B3 CA CAS 226700-79-4 DM4W9B3 CB CHEBI:82941 DM4W9B3 DE Human immunodeficiency virus infection DM9KJLZ ID DM9KJLZ DM9KJLZ DN Foscavir DM9KJLZ HS Approved DM9KJLZ SN Foscarmet; Foscarnet; Phosphonoformate; Triapten; Virudin; Carboxyphosphonic acid; Dihydroxyphosphanecarboxylic acid oxide; Dihydroxyphosphinecarboxylic acid oxide; Dihydroxyphosphinecarboxylic acid oxide trisodium salt; Dihydroxyphosphinecarboxylic acid oxide trisodium salt hexahydrate; FOSCARNET SODIUM; Forscarnet sodium; Foscarnet sodico; Foscarnet sodico [Spanish]; Foscarnet sodique; Foscarnet sodique [French]; Foscarnet sodium hexahydrate; Foscarnet sodium hydrate; Foscarneto sodico; Foscarnetum natricum; Foscarnetum natricum [Latin]; Phgosphonocarboxylic acid; Phosphonoformic acid; Phosphonomethanoic acid; Trisodium carboxyphosphate; Trisodium dioxidophosphanecarboxylate oxide; Trisodium dioxidophosphinecarboxylate oxide; Trisodium phosphonatoformate; Trisodium phosphonatoformate hexahydrate; Trisodium phosphonoformate; Trisodium phosphonoformate hexahydrate; Trisodium phosphonoformte hexahydrate; A 29622; EHB 776; A-29622; DRG-0017; Dihydroxyphosphinecarboxylic acid oxide and MSL, neutralizing monoclonal antibody; EHB-776; Foscarnet sodique [INN-French]; Foscarnet sodium hydrate (JAN); Foscarneto sodico [INN-Spanish]; Foscarnetum natricum [INN-Latin]; Foscavir (TN); HS-0008; MSL & PFA; Phosphonoformic acid, trisodium salt; Trisodium carboxyphosphate (anhydrous); Trisodium phosphonoformate (anhydrous); Foscarnet & IFN-ALPHA; Foscarnet sodium (USAN/INN); Foscarnet sodium [USAN:INN:BAN]; Phosphonoformic acid & IFN-ALPHA; Phosphonoformic acid, trisodium salt, hexahydrate; PFA & rIFN.alpha.A; Phosphinecarboxylic acid, dihydroxy-, oxide; Phosphonoformate(trisodium) & Recombinant Alpha-A Interferon; Sodium dioxidophosphanecarboxylate oxide hydrate(3:1:6); Formic acid, phosphono-, trisodium salt, hexahydrate; Phosphinecarboxylic acid, dihydroxy-, oxide, trisodium salt; Phosphinecarboxylic acid, dihydroxy-, oxide, trisodium salt, hexahydrate DM9KJLZ CP AstraZeneca DM9KJLZ TC Antiviral Agents DM9KJLZ DT Small molecular drug DM9KJLZ PC 44561 DM9KJLZ MW 191.95 DM9KJLZ FM CNa3O5P DM9KJLZ IC InChI=1S/CH3O5P.3Na/c2-1(3)7(4,5)6;;;/h(H,2,3)(H2,4,5,6);;;/q;3*+1/p-3 DM9KJLZ CS C(=O)([O-])P(=O)([O-])[O-].[Na+].[Na+].[Na+] DM9KJLZ IK DFHAXXVZCFXGOQ-UHFFFAOYSA-K DM9KJLZ IU trisodium;phosphonatoformate DM9KJLZ CA CAS 63585-09-1 DM9KJLZ CB CHEBI:141644 DM9KJLZ DE Cytomegalovirus retinitis DMR0TYK ID DMR0TYK DMR0TYK DN Fosdenopterin DMR0TYK HS Approved DMR0TYK SN CPMP; CPMP (molybdenum cofactor deficiency), Alexion; CPMP (molybdenum cofactor deficiency), Orphatec DMR0TYK CP Orphatec Pharmaceuticals GmbH DMR0TYK DT Small molecular drug DMR0TYK PC 135463437 DMR0TYK MW 363.22 DMR0TYK FM C10H14N5O8P DMR0TYK IC InChI=1S/C10H14N5O8P/c11-9-14-6-3(7(16)15-9)12-4-8(13-6)22-2-1-21-24(19,20)23-5(2)10(4,17)18/h2,4-5,8,12,17-18H,1H2,(H,19,20)(H4,11,13,14,15,16)/t2-,4-,5+,8-/m1/s1 DMR0TYK CS C1[C@@H]2[C@@H](C([C@H]3[C@@H](O2)NC4=C(N3)C(=O)NC(=N4)N)(O)O)OP(=O)(O1)O DMR0TYK IK CZAKJJUNKNPTTO-AJFJRRQVSA-N DMR0TYK IU (1R,10R,12S,17R)-5-amino-11,11,14-trihydroxy-14-oxo-13,15,18-trioxa-2,4,6,9-tetraza-14lambda5-phosphatetracyclo[8.8.0.03,8.012,17]octadeca-3(8),4-dien-7-one DMR0TYK CA CAS 150829-29-1 DMR0TYK CB CHEBI:60210 DMR0TYK DE Encephalopathy; Molybdenum cofactor deficiency DMD072M ID DMD072M DMD072M DN Fosfestrol DMD072M HS Approved DMD072M SN fosfestrol; Diethylstilbestrol diphosphate; 522-40-7; Phosphestrol; Phosphoestrolum; Honvan; Stilbestrol diphosphate; Desdp; Diethylstilbestryl diphosphate; Diethylstilbesterol diphosphate; ST52-Asta; Fosfestrolum [INN-Latin]; UNII-A0E0NMA80F; CCRIS 2778; (E)-Hex-3-ene-3,4-diylbis(4,1-phenylene) bis(dihydrogen phosphate); C18H22O8P2; EINECS 208-328-8; A0E0NMA80F; CHEBI:4532; Diethylstilbestrol diphosphate [USP]; NCGC00181335-01; Stilphostrol (TN); alpha,alpha'-Diethyl-(E)-4,4'-stilbenediol bis(dihydrogen phosphate) DMD072M DT Small molecular drug DMD072M PC 3032325 DMD072M MW 428.3 DMD072M FM C18H22O8P2 DMD072M IC InChI=1S/C18H22O8P2/c1-3-17(13-5-9-15(10-6-13)25-27(19,20)21)18(4-2)14-7-11-16(12-8-14)26-28(22,23)24/h5-12H,3-4H2,1-2H3,(H2,19,20,21)(H2,22,23,24)/b18-17+ DMD072M CS CC/C(=C(/CC)\\C1=CC=C(C=C1)OP(=O)(O)O)/C2=CC=C(C=C2)OP(=O)(O)O DMD072M IK NLORYLAYLIXTID-ISLYRVAYSA-N DMD072M IU [4-[(E)-4-(4-phosphonooxyphenyl)hex-3-en-3-yl]phenyl] dihydrogen phosphate DMD072M CA CAS 522-40-7 DMD072M CB CHEBI:4532 DMD072M DE Solid tumour/cancer DMVGPMX ID DMVGPMX DMVGPMX DN Fosfomycin DMVGPMX HS Approved DMVGPMX SN FCM; Phosphomycin; Phosphonemycin; Phosphonomycin; Priomicina; Veramina; Disodium fosfomycin; Disodium phosphonomycin; Fosfocina disodium salt; Fosfomycin disodium; Fosfomycin disodium salt; Fosfomycin sodium; Fosfomycin sodium salt; Fosmicin S; Phosphomycin disodium salt; Phosphonomycin disodium salt; Phosphonomycin sodium; Sodium fosfomycin; MK 955; FOM-Na; Fosfomycin sodium (JP15); Fosmicin S (TN); Fosfomycin (USAN/INN); L-cis-1,2-epoxypropylphosphonic acid; Disodium (1R,2S)-(1,2-epoxypropyl)phosphonate; Disodium[(2r,3s)-3-methyloxiran-2-yl]phosphonate; [(2R,3S)-3-methyloxiran-2-yl]phosphonic acid; Phosphonic acid, (3-methyloxiranyl)-, disodium salt, (2R-cis)-(9CI); (-)-(1R,2S)-(1,2-Epoxypropyl)phosphonicacid; (1R,2S)(-)-(1,2-Epoxypropyl)phosphonic acid disodium salt; (1R,2S)-(1,2-Epoxypropyl)phosphonic acid; (1R,2S)-epoxypropylphosphonate; (1R,2S)-epoxypropylphosphonic acid; (2R-cis)-(3-Methyloxiranyl)phosphonic acid disodium salt DMVGPMX TC Antibiotics DMVGPMX DT Small molecular drug DMVGPMX PC 446987 DMVGPMX MW 138.06 DMVGPMX FM C3H7O4P DMVGPMX IC InChI=1S/C3H7O4P/c1-2-3(7-2)8(4,5)6/h2-3H,1H3,(H2,4,5,6)/t2-,3+/m0/s1 DMVGPMX CS C[C@H]1[C@H](O1)P(=O)(O)O DMVGPMX IK YMDXZJFXQJVXBF-STHAYSLISA-N DMVGPMX IU [(2R,3S)-3-methyloxiran-2-yl]phosphonic acid DMVGPMX CA CAS 23155-02-4 DMVGPMX CB CHEBI:28915 DMVGPMX DE Bacterial infection DMDIC39 ID DMDIC39 DMDIC39 DN Fosfosal DMDIC39 HS Approved DMDIC39 SN Disdolen (TN) DMDIC39 DT Small molecular drug DMDIC39 PC 3418 DMDIC39 MW 218.1 DMDIC39 FM C7H7O6P DMDIC39 IC InChI=1S/C7H7O6P/c8-7(9)5-3-1-2-4-6(5)13-14(10,11)12/h1-4H,(H,8,9)(H2,10,11,12) DMDIC39 CS C1=CC=C(C(=C1)C(=O)O)OP(=O)(O)O DMDIC39 IK FFKUDWZICMJVPA-UHFFFAOYSA-N DMDIC39 IU 2-phosphonooxybenzoic acid DMDIC39 CA CAS 6064-83-1 DMDIC39 CB CHEBI:94564 DMDIC39 DE Pain DM9NJ52 ID DM9NJ52 DM9NJ52 DN Fosinopril DM9NJ52 HS Approved DM9NJ52 SN Acecor; Fosenopril; Monopril; Staril; FOSINOPRIL SODIUM; Fosinopril (INN); Fosinopril [INN:BAN]; Monopril (TN); SQ-28555; SQ-28,555; Fosinopril, (1(S*(R*)),2 alpha,4 beta)-Isomer; (2S,4S)-4-cyclohexyl-1-[2-[(2-methyl-1-propanoyloxypropoxy)-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid; (2S,4S)-4-cyclohexyl-1-[2-[[(1S)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid; (2S,4S)-4-cyclohexyl-1-{2-[(2-methyl-1-propionyloxy-propoxy)-(4-phenyl-butyl)-phosphinoyl]-acetyl}-pyrrolidine-2-carboxylic acid; (4S)-4-cyclohexyl-1-({[2-methyl-1-(propanoyloxy)propoxy](4-phenylbutyl)phosphoryl}acetyl)-L-proline; (4S)-4-cyclohexyl-1-{[{[2-methyl-1-(propanoyloxy)propyl]oxy}(4-phenylbutyl)phosphoryl]acetyl}-L-proline; 4-cyclohexyl-1-[2-[(2-methyl-1-propanoyloxypropoxy)-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid DM9NJ52 CP Bristol-Myers Squibb DM9NJ52 TC Antihypertensive Agents DM9NJ52 DT Small molecular drug DM9NJ52 PC 55891 DM9NJ52 MW 563.7 DM9NJ52 FM C30H46NO7P DM9NJ52 IC InChI=1S/C30H46NO7P/c1-4-28(33)37-30(22(2)3)38-39(36,18-12-11-15-23-13-7-5-8-14-23)21-27(32)31-20-25(19-26(31)29(34)35)24-16-9-6-10-17-24/h5,7-8,13-14,22,24-26,30H,4,6,9-12,15-21H2,1-3H3,(H,34,35)/t25-,26+,30?,39?/m1/s1 DM9NJ52 CS CCC(=O)OC(C(C)C)OP(=O)(CCCCC1=CC=CC=C1)CC(=O)N2C[C@@H](C[C@H]2C(=O)O)C3CCCCC3 DM9NJ52 IK BIDNLKIUORFRQP-FKDWWROVSA-N DM9NJ52 IU (2S,4S)-4-cyclohexyl-1-[2-[(2-methyl-1-propanoyloxypropoxy)-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid DM9NJ52 CA CAS 98048-97-6 DM9NJ52 CB CHEBI:5163 DM9NJ52 DE Hypertension DM7G0EP ID DM7G0EP DM7G0EP DN Fosmidomycin DM7G0EP HS Approved DM7G0EP SN FOM; Fosmidomycina; Fosmidomycine; Fosmidomycinum; FR-31564; Fosmidomycina [INN-Spanish]; Fosmidomycine [INN-French]; Fosmidomycinum [INN-Latin]; {3-[formyl(hydroxy)amino]propyl}phosphonic acid; (3-(Formylhydroxyamino)propyl)phosphonic acid, monosodium salt; (3-(N-Hydroxyformamido)propyl)phosphonic acid; 3-(Formyl-hydroxy-amino)propylphosphonic acid; 3-(N-Formyl-N-hydroxyamino)-propylphosphonic acid; 3-(N-hydroxyformamido)propylphosphonic acid; 3-[FORMYL(HYDROXY)AMINO]PROPYLPHOSPHONIC ACID DM7G0EP TC Antimalarials DM7G0EP DT Small molecular drug DM7G0EP PC 572 DM7G0EP MW 183.1 DM7G0EP FM C4H10NO5P DM7G0EP IC InChI=1S/C4H10NO5P/c6-4-5(7)2-1-3-11(8,9)10/h4,7H,1-3H2,(H2,8,9,10) DM7G0EP CS C(CN(C=O)O)CP(=O)(O)O DM7G0EP IK GJXWDTUCERCKIX-UHFFFAOYSA-N DM7G0EP IU 3-[formyl(hydroxy)amino]propylphosphonic acid DM7G0EP CA CAS 66508-53-0 DM7G0EP CB CHEBI:443725 DM7G0EP DE Malaria DMOX3LB ID DMOX3LB DMOX3LB DN Fosphenytoin DMOX3LB HS Approved DMOX3LB SN Fosfenitoina; Fosphenytoine; Fosphenytoinum; HMPDP; Prodilantin; ACC-9653; Cerebyx (TN); Fosfenitoina [INN-Spanish]; Fosphenytoin (INN); Fosphenytoin [INN:BAN]; Fosphenytoine [INN-French]; Fosphenytoinum [INN-Latin]; Prodilantin (TN); (2,5-dioxo-4,4-diphenylimidazolidin-1-yl)methyl dihydrogen phosphate; (3-Phosphoryloxymethyl)phenytoin; 3-(hydroxymethyl)phenytoin disodium phosphate; 3-(hydroxymethyl)phenytoin phosphate ester DMOX3LB CP Pfizer Pharmaceuticals DMOX3LB TC Anticonvulsants DMOX3LB DT Small molecular drug DMOX3LB PC 56339 DMOX3LB MW 362.27 DMOX3LB FM C16H15N2O6P DMOX3LB IC InChI=1S/C16H15N2O6P/c19-14-16(12-7-3-1-4-8-12,13-9-5-2-6-10-13)17-15(20)18(14)11-24-25(21,22)23/h1-10H,11H2,(H,17,20)(H2,21,22,23) DMOX3LB CS C1=CC=C(C=C1)C2(C(=O)N(C(=O)N2)COP(=O)(O)O)C3=CC=CC=C3 DMOX3LB IK XWLUWCNOOVRFPX-UHFFFAOYSA-N DMOX3LB IU (2,5-dioxo-4,4-diphenylimidazolidin-1-yl)methyl dihydrogen phosphate DMOX3LB CA CAS 93390-81-9 DMOX3LB CB CHEBI:5165 DMOX3LB DE Epilepsy DM8J5XT ID DM8J5XT DM8J5XT DN Fospropofol DM8J5XT HS Approved DM8J5XT SN Fospropofol; Fospropofol [INN]; LZ257RZP7K; SCHEMBL3821874; ZINC2519740; 258516-89-1; AC1MI4YI; ACM258516891; CHEBI:135193; CHEMBL1201766; DB06716; DEA No. 2138; DTXSID50870295; FT-0727559; GTPL7475; UNII-LZ257RZP7K; [2,6-di(propan-2-yl)phenoxy]methyl dihydrogen phosphate DM8J5XT PC 3038498 DM8J5XT MW 288.28 DM8J5XT FM C13H21O5P DM8J5XT IC QVNNONOFASOXQV-UHFFFAOYSA-N DM8J5XT CS CC(C)C1=C(C(=CC=C1)C(C)C)OCOP(=O)(O)O DM8J5XT IK 1S/C13H21O5P/c1-9(2)11-6-5-7-12(10(3)4)13(11)17-8-18-19(14,15)16/h5-7,9-10H,8H2,1-4H3,(H2,14,15,16) DM8J5XT IU [2,6-di(propan-2-yl)phenoxy]methyl dihydrogen phosphate DM8J5XT CA CAS 258516-89-1 DM8J5XT CB CHEBI:135193 DM8J5XT DE Neuropathic pain DMKLJRD ID DMKLJRD DMKLJRD DN Fospropofol disodium DMKLJRD HS Approved DMKLJRD SN Lusedra (TN) DMKLJRD CP Eisai DMKLJRD DT Small molecular drug DMKLJRD PC 3038497 DMKLJRD MW 332.24 DMKLJRD FM C13H19Na2O5P DMKLJRD IC InChI=1S/C13H21O5P.2Na/c1-9(2)11-6-5-7-12(10(3)4)13(11)17-8-18-19(14,15)16;;/h5-7,9-10H,8H2,1-4H3,(H2,14,15,16);;/q;2*+1/p-2 DMKLJRD CS CC(C)C1=C(C(=CC=C1)C(C)C)OCOP(=O)([O-])[O-].[Na+].[Na+] DMKLJRD IK LWYLQNWMSGFCOZ-UHFFFAOYSA-L DMKLJRD IU disodium;[2,6-di(propan-2-yl)phenoxy]methyl phosphate DMKLJRD CA CAS 258516-87-9 DMKLJRD DE Monitored anaesthesia care DM6AUHV ID DM6AUHV DM6AUHV DN Fostamatinib DM6AUHV HS Approved DM6AUHV SN 901119-35-5; R788; Tavalisse; UNII-SQ8A3S5101; R-788 Free acid; R 788; R-788; R-935788 Free acid; SQ8A3S5101; R7935788; Fostamatinib [USAN:INN] DM6AUHV CP Rigel Pharmaceuticals DM6AUHV DT Small molecular drug DM6AUHV PC 11671467 DM6AUHV MW 580.5 DM6AUHV FM C23H26FN6O9P DM6AUHV IC InChI=1S/C23H26FN6O9P/c1-23(2)21(31)30(11-38-40(32,33)34)20-14(39-23)6-7-17(28-20)27-19-13(24)10-25-22(29-19)26-12-8-15(35-3)18(37-5)16(9-12)36-4/h6-10H,11H2,1-5H3,(H2,32,33,34)(H2,25,26,27,28,29) DM6AUHV CS CC1(C(=O)N(C2=C(O1)C=CC(=N2)NC3=NC(=NC=C3F)NC4=CC(=C(C(=C4)OC)OC)OC)COP(=O)(O)O)C DM6AUHV IK GKDRMWXFWHEQQT-UHFFFAOYSA-N DM6AUHV IU [6-[[5-fluoro-2-(3,4,5-trimethoxyanilino)pyrimidin-4-yl]amino]-2,2-dimethyl-3-oxopyrido[3,2-b][1,4]oxazin-4-yl]methyl dihydrogen phosphate DM6AUHV CA CAS 901119-35-5 DM6AUHV DE Immune thrombocytopenic purpura; Rheumatoid arthritis DM50ILT ID DM50ILT DM50ILT DN Fostemsavir DM50ILT HS Approved DM50ILT SN BMS-216; BMS-248; BMS-378806; BMS-626529; BMS-705; BMS-806; BMS-806 series; BMS-853; HIV-1 attachment inhibitors, BMS; HIV-1 entry inhibitors, BMS; BMS-488043 follow-on compounds, BMS; HIV-1 attachment inhibitors, Bristol-Myers Squibb DM50ILT CP Bristol-myers squibb DM50ILT DT Small molecular drug DM50ILT PC 11319217 DM50ILT MW 583.5 DM50ILT FM C25H26N7O8P DM50ILT IC InChI=1S/C25H26N7O8P/c1-16-27-14-32(28-16)23-21-20(19(39-2)12-26-23)18(13-31(21)15-40-41(36,37)38)22(33)25(35)30-10-8-29(9-11-30)24(34)17-6-4-3-5-7-17/h3-7,12-14H,8-11,15H2,1-2H3,(H2,36,37,38) DM50ILT CS CC1=NN(C=N1)C2=NC=C(C3=C2N(C=C3C(=O)C(=O)N4CCN(CC4)C(=O)C5=CC=CC=C5)COP(=O)(O)O)OC DM50ILT IK SWMDAPWAQQTBOG-UHFFFAOYSA-N DM50ILT IU [3-[2-(4-benzoylpiperazin-1-yl)-2-oxoacetyl]-4-methoxy-7-(3-methyl-1,2,4-triazol-1-yl)pyrrolo[2,3-c]pyridin-1-yl]methyl dihydrogen phosphate DM50ILT CA CAS 864953-29-7 DM50ILT DE Human immunodeficiency virus infection DMV62ED ID DMV62ED DMV62ED DN Fotemustine DMV62ED HS Approved DMV62ED SN Fotemustine; 92118-27-9; Diethyl (1-(3-(2-chloroethyl)-3-nitrosoureido)ethyl)phosphonate; Muphoran; Mustophorane; Servier-10036; Fotemustinum [Latin]; Fotemustina [Spanish]; S 10036; C9H19ClN3O5P; CCRIS 6337; S-10036; Fotemustinum; Diethyl-1-(3-(2-chloroethyl)-3-nitrosoureido)ethylphosphonate; (+-)-Diethyl (1-(3-(2-chloroethyl)-3-nitrosoureido)ethyl)phosphonate; Mustoforan; 1-(2-chloroethyl)-3-(1-diethoxyphosphorylethyl)-1-nitrosourea; Fotemustine [BAN:INN] DMV62ED DT Small molecular drug DMV62ED PC 104799 DMV62ED MW 315.69 DMV62ED FM C9H19ClN3O5P DMV62ED IC InChI=1S/C9H19ClN3O5P/c1-4-17-19(16,18-5-2)8(3)11-9(14)13(12-15)7-6-10/h8H,4-7H2,1-3H3,(H,11,14) DMV62ED CS CCOP(=O)(C(C)NC(=O)N(CCCl)N=O)OCC DMV62ED IK YAKWPXVTIGTRJH-UHFFFAOYSA-N DMV62ED IU 1-(2-chloroethyl)-3-(1-diethoxyphosphorylethyl)-1-nitrosourea DMV62ED CA CAS 92118-27-9 DMV62ED CB CHEBI:131852 DMV62ED DE Solid tumour/cancer DMF8DNE ID DMF8DNE DMF8DNE DN Framycetin DMF8DNE HS Approved DMF8DNE SN Neomycin; neomycin; NEOMYCIN B; Soframycin; Actiline; Mycifradin; Fradiomycin; Soframycine; Framycetinum; Framycetine; Framicetina; Neomas; Fradiomycinum; Antibiotique; Nivemycin; Actilin; Neolate; Enterfram; Myacyne; Framygen; Caswell No 595; Vonamycin powder V; Neomycin B sulfate; Neomin; Neomcin; Fradiomycin B; Neo-Rx; Neomicina [DCIT]; Framycetinum [INN-Latin]; PIMAVECORT; Neobrettin; Neo-Fradin; 119-04-0; Neomycine [INN-French]; Neomycinum [INN-Latin]; Framycetine [INN-French]; Framicetina [INN-Spanish]; USAF CB-19; Endomixin; Fraquinol; Myacine; Myciguent; NMY; Neobiotic; Neomicina; Neomycinum; Tuttomycin; VONAMYCIN; NEOMYCIN AND POLYMYXIN B SULFATES; NEOMYCIN SULFATE; Neomycin solution; Soframycin Ophthalmic; Antibiotic 10676; Antibiotic produced by Streptomyces decaris Neomycin B; Framycetin (INN); Soframycin (TN); Framycetin [INN:BAN:DCF]; Sofra-Tulle (TN); BDG-(1-4)CYY-(5-1)RIB-(3-1)IDG; BDG-(1-4)NEB-(5-1)RIB-(3-1)NED; (1R,2R,3S,4R,6S)-4,6-diamino-2-{[3-O-(2,6-diamino-2,6-dideoxy-beta-L-idopyranosyl)-beta-D-ribofuranosyl]oxy}-3-hydroxycyclohexyl 2,6-diamino-2,6-dideoxy-alpha-D-glucopyranoside; (2R,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-[(1R,2R,3S,4R,6S)-4,6-diamino-2-[(2S,3R,4S,5R)-4-[(2R,3R,4R,5S,6S)-3-amino-6-(aminomethyl)-4,5-dihydroxyoxan-2-yl]oxy-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-3-hydroxycyclohexyl]oxyoxane-3,4-diol; D-Streptamine, O-2,6-diamino-2,6-dideoxy-beta-L-idopyranosyl-(1->3)-O-beta-D-ribofuranosyl-(1->5)]-O-[2,6-diamino-2,6-dideoxy-alpha-D-glucopyranosyl-(1->4)]-2-deoxy DMF8DNE TC Antibiotics DMF8DNE DT Small molecular drug DMF8DNE PC 8378 DMF8DNE MW 614.6 DMF8DNE FM C23H46N6O13 DMF8DNE IC InChI=1S/C23H46N6O13/c24-2-7-13(32)15(34)10(28)21(37-7)40-18-6(27)1-5(26)12(31)20(18)42-23-17(36)19(9(4-30)39-23)41-22-11(29)16(35)14(33)8(3-25)38-22/h5-23,30-36H,1-4,24-29H2/t5-,6+,7-,8+,9-,10-,11-,12+,13-,14-,15-,16-,17-,18-,19-,20-,21-,22-,23+/m1/s1 DMF8DNE CS C1[C@H]([C@@H]([C@H]([C@@H]([C@H]1N)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CN)O)O)N)O[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O[C@@H]4[C@@H]([C@H]([C@@H]([C@@H](O4)CN)O)O)N)O)O)N DMF8DNE IK PGBHMTALBVVCIT-VCIWKGPPSA-N DMF8DNE IU (2R,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-[(1R,2R,3S,4R,6S)-4,6-diamino-2-[(2S,3R,4S,5R)-4-[(2R,3R,4R,5S,6S)-3-amino-6-(aminomethyl)-4,5-dihydroxyoxan-2-yl]oxy-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-3-hydroxycyclohexyl]oxyoxane-3,4-diol DMF8DNE CA CAS 119-04-0 DMF8DNE CB CHEBI:7508 DMF8DNE DE Alcoholic cirrhosis of liver; Acute liver failure; Bacterial infection DMDZY54 ID DMDZY54 DMDZY54 DN Fremanezumab DMDZY54 HS Approved DMDZY54 SN Fremanezumab [INN]; Fremanezumab [USAN]; UNII-PF8K38CG54; PF8K38CG54; TEV-48125; PF-04472429 DMDZY54 CP Teva DMDZY54 DT Antibody DMDZY54 DE Hyperprolactinaemia DM7RE8P ID DM7RE8P DM7RE8P DN Frovatriptan DM7RE8P HS Approved DM7RE8P SN Allegro; Auradol; Frova; Frovelan; Migard; Miguard; Rilamig; Allergo filmtabletten; SB 209509; Allergo filmtabletten(TN); Frova (TN); Frovatriptan (INN); SB-209509; (3R)-3-(methylamino)-2,3,4,9-tetrahydro-1H-carbazole-6-carboxamide; (6R)-6-(methylamino)-6,7,8,9-tetrahydro-5H-carbazole-3-carboxamide; (R)-5,6,7,8-Tetrahydro-6-(methylamino)carbazole-3-carboxamide DM7RE8P CP Vernalis DM7RE8P TC Antimigraine Agents DM7RE8P DT Small molecular drug DM7RE8P PC 77992 DM7RE8P MW 243.3 DM7RE8P FM C14H17N3O DM7RE8P IC InChI=1S/C14H17N3O/c1-16-9-3-5-13-11(7-9)10-6-8(14(15)18)2-4-12(10)17-13/h2,4,6,9,16-17H,3,5,7H2,1H3,(H2,15,18)/t9-/m1/s1 DM7RE8P CS CN[C@@H]1CCC2=C(C1)C3=C(N2)C=CC(=C3)C(=O)N DM7RE8P IK XPSQPHWEGNHMSK-SECBINFHSA-N DM7RE8P IU (6R)-6-(methylamino)-6,7,8,9-tetrahydro-5H-carbazole-3-carboxamide DM7RE8P CA CAS 158747-02-5 DM7RE8P CB CHEBI:134991 DM7RE8P DE Migraine DM43AN2 ID DM43AN2 DM43AN2 DN Fructose DM43AN2 HS Approved DM43AN2 SN D-(-)-Fructose; 57-48-7; D(-)-Fructose; (3S,4R,5R)-1,3,4,5,6-pentahydroxyhexan-2-one; 53188-23-1; D-(-)-Levulose; D-Levulose; Nevulose; Furucton; arabino-Hexulose; Sugar, fruit; Fructose, D-; Krystar 300; Hi-Fructo 970; keto-D-fructose; Fructose, pure; Fructose solution; CCRIS 3335; 30237-26-4; EINECS 200-333-3; AI3-23514; DL-Fructose; MFCD00148910; D(-)-Fructose, 99%; Fructon; D-(-)-Fructose, > Methose; Levulosa; Levulosa Baxter; Levulosa Braun; Apir Levulosa; Levulosa Mein; Levulosa Ibys; Levulosa Ife; Levulosado Braun; D-fructose DM43AN2 DT Small molecular drug DM43AN2 PC 2723872 DM43AN2 MW 180.16 DM43AN2 FM C6H12O6 DM43AN2 IC InChI=1S/C6H12O6/c7-2-6(11)5(10)4(9)3(8)1-12-6/h3-5,7-11H,1-2H2/t3-,4-,5+,6?/m1/s1 DM43AN2 CS C1[C@H]([C@H]([C@@H](C(O1)(CO)O)O)O)O DM43AN2 IK LKDRXBCSQODPBY-VRPWFDPXSA-N DM43AN2 IU (3S,4R,5R)-2-(hydroxymethyl)oxane-2,3,4,5-tetrol DM43AN2 CA CAS 6347-01-9 DM43AN2 CB CHEBI:37714 DM43AN2 DE Vomiting DM0YZC6 ID DM0YZC6 DM0YZC6 DN Fulvestrant DM0YZC6 HS Approved DM0YZC6 SN Faslodex; AstraZeneca brand of fulvestrant; Fulvestrant [USAN]; Ici 182780; ZD 182780; ZM 182780; Faslodex (TN); ZD-182780; ZD-9238; ZM-182780; Faslodex(ICI 182,780); Faslodex, ICI 182780, Fulvestrant; Fulvestrant (JAN/USAN/INN); (7R,13S,17S)-13-methyl-7-(9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol; (7R,8R,9S,13S,14S,17S)-13-methyl-7-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol; (7R,8S,9S,13S,14S,17S)-13-methyl-7-[9-(4,4,5,5,5-pentafluoropentylsulfinyl) nonyl]-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol; (7alpha,17beta)-7-{9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl}estra-1,3,5(10)-triene-3,17-diol; 7-(9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl)estra-1,3,5(10)-triene-3,17-diol; 7alpha-(9-((4,4,5,5,5,-Pentafluoropentyl)sulfinyl)nonyl)estra-1,3,5(10)-triene-3,17beta-diol; 7alpha-(9-((4,4,5,5,5-Pentafluoropentyl)sulfinyl)nonyl)estra-1,3,5(10)-triene-3,17beta-diol; 7alpha-[9[(4,4,5,5,5-Pentafluropentyl)sulfinyl]nonyl]-estra-1,3,5(10)-triene-3, 17 beta diol; ICI DM0YZC6 CP AstraZeneca DM0YZC6 TC Anticancer Agents DM0YZC6 DT Small molecular drug DM0YZC6 PC 104741 DM0YZC6 MW 606.8 DM0YZC6 FM C32H47F5O3S DM0YZC6 IC InChI=1S/C32H47F5O3S/c1-30-17-15-26-25-12-11-24(38)21-23(25)20-22(29(26)27(30)13-14-28(30)39)10-7-5-3-2-4-6-8-18-41(40)19-9-16-31(33,34)32(35,36)37/h11-12,21-22,26-29,38-39H,2-10,13-20H2,1H3/t22-,26-,27+,28+,29-,30+,41?/m1/s1 DM0YZC6 CS C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@@H](CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F DM0YZC6 IK VWUXBMIQPBEWFH-WCCTWKNTSA-N DM0YZC6 IU (7R,8R,9S,13S,14S,17S)-13-methyl-7-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol DM0YZC6 CA CAS 129453-61-8 DM0YZC6 CB CHEBI:31638 DM0YZC6 DE Breast cancer DM3P6V7 ID DM3P6V7 DM3P6V7 DN Furazolidone DM3P6V7 HS Approved DM3P6V7 SN Bifuron; Corizium; Coryzium; Diafuron; Enterotoxon; Furall; Furaxon; Furaxone; Furazol; Furazolidine; Furazolidon; Furazolidona; Furazolidonum; Furazolum; Furazon; Furidon; Furovag; Furox; Furoxal; Furoxane; Furoxon; Furoxone; Furozolidine; Giardil; Giarlam; Medaron; Neftin; Nicolen; Nifulidone; Nifuran; Nifurazolidone; Nifurazolidonum; Nitrofurazolidone; Nitrofurazolidonum; Nitrofuroxon; Optazol; Ortazol; Puradin; Roptazol; Sclaventerol; Tikofuran; Topazone; Trichofuron; Tricofuron; Tricoron; Trifurox; Viofuragyn; Fiurox aerosol powder; Furoxone Liquid; Furoxone Swine Mix; NF 180 custom mix ten; F-8900; Furazolidona [INN-Spanish]; Furazolidone [INN:BAN]; Furazolidonum [INN-Latin]; Furox Aerosol Powder (Veterinary); Furoxone (TN); NF-180; Usaf ea-1; Dependal-M (TN); Furazolidone (USP/INN); N-(5-Nitro-2-furfurylidene)-3-amino-2-oxazolidone; N-(5-Nitro-2-furfurylidene)-3-aminooxazolidine-2-one; 3-(((5-Nitro-2-furanyl)methylene)amino)-2-oxazolidinone; 3-((5-Nitrofurfurylidene)amino)-2-oxazolidinone; 3-((5-Nitrofurfurylidene)amino)-2-oxazolidone; 3-((5-Nitrofurylidene)amino)-2-oxazolidone; 3-(5'-Nitrofurfuralamino)-2-oxazolidone; 3-(5-Nitrofurfurylideneamino)-2-oxazolidinone; 3-[(5-Nitrofurfurylidene)amino]-2-oxazolidinone; 3-[(5-Nitrofurfurylidene)amino]-2-oxazolidone; 3-[(5-Nitrofurylidene)amino]-2-oxazolidone; 3-[(E)-(5-nitrofuran-2-yl)methylideneamino]-1,3-oxazolidin-2-one; 3-[[(5-Nitro-2-furanyl)methylene]amino]-2-oxazolidinone; 3-{[(5-Nitro-2-furanyl)methylene]amino}-2-oxazolidinone; 3-{[(5-nitro-2-furyl)methylene]amino}-1,3-oxazolidin-2-one; 3-{[(E)-(5-nitrofuran-2-yl)methylidene]amino}-1,3-oxazolidin-2-one; 5-Nitro-N-(2-oxo-3-oxazolidinyl)-2-furanmethanimine DM3P6V7 CP GlaxoSmithKline DM3P6V7 TC Antiinfective Agents DM3P6V7 DT Small molecular drug DM3P6V7 PC 5323714 DM3P6V7 MW 225.16 DM3P6V7 FM C8H7N3O5 DM3P6V7 IC InChI=1S/C8H7N3O5/c12-8-10(3-4-15-8)9-5-6-1-2-7(16-6)11(13)14/h1-2,5H,3-4H2/b9-5+ DM3P6V7 CS C1COC(=O)N1/N=C/C2=CC=C(O2)[N+](=O)[O-] DM3P6V7 IK PLHJDBGFXBMTGZ-WEVVVXLNSA-N DM3P6V7 IU 3-[(E)-(5-nitrofuran-2-yl)methylideneamino]-1,3-oxazolidin-2-one DM3P6V7 CA CAS 67-45-8 DM3P6V7 CB CHEBI:5195 DM3P6V7 DE Diarrhea DMMQ8ZG ID DMMQ8ZG DMMQ8ZG DN Furosemide DMMQ8ZG HS Approved DMMQ8ZG SN Aisemide; Aldalix; Aldic; Aluzine; Anfuramaide; Aquarid; Aquasin; Arasemide; Beronald; Bioretic; Cetasix; Depix; Desal; Desdemin; Dirine; Disal; Discoid; Disemide; Diural; Diurapid; Diurin; Diurolasa; Diusemide; Diusil; Diuzol; Dranex; Dryptal; Durafurid; Edemid; Edenol; Eliur; Endural; Errolon; Eutensin; FUN; Farsix; Fluidrol; Fluss; Franyl; Frumex; Frumide; Frusedan; Frusema; Frusemid; Frusemide; Frusemin; Frusenex; Frusetic; Frusid; Fulsix; Fuluvamide; Fuluvamine; Fulvamide; Furanthril; Furanthryl; Furantral; Furantril; Furanturil; Furesis; Furetic; Furex; Furfan; Furix; Furmid; Furobeta; Furocot; Furodiurol; Furodrix; Furomen; Furomex; Furorese; Furosan; Furose; Furosedon; Furosemid; Furosemida; Furosemidu; Furosemidum; Furosemix; Furoside; Furosifar; Furosix; Furoter; Furovite; Fursemid; Fursemida; Fursemide; Fursol; Fusid; Golan; Hissuflux; Hydrex; Hydro; Hydroled; Impugan; Jenafusid; Katlex; Kofuzon; Kolkin; Kutrix; Lasemid; Lasex; Lasiletten; Lasilix; Lasix; Laxur; Lazix; Liside; Logirene; Lowpston; Lowpstron; Luscek; Macasirool; Marsemide; Mirfat; Mita; Moilarorin; Myrosemide; Nadis; Nelsix; Novosemide; Odemase; Odemex; Oedemex; Prefemin; Profemin; Promedes; Promide; Protargen; Puresis; Radisemide; Radonna; Radouna; Retep; Rosemide; Rosis; Rusyde; Salinex; Salix; Salurex; Salurid; Seguril; Selectofur; Sigasalur; Spirofur; Synephron; Transit; Trofurit; Uremide; Uresix; Urian; Uridon; Uritol; Urosemide; Vesix; Yidoli; Zafimida; FUROSEMIDE USP; Fu sid; Furosemide Monohydrochloride; Furosemide Monosodium Salt; Furosemidu [Polish]; Lasix Retard; Lasix Special; Less Diur; Polysquall A; Sal diureticum; F0182; F4381_SIGMA; LB 502; Aisemide (TN); Apo-Frusemide; Apo-Furosemide; Beronald (TN); Desdemin (TN); Discoid (TN); Diumide-K; Diural (TN); Diurapid (TN); Dryptal (TN); Durafurid (TN); Errolon (TN); Eutensin (TN); Frudix (TN); Frusetic (TN); Frusid (TN); Fulsix (TN); Fuluvamide (TN); Furesis (TN); Furix (TN); Furo-Basan; Furo-puren; Furomide M.D; Furosedon (TN); Furosemida [INN-Spanish]; Furosemide (mita); Furosemidum [INN-Latin]; Hoe-058A; Hydro-rapid; Impugan (TN); Katlex (TN); LB-502; Lasilix (TN); Lasix (TN); Lodix (TN); Lowpston (TN); Macasirool (TN); Mirfat (TN); Neo-renal; Nicorol (TN); Odemase (TN); Oedemex (TN); Profemin (TN); Rosemide (TN); Rusyde (TN); Salix (TN); Salix (brand of furosemide); Trofurit (TN); Urex (TN); Urex-M; Apo-Furosemide (TN); Furo-Puren (TN); Furomide M.D.; Furosemide [USAN:INN:JAN]; Hydro-rapid(TN); Lasix, Frusemide, Furosemide; Furosemide (JP15/USP/INN); Chlor-N-(2-furylmethyl)-5-sulfamylanthranilsaeure; Chlor-N-(2-furylmethyl)-5-sulfamylanthranilsaeure [German]; 2-Furfurylamino-4-chloro-5-sulfamoylbenzoic acid; 4-Chloro-5-sulfamoyl-N-furfuryl-anthranilic acid; 4-Chloro-N-(2-furylmethyl)-5-sulfamoylanthranilic acid; 4-Chloro-N-furfuryl-5-sulfamoylanthranilic acid; 4-chloro-2-(furan-2-ylmethylamino)-5-sulfamoylbenzoic acid; 4-chloro-2-[(furan-2-ylmethyl)amino]-5-sulfamoylbenzoic acid DMMQ8ZG CP Sanofi-Aventis DMMQ8ZG TC Diuretics DMMQ8ZG DT Small molecular drug DMMQ8ZG PC 3440 DMMQ8ZG MW 330.74 DMMQ8ZG FM C12H11ClN2O5S DMMQ8ZG IC InChI=1S/C12H11ClN2O5S/c13-9-5-10(15-6-7-2-1-3-20-7)8(12(16)17)4-11(9)21(14,18)19/h1-5,15H,6H2,(H,16,17)(H2,14,18,19) DMMQ8ZG CS C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl DMMQ8ZG IK ZZUFCTLCJUWOSV-UHFFFAOYSA-N DMMQ8ZG IU 4-chloro-2-(furan-2-ylmethylamino)-5-sulfamoylbenzoic acid DMMQ8ZG CA CAS 54-31-9 DMMQ8ZG CB CHEBI:47426 DMMQ8ZG DE Congestive heart failure DMWVCF3 ID DMWVCF3 DMWVCF3 DN Fusidic acid DMWVCF3 HS Approved DMWVCF3 SN FUCIDIN; Fucidate; Fucithalmic; Fusidate; Fusidine; Ramycin; Diethanolamine fusidate; Fucidate Sodium; Fucidic acid; Fucidin acid; Fuci (TN); Fucibet (TN); Fucicort (TN); Fucidin (TN); Fucidin Cream 2%; Fucidine (TN); Fucithalmic (TN); Fucizon (TN); Fudic (TN); Fusiderm (TN); Fusidin (TN); SQ 16,603; Fusidic acid (USAN/INN); C.A.S. 62,602; (2Z)-2-[(17Z)-16beta-acetoxy-3alpha,11alpha-dihydroxy-4alpha,8alpha,10,14beta-tetramethyl-5alpha,9beta,13alpha-gonan-17-ylidene]-6-methylhept-5-enoic acid; (2Z)-2-[(3R,4S,5S,8S,9S,10S,11R,13R,14S,16S)-16-acetyloxy-3,11-dihydroxy-4,8,10,14-tetramethyl-2,3,4,5,6,7,9,11,12,13,15,16-dodecahydro-1H-cyclopenta[a]phenanthren-17-ylidene]-6-methylhept-5-enoic acid; (2Z)-2-[(3alpha,4alpha,5alpha,8alpha,9beta,11alpha,13alpha,14beta,16beta,17Z)-16-(acetyloxy)-3,11-dihydroxy-4,8,10,14-tetramethylgonan-17-ylidene]-6-methylhept-5-enoic acid; 16-(Acetyloxy)-3,11-dihydroxy-29-nordammara-17(20),24-dien-21-oic acid; 3.alpha.,11.alpha.,16.beta.-Trihydroxy-29-nor-8.alpha.,9.beta.,13.alpha.,14.beta.-dammara-17(20),24-dien-21-oic acid 16-acetate DMWVCF3 CP Leo Laboratories DMWVCF3 TC Antibiotics DMWVCF3 DT Small molecular drug DMWVCF3 PC 3000226 DMWVCF3 MW 516.7 DMWVCF3 FM C31H48O6 DMWVCF3 IC InChI=1S/C31H48O6/c1-17(2)9-8-10-20(28(35)36)26-22-15-24(34)27-29(5)13-12-23(33)18(3)21(29)11-14-30(27,6)31(22,7)16-25(26)37-19(4)32/h9,18,21-25,27,33-34H,8,10-16H2,1-7H3,(H,35,36)/b26-20-/t18-,21-,22-,23+,24+,25-,27-,29-,30-,31-/m0/s1 DMWVCF3 CS C[C@H]1[C@@H]2CC[C@]3([C@H]([C@]2(CC[C@H]1O)C)[C@@H](C[C@@H]\\4[C@@]3(C[C@@H](/C4=C(/CCC=C(C)C)\\C(=O)O)OC(=O)C)C)O)C DMWVCF3 IK IECPWNUMDGFDKC-MZJAQBGESA-N DMWVCF3 IU (2Z)-2-[(3R,4S,5S,8S,9S,10S,11R,13R,14S,16S)-16-acetyloxy-3,11-dihydroxy-4,8,10,14-tetramethyl-2,3,4,5,6,7,9,11,12,13,15,16-dodecahydro-1H-cyclopenta[a]phenanthren-17-ylidene]-6-methylhept-5-enoic acid DMWVCF3 CA CAS 6990-06-3 DMWVCF3 CB CHEBI:29013 DMWVCF3 DE Bacterial infection; MRSA infection DMZ0P95 ID DMZ0P95 DMZ0P95 DN Ga-68-DOTATOC DMZ0P95 HS Approved DMZ0P95 DT radioactive diagnostic agent DMZ0P95 DE Diagnostic imaging DM6T924 ID DM6T924 DM6T924 DN Gabapentin DM6T924 HS Approved DM6T924 SN Aclonium; GBN; Gabapen; Gabapentina; Gabapentine; Gabapentinium; Gabapentino; Gabapentinum; Gabapetin; Neurontin; Serada; Vultin; Apotex brand of gabapentin; Aventis brand of gabapentin; Gabapentin GR; Gabapentin Hexal; Gabapentin Stada; Gabapentino [Spanish]; Hexal brand of gabapentin; Novopharm brand of gabapentin; Parke Davis brand of gabapentin; Pfizer brand of gabapentin; Pharmascience brand of gabapentin; Ratiopharm brand of gabapentin; Stadapharm brand of gabapentin; GOE 2450; Go 3450; Apo-Gabapentin; DDS-2003; DM-1796; DM-5689; G-154; Gabapentin (Neurontin); Gabapentin-ratiopharm; Gabapentine [INN-French]; Gabapentino [INN-Spanish]; Gabapentinum [INN-Latin]; Goe-3450; Neurontin (TN); Novo-Gabapentin; PMS-Gabapentin; Warner-Lambert brand of gabapentin; Gabapentin [USAN:INN:BAN]; [1-(AMINOMETHYL)CYCLOHEXYL]ACETIC ACID; Gabapentin (JAN/USAN/INN); 1-(Aminomethyl)-cyclohexaneacetic acid; 1-(Aminomethyl)cyclohexaneacetic acid; 2-[1-(aminomethyl)cyclohexyl]acetic acid DM6T924 CP Pfizer DM6T924 TC Analgesics DM6T924 DT Small molecular drug DM6T924 PC 3446 DM6T924 MW 171.24 DM6T924 FM C9H17NO2 DM6T924 IC InChI=1S/C9H17NO2/c10-7-9(6-8(11)12)4-2-1-3-5-9/h1-7,10H2,(H,11,12) DM6T924 CS C1CCC(CC1)(CC(=O)O)CN DM6T924 IK UGJMXCAKCUNAIE-UHFFFAOYSA-N DM6T924 IU 2-[1-(aminomethyl)cyclohexyl]acetic acid DM6T924 CA CAS 60142-96-3 DM6T924 CB CHEBI:42797 DM6T924 DE Complex partial seizure; Solid tumour/cancer DMU9D2F ID DMU9D2F DMU9D2F DN Gabexate DMU9D2F HS Approved DMU9D2F SN gabexate; Gabexate [INN]; 39492-01-8; Gabexatum [INN-Latin]; Gabexato [INN-Spanish]; UNII-4V7M9137X9; CHEMBL87563; C16H23N3O4; Gabexate (INN); 4V7M9137X9; Ethyl p-hydroxybenzoate 6-guanidinohexanoate; ethyl 4-[6-(diaminomethylideneamino)hexanoyloxy]benzoate; Gabexatum; Gabexato; Benzoic acid, 4-((6-((aminoiminomethyl)amino)-1-oxohexyl)oxy)-, ethyl ester; p-carbethoxyphenyl e-guanidinocaproate; AC1L1FYH; Prestwick3_001008; Prestwick2_001008; Prestwick0_001008; Prestwick1_001008; BSPBio_001135; SCHEMBL446024; SPBio_003016; GTPL7863 DMU9D2F DT Small molecular drug DMU9D2F PC 3447 DMU9D2F MW 321.37 DMU9D2F FM C16H23N3O4 DMU9D2F IC InChI=1S/C16H23N3O4/c1-2-22-15(21)12-7-9-13(10-8-12)23-14(20)6-4-3-5-11-19-16(17)18/h7-10H,2-6,11H2,1H3,(H4,17,18,19) DMU9D2F CS CCOC(=O)C1=CC=C(C=C1)OC(=O)CCCCCN=C(N)N DMU9D2F IK YKGYIDJEEQRWQH-UHFFFAOYSA-N DMU9D2F IU ethyl 4-[6-(diaminomethylideneamino)hexanoyloxy]benzoate DMU9D2F CA CAS 39492-01-8 DMU9D2F CB CHEBI:93036 DMU9D2F DE Pancreatitis DMI53FU ID DMI53FU DMI53FU DN Gaboxadol DMI53FU HS Approved DMI53FU SN Gaboxadolum; Gaboxadolum [Latin]; LU 2030; Gaboxadol [USAN:INN]; Lu 02-030; MK-0928; Gaboxadol (USAN/INN); LU-2-030; Lu-02-030; Isoxazolo(5,4-c)pyridin-3(2H)-one, 4,5,6,7-tetrahydro-, hydrate; 4,5,6,7-Tetrahydroisoxazole(5,4-c)pyridin-3-ol; 4,5,6,7-tetrahydro-[1,2]oxazolo[5,4-c]pyridin-3-one DMI53FU CP Merck & Co DMI53FU TC Hypnotics and Sedatives DMI53FU DT Small molecular drug DMI53FU PC 3448 DMI53FU MW 140.14 DMI53FU FM C6H8N2O2 DMI53FU IC InChI=1S/C6H8N2O2/c9-6-4-1-2-7-3-5(4)10-8-6/h7H,1-3H2,(H,8,9) DMI53FU CS C1CNCC2=C1C(=O)NO2 DMI53FU IK ZXRVKCBLGJOCEE-UHFFFAOYSA-N DMI53FU IU 4,5,6,7-tetrahydro-[1,2]oxazolo[5,4-c]pyridin-3-one DMI53FU CA CAS 64603-91-4 DMI53FU CB CHEBI:34373 DMI53FU DE Insomnia DM4VAOG ID DM4VAOG DM4VAOG DN Gadobenate dimeglumine DM4VAOG HS Approved DM4VAOG SN Hydron; Multihance; Gadobenate Dimeglumine [USAN]; Gadobenic acid; Gadobenic acid dimeglumine salt; Meglumine gadobenate; Multihance Multipack; B 1903617; E-7155; Gadobenate dimeglumine (USAN); Gd-BOPTA; Meglumine gadobenate (JAN); Multihance (TN); B-19036/7; Gadolinium(3+); Gd-Bopta/dimeg; Dihydrogen ((+-)-4-carboxy-5,8,11-tris(carboxymethyl)-1-phenyl-2-oxa-5,8,11-triazatridecan-13-oato(5-))gadolinate(2-), compound with 1-deoxy-1-(methylamino)-D-glucitol (1:2); (2R,3R,4R,5S)-6-(methylamino)hexane-1,2,3,4,5-pentol; Gadolinate(2-), (4-carboxy-5,8,11-tris(carboxymethyl)-1-phenyl-2-oxa-5,8,11-triazatridecan-13-oato(5-)-N5,N8,N11,O4,O5,O8,O11,O13)-, dihydrogen, comp. with 1-deoxy-1-(methylamino)-D-glucitol (1:2); 2-[2-[2-[bis(2-oxido-2-oxoethyl)amino]ethyl-(2-oxido-2-oxoethyl)amino]ethyl-(2-oxido-2-oxoethyl)amino]-3-phenylmethoxypropanoate; 2-[carboxymethyl-[2-[2-[carboxymethyl-(2-oxido-2-oxoethyl)amino]ethyl-(2-oxido-2-oxoethyl)amino]ethyl]amino]-3-phenylmethoxypropanoate; D-Glucitol, 1-deoxy-1-(methylamino)-, (4-carboxy-5,8,11-tris(carboxymethyl)-1-phenyl-2-oxa-5,8,11-triazatridecan-13-oato(5-)-N(sup 5),N(sup 8),N(sup 11),O(sup 4),O(sup 5),O(sup 8), O(sup 11),O(sup 13)-gadolinate(2-) (2:1); Gadolinate(2-), (4-carboxy-5,8,11-tris(carboxymethyl)-1-phenyl-2-oxa-5,8,11-triazatridecan-13-oato(5-)-N(sup 5),N(sup 8),N(sup 11),O(sup 4),O(sup 5),O(sup 8),O(sup 11),O(sup 13))-, dihydrogen, comp. with 1-deoxy-1-(methylamino)-D-glucitol (1:2) DM4VAOG TC Contrast Media DM4VAOG DT Small molecular drug DM4VAOG PC 6918204 DM4VAOG MW 1058.1 DM4VAOG FM C36H62GdN5O21 DM4VAOG IC InChI=1S/C22H31N3O11.2C7H17NO5.Gd/c26-18(27)10-23(6-7-24(11-19(28)29)12-20(30)31)8-9-25(13-21(32)33)17(22(34)35)15-36-14-16-4-2-1-3-5-16;2*1-8-2-4(10)6(12)7(13)5(11)3-9;/h1-5,17H,6-15H2,(H,26,27)(H,28,29)(H,30,31)(H,32,33)(H,34,35);2*4-13H,2-3H2,1H3;/q;;;+3/p-3/t;2*4-,5+,6+,7+;/m.00./s1 DM4VAOG CS CNC[C@@H]([C@H]([C@@H]([C@@H](CO)O)O)O)O.CNC[C@@H]([C@H]([C@@H]([C@@H](CO)O)O)O)O.C1=CC=C(C=C1)COCC(C(=O)[O-])N(CCN(CCN(CC(=O)O)CC(=O)[O-])CC(=O)[O-])CC(=O)O.[Gd+3] DM4VAOG IK OCDAWJYGVOLXGZ-VPVMAENOSA-K DM4VAOG IU 2-[2-[carboxylatomethyl-[2-[carboxylatomethyl(carboxymethyl)amino]ethyl]amino]ethyl-(carboxymethyl)amino]-3-phenylmethoxypropanoate;gadolinium(3+);(2R,3R,4R,5S)-6-(methylamino)hexane-1,2,3,4,5-pentol DM4VAOG CA CAS 127000-20-8 DM4VAOG DE Schizophrenia DM5V9U1 ID DM5V9U1 DM5V9U1 DN Gadofosveset DM5V9U1 HS Approved DM5V9U1 SN Vasovist (TN) DM5V9U1 CP Epix DM5V9U1 DT Small molecular drug DM5V9U1 PC 73415770 DM5V9U1 MW 891.9 DM5V9U1 FM C33H41GdN3O14P DM5V9U1 IC InChI=1S/C33H44N3O14P.Gd/c37-28(38)18-34(15-16-35(19-29(39)40)20-30(41)42)17-26(36(21-31(43)44)22-32(45)46)23-49-51(47,48)50-27-11-13-33(14-12-27,24-7-3-1-4-8-24)25-9-5-2-6-10-25;/h1-10,26-27H,11-23H2,(H,37,38)(H,39,40)(H,41,42)(H,43,44)(H,45,46)(H,47,48);/q;+3/p-3/t26-;/m1./s1 DM5V9U1 CS [H+].[H+].[H+].C1CC(CCC1OP(=O)([O-])OC[C@@H](CN(CCN(CC(=O)[O-])CC(=O)[O-])CC(=O)[O-])N(CC(=O)[O-])CC(=O)[O-])(C2=CC=CC=C2)C3=CC=CC=C3.[Gd+3] DM5V9U1 IK ZSDLYSDDELEVDD-UFTMZEDQSA-K DM5V9U1 IU 2-[[(2R)-2-[bis(carboxylatomethyl)amino]-3-[(4,4-diphenylcyclohexyl)oxy-oxidophosphoryl]oxypropyl]-[2-[bis(carboxylatomethyl)amino]ethyl]amino]acetate;gadolinium(3+);hydron DM5V9U1 CA CAS 201688-00-8 DM5V9U1 DE Imaging DMEO794 ID DMEO794 DMEO794 DN Galantamine DMEO794 HS Approved DMEO794 SN GNT; Galantamin; Galantamina; Galantaminum; Galanthamine; Galanthaminum; Jilkon; Lycoremin; Lycoremine; Reminyl; Razadyne ER; Galantamina [INN-Spanish]; Galantamine [USAN:INN]; Galantaminum [INN-Latin]; Nivalin (TN); Razadyne (TN); Razadyne ER (TN); Reminyl (TN); Galantamine (USAN/INN); (-)-Galanthamine; (4aS,6R,8aS)-4a,5,9,10,11,12-Hexahydro-3-methoxy-11-methyl-6H-benzofuro(3a,3,2-ef)(2)benzazepin-6-ol DMEO794 CP Janssen Pharmaceutica DMEO794 TC Parasympathomimetics DMEO794 DT Small molecular drug DMEO794 PC 9651 DMEO794 MW 287.35 DMEO794 FM C17H21NO3 DMEO794 IC InChI=1S/C17H21NO3/c1-18-8-7-17-6-5-12(19)9-14(17)21-16-13(20-2)4-3-11(10-18)15(16)17/h3-6,12,14,19H,7-10H2,1-2H3/t12-,14-,17-/m0/s1 DMEO794 CS CN1CC[C@@]23C=C[C@@H](C[C@@H]2OC4=C(C=CC(=C34)C1)OC)O DMEO794 IK ASUTZQLVASHGKV-JDFRZJQESA-N DMEO794 IU (1S,12S,14R)-9-methoxy-4-methyl-11-oxa-4-azatetracyclo[8.6.1.01,12.06,17]heptadeca-6(17),7,9,15-tetraen-14-ol DMEO794 CA CAS 357-70-0 DMEO794 CB CHEBI:42944 DMEO794 DE Alzheimer disease DMIZ1E8 ID DMIZ1E8 DMIZ1E8 DN Galcanezumab DMIZ1E8 HS Approved DMIZ1E8 SN Galcanezumab [USAN:INN]; UNII-55KHL3P693; 55KHL3P693 DMIZ1E8 CP Eli Lilly DMIZ1E8 DT Antibody DMIZ1E8 DE Hyperprolactinaemia DMPO0MS ID DMPO0MS DMPO0MS DN Gallamine Triethiodide DMPO0MS HS Approved DMPO0MS SN Benzkurin; Flaxedil; Gallaflex; Parexyl; Pirolakson; Pyrolaxon; Relaxan; Remyolan; Retensin; Sincurarine; Syncurarine; Tricuran; Benzcurine iodide; Gallamin triethiodide; Gallamina triodoetilato; Gallamina triodoetilato [DCIT]; Gallamine iodide; Gallamine triethiodide [INN]; Gallamine triiodoethylate; Gallamini triethiodidum; Gallaminii iodidum; Gallaminum triaethjodidum; Gallaminum triaethoiodatum; Gallamone triethiodide; Gallamoni jodidum; Miowas G; Triethiodure de gallamine; Triethiodurode galamina; Triiodoethylate de gallamine; Triiodoethylate de gallamine [French]; F 2559; Fourneau 2559; G 8134; HL 8583; RP 3697; Flaxedil (TN); Gallamine triethiodide (USP); Gallamine-3ETI; Gallamini triethiodidum [INN-Latin]; Triethiodure de gallamine [INN-French]; Triethioduro de galamina [INN-Spanish]; Pyrogallol 1,2,3-(diethylaminoethyl ether) trisethyl iodide; Pyrogallol 1,2,3-(diethylaminoethyl ether) tris(ethyliodide); Tri(iodoethylate) de tri (beta diethylaminoethoxy)-1,2,3 benzene; Tri(iodoethylate) de tri (beta diethylaminoethoxy)-1,2,3 benzene [French]; Triiodoethylate of tri(diethylaminoethyloxy)-1,2,3-benzene; Triiodure de tri(beta-triethylammoniumethoxy)-1,2,3 benzene; Triiodure de tri(beta-triethylammoniumethoxy)-1,2,3 benzene [French]; Ammonium, (v-phenenyltris(oxyethylene))tris(triethyl-, triiodide; Ammonium, (v-phenenyltris(oxyethylene)tris(triethyl-, triiodide; Tri(beta-diethylaminoethoxy)-1,2,3-benzene tri-iodoethylate; Ethanaminium, 2,2',2'-(1,2,3-benzenetriyltris(oxy))tris(N,N,N-triethyl)-, triiodide; Ethanaminium, 2,2',2''-(1,2,3-benzenetriyltris(oxy))tris(N,N,N-triethyl)-, triiodide; Ethanaminium, 2,2',2''-(1,2,3-benzenetriyltris(oxy))tris(N,N,N-triethyl-, triiodide; (v-Phenenyltris(oxyethylene))tris(triethylammonium iodide); (v-Phenenyltris(oxyethylene))tris(triethylammonium) triiodide; (v-Phenenyltris(oxyethylene))tris(triethylammoniumiodide); 1,2,3-Tri(beta-diethylaminoethoxy)benzene triethiodide; 1,2,3-Tris(2-diethylaminoethoxy)benzene triethiodide; 1,2,3-Tris(2-diethylaminoethoxy)benzene tris(ethyliodide); 1,2,3-Tris(2-triethylammonium ethoxy)benzene triiodide; 1,2,3-Tris(diethylaminoethoxy)benzene triethiodide; 2,2',2''-(1,2,3-Benzenetriyltris(oxy))tris(N,N,N-triethylethanaminium) triiodide; 2,2',2''-[benzene-1,2,3-triyltris(oxy)]tris(N,N,N-triethylethanaminium) triiodide; 2-[2,3-bis[2-(triethylazaniumyl)ethoxy]phenoxy]ethyl-triethylazanium triiodide DMPO0MS TC Skeletal Muscle Relaxants DMPO0MS DT Small molecular drug DMPO0MS PC 6172 DMPO0MS MW 891.5 DMPO0MS FM C30H60I3N3O3 DMPO0MS IC InChI=1S/C30H60N3O3.3HI/c1-10-31(11-2,12-3)22-25-34-28-20-19-21-29(35-26-23-32(13-4,14-5)15-6)30(28)36-27-24-33(16-7,17-8)18-9;;;/h19-21H,10-18,22-27H2,1-9H3;3*1H/q+3;;;/p-3 DMPO0MS CS CC[N+](CC)(CC)CCOC1=C(C(=CC=C1)OCC[N+](CC)(CC)CC)OCC[N+](CC)(CC)CC.[I-].[I-].[I-] DMPO0MS IK REEUVFCVXKWOFE-UHFFFAOYSA-K DMPO0MS IU 2-[2,3-bis[2-(triethylazaniumyl)ethoxy]phenoxy]ethyl-triethylazanium;triiodide DMPO0MS CA CAS 65-29-2 DMPO0MS DE Stabilize muscle contraction DMF9O6B ID DMF9O6B DMF9O6B DN Gallium nitrate DMF9O6B HS Approved DMF9O6B SN Ganite (TN) DMF9O6B TC Anticancer Agents DMF9O6B DT Small molecular drug DMF9O6B PC 61635 DMF9O6B MW 255.74 DMF9O6B FM GaN3O9 DMF9O6B IC InChI=1S/Ga.3NO3/c;3*2-1(3)4/q+3;3*-1 DMF9O6B CS [N+](=O)([O-])[O-].[N+](=O)([O-])[O-].[N+](=O)([O-])[O-].[Ga+3] DMF9O6B IK CHPZKNULDCNCBW-UHFFFAOYSA-N DMF9O6B IU gallium;trinitrate DMF9O6B CA CAS 13494-90-1 DMF9O6B DE Hypercalcaemia DMER9YA ID DMER9YA DMER9YA DN Galsulfase DMER9YA HS Approved DMER9YA SN Aryplase; Aryplase (TN); Galsulfase (genetical recombination); Galsulfase (USAN/INN); Galsulfase (genetical recombination) (JAN) DMER9YA TC Enzyme Replacement Agents DMER9YA SQ Galsulfase: SGAGASRPPHLVFLLADDLGWNDVGFHGSRIRTPHLDALAAGGVLLDNYYTQPLCTPSRSQLLTGRYQIRTGLQHQIIWPCQPSCVPLDEKLLPQLLKEAGYTTHMVGKWHLGMYRKECLPTRRGFDTYFGYLLGSEDYYSHERCTLIDALNVTRCALDFRDGEEVATGYKNMYSTNIFTKRAIALITNHPPEKPLFLYLALQSVHEPLQVPEEYLKPYDFIQDKNRHHYAGMVSLMDEAVGNVTAALKSSGLWNNTVFIFSTDNGGQTLAGGNNWPLRGRKWSLWEGGVRGVGFVASPLLKQKGVKNRELIHISDWLPTLVKLARGHTNGTKPLDGFDVWKTISEGSPSPRIELLHNIDPNFVDSSPCPRNSMAPAKDDSSLPEYSAFNTSVHAAIRHGNWKLLTGYPGCGYWFPPPSQYNVSEIPSSDPPTKTLWLFDIDRDPEERHDLSREYPHIVTKLLSRLQFYHKHSVPVYFPAQDPRCDPKATGVWGPWM DMER9YA DE Mucopolysaccharidosis DMGBKVD ID DMGBKVD DMGBKVD DN Gamma hydroxybutyric acid DMGBKVD HS Approved DMGBKVD SN Anetamin; GHB; Hydroxyb; Oxybate; SHB; Somsanit; Xyrem; Gamma OH; Oxybate sodium; Utyric acid monosodium salt; EB 27; WY 3478; Gam-OH; Gamma-Hydroxy butyrate; Gamma-Hydroxy sodium butyrate; Gamma-Hydroxybutanoic acid; Gamma-Hydroxybutyrate sodium; Gamma-Hydroxybutyric acid; Gamma-Hydroxybutyric acid decomposition product; Gamma-Hydroxybutyric acid monosodium salt; Gamma-OH; Xyrem (TN); Gamma-Hydroxybutyric acid, sodium salt; Oxy-n-butyric acid; Sodium Oxybate (4-hydroxybutanoic acid); Sodium .gamma.-hydroxybutyrate; Sodium .gamma.-oxybutyrate; AA3E2AF0-AB7A-4A1E-A391-199C049D7162; Butanoic acid, 4-hydroxy-, monosodium salt; Butanoic acid, 4-hydroxy-, sodium salt; Butyric acid, 4-hydroxy-, monosodium salt; Butyric acid, 4-hydroxy-, sodium salt; 3-carboxypropoxy acid; 4 HB; 4-Hydroxy; 4-Hydroxyacid; 4-Hydroxyalkanoic acid; 4-Hydroxybutanoic acid; 4-Hydroxybuttersaeure; 4-Hydroxybutyrate sodium; 4-Hydroxybutyric acid; 4-Hydroxybutyric acid monosodium salt; 4-Hydroxycarboxylic acid; 4-OHB; 4-hydroxy-butyric acid DMGBKVD CP Jazz Pharmaceuticals DMGBKVD TC Anesthetics DMGBKVD DT Small molecular drug DMGBKVD PC 10413 DMGBKVD MW 104.1 DMGBKVD FM C4H8O3 DMGBKVD IC InChI=1S/C4H8O3/c5-3-1-2-4(6)7/h5H,1-3H2,(H,6,7) DMGBKVD CS C(CC(=O)O)CO DMGBKVD IK SJZRECIVHVDYJC-UHFFFAOYSA-N DMGBKVD IU 4-hydroxybutanoic acid DMGBKVD CA CAS 591-81-1 DMGBKVD CB CHEBI:30830 DMGBKVD DE Narcolepsy DMSXKYG ID DMSXKYG DMSXKYG DN Gamma-homolinolenic acid DMSXKYG HS Approved DMSXKYG SN DGLA; BML3-B11; Ro 12-1989; Star GLA (GNC); Bishomo-gamma-linolenic acid; C 20:3 n-6; Dihomo-gamma-linolenic acid; Homo-gamma-linolenic acid; Homo-gamma-linolensaeure; Tona-lean 1000 CLA (Action Labs); Cis-8,11,14-Eicosatrienoic Acid; Eicosa-8Z,11Z,14Z-trienoic acid; All-cis-8,11,14-Eicosatrienoic acid; All-cis-8,11,14-icosatrienoic acid; All-cis-Eicosa-8,11,14-triensaeure; Cis,cis,cis-8,11,14-Eicosatrienoic acid; Cis-8,cis-11,cis-14-Eicosatrienoic acid; (8E,11E,14E)-8,11,14-Icosatrienoic acid; (8Z,11Z,14Z)-Icosatrienoic acid; (8Z,11Z,14Z)-icosa-8,11,14-trienoic acid; (Z,Z,Z)-8,11,14-Eicosatrienoate; (Z,Z,Z)-8,11,14-Eicosatrienoic acid; (Z,Z,Z)-8,11,14-Icosatrienoate; (Z,Z,Z)-8,11,14-Icosatrienoicacid; 20:3, n-6,9,12 all-cis; 8, 11, 14-eicosatrienoic acid; 8,11,14-Eicosatrienoate; 8,11,14-Eicosatrienoic acid; 8,11,14-Eicosatrienoic acid, (8Z,11Z,14Z)-(9CI); 8,11,14-Eicosatrienoic acid, (Z,Z,Z)-(8CI); 8,11,14-Icosatrienoate; 8,11,14-all-cis-Eicosatrienoic acid; 8c,11c,14c-Eicosatriensaeure; 8c,11c,14c-eicosatrienoic acid DMSXKYG TC Dietary supplement DMSXKYG DT Small molecular drug DMSXKYG PC 5280581 DMSXKYG MW 306.5 DMSXKYG FM C20H34O2 DMSXKYG IC InChI=1S/C20H34O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20(21)22/h6-7,9-10,12-13H,2-5,8,11,14-19H2,1H3,(H,21,22)/b7-6-,10-9-,13-12- DMSXKYG CS CCCCC/C=C\\C/C=C\\C/C=C\\CCCCCCC(=O)O DMSXKYG IK HOBAELRKJCKHQD-QNEBEIHSSA-N DMSXKYG IU (8Z,11Z,14Z)-icosa-8,11,14-trienoic acid DMSXKYG CA CAS 1783-84-2 DMSXKYG CB CHEBI:53486 DMSXKYG DE Malnutrition DMQN30Z ID DMQN30Z DMQN30Z DN Gamolenic acid DMQN30Z HS Approved DMQN30Z SN gamma-Linolenic acid; GAMOLENIC ACID; 506-26-3; (6Z,9Z,12Z)-octadeca-6,9,12-trienoic acid; (Z,Z,Z)-6,9,12-Octadecatrienoic acid; CCRIS 7668; UNII-78YC2MAX4O; Acidum gamolenicum [Latin]; Acido gamolenico [Spanish]; Acide gamolenique [French]; 6,9,12-Octadecatrienoic acid, (Z,Z,Z)-; Gamolenic acid [INN:BAN]; (6,9,12)-linolenic acid; all-cis-6,9,12-Octadecatrienoic acid; cis,cis,cis-6,9,12-Octadecatrienoic acid; 6Z,9Z,12Z-octadecatrienoic acid; 78YC2MAX4O; cis-Delta(6,9,12)-octadecatrienoic acid; CHEMBL464982; CHEBI:28661; Epogam (TN); gamma-linolenic acid DMQN30Z DT Small molecular drug DMQN30Z PC 5280933 DMQN30Z MW 278.4 DMQN30Z FM C18H30O2 DMQN30Z IC InChI=1S/C18H30O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18(19)20/h6-7,9-10,12-13H,2-5,8,11,14-17H2,1H3,(H,19,20)/b7-6-,10-9-,13-12- DMQN30Z CS CCCCC/C=C\\C/C=C\\C/C=C\\CCCCC(=O)O DMQN30Z IK VZCCETWTMQHEPK-QNEBEIHSSA-N DMQN30Z IU (6Z,9Z,12Z)-octadeca-6,9,12-trienoic acid DMQN30Z CA CAS 506-26-3 DMQN30Z CB CHEBI:28661 DMQN30Z DE Allergy DM1MBYQ ID DM1MBYQ DM1MBYQ DN Ganciclovir DM1MBYQ HS Approved DM1MBYQ SN ganciclovir; 82410-32-0; Gancyclovir; Cytovene; Vitrasert; Hydroxyacyclovir; Ganciclovirum; Zirgan; RS-21592; Cymevene; HHEMG; Biolf 62; BW-759U; Ganciclovirum [Latin]; 2'-NDG; 2-Amino-9-(((1,3-dihydroxypropan-2-yl)oxy)methyl)-1H-purin-6(9H)-one; BW 759U; BIOLF-62; 2'-Nor-2'-deoxyguanosine; 9-[(1,3-Dihydroxy-2-propoxy)methyl]guanine; BW-B 759U; UNII-P9G3CKZ4P5; DRG-0018; BW 759; 9-(1,3-DIHYDROXY-PROPOXYMETHANE)GUANINE; 2-amino-9-{[(1,3-dihydroxypropan-2-yl)oxy]methyl}-6,9-dihydro-3H-purin-6-one; CCRIS 9212; GA2; Cytovene-IV; HSDB 6512 DM1MBYQ CP Bausch & Lomb Pharmaceuticals, Inc. DM1MBYQ TC Antiviral Agents DM1MBYQ DT Small molecular drug DM1MBYQ PC 135398740 DM1MBYQ MW 255.23 DM1MBYQ FM C9H13N5O4 DM1MBYQ IC InChI=1S/C9H13N5O4/c10-9-12-7-6(8(17)13-9)11-3-14(7)4-18-5(1-15)2-16/h3,5,15-16H,1-2,4H2,(H3,10,12,13,17) DM1MBYQ CS C1=NC2=C(N1COC(CO)CO)N=C(NC2=O)N DM1MBYQ IK IRSCQMHQWWYFCW-UHFFFAOYSA-N DM1MBYQ IU 2-amino-9-(1,3-dihydroxypropan-2-yloxymethyl)-1H-purin-6-one DM1MBYQ CA CAS 82410-32-0 DM1MBYQ CB CHEBI:465284 DM1MBYQ DE Virus infection DMGMB30 ID DMGMB30 DMGMB30 DN Ganirelix DMGMB30 HS Approved DMGMB30 SN Ganirelixum; Orgalutran; Ganirelix acetate; Antagon (TN); Ganirelix (INN); Ganirelix [INN:BAN]; Ganirelixum [INN-Latin]; Orgalutran (TN); RS-26306 DMGMB30 CP Organon International DMGMB30 TC Abortifacient Agents DMGMB30 DT Small molecular drug DMGMB30 PC 16130957 DMGMB30 MW 1570.3 DMGMB30 FM C80H113ClN18O13 DMGMB30 IC InChI=1S/C80H113ClN18O13/c1-9-84-79(85-10-2)88-38-17-15-24-60(70(104)94-62(41-49(5)6)71(105)93-61(25-16-18-39-89-80(86-11-3)87-12-4)78(112)99-40-20-26-68(99)77(111)90-50(7)69(82)103)92-73(107)64(44-53-30-35-59(102)36-31-53)97-76(110)67(48-100)98-75(109)66(46-55-21-19-37-83-47-55)96-74(108)65(43-52-28-33-58(81)34-29-52)95-72(106)63(91-51(8)101)45-54-27-32-56-22-13-14-23-57(56)42-54/h13-14,19,21-23,27-37,42,47,49-50,60-68,100,102H,9-12,15-18,20,24-26,38-41,43-46,48H2,1-8H3,(H2,82,103)(H,90,111)(H,91,101)(H,92,107)(H,93,105)(H,94,104)(H,95,106)(H,96,108)(H,97,110)(H,98,109)(H2,84,85,88)(H2,86,87,89)/t50-,60-,61+,62+,63-,64+,65-,66-,67+,68+/m1/s1 DMGMB30 CS CCNC(=NCCCC[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN=C(NCC)NCC)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(=O)N)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC3=CN=CC=C3)NC(=O)[C@@H](CC4=CC=C(C=C4)Cl)NC(=O)[C@@H](CC5=CC6=CC=CC=C6C=C5)NC(=O)C)NCC DMGMB30 IK GJNXBNATEDXMAK-PFLSVRRQSA-N DMGMB30 IU (2S)-1-[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-6-[bis(ethylamino)methylideneamino]hexanoyl]amino]-4-methylpentanoyl]amino]-6-[bis(ethylamino)methylideneamino]hexanoyl]-N-[(2R)-1-amino-1-oxopropan-2-yl]pyrrolidine-2-carboxamide DMGMB30 CA CAS 124904-93-4 DMGMB30 CB CHEBI:135910 DMGMB30 DE Ovulation dysfunction DMSL679 ID DMSL679 DMSL679 DN Gatifloxacin DMSL679 HS Approved DMSL679 SN Bonoq; GTFX; Gaity; Gatiflo; Gatilox; Gatiquin; Gatispan; Tequin; Zymar; Zymaxid; Zymer; AM 1155; CG 5501;PD 135432; PD135432; AM-1155; BMS 206584-01; BMS-206584; CG-5501; Gatiflo (TN); Gatifloxacin & Gamma Interferon; Gatifloxacin (INN); Gatifloxacin (TN); Gatifloxacin [USAN:INN]; PD-135432; Tequin (TN); Tequin in dextrose 5% in plastic container; Zymar (TN); Zymer (TN); BMS-206584-01; Gatiflo,Tequin and Zymar, Gatifloxacin; AM-1155 (*Sesquihydrate*); (+-)-1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid; 1-Cyclopropyl-1,4-dihydro-6-fluoro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid; 1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid; 1-cyclopropyl-6-fluoro-8-methoxy-7-(3-methylpiperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 1-cyclopropyl-6-fluoro-8-methoxy-7-(3-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid DMSL679 CP Bristol-Myers Squibb DMSL679 TC Antiinfective Agents DMSL679 DT Small molecular drug DMSL679 PC 5379 DMSL679 MW 375.4 DMSL679 FM C19H22FN3O4 DMSL679 IC InChI=1S/C19H22FN3O4/c1-10-8-22(6-5-21-10)16-14(20)7-12-15(18(16)27-2)23(11-3-4-11)9-13(17(12)24)19(25)26/h7,9-11,21H,3-6,8H2,1-2H3,(H,25,26) DMSL679 CS CC1CN(CCN1)C2=C(C=C3C(=C2OC)N(C=C(C3=O)C(=O)O)C4CC4)F DMSL679 IK XUBOMFCQGDBHNK-UHFFFAOYSA-N DMSL679 IU 1-cyclopropyl-6-fluoro-8-methoxy-7-(3-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid DMSL679 CA CAS 112811-59-3 DMSL679 CB CHEBI:5280 DMSL679 DE Respiratory tract infection DMH0QKA ID DMH0QKA DMH0QKA DN GDC-0199 DMH0QKA HS Approved DMH0QKA CP AbbVie DMH0QKA DT Small molecular drug DMH0QKA PC 49846579 DMH0QKA MW 868.4 DMH0QKA FM C45H50ClN7O7S DMH0QKA IC InChI=1S/C45H50ClN7O7S/c1-45(2)15-11-33(39(26-45)31-3-5-34(46)6-4-31)29-51-17-19-52(20-18-51)35-7-9-38(42(24-35)60-36-23-32-12-16-47-43(32)49-28-36)44(54)50-61(57,58)37-8-10-40(41(25-37)53(55)56)48-27-30-13-21-59-22-14-30/h3-10,12,16,23-25,28,30,48H,11,13-15,17-22,26-27,29H2,1-2H3,(H,47,49)(H,50,54) DMH0QKA CS CC1(CCC(=C(C1)C2=CC=C(C=C2)Cl)CN3CCN(CC3)C4=CC(=C(C=C4)C(=O)NS(=O)(=O)C5=CC(=C(C=C5)NCC6CCOCC6)[N+](=O)[O-])OC7=CN=C8C(=C7)C=CN8)C DMH0QKA IK LQBVNQSMGBZMKD-UHFFFAOYSA-N DMH0QKA IU 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-N-[3-nitro-4-(oxan-4-ylmethylamino)phenyl]sulfonyl-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide DMH0QKA CA CAS 1257044-40-8 DMH0QKA CB CHEBI:133021 DMH0QKA DE Chronic lymphocytic leukaemia; Solid tumour/cancer DM15F0X ID DM15F0X DM15F0X DN Gefitinib DM15F0X HS Approved DM15F0X SN Gefitini; IRE; Iressa; Irressat; Gefitinib [USAN]; ZD 1839; ZD1839; Iressa (TN); Iressa(TM); ZD-1839; CU-00000000396-1; Gefitinib,Iressa, ZD1839; Gefitinib (JAN/USAN/INN); ZD-1839, Iressa, Gefitinib; N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamide; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(morpholin-4-yl)propoxy]quinazolin-4-amine; N-(3-Chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine; 4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline; 6-(3-morpholinopropoxy)-N-(3-chloro-4-fluorophenyl)-7-methoxyquinazolin-4-amine DM15F0X CP AstraZeneca DM15F0X TC Anticancer Agents DM15F0X DT Small molecular drug DM15F0X PC 123631 DM15F0X MW 446.9 DM15F0X FM C22H24ClFN4O3 DM15F0X IC InChI=1S/C22H24ClFN4O3/c1-29-20-13-19-16(12-21(20)31-8-2-5-28-6-9-30-10-7-28)22(26-14-25-19)27-15-3-4-18(24)17(23)11-15/h3-4,11-14H,2,5-10H2,1H3,(H,25,26,27) DM15F0X CS COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4 DM15F0X IK XGALLCVXEZPNRQ-UHFFFAOYSA-N DM15F0X IU N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine DM15F0X CA CAS 184475-35-2 DM15F0X CB CHEBI:49668 DM15F0X DE Solid tumour/cancer; Urethral cancer; Head and neck cancer DMSE3I7 ID DMSE3I7 DMSE3I7 DN Gemcitabine DMSE3I7 HS Approved DMSE3I7 SN Gemcitabine hydrochloride; DDFC; DFdC; DFdCyd; Folfugem; GEO; Gamcitabine; GemLip; Gemcel; Gemcin; Gemcitabina; Gemcitabinum; Gemtro; Gemzar; Zefei; Gemcitabine HCl; Gemcitabine stereoisomer; LY 188011; LY188011; Gemcitabina [INN-Spanish]; Gemcitabinum [INN-Latin]; Gemzar (TN); Gemzar (hydrochloride); Inno-D07001; LY-188011; Gemcitabine (USAN/INN) DMSE3I7 CP Eli Lilly DMSE3I7 TC Anticancer Agents DMSE3I7 DT Small molecular drug DMSE3I7 PC 60750 DMSE3I7 MW 263.2 DMSE3I7 FM C9H11F2N3O4 DMSE3I7 IC InChI=1S/C9H11F2N3O4/c10-9(11)6(16)4(3-15)18-7(9)14-2-1-5(12)13-8(14)17/h1-2,4,6-7,15-16H,3H2,(H2,12,13,17)/t4-,6-,7-/m1/s1 DMSE3I7 CS C1=CN(C(=O)N=C1N)[C@H]2C([C@@H]([C@H](O2)CO)O)(F)F DMSE3I7 IK SDUQYLNIPVEERB-QPPQHZFASA-N DMSE3I7 IU 4-amino-1-[(2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one DMSE3I7 CA CAS 95058-81-4 DMSE3I7 CB CHEBI:175901 DMSE3I7 DE Solid tumour/cancer DMD8Q3J ID DMD8Q3J DMD8Q3J DN Gemfibrozil DMD8Q3J HS Approved DMD8Q3J SN ApoGemfibrozil; Ausgem; Bolutol; Brozil; Cholespid; Clearol; Decrelip; Elmogan; Fetinor; Fibratol; Fibrocit; GFZ; Gemd; Gemfibril; Gemfibromax; Gemfibrosil; Gemfibrozilo; Gemfibrozilum; Gemhexal; Gemlipid; Gemnpid; GenGemfibrozil; Genlip; Gozid; Hidil; Hipolixan; Innogem; Innogen; Ipolipid; Jezil; Lanaterom; Lifibron; Lipazil; Lipigem; Lipira; Lipizyl; Lipozid; Lipur; Litarek; Lopid; Micolip; Normolip; NuGemfibrozil; Pilder; Polyxit; Progemzal; Reducel; Regulip; Renabrazin; Sinelip; Synbrozil; Taborcil; Tentroc; Trialmin; Alphapharm Brand of Gemfibrozil; Apo Gemfibrozil; Apotex Brand of Gemfibrozil; Bayvit Brand of Gemfibrozil; Bexal Brand of Gemfibrozil; Biochemie Brand of Gemfibrozil; Bull Brand of Gemfibrozil; Cantabria Brand of Gemfibrozil; Chem mart Brand of Gemfibrozil; Chem mart Gemfibrozil; DBL Gemfibrozil; Douglas Brand of Gemfibrozil; Farmasierra Brand of Gemfibrozil; Faulding Brand of Gemfibrozil;Ferrer Brand of Gemfibrozil; Gemfibrozilo Bayvit; Gemfibrozilo Bexal; Gemfibrozilo Ur; Gen Gemfibrozil; GenRX Gemfibrozil; Genpharm Brand of Gemfibrozil; Gevilon Uno; Healthsense Brand of Gemfibrozil; Healthsense Gemfibrozil; Hexal Brand of Gemfibrozil; Ipsen Brand of Gemfibrozil; Lipox Gemfi; Lopid R; Menarini Brand of Gemfibrozil; Novo Gemfibrozil; Novopharm Brand of Gemfibrozil; Nu Gemfibrozil; Nu Pharm Brand of Gemfibrozil; PMS Gemfibrozil; Parke Davis Brand of Gemfibrozil; Pfizer Brand of Gemfibrozil; Pharmascience Brand of Gemfibrozil; Quimifar Brand of Gemfibrozil; SBPA Gemfibrozil; Sigma Brand of Gemfibrozil; TAD Brand of Gemfibrozil; Terry White Chemists Brand of Gemfibrozil; Terry White Chemists Gemfibrozil; United Drug Brand of Gemfibrozil; Warner Lambert Brand of Gemfibrozil; CI719; Gemfi 1A Pharma; Apo-Gemfibrozil; Bayvit, Gemfibrozilo; Gem-S; Gemfibrozil, GenRX; Gemfibrozil, Healthsense; Gemfibrozil, SBPA; Gemfibrozilo [INN-Spanish]; Gemfibrozilum [INN-Latin]; Gen-Fibro;Gen-Gemfibrozil; Jezil (TN); Lopid (TN); Low-Lip; Novo-Gemfibrozil; Nu-Gemfibrozil; Nu-Pharm Brand of Gemfibrozil; PMS-Gemfibrozil; TEVA-A; WL-Gemfibrozil; Warner-Lambert Brand of Gemfibrozil; GEMFIBROZIL (SEE ALSO PEROXISOME PROJECT (GEMFIBROZIL)); Gemfibrozil [USAN:BAN:INN]; Gen-Fibro (TN); PEROXISOME PROJECT (GEMFIBROZIL) (SEE ALSO GEMFIBROZIL); Gemfibrozil (JAN/USP/INN); Gemcor, Lopid, Jezil,Gen-Fibro, Gemfibrozil; 1A Brand of Gemfibrozil; 2,2-Dimethyl-5-(2,5-dimethylphenoxy)pentanoic acid; 2,2-Dimethyl-5-(2,5-dimethylphenoxy)valeriansaeure; 2,2-Dimethyl-5-(2,5-xylyloxy)valeriansaeure; 2,2-Dimethyl-5-(2,5-xylyloxy)valeric acid; 5-(2,5-Dimethyl-Phenoxy)-2,2-Dimethyl-Pentanoic Acid; 5-(2,5-Dimethylphenoxy)-2,2-dimethylpentanoic acid; 5-[(2,5-dimethylphenyl)oxy]-2,2-dimethylpentanoic acid DMD8Q3J CP Pfizer Pharmaceuticals DMD8Q3J TC Antilipemic Agents DMD8Q3J DT Small molecular drug DMD8Q3J PC 3463 DMD8Q3J MW 250.33 DMD8Q3J FM C15H22O3 DMD8Q3J IC InChI=1S/C15H22O3/c1-11-6-7-12(2)13(10-11)18-9-5-8-15(3,4)14(16)17/h6-7,10H,5,8-9H2,1-4H3,(H,16,17) DMD8Q3J CS CC1=CC(=C(C=C1)C)OCCCC(C)(C)C(=O)O DMD8Q3J IK HEMJJKBWTPKOJG-UHFFFAOYSA-N DMD8Q3J IU 5-(2,5-dimethylphenoxy)-2,2-dimethylpentanoic acid DMD8Q3J CA CAS 25812-30-0 DMD8Q3J CB CHEBI:5296 DMD8Q3J DE Hyperlipidaemia DMHT34O ID DMHT34O DMHT34O DN Gemifloxacin DMHT34O HS Approved DMHT34O SN Factiv; Factive; Gemifloxacin [INN]; Gemifloxacin mesilate; LB 20304; LB 20304a; SB 265805; Factiv (TN); Factive (TN); Gemifloxacin (INN); LB-20304; SB-265805; 7-(3-Aminomethyl)-4-methoxyimino-pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid; 7-(3-Aminomethyl-4-methoxyimino-pyrrolidine-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-(1,8)-naphthyridine-3-carboxylic acid; 7-[3-(aminomethyl)-4-(methoxyimino)pyrrolidin-1-yl]-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid DMHT34O CP Oscient Pharmaceuticals DMHT34O TC Antibiotics DMHT34O DT Small molecular drug DMHT34O PC 9571107 DMHT34O MW 389.4 DMHT34O FM C18H20FN5O4 DMHT34O IC InChI=1S/C18H20FN5O4/c1-28-22-14-8-23(6-9(14)5-20)17-13(19)4-11-15(25)12(18(26)27)7-24(10-2-3-10)16(11)21-17/h4,7,9-10H,2-3,5-6,8,20H2,1H3,(H,26,27)/b22-14+ DMHT34O CS CO/N=C/1\\CN(CC1CN)C2=C(C=C3C(=O)C(=CN(C3=N2)C4CC4)C(=O)O)F DMHT34O IK ZRCVYEYHRGVLOC-HYARGMPZSA-N DMHT34O IU 7-[(4Z)-3-(aminomethyl)-4-methoxyiminopyrrolidin-1-yl]-1-cyclopropyl-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acid DMHT34O CA CAS 175463-14-6 DMHT34O CB CHEBI:101853 DMHT34O DE Bacterial infection DMJ2O7B ID DMJ2O7B DMJ2O7B DN Gemtuzumab ozogamicin DMJ2O7B HS Approved DMJ2O7B SN Mylotarg (TN) DMJ2O7B CP Wyeth Pharmaceuticals DMJ2O7B TC Anticancer Agents DMJ2O7B DT Antibody DMJ2O7B SQ Light Chain No. 1: QIVLTQSPAIMSASPGEKVTITCSASSSISYMHWFQQKPGTSPKLWIYTTSNLASGVPARFSGSGSGTSYSLTISRMEAEDAATYYCHQRSTYPLTFGSGTKLELK > Light Chain No. 2DIQMTQSPSTLSASVGDRVTITCRASQSINTWLAWYQQKPGKAPKLLMYKASSLESGVPSRFIGSGSGTEFTLTISSLQPDDFATYYCQQYNSDSKMFGQGTKVEVK > Heavy Chain No. 1QVQLQQSGAELAKPGASVKMSCKASGYTFTSYRMHWVKQRPGQGLEWIGYINPSTGYTEYNQKFKDKATLTADKSSSTAYMQLSSLTFEDSAVYYCARGGGVFDYWGQGTTLTVSS > Heavy Chain No. 2QVQLVQSGAEVKKPGSSVKVSCKASGGTFSRSAIIWVRQAPGQGLEWMGGIVPMFGPPNYAQKFQGRVTITADESTNTAYMELSSLRSEDTAFYFCAGGYGIYSPEEYNGGLVTVSS DMJ2O7B DE Acute myeloid leukaemia DMKINJO ID DMKINJO DMKINJO DN Gentamicin DMKINJO HS Approved DMKINJO SN Alcomicin; Apogen; Bristagen; Cidomycin; GENTAMYCIN; Garamycin; Garasol; Gentacidin; Gentacycol; Gentafair; Gentak; Gentamar; Gentamicina; Gentamicine; Gentamicins; Gentamicinum; Gentamycinum; Gentavet; Gentocin; Jenamicin; Refobacin; Uromycine; Garamycin Otic Solution; Genoptic Liquifilm; Gentamcin Sulfate; Gentamicin sulphate sterile; Refobacin TM; Gentamicin C1; G-Mycin; G-Myticin; Garamycin (TN); Gentamicin (BAN); Gentamicin (TN); Gentamicina [INN-Spanish]; Gentamicine [INN-French]; Gentamicinum [INN-Latin];Gentamycin-creme; Gentamycin-creme [German]; Ocu-Mycin; Spectro-Genta; U-Gencin; Genoptic S.O.P.; O-2-amino-2,3,4,6,7-pentadeoxy-6-(methylamino)-alpha-D-ribo-heptopyranosyl-(1-4)-O-(3-deoxy-4-C-methyl-3-(methylamino)-beta-L-arabinopyranosyl-(1-6))-2-deoxy-D-streptamine; (1R,2S,3S,4R,6S)-4,6-diamino-3-[3-deoxy-4-C-methyl-3-(methylamino)-beta-L-arabinopyranosyloxy]-2-hydroxycyclohexyl 2-amino-2,3,4,6,7-pentadeoxy-6-(methylamino)-beta-L-lyxo-heptopyranoside; (1R,2S,3S,4R,6S)-4,6-diamino-3-{[3-deoxy-4-C-methyl-3-(methylamino)-beta-L-arabinopyranosyl]oxy}-2-hydroxycyclohexyl (6x)-2-amino-2,3,4,6,7-pentadeoxy-6-(methylamino)-alpha-D-erythro-heptopyranoside; (2R,3R,4R,5R)-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[(2R,3R,6S)-3-amino-6-[1-(methylamino)ethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol; 2-[4,6-diamino-3-[3-amino-6-[1-(methylamino)ethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol; 4,6-diamino-3-{[3-deoxy-4-c-methyl-3-(methylamino)pentopyranosyl]oxy}-2-hydroxycyclohexyl 2-amino-2,3,4,6,7-pentadeoxy-6-(methylamino)heptopyranoside DMKINJO CP Sandoz DMKINJO TC Antibiotics DMKINJO DT Small molecular drug DMKINJO PC 3467 DMKINJO MW 477.6 DMKINJO FM C21H43N5O7 DMKINJO IC InChI=1S/C21H43N5O7/c1-9(25-3)13-6-5-10(22)19(31-13)32-16-11(23)7-12(24)17(14(16)27)33-20-15(28)18(26-4)21(2,29)8-30-20/h9-20,25-29H,5-8,22-24H2,1-4H3 DMKINJO CS CC(C1CCC(C(O1)OC2C(CC(C(C2O)OC3C(C(C(CO3)(C)O)NC)O)N)N)N)NC DMKINJO IK CEAZRRDELHUEMR-UHFFFAOYSA-N DMKINJO IU 2-[4,6-diamino-3-[3-amino-6-[1-(methylamino)ethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol DMKINJO CA CAS 1403-66-3 DMKINJO DE Bacterial infection DMBT7MI ID DMBT7MI DMBT7MI DN Gentamicine sulfate DMBT7MI HS Approved DMBT7MI SN SCH-9724; (2R,3R,4R,5R)-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[(2R,3R,6S)-3-amino-6-(aminomethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol; (2R,3R,4R,5R)-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[(2R,3R,6S)-3-amino-6-[(1R)-1-(methylamino)ethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol; (2R,3R,4R,5R)-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[(2R,3R,6S)-3-amino-6-[(1R)-1-aminoethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol DMBT7MI TC Antibiotics DMBT7MI DT Small molecular drug DMBT7MI PC 6419933 DMBT7MI MW 1488.8 DMBT7MI FM C60H125N15O25S DMBT7MI IC InChI=1S/C21H43N5O7.C20H41N5O7.C19H39N5O7.H2O4S/c1-9(25-3)13-6-5-10(22)19(31-13)32-16-11(23)7-12(24)17(14(16)27)33-20-15(28)18(26-4)21(2,29)8-30-20;1-8(21)12-5-4-9(22)18(30-12)31-15-10(23)6-11(24)16(13(15)26)32-19-14(27)17(25-3)20(2,28)7-29-19;1-19(27)7-28-18(13(26)16(19)24-2)31-15-11(23)5-10(22)14(12(15)25)30-17-9(21)4-3-8(6-20)29-17;1-5(2,3)4/h9-20,25-29H,5-8,22-24H2,1-4H3;8-19,25-28H,4-7,21-24H2,1-3H3;8-18,24-27H,3-7,20-23H2,1-2H3;(H2,1,2,3,4)/t9-,10-,11+,12-,13+,14+,15-,16-,17+,18-,19-,20-,21+;8-,9-,10+,11-,12+,13+,14-,15-,16+,17-,18-,19-,20+;8-,9+,10-,11+,12-,13+,14+,15-,16+,17+,18+,19-;/m110./s1 DMBT7MI CS C[C@H]([C@@H]1CC[C@H]([C@H](O1)O[C@@H]2[C@H](C[C@H]([C@@H]([C@H]2O)O[C@@H]3[C@@H]([C@H]([C@@](CO3)(C)O)NC)O)N)N)N)N.C[C@H]([C@@H]1CC[C@H]([C@H](O1)O[C@@H]2[C@H](C[C@H]([C@@H]([C@H]2O)O[C@@H]3[C@@H]([C@H]([C@@](CO3)(C)O)NC)O)N)N)N)NC.C[C@@]1(CO[C@@H]([C@@H]([C@H]1NC)O)O[C@H]2[C@@H](C[C@@H]([C@H]([C@@H]2O)O[C@@H]3[C@@H](CC[C@H](O3)CN)N)N)N)O.OS(=O)(=O)O DMBT7MI IK RDEIXVOBVLKYNT-HDZPSJEVSA-N DMBT7MI IU (2R,3R,4R,5R)-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[(2R,3R,6S)-3-amino-6-[(1R)-1-aminoethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;(2R,3R,4R,5R)-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[(2R,3R,6S)-3-amino-6-(aminomethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;(2R,3R,4R,5R)-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[(2R,3R,6S)-3-amino-6-[(1R)-1-(methylamino)ethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;sulfuric acid DMBT7MI CA CAS 1405-41-0 DMBT7MI DE Bacterial infection DMP0OVQ ID DMP0OVQ DMP0OVQ DN Gestrinone DMP0OVQ HS Approved DMP0OVQ SN Dimetrose (TN) DMP0OVQ CP Sarsa DMP0OVQ DT Small molecular drug DMP0OVQ PC 27812 DMP0OVQ MW 308.4 DMP0OVQ FM C21H24O2 DMP0OVQ IC InChI=1S/C21H24O2/c1-3-20-11-9-17-16-8-6-15(22)13-14(16)5-7-18(17)19(20)10-12-21(20,23)4-2/h2,9,11,13,18-19,23H,3,5-8,10,12H2,1H3/t18-,19+,20+,21+/m1/s1 DMP0OVQ CS CC[C@]12C=CC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@]2(C#C)O DMP0OVQ IK BJJXHLWLUDYTGC-ANULTFPQSA-N DMP0OVQ IU (8S,13S,14S,17R)-13-ethyl-17-ethynyl-17-hydroxy-1,2,6,7,8,14,15,16-octahydrocyclopenta[a]phenanthren-3-one DMP0OVQ CA CAS 16320-04-0 DMP0OVQ CB CHEBI:89642 DMP0OVQ DE Breast cancer DMKGH0R ID DMKGH0R DMKGH0R DN GHRP-2 DMKGH0R HS Approved DMKGH0R SN Pralmorelin; D-Alanyl-3-(2-naphthalenyl)-D-alanyl-L-alanyl-L-tryptophyl-D-phenylalanyl-L-lysinamide; KP-102; UNII-E6S6E1F19M; E6S6E1F19M; KP 102; WAY-GPA-748; L-Lysinamide, D-alanyl-3-(2-naphthalenyl)-D-alanyl-L-alanyl-L-tryptophyl-D-phenylalanyl-; (2S)-6-amino-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-aminopropanoyl]amino]-3-naphthalen-2-ylpropanoyl]amino]propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide; KP-102D; Pralmorelin [INN]; GHRP-2 Acetate/; GHRP Kaken 100; AC1OCF7D; (2R)-2-methyl-4-deoxy and 2,4-dideoxy DMKGH0R DT Small molecular drug DMKGH0R PC 6918245 DMKGH0R MW 818 DMKGH0R FM C45H55N9O6 DMKGH0R IC InChI=1S/C45H55N9O6/c1-27(47)41(56)52-38(24-30-19-20-31-14-6-7-15-32(31)22-30)43(58)50-28(2)42(57)53-39(25-33-26-49-35-17-9-8-16-34(33)35)45(60)54-37(23-29-12-4-3-5-13-29)44(59)51-36(40(48)55)18-10-11-21-46/h3-9,12-17,19-20,22,26-28,36-39,49H,10-11,18,21,23-25,46-47H2,1-2H3,(H2,48,55)(H,50,58)(H,51,59)(H,52,56)(H,53,57)(H,54,60)/t27-,28+,36+,37-,38-,39+/m1/s1 DMKGH0R CS C[C@H](C(=O)N[C@H](CC1=CC2=CC=CC=C2C=C1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N[C@H](CC5=CC=CC=C5)C(=O)N[C@@H](CCCCN)C(=O)N)N DMKGH0R IK HRNLPPBUBKMZMT-RDRUQFPZSA-N DMKGH0R IU (2S)-6-amino-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-aminopropanoyl]amino]-3-naphthalen-2-ylpropanoyl]amino]propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide DMKGH0R CA CAS 158861-67-7 DMKGH0R CB CHEBI:135890 DMKGH0R DE Growth hormone deficiency DMTI0ZO ID DMTI0ZO DMTI0ZO DN Gilteritinib DMTI0ZO HS Approved DMTI0ZO SN 6-Ethyl-3-((3-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)-amino)-5-((tetrahydro-2H-pyran-4-yl)amino)pyrazine-2-carboxamide; ASP 2215; Gilteritinib; Gilteritinib (ASP-2215); Gilteritinib (ASP2215); Gilteritinib (USAN/INN); Gilteritinib [USAN:INN]; Gilteritinib(ASP2215); Xospata DMTI0ZO TC Anticancer Agents DMTI0ZO DT Small molecular drug DMTI0ZO PC 49803313 DMTI0ZO MW 552.724 DMTI0ZO FM C29H44N8O3 DMTI0ZO IC InChI=1S/C29H44N8O3/c1-4-23-28(31-20-9-17-40-18-10-20)34-29(26(33-23)27(30)38)32-21-5-6-24(25(19-21)39-3)37-11-7-22(8-12-37)36-15-13-35(2)14-16-36/h5-6,19-20,22H,4,7-18H2,1-3H3,(H2,30,38)(H2,31,32,34) DMTI0ZO CS CCC1=NC(=C(N=C1NC2CCOCC2)NC3=CC(=C(C=C3)N4CCC(CC4)N5CCN(CC5)C)OC)C(=O)N DMTI0ZO IK GYQYAJJFPNQOOW-UHFFFAOYSA-N DMTI0ZO IU 6-ethyl-3-[3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]anilino]-5-(oxan-4-ylamino)pyrazine-2-carboxamide DMTI0ZO CA CAS 1254053-43-4 DMTI0ZO DE Acute myeloid leukemia DMWQ4MZ ID DMWQ4MZ DMWQ4MZ DN Gilteritinib DMWQ4MZ HS Approved DMWQ4MZ SN UNII-66D92MGC8M; 66D92MGC8M; Gilteritinib [USAN:INN]; Gilteritinib(ASP2215); Gilteritinib (USAN/INN); Gilteritinib (ASP2215); Gilteritinib (ASP-2215); SCHEMBL282229; GTPL8708; MolPort-038-934-933; BDBM144315; C29H44N8O3; 3694AH; s7754; AKOS030234455; ZINC113476229; DB12141; CS-3885; KS-0000064E; AS-35199 DMWQ4MZ CP Astellas DMWQ4MZ PC 49803313 DMWQ4MZ MW 552.7 DMWQ4MZ FM C29H44N8O3 DMWQ4MZ IC InChI=1S/C29H44N8O3/c1-4-23-28(31-20-9-17-40-18-10-20)34-29(26(33-23)27(30)38)32-21-5-6-24(25(19-21)39-3)37-11-7-22(8-12-37)36-15-13-35(2)14-16-36/h5-6,19-20,22H,4,7-18H2,1-3H3,(H2,30,38)(H2,31,32,34) DMWQ4MZ CS CCC1=C(N=C(C(=N1)C(=O)N)NC2=CC(=C(C=C2)N3CCC(CC3)N4CCN(CC4)C)OC)NC5CCOCC5 DMWQ4MZ IK GYQYAJJFPNQOOW-UHFFFAOYSA-N DMWQ4MZ IU 6-ethyl-3-[3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]anilino]-5-(oxan-4-ylamino)pyrazine-2-carboxamide DMWQ4MZ CA CAS 1254053-43-4 DMWQ4MZ CB CHEBI:145372 DMWQ4MZ DE Acute myeloid leukaemia DM5PFIJ ID DM5PFIJ DM5PFIJ DN Givosiran DM5PFIJ HS Approved DM5PFIJ SN 1639325-43-1; N-[1,3-Bis[3-[3-[5-[(2R,3R,4R,5R,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypentanoylamino]propylamino]-3-oxopropoxy]-2-[[3-[3-[5-[(2R,3R,4R,5R,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypentanoylamino]propylamino]-3-oxopropoxy]methyl]propan-2-yl]-12-[(2R,4R)-4-hydroxy-2-methylpyrrolidin-1-yl]-12-oxododecanamide; Fitusiran; Givlaari; Givosiran [INN]; Givosiran [USAN]; Givosiran [USAN:INN]; ALN-AS1; UNII-ROV204583W; ROV204583W; WHO 10280 DM5PFIJ CP Alnylam Pharmaceuticals DM5PFIJ DT Small interfering RNA DM5PFIJ PC 119058042 DM5PFIJ MW 1711 DM5PFIJ FM C78H139N11O30 DM5PFIJ IC InChI=1S/C78H139N11O30/c1-50-42-54(96)43-89(50)65(104)26-12-10-8-6-5-7-9-11-25-64(103)88-78(47-111-39-27-61(100)82-33-19-30-79-58(97)22-13-16-36-114-75-66(85-51(2)93)72(108)69(105)55(44-90)117-75,48-112-40-28-62(101)83-34-20-31-80-59(98)23-14-17-37-115-76-67(86-52(3)94)73(109)70(106)56(45-91)118-76)49-113-41-29-63(102)84-35-21-32-81-60(99)24-15-18-38-116-77-68(87-53(4)95)74(110)71(107)57(46-92)119-77/h50,54-57,66-77,90-92,96,105-110H,5-49H2,1-4H3,(H,79,97)(H,80,98)(H,81,99)(H,82,100)(H,83,101)(H,84,102)(H,85,93)(H,86,94)(H,87,95)(H,88,103)/t50-,54-,55-,56-,57-,66-,67-,68-,69+,70+,71+,72-,73-,74-,75-,76-,77-/m1/s1 DM5PFIJ CS C[C@@H]1C[C@H](CN1C(=O)CCCCCCCCCCC(=O)NC(COCCC(=O)NCCCNC(=O)CCCCO[C@H]2[C@@H]([C@H]([C@H]([C@H](O2)CO)O)O)NC(=O)C)(COCCC(=O)NCCCNC(=O)CCCCO[C@H]3[C@@H]([C@H]([C@H]([C@H](O3)CO)O)O)NC(=O)C)COCCC(=O)NCCCNC(=O)CCCCO[C@H]4[C@@H]([C@H]([C@H]([C@H](O4)CO)O)O)NC(=O)C)O DM5PFIJ IK RUPXJRIDSUCQAN-PQNNUJSWSA-N DM5PFIJ IU N-[1,3-bis[3-[3-[5-[(2R,3R,4R,5R,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypentanoylamino]propylamino]-3-oxopropoxy]-2-[[3-[3-[5-[(2R,3R,4R,5R,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypentanoylamino]propylamino]-3-oxopropoxy]methyl]propan-2-yl]-12-[(2R,4R)-4-hydroxy-2-methylpyrrolidin-1-yl]-12-oxododecanamide DM5PFIJ CA CAS 1639325-43-1 DM5PFIJ DE Acute intermittent hepatic porphyria DM83MOK ID DM83MOK DM83MOK DN Glassia DM83MOK HS Approved DM83MOK SN Glassia (TN) DM83MOK CP Baxter DM83MOK DE Emphysema DMAPV1B ID DMAPV1B DMAPV1B DN Glatiramer acetate DMAPV1B HS Approved DMAPV1B SN Glatiramer acetate; Copaxone; 147245-92-9; Copolymer 1; Copolymer-1; COP-1; Protiramer; Glatopa; L-Glutamic acid peptide with L-alanine, L-lysine and L-tyrosine, acetate (salt); L-alanine compound with L-glutamic acid and L-lysine and L-tyrosine and acetic acid (1:1:1:1:1); (2S)-2,6-diaminohexanoic acid; TV 5010; UNII-5M691HL4BO; Glatirameracetat; Glatiramer acetate [USAN:BAN]; AC1MIXQC; 5M691HL4BO DMAPV1B CP Teva Pharmaceuticals DMAPV1B TC Immunosuppressive Agents DMAPV1B DT Small molecular drug DMAPV1B SQ Example Glatiramer peptide: EAYKAAEKAYAAKEAAKEAAKAKAEKKAAYAKAKAAKYEKKAKKAAAEYKKK DMAPV1B PC 3081884 DMAPV1B MW 623.7 DMAPV1B FM C25H45N5O13 DMAPV1B IC InChI=1S/C9H11NO3.C6H14N2O2.C5H9NO4.C3H7NO2.C2H4O2/c10-8(9(12)13)5-6-1-3-7(11)4-2-6;7-4-2-1-3-5(8)6(9)10;6-3(5(9)10)1-2-4(7)8;1-2(4)3(5)6;1-2(3)4/h1-4,8,11H,5,10H2,(H,12,13);5H,1-4,7-8H2,(H,9,10);3H,1-2,6H2,(H,7,8)(H,9,10);2H,4H2,1H3,(H,5,6);1H3,(H,3,4)/t8-;5-;3-;2-;/m0000./s1 DMAPV1B CS C[C@@H](C(=O)O)N.CC(=O)O.C1=CC(=CC=C1C[C@@H](C(=O)O)N)O.C(CCN)C[C@@H](C(=O)O)N.C(CC(=O)O)[C@@H](C(=O)O)N DMAPV1B IK FHEAIOHRHQGZPC-KIWGSFCNSA-N DMAPV1B IU acetic acid;(2S)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2S)-2-aminopentanedioic acid;(2S)-2-aminopropanoic acid;(2S)-2,6-diaminohexanoic acid DMAPV1B CA CAS 147245-92-9 DMAPV1B DE Multiple sclerosis DM31YVO ID DM31YVO DM31YVO DN Glecaprevir DM31YVO HS Approved DM31YVO SN Glecaprevir; Glecaprevir (USAN/INN); Glecaprevir [USAN]; J3.646.120I; K6BUU8J72P; SB19760; SCHEMBL883097; glecaprevirum; 1365970-03-1; A-1282576.0; ABT 493; ABT-493; ABT-493(Glecaprevir); CHEMBL3545363; CS-8098; D10814; DB13879; EX-A1940; HY-17634; UNII-K6BUU8J72P DM31YVO PC 66828839 DM31YVO MW 838.9 DM31YVO FM C38H46F4N6O9S DM31YVO IC MLSQGNCUYAMAHD-ITNVBOSISA-N DM31YVO CS CC1(CC1)S(=O)(=O)NC(=O)C2(CC2C(F)F)NC(=O)C3CC4CN3C(=O)C(NC(=O)OC5CCCC5OCC=CC(C6=NC7=CC=CC=C7N=C6O4)(F)F)C(C)(C)C DM31YVO IK 1S/C38H46F4N6O9S/c1-35(2,3)28-32(50)48-19-20(17-24(48)30(49)46-37(18-21(37)29(39)40)33(51)47-58(53,54)36(4)14-15-36)56-31-27(43-22-9-5-6-10-23(22)44-31)38(41,42)13-8-16-55-25-11-7-12-26(25)57-34(52)45-28/h5-6,8-10,13,20-21,24-26,28-29H,7,11-12,14-19H2,1-4H3,(H,45,52)(H,46,49)(H,47,51)/b13-8+/t20-,21+,24+,25-,26-,28-,37-/m1/s1 DM31YVO IU (1R,14E,18R,22R,26S,29S)-26-tert-butyl-N-[(1R,2R)-2-(difluoromethyl)-1-[(1-methylcyclopropyl)sulfonylcarbamoyl]cyclopropyl]-13,13-difluoro-24,27-dioxo-2,17,23-trioxa-4,11,25,28-tetrazapentacyclo[26.2.1.03,12.05,10.018,22]hentriaconta-3,5,7,9,11,14-hexaene-29-carboxamide DM31YVO CA CAS 1365970-03-1 DM31YVO DE Viral hepatitis DMF6Z5T ID DMF6Z5T DMF6Z5T DN Glecaprevir; pibrentasvir DMF6Z5T HS Approved DMF6Z5T SN pibrentasvir; Maviret; Mavyret; Glecaprevir / pibrentasvir; Glecaprevir and pibrentasvir; ABT-493/ABT-530; Glecaprevir mixture with pibrentasvir; ABT-493 / ABT-530; S900007520 DMF6Z5T CP AbbVie DMF6Z5T DT Combination drug DMF6Z5T PC 66828839; 58031952 DMF6Z5T DE Hepatitis C virus infection DM8JXPZ ID DM8JXPZ DM8JXPZ DN Glibenclamide DM8JXPZ HS Approved DM8JXPZ SN Abbenclamide; Adiab; Azuglucon; Bastiverit; Benclamin; Betanase; Calabren; Cytagon; Daonil; Debtan; Diabeta; Diabiphage; Dibelet; Duraglucon; Euclamin; Euglucan; Euglucon; Euglykon; Gewaglucon; Gilemal; Glamide; Glibadone; Gliban; Gliben; Glibenbeta; Glibenclamida; Glibenclamidum; Glibenil; Glibens; Glibesyn; Glibet; Glibetic; Glibil; Gliboral; Glicem; Glidiabet; Glimel; Glimide; Glimidstata; Glisulin; Glitisol; Glubate; Gluben; Glucobene; Glucohexal; Glucolon; Glucomid; Glucoremed; Glucoven; Glyben; Glybenclamide; Glybenzcyclamide; Glyburide; Glycolande; Glycomin; Glynase; Hexaglucon; Humedia; Lederglib; Libanil; Lisaglucon; Maninil; Melix; Micronase; Miglucan; Nadib; Neogluconin; Normoglucon; Orabetic; Pira; Praeciglucon; PresTab; Prodiabet; Renabetic; Sugril; Suraben; Tiabet; Yuglucon; Euglucon N; Glibenclamid AL; Glibenclamid Basics; Glibenclamid Fabra; Glibenclamid Genericon; Glibenclamid Heumann; Glibenclamid Riker M; Glyburide [USAN]; Micronized glyburide; Betanese 5; Euglucon 5; G 0639; GBN 5; HB 419; HB 420; HB419; HB420; Norglicem 5; U 26452; UR 606; Apo-Glibenclamide; Daonil (TN); Dia-basan; Diabeta (TN); Euglucon (TN); Gen-Glybe; Gliben-Puren N; Glibenclamid Riker M.; Glibenclamid-Cophar; Glibenclamid-Ratiopharm; Glibenclamida [INN-Spanish]; Glibenclamidum [INN-Latin]; Gluco-Tablimen; Glyburide (USP); Glyburide (micronized); Glynase (TN); HB-419; HB-420; Hemi-Daonil; Med-Glionil; Micronase (TN); Novo-Glyburide; Semi-Euglucon; Semi-daonil; U-26452; Glibenclamide (JP15/INN); Semi-Daonil (TN); Semi-Gliben-Puren N; N-p-[2-(5-Chloro-2-methoxybenzamido)ethyl]benzenesulfonyl-N'-cyclohexylurea; N-p-[2-(5-Chloro-2-methoxybenzamido)-ethyl]benzene-sulfonyl-N-cyclohexylurea; N-(4-(2-(5-Chloro-2-methoxybenzamido)ethyl)phenylsulfonyl)-N'-cyclohexylurea; 1-((p-(2-(5-Chloro-o-anisamido)ethyl)phenyl)sulfonyl)-3-cyclohexylurea; 1-(p-(2-(5-Chloro-2-methoxybenzamido)ethyl)benzenesulfonyl)-3-cyclohexylurea; 5-Chloro-N-[4-(cyclohexylureidosulfonyl)phenethyl]-2-methoxybenzamide; 5-chloro-N-[2-[4-(cyclohexylcarbamoylsulfamoyl)phenyl]ethyl]-2-methoxybenzamide DM8JXPZ CP Nigerian-German Chemicals DM8JXPZ TC Hypoglycemic Agents DM8JXPZ DT Small molecular drug DM8JXPZ PC 3488 DM8JXPZ MW 494 DM8JXPZ FM C23H28ClN3O5S DM8JXPZ IC InChI=1S/C23H28ClN3O5S/c1-32-21-12-9-17(24)15-20(21)22(28)25-14-13-16-7-10-19(11-8-16)33(30,31)27-23(29)26-18-5-3-2-4-6-18/h7-12,15,18H,2-6,13-14H2,1H3,(H,25,28)(H2,26,27,29) DM8JXPZ CS COC1=C(C=C(C=C1)Cl)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3 DM8JXPZ IK ZNNLBTZKUZBEKO-UHFFFAOYSA-N DM8JXPZ IU 5-chloro-N-[2-[4-(cyclohexylcarbamoylsulfamoyl)phenyl]ethyl]-2-methoxybenzamide DM8JXPZ CA CAS 10238-21-8 DM8JXPZ CB CHEBI:5441 DM8JXPZ DE Diabetic complication; Stroke DMN6QO5 ID DMN6QO5 DMN6QO5 DN Gliclazide DMN6QO5 HS Approved DMN6QO5 SN Diaikron; Diamicron; Gliclazida; Gliclazidum; Gliklazid; Glimicron; Glyclazide; Nordialex; S 1702; S 852; SE 1702; Diamicron (TN); Dianorm (TN); Gliclazida [INN-Spanish]; Gliclazidum [INN-Latin]; Glimicron (TN); S-1702; S-852; Gliclazide (JAN/INN); Glubitor-OD (TN); Gliclazide [BAN:INN:DCF:JAN]; N-(hexahydrocyclopenta[c]pyrrol-2(1H)-ylcarbamoyl)-4-methylbenzenesulfonamide; N-[(hexahydrocyclopenta[c]pyrrol-2(1H)-ylamino)carbonyl]-4-methylbenzenesulfonamide; N-(4-Methylbenzenesulfonyl)-N'-(3-azabicyclo(3.3.0)oct-3-yl)urea; 1-(3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrol-2-yl)-3-(4-methylphenyl)sulfonylurea; 1-(3-Azabicyclo(3.3.0)oct-3-yl)-3-(p-tolylsulfonyl)urea; 1-(3-Azabicyclo[3.3.0]oct-3-yl)-3-p-tolylsulphonylurea; 1-(Hexahydrocyclopenta(c)pyrrol-2(1H)-yl)-3-(p-tolylsulfonyl)urea DMN6QO5 TC Hypoglycemic Agents DMN6QO5 DT Small molecular drug DMN6QO5 PC 3475 DMN6QO5 MW 323.4 DMN6QO5 FM C15H21N3O3S DMN6QO5 IC InChI=1S/C15H21N3O3S/c1-11-5-7-14(8-6-11)22(20,21)17-15(19)16-18-9-12-3-2-4-13(12)10-18/h5-8,12-13H,2-4,9-10H2,1H3,(H2,16,17,19) DMN6QO5 CS CC1=CC=C(C=C1)S(=O)(=O)NC(=O)NN2CC3CCCC3C2 DMN6QO5 IK BOVGTQGAOIONJV-UHFFFAOYSA-N DMN6QO5 IU 1-(3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrol-2-yl)-3-(4-methylphenyl)sulfonylurea DMN6QO5 CA CAS 21187-98-4 DMN6QO5 CB CHEBI:31654 DMN6QO5 DE Diabetic complication DM5FSJA ID DM5FSJA DM5FSJA DN Glimepiride DM5FSJA HS Approved DM5FSJA SN Amarel; Amaryl; Endial; Glimepirid; Glimepirida; Glimepiridum; Glimepride; Glimer; Glymepirid; Roname; Solosa; Glimepirida [Spanish]; Glimepiridum [Latin]; Sandoz glimepiride; HOE 490; Amaryl (TN); Hoe-490; Novo-glimepiride; PMS-glimepiride; Ratio-glimepiride; Amaryl, Glista OD, Glimepiride; Glimepiride [USAN:BAN:INN]; Glimepiride (JAN/USP/INN); 1-((p-(2-(3-Ethyl-4-methyl-2-oxo-3-pyrroline-1-carboxamido)ethyl)phenyl)sulfonyl)-3-(trans-4-methylcyclohexyl)urea; 1-{[4-(2-{[(3-ethyl-4-methyl-2-oxo-2,5-dihydro-1H-pyrrol-1-yl)carbonyl]amino}ethyl)phenyl]sulfonyl}-3-(trans-4-methylcyclohexyl)urea; 3-ethyl-4-methyl-N-[2-(4-{[(trans-4-methylcyclohexyl)carbamoyl]sulfamoyl}phenyl)ethyl]-2-oxo-2,5-dihydro-1H-pyrrole-1-carboxamide; 3-ethyl-4-methyl-n-(4-(n-((1r,4r)-4-methylcyclohexylcarbamoyl)sulfamoyl)phenethyl)-2-oxo-2,5-dihydro; 4-ethyl-3-methyl-N-[2-[4-[(4-methylcyclohexyl)carbamoylsulfamoyl]phenyl]ethyl]-5-oxo-2H-pyrrole-1-carboxamide; 64598P DM5FSJA CP Sanofi-Aventis DM5FSJA TC Hypoglycemic Agents DM5FSJA DT Small molecular drug DM5FSJA PC 3476 DM5FSJA MW 490.6 DM5FSJA FM C24H34N4O5S DM5FSJA IC InChI=1S/C24H34N4O5S/c1-4-21-17(3)15-28(22(21)29)24(31)25-14-13-18-7-11-20(12-8-18)34(32,33)27-23(30)26-19-9-5-16(2)6-10-19/h7-8,11-12,16,19H,4-6,9-10,13-15H2,1-3H3,(H,25,31)(H2,26,27,30) DM5FSJA CS CCC1=C(CN(C1=O)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCC(CC3)C)C DM5FSJA IK WIGIZIANZCJQQY-UHFFFAOYSA-N DM5FSJA IU 4-ethyl-3-methyl-N-[2-[4-[(4-methylcyclohexyl)carbamoylsulfamoyl]phenyl]ethyl]-5-oxo-2H-pyrrole-1-carboxamide DM5FSJA CA CAS 261361-60-8 DM5FSJA CB CHEBI:5383 DM5FSJA DE Diabetic complication DMZA5PQ ID DMZA5PQ DMZA5PQ DN Glipizide DMZA5PQ HS Approved DMZA5PQ SN Aldiab; Digrin; Dipazide; Glibenese; Glibetin; Glican; Glide; Glidiab; Glidiazinamide; Glipid; Glipizida; Glipizidum; Glucolip; Glucotrol; Glucozide; Glupitel; Glupizide; Glyde; Glydiazinamide; Glypidizine; Melizide; Metaglip; Mindiab; Minidab; Minidiab; Minodiab; Napizide; Ozidia; Semiglynase; Sucrazide; Alphapharm Brand of Glipizide; Glibenese Brand of Glipizide; Glipizide Kenfarma Brand; Glucotrol XL; Kenfarma Brand of Glipizide; Lacer Brand of Glipizide; Lilly Brand of Glipizide; CP 28720; K 4024; K4024; PfizerBrand 1 of Glipizide; Pfizer Brand 2 of Glipizide; TK 1320; CP 28,720; CP-28720; G-117; Glipizida [INN-Spanish]; Glipizide Extended-Release Tablets; Glipizidum [INN-Latin]; Gluco-Rite; Glucotrol (TN); K-4024; KS-1068; Samarium(III) ionophore I; Glipizide (USP/INN); Glipizide [USAN:BAN:INN]; Glucotrol XL, Glucotrol, Glipizide; N-[2-[4-(cyclohexylcarbamoylsulfamoyl)phenyl]ethyl]-5-methylpyrazine-2-carboxamide; N-(2-{4-[(cyclohexylcarbamoyl)sulfamoyl]phenyl}ethyl)-5-methylpyrazine-2-carboxamide; N-[2-(4-{[(cyclohexylcarbamoyl)amino]sulfonyl}phenyl)ethyl]-5-methylpyrazine-2-carboxamide; N-(4-(beta-(5-Methylpyrazine-2-carboxamido)ethyl)benzenesulphonyl)-N'-cyclohexylurea; 1-Cyclohexyl-3-((p-(2-(5-methylpyrazinecarboxamido)ethyl)phenyl)sulfonyl)urea; 1-Cyclohexyl-3-{4-[2-(5-methylpyrazine-2-carboxamido)ethyl]phenylsulfonyl}urea DMZA5PQ CP Pfizer Pharmaceuticals DMZA5PQ TC Hypoglycemic Agents DMZA5PQ DT Small molecular drug DMZA5PQ PC 3478 DMZA5PQ MW 445.5 DMZA5PQ FM C21H27N5O4S DMZA5PQ IC InChI=1S/C21H27N5O4S/c1-15-13-24-19(14-23-15)20(27)22-12-11-16-7-9-18(10-8-16)31(29,30)26-21(28)25-17-5-3-2-4-6-17/h7-10,13-14,17H,2-6,11-12H2,1H3,(H,22,27)(H2,25,26,28) DMZA5PQ CS CC1=CN=C(C=N1)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3 DMZA5PQ IK ZJJXGWJIGJFDTL-UHFFFAOYSA-N DMZA5PQ IU N-[2-[4-(cyclohexylcarbamoylsulfamoyl)phenyl]ethyl]-5-methylpyrazine-2-carboxamide DMZA5PQ CA CAS 29094-61-9 DMZA5PQ CB CHEBI:5384 DMZA5PQ DE Diabetic complication DMB0EUX ID DMB0EUX DMB0EUX DN Gliquidone DMB0EUX HS Approved DMB0EUX SN Beglynor; Beglynora; Glikvidon; Gliquidona; Gliquidonum; Glurenorm; Glycvidon; ARDF 26; ARDF 26 SE; AR-DF 26; Gliquidona [INN-Spanish]; Gliquidone (INN); Gliquidone [BAN:INN]; Gliquidonum [INN-Latin]; Glurenorm (TN); N-[(cyclohexylamino)carbonyl]-4-{2-[4,4-dimethyl-7-(methyloxy)-1,3-dioxo-3,4-dihydroisoquinolin-2(1H)-yl]ethyl}benzenesulfonamide; 1-Cyclohexyl-3-((p-(2-(3,4-dihydro-7-methoxy-4,4-dimethyl-1,3-dioxo-2(1H)-isoquinolyl)ethyl)phenyl)sulfonyl)urea; 1-Cyclohexyl-3-(p-beta-(4,4-dimethyl-2-methoxy-1,3-(2H,4H)-isoquinolinedione-2-yl)phenethyl)sulfonylurea; 1-cyclohexyl-3-(p-beta-(4,4-dimethyl-2-methoxy-1,3-(2H,4H)-isoquinolinedione-2-yl)phenethyl)sulfonylurea; 1-cyclohexyl-3-[4-[2-(7-methoxy-4,4-dimethyl-1,3-dioxoisoquinolin-2-yl)ethyl]phenyl]sulfonylurea DMB0EUX CP Boehriger Ingelheim DMB0EUX TC Hypoglycemic Agents DMB0EUX DT Small molecular drug DMB0EUX PC 91610 DMB0EUX MW 527.6 DMB0EUX FM C27H33N3O6S DMB0EUX IC InChI=1S/C27H33N3O6S/c1-27(2)23-14-11-20(36-3)17-22(23)24(31)30(25(27)32)16-15-18-9-12-21(13-10-18)37(34,35)29-26(33)28-19-7-5-4-6-8-19/h9-14,17,19H,4-8,15-16H2,1-3H3,(H2,28,29,33) DMB0EUX CS CC1(C2=C(C=C(C=C2)OC)C(=O)N(C1=O)CCC3=CC=C(C=C3)S(=O)(=O)NC(=O)NC4CCCCC4)C DMB0EUX IK LLJFMFZYVVLQKT-UHFFFAOYSA-N DMB0EUX IU 1-cyclohexyl-3-[4-[2-(7-methoxy-4,4-dimethyl-1,3-dioxoisoquinolin-2-yl)ethyl]phenyl]sulfonylurea DMB0EUX CA CAS 33342-05-1 DMB0EUX CB CHEBI:93416 DMB0EUX DE Diabetic complication DMJPR2B ID DMJPR2B DMJPR2B DN Glisoxepide DMJPR2B HS Approved DMJPR2B SN Glisepin; Glisoxepid; Glisoxepida; Glisoxepidum; Glisoxepida [Spanish]; BS 4231; Bay B 4231; FBB 4231; RP22410; Glisoxepida [INN-Spanish]; Glisoxepide (INN); Glisoxepidum [INN-Latin]; Pro-Diaban; Glisoxepide [INN:BAN:DCF]; N-[2-[4-(azepan-1-ylcarbamoylsulfamoyl)phenyl]ethyl]-5-methyl-1,2-oxazole-3-carboxamide; N-{2-[4-({[(azepan-1-ylamino)carbonyl]amino}sulfonyl)phenyl]ethyl}-5-methylisoxazole-3-carboxamide; 1-(Hexahydro-1H-azepin-1-yl)-3-((p-(2-(5-methyl-3-isoxazolecarboxamido)ethyl)phenyl)sulfonyl)urea DMJPR2B TC Hypoglycemic Agents DMJPR2B DT Small molecular drug DMJPR2B PC 32778 DMJPR2B MW 449.5 DMJPR2B FM C20H27N5O5S DMJPR2B IC InChI=1S/C20H27N5O5S/c1-15-14-18(23-30-15)19(26)21-11-10-16-6-8-17(9-7-16)31(28,29)24-20(27)22-25-12-4-2-3-5-13-25/h6-9,14H,2-5,10-13H2,1H3,(H,21,26)(H2,22,24,27) DMJPR2B CS CC1=CC(=NO1)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NN3CCCCCC3 DMJPR2B IK ZKUDBRCEOBOWLF-UHFFFAOYSA-N DMJPR2B IU N-[2-[4-(azepan-1-ylcarbamoylsulfamoyl)phenyl]ethyl]-5-methyl-1,2-oxazole-3-carboxamide DMJPR2B CA CAS 25046-79-1 DMJPR2B CB CHEBI:135731 DMJPR2B DE Non-insulin dependent diabetes DMFLUTR ID DMFLUTR DMFLUTR DN Glucagon recombinant DMFLUTR HS Approved DMFLUTR SN Glucagon recombinant; GTPL1136; CHEMBL266481 DMFLUTR TC Antihypoglycemic Agents DMFLUTR DT Small molecular drug DMFLUTR SQ Glucagon for Injection Sequence : HSQGTFTSDYSKYLDSRRAQDFVQWLMNT DMFLUTR PC 44278361 DMFLUTR MW 3482.7 DMFLUTR FM C153H225N43O49S DMFLUTR IC InChI=1S/C153H225N43O49S/c1-72(2)52-97(133(226)176-96(47-51-246-11)132(225)184-104(60-115(159)209)143(236)196-123(78(10)203)151(244)245)179-137(230)103(58-83-64-167-89-29-19-18-28-87(83)89)183-131(224)95(43-46-114(158)208)177-148(241)120(74(5)6)194-141(234)101(54-79-24-14-12-15-25-79)182-138(231)105(61-117(211)212)185-130(223)94(42-45-113(157)207)171-124(217)75(7)170-127(220)91(31-22-49-165-152(160)161)172-128(221)92(32-23-50-166-153(162)163)174-146(239)110(69-199)191-140(233)107(63-119(215)216)186-134(227)98(53-73(3)4)178-135(228)99(56-81-33-37-85(204)38-34-81)180-129(222)90(30-20-21-48-154)173-145(238)109(68-198)190-136(229)100(57-82-35-39-86(205)40-36-82)181-139(232)106(62-118(213)214)187-147(240)111(70-200)192-150(243)122(77(9)202)195-142(235)102(55-80-26-16-13-17-27-80)188-149(242)121(76(8)201)193-116(210)66-168-126(219)93(41-44-112(156)206)175-144(237)108(67-197)189-125(218)88(155)59-84-65-164-71-169-84/h12-19,24-29,33-40,64-65,71-78,88,90-111,120-123,167,197-205H,20-23,30-32,41-63,66-70,154-155H2,1-11H3,(H2,156,206)(H2,157,207)(H2,158,208)(H2,159,209)(H,164,169)(H,168,219)(H,170,220)(H,171,217)(H,172,221)(H,173,238)(H,174,239)(H,175,237)(H,176,226)(H,177,241)(H,178,228)(H,179,230)(H,180,222)(H,181,232)(H,182,231)(H,183,224)(H,184,225)(H,185,223)(H,186,227)(H,187,240)(H,188,242)(H,189,218)(H,190,229)(H,191,233)(H,192,243)(H,193,210)(H,194,234)(H,195,235)(H,196,236)(H,211,212)(H,213,214)(H,215,216)(H,244,245)(H4,160,161,165)(H4,162,163,166)/t75-,76+,77+,78+,88-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,120-,121-,122-,123-/m0/s1 DMFLUTR CS C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC4=CC=CC=C4)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC5=CNC6=CC=CC=C65)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)CNC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC7=CNC=N7)N)O DMFLUTR IK MASNOZXLGMXCHN-ZLPAWPGGSA-N DMFLUTR IU (3S)-3-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-amino-3-(1H-imidazol-4-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]propanoyl]amino]-5-oxopentanoyl]amino]-4-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(1S,2R)-1-carboxy-2-hydroxypropyl]amino]-1,4-dioxobutan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-oxobutanoic acid DMFLUTR CB CHEBI:5391 DMFLUTR DE Hypoglycemia DM6EL5Q ID DM6EL5Q DM6EL5Q DN Glucarpidase DM6EL5Q HS Approved DM6EL5Q SN Voraxaze (TN) DM6EL5Q CP BTG International DM6EL5Q DT Small molecular drug DM6EL5Q SQ Glucarpidase: ALAQKRDNVLFQAATDEQPAVIKTLEKLVNIETGTGDAEGIAAAGNFLEAELKNLGFTVTRSKSAGLVVGDNIVGKIKGRGGKNLLLMSHMDTVYLKGILAKAPFRVEGDKAYGPGIADDKGGNAVILHTLKLLKEYGVRDYGTITVLFNTDEEKGSFGSRDLIQEEAKLADYVLSFEPTSAGDEKLSLGTSGIAYVQVNITGKASHAGAAPELGVNALVEASDLVLRTMNIDDKAKNLRFNWTIAKAGNVSNIIPASATLNADVRYARNEDFDAAMKTLEERAQQKKLPEADVKVIVTRGRPAFNAGEGGKKLVDKAVAYYKEAGGTLGVEERTGGGTDAAYAALSGKPVIESLGLPGFGYHSDKAEYVDISAIPRRLYMAARLIMDLGAGK DM6EL5Q PC 21195079 DM6EL5Q MW 261.5 DM6EL5Q FM Zn4+8 DM6EL5Q IC InChI=1S/4Zn/q4*+2 DM6EL5Q CS [Zn+2].[Zn+2].[Zn+2].[Zn+2] DM6EL5Q IK LZQXMCNBQHANEY-UHFFFAOYSA-N DM6EL5Q IU zinc(2+) DM6EL5Q DE Delayed methotrexate clearance DM4ZLFD ID DM4ZLFD DM4ZLFD DN Glucosamine DM4ZLFD HS Approved DM4ZLFD SN Chitosamine; GCS; Glucosamina; Glucosaminum; D-glucosamine; Glucosamina [INN-Spanish]; Glucosamine [USAN:INN]; Glucosaminum [INN-Latin]; Viartril-S; Beta-D-Glucosamine; Glucosamine (USAN/INN); Partially N-deacetylated poly-beta-1,6-N-acetyl-D-glucosamine; (2R,3R,4R,5S,6R)-3-amino-6-(hydroxymethyl)oxane-2,4,5-triol; (2S,5R)-3-amino-6-(hydroxymethyl)oxane-2,4,5-triol; (3R,4R,5S,6R)-3-amino-6-(hydroxymethyl)oxane-2,4,5-triol; 2-Amino-2-deoxy-D-glucose; 2-Amino-2-deoxy-beta-D-glucopyranose; 2-amino-2-deoxy-D-glucopyranose; 2-amino-2-deoxyglucose DM4ZLFD TC Antiinflammatory Agents DM4ZLFD DT Small molecular drug DM4ZLFD PC 439213 DM4ZLFD MW 179.17 DM4ZLFD FM C6H13NO5 DM4ZLFD IC InChI=1S/C6H13NO5/c7-3-5(10)4(9)2(1-8)12-6(3)11/h2-6,8-11H,1,7H2/t2-,3-,4-,5-,6?/m1/s1 DM4ZLFD CS C([C@@H]1[C@H]([C@@H]([C@H](C(O1)O)N)O)O)O DM4ZLFD IK MSWZFWKMSRAUBD-IVMDWMLBSA-N DM4ZLFD IU (3R,4R,5S,6R)-3-amino-6-(hydroxymethyl)oxane-2,4,5-triol DM4ZLFD CA CAS 3416-24-8 DM4ZLFD CB CHEBI:47977 DM4ZLFD DE Osteoarthritis DMAHMT9 ID DMAHMT9 DMAHMT9 DN Glutathione DMAHMT9 HS Approved DMAHMT9 SN glutathione; 70-18-8; Glutathion; Isethion; Tathion; Glutathione-SH; Glutinal; reduced glutathione; Neuthion; Deltathione; Copren; L-Glutathione reduced; Glutide; Tathione; Triptide; Ledac; Glutatione; GSH; Glutatiol; Panaron; gamma-L-Glutamyl-L-cysteinylglycine; Glutathione SH; L-Glutatione; Glutathione (reduced); Agifutol S; L-gamma-glutamyl-L-cysteinylglycine; gamma-L-glutamyl-L-cysteinyl-glycine; 5-L-Glutamyl-L-cysteinylglycine; Glutathione [JAN]; glutathione red; gamma-L-Glutamylcysteinylglycine; red. glutathione DMAHMT9 DT Small molecular drug DMAHMT9 PC 124886 DMAHMT9 MW 307.33 DMAHMT9 FM C10H17N3O6S DMAHMT9 IC InChI=1S/C10H17N3O6S/c11-5(10(18)19)1-2-7(14)13-6(4-20)9(17)12-3-8(15)16/h5-6,20H,1-4,11H2,(H,12,17)(H,13,14)(H,15,16)(H,18,19)/t5-,6-/m0/s1 DMAHMT9 CS C(CC(=O)N[C@@H](CS)C(=O)NCC(=O)O)[C@@H](C(=O)O)N DMAHMT9 IK RWSXRVCMGQZWBV-WDSKDSINSA-N DMAHMT9 IU (2S)-2-amino-5-[[(2R)-1-(carboxymethylamino)-1-oxo-3-sulfanylpropan-2-yl]amino]-5-oxopentanoic acid DMAHMT9 CA CAS 70-18-8 DMAHMT9 CB CHEBI:16856 DMAHMT9 DE Human immunodeficiency virus infection DMGE0CW ID DMGE0CW DMGE0CW DN Glutethimide DMGE0CW HS Approved DMGE0CW SN Alfimid; Doriden; Dorimide; Elrodorm; Gimid; Glimid; Glutathimid; Glutethimid; Glutethimidum; Glutetimid; Glutetimida; Glutetimide; Glutetimidu; Gluthetimide; Noxiron; Noxyron; Ondasil; Rigenox; Sarodormin; Glutetimide [DCIT]; Glutetimidu [Polish]; CC 11511; LT00114358; Doriden (TN); Doriden-sed; Glutethimide [INN:BAN]; Glutethimidum [INN-Latin]; Glutetimida [INN-Spanish]; Glutethimide (JAN/INN); Phenyl-aethyl-glutarsaeureimid; Phenyl-aethyl-glutarsaeureimid [German]; Alpha-Ethyl-alpha-phenylglutarimide; Alpha-Phenyl-alpha-ethylglutaric acid imide; Alpha-Phenyl-alpha-ethylglutarimide; 2-Ethyl-2-phenylglutarimide; 2-Phenyl-2-ethylglutaric acid imide; 3-Ethyl-3-phenyl-2,6-diketopiperidine; 3-Ethyl-3-phenyl-2,6-dioxopiperidine; 3-Ethyl-3-phenyl-2,6-piperidinedione; 3-Phenyl-3-ethyl-2,6-diketopiperidine; 3-Phenyl-3-ethyl-2,6-dioxopiperidine; 3-ethyl-3-phenylpiperidine-2,6-dione DMGE0CW TC Hypnotics and Sedatives DMGE0CW DT Small molecular drug DMGE0CW PC 3487 DMGE0CW MW 217.26 DMGE0CW FM C13H15NO2 DMGE0CW IC InChI=1S/C13H15NO2/c1-2-13(10-6-4-3-5-7-10)9-8-11(15)14-12(13)16/h3-7H,2,8-9H2,1H3,(H,14,15,16) DMGE0CW CS CCC1(CCC(=O)NC1=O)C2=CC=CC=C2 DMGE0CW IK JMBQKKAJIKAWKF-UHFFFAOYSA-N DMGE0CW IU 3-ethyl-3-phenylpiperidine-2,6-dione DMGE0CW CA CAS 77-21-4 DMGE0CW CB CHEBI:5439 DMGE0CW DE Insomnia DMDGRQO ID DMDGRQO DMDGRQO DN Glycerol phenylbutyrate DMDGRQO HS Approved DMDGRQO SN GT4P; HPN-100; Glyceryl tri-(4-phenylbutyrate) DMDGRQO CP Ucyclyd Pharma Inc DMDGRQO DT Small molecular drug DMDGRQO PC 10482134 DMDGRQO MW 530.6 DMDGRQO FM C33H38O6 DMDGRQO IC InChI=1S/C33H38O6/c34-31(22-10-19-27-13-4-1-5-14-27)37-25-30(39-33(36)24-12-21-29-17-8-3-9-18-29)26-38-32(35)23-11-20-28-15-6-2-7-16-28/h1-9,13-18,30H,10-12,19-26H2 DMDGRQO CS C1=CC=C(C=C1)CCCC(=O)OCC(COC(=O)CCCC2=CC=CC=C2)OC(=O)CCCC3=CC=CC=C3 DMDGRQO IK ZSDBFLMJVAGKOU-UHFFFAOYSA-N DMDGRQO IU 2,3-bis(4-phenylbutanoyloxy)propyl 4-phenylbutanoate DMDGRQO CA CAS 611168-24-2 DMDGRQO CB CHEBI:134745 DMDGRQO DE Hepatic encephalopathy DMIOZ29 ID DMIOZ29 DMIOZ29 DN Glycine DMIOZ29 HS Approved DMIOZ29 SN Aciport; Aminoazijnzuur; Aminoessigsaeure; Amitone; Corilin; Glicina; Glicoamin; Gly; Glycin; Glycinum; Glycocoll; Glycolixir; Glycosthene; Glykokoll; Glyzin; Hgly; Leimzucker; Padil; Polyglycine; Acide aminoacetique; Acido aminoacetico; Acidum aminoaceticum; Aminoacetic acid; Aminoethanoic acid; An alpha amino acid ester; Glycine [INN]; Hampshire glycine; Polyglycine II; Sucre de gelatine; Acide aminoacetique [INN-French]; Acido aminoacetico [INN-Spanish]; Acidum aminoaceticum [INN-Latin]; GLY (IUPAC abbrev); GLYCINE, ACS; Glicina [INN-Spanish]; Glycinum [INN-Latin]; Gyn-hydralin; L-Glycine; S04-0135; AB-131/40217813; AMINOACETIC ACID 1.5% IN PLASTIC CONTAINER; GLYCINE 1.5% IN PLASTIC CONTAINER; Glycine (JP15/USP); Glycine iron sulphate (1:1); Glycine, homopolymer (VAN); Glycine, labeled with carbon-14; Glycine, non-medical; Glycine-UL-14C hydrochloride; H-Gly-OH; H2N-CH2-COOH; L-alpha-amino acids; (1-13c)glycinato; (15N)Glycine; 2,2-dialkylglycines; 2-Aminoacetic acid DMIOZ29 TC Dietary supplement DMIOZ29 DT Small molecular drug DMIOZ29 PC 750 DMIOZ29 MW 75.07 DMIOZ29 FM C2H5NO2 DMIOZ29 IC InChI=1S/C2H5NO2/c3-1-2(4)5/h1,3H2,(H,4,5) DMIOZ29 CS C(C(=O)O)N DMIOZ29 IK DHMQDGOQFOQNFH-UHFFFAOYSA-N DMIOZ29 IU 2-aminoacetic acid DMIOZ29 CA CAS 56-40-6 DMIOZ29 CB CHEBI:15428 DMIOZ29 DE Malnutrition DM1WL9O ID DM1WL9O DM1WL9O DN Glycodiazine DM1WL9O HS Approved DM1WL9O SN GLYMIDINE; Glidiazine; Glycodiazin; Glymidinum; Glycodiazin [German]; Gondafon (TN); N-[5-(2-methoxyethoxy)pyrimidin-2-yl]benzenesulfonamide; N-(5-(2-Methoxyethoxy)-2-pyrimidinyl)benzenesulfonamide; N-(5-(2-Methoxyethoxy)-2-pyrimidinyl)benzenesulphonamide; N-(5-{[2-(methyloxy)ethyl]oxy}pyrimidin-2-yl)benzenesulfonamide; 2-Benzolsulfonamido-5-.beta.-methoxy-aethoxy-pyrimidine; 2-Benzolsulfonamido-5-beta-methoxy-aethoxy-pyrimidine; 2-Benzolsulfonamido-5-beta-methoxy-aethoxy-pyrimidine [German]; 5-beta-(Methoxyethoxy)-2-(phenylsulfonylamido)pyrimidine DM1WL9O TC Hypoglycemic Agents DM1WL9O DT Small molecular drug DM1WL9O PC 9565 DM1WL9O MW 309.34 DM1WL9O FM C13H15N3O4S DM1WL9O IC InChI=1S/C13H15N3O4S/c1-19-7-8-20-11-9-14-13(15-10-11)16-21(17,18)12-5-3-2-4-6-12/h2-6,9-10H,7-8H2,1H3,(H,14,15,16) DM1WL9O CS COCCOC1=CN=C(N=C1)NS(=O)(=O)C2=CC=CC=C2 DM1WL9O IK QFWPJPIVLCBXFJ-UHFFFAOYSA-N DM1WL9O IU N-[5-(2-methoxyethoxy)pyrimidin-2-yl]benzenesulfonamide DM1WL9O CA CAS 339-44-6 DM1WL9O CB CHEBI:146188 DM1WL9O DE Diabetic complication DM2M3ZA ID DM2M3ZA DM2M3ZA DN Glycopyrrolate DM2M3ZA HS Approved DM2M3ZA SN GLYCOPYRROLATE; 596-51-0; Glycopyrrolate bromide; Robinul; Gastrodyn; Tarodyl; Nodapton; Tarodyn; Asecryl; Copyrrolate; Cuvposa; Glycopyrronii bromidum; AHR-504; ROBINUL FORTE; Robinal; Robanul; Bromuro de glicopirronio; Bromure de glycopyrronium; NVA-237; AHR 504; Glycopyrronii bromidum [INN-Latin]; EINECS 209-887-0; Bromure de glycopyrronium [INN-French]; Bromuro de glicopirronio [INN-Spanish]; 3-Hydroxy-1,1-dimethylpyrrolidinium bromide DM2M3ZA CP Novartis DM2M3ZA TC Anticholinergic Agents DM2M3ZA DT Small molecular drug DM2M3ZA PC 11693 DM2M3ZA MW 398.3 DM2M3ZA FM C19H28BrNO3 DM2M3ZA IC InChI=1S/C19H28NO3.BrH/c1-20(2)13-12-17(14-20)23-18(21)19(22,16-10-6-7-11-16)15-8-4-3-5-9-15;/h3-5,8-9,16-17,22H,6-7,10-14H2,1-2H3;1H/q+1;/p-1 DM2M3ZA CS C[N+]1(CCC(C1)OC(=O)C(C2CCCC2)(C3=CC=CC=C3)O)C.[Br-] DM2M3ZA IK VPNYRYCIDCJBOM-UHFFFAOYSA-M DM2M3ZA IU (1,1-dimethylpyrrolidin-1-ium-3-yl) 2-cyclopentyl-2-hydroxy-2-phenylacetate;bromide DM2M3ZA CA CAS 596-51-0 DM2M3ZA CB CHEBI:90972 DM2M3ZA DE Anaesthesia; Chronic obstructive pulmonary disease DMGVJLB ID DMGVJLB DMGVJLB DN GMA-161 DMGVJLB HS Approved (orphan drug) DMGVJLB CP MacroGenics & Genzyme DMGVJLB DE Idiopathic thrombocytopenic purpura DMHZV7X ID DMHZV7X DMHZV7X DN Golimumab DMHZV7X HS Approved DMHZV7X SN Simponi (TN); Golimumab (USAN/INN) DMHZV7X CP Takeda DMHZV7X DT Antibody DMHZV7X DE Rheumatoid arthritis; Inflammatory bowel disease DMAQ469 ID DMAQ469 DMAQ469 DN Gonadorelin DMAQ469 HS Approved DMAQ469 SN Dirigestran; Factrel; Fertagyl; Gonadorelina; Gonadorelinum; Hypocrine; Kryptocur; LFRH; LHFSHRH; Luforan; Luliberin; Lutal; Lutamin; Lutrefact; Relefact; Relisorm; Dirigestran Spofa; Gonadoliberin I; Gonadotropin releasing hormone; LHFSH Releasing Hormone; LUTEINIZING HORMONE; Lutrepulse KIT; MammalianGnRH; Relisorm l; Synthetic LRF; Synthetic gonadoliberin; HOE 471; AY-24031; FSH-Releasing Hormone; Fertagyl (TN); GnRH-I; Gonadorelin (INN); Gonadorelin [INN:BAN]; Gonadorelina [INN-Spanish]; Gonadorelinum [INN-Latin]; Gonadotropin-releasing factor; Gonadotropin-releasing hormone; Gonadotropin-releasing hormone I; Human LH-RH; LH-FSH Releasing Hormone; LH-Releasing hormone; Luteinizing hormone-releasing hormone; Mammalian LH-RH; Mammalian gonadotropin-releasing hormone; Ovine LH-RH; Ovine gonadotropin-releasing hormone; Porchine LH-RH; Porcine LH-releasing factor; Synthetic Gn-RH; Synthetic LH-FSH releasing hormone; Synthetic LH-RF; Synthetic LH-RH; Synthetic LH-releasing factor; Synthetic LH-releasing hormone; Synthetic gonadotropic hormone-releasing hormone; Synthetic gonadotropin-releasing hormone; LH-RH (swine); LH-Releasing factor (pig); LH-Releasing hormone (porcine); Luteinizing hormone-releasing factor (human); Luteinizing hormone-releasing factor (pig); Luteinizing hormone-releasing factor (rat); Luteinizing hormone-releasing factor (sheep); Luteinizing hormone-releasing factor (swine); Luteinizing hormone-releasing hormone (swin); Synthetic LH-FSH-RH; Synthetic decapeptide FSH/LH-RH; Follicle-stimulating hormone-releasing factor (pig); Gonadotropin, luteinizing hormone-releasing hormone, synthetic; Synthetic LH-RH/FSH-RH; Synthetic LH-releasing hormone/FSH-releasing hormone; PyroGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2 DMAQ469 CP Hikma (Maple) Ltd DMAQ469 TC Fertility Agents DMAQ469 DT Small molecular drug DMAQ469 PC 638793 DMAQ469 MW 1182.3 DMAQ469 FM C55H75N17O13 DMAQ469 IC InChI=1S/C55H75N17O13/c1-29(2)19-38(49(80)67-37(9-5-17-60-55(57)58)54(85)72-18-6-10-43(72)53(84)62-25-44(56)75)66-46(77)26-63-47(78)39(20-30-11-13-33(74)14-12-30)68-52(83)42(27-73)71-50(81)40(21-31-23-61-35-8-4-3-7-34(31)35)69-51(82)41(22-32-24-59-28-64-32)70-48(79)36-15-16-45(76)65-36/h3-4,7-8,11-14,23-24,28-29,36-43,61,73-74H,5-6,9-10,15-22,25-27H2,1-2H3,(H2,56,75)(H,59,64)(H,62,84)(H,63,78)(H,65,76)(H,66,77)(H,67,80)(H,68,83)(H,69,82)(H,70,79)(H,71,81)(H4,57,58,60)/t36-,37-,38-,39-,40-,41-,42-,43-/m0/s1 DMAQ469 CS CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N)NC(=O)CNC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)[C@H](CC5=CN=CN5)NC(=O)[C@@H]6CCC(=O)N6 DMAQ469 IK XLXSAKCOAKORKW-AQJXLSMYSA-N DMAQ469 IU (2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[(2S)-2-[(2-amino-2-oxoethyl)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide DMAQ469 CA CAS 9034-40-6 DMAQ469 CB CHEBI:5520 DMAQ469 DE Hypothalamic hypogonadism DMAT8CG ID DMAT8CG DMAT8CG DN Goserelin DMAT8CG HS Approved DMAT8CG SN AstraZeneca (TN); HS-2015; ZD-9393; Zoladex (TN) DMAT8CG CP Zeneca Pharmaceuticals DMAT8CG TC Anticancer Agents DMAT8CG DT Small molecular drug DMAT8CG PC 5311128 DMAT8CG MW 1269.4 DMAT8CG FM C59H84N18O14 DMAT8CG IC InChI=1S/C59H84N18O14/c1-31(2)22-40(49(82)68-39(12-8-20-64-57(60)61)56(89)77-21-9-13-46(77)55(88)75-76-58(62)90)69-54(87)45(29-91-59(3,4)5)74-50(83)41(23-32-14-16-35(79)17-15-32)70-53(86)44(28-78)73-51(84)42(24-33-26-65-37-11-7-6-10-36(33)37)71-52(85)43(25-34-27-63-30-66-34)72-48(81)38-18-19-47(80)67-38/h6-7,10-11,14-17,26-27,30-31,38-46,65,78-79H,8-9,12-13,18-25,28-29H2,1-5H3,(H,63,66)(H,67,80)(H,68,82)(H,69,87)(H,70,86)(H,71,85)(H,72,81)(H,73,84)(H,74,83)(H,75,88)(H4,60,61,64)(H3,62,76,90)/t38-,39-,40-,41-,42-,43-,44-,45+,46-/m0/s1 DMAT8CG CS CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NNC(=O)N)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)[C@H](CC5=CN=CN5)NC(=O)[C@@H]6CCC(=O)N6 DMAT8CG IK BLCLNMBMMGCOAS-URPVMXJPSA-N DMAT8CG IU (2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[(carbamoylamino)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[(2-methylpropan-2-yl)oxy]-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide DMAT8CG CA CAS 65807-02-5 DMAT8CG CB CHEBI:5523 DMAT8CG DE Breast cancer DMPT74U ID DMPT74U DMPT74U DN Gramicidin D DMPT74U HS Approved DMPT74U SN Gramicidins; Gramoderm; Gramacidine S; Gramicidin C; Gramicidin Dubos; Gramicidin J; Gramicidin K; Gramicidin P; Gramicidin S; Gramicidin S [INN]; Gramicidina D; Gramicidina S; Gramicidinum S; Neosporin Ophthalmic Solution; Gramicin S 1; Gramacidine S [INN-French]; Gramicidin A(1); Gramicidin [INN:BAN]; Gramicidina S [INN-Spanish]; Gramicidina [INN-Spanish]; Gramicidine [INN-French]; Gramicidinum S [INN-Latin]; Gramicidinum [INN-Latin]; Gramicin S-A; Cyclo(L-valyl-L-ornithyl-L-leucyl-D-phenylalanyl-L-prolyl-L-valyl-L-ornithyl-L-leucyl-D-phenylalanyl-L-prolyl); 1,10-anhydro(L-leucyl-D-phenylalanyl-L-prolyl-L-valyl-L-ornithyl-L-leucyl-D-phenylalanyl-L-prolyl-L-valyl-L-ornithine) DMPT74U TC Antibiotics DMPT74U DT Small molecular drug DMPT74U PC 45267103 DMPT74U MW 1811.2 DMPT74U FM C96H135N19O16 DMPT74U IC InChI=1S/C96H135N19O16/c1-50(2)36-71(105-79(118)48-102-93(128)80(54(9)10)103-49-117)86(121)104-58(17)84(119)113-82(56(13)14)95(130)115-83(57(15)16)96(131)114-81(55(11)12)94(129)112-78(43-62-47-101-70-33-25-21-29-66(62)70)92(127)108-74(39-53(7)8)89(124)111-77(42-61-46-100-69-32-24-20-28-65(61)69)91(126)107-73(38-52(5)6)88(123)110-76(41-60-45-99-68-31-23-19-27-64(60)68)90(125)106-72(37-51(3)4)87(122)109-75(85(120)97-34-35-116)40-59-44-98-67-30-22-18-26-63(59)67/h18-33,44-47,49-58,71-78,80-83,98-101,116H,34-43,48H2,1-17H3,(H,97,120)(H,102,128)(H,103,117)(H,104,121)(H,105,118)(H,106,125)(H,107,126)(H,108,127)(H,109,122)(H,110,123)(H,111,124)(H,112,129)(H,113,119)(H,114,131)(H,115,130)/t58-,71+,72+,73+,74+,75-,76-,77-,78-,80-,81+,82+,83-/m0/s1 DMPT74U CS C[C@@H](C(=O)N[C@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CC5=CNC6=CC=CC=C65)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CC7=CNC8=CC=CC=C87)C(=O)NCCO)NC(=O)[C@@H](CC(C)C)NC(=O)CNC(=O)[C@H](C(C)C)NC=O DMPT74U IK NDAYQJDHGXTBJL-MWWSRJDJSA-N DMPT74U IU (2R)-2-[[2-[[(2S)-2-formamido-3-methylbutanoyl]amino]acetyl]amino]-N-[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-(2-hydroxyethylamino)-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]-4-methylpentanamide DMPT74U CA CAS 1405-97-6 DMPT74U DE Bacterial infection DMIUW25 ID DMIUW25 DMIUW25 DN Granisetron DMIUW25 HS Approved DMIUW25 SN BRL-43694; Kytril (TN); Granisetron (USAN/INN); 1-methyl-N-[(1S,5R)-9-methyl-9-azabicyclo[3.3.1]nonan-3-yl]indazole-3-carboxamide; 1-methyl-N-[(3-endo)-9-methyl-9-azabicyclo[3.3.1]non-3-yl]-1H-indazole-3-carboxamide DMIUW25 CP Roche Pharmaceuticals DMIUW25 TC Antiemetics DMIUW25 DT Small molecular drug DMIUW25 PC 5284566 DMIUW25 MW 312.4 DMIUW25 FM C18H24N4O DMIUW25 IC InChI=1S/C18H24N4O/c1-21-13-6-5-7-14(21)11-12(10-13)19-18(23)17-15-8-3-4-9-16(15)22(2)20-17/h3-4,8-9,12-14H,5-7,10-11H2,1-2H3,(H,19,23)/t12?,13-,14+ DMIUW25 CS CN1[C@@H]2CCC[C@H]1CC(C2)NC(=O)C3=NN(C4=CC=CC=C43)C DMIUW25 IK MFWNKCLOYSRHCJ-AGUYFDCRSA-N DMIUW25 IU 1-methyl-N-[(1R,5S)-9-methyl-9-azabicyclo[3.3.1]nonan-3-yl]indazole-3-carboxamide DMIUW25 CA CAS 109889-09-0 DMIUW25 CB CHEBI:5537 DMIUW25 DE Nausea and vomiting DMGLX0T ID DMGLX0T DMGLX0T DN Grepafloxacin DMGLX0T HS Approved DMGLX0T SN Raxar; Grepafloxacin [INN]; Grepafloxacin (unspecified); Raxar (TN); (+-)-1-Cyclopropyl-6-fluoro-1,4-dihydro-5-methyl-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid; 1-Cyclopropyl-6-fluoro-1,4-dihydro-5-methyl-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid; 1-cyclopropyl-6-fluoro-5-methyl-7-(3-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid DMGLX0T CP GlaxoSmithKline DMGLX0T TC Antibiotics DMGLX0T DT Small molecular drug DMGLX0T PC 72474 DMGLX0T MW 359.4 DMGLX0T FM C19H22FN3O3 DMGLX0T IC InChI=1S/C19H22FN3O3/c1-10-8-22(6-5-21-10)15-7-14-16(11(2)17(15)20)18(24)13(19(25)26)9-23(14)12-3-4-12/h7,9-10,12,21H,3-6,8H2,1-2H3,(H,25,26) DMGLX0T CS CC1CN(CCN1)C2=C(C(=C3C(=C2)N(C=C(C3=O)C(=O)O)C4CC4)C)F DMGLX0T IK AIJTTZAVMXIJGM-UHFFFAOYSA-N DMGLX0T IU 1-cyclopropyl-6-fluoro-5-methyl-7-(3-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid DMGLX0T CA CAS 119914-60-2 DMGLX0T CB CHEBI:5543 DMGLX0T DE Chronic bronchitis; Bacterial infection DMK54YG ID DMK54YG DMK54YG DN Griseofulvin DMK54YG HS Approved DMK54YG SN Amudane; Delmofulvina; Fulcin; Fulcine; Fulvicin; FulvicinUF; Fulvina; Fulvinil; Fulvistatin; Fungivin; Greosin;Gresfeed; Gricin; Grifulin; Grifulvin; GrisPEG; Grisactin; Griscofulvin; Grisefuline; Griseo; Griseofulvina; Griseofulvine; Griseofulvinum; Griseomix; Griseostatin; Grisetin; Grisofulvin; Grisovin; Grizeofulvin; Grysio; Guservin; Lamoryl; Likuden; Likunden; Murfulvin; Poncyl; Spirofulvin; Sporostatin; Xuanjing; Curling fact or; Curling factor; Fulvican grisactin; Fulvicin U F; Grifulvin V; Gris PEG; Grisactin Ultra; Grise ostatin; Griseofulvin forte; Grisovin FP; Interacts with polymerized microtubules and associated proteins; Sporostatin xan; Biogrisin-FP; FULVICIN P/G 165; FULVICIN P/G 330;Fulvicin Bolus (Veterinary); Fulvicin P/G; Fulvicin U/F; Fulvidex (Veterinary); GRISEOFULVIN, MICROCRYSTALLINE; GRISEOFULVIN, ULTRAMICROCRYSTALLINE; Gris-PEG; Griseofulvin and Alpha-IFN; Griseofulvin-forte; Griseofulvina [INN-Spanish]; Griseofulvine [INN-French]; Griseofulvinum [INN-Latin]; Grisovin (TN); NP-002466; Neo-Fulcin; ULTRAGRIS-165; ULTRAGRIS-330; USAF SC-2; Fulvicin-P/G; Fulvicin-U-F; Fulvicin-U/F; Fulvicin-U/F (Veterinary); Griseofulvin [USAN:INN:BAN:JAN]; (+)-Griseofulvin; 7-Chloro-4,6,2'-trimethoxy-6'-methylgris-2'-en-3,4'-dione DMK54YG TC Antifungal Agents DMK54YG DT Small molecular drug DMK54YG PC 441140 DMK54YG MW 352.8 DMK54YG FM C17H17ClO6 DMK54YG IC InChI=1S/C17H17ClO6/c1-8-5-9(19)6-12(23-4)17(8)16(20)13-10(21-2)7-11(22-3)14(18)15(13)24-17/h6-8H,5H2,1-4H3/t8-,17+/m1/s1 DMK54YG CS C[C@@H]1CC(=O)C=C([C@]12C(=O)C3=C(O2)C(=C(C=C3OC)OC)Cl)OC DMK54YG IK DDUHZTYCFQRHIY-RBHXEPJQSA-N DMK54YG IU (2S,5'R)-7-chloro-3',4,6-trimethoxy-5'-methylspiro[1-benzofuran-2,4'-cyclohex-2-ene]-1',3-dione DMK54YG CA CAS 126-07-8 DMK54YG CB CHEBI:27779 DMK54YG DE Ringworm infection DM1ECNJ ID DM1ECNJ DM1ECNJ DN GS-7340 DM1ECNJ HS Approved DM1ECNJ SN Tenofovir alafenamide; Vemlidy DM1ECNJ CP Gilead Sciences DM1ECNJ DT Small molecular drug DM1ECNJ PC 9574768 DM1ECNJ MW 476.5 DM1ECNJ FM C21H29N6O5P DM1ECNJ IC InChI=1S/C21H29N6O5P/c1-14(2)31-21(28)16(4)26-33(29,32-17-8-6-5-7-9-17)13-30-15(3)10-27-12-25-18-19(22)23-11-24-20(18)27/h5-9,11-12,14-16H,10,13H2,1-4H3,(H,26,29)(H2,22,23,24)/t15-,16+,33+/m1/s1 DM1ECNJ CS C[C@H](CN1C=NC2=C(N=CN=C21)N)OC[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3 DM1ECNJ IK LDEKQSIMHVQZJK-CAQYMETFSA-N DM1ECNJ IU propan-2-yl (2S)-2-[[[(2R)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethyl-phenoxyphosphoryl]amino]propanoate DM1ECNJ CA CAS 379270-37-8 DM1ECNJ CB CHEBI:90926 DM1ECNJ DE Human immunodeficiency virus infection; Hepatitis B virus infection DM8QB0T ID DM8QB0T DM8QB0T DN GSK2592984A DM8QB0T HS Approved DM8QB0T SN GSK-2340269A; GSK-2340272A; Pandemrix (H1N1); H1N1 pandemic influenzavaccine (AS03 adjuvanted) 1, GlaxoSmithKline; H1N1 pandemic influenza vaccine 1 (AS03 adjuvanted), GSK; Influenza vaccines (intramuscular, influenza virus infection), GlaxoSmithKline DM8QB0T CP GlaxoSmithKline plc DM8QB0T DT Vaccine DM8QB0T DE Influenza virus infection DM5QWEL ID DM5QWEL DM5QWEL DN Guanabenz DM5QWEL HS Approved DM5QWEL SN GBZ; Guanabenzo; Guanabenzum; Wytensin; Guanabenz acetate; Guanabenz monoacetate; Wy 8678; Wy 8678 base; BR-750; Guanabenz [USAN:INN]; Guanabenz(USAN); Guanabenzo [INN-Spanish]; Guanabenzum [INN-Latin]; Wy-8678; Wytensin (TN); Guanabenz (USAN/INN); [(2,6-Dichlorobenzylidene)amino]guanidine; N-((2,6-Dichlorobenzylidene)amino)guanidine; Guanidine, ((2,6-dichlorobenzylidene)amino)-(8CI); N-(2,6-Dichlorobenzylidene)-N'-amidinohydrazine; ((2,6-Dichlorobenzylidene)amino)guanidine; 2,6-Dichlorobenzylideneaminoguanidine;2-((2,6-Dichlorophenyl)methylene)-hydrazinecarboximidamide; 2-[(E)-(2,6-dichlorophenyl)methylideneamino]guanidine DM5QWEL CP Eon Labs Manufacturing DM5QWEL TC Sympatholytics DM5QWEL DT Small molecular drug DM5QWEL PC 5702063 DM5QWEL MW 231.08 DM5QWEL FM C8H8Cl2N4 DM5QWEL IC InChI=1S/C8H8Cl2N4/c9-6-2-1-3-7(10)5(6)4-13-14-8(11)12/h1-4H,(H4,11,12,14)/b13-4+ DM5QWEL CS C1=CC(=C(C(=C1)Cl)/C=N/N=C(N)N)Cl DM5QWEL IK WDZVGELJXXEGPV-YIXHJXPBSA-N DM5QWEL IU 2-[(E)-(2,6-dichlorophenyl)methylideneamino]guanidine DM5QWEL CA CAS 60329-03-5 DM5QWEL CB CHEBI:5553 DM5QWEL DE High blood pressure DM6S157 ID DM6S157 DM6S157 DN Guanadrel Sulfate DM6S157 HS Approved DM6S157 SN Hylorel; Hyloride; Guanadrel sulfate [USAN]; CL 1388R; U 28288D; CL-1388R; Guanadrel sulfate (USP); Hylorel (TN); U 28,288D; U-28288D; Guanadrel sulfate (2:1); Guanidine (1,4-dioxaspiro(4.5)dec-2-ylmethyl)-, sulfate (2:1); (1,4-Dioxaspiro(4.5)dec-2-ylmethyl)guanidine sulfate (2:1); 2-(1,4-dioxaspiro[4.5]decan-3-ylmethyl)guanidine DM6S157 TC Antihypertensive Agents DM6S157 DT Small molecular drug DM6S157 PC 68552 DM6S157 MW 524.6 DM6S157 FM C20H40N6O8S DM6S157 IC InChI=1S/2C10H19N3O2.H2O4S/c2*11-9(12)13-6-8-7-14-10(15-8)4-2-1-3-5-10;1-5(2,3)4/h2*8H,1-7H2,(H4,11,12,13);(H2,1,2,3,4) DM6S157 CS C1CCC2(CC1)OCC(O2)CN=C(N)N.C1CCC2(CC1)OCC(O2)CN=C(N)N.OS(=O)(=O)O DM6S157 IK RTEVGQJRTFFMLL-UHFFFAOYSA-N DM6S157 IU 2-(1,4-dioxaspiro[4.5]decan-3-ylmethyl)guanidine;sulfuric acid DM6S157 CA CAS 22195-34-2 DM6S157 CB CHEBI:5556 DM6S157 DE Hypertension DM9NSWT ID DM9NSWT DM9NSWT DN Guanethidine DM9NSWT HS Approved DM9NSWT SN Abapresin; Dopam; Dopom; Eutensol; Guanethidinum; Guanetidina; Ismelin; Isobarin; Octadin; Octadine; Octatensin; Octatensine; Oktadin; Oktatensin; Oktatenzin; Sanotensin; Guanethidine Sulphae; Guanethidine sulfate; Ismelin sulfate; Apo-Guanethidine; Guanethidine (INN); Guanethidine [INN:BAN]; Guanethidinum [INN-Latin]; Guanetidina [INN-Spanish]; Apo-Guanethidine (TN); Beta-1-Azacyclooctylethylguanidine; Guanethidine Sulfate (1:1); Guanethidine Sulfate (2:1); Su 5864 sulfate (1:1); N-(2-Perhydroazocin-1-ylethyl)guanidine; ((2-Hexahydro-1(2H)-azocinyl)ethyl)guanidine; (2-(Octahydro-1-azocinyl)ethyl)guanidine; 1-(2-azocan-1-ylethyl)guanidine; 1-[2-(azocan-1-yl)ethyl]guanidine; 2-(1'-Azacyclooctyl)ethylguanidine; 2-(1-N,N-Heptamethyleneimino)ethylguanidine; 2-[2-(azocan-1-yl)ethyl]guanidine DM9NSWT CP Norvatis Phamaceuticals Corporation DM9NSWT TC Antihypertensive Agents DM9NSWT DT Small molecular drug DM9NSWT PC 3518 DM9NSWT MW 198.31 DM9NSWT FM C10H22N4 DM9NSWT IC InChI=1S/C10H22N4/c11-10(12)13-6-9-14-7-4-2-1-3-5-8-14/h1-9H2,(H4,11,12,13) DM9NSWT CS C1CCCN(CCC1)CCN=C(N)N DM9NSWT IK ACGDKVXYNVEAGU-UHFFFAOYSA-N DM9NSWT IU 2-[2-(azocan-1-yl)ethyl]guanidine DM9NSWT CA CAS 55-65-2 DM9NSWT CB CHEBI:5557 DM9NSWT DE Moderate and severe hypertension DMB1CZ8 ID DMB1CZ8 DMB1CZ8 DN Guanfacine extended release DMB1CZ8 HS Approved DMB1CZ8 SN Palmitoylethanolamide; Palmidrol; 544-31-0; N-(2-Hydroxyethyl)hexadecanamide; Impulsin; Palmitamide MEA; Hydroxyethylpalmitamide; N-palmitoylethanolamine; N-(2-Hydroxyethyl)palmitamide; Palmitic acid monoethanolamide; Palmitoyl-EA; Loramine P 256; Palmitoyl ethanolamide; Palmidrolum; palmitylethanolamide; HEXADECANAMIDE, N-(2-HYDROXYETHYL)-; Palmidrol [INN]; Palmidrolum [INN-Latin]; UNII-6R8T1UDM3V; Palmitinsaeure-beta-hydroxyethylamid; Monoethanolamine palmitic acid amide; NSC 23320; hexadecanoyl ethanolamide; Anandamide (16:0) DMB1CZ8 CP Shire DMB1CZ8 DT Small molecular drug DMB1CZ8 PC 4671 DMB1CZ8 MW 299.5 DMB1CZ8 FM C18H37NO2 DMB1CZ8 IC InChI=1S/C18H37NO2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-18(21)19-16-17-20/h20H,2-17H2,1H3,(H,19,21) DMB1CZ8 CS CCCCCCCCCCCCCCCC(=O)NCCO DMB1CZ8 IK HXYVTAGFYLMHSO-UHFFFAOYSA-N DMB1CZ8 IU N-(2-hydroxyethyl)hexadecanamide DMB1CZ8 CA CAS 544-31-0 DMB1CZ8 CB CHEBI:71464 DMB1CZ8 DE Attention deficit hyperactivity disorder DM0P63W ID DM0P63W DM0P63W DN Guanidine Hydrochloride DM0P63W HS Approved DM0P63W SN Guanidine hydrochloride; 1950/1/1; Guanidinium chloride; Guanidine, monohydrochloride; guanidine HCl; Aminoformamidine hydrochloride; Aminomethanamidine hydrochloride; GUANIDINE MONOHYDROCHLORIDE; Guanidine chloride; Iminourea hydrochloride; Carbamidine hydrochloride; Guanidinium hydrochloride; Guanidine (hydrochloride); UNII-3YQC9ZY4YB; Guanidium chloride; USAF EK-749; Guanidine, hydrochloride (1:1); EINECS 200-002-3; 3YQC9ZY4YB; AI3-19014; MFCD00013026; Guanidine Hydrochloride, ULTROL& Grade; Guanidinehydrochloride DM0P63W CP Merck Sharp And Dohme Corp DM0P63W TC Neurology Agents DM0P63W DT Small molecular drug DM0P63W PC 5742 DM0P63W MW 95.53 DM0P63W FM CH6ClN3 DM0P63W IC InChI=1S/CH5N3.ClH/c2-1(3)4;/h(H5,2,3,4);1H DM0P63W CS C(=N)(N)N.Cl DM0P63W IK PJJJBBJSCAKJQF-UHFFFAOYSA-N DM0P63W IU guanidine;hydrochloride DM0P63W CA CAS 50-01-1 DM0P63W CB CHEBI:32735 DM0P63W DE Muscle fatigue DMP7LK1 ID DMP7LK1 DMP7LK1 DN Guggulsterone DMP7LK1 HS Approved DMP7LK1 SN Guggulsterone E; (E)-Guggulsterone; E-Guggulsterone; Guggulsterones E; trans-Guggulsterone; 39025-24-6; Pregna-4,17-diene-3,16-dione; UNII-9B259YE66O; (17E)-Pregna-4,17(20)-diene-3,16-dione; Z-Guggulsterone; CHEMBL402063; 95975-55-6; 9B259YE66O; (8R,9S,10R,13S,14S,17E)-17-ethylidene-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15-decahydrocyclopenta[a]phenanthrene-3,16-dione; E-Guggulsteron; Pregna-4,17(20)-diene-3,16-dione; Guggulsterone, (E)-; Guglip; Z/E-Guggulsterone; Pregna-4,17(20)-diene-3,16-dione, (17E)-; Guggulsterone E; Guggulsterones Z; Cis-Guggulsterone; Trans-Guggulsterone; (17E)-pregna-4,17-diene-3,16-dione; (17Z)-Pregna-4,17(20)-diene-3,16-dione; (17Z)-pregna-4,17-diene-3,16-dione; (8R,9S,10R,13S,14S,17Z)-17-ethylidene-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15-decahydrocyclopenta[a]phenanthrene-3,16-dione; (Z)-Guggulsterone; 4,17(20)-cis-Pregnadiene-3,16-dione; E-GUGGULSTERONE DMP7LK1 TC Antiinflammatory Agents DMP7LK1 DT Small molecular drug DMP7LK1 PC 6450278 DMP7LK1 MW 312.4 DMP7LK1 FM C21H28O2 DMP7LK1 IC InChI=1S/C21H28O2/c1-4-16-19(23)12-18-15-6-5-13-11-14(22)7-9-20(13,2)17(15)8-10-21(16,18)3/h4,11,15,17-18H,5-10,12H2,1-3H3/b16-4+/t15-,17+,18+,20+,21-/m1/s1 DMP7LK1 CS C/C=C/1\\C(=O)C[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C DMP7LK1 IK WDXRGPWQVHZTQJ-OSJVMJFVSA-N DMP7LK1 IU (8R,9S,10R,13S,14S,17Z)-17-ethylidene-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15-decahydrocyclopenta[a]phenanthrene-3,16-dione DMP7LK1 CA CAS 39025-23-5 DMP7LK1 CB CHEBI:135338 DMP7LK1 DE Osteoarthritis DMV4KOA ID DMV4KOA DMV4KOA DN GW642444 DMV4KOA HS Approved DMV4KOA SN Fumagillinum; Fumagilline; Fumagilina; Fumidil; Fugillin; UNII-7OW73204U1; Amebacillin; Fugilin; CHEMBL32838; Fumagillin DCH; CHEBI:48635; Fumagillina [DCIT]; 7OW73204U1; Fumagillinum [INN-Latin]; Fumagilline [INN-French]; Fumagilina [INN-Spanish]; DSSTox_RID_79580; DSSTox_CID_20736; DSSTox_GSID_40736; Fumagillin [INN:BAN:DCF]; 2,4,6,8-Decatetraenedioic acid, 4-(1,2-epoxy-1,5-dimethyl-4-hexenyl)-5-methoxy-1-oxaspiro(2,5)oct-6-yl ester DMV4KOA CP GSK DMV4KOA DT Small molecular drug DMV4KOA PC 21880659 DMV4KOA MW 486.4 DMV4KOA FM C24H33Cl2NO5 DMV4KOA IC InChI=1S/C24H33Cl2NO5/c25-21-6-5-7-22(26)20(21)17-32-13-12-31-11-4-2-1-3-10-27-15-24(30)18-8-9-23(29)19(14-18)16-28/h5-9,14,24,27-30H,1-4,10-13,15-17H2 DMV4KOA CS C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl DMV4KOA IK DAFYYTQWSAWIGS-UHFFFAOYSA-N DMV4KOA IU 4-[2-[6-[2-[(2,6-dichlorophenyl)methoxy]ethoxy]hexylamino]-1-hydroxyethyl]-2-(hydroxymethyl)phenol DMV4KOA DE Asthma DML72VJ ID DML72VJ DML72VJ DN GW685698X DML72VJ HS Approved DML72VJ SN Allermist; Avamys; Veramyst; Fluticasone furoate; GW 685698X; GW6; GW-685698; GW-685698X; Veramyst (TN); Fluticasone furoate (JAN/USAN/INN); (6alpha,11beta,16alpha,17alpha)-6,9-Difluoro-17-(((fluoromethyl)thio)carbonyl)-11-hydroxy-16-methyl-3-oxoandrosta-1,4-dien-17-yl-2-furancarboxylate; 6alpha,9-Difluoro-17-(((fluoromethyl)sulfanyl)carbonyl)-11beta-hydroxy-16alpha-methyl-3-oxoandrosta-1,4-dien-17alpha-yl furan-2-carboxylate DML72VJ CP GSK DML72VJ DT Small molecular drug DML72VJ PC 9854489 DML72VJ MW 538.6 DML72VJ FM C27H29F3O6S DML72VJ IC InChI=1S/C27H29F3O6S/c1-14-9-16-17-11-19(29)18-10-15(31)6-7-24(18,2)26(17,30)21(32)12-25(16,3)27(14,23(34)37-13-28)36-22(33)20-5-4-8-35-20/h4-8,10,14,16-17,19,21,32H,9,11-13H2,1-3H3/t14-,16+,17+,19+,21+,24+,25+,26+,27+/m1/s1 DML72VJ CS C[C@@H]1C[C@H]2[C@@H]3C[C@@H](C4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)SCF)OC(=O)C5=CC=CO5)C)O)F)C)F DML72VJ IK XTULMSXFIHGYFS-VLSRWLAYSA-N DML72VJ IU [(6S,8S,9R,10S,11S,13S,14S,16R,17R)-6,9-difluoro-17-(fluoromethylsulfanylcarbonyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] furan-2-carboxylate DML72VJ CA CAS 397864-44-7 DML72VJ CB CHEBI:74899 DML72VJ DE Asthma DMFUAXT ID DMFUAXT DMFUAXT DN H1N1 pandemic influenza A vaccine DMFUAXT HS Approved DMFUAXT SN Panflu; H1N1 pandemic influenza A vaccine, Sinovac; Panflu.1; Split viron vaccine (H1N1 influenza), Sinovac; Split viron vaccine + adjuvant (H1N1 influenza), Sinovac; Whole viron vaccine + adjuvant (H1N1 influenza), Sinovac DMFUAXT CP Sinovac Biotech Ltd DMFUAXT DT Vaccine DMFUAXT DE Influenza virus infection DMMHYLB ID DMMHYLB DMMHYLB DN H5N1 influenza vaccine DMMHYLB HS Approved DMMHYLB SN IPSIV; Inactivated Polymer-Subunit H5N1 Influenza Vaccine; H5N1 influenza vaccine (protein subunit, Polyoxidonium adjuvant); H5N1 influenza vaccine (protein subunit, Polyoxidonium adjuvant), Microgen DMMHYLB CP Glaxosmithkline; novavax; vaxart DMMHYLB DT Vaccine DMMHYLB DE Human immunodeficiency virus infection DM7JNTV ID DM7JNTV DM7JNTV DN Halaven DM7JNTV HS Approved DM7JNTV SN Eribulin mesylate; Eribulin (mesylate); Eribulin mesilate; UNII-AV9U0660CW; Eribulin mesylate [USAN]; 441045-17-6; AV9U0660CW; CHEBI:70710; E 7389; E7389; Eribulin mesylate (USAN); B-1939; NSC-707389; Eribulin mesilate (JAN); CHEMBL1683544; QAMYWGZHLCQOOJ-WRNBYXCMSA-N; HY-13442A; AKOS030238218; CS-2803; D08914; 2-(3-amino-2-hydroxypropyl)hexacosahydro-3-methoxy-26-methyl-20,27-bis(methylene)11,15-18,21-24,28-triepoxy-7,9-ethano-12,15-methano-9H,15H-furo(3,2-i)furo(2',3'-5,6)pyrano(4,3-b)(1,4)dioxacyclopent DM7JNTV CP Eisai Woodcliff Lake, NJ DM7JNTV PC 17755248 DM7JNTV MW 826 DM7JNTV FM C41H63NO14S DM7JNTV IC InChI=1S/C40H59NO11.CH4O3S/c1-19-11-24-5-7-28-20(2)12-26(45-28)9-10-40-17-33-36(51-40)37-38(50-33)39(52-40)35-29(49-37)8-6-25(47-35)13-22(42)14-27-31(16-30(46-24)21(19)3)48-32(34(27)44-4)15-23(43)18-41;1-5(2,3)4/h19,23-39,43H,2-3,5-18,41H2,1,4H3;1H3,(H,2,3,4)/t19-,23+,24+,25-,26+,27+,28+,29+,30-,31+,32-,33-,34-,35+,36+,37+,38-,39+,40+;/m1./s1 DM7JNTV CS C[C@@H]1C[C@@H]2CC[C@H]3C(=C)C[C@@H](O3)CC[C@]45C[C@@H]6[C@H](O4)[C@H]7[C@@H](O6)[C@@H](O5)[C@@H]8[C@@H](O7)CC[C@@H](O8)CC(=O)C[C@H]9[C@H](C[C@H](C1=C)O2)O[C@@H]([C@@H]9OC)C[C@@H](CN)O.CS(=O)(=O)O DM7JNTV IK QAMYWGZHLCQOOJ-WRNBYXCMSA-N DM7JNTV IU (1S,3S,6S,9S,12S,14R,16R,18S,20R,21R,22S,26R,29S,31R,32S,33R,35R,36S)-20-[(2S)-3-amino-2-hydroxypropyl]-21-methoxy-14-methyl-8,15-dimethylidene-2,19,30,34,37,39,40,41-octaoxanonacyclo[24.9.2.13,32.13,33.16,9.112,16.018,22.029,36.031,35]hentetracontan-24-one;methanesulfonic acid DM7JNTV CA CAS 441045-17-6 DM7JNTV CB CHEBI:70710 DM7JNTV DE Bladder cancer; Breast cancer DMPFWO6 ID DMPFWO6 DMPFWO6 DN Halazepam DMPFWO6 HS Approved DMPFWO6 SN Halazepamum; Pacinone; Paxipam; Sch 12041; Schering 12041; Alapryl (TN); Halazepamum [INN-Latin]; Pacinone (TN); Paxipam (TN); Sch-12041; Halazepam (USAN/INN); Halazepam [USAN:BAN:INN]; 7-Chloro-1,3-dihydro-5-phenyl-1-(2,2,2-trifluoroethyl)-2H-1,4-benzodiazepin-2-one; 7-Chloro-5-phenyl-1-(2,2,2-trifluoroethyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one; 7-chloro-5-phenyl-1-(2,2,2-trifluoroethyl)-3H-1,4-benzodiazepin-2-one; 7=Chlor-5-phenyl-1-(2,2,2-trifluorethyl)-1H-1,4-benzodiazepin-2(3H)-on DMPFWO6 TC Antianxiety Agents DMPFWO6 DT Small molecular drug DMPFWO6 PC 31640 DMPFWO6 MW 352.7 DMPFWO6 FM C17H12ClF3N2O DMPFWO6 IC InChI=1S/C17H12ClF3N2O/c18-12-6-7-14-13(8-12)16(11-4-2-1-3-5-11)22-9-15(24)23(14)10-17(19,20)21/h1-8H,9-10H2 DMPFWO6 CS C1C(=O)N(C2=C(C=C(C=C2)Cl)C(=N1)C3=CC=CC=C3)CC(F)(F)F DMPFWO6 IK WYCLKVQLVUQKNZ-UHFFFAOYSA-N DMPFWO6 IU 7-chloro-5-phenyl-1-(2,2,2-trifluoroethyl)-3H-1,4-benzodiazepin-2-one DMPFWO6 CA CAS 23092-17-3 DMPFWO6 CB CHEBI:5603 DMPFWO6 DE Anxiety disorder DMGLAX1 ID DMGLAX1 DMGLAX1 DN Halcinonide DMGLAX1 HS Approved DMGLAX1 SN Halog; Halog-e DMGLAX1 CP Ranbaxy Laboratories Inc DMGLAX1 DT Small molecular drug DMGLAX1 PC 443943 DMGLAX1 MW 455 DMGLAX1 FM C24H32ClFO5 DMGLAX1 IC InChI=1S/C24H32ClFO5/c1-20(2)30-19-10-16-15-6-5-13-9-14(27)7-8-21(13,3)23(15,26)17(28)11-22(16,4)24(19,31-20)18(29)12-25/h9,15-17,19,28H,5-8,10-12H2,1-4H3/t15-,16-,17-,19+,21-,22-,23-,24+/m0/s1 DMGLAX1 CS C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@]2([C@H](C[C@]4([C@H]3C[C@@H]5[C@]4(OC(O5)(C)C)C(=O)CCl)C)O)F DMGLAX1 IK MUQNGPZZQDCDFT-JNQJZLCISA-N DMGLAX1 IU (1S,2S,4R,8S,9S,11S,12R,13S)-8-(2-chloroacetyl)-12-fluoro-11-hydroxy-6,6,9,13-tetramethyl-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icos-17-en-16-one DMGLAX1 CA CAS 3093-35-4 DMGLAX1 CB CHEBI:31663 DMGLAX1 DE Skin disease DM3GB6S ID DM3GB6S DM3GB6S DN Halobetasol propionate DM3GB6S HS Approved DM3GB6S SN Halobetasol; Miracorten; Ultravate; Halobetasol propionate [USAN]; Ulobetasol cream; Ulobetasol propionate; BMY 30056; CGP 14 458; CGP 14458; BMY-30056; CGP-14458; Halobetasol propionate (USAN); Ultravate (TN); [(6S,9R,16S,17R)-17-(2-chloroacetyl)-6,9-difluoro-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] propanoate; [(6S,8S,9R,10S,11S,13S,14S,16S,17R)-17-(2-chloroacetyl)-6,9-difluoro-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] propanoate; 21-Chloro-6alpha,9-difluoro-11beta,17-dihydroxy-16beta-methylpregna-1,4-diene-3,20-dione 17-propionate; 6 alpha-fluoroclobetasol 17-propionate; 6-fluoroclobetasol 17-propionate DM3GB6S TC Antiinflammatory Agents DM3GB6S DT Small molecular drug DM3GB6S PC 6918178 DM3GB6S MW 485 DM3GB6S FM C25H31ClF2O5 DM3GB6S IC InChI=1S/C25H31ClF2O5/c1-5-21(32)33-25(20(31)12-26)13(2)8-15-16-10-18(27)17-9-14(29)6-7-22(17,3)24(16,28)19(30)11-23(15,25)4/h6-7,9,13,15-16,18-19,30H,5,8,10-12H2,1-4H3/t13-,15-,16-,18-,19-,22-,23-,24-,25-/m0/s1 DM3GB6S CS CCC(=O)O[C@@]1([C@H](C[C@@H]2[C@@]1(C[C@@H]([C@]3([C@H]2C[C@@H](C4=CC(=O)C=C[C@@]43C)F)F)O)C)C)C(=O)CCl DM3GB6S IK BDSYKGHYMJNPAB-LICBFIPMSA-N DM3GB6S IU [(6S,8S,9R,10S,11S,13S,14S,16S,17R)-17-(2-chloroacetyl)-6,9-difluoro-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] propanoate DM3GB6S CA CAS 66852-54-8 DM3GB6S CB CHEBI:135782 DM3GB6S DE Inflammation DMOMK1V ID DMOMK1V DMOMK1V DN Halofantrine DMOMK1V HS Approved DMOMK1V SN Halfan; Halofantrino; HALOFANTRINE HYDROCHLORIDE; Halofantrine HCl; Halofantrine Hydrochloride [USAN]; Halofantrine [USAN]; Halofantrino [Spanish]; WR 171669; Dl-WR 171669; Halfan (TN); Halofantrine hydrochloride (USAN); WR 171,699; WR-171669; WR-171699; SK&F-102866; WR-171,669; (+-)-Halofantrine hydrochloride; (1)-Halofantrine; 1,3-Dichloro-.alpha.-[2-(dibutylamino)ethyl]-6-(trifluoromethyl)-9-phenanthrene-methanol; 1,3-Dichloro-.alpha.-[2-(dibutylamino)ethyl]-6-(trifluoromethyl)-9-phenathrenemethanol; 1,3-Dichloro-6-trifluoromethyl-9-(3-(dibutylamino)-1-hydroxypropyl)phenanthrene HCl; 1,3-Dichloro-alpha-(2-(dibutylamino)ethyl)-6-(trifluoromethyl)-9-phenanthrenemethanol hydrochloride; 1,3-Dichloro-alpha-(2-(dibutylamino)ethyl)-6-(trifluoromethyl)phenanthren-1-methanol hydrochloride; 1-(1,3-Dichloro-6-trifluoromethyl-9-phenanthryl)-3-(di-n-butylamino)propanol hydrochloride; 1-(1,3-dichloro-6-trifluoromethyl-9-phenanthryl)-3-di(n-butyl)aminopropanol HCl; 3-(Dibutylamino)-1-(1,3-dichloro-6-(trifluoromethyl)phenanthren-9-yl)propan-1-ol hydrochloride; 3-(dibutylamino)-1-[1,3-dichloro-6-(trifluoromethyl)phenanthren-9-yl]propan-1-ol; 3-(dibutylamino)-1-[1,3-dichloro-6-(trifluoromethyl)phenanthren-9-yl]propan-1-ol hydrochloride; 9-(3-(dibutylamino)-1-hydroxypropyl)-1,3-dichloro-6-(trifluoromethyl)phenanthrene hydrochloride; 9-Phenanthrenemethanol, 1,3-dichloro-.alpha.-[2-(dibutylamino)ethyl]-6-(trifluoromethyl)-(1); 9-Phenanthrenemethanol, 1,3-dichloro-alpha-(2-(dibutylamino)ethyl)-6-(trifluoromethyl)-, hydrochloride; 9-Phenanthrenemethanol, 1,3-dichloro-alpha-(2-(dibutylamino)ethyl)-6-(trifluoromethyl)-,hydrochloride DMOMK1V CP GlaxoSmithKline DMOMK1V TC Antimalarials DMOMK1V DT Small molecular drug DMOMK1V PC 37393 DMOMK1V MW 500.4 DMOMK1V FM C26H30Cl2F3NO DMOMK1V IC InChI=1S/C26H30Cl2F3NO/c1-3-5-10-32(11-6-4-2)12-9-25(33)23-16-22-21(14-18(27)15-24(22)28)20-13-17(26(29,30)31)7-8-19(20)23/h7-8,13-16,25,33H,3-6,9-12H2,1-2H3 DMOMK1V CS CCCCN(CCCC)CCC(C1=C2C=CC(=CC2=C3C=C(C=C(C3=C1)Cl)Cl)C(F)(F)F)O DMOMK1V IK FOHHNHSLJDZUGQ-UHFFFAOYSA-N DMOMK1V IU 3-(dibutylamino)-1-[1,3-dichloro-6-(trifluoromethyl)phenanthren-9-yl]propan-1-ol DMOMK1V CA CAS 69756-53-2 DMOMK1V CB CHEBI:94392 DMOMK1V DE Malaria DM96SE0 ID DM96SE0 DM96SE0 DN Haloperidol DM96SE0 HS Approved DM96SE0 SN Aldo; Aloperidin; Aloperidol; Aloperidolo; Aloperidon; Bioperidolo; Brotopon; Dozic; Dozix; Eukystol; Fortunan; Galoperidol; Haldol; Halidol; Halojust; Halol; Halopal; Haloperido; Haloperidolum; Halopidol; Halopoidol; Halosten; Keselan; Linton; Mixidol; Pekuces; Peluces; Peridol; Pernox; Serenace; Serenase; Serenelfi; Sernas; Sernel; Sigaperidol; Ulcolind; Uliolind; Vesalium; Aloperidolo [DCIT]; Aloperidolo [Italian]; Einalon S; Haldol La; Haldol Solutab; Lealgin compositum; Pms Haloperidol; H 1512; R 1625; Aloperidin (TN); Apo-Haloperidol; Bioperidolo (TN); Brotopon (TN); Dozic (TN); Duraperidol (TN); Einalon S (TN); Eukystol (TN); Haldol (TN); Haloperidolum [INN-Latin]; Halosten (TN); Keselan (TN); Linton (TN);Novo-Peridol; Peluces (TN); R-1625; Serenace (TN); Serenase (TN); Sigaperidol (TN); Haloperidol (JP15/USP); McN-JR-1625; Haloperidol (JP15/USP/INN); Haloperidol [USAN:INN:BAN:JAN] DM96SE0 CP Janssen Pharmaceutica DM96SE0 TC Antipsychotic Agents DM96SE0 DT Small molecular drug DM96SE0 PC 3559 DM96SE0 MW 375.9 DM96SE0 FM C21H23ClFNO2 DM96SE0 IC InChI=1S/C21H23ClFNO2/c22-18-7-5-17(6-8-18)21(26)11-14-24(15-12-21)13-1-2-20(25)16-3-9-19(23)10-4-16/h3-10,26H,1-2,11-15H2 DM96SE0 CS C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F DM96SE0 IK LNEPOXFFQSENCJ-UHFFFAOYSA-N DM96SE0 IU 4-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-1-(4-fluorophenyl)butan-1-one DM96SE0 CA CAS 52-86-8 DM96SE0 CB CHEBI:5613 DM96SE0 DE Schizophrenia DMH4IVU ID DMH4IVU DMH4IVU DN Haloprogin DMH4IVU HS Approved DMH4IVU SN Aloprogen; Haloprogina; Haloprogine; Haloproginum; Halotex; Mycanden; Mycilan; Polik; Component of Halotex; M 1028; Haloprogina [INN-Spanish]; Haloprogine [INN-French]; Haloproginum [INN-Latin]; Halotex (TN); Mycanden (TN); Mycilan (TN); Polik (TN); Haloprogin [USAN:INN:JAN]; M-1028 (Meiji); Haloprogin (JAN/USAN/INN); Ether, 3-iodo-2-propynyl 2,4,5-trichlorophenyl; Benzene,1,2,4-trichloro-5-[(3-iodo-2-propynyl)oxy]; (3-Iod-2-propinyl)-(2,4,5-trichlorphenyl)ether; 1,2,4-trichloro-5-(3-iodoprop-2-ynoxy)benzene; 1,2,4-trichloro-5-[(3-iodo-2-propynyl) oxy]benzene; 2,4,5-Trichlorophenyl .gamma.-iodopropargil ether; 2,4,5-Trichlorophenyl .gamma.-iodopropargyl ether; 2,4,5-Trichlorophenyl gamma-iodopropargil ether; 2,4,5-Trichlorophenyl iodopropargyl ether; 2,4,5-Trichlorophenyl-gamma-iodopropargyl ether; 3-Iodo-2-propynyl 2,4,5-trichlorophenyl ether DMH4IVU TC Antifungal Agents DMH4IVU DT Small molecular drug DMH4IVU PC 3561 DMH4IVU MW 361.4 DMH4IVU FM C9H4Cl3IO DMH4IVU IC InChI=1S/C9H4Cl3IO/c10-6-4-8(12)9(5-7(6)11)14-3-1-2-13/h4-5H,3H2 DMH4IVU CS C1=C(C(=CC(=C1Cl)Cl)Cl)OCC#CI DMH4IVU IK CTETYYAZBPJBHE-UHFFFAOYSA-N DMH4IVU IU 1,2,4-trichloro-5-(3-iodoprop-2-ynoxy)benzene DMH4IVU CA CAS 777-11-7 DMH4IVU CB CHEBI:5614 DMH4IVU DE Dermatophytosis; Candidiasis DM80OZ5 ID DM80OZ5 DM80OZ5 DN Halothane DM80OZ5 HS Approved DM80OZ5 SN Alotano; Anestan; Bromchlortrifluoraethanum; Bromochlorotrifluoroethane; Chalothane; Fluktan; Fluorotane; Fluothane; Ftorotan; Ftuorotan; Halan; Halotan; Halotano; Halothan; Halothanum; Halsan; Narcotan; Narcotane; Narkotan; Phthorothanum; Rhodialothan; Alotano [DCIT]; Ftorotan [Russian]; CF3CHClBr; Freon 123B1; Fluothane (TN); Halotano [INN-Spanish]; Halothane [Anaesthetics, volatile]; Halothanum [INN-Latin]; Narcotann NE-spofa [Russian]; Narcotann ne-spofa; Halothane [INN:BAN:JAN]; Halothane (JP15/USP/INN); (+-)-2-Bromo-2-chloro-1,1,1-trifluoroethane; 1,1,1-Trifluoro-2-bromo-2-chloroethane; 1,1,1-Trifluoro-2-chloro-2-bromoethane; 1-Bromo-1-chloro-2,2,2-trifluoroethane; 2,2,2-Trifluoro-1-chloro-1-bromoethane; 2-BROMO-2-CHLORO-1,1,1-TRIFLUOROETHANE; 2-Brom-2-chlor-1,1,1-trifluorethan DM80OZ5 TC Anesthetics DM80OZ5 DT Small molecular drug DM80OZ5 PC 3562 DM80OZ5 MW 197.38 DM80OZ5 FM C2HBrClF3 DM80OZ5 IC InChI=1S/C2HBrClF3/c3-1(4)2(5,6)7/h1H DM80OZ5 CS C(C(F)(F)F)(Cl)Br DM80OZ5 IK BCQZXOMGPXTTIC-UHFFFAOYSA-N DM80OZ5 IU 2-bromo-2-chloro-1,1,1-trifluoroethane DM80OZ5 CA CAS 151-67-7 DM80OZ5 CB CHEBI:5615 DM80OZ5 DE Anaesthesia DMN0S1G ID DMN0S1G DMN0S1G DN HEGF DMN0S1G HS Approved DMN0S1G CP Bharat Biotech DMN0S1G DE Diabetic foot ulcer DMEVXY6 ID DMEVXY6 DMEVXY6 DN Heparin Calcium DMEVXY6 HS Approved DMEVXY6 SN Calciparine DMEVXY6 CP Sanofi Aventis Us Llc DMEVXY6 TC Cardiovascular Agents DMEVXY6 DE Coagulation defect DM9KHZL ID DM9KHZL DM9KHZL DN Heparin Sodium DM9KHZL HS Approved DM9KHZL SN (2S,3S,4R,5R,6R)-6-{[(2S,3S,4S,5R,6S)-6-{[(2R,3S,4S,5R)-2-carboxy-4,6-dihydroxy-5-(sulfooxy)oxan-3-yl]oxy}-2-hydroxy-4-(sulfomethyl)-5-(sulfooxy)oxan-3-yl]oxy}-3-{[(2R,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-[(sulfooxy)methyl]oxan-2-yl]oxy}-4,5-dihydroxyoxane-2-carboxylic acid; HepFlush; GTPL4214; CHEMBL526514; Heparin Sodium 10,000 Units And Dextrose 5% In Plastic Container DM9KHZL CP Hospira Inc DM9KHZL TC Cardiovascular Agents DM9KHZL PC 92044406 DM9KHZL MW 1157.9 DM9KHZL FM C26H42N2NaO37S5+ DM9KHZL IC InChI=1S/C26H42N2O37S5.Na/c1-4(30)27-7-9(31)13(6(56-23(7)39)3-55-67(43,44)45)58-26-19(65-70(52,53)54)12(34)16(20(62-26)22(37)38)60-24-8(28-66(40,41)42)15(63-68(46,47)48)14(5(2-29)57-24)59-25-18(64-69(49,50)51)11(33)10(32)17(61-25)21(35)36;/h5-20,23-26,28-29,31-34,39H,2-3H2,1H3,(H,27,30)(H,35,36)(H,37,38)(H,40,41,42)(H,43,44,45)(H,46,47,48)(H,49,50,51)(H,52,53,54);/q;+1 DM9KHZL CS CC(=O)NC1C(C(C(OC1O)COS(=O)(=O)O)OC2C(C(C(C(O2)C(=O)O)OC3C(C(C(C(O3)CO)OC4C(C(C(C(O4)C(=O)O)O)O)OS(=O)(=O)O)OS(=O)(=O)O)NS(=O)(=O)O)O)OS(=O)(=O)O)O.[Na+] DM9KHZL IK JRTRSJGZMRQDHI-UHFFFAOYSA-N DM9KHZL IU sodium;6-[6-[6-[5-acetamido-4,6-dihydroxy-2-(sulfooxymethyl)oxan-3-yl]oxy-2-carboxy-4-hydroxy-5-sulfooxyoxan-3-yl]oxy-2-(hydroxymethyl)-5-(sulfoamino)-4-sulfooxyoxan-3-yl]oxy-3,4-dihydroxy-5-sulfooxyoxane-2-carboxylic acid DM9KHZL DE Deep vein thrombosis; Coagulation defect DMOB2F3 ID DMOB2F3 DMOB2F3 DN Heptabarbital DMOB2F3 HS Approved DMOB2F3 SN Cycloheptenylethylmalonylurea; Heptabarb; Heptabarbe; Heptabarbitone; Heptabarbo; Heptabarbum; Heptadorm; Heptamal; Heptamalum; Heptbarbital; Medapan; Medomin; Medomine; Noctyn; Cycloheptenylethylbarbituric acid; G 475; Heptabarbe [INN-French]; Heptabarbo [INN-Spanish]; Heptabarbum [INN-Latin]; 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-(1-cyclohepten-1-yl)-5-ethyl-(9CI); 5-(1-CYCLOHEPTEN-1-YL)-5-ETHYLBARBITURIC ACID; 5-(1-Cyclohepten-1-yl)-5-ethyl-2,4,6(1H,3H,5H)-pyrimidinetrione; 5-(1-Cycloheptenyl)-5-ethylbarbitursaeure; 5-(cyclohepten-1-yl)-5-ethyl-1,3-diazinane-2,4,6-trione; 5-Ethyl-5-(1'-cycloheptenyl)-barbituric acid; 5-Ethyl-5-cycloheptenylbarbituric acid DMOB2F3 DT Small molecular drug DMOB2F3 PC 10518 DMOB2F3 MW 250.29 DMOB2F3 FM C13H18N2O3 DMOB2F3 IC InChI=1S/C13H18N2O3/c1-2-13(9-7-5-3-4-6-8-9)10(16)14-12(18)15-11(13)17/h7H,2-6,8H2,1H3,(H2,14,15,16,17,18) DMOB2F3 CS CCC1(C(=O)NC(=O)NC1=O)C2=CCCCCC2 DMOB2F3 IK PAZQYDJGLKSCSI-UHFFFAOYSA-N DMOB2F3 IU 5-(cyclohepten-1-yl)-5-ethyl-1,3-diazinane-2,4,6-trione DMOB2F3 CA CAS 509-86-4 DMOB2F3 CB CHEBI:81297 DMOB2F3 DE Anaesthesia DM6YWBF ID DM6YWBF DM6YWBF DN Herbimycin A DM6YWBF HS Approved DM6YWBF SN Herbimycin; Herbimycin A from Streptomyces hygroscopicus; Antibiotic Tan 420F; [(2R,3S,5S,6R,7S,8E,10S,11S,12E,14E)-2,5,6,11-tetramethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; [(2R,3S,5S,6R,7S,8E,10S,11S,12Z,14E)-2,5,6,11-tetramethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; (2,5,6,11-tetramethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl) carbamate DM6YWBF TC Anticancer Agents DM6YWBF DT Small molecular drug DM6YWBF PC 5311102 DM6YWBF MW 574.7 DM6YWBF FM C30H42N2O9 DM6YWBF IC InChI=1S/C30H42N2O9/c1-16-10-9-11-23(37-5)28(41-30(31)36)18(3)12-17(2)27(40-8)24(38-6)13-19(4)26(39-7)21-14-20(33)15-22(25(21)34)32-29(16)35/h9-12,14-15,17,19,23-24,26-28H,13H2,1-8H3,(H2,31,36)(H,32,35)/b11-9-,16-10+,18-12+/t17-,19-,23-,24-,26+,27+,28-/m0/s1 DM6YWBF CS C[C@H]1C[C@@H]([C@@H]([C@H](/C=C(/[C@@H]([C@H](/C=C\\C=C(\\C(=O)NC2=CC(=O)C=C([C@@H]1OC)C2=O)/C)OC)OC(=O)N)\\C)C)OC)OC DM6YWBF IK MCAHMSDENAOJFZ-BVXDHVRPSA-N DM6YWBF IU [(4E,6Z,8S,9S,10E,12S,13R,14S,16S,17R)-8,13,14,17-tetramethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl] carbamate DM6YWBF CA CAS 70563-58-5 DM6YWBF CB CHEBI:5674 DM6YWBF DE Solid tumour/cancer DMDBWHY ID DMDBWHY DMDBWHY DN Heroin diacetylmorphine DMDBWHY HS Approved DMDBWHY SN Diamorphine (TN) DMDBWHY CP Bayer company DMDBWHY DT Small molecular drug DMDBWHY PC 5462328 DMDBWHY MW 369.4 DMDBWHY FM C21H23NO5 DMDBWHY IC InChI=1S/C21H23NO5/c1-11(23)25-16-6-4-13-10-15-14-5-7-17(26-12(2)24)20-21(14,8-9-22(15)3)18(13)19(16)27-20/h4-7,14-15,17,20H,8-10H2,1-3H3/t14-,15+,17-,20-,21-/m0/s1 DMDBWHY CS CC(=O)O[C@H]1C=C[C@H]2[C@H]3CC4=C5[C@]2([C@H]1OC5=C(C=C4)OC(=O)C)CCN3C DMDBWHY IK GVGLGOZIDCSQPN-PVHGPHFFSA-N DMDBWHY IU [(4R,4aR,7S,7aR,12bS)-9-acetyloxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-yl] acetate DMDBWHY CA CAS 561-27-3 DMDBWHY CB CHEBI:27808 DMDBWHY DE Neurological disorder DMKER83 ID DMKER83 DMKER83 DN Hesperetin DMKER83 HS Approved DMKER83 SN Hesperin; Hesperitin; TNP00238; YSO2; Cyanidanon 4'-methyl ether 1626; Flavanone, 3',5,7-trihydroxy-4'-methoxy-(VAN); Flavanone, 3',5,7-trihydroxy-4'-methoxy-(VAN) (8CI); (-)-hesperetin; (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-2,3-dihydro-4H-chromen-4-one; (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-2,3-dihydrochromen-4-one; (S)-2,3-Dihydro-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-4-benzopyrone; (S)-2,3-dihydro-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-4H-1-benzopyran-4-one; 3',5,7-Trihydroxy-4'-methoxyflavanone; 3',5,7-Trihydroxy-4-methoxyflavanone; 4H-1-Benzopyran-4-one, 2,3-dihydro-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-, (S)-(9CI); 5,7,3'-Trihydroxy-4'-methoxyflavanone DMKER83 TC Anticholesteremic Agents DMKER83 DT Small molecular drug DMKER83 PC 72281 DMKER83 MW 302.28 DMKER83 FM C16H14O6 DMKER83 IC InChI=1S/C16H14O6/c1-21-13-3-2-8(4-10(13)18)14-7-12(20)16-11(19)5-9(17)6-15(16)22-14/h2-6,14,17-19H,7H2,1H3/t14-/m0/s1 DMKER83 CS COC1=C(C=C(C=C1)[C@@H]2CC(=O)C3=C(C=C(C=C3O2)O)O)O DMKER83 IK AIONOLUJZLIMTK-AWEZNQCLSA-N DMKER83 IU (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-2,3-dihydrochromen-4-one DMKER83 CA CAS 520-33-2 DMKER83 CB CHEBI:28230 DMKER83 DE High blood cholesterol level DMI5DW1 ID DMI5DW1 DMI5DW1 DN Hesperidin DMI5DW1 HS Approved DMI5DW1 SN hesperidin; 520-26-3; Cirantin; Hesperidoside; Hesper bitabs; Hesperetin-rutinosid; Hesperidine; UNII-E750O06Y6O; CCRIS 3940; (S)-(-)-Hesperidin; EINECS 208-288-1; NSC 44184; BRN 0075140; Hesperidin, (2S)-; Hesperetin 7-rutinoside; MLS001304066; (2S)-5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-7-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-[[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxymethyl]oxan-2-yl]oxy-2,3-dihydrochromen-4-one; CHEBI:28775; USAF CF-3; Hesperidin, (S)-(-)-; Hesperitin-7-rhamnoglucoside; E750O06Y6O; C28H34O15; HESPERIDINE DMI5DW1 DT Small molecular drug DMI5DW1 PC 10621 DMI5DW1 MW 610.6 DMI5DW1 FM C28H34O15 DMI5DW1 IC InChI=1S/C28H34O15/c1-10-21(32)23(34)25(36)27(40-10)39-9-19-22(33)24(35)26(37)28(43-19)41-12-6-14(30)20-15(31)8-17(42-18(20)7-12)11-3-4-16(38-2)13(29)5-11/h3-7,10,17,19,21-30,32-37H,8-9H2,1-2H3/t10-,17-,19+,21-,22+,23+,24-,25+,26+,27+,28+/m0/s1 DMI5DW1 CS C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OC[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)OC3=CC(=C4C(=O)C[C@H](OC4=C3)C5=CC(=C(C=C5)OC)O)O)O)O)O)O)O)O DMI5DW1 IK QUQPHWDTPGMPEX-QJBIFVCTSA-N DMI5DW1 IU (2S)-5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-7-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-[[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxymethyl]oxan-2-yl]oxy-2,3-dihydrochromen-4-one DMI5DW1 CA CAS 520-26-3 DMI5DW1 CB CHEBI:28775 DMI5DW1 DE Vascular purpura DMPXITB ID DMPXITB DMPXITB DN Hetacillin DMPXITB HS Approved DMPXITB SN Etacillina; Hetacilina; Hetacilline; Hetacillinum; Phenazacillin; Versapen; Etacillina [DCIT]; HETACILLIN POTASSIUM; BRL 804; BL-P 804; BRL-804; Hetacilina [INN-Spanish]; Hetacilline [INN-French]; Hetacillinum [INN-Latin]; Versapen (TN); Hetacillin (USAN/INN); Hetacillin [USAN:INN:BAN]; N,N'-Isopropylidene-A-amino-benzyl penicillin; (2S,%R,6R)-6-(2,2-Dimethyl-5-oxo-4-phenyl-1-imidazolidinyl)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptan-2-carbonsaeure; (2S,5R)-6-[(4R)-2,2-dimethyl-5-oxo-4-phenylimidazolidin-1-yl]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-(2,2-dimethyl-5-oxo-4-phenylimidazolidin-1-yl)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-[(4R)-2,2-dimethyl-5-oxo-4-phenylimidazolidin-1-yl]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 6-(2,2-Dimethyl-5-oxo-4-phenyl-1-imidazolidinyl)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid; 6-(2,2-Dimethyl-5-oxo-4-phenyl-1-imidazolidinyl)penicillansaeure; 6-(2,2-dimethyl-5-oxo-4-phenylimidazolidin-1-yl)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 6beta-[(4R)-2,2-dimethyl-5-oxo-4-phenylimidazolidin-1-yl]-2,2-dimethylpenam-3alpha-carboxylic acid; 6beta-[(4R)-2,2-dimethyl-5-oxo-4-phenylimidazolidin-1-yl]penicillanic acid DMPXITB CP Bristol Laboratories Inc Div Bristol Myers Co DMPXITB TC Antibiotics DMPXITB DT Small molecular drug DMPXITB PC 443387 DMPXITB MW 389.5 DMPXITB FM C19H23N3O4S DMPXITB IC InChI=1S/C19H23N3O4S/c1-18(2)13(17(25)26)21-15(24)12(16(21)27-18)22-14(23)11(20-19(22,3)4)10-8-6-5-7-9-10/h5-9,11-13,16,20H,1-4H3,(H,25,26)/t11-,12-,13+,16-/m1/s1 DMPXITB CS CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)N3C(=O)[C@H](NC3(C)C)C4=CC=CC=C4)C(=O)O)C DMPXITB IK DXVUYOAEDJXBPY-NFFDBFGFSA-N DMPXITB IU (2S,5R,6R)-6-[(4R)-2,2-dimethyl-5-oxo-4-phenylimidazolidin-1-yl]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid DMPXITB CA CAS 3511-16-8 DMPXITB CB CHEBI:5683 DMPXITB DE Bacterial infection DMGUC9T ID DMGUC9T DMGUC9T DN HEV-239 DMGUC9T HS Approved DMGUC9T SN Hecolin; Bacterially-expressed hepatitis E vaccine, Xiamen Innovax Biotech; Hepatitis E vaccine (recombinant), Xiamen Innovax Biotech; Hepatitis E vaccine (alum-adjuvanted), Xiamen Innovax Biotech DMGUC9T CP Beijing Wantai Biological Pharmacy Enterprise Co Ltd DMGUC9T DT Vaccine DMGUC9T DE Hepatitis E virus infection DMLKSE0 ID DMLKSE0 DMLKSE0 DN Hexachlorophene DMLKSE0 HS Approved DMLKSE0 SN Acigena; Almederm; Armohex; Bilevon; Bivelon; Cotofilm; Dermadex; Distodin; Eleven; Esaclorofene; Exofene; Fascol; Fomac; Fostril; Gamophen; Gamophene; Hexabalm; Hexachlorofen; Hexachlorophane; Hexachlorophen; Hexachlorophenum; Hexaclorofeno; Hexafen; Hexascrub; Hexide; Hexophene; Hexosan; Isobac; Nabac; PHisoHex; Phisodan; Ritosept; Septisol; Septofen; Steral; Steraskin; Surofene; TRICHLOROPHENE; Tersaseptic; Trisophen; Turgex; Blockade Anti Bacterial Finish; Brevity Blue Liquid Bacteriostatic Scouring Cream; Brevity Blue Liquid Sanitizing Scouring Cream; Enditch Pet Shampoo; Esaclorofene [DCIT]; Fo stril; Hexachlorofen [Czech]; Hexachlorophene [INN]; Hilo Cat Flea Powder; Hilo Flea Powder; Neosept V; Pedigree Dog Shampoo Bar; Scrubteam Surgical Spongebrush; Staphene O; AT 7; B 32; H3P; Hexachlorophene [UN2875] [Poison]; KUC106447N; M0219; Nabac 25 ec; AT-7; AT17 (TN); AT7 (TN); Acigena (TN); Almederm (TN); At-17; B & b Flea Kontroller for Dogs Only; B 32 (VAN); Bilevon (TN); E-Z Scrub; En-Viron D Concentrated Phenolic Disinfectant; Exofene (TN); Fesia-sin; Fostril (TN); G-11; G-Eleven; G-II; Gamophen (TN); Germa-Medica; Hexa-Germ; Hexachlorophene, Pharma; Hexachlorophenum [INN-Latin]; Hexaclorofeno [INN-Spanish]; Hexaphene-LV; Hexosan (TN); PRE-OP II; Phiso-Scrub; Phisohex(TN); Pre-Op; Septi-Soft; Septisol (TN); Solu-Heks; Soy-dome; Ster-zac; Surgi-Cen; Surgi-Cin; Surofene (TN); Thera-Groom Pet Shampoo for Dogs for Veterinary Use Only; G-11 (TN); GERMA-MEDICA (MG); Germa-Medica (TN); Hexachlorophene (USP/INN); KSC-19-051; Methylenebis(3,4,6-trichlorophenol); Bis(2,3,5-tric hloro-6-hydroxyphenyl)methane; Bis(2,3,5-trichloro-6-hydroxyphenyl)methane; Bis(2-hydroxy-3,5,6-trichlorophenyl)methane; Bis(3,5,6-trichloro-2-hydroxyphenyl)methane; Bis-2,3,5-trichlor-6-hydroxyfenylmethan; Bis-2,3,5-trichloro-6-hydroxyfenylmethan; Bis-2,3,5-trichloro-6-hydroxyfenylmethan [Czech]; Bis(3,5,6-trichloro-2-hydroxyphenyl)-methane; Methane, bis(2,3,5-trichloro-6-hydroxyphenyl); 2,2',3,3',5,5'-Hexachloro-6,6'-dihydroxydiphenylmethane; 2,2'-Dihydroxy-3,5,6,3',5',6'-hexachlorodiphenylmethane; 2,2'-Methylene bis(3,4,6-trichlorophenol); 2,2'-Methylenebis(3,4,6-trichlorophenol); 2,2'-Methylenebis[3,4,6-trichlorophenol]; 2,2'-methanediylbis(3,4,6-trichlorophenol); 2,2-Methylene-bis-[3,4,6-trichlorophenol]; 3,3',5,5',6,6'-Hexachloro-2,2'-dihydroxydiphenylmethane; 3,4,6-trichloro-2-[(2,3,5-trichloro-6-hydroxyphenyl)methyl]phenol DMLKSE0 TC Antiinfective Agents DMLKSE0 DT Small molecular drug DMLKSE0 PC 3598 DMLKSE0 MW 406.9 DMLKSE0 FM C13H6Cl6O2 DMLKSE0 IC InChI=1S/C13H6Cl6O2/c14-6-2-8(16)12(20)4(10(6)18)1-5-11(19)7(15)3-9(17)13(5)21/h2-3,20-21H,1H2 DMLKSE0 CS C1=C(C(=C(C(=C1Cl)Cl)CC2=C(C(=CC(=C2Cl)Cl)Cl)O)O)Cl DMLKSE0 IK ACGUYXCXAPNIKK-UHFFFAOYSA-N DMLKSE0 IU 3,4,6-trichloro-2-[(2,3,5-trichloro-6-hydroxyphenyl)methyl]phenol DMLKSE0 CA CAS 70-30-4 DMLKSE0 CB CHEBI:5693 DMLKSE0 DE Bacterial infection DMFY307 ID DMFY307 DMFY307 DN Hexafluronium bromide DMFY307 HS Approved DMFY307 SN Hexafluorenium; Milaxen; Mylaxen; Bromuro de hexafluronio; Esafluronio bromuro; Esafluronio bromuro [DCIT]; Hexafluorenium bromide; Hexafluorenium bromide [USAN]; Hexafluorenium dibromide; Hexafluorenium dibromide salt; Hexafluronii bromidum; Bromure d'hexafluronium; Bromuro de hexafluronio [INN-Spanish]; Hexafluorenium bromide (USAN); Hexafluronii bromidum [INN-Latin]; Hexafluronium bromide (INN); IN-117; Mylaxen (TN); Bromure d'hexafluronium [INN-French]; Hexamethylene bis(9-fluorenyldimethylammonium)dibromide; Hexamethylenebis(9-fluorenyldimethylammonium bromide); Hexamethylenebis(dimethyl-9-fluorenylammonium bromide); Hexamethylenebis(fluoren-9-yldimethylammonium) dibromide; AMMONIUM, HEXAMETHYLENEBIS(FLUOREN-9-YLDIMETHYL-, DIBROMIDE; Ammonium, hexamethylenebis(fluoren-9-yldimethyl-, bromide; N,N'-Di(9-fluorenyl)-N,N,N',N'-tetramethyly-hexamethylendi(ammoniumbromid); 1,6-Bis(9 fluorenyldimethyl-ammonium)hexane bromide; 1,6-Hexanediaminium, N,N'-di-9H-fluoren-9-yl-N,N,N',N'-tetramethyl-, dibromide; 9H-fluoren-9-yl-[6-[9H-fluoren-9-yl(dimethyl)azaniumyl]hexyl]-dimethylazanium dibromide DMFY307 TC Analgesics DMFY307 DT Small molecular drug DMFY307 PC 9434 DMFY307 MW 662.5 DMFY307 FM C36H42Br2N2 DMFY307 IC InChI=1S/C36H42N2.2BrH/c1-37(2,35-31-21-11-7-17-27(31)28-18-8-12-22-32(28)35)25-15-5-6-16-26-38(3,4)36-33-23-13-9-19-29(33)30-20-10-14-24-34(30)36;;/h7-14,17-24,35-36H,5-6,15-16,25-26H2,1-4H3;2*1H/q+2;;/p-2 DMFY307 CS C[N+](C)(CCCCCC[N+](C)(C)C1C2=CC=CC=C2C3=CC=CC=C13)C4C5=CC=CC=C5C6=CC=CC=C46.[Br-].[Br-] DMFY307 IK WDEFPRUEZRUYNW-UHFFFAOYSA-L DMFY307 IU 9H-fluoren-9-yl-[6-[9H-fluoren-9-yl(dimethyl)azaniumyl]hexyl]-dimethylazanium;dibromide DMFY307 CA CAS 317-52-2 DMFY307 DE Spasm DMQ314B ID DMQ314B DMQ314B DN Hexobarbital DMQ314B HS Approved DMQ314B SN Barbidorm; Citodon; Citopan; Cyclonal; Cyclopan; Dorico; Enhexymal; Enhexymalum; Esobarbitale; Evipal; Evipan; Hexabarbital;Hexobarbitalum; Hexobarbitone; Hexobarbitonum; Methexenyl; Methylhexabarbital; Methylhexabital; Narcosan; Noctivane; Sombucaps; Sombulex; Somnalert; Esobarbitale [DCIT]; Esobarbitale [Italian]; Hexanastab oral; Sodium hexobarbital; Citopan (TN); Evipan (TN); Hexenal (barbiturate); Hexobarbital (VAN); Hexobarbital [INN:JAN]; Hexobarbitalum [INN-Latin]; Hexobarbital (JAN/INN); N-Methyl-5-cyclohexenyl-5-methylbarbituric acid; (+-)-Hexobarbital; 1,5-Dimethyl-5-(1-cyclohexenyl)barbituric acid; 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-(1-cyclohexen-1-yl)-1,5-dimethyl; 5-(1-CYCLOHEXEN-1-YL)-1,5-DIMETHYLBARBITURIC ACID; 5-(1-Cyclohexen-1-yl)-1,5-dimethyl-2,4,6(1H,3H,5H)-pyrimidinetrione; 5-(1-Cyclohexenyl)-1,5-dimethylbarbituric acid; 5-(1-Cyclohexenyl-1)-1-methyl-5-methylbarbituric acid; 5-(cyclohex-1-en-1-yl)-1,5-dimethylpyrimidine-2,4,6(1H,3H,5H)-trione; 5-(cyclohexen-1-yl)-1,5-dimethyl-1,3-diazinane-2,4,6-trione; 5-(delta-1,2-Cyclohexenyl)-5-methyl-N-methyl-barbitursaeure [German]; 5-(delta-1,2-cyclohexenyl)-5-methyl-N-methyl-barbitursaeure; 5-(delta.-1,2-cyclohexenyl)-5-methyl-N-methyl-barbitursaeure; 5-cyclohex-1-en-1-yl-1,5-dimethylpyrimidine-2,4,6(1H,3H,5H)-trione; 5-cyclohex-1-en-1-yl-2-hydroxy-1,5-dimethylpyrimidine-4,6(1H,5H)-dione DMQ314B TC Hypnotics and Sedatives DMQ314B DT Small molecular drug DMQ314B PC 3608 DMQ314B MW 236.27 DMQ314B FM C12H16N2O3 DMQ314B IC InChI=1S/C12H16N2O3/c1-12(8-6-4-3-5-7-8)9(15)13-11(17)14(2)10(12)16/h6H,3-5,7H2,1-2H3,(H,13,15,17) DMQ314B CS CC1(C(=O)NC(=O)N(C1=O)C)C2=CCCCC2 DMQ314B IK UYXAWHWODHRRMR-UHFFFAOYSA-N DMQ314B IU 5-(cyclohexen-1-yl)-1,5-dimethyl-1,3-diazinane-2,4,6-trione DMQ314B CA CAS 56-29-1 DMQ314B CB CHEBI:5706 DMQ314B DE Anaesthesia DMEADRK ID DMEADRK DMEADRK DN Hexylcaine DMEADRK HS Approved DMEADRK SN Hexilcaina; Hexylcainum; Osmocaine; Hexylcaine [INN]; Cyclaine (TN); Hexilcaina [INN-Spanish]; Hexylcainum [INN-Latin]; Osmocaine (TN); (2-Cyclohexylamino-1-methylethyl) benzoate; 1-(Cyclohexylamino)-2-propanol benzoate (ester); 1-(cyclohexylamino)propan-2-yl benzoate; 2-Propanol, 1-(cyclohexylamino)-, benzoate (ester) DMEADRK CP Merck & Co DMEADRK TC Anesthetics DMEADRK DT Small molecular drug DMEADRK PC 10770 DMEADRK MW 261.36 DMEADRK FM C16H23NO2 DMEADRK IC InChI=1S/C16H23NO2/c1-13(12-17-15-10-6-3-7-11-15)19-16(18)14-8-4-2-5-9-14/h2,4-5,8-9,13,15,17H,3,6-7,10-12H2,1H3 DMEADRK CS CC(CNC1CCCCC1)OC(=O)C2=CC=CC=C2 DMEADRK IK DKLKMKYDWHYZTD-UHFFFAOYSA-N DMEADRK IU 1-(cyclohexylamino)propan-2-yl benzoate DMEADRK CA CAS 532-77-4 DMEADRK CB CHEBI:34791 DMEADRK DE Anaesthesia DMV7IM6 ID DMV7IM6 DMV7IM6 DN Histamine Phosphate DMV7IM6 HS Approved DMV7IM6 SN Histamine acid phosphate; Histamine biphosphate; Histamine dihydrogen phosphate; Histamine diphosphate; Histamine phosphate [USP]; Histamine positive; H0147; Histamine phosphate (TN); Histamine phosphate (USP); Histamine phosphate (1:2); 1H-Imidazole-4-ethanamine, phosphate (1:2); 2-Imidazol-4-ylethylamine orthophosphoric acid (1:2); 4-(2-Aminoethyl)imidazole bis(dihydrogen phosphate); 4-(2-Aminoethyl)imidazole di-acid phosphate; 4-2(2-Aminoethyl)Imidazole-Di-Acid Phosphate DMV7IM6 TC Diagnostic Agents DMV7IM6 DT Small molecular drug DMV7IM6 PC 65513 DMV7IM6 MW 307.14 DMV7IM6 FM C5H15N3O8P2 DMV7IM6 IC InChI=1S/C5H9N3.2H3O4P/c6-2-1-5-3-7-4-8-5;2*1-5(2,3)4/h3-4H,1-2,6H2,(H,7,8);2*(H3,1,2,3,4) DMV7IM6 CS C1=C(NC=N1)CCN.OP(=O)(O)O.OP(=O)(O)O DMV7IM6 IK ZHIBQGJKHVBLJJ-UHFFFAOYSA-N DMV7IM6 IU 2-(1H-imidazol-5-yl)ethanamine;phosphoric acid DMV7IM6 CA CAS 51-74-1 DMV7IM6 CB CHEBI:51193 DMV7IM6 DE Diagnostic imaging DMGBPSH ID DMGBPSH DMGBPSH DN Homatropine Methylbromide DMGBPSH HS Approved DMGBPSH SN Arkitropin; Camatropine; Equipin; Esopin; Homapin; Homatromide; Malcotran; Mesopin; Methylhomatropine; Novatrin; Novatrine; Novatropine; Npvatropine; Sethyl; Homatropine methobromide; Homatropine methyl bromide; Homatropini methylbromidum; Humulon lead salt; Methyl Bromide Homatropine; Methylhomatropine bromide; Methylhomatropinum bromatum; Metilbromuro de homatropina; Omatropina metilbromuro; Omatropina metilbromuro [DCIT]; Tropinium methobromide mandelate; DL-Homatropine methyl bromide; DL-Methylbromide; Equipin (TN); Homapin-10; Homapin-5; Homatropine DL-methylbromide; Homatropine methylbromide (USP); Homatropine methylbromide [INN:BAN]; Homatropini methylbromidum [INN-Latin]; Hycodan, probilagol; Isopto Homatropine (TN); Methylbromure d'homatropine; Metilbromuro de homatropina [INN-Spanish]; N-Methylhomatropinium Bromide; Sed-Tems; Methylbromure d'homatropine [INN-French]; HOMATROPINIUM, 8-METHYL-, BROMIDE; [(5S)-8,8-dimethyl-8-azoniabicyclo[3.2.1]octan-3-yl] 2-hydroxy-2-phenylacetate bromide; (8,8-dimethyl-8-azoniabicyclo[3.2.1]octan-3-yl) 2-hydroxy-2-phenylacetate bromide; 3-[2-hydroxy(phenyl)acetoxy]-8,8-dimethyl-8-azoniabicyclo[3.2.1]octane bromide; 3-alpha-Hydroxy-8-methyl-1-alpha-H,5-alpha-H-tropanium bromide mandelate; 3-{[hydroxy(phenyl)acetyl]oxy}-8,8-dimethyl-8-azoniabicyclo[3.2.1]octane bromide; 3alpha-Hydroxy-8-methyl-1alphaH,5alphaH-tropanium bromide mandelate; 8-Methylhomatropinium bromide DMGBPSH TC Antiulcer Agents DMGBPSH DT Small molecular drug DMGBPSH PC 10429215 DMGBPSH MW 370.3 DMGBPSH FM C17H24BrNO3 DMGBPSH IC InChI=1S/C17H24NO3.BrH/c1-18(2)13-8-9-14(18)11-15(10-13)21-17(20)16(19)12-6-4-3-5-7-12;/h3-7,13-16,19H,8-11H2,1-2H3;1H/q+1;/p-1/t13-,14+,15?,16?; DMGBPSH CS C[N+]1([C@@H]2CC[C@H]1CC(C2)OC(=O)C(C3=CC=CC=C3)O)C.[Br-] DMGBPSH IK FUFVKLQESJNNAN-ZZJGABIISA-M DMGBPSH IU [(1S,5R)-8,8-dimethyl-8-azoniabicyclo[3.2.1]octan-3-yl] 2-hydroxy-2-phenylacetate;bromide DMGBPSH CA CAS 80-49-9 DMGBPSH DE Uveitis; Peptic ulcer DM78G6F ID DM78G6F DM78G6F DN HTF 919 DM78G6F HS Approved DM78G6F DT Small molecular drug DM78G6F PC 60918 DM78G6F MW 301.39 DM78G6F FM C16H23N5O DM78G6F IC InChI=1S/C16H23N5O/c1-3-4-5-8-18-16(17)21-20-11-12-10-19-15-7-6-13(22-2)9-14(12)15/h6-7,9-11,19H,3-5,8H2,1-2H3,(H3,17,18,21) DM78G6F CS CCCCCN=C(N)NN=CC1=CNC2=C1C=C(C=C2)OC DM78G6F IK IKBKZGMPCYNSLU-UHFFFAOYSA-N DM78G6F IU 1-[(5-methoxy-1H-indol-3-yl)methylideneamino]-2-pentylguanidine DM78G6F CA CAS 145158-71-0 DM78G6F DE Constipation DMA5OBU ID DMA5OBU DMA5OBU DN Human neutral insulin DMA5OBU HS Approved DMA5OBU DT Small molecular drug DMA5OBU PC 16129672 DMA5OBU MW 5808 DMA5OBU FM C257H383N65O77S6 DMA5OBU IC InChI=1S/C257H383N65O77S6/c1-29-131(23)205(313-193(339)104-259)252(393)317-204(130(21)22)248(389)288-159(75-82-200(349)350)217(358)282-156(71-78-189(263)335)221(362)308-183-116-403-404-117-184-243(384)305-178(111-324)240(381)294-162(88-123(7)8)225(366)295-168(95-140-53-61-146(329)62-54-140)228(369)283-154(69-76-187(261)333)218(359)290-161(87-122(5)6)223(364)285-158(74-81-199(347)348)220(361)302-174(101-190(264)336)235(376)298-170(97-142-57-65-148(331)66-58-142)231(372)309-182(242(383)304-176(255(396)397)103-192(266)338)115-402-401-114-181(214(355)273-107-194(340)278-153(72-79-197(343)344)216(357)281-151(51-42-84-271-257(267)268)212(353)272-108-195(341)279-166(93-138-46-36-32-37-47-138)227(368)297-167(94-139-48-38-33-39-49-139)230(371)299-171(98-143-59-67-149(332)68-60-143)238(379)320-208(135(27)327)254(395)322-85-43-52-186(322)246(387)286-152(50-40-41-83-258)222(363)321-209(136(28)328)256(398)399)311-250(391)203(129(19)20)316-236(377)164(90-125(11)12)292-229(370)169(96-141-55-63-147(330)64-56-141)296-224(365)160(86-121(3)4)289-210(351)133(25)277-215(356)157(73-80-198(345)346)287-247(388)202(128(17)18)315-237(378)165(91-126(13)14)293-233(374)173(100-145-106-270-120-276-145)301-239(380)177(110-323)280-196(342)109-274-213(354)180(113-400-405-118-185(310-244(183)385)245(386)319-207(134(26)326)253(394)306-179(112-325)241(382)318-206(132(24)30-2)251(392)312-184)307-226(367)163(89-124(9)10)291-232(373)172(99-144-105-269-119-275-144)300-219(360)155(70-77-188(262)334)284-234(375)175(102-191(265)337)303-249(390)201(127(15)16)314-211(352)150(260)92-137-44-34-31-35-45-137/h31-39,44-49,53-68,105-106,119-136,150-186,201-209,323-332H,29-30,40-43,50-52,69-104,107-118,258-260H2,1-28H3,(H2,261,333)(H2,262,334)(H2,263,335)(H2,264,336)(H2,265,337)(H2,266,338)(H,269,275)(H,270,276)(H,272,353)(H,273,355)(H,274,354)(H,277,356)(H,278,340)(H,279,341)(H,280,342)(H,281,357)(H,282,358)(H,283,369)(H,284,375)(H,285,364)(H,286,387)(H,287,388)(H,288,389)(H,289,351)(H,290,359)(H,291,373)(H,292,370)(H,293,374)(H,294,381)(H,295,366)(H,296,365)(H,297,368)(H,298,376)(H,299,371)(H,300,360)(H,301,380)(H,302,361)(H,303,390)(H,304,383)(H,305,384)(H,306,394)(H,307,367)(H,308,362)(H,309,372)(H,310,385)(H,311,391)(H,312,392)(H,313,339)(H,314,352)(H,315,378)(H,316,377)(H,317,393)(H,318,382)(H,319,386)(H,320,379)(H,321,363)(H,343,344)(H,345,346)(H,347,348)(H,349,350)(H,396,397)(H,398,399)(H4,267,268,271)/t131-,132-,133-,134+,135+,136+,150-,151-,152-,153-,154-,155-,156-,157-,158-,159-,160-,161-,162-,163-,164-,165-,166-,167-,168-,169-,170-,171-,172-,173-,174-,175-,176-,177-,178-,179-,180-,181-,182-,183-,184-,185-,186-,201-,202-,203-,204-,205-,206-,207-,208-,209-/m0/s1 DMA5OBU CS CC[C@H](C)[C@H]1C(=O)N[C@H]2CSSC[C@@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC2=O)CO)CC(C)C)CC3=CC=C(C=C3)O)CCC(=O)N)CC(C)C)CCC(=O)O)CC(=O)N)CC4=CC=C(C=C4)O)C(=O)N[C@@H](CC(=O)N)C(=O)O)C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CC5=CC=CC=C5)C(=O)N[C@@H](CC6=CC=CC=C6)C(=O)N[C@@H](CC7=CC=C(C=C7)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N8CCC[C@H]8C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)C(C)C)CC(C)C)CC9=CC=C(C=C9)O)CC(C)C)C)CCC(=O)O)C(C)C)CC(C)C)CC2=CN=CN2)CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC2=CN=CN2)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC2=CC=CC=C2)N)C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CO)[C@@H](C)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)CN DMA5OBU IK PBGKTOXHQIOBKM-FHFVDXKLSA-N DMA5OBU IU (4S)-4-[[2-[[(1R,6R,12S,15S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,50S,53S,56S,59S,62S,65S,68S,71S,74R,77S,80S,83S,88R)-88-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[(2-aminoacetyl)amino]-3-methylpentanoyl]amino]-3-methylbutanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]-6-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-amino-3-phenylpropanoyl]amino]-3-methylbutanoyl]amino]-4-oxobutanoyl]amino]-5-oxopentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-47-[[(1S)-3-amino-1-carboxy-3-oxopropyl]carbamoyl]-53-(2-amino-2-oxoethyl)-62-(3-amino-3-oxopropyl)-77-[(2S)-butan-2-yl]-24,56-bis(2-carboxyethyl)-83-[(1R)-1-hydroxyethyl]-12,71,80-tris(hydroxymethyl)-33,50,65-tris[(4-hydroxyphenyl)methyl]-15-(1H-imidazol-5-ylmethyl)-27-methyl-18,30,36,59,68-pentakis(2-methylpropyl)-7,10,13,16,19,22,25,28,31,34,37,40,49,52,55,58,61,64,67,70,73,76,79,82,85,87-hexacosaoxo-21,39-di(propan-2-yl)-3,4,44,45,90,91-hexathia-8,11,14,17,20,23,26,29,32,35,38,41,48,51,54,57,60,63,66,69,72,75,78,81,84,86-hexacosazabicyclo[72.11.7]dononacontane-42-carbonyl]amino]acetyl]amino]-5-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S,3R)-1-[(2S)-2-[[(2S)-6-amino-1-[[(1S,2R)-1-carboxy-2-hydroxypropyl]amino]-1-oxohexan-2-yl]carbamoyl]pyrrolidin-1-yl]-3-hydroxy-1-oxobutan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-oxopentanoic acid DMA5OBU DE Diabetic complication DMPHVQ1 ID DMPHVQ1 DMPHVQ1 DN Human prothrombin complex concentrate DMPHVQ1 HS Approved DMPHVQ1 CP Octapharma usa DMPHVQ1 SQ sp|P00734|THRB_HUMAN Prothrombin OS=Homo sapiens GN=F2 PE=1 SV=2: MAHVRGLQLPGCLALAALCSLVHSQHVFLAPQQARSLLQRVRRANTFLEEVRKGNLERECVEETCSYEEAFEALESSTATDVFWAKYTACETARTPRDKLAACLEGNCAEGLGTNYRGHVNITRSGIECQLWRSRYPHKPEINSTTHPGADLQENFCRNPDSSTTGPWCYTTDPTVRRQECSIPVCGQDQVTVAMTPRSEGSSVNLSPPLEQCVPDRGQQYQGRLAVTTHGLPCLAWASAQAKALSKHQDFNSAVQLVENFCRNPDGDEEGVWCYVAGKPGDFGYCDLNYCEEAVEEETGDGLDEDSDRAIEGRTATSEYQTFFNPRTFGSGEADCGLRPLFEKKSLEDKTERELLESYIDGRIVEGSDAEIGMSPWQVMLFRKSPQELLCGASLISDRWVLTAAHCLLYPPWDKNFTENDLLVRIGKHSRTRYERNIEKISMLEKIYIHPRYNWRENLDRDIALMKLKKPVAFSDYIHPVCLPDRETAASLLQAGYKGRVTGWGNLKETWTANVGKGQPSVLQVVNLPIVERPVCKDSTRIRITDNMFCAGYKPDEGKRGDACEGDSGGPFVMKSPFNNRWYQMGIVSWGEGCDRDGKYGFYTHVFRLKKWIQKVIDQFGE DMPHVQ1 DE Bleeding disorder DMMAWLU ID DMMAWLU DMMAWLU DN Huperzine A DMMAWLU HS Approved DMMAWLU SN Fordine; ( inverted exclamation markA)-Huperazine A; ( inverted exclamation markA)-Huperzine A; C15H18N2O; 5,9-Methanocycloocta(b)pyridin-2(1H)-one, 5-amino-11-ethylidene-5,6,9,10-tetrahydro-7-methyl-; rac-huperzine A; NCGC00159362-02; SCHEMBL679315; SCHEMBL1047469; CHEMBL394259; CHEBI:91724; MolPort-003-941-680 DMMAWLU DT Small molecular drug DMMAWLU PC 854026 DMMAWLU MW 242.32 DMMAWLU FM C15H18N2O DMMAWLU IC InChI=1S/C15H18N2O/c1-3-11-10-6-9(2)8-15(11,16)12-4-5-14(18)17-13(12)7-10/h3-6,10H,7-8,16H2,1-2H3,(H,17,18)/b11-3+/t10-,15+/m0/s1 DMMAWLU CS C/C=C/1\\[C@@H]2CC3=C([C@]1(CC(=C2)C)N)C=CC(=O)N3 DMMAWLU IK ZRJBHWIHUMBLCN-YQEJDHNASA-N DMMAWLU IU (1R,9R,13E)-1-amino-13-ethylidene-11-methyl-6-azatricyclo[7.3.1.02,7]trideca-2(7),3,10-trien-5-one DMMAWLU CA CAS 102518-79-6 DMMAWLU CB CHEBI:78330 DMMAWLU DE Alzheimer disease DMX8M26 ID DMX8M26 DMX8M26 DN Hyaluronate sodium DMX8M26 HS Approved DMX8M26 DT Small molecular drug DMX8M26 PC 3084049 DMX8M26 MW 799.6 DMX8M26 FM C28H44N2NaO23+ DMX8M26 IC InChI=1S/C28H44N2O23.Na/c1-5(33)29-9-18(11(35)7(3-31)47-25(9)46)49-28-17(41)15(39)20(22(53-28)24(44)45)51-26-10(30-6(2)34)19(12(36)8(4-32)48-26)50-27-16(40)13(37)14(38)21(52-27)23(42)43;/h7-22,25-28,31-32,35-41,46H,3-4H2,1-2H3,(H,29,33)(H,30,34)(H,42,43)(H,44,45);/q;+1/t7-,8-,9-,10-,11-,12-,13+,14+,15-,16-,17-,18-,19-,20+,21+,22+,25-,26+,27-,28-;/m1./s1 DMX8M26 CS CC(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@H]1O)CO)O)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)C(=O)O)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)C(=O)O)O)O)O)NC(=O)C)O)O.[Na+] DMX8M26 IK YWIVKILSMZOHHF-QJZPQSOGSA-N DMX8M26 IU sodium;(2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid DMX8M26 CA CAS 9067-32-7 DMX8M26 DE Joint lubricant; Pancytopenia; Enthesopathy DMETWAU ID DMETWAU DMETWAU DN Hyaluronidase (ovine) DMETWAU HS Approved DMETWAU SN Hyaluronidase; Hydase; Vitragan; Vitrase; Hyaluronidase Injection; Hyaluronidase (vitreous hemorrhage), ISTA DMETWAU CP PrimaPharm; Primapharm DMETWAU SQ Hyaluronidase Sequence: MWTGLGPAVTLALVLVVAWATELKPTAPPIFTGRPFVVAWDVPTQDCGPRHKMPLDPKDMKAFDVQASPNEGFVNQNITIFYRDRLGMYPHFNSVGGSVHGGVPQNGSLWVHLEMLKGHVEHYIRTQEPAGLAVIDWEDWRPVWVRNWQDKDVYRRLSRQLVASHHPDWPPERIVKEAQYEFEFAARQFMLETLRFVKAFRPRHLWGFYLFPDCYNHDYVQNWETYTGRCPDVEVSRNDQLSWLWAESTALFPSVYLEETLASSTHGRNFVSFRVQEALRVADVHHANHALPVYVFTRPTYSRGLTGLSEMDLISTIGESAALGAAGVILWGDAGFTTSNETCRRLKDYLTRSLVPYVVNVSWAAQYCSWAQCHGHGRCVRRDPNAHTFLHLSASSFRLVPSHAPDEPRLRPEGELSWADRNHLQTHFRCQCYLGWGGEQCQWDRRRAAGGASGAWAGFHLTGLLAVAVLAFTWTS DMETWAU DE Resorption of radiopaque agents DMU8JGH ID DMU8JGH DMU8JGH DN Hydralazine DMU8JGH HS Approved DMU8JGH SN Apresolin; Apresoline; Apressin; Apressoline; Aprezolin; HLZ; Hidral; Hidralazin; Hidralazina; Hipoftalin; Hydralazin; Hydralazinum; Hydrallazin; Hydrallazine; Hydrazinophthalazine; Hypophthalin; Idralazina; Hidralazina [Spanish]; Idralazina [DCIT]; Idralazina [Italian]; BA 5968; C 5968; Ciba 5968; Praparat 5968; Apresoline (TN); Apressin (pharmaceutical); C-5068; C-5968; Hidral (TN); Hidralazina [INN-Spanish]; Hydralazine (INN); Hydralazine [INN:BAN]; Hydralazinum [INN-Latin]; Hydrazone 1(2H)-phthalazinone; Phthalazin-1-ylhydrazine; [2H-Phthalazin-(1Z)-Ylidene]-Hydrazine Hydrochloride; (1Z)-1(2H)-Phthalazinone hydrazone; (2H)-Phthalazinone hydrazone; 1(2H)-Phthalazinone hydrazone; 1(2H)-Phthalazinone, hydrazone; 1-Hydrazinophthalazine; 1-Phthalazinylhydrazine; 6-Hydralazine DMU8JGH TC Antihypertensive Agents DMU8JGH DT Small molecular drug DMU8JGH PC 3637 DMU8JGH MW 160.18 DMU8JGH FM C8H8N4 DMU8JGH IC InChI=1S/C8H8N4/c9-11-8-7-4-2-1-3-6(7)5-10-12-8/h1-5H,9H2,(H,11,12) DMU8JGH CS C1=CC=C2C(=C1)C=NN=C2NN DMU8JGH IK RPTUSVTUFVMDQK-UHFFFAOYSA-N DMU8JGH IU phthalazin-1-ylhydrazine DMU8JGH CA CAS 86-54-4 DMU8JGH CB CHEBI:5775 DMU8JGH DE Hypertension DMUSZHD ID DMUSZHD DMUSZHD DN Hydrochlorothiazide DMUSZHD HS Approved DMUSZHD SN Acesistem; Acuilix; Acuretic; Aldazida; Aldoril; Apresazide; Aquarills; Aquarius; Bremil; Briazide; Caplaril; Carozide; Catiazida; Chlorizide; Chlorosulthiadil; Chlorzide; Chlothia; Cidrex; Clorana; Condiuren; Diaqua; Dichlorosal; Dichlorotride; Dichlothiazide; Dichlotiazid; Dichlotride; Diclotride; Dicyclotride; Didral; Dihydran; Dihydrochlorothiazid; Dihydrochlorothiazide; Dihydrochlorothiazidum; Dihydrochlorurit; Dihydrochlorurite; Dihydroxychlorothiazidum; Direma; Disalunil; Disothiazid; Diurogen; Dixidrasi; Drenol; Esidrex; Esidrix; Esoidrina; Fluvin; HCT; HCTZ; HCZ; Hidril; Hidrochlortiazid; Hidroclorotiazida; Hidroronol; Hidrosaluretil; Hidrotiazida; Hyclosid; Hydril; HydroDIURIL; Hydrochlorat; Hydrochlorot; Hydrochlorothiazid; Hydrochlorothiazidum; Hydrochlorthiazide; Hydrochlorthiazidum; Hydrocot; Hydrodiuretic; Hydropres; Hydrosaluric; Hydrothide; Hydrozide; Hypothiazid; Hypothiazide; Hytrid; Idroclorotiazide; Idrotiazide; Indroclor; Ivaugan; Manuril; Maschitt; Medozide; Megadiuril; Microzide; Mictrin; Mikorten; Modurcen; Moduretic; Natrinax; Nefrix; Nefrol; Neoflumen; Newtolide; Novodiurex; Oretic; Pantemon; Panurin; Roxane; Saldiuril; Sectrazide; Selozide; Servithiazid; Spironazide; Tandiur; Thiaretic; Thiuretic; Thlaretic; Timolide; Unazid; Urodiazin; Urozide; Vaseretic; Vetidrex; Aquazide H; Chlorsulfonamidodihydrobenzothiadiazine dioxide; Component of Aldactazide; Component of Aldoril; Component of Butizide Prestabs; Component of Caplaril; Component of Cyclex; Component of Dyazide; Component of Esimil; Concor Plus; Diclot ride; Hydro Par; Hydrochlorothiazide Intensol; Idroclorotiazide [DCIT]; Lotensin HCT; Panurin dichloride; Raunova Plus; Diu 25 Vigt; H 4759; MaybridgeCompound 10; Mazide 25 mg; Su 5879; Aldactazide 25/25; Aldectazide 50/50; Apo-Hydro; Aquazide H (TN); Aquazide-H; Dichlotride (TN); Diu-melusin; Esidrex (TN); Esidrix (TN); HCT-Isis; Hidro-Niagrin; Hidroclorotiazida [INN-Spanish]; Hydrex-semi; Hydro-Aquil; Hydro-D; Hydro-Diuril; Hydro-Saluric; Hydro-T; Hydro-chlor; HydroSaluric (TN); Hydrochlorothiazidum [INN-Latin]; Hydrodiuril (TN); Hydrozide Injection, Veterinary; Jen-Diril; Microzide (TN); Neo-Flumen; Neo-Minzil; Neo-codema; Oretic (TN); Ro-hydrazide; AF-614/30832002; Apo-Hydro (TN); Hydrochlorothiazide [INN:BAN:JAN]; Hydrochlorothiazide (JP15/USP/INN); Dro-2H-1,2,4-benzothiadiazine 1,1-dioxide; 3,4-Dihydro-6-chloro-7-sulfamyl-1,2, 4-benzothi; 3,4-Dihydrochlorothiazide; 6-Chloro-7-sulfamoyl-3, 4-dihy DMUSZHD TC Diuretics DMUSZHD DT Small molecular drug DMUSZHD PC 3639 DMUSZHD MW 297.7 DMUSZHD FM C7H8ClN3O4S2 DMUSZHD IC InChI=1S/C7H8ClN3O4S2/c8-4-1-5-7(2-6(4)16(9,12)13)17(14,15)11-3-10-5/h1-2,10-11H,3H2,(H2,9,12,13) DMUSZHD CS C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl DMUSZHD IK JZUFKLXOESDKRF-UHFFFAOYSA-N DMUSZHD IU 6-chloro-1,1-dioxo-3,4-dihydro-2H-1lambda6,2,4-benzothiadiazine-7-sulfonamide DMUSZHD CA CAS 58-93-5 DMUSZHD CB CHEBI:5778 DMUSZHD DE Hypertension DMQ2JO5 ID DMQ2JO5 DMQ2JO5 DN Hydrocodone DMQ2JO5 HS Approved DMQ2JO5 SN HYDROCODONE; Dihydrocodeinone; Hydrocodon; Hydrocone; Hydroconum; Codinovo; Dicodid; Multacodin; Bekadid; hidrocodona; Idrocodone; Hydrocodonum; Idrocodone [DCIT]; DICO; (-)-Dihydrocodeinone; Hydrocodonum [INN-Latin]; 125-29-1; Hidrocodona [INN-Spanish]; Codeinone, dihydro-; Hydrocodone polistirex; Hydrocodone [INN:BAN]; UNII-6YKS4Y3WQ7; 4,5-alpha-Epoxy-3-methoxy-17-methylmorphinan-6-one; 6-Oxo-3-methoxy-N-methyl-4,5-epoxymorphinan; 4,5alpha-Epoxy-3-methoxy-17-methylmorphinan-6-one; HSDB 3097; EINECS 204-733-9; BRN 0094193; Bekadid; Hidrocodona; Hydrocodeinonebitartrate; Hydrocon; Anexsia (TN); Dicodid (TN); Duodin (TN); Hycet (TN); Hycodan (TN); Hycomine (TN); Hydrocodone (INN); Hydrokon (TN); Hydrovo (TN); Kolikodol (TN); Lorcet (TN); Lortab (TN); Mercodinone (TN); Norco (TN); Norgan (TN); Novahistex (TN); Orthoxycol (TN); Symtan (TN); Synkonin (TN); Vicodin (TN); Morphinan-6-one, 4,5alpha-epoxy-3-methoxy-17-methyl-(8CI); Morphinan-6-one, 4,5-epoxy-3-methoxy-17-methyl-, (5alpha)-(9CI); (5alpha)-17-methyl-3-(methyloxy)-4,5-epoxymorphinan-6-one; 3-methoxy-17-methyl-4,5alpha-epoxymorphinan-6-one; KP-201 hydrocodone prodrug DMQ2JO5 CP Abbott Laboratories DMQ2JO5 TC Analgesics DMQ2JO5 DT Small molecular drug DMQ2JO5 PC 5284569 DMQ2JO5 MW 299.4 DMQ2JO5 FM C18H21NO3 DMQ2JO5 IC InChI=1S/C18H21NO3/c1-19-8-7-18-11-4-5-13(20)17(18)22-16-14(21-2)6-3-10(15(16)18)9-12(11)19/h3,6,11-12,17H,4-5,7-9H2,1-2H3/t11-,12+,17-,18-/m0/s1 DMQ2JO5 CS CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)OC)O[C@H]3C(=O)CC4 DMQ2JO5 IK LLPOLZWFYMWNKH-CMKMFDCUSA-N DMQ2JO5 IU (4R,4aR,7aR,12bS)-9-methoxy-3-methyl-1,2,4,4a,5,6,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one DMQ2JO5 CA CAS 125-29-1 DMQ2JO5 CB CHEBI:5779 DMQ2JO5 DE Pain DMIAPBE ID DMIAPBE DMIAPBE DN Hydrocodone bitartrate DMIAPBE HS Approved DMIAPBE SN Hydrocodon; Hydrocodone [INN:BAN]; Hydrocodone polistirex; Hydrocodonum; Hydrocodonum [INN-Latin]; Hydrocone; Hydroconum; Idrocodone; Idrocodone [DCIT]; Multacodin; hidrocodona; (-)-Dihydrocodeinone; 125-29-1; 4,5-alpha-Epoxy-3-methoxy-17-methylmorphinan-6-one; 4,5alpha-Epoxy-3-methoxy-17-methylmorphinan-6-one; 6-Oxo-3-methoxy-N-methyl-4,5-epoxymorphinan; BRN 0094193; DICO; EINECS 204-733-9; HSDB 3097; UNII-6YKS4Y3WQ7; Bekadid; Codeinone, dihydro-; Codinovo; Dicodid; Dihydrocodeinone; HYDROCODONE; Hidrocodona [INN-Spanish]; HYDROCODONE BITARTRATE; OJHZNMVJJKMFGX-RNWHKREASA-N; SCHEMBL154972; .codon; 143-71-5; API0002943; CHEMBL2062267; MFCD00078557 DMIAPBE PC 20831824 DMIAPBE MW 449.4 DMIAPBE FM C22H27NO9 DMIAPBE IC OJHZNMVJJKMFGX-RNWHKREASA-N DMIAPBE CS CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(=O)CC4.C(C(C(=O)O)O)(C(=O)O)O DMIAPBE IK 1S/C18H21NO3.C4H6O6/c1-19-8-7-18-11-4-5-13(20)17(18)22-16-14(21-2)6-3-10(15(16)18)9-12(11)19;5-1(3(7)8)2(6)4(9)10/h3,6,11-12,17H,4-5,7-9H2,1-2H3;1-2,5-6H,(H,7,8)(H,9,10)/t11-,12+,17-,18-;/m0./s1 DMIAPBE IU (4R,4aR,7aR,12bS)-9-methoxy-3-methyl-1,2,4,4a,5,6,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one;2,3-dihydroxybutanedioic acid DMIAPBE CA CAS 143-71-5 DMIAPBE DE Neuropathic pain DM8K1XO ID DM8K1XO DM8K1XO DN Hydrocortamate DM8K1XO HS Approved DM8K1XO SN Hidrocortamato; Hydrocortamatum; Idrocortamato; Magnacort; Hydrocortamate [INN]; Idrocortamato [DCIT]; Hidrocortamato [INN-Spanish]; Hydrocortamatum [INN-Latin]; Hydrocortisone 21-(diethylamino)acetate; Hyddrocortison-21-(beta-diethylaminoacetat); Glycine, N,N-diethyl-, 21-ester with cortisol; Glycine, N,N-diethyl-, (11beta)-11,17-dihydroxy-3,20-dioxopregn-4-en-21-yl ester; [2-[(8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-10,13-dimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-oxoethyl] 2-(diethylamino)acetate; 11beta,17-Dihydroxy-3,20-dioxo-4-pregnen-21-yl 2-(diethylamino)acetat; 11beta,17-dihydroxy-3,20-dioxopregn-4-en-21-yl N,N-diethylglycinate; 11beta,17alpha,21-Trihydroxypregn-4-ene-3,20-dione 21-diethylaminoacetate; 17-Hydroxycorticosterone, 21-(diethylamino)acetate DM8K1XO TC Antiinflammatory Agents DM8K1XO DT Small molecular drug DM8K1XO PC 84088 DM8K1XO MW 475.6 DM8K1XO FM C27H41NO6 DM8K1XO IC InChI=1S/C27H41NO6/c1-5-28(6-2)15-23(32)34-16-22(31)27(33)12-10-20-19-8-7-17-13-18(29)9-11-25(17,3)24(19)21(30)14-26(20,27)4/h13,19-21,24,30,33H,5-12,14-16H2,1-4H3/t19-,20-,21-,24+,25-,26-,27-/m0/s1 DM8K1XO CS CCN(CC)CC(=O)OCC(=O)[C@]1(CC[C@@H]2[C@@]1(C[C@@H]([C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)O)C)O DM8K1XO IK FWFVLWGEFDIZMJ-FOMYWIRZSA-N DM8K1XO IU [2-[(8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-10,13-dimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-oxoethyl] 2-(diethylamino)acetate DM8K1XO CA CAS 76-47-1 DM8K1XO CB CHEBI:50851 DM8K1XO DE Inflammation DMGEMB7 ID DMGEMB7 DMGEMB7 DN Hydrocortisone DMGEMB7 HS Approved DMGEMB7 SN Acticort; Alacort; Algicirtis; Alphaderm; Amberin; Anflam; Anucort; Aquacort; Cetacort; Chronocort; Cleiton; Cobadex; Colocort; Corhydron; Cortanal; Cortef; Cortenema; Cortesal; Corticreme; Cortifair; Cortifan; Cortiment; Cortisol; Cortisolonum; Cortisporin; Cortispray; Cortolotion; Cortonema; Cortoxide; Cortril; Cremesone; Cutisol; Delacort; Dermacort; Dermaspray; Dermil; Dermocortal; Dermolate; Dihydrocostisone; Dioderm; Drotic; DuoCort; Efcorbin; Efcortelan; Efcortelin; Eldecort; Eldercort; Epicort; Epicortisol; Evacort; Ficortril; Fiocortril; Flexicort; Genacort; Glycort; Hidalone; Hycort; Hycortol; Hycortole; Hydracort; Hydrasson; Hydrocortal; Hydrocorticosterone; Hydrocortisyl; Hydrocortone; Hydroskin; Hydroxycortisone; Hytisone; Hytone; Idrocortisone; Kyypakkaus; Lactisona; Lubricort; Maintasone; Medicort; Meusicort; Mildison; Milliderm; Nutracort; Optef; Otocort; Penecort; Permicort; Prepcort; Proctocort; Protocort; Rectoid; Sanatison; Schericur; Sigmacort; Signef; Stiefcorcil; Synacort; Tarcortin; Texacort; Timocort; Traumaide; Uniderm; Vytone; Zenoxone; ACETASOL HC; Aeroseb HC; AnusolHC; Aquanil HC; Barseb HC; CaldeCORT Spray; Clear aid; Component of Lubricort; Component of Otalgine; Cortisol alcohol; Cortisporin Otico; Ef corlin; Epiderm H; Esiderm H; Foille Insetti; HYDROCORTISONE AND ACETIC ACID; HYDROCORTISONE IN ABSORBASE; Heb Cort; Hydrocortisone alcohol; Hydrocortisone base; Hydrocortisone free alcohol; Hydrocortisone solution; Hytone lotion; Idrocortisone [DCIT]; Komed HC; Lacticare HC; Nogenic HC; ORLEX HC; Pediotic Suspension; Polcort H; Preparation H Hydrocortisone Cream; Prevex HC; Proctozone HC; Remederm HC; Scalpicin Capilar; Scheroson F; Systral Hydrocort; Transderma H; VoSol HC; H 4001; Texacort lotion 25; [3H]cortisol; ACETIC ACID W/ HYDROCORTISONE; Acticort (TN); Aeroseb-HC; Ala-Cort; Ala-Scalp; Anti-inflammatory hormone; Anucort-HC; Anusol HC (TN); Balneol-hc; Basan-Corti; Beta-hc; COR-OTICIN; Colocort (TN); Cort-Dome; Cortef (TN); Cortisol, Hydrocortisone; Cremicort-H; Cyclodextrin-encapsulated hydrocortisone; Derm-Aid; Dome-cort; Domolene-HC; Genacort (lotion); Gyno-Cortisone; H-Cort; HC #1; HC #4; HC (HYDROCORTISONE); Heb-Cort; Hi-cor; Hidro-Colisona; Hidrocortisona [INN-Spanish]; Hydro-Adreson; Hydro-Colisona; Hydro-RX; Hydrocortisone-Water Soluble; Hydrocortisonum [INN-Latin]; Hytone (TN); Incortin-H; Incortin-hydrogen; Kendall's compound F; Lacticare-HC; Neo-Cortef; Neosporin-H Ear; Nystaform-HC; Otosone-F; Rectasol-HC; Reichstein's substance M; Scalp-Cort; Stie-cort; Component of Neo-Cort-Dome; Hydrocortisone [INN:BAN:JAN]; Hydrocortisone (JP15/USP/INN); 11-beta-Hydrocortisone; 11-beta-Hydroxycortisone; 11beta,17,21-Trihydroxyprogesterone; 11beta-Hydrocortisone; 11beta-Hydroxycortisone; 17-Hydroxycorticosterone; 17alpha-Hydroxycorticosterone DMGEMB7 CP Merck And Co Inc DMGEMB7 TC Antiinflammatory Agents DMGEMB7 DT Small molecular drug DMGEMB7 PC 5754 DMGEMB7 MW 362.5 DMGEMB7 FM C21H30O5 DMGEMB7 IC InChI=1S/C21H30O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h9,14-16,18,22,24,26H,3-8,10-11H2,1-2H3/t14-,15-,16-,18+,19-,20-,21-/m0/s1 DMGEMB7 CS C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@H]2[C@H](C[C@]4([C@H]3CC[C@@]4(C(=O)CO)O)C)O DMGEMB7 IK JYGXADMDTFJGBT-VWUMJDOOSA-N DMGEMB7 IU (8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one DMGEMB7 CA CAS 50-23-7 DMGEMB7 CB CHEBI:17650 DMGEMB7 DE Inflammation; Congenital adrenal hyperplasia DMVPUQI ID DMVPUQI DMVPUQI DN Hydroflumethiazide DMVPUQI HS Approved DMVPUQI SN Bristab; Bristurin; Dihydroflumethazide; Dihydroflumethiazide; Diucardin; Diuredemina; Diurometon; Elodrin; Elodrine; Enjit; Finuret; Flutizide; Glomerulin; HFZ; Hidroalogen; Hidroflumetiazid; Hidroflumetiazida; Hydol; Hydrenox; Hydroflumethazide; Hydroflumethiazidum; Hydroflumethizide; Idroflumetiazide; Leodrine; Metflorylthiazidine; Metforylthiadiazin; Metforylthiazidin; Methforylthiazidine; NaClex; Olmagran; Rivosil; Robezon; Rodiuran; Rontyl; Saluron; Sisuril; Spandiuril; Trifluoromethylhydrazide; Trifluoromethylhydrothiazide; Vergonil; Component of Salutensin; Idroflumetiazide [DCIT]; SB01887; Di-ademil; Di-adenil; Hidroflumetiazida [INN-Spanish]; Hydroflumethiazidum [INN-Latin]; Naciex (glaxo); Saluron (TN); Hydroflumethiazide [INN:BAN:JAN]; Hydroflumethiazide (JAN/USP/INN); Ethyl-2H-1,2, 4-benzothiadiazine-7-sulfonamide 1,1-dioxide; Fluoromethyl-3, 4-dihydro-1,2,4-benzothiadiazine 1,1-dioxide; 1,1-dioxo-6-(trifluoromethyl)-3,4-dihydro-2H-1; 2H-1,2, 4-Benzothiadiazine-7-sulfonamide, 3, 4-dihydro-6-(trifluoromethyl)-, 1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 3,4-dihydro-6-(trifluoromethyl)-, 1,1-dioxide; 3, 4-Dihydro-6-trifluorom; 3, 4-Dihydro-6-trifluoromethyl-7-sulfamoylbenzo-1,2,4-thiadiazine 1, 1-dioxide; 3,4-Dihydro-6-(trifluoromethyl)-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 3,4-Dihydro-6-trifluoromethyl-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 3,4-Dihydro-6-trifluoromethyl-7-sulfamoylbenzo-1,2,4-thiadiazine 1,1-dioxide; 3,4-Dihydro-7-sulfamoyl-6-trifluoromethyl-2H-1,2, 4-benzothi; 3,4-Dihydro-7-sulfamoyl-6-trifluoromethyl-2H-1,2,4-benzothiadiazine 1,1-dioxide; 3,4-Dihydro-7-sulfamyl-6-trifluoromethyl-2H-1,2,4-benzothiadiazine 1,1-dioxide; 6-(Trifluoromethyl)-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 6-Trifluoromethyl-3, 4-dihydro-7-sulfamoyl-2H-1,2,4-benzothiadiazine 1,1-dioxide; 6-Trifluoromethyl-3,4-dihydro-7-sulfamoyl-2H-1,2,4-benzothiadiazine 1,1-dioxide; 6-Trifluoromethyl-7-sulfamoyl-3,4-dihydro-1,2, 4-benzothiadiazine-1,1-dioxide; 6-Trifluoromethyl-7-sulfamoyl-3,4-dihydro-1,2,4-benzothiadiazine-1,1-dioxide; 6-Trifluoromethyl-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine-1,1-dioxide; 7-Sulfamoyl-6-tri; 7-Sulfamoyl-6-trifluoromethyl-3,4-dihydro-1,2,4-benzothiadiazine 1,1-dioxide; 7-Sulfamyl-6-trifluoromethyl-3,4-dihydro-1,2,4-benzothiadiazine 1, 1-dioxide; 7-Sulfamyl-6-trifluoromethyl-3,4-dihydro-1,2,4-benzothiadiazine 1,1-dioxide DMVPUQI TC Diuretics DMVPUQI DT Small molecular drug DMVPUQI PC 3647 DMVPUQI MW 331.3 DMVPUQI FM C8H8F3N3O4S2 DMVPUQI IC InChI=1S/C8H8F3N3O4S2/c9-8(10,11)4-1-5-7(2-6(4)19(12,15)16)20(17,18)14-3-13-5/h1-2,13-14H,3H2,(H2,12,15,16) DMVPUQI CS C1NC2=C(C=C(C(=C2)C(F)(F)F)S(=O)(=O)N)S(=O)(=O)N1 DMVPUQI IK DMDGGSIALPNSEE-UHFFFAOYSA-N DMVPUQI IU 1,1-dioxo-6-(trifluoromethyl)-3,4-dihydro-2H-1lambda6,2,4-benzothiadiazine-7-sulfonamide DMVPUQI CA CAS 135-09-1 DMVPUQI CB CHEBI:5784 DMVPUQI DE Congestive heart failure DM1NG5W ID DM1NG5W DM1NG5W DN Hydrogen peroxide DM1NG5W HS Approved DM1NG5W SN perhydrol; oxydol; 7722-84-1; Superoxol; Interox; Hydrogen dioxide; hydroperoxide; Peroxaan; Inhibine; Kastone; Hioxyl; Albone; Albone 35; Dihydrogen dioxide; Albone DS; T-Stuff; Lensept; Perone; Elawox; Albone 70; Perone 50; Albone 50; Albone 35CG; Albone 70CG; Albone 50CG; H2O2; Hydrogen peroxide (H2O2); Peroxide; Peroxan; Hydrogen peroxide, 30%; Hydrogen dioxide solution; Hydrogen peroxide, 90%; Perone 35; Perone 30; Hydrogen peroxide, solution; Waterstofperoxyde; Wasserstoffperoxid; Hydrogen peroxide, 3%; Caswell No. 486AA DM1NG5W DT Small molecular drug DM1NG5W PC 784 DM1NG5W MW 34.015 DM1NG5W FM H2O2 DM1NG5W IC InChI=1S/H2O2/c1-2/h1-2H DM1NG5W CS OO DM1NG5W IK MHAJPDPJQMAIIY-UHFFFAOYSA-N DM1NG5W IU hydrogen peroxide DM1NG5W CA CAS 7722-84-1 DM1NG5W CB CHEBI:16240 DM1NG5W DE Infectious disease DMHP21E ID DMHP21E DMHP21E DN Hydromorphone DMHP21E HS Approved DMHP21E SN hydromorphone; Dihydromorphinone; Dimorphone; Idromorfone; Hydromorphon; Dihydromorfinon; Hydromorfona; Laudacon; DiMo; Hydromorphonum; 7,8-Dihydromorphinone; Novolaudon; Hidromorfona; Dilaudid; Dilaudid Oros; Hydromorfona [Spanish]; Dihydromorfinon [Czech]; 466-99-9; Hydromorphonum [INN-Latin]; Hidromorfona [INN-Spanish]; Palladone; 6-Deoxy-7,8-dihydro-6-oxomorphine; Morphinone, dihydro-; Idromorfone [DCIT]; Laudicon; Hydromorphone [INN:BAN]; Dilaudid-hp; 4,5-Epoxy-3-hydroxy-17-methylmorphinan-6-one; DiMo; Hydromorphone HCL; Dilaudid (TN); Hydromorphone (INN); Palladone (TN); Palladone SR (TN); Morphinan-6-one, 4,5alpha-epoxy-3-hydroxy-17-methyl-(8CI); (-)-(5R)-4,5-Epoxy-3-hydroxy-9alpha-methylmorphinan-6-one; (-)-Hydromorphone; (5alpha)-3-hydroxy-17-methyl-4,5-epoxymorphinan-6-one; 3-hydroxy-17-methyl-4,5alpha-epoxymorphinan-6-one; 4,5alpha-Epoxy-3-hydroxy-17-methyl-6-morphinanone; Hydromorphone prodrug DMHP21E CP Knoll DMHP21E TC Analgesics DMHP21E DT Small molecular drug DMHP21E PC 5284570 DMHP21E MW 285.34 DMHP21E FM C17H19NO3 DMHP21E IC InChI=1S/C17H19NO3/c1-18-7-6-17-10-3-5-13(20)16(17)21-15-12(19)4-2-9(14(15)17)8-11(10)18/h2,4,10-11,16,19H,3,5-8H2,1H3/t10-,11+,16-,17-/m0/s1 DMHP21E CS CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)O)O[C@H]3C(=O)CC4 DMHP21E IK WVLOADHCBXTIJK-YNHQPCIGSA-N DMHP21E IU (4R,4aR,7aR,12bS)-9-hydroxy-3-methyl-1,2,4,4a,5,6,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one DMHP21E CA CAS 466-99-9 DMHP21E CB CHEBI:5790 DMHP21E DE Pain; Chronic pain DM6AVR4 ID DM6AVR4 DM6AVR4 DN Hydroquinone DM6AVR4 HS Approved DM6AVR4 SN hydroquinone; 1,4-benzenediol; Benzene-1,4-diol; 123-31-9; 1,4-Dihydroxybenzene; Quinol; p-Benzenediol; p-Hydroxyphenol; p-Hydroquinone; 4-Hydroxyphenol; Eldoquin; Benzoquinol; p-Dihydroxybenzene; hydroquinol; Eldopaque; Phiaquin; p-Dioxybenzene; Hydroquinole; Dihydroquinone; Tecquinol; Idrochinone; Benzohydroquinone; Tequinol; Hidroquinone; Arctuvin; Dihydroxybenzene; Solaquin forte; Derma-Blanch; Tenox HQ; Hydrochinone; Hydrochinon; Artra; Eldoquin Forte; Eldopaque Forte; Diak 5; Benzene, p-dihydroxy-; 1,4-Dihydroxy-benzol; Usaf ek-356; Accutin DM6AVR4 DT Small molecular drug DM6AVR4 PC 785 DM6AVR4 MW 110.11 DM6AVR4 FM C6H6O2 DM6AVR4 IC InChI=1S/C6H6O2/c7-5-1-2-6(8)4-3-5/h1-4,7-8H DM6AVR4 CS C1=CC(=CC=C1O)O DM6AVR4 IK QIGBRXMKCJKVMJ-UHFFFAOYSA-N DM6AVR4 IU benzene-1,4-diol DM6AVR4 CA CAS 123-31-9 DM6AVR4 CB CHEBI:17594 DM6AVR4 DE Melasma DMGKV9D ID DMGKV9D DMGKV9D DN Hydroxocobalamin DMGKV9D HS Approved DMGKV9D SN AlphaRedisol; Axion; Axlon; Cobalex; Codroxomin; Cyanokit; Depogamma; Docclan; Docelan; Docelvita; Docevita; Duradoce; Hidroxocobalamina; Hydrobamine; Hydrocobalamin; Hydrogrisevit; Hydrovit; Hydroxocobalaminacetat; Hydroxocobalamine; Hydroxocobalaminum; Hydroxocobemine; Hydroxomin; Hydroxycobalamin; Hydroxycobalamine; Hyxobamine; Idrogrisevit; Idrossocobalamina; Oxobemin; Vibeden; Vitadurin; Alpha Cobione; Ciplamin H; Hydro Cobex; Hydroxocobalamin acetate; Hydroxocobalamin monohydrochloride; Hydroxy Cobal; Idrossocobalamina [DCIT]; Primabalt RP; Hydroxocobalamin Vitamin B12; Hydroxy vitamin B12; Ohb12; Vitamin B12a; Vitamin B12b; Acti-B12; AlphaRedisol (TN); Benzimidazolyl ribofuranosyl phosphate deriv.; Cyanokit (TN); Ducobee-Hy; Duralta-12; Hidroxocobalamina [INN-Spanish]; Hydroxocobalamine [INN-French]; Hydroxocobalaminum [INN-Latin]; Hydroxycob(lll)alamin; Lyovit-H; Neo-Betalin 12; Neo-cytamen; Neo-macrabin; Neo-rojamin; OH-Cbl; OH-Duphar; Oxolamine (arcum); Redisol-H; Sytobex-H; Vitamin B(sub 12a); Vitamin B-12b; Hydroxocobalamin (JAN/USP/INN); Hydroxocobalamin [USAN:INN:BAN:JAN]; Alpha-(5,6-Dimethylbenzimidazolyl)hydroxocobamide; Hydroxocobalamin(alkaline soln.), OH-replaces CN-in Cyanocobalamin); Coalpha-[alpha-(5,6-dimethylbenzimidazolyl)]-Cobeta-hydroxocobamide; Cobinamide hydroxide phosphate 3'-ester with 5,6-dimethyl-1-alpha-D-ribofuranosylbenzimidazole inner salt; Cobinamide dihydroxide dihydrogen phosphate (ester), mono(inner salt), 3'-ester with 5,6-dimethyl-1-alpha-D-ribofuranosylbenzimidazole; Cobinamide, dihydroxide, dihydrogen phosphate (ester), mono (inner salt), 3'-ester with 5,6-dimethyl-1-alpha-D-ribofuranosylbenzimidazole; Cobinamide, hydroxide, dihydrogen phosphate (ester), inner salt, 3'-ester with 5,6-dimethyl-1-alpha-D-ribofuranosyl-1H-benzimidazole; Cobinamide, dihydroxide, dihydrogen phosphate (ester), mono(inner salt), 3'-ester with 5,6-dimethyl-1-alpha-D-ribofuranosyl-1H-benzimidazole; Cobinamide, Co-hydroxy-, dihydrogen phosphate (ester), inner salt, 3'-ester with (5,6-dimethyl-1-alpha-D-ribofuranosyl-1H-benzimidazole-kappaN3); Cobinamide, Co-hydroxy-, f-(dihydrogen phosphate), inner salt, 3'-ester with (5,6-dimethyl-1-alpha-D-ribofuranosyl-1H-benzimidazole-kappaN3) DMGKV9D TC Vitamins DMGKV9D DT Small molecular drug DMGKV9D PC 70689311 DMGKV9D MW 1347.4 DMGKV9D FM C62H90CoN13O15P DMGKV9D IC InChI=1S/C62H90N13O14P.Co.H2O/c1-29-20-39-40(21-30(29)2)75(28-70-39)57-52(84)53(41(27-76)87-57)89-90(85,86)88-31(3)26-69-49(83)18-19-59(8)37(22-46(66)80)56-62(11)61(10,25-48(68)82)36(14-17-45(65)79)51(74-62)33(5)55-60(9,24-47(67)81)34(12-15-43(63)77)38(71-55)23-42-58(6,7)35(13-16-44(64)78)50(72-42)32(4)54(59)73-56;;/h20-21,23,28,31,34-37,41,52-53,56-57,76,84H,12-19,22,24-27H2,1-11H3,(H15,63,64,65,66,67,68,69,71,72,73,74,77,78,79,80,81,82,83,85,86);;1H2/q;+2;/p-2/t31-,34-,35-,36-,37+,41-,52-,53-,56-,57+,59-,60+,61+,62+;;/m1../s1 DMGKV9D CS CC1=CC2=C(C=C1C)N(C=N2)[C@@H]3[C@@H]([C@@H]([C@H](O3)CO)OP(=O)([O-])O[C@H](C)CNC(=O)CC[C@@]\\4([C@H]([C@@H]5[C@]6([C@@]([C@@H](C(=N6)/C(=C\\7/[C@@]([C@@H](C(=N7)/C=C\\8/C([C@@H](C(=N8)/C(=C4\\[N-]5)/C)CCC(=O)N)(C)C)CCC(=O)N)(C)CC(=O)N)/C)CCC(=O)N)(C)CC(=O)N)C)CC(=O)N)C)O.O.[Co+2] DMGKV9D IK DQOCFCZRZOAIBN-WZHZPDAFSA-L DMGKV9D IU cobalt(2+);[(2R,3S,4R,5S)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2R)-1-[3-[(1R,2R,3R,4Z,7S,9Z,12S,13S,14Z,17S,18S,19R)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7,12,17-tetrahydro-1H-corrin-21-id-3-yl]propanoylamino]propan-2-yl] phosphate;hydrate DMGKV9D CA CAS 13422-51-0 DMGKV9D DE Vitamin B12 deficiency; Lung injury DMJAS3O ID DMJAS3O DMJAS3O DN Hydroxyamphetamine DMJAS3O HS Approved DMJAS3O SN Hydroxyamfetamine; Hydroxyamphetamide; Norpholedrine; Norveritol; Nov-Pholedrin; Oksamfetamin; Oxamfetamin; Oxamphetamine; Oxamphetaminium; Paradrine; Paredrine; Paredrinex; Pedrolon; Phenol, 4-(2-aminopropyl)-; Phenol, p-(2-aminopropyl)-; Phenol,4-(2-aminopropyl)-; Pulsoton; alpha-Methyltyramine; hydroxyamphetamine; p-(2-Aminopropyl)phenol; p-HYDROXYAMPHETAMINE; .alpha.-Methyltyramine; 1-p-Hydroxyphenyl-2-propylamine; 103-86-6; 2-Amino-1-(p-hydroxyphenyl)propane; 4-(2-Aminopropyl)phenol; 4-Hydroxyamphetamine DMJAS3O PC 3651 DMJAS3O MW 151.21 DMJAS3O FM C9H13NO DMJAS3O IC GIKNHHRFLCDOEU-UHFFFAOYSA-N DMJAS3O CS CC(CC1=CC=C(C=C1)O)N DMJAS3O IK 1S/C9H13NO/c1-7(10)6-8-2-4-9(11)5-3-8/h2-5,7,11H,6,10H2,1H3 DMJAS3O IU 4-(2-aminopropyl)phenol DMJAS3O CA CAS 103-86-6 DMJAS3O CB CHEBI:103855 DMJAS3O DE Horner syndrome DMQSGM0 ID DMQSGM0 DMQSGM0 DN Hydroxyamphetamine Hydrobromide DMQSGM0 HS Approved DMQSGM0 SN Paredrine; 4-hydroxyamphetamine DMQSGM0 CP Pharmics Inc DMQSGM0 DT Small molecular drug DMQSGM0 PC 9377 DMQSGM0 MW 232.12 DMQSGM0 FM C9H14BrNO DMQSGM0 IC InChI=1S/C9H13NO.BrH/c1-7(10)6-8-2-4-9(11)5-3-8;/h2-5,7,11H,6,10H2,1H3;1H DMQSGM0 CS CC(CC1=CC=C(C=C1)O)N.Br DMQSGM0 IK RZCJLMTXBMNRAD-UHFFFAOYSA-N DMQSGM0 IU 4-(2-aminopropyl)phenol;hydrobromide DMQSGM0 CA CAS 306-21-8 DMQSGM0 DE Horner syndrome DMSIVND ID DMSIVND DMSIVND DN Hydroxychloroquine DMSIVND HS Approved DMSIVND SN Hidroxicloroquina; Hidroxicloroquina [INN-Spanish]; Hydroxychlorochin; Gen-Hydroxychloroquine 200mg Tablets; HCQ; Hydroxychloroguine; Hydroxychloroquine (INN);Hydroxychloroquine [INN:BAN]; Hydroxychloroquine Sulfate (1:1) Salt; Hydroxychloroquinum; Hydroxychloroquinum [INN-Latin]; Idrossiclorochina; Idrossiclorochina [DCIT]; Oxichlorochinum; Oxichloroquine; Oxychlorochin; Oxychloroquine; Plaquenil (TN); Polirreumin; Polirreumin (TN); Quensyl; WIN 1258 DMSIVND CP Concordia Pharmaceuticals Inc DMSIVND TC Antimalarials DMSIVND DT Small molecular drug DMSIVND PC 3652 DMSIVND MW 335.9 DMSIVND FM C18H26ClN3O DMSIVND IC InChI=1S/C18H26ClN3O/c1-3-22(11-12-23)10-4-5-14(2)21-17-8-9-20-18-13-15(19)6-7-16(17)18/h6-9,13-14,23H,3-5,10-12H2,1-2H3,(H,20,21) DMSIVND CS CCN(CCCC(C)NC1=C2C=CC(=CC2=NC=C1)Cl)CCO DMSIVND IK XXSMGPRMXLTPCZ-UHFFFAOYSA-N DMSIVND IU 2-[4-[(7-chloroquinolin-4-yl)amino]pentyl-ethylamino]ethanol DMSIVND CA CAS 118-42-3 DMSIVND CB CHEBI:5801 DMSIVND DE Malaria DMGIZF5 ID DMGIZF5 DMGIZF5 DN Hydroxyflutamide DMGIZF5 HS Approved DMGIZF5 SN HFT; Hydroxyniphtholide; PC1193; Sch 16423; Hydroxy-flutamide; OH-flutamide; Sch-16423; Alpha, alpha, alpha-trifluoro-2-methyl-4'-nitro-m-lactotoluidide; Alpha,alpha,alpha-Trifluoro-2-methyl-4'-nitro-m-lactotoluidide; 2-Hydroxy-2-methyl-N-(4-nitro-3-(trifluoromethyl)phenyl)propanamide; 2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide DMGIZF5 TC Anticancer Agents DMGIZF5 DT Small molecular drug DMGIZF5 PC 91649 DMGIZF5 MW 292.21 DMGIZF5 FM C11H11F3N2O4 DMGIZF5 IC InChI=1S/C11H11F3N2O4/c1-10(2,18)9(17)15-6-3-4-8(16(19)20)7(5-6)11(12,13)14/h3-5,18H,1-2H3,(H,15,17) DMGIZF5 CS CC(C)(C(=O)NC1=CC(=C(C=C1)[N+](=O)[O-])C(F)(F)F)O DMGIZF5 IK YPQLFJODEKMJEF-UHFFFAOYSA-N DMGIZF5 IU 2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide DMGIZF5 CA CAS 52806-53-8 DMGIZF5 DE Prostate cancer DMIKQH5 ID DMIKQH5 DMIKQH5 DN Hydroxyprogesterone DMIKQH5 HS Approved DMIKQH5 SN Delalutin (TN); Proluton depot (TN) DMIKQH5 CP Bristol Myers Squibb DMIKQH5 DT Small molecular drug DMIKQH5 PC 6238 DMIKQH5 MW 330.5 DMIKQH5 FM C21H30O3 DMIKQH5 IC InChI=1S/C21H30O3/c1-13(22)21(24)11-8-18-16-5-4-14-12-15(23)6-9-19(14,2)17(16)7-10-20(18,21)3/h12,16-18,24H,4-11H2,1-3H3/t16-,17+,18+,19+,20+,21+/m1/s1 DMIKQH5 CS CC(=O)[C@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C)O DMIKQH5 IK DBPWSSGDRRHUNT-CEGNMAFCSA-N DMIKQH5 IU (8R,9S,10R,13S,14S,17R)-17-acetyl-17-hydroxy-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one DMIKQH5 CA CAS 68-96-2 DMIKQH5 CB CHEBI:17252 DMIKQH5 DE Solid tumour/cancer DMR5QS6 ID DMR5QS6 DMR5QS6 DN Hydroxystilbamidine Isethionate DMR5QS6 HS Approved DMR5QS6 SN Hydroxystilbamide; Hydroxystilbamidine diisethionate; FluoroGold (TN); Ethanesulfonic acid, 2-hydroxy-, compd. with 2-hydroxy-4,4'-stilbenedicarboxamidine (2:1); Ethanesulfonic acid, 2-hydroxy-, compd. with 2-hydroxy-4,4'-stilbenedicarboxamidine (2:1) (8CI); Benzenecarboximidamide, 4-(2-(4-(aminoiminomethyl)phenyl)ethenyl)-3-hydroxy-, bis(2-hydroxyethanesulfonate) (salt); Ethanesulfonic acid, 2-hydroxy-, compd. with 4-(2-(4-(aminoiminomethyl)phenyl)ethenyl)-3-hydroxybenzenecarboximidamide (2:1); (4E)-4-[2-[4-(diaminomethylidene)cyclohexa-2,5-dien-1-ylidene]ethylidene]-3-oxocyclohexa-1,5-diene-1-carboximidamide; 2-Hydroxy-4,4'-diamidinostilbene di(beta-hydroxyethanesulfonate); 2-Hydroxy-4,4'-diguanylstilbene diisethionate; 2-Hydroxy-4,4'-stilbenedicarboxamidine bis(2-hydroxyethanesulfonate) (salt); 2-Hydroxy-4,4'-stilbenedicarboxamidine diisethionate; 2-Hydroxyethanesulphonic acid, compoundwith 4-(2-(4-amidinophenyl)vinyl)-3-hydroxybenzenecarboxamidine (2:1); 2-Hydroxystilbamidine diisethionate; 2-Hydroxystilbamidine isethionate; 2-hydroxyethanesulfonic acid DMR5QS6 TC Antifungal Agents DMR5QS6 DT Small molecular drug DMR5QS6 PC 135460345 DMR5QS6 MW 406.5 DMR5QS6 FM C18H22N4O5S DMR5QS6 IC InChI=1S/C16H16N4O.C2H6O4S/c17-15(18)12-5-2-10(3-6-12)1-4-11-7-8-13(16(19)20)9-14(11)21;3-1-2-7(4,5)6/h1-9,21H,(H3,17,18)(H3,19,20);3H,1-2H2,(H,4,5,6)/b4-1+; DMR5QS6 CS C1=CC(=CC=C1/C=C/C2=C(C=C(C=C2)C(=N)N)O)C(=N)N.C(CS(=O)(=O)O)O DMR5QS6 IK HPLUMRXCPMTSQW-DYVSEJHDSA-N DMR5QS6 IU 4-[(E)-2-(4-carbamimidoylphenyl)ethenyl]-3-hydroxybenzenecarboximidamide;2-hydroxyethanesulfonic acid DMR5QS6 CA CAS 533-22-2 DMR5QS6 DE Blastomycosis DMOQVU9 ID DMOQVU9 DMOQVU9 DN Hydroxyurea DMOQVU9 HS Approved DMOQVU9 SN Biosupressin; Droxia; Hidrix; Hidroxicarbamida; Hydrea; Hydreia; Hydroxicarbamidum; Hydroxyaminomethanamide; Hydroxycarbamid; Hydroxycarbamide; Hydroxycarbamidum; Hydroxycarbamine; Hydroxyharnstoff; Hydroxylurea; Hydura; Hydurea; Idrossicarbamide; Litaler; Litalir; Mylocel; NHY; Oncocarbide; Oxyurea; Siklos; Carbamide oxide; Carbamohydroxamic acid; Carbamohydroximic acid; Carbamohydroxyamic acid; Carbamoyl oxime; Carbamyl hydroxamate; Carrbamoyl Oxime; Hydroxyharnstoff [German]; Idrossicarbamide [DCIT]; H 8627; SK 22591; SQ 1089; DRG-0253; Droxia (TM); Droxia (TN); HYDREA (TN); HYDROXY-UREA; Hidroxicarbamida [INN-Spanish]; Hydrea (TM); Hydroxycarbamidum [INN-Latin]; Hydroxyurea (D4); Hydroxyurea (USP); Hydroxyurea [USAN:BAN]; Hydroxyurea(d4); N-Carbamoylhydroxylamine; N-HYDROXY UREA; N-Hydroxymocovina; N-Hydroxymocovina [Czech]; N-Hydroxyurea; Onco-carbide; SQ-1089; Tetratogen: inhibits ribonucleoside diphosphate reductase; Hydroxycarbamide (JAN/INN); N-(Aminocarbonyl) Hydroxyamine; Hydrea, Biosupressin, Cytodrox, Hydroxyurea; S-phase/G-1 interface inhibitor; 1-HYDROXYUREA DMOQVU9 TC Anticancer Agents DMOQVU9 DT Small molecular drug DMOQVU9 PC 3657 DMOQVU9 MW 76.055 DMOQVU9 FM CH4N2O2 DMOQVU9 IC InChI=1S/CH4N2O2/c2-1(4)3-5/h5H,(H3,2,3,4) DMOQVU9 CS C(=O)(N)NO DMOQVU9 IK VSNHCAURESNICA-UHFFFAOYSA-N DMOQVU9 IU hydroxyurea DMOQVU9 CA CAS 127-07-1 DMOQVU9 CB CHEBI:44423 DMOQVU9 DE Chronic myelogenous leukaemia DMF8Y74 ID DMF8Y74 DMF8Y74 DN Hydroxyzine DMF8Y74 HS Approved DMF8Y74 SN Atara; Atarax; Ataraxoid; Atarazoid; Atarox; Atazina; Aterax; Deinait; Durrax; Hidroxizina; Hychotine; Hydroksyzyny; Hydroxine; Hydroxizine; Hydroxizinum; Hydroxycine; Hydroxyzin; Hydroxyzinum; Hydroxyzyne; Idrossizina; Neurozina; Nevrolaks; Orgatrax; Pamazone; Parenteral; Paxistil; Placidol; Plaxidol; Tranquizine; Traquizine; Vistaril; Atarax base; Hydroksyzyny [Polish]; Hydroxyzine Hcl; Hydroxyzine base; Hydroxyzine hydrochloride; Idrossizina [DCIT]; NP 212; UCB 4492; UCB 492; Atarax (TN); Hidroxizina [INN-Spanish]; Hy-Pam 25; Hydroxyzine (INN); Hydroxyzine [INN:BAN]; Hydroxyzinum [INN-Latin]; Marex (TN); Neo-Calma; Tran-Q; U.CB 4492; Vesparaz-Wirkstoff; Vistaril (TN); U.C.B 4492; N-(4-Chlorobenzhydryl)-N'-(hydroxyethoxyethyl)piperazine; N-(4-Chlorobenzhydryl)-N'-(hydroxyethyloxyethyl)piperazine; Ethanol, 2-(2-(4-((4-chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)-(9CI); 1-(p-Chloro-.alpha.-phenylbenzyl)-4-[2-[(2-hydroxyethoxy)ethyl]piperazine; 1-(p-Chloro-alpha-phenylbenzyl)-4-(2-(2-hydroxyethoxy)ethyl)piperazine; 1-(p-Chloro-alpha-phenylbenzyl)-4-(2-hydroxyethoxyethyl)piperazine; 1-(p-Chlorobenzhydryl)-4-(2-(2-hydroxyethoxy)ethyl)diethylenediamine; 1-(p-Chlorobenzhydryl)-4-(2-(2-hydroxyethoxy)ethyl)piperazine; 1-(p-Chlorobenzhydryl)-4-[2-(2-hydroxyethoxy)ethyl]diethylenediamine; 1-(p-Chlorobenzhydryl)-4-[2-(2-hydroxyethoxy)ethyl]piperazine; 1-(p-Chlorodiphenylmethyl)-4-(2-(2-hydroxyethoxy)ethyl)piperazine; 1-(p-Chlorodiphenylmethyl)-4-[2-(2-hydroxyethoxy)ethyl]piperazine; 2-(2-(4-((4-Chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)ethanol; 2-(2-(4-(p-Chloro-alpha-phenylbenzyl)-1-piperazinyl)ethoxy)ethanol; 2-(2-{4-[(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl}ethoxy)ethanol; 2-[(2-{4-[(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl}ethyl)oxy]ethanol; 2-[2-[4-(p-Chloro-.alpha.-phenylbenzyl)-1-piperazinyl]ethoxy]ethanol; 2-[2-[4-[(4-chlorophenyl)-phenylmethyl]piperazin-1-yl]ethoxy]ethanol DMF8Y74 CP Pfizer Pharmaceuticals DMF8Y74 TC Hypnotics and Sedatives DMF8Y74 DT Small molecular drug DMF8Y74 PC 3658 DMF8Y74 MW 374.9 DMF8Y74 FM C21H27ClN2O2 DMF8Y74 IC InChI=1S/C21H27ClN2O2/c22-20-8-6-19(7-9-20)21(18-4-2-1-3-5-18)24-12-10-23(11-13-24)14-16-26-17-15-25/h1-9,21,25H,10-17H2 DMF8Y74 CS C1CN(CCN1CCOCCO)C(C2=CC=CC=C2)C3=CC=C(C=C3)Cl DMF8Y74 IK ZQDWXGKKHFNSQK-UHFFFAOYSA-N DMF8Y74 IU 2-[2-[4-[(4-chlorophenyl)-phenylmethyl]piperazin-1-yl]ethoxy]ethanol DMF8Y74 CA CAS 68-88-2 DMF8Y74 CB CHEBI:5818 DMF8Y74 DE Anxiety disorder DMVAIH4 ID DMVAIH4 DMVAIH4 DN Hylenex DMVAIH4 HS Approved DMVAIH4 CP Halozyme therapeutics; baxter healthcare DMVAIH4 DE Solid tumour/cancer DM804UR ID DM804UR DM804UR DN Hyoscyamine DM804UR HS Approved DM804UR SN L-Hyoscyamine; hyoscyamine; 101-31-5; (-)-Hyoscyamine; Daturine; Duboisine; (-)-Atropine; L-Tropine tropate; (S)-Atropine; (S)-(-)-Hyoscyamine; Hyoscyamine (L); UNII-PX44XO846X; Tropine, (-)-tropate; Levbid; PX44XO846X; Levsinex SR; CHEBI:17486; Hyoscyamine, l-; [3(S)-endo]-alpha-(hydroxymethyl)benzeneacetic acid 8-methyl-8-azabicyclo[321]oct-3-yl ester; (2S)-(1R,5S)-8-Methyl-8-azabicyclo[321]octan-3-yl 3-hydroxy-2-phenylpropanoate; (1R,5S)-8-METHYL-8-AZABICYCLO[321]OCT-3-YL (2R)-3-HYDROXY-2-PHENYLPROPANOATE; Hyocyamine DM804UR TC Antiarrhythmic Agents DM804UR DT Small molecular drug DM804UR PC 154417 DM804UR MW 289.4 DM804UR FM C17H23NO3 DM804UR IC InChI=1S/C17H23NO3/c1-18-13-7-8-14(18)10-15(9-13)21-17(20)16(11-19)12-5-3-2-4-6-12/h2-6,13-16,19H,7-11H2,1H3/t13-,14+,15?,16-/m1/s1 DM804UR CS CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)[C@H](CO)C3=CC=CC=C3 DM804UR IK RKUNBYITZUJHSG-VFSICIBPSA-N DM804UR IU [(1R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] (2S)-3-hydroxy-2-phenylpropanoate DM804UR CA CAS 101-31-5 DM804UR CB CHEBI:17486 DM804UR DE Gastrointestinal disease DM0RXF5 ID DM0RXF5 DM0RXF5 DN Hyqvia DM0RXF5 HS Approved DM0RXF5 SN Immunoglobulin infusion with recombinant hyaluronidase DM0RXF5 CP Baxter DM0RXF5 DE Immunodeficiency DMV67QO ID DMV67QO DMV67QO DN Ibalizumab DMV67QO HS Approved DMV67QO SN Hu5A8; TNX-355 DMV67QO CP TaiMed Biologics/Theratechnologies DMV67QO DT Antibody DMV67QO DE Human immunodeficiency virus infection; Human immunodeficiency virus-1 infection DM0QZBN ID DM0QZBN DM0QZBN DN Ibandronate DM0QZBN HS Approved DM0QZBN SN BFQ; Acid ibandronico; Ibandronic Acid; Bisphosphonate 2; R484; RPR 102289A; Bondronat (TN); Boniva (TN); Bonviva (TN); Ibandronic acid (INN); Ibandronic acid [INN:BAN]; RPR-102289A; Ibandronic acid, sodium salt, monohydrate; Roche brand of ibandronic acid, sodium salt, monohydrate; [1-hydroxy-3-[methyl(pentyl)amino]-1-phosphonopropyl]phosphonic acid; [1-HYDROXY-3-(METHYL-PENTYL-AMINO)-1-PHOSPHONO-PROPYL]-PHOSPHONIC ACID; (1-Hydroxy-3-(methylpentylamino)propylidene)diphosphonic acid; (1-hydroxy-3-(methylpentylamino)propylidene)bisphosphonate; 1-hydroxy-3-(methylpentylamino)propylidenebisphosphonate DM0QZBN CP Roche; GlaxoSmithKline DM0QZBN TC Bone Density Conservation Agents DM0QZBN DT Small molecular drug DM0QZBN PC 60852 DM0QZBN MW 319.23 DM0QZBN FM C9H23NO7P2 DM0QZBN IC InChI=1S/C9H23NO7P2/c1-3-4-5-7-10(2)8-6-9(11,18(12,13)14)19(15,16)17/h11H,3-8H2,1-2H3,(H2,12,13,14)(H2,15,16,17) DM0QZBN CS CCCCCN(C)CCC(O)(P(=O)(O)O)P(=O)(O)O DM0QZBN IK MPBVHIBUJCELCL-UHFFFAOYSA-N DM0QZBN IU [1-hydroxy-3-[methyl(pentyl)amino]-1-phosphonopropyl]phosphonic acid DM0QZBN CA CAS 114084-78-5 DM0QZBN DE Osteoporosis DMGUX67 ID DMGUX67 DMGUX67 DN Ibopamine hci DMGUX67 HS Approved DMGUX67 SN Inopamil (TN); Scandine (TN) DMGUX67 DT Small molecular drug DMGUX67 PC 156320 DMGUX67 MW 343.8 DMGUX67 FM C17H26ClNO4 DMGUX67 IC InChI=1S/C17H25NO4.ClH/c1-11(2)16(19)21-14-7-6-13(8-9-18-5)10-15(14)22-17(20)12(3)4;/h6-7,10-12,18H,8-9H2,1-5H3;1H DMGUX67 CS CC(C)C(=O)OC1=C(C=C(C=C1)CCNC)OC(=O)C(C)C.Cl DMGUX67 IK ALIXRWKJZYLBJI-UHFFFAOYSA-N DMGUX67 IU [4-[2-(methylamino)ethyl]-2-(2-methylpropanoyloxy)phenyl] 2-methylpropanoate;hydrochloride DMGUX67 CA CAS 75011-65-3 DMGUX67 DE Cardiac disease DMG594T ID DMG594T DMG594T DN Ibritumomab DMG594T HS Approved DMG594T SN Zevalin (TN) DMG594T CP Bayer Pharmaceuticals Corporation DMG594T TC Anticancer Agents DMG594T DT Antibody DMG594T SQ Ibritumomab tiuxetan heavy chain: QAYLQQSGAELVRPGASVKMSCKASGYTFTSYNMHWVKQTPRQGLEWIGAIYPGNGDTSYNQKFKGKATLTVDKSSSTAYMQLSSLTSEDSAVYFCARVVYYSNSYWYFDVWGTGTTVTVSAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLYTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSR >Ibritumomab tiuxetan light chainQIVLSQSPAILSASPGEKVTMTCRASSSVSYMHWYQQKPGSSPKPWIYAPSNLASGVPARFSGSGSGTSYSLTISRVEAEDAATYYCQQWSFNPPTFGAGTKLELKRADAAPTVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFN DMG594T DE Non-hodgkin lymphoma; Mantle cell lymphoma DMHZCPO ID DMHZCPO DMHZCPO DN Ibrutinib DMHZCPO HS Approved DMHZCPO SN PCI-32765; Ibrutinib (BTK inhibitor) DMHZCPO CP Janssen Biotech; Pharmacyclics DMHZCPO DT Small molecular drug DMHZCPO PC 24821094 DMHZCPO MW 440.5 DMHZCPO FM C25H24N6O2 DMHZCPO IC InChI=1S/C25H24N6O2/c1-2-21(32)30-14-6-7-18(15-30)31-25-22(24(26)27-16-28-25)23(29-31)17-10-12-20(13-11-17)33-19-8-4-3-5-9-19/h2-5,8-13,16,18H,1,6-7,14-15H2,(H2,26,27,28)/t18-/m1/s1 DMHZCPO CS C=CC(=O)N1CCC[C@H](C1)N2C3=NC=NC(=C3C(=N2)C4=CC=C(C=C4)OC5=CC=CC=C5)N DMHZCPO IK XYFPWWZEPKGCCK-GOSISDBHSA-N DMHZCPO IU 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one DMHZCPO CA CAS 936563-96-1 DMHZCPO CB CHEBI:76612 DMHZCPO DE B-cell non-hodgkin lymphoma; Diffuse large B-cell lymphoma; Follicular lymphoma; Mantle cell lymphoma; Non-hodgkin lymphoma; Pancreatic cancer; Solid tumour/cancer DM4LSPN ID DM4LSPN DM4LSPN DN Ibudilast DM4LSPN HS Approved DM4LSPN SN Eyevinal; Ibudilastum; Ketas; Ibudilastum [Latin]; Ke Tas; AV 411; I 0157; KC 404; AV-411; Ibudilast [INN:JAN]; KC-404; Ketas (TN); MN-166; Ibudilast (JAN/INN); 1-(2-Isopropylpyrazolo(1,5-a)pyridin-3-yl)-2-methyl-1-propanone; 2-Isopropyl-3-isobutyrylpyrazolo(1,5-a)pyridine; 2-Methyl-1-[2-(1-methylethyl)pyrazolo[1,5-a]pyridin-3-yl] 1-propanone; 2-methyl-1-(2-propan-2-ylpyrazolo[1,5-a]pyridin-3-yl)propan-1-one; 3-Isobutyryl-2-isopropylpyrazolo(1,5-a)pyridine; 3-Isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine DM4LSPN CP Avigen DM4LSPN DT Small molecular drug DM4LSPN PC 3671 DM4LSPN MW 230.31 DM4LSPN FM C14H18N2O DM4LSPN IC InChI=1S/C14H18N2O/c1-9(2)13-12(14(17)10(3)4)11-7-5-6-8-16(11)15-13/h5-10H,1-4H3 DM4LSPN CS CC(C)C1=NN2C=CC=CC2=C1C(=O)C(C)C DM4LSPN IK ZJVFLBOZORBYFE-UHFFFAOYSA-N DM4LSPN IU 2-methyl-1-(2-propan-2-ylpyrazolo[1,5-a]pyridin-3-yl)propan-1-one DM4LSPN CA CAS 50847-11-5 DM4LSPN CB CHEBI:31684 DM4LSPN DE Amyotrophic lateral sclerosis; Alcohol dependence; Methamphetamine dependence; Opioid dependence; Multiple sclerosis; Castleman's disease DM8VCBE ID DM8VCBE DM8VCBE DN Ibuprofen DM8VCBE HS Approved DM8VCBE SN ibuprofen; 15687-27-1; 2-(4-Isobutylphenyl)propanoic acid; Motrin; Brufen; Advil; Nurofen; Dolgit; Nuprin; Liptan; Ibuprocin; Buburone; Medipren; Butylenin; Ibumetin; Anflagen; Lamidon; Ebufac; Mynosedin; Trendar; Roidenin; Apsifen; Haltran; Epobron; Nobgen; Adran; Nobfen; Rufen; PediaProfen; Andran; Bluton; Nobfelon; Pantrop; Brufort; Suspren; Rebugen; Tabalon; Inabrin; (RS)-Ibuprofen; Urem; Anco; 2-[4-(2-methylpropyl)phenyl]propanoic acid; Ibu-slo; Napacetin; Brufanic; Ibuprohm; Ibufen; Ibren; 4-Isobutylhydratropic acid; p-Isobutylhydratropic acid; Actiprofen; Alaxan; Algofen; Amelior; Amersol; Amibufen; Anafen; Antagil; Antalfene; Antarene; Antiflam; Artofen; Artril; Balkaprofen; Betaprofen; Bloom; Brofen; Bruflam; Bufeno; Bufigen; Bukrefen; Bupron; Buracaps; Burana; Carol;Cesra; Citalgan; Cobo; Codral; Combiflam; Cunil; Daiprophen; Dalsy; Dansida; Dentigoa; Dibufen; Dignoflex; Dolgirid; Dolibu; Dolmaral; Dolocyl; Dolofen; Dolofin; Dolofort; Dologel; Dolomax; Doloren; Dolormin; Doltibil; Dolven; Dorival; Drin; Duafen; Duobrus; Dysdolen; Easifon; Emflam; Eputex; Ergix; Esprenit; Exneural; Faspic; Femadon; Femafen; Femapirin; Femidol; Fenbid;Fendol; Fenspan; Fibraflex; Gelufene; Gofen; Grefen; Gynofug; Ibol; Ibu; Ibubest; Ibubeta; Ibucasen; Ibudol; Ibudolor; Ibuflamar; Ibufug; Ibugel; Ibugen; Ibugesic; Ibuhexal; Ibulagic; Ibular; Ibulav; Ibuleve; Ibulgan; Ibumed; Ibumerck; Ibupirac; Ibuprin; Ibuprofene; Ibuprofeno; Ibuprofenum; Ibuprophen; Ibusal; Ibutid; Ifen; Inflam; Inoven; Ipren; Irfen; Isodol; Jenaprofen; Junifen; Kesan; Kratalgin; Lebrufen; Librofem; Lidifen; Lopane; Malafene; Manypren; Melfen; Mensoton; Midol; Moment; Narfen; Neobrufen; Nerofen; Noalgil; Nobafon; Noritis; Norton; Novadol; Novogent; Novoprofen; Nuprilan; Optifen; Opturem; Oralfene; Ostarin; Ostofen; Ozonol; Paduden; Panafen; Paxofen; Perofen; Proartinal; Profen; Proflex; Provon; Quadrax; Rafen; Ranofen; Relcofen; Rhinadvil; Rofen; Rufin; Rupan; Sadefen; Salivia; Salprofen; Seclodin; Sednafen; Seklodin; Seskafen; Siyafen; Solpaflex; Solufen; Stelar; Sugafen; Suprafen; Syntofene; Tatanal; Tempil; Tofen; Tonal; Unipron; Upfen; Uprofen; Zafen; Zofen; DOLO PUREN; Deep Relief; Donjust B; Motrin IB; Novogent N; Togal N; Adex 200; Artril 300; Brufen 400; I 4883; IP 82; IP82; Midol 200; RD 13621; Tabalon 400; U 18573; UCB 79171; VUFB 9649; Act-3; Advil (TN); Ak+C2278tren; Aktre (TN); Alaxan (TN); Algoflex (TN); Alivium (TN); Am-Fam 400; Apsifen-F; Arthrofen (TN); Bonifen (TN); Brufen (TN); Bugesic (TN); Burana (TN); Caldolor (TN); Calprofen (TN); Cap-Profen; Dalsy (TN); Dismenol (TN); Diverin (TN); Dolgit (TN); Dolo-Dolgit; Dolofen-F; Dolofort (TN); Doloraz (TN); Dolormin (TN); Dorival (TN); Dura-Ibu; Ebufac (TN); Emflam-200; EmuProfen (TN); Espidifen (TN); Eve (TN); Fenbid (TN); Fenpaed (TN); Finalflex (TN); Galprofen (TN); Hedex (TN); Herron Blue (TN); IB-100; IBUFEN (TN); IP-82; Ibalgin (TN); Ibu-Attritin; Ibu-Tab; Ibu-Tab 200; Ibu-slow; IbuHEXAL (TN); Ibugel (TN); Ibuleve (TN); Ibum (TN); Ibumax (TN); Ibumetin (TN); Ibuprom (TN); Ibuprosyn (TN); Ibux (TN); Ibuxin (TN); Ipren (TN); Kratalgin (TN); Medicol (TN); Moment (TN); Motrin (TN); Nagifen-D; Narfen (TN); Neo-Helvagit; Neo-Mindol; Neobrufen (TN); Neofen (TN); Norvectan (TN); Novo-Profen; Nuprin (TN); Nureflex (TN); Nurofen (TN); Orbifen (TN); Panafen (TN); Pedia-Profen; Perifar (TN); Profin (TN); Ratiodolor (TN); Retard (TN); Rimafen (TN); Salvarina (TN); Solpaflex (TN); Spedifen (TN); Speedpain NANO (TN); Spidifen (TN); Tab-Profen; U-18573; Upfen (TN); ACHES-N-PAIN; Act-3 (TN); Dolo-Spedifen (TN); I-profen (TN); IBU-Ratiopharm (TN); Ibu-Vivimed (TN); U-18,573; IBUPROPHEN DM8VCBE TC Analgesics DM8VCBE DT Small molecular drug DM8VCBE PC 3672 DM8VCBE MW 206.28 DM8VCBE FM C13H18O2 DM8VCBE IC InChI=1S/C13H18O2/c1-9(2)8-11-4-6-12(7-5-11)10(3)13(14)15/h4-7,9-10H,8H2,1-3H3,(H,14,15) DM8VCBE CS CC(C)CC1=CC=C(C=C1)C(C)C(=O)O DM8VCBE IK HEFNNWSXXWATRW-UHFFFAOYSA-N DM8VCBE IU 2-[4-(2-methylpropyl)phenyl]propanoic acid DM8VCBE CA CAS 15687-27-1 DM8VCBE CB CHEBI:5855 DM8VCBE DE Pain DMFJ8LT ID DMFJ8LT DMFJ8LT DN Ibutamoren DMFJ8LT HS Approved DMFJ8LT SN L 163191; MK-0667; MK-677; 2-amino-2-methyl-N-[(2R)-1-(1-methylsulfonylspiro[2H-indole-3,4'-piperidine]-1'-yl)-1-oxo-3-phenylmethoxypropan-2-yl]propanamide DMFJ8LT CP Merck DMFJ8LT DT Small molecular drug DMFJ8LT PC 178024 DMFJ8LT MW 528.7 DMFJ8LT FM C27H36N4O5S DMFJ8LT IC InChI=1S/C27H36N4O5S/c1-26(2,28)25(33)29-22(18-36-17-20-9-5-4-6-10-20)24(32)30-15-13-27(14-16-30)19-31(37(3,34)35)23-12-8-7-11-21(23)27/h4-12,22H,13-19,28H2,1-3H3,(H,29,33)/t22-/m1/s1 DMFJ8LT CS CC(C)(C(=O)N[C@H](COCC1=CC=CC=C1)C(=O)N2CCC3(CC2)CN(C4=CC=CC=C34)S(=O)(=O)C)N DMFJ8LT IK UMUPQWIGCOZEOY-JOCHJYFZSA-N DMFJ8LT IU 2-amino-2-methyl-N-[(2R)-1-(1-methylsulfonylspiro[2H-indole-3,4'-piperidine]-1'-yl)-1-oxo-3-phenylmethoxypropan-2-yl]propanamide DMFJ8LT CA CAS 159634-47-6 DMFJ8LT DE Fibromyalgia DMKXY2R ID DMKXY2R DMKXY2R DN Ibutilide DMKXY2R HS Approved DMKXY2R SN Corvert; Ibutilida; Ibutilidum; Butilide fumarate; IBUTILIDE FUMARATE; Ibutilide Fumarate [USAN]; U 70226E; U82208E; U82209E; Corvert (TN); Ibutilida [INN-Spanish]; Ibutilide (INN); Ibutilide [BAN:INN]; Ibutilide [INN:BAN]; Ibutilide fumarate (USAN); Ibutilidum [INN-Latin]; U-70226E; U-82208E; U-82209E; Ibutilide, (+-)-isomer; N-[4-[4-[ethyl(heptyl)amino]-1-hydroxybutyl]phenyl]methanesulfonamide; Ibutilide, fumarate salt (2:1), (+-)-isomer; N-(4-(4-(ethylheptylamino)-1-hydroxybutyl)phenyl)methanesulfonamide; N-(4-{4-[ethyl(heptyl)amino]-1-hydroxybutyl}phenyl)methanesulfonamide; Methanesulfonamide, N-(4-(4-(ethylheptylamino)-1-hydroxybutyl)phenyl)-, (E)-2-butenedioate (2:1) (salt); Methanesulfonamide, N-(4-(4-(ethylheptylamino)-1-hydroxybutyl)phenyl)-, (+-)-, (E)-2-butenedioate (2:1) (salt); Methanesulfonamide, N-(4-(4-(ethylheptylamino)-1-hydroxybutyl)phenyl)-, (+-)-,(E)-2-butenedioate (2:1) (salt); (+-)-4'-(4-(Ethylheptylamino)-1-hydroxybutyl)methanesulfoanilide (E)-2-butenedioate (2:1); (+-)-4'-(4-(Ethylheptylamino)-1-hydroxybutyl)methanesulfonanilide fumarate (2:1) (salt); (+-)-N-(4-(4-(Ethylheptylamino)-1-hydroxybutyl)phenyl)methanesulfonamide (E)-butenedioate DMKXY2R CP Pfizer Pharmaceuticals DMKXY2R TC Antiarrhythmic Agents DMKXY2R DT Small molecular drug DMKXY2R PC 60753 DMKXY2R MW 384.6 DMKXY2R FM C20H36N2O3S DMKXY2R IC InChI=1S/C20H36N2O3S/c1-4-6-7-8-9-16-22(5-2)17-10-11-20(23)18-12-14-19(15-13-18)21-26(3,24)25/h12-15,20-21,23H,4-11,16-17H2,1-3H3 DMKXY2R CS CCCCCCCN(CC)CCCC(C1=CC=C(C=C1)NS(=O)(=O)C)O DMKXY2R IK ALOBUEHUHMBRLE-UHFFFAOYSA-N DMKXY2R IU N-[4-[4-[ethyl(heptyl)amino]-1-hydroxybutyl]phenyl]methanesulfonamide DMKXY2R CA CAS 122647-31-8 DMKXY2R CB CHEBI:5856 DMKXY2R DE Atrial fibrillation DMQPTOZ ID DMQPTOZ DMQPTOZ DN Icatibant DMQPTOZ HS Approved DMQPTOZ SN Firazyr; Icatibant [INN]; HOE 140; HOE140; JE049; WIN 65365; Hoe-140; WIN-65365; D-Arg(Hyp(3)-Thi(5)-D-Tic(7)-Oic(8))BK DMQPTOZ CP Jerini AG DMQPTOZ TC Antiinflammatory Agents DMQPTOZ DT Small molecular drug DMQPTOZ PC 6918173 DMQPTOZ MW 1304.5 DMQPTOZ FM C59H89N19O13S DMQPTOZ IC InChI=1S/C59H89N19O13S/c60-37(14-5-19-67-57(61)62)48(82)72-38(15-6-20-68-58(63)64)52(86)75-22-8-18-43(75)54(88)77-30-35(80)26-44(77)50(84)70-28-47(81)71-40(27-36-13-9-23-92-36)49(83)74-41(31-79)53(87)76-29-34-12-2-1-10-32(34)24-46(76)55(89)78-42-17-4-3-11-33(42)25-45(78)51(85)73-39(56(90)91)16-7-21-69-59(65)66/h1-2,9-10,12-13,23,33,35,37-46,79-80H,3-8,11,14-22,24-31,60H2,(H,70,84)(H,71,81)(H,72,82)(H,73,85)(H,74,83)(H,90,91)(H4,61,62,67)(H4,63,64,68)(H4,65,66,69)/t33-,35+,37+,38-,39-,40-,41-,42-,43-,44-,45-,46+/m0/s1 DMQPTOZ CS C1CC[C@H]2[C@@H](C1)C[C@H](N2C(=O)[C@H]3CC4=CC=CC=C4CN3C(=O)[C@H](CO)NC(=O)[C@H](CC5=CC=CS5)NC(=O)CNC(=O)[C@@H]6C[C@H](CN6C(=O)[C@@H]7CCCN7C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](CCCN=C(N)N)N)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O DMQPTOZ IK QURWXBZNHXJZBE-SKXRKSCCSA-N DMQPTOZ IU (2S)-2-[[(2S,3aS,7aS)-1-[(3R)-2-[(2S)-2-[[(2S)-2-[[2-[[(2S,4R)-1-[(2S)-1-[(2S)-2-[[(2R)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]-4-hydroxypyrrolidine-2-carbonyl]amino]acetyl]amino]-3-thiophen-2-ylpropanoyl]amino]-3-hydroxypropanoyl]-3,4-dihydro-1H-isoquinoline-3-carbonyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoic acid DMQPTOZ CA CAS 130308-48-4 DMQPTOZ DE Hereditary angioedema DM648X9 ID DM648X9 DM648X9 DN Icodextrin DM648X9 HS Approved DM648X9 SN Extraneal DM648X9 CP Innovata plc DM648X9 DT Small molecular drug DM648X9 PC 3517 DM648X9 MW 231.08 DM648X9 FM C8H8Cl2N4 DM648X9 IC InChI=1S/C8H8Cl2N4/c9-6-2-1-3-7(10)5(6)4-13-14-8(11)12/h1-4H,(H4,11,12,14) DM648X9 CS C1=CC(=C(C(=C1)Cl)C=NN=C(N)N)Cl DM648X9 IK WDZVGELJXXEGPV-UHFFFAOYSA-N DM648X9 IU 2-[(2,6-dichlorophenyl)methylideneamino]guanidine DM648X9 CA CAS 5051-62-7 DM648X9 DE Kidney disease DMJHN0A ID DMJHN0A DMJHN0A DN Icosapent DMJHN0A HS Approved DMJHN0A TC Dietary supplement DMJHN0A DT Small molecular drug DMJHN0A PC 446284 DMJHN0A MW 302.5 DMJHN0A FM C20H30O2 DMJHN0A IC InChI=1S/C20H30O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20(21)22/h3-4,6-7,9-10,12-13,15-16H,2,5,8,11,14,17-19H2,1H3,(H,21,22)/b4-3-,7-6-,10-9-,13-12-,16-15- DMJHN0A CS CC/C=C\\C/C=C\\C/C=C\\C/C=C\\C/C=C\\CCCC(=O)O DMJHN0A IK JAZBEHYOTPTENJ-JLNKQSITSA-N DMJHN0A IU (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoic acid DMJHN0A CA CAS 10417-94-4 DMJHN0A CB CHEBI:28364 DMJHN0A DE Thrombin deficiency; Hyperglyceridemia; Hypertriglyceridemia DMM0XGL ID DMM0XGL DMM0XGL DN Idarubicin DMM0XGL HS Approved DMM0XGL SN DMDR; Idamycin; Idarubicina; Idarubicine; Idarubicinum; Zavedos; Idarubicin Hcl; Idarubicin Hcl Pfs; Idarubicin hydrochloride; DM5; I 1656; IMI 30; IMI-30; Idamycin (TN); Idarubicin (INN); Idarubicin [INN:BAN]; Idarubicina [INN-Spanish]; Idarubicine [INN-French]; Idarubicinum [INN-Latin]; Zavedos (TN); (1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1s,3s)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-A-l-lyxo-hexopyranoside; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S-cis)-9-Acetyl-7-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-5,12-naphthacenedione; 4-DMD; 4-Demethoxydaunomycin; 4-Demethoxydaunorubicin; 4-Desmethoxydaunorubicin DMM0XGL CP Ben Venue Laboratories DMM0XGL TC Anticancer Agents DMM0XGL DT Small molecular drug DMM0XGL PC 42890 DMM0XGL MW 497.5 DMM0XGL FM C26H27NO9 DMM0XGL IC InChI=1S/C26H27NO9/c1-10-21(29)15(27)7-17(35-10)36-16-9-26(34,11(2)28)8-14-18(16)25(33)20-19(24(14)32)22(30)12-5-3-4-6-13(12)23(20)31/h3-6,10,15-17,21,29,32-34H,7-9,27H2,1-2H3/t10-,15-,16-,17-,21+,26-/m0/s1 DMM0XGL CS C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=CC=CC=C5C4=O)O)(C(=O)C)O)N)O DMM0XGL IK XDXDZDZNSLXDNA-TZNDIEGXSA-N DMM0XGL IU (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione DMM0XGL CA CAS 58957-92-9 DMM0XGL CB CHEBI:42068 DMM0XGL DE Acute myeloid leukaemia DMXEACF ID DMXEACF DMXEACF DN Idarucizumab DMXEACF HS Approved DMXEACF SN Praxbind DMXEACF CP Boehringer Ingelheim DMXEACF DT Antibody DMXEACF DE Reversal of the anticoagulant effects of dabigatran DMQFDRC ID DMQFDRC DMQFDRC DN Idebenone DMQFDRC HS Approved DMQFDRC SN idebenone; 58186-27-9; Idebenona; Idebenonum; CV 2619; Idebenonum [Latin]; Idebenona [Spanish]; Idebenone [INN:JAN]; CV-2619; 2-(10-hydroxydecyl)-5,6-dimethoxy-3-methylcyclohexa-2,5-diene-1,4-dione; UNII-HB6PN45W4J; BRN 2001459; 6-(10-Hydroxydecyl)-2,3-dimethoxy-5-methyl-1,4-benzoquinone; HB6PN45W4J; 2-(10-Hydroxydecyl)-5,6-dimethoxy-3-methyl-1,4-benzoquinone; CHEBI:31687; JGPMMRGNQUBGND-UHFFFAOYSA-N; 2,5-Cyclohexadiene-1,4-dione, 2-(10-hydroxydecyl)-5,6-dimethoxy-3-methyl-; NCGC00160514-01; AK161748 DMQFDRC CP Santhera Pharmaceuticals DMQFDRC DT Small molecular drug DMQFDRC PC 3686 DMQFDRC MW 338.4 DMQFDRC FM C19H30O5 DMQFDRC IC InChI=1S/C19H30O5/c1-14-15(12-10-8-6-4-5-7-9-11-13-20)17(22)19(24-3)18(23-2)16(14)21/h20H,4-13H2,1-3H3 DMQFDRC CS CC1=C(C(=O)C(=C(C1=O)OC)OC)CCCCCCCCCCO DMQFDRC IK JGPMMRGNQUBGND-UHFFFAOYSA-N DMQFDRC IU 2-(10-hydroxydecyl)-5,6-dimethoxy-3-methylcyclohexa-2,5-diene-1,4-dione DMQFDRC CA CAS 58186-27-9 DMQFDRC CB CHEBI:31687 DMQFDRC DE Cognitive impairment; Friedreich's ataxia DMP1QTS ID DMP1QTS DMP1QTS DN Idecabtagene vicleucel DMP1QTS HS Approved DMP1QTS SN Bb2121 DMP1QTS CP Celgene DMP1QTS DT CAR T Cell Therapy DMP1QTS DE Multiple myeloma DM602WT ID DM602WT DM602WT DN Idelalisib DM602WT HS Approved DM602WT SN Idelalisib; 870281-82-6; CAL-101; Zydelig; GS-1101; CAL101; CAL 101; (S)-2-(1-((9H-Purin-6-yl)amino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one; UNII-YG57I8T5M0; CAL-101 (Idelalisib, GS-1101); YG57I8T5M0; CHEMBL2216870; CHEBI:82701; 5-Fluoro-3-phenyl-2-((S)-1-(9H-purin-6-ylamino)-propyl)-3H-quinazolin-4-one; AK145603; Idelalisib; CAL-101; (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one; 1146702-54-6; 5-FLUORO-3-PHENYL-2-[(1S)-1-(9H-PURIN-6-YLAMINO)PROPYL]-4(3H)-QUINAZOLINONE DM602WT CP Gilead Sciences DM602WT DT Small molecular drug DM602WT PC 11625818 DM602WT MW 415.4 DM602WT FM C22H18FN7O DM602WT IC InChI=1S/C22H18FN7O/c1-2-15(28-20-18-19(25-11-24-18)26-12-27-20)21-29-16-10-6-9-14(23)17(16)22(31)30(21)13-7-4-3-5-8-13/h3-12,15H,2H2,1H3,(H2,24,25,26,27,28)/t15-/m0/s1 DM602WT CS CC[C@@H](C1=NC2=C(C(=CC=C2)F)C(=O)N1C3=CC=CC=C3)NC4=NC=NC5=C4NC=N5 DM602WT IK IFSDAJWBUCMOAH-HNNXBMFYSA-N DM602WT IU 5-fluoro-3-phenyl-2-[(1S)-1-(7H-purin-6-ylamino)propyl]quinazolin-4-one DM602WT CA CAS 870281-82-6 DM602WT CB CHEBI:82701 DM602WT DE Chronic lymphocytic leukaemia DMDRT0E ID DMDRT0E DMDRT0E DN Idoxuridine DMDRT0E HS Approved DMDRT0E SN Emanil; Herpesil; Herpidu; Idossuridina; Iododeoxyuridine; Kerecide; Ophthalmadine; Synmiol; ID2; LT00440811; SKF 14287; Dendrid (TN); HERPLEX (TN); Herpe-Gel; Herpes-Gel; Iododeoxyuridine-125I; Oftan-IDU; SK&F 14287; SK&F-14287; Idoxuridine (JP15/USP/INN); Idoxuridine [USAN:INN:BAN:JAN]; 1-(2-Deoxy-beta-D-ribofuranosyl)-5-iodouracil; 1-(2-deoxypentofuranosyl)-4-hydroxy-5-iodopyrimidin-2(1H)-one; 1-(2-deoxypentofuranosyl)-5-iodopyrimidine-2,4(1h,3h)-dione; 1-(4-Hydroxy-5-hydroxymethyltetrahydrofuran-2-yl)-5-iodo-1H-pyrimidine-2,4-dione; 1-[(2R,4R,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidine-2,4-dione; 1-[(2R,4R,5S)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidine-2,4-dione; 1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidine-2,4-dione; 1-[(2R,4S,5S)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidine-2,4-dione; 1-[(2R,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidine-2,4-dione; 1-[(2S,4R,5S)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidine-2,4-dione; 1-[(2S,4S,5S)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidine-2,4-dione; 1-[4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidine-2,4-dione; 1-beta-D-2'-Deoxyribofuranosyl-5-iodouracil; 1.beta.-D-2'-Deoxyribofuranosyl-5-iodouracil; 1beta-D-2'-Deoxyribofuranosyl-5-iodouracil; 2'-Deoxy-5-(iodo-125I)uridine; 2'-deoxy-5-(125i)iodouridine; 5-(125-I)-Iodo-2-deoxyuridine; 5-I-2'-dUrd; 5-Iododesoxyuridine; 5IdU DMDRT0E TC Antiviral Agents DMDRT0E DT Small molecular drug DMDRT0E PC 5905 DMDRT0E MW 354.1 DMDRT0E FM C9H11IN2O5 DMDRT0E IC InChI=1S/C9H11IN2O5/c10-4-2-12(9(16)11-8(4)15)7-1-5(14)6(3-13)17-7/h2,5-7,13-14H,1,3H2,(H,11,15,16)/t5-,6+,7+/m0/s1 DMDRT0E CS C1[C@@H]([C@H](O[C@H]1N2C=C(C(=O)NC2=O)I)CO)O DMDRT0E IK XQFRJNBWHJMXHO-RRKCRQDMSA-N DMDRT0E IU 1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidine-2,4-dione DMDRT0E CA CAS 54-42-2 DMDRT0E CB CHEBI:147675 DMDRT0E DE Herpes simplex virus infection DM30SXV ID DM30SXV DM30SXV DN Idursulfase DM30SXV HS Approved DM30SXV SN Elaprase (TN) DM30SXV SQ Idursulfase heavy chain: SETQANSTTDALNVLLIIVDDLRPSLGCYGDKLVRSPNIDQLASHSLLFQNAFAQQAVCAPSRVSFLTGRRPDTTRLYDFNSYWRVHAGNFSTIPQYFKENGYVTMSVGKVFHPGISSNHTDDSPYSWSFPPYHPSSEKYENTKTCRGPDGELHANLLCPVDVLDVPEGTLPDKQSTEQAIQLLEKMKTSASPFFLAVGYHKPHIPFRYPKEFQKLYPLENITLAPDPEVPDGLPPVAYNPWMDIRQREDVQALNISVPYGPIPVDFQRKIRQSYFASVSYLDTQVGRLLSALDDLQLANSTIIAFTSDHGWALGEHGEWAKYSNFDVATHVPLIFYVPGRTASLPEAGEKLFPYLDPFDSASQLMEPGRQSMDLVELVSLFPTLAGLAGLQVPPRCPVPSFHVELCREGKNLLKHFRFRDLEEDPYLPG >Idursulfase light chainNPRELIAYSQYPRPSDIPQWNSDKPSLKDIKIMGYSIRTIDYRYTVWVGFNPDEFLANFSDIHAGELYFVDSDPLQDHNMYNDSQGGDLFQLLMP DM30SXV DE Infertility; Hunter syndrome DMCT3I8 ID DMCT3I8 DMCT3I8 DN Ifosfamide DMCT3I8 HS Approved DMCT3I8 SN Cyfos; Holoxan; Ifex; Ifosfamid; Ifosfamida; Ifosfamidum; Ifosphamide; Ifsofamide; Iphosphamid; Iphosphamide; Isoendoxan; Isofosfamide; Isophosphamide; Isosfamide; Mitoxana; Naxamide; Ifosfamide Sterile; Iso Endoxan; A 4942; ASTA Z 4942; Holoxan 1000; MJF 9325; Z 4942; Z4942; I-Phosphamide; IFEX (TN); Ifex (TN); Ifosfamida [INN-Spanish]; Ifosfamidum [INN-Latin]; Iphosphamid(e); Iso-Endoxan; MJF-9325; Mitoxana (TN); NPFAPI-04; Z-4942; Mitoxana, Ifex, Ifosfamide; Ifosfamide (JAN/USP/INN); Ifosfamide [USAN:INN:BAN:JAN]; N,N-Bis(beta-chloroethyl)-amino-N',O-propylene-phosphoric acid ester diamide; N,3-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide; N,3-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide; N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylen ephosphoric acid diamide; N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylene phosphoric acid ester diamide; N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylenephosphoric acid diamide; N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylenephosphoric acid ester diamide; N-(2-Chloraethyl)-N'-(2-chloraethyl)-N',O-propylen-phosphorsaureester-diamid; N-(2-Chloraethyl)-N'-(2-chloraethyl)-N',O-propylen-phosphorsaureester-diamid [German]; N-(2-Chloroethyl)-N-(3-(2-chloroethyl)-2-oxido-1,3,2-oxazaphosphinan-2-yl)amine; (+-)-Ifosfamid; (+-)-Ifosphamide; (+-)-Tetrahydro-N,3-bis(2-chloroethyl)-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide; (D,L)-Ifosfamide; (R,S)-Ifosphamide; (R,S)-N,3-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide; 1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide; 1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-, 2-oxide; 2,3-(N,N(sup 1)-Bis(2-chloroethyl)diamido)-1,3,2-oxazaphosphoridinoxyd; 2,3-N,N(sup 1)-Bis(2-chloroethyl)diamido-1,3,2-oxazaphosphoridinoxyd; 2H-1,3,2-Oxazaphosphorin-2-amine, N,3-bis(2-chloroethyl)tetrahydro-, 2-oxide; 2H-1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide; 2H-1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide (8CI); 2H-1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-, 2-oxide; 3,} 2-oxazaphosphorine oxide; 3-(2-Chloroethyl)-2-((2-chloroethyl)amino)perhydro-2H-1,3,2-oxazaphosphorine oxide; 3-(2-Chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide; 3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2H-1,3,2-oxazaphosphorine oxide; 3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2H-1,3,2-oxazaphosphorineoxide; 3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide DMCT3I8 TC Anticancer Agents DMCT3I8 DT Small molecular drug DMCT3I8 PC 3690 DMCT3I8 MW 261.079 DMCT3I8 FM C7H15Cl2N2O2P DMCT3I8 IC InChI=1S/C7H15Cl2N2O2P/c8-2-4-10-14(12)11(6-3-9)5-1-7-13-14/h1-7H2,(H,10,12) DMCT3I8 CS C1CN(P(=O)(OC1)NCCCl)CCCl DMCT3I8 IK HOMGKSMUEGBAAB-UHFFFAOYSA-N DMCT3I8 IU N,3-bis(2-chloroethyl)-2-oxo-1,3,2lambda5-oxazaphosphinan-2-amine DMCT3I8 CA CAS 3778-73-2 DMCT3I8 CB CHEBI:5864 DMCT3I8 DE Solid tumour/cancer DM6AUFY ID DM6AUFY DM6AUFY DN Iloperidone DM6AUFY HS Approved DM6AUFY SN Fanapt; Fanapta; Fiapta; Zomaril; HP 873; Fanapt (TN); HP-873; ILO-522; Iloperidone [USAN:INN]; Fanapta, Zomaril, Iloperidone; Iloperidone (USAN/INN); 1-[4-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propoxy]-3-methoxyphenyl]ethanone; 4'-(3-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)propoxy)-3'-methoxyacetophenone DM6AUFY CP Vanda Pharmaceuticals DM6AUFY DT Small molecular drug DM6AUFY PC 71360 DM6AUFY MW 426.5 DM6AUFY FM C24H27FN2O4 DM6AUFY IC InChI=1S/C24H27FN2O4/c1-16(28)18-4-7-21(23(14-18)29-2)30-13-3-10-27-11-8-17(9-12-27)24-20-6-5-19(25)15-22(20)31-26-24/h4-7,14-15,17H,3,8-13H2,1-2H3 DM6AUFY CS CC(=O)C1=CC(=C(C=C1)OCCCN2CCC(CC2)C3=NOC4=C3C=CC(=C4)F)OC DM6AUFY IK XMXHEBAFVSFQEX-UHFFFAOYSA-N DM6AUFY IU 1-[4-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propoxy]-3-methoxyphenyl]ethanone DM6AUFY CA CAS 133454-47-4 DM6AUFY CB CHEBI:65173 DM6AUFY DE Schizophrenia DMVPZBE ID DMVPZBE DMVPZBE DN Iloprost DMVPZBE HS Approved DMVPZBE SN Ciloprost; Endoprost; Ilomedin; Ilomedine; Iloprostum; Ventavis; Iloprostum [Latin]; ZK 36374; E-1030; Iloprost (INN); Iloprost [BAN:INN]; SH-401; Ventavis (TN); ZK-36374; ZK-363775; [3H]-Iloprost; (16R,S)-Methyl-18,18,19,19-tetradehydro-6a-carbaprostaglandin I(sub 2); (5E)-5-[(3aS,4R,5R,6aS)-5-hydroxy-4-[(E,3S)-3-hydroxy-4-methyloct-1-en-6-ynyl]-3,3a,4,5,6,6a-hexahydro-1H-pentalen-2-ylidene]pentanoic acid; (5E)-5-[(3aS,5R,6aS)-5-hydroxy-4-[(1E,3S)-3-hydroxy-4-methyloct-1-en-6-yn-1-yl]hexahydropentalen-2(1H)-ylidene]pentanoic acid; (5E)-5-[(3aS,5R,6aS)-5-hydroxy-4-[(E,3S)-3-hydroxy-4-methyloct-1-en-6-ynyl]-3,3a,4,5,6,6a-hexahydro-1H-pentalen-2-ylidene]pentanoic acid; (5Z)-5-[(3aS,5R,6aS)-5-hydroxy-4-[(E,3R)-3-hydroxy-4-methyloct-1-en-6-ynyl]-3,3a,4,5,6,6a-hexahydro-1H-pentalen-2-ylidene]pentanoic acid; (E)-(3aS,4R,5R,6aS)-Hexahydro-5-hydroxy-4-((E)-(3S,4RS)-3-hydroxy-4-methyl-1-octen-6-ynyl)-delta(sup 2(1H),delta)-pentalenevaleric acid; (E)-5-(3aS,4R,5R,6aS)-5-Hydroxy-4((E)-(3S,4RS)-3-hydroxy-4-methyl-1-octen-6-inyl)perhydropentalen-2-yliden)valeriansaeure DMVPZBE CP Actelion Pharmaceuticals DMVPZBE TC Antihypertensive Agents DMVPZBE DT Small molecular drug DMVPZBE PC 5311181 DMVPZBE MW 360.5 DMVPZBE FM C22H32O4 DMVPZBE IC InChI=1S/C22H32O4/c1-3-4-7-15(2)20(23)11-10-18-19-13-16(8-5-6-9-22(25)26)12-17(19)14-21(18)24/h8,10-11,15,17-21,23-24H,5-7,9,12-14H2,1-2H3,(H,25,26)/b11-10+,16-8+/t15?,17-,18+,19-,20+,21+/m0/s1 DMVPZBE CS CC#CCC(C)[C@@H](/C=C/[C@H]1[C@@H](C[C@H]2[C@@H]1C/C(=C/CCCC(=O)O)/C2)O)O DMVPZBE IK HIFJCPQKFCZDDL-ACWOEMLNSA-N DMVPZBE IU (5E)-5-[(3aS,4R,5R,6aS)-5-hydroxy-4-[(E,3S)-3-hydroxy-4-methyloct-1-en-6-ynyl]-3,3a,4,5,6,6a-hexahydro-1H-pentalen-2-ylidene]pentanoic acid DMVPZBE CA CAS 78919-13-8 DMVPZBE CB CHEBI:63916 DMVPZBE DE Pulmonary arterial hypertension DM7RJXL ID DM7RJXL DM7RJXL DN Imatinib DM7RJXL HS Approved DM7RJXL SN Cgp 57148; Glamox; Glamox (TN); Gleevec (TN); Glivec (TN); Imatinib (INN); Imatinib (STI571); Imatinib Methansulfonate; Imatinib [INN:BAN]; 112GI019; 152459-95-5; BKJ8M8G5HI; CCRIS 9076; CGP-57148; CHEMBL941; Imatinib free base; STI; UNII-BKJ8M8G5HI DM7RJXL CP Novartis AG DM7RJXL TC Anticancer Agents DM7RJXL DT Small molecular drug DM7RJXL PC 5291 DM7RJXL MW 493.6 DM7RJXL FM C29H31N7O DM7RJXL IC InChI=1S/C29H31N7O/c1-21-5-10-25(18-27(21)34-29-31-13-11-26(33-29)24-4-3-12-30-19-24)32-28(37)23-8-6-22(7-9-23)20-36-16-14-35(2)15-17-36/h3-13,18-19H,14-17,20H2,1-2H3,(H,32,37)(H,31,33,34) DM7RJXL CS CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5 DM7RJXL IK KTUFNOKKBVMGRW-UHFFFAOYSA-N DM7RJXL IU 4-[(4-methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide DM7RJXL CA CAS 152459-95-5 DM7RJXL CB CHEBI:45783 DM7RJXL DE Chronic myelogenous leukaemia; Systemic mastocytosis; Lung cancer; Intestinal cancer; Acute lymphoblastic leukaemia DMUL7T1 ID DMUL7T1 DMUL7T1 DN Imidapril DMUL7T1 HS Approved DMUL7T1 SN Tanatil (TN) DMUL7T1 CP Tanabe DMUL7T1 DT Small molecular drug DMUL7T1 PC 5464343 DMUL7T1 MW 405.4 DMUL7T1 FM C20H27N3O6 DMUL7T1 IC InChI=1S/C20H27N3O6/c1-4-29-19(27)15(11-10-14-8-6-5-7-9-14)21-13(2)17(24)23-16(18(25)26)12-22(3)20(23)28/h5-9,13,15-16,21H,4,10-12H2,1-3H3,(H,25,26)/t13-,15-,16-/m0/s1 DMUL7T1 CS CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2[C@@H](CN(C2=O)C)C(=O)O DMUL7T1 IK KLZWOWYOHUKJIG-BPUTZDHNSA-N DMUL7T1 IU (4S)-3-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-1-methyl-2-oxoimidazolidine-4-carboxylic acid DMUL7T1 CA 89371-37-9 DMUL7T1 DE Cardiovascular disease DM3VS7Z ID DM3VS7Z DM3VS7Z DN Imidazole salicylate DM3VS7Z HS Approved DM3VS7Z SN Salizolo; Selezen; ITF-182 DM3VS7Z CP Italfarmaco SpA DM3VS7Z DT Small molecular drug DM3VS7Z PC 37425 DM3VS7Z MW 206.2 DM3VS7Z FM C10H10N2O3 DM3VS7Z IC InChI=1S/C7H6O3.C3H4N2/c8-6-4-2-1-3-5(6)7(9)10;1-2-5-3-4-1/h1-4,8H,(H,9,10);1-3H,(H,4,5) DM3VS7Z CS C1=CC=C(C(=C1)C(=O)O)O.C1=CN=CN1 DM3VS7Z IK XCHHJFVNQPPLJK-UHFFFAOYSA-N DM3VS7Z IU 2-hydroxybenzoic acid;1H-imidazole DM3VS7Z CA CAS 36364-49-5 DM3VS7Z DE Inflammation DMI9FBP ID DMI9FBP DMI9FBP DN Imipenem DMI9FBP HS Approved DMI9FBP SN Imipemide; Tienamycin; Imipenem anhydrous; Imipenem (INN); N-Formimidoylthienamycin; Primaxin (TN); Imipenem, N-Formimidoyl thienamycin; [5R-[5.alpha.,6.alpha.(R*)]]-6-(1-Hydroxyethyl)-3-[[2-[(iminomethyl)amino]ethyl]thio]-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid monohydrate; (5R,6S)-3-(2-Formimidoylamino-ethylsulfanyl)-6-((R)-1-hydroxy-ethyl)-7-oxo-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylic acid; (5R,6S)-3-[2-(aminomethylideneamino)ethylsulfanyl]-6-[(1R)-1-hydroxyethyl]-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; (5R,6S)-6-((R)-1-Hydroxyethyl)-3-(2-(iminomethylamino)ethylthio)-7-oxo-1-azabicyclo(3.2.0)hept-2-ene-2-carbonsaeure; (5R,6S)-6-[(1R)-1-hydroxyethyl]-3-({2-[(iminomethyl)amino]ethyl}thio)-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid DMI9FBP CP Merck & Co DMI9FBP TC Antibiotics DMI9FBP DT Small molecular drug DMI9FBP PC 104838 DMI9FBP MW 299.35 DMI9FBP FM C12H17N3O4S DMI9FBP IC InChI=1S/C12H17N3O4S/c1-6(16)9-7-4-8(20-3-2-14-5-13)10(12(18)19)15(7)11(9)17/h5-7,9,16H,2-4H2,1H3,(H2,13,14)(H,18,19)/t6-,7-,9-/m1/s1 DMI9FBP CS C[C@H]([C@@H]1[C@H]2CC(=C(N2C1=O)C(=O)O)SCCN=CN)O DMI9FBP IK ZSKVGTPCRGIANV-ZXFLCMHBSA-N DMI9FBP IU (5R,6S)-3-[2-(aminomethylideneamino)ethylsulfanyl]-6-[(1R)-1-hydroxyethyl]-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid DMI9FBP CA CAS 64221-86-9 DMI9FBP CB CHEBI:471744 DMI9FBP DE Bacterial infection DM2NUH3 ID DM2NUH3 DM2NUH3 DN Imipramine DM2NUH3 HS Approved DM2NUH3 SN Antideprin; Berkomine; Censtim; Censtin; Declomipramine; Dimipressin; Dpid; Dynaprin; Eupramin; Imavate; Imidobenzyle; Imipramin; Imipramina; Imipraminum; Imiprin; Imizin; Imizinum; Impramine; Intalpram; Iramil; Irmin; Janimine; Melipramin; Melipramine; Nelipramin; Norchlorimipramine; Norfranil; Pramine; Prazepine; Promiben;Psychoforin; Surplix; Timolet; Tofranil; Imipramina [Italian]; Tofraniln A; Antideprin (TN); Deprimin (TN); Deprinol (TN); Depsonil (TN); Dyna-zina; Dynaprin (TN); Eupramin (TN); G-22355; Imipramil (TN); Imipramina [INN-Spanish]; Imipramine (INN); Imipramine [INN:BAN]; Imipraminum [INN-Latin]; Irmin (TN); Janimine (TN); Janimine (hydrochloride); Melipramin (TN); SK-Pramine; Surplix (TN); Tofranil(TN); Tofranil (free base); Tofranil (hydrochloride); Tofranil, base; N-(gamma-Dimethylaminopropyl)iminodibenzyl; N-(gamma.-Dimethylaminopropyl)iminodibenzyl; N-(3-Dimethylaminopropyl)-o-iminodibenzyl; 1-(3-Dimethylaminopropyl)-4,5-dihydro-2,3,6,7-dibenzazepine; 10,11-Dihydro-5-(3-(dimethylamino)propyl)-5H-dibenz[b,f]azepine; 10,11-Dihydro-N,N-dimethyl-5H-dibenz[b,f]azepine-5-propanamine; 2,2'-(3-Dimethylaminopropylimino)bibenzyl; 2,2'-(3-Dimethylaminopropylimino)dibenzyl; 3-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N-dimethylpropan-1-amine; 3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N,N-dimethylpropan-1-amine; 5,6-Dihydro-N-(3-(dimethylamino)propyl)-11H-dibenz(b,e)azepine; 5,6-Dihydro-N-[3-(dimethylamino)propyl]-11H-dibenz[b,e]azepine; 5-(3-(Dimethylamino)propyl)-10,11-dihydro-5H-dibenz(b,f)azepine; 5-(3-Dimethylaminopropyl)-10,11-dihydro-5H-dibenzo(b,f)azepine; 5H-Dibenz(b,f)azepine,5-[3-(dimethylamino)propyl]-10,11-dihydro-mixed with ethyl alcohol; 5H-Dibenz(b,f)azepine-5-propanamine, 10,11-dihydro-N,N-dimethyl-(9CI) DM2NUH3 CP Novartis Pharmaceuticals Corp DM2NUH3 TC Antidepressants DM2NUH3 DT Small molecular drug DM2NUH3 PC 3696 DM2NUH3 MW 280.4 DM2NUH3 FM C19H24N2 DM2NUH3 IC InChI=1S/C19H24N2/c1-20(2)14-7-15-21-18-10-5-3-8-16(18)12-13-17-9-4-6-11-19(17)21/h3-6,8-11H,7,12-15H2,1-2H3 DM2NUH3 CS CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31 DM2NUH3 IK BCGWQEUPMDMJNV-UHFFFAOYSA-N DM2NUH3 IU 3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N,N-dimethylpropan-1-amine DM2NUH3 CA CAS 50-49-7 DM2NUH3 CB CHEBI:47499 DM2NUH3 DE Depression DM1TMA3 ID DM1TMA3 DM1TMA3 DN Imiquimod DM1TMA3 HS Approved DM1TMA3 SN Aldara; Beselna; Zartra; Zyclara; Imiquimod acetate; R 837; S 26308; Aldara (TN); Aldara, Imiquimod; Beselna (TN); DZ-2636; Imiquimod [USAN:INN]; MTD-39; R-837; S-26308; TMX-101; Imiquimod (JAN/USAN/INN); 1-(2-Methylpropyl)-1H-imidazole[4,5-c]quinoline-4-amine; 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine; 1-(2-methylpropyl)imidazo[4,5-c]quinolin-4-amine; 1-isobutyl-1H-imidazo(4,5-c)quinolin-4-amine; 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine; 3M Brand of Imiquimod; 4-Amino-1-isobutyl-1H-imidazo(4,5-c)quinoline; 4-Amino-1-isobutyl-1H-imidazo[4,5-c]quinoline DM1TMA3 CP INova Pharmaceuticals DM1TMA3 TC Antiviral Agents DM1TMA3 DT Small molecular drug DM1TMA3 PC 57469 DM1TMA3 MW 240.3 DM1TMA3 FM C14H16N4 DM1TMA3 IC InChI=1S/C14H16N4/c1-9(2)7-18-8-16-12-13(18)10-5-3-4-6-11(10)17-14(12)15/h3-6,8-9H,7H2,1-2H3,(H2,15,17) DM1TMA3 CS CC(C)CN1C=NC2=C1C3=CC=CC=C3N=C2N DM1TMA3 IK DOUYETYNHWVLEO-UHFFFAOYSA-N DM1TMA3 IU 1-(2-methylpropyl)imidazo[4,5-c]quinolin-4-amine DM1TMA3 CA CAS 99011-02-6 DM1TMA3 CB CHEBI:36704 DM1TMA3 DE Skin cancer DMRMFP4 ID DMRMFP4 DMRMFP4 DN Inamrinone Lactate DMRMFP4 HS Approved DMRMFP4 SN Amrinone; inamrinone; 60719-84-8; Wincoram; Inocor; Cordemcura; Cartonic; 5-Amino-[3,4'-bipyridin]-6(1H)-one; Amrinonum [INN-Latin]; Amrinonum; Amrinona; Amrinona [INN-Spanish]; 3-Amino-5-(4-pyridinyl)-2(1H)-pyridinone; Win-40680; Amcoral; 5-Amino-(3,4'-bipyridin)-6(1H)-one; WIN 40680; AWD 08-250; 3-amino-5-pyridin-4-yl-1H-pyridin-2-one; UNII-JUT23379TN; CCRIS 3794; Amrinone lactate; MLS000069829; EINECS 262-390-0; 5-amino-3,4'-bipyridin-6(1H)-one; BRN 0744819; 5-Amino(3,4'-bipyridin)-6(1H)-one; SMR000058850; CHEMBL12856; JUT23379TN; Amrinone Lactate DMRMFP4 CP Sanofi Aventis Us Llc DMRMFP4 TC Cardiovascular Agents DMRMFP4 DT Small molecular drug DMRMFP4 PC 3035194 DMRMFP4 MW 277.28 DMRMFP4 FM C13H15N3O4 DMRMFP4 IC InChI=1S/C10H9N3O.C3H6O3/c11-9-5-8(6-13-10(9)14)7-1-3-12-4-2-7;1-2(4)3(5)6/h1-6H,11H2,(H,13,14);2,4H,1H3,(H,5,6) DMRMFP4 CS CC(C(=O)O)O.C1=CN=CC=C1C2=CNC(=O)C(=C2)N DMRMFP4 IK DOSIONJFGDSKCQ-UHFFFAOYSA-N DMRMFP4 IU 3-amino-5-pyridin-4-yl-1H-pyridin-2-one;2-hydroxypropanoic acid DMRMFP4 CA CAS 75898-90-7 DMRMFP4 DE Congestive heart failure; Cardiac disease DM3DSVJ ID DM3DSVJ DM3DSVJ DN Incadronate DM3DSVJ HS Approved DM3DSVJ SN Incadronate; 138330-18-4; Disodium Cycloheptylaminomethylene diphosphonate; Bisphonal; Cimadronate sodium; AC1OCF1R; Incadronic acid sodium salt; C8H17NNa2O6P2; CTK8F9264; RT-012376; YM-21175-1; J-007120; disodium [(cycloheptylamino)-[hydroxy(oxido)phosphoryl]methyl]-hydroxyphosphinate DM3DSVJ DT Small molecular drug DM3DSVJ PC 6918123 DM3DSVJ MW 331.15 DM3DSVJ FM C8H17NNa2O6P2 DM3DSVJ IC InChI=1S/C8H19NO6P2.2Na/c10-16(11,12)8(17(13,14)15)9-7-5-3-1-2-4-6-7;;/h7-9H,1-6H2,(H2,10,11,12)(H2,13,14,15);;/q;2*+1/p-2 DM3DSVJ CS C1CCCC(CC1)NC(P(=O)(O)[O-])P(=O)(O)[O-].[Na+].[Na+] DM3DSVJ IK PCSJAAWOSGCAFV-UHFFFAOYSA-L DM3DSVJ IU disodium;[(cycloheptylamino)-[hydroxy(oxido)phosphoryl]methyl]-hydroxyphosphinate DM3DSVJ DE Hypercalcaemia DMKE6YT ID DMKE6YT DMKE6YT DN Incobotulinum toxin A DMKE6YT HS Approved DMKE6YT SN IncobotulinumtoxinA; Xeomin; NT-201; Botulinum toxin type A extract (blepharospasm), Merz/BioteCon DMKE6YT CP Merz DMKE6YT DE Cervical cancer DM32GSJ ID DM32GSJ DM32GSJ DN Incruse ellipta DM32GSJ HS Approved DM32GSJ SN Umeclidinium bromide; 869113-09-7; Umeclidinium (bromide); GSK573719A; Incruse Ellipta; UNII-7AN603V4JV; 7AN603V4JV; GSK-573719; 1-[2-(Benzyloxy)ethyl]-4-(hydroxydiphenylmethyl)-1-quinuclidinium Bromide; 1-(2-(benzyloxy)ethyl)-4-(hydroxydiphenylmethyl)quinuclidin-1-ium bromide; CHEMBL523299; Umeclidinium brom; Umeclidinium bromide [USAN:INN]; umeclidinii bromidum; 1-Azoniabicyclo[2.2.2]octane, 4-(hydroxydiphenylmethyl)-1-[2-(phenylmethoxy)ethyl]-, bromide (1:1); 1-Azoniabicyclo(2.2.2)octane, 4-(hydroxydiphenylmethyl)-1-(2 DM32GSJ CP Glaxosmithkline DM32GSJ DT Small molecular drug DM32GSJ PC 11519069 DM32GSJ MW 508.5 DM32GSJ FM C29H34BrNO2 DM32GSJ IC InChI=1S/C29H34NO2.BrH/c31-29(26-12-6-2-7-13-26,27-14-8-3-9-15-27)28-16-19-30(20-17-28,21-18-28)22-23-32-24-25-10-4-1-5-11-25;/h1-15,31H,16-24H2;1H/q+1;/p-1 DM32GSJ CS C1C[N+]2(CCC1(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)CCOCC5=CC=CC=C5.[Br-] DM32GSJ IK PEJHHXHHNGORMP-UHFFFAOYSA-M DM32GSJ IU diphenyl-[1-(2-phenylmethoxyethyl)-1-azoniabicyclo[2.2.2]octan-4-yl]methanol;bromide DM32GSJ CA CAS 869113-09-7 DM32GSJ CB CHEBI:79040 DM32GSJ DE Chronic obstructive pulmonary disease DMQJHR7 ID DMQJHR7 DMQJHR7 DN Indacaterol DMQJHR7 HS Approved DMQJHR7 SN 312753-06-3; QAB149; Arcapta; Onbrez; QAB-149; QAB 149; UNII-8OR09251MQ; 753498-25-8; CHEMBL1095777; CHEBI:68575; 8OR09251MQ; (R)-5-(2-(5,6-diethyl-2,3-dihydro-1H-inden-2-ylamino)-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one; 5-[(1R)-2-[(5,6-diethyl-2,3-dihydro-1H-inden-2-yl)amino]-1-hydroxyethyl]-8-hydroxy-1H-quinolin-2-one; Indacaterol Maleic Acid Salt; Indacaterol (USAN/INN); Indacaterol [USAN:INN:BAN]; 5-{(1R)-2-[(5,6-diethyl-2,3-dihydro-1H-inden-2-yl)amino]-1-hydroxyethyl}-8-hydroxyquinolin-2(1H)-one; QAB-149; 5-(2-(5,6-Diethylindan-2-ylamino)-1-hydroxyethyl)-8-hydroxy-1H-quinolin-2-one; Indacaterol/mometasone DMQJHR7 CP Novartis DMQJHR7 DT Small molecular drug DMQJHR7 PC 6918554 DMQJHR7 MW 392.5 DMQJHR7 FM C24H28N2O3 DMQJHR7 IC InChI=1S/C24H28N2O3/c1-3-14-9-16-11-18(12-17(16)10-15(14)4-2)25-13-22(28)19-5-7-21(27)24-20(19)6-8-23(29)26-24/h5-10,18,22,25,27-28H,3-4,11-13H2,1-2H3,(H,26,29)/t22-/m0/s1 DMQJHR7 CS CCC1=C(C=C2CC(CC2=C1)NC[C@@H](C3=C4C=CC(=O)NC4=C(C=C3)O)O)CC DMQJHR7 IK QZZUEBNBZAPZLX-QFIPXVFZSA-N DMQJHR7 IU 5-[(1R)-2-[(5,6-diethyl-2,3-dihydro-1H-inden-2-yl)amino]-1-hydroxyethyl]-8-hydroxy-1H-quinolin-2-one DMQJHR7 CA CAS 312753-06-3 DMQJHR7 CB CHEBI:68575 DMQJHR7 DE Chronic obstructive pulmonary disease; Asthma DMGN1PW ID DMGN1PW DMGN1PW DN Indapamide DMGN1PW HS Approved DMGN1PW SN Arifon; Bajaten; Cormil; Damide; Fludex; Idapamide; Indaflex; Indamol; Indapamida; Indapamidum; Ipamix; Lozide; Lozol; Metindamide; Natrilix; Natrix; Noranat; Pressurai; Tandix; Tertensif; Veroxil; RHC 2555; SE 1520; USV 2555; Apo-Indapamide; Indapamida [INN-Spanish]; Indapamide (USP); Indapamidum [INN-Latin]; Lozol (TN); Natrilix (TN); Natrix (TN); Novo-Indapamide; Nu-Indapamide; S-1520; SE-1520; Indapamide (JAN/USP); Indapamide [USAN:INN:BAN:JAN]; N-[4-Chloro-3-sulfamoylbenzamido]-2-methylindoline; NLozol, Arifon, Fludex, Noranat, Veroxil, Tertensif, Indapamide; N-(4-Chloro-3-sulfamoylbenzamido)-2-methylindoline; Benzamide, 3-(aminosulfonyl)-4-chloro-N-(2,3-dihydro-2-methyl-1H-indol-1-yl)-(9CI); 1-(4-Chloro-3-sulfamoylbenzamido)-2-methylindoline; 3-(Aminosulfonyl)-4-chloro-N-(2,3-dihydro-2-methyl-1H-indol-1-yl)benzamide; 4-Chloro-N-(2-methyl-1-indolinyl)-3-sulfamoylbenzamide; 4-chloro-N-(2-methyl-2,3-dihydroindol-1-yl)-3-sulfamoylbenzamide DMGN1PW CP Servier Laboratories DMGN1PW TC Antihypertensive Agents DMGN1PW DT Small molecular drug DMGN1PW PC 3702 DMGN1PW MW 365.8 DMGN1PW FM C16H16ClN3O3S DMGN1PW IC InChI=1S/C16H16ClN3O3S/c1-10-8-11-4-2-3-5-14(11)20(10)19-16(21)12-6-7-13(17)15(9-12)24(18,22)23/h2-7,9-10H,8H2,1H3,(H,19,21)(H2,18,22,23) DMGN1PW CS CC1CC2=CC=CC=C2N1NC(=O)C3=CC(=C(C=C3)Cl)S(=O)(=O)N DMGN1PW IK NDDAHWYSQHTHNT-UHFFFAOYSA-N DMGN1PW IU 4-chloro-N-(2-methyl-2,3-dihydroindol-1-yl)-3-sulfamoylbenzamide DMGN1PW CA CAS 26807-65-8 DMGN1PW CB CHEBI:5893 DMGN1PW DE Hypertension DMUV8OR ID DMUV8OR DMUV8OR DN Indecainide DMUV8OR HS Approved DMUV8OR SN Indecainida; Indecainidum; Ricainid; Ricainide; Indecainida [Spanish]; Indecainide [INN]; Indecainidum [Latin]; Decabid (TN); LY-135837; 9-(3-((1-methylethyl)amino)propyl)-9H-fluorene-9-carboxamide; 9-(3-(Isopropylamino)propyl))fluorene-9-carboxamide; 9-(3-(Isopropylamino)propyl)-9-fluorenylcarboxamid; 9-[3-(propan-2-ylamino)propyl]fluorene-9-carboxamide DMUV8OR CP Eli Lilly And Co DMUV8OR TC Antidysrhythmic Agents DMUV8OR DT Small molecular drug DMUV8OR PC 52195 DMUV8OR MW 308.4 DMUV8OR FM C20H24N2O DMUV8OR IC InChI=1S/C20H24N2O/c1-14(2)22-13-7-12-20(19(21)23)17-10-5-3-8-15(17)16-9-4-6-11-18(16)20/h3-6,8-11,14,22H,7,12-13H2,1-2H3,(H2,21,23) DMUV8OR CS CC(C)NCCCC1(C2=CC=CC=C2C3=CC=CC=C31)C(=O)N DMUV8OR IK UCEWGESNIULAGX-UHFFFAOYSA-N DMUV8OR IU 9-[3-(propan-2-ylamino)propyl]fluorene-9-carboxamide DMUV8OR CA CAS 74517-78-5 DMUV8OR CB CHEBI:135314 DMUV8OR DE Dysrhythmias DMWO3N6 ID DMWO3N6 DMWO3N6 DN Indeloxazine DMWO3N6 HS Approved DMWO3N6 SN Elen; Noin; Indeloxazine hydrochloride; YM-08054 DMWO3N6 CP Yamanouchi Pharmaceutical Co Ltd DMWO3N6 DT Small molecular drug DMWO3N6 PC 3704 DMWO3N6 MW 231.29 DMWO3N6 FM C14H17NO2 DMWO3N6 IC InChI=1S/C14H17NO2/c1-3-11-4-2-6-14(13(11)5-1)17-10-12-9-15-7-8-16-12/h1-4,6,12,15H,5,7-10H2 DMWO3N6 CS C1COC(CN1)COC2=CC=CC3=C2CC=C3 DMWO3N6 IK MADRVGBADLFHMO-UHFFFAOYSA-N DMWO3N6 IU 2-(3H-inden-4-yloxymethyl)morpholine DMWO3N6 CA CAS 60929-23-9 DMWO3N6 CB CHEBI:5894 DMWO3N6 DE Dementia DM0T3YH ID DM0T3YH DM0T3YH DN Indinavir DM0T3YH HS Approved DM0T3YH SN Crixivan; IDV; Indinavir [USAN]; L 735524; Crixivan (TM); Crixivan (TN); L-735 524; L-735524; MK-639; Propolis+Indinavir; RS-253; L-735,524; Indinavir, Sulfate (1:1); Indinavir (*1:1 Sulfate salt*); N-[2(R)-HYDROXY-1(S)-INDANYL]-5-[(2(S)-TERTIARY BUTYLAMINOCARBONYL)-4(3-PYRIDYLMETHYL)PIPERAZINO]-4(S)-HYDROXY-2(R)-PHENYLMETHYLPENTANAMIDE; Propolis & 4-Hydroxy-N-(2-hydroxy-2,3-dihydro-1H-1-indanyl)-N'-(1,1-dimethylethyl)-2-phenylmethyl-5-[4-(3-pyridylmethyl)-1-piperzinyl]hexanediamide; (1(1S,2R),5(S))-2,3,5-Trideoxy-N-(2,3-dihydro-2-hydroxy-1H-inden-1-yl)-5-(2-(((1,1-dimethylethyl)amino)carbonyl)-4-(3-pyridinylmethyl)-1-piperazinyl)-2-(phenylmethyl)-D-erythro-Pentonamide; (2S)-1-[(2S,4S)-4-benzyl-2-hydroxy-5-[[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]amino]-5-oxopentyl]-N-tert-butyl-4-(pyridin-3-ylmethyl)piperazine-2-carboxamide DM0T3YH CP Merck & Co DM0T3YH TC Anti-HIV Agents DM0T3YH DT Small molecular drug DM0T3YH PC 5362440 DM0T3YH MW 613.8 DM0T3YH FM C36H47N5O4 DM0T3YH IC InChI=1S/C36H47N5O4/c1-36(2,3)39-35(45)31-24-40(22-26-12-9-15-37-21-26)16-17-41(31)23-29(42)19-28(18-25-10-5-4-6-11-25)34(44)38-33-30-14-8-7-13-27(30)20-32(33)43/h4-15,21,28-29,31-33,42-43H,16-20,22-24H2,1-3H3,(H,38,44)(H,39,45)/t28-,29+,31+,32-,33+/m1/s1 DM0T3YH CS CC(C)(C)NC(=O)[C@@H]1CN(CCN1C[C@H](C[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H]3[C@@H](CC4=CC=CC=C34)O)O)CC5=CN=CC=C5 DM0T3YH IK CBVCZFGXHXORBI-PXQQMZJSSA-N DM0T3YH IU (2S)-1-[(2S,4R)-4-benzyl-2-hydroxy-5-[[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]amino]-5-oxopentyl]-N-tert-butyl-4-(pyridin-3-ylmethyl)piperazine-2-carboxamide DM0T3YH CA CAS 150378-17-9 DM0T3YH CB CHEBI:44032 DM0T3YH DE Human immunodeficiency virus infection DMOPGHQ ID DMOPGHQ DMOPGHQ DN Indiplon DMOPGHQ HS Approved DMOPGHQ SN NBI 34060; NBI-34060; Indiplon (USAN/INN); N-methyl-N-[3-[3-(thiophene-2-carbonyl)pyrazolo[1,5-a]pyrimidin-7-yl]phenyl]acetamide DMOPGHQ CP Neurocrine Biosciences DMOPGHQ DT Small molecular drug DMOPGHQ PC 6450813 DMOPGHQ MW 376.4 DMOPGHQ FM C20H16N4O2S DMOPGHQ IC InChI=1S/C20H16N4O2S/c1-13(25)23(2)15-6-3-5-14(11-15)17-8-9-21-20-16(12-22-24(17)20)19(26)18-7-4-10-27-18/h3-12H,1-2H3 DMOPGHQ CS CC(=O)N(C)C1=CC=CC(=C1)C2=CC=NC3=C(C=NN23)C(=O)C4=CC=CS4 DMOPGHQ IK CBIAWPMZSFFRGN-UHFFFAOYSA-N DMOPGHQ IU N-methyl-N-[3-[3-(thiophene-2-carbonyl)pyrazolo[1,5-a]pyrimidin-7-yl]phenyl]acetamide DMOPGHQ CA CAS 325715-02-4 DMOPGHQ DE Insomnia; Fibromyalgia DM2NQUY ID DM2NQUY DM2NQUY DN Indocyanine green DM2NQUY HS Approved DM2NQUY SN indocyanine green; Cardiogreen; 3599-32-4; AC1L2DMU; GTPL4844; KS-00000YFZ; MOLI001001; F9995-0163; sodium 4-(2-((1E,3E,5E,7E)-7-(1,1-dimethyl-3-(4-sulfonatobutyl)-1H-benzo[e]indol-2(3H)-ylidene)hepta-1,3,5-trienyl)-1,1-dimethyl-1H-benzo[e]indolium-3-yl)butane-1-sulfonate; sodium 4-[2-[(1E,3E,5E,7Z)-7-[1,1-dimethyl-3-(4-sulfonatobutyl)benzo[e]indol-2-ylidene]hepta-1,3,5-trienyl]-1,1-dimethylbenzo[e]indol-3-ium-3-yl]butane-1-sulfonate; sodium 4-[2-[7-[1,1-dimethyl-3-(4-sulfonatobutyl)benzo[e]indol-3-ium-2-yl]hepta-2,4 DM2NQUY DT Small molecular drug DM2NQUY PC 11967809 DM2NQUY MW 775 DM2NQUY FM C43H47N2NaO6S2 DM2NQUY IC InChI=1S/C43H48N2O6S2.Na/c1-42(2)38(44(28-14-16-30-52(46,47)48)36-26-24-32-18-10-12-20-34(32)40(36)42)22-8-6-5-7-9-23-39-43(3,4)41-35-21-13-11-19-33(35)25-27-37(41)45(39)29-15-17-31-53(49,50)51;/h5-13,18-27H,14-17,28-31H2,1-4H3,(H-,46,47,48,49,50,51);/q;+1/p-1 DM2NQUY CS CC1(C(=[N+](C2=C1C3=CC=CC=C3C=C2)CCCCS(=O)(=O)[O-])/C=C/C=C/C=C/C=C/4\\C(C5=C(N4CCCCS(=O)(=O)[O-])C=CC6=CC=CC=C65)(C)C)C.[Na+] DM2NQUY IK MOFVSTNWEDAEEK-UHFFFAOYSA-M DM2NQUY IU sodium;4-[(2E)-2-[(2E,4E,6E)-7-[1,1-dimethyl-3-(4-sulfonatobutyl)benzo[e]indol-3-ium-2-yl]hepta-2,4,6-trienylidene]-1,1-dimethylbenzo[e]indol-3-yl]butane-1-sulfonate DM2NQUY CA CAS 3599-32-4 DM2NQUY DE Gastrointestinal disease DMSC4A7 ID DMSC4A7 DMSC4A7 DN Indomethacin DMSC4A7 HS Approved DMSC4A7 SN Aconip; Amuno; Arthrexin; Artracin; Artrinovo; Artrivia; Bonidin; Bonidon; Catlep; Confortid; Dolcidium; Dolovin; Durametacin; Elmetacin; Hicin; IMN; Idomethine; Imbrilon; Inacid; Indacin; Indameth; Indmethacine; Indocid; Indocin; Indomecol; Indomed; Indomee; Indometacin; Indometacina; Indometacine; Indometacinum; Indometacyna; Indomethacine; Indomethacinum; Indomethancin; Indomethazine; Indomethegan; Indomethine; Indometicina; Indomo; Indomod; Indoptic; Indoptol; Indorektal; Indoxen; Inflazon; Infrocin; Lausit; Liometacen; Metacen; Metartril; Methazine; Metindol; Mezolin; Miametan; Mikametan; Mobilan; Novomethacin; Reumacide; Sadoreum; Tannex; Vonum; Bonidon Gel; DESMETHYL INDOMETHACIN; Dolcidium PL;Flexin continus; Indocid Pda; Indocid Sr; Indocin Sr; Indolar SR; Indometacyna [Polish]; Indometicina [Spanish]; Inteban sp; Rhemacin LA; Rheumacin LA; I 7378; IN1454; Indomet 140; Aconip (TN); Apo-Indomethacin; Chibro-amuno; Chrono-indicid; Chrono-indocid; Indo-Lemmon; Indo-Spray; Indo-phlogont; Indo-rectolmin; Indo-tablinen; Indocid (TN); Indocid (pharmaceutical); Indocin (TN); Indocin I.V; Indometacina [INN-Spanish]; Indometacine [INN-French]; Indometacinum [INN-Latin]; Indomethacin (USP); Indomethacin [USAN:BAN]; Novo-Methacin; Indochron E-R (TN); Indocin I.V.; Indocin-SR (TN); Indometacin (JP15/INN); Indomethacin & MAP-30; Indomethacin, Indochron E-R, Indocin-SR, Indocid, Indocin, Indomethacin DMSC4A7 CP Recordati Rare Diseases Inc DMSC4A7 TC Antiinflammatory Agents DMSC4A7 DT Small molecular drug DMSC4A7 PC 3715 DMSC4A7 MW 357.8 DMSC4A7 FM C19H16ClNO4 DMSC4A7 IC InChI=1S/C19H16ClNO4/c1-11-15(10-18(22)23)16-9-14(25-2)7-8-17(16)21(11)19(24)12-3-5-13(20)6-4-12/h3-9H,10H2,1-2H3,(H,22,23) DMSC4A7 CS CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)O DMSC4A7 IK CGIGDMFJXJATDK-UHFFFAOYSA-N DMSC4A7 IU 2-[1-(4-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]acetic acid DMSC4A7 CA CAS 53-86-1 DMSC4A7 CB CHEBI:49662 DMSC4A7 DE Rheumatoid arthritis DMI0RHA ID DMI0RHA DMI0RHA DN Inebilizumab DMI0RHA HS Approved DMI0RHA CP MedImmune Gaithersburg, MD DMI0RHA DE Neuromyelitis optica spectrum disorder DMH7OIA ID DMH7OIA DMH7OIA DN Infliximab DMH7OIA HS Approved DMH7OIA SN Remicade (TN) DMH7OIA CP Samsung Bioepsis DMH7OIA TC Immunosuppressive Agents DMH7OIA DT Antibody DMH7OIA DE Plaque psoriasis; Rheumatoid arthritis; Asthma DMK1CZJ ID DMK1CZJ DMK1CZJ DN Ingenol mebutate DMK1CZJ HS Approved DMK1CZJ SN Picato; Ingenol 3-angelate; 75567-37-2; PEP-005; PEP005; 3-Angeloylingenol; UNII-7686S50JAH; PEP 005; 3-Ingenyl angelate; Ingenol-3-angelate; 7686S50JAH; Picato (TN); Euphorbia factor H1; Euphorbia factor An1; Ingenol mebutate [USAN:INN]; [dihydroxy-(hydroxymethyl)-tetramethyl-oxo-[ ]yl] (Z)-2-methylbut-2-enoate; I3A; Ingenol-3- angelate; Ingenol mebutate (USAN); (Z)-2-methylbut-2-enoate; SCHEMBL2526605; GTPL7443; CHEMBL1863513; HSDB 8308; VDJHFHXMUKFKET-WDUFCVPESA-N; MolPort-003-941-761; AN-262; POL-103A DMK1CZJ CP LEO Pharma DMK1CZJ DT Small molecular drug DMK1CZJ PC 6918670 DMK1CZJ MW 430.5 DMK1CZJ FM C25H34O6 DMK1CZJ IC InChI=1S/C25H34O6/c1-7-12(2)22(29)31-21-13(3)10-24-14(4)8-17-18(23(17,5)6)16(20(24)28)9-15(11-26)19(27)25(21,24)30/h7,9-10,14,16-19,21,26-27,30H,8,11H2,1-6H3/b12-7-/t14-,16+,17-,18+,19-,21+,24+,25+/m1/s1 DMK1CZJ CS C/C=C(/C)\\C(=O)O[C@H]1C(=C[C@@]23[C@@]1([C@@H](C(=C[C@H](C2=O)[C@H]4[C@H](C4(C)C)C[C@H]3C)CO)O)O)C DMK1CZJ IK VDJHFHXMUKFKET-WDUFCVPESA-N DMK1CZJ IU [(1S,4S,5S,6R,9S,10R,12R,14R)-5,6-dihydroxy-7-(hydroxymethyl)-3,11,11,14-tetramethyl-15-oxo-4-tetracyclo[7.5.1.01,5.010,12]pentadeca-2,7-dienyl] (Z)-2-methylbut-2-enoate DMK1CZJ CA CAS 75567-37-2 DMK1CZJ CB CHEBI:66913 DMK1CZJ DE Actinic keratosis; Melanoma DMJ93CT ID DMJ93CT DMJ93CT DN Inotersen DMJ93CT HS Approved DMJ93CT SN UNII-0IEO0F56LV; 0IEO0F56LV; Inotersen [USAN]; ISIS 420915 DMJ93CT CP Ionis Pharmaceuticals DMJ93CT PC 121492004 DMJ93CT MW 7183 DMJ93CT FM C230H318N69O121P19S19 DMJ93CT IC InChI=1S/C230H318N69O121P19S19/c1-98-53-280(219(312)262-178(98)231)140-43-110(121(382-140)66-364-425(328,444)406-114-47-144(292-90-254-150-183(236)244-85-249-188(150)292)387-126(114)71-368-423(326,442)404-112-45-142(282-59-104(7)197(303)274-225(282)318)383-122(112)67-363-421(324,440)403-111-44-141(281-58-103(6)196(302)273-224(281)317)385-124(111)69-366-427(330,446)410-119-52-149(297-95-260-156-194(297)268-217(242)271-204(156)310)391-130(119)75-372-431(334,450)419-167-139(401-215(177(167)362-42-32-352-22)299-97-261-157-195(299)269-218(243)272-205(157)311)84-381-438(341,457)418-165-136(398-213(175(165)360-40-30-350-20)291-64-109(12)202(308)279-230(291)323)82-379-437(340,456)417-163-135(397-211(173(163)358-38-28-348-18)289-62-107(10)200(306)277-228(289)321)81-378-435(338,454)414-161-132(394-209(171(161)356-36-26-346-16)286-56-101(4)181(234)265-222(286)315)78-375-433(336,452)412-159-120(65-300)392-207(169(159)354-34-24-344-14)288-61-106(9)199(305)276-227(288)320)402-422(325,441)367-70-125-115(48-145(386-125)293-91-255-151-184(237)245-86-250-189(151)293)407-426(329,445)365-68-123-113(46-143(384-123)283-60-105(8)198(304)275-226(283)319)405-424(327,443)371-74-129-118(51-148(390-129)296-94-259-155-193(296)267-216(241)270-203(155)309)409-429(332,448)370-72-127-116(49-146(388-127)294-92-256-152-185(238)246-87-251-190(152)294)408-428(331,447)369-73-128-117(50-147(389-128)295-93-257-153-186(239)247-88-252-191(153)295)411-430(333,449)374-77-138-166(176(361-41-31-351-21)214(400-138)298-96-258-154-187(240)248-89-253-192(154)298)420-439(342,458)380-83-137-164(174(359-39-29-349-19)212(399-137)290-63-108(11)201(307)278-229(290)322)416-436(339,455)377-80-134-162(172(357-37-27-347-17)210(396-134)287-57-102(5)182(235)266-223(287)316)415-434(337,453)376-79-133-160(170(355-35-25-345-15)208(395-133)285-55-100(3)180(233)264-221(285)314)413-432(335,451)373-76-131-158(301)168(353-33-23-343-13)206(393-131)284-54-99(2)179(232)263-220(284)313/h53-64,85-97,110-149,158-177,206-215,300-301H,23-52,65-84H2,1-22H3,(H,324,440)(H,325,441)(H,326,442)(H,327,443)(H,328,444)(H,329,445)(H,330,446)(H,331,447)(H,332,448)(H,333,449)(H,334,450)(H,335,451)(H,336,452)(H,337,453)(H,338,454)(H,339,455)(H,340,456)(H,341,457)(H,342,458)(H2,231,262,312)(H2,232,263,313)(H2,233,264,314)(H2,234,265,315)(H2,235,266,316)(H2,236,244,249)(H2,237,245,250)(H2,238,246,251)(H2,239,247,252)(H2,240,248,253)(H,273,302,317)(H,274,303,318)(H,275,304,319)(H,276,305,320)(H,277,306,321)(H,278,307,322)(H,279,308,323)(H3,241,267,270,309)(H3,242,268,271,310)(H3,243,269,272,311)/t110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120+,121+,122+,123+,124+,125+,126+,127+,128+,129+,130+,131+,132+,133+,134+,135+,136+,137+,138+,139+,140+,141+,142+,143+,144+,145+,146+,147+,148+,149+,158+,159+,160+,161+,162+,163+,164+,165+,166+,167+,168+,169+,170+,171+,172+,173+,174+,175+,176+,177+,206+,207+,208+,209+,210+,211+,212+,213+,214+,215+,421?,422?,423?,424?,425?,426?,427?,428?,429?,430?,431?,432?,433?,434?,435?,436?,437?,438?,439?/m0/s1 DMJ93CT CS CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)COP(=S)(O)O[C@H]3C[C@@H](O[C@@H]3COP(=S)(O)O[C@H]4C[C@@H](O[C@@H]4COP(=S)(O)O[C@@H]5[C@H](O[C@H]([C@@H]5OCCOC)N6C=NC7=C6N=C(NC7=O)N)COP(=S)(O)O[C@@H]8[C@H](O[C@H]([C@@H]8OCCOC)N9C=C(C(=O)NC9=O)C)COP(=S)(O)O[C@@H]1[C@H](O[C@H]([C@@H]1OCCOC)N1C=C(C(=O)NC1=O)C)COP(=O)(O[C@@H]1[C@H](O[C@H]([C@@H]1OCCOC)N1C=C(C(=NC1=O)N)C)COP(=S)(O)O[C@@H]1[C@H](O[C@H]([C@@H]1OCCOC)N1C=C(C(=O)NC1=O)C)CO)S)N1C=NC2=C1N=C(NC2=O)N)N1C=C(C(=O)NC1=O)C)OP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N1C=NC2=C(N=CN=C21)N)OP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N1C=C(C(=NC1=O)N)C)OP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N1C=NC2=C(N=CN=C21)N)OP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N1C=C(C(=O)NC1=O)C)OP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N1C=NC2=C1N=C(NC2=O)N)OP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N1C=NC2=C(N=CN=C21)N)OP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N1C=NC2=C(N=CN=C21)N)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=NC2=C(N=CN=C21)N)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=C(C(=O)NC1=O)C)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=C(C(=NC1=O)N)C)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=C(C(=NC1=O)N)C)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=C(C(=NC1=O)N)C)OCCOC)O DMJ93CT IK KLEGMTRDCCDFJK-XDQSQZFTSA-N DMJ93CT IU 1-[(2R,4S,5R)-4-[[(2R,3S,5R)-3-[[(2R,3S,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3R,4R,5R)-3-[[(2R,3R,4R,5R)-3-[[(2R,3R,4R,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[(2R,3R,4R,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[(2R,3R,4R,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-hydroxy-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(6-aminopurin-9-yl)-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(2-amino-6-oxo-1H-purin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-2-[[[(2R,3R,4R,5R)-2-[[[(2R,3R,4R,5R)-2-[[[(2R,3R,4R,5R)-2-[[[(2R,3R,4R,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-2-[[hydroxy-[(2R,3R,4R,5R)-2-(hydroxymethyl)-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxyphosphinothioyl]oxymethyl]-4-(2-methoxyethoxy)oxolan-3-yl]oxy-sulfanylphosphoryl]oxymethyl]-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(2-amino-6-oxo-1H-purin-9-yl)-4-(2-methoxyethoxy)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(2-amino-6-oxo-1H-purin-9-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]oxolan-2-yl]-5-methylpyrimidine-2,4-dione DMJ93CT CA CAS 1492984-65-2 DMJ93CT DE Hereditary amyloidosis DMAC130 ID DMAC130 DMAC130 DN Inotuzumab ozogamicin DMAC130 HS Approved DMAC130 CP Pfizer DMAC130 DT Antibody DMAC130 DE Acute lymphocytic leukaemia; Acute lymphoblastic leukaemia DMB7CE0 ID DMB7CE0 DMB7CE0 DN Insulin DMB7CE0 HS Approved DMB7CE0 SN BrioDurance; Insulin (agglomerated vesicle technology, diabetes), Cense Biosciences; Insulin (subcutaneous/nanoparticle/suspension/sustained release formulation, diabetes); Insulin (subcutaneous/nanoparticle/suspension/sustained release formulation, diabetes), Cense Biosciences DMB7CE0 CP Cense Biosciences Inc DMB7CE0 SQ A chain: GIVEQCCTSICSLYQLENYCN >B chainFVNQHLCGSHLVEALYLVCGERGFFYTPKT DMB7CE0 DE Diabetic complication DMPL395 ID DMPL395 DMPL395 DN Insulin degludec DMPL395 HS Approved DMPL395 SN Tresiba (TN) DMPL395 CP Novo Nordisk DMPL395 SQ A Chain: FVNQHLCGSHLVEALYLVCGERGFFYTPK >B ChainGIVEQCCTSICSLYQLENYCN DMPL395 PC 118984462 DMPL395 MW 6104 DMPL395 FM C274H411N65O81S6 DMPL395 IC InChI=1S/C274H411N65O81S6/c1-28-146(23)223(331-210(357)119-275)268(412)335-222(145(21)22)264(408)305-172(89-97-218(369)370)234(378)300-169(84-92-204(279)351)238(382)326-198-131-424-425-132-199-259(403)323-193(126-341)256(400)312-177(103-138(7)8)241(385)313-183(110-154-66-74-160(345)75-67-154)244(388)301-167(82-90-202(277)349)235(379)308-176(102-137(5)6)239(383)303-171(88-96-217(367)368)237(381)320-189(116-205(280)352)251(395)316-185(112-156-70-78-162(347)79-71-156)247(391)327-197(258(402)322-191(273(419)420)118-207(282)354)130-423-422-129-196(231(375)290-122-211(358)295-166(86-94-215(363)364)233(377)299-165(62-53-99-288-274(283)284)229(373)289-123-212(359)297-181(108-152-57-45-41-46-58-152)243(387)315-182(109-153-59-47-42-48-60-153)246(390)317-186(113-157-72-80-163(348)81-73-157)254(398)338-226(150(27)344)270(414)339-100-54-63-201(339)262(406)306-173(271(415)416)61-51-52-98-287-208(355)93-85-174(272(417)418)296-209(356)64-49-38-36-34-32-30-31-33-35-37-39-50-65-214(361)362)329-266(410)221(144(19)20)334-252(396)179(105-140(11)12)310-245(389)184(111-155-68-76-161(346)77-69-155)314-240(384)175(101-136(3)4)307-227(371)148(25)294-232(376)170(87-95-216(365)366)304-263(407)220(143(17)18)333-253(397)180(106-141(13)14)311-249(393)188(115-159-121-286-135-293-159)319-255(399)192(125-340)298-213(360)124-291-230(374)195(128-421-426-133-200(328-260(198)404)261(405)337-225(149(26)343)269(413)324-194(127-342)257(401)336-224(147(24)29-2)267(411)330-199)325-242(386)178(104-139(9)10)309-248(392)187(114-158-120-285-134-292-158)318-236(380)168(83-91-203(278)350)302-250(394)190(117-206(281)353)321-265(409)219(142(15)16)332-228(372)164(276)107-151-55-43-40-44-56-151/h40-48,55-60,66-81,120-121,134-150,164-201,219-226,340-348H,28-39,49-54,61-65,82-119,122-133,275-276H2,1-27H3,(H2,277,349)(H2,278,350)(H2,279,351)(H2,280,352)(H2,281,353)(H2,282,354)(H,285,292)(H,286,293)(H,287,355)(H,289,373)(H,290,375)(H,291,374)(H,294,376)(H,295,358)(H,296,356)(H,297,359)(H,298,360)(H,299,377)(H,300,378)(H,301,388)(H,302,394)(H,303,383)(H,304,407)(H,305,408)(H,306,406)(H,307,371)(H,308,379)(H,309,392)(H,310,389)(H,311,393)(H,312,400)(H,313,385)(H,314,384)(H,315,387)(H,316,395)(H,317,390)(H,318,380)(H,319,399)(H,320,381)(H,321,409)(H,322,402)(H,323,403)(H,324,413)(H,325,386)(H,326,382)(H,327,391)(H,328,404)(H,329,410)(H,330,411)(H,331,357)(H,332,372)(H,333,397)(H,334,396)(H,335,412)(H,336,401)(H,337,405)(H,338,398)(H,361,362)(H,363,364)(H,365,366)(H,367,368)(H,369,370)(H,415,416)(H,417,418)(H,419,420)(H4,283,284,288)/t146-,147-,148-,149+,150+,164-,165-,166-,167-,168-,169-,170-,171-,172-,173-,174-,175-,176-,177-,178-,179-,180-,181-,182-,183-,184-,185-,186-,187-,188-,189-,190-,191-,192-,193-,194-,195-,196-,197-,198-,199-,200-,201-,219-,220-,221-,222-,223-,224-,225-,226-/m0/s1 DMPL395 CS CC[C@H](C)[C@H]1C(=O)N[C@H]2CSSC[C@@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC2=O)CO)CC(C)C)CC3=CC=C(C=C3)O)CCC(=O)N)CC(C)C)CCC(=O)O)CC(=O)N)CC4=CC=C(C=C4)O)C(=O)N[C@@H](CC(=O)N)C(=O)O)C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CC5=CC=CC=C5)C(=O)N[C@@H](CC6=CC=CC=C6)C(=O)N[C@@H](CC7=CC=C(C=C7)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N8CCC[C@H]8C(=O)N[C@@H](CCCCNC(=O)CC[C@@H](C(=O)O)NC(=O)CCCCCCCCCCCCCCC(=O)O)C(=O)O)C(C)C)CC(C)C)CC9=CC=C(C=C9)O)CC(C)C)C)CCC(=O)O)C(C)C)CC(C)C)CC2=CNC=N2)CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC2=CNC=N2)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC2=CC=CC=C2)N)C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CO)[C@@H](C)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)CN DMPL395 IK FYZPCMFQCNBYCY-WIWKJPBBSA-N DMPL395 IU 16-[[(1S)-4-[[(5S)-5-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[2-[[(1R,6R,12S,15S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,50S,53S,56S,59S,62S,65S,68S,71S,74R,77S,80S,83S,88R)-88-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[(2-aminoacetyl)amino]-3-methylpentanoyl]amino]-3-methylbutanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]-6-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-amino-3-phenylpropanoyl]amino]-3-methylbutanoyl]amino]-4-oxobutanoyl]amino]-5-oxopentanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-4-methylpentanoyl]amino]-47-[[(1S)-3-amino-1-carboxy-3-oxopropyl]carbamoyl]-53-(2-amino-2-oxoethyl)-62-(3-amino-3-oxopropyl)-77-[(2S)-butan-2-yl]-24,56-bis(2-carboxyethyl)-83-[(1R)-1-hydroxyethyl]-12,71,80-tris(hydroxymethyl)-33,50,65-tris[(4-hydroxyphenyl)methyl]-15-(1H-imidazol-4-ylmethyl)-27-methyl-18,30,36,59,68-pentakis(2-methylpropyl)-7,10,13,16,19,22,25,28,31,34,37,40,49,52,55,58,61,64,67,70,73,76,79,82,85,87-hexacosaoxo-21,39-di(propan-2-yl)-3,4,44,45,90,91-hexathia-8,11,14,17,20,23,26,29,32,35,38,41,48,51,54,57,60,63,66,69,72,75,78,81,84,86-hexacosazabicyclo[72.11.7]dononacontane-42-carbonyl]amino]acetyl]amino]-4-carboxybutanoyl]amino]-5-carbamimidamidopentanoyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-carboxypentyl]amino]-1-carboxy-4-oxobutyl]amino]-16-oxohexadecanoic acid DMPL395 CA CAS 844439-96-9 DMPL395 DE Type-1/2 diabetes DM79NZ5 ID DM79NZ5 DM79NZ5 DN Insulin determir DM79NZ5 HS Approved DM79NZ5 SN Levemir (TN) DM79NZ5 DE Diabetic complication DM5XHVR ID DM5XHVR DM5XHVR DN Insulin Lyspro recombinant DM5XHVR HS Approved DM5XHVR TC Hypoglycemic Agents DM5XHVR DE Diabetic complication DMYVP5G ID DMYVP5G DMYVP5G DN Insulin recombinant DMYVP5G HS Approved DMYVP5G SN 9004-10-8; Exubera; Insulin recombinant; Endopancrine; Humilin; Dermulin; Decurvon; Musulin; Iszilin; Insulyl; Insular; Iletin; insulin-human; Dal-insulinum; Intesulin B; Insulin, dalanated; Insulina dalanatada; AERx; Insulinum dalanatum; insulin (recombinant); Imusay-131; INSULIN INJECTION; Insulini injectio neutralis; Insulina iniettabile neutra; Injectable insulini neutrale; Inyectable neutro de insulina; CHEBI:5931; CCRIS 5464; Insulinum dalanatum [INN-Latin]; HSDB 3102; Insulin, dalanated [USAN:INN]; AERx [Insulin management system] DMYVP5G TC Hypoglycemic Agents DMYVP5G DT Small molecular drug DMYVP5G PC 70678557 DMYVP5G MW 5794 DMYVP5G FM C256H381N65O77S6 DMYVP5G IC InChI=1S/C256H381N65O77S6/c1-29-130(23)202(311-190(337)103-258)250(391)315-200(128(19)20)246(387)286-158(75-82-197(347)348)216(357)281-154(70-77-186(261)333)220(361)306-181-115-402-403-116-182-241(382)303-176(110-323)238(379)293-161(88-122(7)8)224(365)294-167(95-139-53-61-145(328)62-54-139)227(368)282-153(69-76-185(260)332)217(358)289-160(87-121(5)6)222(363)283-157(74-81-196(345)346)219(360)301-173(101-188(263)335)233(374)297-169(97-141-57-65-147(330)66-58-141)230(371)307-180(240(381)302-174(254(395)396)102-189(264)336)114-401-400-113-179(213(354)272-106-191(338)277-152(72-79-194(341)342)215(356)280-150(51-42-84-270-256(266)267)211(352)271-107-192(339)278-165(93-137-46-36-32-37-47-137)226(367)296-166(94-138-48-38-33-39-49-138)229(370)298-170(98-142-59-67-148(331)68-60-142)236(377)318-205(134(27)326)253(394)321-85-43-52-184(321)244(385)284-151(50-40-41-83-257)221(362)319-206(135(28)327)255(397)398)309-247(388)199(127(17)18)314-234(375)163(90-124(11)12)291-228(369)168(96-140-55-63-146(329)64-56-140)295-223(364)159(86-120(3)4)288-209(350)132(25)276-214(355)156(73-80-195(343)344)285-245(386)198(126(15)16)313-235(376)164(91-125(13)14)292-232(373)172(100-144-105-269-119-275-144)300-237(378)175(109-322)279-193(340)108-273-212(353)178(112-399-404-117-183(308-242(181)383)243(384)317-204(133(26)325)251(392)304-177(111-324)239(380)316-203(131(24)30-2)249(390)310-182)305-225(366)162(89-123(9)10)290-231(372)171(99-143-104-268-118-274-143)299-218(359)155(71-78-187(262)334)287-252(393)207(208(265)349)320-248(389)201(129(21)22)312-210(351)149(259)92-136-44-34-31-35-45-136/h31-39,44-49,53-68,104-105,118-135,149-184,198-207,322-331H,29-30,40-43,50-52,69-103,106-117,257-259H2,1-28H3,(H2,260,332)(H2,261,333)(H2,262,334)(H2,263,335)(H2,264,336)(H2,265,349)(H,268,274)(H,269,275)(H,271,352)(H,272,354)(H,273,353)(H,276,355)(H,277,338)(H,278,339)(H,279,340)(H,280,356)(H,281,357)(H,282,368)(H,283,363)(H,284,385)(H,285,386)(H,286,387)(H,287,393)(H,288,350)(H,289,358)(H,290,372)(H,291,369)(H,292,373)(H,293,379)(H,294,365)(H,295,364)(H,296,367)(H,297,374)(H,298,370)(H,299,359)(H,300,378)(H,301,360)(H,302,381)(H,303,382)(H,304,392)(H,305,366)(H,306,361)(H,307,371)(H,308,383)(H,309,388)(H,310,390)(H,311,337)(H,312,351)(H,313,376)(H,314,375)(H,315,391)(H,316,380)(H,317,384)(H,318,377)(H,319,362)(H,320,389)(H,341,342)(H,343,344)(H,345,346)(H,347,348)(H,395,396)(H,397,398)(H4,266,267,270)/t130-,131-,132+,133+,134+,135+,149+,150+,151+,152+,153+,154+,155+,156+,157+,158+,159+,160+,161+,162+,163+,164+,165+,166+,167+,168+,169+,170+,171+,172+,173+,174+,175+,176+,177+,178+,179+,180+,181+,182-,183+,184+,198+,199+,200+,201+,202+,203+,204+,205+,206+,207+/m1/s1 DMYVP5G CS CC[C@@H](C)[C@H]1C(=O)N[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC2=O)CO)CC(C)C)CC3=CC=C(C=C3)O)CCC(=O)N)CC(C)C)CCC(=O)O)CC(=O)N)CC4=CC=C(C=C4)O)C(=O)N[C@@H](CC(=O)N)C(=O)O)C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CC5=CC=CC=C5)C(=O)N[C@@H](CC6=CC=CC=C6)C(=O)N[C@@H](CC7=CC=C(C=C7)O)C(=O)N[C@@H]([C@H](C)O)C(=O)N8CCC[C@H]8C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@H](C)O)C(=O)O)C(C)C)CC(C)C)CC9=CC=C(C=C9)O)CC(C)C)C)CCC(=O)O)C(C)C)CC(C)C)CC2=CNC=N2)CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC2=CNC=N2)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC2=CC=CC=C2)N)C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CO)[C@H](C)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H]([C@H](C)CC)NC(=O)CN DMYVP5G IK YAJCHEVQCOHZDC-QMMNLEPNSA-N DMYVP5G IU (4S)-4-[[2-[[(1R,6R,12S,15S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,50S,53S,56S,59S,62S,65S,68S,71S,74S,77S,80S,83S,88R)-88-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[(2-aminoacetyl)amino]-3-methylpentanoyl]amino]-3-methylbutanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]-6-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-3-amino-2-[[(2S)-2-[[(2S)-2-amino-3-phenylpropanoyl]amino]-3-methylbutanoyl]amino]-3-oxopropanoyl]amino]-5-oxopentanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-4-methylpentanoyl]amino]-47-[[(1S)-3-amino-1-carboxy-3-oxopropyl]carbamoyl]-53-(2-amino-2-oxoethyl)-62-(3-amino-3-oxopropyl)-77-[(2R)-butan-2-yl]-24,56-bis(2-carboxyethyl)-83-[(1S)-1-hydroxyethyl]-12,71,80-tris(hydroxymethyl)-33,50,65-tris[(4-hydroxyphenyl)methyl]-15-(1H-imidazol-4-ylmethyl)-27-methyl-18,30,36,59,68-pentakis(2-methylpropyl)-7,10,13,16,19,22,25,28,31,34,37,40,49,52,55,58,61,64,67,70,73,76,79,82,85,87-hexacosaoxo-21,39-di(propan-2-yl)-3,4,44,45,90,91-hexathia-8,11,14,17,20,23,26,29,32,35,38,41,48,51,54,57,60,63,66,69,72,75,78,81,84,86-hexacosazabicyclo[72.11.7]dononacontane-42-carbonyl]amino]acetyl]amino]-5-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[(2S)-2-[[(2S)-6-amino-1-[[(1S,2S)-1-carboxy-2-hydroxypropyl]amino]-1-oxohexan-2-yl]carbamoyl]pyrrolidin-1-yl]-3-hydroxy-1-oxobutan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-oxopentanoic acid DMYVP5G CA CAS 9004-10-8 DMYVP5G DE Diabetic complication DMW8KI7 ID DMW8KI7 DMW8KI7 DN Insulin Susp Isophane Recombinant Human DMW8KI7 HS Approved DMW8KI7 SN Nph Insulin; Nph Iletin I (Beef-pork); Nph Iletin Ii; Insulin Insulatard Nph Nordisk; Nph Iletin Ii (Pork); Nph Purified Pork Isophane Insulin; Humulin N; Novolin N; Insulatard Nph Human; Insulin Susp Isophane Beef; Insulin Susp Isophane Beef/Pork; Insulin Susp Isophane Purified Beef; Insulin Susp Isophane Purified Pork; Insulin Susp Isophane Semisynthetic Purified Human DMW8KI7 CP Eli Lilly And Co DMW8KI7 DE Diabetic complication DM0NATE ID DM0NATE DM0NATE DN Insulin Susp Protamine Zinc Beef/Pork DM0NATE HS Approved DM0NATE SN Protamine Zinc & Iletin I (Beef-pork); Protamine Zinc And Iletin Ii; Protamine Zinc Insulin; Protamine Zinc And Iletin Ii (Pork); Insulin Susp Protamine Zinc Purified Beef; Insulin Susp Protamine Zinc Purified Pork DM0NATE CP Eli Lilly And Co DM0NATE DE Diabetic complication DM6MO9X ID DM6MO9X DM6MO9X DN Insulin Zinc Susp Recombinant Human DM6MO9X HS Approved DM6MO9X SN Humulin L; Humulin U; Lentard; Lente; Lente Iletin Ii; Lente Iletin Ii (Pork); Lente Insulin; Novolin L; Semilente; Semilente Insulin; Ultralente; Ultralente Insulin; Insulin Zinc Susp Beef; Insulin Zinc Susp Extended Beef; Insulin Zinc Susp Extended Purified Beef; Insulin Zinc Susp Extended Recombinant Human; Insulin Zinc Susp Prompt Beef; Insulin Zinc Susp Prompt Purified Pork; Insulin Zinc Susp Purified Beef; Insulin Zinc Susp Purified Beef/Pork; Insulin Zinc Susp Purified Pork; Insulin Zinc Susp Semisynthetic Purified Human DM6MO9X CP Eli Lilly And Co DM6MO9X DE Diabetic complication DMO95XI ID DMO95XI DMO95XI DN Insulin, porcine DMO95XI HS Approved DMO95XI SN Velosulin; Hog insulin; Insulin [pig]; Insulin porcine; Neutral insulin; Pig insulin; Porcine insulin; Swine insulin; A neutral, buffered solution of pork insulin; Insulin (Alopex lagopus); Insulin (Canis familiaris); Insulin (Physeter catodon); Insulin (dog); Insulin (ox); Insulin (pig); Insulin (porcine); Insulin (sperm whale); Insulin (swine); Insulin [USAN:JAN]; Insulin, neutral; Insulin,pig; Insulin (Ox), 8A-L-threonine-10A-L-isoleucine-(9CI); 8A-L-Threonine-10A-L-isoleucineinsulin (ox) DMO95XI TC Hypoglycemic Agents DMO95XI DT Small molecular drug DMO95XI PC 16131098 DMO95XI MW 5778 DMO95XI FM C256H381N65O76S6 DMO95XI IC InChI=1S/C256H381N65O76S6/c1-29-131(23)205(313-193(337)104-258)251(391)317-204(130(21)22)247(387)288-159(75-82-200(347)348)217(357)282-156(71-78-189(262)333)221(361)308-183-116-401-402-117-184-242(382)305-178(111-323)239(379)294-162(88-123(7)8)224(364)295-168(95-140-53-61-146(327)62-54-140)227(367)283-154(69-76-187(260)331)218(358)290-161(87-122(5)6)222(362)285-158(74-81-199(345)346)220(360)302-174(101-190(263)334)234(374)298-170(97-142-57-65-148(329)66-58-142)230(370)309-182(241(381)304-176(255(396)397)103-192(265)336)115-400-399-114-181(213(353)272-107-194(338)278-153(72-79-197(341)342)216(356)281-151(51-42-84-270-256(266)267)211(351)271-108-195(339)279-166(93-138-46-36-32-37-47-138)226(366)297-167(94-139-48-38-33-39-49-139)229(369)299-171(98-143-59-67-149(330)68-60-143)237(377)320-208(136(28)326)253(393)321-85-43-52-186(321)245(385)286-152(50-40-41-83-257)214(354)277-134(26)254(394)395)311-249(389)203(129(19)20)316-235(375)164(90-125(11)12)292-228(368)169(96-141-55-63-147(328)64-56-141)296-223(363)160(86-121(3)4)289-209(349)133(25)276-215(355)157(73-80-198(343)344)287-246(386)202(128(17)18)315-236(376)165(91-126(13)14)293-232(372)173(100-145-106-269-120-275-145)301-238(378)177(110-322)280-196(340)109-273-212(352)180(113-398-403-118-185(310-243(183)383)244(384)319-207(135(27)325)252(392)306-179(112-324)240(380)318-206(132(24)30-2)250(390)312-184)307-225(365)163(89-124(9)10)291-231(371)172(99-144-105-268-119-274-144)300-219(359)155(70-77-188(261)332)284-233(373)175(102-191(264)335)303-248(388)201(127(15)16)314-210(350)150(259)92-137-44-34-31-35-45-137/h31-39,44-49,53-68,105-106,119-136,150-186,201-208,322-330H,29-30,40-43,50-52,69-104,107-118,257-259H2,1-28H3,(H2,260,331)(H2,261,332)(H2,262,333)(H2,263,334)(H2,264,335)(H2,265,336)(H,268,274)(H,269,275)(H,271,351)(H,272,353)(H,273,352)(H,276,355)(H,277,354)(H,278,338)(H,279,339)(H,280,340)(H,281,356)(H,282,357)(H,283,367)(H,284,373)(H,285,362)(H,286,385)(H,287,386)(H,288,387)(H,289,349)(H,290,358)(H,291,371)(H,292,368)(H,293,372)(H,294,379)(H,295,364)(H,296,363)(H,297,366)(H,298,374)(H,299,369)(H,300,359)(H,301,378)(H,302,360)(H,303,388)(H,304,381)(H,305,382)(H,306,392)(H,307,365)(H,308,361)(H,309,370)(H,310,383)(H,311,389)(H,312,390)(H,313,337)(H,314,350)(H,315,376)(H,316,375)(H,317,391)(H,318,380)(H,319,384)(H,320,377)(H,341,342)(H,343,344)(H,345,346)(H,347,348)(H,394,395)(H,396,397)(H4,266,267,270)/t131-,132-,133-,134-,135+,136+,150-,151-,152-,153-,154-,155-,156-,157-,158-,159-,160-,161-,162-,163-,164-,165-,166-,167-,168-,169-,170-,171-,172-,173-,174-,175-,176-,177-,178-,179-,180-,181-,182-,183-,184-,185-,186-,201-,202-,203-,204-,205-,206-,207-,208-/m0/s1 DMO95XI CS CC[C@H](C)[C@H]1C(=O)N[C@H]2CSSC[C@@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC2=O)CO)CC(C)C)CC3=CC=C(C=C3)O)CCC(=O)N)CC(C)C)CCC(=O)O)CC(=O)N)CC4=CC=C(C=C4)O)C(=O)N[C@@H](CC(=O)N)C(=O)O)C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CC5=CC=CC=C5)C(=O)N[C@@H](CC6=CC=CC=C6)C(=O)N[C@@H](CC7=CC=C(C=C7)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N8CCC[C@H]8C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)O)C(C)C)CC(C)C)CC9=CC=C(C=C9)O)CC(C)C)C)CCC(=O)O)C(C)C)CC(C)C)CC2=CN=CN2)CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC2=CN=CN2)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC2=CC=CC=C2)N)C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CO)[C@@H](C)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)CN DMO95XI IK NOESYZHRGYRDHS-ZYCCASTOSA-N DMO95XI IU (4S)-4-[[2-[[(1R,6R,12S,15S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,50S,53S,56S,59S,62S,65S,68S,71S,74R,77S,80S,83S,88R)-88-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[(2-aminoacetyl)amino]-3-methylpentanoyl]amino]-3-methylbutanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]-6-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-amino-3-phenylpropanoyl]amino]-3-methylbutanoyl]amino]-4-oxobutanoyl]amino]-5-oxopentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-47-[[(1S)-3-amino-1-carboxy-3-oxopropyl]carbamoyl]-53-(2-amino-2-oxoethyl)-62-(3-amino-3-oxopropyl)-77-[(2S)-butan-2-yl]-24,56-bis(2-carboxyethyl)-83-[(1R)-1-hydroxyethyl]-12,71,80-tris(hydroxymethyl)-33,50,65-tris[(4-hydroxyphenyl)methyl]-15-(1H-imidazol-5-ylmethyl)-27-methyl-18,30,36,59,68-pentakis(2-methylpropyl)-7,10,13,16,19,22,25,28,31,34,37,40,49,52,55,58,61,64,67,70,73,76,79,82,85,87-hexacosaoxo-21,39-di(propan-2-yl)-3,4,44,45,90,91-hexathia-8,11,14,17,20,23,26,29,32,35,38,41,48,51,54,57,60,63,66,69,72,75,78,81,84,86-hexacosazabicyclo[72.11.7]dononacontane-42-carbonyl]amino]acetyl]amino]-5-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S,3R)-1-[(2S)-2-[[(2S)-6-amino-1-[[(1S)-1-carboxyethyl]amino]-1-oxohexan-2-yl]carbamoyl]pyrrolidin-1-yl]-3-hydroxy-1-oxobutan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-oxopentanoic acid DMO95XI CA CAS 12584-58-6 DMO95XI DE Diabetic complication DMX7V28 ID DMX7V28 DMX7V28 DN Insulin-aspart DMX7V28 HS Approved DMX7V28 SN Aspart; NovoLog; NovoRapid; Aspart insulin; Insulin aspart; Insulin aspart [USAN]; Insulin X14; NovoMix 30; NovoRapid 30 Mix; INA-X 14; Novolog mix 70/30; AspB28-insulin (human); B28-Asp-insulin; (AspB28)-human insulin; 28(sup B)-L-Aspartic acid-insulin (human) DMX7V28 TC Hypoglycemic Agents DMX7V28 DT Small molecular drug DMX7V28 SQ A chain: GIVEQCCTSICSLYQLENYCN >B chainFVNQHLCGSHLVEALYLVCGERGFFYTDKT DMX7V28 PC 118984445 DMX7V28 MW 5826 DMX7V28 FM C256H381N65O79S6 DMX7V28 IC InChI=1S/C256H381N65O79S6/c1-29-129(23)204(313-191(338)102-258)251(394)317-203(128(21)22)247(390)287-157(73-80-198(348)349)216(359)282-154(69-76-187(262)334)220(363)308-182-114-404-405-115-183-243(386)305-177(109-323)240(383)293-160(85-121(7)8)224(367)294-166(92-138-51-59-144(328)60-52-138)227(370)283-152(67-74-185(260)332)217(360)289-159(84-120(5)6)222(365)285-156(72-79-197(346)347)219(362)301-172(98-188(263)335)234(377)297-168(94-140-55-63-146(330)64-56-140)230(373)309-181(242(385)304-175(254(397)398)100-190(265)337)113-403-402-112-180(213(356)272-105-192(339)277-151(70-77-195(342)343)215(358)280-149(50-42-82-270-256(266)267)211(354)271-106-193(340)278-164(90-136-45-36-32-37-46-136)226(369)296-165(91-137-47-38-33-39-48-137)229(372)298-169(95-141-57-65-147(331)66-58-141)238(381)319-206(132(26)325)252(395)303-174(101-199(350)351)235(378)281-150(49-40-41-81-257)221(364)321-208(134(28)327)255(399)400)311-249(392)202(127(19)20)316-236(379)162(87-123(11)12)291-228(371)167(93-139-53-61-145(329)62-54-139)295-223(366)158(83-119(3)4)288-209(352)131(25)276-214(357)155(71-78-196(344)345)286-246(389)201(126(17)18)315-237(380)163(88-124(13)14)292-232(375)171(97-143-104-269-118-275-143)300-239(382)176(108-322)279-194(341)107-273-212(355)179(111-401-406-116-184(310-244(182)387)245(388)320-207(133(27)326)253(396)306-178(110-324)241(384)318-205(130(24)30-2)250(393)312-183)307-225(368)161(86-122(9)10)290-231(374)170(96-142-103-268-117-274-142)299-218(361)153(68-75-186(261)333)284-233(376)173(99-189(264)336)302-248(391)200(125(15)16)314-210(353)148(259)89-135-43-34-31-35-44-135/h31-39,43-48,51-66,103-104,117-134,148-184,200-208,322-331H,29-30,40-42,49-50,67-102,105-116,257-259H2,1-28H3,(H2,260,332)(H2,261,333)(H2,262,334)(H2,263,335)(H2,264,336)(H2,265,337)(H,268,274)(H,269,275)(H,271,354)(H,272,356)(H,273,355)(H,276,357)(H,277,339)(H,278,340)(H,279,341)(H,280,358)(H,281,378)(H,282,359)(H,283,370)(H,284,376)(H,285,365)(H,286,389)(H,287,390)(H,288,352)(H,289,360)(H,290,374)(H,291,371)(H,292,375)(H,293,383)(H,294,367)(H,295,366)(H,296,369)(H,297,377)(H,298,372)(H,299,361)(H,300,382)(H,301,362)(H,302,391)(H,303,395)(H,304,385)(H,305,386)(H,306,396)(H,307,368)(H,308,363)(H,309,373)(H,310,387)(H,311,392)(H,312,393)(H,313,338)(H,314,353)(H,315,380)(H,316,379)(H,317,394)(H,318,384)(H,319,381)(H,320,388)(H,321,364)(H,342,343)(H,344,345)(H,346,347)(H,348,349)(H,350,351)(H,397,398)(H,399,400)(H4,266,267,270)/t129-,130-,131-,132+,133+,134+,148-,149-,150-,151-,152-,153-,154-,155-,156-,157-,158-,159-,160-,161-,162-,163-,164-,165-,166-,167-,168-,169-,170-,171-,172-,173-,174-,175-,176-,177-,178-,179-,180-,181-,182-,183-,184-,200-,201-,202-,203-,204-,205-,206-,207-,208-/m0/s1 DMX7V28 CS CC[C@H](C)[C@H]1C(=O)N[C@H]2CSSC[C@@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC2=O)CO)CC(C)C)CC3=CC=C(C=C3)O)CCC(=O)N)CC(C)C)CCC(=O)O)CC(=O)N)CC4=CC=C(C=C4)O)C(=O)N[C@@H](CC(=O)N)C(=O)O)C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CC5=CC=CC=C5)C(=O)N[C@@H](CC6=CC=CC=C6)C(=O)N[C@@H](CC7=CC=C(C=C7)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)C(C)C)CC(C)C)CC8=CC=C(C=C8)O)CC(C)C)C)CCC(=O)O)C(C)C)CC(C)C)CC9=CNC=N9)CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC2=CNC=N2)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC2=CC=CC=C2)N)C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CO)[C@@H](C)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)CN DMX7V28 IK WEDIKSVWBUKTRA-WTKGVUNUSA-N DMX7V28 IU (4S)-4-[[2-[[(1R,6R,12S,15S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,50S,53S,56S,59S,62S,65S,68S,71S,74R,77S,80S,83S,88R)-88-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[(2-aminoacetyl)amino]-3-methylpentanoyl]amino]-3-methylbutanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]-6-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-amino-3-phenylpropanoyl]amino]-3-methylbutanoyl]amino]-4-oxobutanoyl]amino]-5-oxopentanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-4-methylpentanoyl]amino]-47-[[(1S)-3-amino-1-carboxy-3-oxopropyl]carbamoyl]-53-(2-amino-2-oxoethyl)-62-(3-amino-3-oxopropyl)-77-[(2S)-butan-2-yl]-24,56-bis(2-carboxyethyl)-83-[(1R)-1-hydroxyethyl]-12,71,80-tris(hydroxymethyl)-33,50,65-tris[(4-hydroxyphenyl)methyl]-15-(1H-imidazol-4-ylmethyl)-27-methyl-18,30,36,59,68-pentakis(2-methylpropyl)-7,10,13,16,19,22,25,28,31,34,37,40,49,52,55,58,61,64,67,70,73,76,79,82,85,87-hexacosaoxo-21,39-di(propan-2-yl)-3,4,44,45,90,91-hexathia-8,11,14,17,20,23,26,29,32,35,38,41,48,51,54,57,60,63,66,69,72,75,78,81,84,86-hexacosazabicyclo[72.11.7]dononacontane-42-carbonyl]amino]acetyl]amino]-5-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(1S,2R)-1-carboxy-2-hydroxypropyl]amino]-1-oxohexan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-oxopentanoic acid DMX7V28 CA CAS 116094-23-6 DMX7V28 DE Diabetic complication DMOA4VW ID DMOA4VW DMOA4VW DN Insulin-detemir DMOA4VW HS Approved DMOA4VW SN Insulin detemir; UNII-4FT78T86XV; 4FT78T86XV; NN-304; Levemir; Levemir Penfill; Levemir Insulin; Levemir Innolet; Levemir Flexpen; 169148-63-4; Insulin detemir [USAN:INN:BAN]; NN304; NN 304; CHEMBL2104391; INSULIN DETEMIR RECOMBINANT; 29B-(N6-Myristoyl-L-lysine)-30B-de-L-threonineinsulin (human); 29(sup B)-(N(sup 6)-Myristoyl-L-lysine)-30(sup B)-de-L-threonineinsulin (human); 29(sup B)-(N(sup 6)-(1-Oxotetradecyl)-L-lysine)-(1(sup A)-21(sup A)),(1(sup B)-29(sup B))-insulin (human); 270588-25-5 DMOA4VW TC Hypoglycemic Agents DMOA4VW DT Small molecular drug DMOA4VW SQ GIVEQCCTSICSLYQLENYCNFVNQHLCGSHLVEALYLVCGERGFFYTPK DMOA4VW PC 16137271 DMOA4VW MW 5917 DMOA4VW FM C267H402N64O76S6 DMOA4VW IC InChI=1S/C267H402N64O76S6/c1-29-32-33-34-35-36-37-38-39-40-50-64-204(347)280-95-52-51-61-170(265(404)405)298-256(395)197-63-54-97-331(197)264(403)220(147(28)336)330-248(387)182(110-154-71-79-160(340)80-72-154)309-240(379)178(106-150-59-48-43-49-60-150)307-237(376)177(105-149-57-46-42-47-58-149)289-207(350)120-282-223(362)162(62-53-96-281-267(276)277)291-227(366)163(84-91-209(352)353)288-206(349)119-283-225(364)192-126-409-410-127-193(252(391)314-187(266(406)407)115-203(275)346)319-241(380)181(109-153-69-77-159(339)78-70-153)308-245(384)185(113-201(273)344)312-231(370)168(86-93-211(356)357)295-233(372)172(99-134(6)7)300-229(368)164(81-88-198(270)341)293-238(377)179(107-151-65-73-157(337)74-66-151)305-235(374)173(100-135(8)9)304-250(389)189(123-333)315-253(392)195-129-412-411-128-194(318-232(371)166(83-90-200(272)343)292-228(367)169(87-94-212(358)359)297-258(397)216(142(22)23)327-262(401)217(143(24)30-2)323-205(348)116-268)254(393)320-196(255(394)329-219(146(27)335)263(402)316-190(124-334)251(390)328-218(144(25)31-3)261(400)322-195)130-413-408-125-191(317-236(375)174(101-136(10)11)301-242(381)183(111-155-117-278-131-285-155)310-230(369)165(82-89-199(271)342)294-244(383)186(114-202(274)345)313-259(398)213(139(16)17)324-222(361)161(269)104-148-55-44-41-45-56-148)224(363)284-121-208(351)290-188(122-332)249(388)311-184(112-156-118-279-132-286-156)243(382)303-176(103-138(14)15)247(386)325-214(140(18)19)257(396)296-167(85-92-210(354)355)226(365)287-145(26)221(360)299-171(98-133(4)5)234(373)306-180(108-152-67-75-158(338)76-68-152)239(378)302-175(102-137(12)13)246(385)326-215(141(20)21)260(399)321-192/h41-49,55-60,65-80,117-118,131-147,161-197,213-220,332-340H,29-40,50-54,61-64,81-116,119-130,268-269H2,1-28H3,(H2,270,341)(H2,271,342)(H2,272,343)(H2,273,344)(H2,274,345)(H2,275,346)(H,278,285)(H,279,286)(H,280,347)(H,282,362)(H,283,364)(H,284,363)(H,287,365)(H,288,349)(H,289,350)(H,290,351)(H,291,366)(H,292,367)(H,293,377)(H,294,383)(H,295,372)(H,296,396)(H,297,397)(H,298,395)(H,299,360)(H,300,368)(H,301,381)(H,302,378)(H,303,382)(H,304,389)(H,305,374)(H,306,373)(H,307,376)(H,308,384)(H,309,379)(H,310,369)(H,311,388)(H,312,370)(H,313,398)(H,314,391)(H,315,392)(H,316,402)(H,317,375)(H,318,371)(H,319,380)(H,320,393)(H,321,399)(H,322,400)(H,323,348)(H,324,361)(H,325,386)(H,326,385)(H,327,401)(H,328,390)(H,329,394)(H,330,387)(H,352,353)(H,354,355)(H,356,357)(H,358,359)(H,404,405)(H,406,407)(H4,276,277,281)/t143-,144-,145-,146+,147+,161-,162-,163-,164-,165-,166-,167-,168-,169-,170-,171-,172-,173-,174-,175-,176-,177-,178-,179-,180-,181-,182-,183-,184-,185-,186-,187-,188-,189-,190-,191-,192-,193-,194-,195-,196-,197-,213-,214-,215-,216-,217-,218-,219-,220-/m0/s1 DMOA4VW CS CCCCCCCCCCCCCC(=O)NCCCC[C@@H](C(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC4=CC=CC=C4)NC(=O)CNC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@@H]5CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]6CSSC[C@@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N5)C(C)C)CC(C)C)CC7=CC=C(C=C7)O)CC(C)C)C)CCC(=O)O)C(C)C)CC(C)C)CC8=CNC=N8)CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC9=CNC=N9)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC1=CC=CC=C1)N)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N6)[C@@H](C)CC)CO)[C@@H](C)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)CN)CO)CC(C)C)CC1=CC=C(C=C1)O)CCC(=O)N)CC(C)C)CCC(=O)O)CC(=O)N)CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC(=O)N)C(=O)O DMOA4VW IK UGOZVNFCFYTPAZ-IOXYNQHNSA-N DMOA4VW IU (2S)-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[2-[[(1R,6R,12S,15S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,50S,53S,56S,59S,62S,65S,68S,71S,74R,77S,80S,83S,88R)-88-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[(2-aminoacetyl)amino]-3-methylpentanoyl]amino]-3-methylbutanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]-6-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-amino-3-phenylpropanoyl]amino]-3-methylbutanoyl]amino]-4-oxobutanoyl]amino]-5-oxopentanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-4-methylpentanoyl]amino]-47-[[(1S)-3-amino-1-carboxy-3-oxopropyl]carbamoyl]-53-(2-amino-2-oxoethyl)-62-(3-amino-3-oxopropyl)-77-[(2S)-butan-2-yl]-24,56-bis(2-carboxyethyl)-83-[(1R)-1-hydroxyethyl]-12,71,80-tris(hydroxymethyl)-33,50,65-tris[(4-hydroxyphenyl)methyl]-15-(1H-imidazol-4-ylmethyl)-27-methyl-18,30,36,59,68-pentakis(2-methylpropyl)-7,10,13,16,19,22,25,28,31,34,37,40,49,52,55,58,61,64,67,70,73,76,79,82,85,87-hexacosaoxo-21,39-di(propan-2-yl)-3,4,44,45,90,91-hexathia-8,11,14,17,20,23,26,29,32,35,38,41,48,51,54,57,60,63,66,69,72,75,78,81,84,86-hexacosazabicyclo[72.11.7]dononacontane-42-carbonyl]amino]acetyl]amino]-4-carboxybutanoyl]amino]-5-carbamimidamidopentanoyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-6-(tetradecanoylamino)hexanoic acid DMOA4VW CA CAS 169148-63-4 DMOA4VW DE Type-1/2 diabetes DMR4HIW ID DMR4HIW DMR4HIW DN Insulin-glargine DMR4HIW HS Approved DMR4HIW SN Glargine; Lantus; SoloStar; SoloStar [Insulin delivery pen]; A21-Gly-B31-Arg-B32-Arg-insulin DMR4HIW TC Hypoglycemic Agents DMR4HIW DT Small molecular drug DMR4HIW SQ A chain: GIVEQCCTSICSLYQLENYCG >B chainFVNQHLCGSHLVEALYLVCGERGFFYTPKTRR DMR4HIW PC 118984454 DMR4HIW MW 6063 DMR4HIW FM C267H404N72O78S6 DMR4HIW IC InChI=1S/C267H404N72O78S6/c1-29-137(23)212(330-199(355)109-269)260(412)334-211(136(21)22)256(408)305-166(79-86-206(365)366)226(378)298-163(75-82-196(273)352)230(382)326-190-122-421-422-123-191-251(403)322-185(117-341)249(401)312-170(94-129(7)8)234(386)313-176(101-146-57-65-152(346)66-58-146)237(389)299-161(73-80-194(271)350)227(379)308-169(93-128(5)6)232(384)301-165(78-85-205(363)364)229(381)320-182(107-197(274)353)244(396)316-178(103-148-61-69-154(348)70-62-148)240(392)325-188(222(374)290-115-207(367)368)120-418-420-121-189(221(373)288-112-200(356)294-160(76-83-203(359)360)225(377)297-157(53-42-88-284-265(276)277)219(371)287-113-201(357)295-174(99-144-48-36-32-37-49-144)236(388)315-175(100-145-50-38-33-39-51-145)239(391)317-179(104-149-63-71-155(349)72-64-149)247(399)338-216(142(28)345)263(415)339-91-45-56-193(339)254(406)302-158(52-40-41-87-268)231(383)336-214(140(26)343)261(413)303-159(54-43-89-285-266(278)279)224(376)306-167(264(416)417)55-44-90-286-267(280)281)328-258(410)210(135(19)20)333-245(397)172(96-131(11)12)310-238(390)177(102-147-59-67-153(347)68-60-147)314-233(385)168(92-127(3)4)307-217(369)139(25)293-223(375)164(77-84-204(361)362)304-255(407)209(134(17)18)332-246(398)173(97-132(13)14)311-242(394)181(106-151-111-283-126-292-151)319-248(400)184(116-340)296-202(358)114-289-220(372)187(119-419-423-124-192(327-252(190)404)253(405)337-215(141(27)344)262(414)323-186(118-342)250(402)335-213(138(24)30-2)259(411)329-191)324-235(387)171(95-130(9)10)309-241(393)180(105-150-110-282-125-291-150)318-228(380)162(74-81-195(272)351)300-243(395)183(108-198(275)354)321-257(409)208(133(15)16)331-218(370)156(270)98-143-46-34-31-35-47-143/h31-39,46-51,57-72,110-111,125-142,156-193,208-216,340-349H,29-30,40-45,52-56,73-109,112-124,268-270H2,1-28H3,(H2,271,350)(H2,272,351)(H2,273,352)(H2,274,353)(H2,275,354)(H,282,291)(H,283,292)(H,287,371)(H,288,373)(H,289,372)(H,290,374)(H,293,375)(H,294,356)(H,295,357)(H,296,358)(H,297,377)(H,298,378)(H,299,389)(H,300,395)(H,301,384)(H,302,406)(H,303,413)(H,304,407)(H,305,408)(H,306,376)(H,307,369)(H,308,379)(H,309,393)(H,310,390)(H,311,394)(H,312,401)(H,313,386)(H,314,385)(H,315,388)(H,316,396)(H,317,391)(H,318,380)(H,319,400)(H,320,381)(H,321,409)(H,322,403)(H,323,414)(H,324,387)(H,325,392)(H,326,382)(H,327,404)(H,328,410)(H,329,411)(H,330,355)(H,331,370)(H,332,398)(H,333,397)(H,334,412)(H,335,402)(H,336,383)(H,337,405)(H,338,399)(H,359,360)(H,361,362)(H,363,364)(H,365,366)(H,367,368)(H,416,417)(H4,276,277,284)(H4,278,279,285)(H4,280,281,286)/t137-,138-,139-,140+,141+,142+,156-,157-,158-,159-,160-,161-,162-,163-,164-,165-,166-,167-,168-,169-,170-,171-,172-,173-,174-,175-,176-,177-,178-,179-,180-,181-,182-,183-,184-,185-,186-,187-,188-,189-,190-,191-,192-,193-,208-,209-,210-,211-,212-,213-,214-,215-,216-/m0/s1 DMR4HIW CS CC[C@H](C)[C@H]1C(=O)N[C@H]2CSSC[C@@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC2=O)CO)CC(C)C)CC3=CC=C(C=C3)O)CCC(=O)N)CC(C)C)CCC(=O)O)CC(=O)N)CC4=CC=C(C=C4)O)C(=O)NCC(=O)O)C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CC5=CC=CC=C5)C(=O)N[C@@H](CC6=CC=CC=C6)C(=O)N[C@@H](CC7=CC=C(C=C7)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N8CCC[C@H]8C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)C(C)C)CC(C)C)CC9=CC=C(C=C9)O)CC(C)C)C)CCC(=O)O)C(C)C)CC(C)C)CC2=CNC=N2)CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC2=CNC=N2)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC2=CC=CC=C2)N)C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CO)[C@@H](C)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)CN DMR4HIW IK COCFEDIXXNGUNL-RFKWWTKHSA-N DMR4HIW IU (4S)-4-[[2-[[(1R,6R,12S,15S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,50S,53S,56S,59S,62S,65S,68S,71S,74R,77S,80S,83S,88R)-88-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[(2-aminoacetyl)amino]-3-methylpentanoyl]amino]-3-methylbutanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]-6-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-amino-3-phenylpropanoyl]amino]-3-methylbutanoyl]amino]-4-oxobutanoyl]amino]-5-oxopentanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-4-methylpentanoyl]amino]-53-(2-amino-2-oxoethyl)-62-(3-amino-3-oxopropyl)-77-[(2S)-butan-2-yl]-24,56-bis(2-carboxyethyl)-47-(carboxymethylcarbamoyl)-83-[(1R)-1-hydroxyethyl]-12,71,80-tris(hydroxymethyl)-33,50,65-tris[(4-hydroxyphenyl)methyl]-15-(1H-imidazol-4-ylmethyl)-27-methyl-18,30,36,59,68-pentakis(2-methylpropyl)-7,10,13,16,19,22,25,28,31,34,37,40,49,52,55,58,61,64,67,70,73,76,79,82,85,87-hexacosaoxo-21,39-di(propan-2-yl)-3,4,44,45,90,91-hexathia-8,11,14,17,20,23,26,29,32,35,38,41,48,51,54,57,60,63,66,69,72,75,78,81,84,86-hexacosazabicyclo[72.11.7]dononacontane-42-carbonyl]amino]acetyl]amino]-5-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S,3R)-1-[(2S)-2-[[(2S)-6-amino-1-[[(2S,3R)-1-[[(2S)-5-carbamimidamido-1-[[(1S)-4-carbamimidamido-1-carboxybutyl]amino]-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxohexan-2-yl]carbamoyl]pyrrolidin-1-yl]-3-hydroxy-1-oxobutan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-oxopentanoic acid DMR4HIW CA CAS 160337-95-1 DMR4HIW DE Malaria; Type-1 diabetes; Type-2 diabetes; Diabetic complication DMQI0FU ID DMQI0FU DMQI0FU DN Insulin-glulisine DMQI0FU HS Approved DMQI0FU TC Hypoglycemic Agents DMQI0FU SQ A chain: GIVEQCCTSICSLYQLENYCN >B chainFVKQHLCGSHLVEALYLVCGERGFFYTPET DMQI0FU PC 16136701 DMQI0FU MW 5823 DMQI0FU FM C258H384N64O78S6 DMQI0FU IC InChI=1S/C258H384N64O78S6/c1-29-132(23)206(313-193(338)105-260)253(394)317-205(131(21)22)250(391)289-160(75-83-200(348)349)219(360)283-157(71-79-190(264)335)223(364)308-184-117-404-405-118-185-244(385)305-179(112-324)241(382)295-164(90-124(7)8)227(368)296-170(97-141-53-61-147(329)62-54-141)230(371)284-156(70-78-189(263)334)220(361)291-163(89-123(5)6)225(366)285-159(74-82-199(346)347)222(363)303-176(103-191(265)336)236(377)299-172(99-143-57-65-149(331)66-58-143)233(374)309-183(243(384)304-177(256(397)398)104-192(266)337)116-403-402-115-182(215(356)273-108-194(339)278-154(72-80-197(342)343)218(359)281-152(51-42-86-271-258(267)268)213(354)272-109-195(340)279-168(95-139-46-36-32-37-47-139)229(370)298-169(96-140-48-38-33-39-49-140)232(373)300-173(100-144-59-67-150(332)68-60-144)239(380)320-209(136(27)327)255(396)322-87-43-52-187(322)247(388)286-161(76-84-201(350)351)224(365)321-210(137(28)328)257(399)400)311-251(392)204(130(19)20)316-237(378)166(92-126(11)12)293-231(372)171(98-142-55-63-148(330)64-56-142)297-226(367)162(88-122(3)4)290-211(352)134(25)277-216(357)158(73-81-198(344)345)288-249(390)203(129(17)18)315-238(379)167(93-127(13)14)294-235(376)175(102-146-107-270-121-276-146)302-240(381)178(111-323)280-196(341)110-274-214(355)181(114-401-406-119-186(310-245(184)386)246(387)319-208(135(26)326)254(395)306-180(113-325)242(383)318-207(133(24)30-2)252(393)312-185)307-228(369)165(91-125(9)10)292-234(375)174(101-145-106-269-120-275-145)301-221(362)155(69-77-188(262)333)282-217(358)153(50-40-41-85-259)287-248(389)202(128(15)16)314-212(353)151(261)94-138-44-34-31-35-45-138/h31-39,44-49,53-68,106-107,120-137,151-187,202-210,323-332H,29-30,40-43,50-52,69-105,108-119,259-261H2,1-28H3,(H2,262,333)(H2,263,334)(H2,264,335)(H2,265,336)(H2,266,337)(H,269,275)(H,270,276)(H,272,354)(H,273,356)(H,274,355)(H,277,357)(H,278,339)(H,279,340)(H,280,341)(H,281,359)(H,282,358)(H,283,360)(H,284,371)(H,285,366)(H,286,388)(H,287,389)(H,288,390)(H,289,391)(H,290,352)(H,291,361)(H,292,375)(H,293,372)(H,294,376)(H,295,382)(H,296,368)(H,297,367)(H,298,370)(H,299,377)(H,300,373)(H,301,362)(H,302,381)(H,303,363)(H,304,384)(H,305,385)(H,306,395)(H,307,369)(H,308,364)(H,309,374)(H,310,386)(H,311,392)(H,312,393)(H,313,338)(H,314,353)(H,315,379)(H,316,378)(H,317,394)(H,318,383)(H,319,387)(H,320,380)(H,321,365)(H,342,343)(H,344,345)(H,346,347)(H,348,349)(H,350,351)(H,397,398)(H,399,400)(H4,267,268,271)/t132-,133-,134-,135+,136+,137+,151-,152-,153-,154-,155-,156-,157-,158-,159-,160-,161-,162-,163-,164-,165-,166-,167-,168-,169-,170-,171-,172-,173-,174-,175-,176-,177-,178-,179-,180-,181-,182-,183-,184-,185-,186-,187-,202-,203-,204-,205-,206-,207-,208-,209-,210-/m0/s1 DMQI0FU CS CC[C@H](C)[C@H]1C(=O)N[C@H]2CSSC[C@@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC2=O)CO)CC(C)C)CC3=CC=C(C=C3)O)CCC(=O)N)CC(C)C)CCC(=O)O)CC(=O)N)CC4=CC=C(C=C4)O)C(=O)N[C@@H](CC(=O)N)C(=O)O)C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CC5=CC=CC=C5)C(=O)N[C@@H](CC6=CC=CC=C6)C(=O)N[C@@H](CC7=CC=C(C=C7)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N8CCC[C@H]8C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)C(C)C)CC(C)C)CC9=CC=C(C=C9)O)CC(C)C)C)CCC(=O)O)C(C)C)CC(C)C)CC2=CNC=N2)CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC2=CNC=N2)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC2=CC=CC=C2)N)C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CO)[C@@H](C)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)CN DMQI0FU IK RCHHVVGSTHAVPF-ZPHPLDECSA-N DMQI0FU IU (4S)-4-[[2-[[(1R,6R,12S,15S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,50S,53S,56S,59S,62S,65S,68S,71S,74R,77S,80S,83S,88R)-88-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[(2-aminoacetyl)amino]-3-methylpentanoyl]amino]-3-methylbutanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]-6-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-amino-3-phenylpropanoyl]amino]-3-methylbutanoyl]amino]hexanoyl]amino]-5-oxopentanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-4-methylpentanoyl]amino]-47-[[(1S)-3-amino-1-carboxy-3-oxopropyl]carbamoyl]-53-(2-amino-2-oxoethyl)-62-(3-amino-3-oxopropyl)-77-[(2S)-butan-2-yl]-24,56-bis(2-carboxyethyl)-83-[(1R)-1-hydroxyethyl]-12,71,80-tris(hydroxymethyl)-33,50,65-tris[(4-hydroxyphenyl)methyl]-15-(1H-imidazol-4-ylmethyl)-27-methyl-18,30,36,59,68-pentakis(2-methylpropyl)-7,10,13,16,19,22,25,28,31,34,37,40,49,52,55,58,61,64,67,70,73,76,79,82,85,87-hexacosaoxo-21,39-di(propan-2-yl)-3,4,44,45,90,91-hexathia-8,11,14,17,20,23,26,29,32,35,38,41,48,51,54,57,60,63,66,69,72,75,78,81,84,86-hexacosazabicyclo[72.11.7]dononacontane-42-carbonyl]amino]acetyl]amino]-5-[[(2S)-5-carbamimidamido-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S,3R)-1-[(2S)-2-[[(2S)-4-carboxy-1-[[(1S,2R)-1-carboxy-2-hydroxypropyl]amino]-1-oxobutan-2-yl]carbamoyl]pyrrolidin-1-yl]-3-hydroxy-1-oxobutan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]amino]-1-oxopentan-2-yl]amino]-5-oxopentanoic acid DMQI0FU CA CAS 207748-29-6 DMQI0FU DE Diabetic complication DM4O90W ID DM4O90W DM4O90W DN Insulin-lispro DM4O90W HS Approved DM4O90W SN WNRQPCUGRUFHED-DETKDSODSA-N; Insulin lispro [USAN:BAN:INN]; Humalog (TN); Insulin Lispro DM4O90W CP Eli Lilly DM4O90W TC Hypoglycemic Agents DM4O90W DT Small molecular drug DM4O90W PC 16132438 DM4O90W MW 5814 DM4O90W FM C257H389N65O77S6 DM4O90W IC InChI=1S/C158H234N40O42S2.C99H155N25O35S4/c1-79(2)57-104(181-131(213)86(15)173-136(218)102(50-53-125(211)212)179-152(234)127(84(11)12)194-148(230)107(60-82(7)8)184-145(227)113(67-95-70-166-78-172-95)189-150(232)115(74-199)176-123(208)73-170-134(216)116(75-241)191-140(222)105(58-80(3)4)182-144(226)112(66-94-69-165-77-171-94)188-138(220)101(48-51-119(161)204)178-146(228)114(68-120(162)205)190-153(235)126(83(9)10)193-132(214)98(160)61-89-31-21-18-22-32-89)139(221)185-110(64-92-40-44-96(202)45-41-92)142(224)183-106(59-81(5)6)147(229)195-128(85(13)14)154(236)192-117(76-242)135(217)169-71-121(206)174-100(49-52-124(209)210)137(219)177-99(38-29-55-167-158(163)164)133(215)168-72-122(207)175-108(62-90-33-23-19-24-34-90)141(223)186-109(63-91-35-25-20-26-36-91)143(225)187-111(65-93-42-46-97(203)47-43-93)149(231)196-129(87(16)200)155(237)180-103(37-27-28-54-159)156(238)198-56-30-39-118(198)151(233)197-130(88(17)201)157(239)240;1-12-46(9)77(121-73(134)36-100)97(156)122-76(45(7)8)95(154)108-56(25-29-75(137)138)80(139)105-54(23-27-70(102)131)83(142)117-66(40-161)93(152)119-68(42-163)94(153)124-79(48(11)127)98(157)116-64(38-126)90(149)123-78(47(10)13-2)96(155)120-67(41-162)92(151)115-63(37-125)89(148)110-58(31-44(5)6)85(144)111-59(32-49-14-18-51(128)19-15-49)86(145)106-53(22-26-69(101)130)81(140)109-57(30-43(3)4)84(143)107-55(24-28-74(135)136)82(141)113-61(34-71(103)132)88(147)112-60(33-50-16-20-52(129)21-17-50)87(146)118-65(39-160)91(150)114-62(99(158)159)35-72(104)133/h18-26,31-36,40-47,69-70,77-88,98-118,126-130,199-203,241-242H,27-30,37-39,48-68,71-76,159-160H2,1-17H3,(H2,161,204)(H2,162,205)(H,165,171)(H,166,172)(H,168,215)(H,169,217)(H,170,216)(H,173,218)(H,174,206)(H,175,207)(H,176,208)(H,177,219)(H,178,228)(H,179,234)(H,180,237)(H,181,213)(H,182,226)(H,183,224)(H,184,227)(H,185,221)(H,186,223)(H,187,225)(H,188,220)(H,189,232)(H,190,235)(H,191,222)(H,192,236)(H,193,214)(H,194,230)(H,195,229)(H,196,231)(H,197,233)(H,209,210)(H,211,212)(H,239,240)(H4,163,164,167);14-21,43-48,53-68,76-79,125-129,160-163H,12-13,22-42,100H2,1-11H3,(H2,101,130)(H2,102,131)(H2,103,132)(H2,104,133)(H,105,139)(H,106,145)(H,107,143)(H,108,154)(H,109,140)(H,110,148)(H,111,144)(H,112,147)(H,113,141)(H,114,150)(H,115,151)(H,116,157)(H,117,142)(H,118,146)(H,119,152)(H,120,155)(H,121,134)(H,122,156)(H,123,149)(H,124,153)(H,135,136)(H,137,138)(H,158,159)/t86-,87+,88+,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,126-,127-,128-,129-,130-;46-,47-,48+,53-,54-,55-,56-,57-,58-,59-,60-,61-,62-,63-,64-,65-,66-,67-,68-,76-,77-,78-,79-/m00/s1 DM4O90W CS CC[C@H](C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CS)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)CN.C[C@H]([C@@H](C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC4=CC=CC=C4)NC(=O)CNC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@H](CS)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC5=CC=C(C=C5)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC6=CN=CN6)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC7=CN=CN7)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC8=CC=CC=C8)N)O DM4O90W IK WNRQPCUGRUFHED-DETKDSODSA-N DM4O90W IU (4S)-4-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2R)-2-[[(2R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[(2-aminoacetyl)amino]-3-methylpentanoyl]amino]-3-methylbutanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]-3-sulfanylpropanoyl]amino]-3-sulfanylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-5-oxopentanoyl]amino]-4-methylpentanoyl]amino]-5-[[(2S)-4-amino-1-[[(2S)-1-[[(2R)-1-[[(1S)-3-amino-1-carboxy-3-oxopropyl]amino]-1-oxo-3-sulfanylpropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-5-oxopentanoic acid;(4S)-4-[[2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-amino-3-phenylpropanoyl]amino]-3-methylbutanoyl]amino]-4-oxobutanoyl]amino]-5-oxopentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-methylbutanoyl]amino]-4-carboxybutanoyl]amino]propanoyl]amino]-4-methylpentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-3-methylbutanoyl]amino]-3-sulfanylpropanoyl]amino]acetyl]amino]-5-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-6-amino-1-[(2S)-2-[[(1S,2R)-1-carboxy-2-hydroxypropyl]carbamoyl]pyrrolidin-1-yl]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-oxopentanoic acid DM4O90W CA CAS 133107-64-9 DM4O90W DE Diabetic complication DMSTA36 ID DMSTA36 DMSTA36 DN Intedanib DMSTA36 HS Approved DMSTA36 SN Nintedanib; Vargatef; 656247-17-5; BIBF-1120; BIBF 1120; 928326-83-4; BIBF1120; Nintedanib (BIBF 1120); OFEV; UNII-G6HRD2P839; (Z)-methyl 3-((4-(N-methyl-2-(4-methylpiperazin-1-yl)acetamido)phenylamino)(phenyl)methylene)-2-oxoindoline-6-carboxylate; G6HRD2P839; CHEBI:85164; 1160294-26-7; Methyl (3z)-3-{[(4-{methyl[(4-Methylpiperazin-1-Yl)acetyl]amino}phenyl)amino](Phenyl)methylidene}-2-Oxo-2,3-Dihydro-1h-Indole-6-Carboxylate DMSTA36 CP Boehringer Ingelheim Pharmaceuticals DMSTA36 DT Small molecular drug DMSTA36 PC 135423438 DMSTA36 MW 539.6 DMSTA36 FM C31H33N5O4 DMSTA36 IC InChI=1S/C31H33N5O4/c1-34-15-17-36(18-16-34)20-27(37)35(2)24-12-10-23(11-13-24)32-29(21-7-5-4-6-8-21)28-25-14-9-22(31(39)40-3)19-26(25)33-30(28)38/h4-14,19,33,38H,15-18,20H2,1-3H3 DMSTA36 CS CN1CCN(CC1)CC(=O)N(C)C2=CC=C(C=C2)N=C(C3=CC=CC=C3)C4=C(NC5=C4C=CC(=C5)C(=O)OC)O DMSTA36 IK CPMDPSXJELVGJG-UHFFFAOYSA-N DMSTA36 IU methyl 2-hydroxy-3-[N-[4-[methyl-[2-(4-methylpiperazin-1-yl)acetyl]amino]phenyl]-C-phenylcarbonimidoyl]-1H-indole-6-carboxylate DMSTA36 CA CAS 656247-17-5 DMSTA36 CB CHEBI:85164 DMSTA36 DE Colorectal cancer; Idiopathic pulmonary fibrosis; Ovarian cancer; Non-small-cell lung cancer; Mesothelioma DMUTZ8S ID DMUTZ8S DMUTZ8S DN Interferon Alfa-2a, Recombinant DMUTZ8S HS Approved DMUTZ8S SN Roferon A (TN) DMUTZ8S TC Anticancer Agents DMUTZ8S SQ DB00034 sequence: CDLPQTHSLGSRRTLMLLAQMRKISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE DMUTZ8S DE Chronic HCV-1 infection DMWCQP4 ID DMWCQP4 DMWCQP4 DN Interferon alfa-2B DMWCQP4 HS Approved DMWCQP4 SN Intron A; Viraferon DMWCQP4 CP Schering-plough DMWCQP4 TC Anticancer Agents DMWCQP4 DT Small molecular drug DMWCQP4 PC 71306834 DMWCQP4 MW 746.5 DMWCQP4 FM C16H17Cl3I2N3NaO5S DMWCQP4 IC InChI=1S/C15H16Cl3N3O2.CH2I2O3S.Na/c1-2-4-20(15(22)21-5-3-19-10-21)6-7-23-14-12(17)8-11(16)9-13(14)18;2-1(3)7(4,5)6;/h3,5,8-10H,2,4,6-7H2,1H3;1H,(H,4,5,6);/q;;+1/p-1 DMWCQP4 CS CCCN(CCOC1=C(C=C(C=C1Cl)Cl)Cl)C(=O)N2C=CN=C2.C(S(=O)(=O)[O-])(I)I.[Na+] DMWCQP4 IK MIXCUJKCXRNYFM-UHFFFAOYSA-M DMWCQP4 IU sodium;diiodomethanesulfonate;N-propyl-N-[2-(2,4,6-trichlorophenoxy)ethyl]imidazole-1-carboxamide DMWCQP4 CA CAS 98530-12-2 DMWCQP4 DE Melanoma DM3TPY8 ID DM3TPY8 DM3TPY8 DN Interferon Alfa-2b, Recombinant DM3TPY8 HS Approved DM3TPY8 SN Alpharona (TN); Genferon (TN); Gerpferon (TN); Grippferon (TN); Infagel (TN); Intron A (TN); Kipferon (TN); Realderon (TN); Recolin (TN); Teva (TN); Viferon (TN) DM3TPY8 CP Schering-Plough DM3TPY8 TC Anticancer Agents DM3TPY8 SQ DB00105 sequence: CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMNEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE DM3TPY8 DE Hairy cell leukaemia DM90WJH ID DM90WJH DM90WJH DN Interferon alfacon-1 DM90WJH HS Approved DM90WJH SN Advaferon; Infergen; Advaferon (TN); Infergen (TN); Interferon alfacon-1 (genetical recombination); Interferon alfacon-1 (USAN/INN); Interferon alfacon-1 (genetical recombination) (JAN) DM90WJH TC Anticancer Agents DM90WJH SQ Interferon alfacon-1: MCDLPQTHSLGNRRALILLAQMRRISPFSCLKDRHDFGFPQEEFDGNQFQKAQAISVLHEMIQQTFNLFSTKDSSAAWDESLLEKFYTELYQQLNDLEACVIQEVGVEETPLMNVDSILAVKKYFQRITLYLTEKKYSPCAWEVVRAEIMRSFSLSTNLQERLRRKE DM90WJH DE Hepatitis C DM4AK0Q ID DM4AK0Q DM4AK0Q DN Interferon alfa-n1 DM4AK0Q HS Approved DM4AK0Q SN Well-feron; Interferon alfa-n1 (USAN); Well-feron (TN) DM4AK0Q TC Antiviral Agents DM4AK0Q SQ DB00011 sequence: CDLPQTHSLGSRRTLMLLAQMRKISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE DM4AK0Q DE Chronic myelogenous leukaemia DMTZNQ9 ID DMTZNQ9 DMTZNQ9 DN Interferon alfa-n3 DMTZNQ9 HS Approved DMTZNQ9 SN Alferon LDO; Interferon alfa-n3 (oral); Interferon alfa-n3 (oral), Hemispherx; Interferon alfa-n3 (oral), InterferonSciences DMTZNQ9 CP Interferon Sciences Inc DMTZNQ9 SQ DB00018 sequence (alpha-2A): CDLPQTHSLGSRRTLMLLAQMRKISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE >DB00018 sequence (alpha-2B)CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMNEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE >DB00018 sequence (alpha-2C)CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRRDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMNEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE DMTZNQ9 DE Human immunodeficiency virus infection DM1A6RV ID DM1A6RV DM1A6RV DN Interferon beta-1a DM1A6RV HS Approved DM1A6RV SN Avonex; Avonex (TN); Cinnovex (TN); Interferon beta-1a (USAN); Interferon beta-1a (genetical recombination); Interferon beta-1a (genetical recombination) (JAN); Rebif (TN) DM1A6RV TC Immunomodulatory Agents DM1A6RV DT Protein/peptide drug DM1A6RV SQ MSYNLLGFLQRSSNFQCQKLLWQLNGRLEYCLKDRMNFDIPEEIKQLQQFQKEDAALTIYEMLQNIFAIFRQDSSSTGWNETIVENLLANVYHQINHLKTVLEEKLEKEDFTRGKLMSSLHLKRYYGRILHYLKAKEYSHCAWTIVRVEILRNFYFINRLTGYLRN DM1A6RV DE Multiple sclerosis DMCN61Z ID DMCN61Z DMCN61Z DN Interferon beta-1b DMCN61Z HS Approved DMCN61Z SN Betaferon (TN); Betaseron (TN) DMCN61Z TC Immunomodulatory Agents DMCN61Z SQ DB00068 sequence: SYNLLGFLQRSSNFQSQKLLWQLNGRLEYCLKDRMNFDIPEEIKQLQQFQKEDAALTIYEMLQNIFAIFRQDSSSTGWNETIVENLLANVYHQINHLKTVLEEKLEKEDFTRGKLMSSLHLKRYYGRILHYLKAKEYSHCAWTIVRVEILRNFYFINRLTGYLRN DMCN61Z DE Multiple sclerosis DMWUMRL ID DMWUMRL DMWUMRL DN Interferon gamma-1b DMWUMRL HS Approved DMWUMRL TC Immunomodulatory Agents DMWUMRL SQ DB00033 sequence: CYCQDPYVKEAENLKKYFNAGHSDVADNGTLFLGILKNWKEESDRKIMQSQIVSFYFKLFKNFKDDQSIQKSVETIKEDMNVKFFNSNKKKRDDFEKLTNYSVTDLNVQRKAIHELIQVMAELSPAAKTGKRKRSQMLFRGRRASQ DMWUMRL DE Chronic granulomatous disease DM1Y69Q ID DM1Y69Q DM1Y69Q DN Interleukin-3 DM1Y69Q HS Approved DM1Y69Q DE Aplastic anemia DM1Y2JH ID DM1Y2JH DM1Y2JH DN Inulin DM1Y2JH HS Approved DM1Y2JH SN Inulin [BAN]; Inulin and sodium chloride; Inulin from Jerusalem artichokes; Inulin USP 27 DM1Y2JH TC Hypoglycemic Agents DM1Y2JH DT Small molecular drug DM1Y2JH PC 24763 DM1Y2JH MW 6179 DM1Y2JH FM C228H382O191 DM1Y2JH IC InChI=1S/C228H382O191/c229-1-76-114(268)152(306)153(307)191(381-76)419-228(190(344)151(305)113(38-266)418-228)75-380-227(189(343)150(304)112(37-265)417-227)74-379-226(188(342)149(303)111(36-264)416-226)73-378-225(187(341)148(302)110(35-263)415-225)72-377-224(186(340)147(301)109(34-262)414-224)71-376-223(185(339)146(300)108(33-261)413-223)70-375-222(184(338)145(299)107(32-260)412-222)69-374-221(183(337)144(298)106(31-259)411-221)68-373-220(182(336)143(297)105(30-258)410-220)67-372-219(181(335)142(296)104(29-257)409-219)66-371-218(180(334)141(295)103(28-256)408-218)65-370-217(179(333)140(294)102(27-255)407-217)64-369-216(178(332)139(293)101(26-254)406-216)63-368-215(177(331)138(292)100(25-253)405-215)62-367-214(176(330)137(291)99(24-252)404-214)61-366-213(175(329)136(290)98(23-251)403-213)60-365-212(174(328)135(289)97(22-250)402-212)59-364-211(173(327)134(288)96(21-249)401-211)58-363-210(172(326)133(287)95(20-248)400-210)57-362-209(171(325)132(286)94(19-247)399-209)56-361-208(170(324)131(285)93(18-246)398-208)55-360-207(169(323)130(284)92(17-245)397-207)54-359-206(168(322)129(283)91(16-244)396-206)53-358-205(167(321)128(282)90(15-243)395-205)52-357-204(166(320)127(281)89(14-242)394-204)51-356-203(165(319)126(280)88(13-241)393-203)50-355-202(164(318)125(279)87(12-240)392-202)49-354-201(163(317)124(278)86(11-239)391-201)48-353-200(162(316)123(277)85(10-238)390-200)47-352-199(161(315)122(276)84(9-237)389-199)46-351-198(160(314)121(275)83(8-236)388-198)45-350-197(159(313)120(274)82(7-235)387-197)44-349-196(158(312)119(273)81(6-234)386-196)43-348-195(157(311)118(272)80(5-233)385-195)42-347-194(156(310)117(271)79(4-232)384-194)41-346-193(155(309)116(270)78(3-231)383-193)40-345-192(39-267)154(308)115(269)77(2-230)382-192/h76-191,229-344H,1-75H2/t76-,77-,78-,79-,80-,81-,82-,83-,84-,85-,86-,87-,88-,89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,127-,128-,129-,130-,131-,132-,133-,134-,135-,136-,137-,138-,139-,140-,141-,142-,143-,144-,145-,146-,147-,148-,149-,150-,151-,152+,153-,154+,155+,156+,157+,158+,159+,160+,161+,162+,163+,164+,165+,166+,167+,168+,169+,170+,171+,172+,173+,174+,175+,176+,177+,178+,179+,180+,181+,182+,183+,184+,185+,186+,187+,188+,189+,190+,191-,192-,193-,194-,195-,196-,197-,198-,199-,200-,201-,202-,203-,204-,205-,206-,207-,208-,209-,210-,211-,212-,213-,214-,215-,216-,217-,218-,219-,220-,221-,222-,223-,224-,225-,226-,227-,228+/m1/s1 DM1Y2JH CS C([C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)O[C@]2([C@H]([C@@H]([C@H](O2)CO)O)O)CO[C@]3([C@H]([C@@H]([C@H](O3)CO)O)O)CO[C@]4([C@H]([C@@H]([C@H](O4)CO)O)O)CO[C@]5([C@H]([C@@H]([C@H](O5)CO)O)O)CO[C@]6([C@H]([C@@H]([C@H](O6)CO)O)O)CO[C@]7([C@H]([C@@H]([C@H](O7)CO)O)O)CO[C@]8([C@H]([C@@H]([C@H](O8)CO)O)O)CO[C@]9([C@H]([C@@H]([C@H](O9)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO)O)O)O)O DM1Y2JH IK JYJIGFIDKWBXDU-MNNPPOADSA-N DM1Y2JH IU (2R,3R,4S,5S,6R)-2-[(2S,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol DM1Y2JH CA CAS 9005-80-5 DM1Y2JH DE Measure kidney function DMS6ZI0 ID DMS6ZI0 DMS6ZI0 DN Inulin DMS6ZI0 HS Approved DMS6ZI0 SN Inulin [BAN]; Inulin [USP:BAN]; Inulin and sodium chloride; Inulin-oligofructose enriched; JOS53KRJ01; LS-186416; LS-187349; Liquid Agave Inulin; Agave Inulin; Inulin - Liquid; Inulin Powder; 78089-EP2272846A1; 78089-EP2277868A1; 78089-EP2277869A1; 78089-EP2308866A1; 78089-EP2374791A1; AI3-19506; DB00638; EINECS 232-684-3; UNII-JOS53KRJ01 DMS6ZI0 PC 24763 DMS6ZI0 MW 6179 DMS6ZI0 FM C228H382O191 DMS6ZI0 IC JYJIGFIDKWBXDU-MNNPPOADSA-N DMS6ZI0 CS C(C1C(C(C(C(O1)OC2(C(C(C(O2)CO)O)O)COC3(C(C(C(O3)CO)O)O)COC4(C(C(C(O4)CO)O)O)COC5(C(C(C(O5)CO)O)O)COC6(C(C(C(O6)CO)O)O)COC7(C(C(C(O7)CO)O)O)COC8(C(C(C(O8)CO)O)O)COC9(C(C(C(O9)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)CO)O)O)O)O DMS6ZI0 IK 1S/C228H382O191/c229-1-76-114(268)152(306)153(307)191(381-76)419-228(190(344)151(305)113(38-266)418-228)75-380-227(189(343)150(304)112(37-265)417-227)74-379-226(188(342)149(303)111(36-264)416-226)73-378-225(187(341)148(302)110(35-263)415-225)72-377-224(186(340)147(301)109(34-262)414-224)71-376-223(185(339)146(300)108(33-261)413-223)70-375-222(184(338)145(299)107(32-260)412-222)69-374-221(183(337)144(298)106(31-259)411-221)68-373-220(182(336)143(297)105(30-258)410-220)67-372-219(181(335)142(296)104(29-257)409-219)66-371-218(180(334)141(295)103(28-256)408-218)65-370-217(179(333)140(294)102(27-255)407-217)64-369-216(178(332)139(293)101(26-254)406-216)63-368-215(177(331)138(292)100(25-253)405-215)62-367-214(176(330)137(291)99(24-252)404-214)61-366-213(175(329)136(290)98(23-251)403-213)60-365-212(174(328)135(289)97(22-250)402-212)59-364-211(173(327)134(288)96(21-249)401-211)58-363-210(172(326)133(287)95(20-248)400-210)57-362-209(171(325)132(286)94(19-247)399-209)56-361-208(170(324)131(285)93(18-246)398-208)55-360-207(169(323)130(284)92(17-245)397-207)54-359-206(168(322)129(283)91(16-244)396-206)53-358-205(167(321)128(282)90(15-243)395-205)52-357-204(166(320)127(281)89(14-242)394-204)51-356-203(165(319)126(280)88(13-241)393-203)50-355-202(164(318)125(279)87(12-240)392-202)49-354-201(163(317)124(278)86(11-239)391-201)48-353-200(162(316)123(277)85(10-238)390-200)47-352-199(161(315)122(276)84(9-237)389-199)46-351-198(160(314)121(275)83(8-236)388-198)45-350-197(159(313)120(274)82(7-235)387-197)44-349-196(158(312)119(273)81(6-234)386-196)43-348-195(157(311)118(272)80(5-233)385-195)42-347-194(156(310)117(271)79(4-232)384-194)41-346-193(155(309)116(270)78(3-231)383-193)40-345-192(39-267)154(308)115(269)77(2-230)382-192/h76-191,229-344H,1-75H2/t76-,77-,78-,79-,80-,81-,82-,83-,84-,85-,86-,87-,88-,89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,127-,128-,129-,130-,131-,132-,133-,134-,135-,136-,137-,138-,139-,140-,141-,142-,143-,144-,145-,146-,147-,148-,149-,150-,151-,152+,153-,154+,155+,156+,157+,158+,159+,160+,161+,162+,163+,164+,165+,166+,167+,168+,169+,170+,171+,172+,173+,174+,175+,176+,177+,178+,179+,180+,181+,182+,183+,184+,185+,186+,187+,188+,189+,190+,191-,192-,193-,194-,195-,196-,197-,198-,199-,200-,201-,202-,203-,204-,205-,206-,207-,208-,209-,210-,211-,212-,213-,214-,215-,216-,217-,218-,219-,220-,221-,222-,223-,224-,225-,226-,227-,228+/m1/s1 DMS6ZI0 IU (2R,3R,4S,5S,6R)-2-[(2S,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol DMS6ZI0 CA CAS 9005-80-5 DMS6ZI0 DE Acute kidney failure DM80OEZ ID DM80OEZ DM80OEZ DN Iobenguane I-123 DM80OEZ HS Approved DM80OEZ SN Iobenguane (123I); UNII-P2TH1XYZ84; m-Iodobenzylguanidine-123I; P2TH1XYZ84; Adreview; Iobenguane I 123; 123I-MIBG; 2-[(3-iodanylphenyl)methyl]guanidine; 76924-93-1; Iodine-123 metaiodobenzylguanidine; m-(123I)Iodobenzylguanidine; Iobenguane I 123 [USAN]; MyoMIBG-I 123 (TN); (123I)-m-Iodobenzylguanidine; AC1L367T; AC1Q50E3; CHEMBL1615777; SCHEMBL13158600; (123)I-MIBG; CHEBI:135134; 123 iodine metaiodobenzylguanidine; MOLI000966; 3-Iodobenzylguanidine (123I) (JAN); Guanidine, ((3-iodo(123I)phenyl)methyl)-; D01729 DM80OEZ CP GE Healthcare DM80OEZ DT Small molecular drug DM80OEZ PC 135326 DM80OEZ MW 271.09 DM80OEZ FM C8H10IN3 DM80OEZ IC InChI=1S/C8H10IN3/c9-7-3-1-2-6(4-7)5-12-8(10)11/h1-4H,5H2,(H4,10,11,12)/i9-4 DM80OEZ CS C1=CC(=CC(=C1)[123I])CN=C(N)N DM80OEZ IK PDWUPXJEEYOOTR-IUAIQHPESA-N DM80OEZ IU 2-[(3-(123I)iodanylphenyl)methyl]guanidine DM80OEZ CA CAS 76924-93-1 DM80OEZ CB CHEBI:135134 DM80OEZ DE Neuroendocrine cancer DMXIQYS ID DMXIQYS DMXIQYS DN Iodipamide DMXIQYS HS Approved DMXIQYS SN Adipiodon; Adipiodona; Adipiodone; Adipiodonum; Bilignost; Bilignostum; Biligrafin; Cholografin; Cholospect; IDB; Transbilix; Iodipamic acid; Iodipamide [USAN]; Adipiodona [INN-Spanish]; Adipiodonum [INN-Latin]; Iodipamide (USP); Adipiodone (JAN/INN); N,N''-Adipoyl-bis(3-amino-2,4,6-triiodbenzoesaeure); 3,3'(Adipoyldiimino)bis(2,4,6-triiodobenzoic acid); 3,3'-(Adipoyldiimino)bis(2,4,6-triiodobenzoic acid); 3,3'-Adipoyldiiminobis(2,4,6-triiodobenzoic Acid); 3,3'-[(1,6-DIOXOHEXANE-1,6-DIYL)DIIMINO]BIS(2,4,6-TRIIODOBENZOIC ACID); 3-[5-[(3-CARBOXY-2,4,6-TRIIODO-PHENYL)CARBAMOYL]PENTANOYLAMINO]-2,4,6-TRIIODO-BENZOIC ACID; 3-[[6-(3-carboxy-2,4,6-triiodoanilino)-6-oxohexanoyl]amino]-2,4,6-triiodobenzoic acid DMXIQYS TC Contrast Media DMXIQYS DT Small molecular drug DMXIQYS PC 3739 DMXIQYS MW 1139.8 DMXIQYS FM C20H14I6N2O6 DMXIQYS IC InChI=1S/C20H14I6N2O6/c21-7-5-9(23)17(15(25)13(7)19(31)32)27-11(29)3-1-2-4-12(30)28-18-10(24)6-8(22)14(16(18)26)20(33)34/h5-6H,1-4H2,(H,27,29)(H,28,30)(H,31,32)(H,33,34) DMXIQYS CS C1=C(C(=C(C(=C1I)NC(=O)CCCCC(=O)NC2=C(C=C(C(=C2I)C(=O)O)I)I)I)C(=O)O)I DMXIQYS IK FFINMCNLQNTKLU-UHFFFAOYSA-N DMXIQYS IU 3-[[6-(3-carboxy-2,4,6-triiodoanilino)-6-oxohexanoyl]amino]-2,4,6-triiodobenzoic acid DMXIQYS CA CAS 606-17-7 DMXIQYS CB CHEBI:31176 DMXIQYS DE Gallbladder disease DMNARJT ID DMNARJT DMNARJT DN Ioflupane I-123 DMNARJT HS Approved DMNARJT SN Datscan (TN) DMNARJT CP GE Healthcare DMNARJT DT Small molecular drug DMNARJT PC 3086674 DMNARJT MW 427.3 DMNARJT FM C18H23FINO2 DMNARJT IC InChI=1S/C18H23FINO2/c1-23-18(22)17-15(12-3-5-13(20)6-4-12)11-14-7-8-16(17)21(14)10-2-9-19/h3-6,14-17H,2,7-11H2,1H3/t14-,15+,16+,17-/m0/s1/i20-4 DMNARJT CS COC(=O)[C@@H]1[C@H]2CC[C@H](N2CCCF)C[C@@H]1C3=CC=C(C=C3)[123I] DMNARJT IK HXWLAJVUJSVENX-HFIFKADTSA-N DMNARJT IU methyl (1R,2S,3S,5S)-8-(3-fluoropropyl)-3-(4-(123I)iodanylphenyl)-8-azabicyclo[3.2.1]octane-2-carboxylate DMNARJT CA CAS 155798-07-5 DMNARJT CB CHEBI:68855 DMNARJT DE Parkinson disease DMLZTP9 ID DMLZTP9 DMLZTP9 DN Ipecac DMLZTP9 HS Approved DMLZTP9 SN Ipecac syrup DMLZTP9 DE Poison intoxication DMWA24P ID DMWA24P DMWA24P DN IPI-145 DMWA24P HS Approved DMWA24P SN Duvelisib; 1201438-56-3; INK-1197; UNII-610V23S0JI; DMWA24P CP Verastem DMWA24P DT Small molecular drug DMWA24P PC 50905713 DMWA24P MW 416.9 DMWA24P FM C22H17ClN6O DMWA24P IC InChI=1S/C22H17ClN6O/c1-13(28-21-19-20(25-11-24-19)26-12-27-21)17-10-14-6-5-9-16(23)18(14)22(30)29(17)15-7-3-2-4-8-15/h2-13H,1H3,(H2,24,25,26,27,28)/t13-/m0/s1 DMWA24P CS C[C@@H](C1=CC2=C(C(=CC=C2)Cl)C(=O)N1C3=CC=CC=C3)NC4=NC=NC5=C4NC=N5 DMWA24P IK SJVQHLPISAIATJ-ZDUSSCGKSA-N DMWA24P IU 8-chloro-2-phenyl-3-[(1S)-1-(7H-purin-6-ylamino)ethyl]isoquinolin-1-one DMWA24P CA CAS 1201438-56-3 DMWA24P CB CHEBI:131169 DMWA24P DE Small lymphocytic lymphoma; Follicular lymphoma; Arthritis DMJTIYK ID DMJTIYK DMJTIYK DN Ipilimumab DMJTIYK HS Approved DMJTIYK SN BMS-734016; MDX-010; MDX-101; Yervoy (TN) DMJTIYK CP Bristol-Myers Squibb DMJTIYK DT Monoclonal antibody DMJTIYK SQ Ipilimumab heavy chain (patent appl. US20150283234) : QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYTMHWVRQAPGKGLEWVTFISYDGNNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAIYYCARTGWLGPFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK >Ipilimumab light chain EIVLTQSPGTLSLSPGERATLSCRASQSVGSSYLAWYQQKPGQAPRLLIYGAFSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC DMJTIYK DE Melanoma DMFQ320 ID DMFQ320 DMFQ320 DN Ipratropium DMFQ320 HS Approved DMFQ320 SN Aerodose; Atrovent; Atrovent Hfa; Ipatropium Bromide; Ipratropium bromide; X8M; Apo-Ipravent; Apovent (TN); Atrovent (TN); Kendral-Ipratropium; [(5R)-8-methyl-8-propan-2-yl-8-azoniabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate; [(1R,5R)-8-methyl-8-propan-2-yl-8-azoniabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate; [(1R,5S)-8-methyl-8-propan-2-yl-8-azoniabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate; [(1R,5S)-8-methyl-8-propan-2-yl-8-azoniabicyclo[3.2.1]octan-3-yl] (2R)-3-hydroxy-2-phenylpropanoate; (3-endo,8-syn)-3-(3-Hydroxy-1-oxo-2-phenylpropoxy)-8-methyl-8-(1-methylethyl)-8-azoniabicyclo(3.2.1)octane; (3-endo,8-syn)-3-[(3-hydroxy-2-phenylpropanoyl)oxy]-8-isopropyl-8-methyl-8-azoniabicyclo[3.2.1]octane; (8-methyl-8-propan-2-yl-8-azoniabicyclo[3.2.1]octan-3-yl) 3-hydroxy-2-phenylpropanoate; 3-[(3-hydroxy-2-phenylpropanoyl)oxy]-8-methyl-8-(propan-2-yl)-8-azoniabicyclo[3.2.1]octane DMFQ320 TC Bronchodilator Agents DMFQ320 DT Small molecular drug DMFQ320 PC 657309 DMFQ320 MW 332.5 DMFQ320 FM C20H30NO3+ DMFQ320 IC InChI=1S/C20H30NO3/c1-14(2)21(3)16-9-10-17(21)12-18(11-16)24-20(23)19(13-22)15-7-5-4-6-8-15/h4-8,14,16-19,22H,9-13H2,1-3H3/q+1/t16-,17+,18?,19?,21? DMFQ320 CS CC(C)[N+]1([C@@H]2CC[C@H]1CC(C2)OC(=O)C(CO)C3=CC=CC=C3)C DMFQ320 IK OEXHQOGQTVQTAT-BZQJJPTISA-N DMFQ320 IU [(1S,5R)-8-methyl-8-propan-2-yl-8-azoniabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate DMFQ320 CA CAS 60205-81-4 DMFQ320 CB CHEBI:5956 DMFQ320 DE Obstructive lung disease DM0IO13 ID DM0IO13 DM0IO13 DN Ipriflavone DM0IO13 HS Approved DM0IO13 SN Osten (TN) DM0IO13 DT Small molecular drug DM0IO13 PC 3747 DM0IO13 MW 280.3 DM0IO13 FM C18H16O3 DM0IO13 IC InChI=1S/C18H16O3/c1-12(2)21-14-8-9-15-17(10-14)20-11-16(18(15)19)13-6-4-3-5-7-13/h3-12H,1-2H3 DM0IO13 CS CC(C)OC1=CC2=C(C=C1)C(=O)C(=CO2)C3=CC=CC=C3 DM0IO13 IK SFBODOKJTYAUCM-UHFFFAOYSA-N DM0IO13 IU 3-phenyl-7-propan-2-yloxychromen-4-one DM0IO13 CA CAS 35212-22-7 DM0IO13 CB CHEBI:31719 DM0IO13 DE Osteoporosis DMTP1DC ID DMTP1DC DMTP1DC DN Irbesartan DMTP1DC HS Approved DMTP1DC SN irbesartan; 138402-11-6; Aprovel; Avapro; Karvea; SR-47436; BMS-186295; BMS 186295; Irbesartan [USAN:INN]; SR 47436; UNII-J0E2756Z7N; CHEMBL1513; 8-butyl-7-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-7,9-diazaspiro[44]non-8-en-6-one; CHEBI:5959; C25H28N6O; YOSHYTLCDANDAN-UHFFFAOYSA-N; J0E2756Z7N; 2-butyl-3-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1,3-diazaspiro[44]non-1-en-4-one; 3-((2'-(1H-Tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-butyl-1,3-diazaspiro[44]non-1-en-4-one; NCGC00095122-01; AK-57149; DSSTox_CID_3169; Aprovel; Irbesarran; Irbetan; Lrbesartan; BMS Brand of Irbesartan; Bristol Myers Brand of Irbesartan; SanofiWinthrop Brand of Irbesartan; Aprovel (TN); Avalide (TN); Avapro (TN); Karvea (TN); Irbesartan (JAN/USAN/INN); BMS-186295, SR-47436,Aprovel, Karvea, Irbesartan; 2-Butyl-3-(p-(o-1H-tetrazol-5-ylphenyl)benzyl)-1,3-diazaspiro(44)non-1-en-4-one; 2-Butyl-3-[2'-(1H-tetrazol-5-yl)biphenyl-4-ylmethyl]1,3-diaza-spiro[44]non-1-en-4-one; 2-butyl-3-[ p-(o-1 H-tetrazol-5-ylphenyl)benzyl]-1,3-diazaspiro[4,4]non-1-en-4-one; 2-butyl-3-[p-(o-1H-tetrazol-5-ylphenyl)benzyl]-1,3-diazaspiro[44]non-1-en-4-one; 2-butyl-3-{[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl}-1,3-diazaspiro[44]non-1-en-4-one; 2-n-butyl-3-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-1,3-diazaspiro(4,4)non-1-en-4-one; [3H]irbesartan DMTP1DC CP Bristol-Myers Squibb DMTP1DC TC Antihypertensive Agents DMTP1DC DT Small molecular drug DMTP1DC PC 3749 DMTP1DC MW 428.5 DMTP1DC FM C25H28N6O DMTP1DC IC InChI=1S/C25H28N6O/c1-2-3-10-22-26-25(15-6-7-16-25)24(32)31(22)17-18-11-13-19(14-12-18)20-8-4-5-9-21(20)23-27-29-30-28-23/h4-5,8-9,11-14H,2-3,6-7,10,15-17H2,1H3,(H,27,28,29,30) DMTP1DC CS CCCCC1=NC2(CCCC2)C(=O)N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5 DMTP1DC IK YOSHYTLCDANDAN-UHFFFAOYSA-N DMTP1DC IU 2-butyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-1,3-diazaspiro[4.4]non-1-en-4-one DMTP1DC CA CAS 138402-11-6 DMTP1DC CB CHEBI:5959 DMTP1DC DE Hypertension DMP6SC2 ID DMP6SC2 DMP6SC2 DN Irinotecan DMP6SC2 HS Approved DMP6SC2 SN Biotecan; Camptosar; Irinotecanum; IRINOTECAN HYDROCHLORIDE Trihydrate; Irinotecan Hcl; Irinotecan hydrochloride; CP0; Biotecan (TN); Campto (TN); Camptosar (TN); Irinotecan (INN); Irinotecan [INN:BAN]; Irinotecanum [INN-Latin]; IRINOTECAN, CPT-11; Camptosar, Campto, CPT-11, Irinotecan; (+)-Irinotecan; (4S)-4,11-DIETHYL-4-HYDROXY-3,14-DIOXO-3,4,12,14-TETRAHYDRO-1H-PYRANO[3',4':6,7]INDOLIZINO[1,2-B]QUINOLIN-9-YL 1,4'-BIPIPERIDINE-1'-CARBOXYLATE; (4S)-4,11-Diethyl-4-hydroxy-3,14-dioxo-4,12-dihydro-1H-pyrano[3,4-f]quinolino[2,3-a]indolizin-9-yl 4-piperidylpiperidinecarboxylate; Irinotecan (TOPO1 inhibitor); Onivyde DMP6SC2 CP Pfizer Pharmaceuticals DMP6SC2 TC Anticancer Agents DMP6SC2 DT Small molecular drug DMP6SC2 PC 60838 DMP6SC2 MW 586.7 DMP6SC2 FM C33H38N4O6 DMP6SC2 IC InChI=1S/C33H38N4O6/c1-3-22-23-16-21(43-32(40)36-14-10-20(11-15-36)35-12-6-5-7-13-35)8-9-27(23)34-29-24(22)18-37-28(29)17-26-25(30(37)38)19-42-31(39)33(26,41)4-2/h8-9,16-17,20,41H,3-7,10-15,18-19H2,1-2H3/t33-/m0/s1 DMP6SC2 CS CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)[C@@]4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7 DMP6SC2 IK UWKQSNNFCGGAFS-XIFFEERXSA-N DMP6SC2 IU [(19S)-10,19-diethyl-19-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaen-7-yl] 4-piperidin-1-ylpiperidine-1-carboxylate DMP6SC2 CA CAS 97682-44-5 DMP6SC2 CB CHEBI:80630 DMP6SC2 DE Colorectal cancer DMAP8MV ID DMAP8MV DMAP8MV DN Iron DMAP8MV HS Approved DMAP8MV SN Eisen; Feronate; Ferretts; Ferrousal; Ferrum; Hemocyte; Hierro; LOHA; PZhO; Remko; Siderol; Yieronia; Ancor B; Armco iron; Carbonyl iron; Ferrous iron; Ferrovac E; Hoeganaes EH; Iron monocation; Iron standard for AAS; ATW 230; ATW 432; Atomel 28; Atomel 300M200; Atomel 500M; Atomel 95; Atomiron 44MR; Atomiron 5M; Atomiron AFP 25; Atomiron AFP 5; DSP 1000; DSP 128B; DSP 135; DSP 135C; DSP 138; EF 1000; EF 250; EFV 250; GS 6; HS 4849; Hoeganaes ATW 230; NC 100; PZh1M1; PZh2M; PZh2M1; PZh2M2; PZh3; PZh3M; PZh4M; Ancoren 80/150; Copy Powder CS 105-175; Diseases, iron overload; EFV 200/300; EFV 250/400; F 60 (metal); FT 3 (element); Fe-40; Fe1+; Ferro-Caps; Ferro-Time; HF 2 (element); HL (iron); HQ (metal); HS (iron); Iron (Fe); Iron(III) nitrate solution; Iron, elemental; PZh-1M3; PZh-2; SUY-B 2; Vitedyn-Slo; Diseases (animal), iron overload; Ed-In-Sol; Iron (Fe1+); Iron ion (Fe+); Iron ion(1+); Iron(1+); Iron(1+) ion; Iron, ion (Fe1+); Iron, ion (Fe1+) (8CI,9CI); 3ZhP DMAP8MV TC Iron Supplement DMAP8MV DT Small molecular drug DMAP8MV PC 23925 DMAP8MV MW 55.84 DMAP8MV FM Fe DMAP8MV IC InChI=1S/Fe DMAP8MV CS [Fe] DMAP8MV IK XEEYBQQBJWHFJM-UHFFFAOYSA-N DMAP8MV IU iron DMAP8MV CA CAS 7439-89-6 DMAP8MV CB CHEBI:18248 DMAP8MV DE Iron-deficiency anemia DM5OY70 ID DM5OY70 DM5OY70 DN Iron Dextran DM5OY70 HS Approved DM5OY70 SN Chinofer; Dexferrum; Dextrofer; Eisendextran; Fenate; Ferridextran; Ferrodextran; Ferroglucin; Hematran; Icar; Imfergen; Imferon; Imperon; Imposil; Infed; Norferan; Polyfer; Proferdex; Prolongal; Ursoferran; Dextran iron complex; Eisendextran [German]; Fero Gradumet; Ferric dextran; Iron dextran complex; Iron dextran injection; Iron hydrogenated dextran; Ironorm injection; B 75; Dextrofer 75; Ferdex 100; Ferroglukin 75; Myofer 100; A 100 (Pharmaceutical); American Regent Brand of Iron-Dextran Complex; Dextran-Iron Complex; Fe-Dextran; GlaxoSmithKline Brand of Iron-Dextran Complex; Goldline Brand of Iron-Dextran Complex; Hauck Brand of Iron-Dextran Complex; Hawthron Brand of Iron-Dextran Complex; Iro-Jex; Iron-dextran complex; Sanofi Brand of Iron-Dextran Complex; Sulfuric acid, iron salt; Sulphuric acid, iron salt; Vortech Brand of Iron-Dextran Complex; Watson Brand of Iron-Dextran Complex; Sulfuric acid iron salt (1:1); Sulfuric acid, iron salt (1:); Sulfuric acid iron(2+) salt (1:1) DM5OY70 TC Iron Supplement DM5OY70 DT Small molecular drug DM5OY70 PC 105075 DM5OY70 MW 153.93 DM5OY70 FM FeH2O4S DM5OY70 IC InChI=1S/Fe.H2O4S/c;1-5(2,3)4/h;(H2,1,2,3,4) DM5OY70 CS OS(=O)(=O)O.[Fe] DM5OY70 IK MVZXTUSAYBWAAM-UHFFFAOYSA-N DM5OY70 IU iron;sulfuric acid DM5OY70 CA CAS 9004-66-4 DM5OY70 DE Iron-deficiency anemia DMD45S9 ID DMD45S9 DMD45S9 DN Isavuconazonium DMD45S9 HS Approved DMD45S9 SN Isavuconazonium; Isavuconazonium (USAN); Isavuconazonium [USAN]; Isavuconazonium ion; VH2L779W8Q; 742049-41-8; AC1OCFMR; ACN-048059; BCP23773; BAL 8557-000; BAL-8557; BAL8557-000; CHEBI:85978; CHEMBL1183349; DB06636; DTXSID70225203; Glycine, N-methyl-, (2-(((1-(1-((2R,3R)-3-(4-(4-cyanophenyl)-2-thiazolyl)-2-(2,5-difluorophenyl)-2-hydroxybutyl)-1H-1,2,4-triazolium-4-yl)ethoxy)carbonyl)methylamino)-3-pyridinyl)methyl ester; SCHEMBL13133195; UNII-VH2L779W8Q DMD45S9 PC 6918606 DMD45S9 MW 717.8 DMD45S9 FM C35H35F2N8O5S+ DMD45S9 IC RSWOJTICKMKTER-QXLBVTBOSA-N DMD45S9 CS CC(C1=NC(=CS1)C2=CC=C(C=C2)C#N)C(CN3C=[N+](C=N3)C(C)OC(=O)N(C)C4=C(C=CC=N4)COC(=O)CNC)(C5=C(C=CC(=C5)F)F)O DMD45S9 IK 1S/C35H35F2N8O5S/c1-22(33-42-30(18-51-33)25-9-7-24(15-38)8-10-25)35(48,28-14-27(36)11-12-29(28)37)19-45-21-44(20-41-45)23(2)50-34(47)43(4)32-26(6-5-13-40-32)17-49-31(46)16-39-3/h5-14,18,20-23,39,48H,16-17,19H2,1-4H3/q+1/t22-,23?,35+/m0/s1 DMD45S9 IU [2-[1-[1-[(2R,3R)-3-[4-(4-cyanophenyl)-1,3-thiazol-2-yl]-2-(2,5-difluorophenyl)-2-hydroxybutyl]-1,2,4-triazol-4-ium-4-yl]ethoxycarbonyl-methylamino]pyridin-3-yl]methyl 2-(methylamino)acetate DMD45S9 CA CAS 742049-41-8 DMD45S9 CB CHEBI:85978 DMD45S9 DE Allergic bronchopulmonary aspergillosis DMJ9G23 ID DMJ9G23 DMJ9G23 DN ISIS 1570 DMJ9G23 HS Approved DMJ9G23 CP Isis Pharmaceuticals DMJ9G23 DT Antisense drug DMJ9G23 DE Lleum inflammation DMAF1NB ID DMAF1NB DMAF1NB DN Isocarboxazid DMAF1NB HS Approved DMAF1NB SN BMIH; Benazide; Enerzer; Isocarbonazid; Isocarbossazide; Isocarboxazida; Isocarboxazide; Isocarboxazidum; Isocarboxyzid; Maraplan; Marplan; Marplon; Isocarbossazide [DCIT]; Isocarboxazid (INN); Isocarboxazid [INN:BAN]; Isocarboxazida [INN-Spanish]; Isocarboxazide [INN-French]; Isocarboxazidum [INN-Latin]; Marplan (TN); Ro5-0831; Ro 5-0831/1; N'-Benzyl N-methyl-5-isoxazolecarboxylhydrazide-3; N'-benzyl-5-methyl-1,2-oxazole-3-carbohydrazide; 1-Benzyl-2-(5-methyl-3-isoxazolyl-carbonyl)hydrazine; 1-Benzyl-2-(5-methyl-3-isoxazolylcarbonyl)hydrazine; 3-Isoxazolecarboxylic acid, 5-methyl-, 2-(phenylmethyl)hydrazide; 3-Isoxazolecarboxylic acid, 5-methyl-, 2-benzylhydrazide; 5-Methyl-3-isoxazolecarboxylic acid 2-benzylhydrazide; 5-methyl-N'-(phenylmethyl)isoxazole-3-carbohydrazide DMAF1NB CP Hoffmann-La Roche pharmaceutical company DMAF1NB TC Antidepressants DMAF1NB DT Small molecular drug DMAF1NB PC 3759 DMAF1NB MW 231.25 DMAF1NB FM C12H13N3O2 DMAF1NB IC InChI=1S/C12H13N3O2/c1-9-7-11(15-17-9)12(16)14-13-8-10-5-3-2-4-6-10/h2-7,13H,8H2,1H3,(H,14,16) DMAF1NB CS CC1=CC(=NO1)C(=O)NNCC2=CC=CC=C2 DMAF1NB IK XKFPYPQQHFEXRZ-UHFFFAOYSA-N DMAF1NB IU N'-benzyl-5-methyl-1,2-oxazole-3-carbohydrazide DMAF1NB CA CAS 59-63-2 DMAF1NB CB CHEBI:93635 DMAF1NB DE Depression DMITSEH ID DMITSEH DMITSEH DN Isoetharine DMITSEH HS Approved DMITSEH SN Bronkosol; Dilabron; Etyprenaline; Etyprenalinum; Isoetarin; Isoetarina; Isoetarine; Isoetarinum; Neoisuprel; Isoetharine Hcl; Win 3406; Bronkometer (TN); Bronkosol (TN); Dey-Lute Isoetharine; Isoetarina [INN-Spanish]; Isoetarine (INN); Isoetarinum [INN-Latin]; Isoetharine (USP); Isoetharine HCl S/F; Isoetharine [USAN:BAN]; 3,4-Dihydroxy-alpha-(1-(isopropylamino)propyl)benzyl alcohol; 4-[1-hydroxy-2-(propan-2-ylamino)butyl]benzene-1,2-diol DMITSEH TC Bronchodilator Agents DMITSEH DT Small molecular drug DMITSEH PC 3762 DMITSEH MW 239.31 DMITSEH FM C13H21NO3 DMITSEH IC InChI=1S/C13H21NO3/c1-4-10(14-8(2)3)13(17)9-5-6-11(15)12(16)7-9/h5-8,10,13-17H,4H2,1-3H3 DMITSEH CS CCC(C(C1=CC(=C(C=C1)O)O)O)NC(C)C DMITSEH IK HUYWAWARQUIQLE-UHFFFAOYSA-N DMITSEH IU 4-[1-hydroxy-2-(propan-2-ylamino)butyl]benzene-1,2-diol DMITSEH CA CAS 530-08-5 DMITSEH CB CHEBI:6005 DMITSEH DE Asthma DMY6T31 ID DMY6T31 DMY6T31 DN Isoflurane DMY6T31 HS Approved DMY6T31 SN Aerrane; Forane; Forene; IsoFlo; Isoflurano; Isofluranum; AErrane (Veterinary); Forane (TN); Isoflurane [Anaesthetics, volatile]; Isoflurano [INN-Spanish]; Isofluranum [INN-Latin]; R-E 235dal; Isoflurane (JP15/USP/INN); Isoflurane [USAN:BAN:INN:JAN]; Isoflurane [USAN:INN:BAN:JAN]; Ether, 1-chloro-2,2,2-trifluoroethyl difluoromethyl; 1-Chloro-2,2,2-trifluoroethyl difluoromethyl ether; 2-Chloro-2-(difluoromethoxy)-1,1,1-trifluoroethane; 2-chloro-2-difluoromethoxy-1,1,1-trifluoroethane DMY6T31 TC Anesthetics DMY6T31 DT Small molecular drug DMY6T31 PC 3763 DMY6T31 MW 184.49 DMY6T31 FM C3H2ClF5O DMY6T31 IC InChI=1S/C3H2ClF5O/c4-1(3(7,8)9)10-2(5)6/h1-2H DMY6T31 CS C(C(F)(F)F)(OC(F)F)Cl DMY6T31 IK PIWKPBJCKXDKJR-UHFFFAOYSA-N DMY6T31 IU 2-chloro-2-(difluoromethoxy)-1,1,1-trifluoroethane DMY6T31 CA CAS 26675-46-7 DMY6T31 CB CHEBI:6015 DMY6T31 DE Anaesthesia DMBSK7X ID DMBSK7X DMBSK7X DN Isoflurophate DMBSK7X HS Approved DMBSK7X SN DFP; DIFP; Diflupyl; Diflurophate; Diisopropylfluorfosfat; Diisopropylfluorophosphate; Diisopropylfluorphosphorsaeureester; Diisopropylphosphofluoridate; Diisopropylphosphorofluoridate; Dyflos; Floropryl; Fluoropryl; Fluorostigmine; Fluostigmine; Fluropryl; Isofluorophate; Isofluorphate; Isoflurophosphate; Neoglaucit; Di isopropylphosphorofluoridate; Diisopropoxyphosphoryl fluoride; Diisopropyl fluoridophosphate; Diisopropyl fluorophosphate; Diisopropyl fluorophosphonate; Diisopropyl phosphofluoridate; Diisopropyl phosphorofluoridate; Diisopropylfluorfosfat [Czech]; Diisopropylfluorophosphoric acid ester; Diisopropylfluorphosphorsaeureester [German]; Disiopropyl fluorophosphonate; Fluorodiisopropyl phosphate; Isoflurophate [USP]; Isopropyl fluophosphate; Isopropyl phosphorofluoridate; Merck Brand of Isoflurophate; Phosphoric acid diisopropyl ester fluoride; EA 1152; TL 466; DIISOPROPYL-FLUOROPHOSPHATE; Di-isopropylphosphorofluoridate; Floropryl (TN); Fluophosphoric acid, diisopropyl ester; Fluorophosphoric acid, diisopropyl ester; Isoflurophate (USP); PF-3; Phosphorofluoridic acid, diisopropyl ester; T-1703; Bis(1-methylethyl) Phosphorofluoridate; Dipropan-2-yl phosphorofluoridoate; O,O-Diisopropyl fluorophosphate; Bis(propan-2-yl) fluorophosphate; O,O'-Diisopropyl phosphoryl fluoride; Phosphorofluoridic acid, bis(1-methylethyl) ester; 2-[fluoro(propan-2-yloxy)phosphoryl]oxypropane DMBSK7X TC Antiglaucomic Agents DMBSK7X DT Small molecular drug DMBSK7X PC 5936 DMBSK7X MW 184.15 DMBSK7X FM C6H14FO3P DMBSK7X IC InChI=1S/C6H14FO3P/c1-5(2)9-11(7,8)10-6(3)4/h5-6H,1-4H3 DMBSK7X CS CC(C)OP(=O)(OC(C)C)F DMBSK7X IK MUCZHBLJLSDCSD-UHFFFAOYSA-N DMBSK7X IU 2-[fluoro(propan-2-yloxy)phosphoryl]oxypropane DMBSK7X CA CAS 55-91-4 DMBSK7X CB CHEBI:17941 DMBSK7X DE Glaucoma/ocular hypertension DM5JVS3 ID DM5JVS3 DM5JVS3 DN Isoniazid DM5JVS3 HS Approved DM5JVS3 SN Abdizide; Andrazide; Anidrasona; Antimicina; Antituberkulosum; Armacide; Armazid; Armazide; Atcotibine; Azuren; Bacillen; Bacillin; Cedin; Cemidon; Chemiazid; Chemidon; Continazine; Cortinazine; Cotinazin; Cotinizin; Defonin; Dibutin; Diforin; Dinacrin; Ditubin; Ebidene; Eralon; Ertuban; Eutizon; Evalon; Fetefu; Fimalene; HIA; Hidranizil; Hidrasonil; Hidrulta; Hidrun; Hycozid; Hydra; Hydrazid; Hydrazide; Hyozid; Hyzyd; INH; Idrazil; Inah; Inizid; Iscotin; Isidrina; Ismazide; Isobicina; Isocid; Isocidene; Isocotin; Isohydrazide; Isokin; Isolyn; Isonerit; Isonex; Isoniacid; Isoniazida; Isoniazide; Isoniazidum; Isonicazide; Isonicid; Isonico; Isonicotan; Isonicotil; Isonicotinhydrazid; Isonicotinohydrazide; Isonide; Isonidrin; Isonikazid; Isonilex; Isonin; Isonindon; Isonirit; Isoniton; Isonizida; Isonizide; Isotamine; Isotebe; Isotebezid; Isotinyl; Isozid; Isozide; Isozyd; LANIZID; Laniazid; Laniozid; Mybasan; Neoteben; Neoxin; Neumandin; Nevin; Niadrin; Nicazide; Nicetal; Nicizina; Niconyl; Nicotibina; Nicotibine; Nicotisan; Nicozide; Nidaton; Nidrazid; Nikozid; Niplen; Nitadon; Niteban; Nydrazid; Nyscozid; Pelazid; Percin; Phthisen; Pycazide; Pyreazid; Pyricidin; Pyridicin; Pyrizidin; Raumanon; Razide; Retozide; Rimicid; Rimifon; Rimiphone; Rimitsid; Robiselin; Robisellin; Roxifen; Sanohidrazina; Sauterazid; Sauterzid; Stanozide; Tebecid; Tebemid; Tebenic; Tebexin; Tebilon; Tebos; Teebaconin; Tekazin; Tibazide; Tibemid; Tibiazide; Tibinide; Tibison; Tibivis; Tibizide; Tibusan; Tisin; Tisiodrazida; Tizide; Tubazid; Tubazide; Tubeco; Tubecotubercid; Tubercid; Tuberian; Tubicon; Tubilysin; Tubizid; Tubomel; Tyvid; Unicocyde; Unicozyde; Vazadrine; Vederon; Zidafimia; Zinadon; Zonazide; Hid rasonil; Isoco tin; Isoniazid SA; Isozid e; Nidra zid; Rimif on; BP 5015; Bp 5 015; FSR 3; I0138; INHd20; L 1945; Nitebannsc 9659; Preparation 6424; RP 5015; AZT + Isoniazid; Cedin (Aerosol); Dow-Isoniazid; FRS-3; FSR-3; Ido-tebin; In-73; Inh-Burgthal; Isoniazid & EEP; Isoniazid & Propolis; Laniazid (TN); Neo-Tizide; Nydrazid (TN); RP-5015; TB-Phlogin; TB-Razide; TB-Vis; Usaf cb-2; I.A.I; RU-EF-Tb; RY-EF-Tb; I.A.I. DM5JVS3 CP Roche Pharmaceuticals DM5JVS3 TC Antitubercular Agents DM5JVS3 DT Small molecular drug DM5JVS3 PC 3767 DM5JVS3 MW 137.14 DM5JVS3 FM C6H7N3O DM5JVS3 IC InChI=1S/C6H7N3O/c7-9-6(10)5-1-3-8-4-2-5/h1-4H,7H2,(H,9,10) DM5JVS3 CS C1=CN=CC=C1C(=O)NN DM5JVS3 IK QRXWMOHMRWLFEY-UHFFFAOYSA-N DM5JVS3 IU pyridine-4-carbohydrazide DM5JVS3 CA CAS 54-85-3 DM5JVS3 CB CHEBI:6030 DM5JVS3 DE Tuberculosis DMQYV60 ID DMQYV60 DMQYV60 DN Isopropamide iodide DMQYV60 HS Approved DMQYV60 SN Isopropamide Iodide; 71-81-8; Darbid; Isoproponum iodide; Priamide Eupharma; Priamide; Tyrimide; Dipramide; Priazimide; Piaccamide; Sanulcin; Dipramid; Isamid; Marygin-M; UNII-E0KNA372SZ; Isopropamide ioduro [DCIT]; Isopropamidi iodidum [INN-Latin]; SKF 4740; Iodure d'isopropamide [INN-French]; EINECS 200-766-8; NSC 15521; Ioduro de isopropamida [INN-Spanish]; 5579 MD; E0KNA372SZ; R 79; MLS000069749; (3-Carbamoyl-3,3-diphenylpropyl)diisopropylmethylammonium iodide; Benzenepropanaminium, gamma-(aminocarbonyl)-N-methyl-N,N-bis(1-methyl DMQYV60 DT Small molecular drug DMQYV60 PC 6284 DMQYV60 MW 480.4 DMQYV60 FM C23H33IN2O DMQYV60 IC InChI=1S/C23H32N2O.HI/c1-18(2)25(5,19(3)4)17-16-23(22(24)26,20-12-8-6-9-13-20)21-14-10-7-11-15-21;/h6-15,18-19H,16-17H2,1-5H3,(H-,24,26);1H DMQYV60 CS CC(C)[N+](C)(CCC(C1=CC=CC=C1)(C2=CC=CC=C2)C(=O)N)C(C)C.[I-] DMQYV60 IK BFSMWENDZZIWPW-UHFFFAOYSA-N DMQYV60 IU (4-amino-4-oxo-3,3-diphenylbutyl)-methyl-di(propan-2-yl)azanium;iodide DMQYV60 CA CAS 71-81-8 DMQYV60 CB CHEBI:6044 DMQYV60 DE Allergic rhinitis DMK7MEY ID DMK7MEY DMK7MEY DN Isoproterenol DMK7MEY HS Approved DMK7MEY SN isoproterenol; Isoprenaline; Isoprenalin; Norisodrine; Novodrin; Isopropydrin; Isopropylarterenol; Respifral; Assiprenol; Asiprenol; Bellasthman; Asmalar; Aludrine; Aludrin; N-Isopropylnoradrenaline; Bronkephrine; Neodrenal; Lomupren; Isonorene; Isopropyladrenaline; 7683-59-2; N-Isopropylnorepinephrine; Isopropylnorepinephrine; neo-Epinine; Isadrine; Saventrine; Isorenin; Isonorin; Proternol; Isopropylnoradrenaline; Isopropyl noradrenaline; Racemic isoprenaline; dl-Isadrine; Racemic isoproterenol; (+-)-Isoproterenol; Vapo-N-iso; Aerolone; Aleudrine; Dihydroxyphenylethanolisopropylamine; Euspiran; ISOPROP; Isadrin; Isoproterenolum; Isuprel; Isupren; Izadrin; Epinephrine isopropyl homolog; Isoprenaline hydrochloride; Isoproterenol Chloride; Isoproterenol [JAN]; Isuprel Mistometer; WIN 5162; D-Isoprenaline; D-Isopropylarterenol; D-Isoproterenol; DL-Isopropylnorepinephrine; Dl-Ipr; Dl-Isadrine; Dl-Isopropylnoradrenaline; Isoprenalina [INN-Spanish]; Isoprenaline (INN); Isoprenalinum [INN-Latin]; Isuprel (TN); L-Isopropylnoradrenaline; L-Isoproterenol; Medihaler-ISO; Neo-Epinine; Vapo-Iso; Alpha-(Isopropylaminomethyl)protocatechuyl alcohol; Alpha-(Isopropylaminomoethyl)protocatechuyl alcohol; D-N-Isopropylnorepinephrine; Dl-N-Isopropylnoradrenaline; Isopropylaminomethyl(3,4-dihydroxyphenyl)carbinol; Isopropylaminomethyl-3,4-dihydroxyphenyl carbinol; DL(+-)-Isoproterenol; N-Isopropyl-beta-dihydroxyphenyl-beta-hydroxyethylamine; (+)-Isoprenaline; (+)-Isoproterenol; (+-)-Isoprenaline; (-)-Isoproterenol hydrochloride; (S)-(+)-Isoproterenol; (S)-Isoprenaline; (S)-Isoproterenol; 1,2-Benzenediol, 4-(1-hydroxy-2-((1-methylethyl)amino)ethyl)-(9CI); 1,2-Benzenediol, 4-(1-hydroxy-2-((1-methylethyl)amino)ethyl)-, (S)-(9CI); 1-(3,4-Dihydroxyphenyl)-2-(isopropylamino)ethanol; 1-(3,4-Dihydroxyphenyl)-2-isopropylaminoethanol; 3,4-Dihydroxy-alpha-(isopropylaminomethyl)-benzyl alcohol; 3,4-Dihydroxy-alpha-[(isopropylamino)methyl]benzyl alcohol; 3,4-Dihydroxy-alpha-((isopropylamino)methyl)benzyl alcohol; 4-(1-Hydroxy-2(isopropylamino)ethyl)-benzene 1,2-diol; 4-(1-Hydroxy-2-((1-methylethyl)amino)ethyl)-1,2-benzenediol; 4-{1-hydroxy-2-[(1-methylethyl)amino]ethyl}benzene-1,2-diol; AS1409 DMK7MEY CP Abbott Laboratories DMK7MEY TC Cardiotonic Agents DMK7MEY DT Small molecular drug DMK7MEY PC 3779 DMK7MEY MW 211.26 DMK7MEY FM C11H17NO3 DMK7MEY IC InChI=1S/C11H17NO3/c1-7(2)12-6-11(15)8-3-4-9(13)10(14)5-8/h3-5,7,11-15H,6H2,1-2H3 DMK7MEY CS CC(C)NCC(C1=CC(=C(C=C1)O)O)O DMK7MEY IK JWZZKOKVBUJMES-UHFFFAOYSA-N DMK7MEY IU 4-[1-hydroxy-2-(propan-2-ylamino)ethyl]benzene-1,2-diol DMK7MEY CA CAS 7683-59-2 DMK7MEY CB CHEBI:64317 DMK7MEY DE Heart block; Melanoma DMBI4JG ID DMBI4JG DMBI4JG DN Isosorbide dinitrate DMBI4JG HS Approved DMBI4JG SN Angidil; Astridine; BiDil; Cardis; Carvanil; Carvasin; Cedocard; Claodical; Cornilat; Coronex; Corosorbide; Corovliss; Difutrat; Dignionitrat; Dilatrate; Diniket; Dinitroisosorbide; Dinitrosorbide; Disorlon; Emoper; EureCor; Flindix; Frandol; Harrical; ISD; ISDN; IsoBid; Isochron; Isodinit; Isoket; Isorbid; Isordil; Isostat; Isotrate; Korodil; Langoran; Laserdil; Lomilan; Maycor; Myorexon; Nitrosorbid; Nitrosorbide; Nitrosorbon; Nosim; Resoidan; Rigedal; Sorbangil; Sorbide; Sorbidilat; Sorbidinitrate; Sorbidnitrate; Sorbislo; Sorbitrate; Sorbonit; Sorquad; Sorquat; Tinidil; Titradose; Vascardin; Vasodilat; Vasorbate; Xanyl; Cedocard Retard; Dilatrate SR; Dinitrato de isosorbida; Iso Bid; Isomak R; Isordil Tembids; Isosorbide dinitrato; Isosorbide dinitrato [DCIT]; Isosorbidi dinitras; Isosorbidi nitras; Rifloc Retard; Sorbide nitrate; Sorbidi nitras; Cardio 10; Cardonit 40; IBD 20; Isoket Retard 120; Isoket Retard120; Isoket retard 40; TYB 3215; Cedocard (TN); D-Isosorbide dinitrate; Dilatrate-SR; Dinitrate d'isosorbide; Dinitrate, Isosorbide; Dinitrato de isosorbida [INN-Spanish]; Iso-Bid; Iso-Mack; Iso-Puren; Isoket Retard-120; Isordil (TN); Isosorbidi dinitras [INN-Latin]; SDM No. 40; SDM No. 50; SST-101; Sorate-10; Sorate-5; Sorbide, dinitrate; Sorbitrate (TN); D-Isosorbide dinitrate-Lactose mixture; Dianhydrosorbitol 2,5-dinitrate; Dilatrate-sr (TN); Dinitrate d'isosorbide [INN-French]; Isosorbide 2,5-dinitrate; Sorbide T.D.; Glucitol, 1,4:3; Isosorbide dinitrate (JP15/USP/INN); Isosorbide dinitrate [USAN:INN:BAN:JAN]; Isosorbide dinitrate mixture with not <60% lactose, mannose, starch or calcium hydrogen phosphate [UN2907] [Flammable solid]; D-Glucitol, 1,4:3,6-dianhydro-, dinitrate; D-Glucitol, 1,4:3,6-dianhydro-, 2,5-dinitrate; [(3S,3aS,6R,6aS)-3-nitrooxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl] nitrate; 1,4:3, 6-Dianhydro-D-glucitol dinitrate; 1,4:3,6-Dianhydro-D-glucitol dinitrate; 1,4:3,6-Dianhydrosorbitol 2, 5-dinitrate; 1,4:3,6-Dianhydrosorbitol 2,5-dinitrate; 1,4:3,6-dianhydro-2,5-di-O-nitro-D-glucitol DMBI4JG CP Biovail Corporation DMBI4JG TC Vasodilator Agents DMBI4JG DT Small molecular drug DMBI4JG PC 6883 DMBI4JG MW 236.14 DMBI4JG FM C6H8N2O8 DMBI4JG IC InChI=1S/C6H8N2O8/c9-7(10)15-3-1-13-6-4(16-8(11)12)2-14-5(3)6/h3-6H,1-2H2/t3-,4+,5-,6-/m1/s1 DMBI4JG CS C1[C@H]([C@@H]2[C@H](O1)[C@H](CO2)O[N+](=O)[O-])O[N+](=O)[O-] DMBI4JG IK MOYKHGMNXAOIAT-JGWLITMVSA-N DMBI4JG IU [(3S,3aS,6R,6aS)-3-nitrooxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl] nitrate DMBI4JG CA CAS 87-33-2 DMBI4JG CB CHEBI:6061 DMBI4JG DE Anal fissure; Angina pectoris DMYLMU0 ID DMYLMU0 DMYLMU0 DN Isosorbide mononitrate DMYLMU0 HS Approved DMYLMU0 SN Conpin; Corangin; Duride; Edistol; Elantan; Epicordin; Etimonis; IHD; ISMN; ISMO; Imazin; Imdur; Imodur; Imtrate; Ismexin; Ismox; Isomon; Isomonat; Isomonit; Iturol; Medocor; Monicor; Monis; Monisid; Monit; Monizid; MonoSigma; Monocedocard; Monocinque; Monoclair; Monocord; Monoket; Monolong; Monomax; Mononit; Monopront; Monosorb; Monosorbitrate; Monosordil; Monotrate; Multitab; Nitex; Nitramin; Olicard; Olicardin; Orasorbil; Percorina; Pertil; Plodin; Promocard; Sigacora; Sorbimon; Titarane; Turimonit; Uniket; Vasdilat; Vasotrate; Conpin Retardkaps; Corangin SR; Elantan Long; Elantan Retard; ISMN AL; ISMN AbZ; ISMN Apogepha; ISMN Atid; ISMN Basics; ISMN Heumann; ISMN Hexal; ISMN Lannacher; ISMN Stada; Imdur Durules; Isosorbidi mononitras; Isosorbidi mononitras [Latin]; Mono Corax; Mono Corax Retard; Mono Mack; Monodur Durules; Monoket OD; Monoket Retard; Mononitrato de isosorbida; Mononitrato de isosorbida [Spanish]; AHR 4698; IS 5MN; Imdur 60; Monit 20; Mono Mac 50D; Monocord 20; Monocord 40; Monocord 50 SR; Monolong 40; Monolong 60; Mononit 20; Mononit 40; Mononit Retard 50; Monosorb XL 60;Olicard 40; Pentacard 20; AHR-4698; BM 22-145; BM 22.145; Chemydur (TN); Fem-Mono; IS 5-MN; Imdur (TN); Ismo (TN); Ismo-20; Isopen-20; Isosorbide 5-mononitrate; Isosorbide 5-nitrate; Mono-Mack; Mono-Sanorania; Mononitrate d'isosorbide; Mononitrate d'isosorbide [French]; Olicard-retard; BM-22-145; Isosobide-5-mononitrate [UN3251] [Flammable solid]; Isosorbide-5-mononitrate; Isosorbide-5-nitrate; Isosorbide mononitrate (JAN/USP/INN); Isosorbide mononitrate [USAN:BAN:INN:JAN]; Isosorbide mononitrate [USAN:INN:BAN:JAN]; D-Glucitol, 1,4:3,6-dianhydro-, 5-nitrate; [(3S,3aR,6R,6aS)-3-hydroxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl] nitrate; 1,4:3,6-Dianhydro-D-glucitol 5-nitrate; 1,4:3,6-dianhydro-5-O-nitro-D-glucitol; 5-ISMN Durules; 5-Ismn DMYLMU0 CP AstraZeneca DMYLMU0 TC Vasodilator Agents DMYLMU0 DT Small molecular drug DMYLMU0 PC 27661 DMYLMU0 MW 191.14 DMYLMU0 FM C6H9NO6 DMYLMU0 IC InChI=1S/C6H9NO6/c8-3-1-11-6-4(13-7(9)10)2-12-5(3)6/h3-6,8H,1-2H2/t3-,4+,5+,6+/m0/s1 DMYLMU0 CS C1[C@@H]([C@@H]2[C@H](O1)[C@@H](CO2)O[N+](=O)[O-])O DMYLMU0 IK YWXYYJSYQOXTPL-SLPGGIOYSA-N DMYLMU0 IU [(3S,3aR,6R,6aS)-3-hydroxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl] nitrate DMYLMU0 CA CAS 16051-77-7 DMYLMU0 CB CHEBI:6062 DMYLMU0 DE Hydrocephalus DM4QTBN ID DM4QTBN DM4QTBN DN Isotretinoin DM4QTBN HS Approved DM4QTBN SN Accutane; Amnesteem; Claravis; Isotane; Isotretinoine; Isotretinoino; Isotretinoinum; Isotrex; Roaccutan; Roaccutane; Roacutan; Sotret; Teriosal; Neovitamin A acid; R 3255; Ro 4 3780; Ro 43780; Accutane (TN); Amnesteem (TN); BML2-E07; CIP-Isotretinoin; Claravi (TN); Clarus (TN); Decutan (TN); Isotane (TN); Isotretinoin (USP); Isotretinoin Zinc Salt, 13 cis Isomer; Isotretinoine [INN-French]; Isotretinoino [INN-Spanish]; Isotretinoinum [INN-Latin]; Izotek (TN); Oratane (TN); Ro 4-3780; Ro-43780; Roaccutane (TN); Sotret (TN); Isotretinoin [USAN:INN:BAN]; Ro-4-3780; Isotretinoin Zinc Salt, 13-cis-Isomer; (2Z,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenoic acid; (2Z,4E6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenoic acid; (7E,9E,11E,13Z)-retinoic acid; 13-RA; 13-cis RA; 13-cis-Vitamin A acid; 3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)2-cis-4-trans-6-trans-8-trans-nonatetraenoic acid DM4QTBN CP Roche Pharmaceuticals DM4QTBN TC Antiacne Agents DM4QTBN DT Small molecular drug DM4QTBN PC 5282379 DM4QTBN MW 300.4 DM4QTBN FM C20H28O2 DM4QTBN IC InChI=1S/C20H28O2/c1-15(8-6-9-16(2)14-19(21)22)11-12-18-17(3)10-7-13-20(18,4)5/h6,8-9,11-12,14H,7,10,13H2,1-5H3,(H,21,22)/b9-6+,12-11+,15-8+,16-14- DM4QTBN CS CC1=C(C(CCC1)(C)C)/C=C/C(=C/C=C/C(=C\\C(=O)O)/C)/C DM4QTBN IK SHGAZHPCJJPHSC-XFYACQKRSA-N DM4QTBN IU (2Z,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenoic acid DM4QTBN CA CAS 4759-48-2 DM4QTBN CB CHEBI:6067 DM4QTBN DE Acne vulgaris DMX7LKS ID DMX7LKS DMX7LKS DN Isovanillin DMX7LKS HS Approved DMX7LKS SN Isovanilin; Isovanilline; Iso-Vanillin; Oxy-3 methoxy-4 benzaldehyde; Oxy-3 methoxy-4 benzaldehyde [French]; P-Anisaldehyde, 3-hydroxy-(8CI); 3-Hydroxy-4-methoxybenzaldehyde; 3-Hydroxy-p-anisaldehyde; 3-Hydroxyanisaldehyde; 3-hydroxy-4-anisaldehyde; 4-Methoxy-3-hydroxybenzaldehyde; 5-Formylguaiacol DMX7LKS TC Anticancer Agents DMX7LKS DT Small molecular drug DMX7LKS PC 12127 DMX7LKS MW 152.15 DMX7LKS FM C8H8O3 DMX7LKS IC InChI=1S/C8H8O3/c1-11-8-3-2-6(5-9)4-7(8)10/h2-5,10H,1H3 DMX7LKS CS COC1=C(C=C(C=C1)C=O)O DMX7LKS IK JVTZFYYHCGSXJV-UHFFFAOYSA-N DMX7LKS IU 3-hydroxy-4-methoxybenzaldehyde DMX7LKS CA CAS 621-59-0 DMX7LKS DE Solid tumour/cancer DMJL10P ID DMJL10P DMJL10P DN Isoxyl DMJL10P HS Approved DMJL10P SN Tiocarlide; Thiocarlide; Tiocarlid; 910-86-1; Disocarban; Datanil; Tiocarlidum [INN-Latin]; Tiocarlida [INN-Spanish]; 4,4'-Diisoamyloxythiocarbanilide; 4,4'-Bis(isopentyloxy)thiocarbanilide; Tiocarlide [INN:BAN:DCF]; UNII-43M23X81Y2; C23H32N2O2S; N,N'-Bis(4-(3-methylbutoxy)phenyl)thiourea; EINECS 213-006-5; CARBANILIDE, 4,4'-BIS(ISOPENTYLOXY)THIO-; BRN 2546347; Thiourea, N,N'-bis[4-(3-methylbutoxy)phenyl]-; Thiourea, N,N'-bis(4-(3-methylbutoxy)phenyl)-; NSC742400; 43M23X81Y2; Amixyl; Disoxyl; Tiocarlida; Tiocarlidum; BRN2546347; Tiocarlide (INN); Tiocarlide [INN:DCF]; Thiourea, N,N'-bis(4-(3-methylbutoxy)phenyl)-(9CI) DMJL10P DT Small molecular drug DMJL10P PC 3001386 DMJL10P MW 400.6 DMJL10P FM C23H32N2O2S DMJL10P IC InChI=1S/C23H32N2O2S/c1-17(2)13-15-26-21-9-5-19(6-10-21)24-23(28)25-20-7-11-22(12-8-20)27-16-14-18(3)4/h5-12,17-18H,13-16H2,1-4H3,(H2,24,25,28) DMJL10P CS CC(C)CCOC1=CC=C(C=C1)NC(=S)NC2=CC=C(C=C2)OCCC(C)C DMJL10P IK BWBONKHPVHMQHE-UHFFFAOYSA-N DMJL10P IU 1,3-bis[4-(3-methylbutoxy)phenyl]thiourea DMJL10P CA CAS 910-86-1 DMJL10P CB CHEBI:135637 DMJL10P DE Bacterial infection DMWCRN1 ID DMWCRN1 DMWCRN1 DN Ispaghula DMWCRN1 HS Approved DMWCRN1 SN Fiberall; Metamucil; PSYLLIUM; Plantaglucide; Psyllium Husk [USP]; Psyllium gum; Psyllium seed gum; Psyllium seed husk DMWCRN1 CP Reckitt; Colman DMWCRN1 DE Irritable bowel syndrome DMA5XGH ID DMA5XGH DMA5XGH DN Isradipine DMA5XGH HS Approved DMA5XGH SN Clivoten; DynaCirc; DynaCire; Dynacrine; Esradin; Icaz; Isradipin; Isradipino; Isradipinum; Isrodipine; Lomir; Prescal; Rebriden; DynaCire CR; Dynacirc CR; Isradipino [Spanish]; Isradipinum [Latin]; PN 205 033; PN 205 034; PN 205033; PN 205034; PN205033; PN205034; DynaCirc (TN); PN 200-110; PN 205-033; PN 205-034; PN-200110; Prescal (TN); Isradipine (USP/INN); Isradipine [USAN:INN:BAN]; PN-200-110; PN-205-033; PN-205-034; Isradipine, (R)-Isomer; Isradipine, (S)-Isomer; Isradipine, (+-)-Isomer; DynaCirc, Prescal, PN-200-110, Clivoten, Esradin, Isradipine; Isopropyl methyl (+-)-4-(4-benzofurazanyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate; Isopropyl 4-(2,1,3-benzoxadiazol-4-yl)-1,4-dihydro-5-methoxycarbonyl-2,6-dimethyl-3-pyridinecarboxylate; Methyl 1-methylethyl 4-(2,1,3-benzoxadiazol-4-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate; O5-methyl O3-propan-2-yl 4-(2,1,3-benzoxadiazol-7-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate; (+-)-Isradipine; (+/-)-Isradipine; 2,1,3-Benzoxadiazole, 3,5-pyridinedicarboxylic acid deriv.; 3,5-Pyridinedicarboxylic acid, 4-(2,1,3-benzoxadiazol-4-yl)-1,4-dihydro-2,6-dimethyl-, 3-methyl 5-(1-methylethyl) ester; 3,5-Pyridinedicarboxylic acid, 4-(2,1,3-benzoxadiazol-4-yl)-1,4-dihydro-2,6-dimethyl-, methyl 1-methylethyl ester; 3,5-Pyridinedicarboxylic acid, 4-(2,1,3-benzoxadiazol-4-yl)-1,4-dihydro-2,6-dimethyl-, methyl 1-methylethyl ester (9CI); 3,5-Pyridinedicarboxylic acid, 4-(4-benzofurazanyl)-1,4-dihydro-2,6-dimethyl-, methyl 1-methylethyl ester; 3-O-methyl 5-O-propan-2-yl 4-(2,1,3-benzoxadiazol-4-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate; 4-(2,1,3-Benzooxadiazol-4-yl)-2.6-dimethyl-1,4-dihydro-3-isopropyloxycarbonylpyridine-5-carboxylic Acid Methyl Ester; 4-(4-Benzofurazanyl)-1,-4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid methyl 1-methhylethyl ester; 4-(4-Benzofurazanyl)-1,-4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid methyl 1-methylethyl ester; 4-(4-Benzofurazanyl)-1,4-dihydro-2,-6-dimethyl-3,5-pyridinedicarboxylic acid methyl 1-methylethyl ester DMA5XGH CP Norvatis Phamaceuticals Corporation DMA5XGH TC Antihypertensive Agents DMA5XGH DT Small molecular drug DMA5XGH PC 3784 DMA5XGH MW 371.4 DMA5XGH FM C19H21N3O5 DMA5XGH IC InChI=1S/C19H21N3O5/c1-9(2)26-19(24)15-11(4)20-10(3)14(18(23)25-5)16(15)12-7-6-8-13-17(12)22-27-21-13/h6-9,16,20H,1-5H3 DMA5XGH CS CC1=C(C(C(=C(N1)C)C(=O)OC(C)C)C2=CC=CC3=NON=C32)C(=O)OC DMA5XGH IK HMJIYCCIJYRONP-UHFFFAOYSA-N DMA5XGH IU 3-O-methyl 5-O-propan-2-yl 4-(2,1,3-benzoxadiazol-4-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate DMA5XGH CA CAS 75695-93-1 DMA5XGH CB CHEBI:6073 DMA5XGH DE Hypertension; Herpes simplex virus infection DM20VSK ID DM20VSK DM20VSK DN Istradefylline DM20VSK HS Approved DM20VSK SN KW 6002; Istradefylline [USAN:INN]; Istradefylline (JAN/USAN/INN); (E)-8-(3,4-Dimethoxystyryl)-1,3-diethyl-7-methyl-3,7-dihydro-1H-purine-2,6-dione; (E)-8-(3,4-Dimethoxystyryl)-1,3-diethyl-7-methylxanthine; 8-((1E)-2-(3,4-Dimethoxyphenyl)ethenyl)-1,3-diethyl-7-methyl-3,7-dihydro-1H-purine-2,6-dione; 8-(2-(3,4-dimethoxyphenyl)ethenyl)-1,3-diethyl-3,7-dihydro-7-methyl-1H-purine-2,6-dione; 8-[(E)-2-(3,4-dimethoxyphenyl)ethenyl]-1,3-diethyl-7-methylpurine-2,6-dione DM20VSK CP Kyowa Hakko Pharmaceuticals DM20VSK DT Small molecular drug DM20VSK PC 5311037 DM20VSK MW 384.4 DM20VSK FM C20H24N4O4 DM20VSK IC InChI=1S/C20H24N4O4/c1-6-23-18-17(19(25)24(7-2)20(23)26)22(3)16(21-18)11-9-13-8-10-14(27-4)15(12-13)28-5/h8-12H,6-7H2,1-5H3/b11-9+ DM20VSK CS CCN1C2=C(C(=O)N(C1=O)CC)N(C(=N2)/C=C/C3=CC(=C(C=C3)OC)OC)C DM20VSK IK IQVRBWUUXZMOPW-PKNBQFBNSA-N DM20VSK IU 8-[(E)-2-(3,4-dimethoxyphenyl)ethenyl]-1,3-diethyl-7-methylpurine-2,6-dione DM20VSK CA CAS 155270-99-8 DM20VSK CB CHEBI:134726 DM20VSK DE Substance use disorder; Parkinson disease DMCR1MV ID DMCR1MV DMCR1MV DN Itraconazole DMCR1MV HS Approved DMCR1MV SN Canadiol; Hyphanox; ITCZ; ITZ; Intraconazole; Itraconazol; Itraconazolum; Itrizole; Oriconazole; Orungal; Prokanazol; Sempera; Spherazole; Sporal; Sporanos; Sporanox; Sporonox; Triasporn; Itraconazol [Spanish]; Itraconazole oral solution; Itraconazolum [Latin]; R 51211; Cis-Itraconazole; Itraconazole & Bovine Lactoferrin; Itraconazole & Nyotran; Itrizole (TN); R-51211; Sporanox (TN); Itraconazole & Nyotran(Liposomal Nystatin); Itraconazole (JAN/USAN); Oriconazole, R51211, Sporanox; Itraconazole [USAN:BAN:INN:JAN]; (+-)-1-sec-Butyl-4-(p-(4-(p-(((2R*,4S*)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl)methoxy)phenyl)-1-piperazinyl)phenyl)-delta(sup 2)-1,2,4-triazolin-5-one; (1)-cis-4-(4-(4-(4-((2-(2,4-Dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl)methoxy)phenyl)piperazin-1-yl)phenyl)-2,4-dihydro-2-sec-butyl-3H-1,2,4-triazol-3-one; 2-(butan-2-yl)-4-{4-[4-(4-{[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazin-1-yl]phenyl}-2,4-dihydro-3H-1,2,4-triazol-3-one; 2-butan-2-yl-4-[4-[4-[4-[[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one; 2-butan-2-yl-4-[4-[4-[4-[[(2S,4R)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one; 2-butan-2-yl-4-[4-[4-[4-[[2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one; 3H-1,2,4-Triazol-3-one, 4-[4-[4-[4-[[2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-1-pipera-zinyl]phenyl]-2,4-dihydro-2-(1-methylpropyl); 4-(4-{4-[4-({[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methyl}oxy)phenyl]piperazin-1-yl}phenyl)-2-(1-methylpropyl)-2,4-dihydro-3H-1,2,4-triazol-3-one DMCR1MV CP Janssen Pharmaceutica DMCR1MV TC Antifungal Agents DMCR1MV DT Small molecular drug DMCR1MV PC 55283 DMCR1MV MW 705.6 DMCR1MV FM C35H38Cl2N8O4 DMCR1MV IC InChI=1S/C35H38Cl2N8O4/c1-3-25(2)45-34(46)44(24-40-45)29-7-5-27(6-8-29)41-14-16-42(17-15-41)28-9-11-30(12-10-28)47-19-31-20-48-35(49-31,21-43-23-38-22-39-43)32-13-4-26(36)18-33(32)37/h4-13,18,22-25,31H,3,14-17,19-21H2,1-2H3/t25?,31-,35-/m0/s1 DMCR1MV CS CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl DMCR1MV IK VHVPQPYKVGDNFY-ZPGVKDDISA-N DMCR1MV IU 2-butan-2-yl-4-[4-[4-[4-[[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one DMCR1MV CA CAS 84625-61-6 DMCR1MV CB CHEBI:6076 DMCR1MV DE Fungal infection DM0L594 ID DM0L594 DM0L594 DN Ivabradine DM0L594 HS Approved DM0L594 SN Ivabradine; 155974-00-8; Procoralan; Corlanor; Corlentor; UNII-3H48L0LPZQ; S 16257; S-16257; S-16257-2; S 16257-2; 3H48L0LPZQ; CHEMBL471737; CHEBI:85966; C27H36N2O5; 7,8-Dimethoxy-3-(3-(((4,5-dimethoxybenzocyclobutan-1-yl)methyl)methylamino)propyl)-1,3,4,5-tetrahydro-2H-benzazepin-2-one; S-16260-2; s16257; (S)-3-(3-(((3,4-Dimethoxybicyclo(4.2.0)octa-1,3,5-trien-7-yl)methyl)methylamino)propyl)-1,3,4,5-tetrahydro-7,8-dimethoxy-2H-3-benzazepin-2-one; Ivabradine [INN] DM0L594 CP Servier DM0L594 DT Small molecular drug DM0L594 PC 132999 DM0L594 MW 468.6 DM0L594 FM C27H36N2O5 DM0L594 IC InChI=1S/C27H36N2O5/c1-28(17-21-11-20-14-25(33-4)26(34-5)16-22(20)21)8-6-9-29-10-7-18-12-23(31-2)24(32-3)13-19(18)15-27(29)30/h12-14,16,21H,6-11,15,17H2,1-5H3/t21-/m1/s1 DM0L594 CS CN(CCCN1CCC2=CC(=C(C=C2CC1=O)OC)OC)C[C@H]3CC4=CC(=C(C=C34)OC)OC DM0L594 IK ACRHBAYQBXXRTO-OAQYLSRUSA-N DM0L594 IU 3-[3-[[(7S)-3,4-dimethoxy-7-bicyclo[4.2.0]octa-1,3,5-trienyl]methyl-methylamino]propyl]-7,8-dimethoxy-2,5-dihydro-1H-3-benzazepin-4-one DM0L594 CA CAS 155974-00-8 DM0L594 CB CHEBI:85966 DM0L594 DE Angina pectoris DMZC1HS ID DMZC1HS DMZC1HS DN Ivacaftor DMZC1HS HS Approved DMZC1HS SN Kalydeco (TN) DMZC1HS CP Vertex DMZC1HS DT Small molecular drug DMZC1HS PC 16220172 DMZC1HS MW 392.5 DMZC1HS FM C24H28N2O3 DMZC1HS IC InChI=1S/C24H28N2O3/c1-23(2,3)16-11-17(24(4,5)6)20(27)12-19(16)26-22(29)15-13-25-18-10-8-7-9-14(18)21(15)28/h7-13,27H,1-6H3,(H,25,28)(H,26,29) DMZC1HS CS CC(C)(C)C1=CC(=C(C=C1NC(=O)C2=CNC3=CC=CC=C3C2=O)O)C(C)(C)C DMZC1HS IK PURKAOJPTOLRMP-UHFFFAOYSA-N DMZC1HS IU N-(2,4-ditert-butyl-5-hydroxyphenyl)-4-oxo-1H-quinoline-3-carboxamide DMZC1HS CA CAS 873054-44-5 DMZC1HS CB CHEBI:66901 DMZC1HS DE Cystic fibrosis DMDBX5F ID DMDBX5F DMDBX5F DN Ivermectin DMDBX5F HS Approved DMDBX5F SN I 8898; Ivexterm (TN); MK-933; Mectizan (TN); Stromectol (TN) DMDBX5F CP Merck & Co DMDBX5F TC Antiprotozoal Agents DMDBX5F DT Small molecular drug DMDBX5F PC 6321424 DMDBX5F MW 875.1 DMDBX5F FM C48H74O14 DMDBX5F IC InChI=1S/C48H74O14/c1-11-25(2)43-28(5)17-18-47(62-43)23-34-20-33(61-47)16-15-27(4)42(26(3)13-12-14-32-24-55-45-40(49)29(6)19-35(46(51)58-34)48(32,45)52)59-39-22-37(54-10)44(31(8)57-39)60-38-21-36(53-9)41(50)30(7)56-38/h12-15,19,25-26,28,30-31,33-45,49-50,52H,11,16-18,20-24H2,1-10H3/b13-12+,27-15+,32-14+/t25-,26-,28-,30-,31-,33+,34-,35-,36-,37-,38-,39-,40+,41-,42-,43+,44-,45+,47+,48+/m0/s1 DMDBX5F CS CC[C@H](C)[C@@H]1[C@H](CC[C@@]2(O1)C[C@@H]3C[C@H](O2)C/C=C(/[C@H]([C@H](/C=C/C=C/4\\CO[C@H]5[C@@]4([C@@H](C=C([C@H]5O)C)C(=O)O3)O)C)O[C@H]6C[C@@H]([C@H]([C@@H](O6)C)O[C@H]7C[C@@H]([C@H]([C@@H](O7)C)O)OC)OC)\\C)C DMDBX5F IK AZSNMRSAGSSBNP-XPNPUAGNSA-N DMDBX5F IU (1R,4S,5'S,6R,6'R,8R,10E,12S,13S,14E,16E,20R,21R,24S)-6'-[(2S)-butan-2-yl]-21,24-dihydroxy-12-[(2R,4S,5S,6S)-5-[(2S,4S,5S,6S)-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy-4-methoxy-6-methyloxan-2-yl]oxy-5',11,13,22-tetramethylspiro[3,7,19-trioxatetracyclo[15.6.1.14,8.020,24]pentacosa-10,14,16,22-tetraene-6,2'-oxane]-2-one DMDBX5F CA CAS 71827-03-7 DMDBX5F CB CHEBI:63941 DMDBX5F DE Intestinal strongyloidiasis due to nematode parasite DM8S6T7 ID DM8S6T7 DM8S6T7 DN Ivosidenib DM8S6T7 HS Approved DM8S6T7 SN UNII-Q2PCN8MAM6; Q2PCN8MAM6; Ivosidenib [INN]; Ivosidenib [USAN]; Ivosidenib [WHO-DD]; GTPL9217; SCHEMBL15122512; EX-A992; MolPort-044-560-317; RG120; s8206; 1448347-49-6 (Ivosidenib); AKOS028113340; ZINC205136523; CS-5122; AS-35058; HY-18767 DM8S6T7 CP Agios Pharmaceuticals DM8S6T7 PC 71657455 DM8S6T7 MW 583 DM8S6T7 FM C28H22ClF3N6O3 DM8S6T7 IC InChI=1S/C28H22ClF3N6O3/c29-21-4-2-1-3-20(21)25(26(40)36-18-11-28(31,32)12-18)37(19-10-17(30)14-34-15-19)27(41)22-5-6-24(39)38(22)23-9-16(13-33)7-8-35-23/h1-4,7-10,14-15,18,22,25H,5-6,11-12H2,(H,36,40)/t22-,25-/m0/s1 DM8S6T7 CS C1CC(=O)N([C@@H]1C(=O)N(C2=CC(=CN=C2)F)[C@@H](C3=CC=CC=C3Cl)C(=O)NC4CC(C4)(F)F)C5=NC=CC(=C5)C#N DM8S6T7 IK WIJZXSAJMHAVGX-DHLKQENFSA-N DM8S6T7 IU (2S)-N-[(1S)-1-(2-chlorophenyl)-2-[(3,3-difluorocyclobutyl)amino]-2-oxoethyl]-1-(4-cyanopyridin-2-yl)-N-(5-fluoropyridin-3-yl)-5-oxopyrrolidine-2-carboxamide DM8S6T7 CA CAS 1448347-49-6 DM8S6T7 CB CHEBI:145430 DM8S6T7 DE Haematological malignancy; Acute myeloid leukaemia; Cholangiocarcinoma DMRVITQ ID DMRVITQ DMRVITQ DN Ivosidenib DMRVITQ HS Approved DMRVITQ SN (2S)-N-[(1S)-1-(2-chlorophenyl)-2-[(3,3-difluorocyclobutyl)amino]-2-oxoethyl]-1-(4-cyanopyridin-2-yl)-N-(5-fluoropyridin-3-yl)-5-oxopyrrolidine-2-carboxamide; Ivosidenib; Ivosidenib (USAN/INN); Ivosidenib [INN]; Ivosidenib [USAN]; Ivosidenib [WHO-DD]; Tibsovo DMRVITQ TC Anticancer Agents DMRVITQ DT Small molecular drug DMRVITQ PC 71657455 DMRVITQ MW 582.968 DMRVITQ FM C28H22ClF3N6O3 DMRVITQ IC InChI=1S/C28H22ClF3N6O3/c29-21-4-2-1-3-20(21)25(26(40)36-18-11-28(31,32)12-18)37(19-10-17(30)14-34-15-19)27(41)22-5-6-24(39)38(22)23-9-16(13-33)7-8-35-23/h1-4,7-10,14-15,18,22,25H,5-6,11-12H2,(H,36,40)/t22-,25-/m0/s1 DMRVITQ CS C1CC(=O)N(C1C(=O)N(C2=CC(=CN=C2)F)C(C3=CC=CC=C3Cl)C(=O)NC4CC(C4)(F)F)C5=NC=CC(=C5)C#N DMRVITQ IK WIJZXSAJMHAVGX-DHLKQENFSA-N DMRVITQ IU (2S)-N-[(1S)-1-(2-chlorophenyl)-2-[(3,3-difluorocyclobutyl)amino]-2-oxoethyl]-1-(4-cyanopyridin-2-yl)-N-(5-fluoropyridin-3-yl)-5-oxopyrrolidine-2-carboxamide DMRVITQ CA CAS 1448347-49-6 DMRVITQ DE Acute myeloid leukemia; Cholangiocarcinoma DM2OZ3G ID DM2OZ3G DM2OZ3G DN Ixabepilone DM2OZ3G HS Approved DM2OZ3G SN Azaepothilone B; BMS-247550; Ixempra (TN) DM2OZ3G CP Bristol-Myers Squibb DM2OZ3G DT Small molecular drug DM2OZ3G PC 6445540 DM2OZ3G MW 506.7 DM2OZ3G FM C27H42N2O5S DM2OZ3G IC InChI=1S/C27H42N2O5S/c1-15-9-8-10-27(7)22(34-27)12-20(16(2)11-19-14-35-18(4)28-19)29-23(31)13-21(30)26(5,6)25(33)17(3)24(15)32/h11,14-15,17,20-22,24,30,32H,8-10,12-13H2,1-7H3,(H,29,31)/b16-11+/t15-,17+,20-,21-,22-,24-,27+/m0/s1 DM2OZ3G CS C[C@H]1CCC[C@@]2([C@@H](O2)C[C@H](NC(=O)C[C@@H](C(C(=O)[C@@H]([C@H]1O)C)(C)C)O)/C(=C/C3=CSC(=N3)C)/C)C DM2OZ3G IK FABUFPQFXZVHFB-PVYNADRNSA-N DM2OZ3G IU (1S,3S,7S,10R,11S,12S,16R)-7,11-dihydroxy-8,8,10,12,16-pentamethyl-3-[(E)-1-(2-methyl-1,3-thiazol-4-yl)prop-1-en-2-yl]-17-oxa-4-azabicyclo[14.1.0]heptadecane-5,9-dione DM2OZ3G CA CAS 219989-84-1 DM2OZ3G CB CHEBI:63605 DM2OZ3G DE Breast cancer DMXW92T ID DMXW92T DMXW92T DN Ixekizumab DMXW92T HS Approved DMXW92T SN LY2439821 DMXW92T CP Eli Lilly DMXW92T DT Monoclonal antibody DMXW92T SQ Heavy Chain Sequence: QVQLVQSGAEVKKPGSSVKVSCKASGYSFTDYHIHWVRQAPGQGLEWMGVINPMYGTTDYNQRFKGRVTITADESTSTAYMELSSLRSEDTAVYYCARYDYFTGTGVYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLG >Light Chain SequenceDIVMTQTPLSLSVTPGQPASISCRSSRSLVHSRGNTYLHWYLQKPGQSPQLLIYKVSNRFIGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQSTHLPFTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC DMXW92T DE Plaque psoriasis; Psoriatic arthritis DMKJ8LB ID DMKJ8LB DMKJ8LB DN Josamycin DMKJ8LB HS Approved DMKJ8LB SN Josacine; Josamicina; Josamycine; Josamycinum; EN 141; Kitasamycin A3; Leucomycin A3; Turimycin A5; Antibiotic yl-704 A3; Iosalide (TN); Josacine (TN); Josalid (TN); Josamicina [INN-Spanish]; Josamina (TN); Josamy (TN); Josamycin (TN); Josamycine [INN-French]; Josamycinum [INN-Latin]; Wilprafen (TN); Yl-704 A3; Josamycin [USAN:INN:JAN]; Josamycin (JP15/USAN/INN); Dro-2H-pyran-3-yl 3-methylbutanoate; Leucomycin V, 3-acetate 4B-(3-methylbutanoate); Leucomycin V, 3-acetate 4(sup B)-(3-methylbutanoate); Leucomycin V,3-acetate 4(sup beta)-(3-methylbutanoate) DMKJ8LB TC Antibiotics DMKJ8LB DT Small molecular drug DMKJ8LB PC 5282165 DMKJ8LB MW 828 DMKJ8LB FM C42H69NO15 DMKJ8LB IC InChI=1S/C42H69NO15/c1-23(2)19-32(47)56-40-27(6)53-34(22-42(40,8)50)57-37-26(5)54-41(36(49)35(37)43(9)10)58-38-29(17-18-44)20-24(3)30(46)16-14-12-13-15-25(4)52-33(48)21-31(39(38)51-11)55-28(7)45/h12-14,16,18,23-27,29-31,34-41,46,49-50H,15,17,19-22H2,1-11H3/b13-12+,16-14+/t24-,25-,26-,27+,29+,30+,31-,34+,35-,36-,37-,38+,39+,40+,41+,42-/m1/s1 DMKJ8LB CS C[C@@H]1C/C=C/C=C/[C@@H]([C@@H](C[C@@H]([C@@H]([C@H]([C@@H](CC(=O)O1)OC(=O)C)OC)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)C)O[C@H]3C[C@@]([C@H]([C@@H](O3)C)OC(=O)CC(C)C)(C)O)N(C)C)O)CC=O)C)O DMKJ8LB IK XJSFLOJWULLJQS-NGVXBBESSA-N DMKJ8LB IU [(2S,3S,4R,6S)-6-[(2R,3S,4R,5R,6S)-6-[[(4R,5S,6S,7R,9R,10R,11E,13E,16R)-4-acetyloxy-10-hydroxy-5-methoxy-9,16-dimethyl-2-oxo-7-(2-oxoethyl)-1-oxacyclohexadeca-11,13-dien-6-yl]oxy]-4-(dimethylamino)-5-hydroxy-2-methyloxan-3-yl]oxy-4-hydroxy-2,4-dimethyloxan-3-yl] 3-methylbutanoate DMKJ8LB CA CAS 16846-24-5 DMKJ8LB CB CHEBI:31739 DMKJ8LB DE Bacterial infection DM2DMPO ID DM2DMPO DM2DMPO DN Kanamycin DM2DMPO HS Approved DM2DMPO SN Aspidium; KAN; Kanamicina; Kanamycine; Kanamycinum; Kantrex; Klebcil; KANAMYCIN A; Kanamicina [Italian]; Kanamycin A tetracation; Kanamycin Base; Kanamycin monosulfate; Kanamycin sulfate; Kenamycin A; Liposomal Kanamycin; KM (the Antibiotic); Kanamycin [INN:BAN]; Kanamycin monosulfate (JP15); Kanamycinsulfate (JP15); Kanamycin sulfate (TN); Kanamycin sulfate (USP); Kanamycine [INN-French]; Kanamycinum [INN-Latin]; Kantrex (TN); Kantrex (1:1 sulfate); Klebcil (1:1 sulfate); O-3-amino-3-deoxy-alpha-D-glucopyranosyl-(1->6)-O-(6-amino-6-deoxy-alpha-D-glucopyranosyl-(1->4))-2-deoxy-D-streptamine; O-3-Amino-3-deoxy-.alpha.-D-glucopyranosyl-(1->6)-O-[6-amino-6-deoxy-.alpha.-D-glucopyranosyl-(1->4)]-2-deoxy-D-streptamine; (1S,2R,3R,4S,6R)-4,6-diamino-3-(6-amino-6-deoxy-alpha-D-glucopyranosyloxy)-2-hydroxycyclohexyl 3-amino-3-deoxy-alpha-D-glucopyranoside; (1S,2R,3R,4S,6R)-4,6-diamino-3-[(6-amino-6-deoxy-alpha-D-glucopyranosyl)oxy]-2-hydroxycyclohexyl 3-amino-3-deoxy-alpha-D-glucopyranoside; (1S,2R,3R,4S,6R)-4,6-diazaniumyl-3-(6-azaniumyl-6-deoxy-alpha-D-glucopyranosyloxy)-2-hydroxycyclohexyl 3-azaniumyl-3-deoxy-alpha-D-glucopyranoside; (2R,3S,4S,5R,6R)-2-(aminomethyl)-6-[(1R,2R,3S,4R,6S)-4,6-diamino-3-[(2S,3R,4S,5S,6R)-4-amino-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxyoxane-3,4,5-triol; 4,6-Diamino-2-hydroxy-1,3-cyclohexane 3,6'diamino-3,6'-dideoxydi-alpha-D-glucoside; 4,6-diamino-2-hydroxy-1,3-cyclohexylene 3,6'-diamino-3,6'-dideoxydi-D-glucopyranoside DM2DMPO CP Sigma Chemical Company DM2DMPO TC Antibiotics DM2DMPO DT Small molecular drug DM2DMPO PC 6032 DM2DMPO MW 484.5 DM2DMPO FM C18H36N4O11 DM2DMPO IC InChI=1S/C18H36N4O11/c19-2-6-10(25)12(27)13(28)18(30-6)33-16-5(21)1-4(20)15(14(16)29)32-17-11(26)8(22)9(24)7(3-23)31-17/h4-18,23-29H,1-3,19-22H2/t4-,5+,6-,7-,8+,9-,10-,11-,12+,13-,14-,15+,16-,17-,18-/m1/s1 DM2DMPO CS C1[C@H]([C@@H]([C@H]([C@@H]([C@H]1N)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CN)O)O)O)O)O[C@@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)N)O)N DM2DMPO IK SBUJHOSQTJFQJX-NOAMYHISSA-N DM2DMPO IU (2R,3S,4S,5R,6R)-2-(aminomethyl)-6-[(1R,2R,3S,4R,6S)-4,6-diamino-3-[(2S,3R,4S,5S,6R)-4-amino-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxyoxane-3,4,5-triol DM2DMPO CA CAS 59-01-8 DM2DMPO CB CHEBI:17630 DM2DMPO DE Bacterial infection DMITFB8 ID DMITFB8 DMITFB8 DN Kanamycin DMITFB8 HS Approved DMITFB8 SN Kanamicina; Kanamicina [Italian]; Kanamycin Base; EQK9Q303C5; KANAMYCIN A; KM (the Antibiotic); Kanamycin [INN:BAN]; Kanamycin sulfate; Kanamycine; Kanamycine [INN-French]; Kanamycinum; Kanamycinum [INN-Latin]; kanamycin; 4,6-Diamino-2-hydroxy-1,3-cyclohexane 3,6'diamino-3,6'-dideoxydi-alpha-D-glucoside; BRN 0061647; C18H36N4O11; CHEBI:17630; EINECS 200-411-7; Glucopyranoside, 4,6-diamino-2-hydroxy-1,3-cyclohexylene 3,6'-diamino-3,6'-dideoxydi-, D-; HSDB 3107; KAN; UNII-EQK9Q303C5 DMITFB8 PC 6032 DMITFB8 MW 484.5 DMITFB8 FM C18H36N4O11 DMITFB8 IC SBUJHOSQTJFQJX-NOAMYHISSA-N DMITFB8 CS C1C(C(C(C(C1N)OC2C(C(C(C(O2)CN)O)O)O)O)OC3C(C(C(C(O3)CO)O)N)O)N DMITFB8 IK 1S/C18H36N4O11/c19-2-6-10(25)12(27)13(28)18(30-6)33-16-5(21)1-4(20)15(14(16)29)32-17-11(26)8(22)9(24)7(3-23)31-17/h4-18,23-29H,1-3,19-22H2/t4-,5+,6-,7-,8+,9-,10-,11-,12+,13-,14-,15+,16-,17-,18-/m1/s1 DMITFB8 IU (2R,3S,4S,5R,6R)-2-(aminomethyl)-6-[(1R,2R,3S,4R,6S)-4,6-diamino-3-[(2S,3R,4S,5S,6R)-4-amino-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxyoxane-3,4,5-triol DMITFB8 CA CAS 59-01-8 DMITFB8 CB CHEBI:17630 DMITFB8 DE Pulmonary tuberculosis DMT5HA4 ID DMT5HA4 DMT5HA4 DN Ketamine DMT5HA4 HS Approved DMT5HA4 SN Calypsol; Cetamina; Green; Ketaject; Ketalar; Ketaminum; Ketanest; Ketoject; Ketolar; Tekam; KETAMINE HCL; Ketalar base; Ketamine Base; Special K; Special K [street name]; CLSTA 20; T385; Cetamina [INN-Spanish]; Dl-Ketamine; Ketalar (TN); Ketamine (INN); Ketamine [INN:BAN]; Ketaminum [INN-Latin]; Ketanest (TN); Ketaset (TN); Tekam (TN); Cyclohexanone, 2-(2-chlorophenyl)-2-(methylamino)-(9CI); Cyclohexanone, 2-(2-chlorophenyl)-2-(methylamino)-, (+-)-(9CI); Cyclohexanone, 2-(o-chlorophenyl)-2-(methylamino)-, (+/-)-(8CI); (+/-)-2-(2-Chlorophenyl)-2-(methylamino)cyclohexanone; (+/-)-2-(o-Chlorophenyl)-2-(methylamino)cyclohexanone; 2-(2-Chlorophenyl)-2-(methylamino)cyclohexanone; 2-(2-chlorophenyl)-2-(methylamino)cyclohexan-1-one; 2-(Methylamino)-2-(2-chlorophenyl)cyclohexanone; 2-(o-Chlorophenyl)-2-(methylamino)-cyclohexanone; 2-(o-Chlorophenyl)-2-(methylamino)cyclohexanone DMT5HA4 CP Pfizer Pharmaceuticals DMT5HA4 TC Analgesics DMT5HA4 DT Small molecular drug DMT5HA4 PC 3821 DMT5HA4 MW 237.72 DMT5HA4 FM C13H16ClNO DMT5HA4 IC InChI=1S/C13H16ClNO/c1-15-13(9-5-4-8-12(13)16)10-6-2-3-7-11(10)14/h2-3,6-7,15H,4-5,8-9H2,1H3 DMT5HA4 CS CNC1(CCCCC1=O)C2=CC=CC=C2Cl DMT5HA4 IK YQEZLKZALYSWHR-UHFFFAOYSA-N DMT5HA4 IU 2-(2-chlorophenyl)-2-(methylamino)cyclohexan-1-one DMT5HA4 CA CAS 6740-88-1 DMT5HA4 CB CHEBI:6121 DMT5HA4 DE Anaesthesia DMVLMW6 ID DMVLMW6 DMVLMW6 DN Ketanserin DMVLMW6 HS Approved DMVLMW6 SN Ketanserina; Ketanserine; Ketanserinum; Ketaserin; Perketal; Serefrex; Sufrexal; Taseron; Ketanserina [INN-Spanish]; Ketanserine [INN-French]; Ketanserinum [INN-Latin]; R 41,468; R-41468; [3H]-Ketanserin; Ketanserin (USAN/INN); Ketanserin [USAN:BAN:INN]; R-41,468; (+)-3-[2-[4-(4-Fluorobenzoyl)-1-piperidinyl]ethyl]-2,4(1H,3H)-quinazolinedione; 3-(2-(4-(4-Fluorobenzoyl)piperidinol)ethyl)-2,4(1H,3H)-quinazolinedione; 3-(2-(4-(p-Fluorobenzoyl)piperidino)ethyl)-2,4-(1H,3H)-quinazolinedione; 3-(2-{4-[(4-fluorophenyl)carbonyl]piperidin-1-yl}ethyl)quinazoline-2,4(1H,3H)-dione; 3-[2-[4-(4-fluorobenzoyl)-1-piperidyl]ethyl]-1H-quinazoline-2,4-dione; 3-[2-[4-(4-fluorobenzoyl)piperidin-1-yl]ethyl]-1H-quinazoline-2,4-dione; 3-{2-[4-(4-fluorobenzoyl)piperidin-1-yl]ethyl}quinazoline-2,4(1H,3H)-dione DMVLMW6 CP Janssen Pharmaceutica DMVLMW6 TC Antihypertensive Agents DMVLMW6 DT Small molecular drug DMVLMW6 PC 3822 DMVLMW6 MW 395.4 DMVLMW6 FM C22H22FN3O3 DMVLMW6 IC InChI=1S/C22H22FN3O3/c23-17-7-5-15(6-8-17)20(27)16-9-11-25(12-10-16)13-14-26-21(28)18-3-1-2-4-19(18)24-22(26)29/h1-8,16H,9-14H2,(H,24,29) DMVLMW6 CS C1CN(CCC1C(=O)C2=CC=C(C=C2)F)CCN3C(=O)C4=CC=CC=C4NC3=O DMVLMW6 IK FPCCSQOGAWCVBH-UHFFFAOYSA-N DMVLMW6 IU 3-[2-[4-(4-fluorobenzoyl)piperidin-1-yl]ethyl]-1H-quinazoline-2,4-dione DMVLMW6 CA CAS 74050-98-9 DMVLMW6 CB CHEBI:6123 DMVLMW6 DE Hypertension DMM3L6Z ID DMM3L6Z DMM3L6Z DN Ketobemidone DMM3L6Z HS Approved DMM3L6Z SN Ketobemidone hydrochloride; Cliradon hydrochloride; Ketobimedon hydrochloride; UNII-U9U6LTV80K; 5965-49-1; EINECS 227-749-8; U9U6LTV80K; 1-Methyl-4-(m-hydroxyphenyl)piperidine-4-ethylketone hydrochloride; Ketobemidone HCl; 1-Propanone, 1-(4-(m-hydroxyphenyl)-1-methyl-4-piperidyl)-, hydrochloride; Ketogan (TN); AC1L2YOJ; 1-[4-(3-hydroxyphenyl)-1-methylpiperidin-4-yl]propan-1-one hydrochloride(1:1); AC1Q5G7W; SCHEMBL9706814; 469-79-4 (Parent); DTXSID00208327; LS-123062; D08101 DMM3L6Z DT Small molecular drug DMM3L6Z PC 10101 DMM3L6Z MW 247.33 DMM3L6Z FM C15H21NO2 DMM3L6Z IC InChI=1S/C15H21NO2/c1-3-14(18)15(7-9-16(2)10-8-15)12-5-4-6-13(17)11-12/h4-6,11,17H,3,7-10H2,1-2H3 DMM3L6Z CS CCC(=O)C1(CCN(CC1)C)C2=CC(=CC=C2)O DMM3L6Z IK ALFGKMXHOUSVAD-UHFFFAOYSA-N DMM3L6Z IU 1-[4-(3-hydroxyphenyl)-1-methylpiperidin-4-yl]propan-1-one DMM3L6Z CA CAS 469-79-4 DMM3L6Z CB CHEBI:6125 DMM3L6Z DE Pain DMPZI3Q ID DMPZI3Q DMPZI3Q DN Ketoconazole DMPZI3Q HS Approved DMPZI3Q SN KCZ; KTZ; K 1003; R 41400; R41400; KS-1205; KW-1414; Perkhotal (TN); R 41,400; R-41400; R41,400; Ketoconazole [USAN:INN:BAN:JAN]; Nizoral, Extina, Xolegel, Kuric, Ketoconazole; Dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-piperazine; Cis-1-Acetyl-4-[4-[[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazine; CIS-1-ACETYL-4-(4-((2-(2,4-DICHLOROPHENYL)-2-(1H-IMIDAZOL-1-YLMETHYL)-1,3-DIOXOLAN-4-YL)METHOXY)PHENYL)PIPERAZINE; (+-)-cis-1-Acetyl-4-(p-((2-(2,4-dichlorophenyl)-2-(imidazol-1-ylmethyl)-1,3-dioxolan-4-yl)methoxy)phenyl)piperazine; (+/-)-cis-1-Acetyl-4-(4-[(2-[2,4-dichlorophenyl]-2-[1H-imidazol-1-ylmethyl]-1,3-dioxolan-4-yl)-methoxy]phenyl)piperazine; (+/-)-cis-1-Acetyl-4-[4-[[2-(2,4-dichlorophenyl)-2-(imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazine; 1-[4-[4-[[(2R,4S)-2-(2,4-dichlorophenyl)-2-(imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]ethanone; 1-acetyl-4-(4-{[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine DMPZI3Q CP Johnson & Johnson DMPZI3Q TC Antifungal Agents DMPZI3Q DT Small molecular drug DMPZI3Q PC 456201 DMPZI3Q MW 531.4 DMPZI3Q FM C26H28Cl2N4O4 DMPZI3Q IC InChI=1S/C26H28Cl2N4O4/c1-19(33)31-10-12-32(13-11-31)21-3-5-22(6-4-21)34-15-23-16-35-26(36-23,17-30-9-8-29-18-30)24-7-2-20(27)14-25(24)28/h2-9,14,18,23H,10-13,15-17H2,1H3/t23-,26-/m0/s1 DMPZI3Q CS CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl DMPZI3Q IK XMAYWYJOQHXEEK-OZXSUGGESA-N DMPZI3Q IU 1-[4-[4-[[(2R,4S)-2-(2,4-dichlorophenyl)-2-(imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]ethanone DMPZI3Q CA CAS 65277-42-1 DMPZI3Q CB CHEBI:48336 DMPZI3Q DE Fungal infection DMRKXPT ID DMRKXPT DMRKXPT DN Ketoprofen DMRKXPT HS Approved DMRKXPT SN Actron; Alrheumat; Alrheumum; Alrheumun; Aneol; Capisten; Dexal; Epatec; Fastum; Kefenid; Ketoprofene; Ketoprofeno; Ketoprofenum; Ketopron; Ketoprophene; Lertus; Menamin; Meprofen; Orudis; Orugesic; Oruvail; Oscorel; Profenid; Toprec; Toprek; Benzoylhydratropic Acid; Orudis KT; K 1751; RP 19583; RP19583; RU 4733; Arthril (TN); Fastum (TN); Fastum Gel (TN); Iso-K; Keto (TN); Ketoflam (TN); Ketomex (TN); Ketonal (TN); Ketoprofenas (TN); Ketoprofene (TN); Ketoprofene [INN-French]; Ketoprofeno [INN-Spanish]; Ketoprofenum (TN); Ketoprofenum [INN-Latin]; Ketorin (TN); Ketospray (TN); Lasonil (TN); M-Benzoylhydratropic acid; Oki (TN); Orudis (TN); Oruvail (TN); RP-19583; Racemic-Ketoprofen; Zon (TN); Bi-Profnid (TN); RP, 19,583; Ketoprofen (JP15/USP/INN); Ketoprofen [USAN:INN:BAN:JAN]; Orudis, Oruvail, Ketoflam, Orudis KT, Ketoprofen; Acide (benzoyl-3-phenyl)-2-propionique; Acide (benzoyl-3-phenyl)-2-propionique [French]; L'Acide (benzoyl-3-phenyl)-2-propionique; (+-)-m-Benzoylhydratropic acid; 2-(3-Benzoylphenyl)propanoic acid; 2-(3-Benzoylphenyl)propionic acid; 2-(m-Benzoylphenyl)propionic acid; 2-[3-(benzoyl)phenyl]propanoic acid; 2-[3-(phenylcarbonyl)phenyl]propanoic acid; 2-[3-Benzoylphenyl]propionic acid; 3-Benzoylhydratropic acid DMRKXPT CP ProEthic Pharmaceuticals DMRKXPT TC Analgesics DMRKXPT DT Small molecular drug DMRKXPT PC 3825 DMRKXPT MW 254.28 DMRKXPT FM C16H14O3 DMRKXPT IC InChI=1S/C16H14O3/c1-11(16(18)19)13-8-5-9-14(10-13)15(17)12-6-3-2-4-7-12/h2-11H,1H3,(H,18,19) DMRKXPT CS CC(C1=CC(=CC=C1)C(=O)C2=CC=CC=C2)C(=O)O DMRKXPT IK DKYWVDODHFEZIM-UHFFFAOYSA-N DMRKXPT IU 2-(3-benzoylphenyl)propanoic acid DMRKXPT CA CAS 22071-15-4 DMRKXPT CB CHEBI:6128 DMRKXPT DE Pain; Osteoarthritis; Musculoskeletal pain; Migraine DMI4EL5 ID DMI4EL5 DMI4EL5 DN Ketorolac DMI4EL5 HS Approved DMI4EL5 SN Ketoralac; Ketorolaco; Ketorolacum; Macril; Ketorolaco [Spanish]; Ketorolacum [Latin]; RS 37619; Acular (TN); Ketorolac (INN); Ketorolac [INN:BAN]; RS-37619; Toradol (TN); (+-)-5-Benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid; (+-)-Ketorolac; (+-)-isomer; (+/-)-2,3-Dihydro-5-benzoyl-1H-pyrrolizine-1-carboxylic acid; 1H-Pyrrolizine-1-carboxylic acid, 5-benzoyl-2,3-dihydro; 5-(phenylcarbonyl)-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid; 5-Benzoyl-1,2-dihydro-3H-pyrrolo(1,2a)pyrrole-1-carboxylic acid; 5-Benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid DMI4EL5 CP Laboratorios Syntex SA DMI4EL5 TC Analgesics DMI4EL5 DT Small molecular drug DMI4EL5 PC 3826 DMI4EL5 MW 255.27 DMI4EL5 FM C15H13NO3 DMI4EL5 IC InChI=1S/C15H13NO3/c17-14(10-4-2-1-3-5-10)13-7-6-12-11(15(18)19)8-9-16(12)13/h1-7,11H,8-9H2,(H,18,19) DMI4EL5 CS C1CN2C(=CC=C2C(=O)C3=CC=CC=C3)C1C(=O)O DMI4EL5 IK OZWKMVRBQXNZKK-UHFFFAOYSA-N DMI4EL5 IU 5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid DMI4EL5 CA CAS 74103-06-3 DMI4EL5 CB CHEBI:76223 DMI4EL5 DE Postoperative inflammation DM74XKS ID DM74XKS DM74XKS DN Ketotifen DM74XKS HS Approved DM74XKS SN Ketotifen [INN:BAN]; Ketotifene; Ketotifene [INN-French]; Ketotifeno; Ketotifeno [INN-Spanish]; Ketotifenum; Ketotifenum [INN-Latin]; HC 20-511; ZCVMWBYGMWKGHF-UHFFFAOYSA-N; Zaditor; ketotifen; 34580-13-7; 4,9-Dihydro-4-(1-methyl-4-piperidinylidene)-10H-benzo(4,5)cyclohepta(1,2-b)thiophen-10-one; 4-(1-methylpiperidin-4-ylidene)-4,9-dihydro-10H-benzo[4,5]cyclohepta[1,2-b]thiophen-10-one; BRN 3983897; CHEMBL534; EINECS 252-099-7; HSDB 7283; UNII-X49220T18G DM74XKS PC 3827 DM74XKS MW 309.4 DM74XKS FM C19H19NOS DM74XKS IC ZCVMWBYGMWKGHF-UHFFFAOYSA-N DM74XKS CS CN1CCC(=C2C3=C(C(=O)CC4=CC=CC=C42)SC=C3)CC1 DM74XKS IK 1S/C19H19NOS/c1-20-9-6-13(7-10-20)18-15-5-3-2-4-14(15)12-17(21)19-16(18)8-11-22-19/h2-5,8,11H,6-7,9-10,12H2,1H3 DM74XKS IU 2-(1-methylpiperidin-4-ylidene)-6-thiatricyclo[8.4.0.03,7]tetradeca-1(14),3(7),4,10,12-pentaen-8-one DM74XKS CA CAS 34580-13-7 DM74XKS CB CHEBI:92511 DM74XKS DE Conjunctivitis DMOVY05 ID DMOVY05 DMOVY05 DN Ketotifen DMOVY05 HS Approved DMOVY05 SN Ketotifene; Ketotifeno; Ketotifenum; Ketotifin; Ketotiphen; Ketotiphene; Zaditor; Ketotifene fumarate; Alaway (TN); HC 20-511; Ketotifen (INN); Ketotifen [INN:BAN]; Ketotifene [INN-French]; Ketotifeno [INN-Spanish]; Ketotifenum [INN-Latin]; Zaditor (TN); 10H-Benzo[4,5]cyclohepta[1,2-b]thiophen-10-one, 4,9-dihydro-4-(1-methyl-4-piperidinylidene)-, (2E)-2-butenedioate (1:1); 4,9-Dihydro-4-(1-methyl-4-piperidinylidene)-10H-benzo(4,5)cyclohepta(1,2-b)thiophen-10-one; 4,9-Dihydro-4-(1-methyl-4-piperidylidene)-10H-benzo(4,5)-cyclohepta(1,2-b)thiophen-10-one; 4-(1-Methyl-4-piperidylidene)-9-hydrobenzo[a]thiopheno[3,2-d][7]annulen-10-one; 4-(1-Methyl-piperidin-4-ylidene)-4,9-dihydro-1-thia-benzo[f]azulen-10-one; 4-(1-methylpiperidin-4-ylidene)-4,9-dihydro-10H-benzo[4,5]cyclohepta[1,2-b]thiophen-10-one DMOVY05 CP Norvatis Phamaceuticals Corporation DMOVY05 TC Antiallergic Agents DMOVY05 DT Small molecular drug DMOVY05 PC 3827 DMOVY05 MW 309.4 DMOVY05 FM C19H19NOS DMOVY05 IC InChI=1S/C19H19NOS/c1-20-9-6-13(7-10-20)18-15-5-3-2-4-14(15)12-17(21)19-16(18)8-11-22-19/h2-5,8,11H,6-7,9-10,12H2,1H3 DMOVY05 CS CN1CCC(=C2C3=C(C(=O)CC4=CC=CC=C42)SC=C3)CC1 DMOVY05 IK ZCVMWBYGMWKGHF-UHFFFAOYSA-N DMOVY05 IU 2-(1-methylpiperidin-4-ylidene)-6-thiatricyclo[8.4.0.03,7]tetradeca-1(14),3(7),4,10,12-pentaen-8-one DMOVY05 CA CAS 34580-13-7 DMOVY05 CB CHEBI:92511 DMOVY05 DE Allergic conjunctivitis DM0KAE6 ID DM0KAE6 DM0KAE6 DN Kombiglyze XR/Komboglyze FDC DM0KAE6 HS Approved DM0KAE6 SN Metformin mixture with saxagliptin; 1198772-17-6; Kombiglyze; Komboglyze; Kombiglyze XR; Saxagliptin / metformin; Metformin / saxagliptin DM0KAE6 CP AstraZeneca DM0KAE6 DT Small molecular drug DM0KAE6 PC 56842229 DM0KAE6 MW 444.6 DM0KAE6 FM C22H36N8O2 DM0KAE6 IC InChI=1S/C18H25N3O2.C4H11N5/c19-8-13-2-12-3-14(12)21(13)16(22)15(20)17-4-10-1-11(5-17)7-18(23,6-10)9-17;1-9(2)4(7)8-3(5)6/h10-15,23H,1-7,9,20H2;1-2H3,(H5,5,6,7,8)/t10?,11?,12?,13-,14-,15+,17?,18?;/m1./s1 DM0KAE6 CS CN(C)C(=N)N=C(N)N.C1[C@@H](N([C@H]2C1C2)C(=O)[C@@H](C34CC5CC(C3)CC(C5)(C4)O)N)C#N DM0KAE6 IK QUKZWYNGKYRRKE-RIKNOMPASA-N DM0KAE6 IU (1R,3R)-2-[(2R)-2-amino-2-(3-hydroxy-1-adamantyl)acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile;3-(diaminomethylidene)-1,1-dimethylguanidine DM0KAE6 CA CAS 1198772-17-6 DM0KAE6 DE Diabetic complication DMSA4HZ ID DMSA4HZ DMSA4HZ DN KU-0058948 DMSA4HZ HS Approved DMSA4HZ SN CHEMBL380648; KU-0058948; 4-[3-(1,4-diazepan-1-ylcarbonyl)-4-fluorobenzyl]phthalazin-1(2H)-one; 4-(3-(1,4-diazepane-1-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one; Homopiperazine analogue, 14; SCHEMBL864319; BDBM27533; HGEPGGJUGUMFHT-UHFFFAOYSA-N; ZINC3821234; DB08058; NCGC00386677-01; KU-58948; FT-0670691; TL80090044; 4-[3-([1,4]diazepane-1-carbonyl)-4 -fluorobenzyl]-2H-phthalazin-1-one; 4-[3-([1,4]diazepane-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one DMSA4HZ DT Small molecular drug DMSA4HZ PC 11291932 DMSA4HZ MW 380.4 DMSA4HZ FM C21H21FN4O2 DMSA4HZ IC InChI=1S/C21H21FN4O2/c22-18-7-6-14(12-17(18)21(28)26-10-3-8-23-9-11-26)13-19-15-4-1-2-5-16(15)20(27)25-24-19/h1-2,4-7,12,23H,3,8-11,13H2,(H,25,27) DMSA4HZ CS C1CNCCN(C1)C(=O)C2=C(C=CC(=C2)CC3=NNC(=O)C4=CC=CC=C43)F DMSA4HZ IK HGEPGGJUGUMFHT-UHFFFAOYSA-N DMSA4HZ IU 4-[[3-(1,4-diazepane-1-carbonyl)-4-fluorophenyl]methyl]-2H-phthalazin-1-one DMSA4HZ DE Ovarian cancer DMK8U72 ID DMK8U72 DMK8U72 DN Labetalol DMK8U72 HS Approved DMK8U72 SN Albetol; Ibidomide; Labetalolum; Labetolol; NORMOZIDE; AH 5158; AH-5158; Labetalol (INN); Labetalol [INN:BAN]; Labetalolum [INN-Latin]; Normodyne (TN); Sch-19927; Trandate (TN); 2-Hydroxy-5-(1-hydroxy-2-((1-methyl-3-phenylpropyl)amino)ethyl)benzamide; 2-hydroxy-5-[1-hydroxy-2-(4-phenylbutan-2-ylamino)ethyl]benzamide; 2-hydroxy-5-{1-hydroxy-2-[(1-methyl-3-phenylpropyl)amino]ethyl}benzamide; 3-Carboxamido-4-hydroxy-alpha-((1-methyl-3-phenylpropylamino)methyl)benzyl alcohol; 5-(1-Hydroxy-2-(1-methyl-3-phenylpropylamino)ethyl)salicylamide DMK8U72 CP Allen & Handbury DMK8U72 TC Antihypertensive Agents DMK8U72 DT Small molecular drug DMK8U72 PC 3869 DMK8U72 MW 328.4 DMK8U72 FM C19H24N2O3 DMK8U72 IC InChI=1S/C19H24N2O3/c1-13(7-8-14-5-3-2-4-6-14)21-12-18(23)15-9-10-17(22)16(11-15)19(20)24/h2-6,9-11,13,18,21-23H,7-8,12H2,1H3,(H2,20,24) DMK8U72 CS CC(CCC1=CC=CC=C1)NCC(C2=CC(=C(C=C2)O)C(=O)N)O DMK8U72 IK SGUAFYQXFOLMHL-UHFFFAOYSA-N DMK8U72 IU 2-hydroxy-5-[1-hydroxy-2-(4-phenylbutan-2-ylamino)ethyl]benzamide DMK8U72 CA CAS 36894-69-6 DMK8U72 CB CHEBI:6343 DMK8U72 DE Hypertension DMVM6QR ID DMVM6QR DMVM6QR DN Lacosamide DMVM6QR HS Approved DMVM6QR SN Erlosamide; Harkoseride; Vimpat; Erlosamide [INN]; Lacosamide [USAN]; ADD 234037; SPM 927; ADD-234037; SPM-927; SPM-929; Erlosamide, Vimpat, Lacosamide; Lacosamide (USAN/INN); (2R)-2-(Acetylamino)-N-benzyl-3-methoxypropanamide; (2R)-2-(acetylamino)-N-benzyl-3-methoxypropanamide; (2R)-2-acetamido-N-benzyl-3-methoxypropanamide DMVM6QR CP Schwarz Pharma DMVM6QR TC Analgesics DMVM6QR DT Small molecular drug DMVM6QR PC 219078 DMVM6QR MW 250.29 DMVM6QR FM C13H18N2O3 DMVM6QR IC InChI=1S/C13H18N2O3/c1-10(16)15-12(9-18-2)13(17)14-8-11-6-4-3-5-7-11/h3-7,12H,8-9H2,1-2H3,(H,14,17)(H,15,16)/t12-/m1/s1 DMVM6QR CS CC(=O)N[C@H](COC)C(=O)NCC1=CC=CC=C1 DMVM6QR IK VPPJLAIAVCUEMN-GFCCVEGCSA-N DMVM6QR IU (2R)-2-acetamido-N-benzyl-3-methoxypropanamide DMVM6QR CA CAS 175481-36-4 DMVM6QR CB CHEBI:135939 DMVM6QR DE Convulsion; Diabetic neuropathy; Epilepsy DMA7QTC ID DMA7QTC DMA7QTC DN Lactoferrin DMA7QTC HS Approved DMA7QTC SN Lactoferroxin B; Lactoferroxin-B; AC1L4UTC; Arg-tyr-tyr-gly-tyr-och3; AC1Q5JP4; methyl n5-(diaminomethylidene)-l-ornithyl-l-tyrosyl-l-tyrosylglycyl-l-tyrosinate; 117667-26-2; L-Tyrosine, N-(N-(N-(N-L-arginyl-L-tyrosyl)-L-tyrosyl)glycyl)-, methyl ester; methyl (2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]-3-(4-hydroxyphenyl)propanoate DMA7QTC DT Small molecular drug DMA7QTC PC 126456119 DMA7QTC MW 3125.8 DMA7QTC FM C141H226N46O29S3 DMA7QTC IC InChI=1S/C141H226N46O29S3/c1-11-77(6)111(133(212)186-112(80(9)189)134(213)183-106(74-218)130(209)184-110(76(4)5)132(211)176-97(49-32-61-161-141(155)156)120(199)170-93(45-28-57-157-137(147)148)116(195)166-78(7)113(192)180-103(136(215)216)66-82-36-16-13-17-37-82)185-128(207)104(72-188)181-131(210)107-50-33-62-187(107)135(214)79(8)165-109(191)71-164-115(194)100(64-75(2)3)177-121(200)92(44-24-27-56-144)168-117(196)91(43-23-26-55-143)169-125(204)99(53-63-219-10)175-119(198)94(46-29-58-158-138(149)150)172-126(205)101(67-83-69-162-88-40-20-18-38-85(83)88)179-124(203)98(51-52-108(146)190)174-127(206)102(68-84-70-163-89-41-21-19-39-86(84)89)178-122(201)96(48-31-60-160-140(153)154)171-118(197)95(47-30-59-159-139(151)152)173-129(208)105(73-217)182-123(202)90(42-22-25-54-142)167-114(193)87(145)65-81-34-14-12-15-35-81/h12-21,34-41,69-70,75-80,87,90-107,110-112,162-163,188-189,217-218H,11,22-33,42-68,71-74,142-145H2,1-10H3,(H2,146,190)(H,164,194)(H,165,191)(H,166,195)(H,167,193)(H,168,196)(H,169,204)(H,170,199)(H,171,197)(H,172,205)(H,173,208)(H,174,206)(H,175,198)(H,176,211)(H,177,200)(H,178,201)(H,179,203)(H,180,192)(H,181,210)(H,182,202)(H,183,213)(H,184,209)(H,185,207)(H,186,212)(H,215,216)(H4,147,148,157)(H4,149,150,158)(H4,151,152,159)(H4,153,154,160)(H4,155,156,161)/t77-,78-,79-,80+,87-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,110-,111-,112-/m0/s1 DMA7QTC CS CC[C@H](C)[C@@H](C(=N[C@@H]([C@@H](C)O)C(=N[C@@H](CS)C(=N[C@@H](C(C)C)C(=N[C@@H](CCCNC(=N)N)C(=N[C@@H](CCCNC(=N)N)C(=N[C@@H](C)C(=N[C@@H](CC1=CC=CC=C1)C(=O)O)O)O)O)O)O)O)O)N=C([C@H](CO)N=C([C@@H]2CCCN2C(=O)[C@H](C)N=C(CN=C([C@H](CC(C)C)N=C([C@H](CCCCN)N=C([C@H](CCCCN)N=C([C@H](CCSC)N=C([C@H](CCCNC(=N)N)N=C([C@H](CC3=CNC4=CC=CC=C43)N=C([C@H](CCC(=N)O)N=C([C@H](CC5=CNC6=CC=CC=C65)N=C([C@H](CCCNC(=N)N)N=C([C@H](CCCNC(=N)N)N=C([C@H](CS)N=C([C@H](CCCCN)N=C([C@H](CC7=CC=CC=C7)N)O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)O DMA7QTC IK CSSYQJWUGATIHM-IKGCZBKSSA-N DMA7QTC IU (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3R)-2-[[(2S,3S)-2-[[(2S)-2-[[[(2S)-1-[(2S)-2-[[2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-6-amino-2-[[(2S)-2-amino-1-hydroxy-3-phenylpropylidene]amino]-1-hydroxyhexylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-5-carbamimidamido-1-hydroxypentylidene]amino]-5-carbamimidamido-1-hydroxypentylidene]amino]-1-hydroxy-3-(1H-indol-3-yl)propylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-(1H-indol-3-yl)propylidene]amino]-5-carbamimidamido-1-hydroxypentylidene]amino]-1-hydroxy-4-methylsulfanylbutylidene]amino]-1-hydroxyhexylidene]amino]-1-hydroxyhexylidene]amino]-1-hydroxy-4-methylpentylidene]amino]-1-hydroxyethylidene]amino]propanoyl]pyrrolidin-2-yl]-hydroxymethylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-methylpentylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxy-3-methylbutylidene]amino]-5-carbamimidamido-1-hydroxypentylidene]amino]-5-carbamimidamido-1-hydroxypentylidene]amino]-1-hydroxypropylidene]amino]-3-phenylpropanoic acid DMA7QTC CA CAS 151186-19-5 DMA7QTC DE Solid tumour/cancer DMV7OPN ID DMV7OPN DMV7OPN DN Lactulose DMV7OPN HS Approved DMV7OPN SN Lactulosa; Lactulosa [INN-Spanish]; Lactulosa [Spanish]; Lactulosum; Lactulosum [INN-Latin]; Lactulosum [Latin]; Laevolac; Lattulosio [Italian]; Laxilose; Portalac; lactulose; 4-O-beta-D-Galactopyranosyl-D-fructofuranose; 4-O-beta-D-Galactopyranosyl-D-fructose; Acilac; Bifiteral; Cephulac; Cholac; Chronulac; Constilac; Constulose; D-Lactulose; Duphalac; Enulose; Generlac; Heptalac; Isolactose; 4-O-beta-D-galactopyranosyl-beta-D-fructofuranose; 9XH2P2N8EP; BRN 0093773; BRN 6278818; EINECS 225-027-7; UNII-9XH2P2N8EP DMV7OPN PC 11333 DMV7OPN MW 342.3 DMV7OPN FM C12H22O11 DMV7OPN IC JCQLYHFGKNRPGE-FCVZTGTOSA-N DMV7OPN CS C(C1C(C(C(C(O1)OC2C(OC(C2O)(CO)O)CO)O)O)O)O DMV7OPN IK 1S/C12H22O11/c13-1-4-6(16)7(17)8(18)11(21-4)22-9-5(2-14)23-12(20,3-15)10(9)19/h4-11,13-20H,1-3H2/t4-,5-,6+,7+,8-,9-,10+,11+,12-/m1/s1 DMV7OPN IU (2S,3R,4S,5R,6R)-2-[(2R,3S,4S,5R)-4,5-dihydroxy-2,5-bis(hydroxymethyl)oxolan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol DMV7OPN CA CAS 4618-18-2 DMV7OPN CB CHEBI:6359 DMV7OPN DE Hepatic encephalopathy DMZDN4W ID DMZDN4W DMZDN4W DN L-alanine DMZDN4W HS Approved DMZDN4W SN ALA; Alaninum; LPG; Polyalanine; A-Alanine; A-Aminopropionic acid; Alanina [DCIT,Spanish]; Alanine (USP); L-A-Aminopropionicacid; L-Alanine (9CI); L-Alanine (JAN); L-Alanine, homopolymer; L-Alanine, labeled with tritium; L-a-Alanine; L-a-Aminopropionic acid; Poly-DL-alanine; L-Alanine, labeled with carbon-14; Alanine, L-(7CI,8CI); F4F207FF-8FF8-4789-99A1-147AE0A36673; L-Alanine, N-coco alkyl derivs.; Propanoic acid, 2-amino-, (S); (C14)L-Alanine; (S)-2-Aminopropionic acid; 14C-L-Alanine DMZDN4W TC Dietary supplement DMZDN4W DT Small molecular drug DMZDN4W PC 5950 DMZDN4W MW 89.09 DMZDN4W FM C3H7NO2 DMZDN4W IC InChI=1S/C3H7NO2/c1-2(4)3(5)6/h2H,4H2,1H3,(H,5,6)/t2-/m0/s1 DMZDN4W CS C[C@@H](C(=O)O)N DMZDN4W IK QNAYBMKLOCPYGJ-REOHCLBHSA-N DMZDN4W IU (2S)-2-aminopropanoic acid DMZDN4W CA CAS 56-41-7 DMZDN4W CB CHEBI:16977 DMZDN4W DE Glioma; Dietary shortage DMANBR7 ID DMANBR7 DMANBR7 DN L-alanyl-l-glutamine DMANBR7 HS Approved DMANBR7 SN Dipeptiven (TN) DMANBR7 DT Small molecular drug DMANBR7 PC 123935 DMANBR7 MW 217.22 DMANBR7 FM C8H15N3O4 DMANBR7 IC InChI=1S/C8H15N3O4/c1-4(9)7(13)11-5(8(14)15)2-3-6(10)12/h4-5H,2-3,9H2,1H3,(H2,10,12)(H,11,13)(H,14,15)/t4-,5-/m0/s1 DMANBR7 CS C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)N DMANBR7 IK HJCMDXDYPOUFDY-WHFBIAKZSA-N DMANBR7 IU (2S)-5-amino-2-[[(2S)-2-aminopropanoyl]amino]-5-oxopentanoic acid DMANBR7 CA CAS 39537-23-0 DMANBR7 CB CHEBI:73788 DMANBR7 DE Mucositis DMI347A ID DMI347A DMI347A DN Lamivudine DMI347A HS Approved DMI347A SN lamivudine; 134678-17-4; Epivir; Zeffix; Heptovir; Epivir-HBV; Hepitec; Heptodin; BCH-189; 3TC; Heptivir; CIS-LAMIVUDINE; (-)-2'-Deoxy-3'-thiacytidine; 4-amino-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)pyrimidin-2(1H)-one; GR-109714X; 3'-Thia-2',3'-dideoxycytidine; (-)-BCH-189; Lamivudine [USAN:BAN:INN]; GR109714X; beta-L-3'-Thia-2',3'-dideoxycytidine; beta-L-2',3'-Dideoxy-3'-thiacytidine; (-)NGPB-21; 136891-12-8; 2',3'-Dideoxy-3'-thiacytidine; (-)-BCH 189; UNII-2T8Q726O95; HSDB 7155; GR 109714X; DTHC; LMV; Lamivir; Zefix; BCH 189; BCH189; BCH-790; DRG-0126; Epivir (TN); Epivir(TM); GG-714; HHA & 3TC; HHA & Lamivudine; Heptovir (TN); Lamivudine & GNA; Zeffix (TN); Epivir-HBV (TN); Lamivudine [USAN:INN:BAN]; Lamivudine (JAN/USP/INN); Lamivudine, (2S-cis)-Isomer; Beta-L-2',3'-Dideoxy-3'-thiacytidine; Beta-L-3'-Thia-2',3'-dideoxycytidine; Beta-L-(-)-2',3'-dideoxy-3'-thiacytidine & Sho-Saiko-To; (+/-)-(Cis)-1-[2-(Hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine; (+/-)-3TC; (+/-)-BCH-189; (+/-)-SddC; (-)-(2'R,5'S)-1-[2'-Hydroxymethyl-5'-(1,3-oxathiolanyl)]cytosine; (-)-1-((2R,5S)-2-(Hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine; (-)-1-[(2R,5S)-2-(Hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine; (-)-NGPB-21; (-)-SddC; (-)-beta-L-2',3'-Dideoxy-3'-thiacytidine; (2R,cis)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one; 2',3' Dideoxy 3' thiacytidine; 2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (+/-)-(Cis); 2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (-)-(2R,5S); 2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (-)-(2R,5S) & Galanthus Nivalis Agglutinin (GNA); 2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (-)-(2R,5S) & Hippeastrum hybrid agglutinin(HHA); 3TC & GNA; 3TC & SST; 3TC (AIDS INITIATIVE) (AIDS INITIATIVE); 3TC and NV-01; 3TC, Zeffix, Heptovir, Epivir, Epivir-HBV, Lamivudine; 4-Amino-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-2(1H)-pyrimidinone; 4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2(1H)-one; 4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one; Efavirenz/lamivudine/tenofovir fumarate DMI347A CP Glaxo Smith Kline Pharmaceuticals DMI347A TC Anti-HIV Agents DMI347A DT Small molecular drug DMI347A PC 60825 DMI347A MW 229.26 DMI347A FM C8H11N3O3S DMI347A IC InChI=1S/C8H11N3O3S/c9-5-1-2-11(8(13)10-5)6-4-15-7(3-12)14-6/h1-2,6-7,12H,3-4H2,(H2,9,10,13)/t6-,7+/m0/s1 DMI347A CS C1[C@H](O[C@H](S1)CO)N2C=CC(=NC2=O)N DMI347A IK JTEGQNOMFQHVDC-NKWVEPMBSA-N DMI347A IU 4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one DMI347A CA CAS 134678-17-4 DMI347A CB CHEBI:63577 DMI347A DE Chronic HBV infection; Human immunodeficiency virus infection; Human immunodeficiency virus-1 infection DM8SXYG ID DM8SXYG DM8SXYG DN Lamotrigine DM8SXYG HS Approved DM8SXYG SN Crisomet; Labileno; Lamictal; Lamictin; Lamiktal; Lamitor; Lamotrigina; Lamotriginum; Desitin Brand of Lamotrigine; Faes Brand of Lamotrigine; Glaxo Wellcome Brand of Lamotrigine; GlaxoSmithKline Brand of Lamotrigine; Juste Brand of Lamotrigine; Lamictal Cd; Lamictal ODT; Lamictal XR; Lamotrigina [Spanish]; Lamotriginum [Latin]; BW 430C; GI 267119X; GW 273293; L 3791; BW-430C; EUR-1048; Lamictal (TN); Lamictin (TN); Lamotrigine [USAN:INN:BAN]; Lamotrigine (JAN/USAN/INN); 3,5-Diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine; 3,5-Diamino-6-(2,3-dichlorophenyl)-as-triazine; 3,5-diamino-6-(2,3-dichlorophenyl)-as-triazine; 6-(2,3-Dichlorophenyl)-1,2,4-triazine-3,5-diamine; 6-(2,3-Dichlorophenyl)-1,2,4-triazine-3,5-diyldiamine; 6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine DM8SXYG CP GSK DM8SXYG TC Anticonvulsants DM8SXYG DT Small molecular drug DM8SXYG PC 3878 DM8SXYG MW 256.089 DM8SXYG FM C9H7Cl2N5 DM8SXYG IC InChI=1S/C9H7Cl2N5/c10-5-3-1-2-4(6(5)11)7-8(12)14-9(13)16-15-7/h1-3H,(H4,12,13,14,16) DM8SXYG CS C1=CC(=C(C(=C1)Cl)Cl)C2=C(N=C(N=N2)N)N DM8SXYG IK PYZRQGJRPPTADH-UHFFFAOYSA-N DM8SXYG IU 6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine DM8SXYG CA CAS 84057-84-1 DM8SXYG CB CHEBI:6367 DM8SXYG DE Bipolar disorder; Epilepsy DMEH7YU ID DMEH7YU DMEH7YU DN Lanadelumab DMEH7YU HS Approved DMEH7YU SN Lanadelumab [USAN]; UNII-2372V1TKXK; 2372V1TKXK; DX-2930 DMEH7YU CP Dyax/Shire DMEH7YU DE Hereditary angioedema DMG6ZU4 ID DMG6ZU4 DMG6ZU4 DN Lanreotide acetate DMG6ZU4 HS Approved DMG6ZU4 SN Lanreotide; Angiopeptin acetate; Somatuline; Somatulin; 127984-74-1; DC 13-116; Autogel; 108736-35-2; BIM 23014; Bim-23014; Lanreotide [INN:BAN]; Lanreotidum [INN-Latin]; Lanreotida [INN-Spanish]; Nal-cyclo(cys-tyr-trp-lys-val-cys)-thr-NH2; 10-(4-Aminobutyl)-19-[(2-amino-3-naphthalen-2-yl-propanoyl)amino]-N-(1 -carbamoyl-2-hydroxy-propyl)-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol -3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14, 17-pentazacycloicosane-4-carboxamide; Somatuline lp (TN); Lanreotide Autogel DMG6ZU4 CP Beaufour-Ipsen DMG6ZU4 DT Small molecular drug DMG6ZU4 PC 71349 DMG6ZU4 MW 1096.3 DMG6ZU4 FM C54H69N11O10S2 DMG6ZU4 IC InChI=1S/C54H69N11O10S2/c1-29(2)45-54(75)63-44(53(74)65-46(30(3)66)47(57)68)28-77-76-27-43(62-48(69)38(56)23-32-15-18-33-10-4-5-11-34(33)22-32)52(73)60-41(24-31-16-19-36(67)20-17-31)50(71)61-42(25-35-26-58-39-13-7-6-12-37(35)39)51(72)59-40(49(70)64-45)14-8-9-21-55/h4-7,10-13,15-20,22,26,29-30,38,40-46,58,66-67H,8-9,14,21,23-25,27-28,55-56H2,1-3H3,(H2,57,68)(H,59,72)(H,60,73)(H,61,71)(H,62,69)(H,63,75)(H,64,70)(H,65,74) DMG6ZU4 CS CC(C)C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)C(CC5=CC6=CC=CC=C6C=C5)N)C(=O)NC(C(C)O)C(=O)N DMG6ZU4 IK PUDHBTGHUJUUFI-UHFFFAOYSA-N DMG6ZU4 IU 10-(4-aminobutyl)-N-(1-amino-3-hydroxy-1-oxobutan-2-yl)-19-[(2-amino-3-naphthalen-2-ylpropanoyl)amino]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide DMG6ZU4 CA CAS 108736-35-2 DMG6ZU4 DE Acromegaly DMXYLQ3 ID DMXYLQ3 DMXYLQ3 DN Lansoprazole DMXYLQ3 HS Approved DMXYLQ3 SN Lancid; Lanproton; Lansopep; Lansoprazol; Lansoprazol [INN-Spanish]; Lansoprazole [USAN:BAN:INN]; Lansoprazolum; Lansoprazolum [INN-Latin]; Lansox; Lanston; Lanzol-30; Lanzopral; Lanzor; Lasoprol; Limpidex; Mesactol; Monolitum; Ogastro; Opiren; Agopton; Aprazol; Bamalite; Blason; Compraz; Ilsatec; Ketian; Prevacid; Prevacid 24HR; Prevacid Iv; Prevacid NapraPAC; Prevacid SoluTab; Prezal; Pro Ulco; Prosogan; Suprecid; Takepron; Zoprol; lansoprazole; 103577-45-3; A-65006; AG 1749; AG-1749; CHEBI:6375; Dakar; HSDB 7204; Lanz; Lanzo; Ogast; Promp; Ulpax; Zoton DMXYLQ3 PC 3883 DMXYLQ3 MW 369.4 DMXYLQ3 FM C16H14F3N3O2S DMXYLQ3 IC MJIHNNLFOKEZEW-UHFFFAOYSA-N DMXYLQ3 CS CC1=C(C=CN=C1CS(=O)C2=NC3=CC=CC=C3N2)OCC(F)(F)F DMXYLQ3 IK 1S/C16H14F3N3O2S/c1-10-13(20-7-6-14(10)24-9-16(17,18)19)8-25(23)15-21-11-4-2-3-5-12(11)22-15/h2-7H,8-9H2,1H3,(H,21,22) DMXYLQ3 IU 2-[[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methylsulfinyl]-1H-benzimidazole DMXYLQ3 CA CAS 103577-45-3 DMXYLQ3 CB CHEBI:6375 DMXYLQ3 DE Duodenal ulcer DMMJQSH ID DMMJQSH DMMJQSH DN Lanthanum carbonate DMMJQSH HS Approved DMMJQSH SN Fosrenol; Foznol; Lambda; Lanthanum; Phosphate binding agent, Shire/Johnson Matthey; Project Lambda, Shire/Johnson Matthey DMMJQSH CP Shire Pharm DMMJQSH DT Small molecular drug DMMJQSH PC 168924 DMMJQSH MW 457.84 DMMJQSH FM C3La2O9 DMMJQSH IC InChI=1S/3CH2O3.2La/c3*2-1(3)4;;/h3*(H2,2,3,4);;/q;;;2*+3/p-6 DMMJQSH CS C(=O)([O-])[O-].C(=O)([O-])[O-].C(=O)([O-])[O-].[La+3].[La+3] DMMJQSH IK NZPIUJUFIFZSPW-UHFFFAOYSA-H DMMJQSH IU lanthanum(3+);tricarbonate DMMJQSH CA CAS 587-26-8 DMMJQSH DE Hypophosphatasia DM3BH1Y ID DM3BH1Y DM3BH1Y DN Lapatinib DM3BH1Y HS Approved DM3BH1Y SN FMM; Tycerb; Lapatinib Ditosylate; Lapatinib [INN]; Lapatinib tosilate hydrate; GSK 572016; GSK572016; GW 572016; GW 572016X; GW572016; Lapatinib (INN); Tykerb (TN); Lapatinib, Tykerb, GW572016; N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine; N-{3-CHLORO-4-[(3-FLUOROBENZYL)OXY]PHENYL}-6-[5-({[2-(METHYLSULFONYL)ETHYL]AMINO}METHYL)-2-FURYL]-4-QUINAZOLINAMINE; N-(3-Chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-((2-methylsulfonylethylamino)methyl)-2-furyl)quinazolin-4-amine; N-(3-Chloro-4-{[(3-fluorophenyl)methyl]oxy}phenyl)-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furanyl]-4-quinazolinamine; 4-[[3-Chloro-4-(3-fluorobenzyloxy)phenyl]amino]-6-[5-[[(2-methanesulfonylethyl)amino]methyl]furan-2-yl]quinazoline; Lapatinib (ERBB2 inhibitor) DM3BH1Y CP GlaxoSmithKline DM3BH1Y TC Anticancer Agents DM3BH1Y DT Small molecular drug DM3BH1Y PC 208908 DM3BH1Y MW 581.1 DM3BH1Y FM C29H26ClFN4O4S DM3BH1Y IC InChI=1S/C29H26ClFN4O4S/c1-40(36,37)12-11-32-16-23-7-10-27(39-23)20-5-8-26-24(14-20)29(34-18-33-26)35-22-6-9-28(25(30)15-22)38-17-19-3-2-4-21(31)13-19/h2-10,13-15,18,32H,11-12,16-17H2,1H3,(H,33,34,35) DM3BH1Y CS CS(=O)(=O)CCNCC1=CC=C(O1)C2=CC3=C(C=C2)N=CN=C3NC4=CC(=C(C=C4)OCC5=CC(=CC=C5)F)Cl DM3BH1Y IK BCFGMOOMADDAQU-UHFFFAOYSA-N DM3BH1Y IU N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine DM3BH1Y CA CAS 231277-92-2 DM3BH1Y CB CHEBI:49603 DM3BH1Y DE Breast cancer DM26CQR ID DM26CQR DM26CQR DN Larotrectinib DM26CQR HS Approved DM26CQR SN UNII-PF9462I9HX; PF9462I9HX; ARRY 470; Larotrectinib [USAN:INN]; GTPL8909; SCHEMBL2241012; NYNZQNWKBKUAII-KBXCAEBGSA-N; BDBM136597; ZINC118399834; AKOS027338709; example 14 [US8865698 B2]; CS-5722; HY-12866; AS-35231; J3.628.138C; US8865698, 14; ARRY470; ARRY-470 DM26CQR CP Loxo Oncology/Bayer DM26CQR PC 46188928 DM26CQR MW 428.4 DM26CQR FM C21H22F2N6O2 DM26CQR IC InChI=1S/C21H22F2N6O2/c22-13-3-4-16(23)15(10-13)18-2-1-7-28(18)19-6-9-29-20(26-19)17(11-24-29)25-21(31)27-8-5-14(30)12-27/h3-4,6,9-11,14,18,30H,1-2,5,7-8,12H2,(H,25,31)/t14-,18+/m0/s1 DM26CQR CS C1C[C@@H](N(C1)C2=NC3=C(C=NN3C=C2)NC(=O)N4CC[C@@H](C4)O)C5=C(C=CC(=C5)F)F DM26CQR IK NYNZQNWKBKUAII-KBXCAEBGSA-N DM26CQR IU (3S)-N-[5-[(2R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidin-3-yl]-3-hydroxypyrrolidine-1-carboxamide DM26CQR CA CAS 1223403-58-4 DM26CQR DE Solid tumour/cancer DMSQ1JV ID DMSQ1JV DMSQ1JV DN LAS-34273 DMSQ1JV HS Approved DMSQ1JV SN Bretaris; Eklira; Aclidinium bromide; LAS-W-330; [1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]oct-8-yl] 2-hydroxy-2,2-dithiophen-2-yl-acetate Bromide DMSQ1JV CP Almirall DMSQ1JV DT Small molecular drug DMSQ1JV PC 11519741 DMSQ1JV MW 564.6 DMSQ1JV FM C26H30BrNO4S2 DMSQ1JV IC InChI=1S/C26H30NO4S2.BrH/c28-25(26(29,23-9-4-17-32-23)24-10-5-18-33-24)31-22-19-27(14-11-20(22)12-15-27)13-6-16-30-21-7-2-1-3-8-21;/h1-5,7-10,17-18,20,22,29H,6,11-16,19H2;1H/q+1;/p-1/t20?,22-,27?;/m0./s1 DMSQ1JV CS C1C[N+]2(CCC1[C@H](C2)OC(=O)C(C3=CC=CS3)(C4=CC=CS4)O)CCCOC5=CC=CC=C5.[Br-] DMSQ1JV IK XLAKJQPTOJHYDR-QTQXQZBYSA-M DMSQ1JV IU [(3R)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octan-3-yl] 2-hydroxy-2,2-dithiophen-2-ylacetate;bromide DMSQ1JV CA CAS 320345-99-1 DMSQ1JV CB CHEBI:65344 DMSQ1JV DE Chronic obstructive pulmonary disease DMXLVDT ID DMXLVDT DMXLVDT DN Lasmiditan DMXLVDT HS Approved DMXLVDT SN COL-144; LY-573144; Migraine therapy, CoLucid DMXLVDT CP Colucid pharmaceuticals DMXLVDT DT Small molecular drug DMXLVDT PC 11610526 DMXLVDT MW 377.4 DMXLVDT FM C19H18F3N3O2 DMXLVDT IC InChI=1S/C19H18F3N3O2/c1-25-7-5-11(6-8-25)18(26)15-3-2-4-16(23-15)24-19(27)17-13(21)9-12(20)10-14(17)22/h2-4,9-11H,5-8H2,1H3,(H,23,24,27) DMXLVDT CS CN1CCC(CC1)C(=O)C2=NC(=CC=C2)NC(=O)C3=C(C=C(C=C3F)F)F DMXLVDT IK XEDHVZKDSYZQBF-UHFFFAOYSA-N DMXLVDT IU 2,4,6-trifluoro-N-[6-(1-methylpiperidine-4-carbonyl)pyridin-2-yl]benzamide DMXLVDT CA CAS 439239-90-4 DMXLVDT DE Migraine DMHA18P ID DMHA18P DMHA18P DN Lasofoxifene DMHA18P HS Approved DMHA18P SN Oporia; 180916-16-9; rac-Lasofoxifene; CP 336156; Fablyn; UNII-337G83N988; (5R,6S)-6-phenyl-5-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalen-2-ol; CHEMBL328190; 337G83N988; (-)-cis-5,6,7,8-Tetrahydro-6-phenyl-5-(p-(2-(1-pyrrolidinyl)ethoxy)phenyl)-2-naphthol; 180915-78-0; CP-336,156; LASOFOXIFENE HCL; Lasofoxifene [INN:BAN]; AC1L50OI; SCHEMBL26815; GTPL7542; CTK8F1062; BDBM20606; DTXSID50171037; GXESHMAMLJKROZ-IAPPQJPRSA-N; ZINC3918428; BCP03626; AKOS030241621; AN-3516; BCP9000842; DB06202; Oporia; Lasofoxifene [INN]; Cis-1R-(4'-pyrrolidinoethoxyphenyl)-2S-phenyl-6-hydroxy-1,2,3,4-tetrahydronaphthalene, tartrate salt; AZD9639 DMHA18P CP Pfizer DMHA18P DT Small molecular drug DMHA18P PC 216416 DMHA18P MW 413.5 DMHA18P FM C28H31NO2 DMHA18P IC InChI=1S/C28H31NO2/c30-24-11-15-27-23(20-24)10-14-26(21-6-2-1-3-7-21)28(27)22-8-12-25(13-9-22)31-19-18-29-16-4-5-17-29/h1-3,6-9,11-13,15,20,26,28,30H,4-5,10,14,16-19H2/t26-,28+/m1/s1 DMHA18P CS C1CCN(C1)CCOC2=CC=C(C=C2)[C@H]3[C@H](CCC4=C3C=CC(=C4)O)C5=CC=CC=C5 DMHA18P IK GXESHMAMLJKROZ-IAPPQJPRSA-N DMHA18P IU (5R,6S)-6-phenyl-5-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalen-2-ol DMHA18P CA CAS 180916-16-9 DMHA18P CB CHEBI:135938 DMHA18P DE Osteoporosis; Virus infection DMANL0D ID DMANL0D DMANL0D DN Latamoxef DMANL0D HS Approved DMANL0D SN Festamoxin; LMOX; Lamoxactam; Latamoxefum; Moxalactam; Disodium Moxalactam; Lilly 127935; Ly127935; Sid 734787; Latamoxef (INN); Latamoxef [INN:BAN]; Latamoxefum [INN-Latin]; Oxa-cephem; S-6059; (6R,7R)-7-[[3-hydroxy-2-(4-hydroxyphenyl)-3-oxopropanoyl]amino]-7-methoxy-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[carboxy(4-hydroxyphenyl)acetyl]amino}-7-(methyloxy)-3-{[(1-methyl-1H-tetrazol-5-yl)thio]methyl}-8-oxo-5-oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[carboxy(4-hydroxyphenyl)acetyl]amino}-7-methoxy-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R-(6alpha,7alpha,7(S*)))-7-((Carboxy(4-hydroxyphenyl)acetyl)amino)-7-methoxy-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-8-oxo-5-oxa-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid; 1-Oxacephalosporin; 7b-[2-carboxy-2-(4-hydroxyphenyl)acetamido]-7a-methoxy-3-[[(1-methyl-1h-tetrazol-5-yl)thio]methyl]-1-oxa-1-dethia-3-cephem-4-carboxylic acid; 7beta-(2-Carboxy-2-(4-hydroxyphenyl)acetamido)-7alpha-methoxy-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-1-oxa-1-dethia-3-cephem-4-carboxylic acid DMANL0D TC Antibiotics DMANL0D DT Small molecular drug DMANL0D PC 47499 DMANL0D MW 520.5 DMANL0D FM C20H20N6O9S DMANL0D IC InChI=1S/C20H20N6O9S/c1-25-19(22-23-24-25)36-8-10-7-35-18-20(34-2,17(33)26(18)13(10)16(31)32)21-14(28)12(15(29)30)9-3-5-11(27)6-4-9/h3-6,12,18,27H,7-8H2,1-2H3,(H,21,28)(H,29,30)(H,31,32)/t12?,18-,20+/m1/s1 DMANL0D CS CN1C(=NN=N1)SCC2=C(N3[C@@H]([C@@](C3=O)(NC(=O)C(C4=CC=C(C=C4)O)C(=O)O)OC)OC2)C(=O)O DMANL0D IK JWCSIUVGFCSJCK-CAVRMKNVSA-N DMANL0D IU (6R,7R)-7-[[2-carboxy-2-(4-hydroxyphenyl)acetyl]amino]-7-methoxy-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid DMANL0D CA CAS 64952-97-2 DMANL0D CB CHEBI:599928 DMANL0D DE Bacterial infection DMI5OXG ID DMI5OXG DMI5OXG DN Latanoprost DMI5OXG HS Approved DMI5OXG SN Catioprost; Xalatan; Latanoprost free acid; L1167_SIGMA; PhXA41; XA41; AR-202; Nova-21027; PHXA-41; XA-41; Xalatan (TN); Latanoprost (JAN/USAN/INN); PhXA34 [as 15(R,S)-isomer]; Isopropyl (5Z,9alpha,11alpha,15R)-9,11,15-trihydroxy-17-phenyl-18,19,20-trinorprost-5-en-1-oate; Isopropyl (5Z,9alpha,11alpha,15R)-9,11,15-trihydroxy-17-phenyl-18,19,20-trinor-prost-5-en-1-oate; Isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((3R)-3-hydroxy-5-phenylpentyl)cyclopentyl)-5-heptenoate; Propan-2-yl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]hept-5-enoate; Propan-2-yl (5Z)-7-{(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl}hept-5-enoate DMI5OXG CP Pfizer Pharmaceuticals DMI5OXG TC Antihypertensive Agents DMI5OXG DT Small molecular drug DMI5OXG PC 5311221 DMI5OXG MW 432.6 DMI5OXG FM C26H40O5 DMI5OXG IC InChI=1S/C26H40O5/c1-19(2)31-26(30)13-9-4-3-8-12-22-23(25(29)18-24(22)28)17-16-21(27)15-14-20-10-6-5-7-11-20/h3,5-8,10-11,19,21-25,27-29H,4,9,12-18H2,1-2H3/b8-3-/t21-,22+,23+,24-,25+/m0/s1 DMI5OXG CS CC(C)OC(=O)CCC/C=C\\C[C@H]1[C@H](C[C@H]([C@@H]1CC[C@H](CCC2=CC=CC=C2)O)O)O DMI5OXG IK GGXICVAJURFBLW-CEYXHVGTSA-N DMI5OXG IU propan-2-yl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]hept-5-enoate DMI5OXG CA CAS 130209-82-4 DMI5OXG CB CHEBI:6384 DMI5OXG DE Open-angle glaucoma; Glaucoma/ocular hypertension; Ocular disease DMLFX7K ID DMLFX7K DMLFX7K DN LCZ696 DMLFX7K HS Approved DMLFX7K SN DTXSID50239500 DMLFX7K CP Novartis Pharmaceuticals DMLFX7K DT Small molecular drug DMLFX7K PC 71300864 DMLFX7K MW 970 DMLFX7K FM C48H64N6Na3O11+3 DMLFX7K IC InChI=1S/C24H29N5O3.C24H29NO5.3Na.3H2O/c1-4-5-10-21(30)29(22(16(2)3)24(31)32)15-17-11-13-18(14-12-17)19-8-6-7-9-20(19)23-25-27-28-26-23;1-3-30-24(29)17(2)15-21(25-22(26)13-14-23(27)28)16-18-9-11-20(12-10-18)19-7-5-4-6-8-19;;;;;;/h6-9,11-14,16,22H,4-5,10,15H2,1-3H3,(H,31,32)(H,25,26,27,28);4-12,17,21H,3,13-16H2,1-2H3,(H,25,26)(H,27,28);;;;3*1H2/q;;3*+1;;;/t22-;17-,21+;;;;;;/m01....../s1 DMLFX7K CS CCCCC(=O)N(CC1=CC=C(C=C1)C2=CC=CC=C2C3=NNN=N3)[C@@H](C(C)C)C(=O)O.CCOC(=O)[C@H](C)C[C@@H](CC1=CC=C(C=C1)C2=CC=CC=C2)NC(=O)CCC(=O)O.O.O.O.[Na+].[Na+].[Na+] DMLFX7K IK ACXLNSLRLQLEAL-HWSDWTSLSA-N DMLFX7K IU trisodium;4-[[(2S,4R)-5-ethoxy-4-methyl-5-oxo-1-(4-phenylphenyl)pentan-2-yl]amino]-4-oxobutanoic acid;(2S)-3-methyl-2-[pentanoyl-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]amino]butanoic acid;trihydrate DMLFX7K DE Heart failure DME6G97 ID DME6G97 DME6G97 DN Lefamulin DME6G97 HS Approved DME6G97 SN UNII-21904A5386; 1061337-51-6; CHEMBL3291398; 21904A5386; Lefamulin [INN]; Acetic acid, 2-(((1R,2R,4R)-4-amino-2-hydroxycyclohexyl)thio)-, (3aS,4R,5S,6S,8R,9R,9aR,10R)-6-ethenyldecahydro-5-hydroxy-4,6,9,10-tetramethyl-1-oxo-3a,9-propano-3ah-cyclopentacycloocten-8-yl ester; Lefamulin(BC-3781); Lefamulin [USAN:INN]; Acetic acid, 2-[[(1R,2R,4R)-4-amino-2-hydroxycyclohexyl]thio]-, (3aS,4R,5S,6S,8R,9R,9aR,10R)-6-ethenyldecahydro-5-hydroxy-4,6,9,10-tetramethyl-1-oxo-3a,9-propano-3aH-cyclopentacycloocten DME6G97 CP Nabriva Therapeutics King of Prussia, PA DME6G97 PC 25185057 DME6G97 MW 507.7 DME6G97 FM C28H45NO5S DME6G97 IC InChI=1S/C28H45NO5S/c1-6-26(4)14-22(34-23(32)15-35-21-8-7-18(29)13-20(21)31)27(5)16(2)9-11-28(17(3)25(26)33)12-10-19(30)24(27)28/h6,16-18,20-22,24-25,31,33H,1,7-15,29H2,2-5H3/t16-,17+,18-,20-,21-,22-,24+,25+,26-,27+,28+/m1/s1 DME6G97 CS C[C@@H]1CC[C@@]23CCC(=O)[C@H]2[C@@]1([C@@H](C[C@@]([C@H]([C@@H]3C)O)(C)C=C)OC(=O)CS[C@@H]4CC[C@H](C[C@H]4O)N)C DME6G97 IK KPVIXBKIJXZQJX-FCEONZPQSA-N DME6G97 IU [(1S,2R,3S,4S,6R,7R,8R,14R)-4-ethenyl-3-hydroxy-2,4,7,14-tetramethyl-9-oxo-6-tricyclo[5.4.3.01,8]tetradecanyl] 2-[(1R,2R,4R)-4-amino-2-hydroxycyclohexyl]sulfanylacetate DME6G97 CA CAS 1061337-51-6 DME6G97 DE Acute bacterial skin infection; Community-acquired pneumonia DMR8ONJ ID DMR8ONJ DMR8ONJ DN Leflunomide DMR8ONJ HS Approved DMR8ONJ SN Arava; Leflunomid; Leflunomida; Leflunomidum; Lefunamide; Aventis Behring Brand of Leflunomide; Aventis Brand of Leflunomide; Aventis Pharma Brand of Leflunomide; Hoechst Brand of Leflunomide; HWA 486; L 5025; SU 101; SU101; Arava (TN); Arava, Leflunomide; HWA-486; Leflunomida [INN-Spanish]; Leflunomide [USAN:INN]; Leflunomidum [INN-Latin]; Lefunomide [Inn-Spanish]; RS-34821; SU 101 (pharmaceutical); SU-101; AP-501/42475599; Leflunomide (JAN/USAN/INN); N-(4-trifluoromethyphenyl)-5-methylisoxazole-4-carboxamide; N-(4'-Trifluoromethylphenyl)-5-methylisoxazole-4-carboxamide; Alpha,alpha,alpha-Trifluoro-5-methyl-4-isoxazolecarboxy-p-toluidide; 4-Isoxazolecarboxamide, 5-methyl-N-(4-(trifluoromethyl)phenyl; 4-isoxazolecarboxamide,5-methyl-N-(4-(trifluoromethyl)phenyl); 5-Methyl-N-(4-(trifluoromethyl)phenyl)-4-isoxazolecarboxamide; 5-Methylisoxazole-4-(4-trifluoromethyl)carboxanilide; 5-Methylisoxazole-4-(4-trifluoromethylcarboxanilide); 5-Methylisoxazole-4-carboxylic acid (4-trifluoromethyl)anilide; 5-methyl-N-[4-(trifluoromethyl)phenyl]-1,2-oxazole-4-carboxamide; 5-methyl-N-[4-(trifluoromethyl)phenyl]-4-isoxazolecarboxamide; 5-methyl-N-[4-(trifluoromethyl)phenyl]isoxazole-4-carboxamide DMR8ONJ CP Sanofi-Aventis DMR8ONJ TC Antiinflammatory Agents DMR8ONJ DT Small molecular drug DMR8ONJ PC 3899 DMR8ONJ MW 270.21 DMR8ONJ FM C12H9F3N2O2 DMR8ONJ IC InChI=1S/C12H9F3N2O2/c1-7-10(6-16-19-7)11(18)17-9-4-2-8(3-5-9)12(13,14)15/h2-6H,1H3,(H,17,18) DMR8ONJ CS CC1=C(C=NO1)C(=O)NC2=CC=C(C=C2)C(F)(F)F DMR8ONJ IK VHOGYURTWQBHIL-UHFFFAOYSA-N DMR8ONJ IU 5-methyl-N-[4-(trifluoromethyl)phenyl]-1,2-oxazole-4-carboxamide DMR8ONJ CA CAS 75706-12-6 DMR8ONJ CB CHEBI:6402 DMR8ONJ DE Arthritis; Multiple sclerosis DM6Q7U4 ID DM6Q7U4 DM6Q7U4 DN Lenalidomide DM6Q7U4 HS Approved DM6Q7U4 SN Revamid; Revimid; Revlimid; Celgene brand of lenalidomide; Lenalidomide [USAN]; CC 5013; CC5013; CDC 501; IMiD3; IMiD3cpd; ALBB-015321; CC-5013; CDC-501; CDC-5013; ENMD-0997; IMID-5013; Revlimid (Celgene); Revlimid (TN); Thalidomide analog CC-5013; Lenalidomide (USAN/INN); CC-5013, Revlimid, Lenalidomide; 3-(4-Amino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione; 3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(7-Amino-3-oxo-1H-isoindol-2-yl)-piperidine-2,6-dione; 3-(7-amino-3-oxo-1H-isoindol-2-yl)piperidine-2,6-dione; Lenalidomide (Immunomodulator) DM6Q7U4 CP Celgene Corporation DM6Q7U4 TC Anticancer Agents DM6Q7U4 DT Small molecular drug DM6Q7U4 PC 216326 DM6Q7U4 MW 259.26 DM6Q7U4 FM C13H13N3O3 DM6Q7U4 IC InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18) DM6Q7U4 CS C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC=C3N DM6Q7U4 IK GOTYRUGSSMKFNF-UHFFFAOYSA-N DM6Q7U4 IU 3-(7-amino-3-oxo-1H-isoindol-2-yl)piperidine-2,6-dione DM6Q7U4 CA CAS 191732-72-6 DM6Q7U4 CB CHEBI:63791 DM6Q7U4 DE Multiple myeloma DMB1IU4 ID DMB1IU4 DMB1IU4 DN Lenvatinib DMB1IU4 HS Approved DMB1IU4 SN E 7080; E-7080, E7080; 4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxy-quinoline-6-carboxamide DMB1IU4 CP Eisai Co. Ltd. DMB1IU4 DT Small molecular drug DMB1IU4 PC 9823820 DMB1IU4 MW 426.9 DMB1IU4 FM C21H19ClN4O4 DMB1IU4 IC InChI=1S/C21H19ClN4O4/c1-29-19-10-17-13(9-14(19)20(23)27)18(6-7-24-17)30-12-4-5-16(15(22)8-12)26-21(28)25-11-2-3-11/h4-11H,2-3H2,1H3,(H2,23,27)(H2,25,26,28) DMB1IU4 CS COC1=CC2=NC=CC(=C2C=C1C(=O)N)OC3=CC(=C(C=C3)NC(=O)NC4CC4)Cl DMB1IU4 IK WOSKHXYHFSIKNG-UHFFFAOYSA-N DMB1IU4 IU 4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxyquinoline-6-carboxamide DMB1IU4 CA CAS 417716-92-8 DMB1IU4 CB CHEBI:85994 DMB1IU4 DE Ovarian cancer; Hepatocellular carcinoma; Melanoma; Solid tumour/cancer; Non-small-cell lung cancer; Renal cell carcinoma; Thyroid cancer DM1I3D5 ID DM1I3D5 DM1I3D5 DN Lepirudin DM1I3D5 HS Approved DM1I3D5 SN Refludan; Refludin; Aventis Behring Brand of Lepirudin; Aventis Brand Lepirudin; Aventis Pharma Brand of Lepirudin; Berlex Brand of Lepirudin; Hoechst Brand of Lepirudin; Lepirudin recombinant; Pharmion Brand of Lepirudin; Schering Brand of Lepirudin; Hbw 023; Hbw-023; 1-L-Leucine-2-L-threonine-63-desulfohirudin (Hirudomedicinalis isoform HV1); 1-Leu-2-thr-63-desulfohirudin DM1I3D5 TC Antithrombotic Agents DM1I3D5 DT Small molecular drug DM1I3D5 SQ DB00001 sequence: LVYTDCTESGQNLCLCEGSNVCGQGNKCILGSDGEKNQCVTGEGTPKPQSHNDGDFEEIPEEYLQ DM1I3D5 PC 118856773 DM1I3D5 MW 6979 DM1I3D5 FM C287H440N80O111S6 DM1I3D5 IC InChI=1S/C287H440N80O111S6/c1-24-132(17)225-280(470)345-162(87-126(5)6)236(426)306-111-209(396)320-181(116-370)267(457)344-176(101-220(416)417)238(428)307-105-203(390)316-152(61-74-213(402)403)243(433)321-146(40-29-32-80-288)241(431)339-171(96-198(298)385)259(449)326-153(56-69-194(294)381)250(440)351-186(121-482-479-118-183-240(430)310-107-202(389)313-148(54-67-192(292)379)233(423)303-108-206(393)317-170(95-197(297)384)258(448)322-147(41-30-33-81-289)242(432)350-187(272(462)359-225)122-483-480-119-184(269(459)323-150(60-73-212(400)401)235(425)304-110-208(395)319-180(115-369)266(456)342-174(99-201(301)388)265(455)357-223(130(13)14)278(468)355-183)352-254(444)165(90-129(11)12)335-270(460)185-120-481-484-123-188(354-263(453)178(103-222(420)421)347-283(473)230(137(22)375)362-264(454)168(93-141-48-52-144(378)53-49-141)346-282(472)228(135(20)373)361-232(422)145(291)86-125(3)4)273(463)363-229(136(21)374)281(471)330-158(65-78-217(410)411)249(439)348-179(114-368)239(429)309-106-204(391)315-151(55-68-193(293)380)244(434)340-172(97-199(299)386)260(450)334-164(89-128(9)10)253(443)353-185)271(461)358-224(131(15)16)279(469)364-227(134(19)372)277(467)311-112-205(392)314-149(59-72-211(398)399)234(424)305-113-210(397)356-231(138(23)376)286(476)367-85-37-45-191(367)276(466)331-160(42-31-34-82-290)284(474)365-83-35-43-189(365)274(464)328-154(57-70-195(295)382)248(438)349-182(117-371)268(458)338-169(94-142-104-302-124-312-142)257(447)341-173(98-200(300)387)261(451)343-175(100-219(414)415)237(427)308-109-207(394)318-177(102-221(418)419)262(452)337-166(91-139-38-27-26-28-39-139)255(445)327-155(62-75-214(404)405)245(435)325-159(66-79-218(412)413)251(441)360-226(133(18)25-2)285(475)366-84-36-44-190(366)275(465)329-157(64-77-216(408)409)246(436)324-156(63-76-215(406)407)247(437)336-167(92-140-46-50-143(377)51-47-140)256(446)333-163(88-127(7)8)252(442)332-161(287(477)478)58-71-196(296)383/h26-28,38-39,46-53,104,124-138,145-191,223-231,368-378H,24-25,29-37,40-45,54-103,105-123,288-291H2,1-23H3,(H2,292,379)(H2,293,380)(H2,294,381)(H2,295,382)(H2,296,383)(H2,297,384)(H2,298,385)(H2,299,386)(H2,300,387)(H2,301,388)(H,302,312)(H,303,423)(H,304,425)(H,305,424)(H,306,426)(H,307,428)(H,308,427)(H,309,429)(H,310,430)(H,311,467)(H,313,389)(H,314,392)(H,315,391)(H,316,390)(H,317,393)(H,318,394)(H,319,395)(H,320,396)(H,321,433)(H,322,448)(H,323,459)(H,324,436)(H,325,435)(H,326,449)(H,327,445)(H,328,464)(H,329,465)(H,330,471)(H,331,466)(H,332,442)(H,333,446)(H,334,450)(H,335,460)(H,336,437)(H,337,452)(H,338,458)(H,339,431)(H,340,434)(H,341,447)(H,342,456)(H,343,451)(H,344,457)(H,345,470)(H,346,472)(H,347,473)(H,348,439)(H,349,438)(H,350,432)(H,351,440)(H,352,444)(H,353,443)(H,354,453)(H,355,468)(H,356,397)(H,357,455)(H,358,461)(H,359,462)(H,360,441)(H,361,422)(H,362,454)(H,363,463)(H,364,469)(H,398,399)(H,400,401)(H,402,403)(H,404,405)(H,406,407)(H,408,409)(H,410,411)(H,412,413)(H,414,415)(H,416,417)(H,418,419)(H,420,421)(H,477,478)/t132-,133-,134+,135+,136+,137+,138+,145-,146-,147-,148-,149-,150-,151-,152-,153-,154-,155-,156-,157-,158-,159-,160-,161-,162-,163-,164-,165-,166-,167-,168-,169-,170-,171-,172-,173-,174-,175-,176-,177-,178-,179-,180-,181-,182-,183-,184-,185-,186-,187-,188-,189-,190-,191-,223-,224-,225-,226-,227-,228-,229-,230-,231-/m0/s1 DM1I3D5 CS CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H]2C(=O)NCC(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)C(C)C)CC(=O)N)CO)CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]3CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N3)CC(C)C)CC(=O)N)CCC(=O)N)CO)CCC(=O)O)[C@@H](C)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)N)C(=O)N1)CCCCN)CC(=O)N)CCC(=O)N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N5CCC[C@H]5C(=O)N[C@@H](CCCCN)C(=O)N6CCC[C@H]6C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC7=CNC=N7)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)NCC(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC8=CC=CC=C8)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N9CCC[C@H]9C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)O)CCC(=O)N)CC(=O)N)CCCCN)CCC(=O)O)CC(=O)O)CO)CC(C)C DM1I3D5 IK FIBJDTSHOUXTKV-BRHMIFOHSA-N DM1I3D5 IU (2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2S,3R)-2-[[2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2S)-2-[[(1R,6R,9S,12S,15S,18S,24S,27S,33S,36S,39R,44R,47S,53S,56S,59S,67S,73S,76S)-15,76-bis(4-aminobutyl)-44-[[(2S)-2-[[(4R,7S,10S,13S,19S,22S,25S,28R)-28-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-amino-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxybutanoyl]amino]-3-carboxypropanoyl]amino]-10-(2-amino-2-oxoethyl)-13-(3-amino-3-oxopropyl)-22-(2-carboxyethyl)-25-[(1R)-1-hydroxyethyl]-19-(hydroxymethyl)-7-(2-methylpropyl)-6,9,12,15,18,21,24,27-octaoxo-1,2-dithia-5,8,11,14,17,20,23,26-octazacyclononacosane-4-carbonyl]amino]-4-methylpentanoyl]amino]-12,56,73-tris(2-amino-2-oxoethyl)-9,67-bis(3-amino-3-oxopropyl)-36-[(2S)-butan-2-yl]-18,47-bis(2-carboxyethyl)-24-(carboxymethyl)-27,53-bis(hydroxymethyl)-33-(2-methylpropyl)-8,11,14,17,20,23,26,29,32,35,38,45,48,51,54,57,60,62,65,68,71,74,77-tricosaoxo-59-propan-2-yl-3,4,41,42-tetrathia-7,10,13,16,19,22,25,28,31,34,37,46,49,52,55,58,61,63,66,69,72,75,78-tricosazabicyclo[37.22.17]octaheptacontane-6-carbonyl]amino]-3-methylbutanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]-4-carboxybutanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-4-oxobutanoyl]amino]-3-carboxypropanoyl]amino]acetyl]amino]-3-carboxypropanoyl]amino]-3-phenylpropanoyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbonyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-5-oxopentanoic acid DM1I3D5 CA CAS 138068-37-8 DM1I3D5 CB CHEBI:142437 DM1I3D5 DE Thrombocytopenia DMPWSEM ID DMPWSEM DMPWSEM DN Lercanidipine DMPWSEM HS Approved DMPWSEM SN Lercanil; Masnidipine; Lercanidipine [INN]; Lercanidipine (INN); Lercanil (TN); REC 15-2375; Zanidip (TN); REC-15-2375; Methyl-1,1-dimethyl-2-(N-(3,3-diphenylpropyl)-N-methylamino)ethyl-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; (+-)-2-((3,3-Diphenylpropyl)methylamino)-1,1-dimethylethyl methyl1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate; 1-[(3,3-diphenylpropyl)(methyl)amino]-2-methylpropan-2-yl methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 3-[2-[(3,3-diphenylpropyl)methylamino]-1,1-dimethylethyl] 5-methyl ester; 5-O-[1-[3,3-diphenylpropyl(methyl)amino]-2-methylpropan-2-yl] 3-O-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate DMPWSEM CP Forest Laboratories DMPWSEM TC Antihypertensive Agents DMPWSEM DT Small molecular drug DMPWSEM PC 65866 DMPWSEM MW 611.7 DMPWSEM FM C36H41N3O6 DMPWSEM IC InChI=1S/C36H41N3O6/c1-24-31(34(40)44-6)33(28-18-13-19-29(22-28)39(42)43)32(25(2)37-24)35(41)45-36(3,4)23-38(5)21-20-30(26-14-9-7-10-15-26)27-16-11-8-12-17-27/h7-19,22,30,33,37H,20-21,23H2,1-6H3 DMPWSEM CS CC1=C(C(C(=C(N1)C)C(=O)OC(C)(C)CN(C)CCC(C2=CC=CC=C2)C3=CC=CC=C3)C4=CC(=CC=C4)[N+](=O)[O-])C(=O)OC DMPWSEM IK ZDXUKAKRHYTAKV-UHFFFAOYSA-N DMPWSEM IU 5-O-[1-[3,3-diphenylpropyl(methyl)amino]-2-methylpropan-2-yl] 3-O-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate DMPWSEM CA CAS 100427-26-7 DMPWSEM CB CHEBI:135930 DMPWSEM DE Hypertension DMUR64T ID DMUR64T DMUR64T DN Lesinurad DMUR64T HS Approved DMUR64T SN LESINURAD; 878672-00-5; RDEA594; Zurampic; RDEA 594; UNII-09ERP08I3W; RDEA-594; 2-((5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-yl)thio)acetic acid; 09ERP08I3W; AK323774; C17H14BrN3O2S; 2-[[5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-yl]thio]acetic acid; 2-[[5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-1,2,4-triazol-3-yl]sulfanyl]acetic acid; 2-(5-Bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid DMUR64T CP Ardea Biosciences DMUR64T DT Small molecular drug DMUR64T PC 53465279 DMUR64T MW 404.3 DMUR64T FM C17H14BrN3O2S DMUR64T IC InChI=1S/C17H14BrN3O2S/c18-16-19-20-17(24-9-15(22)23)21(16)14-8-7-11(10-5-6-10)12-3-1-2-4-13(12)14/h1-4,7-8,10H,5-6,9H2,(H,22,23) DMUR64T CS C1CC1C2=CC=C(C3=CC=CC=C23)N4C(=NN=C4Br)SCC(=O)O DMUR64T IK FGQFOYHRJSUHMR-UHFFFAOYSA-N DMUR64T IU 2-[[5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-1,2,4-triazol-3-yl]sulfanyl]acetic acid DMUR64T CA CAS 878672-00-5 DMUR64T CB CHEBI:90929 DMUR64T DE Hyperuricaemia DMQ2AIJ ID DMQ2AIJ DMQ2AIJ DN Lestaurtinib DMQ2AIJ HS Approved (orphan drug) DMQ2AIJ SN A 1544750; CEP 701; KT 5555; KT5555; SP 924; CEP-701; KT-5555; SPM-924; Lestaurtinib (USAN/INN) DMQ2AIJ CP Cephalon; Kyowa Hakko Kogyo DMQ2AIJ TC Anticancer Agents DMQ2AIJ DT Small molecular drug DMQ2AIJ PC 126565 DMQ2AIJ MW 439.5 DMQ2AIJ FM C26H21N3O4 DMQ2AIJ IC InChI=1S/C26H21N3O4/c1-25-26(32,12-30)10-18(33-25)28-16-8-4-2-6-13(16)20-21-15(11-27-24(21)31)19-14-7-3-5-9-17(14)29(25)23(19)22(20)28/h2-9,18,30,32H,10-12H2,1H3,(H,27,31)/t18-,25+,26+/m1/s1 DMQ2AIJ CS C[C@@]12[C@](C[C@@H](O1)N3C4=CC=CC=C4C5=C6C(=C7C8=CC=CC=C8N2C7=C53)CNC6=O)(CO)O DMQ2AIJ IK UIARLYUEJFELEN-LROUJFHJSA-N DMQ2AIJ IU (15S,16S,18R)-16-hydroxy-16-(hydroxymethyl)-15-methyl-28-oxa-4,14,19-triazaoctacyclo[12.11.2.115,18.02,6.07,27.08,13.019,26.020,25]octacosa-1,6,8,10,12,20,22,24,26-nonaen-3-one DMQ2AIJ CA CAS 111358-88-4 DMQ2AIJ CB CHEBI:91471 DMQ2AIJ DE Acute myeloid leukaemia; Psoriasis vulgaris; Myeloid leukaemia DMH07Y3 ID DMH07Y3 DMH07Y3 DN Letrozole DMH07Y3 HS Approved DMH07Y3 SN Femara; Femera; Letoval; Letrozol; Novartis Brand of Letrozole; CGS 20267; CGS-20267; FEM-345; Femara (TN); Letrozole [USAN:INN]; CGS 20267, Femara, Piroxicam, Letrozole; Letrozole (JAN/USP/INN); 1-[Bis-(4-cyanophenyl)methyl]-1,2,4-triazole; 1-[bis(4-cyanophenyl)methyl]-1,2,4-triazole; 4,4'-((1h-1,2,4-triazol-1-yl)methylene)dibenzonitrile; 4,4'-(1H-1,2,4-Triazol-1-ylmethylene)dibenzonitrile; 4,4'-(1H-1,2,4-triazol-1-yl-methylene)-bis(benzonitrile); 4,4'-(1H-1,2,4-triazol-1-ylmethanediyl)dibenzonitrile; 4,4'-(1H-1,2,4-triazol-1-ylmethylene)bis-Benzonitrile Letrozole; 4,4'-(1h-1,2,4-triazol-1-ylmethylene) bis-benzonitrile; 4,4'-(1h-1,2,4-triazol-1-ylmethylene)bis-benzonitrile; 4,4'-(1h-1,2,4-triazol-1-ylmethylene)bisbenzonitrile; 4-[(4-cyanophenyl)-(1,2,4-triazol-1-yl)methyl]benzonitrile DMH07Y3 TC Anticancer Agents DMH07Y3 DT Small molecular drug DMH07Y3 PC 3902 DMH07Y3 MW 285.3 DMH07Y3 FM C17H11N5 DMH07Y3 IC InChI=1S/C17H11N5/c18-9-13-1-5-15(6-2-13)17(22-12-20-11-21-22)16-7-3-14(10-19)4-8-16/h1-8,11-12,17H DMH07Y3 CS C1=CC(=CC=C1C#N)C(C2=CC=C(C=C2)C#N)N3C=NC=N3 DMH07Y3 IK HPJKCIUCZWXJDR-UHFFFAOYSA-N DMH07Y3 IU 4-[(4-cyanophenyl)-(1,2,4-triazol-1-yl)methyl]benzonitrile DMH07Y3 CA CAS 112809-51-5 DMH07Y3 CB CHEBI:6413 DMH07Y3 DE Hormonally-responsive breast cancer DMUAZWG ID DMUAZWG DMUAZWG DN Leucovorin DMUAZWG HS Approved DMUAZWG SN 5-formyltetrahydrofolate; Citrovorum factor; Folinic acid DMUAZWG TC Vitamins DMUAZWG DT Small molecular drug DMUAZWG PC 135403648 DMUAZWG MW 473.446 DMUAZWG FM C20H23N7O7 DMUAZWG IC InChI=1S/C20H23N7O7/c21-20-25-16-15(18(32)26-20)27(9-28)12(8-23-16)7-22-11-3-1-10(2-4-11)17(31)24-13(19(33)34)5-6-14(29)30/h1-4,9,12-13,22H,5-8H2,(H,24,31)(H,29,30)(H,33,34)(H4,21,23,25,26,32)/t12?,13-/m0/s1 DMUAZWG CS C1C(N(C2=C(N1)N=C(NC2=O)N)C=O)CNC3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O DMUAZWG IK VVIAGPKUTFNRDU-ABLWVSNPSA-N DMUAZWG IU (2S)-2-[[4-[(2-amino-5-formyl-4-oxo-3,6,7,8-tetrahydropteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid DMUAZWG CA CAS 58-05-9 DMUAZWG CB CHEBI:15640 DMUAZWG DE Colorectal cancer DMNWZJG ID DMNWZJG DMNWZJG DN Leucovorin Calcium DMNWZJG HS Approved DMNWZJG SN Leucovorin Calcium Preservative Free; Wellcovorin DMNWZJG CP Hospira Inc DMNWZJG TC Anticancer Agents DMNWZJG DT Small molecular drug DMNWZJG PC 135403647 DMNWZJG MW 511.5 DMNWZJG FM C20H21CaN7O7 DMNWZJG IC InChI=1S/C20H23N7O7.Ca/c21-20-25-16-15(18(32)26-20)27(9-28)12(8-23-16)7-22-11-3-1-10(2-4-11)17(31)24-13(19(33)34)5-6-14(29)30;/h1-4,9,12-13,22H,5-8H2,(H,24,31)(H,29,30)(H,33,34)(H4,21,23,25,26,32);/q;+2/p-2/t12?,13-;/m0./s1 DMNWZJG CS C1C(N(C2=C(N1)N=C(NC2=O)N)C=O)CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)[O-])C(=O)[O-].[Ca+2] DMNWZJG IK KVUAALJSMIVURS-ZEDZUCNESA-L DMNWZJG IU calcium;(2S)-2-[[4-[(2-amino-5-formyl-4-oxo-3,6,7,8-tetrahydropteridin-6-yl)methylamino]benzoyl]amino]pentanedioate DMNWZJG CA CAS 1492-18-8 DMNWZJG CB CHEBI:31340 DMNWZJG DE Solid tumour/cancer DMZT4N7 ID DMZT4N7 DMZT4N7 DN Leucovorin/5-fluorouracil DMZT4N7 HS Approved DMZT4N7 TC Vitamins DMZT4N7 DT Small molecular drug DMZT4N7 PC 54575 DMZT4N7 DE Colon cancer DM5XPIJ ID DM5XPIJ DM5XPIJ DN Leuprolide DM5XPIJ HS Approved DM5XPIJ SN Enantone; Eligard (TN); Leuprorelin (INN); Viadur (TN); 5-oxoprolylhistidyltryptophylseryltyrosylleucylleucyl-n5-(diaminomethylidene)ornithyl-n-ethylprolinamide DM5XPIJ CP Abbott Laboratories DM5XPIJ TC Anticancer Agents DM5XPIJ DT Small molecular drug DM5XPIJ SQ Leuprolide: PHWSYLLR DM5XPIJ PC 657181 DM5XPIJ MW 1209.4 DM5XPIJ FM C59H84N16O12 DM5XPIJ IC InChI=1S/C59H84N16O12/c1-6-63-57(86)48-14-10-22-75(48)58(87)41(13-9-21-64-59(60)61)68-51(80)42(23-32(2)3)69-52(81)43(24-33(4)5)70-53(82)44(25-34-15-17-37(77)18-16-34)71-56(85)47(30-76)74-54(83)45(26-35-28-65-39-12-8-7-11-38(35)39)72-55(84)46(27-36-29-62-31-66-36)73-50(79)40-19-20-49(78)67-40/h7-8,11-12,15-18,28-29,31-33,40-48,65,76-77H,6,9-10,13-14,19-27,30H2,1-5H3,(H,62,66)(H,63,86)(H,67,78)(H,68,80)(H,69,81)(H,70,82)(H,71,85)(H,72,84)(H,73,79)(H,74,83)(H4,60,61,64)/t40-,41-,42-,43+,44-,45-,46-,47-,48-/m0/s1 DM5XPIJ CS CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)[C@H](CC5=CN=CN5)NC(=O)[C@@H]6CCC(=O)N6 DM5XPIJ IK GFIJNRVAKGFPGQ-LIJARHBVSA-N DM5XPIJ IU (2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-5-(diaminomethylideneamino)-1-[(2S)-2-(ethylcarbamoyl)pyrrolidin-1-yl]-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide DM5XPIJ CA CAS 53714-56-0 DM5XPIJ CB CHEBI:6427 DM5XPIJ DE Prostate cancer DM15HAT ID DM15HAT DM15HAT DN Leuprorelin acetate DM15HAT HS Approved DM15HAT SN Leuprolide acetate; Leuplin (TN); Leuprorelin acetate (JAN); 5-oxoPro-His-Trp-Ser-Tyr-D-Leu-Leu-Arg-ProNHC2H5 dihydrate DM15HAT CP Takeda DM15HAT DT Small molecular drug DM15HAT PC 657180 DM15HAT MW 1269.4 DM15HAT FM C61H88N16O14 DM15HAT IC InChI=1S/C59H84N16O12.C2H4O2/c1-6-63-57(86)48-14-10-22-75(48)58(87)41(13-9-21-64-59(60)61)68-51(80)42(23-32(2)3)69-52(81)43(24-33(4)5)70-53(82)44(25-34-15-17-37(77)18-16-34)71-56(85)47(30-76)74-54(83)45(26-35-28-65-39-12-8-7-11-38(35)39)72-55(84)46(27-36-29-62-31-66-36)73-50(79)40-19-20-49(78)67-40;1-2(3)4/h7-8,11-12,15-18,28-29,31-33,40-48,65,76-77H,6,9-10,13-14,19-27,30H2,1-5H3,(H,62,66)(H,63,86)(H,67,78)(H,68,80)(H,69,81)(H,70,82)(H,71,85)(H,72,84)(H,73,79)(H,74,83)(H4,60,61,64);1H3,(H,3,4)/t40-,41-,42-,43+,44-,45-,46-,47-,48-;/m0./s1 DM15HAT CS CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)[C@H](CC5=CN=CN5)NC(=O)[C@@H]6CCC(=O)N6.CC(=O)O DM15HAT IK RGLRXNKKBLIBQS-XNHQSDQCSA-N DM15HAT IU acetic acid;(2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-5-(diaminomethylideneamino)-1-[(2S)-2-(ethylcarbamoyl)pyrrolidin-1-yl]-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide DM15HAT CA CAS 74381-53-6 DM15HAT CB CHEBI:63597 DM15HAT DE Prostate cancer DMJBOCR ID DMJBOCR DMJBOCR DN Levacecarnine HCL DMJBOCR HS Approved DMJBOCR SN Levocarnitine; L-carnitine; 541-15-1; vitamin BT; (R)-Carnitine; Carnitor; (-)-Carnitine; Carnitine; Karnitin; (-)-L-Carnitine; L-(-)-Carnitine; Levocarnitina; Carnitene; Levocarnitinum; Metina; L-Carnitine inner salt; Carniking; Carnovis; Carnitolo; Carnilean; Carrier; Lefcar; Carnitine, (-)-; L-carnitine Base; Levocarnitinum [Latin]; Levocarnitina [Spanish]; ST 198; L(-)-Carnitine; Carniking 50; (3R)-3-hydroxy-4-(trimethylammonio)butanoate; Levocarnitine [USAN:INN]; gamma-Trimethyl-beta-hydroxybutyrobetaine; bicarnesine; Nicetile (TN); L-Carnitine DMJBOCR DT Small molecular drug DMJBOCR PC 10917 DMJBOCR MW 161.2 DMJBOCR FM C7H15NO3 DMJBOCR IC InChI=1S/C7H15NO3/c1-8(2,3)5-6(9)4-7(10)11/h6,9H,4-5H2,1-3H3/t6-/m1/s1 DMJBOCR CS C[N+](C)(C)C[C@@H](CC(=O)[O-])O DMJBOCR IK PHIQHXFUZVPYII-ZCFIWIBFSA-N DMJBOCR IU (3R)-3-hydroxy-4-(trimethylazaniumyl)butanoate DMJBOCR CA CAS 541-15-1 DMJBOCR CB CHEBI:16347 DMJBOCR DE Nutritional deficiency; Cognitive impairment DM5YBO1 ID DM5YBO1 DM5YBO1 DN Levalbuterol DM5YBO1 HS Approved DM5YBO1 SN Levosalbutamol; 34391-04-3; (R)-salbutamol; Xopenex; R-Salbutamol; R-Albuterol; (r)-(-)-salbutamol; UNII-EDN2NBH5SS; 4-[(1R)-2-(tert-butylamino)-1-hydroxyethyl]-2-(hydroxymethyl)phenol; EDN2NBH5SS; CHEBI:8746; Levosalbutamol (INN); Levosalbutamol [INN]; (R)-albuterol; m-Xylene-alpha,alpha'-diol, alpha(sup 1)-((tert-butylamino)methyl)-4-hydroxy-, (R)-(-)-; (-)-alpha(sup 1)-(((1,1-Dimethylethyl)amino)methyl)-4-hydroxy-1,3-benzenedimethanol DM5YBO1 DT Small molecular drug DM5YBO1 PC 123600 DM5YBO1 MW 239.31 DM5YBO1 FM C13H21NO3 DM5YBO1 IC InChI=1S/C13H21NO3/c1-13(2,3)14-7-12(17)9-4-5-11(16)10(6-9)8-15/h4-6,12,14-17H,7-8H2,1-3H3/t12-/m0/s1 DM5YBO1 CS CC(C)(C)NC[C@@H](C1=CC(=C(C=C1)O)CO)O DM5YBO1 IK NDAUXUAQIAJITI-LBPRGKRZSA-N DM5YBO1 IU 4-[(1R)-2-(tert-butylamino)-1-hydroxyethyl]-2-(hydroxymethyl)phenol DM5YBO1 CA CAS 34391-04-3 DM5YBO1 CB CHEBI:8746 DM5YBO1 DE Asthma DMCOLUP ID DMCOLUP DMCOLUP DN Levallorphan DMCOLUP HS Approved DMCOLUP SN Levallofano; Levallorphane; Levallorphanum; Levalorfano; Naloxiphan; Levallofano [DCIT]; Levallorphan [INN:BAN]; Levallorphane [INN-French]; Levallorphanum [INN-Latin]; Levalorfano [INN-Spanish]; Lorfan (TN); Ro-1-7700; N-Allyl-3-hydroxymorphinan; L-N-Allyl-3-hydroxymorphinan; Levo-3-hydroxy-N-allyl morphinan; (-)-3-Hydroxy-N-allylmorphinan; 17-Allylmorphinan-3-ol; 17-prop-2-en-1-ylmorphinan-3-ol DMCOLUP CP Hoffmann La Roche Inc DMCOLUP TC Antinarcotic Agents DMCOLUP DT Small molecular drug DMCOLUP PC 5359371 DMCOLUP MW 283.4 DMCOLUP FM C19H25NO DMCOLUP IC InChI=1S/C19H25NO/c1-2-10-20-11-9-19-8-4-3-5-16(19)18(20)12-14-6-7-15(21)13-17(14)19/h2,6-7,13,16,18,21H,1,3-5,8-12H2/t16-,18+,19+/m0/s1 DMCOLUP CS C=CCN1CC[C@]23CCCC[C@H]2[C@H]1CC4=C3C=C(C=C4)O DMCOLUP IK OZYUPQUCAUTOBP-QXAKKESOSA-N DMCOLUP IU (1R,9R,10R)-17-prop-2-enyl-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-4-ol DMCOLUP CA CAS 152-02-3 DMCOLUP CB CHEBI:6431 DMCOLUP DE Narcotic depression DM5EN79 ID DM5EN79 DM5EN79 DN Levamisole DM5EN79 HS Approved DM5EN79 SN Ketrax; LEVOMYSOL; Lepuron; Levamisol; Levamisolum; Levotetramisole; Tetramisol; Wormicid; Levamisole Base;Nilverm base; P00039; Vermisol 150; Dl-Tetramisol; Dl-Tetramisole; Ergamisol (TN); Ketrax (TN); L-Tetramisole; Levamisol [INN-Spanish]; Levamisole (INN); Levamisole [INN:BAN]; Levamisolum [INN-Latin]; TCMDC-125847; L(-)-Levamisole; L-2,3,5,6-Tetrahyro-6-phenylimidazo(2,1-b)thiazole; (-)-Tetramisole; (6S)-6-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b][1,3]thiazole; (S)-(-)-Levamisole DM5EN79 CP Janssen Pharmaceutica DM5EN79 TC Anticancer Agents DM5EN79 DT Small molecular drug DM5EN79 PC 26879 DM5EN79 MW 204.29 DM5EN79 FM C11H12N2S DM5EN79 IC InChI=1S/C11H12N2S/c1-2-4-9(5-3-1)10-8-13-6-7-14-11(13)12-10/h1-5,10H,6-8H2/t10-/m1/s1 DM5EN79 CS C1CSC2=N[C@H](CN21)C3=CC=CC=C3 DM5EN79 IK HLFSDGLLUJUHTE-SNVBAGLBSA-N DM5EN79 IU (6S)-6-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b][1,3]thiazole DM5EN79 CA CAS 14769-73-4 DM5EN79 CB CHEBI:6432 DM5EN79 DE Parasitic infection; Colon cancer DMTGDN8 ID DMTGDN8 DMTGDN8 DN Levetiracetam DMTGDN8 HS Approved DMTGDN8 SN 102767-28-2; Keppra; (S)-2-(2-Oxopyrrolidin-1-yl)butanamide; Keppra XR; Levetiracetamum; ucb L059; (2S)-2-(2-oxopyrrolidin-1-yl)butanamide; UCB-L 059; UCB-L059; Spritam; (S)-alpha-Ethyl-2-oxo-1-pyrrolidineacetamide; (-)-(S)-alpha-Ethyl-2-oxo-1-pyrrolidineacetamide; SIB-S1; UNII-44YRR34555; 1-Pyrrolidineacetamide, alpha-ethyl-2-oxo-, (alphaS)-; UCB-22059; Levetiracetamum [INN-Latin]; Levetiractam; CHEBI:6437; ucb L060; Levetiracetam In Sodium Chloride; 44YRR34555; Levroxa; 1-Pyrrolidineacetamide, alpha-ethyl-2-oxo-,; Keppra; Leviteracetam; Torleva; Levetiracetam [INN]; Ucb L060; Etiracetam levo-isomer; Keppra (TN); L-059; Etiracetam, S-isomer; Keppra, Keppra XR),Levetiracetam; Levetriacetam DMTGDN8 CP UCB Pharmaceuticals Inc DMTGDN8 TC Anticonvulsants DMTGDN8 DT Small molecular drug DMTGDN8 PC 5284583 DMTGDN8 MW 170.21 DMTGDN8 FM C8H14N2O2 DMTGDN8 IC InChI=1S/C8H14N2O2/c1-2-6(8(9)12)10-5-3-4-7(10)11/h6H,2-5H2,1H3,(H2,9,12)/t6-/m0/s1 DMTGDN8 CS CC[C@@H](C(=O)N)N1CCCC1=O DMTGDN8 IK HPHUVLMMVZITSG-LURJTMIESA-N DMTGDN8 IU (2S)-2-(2-oxopyrrolidin-1-yl)butanamide DMTGDN8 CA CAS 102767-28-2 DMTGDN8 CB CHEBI:6437 DMTGDN8 DE Fibromyalgia; Epilepsy DMSREPX ID DMSREPX DMSREPX DN Levobetaxolol DMSREPX HS Approved DMSREPX SN Levobetaxolol [INN]; Betaxon (TN); (2S)-1-[4-[2-(cyclopropylmethoxy)ethyl]phenoxy]-3-(propan-2-ylamino)propan-2-ol; (2S)-1-{4-[2-(cyclopropylmethoxy)ethyl]phenoxy}-3-(propan-2-ylamino)propan-2-ol; (2s)-1-{4-[2-(cyclopropylmethoxy)ethyl]phenoxy}-3-(isopropylamino)propan-2-ol; (S)-(-)-Betaxolol; (S)-1-(isopropylamino)-3-[p-(cyclopropylmethoxyethyl)phenoxy]-2-propanol; (S)-Betaxolol DMSREPX CP Alcon Pharmaceuticals Ltd DMSREPX TC Cardiotonic Agents DMSREPX DT Small molecular drug DMSREPX PC 60657 DMSREPX MW 307.4 DMSREPX FM C18H29NO3 DMSREPX IC InChI=1S/C18H29NO3/c1-14(2)19-11-17(20)13-22-18-7-5-15(6-8-18)9-10-21-12-16-3-4-16/h5-8,14,16-17,19-20H,3-4,9-13H2,1-2H3/t17-/m0/s1 DMSREPX CS CC(C)NC[C@@H](COC1=CC=C(C=C1)CCOCC2CC2)O DMSREPX IK NWIUTZDMDHAVTP-KRWDZBQOSA-N DMSREPX IU (2S)-1-[4-[2-(cyclopropylmethoxy)ethyl]phenoxy]-3-(propan-2-ylamino)propan-2-ol DMSREPX CA CAS 93221-48-8 DMSREPX CB CHEBI:59254 DMSREPX DE Chronic open-angle glaucoma DMTNFCQ ID DMTNFCQ DMTNFCQ DN Levobunolol DMTNFCQ HS Approved DMTNFCQ SN Akbeta; Betagan; Levobunololum; Levobunolol HCl; Betegan (TN); Levobunolol (INN); Levobunolol [INN:BAN]; Levobunololum [INN-Latin]; Liquifilm (TN); W-6412A; W-7000A; AK-Beta (TN); (-)-Bunolol; (S)-5-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)-3,4-dihydro-1(2H)-naphthalenone; 5-[(2S)-3-(tert-butylamino)-2-hydroxypropoxy]-3,4-dihydro-2H-naphthalen-1-one; 5-[(2S)-3-(tert-butylamino)-2-hydroxypropoxy]-3,4-dihydronaphthalen-1(2H)-one DMTNFCQ CP Allergan Pharmaceuticals DMTNFCQ TC Sympatholytics DMTNFCQ DT Small molecular drug DMTNFCQ PC 39468 DMTNFCQ MW 291.4 DMTNFCQ FM C17H25NO3 DMTNFCQ IC InChI=1S/C17H25NO3/c1-17(2,3)18-10-12(19)11-21-16-9-5-6-13-14(16)7-4-8-15(13)20/h5-6,9,12,18-19H,4,7-8,10-11H2,1-3H3/t12-/m0/s1 DMTNFCQ CS CC(C)(C)NC[C@@H](COC1=CC=CC2=C1CCCC2=O)O DMTNFCQ IK IXHBTMCLRNMKHZ-LBPRGKRZSA-N DMTNFCQ IU 5-[(2S)-3-(tert-butylamino)-2-hydroxypropoxy]-3,4-dihydro-2H-naphthalen-1-one DMTNFCQ CA CAS 47141-42-4 DMTNFCQ CB CHEBI:6438 DMTNFCQ DE Open-angle glaucoma DM783CH ID DM783CH DM783CH DN Levobupivacaine DM783CH HS Approved DM783CH SN Novabupi; Chirocaine (TN); Levobupivacaine (INN); Levobupivacaine [INN:BAN]; Novabupi (TN); L(-)-Bupivacaine; L-(-)-bupivacaine; L-(-)-1-Butyl-2',6'-pipecoloxylidide; (2S)-1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide; (S)-1-Butyl-2',6'-pipecoloxylidide; (S)-bupivacaine DM783CH CP AstraZeneca DM783CH TC Anesthetics DM783CH DT Small molecular drug DM783CH PC 92253 DM783CH MW 288.4 DM783CH FM C18H28N2O DM783CH IC InChI=1S/C18H28N2O/c1-4-5-12-20-13-7-6-11-16(20)18(21)19-17-14(2)9-8-10-15(17)3/h8-10,16H,4-7,11-13H2,1-3H3,(H,19,21)/t16-/m0/s1 DM783CH CS CCCCN1CCCC[C@H]1C(=O)NC2=C(C=CC=C2C)C DM783CH IK LEBVLXFERQHONN-INIZCTEOSA-N DM783CH IU (2S)-1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide DM783CH CA CAS 27262-47-1 DM783CH CB CHEBI:6149 DM783CH DE Anaesthesia DMMZPWT ID DMMZPWT DMMZPWT DN Levocabastine DMMZPWT HS Approved DMMZPWT SN Levocabastin; Levocabastina; Levocabastinum; Livostin; Levocabastina [Spanish]; Levocabastinum [Latin]; Levocabastine (INN); Levocabastine [INN:BAN]; Livostin (TN); (3S,4R)-1-[4-cyano-4-(4-fluorophenyl)cyclohexyl]-3-methyl-4-phenylpiperidine-4-carboxylic acid; 1-(4-cyano-4-(4-fluorophenyl)cyclohexyl)-3-methyl-4-phenyl-4-piperidinecarboxylic acid DMMZPWT CP Janssen Pharmaceutica DMMZPWT TC Antiallergic Agents DMMZPWT DT Small molecular drug DMMZPWT PC 54385 DMMZPWT MW 420.5 DMMZPWT FM C26H29FN2O2 DMMZPWT IC InChI=1S/C26H29FN2O2/c1-19-17-29(16-15-26(19,24(30)31)21-5-3-2-4-6-21)23-11-13-25(18-28,14-12-23)20-7-9-22(27)10-8-20/h2-10,19,23H,11-17H2,1H3,(H,30,31)/t19-,23?,25?,26-/m1/s1 DMMZPWT CS C[C@@H]1CN(CC[C@@]1(C2=CC=CC=C2)C(=O)O)C3CCC(CC3)(C#N)C4=CC=C(C=C4)F DMMZPWT IK ZCGOMHNNNFPNMX-YHYDXASRSA-N DMMZPWT IU (3S,4R)-1-[4-cyano-4-(4-fluorophenyl)cyclohexyl]-3-methyl-4-phenylpiperidine-4-carboxylic acid DMMZPWT CA CAS 79449-98-2 DMMZPWT CB CHEBI:92584 DMMZPWT DE Allergic conjunctivitis DMQYLGP ID DMQYLGP DMQYLGP DN Levocetirizine DMQYLGP HS Approved DMQYLGP SN (-)-Cetirizine; (-)-Cetirizine Dihydrochloride; (2-(4-((R-p-Chloro-alpha-phenylbenzyl)-1-piperazinyl)ethoxy)acetic acid; (2-{4-[(R)-(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl}ethoxy)acetic acid; (R)-2-(2-(4-((4-Chlorophenyl)(phenyl)methyl)piperazin-1-yl)ethoxy)acetic acid; (R)-Cetirizine dihydrochloride; 6U5EA9RT2O; Acetic acid, (2-(4-((R)-(4-chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)-; Levocetirizine; Levocetirizine HCl; UNII-6U5EA9RT2O; Xarlin; Xyzal; cetirizine-d4; levocetrizine DMQYLGP DT Small molecular drug DMQYLGP PC 1549000 DMQYLGP MW 388.892 DMQYLGP FM C21H25ClN2O3 DMQYLGP IC InChI=1S/C21H25ClN2O3/c22-19-8-6-18(7-9-19)21(17-4-2-1-3-5-17)24-12-10-23(11-13-24)14-15-27-16-20(25)26/h1-9,21H,10-16H2,(H,25,26)/t21-/m1/s1 DMQYLGP CS C1CN(CCN1CCOCC(=O)O)C(C2=CC=CC=C2)C3=CC=C(C=C3)Cl DMQYLGP IK ZKLPARSLTMPFCP-OAQYLSRUSA-N DMQYLGP IU 2-[2-[4-[(R)-(4-chlorophenyl)-phenylmethyl]piperazin-1-yl]ethoxy]acetic acid DMQYLGP CA CAS 130018-77-8 DMQYLGP CB CHEBI:94559 DMQYLGP DE Allergy DMW6ZJI ID DMW6ZJI DMW6ZJI DN Levocetirizine dihydrochloride DMW6ZJI HS Approved DMW6ZJI SN Xyzal; Xyzall; Levocetirizine HCl; Levocetirizine dihydrochloride [USAN]; Levocetirizine hydrochloride; Levocetirizine 2HCl; KS-1177; Levocetirizine hydrochloride (JAN); Vozet (TN); Xozal (TN); Xusal (TN); Xuzal (TN); Xyzal (TN); Xyzall (TN); Acetic acid, (2-(4-((R)-(4-chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)-, dihydrochloride; (2-(4-((R)-(4-Chlorophenyl)phenylmethyl)piperazin-1-yl)ethoxy)acetic acid dihydrochloride DMW6ZJI CP GlaxoSmithKline DMW6ZJI TC Antiallergic Agents DMW6ZJI DT Small molecular drug DMW6ZJI PC 9955977 DMW6ZJI MW 461.8 DMW6ZJI FM C21H27Cl3N2O3 DMW6ZJI IC InChI=1S/C21H25ClN2O3.2ClH/c22-19-8-6-18(7-9-19)21(17-4-2-1-3-5-17)24-12-10-23(11-13-24)14-15-27-16-20(25)26;;/h1-9,21H,10-16H2,(H,25,26);2*1H/t21-;;/m1../s1 DMW6ZJI CS C1CN(CCN1CCOCC(=O)O)[C@H](C2=CC=CC=C2)C3=CC=C(C=C3)Cl.Cl.Cl DMW6ZJI IK PGLIUCLTXOYQMV-GHVWMZMZSA-N DMW6ZJI IU 2-[2-[4-[(R)-(4-chlorophenyl)-phenylmethyl]piperazin-1-yl]ethoxy]acetic acid;dihydrochloride DMW6ZJI CA CAS 130018-87-0 DMW6ZJI DE Allergic rhinitis DMN3E57 ID DMN3E57 DMN3E57 DN Levodopa DMN3E57 HS Approved DMN3E57 SN Levodopa (optimized formulation, Parkinson's disease); More effective levodopa (Parkinson's disease), Orion; Levodopa (optimized formulation, Parkinson's disease), Orion DMN3E57 CP Orion Corp DMN3E57 DT Small molecular drug DMN3E57 PC 6047 DMN3E57 MW 197.19 DMN3E57 FM C9H11NO4 DMN3E57 IC InChI=1S/C9H11NO4/c10-6(9(13)14)3-5-1-2-7(11)8(12)4-5/h1-2,4,6,11-12H,3,10H2,(H,13,14)/t6-/m0/s1 DMN3E57 CS C1=CC(=C(C=C1C[C@@H](C(=O)O)N)O)O DMN3E57 IK WTDRDQBEARUVNC-LURJTMIESA-N DMN3E57 IU (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid DMN3E57 CA CAS 59-92-7 DMN3E57 CB CHEBI:15765 DMN3E57 DE Parkinson disease DMS60RB ID DMS60RB DMS60RB DN Levofloxacin DMS60RB HS Approved DMS60RB SN Aeroquin; Cravit; Elequine; Floxacin; Floxel; Iquix; LFX; LVX; Leroxacin; Lesacin; Levaquin; Levofloxacine; Levofloxacino; Levofloxacinum; Levokacin; Levox; Levoxacin; Mosardal; Nofaxin; Oftaquix; Quixin; Reskuin; Tavanic; Volequin; Cravit Ophthalmic; DR 3354; DR3355; HR 355; Cravit (TN); D-Levofloxacin; DR-3355; HR-355; Iquix (TN); L-Ofloxacin; LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER; Levaquin (TN); Levofloxacin (INN); Levofloxacin tablet, suspension or intravenous; Levofloxacine [INN-French]; Levofloxacino [INN-Spanish]; Levofloxacinum [INN-Latin]; MP-376; Oftaquix (TN); Quixin (TN); R-Ofloxacin; RWJ 25213-097; RWJ-25213; Tavanic (TN); Levofloxacin [USAN:INN:JAN]; DR-3355: L-isomer of ofloxacin; Ofloxacin S-(-)-form; S-(-)-Ofloxacin; (-)-(S)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid; (-)-(S)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyridol[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid hemihydrate; (-)-(S)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7Hpyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid hemihydrate; (3S)-9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid; (R)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid; (R)-isomer; (S)-(-)-Ofloxacin; (S)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid; (S)-Ofloxacin DMS60RB CP Sanofi-Aventis DMS60RB TC Antibiotics DMS60RB DT Small molecular drug DMS60RB PC 149096 DMS60RB MW 361.4 DMS60RB FM C18H20FN3O4 DMS60RB IC InChI=1S/C18H20FN3O4/c1-10-9-26-17-14-11(16(23)12(18(24)25)8-22(10)14)7-13(19)15(17)21-5-3-20(2)4-6-21/h7-8,10H,3-6,9H2,1-2H3,(H,24,25)/t10-/m0/s1 DMS60RB CS C[C@H]1COC2=C3N1C=C(C(=O)C3=CC(=C2N4CCN(CC4)C)F)C(=O)O DMS60RB IK GSDSWSVVBLHKDQ-JTQLQIEISA-N DMS60RB IU (2S)-7-fluoro-2-methyl-6-(4-methylpiperazin-1-yl)-10-oxo-4-oxa-1-azatricyclo[7.3.1.05,13]trideca-5(13),6,8,11-tetraene-11-carboxylic acid DMS60RB CA CAS 100986-85-4 DMS60RB CB CHEBI:63598 DMS60RB DE Bacterial infection DMUV5JB ID DMUV5JB DMUV5JB DN Levomefolic acid DMUV5JB HS Approved DMUV5JB SN Levomefolic acid; Levomefolinic acid; Metafolin; Metafolin (TN); L-5-Methyltetrahydrofolate; LEVOMEFOLATE; (6s)-5-methyltetrahydrofolic acid; (S)-2-(4-((((S)-2-Amino-5-methyl-4-oxo-3,4,5,6,7,8-hexahydropteridin-6-yl)methyl)amino)benzamido)pentanedioic acid; 31690-09-2; 5-METHYL-5,6,7,8-TETRAHYDROFOLIC ACID; 5-Methyltetrahydrofolate; 8S95DH25XC; C20H25N7O6; CHEBI:15641; LMSR; N-(5-methyl-5,6,7,8-tetrahydropteroyl)-L-glutamic acid; UNII-8S95DH25XC; [(6S)-5-methyl-5,6,7,8-tetrahydropteroyl]glutamate DMUV5JB PC 135398561 DMUV5JB MW 459.5 DMUV5JB FM C20H25N7O6 DMUV5JB IC ZNOVTXRBGFNYRX-STQMWFEESA-N DMUV5JB CS CN1C(CNC2=C1C(=O)NC(=N2)N)CNC3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O DMUV5JB IK 1S/C20H25N7O6/c1-27-12(9-23-16-15(27)18(31)26-20(21)25-16)8-22-11-4-2-10(3-5-11)17(30)24-13(19(32)33)6-7-14(28)29/h2-5,12-13,22H,6-9H2,1H3,(H,24,30)(H,28,29)(H,32,33)(H4,21,23,25,26,31)/t12-,13-/m0/s1 DMUV5JB IU (2S)-2-[[4-[[(6S)-2-amino-5-methyl-4-oxo-3,6,7,8-tetrahydropteridin-6-yl]methylamino]benzoyl]amino]pentanedioic acid DMUV5JB CA CAS 31690-09-2 DMUV5JB CB CHEBI:15641 DMUV5JB DE Contraception DMIKFEL ID DMIKFEL DMIKFEL DN Levomepromazine DMIKFEL HS Approved DMIKFEL SN METHOTRIMEPRAZINE; Nozinan; 60-99-1; Levoprome; Levomepromazina; Levomepromazinum; Levomepromazin; Nosinan; UNII-9G0LAW7ATQ; 2-Methoxytrimeprazine; Neozine; Levotomin; Minozinan; Milezin; 9G0LAW7ATQ; RP-7044; Levopromazioni; Veractil; Nomizan; Hirnamine; Dedoran; Nocinan; Nirnamine; CHEBI:6838; XP03; Methoxytrimeprazine; F-5116; Methotrimeprazine [USP]; Methotrimeprazine (USP); Bayer 1213; Arc-VI-C-5; CL 36467; CL 39743; Levomepromazinum [INN-Latin]; Levomepromazina [INN-Spanish]; EINECS 200-495-5; Methotrimeprazine DMIKFEL CP Immunex Corp DMIKFEL DT Small molecular drug DMIKFEL PC 72287 DMIKFEL MW 328.5 DMIKFEL FM C19H24N2OS DMIKFEL IC InChI=1S/C19H24N2OS/c1-14(12-20(2)3)13-21-16-7-5-6-8-18(16)23-19-10-9-15(22-4)11-17(19)21/h5-11,14H,12-13H2,1-4H3/t14-/m1/s1 DMIKFEL CS C[C@@H](CN1C2=CC=CC=C2SC3=C1C=C(C=C3)OC)CN(C)C DMIKFEL IK VRQVVMDWGGWHTJ-CQSZACIVSA-N DMIKFEL IU (2R)-3-(2-methoxyphenothiazin-10-yl)-N,N,2-trimethylpropan-1-amine DMIKFEL CA CAS 60-99-1 DMIKFEL CB CHEBI:6838 DMIKFEL DE Psychotic disorder; Bipolar disorder DM06HG5 ID DM06HG5 DM06HG5 DN Levomethadyl Acetate DM06HG5 HS Approved DM06HG5 SN LAAM; Levacetilmetadol; Levacetylmethadol; Levacetylmethadolum; Levomethadyl; Orlaam; Levacetylmethadol [INN]; Levacetilmetadol [INN-Spanish]; Levacetylmethadol (INN); Levacetylmethadolum [INN-Latin]; Levo-Alphacetylmethadol; Levo-Methadyl acetate; Levomethadyl acetate (USAN); Orlaam (TN); A-l-acetylmethadol; Alpha-l-Acetylmethadol; L-alpha-Acetylmethadol; Levo-alpha-Acetylmethadol; N-alpha-Acetylmethadol; Alpha-(-)-Acetylmethadol; [(3S,6S)-6-(dimethylamino)-4,4-diphenylheptan-3-yl] acetate; [S-(R*,R*)]-beta-[2-Dimethylamino)propyl]-alpha-ethyl-beta-phenylbenzeneethanol acetate (ester); Benzeneethanol, beta-[(2S)-2-(dimethylamino)propyl]-alpha-ethyl-beta-phenyl-, acetate (ester), (alphaS)-(9CI); (-)-alpha-Acetylmethadol; (1S,4S)-4-(dimethylamino)-1-ethyl-2,2-diphenylpentyl acetate; (3S,6S)-6-(dimethylamino)-4,4-diphenylheptan-2-yl acetate; 1-alpha-Acetylmethadol; 3-Heptanol, 6-(dimethylamino)-4,4-diphenyl-, acetate (ester), (3S,6S)-(-)-(8CI) DM06HG5 CP Roxane Laboratories DM06HG5 TC Analgesics DM06HG5 DT Small molecular drug DM06HG5 PC 15130 DM06HG5 MW 353.5 DM06HG5 FM C23H31NO2 DM06HG5 IC InChI=1S/C23H31NO2/c1-6-22(26-19(3)25)23(17-18(2)24(4)5,20-13-9-7-10-14-20)21-15-11-8-12-16-21/h7-16,18,22H,6,17H2,1-5H3/t18-,22-/m0/s1 DM06HG5 CS CC[C@@H](C(C[C@H](C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2)OC(=O)C DM06HG5 IK XBMIVRRWGCYBTQ-AVRDEDQJSA-N DM06HG5 IU [(3S,6S)-6-(dimethylamino)-4,4-diphenylheptan-3-yl] acetate DM06HG5 CA CAS 1477-40-3 DM06HG5 CB CHEBI:6441 DM06HG5 DE Opioid dependence DM429AE ID DM429AE DM429AE DN Levomethadyl acetate hydrochloride DM429AE HS Approved DM429AE SN Levacetilmetadol; Levacetilmetadol [INN-Spanish]; Levacetylmethadol; Levacetylmethadol (INN); Levacetylmethadol [INN]; Levacetylmethadolum; Levacetylmethadolum [INN-Latin]; Levomethadyl; Levomethadyl acetate; Levacetyl methadol hydrochloride; LAAM hydrochloride; Levomethadyl acetate HCl; MK 790; MK-790 hydrochloride; ORLAAM hydrochloride; l-Acetylmethadol hydrochloride; (-)-(3S,6S)-6-(Dimethylamino)-4,4-diphenyl-3-heptanol acetate (ester), hydrochloride; 43033-72-3; 6-Dimethylamino-4,4-diphenyl-3-heptanolacetate.HCl; B54CW5KG52; CCRIS 3321; Levomethadyl acetate hydrochloride; Levomethadyl acetate hydrochloride [USAN]; UNII-B54CW5KG52; alpha-l-Acetylmethadol hydrochloride; l-alpha-Acetylmethadol hydrochloride; N-alpha-Acetylmethadol; Orlaam; alpha-l-Acetylmethadol; l-alpha-Acetylmethadol; levo-Alphacetylmethadol; levo-Methadyl acetate; levo-alpha-Acetylmethadol; (-)-alpha-Acetylmethadol; 1-alpha-Acetylmethadol; 1477-40-3; DEA No. 9648; LAAM; UNII-R3B637Y991; alpha-(-)-Acetylmethadol DM429AE PC 39371 DM429AE MW 390 DM429AE FM C23H32ClNO2 DM429AE IC UXBPQRGCVJOTNT-COBSGTNCSA-N DM429AE CS CCC(C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2)OC(=O)C.Cl DM429AE IK 1S/C23H31NO2.ClH/c1-6-22(26-19(3)25)23(17-18(2)24(4)5,20-13-9-7-10-14-20)21-15-11-8-12-16-21;/h7-16,18,22H,6,17H2,1-5H3;1H/t18-,22-;/m0./s1 DM429AE IU [(3S,6S)-6-(dimethylamino)-4,4-diphenylheptan-3-yl] acetate;hydrochloride DM429AE CA CAS 43033-72-3 DM429AE CB CHEBI:6442 DM429AE DE Opiate dependence DMV26S8 ID DMV26S8 DMV26S8 DN Levomilnacipran DMV26S8 HS Approved DMV26S8 SN Fetzima; UNII-UGM0326TXX; Levomilnacipran HCl; 96847-54-0; UGM0326TXX; CHEMBL99946; F-2695; (1S,2R)-2-(aminomethyl)-N,N-diethyl-1-phenylcyclopropanecarboxamide; (1S,2R)-2-(aminomethyl)-N,N-diethyl-1-phenylcyclopropane-1-carboxamide; Levomilnacipran [USAN:INN]; Milnacipram; AC1OCEN8; F 2695; Levomilnacipran (USAN/INN); ZINC506; SCHEMBL1414867; GTPL7435; GJJFMKBJSRMPLA-DZGCQCFKSA-N; CHEBI:136040; BDBM50032379; SB17447; DB08918; f2-695; D10072 DMV26S8 CP Forest Laboratories DMV26S8 DT Small molecular drug DMV26S8 PC 6917779 DMV26S8 MW 246.35 DMV26S8 FM C15H22N2O DMV26S8 IC InChI=1S/C15H22N2O/c1-3-17(4-2)14(18)15(10-13(15)11-16)12-8-6-5-7-9-12/h5-9,13H,3-4,10-11,16H2,1-2H3/t13-,15+/m0/s1 DMV26S8 CS CCN(CC)C(=O)[C@]1(C[C@H]1CN)C2=CC=CC=C2 DMV26S8 IK GJJFMKBJSRMPLA-DZGCQCFKSA-N DMV26S8 IU (1S,2R)-2-(aminomethyl)-N,N-diethyl-1-phenylcyclopropane-1-carboxamide DMV26S8 CA CAS 96847-54-0 DMV26S8 CB CHEBI:136040 DMV26S8 DE Fibromyalgia DM1DP7T ID DM1DP7T DM1DP7T DN Levonorgestrel DM1DP7T HS Approved DM1DP7T SN norgestrel; 797-63-7; D-Norgestrel; (-)-Norgestrel; Microval; Levonova; Postinor; Mirena; Ovrette; Neogest; Jadelle; Plan B; NORPLANT; Norplant 2; Microlution; Follistrel; Trivora; Monovar; Triciclor; Microgyn; Ovranette; Triagynon; Microlut; Nordet; Trigoa; 18-Methylnorethisterone; Levonorgestrelum; Microgynon CD; Microgest ED; Norplant II; Ovral-Lo; Logynon ED; Levlen ED; Trinordiol 28; Trinordiol 21; Microgynon 28; Microgynon 21; d(-)-Norgestrel; Neogynon 21; Monofeme 28; Nordette 28; Minivlar 30; Stediril 30; Nordette 21; Trifeme; Capronor; DNorgestrel; Levlen; Levonelle; Methylnorethindrone; Microluton; NorLevo; Norgeston; Norgestrel; Norgestrelum; Preven; Tetragynon; LD norgestrel [French]; Ld norgestrel; Levonorgestrel implants; Norgestrel [Progestins]; Norplant System in Plastic Container; Triquilar ED; Microgynon 30 ED; SH 70850; SH 850; Trifeme 28; Triphasil 21; Triphasil 28; Wy 3707; Alpha-Norgestrel; Component of Lo/ovral; Dl-Norgestrel; FH 122-A; LO/Ovral; Levonorgestrelum [INN-Latin]; Levora-21; Levora-28; Mirena (TN); Norgestrelum [INN-Latin]; Norplant (TN); Norplant-2; Ovoplex 30-150; Ovrette (TN); Postinor-2; Rigevidon 21+7; SOH-075; Tri-Levlen 21; Wy-3707; Wy-5104; E-Gen-C; Levonorgestrel [USAN:INN:BAN]; D(-)-Norgestrel; Levonorgestrel (JAN/USP/INN); Norgestrel (JP15/USP/INN); Norgestrel [USAN:BAN:INN:JAN]; Norgestrel [USAN:INN:BAN:JAN]; D-(-)-Norgestrel; Levonelle, D-Norgestrel, Levonova, Levonorgestrel; Norgestrel-(-)-D; Dl-13-beta-Ethyl-17-alpha-ethynyl-19-nortestosterone; 13-BETA-ETHYL-17-ALPHA-ETHYNYL-17-BETA-HYDROXYGON-4-EN-3-ONE; 13-Ehyl-17alpha-ethynyl-17-hydroxygon-4-en-3-one; 13-Ethyl-17-alpha-ethynyl-17-beta-hydroxy-4-gonen-3-one; 13-Ethyl-17-alpha-ethynylgon-4-en-17-beta-ol-3-one; 13-Ethyl-17alpha-ethynylgon-4-en-17beta-ol-3-one; 13-beta-Ethyl-17alpha-ethynyl-17beta-hydroxygon-4-en-3-one; 13beta-Ethyl-17alpha-ethynyl-17beta-hydroxygon-4-en-3-one; 17-Ethynyl-18-methyl-19-nortestosterone; 17-alpha-Ethynyl-13-ethyl-19-nortestosterone; 17alpha-Ethynyl-13-ethyl-19-nortestosterone; 17alpha-Ethynyl-13beta-ethyl-3-oxo-4-estren-17beta-ol; 17alpha-Ethynyl-17-hydroxy-18-methylestr-4-en-3-one; 17alpha-Ethynyl-18-homo-19-nor-testosterone; 17alpha-Ethynyl-18-homo-19-nortestosterone; 17alpha-ethynyl-17beta-hydroxy-18a-homoestr-4-en-3-one; 18,19-Dinor-4-pregnen-20-yn-3-one; 18-Methyl-17-alpha-ethynyl-19-nortestosterone; 72-HOURS DM1DP7T TC Contraceptive Agents DM1DP7T DT Small molecular drug DM1DP7T PC 13109 DM1DP7T MW 312.4 DM1DP7T FM C21H28O2 DM1DP7T IC InChI=1S/C21H28O2/c1-3-20-11-9-17-16-8-6-15(22)13-14(16)5-7-18(17)19(20)10-12-21(20,23)4-2/h2,13,16-19,23H,3,5-12H2,1H3/t16-,17+,18+,19-,20-,21-/m0/s1 DM1DP7T CS CC[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC(=O)CC[C@H]34 DM1DP7T IK WWYNJERNGUHSAO-XUDSTZEESA-N DM1DP7T IU (8R,9S,10R,13S,14S,17R)-13-ethyl-17-ethynyl-17-hydroxy-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-one DM1DP7T CA CAS 797-63-7 DM1DP7T CB CHEBI:6443 DM1DP7T DE Contraception DMECB4H ID DMECB4H DMECB4H DN Levopropoxyphene Napsylate Anhydrous DMECB4H HS Approved DMECB4H SN Novrad DMECB4H CP Eli Lilly Industries Inc DMECB4H DT Small molecular drug DMECB4H PC 6604497 DMECB4H MW 547.7 DMECB4H FM C32H37NO5S DMECB4H IC InChI=1S/C22H29NO2.C10H8O3S/c1-5-21(24)25-22(18(2)17-23(3)4,20-14-10-7-11-15-20)16-19-12-8-6-9-13-19;11-14(12,13)10-6-5-8-3-1-2-4-9(8)7-10/h6-15,18H,5,16-17H2,1-4H3;1-7H,(H,11,12,13)/t18-,22+;/m0./s1 DMECB4H CS CCC(=O)O[C@@](CC1=CC=CC=C1)(C2=CC=CC=C2)[C@@H](C)CN(C)C.C1=CC=C2C=C(C=CC2=C1)S(=O)(=O)O DMECB4H IK VZPXFHVJUUSVLH-VNJAQMQMSA-N DMECB4H IU [(2R,3S)-4-(dimethylamino)-3-methyl-1,2-diphenylbutan-2-yl] propanoate;naphthalene-2-sulfonic acid DMECB4H CA CAS 5714-90-9 DMECB4H DE Cough DM2XVNI ID DM2XVNI DM2XVNI DN Levormeloxifene DM2XVNI HS Approved DM2XVNI SN Centchroman; Centron; Levormeloxifene; Ormeloxifene; Saheli; NNC-46-0020; Non-steroidal (oral, contraception/cancer); Non-steroidal (oral, contraception/cancer), Central Drug Research Institute (CDRI) DM2XVNI CP Novo Nordisk A/S; Central Drug Research Institute DM2XVNI DT Small molecular drug DM2XVNI PC 35805 DM2XVNI MW 457.6 DM2XVNI FM C30H35NO3 DM2XVNI IC InChI=1S/C30H35NO3/c1-30(2)29(23-9-5-4-6-10-23)28(26-16-15-25(32-3)21-27(26)34-30)22-11-13-24(14-12-22)33-20-19-31-17-7-8-18-31/h4-6,9-16,21,28-29H,7-8,17-20H2,1-3H3/t28-,29+/m1/s1 DM2XVNI CS CC1([C@H]([C@@H](C2=C(O1)C=C(C=C2)OC)C3=CC=C(C=C3)OCCN4CCCC4)C5=CC=CC=C5)C DM2XVNI IK XZEUAXYWNKYKPL-WDYNHAJCSA-N DM2XVNI IU 1-[2-[4-[(3R,4R)-7-methoxy-2,2-dimethyl-3-phenyl-3,4-dihydrochromen-4-yl]phenoxy]ethyl]pyrrolidine DM2XVNI CA 78994-23-7 DM2XVNI DE Breast cancer DMGS80V ID DMGS80V DMGS80V DN Levorphanol DMGS80V HS Approved DMGS80V SN levorphanol; Levorphan; Methorphinan; Aromarone; Racemethorphanum; Dromoran; Cetarin; Antalgin; Levo-Dromoran; Racemic dromoran; Methorfinan [Czech]; Levorfanolo [DCIT]; Levorphanolum; Levorfanol; Orphan; Levorfanol [INN-Spanish]; Levorphanolum [INN-Latin]; Racemorfano [INN-Spanish]; 17-Methylmorphinan-3-ol; N-Methyl-3-hydroxymorphinan; Racemorphan; Racemorphan [INN:BAN]; Racemorphane [INN-French]; Racemorphanum [INN-Latin]; (-)-N-Methylmorphinan-3-ol; Morphinan-3-ol, 17-methyl-; Levorphanal; dl-3-Hydroxy-N-methylmorphinan; DEA No; Antalgin; DEXTRORPHAN; Levodroman; Levorfanolo; Methorfinan; Racemorfano; Racemorphane; Racemorphanum; NU 2206; L-Dromoran; Levorphanol (INN); Ro 1-5431; Levo-Dromoran (TN); Dl-3-Hydroxy-N-methylmorphinan; (+)-3-Hydroxy-17-methylmorphinan; (+-)-17-Methylmorphinan-3-ol; (+-)-3-Hydroxy-N-methylmorphinan; (-)-3-Hydroxy-N-methylmorphinan; 1,3,4,9,10,10a-Hexahydro-11-methyl-2H-10,4a-iminoethanophenanthren-6-ol, dl-mixture; 1,3,4,9,10,10a-Hexahydro-6-hydroxy-2H-10,4a-(iminoethano)-11-methylphenanthrene; 3-Hydroxy-N-methylmorphinan; Dextrorphan DMGS80V CP Roxane Laboratories DMGS80V TC Analgesics DMGS80V DT Small molecular drug DMGS80V PC 5359272 DMGS80V MW 257.37 DMGS80V FM C17H23NO DMGS80V IC InChI=1S/C17H23NO/c1-18-9-8-17-7-3-2-4-14(17)16(18)10-12-5-6-13(19)11-15(12)17/h5-6,11,14,16,19H,2-4,7-10H2,1H3/t14-,16+,17+/m0/s1 DMGS80V CS CN1CC[C@]23CCCC[C@H]2[C@H]1CC4=C3C=C(C=C4)O DMGS80V IK JAQUASYNZVUNQP-USXIJHARSA-N DMGS80V IU (1R,9R,10R)-17-methyl-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-4-ol DMGS80V CA CAS 297-90-5 DMGS80V CB CHEBI:6444 DMGS80V DE Pain; Ischemic stroke DMKBOS2 ID DMKBOS2 DMKBOS2 DN Levosimendan DMKBOS2 HS Approved DMKBOS2 SN Levosimedan; Levosimendanum; Simdax; Levosimendan [INN]; Simdax (TN); Levosimendan (USAN/INN); Mesoxalonitrile(p-((R)-1,4,5,6-tetrahydro-4-methyl-6-oxo-pyridazinyl)phenyl)hydrazone; Mesoxalonitrile (-)-(p((R)-1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl)hydrazone; ((4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl)hydrazono)propanedinitrile; (-)-OR-1259; (R)-((4-(1,4,5,6-Tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl)hydrazono) propanedintrile; (R)-((4-(1,4,5,6-Tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl)hydrazono)propanedinitrile; ({4-[(4R)-4-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl]phenyl}hydrazono)propanedintrile; 2-[[4-[(4R)-4-methyl-6-oxo-4,5-dihydro-1H-pyridazin-3-yl]phenyl]hydrazinylidene]propanedinitrile DMKBOS2 CP Abbott Laboratories DMKBOS2 TC Cardiotonic Agents DMKBOS2 DT Small molecular drug DMKBOS2 PC 3033825 DMKBOS2 MW 280.28 DMKBOS2 FM C14H12N6O DMKBOS2 IC InChI=1S/C14H12N6O/c1-9-6-13(21)19-20-14(9)10-2-4-11(5-3-10)17-18-12(7-15)8-16/h2-5,9,17H,6H2,1H3,(H,19,21)/t9-/m1/s1 DMKBOS2 CS C[C@@H]1CC(=O)NN=C1C2=CC=C(C=C2)NN=C(C#N)C#N DMKBOS2 IK WHXMKTBCFHIYNQ-SECBINFHSA-N DMKBOS2 IU 2-[[4-[(4R)-4-methyl-6-oxo-4,5-dihydro-1H-pyridazin-3-yl]phenyl]hydrazinylidene]propanedinitrile DMKBOS2 CA CAS 141505-33-1 DMKBOS2 CB CHEBI:50567 DMKBOS2 DE Cardiac output syndrome; Pulmonary hypertension; Congestive heart failure; Heart failure DMHN027 ID DMHN027 DMHN027 DN Levothyroxine DMHN027 HS Approved DMHN027 SN Eltroxin; Euthyrox; Forthyron; Laevothyroxinum; Laevoxin; Levolet; Levothroid; Levothyrox; Levothyroxin; Levoxyl; Oroxine; Synthroid; THX; Tetraiodothyronine; Thyratabs; Thyrax; Thyreoideum; Thyroxevan; Thyroxin; Thyroxinal; Levothyroxine sodium; Synthroid sodium; Thyroxine [BAN]; Thyroxine iodine; LT00440967; T4 levothyroxine; DL-Thyroxin; Eltroxin (TN); Euthyrox (TN); Eutirox (TN); Forthyron (TN); L-Thryoxin; L-Thyroxin; L-thyroxine; Laevothyroxinum (acid); Levaxin (TN); Levo-T; Levothyroxine (BAN); Levothyroxinum (acid); Levoxyl (TN); Synthroid (TN); T-3850; T4 (Hormone); Thyrax (TN); Thyrox (TN); Thyroxine (VAN); Thyroxine (l); L-thyroxine (TN); Levothyroxine Sodium (L-thyroxine); Levothroid (*Sodiumsalt*); Synthroid (*Sodium salt*); Thyroxine, L-(8CI); L-3,5,3',5'-Tetraiodothyronine; O-(4-Hydroxy-3,5-diiodophenyl)-3,5-diiodotyrosine; Beta-((3,5-Diiodo-4-hydroxyphenoxy)-3,5-diiodophenyl)alanine; O-(4-Hydroxy-3,5-diidophenyl)-3,5-diiodo-L-tyrosine; O-(4-hydroxy-3,5-diiodophenyl)-3,5-diiodo-L-tyrosine; (-)-Thyroxine; (125I)T4; (2S)-2-amino-3-[4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]propanoic acid; 2-amino-3-[4-(4-hydroxy-3,5-diiodo-phenoxy)-3,5-diiodo-phenyl]-propanoic acid; 3,3',5,5"-Tetraiodo-L-thyronine; 3,3',5,5''-Tetraiodo-L-thyronine; 3,3',5,5'-Tetraiodo-L-thyronine; 3,5,3',5'-Tetraiodo-L-thyronine; 3,5,3',5'-Tetraiodothyronine; 3,5,3'5'-Tetraiodo-L-thyronine; 3-(4-(4-Hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl)alanine; 3-[4-(4-Hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]-L-alanine; 4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodo-L-phenylalanine DMHN027 CP Abbott Laboratories DMHN027 TC Antithyroid Agents DMHN027 DT Small molecular drug DMHN027 PC 5819 DMHN027 MW 776.87 DMHN027 FM C15H11I4NO4 DMHN027 IC InChI=1S/C15H11I4NO4/c16-8-4-7(5-9(17)13(8)21)24-14-10(18)1-6(2-11(14)19)3-12(20)15(22)23/h1-2,4-5,12,21H,3,20H2,(H,22,23)/t12-/m0/s1 DMHN027 CS C1=C(C=C(C(=C1I)OC2=CC(=C(C(=C2)I)O)I)I)C[C@@H](C(=O)O)N DMHN027 IK XUIIKFGFIJCVMT-LBPRGKRZSA-N DMHN027 IU (2S)-2-amino-3-[4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]propanoic acid DMHN027 CA CAS 51-48-9 DMHN027 CB CHEBI:18332 DMHN027 DE Hypothyroidism DM4PUDW ID DM4PUDW DM4PUDW DN L-glutamic acid DM4PUDW HS Approved DM4PUDW SN Aciglut; Glu; Glusate; Glut; Glutacid; Glutamicol; Glutamidex; Glutaminol; Glutaton; Gulutamine; Acide glutamique; Acido glutamico; Acidum glutamicum; Acidum glutaminicum; Glutamic acid polymer; Glutaminic acid; E 620; A-Aminoglutaric acid; A-Glutamic acid; Acide glutamique [INN-French]; Acido glutamico [INN-Spanish]; Acidum glutamicum [INN-Latin]; D-Glutamiensuur; Glutamic Acid [USAN:INN]; Glutamic acid (VAN); Glutaminic acid (VAN); Gulutamine (USP); L-Glutamic acid hydrochloride; L-Glutaminic acid; L-Glutaminsaeure; L-glu; L-glutamate; Alpha-Aminoglutaric acid (VAN); Alpha-L-Glutamic acid polymer; Glutamic Acid (L-glutamic acid); Glutamic acid (H-3); H-Glu-OH; L-2-Aminoglutaric acid; L-Glutamic acid (9CI); L-Glutamic acid (JAN); L-Glutamic acid, homopolymer; L-a-Aminoglutaric acid; L-alpha-Aminoglutaric acid; Poly-L-glutamate; Sodium Glutamate (L-glutamic Acid); Glutamic acid, L-, peptides; L-Glutamic acid, homopolymer (9CI); Poly(alpha-L-glutamic acid); Glutamic acid, L-(7CI,8CI); L-(+)-glutamic acid; (S)-(+)-Glutamic acid; (S)-2-Aminopentanedioic acid; (S)-Glutamic acid; 1-Aminopropane-1,3-dicarboxylic acid DM4PUDW TC Dietary supplement DM4PUDW DT Small molecular drug DM4PUDW PC 33032 DM4PUDW MW 147.13 DM4PUDW FM C5H9NO4 DM4PUDW IC InChI=1S/C5H9NO4/c6-3(5(9)10)1-2-4(7)8/h3H,1-2,6H2,(H,7,8)(H,9,10)/t3-/m0/s1 DM4PUDW CS C(CC(=O)O)[C@@H](C(=O)O)N DM4PUDW IK WHUUTDBJXJRKMK-VKHMYHEASA-N DM4PUDW IU (2S)-2-aminopentanedioic acid DM4PUDW CA CAS 56-86-0 DM4PUDW CB CHEBI:16015 DM4PUDW DE Schizophrenia DM69G8X ID DM69G8X DM69G8X DN L-glutamine DM69G8X HS Approved DM69G8X SN NutreStore; AES-14; Aesgen-14; Glutamine (INN); L-glutamine (oral, short bowel syndrome), Emmaus; L-glutamine (topical, chemotherapy-induced mucositis), Aesgen; L-glutamine (oral, sickle cell anemia/sickle beta-0 thalassemia), Emmaus; L-glutamine (oral, sickle cell anemia/sickle beta-0 thalassemia), Emmaus/University of California Los Angeles DM69G8X CP Nutritional Restart DM69G8X DT Small molecular drug DM69G8X PC 5961 DM69G8X MW 146.14 DM69G8X FM C5H10N2O3 DM69G8X IC InChI=1S/C5H10N2O3/c6-3(5(9)10)1-2-4(7)8/h3H,1-2,6H2,(H2,7,8)(H,9,10)/t3-/m0/s1 DM69G8X CS C(CC(=O)N)[C@@H](C(=O)O)N DM69G8X IK ZDXPYRJPNDTMRX-VKHMYHEASA-N DM69G8X IU (2S)-2,5-diamino-5-oxopentanoic acid DM69G8X CA CAS 56-85-9 DM69G8X CB CHEBI:18050 DM69G8X DE Short bowel syndrome DMNQXV8 ID DMNQXV8 DMNQXV8 DN LGX818 DMNQXV8 HS Approved DMNQXV8 SN Encorafenib; 1269440-17-6; LGX-818; Encorafenib (LGX818); UNII-8L7891MRB6; LGX 818; 8L7891MRB6; Encorafenib [USAN:INN]; LGX-818(Encorafenib) DMNQXV8 CP Array BioPharma DMNQXV8 DT Small molecular drug DMNQXV8 PC 50922675 DMNQXV8 MW 540 DMNQXV8 FM C22H27ClFN7O4S DMNQXV8 IC InChI=1S/C22H27ClFN7O4S/c1-12(2)31-11-16(17-6-7-25-21(28-17)26-10-13(3)27-22(32)35-4)20(29-31)15-8-14(23)9-18(19(15)24)30-36(5,33)34/h6-9,11-13,30H,10H2,1-5H3,(H,27,32)(H,25,26,28)/t13-/m0/s1 DMNQXV8 CS C[C@@H](CNC1=NC=CC(=N1)C2=CN(N=C2C3=C(C(=CC(=C3)Cl)NS(=O)(=O)C)F)C(C)C)NC(=O)OC DMNQXV8 IK CMJCXYNUCSMDBY-ZDUSSCGKSA-N DMNQXV8 IU methyl N-[(2S)-1-[[4-[3-[5-chloro-2-fluoro-3-(methanesulfonamido)phenyl]-1-propan-2-ylpyrazol-4-yl]pyrimidin-2-yl]amino]propan-2-yl]carbamate DMNQXV8 CA CAS 1269440-17-6 DMNQXV8 DE Melanoma DML4ZOT ID DML4ZOT DML4ZOT DN Lidocaine DML4ZOT HS Approved DML4ZOT SN Alphacaine; Anestacon; Cappicaine; Cuivasil; Dalcaine; Dentipatch; DermaFlex; Dilocaine; Duncaine; EMBOLEX; Esracaine; Gravocain; Isicaina; Isicaine; Jetocaine; LIDOPEN; LQZ; Lanabiotic; Leostesin; Lidocaina; Lidocainum; Lidocaton; Lidoderm; Lignocaine; Lignocainum; Lingocaine; Maricaine; Octocaine; Remicaine; Rucaina; Solcain; Xilina; Xilocaina; Xllina; Xycaine; Xylestesin; Xylesthesin; Xylocain; Xylocaine; Xylocard; Xylocitin; Xylotox; Zingo; After Burn Double Strength Gel; After Burn Double Strength Spray; After Burn Gel; After Burn Spray; Anestacon Jelly; Cito optadren; Emla Cream; Lidocaine Carbonate; Lidocaine Hydrocarbonate; Lidocaine Monohydrochloride; Norwood Sunburn Spray; Rocephin Kit; Solarcaine aloe extraburn relief cream; Xilocaina [Italian]; Xylocaine Dental Ointment; Xylocaine Endotracheal; Xylocaine Test Dose; Xylocaine Viscous; CDS1_000283; L1026_SIGMA; Xylocaine CO2; Dentipatch (TN); ELA-Max; L-Caine; Lida-Mantle; Lidocaina [INN-Spanish]; Lidocaine (VAN); Lidocainum [INN-Latin]; Lidoject-1; Lidoject-2; Octocaine-100; Octocaine-50; Xylocaine (TN); Xylocaine 5% Spinal; Xylocaine-Mpf; Xylocaine-Mpf with Glucose; Xyloneural (free base); Zilactin-L; Lidocaine [USAN:INN:JAN]; Diethylaminoaceto-2,6-xylidide; Lidocaine (JP15/USP/INN); Alfa-Dietilamino-2,6-dimetilacetanilide; Alfa-Dietilamino-2,6-dimetilacetanilide [Italian]; Alpha-Diethylamino-2,6-dimethylacetanilide; Alpha-Diethylaminoaceto-2,6-xylidide; LIDOCAINE (73-58-6 (MONOHYDROCHLORIDE); Omega-Diethylamino-2,6-dimethylacetanilide; Alpha-(Diethylamino)-2,6-acetoxylidide; N-(2,6-dimethylphenyl)-N(2),N(2)-diethylglycinamide; N-(2,6-dimethylphenyl)-N~2~,N~2~-diethylglycinamide; 2-(Diethylamino)-2',6'-acetoxylidide; 2-(Diethylamino)-N-(2,6-dimethylphenyl)acetamide; 2-Diethylamino-N-(2,6-dimethyl-phenyl)-acetamide; 2-Diethylamino-N-(2,6-dimethylphenyl)acetamide DML4ZOT CP Endo Pharmaceuticals DML4ZOT TC Anesthetics DML4ZOT DT Small molecular drug DML4ZOT PC 3676 DML4ZOT MW 234.34 DML4ZOT FM C14H22N2O DML4ZOT IC InChI=1S/C14H22N2O/c1-5-16(6-2)10-13(17)15-14-11(3)8-7-9-12(14)4/h7-9H,5-6,10H2,1-4H3,(H,15,17) DML4ZOT CS CCN(CC)CC(=O)NC1=C(C=CC=C1C)C DML4ZOT IK NNJVILVZKWQKPM-UHFFFAOYSA-N DML4ZOT IU 2-(diethylamino)-N-(2,6-dimethylphenyl)acetamide DML4ZOT CA CAS 137-58-6 DML4ZOT CB CHEBI:6456 DML4ZOT DE Anaesthesia; Dysmenorrhea DMV23GL ID DMV23GL DMV23GL DN Lidoflazine DMV23GL HS Approved DMV23GL SN LIDOFLAZINE; Ordiflazine; Corflazine; Clinium; Lidoflazinum; Lidoflazin; 3416-26-0; Klinium; Angex; Lidoflazina [Italian]; McN-JR 7904; UNII-J4ZHN3HBTE; Lidoflazinum [INN-Latin]; Lidoflazina [INN-Spanish]; Lidoflazine [USAN:INN:BAN]; C30H35F2N3O; J4ZHN3HBTE; EINECS 222-312-8; R 7904; BRN 0904339; CHEMBL92870; MCN-JR-7904; 4-(4,4-Bis(p-fluorophenyl)butyl)-1-piperazineaceto-2',6'-xylidide; 1-Piperazineacetamide, 4-(4,4-bis(4-fluorophenyl)butyl)-N-(2,6-dimethylphenyl)-; NCGC00016627-01; NCGC00016627-04; CAS-3416-26-0 DMV23GL DT Small molecular drug DMV23GL PC 3926 DMV23GL MW 491.6 DMV23GL FM C30H35F2N3O DMV23GL IC InChI=1S/C30H35F2N3O/c1-22-5-3-6-23(2)30(22)33-29(36)21-35-19-17-34(18-20-35)16-4-7-28(24-8-12-26(31)13-9-24)25-10-14-27(32)15-11-25/h3,5-6,8-15,28H,4,7,16-21H2,1-2H3,(H,33,36) DMV23GL CS CC1=C(C(=CC=C1)C)NC(=O)CN2CCN(CC2)CCCC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F DMV23GL IK ZBIAKUMOEKILTF-UHFFFAOYSA-N DMV23GL IU 2-[4-[4,4-bis(4-fluorophenyl)butyl]piperazin-1-yl]-N-(2,6-dimethylphenyl)acetamide DMV23GL CA CAS 3416-26-0 DMV23GL CB CHEBI:93095 DMV23GL DE Angina pectoris DM4WVC5 ID DM4WVC5 DM4WVC5 DN Lifitegrast DM4WVC5 HS Approved DM4WVC5 SN Lifitegrast; Xiidra; 1025967-78-5; SAR-1118; SAR 1118; UNII-038E5L962W; CHEMBL2048028; 038E5L962W; (S)-2-(2-(benzofuran-6-carbonyl)-5,7-dichloro-1,2,3,4-tetrahydroisoquinoline-6-carboxamido)-3-(3-(methylsulfonyl)phenyl)propanoic acid; (S)-2-(2-(benzofuran-6-carbonyl)-5,7-dichloro-1,2,3,4-tetrahydroisoquinoline-6-carboxamido)-3-(3-(methylsulfonyl)phenyl)propanoic acid;(S)-2-(2-(benzofuran-6-carbonyl)-5,7-dichloro-1,2,3,4-tetrahydroisoquinoline-6-carboxamido)-3-(3-(methylsulfonyl)phenyl)propanoic acid; SAR-1118; SAR-1119; SHP606; SPD606 DM4WVC5 CP Shire Pharmaceuticals DM4WVC5 DT Small molecular drug DM4WVC5 PC 11965427 DM4WVC5 MW 615.5 DM4WVC5 FM C29H24Cl2N2O7S DM4WVC5 IC InChI=1S/C29H24Cl2N2O7S/c1-41(38,39)20-4-2-3-16(11-20)12-23(29(36)37)32-27(34)25-22(30)13-19-15-33(9-7-21(19)26(25)31)28(35)18-6-5-17-8-10-40-24(17)14-18/h2-6,8,10-11,13-14,23H,7,9,12,15H2,1H3,(H,32,34)(H,36,37)/t23-/m0/s1 DM4WVC5 CS CS(=O)(=O)C1=CC=CC(=C1)C[C@@H](C(=O)O)NC(=O)C2=C(C=C3CN(CCC3=C2Cl)C(=O)C4=CC5=C(C=C4)C=CO5)Cl DM4WVC5 IK JFOZKMSJYSPYLN-QHCPKHFHSA-N DM4WVC5 IU (2S)-2-[[2-(1-benzofuran-6-carbonyl)-5,7-dichloro-3,4-dihydro-1H-isoquinoline-6-carbonyl]amino]-3-(3-methylsulfonylphenyl)propanoic acid DM4WVC5 CA CAS 1025967-78-5 DM4WVC5 CB CHEBI:133023 DM4WVC5 DE Dry eye disease; Allergic conjunctivitis DM4EGV0 ID DM4EGV0 DM4EGV0 DN Linaclotide DM4EGV0 HS Approved DM4EGV0 SN Linaclotide (USAN) DM4EGV0 CP Microbia DM4EGV0 DT Small molecular drug DM4EGV0 PC 16158208 DM4EGV0 MW 1526.8 DM4EGV0 FM C59H79N15O21S6 DM4EGV0 IC InChI=1S/C59H79N15O21S6/c1-26-47(82)69-41-25-101-99-22-38-52(87)65-33(13-14-45(80)81)49(84)66-34(16-28-5-9-30(76)10-6-28)50(85)71-40(54(89)72-39(23-97-96-20-32(60)48(83)70-38)53(88)67-35(18-43(61)78)58(93)74-15-3-4-42(74)56(91)63-26)24-100-98-21-37(64-44(79)19-62-57(92)46(27(2)75)73-55(41)90)51(86)68-36(59(94)95)17-29-7-11-31(77)12-8-29/h5-12,26-27,32-42,46,75-77H,3-4,13-25,60H2,1-2H3,(H2,61,78)(H,62,92)(H,63,91)(H,64,79)(H,65,87)(H,66,84)(H,67,88)(H,68,86)(H,69,82)(H,70,83)(H,71,85)(H,72,89)(H,73,90)(H,80,81)(H,94,95)/t26-,27+,32-,33-,34-,35-,36-,37-,38-,39-,40-,41-,42-,46-/m0/s1 DM4EGV0 CS C[C@H]1C(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](NC(=O)CNC(=O)[C@@H](NC2=O)[C@@H](C)O)C(=O)N[C@@H](CC4=CC=C(C=C4)O)C(=O)O)C(=O)N[C@@H](CSSC[C@@H](C(=O)N3)N)C(=O)N[C@H](C(=O)N5CCC[C@H]5C(=O)N1)CC(=O)N)CC6=CC=C(C=C6)O)CCC(=O)O DM4EGV0 IK KXGCNMMJRFDFNR-WDRJZQOASA-N DM4EGV0 IU (2S)-2-[[(1R,4S,7S,13S,16R,21R,24R,27S,30S,33R,38R,44S)-21-amino-13-(2-amino-2-oxoethyl)-27-(2-carboxyethyl)-44-[(1R)-1-hydroxyethyl]-30-[(4-hydroxyphenyl)methyl]-4-methyl-3,6,12,15,22,25,28,31,40,43,46,51-dodecaoxo-18,19,35,36,48,49-hexathia-2,5,11,14,23,26,29,32,39,42,45,52-dodecazatetracyclo[22.22.4.216,33.07,11]dopentacontane-38-carbonyl]amino]-3-(4-hydroxyphenyl)propanoic acid DM4EGV0 CA CAS 851199-59-2 DM4EGV0 CB CHEBI:68551 DM4EGV0 DE Irritable bowel syndrome DMWFJTR ID DMWFJTR DMWFJTR DN Linagliptin DMWFJTR HS Approved DMWFJTR SN Ondero; BI 1356; BI-1356; Ondero (TN); BI-1356-BS; (R)-8-(3-Amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione DMWFJTR CP Boehringer Ingelheim DMWFJTR DT Small molecular drug DMWFJTR PC 10096344 DMWFJTR MW 472.5 DMWFJTR FM C25H28N8O2 DMWFJTR IC InChI=1S/C25H28N8O2/c1-4-5-13-32-21-22(29-24(32)31-12-8-9-17(26)14-31)30(3)25(35)33(23(21)34)15-20-27-16(2)18-10-6-7-11-19(18)28-20/h6-7,10-11,17H,8-9,12-15,26H2,1-3H3/t17-/m1/s1 DMWFJTR CS CC#CCN1C2=C(N=C1N3CCC[C@H](C3)N)N(C(=O)N(C2=O)CC4=NC5=CC=CC=C5C(=N4)C)C DMWFJTR IK LTXREWYXXSTFRX-QGZVFWFLSA-N DMWFJTR IU 8-[(3R)-3-aminopiperidin-1-yl]-7-but-2-ynyl-3-methyl-1-[(4-methylquinazolin-2-yl)methyl]purine-2,6-dione DMWFJTR CA CAS 668270-12-0 DMWFJTR CB CHEBI:68610 DMWFJTR DE Type-2 diabetes DMVTHER ID DMVTHER DMVTHER DN Lincomycin DMVTHER HS Approved DMVTHER SN Cillimycin; Epilincomycin; Jiemycin; LCM; Lincocin; Lincocine; Lincolcina; Lincolnensin; Lincomicina; Lincomix; Lincomycine; Lincomycinum; Lincomyocin; Lincorex; Mycivin; Lincomycin A; Lincomycine [French]; CBMicro_021584; Lincomix 20; Pura Ject 100; Lincocin (TN); Lincomicina [INN-Spanish]; Lincomycine [INN-French]; Lincomycinum [INN-Latin]; U 10,149A; Lincomycin (USAN/INN); Lincomycin [USAN:INN:BAN]; Lincomycin, (2S-cis)-Isomer; Methyl 6,8-dideoxy-6-[(1-methyl-4-propylprolyl)amino]-1-thiooctopyranoside DMVTHER TC Antibiotics DMVTHER DT Small molecular drug DMVTHER PC 3000540 DMVTHER MW 406.5 DMVTHER FM C18H34N2O6S DMVTHER IC InChI=1S/C18H34N2O6S/c1-5-6-10-7-11(20(3)8-10)17(25)19-12(9(2)21)16-14(23)13(22)15(24)18(26-16)27-4/h9-16,18,21-24H,5-8H2,1-4H3,(H,19,25)/t9-,10-,11+,12-,13+,14-,15-,16-,18-/m1/s1 DMVTHER CS CCC[C@@H]1C[C@H](N(C1)C)C(=O)N[C@@H]([C@@H]2[C@@H]([C@@H]([C@H]([C@H](O2)SC)O)O)O)[C@@H](C)O DMVTHER IK OJMMVQQUTAEWLP-KIDUDLJLSA-N DMVTHER IU (2S,4R)-N-[(1R,2R)-2-hydroxy-1-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-methylsulfanyloxan-2-yl]propyl]-1-methyl-4-propylpyrrolidine-2-carboxamide DMVTHER CA CAS 154-21-2 DMVTHER CB CHEBI:6472 DMVTHER DE Gram-positive bacterial infection DMB8CNL ID DMB8CNL DMB8CNL DN Lindane DMB8CNL HS Approved DMB8CNL SN Aalindan; Aficide; Agrocide; Agronexit; Ameisenatod; Ameisentod; Aparasin; Aphtiria; Aphtitria; Aplidal; Arbitex; BBH; Benhexachlor; Benhexol; Benzanex; Benzex; Bexol; Celanex; Chloresene; Codechine; Devoran; Dolmix; Entomoxan; Esoderm; Exagama; Forlin; Gallogama; Gamacarbatox; Gamacid; Gamacide; Gamaphex; Gamene; Gamiso; Gammahexa; Gammahexane; Gammalin; Gammasan; Gammaterr; Gammex; Gammexane; Gammopaz; Gamtox; Geobilan; Gexane; Gyben; HCH; Hcch; Heclotox; Hecoltox; Hexa; Hexablanc; Hexachlor; Hexachloran; Hexachlorane; Hexamul; Hexapoudre; Hexatox; Hexaverm; Hexcidum; Hexicide; Hexit; Hexyclan; Hilbeech; Hortex; Inexit; Isatox; Isotox; Jacutin; Kokotine; Kwell; Lasochron; Lendine; Lentox; Lidenal; Lindafor; Lindagam; Lindagrain; Lindagranox; Lindalo; Lindamul; Lindan; Lindano; Lindanum; Lindapoudre; Lindaterra; Lindatox; Lindex; Lindosep; Lintox; Linvur; Lorexane; Mszycol; Nexit; Nicochloran; Novigam; Novigan; Omnitox; Ovadziak; Owadziak; PLK; Pedraczak; Pflanzol; Quellada; Scabene; Silvanol; Streunex; Submar; Viton; Agrocide III; Agrocide WP; Am eisenatod; Arcotal S; BHCor HCH; Borer Spray; DOL GRANULE; Eso derm; Gamma BHC; HCH [BSI]; HCH [ISO]; Hilbeec h; Isot ox; Lacco HI lin; Lindam ul; Mglawik L; New kotol; Nexen fb; PMS Lindane; Sang gamma; Agrocide 2; Agrocide6G; Agrocide 7; Bentox 10; Detox 25; Gamacide 20; Gammalin 20; Geolin G 3; Hungaria L7; Latka 666; Milbol 49; PS71_SUPELCO; TAP 85; Agrisol G-20; Alpha-BHC; Alpha-HCH; Ben-Hex; Beta-BHC; Beta-HCH; Beta-Lindane; Beta-isomer; D-BHC; Delta-BHC; Delta-HCH; ENT 7,796; ENT 8,601; ENT 9,232; ENT 9,233; ENT 9,234; Epsilon-HCH; Forst-nexen; Gamma-BHC; Gamma-HCH; Gamma-col; HCH (alpha); HCH (beta); KWELL (TN); Kwell-R; Nexen-fb; Nexi t-stark; Nexit-stark; Nexol-E; Sang-gamma; T-HCH; TRI-6; Trives-T DMB8CNL CP Morton Grove Pharmaceuticals DMB8CNL TC Antiscabies Agent DMB8CNL DT Small molecular drug DMB8CNL PC 727 DMB8CNL MW 290.8 DMB8CNL FM C6H6Cl6 DMB8CNL IC InChI=1S/C6H6Cl6/c7-1-2(8)4(10)6(12)5(11)3(1)9/h1-6H DMB8CNL CS C1(C(C(C(C(C1Cl)Cl)Cl)Cl)Cl)Cl DMB8CNL IK JLYXXMFPNIAWKQ-UHFFFAOYSA-N DMB8CNL IU 1,2,3,4,5,6-hexachlorocyclohexane DMB8CNL CB CHEBI:24536 DMB8CNL DE Infestations of lice and scabies DMGFPU2 ID DMGFPU2 DMGFPU2 DN Linezolid DMGFPU2 HS Approved DMGFPU2 SN Linezlid; ZLD; Zyvox; Zyvoxa; Zyvoxam; Zyvoxid; PNU 100766; U 100766; Linezolid & VRC3375; Linezolid [USAN:INN]; PNU-100766; U-100766; Zyvox (TN); Zyvoxam (TN); Zyvoxid (TN); NDA 21-130 Zyvox (linezolid tablets); NDA 21-131 Zyvox for injection (linezolid injection); NDA 21-132 Zyvox oral suspension (linzolid oral suspension); Linezolid (JAN/USAN/INN); PNU-100766, U-100766, Zyvoxid, Zyvoxam, Linezolid; N-((3-(3-fluoro-4-morpholinylphenyl)-2-oxo-5-oxazolidinyl)methyl)acetamide; N-(((S)-3-(3-Fluoro-4-morpholinophenyl)-2-oxo-5-oxazolidinyl)methyl)acetamide; N-[[(5S)-3-(3-fluoro-4-morpholin-4-ylphenyl)-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide; N-({5S)-3-[3-Fluoro-4-(4-morpholinyl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)acetamide, N-[[(S)-3-(3-Fluoro-4-morpholinophenyl)-2-oxo-5-oxazolidinyl]methyl]acetamide; (S)-N-[[3-(3-fluoro-4-morpholinylphenyl)-2-oxo-5-oxazolidinyl]methyl]acetamide; 111GE017 DMGFPU2 CP Pfizer Pharmaceuticals DMGFPU2 TC Antibiotics DMGFPU2 DT Small molecular drug DMGFPU2 PC 441401 DMGFPU2 MW 337.35 DMGFPU2 FM C16H20FN3O4 DMGFPU2 IC InChI=1S/C16H20FN3O4/c1-11(21)18-9-13-10-20(16(22)24-13)12-2-3-15(14(17)8-12)19-4-6-23-7-5-19/h2-3,8,13H,4-7,9-10H2,1H3,(H,18,21)/t13-/m0/s1 DMGFPU2 CS CC(=O)NC[C@H]1CN(C(=O)O1)C2=CC(=C(C=C2)N3CCOCC3)F DMGFPU2 IK TYZROVQLWOKYKF-ZDUSSCGKSA-N DMGFPU2 IU N-[[(5S)-3-(3-fluoro-4-morpholin-4-ylphenyl)-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide DMGFPU2 CA CAS 165800-03-3 DMGFPU2 CB CHEBI:63607 DMGFPU2 DE Bacterial infection DM6IR3P ID DM6IR3P DM6IR3P DN Liothyronine DM6IR3P HS Approved DM6IR3P SN liothyronine; 3,3',5-Triiodo-L-thyronine; 6893/2/3; Liothyronin; Tresitope; 3,5,3'-triiodothyronine; L-Liothyronine; O-(4-Hydroxy-3-iodophenyl)-3,5-diiodo-L-tyrosine; triothyrone; Liothyroninum; Liotironina; 3,5,3'-Triiodo-L-thyronine; L-T3; T3; 3,3',5-Triiodothyronine; Triiodo-L-thyronine; Lyothyronine; 3,5,3'TRIIODOTHYRONINE; L-3,5,3'-Triiodothyronine; (2S)-2-amino-3-[4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl]propanoic acid; T3 (amino acid); T3 (Hormone); L-3,3',5-TriioDOThyronine; Liothyronine [INN:BAN]; Rathyronine; Triothyrone; THYROID HORMONE; Liothyronine I 131; Liothyronine I 131 [USAN]; T3 liothyronine; Cytomel (TN); Euthroid-1; Euthroid-2; Euthroid-3; Liothyronine (INN); Liothyroninum[INN-Latin]; Liotironina [INN-Spanish]; T3 (Triiodothyronine); T3 (VAN); Tertroxin (TN); Thyrolar-1; Thyrolar-2; Thyrolar-3; Tri-Thyrotope; Triiodothyronine (T3); Triomet-131; Euthroid-05; Thyrolar-025; Thyrolar-05; TRIIODOTHYRONINE (T3 OR LIOTHYRONINE, ACTIVE) (6-11%); Thyronine, 3,3',5-triiodo-, L-(6CI); L-3-(4-(4-Hydroxy-3-iodophenoxy)-3,5-diiodophenyl)alanine; L-Tyrosine, O-(4-hydroxy-3-iodophenyl)-3,5-diiodo-(9CI); 3,3'5-Triiodo-L-thyronine; 3,5,3'-Tri-iodo-L-thyronine; 4-(3-Iodo-4-hydroxyphenoxy)-3,5-diiodophenylalanine; 4-(4-Hydroxy-3-iodophenoxy)-3,5-diiodophenylalanine; 4-(4-hydroxy-3-iodophenoxy)-3,5-diiodo-L-phenylalanine DM6IR3P CP King Pharmaceuticals, Inc DM6IR3P TC Hormone Replacement Agents DM6IR3P DT Small molecular drug DM6IR3P PC 5920 DM6IR3P MW 650.97 DM6IR3P FM C15H12I3NO4 DM6IR3P IC InChI=1S/C15H12I3NO4/c16-9-6-8(1-2-13(9)20)23-14-10(17)3-7(4-11(14)18)5-12(19)15(21)22/h1-4,6,12,20H,5,19H2,(H,21,22)/t12-/m0/s1 DM6IR3P CS C1=CC(=C(C=C1OC2=C(C=C(C=C2I)C[C@@H](C(=O)O)N)I)I)O DM6IR3P IK AUYYCJSJGJYCDS-LBPRGKRZSA-N DM6IR3P IU (2S)-2-amino-3-[4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl]propanoic acid DM6IR3P CA CAS 15785-49-6 DM6IR3P CB CHEBI:18258 DM6IR3P DE Hypothyroidism; Congestive heart failure DMSTXWR ID DMSTXWR DMSTXWR DN Liotrix DMSTXWR HS Approved DMSTXWR SN Liotrix; Novothyral; Thyrolar; Combithyrex; Diotroxin; Euthroid; W 1782; 8065-29-0; L-Tyrosine, O-(4-hydroxy-3,5-diiodophenyl)-3,5-diiodo-, monosodium salt, mixt. with O-(4-hydroxy-3-iodophenyl)-3,5-diiodo-L-tyrosine monosodium salt; Levothyroxine Sodium mixture with Liothyronine Sodium; Liothyronine Sodium and Levothyroxine Sodium; Monosodium L-thyroxine hydrate mixt. with monosodium L-3-(4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl)alanine DMSTXWR PC 71371 DMSTXWR MW 1471.8 DMSTXWR FM C30H21I7N2Na2O8 DMSTXWR IC LKYWLLWWYBVUPP-XOCLESOZSA-L DMSTXWR CS C1=CC(=C(C=C1OC2=C(C=C(C=C2I)CC(C(=O)[O-])N)I)I)O.C1=C(C=C(C(=C1I)OC2=CC(=C(C(=C2)I)O)I)I)CC(C(=O)[O-])N.[Na+].[Na+] DMSTXWR IK 1S/C15H11I4NO4.C15H12I3NO4.2Na/c16-8-4-7(5-9(17)13(8)21)24-14-10(18)1-6(2-11(14)19)3-12(20)15(22)23;16-9-6-8(1-2-13(9)20)23-14-10(17)3-7(4-11(14)18)5-12(19)15(21)22;;/h1-2,4-5,12,21H,3,20H2,(H,22,23);1-4,6,12,20H,5,19H2,(H,21,22);;/q;;2*+1/p-2/t2*12-;;/m00../s1 DMSTXWR IU disodium;(2S)-2-amino-3-[4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]propanoate;(2S)-2-amino-3-[4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl]propanoate DMSTXWR CA CAS 8065-29-0 DMSTXWR CB CHEBI:6485 DMSTXWR DE Hypothyroidism DM3FXPS ID DM3FXPS DM3FXPS DN Liraglutide DM3FXPS HS Approved DM3FXPS SN Liraglutida; Liraglutidum; Victoza; NN 2211; NN2211; Liraglutida [INN-Spanish]; Liraglutide [USAN:INN]; Liraglutidum [INN-Latin]; NN-2211; Victoza (TN); N26-(Hexadecanoyl-gamma-glutamyle)-(34-arginine)GLP-1-(7-37)-peptide; N26-(Hexadecanoyl-gamma-glutamyle)-(34-arginine)glucagon-like-peptide-1-(7-37)-peptide DM3FXPS CP Novo Nordisk Massachusetts General Hospital DM3FXPS DT Small molecular drug DM3FXPS SQ Liraglutide Sequence: HAEGTFTSDVSSYLEGQAAKEEFIIAWLVKGRG DM3FXPS PC 16134956 DM3FXPS MW 3751 DM3FXPS FM C172H265N43O51 DM3FXPS IC InChI=1S/C172H265N43O51/c1-18-20-21-22-23-24-25-26-27-28-29-30-37-53-129(224)195-116(170(265)266)59-64-128(223)180-68-41-40-50-111(153(248)199-115(62-67-135(232)233)154(249)204-120(73-100-44-33-31-34-45-100)159(254)214-140(93(11)19-2)167(262)192-97(15)146(241)201-122(76-103-79-183-108-49-39-38-48-106(103)108)157(252)203-118(72-90(5)6)158(253)212-138(91(7)8)165(260)200-110(52-43-70-182-172(177)178)149(244)184-81-130(225)193-109(51-42-69-181-171(175)176)148(243)187-84-137(236)237)196-144(239)95(13)189-143(238)94(12)191-152(247)114(58-63-127(174)222)194-131(226)82-185-151(246)113(61-66-134(230)231)198-155(250)117(71-89(3)4)202-156(251)119(75-102-54-56-105(221)57-55-102)205-162(257)124(85-216)208-164(259)126(87-218)209-166(261)139(92(9)10)213-161(256)123(78-136(234)235)206-163(258)125(86-217)210-169(264)142(99(17)220)215-160(255)121(74-101-46-35-32-36-47-101)207-168(263)141(98(16)219)211-132(227)83-186-150(245)112(60-65-133(228)229)197-145(240)96(14)190-147(242)107(173)77-104-80-179-88-188-104/h31-36,38-39,44-49,54-57,79-80,88-99,107,109-126,138-142,183,216-221H,18-30,37,40-43,50-53,58-78,81-87,173H2,1-17H3,(H2,174,222)(H,179,188)(H,180,223)(H,184,244)(H,185,246)(H,186,245)(H,187,243)(H,189,238)(H,190,242)(H,191,247)(H,192,262)(H,193,225)(H,194,226)(H,195,224)(H,196,239)(H,197,240)(H,198,250)(H,199,248)(H,200,260)(H,201,241)(H,202,251)(H,203,252)(H,204,249)(H,205,257)(H,206,258)(H,207,263)(H,208,259)(H,209,261)(H,210,264)(H,211,227)(H,212,253)(H,213,256)(H,214,254)(H,215,255)(H,228,229)(H,230,231)(H,232,233)(H,234,235)(H,236,237)(H,265,266)(H4,175,176,181)(H4,177,178,182)/t93-,94-,95-,96-,97-,98+,99+,107-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,138-,139-,140-,141-,142-/m0/s1 DM3FXPS CS CCCCCCCCCCCCCCCC(=O)N[C@@H](CCC(=O)NCCCC[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)N)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](CC6=CN=CN6)N)C(=O)O DM3FXPS IK YSDQQAXHVYUZIW-QCIJIYAXSA-N DM3FXPS IU (2S)-5-[[(5S)-5-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]propanoyl]amino]-4-carboxybutanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-4-carboxybutanoyl]amino]acetyl]amino]-5-oxopentanoyl]amino]propanoyl]amino]propanoyl]amino]-6-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-carbamimidamido-1-[[2-[[(2S)-5-carbamimidamido-1-(carboxymethylamino)-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-6-oxohexyl]amino]-2-(hexadecanoylamino)-5-oxopentanoic acid DM3FXPS CA CAS 204656-20-2 DM3FXPS CB CHEBI:71193 DM3FXPS DE Type-2 diabetes; Obesity DM6W8V5 ID DM6W8V5 DM6W8V5 DN Lisdexamfetamine DM6W8V5 HS Approved DM6W8V5 SN NRP104; Lisdexamfetamine (INN); Vyvanse (TN) DM6W8V5 CP New River Pharmaceuticals DM6W8V5 DT Small molecular drug DM6W8V5 PC 11597698 DM6W8V5 MW 263.38 DM6W8V5 FM C15H25N3O DM6W8V5 IC InChI=1S/C15H25N3O/c1-12(11-13-7-3-2-4-8-13)18-15(19)14(17)9-5-6-10-16/h2-4,7-8,12,14H,5-6,9-11,16-17H2,1H3,(H,18,19)/t12-,14-/m0/s1 DM6W8V5 CS C[C@@H](CC1=CC=CC=C1)NC(=O)[C@H](CCCCN)N DM6W8V5 IK VOBHXZCDAVEXEY-JSGCOSHPSA-N DM6W8V5 IU (2S)-2,6-diamino-N-[(2S)-1-phenylpropan-2-yl]hexanamide DM6W8V5 CA CAS 608137-32-2 DM6W8V5 CB CHEBI:135925 DM6W8V5 DE Attention deficit hyperactivity disorder DMUOK4C ID DMUOK4C DMUOK4C DN Lisinopril DMUOK4C HS Approved DMUOK4C SN Acerbon; Acercomp; Alapril; Carace; Cipral; Cipril; Coric; Doneka; Hipril (TN); Inhibril; Inopril; LPR; Linopril; Linvas; Lipril; Lisinal; Lisinopril (INN); Lisinopril (anhydrous); Lisinopril anhydrous; Lisinoprilum; Lisinoprilum [Latin]; Lisipril; Lisoril; Lispril; Longes; Loril; Lysinopril; MK 521; MK 522; MK-521; Noperten; Novatec; Presiten; Prinil; Prinivil; Prinivil (TN); Sinopril; Sinopryl; Tensopril; Tensopril (TN); Tensyn; Tersif; Vivatec; Zestril; Zestril (TN) DMUOK4C CP Merck & Co DMUOK4C TC Antihypertensive Agents DMUOK4C DT Small molecular drug DMUOK4C PC 5362119 DMUOK4C MW 405.5 DMUOK4C FM C21H31N3O5 DMUOK4C IC InChI=1S/C21H31N3O5/c22-13-5-4-9-16(19(25)24-14-6-10-18(24)21(28)29)23-17(20(26)27)12-11-15-7-2-1-3-8-15/h1-3,7-8,16-18,23H,4-6,9-14,22H2,(H,26,27)(H,28,29)/t16-,17-,18-/m0/s1 DMUOK4C CS C1C[C@H](N(C1)C(=O)[C@H](CCCCN)N[C@@H](CCC2=CC=CC=C2)C(=O)O)C(=O)O DMUOK4C IK RLAWWYSOJDYHDC-BZSNNMDCSA-N DMUOK4C IU (2S)-1-[(2S)-6-amino-2-[[(1S)-1-carboxy-3-phenylpropyl]amino]hexanoyl]pyrrolidine-2-carboxylic acid DMUOK4C CA CAS 76547-98-3 DMUOK4C CB CHEBI:43755 DMUOK4C DE Hypertension DMP45ME ID DMP45ME DMP45ME DN Lisocabtagene maraleucel DMP45ME HS Approved DMP45ME SN JCAR017 DMP45ME CP Celgene DMP45ME DT CAR T Cell Therapy DMP45ME DE Central nervous system lymphoma; Precursor B-lymphoblastic neoplasm; Follicular lymphoma; Richter syndrome; Non-hodgkin lymphoma; Large B-cell lymphoma DMCME17 ID DMCME17 DMCME17 DN Lisuride DMCME17 HS Approved DMCME17 SN Lisurida; Lisuridum; Lysurid; Lysuride; Lisuride [INN]; Lysuride Hydrogen Maleate; Methylergol Carbamide; Arolac (TN); Cuvalit (TN); Dipergon (TN); Dopergin (TN); Dopergine (TN); Lisurida [INN-Spanish]; Lisuride (INN); Lisuridum [INN-Latin]; Lysenyl Forte (TN); Prolacam (TN); Revanil (TN); Lisuride Maleate (1:1); N'-((8alpha)-9,10-Didehydro-6-methylergolin-8-yl)-N,N-diethylurea; 1,1-diethyl-3-[(8alpha)-6-methyl-9,10-didehydroergolin-8-yl]urea; 3-(9,10-Didehydro-6-methylergolin-8alpha-yl)-1,1-diethylurea DMCME17 CP IVAX Pharmaceuticals DMCME17 TC Antiparkinson Agents DMCME17 DT Small molecular drug DMCME17 PC 28864 DMCME17 MW 338.4 DMCME17 FM C20H26N4O DMCME17 IC InChI=1S/C20H26N4O/c1-4-24(5-2)20(25)22-14-10-16-15-7-6-8-17-19(15)13(11-21-17)9-18(16)23(3)12-14/h6-8,10-11,14,18,21H,4-5,9,12H2,1-3H3,(H,22,25)/t14-,18+/m0/s1 DMCME17 CS CCN(CC)C(=O)N[C@@H]1CN([C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1)C DMCME17 IK BKRGVLQUQGGVSM-KBXCAEBGSA-N DMCME17 IU 3-[(6aR,9S)-7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinolin-9-yl]-1,1-diethylurea DMCME17 CA CAS 18016-80-3 DMCME17 CB CHEBI:51164 DMCME17 DE Parkinson disease; Fibrosis DMX9PIA ID DMX9PIA DMX9PIA DN Live attenuated influenza vaccine DMX9PIA HS Approved DMX9PIA SN Influenza vaccine, BioDiem; Influenza vaccine, St Petersburg Institute of Experimental Medicine; Live attenuated influenza vaccine (CoVaccine adjuvant); SCH-900795; Cold-adapted flu virus vaccine, St Petersburg Institute of Experimental Medicine; Influenza vaccine (live attenuated, nasal), BioDiem; Influenza vaccine, BioDiem/Merck & Co; LAIV (CoVaccine adjuvant), Nobilon/NV Organon; Live attenuated influenza vaccine (CoVaccine adjuvant), BioDiem/ Serum Institute of India; Live attenuated influenza vaccine (CoVaccine adjuvant), Schering Plough/BioDiem; Live attenuated influenza vaccine (CoVaccine adjuvant), Merck & Co/BioDiem DMX9PIA CP St Petersburg Institute of Experimental Medicine DMX9PIA DT Vaccine DMX9PIA DE Influenza virus infection DM0QJDC ID DM0QJDC DM0QJDC DN Lixisenatide DM0QJDC HS Approved DM0QJDC SN Lyxumia (TN) DM0QJDC CP Sanofi DM0QJDC DT Small molecular drug DM0QJDC PC 90472060 DM0QJDC MW 4858 DM0QJDC FM C215H347N61O65S DM0QJDC IC InChI=1S/C215H347N61O65S/c1-16-115(10)173(210(337)256-141(68-74-170(299)300)194(321)261-148(94-122-98-232-126-50-24-23-49-124(122)126)199(326)258-143(89-111(2)3)196(323)247-134(58-32-40-83-223)189(316)262-149(96-160(226)285)180(307)235-100-161(286)233-104-165(290)274-85-42-60-156(274)207(334)267-154(108-280)206(333)265-151(105-277)181(308)237-101-162(287)239-117(12)213(340)276-87-44-62-158(276)214(341)275-86-43-61-157(275)208(335)268-153(107-279)204(331)249-132(56-30-38-81-221)187(314)246-131(55-29-37-80-220)186(313)245-130(54-28-36-79-219)185(312)244-129(53-27-35-78-218)184(311)243-128(52-26-34-77-217)183(310)242-127(176(227)303)51-25-33-76-216)272-201(328)146(92-120-45-19-17-20-46-120)260-197(324)144(90-112(4)5)257-190(317)135(59-41-84-231-215(228)229)255-209(336)172(114(8)9)271-177(304)116(11)240-182(309)138(65-71-167(293)294)251-192(319)139(66-72-168(295)296)252-193(320)140(67-73-169(297)298)253-195(322)142(75-88-342-15)254-191(318)137(63-69-159(225)284)250-188(315)133(57-31-39-82-222)248-203(330)152(106-278)266-198(325)145(91-113(6)7)259-200(327)150(97-171(301)302)263-205(332)155(109-281)269-212(339)175(119(14)283)273-202(329)147(93-121-47-21-18-22-48-121)264-211(338)174(118(13)282)270-164(289)103-236-179(306)136(64-70-166(291)292)241-163(288)102-234-178(305)125(224)95-123-99-230-110-238-123/h17-24,45-50,98-99,110-119,125,127-158,172-175,232,277-283H,16,25-44,51-97,100-109,216-224H2,1-15H3,(H2,225,284)(H2,226,285)(H2,227,303)(H,230,238)(H,233,286)(H,234,305)(H,235,307)(H,236,306)(H,237,308)(H,239,287)(H,240,309)(H,241,288)(H,242,310)(H,243,311)(H,244,312)(H,245,313)(H,246,314)(H,247,323)(H,248,330)(H,249,331)(H,250,315)(H,251,319)(H,252,320)(H,253,322)(H,254,318)(H,255,336)(H,256,337)(H,257,317)(H,258,326)(H,259,327)(H,260,324)(H,261,321)(H,262,316)(H,263,332)(H,264,338)(H,265,333)(H,266,325)(H,267,334)(H,268,335)(H,269,339)(H,270,289)(H,271,304)(H,272,328)(H,273,329)(H,291,292)(H,293,294)(H,295,296)(H,297,298)(H,299,300)(H,301,302)(H4,228,229,231)/t115-,116-,117-,118+,119+,125-,127-,128-,129-,130-,131-,132-,133-,134-,135-,136-,137-,138-,139-,140-,141-,142-,143-,144-,145-,146-,147-,148-,149-,150-,151-,152-,153-,154-,155-,156-,157-,158-,172-,173-,174-,175-/m0/s1 DM0QJDC CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N)C(=O)NCC(=O)NCC(=O)N3CCC[C@H]3C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N4CCC[C@H]4C(=O)N5CCC[C@H]5C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N)NC(=O)[C@H](CC6=CC=CC=C6)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC7=CC=CC=C7)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@H](CC8=CNC=N8)N DM0QJDC IK XVVOERDUTLJJHN-IAEQDCLQSA-N DM0QJDC IU (4S)-5-[[2-[[(2S,3R)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-4-amino-1-[[2-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[(2S)-2-[(2S)-2-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1,6-diamino-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]carbamoyl]pyrrolidine-1-carbonyl]pyrrolidin-1-yl]-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-2-oxoethyl]amino]-1,4-dioxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-4-[[2-[[(2S)-2-amino-3-(1H-imidazol-4-yl)propanoyl]amino]acetyl]amino]-5-oxopentanoic acid DM0QJDC CA CAS 320367-13-3 DM0QJDC CB CHEBI:85662 DM0QJDC DE Type-2 diabetes DMJPD06 ID DMJPD06 DMJPD06 DN Lmw heparin DMJPD06 HS Approved DMJPD06 SN Fragmin; Heparinin; MolPort-042-652-620; Logiparin (TN); Sandoparin (TN) DMJPD06 DT Small molecular drug DMJPD06 PC 25244225 DMJPD06 MW 591.5 DMJPD06 FM C12H17NO20S3-4 DMJPD06 IC InChI=1S/C12H21NO20S3/c14-4-3(13-34(20,21)22)11(19)30-2(1-29-35(23,24)25)7(4)31-12-9(33-36(26,27)28)6(16)5(15)8(32-12)10(17)18/h2-9,11-16,19H,1H2,(H,17,18)(H,20,21,22)(H,23,24,25)(H,26,27,28)/p-4/t2-,3?,4-,5?,6+,7?,8?,9?,11?,12-/m1/s1 DMJPD06 CS C([C@@H]1C([C@@H](C(C(O1)O)NS(=O)(=O)[O-])O)O[C@H]2C([C@H](C(C(O2)C(=O)[O-])O)O)OS(=O)(=O)[O-])OS(=O)(=O)[O-] DMJPD06 IK OHJKXVLJWUPWQG-IUYNYSEKSA-J DMJPD06 IU (4S,6R)-6-[(2R,4R)-4,6-dihydroxy-5-(sulfonatoamino)-2-(sulfonatooxymethyl)oxan-3-yl]oxy-3,4-dihydroxy-5-sulfonatooxyoxane-2-carboxylate DMJPD06 DE Hematologic disease; Coagulation defect DMHY3IP ID DMHY3IP DMHY3IP DN Lobeglitazone DMHY3IP HS Approved DMHY3IP SN Lobeglitazone sulfate; CKD-501; Dual PPARalpha/delta (type 2 diabetes), Chong Kun Dang DMHY3IP CP Chong Kun Dang Pharmaceutical Corp DMHY3IP DT Small molecular drug DMHY3IP PC 9826451 DMHY3IP MW 480.5 DMHY3IP FM C24H24N4O5S DMHY3IP IC InChI=1S/C24H24N4O5S/c1-28(21-14-22(26-15-25-21)33-19-9-7-17(31-2)8-10-19)11-12-32-18-5-3-16(4-6-18)13-20-23(29)27-24(30)34-20/h3-10,14-15,20H,11-13H2,1-2H3,(H,27,29,30) DMHY3IP CS CN(CCOC1=CC=C(C=C1)CC2C(=O)NC(=O)S2)C3=CC(=NC=N3)OC4=CC=C(C=C4)OC DMHY3IP IK CHHXEZSCHQVSRE-UHFFFAOYSA-N DMHY3IP IU 5-[[4-[2-[[6-(4-methoxyphenoxy)pyrimidin-4-yl]-methylamino]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione DMHY3IP CA CAS 607723-33-1 DMHY3IP CB CHEBI:136052 DMHY3IP DE Type-2 diabetes DM1WXA6 ID DM1WXA6 DM1WXA6 DN Lofexidine DM1WXA6 HS Approved DM1WXA6 SN Britlofex; Lofexidina; Lofexidinum; Britlofex (TN); Lofexidina [INN-Spanish]; Lofexidine (INN); Lofexidine [INN:BAN]; Lofexidinum [INN-Latin]; 1H-Imidazole, 2-(1-(2,6-dichlorophenoxy)ethyl)-4,5-dihydro-(9CI); 2-(1-(2,6-Dichlorophenoxy)ethyl)-4,5-dihydro-1H-imidazole; 2-(a-(2,6-dichlorophenoxy)ethyl)2-imidazoline; 2-(alpha-(2,6-Dichlorophenoxy)ethyl)2-imidazoline; 2-(alpha-(2,6-dichlorophenoxy)ethyl) delta-2-imidazoline; 2-[1-(2,6-dichlorophenoxy)ethyl]-4,5-dihydro-1H-imidazole; 2-{1-[(2,6-dichlorophenyl)oxy]ethyl}-4,5-dihydro-1H-imidazole DM1WXA6 CP US WorldMeds DM1WXA6 TC Antihypertensive Agents DM1WXA6 DT Small molecular drug DM1WXA6 PC 30668 DM1WXA6 MW 259.13 DM1WXA6 FM C11H12Cl2N2O DM1WXA6 IC InChI=1S/C11H12Cl2N2O/c1-7(11-14-5-6-15-11)16-10-8(12)3-2-4-9(10)13/h2-4,7H,5-6H2,1H3,(H,14,15) DM1WXA6 CS CC(C1=NCCN1)OC2=C(C=CC=C2Cl)Cl DM1WXA6 IK KSMAGQUYOIHWFS-UHFFFAOYSA-N DM1WXA6 IU 2-[1-(2,6-dichlorophenoxy)ethyl]-4,5-dihydro-1H-imidazole DM1WXA6 CA CAS 31036-80-3 DM1WXA6 CB CHEBI:51368 DM1WXA6 DE Opioid dependence; Heroin and opiate withdrawal DMVRH9C ID DMVRH9C DMVRH9C DN Lomefloxacin DMVRH9C HS Approved DMVRH9C SN LFLX; Lomefloxacine; Lomefloxacino; Lomefloxacinum; Lomefloxacine [French]; Lomefloxacino [Spanish]; Lomefloxacinum[Latin]; SC 4711; SC 47111A; DM 10 (bactericide); DM-10; Lomefloxacin (USAN); Maxaquin (TN); Maxaquin (hydrochloride); Okacyn (TN); SC-4711; SC-47111A; Uniquin (TN); Lomefloxacin [USAN:BAN:INN]; NY-198 (hydrochloride); SC-47111 (hydrochloride); SC-47111B (mesylate); (+-)-1-Ethyl-6,8-difluoro-1,4-dihydro-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid; 1,4-Dihydro-6,8-difluoro-1-ethyl-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid; 1-Ethyl-6,8-difluoro-1,4-dihydro-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid; 1-ethyl-6,8-difluoro-7-(3-methylpiperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 1-ethyl-6,8-difluoro-7-(3-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid; 3-Quinolinecarboxylic acid, 1-ethyl-6,8-difluoro-1,4-dihydro-7-(3-methyl-1-piperazinyl)-4-oxo-, monohydrochloride DMVRH9C CP Pharmacia Corp DMVRH9C TC Antibiotics DMVRH9C DT Small molecular drug DMVRH9C PC 3948 DMVRH9C MW 351.35 DMVRH9C FM C17H19F2N3O3 DMVRH9C IC InChI=1S/C17H19F2N3O3/c1-3-21-8-11(17(24)25)16(23)10-6-12(18)15(13(19)14(10)21)22-5-4-20-9(2)7-22/h6,8-9,20H,3-5,7H2,1-2H3,(H,24,25) DMVRH9C CS CCN1C=C(C(=O)C2=CC(=C(C(=C21)F)N3CCNC(C3)C)F)C(=O)O DMVRH9C IK ZEKZLJVOYLTDKK-UHFFFAOYSA-N DMVRH9C IU 1-ethyl-6,8-difluoro-7-(3-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid DMVRH9C CA CAS 98079-51-7 DMVRH9C CB CHEBI:116278 DMVRH9C DE Bacterial infection DME0TC8 ID DME0TC8 DME0TC8 DN Lomerizine DME0TC8 HS Approved DME0TC8 SN lomerizine; 101477-55-8; Lomerizine [INN]; UNII-DEE37CY4VO; 1-[bis(4-fluorophenyl)methyl]-4-[(2,3,4-trimethoxyphenyl)methyl]piperazine; C27H30F2N2O3; DEE37CY4VO; CHEMBL29188; Terranas; 1-(Bis(p-fluorophenyl)methyl)-4-(2,3,4-trimethoxybenzyl)piperazine; 1-(Bis(p-fluorophenyl)-methyl)-4-(2,3,4-trimethoxybenzyl)piperazine; NCGC00164543-01; iomerizine; 1-(2,3,4-trimethoxybenzyl)-4-[bis(4-fluorophenyl)methyl]piperazine; 1-(2,3,4-trimethoxybenzyl)-4-(bis(4-fluorophenyl)methyl)piperazine; AC1Q4NME DME0TC8 DT Small molecular drug DME0TC8 PC 3949 DME0TC8 MW 468.5 DME0TC8 FM C27H30F2N2O3 DME0TC8 IC InChI=1S/C27H30F2N2O3/c1-32-24-13-8-21(26(33-2)27(24)34-3)18-30-14-16-31(17-15-30)25(19-4-9-22(28)10-5-19)20-6-11-23(29)12-7-20/h4-13,25H,14-18H2,1-3H3 DME0TC8 CS COC1=C(C(=C(C=C1)CN2CCN(CC2)C(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F)OC)OC DME0TC8 IK JQSAYKKFZOSZGJ-UHFFFAOYSA-N DME0TC8 IU 1-[bis(4-fluorophenyl)methyl]-4-[(2,3,4-trimethoxyphenyl)methyl]piperazine DME0TC8 CA CAS 101477-55-8 DME0TC8 CB CHEBI:94682 DME0TC8 DE Migraine DMLB4PE ID DMLB4PE DMLB4PE DN Lomitapide mesylate DMLB4PE HS Approved DMLB4PE SN Lomitapide (mesylate); Lomitapide mesylate; Lomitapide mesylate (USAN); Lomitapide mesylate [USAN]; X4S83CP54E; lomitapide-mesylate; 202914-84-9; BMS 201038-04; BMS-201038-04; CHEBI:72299; N-(2,2,2-trifluoroethyl)-9-(4-(4-(4'-(trifluoromethyl)biphenyl-2-ylcarboxamido)piperidin-1-yl)butyl)-9H-fluorene-9-carboxamide methanesulfonate; UNII-X4S83CP54E; Juxtapid (TN) DMLB4PE PC 11274333 DMLB4PE MW 789.8 DMLB4PE FM C40H41F6N3O5S DMLB4PE IC QKVKOFVWUHNEBX-UHFFFAOYSA-N DMLB4PE CS CS(=O)(=O)O.C1CN(CCC1NC(=O)C2=CC=CC=C2C3=CC=C(C=C3)C(F)(F)F)CCCCC4(C5=CC=CC=C5C6=CC=CC=C64)C(=O)NCC(F)(F)F DMLB4PE IK 1S/C39H37F6N3O2.CH4O3S/c40-38(41,42)25-46-36(50)37(33-13-5-3-10-30(33)31-11-4-6-14-34(31)37)21-7-8-22-48-23-19-28(20-24-48)47-35(49)32-12-2-1-9-29(32)26-15-17-27(18-16-26)39(43,44)45;1-5(2,3)4/h1-6,9-18,28H,7-8,19-25H2,(H,46,50)(H,47,49);1H3,(H,2,3,4) DMLB4PE IU methanesulfonic acid;N-(2,2,2-trifluoroethyl)-9-[4-[4-[[2-[4-(trifluoromethyl)phenyl]benzoyl]amino]piperidin-1-yl]butyl]fluorene-9-carboxamide DMLB4PE CA CAS 202914-84-9 DMLB4PE CB CHEBI:72299 DMLB4PE DE Hypertriglyceridaemia DMMWSUL ID DMMWSUL DMMWSUL DN Lomustine DMMWSUL HS Approved DMMWSUL SN Belustine; CCNU; CINU; Cecenu; CeeNU; Chloroethylcyclohexylnitrosourea; Lomustina; Lomustinum; Bristol Myers Squibb Brand of Lomustine; CCNU [Chloroethyl nitrosoureas]; Cyclohexyl chloroethyl nitrosourea; Lomustine medac Brand; Medac Brand of Lomustine; Rhone Poulenc Rorer Brand of Lomustine; OR5087; RB 1509; SRI 2200; Bristol-Myers Squibb Brand of Lomustine; CeeNU (TN); Lomustina [INN-Spanish]; Lomustinum [INN-Latin]; NPFAPI-06; Rhone-Poulenc Rorer Brand of Lomustine; CeeNU, CCNU, Lomustine; Lomustine (USAN/INN); Lomustine [USAN:BAN:INN]; N-(2-Chloroethyl)-N'-cyclohexyl-N-nitrosourea; (Chloro-2-ethyl)-1-cyclohexyl-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea [Italian];1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea; 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea [Chloroethyl nitrosoureas]; 1-(2-Chloroethyl)-3-cyclohexylnitrosourea DMMWSUL TC Anticancer Agents DMMWSUL DT Small molecular drug DMMWSUL PC 3950 DMMWSUL MW 233.69 DMMWSUL FM C9H16ClN3O2 DMMWSUL IC InChI=1S/C9H16ClN3O2/c10-6-7-13(12-15)9(14)11-8-4-2-1-3-5-8/h8H,1-7H2,(H,11,14) DMMWSUL CS C1CCC(CC1)NC(=O)N(CCCl)N=O DMMWSUL IK GQYIWUVLTXOXAJ-UHFFFAOYSA-N DMMWSUL IU 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea DMMWSUL CA CAS 13010-47-4 DMMWSUL CB CHEBI:6520 DMMWSUL DE Brain cancer DMGM2Z6 ID DMGM2Z6 DMGM2Z6 DN Lonafarnib DMGM2Z6 HS Approved DMGM2Z6 SN Sarasar; Lonafarnib [USAN]; Sch 66336; Sch66336; SCH-066336; Sch-66336; Lonafarnib (USAN/INN); (+)-4-(2-(4-(11R)-3,10-Dibromo-8-chloro-6,11-dihydro-5H-benzo(5,6)cyclohepta(1,2-b)pyridin-11-yl)-piperidin-1-yl))-2-oxoethyl)-piperidine-1-carboxamide; (+)-4-(2-(4-(8-chloro-3,10-dibromo-6,11-dihydro-5H-benzo(5,6)cyclohepta(1,2-b)pyridin-11-yl)-1-piperidinyl)-2-oxoethyl)-1-piperidinecarboxamide; (+)-4[2-[4-(8-Chloro-3,10-dibromo-6,11-dihydro-5H-benzo[5,6] cyclohepta[1,2-b]-pyridin-11(R)-yl-1-piperidinyl]-2-oxo-ethyl]-1-piperidinecarboxamide; 4-(2-(4-(8-Chloro-3,10-dibromo-6,11-dihydro-5H-benzo(5,6)cyclohepta(1,2-b)pyridin-11-yl)-1-piperidinyl)-2-oxoethyl)-1-piperidinecarboxamide; 4-(2-(4-(8-Chloro-3,10-dibromo-6,11-dihydro-5H-benzo-(5,6)-cyclohepta(1,2-b)-pyridin-11(R)-yl)-1-piperidinyl)-2-oxo-ethyl)-1-piperidinecarboxamide; 4-{2-[4-(3,10-DIBROMO-8-CHLORO-6,11-DIHYDRO-5H-BENZO[5,6]CYCLOHEPTA[1,2-B]PYRIDIN-11-YL)PIPERIDIN-1-YL]-2-OXOETHYL}PIPERIDINE-1-CARBOXAMIDE DMGM2Z6 CP Schering-Plough DMGM2Z6 TC Anticancer Agents DMGM2Z6 DT Small molecular drug DMGM2Z6 PC 148195 DMGM2Z6 MW 638.8 DMGM2Z6 FM C27H31Br2ClN4O2 DMGM2Z6 IC InChI=1S/C27H31Br2ClN4O2/c28-20-12-19-2-1-18-13-21(30)14-22(29)24(18)25(26(19)32-15-20)17-5-9-33(10-6-17)23(35)11-16-3-7-34(8-4-16)27(31)36/h12-17,25H,1-11H2,(H2,31,36)/t25-/m1/s1 DMGM2Z6 CS C1CN(CCC1CC(=O)N2CCC(CC2)[C@@H]3C4=C(CCC5=C3N=CC(=C5)Br)C=C(C=C4Br)Cl)C(=O)N DMGM2Z6 IK DHMTURDWPRKSOA-RUZDIDTESA-N DMGM2Z6 IU 4-[2-[4-[(2R)-6,15-dibromo-13-chloro-4-azatricyclo[9.4.0.03,8]pentadeca-1(11),3(8),4,6,12,14-hexaen-2-yl]piperidin-1-yl]-2-oxoethyl]piperidine-1-carboxamide DMGM2Z6 CA CAS 193275-84-2 DMGM2Z6 CB CHEBI:47097 DMGM2Z6 DE Non-small-cell lung cancer; Hepatitis D virus infection; Myelodysplastic syndrome; Hutchinson-Gilford progeria syndrome DMXSVGI ID DMXSVGI DMXSVGI DN Loncastuximab tesirine DMXSVGI HS Approved DMXSVGI CP ADC Therapeutics DMXSVGI DT Antibody drug conjugate DMXSVGI DE Diffuse large B-cell lymphoma; Follicular lymphoma DMOJZQ9 ID DMOJZQ9 DMOJZQ9 DN Loperamide DMOJZQ9 HS Approved DMOJZQ9 SN Ioperamide; Loperacap; Loperamida; Loperamidum; Kaopectate II; Loperamide Monohydrochloride; Pepto Diarrhea Control; Apo-Loperamide; Diamide (TN); Diarr-Eze; Dimor (TN); Imodium (TN); Imodium A-D Caplets; Loperamida [INN-Spanish]; Loperamide (INN); Loperamide [INN:BAN]; Loperamidum [INN-Latin]; Lopex (TN); Maalox Anti-Diarrheal; Nu-Loperamide; PMS-Loperamide; Pepto (TN); R-18553; Rho-Loperamide DMOJZQ9 CP Janssen Pharmaceutica DMOJZQ9 TC Antidiarrheals DMOJZQ9 DT Small molecular drug DMOJZQ9 PC 3955 DMOJZQ9 MW 477 DMOJZQ9 FM C29H33ClN2O2 DMOJZQ9 IC InChI=1S/C29H33ClN2O2/c1-31(2)27(33)29(24-9-5-3-6-10-24,25-11-7-4-8-12-25)19-22-32-20-17-28(34,18-21-32)23-13-15-26(30)16-14-23/h3-16,34H,17-22H2,1-2H3 DMOJZQ9 CS CN(C)C(=O)C(CCN1CCC(CC1)(C2=CC=C(C=C2)Cl)O)(C3=CC=CC=C3)C4=CC=CC=C4 DMOJZQ9 IK RDOIQAHITMMDAJ-UHFFFAOYSA-N DMOJZQ9 IU 4-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-N,N-dimethyl-2,2-diphenylbutanamide DMOJZQ9 CA CAS 53179-11-6 DMOJZQ9 CB CHEBI:6532 DMOJZQ9 DE Diarrhea DMITQS0 ID DMITQS0 DMITQS0 DN Lopinavir DMITQS0 HS Approved DMITQS0 SN AIDS032937; Aluvia (TN); Aluviran; Kaletra (TN); Koletra; LPV; Lopinavir (JAN/USAN/INN); Lopinavir [USAN:INN:BAN]; RS-346; A 157378; A 157378.0; A-157378-0; A-157378.0; ABT 157378; ABT 378; ABT-378; ABT-378 DMITQS0 CP Abbott Laboratories DMITQS0 TC Anti-HIV Agents DMITQS0 DT Small molecular drug DMITQS0 PC 92727 DMITQS0 MW 628.8 DMITQS0 FM C37H48N4O5 DMITQS0 IC InChI=1S/C37H48N4O5/c1-25(2)34(41-20-12-19-38-37(41)45)36(44)39-30(21-28-15-7-5-8-16-28)23-32(42)31(22-29-17-9-6-10-18-29)40-33(43)24-46-35-26(3)13-11-14-27(35)4/h5-11,13-18,25,30-32,34,42H,12,19-24H2,1-4H3,(H,38,45)(H,39,44)(H,40,43)/t30-,31-,32-,34-/m0/s1 DMITQS0 CS CC1=C(C(=CC=C1)C)OCC(=O)N[C@@H](CC2=CC=CC=C2)[C@H](C[C@H](CC3=CC=CC=C3)NC(=O)[C@H](C(C)C)N4CCCNC4=O)O DMITQS0 IK KJHKTHWMRKYKJE-SUGCFTRWSA-N DMITQS0 IU (2S)-N-[(2S,4S,5S)-5-[[2-(2,6-dimethylphenoxy)acetyl]amino]-4-hydroxy-1,6-diphenylhexan-2-yl]-3-methyl-2-(2-oxo-1,3-diazinan-1-yl)butanamide DMITQS0 CA CAS 192725-17-0 DMITQS0 CB CHEBI:31781 DMITQS0 DE Human immunodeficiency virus infection DM4L8H3 ID DM4L8H3 DM4L8H3 DN Loracarbef DM4L8H3 HS Approved DM4L8H3 SN Lorabid; Loracarbefum; Lorafem; Loracarbef hydrate; KT-3777; LY-163892; Lorabid (TN); (6R,7S)-7-[[(2R)-2-amino-2-phenylacetyl]amino]-3-chloro-8-oxo-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7S)-7-[[(2R)-2-amino-2-phenylacetyl]amino]-3-chloro-8-oxo-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid hydrate; (6R,7S)-7-{[(2R)-2-amino-2-phenylacetyl]amino}-3-chloro-8-oxo-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; (6R,7S)-7-{[(2R)-2-amino-2-phenylacetyl]amino}-3-chloro-8-oxo-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7S)-7-{[(2R)-2-amino-2-phenylacetyl]amino}-3-chloro-8-oxo-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid hydrate; (6R,7S)-7-{[(2R)-2-ammonio-2-phenylacetyl]amino}-3-chloro-8-oxo-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; 7beta-[(2R)-2-amino-2-phenylacetyl]nitrilo-3-chloro-3,4-didehydrocepham-4-carboxylate; 7beta-[(2R)-2-amino-2-phenylacetyl]nitrilo-3-chloro-3,4-didehydrocepham-4-carboxylic acid; 7beta-[(2R)-2-ammonio-2-phenylacetyl]nitrilo-3-chloro-3,4-didehydrocepham-4-carboxylate DM4L8H3 CP Eli Lilly DM4L8H3 TC Antibiotics DM4L8H3 DT Small molecular drug DM4L8H3 PC 5284585 DM4L8H3 MW 349.77 DM4L8H3 FM C16H16ClN3O4 DM4L8H3 IC InChI=1S/C16H16ClN3O4/c17-9-6-7-10-12(15(22)20(10)13(9)16(23)24)19-14(21)11(18)8-4-2-1-3-5-8/h1-5,10-12H,6-7,18H2,(H,19,21)(H,23,24)/t10-,11-,12+/m1/s1 DM4L8H3 CS C1CC(=C(N2[C@H]1[C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)N)C(=O)O)Cl DM4L8H3 IK JAPHQRWPEGVNBT-UTUOFQBUSA-N DM4L8H3 IU (6R,7S)-7-[[(2R)-2-amino-2-phenylacetyl]amino]-3-chloro-8-oxo-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid DM4L8H3 CA CAS 76470-66-1 DM4L8H3 CB CHEBI:47544 DM4L8H3 DE Bacterial infection DMF3AN7 ID DMF3AN7 DMF3AN7 DN Loratadine DMF3AN7 HS Approved DMF3AN7 SN Aerotina; Alarin; Alavert; Alerpriv; Allertidin; Anhissen; Biloina; Bonalerg; Civeran; Claratyne; Clarinase; Claritin; Claritine; Clarityn; Clarityne; Clarium; Fristamin; Histaloran; Lergy; Lertamine; Lesidas; Lisino; Loracert; Loradex; Loradif; Loranox; Lorantis; Lorastine; Loratadina; Loratadinum; Loratidine; Loratyne; Loraver; Lorfast; Loritine; Lowadina; Nularef; Optimin; Polaratyne; Pylor; Restamine; Rhinase; Rinomex; Roletra; Sanelor; Sensibit; Sohotin; Tadine; Velodan; Versal; Zeos; Bedix Loratadina; Claratyne Cold; Claratyne Decongestant; Clarinase Reperabs; Claritin D; Claritin Hives Relief; Claritin Hives Relief Reditab; Claritin Reditabs; Claritin reditab; Clarityne Dy Repetabs; Loratadina [Spanish]; Loratadine Redidose; Loratadine Wyeth Brand; Loratadinum [Latin]; Sinhistan Dy; Talorat Dy; Wyeth Brand of Loratadine; L 9664; Sch 29851; Sch29851; Alavert (TN); AllergyX (TN); Children's Claritin; Claritin (TN); Claritine (TN); Clarityn (TN); Clarityne (TN); Clarityne-D; Flonidan (TN); Fristamin (TN); Lomilan (TN); Lorfast (TN); Rinolan (TN); Roletra (TN); Sch-29851; Symphoral (TN); Tidilor (TN); Alavert, Claritin, Loratadine; Loratadine [USAN:BAN:INN]; Loratadine (JAN/USAN/INN); Ethyl 4-(8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)piperidine-1-carboxylate; Ethyl 4-(8-chloro-5,6-dihydro-11H-benzo(5,6)cyclohepta(1,2-b)pyridin-11-ylidene)-1-piperidinecarboxylate; 1-Piperidenecarboxylic acid, 4-(8-chloro-5,6-duhydro-11H-benzo [5,6]cyclohepta[1,2-b]-pyridin-11-ylidene)-, ethyl ester; 1-Piperidinecarboxylic acid, 4-(8-chloro-5,6-dihydro-11H-benzo(5,6)cyclohepta(1,2-b)pyridin-11-ylidene)-, ethyl ester; 1-Piperidinecarboxylic acid, 4-(8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)-, ethyl ester; 1-piperidinecarboxylic acid,4-(8-chloro-5,6-dihydro-11H-benzo(5,6)cyclohepta(1,2-b)pyridin-11-ylidene)-,ethyl ester; 4-(8-Chloro-5,6-dihydro-11H-benzo(5,6)cyclohepta(1,2-b)pyridin-11-ylidene)-1-piperidinecarboxylic Acid Ethyl Ester; 4-(8-Chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene-1-piperidinecarboxylic acidethyl ester; 4-(8-chloro-5,6-dihydro-11H-benzo[5,6]cycloheptal[1,2-b]pyridin-11-ylidene-1-piperidinecarboxylic acid ethyl ester DMF3AN7 CP Schering-Plough Corporation DMF3AN7 TC Antihistamines DMF3AN7 DT Small molecular drug DMF3AN7 PC 3957 DMF3AN7 MW 382.9 DMF3AN7 FM C22H23ClN2O2 DMF3AN7 IC InChI=1S/C22H23ClN2O2/c1-2-27-22(26)25-12-9-15(10-13-25)20-19-8-7-18(23)14-17(19)6-5-16-4-3-11-24-21(16)20/h3-4,7-8,11,14H,2,5-6,9-10,12-13H2,1H3 DMF3AN7 CS CCOC(=O)N1CCC(=C2C3=C(CCC4=C2N=CC=C4)C=C(C=C3)Cl)CC1 DMF3AN7 IK JCCNYMKQOSZNPW-UHFFFAOYSA-N DMF3AN7 IU ethyl 4-(13-chloro-4-azatricyclo[9.4.0.03,8]pentadeca-1(11),3(8),4,6,12,14-hexaen-2-ylidene)piperidine-1-carboxylate DMF3AN7 CA CAS 79794-75-5 DMF3AN7 CB CHEBI:6538 DMF3AN7 DE Allergy; Allergic rhinitis DM84ZXF ID DM84ZXF DM84ZXF DN Lorazepam DM84ZXF HS Approved DM84ZXF SN Almazine; Alzapam; Anxiedin; Anxira; Anzepam; Aplacasse; Aplacassee; ApoLorazepam; Aripax; Ativan; Azurogen; Bonatranquan; Bonton; Delormetazepam; Demethyllormetazepam; Donix; Duralozam; Durazolam; Efasedan; Emotion; Emotival; Equitam; Idalprem; Kalmalin; Larpose; Laubeel; Lomesta; Lopam; Lorabenz; Lorafen; Loram; Lorans; Lorapam; Lorat; Lorax; Loraz; Lorazene; Lorazep; Lorazepamum; Lorazin; Lorazon; Lorenin; Loridem; Lorivan; Lorsedal; Lorsilan; Lorzem; Lozepam; Merlit; Nervistopl; Norlormetazepam; Novhepar; Novolorazem; NuLoraz; Orfidal; Punktyl; Quait; Renaquil; Rocosgen; Securit; Sedatival; Sedazin; Sedicepan; Sedizepan; Sidenar; Silence; Sinestron; Somagerol; Stapam; Tavor; Temesta; Tolid; Tranqipam; Trapax; Upan; Vigiten; Wypax; AHP Brand of Lorazepam; Apo Lorazepam; Apotex Brand of Lorazepam; Baxter Brand of Lorazepam; Ct Arzneimittel Brand of Lorazepam; Desitin Brand of Lorazepam; Dolorgiet Brand of Lorazepam; Llorens Brand of Lorazepam; Lorazep von ct; Lorazepam AHP Brand; Lorazepam Apotex Brand; Lorazepam Baxter Brand; Lorazepam Desitin Brand; Lorazepam Dolorgiet Brand; Lorazepam Fabra; Lorazepam Genericon; Lorazepam Intensol; Lorazepam Lannacher; Lorazepam Llorens Brand; Lorazepam Medical; Lorazepam Medical Brand; Lorazepam Medix Brand; Lorazepam Novartis Brand; Lorazepam Novopharm Brand; Lorazepam Riemser Brand; Lorazepam Wyeth Brand; Lorazepam neuraxpharm; Lorazepam neuraxpharm Brand; Lorazepam preservative free; Lorazepam ratiopharm; Lorazepam ratiopharm Brand; Lorazepan Chobet; Lorazepan Richet; Max Pax; Medical Brand of Lorazepam; Medix Brand of Lorazepam; Merck dura Brand of Lorazepam; Nervistop L; Neuraxpharm Brand of Lorazepam; Novartis Brand of Lorazepam; Novo Lorazem; Novopharm Brand of Lorazepam; Nu Loraz; Nu Pharm Brand of Lorazepam; Orfidal Wyeth; Pro dorm; Ratiopharm Brand of Lorazepam; Riemser Brand of Lorazepam; Serra Pamies Brand of Lorazepam; Wyeth Brand of Lorazepam; L1764_SIGMA; WY4036; Wy 4036; Apo-Lorazepam; Ativan (TN); Ct-Arzneimittel Brand of Lorazepam; Lorazepam (Ativan); Lorazepam Nu-Pharm Brand; Lorazepam ct-Arzneimittel Brand; Lorazepam-Efeka; Lorazepam-neuraxpharm; Lorazepam-ratiopharm; Lorazepamum [INN-Latin]; Medical, Lorazepam; Novo-Lorazem; Nu-Loraz; Nu-Pharm Brand of Lorazepam; O-Chlorooxazepam; O-Chloroxazepam; Temesta (TN); Wy-4036; Wyeth, Orfidal; Lorazepam (JP15/USP/INN); Lorazepam [USAN:INN:BAN:JAN]; (+-)-7-Chloro-5-(o-chlorophenyl)-1,3-dihydro-3-hydroxy-2H-1,4-benzodiazepin-2-one; (+/-)-Lorazepam; 7-Chloro-5-(2-chlorophenyl)-1,3-dihydro-3-hydroxy-2H-1,4-benzodiazepin-2-one; 7-Chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-2H-1,4-benzodiazepin-2-one; 7-Chloro-5-(2-chlorophenyl)-3-hydroxy-1H-1,4-benzodiazepin-2(3H)-one; 7-Chloro-5-(o-chlorophenyl)-1,3-dihydro-3-hydroxy-2H-1,4-benzodiazepin-2-one; 7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one DM84ZXF CP Wyeth Pharmaceuticals DM84ZXF TC Antianxiety Agents DM84ZXF DT Small molecular drug DM84ZXF PC 3958 DM84ZXF MW 321.2 DM84ZXF FM C15H10Cl2N2O2 DM84ZXF IC InChI=1S/C15H10Cl2N2O2/c16-8-5-6-12-10(7-8)13(19-15(21)14(20)18-12)9-3-1-2-4-11(9)17/h1-7,15,21H,(H,18,20) DM84ZXF CS C1=CC=C(C(=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)O)Cl DM84ZXF IK DIWRORZWFLOCLC-UHFFFAOYSA-N DM84ZXF IU 7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one DM84ZXF CA CAS 846-49-1 DM84ZXF CB CHEBI:6539 DM84ZXF DE Anxiety disorder DMG6OYJ ID DMG6OYJ DMG6OYJ DN Lorcaserin DMG6OYJ HS Approved DMG6OYJ SN APD 356; APD356; AR-10A; (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 10-chloro-2-methyl-4-azabicyclo[5.4.0]undeca-8,10,12-triene DMG6OYJ CP Arena Pharmaceuticals Inc. DMG6OYJ DT Small molecular drug DMG6OYJ PC 11658860 DMG6OYJ MW 195.69 DMG6OYJ FM C11H14ClN DMG6OYJ IC InChI=1S/C11H14ClN/c1-8-7-13-5-4-9-2-3-10(12)6-11(8)9/h2-3,6,8,13H,4-5,7H2,1H3/t8-/m0/s1 DMG6OYJ CS C[C@H]1CNCCC2=C1C=C(C=C2)Cl DMG6OYJ IK XTTZERNUQAFMOF-QMMMGPOBSA-N DMG6OYJ IU (5R)-7-chloro-5-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine DMG6OYJ CA CAS 616202-92-7 DMG6OYJ CB CHEBI:65353 DMG6OYJ DE Obesity; Drug abuse DMICDLV ID DMICDLV DMICDLV DN Lorlatinib DMICDLV HS Approved DMICDLV SN Loratinib; UNII-OSP71S83EU; Lorlatinib,PF-06463922; OSP71S83EU; lorlantinib; 4clj; 4cli; Lorlatinib [USAN:INN]; Lorlatinib (JAN/USAN/INN); PF06463922(Lorlatinib); GTPL7476; SCHEMBL15261807; EX-A828; MolPort-035-789-724; KS-00000T6C; 2641AH; ZINC98208524; s7536; MFCD28144520; BDBM50018830; AKOS027250753; DB12130; CS-39 DMICDLV CP Pfizer DMICDLV PC 71731823 DMICDLV MW 406.4 DMICDLV FM C21H19FN6O2 DMICDLV IC InChI=1S/C21H19FN6O2/c1-11-15-7-13(22)4-5-14(15)21(29)27(2)10-16-19(17(8-23)28(3)26-16)12-6-18(30-11)20(24)25-9-12/h4-7,9,11H,10H2,1-3H3,(H2,24,25)/t11-/m1/s1 DMICDLV CS C[C@@H]1C2=C(C=CC(=C2)F)C(=O)N(CC3=NN(C(=C3C4=CC(=C(N=C4)N)O1)C#N)C)C DMICDLV IK IIXWYSCJSQVBQM-LLVKDONJSA-N DMICDLV IU (16R)-19-amino-13-fluoro-4,8,16-trimethyl-9-oxo-17-oxa-4,5,8,20-tetrazatetracyclo[16.3.1.02,6.010,15]docosa-1(22),2,5,10(15),11,13,18,20-octaene-3-carbonitrile DMICDLV CA CAS 1454846-35-5 DMICDLV CB CHEBI:143117 DMICDLV DE Non-small-cell lung cancer DMYZFXN ID DMYZFXN DMYZFXN DN Lornoxicam DMYZFXN HS Approved DMYZFXN SN CTX; Chlortenoxicam; Lorcam; Safem; Telos; Xefo; Xefo Rapid; HN-10000; TS-110; Ro-13-9297 DMYZFXN CP Roche Holding AG DMYZFXN DT Small molecular drug DMYZFXN PC 54690031 DMYZFXN MW 371.8 DMYZFXN FM C13H10ClN3O4S2 DMYZFXN IC InChI=1S/C13H10ClN3O4S2/c1-17-10(13(19)16-9-4-2-3-5-15-9)11(18)12-7(23(17,20)21)6-8(14)22-12/h2-6,18H,1H3,(H,15,16,19) DMYZFXN CS CN1C(=C(C2=C(S1(=O)=O)C=C(S2)Cl)O)C(=O)NC3=CC=CC=N3 DMYZFXN IK WLHQHAUOOXYABV-UHFFFAOYSA-N DMYZFXN IU 6-chloro-4-hydroxy-2-methyl-1,1-dioxo-N-pyridin-2-ylthieno[2,3-e]thiazine-3-carboxamide DMYZFXN CA CAS 70374-39-9 DMYZFXN CB CHEBI:31783 DMYZFXN DE Migraine DM72JXH ID DM72JXH DM72JXH DN Losartan DM72JXH HS Approved DM72JXH SN Cozaar; Cozaar (TN); DUP 89; DuP 753; DuP-753; Hyzaar; JMS50MPO89; LOSARTAN POTASSIUM; Lortaan; Losartan (INN); 114798-26-4; C22H23ClN6O; CHEBI:6541; CL23623; Losartan [INN:BAN]; Losartan monopotassium salt; Losartic; Losartic (TN); MK-954; MK954; UNII-JMS50MPO89; [3H]losartan DM72JXH CP Merck & Co DM72JXH TC Antihypertensive Agents DM72JXH DT Small molecular drug DM72JXH PC 3961 DM72JXH MW 422.9 DM72JXH FM C22H23ClN6O DM72JXH IC InChI=1S/C22H23ClN6O/c1-2-3-8-20-24-21(23)19(14-30)29(20)13-15-9-11-16(12-10-15)17-6-4-5-7-18(17)22-25-27-28-26-22/h4-7,9-12,30H,2-3,8,13-14H2,1H3,(H,25,26,27,28) DM72JXH CS CCCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)CO)Cl DM72JXH IK PSIFNNKUMBGKDQ-UHFFFAOYSA-N DM72JXH IU [2-butyl-5-chloro-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol DM72JXH CA CAS 114798-26-4 DM72JXH CB CHEBI:6541 DM72JXH DE Hypertension DM8QTJI ID DM8QTJI DM8QTJI DN Loteprednol etabonate DM8QTJI HS Approved DM8QTJI SN Alrex; Locort; Loteflam; Lotemax; Loterox; CDDD-5604; HGP-1; IDR-90102; IDR-90103; Lotemax (TN); P-5604; Alrex, Lotemax, Loteprednol etabonate; Loteprednol etabonate (JAN/USAN); Chloromethyl 17alpha-[(ethoxycarbonyl)oxy]-11beta-hydroxy-3-oxoandrosta-1,4-diene-17beta-carboxylate; Chloromethyl (8S,9S,10R,11S,13S,14S,17R)-17-ethoxycarbonyloxy-11-hydroxy-10,13-dimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthrene-17-carboxylate DM8QTJI CP Bausch & Lomb Pharmaceuticals, Inc. DM8QTJI TC Antiallergic Agents DM8QTJI DT Small molecular drug DM8QTJI PC 444025 DM8QTJI MW 466.9 DM8QTJI FM C24H31ClO7 DM8QTJI IC InChI=1S/C24H31ClO7/c1-4-30-21(29)32-24(20(28)31-13-25)10-8-17-16-6-5-14-11-15(26)7-9-22(14,2)19(16)18(27)12-23(17,24)3/h7,9,11,16-19,27H,4-6,8,10,12-13H2,1-3H3/t16-,17-,18-,19+,22-,23-,24-/m0/s1 DM8QTJI CS CCOC(=O)O[C@@]1(CC[C@@H]2[C@@]1(C[C@@H]([C@H]3[C@H]2CCC4=CC(=O)C=C[C@]34C)O)C)C(=O)OCCl DM8QTJI IK DMKSVUSAATWOCU-HROMYWEYSA-N DM8QTJI IU chloromethyl (8S,9S,10R,11S,13S,14S,17R)-17-ethoxycarbonyloxy-11-hydroxy-10,13-dimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthrene-17-carboxylate DM8QTJI CA CAS 82034-46-6 DM8QTJI CB CHEBI:31784 DM8QTJI DE Eye inflammation DM9OZWQ ID DM9OZWQ DM9OZWQ DN Lovastatin DM9OZWQ HS Approved DM9OZWQ SN lovastatin; 75330-75-5; mevinolin; Mevacor; Lovalip; Monacolin K; Lovalord; Mevinacor; Altoprev; Nergadan; Artein; Altocor; 6alpha-Methylcompactin; MK-803; Hipovastin; Lovastatine; Lovasterol; Paschol; Lipivas; Closterol; Teroltrat; Tecnolip; Rovacor; Cholestra; Rodatin; Lozutin; Lipofren; Lestatin; Hipolip; Colevix; Sivlor; Taucor; Lipdip; Belvas; Mevlor; Lovastatine [French]; Lovastatinum [Latin]; Lovastatina [Spanish]; 6-alpha-Methylcompactin; Lovastatinum; Lovastatina; Lovastin; MSD 803; MK 803; 6 alpha-Methylcompactin; UNII-9LHU78OQFD; Altocor; Liposcler; Mevinolin; Rextat; Sivlor;Taucor; Monakolin K; MK803; Advicor (TN); Altocor (TN); Altoprev (TN); L-154803; Lovastatin & Primycin; ML-530B; Mevacor (TN); Mevinolin from Aspergillus sp; Statosan (TN); Lovastatin (USP/INN); Lovastatin [USAN:BAN:INN]; Lovastatin, (1 alpha(S*))-Isomer; Lovastatin, 1 alpha-Isomer (without R*/S* notation); 2beta,6alpha-Dimethyl-8alpha-(2-methyl-1-oxobutoxy)-mevinic acid lactone; 6 Methylcompactin; 6-Methylcompactin; Aspirin/lisinopril/ lovastatin fixed-dose combination DM9OZWQ CP Atos Pharma DM9OZWQ TC Anticholesteremic Agents DM9OZWQ DT Small molecular drug DM9OZWQ PC 53232 DM9OZWQ MW 404.5 DM9OZWQ FM C24H36O5 DM9OZWQ IC InChI=1S/C24H36O5/c1-5-15(3)24(27)29-21-11-14(2)10-17-7-6-16(4)20(23(17)21)9-8-19-12-18(25)13-22(26)28-19/h6-7,10,14-16,18-21,23,25H,5,8-9,11-13H2,1-4H3/t14-,15-,16-,18+,19+,20-,21-,23-/m0/s1 DM9OZWQ CS CC[C@H](C)C(=O)O[C@H]1C[C@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@@H]3C[C@H](CC(=O)O3)O)C DM9OZWQ IK PCZOHLXUXFIOCF-BXMDZJJMSA-N DM9OZWQ IU [(1S,3R,7S,8S,8aR)-8-[2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] (2S)-2-methylbutanoate DM9OZWQ CA CAS 75330-75-5 DM9OZWQ CB CHEBI:40303 DM9OZWQ DE Hypercholesterolaemia; Cardiovascular disease DMGCQ4E ID DMGCQ4E DMGCQ4E DN Lovastatin acid DMGCQ4E HS Approved DMGCQ4E SN Lovastatin acid; Mevinolinic acid; Monacolinic K acid; MSD 803 acid; MSD 803 free acid; UNII-5CLV35Y90C; MK 819; L-154819; L 154819; 5CLV35Y90C; CHEBI:82985; (3R,5R)-7-((1R,2R,6S,8R,8AS)-2,6-DIMETHYL-8-{[(2R)-2-METHYLBUTANOYL]OXY}-1,2,6,7,8,8A-HEXAHYDRONAPHTHALEN-1-YL)-3,5-DIHYDROXYHEPTANOIC ACID; (3R,5R)-7-[(1S,2S,6R,8S,8aR)-2,6-dimethyl-8-{[(2S)-2-methylbutanoyl]oxy}-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid DMGCQ4E PC 64727 DMGCQ4E MW 422.6 DMGCQ4E FM C24H38O6 DMGCQ4E IC InChI=1S/C24H38O6/c1-5-15(3)24(29)30-21-11-14(2)10-17-7-6-16(4)20(23(17)21)9-8-18(25)12-19(26)13-22(27)28/h6-7,10,14-16,18-21,23,25-26H,5,8-9,11-13H2,1-4H3,(H,27,28)/t14-,15-,16-,18+,19+,20-,21-,23-/m0/s1 DMGCQ4E CS CCC(C)C(=O)OC1CC(C=C2C1C(C(C=C2)C)CCC(CC(CC(=O)O)O)O)C DMGCQ4E IK QLJODMDSTUBWDW-BXMDZJJMSA-N DMGCQ4E IU (3R,5R)-7-[(1S,2S,6R,8S,8aR)-2,6-dimethyl-8-[(2S)-2-methylbutanoyl]oxy-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid DMGCQ4E CA CAS 75225-51-3 DMGCQ4E CB CHEBI:82985 DMGCQ4E DE Hypercholesterolemia DM8AI9U ID DM8AI9U DM8AI9U DN Loxapine DM8AI9U HS Approved DM8AI9U SN Cloxazepine; Dibenzacepin; Dibenzoazepine; Lossapina; Loxapin; Loxapina; Loxapinsuccinate; Loxapinum; Loxepine; Oxilapine; Lossapina [DCIT]; Loxitane IM; CL 62362; HF 3170; HF3170; Hydrofluoride 3170; LW 3170; S 805; SUM 3170; CL-62362; Loxapac (TN); Loxapina [INN-Spanish]; Loxapinum [INN-Latin]; Loxitane (TN); S-805;SUM-3170; CL-71,563; Loxapine (USAN/INN); Loxapine [USAN:BAN:INN]; Loxapine [USAN:INN:BAN]; 2-Chloro-11-(4-methyl-1-piperazinyl)-dibenz(b,f)(1,4)oxazepine; 2-Chloro-11-(4-methyl-1-piperazinyl)dibenz(b,f)(1,4)oxazepine; 2-Chloro-11-(4-methylpiperazino)dibenzo(b,f)(1,4)oxazepine; 2-chloro-11-(4-methylpiperazin-1-yl)dibenzo[b,f][1,4]oxazepine; 8-chloro-6-(4-methylpiperazin-1-yl)benzo[b][1,4]benzoxazepine; 8-chloro-6-(4-methylpiperazin-1-yl)benzo[b][1,5]benzoxazepine DM8AI9U CP Watson Laboratories DM8AI9U TC Antipsychotic Agents DM8AI9U DT Small molecular drug DM8AI9U PC 3964 DM8AI9U MW 327.8 DM8AI9U FM C18H18ClN3O DM8AI9U IC InChI=1S/C18H18ClN3O/c1-21-8-10-22(11-9-21)18-14-12-13(19)6-7-16(14)23-17-5-3-2-4-15(17)20-18/h2-7,12H,8-11H2,1H3 DM8AI9U CS CN1CCN(CC1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl DM8AI9U IK XJGVXQDUIWGIRW-UHFFFAOYSA-N DM8AI9U IU 8-chloro-6-(4-methylpiperazin-1-yl)benzo[b][1,4]benzoxazepine DM8AI9U CA CAS 1977-10-2 DM8AI9U CB CHEBI:50841 DM8AI9U DE Schizophrenia DMQMGXV ID DMQMGXV DMQMGXV DN Loxoprofen gel DMQMGXV HS Approved DMQMGXV SN Loxonin; Loxoprofen; Loxonin Pap; Loxonin Tape; CS-600G; LX-A; LX-P; Loxonin Gel 1%; Lipoxin A, Daiichi Sankyo/Lead Chemical; Lipoxin A, Sankyo/ Lead Chemical; Loxoprofen (gel, pain/ inflammation), Daiichi Sankyo; Loxoprofen (gel, pain/ inflammation), Sankyo; Loxoprofen (patch, pain/inflammation), Daiichi Sankyo/ Lead Chemical; Loxoprofen (patch, pain/inflammation), Sankyo/ Lead Chemical DMQMGXV CP Sankyo Co Ltd DMQMGXV DT Small molecular drug DMQMGXV PC 3965 DMQMGXV MW 246.3 DMQMGXV FM C15H18O3 DMQMGXV IC InChI=1S/C15H18O3/c1-10(15(17)18)12-7-5-11(6-8-12)9-13-3-2-4-14(13)16/h5-8,10,13H,2-4,9H2,1H3,(H,17,18) DMQMGXV CS CC(C1=CC=C(C=C1)CC2CCCC2=O)C(=O)O DMQMGXV IK YMBXTVYHTMGZDW-UHFFFAOYSA-N DMQMGXV IU 2-[4-[(2-oxocyclopentyl)methyl]phenyl]propanoic acid DMQMGXV CA 68767-14-6 DMQMGXV DE Inflammation DMQXI9F ID DMQXI9F DMQXI9F DN L-Phenylalanine DMQXI9F HS Approved DMQXI9F SN Endophenyl; Fenilalanina; Phe; Phenylalanine; Phenylalaninum; Fenilalanina [Spanish]; Phenylalaninum [Latin]; Antibiotic FN 1636; CB 3208; NCI9959; Alpha-Aminohydrocinnamic acid; Beta-Phenylalanine; L-Antibiotic FN 1636; L-PHENYLALININE; N-Formylmelphalan; Phenylalanine (VAN); H-Phe-OH; L-Phenylalanine (JP15); Phenylalanine (USP/INN); Phenylalanine [USAN:INN:JAN]; Beta-Phenyl-L-alanine; N-Formyl-L-sarcolysin; N-Formyl-L-p-sarcolysin; L-PHENYL ALANINE (SEE ALSO 22839-47-0, ASPARTAME; L-3-(p-(Bis(2-chloroethyl)amino)phenyl)-N-formylalanine; L-Phenylalanine, 4-(bis(2-chloroethyl)amino)-N-formyl-(9CI); (2S)-2-amino-3-phenylpropanoic acid; (L)-Phenylalanine; (S)-(-)-Phenylalanine; (S)-2-Amino-3-phenylpropanoic acid; (S)-2-Amino-3-phenylpropionic acid; (S)-Phenylalanine; (S)-alpha-Amino-benzenepropanoic acid; (S)-alpha-Amino-beta-phenylpropionic acid; (S)-alpha-Aminohydrocinnamic acid; 1F9436B3-8B0D-4AC6-A004-4249B0BDA436; 3-Phenyl-L-alanine; 3-Phenylalanine; 3-[4-[bis(2-chloroethyl)amino]phenyl]-2-formamidopropanoic acid DMQXI9F TC Dietary supplement DMQXI9F DT Small molecular drug DMQXI9F PC 6140 DMQXI9F MW 165.19 DMQXI9F FM C9H11NO2 DMQXI9F IC InChI=1S/C9H11NO2/c10-8(9(11)12)6-7-4-2-1-3-5-7/h1-5,8H,6,10H2,(H,11,12)/t8-/m0/s1 DMQXI9F CS C1=CC=C(C=C1)C[C@@H](C(=O)O)N DMQXI9F IK COLNVLDHVKWLRT-QMMMGPOBSA-N DMQXI9F IU (2S)-2-amino-3-phenylpropanoic acid DMQXI9F CA CAS 63-91-2 DMQXI9F CB CHEBI:17295 DMQXI9F DE Malnutrition DMKSTWR ID DMKSTWR DMKSTWR DN L-Proline DMKSTWR HS Approved DMKSTWR SN Carboxypyrrolidine; Pro; Prolina; Prolinum; Prolina [Spanish]; Prolinum [Latin]; CB 1707; L-Prolin; PRO (IUPACabbreviation); Proline (USP); Proline (VAN); Proline [USAN:INN]; H-Pro-OH; L-Proline (JAN); L-Proline-15N; L-alpha-Pyrrolidinecarboxylic acid; L-Proline, labeled with carbon-14; L-Pyrrolidine-2-carboxylic acid; L-(2,3-3H)Proline; (-)-(S)-Proline; (-)-2-Pyrrolidinecarboxylic acid; (-)-Proline (S)-2-Carboxypyrrolidine; (2S)-pyrrolidine-2-carboxylic acid; (S)-2-Carboxypyrrolidine; (S)-2-Pyrrolidinecarboxylic acid; (S)-Proline; (S)-Pyrrolidine-2-carboxylic acid; 2-pyrrolidinecarboxylic acid DMKSTWR TC Dietary supplement DMKSTWR DT Small molecular drug DMKSTWR PC 145742 DMKSTWR MW 115.13 DMKSTWR FM C5H9NO2 DMKSTWR IC InChI=1S/C5H9NO2/c7-5(8)4-2-1-3-6-4/h4,6H,1-3H2,(H,7,8)/t4-/m0/s1 DMKSTWR CS C1C[C@H](NC1)C(=O)O DMKSTWR IK ONIBWKKTOPOVIA-BYPYZUCNSA-N DMKSTWR IU (2S)-pyrrolidine-2-carboxylic acid DMKSTWR CA CAS 4305-67-3 DMKSTWR CB CHEBI:17203 DMKSTWR DE Malnutrition DMIBH7M ID DMIBH7M DMIBH7M DN L-tryptophan DMIBH7M HS Approved DMIBH7M SN Ardeytropin; Kalma; LTR; Lyphan; Optimax; Pacitron; Sedanoct; Triptofano; Trofan; Trp; Tryptacin; Tryptan; Tryptophane; Tryptophanum; Triptofano [Spanish]; Tryptophane [French]; Tryptophanum [Latin]; EH 121; MT1; T 0254; Alti-Tryptophan; L-TRYPTOPHAN SIGMA GRADE; L-Trp; L-Tryptofan; L-Tryptophane; L-Ttp; TRP NH3+ COOH; TRP-01; Tryptophan (VAN); Tryptophan [USAN:INN]; H-Trp-oh; Indole-3-alanine; L-Tryptophan (9CI); L-Tryptophan (JP15); Tryptophan (H-3); Tryptophan (USP/INN); L-b-3-Indolylalanine; L-beta-3-Indolylalanine; Tryptophan, L-(8CI); Alanine, 3-indol-3-yl; Alpha'-Amino-3-indolepropionic acid; L-(-)-Tryptophan; L-(-)-Tryptophane; L-a-Aminoindole-3-propionic acid; L-alpha-Aminoindole-3-propionic acid; L-alpha-amino-3-indolepropionic acid; Alpha-Amino-beta-(3-indolyl)-propionic acid; Alpha-amino-beta-(3-indolyl)-pr opionic acid; Propionic acid, 2-amino-3-indol-3-yl; S(-)-1-alpha-Aminoindole-3-propionic acid; (2S)-2-amino-3-(1H-indol-3-yl)propanoic acid; (L)-TRYPTOPHAN; (S)-(-)-2-Amino-3-(3-indolyl)propionic Acid; (S)-(-)-Tryptopha n; (S)-(-)-Tryptophan; (S)-2-Amino-3-(1H-indol-3-yl)propanoic acid; (S)-2-Amino-3-(3-indolyl)propionic acid; (S)-Tryptophan; (S)-a-Amino-1H-indole-3-propanoic acid; (S)-a-Amino-b-indolepropionic acid; (S)-a-Aminoindole-3-propionic acid; (S)-alpha-Amino-1H-indole-3-propanoic acid; (S)-alpha-Amino-beta-indolepropionic acid; (S)-alpha-Aminoindole-3-propionic acid; (S)-alpha-amino-beta-(3-indolyl)-propionic acid; 1-beta-3-Indolylalanine; 151A3008-4CFE-40C9-AC0B-467EF0CB50EA; 1H-Indole-3-alanine; 1H-Indole-3-alanine (VAN); 1beta-3-Indolylalanine; 2-Amino-3-(lH-indol-3-yl)-propanoic acid; 2-Amino-3-indolylpropanoic acid; 2-amino-3-indol-3-ylpropionic acid; 3-Indol-3-ylalanine DMIBH7M TC Antidepressants DMIBH7M DT Small molecular drug DMIBH7M PC 6305 DMIBH7M MW 204.22 DMIBH7M FM C11H12N2O2 DMIBH7M IC InChI=1S/C11H12N2O2/c12-9(11(14)15)5-7-6-13-10-4-2-1-3-8(7)10/h1-4,6,9,13H,5,12H2,(H,14,15)/t9-/m0/s1 DMIBH7M CS C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)O)N DMIBH7M IK QIVBCDIJIAJPQS-VIFPVBQESA-N DMIBH7M IU (2S)-2-amino-3-(1H-indol-3-yl)propanoic acid DMIBH7M CA CAS 73-22-3 DMIBH7M CB CHEBI:16828 DMIBH7M DE Depression DM9O8DT ID DM9O8DT DM9O8DT DN L-tyrosine DM9O8DT HS Approved DM9O8DT SN DTY; Rxosine; Tirosina; Tyr; Tyrosine; Tyrosinum; Tirosina [Spanish]; Tyrosine Power; Tyrosinum [Latin]; Melanin synthesized from Tyr substrate catalyzed by tyrosinase for 6 hrs; L-Tyrosin; L-Tyrosine hydrochloride; Melanin synthesized from Tyr substrate catalyzed by tyrosinase for 6 hrs, oxidized with hydrogen peroxide; P-Tyrosine; TYR NH3+ COOH; Tyrosine (VAN); Tyrosine [USAN:INN]; Free-Form L-Tyrosine; H-Tyr-OH; L-Tyrosine (9CI); L-Tyrosine (JAN); L-Tyrosine, homopolymer; L-Tyrosine, monomer; L-p-Tyrosine; Melanin synthesized from Tyr substrate catalyzed by tyrosinase, brominated with N-bromosuccinimide; Tyrosine (USP/INN); Beta-(p-Hydroxyphenyl)alanine; Melanin synthesized from Tyr substrate catalyzed by tyrosinase for 6 hrs, oxidized with hydrogen peroxide, <3 kd fraction; Tyrosine, L-(8CI); DD69927C-C6A8-4BC6-8E9A-0AB423B176E7; L-(-)-Tyrosine; Melanin synthesized from Tyr substrate catalyzed by tyrosinase, sulfonated using sulfur trioxide/DMF complex for 1.5-7 hours; Alpha-Amino-beta-(4-hydroxyphenyl)propionic acid; L-2-Amino-3-p-hydroxyphenylpropanoic acid; (-)-alpha-Amino-p-hydroxyhydrocinnamic acid; (S)-2-Amino-3-(4-hydroxyphenyl)propionic acid; (S)-2-Amino-3-(p-hydroxyphenyl)propionic acid; (S)-3-(p-Hydroxyphenyl)alanine; (S)-Tyrosine; (S)-alpha-Amino-4-hydroxybenzenepropanoic acid; 2-Amino-3-(p-hydroxyphenyl)propionic acid; 3-(4-Hydroxyphenyl)-L-alanine; 3-(p-Hydroxyphenyl)alanine; 4-Hydroxy-L-phenylalanine; 4ts1 DM9O8DT TC Dietary supplement DM9O8DT DT Small molecular drug DM9O8DT PC 6057 DM9O8DT MW 181.19 DM9O8DT FM C9H11NO3 DM9O8DT IC InChI=1S/C9H11NO3/c10-8(9(12)13)5-6-1-3-7(11)4-2-6/h1-4,8,11H,5,10H2,(H,12,13)/t8-/m0/s1 DM9O8DT CS C1=CC(=CC=C1C[C@@H](C(=O)O)N)O DM9O8DT IK OUYCCCASQSFEME-QMMMGPOBSA-N DM9O8DT IU (2S)-2-amino-3-(4-hydroxyphenyl)propanoic acid DM9O8DT CA CAS 60-18-4 DM9O8DT CB CHEBI:17895 DM9O8DT DE Malnutrition DMMJVXZ ID DMMJVXZ DMMJVXZ DN LU302146 DMMJVXZ HS Approved DMMJVXZ DE Pulmonary hypertension DMJTEMW ID DMJTEMW DMJTEMW DN Lubiprostone DMJTEMW HS Approved DMJTEMW SN Amitiza; Lubiprostone [USAN]; RU 0211; RU0211; SPI 0211; SPI0211; AMITIZA (TN); RU-0211; SPI-0211; Amitiza, RU-0211, SPI-0211, Lubiprostone; (-)-7-((2R,4aR,5R,7aR)-2-(1,1-Difluoropentyl)-2-hydroxy-6-oxooctahydrocyclopenta (b)pyran-5-yl)heptanoic acid; (-)-7-((2R,4aR,5R,7aR)-2-(1,1-Difluoropentyl)-2-hydroxy-6-oxooctahydrocyclopenta(b)pyran-5-yl)heptanoic acid; 7-((1R,4R,6R,9R)-4-(1,1-difluoropentyl)-4-hydroxy-8-oxo-5-oxabicyclo(4.3.0)non-9-yl)heptanoic acid; 7-[(2R,4aR,5R,7aR)-2-(1,1-difluoropentyl)-2-hydroxy-6-oxo-3,4,4a,5,7,7a-hexahydrocyclopenta[b]pyran-5-yl]heptanoic acid DMJTEMW CP Takeda DMJTEMW TC Anticonstipation Agents DMJTEMW DT Small molecular drug DMJTEMW PC 157920 DMJTEMW MW 390.5 DMJTEMW FM C20H32F2O5 DMJTEMW IC InChI=1S/C20H32F2O5/c1-2-3-11-19(21,22)20(26)12-10-15-14(16(23)13-17(15)27-20)8-6-4-5-7-9-18(24)25/h14-15,17,26H,2-13H2,1H3,(H,24,25)/t14-,15-,17-,20-/m1/s1 DMJTEMW CS CCCCC([C@]1(CC[C@H]2[C@H](O1)CC(=O)[C@@H]2CCCCCCC(=O)O)O)(F)F DMJTEMW IK WGFOBBZOWHGYQH-MXHNKVEKSA-N DMJTEMW IU 7-[(2R,4aR,5R,7aR)-2-(1,1-difluoropentyl)-2-hydroxy-6-oxo-3,4,4a,5,7,7a-hexahydrocyclopenta[b]pyran-5-yl]heptanoic acid DMJTEMW CA CAS 333963-40-9 DMJTEMW DE Chronic idiopathic constipation DMZLBUO ID DMZLBUO DMZLBUO DN Lucanthone DMZLBUO HS Approved DMZLBUO SN Lucanthon; Lucanthonum; Lucantona; Miracol; Nilodin; Scapuren; Tixantone; LUCANTHONE HYDROCHLORIDE; Lucanthone monohydrochloride; Miracil D; BW 57223; CBC 900139; DR-15771; Lucanthone [INN:BAN]; Lucanthonum [INN-Latin]; Lucantona [INN-Spanish]; 1-((2-(Diethylamino)ethyl)amino)-4-methylthioxanthen-9-one; 1-(2-diethylaminoethylamino)-4-methylthioxanthen-9-one; 1-[[2-(Diethylamino)ethyl]amino]-4-methylthioxanthone; 1-{[2-(Diethylamino)ethyl]amino}-4-methyl-9H-thioxanthen-9-one; 9H-Thioxanthen-9-one, 1-((2-(diethylamino)ethyl)amino)-4-methyl-(9CI) DMZLBUO CP Spectrum DMZLBUO TC Anticancer Agents DMZLBUO DT Small molecular drug DMZLBUO PC 10180 DMZLBUO MW 340.5 DMZLBUO FM C20H24N2OS DMZLBUO IC InChI=1S/C20H24N2OS/c1-4-22(5-2)13-12-21-16-11-10-14(3)20-18(16)19(23)15-8-6-7-9-17(15)24-20/h6-11,21H,4-5,12-13H2,1-3H3 DMZLBUO CS CCN(CC)CCNC1=C2C(=C(C=C1)C)SC3=CC=CC=C3C2=O DMZLBUO IK FBQPGGIHOFZRGH-UHFFFAOYSA-N DMZLBUO IU 1-[2-(diethylamino)ethylamino]-4-methylthioxanthen-9-one DMZLBUO CA CAS 479-50-5 DMZLBUO CB CHEBI:51052 DMZLBUO DE Solid tumour/cancer DMT73J8 ID DMT73J8 DMT73J8 DN Luliconazole DMT73J8 HS Approved DMT73J8 SN Lulicon; Lulifin; JA-004; JA-005; NND-502; PR-2699 DMT73J8 CP Medicis DMT73J8 DT Small molecular drug DMT73J8 PC 3003141 DMT73J8 MW 354.3 DMT73J8 FM C14H9Cl2N3S2 DMT73J8 IC InChI=1S/C14H9Cl2N3S2/c15-9-1-2-10(11(16)5-9)13-7-20-14(21-13)12(6-17)19-4-3-18-8-19/h1-5,8,13H,7H2/b14-12+/t13-/m0/s1 DMT73J8 CS C1[C@H](S/C(=C(\\C#N)/N2C=CN=C2)/S1)C3=C(C=C(C=C3)Cl)Cl DMT73J8 IK YTAOBBFIOAEMLL-REQDGWNSSA-N DMT73J8 IU (2E)-2-[(4R)-4-(2,4-dichlorophenyl)-1,3-dithiolan-2-ylidene]-2-imidazol-1-ylacetonitrile DMT73J8 CA CAS 187164-19-8 DMT73J8 CB CHEBI:34825 DMT73J8 DE Tinea pedis; Dry eye disease DMUPOGR ID DMUPOGR DMUPOGR DN Lumacaftor + Ivacaftor DMUPOGR HS Approved DMUPOGR CP Vertex DMUPOGR DE Cystic fibrosis; Acute lung injury DMEBQAO ID DMEBQAO DMEBQAO DN Lumasiran DMEBQAO HS Approved DMEBQAO CP Alnylam Pharmaceuticals DMEBQAO DT Small interfering RNA DMEBQAO DE Hyperoxaluria DMQ8HOJ ID DMQ8HOJ DMQ8HOJ DN lumateperone tosylate DMQ8HOJ HS Approved DMQ8HOJ SN lumateperone Tosylate; lumateperone (Tosylate); 1187020-80-9; UNII-JIE88N006O; ITI-007 tosylate; JIE88N006O; 1187020-80-9 (tosylate); ITI007; ITI 007; ITI-007; Lumateperone tosylate (USAN); Lumateperone tosylate [USAN]; CHEMBL3233142; 1-(4-fluorophenyl)-4-[(6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl]butan-1-one toluenesulfonic acid; Caplyta (TN); SCHEMBL1769664; CS-5540; HY-19733; D11170; Q27281520; 1-(4-Fluoro-phenyl)-4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one tosylate salt DMQ8HOJ DT Small molecular drug DMQ8HOJ PC 44241743 DMQ8HOJ MW 565.7 DMQ8HOJ FM C31H36FN3O4S DMQ8HOJ IC InChI=1S/C24H28FN3O.C7H8O3S/c1-26-14-15-28-21-11-13-27(16-20(21)19-4-2-5-22(26)24(19)28)12-3-6-23(29)17-7-9-18(25)10-8-17;1-6-2-4-7(5-3-6)11(8,9)10/h2,4-5,7-10,20-21H,3,6,11-16H2,1H3;2-5H,1H3,(H,8,9,10)/t20-,21-;/m0./s1 DMQ8HOJ CS CC1=CC=C(C=C1)S(=O)(=O)O.CN1CCN2[C@H]3CCN(C[C@H]3C4=C2C1=CC=C4)CCCC(=O)C5=CC=C(C=C5)F DMQ8HOJ IK LHAPOGAFBLSJJQ-GUTACTQSSA-N DMQ8HOJ IU 1-(4-fluorophenyl)-4-[(10R,15S)-4-methyl-1,4,12-triazatetracyclo[7.6.1.05,16.010,15]hexadeca-5,7,9(16)-trien-12-yl]butan-1-one;4-methylbenzenesulfonic acid DMQ8HOJ CA CAS 1187020-80-9 DMQ8HOJ DE Schizophrenia DM29GAD ID DM29GAD DM29GAD DN Lumefantrine DM29GAD HS Approved DM29GAD SN Benflumetol; Coartem; Dl-Benflumelol; Lumefantrine (INN); Lumefantrine [INN:BAN]; (+-)-2,7-Dichloro-9-((Z)-p-chlorobenzylidene)-alpha((dibutylamino)methyl)fluorene-4-methanol; (+-)-2,7-Dichloro-9-((Z)-p-chlorobenzylidene)-alpha-((dibutylamino)methyl)fluorene-4-methanol; 2-(dibutylamino)-1-[(9Z)-2,7-dichloro-9-(4-chlorobenzylidene)-9H-fluoren-4-yl]ethanol; 2-(dibutylamino)-1-[(9Z)-2,7-dichloro-9-[(4-chlorophenyl)methylidene]fluoren-4-yl]ethanol; 2-Dibutylamino-1-[2,7-dichloro-9-(4-chloro-benzylidene)-9H-fluoren-4-yl]-ethanol; 2-Dibutylamino-1-{2,7-dichloro-9-[1-(4-chloro-phenyl)-meth-(Z)-ylidene]-9H-fluoren-4-yl}-ethanol DM29GAD DT Small molecular drug DM29GAD PC 6437380 DM29GAD MW 528.9 DM29GAD FM C30H32Cl3NO DM29GAD IC InChI=1S/C30H32Cl3NO/c1-3-5-13-34(14-6-4-2)19-29(35)28-18-23(33)17-27-25(15-20-7-9-21(31)10-8-20)26-16-22(32)11-12-24(26)30(27)28/h7-12,15-18,29,35H,3-6,13-14,19H2,1-2H3/b25-15- DM29GAD CS CCCCN(CCCC)CC(C1=CC(=CC\\2=C1C3=C(/C2=C/C4=CC=C(C=C4)Cl)C=C(C=C3)Cl)Cl)O DM29GAD IK DYLGFOYVTXJFJP-MYYYXRDXSA-N DM29GAD IU 2-(dibutylamino)-1-[(9Z)-2,7-dichloro-9-[(4-chlorophenyl)methylidene]fluoren-4-yl]ethanol DM29GAD CA CAS 82186-77-4 DM29GAD CB CHEBI:156095 DM29GAD DE Malaria DM1S4AG ID DM1S4AG DM1S4AG DN Lumiracoxib DM1S4AG HS Approved DM1S4AG SN Joicela; Prexige; Novartis brand of lumiracoxib; COX 189; COX189; COX-189; Lumiracoxib [USAN:INN]; Prexige (Novartis); Prexige (TN); Lumiracoxib (USAN/INN); 2-((2-Chloro-6-fluorophenyl)amino)-5-methylbenzeneacetic acid; 2-((2-Chloro-6-fluorophenyl)amino)-5-methylphenyl)acetic acid; 2-(2-((2-chloro-6-fluoro-phenyl)amino)-5-methyl-phenyl)acetic acid; 2-[2-(2-chloro-6-fluoroanilino)-5-methylphenyl]acetic acid DM1S4AG CP Norvatis Phamaceuticals Corporation DM1S4AG TC Antiinflammatory Agents DM1S4AG DT Small molecular drug DM1S4AG PC 151166 DM1S4AG MW 293.72 DM1S4AG FM C15H13ClFNO2 DM1S4AG IC InChI=1S/C15H13ClFNO2/c1-9-5-6-13(10(7-9)8-14(19)20)18-15-11(16)3-2-4-12(15)17/h2-7,18H,8H2,1H3,(H,19,20) DM1S4AG CS CC1=CC(=C(C=C1)NC2=C(C=CC=C2Cl)F)CC(=O)O DM1S4AG IK KHPKQFYUPIUARC-UHFFFAOYSA-N DM1S4AG IU 2-[2-(2-chloro-6-fluoroanilino)-5-methylphenyl]acetic acid DM1S4AG CA CAS 220991-20-8 DM1S4AG CB CHEBI:73044 DM1S4AG DE Knee osteoarthritis DMCVPXO ID DMCVPXO DMCVPXO DN Lurasidone hydrochloride DMCVPXO HS Approved DMCVPXO SN Lurasidone HCl; SM 13496; Lurasidone hydrochloride (USAN); MK-3756; SM-13496; SMP-13496; N-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinylmethyl)-1-cyclohexylmethyl)-2,3-bicyclo(2.2.1)heptanedicarboximide DMCVPXO CP Sumitomo DMCVPXO DT Small molecular drug DMCVPXO PC 11237860 DMCVPXO MW 529.1 DMCVPXO FM C28H37ClN4O2S DMCVPXO IC InChI=1S/C28H36N4O2S.ClH/c33-27-24-18-9-10-19(15-18)25(24)28(34)32(27)17-21-6-2-1-5-20(21)16-30-11-13-31(14-12-30)26-22-7-3-4-8-23(22)35-29-26;/h3-4,7-8,18-21,24-25H,1-2,5-6,9-17H2;1H/t18-,19+,20-,21-,24+,25-;/m0./s1 DMCVPXO CS C1CC[C@H]([C@@H](C1)CN2CCN(CC2)C3=NSC4=CC=CC=C43)CN5C(=O)[C@H]6[C@@H]7CC[C@@H](C7)[C@H]6C5=O.Cl DMCVPXO IK NEKCRUIRPWNMLK-SCIYSFAVSA-N DMCVPXO IU (1S,2R,6S,7R)-4-[[(1R,2R)-2-[[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]methyl]cyclohexyl]methyl]-4-azatricyclo[5.2.1.02,6]decane-3,5-dione;hydrochloride DMCVPXO CA CAS 367514-88-3 DMCVPXO CB CHEBI:70732 DMCVPXO DE Schizophrenia DMEFRTZ ID DMEFRTZ DMEFRTZ DN Lurbinectedin DMEFRTZ HS Approved DMEFRTZ SN UNII-2CN60TN6ZS; 497871-47-3; 2CN60TN6ZS; Lurbinectedin [INN]; SCHEMBL16152477; DTXSID30198065; DB12674; CS-6323; HY-16293; J3.652.626B DMEFRTZ CP PharmaMar DMEFRTZ DT Small molecular drug DMEFRTZ PC 57327016 DMEFRTZ MW 784.9 DMEFRTZ FM C41H44N4O10S DMEFRTZ IC InChI=1S/C41H44N4O10S/c1-17-11-20-12-25-39(48)45-26-14-52-40(49)41(38-22(9-10-42-41)23-13-21(50-5)7-8-24(23)43-38)15-56-37(31(45)30(44(25)4)27(20)32(47)33(17)51-6)29-28(26)36-35(53-16-54-36)18(2)34(29)55-19(3)46/h7-8,11,13,25-26,30-31,37,39,42-43,47-48H,9-10,12,14-16H2,1-6H3/t25-,26-,30+,31+,37+,39-,41+/m0/s1 DMEFRTZ CS CC1=CC2=C([C@@H]3[C@@H]4[C@H]5C6=C(C(=C7C(=C6[C@@H](N4[C@H]([C@H](C2)N3C)O)COC(=O)[C@@]8(CS5)C9=C(CCN8)C2=C(N9)C=CC(=C2)OC)OCO7)C)OC(=O)C)C(=C1OC)O DMEFRTZ IK YDDMIZRDDREKEP-HWTBNCOESA-N DMEFRTZ IU [(1R,2R,3R,11S,12S,14R,26R)-5,12-dihydroxy-6,6'-dimethoxy-7,21,30-trimethyl-27-oxospiro[17,19,28-trioxa-24-thia-13,30-diazaheptacyclo[12.9.6.13,11.02,13.04,9.015,23.016,20]triaconta-4(9),5,7,15,20,22-hexaene-26,1'-2,3,4,9-tetrahydropyrido[3,4-b]indole]-22-yl] acetate DMEFRTZ CA CAS 497871-47-3 DMEFRTZ DE leukaemia; Solid tumour/cancer; Endometrial cancer; Ovarian cancer; Small-cell lung cancer DMH6IKO ID DMH6IKO DMH6IKO DN Lusutrombopag DMH6IKO HS Approved DMH6IKO SN LUSUTROMBOPAG; mulpleta; UNII-6LL5JFU42F; 6LL5JFU42F; 2-Propenoic acid, Lusutrombopag [USAN:INN]; SCHEMBL3062 DMH6IKO CP Shionogi DMH6IKO PC 49843517 DMH6IKO MW 591.5 DMH6IKO FM C29H32Cl2N2O5S DMH6IKO IC InChI=1S/C29H32Cl2N2O5S/c1-5-6-7-8-12-38-18(3)20-10-9-11-21(26(20)37-4)25-16-39-29(32-25)33-27(34)19-14-23(30)22(24(31)15-19)13-17(2)28(35)36/h9-11,13-16,18H,5-8,12H2,1-4H3,(H,35,36)(H,32,33,34)/b17-13+/t18-/m0/s1 DMH6IKO CS CCCCCCO[C@@H](C)C1=CC=CC(=C1OC)C2=CSC(=N2)NC(=O)C3=CC(=C(C(=C3)Cl)/C=C(\\C)/C(=O)O)Cl DMH6IKO IK NOZIJMHMKORZBA-KJCUYJGMSA-N DMH6IKO IU (E)-3-[2,6-dichloro-4-[[4-[3-[(1S)-1-hexoxyethyl]-2-methoxyphenyl]-1,3-thiazol-2-yl]carbamoyl]phenyl]-2-methylprop-2-enoic acid DMH6IKO CA CAS 1110766-97-6 DMH6IKO CB CHEBI:136051 DMH6IKO DE Thrombocytopenia; Liver disease DMN1XVC ID DMN1XVC DMN1XVC DN Lutetium Lu 177 dotatate DMN1XVC HS Approved DMN1XVC SN UNII-AE221IM3BB; Dotatate lutenium Lu-177; AE221IM3BB; Lu-DOTA-TATE; 177Lu-DOTA-octreotate; Lutetium Lu 177 Dotatate; 177Lu-DOTA-Tyr3-octreotate DMN1XVC CP Advanced Accelerator Applications/Novartis DMN1XVC PC 132274234 DMN1XVC MW 1609.5 DMN1XVC FM C65H87LuN14O19S2 DMN1XVC IC InChI=1S/C65H90N14O19S2.Lu/c1-38(80)56-64(96)73-51(63(95)75-57(39(2)81)65(97)98)37-100-99-36-50(72-59(91)47(28-40-10-4-3-5-11-40)68-52(83)32-76-20-22-77(33-53(84)85)24-26-79(35-55(88)89)27-25-78(23-21-76)34-54(86)87)62(94)70-48(29-41-15-17-43(82)18-16-41)60(92)71-49(30-42-31-67-45-13-7-6-12-44(42)45)61(93)69-46(58(90)74-56)14-8-9-19-66;/h3-7,10-13,15-18,31,38-39,46-51,56-57,67,80-82H,8-9,14,19-30,32-37,66H2,1-2H3,(H,68,83)(H,69,93)(H,70,94)(H,71,92)(H,72,91)(H,73,96)(H,74,90)(H,75,95)(H,84,85)(H,86,87)(H,88,89)(H,97,98);/q;+3/p-3/t38-,39-,46+,47-,48+,49-,50+,51+,56+,57+;/m1./s1/i;1+2 DMN1XVC CS C[C@H]([C@H]1C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@@H](CC5=CC=CC=C5)NC(=O)CN6CCN(CCN(CCN(CC6)CC(=O)[O-])CC(=O)[O-])CC(=O)[O-])C(=O)N[C@@H]([C@@H](C)O)C(=O)O)O.[177Lu+3] DMN1XVC IK MXDPZUIOZWKRAA-PRDSJKGBSA-K DMN1XVC IU 2-[4-[2-[[(2R)-1-[[(4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-4-[[(1S,2R)-1-carboxy-2-hydroxypropyl]carbamoyl]-7-[(1R)-1-hydroxyethyl]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicos-19-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]-7,10-bis(carboxylatomethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetate;lutetium-177(3+) DMN1XVC CA CAS 437608-50-9 DMN1XVC DE Neuroendocrine cancer DM7K5GD ID DM7K5GD DM7K5GD DN Lutropin alfa DM7K5GD HS Approved DM7K5GD SN Luveris; Luveris (TN); Lutropin alfa (USAN/INN) DM7K5GD TC Fertility Agents DM7K5GD SQ Alpha Chain: APDVQDCPECTLQENPFFSQPGAPILQCMGCCFSRAYPTPLRSKKTMLVQKNVTSESTCCVAKSYNRVTVMGGFKVENHTACHCSTCYYHKS >Beta Chain (LH)SREPLRPWCHPINAILAVEKEGCPVCITVNTTICAGYCPTMMRVLQAVLPPLPQVVCTYRDVRFESIRLPGCPRGVDPVVSFPVALSCRCGPCRRSTSDCGGPKDHPLTCDHPQLSGLLFL DM7K5GD DE Female infertility DMJKROX ID DMJKROX DMJKROX DN Luvox DMJKROX HS Approved DMJKROX SN FLUVOXAMINE MALEATE; 61718-82-9; Fevarin; Luvox CR; Fluvoxamine (maleate); UNII-5LGN83G74V; DU23000; DU-23000; SME 3110; 5LGN83G74V; MK-264; 54739-18-3; 5-Methoxy-4'-trifluoromethylvalerophenone (E)-O-2-aminoethyloxime monomaleate; 5-Methoxy-4'-(trifluoromethyl)valerophenone (E)-O-(2-aminoethyl)oxime, maleate (1:1); 54739-20-7; 1-Pentanone, 5-methoxy-1-(4-(trifluoromethyl)phenyl)-, O-(2-aminoethyl)oxime, (E)-, (Z)-2-butenedioate (1:1); C19H25F3N2O6 DMJKROX DT Small molecular drug DMJKROX PC 9560989 DMJKROX MW 434.4 DMJKROX FM C19H25F3N2O6 DMJKROX IC InChI=1S/C15H21F3N2O2.C4H4O4/c1-21-10-3-2-4-14(20-22-11-9-19)12-5-7-13(8-6-12)15(16,17)18;5-3(6)1-2-4(7)8/h5-8H,2-4,9-11,19H2,1H3;1-2H,(H,5,6)(H,7,8)/b20-14+;2-1- DMJKROX CS COCCCC/C(=N\\OCCN)/C1=CC=C(C=C1)C(F)(F)F.C(=C\\C(=O)O)\\C(=O)O DMJKROX IK LFMYNZPAVPMEGP-PIDGMYBPSA-N DMJKROX IU (Z)-but-2-enedioic acid;2-[(E)-[5-methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene]amino]oxyethanamine DMJKROX CA CAS 61718-82-9 DMJKROX CB CHEBI:5139 DMJKROX DE Anxiety disorder DM93VBZ ID DM93VBZ DM93VBZ DN LY2835219 DM93VBZ HS Approved DM93VBZ SN Abemaciclib; 1231929-97-7; Verzenio; LY-2835219; UNII-60UAB198HK; LY2835219 (free base); DM93VBZ CP Eli Lilly DM93VBZ DT Small molecular drug DM93VBZ PC 46220502 DM93VBZ MW 506.6 DM93VBZ FM C27H32F2N8 DM93VBZ IC InChI=1S/C27H32F2N8/c1-5-35-8-10-36(11-9-35)16-19-6-7-24(30-14-19)33-27-31-15-22(29)25(34-27)20-12-21(28)26-23(13-20)37(17(2)3)18(4)32-26/h6-7,12-15,17H,5,8-11,16H2,1-4H3,(H,30,31,33,34) DM93VBZ CS CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F DM93VBZ IK UZWDCWONPYILKI-UHFFFAOYSA-N DM93VBZ IU N-[5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl]-5-fluoro-4-(7-fluoro-2-methyl-3-propan-2-ylbenzimidazol-5-yl)pyrimidin-2-amine DM93VBZ CA CAS 1231929-97-7 DM93VBZ DE Breast cancer; Solid tumour/cancer DMOMLHJ ID DMOMLHJ DMOMLHJ DN Lymecycline DMOMLHJ HS Approved DMOMLHJ SN Aureociclin; Aureomicina; Aurofac; Biovetin; Centraureo; Chlortetracyclin; Chrusomykine; Limeciclina; Lymecyclinum; Orospray; Acronize PD; Aurofac 10; Tetrlysal 300; Lymecycline (INN); Tetralysal 300 (TN); N(2)-(((+)-5-Amino-5-carboxypentylamino)methyl)tetracycline; N(6)-[({[(4S,4aS,5aS,6S,12aS)-4-(dimethylamino)-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracen-2-yl]carbonyl}amino)methyl]-L-lysine; (+)-N-(5-Amino-5-carboxypentylaminomethyl)-4-dimethylamino-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxonaphthacene-2-carboxamide DMOMLHJ CP Galderma DMOMLHJ TC Antibiotics DMOMLHJ DT Small molecular drug DMOMLHJ PC 54707177 DMOMLHJ MW 602.6 DMOMLHJ FM C29H38N4O10 DMOMLHJ IC InChI=1S/C29H38N4O10/c1-28(42)13-7-6-9-17(34)18(13)22(35)19-14(28)11-15-21(33(2)3)23(36)20(25(38)29(15,43)24(19)37)26(39)32-12-31-10-5-4-8-16(30)27(40)41/h6-7,9,14-16,21,31,34-35,38,42-43H,4-5,8,10-12,30H2,1-3H3,(H,32,39)(H,40,41)/t14-,15-,16-,21-,28+,29-/m0/s1 DMOMLHJ CS C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)NCNCCCC[C@@H](C(=O)O)N)N(C)C)O DMOMLHJ IK PZTCVADFMACKLU-UEPZRUIBSA-N DMOMLHJ IU (2S)-6-[[[(4S,4aS,5aS,6S,12aR)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carbonyl]amino]methylamino]-2-aminohexanoic acid DMOMLHJ CA CAS 992-21-2 DMOMLHJ CB CHEBI:59040 DMOMLHJ DE Bacterial infection DM154EB ID DM154EB DM154EB DN Lypressin DM154EB HS Approved DM154EB SN Lysine-vasopressin; Lysine-8-vasopressin DM154EB DT Small molecular drug DM154EB PC 644076 DM154EB MW 1056.2 DM154EB FM C46H65N13O12S2 DM154EB IC InChI=1S/C46H65N13O12S2/c47-17-5-4-9-29(40(65)52-22-38(51)63)54-45(70)35-10-6-18-59(35)46(71)34-24-73-72-23-28(48)39(64)55-31(20-26-11-13-27(60)14-12-26)43(68)56-32(19-25-7-2-1-3-8-25)42(67)53-30(15-16-36(49)61)41(66)57-33(21-37(50)62)44(69)58-34/h1-3,7-8,11-14,28-35,60H,4-6,9-10,15-24,47-48H2,(H2,49,61)(H2,50,62)(H2,51,63)(H,52,65)(H,53,67)(H,54,70)(H,55,64)(H,56,68)(H,57,66)(H,58,69)/t28-,29-,30-,31-,32-,33-,34-,35-/m0/s1 DM154EB CS C1C[C@H](N(C1)C(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)N)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N DM154EB IK BJFIDCADFRDPIO-DZCXQCEKSA-N DM154EB IU (2S)-N-[(2S)-6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]-1-[(4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]pyrrolidine-2-carboxamide DM154EB CA CAS 50-57-7 DM154EB CB CHEBI:94802 DM154EB DE Amnesia DMQYJIR ID DMQYJIR DMQYJIR DN Macimorelin DMQYJIR HS Approved DMQYJIR SN Solorel; AEZS-130; ARD-07; ARD-0705; EP-01572; EP-1572; JMV-1843 DMQYJIR CP Aeterna Zentaris DMQYJIR DT Small molecular drug DMQYJIR PC 9804938 DMQYJIR MW 474.6 DMQYJIR FM C26H30N6O3 DMQYJIR IC InChI=1S/C26H30N6O3/c1-26(2,27)25(35)31-22(11-16-13-28-20-9-5-3-7-18(16)20)24(34)32-23(30-15-33)12-17-14-29-21-10-6-4-8-19(17)21/h3-10,13-15,22-23,28-29H,11-12,27H2,1-2H3,(H,30,33)(H,31,35)(H,32,34)/t22-,23-/m1/s1 DMQYJIR CS CC(C)(C(=O)N[C@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@H](CC3=CNC4=CC=CC=C43)NC=O)N DMQYJIR IK UJVDJAPJQWZRFR-DHIUTWEWSA-N DMQYJIR IU 2-amino-N-[(2R)-1-[[(1R)-1-formamido-2-(1H-indol-3-yl)ethyl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]-2-methylpropanamide DMQYJIR CA CAS 381231-18-1 DMQYJIR DE Somatotropin deficiency; Growth hormone deficiency DMP79A1 ID DMP79A1 DMP79A1 DN Macitentan DMP79A1 HS Approved DMP79A1 SN Macitentan; 441798-33-0; Opsumit; ACT-064992; ACT 064992; UNII-Z9K9Y9WMVL; ACT064992; Z9K9Y9WMVL; N-[5-(4-Bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N'-propylsulfamide; N-(5-(4-Bromophenyl)-6-(2-((5-bromo-2-pyrimidinyl)oxy)ethoxy)-4-pyrimidinyl)-N'-propylsulfamide; CHEBI:76607; Actelion-1; Macitentan [USAN:INN]; macitentanum; zlchem 5; Opsumit (TN); Macitentan (JAN/USAN); (non-labelled)Macitentan-d7; MLS006011174; C19H20Br2N6O4S; SCHEMBL1445625; GTPL7352; CHEMBL2103873; ZLA0005; EX-A544; DTXSID50196063 DMP79A1 CP Actelion Pharmaceuticals DMP79A1 DT Small molecular drug DMP79A1 PC 16004692 DMP79A1 MW 588.3 DMP79A1 FM C19H20Br2N6O4S DMP79A1 IC InChI=1S/C19H20Br2N6O4S/c1-2-7-26-32(28,29)27-17-16(13-3-5-14(20)6-4-13)18(25-12-24-17)30-8-9-31-19-22-10-15(21)11-23-19/h3-6,10-12,26H,2,7-9H2,1H3,(H,24,25,27) DMP79A1 CS CCCNS(=O)(=O)NC1=C(C(=NC=N1)OCCOC2=NC=C(C=N2)Br)C3=CC=C(C=C3)Br DMP79A1 IK JGCMEBMXRHSZKX-UHFFFAOYSA-N DMP79A1 IU 5-(4-bromophenyl)-6-[2-(5-bromopyrimidin-2-yl)oxyethoxy]-N-(propylsulfamoyl)pyrimidin-4-amine DMP79A1 CA CAS 441798-33-0 DMP79A1 CB CHEBI:76607 DMP79A1 DE Cardiovascular disease DM3BS97 ID DM3BS97 DM3BS97 DN Macrolides DM3BS97 HS Approved DM3BS97 SN Tylosin; tylosin tartrate; Tilosina; Tylosinum; UNII-YEF4JXN031; Tylosine; Tylocine; Tylan; Tylosin A; 1401-69-0; YEF4JXN031; Fradizine; CHEBI:17658; Vubityl 200; Tylosinum [INN-Latin]; Tylosine [INN-French]; Tilosina [INN-Spanish]; HSDB 7022; EINECS 215-754-8; AI3-29799; SR-05000002057; Tylosin [USP:INN:BAN]; Tylan (TN); Tylosin (USP/INN); AC1NQX0W DM3BS97 DT Small molecular drug DM3BS97 PC 5280440 DM3BS97 MW 916.1 DM3BS97 FM C46H77NO17 DM3BS97 IC InChI=1S/C46H77NO17/c1-13-33-30(22-58-45-42(57-12)41(56-11)37(52)26(5)60-45)18-23(2)14-15-31(49)24(3)19-29(16-17-48)39(25(4)32(50)20-34(51)62-33)64-44-38(53)36(47(9)10)40(27(6)61-44)63-35-21-46(8,55)43(54)28(7)59-35/h14-15,17-18,24-30,32-33,35-45,50,52-55H,13,16,19-22H2,1-12H3/b15-14+,23-18+/t24-,25+,26-,27-,28+,29+,30-,32-,33-,35+,36-,37-,38-,39-,40-,41-,42-,43+,44+,45-,46-/m1/s1 DM3BS97 CS CC[C@@H]1[C@H](/C=C(/C=C/C(=O)[C@@H](C[C@@H]([C@@H]([C@H]([C@@H](CC(=O)O1)O)C)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)C)O[C@H]3C[C@@]([C@H]([C@@H](O3)C)O)(C)O)N(C)C)O)CC=O)C)\\C)CO[C@H]4[C@@H]([C@@H]([C@@H]([C@H](O4)C)O)OC)OC DM3BS97 IK WBPYTXDJUQJLPQ-VMXQISHHSA-N DM3BS97 IU 2-[(4R,5S,6S,7R,9R,11E,13E,15R,16R)-6-[(2R,3R,4R,5S,6R)-5-[(2S,4R,5S,6S)-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-16-ethyl-4-hydroxy-15-[[(2R,3R,4R,5R,6R)-5-hydroxy-3,4-dimethoxy-6-methyloxan-2-yl]oxymethyl]-5,9,13-trimethyl-2,10-dioxo-1-oxacyclohexadeca-11,13-dien-7-yl]acetaldehyde DM3BS97 CA CAS 1401-69-0 DM3BS97 CB CHEBI:17658 DM3BS97 DE Bacterial infection DMU4ORS ID DMU4ORS DMU4ORS DN Magnesium DMU4ORS HS Approved DMU4ORS SN Magnesio; Magnesio [Italian]; Magnesium Matrix Modifier; Magnesium modifier; Magnesium powdered; Magnesium preparation; Magnesium sheet; LTBB002624; Magnesium hydride [UN2010] [Dangerous when wet]; MAGNESIUM NITRATE, ACS; Magnesium nitrate-nitric acid solution; Rieke's active magnesium; MAGNESIUM, ATOMIZED POWDER,18MICRON; Magnesium granules, coated particle size not50% magnesium in pellets, turnings or ribbons [UN1869] [Flammable solid]; Magnesium, powder or magnesium alloys, powder [UN1418] [Dangerous when wet, Spontaneously combustible]; AQUANAL-plus magnesium (Mg) 100-1500 mg/L; AQUANAL(R)-plus magnesium (Mg) 100-1500 mg/L;12Mg DMU4ORS CP AstraZeneca DMU4ORS DT Small molecular drug DMU4ORS PC 5462224 DMU4ORS MW 24.305 DMU4ORS FM Mg DMU4ORS IC InChI=1S/Mg DMU4ORS CS [Mg] DMU4ORS IK FYYHWMGAXLPEAU-UHFFFAOYSA-N DMU4ORS IU magnesium DMU4ORS CA CAS 7439-95-4 DMU4ORS CB CHEBI:25107 DMU4ORS DE Ischemic stroke DMVEK07 ID DMVEK07 DMVEK07 DN Magnesium Sulfate DMVEK07 HS Approved DMVEK07 SN Magnesiumsulfat; Bitter salt; Epsom salt; Hair salt; Heptahydrate Magnesium Sulfate; Kieserite [as monohydrate]; Magnesium Sulfate In Plastic Container; Magnesium Sulphate Hydrate; Magnesium bisulfate; Magnesium hydrogensulphate; Magnesium sulfate anhydrous; Magnesium sulfate dried; Magnesium sulfate hexahydrate; Magnesium sulfate solution; Magnesium sulphate; Sal Angalis; Sal De sedlitz; Sal amarum; Sal anglicum; Sal catharticum; Sal seidlitense; Salts of england; Sulfuric acid magnesium salt; Tomix OT; MgSO4; Epsom Sa (TN); Magnesium Sulfate, Heptahydrate; Magnesium sulfate in dextrose 5% in plastic container; Magnesium(II) sulfate; OT-S; Sel d'angleterre; Sulfate, Magnesium; Sulfuric acid magnesium salt (VAN); Sulfuric acid, magnesium salt; Magnesium sulfate (1:1); Magnesium(2+) ion sulfate; OT-S (drying agent); SDA 15-062-07; Sulfuric acid magnesium salt (1:1); Sulfuric acid, C10-16 alkyl ester, magnesium salt; Sulfuric acid, magnesium salt (1:1); Sulfuric acid, mono-C10-16-alkyl esters, magnesium salts; (C10-C16) Alkylalcohol sulfuric acid, magnesium salt DMVEK07 CP Mitsuwa Kinzoku Co DMVEK07 TC Analgesics DMVEK07 DT Small molecular drug DMVEK07 PC 24083 DMVEK07 MW 120.37 DMVEK07 FM MgO4S DMVEK07 IC InChI=1S/Mg.H2O4S/c;1-5(2,3)4/h;(H2,1,2,3,4)/q+2;/p-2 DMVEK07 CS [O-]S(=O)(=O)[O-].[Mg+2] DMVEK07 IK CSNNHWWHGAXBCP-UHFFFAOYSA-L DMVEK07 IU magnesium;sulfate DMVEK07 CA CAS 7487-88-9 DMVEK07 CB CHEBI:32599 DMVEK07 DE Acute pain DMXZ84M ID DMXZ84M DMXZ84M DN Malathion DMXZ84M HS Approved DMXZ84M SN Calmathion; Camathion; Carbafos; Carbetovur; Carbetox; Carbofos; Carbophos; Celthion; Chemathion; Cimexan; Cleensheen; Cythion; Dorthion; Emmatos; Ethiolacar; Etiol; Extermathion; Flair; Forthion; Fosfothion; Fosfotion; Fyfanon; Hilthion; Karbofos; Kypfos; Malacide; Malafor; Malagran; Malakill; Malamar; Malaphele; Malaphos; Malasol; Malaspray; Malataf; Malathiazol; Malathione; Malathiozoo; Malathon; Malathyl; Malation; Malatol; Malatox; Maldison; Malmed; Malphos; Maltox; Mercaptothion; Mercaptotion; Moscarda; Oleophosphothion; Organoderm; Ovide; Paladin; Phosphothion; Prioderm; Sadofos; Sadophos; Sumitox; TAK; Taskil; Vetiol; Zithiol; Carbethoxy malathion; Detm ol ma; Detmol MA; Emmatos extra; Lice Rid;Malathion LV Concentrate; Malathion [USP]; Malation [Polish]; Maltox MLT; Mercaptosuccinic acid diethyl ester; Mercaptotion [Spanish]; Ortho Malathion; Siptox I; Vegfru malatox; AC 26691; EL 4049; Experimental insecticide 4049; Fog 3; Fosfotion 550; Hilthion 25wdp; IFO 13140; Latka 4049; Latka 4049 [Czech]; MET86C_SUPELCO; Malamar 50; Malathion 60; Malathion E50; OMS 1; PS86_SUPELCO; SF 60; Sadofos 30; American cyanamid 4,049; Derbac-M; ENT 17,034; Four thousand forty-nine; Insecticide no. 4049; Kop-Thionkypfosmalacide; Kop-thion; Malathion (USP); Malathion (old ID); Ovide (TN); Staeubol-Puder; Suleo-M; TM-4049; Kill-A-Mite; MALATHION, 96%; Malathion-2,3-14C; 8059HC DMXZ84M TC Parasympathomimetics DMXZ84M DT Small molecular drug DMXZ84M PC 4004 DMXZ84M MW 330.4 DMXZ84M FM C10H19O6PS2 DMXZ84M IC InChI=1S/C10H19O6PS2/c1-5-15-9(11)7-8(10(12)16-6-2)19-17(18,13-3)14-4/h8H,5-7H2,1-4H3 DMXZ84M CS CCOC(=O)CC(C(=O)OCC)SP(=S)(OC)OC DMXZ84M IK JXSJBGJIGXNWCI-UHFFFAOYSA-N DMXZ84M IU diethyl 2-dimethoxyphosphinothioylsulfanylbutanedioate DMXZ84M CA CAS 121-75-5 DMXZ84M CB CHEBI:6651 DMXZ84M DE Pediculus capitis infestation DMSCDY9 ID DMSCDY9 DMSCDY9 DN Mannitol DMSCDY9 HS Approved DMSCDY9 SN Diosmol; Hexahydroxyhexane; Invenex; Isotol; MTL; Manita; Mannazucker; Mannidex; Mannigen; Mannistol; Mannit; Mannite; Osmitrol; Osmofundin; Osmosal; Resectisol; Cordycepic acid; Cpd without stereochemical designation; Manna sugar; Mannitol [USAN]; Marine Crystal; Resectisol In Plastic Container; M0044; Mannidex 16700; Mannogem 2080; D-mannite; D-mannitol; DL-Mannitol; MANNITOL 25%; Maniton-S; Mannitol (USP); Mannitol (VAN); Mannitol 10%; Mannitol 10% In Plastic Container; Mannitol 15%; Mannitol 15% In Plastic Container; Mannitol 20%; Mannitol 20% In Plastic Container; Mannitol 5%; Mannitol 5% In Plastic Container; OSMITROL 10% IN WATER IN PLASTIC CONTAINER; OSMITROL 15% IN WATER IN PLASTIC CONTAINER; OSMITROL 20% IN WATER IN PLASTIC CONTAINER; OSMITROL 5% IN WATER IN PLASTIC CONTAINER; Osmitrol (TN); Osmitrol 10% In Water; Osmitrol 15% In Water; Osmitrol 20% In Water; Osmitrol 5% In Water; SDM No. 35; SORBITOL-MANNITOL IN PLASTIC CONTAINER; Sorbitol-Mannitol; D-Mannitol (JP15); MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER; D-(-)-Mannitol; ED1D1E61-FEFB-430A-AFDC-D1F4A957FC3D; MANNITOL 15% DEXTROSE 5% IN SODIUM CHLORIDE 0.45%; MANNITOL 5% DEXTROSE 5% IN SODIUM CHLORIDE 0.12%; (2R,3R,4R,5R)-hexane-1,2,3,4,5,6-hexol; (L)-Mannitol DMSCDY9 TC Sweetening Agents DMSCDY9 DT Small molecular drug DMSCDY9 PC 6251 DMSCDY9 MW 182.17 DMSCDY9 FM C6H14O6 DMSCDY9 IC InChI=1S/C6H14O6/c7-1-3(9)5(11)6(12)4(10)2-8/h3-12H,1-2H2/t3-,4-,5-,6-/m1/s1 DMSCDY9 CS C([C@H]([C@H]([C@@H]([C@@H](CO)O)O)O)O)O DMSCDY9 IK FBPFZTCFMRRESA-KVTDHHQDSA-N DMSCDY9 IU (2R,3R,4R,5R)-hexane-1,2,3,4,5,6-hexol DMSCDY9 CA CAS 69-65-8 DMSCDY9 CB CHEBI:16899 DMSCDY9 DE Bronchiectasis; Renal failure DMPWB7T ID DMPWB7T DMPWB7T DN Maprotiline DMPWB7T HS Approved DMPWB7T SN Deprilept; Dibencycladine; Maprotilin; Maprotilina; Maprotilinum; Maprotylina; Maprotylina [Polish]; TBB066626; BA-34276; Deprilept (TN); Ludiomil (TN); Maprotilina [INN-Spanish]; Maprotiline (USAN); Maprotilinum [INN-Latin]; Psymion (TN); Ba-34,276; Maprotiline [USAN:BAN:INN]; N-Methyl-9,10-ethanoanthracene-9(10H)-propanamine; N-Methyl-9,10-ethanoanthracene-9(10H)-propylamine; 3-(9,10-Dihydro-9,10-ethanoanthracen-9-yl)propylmethylamine; 3-(9,10-ethanoanthracen-9(10H)-yl)-N-methylpropan-1-amine DMPWB7T CP Norvatis Phamaceuticals Corporation DMPWB7T TC Antidepressants DMPWB7T DT Small molecular drug DMPWB7T PC 4011 DMPWB7T MW 277.4 DMPWB7T FM C20H23N DMPWB7T IC InChI=1S/C20H23N/c1-21-14-6-12-20-13-11-15(16-7-2-4-9-18(16)20)17-8-3-5-10-19(17)20/h2-5,7-10,15,21H,6,11-14H2,1H3 DMPWB7T CS CNCCCC12CCC(C3=CC=CC=C31)C4=CC=CC=C24 DMPWB7T IK QSLMDECMDJKHMQ-UHFFFAOYSA-N DMPWB7T IU N-methyl-3-(1-tetracyclo[6.6.2.02,7.09,14]hexadeca-2,4,6,9,11,13-hexaenyl)propan-1-amine DMPWB7T CA CAS 10262-69-8 DMPWB7T CB CHEBI:6690 DMPWB7T DE Major depressive disorder DMTL94F ID DMTL94F DMTL94F DN Maraviroc DMTL94F HS Approved DMTL94F SN 376348-65-1; Selzentry; Celsentri; UK-427857; UK-427,857; UK 427857; UNII-MD6P741W8A; MD6P741W8A; CHEMBL256907; MVC; CHEMBL1201187; CHEBI:63608; 4,4-difluoro-N-[(1S)-3-[(1R,5S)-3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[321]octan-8-yl]-1-phenylpropyl]cyclohexane-1-carboxamide; Isopropyl, 4,4-difluoro-N-((1S)-3-{(1R,3s,5S)-3-(3-methyl-5-(propan-2-yl)-4H-1,2,4-triazol-4-yl)-8-azabicyclo(321)octan-8-yl}-1-phenylpropyl)cyclohexanecarboxamide; Maraviroc [USAN]; Celsentri (TN); Celsentri(TM); PRO 140 & Maraviroc; Selzentry (TN); Selzentry(TM); UK-427,857 maraviroc (MVC); Exo-4,4-Difluoro-N-[3-[3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[321]oct-8-yl]-1(S)-phenylpropyl]cyclohexanecarboxamide; PRO 140 (Anti-CCR5 monoclonal antibody) & exo-4,4-Difluoro-N-[3-[3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[321]oct-8-yl]-1(S)-phenylpropyl]cyclohexanecarboxamide; 4,4-Difluoro-N-((1S)-3-(exo-3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo(321)oct-8-yl)-1-phenylpropyl)cyclohexanecarboxamide; [3H]maraviroc DMTL94F CP Pfizer; AstraZeneca DMTL94F TC Anti-HIV Agents DMTL94F DT Small molecular drug DMTL94F PC 3002977 DMTL94F MW 513.7 DMTL94F FM C29H41F2N5O DMTL94F IC InChI=1S/C29H41F2N5O/c1-19(2)27-34-33-20(3)36(27)25-17-23-9-10-24(18-25)35(23)16-13-26(21-7-5-4-6-8-21)32-28(37)22-11-14-29(30,31)15-12-22/h4-8,19,22-26H,9-18H2,1-3H3,(H,32,37)/t23-,24+,25?,26-/m0/s1 DMTL94F CS CC1=NN=C(N1C2C[C@H]3CC[C@@H](C2)N3CC[C@@H](C4=CC=CC=C4)NC(=O)C5CCC(CC5)(F)F)C(C)C DMTL94F IK GSNHKUDZZFZSJB-HLMSNRGBSA-N DMTL94F IU 4,4-difluoro-N-[(1S)-3-[(1S,5R)-3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-phenylpropyl]cyclohexane-1-carboxamide DMTL94F CA CAS 376348-65-1 DMTL94F CB CHEBI:63608 DMTL94F DE Human immunodeficiency virus infection; Chronic obstructive pulmonary disease DMKEY6S ID DMKEY6S DMKEY6S DN Margetuximab DMKEY6S HS Approved DMKEY6S CP Macrogenics DMKEY6S DT Antibody DMKEY6S DE Gastrointestinal cancer; Gastric adenocarcinoma; HER2-positive breast cancer DM70IK5 ID DM70IK5 DM70IK5 DN Marinol DM70IK5 HS Approved DM70IK5 SN Dronabinol; TETRAHYDROCANNABINOL; delta9-Tetrahydrocannabinol; delta9-THC; Deltanyne; Dronabinolum; delta-9-tetrahydrocannabinol; Abbott 40566; delta-9-THC; delta(9)-THC; 1972/8/3; delta1-THC; delta(sup 1)-Thc; delta(sup 9)-Thc; 1-trans-delta-9-Tetrahydrocannabinol; THC; Namisol; Dronabinolum [Latin]; 9-tetrahydrocannabinol; delta(9)-Tetrahydrocannabinol; delta(1)-Tetrahydrocannabinol; (-)-delta9-trans-Tetrahydrocannabinol; delta1-Tetrahydrocannabinol; 1-trans-delta9-Tetrahydrocannabinol; delta(9)-Tetrahydrocannibinol; SP; Compassia; Ganja; Hashish; Marincap; MaxEPA; Omegaven; Promega; Relivar; Sonergx; Tetranabinex; Cannabis resin; Drona binol; QCD 84924; SP 104; Tetrahydrocannabinol delta9; CAT-310; DELTA1-THC; DELTA1-Tetrahydrocannabinol;DELTA9-THC; DRG-0138; Delta-THC; Delta1-THC; Delta1-Tetrahydrocannabinol; Delta9-THC; Delta9-Tetrahydrocannabinol; Delta9-Tetrahydrocannabinol solution; Dronabinol [USAN:INN]; Marinol (TN); Pro-Mega;QCD-84924; Trans-tetrahydrocannabinol; DELTA9-trans-Tetrahydrocannabinol; Delta(1)-THC; Delta(1)-Tetrahydrocannabinol; Delta(9)-THC; Delta(9)-Tetrahydrocannabinol; Delta(9)-Tetrahydrocannibinol; Delta(sup 1)-Tetrahydrocannabinol; Delta(sup 1)-Thc; Delta(sup 9)-Tetrahydrocannabinol; Delta(sup 9)-Thc; Delta(sup9)-THC; Delta-9-THC; Delta-9-tetrahydrocannabinol; Delta1-Tetrahydrocannabinol (VAN); Delta9-Tetrahydrocannabinol (VAN); Delta9-trans-Tetrahydrocannabinol; Dronabinol (USP/INN); Omega-3-Fatty acid; THC-delta-9; Trans-delta9-Tetrahydrocannabinol; Cannabinol, tetrahydro-(6CI); Fish oils, n-3 fatty acid-high; Fish oils, omega-3 fatty acid-high; L-delta(sup 1)-tetrahydrocannabinol; L-delta1-trans-Tetrahydrocannabinol; L-trans-delta9-Tetrahydrocannabinol; Trans-delta-9-Tetrahydrocannabinol; Cannabinol, Delta1-tetrahydro-(7CI); Fats and Glyceridic oils, fish, n-3 fatty acid-high; L-delta1-Tetrahydrocannabinol; Trans-DELTA9-Tetrahydrocannabinol; L-delta1-trans-Tetrahydrocannabinol;L-trans-delta9-Tetrahydrocannabinol; Tetrahydrocannabinols (-)-delta1-3,4-trans-form; (-)-DELTA1-Tetrahydrocannabinol; (-)-DELTA9-THC; (-)-DELTA9-Tetrahydrocannabinol; (-)-DELTA9-trans-Tetrahydrocannabinol; (-)-delta(sup9)-trans-Tetrahydrocannabinol; (-)-3,4-trans-Delta1-Tetrahydrocannabinol; (-)-delta(sup 1)-3,4-trans-Tetrahydrocannabinol; (-)-delta1-Tetrahydrocannabinol; (-)-delta9-(trans)-Tetrahydrocannabinol; (-)-delta9-Tetrahydrocannabinol; (-)-trans-DELTA9-Tetrahydrocannabinol; (-)-trans-Delta1-Tetrahydrocannabinol; (-)-trans-Delta9-THC; (-)-trans-delta9-Tetrahydrocannabinol; (L)-delta1-Tetrahydrocannabinol; (l)-delta(sup 1)-Tetrahydrocannabinol; (l)-delta1-Tetrahydrocannabinol; 1-trans-delta(sup9)-tetrahydrocannabinol; 1-trans-D9-Tetrahydrocannabinol; 1-trans-delta(sup 9)-Tetrahydrocannabinol; 14C-DELTA1-Tetrahydrocannabinol; 6H-Dibenzo; 9-delta-Tetrahydrocannabinol; 9-ene-Tetrahydrocannabinol; Delta(9)-tetrahydrocannabinol DM70IK5 CP Unimed Pharmaceuticals DM70IK5 TC Analgesics DM70IK5 DT Small molecular drug DM70IK5 PC 16078 DM70IK5 MW 314.5 DM70IK5 FM C21H30O2 DM70IK5 IC InChI=1S/C21H30O2/c1-5-6-7-8-15-12-18(22)20-16-11-14(2)9-10-17(16)21(3,4)23-19(20)13-15/h11-13,16-17,22H,5-10H2,1-4H3/t16-,17-/m1/s1 DM70IK5 CS CCCCCC1=CC(=C2[C@@H]3C=C(CC[C@H]3C(OC2=C1)(C)C)C)O DM70IK5 IK CYQFCXCEBYINGO-IAGOWNOFSA-N DM70IK5 IU (6aR,10aR)-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-ol DM70IK5 CA CAS 1972-08-3 DM70IK5 CB CHEBI:66964 DM70IK5 DE Anorexia nervosa cachexia; Chemotherapy-induced nausea DMMVNZ0 ID DMMVNZ0 DMMVNZ0 DN Masoprocol DMMVNZ0 HS Approved DMMVNZ0 SN NDGA; N 5023; TNP00263; Actinex (TN); Nordihydroguaiaretic acid (meso-form); (R*,S*)-4,4'-(2,3-Dimethylbutane-1,4-diyl)bispyrocatechol; 4-[(2S,3R)-4-(3,4-dihydroxyphenyl)-2,3-dimethylbutyl]benzene-1,2-diol DMMVNZ0 TC Anticancer Agents DMMVNZ0 DT Small molecular drug DMMVNZ0 PC 71398 DMMVNZ0 MW 302.4 DMMVNZ0 FM C18H22O4 DMMVNZ0 IC InChI=1S/C18H22O4/c1-11(7-13-3-5-15(19)17(21)9-13)12(2)8-14-4-6-16(20)18(22)10-14/h3-6,9-12,19-22H,7-8H2,1-2H3/t11-,12+ DMMVNZ0 CS C[C@H](CC1=CC(=C(C=C1)O)O)[C@@H](C)CC2=CC(=C(C=C2)O)O DMMVNZ0 IK HCZKYJDFEPMADG-TXEJJXNPSA-N DMMVNZ0 IU 4-[(2S,3R)-4-(3,4-dihydroxyphenyl)-2,3-dimethylbutyl]benzene-1,2-diol DMMVNZ0 CA CAS 27686-84-6 DMMVNZ0 CB CHEBI:73468 DMMVNZ0 DE Prostate cancer DMZ36RN ID DMZ36RN DMZ36RN DN Mazindol DMZ36RN HS Approved DMZ36RN SN mazindol; Mazanor; Sanorex; Teronac; Mazildene; 22232-71-9; Magrilon; Dimagrir; Mazindolum; Mazindole; Mazindolum [INN-Latin]; Terenac; AN 448; Mazindol [USAN:BAN:INN]; SAH 42548; CCRIS 3152; DEA No 1605; 5-(4-Chlorophenyl)-3,5-dihydro-2H-imidazo[2,1-a]isoindol-5-ol; 5-(4-Chlorophenyl)-2,5-dihydro-3H-imidazo[2,1-a]isoindol-5-ol; HSDB 3112; SA 42-548; 5-(4-Chlorophenyl)-2,3-dihydro-5-hydroxy-5H-imidazo[2,1-a]isoindole; EINECS 244-857-0; S 42548; CHEMBL781; 5-p-Chlorophenyl-2,3-dihydro-5H-imidazo(2,1-a)isoindol-5-ol; BRN 0546547; Diestet; Sanjorex; Solucaps; Teronak; Mazindol Medix Brand; Mazindol Novartis Brand; Mazindol Searle Brand; Mazindol Wyeth Brand; Medix Brand of Mazindol; Novartis Brand of Mazindol; Searle Brand of Mazindol; Wyeth Brand of Mazindol; AN 448;AN448; AN-448; Mazanor (TN); SANOREX (TN); Sanorex (TN); Mazindol (JAN/USP/INN); (+-)-5-(p-Chlorophenyl)-2,5-dihydro-3H-imidazo(2,1-a)isoindol-5-ol; 5-(4-Chlorophenyl)-2,3-dihydro-5-hydroxy-5H-imidazo(2,1-a)isoindole; 5-(4-chlorophenyl)-2,3-dihydroimidazo[1,2-b]isoindol-5-ol; 5-(p-Chlorophenyl)-2,5-dihydro-3H-imidazo(2,1-a)isoindol-5-ol; 5H-Imidazo(2,1-a)isoindol-5-ol, 5-(4-chlorophenyl)-2,3-dihydro; [3H]mazindol DMZ36RN TC Central Nervous System Stimulants DMZ36RN DT Small molecular drug DMZ36RN PC 4020 DMZ36RN MW 284.74 DMZ36RN FM C16H13ClN2O DMZ36RN IC InChI=1S/C16H13ClN2O/c17-12-7-5-11(6-8-12)16(20)14-4-2-1-3-13(14)15-18-9-10-19(15)16/h1-8,20H,9-10H2 DMZ36RN CS C1CN2C(=N1)C3=CC=CC=C3C2(C4=CC=C(C=C4)Cl)O DMZ36RN IK ZPXSCAKFGYXMGA-UHFFFAOYSA-N DMZ36RN IU 5-(4-chlorophenyl)-2,3-dihydroimidazo[1,2-b]isoindol-5-ol DMZ36RN CA CAS 22232-71-9 DMZ36RN CB CHEBI:6702 DMZ36RN DE Obesity DM0R4Z5 ID DM0R4Z5 DM0R4Z5 DN MCB-3837 DM0R4Z5 HS Approved DM0R4Z5 SN Oxaquin DM0R4Z5 CP Biovertis DM0R4Z5 DT Small molecular drug DM0R4Z5 PC 44201350 DM0R4Z5 MW 706.6 DM0R4Z5 FM C31H33F2N4O11P DM0R4Z5 IC InChI=1S/C31H33F2N4O11P/c1-17(38)34-13-20-14-37(30(42)47-20)19-4-5-27(24(33)10-19)46-16-31(48-49(43,44)45)6-8-35(9-7-31)26-12-25-21(11-23(26)32)28(39)22(29(40)41)15-36(25)18-2-3-18/h4-5,10-12,15,18,20H,2-3,6-9,13-14,16H2,1H3,(H,34,38)(H,40,41)(H2,43,44,45)/t20-/m0/s1 DM0R4Z5 CS CC(=O)NC[C@H]1CN(C(=O)O1)C2=CC(=C(C=C2)OCC3(CCN(CC3)C4=C(C=C5C(=C4)N(C=C(C5=O)C(=O)O)C6CC6)F)OP(=O)(O)O)F DM0R4Z5 IK MNABRWLVTSGIMU-FQEVSTJZSA-N DM0R4Z5 IU 7-[4-[[4-[(5S)-5-(acetamidomethyl)-2-oxo-1,3-oxazolidin-3-yl]-2-fluorophenoxy]methyl]-4-phosphonooxypiperidin-1-yl]-1-cyclopropyl-6-fluoro-4-oxoquinoline-3-carboxylic acid DM0R4Z5 CA CAS 790704-50-6 DM0R4Z5 DE Malaria DM8ZHP1 ID DM8ZHP1 DM8ZHP1 DN MCI-186 DM8ZHP1 HS Approved DM8ZHP1 SN Edarabone; Edaravone; Methylphenylpyrazolone; Monopyrazolone; Norantipyrine; Norphenazone; Phenylmethylpyrazolone; Radicut; Developer Z; Edaravone [INN]; Phenyl methyl pyrazolone; CDS1_000986; CI Developer 1; IN1263; M0687; MCI 186; Edaravone(jan); Radicut (TN); AE-641/00371017; C.I. Developer 1; Edaravone (JAN/INN); (MCI-186); 1-Fenyl-3-methyl-2-pyrazolin-5-on; 1-Fenyl-3-methyl-2-pyrazolin-5-on [Czech]; 1-Phenyl-3-methyl-5-oxo-2-pyrazoline; 1-Phenyl-3-methyl-5-pyrazolone; 1-Phenyl-3-methylpyrazolone; 1-Phenyl-3-methylpyrazolone-5; 2,4-Dihydro-5-methyl-2-phenyl-3H-pyrazol-3-one; 3-METHYL-1-PHENYL-2-PYRAZOLIN-5-ONE; 3-Methyl-1-phenyl-2-pyrazoline-5-one; 3-Methyl-1-phenyl-5-pyrazolone; 3-Methyl-1-phenylpyrazol-5-one; 5-Methyl-2-phenyl-2,4-dihydro-3H-pyrazol-3-one; 5-methyl-2-phenyl-4H-pyrazol-3-one DM8ZHP1 CP Mitsubishi Tanabe DM8ZHP1 DT Small molecular drug DM8ZHP1 PC 4021 DM8ZHP1 MW 174.2 DM8ZHP1 FM C10H10N2O DM8ZHP1 IC InChI=1S/C10H10N2O/c1-8-7-10(13)12(11-8)9-5-3-2-4-6-9/h2-6H,7H2,1H3 DM8ZHP1 CS CC1=NN(C(=O)C1)C2=CC=CC=C2 DM8ZHP1 IK QELUYTUMUWHWMC-UHFFFAOYSA-N DM8ZHP1 IU 5-methyl-2-phenyl-4H-pyrazol-3-one DM8ZHP1 CA CAS 89-25-8 DM8ZHP1 CB CHEBI:31530 DM8ZHP1 DE Amyotrophic lateral sclerosis DM4IAKR ID DM4IAKR DM4IAKR DN MD-1100 DM4IAKR HS Approved DM4IAKR SN Linaclotide acetate; Linaclotide acetate (USAN); MM-416775 DM4IAKR CP Microbia DM4IAKR DT Small molecular drug DM4IAKR PC 16158207 DM4IAKR MW 1586.8 DM4IAKR FM C61H83N15O23S6 DM4IAKR IC InChI=1S/C59H79N15O21S6.C2H4O2/c1-26-47(82)69-41-25-101-99-22-38-52(87)65-33(13-14-45(80)81)49(84)66-34(16-28-5-9-30(76)10-6-28)50(85)71-40(54(89)72-39(23-97-96-20-32(60)48(83)70-38)53(88)67-35(18-43(61)78)58(93)74-15-3-4-42(74)56(91)63-26)24-100-98-21-37(64-44(79)19-62-57(92)46(27(2)75)73-55(41)90)51(86)68-36(59(94)95)17-29-7-11-31(77)12-8-29;1-2(3)4/h5-12,26-27,32-42,46,75-77H,3-4,13-25,60H2,1-2H3,(H2,61,78)(H,62,92)(H,63,91)(H,64,79)(H,65,87)(H,66,84)(H,67,88)(H,68,86)(H,69,82)(H,70,83)(H,71,85)(H,72,89)(H,73,90)(H,80,81)(H,94,95);1H3,(H,3,4)/t26-,27+,32-,33-,34-,35-,36-,37-,38-,39-,40-,41-,42-,46-;/m0./s1 DM4IAKR CS C[C@H]1C(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](NC(=O)CNC(=O)[C@@H](NC2=O)[C@@H](C)O)C(=O)N[C@@H](CC4=CC=C(C=C4)O)C(=O)O)C(=O)N[C@@H](CSSC[C@@H](C(=O)N3)N)C(=O)N[C@H](C(=O)N5CCC[C@H]5C(=O)N1)CC(=O)N)CC6=CC=C(C=C6)O)CCC(=O)O.CC(=O)O DM4IAKR IK KWFNVZFWXXEJKL-YZDVLOIKSA-N DM4IAKR IU acetic acid;(2S)-2-[[(1R,4S,7S,13S,16R,21R,24R,27S,30S,33R,38R,44S)-21-amino-13-(2-amino-2-oxoethyl)-27-(2-carboxyethyl)-44-[(1R)-1-hydroxyethyl]-30-[(4-hydroxyphenyl)methyl]-4-methyl-3,6,12,15,22,25,28,31,40,43,46,51-dodecaoxo-18,19,35,36,48,49-hexathia-2,5,11,14,23,26,29,32,39,42,45,52-dodecazatetracyclo[22.22.4.216,33.07,11]dopentacontane-38-carbonyl]amino]-3-(4-hydroxyphenyl)propanoic acid DM4IAKR CA CAS 851199-60-5 DM4IAKR DE Constipation; Irritable bowel syndrome DMO14SG ID DMO14SG DMO14SG DN Mebendazole DMO14SG HS Approved DMO14SG SN Bantenol; Banworm; Besantin; Lomper; MBDZ; Madicure; Mebendan; Mebendazol; Mebendazolum; Mebenoazole; Mebenvet; Mebex; Mebutar; Noverme; Ovitelmin; Pantelmin; Sqworm; Sufil; Surfont; Telmin; Vermicidin; Vermicol; Vermidil; Vermin; Vermirax; Vermox; Verpanyl; Versid; Wormkuur; Abello Farmacia Brand of Mebendazole; Anti Worm; Ardeypharm Brand of Mebendazole; Boots Brand of Mebendazole; Boots Threadworm Treatment; Diba Brand of Mebendazole; Elfar Brand of Mebendazole; Equivurm Plus; Esteve Brand of Mebendazole; Healthypharm Brand of Mebendazole; Janssen Brand of Mebendazole; Leidapharm Brand of Mebendazole; Norgine Brand of Mebendazole; Pfizer Brand of Mebendazole; Pripsen Mebendazole; SSL Brand of Mebendazole; Streger Brand of Mebendazole; Taxandria Brand of Mebendazole; Tedec Meiji Brand of Mebendazole; R 17635; R17635; Anti-Worm; Antiox (TN); Degort's Brand of Mebendazole; Mebendazol [INN-Spanish]; Mebendazole(USAN); Mebendazolum [INN-Latin]; Ovex (TN); Pripsen (TN); R 17,635; R-17635; Vermox (TN); MEBENDAZOLE, 99%; Mebendazole (JAN/USP); Mebendazole (JAN/USP/INN); Mebendazole [USAN:INN:BAN:JAN]; Methyl5-benzoyl benzimidazole-2-carbamate; Methyl 5-benzoyl-2-benzimidazolecarbamate; Methyl 5-benzoyl-2-benzimidazolylcarbamate; N-2 (5-Benzoyl-benzimidazole) carbamate de methyle; N-2 (5-Benzoyl-benzimidazole) carbamate de methyle [French]; Methyl N-(5-benzoyl-2-benzimidazolyl)carbamate; Methyl (5-benzoyl-1H-benzimidazol-2-yl)carbamate; Methyl [5-(phenylcarbonyl)-1H-benzimidazol-2-yl]carbamate; N-(Benzoyl-5, benzimidazolyl)-2, carbamate de methyle; N-(Benzoyl-5, benzimidazolyl)-2, carbamate de methyle [French]; Methyl N-(5-benzoyl-1H-benzimidazol-2-yl)carbamate; Methyl N-(6-benzoyl-1H-benzimidazol-2-yl)carbamate; Carbamic acid, N-(5-benzoylbenzimidazol-2-yl)-, methyl ester; Carbamic acid, (5-benzoyl-1H-benzimidazol-2-yl)-, methyl ester; Methyl N-(6-benzoyl-1H-1,3-benzodiazol-2-yl)carbamate; Carbamic acid, (5-benzoyl-1H-benzimidazol-2-yl)-, methyl ester (9CI); (5-Benzoyl-1H-benzimidazol-2-yl)-carbamic acid methyl ester; (5-Benzoyl-1H-benzimidazol-2-yl)carbamic acid methyl ester; (5-Benzoyl-1H-benzoimidazol-2-yl)-carbamic acid methyl ester; 2-Benzimidazolecarbamic acid, 5-benzoyl-, methyl ester; 2-Benzimidazolecarbamic acid, 5-benzoyl-, methyl ester (8CI); 5-Benzoyl-2-benzimidazolecarbamic acid methyl ester; 5-Benzoyl-2-benzimidazolecarbamic acid, methyl ester DMO14SG CP Janssen Pharmaceutica DMO14SG TC Antinematodal Agents DMO14SG DT Small molecular drug DMO14SG PC 4030 DMO14SG MW 295.29 DMO14SG FM C16H13N3O3 DMO14SG IC InChI=1S/C16H13N3O3/c1-22-16(21)19-15-17-12-8-7-11(9-13(12)18-15)14(20)10-5-3-2-4-6-10/h2-9H,1H3,(H2,17,18,19,21) DMO14SG CS COC(=O)NC1=NC2=C(N1)C=C(C=C2)C(=O)C3=CC=CC=C3 DMO14SG IK OPXLLQIJSORQAM-UHFFFAOYSA-N DMO14SG IU methyl N-(6-benzoyl-1H-benzimidazol-2-yl)carbamate DMO14SG CA CAS 31431-39-7 DMO14SG CB CHEBI:6704 DMO14SG DE Worm infection DMNOBFQ ID DMNOBFQ DMNOBFQ DN Mebeverine DMNOBFQ HS Approved DMNOBFQ SN Arluy; Mebeverina; Mebeverinum; Arluy (TN); Mebeverina [INN-Spanish]; Mebeverine (INN); Mebeverine [INN:BAN]; Mebeverinum [INN-Latin]; Mebeverine (USAN)(*hydrochloride*); Veratric acid, 4-[ethyl(p-me; Veratric acid, 4-((ethyl(p-methoxy-alpha-methylphenethyl))amino)butyl ester; Veratric acid, 4-((ethyl(p-methoxy-.alpha.-methylphenethyl))amino)butyl ester; Benzoic acid, 3,4-dimethoxy-, 4-[ethyl[2-(4-methoxyphenyl)-1-methylethyl]amino]butyl ester; Benzoic acid, 3,4-dimethoxy-, {4-[ethyl[2-(4-methoxyphenyl)-1-methylethyl]amino]butyl} ester; Benzoic acid, 3,4-dimethoxy-, 4-(ethyl(2-(4-methoxyphenyl)-1-methylethyl)amino)butyl ester; 4-(Ethyl(2-(4-methoxyphenyl)-1-methylethyl)amino)butyl 3,4-dimethoxybenzoate;4-(ethyl-(4-methoxy-alpha-methylphenethyl)aminobutyl) veratrate; 4-(ethyl{1-methyl-2-[4-(methyloxy)phenyl]ethyl}amino)butyl 3,4-bis(methyloxy)benzoate; 4-[ethyl-[1-(4-methoxyphenyl)propan-2-yl]amino]butyl 3,4-dimethoxybenzoate DMNOBFQ CP Reckitt; Colman DMNOBFQ DT Small molecular drug DMNOBFQ PC 4031 DMNOBFQ MW 429.5 DMNOBFQ FM C25H35NO5 DMNOBFQ IC InChI=1S/C25H35NO5/c1-6-26(19(2)17-20-9-12-22(28-3)13-10-20)15-7-8-16-31-25(27)21-11-14-23(29-4)24(18-21)30-5/h9-14,18-19H,6-8,15-17H2,1-5H3 DMNOBFQ CS CCN(CCCCOC(=O)C1=CC(=C(C=C1)OC)OC)C(C)CC2=CC=C(C=C2)OC DMNOBFQ IK VYVKHNNGDFVQGA-UHFFFAOYSA-N DMNOBFQ IU 4-[ethyl-[1-(4-methoxyphenyl)propan-2-yl]amino]butyl 3,4-dimethoxybenzoate DMNOBFQ CA CAS 3625-06-7 DMNOBFQ CB CHEBI:91514 DMNOBFQ DE Irritable bowel syndrome DM0KYI4 ID DM0KYI4 DM0KYI4 DN Mebutamate DM0KYI4 HS Approved DM0KYI4 SN Dormate DM0KYI4 CP Medpointe Pharmaceuticals Medpointe Healthcare Inc DM0KYI4 DT Small molecular drug DM0KYI4 PC 6151 DM0KYI4 MW 232.28 DM0KYI4 FM C10H20N2O4 DM0KYI4 IC InChI=1S/C10H20N2O4/c1-4-7(2)10(3,5-15-8(11)13)6-16-9(12)14/h7H,4-6H2,1-3H3,(H2,11,13)(H2,12,14) DM0KYI4 CS CCC(C)C(C)(COC(=O)N)COC(=O)N DM0KYI4 IK LEROTMJVBFSIMP-UHFFFAOYSA-N DM0KYI4 IU [2-(carbamoyloxymethyl)-2,3-dimethylpentyl] carbamate DM0KYI4 CA CAS 64-55-1 DM0KYI4 CB CHEBI:31804 DM0KYI4 DE Anxiety disorder DMGQFYB ID DMGQFYB DMGQFYB DN Mecamylamine DMGQFYB HS Approved DMGQFYB SN Mecamilamina; Mecamine; Mecamylaminum; Mekamine; Mevasine; Revertina; Versamine; Inversine hydrochloride; Mecamilamina [DCIT]; Mecamilamina [Italian]; Mevasin hydrochloride; Inversine (TN); Mecamylamine [INN:BAN]; Mecamylaminum [INN-Latin]; N-Methyl-2-isocamphanamine; N,2,3,3-Tetramethyl-2-norbornamine; N,2,3,3-Tetramethyl-2-norcamphanamine; N,2,2,3-tetramethylbicyclo[2.2.1]heptan-3-amine; N,2,3,3-Tetramethylbicyclo[2.2.1]heptan-2-amine; 2-Methylamino-2,3,3-trimethylnorbornane; 2-Methylaminoisocamphane; 3-Methylaminoisocamphane; 3-Methylaminoisokamfan; 3-Methylaminoisokamfan [Czech]; 3-beta-Methylamino-2,2,3-trimethylbicyclo(2.2.1)heptane DMGQFYB CP Mecamylamine DMGQFYB TC Antihypertensive Agents DMGQFYB DT Small molecular drug DMGQFYB PC 4032 DMGQFYB MW 167.29 DMGQFYB FM C11H21N DMGQFYB IC InChI=1S/C11H21N/c1-10(2)8-5-6-9(7-8)11(10,3)12-4/h8-9,12H,5-7H2,1-4H3 DMGQFYB CS CC1(C2CCC(C2)C1(C)NC)C DMGQFYB IK IMYZQPCYWPFTAG-UHFFFAOYSA-N DMGQFYB IU N,2,3,3-tetramethylbicyclo[2.2.1]heptan-2-amine DMGQFYB CA CAS 60-40-2 DMGQFYB CB CHEBI:6706 DMGQFYB DE Essential hypertension DM1O3BY ID DM1O3BY DM1O3BY DN Mecasermin DM1O3BY HS Approved DM1O3BY SN Increlex (TN) DM1O3BY TC Immunomodulatory Agents DM1O3BY SQ Mecasermin: GPETLCGAELVDALQFVCGDRGFYFNKPTGYGSSSRRAPQTGIVDECCFRSCDLRRLEMYCAPLKPAKSA DM1O3BY DE Growth failure DM0CVXA ID DM0CVXA DM0CVXA DN Mechlorethamine DM0CVXA HS Approved DM0CVXA SN Antimit; Carolysine; Caryolysin; Caryolysine; Chlorethazine; Chlormethine; Cloramin; Clormetina; Dichloren; Embechine; Embichin; MBA; Mebichloramine; Mechlorethanamine; Mechloroethamine; Mecloretamina; Mustargen; Mustine; Mutagen; Nitrogranulogen; Thyldiethylamine; Dichlor amine; Me chloroethamine; Mecloretamina [Italian]; Mustine note; Nitrogen mustard; HN2; T 1024; TL 146; Chloramine (the nitrogen mustard); Chlormethine (INN); Chlormethine [INN:BAN]; Chlormethinum [INN-Latin]; Clormetina [INN-Spanish]; ENT-25294; HN-2; IBS-L0033631; Mustargen (TN); N-Lost; N-Methyl lost; Stickstofflost (ebewe); T-1024; Bis(2-chloroethyl)methylamine; Bis(beta-chloroethyl) methylamine; Bis(beta-chloroethyl)methylamine; Di(2-chloroethyl)methylamine; Methylbis(2-chloroethyl)amine; Methylbis(beta-chloroethyl)amine; Methyldi(2-chloroethyl)amine; N-Methyl-lost; N-Methyl-lost [German]; Nitrogen mustard (HN-2); Mitoxine (*Hydrochloride*); N,N-Di(chloroethyl)methylamine; N-Methyl-bis-chloraethylamin; N-Methyl-bis-chloraethylamin [German]; Nitol (*Hydrochloride*); Stickstofflost (*Hydrochloride*); N,N-Bis(2-chloroethyl)methylamine; N-Methyl-bis(2-chloroethyl)amine; N-Methyl-bis(beta-chloroethyl)amine; Beta,beta'-Dichlorodiethyl-N-methylamine; N-Methyl-2,2'-dichlorodiethylamine; N,N-Bis(2-chloroethyl)-N-methylamine; 1,5-Dichloro-3-methyl-3-azapentane hydrochloride; 2,2'-Dichloro-N-me; 2,2'-Dichloro-N-methyldiethylamine; 2,2'-Dichlorodiethyl-methylamine; 2-Chloro-N-(2-chloroethyl)-N-methylethanamine DM0CVXA CP Recordati Rare Diseases Inc DM0CVXA TC Anticancer Agents DM0CVXA DT Small molecular drug DM0CVXA PC 4033 DM0CVXA MW 156.05 DM0CVXA FM C5H11Cl2N DM0CVXA IC InChI=1S/C5H11Cl2N/c1-8(4-2-6)5-3-7/h2-5H2,1H3 DM0CVXA CS CN(CCCl)CCCl DM0CVXA IK HAWPXGHAZFHHAD-UHFFFAOYSA-N DM0CVXA IU 2-chloro-N-(2-chloroethyl)-N-methylethanamine DM0CVXA CA CAS 51-75-2 DM0CVXA CB CHEBI:28925 DM0CVXA DE T-cell lymphoma; Hodgkin lymphoma DMS7T13 ID DMS7T13 DMS7T13 DN Meclizine DMS7T13 HS Approved DMS7T13 SN Ancolan; Ancolon; Antivert; Bonadettes; Bonine; Calmonal; Chiclida; Diadril; Histamethine; Histamethizine; Histametizine; Histametizyn; Histametizyne; Itinerol; Marex; Meclicot; Meclozina; Meclozine; Meclozinum; Medivert; Monamine; Navicalm; Nevidoxine; Parachloramine; Peremesin; Postafene; Ravelon; Sabari; Siguran; Subari; Suprimal; Travelon; Veritab; Vomisseis; Vomissels; Dramamine II; Meclizine Hcl; UCB 170; UCB 5052; UCB 5062; Antivert (TN); Antivert/25; Antivert/50; Bonamine (TN); Bonine (TN); Meclizine [INN:BAN]; Meclozina [INN-Spanish]; Meclozine (BAN); Meclozinum [INN-Latin]; Neo-istafene; Neo-suprimal; Neo-suprimel; Nevidoxine (TN); Postafen (TN); Sea-Legs; Ru-Vert-M; U. C. B. 5062; U.C.B. 5062; (+-)-Meclizine; 1-((4-Chlorophenyl)phenylmethyl)-4-((3-methylphenyl)methyl)piperazine; 1-(p-Chloro-.alpha.-phenylbenzyl)-4-(m-methylbenzyl)piperazine; 1-(p-Chloro-alpha-phenylbenzyl)-4-(m-methylbenzyl)piperazine; 1-(p-Chlorobenzhydryl)-4-(m-methylbenzyl)diethylenediamine; 1-(p-Chlorobenzhydryl)-4-(m-methylbenzyl)piperazine; 1-[(4-chlorophenyl)(phenyl)methyl]-4-[(3-methylphenyl)methyl]piperazine; 1-[(4-chlorophenyl)-phenylmethyl]-4-[(3-methylphenyl)methyl]piperazine; 1-p-Chlorobenzhydryl-4-m-methylbenzylpiperazine DMS7T13 CP Citron Pharma Llc DMS7T13 TC Antiallergic Agents DMS7T13 DT Small molecular drug DMS7T13 PC 4034 DMS7T13 MW 390.9 DMS7T13 FM C25H27ClN2 DMS7T13 IC InChI=1S/C25H27ClN2/c1-20-6-5-7-21(18-20)19-27-14-16-28(17-15-27)25(22-8-3-2-4-9-22)23-10-12-24(26)13-11-23/h2-13,18,25H,14-17,19H2,1H3 DMS7T13 CS CC1=CC(=CC=C1)CN2CCN(CC2)C(C3=CC=CC=C3)C4=CC=C(C=C4)Cl DMS7T13 IK OCJYIGYOJCODJL-UHFFFAOYSA-N DMS7T13 IU 1-[(4-chlorophenyl)-phenylmethyl]-4-[(3-methylphenyl)methyl]piperazine DMS7T13 CA CAS 569-65-3 DMS7T13 CB CHEBI:6709 DMS7T13 DE Dizziness DMSFQ8I ID DMSFQ8I DMSFQ8I DN Meclocycline DMSFQ8I HS Approved DMSFQ8I SN Meclociclina; Meclocyclinum; Meclosorb; Samil; Meclociclina [Italian]; GS 2989; GS-2989; Meclociclina [INN-Spanish]; Meclocycline(USAN); Meclocyclinum [INN-Latin]; Meclocycline (USAN/INN); Meclocycline [USAN:INN:BAN]; (2E,4S,4aR,5S,5aR,12aS)-2-[amino(hydroxy)methylidene]-7-chloro-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methylidene-4,4a,5,5a-tetrahydrotetracene-1,3,12-trione; (2E,4aR,5S,5aS,12aS)-2-[amino(hydroxy)methylidene]-7-chloro-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methylidene-4,4a,5,5a-tetrahydrotetracene-1,3,12-trione; (2Z)-2-[amino(hydroxy)methylidene]-7-chloro-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methylidene-4,4a,5,5a-tetrahydrotetracene-1,3,12-trione; (2Z,4S,4aR,5S,5aR,12aS)-2-[amino(hydroxy)methylidene]-7-chloro-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methylidene-4,4a,5,5a-tetrahydrotetracene-1,3,12-trione; 2-Naphthacenecarboxamide, 7-chloro-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methylene-1,11-dioxo-, [4S-(4.alpha.,4a.alpha.,5.alpha.,5a.alpha.,12a.alpha.)]-(9CI); 2-Naphthacenecarboxamide, 7-chloro-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methylene-1,11-dioxo-, [4S-(4.alpha.,4aal; 2-[amino(hydroxy)methylidene]-7-chloro-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methylidene-4,4a,5,5a-tetrahydrotetracene-1,3,12-trione; 7-Chloro-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methylene-1,11-dioxo-2-naphthacenecarboxamide; 7-Chloro-6-methylene-5-oxytetracycline; 7-Cloro-6-metilene-5-ossitetraciclina; 7-Cloro-6-metilene-5-ossitetraciclina [Italian]; 7-chloro-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methylene-1,11-dioxo-2-naphthacene carboxamide DMSFQ8I CP Johnson And Johnson Consumer Companies Inc DMSFQ8I TC Antibiotics DMSFQ8I DT Small molecular drug DMSFQ8I PC 54676539 DMSFQ8I MW 476.9 DMSFQ8I FM C22H21ClN2O8 DMSFQ8I IC InChI=1S/C22H21ClN2O8/c1-6-9-7(23)4-5-8(26)11(9)16(27)12-10(6)17(28)14-15(25(2)3)18(29)13(21(24)32)20(31)22(14,33)19(12)30/h4-5,10,14-15,17,26-28,31,33H,1H2,2-3H3,(H2,24,32)/t10-,14-,15+,17+,22+/m1/s1 DMSFQ8I CS CN(C)[C@H]1[C@@H]2[C@H]([C@@H]3C(=C)C4=C(C=CC(=C4C(=C3C(=O)[C@@]2(C(=C(C1=O)C(=O)N)O)O)O)O)Cl)O DMSFQ8I IK RNIADBXQDMCFEN-IWVLMIASSA-N DMSFQ8I IU (4S,4aR,5S,5aR,12aR)-7-chloro-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methylidene-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide DMSFQ8I CA CAS 2013-58-3 DMSFQ8I CB CHEBI:135772 DMSFQ8I DE Bacterial infection DMNL98G ID DMNL98G DMNL98G DN Meclofenamate sodium DMNL98G HS Approved DMNL98G CP Parke Davis Div Warner Lambert Co DMNL98G DT Small molecular drug DMNL98G PC 4038 DMNL98G MW 318.1 DMNL98G FM C14H10Cl2NNaO2 DMNL98G IC InChI=1S/C14H11Cl2NO2.Na/c1-8-6-7-10(15)13(12(8)16)17-11-5-3-2-4-9(11)14(18)19;/h2-7,17H,1H3,(H,18,19);/q;+1/p-1 DMNL98G CS CC1=C(C(=C(C=C1)Cl)NC2=CC=CC=C2C(=O)[O-])Cl.[Na+] DMNL98G IK OGPIIGMUPMPMNT-UHFFFAOYSA-M DMNL98G IU sodium;2-(2,6-dichloro-3-methylanilino)benzoate DMNL98G CA CAS 6385-02-0 DMNL98G CB CHEBI:6711 DMNL98G DE Arthritis DM05FXR ID DM05FXR DM05FXR DN Meclofenamic acid DM05FXR HS Approved DM05FXR SN Arquel; Meclofenamate; Acide meclofenamique; Acido meclofenamico; Acidum meclofenamicum; Meclophenamic acid; CL 583; INF 4668; Acide meclofenamique [INN-French]; Acido meclofenamico [INN-Spanish]; Acidum meclofenamicum [INN-Latin]; INF-4668; Meclomen (free acid); Meclofenamic acid (USAN/INN); Meclofenamic acid [USAN:INN:BAN]; N-(2,6-Dichloro-3-methylphenyl)anthranilic acid; N-(2,6-Dichloro-m-tolyl)anthranilic acid; N-(3-Methyl-2,6-dichlorophenyl)anthranilic acid; 2-((2,6-Dichloro-3-methylphenyl)amino)benzoic acid; 2-(2,6-Dichloro-3-methylphenyl)aminobenzoic acid; 2-(2,6-dichloro-3-methylanilino)benzoic acid; 2-[(2,6-dichloro-3-methylphenyl)amino]benzoic acid DM05FXR TC Analgesics DM05FXR DT Small molecular drug DM05FXR PC 4037 DM05FXR MW 296.1 DM05FXR FM C14H11Cl2NO2 DM05FXR IC InChI=1S/C14H11Cl2NO2/c1-8-6-7-10(15)13(12(8)16)17-11-5-3-2-4-9(11)14(18)19/h2-7,17H,1H3,(H,18,19) DM05FXR CS CC1=C(C(=C(C=C1)Cl)NC2=CC=CC=C2C(=O)O)Cl DM05FXR IK SBDNJUWAMKYJOX-UHFFFAOYSA-N DM05FXR IU 2-(2,6-dichloro-3-methylanilino)benzoic acid DM05FXR CA CAS 644-62-2 DM05FXR CB CHEBI:6710 DM05FXR DE Ankylosing spondylitis; Joint pain DMBGWPH ID DMBGWPH DMBGWPH DN Medroxyprogesterone DMBGWPH HS Approved DMBGWPH SN Asconale; Colirest; Hematrol; Hydroxymethylprogesterone; Lunelle; Medrossiprogesterone; Medroxiprogesterona; Medroxiprogesteronum; Medroxyprogesteron; Medroxyprogesteronum; Methylhydroxyprogesterone; Adgyn Medro; Farlutal inyectable; Medroprogesterone Acetate; Medrossiprogesterone [DCIT]; Medroxyprogesteron acetate; Medroxyprogesterone Strakan Brand; Sodelut G; Strakan Brand of Medroxyprogesterone; MPA Gyn 5; U 8840; CBP-1011; Farlutal inyectable (TN); G-Farlutal; Medroxiprogesterona [INN-Spanish]; Medroxyprogesterone (INN); Medroxyprogesterone [INN:BAN]; Medroxyprogesteronum [INN-Latin]; Novo-Medrone; Pregn-4-ene-3,20-dione, 17-hydroxy-6-methyl-, (6alpha)-(9CI); Pregn-4-ene-3,20-dione, 17-hydroxy-6-methyl-, (6-alpha)-(9CI); (6S,8R,9S,10R,13S,14S,17R)-17-acetyl-17-hydroxy-6,10,13-trimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one; (6alpha)-17-hydroxy-6-methylpregn-4-ene-3,20-dione; 17 alpha Hydroxy 6 alpha Methylprogesterone; 17 alpha-Hydroxy-6 alpha-Methylprogesterone; 17-Hydroxy-6.alpha.-methylprogesterone; 17-Hydroxy-6alpha-methyl-pregn-4-ene-3,20-dione; 17-Hydroxy-6alpha-methylprogesterone; 17.alpha.-Hydroxy-6.alpha.-methylprogesterone; 17alpha-Hydroxy-6alpha-methyl-4-pregnene-3,20-dione; 17alpha-Hydroxy-6alpha-methylprogesterone; 6-Dihydromegestrol; 6-alpha-Methyl-17-alpha-hydroxyprogesterone; 6.alpha.-Methyl-17.alpha.-hydroxyprogesterone; 6alpha-Methyl-17alpha-hydroxyprogesterone; 6alpha-Methyl-4-pregnen-17alpha-ol-3,20-dione; 6alpha-Methyl-5-pregnen-17alpha-ol-3,20-dione DMBGWPH CP Pharmacia And Upjohn Co DMBGWPH TC Contraceptive Agents DMBGWPH DT Small molecular drug DMBGWPH PC 10631 DMBGWPH MW 344.5 DMBGWPH FM C22H32O3 DMBGWPH IC InChI=1S/C22H32O3/c1-13-11-16-17(20(3)8-5-15(24)12-19(13)20)6-9-21(4)18(16)7-10-22(21,25)14(2)23/h12-13,16-18,25H,5-11H2,1-4H3/t13-,16+,17-,18-,20+,21-,22-/m0/s1 DMBGWPH CS C[C@H]1C[C@@H]2[C@H](CC[C@]3([C@H]2CC[C@@]3(C(=O)C)O)C)[C@@]4(C1=CC(=O)CC4)C DMBGWPH IK FRQMUZJSZHZSGN-HBNHAYAOSA-N DMBGWPH IU (6S,8R,9S,10R,13S,14S,17R)-17-acetyl-17-hydroxy-6,10,13-trimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one DMBGWPH CA CAS 520-85-4 DMBGWPH CB CHEBI:6715 DMBGWPH DE Solid tumour/cancer DMJ90O5 ID DMJ90O5 DMJ90O5 DN Medrysone DMJ90O5 HS Approved DMJ90O5 SN Hydroxymesterone; Medrifar; Medritonic; Medrocort; Visudrisone; Medrysone (USAN); U-8471; (6S,8S,9S,10R,11S,13S,14S,17S)-17-acetyl-11-hydroxy-6,10,13-trimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one; 11.beta.-Hydroxy-6.alpha.-methylpregn-4-ene-3,20-dione; 11.beta.-Hydroxy-6.alpha.-methylprogesterone; 11beta-Hydroxy-6alpha-methyl-4-pregnene-3,20-dione; 11beta-Hydroxy-6alpha-methylpregn-4-ene-3,20-dione; 6.alpha.-Methyl-11.beta.-hydroxyprogesterone DMJ90O5 DT Small molecular drug DMJ90O5 PC 247839 DMJ90O5 MW 344.5 DMJ90O5 FM C22H32O3 DMJ90O5 IC InChI=1S/C22H32O3/c1-12-9-15-17-6-5-16(13(2)23)22(17,4)11-19(25)20(15)21(3)8-7-14(24)10-18(12)21/h10,12,15-17,19-20,25H,5-9,11H2,1-4H3/t12-,15-,16+,17-,19-,20+,21-,22+/m0/s1 DMJ90O5 CS C[C@H]1C[C@H]2[C@@H]3CC[C@@H]([C@]3(C[C@@H]([C@@H]2[C@@]4(C1=CC(=O)CC4)C)O)C)C(=O)C DMJ90O5 IK GZENKSODFLBBHQ-ILSZZQPISA-N DMJ90O5 IU (6S,8S,9S,10R,11S,13S,14S,17S)-17-acetyl-11-hydroxy-6,10,13-trimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one DMJ90O5 CA CAS 2668-66-8 DMJ90O5 CB CHEBI:34829 DMJ90O5 DE Eye inflammation DMK7HFI ID DMK7HFI DMK7HFI DN Mefenamic acid DMK7HFI HS Approved DMK7HFI SN ApoMefenamic; Bonabol; Contraflam; Coslan; Dysman; Lysalgo; Mefac; Mefacit; Mefedolo; Mefenacid;Mefenamate; Mefenaminsaeure; Mefic; Mycasaal; Namphen; NuMefenamic; Parkemed; Pinalgesic; Ponalar; Ponalgic; Ponmel; Ponstan; Ponstel; Ponstil; Ponstyl; Ponsyl; Pontal; Rolan; Tanston; Vialidon; APS Brand of Mefenamic Acid; Acide mefenamique; Acide mefenamique [French]; Acido mefenamico; Acidum mefenamicum; Antigen Brand of Mefenamic Acid; Apo Mefenamic; Apotex Brand of Mefenamic Acid; Ashbourne Brand of Mefenamic Acid; Chemidex Brand of Mefenamic Acid; Clonmel Brand of Mefenamic Acid; Elan Brand of Mefenamic Acid; Farmasierra Brand of Mefenamic Acid; First Horizon Brand of Mefenamic Acid; Godecke Brand of Mefenamic Acid; Mefanamic acid; Mefenaminic Acid; Mefenaminsaeure [German]; Mephenamic acid; Mephenaminic acid; Methenamic acid; Nu Mefenamic; Nu Pharm Brand of Mefenamic Acid; PMS Mefenamic Acid; Parke Davis Brand of Mefenamic Acid; Pfizer Brand of Mefenamic Acid; Pharmascience Brand of Mefenamic Acid; Pinewood Brand of Mefenamic Acid; Ponstan forte; Rowa Brand of Mefenamic Acid; Tamany Bonsan; Warner Lambert Brand of Mefenamic Acid; CL 473; CN 35355; HL 1; ID8; INF 3355; M1782; AGN-1255; Ac. mefenamico; Ac. mefenamico [Italian]; Acid, Mefenamic; Acid, Mefenaminic; Acide mefenamique [INN-French]; Acido mefenamico [INN-Spanish]; Acidum mefenamicum [INN-Latin]; Apo-Mefenamic; Bafameritin-M; Bafhameritin-M; CN-35355; Dyfenamic (TN); F0850-6853; Forte, Ponstan; INF-3355; In-M; Mafepain (TN); Meftal (TN); Mephadolor (TN); Nu-Mefenamic; Nu-Pharm Brand of Mefenamic Acid; PMS-Mefenamic Acid; Parkemed (TN); Ponstal (TN); Ponstan (TN); Ponstel (TN); Potarlon (TN); Warner-Lambert Brand of Mefenamic Acid; Mefenamic acid (JP15/USP/INN); Mefenamic acid [USAN:INN:BAN:JAN]; N-2,3-Xylylanthranilic acid; N-(2,3-Dimethylphenyl)anthranilic acid; N-(2,3-Xylyl)anthranilic acid; N-(2,3-Xylyl)-2-aminobenzoic acid; 2-((2,3-Dimethylphenyl)amino)benzoic acid; 2-(2,3-Dimethylanilino)benzoic acid; 2-(2,3-Xylidino)benzoic Acid; 2-(2,3-dimethylphenylamino)benzoic acid; 2-[(2,3-dimethylphenyl)amino]benzoic acid DMK7HFI TC Antiinflammatory Agents DMK7HFI DT Small molecular drug DMK7HFI PC 4044 DMK7HFI MW 241.28 DMK7HFI FM C15H15NO2 DMK7HFI IC InChI=1S/C15H15NO2/c1-10-6-5-9-13(11(10)2)16-14-8-4-3-7-12(14)15(17)18/h3-9,16H,1-2H3,(H,17,18) DMK7HFI CS CC1=C(C(=CC=C1)NC2=CC=CC=C2C(=O)O)C DMK7HFI IK HYYBABOKPJLUIN-UHFFFAOYSA-N DMK7HFI IU 2-(2,3-dimethylanilino)benzoic acid DMK7HFI CA CAS 61-68-7 DMK7HFI CB CHEBI:6717 DMK7HFI DE Dysmenorrhea DMWT905 ID DMWT905 DMWT905 DN Mefloquine DMWT905 HS Approved DMWT905 SN Lariam; Mefloquin; Mefloquina; Mefloquinone; Mefloquinum; Mephloquine; Racemic mefloquine; Ro 215998; WR 142490; Lariam (Hydrochloride); Lariam (TN); Mefaquin (TN); Mefloquina [INN-Spanish]; Mefloquinum [INN-Latin]; RO 13-7224; RO 13-7225; Ro 21-5998; SPB-80406; WR-142490; Mefloquine (USAN/INN); Mefloquine [USAN:INN:BAN]; RTI1169-1-1; RTI1172-1-1; RTI1173-1-1; RTI1174-1-1; RTI1188-1-1; RTI1189-1-1; Ro 21-5998 (Hydrochloride); WR-142,490; WR-177,602; Ro-21-5998-001; Alpha-2-Piperidinyl-2,8-bis(trifluoromethyl)-4-quinolinemethanol; Alpha-2-Piperidyl-2,8-bis(trifluoromethyl)quinoline-4-methanol; [2,8-bis(trifluoromethyl)quinolin-4-yl]-piperidin-2-ylmethanol; Erthro-.alpha.-[2-piperidyl]-2,8-bis[trifluoromethyl]-4-quinolinemethanol; (+)-(11R,2'S)-erythro-Mefloquine; (+)-Mefloquine; (+)-Threo-Mefloquine; (-)-(11S,2'R)-erythro-Mefloquine; (-)-Mefloquine; (-)-Threo-Mefloquine; (DL-erythro-alpha-2-Piperidyl-2,8-bis(trifluoromethyl)-4-quinolinemethanol; (R)-[2,8-bis(trifluoromethyl)quinolin-4-yl]-[(2R)-piperidin-2-yl]methanol; (R)-[2,8-bis(trifluoromethyl)quinolin-4-yl]-[(2S)-piperidin-2-yl]methanol; (S)-[2,8-bis(trifluoromethyl)quinolin-4-yl]-[(2R)-piperidin-2-yl]methanol; (S)-[2,8-bis(trifluoromethyl)quinolin-4-yl]-[(2S)-piperidin-2-yl]methanol; (S)-[2,8-bis(trifluoromethyl)quinolin-4-yl][(2R)-piperidin-2-yl]methanol DMWT905 CP Hoffmann-La Roche pharmaceutical company DMWT905 TC Antimalarials DMWT905 DT Small molecular drug DMWT905 PC 4046 DMWT905 MW 378.31 DMWT905 FM C17H16F6N2O DMWT905 IC InChI=1S/C17H16F6N2O/c18-16(19,20)11-5-3-4-9-10(15(26)12-6-1-2-7-24-12)8-13(17(21,22)23)25-14(9)11/h3-5,8,12,15,24,26H,1-2,6-7H2 DMWT905 CS C1CCNC(C1)C(C2=CC(=NC3=C2C=CC=C3C(F)(F)F)C(F)(F)F)O DMWT905 IK XEEQGYMUWCZPDN-UHFFFAOYSA-N DMWT905 IU [2,8-bis(trifluoromethyl)quinolin-4-yl]-piperidin-2-ylmethanol DMWT905 CA CAS 49752-90-1 DMWT905 CB CHEBI:63681 DMWT905 DE Malaria DMDH9KX ID DMDH9KX DMDH9KX DN Megestrol DMDH9KX HS Approved DMDH9KX SN Chronopil; Megestrolo; Megestrolo [DCIT]; Chronopil (TN); Megace (TN); Megestrol (INN); Megestrol [INN:BAN]; Megestrolum [INN-Latin]; (8R,9S,10R,13S,14S,17R)-17-acetyl-17-hydroxy-6,10,13-trimethyl-2,8,9,11,12,14,15,16-octahydro-1H-cyclopenta[a]phenanthren-3-one; 17-Hydroxy-6-methylpregna-4,6-diene-3,20-dione DMDH9KX CP Bristol Myers Squibb DMDH9KX TC Anticancer Agents DMDH9KX DT Small molecular drug DMDH9KX PC 19090 DMDH9KX MW 342.5 DMDH9KX FM C22H30O3 DMDH9KX IC InChI=1S/C22H30O3/c1-13-11-16-17(20(3)8-5-15(24)12-19(13)20)6-9-21(4)18(16)7-10-22(21,25)14(2)23/h11-12,16-18,25H,5-10H2,1-4H3/t16-,17+,18+,20-,21+,22+/m1/s1 DMDH9KX CS CC1=C[C@@H]2[C@H](CC[C@]3([C@H]2CC[C@@]3(C(=O)C)O)C)[C@@]4(C1=CC(=O)CC4)C DMDH9KX IK VXIMPSPISRVBPZ-NWUMPJBXSA-N DMDH9KX IU (8R,9S,10R,13S,14S,17R)-17-acetyl-17-hydroxy-6,10,13-trimethyl-2,8,9,11,12,14,15,16-octahydro-1H-cyclopenta[a]phenanthren-3-one DMDH9KX CA CAS 3562-63-8 DMDH9KX DE Breast cancer DM1OFHN ID DM1OFHN DM1OFHN DN Meglitinides DM1OFHN HS Approved DM1OFHN DT Small molecular drug DM1OFHN PC 3033769 DM1OFHN MW 347.2 DM1OFHN FM C15H20Cl2N2O3 DM1OFHN IC InChI=1S/C15H20Cl2N2O3/c1-3-19-6-4-5-9(19)8-18-15(21)12-13(20)10(16)7-11(17)14(12)22-2/h7,9,20H,3-6,8H2,1-2H3,(H,18,21)/t9-/m0/s1 DM1OFHN CS CCN1CCC[C@H]1CNC(=O)C2=C(C(=CC(=C2OC)Cl)Cl)O DM1OFHN IK WAOQONBSWFLFPE-VIFPVBQESA-N DM1OFHN IU 3,5-dichloro-N-[[(2S)-1-ethylpyrrolidin-2-yl]methyl]-2-hydroxy-6-methoxybenzamide DM1OFHN CA CAS 84225-95-6 DM1OFHN CB CHEBI:92070 DM1OFHN DE Type-2 diabetes; Psychotic disorder DMGUZ0W ID DMGUZ0W DMGUZ0W DN MELARSOPROL DMGUZ0W HS Approved DMGUZ0W SN MELARSOPROL; Mel B; Arsobal; 494-79-1; Melarsoprolum [INN-Latin]; EINECS 207-793-4; Melarsoprol [INN:BAN:DCF]; RP 3854; CHEBI:6729; [2-[4-[(4,6-diamino-1,3,5-triazin-2-yl)amino]phenyl]-1,3,2-dithiarsolan-4-yl]methanol; 1,3,2-Dithiarsolane-4-methanol, 2-(4-((4,6-diamino-1,3,5-triazin-2-yl)amino)phenyl)-; Melarsoprolum; Melarsenoxid-BAL; 2-(p-(4,6-Diamino-s-triazin-2-ylamino)phenyl)-1,3,2-dithiarsolane-4-methanol; C12H15AsN6OS2; Specia; UNII-ZF3786Q2E8; Melarsoprol (INN); AC1L1UXN; Mel B (TN); CHEMBL166; SCHEMBL61707; ZF3786Q2E8 DMGUZ0W DT Small molecular drug DMGUZ0W PC 10311 DMGUZ0W MW 398.3 DMGUZ0W FM C12H15AsN6OS2 DMGUZ0W IC InChI=1S/C12H15AsN6OS2/c14-10-17-11(15)19-12(18-10)16-8-3-1-7(2-4-8)13-21-6-9(5-20)22-13/h1-4,9,20H,5-6H2,(H5,14,15,16,17,18,19) DMGUZ0W CS C1C(S[As](S1)C2=CC=C(C=C2)NC3=NC(=NC(=N3)N)N)CO DMGUZ0W IK JCYZMTMYPZHVBF-UHFFFAOYSA-N DMGUZ0W IU [2-[4-[(4,6-diamino-1,3,5-triazin-2-yl)amino]phenyl]-1,3,2-dithiarsolan-4-yl]methanol DMGUZ0W CA CAS 494-79-1 DMGUZ0W CB CHEBI:6729 DMGUZ0W DE Trypanosomiasis DMKWFBT ID DMKWFBT DMKWFBT DN Melatonin DMKWFBT HS Approved DMKWFBT SN 73-31-4; Melatonine; N-Acetyl-5-methoxytryptamine; Circadin; 5-Methoxy-N-acetyltryptamine; N-[2-(5-Methoxy-1H-indol-3-yl)ethyl]acetamide; N-(2-(5-Methoxy-1H-indol-3-yl)ethyl)acetamide; Melatol; Melovine; Melatonex; N-[2-(5-methoxyindol-3-yl)ethyl]acetamide; Acetamide, N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-; UNII-JL5DK93RCL; N-(2-(5-Methoxyindol-3-yl)ethyl)acetamide; N-acetyl-5-methoxy-tryptamine; NSC 113928; CCRIS 3472; CHEMBL45; EINECS 200-797-7; JL5DK93RCL; Acetamide, N-(2-(5-methoxyindol-3-yl)ethyl)-; BRN 0205542; Circadin; Melapure; Melatonina; Posidorm; Vivitas; Night Rest; Pineal Hormone; Revital Melatonin; Rx Balance; Sleep Right; IN1244; M 5250; M1105; ML1; MT6; TNP00300; M-1200; M-1250; Mela-T; Melatonex, Melatonin; Melatonina (TN); NMR/14327425; Nature'S Harmony; PREVENTION 2 (MELATONIN); PREVENTION 3 (MELATONIN); PREVENTION 4 (MELATONIN); PREVENTION 5 (MELATONIN); PREVENTION 1 (MELATONIN) (PREVENTION 1); Acetamide, {N-[2-(5-methoxyindol-3-yl)ethyl]-}; Acetamide, N-[2-(5-methoxyindol-3-yl)ethyl]-(6CI,8CI); N-[2-(5-Methoxy-1H-indol-3-yl)-ethyl]-acetamide; Acetamide, N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-(9CI); Acetamide, {N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-}; Acetamide, N-(2-(5-methoxy-1H-indol-3-yl)ethyl)-(9CI); 4-ACETAMIDO-4'-ISOTHIO-CYANATOSTILBENE-2,2'-DISULFONIC ACID; [3H]melatonin; N-[2-(5-methoxy-1H-indol-3-yl)ethyl]acetamide DMKWFBT TC Central Nervous System Stimulants DMKWFBT DT Small molecular drug DMKWFBT PC 896 DMKWFBT MW 232.28 DMKWFBT FM C13H16N2O2 DMKWFBT IC InChI=1S/C13H16N2O2/c1-9(16)14-6-5-10-8-15-13-4-3-11(17-2)7-12(10)13/h3-4,7-8,15H,5-6H2,1-2H3,(H,14,16) DMKWFBT CS CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC DMKWFBT IK DRLFMBDRBRZALE-UHFFFAOYSA-N DMKWFBT IU N-[2-(5-methoxy-1H-indol-3-yl)ethyl]acetamide DMKWFBT CA CAS 73-31-4 DMKWFBT CB CHEBI:16796 DMKWFBT DE Insomnia DM2AR7L ID DM2AR7L DM2AR7L DN Meloxicam DM2AR7L HS Approved DM2AR7L SN Meloxicam (SoluMatrix/arthritis); Meloxicam nanoformulation capsules (arthritis), iCeutica; Meloxicam (SoluMatrix/arthritis), iCeutica DM2AR7L CP Iroko pharmaceuticals DM2AR7L DT Small molecular drug DM2AR7L PC 54677470 DM2AR7L MW 351.4 DM2AR7L FM C14H13N3O4S2 DM2AR7L IC InChI=1S/C14H13N3O4S2/c1-8-7-15-14(22-8)16-13(19)11-12(18)9-5-3-4-6-10(9)23(20,21)17(11)2/h3-7,18H,1-2H3,(H,15,16,19) DM2AR7L CS CC1=CN=C(S1)NC(=O)C2=C(C3=CC=CC=C3S(=O)(=O)N2C)O DM2AR7L IK ZRVUJXDFFKFLMG-UHFFFAOYSA-N DM2AR7L IU 4-hydroxy-2-methyl-N-(5-methyl-1,3-thiazol-2-yl)-1,1-dioxo-1lambda6,2-benzothiazine-3-carboxamide DM2AR7L CA CAS 71125-38-7 DM2AR7L CB CHEBI:6741 DM2AR7L DE Arthritis DMOLNHF ID DMOLNHF DMOLNHF DN Melphalan DMOLNHF HS Approved DMOLNHF SN Alkeran; Levofalan; Levofolan; Levopholan; Melfalan; Melfalano; Melphalanum; Alanine Nitrogen Mustard; Phenylalanine mustard; Phenylalanine nitrogen mu stard; Phenylalanine nitrogen mustard; AY3360000; CB 3025; ALKERAN (TN); Alkeran (TN); At-290; CB-3025; L-PAM; L-Phenylalanine mustard; L-Sarcolysin; L-Sarcolysine; L-Sarkolysin; Melfalano [INN-Spanish]; Melphalanum [INN-Latin]; SK-15673; TRANSGENIC MODEL EVALUATION (MELPHALAN); MELPHALAN (SEE ALSO TRANSGENIC MODEL EVALUATION (MELPHALAN)); P-L-Sarcolysin; P-L-sarcolysine; TRANSGENIC LEP (MELPHALAN) (SEE ALSO MELPHALAN); Melphalan (JP15/USP/INN); Melphalan [USAN:INN:BAN:JAN]; P-Bis(beta-chloroethyl)aminophenylalanine; P-N-Di(chloroethyl)aminophenylalanine; P-N-di(chloroethyl)aminophenylala nine; P-Di-(2-chloroethyl)amino-L-phenylalanine; P-N-Bis(2-chloroethyl)amino-L-phenylalanine; L-3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine; L-3-(para-(Bis(2-chloroethyl)amino)phenyl)alanine; P-N,N-bis(2-chloroethyl)amino-L-phenylalanine; (2S)-2-amino-3-[4-[bis(2-chloroethyl)amino]phenyl]propanoic acid; (2s)-2-amino-3-(4-[bis(2-chloroethyl)amino]phenyl)propanoic acid; 3-(p-(Bis(2-chloroethyl)amino)phenyl)-L-alanine; 3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine; 3-p-(Di(2-chloroethyl)amino)-phenyl-L-alanine; 4-(Bis(2-chloroethyl)amino)-L-phenylalanine; 4-[Bis(2-chloroethyl)amino]-L-phenylalanine; 4-[Bis-(2-chloroethyl)amino]-L-phenylalanine DMOLNHF TC Anticancer Agents DMOLNHF DT Small molecular drug DMOLNHF PC 460612 DMOLNHF MW 305.2 DMOLNHF FM C13H18Cl2N2O2 DMOLNHF IC InChI=1S/C13H18Cl2N2O2/c14-5-7-17(8-6-15)11-3-1-10(2-4-11)9-12(16)13(18)19/h1-4,12H,5-9,16H2,(H,18,19)/t12-/m0/s1 DMOLNHF CS C1=CC(=CC=C1C[C@@H](C(=O)O)N)N(CCCl)CCCl DMOLNHF IK SGDBTWWWUNNDEQ-LBPRGKRZSA-N DMOLNHF IU (2S)-2-amino-3-[4-[bis(2-chloroethyl)amino]phenyl]propanoic acid DMOLNHF CA CAS 148-82-3 DMOLNHF CB CHEBI:28876 DMOLNHF DE Multiple myeloma; Intrahepatic cholangiocarcinoma DMWF5R4 ID DMWF5R4 DMWF5R4 DN Melphalan flufenamide DMWF5R4 HS Approved DMWF5R4 SN J-1; Dipeptide-conjugated melphalan prodrug (iv formulation, ovary tumor), Oncopeptides DMWF5R4 CP Oncopeptides AB DMWF5R4 DT Small molecular drug DMWF5R4 PC 9935639 DMWF5R4 MW 498.4 DMWF5R4 FM C24H30Cl2FN3O3 DMWF5R4 IC InChI=1S/C24H30Cl2FN3O3/c1-2-33-24(32)22(16-18-3-7-19(27)8-4-18)29-23(31)21(28)15-17-5-9-20(10-6-17)30(13-11-25)14-12-26/h3-10,21-22H,2,11-16,28H2,1H3,(H,29,31)/t21-,22-/m0/s1 DMWF5R4 CS CCOC(=O)[C@H](CC1=CC=C(C=C1)F)NC(=O)[C@H](CC2=CC=C(C=C2)N(CCCl)CCCl)N DMWF5R4 IK YQZNKYXGZSVEHI-VXKWHMMOSA-N DMWF5R4 IU ethyl (2S)-2-[[(2S)-2-amino-3-[4-[bis(2-chloroethyl)amino]phenyl]propanoyl]amino]-3-(4-fluorophenyl)propanoate DMWF5R4 CA CAS 380449-51-4 DMWF5R4 DE Ovarian cancer; Plasma cell myeloma; Multiple myeloma DMD9WSC ID DMD9WSC DMD9WSC DN Memantine DMD9WSC HS Approved DMD9WSC SN Memantine ER; Namenda XR; Memantine (extended release); Memantine (extended release), Forest DMD9WSC CP Merz & Co GmbH DMD9WSC DT Small molecular drug DMD9WSC PC 4054 DMD9WSC MW 179.3 DMD9WSC FM C12H21N DMD9WSC IC InChI=1S/C12H21N/c1-10-3-9-4-11(2,6-10)8-12(13,5-9)7-10/h9H,3-8,13H2,1-2H3 DMD9WSC CS CC12CC3CC(C1)(CC(C3)(C2)N)C DMD9WSC IK BUGYDGFZZOZRHP-UHFFFAOYSA-N DMD9WSC IU 3,5-dimethyladamantan-1-amine DMD9WSC CA CAS 19982-08-2 DMD9WSC CB CHEBI:64312 DMD9WSC DE Alzheimer disease DMP9N85 ID DMP9N85 DMP9N85 DN Menadiol sodium diphosphate DMP9N85 HS Approved DMP9N85 SN Kappadione; Synkavit; Procoagulo; Synkavite; Thylokay; Kipca water soluble; Synkayvite; Menadiol sodium diphosphate; Menadione sodium phosphate; Sodium menadione diphosphate; Menadiol Sodium Diphosphate Anhydrous; UNII-R2L46WE615; Menadiol tetrasodium diphosphate; EINECS 205-012-1; Menadione diphosphate tetrasodium salt; 1:4-Naphthaquinol-bisdisodium phosphate; 131-13-5; Menadiol sodium diphosphate anhydrous [USAN]; R2L46WE615; 2-Methyl-1,4-naphthaquinol bis(disodium phosphate); Tetrasodium 2-methyl-1,4-naphthalenediol diphosp DMP9N85 DT Small molecular drug DMP9N85 PC 8555 DMP9N85 MW 422.08 DMP9N85 FM C11H8Na4O8P2 DMP9N85 IC InChI=1S/C11H12O8P2.4Na/c1-7-6-10(18-20(12,13)14)8-4-2-3-5-9(8)11(7)19-21(15,16)17;;;;/h2-6H,1H3,(H2,12,13,14)(H2,15,16,17);;;;/q;4*+1/p-4 DMP9N85 CS CC1=C(C2=CC=CC=C2C(=C1)OP(=O)([O-])[O-])OP(=O)([O-])[O-].[Na+].[Na+].[Na+].[Na+] DMP9N85 IK GZBACHSOZNEZOG-UHFFFAOYSA-J DMP9N85 IU tetrasodium;(2-methyl-4-phosphonatooxynaphthalen-1-yl) phosphate DMP9N85 CA CAS 131-13-5 DMP9N85 DE Coagulation defect DMSJDTY ID DMSJDTY DMSJDTY DN Menadione DMSJDTY HS Approved DMSJDTY SN menadione; 58-27-5; Vitamin K3; 2-Methyl-1,4-naphthoquinone; Menaphthone; 2-methylnaphthalene-1,4-dione; 2-Methylnaphthoquinone; Thyloquinone; Panosine; Klottone; Kayquinone; Kappaxin; Kayklot; Kolklot; 2-Methyl-1,4-naphthalenedione; Menaphthon; Menadion; Kipca; Kanone; Mitenone; Kativ-G; Kaergona; Aquinone; Prokayvit; Mitenon; Koaxin; Kaykot; Kareon; Hemodal; Aquakay; Synkay; Karcon; K-Thrombyl; K-Vitan; Kipca-Oil Soluble; Juva-K; Vitamin K2(0); Vitamin K0; Menaquinone 0; Vitamin K 3; Menaphtone; Menadionum; 2-Methyl-1,4-naphthochinon; Usaf; Aquakay; Klottone;Koaxin; Memodol; Methylnaphthoquinone; Vicasol; Menadione semiquinone; M0373; VK3; Kappaxan (VAN); Kappaxin (TN); Kipca, oil soluble; Menadione (K3); Menadione (USP); Menadione [USAN:BAN]; Usaf ek-5185; Vitamin-K3; Methyl-1,4-naphthalenedione; Methyl-1,4-naphthoquinone; Vitamin K3 : 2-Methyl-1,4-naphthoquinone; 1,4-Naphthalenedione, 2-methyl-,radical ion(1-); 2-Methyl-1,4-naftochinon; 2-Methyl-1,4-naftochinon [Czech]; 2-Methyl-1,4-naphthochinon [German]; 2-methyl-1,4-naphthoquinone, 5; 3-Methyl-1,4-naphthoquinone; Ascorbic acid/menadione; Triglycyl-lysine-vasopressin DMSJDTY TC Vitamins DMSJDTY DT Small molecular drug DMSJDTY PC 4055 DMSJDTY MW 172.18 DMSJDTY FM C11H8O2 DMSJDTY IC InChI=1S/C11H8O2/c1-7-6-10(12)8-4-2-3-5-9(8)11(7)13/h2-6H,1H3 DMSJDTY CS CC1=CC(=O)C2=CC=CC=C2C1=O DMSJDTY IK MJVAVZPDRWSRRC-UHFFFAOYSA-N DMSJDTY IU 2-methylnaphthalene-1,4-dione DMSJDTY CA CAS 58-27-5 DMSJDTY CB CHEBI:28869 DMSJDTY DE Vitamin K deficiency; Prostate cancer DM2SR1J ID DM2SR1J DM2SR1J DN Meningococcal groups A, C, Y and W-135 conjugate vaccine DM2SR1J HS Approved DM2SR1J SN Menveo (TN) DM2SR1J CP Novartis DM2SR1J DE Meningococcal infection DM4CF18 ID DM4CF18 DM4CF18 DN Menotropins DM4CF18 HS Approved DM4CF18 SN Humegon; Human Menopausal Gonadotrophin; Human Menopausal Gonadotrophin (JP15); Humegon (TN); Menotropins (USP) DM4CF18 TC Fertility Agents DM4CF18 SQ AlphaChain (LH): APDVQDCPECTLQENPFFSQPGAPILQCMGCCFSRAYPTPLRSKKTMLVQKNVTSESTCCVAKSYNRVTVMGGFKVENHTACHCSTCYYHKS >BetaChain (LH)SREPLRPWCHPINAILAVEKEGCPVCITVNTTICAGYCPTMMRVLQAVLPPLPQVVCTYRDVRFESIRLPGCPRGVDPVVSFPVALSCRCGPCRRSTSDCGGPKDHPLTCDHPQLSGLLFL >AlphaChain (FSH)APDVQDCPECTLQENPFFSQPGAPILQCMGCCFSRAYPTPLRSKKTMLVQKNVTSESTCCVAKSYNRVTVMGGFKVENHTACHCSTCYYHKS >BetaChain (FSH)NSCELTNITIAIEKEECRFCISINTTWCAGYCYTRDLVYKDPARPKIQKTCTFKELVYETVRVPGCAHHADSLYTYPVATQCHCGKCDSDSTDCTVRGLGPSYCSFGEMKE DM4CF18 DE Female infertility DMG2KW7 ID DMG2KW7 DMG2KW7 DN Menthol DMG2KW7 HS Approved DMG2KW7 SN Hexahydrothymol; Levomenthol; Levomentholum; Menthacamphor; Menthomenthol; Neoisomenthol; Racementhol; Racementholum; Racementol; Headache crystals; Menthol natural; Menthol racemic; Menthol racemique; Menthol racemique [French]; Menthol solution; Menthyl alcohol; Peppermint camphor; Racemic menthol; Robitussin Cough Drops; M0321; M0545; D-Menthol; D-Neomenthol; Dl-Menthol; Fisherman's friend lozenges; L-Menthol; Levomenthol [INN:BAN]; Levomentholum [INN-Latin]; Menthol (USP); Menthol (VAN); Menthol natural, brazilian; NOOLISFMXDJSKH-KXUCPTDWBX; Rac-Menthol; Racementhol [INN:BAN]; Racementholum [INN-Latin]; Racementol [INN-Spanish]; Tra-kill tracheal mite killer; D,l-Menthol; Dl-Menthol (JP15); Fisherman's friendlozenges (TN); L-Menthol (JP15); L-Menthol (TN); L-Menthol (natural); Dl-3-p-Menthanol; P-Menthan-3-ol; RACEMIC MENTHOL U.S.P.; U.S.P. Menthol; D-(-)-Menthol; D-p-Menthan-3-ol; L-(-)-Menthol; Menthol, (1alpha,2beta,5alpha)-Isomer; Cis-1 ,3-trans-1,4-(+-)-menthol; Cis-1,3-trans-1,4-(+-)-menthol; (+)-Neo-menthol; (+)-p-Menthan-3-ol; (+-)-(1R*,3R*,4S*)-Menthol; (+-)-Menthol; (+/-)-Menthol; (+/-)-p-Menthan-3-ol; (-)-(1R,3R,4S)-Menthol; (-)-Menthyl alcohol; (-)-menthol; (-)-p-Menthan-3-ol; (-)-trans-p-Menthan-cis-ol; (1R)-(-)-Menthol; (1R,2S,5R)-Menthol; (1R,3R,4S)-(-)-MENTHOL; (1S, 2S, 5R)-(+)-Neomenthol; (1S,2R,5R)-(+)-Isomenthol; (1S,2R,5S)-(+)-Menthol; (1S,2R,5S)-Menthol; (1r,2s,5r)-(-)-menthol; (L)-MENTHOL; (R)-(-)-Menthol; 2-Isopropyl-5-methylcyclohexanol; 3-p-Menthol; 4-Isopropyl-1-methylcyclohexan-3-ol; 5-Methyl-2-(1-methylethyl)-cyclohexanol; 5-Methyl-2-(1-methylethyl)cyclohexanol; 5-methyl-2-(propan-2-yl)cyclohexanol; 5-methyl-2-propan-2-ylcyclohexan-1-ol DMG2KW7 TC Antipruritics DMG2KW7 DT Small molecular drug DMG2KW7 PC 1254 DMG2KW7 MW 156.26 DMG2KW7 FM C10H20O DMG2KW7 IC InChI=1S/C10H20O/c1-7(2)9-5-4-8(3)6-10(9)11/h7-11H,4-6H2,1-3H3 DMG2KW7 CS CC1CCC(C(C1)O)C(C)C DMG2KW7 IK NOOLISFMXDJSKH-UHFFFAOYSA-N DMG2KW7 IU 5-methyl-2-propan-2-ylcyclohexan-1-ol DMG2KW7 CA CAS 89-78-1 DMG2KW7 CB CHEBI:25187 DMG2KW7 DE Throat irritation DM8YU2F ID DM8YU2F DM8YU2F DN Mepenzolate DM8YU2F HS Approved DM8YU2F SN Cantil; Cantilaque; Cantilon; Cantril; Colibantil; Colopiril; Colum; Delevil; Eftoron; Gastropidil; Glycophenylate; Mepenzolon; Tralanta; Trancolon; Trokonil; Bromure de mepenzolate; Bromuro de mepenzolato; MEPENZOLATE BROMIDE; Mepenzolate Methylbromide; Mepenzolati bromidum; Mepenzolic acid; Mepenzolone Bromide; JB 340; Bromure de mepenzolate [INN-French]; Bromuro de mepenzolato [INN-Spanish]; Cantil (TN); Mepenzolati bromidum [INN-Latin]; Mepenzolic acid, bromine salt; Mepenzolate bromide (JP15/INN); Mepenzolate bromide [INN:BAN:JAN]; N-Methyl-3-piperidyl benzilate methobromide; N-Methyl-3-piperidyl benzilate methyl bromide; N-Methyl-3-piperidyldiphenylglycolate methobromide; N-methyl-3-piperidylbenzilate methyl bromide; Benzilic acid, 1-methyl-3-piperidyl ester methobromide; Benzilic acid, ester with 3-hydroxy-1,1-dimethylpiperidinium bromide; Piperidinium, 3-[(hydroxydiphenylacetyl)oxy]-1,1-dimethyl-, bromide; Piperidinium, 3-hydroxy-1,1-dimethyl-, benzilate (ester); Piperidinium, 3-hydroxy-1,1-dimethyl-, bromide, benzilate; Piperidinium, 3-((hydroxydiphenylacetyl)oxy)-1,1-dimethyl-(VAN); Piperidinium, 3-((hydroxydiphenylacetyl)oxy)-1,1-dimethyl-, bromide; (1,1-dimethylpiperidin-1-ium-3-yl) 2-hydroxy-2,2-diphenylacetate; (1,1-dimethylpiperidin-1-ium-3-yl) 2-hydroxy-2,2-diphenylacetate bromide; 1-Methyl-3-piperidyl benzilate methyl bromide; 1-Methyl-3-piperidyl benzilate methylbromide; 2-(1,1-dimethylpiperidin-1-ium-3-yl)oxy-2-oxo-1,1-diphenylethanolate; 2-[(1,1-dimethylpiperidinium-3-yl)oxy]-2-oxo-1,1-diphenylethanolate; 3-((Hydroxydiphenylacetyl)oxy)-1,1-dimethylpiperidinium bromide; 3-Hydroxy-1,1-dimethylpiperidinium bromide benzilate; 3-{[hydroxy(diphenyl)acetyl]oxy}-1,1-dimethylpiperidinium bromide DM8YU2F TC Parasympatholytics DM8YU2F DT Small molecular drug DM8YU2F PC 4057 DM8YU2F MW 340.4 DM8YU2F FM C21H26NO3+ DM8YU2F IC InChI=1S/C21H26NO3/c1-22(2)15-9-14-19(16-22)25-20(23)21(24,17-10-5-3-6-11-17)18-12-7-4-8-13-18/h3-8,10-13,19,24H,9,14-16H2,1-2H3/q+1 DM8YU2F CS C[N+]1(CCCC(C1)OC(=O)C(C2=CC=CC=C2)(C3=CC=CC=C3)O)C DM8YU2F IK GKNPSSNBBWDAGH-UHFFFAOYSA-N DM8YU2F IU (1,1-dimethylpiperidin-1-ium-3-yl) 2-hydroxy-2,2-diphenylacetate DM8YU2F CA CAS 25990-43-6 DM8YU2F CB CHEBI:94411 DM8YU2F DE Gastrointestinal disease; Peptic ulcer DMX4GND ID DMX4GND DMX4GND DN Meperidine DMX4GND HS Approved DMX4GND SN Demarol; Demerol; Dolcontral; Dolosal; Dolsin; Isonipecain; Isonipecaine; Lidol; Lydol; Meperidol; Nemerol; Pethanol; Pethidin; Pethidine; Pethidineter; Pethidinum; Petidina; Petydyna; Phetidine; Piperosal; Pipersal; Meperidine solution; Methyl phenylpiperidine carbonic acid ethyl ester; Operidine EPJ I; Pethidine DBL; Petydyna [Polish]; Demerol (TN); Operidine EPJ-I; Pethidine (INN); Pethidine DBL (TN); Pethidinum [INN-Latin]; Petidina [INN-Spanish]; Ethyl 1-methyl-4-phenylisonipecotate; Ethyl 1-methyl-4-phenylpiperidine-4-carboxylate; N-Methyl-4-phenyl-4-carbethoxypiperidine; Isonipecotic acid, 1-methyl-4-phenyl-, ethyl ester; YIsonipecotic acid, 1-methyl-4-phenyl-, ethyl ester (8CI); 1-Methyl-4-phenyl-4-piperidinecarboxylic acid ethyl ester; 1-Methyl-4-phenyl-piperidin-4-carbon-saeure-aethylester; 1-Methyl-4-phenyl-piperidin-4-carbon-saeure-aethylester [German]; 1-Methyl-4-phenylisonipecotic acid, ethyl ester;1-Methyl-4-phenylpiperidine-4-carboxylic acid ethyl ester; 4-Carbethoxy-1-methyl-4-phenylpiperidine; 4-Piperidinecarboxylic acid, 1-methyl-4-phenyl-, ethyl ester DMX4GND CP Apotex Inc DMX4GND TC Anesthetics DMX4GND DT Small molecular drug DMX4GND PC 4058 DMX4GND MW 247.33 DMX4GND FM C15H21NO2 DMX4GND IC InChI=1S/C15H21NO2/c1-3-18-14(17)15(9-11-16(2)12-10-15)13-7-5-4-6-8-13/h4-8H,3,9-12H2,1-2H3 DMX4GND CS CCOC(=O)C1(CCN(CC1)C)C2=CC=CC=C2 DMX4GND IK XADCESSVHJOZHK-UHFFFAOYSA-N DMX4GND IU ethyl 1-methyl-4-phenylpiperidine-4-carboxylate DMX4GND CA CAS 57-42-1 DMX4GND CB CHEBI:6754 DMX4GND DE Pain DMFJH5Q ID DMFJH5Q DMFJH5Q DN Mephentermine DMFJH5Q HS Approved DMFJH5Q SN Mefenterdrin; Mefentermin; Mefentermina; Mephenterdrine; Mephenterdrinum; Mephenterminum; Mephetedrine; Mephine; Vialin; Wyamine; Wyfentermina; Mefentermina [INN-Spanish]; Mephentermine (INN); Mephentermine [INN:BAN]; Mephenterminum [INN-Latin]; N-Methylphentermine; WY-585; Mephentermine Sulfate (2:1); N,alpha,alpha-Trimethylbenzeneethanamine; N,alpha,alpha-Trimethylphenethylamine; Omega-Phenyl-tert-butyl-methylamine; N-Methyl-omega-phenyl-t-butylamine; N-Methyl-omega-phenyl-tert-butylamine; N,2-dimethyl-1-phenylpropan-2-amine; 2-Methyl-2-methylamino-1-phenylpropane; 2-Methylamino-2-methyl-1-phenylpropane DMFJH5Q CP Baxter Healthcare Corp Anesthesia Critical Care DMFJH5Q TC Vasoconstrictor Agents DMFJH5Q DT Small molecular drug DMFJH5Q PC 3677 DMFJH5Q MW 163.26 DMFJH5Q FM C11H17N DMFJH5Q IC InChI=1S/C11H17N/c1-11(2,12-3)9-10-7-5-4-6-8-10/h4-8,12H,9H2,1-3H3 DMFJH5Q CS CC(C)(CC1=CC=CC=C1)NC DMFJH5Q IK RXQCGGRTAILOIN-UHFFFAOYSA-N DMFJH5Q IU N,2-dimethyl-1-phenylpropan-2-amine DMFJH5Q CA CAS 100-92-5 DMFJH5Q CB CHEBI:6755 DMFJH5Q DE High blood pressure DM5UGDK ID DM5UGDK DM5UGDK DN Mephenytoin DM5UGDK HS Approved DM5UGDK SN Epiazin; Epilan; Fenantoin; Insulton; Mefenetoin; Mefenitoina; Mephenetoinum; Mephentoin; Mephenytoine; Mephenytoinum; Mesantoin; Mesdontoin; Mesontoin; Methoin; Methylphenetoin; Metydan; Phenantoin; Phenylethylmethylhydantoin; Sacerno; Sedantional; Sedantoin; Sedantoinal; Triantoin; Ydantoin; Methyl Phenetoin; Methyl hydantoin; MU2276000; Gerot-epilan; L-Mephenytoin; Mefenitoina [INN-Spanish]; Mephenytoin [USAN:INN]; Mephenytoine [INN-French]; Mephenytoinum [INN-Latin]; Mesantoin (TN); Phenetoin, Methyl;Mephenytoin (USP/INN); L-3-Methyl-5-ethyl-5-phenylhydantoin; (+-)-5-Ethyl-3-methyl-5-phenylhydantoin; (+-)-Mephenytoin; (-)-5-Ethyl-3-methyl-5-phenylhydantoin; 3-Ethylnirvanol; 3-Methyl-5, 5-ethylphenylhydantoin; 3-Methyl-5,5-ethylphenylhydantoin; 3-Methyl-5,5-phenylethylhydantoin; 3-Methyl-5-ethyl-5-phenylh; 3-Methyl-5-ethyl-5-phenylhydantoin; 5 Ethyl 3 Methyl 5 Phenylhydantoin; 5-Ethyl-3-methyl-5-phenyl-2,4(3H,5H)-imidazoledione; 5-Ethyl-3-methyl-5-phenyl-2,4-imidazolidinedione; 5-Ethyl-3-methyl-5-phenylhydantoin; 5-Ethyl-3-methyl-5-phenylimidazolidin-2,4-dione; 5-Ethyl-5-fenyl-3-methylhydantoin; 5-Ethyl-5-fenyl-3-methylhydantoin [Czech]; 5-ethyl-3-methyl-5-phenylimidazolidine-2,4-dione DM5UGDK CP Norvatis Phamaceuticals Corporation DM5UGDK TC Anticonvulsants DM5UGDK DT Small molecular drug DM5UGDK PC 4060 DM5UGDK MW 218.25 DM5UGDK FM C12H14N2O2 DM5UGDK IC InChI=1S/C12H14N2O2/c1-3-12(9-7-5-4-6-8-9)10(15)14(2)11(16)13-12/h4-8H,3H2,1-2H3,(H,13,16) DM5UGDK CS CCC1(C(=O)N(C(=O)N1)C)C2=CC=CC=C2 DM5UGDK IK GMHKMTDVRCWUDX-UHFFFAOYSA-N DM5UGDK IU 5-ethyl-3-methyl-5-phenylimidazolidine-2,4-dione DM5UGDK CA CAS 50-12-4 DM5UGDK CB CHEBI:6757 DM5UGDK DE Epilepsy DMUDWP9 ID DMUDWP9 DMUDWP9 DN Mepindolol DMUDWP9 HS Approved DMUDWP9 SN Mepindolol Bio Tsd; PH-851; Mepindolol, Pharmed/SB DMUDWP9 CP Pharmed Dr Liedtke GmbH DMUDWP9 DT Small molecular drug DMUDWP9 PC 71698 DMUDWP9 MW 262.35 DMUDWP9 FM C15H22N2O2 DMUDWP9 IC InChI=1S/C15H22N2O2/c1-10(2)16-8-12(18)9-19-15-6-4-5-14-13(15)7-11(3)17-14/h4-7,10,12,16-18H,8-9H2,1-3H3 DMUDWP9 CS CC1=CC2=C(N1)C=CC=C2OCC(CNC(C)C)O DMUDWP9 IK NXWGWUVGUSFQJC-UHFFFAOYSA-N DMUDWP9 IU 1-[(2-methyl-1H-indol-4-yl)oxy]-3-(propan-2-ylamino)propan-2-ol DMUDWP9 CA CAS 23694-81-7 DMUDWP9 CB CHEBI:135082 DMUDWP9 DE Angina pectoris DMH2NMY ID DMH2NMY DMH2NMY DN Mepivacaine DMH2NMY HS Approved DMH2NMY SN Carbocaine; Mepivacaina; Mepivacainum; Mepivicaine; Scandicain; Scandicaine; Scandicane; Arestocaine HCL; Carboplyin Dental; Isocaine HCL; Carbocaine (TN); Carboplyin Dental (TN); D-mepivacaine; DL-Mepivacaine; Mepivacaina [INN-Spanish]; Mepivacaine (INN); Mepivacaine [INN:BAN]; Mepivacainum [INN-Latin]; Polocaine (TN); Polocaine-Mpf; S-Ropivacaine Mesylate; D(-)-Mepivacaine; N-Methyl-2-pipecolic acid, 2,6-dimethylanilide; N-Methyl-2-pipecolic acid, 2,6-xylidide; N-Methylhexahydro-2-picolinic acid, 2,6-dimethylanilide; N-(2,6-Dimethylphenyl)-1-methyl-2-piperidinecarboxamide; N-(2,6-Dimethylphenyl)-1-methylpiperidine-2-carboxamide; (+-)-1-Methyl-2',6'-pipecoloxylidide; 1-METHYL-2',6'-PIPECOLOXYLIDIDE DMH2NMY CP Eastman Kodak Co DMH2NMY TC Anesthetics DMH2NMY DT Small molecular drug DMH2NMY PC 4062 DMH2NMY MW 246.35 DMH2NMY FM C15H22N2O DMH2NMY IC InChI=1S/C15H22N2O/c1-11-7-6-8-12(2)14(11)16-15(18)13-9-4-5-10-17(13)3/h6-8,13H,4-5,9-10H2,1-3H3,(H,16,18) DMH2NMY CS CC1=C(C(=CC=C1)C)NC(=O)C2CCCCN2C DMH2NMY IK INWLQCZOYSRPNW-UHFFFAOYSA-N DMH2NMY IU N-(2,6-dimethylphenyl)-1-methylpiperidine-2-carboxamide DMH2NMY CA CAS 96-88-8 DMH2NMY CB CHEBI:6759 DMH2NMY DE Analgesia DMW2GEJ ID DMW2GEJ DMW2GEJ DN Mepolizumab DMW2GEJ HS Approved DMW2GEJ SN Bosatria; Scoparianoside C; SB 240563; Immunoglobulin G1, anti-(human interleukin 5) (human-mouse monoclonal SB-240563 gamma1-chain), disulfide with human-mouse monoclonal SB-240563 kappa-chain, dimer; (2S,3S,4S,5R,6R)-6-[[(3S,4aR,6aR,6bS,8aS,14aR,14bR)-8a-carboxy-4,4,6a,6b,11,11,14b-heptamethyl-1,2,3,4a,5,6,7,8,9,10,12,13,14,14a-tetradecahydropicen-3-yl]oxy]-3,5-dihydroxy-4-[(2S,3R,4S,5R)-3,4,5-trihydroxyoxan-2-yl]oxyoxane-2-carboxylic acid DMW2GEJ CP MedImmune DMW2GEJ DT Monoclonal antibody DMW2GEJ DE Severe asthma; Asthma DMTL9IP ID DMTL9IP DMTL9IP DN Meprednisone DMTL9IP HS Approved DMTL9IP SN Betapar DMTL9IP CP Schering Corp Sub Schering Plough Corp DMTL9IP DT Small molecular drug DMTL9IP PC 5284587 DMTL9IP MW 372.5 DMTL9IP FM C22H28O5 DMTL9IP IC InChI=1S/C22H28O5/c1-12-8-16-15-5-4-13-9-14(24)6-7-20(13,2)19(15)17(25)10-21(16,3)22(12,27)18(26)11-23/h6-7,9,12,15-16,19,23,27H,4-5,8,10-11H2,1-3H3/t12-,15-,16-,19+,20-,21-,22-/m0/s1 DMTL9IP CS C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@H]3C(=O)C[C@@]2([C@]1(C(=O)CO)O)C)C DMTL9IP IK PIDANAQULIKBQS-RNUIGHNZSA-N DMTL9IP IU (8S,9S,10R,13S,14S,16S,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,9,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,11-dione DMTL9IP CA CAS 1247-42-3 DMTL9IP CB CHEBI:135573 DMTL9IP DE Chronic obstructive pulmonary disease DMHM93Y ID DMHM93Y DMHM93Y DN Meprobamate DMHM93Y HS Approved DMHM93Y SN meprobamate; Meprospan; Meprobamat; Equanil; Miltown; Amepromat; Meprocompren; Meproban; Tranmep; Meprobam; Dapaz; Metractyl; Meprotabs; Meprosin; Meprodil; Mepiosine; Libiolan; Crestanil; Calmiren; Ayeramate; Andaksin; Anatimon; Anathylmon; Holbamate; Despasmol; Cirponyl; Biobamat; Neuramate; Metranquil; Meprocon; Mepantin; Lepetown; Ipsotian; Equilium; Equatrate; Carbaxin; Biobamate; Ansiatan; Anastress; Miltamato; Meprotil; Meprotan; Meprosan; Meproleaf; Meprindon; Mepranil; Mepavlon; Margonil; Harmonin; Dicandiol; Calmadin; Auxietil; Anxietil; Ansiowas; Amepromat; Amosene; Andaxin; Aneural; Aneurol; Aneusral; Aneuxal; Aneuxral; Ansietan; Ansil; Anural; Anzil; Apascil; Apasil; Appetrol; Arcoban; Arpon; Artolon; Ataraxine; Atraxin; Ayermate; Bamate; Brobamate; Calmax; Cirpon; Coprobate; Cypron; Cyrpon; Deprol; Diron; Diurnal; Diurnaldiverondormabrol; Diveron; Dormabrol; Ecuanil; Edenal; Enorden; Epicur; Epikur; Equinil; Equitar; Erina; Estasil; Gadexyl; Gagexyl; Hartol; Kessobamate; Klort; Larten; Lepenil; Letyl; Mendel; Mepamtin; Meposed; Mepriam; Meprin; Meprobamato; Meprobamatum; Meprodiol; Meprol; Meprosa; Meprotanum; Meproten; Meprovan; Meprovanmeprozine; Meprozine; Meptran; Meptranactylmilprem; Micrainin; Milpath; Milprem; Miltann; Miltaun; Miltuan; Miltwon; Misedant; Morbam; Multaun; Nephentine; Nervonus; Oasil; Optarket;Orlevol; Orolevol; Pancalma; Panediol; Pankalma; Pathibamate; Paxin; Pensive; Perequietil; Perequil; Perquietil; Pertranquil; Pimal; Placidon; Placitate; Prequil; Probamato; Probamyl; Probate; Procalmadiol; Procalmadol; Procalmidol; Procarbamide; Promate; Promato; Proquanil; Protran; Quaname; Quanane; Quanil; Quietidon; Quivet; Rastenil; Reostral; Restenil; Restenyl; Restinal; Restinil; Robamate;Sadanyl; Scolazil; Sedabamate; Sedanil; Sedanyl; Sedazil; Sedoquil; Sedoselecta; Selene; Seril; Setran; Shalvaton; Sowell; Spantran; Stensolo; Tamate; Tensol; Tensonal; Trancot; Trankvilan; Tranlisant; Tranquilan; Tranquilate; Tranquilax; Tranquiline; Tranquilsan; Tranquinol; Trelmar; Urbil; Urbilat; Vistabamate; Wardamate; Wyseals; Zirpon; Component of Appetrol; Component of Bamadex; Component of Equalysen; Component of Milpath; Component of Milprem; Component of Miltrate; Equanil suspension; Meprobamat [German]; Meprobamate and Aspirin Tablets; Meprobamato [Italian]; Meprobamic acid; Meprocon CMC; Solevione anastress; Bamd 400; Bamo 400; Canquil 400; Miltown 600; PMB 200; PMB 400; Apo-Meprobamate; Appetrol-Sr; Canquil-400; Component of PMB-400; Equanil (TN); Equazine-M; Fas-Cile; Fas-Cile 200; Kesso-Bamate; Mar-Bate; Meprin (VAN); Mepro-Aspirin; Mepro-analgesic; Meprobamato [INN-Spanish]; Meprobamatum [INN-Latin]; Meprospan (TN); Meprospan-200; Meprospan-400; Milprem-200; Milprem-400; Miltown (TN); My-trans; Neo-Tran; PMB-200; PMB-400; Pan-tranquil; Q-Gesic; SK-Bamate; Tranquiline (Intra); Vio-Bamate; Cap-O-Tran; Carbamic acid 2-methyl-2-propyltrimethylene ester; Meprobamate (JAN/USP/INN); Meprobamate [USAN:INN:BAN:JAN]; Carbamic acid, 2-methyl-2-propyltrimethylene ester; [2-(carbamoyloxymethyl)-2-methylpentyl] carbamate; {2-[(carbamoyloxy)methyl]-2-methylpentyl} carbamate; 1,3-Propanediol, 2-methyl-2-propyl-, 1,3-dicarbamate; 1,3-Propanediol, 2-methyl-2-propyl-, dicarbamate; 2,2-Di(carbamoyloxymethyl)pentane; 2-Methyl-2-n-propyl-1,3-propanediol dicarbamate; 2-Methyl-2-propyl-1,3-propanediol dicarbamate; 2-Methyl-2-propylpropane-1,3-diol dicarbamate; 2-Methyl-2-propyltrimethylene carbamate; 2-Metil-2-n-propil-1,3-propanediol dicarbamato; 2-Metil-2-n-propil-1,3-propanediol dicarbamato [Spanish]; 2-[(carbamoyloxy)methyl]-2-methylpentyl carbamate; 3P Bamate; KAI-1455 DMHM93Y CP Wyeth Pharmaceuticals DMHM93Y TC Antianxiety Agents DMHM93Y DT Small molecular drug DMHM93Y PC 4064 DMHM93Y MW 218.25 DMHM93Y FM C9H18N2O4 DMHM93Y IC InChI=1S/C9H18N2O4/c1-3-4-9(2,5-14-7(10)12)6-15-8(11)13/h3-6H2,1-2H3,(H2,10,12)(H2,11,13) DMHM93Y CS CCCC(C)(COC(=O)N)COC(=O)N DMHM93Y IK NPPQSCRMBWNHMW-UHFFFAOYSA-N DMHM93Y IU [2-(carbamoyloxymethyl)-2-methylpentyl] carbamate DMHM93Y CA CAS 57-53-4 DMHM93Y CB CHEBI:6761 DMHM93Y DE Malaria; Anxiety disorder; Ischemic reperfusion injury DMPSB8F ID DMPSB8F DMPSB8F DN MEPTAZINOL DMPSB8F HS Approved DMPSB8F SN MEPTAZINOL HYDROCHLORIDE; 59263-76-2; Meptazinol HCl; Meptazinol (hydrochloride); 3-(3-Ethylhexahydro-1-methyl-1H-azepin-3-yl)phenol hydrochloride; Meptazinol hydrochloride [USAN]; EINECS 261-683-0; WY-22811 hydrochloride; IL-22811 hydrochloride; WY 22811; IL 22811; 3-(3-ethyl-1-methylazepan-3-yl)phenol hydrochloride; m-(3-Ethyl-1-methyl-hexahydro-1H-azepin-3-yl)phenol hydrochloride; m-(3-Ethylhexahydro-1-methyl-1H-azepin-3-yl)phenol hydrochloride; Phenol, m-(3-ethyl-1-methyl-hexahydro-1H-azepin-3-yl)-, hydrochloride DMPSB8F DT Small molecular drug DMPSB8F PC 41049 DMPSB8F MW 233.35 DMPSB8F FM C15H23NO DMPSB8F IC InChI=1S/C15H23NO/c1-3-15(9-4-5-10-16(2)12-15)13-7-6-8-14(17)11-13/h6-8,11,17H,3-5,9-10,12H2,1-2H3 DMPSB8F CS CCC1(CCCCN(C1)C)C2=CC(=CC=C2)O DMPSB8F IK JLICHNCFTLFZJN-UHFFFAOYSA-N DMPSB8F IU 3-(3-ethyl-1-methylazepan-3-yl)phenol DMPSB8F CA CAS 54340-58-8 DMPSB8F CB CHEBI:91484 DMPSB8F DE Pain DMB4SFH ID DMB4SFH DMB4SFH DN Mepyramine DMB4SFH HS Approved DMB4SFH SN Anhistabs; Anhistol; Antalergan; Antallergan; Antamine; Anthisan; Copsamine; Coradon; Dipane; Dorantamin; Harvamine; Histacap; Histalon; Histapyran; Histasan; Isamin; Kriptin; Maranhist; Mepiramina; Mepiramine; Mepyramin; Mepyraminum; Mepyren; Neoantergan; Neobridal; Nyscaps; PYRA; Paraminyl; Parmal; Pyramal; Pyranisamine; Pyrilamide; Pyrilamine; Stamine; Stangen; Statomin; Thylogen; Mepyramin [German]; Pyrilamine salt with fine resin; RP 2786; [3H]mepyramine; [3H]pyrilamine; Afko-Hist; Mepiramina [INN-Spanish]; Mepyramine (INN); Mepyramine [INN:BAN]; Mepyraminum [INN-Latin]; Neo-Bridal; Wait's green mountain antihistamine; R.d. 2786; P-Methoxybenzyl-alpha-pyridyl-dimethyl-aethylendiamin; P-Methoxybenzyl-alpha-pyridyl-dimethyl-aethylendiamin [German]; P-Methoxy-benzyl-.alpha.-pyridyl-dimethyl-aethylendiamin; N-[2-(dimethylamino)ethyl]-N-[(4-methoxyphenyl)methyl]pyridin-2-amine; N-p-Methoxybenzyl-N',N'-dimethyl-N-alpha-pyridylethylenediamine; N-para-Methoxybenzyl-N',N'-dimethyl-N-alpha-pyridylethylenediamine; N-(p-Methoxybenzyl)-N',N'-dimethyl-N-2-pyridylethylenediamine; N-(para-Methoxybenzyl)-N',N'-dimethyl-N-2-pyridylethylenediamine; N',N'-Dimethyl-N-(p-methoxybenzyl)-N-(2-pyridyl)ethylenediamine; N-(p-Methoxybenzyl)-N',N'-dimethyl-N-(alpha-pyridyl)ethylenediamine; N-(p-Methoxybenzyl)-N',N'-dimethyl-N-2-(pyridylethylene)diamine; N-Dimethylamino-aethyl-N-p-methoxy-benzyl-.alpha.-amino-pyridin-maleat; N-(p-Methoxybenzyl)-N',N'-dimethyl-N-(alpha.-pyridyl)ethylenediamine; N-(p-Methoxybenzyl)-N',N'-dimethyl-N-2-pyridyl-1,2-ethanediamine; N-[(4-methoxyphenyl)methyl]-N',N'-dimethyl-N-2-pyridinyl-1,2-ethanediamine; N-((4-Methoxyphenyl)methyl)-N',N'-dimethyl-N-2-pyridinyl-1,2-ethanediamine; N-(4-methoxybenzyl)-N',N'-dimethyl-N-pyridin-2-ylethane-1,2-diamine; N,N-dimethyl-N'-{[4-(methyloxy)phenyl]methyl}-N'-pyridin-2-ylethane-1,2-diamine; 2-((2-(Dimethylamino)ethyl)-(p-methoxybenzyl)amino)pyridine; 2-((p-Methoxybenzyl)(2-(dimethylamino)ethyl)amino)pyridine; 2-[(p-Methoxybenzyl)[2-(dimethylamino)ethyl]amino]pyridine; 2-[[2-(Dimethylamino)ethyl](p-methoxybenzyl)amino]pyridine; 2-[[2-(Dimethylamino)ethyl]-(p-methoxybenzyl)amino]pyridine; 2-dimethylaminoethyl-p-anisyl-(2-pyridyl)amine DMB4SFH TC Antiasthmatic Agents DMB4SFH DT Small molecular drug DMB4SFH PC 4992 DMB4SFH MW 285.4 DMB4SFH FM C17H23N3O DMB4SFH IC InChI=1S/C17H23N3O/c1-19(2)12-13-20(17-6-4-5-11-18-17)14-15-7-9-16(21-3)10-8-15/h4-11H,12-14H2,1-3H3 DMB4SFH CS CN(C)CCN(CC1=CC=C(C=C1)OC)C2=CC=CC=N2 DMB4SFH IK YECBIJXISLIIDS-UHFFFAOYSA-N DMB4SFH IU N'-[(4-methoxyphenyl)methyl]-N,N-dimethyl-N'-pyridin-2-ylethane-1,2-diamine DMB4SFH CA CAS 91-84-9 DMB4SFH CB CHEBI:6762 DMB4SFH DE Allergy DM7F5OW ID DM7F5OW DM7F5OW DN Mepyramine maleate DM7F5OW HS Approved DM7F5OW SN Pyrilamine maleate; PYRILAMINE MALEATE; 59-33-6; Anisopyradamine; Histosol; Minihist; Diaminide maleate; Paraminyl maleate; Renstamin; Histatex; Pyraninyl; Pymafed; Paramal; Histine; Antihist; Histan; Pyramal maleate; Stangen maleate; Thylogen maleate; Anthisan maleate; Statomin maleate; Pyra-Maleate; Pyrilamine maleate salt; Neoantergan maleate; Pyranisamine maleate; Pyranilamine maleate; Kriptin maleate; Neo-Antergan maleate; Pyra maleate; Prefrin A; Dorantamin maleate; 2786 RP maleate; Histavet-P (veterinary); Mepyramine hydrogen; Enrumay; Pyma; Component of Pyrdex; Mepiramine maleate; Mepyramine hydrogen maleinate; Mepyramine maleate salt; Midol Maximum Strength PMS; Pyranilamine m aleate; Pyrilamine maleate [USAN]; P 5514; Component of Endotussin-NN; Histavet-P; Pymafed (TN); Pyrilamine maleate (USP); PYRILAMINE MALEATE (SEE ALSO PYRILAMINE, CAS 91-84-9); N-Dimethylaminoethyl-N-p-methoxy-alpha-aminopyridine maleate; N-(dimethylaminoethyl)-N-(p-methoxyphenyl)-alpha-aminopyridine maleate; N-(Dimethylamino)ethyl-N-(p-methoxy)-alpha-aminopyridine maleate; N-p-Methoxybenzyl-N',N'-dimethyl-N-alpha-pyridylethylenediamine maleate; Pyridine, 2-[[2-(dimethylamino)ethyl](p-methoxybenzyl)amino]-, maleate (1:1); N,N-Dimethyl-N'-(4-methoxybenzyl)-N'-(2-pyridyl)ethylenediamine maleate; N-(p-me thoxybenzyl)-N',N'-dimethyl-N-(alpha-pyridyl)ethylenediamine maleate; N-(p-methoxybenzyl)-N',N'-dimethyl-N-(alpha-pyridyl)ethylenediamine maleate; Pyridine, 2-((2-(dimethylamino)ethyl)(p-methoxybenzyl)amino)-, maleate (1:1); N-(4-Methoxyphenyl)methyl-N inverted exclamation marka,Ninverted exclamation marka-dimethyl-N-(2-pyridinyl)-1,2-ethanediamine maleate salt; N-(p-Methoxybenzyl)-N',N'-dimethyl-N-alpha-pyridylethylenediamine maleate; N-(p-Methoxybenzyl)-N,N'-dimethyl-N-2-pyridyl-1,2-ethanediamine, maleic acid salt; N-(4-Methoxyphenyl)methyl-N',N'-dimethyl-N-(2-pyridinyl)-1,2-ethanediamine maleate salt; N-(4-methoxybenzyl)-N',N'-dimethyl-N-pyridin-2-ylethane-1,2-diamine but-2-enedioate; N,N-dimethyl-N'-{[4-(methyloxy)phenyl]methyl}-N'-pyridin-2-ylethane-1,2-diamine (2Z)-but-2-enedioate; 1,2-Ethanediamine, N-((4-methoxyphenyl)methyl)-N',N'-dimethyl-N-2-pyridinyl-, (2Z)-2-butenedioate (1:1); 1,2-Ethanediamine, N-((4-methoxyphenyl)methyl)-N',N'-dimethyl-N-2-pyridinyl-, (Z)-2-butenedioate (1:1); 1,2-Ethanediamine, N-[(4-methoxyphenyl)methyl]-N',N'-dimethyl-N-2-pyridinyl-, (Z)-2-butenedioate (1:1); 1,2-Ethanediamine, N1-((4-methoxyphenyl)methyl)-N2,N2-dimethyl-N1-2-pyridinyl-, (2Z)-2-butenedioate (1:1); 2-((2-(Dimethylamino)ethyl)(p-methoxybenzyl)amino)pyridine bimaleate; 2-((2-(Dimethylamino)ethyl)(p-methoxybenzyl)amino)pyridine maleate; 2-((2-(Dimethylamino)ethyl)(p-methoxybenzyl)amino)pyridine maleate (1:1); 2-((2-(dimethylamino)ethyl)(p-methoxybenzyl)amino)pyridine maleate; 2-[[2-(Dimethylamino)ethyl](p-methoxybenzyl)amino]pyridine bimaleate; 2-[[2-(Dimethylamino)ethyl](p-methoxybenzyl)amino]pyridine maleate; Pyrilamine Maleate DM7F5OW TC Antiasthmatic Agents DM7F5OW DT Small molecular drug DM7F5OW PC 5284451 DM7F5OW MW 401.5 DM7F5OW FM C21H27N3O5 DM7F5OW IC InChI=1S/C17H23N3O.C4H4O4/c1-19(2)12-13-20(17-6-4-5-11-18-17)14-15-7-9-16(21-3)10-8-15;5-3(6)1-2-4(7)8/h4-11H,12-14H2,1-3H3;1-2H,(H,5,6)(H,7,8)/b;2-1- DM7F5OW CS CN(C)CCN(CC1=CC=C(C=C1)OC)C2=CC=CC=N2.C(=C\\C(=O)O)\\C(=O)O DM7F5OW IK JXYWFNAQESKDNC-BTJKTKAUSA-N DM7F5OW IU (Z)-but-2-enedioic acid;N'-[(4-methoxyphenyl)methyl]-N,N-dimethyl-N'-pyridin-2-ylethane-1,2-diamine DM7F5OW CA CAS 59-33-6 DM7F5OW DE Headache; Allergy DMAFBCY ID DMAFBCY DMAFBCY DN Mequitazine DMAFBCY HS Approved DMAFBCY SN Butix; Instotal; Kitazemin; Mequitazina; Mequitazinum; Metaplexan; Mircol; Primalan; Quitadrill; Vigigan; Virginan; Zesulan; Italfarmaco brand of mequitazine; Mequitazina [Spanish]; Mequitazine hydrochloride; Pierre Fabre brand of mequitazine; LM 209; Kitazemin (TN); LM-209; Mequitazina [INN-Spanish]; Mequitazinum [INN-Latin]; Mequitazine (JP15/INN); Mequitazine [INN:BAN:DCF:JAN]; Mequitazine tartrate, (R-(R*,R*))-isomer; 10-(1-Azabicyclo[2.2.2]oct-3-ylmethyl)-10H-phenothiazine; 10-(1-azabicyclo(2.2.2)oct-8-ylmethyl)phenothiazine; 10-(1-azabicyclo[2.2.2]octan-3-ylmethyl)phenothiazine; 10-(3-Quinuclidinylmethyl)phenothiazine; 10H-Phenothiazine, 10-(1-azabicyclo(2.2.2)oct-3-ylmethyl)-(9CI); 3-Methylquinuclidinyl-10-phenothiazine DMAFBCY CP Pierre Fabre SA DMAFBCY TC Antihistamines DMAFBCY DT Small molecular drug DMAFBCY PC 4066 DMAFBCY MW 322.5 DMAFBCY FM C20H22N2S DMAFBCY IC InChI=1S/C20H22N2S/c1-3-7-19-17(5-1)22(18-6-2-4-8-20(18)23-19)14-16-13-21-11-9-15(16)10-12-21/h1-8,15-16H,9-14H2 DMAFBCY CS C1CN2CCC1C(C2)CN3C4=CC=CC=C4SC5=CC=CC=C53 DMAFBCY IK HOKDBMAJZXIPGC-UHFFFAOYSA-N DMAFBCY IU 10-(1-azabicyclo[2.2.2]octan-3-ylmethyl)phenothiazine DMAFBCY CA CAS 29216-28-2 DMAFBCY CB CHEBI:31821 DMAFBCY DE Allergic rhinitis; Respiratory disease DMTM2IK ID DMTM2IK DMTM2IK DN Mercaptopurine DMTM2IK HS Approved DMTM2IK SN 6-mercaptopurine; Ismipur; Leukerin; Leupurin; Mercaleukim; Mercaleukin; Mercaptopurin; Mercaptopurina; Mercaptopurinum; Mercapurin; Merkaptopuryna; Mern; Purimethol; Purinethiol; Purinethol; Thiopurine; Leupu rin; Mercaptopurin [German]; Mercaptopurina Wellcome; Mercaptopurine anhydrous; Merkaptopuryna [Polish]; Puri Nethol; BW 57 323H; Glaxo Wellcome Brand of 6 Mercaptopurine; GlaxoSmithKline Brand of 6 Mercaptopurine; M0063; NCIMech_000025; PM6; Wellcome Brand of 6 Mercaptopurine; Glaxo Wellcome Brand of 6-Mercaptopurine; GlaxoSmithKline Brand of 6-Mercaptopurine; Mercaptopurina [INN-Spanish]; Mercaptopurine (INN); Mercaptopurine (VAN); Mercaptopurine (anhydrous); Mercaptopurinum [INN-Latin]; Puri-Nethol; Purineantimetabolite: inhibits nucleic acid replication; Purinethol (TN); U-4748; Wellcome Brand of 6-Mercaptopurine; AG-670/31547064; Purine-6-thiol; Leukerin, 99%-Carc; Purine-6(1H)-thione; Purinethol, 6-mercaptopurine, 6-MP, Mercaptopurine; 6 MP; 6 Mercaptopurine Monohydrate; 6 Thiohypoxanthine; 6 Thiopurine; 6-MERCAPTOPURINE MONOHYDRATE; 6-MP; 6-Mercaptopurin; 6-Merkaptopurin; 6-Merkaptopurin [Czech]; 6-Purinethiol; 6-Thiohypoxanthine; 6-Thiopurine; 6-Thioxopurine; Mercaptopurine (Purine analog) DMTM2IK CP Novopharm DMTM2IK TC Anticancer Agents DMTM2IK DT Small molecular drug DMTM2IK PC 667490 DMTM2IK MW 152.18 DMTM2IK FM C5H4N4S DMTM2IK IC InChI=1S/C5H4N4S/c10-5-3-4(7-1-6-3)8-2-9-5/h1-2H,(H2,6,7,8,9,10) DMTM2IK CS C1=NC2=C(N1)C(=S)N=CN2 DMTM2IK IK GLVAUDGFNGKCSF-UHFFFAOYSA-N DMTM2IK IU 3,7-dihydropurine-6-thione DMTM2IK CA CAS 50-44-2 DMTM2IK CB CHEBI:2208 DMTM2IK DE Acute lymphoblastic leukaemia; Crohn disease DM0HS92 ID DM0HS92 DM0HS92 DN Merimepodib DM0HS92 HS Approved DM0HS92 SN Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid DM0HS92 CP GSK DM0HS92 DT Small molecular drug DM0HS92 PC 153241 DM0HS92 MW 452.5 DM0HS92 FM C23H24N4O6 DM0HS92 IC InChI=1S/C23H24N4O6/c1-30-20-10-17(5-6-19(20)21-12-24-14-32-21)27-22(28)26-16-4-2-3-15(9-16)11-25-23(29)33-18-7-8-31-13-18/h2-6,9-10,12,14,18H,7-8,11,13H2,1H3,(H,25,29)(H2,26,27,28)/t18-/m0/s1 DM0HS92 CS COC1=C(C=CC(=C1)NC(=O)NC2=CC=CC(=C2)CNC(=O)O[C@H]3CCOC3)C4=CN=CO4 DM0HS92 IK JBPUGFODGPKTDW-SFHVURJKSA-N DM0HS92 IU [(3S)-oxolan-3-yl] N-[[3-[[3-methoxy-4-(1,3-oxazol-5-yl)phenyl]carbamoylamino]phenyl]methyl]carbamate DM0HS92 CA CAS 198821-22-6 DM0HS92 DE Hepatitis C virus infection; Breast cancer; Hepatitis virus infection; Head and neck cancer; Gastric adenocarcinoma DM62UHC ID DM62UHC DM62UHC DN Meropenem DM62UHC HS Approved DM62UHC SN MEPM; MERONEM; Meropen; Merrem; Meropenem anhydrous; Mepem (TN); Meronem (TN); Meropen (TN); Meropenem (INN); Merrem (TN); Neopenem (TN); SM-7338; Meronem; Merrem I.V. (TN); (1R,5S,6S)-2-[(3S,5S)-5-(dimethylaminocarbonyl)pyrrolidin-3-ylthio]-6-[(R)-1-hydroxyethyl]-1-methylcarbapen-2-em-3-carboxylic acid trihydrate; (2S,3R,4R)-2-[(1S,2R)-1-carboxy-2-hydroxypropyl]-4-{[(3S,5R)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]sulfanyl}-3-methyl-3,4-dihydro-2H-pyrrole-5-carboxylic acid; (4R,5S,6S)-3-[(3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]sulfanyl-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; (4R,5S,6S)-3-{[(3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]thio}-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; (5S,6S)-3-((3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-ylthio)-6-((S)-1-hydroxyethyl)-4-methyl-7-oxo-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylic acid; (6S)-2-{[(3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]sulfanyl}-6-[(1R)-1-hydroxyethyl]-1beta-methyl-2,3-didehydro-1-carbapenam-3-carboxylic acid DM62UHC CP AstraZeneca DM62UHC TC Antibiotics DM62UHC DT Small molecular drug DM62UHC PC 441130 DM62UHC MW 383.5 DM62UHC FM C17H25N3O5S DM62UHC IC InChI=1S/C17H25N3O5S/c1-7-12-11(8(2)21)16(23)20(12)13(17(24)25)14(7)26-9-5-10(18-6-9)15(22)19(3)4/h7-12,18,21H,5-6H2,1-4H3,(H,24,25)/t7-,8-,9+,10+,11-,12-/m1/s1 DM62UHC CS C[C@@H]1[C@@H]2[C@H](C(=O)N2C(=C1S[C@H]3C[C@H](NC3)C(=O)N(C)C)C(=O)O)[C@@H](C)O DM62UHC IK DMJNNHOOLUXYBV-PQTSNVLCSA-N DM62UHC IU (4R,5S,6S)-3-[(3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]sulfanyl-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid DM62UHC CA CAS 96036-03-2 DM62UHC CB CHEBI:43968 DM62UHC DE Bacterial infection DMOVAIX ID DMOVAIX DMOVAIX DN Meropenem + vaborbactam DMOVAIX HS Approved DMOVAIX SN Vabomere; Meropenem / vaborbactam; Meropenem and vaborbactam; Meropenem mixture with vaborbactam; Carbavance DMOVAIX CP The Medicines Company/Rempex Pharmaceuticals DMOVAIX PC 86298703 DMOVAIX MW 680.6 DMOVAIX FM C29H41BN4O10S2 DMOVAIX IC InChI=1S/C17H25N3O5S.C12H16BNO5S/c1-7-12-11(8(2)21)16(23)20(12)13(17(24)25)14(7)26-9-5-10(18-6-9)15(22)19(3)4;15-11(7-9-2-1-5-20-9)14-10-4-3-8(6-12(16)17)19-13(10)18/h7-12,18,21H,5-6H2,1-4H3,(H,24,25);1-2,5,8,10,18H,3-4,6-7H2,(H,14,15)(H,16,17)/t7-,8-,9+,10+,11-,12-;8-,10-/m10/s1 DMOVAIX CS B1([C@H](CC[C@H](O1)CC(=O)O)NC(=O)CC2=CC=CS2)O.C[C@@H]1[C@@H]2[C@H](C(=O)N2C(=C1S[C@H]3C[C@H](NC3)C(=O)N(C)C)C(=O)O)[C@@H](C)O DMOVAIX IK SDJYWZHQLNEXKV-SSHSFQATSA-N DMOVAIX IU (4R,5S,6S)-3-[(3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]sulfanyl-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid;2-[(3R,6S)-2-hydroxy-3-[(2-thiophen-2-ylacetyl)amino]oxaborinan-6-yl]acetic acid DMOVAIX CA CAS 2031124-72-6 DMOVAIX DE Urinary tract infection; Intra-abdominal infection DMOL5IU ID DMOL5IU DMOL5IU DN Mesalazine DMOL5IU HS Approved DMOL5IU SN Apriso; Asacol; Asacolitin; Asacolon; Asalit; Ascolitin; Canasa; Claversal; Fisalamine; Fivasa; Iialda; Ipocol; Lialda; Lixacol; Mesacol; Mesalamine; Mesalazina; Mesalazinum; Mesasal; Mesavance; Mesavancol; Mezavant; Pentacol; Pentasa; Rowasa; Salofalk; Salozinal; SfRowasa; Allphar Brand of Mesalamine; Antigen Brand of Mesalamine; Asacol HD; Axcan Brand of Mesalamine; Byk Brand of Mesalamine; Celltech Brand of Mesalamine; Falk Brand of Mesalamine; Farmasa Brand of Mesalamine; Ferring Brand of Mesalamine; GlaxoSmithKline Brand of Mesalamine; Henning Berlin Brand of Mesalamine; M Aminosalicylic Acid; Merckle Brand of Mesalamine; Mesalamine Hydrochloride; Mesalamine Monosodium Salt; Mesalamine [USAN]; Mesalazina[Spanish]; Mesalazine MMX; Mesalazinum [Latin]; Meta Aminosalicylic Acid; Mezavant XL; Minosalicylic acid; Norgine Brand of Mesalamine; Novopharm Brand of Mesalamine; Provalis Brand of Mesalamine; Sanofi Synthelabo Brand of Mesalamine; Schering Plough Brand of Mesalamine; SmithKline Brand of Mesalamine; Solvay Brand of Mesalamine; Yamanouchi Brand of Mesalamine; Novo 5 ASA; Novo5 ASA; AJG-501; Apriso (TN); Asacol (TN); Canasa (TN); Hydrochloride, Mesalamine; Iialda (TN); Ipocal (TN); Lialda (TN); M-A; M-Aminosalicylic acid; MAX-002; MD-0901; Masacol (TN); Mesalamine (USP); Meta-AminosalicylicAcid; Monosodium Salt, Mesalamine; Novo-5 ASA; P-Aminosalicylsaeure; P-Aminosalicylsaeure [German]; Pentasa (TN); Procter & Gamble Brand of Mesalamine; Rowasa (TN); SPD-476; SPD-480; Salofalk (TN); Salofalk Granu-Stix; Schering-Plough Brand of Mesalamine; Z-206; Mesalazine (JAN/INN); Salicylic acid, 5-amino-(8CI); 2-Hydroxy-5-aminobenzoic acid; 3-carboxy-4-hydroxyaniline; 5 Aminosalicylate; 5 Aminosalicylic Acid; 5-AS; 5-ASA; 5-Amino-2-hydroxybenzoic acid; 5-Aminosalicylate; 5-Aminosalicylic acid; 5-amino-2-hydroxy-benzoic acid; 5-aminosalicylic acid, Mesalazine, Asacol, Pentasa, Canasa, Mesalamine DMOL5IU TC Antiinflammatory Agents DMOL5IU DT Small molecular drug DMOL5IU PC 4075 DMOL5IU MW 153.14 DMOL5IU FM C7H7NO3 DMOL5IU IC InChI=1S/C7H7NO3/c8-4-1-2-6(9)5(3-4)7(10)11/h1-3,9H,8H2,(H,10,11) DMOL5IU CS C1=CC(=C(C=C1N)C(=O)O)O DMOL5IU IK KBOPZPXVLCULAV-UHFFFAOYSA-N DMOL5IU IU 5-amino-2-hydroxybenzoic acid DMOL5IU CA CAS 89-57-6 DMOL5IU CB CHEBI:6775 DMOL5IU DE Ulcerative colitis DM2ZGAN ID DM2ZGAN DM2ZGAN DN Mesoridazine DM2ZGAN HS Approved DM2ZGAN SN Calodal; Lidanar; Lidanil; Mesoridazina; Mesoridazinum; Serentil; Serentil Concentrate; Thioridazien thiomethyl sulfoxide; Thioridazine monosulfoxide analog; Thioridazine thiomethyl sulfoxide; TPS 23; Tps23; Lidanar (TN); Mesoridazina [INN-Spanish]; Mesoridazinum [INN-Latin]; NC-123; Serentil (TN); TPS-23; Mesoridazine (USAN/INN); Mesoridazine [USAN:BAN:INN]; T-2-SO; THD-2-SO; Thioridazine-2-sulfoxide; 10-(2(1-Methyl-2-piperidyl)ethyl)-2-(methylsulfinyl)-phenothiazine; 10-(2(1-Methyl-2-piperidyl)ethyl)-2-(methylsulfinyl)phenothiazine; 10-(2-(1-Methyl-2-piperidinyl)ethyl)-2-(methylsulfinyl)-10H-phenothiazine; 10-(2-(1-Methyl-2-piperidyl)ethyl)-2-methylsulfinyl phenothiazine; 10-[2(1-Methyl-2-piperidyl)ethyl]-2-(methylsulfinyl)phenothiazine; 10-[2-(1-Methyl-2-piperidyl)ethyl]-2-methylsulfinyl phenothiazine; 10-[2-(1-methylpiperidin-2-yl)ethyl]-2-(methylsulfinyl)-10H-phenothiazine; 10-[2-(1-methylpiperidin-2-yl)ethyl]-2-methylsulfinylphenothiazine DM2ZGAN CP Norvatis Phamaceuticals Corporation DM2ZGAN TC Antipsychotic Agents DM2ZGAN DT Small molecular drug DM2ZGAN PC 4078 DM2ZGAN MW 386.6 DM2ZGAN FM C21H26N2OS2 DM2ZGAN IC InChI=1S/C21H26N2OS2/c1-22-13-6-5-7-16(22)12-14-23-18-8-3-4-9-20(18)25-21-11-10-17(26(2)24)15-19(21)23/h3-4,8-11,15-16H,5-7,12-14H2,1-2H3 DM2ZGAN CS CN1CCCCC1CCN2C3=CC=CC=C3SC4=C2C=C(C=C4)S(=O)C DM2ZGAN IK SLVMESMUVMCQIY-UHFFFAOYSA-N DM2ZGAN IU 10-[2-(1-methylpiperidin-2-yl)ethyl]-2-methylsulfinylphenothiazine DM2ZGAN CA CAS 5588-33-0 DM2ZGAN CB CHEBI:6780 DM2ZGAN DE Schizophrenia DMG3F94 ID DMG3F94 DMG3F94 DN Mestranol DMG3F94 HS Approved DMG3F94 SN Devocin; Menophase; Mestranolo; Mestranolum; Norquen; Ovastol; Component of Norinyl; Component of Norquen; Component of Ovulen; Ethynylestradiol methyl ether; Mestranol [Steroidal oestrogens]; Mestranolo [DCIT]; EE3ME; Ethinyl Estradiol 3 Methyl Ether; SC 4725; Component of Ortho-Novum; Delta-MVE; EE(sub3)ME; EthinylEstradiol 3-Methyl Ether; Ethinylestradiol 3-methyl ether; Ethinyloestradiol 3-methyl ether; Ethynylestradiol 3-methyl ether; Ethynyloestradiol 3-methyl ether; Inostral (steroid); Mestranolum [INN-Latin]; Mestranol (JP15/USP/INN); Mestranol [USAN:INN:BAN:JAN]; Alpha.-19-Norpregna-1,3,5(10)-trien-20-yn-17-ol, 3-meth; (17beta)-17-ethynyl-3-(methyloxy)estra-1,3,5(10)-trien-17-ol; 17-Ethynyl-3-methoxy-1,3,5(10)-oestratien-17-beta-ol; 17-Ethynyl-3-methoxyestra-1,3,5(10)-trien-17-ol; 17-Ethynylestradiol 3-methyl ether; 17-Ethynyloestradiol 3-methyl ether; 17-alpha-Ethinyl estradiol 3-methyl ether; 17-alpha-Ethinyl oestradiol 3-methyl ether; 17-alpha-Ethynyl-3-methoxy-1,3,5(10)-estratrien-17-beta-ol; 17-alpha-Ethynyloestradiol methyl ether; 17-ethynyl-3-methoxyestra-1(10),2,4-trien-17beta-ol; 17-ethynyl-3-methoxyoestra-1(10),2,4-trien-17beta-ol; 17alpha-Ethinyl estradiol 3-methyl ether; 17alpha-Ethinyl oestradiol 3-methyl ether; 17alpha-Ethinylestradiol 3-methyl ether; 17alpha-Ethynylestradiol 3-methyl ether; 17alpha-Ethynylestradiol methyl ether; 17alpha-Ethynyloestradiol 3-methyl ether; 17beta-Estradiol, 17-ethynyl-, 3-(methyl ether); 3-Methoxy-17-alpha-19-norpregna-1,3,5(10)-trien-20-yn-17-ol; 3-Methoxy-17-alpha-ethinylestradiol; 3-Methoxy-17-alpha-ethinyloestradiol; 3-Methoxy-17-alpha-ethynyl-1,3,5(10)-estratrien-17-beta-ol; 3-Methoxy-17-alpha-ethynyl-1,3,5(10)-oestratrien-17-beta-ol; 3-Methoxy-17-alpha-ethynylestradiol; 3-Methoxy-17-alpha-ethynyloestradiol; 3-Methoxy-17-ethynyloestradiol-17-beta; 3-Methoxy-17alpha-ethinylestradiol; 3-Methoxy-17alpha-ethinyloestradiol; 3-Methoxy-17alpha-ethynyl-1,3,5(10)-estratrien-17beta-ol; 3-Methoxy-17alpha-ethynyl-1,3,5(10)-oestratrien-17beta-ol; 3-Methoxy-17alpha-ethynylestradiol; 3-Methoxy-17alpha-ethynyloestradiol; 3-Methoxy-19-nor-17-alpha-pregna-1,3,5(10)-trien-20-yn-17-ol; 3-Methoxy-19-nor-17alpha-pregna-1,3,5(10)-trien-20-yn-17-ol; 3-Methoxy-19-norpregna-1,3,5(10)-trien-20-yn-17beta-ol; 3-Methoxyethynylestradiol; 3-Methoxyethynyloestradiol; 3-Methylethynylestradiol; 3-Methylethynyloestradiol; 3-O-Methylethynylestradiol DMG3F94 TC Estrogens DMG3F94 DT Small molecular drug DMG3F94 PC 6291 DMG3F94 MW 310.4 DMG3F94 FM C21H26O2 DMG3F94 IC InChI=1S/C21H26O2/c1-4-21(22)12-10-19-18-7-5-14-13-15(23-3)6-8-16(14)17(18)9-11-20(19,21)2/h1,6,8,13,17-19,22H,5,7,9-12H2,2-3H3/t17-,18-,19+,20+,21+/m1/s1 DMG3F94 CS C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)OC DMG3F94 IK IMSSROKUHAOUJS-MJCUULBUSA-N DMG3F94 IU (8R,9S,13S,14S,17R)-17-ethynyl-3-methoxy-13-methyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-ol DMG3F94 CA CAS 72-33-3 DMG3F94 CB CHEBI:6784 DMG3F94 DE Contraception DMM4QOJ ID DMM4QOJ DMM4QOJ DN Metadoxine DMM4QOJ HS Approved DMM4QOJ SN MG01CI; Metadoxine (oral sustained release, ADHD); Metadoxine (oral extended release, ADHD), Alcobra; Metadoxine (oral sustained release, ADHD), Alcobra DMM4QOJ CP Alcobra DMM4QOJ DT Small molecular drug DMM4QOJ PC 115198 DMM4QOJ MW 298.29 DMM4QOJ FM C13H18N2O6 DMM4QOJ IC InChI=1S/C8H11NO3.C5H7NO3/c1-5-8(12)7(4-11)6(3-10)2-9-5;7-4-2-1-3(6-4)5(8)9/h2,10-12H,3-4H2,1H3;3H,1-2H2,(H,6,7)(H,8,9)/t;3-/m.0/s1 DMM4QOJ CS CC1=NC=C(C(=C1O)CO)CO.C1CC(=O)N[C@@H]1C(=O)O DMM4QOJ IK RYKKQQUKJJGFMN-HVDRVSQOSA-N DMM4QOJ IU 4,5-bis(hydroxymethyl)-2-methylpyridin-3-ol;(2S)-5-oxopyrrolidine-2-carboxylic acid DMM4QOJ CA CAS 74536-44-0 DMM4QOJ DE Multiple myeloma DMTQS9A ID DMTQS9A DMTQS9A DN Metaproterenol sulfate DMTQS9A HS Approved DMTQS9A SN Metaproterenol; metaproterenol; ORCIPRENALINE; Alupent; 586-06-1; Orciprenalinum; Metaproterenol sulfate; Orciprenalina; Orciprenalinum [INN-Latin]; Orciprenalina [INN-Spanish]; Metaproterenol polistirex; Metaprel; Alotec; Prometa; Orciprenaline [INN]; CCRIS 9017; Orciprenaline (INN); EINECS 209-569-1; CHEMBL776; BRN 2807247; (RS)-1-(3,5-Dihydroxyphenyl)-2-isopropylaminoethanol; CHEBI:6792; 3,5-Dihydroxy-alpha-((isopropylamino)methyl)benzyl alcohol; 5-[1-hydroxy-2-(propan-2-ylamino)ethyl]benzene-1,3-diol; Alupent; Orciprenaline DMTQS9A CP Boehringer Ingelheim Pharmaceuticals Inc DMTQS9A DT Small molecular drug DMTQS9A PC 441333 DMTQS9A MW 520.6 DMTQS9A FM C22H36N2O10S DMTQS9A IC InChI=1S/2C11H17NO3.H2O4S/c2*1-7(2)12-6-11(15)8-3-9(13)5-10(14)4-8;1-5(2,3)4/h2*3-5,7,11-15H,6H2,1-2H3;(H2,1,2,3,4) DMTQS9A CS CC(C)NCC(C1=CC(=CC(=C1)O)O)O.CC(C)NCC(C1=CC(=CC(=C1)O)O)O.OS(=O)(=O)O DMTQS9A IK MKFFGUZYVNDHIH-UHFFFAOYSA-N DMTQS9A IU 5-[1-hydroxy-2-(propan-2-ylamino)ethyl]benzene-1,3-diol;sulfuric acid DMTQS9A CA CAS 5874-97-5 DMTQS9A DE Asthma DMWIX23 ID DMWIX23 DMWIX23 DN Metaraminol DMWIX23 HS Approved DMWIX23 SN Araminol; Hydroxynorephedrine; Isophenylephrine; Metaradrin; Metaradrine; Metaraminolum; Pressonex; Pressorol; Icoral B; Metaraminolum [Latin]; Aramine (TN); L-Metaraminol; M-Hydroxy norephedrine; M-Hydroxynorephedrine; M-Hydroxyphenylpropanolamine; M-Hydroxypropadrine; Meta-Hydroxynorephedrine; Metaraminol (INN); Metaraminol [INN:BAN]; Metaraminolum [INN-Latin]; Alpha-(1-Aminoethyl)-3-hydroxybenzenemethanol; Alpha-(1-Aminoethyl)-m-hydroxybenzyl alcohol; Alpha-(m-Hydroxyphenyl)-beta-aminopropanol; M-Hydroxy-alpha-(1-aminoethyl)-benzyl alcohol; Benzenemethanol, alpha-(1-aminoethyl)-3-hydroxy-, (R-(R*,S*))-(9CI); (-)-Erythro-metaraminol; 1-(m-Hydroxyphenyl)-2-amino-1-propanol; 1-Metaraminol; 1-alpha-(1-Aminoethyl)-m-hydroxybenzyl alcohol; 2-Amino-1-(m-hydroxyphenyl)-1-propanol; 3-Hydroxyphenylisopropanolamine; 3-[(1R,2S)-2-amino-1-hydroxypropyl]phenol DMWIX23 CP Merck Sharp & Dohme Pharmaceuticals DMWIX23 TC Antihypertensive Agents DMWIX23 DT Small molecular drug DMWIX23 PC 5906 DMWIX23 MW 167.2 DMWIX23 FM C9H13NO2 DMWIX23 IC InChI=1S/C9H13NO2/c1-6(10)9(12)7-3-2-4-8(11)5-7/h2-6,9,11-12H,10H2,1H3/t6-,9-/m0/s1 DMWIX23 CS C[C@@H]([C@@H](C1=CC(=CC=C1)O)O)N DMWIX23 IK WXFIGDLSSYIKKV-RCOVLWMOSA-N DMWIX23 IU 3-[(1R,2S)-2-amino-1-hydroxypropyl]phenol DMWIX23 CA CAS 54-49-9 DMWIX23 CB CHEBI:6794 DMWIX23 DE Hypotension DMJFP6G ID DMJFP6G DMJFP6G DN Metergolin DMJFP6G HS Approved DMJFP6G SN Metergoline; metergoline; Liserdol; 17692-51-2; Methergoline; Metergolina; Metergolinum; Metergolina [DCIT]; Metergolinum [Latin]; Metergolina [Spanish]; Substance 355/255; Metergoline [INN:BAN]; Metergolinum [INN-Latin]; 1-Methyl-N-carbobenzyloxydihydro-D-lysergamin; FI-6337; MLS000069437; UNII-1501393LY5; C25H29N3O2; AHR 3009; 1-Methyl-8-beta-carbobenzyloxyaminomethyl-10-alpha-ergoline; EINECS 241-686-3; 1,6-Dimethyl-8-beta-carbobenzyloxaminomethyl-10-alpha-ergoline; FI 6337; Liserdol (TN) DMJFP6G DT Small molecular drug DMJFP6G PC 28693 DMJFP6G MW 403.5 DMJFP6G FM C25H29N3O2 DMJFP6G IC InChI=1S/C25H29N3O2/c1-27-14-18(13-26-25(29)30-16-17-7-4-3-5-8-17)11-21-20-9-6-10-22-24(20)19(12-23(21)27)15-28(22)2/h3-10,15,18,21,23H,11-14,16H2,1-2H3,(H,26,29)/t18-,21+,23+/m0/s1 DMJFP6G CS CN1C[C@@H](C[C@H]2[C@H]1CC3=CN(C4=CC=CC2=C34)C)CNC(=O)OCC5=CC=CC=C5 DMJFP6G IK WZHJKEUHNJHDLS-QTGUNEKASA-N DMJFP6G IU benzyl N-[[(6aR,9S,10aR)-4,7-dimethyl-6,6a,8,9,10,10a-hexahydroindolo[4,3-fg]quinolin-9-yl]methyl]carbamate DMJFP6G CA CAS 17692-51-2 DMJFP6G CB CHEBI:64216 DMJFP6G DE Hyperprolactinaemia DM89QE1 ID DM89QE1 DM89QE1 DN Metformin DM89QE1 HS Approved DM89QE1 SN 657-24-9; 1,1-Dimethylbiguanide; N,N-dimethylimidodicarbonimidic diamide; Metiguanide; Dimethylbiguanide; Glucophage; Haurymelin; Gliguanid; Fluamine; Glumetza; Flumamine; Melbin; Diabex; N,N-Dimethylbiguanide; Metformina; Metforminum; Metformine; Islotin; Glifage; Siofor; N1,N1-Dimethylbiguanide; DMGG; NNDG; Dimethyldiguanide; N,N-Dimethyldiguanide; Metformina [DCIT]; Imidodicarbonimidic diamide, N,N-dimethyl-; Metformina [Spanish]; Metforminum [INN-Latin]; Metformine [INN-French]; Metformin [USAN:INN:BAN]; 1,1-Dimethyl; Diabetosan; Dimethylbiguanidine; Dimethylguanylguanidine; Glycon; Diabex (TN); Diaformin (TN); Dianben (TN); Fortamet (TN); Gen-Metformin; Glucophage (TN); Glumetza (TN); LA-6023; Nu-Metformin; Obimet (TN); Riomet (TN); Metformin (USAN/INN); 1,1-Dimethyl biguanide; 3-(diaminomethylidene)-1,1-dimethylguanidine; [14C]metformin DM89QE1 CP Bristol-Myers Squibb DM89QE1 TC Hypoglycemic Agents DM89QE1 DT Small molecular drug DM89QE1 PC 4091 DM89QE1 MW 129.16 DM89QE1 FM C4H11N5 DM89QE1 IC InChI=1S/C4H11N5/c1-9(2)4(7)8-3(5)6/h1-2H3,(H5,5,6,7,8) DM89QE1 CS CN(C)C(=N)N=C(N)N DM89QE1 IK XZWYZXLIPXDOLR-UHFFFAOYSA-N DM89QE1 IU 3-(diaminomethylidene)-1,1-dimethylguanidine DM89QE1 CA CAS 657-24-9 DM89QE1 CB CHEBI:6801 DM89QE1 DE Type-2 diabetes DMTPAM3 ID DMTPAM3 DMTPAM3 DN Metformin arginine-hemisuccinimide DMTPAM3 HS Approved DMTPAM3 SN Diap-2; Metformin arginine-hemisuccinate-hemisuccinamide; Metformin arginine-hemisuccinimide (type 2 diabetes); Diap-2 (type 2 diabetes), Arteria; Metformin arginine-hemisuccinimide (type 2 diabetes), Arteria DMTPAM3 CP Boehringer Ingelheim Pharmaceuticals; Merck; Depomed; Janssen Research & Development; AstraZeneca; Bristol-Myers Squibb DMTPAM3 DE Type-2 diabetes DMGS4QH ID DMGS4QH DMGS4QH DN Methacholine Chloride DMGS4QH HS Approved DMGS4QH SN Methacholine; methacholine; Acetylmethylcholine; Methacholin; Mecholine; Mecholin; Provocholine; Methacholinum; beta-Methylacetylcholine; 55-92-5; Choline, acetyl-beta-methyl-; Acetyl-beta-methylcholine; BRN 1769932; CHEBI:6804; 1-Propanaminium, 2-(acetyloxy)-N,N,N-trimethyl-; AMMONIUM, (2-HYDROXYPROPYL)TRIMETHYL-, ACETATE (ESTER); 2-acetyloxypropyl(trimethyl)azanium; C8H18NO2; AC1Q5XYD; AC1L1COQ; Prestwick2_000759; Prestwick0_000759; Prestwick3_000759; Prestwick1_000759; CHEMBL978; 2-(acetyloxy)-n,n,n-trimethylpropan-1-aminium; METHACHOLINE DMGS4QH CP Methapharm Inc DMGS4QH DT Small molecular drug DMGS4QH PC 6114 DMGS4QH MW 195.69 DMGS4QH FM C8H18ClNO2 DMGS4QH IC InChI=1S/C8H18NO2.ClH/c1-7(11-8(2)10)6-9(3,4)5;/h7H,6H2,1-5H3;1H/q+1;/p-1 DMGS4QH CS CC(C[N+](C)(C)C)OC(=O)C.[Cl-] DMGS4QH IK JHPHVAVFUYTVCL-UHFFFAOYSA-M DMGS4QH IU 2-acetyloxypropyl(trimethyl)azanium;chloride DMGS4QH CA CAS 62-51-1 DMGS4QH CB CHEBI:50142 DMGS4QH DE bronchial hyperreactivity; Asthma DMAY96V ID DMAY96V DMAY96V DN Methacycline DMAY96V HS Approved DMAY96V SN Bialatan; Metaciclina; Metacycline; Metacyclinum; Methacyclin; Methacyclinum; Methylenecycline; Methyleneoxytetracycline; Rondomycin; Methacycline amphoteric; Methacycline base; GS 2876; GS-2876; Metaciclina [INN-Spanish]; Metacycline (INN); Metacyclinum [INN-Latin]; Methacycline (USAN); Methacycline [USAN:BAN]; Tri-methacycline; (2Z,4S,4aR,5S,5aR,12aS)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methylidene-4,4a,5,5a-tetrahydrotetracene-1,3,12-trione; (4S,4aR,5S,5aR,12aS)-4-(dimethylamino)-3,5,10,12,12a-pentahydroxy-6-methylidene-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide; 4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methylene-1,11-dioxo-2-naphthacenecarboxamide; 6-Demethyl-6-deoxy-5-hydroxy-6-methylenetetracycline; 6-Deoxy-6-demethyl-6-methylene-5-oxytetracycline; 6-Methylene-5-hydroxytetracycline; 6-Methylene-5-oxytetracycline; 6-Methyleneoxytetracycline DMAY96V TC Antibiotics DMAY96V DT Small molecular drug DMAY96V PC 54675785 DMAY96V MW 442.4 DMAY96V FM C22H22N2O8 DMAY96V IC InChI=1S/C22H22N2O8/c1-7-8-5-4-6-9(25)11(8)16(26)12-10(7)17(27)14-15(24(2)3)18(28)13(21(23)31)20(30)22(14,32)19(12)29/h4-6,10,14-15,17,25-27,30,32H,1H2,2-3H3,(H2,23,31)/t10-,14-,15+,17+,22+/m1/s1 DMAY96V CS CN(C)[C@H]1[C@@H]2[C@H]([C@@H]3C(=C)C4=C(C(=CC=C4)O)C(=C3C(=O)[C@@]2(C(=C(C1=O)C(=O)N)O)O)O)O DMAY96V IK XIYOPDCBBDCGOE-IWVLMIASSA-N DMAY96V IU (4S,4aR,5S,5aR,12aR)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methylidene-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide DMAY96V CA CAS 914-00-1 DMAY96V CB CHEBI:6805 DMAY96V DE Bacterial infection DMTW6IU ID DMTW6IU DMTW6IU DN Methadone DMTW6IU HS Approved DMTW6IU SN Adanon; Algovetin; Althose; Amidon; Amidone; Biscuits; Dextromethadone; Diaminon; Dollies; Dolly; Dolophin; Dolophine; Heptadone; Heptanon; Ketalgin; Levometadona; Levomethadonum; Levothyl; Metadona; Metadone; Metasedin; Methadon; Methadona; Methadonum; Methaquaione; Phenadone; Polamidone; Polamivet; Westadone; Dolophine HCL; Levomethadone [INN]; Metadona [Spanish]; Metadone [DCIT]; Methadona [Spanish]; Methadone HCL Intensol; Methadone M; Methadonum [Latin]; Racemic methadone; A 4624; AN 148; Hoechst 10820; K 174; Amidone (TN); D-Methadone; Dl-Methadone; Dolophine (TN); Heptadon (TN); Heptanon (pharmaceutical); L-Methadone; L-Polamidon; L-Polamivet; Levometadona [INN-Spanish]; Levomethadonum [INN-Latin]; Metadona [INN-Spanish]; Methadone (BAN); Methadone [INN:BAN]; Methadonum [INN-Latin]; Methadose (TN); Physeptone (TN); Sedo-Rapide; Symoron (TN); Dolophine (*Hydrochloride*); Fenadone (*Hydrochloride*); Heptadone (*Hydrochloride*); Heptanon (*Hydrochloride*); Hoescht 10820 (*Hydrochloride*); Phenadone (*Hydrochloride*); AN-148 (*Hydrochloride*); L-(+)-Methadone; S-(+)-Methadone; D-6-(Dimethylamino)-4,4-diphenyl-3-heptanone; L-6-(Dimethylamino)-4,4-diphenyl-3-heptanone; (+)-Methadone; (+-)-Methadone; (+/-)-Methadone; (+/-)-Tussal; (-)-(R)-6-(Dimethylamino)-4,4-diphenyl-3-heptanone; (-)-Methadone; (6R)-Methadone; (R)-6-(Dimethylamino)-4,4-diphenyl-3-heptanone; (R)-6-(Dimethylamino)-4,4-diphenyl-3-hetpanone; (S)-6-(Dimethylamino)-4,4-diphenyl-3-heptanone; 3-Hetpanone, 6-(dimethylamino)-4,4-diphenyl-, (R)-(9CI); 6-(Dimethylamino)-4,4-diphenyl-3-heptanone dl-mixture; 6-(dimethylamino)-4,4-diphenylheptan-3-one; 6-Dimethylamino-4,4-diphenyl-3-heptanone; 6-dimethylamino-4,4-di(phenyl)heptan-3-one; 6S-Methadone DMTW6IU CP Eli Lilly DMTW6IU TC Analgesics DMTW6IU DT Small molecular drug DMTW6IU PC 4095 DMTW6IU MW 309.4 DMTW6IU FM C21H27NO DMTW6IU IC InChI=1S/C21H27NO/c1-5-20(23)21(16-17(2)22(3)4,18-12-8-6-9-13-18)19-14-10-7-11-15-19/h6-15,17H,5,16H2,1-4H3 DMTW6IU CS CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2 DMTW6IU IK USSIQXCVUWKGNF-UHFFFAOYSA-N DMTW6IU IU 6-(dimethylamino)-4,4-diphenylheptan-3-one DMTW6IU CA CAS 76-99-3 DMTW6IU CB CHEBI:6807 DMTW6IU DE Dry cough DMIRMVB ID DMIRMVB DMIRMVB DN Methadyl Acetate DMIRMVB HS Approved DMIRMVB SN ALPHACETYLMETHADOL; Acemethadone; Acetilmetadol; Acetylmethadol; Acetylmethadolum; Amidolacetate; Levamethadyl; Acetilmetadol [INN-Spanish]; Acetylmethadol (INN); Acetylmethadolum [INN-Latin]; Methadyl acetate (USAN); Methadyl acetate [USAN:BAN]; N-LAMM; Race-Acetylmethadol; [6-(dimethylamino)-4,4-diphenylheptan-3-yl] acetate; Benzeneethanol, beta-(2-(dimethylamino)propyl)-alpha-ethyl-beta-phenyl-, acetate (ester); Benzeneethanol, .beta.-[2-(dimethylamino)propyl]-.alpha.-ethyl-.beta.-phenyl-, acetate; (R,S)-4-Dimethylamino-1-ethyl-2,2-diphenylpentyl acetat; 1-Ethyl-4-dimethylamino-2,2-diphenylpentylacetat; 3-Acetoxy-6-dimethylamino-4,4-diphenylheptane; 4-(Dimethylamino)-1-ethyl-2,2-diphenylpentyl acetate; 6-(Dimethylamino)-4,4-Diphenyl-3-Heptanol Acetate DMIRMVB TC Narcotics DMIRMVB DT Small molecular drug DMIRMVB PC 10517 DMIRMVB MW 353.5 DMIRMVB FM C23H31NO2 DMIRMVB IC InChI=1S/C23H31NO2/c1-6-22(26-19(3)25)23(17-18(2)24(4)5,20-13-9-7-10-14-20)21-15-11-8-12-16-21/h7-16,18,22H,6,17H2,1-5H3 DMIRMVB CS CCC(C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2)OC(=O)C DMIRMVB IK XBMIVRRWGCYBTQ-UHFFFAOYSA-N DMIRMVB IU [6-(dimethylamino)-4,4-diphenylheptan-3-yl] acetate DMIRMVB CA CAS 509-74-0 DMIRMVB CB CHEBI:135491 DMIRMVB DE Opioid dependence DMPM4SK ID DMPM4SK DMPM4SK DN Methamphetamine DMPM4SK HS Approved DMPM4SK SN METHAMPHETAMINE; Metamfetamine; d-Deoxyephedrine; d-Desoxyephedrine; d-Methamphetamine; d-N-Methylamphetamine; Metamphetamine; L-Methamphetamine; d-Methylamphetamine; Methylamphetamine; d-Phenylisopropylmethylamine; N-Methylamphetamine; (S)-Methamphetamine; Norodin; (+)-Methylamphetamine; d-(S)-Methamphetamine; D-1-Phenyl-2-methylaminopropane; Metamfetaminum; Desyphed; (+)-N-Methylamphetamine; (S)-Methylamphetamine; (+)-(S)-Deoxyephedrine; Methyl-beta-phenylisopropylamine; 1-Phenyl-2-methylaminopropane; (S)-(+)-Deoxyephedrine; Crank; Desohyephedrine; Metamfetamina; Meth; Methamphetaminum; Speed; Stimulex; Crank [Street Name]; Crystal Meth; Crystal Meth [Street Name]; Desyphed hydrochloride; ICE [Street Name]; Metamfetamine [INN];Metamfetaminum [Latin]; Metanfetamina [Spanish]; Methamphetaminum [JP]; Speed [Street Name]; D-Deoxyephedrine; D-Desoxyephedrine; D-Methamphetamine; D-Methylamphetamine; D-Phenylisopropylmethylamine;Desoxyn (TN); Metamfetamina [INN-Spanish]; Metamfetamine (INN); Metamfetamine-m; Metamfetaminum [INN-Latin]; Metanfetamina [INN-Spanish]; Meth (Street Name); Methamphetaminum [INN-Latin]; D-N-Methylamphetamine; D-(S)-Methamphetamine; D-N,alpha-dimethylphenethylamine; Methamphetamine, its salts, isomers, and salts of its isomers; N-Methyl-beta-phenylisopropylamin; N-Methyl-beta-phenylisopropylamin [German]; N-Methyl-beta-phenylisopropylamine; D-1-Phenyl-2-methylaminopropan; D-1-Phenyl-2-methylaminopropan [German]; S-(+)-Methamphetamine; D-N,alpha-Dimethylphenethylamine; N-Methyl-1-phenyl-2-propanamine; Benzeneethanamine, N,alpha-dimethyl-, (S)-(9CI); Benzeneethanamine, N,alpha-dimethyl-, (alphaS)-(9CI); Phenethylamine, N,alpha-dimethyl-, (S)-(+)-(8CI); (+)-(S)-N-alpha-Dimethylphenethylamine; (+)-2-(N-Methylamino)-1-phenylpropane; (+)-N,alpha-Dimethyl-beta-phenylethylamine; (+)-N,alpha-Dimethylphenethylamine; (+)-methamphetamine; (2S)-N-methyl-1-phenylpropan-2-amine; (S)-(+)-Methamphetamine; (S)-(+)-N,alpha,dimethylphenethylamine; (S)-N,alpha-Dimethylbenzeneethanamine; (S)-N,alpha-Dimethylbenzeneethanoamine; (alphaS)-N,alpha-dimethylbenzeneethanamine; 1-Phenyl-2-methylamino-propan; 1-Phenyl-2-methylamino-propan [German]; 2S-(+)-Methamphetamine; Methamfetamine DMPM4SK CP Ovation Pharma DMPM4SK TC Central Nervous System Stimulants DMPM4SK DT Small molecular drug DMPM4SK PC 10836 DMPM4SK MW 149.23 DMPM4SK FM C10H15N DMPM4SK IC InChI=1S/C10H15N/c1-9(11-2)8-10-6-4-3-5-7-10/h3-7,9,11H,8H2,1-2H3/t9-/m0/s1 DMPM4SK CS C[C@@H](CC1=CC=CC=C1)NC DMPM4SK IK MYWUZJCMWCOHBA-VIFPVBQESA-N DMPM4SK IU (2S)-N-methyl-1-phenylpropan-2-amine DMPM4SK CA CAS 537-46-2 DMPM4SK CB CHEBI:6809 DMPM4SK DE Pain; Attention deficit hyperactivity disorder DMO2JBC ID DMO2JBC DMO2JBC DN Methamphetamine hydrochloride DMO2JBC HS Approved DMO2JBC SN Methamphetamine HCL; Methamphetamine hydrochloride; Methamphetaminium chloride; Methylamphetamine hydrochloride; Methylisomyn; Norodin hydrochloride; Adipex; Chestox; Deofed; Des-O-E; Desepin; Desodex; Desoxo-5; Desoxyfed; Desoxyne; Destim; Dexoval; Dexstim; Dextim; Dosoxy; Doxyfed; Drinalfa; Efroxine; Eufodrinal; Gerovit; Hyphet; Isophen; Isophen (VAN); Obedrin-LA; Pervitin; Philopon; Soxysympamine; Syndrox; Tonedron; d-Methaphetamine hydrochloride; (+)-Methamphetamine hydrochloride; 51-57-0; S-(+)-Methamphetamine hydrochloride DMO2JBC PC 66124 DMO2JBC MW 185.69 DMO2JBC FM C10H16ClN DMO2JBC IC TWXDDNPPQUTEOV-FVGYRXGTSA-N DMO2JBC CS CC(CC1=CC=CC=C1)NC.Cl DMO2JBC IK 1S/C10H15N.ClH/c1-9(11-2)8-10-6-4-3-5-7-10;/h3-7,9,11H,8H2,1-2H3;1H/t9-;/m0./s1 DMO2JBC IU (2S)-N-methyl-1-phenylpropan-2-amine;hydrochloride DMO2JBC CA CAS 51-57-0 DMO2JBC CB CHEBI:35340 DMO2JBC DE Attention deficit hyperactivity disorder DM8X4A1 ID DM8X4A1 DM8X4A1 DN Methantheline DM8X4A1 HS Approved DM8X4A1 SN Mantheline; Methanide; Methanthelinium; Methanthelinum; Banthine bromide; Gastrin I; Methanthine bromide; Gastrin-1 Human; Diethyl-methyl-[2-(9H-xanthene-9-carbonyloxy)ethyl]azanium; N,N-Diethyl-N-methyl-2-[(9H-xanthen-9-ylcarbonyl)oxy]ethanaminium DM8X4A1 CP Shire Development Inc DM8X4A1 TC Anticholinergic Agents DM8X4A1 DT Small molecular drug DM8X4A1 PC 4097 DM8X4A1 MW 340.4 DM8X4A1 FM C21H26NO3+ DM8X4A1 IC InChI=1S/C21H26NO3/c1-4-22(3,5-2)14-15-24-21(23)20-16-10-6-8-12-18(16)25-19-13-9-7-11-17(19)20/h6-13,20H,4-5,14-15H2,1-3H3/q+1 DM8X4A1 CS CC[N+](C)(CC)CCOC(=O)C1C2=CC=CC=C2OC3=CC=CC=C13 DM8X4A1 IK GZHFODJQISUKAY-UHFFFAOYSA-N DM8X4A1 IU diethyl-methyl-[2-(9H-xanthene-9-carbonyloxy)ethyl]azanium DM8X4A1 CA CAS 5818-17-7 DM8X4A1 CB CHEBI:6817 DM8X4A1 DE Gastritis; Pancreatitis; Irritable bowel syndrome; Peptic ulcer DM5A38V ID DM5A38V DM5A38V DN Metharbital DM5A38V HS Approved DM5A38V SN Endiemal; Endiemalum; Gemonal; Gemonil; Gemonit; Metabarbital; Metarbital; Metarbitale; Methabarbital; Methabarbitone; Metharbitalum; Metharbitone; Metharbutal; Methylbarbital; Metarbitale [DCIT]; AN 23; Sch 412; Gemonil (TN); Metarbital [INN-Spanish]; Metharbital [INN:JAN]; Metharbitalum [INN-Latin]; N-Methylbarbital; Metharbital (JAN/INN); 1-Methylbarbital; 5,5-Diethyl-1-methyl-2,4,6(1H,3H,5H)-pyrimidinetrione; 5,5-Diethyl-1-methylbarbituric acid; 5,5-diethyl-1-methyl-1,3-diazinane-2,4,6-trione; 5,5-diethyl-1-methylpyrimidine-2,4,6(1H,3H,5H)-trione DM5A38V CP Abbott Laboratories DM5A38V TC Anticonvulsants DM5A38V DT Small molecular drug DM5A38V PC 4099 DM5A38V MW 198.22 DM5A38V FM C9H14N2O3 DM5A38V IC InChI=1S/C9H14N2O3/c1-4-9(5-2)6(12)10-8(14)11(3)7(9)13/h4-5H2,1-3H3,(H,10,12,14) DM5A38V CS CCC1(C(=O)NC(=O)N(C1=O)C)CC DM5A38V IK FWJKNZONDWOGMI-UHFFFAOYSA-N DM5A38V IU 5,5-diethyl-1-methyl-1,3-diazinane-2,4,6-trione DM5A38V CA CAS 50-11-3 DM5A38V CB CHEBI:31827 DM5A38V DE Epilepsy DM7J2TA ID DM7J2TA DM7J2TA DN Methazolamide DM7J2TA HS Approved DM7J2TA SN Methazolamide (oral, sustained release) DM7J2TA CP Effcon Laboratories Inc DM7J2TA DT Small molecular drug DM7J2TA PC 4100 DM7J2TA MW 236.3 DM7J2TA FM C5H8N4O3S2 DM7J2TA IC InChI=1S/C5H8N4O3S2/c1-3(10)7-4-9(2)8-5(13-4)14(6,11)12/h1-2H3,(H2,6,11,12) DM7J2TA CS CC(=O)N=C1N(N=C(S1)S(=O)(=O)N)C DM7J2TA IK FLOSMHQXBMRNHR-UHFFFAOYSA-N DM7J2TA IU N-(3-methyl-5-sulfamoyl-1,3,4-thiadiazol-2-ylidene)acetamide DM7J2TA CA CAS 554-57-4 DM7J2TA CB CHEBI:6822 DM7J2TA DE Glaucoma/ocular hypertension DMAUHQX ID DMAUHQX DMAUHQX DN Methdilazine DMAUHQX HS Approved DMAUHQX SN Disyncram; Methdilazinum; Methodilazine; Metodilazina; Tacaryl; Tacazyl; Tacryl; Methilazine hydrochloride; Methdilazine (INN); Methdilazinum [INN-Latin]; Metodilazina [INN-Spanish]; Tacaryl (TN); Methdilazine [USAN:INN:BAN]; 10-((1-Methyl-3-pyrrolidinyl)methyl)phenothiazine; 10-((1-methyl-3-pyrrolidinyl)methyl)-10H-phenothiazine; 10-[(1-Methylpyrrolidin-3-yl)methyl]phenothiazine; 10-[(1-methylpyrrolidin-3-yl)methyl]-10H-phenothiazine DMAUHQX TC Antihistamines DMAUHQX DT Small molecular drug DMAUHQX PC 14677 DMAUHQX MW 296.4 DMAUHQX FM C18H20N2S DMAUHQX IC InChI=1S/C18H20N2S/c1-19-11-10-14(12-19)13-20-15-6-2-4-8-17(15)21-18-9-5-3-7-16(18)20/h2-9,14H,10-13H2,1H3 DMAUHQX CS CN1CCC(C1)CN2C3=CC=CC=C3SC4=CC=CC=C42 DMAUHQX IK HTMIBDQKFHUPSX-UHFFFAOYSA-N DMAUHQX IU 10-[(1-methylpyrrolidin-3-yl)methyl]phenothiazine DMAUHQX CA CAS 1982-37-2 DMAUHQX CB CHEBI:6823 DMAUHQX DE Allergic rhinitis DM25FL8 ID DM25FL8 DM25FL8 DN Methimazole DM25FL8 HS Approved DM25FL8 SN methimazole; 60-56-0; thiamazole; Tapazole; 2-Mercapto-1-methylimidazole; Mercazolyl; 1-Methylimidazole-2-thiol; Thymidazole; Mercazole; Methimazol; Thymidazol; Thiamazol; Metazolo; Thycapzol; Metothyrine; Metothyrin; Merkazolil; Mercaptazole; Strumazol; Favistan; Basolan; Thycapsol; Metotirin; Danantizol; Thacapzol; Merkastan; Frentirox; Metizol; Tiamazol; Mercasolyl; 1-Methyl-1H-imidazole-2-thiol; Methylmercaptoimidazole; 1-Methyl-2-mercaptoimidazole; Methiamazole; Usaf el-30; Methimazolum; Mercazolylum; Tapuzole; Metimazol; Thimazole; Basolan; MMZ; Mercazol; Methamazole; Methizol; Methymazol; Metisol; Strumazole; Thiamazole; Thiamazolum; Thimazol; Thyrozol; Tiamazolo; Tirodril; EliLilly Brand of Methimazole; Estedi Brand of Methimazole; Henning Berlin Brand of Methimazole; Hexal Brand of Methimazole; Jones Brand of Methimazole; Merck Brand of Methimazole; Nourypharma Brand of Methimazole; Philopharm Brand of Methimazole; Sanofi Synthelabo Brand of Methimazole; Temmler Brand of Methimazole; Thiamazol Henning; Thiamazol Hexal; Tiamazolo [DCIT]; M0868; Henning, Thiamazol; Hexal, Thiamazol; Methimazole (USP); Methimazole [USAN:BAN]; Tapazole (TN); Thiamazol [INN-French]; Thiamazolum [INN-Latin]; Tiamazol [INN-Spanish]; Mestinon, Regonol, Pyridostigmine Bromide;Thiamazole (JP15/INN); N-Methyl-2-mercaptoimidazole; 1 Methyl 2 mercaptoimidazole; 1,3-Dihydro-1-Methyl-2H-Imidazol-2-Thione; 1,3-Dihydro-1-methyl-2H-imidazole-2-thione; 1-METHYL-1,3-DIHYDRO-2H-IMIDAZOLE-2-THIONE; 1-Methyl-1,3-dihydroimidazole-2-thione; 1-Methyl-2-Imidazolethione; 1-Methyl-2-imidazolethiol; 1-Methyl-imidazole-2-thiol; 1-Methylimidazole-2(3H)-thione; 1-Metylo 2 merkaptoimidazolem; 1-Metylo 2 merkaptoimidazolem [Polish]; 2-Mercaptomethylimidazole; 3-methyl-1H-imidazole-2-thione DM25FL8 TC Antithyroid Agents DM25FL8 DT Small molecular drug DM25FL8 PC 1349907 DM25FL8 MW 114.17 DM25FL8 FM C4H6N2S DM25FL8 IC InChI=1S/C4H6N2S/c1-6-3-2-5-4(6)7/h2-3H,1H3,(H,5,7) DM25FL8 CS CN1C=CNC1=S DM25FL8 IK PMRYVIKBURPHAH-UHFFFAOYSA-N DM25FL8 IU 3-methyl-1H-imidazole-2-thione DM25FL8 CA CAS 60-56-0 DM25FL8 CB CHEBI:50673 DM25FL8 DE Hyperthyroidism DM3Z217 ID DM3Z217 DM3Z217 DN Methimazole DM3Z217 HS Approved DM3Z217 SN Mercaptazole; Mercasolyl; Mercazole; Mercazolyl; Mercazolylum; Merkastan; Merkazolil; Metazolo; Methiamazole; Methimazol; Methimazolum; Methylmercaptoimidazole; Metizol; Metothyrin; Metothyrine; Metotirin; Strumazol; Tapazole; Thacapzol; Basolan; Danantizol; Favistan; Frentirox; Thiamazol; Thycapsol; Thycapzol; Thymidazol; Thymidazole; Tiamazol; Usaf el-30; methimazole; thiamazole; 1-Methyl-1H-imidazole-2-thiol; 1-Methyl-2-mercaptoimidazole; 1-Methylimidazole-2-thiol; 2-Mercapto-1-methylimidazole; 3-methyl-1H-imidazole-2-thione; 60-56-0 DM3Z217 PC 1349907 DM3Z217 MW 114.17 DM3Z217 FM C4H6N2S DM3Z217 IC PMRYVIKBURPHAH-UHFFFAOYSA-N DM3Z217 CS CN1C=CNC1=S DM3Z217 IK 1S/C4H6N2S/c1-6-3-2-5-4(6)7/h2-3H,1H3,(H,5,7) DM3Z217 IU 3-methyl-1H-imidazole-2-thione DM3Z217 CA CAS 60-56-0 DM3Z217 CB CHEBI:50673 DM3Z217 DE Thyrotoxicosis DM7YMIT ID DM7YMIT DM7YMIT DN Methohexital DM7YMIT HS Approved DM7YMIT SN Brevital; Brietal; Enallynymall; Enallynymalum; Methodrexitone; Methohexitalum; Methohexitone; Metoesital; Metohexital; Metoesital [DCIT]; Brevital (TN); Methohexital, Monosodium Salt; Methohexitalum [INN-Latin]; Metohexital [INN-Spanish]; Methohexital (USP/INN); Alpha-DL-1-Methyl-5-allyl-5-(1'-methylpentyn-2-yl)barbituricacid; (+-)-5-Allyl-1-methyl-5-(1-methyl-2-pentynyl)barbituric acid; 1-methyl-5-(1-methylpent-2-yn-1-yl)-5-(prop-2-en-1-yl)pyrimidine-2,4,6(1H,3H,5H)-trione; 1-methyl-5-(1-methylpent-2-yn-1-yl)-5-prop-2-en-1-ylpyrimidine-2,4,6(1H,3H,5H)-trione; 5-Allyl-1-methyl-5-(1-methyl-2-pentynyl)-2,4,6(1H,3H,5H)-pyrimidinetrione; 5-Allyl-1-methyl-5-(1-methyl-pent-2-ynyl)-pyrimidine-2,4,6-trione; 5-Allyl-5-(3-hexyn-2-yl)-1-methylbarbituric acid; 5-hex-3-yn-2-yl-1-methyl-5-prop-2-enyl-1,3-diazinane-2,4,6-trione DM7YMIT CP Par Sterile Products Llc DM7YMIT TC Anesthetics DM7YMIT DT Small molecular drug DM7YMIT PC 9034 DM7YMIT MW 262.3 DM7YMIT FM C14H18N2O3 DM7YMIT IC InChI=1S/C14H18N2O3/c1-5-7-8-10(3)14(9-6-2)11(17)15-13(19)16(4)12(14)18/h6,10H,2,5,9H2,1,3-4H3,(H,15,17,19) DM7YMIT CS CCC#CC(C)C1(C(=O)NC(=O)N(C1=O)C)CC=C DM7YMIT IK NZXKDOXHBHYTKP-UHFFFAOYSA-N DM7YMIT IU 5-hex-3-yn-2-yl-1-methyl-5-prop-2-enyl-1,3-diazinane-2,4,6-trione DM7YMIT CA CAS 151-83-7 DM7YMIT CB CHEBI:102216 DM7YMIT DE Anaesthesia DM2TEOL ID DM2TEOL DM2TEOL DN Methotrexate DM2TEOL HS Approved DM2TEOL SN methotrexate; 1959/5/2; Rheumatrex; Amethopterin; Metatrexan; Hdmtx; Abitrexate; Mexate; Methylaminopterinum; Methotrexatum; Antifolan; Metotrexato; Methylaminopterin; MTX; (S)-2-(4-(((2,4-Diaminopteridin-6-yl)methyl)(methyl)amino)benzamido)pentanedioic acid; Methotrexat; Amethopterine; Maxtrex; Rasuvo; L-Amethopterin; A-Methopterin; A-Methpterin; Amethopterin L-; Folex-Pfs; Methotrexat-Ebewe; N-Bismethylpteroylglutamic acid; Methotrexate, L-; Metotressato [DCIT]; Methotextrate; Mexate-Aq; [3H]methotrexate DM2TEOL DT Small molecular drug DM2TEOL PC 126941 DM2TEOL MW 454.4 DM2TEOL FM C20H22N8O5 DM2TEOL IC InChI=1S/C20H22N8O5/c1-28(9-11-8-23-17-15(24-11)16(21)26-20(22)27-17)12-4-2-10(3-5-12)18(31)25-13(19(32)33)6-7-14(29)30/h2-5,8,13H,6-7,9H2,1H3,(H,25,31)(H,29,30)(H,32,33)(H4,21,22,23,26,27)/t13-/m0/s1 DM2TEOL CS CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O DM2TEOL IK FBOZXECLQNJBKD-ZDUSSCGKSA-N DM2TEOL IU (2S)-2-[[4-[(2,4-diaminopteridin-6-yl)methyl-methylamino]benzoyl]amino]pentanedioic acid DM2TEOL CA CAS 59-05-2 DM2TEOL CB CHEBI:44185 DM2TEOL DE leukaemia; Solid tumour/cancer; Prostate cancer; Rheumatoid arthritis; Proliferative vitreoretinopathy DM5XH2C ID DM5XH2C DM5XH2C DN Methotrexate Sodium DM5XH2C HS Approved DM5XH2C SN Methotrexate disodium salt; 7413-34-5; Sodium methotrexate; MTX disodium; methotrexate disodium; UNII-3IG1E710ZN; 3IG1E710ZN; CHEBI:50679; Amethopterin sodium; Disodium methotrexate; Methotrexat dinatrium; Mexate-Aq Preserved; Methotrexate sodium salt; EINECS 231-022-0; 59-05-2 (Parent); Methotrexate Preservative Free; 4-Amino-N(sup 10)-methylpteroylglutamic acid disodium salt; METHOTREXATE SODIUM PRESERVATIVE FREE DM5XH2C CP Hospira Inc DM5XH2C TC Anticancer Agents DM5XH2C DT Small molecular drug DM5XH2C PC 11329481 DM5XH2C MW 498.4 DM5XH2C FM C20H20N8Na2O5 DM5XH2C IC InChI=1S/C20H22N8O5.2Na/c1-28(9-11-8-23-17-15(24-11)16(21)26-20(22)27-17)12-4-2-10(3-5-12)18(31)25-13(19(32)33)6-7-14(29)30;;/h2-5,8,13H,6-7,9H2,1H3,(H,25,31)(H,29,30)(H,32,33)(H4,21,22,23,26,27);;/q;2*+1/p-2/t13-;;/m0../s1 DM5XH2C CS CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)[O-])C(=O)[O-].[Na+].[Na+] DM5XH2C IK DASQOOZCTWOQPA-GXKRWWSZSA-L DM5XH2C IU disodium;(2S)-2-[[4-[(2,4-diaminopteridin-6-yl)methyl-methylamino]benzoyl]amino]pentanedioate DM5XH2C CA CAS 7413-34-5 DM5XH2C CB CHEBI:50679 DM5XH2C DE Solid tumour/cancer DMF5XQH ID DMF5XQH DMF5XQH DN Methoxamine DMF5XQH HS Approved DMF5XQH SN Methoxamedrin; Methoxamedrine; Methoxamin; Methoxaminum; Metossamina; Metoxamina; Pseudomethoxamine; Vasoxin; Vasoxine; Metossamina [DCIT]; Methoxamine (BAN); Methoxamine [INN:BAN]; Methoxaminum [INN-Latin]; Metoxamina [INN-Spanish]; AQ-387/40213491; Alpha-(1-Aminoethyl)-2,5-dimethoxybenzyl alcohol; DL-2-Amino-1-(2,5-dimethoxyphenyl)propanol; 2-Amino-1-(2,5-dimethoxyphenyl)-1-propanol; 2-Amino-1-(2,5-dimethoxyphenyl)propanol; 2-amino-1-(2,5-dimethoxyphenyl)propan-1-ol; 2-amino-1-[2,5-bis(methyloxy)phenyl]propan-1-ol DMF5XQH CP Glaxosmithkline DMF5XQH TC Antihypertensive Agents DMF5XQH DT Small molecular drug DMF5XQH PC 6082 DMF5XQH MW 211.26 DMF5XQH FM C11H17NO3 DMF5XQH IC InChI=1S/C11H17NO3/c1-7(12)11(13)9-6-8(14-2)4-5-10(9)15-3/h4-7,11,13H,12H2,1-3H3 DMF5XQH CS CC(C(C1=C(C=CC(=C1)OC)OC)O)N DMF5XQH IK WJAJPNHVVFWKKL-UHFFFAOYSA-N DMF5XQH IU 2-amino-1-(2,5-dimethoxyphenyl)propan-1-ol DMF5XQH CA CAS 390-28-3 DMF5XQH CB CHEBI:6839 DMF5XQH DE Hypertension DME8FZ9 ID DME8FZ9 DME8FZ9 DN Methoxsalen DME8FZ9 HS Approved DME8FZ9 SN Ammodin; Ammoidin; Deltasoralen; Dermox; Geroxalen; Meladinin; Meladinina; Meladinine; Meladoxen; Meloxine; Methoxalen; Methoxaten; Oxoralen; Oxsoralen; Oxypsoralen; Puvalen; Puvamet; Ultramop; Uvadex; XANTHOTOXIN; Xanthotoxine; Zanthotoxin; Boehringer Ingelheim Brand of Methoxsalen; Canderm Brand of Methoxsalen; Chinoin Brand of Methoxsalen; DB Brand of Methoxsalen; Delta Brand of Methoxsalen; Dermatech Brand of Methoxsalen; Galderma Brand of Methoxsalen; Methoxa Dome; Methoxsalen Canderm Brand; Methoxsalen Chinoin Brand; Methoxsalen Delta Brand; Methoxsalen Dermatech Brand; Methoxsalen plus ultraviolet radiation; Mex America Brand of Methoxsalen; Oxsoralen Ul tra; Oxsoralen Ultra; Oxsoralen lotion; Sanofi Synthelabo Brand of Methoxsalen; Ultra Mop; Ultramop Lotion; ICN Brand 1 of Methoxsalen; ICN Brand 2 of Methoxsalen; ICN Brand 3 of Methoxsalen; X0009; An 8-methoxyfurocoumarin; Meladinin (VAN); Methoxa-Dome; Methoxsalen Mex-America Brand; Methoxsalen Sanofi-Synthelabo Brand; Methoxsalen [BAN:JAN]; Methoxsalen with ultra-violet A theraphy; Mex-America Brand of Methoxsalen; New-Meladinin; O-methylxanthotoxol; OXSORALEN (TN); Oxsoralen (TN); Oxsoralen-ultra; Proralone-mop; Psoralen-mop; Psoralon-MOP; Sanofi-Synthelabo Brand of Methoxsalen; Methoxsalen (JP15/USP); Methoxy-8-psoralen; 5-Benzofuranacrylic acid, 6-hydroxy-7-methoxy-, .delta.-lactone; 5-Benzofuranacrylic acid, 6-hydroxy-7-methoxy-, delta-lactone; 6-Hydroxy-7-methoxy-5-benzofuranacrylic acid delta-lactone; 7-Furocoumarin; 8 Methoxypsoralen; 8-METHOXYPSORALEN + UVA (SEE ALSO C55903); 8-MOP; 8-Methoxy; 8-Methoxy(furano-3'.2':6.7-coumarin); 8-Methoxy-(furano-3'.2':6.7-coumarin); 8-Methoxy-2',3',6,7-furocoumarin; 8-Methoxy-4',5',6,7-furocoumarin; 8-Methoxy-4',5':6,7-furocoumarin; 8-Methoxy-[furano-3'.2':6.7-coumarin]; 8-Methoxyfuranocoumarin; 8-Methoxypsoralen; 8-Methoxypsoralen with ultraviolet A therapy; 8-Methoxypsoralene; 8-methoxyfuranocoumarins; 8-methoxyfurocoumarins; 8MO; 8MOP; 9-(methyloxy)-7H-furo[3,2-g]chromen-7-one; 9-Methoxy-7H-furo(3,2-g)(1)benzopyran-7-one; 9-Methoxy-7H-furo(3,2-g)benzopyran-7-one; 9-Methoxy-7H-furo[3,2-g][1]benzopyran-7-one; 9-Methoxy-7H-furo[3,2-g]chromen-7-one; 9-Methoxyfuro(3,2-g)chromen-7-one; 9-Methoxyfuro[3,2-g][1]benzopyran-7-one; 9-Methoxypsoralen; 9-metho xy-7H-furo(3,2-g)benzopyran-7-one; 9-methoxyfuro[3,2-g]chromen-7-one DME8FZ9 TC Anticancer Agents DME8FZ9 DT Small molecular drug DME8FZ9 PC 4114 DME8FZ9 MW 216.19 DME8FZ9 FM C12H8O4 DME8FZ9 IC InChI=1S/C12H8O4/c1-14-12-10-8(4-5-15-10)6-7-2-3-9(13)16-11(7)12/h2-6H,1H3 DME8FZ9 CS COC1=C2C(=CC3=C1OC=C3)C=CC(=O)O2 DME8FZ9 IK QXKHYNVANLEOEG-UHFFFAOYSA-N DME8FZ9 IU 9-methoxyfuro[3,2-g]chromen-7-one DME8FZ9 CA CAS 298-81-7 DME8FZ9 CB CHEBI:18358 DME8FZ9 DE Cutaneous T-cell lymphoma; Psoriasis vulgaris DMK1LZD ID DMK1LZD DMK1LZD DN Methoxy polyethylene glycol-epoetin beta DMK1LZD HS Approved DMK1LZD SN Mircera (TN) DMK1LZD DE Kidney transplant rejection DML0RAE ID DML0RAE DML0RAE DN Methoxyflurane DML0RAE HS Approved DML0RAE SN Analgizer; Anecotan; Ingalan; Inhalan; Methofane; Methoflurane; Methofluranum; Methoxane; Methoxiflurane; Methoxifluranum;Methoxyfluoran; Methoxyfluorane; Methoxyfluran; Methoxyfluranum; Metofane; Metossiflurano; Metoxfluran; Metoxifluran; Metoxiflurano; Penthrane; Pentran; Pentrane; Metossiflurano [DCIT]; Methoxyflurane [Anaesthetics, volatile]; Methoxyfluranum [INN-Latin]; Metofane (VAN); Metoxiflurano [INN-Spanish]; Penthrane (TN); Penthrane (VAN); Methoxyflurane (USP/INN); Methoxyflurane [USAN:INN:BAN]; Methyl 1,1-difluoro-2,2-dichloroethyl ether; Ether, 2,2-dichloro-1,1-difluoroethyl methyl; (2,2-dichloro-1,1-difluoroethyl) methyl ether; 2,2-Dichloro-1,1-difluoro-1-methoxyethane; 2,2-Dichloro-1,1-difluoroethyl methyl ether DML0RAE TC Anesthetics DML0RAE DT Small molecular drug DML0RAE PC 4116 DML0RAE MW 164.96 DML0RAE FM C3H4Cl2F2O DML0RAE IC InChI=1S/C3H4Cl2F2O/c1-8-3(6,7)2(4)5/h2H,1H3 DML0RAE CS COC(C(Cl)Cl)(F)F DML0RAE IK RFKMCNOHBTXSMU-UHFFFAOYSA-N DML0RAE IU 2,2-dichloro-1,1-difluoro-1-methoxyethane DML0RAE CA CAS 76-38-0 DML0RAE CB CHEBI:6843 DML0RAE DE Anaesthesia DMHP8FI ID DMHP8FI DMHP8FI DN Methscopolamine bromide DMHP8FI HS Approved DMHP8FI SN Pamine Forte DMHP8FI CP Private Formulations Inc DMHP8FI DT Small molecular drug DMHP8FI PC 5459110 DMHP8FI MW 398.3 DMHP8FI FM C18H24BrNO4 DMHP8FI IC InChI=1S/C18H24NO4.BrH/c1-19(2)14-8-12(9-15(19)17-16(14)23-17)22-18(21)13(10-20)11-6-4-3-5-7-11;/h3-7,12-17,20H,8-10H2,1-2H3;1H/q+1;/p-1/t12?,13-,14-,15+,16-,17+;/m1./s1 DMHP8FI CS C[N+]1([C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4)C.[Br-] DMHP8FI IK CXYRUNPLKGGUJF-OZVSTBQFSA-M DMHP8FI IU [(1R,2R,4S,5S)-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonan-7-yl] (2S)-3-hydroxy-2-phenylpropanoate;bromide DMHP8FI CA CAS 155-41-9 DMHP8FI CB CHEBI:61276 DMHP8FI DE Nausea and vomiting DM6L5VO ID DM6L5VO DM6L5VO DN Methsuximide DM6L5VO HS Approved DM6L5VO SN Celontin; Mesuximid; Mesuximida; Mesuximide; Mesuximidum; Methsuximid; Metosuccimmide; Metsuccimide; Petinutin; Methsuximide [BAN]; Metosuccimmide [DCIT]; PM 396; Alpha-Methylphensuximide; Celontin (TN); Mesuximida [INN-Spanish]; Mesuximide (INN); Mesuximidum [INN-Latin]; Methsuximide (USP); Petinutin (TN); Alpha-Methyl-alpha-phenyl N-methyl succinimide; N,2-Dimethyl-2-phenylsuccinimide; N-Methyl-alpha-methyl-alpha-phenylsuccinimide; (+-)-N,2-Dimethyl-2-phenylsuccinimide; (RS)-1,3-Dimethyl-3-phenyl-2,5-pyrrolidindion; 1,3-Dimethyl-3-phenyl-2,5-dioxopyrrolidine; 1,3-Dimethyl-3-phenyl-2,5-pyrrolidinedione; 1,3-Dimethyl-3-phenyl-pyrrolidin-2,5-dione; 1,3-Dimethyl-3-phenylsuccinimide; 1,3-dimethyl-3-phenylpyrrolidine-2,5-dione DM6L5VO CP Pfizer Pharmaceuticals DM6L5VO TC Anticonvulsants DM6L5VO DT Small molecular drug DM6L5VO PC 6476 DM6L5VO MW 203.24 DM6L5VO FM C12H13NO2 DM6L5VO IC InChI=1S/C12H13NO2/c1-12(9-6-4-3-5-7-9)8-10(14)13(2)11(12)15/h3-7H,8H2,1-2H3 DM6L5VO CS CC1(CC(=O)N(C1=O)C)C2=CC=CC=C2 DM6L5VO IK AJXPJJZHWIXJCJ-UHFFFAOYSA-N DM6L5VO IU 1,3-dimethyl-3-phenylpyrrolidine-2,5-dione DM6L5VO CA CAS 77-41-8 DM6L5VO CB CHEBI:6846 DM6L5VO DE Epileptic seizures DMN7SDE ID DMN7SDE DMN7SDE DN Methyclothiazide DMN7SDE HS Approved DMN7SDE SN Aquaresen; Aquatensen; Duretic; Enduron; Enduronum; METHYLCLOTHIAZIDE; Methychlothiazide; Methyclothiazid; Methyclothiazidum;Methycyclothiazide; Methylchlorothiazide; Methylcyclothiazide; Meticlotiazida; Meticlotiazide; Naturon; Meticlotiazide [DCIT]; Ciba 7272-Su; Enduron (TN); Methyclothiazidum [INN-Latin]; Meticlotiazida [INN-Spanish]; Naturon (VAN); Methyclothiazide (JAN/USP/INN); Methyclothiazide [USAN:INN:BAN:JAN]; (+-)-6-Chloro-3-(chloromethyl)-3,4-dihydro-2-methyl-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3-(chloromethyl)-3,4-dihydro-,1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3-(chloromethyl)-3,4-dihydro-2-methyl-, 1,1-dioxid;2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3-(chloromethyl)-3,4-dihydro-2-methyl-, 1,1-dioxide; 6-Chloro-3-(chloromethyl)-2-methyl-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 6-Chloro-3-(chloromethyl)-3,4-dihydro-2-methyl-2H-1,2, 4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 6-Chloro-3-(chloromethyl)-3,4-dihydro-2-methyl-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 6-Chloro-3-chloromethyl-2-methyl-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine 1,1-dioxide; 6-chloro-3-(chloromethyl)-2-methyl-1,1-dioxo-3,4-dihydro-1 DMN7SDE TC Antihypertensive Agents DMN7SDE DT Small molecular drug DMN7SDE PC 4121 DMN7SDE MW 360.2 DMN7SDE FM C9H11Cl2N3O4S2 DMN7SDE IC InChI=1S/C9H11Cl2N3O4S2/c1-14-9(4-10)13-6-2-5(11)7(19(12,15)16)3-8(6)20(14,17)18/h2-3,9,13H,4H2,1H3,(H2,12,15,16) DMN7SDE CS CN1C(NC2=CC(=C(C=C2S1(=O)=O)S(=O)(=O)N)Cl)CCl DMN7SDE IK CESYKOGBSMNBPD-UHFFFAOYSA-N DMN7SDE IU 6-chloro-3-(chloromethyl)-2-methyl-1,1-dioxo-3,4-dihydro-1lambda6,2,4-benzothiadiazine-7-sulfonamide DMN7SDE CA CAS 135-07-9 DMN7SDE CB CHEBI:6847 DMN7SDE DE Edema; Hypertension DMIUX3D ID DMIUX3D DMIUX3D DN Methyl aminolevulinate DMIUX3D HS Approved DMIUX3D SN Metvix; Aminolevulinic acid methyl ester; Methyl 5-aminolevulinate; Methyl delta-aminolevulinate; Methyl5-amino-4-oxopentanoate; Levulinic acid, 5-amino-, methyl ester; Pentanoic acid, 5-amino-4-oxo-, methyl ester; 5-Aminolevulinic acid methyl ester DMIUX3D TC Anticancer Agents DMIUX3D DT Small molecular drug DMIUX3D PC 157922 DMIUX3D MW 145.16 DMIUX3D FM C6H11NO3 DMIUX3D IC InChI=1S/C6H11NO3/c1-10-6(9)3-2-5(8)4-7/h2-4,7H2,1H3 DMIUX3D CS COC(=O)CCC(=O)CN DMIUX3D IK YUUAYBAIHCDHHD-UHFFFAOYSA-N DMIUX3D IU methyl 5-amino-4-oxopentanoate DMIUX3D CA CAS 33320-16-0 DMIUX3D CB CHEBI:724125 DMIUX3D DE Acne vulgaris DM5I621 ID DM5I621 DM5I621 DN Methyldopa DM5I621 HS Approved DM5I621 SN AMD; Aldometil; Aldomin; Alphamethyldopa; Baypresol; Becanta; Dopamet; Dopamethyperpax; Dopatec; Dopegit; Dopegyt; Dopergit; Grospisk; Hyperpax; Hypolag; Medomet; Medopa; Medopal; Medopren; Methoplain; Methyldopum; Metildopa; Novomedopa; Presinol; Presolisin; Sedometil; Sembrina; Alpha medopa; Methyl dopa; Methyldopa anhydrous; Aldoril D30; Aldoril D50; Bayer 1440 L; LT00847269; MK 351; Aldomet (TN); Aldoril (TN); Alpha-Methyl dopa; Alpha-Methyldihydroxyphenylalanine; Alpha-Methyldopa; Apo-Methyldopa; Dopamet (TN); Dopegyt (TN); L-Methyl Dopa; L-Methyldopa; METHYL DOPA (SEE ALSO METHYL DOPA SESQUIHYDRATE); MK-351; Methyldopa (INN); Methyldopa (anhydrous); Methyldopum [INN-Latin]; Metildopa [INN-Spanish]; Mk. b51; Nr.C 2294; Nu-Medopa; Alpha-Methyldopa (VAN); L-alpha-Methyl DOPA; L-alpha-Methyldopa; Methyl-L-dopa; Aldoril, Dopamet, Dopegyt, Methyldopa; L-(alpha-Md); Methyldopa (L,-); Alpha-Methyl-L-3,4-dihydroxyphenylalanine; L-alpha-Methyl-3,4-dihydroxyphenylalanine; L-3-(3,4-Dihydroxyphenyl)-2-methylalanine; Levo-3-(3,4-Dihydroxyphenyl)-2-methylalanine; Alpha-Methyl-beta-(3,4-dihydroxyphenyl)-L-alanine; L(-)-beta-(3,4-Dihydroxyphenyl)-alpha-methylalanine; L-2-Amino-2-methyl-3-(3,4-dihydroxyphenyl)propionic acid; L-(-)-3-(3,4-Dihydroxyphenyl)-2-methylalanine; L-(-)-alpha-Methyl-beta-(3,4-dihydroxyphenyl)alanine; (-)-3-(3,4-Dihydroxyphenyl)-2-Methyl-L-Alanine Sesqui-Hydrate; (2S)-2-amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoic acid; (S)-(-)-alpha-Methyldopa; 3-(3,4-DIHYDROXYPHENYL)-2-METHYL-L-ALANINE; 3-Hydroxy-.alpha.-methyl-L-tyrosine; 3-Hydroxy-alpha-methyl-L-tyrosine DM5I621 CP Ivax pharmaceutical DM5I621 TC Antihypertensive Agents DM5I621 DT Small molecular drug DM5I621 PC 38853 DM5I621 MW 211.21 DM5I621 FM C10H13NO4 DM5I621 IC InChI=1S/C10H13NO4/c1-10(11,9(14)15)5-6-2-3-7(12)8(13)4-6/h2-4,12-13H,5,11H2,1H3,(H,14,15)/t10-/m0/s1 DM5I621 CS C[C@](CC1=CC(=C(C=C1)O)O)(C(=O)O)N DM5I621 IK CJCSPKMFHVPWAR-JTQLQIEISA-N DM5I621 IU (2S)-2-amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoic acid DM5I621 CA CAS 555-30-6 DM5I621 CB CHEBI:61058 DM5I621 DE Hypertension DM8XI09 ID DM8XI09 DM8XI09 DN Methyldopate Hydrochloride DM8XI09 HS Approved DM8XI09 CP Merck And Co Inc DM8XI09 TC Cardiovascular Agents DM8XI09 DT Small molecular drug DM8XI09 PC 17276 DM8XI09 MW 275.73 DM8XI09 FM C12H18ClNO4 DM8XI09 IC InChI=1S/C12H17NO4.ClH/c1-3-17-11(16)12(2,13)7-8-4-5-9(14)10(15)6-8;/h4-6,14-15H,3,7,13H2,1-2H3;1H/t12-;/m0./s1 DM8XI09 CS CCOC(=O)[C@](C)(CC1=CC(=C(C=C1)O)O)N.Cl DM8XI09 IK QSRVZCCJDKYRRF-YDALLXLXSA-N DM8XI09 IU ethyl (2S)-2-amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoate;hydrochloride DM8XI09 CA CAS 2508-79-4 DM8XI09 DE Hypertension DMJAPE7 ID DMJAPE7 DMJAPE7 DN Methylene blue DMJAPE7 HS Approved DMJAPE7 SN methylene blue; 61-73-4; Methylthioninium chloride; Swiss Blue; Chromosmon; Methylene Blue N; Methylenium ceruleum; Urolene blue; Methylene Blue chloride; Solvent blue 8; Bleu de methylene; Methylene Blue G; Methylene Blue A; External Blue 1; Methylene Blue D; Methylene Blue B; Methylene Blue anhydrous; CI Basic Blue 9; Methylene Blue ZF; Methylene Blue SP; Methylene Blue NZ; Methylene Blue BX; Methylene Blue BD; Methylene Blue SG; Tetramethylene Blue; Methylene Blue ZX; Methylene Blue FZ; Methylene Blue BP; Calcozine; 3,7-Bis-dimethylamino-phenothiazin-5-ylium DMJAPE7 PC 6099 DMJAPE7 MW 319.9 DMJAPE7 FM C16H18ClN3S DMJAPE7 IC InChI=1S/C16H18N3S.ClH/c1-18(2)11-5-7-13-15(9-11)20-16-10-12(19(3)4)6-8-14(16)17-13;/h5-10H,1-4H3;1H/q+1;/p-1 DMJAPE7 CS CN(C)C1=CC2=C(C=C1)N=C3C=CC(=[N+](C)C)C=C3S2.[Cl-] DMJAPE7 IK CXKWCBBOMKCUKX-UHFFFAOYSA-M DMJAPE7 IU [7-(dimethylamino)phenothiazin-3-ylidene]-dimethylazanium;chloride DMJAPE7 CA CAS 61-73-4 DMJAPE7 CB CHEBI:6872 DMJAPE7 DE Acquired methemoglobinemia DMBEX4O ID DMBEX4O DMBEX4O DN Methylergonovine DMBEX4O HS Approved DMBEX4O SN Basofortina; Ergotyl; Metenarin; Methergen; Methergin; Methergine; Methylergobasin; Methylergobasine; Methylergobrevin; Methylergometrin; Methylergometrine; Methylergometrinum; Methylergonovin; Metilergometrina; Metilergometrinio; Partergin; Ryegonovin; Lysergic acid butanolamide; Methylergometrine maleate; Metilergometrina [DCIT]; ME 277; Ergotyl (TN); Methergine (TN); Methylergometrine (INN); Methylergometrine [INN:BAN]; Methylergometrinum [INN-Latin]; Metilergometrinio [INN-Spanish]; Spametrin-M; D-Lysergic acid-dl-hydroxybutylamide-2; N-(alpha-(Hydroxymethyl)propyl)-D-lysergamide; D-Lysergic acid-(+)-butanolamide-(2); (8beta)-N-[(1S)-1-(hydroxymethyl)propyl]-6-methyl-9,10-didehydroergoline-8-carboxamide; 9,10-Didehydro-N-(1-(hydroxymethyl)propyl)-6-methylergoline-8-carboxamide; 9,10-Didehydro-N-(alpha-(hydroxymethyl)propyl)-6-methyl-ergoline-8-beta-carboxamide DMBEX4O CP Edison Therapeutics Llc DMBEX4O TC Oxytocics DMBEX4O DT Small molecular drug DMBEX4O PC 8226 DMBEX4O MW 339.4 DMBEX4O FM C20H25N3O2 DMBEX4O IC InChI=1S/C20H25N3O2/c1-3-14(11-24)22-20(25)13-7-16-15-5-4-6-17-19(15)12(9-21-17)8-18(16)23(2)10-13/h4-7,9,13-14,18,21,24H,3,8,10-11H2,1-2H3,(H,22,25)/t13-,14+,18-/m1/s1 DMBEX4O CS CC[C@@H](CO)NC(=O)[C@H]1CN([C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1)C DMBEX4O IK UNBRKDKAWYKMIV-QWQRMKEZSA-N DMBEX4O IU (6aR,9R)-N-[(2S)-1-hydroxybutan-2-yl]-7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide DMBEX4O CA CAS 113-42-8 DMBEX4O CB CHEBI:92607 DMBEX4O DE Spontaneous abortion DMZTGN2 ID DMZTGN2 DMZTGN2 DN Methylnaltrexone bromide DMZTGN2 HS Approved DMZTGN2 SN Relistor; Methylnaltrexone (Bromide); Naltrexone methobromide; 73232-52-7; N-Methylnaltrexone Bromide; MRZ-2663BR; N-Cyclopropylmethyl-noroxymorphone Methobromide; Methylnaltrexone; MNTX; C21H26NO4Br; MOA-728; Relistor (TN); MRZ 2663BR; Naltrexone Methyl Bromide; N-Methyl Naltrexone Bromide; MNTX-302; SCHEMBL2798188; CHEMBL1201770; IFGIYSGOEZJNBE-KNLJMPJLSA-N; ONO-3849; Methylnaltrexone bromide (JAN/USAN); 3844AH; AKOS015896214; CS-0762; AN-37324; HY-75766; Methylnaltrexone bromide, > W-5330; CHIR-01020 DMZTGN2 CP Progenics DMZTGN2 DT Small molecular drug DMZTGN2 PC 5361917 DMZTGN2 MW 436.3 DMZTGN2 FM C21H26BrNO4 DMZTGN2 IC InChI=1S/C21H25NO4.BrH/c1-22(11-12-2-3-12)9-8-20-17-13-4-5-14(23)18(17)26-19(20)15(24)6-7-21(20,25)16(22)10-13;/h4-5,12,16,19,25H,2-3,6-11H2,1H3;1H/t16-,19+,20+,21-,22?;/m1./s1 DMZTGN2 CS C[N+]1(CC[C@]23[C@@H]4C(=O)CC[C@]2([C@H]1CC5=C3C(=C(C=C5)O)O4)O)CC6CC6.[Br-] DMZTGN2 IK IFGIYSGOEZJNBE-KNLJMPJLSA-N DMZTGN2 IU (4R,4aS,7aR,12bS)-3-(cyclopropylmethyl)-4a,9-dihydroxy-3-methyl-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-3-ium-7-one;bromide DMZTGN2 CA CAS 73232-52-7 DMZTGN2 DE Opioid-induced constipation; Obesity DM7SJD6 ID DM7SJD6 DM7SJD6 DN Methylphenidate DM7SJD6 HS Approved DM7SJD6 SN Calocain; Centedein; Centedrin; Centredin; Concerta; Daytrana; Meridil; Metadate; Methylfenidan; Methylin; Methylofenidan; Methylphen; Methylphenidan; Methylphenidatum; Metilfenidato; Phenidylate; Plimasine; Riphenidate; Ritalin; Ritaline; Tsentedrin; Metadate CD; Metadate ER; Methyl phenidate; Methyl phenidyl acetate; Methyl phenidylacetate; Methylin ER; Metilfenidato [Italian]; Ritalin LA; Ritalin SR; Ritcher works; C 4311; Attenta (TN); Biphentin (TN); Concerta (TN); D-methylphenidate HCl; Daytrana (TN); Equasym (TN); Metadate ER (TN); Methylin (TN); Methylphenidate [INN:BAN]; Methylphenidatum [INN-Latin]; Metilfenidato [INN-Spanish]; Motiron (TN); PMS-Methylphenidate; Ritalin (TN); Ritalin LA (TN); Ritalin-SR; Rubifen (TN); Methylphenidate (USAN/INN); Alpha-Phenyl-2-piperidineacetic acid methyl ester; Methyl phenyl(piperidin-2-yl)acetate; Methyl alpha-phenyl-alpha-2-piperidinylacetate; Alpha-Phenyl-alpha-(2-piperidyl)acetic acid methyl ester; Methyl 2-phenyl-2-piperidin-2-ylacetate; Methyl alpha-phenyl-alpha-(2-piperidyl)acetate; Methyl (2-phenyl-2-(2-piperidyl)acetate); METHYLPHENIDATE (SEE ALSO: METHYLPHENIDATE HYDROCHLORIDE, CAS 298-59-9, NTPNO 10266-R); 2-Piperidineacetic acid, .alpha.-phenyl-, methyl ester; 2-Piperidineacetic acid, alpha-phenyl-, methyl ester DM7SJD6 CP Novartis DM7SJD6 TC Central Nervous System Stimulants DM7SJD6 DT Small molecular drug DM7SJD6 PC 4158 DM7SJD6 MW 233.31 DM7SJD6 FM C14H19NO2 DM7SJD6 IC InChI=1S/C14H19NO2/c1-17-14(16)13(11-7-3-2-4-8-11)12-9-5-6-10-15-12/h2-4,7-8,12-13,15H,5-6,9-10H2,1H3 DM7SJD6 CS COC(=O)C(C1CCCCN1)C2=CC=CC=C2 DM7SJD6 IK DUGOZIWVEXMGBE-UHFFFAOYSA-N DM7SJD6 IU methyl 2-phenyl-2-piperidin-2-ylacetate DM7SJD6 CA CAS 113-45-1 DM7SJD6 CB CHEBI:84276 DM7SJD6 DE Attention deficit hyperactivity disorder; Traumatic brain injury DMDSWAG ID DMDSWAG DMDSWAG DN Methylphenobarbital DMDSWAG HS Approved DMDSWAG SN Enfenemal; Enphenemal; Enphenemalum; Mebaral; Meberal; Mebroin; Mephobarbital; Mephobarbitone; Mephytal; Methylphenobarbitalum; Methylphenobarbitone; Methylphenobarbitonum; Methylphenolbarbital; Metilfenobarbital; Metilfenobarbitale; Metylfenemal; Metyna; Morbusan; Phemetone; Phemiton; Phemitone; Phenmiton; Prominal; Prominaletten; Prominalum; Mephobarbital [JAN]; Methyl phenobarbitone; Methylphenylbarbituric acid; Metilfenobarbitale [DCIT]; Sanofi Brand of Mephobarbital; Sanofi Synthelabo Brand of Mephobarbital; Isonal (roussel); Mebaral (TN); Menta-Bal; Methyl-calminal; Methylphenobarbital (INN); Methylphenobarbitalum [INN-Latin]; Metilfenobarbital [INN-Spanish]; N-Ethylmethylphenylbarbituric acid; N-Methylethylphenylbarbituric acid; N-Methylphenobarbital; N-Methylphenolbarbitol; Mephobarbital (JAN/USP); N-Methyl-5-phenyl-5-ethylbarbital; 1-Methyl-5-ethyl-5-phenylbarbituric acid; 1-Methyl-5-phenyl-5-ethylbarbituric acid; 1-Methylphenobarbital; 5-Ethyl-1-methyl-5-phenyl-2,4,6(1H,3H,5H)-pyrimidinetrione; 5-Ethyl-1-methyl-5-phenylbarbituric acid; 5-Ethyl-5-phenyl-N-methyl-bartituric acid; 5-Ethyl-N-methyl-5-phenylbarbituric acid; 5-Phenyl-5-ethyl-3-methylbarbituric acid; 5-ethyl-1-methyl-5-phenyl-1,3-diazinane-2,4,6-trione; 5-ethyl-1-methyl-5-phenylpyrimidine-2,4,6(1H,3H,5H)-trione DMDSWAG CP Ovation Pharmaceuticals DMDSWAG TC Hypnotics and Sedatives DMDSWAG DT Small molecular drug DMDSWAG PC 8271 DMDSWAG MW 246.26 DMDSWAG FM C13H14N2O3 DMDSWAG IC InChI=1S/C13H14N2O3/c1-3-13(9-7-5-4-6-8-9)10(16)14-12(18)15(2)11(13)17/h4-8H,3H2,1-2H3,(H,14,16,18) DMDSWAG CS CCC1(C(=O)NC(=O)N(C1=O)C)C2=CC=CC=C2 DMDSWAG IK ALARQZQTBTVLJV-UHFFFAOYSA-N DMDSWAG IU 5-ethyl-1-methyl-5-phenyl-1,3-diazinane-2,4,6-trione DMDSWAG CA CAS 115-38-8 DMDSWAG CB CHEBI:6758 DMDSWAG DE Anxiety disorder DM4BDON ID DM4BDON DM4BDON DN Methylprednisolone DM4BDON HS Approved DM4BDON SN Depo-medrol; M-predrol; Medrol; Medrol Acetate DM4BDON CP Pharmacia And Upjohn Co DM4BDON TC Anticancer Agents DM4BDON DT Small molecular drug DM4BDON PC 6741 DM4BDON MW 374.5 DM4BDON FM C22H30O5 DM4BDON IC InChI=1S/C22H30O5/c1-12-8-14-15-5-7-22(27,18(26)11-23)21(15,3)10-17(25)19(14)20(2)6-4-13(24)9-16(12)20/h4,6,9,12,14-15,17,19,23,25,27H,5,7-8,10-11H2,1-3H3/t12-,14-,15-,17-,19+,20-,21-,22-/m0/s1 DM4BDON CS C[C@H]1C[C@H]2[C@@H]3CC[C@@]([C@]3(C[C@@H]([C@@H]2[C@@]4(C1=CC(=O)C=C4)C)O)C)(C(=O)CO)O DM4BDON IK VHRSUDSXCMQTMA-PJHHCJLFSA-N DM4BDON IU (6S,8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-17-(2-hydroxyacetyl)-6,10,13-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one DM4BDON CA CAS 83-43-2 DM4BDON CB CHEBI:6888 DM4BDON DE Solid tumour/cancer; Spinal cord injury DM5VWOB ID DM5VWOB DM5VWOB DN Methylscopolamine DM5VWOB HS Approved DM5VWOB SN Methscopolamine; methscopolamine; N-Methylscopolamine; N-methyl scopolamine; UNII-VDR09VTQ8U; VDR09VTQ8U; 13265-10-6; CHEMBL376897; (1r,2r,4s,5s)-7-{[(2s)-3-hydroxy-2-phenylpropanoyl]oxy}-9,9-dimethyl-3-oxa-9-azoniatricyclo[33102,4]nonane; Metylskopolamin; 56552-70-6; 3-Oxa-9-azoniatricyclo[33102,4]nonane, 7-[(2S)-3-hydroxy-1-oxo-2-phenylpropoxy]-9,9-dimethyl-, (1a,2b,4b,5a,7b); HSDB 5420; [3H]N-methylscopolamine; [3H]N-methyl scopolamine; [3H]NMS; Methyl scopolamine; 3C0 DM5VWOB TC Anticholinergic Agents DM5VWOB DT Small molecular drug DM5VWOB PC 71183 DM5VWOB MW 318.4 DM5VWOB FM C18H24NO4+ DM5VWOB IC InChI=1S/C18H24NO4/c1-19(2)14-8-12(9-15(19)17-16(14)23-17)22-18(21)13(10-20)11-6-4-3-5-7-11/h3-7,12-17,20H,8-10H2,1-2H3/q+1/t12?,13-,14-,15+,16-,17+/m1/s1 DM5VWOB CS C[N+]1([C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4)C DM5VWOB IK LZCOQTDXKCNBEE-XJMZPCNVSA-N DM5VWOB IU [(1S,2S,4R,5R)-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonan-7-yl] (2S)-3-hydroxy-2-phenylpropanoate DM5VWOB CA CAS 13265-10-6 DM5VWOB CB CHEBI:135361 DM5VWOB DE Peptic ulcer DMWLFGO ID DMWLFGO DMWLFGO DN Methyltestosterone DMWLFGO HS Approved DMWLFGO SN Android (TN) DMWLFGO CP Valeant Pharmaceuticals DMWLFGO DT Small molecular drug DMWLFGO PC 6010 DMWLFGO MW 302.5 DMWLFGO FM C20H30O2 DMWLFGO IC InChI=1S/C20H30O2/c1-18-9-6-14(21)12-13(18)4-5-15-16(18)7-10-19(2)17(15)8-11-20(19,3)22/h12,15-17,22H,4-11H2,1-3H3/t15-,16+,17+,18+,19+,20+/m1/s1 DMWLFGO CS C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC[C@]4(C)O)C DMWLFGO IK GCKMFJBGXUYNAG-HLXURNFRSA-N DMWLFGO IU (8R,9S,10R,13S,14S,17S)-17-hydroxy-10,13,17-trimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one DMWLFGO CA CAS 58-18-4 DMWLFGO CB CHEBI:27436 DMWLFGO DE Solid tumour/cancer DMBW7VH ID DMBW7VH DMBW7VH DN Methyprylon DMBW7VH HS Approved DMBW7VH SN Dimerin; Methprylon; Methyprolon; Methyprylone; Methyprylonum; Metiprilon; Metiprilona; Metiprilone; Noctan; Nodular; Noludar; Methyprylon [INN]; Methyprylone [INN-French]; Methyprylonum [INN-Latin]; Metiprilona [INN-Spanish]; Noludar (TN); Ro 1-6463; Methyprylon (JAN/INN); 2,4-Dioxo-3,3-diethyl-5-methylpiperidine; 2,4-Dioxy-3,3-diethyl-5-methylpiperidine; 3,3-Diethyl-2,4-dioxo-5-methylpiperidine; 3,3-Diethyl-5-methyl-2,4-piperidinedione; 3,3-Diethyl-5-methylpiperidine-2,4-dione DMBW7VH TC Sedatives and Hypnotics DMBW7VH DT Small molecular drug DMBW7VH PC 4162 DMBW7VH MW 183.25 DMBW7VH FM C10H17NO2 DMBW7VH IC InChI=1S/C10H17NO2/c1-4-10(5-2)8(12)7(3)6-11-9(10)13/h7H,4-6H2,1-3H3,(H,11,13) DMBW7VH CS CCC1(C(=O)C(CNC1=O)C)CC DMBW7VH IK SIDLZWOQUZRBRU-UHFFFAOYSA-N DMBW7VH IU 3,3-diethyl-5-methylpiperidine-2,4-dione DMBW7VH CA CAS 125-64-4 DMBW7VH CB CHEBI:31837 DMBW7VH DE Insomnia DM1EF73 ID DM1EF73 DM1EF73 DN Methysergide DM1EF73 HS Approved DM1EF73 SN Deseril; Desernil; Desernyl; Deseryl; Desril; Dimethylergometrin; Methylmethylergonovine; Methysergid; Methysergidum; Metisergide; Metisergido; Sansert; Methyllysergic acid butanolamide; Metisergide [DCIT]; UML 491; Deseril (TN); Methysergidum [INN-Latin]; Metisergido [INN-Spanish]; Sansert (TN); UML-491; Methysergide (USAN/INN); Methysergide [USAN:INN:BAN]; N-(alpha-(Hydroxymethyl)propyl)-1-methyl-dextro-lysergamide; N-(1-(Hydroxymethyl)propyl)-1-methyl-dextro-(+)-lysergamide; (+)-9,10-Didehydro-N-(1-(hydroxymethyl)propyl)-1,6-dimethylergoline-8beta-carboxamide; (+)-N-(1-(Hydroxymethyl)propyl)-1-methyl-D-lysergamide; (8beta)-N-[(1S)-1-(hydroxymethyl)propyl]-1,6-dimethyl-9,10-didehydroergoline-8-carboxamide; 1-Methyl-D-lysergic acid butanolamide; 1-Methyl-dextro-lysergic acid (+)-1-hydroxy-2-butylamide; 1-Methylmethylergonovine; 9,10-Didehydro-N-(1-(hydroxymethyl)propyl)-1,6-dimethylergoline-8-carboxamide DM1EF73 CP Norvatis Phamaceuticals Corporation DM1EF73 TC Vasoconstrictor Agents DM1EF73 DT Small molecular drug DM1EF73 PC 9681 DM1EF73 MW 353.5 DM1EF73 FM C21H27N3O2 DM1EF73 IC InChI=1S/C21H27N3O2/c1-4-15(12-25)22-21(26)14-8-17-16-6-5-7-18-20(16)13(10-23(18)2)9-19(17)24(3)11-14/h5-8,10,14-15,19,25H,4,9,11-12H2,1-3H3,(H,22,26)/t14-,15+,19-/m1/s1 DM1EF73 CS CC[C@@H](CO)NC(=O)[C@H]1CN([C@@H]2CC3=CN(C4=CC=CC(=C34)C2=C1)C)C DM1EF73 IK KPJZHOPZRAFDTN-ZRGWGRIASA-N DM1EF73 IU (6aR,9R)-N-[(2S)-1-hydroxybutan-2-yl]-4,7-dimethyl-6,6a,8,9-tetrahydroindolo[4,3-fg]quinoline-9-carboxamide DM1EF73 CA CAS 361-37-5 DM1EF73 CB CHEBI:92629 DM1EF73 DE Migraine DMIKHN0 ID DMIKHN0 DMIKHN0 DN Meticillin DMIKHN0 HS Approved DMIKHN0 SN Dimocillin; MII; Metacillin; Methicillin; Methicillinum; Methycillin; Meticilina; Meticillina; Meticilline; Meticillinum; Staphcillin; Methicillin [BAN]; Meticillin [INN]; Meticillina [DCIT]; BRL 1241; Methicillin Monohydrate, Monosodium Salt; Meticilina [INN-Spanish]; Meticilline [INN-French]; Meticillinum [INN-Latin]; Penicillin, Dimethoxyphenyl; (2,6-Dimethoxyphenyl)penicillin; (2S,5R,6R)-6-[(2,6-dimethoxybenzoyl)amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-{[(2,6-dimethoxyphenyl)carbonyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 6-(2,3-Dimethoxybenzamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid; 6-(2,6-Dimethoxybenzamido)penicillanic acid; 6beta-(2,6-dimethoxybenzamido)-2,2-dimethylpenam-3alpha-carboxylic acid; 6beta-(2,6-dimethoxybenzamido)penicillanic acid DMIKHN0 CP Beecham phamaceuticals DMIKHN0 TC Antibiotics DMIKHN0 DT Small molecular drug DMIKHN0 PC 6087 DMIKHN0 MW 380.4 DMIKHN0 FM C17H20N2O6S DMIKHN0 IC InChI=1S/C17H20N2O6S/c1-17(2)12(16(22)23)19-14(21)11(15(19)26-17)18-13(20)10-8(24-3)6-5-7-9(10)25-4/h5-7,11-12,15H,1-4H3,(H,18,20)(H,22,23)/t11-,12+,15-/m1/s1 DMIKHN0 CS CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)C3=C(C=CC=C3OC)OC)C(=O)O)C DMIKHN0 IK RJQXTJLFIWVMTO-TYNCELHUSA-N DMIKHN0 IU (2S,5R,6R)-6-[(2,6-dimethoxybenzoyl)amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid DMIKHN0 CA CAS 61-32-5 DMIKHN0 CB CHEBI:6827 DMIKHN0 DE Bacterial infection; Neurological disorder DMJMVKI ID DMJMVKI DMJMVKI DN Metipranolol DMJMVKI HS Approved DMJMVKI SN Disorat; Methypranol; Metipranololum; Trimepranol; Turoptin; BM-01004; Betanol (TN); Disorat (TN); Metipranololum [INN-Latin]; OptiPranolol (TN); Trimepranol (TN); VUAB-6453; VUFB-6453; Metipranolol (USAN/INN); Metipranolol [USAN:BAN:INN]; [4-[2-hydroxy-3-(propan-2-ylamino)propoxy]-2,3,6-trimethylphenyl] acetate; Phenol, 4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)-2,3,6-trimethyl-, 1-acetate; Phenol, 4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)-2,3,6-trimethyl-, 1-acetate (9CI); Phenol,4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)-2,3,6-trimethyl-, (+-)-, 1-acetate; (+-)-1-(4-Hydroxy-2,3,5-trimethylphenoxy)-3-(isopropylamino)-2-propanol 4-acetate; (RS)-4-(2-Hydroxy-3-isopropylaminopropoxy)-2,3,6-trimethylphenyl acetat; 1-(4-Acetoxy-2,3,5-Trimethylphenoxy)-3-Isopropylamino-2-Propanol; 1-(4-Hydroxy-2,3,5-trimethylphenoxy)-3-(isopropylamino)-2-propanol 4-acetate; 2-Propanol, 1-(4-hydroxy-2,3,5-trimethylphenoxy)-3-(isopropylamino)-, 4-acetate; 4-(2-Hydroxy-3-((1-methylethyl)-amino)propoxy)-2,3,6-trimethylphenol 1-acetate; 4-[2-hydroxy-3-(isopropylamino)propoxy]-2,3,6-trimethylphenyl acetate; 62164P DMJMVKI TC Antihypertensive Agents DMJMVKI DT Small molecular drug DMJMVKI PC 31477 DMJMVKI MW 309.4 DMJMVKI FM C17H27NO4 DMJMVKI IC InChI=1S/C17H27NO4/c1-10(2)18-8-15(20)9-21-16-7-11(3)17(22-14(6)19)13(5)12(16)4/h7,10,15,18,20H,8-9H2,1-6H3 DMJMVKI CS CC1=CC(=C(C(=C1OC(=O)C)C)C)OCC(CNC(C)C)O DMJMVKI IK BQIPXWYNLPYNHW-UHFFFAOYSA-N DMJMVKI IU [4-[2-hydroxy-3-(propan-2-ylamino)propoxy]-2,3,6-trimethylphenyl] acetate DMJMVKI CA CAS 22664-55-7 DMJMVKI CB CHEBI:6897 DMJMVKI DE Open-angle glaucoma DM0JE6N ID DM0JE6N DM0JE6N DN Metixene DM0JE6N HS Approved DM0JE6N SN Atosil; Contalyl; Dalpan; METHIXENE; Methixart; Methixen; Methyloxan; Metisene; Metixeno; Metixenum; Raunana; Tremaril;Tremarit; Tremonil; Tremoquil; Trest; Methixen [German]; Methixene hydrochloride; Metisene [DCIT]; Metixene hydrochloride; Tremaril hydrochloride; Metixene (INN); Metixene (TN); Metixene [INN:BAN]; Metixeno [INN-Spanish]; Metixenum [INN-Latin]; Methixene (*hydrochloride*); Metixene (*hydrochloride*); Tremonil (*hydrochloride*); 1-Methyl-3-(9H-thioxanthen-9-yl-methyl)piperidine; 1-Methyl-3-(9H-thioxanthen-9-ylmethyl)piperidine; 1-Methyl-3-(thioxanthen-9-ylmethyl) piperidine; 1-Methyl-3-(thioxanthen-9-ylmethyl)-1-piperidine; 1-methyl-3-(thioxanthen-9-ylmethyl)-piperidine hydrochloride; 60 SJ 1977; 60 SJ 1977 (*hydrochloride*); 9-(1'-Methylpiperidine-3'-methyl)thioxanthene DM0JE6N CP Norvatis Phamaceuticals Corporation DM0JE6N TC Antiparkinson Agents DM0JE6N DT Small molecular drug DM0JE6N PC 4167 DM0JE6N MW 309.5 DM0JE6N FM C20H23NS DM0JE6N IC InChI=1S/C20H23NS/c1-21-12-6-7-15(14-21)13-18-16-8-2-4-10-19(16)22-20-11-5-3-9-17(18)20/h2-5,8-11,15,18H,6-7,12-14H2,1H3 DM0JE6N CS CN1CCCC(C1)CC2C3=CC=CC=C3SC4=CC=CC=C24 DM0JE6N IK MJFJKKXQDNNUJF-UHFFFAOYSA-N DM0JE6N IU 1-methyl-3-(9H-thioxanthen-9-ylmethyl)piperidine DM0JE6N CA CAS 4969-02-2 DM0JE6N CB CHEBI:51024 DM0JE6N DE Parkinson disease DMFA5MY ID DMFA5MY DMFA5MY DN Metoclopramide DMFA5MY HS Approved DMFA5MY SN Cerucal; Clopra; Clopromate; Duraclamid; Elieten; Emetid; Emitasol; Emperal; Eucil; Gastrese; Gastrobid; Gastromax; Gastronerton; Gastrosil; Gastrotablinen; Gastrotem; Imperan; Maxeran; Maxolon; Meclopran; Metaclopramide; Metaclopromide; Metamide; Methochlopramide; Methoclopramide; Metochlopramide; Metoclol; Metoclopramida; Metoclopramidum; Metocobil; Metramid; Moriperan; Mygdalon; Octamide; Parmid; Paspertin; Peraprin; Plasil; Pramidin; Pramiel; Pramin; Primperan; Reclomide; Reglan; Reliveran; Terperan; Metoclopramide Omega; DEL 1267; Apo-Metoclop; CLOPRA-YELLOW; Clopra-Yellow; Degan (TN); Elieten (TN); Gastro-Timelets; Maxeran (TN); Maxolon (TN); Metoclopramida [INN-Spanish]; Metoclopramide Monohydrochloride, Monohydrate; Metoclopramidum [INN-Latin]; Neu-Sensamide; Nu-Metoclopramide; Plasil (pharmaceutical); Pms-Metoclopramide; Primperan (TN); Pylomid (TN); Reglan (TN); Terperan (TN); Metoclopramide (JP15/INN); Metoclopramide [INN:BAN:JAN]; N-(Diethylaminoethyl)-2-methoxy-4-amino-5-chlorobenzamide; O-Anisamide, 4-amino-5-chloro-N-(2-(diethylamino)ethyl)-(8CI); Benzamide, 4-amino-5-chloro-N-(2-(diethylamino)ethyl)-2-methoxy-(9CI); (metaclopramide)4-Amino-5-chloro-N-(2-diethylamino-ethyl)-2-methoxy-benzamide; (metoclopramide)4-Amino-5-chloro-N-(2-diethylamino-ethyl)-2-methoxy-benzamide; 1,5-Dimethyl-2-phenyl-1,2-dihydro-pyrazol-3-one; 2-Methoxy-4-amino-5-chloro-N,N-dimethylaminoethyl)benzamide; 2-Methoxy-5-chloroprocainamide; 2-methoxy-4-amino-5-chloro-N,N-(dimethylaminoethyl)benzamide; 4 Amino-5-chloro-N-(2-(diethylamino)ethyl)-2-methoxybenzamide; 4-Amino-5-chloro-2-methoxy-N-(beta-diethylaminoethyl)benzamide; 4-Amino-5-chloro-N-(2-(diethylamino)ethyl)-2-methoxybenzamide; 4-Amino-5-chloro-N-(2-(diethylamino)ethyl)-o-anisamide; 4-Amino-5-chloro-N-(2-diethylamino-ethyl)-2-methoxy-benzamide; 4-Amino-5-chloro-N-(2-diethylamino-ethyl)-2-methoxy-benzamide (Mcp); 4-Amino-5-chloro-N-(2-diethylamino-ethyl)-2-methoxy-benzamide (metoclopramide); 4-Amino-5-chloro-N-(2-diethylamino-ethyl)-2-methoxy-benzamide(Metoclopramide); 4-amino-5-chloro-N-(2-diethylaminoethyl)-2-methoxybenzamide; 4-amino-5-chloro-N-[2-(diethylamino)ethyl]-2-methoxybenzamide; 5-Chloro-2-methoxyprocainamide DMFA5MY CP Sanofi-Aventis DMFA5MY TC Antiemetics DMFA5MY DT Small molecular drug DMFA5MY PC 4168 DMFA5MY MW 299.79 DMFA5MY FM C14H22ClN3O2 DMFA5MY IC InChI=1S/C14H22ClN3O2/c1-4-18(5-2)7-6-17-14(19)10-8-11(15)12(16)9-13(10)20-3/h8-9H,4-7,16H2,1-3H3,(H,17,19) DMFA5MY CS CCN(CC)CCNC(=O)C1=CC(=C(C=C1OC)N)Cl DMFA5MY IK TTWJBBZEZQICBI-UHFFFAOYSA-N DMFA5MY IU 4-amino-5-chloro-N-[2-(diethylamino)ethyl]-2-methoxybenzamide DMFA5MY CA CAS 364-62-5 DMFA5MY CB CHEBI:107736 DMFA5MY DE Nausea DMZJYBW ID DMZJYBW DMZJYBW DN Metocurine Iodide DMZJYBW HS Approved DMZJYBW SN Metokuriinijodidi; Metokurinjodid; Metubine; Dimethyl tubocurarine iodide; Dimethylchondrocurarine iodide; Dimethyltubocurarine Iodide; Metocurine diiodide; Metocurine iodide [USAN]; Metocurini Iodidum; Metubine iodide; Mutubine Iodide; Trimethyltubocurarine Iodide; Dimethylether of d-tubocurarine iodide; Dimetiltubocurarinio, ioduro de; Methyl-curarin; Methyl-curarin [German]; Metocurine iodide (USAN); Metubine iodide (TN); O,O'-Dimethylchondrocurarine diiodide; Tubocurarine, O,O'-dimethyl-, diiodide; Tubocuraranium, 6,6',7',12'-tetramethoxy-2,2,2',2'-tetramethyl-, diiodide; (+)-O,O'-Dimethylchondrocurarine Di-iodide; (+)-O,O'-Dimethylchondrocurarine diiodide; 2,2,2',2'-tetramethyl-6,6',7',12'-tetrakis(methyloxy)tubocuraran-2,2'-diium diiodide; 6,6',7',12'-Tetramethoxy-2,2,2',2'-tetramethyltubocuraranium diiodide DMZJYBW TC Anesthetics DMZJYBW DT Small molecular drug DMZJYBW PC 24244 DMZJYBW MW 906.6 DMZJYBW FM C40H48I2N2O6 DMZJYBW IC InChI=1S/C40H48N2O6.2HI/c1-41(2)17-15-27-22-34(44-6)36-24-30(27)31(41)19-25-9-12-29(13-10-25)47-40-38-28(23-37(45-7)39(40)46-8)16-18-42(3,4)32(38)20-26-11-14-33(43-5)35(21-26)48-36;;/h9-14,21-24,31-32H,15-20H2,1-8H3;2*1H/q+2;;/p-2/t31-,32+;;/m0../s1 DMZJYBW CS C[N+]1(CCC2=CC(=C3C=C2[C@@H]1CC4=CC=C(C=C4)OC5=C6[C@@H](CC7=CC(=C(C=C7)OC)O3)[N+](CCC6=CC(=C5OC)OC)(C)C)OC)C.[I-].[I-] DMZJYBW IK DIGFQJFCDPKEPF-OIUSMDOTSA-L DMZJYBW IU (1S,16R)-9,10,21,25-tetramethoxy-15,15,30,30-tetramethyl-7,23-dioxa-15,30-diazoniaheptacyclo[22.6.2.23,6.18,12.118,22.027,31.016,34]hexatriaconta-3(36),4,6(35),8(34),9,11,18(33),19,21,24,26,31-dodecaene;diiodide DMZJYBW CA CAS 7601-55-0 DMZJYBW CB CHEBI:6901 DMZJYBW DE Anaesthesia DMB39LO ID DMB39LO DMB39LO DN Metolazone DMB39LO HS Approved DMB39LO SN Diulo; Metalazone; Metalozone; Metenix; Metolazona; Metolazonum; Microx; Mykrox; Oldren; Xuret; Zaroxolyn; Metolazona [INN-Spanish]; Metolazonum [INN-Latin]; Mykrox (TN); SR 720-22; Zaroxolyn (TN); SR-720-22; Metolazone (JAN/USP/INN); Metolazone [USAN:BAN:INN:JAN]; Mykrox, Zaroxolyn, Diulo, Metolazone; 2-Methyl-3-o-tolyl-6-sulfamyl-7-chloro-1,2,3,4-tetrahydro-4-quinazolinone; 7-Chloro-1,2,3,4-tetrahydro-2-methyl-3-(2-methylphenyl)-4-oxo-6-quinazolinesulfonamide; 7-Chloro-1,2,3,4-tetrahydro-2-methyl-4-oxo-3-o-tolyl-6-quinazolinesulfonamide; 7-chloro-2-methyl-3-(2-methylphenyl)-4-oxo-1,2-dihydroquinazoline-6-sulfonamide DMB39LO TC Antihypertensive Agents DMB39LO DT Small molecular drug DMB39LO PC 4170 DMB39LO MW 365.8 DMB39LO FM C16H16ClN3O3S DMB39LO IC InChI=1S/C16H16ClN3O3S/c1-9-5-3-4-6-14(9)20-10(2)19-13-8-12(17)15(24(18,22)23)7-11(13)16(20)21/h3-8,10,19H,1-2H3,(H2,18,22,23) DMB39LO CS CC1NC2=CC(=C(C=C2C(=O)N1C3=CC=CC=C3C)S(=O)(=O)N)Cl DMB39LO IK AQCHWTWZEMGIFD-UHFFFAOYSA-N DMB39LO IU 7-chloro-2-methyl-3-(2-methylphenyl)-4-oxo-1,2-dihydroquinazoline-6-sulfonamide DMB39LO CA CAS 17560-51-9 DMB39LO CB CHEBI:64354 DMB39LO DE Edema; Hypertension DMOJ0V6 ID DMOJ0V6 DMOJ0V6 DN Metoprolol DMOJ0V6 HS Approved DMOJ0V6 SN Beatrolol; BelocDuriles; Betaloc; BetalocAstra; Betalok; Dutoprol; LOPRESSIDONE; Lopresor; Lopresoretic; Lopressor; Meijoprolol; Metohexal; Metoprololum; Metroprolol; Preblok; Presolol; Seloken; Seroken; Spesicor; Spesikor; Toprol; AstraZeneca Brand of Metaoprolol Tartrate; AstraZeneca Brand of Seloken; Beloc Duriles; Betaloc Astra; Leiras Brand of Metoprolol Succinate or Metoprolol Tartrate; Metoprolol succinate; Novartis Brand of Metprolol Tartrate; Seloken AstraZeneca Brand; CGP 2175; CGP2175; H 93 26; H 9326; Beloc-Duriles; Betaloc (TN); Betaloc-Astra; CGP-2175; Corvitol (TN); Dl-Metoprolol; H 93-26; Lopressor (TN); Metoprololum [INN-Latin]; Metrol (TN); Minax (TN); Neobloc (TN); Selo-Zok; Selokeen (TN); TOPROL-XL; Tartrate, Metoprolol; Metoprolol (USAN/INN); Metoprolol [USAN:INN:BAN]; Toprol-XL (TN); (RS)-Metoprolol; 1-(Isopropylamino)-3-(4-(2-methoxyethyl)phenoxy)propan-2-ol; 1-(Isopropylamino)-3-(p-(2-methoxyethyl)phenoxy)-2-propanol; 1-(isopropylamino)-3-[4-(2-methoxyethyl)phenoxy]propan-2-ol; 1-[(1-methylethyl)amino]-3-({4-[2-(methyloxy)ethyl]phenyl}oxy)propan-2-ol; 1-[4-(2-methoxyethyl)phenoxy]-3-(propan-2-ylamino)propan-2-ol; 1-[4-(2-methoxyethyl)phenoxy]-3-propan-2-ylamino-propan-2-ol; 3-[4-(2-methoxyethyl)phenoxy]-1-(propan-2-ylamino)propan-2-ol DMOJ0V6 CP AstraZeneca DMOJ0V6 TC Antihypertensive Agents DMOJ0V6 DT Small molecular drug DMOJ0V6 PC 4171 DMOJ0V6 MW 267.36 DMOJ0V6 FM C15H25NO3 DMOJ0V6 IC InChI=1S/C15H25NO3/c1-12(2)16-10-14(17)11-19-15-6-4-13(5-7-15)8-9-18-3/h4-7,12,14,16-17H,8-11H2,1-3H3 DMOJ0V6 CS CC(C)NCC(COC1=CC=C(C=C1)CCOC)O DMOJ0V6 IK IUBSYMUCCVWXPE-UHFFFAOYSA-N DMOJ0V6 IU 1-[4-(2-methoxyethyl)phenoxy]-3-(propan-2-ylamino)propan-2-ol DMOJ0V6 CA CAS 51384-51-1 DMOJ0V6 CB CHEBI:6904 DMOJ0V6 DE Hypertension DM1NOEK ID DM1NOEK DM1NOEK DN Metreleptin DM1NOEK HS Approved DM1NOEK CP Amylin Pharmaceuticals DM1NOEK SQ Peptide Sequence : MVPIQKVQDDTKTLIKTIVTRINDISHTQSVSSKQKVTGLDFIPGLHPILTLSKMDQTLAVYQQILTSMPSRNVIQISNDLENLRDLLHVLAFSKSCHLPWASGLETLDSLGGVLEASGYSTEVVALSRLQGSLQDMLWQLDLSPGC DM1NOEK DE Diabetic complication DMTIVEN ID DMTIVEN DMTIVEN DN Metronidazole DMTIVEN HS Approved DMTIVEN SN APMN; Acromona; Anagiardil; Arilin; Atrivyl; Bexon; CONT; Clont; Danizol; Deflamon; Efloran; Elyzol; Entizol; Eumin; Flagemona; Flagesol; Flagil; Flagyl; Flegyl; Florazole; Fossyol; Giatricol; Gineflavir; Giniflavir; Klion; Klont; Meronidal; Methronidazole; Metric; MetroCream; MetroGel; MetroLotion; Metrodzhil; Metrogyl; Metrolag; Metrolyl; Metromidol; Metronidaz; Metronidazol; Metronidazolo; Metronidazolum; Metrotop; Metrozine; Metryl; Mexibol; Monagyl; Monasin; NIDA; Nalox; Nidagel; Noritate; Novonidazol; Orvagil; Protostat; Rathimed; Rosased; Sanatrichom; Satric; Takimetol; Trichazol; Trichex; Trichocide; Trichomol; Trichopal; Trichopol; Tricocet; Tricom; Trikacide; Trikamon; Trikojol; Trikozol; Trimeks; Trivazol; Vagilen; Vagimid; Vandazole; Vertisal; Wagitran; Zadstat; Zidoval; Flagyl Er; Ginefla vir; METRONIDAZOLE USP; Metro Cream; Metro Gel; Metronidazole Monohydrochloride; Metronidazole Phosphoester; Metronidazole in Plastic Container; Metronidazolo [DCIT]; Tricho cordes; Trichomonacid pharmachim; Tricowas B; Bayer 5360; Flagyl 375; M0924; Metric 21; RP 8823; SC 10295; Anabact (TN); Apo-Metronidazole; Deflamon-wirkstoff; Flagyl (TN); IDR-90105; METRO I.V; MetroGel (TN); MetroGel-Vaginal; Metronidazol [INN-Spanish]; Metronidazolum [INN-Latin]; Mexibol (silanes); Neo-Tric; Noritate (TN); RP-8823; Rozex (TN); Tricho-gynaedron; ZERO/004064; CB-01-14 MMX; FLAGYL I.V. RTU IN PLASTIC CONTAINER; Flagyl I.V.; Flagyl I.V. RTU; Metro I.V.; Metro I.V. In Plastic Container; Metrogel-vaginal (TN); Metronidazole (JP15/USP/INN); Metronidazole [USAN:INN:BAN:JAN]; Methyl-5-nitroimidazole-1-ethanol; 1-Hydroxyethyl-2-methyl-5-nitroimidazole; 2-(2-methyl-5-nitroimidazol-1-yl)ethanol; 2-Methyl-5-nitro-1-imidazoleethanol; 2-Methyl-5-nitroimidazole-1-ethanol; MNZ DMTIVEN CP Pfizer Pharmaceuticals DMTIVEN TC Antiinfective Agents DMTIVEN DT Small molecular drug DMTIVEN PC 4173 DMTIVEN MW 171.15 DMTIVEN FM C6H9N3O3 DMTIVEN IC InChI=1S/C6H9N3O3/c1-5-7-4-6(9(11)12)8(5)2-3-10/h4,10H,2-3H2,1H3 DMTIVEN CS CC1=NC=C(N1CCO)[N+](=O)[O-] DMTIVEN IK VAOCPAMSLUNLGC-UHFFFAOYSA-N DMTIVEN IU 2-(2-methyl-5-nitroimidazol-1-yl)ethanol DMTIVEN CA CAS 443-48-1 DMTIVEN CB CHEBI:6909 DMTIVEN DE Amoebiasis; Crohn disease; Perianal crohn disease DMI7FVQ ID DMI7FVQ DMI7FVQ DN Metyrapone DMI7FVQ HS Approved DMI7FVQ SN MYT; Mepyrapone; Metapirone; Metapyron; Methapyrapone; Methbipyranone; Methopirapone; Methopyrapone; Methopyrinine; Methopyrone; Metirapona; Metopiron; Metopirone; Metopyrone; Metroprione; Metyrapon; Metyraponum; Alliance Brand of Metyrapone; Metyrapone Alliance Brand; Metyrapone Novartis Brand; Novartis Brand of Metyrapone; Su 4885; METOPIRONE (TN); Metirapona [INN-Spanish]; Metopirone (TN); Metyraponum [INN-Latin]; Su-4885; Metyrapone (JP15/USP/INN); Metyrapone [USAN:INN:BAN:JAN]; 1,2-Di-3-pyridyl-2-methyl-1-propanone; 2-Methyl-1,2-bis(3-pyridyl)-1-propanone; 2-Methyl-1,2-di-3-pyridinyl-1-propanone; 2-Methyl-1,2-di-3-pyridyl-1-propanone; 2-methyl-1,2-dipyridin-3-yl-propan-1-one; 2-methyl-1,2-dipyridin-3-ylpropan-1-one DMI7FVQ CP Norvatis Phamaceuticals Corporation DMI7FVQ TC Antimetabolites DMI7FVQ DT Small molecular drug DMI7FVQ PC 4174 DMI7FVQ MW 226.27 DMI7FVQ FM C14H14N2O DMI7FVQ IC InChI=1S/C14H14N2O/c1-14(2,12-6-4-8-16-10-12)13(17)11-5-3-7-15-9-11/h3-10H,1-2H3 DMI7FVQ CS CC(C)(C1=CN=CC=C1)C(=O)C2=CN=CC=C2 DMI7FVQ IK FJLBFSROUSIWMA-UHFFFAOYSA-N DMI7FVQ IU 2-methyl-1,2-dipyridin-3-ylpropan-1-one DMI7FVQ CA CAS 54-36-4 DMI7FVQ CB CHEBI:44241 DMI7FVQ DE Cushing disease DMBYCU0 ID DMBYCU0 DMBYCU0 DN Metyrosine DMBYCU0 HS Approved DMBYCU0 SN Demser; Methyltyrosine; Metirosina; Metirosine; Metirosinum; Racemetirosina; Racemetirosine; Racemetirosinum; Metyrosine[USAN]; Racemetirosine [INN]; M 8131; MK 781; Alpha-MPT; Alpha-Methyltyrosine; Demser (TN); H 9/88; L 588357-0; L-AMPT; M-5185; MK-781; Metirosina [INN-Spanish]; Metirosine (INN); Metirosinum [INN-Latin]; Metyrosine (USP); Racemetirosina [INN-Spanish]; Racemetirosinum [INN-Latin]; DL-alpha-Methyltyrosine; L-588357-0; Alpha-Methyl-L-tyrosine; Alpha-Methyl-dl-tyrosine; Alpha-Methyl-p-tyrosine; Alpha-Methyl-para-tyrosine; A-methyl-L-p-tyrosine; Alpha-Methyl-L-P-Tyrosine; Alpha-Methyltyrosine, (L)-Isomer; DL-alpha-Methyl-p-tyrosine; L-alpha-Methyl-p-tyrosine; Alpha-Methyltyrosine, (D,L)-Isomer; DL-2-Methyl-3-(4-hydroxyphenyl)alanine; Alpha-Methyltyrosine, (+,-)-Isomer; L-2-Methyl-3-(4-hydroxy-phenyl)alanine; (+-)-alpha-Methyl-DL-tyrosine; (-)-(S)-2-Amino-3-(4-hydroxyphenyl)-2-methylpropionsaeure; (-)-alpha-Methyl-DL-tyrosine; (-)-alpha-Methyl-L-tyrosine; (2R)-2-amino-3-(4-hydroxyphenyl)-2-methylpropanoic acid; (2S)-2-amino-3-(4-hydroxyphenyl)-2-methylpropanoic acid; (R,S)-2-Amino-3-(4-hydroxyphenyl)-2-methylpropionsaeure; (S)-alpha-Methyltyrosine; 2-amino-3-(4-hydroxyphenyl)-2-methylpropanoic acid; 4-Hydroxy-alpha-methylphenylalanine DMBYCU0 TC Anticancer Agents DMBYCU0 DT Small molecular drug DMBYCU0 PC 441350 DMBYCU0 MW 195.21 DMBYCU0 FM C10H13NO3 DMBYCU0 IC InChI=1S/C10H13NO3/c1-10(11,9(13)14)6-7-2-4-8(12)5-3-7/h2-5,12H,6,11H2,1H3,(H,13,14)/t10-/m0/s1 DMBYCU0 CS C[C@](CC1=CC=C(C=C1)O)(C(=O)O)N DMBYCU0 IK NHTGHBARYWONDQ-JTQLQIEISA-N DMBYCU0 IU (2S)-2-amino-3-(4-hydroxyphenyl)-2-methylpropanoic acid DMBYCU0 CA CAS 672-87-7 DMBYCU0 CB CHEBI:6912 DMBYCU0 DE Pheochromocytoma DMCTE9R ID DMCTE9R DMCTE9R DN Mexiletine DMCTE9R HS Approved DMCTE9R SN Mexiletene; Mexiletina; Mexiletinum; Mexilitine; Mexityl; Mexiletine HCL; KO1173; KO-1173; KOE-1173; Mexiletina [INN-Spanish]; Mexiletine (INN); Mexiletine [INN:BAN]; Mexiletinum [INN-Latin]; Mexitil (TN); (+-)-1-(2,6-dimethylphenoxy)propan-2-amine; (2RS)-1-(2,6-dimethylphenoxy)-2-aminopropane; 1-(2',6'-Dimethylphenoxy)-2-aminopropane; 1-(2,6-Dimethylphenoxy)-2-propanamine; 1-(2,6-dimethylphenoxy)propan-2-amine; 1-Methyl-2-(2,6-xylyloxy)ethylamine; 1-methyl-2-(2,6-xylyloxy)ethanamine; 2-(2-Aminopropoxy)-1,3-DiMethyl-Benzene Hydrochloride; 2-(2-aminopropoxy)-1,3-dimethylbenzene DMCTE9R CP Boehringer Ingelheim DMCTE9R TC Antiarrhythmic Agents DMCTE9R DT Small molecular drug DMCTE9R PC 4178 DMCTE9R MW 179.26 DMCTE9R FM C11H17NO DMCTE9R IC InChI=1S/C11H17NO/c1-8-5-4-6-9(2)11(8)13-7-10(3)12/h4-6,10H,7,12H2,1-3H3 DMCTE9R CS CC1=C(C(=CC=C1)C)OCC(C)N DMCTE9R IK VLPIATFUUWWMKC-UHFFFAOYSA-N DMCTE9R IU 1-(2,6-dimethylphenoxy)propan-2-amine DMCTE9R CA CAS 31828-71-4 DMCTE9R CB CHEBI:6916 DMCTE9R DE Ventricular tachycardia DMY5JEP ID DMY5JEP DMY5JEP DN Mezlocillin DMY5JEP HS Approved DMY5JEP SN Mezlin; Mezlocilina; Mezlocillinum; Mezlocillin (USAN/INN); (2S,5R,6R)-3,3-dimethyl-6-[[(2R)-2-[(3-methylsulfonyl-2-oxoimidazolidine-1-carbonyl)amino]-2-phenylacetyl]amino]-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-3,3-dimethyl-6-{[(2R)-2-({[3-(methylsulfonyl)-2-oxoimidazolidin-1-yl]carbonyl}amino)-2-phenylacetyl]amino}-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 6beta-{(2R)-2-[3-(methanesulfonyl)-2-oxoimidazolidine-1-carboxamido]-2-phenylacetamido}-2,2-dimethylpenam-3alpha-carboxylic acid; 6beta-{(2R)-2-[3-(methanesulfonyl)-2-oxoimidazolidine-1-carboxamido]-2-phenylacetamido}penicillanic acid DMY5JEP TC Antibiotics DMY5JEP DT Small molecular drug DMY5JEP PC 656511 DMY5JEP MW 539.6 DMY5JEP FM C21H25N5O8S2 DMY5JEP IC InChI=1S/C21H25N5O8S2/c1-21(2)14(18(29)30)26-16(28)13(17(26)35-21)22-15(27)12(11-7-5-4-6-8-11)23-19(31)24-9-10-25(20(24)32)36(3,33)34/h4-8,12-14,17H,9-10H2,1-3H3,(H,22,27)(H,23,31)(H,29,30)/t12-,13-,14+,17-/m1/s1 DMY5JEP CS CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)NC(=O)N4CCN(C4=O)S(=O)(=O)C)C(=O)O)C DMY5JEP IK YPBATNHYBCGSSN-VWPFQQQWSA-N DMY5JEP IU (2S,5R,6R)-3,3-dimethyl-6-[[(2R)-2-[(3-methylsulfonyl-2-oxoimidazolidine-1-carbonyl)amino]-2-phenylacetyl]amino]-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid DMY5JEP CA CAS 51481-65-3 DMY5JEP CB CHEBI:6919 DMY5JEP DE Urinary tract infection DMVKA4O ID DMVKA4O DMVKA4O DN Mianserin DMVKA4O HS Approved DMVKA4O SN Mianserina; Mianserine; Mianserinum; Mianseryna; Norval; Tolvan; Tolvon; Mianserin Monohydrochloride; Mianseryna [Polish]; Bolvidon (TN); Mianserin (INN); Mianserin [INN:BAN]; Mianserina [INN-Spanish]; Mianserine [INN-French]; Mianserinum [INN-Latin]; Norval (TN); Tolvin (TN); Tolvon (TN); 1,2,3,4,10,14b-Hexahydro-2-methyldibenzo(c,f)pyrazino(1,2-a)azepine; 2-Methyl-1,2,3,4,10,14b-hexahydrodibenzo[c,f]pyrazino[1,2-a]azepine DMVKA4O CP GlaxoSmithKline DMVKA4O TC Antidepressants DMVKA4O DT Small molecular drug DMVKA4O PC 4184 DMVKA4O MW 264.4 DMVKA4O FM C18H20N2 DMVKA4O IC InChI=1S/C18H20N2/c1-19-10-11-20-17-9-5-3-7-15(17)12-14-6-2-4-8-16(14)18(20)13-19/h2-9,18H,10-13H2,1H3 DMVKA4O CS CN1CCN2C(C1)C3=CC=CC=C3CC4=CC=CC=C42 DMVKA4O IK UEQUQVLFIPOEMF-UHFFFAOYSA-N DMVKA4O IU 5-methyl-2,5-diazatetracyclo[13.4.0.02,7.08,13]nonadeca-1(19),8,10,12,15,17-hexaene DMVKA4O CA CAS 24219-97-4 DMVKA4O CB CHEBI:51137 DMVKA4O DE Depression DM6Y3AN ID DM6Y3AN DM6Y3AN DN Micafungin DM6Y3AN HS Approved DM6Y3AN SN Mycamine; FK463; FK-463; Mycamine (TN); Mycamine(TM) DM6Y3AN CP Astellas Pharma DM6Y3AN TC Antifungal Agents DM6Y3AN DT Small molecular drug DM6Y3AN PC 477468 DM6Y3AN MW 1270.3 DM6Y3AN FM C56H71N9O23S DM6Y3AN IC InChI=1S/C56H71N9O23S/c1-4-5-6-17-86-32-14-11-28(12-15-32)39-21-33(63-87-39)27-7-9-29(10-8-27)49(75)58-34-20-38(70)52(78)62-54(80)45-46(72)25(2)23-65(45)56(82)43(37(69)22-41(57)71)60-53(79)44(48(74)47(73)30-13-16-36(68)40(18-30)88-89(83,84)85)61-51(77)35-19-31(67)24-64(35)55(81)42(26(3)66)59-50(34)76/h7-16,18,21,25-26,31,34-35,37-38,42-48,52,66-70,72-74,78H,4-6,17,19-20,22-24H2,1-3H3,(H2,57,71)(H,58,75)(H,59,76)(H,60,79)(H,61,77)(H,62,80)(H,83,84,85)/t25-,26+,31+,34-,35-,37+,38+,42-,43-,44-,45-,46-,47-,48-,52+/m0/s1 DM6Y3AN CS CCCCCOC1=CC=C(C=C1)C2=CC(=NO2)C3=CC=C(C=C3)C(=O)N[C@H]4C[C@H]([C@H](NC(=O)[C@@H]5[C@H]([C@H](CN5C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]6C[C@H](CN6C(=O)[C@@H](NC4=O)[C@@H](C)O)O)[C@@H]([C@H](C7=CC(=C(C=C7)O)OS(=O)(=O)O)O)O)[C@@H](CC(=O)N)O)C)O)O)O DM6Y3AN IK PIEUQSKUWLMALL-YABMTYFHSA-N DM6Y3AN IU [5-[(1S,2S)-2-[(3S,6S,9S,11R,15S,18S,20R,21R,24S,25S,26S)-3-[(1R)-3-amino-1-hydroxy-3-oxopropyl]-11,20,21,25-tetrahydroxy-15-[(1R)-1-hydroxyethyl]-26-methyl-2,5,8,14,17,23-hexaoxo-18-[[4-[5-(4-pentoxyphenyl)-1,2-oxazol-3-yl]benzoyl]amino]-1,4,7,13,16,22-hexazatricyclo[22.3.0.09,13]heptacosan-6-yl]-1,2-dihydroxyethyl]-2-hydroxyphenyl] hydrogen sulfate DM6Y3AN CA CAS 235114-32-6 DM6Y3AN CB CHEBI:600520 DM6Y3AN DE Candidiasis DM3O6CY ID DM3O6CY DM3O6CY DN Micardis telmisartan DM3O6CY HS Approved DM3O6CY CP Boehringer-Ingelheim Pharmaceuticals DM3O6CY DE Hypertension DMPMYE8 ID DMPMYE8 DMPMYE8 DN Miconazole DMPMYE8 HS Approved DMPMYE8 SN Dactarin; MCZ; Miconazol; Miconazolo; Miconazolum; Micozole; Minostate; Monistat; Vusion; Zimycan; Daktarin IV; Miconasil Nitrate; Miconazole nitrate salt; Miconazolo [DCIT]; Monistat IV; MJR 1762; Miconazole 3; Miconazole 3 Combination Pack; Miconazole 7 Combination Pack; Monazole 7; Monistat 1 Combination Pack; Monistat 3 Vaginal Ovules; Monistat 5 Tampon; Monistat 7 Vaginal Suppositories; R 18134; Aflorix(nitrate); Albistat(nitrate); Andergin(nitrate); Conofite(nitrate); Daktarin (TN); Femizol (TN); Femizol-M; Florid(nitrate); Lotrimin AF(nitrate); Micantin (nitrate); Micatin (TN); Miconazex (TN); Miconazol [INN-Spanish]; Miconazole-7; Miconazolum [INN-Latin]; Monista (nitrate); Monistat (TN); Monistat 3 Dual-Pak; Monistat 7 Dual-Pak; Monistat Dual-PAK; Monistat iv (TN); Monistat-Derm; Novo-Miconazole Vaginal Ovules; Epi-Monistat(nitrate); Gyno-Daktar(nitrate); Monistat-Derm (TN); R-14,889; Miconazole (JP15/USP/INN); Miconazole [USAN:BAN:INN:JAN]; Imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl) methoxy)ethyl)-(9CI); Imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl)methoxy)ethyl)-(9CI); (+-)-1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole; 1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole; 1-(2,4-dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl) imidazole; 1-[2,4-Dichloro-beta-([2,4-dichloro-benzyl]oxy)phenethyl]imidazole; 1-[2-(2,4-Dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-1H-imidazole; 1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole; 1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole; 1-[2-(2,4-dichlorophenyl)-2-{[(2,4-dichlorophenyl)methyl]oxy}ethyl]-1H-imidazole; 1-{2-[(2,4-dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole DMPMYE8 CP Janssen Pharmaceutica DMPMYE8 TC Antifungal Agents DMPMYE8 DT Small molecular drug DMPMYE8 PC 4189 DMPMYE8 MW 416.1 DMPMYE8 FM C18H14Cl4N2O DMPMYE8 IC InChI=1S/C18H14Cl4N2O/c19-13-2-1-12(16(21)7-13)10-25-18(9-24-6-5-23-11-24)15-4-3-14(20)8-17(15)22/h1-8,11,18H,9-10H2 DMPMYE8 CS C1=CC(=C(C=C1Cl)Cl)COC(CN2C=CN=C2)C3=C(C=C(C=C3)Cl)Cl DMPMYE8 IK BYBLEWFAAKGYCD-UHFFFAOYSA-N DMPMYE8 IU 1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole DMPMYE8 CA CAS 22916-47-8 DMPMYE8 CB CHEBI:82892 DMPMYE8 DE Fungal infection DMXOELT ID DMXOELT DMXOELT DN Midazolam DMXOELT HS Approved DMXOELT SN Dazolam; Dormicum; Midanium; Midazolamum; Midosed; Versed; Midazolam Base; Dormicum (TN); Hypnovel (TN); Midacum (TN); Midazolamum [INN-Latin]; Ro 21-3981; Versed (TN); Midazolam (JAN/INN); Midazolam [INN:BAN:JAN]; 4H-Imidazo[1,5-a][1,4]benzodiazepine, 8-chloro-6-(2-fluoro-phenyl)-1-methyl-, (Z)-2-butenedioate; 8-Chlor-6-(2-fluorphenyl)-1-methyl-4H-imidazo(1,5-a)(1,4)benzodiazepin; 8-Chloro-6-(2-fluorophenyl)-1-methyl-4H-imidazo[1,5-a][1,4]benzodiazepine; 8-Chloro-6-(2-fluorophenyl)-1-methyl-4H-imidazo[1,5a][1,4]benzodiazepine hydrochloride; 8-Chloro-6-(O-fluorophenyl)-1-methyl-4H-imidazo[1,5-a][1,4]-benzodiazepine; 8-Chloro-6-(o-fluorophenyl)-1-methyl-4H-imidazo(1,5-a)(1,4)benzodiazepine DMXOELT CP Roche Pharmaceuticals DMXOELT TC Hypnotics and Sedatives DMXOELT DT Small molecular drug DMXOELT PC 4192 DMXOELT MW 325.8 DMXOELT FM C18H13ClFN3 DMXOELT IC InChI=1S/C18H13ClFN3/c1-11-21-9-13-10-22-18(14-4-2-3-5-16(14)20)15-8-12(19)6-7-17(15)23(11)13/h2-9H,10H2,1H3 DMXOELT CS CC1=NC=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4F DMXOELT IK DDLIGBOFAVUZHB-UHFFFAOYSA-N DMXOELT IU 8-chloro-6-(2-fluorophenyl)-1-methyl-4H-imidazo[1,5-a][1,4]benzodiazepine DMXOELT CA CAS 59467-70-8 DMXOELT CB CHEBI:6931 DMXOELT DE Irritability; Epilepsy DME2PY5 ID DME2PY5 DME2PY5 DN Midodrine DME2PY5 HS Approved DME2PY5 SN Alphamine; Amatine; Gutron; Hipertan; Metligene; Midamine; Midodrin; Midodrina; Midodrinum; ProAmatine; MIDODRINE HYDROCHLORIDE; Midodrine HCL; Midodrine Monohydrochloride; Midodrine hydrochloride [USAN]; A 4020 Linz; St 1085; TS 701; A-4020 Linz; Midodrina [INN-Spanish]; Midodrine (INN); Midodrine [BAN:INN]; Midodrine [INN:BAN]; Midodrine hydrochloride [USAN:JAN]; Midodrinum [INN-Latin]; Pro-Amatine; Proamatine (TN); ST-1085; St. Peter 224; Midodrine hydrochloride (JAN/USAN); Pro-Amatine (TN); DL-N1-(beta-Hydroxy-2,5-dimethoxyphenethyl)glycinamid; N-[2-(2,5-dimethoxyphenyl)-2-hydroxyethyl]glycinamide; N-{2-[2,5-bis(methyloxy)phenyl]-2-hydroxyethyl}glycinamide; [+/-]-1-[2,5-Dimethoxyphenyl]-2-glycinamidoethanol; Acetamide, 2-amino-N-(beta-hydroxy-2,5-dimethoxyphenethyl)-, hydrochloride; Acetamide, 2-amino-N-(2-(2,5-dimethoxyphenyl)-2-hydroxyethyl)-, monohydrochloride; (+-)-1-(2',5'-Dimethoxyphenyl)-2-glycinamidoethanol hydrochloride; (+-)-2-Amino-N-(beta-hydroxy-2,5-dimethoxyphenethyl)acetamide monohydrochloride; (+-)-Midodrine hydrochloride; (+/-)-1-(2,5-Dimethoxyphenyl)-2-glycinamidoethanol; (-)-Midodrin hydrochloride; (-)-Midodrine hydrochloride; (RS)-N'-(beta-Hydroxy-2,5-dimethoxy-phenethyl)glycinamid; 1-(2',5'-Dimethoxyphenyl)-2-glycinamidoethanol; 1-(2',5'-Dimethoxyphenyl)-2-glycinamidoethanol hydrochloride; 1-(2,5-Dimethoxyphenyl)-2-glycinamidoethanol; 2-Amino-N-(2,5-dimethoxy-beta-hydroxyphenethyl)acetamid; 2-Amino-N-(2,5-dimethoxy-beta-hydroxyphenethyl)acetamide; 2-Amino-N-(2,5-dimethoxy-beta-hydroxyphenethylacetamide; 2-Amino-N-(2-(2,5-dimethoxyphenyl)-2-hydroxyethyl)acetamide monohydrochloride; 2-Amino-N-(2-(2,5-dimethoxyphenyl)-2-hyyroxyethyl)acetamide monohydrochloride; 2-amino-N-[2-(2,5-dimethoxyphenyl)-2-hydroxyethyl]acetamide; 2-amino-N-[2-(2,5-dimethoxyphenyl)-2-hydroxyethyl]acetamide hydrochloride DME2PY5 CP Shire Canada Inc DME2PY5 TC Vasoconstrictor Agents DME2PY5 DT Small molecular drug DME2PY5 PC 4195 DME2PY5 MW 254.28 DME2PY5 FM C12H18N2O4 DME2PY5 IC InChI=1S/C12H18N2O4/c1-17-8-3-4-11(18-2)9(5-8)10(15)7-14-12(16)6-13/h3-5,10,15H,6-7,13H2,1-2H3,(H,14,16) DME2PY5 CS COC1=CC(=C(C=C1)OC)C(CNC(=O)CN)O DME2PY5 IK PTKSEFOSCHHMPD-UHFFFAOYSA-N DME2PY5 IU 2-amino-N-[2-(2,5-dimethoxyphenyl)-2-hydroxyethyl]acetamide DME2PY5 CA CAS 42794-76-3 DME2PY5 CB CHEBI:6933 DME2PY5 DE Orthostatic hypotension DMI6E0R ID DMI6E0R DMI6E0R DN Midostaurin DMI6E0R HS Approved DMI6E0R SN PKC412; 120685-11-2; Cgp 41251; 4'-N-Benzoylstaurosporine; CGP-41251; Benzoylstaurosporine; PKC-412; RYDAPT; PKC 412; UNII-ID912S5VON; N-Benzoylstaurosporine; ID912S5VON; CHEMBL608533; CHEBI:63452; Cgp 41 251; N-[(5S,6R,7R,9R)-6-methoxy-5-methyl-14-oxo-6,7,8,9,15,16-hexahydro-5H,14H-5,9-epoxy-4b,9a,15-triazadibenzo[b,h]cyclonona[1,2,3,4-jkl]cyclopenta[e]-as-indacen-7-yl]-N-methylbenzamide; PKC-412(Midostaurin); Midostaurin (PKC412); Midostaurin (USAN/INN); Midostaurin [USAN:INN]; CGP 41231; Rydapt (TN); CPG 41251 DMI6E0R CP Novartis DMI6E0R TC Anticancer Agents DMI6E0R DT Small molecular drug DMI6E0R PC 9829523 DMI6E0R MW 570.6 DMI6E0R FM C35H30N4O4 DMI6E0R IC InChI=1S/C35H30N4O4/c1-35-32(42-3)25(37(2)34(41)19-11-5-4-6-12-19)17-26(43-35)38-23-15-9-7-13-20(23)28-29-22(18-36-33(29)40)27-21-14-8-10-16-24(21)39(35)31(27)30(28)38/h4-16,25-26,32H,17-18H2,1-3H3,(H,36,40)/t25-,26-,32-,35+/m1/s1 DMI6E0R CS C[C@@]12[C@@H]([C@@H](C[C@@H](O1)N3C4=CC=CC=C4C5=C6C(=C7C8=CC=CC=C8N2C7=C53)CNC6=O)N(C)C(=O)C9=CC=CC=C9)OC DMI6E0R IK BMGQWWVMWDBQGC-IIFHNQTCSA-N DMI6E0R IU N-[(2S,3R,4R,6R)-3-methoxy-2-methyl-16-oxo-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8,10,12,14,19,21,23,25,27-nonaen-4-yl]-N-methylbenzamide DMI6E0R CA CAS 120685-11-2 DMI6E0R CB CHEBI:63452 DMI6E0R DE Acute myeloid leukaemia; Systemic mastocytosis; Colorectal cancer; Chronic myelomonocytic leukaemia DMGZQEF ID DMGZQEF DMGZQEF DN Mifepristone DMGZQEF HS Approved DMGZQEF SN Mifedren; HRA-052015; Mifepristone (Cushing's disease); ACTH modulator (Cushing's disease), HRA; Adrenocorticotropic hormone modulator (Cushing's disease), HRA Pharma; Mifepristone (Cushing's disease), HRA pharma DMGZQEF CP HRA Pharma DMGZQEF DT Small molecular drug DMGZQEF PC 55245 DMGZQEF MW 429.6 DMGZQEF FM C29H35NO2 DMGZQEF IC InChI=1S/C29H35NO2/c1-5-15-29(32)16-14-26-24-12-8-20-17-22(31)11-13-23(20)27(24)25(18-28(26,29)2)19-6-9-21(10-7-19)30(3)4/h6-7,9-10,17,24-26,32H,8,11-14,16,18H2,1-4H3/t24-,25+,26-,28-,29-/m0/s1 DMGZQEF CS CC#C[C@@]1(CC[C@@H]2[C@@]1(C[C@@H](C3=C4CCC(=O)C=C4CC[C@@H]23)C5=CC=C(C=C5)N(C)C)C)O DMGZQEF IK VKHAHZOOUSRJNA-GCNJZUOMSA-N DMGZQEF IU (8S,11R,13S,14S,17S)-11-[4-(dimethylamino)phenyl]-17-hydroxy-13-methyl-17-prop-1-ynyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one DMGZQEF CA CAS 84371-65-3 DMGZQEF CB CHEBI:50692 DMGZQEF DE Cushing disease DMFIQ2H ID DMFIQ2H DMFIQ2H DN Migalastat DMFIQ2H HS Approved DMFIQ2H SN DDIG; D-Galactitol, 1,5-dideoxy-1,5-imino; (2R,3S,4R,5S)-2-(hydroxymethyl)piperidine-3,4,5-triol; 1,5-Dideoxy-1,5-iminogalactitol; 2-(Hydroxymethyl)-3,4,5-piperidinetriol hydrochloride DMFIQ2H CP Amicus Therapeutics DMFIQ2H DT Small molecular drug DMFIQ2H PC 176077 DMFIQ2H MW 163.17 DMFIQ2H FM C6H13NO4 DMFIQ2H IC InChI=1S/C6H13NO4/c8-2-3-5(10)6(11)4(9)1-7-3/h3-11H,1-2H2/t3-,4+,5+,6-/m1/s1 DMFIQ2H CS C1[C@@H]([C@H]([C@H]([C@H](N1)CO)O)O)O DMFIQ2H IK LXBIFEVIBLOUGU-DPYQTVNSSA-N DMFIQ2H IU (2R,3S,4R,5S)-2-(hydroxymethyl)piperidine-3,4,5-triol DMFIQ2H CA CAS 108147-54-2 DMFIQ2H CB CHEBI:135923 DMFIQ2H DE Fabry disease DMXBQAM ID DMXBQAM DMXBQAM DN Miglitol DMXBQAM HS Approved DMXBQAM SN Diastabol; Glyset; Plumarol; Seibule; Glyset (TN); SK-983; Bay-m-1099; Miglitol (JAN/USAN/INN); (2R,3R,4R,5S)-1-(2-hydroxyethyl)-2-(hydroxymethyl)piperidine-3,4,5-triol DMXBQAM TC Hypoglycemic Agents DMXBQAM DT Small molecular drug DMXBQAM PC 441314 DMXBQAM MW 207.22 DMXBQAM FM C8H17NO5 DMXBQAM IC InChI=1S/C8H17NO5/c10-2-1-9-3-6(12)8(14)7(13)5(9)4-11/h5-8,10-14H,1-4H2/t5-,6+,7-,8-/m1/s1 DMXBQAM CS C1[C@@H]([C@H]([C@@H]([C@H](N1CCO)CO)O)O)O DMXBQAM IK IBAQFPQHRJAVAV-ULAWRXDQSA-N DMXBQAM IU (2R,3R,4R,5S)-1-(2-hydroxyethyl)-2-(hydroxymethyl)piperidine-3,4,5-triol DMXBQAM CA CAS 72432-03-2 DMXBQAM CB CHEBI:6935 DMXBQAM DE Diabetic complication DM5J64S ID DM5J64S DM5J64S DN Miglustat DM5J64S HS Approved DM5J64S SN BuDNJ; Butyldeoxynojirimycin; Miglustatum; NBV; Vevesca; Zavesca; Miglustat [USAN]; OGT 918; SC 48334; SC48334; Miglustat, Hydrochloride; N-Butyl deoxynojirimycin; N-Butyl dnj; N-Butyldeoxynojirimycin; N-Butylmoranoline; NB-DNJ; OGT-918; SC-48334; Zavesca (TN); Miglustat (USAN/INN); N-Bu-DNJ; N-Butyl-DNJ; N-Butyl-deoxynojirimycin; N-(n-Butyl)deoxynojirimycin; N-butyl-1-deoxynojirimycin; N-(n-butyl)-1,5-dideoxy-1,5-imino-D-glucitol; (2R,3R,4R,5S)-1-butyl-2-(hydroxymethyl)piperidine-3,4,5-triol; 1,5-Dideoxy-1,5-N-butylimino-D-glucitol DM5J64S TC Anti-HIV Agents DM5J64S DT Small molecular drug DM5J64S PC 51634 DM5J64S MW 219.28 DM5J64S FM C10H21NO4 DM5J64S IC InChI=1S/C10H21NO4/c1-2-3-4-11-5-8(13)10(15)9(14)7(11)6-12/h7-10,12-15H,2-6H2,1H3/t7-,8+,9-,10-/m1/s1 DM5J64S CS CCCCN1C[C@@H]([C@H]([C@@H]([C@H]1CO)O)O)O DM5J64S IK UQRORFVVSGFNRO-UTINFBMNSA-N DM5J64S IU (2R,3R,4R,5S)-1-butyl-2-(hydroxymethyl)piperidine-3,4,5-triol DM5J64S CA CAS 72599-27-0 DM5J64S CB CHEBI:50381 DM5J64S DE Type 1 gaucher disease DMBFE74 ID DMBFE74 DMBFE74 DN Milnacipran DMBFE74 HS Approved DMBFE74 SN Ixel; Midalcipran; Milnacipranum; Toledomin; Milnacipran [INN]; Milnacipranum [Latin]; F 2207; F-2207; Ixel (TN); Milnacipran(INN); Savella (TN); (+-)-cis-2-(Aminomethyl)-N,N-diethyl-1-phenylcyclopropanecarboxamide; (1R,2S)-2-(aminomethyl)-N,N-diethyl-1-phenylcyclopropane-1-carboxamide; 1-phenyl-1-diethylaminocarbonyl-2-aminomethylcyclopropane HCl DMBFE74 CP Silesia Laboratories DMBFE74 TC Antidepressants DMBFE74 DT Small molecular drug DMBFE74 PC 65833 DMBFE74 MW 246.35 DMBFE74 FM C15H22N2O DMBFE74 IC InChI=1S/C15H22N2O/c1-3-17(4-2)14(18)15(10-13(15)11-16)12-8-6-5-7-9-12/h5-9,13H,3-4,10-11,16H2,1-2H3/t13-,15+/m1/s1 DMBFE74 CS CCN(CC)C(=O)[C@@]1(C[C@@H]1CN)C2=CC=CC=C2 DMBFE74 IK GJJFMKBJSRMPLA-HIFRSBDPSA-N DMBFE74 IU (1R,2S)-2-(aminomethyl)-N,N-diethyl-1-phenylcyclopropane-1-carboxamide DMBFE74 CA CAS 96847-55-1 DMBFE74 CB CHEBI:94468 DMBFE74 DE Depression DM8TUPF ID DM8TUPF DM8TUPF DN Milrinone DM8TUPF HS Approved DM8TUPF SN Corotrop; Corotrope; Milrila; Milrinona; Milrinonum; Primacor; Milrinona [Spanish]; Milrinonum [Latin]; M 4659; M1663; YM 018; MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER; Milrila (TN); PRIMACOR IN DEXTROSE 5% IN PLASTIC CONTAINER; Primacor (TN); WIN 47203-2; Win-47203; Milrinone [USAN:BAN:INN]; Win-47203-2; Milrinone (JAN/USAN/INN); 1,6-Dihydro-2-methyl-6-oxo(3,4'-bipyridine)-5-carbonitrile; 1,6-Dihydro-2-methyl-6-oxo-(3,4′-bipyridine)-5-carbonitrile; 1,6-Dihydro-2-methyl-6-oxo-(3,4'-bipyridine)-5-carbonitrile; 1,6-Dihydro-2-methyl-6-oxo-3,4-bipyridine-5-carbonitrile; 1,6-Dihydro-2-methyl-6-oxo-[3,4'-bipyridine]-5-carbonitrile; 111GE027; 2-methyl-6-oxo-1,6-dihydro-3,4'-bipyridine-5-carbonitrile; 3-Cyano-6-methyl-5-(4-pyridyl)-2-pyridone; 6-Methyl-5-(4-pyridyl)-2-pyridone-3-carbonitrile; 6-methyl-2-oxo-5-pyridin-4-yl-1H-pyridine-3-carbonitrile DM8TUPF CP Sanofi-Synthelabo Inc DM8TUPF TC Cardiotonic Agents DM8TUPF DT Small molecular drug DM8TUPF PC 4197 DM8TUPF MW 211.22 DM8TUPF FM C12H9N3O DM8TUPF IC InChI=1S/C12H9N3O/c1-8-11(9-2-4-14-5-3-9)6-10(7-13)12(16)15-8/h2-6H,1H3,(H,15,16) DM8TUPF CS CC1=C(C=C(C(=O)N1)C#N)C2=CC=NC=C2 DM8TUPF IK PZRHRDRVRGEVNW-UHFFFAOYSA-N DM8TUPF IU 6-methyl-2-oxo-5-pyridin-4-yl-1H-pyridine-3-carbonitrile DM8TUPF CA CAS 78415-72-2 DM8TUPF CB CHEBI:50693 DM8TUPF DE Congestive heart failure DMND304 ID DMND304 DMND304 DN Miltefosine DMND304 HS Approved DMND304 SN HDPC; HePC; Hexadecylphosphocholine; Hexadecylphosphorylcholine; Impavido; Miltefosina; Miltefosinum; Miltex; Baxter Oncology brand of miltefosine; Baxter brand of miltefosine; Miltefosin C; Prasfarma brand of miltefosine; D 18506; IN1227; D-18506; H-1850; M-7200; Miltefosina [INN-Spanish]; Miltefosine (INN); Miltefosine[INN:BAN]; Miltefosinum [INN-Latin]; N-Hexadecylphosphorylcholine; TF-002; Choline hydroxide, hexadecyl hydrogen phosphate, inner salt; Choline, hexadecyl hydrogen phosphate, inner salt; Hexadecyl 2-(trimethylazaniumyl)ethyl phosphate; Choline phosphate, hexadecyl ester, hydroxide, inner salt; Choline phosphate, hexadecyl ester, hydroxide, inner salt (6CI); Hexadecyl 2-(trimethyl-.lambda.~5~-azanyl)ethyl hydrogen phosphate; Ethanaminium, 2-(((hexadecyloxy)hydroxyphosphinyl)oxy)-N,N,N-trimethyl-, hydroxide, inner salt; Ethanaminium, 2-(((hexadecyloxy)hydroxyphosphinyl)oxy)-N,N,N-trimethyl-, hydroxide, innner salt; 1-Hexadecylphosphorylcholine; 2-(((Hexadecyloxy)hydroxyphosphinyl)oxy)-N,N,N-trimethylethanaminium hydroxide, inner salt; 3,5-Dioxa-4-phosphaunacosan-1-aminium, 4-hydroxy-N,N,N-trimethyl-, hydroxide, inner salt, 4-oxide DMND304 CP Aeterna Zentaris DMND304 TC Antifungal Agents DMND304 DT Small molecular drug DMND304 PC 3599 DMND304 MW 407.6 DMND304 FM C21H46NO4P DMND304 IC InChI=1S/C21H46NO4P/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18-20-25-27(23,24)26-21-19-22(2,3)4/h5-21H2,1-4H3 DMND304 CS CCCCCCCCCCCCCCCCOP(=O)([O-])OCC[N+](C)(C)C DMND304 IK PQLXHQMOHUQAKB-UHFFFAOYSA-N DMND304 IU hexadecyl 2-(trimethylazaniumyl)ethyl phosphate DMND304 CA CAS 58066-85-6 DMND304 CB CHEBI:75283 DMND304 DE Leishmaniasis; Visceral leishmaniasis DM0EP7M ID DM0EP7M DM0EP7M DN Minaprine DM0EP7M HS Approved DM0EP7M SN Brantur; Cantor; Minaprina; Minaprinum; Minaprine dihydrochloride; AGR 1240; CB 30038; Cantor (TN); Minaprina [INN-Spanish]; Minaprinum [INN-Latin]; Minaprine (USAN/INN); Minaprine [USAN:BAN:INN]; N-(4-Methyl-6-phenyl-3-pyridazinyl)-4-morpholineethanamine; 3-(morpholinoethyl)amino-4-methyl-6-phenylpyridazine; 4-(2-((4-Methyl-6-phenyl-3-pyridazinyl)amino)ethyl)morpholine; 4-Methyl-3-(2-morpholinoethylamino)-6-phenylpyridazin; 4-methyl-N-(2-morpholin-4-ylethyl)-6-phenylpyridazin-3-amine DM0EP7M TC Antidepressants DM0EP7M DT Small molecular drug DM0EP7M PC 4199 DM0EP7M MW 298.4 DM0EP7M FM C17H22N4O DM0EP7M IC InChI=1S/C17H22N4O/c1-14-13-16(15-5-3-2-4-6-15)19-20-17(14)18-7-8-21-9-11-22-12-10-21/h2-6,13H,7-12H2,1H3,(H,18,20) DM0EP7M CS CC1=CC(=NN=C1NCCN2CCOCC2)C3=CC=CC=C3 DM0EP7M IK LDMWSLGGVTVJPG-UHFFFAOYSA-N DM0EP7M IU 4-methyl-N-(2-morpholin-4-ylethyl)-6-phenylpyridazin-3-amine DM0EP7M CA CAS 25905-77-5 DM0EP7M CB CHEBI:51038 DM0EP7M DE Depression DMVN5OH ID DMVN5OH DMVN5OH DN Minocycline DMVN5OH HS Approved DMVN5OH SN Borymycin; MINO; MIY; Minociclina; Minociclinum; Minocin; Minocline; Minocyclin; Minocyclinum; Minocycline Monohydrochloride; CL 59806; Lactoferrin B & Minocycline; Lactoferrin H & Minocycline; Minociclina [INN-Spanish]; Minocin (Hydrochloride); Minocin (TN); Minocyclinum [INN-Latin]; Vectrin (Hydrochloride); CRL-1605 & Minocycline; Minocycline (USAN/INN); Minocycline [USAN:BAN:INN]; (2Z,4S,4aS,5aR,12aS)-2-[amino(hydroxy)methylidene]-4,7-bis(dimethylamino)-10,11,12a-trihydroxy-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione; (4S,4AS,5AR,12AS)-4,7-BIS(DIMETHYLAMINO)-3,10,12,12A-TETRAHYDROXY-1,11-DIOXO-1,4,4A,5,5A,6,11,12A-OCTAHYDROTETRACENE-2-CARBOXAMIDE; 4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide; 7-Dimethylamino-6-demethyl-6-deoxytetracycline DMVN5OH CP Lederle Laboratories DMVN5OH TC Antibiotics DMVN5OH DT Small molecular drug DMVN5OH PC 54675783 DMVN5OH MW 457.5 DMVN5OH FM C23H27N3O7 DMVN5OH IC InChI=1S/C23H27N3O7/c1-25(2)12-5-6-13(27)15-10(12)7-9-8-11-17(26(3)4)19(29)16(22(24)32)21(31)23(11,33)20(30)14(9)18(15)28/h5-6,9,11,17,27-28,31,33H,7-8H2,1-4H3,(H2,24,32)/t9-,11-,17-,23-/m0/s1 DMVN5OH CS CN(C)[C@H]1[C@@H]2C[C@@H]3CC4=C(C=CC(=C4C(=C3C(=O)[C@@]2(C(=C(C1=O)C(=O)N)O)O)O)O)N(C)C DMVN5OH IK FFTVPQUHLQBXQZ-KVUCHLLUSA-N DMVN5OH IU (4S,4aS,5aR,12aR)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4H-tetracene-2-carboxamide DMVN5OH CA CAS 10118-90-8 DMVN5OH CB CHEBI:50694 DMVN5OH DE Bacterial infection; Rosacea DM50PMY ID DM50PMY DM50PMY DN Minodronate DM50PMY HS Approved DM50PMY SN Minodronic acid; 180064-38-4; (1-Hydroxy-2-(imidazo[1,2-a]pyridin-3-yl)ethane-1,1-diyl)diphosphonic acid; Recalbon; Bonoteo; BPH 261; ONO 5920; YH 529; Phosphonic acid, (1-hydroxy-2-imidazo(1,2-a)pyridin-3-ylethylidene)bis-; UNII-40SGR63TGL; YM 529; 40SGR63TGL; Ono-5920; NSC725590; YH-529; 127657-42-5; NCGC00183829-01; AK119862; Phosphonic acid, (1-hydroxy-2-imidazo[1,2-a]pyridin-3-ylethylidene)bis-; (1-hydroxy-2-{imidazo[1,2-a]pyridin-3-yl}-1-phosphonoethyl)phosphonic acid; minodronic acid DM50PMY DT Small molecular drug DM50PMY PC 130956 DM50PMY MW 322.15 DM50PMY FM C9H12N2O7P2 DM50PMY IC InChI=1S/C9H12N2O7P2/c12-9(19(13,14)15,20(16,17)18)5-7-6-10-8-3-1-2-4-11(7)8/h1-4,6,12H,5H2,(H2,13,14,15)(H2,16,17,18) DM50PMY CS C1=CC2=NC=C(N2C=C1)CC(O)(P(=O)(O)O)P(=O)(O)O DM50PMY IK VMMKGHQPQIEGSQ-UHFFFAOYSA-N DM50PMY IU (1-hydroxy-2-imidazo[1,2-a]pyridin-3-yl-1-phosphonoethyl)phosphonic acid DM50PMY CA CAS 180064-38-4 DM50PMY DE Osteoporosis DMA2Z4F ID DMA2Z4F DMA2Z4F DN Minoxidil DMA2Z4F HS Approved DMA2Z4F SN Alopexil; Alostil; Loniten; Lonolox; Minodyl; Minossidile; Minoxidilum; Minoxigaine; Minoximen; Neoxidil; Normoxidil; Pierminox; Prexidil; Regaine; RiUP; Rogaine; Theroxidil; Tricoxidil; Trocoxidil; MINOXIDIL EXTRA STRENGTH FOR MEN; Men s Rogaine Foam; Mens Rogaine Foam; Minossidile [Italian]; Minoxidil Pfizer Brand; PfizerBrand of Minoxidil; Rogaine Extra Strength for Men; Rogaine for Men; Rogaine for Women; M 4145; M1389; U 10858; Apo-Gain; Gen-Minoxidil; Loniten (TN); MINOXIDIL (FOR MEN); MINOXIDIL (FOR WOMEN); MINOXIDIL EXTRA STRENGTH (FOR MEN); Men's Rogaine; Minoxidilum [INN-Latin]; ROGAINE (FOR MEN); ROGAINE (FOR WOMEN); ROGAINE EXTRA STRENGTH (FOR MEN); Regaine (TN); Riup (TN); Rogaine (TN); TM-160; U-10858; Minoxidil (USP/INN); Minoxidil [USAN:BAN:INN]; U-10,858; Rogaine, Regaine, Avacor and Mintop, Minoxidil; Pyrimidine, 2,4-diamino-6-piperidino-, 3-oxide; 2,3-Dihydro-3-hydroxy-2-imino-6-(1-piperidinyl)-4-pyrimidinamine; 2,4-Diamino-6-piperidinilpirimidina-3-ossido; 2,4-Diamino-6-piperidinilpirimidina-3-ossido [Italian]; 2,4-Diamino-6-piperidino-pyrimidine-3-oxide; 2,4-Diamino-6-piperidinopyrimidine 3-N-oxide; 2,4-Diamino-6-piperidinopyrimidine 3-oxide; 2,4-Pyrimidinediamine, 6-(1-piperidinyl)-, 3-oxide; 2,6-Diamino-4-piperidinopyrimidin-1-oxid; 3-hydroxy-2-imino-6-(1-piperidyl)pyrimidin-4-amine; 3-hydroxy-2-imino-6-piperidin-1-ylpyrimidin-4-amine; 6-(1-Piperidinyl)-2,4-pyrimidinediamine 3-oxide; 6-(piperidin-1-yl)pyrimidine-2,4-diamine 3-oxide; 6-Amino-1,2-dihydro-1-hydroxy-2-imino-4-piperidinopyrimidine; 6-Piperidino-2,4-diaminopyrimidine 3-oxide; 6-[1-Piperidinyl]pyrimidine-2,4-diamine 3 oxide DMA2Z4F CP Upjohn Corporation DMA2Z4F TC Antihypertensive Agents DMA2Z4F DT Small molecular drug DMA2Z4F PC 4201 DMA2Z4F MW 209.25 DMA2Z4F FM C9H15N5O DMA2Z4F IC InChI=1S/C9H15N5O/c10-7-6-8(12-9(11)14(7)15)13-4-2-1-3-5-13/h6,11,15H,1-5,10H2 DMA2Z4F CS C1CCN(CC1)C2=NC(=N)N(C(=C2)N)O DMA2Z4F IK ZIMGGGWCDYVHOY-UHFFFAOYSA-N DMA2Z4F IU 3-hydroxy-2-imino-6-piperidin-1-ylpyrimidin-4-amine DMA2Z4F CA CAS 38304-91-5 DMA2Z4F CB CHEBI:6942 DMA2Z4F DE Hypertension DMGSRN1 ID DMGSRN1 DMGSRN1 DN Mipomersen DMGSRN1 HS Approved DMGSRN1 SN Mipomersen DMGSRN1 CP Isis Pharmaceuticals DMGSRN1 TC Antisense DMGSRN1 DT Antisense drug DMGSRN1 SQ 5'-GCCUCAGTCTGCTTCGCACC DMGSRN1 PC 71301230 DMGSRN1 MW 7158 DMGSRN1 FM C230H305N67O122P19S19-19 DMGSRN1 IC InChI=1S/C230H324N67O122P19S19/c1-97-55-278(217(309)256-177(97)231)141-45-131(112(400-141)70-381-422(327,328)442-136-50-146(283-66-108(12)196(302)275-228(283)320)406-118(136)76-387-427(337,338)448-140-54-150(294-93-253-154-191(294)266-214(243)270-200(154)306)409-120(140)78-389-428(339,340)446-138-52-148(292-91-250-151-186(240)246-89-248-188(151)292)407-121(138)79-390-430(343,344)450-169-124(413-204(160(169)373-37-27-363-17)286-59-101(5)181(235)260-221(286)313)83-394-435(353,354)455-174-128(417-209(165(174)378-42-32-368-22)291-68-110(14)198(304)277-230(291)322)87-396-434(351,352)453-172-126(415-207(163(172)376-40-30-366-20)289-62-104(8)184(238)263-224(289)316)85-395-433(349,350)452-171-123(412-206(162(171)375-39-29-365-19)288-61-103(7)183(237)262-223(288)315)82-393-432(347,348)449-168-111(69-298)410-211(159(168)372-36-26-362-16)296-95-254-155-192(296)267-215(244)271-201(155)307)439-420(323,324)384-74-117-137(51-147(405-117)284-67-109(13)197(303)276-229(284)321)444-425(333,334)388-77-119-139(53-149(408-119)293-92-252-153-190(293)265-213(242)269-199(153)305)447-426(335,336)386-71-113-132(46-142(401-113)279-56-98(2)178(232)257-218(279)310)440-421(325,326)383-73-115-135(49-145(403-115)282-65-107(11)195(301)274-227(282)319)443-424(331,332)385-75-116-134(48-144(404-116)281-64-106(10)194(300)273-226(281)318)441-423(329,330)382-72-114-133(47-143(402-114)280-57-99(3)179(233)258-219(280)311)445-429(341,342)392-81-129-176(167(380-44-34-370-24)212(419-129)297-96-255-156-193(297)268-216(245)272-202(156)308)457-438(359,360)398-86-127-173(164(377-41-31-367-21)208(416-127)290-63-105(9)185(239)264-225(290)317)454-436(355,356)399-88-130-175(166(379-43-33-369-23)210(418-130)295-94-251-152-187(241)247-90-249-189(152)295)456-437(357,358)397-84-125-170(161(374-38-28-364-18)205(414-125)287-60-102(6)182(236)261-222(287)314)451-431(345,346)391-80-122-157(299)158(371-35-25-361-15)203(411-122)285-58-100(4)180(234)259-220(285)312/h55-68,89-96,111-150,157-176,203-212,298-299H,25-54,69-88H2,1-24H3,(H,323,324)(H,325,326)(H,327,328)(H,329,330)(H,331,332)(H,333,334)(H,335,336)(H,337,338)(H,339,340)(H,341,342)(H,343,344)(H,345,346)(H,347,348)(H,349,350)(H,351,352)(H,353,354)(H,355,356)(H,357,358)(H,359,360)(H2,231,256,309)(H2,232,257,310)(H2,233,258,311)(H2,234,259,312)(H2,235,260,313)(H2,236,261,314)(H2,237,262,315)(H2,238,263,316)(H2,239,264,317)(H2,240,246,248)(H2,241,247,249)(H,273,300,318)(H,274,301,319)(H,275,302,320)(H,276,303,321)(H,277,304,322)(H3,242,265,269,305)(H3,243,266,270,306)(H3,244,267,271,307)(H3,245,268,272,308)/p-19/t111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122+,123-,124-,125+,126-,127+,128-,129-,130+,131+,132+,133+,134+,135+,136+,137+,138+,139+,140+,141-,142-,143-,144-,145-,146-,147-,148-,149-,150-,157+,158+,159-,160-,161+,162-,163-,164+,165-,166+,167-,168-,169-,170+,171-,172-,173+,174-,175+,176-,203+,204-,205+,206-,207-,208+,209-,210+,211-,212-/m1/s1 DMGSRN1 CS CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)COP(=O)([O-])S[C@H]3C[C@@H](O[C@@H]3COP(=O)([O-])S[C@H]4C[C@@H](O[C@@H]4COP(=O)([O-])S[C@H]5C[C@@H](O[C@@H]5COP(=O)([O-])S[C@H]6C[C@@H](O[C@@H]6COP(=O)([O-])S[C@H]7C[C@@H](O[C@@H]7COP(=O)([O-])S[C@H]8C[C@@H](O[C@@H]8COP(=O)([O-])S[C@H]9C[C@@H](O[C@@H]9COP(=O)([O-])S[C@@H]1[C@H](O[C@H]([C@@H]1OCCOC)N1C=C(C(=NC1=O)N)C)COP(=O)([O-])S[C@@H]1[C@H](O[C@H]([C@@H]1OCCOC)N1C=C(C(=O)NC1=O)C)COP(=O)([O-])S[C@@H]1[C@H](O[C@H]([C@@H]1OCCOC)N1C=C(C(=NC1=O)N)C)COP(=O)([O-])S[C@@H]1[C@H](O[C@H]([C@@H]1OCCOC)N1C=C(C(=NC1=O)N)C)COP(=O)([O-])S[C@@H]1[C@H](O[C@H]([C@@H]1OCCOC)N1C=NC2=C1N=C(NC2=O)N)CO)N1C=NC2=C(N=CN=C21)N)N1C=NC2=C1N=C(NC2=O)N)N1C=C(C(=O)NC1=O)C)N1C=C(C(=NC1=O)N)C)N1C=C(C(=O)NC1=O)C)N1C=NC2=C1N=C(NC2=O)N)N1C=C(C(=NC1=O)N)C)SP(=O)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=C(C(=O)NC1=O)C)SP(=O)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=C(C(=NC1=O)N)C)SP(=O)([O-])OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=NC2=C1N=C(NC2=O)N)OCCOC)SP(=O)([O-])OC[C@H]1[C@@H]([C@@H]([C@H](O1)N1C=C(C(=NC1=O)N)C)OCCOC)SP(=O)([O-])OC[C@H]1[C@@H]([C@@H]([C@H](O1)N1C=NC2=C(N=CN=C21)N)OCCOC)SP(=O)([O-])OC[C@H]1[C@@H]([C@@H]([C@H](O1)N1C=C(C(=NC1=O)N)C)OCCOC)SP(=O)([O-])OC[C@H]1[C@@H]([C@@H]([C@H](O1)N1C=C(C(=NC1=O)N)C)OCCOC)O DMGSRN1 IK TZRFSLHOCZEXCC-HIVFKXHNSA-A DMGSRN1 IU [(2R,3R,4S,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[(2R,3R,4S,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[(2R,3R,4S,5R)-3-[[(2R,3R,4S,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[(2R,3R,4S,5R)-3-[[(2S,3S,4R,5S)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[(2S,3S,4R,5S)-3-[[(2S,3S,4R,5S)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[(2S,3S,4S,5S)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-hydroxy-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-oxidophosphoryl]sulfanyl-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-oxidophosphoryl]sulfanyl-5-(6-aminopurin-9-yl)-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-oxidophosphoryl]sulfanyl-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-oxidophosphoryl]sulfanyl-5-(2-amino-6-oxo-1H-purin-9-yl)-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-oxidophosphoryl]sulfanyloxolan-2-yl]methoxy-oxidophosphoryl]sulfanyl-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-oxidophosphoryl]sulfanyl-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-oxidophosphoryl]sulfanyloxolan-2-yl]methoxy-oxidophosphoryl]sulfanyl-5-(2-amino-6-oxo-1H-purin-9-yl)oxolan-2-yl]methoxy-oxidophosphoryl]sulfanyl-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-oxidophosphoryl]sulfanyloxolan-2-yl]methoxy-oxidophosphoryl]sulfanyl-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-oxidophosphoryl]sulfanyl-5-(2-amino-6-oxo-1H-purin-9-yl)oxolan-2-yl]methoxy-oxidophosphoryl]sulfanyl-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-oxidophosphoryl]sulfanyl-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-oxidophosphoryl]sulfanyl-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-oxidophosphoryl]sulfanyl-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-oxidophosphoryl]sulfanyl-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-[(2R,3R,4S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-2-(hydroxymethyl)-4-(2-methoxyethoxy)oxolan-3-yl]sulfanylphosphinate DMGSRN1 CA CAS 1000120-98-8 DMGSRN1 DE Familial hypercholesterolemia DMS1GYT ID DMS1GYT DMS1GYT DN Mirabegron DMS1GYT HS Approved DMS1GYT SN Myrbetriq (TN) DMS1GYT CP Astellas DMS1GYT DT Small molecular drug DMS1GYT PC 9865528 DMS1GYT MW 396.5 DMS1GYT FM C21H24N4O2S DMS1GYT IC InChI=1S/C21H24N4O2S/c22-21-25-18(14-28-21)12-20(27)24-17-8-6-15(7-9-17)10-11-23-13-19(26)16-4-2-1-3-5-16/h1-9,14,19,23,26H,10-13H2,(H2,22,25)(H,24,27)/t19-/m0/s1 DMS1GYT CS C1=CC=C(C=C1)[C@H](CNCCC2=CC=C(C=C2)NC(=O)CC3=CSC(=N3)N)O DMS1GYT IK PBAPPPCECJKMCM-IBGZPJMESA-N DMS1GYT IU 2-(2-amino-1,3-thiazol-4-yl)-N-[4-[2-[[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]acetamide DMS1GYT CA CAS 223673-61-8 DMS1GYT CB CHEBI:65349 DMS1GYT DE Overactive bladder DML53ZJ ID DML53ZJ DML53ZJ DN Mirtazapine DML53ZJ HS Approved DML53ZJ SN Avanza; Axit; Azamianserin; Mepirzapin; Mepirzepine; Mirtabene; Mirtaz; Mirtazapina; Mirtazapinum; Mirtazepine; Mirtazipine; Mirtazon; Norset; Promyrtil; Remergil; Remergon; Remeron; Rexer; Zispin; Celltech brand of mirtazapine; Mundogen brand of mirtazapine; Organon brand of mirtazapine; Remeron SolTab; ORG 3770; Afloyan (TN); Alphamirt (TN); Alphazagen (TN); Amirel (TN); Arintapin (TN); Arintapina (TN); Avanza (TN); Axit (TN); Bexzis (TN); Calixta (TN); Ciblex (TN); Combar (TN); Comenter (TN); Divaril (TN); Esprital (TN); Finmirtaza (TN); Finpharma (TN); Finscope (TN); Genamirt (TN); Hexazipin (TN); Loxozapin (TN); ME-2040; Medizapin (TN); Miralix (TN); Mirap (TN); Mirazep (TN); Miro (TN); Miron (TN); Mirta (TN); Mirtabene (TN); Mirtachem (TN); Mirtacur (TN); Mirtadepi (TN); Mirtagamma (TN); Mirtal (TN); Mirtalich (TN); Mirtalphagen (TN); Mirtamed (TN); Mirtamerck (TN); Mirtapax (TN); Mirtapharm (TN); Mirtapin(TN); Mirtaratio (TN); Mirtaril (TN); Mirtaron (TN); Mirtascope (TN); Mirtasole (TN); Mirtastad (TN); Mirtastada (TN); Mirtatifi (TN); Mirtatsapiini (TN); Mirtawin (TN); Mirtaz (TN); Mirtazapin (TN);Mirtazapina (TN); Mirtazapina [INN-Spanish]; Mirtazapinum [INN-Latin]; Mirtazelon (TN); Mirtazen (TN); Mirtazep (TN); Mirtazepin (TN); Mirtazon (TN); Mirtazza (TN); Mirtel (TN); Mirtoral (TN); Mirzagen (TN); Mirzalux (TN); Mirzaten (TN); Mitrazen (TN); Mizapin (TN); Mizapin Sol (TN); Norset (TN); Noxibel (TN); Pharmasole (TN); Pharmazepine (TN); Promyrtil (TN); Remergil (TN); Remergon (TN); Remeron (TN); Remeron SolTab (TN); Remirta (TN); Rexer (TN); SolTab (TN); Tarzapine (TN); Tazamel (TN); Tazapin (TN); Tazascope (TN); Tirzamed (TN); Valdren (TN); Vastat (TN); Zapex (TN); Zicomber (TN); Zismirt (TN); Zispin (TN); Zispin SolTab (TN); Zuleptan (TN); Mirtazapine [USAN:BAN:INN]; Mirtazapine [USAN:INN:BAN]; Mirzaten Q-Tab (TN); Zistap. (TN); Mirtazapine (JAN/USAN/INN); (1)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino(2,1-a)pyrido(2,3-c)(2)benzazepine; (N-methyl-11C)mirtazapine; 1,2,3,4,10,14b-Hexahydro-2-methylpyrazino(2,1-a)pyrido(2,3-c)benzazepine; 1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine; 2-Methyl-1,2,3,4,10,14b-hexahydropyrazino[2,1-a]pyrido[2,3-c][2]benzazepine; 5-methyl-2,5,19-triazatetracyclo[13.4.0.0^{2,7}.0^{8,13}]nonadeca-1(15),8(13),9,11,16,18-hexaene; 6-Azamianserin DML53ZJ CP Organon International DML53ZJ TC Antidepressants DML53ZJ DT Small molecular drug DML53ZJ PC 4205 DML53ZJ MW 265.35 DML53ZJ FM C17H19N3 DML53ZJ IC InChI=1S/C17H19N3/c1-19-9-10-20-16(12-19)15-7-3-2-5-13(15)11-14-6-4-8-18-17(14)20/h2-8,16H,9-12H2,1H3 DML53ZJ CS CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4 DML53ZJ IK RONZAEMNMFQXRA-UHFFFAOYSA-N DML53ZJ IU 5-methyl-2,5,19-triazatetracyclo[13.4.0.02,7.08,13]nonadeca-1(15),8,10,12,16,18-hexaene DML53ZJ CA CAS 85650-52-8 DML53ZJ CB CHEBI:6950 DML53ZJ DE Depression DMHVJFK ID DMHVJFK DMHVJFK DN Misoprostol DMHVJFK HS Approved DMHVJFK SN Cytotec; GyMiso; Isprelor; Misopess; Misoprostolum; Misotol; SC 29333; Cytotec (TN); Misoprostolum [INN-Latin]; SC-29333; XP-16J; Misoprostol (JAN/USAN/INN); Methyl (11alpha,13E)-11,16-dihydroxy-16-methyl-9-oxoprost-13-en-1-oate; Methyl (+-)-11-alpha,16-dihydroxy-16-methyl-9-oxoprost-13-en-1-oate; Methyl 7-[(1R,2R,3R)-3-hydroxy-2-[(E)-4-hydroxy-4-methyloct-1-enyl]-5-oxocyclopentyl]heptanoate; (+/-)-15-Deoxy-(16RS)-16-hydroxy-16-methylprostaglandin E1 methyl ester; (11-alpha,13E)-(+-)-11,16-Dihydroxy-16-methyl-9-oxoprost-13-en-1-oic acid methyl ester DMHVJFK CP Pfizer Pharmaceuticals DMHVJFK TC Abortifacient Agents DMHVJFK DT Small molecular drug DMHVJFK PC 5282381 DMHVJFK MW 382.5 DMHVJFK FM C22H38O5 DMHVJFK IC InChI=1S/C22H38O5/c1-4-5-14-22(2,26)15-10-12-18-17(19(23)16-20(18)24)11-8-6-7-9-13-21(25)27-3/h10,12,17-18,20,24,26H,4-9,11,13-16H2,1-3H3/b12-10+/t17-,18-,20-,22?/m1/s1 DMHVJFK CS CCCCC(C)(C/C=C/[C@H]1[C@@H](CC(=O)[C@@H]1CCCCCCC(=O)OC)O)O DMHVJFK IK OJLOPKGSLYJEMD-URPKTTJQSA-N DMHVJFK IU methyl 7-[(1R,2R,3R)-3-hydroxy-2-[(E)-4-hydroxy-4-methyloct-1-enyl]-5-oxocyclopentyl]heptanoate DMHVJFK CA CAS 59122-46-2 DMHVJFK CB CHEBI:94387 DMHVJFK DE Medical abortion DMP8HEL ID DMP8HEL DMP8HEL DN Mitiglinide DMP8HEL HS Approved DMP8HEL SN Mitiglinide calcium; Mitiglinide calcium hydrate; KAD 1229; S21403; Glufast (TN); Kad-1229; Calcium 2-benzyl-3-(cis-hexahydro-2-isoindolinylcarbonyl)propionate dihydrate; Calcium (2S)-4-[(3aS,7aR)-1,3,3a,4,5,6,7,7a-octahydroisoindol-2-yl]-2-benzyl-4-oxobutanoate; (2S)-4-[(3aR,7aS)-1,3,3a,4,5,6,7,7a-octahydroisoindol-2-yl]-2-benzyl-4-oxobutanoic acid; 2-Benzyl-3-(hexahydro-2-isoindolinylcarbonyl)propionate DMP8HEL CP Elixir Pharmaceuticals DMP8HEL TC Hypoglycemic Agents DMP8HEL DT Small molecular drug DMP8HEL PC 121891 DMP8HEL MW 315.4 DMP8HEL FM C19H25NO3 DMP8HEL IC InChI=1S/C19H25NO3/c21-18(20-12-15-8-4-5-9-16(15)13-20)11-17(19(22)23)10-14-6-2-1-3-7-14/h1-3,6-7,15-17H,4-5,8-13H2,(H,22,23)/t15-,16+,17-/m0/s1 DMP8HEL CS C1CC[C@H]2CN(C[C@H]2C1)C(=O)C[C@H](CC3=CC=CC=C3)C(=O)O DMP8HEL IK WPGGHFDDFPHPOB-BBWFWOEESA-N DMP8HEL IU (2S)-4-[(3aR,7aS)-1,3,3a,4,5,6,7,7a-octahydroisoindol-2-yl]-2-benzyl-4-oxobutanoic acid DMP8HEL CA CAS 145375-43-5 DMP8HEL CB CHEBI:135349 DMP8HEL DE Diabetic complication DMH0ZJE ID DMH0ZJE DMH0ZJE DN Mitomycin DMH0ZJE HS Approved DMH0ZJE SN Mitomycin C; mitomycin C; 1950/7/7; Mutamycin; Ametycine; Mitocin-C; Ametycin; Mitomycin-C; Mytozytrex; Mitomycinum; Mytomycin; Mitozytrex; Mitomycinum C; Mitocin C; Mitomycins; Mitamycin; MMC; Mitosol; Mitomycyna C; 7-Amino-9alpha-methoxymitosane; NSC-26980; Mitomycyna C [Polish]; Mito-C; Mit-C; Mitomycin (TN); Mitomycinum [INN-Latin]; Mitomycine [INN-French]; Mitomicina [INN-Spanish]; NCI-C04706; RCRA waste number U010; NSC26980; NSC 26980; Mitomycine; CCRIS 414; UNII-50SG953SK6; HSDB 3239; C15H18N4O5; EINECS 200-008-6; Mitomycin C,; Ametycin; Mitomicina; Muamycin; Mitomycin C from Streptomyces caespitosus; Mitomycin C (JP15); Mitomycin C, Streptomyces caespitosus; Muamycin (TN); Mitomycin (USP/INN); Mitomycin [USAN:INN:BAN]; Mitomycin C, Streptomyces caespitosus, Carrier-Free DMH0ZJE TC Anticancer Agents DMH0ZJE DT Small molecular drug DMH0ZJE PC 5746 DMH0ZJE MW 334.33 DMH0ZJE FM C15H18N4O5 DMH0ZJE IC InChI=1S/C15H18N4O5/c1-5-9(16)12(21)8-6(4-24-14(17)22)15(23-2)13-7(18-13)3-19(15)10(8)11(5)20/h6-7,13,18H,3-4,16H2,1-2H3,(H2,17,22)/t6-,7+,13+,15-/m1/s1 DMH0ZJE CS CC1=C(C(=O)C2=C(C1=O)N3C[C@H]4[C@@H]([C@@]3([C@@H]2COC(=O)N)OC)N4)N DMH0ZJE IK NWIBSHFKIJFRCO-WUDYKRTCSA-N DMH0ZJE IU [(4S,6S,7R,8S)-11-amino-7-methoxy-12-methyl-10,13-dioxo-2,5-diazatetracyclo[7.4.0.02,7.04,6]trideca-1(9),11-dien-8-yl]methyl carbamate DMH0ZJE CA CAS 50-07-7 DMH0ZJE CB CHEBI:27504 DMH0ZJE DE Breast cancer; Gastrointestinal cancer; Solid tumour/cancer DM4PF81 ID DM4PF81 DM4PF81 DN Mitomycin A DM4PF81 HS Approved DM4PF81 SN Azirino[2',3':3,4]pyrrolo[1,2-a]indole-4,7-dione, 1,1a,2,8,8a,8b-hexahydro-8-(hydroxymethyl)-6,8a-dimethoxy-5-methyl-, carbamate; Azirino(2',3':3,4)pyrrolo(1,2-a)indole-4,7-dione, 1,1a,2,8,8a,8b-hexahydro-8-(hydroxymethyl)-6,8a-dimethoxy-5-methyl-, carbamate (ester); [(1ar,8r,8as,8br)-6,8a-dimethoxy-5-methyl-4,7-dioxo-1,1a,2,4,7,8,8a,8b-octahydroazireno[2',3':3,4]pyrrolo[1,2-a]indol-8-yl]methyl carbamate; Azirino(2',3':3,4)pyrrolo(1,2-a)indole-4,7-dione, 8-(((aminocarbonyl)oxy)methyl)-1,1a,2,8,8a,8b-hexahydro-6,8a-dimethoxy-5-methyl-, (1aR-(1aalpha,8beta,8aalpha,8balpha))-(9CI) DM4PF81 TC Anticancer Agents DM4PF81 DT Small molecular drug DM4PF81 PC 19972 DM4PF81 MW 349.34 DM4PF81 FM C16H19N3O6 DM4PF81 IC InChI=1S/C16H19N3O6/c1-6-11(20)10-9(12(21)13(6)23-2)7(5-25-15(17)22)16(24-3)14-8(18-14)4-19(10)16/h7-8,14,18H,4-5H2,1-3H3,(H2,17,22)/t7-,8+,14+,16-/m1/s1 DM4PF81 CS CC1=C(C(=O)C2=C(C1=O)N3C[C@H]4[C@@H]([C@@]3([C@@H]2COC(=O)N)OC)N4)OC DM4PF81 IK HYFMSAFINFJTFH-NGSRAFSJSA-N DM4PF81 IU [(4S,6S,7R,8S)-7,11-dimethoxy-12-methyl-10,13-dioxo-2,5-diazatetracyclo[7.4.0.02,7.04,6]trideca-1(9),11-dien-8-yl]methyl carbamate DM4PF81 CA CAS 4055-39-4 DM4PF81 CB CHEBI:85412 DM4PF81 DE Solid tumour/cancer DMU1GX0 ID DMU1GX0 DMU1GX0 DN Mitotane DMU1GX0 HS Approved DMU1GX0 SN Chloditan; Chlodithan; Chlodithane; Khloditan; Khlodithan; Lysodren; Mitotan; Mitotano; Mitotanum; Mytotan; Bristol Myers Squibb Brand of Mitotane; C 3010; CB 313; CB313; PS694_SUPELCO; Bristol-Myers Squibb Brand of Mitotane; CB-313; Lysodren (TN); Mitotano [INN-Spanish]; Mitotanum [INN-Latin]; Ortho,para DDD; Mitotane [USAN:INN:JAN]; O,p-DDD; O,p-Tde; Ortho,para-DDD; Mitotane (JAN/USP/INN); O,p'-DDD; O,p'-Dichlorodiphenyldichloroethane; O,p'-TDE; Ethane, 1,1-dichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)-(8CI); (+-)-1,1-Dichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)ethane; (2,4'-Dichlorodiphenyl)dichloroethane; (o,p)-DDD; 1,1-Dichloro-2,2-bis(2,4'-dichlorophenyl)ethane; 1,1-Dichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)ethane; 1,1-Dichloro-2-(p-chlorophenyl)-2-(o-chlorophenyl)ethane; 1-(2-Chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane; 1-Chloro-2-(2,2-dichloro-1-(4-chlorophenyl)ethyl)benzene; 1-Chloro-2-[2,2-dichloro-1-(4-chlorophenyl)ethyl]benzene; 2,2-Bis(2-chlorophenyl-4-chlorophenyl)-1,1-dichloroethane; 2,4'-Ddd; 2,4'-Dichlorodiphenyldichloroethane; 2,4'-Dichlorophenyldichlorethane; 2-(2-Chlorophenyl)-2-(4-chlorophenyl)-1,1-dichloroethane; 2-(o-Chlorophenyl)-2-(p-chlorophenyl)-1,1-dichloroethane DMU1GX0 CP Bristol Myers Squibb DMU1GX0 TC Anticancer Agents DMU1GX0 DT Small molecular drug DMU1GX0 PC 4211 DMU1GX0 MW 320 DMU1GX0 FM C14H10Cl4 DMU1GX0 IC InChI=1S/C14H10Cl4/c15-10-7-5-9(6-8-10)13(14(17)18)11-3-1-2-4-12(11)16/h1-8,13-14H DMU1GX0 CS C1=CC=C(C(=C1)C(C2=CC=C(C=C2)Cl)C(Cl)Cl)Cl DMU1GX0 IK JWBOIMRXGHLCPP-UHFFFAOYSA-N DMU1GX0 IU 1-chloro-2-[2,2-dichloro-1-(4-chlorophenyl)ethyl]benzene DMU1GX0 CA CAS 53-19-0 DMU1GX0 CB CHEBI:6954 DMU1GX0 DE Adrenocortical carcinoma DMM39BF ID DMM39BF DMM39BF DN Mitoxantrone DMM39BF HS Approved DMM39BF SN DHAD; DHAQ; Dihydroxyanthraquinone; MIX; Misostol; Mitoxanthrone; Mitoxantron; Mitoxantrona; Mitoxantronum; Mitozantrone; DHAQ HCl; Mitoxantrone [INN]; Mitozantrone hydrochloride; Mitoxantrone 2HCl; Liposome Encapsulated Mitoxantrone (LEM); Misostol (TN); Mitoxantrona [INN-Spanish]; Mitoxantrone (INN); Mitoxantrone (free base); Mitoxantronum [INN-Latin]; Novantrone (TN); AN-584/42007670; Novantrone(R) (mitoxantrone for injection concentrate); DHAQ (*Diacetate salt*); MITOXANTRONE, Mitoxantrone Hydrochloride, Mitoxantrone dihydrochloride, MITOXANTHRONE HYDROCHLORIDE; MITOXANTRONE, 1,4-DIHYDROXY-5,8-BIS({2-[(2-HYDROXYETHYL)AMINO]ETHYL}AMINO)ANTHRA-9,10-QUINONE; 1,4-Bis(2-(2-hydroxyethylamino)ethyl)amino)-5,8-dihydroxyanthraquinone; 1,4-DIHYDROXY-5,8-BIS({2-[(2-HYDROXYETHYL)AMINO]ETHYL}AMINO)-9,10-ANTHRACENEDIONE; 1,4-Dihydroxy-5,8-bis(2-((2-hydroxyethyl)amino)ethylamino)-9,10-anthracenedione; 1,4-Dihydroxy-5,8-bis(5-hydroxy-3-azapentylamino)anthrachinon; 1,4-Dihydroxy-5,8-bis[2-(2-hydroxyethylamino)ethylamino]anthracene-9,10-dione; 1,4-Dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]-9,10-anthracenedione; 1,4-dihydroxy-5,8-bis({2-[(2-hydroxyethyl)amino]ethyl}amino)anthra-9,10-quinone; 1,4-dihydroxy-5,8-bis({2-[(2-hydroxyethyl)amino]ethyl}amino)anthracene-9,10-dione; 5,8-Bis((2-((2-hydroxyethyl)amino)ethyl)amino)-1,4-dihydroxyanthraquinone; 9,10-Anthracenedione, 1,4-dihydroxy-5,8-bis((2-((2-hydroxyethyl)amino)ethyl)amino)-(9CI) DMM39BF CP Serono DMM39BF TC Analgesics DMM39BF DT Small molecular drug DMM39BF PC 4212 DMM39BF MW 444.5 DMM39BF FM C22H28N4O6 DMM39BF IC InChI=1S/C22H28N4O6/c27-11-9-23-5-7-25-13-1-2-14(26-8-6-24-10-12-28)18-17(13)21(31)19-15(29)3-4-16(30)20(19)22(18)32/h1-4,23-30H,5-12H2 DMM39BF CS C1=CC(=C2C(=C1NCCNCCO)C(=O)C3=C(C=CC(=C3C2=O)O)O)NCCNCCO DMM39BF IK KKZJGLLVHKMTCM-UHFFFAOYSA-N DMM39BF IU 1,4-dihydroxy-5,8-bis[2-(2-hydroxyethylamino)ethylamino]anthracene-9,10-dione DMM39BF CA CAS 65271-80-9 DMM39BF CB CHEBI:50729 DMM39BF DE Solid tumour/cancer; Non-hodgkin lymphoma DM473VD ID DM473VD DM473VD DN Mivacurium DM473VD HS Approved DM473VD SN Mivacron; Chlorure de mivacurium; Chlorure de mivacurium [French]; Cloruro de mivacurio; Cloruro de mivacurio [Spanish]; MIVACURIUM CHLORIDE; Mivacurii chloridum; Mivacurii chloridum [Latin]; BW B109OU dichloride; BWB109OU; BW-B1090U; BW-B109OU; MIVACRON IN DEXTROSE 5% IN PLASTIC CONTAINER; Mivacron (TN); Mivacurium chloride(USAN/INN); Mivacurium chloride [USAN:INN:BAN]; Bis[3-[(1R)-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propyl] (E)-oct-4-enedioate; Bis[3-[(1R)-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propyl] (E)-oct-4-enedioate dichloride; (R)-1,2,3,4-Tetrahydro-2-(3-hydroxypropyl)-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxybenzyl)isoquinolinium chloride, (E)-4-octenedioate (2:1) DM473VD TC Neuromuscular Nondepolarizing Agents DM473VD DT Small molecular drug DM473VD PC 5281042 DM473VD MW 1029.3 DM473VD FM C58H80N2O14+2 DM473VD IC InChI=1S/C58H80N2O14/c1-59(25-21-41-35-47(63-3)49(65-5)37-43(41)45(59)29-39-31-51(67-7)57(71-11)52(32-39)68-8)23-17-27-73-55(61)19-15-13-14-16-20-56(62)74-28-18-24-60(2)26-22-42-36-48(64-4)50(66-6)38-44(42)46(60)30-40-33-53(69-9)58(72-12)54(34-40)70-10/h13-14,31-38,45-46H,15-30H2,1-12H3/q+2/b14-13+/t45-,46-,59?,60?/m1/s1 DM473VD CS C[N+]1(CCC2=CC(=C(C=C2[C@H]1CC3=CC(=C(C(=C3)OC)OC)OC)OC)OC)CCCOC(=O)CC/C=C/CCC(=O)OCCC[N+]4(CCC5=CC(=C(C=C5[C@H]4CC6=CC(=C(C(=C6)OC)OC)OC)OC)OC)C DM473VD IK ILVYCEVXHALBSC-OTBYEXOQSA-N DM473VD IU bis[3-[(1R)-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propyl] (E)-oct-4-enedioate DM473VD CA CAS 133814-19-4 DM473VD CB CHEBI:6958 DM473VD DE Anaesthesia DM1FDN8 ID DM1FDN8 DM1FDN8 DN Mizolastine DM1FDN8 HS Approved DM1FDN8 SN Mistalin; Mistamine; Mizolastina; Mizolastinum; Mizolen; Mizollen; Zolim; Zolistam; Zolistan; Allphar brand of mizolastine; Galderma brand of mizolastine; Mizolastine [INN]; Novag brand of mizolastine; Sanofi Synthelabo brand of mizolastine; Schwarz brand of mizolastine; MKC-431; Mizolastina [INN-Spanish]; Mizolastinum [INN-Latin]; Mizollen (TN); SL 85.0324; Mizolastine (JAN/INN); SL-85.0324; 2-((1-(1-(p-Fluorobenzyl)-2-benzimidazolyl)-4-piperidyl)methylamino)-4(3H)-pyrimidinone; 2-[[1-[1-[(4-fluorophenyl)methyl]benzimidazol-2-yl]piperidin-4-yl]-methylamino]-1H-pyrimidin-6-one DM1FDN8 TC Antiallergic Agents DM1FDN8 DT Small molecular drug DM1FDN8 PC 65906 DM1FDN8 MW 432.5 DM1FDN8 FM C24H25FN6O DM1FDN8 IC InChI=1S/C24H25FN6O/c1-29(23-26-13-10-22(32)28-23)19-11-14-30(15-12-19)24-27-20-4-2-3-5-21(20)31(24)16-17-6-8-18(25)9-7-17/h2-10,13,19H,11-12,14-16H2,1H3,(H,26,28,32) DM1FDN8 CS CN(C1CCN(CC1)C2=NC3=CC=CC=C3N2CC4=CC=C(C=C4)F)C5=NC=CC(=O)N5 DM1FDN8 IK PVLJETXTTWAYEW-UHFFFAOYSA-N DM1FDN8 IU 2-[[1-[1-[(4-fluorophenyl)methyl]benzimidazol-2-yl]piperidin-4-yl]-methylamino]-1H-pyrimidin-6-one DM1FDN8 CA CAS 108612-45-9 DM1FDN8 CB CHEBI:31857 DM1FDN8 DE Allergic rhinitis DMW6F0S ID DMW6F0S DMW6F0S DN Mizoribine DMW6F0S HS Approved DMW6F0S SN Bredinin; Bredinine; MZR; Mizoribina; Mizoribinum; M 3047; Bredinin (TN); HE-69; HS-0046; Mizoribina [INN-Spanish]; Mizoribine [INN:JAN]; Mizoribinum [INN-Latin]; Mizoribine (JAN/INN); Bredinin, HE 69, NSC 289637, MZB, Mizoribine; Anhydro-4-carbamoyl-5-hydroxy-1-beta-D-ribofuranosyl-imidazolium hydroxide; N'-(beta-D-Ribofuranosyl)-5-hydroxyimidazole-4-carboxamide; N'-(beta-D-Ribofuranosyl)-5-hydroxy-imida-zole-4-carboxamide; 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-hydroxyimidazole-4-carboxamide;4-Carbamoyl-1-beta-D-ribofuranosyl-imidazolium-5-olate; 4-carbamoyl-1-b-d-ribofuranosylimidazolium-5-olate; 5-Hydroxy-1-beta-D-ribofuranosyl-1H-imidazole-4-carboxamide; 5-Hydroxy-1-beta-D-ribofuranosylimidazole-4-carboxamide DMW6F0S TC Antimetabolites DMW6F0S DT Small molecular drug DMW6F0S PC 104762 DMW6F0S MW 259.22 DMW6F0S FM C9H13N3O6 DMW6F0S IC InChI=1S/C9H13N3O6/c10-7(16)4-8(17)12(2-11-4)9-6(15)5(14)3(1-13)18-9/h2-3,5-6,9,13-15,17H,1H2,(H2,10,16)/t3-,5-,6-,9-/m1/s1 DMW6F0S CS C1=NC(=C(N1[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O)O)C(=O)N DMW6F0S IK HZQDCMWJEBCWBR-UUOKFMHZSA-N DMW6F0S IU 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-hydroxyimidazole-4-carboxamide DMW6F0S CA CAS 50924-49-7 DMW6F0S CB CHEBI:31858 DMW6F0S DE Transplant rejection DM215WE ID DM215WE DM215WE DN MK-1439 DM215WE HS Approved DM215WE SN Doravirine; 1338225-97-0; UNII-913P6LK81M; MK1439; 913P6LK81M; MK 1439 DM215WE CP Merck & Co. DM215WE DT Small molecular drug DM215WE PC 58460047 DM215WE MW 425.7 DM215WE FM C17H11ClF3N5O3 DM215WE IC InChI=1S/C17H11ClF3N5O3/c1-25-13(23-24-16(25)28)8-26-3-2-12(17(19,20)21)14(15(26)27)29-11-5-9(7-22)4-10(18)6-11/h2-6H,8H2,1H3,(H,24,28) DM215WE CS CN1C(=NNC1=O)CN2C=CC(=C(C2=O)OC3=CC(=CC(=C3)C#N)Cl)C(F)(F)F DM215WE IK ZIAOVIPSKUPPQW-UHFFFAOYSA-N DM215WE IU 3-chloro-5-[1-[(4-methyl-5-oxo-1H-1,2,4-triazol-3-yl)methyl]-2-oxo-4-(trifluoromethyl)pyridin-3-yl]oxybenzonitrile DM215WE CA CAS 1338225-97-0 DM215WE DE Human immunodeficiency virus infection DMBYNW0 ID DMBYNW0 DMBYNW0 DN MK-3475 DMBYNW0 HS Approved DMBYNW0 CP Merck DMBYNW0 DT Monoclonal antibody DMBYNW0 DE Melanoma DMOB58Q ID DMOB58Q DMOB58Q DN MK-8228 DMOB58Q HS Approved DMOB58Q SN Letermovir DMOB58Q CP Merck & Co. DMOB58Q DT Small molecular drug DMOB58Q PC 45138674 DMOB58Q MW 572.5 DMOB58Q FM C29H28F4N4O4 DMOB58Q IC InChI=1S/C29H28F4N4O4/c1-40-20-6-3-5-19(16-20)35-11-13-36(14-12-35)28-34-27-21(7-4-8-22(27)30)23(17-26(38)39)37(28)24-15-18(29(31,32)33)9-10-25(24)41-2/h3-10,15-16,23H,11-14,17H2,1-2H3,(H,38,39)/t23-/m0/s1 DMOB58Q CS COC1=C(C=C(C=C1)C(F)(F)F)N2[C@H](C3=C(C(=CC=C3)F)N=C2N4CCN(CC4)C5=CC(=CC=C5)OC)CC(=O)O DMOB58Q IK FWYSMLBETOMXAG-QHCPKHFHSA-N DMOB58Q IU 2-[(4S)-8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-4H-quinazolin-4-yl]acetic acid DMOB58Q CA CAS 917389-32-3 DMOB58Q DE Cytomegalovirus Disease; Cytomegalovirus infection DMP2LZ8 ID DMP2LZ8 DMP2LZ8 DN MLN0002 DMP2LZ8 HS Approved DMP2LZ8 SN Vedolizumab DMP2LZ8 CP Takeda DMP2LZ8 SQ Heavy Chain Sequence: QVQLVQSGAEVKKPGASVKVSCKGSGYTFTSYWMHWVRQAPGQRLEWIGEIDPSESNTNYNQKFKGRVTLTVDISASTAYMELSSLRSEDTAVYYCARGGYDGWDYAIDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELAGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK >Light Chain SequenceDVVMTQSPLSLPVTPGEPASISCRSSQSLAKSYGNTYLSWYLQKPGQSPQLLIYGISNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCLQGTHQPYTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC DMP2LZ8 DE Crohn disease DMCMETN ID DMCMETN DMCMETN DN MLN9708 DMCMETN HS Approved DMCMETN CP Millennium Pharmaceuticals DMCMETN DT Small molecular drug DMCMETN PC 49867936 DMCMETN MW 517.1 DMCMETN FM C20H23BCl2N2O9 DMCMETN IC InChI=1S/C20H23BCl2N2O9/c1-10(2)5-14(21-33-17(29)8-20(34-21,19(31)32)7-16(27)28)25-15(26)9-24-18(30)12-6-11(22)3-4-13(12)23/h3-4,6,10,14H,5,7-9H2,1-2H3,(H,24,30)(H,25,26)(H,27,28)(H,31,32)/t14-,20?/m0/s1 DMCMETN CS B1(OC(=O)CC(O1)(CC(=O)O)C(=O)O)[C@H](CC(C)C)NC(=O)CNC(=O)C2=C(C=CC(=C2)Cl)Cl DMCMETN IK YTXSYWAKVMZICI-PVCZSOGJSA-N DMCMETN IU 4-(carboxymethyl)-2-[(1R)-1-[[2-[(2,5-dichlorobenzoyl)amino]acetyl]amino]-3-methylbutyl]-6-oxo-1,3,2-dioxaborinane-4-carboxylic acid DMCMETN CA CAS 1201902-80-8 DMCMETN DE Amyloidosis; Multiple myeloma DMNZWL7 ID DMNZWL7 DMNZWL7 DN Moclobemide DMNZWL7 HS Approved DMNZWL7 SN Arima; Aurorex; Aurorix; Deprenorm; Feraken; Manerix; Moclaime; Moclamide; Moclamine; Moclix; Moclobamide; Moclobemid; Moclobemida; Moclobemidum; Moclobeta; Moclodura; Moclonorm; NovoMoclobemide; NuMoclobemide; Rimoc; Alphapharm Brand of Moclobemide; Alpharma Brand of Moclobemide; Apo Moclobemide; Apotex Brand of Moclobemide; Azupharma Brand of Moclobemide; BC Brand of Moclobemide; Betapharm Brand of Moclobemide; Bull Brand of Moclobemide; Chem mart Brand of Moclobemide; Chem mart Moclobemide; Ct Arzneimittel Brand of Moclobemide; DBL Moclobemide; Esparma Brand of Moclobemide; Faulding Brand of Moclobemide; GenRX Moclobemide; Healthsense Brand of Moclobemide; Healthsense Moclobemide; Hexal Brand of Moclobemide; Hoffmann La Roche Brand of Moclobemide; Kendrick Brand of Moclobemide; Merck dura Brand of Moclobemide; Moclobemid AZU; Moclobemid Puren; Moclobemid Stada; Moclobemid ratiopharm; Moclobemid von ct; Moclobemide Alphapharm Brand; Moclobemide Alpharma Brand; Moclobemide Apotex Brand; Moclobemide Azupharma Brand; Moclobemide BC Brand; Moclobemide Bull Brand; Moclobemide Faulding Brand; Moclobemide Healthsense Brand; Moclobemide Hexal Brand; Moclobemide Kendrick Brand; Moclobemide Novopharm Brand; Moclobemide Pharmascience Brand; Moclobemide Roche Brand; Moclobemide Stadapharm Brand; Moclobemide Temmler Brand; Moclobemide betapharm Brand; Moclobemide esparma Brand; Moclobemide ratiopharm Brand; Novo Moclobemide; Novopharm Brand of Moclobemide; Nu Moclobemide; Nu Pharm Brand of Moclobemide; PMS Moclobemide; Pharmascience Brand of Moclobemide; Ratiopharm Brand of Moclobemide; Roche Brand of Moclobemide; Stadapharm Brand of Moclobemide; Temmler Brand of Moclobemide; Terry White Chemists Brand of Moclobemide; Terry White Chemists Moclobemide; CBMicro_048319; Moclobemid 1A Pharma; Moclobemid1A Pharma; Moclobemide 1A Brand; Ro 11 1163; AZU, Moclobemid; Apo-Moclobemide; Aurorix (TN); Ct-Arzneimittel Brand of Moclobemide; Hoffmann-La Roche Brand of Moclobemide; Manerix (TN); Moclobemid-1A Pharma; Moclobemid-Puren; Moclobemid-ratiopharm; Moclobemida [INN-Spanish]; Moclobemide Nu-Pharm Brand; Moclobemide ct-Arzneimittel Brand; Moclobemide, Chem mart; Moclobemide, DBL; Moclobemide, GenRX; Moclobemide, Healthsense; Moclobemidum [INN-Latin]; Novo-Moclobemide; Nu-Moclobemide; Nu-Pharm Brand of Moclobemide; PMS-Moclobemide; Ro 11-1163; Stada, Moclobemid; Von ct, Moclobemid; GNF-PF-695; Moclobemide (USAN/INN); Moclobemide [USAN:BAN:INN]; Moclobemide [USAN:INN:BAN]; Ro 11-1163/000; Ro-11-1163; P-Chloro-N-(2-morpholinoethyl)benzamide; 1A Brand of Moclobemide; 4-Chlor-N-(2-morpholinoethyl)benzamid; 4-Chloro-N-(2-(4-morpholinyl)ethyl)benzamide; 4-Chloro-N-(2-morpholin-4-yl-ethyl)-benzamide; 4-chloro-N-(2-morpholin-4-ylethyl)benzamide; 4-chloro-N-[2-(morpholin-4-yl)ethyl]benzamide DMNZWL7 CP Hoffmann-La Roche pharmaceutical company DMNZWL7 TC Antidepressants DMNZWL7 DT Small molecular drug DMNZWL7 PC 4235 DMNZWL7 MW 268.74 DMNZWL7 FM C13H17ClN2O2 DMNZWL7 IC InChI=1S/C13H17ClN2O2/c14-12-3-1-11(2-4-12)13(17)15-5-6-16-7-9-18-10-8-16/h1-4H,5-10H2,(H,15,17) DMNZWL7 CS C1COCCN1CCNC(=O)C2=CC=C(C=C2)Cl DMNZWL7 IK YHXISWVBGDMDLQ-UHFFFAOYSA-N DMNZWL7 IU 4-chloro-N-(2-morpholin-4-ylethyl)benzamide DMNZWL7 CA CAS 71320-77-9 DMNZWL7 CB CHEBI:83531 DMNZWL7 DE Skin imperfections; Depression DMYILBE ID DMYILBE DMYILBE DN Modafinil DMYILBE HS Approved DMYILBE SN Provigil; Modiodal DMYILBE CP Cephalon Inc DMYILBE TC Neurology Agents DMYILBE DT Small molecular drug DMYILBE PC 4236 DMYILBE MW 273.4 DMYILBE FM C15H15NO2S DMYILBE IC InChI=1S/C15H15NO2S/c16-14(17)11-19(18)15(12-7-3-1-4-8-12)13-9-5-2-6-10-13/h1-10,15H,11H2,(H2,16,17) DMYILBE CS C1=CC=C(C=C1)C(C2=CC=CC=C2)S(=O)CC(=O)N DMYILBE IK YFGHCGITMMYXAQ-UHFFFAOYSA-N DMYILBE IU 2-benzhydrylsulfinylacetamide DMYILBE CA CAS 68693-11-8 DMYILBE CB CHEBI:77585 DMYILBE DE Narcolepsy; Brain injury; Bipolar disorder DM26E4B ID DM26E4B DM26E4B DN Moexipril DM26E4B HS Approved DM26E4B SN Moexiprilum; Uniretic; Moexipril (INN); Moexipril [INN:BAN]; Moexiprilum [INN-Latin]; Perdix (TN); Univasc (TN); (3S)-2-(N-{(1S)-1-[(ethyloxy)carbonyl]-3-phenylpropyl}-L-alanyl)-6,7-bis(methyloxy)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid; (3S)-2-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-6,7-dimethoxy-3,4-dihydro-1H-isoquinoline-3-carboxylic acid DM26E4B CP Ucb Inc DM26E4B TC Antihypertensive Agents DM26E4B DT Small molecular drug DM26E4B PC 91270 DM26E4B MW 498.6 DM26E4B FM C27H34N2O7 DM26E4B IC InChI=1S/C27H34N2O7/c1-5-36-27(33)21(12-11-18-9-7-6-8-10-18)28-17(2)25(30)29-16-20-15-24(35-4)23(34-3)14-19(20)13-22(29)26(31)32/h6-10,14-15,17,21-22,28H,5,11-13,16H2,1-4H3,(H,31,32)/t17-,21-,22-/m0/s1 DM26E4B CS CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2CC3=CC(=C(C=C3C[C@H]2C(=O)O)OC)OC DM26E4B IK UWWDHYUMIORJTA-HSQYWUDLSA-N DM26E4B IU (3S)-2-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-6,7-dimethoxy-3,4-dihydro-1H-isoquinoline-3-carboxylic acid DM26E4B CA CAS 103775-10-6 DM26E4B CB CHEBI:6960 DM26E4B DE Hypertension DMISH0Z ID DMISH0Z DMISH0Z DN Mogamulizumab DMISH0Z HS Approved DMISH0Z CP Kyowa Hakko Kirin DMISH0Z DT Monoclonal antibody DMISH0Z DE Cutaneous T-cell lymphoma; Solid tumour/cancer; T-cell leukaemia; Sezary syndrome; Mycosis fungoides DMAH70G ID DMAH70G DMAH70G DN Molindone DMAH70G HS Approved DMAH70G SN Molindona; Molindonum; Molindone Monohydrochloride; Molindona [INN-Spanish]; Molindone (INN); Molindone (MOL); Molindone [INN:BAN]; Molindonum [INN-Latin]; (+-)-Molindone; 3-Ethyl-1,5,6,7-tetrahydro-2-methyl-5-(4-morpholinylmethyl)-4H-indol-4-one; 3-Ethyl-6,7-dihydro-2-methyl-5-(morpholinomethyl)indol-4(5H)-one; 3-ethyl-2-methyl-5-(morpholin-4-ylmethyl)-1,5,6,7-tetrahydro-4H-indol-4-one; 3-ethyl-2-methyl-5-(morpholin-4-ylmethyl)-1,5,6,7-tetrahydroindol-4-one; 3-ethyl-2-methyl-5-(morpholin-4-ylmethyl)-4,5,6,7-tetrahydro-1H-indol-4-one DMAH70G TC Antipsychotic Agents DMAH70G DT Small molecular drug DMAH70G PC 23897 DMAH70G MW 276.37 DMAH70G FM C16H24N2O2 DMAH70G IC InChI=1S/C16H24N2O2/c1-3-13-11(2)17-14-5-4-12(16(19)15(13)14)10-18-6-8-20-9-7-18/h12,17H,3-10H2,1-2H3 DMAH70G CS CCC1=C(NC2=C1C(=O)C(CC2)CN3CCOCC3)C DMAH70G IK KLPWJLBORRMFGK-UHFFFAOYSA-N DMAH70G IU 3-ethyl-2-methyl-5-(morpholin-4-ylmethyl)-1,5,6,7-tetrahydroindol-4-one DMAH70G CA CAS 7416-34-4 DMAH70G CB CHEBI:6965 DMAH70G DE Schizophrenia DM9MA8O ID DM9MA8O DM9MA8O DN Molsidomine DM9MA8O HS Approved DM9MA8O SN molsidomine; morsydomine; Corvaton; 25717-80-0; Molsidolat; Motazomin; SIN-10; Sydnopharm; Morial; N-Ethoxycarbonyl-3-morpholinosydnonimine; Molsidominum [INN-Latin]; Molsidomina [INN-Spanish]; Molsidomin; MLS000028573; UNII-D46583G77X; CAS 276; EINECS 247-207-4; BRN 3999414; SMR000058990; Sydnone imine, N-(ethoxycarbonyl)-3-(4-morpholinyl)-; N-Carboxy-3-morpholinosydnonimine ethyl ester; N-Carboxy-3-morpholinosydnone imine ethyl ester; N-(Ethoxycarbonyl)-3-(4-morpholino)sydnone imine; Corvasal; Coruno; Sydnone imine, N-carboxy-3-m DM9MA8O DT Small molecular drug DM9MA8O PC 5353788 DM9MA8O MW 242.23 DM9MA8O FM C9H14N4O4 DM9MA8O IC InChI=1S/C9H14N4O4/c1-2-16-9(14)10-8-7-13(11-17-8)12-3-5-15-6-4-12/h7H,2-6H2,1H3 DM9MA8O CS CCO/C(=N/C1=C[N+](=NO1)N2CCOCC2)/[O-] DM9MA8O IK XLFWDASMENKTKL-UHFFFAOYSA-N DM9MA8O IU (1E)-1-ethoxy-N-(3-morpholin-4-yloxadiazol-3-ium-5-yl)methanimidate DM9MA8O CA CAS 25717-80-0 DM9MA8O CB CHEBI:92623 DM9MA8O DE Angina pectoris DM45OJN ID DM45OJN DM45OJN DN Mometasone DM45OJN HS Approved DM45OJN SN Elocom; Mometasona; Mometasonum; Mometasona [Spanish]; Mometasonum [Latin]; Asmanex (TN); Elocon (TN); Mometasone (INN); Nasonex (TN); Twisthaler (TN); (+)-Mometasone; (8S,9R,10S,11S,13S,14S,16R,17R)-9-chloro-17-(2-chloroacetyl)-11,17-dihydroxy-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; (9R,10S,11S,13S,14S,16R,17R)-9-chloro-17-(2-chloroacetyl)-11,17-dihydroxy-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; 9,21-dichloro-11beta,17-dihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione DM45OJN CP Schering-Plough DM45OJN TC Antiinflammatory Agents DM45OJN DT Small molecular drug DM45OJN PC 441335 DM45OJN MW 427.4 DM45OJN FM C22H28Cl2O4 DM45OJN IC InChI=1S/C22H28Cl2O4/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,24)17(26)10-20(16,3)22(12,28)18(27)11-23/h6-7,9,12,15-17,26,28H,4-5,8,10-11H2,1-3H3/t12-,15+,16+,17+,19+,20+,21+,22+/m1/s1 DM45OJN CS C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CCl)O)C)O)Cl)C DM45OJN IK QLIIKPVHVRXHRI-CXSFZGCWSA-N DM45OJN IU (8S,9R,10S,11S,13S,14S,16R,17R)-9-chloro-17-(2-chloroacetyl)-11,17-dihydroxy-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one DM45OJN CA CAS 105102-22-5 DM45OJN CB CHEBI:6970 DM45OJN DE Skin allergy DMVJS2K ID DMVJS2K DMVJS2K DN Monobenzone DMVJS2K HS Approved DMVJS2K SN Agerite; Alba; Benoquin; Benzoquin; Carmifal; Depigman; Dermochinona; Leucodinine; Monobenzon; Monobenzona; Monobenzonum; PBP; Pigmex; Superlite; Agerite alba; Benzyl hydroquinone; Hydrochinon monobenzylether; Hydrochinon monobenzylether [Czech]; Hydroquinone benzyl ether; Hydroquinone monobenzyl ether; ICN brand of monobenzone; Monobenzone [INN]; Monobenzyl Ether of Hydroquinone; Monobenzyl ether hydroquinone; Monobenzyl hydroquinone; Alba-Dome; Benoquin (TN); Benoquin, Monobenzone; Benzyl p-hydroxyphenyl ether; Carmifal(TN); Depigman (TN); Dermochinona (TN); HYDROQUINONE MONOBENZYL ETHER, N F; Leucodinine (TN); Monobenzon (TN); Monobenzona [INN-Spanish]; Monobenzonum [INN-Latin]; Novo-depigman; P-BENZYLOXYPHENOL; P-Hydroxyphenyl benzyl ether; Pigmex (TN); Superlite (TN); Superlite (antioxidant); Monobenzone (USP/INN); P-(BENZYLOXY)PHENOL; 4-(Benzyl-Oxy)Phenol; 4-(Benzyloxy)phenol; 4-(Benzyloxyl)phenol; 4-(Phenylmethoxy)phenol; 4-Benzyloxyphenol; 4-benzyloxy phenol; 4-phenylmethoxy-phenol; 4-phenylmethoxyphenol DMVJS2K TC Dermatologic Agents DMVJS2K DT Small molecular drug DMVJS2K PC 7638 DMVJS2K MW 200.23 DMVJS2K FM C13H12O2 DMVJS2K IC InChI=1S/C13H12O2/c14-12-6-8-13(9-7-12)15-10-11-4-2-1-3-5-11/h1-9,14H,10H2 DMVJS2K CS C1=CC=C(C=C1)COC2=CC=C(C=C2)O DMVJS2K IK VYQNWZOUAUKGHI-UHFFFAOYSA-N DMVJS2K IU 4-phenylmethoxyphenol DMVJS2K CA CAS 103-16-2 DMVJS2K CB CHEBI:34380 DMVJS2K DE Vitiligo DMD157S ID DMD157S DMD157S DN Montelukast DMD157S HS Approved DMD157S SN Brondilat; Montair; Singular; Apxi toxin; MK 0476; Brondilat (TN); MK-0476; Montelukast (INN); Montelukast [INN:BAN]; Singulair (TN); Sodium 1-(((1-(3-(2-(7-chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropylacetate; {1-[({(1R)-1-{3-[(E)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl}-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl}sulfanyl)methyl]cyclopropyl}acetic acid; (R-(E))-1-(((1-(3-(2-(7-Chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropaneacetic acid; 1-((((1R)-1-(3-((1E)-2-(7-Chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropaneacetic acid; 2-[1-[[(1R)-1-[3-[(E)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl]-3-[2-(2-hydroxypropan-2-yl)phenyl]propyl]sulfanylmethyl]cyclopropyl]acetic acid DMD157S CP Schering-Plough Corporation DMD157S TC Antiasthmatic Agents DMD157S DT Small molecular drug DMD157S PC 5281040 DMD157S MW 586.2 DMD157S FM C35H36ClNO3S DMD157S IC InChI=1S/C35H36ClNO3S/c1-34(2,40)30-9-4-3-7-25(30)13-17-32(41-23-35(18-19-35)22-33(38)39)27-8-5-6-24(20-27)10-15-29-16-12-26-11-14-28(36)21-31(26)37-29/h3-12,14-16,20-21,32,40H,13,17-19,22-23H2,1-2H3,(H,38,39)/b15-10+/t32-/m1/s1 DMD157S CS CC(C)(C1=CC=CC=C1CC[C@H](C2=CC=CC(=C2)/C=C/C3=NC4=C(C=CC(=C4)Cl)C=C3)SCC5(CC5)CC(=O)O)O DMD157S IK UCHDWCPVSPXUMX-TZIWLTJVSA-N DMD157S IU 2-[1-[[(1R)-1-[3-[(E)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl]-3-[2-(2-hydroxypropan-2-yl)phenyl]propyl]sulfanylmethyl]cyclopropyl]acetic acid DMD157S CA CAS 158966-92-8 DMD157S CB CHEBI:50730 DMD157S DE Asthma DM560Y3 ID DM560Y3 DM560Y3 DN Morantel tartrate DM560Y3 HS Approved DM560Y3 SN Paratect; Banminth II; MORANTEL TARTRATE SALT; Morantel tartrate [USAN]; Morantel tartrate hydrate; CP 12009-18; Morantel tartrate (USP); Pyrimidine, 1,4,5,6-tetrahydro-1-methyl-2-(2-(3-methyl-2-thienyl)vinyl)-, (E)-, tartrate (1:1); Pyrimidine, 1,4,5,6-tetrahydro-1-methyl-2-(2-(3-methyl-2-thienyl)vinyl)-, (E)-,tartrate (1:1); Pyrimidine, 1,4,5,6-tetrahydro-1-methyl-2-(2-(3-methyl-2-thienyl)ethenyl)-, (E)-, (R-(R*,R*))-2,3-dihydroxybutanedioate (1:1); Pyrimidine, 1,4,5,6-tetrahydro-1-methyl-2-(2-(3-methyl-2-thienyl)ethenyl)-, (E)-,(R-(R*,R*))-2,3-dihydroxybutanedioate (1:1); (E)-1,4,5,6-Tetrahydro-1-methyl-2-(2-(3-methyl-2-thienyl)vinyl)pyrimidine tartrate (1:1); 1-methyl-2-[(E)-2-(3-methylthiophen-2-yl)ethenyl]-5,6-dihydro-4H-pyrimidine; 2,3-dihydroxybutanedioic acid DM560Y3 TC Anthelmintics DM560Y3 DT Small molecular drug DM560Y3 PC 6433951 DM560Y3 MW 370.4 DM560Y3 FM C16H22N2O6S DM560Y3 IC InChI=1S/C12H16N2S.C4H6O6/c1-10-6-9-15-11(10)4-5-12-13-7-3-8-14(12)2;5-1(3(7)8)2(6)4(9)10/h4-6,9H,3,7-8H2,1-2H3;1-2,5-6H,(H,7,8)(H,9,10)/b5-4+;/t;1-,2-/m.1/s1 DM560Y3 CS CC1=C(SC=C1)/C=C/C2=NCCCN2C.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O DM560Y3 IK GGXQONWGCAQGNA-UUSVNAAPSA-N DM560Y3 IU (2R,3R)-2,3-dihydroxybutanedioic acid;1-methyl-2-[(E)-2-(3-methylthiophen-2-yl)ethenyl]-5,6-dihydro-4H-pyrimidine DM560Y3 CA CAS 26155-31-7 DM560Y3 DE Mature gastrointestinal nematode infection DMOMBJW ID DMOMBJW DMOMBJW DN Moricizine DMOMBJW HS Approved DMOMBJW SN Moracizin; Moracizina; Moracizine; Moracizinum; Moricizine [USAN]; G 214; EN-313; Moracizina [INN-Spanish]; Moracizine (INN); Moracizinum [INN-Latin]; Moricizine (USAN); Ethyl 10-(3-morpholinopropionyl)phenothiazine-2-carbamate; Ethyl 10-(beta-N-morpholinylpropionyl)phenothiazine-2-carbamate; Ethyl N-[10-(3-morpholin-4-ylpropanoyl)phenothiazin-2-yl]carbamate; Phenothiazine-2-carbamic acid, 10-(3-morpholinopropionyl)-, ethyl ester; Ethyl [10-(3-morpholin-4-ylpropanoyl)-10H-phenothiazin-2-yl]carbamate; Ethyl {10-[3-(morpholin-4-yl)propanoyl]-10H-phenothiazin-2-yl}carbamate; Ethyl N-{10-[3-(morpholin-4-yl)propanoyl]-10H-phenothiazin-2-yl}carbamate; Ethyl (10-(3-(4-morpholinyl)-1-oxopropyl)-10H-phenothiazin-2-yl)carbamate; Carbamic acid, (10-(3-(4-morpholinyl)-1-oxopropyl)-10H-phenothiazin-2-yl)-, ethyl ester DMOMBJW CP Shire Development Inc DMOMBJW TC Antiarrhythmic Agents DMOMBJW DT Small molecular drug DMOMBJW PC 34633 DMOMBJW MW 427.5 DMOMBJW FM C22H25N3O4S DMOMBJW IC InChI=1S/C22H25N3O4S/c1-2-29-22(27)23-16-7-8-20-18(15-16)25(17-5-3-4-6-19(17)30-20)21(26)9-10-24-11-13-28-14-12-24/h3-8,15H,2,9-14H2,1H3,(H,23,27) DMOMBJW CS CCOC(=O)NC1=CC2=C(C=C1)SC3=CC=CC=C3N2C(=O)CCN4CCOCC4 DMOMBJW IK FUBVWMNBEHXPSU-UHFFFAOYSA-N DMOMBJW IU ethyl N-[10-(3-morpholin-4-ylpropanoyl)phenothiazin-2-yl]carbamate DMOMBJW CA CAS 31883-05-3 DMOMBJW CB CHEBI:6997 DMOMBJW DE Arrhythmia; Heart arrhythmia DM9UTDE ID DM9UTDE DM9UTDE DN Morniflumate DM9UTDE HS Approved DM9UTDE SN morniflumate; 65847-85-0; UNII-R133MWH7X1; 2-Morpholinoethyl 2-((3-(trifluoromethyl)phenyl)amino)nicotinate; R133MWH7X1; Morniflumatum; Morniflumato; 2-morpholin-4-ylethyl 2-[3-(trifluoromethyl)anilino]pyridine-3-carboxylate; Morniflumate [USAN:INN]; Morniflumatum [INN-Latin]; Morniflumato [INN-Spanish]; Nifluminsaeure 2-morpholinoethylester; UP 164; Morniflumate (USAN); Niflumic acid beta-morpholinoethyl ester; AC1Q4JLB; AC1L2HFJ; DSSTox_RID_97471; DSSTox_CID_31587; DSSTox_GSID_57798; SCHEMBL50683; CHEMBL2105059; DTXSID6057798 DM9UTDE DT Small molecular drug DM9UTDE PC 72106 DM9UTDE MW 395.4 DM9UTDE FM C19H20F3N3O3 DM9UTDE IC InChI=1S/C19H20F3N3O3/c20-19(21,22)14-3-1-4-15(13-14)24-17-16(5-2-6-23-17)18(26)28-12-9-25-7-10-27-11-8-25/h1-6,13H,7-12H2,(H,23,24) DM9UTDE CS C1COCCN1CCOC(=O)C2=C(N=CC=C2)NC3=CC=CC(=C3)C(F)(F)F DM9UTDE IK LDXSPUSKBDTEKA-UHFFFAOYSA-N DM9UTDE IU 2-morpholin-4-ylethyl 2-[3-(trifluoromethyl)anilino]pyridine-3-carboxylate DM9UTDE CA CAS 65847-85-0 DM9UTDE CB CHEBI:136018 DM9UTDE DE Otitis media DMRMS0L ID DMRMS0L DMRMS0L DN Morphine DMRMS0L HS Approved DMRMS0L SN Avinza; Kadian; Morphine Sulfate; Depodur; Astramorph Pf; Duramorph Pf; Infumorph; Ms Contin; Oramorph Sr DMRMS0L CP Eurohealth International Sarl DMRMS0L TC Analgesics DMRMS0L DT Small molecular drug DMRMS0L PC 5288826 DMRMS0L MW 285.34 DMRMS0L FM C17H19NO3 DMRMS0L IC InChI=1S/C17H19NO3/c1-18-7-6-17-10-3-5-13(20)16(17)21-15-12(19)4-2-9(14(15)17)8-11(10)18/h2-5,10-11,13,16,19-20H,6-8H2,1H3/t10-,11+,13-,16-,17-/m0/s1 DMRMS0L CS CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)O)O[C@H]3[C@H](C=C4)O DMRMS0L IK BQJCRHHNABKAKU-KBQPJGBKSA-N DMRMS0L IU (4R,4aR,7S,7aR,12bS)-3-methyl-2,4,4a,7,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-7,9-diol DMRMS0L CA CAS 57-27-2 DMRMS0L CB CHEBI:17303 DMRMS0L DE Chronic pain DMEJKRF ID DMEJKRF DMEJKRF DN Motexafin gadolinium DMEJKRF HS Approved DMEJKRF SN Xcytrin; Gadolinium texaphyrin; GdT2B2; GD-Tex; Motexafin gadolinium (USAN); PCI-0120; Xcytrin (TN) DMEJKRF CP Pharmacyclics, Inc DMEJKRF TC Anticancer Agents DMEJKRF DT Small molecular drug DMEJKRF PC 158385 DMEJKRF MW 1148.4 DMEJKRF FM C52H72GdN5O14 DMEJKRF IC InChI=1S/C48H66N5O10.2C2H4O2.Gd/c1-7-35-36(8-2)40-28-42-38(12-10-14-55)34(4)46(53-42)32-50-44-30-48(63-26-24-61-22-20-59-18-16-57-6)47(62-25-23-60-21-19-58-17-15-56-5)29-43(44)49-31-45-33(3)37(11-9-13-54)41(52-45)27-39(35)51-40;2*1-2(3)4;/h27-32,54-55H,7-26H2,1-6H3;2*1H3,(H,3,4);/q-1;;;+3/p-2 DMEJKRF CS CCC1=C(C2=CC3=NC(=CN=C4C=C(C(=CC4=NC=C5C(=C(C(=N5)C=C1[N-]2)CCCO)C)OCCOCCOCCOC)OCCOCCOCCOC)C(=C3CCCO)C)CC.CC(=O)[O-].CC(=O)[O-].[Gd+3] DMEJKRF IK VAZLWPAHMORDGR-UHFFFAOYSA-L DMEJKRF IU 3-[4,5-diethyl-24-(3-hydroxypropyl)-16,17-bis[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]-10,23-dimethyl-13,20,25,26-tetraza-27-azanidapentacyclo[20.2.1.13,6.18,11.014,19]heptacosa-1(25),2,4,6,8(26),9,11,13,15,17,19,21,23-tridecaen-9-yl]propan-1-ol;gadolinium(3+);diacetate DMEJKRF CA CAS 246252-06-2 DMEJKRF DE Brain cancer; Human immunodeficiency virus infection DMYKUNR ID DMYKUNR DMYKUNR DN Moxalactam Disodium DMYKUNR HS Approved DMYKUNR SN Moxam; Shiomarin DMYKUNR CP Eli Lilly And Co DMYKUNR TC Antiinfective Agents DMYKUNR DT Small molecular drug DMYKUNR PC 441242 DMYKUNR MW 564.4 DMYKUNR FM C20H18N6Na2O9S DMYKUNR IC InChI=1S/C20H20N6O9S.2Na/c1-25-19(22-23-24-25)36-8-10-7-35-18-20(34-2,17(33)26(18)13(10)16(31)32)21-14(28)12(15(29)30)9-3-5-11(27)6-4-9;;/h3-6,12,18,27H,7-8H2,1-2H3,(H,21,28)(H,29,30)(H,31,32);;/q;2*+1/p-2/t12?,18-,20+;;/m1../s1 DMYKUNR CS CN1C(=NN=N1)SCC2=C(N3[C@@H]([C@@](C3=O)(NC(=O)C(C4=CC=C(C=C4)O)C(=O)[O-])OC)OC2)C(=O)[O-].[Na+].[Na+] DMYKUNR IK GRIXGZQULWMCLU-HUTAOCTPSA-L DMYKUNR IU disodium;(6R,7R)-7-[[2-carboxylato-2-(4-hydroxyphenyl)acetyl]amino]-7-methoxy-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate DMYKUNR CA CAS 64953-12-4 DMYKUNR DE Bacterial infection DMN63DZ ID DMN63DZ DMN63DZ DN Moxetumomab pasudotox DMN63DZ HS Approved DMN63DZ SN CAT-8015; GCR-8015; HA22; UNII-2NDX4B6N8F; Moxetumomab pasudotox [USAN]; Immunoglobulin, anti-(human CD22 (antigen)) (synthetic Mus musculus CAT-8015 heavy chain variable region fragment) fusion protein with exotoxin PE38 (Pseudomonas fragment), disulfide with immunoglobulin, anti-(human CD22 (antigen)) (synthetic Mus musculus CAT-8015 light chain fragment) DMN63DZ CP AstraZeneca DMN63DZ TC Anticancer Agents DMN63DZ DT Monoclonal antibody DMN63DZ SQ RNA, (A-U-G-G-A-A-Um-A-C-U-C-U-U-G-G-U-Um-A-C-dT-dT), complex with RNA(G-Um-A-A-Cm-Cm-A-A-G-A-G-Um-A-Um-Um-Cm-Cm-A-Um-dT-dT) (1:1) DMN63DZ DE Haematological malignancy; Hairy cell leukaemia DMYGHX5 ID DMYGHX5 DMYGHX5 DN Moxidectin DMYGHX5 HS Approved DMYGHX5 SN Moxidectin; ProHeart 6; UNII-NGU5H31YO9; Cydectin; NGU5H31YO9; Moxidectine [INN-French]; Moxidectinum [INN-Latin]; Moxidectina [INN-Spanish]; C37H53NO8; Moxidectina; Moxidectine; Moxidectinum; Moxidectin [USAN:INN:BAN] DMYGHX5 CP Medicines Development for Global Health DMYGHX5 PC 9832912 DMYGHX5 MW 639.8 DMYGHX5 FM C37H53NO8 DMYGHX5 IC InChI=1S/C37H53NO8/c1-21(2)14-25(6)33-26(7)31(38-42-8)19-36(46-33)18-29-17-28(45-36)13-12-23(4)15-22(3)10-9-11-27-20-43-34-32(39)24(5)16-30(35(40)44-29)37(27,34)41/h9-12,14,16,21-22,26,28-30,32-34,39,41H,13,15,17-20H2,1-8H3/b10-9+,23-12+,25-14+,27-11+,38-31+/t22-,26-,28+,29-,30-,32+,33+,34+,36-,37+/m0/s1 DMYGHX5 CS C[C@@H]\\1C/C(=C/C[C@@H]2C[C@@H](C[C@@]3(O2)C/C(=N\\OC)/[C@@H]([C@H](O3)/C(=C/C(C)C)/C)C)OC(=O)[C@@H]4C=C([C@H]([C@@H]5[C@]4(/C(=C/C=C1)/CO5)O)O)C)/C DMYGHX5 IK YZBLFMPOMVTDJY-LSGXYNIPSA-N DMYGHX5 IU (1R,4S,4'E,5'S,6R,6'S,8R,10E,13R,14E,16E,20R,21R,24S)-21,24-dihydroxy-4'-methoxyimino-5',11,13,22-tetramethyl-6'-[(E)-4-methylpent-2-en-2-yl]spiro[3,7,19-trioxatetracyclo[15.6.1.14,8.020,24]pentacosa-10,14,16,22-tetraene-6,2'-oxane]-2-one DMYGHX5 CA CAS 113507-06-5 DMYGHX5 DE River blindness; Onchocerciasis DMU8V4S ID DMU8V4S DMU8V4S DN Moxifloxacin DMU8V4S HS Approved DMU8V4S SN Avelox; MFX; MXF; MXFX; Vigamox; Avalox (TN); Avelon (TN); Avelox (TN); Moxifloxacin [INN:BAN]; Vigamox (TN); Avelox I.V.; Actira (*Hydrochloride*); Avelox (*Hydrochloride*); (1'S,6'S)-1-Cyclopropyl-7-(2,8-diazabicyclo[4.3.0]non-8-yl)-6-fluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-((4aS,7aS)-octahydro-6H-pyrrolo(3,4-b)pyridin-6-yl)-4-oxo-3-quinolinecarboxylic acid; 7-[(4aS,7aS)-1,2,3,4,4a,5,7,7a-octahydropyrrolo[3,4-b]pyridin-6-yl]-1-cyclopropyl-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid DMU8V4S CP Bayer AG DMU8V4S TC Antibiotics DMU8V4S DT Small molecular drug DMU8V4S PC 152946 DMU8V4S MW 401.4 DMU8V4S FM C21H24FN3O4 DMU8V4S IC InChI=1S/C21H24FN3O4/c1-29-20-17-13(19(26)14(21(27)28)9-25(17)12-4-5-12)7-15(22)18(20)24-8-11-3-2-6-23-16(11)10-24/h7,9,11-12,16,23H,2-6,8,10H2,1H3,(H,27,28)/t11-,16+/m0/s1 DMU8V4S CS COC1=C2C(=CC(=C1N3C[C@@H]4CCCN[C@@H]4C3)F)C(=O)C(=CN2C5CC5)C(=O)O DMU8V4S IK FABPRXSRWADJSP-MEDUHNTESA-N DMU8V4S IU 7-[(4aS,7aS)-1,2,3,4,4a,5,7,7a-octahydropyrrolo[3,4-b]pyridin-6-yl]-1-cyclopropyl-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid DMU8V4S CA CAS 151096-09-2 DMU8V4S CB CHEBI:63611 DMU8V4S DE Bacterial infection DMFCLYW ID DMFCLYW DMFCLYW DN Moxisylyte DMFCLYW HS Approved DMFCLYW SN Thymoxamine DMFCLYW DT Small molecular drug DMFCLYW PC 4260 DMFCLYW MW 279.37 DMFCLYW FM C16H25NO3 DMFCLYW IC InChI=1S/C16H25NO3/c1-11(2)14-10-15(20-13(4)18)12(3)9-16(14)19-8-7-17(5)6/h9-11H,7-8H2,1-6H3 DMFCLYW CS CC1=CC(=C(C=C1OC(=O)C)C(C)C)OCCN(C)C DMFCLYW IK VRYMTAVOXVTQEF-UHFFFAOYSA-N DMFCLYW IU [4-[2-(dimethylamino)ethoxy]-2-methyl-5-propan-2-ylphenyl] acetate DMFCLYW CA CAS 54-32-0 DMFCLYW CB CHEBI:94754 DMFCLYW DE Erectile dysfunction DMGFB0E ID DMGFB0E DMGFB0E DN MOXONIDINE DMGFB0E HS Approved DMGFB0E SN BDF-5895; BE-5895; Normoxin; AC1OCENE; SCHEMBL1230620; Moxonidine hydrochloride hydrate; moxonidine hydrochloride monohydrate; LY-326869; 4-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-6-methoxy-2-methylpyrimidin-5-amine hydrate hydrochloride DMGFB0E DT Small molecular drug DMGFB0E PC 4810 DMGFB0E MW 241.68 DMGFB0E FM C9H12ClN5O DMGFB0E IC InChI=1S/C9H12ClN5O/c1-5-13-7(10)6(8(14-5)16-2)15-9-11-3-4-12-9/h3-4H2,1-2H3,(H2,11,12,15) DMGFB0E CS CC1=NC(=C(C(=N1)Cl)NC2=NCCN2)OC DMGFB0E IK WPNJAUFVNXKLIM-UHFFFAOYSA-N DMGFB0E IU 4-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-6-methoxy-2-methylpyrimidin-5-amine DMGFB0E CA CAS 75438-57-2 DMGFB0E CB CHEBI:7009 DMGFB0E DE Alcohol dependence DMZ905C ID DMZ905C DMZ905C DN Mozavaptan DMZ905C HS Approved DMZ905C SN 137975-06-5; Opc-31260; Opc 31260; Mozavaptan [INN]; CHEMBL420762; OPC31260; 5-Dimethylamino-1-(4-(2-methylbenzoylamino)benzoyl)-2,3,4,5-tetrahydro-1H-benzazepine; N-(4-(5-(dimethylamino)-2,3,4,5-tetrahydro-1H-benzo[b]azepine-1-carbonyl)phenyl)-2-methylbenzamide; N-(4-((5-(Dimethylamino)-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl)phenyl)-2-methylbenzamide; N-(4-(((5RS)-5-(Dimethylamino)-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl)phenyl)-2-methylbenzamide; C27H29N3O2; OPC-31260 DMZ905C DT Small molecular drug DMZ905C PC 119369 DMZ905C MW 427.5 DMZ905C FM C27H29N3O2 DMZ905C IC InChI=1S/C27H29N3O2/c1-19-9-4-5-10-22(19)26(31)28-21-16-14-20(15-17-21)27(32)30-18-8-13-24(29(2)3)23-11-6-7-12-25(23)30/h4-7,9-12,14-17,24H,8,13,18H2,1-3H3,(H,28,31) DMZ905C CS CC1=CC=CC=C1C(=O)NC2=CC=C(C=C2)C(=O)N3CCCC(C4=CC=CC=C43)N(C)C DMZ905C IK WRNXUQJJCIZICJ-UHFFFAOYSA-N DMZ905C IU N-[4-[5-(dimethylamino)-2,3,4,5-tetrahydro-1-benzazepine-1-carbonyl]phenyl]-2-methylbenzamide DMZ905C CA CAS 137975-06-5 DMZ905C CB CHEBI:135694 DMZ905C DE Hyponatraemia DMWX683 ID DMWX683 DMWX683 DN Mupirocin DMWX683 HS Approved DMWX683 SN Bactoderm; Bactroban; Centany; MRC; Mupirocina; Mupirocine; Mupirocinum; Plasimine; Bactroban Nasal; Mupirocina [Spanish]; Mupirocine [French]; Mupirocinum [Latin]; Pseudomonic acid; Pseudomonic acid A; BRL 4910A; BRL-4910A; Bactroban (TN); Centany (TN); Mupirocin (USP/INN); Mupirocin, 14C-Labeled; 5,9-Anhydro-2,3,4,8-tetradeoxy-8-[[3-(2-hydroxy-1-methylpropyl)oxiranyl]methyl]-3-methyl-[2E,8[2S,3S(1S,2S); 8-Carboxyoctyl (E)-4-(2S,3R,4R,5S)-5-((2S,3S,4S,5S)-2,3-epoxy-5-hydroxy-4-methylhexyl)-3,4-dihydroxytetrahydro-2H-pyran-2-yl)-3-methylcrotonat; 9-[(E)-4-[(2S,3R,4R,5S)-3,4-dihydroxy-5-[[(2S,3S)-3-[(2S,3S)-3-hydroxybutan-2-yl]oxiran-2-yl]methyl]oxan-2-yl]-3-methylbut-2-enoyl]oxynonanoic acid DMWX683 CP GlaxoSmithKline DMWX683 TC Antibiotics DMWX683 DT Small molecular drug DMWX683 PC 446596 DMWX683 MW 500.6 DMWX683 FM C26H44O9 DMWX683 IC InChI=1S/C26H44O9/c1-16(13-23(30)33-11-9-7-5-4-6-8-10-22(28)29)12-20-25(32)24(31)19(15-34-20)14-21-26(35-21)17(2)18(3)27/h13,17-21,24-27,31-32H,4-12,14-15H2,1-3H3,(H,28,29)/b16-13+/t17-,18-,19-,20-,21-,24+,25-,26-/m0/s1 DMWX683 CS C[C@H]([C@H]1[C@@H](O1)C[C@H]2CO[C@H]([C@@H]([C@@H]2O)O)C/C(=C/C(=O)OCCCCCCCCC(=O)O)/C)[C@H](C)O DMWX683 IK MINDHVHHQZYEEK-HBBNESRFSA-N DMWX683 IU 9-[(E)-4-[(2S,3R,4R,5S)-3,4-dihydroxy-5-[[(2S,3S)-3-[(2S,3S)-3-hydroxybutan-2-yl]oxiran-2-yl]methyl]oxan-2-yl]-3-methylbut-2-enoyl]oxynonanoic acid DMWX683 CA CAS 12650-69-0 DMWX683 CB CHEBI:7025 DMWX683 DE Bacterial infection DM8ANCF ID DM8ANCF DM8ANCF DN Muromonab DM8ANCF HS Approved DM8ANCF TC Immunomodulatory Agents DM8ANCF SQ Muromonab-CD3 light chain: QIVLTQSPAIMSASPGEKVTMTCSASSSVSYMNWYQQKSGTSPKRWIYDTSKLASGVPAHFRGSGSGTSYSLTISGMEAEDAATYYCQQWSSNPFTFGSGTKLEINRADTAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEYERHNSYTCEATHKTSTSPIVKSFNRNEC >Muromonab-CD3 heavy chainQVQLQQSGAELARPGASVKMSCKASGYTFTRYTMHWVKQRPGQGLEWIGYINPSRGYTNYNQKFKDKATLTTDKSSSTAYMQLSSLTSEDSAVYYCARYYDDHYCLDYWGQGTTLTVSSAKTTAPSVYPLAPVCGGTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLYTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK DM8ANCF DE Organ transplant rejection DMPQAGE ID DMPQAGE DMPQAGE DN Mycophenolate mofetil DMPQAGE HS Approved DMPQAGE SN mycophenolate mofetil; 128794-94-5; CellCept; 115007-34-6; RS 61443; RS-61443; Munoloc; Mycophenolic acid morpholinoethyl ester; TM-MMF; Mycophenylate mofetil; Mycophenolatemofetil; UNII-9242ECW6R0; HSDB 7436; Cellcept (TN); 2-Morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate; CHEBI:8764; C23H31NO7; Mycophenolate mofetil (CellCept); 9242ECW6R0; 2-(morpholin-4-yl)ethyl (4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enoate; Myfenax; RS-61443-190; CellCept; MMF; CellCept (TN); ME-MPA; MMF CellCept(TM); R-99; Mycophenolate mofetil (JAN/USAN); CellCept, RS 61443, TM-MMF, Mycophenolate mofetil; 2-Morpholinoethyl (4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate; 2-morpholin-4-ylethyl (4E)-6-[4-hydroxy-7-methyl-6-(methyloxy)-3-oxo-1,3-dihydro-2-benzofuran-5-yl]-4-methylhex-4-enoate; 2-morpholin-4-ylethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1H-2-benzofuran-5-yl)-4-methylhex-4-enoate;4-Hexenoic acid, 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-, 2-(4-morpholinyl)ethyl ester, (4E) DMPQAGE CP Roche DMPQAGE TC Immunosuppressive Agents DMPQAGE DT Small molecular drug DMPQAGE PC 5281078 DMPQAGE MW 433.5 DMPQAGE FM C23H31NO7 DMPQAGE IC InChI=1S/C23H31NO7/c1-15(5-7-19(25)30-13-10-24-8-11-29-12-9-24)4-6-17-21(26)20-18(14-31-23(20)27)16(2)22(17)28-3/h4,26H,5-14H2,1-3H3/b15-4+ DMPQAGE CS CC1=C2COC(=O)C2=C(C(=C1OC)C/C=C(\\C)/CCC(=O)OCCN3CCOCC3)O DMPQAGE IK RTGDFNSFWBGLEC-SYZQJQIISA-N DMPQAGE IU 2-morpholin-4-ylethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1H-2-benzofuran-5-yl)-4-methylhex-4-enoate DMPQAGE CA CAS 128794-94-5 DMPQAGE CB CHEBI:8764 DMPQAGE DE Organ transplant rejection; Immune System disease; Pemphigus vulgaris DMRBMAU ID DMRBMAU DMRBMAU DN Mycophenolic acid DMRBMAU HS Approved DMRBMAU SN Micofenolico acido; Micofenolico acido [Spanish]; Mycophenoic acid; Mycophenolate; Mycophenolsaeure; Myfortic; mycophenolic acid; Acide mycophenolique; Acido micofenolico; Acido micofenolico [INN-Spanish]; Acidum mycophenolicum; Lilly-68618; Ly 68618; Melbex; (4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enoic acid; 24280-93-1; 6-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoic acid; CCRIS 5565; NSC 129185; NSC-129185; UNII-HU9DX48N0T DMRBMAU PC 446541 DMRBMAU MW 320.3 DMRBMAU FM C17H20O6 DMRBMAU IC HPNSFSBZBAHARI-RUDMXATFSA-N DMRBMAU CS CC1=C2COC(=O)C2=C(C(=C1OC)CC=C(C)CCC(=O)O)O DMRBMAU IK 1S/C17H20O6/c1-9(5-7-13(18)19)4-6-11-15(20)14-12(8-23-17(14)21)10(2)16(11)22-3/h4,20H,5-8H2,1-3H3,(H,18,19)/b9-4+ DMRBMAU IU (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1H-2-benzofuran-5-yl)-4-methylhex-4-enoic acid DMRBMAU CA CAS 483-60-3 DMRBMAU CB CHEBI:168396 DMRBMAU DE Crohn disease DMYTN18 ID DMYTN18 DMYTN18 DN Mycophenolic acid DMYTN18 HS Approved DMYTN18 SN (4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enoic acid; 6-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoic acid; Acide mycophenolique; Acido micofenolico; Acido micofenolico [INN-Spanish]; Acidum mycophenolicum; CCRIS 5565; Lilly-68618; Ly 68618; Melbex; Micofenolico acido; Micofenolico acido [Spanish]; Mycophenoic acid; Mycophenolate; Mycophenolsaeure; Myfortic; NSC 129185; NSC-129185; UNII-HU9DX48N0T; mycophenolic acid DMYTN18 DT Small molecular drug DMYTN18 PC 446541 DMYTN18 MW 320.341 DMYTN18 FM C17H20O6 DMYTN18 IC InChI=1S/C17H20O6/c1-9(5-7-13(18)19)4-6-11-15(20)14-12(8-23-17(14)21)10(2)16(11)22-3/h4,20H,5-8H2,1-3H3,(H,18,19)/b9-4+ DMYTN18 CS CC1=C(C(=C(C2=C1COC2=O)O)CC=C(C)CCC(=O)O)OC DMYTN18 IK HPNSFSBZBAHARI-RUDMXATFSA-N DMYTN18 IU (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1H-2-benzofuran-5-yl)-4-methylhex-4-enoic acid DMYTN18 CA CAS 483-60-3 DMYTN18 CB CHEBI:168396 DMYTN18 DE Organ transplant rejection DMSOAJ2 ID DMSOAJ2 DMSOAJ2 DN N-0923 DMSOAJ2 HS Approved DMSOAJ2 SN ent-Rotigotine; 92206-54-7; N-0437; 6-(Propyl(2-(2-thienyl)ethyl)amino)-5,6,7,8-tetrahydro-1-naphthalenol; 112835-48-0; 6-[propyl(2-thiophen-2-ylethyl)amino]-5,6,7,8-tetrahydronaphthalen-1-ol; 1-Naphthalenol, 5,6,7,8-tetrahydro-6-[propyl[2-(2-thienyl)ethyl]amino]-; 1-Naphthalenol, 5,6,7,8-tetrahydro-6-(propyl(2-(2-thienyl)ethyl)amino)-; 2-(N-n-Propyl-N-2-thienylethylamino)-5-hydroxytetralin; PubChem16422; AC1Q7ALS; rotigotine transdermal patch; AC1L1N7C; SCHEMBL50425; CHEMBL104383; CTK8E7910 DMSOAJ2 CP National Cancer Institute (NCI) DMSOAJ2 DT Small molecular drug DMSOAJ2 PC 57537 DMSOAJ2 MW 315.5 DMSOAJ2 FM C19H25NOS DMSOAJ2 IC InChI=1S/C19H25NOS/c1-2-11-20(12-10-17-6-4-13-22-17)16-8-9-18-15(14-16)5-3-7-19(18)21/h3-7,13,16,21H,2,8-12,14H2,1H3 DMSOAJ2 CS CCCN(CCC1=CC=CS1)C2CCC3=C(C2)C=CC=C3O DMSOAJ2 IK KFQYTPMOWPVWEJ-UHFFFAOYSA-N DMSOAJ2 IU 6-[propyl(2-thiophen-2-ylethyl)amino]-5,6,7,8-tetrahydronaphthalen-1-ol DMSOAJ2 CA CAS 92206-54-7 DMSOAJ2 DE Parkinson disease DMHJVOL ID DMHJVOL DMHJVOL DN Nabi-HB DMHJVOL HS Approved DMHJVOL SN Reformulated HBV therapy, Nabi; Hepatitis B virus immune globulin (intramuscular), Nabi; H-BIG 5%iv formulation, Nabi DMHJVOL CP Nabi Biologics DMHJVOL DE Hepatitis B virus infection DMVRYT2 ID DMVRYT2 DMVRYT2 DN Nabilone DMVRYT2 HS Approved DMVRYT2 SN Nabilone; Nabilona; Nabilonum; Cesamet; 51022-71-0; CHEMBL947; GECBBEABIDMGGL-RTBURBONSA-N; Nabilonum [Latin]; Nabilona [Spanish]; Nabilone [USAN:INN:BAN]; DEA No. 7379; Nabilon; CPD 109514; CPD-109514; 9H-Dibenzo(b,d)pyran-9-one, 3-(1,1-dimethylheptyl)-6,6a,7,8,10,10a-hexahydro-1-hydroxy-6,6-dimethyl-, (6aR,10aR)-rel-; 9H-Dibenzo[b,d]pyran-9-one, 3-(1,1-dimethylheptyl)-6,6a,7,8,10,10a-hexahydro-1-hydroxy-6,6-dimethyl-, (6aR,10aR)-rel- DMVRYT2 DT Small molecular drug DMVRYT2 PC 5284592 DMVRYT2 MW 372.5 DMVRYT2 FM C24H36O3 DMVRYT2 IC InChI=1S/C24H36O3/c1-6-7-8-9-12-23(2,3)16-13-20(26)22-18-15-17(25)10-11-19(18)24(4,5)27-21(22)14-16/h13-14,18-19,26H,6-12,15H2,1-5H3/t18-,19-/m1/s1 DMVRYT2 CS CCCCCCC(C)(C)C1=CC(=C2[C@@H]3CC(=O)CC[C@H]3C(OC2=C1)(C)C)O DMVRYT2 IK GECBBEABIDMGGL-RTBURBONSA-N DMVRYT2 IU (6aR,10aR)-1-hydroxy-6,6-dimethyl-3-(2-methyloctan-2-yl)-7,8,10,10a-tetrahydro-6aH-benzo[c]chromen-9-one DMVRYT2 CA CAS 51022-71-0 DMVRYT2 DE Insomnia DMAT2XH ID DMAT2XH DMAT2XH DN Nabumetone DMAT2XH HS Approved DMAT2XH SN NNB-001; NNB-004; NNB-005; Nabumetone (oral); Nabumetone (oral), Nobex; 6-MNA (oral), Nobex DMAT2XH CP Nobex Corp DMAT2XH DT Small molecular drug DMAT2XH PC 4409 DMAT2XH MW 228.29 DMAT2XH FM C15H16O2 DMAT2XH IC InChI=1S/C15H16O2/c1-11(16)3-4-12-5-6-14-10-15(17-2)8-7-13(14)9-12/h5-10H,3-4H2,1-2H3 DMAT2XH CS CC(=O)CCC1=CC2=C(C=C1)C=C(C=C2)OC DMAT2XH IK BLXXJMDCKKHMKV-UHFFFAOYSA-N DMAT2XH IU 4-(6-methoxynaphthalen-2-yl)butan-2-one DMAT2XH CA CAS 42924-53-8 DMAT2XH CB CHEBI:7443 DMAT2XH DE Pain DM1XBWR ID DM1XBWR DM1XBWR DN N-acetyl-D-glucosamine DM1XBWR HS Approved DM1XBWR SN Aflexa; GlcNAc; NAcGlc; NDG; Crab Shell Chitin; Glucosamine Complex; Maxi GS; Natures Blend Glucosamine; Pharmaceutical aid; JFD00446; SB01966; GS-500; N-Acetylchitosamine; N-Acetylchondrosamine; N-Acetylgalactosamine; N-Acetylhexosamine; Glucosamine, N-acetyl; N-Acetyl-D-Allosamine; N-Acetyl-D-galactosamine; N-Acetyl-D-hexosamine; N-acetyl-D-mannosamine; N-Acetyl-D-glucosamine-Agarose; N-Acetyl-alpha-D-glucosamine; N-acetyl-alpha-D-glucosaminides; N-[2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide; N-[(3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide; N-[(2R,3R,4S,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide; N-[(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide; 2-(Acetylamino)-2-deoxyhexopyranose; 2-ACETAMIDO-2-DEOXY-D-ALLOSE; 2-Acetamido-2-deoxy-D-glucose; 2-Acetamido-2-deoxyglucose; 2-Acetamido-D-glucose; 2-acetamido-2-deoxy-D-glucopyranose; 2-acetamido-2-deoxyhexopyranose; 6-Acetamido-6-deoxy-.alpha.-D-glucopyranose; 6-Acetamido-6-deoxy-acpha-D-glucopyranose DM1XBWR TC Antiinflammatory Agents DM1XBWR DT Small molecular drug DM1XBWR PC 439174 DM1XBWR MW 221.21 DM1XBWR FM C8H15NO6 DM1XBWR IC InChI=1S/C8H15NO6/c1-3(11)9-5-7(13)6(12)4(2-10)15-8(5)14/h4-8,10,12-14H,2H2,1H3,(H,9,11)/t4-,5-,6-,7-,8?/m1/s1 DM1XBWR CS CC(=O)N[C@@H]1[C@H]([C@@H]([C@H](OC1O)CO)O)O DM1XBWR IK OVRNDRQMDRJTHS-RTRLPJTCSA-N DM1XBWR IU N-[(3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide DM1XBWR CA CAS 72-87-7 DM1XBWR CB CHEBI:506227 DM1XBWR DE Autoimmune diabetes DM5NM6E ID DM5NM6E DM5NM6E DN NADH DM5NM6E HS Approved DM5NM6E SN DPNH; Dihydrodiphosphopyridine nucleotide; Dihydronicotinamide adenine dinucleotide; Diphosphopyridine nucleotide reduced; NADH dianion; Nicotinamide adenine dinucleotide reduced; Reduced Nicotinamide Adenine Dinucleotide; NADH2; Beta-DPNH; Beta-NADH; Coenzyme I, reduced; Cozymase I, reduced; Diphosphopyridine nucleotide,reduced form; NAD-reduced; Nicotinamide adenine dinucleotide, reduced form; Reduced nicotinamide-adenine dinucleotide; Beta-Nicotinamide adenine dinucleotide, reduced dipotassium salt; NADH+H+; Nicotinaminde-Adenine-Dinucleotide; Adenosine pyrophosphate, 5'->5'-ester with 1,4-dihydro-1-beta-D-ribofuranosylnicotinamide (7CI); Adenosine 5'-(trihydrogen pyrophosphate), 5'->5'-ester with 1,4-dihydro-1-beta-D-ribofuranosylnicotinamide (8CI); Adenosine 5'-(trihydrogen diphosphate), P'->5'-ester with 1,4-dihydro-1-beta-D-ribofuranosyl-3-pyridinecarboxamide (9CI); Adenosine 5'-{3-[1-(3-carbamoyl-1,4-dihydropyridin-1-yl)-1,4-anhydro-D-ribitol-5-yl] dihydrogen diphosphate}; Adenosine 5'-{3-[1-(3-carbamoyl-1,4-dihydropyridin-1-yl)-1,4-anhydro-D-ribitol-5-yl] diphosphate}; [5-(6-Aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl [[5-(3-carbamoyl-4H-pyridin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] hydrogen phosphate; [[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2R,3S,4R,5R)-5-(3-carbamoyl-4H-pyridin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl hydrogen phosphate; [(2R,3S,4R,5R)-5-(6-Aminopurin-9-yl)-3,4-dihydroxy-oxolan-2-yl]methoxy-[[(2R,3S,4R,5R)-5-(3-carbamoyl-4H-pyridin-1-yl)-3,4-dihydroxy-oxolan-2-yl]methoxy-hydroxy-phosphoryl]oxy-phosphinic acid DM5NM6E TC Dietary supplement DM5NM6E DT Small molecular drug DM5NM6E PC 439153 DM5NM6E MW 665.4 DM5NM6E FM C21H29N7O14P2 DM5NM6E IC InChI=1S/C21H29N7O14P2/c22-17-12-19(25-7-24-17)28(8-26-12)21-16(32)14(30)11(41-21)6-39-44(36,37)42-43(34,35)38-5-10-13(29)15(31)20(40-10)27-3-1-2-9(4-27)18(23)33/h1,3-4,7-8,10-11,13-16,20-21,29-32H,2,5-6H2,(H2,23,33)(H,34,35)(H,36,37)(H2,22,24,25)/t10-,11-,13-,14-,15-,16-,20-,21-/m1/s1 DM5NM6E CS C1C=CN(C=C1C(=O)N)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)OC[C@@H]3[C@H]([C@H]([C@@H](O3)N4C=NC5=C(N=CN=C54)N)O)O)O)O DM5NM6E IK BOPGDPNILDQYTO-NNYOXOHSSA-N DM5NM6E IU [[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2R,3S,4R,5R)-5-(3-carbamoyl-4H-pyridin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl hydrogen phosphate DM5NM6E CA CAS 58-68-4 DM5NM6E CB CHEBI:16908 DM5NM6E DE Parkinson disease DMW6GVL ID DMW6GVL DMW6GVL DN Nadolol DMW6GVL HS Approved DMW6GVL SN Anabet; Corgard; Corgaretic; Nadic; Nadololum; Solgol; SQ 11725; SQ11725; Anabet (TN); Corgard (TN); Corzide (TN); Nadololum [INN-Latin]; SQ-11725; Solgol (TN); Alti-Nadolol (TN); Apo-Nadol (TN); Novo-Nadolol (TN); Nadolol (JP15/USP/INN); Nadolol [USAN:BAN:INN:JAN]; (2R,3S)-5-(3-(tert-Butylamino)-2-hydroxypropoxy)-1,2,3,4-tetrahydronaphthalene-2,3-diol; (2R,3S)-5-({3-[(1,1-dimethylethyl)amino]-2-hydroxypropyl}oxy)-1,2,3,4-tetrahydronaphthalene-2,3-diol; (2R,3S)-5-[3-(tert-butylamino)-2-hydroxypropoxy]-1,2,3,4-tetrahydronaphthalene-2,3-diol; 2,3-cis-1,2,3,4-Tetrahydro-5-((2-hydroxy-3-tert-butylamino)propoxy)-2,3-naphthalenediol; 5-(3-((1,1-Dimethylethyl)amino)-2-hydroxypropoxy)-1,2,3,4-tetrahydro-2,3-naphthalenediol DMW6GVL CP Apotex Inc DMW6GVL TC Antihypertensive Agents DMW6GVL DT Small molecular drug DMW6GVL PC 39147 DMW6GVL MW 309.4 DMW6GVL FM C17H27NO4 DMW6GVL IC InChI=1S/C17H27NO4/c1-17(2,3)18-9-12(19)10-22-16-6-4-5-11-7-14(20)15(21)8-13(11)16/h4-6,12,14-15,18-21H,7-10H2,1-3H3/t12?,14-,15+/m1/s1 DMW6GVL CS CC(C)(C)NCC(COC1=CC=CC2=C1C[C@@H]([C@@H](C2)O)O)O DMW6GVL IK VWPOSFSPZNDTMJ-UCWKZMIHSA-N DMW6GVL IU (2R,3S)-5-[3-(tert-butylamino)-2-hydroxypropoxy]-1,2,3,4-tetrahydronaphthalene-2,3-diol DMW6GVL CA CAS 220045-89-6 DMW6GVL DE High blood pressure DMBNKST ID DMBNKST DMBNKST DN Nadroparin calcium DMBNKST HS Approved DMBNKST SN Fraxiparine (TN) DMBNKST DE Coagulation defect DMU1XOD ID DMU1XOD DMU1XOD DN Nafamostat DMU1XOD HS Approved DMU1XOD SN FUT-175; Nafamostat [INN]; Nafamostatum [Latin]; UNII-Y25LQ0H97D; Nafamstat; Nafamstat Mesilate; 6-Amidino2-naphthyl 4-guanidinobenzoate; Y25LQ0H97D; CHEMBL273264; C19H17N5O2; Nafamostat (INN); p-Guanidinobenzoic acid ester with 6-hydroxy-2-naphthamidine; Nafamostatum DMU1XOD DT Small molecular drug DMU1XOD PC 4413 DMU1XOD MW 347.4 DMU1XOD FM C19H17N5O2 DMU1XOD IC InChI=1S/C19H17N5O2/c20-17(21)14-2-1-13-10-16(8-5-12(13)9-14)26-18(25)11-3-6-15(7-4-11)24-19(22)23/h1-10H,(H3,20,21)(H4,22,23,24) DMU1XOD CS C1=CC(=CC=C1C(=O)OC2=CC3=C(C=C2)C=C(C=C3)C(=N)N)N=C(N)N DMU1XOD IK MQQNFDZXWVTQEH-UHFFFAOYSA-N DMU1XOD IU (6-carbamimidoylnaphthalen-2-yl) 4-(diaminomethylideneamino)benzoate DMU1XOD CA CAS 81525-10-2 DMU1XOD CB CHEBI:135466 DMU1XOD DE Pancreatitis; Sepsis DMAHEFY ID DMAHEFY DMAHEFY DN Nafarelin DMAHEFY HS Approved DMAHEFY SN Nafarelina; Nafareline; Nafarelinum; Synarel; NAFARELIN ACETATE; Nafarelina [Spanish]; Nafareline [French]; Nafarelinum [Latin]; HS-2018; Nafarelin (INN); Nafarelin Acetate, Hydrate; Nafarelin [INN:BAN]; Synarel (TN); RS-94991-298; 6-(3-(2-Naphthalenyl)-D-alanine)luteinizing hormone-releasing factor (pig) DMAHEFY CP Pfizer Pharmaceuticals DMAHEFY TC Fertility Agents DMAHEFY DT Small molecular drug DMAHEFY PC 25077405 DMAHEFY MW 1322.5 DMAHEFY FM C66H83N17O13 DMAHEFY IC InChI=1S/C66H83N17O13/c1-36(2)25-48(58(89)76-47(13-7-23-71-66(68)69)65(96)83-24-8-14-54(83)64(95)73-33-55(67)86)77-60(91)50(28-38-15-18-39-9-3-4-10-40(39)26-38)78-59(90)49(27-37-16-19-43(85)20-17-37)79-63(94)53(34-84)82-61(92)51(29-41-31-72-45-12-6-5-11-44(41)45)80-62(93)52(30-42-32-70-35-74-42)81-57(88)46-21-22-56(87)75-46/h3-6,9-12,15-20,26,31-32,35-36,46-54,72,84-85H,7-8,13-14,21-25,27-30,33-34H2,1-2H3,(H2,67,86)(H,70,74)(H,73,95)(H,75,87)(H,76,89)(H,77,91)(H,78,90)(H,79,94)(H,80,93)(H,81,88)(H,82,92)(H4,68,69,71)/t46-,47-,48-,49-,50+,51-,52-,53-,54-/m0/s1 DMAHEFY CS CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N)NC(=O)[C@@H](CC2=CC3=CC=CC=C3C=C2)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC5=CNC6=CC=CC=C65)NC(=O)[C@H](CC7=CN=CN7)NC(=O)[C@@H]8CCC(=O)N8 DMAHEFY IK RWHUEXWOYVBUCI-ITQXDASVSA-N DMAHEFY IU (2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[(2-amino-2-oxoethyl)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-naphthalen-2-yl-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide DMAHEFY CA CAS 76932-56-4 DMAHEFY DE Endometriosis DMN9RPO ID DMN9RPO DMN9RPO DN Nafcillin DMN9RPO HS Approved DMN9RPO SN Nafcilina; Nafcilline; Nafcillinum; Nallpen; Naphcillin; Naphthamidopenicillin; Unipen; NAFCILLIN SODIUM; Nafcillin sodium for injection; Nallpen In Plastic Container; Nafcilin-1; Nafcilina [INN-Spanish]; Nafcillin & VRC3375; Nafcillin (INN); Nafcillin [INN:BAN]; Nafcilline [INN-French]; Nafcillinum [INN-Latin]; Nafcillin, Monosodium Salt, Anhydrous; (2-Ethoxy-1-naphthyl)penicillin; (2-ethoxy-1-naphthalenyl)penicillin; (2S,5R,6R)-6-({[2-(ethyloxy)naphthalen-1-yl]carbonyl}amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-[(2-ethoxynaphthalene-1-carbonyl)amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-{[(2-ethoxynaphthalen-1-yl)carbonyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 6-(2-ethoxy-1-naphthamido)penicillanic acid; 6-[(2-Ethoxy-naphthalene-1-carbonyl)-amino]-3,3-dimethyl-7-oxo-4-thia-1-aza-bicyclo[3.2.0]heptane-2-carboxylic acid anion; 6beta-(2-ethoxynaphthalene-1-carboxamido)-2,2-dimethylpenam-3alpha-carboxylic acid DMN9RPO TC Antibiotics DMN9RPO DT Small molecular drug DMN9RPO PC 8982 DMN9RPO MW 414.5 DMN9RPO FM C21H22N2O5S DMN9RPO IC InChI=1S/C21H22N2O5S/c1-4-28-13-10-9-11-7-5-6-8-12(11)14(13)17(24)22-15-18(25)23-16(20(26)27)21(2,3)29-19(15)23/h5-10,15-16,19H,4H2,1-3H3,(H,22,24)(H,26,27)/t15-,16+,19-/m1/s1 DMN9RPO CS CCOC1=C(C2=CC=CC=C2C=C1)C(=O)N[C@H]3[C@@H]4N(C3=O)[C@H](C(S4)(C)C)C(=O)O DMN9RPO IK GPXLMGHLHQJAGZ-JTDSTZFVSA-N DMN9RPO IU (2S,5R,6R)-6-[(2-ethoxynaphthalene-1-carbonyl)amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid DMN9RPO CA CAS 147-52-4 DMN9RPO CB CHEBI:7447 DMN9RPO DE Arthritis DMVMQ1L ID DMVMQ1L DMVMQ1L DN Nafronyl DMVMQ1L HS Approved DMVMQ1L SN Nafronyl oxalate; 3200-06-4; Naftidrofuryl oxalate; Nafronyl oxalate salt; 2-(Diethylamino)ethyl 3-(naphthalen-1-yl)-2-((tetrahydrofuran-2-yl)methyl)propanoate oxalate; Naftidrofuryl (oxalate); Dusodril; Dubimax; Praxilene; Iridus; LS-121; EU-1806; DSSTox_RID_80935; DSSTox_CID_25533; DSSTox_GSID_45533; naftidrofuryl hydrogen oxalate; CHEMBL1439099; alpha-[1-Naphthylmethyl]-2-tetrahydrofuranpropionic acid diethylaminoethyl ester; SMR000539007; Nafronyl oxalate salt, analytical standard; CAS-3200-06-4; NSC225233; LS 121 DMVMQ1L DT Small molecular drug DMVMQ1L PC 4417 DMVMQ1L MW 383.5 DMVMQ1L FM C24H33NO3 DMVMQ1L IC InChI=1S/C24H33NO3/c1-3-25(4-2)14-16-28-24(26)21(18-22-12-8-15-27-22)17-20-11-7-10-19-9-5-6-13-23(19)20/h5-7,9-11,13,21-22H,3-4,8,12,14-18H2,1-2H3 DMVMQ1L CS CCN(CC)CCOC(=O)C(CC1CCCO1)CC2=CC=CC3=CC=CC=C32 DMVMQ1L IK KBAFPSLPKGSANY-UHFFFAOYSA-N DMVMQ1L IU 2-(diethylamino)ethyl 2-(naphthalen-1-ylmethyl)-3-(oxolan-2-yl)propanoate DMVMQ1L CA CAS 31329-57-4 DMVMQ1L CB CHEBI:91817 DMVMQ1L DE Cerebrovascular ischaemia DMHVBG1 ID DMHVBG1 DMHVBG1 DN Naftifine DMHVBG1 HS Approved DMHVBG1 SN Naftifin; Naftifina; Naftifinum; Naftifine HCl; Naftifina [INN-Spanish]; Naftifine (INN); Naftifine [INN:BAN]; Naftifinum[INN-Latin]; Naftin (TN); SN 105-843; N-cinnamyl-N-methyl-1-naphthalenemethylamine hydrochloride; N-Methyl-N-(1-naphthyl methyl)-3-phenyl-2-propen-1-amine(E), hydrochloride; (2E)-N-methyl-N-(1-naphthylmethyl)-3-phenyl-2-propen-1-amine; (E)-N-Cinnamyl-N-methyl-1-naphthalenemethylamine; (E)-N-Cinnamyl-N-methyl-1-naphthalinmethylamin; (E)-N-Cinnamyl-N-methyl-1-naphthylmethylamin; (E)-N-methyl-N-(naphthalen-1-ylmethyl)-3-phenylprop-2-en-1-amine DMHVBG1 CP Merz Pharmaceuticals Llc DMHVBG1 TC Antifungal Agents DMHVBG1 DT Small molecular drug DMHVBG1 PC 47641 DMHVBG1 MW 287.4 DMHVBG1 FM C21H21N DMHVBG1 IC InChI=1S/C21H21N/c1-22(16-8-11-18-9-3-2-4-10-18)17-20-14-7-13-19-12-5-6-15-21(19)20/h2-15H,16-17H2,1H3/b11-8+ DMHVBG1 CS CN(C/C=C/C1=CC=CC=C1)CC2=CC=CC3=CC=CC=C32 DMHVBG1 IK OZGNYLLQHRPOBR-DHZHZOJOSA-N DMHVBG1 IU (E)-N-methyl-N-(naphthalen-1-ylmethyl)-3-phenylprop-2-en-1-amine DMHVBG1 CA CAS 65472-88-0 DMHVBG1 CB CHEBI:7451 DMHVBG1 DE Dermatomycosis DMQ8R4E ID DMQ8R4E DMQ8R4E DN Naftopidil DMQ8R4E HS Approved DMQ8R4E SN naftopidil; 57149-07-2; Flivas; KT-611; Naftopidil [INN]; Avishot; Naftopidilum [Latin]; Naftopidil (Flivas); BM-15275; Naftopidil (unspecified); BRN 0629965; CHEMBL142635; C24H28N2O3; 1-(4-(2-methoxyphenyl)piperazin-1-yl)-3-(naphthalen-1-yloxy)propan-2-ol; NCGC00015718-06; (+-)-1-(4-(2-Methoxyphenyl)piperazinyl)-3-(1-naphthyloxy)propan-2-ol; 4-(2-Methoxyphenyl)-alpha-((1-naphthalenyloxy)methyl)-1-pioerazineethanol; (RS)-1-(4-(2-methoxyphenyl)-1-piperazinyl)-3-(1-naphthyloxy)-2-propanol; DSSTox_RID_80725; DSSTox_CID_25176 DMQ8R4E DT Small molecular drug DMQ8R4E PC 4418 DMQ8R4E MW 392.5 DMQ8R4E FM C24H28N2O3 DMQ8R4E IC InChI=1S/C24H28N2O3/c1-28-24-11-5-4-10-22(24)26-15-13-25(14-16-26)17-20(27)18-29-23-12-6-8-19-7-2-3-9-21(19)23/h2-12,20,27H,13-18H2,1H3 DMQ8R4E CS COC1=CC=CC=C1N2CCN(CC2)CC(COC3=CC=CC4=CC=CC=C43)O DMQ8R4E IK HRRBJVNMSRJFHQ-UHFFFAOYSA-N DMQ8R4E IU 1-[4-(2-methoxyphenyl)piperazin-1-yl]-3-naphthalen-1-yloxypropan-2-ol DMQ8R4E CA CAS 57149-07-2 DMQ8R4E CB CHEBI:31891 DMQ8R4E DE Hypertension DMOSQGU ID DMOSQGU DMOSQGU DN Nalbuphine DMOSQGU HS Approved DMOSQGU SN Intapan; Nalbufina; Nalbuphinum; Intapan (TN); Nalbuphine (INN); Nubain (TN); (5alpha,6alpha)-17-(cyclobutylmethyl)-4,5-epoxymorphinan-3,6,14-triol; 17-cyclobutylmethyl-4,5alpha-epoxymorphinan-3,6alpha,14-triol DMOSQGU CP Endo Pharmaceuticals DMOSQGU TC Analgesics DMOSQGU DT Small molecular drug DMOSQGU PC 5311304 DMOSQGU MW 357.4 DMOSQGU FM C21H27NO4 DMOSQGU IC InChI=1S/C21H27NO4/c23-14-5-4-13-10-16-21(25)7-6-15(24)19-20(21,17(13)18(14)26-19)8-9-22(16)11-12-2-1-3-12/h4-5,12,15-16,19,23-25H,1-3,6-11H2/t15-,16+,19-,20-,21+/m0/s1 DMOSQGU CS C1CC(C1)CN2CC[C@]34[C@@H]5[C@H](CC[C@]3([C@H]2CC6=C4C(=C(C=C6)O)O5)O)O DMOSQGU IK NETZHAKZCGBWSS-CEDHKZHLSA-N DMOSQGU IU (4R,4aS,7S,7aR,12bS)-3-(cyclobutylmethyl)-1,2,4,5,6,7,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-4a,7,9-triol DMOSQGU CA CAS 20594-83-6 DMOSQGU CB CHEBI:7454 DMOSQGU DE Prurigo nodularis; Uremic pruritus; Pain DMGD3YH ID DMGD3YH DMGD3YH DN Naldemedine Tosylate DMGD3YH HS Approved DMGD3YH CP Shionogi DMGD3YH DT Small molecular drug DMGD3YH PC 56837137 DMGD3YH MW 742.8 DMGD3YH FM C39H42N4O9S DMGD3YH IC InChI=1S/C32H34N4O6.C7H8O3S/c1-30(2,29-33-27(35-42-29)18-6-4-3-5-7-18)34-28(39)20-15-32(40)22-14-19-10-11-21(37)25-23(19)31(32,26(41-25)24(20)38)12-13-36(22)16-17-8-9-17;1-6-2-4-7(5-3-6)11(8,9)10/h3-7,10-11,17,22,26,37-38,40H,8-9,12-16H2,1-2H3,(H,34,39);2-5H,1H3,(H,8,9,10)/t22-,26+,31+,32-;/m1./s1 DMGD3YH CS CC1=CC=C(C=C1)S(=O)(=O)O.CC(C)(C1=NC(=NO1)C2=CC=CC=C2)NC(=O)C3=C([C@H]4[C@@]56CCN([C@@H]([C@@]5(C3)O)CC7=C6C(=C(C=C7)O)O4)CC8CC8)O DMGD3YH IK WCYDLROFMZJJLE-RTMHEQJQSA-N DMGD3YH IU (4R,4aS,7aR,12bS)-3-(cyclopropylmethyl)-4a,7,9-trihydroxy-N-[2-(3-phenyl-1,2,4-oxadiazol-5-yl)propan-2-yl]-1,2,4,5,7a,13-hexahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-6-carboxamide;4-methylbenzenesulfonic acid DMGD3YH CA CAS 1345728-04-2 DMGD3YH DE Opioid-induced constipation DMA9DHW ID DMA9DHW DMA9DHW DN Nalfurafine hcl DMA9DHW HS Approved DMA9DHW SN Nalfurafine hydrochloride; Nalfurafine HCl; TRK-820; Remitch; Nalfurafine (hydrochloride); 152658-17-8; UNII-25CC4N0P8J; 25CC4N0P8J; CHEMBL490665; AC 820; Nalfurafine hydrochloride [USAN:JAN]; (-)-17-(Cyclopropylmethyl)-3,14; A-dihydroxy-4,5; A-epoxy-6; A-[N-methyl-trans-3-(3-furyl)acrylamido]morphinan Hydrochloride; (2E)-N-[(5; A)-17-(Cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinan-6-yl]-3-(3-furanyl)-N-methyl-2-propenamide Hydrochloride; SCHEMBL19856501; DTXSID70426071; DJSFYNINGIMKAG-FQJQBBMWSA-N; BCP15625; Remitch (TN) DMA9DHW DT Small molecular drug DMA9DHW PC 6918287 DMA9DHW MW 513 DMA9DHW FM C28H33ClN2O5 DMA9DHW IC InChI=1S/C28H32N2O5.ClH/c1-29(23(32)7-4-18-9-13-34-16-18)20-8-10-28(33)22-14-19-5-6-21(31)25-24(19)27(28,26(20)35-25)11-12-30(22)15-17-2-3-17;/h4-7,9,13,16-17,20,22,26,31,33H,2-3,8,10-12,14-15H2,1H3;1H/b7-4+;/t20-,22-,26+,27+,28-;/m1./s1 DMA9DHW CS CN([C@@H]1CC[C@]2([C@H]3CC4=C5[C@]2([C@H]1OC5=C(C=C4)O)CCN3CC6CC6)O)C(=O)/C=C/C7=COC=C7.Cl DMA9DHW IK DJSFYNINGIMKAG-FQJQBBMWSA-N DMA9DHW IU (E)-N-[(4R,4aS,7R,7aR,12bS)-3-(cyclopropylmethyl)-4a,9-dihydroxy-1,2,4,5,6,7,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinolin-7-yl]-3-(furan-3-yl)-N-methylprop-2-enamide;hydrochloride DMA9DHW CA CAS 152658-17-8 DMA9DHW DE Uremic pruritus DMRM0JV ID DMRM0JV DMRM0JV DN Nalidixic acid DMRM0JV HS Approved DMRM0JV SN Betaxina; Cybis; Dixiben; Dixinal; Eucistin; Innoxalon; Jicsron; Kusnarin; Nalidicron; Nalidixan; Nalidixane; Nalidixate; Nalidixic; Nalidixin; Nalitucsan; Nalix; Nalurin; Narigix; Naxuril; NegGram; Negram; Nevigramon; Nicelate; Nogram; Poleon; Sicmylon; Specifen; Specifin; Unaserus; Uralgin; Uriben; Uriclar; Urisal; Urodixin; Uroman; Uroneg; Uronidix; Uropan; Wintomylon; Wintron; Acide nalidixico; Acide nalidixico [Italian]; Acide nalidixique; Acide nalidixique [French]; Acido nalidissico; Acido nalidissico [DCIT]; Acido nalidixico; Acidum nalidixicum; NALIDIXATE SODIUM; Naladixic acid; Naldixic acid; Nalidic acid; Nalidixinic acid; Nalidixic acid USP27; WIN 183203; Acid, Nalidixic; Acide nalidixique [INN-French]; Acido nalidixico [INN-Spanish]; Acidum nalidixicum [INN-Latin]; N-1200; NegGram (TN); Neggram (TN); Sodium Nalidixic Acid, Anhydrous; Sodium Nalidixic Acid, Monohydrate; Sodium,Nalidixate; WIN 18,320; WIN-18320; Wil 18,320; Wintomylon (TN); ZERO/002632; WIN-18320 (TN); Nalidixic acid (JP15/USP/INN); Nalidixic acid [USAN:INN:BAN:JAN]; Acide 1-etil-7-metil-1,8-naftiridin-4-one-3-carbossilico; Acide 1-etil-7-metil-1,8-naftiridin-4-one-3-carbossilico [Italian]; 1,4-Dihydro-1-ethyl-7-methyl-1,8-naphthyridin-4-one-3-carboxylic acid; 1,4-Dihydro-1-ethyl-7-methyl-4-oxo-1,8-naphthyridine-3-carboxylic acid; 1-Aethyl-7-methyl-1,8-naphthyridin-4-on-3-karbonsaeure; 1-Aethyl-7-methyl-1,8-naphthyridin-4-on-3-karbonsaeure [German]; 1-Ethyl-1,4-dihydro-7-methyl-4-oxo-1,8-naphthyridine-3-carboxilic acid; 1-Ethyl-1,4-dihydro-7-methyl-4-oxo-1,8-naphthyridine-3-carboxylic acid; 1-Ethyl-7-methyl-1,4-dihydro-1,8-naphthyridin-4-one-3-carboxylic acid; 1-Ethyl-7-methyl-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid; 1-Ethyl-7-methyl-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid; 1-ethyl-7-methyl-1,4-dihydro-1,8-naphthyridin-4-one-3-ca rboxylic acid; 1-ethyl-7-methyl-4-oxo-1,8-naphthyridine-3-carboxylic acid; 3-Carboxy-1-ethyl-7-methyl-1,8-naphthidin-4-one; 3-Carboxy-1-ethyl-7-methyl-1,8-naphthyridin-4-one DMRM0JV TC Antibiotics DMRM0JV DT Small molecular drug DMRM0JV PC 4421 DMRM0JV MW 232.23 DMRM0JV FM C12H12N2O3 DMRM0JV IC InChI=1S/C12H12N2O3/c1-3-14-6-9(12(16)17)10(15)8-5-4-7(2)13-11(8)14/h4-6H,3H2,1-2H3,(H,16,17) DMRM0JV CS CCN1C=C(C(=O)C2=C1N=C(C=C2)C)C(=O)O DMRM0JV IK MHWLWQUZZRMNGJ-UHFFFAOYSA-N DMRM0JV IU 1-ethyl-7-methyl-4-oxo-1,8-naphthyridine-3-carboxylic acid DMRM0JV CA CAS 389-08-2 DMRM0JV CB CHEBI:100147 DMRM0JV DE Urinary tract infection DM4YWCZ ID DM4YWCZ DM4YWCZ DN Nalmefene DM4YWCZ HS Approved DM4YWCZ SN Alcofene; Arthene; Cervene; Cessal; Incystene; Nalmefeno; Nalmefenum; Nalmetrene; Nalmetreno; Nalmetrenum; Revex; Soberal; JF 1; ORF 11676; JF-1; NIH-10365; Nalmefeno [INN-Spanish]; Nalmefenum [INN-Latin]; Nalmetreno [INN-Spanish]; Nalmetrenum [INN-Latin]; ORF-11676; Revex (TN); Nalmefene (USAN/INN); Nalmefene [USAN:BAN:INN]; (5alpha)-17-(Cyclopropylmethyl)-4,5-epoxy-6-methylenemorphinan-3,14-diol; (5alpha)-17-(Cyclopropylmethyl)-4,5-epoxy-6-methylenemorphinon-3,14-diol; (5alpha)-17-(cyclopropylmethyl)-6-methylidene-4,5-epoxymorphinan-3,14-diol; 17-(Cyclopropylmethyl)-4,5alpha-epoxy-6-methylenemorphinan-3,14-diol; 6-Desoxy-6-methylenenaltrexone; 9a-(Cyclopropylmethyl)-4,5alpha-epoxy-6-methylen-3,14-morphinandiol DM4YWCZ CP Eurohealth International Sarl DM4YWCZ TC Anticraving Agents DM4YWCZ DT Small molecular drug DM4YWCZ PC 5284594 DM4YWCZ MW 339.4 DM4YWCZ FM C21H25NO3 DM4YWCZ IC InChI=1S/C21H25NO3/c1-12-6-7-21(24)16-10-14-4-5-15(23)18-17(14)20(21,19(12)25-18)8-9-22(16)11-13-2-3-13/h4-5,13,16,19,23-24H,1-3,6-11H2/t16-,19+,20+,21-/m1/s1 DM4YWCZ CS C=C1CC[C@]2([C@H]3CC4=C5[C@]2([C@H]1OC5=C(C=C4)O)CCN3CC6CC6)O DM4YWCZ IK WJBLNOPPDWQMCH-MBPVOVBZSA-N DM4YWCZ IU (4R,4aS,7aS,12bS)-3-(cyclopropylmethyl)-7-methylidene-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-4a,9-diol DM4YWCZ CA CAS 55096-26-9 DM4YWCZ CB CHEBI:7457 DM4YWCZ DE Opioid dependence DML0B41 ID DML0B41 DML0B41 DN Naloxegol DML0B41 HS Approved DML0B41 SN NKTR-118 DML0B41 CP AstraZeneca DML0B41 DT Small molecular drug DML0B41 PC 56959087 DML0B41 MW 651.8 DML0B41 FM C34H53NO11 DML0B41 IC InChI=1S/C34H53NO11/c1-3-9-35-10-8-33-30-26-4-5-27(36)31(30)46-32(33)28(6-7-34(33,37)29(35)25-26)45-24-23-44-22-21-43-20-19-42-18-17-41-16-15-40-14-13-39-12-11-38-2/h3-5,28-29,32,36-37H,1,6-25H2,2H3/t28-,29+,32-,33-,34+/m0/s1 DML0B41 CS COCCOCCOCCOCCOCCOCCOCCO[C@H]1CC[C@]2([C@H]3CC4=C5[C@]2([C@H]1OC5=C(C=C4)O)CCN3CC=C)O DML0B41 IK XNKCCCKFOQNXKV-ZRSCBOBOSA-N DML0B41 IU (4R,4aS,7S,7aR,12bS)-7-[2-[2-[2-[2-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]-3-prop-2-enyl-1,2,4,5,6,7,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-4a,9-diol DML0B41 CA CAS 854601-70-0 DML0B41 CB CHEBI:82975 DML0B41 DE Opioid-induced constipation DM3FXMA ID DM3FXMA DM3FXMA DN Naloxone DM3FXMA HS Approved DM3FXMA SN Nalone; Nalossone; Naloxona; Naloxonum; Narcan; Narcanti; Narcon; DBL Naloxone; Nalossone [DCIT]; Naloxone HCl; EN 1530base; DBL Naloxone (TN); L-Naloxone; N-Allylnoroxymorphone; Nalone (TN); Naloxona [INN-Spanish]; Naloxone (INN); Naloxone [INN:BAN]; Naloxonum [INN-Latin]; Narcan (TN); Narcanti (TN); N-Allyl-noroxymorphone; L-N-Allyl-14-hydroxynordihydromorphinone; L-N-Allyl-7,8-dihydro-14-hydroxynormorphinone; N-Allyl-4,5alpha-epoxy-3,14-dihydroxy-6-morphinanon; Morphinan-6-one, 17-allyl-4,5alpha-epoxy-3,14-dihydroxy-(8CI); Morphinan-6-one, 4,5-epoxy-3,14-dihydroxy-17-(2-propenyl)-, (5alpha)-(9CI); (-)-N-allyl-14-hydroxynordihydroxymorphinan-6-one; (-)-Naloxone; (5alpha)-3,14-dihydroxy-17-prop-2-en-1-yl-4,5-epoxymorphinan-6-one; (5alpha)-4,5-Epoxy-3,14-dihydroxy-17-(2-propenyl)morphinan-6-one; 1-N-Allyl-14-hydroxynordihydromorphinone; 1-N-Allyl-7,8-dihydro-14-hydroxynormorphinone; 12-Allyl-7,7a,8,9-tetrahydro-3,7a-dihydroxy-4aH-8,9c-iminoethanophenanthro(4,5-bcd)furanone; 12-Allyl-7,7a,8,9-tetrahydro-3,7a-dihydroxy-4aH-8,9c-iminoethanophenanthro[4,5-bcd]furan-5(6H)-one; 17-Allyl-4,5-alpha-epoxy-3,14-dihydroxymorphinan-6-one; 17-Allyl-4,5alpha-epoxy-3,14-dihydroxymorphinan-6-one; 17-allyl-3,14-dihydroxy-4,5alpha-epoxymorphinan-6-one; 3,14-dihydroxy-17-(prop-2-en-1-yl)-4,5alpha-epoxymorphinan-6-one DM3FXMA CP Bristol Meyers Squibb DM3FXMA TC Antinarcotic Agents DM3FXMA DT Small molecular drug DM3FXMA PC 5284596 DM3FXMA MW 327.4 DM3FXMA FM C19H21NO4 DM3FXMA IC InChI=1S/C19H21NO4/c1-2-8-20-9-7-18-15-11-3-4-12(21)16(15)24-17(18)13(22)5-6-19(18,23)14(20)10-11/h2-4,14,17,21,23H,1,5-10H2/t14-,17+,18+,19-/m1/s1 DM3FXMA CS C=CCN1CC[C@]23[C@@H]4C(=O)CC[C@]2([C@H]1CC5=C3C(=C(C=C5)O)O4)O DM3FXMA IK UZHSEJADLWPNLE-GRGSLBFTSA-N DM3FXMA IU (4R,4aS,7aR,12bS)-4a,9-dihydroxy-3-prop-2-enyl-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one DM3FXMA CA CAS 465-65-6 DM3FXMA CB CHEBI:7459 DM3FXMA DE Narcotic depression; Opioid dependence; Respiratory depression; Pruritus DMUL45H ID DMUL45H DMUL45H DN Naltrexone DMUL45H HS Approved DMUL45H SN Depotrex; Naltrel; Vivitrex; Vivitrol; Naltrexone Depot; IBS therapy, Pain Therapeutics; Irritable bowel syndrome therapy, Pain Therapeutics; PTI-901; XR-NTX; Naltrexone (sustained release), DAS; Naltrexone (sustained release), elbion; Naltrexone depot (injectable suspension), DrugAbuse Sciences; Naltrexone depot (injectable suspension), elbion; Opioid antagonists (irritable bowel syndrome), Pain Therapeutics; Naltrexone (low-dose), Pain Therapeutics; Naltrexone (polymer microcapsule depot, opioid addiction/alcohol dependency), Biotek; Naltrexone (transdermal, alcohol/opioid dependence), Syntropharma; Naltrexone (once-monthly controlled-release, Medisorb), Alkermes DMUL45H CP Tni biotech; DrugAbuse Sciences; Alkermes Inc DMUL45H DT Small molecular drug DMUL45H PC 5360515 DMUL45H MW 341.4 DMUL45H FM C20H23NO4 DMUL45H IC InChI=1S/C20H23NO4/c22-13-4-3-12-9-15-20(24)6-5-14(23)18-19(20,16(12)17(13)25-18)7-8-21(15)10-11-1-2-11/h3-4,11,15,18,22,24H,1-2,5-10H2/t15-,18+,19+,20-/m1/s1 DMUL45H CS C1CC1CN2CC[C@]34[C@@H]5C(=O)CC[C@]3([C@H]2CC6=C4C(=C(C=C6)O)O5)O DMUL45H IK DQCKKXVULJGBQN-XFWGSAIBSA-N DMUL45H IU (4R,4aS,7aR,12bS)-3-(cyclopropylmethyl)-4a,9-dihydroxy-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one DMUL45H CA CAS 16590-41-3 DMUL45H CB CHEBI:7465 DMUL45H DE Alcohol dependence; Human immunodeficiency virus infection DMFWKG1 ID DMFWKG1 DMFWKG1 DN Nandrolone DMFWKG1 HS Approved DMFWKG1 SN Decadura; Estrenolone; Menidrabol; Nadrolone; Nandrolon; Nandrolona; Nandrolonum; Norandrostenolon;Norandrostenolone; Nortestonate; Nortestosterone; Nortestosteronum; Oestrenolon; LT03330030; U 2410; Decadura (TN); Durabolin (TN); Nandrolona [INN-Spanish]; Nandrolone (INN); Nandrolonum [INN-Latin]; Estr-4-en-3-one, 17beta-hydroxy-(8CI); Estr-4-en-3-one, 17-hydroxy-, (17beta)-(9CI); Estr-4-en-3-one, 17-hydroxy-, (17-beta)-(9CI); (17-beta)-17-Hydroxyestr-4-en-3-one; (17beta)-17-hydroxyestr-4-en-3-one; (8R,9S,10R,13S,14S,17S)-17-hydroxy-13-methyl-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-one; 17-Hydroxy-Estr-4-Ene-3-One; 17-beta-Hydroestr-4-en-3-one; 17beta-Hydroxy-19-nor-4-androsten-3-one; 17beta-Hydroxy-19-norandrost-4-en-3-one; 17beta-Hydroxy-4-estren-3-one; 17beta-hydroxy-19-nor-4-androsten-3-one; 17beta-hydroxy-4-estren-3-one; 17beta-hydroxyestr-4-en-3-one; 19-Norandrostenolone; 19-Nortestosterone; 4-Estren-17beta-ol-3-one; 4-estren-17beta-ol-3-one DMFWKG1 CP Aspen Global Inc DMFWKG1 TC Anabolic Agents DMFWKG1 DT Small molecular drug DMFWKG1 PC 9904 DMFWKG1 MW 274.4 DMFWKG1 FM C18H26O2 DMFWKG1 IC InChI=1S/C18H26O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h10,13-17,20H,2-9H2,1H3/t13-,14+,15+,16-,17-,18-/m0/s1 DMFWKG1 CS C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CCC4=CC(=O)CC[C@H]34 DMFWKG1 IK NPAGDVCDWIYMMC-IZPLOLCNSA-N DMFWKG1 IU (8R,9S,10R,13S,14S,17S)-17-hydroxy-13-methyl-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-one DMFWKG1 CA CAS 434-22-0 DMFWKG1 CB CHEBI:7466 DMFWKG1 DE Osteoporosis DMJFZDL ID DMJFZDL DMJFZDL DN Naphazoline DMJFZDL HS Approved DMJFZDL SN Antan; Clearine; Nafazolin; Nafazolina; Nafazoline; Naphazolinum; Naphthizine; Opcon; Nafazolina [DCIT]; Nafazoline [Spanish]; Naphazoline Monohydrochloride; Naphazolinum [Latin]; Enamine_000333; Alpha-Naphthylmethyl imidazoline; Ciba 2020/R; Nafazolin (TN); Naphazoline (INN); Naphazoline [INN:BAN]; Naphazolinum [INN-Latin]; AK-968/41090774; 2-(1-Naphthylmethyl)-2-imidazoline; 2-(1-Naphthylmethyl)-4,5-dihydro-1H-imidazole; 2-(Naphthyl-(1')-methyl)imidazolin; 2-(Naphthyl-(1')-methyl)imidazolin [German]; 2-(alpha-Naphthylmethyl)-imidazoline; 2-(naphthalen-1-ylmethyl)-4,5-dihydro-1H-imidazole; 4,5-Dihydro-2-(1-naphthylmethyl)imidazole DMJFZDL CP Allergan Inc DMJFZDL TC Anticancer Agents DMJFZDL DT Small molecular drug DMJFZDL PC 4436 DMJFZDL MW 210.27 DMJFZDL FM C14H14N2 DMJFZDL IC InChI=1S/C14H14N2/c1-2-7-13-11(4-1)5-3-6-12(13)10-14-15-8-9-16-14/h1-7H,8-10H2,(H,15,16) DMJFZDL CS C1CN=C(N1)CC2=CC=CC3=CC=CC=C32 DMJFZDL IK CNIIGCLFLJGOGP-UHFFFAOYSA-N DMJFZDL IU 2-(naphthalen-1-ylmethyl)-4,5-dihydro-1H-imidazole DMJFZDL CA CAS 835-31-4 DMJFZDL CB CHEBI:93363 DMJFZDL DE Itching; Hyperaemia DMZ5RGV ID DMZ5RGV DMZ5RGV DN Naproxen DMZ5RGV HS Approved DMZ5RGV SN NAPROXEN; 22204-53-1; (S)-Naproxen; Naproxene; Naprosyn; (+)-Naproxen; Equiproxen; Laraflex; Naproxenum; Naproxeno; d-Naproxen; (S)-(+)-2-(6-Methoxy-2-naphthyl)propionic acid; (S)-(+)-Naproxen; Calosen; Nycopren; Naprosyne; Bonyl; Reuxen; Naixan; Axer; (+)-(S)-Naproxen; Ec-Naprosyn; (S)-2-(6-methoxynaphthalen-2-yl)propanoic acid; Flexipen; Clinosyn; Artrixen; Anexopen; Acusprain; Novonaprox; Arthrisil; Leniartil; Danaprox; Bipronyl; Artroxen; Napren; Naposin; Napflam; Genoxen; Daprox; Atiflan; Artagen; Apronax; Naprius; Nalyxan; Lefaine; Congex DMZ5RGV CP Iroko pharmaceuticals; PLx Pharma; CeNeS Pharmaceuticals plc DMZ5RGV DT Small molecular drug DMZ5RGV PC 156391 DMZ5RGV MW 230.26 DMZ5RGV FM C14H14O3 DMZ5RGV IC InChI=1S/C14H14O3/c1-9(14(15)16)10-3-4-12-8-13(17-2)6-5-11(12)7-10/h3-9H,1-2H3,(H,15,16)/t9-/m0/s1 DMZ5RGV CS C[C@@H](C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O DMZ5RGV IK CMWTZPSULFXXJA-VIFPVBQESA-N DMZ5RGV IU (2S)-2-(6-methoxynaphthalen-2-yl)propanoic acid DMZ5RGV CA CAS 22204-53-1 DMZ5RGV CB CHEBI:7476 DMZ5RGV DE Osteoarthritis; Endometriosis; Pain DMO50U2 ID DMO50U2 DMO50U2 DN Naratriptan DMO50U2 HS Approved DMO50U2 SN Colatan; Naramig; Naratriptanum; Amerge (TN); Naramig (TN); Naratriptan (INN); Amerge, Naramig,Naratriptan; N-methyl-2-(3-(1-methylpiperiden-4-yl)indole-5-yl)ethanesulfonamide; N-methyl-2-[3-(1-methylpiperidin-4-yl)-1H-indol-5-yl]ethanesulfonamide; N-methyl-2-[3-(1-methyl-4-piperidyl)-1H-indol-5-yl]-ethanesulfonamide DMO50U2 CP GlaxoSmithKline DMO50U2 TC Vasoconstrictor Agents DMO50U2 DT Small molecular drug DMO50U2 PC 4440 DMO50U2 MW 335.5 DMO50U2 FM C17H25N3O2S DMO50U2 IC InChI=1S/C17H25N3O2S/c1-18-23(21,22)10-7-13-3-4-17-15(11-13)16(12-19-17)14-5-8-20(2)9-6-14/h3-4,11-12,14,18-19H,5-10H2,1-2H3 DMO50U2 CS CNS(=O)(=O)CCC1=CC2=C(C=C1)NC=C2C3CCN(CC3)C DMO50U2 IK AMKVXSZCKVJAGH-UHFFFAOYSA-N DMO50U2 IU N-methyl-2-[3-(1-methylpiperidin-4-yl)-1H-indol-5-yl]ethanesulfonamide DMO50U2 CA CAS 121679-13-8 DMO50U2 CB CHEBI:7478 DMO50U2 DE Migraine DMFEHXD ID DMFEHXD DMFEHXD DN Natamycin DMFEHXD HS Approved DMFEHXD SN Delvocid; Delvolan; Delvopos; Mycophyt; Myprozine; Natacyn; Natafucin; Natamicina; Natamycine; Natamycinum; Pimafucin; Pimaricin; Pimaricine; Pimarizin; Synogil; Tennecetin; Natamycin preparation; Pimaricin preparation; Pimarizin [German]; CL 12625; Antibiotic A-5283; CL 12,625; CL-12625; Natacyn (TN); Natamicina [INN-Spanish]; Natamycine [INN-French]; Natamycinum [INN-Latin]; Pimaricin (JP15); Natamycin (USP/INN); Natamycin [USAN:INN:BAN]; Stereoisomer of 22-((3-amino-3,6-dideoxy-beta-D-mannopyranosyl)oxy)-1,3,26-trihydroxy-12-methyl-10-oxo-6,11,28-trioxatricyclo(22.3.1.0(sup 5,7))octacosa-8,14,16,18,20-pentaene-25-carboxylic acid; (1R,3S,5R,7R,8E,12R,14E,16E,18E,20E,22R,24S,25R,26S)-22-[(3-amino-3,6-dideoxy-beta-D-mannopyranosyl)oxy]-1,3,26-trihydroxy-12-methyl-10-oxo-6,11,28-trioxatricyclo[22.3.1.0~5,7~]octacosa-8,14,16,18,20-pentaene-25-carboxylic acid; 16-(3-Amino-3,6-didesoxy-beta-D-mannopyranosyloxy)-5,6-epoxy-8,12,14-trihydroxy-26-methyl-2,10-dioxo-1-oxacyclohexacosa-3,17,19,21,23-pentaen-13-carbonsaeure; 6,11,28-Trioxatricyclo[22.3.1.05,7]octacosa-8,14,16,18,20-pentaene-25-carboxylic acid, 22-[(3-amino-3,6-dideoxy-.beta.-D-mannopyranosyl)oxy]-1,3,26-trihydroxy-12-methyl-10-oxo-, (1R,3S,5R,7R,8E,12R,14 DMFEHXD TC Antifungal Agents DMFEHXD DT Small molecular drug DMFEHXD PC 5284447 DMFEHXD MW 665.7 DMFEHXD FM C33H47NO13 DMFEHXD IC InChI=1S/C33H47NO13/c1-18-10-8-6-4-3-5-7-9-11-21(45-32-30(39)28(34)29(38)19(2)44-32)15-25-27(31(40)41)22(36)17-33(42,47-25)16-20(35)14-24-23(46-24)12-13-26(37)43-18/h3-9,11-13,18-25,27-30,32,35-36,38-39,42H,10,14-17,34H2,1-2H3,(H,40,41)/b4-3+,7-5+,8-6+,11-9+,13-12+/t18-,19-,20+,21+,22+,23-,24-,25+,27-,28+,29-,30+,32+,33-/m1/s1 DMFEHXD CS C[C@@H]1C/C=C/C=C/C=C/C=C/[C@@H](C[C@H]2[C@@H]([C@H](C[C@](O2)(C[C@H](C[C@@H]3[C@H](O3)/C=C/C(=O)O1)O)O)O)C(=O)O)O[C@H]4[C@H]([C@H]([C@@H]([C@H](O4)C)O)N)O DMFEHXD IK NCXMLFZGDNKEPB-FFPOYIOWSA-N DMFEHXD IU (1R,3S,5R,7R,8E,12R,14E,16E,18E,20E,22R,24S,25R,26S)-22-[(2R,3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-1,3,26-trihydroxy-12-methyl-10-oxo-6,11,28-trioxatricyclo[22.3.1.05,7]octacosa-8,14,16,18,20-pentaene-25-carboxylic acid DMFEHXD CA CAS 7681-93-8 DMFEHXD DE Conjunctivitis DMLK2QH ID DMLK2QH DMLK2QH DN Nateglinide DMLK2QH HS Approved DMLK2QH SN Fastic; IPCCPA; Senaglinide; Starlix; Starsis; Trazec; Nateglinide [INN]; Novartis brand of nateglinide; DJN 608; A-4166; AY-4166; DJN-608; Nate-glinide; Starlix (TN); YM-026; SDZ-DJN-608; N-((4-isopropylcyclohexyl)carbonyl)phenylalanine; Nateglinide, (D-Phe)-isomer; Nateglinide, (cis,D-Phe)-isomer; N-{[4-(propan-2-yl)cyclohexyl]carbonyl}phenylalanine; N-{[trans-4-(propan-2-yl)cyclohexyl]carbonyl}-D-phenylalanine; (2R)-3-phenyl-2-[(4-propan-2-ylcyclohexanecarbonyl)amino]propanoic acid; 3-phenyl-2-[(4-propan-2-ylcyclohexanecarbonyl)amino]propanoic acid DMLK2QH CP Norvatis Phamaceuticals Corporation DMLK2QH TC Hypoglycemic Agents DMLK2QH DT Small molecular drug DMLK2QH PC 5311309 DMLK2QH MW 317.4 DMLK2QH FM C19H27NO3 DMLK2QH IC InChI=1S/C19H27NO3/c1-13(2)15-8-10-16(11-9-15)18(21)20-17(19(22)23)12-14-6-4-3-5-7-14/h3-7,13,15-17H,8-12H2,1-2H3,(H,20,21)(H,22,23)/t15?,16?,17-/m1/s1 DMLK2QH CS CC(C)C1CCC(CC1)C(=O)N[C@H](CC2=CC=CC=C2)C(=O)O DMLK2QH IK OELFLUMRDSZNSF-OFLPRAFFSA-N DMLK2QH IU (2R)-3-phenyl-2-[(4-propan-2-ylcyclohexanecarbonyl)amino]propanoic acid DMLK2QH CA CAS 105816-04-4 DMLK2QH CB CHEBI:31897 DMLK2QH DE Diabetic complication DM7F1PA ID DM7F1PA DM7F1PA DN Nebivolol DM7F1PA HS Approved DM7F1PA SN Bystolic; Lobivon; Nebilet; Nebilong; Nebipill; Nebivololum; Nubeta; Nebivololum [Latin]; R 67555; Bystolic (TN); Nebicard-5;Nebilet (TN); Nebilong (TN); Nodon (TN); Nubeta (TN); PI-21858; R-67555; R65,824; Nebicard-5 (TN); Nebivolol (USAN/INN); Nebivolol [USAN:INN:BAN]; Alpha,alpha'-(Iminodimethylene)bis(6-fluoro-2-chromanmethanol); Alpha,alpha'-(Iminobis(methylene))bis(6-fluoro-3,4-dihydro-2H-1-benzopyran-2-methanol); Alpha,alpha'-(iminobis(methylene))bis(6-fluoro-3,4-dihydro)-2H-1-benzopyran-2-methanol; 1-(6-fluoro-3,4-dihydro-2H-chromen-2-yl)-2-[[2-(6-fluoro-3,4-dihydro-2H-chromen-2-yl)-2-hydroxyethyl]amino]ethanol; 2,2'-iminobis[1-(6-fluoro-3,4-dihydro-2H-chromen-2-yl)ethanol] DM7F1PA CP Forest Laboratories DM7F1PA TC Antihypertensive Agents DM7F1PA DT Small molecular drug DM7F1PA PC 71301 DM7F1PA MW 405.4 DM7F1PA FM C22H25F2NO4 DM7F1PA IC InChI=1S/C22H25F2NO4/c23-15-3-7-19-13(9-15)1-5-21(28-19)17(26)11-25-12-18(27)22-6-2-14-10-16(24)4-8-20(14)29-22/h3-4,7-10,17-18,21-22,25-27H,1-2,5-6,11-12H2 DM7F1PA CS C1CC2=C(C=CC(=C2)F)OC1C(CNCC(C3CCC4=C(O3)C=CC(=C4)F)O)O DM7F1PA IK KOHIRBRYDXPAMZ-UHFFFAOYSA-N DM7F1PA IU 1-(6-fluoro-3,4-dihydro-2H-chromen-2-yl)-2-[[2-(6-fluoro-3,4-dihydro-2H-chromen-2-yl)-2-hydroxyethyl]amino]ethanol DM7F1PA CA CAS 99200-09-6 DM7F1PA CB CHEBI:64019 DM7F1PA DE Hypertension DMKOJSN ID DMKOJSN DMKOJSN DN Necitumumab DMKOJSN HS Approved DMKOJSN SN LY3012211 DMKOJSN CP Lilly DMKOJSN DT Monoclonal antibody DMKOJSN SQ Sequence A: QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGDYYWSWIRQPPGKGLEWIGYIYYSGSTDYNPSLKSRVTMSVDTSKNQFSLKVNSVTAADTAVYYCARVSIFGVGTFDYWGQGTLVTVSSASTKGPSVLPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK >Sequence A'QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGDYYWSWIRQPPGKGLEWIGYIYYSGSTDYNPSLKSRVTMSVDTSKNQFSLKVNSVTAADTAVYYCARVSIFGVGTFDYWGQGTLVTVSSASTKGPSVLPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK >Sequence BEIVMTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCHQYGSTPLTFGGGTKAEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC >Sequence B'EIVMTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCHQYGSTPLTFGGGTKAEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC DMKOJSN DE Colorectal cancer DM4ZS8M ID DM4ZS8M DM4ZS8M DN Nefazodone DM4ZS8M HS Approved DM4ZS8M SN Nefazodona; Nefazodonum; Nefazodona [Spanish]; Nefazodone Hcl; Nefazodonum [Latin]; Nefadar (TN); Nefazodone (INN); Nefazodone [INN:BAN]; Serzone (TN); 1-(3-(4-(3-Chlorpheyl-1-piperazinylpropyl)-3-ethyl-4,5-dihydro-4-(2-phenoxyethyl)-1,2,4-triazol-5-on; 1-(3-(4-(m-Chlorophenyl)-1-piperazinyl)propyl)-3-ethyl-4-(2-phenoxyethyl)-delta2-1,2,4-triazolin-5-one; 2-[3-[4-(3-Chlorophenyl)-1-piperazinyl]propyl]-5-ethyl-2,4-dihydro-4-(2-phenoxyethyl)-3H-1,2,4-triazol-3-one; 2-[3-[4-(3-chlorophenyl)piperazin-1-yl]propyl]-5-ethyl-4-(2-phenoxyethyl)-1,2,4-triazol-3-one; 2-{3-[4-(3-chlorophenyl)piperazin-1-yl]propyl}-5-ethyl-4-(2-phenoxyethyl)-2,4-dihydro-3H-1,2,4-triazol-3-one; 2-{3-[4-(3-chlorophenyl)piperazin-1-yl]propyl}-5-ethyl-4-[2-(phenyloxy)ethyl]-2,4-dihydro-3H-1,2,4-triazol-3-one DM4ZS8M CP Bristol-Myers Squibb DM4ZS8M TC Antidepressants DM4ZS8M DT Small molecular drug DM4ZS8M PC 4449 DM4ZS8M MW 470 DM4ZS8M FM C25H32ClN5O2 DM4ZS8M IC InChI=1S/C25H32ClN5O2/c1-2-24-27-31(25(32)30(24)18-19-33-23-10-4-3-5-11-23)13-7-12-28-14-16-29(17-15-28)22-9-6-8-21(26)20-22/h3-6,8-11,20H,2,7,12-19H2,1H3 DM4ZS8M CS CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl DM4ZS8M IK VRBKIVRKKCLPHA-UHFFFAOYSA-N DM4ZS8M IU 2-[3-[4-(3-chlorophenyl)piperazin-1-yl]propyl]-5-ethyl-4-(2-phenoxyethyl)-1,2,4-triazol-3-one DM4ZS8M CA CAS 83366-66-9 DM4ZS8M CB CHEBI:7494 DM4ZS8M DE Major depressive disorder; Depression DMB6VEG ID DMB6VEG DMB6VEG DN Nelarabine DMB6VEG HS Approved DMB6VEG SN Arranon; ArranonG; Atriance; Nelzarabine; Nelarabine [USAN]; Nelzarabine [USAN]; GW 506U78; GW506U78; U78; Arranon (GlaxoSmithKline); Arranon (TN); Arranon, Nelarabine; Atriance (TN); GW-506U; GW-506U78; Nelarabine (INN); Nelzarabine (USAN); O-Methoxydeoxyguanosine; O-Methylguanosine; Nelarabine (JAN/USAN); (2R,3R,4S,5R)-2-(2-amino-6-methoxypurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol; (2R,3S,4S,5R)-2-(2-amino-6-methoxypurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol; (3S,4S,5R)-2-(2-amino-6-methoxypurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol; 2-(2-Amino-6-methoxy-purin-9-yl)-5-hydroxymethyl-tetrahydro-furan-3,4-diol; 2-(2-amino-6-methoxypurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol; 2-Amino-6-methoxypurine arabinoside; 2-Amino-9-beta-D-arabinofuranosyl-6-methoxy-9H-purine; 6'-O-Methylguanosine; 9-beta-D-Arabinofuranosyl-6-methoxy-9H-purin-2-amine; 9beta-D-Arabinofuranosyl-6-methoxy-9H-purin-2-amine DMB6VEG CP GlaxoSmithKline DMB6VEG TC Anticancer Agents DMB6VEG DT Small molecular drug DMB6VEG PC 3011155 DMB6VEG MW 297.27 DMB6VEG FM C11H15N5O5 DMB6VEG IC InChI=1S/C11H15N5O5/c1-20-9-5-8(14-11(12)15-9)16(3-13-5)10-7(19)6(18)4(2-17)21-10/h3-4,6-7,10,17-19H,2H2,1H3,(H2,12,14,15)/t4-,6-,7+,10-/m1/s1 DMB6VEG CS COC1=NC(=NC2=C1N=CN2[C@H]3[C@H]([C@@H]([C@H](O3)CO)O)O)N DMB6VEG IK IXOXBSCIXZEQEQ-UHTZMRCNSA-N DMB6VEG IU (2R,3S,4S,5R)-2-(2-amino-6-methoxypurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol DMB6VEG CA CAS 121032-29-9 DMB6VEG CB CHEBI:63612 DMB6VEG DE leukaemia DMFX6G8 ID DMFX6G8 DMFX6G8 DN Nelfinavir mesylate DMFX6G8 HS Approved DMFX6G8 SN Nelfin; Nelfinavir (Mesylate); Nelfinavir Mesylate [USAN]; Nelfinavir Methanesulfonate; Nelfinavir mesilate; Nelfinavir mesylate; Nelfinavir mesylate hydrate; Nelfinavir; NELFINAVIR MESYLATE AG1343; Nelfinavir [INN:BAN]; (3S-(2(2S*,3S*),3alpha,4abeta,8abeta))-N-(1,1-Dimethylethyl)decahydro-2-(2-hydroxy-3-((3-hydroxy-2-methylbenzoyl)amino)-4-(phenylthio)butyl)-3-isoquinolinecarboxamide; 159989-64-7; 1UN; 2-[2-HYDROXY-3-(3-HYDROXY-2-METHYL-BENZOYLAMINO)-4-PHENYL SULFANYL-BUTYL]-DECAHYDRO-ISOQUINOLINE-3-CARBOXYLIC ACID TERT-BUTYLAMIDE; C32H45N3O4S; CHEBI:7496; HO3OGH5D7I; NLF; UNII-HO3OGH5D7I; 98D603VP8V; C32H45N3O4S.CH4O3S; CHEBI:7497; CHEMBL1205; DSSTox_CID_10777; DSSTox_GSID_33736; DSSTox_RID_79093; HSDB 7159; MFCD00931436; Nelfinavir methanesulfonate hydrate; UNII-98D603VP8V DMFX6G8 PC 64142 DMFX6G8 MW 663.9 DMFX6G8 FM C33H49N3O7S2 DMFX6G8 IC NQHXCOAXSHGTIA-SKXNDZRYSA-N DMFX6G8 CS CC1=C(C=CC=C1O)C(=O)NC(CSC2=CC=CC=C2)C(CN3CC4CCCCC4CC3C(=O)NC(C)(C)C)O.CS(=O)(=O)O DMFX6G8 IK 1S/C32H45N3O4S.CH4O3S/c1-21-25(15-10-16-28(21)36)30(38)33-26(20-40-24-13-6-5-7-14-24)29(37)19-35-18-23-12-9-8-11-22(23)17-27(35)31(39)34-32(2,3)4;1-5(2,3)4/h5-7,10,13-16,22-23,26-27,29,36-37H,8-9,11-12,17-20H2,1-4H3,(H,33,38)(H,34,39);1H3,(H,2,3,4)/t22-,23+,26-,27-,29+;/m0./s1 DMFX6G8 IU (3S,4aS,8aS)-N-tert-butyl-2-[(2R,3R)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-phenylsulfanylbutyl]-3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinoline-3-carboxamide;methanesulfonic acid DMFX6G8 CA CAS 159989-65-8 DMFX6G8 CB CHEBI:7497 DMFX6G8 DE Human immunodeficiency virus infection DMY0EKH ID DMY0EKH DMY0EKH DN Nemonapride DMY0EKH HS Approved DMY0EKH SN Emilace (TN); Nemonapride (JAN/INN); Nemonapride, (cis)-isomer DMY0EKH CP Astellas DMY0EKH DT Small molecular drug DMY0EKH PC 156333 DMY0EKH MW 387.9 DMY0EKH FM C21H26ClN3O2 DMY0EKH IC InChI=1S/C21H26ClN3O2/c1-14-18(9-10-25(14)13-15-7-5-4-6-8-15)24-21(26)16-11-17(22)19(23-2)12-20(16)27-3/h4-8,11-12,14,18,23H,9-10,13H2,1-3H3,(H,24,26)/t14-,18-/m1/s1 DMY0EKH CS C[C@@H]1[C@@H](CCN1CC2=CC=CC=C2)NC(=O)C3=CC(=C(C=C3OC)NC)Cl DMY0EKH IK KRVOJOCLBAAKSJ-RDTXWAMCSA-N DMY0EKH IU N-[(2R,3R)-1-benzyl-2-methylpyrrolidin-3-yl]-5-chloro-2-methoxy-4-(methylamino)benzamide DMY0EKH CA CAS 187139-87-3 DMY0EKH CB CHEBI:64219 DMY0EKH DE Schizophrenia DM0S9Z1 ID DM0S9Z1 DM0S9Z1 DN Nemonoxacin DM0S9Z1 HS Approved DM0S9Z1 SN Nemonoxacin; 378746-64-6; UNII-P94L0PVO94; TG-873870; P94L0PVO94; Nemonoxacin [INN]; 7-((3S,5S)-3-amino-5-methylpiperidin-1-yl)-1-cyclopropyl-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-[(3S,5S)-3-Amino-5-methylpiperidin-1-yl]-1-cyclopropyl-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; SCHEMBL1006373; CHEMBL1213456; CHEBI:136053; ZINC40435195; SB16570; FT-0700967; 7-[(3S,5S)-3-amino-5-methylpiperidin-1-yl]-1-cyclopropyl-8-methoxy-4- oxo-1,4-dihydroquinoline-3-carboxylic acid DM0S9Z1 CP TaiGen Biotechnology DM0S9Z1 DT Small molecular drug DM0S9Z1 PC 11993740 DM0S9Z1 MW 371.4 DM0S9Z1 FM C20H25N3O4 DM0S9Z1 IC InChI=1S/C20H25N3O4/c1-11-7-12(21)9-22(8-11)16-6-5-14-17(19(16)27-2)23(13-3-4-13)10-15(18(14)24)20(25)26/h5-6,10-13H,3-4,7-9,21H2,1-2H3,(H,25,26)/t11-,12-/m0/s1 DM0S9Z1 CS C[C@H]1C[C@@H](CN(C1)C2=C(C3=C(C=C2)C(=O)C(=CN3C4CC4)C(=O)O)OC)N DM0S9Z1 IK AVPQPGFLVZTJOR-RYUDHWBXSA-N DM0S9Z1 IU 7-[(3S,5S)-3-amino-5-methylpiperidin-1-yl]-1-cyclopropyl-8-methoxy-4-oxoquinoline-3-carboxylic acid DM0S9Z1 CA CAS 378746-64-6 DM0S9Z1 CB CHEBI:136053 DM0S9Z1 DE infection associated with diabetic foot ulcers; Community-acquired pneumonia DMPWCTH ID DMPWCTH DMPWCTH DN Neocarzinostatin DMPWCTH HS Approved DMPWCTH SN ZINOSTATIN; Neocarzinostatin (JAN); Zinostatin (USAN/INN); SCHEMBL1347615; D02046; 33862-EP2311453A1; 33862-EP2298765A1; 33862-EP2295426A1; 33862-EP2298764A1; 33862-EP2298748A2; 33862-EP2295427A1; 33862-EP2295055A2; 33862-EP2272832A1; 33862-EP2311829A1; 33862-EP2305642A2; 33862-EP2275420A1; 33862-EP2311808A1; 33862-EP2298768A1; 33862-EP2295416A2; 120130-EP2272832A1 DMPWCTH DT Small molecular drug DMPWCTH PC 5282473 DMPWCTH MW 661.6 DMPWCTH FM C35H35NO12 DMPWCTH IC InChI=1S/C35H35NO12/c1-16-12-19(42-4)14-22-20(16)8-9-23(37)27(22)32(40)45-24-13-18-10-11-35(26-15-43-34(41)46-26)25(48-35)7-5-6-21(18)31(24)47-33-28(36-3)30(39)29(38)17(2)44-33/h8-9,12-14,17,21,24-26,28-31,33,36-39H,6,15H2,1-4H3/t17-,21?,24-,25-,26-,28-,29+,30-,31-,33-,35+/m1/s1 DMPWCTH CS C[C@@H]1[C@@H]([C@@H]([C@H]([C@H](O1)O[C@H]2[C@@H](C=C3C2CC#C[C@@H]4[C@@](O4)(C#C3)[C@H]5COC(=O)O5)OC(=O)C6=C(C=CC7=C6C=C(C=C7C)OC)O)NC)O)O DMPWCTH IK BLXZMHNVKCEIJX-PNKAXBHOSA-N DMPWCTH IU [(4S,6R,11R,12R)-11-[(2R,3R,4R,5R,6R)-4,5-dihydroxy-6-methyl-3-(methylamino)oxan-2-yl]oxy-4-[(4R)-2-oxo-1,3-dioxolan-4-yl]-5-oxatricyclo[8.3.0.04,6]tridec-1(13)-en-2,7-diyn-12-yl] 2-hydroxy-7-methoxy-5-methylnaphthalene-1-carboxylate DMPWCTH CA CAS 9014-02-2 DMPWCTH DE Solid tumour/cancer DM6T2J3 ID DM6T2J3 DM6T2J3 DN Neostigmine DM6T2J3 HS Approved DM6T2J3 SN Eustigmin; Eustigmine; Intrastigmina; Juvastigmin; Neostigmin; Neostigminum; Prostigmin; Prostigmine; Prozerin; Sulfonatooxymethane; Synstigmin; Syntostigmine; Vagostigmin; Vagostigmine; Neostigmine [BAN]; Neostigmine omega; M-Trimethylammoniumphenyldimethylcarbamate; Neostigmine (BAN); Prostigmin (TN); Vagostigmin (TN); [3-(dimethylcarbamoyloxy)phenyl]-trimethylazanium; [3-(dimethylcarbamoyloxy)phenyl]-trimethyl-azanium; [3-(dimethylcarbamoyloxy)phenyl]-trimethyl-azanium bromide; Ammonium, (m-hydroxyphenyl)trimethyl-, dimethylcarbamate (ester); Benzenaminium, 3-(((dimethylamino)carbonyl)oxy)-N,N,N-trimethyl-(9CI); (m-Hydroxyphenyl)trimethylammonium dimethylcarbamate; (m-Hydroxyphenyl)trimethylammonium dimethylcarbamate (ester); 3-Trimethylammoniumphenyl N,N-dimethylcarbamate; 3-[(dimethylcarbamoyl)oxy]-N,N,N-trimethylanilinium; 3-{[(dimethylamino)carbonyl]oxy}-N,N,N-trimethylanilinium DM6T2J3 TC Parasympathomimetics DM6T2J3 DT Small molecular drug DM6T2J3 PC 4456 DM6T2J3 MW 223.29 DM6T2J3 FM C12H19N2O2+ DM6T2J3 IC InChI=1S/C12H19N2O2/c1-13(2)12(15)16-11-8-6-7-10(9-11)14(3,4)5/h6-9H,1-5H3/q+1 DM6T2J3 CS CN(C)C(=O)OC1=CC=CC(=C1)[N+](C)(C)C DM6T2J3 IK ALWKGYPQUAPLQC-UHFFFAOYSA-N DM6T2J3 IU [3-(dimethylcarbamoyloxy)phenyl]-trimethylazanium DM6T2J3 CA CAS 59-99-4 DM6T2J3 CB CHEBI:7514 DM6T2J3 DE Myasthenia gravis DMYK490 ID DMYK490 DMYK490 DN Nepafenac DMYK490 HS Approved DMYK490 SN Nevanac; AHR-9434; AL-6515 DMYK490 CP Alcon DMYK490 DT Small molecular drug DMYK490 PC 151075 DMYK490 MW 254.28 DMYK490 FM C15H14N2O2 DMYK490 IC InChI=1S/C15H14N2O2/c16-13(18)9-11-7-4-8-12(14(11)17)15(19)10-5-2-1-3-6-10/h1-8H,9,17H2,(H2,16,18) DMYK490 CS C1=CC=C(C=C1)C(=O)C2=CC=CC(=C2N)CC(=O)N DMYK490 IK QEFAQIPZVLVERP-UHFFFAOYSA-N DMYK490 IU 2-(2-amino-3-benzoylphenyl)acetamide DMYK490 CA CAS 78281-72-8 DMYK490 CB CHEBI:75922 DMYK490 DE Osteoarthritis DMEDU7B ID DMEDU7B DMEDU7B DN NERATINIB MALEATE DMEDU7B HS Approved DMEDU7B SN Neratinib maleate; UNII-9RM7XY23ZS; 9RM7XY23ZS; Neratinib maleate [MI]; hki-272 maleate; Nerlynx (TN); SCHEMBL2180998; MolPort-044-561-003; AKOS030524209; DS-19892 DMEDU7B CP Puma Biotechnology DMEDU7B PC 67307512 DMEDU7B MW 673.1 DMEDU7B FM C34H33ClN6O7 DMEDU7B IC InChI=1S/C30H29ClN6O3.C4H4O4/c1-4-39-28-16-25-23(15-26(28)36-29(38)9-7-13-37(2)3)30(20(17-32)18-34-25)35-21-10-11-27(24(31)14-21)40-19-22-8-5-6-12-33-22;5-3(6)1-2-4(7)8/h5-12,14-16,18H,4,13,19H2,1-3H3,(H,34,35)(H,36,38);1-2H,(H,5,6)(H,7,8)/b9-7+;2-1- DMEDU7B CS CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)/C=C/CN(C)C.C(=C\\C(=O)O)\\C(=O)O DMEDU7B IK VXZCUHNJXSIJIM-MEBGWEOYSA-N DMEDU7B IU (Z)-but-2-enedioic acid;(E)-N-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]-3-cyano-7-ethoxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide DMEDU7B CA CAS 915942-22-2 DMEDU7B DE HER2/NEU overexpressing breast cancer DMMPG5V ID DMMPG5V DMMPG5V DN NERIDRONIC ACID DMMPG5V HS Approved DMMPG5V SN Neridronic acid; 79778-41-9; Nerixia; Neridronic acid [INN]; (6-Amino-1-hydroxyhexane-1,1-diyl)diphosphonic acid; UNII-8U27U3RIN4; Acide neridronique [INN-French]; Acido neridronico [INN-Spanish]; Acidum neridronicum [INN-Latin]; CHEMBL55214; 8U27U3RIN4; NERIDRONATE SODIUM HYDRATE; (6-Amino-1-hydroxyhexylidene)diphosphonic acid; 6-Amino-1-hydroxyhexane-1,1-diphosphonate; 6-amino-1-hydroxyhexane-1,1-diyldiphosphonic acid; W-203821; Phosphonic acid, (6-amino-1-hydroxyhexylidene)bis- DMMPG5V DT Small molecular drug DMMPG5V PC 71237 DMMPG5V MW 277.15 DMMPG5V FM C6H17NO7P2 DMMPG5V IC InChI=1S/C6H17NO7P2/c7-5-3-1-2-4-6(8,15(9,10)11)16(12,13)14/h8H,1-5,7H2,(H2,9,10,11)(H2,12,13,14) DMMPG5V CS C(CCC(O)(P(=O)(O)O)P(=O)(O)O)CCN DMMPG5V IK PUUSSSIBPPTKTP-UHFFFAOYSA-N DMMPG5V IU (6-amino-1-hydroxy-1-phosphonohexyl)phosphonic acid DMMPG5V CA CAS 79778-41-9 DMMPG5V CB CHEBI:135145 DMMPG5V DE Bone disease; Complex regional pain syndrome DMFOIA8 ID DMFOIA8 DMFOIA8 DN Nesiritide DMFOIA8 HS Approved DMFOIA8 SN Natrecor (TN) DMFOIA8 CP Scios Llc DMFOIA8 DT Small molecular drug DMFOIA8 SQ DB04899: Natriuretic peptides B: SPKMVQGSGCFGRKMDRISSSSGLGCKVLRRH DMFOIA8 PC 71308561 DMFOIA8 MW 3464 DMFOIA8 FM C143H244N50O42S4 DMFOIA8 IC InChI=1S/C143H244N50O42S4/c1-13-76(10)112-137(232)189-99(68-199)131(226)188-98(67-198)130(225)187-97(66-197)129(224)186-96(65-196)117(212)166-59-105(202)169-90(52-72(2)3)114(209)163-61-107(204)171-100(132(227)177-83(32-19-22-44-146)124(219)190-111(75(8)9)136(231)184-91(53-73(4)5)127(222)175-84(34-24-46-159-141(151)152)121(216)174-85(35-25-47-160-142(153)154)122(217)185-94(139(234)235)55-78-57-157-71-167-78)69-238-239-70-101(172-108(205)62-165-116(211)95(64-195)170-106(203)60-162-113(208)87(38-39-103(148)200)181-135(230)110(74(6)7)191-126(221)89(41-51-237-12)179-120(215)82(31-18-21-43-145)180-134(229)102-37-27-49-193(102)138(233)79(147)63-194)133(228)182-92(54-77-28-15-14-16-29-77)115(210)164-58-104(201)168-80(33-23-45-158-140(149)150)118(213)173-81(30-17-20-42-144)119(214)178-88(40-50-236-11)123(218)183-93(56-109(206)207)128(223)176-86(125(220)192-112)36-26-48-161-143(155)156/h14-16,28-29,57,71-76,79-102,110-112,194-199H,13,17-27,30-56,58-70,144-147H2,1-12H3,(H2,148,200)(H,157,167)(H,162,208)(H,163,209)(H,164,210)(H,165,211)(H,166,212)(H,168,201)(H,169,202)(H,170,203)(H,171,204)(H,172,205)(H,173,213)(H,174,216)(H,175,222)(H,176,223)(H,177,227)(H,178,214)(H,179,215)(H,180,229)(H,181,230)(H,182,228)(H,183,218)(H,184,231)(H,185,217)(H,186,224)(H,187,225)(H,188,226)(H,189,232)(H,190,219)(H,191,221)(H,192,220)(H,206,207)(H,234,235)(H4,149,150,158)(H4,151,152,159)(H4,153,154,160)(H4,155,156,161)/t76-,79-,80-,81-,82-,83-,84-,85-,86-,87-,88-,89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,110-,111-,112-/m0/s1 DMFOIA8 CS CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CCCNC(=N)N)CC(=O)O)CCSC)CCCCN)CCCNC(=N)N)CC2=CC=CC=C2)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CO)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC4=CNC=N4)C(=O)O)CC(C)C)CO)CO)CO)CO DMFOIA8 IK HPNRHPKXQZSDFX-OAQDCNSJSA-N DMFOIA8 IU (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(4R,10S,16S,19S,22S,25S,28S,31S,34S,37S,40S,43S,49S,52R)-52-[[2-[[(2S)-2-[[2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-1-[(2S)-2-amino-3-hydroxypropanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]amino]-4-methylsulfanylbutanoyl]amino]-3-methylbutanoyl]amino]-5-oxopentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-40-(4-aminobutyl)-49-benzyl-28-[(2S)-butan-2-yl]-31,43-bis(3-carbamimidamidopropyl)-34-(carboxymethyl)-16,19,22,25-tetrakis(hydroxymethyl)-10-(2-methylpropyl)-37-(2-methylsulfanylethyl)-6,9,12,15,18,21,24,27,30,33,36,39,42,45,48,51-hexadecaoxo-1,2-dithia-5,8,11,14,17,20,23,26,29,32,35,38,41,44,47,50-hexadecazacyclotripentacontane-4-carbonyl]amino]hexanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-imidazol-4-yl)propanoic acid DMFOIA8 CB CHEBI:135919 DMFOIA8 DE Congestive heart failure DM0LPI9 ID DM0LPI9 DM0LPI9 DN Netarsudil DM0LPI9 HS Approved DM0LPI9 SN UNII-W6I5QDT7QI; W6I5QDT7QI; Netarsudil mesylate; Netarsudil [USAN]; AR-11324 free base; Netarsudil [USAN:INN]; Netarsudil (USAN/INN); GTPL9322; SCHEMBL16036278; ZINC113149554; AR11324; AR-11324; ester 60; 1628418-15-4 DM0LPI9 CP Aerie Pharmaceuticals DM0LPI9 PC 66599893 DM0LPI9 MW 453.5 DM0LPI9 FM C28H27N3O3 DM0LPI9 IC InChI=1S/C28H27N3O3/c1-18-3-10-25(19(2)13-18)28(33)34-17-20-4-6-21(7-5-20)26(15-29)27(32)31-24-9-8-23-16-30-12-11-22(23)14-24/h3-14,16,26H,15,17,29H2,1-2H3,(H,31,32)/t26-/m1/s1 DM0LPI9 CS CC1=CC(=C(C=C1)C(=O)OCC2=CC=C(C=C2)[C@@H](CN)C(=O)NC3=CC4=C(C=C3)C=NC=C4)C DM0LPI9 IK OURRXQUGYQRVML-AREMUKBSSA-N DM0LPI9 IU [4-[(2S)-3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl]phenyl]methyl 2,4-dimethylbenzoate DM0LPI9 CA CAS 1254032-66-0 DM0LPI9 DE Open-angle glaucoma; Glaucoma/ocular hypertension DMRD1QK ID DMRD1QK DMRD1QK DN Netilmicin DMRD1QK HS Approved DMRD1QK SN NTL; Netilmicina; Netilmicine; Netilmicinum; Netilyn; Netira; Nettacin; Vectacin; NETILMICIN SULFATE; Sch 20569; Netilmicin (INN); Netilmicin [INN:BAN]; Netilmicina [INN-Spanish]; Netilmicine [INN-French]; Netilmicinum [INN-Latin]; Netira (TN); Nettacin (TN); Sch-20569; O-(2,6-Diamino-2,3,4,6-tetradesoxy-alpha-glycero-4-hexenopyranosyl-(1-4)-O-(3-desoxy-4-C-methyl-3-methylamino-beta-L-arabinopyranosyl-(1-6)-2-desoxy-N1-ethyl-D-streptamin; (2R,3R,4R,5R)-2-[(1S,2S,3R,4S,6R)-4-amino-3-[[(2S,3R)-3-amino-6-(aminomethyl)-3,4-dihydro-2H-pyran-2-yl]oxy]-6-(ethylamino)-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol; (2R,3R,4R,5R)-2-[(1S,2S,3R,4S,6R)-4-amino-3-[[3-amino-6-(aminomethyl)-3,4-dihydro-2H-pyran-2-yl]oxy]-6-(ethylamino)-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol; (2R,3S,4S,5S)-2-[(1S,2R,3S,4S,6R)-4-amino-3-[[(2S,3R)-3-amino-6-(aminomethyl)-3,4-dihydro-2H-pyran-2-yl]oxy]-6-(ethylamino)-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol; 1-N-Aethylsisomicin; 1-N-Ethylsisomicin; 2-[4-amino-3-[[3-amino-6-(aminomethyl)-3,4-dihydro-2H-pyran-2-yl]oxy]-6-(ethylamino)-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol; 4-amino-3-{[3-amino-6-(aminomethyl)-3,4-dihydro-2h-pyran-2-yl]oxy}-6-(ethylamino)-2-hydroxycyclohexyl 3-deoxy-4-c-methyl-3-(methylamino)pentopyranoside DMRD1QK CP Abbott Laboratories DMRD1QK TC Antibiotics DMRD1QK DT Small molecular drug DMRD1QK PC 441306 DMRD1QK MW 475.6 DMRD1QK FM C21H41N5O7 DMRD1QK IC InChI=1S/C21H41N5O7/c1-4-26-13-7-12(24)16(32-19-11(23)6-5-10(8-22)31-19)14(27)17(13)33-20-15(28)18(25-3)21(2,29)9-30-20/h5,11-20,25-29H,4,6-9,22-24H2,1-3H3/t11-,12+,13-,14+,15-,16-,17+,18-,19-,20-,21+/m1/s1 DMRD1QK CS CCN[C@@H]1C[C@@H]([C@H]([C@@H]([C@H]1O[C@@H]2[C@@H]([C@H]([C@@](CO2)(C)O)NC)O)O)O[C@@H]3[C@@H](CC=C(O3)CN)N)N DMRD1QK IK CIDUJQMULVCIBT-MQDUPKMGSA-N DMRD1QK IU (2R,3R,4R,5R)-2-[(1S,2S,3R,4S,6R)-4-amino-3-[[(2S,3R)-3-amino-6-(aminomethyl)-3,4-dihydro-2H-pyran-2-yl]oxy]-6-(ethylamino)-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol DMRD1QK CA CAS 56391-56-1 DMRD1QK DE Bacterial infection DM6HX9B ID DM6HX9B DM6HX9B DN Nevirapine DM6HX9B HS Approved DM6HX9B SN NEV; NVP; Viramune; Cahill May Roberts Brand of Nevirapine; Promeco Brand of Nevirapine; BI RG 587; BIRG 0587; BIRG 587; BIRG587; BIRG-0587; BIRG-587; NON-NUCLEOSIDE RT INHIBITOR NEVIRAPINE; Nevirapine & PRO 140; Nevirapine [USAN:INN]; Viramune (TN); Viramune(TM); BI-RG-587; Nevirapine & CD4-IgG; Nevirapine (JAN/USP/INN); Viramune, BI-RG 587, Nevirapine; BI-RG-587 & CD4-IgG; N11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e]-[1,4]diazepin-6-one & CD4-immunoadhesin; 11-CYCLOPROPYL-5,11-DIHYDRO-4-METHYL-6H-DIPYRIDO[3,2-B:2',3'-E][1,4]DIAZEPIN-6-ONE; 11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[2,3-e:3',2'-b][1,4]diazepin-6-one; 11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[2,3-e:3',2'-b][1,4]diazepin-6-one & PRO 140 (Anti-CCR5 monoclonal antibody); 11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one; 11-Cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido(3,2-b:2',3'-e)(1,4)diazepin-6-one DM6HX9B CP Boehringer Ingelheim DM6HX9B TC Anti-HIV Agents DM6HX9B DT Small molecular drug DM6HX9B PC 4463 DM6HX9B MW 266.3 DM6HX9B FM C15H14N4O DM6HX9B IC InChI=1S/C15H14N4O/c1-9-6-8-17-14-12(9)18-15(20)11-3-2-7-16-13(11)19(14)10-4-5-10/h2-3,6-8,10H,4-5H2,1H3,(H,18,20) DM6HX9B CS CC1=C2C(=NC=C1)N(C3=C(C=CC=N3)C(=O)N2)C4CC4 DM6HX9B IK NQDJXKOVJZTUJA-UHFFFAOYSA-N DM6HX9B IU 2-cyclopropyl-7-methyl-2,4,9,15-tetrazatricyclo[9.4.0.03,8]pentadeca-1(11),3,5,7,12,14-hexaen-10-one DM6HX9B CA CAS 129618-40-2 DM6HX9B CB CHEBI:63613 DM6HX9B DE Human immunodeficiency virus infection DMCDYW7 ID DMCDYW7 DMCDYW7 DN Nicardipine DMCDYW7 HS Approved DMCDYW7 SN Nicardipino; Nicardipinum; Cardene IV; Nicardipine LA; Cardene (TN); Nicardipine (INN); Nicardipine [INN:BAN]; Nicardipino [INN-Spanish]; Nicardipinum [INN-Latin]; Y-93; Methyl 2-[methyl(phenylmethyl)amino]ethyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; 2-(Benzylmethylamino)ethylmethyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)pyridine-3,5-dicarboxylate; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 2-(benzylmethylamino)ethyl methyl ester; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, methyl 2-(methyl(phenylmethyl)amino)ethyl ester; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, methyl 2-[methyl(phenylmethyl)amino]ethyl ester; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-,2-(benzylmethylamino)ethyl methyl ester; 5-O-[2-[benzyl(methyl)amino]ethyl] 3-O-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate DMCDYW7 CP Chiesi Usa Inc DMCDYW7 TC Antihypertensive Agents DMCDYW7 DT Small molecular drug DMCDYW7 PC 4474 DMCDYW7 MW 479.5 DMCDYW7 FM C26H29N3O6 DMCDYW7 IC InChI=1S/C26H29N3O6/c1-17-22(25(30)34-4)24(20-11-8-12-21(15-20)29(32)33)23(18(2)27-17)26(31)35-14-13-28(3)16-19-9-6-5-7-10-19/h5-12,15,24,27H,13-14,16H2,1-4H3 DMCDYW7 CS CC1=C(C(C(=C(N1)C)C(=O)OCCN(C)CC2=CC=CC=C2)C3=CC(=CC=C3)[N+](=O)[O-])C(=O)OC DMCDYW7 IK ZBBHBTPTTSWHBA-UHFFFAOYSA-N DMCDYW7 IU 5-O-[2-[benzyl(methyl)amino]ethyl] 3-O-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate DMCDYW7 CA CAS 55985-32-5 DMCDYW7 CB CHEBI:7550 DMCDYW7 DE High blood pressure DMBCM8L ID DMBCM8L DMBCM8L DN Nicergoline DMBCM8L HS Approved DMBCM8L SN MNE; Nargoline; Nicergolin; Nicergolina; Nicergolinum; Nicotergoline; Nimergoline; Sermion; Nicergolin [German]; Nicergolina [DCIT]; Nimergoline base; FI 6714; RP 19651; Nicergolinum [INN-Latin]; Sermion (TN); Nicergoline (JP15/USAN/INN); Nicergoline [USAN:BAN:INN:JAN]; Ergoline-8beta-methanol, 10-methoxy-1,6-dimethyl-, 5-bromonicotinate (ester); Ergoline-8-beta-methanol, 10-methoxy-1,6-dimethyl-, 5-bromonicotinate (ester); Ergoline-8beta-methanol, 10-methoxy-1,6-dimethyl-, 5-bromonicotinate (ester) (8CI); Ergoline-8-beta-methanol, 10-methoxy-1,6-dimethyl-, 5-bromo-3-pyridinecarboxylate (ester); Ergoline-8-methanol, 10-methoxy-1,6-dimethyl-, (8beta)-, 5-bromo-3-pyridinecarboxylate (ester); (+)-10-Methoxy-1,6-dimethylergoline-8-beta-methanol 5-bromonicotinate; 1-Methyl-lumilysergol 8-(5-bromonicotinate) 10-methyl ether; 10-Methoxy-1,6-dimethyl-ergolin-8-beta-methanol-(5-bromnicotinat); 10-Methoxy-1,6-dimethyl-ergolin-8-beta-methanol-(5-bromnicotinat) [German]; 10-Methoxy-1,6-dimethylergoline-8-methanol 5-bromo-3-pyrindinecarboxylate (ester); 10-Methoxy-1,6-dimethylergoline-8beta-methanol 5-bromonicotinate; 10-Methoxy-1,6-dimethylergoline-8beta-methanol 5-bromonicotinate (ester); 5-Bromonicotinic acid 10-methoxy-1,6-dimethylergoline-8-methyl ester; 8-beta-((5-Bromonicotinoyloxy)methyl)-1,6-dimethyl-10-alpha-methoxyergoline DMBCM8L TC Vasodilator Agents DMBCM8L DT Small molecular drug DMBCM8L PC 34040 DMBCM8L MW 484.4 DMBCM8L FM C24H26BrN3O3 DMBCM8L IC InChI=1S/C24H26BrN3O3/c1-27-13-17-8-21-24(30-3,19-5-4-6-20(27)22(17)19)9-15(12-28(21)2)14-31-23(29)16-7-18(25)11-26-10-16/h4-7,10-11,13,15,21H,8-9,12,14H2,1-3H3/t15-,21-,24+/m1/s1 DMBCM8L CS CN1C[C@@H](C[C@]2([C@H]1CC3=CN(C4=CC=CC2=C34)C)OC)COC(=O)C5=CC(=CN=C5)Br DMBCM8L IK YSEXMKHXIOCEJA-FVFQAYNVSA-N DMBCM8L IU [(6aR,9R,10aS)-10a-methoxy-4,7-dimethyl-6a,8,9,10-tetrahydro-6H-indolo[4,3-fg]quinolin-9-yl]methyl 5-bromopyridine-3-carboxylate DMBCM8L CA CAS 27848-84-6 DMBCM8L CB CHEBI:31902 DMBCM8L DE Brain ischaemia; Senile dementia DMJAGXQ ID DMJAGXQ DMJAGXQ DN Niclosamide DMJAGXQ HS Approved DMJAGXQ SN niclosamide; 50-65-7; Niclocide; 5-Chloro-N-(2-chloro-4-nitrophenyl)-2-hydroxybenzamide; Tredemine; Bayluscid; Phenasal; Yomesan; Fenasal; Dichlosale; Helmiantin; Sagimid; Iomezan; Devermine; Atenase; Vermitid; Radeverm; Mansonil; Iomesan; Devermin; Cestocid; Sulqui; Lintex; Nasemo; Mato; Fedal-Telmin; Bayer 73; Radewerm; Zestocarp; Bayer 2353; 2',5-Dichloro-4'-nitrosalicylanilide; Chemagro 2353; BAY 2353; Benzamide, 5-chloro-N-(2-chloro-4-nitrophenyl)-2-hydroxy-; 5-Chloro-2'-chloro-4'-nitrosalicylanilide; nicolsamide; HL 2447; Niclosamidum [I DMJAGXQ DT Small molecular drug DMJAGXQ PC 4477 DMJAGXQ MW 327.12 DMJAGXQ FM C13H8Cl2N2O4 DMJAGXQ IC InChI=1S/C13H8Cl2N2O4/c14-7-1-4-12(18)9(5-7)13(19)16-11-3-2-8(17(20)21)6-10(11)15/h1-6,18H,(H,16,19) DMJAGXQ CS C1=CC(=C(C=C1[N+](=O)[O-])Cl)NC(=O)C2=C(C=CC(=C2)Cl)O DMJAGXQ IK RJMUSRYZPJIFPJ-UHFFFAOYSA-N DMJAGXQ IU 5-chloro-N-(2-chloro-4-nitrophenyl)-2-hydroxybenzamide DMJAGXQ CA CAS 50-65-7 DMJAGXQ CB CHEBI:7553 DMJAGXQ DE Cestodes infection DMIYJFV ID DMIYJFV DMIYJFV DN Nicorandil DMIYJFV HS Approved DMIYJFV SN Adancor; Dancor; Ikorel; Nicorandilum; Sigmart; Aventis Brand of Nicorandil; Aventis Pharma Brand of Nicorandil; Merck Brand of Nicorandil; Merck Lipha Sante Brand of Nicorandil; Nicorandil Aventis Brand; Nicorandil Merck Brand; Rhone Poulenc Rorer Brand of Nicorandil; SG 75; SG75; Ikorel (TN); Nicorandilum [INN-Latin]; RP-46417; Rhone-Poulenc Rorer Brand of Nicorandil; SG-75; Sigmart (TN); Nitrate, 2-Nicotinamidethyl; Nitrate, 2-Nicotinamidoethyl; N-(2-Hydroxyethyl)nicotinamide nitrate; Nicorandil (JP15/USAN/INN); Nicorandil [USAN:BAN:INN:JAN]; N-(2-Hydroxyethyl)nicotinamide nitrate (ester); N-[2-(Nitrooxy)ethyl]pyridine-3-carboxamide; 2 Nicotinamidethyl Nitrate; 2 Nicotinamidoethyl Nitrate; 2-(Nicotinamido)ethyl nitrat; 2-(Pyridine-3-carboxamido)ethyl Nitrate; 2-(pyridine-3-carbonylamino)ethyl nitrate; 2-Nicotinamidethyl Nitrate; 2-Nicotinamidoethyl nitrate; 2-[(pyridin-3-ylcarbonyl)amino]ethylnitrat DMIYJFV CP Chugai; Roche; Sanofi-Aventis; Merk KGaA; Pfizer; 3M Pharmaceutical DMIYJFV TC Vasodilator Agents DMIYJFV DT Small molecular drug DMIYJFV PC 47528 DMIYJFV MW 211.17 DMIYJFV FM C8H9N3O4 DMIYJFV IC InChI=1S/C8H9N3O4/c12-8(7-2-1-3-9-6-7)10-4-5-15-11(13)14/h1-3,6H,4-5H2,(H,10,12) DMIYJFV CS C1=CC(=CN=C1)C(=O)NCCO[N+](=O)[O-] DMIYJFV IK LBHIOVVIQHSOQN-UHFFFAOYSA-N DMIYJFV IU 2-(pyridine-3-carbonylamino)ethyl nitrate DMIYJFV CA CAS 65141-46-0 DMIYJFV CB CHEBI:31905 DMIYJFV DE Angina pectoris DMUPE07 ID DMUPE07 DMUPE07 DN Nicotinamide DMUPE07 HS Approved DMUPE07 SN Aminicotin; Amixicotyn; Amnicotin; Benicot; Dipegyl; Endobion; Enduramide; Hansamid; Mediatric; Niacevit; Niacinamide; Niacotinamide; Niamide; Nicamina; Nicamindon; Nicasir; Nicobion; Nicofort; Nicogen; Nicomidol; Nicosylamide; Nicota; Nicotamide; Nicotilamide; Nicotililamido; Nicotinamid; Nicotinamida; Nicotinamidum; Nicotinsaeureamid; Nicotinsaureamid; Nicotol; Nicotylamide; Nicotylamidum; Nicovit; Nicovitina; Nicovitol; Nicozymin; Nikasan; Nikazan; Nikotinamid; Nikotinsaeureamid; Niocinamide; Niozymin; Papulex; Pelmin; Pelmine; Savacotyl; Amid kyseliny nikotinove; Amid kyseliny nikotinove [Czech]; Amide PP; Astra Brand of Niacinamide; Austrovit PP; Delonin amide; Factor pp; Inovitan PP; Jenapharm Brand of Niacinamide; Merck Brand of Niacinamide; Niacinamide Astra Brand; Niacinamide Jenapharm Brand; Niacinamide Merck Brand; Niacinamide Pharmagenix Brand; Niacinamide [USAN]; Niavit PP; Nicotine acid amide; Nicotine amide; Nicotinic acid amide; Nicotinic amide; Nicotinsaureamid Jenapharm; Nicotinsaureamid [German]; Nikotinsaeureamid [German]; Pelonin amide; Pharmagenix Brand of Niacinamide; Vitamin B; Vitamin PP; Witamina PP; Nicosan 2; Vitamin H1; B 3, Vitamin; B3, Vitamin; Beta-Pyridinecarboxamide; Jenapharm, Nicotinsaureamid; Nandervit-N; Niacin-Vitamin B3; Niacinamide (USP); Nicotinamida [INN-Spanish]; Nicotinamide (Niacinamide); Nicotinamidum [INN-Latin]; Niko-tamin; PP-Faktor; Vi-Nicotyl; Vitamin B (VAN); M-(Aminocarbonyl)pyridine; Niacinamide, Nicotinic acid amide, Nicotinamide; Nicotinamide (JP15/INN); Nicotinamide, niacin, vitamin B3; Nicotinamide-carbonyl-14C; Pyridine-3-carboxamide; Pyridine-3-carboxylic acid amide; 3 Pyridinecarboxamide; 3-Carbamoylpyridine; 3-Pyridinecarboxamide; 3-Pyridinecarboxylic acid amide DMUPE07 TC Antiinflammatory Agents DMUPE07 DT Small molecular drug DMUPE07 PC 936 DMUPE07 MW 122.12 DMUPE07 FM C6H6N2O DMUPE07 IC InChI=1S/C6H6N2O/c7-6(9)5-2-1-3-8-4-5/h1-4H,(H2,7,9) DMUPE07 CS C1=CC(=CN=C1)C(=O)N DMUPE07 IK DFPAKSUCGFBDDF-UHFFFAOYSA-N DMUPE07 IU pyridine-3-carboxamide DMUPE07 CA CAS 98-92-0 DMUPE07 CB CHEBI:17154 DMUPE07 DE Inflammatory skin condition DMWX5CO ID DMWX5CO DMWX5CO DN Nicotine DMWX5CO HS Approved DMWX5CO SN Habitrol; Micotine; NCT; NICOTINE AND SALTS; Nicoderm Patch; Nicotina [Italian]; Nicotine Patch; Nicotine [USAN]; Nicotine replacement patch; Nicotine solution; Nictoine patch; Nikotin [German]; Nikotyna [Polish]; Transdermal Nicotine; Nicotine [UN1654] [Poison]; ENT 3,424; Habitrol (TN); Nicorette (TN); Nicotine (USP); Nicotine (compounds related to); Nicotine [BSI:ISO]; L(-)-nicotine; Beta-Pyridyl-alpha-N-methyl pyrrolidine; (-)-Nicotine solution; (2S) 3-(1-Methyl-pyrrolidin-2-yl)-pyridine; (S)-(-)-NICOTINE, 3-[(2S)-1-METHYL-2-PYRROLIDINYL] PYRIDINE; (S)-(-)-Nicotine; (S)-3-(1-methylpyrrolidin-2-yl)pyridine; (S)-3-(N-methylpyrrolidin-2-yl)pyridine; (S)-Nicotine; 3-(2-(N-methylpyrrolidinyl))pyridine; 3-(N-Methylpyrollidino)pyridine; 3-(N-Methylpyrrolidino)pyridine; 3-[(2S)-1-methylpyrrolidin-2-yl]pyridine DMWX5CO CP Upjohn Corporation DMWX5CO DT Small molecular drug DMWX5CO PC 89594 DMWX5CO MW 162.23 DMWX5CO FM C10H14N2 DMWX5CO IC InChI=1S/C10H14N2/c1-12-7-3-5-10(12)9-4-2-6-11-8-9/h2,4,6,8,10H,3,5,7H2,1H3/t10-/m0/s1 DMWX5CO CS CN1CCC[C@H]1C2=CN=CC=C2 DMWX5CO IK SNICXCGAKADSCV-JTQLQIEISA-N DMWX5CO IU 3-[(2S)-1-methylpyrrolidin-2-yl]pyridine DMWX5CO CA CAS 54-11-5 DMWX5CO CB CHEBI:17688 DMWX5CO DE Nicotine dependence; Tobacco dependence DMSVOZT ID DMSVOZT DMSVOZT DN Nifedipine DMSVOZT HS Approved DMSVOZT SN Adalat; Adalate; Adapine; Adapress; Afeditab; Alat; Aldipin; Alfadal; Alonix; Angipec; Anifed; Anpine; Aprical; Bonacid; Calcibloc; Calcigard; Calcilat; Camont; Cardifen; Cardilat; Cardionorm; Chronadalate; Citilat; Coracten; Coral; Cordafen; Cordaflex; Cordalat; Cordicant; Cordilan; Cordipin; Cordipine; Corinfar; Corotrend; Corynphar; Depin; Dignokonstant; Dilafed; Dipinkor; Duranifin; Ecodipi; Ecodipin; Emaberin; Fedcor; Fenamon; Fenigidin; Fenihidin; Fenihidine; Glopir; Hadipin; Hexadilat; Infedipin; Introcar; Kordafen; Korinfar; Macorel; Megalat; Myogard; Nedipin; Nicardia; Nifangin; Nifar; Nifdemin; Nifebene; Nifecard; Nifecor; Nifedepat; Nifediac; Nifedical; Nifedicor; Nifedin; Nifedine; Nifedipino; Nifedipinum; Nifedipres; Nifelan; Nifelat; Nifelate; Nificard; Nifidine; Nifipen; Niphedipine; Orix; Oxcord; Pidilat; Procardia; Sepamit; Tibricol; Vascard; Zenusin; AWD Pharma Brand of Nifedipine; Adalat CC; Adalat CR; Adalat Crono; Adalat FT; Adalat GITS; Adalat LA; Adalat LP; Adalat Oros; Adalat PA; Adalat Retard; Adalat XL; Adalate LP; Adcock Ingram Brand of Nifedipine; Adipine XL; Afeditab CR; Alonix S; Aprical long; Bayer Brand of Nifedipine; Chronadalate LP; Coracten XL; Ecodipin E; Fedcor Retard; Fenamon SR; Fortipine LA; KRKA Brand of Nifedipine; Nifedical XL; Nifedipine Bayer Brand; Nifedipine GTIS; Nifedipine KRKA Brand; Nifedipine Monohydrochloride; Nifedipine Orion Brand; Nifedipine Pfizer Brand; Nifedipine Retard; Nifedirex LP; Nifelat Q; Nifensar XL; Orion Brand of Nifedipine; Pfizer Brand of Nifedipine; Procardia XL; Slofedipine XL; Tensipine MR; Adalat 10; Adalat 20; Adalat 5; Adalat GITS 30; Bay1040; N 7634; N1fedilat; Adalat (TN); Afeditab CR (TN); Alpha-Nifedipine Retard;Apo-Nifed; Bay-1040; KB-1712P; Monohydrochloride, Nifedipine; Nifedical (TN); Nifedipine-GTIS; Nifedipino [INN-Spanish]; Nifedipinum [INN-Latin]; Procardia (TN); Bay-a-1040; Nifedipine (JP15/USP/INN); Nifedipine [USAN:BAN:INN:JAN] DMSVOZT CP Bayer DMSVOZT TC Analgesics DMSVOZT DT Small molecular drug DMSVOZT PC 4485 DMSVOZT MW 346.3 DMSVOZT FM C17H18N2O6 DMSVOZT IC InChI=1S/C17H18N2O6/c1-9-13(16(20)24-3)15(14(10(2)18-9)17(21)25-4)11-7-5-6-8-12(11)19(22)23/h5-8,15,18H,1-4H3 DMSVOZT CS CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC DMSVOZT IK HYIMSNHJOBLJNT-UHFFFAOYSA-N DMSVOZT IU dimethyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate DMSVOZT CA CAS 21829-25-4 DMSVOZT CB CHEBI:7565 DMSVOZT DE Angina pectoris DMJ3I1Q ID DMJ3I1Q DMJ3I1Q DN Niflumic acid DMJ3I1Q HS Approved DMJ3I1Q SN Actol; Donalgin; Flunir; Forenol; Landruma; NFL; Niflactol; Niflam; Niflugel; Niflumate; Nifluril; Acide niflumique; Acide niflumique [French]; Acido niflumico; Acido niflumico [Italian]; Acidum niflumicum; Nifluminic acid; UPSA Conseil Brand of Niflumic Acid; Upsamedica Brand of Niflumic Acid; N 0630; SC 1332; UP 83; UPSA Brand 1 of Niflumic Acid; UPSA Brand 2 of Niflumic Acid; Acid, Niflumic; Acide niflumique [INN-French]; Acido niflumico [INN-Spanish]; Acidum niflumicum [INN-Latin]; Niflugel (TN); Niflumic acid (INN); Niflumic acid [INN:DCF]; Aza-2 dimethyl-2',3' (tetrazolyl-5)-6 diphenylamino; Aza-2 dimethyl-2',3' (tetrazolyl-5)-6 diphenylamino [French]; 2-(3-(Trifluoromethyl)-phenyl)aminonicotinic acid; 2-(3-(Trifluoromethyl)anilino)nicotinic acid; 2-(3-Trifluoromethyl-phenylamino)-nicotinic acid; 2-(3-Trifluoromethylanilino)nicotinic Acid; 2-(3-[Trifluoromethyl]anilino)nicotinic acid; 2-(A,A,A-Trifluoro-m-toluidino)nicotinic acid; 2-(alpha,alpha,alpha-Trifluoro-m-toluidino)nicotinic acid; 2-[(3-TRIFLUOROMETHYL)PHENYL]AMINO-3-PYRIDINE-CARBOXYLIC ACID; 2-[(3-Trifluoromethyl)phenyl]amino]-3-pyridinecarboxylic Acid; 2-[(3-Trifluoromethylphenyl)amino]nicotinic Acid; 2-[3-(Trifluoromethyl)anilino]nicotinic acid; 2-[3-(trifluoromethyl)anilino]pyridine-3-carboxylic acid; 2-[alpha,alpha,alpha-trifluoro-m-toluidino]-nicotinic acid; 2-{[3-(TRIFLUOROMETHYL)PHENYL]AMINO}NICOTINIC ACID; 2-{[3-(trifluoromethyl)phenyl]amino}pyridine-3-carboxylic acid; 39690A DMJ3I1Q TC Antiinflammatory Agents DMJ3I1Q DT Small molecular drug DMJ3I1Q PC 4488 DMJ3I1Q MW 282.22 DMJ3I1Q FM C13H9F3N2O2 DMJ3I1Q IC InChI=1S/C13H9F3N2O2/c14-13(15,16)8-3-1-4-9(7-8)18-11-10(12(19)20)5-2-6-17-11/h1-7H,(H,17,18)(H,19,20) DMJ3I1Q CS C1=CC(=CC(=C1)NC2=C(C=CC=N2)C(=O)O)C(F)(F)F DMJ3I1Q IK JZFPYUNJRRFVQU-UHFFFAOYSA-N DMJ3I1Q IU 2-[3-(trifluoromethyl)anilino]pyridine-3-carboxylic acid DMJ3I1Q CA CAS 4394-00-7 DMJ3I1Q CB CHEBI:34888 DMJ3I1Q DE Rheumatoid arthritis DMSQLZJ ID DMSQLZJ DMSQLZJ DN Nifurtimox DMSQLZJ HS Approved DMSQLZJ SN NIFURTIMOX; Lampit; Bayer 2502; 23256-30-6; BAY 2502; Nifurtimox [INN:BAN]; Nifurtimoxum [INN-Latin]; CCRIS 2201; EINECS 245-531-0; CHEBI:7566; C10H13N3O5S; 4-Thiomorpholinamine, 3-methyl-N-((5-nitro-2-furanyl)methylene)-, 1,1-dioxide; 4-((5-Nitrofurfurylidene)amino)-3-methylthiomorpholine-1,1-dioxide; 3-Methyl-N-[(5-nitro-2-furanyl)methylene]-4-thiomorpholinamine 1,1-dioxide; 3-Methyl-4-(5'-nitrofurylidene-amino)-tetrahydro-4H-1,4-thiazine-1,1-dioxide DMSQLZJ CP Bayer healthcare pharmaceuticals DMSQLZJ DT Small molecular drug DMSQLZJ PC 6842999 DMSQLZJ MW 287.29 DMSQLZJ FM C10H13N3O5S DMSQLZJ IC InChI=1S/C10H13N3O5S/c1-8-7-19(16,17)5-4-12(8)11-6-9-2-3-10(18-9)13(14)15/h2-3,6,8H,4-5,7H2,1H3/b11-6+ DMSQLZJ CS CC1CS(=O)(=O)CCN1/N=C/C2=CC=C(O2)[N+](=O)[O-] DMSQLZJ IK ARFHIAQFJWUCFH-IZZDOVSWSA-N DMSQLZJ IU (E)-N-(3-methyl-1,1-dioxo-1,4-thiazinan-4-yl)-1-(5-nitrofuran-2-yl)methanimine DMSQLZJ CA CAS 23256-30-6 DMSQLZJ CB CHEBI:7566 DMSQLZJ DE Trypanosomiasis; Chagas disease DM7HXWT ID DM7HXWT DM7HXWT DN Nilotinib DM7HXWT HS Approved DM7HXWT SN NIL; Nilotinibum; Tasigna (Novartis); Nilotinib (INN/USAN); Nilotinib, AMN107, Tasigna; Tasigna, AMN-107, Nilotinib; L-1-yl)-3-(trifluoromethyl)phenyl]benzamide; Benzamide, 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-(9CI); 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazo; 4-Methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide; 4-Methyl-N-[3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl]-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]benzamide; 4-methyl-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]benzamide; Nilotinib (BCR-ABL inhibitor 2nd gen) DM7HXWT CP Novartis AG DM7HXWT TC Anticancer Agents DM7HXWT DT Small molecular drug DM7HXWT PC 644241 DM7HXWT MW 529.5 DM7HXWT FM C28H22F3N7O DM7HXWT IC InChI=1S/C28H22F3N7O/c1-17-5-6-19(10-25(17)37-27-33-9-7-24(36-27)20-4-3-8-32-14-20)26(39)35-22-11-21(28(29,30)31)12-23(13-22)38-15-18(2)34-16-38/h3-16H,1-2H3,(H,35,39)(H,33,36,37) DM7HXWT CS CC1=C(C=C(C=C1)C(=O)NC2=CC(=CC(=C2)C(F)(F)F)N3C=C(N=C3)C)NC4=NC=CC(=N4)C5=CN=CC=C5 DM7HXWT IK HHZIURLSWUIHRB-UHFFFAOYSA-N DM7HXWT IU 4-methyl-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]benzamide DM7HXWT CA CAS 641571-10-0 DM7HXWT CB CHEBI:52172 DM7HXWT DE Chronic myelogenous leukaemia DMFN07X ID DMFN07X DMFN07X DN Nilutamide DMFN07X HS Approved DMFN07X SN Anandron; Nilandron; Nilandrone; Nilutamida; Nilutamidum; Aventis Behring Brand of Nilutamide; Aventis Brand of Nilutamide; Hoechst Brand of Nilutamide; Nilutamida [Spanish]; Nilutamidum [Latin]; N 8534; RU 23908; Anandron (TN); RU 23908-10; RU-23908; Nilutamide (USAN/INN); Nilutamide [USAN:BAN:INN]; Nilutamide [USAN:INN:BAN]; 1-(3'-Trifluoromethyl-4'-nitrophenyl)-4,4-dimethylimidazolidine-2,5-dione; 5,5-Dimethyl-3-(4-nitro-3-(trifluoromethyl)phenyl)-2,4-imidazolidinedione; 5,5-Dimethyl-3-(alpha,alpha,alpha-trifluoro-4-nitro-m-tolyl)hydantoin; 5,5-Dimethyl-3-[4-nitro-3-(trifluoromethyl)phenyl]-2,4-imidazolidinedione; 5,5-dimethyl-3-(4-nitro-3-(trifluoromethyl)phenyl)-2,4-imidazolidinedione; 5,5-dimethyl-3-[4-nitro-3-(trifluoromethyl)phenyl]imidazolidine-2,4-dione DMFN07X CP Aventis Pharmaceuticals Inc. DMFN07X TC Anticancer Agents DMFN07X DT Small molecular drug DMFN07X PC 4493 DMFN07X MW 317.22 DMFN07X FM C12H10F3N3O4 DMFN07X IC InChI=1S/C12H10F3N3O4/c1-11(2)9(19)17(10(20)16-11)6-3-4-8(18(21)22)7(5-6)12(13,14)15/h3-5H,1-2H3,(H,16,20) DMFN07X CS CC1(C(=O)N(C(=O)N1)C2=CC(=C(C=C2)[N+](=O)[O-])C(F)(F)F)C DMFN07X IK XWXYUMMDTVBTOU-UHFFFAOYSA-N DMFN07X IU 5,5-dimethyl-3-[4-nitro-3-(trifluoromethyl)phenyl]imidazolidine-2,4-dione DMFN07X CA CAS 63612-50-0 DMFN07X CB CHEBI:7573 DMFN07X DE Prostate cancer DMQ0RKZ ID DMQ0RKZ DMQ0RKZ DN Nimodipine DMQ0RKZ HS Approved DMQ0RKZ SN Admon; Brainal; Calnit; Kenesil; Modus; NimoGel; NimodipinISIS; Nimodipino; Nimodipinum; Nimotop; Periplum; Remontal; Almirall Brand of Nimodipine; Alpharma Brand of Nimodipine; Andromaco Brand of Nimodipine; Bayer Brand of Nimodipine; Bayvit Brand of Nimodipine; Cantabria Brand of Nimodipine; Elan Brand of Nimodipine; Esteve Brand of Nimodipine; Hexal Brand of Nimodipine; Nimodipin Hexal; Nimodipin ISIS; Nimodipino Bayvit; Vita Brand of Nimodipine; Bay-E 9736; DRG-0139; EG-1961; N-149; NIMOTOP (TN); Nimodipin-ISIS; Nimodipino [INN-Spanish]; Nimodipinum [INN-Latin]; Nimotop (TN); Nimotop(TM); Nimotop, Nimodipine; Bay-e-9736; Nimodipine (USAN/INN); Nimodipine [USAN:BAN:INN]; Periplum, Nimotop, BRN 0459792, DRG-0139; Isopropyl 2-methoxyethyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate; 1,4-Dihydro-2,6-dimethyl-4-(3′-nitrophenyl)-3,5-pyridinedicarboxylic acid 2-methoxyethyl-1-methylethyl Ester; 1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid; 1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 2-methoxyethyl 1-methylethyl ester;1-methylethyl 2-(methyloxy)ethyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; 2-Methoxyethyl-1-methylethyl ester; 2-methoxyethyl propan-2-yl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 2-methoxyethyl 1-methylethyl ester; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-,2-methoxyethyl 1-methylethyl ester; 3,5-pyridinecarboxylic acid 2-methoxyethyl 1-methylethyl ester; 3,5-pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl), 2-methoxyethyl 1-methylethyl ester; 3-(2-methoxyethyl) 5-propan-2-yl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; 3-O-(2-methoxyethyl) 5-O-propan-2-yl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; 4-[4-(4-chlorophenyl)-4-hydroxy-1-piperidyl]-N,N-dimethyl-2,2-diphenyl-butanamide DMQ0RKZ CP Bayer Pharmaceuticals Corporation DMQ0RKZ TC Vasodilator Agents DMQ0RKZ DT Small molecular drug DMQ0RKZ PC 4497 DMQ0RKZ MW 418.4 DMQ0RKZ FM C21H26N2O7 DMQ0RKZ IC InChI=1S/C21H26N2O7/c1-12(2)30-21(25)18-14(4)22-13(3)17(20(24)29-10-9-28-5)19(18)15-7-6-8-16(11-15)23(26)27/h6-8,11-12,19,22H,9-10H2,1-5H3 DMQ0RKZ CS CC1=C(C(C(=C(N1)C)C(=O)OC(C)C)C2=CC(=CC=C2)[N+](=O)[O-])C(=O)OCCOC DMQ0RKZ IK UIAGMCDKSXEBJQ-UHFFFAOYSA-N DMQ0RKZ IU 3-O-(2-methoxyethyl) 5-O-propan-2-yl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate DMQ0RKZ CA CAS 66085-59-4 DMQ0RKZ CB CHEBI:7575 DMQ0RKZ DE Cerebral vasospasm DMA65ER ID DMA65ER DMA65ER DN Nipradilol DMA65ER HS Approved DMA65ER SN Nipradilol; Nipradolol; Hypadil; 81486-22-8; Nipradilolum [Latin]; Nipradilol [INN:JAN]; UNII-FVM336I71Y; Hypadil (TN); CCRIS 2515; K 351; BRN 3566879; FVM336I71Y; 8-(2-Hydroxy-3-(isopropylamino)propoxy)chroman-3-yl nitrate; C15H22N2O6; 8-(2-Hydroxy-3-(isopropylamino)propoxy)-3-chromanyl nitrat; 8-(2-Hydroxy-3-(isopropylamino)propoxy)-3-chromanol 3-nitrate; K-351; 3,4-Dihydro-8-(2-hydroxy-3-isopropylamino)propoxy-3-nitroxy-2H-1-benzopyran; 3,4-Dihydro-8-(2-hydroxy-3-((1-methylethyl)amino)propoxy)-2H-1-benzopyran-3-ol 3-nitra DMA65ER DT Small molecular drug DMA65ER PC 72006 DMA65ER MW 326.34 DMA65ER FM C15H22N2O6 DMA65ER IC InChI=1S/C15H22N2O6/c1-10(2)16-7-12(18)8-21-14-5-3-4-11-6-13(23-17(19)20)9-22-15(11)14/h3-5,10,12-13,16,18H,6-9H2,1-2H3 DMA65ER CS CC(C)NCC(COC1=CC=CC2=C1OCC(C2)O[N+](=O)[O-])O DMA65ER IK OMCPLEZZPVJJIS-UHFFFAOYSA-N DMA65ER IU [8-[2-hydroxy-3-(propan-2-ylamino)propoxy]-3,4-dihydro-2H-chromen-3-yl] nitrate DMA65ER CA CAS 81486-22-8 DMA65ER CB CHEBI:31682 DMA65ER DE Angina pectoris DMLPSWQ ID DMLPSWQ DMLPSWQ DN Niraparib Tosylate DMLPSWQ HS Approved DMLPSWQ SN 1038915-73-9; MK-4827 (tosylate); MK-4827 tosylate; UNII-75KE12AY9U; MK-4827(Niraparib) tosylate; 75KE12AY9U; MK-4827-tosylate; MK 4827 tosylate; Niraparib(MK-4827) tosylate; KS-00000TSH; MolPort-044-556-849; s7625; HY-10619B; AKOS030632785; CS-2283; AC-30383; KB-335358; AX8326059 DMLPSWQ CP Tesaro DMLPSWQ TC Antihypertensive Agents DMLPSWQ DT Small molecular drug DMLPSWQ PC 78357761 DMLPSWQ MW 492.6 DMLPSWQ FM C26H28N4O4S DMLPSWQ IC InChI=1S/C19H20N4O.C7H8O3S/c20-19(24)17-5-1-3-15-12-23(22-18(15)17)16-8-6-13(7-9-16)14-4-2-10-21-11-14;1-6-2-4-7(5-3-6)11(8,9)10/h1,3,5-9,12,14,21H,2,4,10-11H2,(H2,20,24);2-5H,1H3,(H,8,9,10)/t14-;/m1./s1 DMLPSWQ CS CC1=CC=C(C=C1)S(=O)(=O)O.C1C[C@H](CNC1)C2=CC=C(C=C2)N3C=C4C=CC=C(C4=N3)C(=O)N DMLPSWQ IK LCPFHXWLJMNKNC-PFEQFJNWSA-N DMLPSWQ IU 4-methylbenzenesulfonic acid;2-[4-[(3S)-piperidin-3-yl]phenyl]indazole-7-carboxamide DMLPSWQ CA CAS 1038915-73-9 DMLPSWQ DE Peritoneal cancer; Fallopian tube cancer DM7ISKJ ID DM7ISKJ DM7ISKJ DN Nisoldipine DM7ISKJ HS Approved DM7ISKJ SN Baymycard; Nisocor; Nisoldipin; Nisoldipino; Nisoldipinum; Sular; Syscor; Zadipina; Bay k 5552; Nisoldipino [INN-Spanish]; Nisoldipinum [INN-Latin]; Sular (TN); Bay-k-5552; Nisoldipine (JAN/USAN/INN); Nisoldipine [USAN:BAN:INN:JAN]; Isobutyl 1,4-dihydro-5-methoxycarbonyl-2,6-dimethyl-4-(2-nitrophenyl)-3-pyridincarboxylat;Methyl 2-methylpropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; (+-)-Isobutyl methyl 1,4-dihydro-2,6-dimethyl-4-(o-nitrophenyl)-3,5-pyridinedicarboxylate; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-, methyl 2-methylpropyl ester; 3-O-methyl 5-O-(2-methylpropyl) 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate DM7ISKJ TC Antihypertensive Agents DM7ISKJ DT Small molecular drug DM7ISKJ PC 4499 DM7ISKJ MW 388.4 DM7ISKJ FM C20H24N2O6 DM7ISKJ IC InChI=1S/C20H24N2O6/c1-11(2)10-28-20(24)17-13(4)21-12(3)16(19(23)27-5)18(17)14-8-6-7-9-15(14)22(25)26/h6-9,11,18,21H,10H2,1-5H3 DM7ISKJ CS CC1=C(C(C(=C(N1)C)C(=O)OCC(C)C)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC DM7ISKJ IK VKQFCGNPDRICFG-UHFFFAOYSA-N DM7ISKJ IU 3-O-methyl 5-O-(2-methylpropyl) 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate DM7ISKJ CA CAS 63675-72-9 DM7ISKJ CB CHEBI:76917 DM7ISKJ DE Hypertension DMOWLVG ID DMOWLVG DMOWLVG DN Nitazoxanide DMOWLVG HS Approved DMOWLVG SN Alinia; Colufase; Cryptaz; Daxon; Heliton; Nitazoxanid; Nitazoxanida; Nitazoxanidum; Taenitaz; Tizoxanide glucuronide; AZT + Nitazoxanide; Alinia (TN); Annita (TN); Azt+ nitazoxanide; Daxon (TN); Dexidex (TN); Kidonax (TN); Nitax (TN); Nitazox (TN); Nitazoxanida [INN-Spanish]; Nitazoxanide [USAN:INN]; Nitazoxanidum [INN-Latin]; Pacovanton (TN); Paramix (TN); Phavic-1; Zox (TN); Nitazoxanide (USAN/INN); Daxon, Dexidex, Kidonax, Pacovanton, Paramix, Nitax, Zox, Nitazoxanide DMOWLVG CP Unimed Pharmaceuticals DMOWLVG TC Antiparasitic Agents DMOWLVG DT Small molecular drug DMOWLVG PC 41684 DMOWLVG MW 307.28 DMOWLVG FM C12H9N3O5S DMOWLVG IC InChI=1S/C12H9N3O5S/c1-7(16)20-9-5-3-2-4-8(9)11(17)14-12-13-6-10(21-12)15(18)19/h2-6H,1H3,(H,13,14,17) DMOWLVG CS CC(=O)OC1=CC=CC=C1C(=O)NC2=NC=C(S2)[N+](=O)[O-] DMOWLVG IK YQNQNVDNTFHQSW-UHFFFAOYSA-N DMOWLVG IU [2-[(5-nitro-1,3-thiazol-2-yl)carbamoyl]phenyl] acetate DMOWLVG CA CAS 55981-09-4 DMOWLVG CB CHEBI:94807 DMOWLVG DE Diarrhea DMVS9WQ ID DMVS9WQ DMVS9WQ DN Nitisinone DMVS9WQ HS Approved DMVS9WQ SN Nitisinona; Nitisinonum; Nitisone; Orfadin; Nitisinone [INN]; SC 0735; FE-0200; Nitisinone (NTBC); Nitisinone [USAN:INN]; Orfadin (TN); Nitisinone (JAN/USAN/INN); 2-(2-Nitro-4-trifluoromethylbenzoyl)cyclohexane-1,3-dione; 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione; 2-(Alpha,alpha,alpha-trifluoro-2-nitro-p-tuluoyl)-1,3-cyclohexanedione; 2-[2-nitro-4-(trifluoromethyl)benzoyl]cyclohexane-1,3-dione; 2-{[2-nitro-4-(trifluoromethyl)phenyl]carbonyl}cyclohexane-1,3-dione DMVS9WQ TC Anticancer Agents DMVS9WQ DT Small molecular drug DMVS9WQ PC 115355 DMVS9WQ MW 329.23 DMVS9WQ FM C14H10F3NO5 DMVS9WQ IC InChI=1S/C14H10F3NO5/c15-14(16,17)7-4-5-8(9(6-7)18(22)23)13(21)12-10(19)2-1-3-11(12)20/h4-6,12H,1-3H2 DMVS9WQ CS C1CC(=O)C(C(=O)C1)C(=O)C2=C(C=C(C=C2)C(F)(F)F)[N+](=O)[O-] DMVS9WQ IK OUBCNLGXQFSTLU-UHFFFAOYSA-N DMVS9WQ IU 2-[2-nitro-4-(trifluoromethyl)benzoyl]cyclohexane-1,3-dione DMVS9WQ CA CAS 104206-65-7 DMVS9WQ CB CHEBI:50378 DMVS9WQ DE Hereditary tyrosinemia type 1 DMEGIQ6 ID DMEGIQ6 DMEGIQ6 DN Nitrazepam DMEGIQ6 HS Approved DMEGIQ6 SN Alodorm; Apodorm; Benzalin; Calsamin; Calsmin; Cerson; Dormalon; Dumolid; Eatan; Epibenzalin; Epinelbon; Eunoctin; Eunoktin; Gerson; Hipnax; Hipsal; Ibrovek; Imadorm; Imeson; Imesont; Ipersed; Magadon; Megadon; Mitidin; Mogadan; Mogadon; Mogadone; Nelbon; Nelmat; Neozepam; Neuchlonic; Nitrados; Nitravet; Nitrazadon; Nitrazep; Nitrazepamum; Nitrempax; Nitrenpax; Nitrodiazepam; Noctesed; Novanox; Pacisyn; Paxisyn; Pelson; Persopit; Radedorm; Relact; Remnos; Serenade; Somitran; Somnased; Somnibel; Somnite; Sonebon; Sonnolin; Surem; Trazenin; Unisomnia; Aliud Brand of Nitrazepam; Allphar Brand of Nitrazepam; Alphapharma Brand of Nitrazepam; Alpharma Brand of Nitrazepam; Alter Brand of Nitrazepam; CSP Brand of Nitrazepam; DDSA Brand of Nitrazepam; Dermatech Brand of Nitrazepam; Desitin Brand of Nitrazepam; Dormicum Brand of Nitrazepam; Eatan N; ICN Brand of Nitrazepam; Neuraxpharm Brand of Nitrazepam; Nitrazepam AL; Norgine Brand of Nitrazepam; Pfleger Brand of Nitrazepam; Protea Brand of Nitrazepam; Rhoxalpharma Brand of Nitrazepam; Sandoz nitrazepam; Scheurich Brand of Nitrazepam; Sonebon Tofraniln A; Taurus Brandof Nitrazepam; United Drug Brand of Nitrazepam; Wernigerode Brand of Nitrazepam; LA 1; S 2000; Alodorm (TN); Apo-nitrazepam tablets BP; Apodorm (TN); Arem (TN); Benzalin (TN); Cavodan (TN); Ct-Arzneimittel Brand of Nitrazepam; Dima (TN); Dormalon (TN); Dormicum (anticonvulsant); Dormigen (TN); Dormin-5; Dormo-Puren; Dumolid (TN); Eatan N (TN); Eunoctin (TN); Hypnotex (TN); ISOPROPYLACETATE/NITRAZEPAM; Imeson (TN); Insoma (TN); Insomin (TN); Ipersed (TN); LA 1 (VAN); Mitidin (TN); Mogadan (TN); Mogadon (TN); N-Desmethylnimetazepam; Nitavan (TN); Nitepam (TN); Nitrados (TN); Nitrapan (TN); Nitravet (TN); Nitrazadon (TN); Nitrazep (TN); Nitrazepam (TN); Nitrazepam Capsules BP 1993 (TN); Nitrazepam Oral Suspension BP 1993 (TN); Nitrazepam Tablets BP 1993 (TN); Nitrazepam-10; Nitrazepam-5; Nitrazepam-neuraxpharm; Nitrazepamum [INN-Latin]; Nitrazepan (TN); Nitrazepol (TN); Nitredon (TN); Nitrosun (TN); Novanox (TN); Numbon (TN); Onirema (TN); Ormodon (TN); Pacisyn (TN); Paxadorm (TN); Pelson (TN); Pelsonfilina (TN); Protraz (TN); Radedorm (TN); Remnos (TN); Rhoxal-nitrazepam; Ro 4-5360; Ro 5-3059; Ro 53-60; Serenade (TN); Somnibel N (TN); Somnipar (TN); Somnite (TN); Sonebon (TN); Sonotrat (TN); Surem (TN); Tri (TN); Unisomnia (TN); Dormo-Puren (TN); Nitrazepam (JP15/USAN/INN); Nitrazepam [USAN:INN:BAN:JAN]; 1,3-Dihydro-7-nitro-5-phenyl-2H-1,4-benzodiazepin-2-one; 2,3-Dihydro-7-nitro-5-phenyl-1H-1,4-benzodiazepin-2-on; 7-Nitro-1,3-dihydro-5-phenyl-2H-1,4-benzodiazepin-2-one; 7-Nitro-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one; 7-Nitro-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-2-one; 7-nitro-5-phenyl-1,3-dihydro-1,4-benzodiazepin-2-one DMEGIQ6 TC Antianxiety Agents DMEGIQ6 DT Small molecular drug DMEGIQ6 PC 4506 DMEGIQ6 MW 281.27 DMEGIQ6 FM C15H11N3O3 DMEGIQ6 IC InChI=1S/C15H11N3O3/c19-14-9-16-15(10-4-2-1-3-5-10)12-8-11(18(20)21)6-7-13(12)17-14/h1-8H,9H2,(H,17,19) DMEGIQ6 CS C1C(=O)NC2=C(C=C(C=C2)[N+](=O)[O-])C(=N1)C3=CC=CC=C3 DMEGIQ6 IK KJONHKAYOJNZEC-UHFFFAOYSA-N DMEGIQ6 IU 7-nitro-5-phenyl-1,3-dihydro-1,4-benzodiazepin-2-one DMEGIQ6 CA CAS 146-22-5 DMEGIQ6 CB CHEBI:7581 DMEGIQ6 DE Epilepsy; Insomnia DM21C09 ID DM21C09 DM21C09 DN Nitrendipine DM21C09 HS Approved DM21C09 SN Baylotensin; Bayotensin; Baypress; Bylotensin; Deiten; Gericin; Jutapress; Nidrel; Niprina; NitrePuren; Nitregamma; Nitrendepat; Nitrendidoc; Nitrendimerck; Nitrendipin; Nitrendipincorax; Nitrendipino; Nitrendipinum; Nitrensal; Nitrepin; Nitrepress; Tensogradal; Trendinol; Vastensium; Nitre AbZ; Nitre Puren; Nitren Lich;Nitren acis; Nitrend KSK; Nitrendi Biochemie; Nitrendipin AL; Nitrendipin Apogepha; Nitrendipin Atid; Nitrendipin Basics; Nitrendipin Heumann; Nitrendipin Lindo; Nitrendipin Stada; Nitrendipin beta; Nitrendipin corax; Nitrendipin von ct; Nitrendipino Bayvit; Nitren 1A Pharma; AL, Nitrendipin; AbZ, Nitre; Acis, Nitren; Atid, Nitrendipin; Basics, Nitrendipin; Baypress (TN); Bayvit, Nitrendipino; Beta, Nitrendipin; Biochemie, Nitrendi; Ct, nitrendipin von; Heumann, Nitrendipin; KSK, Nitrend; Lich, Nitren; Lindo, Nitrendipin; N-144; Nitre-Puren; Nitrendipin-corax; Pharma, Nitren 1A; Stada, Nitrendipin; Von ct, nitrendipin; Bay-e-5009; 1A Pharma, Nitren DM21C09 TC Antihypertensive Agents DM21C09 DT Small molecular drug DM21C09 PC 4507 DM21C09 MW 360.4 DM21C09 FM C18H20N2O6 DM21C09 IC InChI=1S/C18H20N2O6/c1-5-26-18(22)15-11(3)19-10(2)14(17(21)25-4)16(15)12-7-6-8-13(9-12)20(23)24/h6-9,16,19H,5H2,1-4H3 DM21C09 CS CCOC(=O)C1=C(NC(=C(C1C2=CC(=CC=C2)[N+](=O)[O-])C(=O)OC)C)C DM21C09 IK PVHUJELLJLJGLN-UHFFFAOYSA-N DM21C09 IU 5-O-ethyl 3-O-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate DM21C09 CA CAS 39562-70-4 DM21C09 CB CHEBI:7582 DM21C09 DE Hypertension DM1RBYG ID DM1RBYG DM1RBYG DN Nitric Oxide DM1RBYG HS Approved DM1RBYG SN Nitric oxide; nitric oxide; nitrogen monoxide; Mononitrogen monoxide; 10102-43-9; nitrogen monooxide; nitrogen protoxide; nitrosyl; Nitrosyl radical; EDRF; CHEBI:16480; endothelium-derived relaxing factor; monoxyde d'azote; oxoazanyl; oxyde azotique; oxido nitrico; Stickstoffmonoxid; Nitric oxide trimer; monoxido de nitrogeno; Stickstoff(II)-oxid; Nitric oxide (JAN); INOmax (TN); oxido de nitrogeno(II); Nitrosoradical; [NO]; oxidonitrogen(); Nitrogen(II) oxide; OHM 11771; AC1L3QHF; Nitric oxide, 985%; DTXSID1020938; CHEMBL1200689; CTK0H7679; ()NO; HNO; INOmax; Nitrosyl; Nitroxyl; Oxoazanyl; Stickmonoxyd; Endogenous Nitrate Vasodilator; Monoxido de nitrogeno; Nitrogen monooxide; Nitrogen monoxide; Nitrosyl hydride; Nitroxide radical; Oxido nitrico; Oxyde azotique; Oxyde nitrique [French]; Stickmonoxyd [German]; Bioxyde d'azote; Bioxyde d'azote [French]; Endothelium-Derived Nitric Oxide; Monoxide, Mononitrogen; Monoxide, Nitrogen; Monoxyde d'azote; NITRIC-OXIDE; NO(); Nitrate Vasodilator, Endogenous; Nitric Oxide, Endothelium Derived; Nitric oxide 10% by volume or more; Nitric oxide, compressed [UN1660] [Poison gas]; Nitrogen oxide (NO); Oxide, Nitric; Oxido de nitrogeno(II); Oxidonitrogen(); Vasodilator, Endogenous Nitrate; Nitric Oxide, Endothelium-Derived; Nitrosyl hydride ((NO)H); Endothelium-derived relaxing factor (EDRF) DM1RBYG CP NB therapeutics; University of Akron DM1RBYG TC Bronchodilator Agents DM1RBYG DT Small molecular drug DM1RBYG PC 145068 DM1RBYG MW 30.006 DM1RBYG FM NO DM1RBYG IC InChI=1S/NO/c1-2 DM1RBYG CS [N]=O DM1RBYG IK MWUXSHHQAYIFBG-UHFFFAOYSA-N DM1RBYG IU nitric oxide DM1RBYG CA CAS 10102-43-9 DM1RBYG CB CHEBI:16480 DM1RBYG DE Respiratory failure; Solid tumour/cancer; Tinea pedis DM7PQIK ID DM7PQIK DM7PQIK DN Nitrofurantoin DM7PQIK HS Approved DM7PQIK SN Alfuran; Benkfuran; Berkfuran; Berkfurin; Ceduran; Chemiofuran; Cistofuran; Cyantin; Cystit; Dantafur; Furabid; Furachel; Furadantin; Furadantine; Furadantoin; Furadoine; Furadonin; Furadonine; Furadoninum; Furadontin; Furalan; Furaloid; Furantoin; Furatoin; Furedan; Furina; Furobactina; Furodantin; Furophen; Gerofuran; Ituran; Macpac; Macrobid; Macrodantin; Macrodantina; Macrofuran; Macrofurin; NITROFURANTION; Nierofu; Nifurantin; Nifuretten; Nitoin; Nitrex; Nitrofuradantin; Nitrofurantoina; Nitrofurantoine; Nitrofurantoinum; Novofuran; Orafuran; Parfuran; Phenurin; PiyEloseptyl; Siraliden; Trantoin; Uerineks; Urantoin; Urizept; Urodil; Urodin; Urofuran; Urofurin; Urolisa; Urolong; Welfurin; Zoofurin; Fua Med; Furadantin Retard; Furadantina MC; Furadantine mc; Furophen T; NITROFURANTOIN MACROCRYSTALLINE; Nitrofurantoina [DCIT]; Fua-med; Fur-ren; Furadantin (TN); Furadantine-MC; Macrobid (TN); Macrodantin (TN); N-Toin; ND-3320; ND-7248; NITROFURANTOIN, MACROCRYSTALLINE; Nitro Macro (TN); Nitrofur-C; Nitrofurantoine [INN-French]; Nitrofurantoinum [INN-Latin]; Ro-Antoin; Urantoin (TN); Uro-Selz; Uro-Tablinen; Uro-tablineu; Usaf ea-2; Nitrofurantoin (JAN/USP/INN); Nitrofurantoin [USAN:INN:BAN:JAN]; N-(5-Nitrofurfurylidene)-1-aminohydantoin; N-(5-Nitro-2-furfurylidene)-1-aminohydantoin; N-(5-Nitro-2-furfurylideno)-1-aminohydantoina; N-(5-Nitro-2-furfurylideno)-1-aminohydantoina [Polish]; N-(5-nitro-2-furfurylidene)-1-aminohyda ntoin; 1-(((5-nitro-2-furanyl)methylene)amino)-2,4-imidazolidinedione; 1-((5-Nitrofurfurylidene)amino)hydantoin; 1-(5-Nitro-2-furfurylidenamino)hydantoin; 1-(5-Nitro-2-furfurylideneamino)hydantoin; 1-[(5-:nitrofurfurylidene)amino]hydantoin; 1-[(5-Nitrofurfurylidene)amino]hydantoin; 1-[(E)-(5-nitrofuran-2-yl)methylideneamino]imidazolidine-2,4-dione; 1-[[(5-Nitro-2-furanyl)methylene]amino]-2,4-imidazolidinedione; 1-{[(1E)-(5-nitro-2-furyl)methylene]amino}imidazolidine-2,4-dione; 1-{[(1E)-(5-nitrofuran-2-yl)methylidene]amino}imidazolidine-2,4-dione; 5-Nitrofurantoin DM7PQIK CP Procter And Gamble Pharmaceuticals Inc Sub Procter And Gamble Co DM7PQIK TC Antiinfective Agents DM7PQIK DT Small molecular drug DM7PQIK PC 6604200 DM7PQIK MW 238.16 DM7PQIK FM C8H6N4O5 DM7PQIK IC InChI=1S/C8H6N4O5/c13-6-4-11(8(14)10-6)9-3-5-1-2-7(17-5)12(15)16/h1-3H,4H2,(H,10,13,14)/b9-3+ DM7PQIK CS C1C(=O)NC(=O)N1/N=C/C2=CC=C(O2)[N+](=O)[O-] DM7PQIK IK NXFQHRVNIOXGAQ-YCRREMRBSA-N DM7PQIK IU 1-[(E)-(5-nitrofuran-2-yl)methylideneamino]imidazolidine-2,4-dione DM7PQIK CA CAS 67-20-9 DM7PQIK CB CHEBI:71415 DM7PQIK DE Urinary tract infection DMSM2KE ID DMSM2KE DMSM2KE DN Nitrofurazone DMSM2KE HS Approved DMSM2KE SN nitrofurazone; Nitrofural; Furacilin; 59-87-0; Furacin; Furacillin; Furacine; Aldomycin; Furaldon; Nifuzon; Actin-N; Furacycline; Furacoccid; Otofuran; Nitrofurazan; Monafuracin; Furaziline; Furacinetten; Babrocid; Nitrozone; Mastofuran; Furazone; Chemofuran; Mammex; Amifur; Alfucin; Furesol; Furazol W; 5-Nitro-2-furaldehyde semicarbazone; Monofuracin; Dermofural; Monafuracis; Furaseptyl; Furatsilin; Nitrofurol; Fuvacillin; Furametral; Biofuracina; Becafurazone; Nifucin; Ibiofural; Hemofuran; Furalone; Furacort; Eldezol; Vadrocid; Vabrocid; Furazyme DMSM2KE DT Small molecular drug DMSM2KE PC 5447130 DMSM2KE MW 198.14 DMSM2KE FM C6H6N4O4 DMSM2KE IC InChI=1S/C6H6N4O4/c7-6(11)9-8-3-4-1-2-5(14-4)10(12)13/h1-3H,(H3,7,9,11)/b8-3+ DMSM2KE CS C1=C(OC(=C1)[N+](=O)[O-])/C=N/NC(=O)N DMSM2KE IK IAIWVQXQOWNYOU-FPYGCLRLSA-N DMSM2KE IU [(E)-(5-nitrofuran-2-yl)methylideneamino]urea DMSM2KE CA CAS 59-87-0 DMSM2KE CB CHEBI:44368 DMSM2KE DE Skin burns; Bacterial infection DMQ2491 ID DMQ2491 DMQ2491 DN Nitroglycerin DMQ2491 HS Approved DMQ2491 SN nitroglycerin; Glyceryl trinitrate; Trinitroglycerin; Nitroglycerol; Nitrostat; Nitroglycerine; Nitro-dur; Minitran; Trinitroglycerol; 55-63-0; Nitroderm; Nitroglyn; Nitrospan; Nitronet; Tridil; Glycerol trinitrate; Transderm-nitro; Transderm Nitro; Epinitril; Susadrin; Perlinganit; Nitrolingual; Nitrolan; Sustonit; Nitrocine; Trinitrin; Natispray; Lenitral; Nitrong; Niong; Nitro-Bid; Nitroderm TTS; Trinitrosan; Rectogesic; Nitroglicerina; Cordipatch; Perglottal; Nitrorectal; Gilustenon; Nitroretard; Nitroplast; Corditrine; Trinitrolong; Adesitrin; Aldonitrin; Angibid; Angiolingual; Angiplex; Anglix; Angonist; Angorin; Anogesic; Buccal; Buccard; Cardabid; Cardamist; Cardinit; Cardiodisco; Cellegesic; Chitamite; Colenitral; Dauxona; Deponit; Diafusor; Discotrine; Dynamite; GTN; Glonoin; Glycerintrinitrate; Glyceroltrinitraat; Glyceryl; Glycerylnitrat; Glytrin; Herwicard; Herzer; Klavikordal; Lentonitrina; Millisrol; Minitram; Minitro; Mionitrat; Myocon; Myoglycerin; Myovin; NTG; Niglin; Niglycon; Nirmin; Nitora; Nitradisc; Nitrangin; Nitrek; Nitriderm; NitroBid; NitroCor; NitroDur; NitroMist; NitroQuick; NitroQuik; Nitroard; Nitrobaat; Nitrobukal; Nitrocap; Nitrocard; Nitrocerin; Nitroclyn; Nitrocontin; Nitrocot; Nitrodisc; Nitrodyl; Nitrogard; Nitrogliceryna; Nitroglin; Nitroject; Nitroletten; Nitrolin; Nitrolowe; Nitromel; Nitromex; Nitromint; Nitropatch; Nitropen; Nitropercuten; Nitroperlinit; Nitroprol; Nitropront; Nitroprontan; Nitrorex; Nitrostabilin; Nitrovis; Nysconitrine; Percutol; Perganit; Plastranit; Polnitrin; Ratiopharm; Soup; Suscard; Sustac; Sustak; TNG; Temponitrin; Trinalgon; Trinipatch; Triniplas; Trinitrol; Trinitron; Turicard; Vascana; Vasoglyn; Vasolator; Vernies; Willong; Blasting gelatin; Blasting oil; Gepan Nitroglicerin; Gilucor nitro; Glycerin trinitrate; Glycerine trinitrate; Glyceryl nitrate; NITRO IV; Neos nitro OPT; Niong Retard; Nitradisc Pad; Nitradisc TTS; Nitriderm TTS; Nitro Bid; Nitro Dur; Nitro Dur TTS; Nitro Mack Retard; Nitro Retard; Nitro Rorer; Nitrobid Oint; Nitrocontin Continus; Nitroderm TTS Ext; Nitrodyl TTS; Nitrol Ointment; Nitrolingual Spray; Nitromack Retard; Nitromint Aerosol; Nitromint Retard; Nitronal Aqueous; Nitrong Retard; Nitrong parenteral; Nitrozell retard; Percutol Oint; Spirit of glonoin; Tridil sublin; Trinitrin Tablets; Trinitrina Erba; Deponit 5; Deponit TTS 10; Deponit TTS 5; Nitrocine 5; Aquo-Trimitrosan; Coro-Nitro; Deponit-5; GTN-Pohl; IMX-150; MED-2002; MQX-503; Mi-Trates; Minitran (TN); NK-843; Natispray (TN); Nit-Ret; Nitrine-TDC; Nitro-Dur 10; Nitro-Dur 5; Nitro-Gesanit Retard; Nitro-Mack Retard; Nitro-Par; Nitro-Pflaster; Nitro-Span; Nitro-Time; Nitro-lent; NitrocapTD; Nitroderm TTS-5; Nitrogard-SR; Nitroglycerin (NG); Nitroglycerin-ACC; Nitrolingual Pump Spray (TN); Nitromist (TN); Nitrong-SR; Nitrospan (TN); Nitrostat (TN); SDM No 17; SK-106N; SK-866; SK-878; Top-Nitro; Transderm Nitro (TN); Transderm-N TTS; Transderm-Nitro TTS; Transiderm-nitro; Tridil (TN); Trinipatch (TN); Trinitrate, Glyceryl; Nitro-Dur (TN); Nitro-M-Bid; Nitro-bid (TN); Nitro-dur (TN); Transderm-nitro (TN); DWP-401 DMQ2491 TC Vasodilator Agents DMQ2491 DT Small molecular drug DMQ2491 PC 4510 DMQ2491 MW 227.09 DMQ2491 FM C3H5N3O9 DMQ2491 IC InChI=1S/C3H5N3O9/c7-4(8)13-1-3(15-6(11)12)2-14-5(9)10/h3H,1-2H2 DMQ2491 CS C(C(CO[N+](=O)[O-])O[N+](=O)[O-])O[N+](=O)[O-] DMQ2491 IK SNIOPGDIGTZGOP-UHFFFAOYSA-N DMQ2491 IU 1,3-dinitrooxypropan-2-yl nitrate DMQ2491 CA CAS 55-63-0 DMQ2491 CB CHEBI:28787 DMQ2491 DE Diabetic foot ulcer; Angina pectoris DMLUA2J ID DMLUA2J DMLUA2J DN Nitroprusside DMLUA2J HS Approved DMLUA2J SN Nitropress (TN); Nitroprusside sodium; Sodium nitroprusside (USP); Tox21_110314; Tox21_110314_1; 13755-38-9; 7304AF; A-8282; C07695; NITROPRUSSIDE SODIUM DIHYDRATE; C5FeN6O.2Na.2H2O; CAS-13755-38-9; CHEBI:9179; D00614; DSSTox_CID_21126; DSSTox_GSID_41126; DSSTox_RID_79630; DTXSID7041126; MFCD00149192; NCGC00166055-03; Na2[Fe(CN)5(NO)].2H2O; Sodium nitroferricyanide dihydrate, 99+%; Sodium nitroferricyanide dihydrate, reagent ACS; Sodium nitroferricyanide(III) dihydrate; Sodium nitroprusside hydrate (JAN) DMLUA2J PC 11953895 DMLUA2J MW 297.95 DMLUA2J FM C5H4FeN6Na2O3 DMLUA2J IC XRKMNJXYOFSTBE-UHFFFAOYSA-N DMLUA2J CS [C-]#N.[C-]#N.[C-]#N.[C-]#N.[C-]#N.[N-]=O.O.O.[Na+].[Na+].[Fe+4] DMLUA2J IK 1S/5CN.Fe.NO.2Na.2H2O/c5*1-2;;1-2;;;;/h;;;;;;;;;2*1H2/q5*-1;+4;-1;2*+1;; DMLUA2J IU disodium;iron(4+);nitroxyl anion;pentacyanide;dihydrate DMLUA2J CA CAS 13755-38-9 DMLUA2J CB CHEBI:9179 DMLUA2J DE Congestive heart failure DMM765C ID DMM765C DMM765C DN Nitroprusside DMM765C HS Approved DMM765C SN C07269; LS-187044 DMM765C TC Antihypertensive Agents DMM765C DT Small molecular drug DMM765C PC 11953891 DMM765C MW 215.94 DMM765C FM C5FeN6O DMM765C IC InChI=1S/5CN.Fe.NO/c5*1-2;;1-2/q5*-1;+6;-1 DMM765C CS [C-]#N.[C-]#N.[C-]#N.[C-]#N.[C-]#N.[N-]=O.[Fe+6] DMM765C IK CDLSWOALPINAJL-UHFFFAOYSA-N DMM765C IU iron(6+);nitroxyl anion;pentacyanide DMM765C DE Hypertension DMTHWBI ID DMTHWBI DMTHWBI DN Nitrous oxide DMTHWBI HS Approved DMTHWBI SN Distickstoffmonoxid; Lachgas; Stickdioxyd; Dinitrogen monoxide; Dinitrogen oxide; Factitious air; Gaz hilarant; Hyponitrous acid anhydride; Laughing gas; Nitrogen hypoxide; Nitrogenium oxydulatum; Nitrous oxide [JAN]; Oxido nitroso; Oxido nitroso [Spanish]; Oxyde nitreux; Stickdioxyd [German]; N2O; Nitrous oxide [UN1070] [Nonflammable gas]; Diazyne 1-oxide; Gas, Laughing; NITROUS-OXIDE; Nitrogen oxide (N2O); Nitrous oxide (TN); Nitrous oxide [Anaesthetics, volatile]; Nitrous oxide, compressed; Nitrous oxide, refrigerated liquid; Nitrous oxide, refrigerated liquid [UN2201] [Nonflammable gas]; Oxide, Nitrous; Protoxyde d'azote; Protoxyde d'azote [French]; Nitrous oxide (JP15/USP); Oxidodinitrogen(N-N); Stickstoff(I)-oxid DMTHWBI DT Small molecular drug DMTHWBI PC 948 DMTHWBI MW 44.013 DMTHWBI FM N2O DMTHWBI IC InChI=1S/N2O/c1-2-3 DMTHWBI CS [N-]=[N+]=O DMTHWBI IK GQPLMRYTRLFLPF-UHFFFAOYSA-N DMTHWBI IU nitrous oxide DMTHWBI CA CAS 10024-97-2 DMTHWBI CB CHEBI:17045 DMTHWBI DE Anxiety disorder DMAB9QE ID DMAB9QE DMAB9QE DN Nivolumab DMAB9QE HS Approved DMAB9QE CP Bristol-Myers Squibb DMAB9QE DT Monoclonal antibody DMAB9QE SQ Heavy Chain Sequence: QVQLVESGGGVVQPGRSLRLDCKASGITFSNSGMHWVRQAPGKGLEWVAVIWYDGSKRYYADSVKGRFTISRDNSKNTLFLQMNSLRAEDTAVYYCATNDDYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK >Light Chain SequenceEIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQSSNWPRTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC DMAB9QE DE Central nervous system lymphoma; Chronic myelogenous leukaemia; Diffuse large B-cell lymphoma; Follicular lymphoma; Malignant pleural mesothelioma; Multiple myeloma; Ovarian cancer; Pancreatic cancer; Prostate cancer; Small-cell lung cancer; Esophageal cancer; Gastric adenocarcinoma; Recurrent glioblastoma; Renal cell carcinoma; Triple negative breast cancer; Melanoma; Non-small-cell lung cancer DMGFV3Z ID DMGFV3Z DMGFV3Z DN Nizatidine DMGFV3Z HS Approved DMGFV3Z SN Acinon; Antizid; Axid; Calmaxid; Cronizat; Distaxid; Galitidin; Gastrax; Naxidine; Niatidine; Nizatidina; Nizatidinum; Nizax; Nizaxid; Panaxid; Tazac; Ulcosol; Ulxid; Zanizal; Zinga; Axid Ar; Nizatidina [Spanish]; Nizatidinum [Latin]; Splendil ER; LY 139037; Acinon (TN); Axid (TN); LY-139037; Tazac (TN); ZE-101; ZL-101; Nizatidine (JAN/USP/INN); Nizatidine [USAN:BAN:INN:JAN]; N-(2-(((2-((Dimethylamino)methyl)-4-thiazolyl)methyl)thio)ethyl)-N'-methyl-2-nitro-1,1-ethenediamine; N-(4-(6-Methylamino-7-nitro-2-thia-5-aza-6-hepten-1-yl)-2-thiazolylmethyl)-N,N-dimethylamin; (E)-1-N'-[2-[[2-(dimethylaminomethyl)-1,3-thiazol-4-yl]methylsulfanyl]ethyl]-1-N-methyl-2-nitroethene-1,1-diamine; (E)-N-[2-[[2-(dimethylaminomethyl)-1,3-thiazol-4-yl]methylsulfanyl]ethyl]-N'-methyl-2-nitroethene-1,1-diamine; (E)-N-{2-[({2-[(dimethylamino)methyl]-1,3-thiazol-4-yl}methyl)thio]ethyl}-N'-methyl-2-nitroethene-1,1-diamine DMGFV3Z CP Eli Lilly DMGFV3Z TC Antiulcer Agents DMGFV3Z DT Small molecular drug DMGFV3Z PC 3033637 DMGFV3Z MW 331.5 DMGFV3Z FM C12H21N5O2S2 DMGFV3Z IC InChI=1S/C12H21N5O2S2/c1-13-11(6-17(18)19)14-4-5-20-8-10-9-21-12(15-10)7-16(2)3/h6,9,13-14H,4-5,7-8H2,1-3H3/b11-6+ DMGFV3Z CS CN/C(=C\\[N+](=O)[O-])/NCCSCC1=CSC(=N1)CN(C)C DMGFV3Z IK SGXXNSQHWDMGGP-IZZDOVSWSA-N DMGFV3Z IU (E)-1-N'-[2-[[2-[(dimethylamino)methyl]-1,3-thiazol-4-yl]methylsulfanyl]ethyl]-1-N-methyl-2-nitroethene-1,1-diamine DMGFV3Z CA CAS 76963-41-2 DMGFV3Z CB CHEBI:7601 DMGFV3Z DE Acid-reflux disorder DMRJ7D1 ID DMRJ7D1 DMRJ7D1 DN Nomegestrol acetate DMRJ7D1 HS Approved DMRJ7D1 SN Lutenyl (TN) DMRJ7D1 CP Theramex DMRJ7D1 DT Small molecular drug DMRJ7D1 PC 91668 DMRJ7D1 MW 370.5 DMRJ7D1 FM C23H30O4 DMRJ7D1 IC InChI=1S/C23H30O4/c1-13-11-20-18(17-6-5-16(26)12-19(13)17)7-9-22(4)21(20)8-10-23(22,14(2)24)27-15(3)25/h11-12,17-18,20-21H,5-10H2,1-4H3/t17-,18-,20-,21+,22+,23+/m1/s1 DMRJ7D1 CS CC1=C[C@@H]2[C@H](CC[C@]3([C@H]2CC[C@@]3(C(=O)C)OC(=O)C)C)[C@@H]4C1=CC(=O)CC4 DMRJ7D1 IK IIVBFTNIGYRNQY-YQLZSBIMSA-N DMRJ7D1 IU [(8S,9S,10R,13S,14S,17R)-17-acetyl-6,13-dimethyl-3-oxo-1,2,8,9,10,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-17-yl] acetate DMRJ7D1 CA CAS 58652-20-3 DMRJ7D1 CB CHEBI:135564 DMRJ7D1 DE Breast cancer DMOUC09 ID DMOUC09 DMOUC09 DN Norepinephrine DMOUC09 HS Approved DMOUC09 SN norepinephrine; L-Noradrenaline; Levarterenol; 51-41-2; L-Norepinephrine; Levophed; (-)-Norepinephrine; L-arterenol; (R)-Noradrenaline; (R)-Norepinephrine; Levonor; Levonorepinephrine; Adrenor; Aktamin; Levonoradrenaline; Sympathin E; (R)-(-)-Norepinephrine; 4-[(1R)-2-amino-1-hydroxyethyl]benzene-1,2-diol; Noradrenalin; Norepirenamine; norepinephrinum; Noradrenalinum; Levoarterenol; Norartrinal; Nor-Epirenan; L-3,4-dihydroxyphenylethanolamine; Levarterenolo; Noreinefrina; Norepinefrina; Norepinephrinum; Levarterenolo [DCIT]; Nor adrenalin; Noradrenalina [Italian]; Norepinephrine Noradrenalin; LT03330026; ALBB-006229; Nor adrenalin (TN); Noradrenaline (JP15); Noreinefrina [INN-Spanish]; Norepinephrine (INN); Norepinephrine [INN:JAN]; Norepinephrinum [INN-Latin]; Norepinephrine l-Tartrate (1:1); D-(-)-Noradrenaline; D53D5E3A-2360-4CA9-8031-6C2CD4062FD5; L-alpha-(aminomethyl)-3,4-dihydroxybenzyl alcohol; L-1-(3,4-Dihydroxyphenyl)-2-aminoethanol; L-2-Amino-1-(3,4-dihydroxyphenyl)ethanol; (-)-(R)-Norepinephrine; (-)-Arterenol free base; (-)-alpha-(Aminomethyl)protocatechuyl alcohol; (R)-4-(2-Amino-1-hydroxyethyl)-1,2-benzenediol; 1,2-Benzenediol, 4-(2-amino-1-hydroxyethyl)-, (R)-(9CI); 4-[(1R)-2-Amino-1-hydroxyethyl]-1,2-benzenediol; Ecteinascidins DMOUC09 CP Bedford Laboratories DMOUC09 TC Vasoconstrictor Agents DMOUC09 DT Small molecular drug DMOUC09 PC 439260 DMOUC09 MW 169.18 DMOUC09 FM C8H11NO3 DMOUC09 IC InChI=1S/C8H11NO3/c9-4-8(12)5-1-2-6(10)7(11)3-5/h1-3,8,10-12H,4,9H2/t8-/m0/s1 DMOUC09 CS C1=CC(=C(C=C1[C@H](CN)O)O)O DMOUC09 IK SFLSHLFXELFNJZ-QMMMGPOBSA-N DMOUC09 IU 4-[(1R)-2-amino-1-hydroxyethyl]benzene-1,2-diol DMOUC09 CA CAS 51-41-2 DMOUC09 CB CHEBI:18357 DMOUC09 DE Sepsis DMTY169 ID DMTY169 DMTY169 DN Norethindrone DMTY169 HS Approved DMTY169 SN Activella; Anhydrohydroxynorprogesterone; Anovulatorio; Anovule; Brevicon; Brevinor; Camila; Ciclovulan; Conceplan;Conludaf; Conludag; Demulen; Errin; Estrinor; Ethinylnortestosterone; Ethynylmortestosterone; Ethynylnortestosterone; Gencept; Genora; Gestest; Jenest; Loestrin; Menzol; Microneth; Micronett; Micronor; Micronovum; Milli; Minovlar; Nelova; Nodiol; Noraethisteronum; Noralutin; Norcept; Norcolut; Norcolute; Noresthisterone; Norethadrone; Norethin; Norethindirone; Norethisteron; Norethisterone; Norethisteronum; Norethyndron; Norethynodron; Norethynodrone; Noretisterona; Noretisterone; Norfor; Norgestin; Noriday; Norluten; Norlutin; Norluton; Normapause; Norpregneninlone; Norpregneninolone; Norpregneninotone; Orlest; Proluteasi; Synphase; Triella; Utovlan; Utovlar; Component of Noriday; Norethindrone Norethisterone; Norethindrone [USAN]; Norethisterone [Progestins]; Noretisterone [DCIT]; Primolut N; Brevinor 21; Brevinor 28; Noriday 28; Ortho 1 35; Ortho 7 7 7; Ovysmen 1 35; SC 4640; Synphasic 28; Trinovum 21; Brevinor-1 21; Brevinor-1 28; Camila (TN); Jenest-28; Micronor (TN); Mini-Pe; Mini-pill; Nor-QD; Nora-BE; Norcept-E; Norethin 1/35 E; Norethin 1/50 M; Norethindrone (USP); Norethisterone (JP15); Norethisteronum [INN-Latin]; Noretisterona [INN-Spanish]; Ortho-Novum 1 35; Ortho-Novum 1 50; Ortho-Novum 7 7 7; Ovysmen 0.5 35; Primolut-N; Tri-Norinyl; Ethinyl-19-nortestosterone; Nor-Q.D; Primolut-N (TN); Nor-Q.D.; 17-Ethinyl-19-nortestosterone; 17-Ethynyl-17-hydroxyestr-4-en-3-one; 17-alpha-Ethynyl-19-nortestosterone; 17-alpha-Ethynyl-4-estren-17-ol-3-one; 17-ethynyl-17beta-hydroxyestr-4-en-3-one; 17.alpha.-Ethinyl-19-nortestosterone; 17.alpha.-Ethynyl-19-nortestosterone; 17.alpha.-Ethynyl-4-estren-17-ol-3-one; 17alpha-Ethinyl-19-nortestosterone; 17alpha-Ethynyl-19-nortestosterone; 17alpha-Ethynyl-4-estren-17-ol-3-one; 19-Nor-17-alpha-ethynyltestosterone; 19-Nor-17-ethinyltestosterone; 19-Nor-17.alpha.-ethynyltestosterone; 19-Nor-17alpa-ethynyltestosterone; 19-Nor-17alpha-ethynyltestosterone; 19-Nor-ethindrone; 19-Nor-ethinyl-4,5-testosterone; 19-Norethindrone; 19-Norethinyltestosterone; 19-Norethisterone; 4-Estren-17alpha-ethynyl-17beta-ol-3-one DMTY169 CP Parke Davis Div Warner Lambert Co DMTY169 TC Contraceptive Agents DMTY169 DT Small molecular drug DMTY169 PC 6230 DMTY169 MW 298.4 DMTY169 FM C20H26O2 DMTY169 IC InChI=1S/C20H26O2/c1-3-20(22)11-9-18-17-6-4-13-12-14(21)5-7-15(13)16(17)8-10-19(18,20)2/h1,12,15-18,22H,4-11H2,2H3/t15-,16+,17+,18-,19-,20-/m0/s1 DMTY169 CS C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC(=O)CC[C@H]34 DMTY169 IK VIKNJXKGJWUCNN-XGXHKTLJSA-N DMTY169 IU (8R,9S,10R,13S,14S,17R)-17-ethynyl-17-hydroxy-13-methyl-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-one DMTY169 CA CAS 68-22-4 DMTY169 CB CHEBI:7627 DMTY169 DE Solid tumour/cancer DMDGCQP ID DMDGCQP DMDGCQP DN Norethindrone acetate DMDGCQP HS Approved DMDGCQP SN Noresthisterone; Norethadrone; Norethisteron; Norethisterone; Norethisteronum; Norethyndron; Norethynodron; Norethynodrone; Noretisterona; Norfor; Norgestin; Noriday; Norluten; Norlutin; Norluton; Norpregneninlone; Norpregneninolone; Primolut-N; Proluteasi; Synphase; Triella; Utovlan; Utovlar; norethindrone; 19-Nor-ethindrone; 19-Norethisterone; 68-22-4; Anovulatorio; Anovule; Camila; Ciclovulan; Conludaf; Conludag; Ethinylnortestosterone; Gestest; Microneth; Micronett; Micronor; Micronovum; Mini-Pe; Mini-pill; Minovlar; Nor-QD; Noralutin; Norcolut; 1-(Ethylsulfonyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]-3-azetidineacetonitrile DMDGCQP PC 5832 DMDGCQP MW 340.5 DMDGCQP FM C22H28O3 DMDGCQP IC IMONTRJLAWHYGT-ZCPXKWAGSA-N DMDGCQP CS CC(=O)OC1(CCC2C1(CCC3C2CCC4=CC(=O)CCC34)C)C#C DMDGCQP IK 1S/C22H28O3/c1-4-22(25-14(2)23)12-10-20-19-7-5-15-13-16(24)6-8-17(15)18(19)9-11-21(20,22)3/h1,13,17-20H,5-12H2,2-3H3/t17-,18+,19+,20-,21-,22-/m0/s1 DMDGCQP IU [(8R,9S,10R,13S,14S,17R)-17-ethynyl-13-methyl-3-oxo-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-yl] acetate DMDGCQP CA CAS 51-98-9 DMDGCQP CB CHEBI:7628 DMDGCQP DE Menorrhagia DMIZ6W2 ID DMIZ6W2 DMIZ6W2 DN Norfloxacin DMIZ6W2 HS Approved DMIZ6W2 SN Baccidal; Barazan; Chibroxin; Fulgram; Lexinor; NFLX; Norflo; Norfloxacine; Norfloxacino; Norfloxacinum; Noroxin; Sebercim; Merck Brand of Norfloxacin; Norfloxacin Merck Brand; AM 0715; AM 715; AM0715; MK 0366; MK 366; MK0366; MK366; AM-0715; AM-715; Chibroxin (TN); Insensye (TN); MK-0366; MK-366; Norflohexal (TN); Norfloxacine [INN-French]; Norfloxacino [INN-Spanish]; Norfloxacinum [INN-Latin]; Norfocin (TN); Noroxin (TN); Nufloxib (TN); Roxin (TN); Utin (TN); Utinor (TN); Apo-Norflox (TN); Norfloxacin (JP15/USP/INN); Norfloxacin [USAN:BAN:INN:JAN]; Chibroxin, MK-366, Baccidal, Sebercim, Zoroxin, Norfloxacin; 1,4-Dihydro-1-ethyl-6-fluoro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid; 1-Ethyl-6-fluor-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-chinolincarbonsaeure; 1-Ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid; 1-Ethyl-6-fluoro-1,4-dihydro-4-oxo-7-[1-piperazinyl]-3-quinoline-carboxylic acid; 1-ethyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid; 1-ethyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydroquinoline-3-carboxylic acid; 1-ethyl-6-fluoro-4-oxo-7-piperazin-1-ylquinoline-3-carboxylic acid DMIZ6W2 TC Antibiotics DMIZ6W2 DT Small molecular drug DMIZ6W2 PC 4539 DMIZ6W2 MW 319.33 DMIZ6W2 FM C16H18FN3O3 DMIZ6W2 IC InChI=1S/C16H18FN3O3/c1-2-19-9-11(16(22)23)15(21)10-7-12(17)14(8-13(10)19)20-5-3-18-4-6-20/h7-9,18H,2-6H2,1H3,(H,22,23) DMIZ6W2 CS CCN1C=C(C(=O)C2=CC(=C(C=C21)N3CCNCC3)F)C(=O)O DMIZ6W2 IK OGJPXUAPXNRGGI-UHFFFAOYSA-N DMIZ6W2 IU 1-ethyl-6-fluoro-4-oxo-7-piperazin-1-ylquinoline-3-carboxylic acid DMIZ6W2 CA CAS 70458-96-7 DMIZ6W2 CB CHEBI:100246 DMIZ6W2 DE Bacterial infection DMYP4XC ID DMYP4XC DMYP4XC DN Norgestimate DMYP4XC HS Approved DMYP4XC SN Norgestimato; Norgestimatum; Dexnorgestrel acetime; Norgestrel oxime acetate; D 138; ORF 10131; RWJ 10131; Norgestimato [INN-Spanish]; Norgestimatum [INN-Latin]; ORF-10131; Ortho-Prefest; RWJ-10131; Norgestimate (USP/INN); Norgestimate [USAN:INN:BAN]; D-13beta-Ethyl-17alpha-ethynyl-17beta-acetoxygon-4-en-3-oneoxime; D-13-beta-Ethyl-17-alpha-ethynyl-17-beta-acetoxygon-4-en-3-one oxime; [(3E,8R,9S,10R,13S,14S,17R)-13-ethyl-17-ethynyl-3-hydroxyimino-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-yl] acetate; (+)-13-Ethyl-17-hydroxy-18,19-dinor-17alpha-pregn-4-en-20-yn-3-one oxime acetate (ester); (17-alpha)-17-(Acetyloxy)-13-ethyl-18,19-dinorpregn-4-en-20-yn-3-one 3-oxime; (17alpha)-17-(Acetyloxy)-13-ethyl-18,19-dinorpregn-4-en-20-yn-3-one 3-oxime; (3E)-17alpha-ethynyl-3-(hydroxyimino)-18a-homoestr-4-en-17beta-yl acetate DMYP4XC TC Contraceptive Agents DMYP4XC DT Small molecular drug DMYP4XC PC 6540478 DMYP4XC MW 369.5 DMYP4XC FM C23H31NO3 DMYP4XC IC InChI=1S/C23H31NO3/c1-4-22-12-10-19-18-9-7-17(24-26)14-16(18)6-8-20(19)21(22)11-13-23(22,5-2)27-15(3)25/h2,14,18-21,26H,4,6-13H2,1,3H3/b24-17+/t18-,19+,20+,21-,22-,23-/m0/s1 DMYP4XC CS CC[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)OC(=O)C)CCC4=C/C(=N/O)/CC[C@H]34 DMYP4XC IK KIQQMECNKUGGKA-NMYWJIRASA-N DMYP4XC IU [(3E,8R,9S,10R,13S,14S,17R)-13-ethyl-17-ethynyl-3-hydroxyimino-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-yl] acetate DMYP4XC CA CAS 20799-27-3 DMYP4XC CB CHEBI:50815 DMYP4XC DE Contraception DM4KDYJ ID DM4KDYJ DM4KDYJ DN Nortriptyline DM4KDYJ HS Approved DM4KDYJ SN Acetexa; Allegron; Altilev; Ateben; Avantyl; Aventyl; Demethylamitriptylene; Demethylamitriptyline; Demethylamitryptyline; Desitriptilina; Desitriptyline; Desmethylamitriptylin; Desmethylamitriptyline; Lumbeck; Noramitriptyline; Noritren; Nortrilen; Nortriptilina; Nortriptylinum; Nortryptiline; Nortryptyline; Pamelor; Psychostyl; Sensaval; Sesaval; Vividyl; AVENTYL HCL; Nortriptilina [DCIT]; Nortriptylene hydrochloride; Pamelor hydrochloride; Sensival Ventyl; NCI169453; Allegron (TN); Aventyl (TN); Norpress (TN); Nortrilen (TN); Nortriptyline (INN); Nortriptyline [INN:BAN]; Nortriptylinum [INN-Latin]; Pamelor (TN); Sensoval (TN); N-Methyl-3-(10,11-dihydro-5H-dibenzo(a,d)cyclohepten-5-yliden)propylamin; (2)10,11-Dihydro-N-methyl-5H-dibenzo[a,d]cycloheptene-.delta.5.gamma.-propylamine; 10,11-Dihydro-5-(3-methylaminopropylidene)-5H-dibenzo(a,d)(1,4)cycloheptene; 10,11-Dihydro-N-methyl-5H-dibenzo(a,d)cycloheptene-delta(5,gamma)-propylamine; 10,11-dihydro-N-methyl-5H-dibenzo[a,d]cycloheptene-Delta(5,gamma)-propylamine; 3-(10,11-Dihydro-5H-dibenzo(a,d)cyclohepten-5-ylidene)-N-methylpropylamine; 3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine; 3-(10,11-dihydro-5H-dibenzo[a,d][7]annulen-5-ylidene)-N-methylpropan-1-amine; 5-(3-(Methylamino)propylidene)dibenzo(a,e)cyclohepta(1,5)diene; 5-(3-Methylaminopropylidene)-10,11-dihydro-5H-dibenzo(a,d)cycloheptene; 5-(alpha-Methylaminopropylidene)dibenzo(a,d)cyclohepta(1,4)diene DM4KDYJ TC Antidepressants DM4KDYJ DT Small molecular drug DM4KDYJ PC 4543 DM4KDYJ MW 263.4 DM4KDYJ FM C19H21N DM4KDYJ IC InChI=1S/C19H21N/c1-20-14-6-11-19-17-9-4-2-7-15(17)12-13-16-8-3-5-10-18(16)19/h2-5,7-11,20H,6,12-14H2,1H3 DM4KDYJ CS CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31 DM4KDYJ IK PHVGLTMQBUFIQQ-UHFFFAOYSA-N DM4KDYJ IU N-methyl-3-(2-tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,11,13-hexaenylidene)propan-1-amine DM4KDYJ CA CAS 72-69-5 DM4KDYJ CB CHEBI:7640 DM4KDYJ DE Depression DMRFWGK ID DMRFWGK DMRFWGK DN Novobiocin DMRFWGK HS Approved DMRFWGK SN Albamix; Albamycin; Cardelmycin; Cathocin; Cathomycin; Inamycin; NOV; Novobiocina; Novobiocine; Novobiocinum; Robiocina; Sirbiocina; Spheromycin; Stilbiocina; Streptonivicin; Crystallinic acid; Novobiocin sodium salt; PA 93; U 6391; Albamycin (TN); Antibiotic PA-93; Novo-R; Novobiocin [INN:BAN]; Novobiocina [INN-Spanish]; Novobiocine [INN-French]; Novobiocinum [INN-Latin]; Streptonivicin (*Sodium salt*); [(3R,4S,5R,6R)-5-hydroxy-6-[2-hydroxy-3-[[4-hydroxy-3-(3-methylbut-2-enyl)benzoyl]amino]-8-methyl-4-oxochromen-7-yl]oxy-3-methoxy-2,2-dimethyloxan-4-yl] carbamate; N-[7-[[3-O-(Aminocarbonyl)-6-deoxy-5-C-methyl-4-O-methyl-.beta.-L-lyxo-hexopyranosyl]oxy]-4-hydroxy-8-methyl-2-oxo-2H-1-benzopyran-3-yl]-4-hydroxy-3-(3-methyl-2-butenyl); (3R,4S,5R,6R)-5-hydroxy-6-{[4-hydroxy-3-({[4-hydroxy-3-(3-methylbut-2-en-1-yl)phenyl]carbonyl}amino)-8-methyl-2-oxo-2H-chromen-7-yl]oxy}-3-methoxy-2,2-dimethyltetrahydro-2H-pyran-4-yl carbamate; (3r,4s,5r,6r)-5-hydroxy-6-[(2-hydroxy-3-{[4-hydroxy-3-(3-methylbut-2-en-1-yl)benzoyl]amino}-8-methyl-4-oxo-4h-chromen-7-yl)oxy]-3-methoxy-2,2-dimethyltetrahydro-2h-pyran-4-yl carbamate(non-preferred name); 7-(3-(O-Carbamoyl)-4-(O-methyl)-5,5-dimethyl-alpha-L-lyxopyranosyloxy)-4-hydroxy-3-(4-hydroxy-3-(3-methyl-2-butenyl)benzamidol)-8-methylcumarin; 7-(Carbamoyltetrahydro-3-hydroxy-5-methoxy-6,6-dimethylpyran-2-yloxy)-4-hydroxy-3-(4-hydroxy-3-(3-methylbut-2-enyl)benzamide)-8-methyl-2H-chromen-2-one DMRFWGK CP Pfizer Pharmaceuticals DMRFWGK TC Antibiotics DMRFWGK DT Small molecular drug DMRFWGK PC 54675769 DMRFWGK MW 612.6 DMRFWGK FM C31H36N2O11 DMRFWGK IC InChI=1S/C31H36N2O11/c1-14(2)7-8-16-13-17(9-11-19(16)34)27(37)33-21-22(35)18-10-12-20(15(3)24(18)42-28(21)38)41-29-23(36)25(43-30(32)39)26(40-6)31(4,5)44-29/h7,9-13,23,25-26,29,34-36H,8H2,1-6H3,(H2,32,39)(H,33,37)/t23-,25+,26-,29-/m1/s1 DMRFWGK CS CC1=C(C=CC2=C1OC(=O)C(=C2O)NC(=O)C3=CC(=C(C=C3)O)CC=C(C)C)O[C@H]4[C@@H]([C@@H]([C@H](C(O4)(C)C)OC)OC(=O)N)O DMRFWGK IK YJQPYGGHQPGBLI-KGSXXDOSSA-N DMRFWGK IU [(3R,4S,5R,6R)-5-hydroxy-6-[4-hydroxy-3-[[4-hydroxy-3-(3-methylbut-2-enyl)benzoyl]amino]-8-methyl-2-oxochromen-7-yl]oxy-3-methoxy-2,2-dimethyloxan-4-yl] carbamate DMRFWGK CA CAS 303-81-1 DMRFWGK CB CHEBI:28368 DMRFWGK DE Bacterial infection DM6ZPLQ ID DM6ZPLQ DM6ZPLQ DN Novolimus DM6ZPLQ HS Approved DM6ZPLQ CP Elixir Medical DM6ZPLQ PC 9854320 DM6ZPLQ MW 900.1 DM6ZPLQ FM C50H77NO13 DM6ZPLQ IC InChI=1S/C50H77NO13/c1-29-15-11-10-12-16-30(2)40(53)27-37-20-18-35(7)50(60,64-37)47(57)48(58)51-22-14-13-17-38(51)49(59)63-42(32(4)25-36-19-21-39(52)43(26-36)61-8)28-41(54)31(3)24-34(6)45(56)46(62-9)44(55)33(5)23-29/h10-12,15-16,24,29,31-33,35-40,42-43,45-46,52-53,56,60H,13-14,17-23,25-28H2,1-9H3/b12-10+,15-11+,30-16+,34-24+/t29-,31-,32-,33-,35-,36+,37+,38+,39-,40+,42+,43-,45-,46+,50-/m1/s1 DM6ZPLQ CS C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)O DM6ZPLQ IK ZHYGVVKSAGDVDY-QQQXYHJWSA-N DM6ZPLQ IU (1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18,30-trihydroxy-12-[(2R)-1-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]propan-2-yl]-19-methoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone DM6ZPLQ CA CAS 151519-50-5 DM6ZPLQ DE Artery stenosis DMRSX53 ID DMRSX53 DMRSX53 DN nusinersen DMRSX53 HS Approved DMRSX53 SN BIIB 058; IONIS-SMNRx; ISIS-396443; Spinraza DMRSX53 CP Biogen/Ionis Pharmaceuticals DMRSX53 DT Antisense drug DMRSX53 SQ 5'-UCACUUUCAUAAUGCUGG DMRSX53 DE Spinal muscular atrophy DM63QS9 ID DM63QS9 DM63QS9 DN Nystatin DM63QS9 HS Approved DM63QS9 SN Biofanal; Comycin; Diastatin; Fungicidin; Herniocid; Korostatin; Moronal; Myconystatin; Mycostatin; Mykinac; Mykostatyna; Nilstat; Nistatin; Nistatina; Nyamyc; Nyotran; Nystaform; Nystan; Nystatine; Nystatinum; Nystatyna; Nystavescent; Nystex; Nystop; Stamicin; Stamycin; Terrastatin; Candex Lotion; Mycostatin Pastilles; Nystatin A; Nystatin G; Nystatin preparation; Nystatyna [Polish]; Zydin E; Barstatin 100; Mycostatin 20; Nystatin A1; Nystatin A2; Nystatin A3; Animax (TN); Candio-hermal; Flagystatin II (TN); Infestat (TN); Korostatin (TN); Lystin (TN); Moronal (antibiotic); Mycostatin (TN); Mykacet (TN); Mykinac (TN); Mytrex (TN); Nidoflor (TN); Nilstat (TN); Nistatina (TN); Nistatina [INN-Spanish]; Nysert (TN);Nystaform (TN); Nystalocal (TN); Nystamont (TN); Nystan (TN); Nystatin LF (liposome); Nystatine [INN-French]; Nystatinum [INN-Latin]; Nystex (TN); Nystop (TN); O-V Statin; Myco-Triacet II (TN); Mycolog-II (TN); Nystatin A1, A2, A3 complex; Nystatin [INN:BAN:JAN]; (1S,15S,16R,17R,18S,19E,21E,25E,27E,29E,31E)-33-[(3-amino-3,6-dideoxy-a-D-mannopyranosyl)oxy]-1,3,4,7,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-14,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,25,27,29,31-hexaene-36-carboxylic acid; (1S,15S,16R,17R,18S,19E,21E,25E,27E,29E,31E)-33-[(3-amino-3,6-dideoxy-alpha-D-mannopyranosyl)oxy]-1,3,4,7,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-14,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,25,27,29,31-hexaene-36-carboxylic acid; (4E,6E,8E,10E,14E,16E)-3-[(2R,3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-19,25,27,29,32,33,35,37-octahydroxy-18,20,21-trimethyl-23-oxo-22,39-dioxabicyclo[33.3.1]nonatriaconta-4,6,8,10,14,16-hexaene-38-carboxylic acid; (4E,6E,8E,10E,14E,16E,18S,19R,20R,21S,35S)-3-[(2S,3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-19,25,27,29,32,33,35,37-octahydroxy-18,20,21-trimethyl-23-oxo-22,39-dioxabicyclo[33.3.1]nonatriaconta-4,6,8,10,14,16-hexaene-38-carboxylic acid; (4E,6E,8E,10E,14E,16E,18S,19R,21S,35S)-3-[(3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-19,25,27,29,32,33,35,37-octahydroxy-18,20,21-trimethyl-23-oxo-22,39-dioxabicyclo[33.3.1]nonatriaconta-4,6,8,10,14,16-hexaene-38-carboxylic acid DM63QS9 CP Bristol-Myers Squibb DM63QS9 TC Antifungal Agents DM63QS9 DT Small molecular drug DM63QS9 PC 6433272 DM63QS9 MW 926.1 DM63QS9 FM C47H75NO17 DM63QS9 IC InChI=1S/C47H75NO17/c1-27-17-15-13-11-9-7-5-6-8-10-12-14-16-18-34(64-46-44(58)41(48)43(57)30(4)63-46)24-38-40(45(59)60)37(54)26-47(61,65-38)25-36(53)35(52)20-19-31(49)21-32(50)22-33(51)23-39(55)62-29(3)28(2)42(27)56/h5-6,8,10-18,27-38,40-44,46,49-54,56-58,61H,7,9,19-26,48H2,1-4H3,(H,59,60)/b6-5+,10-8+,13-11+,14-12+,17-15+,18-16+/t27-,28-,29-,30+,31?,32?,33?,34?,35?,36?,37?,38?,40?,41-,42+,43+,44-,46+,47+/m0/s1 DM63QS9 CS C[C@H]1/C=C/C=C/CC/C=C/C=C/C=C/C=C/C(CC2C(C(C[C@](O2)(CC(C(CCC(CC(CC(CC(=O)O[C@H]([C@@H]([C@@H]1O)C)C)O)O)O)O)O)O)O)C(=O)O)O[C@@H]3[C@H]([C@H]([C@@H]([C@H](O3)C)O)N)O DM63QS9 IK VQOXZBDYSJBXMA-RKEBNKJGSA-N DM63QS9 IU (1S,15S,16R,17R,18S,19E,21E,25E,27E,29E,31E)-33-[(2S,3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-1,3,4,7,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-14,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,25,27,29,31-hexaene-36-carboxylic acid DM63QS9 CA CAS 1400-61-9 DM63QS9 CB CHEBI:473992 DM63QS9 DE Fungal infection DM3Q1SM ID DM3Q1SM DM3Q1SM DN Obeticholic acid DM3Q1SM HS Approved DM3Q1SM SN INT747; INT-747; 6-ethylchenodeoxycholic acid; 6-ECDCA; OCA; 6-Et CDCA DM3Q1SM CP Intercept DM3Q1SM DT Small molecular drug DM3Q1SM PC 447715 DM3Q1SM MW 420.6 DM3Q1SM FM C26H44O4 DM3Q1SM IC InChI=1S/C26H44O4/c1-5-17-21-14-16(27)10-12-26(21,4)20-11-13-25(3)18(15(2)6-9-22(28)29)7-8-19(25)23(20)24(17)30/h15-21,23-24,27,30H,5-14H2,1-4H3,(H,28,29)/t15-,16-,17-,18-,19+,20+,21+,23+,24-,25-,26-/m1/s1 DM3Q1SM CS CC[C@@H]1[C@@H]2C[C@@H](CC[C@@]2([C@H]3CC[C@]4([C@H]([C@@H]3[C@@H]1O)CC[C@@H]4[C@H](C)CCC(=O)O)C)C)O DM3Q1SM IK ZXERDUOLZKYMJM-ZWECCWDJSA-N DM3Q1SM IU (4R)-4-[(3R,5S,6R,7R,8S,9S,10S,13R,14S,17R)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid DM3Q1SM CA CAS 459789-99-2 DM3Q1SM CB CHEBI:43602 DM3Q1SM DE Primary biliary cholangitis; Insomnia DM3BVAE ID DM3BVAE DM3BVAE DN Obinutuzumab DM3BVAE HS Approved DM3BVAE SN GA101/RG7159 DM3BVAE CP Biogen Idec; Genentech DM3BVAE DT Antibody DM3BVAE DE Chronic lymphocytic leukaemia; Haematological malignancy DMEZ2KH ID DMEZ2KH DMEZ2KH DN Ocrelizumab DMEZ2KH HS Approved DMEZ2KH SN Ocrelizumab (USAN); Ocrelizumab (genetical recombination); Ocrelizumab (genetical recombination) (JAN) DMEZ2KH CP Roche/Genentech DMEZ2KH DT Antibody DMEZ2KH DE Multiple sclerosis; Diffuse large B-cell lymphoma DM7AVGW ID DM7AVGW DM7AVGW DN Ocriplasmin DM7AVGW HS Approved DM7AVGW CP ThromboGenics DM7AVGW SQ Protein sequence for the truncated heavy chain: APSFDCGKPQVEPKKCPGR >Protein sequence for the light chain VVGGCVAHPHSWPWQVSLRTRFGMHFCGGTLISPEWVLTAAHCLEKSPRPSSYKVILGAHQEVNLEPHVQEIEVSRLFLEPTRKDIALLKLSSPAVITDKVIPACLPSPNYVVADRTECFITGWGETQGTFGAGLLKEAQLPVIENKVCNRYEFLNGRVQSTELCAGHLAGGTDSCQGDSGGPLVCFEKDKYILQGVTSWGLGCARPNKPGVYVRVSRFVTWIEGVMRNN DM7AVGW DE Symptomatic vitreomacular adhesion DMHIDCJ ID DMHIDCJ DMHIDCJ DN Octreotide DMHIDCJ HS Approved DMHIDCJ SN Longastatin; Octreotida; Octreotidum; Sandostatine; Octreotida [Spanish]; Octreotide Acetate Salt; Octreotidum [Latin]; DRG-0115; HS-2020; Octreotide-LAR; SAN 201-995; SM 201-995; SMS 201-995; Sandostatin (TN); Sandoz 201-995; Octreotide (USAN/INN); Octreotide [USAN:INN:BAN]; SMS-201-995; Zacycloicosane-4-carboxamide acetate; D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-L-cysteinyl-L-threoninol cyclic (2-7)-disulfide; D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L-cysteinamide cyclic (2-7)-disulfide; L-Cysteinamide, D-phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-(2-hydroxy-1-(hydroxymethyl)propyl)-, cyclic (2->7)-disulfide; D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L-cysteinamide cyclic (2->7)-disulfide; 10-(4-Aminobutyl)-19-((2-amino-3-phenylpropanoyl)amino)-16-benzyl-7-(1-hydroxyethyl)-N-(2-hydroxy-1-(hydroxymethyl)propyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaa;10-(4-aminobutyl)-19-[(2-amino-3-phenylpropanoyl)amino]-16-benzyl-N-(1,3-dihydroxybutan-2-yl)-7-(1-hydroxyethyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide; 10-(4-aminobutyl)-19-[(2-amino-3-phenylpropanoyl)amino]-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-(1-hydroxyethyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide DMHIDCJ CP Norvatis Phamaceuticals Corporation DMHIDCJ TC Anabolic Agents DMHIDCJ DT Small molecular drug DMHIDCJ PC 448601 DMHIDCJ MW 1019.2 DMHIDCJ FM C49H66N10O10S2 DMHIDCJ IC InChI=1S/C49H66N10O10S2/c1-28(61)39(25-60)56-48(68)41-27-71-70-26-40(57-43(63)34(51)21-30-13-5-3-6-14-30)47(67)54-37(22-31-15-7-4-8-16-31)45(65)55-38(23-32-24-52-35-18-10-9-17-33(32)35)46(66)53-36(19-11-12-20-50)44(64)59-42(29(2)62)49(69)58-41/h3-10,13-18,24,28-29,34,36-42,52,60-62H,11-12,19-23,25-27,50-51H2,1-2H3,(H,53,66)(H,54,67)(H,55,65)(H,56,68)(H,57,63)(H,58,69)(H,59,64)/t28-,29-,34-,36+,37+,38-,39-,40+,41+,42+/m1/s1 DMHIDCJ CS C[C@H]([C@H]1C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)[C@@H](CC5=CC=CC=C5)N)C(=O)N[C@H](CO)[C@@H](C)O)O DMHIDCJ IK DEQANNDTNATYII-OULOTJBUSA-N DMHIDCJ IU (4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-19-[[(2R)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-[(1R)-1-hydroxyethyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide DMHIDCJ CA CAS 83150-76-9 DMHIDCJ DE Acromegaly DMZK0FQ ID DMZK0FQ DMZK0FQ DN Oestradiol valerate and dienogest DMZK0FQ HS Approved DMZK0FQ SN Dienogest; 65928-58-7; Dienogestrel; Dienogestum; Dienogestril; Dinagest; Natazia; Endometrion; Visanne; STS-557; STS 557; Dienogestum [Latin]; UNII-46M3EV8HHE; MJR-35; 17alpha-17-Hydroxy-3-oxo-19-norpregna-4,9-diene-21-nitrile; BAY86-5258; BAY 86-5258; 46M3EV8HHE; CHEBI:70708; 17-alpha-Cyanomethyl-17-beta-hydroxy-estra-4,9(10)-dien-3-one; 2-[(8S,13S,14S,17R)-17-hydroxy-13-methyl-3-oxo-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-17-yl]acetonitrile; 17-alpha-Cyanomethyl-17-beta-hydroxyestra-4,9(10)-diene-3-one; Natazia (TN) DMZK0FQ CP Bayer DMZK0FQ DT Small molecular drug DMZK0FQ PC 68861 DMZK0FQ MW 311.4 DMZK0FQ FM C20H25NO2 DMZK0FQ IC InChI=1S/C20H25NO2/c1-19-8-6-16-15-5-3-14(22)12-13(15)2-4-17(16)18(19)7-9-20(19,23)10-11-21/h12,17-18,23H,2-10H2,1H3/t17-,18+,19+,20-/m1/s1 DMZK0FQ CS C[C@]12CCC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@]2(CC#N)O DMZK0FQ IK AZFLJNIPTRTECV-FUMNGEBKSA-N DMZK0FQ IU 2-[(8S,13S,14S,17R)-17-hydroxy-13-methyl-3-oxo-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-17-yl]acetonitrile DMZK0FQ CA CAS 65928-58-7 DMZK0FQ CB CHEBI:70708 DMZK0FQ DE Endometriosis; Contraception DM295PR ID DM295PR DM295PR DN Ofatumumab DM295PR HS Approved DM295PR SN Arzerra (TN) DM295PR CP GlaxoSmithKline DM295PR DT Antibody DM295PR SQ Ofatumumab Heavy Chain: EVQLVESGGGLVQPGRSLRLSCAASGFTFNDYAMHWVRQAPGKGLEWVSTISWNSGSIGYADSVKGRFTISRDNAKKSLYLQMNSLRAEDTALYYCAKDIQYGNYYYGMDVWGQGTTVTVSSASTKGPSVFPLAPGSSKSTSGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEP >Ofatumumab Light ChainEIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPITFGQGTRLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR DM295PR DE Chronic lymphocytic leukaemia; Rheumatoid arthritis; Diffuse large B-cell lymphoma; Non-hodgkin lymphoma DM0VQN3 ID DM0VQN3 DM0VQN3 DN Ofloxacin DM0VQN3 HS Approved DM0VQN3 SN Bactocin; DEXTROFLOXACINE; Danoflox; Effexin; Exocin; Exocine; Flobacin; Flodemex; Flotavid; Flovid; Floxal; Floxil; Floxin; Floxstat; Fugacin; Inoflox; Kinflocin; Kinoxacin; Liflox; Loxinter; Marfloxacin; Medofloxine; Mergexin; Novecin; Nufafloqo; OFLX; OFX; Obide; Occidal; Ocuflox; Ofcin; Oflin; Oflocee; Oflocet; Oflocin; Oflodal; Oflodex; Oflodura; Oflox; Ofloxacina; Ofloxacine; Ofloxacino; Ofloxacinum; Ofloxin; Ofus; Onexacin; Operan; Orocin; Otonil; Oxaldin; Pharflox; Praxin; Puiritol; Qinolon; Qipro; Quinolon; Quotavil; Rilox; Sinflo; Tabrin; Taravid; Tariflox; Tarivid; Telbit; Tructum; Viotisone; Visiren; XED; Zanocin; Floxin otic; Ofloxacin Otic; Ofloxacina [DCIT]; Ofloxacine [French]; Ofloxacino [Spanish]; Ofloxacinum [Latin]; Uro Tarivid; DL 8280; HOE 280; O 8757; ORF 18489; PT 01; DL-8280; FLOXIN IN DEXTROSE 5%; FLOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER; Floxin Otic (TN); HOE-280; Hoe-280; Marfloxacin (TN); O-Flox; ORF-28489; Ocuflox (TN); Ru-43280; WP-0405; Ofloxacin (JP15/USP/INN); Ofloxacin [USAN:BAN:INN:JAN]; Ofloxacin, (S)-Isomer; DL-8280, HOE-280, Exocin, Flobacin, Floxin, Floxil, Monoflocet, Ofloxacin; (+-)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid; (+/-)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperaz inyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid; (+/-)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid; (+/-)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid; (+/-)-Floxin; (-)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)(1,4)benzoxazin-6-carbonsaeure; 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid DM0VQN3 CP Janssen Pharmaceutica DM0VQN3 TC Antibiotics DM0VQN3 DT Small molecular drug DM0VQN3 PC 4583 DM0VQN3 MW 361.4 DM0VQN3 FM C18H20FN3O4 DM0VQN3 IC InChI=1S/C18H20FN3O4/c1-10-9-26-17-14-11(16(23)12(18(24)25)8-22(10)14)7-13(19)15(17)21-5-3-20(2)4-6-21/h7-8,10H,3-6,9H2,1-2H3,(H,24,25) DM0VQN3 CS CC1COC2=C3N1C=C(C(=O)C3=CC(=C2N4CCN(CC4)C)F)C(=O)O DM0VQN3 IK GSDSWSVVBLHKDQ-UHFFFAOYSA-N DM0VQN3 IU 7-fluoro-2-methyl-6-(4-methylpiperazin-1-yl)-10-oxo-4-oxa-1-azatricyclo[7.3.1.05,13]trideca-5(13),6,8,11-tetraene-11-carboxylic acid DM0VQN3 CA CAS 82419-36-1 DM0VQN3 CB CHEBI:7731 DM0VQN3 DE Bacterial infection DMQ4PKA ID DMQ4PKA DMQ4PKA DN Olamufloxacin DMQ4PKA HS Approved DMQ4PKA SN Olamufloxacin; HSR-903; UNII-LJG8KL1435; HSR 903; LJG8KL1435; J-502473; (S)-5-Amino-7-(7-amino-5-azaspiro[2.4]heptan-5-yl)-1-cyclopropyl-6-fluoro-8-methyl-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; (S)-(-)-5-Amino-7-(7-amino-5-azaspiro[2,4]hept-5-yl)-1-cyclopropyl-6-fluoro-1,4-dihydro-8-methyl-4-oxoquinoline-3-carboxylic acid; 5-amino-7-[(7S)-7-amino-5-azaspiro[2.4]heptan-5-yl]-1-cyclopropyl-6-fluoro-8-methyl-4-oxo-quinoline-3-carboxylic acid; Olamufloxacin [INN]; AC1Q5RCW; AC1L9XAZ; SCHEMBL1851976 DMQ4PKA PC 477670 DMQ4PKA MW 386.4 DMQ4PKA FM C20H23FN4O3 DMQ4PKA IC InChI=1S/C20H23FN4O3/c1-9-16-13(18(26)11(19(27)28)6-25(16)10-2-3-10)15(23)14(21)17(9)24-7-12(22)20(8-24)4-5-20/h6,10,12H,2-5,7-8,22-23H2,1H3,(H,27,28)/t12-/m1/s1 DMQ4PKA CS CC1=C2C(=C(C(=C1N3CC(C4(C3)CC4)N)F)N)C(=O)C(=CN2C5CC5)C(=O)O DMQ4PKA IK LEILBPMISZFZQK-GFCCVEGCSA-N DMQ4PKA IU 5-amino-7-[(7S)-7-amino-5-azaspiro[2.4]heptan-5-yl]-1-cyclopropyl-6-fluoro-8-methyl-4-oxoquinoline-3-carboxylic acid DMQ4PKA CA CAS 167887-97-0 DMQ4PKA DE Bacterial infections DMPFN6Y ID DMPFN6Y DMPFN6Y DN Olanzapine DMPFN6Y HS Approved DMPFN6Y SN Lanzac; Midax; Olansek; Olanzapina; Olanzapinum; Symbyax; Zalasta; Zydis; Zyprexa; Eli Lilly brand of olanzapine; Lilly brand of olanzapine; Zyprexa Intramuscular; Zyprexa Velotab; Zyprexa Zydis; LY 170053; ALKS-7921; KS-1090; LY-170052; LY-170053; Olanzapine (OLA); Olanzapine [USAN:INN]; Olzapin (TN); Rexapin (TN); Zalasta (TN); Zolafren (TN); Zydis (TN); Zyprexa (TN); Olanzapine (JAN/USAN/INN); 2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno(2,3-b)(1,5)benzodiazepine; 2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine; 2-methyl-4-(4-methyl-1-piperazinyl)-10 H-thieno[2,3-b ] [1,5]benzodiazepine; 2-methyl-4-(4-methylpiperazin-1-yl)-10H-thieno[2,3-b][1,5]benzodiazepine; 2-methyl-4-(4-methylpiperazin-1-yl)-5H-thieno[2,3-b][1,5]benzodiazepine; 2-methyl-4-(4-methylpiperazin-1-yl)-5H-thieno[3,2-c][1,5]benzodiazepine DMPFN6Y CP Eli Lilly DMPFN6Y TC Antipsychotic Agents DMPFN6Y DT Small molecular drug DMPFN6Y PC 135398745 DMPFN6Y MW 312.4 DMPFN6Y FM C17H20N4S DMPFN6Y IC InChI=1S/C17H20N4S/c1-12-11-13-16(21-9-7-20(2)8-10-21)18-14-5-3-4-6-15(14)19-17(13)22-12/h3-6,11,19H,7-10H2,1-2H3 DMPFN6Y CS CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C DMPFN6Y IK KVWDHTXUZHCGIO-UHFFFAOYSA-N DMPFN6Y IU 2-methyl-4-(4-methylpiperazin-1-yl)-10H-thieno[2,3-b][1,5]benzodiazepine DMPFN6Y CA CAS 132539-06-1 DMPFN6Y CB CHEBI:7735 DMPFN6Y DE Schizophrenia DM0Y49P ID DM0Y49P DM0Y49P DN Olanzapine/fluoxetine combination DM0Y49P HS Approved DM0Y49P SN Symbyax (Zyprexa/Prozac) DM0Y49P CP Eli Lilly; Eli Lilly & Co DM0Y49P DT Small molecular drug DM0Y49P PC 24848071 DM0Y49P DE Depression DM8QB1D ID DM8QB1D DM8QB1D DN Olaparib DM8QB1D HS Approved DM8QB1D SN AZD 2281; AZD2281; AZD-2281; Acylpiperazine analogue, 47; KU-0059436; KU-59436; Olaparib, KU-0059436, AZD2281,KU0059436, AZD2281; 4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one; 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one DM8QB1D CP AstraZeneca DM8QB1D DT Small molecular drug DM8QB1D PC 23725625 DM8QB1D MW 434.5 DM8QB1D FM C24H23FN4O3 DM8QB1D IC InChI=1S/C24H23FN4O3/c25-20-8-5-15(14-21-17-3-1-2-4-18(17)22(30)27-26-21)13-19(20)24(32)29-11-9-28(10-12-29)23(31)16-6-7-16/h1-5,8,13,16H,6-7,9-12,14H2,(H,27,30) DM8QB1D CS C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F DM8QB1D IK FDLYAMZZIXQODN-UHFFFAOYSA-N DM8QB1D IU 4-[[3-[4-(cyclopropanecarbonyl)piperazine-1-carbonyl]-4-fluorophenyl]methyl]-2H-phthalazin-1-one DM8QB1D CA CAS 763113-22-0 DM8QB1D CB CHEBI:83766 DM8QB1D DE Ovarian cancer; Pancreatic cancer; Prostate cancer DMNYOIX ID DMNYOIX DMNYOIX DN Olaratumab DMNYOIX HS Approved DMNYOIX SN LY3012207 DMNYOIX CP Eli Lilly DMNYOIX DT Monoclonal antibody DMNYOIX SQ Heavy Chain: QLQLQESGPGLVKPSETLSLTCTVSGGSINSSSYYWGWLRQSPGKGLEWIGSFFYTGSTYYNPSLRSRLTISVDTSKNQFSLMLSSVTAADTAVYYCARQSTYYYGSGNYYGWFDRWDQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK >Light ChainEIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPAFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC DMNYOIX DE Soft tissue sarcoma; Non-small-cell lung cancer DM6MDCF ID DM6MDCF DM6MDCF DN Oliceridine DM6MDCF HS Approved DM6MDCF SN TRV130A DM6MDCF DT Small molecular drug DM6MDCF PC 66553195 DM6MDCF MW 386.6 DM6MDCF FM C22H30N2O2S DM6MDCF IC InChI=1S/C22H30N2O2S/c1-25-18-7-15-27-19(18)16-23-13-10-21(20-6-2-5-12-24-20)11-14-26-22(17-21)8-3-4-9-22/h2,5-7,12,15,23H,3-4,8-11,13-14,16-17H2,1H3/t21-/m1/s1 DM6MDCF CS COC1=C(SC=C1)CNCC[C@]2(CCOC3(C2)CCCC3)C4=CC=CC=N4 DM6MDCF IK DMNOVGJWPASQDL-OAQYLSRUSA-N DM6MDCF IU N-[(3-methoxythiophen-2-yl)methyl]-2-[(9R)-9-pyridin-2-yl-6-oxaspiro[4.5]decan-9-yl]ethanamine DM6MDCF CA CAS 1401028-24-7 DM6MDCF DE Thyroid disease; Acute pain DMWBHRY ID DMWBHRY DMWBHRY DN Olmesartan medoxomil DMWBHRY HS Approved DMWBHRY SN Benevas; Benicar; Olmetec; Olvance; Forest Brand of Olmesartan Medoxomil; Olmesartan medoximil; Sankyo Brand of Olmesartan Medoxomil; Cs 866; Benicar (TN); Berlin-Chemie Brand of Olmesartan Medoxomil; CS-866; CS-866DM; CS-866RN; DE-092; KS-1182; Olmetec (TN); Benicar, Olmetec,Olmesartan; Olmesartan medoxomil (JAN/USAN); (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 5-(2-hydroxypropan-2-yl)-2-propyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazole-4-carboxylate; (5-methyl-2-oxo-1,3-dioxolen-4-yl)methoxy-4-(1-hydroxy-1-methylethyl)-2-propyl-1-(4-(2-(tetrazol-5-yl)phenyl)phenyl)methylimidazol-5-carboxylate; 1H-Imidazole-5-carboxylic acid, 4-(1-hydroxy-1-methylethyl)-2-propyl-1-((2'-(1H-tetrazol-5-yl) (1,1'-biphenyl)-4-yl)methyl)-, (5-methyl-2-oxo-1,3-dioxol-4-yl) methyl ester; 1H-Imidazole-5-carboxylic acid, 4-(1-hydroxy-1-methylethyl)-2-propyl-1-((2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester; 1H-imidazole-5-carboxylic acid, 4-(1-hydroxy-1-methylethyl)-2-propyl-1-((2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-,(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester DMWBHRY TC Antihypertensive Agents DMWBHRY DT Small molecular drug DMWBHRY PC 130881 DMWBHRY MW 558.6 DMWBHRY FM C29H30N6O6 DMWBHRY IC InChI=1S/C29H30N6O6/c1-5-8-23-30-25(29(3,4)38)24(27(36)39-16-22-17(2)40-28(37)41-22)35(23)15-18-11-13-19(14-12-18)20-9-6-7-10-21(20)26-31-33-34-32-26/h6-7,9-14,38H,5,8,15-16H2,1-4H3,(H,31,32,33,34) DMWBHRY CS CCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)C(=O)OCC5=C(OC(=O)O5)C)C(C)(C)O DMWBHRY IK UQGKUQLKSCSZGY-UHFFFAOYSA-N DMWBHRY IU (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 5-(2-hydroxypropan-2-yl)-2-propyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazole-4-carboxylate DMWBHRY CA CAS 144689-63-4 DMWBHRY CB CHEBI:31932 DMWBHRY DE High blood pressure DM62B78 ID DM62B78 DM62B78 DN Olodaterol DM62B78 HS Approved DM62B78 SN BI-1744 DM62B78 CP Boehringer Ingelheim Pharmaceuticals DM62B78 DT Small molecular drug DM62B78 PC 11504295 DM62B78 MW 386.4 DM62B78 FM C21H26N2O5 DM62B78 IC InChI=1S/C21H26N2O5/c1-21(2,10-13-4-6-15(27-3)7-5-13)22-11-18(25)16-8-14(24)9-17-20(16)28-12-19(26)23-17/h4-9,18,22,24-25H,10-12H2,1-3H3,(H,23,26)/t18-/m0/s1 DM62B78 CS CC(C)(CC1=CC=C(C=C1)OC)NC[C@@H](C2=C3C(=CC(=C2)O)NC(=O)CO3)O DM62B78 IK COUYJEVMBVSIHV-SFHVURJKSA-N DM62B78 IU 6-hydroxy-8-[(1R)-1-hydroxy-2-[[1-(4-methoxyphenyl)-2-methylpropan-2-yl]amino]ethyl]-4H-1,4-benzoxazin-3-one DM62B78 CA CAS 868049-49-4 DM62B78 CB CHEBI:82700 DM62B78 DE Chronic obstructive pulmonary disease DMKMWQG ID DMKMWQG DMKMWQG DN Olopatadine DMKMWQG HS Approved DMKMWQG SN Allelock; Opatanol; Pataday; Patanase; Patanol; OLOPATADINE HCl; OLOPATADINE HYDROCHLORIDE; ALO4943A; HCl of KW 4679; KW 4679; O0361; AL-4943A; ALO-4943A; Allelock (TN); KW-4679; KW-4943A; Olopatadine [INN:BAN]; Pataday (TN); Patanase (TN); Patanol S (TN); {(11Z)-11-[3-(dimethylamino)propylidene]-6,11-dihydrodibenzo[b,e]oxepin-2-yl}acetic acid; 11-((Z)-3-(Dimethylamino)propylidene)-6,11-dihydrodibenz(b,e)oxepin-2-acetic acid; 11-((Z)-3-(Dimethylamino)propylidene)-6,11-dihydrodibenz(b,e)oxepin-2-acetic acid hydrochloride; 11-((Z)-3-(Dimethylamino)propylidene)-6,11-dihydrodibenz(b,e)oxepin-2-acetic acid, hydrochloride; 11-(3-(dimethylamino)propylidene)-6,11-dihydrodibenz(b,e)oxepin-2-acetic acid; 2-[(11Z)-11-[3-(dimethylamino)propylidene]-6H-benzo[c][1]benzoxepin-2-yl]acetic acid; 2-[(11Z)-11-[3-(dimethylamino)propylidene]-6H-benzo[c][1]benzoxepin-2-yl]acetic acid hydrochloride DMKMWQG CP Alcon DMKMWQG TC Antiallergic Agents DMKMWQG DT Small molecular drug DMKMWQG PC 5281071 DMKMWQG MW 337.4 DMKMWQG FM C21H23NO3 DMKMWQG IC InChI=1S/C21H23NO3/c1-22(2)11-5-8-18-17-7-4-3-6-16(17)14-25-20-10-9-15(12-19(18)20)13-21(23)24/h3-4,6-10,12H,5,11,13-14H2,1-2H3,(H,23,24)/b18-8- DMKMWQG CS CN(C)CC/C=C\\1/C2=CC=CC=C2COC3=C1C=C(C=C3)CC(=O)O DMKMWQG IK JBIMVDZLSHOPLA-LSCVHKIXSA-N DMKMWQG IU 2-[(11Z)-11-[3-(dimethylamino)propylidene]-6H-benzo[c][1]benzoxepin-2-yl]acetic acid DMKMWQG CA CAS 113806-05-6 DMKMWQG CB CHEBI:94593 DMKMWQG DE Allergic conjunctivitis; Ocular allergy DMWBQKU ID DMWBQKU DMWBQKU DN Olprinone DMWBQKU HS Approved DMWBQKU SN Olprinone; 106730-54-5; loprinone; Coretec; Olprinone [INN]; UNII-4Y8BMI9YGC; 4Y8BMI9YGC; C14H10N4O; Olprinone (INN); 5-imidazo[1,2-a]pyridin-6-yl-6-methyl-2-oxo-1H-pyridine-3-carbonitrile; 1,2-Dihydro-5-imidazo(1,2-alpha)pyridin-6-yl-6-methyl-2-oxonicotinonitrile; 1,2-dihydro-6-methyl-2-oxo-5-(imidazo[1,2-a]pyridin-6-yl)-3-pyridinecarbonitrile; AC1L1IIG; AC1Q4Q1U; SCHEMBL27661; DTXSID1048461; CHEMBL1474900; KS-00000EYK; MolPort-006-394-808; JPAWFIIYTJQOKW-UHFFFAOYSA-N; CHEBI:135019; BCP09781; ZINC38192538; HY-14254A; 3950AH DMWBQKU DT Small molecular drug DMWBQKU PC 4593 DMWBQKU MW 250.25 DMWBQKU FM C14H10N4O DMWBQKU IC InChI=1S/C14H10N4O/c1-9-12(6-11(7-15)14(19)17-9)10-2-3-13-16-4-5-18(13)8-10/h2-6,8H,1H3,(H,17,19) DMWBQKU CS CC1=C(C=C(C(=O)N1)C#N)C2=CN3C=CN=C3C=C2 DMWBQKU IK JPAWFIIYTJQOKW-UHFFFAOYSA-N DMWBQKU IU 5-imidazo[1,2-a]pyridin-6-yl-6-methyl-2-oxo-1H-pyridine-3-carbonitrile DMWBQKU CA CAS 106730-54-5 DMWBQKU CB CHEBI:135019 DMWBQKU DE Heart failure DMZW9HA ID DMZW9HA DMZW9HA DN Olsalazine DMZW9HA HS Approved DMZW9HA SN Azodisal; Dipentum; Olsalazine sodium; Di-mesalazine DMZW9HA CP Pharmacia & Upjohn AB DMZW9HA DT Small molecular drug DMZW9HA PC 22419 DMZW9HA MW 302.24 DMZW9HA FM C14H10N2O6 DMZW9HA IC InChI=1S/C14H10N2O6/c17-11-3-1-7(5-9(11)13(19)20)15-16-8-2-4-12(18)10(6-8)14(21)22/h1-6,17-18H,(H,19,20)(H,21,22) DMZW9HA CS C1=CC(=C(C=C1N=NC2=CC(=C(C=C2)O)C(=O)O)C(=O)O)O DMZW9HA IK QQBDLJCYGRGAKP-UHFFFAOYSA-N DMZW9HA IU 5-[(3-carboxy-4-hydroxyphenyl)diazenyl]-2-hydroxybenzoic acid DMZW9HA CA CAS 15722-48-2 DMZW9HA CB CHEBI:7770 DMZW9HA DE Ulcerative colitis DMPU2WX ID DMPU2WX DMPU2WX DN Omacetaxine mepesuccinate DMPU2WX HS Approved DMPU2WX SN Synribo (TN) DMPU2WX CP Ivax DMPU2WX DT Small molecular drug DMPU2WX PC 285033 DMPU2WX MW 545.6 DMPU2WX FM C29H39NO9 DMPU2WX IC InChI=1S/C29H39NO9/c1-27(2,33)8-5-10-29(34,16-23(31)36-4)26(32)39-25-22(35-3)15-28-9-6-11-30(28)12-7-18-13-20-21(38-17-37-20)14-19(18)24(25)28/h13-15,24-25,33-34H,5-12,16-17H2,1-4H3/t24-,25-,28+,29-/m1/s1 DMPU2WX CS CC(C)(CCC[C@@](CC(=O)OC)(C(=O)O[C@H]1[C@H]2C3=CC4=C(C=C3CCN5[C@@]2(CCC5)C=C1OC)OCO4)O)O DMPU2WX IK HYFHYPWGAURHIV-JFIAXGOJSA-N DMPU2WX IU 1-O-[(2S,3S,6R)-4-methoxy-16,18-dioxa-10-azapentacyclo[11.7.0.02,6.06,10.015,19]icosa-1(20),4,13,15(19)-tetraen-3-yl] 4-O-methyl (2R)-2-hydroxy-2-(4-hydroxy-4-methylpentyl)butanedioate DMPU2WX CA CAS 26833-87-4 DMPU2WX CB CHEBI:71019 DMPU2WX DE Chronic myeloid leukaemia DMR2J95 ID DMR2J95 DMR2J95 DN Omadacycline DMR2J95 HS Approved DMR2J95 SN UNII-090IP5RV8F; 090IP5RV8F; Omadacycline [USAN:INN]; Omadacycline (USAN); AC1NUY3H; Amadacycline methanesulfonate; SCHEMBL152 DMR2J95 CP Paratek Pharmaceuticals DMR2J95 PC 54697325 DMR2J95 MW 556.6 DMR2J95 FM C29H40N4O7 DMR2J95 IC InChI=1S/C29H40N4O7/c1-28(2,3)12-31-11-14-10-17(32(4)5)15-8-13-9-16-21(33(6)7)24(36)20(27(30)39)26(38)29(16,40)25(37)18(13)23(35)19(15)22(14)34/h10,13,16,21,31,34-35,38,40H,8-9,11-12H2,1-7H3,(H2,30,39)/t13-,16-,21-,29-/m0/s1 DMR2J95 CS CC(C)(C)CNCC1=CC(=C2C[C@H]3C[C@H]4[C@@H](C(=O)C(=C([C@]4(C(=O)C3=C(C2=C1O)O)O)O)C(=O)N)N(C)C)N(C)C DMR2J95 IK VJYKVCURWJGLPG-IQZGDKDPSA-N DMR2J95 IU (4S,4aS,5aR,12aR)-4,7-bis(dimethylamino)-9-[(2,2-dimethylpropylamino)methyl]-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4H-tetracene-2-carboxamide DMR2J95 CA CAS 389139-89-3 DMR2J95 DE Acute bacterial skin infection; Bacterial pneumonia; Bacterial infection DMU5G01 ID DMU5G01 DMU5G01 DN Omadacycline DMU5G01 HS Approved DMU5G01 SN Amadacycline; Amadacycline (intravenous), Merck & Co; Amadacycline (intravenous), Paratek/Novartis; Amadacycline (oral), Merck & Co; Amadacycline (oral), Paratek/ Novartis; Antibacterial aminomethycyclines, Paratek/Bayer; MK-2764; Omadacycline; Omadacycline (intravenous), Merck & Co; Omadacycline (intravenous), Paratek; Omadacycline (intravenous), Paratek/ Novartis; Omadacycline (oral), Merck & Co; Omadacycline (oral), Paratek; Omadacycline (oral), Paratek/ Novartis; Omadacycline tosylate; P-000538; P-000642; P-001075; P-001207; P-001221; P-00136; P-002352; PTK-0796; PTK-796; Sancycline derivatives, Paratek; Tetracycline analogs, GlaxoSmithKline/Paratek; Tetracycline analogs, Paratek/Merck & Co;Tetracycline analogs (multi-drug-resistant infections), Paratek/Bayer DMU5G01 TC Antibiotics DMU5G01 DT Small molecular drug DMU5G01 PC 54697325 DMU5G01 MW 556.66 DMU5G01 FM C29H40N4O7 DMU5G01 IC InChI=1S/C29H40N4O7/c1-28(2,3)12-31-11-14-10-17(32(4)5)15-8-13-9-16-21(33(6)7)24(36)20(27(30)39)26(38)29(16,40)25(37)18(13)23(35)19(15)22(14)34/h10,13,16,21,31,34-35,38,40H,8-9,11-12H2,1-7H3,(H2,30,39)/t13-,16-,21-,29-/m0/s1 DMU5G01 CS CC(C)(C)CNCC1=CC(=C2CC3CC4C(C(=O)C(=C(C4(C(=O)C3=C(C2=C1O)O)O)O)C(=O)N)N(C)C)N(C)C DMU5G01 IK VJYKVCURWJGLPG-IQZGDKDPSA-N DMU5G01 IU (4S,4aS,5aR,12aR)-4,7-bis(dimethylamino)-9-[(2,2-dimethylpropylamino)methyl]-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4H-tetracene-2-carboxamide DMU5G01 CA CAS 389139-89-3 DMU5G01 DE Acute skin infections; Community-acquired bacterial pneumonia DMETVFJ ID DMETVFJ DMETVFJ DN Omalizumab DMETVFJ HS Approved DMETVFJ SN Xolair; Omalizumab (genetical recombination); Xolair (TN); Omalizumab (USAN/INN); Omalizumab (genetical recombination) (JAN) DMETVFJ CP National University Hospital, Singapore|National University, Singapore DMETVFJ TC Antiasthmatic Agents DMETVFJ DT Monoclonal antibody DMETVFJ SQ Omalizumab heavy chain: EVQLVESGGGLVQPGGSLRLSCAVSGYSITSGYSWNWIRQAPGKGLEWVASITYDGSTNYADSVKGRFTISRDDSKNTFYLQMNSLRAEDTAVYYCARGSHYFGHWHFAVWGQGTLVTVSSGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKAEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK >Omalizumab light chainDIQLTQSPSSLSASVGDRVTITCRASQSVDYDGDSYMNWYQQKPGKAPKLLIYAASYLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSHEDPYTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR DMETVFJ DE Asthma; Chronic idiopathic urticaria DML9TI0 ID DML9TI0 DML9TI0 DN Ombitasvir + paritaprevir + ritonavir DML9TI0 HS Approved DML9TI0 SN ABT-267/ABT-450/ritonavir; ABT-267/ritonavir/ABT-450; ABT-450/ABT-267/ritonavir; ABT-450/r + NS5A; ABT-450/r/ABT-267; ABT-450/ritonavir/ABT-267; HOLKIRA PAK; OBV/PTV/r; Ombitasvir/ABT 450/ritonavir; Ombitasvir/ritonavir/ABT-450; Ombitasvir/ritonavir/veruprevir; Paritaprevir/ombitasvir/ritonavir; Ritonavir/ABT 450/ombitasvir; Ritonavir/ABT-267/ABT-450; Ritonavir/ABT-450/ABT-267; Ritonavir/ombitasvir/ABT-450; Ritonavir/ombitasvir/paritaprevir; Ritonavir/veruprevir/ombitasvir; TECHNIVIE; Veruprevir/ombitasvir/ritonavir; Viekira Pak (ombitasvir/paritaprevir/ritonavir combination therapy); Viekirax DML9TI0 TC Antiinfective Agents DML9TI0 DE Hepatitis C virus infection DM471KJ ID DM471KJ DM471KJ DN Omeprazole DM471KJ HS Approved DM471KJ SN Losec (TN) DM471KJ CP AstraZeneca DM471KJ TC Antiulcer Agents DM471KJ DT Small molecular drug DM471KJ PC 4594 DM471KJ MW 345.4 DM471KJ FM C17H19N3O3S DM471KJ IC InChI=1S/C17H19N3O3S/c1-10-8-18-15(11(2)16(10)23-4)9-24(21)17-19-13-6-5-12(22-3)7-14(13)20-17/h5-8H,9H2,1-4H3,(H,19,20) DM471KJ CS CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC DM471KJ IK SUBDBMMJDZJVOS-UHFFFAOYSA-N DM471KJ IU 6-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]-1H-benzimidazole DM471KJ CA CAS 73590-58-6 DM471KJ CB CHEBI:77260 DM471KJ DE Gastroesophageal reflux disease DMOTQ1I ID DMOTQ1I DMOTQ1I DN Ondansetron DMOTQ1I HS Approved DMOTQ1I SN DESMETHYLONDANSETRON; Zofran; Zophren; Zudan; Sandoz ondansetron; ZOFRAN IN PLASTIC CONTAINER; Zofran ODT; GR 38032; GR 38032X; GR38032F; Apo-ondansetron; GR-38032F; Novo-ondansetron; Ondansetron (Zofran); PHL-ondansetron; PMS-ondansetron; Ratio-ondansetron; SN-307; Zofran (TN); Zofran ODT (TN); Ondansetron [USAN:INN:BAN]; Ondansetron (JAN/USP/INN); Ondansetron, (+,-)-Isomer; (RS)-1,2,3,9-Tetrahydro-9-methyl-3-(2-methylimidazol-1-ylmethyl)carbazol-4-one; 1,2,3,9-Tetrahydro-9-methyl-3-((2-methyl-1H-imidazol-1-yl)methyl)-4H-carbazol-4-one; 9-Methyl-3-(2-methyl-imidazol-1-ylmethyl)-1,2,3,9-tetrahydro-carbazol-4-one; 9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-1,2,3,9-tetrahydro-4H-carbazol-4-one; 9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1H-carbazol-4-one DMOTQ1I CP GlaxoSmithKline DMOTQ1I TC Antiemetics DMOTQ1I DT Small molecular drug DMOTQ1I PC 4595 DMOTQ1I MW 293.4 DMOTQ1I FM C18H19N3O DMOTQ1I IC InChI=1S/C18H19N3O/c1-12-19-9-10-21(12)11-13-7-8-16-17(18(13)22)14-5-3-4-6-15(14)20(16)2/h3-6,9-10,13H,7-8,11H2,1-2H3 DMOTQ1I CS CC1=NC=CN1CC2CCC3=C(C2=O)C4=CC=CC=C4N3C DMOTQ1I IK FELGMEQIXOGIFQ-UHFFFAOYSA-N DMOTQ1I IU 9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1H-carbazol-4-one DMOTQ1I CA CAS 99614-02-5 DMOTQ1I CB CHEBI:7773 DMOTQ1I DE Chemotherapy-induced nausea; Alcohol dependence DMHG57U ID DMHG57U DMHG57U DN OPC-34712 DMHG57U HS Approved DMHG57U SN Brexpiprazole DMHG57U CP Lundbeck; Otsuka America Pharmaceutical DMHG57U DT Small molecular drug DMHG57U PC 11978813 DMHG57U MW 433.6 DMHG57U FM C25H27N3O2S DMHG57U IC InChI=1S/C25H27N3O2S/c29-25-9-7-19-6-8-20(18-22(19)26-25)30-16-2-1-11-27-12-14-28(15-13-27)23-4-3-5-24-21(23)10-17-31-24/h3-10,17-18H,1-2,11-16H2,(H,26,29) DMHG57U CS C1CN(CCN1CCCCOC2=CC3=C(C=C2)C=CC(=O)N3)C4=C5C=CSC5=CC=C4 DMHG57U IK ZKIAIYBUSXZPLP-UHFFFAOYSA-N DMHG57U IU 7-[4-[4-(1-benzothiophen-4-yl)piperazin-1-yl]butoxy]-1H-quinolin-2-one DMHG57U CA CAS 913611-97-9 DMHG57U CB CHEBI:134716 DMHG57U DE Major depressive disorder DM1BKA6 ID DM1BKA6 DM1BKA6 DN Opicapone DM1BKA6 HS Approved DM1BKA6 SN BIA-9-1067 DM1BKA6 CP Portela & Ca SA DM1BKA6 PC 135565903 DM1BKA6 MW 413.2 DM1BKA6 FM C15H10Cl2N4O6 DM1BKA6 IC InChI=1S/C15H10Cl2N4O6/c1-5-10(13(17)20(24)6(2)11(5)16)14-18-15(27-19-14)7-3-8(21(25)26)12(23)9(22)4-7/h3-4,22-23H,1-2H3 DM1BKA6 CS CC1=C(C(=[N+](C(=C1Cl)C)[O-])Cl)C2=NOC(=N2)C3=CC(=C(C(=C3)O)O)[N+](=O)[O-] DM1BKA6 IK ASOADIZOVZTJSR-UHFFFAOYSA-N DM1BKA6 IU 5-[3-(2,5-dichloro-4,6-dimethyl-1-oxidopyridin-1-ium-3-yl)-1,2,4-oxadiazol-5-yl]-3-nitrobenzene-1,2-diol DM1BKA6 CA CAS 923287-50-7 DM1BKA6 CB CHEBI:134699 DM1BKA6 DE Parkinson disease DMPUOXF ID DMPUOXF DMPUOXF DN Opipramol DMPUOXF HS Approved DMPUOXF SN Opipramolo; Opipramolum; Opipramol dihydrochloride; Opipramol hydrochloride; Opipramoli hydrochloridum; G 33 040 DMPUOXF DT Small molecular drug DMPUOXF PC 9417 DMPUOXF MW 363.5 DMPUOXF FM C23H29N3O DMPUOXF IC InChI=1S/C23H29N3O/c27-19-18-25-16-14-24(15-17-25)12-5-13-26-22-8-3-1-6-20(22)10-11-21-7-2-4-9-23(21)26/h1-4,6-11,27H,5,12-19H2 DMPUOXF CS C1CN(CCN1CCCN2C3=CC=CC=C3C=CC4=CC=CC=C42)CCO DMPUOXF IK YNZFUWZUGRBMHL-UHFFFAOYSA-N DMPUOXF IU 2-[4-(3-benzo[b][1]benzazepin-11-ylpropyl)piperazin-1-yl]ethanol DMPUOXF CA CAS 315-72-0 DMPUOXF CB CHEBI:94614 DMPUOXF DE Anxiety disorder DMTSRI6 ID DMTSRI6 DMTSRI6 DN Oprelvekin DMTSRI6 HS Approved DMTSRI6 SN Neumega; Neumega (TN); Oprelvekin (genetical recombination); Oprelvekin (USAN/INN); Oprelvekin (genetical recombination) (JAN) DMTSRI6 CP Wyeth Pharmaceuticals DMTSRI6 TC Anticoagulants DMTSRI6 SQ DB00038 sequence: GPPPGPPRVSPDPRAELDSTVLLTRSLLADTRQLAAQLRDKFPADGDHNLDSLPTLAMSAGALGALQLPGVLTRLRADLLSYLRHVQWLRRAGGSSLKTLEPELGTLQARLDRLLRRLQLLMSRLALPQPPPDPPAPPLAPPSSAWGGIRAAHAILGGLHLTLDWAVRGLLLLKTRL DMTSRI6 DE Thrombocytopenia DM28D05 ID DM28D05 DM28D05 DN Oritavancin DM28D05 HS Approved DM28D05 SN Nuvocid; Oritavancin [INN]; LY333328; Chlorobiphenyl-chloroeremomycin; (3S,6R,7R,22R,23S,26S,36R,38aR)-22-(3-Amino-2,3,6-trideoxy-3-C-methyl-alpha-L-mannopyranosyloxy)-3-(carbamoylmethyl)-10,19-dichloro-44-[2-O-[3-(4'-chlorobiphenyl-4-ylmethylamino)-2,3,6-trideoxy-3-C-me; (4''R)-22-O-(3-Amino-2,3,6-trideoxy-3-C-methyl-alpha-L-arabino-hexopyranosyl)-N3''-(4'-chloro[1,1'-biphenyl]-4-ylmethyl)vancomycin; (4''R)-22-O-(3-Amino-2,3,6-trideoxy-3-C-methyl-alpha-L-arabinohexopyranosyl)-N3''-(p-(p-chlorophenyl)benzyl)vancomycin DM28D05 CP Eli Lilly DM28D05 DT Small molecular drug DM28D05 PC 16136912 DM28D05 MW 1793.1 DM28D05 FM C86H97Cl3N10O26 DM28D05 IC InChI=1S/C86H97Cl3N10O26/c1-35(2)22-51(92-7)77(110)98-67-69(105)42-15-20-55(49(88)24-42)120-57-26-44-27-58(73(57)125-84-74(71(107)70(106)59(34-100)122-84)124-62-32-86(6,76(109)37(4)119-62)93-33-38-8-10-39(11-9-38)40-12-17-45(87)18-13-40)121-56-21-16-43(25-50(56)89)72(123-61-31-85(5,91)75(108)36(3)118-61)68-82(115)97-66(83(116)117)48-28-46(101)29-54(103)63(48)47-23-41(14-19-53(47)102)64(79(112)99-68)96-80(113)65(44)95-78(111)52(30-60(90)104)94-81(67)114/h8-21,23-29,35-37,51-52,59,61-62,64-72,74-76,84,92-93,100-103,105-109H,22,30-34,91H2,1-7H3,(H2,90,104)(H,94,114)(H,95,111)(H,96,113)(H,97,115)(H,98,110)(H,99,112)(H,116,117)/t36-,37-,51+,52-,59+,61-,62-,64+,65+,66-,67+,68-,69+,70+,71-,72+,74+,75-,76-,84-,85-,86-/m0/s1 DM28D05 CS C[C@H]1[C@@H]([C@@](C[C@@H](O1)O[C@H]2[C@H]3C(=O)N[C@@H](C4=C(C(=CC(=C4)O)O)C5=C(C=CC(=C5)[C@H](C(=O)N3)NC(=O)[C@H]6C7=CC(=C(C(=C7)OC8=C(C=C2C=C8)Cl)O[C@H]9[C@@H]([C@H]([C@@H]([C@H](O9)CO)O)O)O[C@H]1C[C@]([C@H]([C@@H](O1)C)O)(C)NCC1=CC=C(C=C1)C1=CC=C(C=C1)Cl)OC1=C(C=C(C=C1)[C@H]([C@H](C(=O)N[C@H](C(=O)N6)CC(=O)N)NC(=O)[C@@H](CC(C)C)NC)O)Cl)O)C(=O)O)(C)N)O DM28D05 IK VHFGEBVPHAGQPI-LXKZPTCJSA-N DM28D05 IU (1S,2R,18R,19R,22S,25R,28R,40S)-2-[(2R,4S,5R,6S)-4-amino-5-hydroxy-4,6-dimethyloxan-2-yl]oxy-22-(2-amino-2-oxoethyl)-5,15-dichloro-48-[(2S,3R,4S,5S,6R)-3-[(2S,4S,5R,6S)-4-[[4-(4-chlorophenyl)phenyl]methylamino]-5-hydroxy-4,6-dimethyloxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-18,32,35,37-tetrahydroxy-19-[[(2R)-4-methyl-2-(methylamino)pentanoyl]amino]-20,23,26,42,44-pentaoxo-7,13-dioxa-21,24,27,41,43-pentazaoctacyclo[26.14.2.23,6.214,17.18,12.129,33.010,25.034,39]pentaconta-3,5,8,10,12(48),14,16,29(45),30,32,34(39),35,37,46,49-pentadecaene-40-carboxylic acid DM28D05 CA CAS 171099-57-3 DM28D05 CB CHEBI:82699 DM28D05 DE Bacterial infection; Gram-positive bacterial infection DMRJSP8 ID DMRJSP8 DMRJSP8 DN Orlistat DMRJSP8 HS Approved DMRJSP8 SN orlistat; 96829-58-2; Tetrahydrolipstatin; Xenical; Alli; Orlipastat; (-)-Tetrahydrolipstatin; Orlipastatum; Orlipastatum [INN-Latin]; THLP; Ro-18-0647; UNII-95M8R751W8; C29H53NO5; Ro 18-0647/002; N-Formyl-L-leucine (1S)-1-[[(2S,3S)-3-hexyl-4-oxo-2-oxetanyl]methyl]dodecyl ester; (2S)-1-[(2S,3S)-3-hexyl-4-oxooxetan-2-yl]tridecan-2-yl (2S)-2-formamido-4-methylpentanoate; Orlistat (Alli, Xenical); MLS002207022; [(2S)-1-[(2S,3S)-3-hexyl-4-oxooxetan-2-yl]tridecan-2-yl] (2S)-2-formamido-4-methylpentanoate; CHEMBL175247; Alli; GlaxoSmithKline brand of orlistat; Roche brand of orlistat; Alli (TN); Hoffmann-La Roche brand of orlistat; KS-1183; Orlistat [USAN:INN]; R-212; Xenical (TN); Orlistat (USAN/INN); Ro 18-0647/008; Alli, Xenical, Tetrahydrolipstatin, Orlistat; N-Formyl-L-leucine, ester with (3S,4S)-3-hexyl-4-((2S)-2-hydroxytridecyl)-2-oxetanone; L-Leucine, N-formyl-, (1S)-1-(((2S,3S)-3-hexyl-4-oxo-2-oxetanyl)methyl)dodecyl ester; L-Leucine,N-formyl-, (1S)-1-(((2S,3S)-3-hexyl-4-oxo-2-oxetanyl)methyl)dodecyl ester; 1-((3-hexyl-4-oxo-2-oxetanyl)methyl)dodecyl-2-formamido-4-methylvalerate; TETRAHYDROLIPSTATIN DMRJSP8 CP GlaxoSmithKline plc DMRJSP8 TC Antiobesity Agents DMRJSP8 DT Small molecular drug DMRJSP8 PC 3034010 DMRJSP8 MW 495.7 DMRJSP8 FM C29H53NO5 DMRJSP8 IC InChI=1S/C29H53NO5/c1-5-7-9-11-12-13-14-15-16-18-24(34-29(33)26(30-22-31)20-23(3)4)21-27-25(28(32)35-27)19-17-10-8-6-2/h22-27H,5-21H2,1-4H3,(H,30,31)/t24-,25-,26-,27-/m0/s1 DMRJSP8 CS CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O DMRJSP8 IK AHLBNYSZXLDEJQ-FWEHEUNISA-N DMRJSP8 IU [(2S)-1-[(2S,3S)-3-hexyl-4-oxooxetan-2-yl]tridecan-2-yl] (2S)-2-formamido-4-methylpentanoate DMRJSP8 CA CAS 96829-58-2 DMRJSP8 CB CHEBI:94686 DMRJSP8 DE Obesity DM6QHDJ ID DM6QHDJ DM6QHDJ DN Ornidazole DM6QHDJ HS Approved DM6QHDJ DT Small molecular drug DM6QHDJ PC 28061 DM6QHDJ MW 219.62 DM6QHDJ FM C7H10ClN3O3 DM6QHDJ IC InChI=1S/C7H10ClN3O3/c1-5-9-3-7(11(13)14)10(5)4-6(12)2-8/h3,6,12H,2,4H2,1H3 DM6QHDJ CS CC1=NC=C(N1CC(CCl)O)[N+](=O)[O-] DM6QHDJ IK IPWKIXLWTCNBKN-UHFFFAOYSA-N DM6QHDJ IU 1-chloro-3-(2-methyl-5-nitroimidazol-1-yl)propan-2-ol DM6QHDJ CA CAS 16773-42-5 DM6QHDJ CB CHEBI:75176 DM6QHDJ DE Amoebiasis DMW542E ID DMW542E DMW542E DN Orphenadrine DMW542E HS Approved DMW542E SN Antiflex; Biorphen; Brocadisipal; Brocasipal; Disipal; Lysantin; Mefenamine; Mephenamine; Methyldiphenylhydramine; Myolin; Myotrol; ORP; Orfenadrina; Orfro; Orphenadine; Orphenadinum; Orphenadrin; Orphenadrinum; Orphenate; Orphenedrine; Norflex Orphenadrine Citrate; Sodium Mefenamine; WS 2434; Banflex (TN); Biorphen (TN); Brocasipal (TN); Disipal (TN); Flexon (TN); Mephenamin (TN); Mialgin (TN); Norflex (TN); O-Methyldiphenhydramine; O-Monomethyldiphenhydramine; Orfenadrina [INN-Spanish]; Orphenadrine(INN); Orphenadrine [INN:BAN]; Orphenadrinum [INN-Latin]; Beta-Dimethylaminoethyl 2-methylbenzhydryl ether; Phenyl-o-tolylmethyl dimethyaminoethyl ether; Beta-Dimethylaminoethyl-2-methylbenzhydryl ether; N,N-Dimethyl-2-(alpha-2-tolylbenzoyloxy)ethylamin; N,N-Dimethyl-2-[(2-methylphenyl)(phenyl)methoxy]ethanamine; N,N-dimethyl-2-(alpha-2-tolylbenzoyloxy)ethylamine; N,N-dimethyl-2-[(2-methylphenyl)-phenylmethoxy]ethanamine; N,N-Dimethyl-2-(o-methyl-alpha-phenylbenzyl)oxy)ethylamine; N,N-Dimethyl-2-[(o-methyl-alpha-phenylbenzyl)oxy]ethylamine; N,N-dimethyl-2-{[(2-methylphenyl)(phenyl)methyl]oxy}ethanamine; 2-(Phenyl-o-tolylmethoxy)ethyldimethylamine; 2-Methyldiphenhydramine DMW542E CP 3M Pharmaceuticals DMW542E TC Antiparkinson Agents DMW542E DT Small molecular drug DMW542E PC 4601 DMW542E MW 269.4 DMW542E FM C18H23NO DMW542E IC InChI=1S/C18H23NO/c1-15-9-7-8-12-17(15)18(20-14-13-19(2)3)16-10-5-4-6-11-16/h4-12,18H,13-14H2,1-3H3 DMW542E CS CC1=CC=CC=C1C(C2=CC=CC=C2)OCCN(C)C DMW542E IK QVYRGXJJSLMXQH-UHFFFAOYSA-N DMW542E IU N,N-dimethyl-2-[(2-methylphenyl)-phenylmethoxy]ethanamine DMW542E CA CAS 83-98-7 DMW542E CB CHEBI:7789 DMW542E DE Parkinson disease DMFIQ20 ID DMFIQ20 DMFIQ20 DN Orphenadrine citrate DMFIQ20 HS Approved DMFIQ20 SN Orfenadrina; Orfenadrina [INN-Spanish]; Orphenadine; Orphenadinum; Orphenadrin; Orphenadrine [INN:BAN]; Orphenadrinum; Orphenadrinum [INN-Latin]; Orphenate; Orphenedrine; WS 2434; o-Methyldiphenhydramine; o-Monomethyldiphenhydramine; orphenadrine; 2-(Phenyl-o-tolylmethoxy)ethyldimethylamine; 2-Methyldiphenhydramine; 83-98-7; EINECS 201-509-2; HSDB 3139; Phenyl-o-tolylmethyl dimethyaminoethyl ether; beta-Dimethylaminoethyl 2-methylbenzhydryl ether; Biorphen; Brocadisipal; Brocasipal; Disipal; Invagesic; Mephenamine; Norgesic; Banflex; Euflex; Flexoject; Flexon; Flexor; Norflex; Norflex (pharmaceutical); Orphenadrine (Citrate); Orphenadrine citrate; Orphenadrine citrate (Norflex); Orphenadrine citrate [USP]; Orphenadrine citrate salt; Orphenadrine dihydrogen citrate; Plenactol; Tega-Flex; X-Otag; 2-hydroxypropane-1,2,3-tricarboxylic acid; 4596-23-0; 4682-36-4; CHEBI:7790; EINECS 225-137-5; N,N-Dimethyl-2-((o-methyl-alpha-phenylbenzyl)oxy)ethylamine citrate (1:1); NCGC00094745-01; dimethyl({2-[(2-methylphenyl)(phenyl)methoxy]ethyl})amine DMFIQ20 PC 83823 DMFIQ20 MW 461.5 DMFIQ20 FM C24H31NO8 DMFIQ20 IC MMMNTDFSPSQXJP-UHFFFAOYSA-N DMFIQ20 CS CC1=CC=CC=C1C(C2=CC=CC=C2)OCCN(C)C.C(C(=O)O)C(CC(=O)O)(C(=O)O)O DMFIQ20 IK 1S/C18H23NO.C6H8O7/c1-15-9-7-8-12-17(15)18(20-14-13-19(2)3)16-10-5-4-6-11-16;7-3(8)1-6(13,5(11)12)2-4(9)10/h4-12,18H,13-14H2,1-3H3;13H,1-2H2,(H,7,8)(H,9,10)(H,11,12) DMFIQ20 IU N,N-dimethyl-2-[(2-methylphenyl)-phenylmethoxy]ethanamine;2-hydroxypropane-1,2,3-tricarboxylic acid DMFIQ20 CA CAS 4682-36-4 DMFIQ20 CB CHEBI:7790 DMFIQ20 DE Myalgia DMGO72P ID DMGO72P DMGO72P DN Oseltamivir DMGO72P HS Approved DMGO72P SN Tamiflu (*Phosphate salt 1:1*); Agucort; Oseltamivirum; Tamvir; GS 4104; GS4104; Agucort (TN); GS-4104; Oseltamivir (INN); Oseltamivir [INN:BAN]; Ro-640796; Tamiflu (TN); Tamiflu-Free; Ro-64-0796; OTV DMGO72P CP Hoffmann-La Roche pharmaceutical company DMGO72P TC Antiviral Agents DMGO72P DT Small molecular drug DMGO72P PC 65028 DMGO72P MW 312.4 DMGO72P FM C16H28N2O4 DMGO72P IC InChI=1S/C16H28N2O4/c1-5-12(6-2)22-14-9-11(16(20)21-7-3)8-13(17)15(14)18-10(4)19/h9,12-15H,5-8,17H2,1-4H3,(H,18,19)/t13-,14+,15+/m0/s1 DMGO72P CS CCC(CC)O[C@@H]1C=C(C[C@@H]([C@H]1NC(=O)C)N)C(=O)OCC DMGO72P IK VSZGPKBBMSAYNT-RRFJBIMHSA-N DMGO72P IU ethyl (3R,4R,5S)-4-acetamido-5-amino-3-pentan-3-yloxycyclohexene-1-carboxylate DMGO72P CA CAS 196618-13-0 DMGO72P CB CHEBI:7798 DMGO72P DE Influenza virus infection DMIJC9X ID DMIJC9X DMIJC9X DN Osilodrostat DMIJC9X HS Approved DMIJC9X SN LCI699; 928134-65-0; LCI-699; UNII-5YL4IQ1078; CHEMBL3099695; 5YL4IQ1078; Osilodrostat;4-[(5R)-6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl]-3-fluorobenzonitrile; 1304733-26-3; Osilodrostat [USAN:INN]; LCI 699; Osilodrostat (USAN/INN); LCI699-NX; GTPL8310; SCHEMBL12460772; DTXSID40156570; MolPort-044-560-410; EX-A1397; ZINC72318114; s7456; BDBM50444549; AKOS027323750; DB11837; CS-6896; HY-16276; KB-78108; Z-3271; D11061; 4-[(5R)-6,7-Dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl]-3-fluorobenzo nitrile DMIJC9X CP Novartis Pharmaceuticals DMIJC9X DT Small molecular drug DMIJC9X PC 44139752 DMIJC9X MW 227.24 DMIJC9X FM C13H10FN3 DMIJC9X IC InChI=1S/C13H10FN3/c14-12-5-9(6-15)1-3-11(12)13-4-2-10-7-16-8-17(10)13/h1,3,5,7-8,13H,2,4H2/t13-/m1/s1 DMIJC9X CS C1CC2=CN=CN2[C@H]1C3=C(C=C(C=C3)C#N)F DMIJC9X IK USUZGMWDZDXMDG-CYBMUJFWSA-N DMIJC9X IU 4-[(5R)-6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl]-3-fluorobenzonitrile DMIJC9X CA CAS 928134-65-0 DMIJC9X DE Cushing disease DMRJLAT ID DMRJLAT DMRJLAT DN Osimertinib DMRJLAT HS Approved DMRJLAT SN Tagrisso DMRJLAT CP Astrazeneca DMRJLAT DT Small molecular drug DMRJLAT PC 71496458 DMRJLAT MW 499.6 DMRJLAT FM C28H33N7O2 DMRJLAT IC InChI=1S/C28H33N7O2/c1-7-27(36)30-22-16-23(26(37-6)17-25(22)34(4)15-14-33(2)3)32-28-29-13-12-21(31-28)20-18-35(5)24-11-9-8-10-19(20)24/h7-13,16-18H,1,14-15H2,2-6H3,(H,30,36)(H,29,31,32) DMRJLAT CS CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC DMRJLAT IK DUYJMQONPNNFPI-UHFFFAOYSA-N DMRJLAT IU N-[2-[2-(dimethylamino)ethyl-methylamino]-4-methoxy-5-[[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino]phenyl]prop-2-enamide DMRJLAT CA CAS 1421373-65-0 DMRJLAT CB CHEBI:90943 DMRJLAT DE Non-small-cell lung cancer; Melanoma DMF5ZB3 ID DMF5ZB3 DMF5ZB3 DN OspA lipoprotein DMF5ZB3 HS Approved DMF5ZB3 TC Vaccines DMF5ZB3 DT Vaccine DMF5ZB3 SQ OspA lipoprotein: MKKYLLGIGLILALIACKQNVSSLDEKNSVSVDVPGGMKVLVSKEKNKDGKYDLMATVDNVDLKGTSDKNNGSGILEGVKADKSKVKLTVADDLSKTTLEVLKEDGTVVSRKVTSKDKSTTEAKFNEKGELSEKTMTRANGTTLEYSQMTNEDNAAKAVETLKNGIKFEGNLASGKTAVEIKEGTVTLKREIDKNGKVTVSLNDTASGSKKTASWQESTSTLTISANSKKTKDLVFLTNGTITVQNYDSAGTKLEGSAAEIKKLDELKNALR DMF5ZB3 DE Lyme disease DMC4GEI ID DMC4GEI DMC4GEI DN Ospemifene DMC4GEI HS Approved DMC4GEI SN Ospemifene; 128607-22-7; Osphena; FC-1271a; Deamino-hydroxytoremifene; Fc-1271; 2-(4-(4-chloro-1,2-diphenyl-but-1-enyl)phenoxy)ethanol; UNII-B0P231ILBK; CCRIS 9205; B0P231ILBK; CHEBI:73275; 2-(p-((Z)-4-Chloro-1,2-diphenyl-1-butenyl)phenoxy)ethanol; senshio; Ethanol, 2-[4-[(1Z)-4-chloro-1,2-diphenyl-1-butenyl]phenoxy]-; 2-{4-[(1Z)-4-chloro-1,2-diphenylbut-1-en-1-yl]phenoxy}ethanol; Ophena; Ospemifene [USAN:INN:BAN]; Deaminotoremifene; Osphena (TN); Deaminohydroxytoremifene; AC1MI19T; C24H23ClO2 DMC4GEI CP Shionogi; QuatRx DMC4GEI DT Small molecular drug DMC4GEI PC 3036505 DMC4GEI MW 378.9 DMC4GEI FM C24H23ClO2 DMC4GEI IC InChI=1S/C24H23ClO2/c25-16-15-23(19-7-3-1-4-8-19)24(20-9-5-2-6-10-20)21-11-13-22(14-12-21)27-18-17-26/h1-14,26H,15-18H2/b24-23- DMC4GEI CS C1=CC=C(C=C1)/C(=C(/C2=CC=CC=C2)\\C3=CC=C(C=C3)OCCO)/CCCl DMC4GEI IK LUMKNAVTFCDUIE-VHXPQNKSSA-N DMC4GEI IU 2-[4-[(Z)-4-chloro-1,2-diphenylbut-1-enyl]phenoxy]ethanol DMC4GEI CA CAS 128607-22-7 DMC4GEI CB CHEBI:73275 DMC4GEI DE Dyspareunia; Postmenopausal vaginal atrophy DM05968 ID DM05968 DM05968 DN Otilonium bromide DM05968 HS Approved DM05968 SN Otilonium Bromide; 26095-59-0; Octylonium bromide; Spasmomen; Octylonium; Otilonium (bromide); SP63; Ottilonio bromuro [Italian]; UNII-21HN3N72PV; Otilonium bromide [INN:BAN]; Otilonii bromidum [INN-Latin]; Bromure d'otilonium [INN-French]; Bromuro de otilonio [INN-Spanish]; EINECS 247-457-4; 21HN3N72PV; Diethyl(2-hydroxyethyl)methylammonium bromide p-(o-(octyloxy)benzamido)benzoate; Ethanaminium, N,N-diethyl-N-methyl-2-((4-((2-(octyloxy)benzoyl)amino)benzoyl)oxy)-, bromide; DSSTox_CID_26357; DSSTox_RID_81559 DM05968 CP Menarini DM05968 DT Small molecular drug DM05968 PC 72092 DM05968 MW 563.6 DM05968 FM C29H43BrN2O4 DM05968 IC InChI=1S/C29H42N2O4.BrH/c1-5-8-9-10-11-14-22-34-27-16-13-12-15-26(27)28(32)30-25-19-17-24(18-20-25)29(33)35-23-21-31(4,6-2)7-3;/h12-13,15-20H,5-11,14,21-23H2,1-4H3;1H DM05968 CS CCCCCCCCOC1=CC=CC=C1C(=O)NC2=CC=C(C=C2)C(=O)OCC[N+](C)(CC)CC.[Br-] DM05968 IK VWZPIJGXYWHBOW-UHFFFAOYSA-N DM05968 IU diethyl-methyl-[2-[4-[(2-octoxybenzoyl)amino]benzoyl]oxyethyl]azanium;bromide DM05968 CA CAS 26095-59-0 DM05968 DE Gastric motility disorder DMQNI7O ID DMQNI7O DMQNI7O DN OTL-200 DMQNI7O HS Approved DMQNI7O SN Libmeldy DMQNI7O CP Orchard Therapeutics DMQNI7O DT Gene therapy DMQNI7O DE Metachromatic leukodystrophy DME0F98 ID DME0F98 DME0F98 DN Ovine corticotropin-releasing hormone DME0F98 HS Approved DME0F98 SN Ovine CRF; Ovine CRH; Ovine CRF 41; Ovine corticotropin-releasing factor; Ovine ACTH releasing factor; 79804-71-0; Corticotropin-releasing factor (sheep); Sheep corticotropin-releasing factor (1-41); Corticotropin-releasing factor (sheep hypothalamus); Amunine; Amunin; Corticorelin ovine; oCRH; Corticorelin triflutate; AC1Q2C7A; CRF(OVINE)TRIFLUOROACETATE; Sheep corticotropin-releasing factor; Corticotropin-releasing hormone, ovine; Corticotropin-releasing f DME0F98 DT Small molecular drug DME0F98 PC 16132344 DME0F98 MW 4670 DME0F98 FM C205H339N59O63S DME0F98 IC InChI=1S/C205H339N59O63S/c1-30-104(21)159(198(322)225-106(23)163(214)287)259-193(317)142(87-157(285)286)253-184(308)132(77-99(11)12)246-182(306)130(75-97(7)8)244-172(296)117(46-36-38-67-207)231-170(294)118(47-39-68-221-204(215)216)233-189(313)139(84-151(213)274)251-194(318)143(91-266)256-188(312)137(82-113-88-219-93-223-113)241-165(289)108(25)227-169(293)120(51-58-147(209)270)234-173(297)121(52-59-148(210)271)229-164(288)107(24)228-179(303)128(73-95(3)4)243-176(300)123(54-61-150(212)273)236-190(314)140(85-155(281)282)242-166(290)109(26)226-168(292)116(45-35-37-66-206)239-200(324)161(110(27)268)261-178(302)126(65-72-328-29)238-174(298)124(55-62-152(275)276)237-181(305)134(79-101(15)16)254-197(321)158(103(19)20)258-177(301)125(56-63-153(277)278)235-171(295)119(48-40-69-222-205(217)218)232-180(304)129(74-96(5)6)245-183(307)131(76-98(9)10)247-187(311)138(83-114-89-220-94-224-114)250-186(310)136(81-112-43-33-32-34-44-112)255-201(325)162(111(28)269)262-192(316)135(80-102(17)18)248-191(315)141(86-156(283)284)252-185(309)133(78-100(13)14)249-195(319)144(92-267)257-199(323)160(105(22)31-2)260-196(320)145-49-41-70-263(145)203(327)146-50-42-71-264(146)202(326)127(57-64-154(279)280)240-175(299)122(53-60-149(211)272)230-167(291)115(208)90-265/h32-34,43-44,88-89,93-111,115-146,158-162,265-269H,30-31,35-42,45-87,90-92,206-208H2,1-29H3,(H2,209,270)(H2,210,271)(H2,211,272)(H2,212,273)(H2,213,274)(H2,214,287)(H,219,223)(H,220,224)(H,225,322)(H,226,292)(H,227,293)(H,228,303)(H,229,288)(H,230,291)(H,231,294)(H,232,304)(H,233,313)(H,234,297)(H,235,295)(H,236,314)(H,237,305)(H,238,298)(H,239,324)(H,240,299)(H,241,289)(H,242,290)(H,243,300)(H,244,296)(H,245,307)(H,246,306)(H,247,311)(H,248,315)(H,249,319)(H,250,310)(H,251,318)(H,252,309)(H,253,308)(H,254,321)(H,255,325)(H,256,312)(H,257,323)(H,258,301)(H,259,317)(H,260,320)(H,261,302)(H,262,316)(H,275,276)(H,277,278)(H,279,280)(H,281,282)(H,283,284)(H,285,286)(H4,215,216,221)(H4,217,218,222)/t104-,105-,106-,107-,108-,109-,110+,111+,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,127-,128-,129-,130-,131-,132-,133-,134-,135-,136-,137-,138-,139-,140-,141-,142-,143-,144-,145-,146-,158-,159-,160-,161-,162-/m0/s1 DME0F98 CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC2=CN=CN2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC3=CN=CN3)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N)NC(=O)[C@@H]4CCCN4C(=O)[C@@H]5CCCN5C(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CO)N DME0F98 IK QEEJLLNYQOBRRM-KSHGRFHLSA-N DME0F98 IU (4S)-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-amino-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-1-[(2S)-1-[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-amino-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-4-carboxybutanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]-3-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-carboxypropanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoic acid DME0F98 CA CAS 79804-71-0 DME0F98 DE Cushing disease; Diagnostic imaging DMTAFY4 ID DMTAFY4 DMTAFY4 DN Oxacillin DMTAFY4 HS Approved DMTAFY4 SN Bactocill; Ossacillina; Oxacilina; Oxacilline; Oxacillinum; Oxazocillin; Oxazocilline; Prostaphlin; Prostaphlyn; OXACILLIN SODIUM; Ossacillina [DCIT]; Sodium oxacillin; Bactocill (TN); MPI-penicillin; MPi-PC; Oxacilina (TN); Oxacilina [INN-Spanish]; Oxacillin (INN); Oxacillin [INN:BAN]; Oxacilline [INN-French]; Oxacillinum [INN-Latin]; Penicillin, Methylphenylisoxazolyl; Oxacillin, Monosodium Salt, Anhydrous; (2S,5R,6R)-3,3-dimethyl-6-[(5-methyl-3-phenyl-1,2-oxazole-4-carbonyl)amino]-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-3,3-dimethyl-6-{[(5-methyl-3-phenylisoxazol-4-yl)carbonyl]amino}-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (5-methyl-3-phenyl-4-isoxazolyl)penicillin; 2,2-dimethyl-6beta-(5-methyl-3-phenyl-1,2-oxazole-4-carboxamido)penam-3alpha-carboxylic acid; 5-Methyl-3-phenyl-4-isoxazolyl-penicillin; 6beta-(5-methyl-3-phenylisoxazol-4-yl)penicillanic acid DMTAFY4 CP Sandoz Inc DMTAFY4 TC Antibiotics DMTAFY4 DT Small molecular drug DMTAFY4 PC 6196 DMTAFY4 MW 401.4 DMTAFY4 FM C19H19N3O5S DMTAFY4 IC InChI=1S/C19H19N3O5S/c1-9-11(12(21-27-9)10-7-5-4-6-8-10)15(23)20-13-16(24)22-14(18(25)26)19(2,3)28-17(13)22/h4-8,13-14,17H,1-3H3,(H,20,23)(H,25,26)/t13-,14+,17-/m1/s1 DMTAFY4 CS CC1=C(C(=NO1)C2=CC=CC=C2)C(=O)N[C@H]3[C@@H]4N(C3=O)[C@H](C(S4)(C)C)C(=O)O DMTAFY4 IK UWYHMGVUTGAWSP-JKIFEVAISA-N DMTAFY4 IU (2S,5R,6R)-3,3-dimethyl-6-[(5-methyl-3-phenyl-1,2-oxazole-4-carbonyl)amino]-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid DMTAFY4 CA CAS 66-79-5 DMTAFY4 CB CHEBI:7809 DMTAFY4 DE Bacterial infection DMQNWRD ID DMQNWRD DMQNWRD DN Oxaliplatin DMQNWRD HS Approved DMQNWRD SN Eloxatin (TN); Medac (TN); Oxaliplatin (TN); Oxaliplatin (JAN/USAN/INN) DMQNWRD CP Sanofi-Aventis DMQNWRD TC Anticancer Agents DMQNWRD DT Small molecular drug DMQNWRD PC 9887053 DMQNWRD MW 397.29 DMQNWRD FM C8H14N2O4Pt DMQNWRD IC InChI=1S/C6H12N2.C2H2O4.Pt/c7-5-3-1-2-4-6(5)8;3-1(4)2(5)6;/h5-8H,1-4H2;(H,3,4)(H,5,6);/q-2;;+2/t5-,6-;;/m1../s1 DMQNWRD CS C1CC[C@H]([C@@H](C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2] DMQNWRD IK DRMCATBEKSVAPL-BNTLRKBRSA-N DMQNWRD IU [(1R,2R)-2-azanidylcyclohexyl]azanide;oxalic acid;platinum(2+) DMQNWRD CA CAS 61825-94-3 DMQNWRD DE Colorectal cancer DM2QDX1 ID DM2QDX1 DM2QDX1 DN Oxamniquine DM2QDX1 HS Approved DM2QDX1 SN Mansil; Oxaminiquine; Oxamniquina; Oxamniquinum; Vansil; UK 4261; UK 4271; Mansil (TN); Oxamniquina [INN-Spanish]; Oxamniquinum [INN-Latin]; UK-4271; Vansil (TN); Oxamniquine (USAN/INN); Oxamniquine [USAN:BAN:INN]; {2-[(Isopropylamino)methyl]-7-nitro-1,2,3,4-tetrahydroquinolin-6-yl}methanol; [7-nitro-2-[(propan-2-ylamino)methyl]-1,2,3,4-tetrahydroquinolin-6-yl]methanol; (2-{[(1-methylethyl)amino]methyl}-7-nitro-1,2,3,4-tetrahydroquinolin-6-yl)methanol; 1,2,3,4-Tetrahydro-2-(((1-methylethyl)amino)methyl)-7-nitro-6-quinolinemethanol; 1,2,3,4-Tetrahydro-2-((isopropylamino)methyl)-7-nitro-6-quinolinemethanol; 1,2,3,4-Tetrahydro-2-[(isopropylamino)methyl]-7-nitro-6-quinolinemethanol; 2-((Isopropylamino)methyl)-7-nitro-1,2,3,4-tetrahydro-6-quinolinemethanol; 2-(Isopropylaminomethyl)-7-nitro-1,2,3,4-tetrahydroquinoline-6-methanol; 6-Hydroxymethyl-2-isopropylaminomethyl-7-nitro-1,2,3,4-tetrahydroquinoline DM2QDX1 CP Pfizer Pharmaceuticals DM2QDX1 TC Schistosomicides DM2QDX1 DT Small molecular drug DM2QDX1 PC 4612 DM2QDX1 MW 279.33 DM2QDX1 FM C14H21N3O3 DM2QDX1 IC InChI=1S/C14H21N3O3/c1-9(2)15-7-12-4-3-10-5-11(8-18)14(17(19)20)6-13(10)16-12/h5-6,9,12,15-16,18H,3-4,7-8H2,1-2H3 DM2QDX1 CS CC(C)NCC1CCC2=CC(=C(C=C2N1)[N+](=O)[O-])CO DM2QDX1 IK XCGYUJZMCCFSRP-UHFFFAOYSA-N DM2QDX1 IU [7-nitro-2-[(propan-2-ylamino)methyl]-1,2,3,4-tetrahydroquinolin-6-yl]methanol DM2QDX1 CA CAS 21738-42-1 DM2QDX1 CB CHEBI:78416 DM2QDX1 DE Schistosomiasis DMU9MYJ ID DMU9MYJ DMU9MYJ DN Oxandrolone DMU9MYJ HS Approved DMU9MYJ SN Anavar; Lonavar; Ossandrolone; Oxandrin; Oxandrolona; Oxandrolonum; Protivar; Provitar; Vasorome; Ossandrolone [DCIT]; SC 11585; Anavar (TN); Oxandrin (TN); Oxandrolona [INN-Spanish]; Oxandrolonum [INN-Latin]; SC-11585; Oxandrin, Anavar, Oxandrolone; Oxandrolone (JAN/USP/INN); Oxandrolone [USAN:INN:BAN:JAN]; Dodecahydro-3-hydroxy-6-(hydroxy-methyl)-3,3a,6-trimethyl-1H-benz(e)indene-7-acetic acid delta-lactone; (1S,3aS,3bR,5aS,9aS,9bS,11aS)-1-hydroxy-1,9a,11a-trimethyl-2,3,3a,3b,4,5,5a,6,9,9b,10,11-dodecahydroindeno[4,5-h]isochromen-7-one; (4aS,4bS,6aS,7S,9aS,9bR,11aS)-7-hydroxy-4a,6a,7-trimethyltetradecahydroindeno[4,5-h]isochromen-2(1H)-one; 17-beta-hydroxy-17-methyl-2-oxa-androstan-3-one; 17-beta-hydroxy-17-methyl-2-oxa-androstan-3-one (9CI); 17beta-Hydroxy-17-methyl-2-oxa-5alpha-androstan-3-one; 17beta-Hydroxy-17alpha-methyl-2-oxa-5alpha-androstan-3-one; 2-Oxa-5alpha-androstan-3-one, 17beta-hydroxy-17-methyl-(8CI); 2-Oxaandrostan-3-one, 17-hydroxy-17-methyl-, (5-alpha,17-beta)-(9CI) DMU9MYJ CP Pfizer Pharmaceuticals DMU9MYJ DT Small molecular drug DMU9MYJ PC 5878 DMU9MYJ MW 306.4 DMU9MYJ FM C19H30O3 DMU9MYJ IC InChI=1S/C19H30O3/c1-17-11-22-16(20)10-12(17)4-5-13-14(17)6-8-18(2)15(13)7-9-19(18,3)21/h12-15,21H,4-11H2,1-3H3/t12-,13+,14-,15-,17-,18-,19-/m0/s1 DMU9MYJ CS C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C)O)CC[C@@H]4[C@@]3(COC(=O)C4)C DMU9MYJ IK QSLJIVKCVHQPLV-PEMPUTJUSA-N DMU9MYJ IU (1S,3aS,3bR,5aS,9aS,9bS,11aS)-1-hydroxy-1,9a,11a-trimethyl-2,3,3a,3b,4,5,5a,6,9,9b,10,11-dodecahydroindeno[4,5-h]isochromen-7-one DMU9MYJ CA CAS 53-39-4 DMU9MYJ CB CHEBI:7820 DMU9MYJ DE Alcoholic hepatitis DMZ30JT ID DMZ30JT DMZ30JT DN Oxantel pamoate DMZ30JT HS Approved DMZ30JT SN Telopar; Oxantel embonate; CP-14445; Oxantel pamoate (USAN); Telopar (TN); CP-14445-16; Phenol, 3-(2-(1,4,5,6-tetrahydro-1-methyl-2-pyrimidinyl)ethenyl), (E)-, 4,4'-methylenebis(3-hydroxy-2-naphthalenecarboxylate) (1:1) (salt); 4,4'-Methylenebis(3-hydroxy-2-naphthoic) acid, compound with (E)-3-(2-(1,4,5,6-tetrahydro-1-methylpyrimidin-2-yl)vinyl)phenol (1:1) DMZ30JT TC Anthelmintics DMZ30JT DT Small molecular drug DMZ30JT PC 5281086 DMZ30JT MW 604.6 DMZ30JT FM C36H32N2O7 DMZ30JT IC InChI=1S/C23H16O6.C13H16N2O/c24-20-16(14-7-3-1-5-12(14)9-18(20)22(26)27)11-17-15-8-4-2-6-13(15)10-19(21(17)25)23(28)29;1-15-9-3-8-14-13(15)7-6-11-4-2-5-12(16)10-11/h1-10,24-25H,11H2,(H,26,27)(H,28,29);2,4-7,10,16H,3,8-9H2,1H3/b;7-6+ DMZ30JT CS CN1CCCN=C1/C=C/C2=CC(=CC=C2)O.C1=CC=C2C(=C1)C=C(C(=C2CC3=C(C(=CC4=CC=CC=C43)C(=O)O)O)O)C(=O)O DMZ30JT IK CCOAINFUFGBHBA-UETGHTDLSA-N DMZ30JT IU 4-[(3-carboxy-2-hydroxynaphthalen-1-yl)methyl]-3-hydroxynaphthalene-2-carboxylic acid;3-[(E)-2-(1-methyl-5,6-dihydro-4H-pyrimidin-2-yl)ethenyl]phenol DMZ30JT CA CAS 68813-55-8 DMZ30JT CB CHEBI:7821 DMZ30JT DE Trichuris trichiura infection DM9UB0P ID DM9UB0P DM9UB0P DN Oxaprozin DM9UB0P HS Approved DM9UB0P SN Actirin; Alvo; Danoprox; Daypro; Dayrun; Deflam; Oxaprozina; Oxaprozine; Oxaprozinum; Voir; Xopane; Apotex brand of oxaprozin; CSC brand of oxaprozin; Pfizer brand of oxaprozin; Rhoxalpharma brand of oxaprozin; TRB brand of oxaprozin; Lyl)propenoic acid; NCI310839; O 9637; WY 21743; Apo-Oxaprozin; Daypro (TN); Duraprox (TN); Oxaprozina [INN-Spanish]; Oxaprozine [INN-French]; Oxaprozinum [INN-Latin]; Rhoxal-oxaprozin; WY-21743; WY-21,743; Oxaprozin (JP15/USAN/INN); Oxaprozin [USAN:BAN:INN:JAN]; Beta-(4,5-Diphenyloxazol-2-yl)propionic acid; 3-(4, 5-Diphenyl-2-oxazo; 3-(4,5-Diphenyl-1,3-oxazol-2-yl)propanoic acid; 3-(4,5-Diphenyl-2-oxazolyl)propenoic acid; 4, 5-Diphenyl-2-oxazolepropionic acid; 4,5-Diphenyl-2-oxazolepropanoic acid; 4,5-Diphenyl-2-oxazolepropionic acid DM9UB0P CP Gd Searle Llc DM9UB0P TC Antiinflammatory Agents DM9UB0P DT Small molecular drug DM9UB0P PC 4614 DM9UB0P MW 293.3 DM9UB0P FM C18H15NO3 DM9UB0P IC InChI=1S/C18H15NO3/c20-16(21)12-11-15-19-17(13-7-3-1-4-8-13)18(22-15)14-9-5-2-6-10-14/h1-10H,11-12H2,(H,20,21) DM9UB0P CS C1=CC=C(C=C1)C2=C(OC(=N2)CCC(=O)O)C3=CC=CC=C3 DM9UB0P IK OFPXSFXSNFPTHF-UHFFFAOYSA-N DM9UB0P IU 3-(4,5-diphenyl-1,3-oxazol-2-yl)propanoic acid DM9UB0P CA CAS 21256-18-8 DM9UB0P CB CHEBI:7822 DM9UB0P DE Rheumatoid arthritis DM1F42Z ID DM1F42Z DM1F42Z DN Oxatomide DM1F42Z HS Approved DM1F42Z SN Celtect; Oxatimide; Oxatomida; Oxatomidum; Oxetal; Tinset; CBMicro_024634; KW 4354; O 9387; R 35443; R35443; Celtect (TN); KW-4354; McN-JR 35443; Oxatomida [INN-Spanish]; Oxatomide (tinset); Oxatomidum [INN-Latin]; R 35,443; R-35443; Oxatomide (JAN/USAN/INN); Oxatomide [USAN:BAN:INN:JAN]; 1-(3-(4-(Diphenylmethyl)-1-piperazinyl)propyl)-1,3-dihydro-2H-benzimidazol-2-one; 1-(3-(4-(Diphenylmethyl)-1-piperazinyl)propyl)-2-benzimidazolinone; 1-[3-(4-Benzhydryl-piperazin-1-yl)-propyl]-1,3-dihydro-benzoimidazol-2-one; 1-[3-[4-(Diphenylmethyl)-1-piperazinyl]propyl]-1,3-dihydro-2H-benzimidazol-2-one; 1-[3-[4-(Diphenylmethyl)-1-piperazinyl]propyl]-2-benzimidazolinone; 3-[3-(4-benzhydrylpiperazin-1-yl)propyl]-1H-benzimidazol-2-one DM1F42Z CP Janssen Pharmaceutica DM1F42Z TC Antiallergic Agents DM1F42Z DT Small molecular drug DM1F42Z PC 4615 DM1F42Z MW 426.6 DM1F42Z FM C27H30N4O DM1F42Z IC InChI=1S/C27H30N4O/c32-27-28-24-14-7-8-15-25(24)31(27)17-9-16-29-18-20-30(21-19-29)26(22-10-3-1-4-11-22)23-12-5-2-6-13-23/h1-8,10-15,26H,9,16-21H2,(H,28,32) DM1F42Z CS C1CN(CCN1CCCN2C3=CC=CC=C3NC2=O)C(C4=CC=CC=C4)C5=CC=CC=C5 DM1F42Z IK BAINIUMDFURPJM-UHFFFAOYSA-N DM1F42Z IU 3-[3-(4-benzhydrylpiperazin-1-yl)propyl]-1H-benzimidazol-2-one DM1F42Z CA CAS 60607-34-3 DM1F42Z CB CHEBI:31943 DM1F42Z DE Hay fever DMXNZM4 ID DMXNZM4 DMXNZM4 DN Oxazepam DMXNZM4 HS Approved DMXNZM4 SN Abboxampam; Abboxapam; Adumbran; Alepam; Ansioxacepam; Anxiolit; Aplakil; Astress; Azutranguil; Azutranquil; Bonare; Drimuel; Droxacepam; Durazepam; Hilong; Isodin; Lederpam; Limbial; Murelax; Nesontil; Noctazepam; Nortemazepam; Nozepam; Ossazepam; Oxanid; Oxazepamum; Oxazipam; Oxozepam; Pacienx; Praxiten; Propax; Psicopax; Psiquiwas; QUEN; Quilibrex; Rondar; Sedigoa; Serax; Serenal; Serenid; Serepax; Seresta; Serpax; Sigacalm; Sobril; Tacepam; Tarchomin; Tazepam; Uskan; Vaben; Zaxopam; Anxiolit retard; Ossazepam [DCIT]; P acienx; CB 8092; DF2371850; O5254_SIGMA; Wy 3498; Z 10 tr; Alepam (TN); Apo-astress; Hi-Long; Medopam (TN); Murelax (TN); N-Desmethyltemazepam; Noripam (TN); Oxa-puren; Oxazepamum [INN-Latin]; Purata (TN); Ro 5-6789; Serax (TN); Serenid-D; Serepax (TN); WY-3498; Wy-3498 stic; Z10-Tr; Ox-Pam (TN); Tranquo-buscopan-wirkstoff; Oxazepam (JAN/USP/INN); Oxazepam [USAN:INN:BAN:JAN]; (+-)-7-Chloro-1,3-dihydro-3-hydroxy-5-phenyl-2H-1,4-benzodiazepin-2-one; (+-)-Oxazepam; (RS)-Oxazepam; 1,3-Dihydro-7-chloro-3-hydroxy-5-phenyl-2H-1,4-benzodiazepin-2-one; 1,3-Dihydro-7-chloro-3-hydroxy-5-phenyl-3H-1,4-benzodiazepin-2-one; 7-Chloro-1,3-dihydro-3-hydroxy-5-phenyl-1,4(2H)-benzodiazepin-2-one; 7-Chloro-1,3-dihydro-3-hydroxy-5-phenyl-2H-1,4-benzodiazepin-2-one; 7-Chloro-1,3-dihydro-3-hydroxy-5-phenyl-2H-1,4-benzodiazepine-2-one; 7-Chloro-3-hydroxy-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one; 7-chloro-3-hydroxy-5-phenyl-1,3-dihydro-1,4-benzodiazepin-2-one DMXNZM4 CP Genus Pharms DMXNZM4 TC Hypnotics and Sedatives DMXNZM4 DT Small molecular drug DMXNZM4 PC 4616 DMXNZM4 MW 286.71 DMXNZM4 FM C15H11ClN2O2 DMXNZM4 IC InChI=1S/C15H11ClN2O2/c16-10-6-7-12-11(8-10)13(9-4-2-1-3-5-9)18-15(20)14(19)17-12/h1-8,15,20H,(H,17,19) DMXNZM4 CS C1=CC=C(C=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)O DMXNZM4 IK ADIMAYPTOBDMTL-UHFFFAOYSA-N DMXNZM4 IU 7-chloro-3-hydroxy-5-phenyl-1,3-dihydro-1,4-benzodiazepin-2-one DMXNZM4 CA CAS 604-75-1 DMXNZM4 CB CHEBI:7823 DMXNZM4 DE Anxiety disorder DM5PU6O ID DM5PU6O DM5PU6O DN Oxcarbazepine DM5PU6O HS Approved DM5PU6O SN Epilexter; Epliga; Oxacarbazepine; Oxcarbamazepine; Oxcarbazepime; Oxcarbazepina; Oxcarbazepinum; Timox; Trileptal; Desitin brand of oxcarbazepine; Novartis brand of oxcarbazepine; Oxcarbazepine [INN]; GP 47680; O0363; GP-47680; KIN-493; Oxaleptal (TN); Oxcarbazepina [INN-Spanish]; Oxcarbazepinum [INN-Latin]; SPN-804; Trileptal (TN); Oxcarbazepine (USAN/INN); 10,11-Dihydro-10-oxo-5H-debenz(b,f)azepine-5-carboxamide; 10,11-Dihydro-10-oxo-5H-dibenz(b,f)azepine-5-carboxamide; 10,11-Dihydro-10-oxo-5H-dibenz[b,f]azepine-5-carboxamide; 10,11-Dihydro-10-oxo-5H-dibenzo[b,f]azepine-5-carboxamide; 10,11-Dihydro-10-oxo-5h-dibenz[b,f]azepine-5-carboxamide; 10-Oxo-10,11-dihydro-5H-dibenzo[b,f]azepine-5-carboxamide; 5-oxo-6H-benzo[b][1]benzazepine-11-carboxamide DM5PU6O CP Norvatis Phamaceuticals Corporation DM5PU6O TC Anticonvulsants DM5PU6O DT Small molecular drug DM5PU6O PC 34312 DM5PU6O MW 252.27 DM5PU6O FM C15H12N2O2 DM5PU6O IC InChI=1S/C15H12N2O2/c16-15(19)17-12-7-3-1-5-10(12)9-14(18)11-6-2-4-8-13(11)17/h1-8H,9H2,(H2,16,19) DM5PU6O CS C1C2=CC=CC=C2N(C3=CC=CC=C3C1=O)C(=O)N DM5PU6O IK CTRLABGOLIVAIY-UHFFFAOYSA-N DM5PU6O IU 5-oxo-6H-benzo[b][1]benzazepine-11-carboxamide DM5PU6O CA CAS 28721-07-5 DM5PU6O CB CHEBI:7824 DM5PU6O DE Epilepsy DME7KRM ID DME7KRM DME7KRM DN Oxiconazole DME7KRM HS Approved DME7KRM SN Oxiconazol; Oxiconazolum; Oxyconazole; Oxiconazol [INN-Spanish]; Oxiconazole (INN); Oxiconazole [INN:BAN]; Oxiconazolum [INN-Latin]; Ro 13-8996; Sgd 301-76; RO-13-8996; (Z)-1-(2,4-dichlorophenyl)-2-(1H-imidazol-1-yl)-O-(2,4-dichlorobenzyl) ethanone oxime nitrate; 1-(2,4-dichlorophenyl)-N-[(2,4-dichlorophenyl)methoxy]-2-imidazol-1-ylethanimine; 2',4'-Dichlor-O-(2,4-dichlorbenzyl)-2-(1-imidazolyl)-(Z)-acetophenonoxim; 2',4'-Dichloro-2-imidazol-1-ylacetophenone (Z)-(O-(2,4-dichlorobenzyl)oxime) DME7KRM CP Fougera Pharmaceuticals Inc DME7KRM TC Antifungal Agents DME7KRM DT Small molecular drug DME7KRM PC 5353853 DME7KRM MW 429.1 DME7KRM FM C18H13Cl4N3O DME7KRM IC InChI=1S/C18H13Cl4N3O/c19-13-2-1-12(16(21)7-13)10-26-24-18(9-25-6-5-23-11-25)15-4-3-14(20)8-17(15)22/h1-8,11H,9-10H2/b24-18+ DME7KRM CS C1=CC(=C(C=C1Cl)Cl)CO/N=C(\\CN2C=CN=C2)/C3=C(C=C(C=C3)Cl)Cl DME7KRM IK QRJJEGAJXVEBNE-HKOYGPOVSA-N DME7KRM IU (Z)-1-(2,4-dichlorophenyl)-N-[(2,4-dichlorophenyl)methoxy]-2-imidazol-1-ylethanimine DME7KRM CA CAS 64211-45-6 DME7KRM CB CHEBI:7825 DME7KRM DE Tinea pedis DM9EQC0 ID DM9EQC0 DM9EQC0 DN Oxidized glutathione DM9EQC0 HS Approved DM9EQC0 DT Small molecular drug DM9EQC0 PC 65359 DM9EQC0 MW 612.6 DM9EQC0 FM C20H32N6O12S2 DM9EQC0 IC InChI=1S/C20H32N6O12S2/c21-9(19(35)36)1-3-13(27)25-11(17(33)23-5-15(29)30)7-39-40-8-12(18(34)24-6-16(31)32)26-14(28)4-2-10(22)20(37)38/h9-12H,1-8,21-22H2,(H,23,33)(H,24,34)(H,25,27)(H,26,28)(H,29,30)(H,31,32)(H,35,36)(H,37,38)/t9-,10-,11-,12-/m0/s1 DM9EQC0 CS C(CC(=O)N[C@@H](CSSC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@@H](C(=O)O)N)C(=O)NCC(=O)O)[C@@H](C(=O)O)N DM9EQC0 IK YPZRWBKMTBYPTK-BJDJZHNGSA-N DM9EQC0 IU (2S)-2-amino-5-[[(2R)-3-[[(2R)-2-[[(4S)-4-amino-4-carboxybutanoyl]amino]-3-(carboxymethylamino)-3-oxopropyl]disulfanyl]-1-(carboxymethylamino)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid DM9EQC0 CA CAS 27025-41-8 DM9EQC0 CB CHEBI:17858 DM9EQC0 DE Breast cancer; Bacterial infection DMRKOS1 ID DMRKOS1 DMRKOS1 DN Oxilofrine DMRKOS1 HS Approved DMRKOS1 SN Oxilofrine hydrochloride; Carnigen (TN) DMRKOS1 DT Small molecular drug DMRKOS1 PC 688009 DMRKOS1 MW 181.23 DMRKOS1 FM C10H15NO2 DMRKOS1 IC InChI=1S/C10H15NO2/c1-7(11-2)10(13)8-3-5-9(12)6-4-8/h3-7,10-13H,1-2H3/t7-,10-/m0/s1 DMRKOS1 CS C[C@@H]([C@@H](C1=CC=C(C=C1)O)O)NC DMRKOS1 IK OXFGTKPPFSCSMA-XVKPBYJWSA-N DMRKOS1 IU 4-[(1R,2S)-1-hydroxy-2-(methylamino)propyl]phenol DMRKOS1 CA CAS 365-26-4 DMRKOS1 CB CHEBI:134822 DMRKOS1 DE Orthostatic hypotension DM9FKSR ID DM9FKSR DM9FKSR DN Oxitropium bromide DM9FKSR HS Approved DM9FKSR SN Oxivent (TN) DM9FKSR CP Dieckmann DM9FKSR DT Small molecular drug DM9FKSR PC 6917865 DM9FKSR MW 412.3 DM9FKSR FM C19H26BrNO4 DM9FKSR IC InChI=1S/C19H26NO4.BrH/c1-3-20(2)15-9-13(10-16(20)18-17(15)24-18)23-19(22)14(11-21)12-7-5-4-6-8-12;/h4-8,13-18,21H,3,9-11H2,1-2H3;1H/q+1;/p-1/t13?,14-,15-,16+,17-,18+,20?;/m1./s1 DM9FKSR CS CC[N+]1([C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4)C.[Br-] DM9FKSR IK LCELQERNWLBPSY-YAYGZGPXSA-M DM9FKSR IU [(1R,2R,4S,5S)-9-ethyl-9-methyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonan-7-yl] (2S)-3-hydroxy-2-phenylpropanoate;bromide DM9FKSR CA CAS 30286-75-0 DM9FKSR DE Asthma DM51OQW ID DM51OQW DM51OQW DN Oxprenolol DM51OQW HS Approved DM51OQW SN Coretal; Koretal; Laracor; Osprenololo; Oxprenololum; Tevacor; Trasacor; Trasicor; Osprenololo [DCIT]; Slow Trasicor; Trasicor 80; Captol (TN); Corbeton (TN); Coretal (TN); Dl-Alprenolol; Dl-Oxprenolol; Laracor (TN); Oxprenolol (INN); Oxprenolol (TN); Oxprenolol [INN:BAN]; Oxprenololum [INN-Latin]; Slow-pren; Tevacor (TN);Trasacor (TN); Trasicor (TN); Trasidex (TN); Trasitensin (TN); Slow-Pren (TN); Slow-Trasicor (TN); Coretal (*hydrochloride*); Laracor (*hydrochloride*); Oxprenolol Ba 39089 (*hydrochloride*); Trasacor (*hydrochloride*); Trasicor (*hydrochloride*); Slow-Pren (*hydrochloride*); (+)-1-(o-(Allyloxy)phenoxy)-3-(isopropylamino)propan-2-ol; (+-)-Oxprenolol; (1)-1-(o-(Allyloxy)phenoxy)-3-(isopropylamino)propan-2-ol; 1-((1-Methylethyl)amino)-3-(2-(2-propenyloxy)phenoxy)-2-propanol; 1-(Isopropylamino)-2-hydroxy-3-(o-(allyloxy)phenoxy)propane; 1-(o-(Allyloxy)phenoxy)-3-(isopropylamino)-2-propanol; 1-(propan-2-ylamino)-3-(2-prop-2-enoxyphenoxy)propan-2-ol; 1-[(1-Methylethyl)amino]-3-[2-(2-propenyloxy)phenoxy]-2-propanol; 1-[2-(Allyloxy)phenoxy]-3-(isopropylamino)-2-propanol DM51OQW TC Antihypertensive Agents DM51OQW DT Small molecular drug DM51OQW PC 4631 DM51OQW MW 265.35 DM51OQW FM C15H23NO3 DM51OQW IC InChI=1S/C15H23NO3/c1-4-9-18-14-7-5-6-8-15(14)19-11-13(17)10-16-12(2)3/h4-8,12-13,16-17H,1,9-11H2,2-3H3 DM51OQW CS CC(C)NCC(COC1=CC=CC=C1OCC=C)O DM51OQW IK CEMAWMOMDPGJMB-UHFFFAOYSA-N DM51OQW IU 1-(propan-2-ylamino)-3-(2-prop-2-enoxyphenoxy)propan-2-ol DM51OQW CA CAS 6452-71-7 DM51OQW CB CHEBI:91704 DM51OQW DE Hypertension DMLHSE3 ID DMLHSE3 DMLHSE3 DN Oxtriphylline DMLHSE3 HS Approved DMLHSE3 SN Choledyl; Cholegyl; Cholinophyllin; Cholinophylline; Filoral; Oxtrimethylline; Sabidal; Soliphylline; Teofilcolina; Teokolin; Theoxylline; Choline theophylline salt; Cholini theophyllinas; Colina teofillinato; Colina teofillinato [DCIT]; Oxtriphylline [USAN]; Oxtriphylline pediatric; Teofilinato de colina; Theophyllinate de choline; Theophylline cholinate; Theophylline salt of choline; Choledyl SA 400; Zy 15061; Choledyl (TN); Cholini theophyllinas [INN-Latin]; Teofilinato de colina [INN-Spanish]; Theophyllinate de choline[INN-French]; Choline salt with theophylline (1:1); Theophylline, compd. with choline; Choline, compd. with theophylline (1:1); Choline, hydroxide, compd. with theophylline (1:1); Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with 3,7-dihydro-1,3-dimethylpurine-2,6-dione; Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with 3,7-dihydro-1,3-dimethyl-1H-purine-2,6-dione; Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with 3,7-dihydro-1,3-dimethyl-1H-purine-2,6-dione (1:1); (2-Hydroxyethyl)trimethylammonium compound with theophylline; 1,3-dimethyl-7H-purine-2,6-dione; 1H-Purine-2,6-dione, 3,7-dihydro-1,3-dimethyl-, ion(1-), 2-hydroxy-N,N,N-trimethylethanaminium DMLHSE3 TC Bronchodilator Agents DMLHSE3 DT Small molecular drug DMLHSE3 PC 656652 DMLHSE3 MW 283.33 DMLHSE3 FM C12H21N5O3 DMLHSE3 IC InChI=1S/C7H8N4O2.C5H14NO/c1-10-5-4(8-3-9-5)6(12)11(2)7(10)13;1-6(2,3)4-5-7/h3,12H,1-2H3;7H,4-5H2,1-3H3/q;+1/p-1 DMLHSE3 CS CN1C(=C2C(=NC=N2)N(C1=O)C)[O-].C[N+](C)(C)CCO DMLHSE3 IK SOELXOBIIIBLRJ-UHFFFAOYSA-M DMLHSE3 IU 1,3-dimethyl-2-oxopurin-6-olate;2-hydroxyethyl(trimethyl)azanium DMLHSE3 CA CAS 4499-40-5 DMLHSE3 DE Cough DMI0GDH ID DMI0GDH DMI0GDH DN Oxybuprocaine DMI0GDH HS Approved DMI0GDH SN Benoxil; Benoxinate; Butoxyaminobenzoyldiethylaminoethanol; Butoxyprocaine; Conjucain; Dorsacain; Novescine; Novesinol; Oxibuprocaina; Oxibuprocainum; Oxibuprokain; Oxybucaine; Oxybuprocainum; Oxyriprocaine; Prescaina; Benoxinate hydrochloride; Monofree oxybuprocaine; Oxybuprocaine HCL; Oxybuprocaine hydrochloride; S 749;Monofree oxybuprocaine (TN); Novesin (TN); Novesine (TN); Oxibuprocaina [INN-Spanish]; Oxybuprocaine (INN); Oxybuprocaine [INN:BAN]; Oxybuprocainum [INN-Latin]; Diethylaminoethyl-4-amino-3-butoxybenzoate; BENZOIC ACID, 4-AMINO-3-BUTOXY-, 2-(DIETHYLAMINO)ETHYL ESTER; Benzoic acid, 4-amino-3-butoxy-, 2-(diethylamino)ethyl ester (7CI,8CI,9CI); 2-(Diethylamino)ethyl 4-amino-3-butoxybenzoate; 2-(diethylamino)ethyl 4-amino-3-n-butoxybenzoate; 2-Diethylaminoethyl 4-amino-3-butoxybenzoate; 3-Butoxy-4-aminobenzoic acid 2-(diethylamino)ethyl ester; 3-Butoxy-4-aminobenzoic acid 2-diethylaminoethyl ester; 4-Amino-3-butoxy-2-(diethylamino)ethyl ester benzoic acid; 4-Amino-3-butoxy-benzoic acid 2-diethylamino-ethyl ester; 4-Amino-3-butoxybenzoic acid 2-(diethylamino)ethyl ester; 4-Amino-3-butoxybenzoicacid 2-diethylaminoethyl ester; 4-Amino-3-n-butoxy-benzoesaeure-diaethylaminoaethylester; 4-Amino-3-n-butoxy-benzoesaeure-diaethylaminoaethylester [German] DMI0GDH CP Norvatis Phamaceuticals Corporation DMI0GDH TC Anesthetics DMI0GDH DT Small molecular drug DMI0GDH PC 4633 DMI0GDH MW 308.4 DMI0GDH FM C17H28N2O3 DMI0GDH IC InChI=1S/C17H28N2O3/c1-4-7-11-21-16-13-14(8-9-15(16)18)17(20)22-12-10-19(5-2)6-3/h8-9,13H,4-7,10-12,18H2,1-3H3 DMI0GDH CS CCCCOC1=C(C=CC(=C1)C(=O)OCCN(CC)CC)N DMI0GDH IK CMHHMUWAYWTMGS-UHFFFAOYSA-N DMI0GDH IU 2-(diethylamino)ethyl 4-amino-3-butoxybenzoate DMI0GDH CA CAS 99-43-4 DMI0GDH CB CHEBI:309594 DMI0GDH DE Anaesthesia DMF2KLU ID DMF2KLU DMF2KLU DN Oxybutynin hydrochloride DMF2KLU HS Approved DMF2KLU SN HOB-294; Oxybutynin hydrochloride (transdermal patch, overactive bladder); Oxybutynin hydrochloride (transdermal patch, overactive bladder), Hisamitsu DMF2KLU CP Watson Pharmaceuticals DMF2KLU DT Small molecular drug DMF2KLU PC 91505 DMF2KLU MW 393.9 DMF2KLU FM C22H32ClNO3 DMF2KLU IC InChI=1S/C22H31NO3.ClH/c1-3-23(4-2)17-11-12-18-26-21(24)22(25,19-13-7-5-8-14-19)20-15-9-6-10-16-20;/h5,7-8,13-14,20,25H,3-4,6,9-10,15-18H2,1-2H3;1H DMF2KLU CS CCN(CC)CC#CCOC(=O)C(C1CCCCC1)(C2=CC=CC=C2)O.Cl DMF2KLU IK SWIJYDAEGSIQPZ-UHFFFAOYSA-N DMF2KLU IU 4-(diethylamino)but-2-ynyl 2-cyclohexyl-2-hydroxy-2-phenylacetate;hydrochloride DMF2KLU CA CAS 1508-65-2 DMF2KLU CB CHEBI:7857 DMF2KLU DE Urinary incontinence DMXLKHV ID DMXLKHV DMXLKHV DN Oxycodone DMXLKHV HS Approved DMXLKHV CP Watson Laboratories DMXLKHV TC Analgesics DMXLKHV DT Small molecular drug DMXLKHV PC 5284603 DMXLKHV MW 315.4 DMXLKHV FM C18H21NO4 DMXLKHV IC InChI=1S/C18H21NO4/c1-19-8-7-17-14-10-3-4-12(22-2)15(14)23-16(17)11(20)5-6-18(17,21)13(19)9-10/h3-4,13,16,21H,5-9H2,1-2H3/t13-,16+,17+,18-/m1/s1 DMXLKHV CS CN1CC[C@]23[C@@H]4C(=O)CC[C@]2([C@H]1CC5=C3C(=C(C=C5)OC)O4)O DMXLKHV IK BRUQQQPBMZOVGD-XFKAJCMBSA-N DMXLKHV IU (4R,4aS,7aR,12bS)-4a-hydroxy-9-methoxy-3-methyl-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one DMXLKHV CA CAS 76-42-6 DMXLKHV CB CHEBI:7852 DMXLKHV DE Pain; Back pain DM8ZXT6 ID DM8ZXT6 DM8ZXT6 DN Oxymetazoline DM8ZXT6 HS Approved DM8ZXT6 SN Hazol; Iliadin; Nafrine; Navasin; Navisin; Nezeril; Oximetazolina; Oximetazolinum; Oxylazine; Oxymetazolinum; Oxymethazoline; Oxymetozoline; Rhinofrenol; Rhinolitan; Sinerol; Dristan Long Lasting Mentholated Nasal Spray; Dristan Long Lasting Nasal Mist; Drixoral Nasal Solution; Oxymeta zoline; Oxymetazoline hydrochloride crystalline; Afrin Cherry 12 Hour Nasal Spray; Afrin Extra Moisturizing 12 Hour Nasal Spray; Afrin Original 12 Hour Nasal Spray; Afrin Original 12 Hour Nose Drops; Afrin Original 12 Hour Pump Mist; Afrin Sinus 12 Hour Nasal Spray; Duramist Plus Up To 12 Hour Nasal Decongestant Spray; Genasal Nasal Spray Up to 12 Hour Relief; H 990; Nasal Relief 12 Hour Nasal Spray; Nostrilla 12 Hour Nasal Decongestant; Vicks Sinex 12 Hour Nasal Spray; Vicks Sinex 12 Hour Ultra Fine Mist for Sinus Relief; Decongestant (TN); Neo-Synephrine 12 Hour Spray; Operil (TN); Oximetazolina [INN-Spanish]; Oxymetazoline (INN); Oxymetazoline [INN:BAN]; Oxymetazolinum [INN-Latin]; Visine L.R; Visine L.R.; Phenol, 6-tert-butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethyl-(7CI,8CI); Phenol, 3-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-6-(1,1-dimethylethyl)-2,4-dimethyl-(9CI); 2-(4-tert-Butyl-2,6-dimethyl-3-hydroxybenzyl)-2-imidazoline; 3-(4,5-dihydro-1H-imidazol-2-ylmethyl)-2,4-dimethyl-6-tert-butyl-phenol; 3-[(4,5-Dihydro-1H-imidazol-2-yl)methyl]-6-(1,1-dimethylethyl)-2,4-dimethylphenol; 6-t-Butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethylphenol; 6-tert-Butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethylphenol; 6-tert-Butyl-3-(4,5-dihydro-1H-imidazol-2-ylmethyl)-2,4-dimethylphenol DM8ZXT6 CP Schein Pharmaceutical DM8ZXT6 TC Nasal Decongestants DM8ZXT6 DT Small molecular drug DM8ZXT6 PC 4636 DM8ZXT6 MW 260.37 DM8ZXT6 FM C16H24N2O DM8ZXT6 IC InChI=1S/C16H24N2O/c1-10-8-13(16(3,4)5)15(19)11(2)12(10)9-14-17-6-7-18-14/h8,19H,6-7,9H2,1-5H3,(H,17,18) DM8ZXT6 CS CC1=CC(=C(C(=C1CC2=NCCN2)C)O)C(C)(C)C DM8ZXT6 IK WYWIFABBXFUGLM-UHFFFAOYSA-N DM8ZXT6 IU 6-tert-butyl-3-(4,5-dihydro-1H-imidazol-2-ylmethyl)-2,4-dimethylphenol DM8ZXT6 CA CAS 1491-59-4 DM8ZXT6 CB CHEBI:7862 DM8ZXT6 DE Eye inflammation; Nasal congestion DMFXUT8 ID DMFXUT8 DMFXUT8 DN Oxymetholone DMFXUT8 HS Approved DMFXUT8 SN oxymetholone; Anasterone; 434-07-1; HMS3393H15 DMFXUT8 CP Solvay Pharmaceuticals DMFXUT8 DT Small molecular drug DMFXUT8 PC 5281034 DMFXUT8 MW 332.5 DMFXUT8 FM C21H32O3 DMFXUT8 IC InChI=1S/C21H32O3/c1-19-11-13(12-22)18(23)10-14(19)4-5-15-16(19)6-8-20(2)17(15)7-9-21(20,3)24/h12,14-17,22,24H,4-11H2,1-3H3/b13-12-/t14-,15+,16-,17-,19-,20-,21-/m0/s1 DMFXUT8 CS C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C)O)CC[C@@H]4[C@@]3(C/C(=C/O)/C(=O)C4)C DMFXUT8 IK ICMWWNHDUZJFDW-DHODBPELSA-N DMFXUT8 IU (2Z,5S,8R,9S,10S,13S,14S,17S)-17-hydroxy-2-(hydroxymethylidene)-10,13,17-trimethyl-1,4,5,6,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-one DMFXUT8 CA CAS 434-07-1 DMFXUT8 CB CHEBI:7864 DMFXUT8 DE Aplastic anemia DM65AGJ ID DM65AGJ DM65AGJ DN Oxymorphone DM65AGJ HS Approved DM65AGJ SN Oxymorphone (abuse-resistant, pain); Oxymorphone (abuse-resistant, pain), Pain Therapeutics/ King Pharmaceuticals; Oxymorphone (abuse-resistant, pain), Pain Therapeutics/Pfizer DM65AGJ CP Pain Therapeutics Inc DM65AGJ TC Neurology Agents DM65AGJ DT Small molecular drug DM65AGJ PC 5284604 DM65AGJ MW 301.34 DM65AGJ FM C17H19NO4 DM65AGJ IC InChI=1S/C17H19NO4/c1-18-7-6-16-13-9-2-3-10(19)14(13)22-15(16)11(20)4-5-17(16,21)12(18)8-9/h2-3,12,15,19,21H,4-8H2,1H3/t12-,15+,16+,17-/m1/s1 DM65AGJ CS CN1CC[C@]23[C@@H]4C(=O)CC[C@]2([C@H]1CC5=C3C(=C(C=C5)O)O4)O DM65AGJ IK UQCNKQCJZOAFTQ-ISWURRPUSA-N DM65AGJ IU (4R,4aS,7aR,12bS)-4a,9-dihydroxy-3-methyl-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one DM65AGJ CA CAS 76-41-5 DM65AGJ CB CHEBI:7865 DM65AGJ DE Pain DMPZS7U ID DMPZS7U DMPZS7U DN Oxyphenbutazone DMPZS7U HS Approved DMPZS7U SN Tandearil DMPZS7U CP Novartis Pharmaceuticals Corp DMPZS7U DT Small molecular drug DMPZS7U PC 4641 DMPZS7U MW 324.4 DMPZS7U FM C19H20N2O3 DMPZS7U IC InChI=1S/C19H20N2O3/c1-2-3-9-17-18(23)20(14-7-5-4-6-8-14)21(19(17)24)15-10-12-16(22)13-11-15/h4-8,10-13,17,22H,2-3,9H2,1H3 DMPZS7U CS CCCCC1C(=O)N(N(C1=O)C2=CC=C(C=C2)O)C3=CC=CC=C3 DMPZS7U IK HFHZKZSRXITVMK-UHFFFAOYSA-N DMPZS7U IU 4-butyl-1-(4-hydroxyphenyl)-2-phenylpyrazolidine-3,5-dione DMPZS7U CA CAS 129-20-4 DMPZS7U CB CHEBI:76258 DMPZS7U DE Arthritis DM3TABW ID DM3TABW DM3TABW DN Oxyphencyclimine DM3TABW HS Approved DM3TABW SN Antulcus; Caridan; Daricol; Manir; Naridan; Oxifencicliminum; Oxiphencycliminum; Oxyphencycliminum; Zamanil; Oxifencicliminum [INN-Spanish]; Oxyphencyclimine (INN); Oxyphencyclimine [INN:BAN]; Oxyphencycliminum [INN-Latin]; Benzeneacetic acid, .alpha.-cyclohexyl-.alpha.-hydroxy-, (1,4,5,6-tetrahydro-1-methyl-2-pyrimidinyl)methyl ester; (1-methyl-1,4,5,6-tetrahydropyrimidin-2-yl)methyl cyclohexyl(hydroxy)phenylacetate; (1-methyl-5,6-dihydro-4H-pyrimidin-2-yl)methyl 2-cyclohexyl-2-hydroxy-2-phenylacetate; 1,4,5,6-Tetrahydro-1-methyl-2-pyrimidinemethanol-alpha-phenylcyclohexaneglycolate; 1,4,5,6-Tetrahydro-1-methyl-2-pyrimidinylmethyl alpha-cyclohexyl-alpha-phenylglycolat; 1-Methyl-1,4,5,6-tetrahydro-2-pyrimidinylmethyl-alpha-cyclohexylmandelat DM3TABW CP Pfizer Laboratories Div Pfizer Inc DM3TABW TC Anticholinergic Agents DM3TABW DT Small molecular drug DM3TABW PC 4642 DM3TABW MW 344.4 DM3TABW FM C20H28N2O3 DM3TABW IC InChI=1S/C20H28N2O3/c1-22-14-8-13-21-18(22)15-25-19(23)20(24,16-9-4-2-5-10-16)17-11-6-3-7-12-17/h2,4-5,9-10,17,24H,3,6-8,11-15H2,1H3 DM3TABW CS CN1CCCN=C1COC(=O)C(C2CCCCC2)(C3=CC=CC=C3)O DM3TABW IK DUDKAZCAISNGQN-UHFFFAOYSA-N DM3TABW IU (1-methyl-5,6-dihydro-4H-pyrimidin-2-yl)methyl 2-cyclohexyl-2-hydroxy-2-phenylacetate DM3TABW CA CAS 125-53-1 DM3TABW CB CHEBI:7868 DM3TABW DE Peptic ulcer DMMQHOZ ID DMMQHOZ DMMQHOZ DN Oxyphenonium DMMQHOZ HS Approved DMMQHOZ SN Argicillin; Atrenyl; Hydroxymethylgramicidin; Methacin; Methocidin; Methocidine; Methocidinum; Metocidina; Oxiphenonum; Spastrex;Oxyphenonium Chloride; Oxyphenonium Iodide; Methocidin [DCF:INN]; Methocidine [INN-French]; Methocidinum [INN-Latin]; Metocidina [INN-Spanish]; [2-(2-Cyclohexyl-2-hydroxy-2-phenyl-acetoxy)-ethyl]-diethyl-methyl-ammonium; 2-((Cyclohexylhydroxyphenylacetyl)oxy)-N,N-diethyl-N-methylethanaminium; 2-(2-cyclohexyl-2-hydroxy-2-phenylacetyl)oxyethyl-diethyl-methylazanium; 2-[2-cyclohexyl(hydroxy)phenylacetoxy]-n,n-diethyl-n-methylethanaminium DMMQHOZ CP Novartis Pharmaceuticals Corp DMMQHOZ TC Parasympatholytics DMMQHOZ DT Small molecular drug DMMQHOZ PC 5749 DMMQHOZ MW 348.5 DMMQHOZ FM C21H34NO3+ DMMQHOZ IC InChI=1S/C21H34NO3/c1-4-22(3,5-2)16-17-25-20(23)21(24,18-12-8-6-9-13-18)19-14-10-7-11-15-19/h6,8-9,12-13,19,24H,4-5,7,10-11,14-17H2,1-3H3/q+1 DMMQHOZ CS CC[N+](C)(CC)CCOC(=O)C(C1CCCCC1)(C2=CC=CC=C2)O DMMQHOZ IK GFRUPHOKLBPHTQ-UHFFFAOYSA-N DMMQHOZ IU 2-(2-cyclohexyl-2-hydroxy-2-phenylacetyl)oxyethyl-diethyl-methylazanium DMMQHOZ CA CAS 14214-84-7 DMMQHOZ CB CHEBI:94329 DMMQHOZ DE Visceral spasms DMOVH1M ID DMOVH1M DMOVH1M DN Oxytetracycline DMOVH1M HS Approved DMOVH1M SN Adamycin; Biostat; Dabicycline; Dalimycin; Fanterrin; Geomycin; Geotilin; Hydroxytetracycline; Imperacin; Lenocycline; Macocyn; OTC; Oksisyklin; Ossitetraciclina; Oxacycline; Oxitetraciclina; Oxitetracyclin; Oxitetracycline; Oxitetracyclinum; Oxymycin; Oxymykoin; Oxypam; Oxyterracin; Oxyterracine; Oxyterracyne; Oxytetracid; Oxytetracyclin; Oxytetracyclinum; Proteroxyna; Riomitsin; Ryomycin; Solkaciclina; Tarocyn; Tarosin; Teravit; Terrafungine; Terramitsin; Terramycin; Tetran; Unimycin; Ursocyclin; Ursocycline; Vendarcin; Biostat PA; Ossitetraciclina [DCIT]; Oxytetracycline HCl; Oxytetracycline [INN]; Oxytetracycline amphoteric; Oxytetracycline anhydrous; Oxytetracycline calcium; Terramycin im; Antibiotic TM 25; LA 200; Liquamycin LA 200; Mycoshield TMQTHC 20; Pennox 200; TM 5; Terramycin Q50; Geomycin (Streptomyces vimosus); OTC (antibiotic); Oxitetraciclina [INN-Spanish]; Oxytetracycline (anhydrous); Oxytetracycline (internal use); Oxytetracyclinum [INN-Latin]; Terramycin, Liquamycin, Oxytetracycline; (2E,4S,4aR,5S,5aR,6S,12aS)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,6,10,11,12a-pentahydroxy-6-methyl-4,4a,5,5a-tetrahydrotetracene-1,3,12-trione; (2E,4S,6S,12aS)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,6,10,11,12a-pentahydroxy-6-methyl-4,4a,5,5a-tetrahydrotetracene-1,3,12-trione; (2Z)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,6,10,11,12a-pentahydroxy-6-methyl-4,4a,5,5a-tetrahydrotetracene-1,3,12-trione; (2Z,4S,4aR,5S,5aR,6S,12aS)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,6,10,11,12a-pentahydroxy-6-methyl-4,4a,5,5a-tetrahydrotetracene-1,3,12-trione; (4S,4aR,5S,5aR,6S,12aS)-4-(dimethylamino)-3,5,6,10,12,12a-hexahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide; 5-Hydroxytetracycline DMOVH1M CP Pfizer Pharmaceuticals DMOVH1M TC Antibiotics DMOVH1M DT Small molecular drug DMOVH1M PC 54675779 DMOVH1M MW 460.4 DMOVH1M FM C22H24N2O9 DMOVH1M IC InChI=1S/C22H24N2O9/c1-21(32)7-5-4-6-8(25)9(7)15(26)10-12(21)17(28)13-14(24(2)3)16(27)11(20(23)31)19(30)22(13,33)18(10)29/h4-6,12-14,17,25-26,28,30,32-33H,1-3H3,(H2,23,31)/t12-,13-,14+,17+,21-,22+/m1/s1 DMOVH1M CS C[C@@]1([C@H]2[C@@H]([C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O)O DMOVH1M IK OWFJMIVZYSDULZ-PXOLEDIWSA-N DMOVH1M IU (4S,4aR,5S,5aR,6S,12aR)-4-(dimethylamino)-1,5,6,10,11,12a-hexahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide DMOVH1M CA CAS 2058-46-0 DMOVH1M CB CHEBI:27701 DMOVH1M DE Bacterial infection DMDL27I ID DMDL27I DMDL27I DN Oxytocin DMDL27I HS Approved DMDL27I SN OXYTOCIN; Pitocin; 50-56-6; Ocytocin; Endopituitrina; Orasthin; Syntocinon; Oxytocine; Oxitocina; Oxytocinum; (1-Hemicystine)oxytocin; Piton S; Oxytocic hormone; UNII-1JQS135EYN; 3-Isoleucine-8-leucine vasopressin; Partocon; Oxystin; alpha-Hypophamine; Synthetic oxytocin; 1JQS135EYN; Ocytocinum; Syntocinone; Utedrin; Oxtocin; Uteracon; Syntocin; Synpitan; Presoxin; Di-sipidin; CHEMBL395429; CHEBI:7872; Nobitocin S; Atonin O; Oxetakain [Czech]; Ossitocina [DCIT]; Oxytocine [INN-French]; Oxytocinum [INN-Latin]; Oxitocina [INN-Spanish]; Posterior; Oxytocin (intranasal/ muco system, autism); [3H]OT (human, mouse, rat) DMDL27I CP Pastorus Pharma Llc DMDL27I DT Small molecular drug DMDL27I SQ DB00107 sequence: CYIQNCPLG DMDL27I PC 439302 DMDL27I MW 1007.2 DMDL27I FM C43H66N12O12S2 DMDL27I IC InChI=1S/C43H66N12O12S2/c1-5-22(4)35-42(66)49-26(12-13-32(45)57)38(62)51-29(17-33(46)58)39(63)53-30(20-69-68-19-25(44)36(60)50-28(40(64)54-35)16-23-8-10-24(56)11-9-23)43(67)55-14-6-7-31(55)41(65)52-27(15-21(2)3)37(61)48-18-34(47)59/h8-11,21-22,25-31,35,56H,5-7,12-20,44H2,1-4H3,(H2,45,57)(H2,46,58)(H2,47,59)(H,48,61)(H,49,66)(H,50,60)(H,51,62)(H,52,65)(H,53,63)(H,54,64)/t22-,25-,26-,27-,28-,29-,30-,31-,35-/m0/s1 DMDL27I CS CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N1)CC2=CC=C(C=C2)O)N)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N DMDL27I IK XNOPRXBHLZRZKH-DSZYJQQASA-N DMDL27I IU (2S)-1-[(4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-[(2S)-butan-2-yl]-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]-N-[(2S)-1-[(2-amino-2-oxoethyl)amino]-4-methyl-1-oxopentan-2-yl]pyrrolidine-2-carboxamide DMDL27I CA CAS 50-56-6 DMDL27I CB CHEBI:7872 DMDL27I DE Autism spectrum disorder; Lactation failure DM1YB0R ID DM1YB0R DM1YB0R DN OZ277 DM1YB0R HS Approved DM1YB0R SN Arterolane; UNII-3N1TN351VB; 664338-39-0; OZ277; 3N1TN351VB; OZ-277; C22H36N2O4; Arterolane [INN]; RBx11160; OZ 277; SCHEMBL4547841; CHEMBL404431; CHEMBL580910; CHEMBL221773; SCHEMBL12612733; CHEMBL1197433; SCHEMBL13951812; SCHEMBL11379522; SCHEMBL10307589; VXYZBLXGCYNIHP-BBMJWGJISA-N; VXYZBLXGCYNIHP-CAGINOIPSA-N; ZINC14191464; RBX-11160; NCGC00274173-01; HY-10852; Y1261 DM1YB0R DT Small molecular drug DM1YB0R PC 10475633 DM1YB0R MW 392.5 DM1YB0R FM C22H36N2O4 DM1YB0R IC InChI=1S/C22H36N2O4/c1-20(2,23)13-24-19(25)12-14-3-5-21(6-4-14)26-22(28-27-21)17-8-15-7-16(10-17)11-18(22)9-15/h14-18H,3-13,23H2,1-2H3,(H,24,25) DM1YB0R CS CC(C)(CNC(=O)CC1CCC2(CC1)OC3(C4CC5CC(C4)CC3C5)OO2)N DM1YB0R IK VXYZBLXGCYNIHP-UHFFFAOYSA-N DM1YB0R CA CAS 664338-39-0 DM1YB0R CB CHEBI:136054 DM1YB0R DE Malaria DMT6AM2 ID DMT6AM2 DMT6AM2 DN Ozanimod DMT6AM2 HS Approved DMT6AM2 SN 1306760-87-1; Ozanimod (RPC1063); UNII-Z80293URPV; Z80293URPV; (S)-5-(3-(1-((2-hydroxyethyl)amino)-2,3-dihydro-1H-inden-4-yl)-1,2,4-oxadiazol-5-yl)-2-isopropoxybenzonitrile; Ozanimod [USAN:INN]; Ozanimod (USAN/INN); SCHEMBL2195490; GTPL8709; CHEMBL3707247; 5-[3-[(1S)-1-(2-hydroxyethylamino)-2,3-dihydro-1H-inden-4-yl]-1,2,4-oxadiazol-5-yl]-2-propan-2-yloxybenzonitrile; EX-A1316; s7952; ZINC116109867; AKOS026674086; DB12612; CS-5070; HY-12288; AC-29883; Benzonitrile, 5-(3-((1 DMT6AM2 CP Receptos San Diego, CA DMT6AM2 PC 52938427 DMT6AM2 MW 404.5 DMT6AM2 FM C23H24N4O3 DMT6AM2 IC InChI=1S/C23H24N4O3/c1-14(2)29-21-9-6-15(12-16(21)13-24)23-26-22(27-30-23)19-5-3-4-18-17(19)7-8-20(18)25-10-11-28/h3-6,9,12,14,20,25,28H,7-8,10-11H2,1-2H3/t20-/m0/s1 DMT6AM2 CS CC(C)OC1=C(C=C(C=C1)C2=NC(=NO2)C3=C4CC[C@@H](C4=CC=C3)NCCO)C#N DMT6AM2 IK XRVDGNKRPOAQTN-FQEVSTJZSA-N DMT6AM2 IU 5-[3-[(1S)-1-(2-hydroxyethylamino)-2,3-dihydro-1H-inden-4-yl]-1,2,4-oxadiazol-5-yl]-2-propan-2-yloxybenzonitrile DMT6AM2 CA CAS 1306760-87-1 DMT6AM2 DE Crohn disease; Ulcerative colitis; Non-small-cell lung cancer; Multiple sclerosis DM6KZMG ID DM6KZMG DM6KZMG DN Ozenoxacin DM6KZMG HS Approved DM6KZMG SN T-3912; GF-001001-00; Non-fluorinated quinolone (Gram positive bacterial infection), Ferrer DM6KZMG CP Ferrer Internacional DM6KZMG PC 9863827 DM6KZMG MW 363.4 DM6KZMG FM C21H21N3O3 DM6KZMG IC InChI=1S/C21H21N3O3/c1-11-8-13(9-23-20(11)22-3)15-6-7-16-18(12(15)2)24(14-4-5-14)10-17(19(16)25)21(26)27/h6-10,14H,4-5H2,1-3H3,(H,22,23)(H,26,27) DM6KZMG CS CC1=CC(=CN=C1NC)C2=C(C3=C(C=C2)C(=O)C(=CN3C4CC4)C(=O)O)C DM6KZMG IK XPIJWUTXQAGSLK-UHFFFAOYSA-N DM6KZMG IU 1-cyclopropyl-8-methyl-7-[5-methyl-6-(methylamino)pyridin-3-yl]-4-oxoquinoline-3-carboxylic acid DM6KZMG CA CAS 245765-41-7 DM6KZMG CB CHEBI:136050 DM6KZMG DE Impetigo; Bacterial infection DMNKT8Z ID DMNKT8Z DMNKT8Z DN Pachycarpine DMNKT8Z HS Approved DMNKT8Z SN (+)-sparteine DMNKT8Z DT Small molecular drug DMNKT8Z PC 7014 DMNKT8Z MW 234.38 DMNKT8Z FM C15H26N2 DMNKT8Z IC InChI=1S/C15H26N2/c1-3-7-16-11-13-9-12(14(16)5-1)10-17-8-4-2-6-15(13)17/h12-15H,1-11H2/t12-,13-,14-,15+/m1/s1 DMNKT8Z CS C1CCN2C[C@H]3C[C@@H]([C@H]2C1)CN4[C@H]3CCCC4 DMNKT8Z IK SLRCCWJSBJZJBV-TUVASFSCSA-N DMNKT8Z IU (1R,2S,9R,10R)-7,15-diazatetracyclo[7.7.1.02,7.010,15]heptadecane DMNKT8Z CA CAS 492-08-0 DMNKT8Z DE Postpartum haemorrhage DMLB81S ID DMLB81S DMLB81S DN Paclitaxel DMLB81S HS Approved DMLB81S SN 5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-b; 7-epi-Paclitaxel; ABI-007; Abraxane; Capxol; Ebetaxel; EmPAC; Genaxol; Genetaxyl; Genexol; Intaxel; LipoPac; OncoGel; Onxol; Paclitaxel (Taxol); Paxceed; Paxene; Plaxicel; TAXOL; TaxAlbin; Taxol A; Xorane; Yewtaxan; Zisu; nab-paclitaxel; paclitaxel DMLB81S TC Anticancer Agents DMLB81S DT Small molecular drug DMLB81S PC 36314 DMLB81S MW 853.918 DMLB81S FM C47H51NO14 DMLB81S IC InChI=1S/C47H51NO14/c1-25-31(60-43(56)36(52)35(28-16-10-7-11-17-28)48-41(54)29-18-12-8-13-19-29)23-47(57)40(61-42(55)30-20-14-9-15-21-30)38-45(6,32(51)22-33-46(38,24-58-33)62-27(3)50)39(53)37(59-26(2)49)34(25)44(47,4)5/h7-21,31-33,35-38,40,51-52,57H,22-24H2,1-6H3,(H,48,54)/t31-,32-,33+,35-,36+,37+,38-,40-,45+,46-,47+/m0/s1 DMLB81S CS CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C DMLB81S IK RCINICONZNJXQF-MZXODVADSA-N DMLB81S IU [(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,12-diacetyloxy-15-[(2R,3S)-3-benzamido-2-hydroxy-3-phenylpropanoyl]oxy-1,9-dihydroxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl] benzoate DMLB81S CA CAS 33069-62-4 DMLB81S CB ChEBI:45863 DMLB81S DE Breast cancer DMD7L94 ID DMD7L94 DMD7L94 DN Palbociclib DMD7L94 HS Approved DMD7L94 SN 571190-30-2; PD0332991; PD-0332991; Ibrance; PD 0332991; UNII-G9ZF61LE7G; Palbociclib(PD0332991); 6-Acetyl-8-cyclopentyl-5-methyl-2-[[5-(piperazin-1-yl)pyridin-2-yl]amino]-8H-pyrido[2,3-d]pyrimidin-7-one; 6-acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one; G9ZF61LE7G; PD 332991; 6-ACETYL-8-CYCLOPENTYL-5-METHYL-2-[(5-PIPERAZIN-1-YLPYRIDIN-2-YL)AMINO]PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE; LQQ; PD 332991, PD 0332991, PD0332991; 6-Acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-ylpyridin-2-ylamino)-8H-pyrido(2,3-d)pyrimidin-7-one; 6-acetyl-8-cyclopentyl-5-methyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrido[2,3-d]pyrimidin-7-one; HMR-2934 DMD7L94 CP Onyx Pharmaceuticals; Pfizer DMD7L94 TC Anticancer Agents DMD7L94 DT Small molecular drug DMD7L94 PC 5330286 DMD7L94 MW 447.5 DMD7L94 FM C24H29N7O2 DMD7L94 IC InChI=1S/C24H29N7O2/c1-15-19-14-27-24(28-20-8-7-18(13-26-20)30-11-9-25-10-12-30)29-22(19)31(17-5-3-4-6-17)23(33)21(15)16(2)32/h7-8,13-14,17,25H,3-6,9-12H2,1-2H3,(H,26,27,28,29) DMD7L94 CS CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C DMD7L94 IK AHJRHEGDXFFMBM-UHFFFAOYSA-N DMD7L94 IU 6-acetyl-8-cyclopentyl-5-methyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrido[2,3-d]pyrimidin-7-one DMD7L94 CA CAS 571190-30-2 DMD7L94 CB CHEBI:85993 DMD7L94 DE Solid tumour/cancer; Schizophrenia; Breast cancer DM9JOYP ID DM9JOYP DM9JOYP DN Palifermin DM9JOYP HS Approved DM9JOYP SN Kepivance; Kepivance (TN); Palifermin (USAN/INN) DM9JOYP TC Antimucositis Agents DM9JOYP SQ Palifermin sequence: SYDYMEGGDIRVRRLFCRTQWYLRIDKRGKVKGTQEMKNNYNIMEIRTVAVGIVAIKGVESEFYLAMNKEGKLYAKKECNEDCNFKELILENHYNTYASAKWTHNGGEMFVALNQKGIPVRGKKTKKEQKTAHFLPMAIT DM9JOYP DE Oral mucositis DM7NPJS ID DM7NPJS DM7NPJS DN Paliperidone DM7NPJS HS Approved DM7NPJS SN Xeplion; Invega Sustenna; Paliperidone palmitate; JNS-010; Paliperidone (depot injection, NanoCrystal); Paliperidone (injectable, NanoCrystal), Elan; Paliperidone (depot injection, NanoCrystal), Johnson & Johnson DM7NPJS CP Johnson & Johnson DM7NPJS DT Small molecular drug DM7NPJS PC 115237 DM7NPJS MW 426.5 DM7NPJS FM C23H27FN4O3 DM7NPJS IC InChI=1S/C23H27FN4O3/c1-14-17(23(30)28-9-2-3-19(29)22(28)25-14)8-12-27-10-6-15(7-11-27)21-18-5-4-16(24)13-20(18)31-26-21/h4-5,13,15,19,29H,2-3,6-12H2,1H3 DM7NPJS CS CC1=C(C(=O)N2CCCC(C2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F DM7NPJS IK PMXMIIMHBWHSKN-UHFFFAOYSA-N DM7NPJS IU 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-9-hydroxy-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one DM7NPJS CA CAS 144598-75-4 DM7NPJS CB CHEBI:83804 DM7NPJS DE Schizophrenia DMQM9S0 ID DMQM9S0 DMQM9S0 DN Palivizumab DMQM9S0 HS Approved DMQM9S0 SN Synagis; Abbosynagis (TN); Palivizumab (INN); Palivizumab (genetical recombination); Synagis (TN); Palivizumab (genetical recombination) (JAN) DMQM9S0 CP Medlmmune DMQM9S0 TC Antiviral Agents DMQM9S0 DT Monoclonal antibody DMQM9S0 SQ VH region MEDI-493: QVTLRESGPALVKPTQTLTLTCTFSGFSLSTSGMSVGWIRQPPGKALEWLADIWWDDKKDYNPSLKSRLTISKDTSKNQVVLKVTNMDPADTATYYCARSMITNWYFDVWGAGTTVTVSS >VH RegionQVTLRESGPALVKPTQTLTLTCTFSGFSLSTSGMSVGWIRQPPGKALEWLADIWWDDKKDYNPSLKSRLTISKDTSKNQVVLKVTNMDPADTATYYCARSMITNWYFDVWGAGTTVTVSS DMQM9S0 DE Respiratory syncytial virus infection DMBHMOX ID DMBHMOX DMBHMOX DN Palonosetron DMBHMOX HS Approved DMBHMOX SN Aloxi; Onicit; Palonosetron [INN]; Aloxi (TN); RS 25233-197; RS 25259-197; RS-25233-197; RS-25259-197; (S-(R*,R*))-2-(1-Azabicyclo(2.2.2)oct-3-yl)-2,3,3a,4,5,6-hexahydro-1H-benz(de)isoquinolin-1-one DMBHMOX CP Eisai Inc DMBHMOX TC Antiemetics DMBHMOX DT Small molecular drug DMBHMOX PC 6337614 DMBHMOX MW 296.4 DMBHMOX FM C19H24N2O DMBHMOX IC InChI=1S/C19H24N2O/c22-19-16-6-2-4-14-3-1-5-15(18(14)16)11-21(19)17-12-20-9-7-13(17)8-10-20/h2,4,6,13,15,17H,1,3,5,7-12H2/t15-,17-/m1/s1 DMBHMOX CS C1C[C@@H]2CN(C(=O)C3=CC=CC(=C23)C1)[C@@H]4CN5CCC4CC5 DMBHMOX IK CPZBLNMUGSZIPR-NVXWUHKLSA-N DMBHMOX IU (3aS)-2-[(3S)-1-azabicyclo[2.2.2]octan-3-yl]-3a,4,5,6-tetrahydro-3H-benzo[de]isoquinolin-1-one DMBHMOX CA CAS 135729-61-2 DMBHMOX CB CHEBI:85161 DMBHMOX DE Nausea DMK2PBD ID DMK2PBD DMK2PBD DN Palonosetron + fosnetupitant DMK2PBD HS Approved DMK2PBD CP Helsinn Group DMK2PBD DT Antibody DMK2PBD DE Chemotherapy-induced nausea DMB4AVP ID DMB4AVP DMB4AVP DN Pamidronate DMB4AVP HS Approved DMB4AVP SN AHPrBP; Amidronate; Aminomux; Aminopropanehydroxydiphosphonate; Aredia; Ribodroat; Acide pamidronique; Acido pamidronico; Acidum pamidronicum; Aminohydroxypropylidene diphosphonate; Novartis brand of pamidronate disodium salt; PAMIDRONATE DISODIUM; PAMIDRONIC ACID; Pamidronate calcium; Pamidronate monosodium; Bisphosphonate 6; Acide pamidronique [INN-French]; Acido pamidronico [INN-Spanish]; Acidum pamidronicum [INN-Latin]; Pamidronic acid (INN); Pamidronic acid [INN:BAN]; Ribodroat (TN); Amino-1-hydroxypropane-1,1-diphosphonate; (3-AMINO-1-HYDROXY-1-PHOSPHONO-PROPYL)PHOSPHONIC ACID; (3-Amino-1-hydroxypropylidene)bisphosphonic acid; (3-Amino-1-hydroxypropylidene)diphosphonic acid; (3-amino-1-hydroxy-1-phosphonopropyl)phosphonic acid; (3-amino-1-hydroxypropane-1,1-diyl)bis(phosphonic acid); (3-amino-1-hydroxypropylidene)-1,1-biphosphonate; (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate; 1-hydroxy-3-aminopropane-1,1-diphosphonic acid; 3-Amino-1-hydroxypropylidene-1,1-diphosphonate DMB4AVP TC Antiinflammatory Agents DMB4AVP DT Small molecular drug DMB4AVP PC 4674 DMB4AVP MW 235.07 DMB4AVP FM C3H11NO7P2 DMB4AVP IC InChI=1S/C3H11NO7P2/c4-2-1-3(5,12(6,7)8)13(9,10)11/h5H,1-2,4H2,(H2,6,7,8)(H2,9,10,11) DMB4AVP CS C(CN)C(O)(P(=O)(O)O)P(=O)(O)O DMB4AVP IK WRUUGTRCQOWXEG-UHFFFAOYSA-N DMB4AVP IU (3-amino-1-hydroxy-1-phosphonopropyl)phosphonic acid DMB4AVP CA CAS 40391-99-9 DMB4AVP CB CHEBI:7903 DMB4AVP DE Hypercalcaemia DMB0VY8 ID DMB0VY8 DMB0VY8 DN Pancuronium DMB0VY8 HS Approved DMB0VY8 SN Mioblock; Pavulon; Bromure de pancuronium; Bromuro de pancuronio; PANCURONIUM BROMIDE; Pancuronii bromidum; Pancuronium dibromide; Poncuronium bromide; NA 97; ORG NA 97; P 1918; Bromure de pancuronium [INN-French]; Bromuro de pancuronio [INN-Spanish]; ORG-NA 97; Pancuronii bromidum [INN-Latin]; Pavulon (TN); Pancuronium bromide (JP15/USAN/INN); Pancuronium bromide [USAN:BAN:INN:JAN]; Piperidinium, 1,1'-(3alpha,17beta-dihydroxy-5alpha-androstan-2beta,16beta-ylene)bis(1-methyl-, dibromide, diacetate; Piperidinium, 1,1'-(3alpha,17beta-dihydroxy-5alpha-androstan-2beta,16beta-ylene)bis(1-methyl-, dibromide, diacetate (8CI); Piperidinium, 1,1'-((2beta,3alpha,5alpha,16beta,17beta)-3,17-bis(acetyloxy)androstane-2,16-diyl)bis(1-methyl)-, dibromide; Piperidinium, 1,1'-((2beta,3alpha,5alpha,16beta,17beta)-3,17-bis(acetyloxy)androstane-2,16-diyl)bis(1-methyl-, dibromide; Piperidinium, 1,1'-(2-beta,16-beta-(3-alpha,17-beta-dihydroxy-5-alpha-androstanylene))bis(1-methyl-, dibromide, diacetate; Piperidinium, 1,1'-[(2.beta.,3.alpha.,5.alpha.,16.beta.,17.beta.)-3,17-bis(acetyloxy)androstane-2,16-diyl]bis[1-methyl-, dibromide; (2beta,3alpha,5alpha,16beta,17beta)-3,17-bis(acetyloxy)-2,16-bis(1-methylpiperidinium-1-yl)androstane dibromide; [(2S,3S,5S,8R,9S,10S,13S,14S,16S,17R)-17-acetyloxy-10,13-dimethyl-2,16-bis(1-methylpiperidin-1-ium-1-yl)-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl] acetate; [(2S,3S,5S,8R,9S,10S,13S,14S,16S,17R)-17-acetyloxy-10,13-dimethyl-2,16-bis(1-methylpiperidin-1-ium-1-yl)-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl] acetate dibromide; 1,1'-(3,17-Bis(acetyloxy)androstane-2,16-diyl)bis(1-methylpiperidinium) dibromide; 1,1'-(3alpha,17beta-Bis(acetyloxy)-5alpha-androstane-2beta,16beta-diyl)bis(1-methylpiperidinium) dibromide; 1,1'-(3alpha,17beta-Dihydroxy-5alpha-androstan-2beta,16beta-ylene)bis(1-methylpiperidinium) dibromide diacetate; 1,1'-([2beta,3alpha,5alpha,16beta,17beta]-3,17-Bis[acetyloxy]androstane-2,16-diyl)bis(1-methylpiperidinium) dibromide; 1,1'-[(2beta,3alpha,5alpha,16beta,17beta)-3,17-bis(Acetyloxy)androstane-2,16-diyl]bis(1-methylpiperidinium) dibromide; 2beta,16beta-Dipiperidino-5alpha-androstane-3alpha,17beta-diol diacetate dimethobromide; 2beta,16beta-Dipiperidino-5alpha-androstane-3alpha,17beta-dioldiacetatedimethobromide; 3-alpha,17-beta-Diacetoxy-2-beta,16-beta-dipiperidino-5-alpha-androstane dimethobromide; 3alpha,17beta-Diacetoxy-2beta,16beta-dipiperidino-5alpha-androstane dimethobromide; 3alpha,17beta-diacetoxy-2beta,16beta-bis(1-methylpiperidinium-1-yl)-5alpha-androstane; 3alpha,17beta-diacetoxy-2beta,16beta-bis(1-methylpiperidinium-1-yl)-5alpha-androstane dibromide; 5alpha-Androstan-3alpha,17beta-diol, 2beta,16beta-dipipecolinio-, dibromide, diacetate DMB0VY8 CP Organon International DMB0VY8 TC Neuromuscular Nondepolarizing Agents DMB0VY8 DT Small molecular drug DMB0VY8 PC 441289 DMB0VY8 MW 572.9 DMB0VY8 FM C35H60N2O4+2 DMB0VY8 IC InChI=1S/C35H60N2O4/c1-24(38)40-32-21-26-13-14-27-28(35(26,4)23-31(32)37(6)19-11-8-12-20-37)15-16-34(3)29(27)22-30(33(34)41-25(2)39)36(5)17-9-7-10-18-36/h26-33H,7-23H2,1-6H3/q+2/t26-,27+,28-,29-,30-,31-,32-,33-,34-,35-/m0/s1 DMB0VY8 CS CC(=O)O[C@H]1C[C@@H]2CC[C@@H]3[C@@H]([C@]2(C[C@@H]1[N+]4(CCCCC4)C)C)CC[C@]5([C@H]3C[C@@H]([C@@H]5OC(=O)C)[N+]6(CCCCC6)C)C DMB0VY8 IK GVEAYVLWDAFXET-XGHATYIMSA-N DMB0VY8 IU [(2S,3S,5S,8R,9S,10S,13S,14S,16S,17R)-17-acetyloxy-10,13-dimethyl-2,16-bis(1-methylpiperidin-1-ium-1-yl)-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl] acetate DMB0VY8 CA CAS 16974-53-1 DMB0VY8 CB CHEBI:7907 DMB0VY8 DE Anaesthesia DMQPD1F ID DMQPD1F DMQPD1F DN Panitumumab DMQPD1F HS Approved DMQPD1F SN Vectibix; Panitumumab (genetical recombination); Vectibix (TN); Panitumumab (USAN/INN); Panitumumab (genetical recombination) (JAN); Panitumumab (EGFR mAb inhibitor) DMQPD1F CP Amgen & Takeda DMQPD1F TC Anticancer Agents DMQPD1F DT Monoclonal antibody DMQPD1F DE Colorectal cancer; Head and neck cancer DM58WKG ID DM58WKG DM58WKG DN Panobinostat DM58WKG HS Approved DM58WKG SN Faridak; LBH 589; LBH589; LBH-589; LBH-589B; NVP-LBH589; NVP-LBH-589; Panobinostat, NVP-LBH589, LBH589; (E)-N-HYDROXY-3-(4-{[2-(2-METHYL-1H-INDOL-3-YL)-ETHYLAMINO]-METHYL}-PHENYL)-ACRYLAMIDE; (E)-N-hydroxy-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide DM58WKG CP Novartis DM58WKG DT Small molecular drug DM58WKG PC 6918837 DM58WKG MW 349.4 DM58WKG FM C21H23N3O2 DM58WKG IC InChI=1S/C21H23N3O2/c1-15-18(19-4-2-3-5-20(19)23-15)12-13-22-14-17-8-6-16(7-9-17)10-11-21(25)24-26/h2-11,22-23,26H,12-14H2,1H3,(H,24,25)/b11-10+ DM58WKG CS CC1=C(C2=CC=CC=C2N1)CCNCC3=CC=C(C=C3)/C=C/C(=O)NO DM58WKG IK FPOHNWQLNRZRFC-ZHACJKMWSA-N DM58WKG IU (E)-N-hydroxy-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide DM58WKG CA CAS 404950-80-7 DM58WKG CB CHEBI:85990 DM58WKG DE Multiple myeloma; Primary myelofibrosis; Type-2 diabetes DMSVOCZ ID DMSVOCZ DMSVOCZ DN Pantoprazole DMSVOCZ HS Approved DMSVOCZ SN Astropan; Pantoprazol; Pantoprazolum; Pantoprozole; Pantor; Pantozol; Protium; Protonix; Somac; Pantoprazole Na; Pantoprazole Sodium; Protonix IV; BY 1023; Astropan (TN); BY-1023; Controloc (TN); Inipomp (TN); Pantecta (TN); Pantoloc (TN); Pantopan (TN); Pantoprazol [INN-Spanish]; Pantoprazolum [INN-Latin]; Pantor (TN); Pantotab (TN); Pantozol (TN); Protium (TN); Protonix (TN); SK&F 96022; SK-96022; SKF-96022; Somac (TN); Ulcepraz (TN); Pantoprazole (USAN/INN); Pantoprazole [USAN:BAN:INN]; SK&F-96022; 5-(Difluoromethoxy)-2-(((3,4-dimethoxy-2-pyridyl)methyl)sulfinyl)benzimidazole; 5-(difluoromethoxy)-2-{[(3,4-dimethoxypyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole; 6-(difluoromethoxy)-2-[(3,4-dimethoxypyridin-2-yl)methylsulfinyl]-1H-benzimidazole DMSVOCZ CP Wyeth; Altana; Solvay DMSVOCZ TC Antiulcer Agents DMSVOCZ DT Small molecular drug DMSVOCZ PC 4679 DMSVOCZ MW 383.4 DMSVOCZ FM C16H15F2N3O4S DMSVOCZ IC InChI=1S/C16H15F2N3O4S/c1-23-13-5-6-19-12(14(13)24-2)8-26(22)16-20-10-4-3-9(25-15(17)18)7-11(10)21-16/h3-7,15H,8H2,1-2H3,(H,20,21) DMSVOCZ CS COC1=C(C(=NC=C1)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC(F)F)OC DMSVOCZ IK IQPSEEYGBUAQFF-UHFFFAOYSA-N DMSVOCZ IU 6-(difluoromethoxy)-2-[(3,4-dimethoxypyridin-2-yl)methylsulfinyl]-1H-benzimidazole DMSVOCZ CA CAS 102625-70-7 DMSVOCZ CB CHEBI:7915 DMSVOCZ DE Gastroesophageal reflux disease DM091H2 ID DM091H2 DM091H2 DN Pantothenic acid DM091H2 HS Approved DM091H2 SN D-pantothenic acid; pantothenic acid; vitamin B5; 79-83-4; pantothenate; Chick antidermatitis factor; (+)-Pantothenic acid; PANTOTHENOIC ACID; (R)-pantothenate; (D)-(+)-Pantothenic acid; Kyselina pantothenova [Czech]; HSDB 1020; Pantothenic Acid [BAN]; D(+)-N-(2,4-Dihydroxy-3,3-dimethylbutyryl)-beta-alanine; BRN 1727064; UNII-19F5HK2737; (R)-pantothenic acid; beta-Alanine, N-(2,4-dihydroxy-3,3-dimethyl-1-oxobutyl)-, (R)-; EINECS 201-229-0; (D,+)-N(alpha-gamma-Dihydroxy-beta,beta-dimethylbutyryl)-beta-alanine DM091H2 DT Small molecular drug DM091H2 PC 6613 DM091H2 MW 219.23 DM091H2 FM C9H17NO5 DM091H2 IC InChI=1S/C9H17NO5/c1-9(2,5-11)7(14)8(15)10-4-3-6(12)13/h7,11,14H,3-5H2,1-2H3,(H,10,15)(H,12,13)/t7-/m0/s1 DM091H2 CS CC(C)(CO)[C@H](C(=O)NCCC(=O)O)O DM091H2 IK GHOKWGTUZJEAQD-ZETCQYMHSA-N DM091H2 IU 3-[[(2R)-2,4-dihydroxy-3,3-dimethylbutanoyl]amino]propanoic acid DM091H2 CA CAS 79-83-4 DM091H2 CB CHEBI:46905 DM091H2 DE Vitamin deficiency DMCA9QP ID DMCA9QP DMCA9QP DN Papaverine DMCA9QP HS Approved DMCA9QP SN papaverine; Papaverin; Papanerine; Robaxapap; 58-74-2; Papanerin; Pavabid; Papaverina; Pavatym; 1-(3,4-Dimethoxybenzyl)-6,7-dimethoxyisoquinoline; Cerespan; Papaverine [BAN]; Pavacot; Papaverina [Italian]; 6,7-Dimethoxy-1-veratrylisoquinoline; Papaverine Hcl; NSC 136630; UNII-DAA13NKG2Q; Isoquinoline, 6,7-dimethoxy-1-veratryl-; S-M-R; Papaverine (BAN); Pamelon; Chlorhydrate de papaverine; Qua bid; 1-(3,4-Dimethoxy-benzyl)-6,7-dimethoxy-isoquinoline; 1-((3,4-Dimethoxyphenyl)methyl)-6,7-dimethoxyisoquinoline; Alapav; Cardiospan; Cardoverina; Ceraspan; Cerebid; Delapav; Dilaves; Dispamil; Drapavel; Durapav; Dynovas; Forpavin; Genabid; Mesotina; Myobid; Pameion; Panergon; Papacon; Papalease; Papaversan; Pavacap; Pavacels; Pavacen; Pavagen; Pavarine; Pavatest; Pavatine; Paverolan; Paveron; Pavnell; Vasal; PAP H; Papavarine chlorhydrate; Papaverine chlorohydrate; Papaverine monohydrochloride; Papaverinium chloride; Pavabid Hp; RS 47; TNP00305; Alapav (TN); Albatran (TN); Artegodan (TN); Cardiospan (TN); Cardioverina (TN); Cepaverin (TN); Cerebid (TN); Cerespan (TN); Delapav (TN); Dicertan (TN); Dilaves (TN); Dispamil (TN); Drapavel (TN); Durapav (TN); Dynovas (TN); Forpaven (TN); Houde (TN); Mesotina (TN); Myobid (TN); Opdensit (TN); Optenyl (TN); Pameion (TN); Pamelon (TN); Panergon (TN); Papacon (TN); Papalease (TN); Papanerin-hcl; Papaversan (TN); Pavabid (TN); Pavacap (TN); Pavacen (TN); Pavadel (TN); Pavadyl (TN); Pavagen (TN); Pavakey (TN); Pavased (TN); Pavatest (TN); Paverina (TN); Paverolan (TN); Paveron (TN); Pavnell (TN); Qua bid (TN); Ro-Papav; Therapav (TN); Vasal (TN); Vaso-Pav; Vasospan (TN); Papanerin-hcl (TN); Papaverin-Hamelin (TN); Papital TR; Paptial TR; Ro-Papav (TN); Spasmo-Nit (TN); Vaso-Pav (TN); Pap-Kaps-150 (TN); Papital TR (TN); Paptial TR (TN); Isoquinoline,6,7-dimethoxy-1-veratryl-(8CI); Isoquinoline, 6,7-dimethoxy-1-veratryl-(8Cl); 1-[(3,4-Dimethoxyphenyl)methyl]6,7-dimethoxyisoquinoline; 1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxyisoquinoline; 1-{[3,4-bis(methyloxy)phenyl]methyl}-6,7-bis(methyloxy)isoquinoline; 4-[(6,7-Dimethoxyisoquinolyl)methyl]-1,2-dimethoxybenzene; 6,7-Dimethoxy-1-(3,4-dimethoxybenzyl)isoquinoline; 1-(3,4-DIMETHOXYBENZYL)-6,7-DIMETHOXYISOQUINOLINE DMCA9QP TC Vasodilator Agents DMCA9QP DT Small molecular drug DMCA9QP PC 4680 DMCA9QP MW 339.4 DMCA9QP FM C20H21NO4 DMCA9QP IC InChI=1S/C20H21NO4/c1-22-17-6-5-13(10-18(17)23-2)9-16-15-12-20(25-4)19(24-3)11-14(15)7-8-21-16/h5-8,10-12H,9H2,1-4H3 DMCA9QP CS COC1=C(C=C(C=C1)CC2=NC=CC3=CC(=C(C=C32)OC)OC)OC DMCA9QP IK XQYZDYMELSJDRZ-UHFFFAOYSA-N DMCA9QP IU 1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxyisoquinoline DMCA9QP CA CAS 58-74-2 DMCA9QP CB CHEBI:28241 DMCA9QP DE Spasm DMOC1BX ID DMOC1BX DMOC1BX DN Paraldehyde DMOC1BX HS Approved DMOC1BX SN UNII-S6M3YBG8QA; S6M3YBG8QA DMOC1BX DT Small molecular drug DMOC1BX PC 31264 DMOC1BX MW 132.16 DMOC1BX FM C6H12O3 DMOC1BX IC InChI=1S/C6H12O3/c1-4-7-5(2)9-6(3)8-4/h4-6H,1-3H3 DMOC1BX CS CC1OC(OC(O1)C)C DMOC1BX IK SQYNKIJPMDEDEG-UHFFFAOYSA-N DMOC1BX IU 2,4,6-trimethyl-1,3,5-trioxane DMOC1BX CA CAS 123-63-7 DMOC1BX CB CHEBI:27909 DMOC1BX DE Insomnia DMR5ZUP ID DMR5ZUP DMR5ZUP DN Paramethadione DMR5ZUP HS Approved DMR5ZUP SN Isoethadione; Paradione; Parametadiona; Parametadione; Paramethadionum; Parametadione [DCIT]; A 348; Paradione (TN); Parametadiona [INN-Spanish]; Paramethadione (INN); Paramethadione [BAN:INN]; Paramethadione [INN:BAN]; Paramethadionum [INN-Latin]; 3,5-Dimethyl-5-ethyloxazolidine-2,4-dione; 5-Ethyl-3,5-dimethyl-1,3-oxazolidine-2,4-dione; 5-Ethyl-3,5-dimethyl-2,4-oxazolidinedione DMR5ZUP TC Anticonvulsants DMR5ZUP DT Small molecular drug DMR5ZUP PC 8280 DMR5ZUP MW 157.17 DMR5ZUP FM C7H11NO3 DMR5ZUP IC InChI=1S/C7H11NO3/c1-4-7(2)5(9)8(3)6(10)11-7/h4H2,1-3H3 DMR5ZUP CS CCC1(C(=O)N(C(=O)O1)C)C DMR5ZUP IK VQASKUSHBVDKGU-UHFFFAOYSA-N DMR5ZUP IU 5-ethyl-3,5-dimethyl-1,3-oxazolidine-2,4-dione DMR5ZUP CA CAS 115-67-3 DMR5ZUP CB CHEBI:7921 DMR5ZUP DE Seizure disorder; Fetal trimethadione syndrome DM6PR40 ID DM6PR40 DM6PR40 DN Paramethasone DM6PR40 HS Approved DM6PR40 SN Cassenne; Cortiden; Dillar; Flumethone; Metilar; Parametasona; Parametasone; Paramethasonum; Paramezone; Parametasone [DCIT]; CS 1483; Dillar (TN); Parametasona [INN-Spanish]; Paramethasone (INN); Paramethasone [INN:BAN]; Paramethasonum [INN-Latin]; (6S,8S,9S,10R,11S,13S,14S,16R,17R)-6-fluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one; (6alpha,11beta,16alpha)-6-fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione; 16alpha-Methyl-6alpha-fluoroprednisolone; 6alpha-Fluoro-16alpha-methylprednisolone DM6PR40 CP Eli Lilly And Co DM6PR40 TC Antiinflammatory Agents DM6PR40 DT Small molecular drug DM6PR40 PC 5875 DM6PR40 MW 392.5 DM6PR40 FM C22H29FO5 DM6PR40 IC InChI=1S/C22H29FO5/c1-11-6-14-13-8-16(23)15-7-12(25)4-5-20(15,2)19(13)17(26)9-21(14,3)22(11,28)18(27)10-24/h4-5,7,11,13-14,16-17,19,24,26,28H,6,8-10H2,1-3H3/t11-,13+,14+,16+,17+,19-,20+,21+,22+/m1/s1 DM6PR40 CS C[C@@H]1C[C@H]2[C@@H]3C[C@@H](C4=CC(=O)C=C[C@@]4([C@H]3[C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)C)F DM6PR40 IK MKPDWECBUAZOHP-AFYJWTTESA-N DM6PR40 IU (6S,8S,9S,10R,11S,13S,14S,16R,17R)-6-fluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one DM6PR40 CA CAS 53-33-8 DM6PR40 CB CHEBI:7922 DM6PR40 DE Inflammation; Diabetic macular edema DMM0HR1 ID DMM0HR1 DMM0HR1 DN Pargyline DMM0HR1 HS Approved DMM0HR1 SN Benzylmethylpropargylamine; Benzylmethylpropynylamine; Eudatin; Eutron; Methylbenzylpropynylamine; Paragyline; Pargilina; Pargylamine; Pargylin; Pargylinum; Supirdyl; A 19120; MO 911; Pargilina [INN-Spanish]; Pargyline (INN); Pargyline [INN:BAN]; Pargylinum [INN-Latin]; Benzyl-methyl-2-propinylamin; Benzyl-methyl-2-propinylamin [Czech]; N-Methyl-N-benzylpropynylamine; N-Methyl-N-propargylbenzylamine; N-Methyl-N-2-propynylbenzylamine; N-Benzyl-N-methyl-2-propynylamine; N-Benzyl-N-methyl-2-propyn-1; N-Benzyl-N-methyl-2-propyn-1-amine; N-benzyl-N-methylprop-2-yn-1-amine; N-methyl-N-(phenylmethyl)prop-2-yn-1-amine DMM0HR1 CP Abbott Laboratories Pharmaceutical Products Div DMM0HR1 TC Antihypertensive Agents DMM0HR1 DT Small molecular drug DMM0HR1 PC 4688 DMM0HR1 MW 159.23 DMM0HR1 FM C11H13N DMM0HR1 IC InChI=1S/C11H13N/c1-3-9-12(2)10-11-7-5-4-6-8-11/h1,4-8H,9-10H2,2H3 DMM0HR1 CS CN(CC#C)CC1=CC=CC=C1 DMM0HR1 IK DPWPWRLQFGFJFI-UHFFFAOYSA-N DMM0HR1 IU N-benzyl-N-methylprop-2-yn-1-amine DMM0HR1 CA CAS 555-57-7 DMM0HR1 CB CHEBI:7930 DMM0HR1 DE Skin imperfections; Muscular dystrophy; Hypertension DMYBV3G ID DMYBV3G DMYBV3G DN Paricalcitol DMYBV3G HS Approved DMYBV3G SN Paracalcin; Zemplar; Abbott brand of paricalcitol; Paricalcitol [USAN]; Ab 122358; ABT-358; Zemplar (TN); Paricalcitol (USAN/INN); Paricalcitol, 19-nor-(OH)2-vitD2, paracalcin; (1R,3R)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5S)-6-hydroxy-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]cyclohexane-1,3-diol; (1R,3R,7E)-17beta-[(2R,3E,5S)-6-hydroxy-5,6-dimethylhept-3-en-2-yl]-9,10-secoestra-5,7-diene-1,3-diol; (1alpha.3beta,7E,22E)-19-Nor-9,10-secoergosta-5,7,22-triene-1,3,25-triol; (7E,22E)-19-Nor-9,10-secoergosta-5,7,22-triene-1alpha,3beta,25-triol; 19-Nor-1,25-(OH)2D2; 19-Nor-1-alpha,25-dihydroxyvitamin D2; 19-Nor-1alpha,25-dihydroxyvitamin D2; 19-Nor-9,10-secoergosta-5,7,22-triene-1,3,25-triol,(1alpha,3beta,7E,22E) DMYBV3G CP Abbott Laboratories DMYBV3G TC Parasympathomimetics DMYBV3G DT Small molecular drug DMYBV3G PC 5281104 DMYBV3G MW 416.6 DMYBV3G FM C27H44O3 DMYBV3G IC InChI=1S/C27H44O3/c1-18(8-9-19(2)26(3,4)30)24-12-13-25-21(7-6-14-27(24,25)5)11-10-20-15-22(28)17-23(29)16-20/h8-11,18-19,22-25,28-30H,6-7,12-17H2,1-5H3/b9-8+,21-11+/t18-,19+,22-,23-,24-,25+,27-/m1/s1 DMYBV3G CS C[C@H](/C=C/[C@H](C)C(C)(C)O)[C@H]1CC[C@@H]\\2[C@@]1(CCC/C2=C\\C=C3C[C@H](C[C@@H](C3)O)O)C DMYBV3G IK BPKAHTKRCLCHEA-UBFJEZKGSA-N DMYBV3G IU (1R,3R)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5S)-6-hydroxy-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]cyclohexane-1,3-diol DMYBV3G CA CAS 131918-61-1 DMYBV3G CB CHEBI:7931 DMYBV3G DE Hyperparathyroidism DM1AGXN ID DM1AGXN DM1AGXN DN Paromomycin DM1AGXN HS Approved DM1AGXN SN Aminosidin; Catenulin; Humatin; Hydroxymycin sulfate; Paramomycin Sulfate; Paromomycin I; Paromomycin sulfate Rx346208; Aminosidine, sulfate; HATT & Paromomycin; Humatin (TN); Paromomycin (INN); Paromomycin (TN); Paromomycin (complex); PA1-PA2-PA3-PA4; Human .alpha.-1-antitrypsin & Paromomyin; PAROMOMYCIN I, AMMINOSIDIN, CATENULIN, CRESTOMYCIN, MONOMYCIN A, NEOMYCIN E; (1R,2R,3S,4R,6S)-4,6-diamino-2-{[3-O-(2,6-diamino-2,6-dideoxy-beta-L-idopyranosyl)-beta-D-ribofuranosyl]oxy}-3-hydroxycyclohexyl 2-amino-2-deoxy-alpha-D-glucopyranoside; (2S,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-[(2R,3S,4R,5S)-5-[(1R,2R,3S,5R,6S)-3,5-diamino-2-[(2S,3R,4R,5S,6R)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol; O-2-Amino-2-deoxy-.alpha.-D-glucopyranosyl-(1->4)-O-[O-2,6-diamino-2,6-dideoxy-.beta.-L-idopyranosyl-(1->3)-.beta.D-ribofuranosyl(1->5)]-2-deoxy-D-streptamine DM1AGXN CP King Pharmaceuticals DM1AGXN TC Antibiotics DM1AGXN DT Small molecular drug DM1AGXN PC 165580 DM1AGXN MW 615.6 DM1AGXN FM C23H45N5O14 DM1AGXN IC InChI=1S/C23H45N5O14/c24-2-7-13(32)15(34)10(27)21(37-7)41-19-9(4-30)39-23(17(19)36)42-20-12(31)5(25)1-6(26)18(20)40-22-11(28)16(35)14(33)8(3-29)38-22/h5-23,29-36H,1-4,24-28H2/t5-,6+,7+,8-,9-,10-,11-,12+,13-,14-,15-,16-,17-,18-,19-,20-,21-,22-,23+/m1/s1 DM1AGXN CS C1[C@H]([C@@H]([C@H]([C@@H]([C@H]1N)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)N)O[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O[C@@H]4[C@@H]([C@H]([C@@H]([C@@H](O4)CN)O)O)N)O)O)N DM1AGXN IK UOZODPSAJZTQNH-LSWIJEOBSA-N DM1AGXN IU (2S,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-[(2R,3S,4R,5S)-5-[(1R,2R,3S,5R,6S)-3,5-diamino-2-[(2S,3R,4R,5S,6R)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol DM1AGXN CA CAS 7542-37-2 DM1AGXN CB CHEBI:7934 DM1AGXN DE Intestinal amebiasis DM5PVQE ID DM5PVQE DM5PVQE DN Paroxetine DM5PVQE HS Approved DM5PVQE SN Seroxat (TN) DM5PVQE CP GlaxoSmithKline DM5PVQE TC Antidepressants DM5PVQE DT Small molecular drug DM5PVQE PC 43815 DM5PVQE MW 329.4 DM5PVQE FM C19H20FNO3 DM5PVQE IC InChI=1S/C19H20FNO3/c20-15-3-1-13(2-4-15)17-7-8-21-10-14(17)11-22-16-5-6-18-19(9-16)24-12-23-18/h1-6,9,14,17,21H,7-8,10-12H2/t14-,17-/m0/s1 DM5PVQE CS C1CNC[C@H]([C@@H]1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4 DM5PVQE IK AHOUBRCZNHFOSL-YOEHRIQHSA-N DM5PVQE IU (3S,4R)-3-(1,3-benzodioxol-5-yloxymethyl)-4-(4-fluorophenyl)piperidine DM5PVQE CA CAS 61869-08-7 DM5PVQE CB CHEBI:7936 DM5PVQE DE Depression DMHM7JS ID DMHM7JS DMHM7JS DN Pasireotide DMHM7JS HS Approved DMHM7JS SN Signifor; UNII-I4P76SY3N4; Pasireotide diaspartate; I4P76SY3N4; SOM230; 820232-50-6; pasireotide aspartate; Pasireotide diaspartate [EMA EPAR]; CHEBI:72313; Cyclo((2R)-2-phenylglycyl-d-tryptophyl-l-lysyl-o-(phenylmethyl)-l-tyrosyl-l-phenylalanyl-(4R)-4-((((2-aminoethyl)amino)carbonyl)oxy)-l-prolyl), l-aspartate; Signifor (TN); SOM 230; SOM-230 DMHM7JS CP Novartis DMHM7JS DT Small molecular drug DMHM7JS PC 9941444 DMHM7JS MW 1047.2 DMHM7JS FM C58H66N10O9 DMHM7JS IC InChI=1S/C58H66N10O9/c59-27-13-12-22-46-52(69)64-47(30-38-23-25-42(26-24-38)76-36-39-16-6-2-7-17-39)53(70)66-49(31-37-14-4-1-5-15-37)57(74)68-35-43(77-58(75)61-29-28-60)33-50(68)55(72)67-51(40-18-8-3-9-19-40)56(73)65-48(54(71)63-46)32-41-34-62-45-21-11-10-20-44(41)45/h1-11,14-21,23-26,34,43,46-51,62H,12-13,22,27-33,35-36,59-60H2,(H,61,75)(H,63,71)(H,64,69)(H,65,73)(H,66,70)(H,67,72)/t43-,46+,47+,48-,49+,50+,51+/m1/s1 DMHM7JS CS C1[C@H](CN2[C@@H]1C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN DMHM7JS IK VMZMNAABQBOLAK-DBILLSOUSA-N DMHM7JS IU [(3S,6S,9S,12R,15S,18S,20R)-9-(4-aminobutyl)-3-benzyl-12-(1H-indol-3-ylmethyl)-2,5,8,11,14,17-hexaoxo-15-phenyl-6-[(4-phenylmethoxyphenyl)methyl]-1,4,7,10,13,16-hexazabicyclo[16.3.0]henicosan-20-yl] N-(2-aminoethyl)carbamate DMHM7JS CA CAS 396091-73-9 DMHM7JS CB CHEBI:72312 DMHM7JS DE Cushing disease DMMIQ20 ID DMMIQ20 DMMIQ20 DN Patiromer calcium DMMIQ20 HS Approved DMMIQ20 SN Patiromer; RLY-5016; Potassium binder (hyperkalemia), Relypsa DMMIQ20 CP Relypsa Inc DMMIQ20 DE Hyperkalemia DMWSA0V ID DMWSA0V DMWSA0V DN Patisiran DMWSA0V HS Approved DMWSA0V SN Patisiran [INN]; Patisiran [USAN:INN]; UNII-50FKX8CB2Y; 50FKX8CB2Y; ALN-18328 DMWSA0V CP Alnylam Pharmaceuticals DMWSA0V DT siRNA drug DMWSA0V SQ RNA, (A-U-G-G-A-A-Um-A-C-U-C-U-U-G-G-U-Um-A-C-dT-dT), complex with RNA(G-Um-A-A-Cm-Cm-A-A-G-A-G-Um-A-Um-Um-Cm-Cm-A-Um-dT-dT) (1:1) DMWSA0V DE Amyloidosis; Amyloid cardiomyopathy; Hereditary amyloidosis; Transthyretin familial amyloid cardiomyopathy DMF57DM ID DMF57DM DMF57DM DN Pazopanib DMF57DM HS Approved DMF57DM SN Pazopanib; Pazopanib (GW-786034); 444731-52-6; 5-((4-((2,3-dimethyl-2H-indazol-6-yl)(methyl)amino)pyrimidin-2-yl)amino)-2-methylbenzenesulfonamide; 5-(4-((2,3-dimethyl-2H-indazol-6-yl)(methyl)amino)pyrimidin-2-ylamino)-2-methylbenzenesulfonamide; 5-[[4-[(2,3-dimethylindazol-6-yl)-methyl-amino]pyrimidin-2-yl]amino]-2-methyl-benzenesulfonamide; 790713-33-6; 7RN5DR86CK; CHEBI:71219; DSSTox_CID_28659; DSSTox_GSID_48733; DSSTox_RID_82929; GW 78603; GW 786034; GW-786034; GW786034; MFCD11616589; NCGC00188865-01; UNII-7RN5DR86CK DMF57DM PC 10113978 DMF57DM MW 437.5 DMF57DM FM C21H23N7O2S DMF57DM IC CUIHSIWYWATEQL-UHFFFAOYSA-N DMF57DM CS CC1=C(C=C(C=C1)NC2=NC=CC(=N2)N(C)C3=CC4=NN(C(=C4C=C3)C)C)S(=O)(=O)N DMF57DM IK 1S/C21H23N7O2S/c1-13-5-6-15(11-19(13)31(22,29)30)24-21-23-10-9-20(25-21)27(3)16-7-8-17-14(2)28(4)26-18(17)12-16/h5-12H,1-4H3,(H2,22,29,30)(H,23,24,25) DMF57DM IU 5-[[4-[(2,3-dimethylindazol-6-yl)-methylamino]pyrimidin-2-yl]amino]-2-methylbenzenesulfonamide DMF57DM CA CAS 444731-52-6 DMF57DM CB CHEBI:71219 DMF57DM DE Renal cell carcinoma DM6U9CQ ID DM6U9CQ DM6U9CQ DN Pazopanib HCl DM6U9CQ HS Approved DM6U9CQ SN Votrient (TN) DM6U9CQ CP GlaxoSmithKline DM6U9CQ DT Small molecular drug DM6U9CQ PC 11525740 DM6U9CQ MW 474 DM6U9CQ FM C21H24ClN7O2S DM6U9CQ IC InChI=1S/C21H23N7O2S.ClH/c1-13-5-6-15(11-19(13)31(22,29)30)24-21-23-10-9-20(25-21)27(3)16-7-8-17-14(2)28(4)26-18(17)12-16;/h5-12H,1-4H3,(H2,22,29,30)(H,23,24,25);1H DM6U9CQ CS CC1=C(C=C(C=C1)NC2=NC=CC(=N2)N(C)C3=CC4=NN(C(=C4C=C3)C)C)S(=O)(=O)N.Cl DM6U9CQ IK MQHIQUBXFFAOMK-UHFFFAOYSA-N DM6U9CQ IU 5-[[4-[(2,3-dimethylindazol-6-yl)-methylamino]pyrimidin-2-yl]amino]-2-methylbenzenesulfonamide;hydrochloride DM6U9CQ CA CAS 635702-64-6 DM6U9CQ CB CHEBI:71217 DM6U9CQ DE Renal cell carcinoma DM49IGF ID DM49IGF DM49IGF DN Pefloxacin DM49IGF HS Approved DM49IGF SN Abactal; Labocton; PERFLOXACIN; PFLX; Peflacine; Pefloxacine; Pefloxacino; Pefloxacinum; Pefloxacin methanesulfonate; Silver Pefloxacin; AM-725; EU-5306; Pefloxacin [INN-French]; Pefloxacino [INN-Spanish]; Pefloxacinum [INN-Latin]; Pefloxacin (USAN/INN); Pefloxacin [USAN:BAN:INN]; 1-Ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(4-methyl-1-piperazinyl)-3-quinolinecarboxylic acid; 1-Ethyl-6-fluoro-1,4-dihydro-7-(4-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid; 1-ethyl-6-fluoro-7-(4-methyl-1-piperazinyl)-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid; 1-ethyl-6-fluoro-7-(4-methylpiperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 1-ethyl-6-fluoro-7-(4-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid; 3-Quinolinecarboxylic acid, 1-ethyl-6-fluoro-1,4-dihydro-7-(4-methyl-1-piperazinyl)-4-oxo DM49IGF TC Antiinfective Agents DM49IGF DT Small molecular drug DM49IGF PC 51081 DM49IGF MW 333.36 DM49IGF FM C17H20FN3O3 DM49IGF IC InChI=1S/C17H20FN3O3/c1-3-20-10-12(17(23)24)16(22)11-8-13(18)15(9-14(11)20)21-6-4-19(2)5-7-21/h8-10H,3-7H2,1-2H3,(H,23,24) DM49IGF CS CCN1C=C(C(=O)C2=CC(=C(C=C21)N3CCN(CC3)C)F)C(=O)O DM49IGF IK FHFYDNQZQSQIAI-UHFFFAOYSA-N DM49IGF IU 1-ethyl-6-fluoro-7-(4-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid DM49IGF CA CAS 70458-92-3 DM49IGF CB CHEBI:50199 DM49IGF DE Gonococcal urethritis DMOWEBU ID DMOWEBU DMOWEBU DN Pegaptanib DMOWEBU HS Approved DMOWEBU SN Macugen (TN); Pegaptanib Octasodium; Pegaptanib sodium; EYE 001; NX 1838; NX1838 DMOWEBU CP Eyetech pharmaceuticals and Pfizer DMOWEBU TC Antiangiogenic Agents DMOWEBU DT Aptamer DMOWEBU PC 56603655 DMOWEBU MW 541.6 DMOWEBU FM C22H44N3O10P DMOWEBU IC InChI=1S/C22H44N3O10P/c1-31-15-17-33-21(27)24-13-9-7-11-19(25-22(28)34-18-16-32-2)20(26)23-12-8-5-4-6-10-14-35-36(3,29)30/h19H,4-18H2,1-3H3,(H,23,26)(H,24,27)(H,25,28)(H,29,30)/t19-/m0/s1 DMOWEBU CS COCCOC(=O)NCCCC[C@@H](C(=O)NCCCCCCCOP(=O)(C)O)NC(=O)OCCOC DMOWEBU IK WLCZTRVUXYALDD-IBGZPJMESA-N DMOWEBU IU 7-[[(2S)-2,6-bis(2-methoxyethoxycarbonylamino)hexanoyl]amino]heptoxy-methylphosphinic acid DMOWEBU DE Neovascular age-related macular degeneration DM7UP8X ID DM7UP8X DM7UP8X DN Pegfilgrastim DM7UP8X HS Approved DM7UP8X SN Neulasta; Neulasta (TN); Pegfilgrastim (INN) DM7UP8X CP Amgen Inc DM7UP8X TC Immunomodulatory Agents DM7UP8X DT Small molecular drug DM7UP8X SQ Pegfilgrastim sequence: MTPLGPASSLPQSFLLKCLEQVRKIQGDGAALQEKLCATYKLCHPEELVLLGHSLGIPWAPLSSCPSQALQLAGCLSQLHSGLFLYQGLLQALEGISPELGPTLDTLQLDVADFATTIWQQMEELGMAPALQPTQGAMPAFASAFQRRAGGVLVASHLQSFLEVSYRVLRHLAQP DM7UP8X PC 70683024 DM7UP8X MW 730.7 DM7UP8X FM C27H46N4O19 DM7UP8X IC InChI=1S/C27H46N4O19/c1-10(16(28)23(40)41)48-24-18(30-11(2)33)21(39)20(38)14(49-24)9-47-27(25(42)43)6-12(34)17(22(50-27)19(37)13(35)8-32)31-15(36)7-29-26(44)46-5-4-45-3/h10,12-14,16-22,24,32,34-35,37-39H,4-9,28H2,1-3H3,(H,29,44)(H,30,33)(H,31,36)(H,40,41)(H,42,43)/t10-,12+,13-,14-,16+,17-,18-,19-,20+,21-,22-,24+,27-/m1/s1 DM7UP8X CS C[C@H]([C@@H](C(=O)O)N)O[C@@H]1[C@@H]([C@H]([C@H]([C@H](O1)CO[C@@]2(C[C@@H]([C@H]([C@@H](O2)[C@@H]([C@@H](CO)O)O)NC(=O)CNC(=O)OCCOC)O)C(=O)O)O)O)NC(=O)C DM7UP8X IK GAQMWPRWVIGRRV-IVDGIBIRSA-N DM7UP8X IU (2R,4S,5R,6R)-2-[[(2R,3R,4R,5R,6S)-5-acetamido-6-[(1S,2R)-1-amino-1-carboxypropan-2-yl]oxy-3,4-dihydroxyoxan-2-yl]methoxy]-4-hydroxy-5-[[2-(2-methoxyethoxycarbonylamino)acetyl]amino]-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid DM7UP8X DE Malignant solid tumour DMJI3BA ID DMJI3BA DMJI3BA DN Peginterferon alfa-2a DMJI3BA HS Approved DMJI3BA SN Pegasys; Peginterferon alfa-2a (genetical recombination); Peginterferon alfa-2a (USAN/INN); Peginterferon alfa-2a (genetical recombination) (JAN) DMJI3BA CP Hoffmann-La Roche pharmaceutical company DMJI3BA TC Anticancer Agents DMJI3BA SQ Peginterferon alfa-2a sequence: CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE DMJI3BA DE Hairy cell leukaemia DMAP58Y ID DMAP58Y DMAP58Y DN Peginterferon alfa-2b DMAP58Y HS Approved DMAP58Y SN PegIntron; Peginterferon alfa-2b (INN); Peginterferon alfa-2b (generical recombination); Peginterferon alfa-2b (generical recombination) (JAN) DMAP58Y CP Schering-Plough DMAP58Y TC Antiviral Agents DMAP58Y SQ DB00022 sequence: CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE DMAP58Y DE Hepatitis C virus infection DMCLR6G ID DMCLR6G DMCLR6G DN Pegloticase DMCLR6G HS Approved DMCLR6G SN Krystexxa (TN) DMCLR6G CP Savient DMCLR6G SQ Pegloticase: TYKKNDEVEFVRTGYGKDMIKVLHIQRDGKYHSIKEVATTVQLTLSSKKDYLHGDNSDVIPTDTIKNTVNVLAKFKGIKSIETFAVTICEHFLSSFKHVIRAQVYVEEVPWKRFEKNGVKHVHAFIYTPTGTHFCEVEQIRNGPPVIHSGIKDLKVLKTTQSGFEGFIKDQFTTLPEVKDRCFATQVYCKWRYHQGRDVDFEATWDTVRSIVLQKFAGPYDKGEYSPSVQKTLYDIQVLTLGQVPEIEDMEISLPNIHYLNIDMSKMGLINKEEVLLPLDNPYGKITGTVKRKLSSRL DMCLR6G DE Gout DM6NZ2P ID DM6NZ2P DM6NZ2P DN Pegvaliase DM6NZ2P HS Approved DM6NZ2P SN BMN 165; Pegvaliase [INN]; UNII-N6UAH27EUV; N6UAH27EUV DM6NZ2P CP BioMarin Pharmaceutical DM6NZ2P PC 86278362 DM6NZ2P MW 318.41 DM6NZ2P FM C15H30N2O5 DM6NZ2P IC InChI=1S/C15H30N2O5/c1-21-11-12-22-10-6-2-3-8-14(18)17-9-5-4-7-13(16)15(19)20/h13H,2-12,16H2,1H3,(H,17,18)(H,19,20)/t13-/m0/s1 DM6NZ2P CS COCCOCCCCCC(=O)NCCCC[C@@H](C(=O)O)N DM6NZ2P IK NPOCDVAOUKODSQ-ZDUSSCGKSA-N DM6NZ2P IU (2S)-2-amino-6-[6-(2-methoxyethoxy)hexanoylamino]hexanoic acid DM6NZ2P CA CAS 1585984-95-7 DM6NZ2P DE Phenylketonuria DMDEZI3 ID DMDEZI3 DMDEZI3 DN Pegvisomant DMDEZI3 HS Approved DMDEZI3 SN Somavent; Pegvisomant (genetical recombination); Somavent (TN); Somavert (TN); Pegvisomant (USAN/INN); Pegvisomant (genetical recombination) (JAN) DMDEZI3 CP Abbott Laboratories DMDEZI3 TC Anabolic Agents DMDEZI3 SQ DB00082 sequence: FPTIPLSRLFDNAMLRAHRLHQLAFDTYQEFEEAYIPKEQKYSFLQNPQTSLCFSESIPTPSNREETQQKSNLELLRISLLLIQSWLEPVQFLRSVFANSLVYGASDSNVYDLLKDLEEGIQTLMGRLEDGSPRTGQIFKQTYSKFDTNSHNDDALLKNYGLLYCFRKDMDKVETFLRIVQCRSVEGSCGF DMDEZI3 DE Acromegaly DMRH0D5 ID DMRH0D5 DMRH0D5 DN PEGylated IFN beta 1-a DMRH0D5 HS Approved DMRH0D5 SN BIIB-017; PEG-Avonex; PEGylated IFN beta 1-a (multiple sclerosis); PEGylated IFN beta 1-a (multiple sclerosis), Biogen Idec; PEGylated interferon beta 1-a (multiple sclerosis), Biogen Idec DMRH0D5 CP Biogen idec DMRH0D5 DE Type-2 diabetes DM8DQV9 ID DM8DQV9 DM8DQV9 DN Pelubiprofen DM8DQV9 HS Approved DM8DQV9 SN Pelubi; Rubione; CS-670; DW-330; RS-2131 DM8DQV9 CP Sankyo Co Ltd DM8DQV9 DT Small molecular drug DM8DQV9 PC 5282203 DM8DQV9 MW 258.31 DM8DQV9 FM C16H18O3 DM8DQV9 IC InChI=1S/C16H18O3/c1-11(16(18)19)13-8-6-12(7-9-13)10-14-4-2-3-5-15(14)17/h6-11H,2-5H2,1H3,(H,18,19)/b14-10+ DM8DQV9 CS CC(C1=CC=C(C=C1)/C=C/2\\CCCCC2=O)C(=O)O DM8DQV9 IK AUZUGWXLBGZUPP-GXDHUFHOSA-N DM8DQV9 IU 2-[4-[(E)-(2-oxocyclohexylidene)methyl]phenyl]propanoic acid DM8DQV9 CA CAS 69956-77-0 DM8DQV9 DE Back pain DMD1VZL ID DMD1VZL DMD1VZL DN Pemafibrate DMD1VZL HS Approved DMD1VZL SN K-877 DMD1VZL CP Kowa Co Ltd DMD1VZL PC 11526038 DMD1VZL MW 490.5 DMD1VZL FM C28H30N2O6 DMD1VZL IC InChI=1S/C28H30N2O6/c1-3-25(27(31)32)35-23-9-6-8-20(18-23)19-30(28-29-24-10-4-5-11-26(24)36-28)16-7-17-34-22-14-12-21(33-2)13-15-22/h4-6,8-15,18,25H,3,7,16-17,19H2,1-2H3,(H,31,32)/t25-/m1/s1 DMD1VZL CS CC[C@H](C(=O)O)OC1=CC=CC(=C1)CN(CCCOC2=CC=C(C=C2)OC)C3=NC4=CC=CC=C4O3 DMD1VZL IK ZHKNLJLMDFQVHJ-RUZDIDTESA-N DMD1VZL IU (2R)-2-[3-[[1,3-benzoxazol-2-yl-[3-(4-methoxyphenoxy)propyl]amino]methyl]phenoxy]butanoic acid DMD1VZL CA CAS 848259-27-8 DMD1VZL DE Lipid metabolism disorder; Cardiovascular disease; Hyperlipidemia DMFQEA6 ID DMFQEA6 DMFQEA6 DN Pembrolizumab DMFQEA6 HS Approved DMFQEA6 CP Merck Kenilworth, NJ DMFQEA6 DT Monoclonal antibody DMFQEA6 SQ Heavy Chain Sequence: QVQLVQSGVEVKKPGASVKVSCKASGYTFTNYYMYWVRQAPGQGLEWMGGINPSNGGTNFNEKFKNRVTLTTDSSTTTAYMELKSLQFDDTAVYYCARRDYRFDMGFDYWGQGTTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK >Light Chain SequenceEIVLTQSPATLSLSPGERATLSCRASKGVSTSGYSYLHWYQQKPGQAPRLLIYLASYLESGVPARFSGSGSGTDFTLTISSLEPEDFAVYYCQHSRDLPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC DMFQEA6 DE Solid tumour/cancer; Hepatocellular carcinoma; Ovarian cancer; Primary mediastinal B-cell lymphoma; Prostate cancer; Renal cell carcinoma; Small-cell lung cancer; Breast cancer; Colorectal cancer; Cutaneous squamous cell carcinoma; Esophageal cancer; Melanoma DMMX2E6 ID DMMX2E6 DMMX2E6 DN Pemetrexed DMMX2E6 HS Approved DMMX2E6 SN Alimta; LYA; LY 231514; LY231514; Alimta (TN); LY 231,514; LY-2315; LY-231514; Pemetrexed (INN); Pemetrexed [INN:BAN]; LY-231,514; N-(4-(2-(2-Amino-3,4-dihydro-4-oxo-7H-pyrrolo(2,3-d)pyrimdin-5-yl)ethyl)benzoyl)glutamic acid; N-{4-[2-(2-amino-4-oxo-4,7-dihydro-1h-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl}-d-glutamic acid; (2R)-2-[[4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioic acid; (2S)-2-[[4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioic acid; 2-[[4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioic acid; 2-{4-[2-(2-AMINO-4-OXO-4,7-DIHYDRO-3H-PYRROLO[2,3-D]PYRIMIDIN-5-YL)-ETHYL]-BENZOYLAMINO}-PENTANEDIOIC ACID DMMX2E6 CP Eli Lilly DMMX2E6 TC Anticancer Agents DMMX2E6 DT Small molecular drug DMMX2E6 PC 135410875 DMMX2E6 MW 427.4 DMMX2E6 FM C20H21N5O6 DMMX2E6 IC InChI=1S/C20H21N5O6/c21-20-24-16-15(18(29)25-20)12(9-22-16)6-3-10-1-4-11(5-2-10)17(28)23-13(19(30)31)7-8-14(26)27/h1-2,4-5,9,13H,3,6-8H2,(H,23,28)(H,26,27)(H,30,31)(H4,21,22,24,25,29)/t13-/m0/s1 DMMX2E6 CS C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)N[C@@H](CCC(=O)O)C(=O)O DMMX2E6 IK WBXPDJSOTKVWSJ-ZDUSSCGKSA-N DMMX2E6 IU (2S)-2-[[4-[2-(2-amino-4-oxo-3,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioic acid DMMX2E6 CA CAS 137281-23-3 DMMX2E6 CB CHEBI:63616 DMMX2E6 DE Malignant pleural mesothelioma DM819JF ID DM819JF DM819JF DN Pemigatinib DM819JF HS Approved DM819JF SN Unii-Y6BX7BL23K; UNII-Y6BX7BL23K; Y6BX7BL23K; GTPL9767; SCHEMBL15556271; HCDMJFOHIXMBOV-UHFFFAOYSA-N; example 126 [WO2014007951]; 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one; 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one; INCB54828 DM819JF CP Incyte Wilmington, DE DM819JF PC 86705695 DM819JF MW 487.5 DM819JF FM C24H27F2N5O4 DM819JF IC InChI=1S/C24H27F2N5O4/c1-4-30-21-14(11-27-23-16(21)9-15(28-23)13-29-5-7-35-8-6-29)12-31(24(30)32)22-19(25)17(33-2)10-18(34-3)20(22)26/h9-11H,4-8,12-13H2,1-3H3,(H,27,28) DM819JF CS CCN1C2=C3C=C(NC3=NC=C2CN(C1=O)C4=C(C(=CC(=C4F)OC)OC)F)CN5CCOCC5 DM819JF IK HCDMJFOHIXMBOV-UHFFFAOYSA-N DM819JF IU 11-(2,6-difluoro-3,5-dimethoxyphenyl)-13-ethyl-4-(morpholin-4-ylmethyl)-5,7,11,13-tetrazatricyclo[7.4.0.02,6]trideca-1,3,6,8-tetraen-12-one DM819JF CA CAS 1513857-77-6 DM819JF DE Bladder cancer; Myeloproliferative syndrome; Cholangiocarcinoma DML97WV ID DML97WV DML97WV DN Pemirolast DML97WV HS Approved DML97WV SN Pemirolastum; Pemirox; Pemirolast [INN]; Pemiroplast Potassium; Alamast (TN); Alegysal (TN); Pemirolast (INN); Pemirolastum [INN-Latin]; Pemirox (TN); 9-TBX; 9-methyl-3-(1H-tetrazol-5-yl)-4H-pyrido(1,2-a)pyrimidin-4-one; 9-methyl-3-(2H-tetrazol-5-yl)pyrido[1,2-a]pyrimidin-4-one DML97WV TC Antiallergic Agents DML97WV DT Small molecular drug DML97WV PC 57697 DML97WV MW 228.21 DML97WV FM C10H8N6O DML97WV IC InChI=1S/C10H8N6O/c1-6-3-2-4-16-9(6)11-5-7(10(16)17)8-12-14-15-13-8/h2-5H,1H3,(H,12,13,14,15) DML97WV CS CC1=CC=CN2C1=NC=C(C2=O)C3=NNN=N3 DML97WV IK HIANJWSAHKJQTH-UHFFFAOYSA-N DML97WV IU 9-methyl-3-(2H-tetrazol-5-yl)pyrido[1,2-a]pyrimidin-4-one DML97WV CA CAS 69372-19-6 DML97WV CB CHEBI:134936 DML97WV DE Allergic conjunctivitis DM4ES8F ID DM4ES8F DM4ES8F DN Penbutolol DM4ES8F HS Approved DM4ES8F SN Betapressin; Levatol; Levatolol; Levopenbutol; Lobeta; Paginol; Penbutololum; PENBUTOLOL SULFATE; HOE 893; HOE 893d; Betapressin (TN); Hostabloc (TN); L-Penbutolol; Levatol (TN); Levatolol (TN); Lobeta (TN); Paginol (TN); Penbutolol (INN); Penbutolol [INN:BAN]; Penbutololum [INN-Latin]; Penbutolol Sulfate (2:1); S(-)-Penbutolol; (-)-Penbutolol; (2S)-1-(tert-butylamino)-3-(2-cyclopentylphenoxy)propan-2-ol; 1-(tert-Butylamino)-3-(o-cyclopentylphenoxy)propan-2-ol DM4ES8F TC Antihypertensive Agents DM4ES8F DT Small molecular drug DM4ES8F PC 37464 DM4ES8F MW 291.4 DM4ES8F FM C18H29NO2 DM4ES8F IC InChI=1S/C18H29NO2/c1-18(2,3)19-12-15(20)13-21-17-11-7-6-10-16(17)14-8-4-5-9-14/h6-7,10-11,14-15,19-20H,4-5,8-9,12-13H2,1-3H3/t15-/m0/s1 DM4ES8F CS CC(C)(C)NC[C@@H](COC1=CC=CC=C1C2CCCC2)O DM4ES8F IK KQXKVJAGOJTNJS-HNNXBMFYSA-N DM4ES8F IU (2S)-1-(tert-butylamino)-3-(2-cyclopentylphenoxy)propan-2-ol DM4ES8F CA CAS 38363-40-5 DM4ES8F CB CHEBI:7954 DM4ES8F DE Hypertension DMOUMDV ID DMOUMDV DMOUMDV DN Penciclovir DMOUMDV HS Approved DMOUMDV SN penciclovir; 39809-25-1; Denavir; Penciclovirum; Vectavir; Penciclovirum [INN-Latin]; Pencyclovir; BRL-39123; BRL 39123; Penciclovir [USAN:INN:BAN]; Penciceovir; UNII-359HUE8FJC; CCRIS 9213; PE2 DMOUMDV TC Antiviral Agents DMOUMDV DT Small molecular drug DMOUMDV PC 135398748 DMOUMDV MW 253.26 DMOUMDV FM C10H15N5O3 DMOUMDV IC InChI=1S/C10H15N5O3/c11-10-13-8-7(9(18)14-10)12-5-15(8)2-1-6(3-16)4-17/h5-6,16-17H,1-4H2,(H3,11,13,14,18) DMOUMDV CS C1=NC2=C(N1CCC(CO)CO)N=C(NC2=O)N DMOUMDV IK JNTOCHDNEULJHD-UHFFFAOYSA-N DMOUMDV IU 2-amino-9-[4-hydroxy-3-(hydroxymethyl)butyl]-1H-purin-6-one DMOUMDV CA CAS 39809-25-1 DMOUMDV CB CHEBI:7956 DMOUMDV DE Human immunodeficiency virus infection DMG1DTE ID DMG1DTE DMG1DTE DN Penfluridol DMG1DTE HS Approved DMG1DTE SN PENFLURIDOL; 26864-56-2; Semap; 1-(4,4-bis(4-fluorophenyl)butyl)-4-(4-chloro-3-(trifluoromethyl)phenyl)piperidin-4-ol; TLP-607; McN-JR-16,341; 1-[4,4-Bis(4-fluorophenyl)butyl]-4-[4-chloro-3-(trifluoromethyl)phenyl]-4-piperidinol; Penfluridolum [INN-Latin]; C28H27ClF5NO; UNII-25TLU22Q8H; R 16341; EINECS 248-074-5; R-16341; BRN 1558826; CHEMBL47050; 25TLU22Q8H; MDLAAYDRRZXJIF-UHFFFAOYSA-N; 4-Piperidinol, 1-(4,4-bis(4-fluorophenyl)butyl)-4-(4-chloro-3-(trifluoromethyl)phenyl)-; 4-Piperidinol,; Hydroxamates DMG1DTE DT Small molecular drug DMG1DTE PC 33630 DMG1DTE MW 524 DMG1DTE FM C28H27ClF5NO DMG1DTE IC InChI=1S/C28H27ClF5NO/c29-26-12-7-21(18-25(26)28(32,33)34)27(36)13-16-35(17-14-27)15-1-2-24(19-3-8-22(30)9-4-19)20-5-10-23(31)11-6-20/h3-12,18,24,36H,1-2,13-17H2 DMG1DTE CS C1CN(CCC1(C2=CC(=C(C=C2)Cl)C(F)(F)F)O)CCCC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F DMG1DTE IK MDLAAYDRRZXJIF-UHFFFAOYSA-N DMG1DTE IU 1-[4,4-bis(4-fluorophenyl)butyl]-4-[4-chloro-3-(trifluoromethyl)phenyl]piperidin-4-ol DMG1DTE CA CAS 26864-56-2 DMG1DTE CB CHEBI:92278 DMG1DTE DE Schizophrenia DM40EF6 ID DM40EF6 DM40EF6 DN Penicillamine DM40EF6 HS Approved DM40EF6 SN D-Penicillamine; penicillamine; 52-67-5; Cuprimine; D-(-)-Penicillamine; 3-Mercapto-D-valine; Depen; Cuprenil; D-Penamine; (-)-Penicillamine; (2S)-2-Amino-3-methyl-3-sulfanylbutanoic acid; D-Mercaptovaline; Mercaptovaline; Perdolat; Penicillamin; Pendramine; Kuprenil; Depamine; Mercaptyl; Trolovol; Metalcaptase; Artamine; Cupripen; (S)-3,3-Dimethylcysteine; D-Valine, 3-mercapto-; Penicillaminum; Penicilamina; Sufirtan; beta-Thiovaline; Dimethylcysteine; D-beta,beta-Dimethylcysteine; D-3-Mercaptovaline; beta,beta-Dimethylcysteine; Penicillamina; Penicilllamine; Sufortan; Copper penicillaminate; D Penicillamine; Penicillamina [DCIT]; Reduced penicillamine; D 3 Mercaptovaline; TBB068824; Beta,beta Dimethylcysteine; Beta-Thiovaline; Cuprimine (TN); D-Penicilamine; D-Penicyllamine; Depen (TN); P-1280; Penicilamina [INN-Spanish]; Penicillaminate, Copper; Penicillaminum [INN-Latin]; Reduced D-penicillamine; Beta,beta-Dimethylcysteine; D,3-Mercaptovaline; D-beta-Mercaptovaline; Distamine (*Hydrochloride*); Metalcaptase (*Hydrochloride*); Penicillamine (JAN/USP/INN); Penicillamine [USAN:INN:BAN:JAN]; Alpha-Amino-beta-methyl-beta-mercaptobutyric acid; D-(-)-2-Amino-3-mercapto-3-methylbutanoic acid; (2S)-2-amino-3-methyl-3-sulfanyl-butanoic acid; (D)-PENICILLAMINE; (S)-Penicillamin; (S)-Penicillamine; 2-Amino-3-mercapto-3-methylbutanoic acid; 3,3-Dimethyl-D-cysteine; 3-Mercaptovaline; 3-sulfanyl-D-valine; D-penicillamine DM40EF6 TC Antidotes DM40EF6 DT Small molecular drug DM40EF6 PC 5852 DM40EF6 MW 149.21 DM40EF6 FM C5H11NO2S DM40EF6 IC InChI=1S/C5H11NO2S/c1-5(2,9)3(6)4(7)8/h3,9H,6H2,1-2H3,(H,7,8)/t3-/m0/s1 DM40EF6 CS CC(C)([C@H](C(=O)O)N)S DM40EF6 IK VVNCNSJFMMFHPL-VKHMYHEASA-N DM40EF6 IU (2S)-2-amino-3-methyl-3-sulfanylbutanoic acid DM40EF6 CA CAS 771431-20-0 DM40EF6 CB CHEBI:7959 DM40EF6 DE Rheumatoid arthritis DMNMHBV ID DMNMHBV DMNMHBV DN Penicillin DMNMHBV HS Approved DMNMHBV SN Cillin; Pentids; 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 3,3-Dimethyl-7-oxo-6-[(phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (Phenylmethyl)penicillin; 7005-30-3; NSC131815; (Phenylmethyl)penicillinic acid; 3,3-dimethyl-7-oxo-6-((phenylacetyl)amino)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; AC1L1DHC; AC1Q5UVJ; Penicilline G sodium salt; Oprea1_713794; Oprea1_861345; CHEMBL300052; SCHEMBL2109546; CTK2H5530 DMNMHBV DT Small molecular drug DMNMHBV PC 2349 DMNMHBV MW 334.4 DMNMHBV FM C16H18N2O4S DMNMHBV IC InChI=1S/C16H18N2O4S/c1-16(2)12(15(21)22)18-13(20)11(14(18)23-16)17-10(19)8-9-6-4-3-5-7-9/h3-7,11-12,14H,8H2,1-2H3,(H,17,19)(H,21,22) DMNMHBV CS CC1(C(N2C(S1)C(C2=O)NC(=O)CC3=CC=CC=C3)C(=O)O)C DMNMHBV IK JGSARLDLIJGVTE-UHFFFAOYSA-N DMNMHBV IU 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid DMNMHBV CA CAS 61-33-6 DMNMHBV DE Bacterial infection DM49VEW ID DM49VEW DM49VEW DN Penicillin G Benzathine DM49VEW HS Approved DM49VEW SN Bicillin L-a; Permapen; Bicillin DM49VEW CP King Pharmaceuticals Inc DM49VEW TC Antiinfective Agents DM49VEW DT Small molecular drug DM49VEW PC 656811 DM49VEW MW 981.2 DM49VEW FM C48H64N6O12S2 DM49VEW IC InChI=1S/2C16H18N2O4S.C16H20N2.4H2O/c2*1-16(2)12(15(21)22)18-13(20)11(14(18)23-16)17-10(19)8-9-6-4-3-5-7-9;1-3-7-15(8-4-1)13-17-11-12-18-14-16-9-5-2-6-10-16;;;;/h2*3-7,11-12,14H,8H2,1-2H3,(H,17,19)(H,21,22);1-10,17-18H,11-14H2;4*1H2/t2*11-,12+,14-;;;;;/m11...../s1 DM49VEW CS CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)CC3=CC=CC=C3)C(=O)O)C.CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)CC3=CC=CC=C3)C(=O)O)C.C1=CC=C(C=C1)CNCCNCC2=CC=CC=C2.O.O.O.O DM49VEW IK WIDKTXGNSOORHA-CJHXQPGBSA-N DM49VEW IU N,N'-dibenzylethane-1,2-diamine;(2S,5R,6R)-3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;tetrahydrate DM49VEW CA CAS 41372-02-5 DM49VEW DE Bacterial infection DMU4JLB ID DMU4JLB DMU4JLB DN Penicillin G Procaine DMU4JLB HS Approved DMU4JLB SN Duracillin A.S.; Pfizerpen-as DMU4JLB CP Eli Lilly And Co DMU4JLB TC Antiinfective Agents DMU4JLB DT Small molecular drug DMU4JLB PC 22502 DMU4JLB MW 588.7 DMU4JLB FM C29H40N4O7S DMU4JLB IC InChI=1S/C16H18N2O4S.C13H20N2O2.H2O/c1-16(2)12(15(21)22)18-13(20)11(14(18)23-16)17-10(19)8-9-6-4-3-5-7-9;1-3-15(4-2)9-10-17-13(16)11-5-7-12(14)8-6-11;/h3-7,11-12,14H,8H2,1-2H3,(H,17,19)(H,21,22);5-8H,3-4,9-10,14H2,1-2H3;1H2/t11-,12+,14-;;/m1../s1 DMU4JLB CS CCN(CC)CCOC(=O)C1=CC=C(C=C1)N.CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)CC3=CC=CC=C3)C(=O)O)C.O DMU4JLB IK KZDCMKVLEYCGQX-UDPGNSCCSA-N DMU4JLB IU 2-(diethylamino)ethyl 4-aminobenzoate;(2S,5R,6R)-3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;hydrate DMU4JLB CA CAS 6130-64-9 DMU4JLB DE Bacterial infection DMY18XK ID DMY18XK DMY18XK DN Penicillin G Sodium DMY18XK HS Approved DMY18XK SN Penicillin G sodium salt; 69-57-8; Benzylpenicillin sodium; Crystapen; American penicillin; Pencillin G sodium; Sodium penicillin G; BENZYLPENICILLIN SODIUM SALT; Sodium penicillin; Sodium benzylpenicillinate; Sodium penicillin II; Veticillin; Penilaryn; Mycofarm; Novocillin; Sodium benzylpenicillin; Kesso-Pen; Pen-A-Brasive; Sodium benzylpenicillin G; Monosodium benzylpenicillin; Benzylpenicillinic acid sodium salt; Sugracillin sodium salt; Penicillin G Sodium, Crystalline; Sodium benzylp DMY18XK CP Bristol Myers Squibb Spa DMY18XK TC Antiinfective Agents DMY18XK DT Small molecular drug DMY18XK PC 23668834 DMY18XK MW 356.4 DMY18XK FM C16H17N2NaO4S DMY18XK IC InChI=1S/C16H18N2O4S.Na/c1-16(2)12(15(21)22)18-13(20)11(14(18)23-16)17-10(19)8-9-6-4-3-5-7-9;/h3-7,11-12,14H,8H2,1-2H3,(H,17,19)(H,21,22);/q;+1/p-1/t11-,12+,14-;/m1./s1 DMY18XK CS CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)CC3=CC=CC=C3)C(=O)[O-])C.[Na+] DMY18XK IK FCPVYOBCFFNJFS-LQDWTQKMSA-M DMY18XK IU sodium;(2S,5R,6R)-3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate DMY18XK CA CAS 69-57-8 DMY18XK CB CHEBI:51765 DMY18XK DE Bacterial infection DMKVOYF ID DMKVOYF DMKVOYF DN Penicillin V DMKVOYF HS Approved DMKVOYF SN Apocillin; Apopen; Beromycin; Calcipen; Fenacilin; Fenospen; Fenossimetilpenicillina; Fenoximetilpenicilina; Fenoxymethylpenicillin; Fenoxypen; Meropenin; Oracillin; Oratren; Ospen; PNV; PVA; Phenocillin; Phenomycilline; Phenopenicillin; Phenoximethylpenicillinum; Phenoxomethylpenicillanyl; Phenoxomethylpenicillin; Phenoxymethylpenicillanyl; Phenoxymethylpenicillin; Phenoxymethylpenicilline; Phenoxymethylpenicillinum; Robicillin; Rocilin; Stabicillin; Vebecillin; Vegacillin; Acipen V; Compocillin V; Crystapen V; Distaquaine V; Eskacillian V; Eskacillin V; Fenossimetilpenicillina [DCIT]; Penicillin V [USAN]; Penicillin phenoxymethyl; Phenoxymethyl penicillin; Phenoxymethylenepenicillinic acid; Phenoxymethylpenicillinic acid; Phenoxymethylpenicillinic acid potassium salt; Acipen-v; Beromycin, Penicillin; Berromycin, Penicillin; Fenoximetilpenicilina [INN-Spanish]; Pen-Oral; Pen-V; Pen-vee; Penicillin V (USP); Penicillin, Phenoxymethyl; Phenoxymethylpenicillin (INN); Phenoxymethylpenicilline [INN-French]; Phenoxymethylpenicillinum [INN-Latin]; V-Cil; V-Cillin; V-Cylina; V-Cyline; V-Tablopen; P-Mega-Tablinen; V-Cillin (TN); (2S,5R,6R)-3,3-DIMETHYL-7-OXO-6-(2-PHENOXYACETAMIDO)-4-THIA-1-AZABICYCLO(3.2.0)HEPTANE-2-CARBOXYLIC ACID; (2S,5R,6R)-3,3-Dimethyl-7-oxo-6-(2-phenoxyacetamido)-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid; (2S,5R,6R)-3,3-Dimethyl-7-oxo-6-[(phenoxyacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-3,3-dimethyl-7-oxo-6-[(2-phenoxyacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-3,3-dimethyl-7-oxo-6-{[(phenyloxy)acetyl]amino}-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 2,2-dimethyl-6beta-[(phenoxyacetyl)amino]penam-3alpha-carbonyl; 2,2-dimethyl-6beta-[(phenoxyacetyl)amino]penam-3alpha-carboxylic acid; 3,3-Dimethyl-7-oxo-6-((phenyloxyacetyl)amino)-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid; 3,3-dimethyl-6beta-[(phenoxyacetyl)amino]penam-2alpha-carboxylic acid (PIN); 6-Phenoxyacetamidopenicillanic acid DMKVOYF TC Antibiotics DMKVOYF DT Small molecular drug DMKVOYF PC 6869 DMKVOYF MW 350.4 DMKVOYF FM C16H18N2O5S DMKVOYF IC InChI=1S/C16H18N2O5S/c1-16(2)12(15(21)22)18-13(20)11(14(18)24-16)17-10(19)8-23-9-6-4-3-5-7-9/h3-7,11-12,14H,8H2,1-2H3,(H,17,19)(H,21,22)/t11-,12+,14-/m1/s1 DMKVOYF CS CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)COC3=CC=CC=C3)C(=O)O)C DMKVOYF IK BPLBGHOLXOTWMN-MBNYWOFBSA-N DMKVOYF IU (2S,5R,6R)-3,3-dimethyl-7-oxo-6-[(2-phenoxyacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid DMKVOYF CA CAS 87-08-1 DMKVOYF CB CHEBI:27446 DMKVOYF DE Bacterial infection DM8LX76 ID DM8LX76 DM8LX76 DN Penicillin V Potassium DM8LX76 HS Approved DM8LX76 SN Ledercillin Vk; Pen-vee K; Pfizerpen Vk; Veetids; Veetids '125'; Veetids '250'; Uticillin Vk; Veetids '500' DM8LX76 CP Glaxosmithkline DM8LX76 TC Antiinfective Agents DM8LX76 DT Small molecular drug DM8LX76 PC 23676814 DM8LX76 MW 388.5 DM8LX76 FM C16H17KN2O5S DM8LX76 IC InChI=1S/C16H18N2O5S.K/c1-16(2)12(15(21)22)18-13(20)11(14(18)24-16)17-10(19)8-23-9-6-4-3-5-7-9;/h3-7,11-12,14H,8H2,1-2H3,(H,17,19)(H,21,22);/q;+1/p-1/t11-,12+,14-;/m1./s1 DM8LX76 CS CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)COC3=CC=CC=C3)C(=O)[O-])C.[K+] DM8LX76 IK HCTVWSOKIJULET-LQDWTQKMSA-M DM8LX76 IU potassium;(2S,5R,6R)-3,3-dimethyl-7-oxo-6-[(2-phenoxyacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate DM8LX76 CA CAS 132-98-9 DM8LX76 CB CHEBI:7967 DM8LX76 DE Bacterial infection DMZ9MO5 ID DMZ9MO5 DMZ9MO5 DN Pentaerythritol tetranitrate DMZ9MO5 HS Approved DMZ9MO5 SN PENTAERYTHRITOL TETRANITRATE; PETN; Penthrite; Nitropentaerythrite; Nitropentaerythritol; Nitropenta; Pentaerithrityl tetranitrate; Vasodiatol; Pentanitrine; Pentanitrol; Quintrate; Corpent; Baritrate; Angicap; Perityl; Peritrate; Penthrit; Antora; Erinit; Peridex-LA; 78-11-5; Deltrate-20; Neopentanetetrayl nitrate; Tetrasule; Pergitral; Pentritol; Pentrite; Nitrotalans; Kaytrate; Duotrate; Subicard; Rythritol; Prevangor; Pentryate; Nitropenton; Nitropent; Pentrate; Pentitrate; Pentafin; Nitrinal; Niperyth; Mycardol; Metranil; Lowetrate; Arcotrate DMZ9MO5 DT Small molecular drug DMZ9MO5 PC 6518 DMZ9MO5 MW 316.14 DMZ9MO5 FM C5H8N4O12 DMZ9MO5 IC InChI=1S/C5H8N4O12/c10-6(11)18-1-5(2-19-7(12)13,3-20-8(14)15)4-21-9(16)17/h1-4H2 DMZ9MO5 CS C(C(CO[N+](=O)[O-])(CO[N+](=O)[O-])CO[N+](=O)[O-])O[N+](=O)[O-] DMZ9MO5 IK TZRXHJWUDPFEEY-UHFFFAOYSA-N DMZ9MO5 IU [3-nitrooxy-2,2-bis(nitrooxymethyl)propyl] nitrate DMZ9MO5 CA CAS 78-11-5 DMZ9MO5 CB CHEBI:25879 DMZ9MO5 DE Angina pectoris DMRCLZB ID DMRCLZB DMRCLZB DN Pentagastrin DMRCLZB HS Approved DMRCLZB SN Peptavlon; Peptavlon (TN); Pentagastrin (JAN/USAN/INN); (3S)-4-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-3-[[(2S)-2-[[(2S)-3-(1H-indol-3-yl)-2-[3-(2-methylpropoxycarbonylamino)propanoylamino]propanoyl]amino]-4-methylsulfanylbutanoyl]amino]-4-oxobutanoic acid DMRCLZB TC Diagnostic Agents DMRCLZB DT Small molecular drug DMRCLZB PC 9853654 DMRCLZB MW 767.9 DMRCLZB FM C37H49N7O9S DMRCLZB IC InChI=1S/C37H49N7O9S/c1-37(2,3)53-36(52)39-16-14-30(45)41-28(19-23-21-40-25-13-9-8-12-24(23)25)34(50)42-26(15-17-54-4)33(49)44-29(20-31(46)47)35(51)43-27(32(38)48)18-22-10-6-5-7-11-22/h5-13,21,26-29,40H,14-20H2,1-4H3,(H2,38,48)(H,39,52)(H,41,45)(H,42,50)(H,43,51)(H,44,49)(H,46,47)/t26-,27-,28-,29-/m0/s1 DMRCLZB CS CC(C)(C)OC(=O)NCCC(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N DMRCLZB IK NEYNJQRKHLUJRU-DZUOILHNSA-N DMRCLZB IU (3S)-4-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-3-[[(2S)-2-[[(2S)-3-(1H-indol-3-yl)-2-[3-[(2-methylpropan-2-yl)oxycarbonylamino]propanoylamino]propanoyl]amino]-4-methylsulfanylbutanoyl]amino]-4-oxobutanoic acid DMRCLZB CA CAS 5534-95-2 DMRCLZB CB CHEBI:31974 DMRCLZB DE Diagnostic imaging DMHZJCG ID DMHZJCG DMHZJCG DN Pentamidine DMHZJCG HS Approved DMHZJCG SN Lomidine; Nebupent; PENTAM; PNT; Pentacarinat; Pentamide; Pentamidin; Pentamidina; Pentamidinum; Pneumopent; PENTAMIDINE ISETHIONATE; Pentamidina [DCIT]; Pentamidine isetionate; Pentamidine mesylate; MB 800; Pentam 300; Lomidine (TN); MB-800; Nebupent (as isethionate); Pentacarinat (as isethionate); Pentam 300 (as isethionate); Pentamidine (INN); Pentamidinum [INN-Latin]; RP-2512; Nebupent (*Isethionate); Pentacarinat (*Isethionate); Pentam 300 (*Isethionate); Pentamidine Isethionate 2-Hydroxy-Ethanesulfonic Acid;Pentamidine [INN:BAN:DCF]; RP 2512 (*Isethionate); P,p'-(Pentamethylenedioxy)bis[benzamidine]; P,p'-(Pentamethylenedioxy)dibenzamidine; P,p'-(Pentamethylene-dioxy)bis-benzamidine; Benzenecarboximidamide, 4,4'-(1,5-pentanediylbis(oxy))bis-(9CI); 1,3-BIS(4-AMIDINOPHENOXY)PENTANE; 4, 4'-Diamidinodiphenoxypentane; 4,4'-(1,5-Pentanediylbis(oxy))bis-benzenecarboximidamide; 4,4'-(Pentamethylenedioxy)dibenzamide; 4,4'-(Pentamethylenedioxy)dibenzamidine; 4,4'-Diamidino-.alpha.,.omega.-diphenoxypentane; 4,4'-Diamidinodiphenoxypentane; 4,4'-[pentane-1,5-diylbis(oxy)]dibenzenecarboximidamide; 4-[5-(4-Carbamimidoylphenoxy)pentoxy]benzenecarboximidamide DMHZJCG TC Antifungal Agents DMHZJCG DT Small molecular drug DMHZJCG PC 4735 DMHZJCG MW 340.4 DMHZJCG FM C19H24N4O2 DMHZJCG IC InChI=1S/C19H24N4O2/c20-18(21)14-4-8-16(9-5-14)24-12-2-1-3-13-25-17-10-6-15(7-11-17)19(22)23/h4-11H,1-3,12-13H2,(H3,20,21)(H3,22,23) DMHZJCG CS C1=CC(=CC=C1C(=N)N)OCCCCCOC2=CC=C(C=C2)C(=N)N DMHZJCG IK XDRYMKDFEDOLFX-UHFFFAOYSA-N DMHZJCG IU 4-[5-(4-carbamimidoylphenoxy)pentoxy]benzenecarboximidamide DMHZJCG CA CAS 100-33-4 DMHZJCG CB CHEBI:45081 DMHZJCG DE Fungal infection; Human immunodeficiency virus infection DM1XBHS ID DM1XBHS DM1XBHS DN Pentazocine DM1XBHS HS Approved DM1XBHS SN Fortalgesic; Fortalin; Fortral; Lexir; Liticon; Pentagin; Pentazocaine; Pentazocin; Pentazocina; Pentazocinum; Sosegon; Soseton; Sosigon; Talacen; Talwan; Pentazocina [DCIT]; NIH 7958; WIN 20228; Algopent (free base); Fortal (TN); Fortral (TN); Fortwin (TN); KF-1820; L-pentazocine; Pentazocinum [INN-Latin]; Talacen (TN); Talwin (TN); Talwin NX (TN); Talwin PX (TN); II-C-2; Pentazocine (JP15/USP/INN); Pentazocine [USAN:INN:BAN:JAN]; Pentazocine, Pentazocin, Sosegon, WIN 20228; (2R*,6R*,11R*)-1,2,3,4,5,6-Hexahydro-6,11-dimethyl-3-(3-methyl-2-butenyl)-2,6-methano-3-benzazocin-8-ol; (2R,6R,11R)-6,11-dimethyl-3-(3-methylbut-2-en-1-yl)-1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin-8-ol; (2alpha,6alpha,11R*)-(1)-1,2,3,4,5,6-Hexahydro-6,11-dimethyl-3-(3-methylbut-2-enyl)-2,6-methano-3-benzazocin-8-ol; 1,2,3,4,5,6-Hexahydro-6,11-dimethyl-3-(3-methyl-2-butenyl)-2,6-methano-3-benzazocin-8-ol; 1,2,3,4,5,6-Hexahydro-6,11-dimethyl-3-(3-methylbut-2-enyl)-2,6-methano-3-benzazocin-8-ol; 2'-Hydroxy-5,9-dimethyl-2-(3,3-dimethylallyl)-6,7-benzomorphan; 2-(3,3-Dimethylallyl)-2',2'-hydroxy-5,9-dimethyl-6,7-benzomorphan; 2-(3,3-Dimethylallyl)cyclazocine; 2-Dimethylallyl-5,9-dimethyl-2'-hydroxybenzomorphan; 3-(3-Methyl-2-butenyl)-1,2,3,4,5,6-hexahydro-6,11-dimethyl-2,6-methano-3-benzazocin-8-ol DM1XBHS CP Sterling Drug Company DM1XBHS TC Anesthetics DM1XBHS DT Small molecular drug DM1XBHS PC 441278 DM1XBHS MW 285.4 DM1XBHS FM C19H27NO DM1XBHS IC InChI=1S/C19H27NO/c1-13(2)7-9-20-10-8-19(4)14(3)18(20)11-15-5-6-16(21)12-17(15)19/h5-7,12,14,18,21H,8-11H2,1-4H3/t14-,18+,19+/m0/s1 DM1XBHS CS C[C@H]1[C@H]2CC3=C([C@@]1(CCN2CC=C(C)C)C)C=C(C=C3)O DM1XBHS IK VOKSWYLNZZRQPF-GDIGMMSISA-N DM1XBHS IU (1R,9R,13R)-1,13-dimethyl-10-(3-methylbut-2-enyl)-10-azatricyclo[7.3.1.02,7]trideca-2(7),3,5-trien-4-ol DM1XBHS CA CAS 359-83-1 DM1XBHS CB CHEBI:7982 DM1XBHS DE Pain DMFNH7L ID DMFNH7L DMFNH7L DN Pentobarbital DMFNH7L HS Approved DMFNH7L SN Aethaminalum; Dorsital; Etaminal; Ethaminal; Mebubarbital; Mebumal; Nebralin; Nembutal; Neodorm; Pentabarbital; Pentabarbitone; Pentobarbitale; Pentobarbitalum; Pentobarbitone; Pentobarbiturate; Rivadorm; Pentobarbital calcium; Pentobarbital suppository dosage form; Pentobarbitale [DCIT]; Pentobarbituric acid; Ethyl-propylmethylcarbinylbarbituric acid; Nembutal (TN); Nembutal (VAN); Neodorm (VAN); Neodorm (new); Pentobarbital (VAN); Pentobarbital [USP:INN]; Pentobarbital, Monosodium Salt; Pentobarbitalum [INN-Latin]; Pentobarbitone (VAN); Pentobarbital (USP/INN); (+-)-5-Ethyl-5-(1-methylbutyl)barbituric acid; 5-Ethyl-5-(1-methylbutyl)-2,4,6(1H,3H,5H)-pyrimidinetrione; 5-Ethyl-5-(1-methylbutyl)barbituric acid; 5-Ethyl-5-(1-methylbutyl)malonylurea; 5-Ethyl-5-(sec-pentyl)barbituric acid; 5-ethyl-2-hydroxy-5-(1-methylbutyl)pyrimidine-4,6(1H,5H)-dione; 5-ethyl-5-(pentan-2-yl)pyrimidine-2,4,6(1H,3H,5H)-trione;5-ethyl-5-pentan-2-yl-1,3-diazinane-2,4,6-trione DMFNH7L CP Oak Pharmaceuticals Inc DMFNH7L TC Hypnotics and Sedatives DMFNH7L DT Small molecular drug DMFNH7L PC 4737 DMFNH7L MW 226.27 DMFNH7L FM C11H18N2O3 DMFNH7L IC InChI=1S/C11H18N2O3/c1-4-6-7(3)11(5-2)8(14)12-10(16)13-9(11)15/h7H,4-6H2,1-3H3,(H2,12,13,14,15,16) DMFNH7L CS CCCC(C)C1(C(=O)NC(=O)NC1=O)CC DMFNH7L IK WEXRUCMBJFQVBZ-UHFFFAOYSA-N DMFNH7L IU 5-ethyl-5-pentan-2-yl-1,3-diazinane-2,4,6-trione DMFNH7L CA CAS 76-74-4 DMFNH7L CB CHEBI:7983 DMFNH7L DE Insomnia DM38VYQ ID DM38VYQ DM38VYQ DN Pentolinium DM38VYQ HS Approved DM38VYQ SN Pentolineum; Pentolonium; Pentolonum; 1,1'-pentane-1,5-diylbis(1-methylpyrrolidinium); 1-methyl-1-[5-(1-methylpyrrolidin-1-ium-1-yl)pentyl]pyrrolidin-1-ium DM38VYQ CP Wyeth Ayerst Laboratories DM38VYQ TC Antihypertensive Agents DM38VYQ DT Small molecular drug DM38VYQ PC 5850 DM38VYQ MW 240.43 DM38VYQ FM C15H32N2+2 DM38VYQ IC InChI=1S/C15H32N2/c1-16(12-6-7-13-16)10-4-3-5-11-17(2)14-8-9-15-17/h3-15H2,1-2H3/q+2 DM38VYQ CS C[N+]1(CCCC1)CCCCC[N+]2(CCCC2)C DM38VYQ IK XSBSKEQEUFOSDD-UHFFFAOYSA-N DM38VYQ IU 1-methyl-1-[5-(1-methylpyrrolidin-1-ium-1-yl)pentyl]pyrrolidin-1-ium DM38VYQ CA CAS 144-44-5 DM38VYQ CB CHEBI:347401 DM38VYQ DE Hypotension DM2HRKE ID DM2HRKE DM2HRKE DN Pentosan polysulfate DM2HRKE HS Approved DM2HRKE SN Elmiron; Pentosan sulfuric polyester; Polypentose sulfate; Elmiron (TN); Xylan,hydrogen sulfate; [(2R,3R,4S,5R)-2-hydroxy-5-[(2S,3R,4S,5R)-5-hydroxy-3,4-disulfooxyoxan-2-yl]oxy-3-sulfooxyoxan-4-yl] hydrogen sulfate DM2HRKE CP Ortho-McNeil Pharmaceutical DM2HRKE TC Anticoagulants DM2HRKE DT Small molecular drug DM2HRKE PC 37720 DM2HRKE MW 602.5 DM2HRKE FM C10H18O21S4 DM2HRKE IC InChI=1S/C10H18O21S4/c11-3-1-26-10(8(31-35(22,23)24)5(3)28-32(13,14)15)27-4-2-25-9(12)7(30-34(19,20)21)6(4)29-33(16,17)18/h3-12H,1-2H2,(H,13,14,15)(H,16,17,18)(H,19,20,21)(H,22,23,24)/t3-,4-,5+,6+,7-,8-,9-,10+/m1/s1 DM2HRKE CS C1[C@H]([C@@H]([C@H]([C@@H](O1)O[C@@H]2CO[C@H]([C@@H]([C@H]2OS(=O)(=O)O)OS(=O)(=O)O)O)OS(=O)(=O)O)OS(=O)(=O)O)O DM2HRKE IK FCCNSUIJIOOXEZ-SJYYZXOBSA-N DM2HRKE IU [(2R,3R,4S,5R)-2-hydroxy-5-[(2S,3R,4S,5R)-5-hydroxy-3,4-disulfooxyoxan-2-yl]oxy-3-sulfooxyoxan-4-yl] hydrogen sulfate DM2HRKE CA CAS 37300-21-3 DM2HRKE DE Painful bladder syndrome; Interstitial cystitis DM0HXDS ID DM0HXDS DM0HXDS DN Pentostatin DM0HXDS HS Approved DM0HXDS SN Coforin; Covidarabine; Deoxycoformycin; Nipent; Oncopent; Vidarbine; Vira A deaminase inhibitor; CL-67310465; CO-Vidarabine; Co-V; Nipent (TN); PD-81565; PD-ADI; Pentostatin (JAN/USAN/INN); (8R)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol; (8R)-3-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7,8-dihydro-4H-imidazo[4,5-d][1,3]diazepin-8-ol; (R)-3-(2-Deoxy-.beta.-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo(4,5-d)(1,3)diazepin-8-ol; 2'-DCF; 2'-Deoxycoformycin; 2'-Dexoycoformycin DM0HXDS TC Anticancer Agents DM0HXDS DT Small molecular drug DM0HXDS PC 439693 DM0HXDS MW 268.27 DM0HXDS FM C11H16N4O4 DM0HXDS IC InChI=1S/C11H16N4O4/c16-3-8-6(17)1-9(19-8)15-5-14-10-7(18)2-12-4-13-11(10)15/h4-9,16-18H,1-3H2,(H,12,13)/t6-,7+,8+,9+/m0/s1 DM0HXDS CS C1[C@@H]([C@H](O[C@H]1N2C=NC3=C2NC=NC[C@H]3O)CO)O DM0HXDS IK FPVKHBSQESCIEP-JQCXWYLXSA-N DM0HXDS IU (8R)-3-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7,8-dihydro-4H-imidazo[4,5-d][1,3]diazepin-8-ol DM0HXDS CA CAS 53910-25-1 DM0HXDS DE Hairy cell leukaemia DMU3DNC ID DMU3DNC DMU3DNC DN Pentoxifylline DMU3DNC HS Approved DMU3DNC SN Agapurin; Azupentat; Dimethyloxohexylxanthine; Durapental; Hemovas; Ikomio; Oxpentifylline; PENTOXYPHYLINE;PNX; Pentoxifilina; Pentoxifyllin; Pentoxifyllinum; Pentoxil; Pentoxiphyllin; Pentoxiphylline; Pentoxiphyllium; Pentoxyfylline; Pentoxyphyllin; Pentoxyphylline; Ralofect; Rentylin; Torental; Trental;Vasofirin; Vazofirin; Agapurin Retard; BL 191; BL191; EHT 0201; EHT0201; IN1161; P 1784; Artal (TN); BL-191; EHT-0201; EHT-201; Flexital (TN); Pentox (TN); Pentoxifilina [INN-Spanish]; Pentoxifyllinum [INN-Latin]; Pentoxil (TN); Pentoxin (TN); Trental (TN); Cis-9-Octadecenoyl coenzyme A; Pentoxifylline [USAN:INN:JAN]; Pentoxifylline (JAN/USP/INN); 1,2,3,6-Tetrahydro-3,7-dimethyl-1-(5-oxohexyl)-2,6-purindion; 1-(5-Oxohexyl)-3,7-dimethylxanthine; 1-(5-Oxohexyl)theobromine; 3,7-Dihydro-3,7-dimethyl-1-(5-oxohexyl)-1H-purine-2,6-dione; 3,7-Dimethyl-1-(5-oxo-hexyl)-3,7-dihydro-purine-2,6-dione; 3,7-Dimethyl-1-(5-oxohexyl) xantine; 3,7-Dimethyl-1-(5-oxohexyl)-1H,3H-purin-2,6-dione; 3,7-Dimethyl-1-(5-oxohexyl)-3,7-dihydro-1H-purine-2,6-dione; 3,7-Dimethyl-1-(5-oxohexyl)xanthine; 3,7-Dimethyl-1-(5-oxohexyl)xantine; 3,7-dimethyl-1-(5-oxohexyl)purine-2,6-dione DMU3DNC CP Aventis Pharmaceuticals Inc. DMU3DNC TC Vasodilator Agents DMU3DNC DT Small molecular drug DMU3DNC PC 4740 DMU3DNC MW 278.31 DMU3DNC FM C13H18N4O3 DMU3DNC IC InChI=1S/C13H18N4O3/c1-9(18)6-4-5-7-17-12(19)10-11(14-8-15(10)2)16(3)13(17)20/h8H,4-7H2,1-3H3 DMU3DNC CS CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C DMU3DNC IK BYPFEZZEUUWMEJ-UHFFFAOYSA-N DMU3DNC IU 3,7-dimethyl-1-(5-oxohexyl)purine-2,6-dione DMU3DNC CA CAS 6493-05-6 DMU3DNC CB CHEBI:7986 DMU3DNC DE Intermittent claudication DMNXY5K ID DMNXY5K DMNXY5K DN Peramivir DMNXY5K HS Approved DMNXY5K SN PeramiFlu; S-021812; (1S,2S,3S,4R)-3-(1-acetamido-2-ethylbutyl)-4-(diaminomethylideneamino)-2-hydroxycyclopentane-1-carboxylic acid; (1S,2S,3S,4R)-3-[(1S)-1-acetamido-2-ethylbutyl]-4-(diaminomethylideneamino)-2-hydroxycyclopentane-1-carboxylic acid; PRV DMNXY5K CP BioCryst Pharmaceuticals DMNXY5K DT Small molecular drug DMNXY5K PC 154234 DMNXY5K MW 328.41 DMNXY5K FM C15H28N4O4 DMNXY5K IC InChI=1S/C15H28N4O4/c1-4-8(5-2)12(18-7(3)20)11-10(19-15(16)17)6-9(13(11)21)14(22)23/h8-13,21H,4-6H2,1-3H3,(H,18,20)(H,22,23)(H4,16,17,19)/t9-,10+,11+,12-,13+/m0/s1 DMNXY5K CS CCC(CC)[C@@H]([C@H]1[C@@H](C[C@@H]([C@H]1O)C(=O)O)N=C(N)N)NC(=O)C DMNXY5K IK XRQDFNLINLXZLB-CKIKVBCHSA-N DMNXY5K IU (1S,2S,3S,4R)-3-[(1S)-1-acetamido-2-ethylbutyl]-4-(diaminomethylideneamino)-2-hydroxycyclopentane-1-carboxylic acid DMNXY5K CA CAS 330600-85-6 DMNXY5K CB CHEBI:85202 DMNXY5K DE Influenza virus infection DM2AOTZ ID DM2AOTZ DM2AOTZ DN Perazine DM2AOTZ HS Approved DM2AOTZ SN Perazine maleate; Phenothiazine, 10-(3-(4-methyl-1-piperazinyl)propyl)-, maleate; 84-97-9 (Parent); 10H-Phenothiazine, 10-(3-(4-methyl-1-piperazinyl)propyl)-, (Z)-2-butenedioate; SCHEMBL220704; AC1O6123; LS-105593; 10-[3-(4-methylpiperazin-1-yl)propyl]phenothiazine DM2AOTZ DT Small molecular drug DM2AOTZ PC 4744 DM2AOTZ MW 339.5 DM2AOTZ FM C20H25N3S DM2AOTZ IC InChI=1S/C20H25N3S/c1-21-13-15-22(16-14-21)11-6-12-23-17-7-2-4-9-19(17)24-20-10-5-3-8-18(20)23/h2-5,7-10H,6,11-16H2,1H3 DM2AOTZ CS CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=CC=CC=C42 DM2AOTZ IK WEYVCQFUGFRXOM-UHFFFAOYSA-N DM2AOTZ IU 10-[3-(4-methylpiperazin-1-yl)propyl]phenothiazine DM2AOTZ CA CAS 84-97-9 DM2AOTZ CB CHEBI:59118 DM2AOTZ DE Psychotic disorder DM14MAE ID DM14MAE DM14MAE DN Pergolide DM14MAE HS Approved DM14MAE SN Pergolida; Pergolidum; Permax; Pergolida [INN-Spanish]; Pergolide (INN); Pergolide [INN:BAN]; Pergolidum [INN-Latin]; Permax (TN); LY-127,809; (6aR,9R,10aR)-9-(Methylthiomethyl)-7-propyl-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinoline; (8beta)-8-[(methylsulfanyl)methyl]-6-propylergoline; (8beta)-8-[(methylthio)methyl]-6-propylergoline DM14MAE CP Valeant Pharmaceuticals DM14MAE TC Antiparkinson Agents DM14MAE DT Small molecular drug DM14MAE PC 47811 DM14MAE MW 314.5 DM14MAE FM C19H26N2S DM14MAE IC InChI=1S/C19H26N2S/c1-3-7-21-11-13(12-22-2)8-16-15-5-4-6-17-19(15)14(10-20-17)9-18(16)21/h4-6,10,13,16,18,20H,3,7-9,11-12H2,1-2H3/t13-,16-,18-/m1/s1 DM14MAE CS CCCN1C[C@@H](C[C@H]2[C@H]1CC3=CNC4=CC=CC2=C34)CSC DM14MAE IK YEHCICAEULNIGD-MZMPZRCHSA-N DM14MAE IU (6aR,9R,10aR)-9-(methylsulfanylmethyl)-7-propyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline DM14MAE CA CAS 66104-22-1 DM14MAE CB CHEBI:63617 DM14MAE DE Parkinson disease DM5GKOV ID DM5GKOV DM5GKOV DN Pergolide mesylate DM5GKOV HS Approved DM5GKOV SN Pergolida; Pergolide (mesylate); Pergolide Methanesulfonate; Pergolide mesilate; Permax (TN); LY127809; PERGOLIDE MESYLATE; PERGOLIDE MESYLATE SALT; 55B9HQY616; 66104-23-2; 8-beta-((Methylthio)methyl)-6-propylergoline methanesulfonate; 8-beta-((Methylthio)methyl)-6-propylergoline monomethane sulfonate; 8beta-((Methylthio)methyl)-6-propylergoline monomethanesulfonate; CHEBI:8021; CHEMBL1275; CPD000058504; DSSTox_CID_20583; DSSTox_GSID_40583; DSSTox_RID_77029; MLS000069837; MPE; SMR000058504; UNII-55B9HQY616; LY-127,809; LY-127809; Pergolida [INN-Spanish]; Pergolide (INN); Pergolide [INN:BAN]; Pergolidum; Pergolidum [INN-Latin]; Permax; Prestwick0_000295; Prestwick1_000295; Prestwick2_000295; Prestwick3_000295; SR-01000721840; Spectrum2_001970; Spectrum4_000835; Spectrum5_001649; Spectrum_001647; TNP00315; pergolide; (8beta)-8-[(methylsulfanyl)methyl]-6-propylergoline; 24MJ822NZ9; 66104-22-1; CHEBI:63617; CHEMBL531; Ergoline, 8-((methylthio)methyl)-6-propyl-, (8beta)-; NCGC00017366-04; UNII-24MJ822NZ9 DM5GKOV PC 47812 DM5GKOV MW 410.6 DM5GKOV FM C20H30N2O3S2 DM5GKOV IC UWCVGPLTGZWHGS-ZORIOUSZSA-N DM5GKOV CS CCCN1CC(CC2C1CC3=CNC4=CC=CC2=C34)CSC.CS(=O)(=O)O DM5GKOV IK 1S/C19H26N2S.CH4O3S/c1-3-7-21-11-13(12-22-2)8-16-15-5-4-6-17-19(15)14(10-20-17)9-18(16)21;1-5(2,3)4/h4-6,10,13,16,18,20H,3,7-9,11-12H2,1-2H3;1H3,(H,2,3,4)/t13-,16-,18-;/m1./s1 DM5GKOV IU (6aR,9R,10aR)-9-(methylsulfanylmethyl)-7-propyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline;methanesulfonic acid DM5GKOV CA CAS 66104-23-2 DM5GKOV CB CHEBI:8021 DM5GKOV DE Parkinsonism DMINO7Z ID DMINO7Z DMINO7Z DN Perhexiline DMINO7Z HS Approved DMINO7Z SN Perhexilene; Perhexilina; Perhexilinum; Perhexilline; Perhexilina [INN-Spanish]; Perhexiline (INN); Perhexiline [INN:BAN]; Perhexilinum [INN-Latin]; (+)-2-(2,2-Dicyclohexylethyl)piperidine; (-)-2-(2,2-Dicyclohexylethyl)piperidine; 2-(2,2-Dicyclohexylethyl)piperidine DMINO7Z TC Vasodilator Agents DMINO7Z DT Small molecular drug DMINO7Z PC 4746 DMINO7Z MW 277.5 DMINO7Z FM C19H35N DMINO7Z IC InChI=1S/C19H35N/c1-3-9-16(10-4-1)19(17-11-5-2-6-12-17)15-18-13-7-8-14-20-18/h16-20H,1-15H2 DMINO7Z CS C1CCC(CC1)C(CC2CCCCN2)C3CCCCC3 DMINO7Z IK CYXKNKQEMFBLER-UHFFFAOYSA-N DMINO7Z IU 2-(2,2-dicyclohexylethyl)piperidine DMINO7Z CA CAS 39648-47-0 DMINO7Z CB CHEBI:35553 DMINO7Z DE Angina pectoris DMOPZDT ID DMOPZDT DMOPZDT DN Perindopril DMOPZDT HS Approved DMOPZDT SN ACEON; Coverex; Coversum; Coversyl; Prestarium; Coverene Cor; Cpd with unspecified MF; Aceon (TN); Acertil (TN); Armix (TN); Coverene (TN); Coverex (TN); Coversum (TN); DW-7950; Prestarium (TN); Prexanil (TN); Prexum (TN); Procaptan (TN); S-9490; SED-9490; McN-A-2833; Perindopril (USAN/INN); Ethyl N-{(2S)-1-[(2S,3aS,7aS)-2-carboxyoctahydro-1H-indol-1-yl]-1-oxopropan-2-yl}-L-norvalinate; (2S)-2-[(1S)-1-Carbethoxybutylamino]-1-oxopropyl-(2S,3aS,7aS)-perhydroindole-2-carboxylic acid; (2S,3aS,7aS)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxopentan-2-yl]amino]propanoyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carboxylic acid; (2S,3aS,7aS)-1-[(2S)-2-{[(2S)-1-ethoxy-1-oxopentan-2-yl]amino}propanoyl]octahydro-1H-indole-2-carboxylic acid DMOPZDT TC Antihypertensive Agents DMOPZDT DT Small molecular drug DMOPZDT PC 107807 DMOPZDT MW 368.5 DMOPZDT FM C19H32N2O5 DMOPZDT IC InChI=1S/C19H32N2O5/c1-4-8-14(19(25)26-5-2)20-12(3)17(22)21-15-10-7-6-9-13(15)11-16(21)18(23)24/h12-16,20H,4-11H2,1-3H3,(H,23,24)/t12-,13-,14-,15-,16-/m0/s1 DMOPZDT CS CCC[C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(=O)O DMOPZDT IK IPVQLZZIHOAWMC-QXKUPLGCSA-N DMOPZDT IU (2S,3aS,7aS)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxopentan-2-yl]amino]propanoyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carboxylic acid DMOPZDT CA CAS 82834-16-0 DMOPZDT CB CHEBI:8024 DMOPZDT DE Hypertension DMZ0Q1G ID DMZ0Q1G DMZ0Q1G DN Permethrin DMZ0Q1G HS Approved DMZ0Q1G SN Ambush; PerFoam; Transpermethrin; Acticin Cream; Elimite Cream; Nix Cream Rinse; Transpermethrin [ISO];FMC 35171; NRDC 146; NRDC 148; PS758_SUPELCO; Permethrin (isomers); Permethrin (isomers) solution; Permethrine,c&t; Trans-(+-)-Permethrin; [3-(phenyloxy)phenyl]methyl 3-(2,2-dichloroethenyl)-2,2-dimethylcyclopropanecarboxylate; (+)-CIS-PERMETHRIN; (+)-trans-Permethrin; (+-)-cis-Fmc 33297; (+-)-cis-Permethrin; (+-)-trans-Permethrin; (3-Phenoxyphenyl)methyl (+-)-cis,trans-3-(2,2-dichloroethenyl)-2,2-dimethylcyclopropanecarboxylate; (3-phenoxyphenyl)methyl 3-(2,2-dichloroethenyl)-2,2-dimethylcyclopropane-1-carboxylate; 1RS,cis-Permethrin; 1RS-trans-Permethrin; 3-Phenoxybenzyle (1RS)-cis, trans-3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropane carboxylate; 3-phenoxybenzyl 3-(2,2-dichloroethenyl)-2,2-dimethylcyclopropanecarboxylate DMZ0Q1G TC Insecticides DMZ0Q1G DT Small molecular drug DMZ0Q1G PC 40326 DMZ0Q1G MW 391.3 DMZ0Q1G FM C21H20Cl2O3 DMZ0Q1G IC InChI=1S/C21H20Cl2O3/c1-21(2)17(12-18(22)23)19(21)20(24)25-13-14-7-6-10-16(11-14)26-15-8-4-3-5-9-15/h3-12,17,19H,13H2,1-2H3 DMZ0Q1G CS CC1(C(C1C(=O)OCC2=CC(=CC=C2)OC3=CC=CC=C3)C=C(Cl)Cl)C DMZ0Q1G IK RLLPVAHGXHCWKJ-UHFFFAOYSA-N DMZ0Q1G IU (3-phenoxyphenyl)methyl 3-(2,2-dichloroethenyl)-2,2-dimethylcyclopropane-1-carboxylate DMZ0Q1G CA CAS 52645-53-1 DMZ0Q1G CB CHEBI:34911 DMZ0Q1G DE Sarcoptes scabiei infection DMVHJLX ID DMVHJLX DMVHJLX DN Perospirone DMVHJLX HS Approved DMVHJLX SN Lullan; SM-9018 DMVHJLX CP Sumitomo Pharmaceuticals Co Ltd DMVHJLX DT Small molecular drug DMVHJLX PC 115368 DMVHJLX MW 426.6 DMVHJLX FM C23H30N4O2S DMVHJLX IC InChI=1S/C23H30N4O2S/c28-22-17-7-1-2-8-18(17)23(29)27(22)12-6-5-11-25-13-15-26(16-14-25)21-19-9-3-4-10-20(19)30-24-21/h3-4,9-10,17-18H,1-2,5-8,11-16H2/t17-,18+ DMVHJLX CS C1CC[C@H]2[C@@H](C1)C(=O)N(C2=O)CCCCN3CCN(CC3)C4=NSC5=CC=CC=C54 DMVHJLX IK FBVFZWUMDDXLLG-HDICACEKSA-N DMVHJLX IU (3aR,7aS)-2-[4-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]butyl]-3a,4,5,6,7,7a-hexahydroisoindole-1,3-dione DMVHJLX CA CAS 150915-41-6 DMVHJLX CB CHEBI:94777 DMVHJLX DE Psychotic disorder DMA4MRX ID DMA4MRX DMA4MRX DN Perphenazine DMA4MRX HS Approved DMA4MRX SN Chlorperphenazine; Chlorpiprazine; Decentan; Emesinal; Etaperazin; Etaperazine; Ethaperazine; Fentazin;PZC; Perfenazina; Perfenazine; Perphenan; Perphenazin; Perphenazinum; Thilatazin; Tranquisan; Trifaron; Trilafon; Trilifan; Triphenot; Perfenazina [Italian]; Perphenazine [Trilafon]; Perphenazine maleate; P 6402; Sch 3940; Apo-Perphenazine; F-mon; Perfenazina [INN-Spanish]; Perphenazinum [INN-Latin]; SCH-3940; Siquil (TN); Triavil (TN); Perphenazine [INN:BAN:JAN]; Perphenazine (JP15/USP/INN); Gamma-[4-(beta-Hydroxyethyl)piperazin-1-yl]propyl-2-chlorophenothiazine; Gamma-(4-(beta-Hydroxyethyl)piperazin-1-yl)propyl-2-chlorophenothiazine; 1',1-(2-Idrossietil)-4,3-(2-cloro-10-fenotiazil)propilpiperazina; 1',1-(2-Idrossietil)-4,3-(2-cloro-10-fenotiazil)propilpiperazina [Italian]; 1-(2-Hydroxyethyl)-4-(3-(2-chloro-10-phenothiazinyl)propyl)piperazine; 1-(2-Hydroxyethyl)-4-[3-(2-chloro-10-phenothiazinyl)propyl]piperazine; 1-Piperazineethanol, 4-[3-(2-chlorophenothiazin-10-yl)propyl]-, trihydrochloride; 2-(4-[3-(2-Chloro-10H-phenothiazin-10-yl)propyl]-1-piperazinyl)ethanol; 2-Chloro-10-(3-(1-(2-hydroxyethyl)-4-piperazinyl)propyl)phenothiazine; 2-Chloro-10-(3-(4-(2-hydroxyethyl)piperazin-1-yl)propyl)phenothiazine; 2-Chloro-10-3-(1-(2-hydroxyethyl)-4-piperazinyl)propyl phenothiazine; 2-Chloro-10-3-[1-(2-hydroxyethyl)-4-piperazinyl]propyl phenothiazine; 2-Chloro-10-[3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl]phenothiazine; 2-[4-[3-(2-Chlorophenothiazin-10-yl)propyl]piperazin-1-yl]ethanol;2-{4-[3-(2-Chloro-phenothiazin-10-yl)-propyl]-piperazin-1-yl}-ethanol; 2-{4-[3-(2-chloro-10H-phenothiazin-10-yl)propyl]piperazin-1-yl}ethanol; 4-(3-(2-Chlorophenothiazin-10-yl)propyl)-1-piperazineethanol; 4-[3-(2-Chloro-10H-phenothiazin-10-yl)propyl]-1-piperazineethanol; 4-[3-(2-Chlorophenothiazin-10-yl)propyl]-1-piperazineethanol DMA4MRX CP Schering-Plough Corporation DMA4MRX TC Antipsychotic Agents DMA4MRX DT Small molecular drug DMA4MRX PC 4748 DMA4MRX MW 404 DMA4MRX FM C21H26ClN3OS DMA4MRX IC InChI=1S/C21H26ClN3OS/c22-17-6-7-21-19(16-17)25(18-4-1-2-5-20(18)27-21)9-3-8-23-10-12-24(13-11-23)14-15-26/h1-2,4-7,16,26H,3,8-15H2 DMA4MRX CS C1CN(CCN1CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl)CCO DMA4MRX IK RGCVKNLCSQQDEP-UHFFFAOYSA-N DMA4MRX IU 2-[4-[3-(2-chlorophenothiazin-10-yl)propyl]piperazin-1-yl]ethanol DMA4MRX CA CAS 58-39-9 DMA4MRX CB CHEBI:8028 DMA4MRX DE Schizophrenia DMHJV0X ID DMHJV0X DMHJV0X DN Pertuzumab DMHJV0X HS Approved DMHJV0X SN Pertuzumab (genetical recombination); Pertuzumab (USAN/INN); Pertuzumab (genetical recombination) (JAN); Pertuzumab (ERBB2 mAb inhibitor) DMHJV0X CP Roche; Genentech DMHJV0X DT Monoclonal antibody DMHJV0X SQ Amino acid sequence for pertuzumab light chain : DIQMTQSPSSLSASVGDRVTITCKASQDVSIGVAWYQQKPGKAPKLLIYSASYRYTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYYIYPYTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC >Amino acid sequence for pertuzumab heavy chain EVQLVESGGGLVQPGGSLRLSCAASGFTFTDYTMDWVRQAPGKGLEWVADVNPNSGGSIYNQRFKGRFTLSVDRSKNTLYLQMNSLRAEDTAVYYCARNLGPSFYFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG DMHJV0X DE Breast cancer DMS2J0Z ID DMS2J0Z DMS2J0Z DN Pexidartinib DMS2J0Z HS Approved DMS2J0Z SN PLX-3397 DMS2J0Z CP Plexxikon Inc DMS2J0Z PC 25151352 DMS2J0Z MW 417.8 DMS2J0Z FM C20H15ClF3N5 DMS2J0Z IC InChI=1S/C20H15ClF3N5/c21-15-6-16-14(10-28-19(16)29-11-15)5-12-2-4-18(26-7-12)27-9-13-1-3-17(25-8-13)20(22,23)24/h1-4,6-8,10-11H,5,9H2,(H,26,27)(H,28,29) DMS2J0Z CS C1=CC(=NC=C1CC2=CNC3=C2C=C(C=N3)Cl)NCC4=CN=C(C=C4)C(F)(F)F DMS2J0Z IK JGWRKYUXBBNENE-UHFFFAOYSA-N DMS2J0Z IU 5-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)methyl]-N-[[6-(trifluoromethyl)pyridin-3-yl]methyl]pyridin-2-amine DMS2J0Z CA CAS 1029044-16-3 DMS2J0Z CB CHEBI:145373 DMS2J0Z DE Alzheimer disease; Pigmented villonodular synovitis; Neurofibromatosis type 1; Tenosynovial giant cell tumour DMSB068 ID DMSB068 DMSB068 DN PF-04449913 DMSB068 HS Approved DMSB068 SN Glasdegib; 1095173-27-5; PF 04449913; UNII-K673DMO5H9; K673DMO5H9; CHEMBL2043437; Glasdegib (PF-04449913); Glasdegib [USAN:INN]; Glasdegib (USAN/INN); PF-04449913;Glasdegib; GTPL8201; Glasdegib(PF-04449913); EX-A858; MolPort-035-789-706; SFNSLLSYNZWZQG-VQIMIIECSA-N; ZINC68251434; PF-913; BDBM50385635; 2640AH; AKOS027324121; CS-2 DMSB068 CP Pfizer DMSB068 DT Small molecular drug DMSB068 PC 25166913 DMSB068 MW 374.4 DMSB068 FM C21H22N6O DMSB068 IC InChI=1S/C21H22N6O/c1-27-11-10-16(24-21(28)23-15-8-6-14(13-22)7-9-15)12-19(27)20-25-17-4-2-3-5-18(17)26-20/h2-9,16,19H,10-12H2,1H3,(H,25,26)(H2,23,24,28)/t16-,19-/m1/s1 DMSB068 CS CN1CC[C@H](C[C@@H]1C2=NC3=CC=CC=C3N2)NC(=O)NC4=CC=C(C=C4)C#N DMSB068 IK SFNSLLSYNZWZQG-VQIMIIECSA-N DMSB068 IU 1-[(2R,4R)-2-(1H-benzimidazol-2-yl)-1-methylpiperidin-4-yl]-3-(4-cyanophenyl)urea DMSB068 CA CAS 1095173-27-5 DMSB068 CB CHEBI:145428 DMSB068 DE Chronic myelomonocytic leukaemia; Solid tumour/cancer DM79VXT ID DM79VXT DM79VXT DN PF-04971729 DM79VXT HS Approved DM79VXT SN Ertugliflozin; 1210344-57-2; PF04971729; UNII-6C282481IP; PF 04971729; CHEMBL1770248; 6C282481IP; AK174928; 1,6-Anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-5-C-(hydroxymethyl)-beta-L-idopyranose; Steglatro; (1S,2S,3S,4R,5S)-5-(4-chloro-3-(4-ethoxybenzyl)phenyl)-1-(hydroxymethyl)-6,8-dioxabicyclo[321]octane-2,3,4-triol; (1S,2S,3S,4R,5S)-5-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-1-(hydroxymethyl)-6,8-dioxabicyclo[321]octane-2,3,4-triol; Ertugliflozin [USAN:INN]; C22H25ClO7; PF-4971729; SGLT2 inhibitor (oral, type 2 diabetes), Pfizer; Sodium glucose cotransporter-2 inhibitor (oral, type 2 diabetes), Pfizer; Ertugliflozin/PF-04971729 DM79VXT CP Merck & Co./Pfizer DM79VXT DT Small molecular drug DM79VXT PC 44814423 DM79VXT MW 436.9 DM79VXT FM C22H25ClO7 DM79VXT IC InChI=1S/C22H25ClO7/c1-2-28-16-6-3-13(4-7-16)9-14-10-15(5-8-17(14)23)22-20(27)18(25)19(26)21(11-24,30-22)12-29-22/h3-8,10,18-20,24-27H,2,9,11-12H2,1H3/t18-,19-,20+,21-,22-/m0/s1 DM79VXT CS CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)[C@@]34[C@@H]([C@H]([C@@H]([C@@](O3)(CO4)CO)O)O)O)Cl DM79VXT IK MCIACXAZCBVDEE-CUUWFGFTSA-N DM79VXT IU (1S,2S,3S,4R,5S)-5-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-1-(hydroxymethyl)-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triol DM79VXT CA CAS 1210344-57-2 DM79VXT DE Type-2 diabetes DMOHS9P ID DMOHS9P DMOHS9P DN Phenacemide DMOHS9P HS Approved DMOHS9P SN Acetylureum; Carbanmide; Cetylureum; Comitiadone; Eferon; Efron; Epheron; Epiclase; Felurea; Fenacemid; Fenacemida; Fenacemide;Fenacetamide; Fenilep; Fenised; Fenostenyl; Fenural; Fenurea; Fenurone; Fenylacetylmocovina; Fenytan; Neophedan; Neophenal; Phacetur; Phenacalum; Phenacemidum; Phenacereum; Phenacerum; Phenacetur; Phenacetylcarbamide; Phenacetylurea; Phenarone; Phenicarb; Phenuron; Phenurone; Phenutal; Phenylacetylurea; Phenylacetyluree; Phenyrit; Phetylureum; Carbamide phenylacetate; Fenacemide [DCIT]; Fenylacetylmocovina [Czech]; Phenylacetyluree [French]; A-1348; Alpha-Phenylacetylurea; Fenacemida [INN-Spanish]; Fenacetil-karbamide; Phenacemide [INN:BAN]; Phenacemidum [INN-Latin]; Phenurone (TN); Sym-PHENYLACETYLUREA; N-(Aminocarbonyl)benzeneacetamide; Phenacemide (JAN/INN); N-carbamoyl-2-phenylacetamide; N-(aminocarbonyl)-2-phenylacetamide; (2-phenylacetyl)urea; (Phenylacetyl)urea DMOHS9P TC Anticonvulsants DMOHS9P DT Small molecular drug DMOHS9P PC 4753 DMOHS9P MW 178.19 DMOHS9P FM C9H10N2O2 DMOHS9P IC InChI=1S/C9H10N2O2/c10-9(13)11-8(12)6-7-4-2-1-3-5-7/h1-5H,6H2,(H3,10,11,12,13) DMOHS9P CS C1=CC=C(C=C1)CC(=O)NC(=O)N DMOHS9P IK XPFRXWCVYUEORT-UHFFFAOYSA-N DMOHS9P IU N-carbamoyl-2-phenylacetamide DMOHS9P CA CAS 63-98-9 DMOHS9P CB CHEBI:8049 DMOHS9P DE Epilepsy DM6TS1N ID DM6TS1N DM6TS1N DN Phendimetrazine DM6TS1N HS Approved DM6TS1N SN Adphen; Antapentan; Dyrexan; Fendimetrazina; Hyrex; Mephenmetrazine; Phendimetrazinum; Sedafamen; Wehless; Adipost (TN); Adphen (base); Appecon (TN); Bontril PDM (TN); Fendimetrazina [INN-Spanish]; Melfiat (TN); Obezine (TN); Phendiet (TN); Phendimetrazine (INN); Phendimetrazine [INN:BAN]; Phendimetrazinum [INN-Latin]; Plegine (TN); Statobex (TN); X-Trozine; Anorex-SR (TN); Prelu-2 (TN); Phendimetrazine, (2S-trans)-isomer; D-2-Phenyl-3,4-dimethylmorpholine; Morpholine, 3,4-dimethyl-2-phenyl; (+)-3,4-Dimethyl-2-phenylmorpholine; (+)-Phendimetrazine; (2R-trans)-3,4-Dimethyl-2-phenylmorpholine; (2S,3S)-3,4-Dimethyl-2-phenylmorpholine; 3,4-Dimethyl-2-phenylmorpholine; 3,4-Dimethyl-2-phenyltetrahydro-1,4-oxazine; 3-Phenyl-2-methylmorpholine DM6TS1N CP Sandoz Inc DM6TS1N TC Anorexigenic Agents DM6TS1N DT Small molecular drug DM6TS1N PC 30487 DM6TS1N MW 191.27 DM6TS1N FM C12H17NO DM6TS1N IC InChI=1S/C12H17NO/c1-10-12(14-9-8-13(10)2)11-6-4-3-5-7-11/h3-7,10,12H,8-9H2,1-2H3/t10-,12+/m0/s1 DM6TS1N CS C[C@H]1[C@@H](OCCN1C)C2=CC=CC=C2 DM6TS1N IK MFOCDFTXLCYLKU-CMPLNLGQSA-N DM6TS1N IU (2S,3S)-3,4-dimethyl-2-phenylmorpholine DM6TS1N CA CAS 634-03-7 DM6TS1N CB CHEBI:8059 DM6TS1N DE Obesity DMHIDUE ID DMHIDUE DMHIDUE DN Phenelzine DMHIDUE HS Approved DMHIDUE SN Fenelzina; Fenelzyna; Fenelzyne; Phenelezine; Phenelzinum; Phenethylhydrazine; Phenylethylhydrazine; Fenelzyna [Polish]; Fenelzyne [Polish]; W1544; Beta-Phenylethylhydrazine; Fenelzina [INN-Spanish]; Nardelzine (TN); Nardil (TN); Phenelzine (BAN); Phenelzine [INN:BAN]; Phenelzinum [INN-Latin]; Phenylethyl hydrazine-HCl; W 1544-A; 1-Hydrazino-2-phenylethane; 2-Phenethylhydrazine; 2-Phenylethylhydrazine DMHIDUE CP Parke Davis Div Warner Lambert Co DMHIDUE TC Antidepressants DMHIDUE DT Small molecular drug DMHIDUE PC 3675 DMHIDUE MW 136.19 DMHIDUE FM C8H12N2 DMHIDUE IC InChI=1S/C8H12N2/c9-10-7-6-8-4-2-1-3-5-8/h1-5,10H,6-7,9H2 DMHIDUE CS C1=CC=C(C=C1)CCNN DMHIDUE IK RMUCZJUITONUFY-UHFFFAOYSA-N DMHIDUE IU 2-phenylethylhydrazine DMHIDUE CA CAS 51-71-8 DMHIDUE CB CHEBI:8060 DMHIDUE DE Skin imperfections; Depression DMDTC7R ID DMDTC7R DMDTC7R DN Phenindamine DMDTC7R HS Approved DMDTC7R SN Fenindamina; Phenindaminum; Phenindiamine; Thephorin; NU 1504; Fenindamina [INN-Spanish]; Nolahist (TN); Phenindamine (INN); Phenindamine [INN:BAN]; Phenindaminum [INN-Latin]; Thephorin (TN); 2,3,4,9-Tetrahydro-2-methyl-9-phenyl-1H-indeno(2,1-c)pyridine; 2,3,4,9-Tetrahydro-2-methyl-9-phenyl-lH-indeno(2,1-c)pyridine; 2,3,4,9-tetrahydro-2-methyl-9-phenyl-lH-indeno-(2,1-c)pyridine; 2-Methyl-9-phenyl-2,3,4,9-tetrahydro-1H-indeno[2,1-c]pyridine; 2-methyl-9-phenyl-1,3,4,9-tetrahydroindeno[2,1-c]pyridine DMDTC7R CP Amarin Pharmaceuticals DMDTC7R TC Antihistamines DMDTC7R DT Small molecular drug DMDTC7R PC 11291 DMDTC7R MW 261.399 DMDTC7R FM C19H19N DMDTC7R IC InChI=1S/C19H19N/c1-20-12-11-16-15-9-5-6-10-17(15)19(18(16)13-20)14-7-3-2-4-8-14/h2-10,19H,11-13H2,1H3 DMDTC7R CS CN1CCC2=C(C1)C(C3=CC=CC=C23)C4=CC=CC=C4 DMDTC7R IK ISFHAYSTHMVOJR-UHFFFAOYSA-N DMDTC7R IU 2-methyl-9-phenyl-1,3,4,9-tetrahydroindeno[2,1-c]pyridine DMDTC7R CA CAS 82-88-2 DMDTC7R CB CHEBI:8065 DMDTC7R DE Common cold DM2PYNR ID DM2PYNR DM2PYNR DN Phenindione DM2PYNR HS Approved DM2PYNR SN Athrombon; Bindan; Cronodione; Danedion; Danilon; Danilone; Diadilan; Dindevan; Dineval; Diophindane; Emandion; Emandione; Eridione; Fenhydren; Fenilin; Fenindion; Fenindiona; Hedulin; Hemolidione; Indema; Indion; Indon; Phenhydren; Phenillin; Phenindionum; Phenylen; Phenylin; Phenylindanedione; Phenylindione; Phenyline; Phenyllin; Pindione; Rectadione; Theradione; Thrombasal; Tromazal; Trombol; Boots Brand of Phenindione; Goldshield Brand of Phenindione; Merck Lipha Sante Brand of Phenindione; P1029; P26406_ALDRICH; Fenindiona [INN-Spanish]; Hedulin (TN); Phenindione (INN); Phenindione [INN:BAN]; Phenindionum [INN-Latin]; 2 Phenyl 1,3 indandione; 2-Fenyloindandion-1,3; 2-Fenyloindandion-1,3 [Polish]; 2-Phenyl-1,3-diketohydrindene; 2-Phenyl-1,3-indandione; 2-Phenyl-1,3-indanedione; 2-Phenyl-1H-indene-1,3(2H)-dione; 2-Phenylindan-1,3-dione; 2-Phenylindandione; 2-phenyl-1,3(2H)-Indenedione; 2-phenyl-2,3-dihydro-1H-indene-1,3-dione; 2-phenylindene-1,3-dione DM2PYNR TC Anticoagulants DM2PYNR DT Small molecular drug DM2PYNR PC 4760 DM2PYNR MW 222.24 DM2PYNR FM C15H10O2 DM2PYNR IC InChI=1S/C15H10O2/c16-14-11-8-4-5-9-12(11)15(17)13(14)10-6-2-1-3-7-10/h1-9,13H DM2PYNR CS C1=CC=C(C=C1)C2C(=O)C3=CC=CC=C3C2=O DM2PYNR IK NFBAXHOPROOJAW-UHFFFAOYSA-N DM2PYNR IU 2-phenylindene-1,3-dione DM2PYNR CA CAS 83-12-5 DM2PYNR CB CHEBI:8066 DM2PYNR DE Coagulation defect; Pulmonary embolism DMCH7RU ID DMCH7RU DMCH7RU DN Pheniramine DMCH7RU HS Approved DMCH7RU SN Avil; Feniramina; Feniramine; Histapyridamine; Metron; Pheniraminum; Propheniramine; Prophenpyridamine; Pyriton; Trimeton; Tripoton; Pheniramine Bimaleate; Avil (TN); Feniramina [INN-Spanish]; P-Aminosalicylsaures salz; Pheniramine (INN); Pheniramine [INN:BAN]; Pheniraminum [INN-Latin]; PHENIRAMINE (SEE ALSO PHENIRAMINE MALEATE 132-20-7); Dimethyl(3-phenyl-3-(2-pyridyl)propyl)amine; N,N-Dimethyl-3-phenyl-3-(2-pyridyl)propylamine; N,N-dimethyl-3-phenyl-3-pyridin-2-ylpropan-1-amine; 1-Phenyl-1-(2-pyridyl)-3-dimethylaminopropane; 2-(3-Dimethylamino-1-phenylpropyl)pyridine; 2-(alpha-(2-Dimethylaminoethyl)benzyl)pyridine; 2-Pyridinepropanamine, N,N-dimethyl-gamma-phenyl-(9CI); 2-[.alpha.-(2-Dimethylaminoethyl)benzyl]pyridine; 2-[.alpha.-[2-(Dimethylamino)ethyl]benzyl]pyridine; 3-Phenyl-3-(2-pyridyl)-N,N-dimethylpropylamine; 3-Phenyl-3-(2-pyridyl)-N,N-dimethylpropylanine DMCH7RU CP Aventis Pharmaceuticals Inc. DMCH7RU TC Antiallergic Agents DMCH7RU DT Small molecular drug DMCH7RU PC 4761 DMCH7RU MW 240.34 DMCH7RU FM C16H20N2 DMCH7RU IC InChI=1S/C16H20N2/c1-18(2)13-11-15(14-8-4-3-5-9-14)16-10-6-7-12-17-16/h3-10,12,15H,11,13H2,1-2H3 DMCH7RU CS CN(C)CCC(C1=CC=CC=C1)C2=CC=CC=N2 DMCH7RU IK IJHNSHDBIRRJRN-UHFFFAOYSA-N DMCH7RU IU N,N-dimethyl-3-phenyl-3-pyridin-2-ylpropan-1-amine DMCH7RU CA CAS 86-21-5 DMCH7RU CB CHEBI:91591 DMCH7RU DE Hay fever DMXYTN9 ID DMXYTN9 DMXYTN9 DN Phenmetrazine DMXYTN9 HS Approved DMXYTN9 SN Cafilon; Defenmetrazin; Dexphenmetrazine; Fenmetrazin; Fenmetrazina; Oxazimedrine; Phenmetraline; Phenmetrazin; Phenmetrazinum; Preludin hydrochloride; A 66; Psychamine A 66; Defenmetrazin (TN); Fenmetrazin (TN); Fenmetrazina [INN-Spanish]; Oxazimedrine (TN); Phenmetraline (TN); Phenmetrazine [INN:BAN]; Phenmetrazinum [INN-Latin]; Dl-2-Phenyl-3-methyltetrahydro-1,4-oxazine; 2-Fenyl-3-methylmorfolin; 2-Fenyl-3-methylmorfolin [Czech]; 2-Phenyl-3-methylmorpholine; 3-Methyl-2-phenylmorpholine; 3-Methyl-2-phenyltetrahydro-2H-1,4-oxazine DMXYTN9 CP Boehringer Ingelheim GmbH DMXYTN9 TC Appetite Depressants DMXYTN9 DT Small molecular drug DMXYTN9 PC 4762 DMXYTN9 MW 177.24 DMXYTN9 FM C11H15NO DMXYTN9 IC InChI=1S/C11H15NO/c1-9-11(13-8-7-12-9)10-5-3-2-4-6-10/h2-6,9,11-12H,7-8H2,1H3 DMXYTN9 CS CC1C(OCCN1)C2=CC=CC=C2 DMXYTN9 IK OOBHFESNSZDWIU-UHFFFAOYSA-N DMXYTN9 IU 3-methyl-2-phenylmorpholine DMXYTN9 CA CAS 134-49-6 DMXYTN9 CB CHEBI:8067 DMXYTN9 DE Obesity DMXZOCG ID DMXZOCG DMXZOCG DN Phenobarbital DMXZOCG HS Approved DMXZOCG SN Adonal; Aephenal; Agrypnal; Amylofene; Antrocol; Aphenylbarbit; Aphenyletten; Austrominal; Barbapil; Barbellen; Barbellon; Barbenyl; Barbilehae; Barbinal; Barbipenyl; Barbiphen; Barbiphenyl; Barbipil; Barbita; Barbivis; Barbonal; Barbophen; Bardorm; Bartol; Bialminal; Cabronal; Calmetten; Calminal; Cardenal; Chinoin; Codibarbita; Coronaletta; Cratecil; Damoral; Dezibarbitur; Donphen; Dormina; Dormiral; Dormital; Doscalun; Duneryl; Ensobarb; Ensodorm; Epanal; Epidorm; Epilol; Episedal; Epsylone; Eskabarb; Etilfen; Euneryl; Ezibarbitur; Fenbital; Fenemal; Fenobarbital; Fenobarbitale; Fenosed; Fenylettae; Gardenal; Gardepanyl; Glysoletten; Haplopan; Haplos; Helional; Hennoletten; Henotal; Hypnaletten; Hypnette; Hypnogen; Hypnolone; Hypnoltol; Hysteps; Lefebar; Leonal; Lephebar; Lepinal; Lepinaletten; Linasen; Liquital; Lixophen; Lubergal; Lubrokal; Lumen; Lumesettes; Lumesyn; Luminal; Lumofridetten; Luphenil; Luramin; Molinal; Neurobarb; Nirvonal; Noptil; Nunol; PHOB; Parkotal; Pharmetten; Phenaemal; Phenemal; Phenemalum; Phenobal; Phenobarb; Phenobarbitalum; Phenobarbitol; Phenobarbitone; Phenobarbitonum; Phenobarbyl; Phenoluric; Phenolurio; Phenomet; Phenonyl; Phenoturic; Phenylaethylbarbitursaeure; Phenylethylbarbiturate; Phenylethylbarbitursaeure; Phenylethylmalonylurea; Phenyletten; Phenylral; Phenyral; Polcominal; Promptonal; Sedabar; Sedicat; Sedizorin; Sedlyn; Sedofen; Sedonal; Sedonettes; Sedophen; Sevenal; Solfoton; Sombutol; Somnolens; Somnoletten; Somnosan; Somonal; Spasepilin; Starifen; Starilettae; Stental; Talpheno; Teolaxin; Teoloxin; Thenobarbital; Theoloxin; Theominal; Triabarb; Tridezibarbitur; Triphenatol; Versomnal; Zadoletten; Zadonal; Aephe nal; Component of Antrocol; Component of Bronkotabs; Component of Hecadrol; Component of Primatene P; Component of Slowten; Component of Tedral; Elixir of phenobarbital; Fen osed; Fenobarbitale [DCIT]; Le phebar; Levsin PB Drops and Tablets; PUBERTAL PHENOBARBITAL STUDY; Pamine PB; Phenobarbitalum [INN]; Phenobarbituric acid; Phenylethyl barbituric acid; Phenylethylbarbituric acid; Solfoton talpheno; Stental Extentabs; Stental exte ntabs; Arco-Lase Plus; Barbilehae (barbilettae); Blu-phen; Chardonna-2; Component of Valpin 50-PB; Fenobarbital [INN-Spanish]; Gustase-Plus; Hypno-Tablinetten; Luminal (TN); Nova-Pheno; Phazyme-PB; Phen-Bar; Phenobarbital (PB); Phenobarbital, Monosodium Salt; Phenobarbitalum [INN-Latin]; SK-Phenobarbital; Seda-Tablinen; Seda-tabl inen; Sedonal (sedative); Solu-Barb; Valprin 50-PB; Phenobarbital [USAN:INN:JAN]; Phenyl-ethyl-barbituric acid; Acido 5-fenil-5-etilbarbiturico; Acido 5-fenil-5-etilbarbiturico [Italian]; Phenobarbital (JP15/USP/INN); 5-Ethyl-5-phenyl-2,4,6(1H,3H,5H)-pyrimidinetrione;5-Ethyl-5-phenyl-2,4,6-(1H,3H,5H)pyrimidinetrione; 5-Ethyl-5-phenyl-2,4,6-pyrimidinetrione; 5-Ethyl-5-phenyl-pyrimidine-2,4,6-trione; 5-Ethyl-5-phenylbarbituric acid; 5-Phenyl-5-ethylbarbituric acid;5-ethyl-5-phenyl-1,3-diazinane-2,4,6-trione; 5-ethyl-5-phenylpyrimidine-2,4,6(1H,3H,5H)-trione DMXZOCG CP FISCHER and ROCH DMXZOCG TC Anticonvulsants DMXZOCG DT Small molecular drug DMXZOCG PC 4763 DMXZOCG MW 232.23 DMXZOCG FM C12H12N2O3 DMXZOCG IC InChI=1S/C12H12N2O3/c1-2-12(8-6-4-3-5-7-8)9(15)13-11(17)14-10(12)16/h3-7H,2H2,1H3,(H2,13,14,15,16,17) DMXZOCG CS CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2 DMXZOCG IK DDBREPKUVSBGFI-UHFFFAOYSA-N DMXZOCG IU 5-ethyl-5-phenyl-1,3-diazinane-2,4,6-trione DMXZOCG CA CAS 50-06-6 DMXZOCG CB CHEBI:8069 DMXZOCG DE Seizure disorder DM8KSQH ID DM8KSQH DM8KSQH DN Phenoxybenzamine DM8KSQH HS Approved DM8KSQH SN Bensylyt; Bensylyte; Benzylyt; Dibenylene; Dibenylin; Dibenyline; Dibenziran; Dibenzylene; Dibenzylin; Dibenzyran; Fenossibenzamina; Fenoxibenzamina; Phenoxybenzaminum; Bensylyt NEN; Fenossibenzamina [DCIT]; POB HCl; Phenoxybenzamine Hcl; A 688; Dibenzyline (TN); Fenoxibenzamina [INN-Spanish]; Phenoxybenzamine (INN);Phenoxybenzamine [INN:BAN]; Phenoxybenzaminum [INN-Latin]; N-Phenoxyisopropyl-N-benzyl-beta-chloroethylamine; Benzyl(2-chloroethyl)-(1-methyl-2-phenoxyethyl)amine; N-(2-Chloroethyl)-N-(1-methyl-2-phenoxyethyl)benzenemethanamine; N-(2-Chloroethyl)-N-(1-methyl-2-phenoxyethyl)benzylamine; N-benzyl-N-(2-chloroethyl)-1-phenoxypropan-2-amine; N-(2-chloroethyl)-N-(phenylmethyl)-1-(phenyloxy)propan-2-amine; 2-(N-Benzyl-2-chloroethylamino)-1-phenoxypropane; 688A DM8KSQH CP Concordia Pharmaceuticals Inc DM8KSQH TC Antihypertensive Agents DM8KSQH DT Small molecular drug DM8KSQH PC 4768 DM8KSQH MW 303.8 DM8KSQH FM C18H22ClNO DM8KSQH IC InChI=1S/C18H22ClNO/c1-16(15-21-18-10-6-3-7-11-18)20(13-12-19)14-17-8-4-2-5-9-17/h2-11,16H,12-15H2,1H3 DM8KSQH CS CC(COC1=CC=CC=C1)N(CCCl)CC2=CC=CC=C2 DM8KSQH IK QZVCTJOXCFMACW-UHFFFAOYSA-N DM8KSQH IU N-benzyl-N-(2-chloroethyl)-1-phenoxypropan-2-amine DM8KSQH CA CAS 59-96-1 DM8KSQH CB CHEBI:8077 DM8KSQH DE Malignant essential hypertension DMDO279 ID DMDO279 DMDO279 DN Phenprocoumon DMDO279 HS Approved DMDO279 SN Falithiom; Falithrom; Fencumar; Fenprocoumona; Fenprocumon; Fenprocumone; Liquamar; Marcoumar; Marcumar; Marcuphen; Phenprocoumalol; Phenprocoumarol; Phenprocoumarole; Phenprocoumone; Phenprocoumonum; Phenprocumone; Phenprocumonum; Phenprogramma; Phenylpropylhydroxycumarinum; Fenprocumone [DCIT]; Hexal Brand of Phenprocoumon; Roche Brand of Phenprocoumon; Worwag Brand of Phenprocoumon; U29342; Falithrom (TN); Fenprocoumona [INN-Spanish]; Liquamar (TN); Marcoumar (TN); Marcumar (TN); Phenprocoumone [INN-French]; Phenprocoumonum [INN-Latin]; Ro 1-4849; Phenprocoumon (USAN/INN); Phenprocoumon [USAN:INN:BAN]; 2-hydroxy-3-(1-phenylpropyl)chromen-4-one; 3-(1'-Phenyl-propyl)-4-oxycoumarin; 3-(1'-Phenyl-propyl)-4-oxycoumarin [German]; 3-(1-Phenylpropyl)-4-hydroxycoumarin; 3-(alpha-Ethylbenzyl)-4-hydroxycoumarin; 3-(alpha-Phenylpropyl)-4-hydroxycoumarin; 4-Hydroxy-3-(1-phenylpropyl)-2H-1-benzopyran-2-one; 4-Hydroxy-3-(1-phenylpropyl)-2H-chromen-2-one DMDO279 TC Anticoagulants DMDO279 DT Small molecular drug DMDO279 PC 54680692 DMDO279 MW 280.3 DMDO279 FM C18H16O3 DMDO279 IC InChI=1S/C18H16O3/c1-2-13(12-8-4-3-5-9-12)16-17(19)14-10-6-7-11-15(14)21-18(16)20/h3-11,13,19H,2H2,1H3 DMDO279 CS CCC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O DMDO279 IK DQDAYGNAKTZFIW-UHFFFAOYSA-N DMDO279 IU 4-hydroxy-3-(1-phenylpropyl)chromen-2-one DMDO279 CA CAS 435-97-2 DMDO279 CB CHEBI:50438 DMDO279 DE Thrombosis DMG60XN ID DMG60XN DMG60XN DN Phentermine DMG60XN HS Approved DMG60XN SN Duromine; Fastin; Fentermina; Inoamin; Ionamin; Ionamine; Linyl; Lipopill; Lonamin; Mirapront; Normephentermine; Obenix; Obermine; Omnibex; Ortetamin; Ortetamina; Ortetaminum; Phentercot; Phenterminum; Phentride; Phentrol; Wilpo; Zantryl; Ona Mast; Ortetamine [INN]; Phentermine HCl; Phentermine resin complex; AmbkkkkK744; Phentermine Resin 30; Phentrol 2; Phentrol 3; Phentrol 4; Adipex P (TN); Adipex-P; Alpha-Benzylisopropylamine; Duromine (TN); Fastin (TN); Fentermina [INN-Spanish]; Ionamin (TN); Mirapront (TN); Obenix (TN); Obephen (TN); Obermine (TN); Oby-Trim; Panbesy (TN); Phenterex (TN); Phentermine (TN); Phenterminum [INN-Latin]; Phentremene (TN); Phentrol (TN); Phentromin (TN); Pro-Fast; Redusa (TN); Sinpet (TN); Supremin (TN); Teramine (TN); Trenker (TN); Umine (TN); Weltmine (TN); Zantryl (TN); Alpha,alpha-Dimethylbenzeneethanamine; Alpha,alpha-Dimethylphenethylamine; Anoxine-AM (TN); Obestin-30 (TN); Oby-Trim (TN); Phentermine (USAN/INN); Phentermine [USAN:INN:BAN]; Phenyl-tert-butylamine; Phenyl-tertiary-butylamine; Pro-Fast SA (TN); Alpha,alpha-Dimethyl-beta-phenylethylamine; Alpha.,.alpha.-dimethyl-Benzeneethanamine; (alpha,alpha)-Dimethylphenethylamine; 1,1-Dimethyl-2-phenylethylamine; 1-(2-Methylphenyl)-2-propylamin; 1-(2-Tolyl)-2-propylamine; 2-Amino-2-methyl-1-phenylpropane; 2-Methyl-1-phenyl-2-propanamine; 2-Phenyl-tert-butylamine DMG60XN CP Medeva Pharmaceuticals DMG60XN TC Appetite Depressants DMG60XN DT Small molecular drug DMG60XN PC 4771 DMG60XN MW 149.23 DMG60XN FM C10H15N DMG60XN IC InChI=1S/C10H15N/c1-10(2,11)8-9-6-4-3-5-7-9/h3-7H,8,11H2,1-2H3 DMG60XN CS CC(C)(CC1=CC=CC=C1)N DMG60XN IK DHHVAGZRUROJKS-UHFFFAOYSA-N DMG60XN IU 2-methyl-1-phenylpropan-2-amine DMG60XN CA CAS 122-09-8 DMG60XN CB CHEBI:8080 DMG60XN DE Obesity DMXYJOB ID DMXYJOB DMXYJOB DN Phentolamine DMXYJOB HS Approved DMXYJOB SN Dibasin; Fentolamin; Fentolamina; Phenotolamine; Phentalamine; Phentolaminum; Regitin; Regitine; Regitipe; Regityn; Rogitine; Phentolamine mesylate [USAN]; Phentolamine methanesulfonate; C 7337; C 7337 Ciba; Fentolamina [INN-Spanish]; Phentolamine (INN); Phentolamine [INN:BAN]; Phentolamine, methyl sulfonate; Phentolaminum [INN-Latin]; Vasomax (TN); 2-((N-(m-Hydroxyphenyl)-p-toluidino)methyl)-2-imidazoline; 2-(N'-p-Tolyl-N'-m-hydroxyphenylaminomethyl)-2-imidazoline; 2-(N-(m-Hydroxyphenyl)-p-toluidinomethyl)imidazoline; 2-(m-Hydroxy-N-p-tolylanilinomethyl)-2-imidazoline; 3-[(4,5-dihydro-1H-imidazol-2-ylmethyl)(4-methylphenyl)amino]phenol; 3-[N-(4,5-dihydro-1H-imidazol-2-ylmethyl)-4-methylanilino]phenol DMXYJOB CP Bedford Laboratories DMXYJOB TC Antihypertensive Agents DMXYJOB DT Small molecular drug DMXYJOB PC 5775 DMXYJOB MW 281.35 DMXYJOB FM C17H19N3O DMXYJOB IC InChI=1S/C17H19N3O/c1-13-5-7-14(8-6-13)20(12-17-18-9-10-19-17)15-3-2-4-16(21)11-15/h2-8,11,21H,9-10,12H2,1H3,(H,18,19) DMXYJOB CS CC1=CC=C(C=C1)N(CC2=NCCN2)C3=CC(=CC=C3)O DMXYJOB IK MRBDMNSDAVCSSF-UHFFFAOYSA-N DMXYJOB IU 3-[N-(4,5-dihydro-1H-imidazol-2-ylmethyl)-4-methylanilino]phenol DMXYJOB CA CAS 50-60-2 DMXYJOB CB CHEBI:8081 DMXYJOB DE Dermal necrosis DMQ95GE ID DMQ95GE DMQ95GE DN Phenylacetic acid DMQ95GE HS Approved DMQ95GE SN .alpha.-Toluic acid; .omega.-Phenylacetic acid; 2-Phenylacetic acid; Acetic acid, phenyl-; Benzenacetic acid; Benzeneacetic acid; Benzylcarboxylic acid; Benzylformic acid; Kyselina fenyloctova; Kyselina fenyloctova [Czech]; PHENYL ACETIC ACID; PHENYL-ACETIC ACID; PHENYLACETIC ACID; Phenylacetic acid (natural); Phenylethanoic acid; Phenyllacetic acid; alpha-Toluic acid; omega-Phenylacetic acid; phenylacetate DMQ95GE DT Small molecular drug DMQ95GE PC 999 DMQ95GE MW 136.15 DMQ95GE FM C8H8O2 DMQ95GE IC InChI=1S/C8H8O2/c9-8(10)6-7-4-2-1-3-5-7/h1-5H,6H2,(H,9,10) DMQ95GE CS C1=CC=C(C=C1)CC(=O)O DMQ95GE IK WLJVXDMOQOGPHL-UHFFFAOYSA-N DMQ95GE IU 2-phenylacetic acid DMQ95GE CA CAS 103-82-2 DMQ95GE CB ChEBI:30745 DMQ95GE DE Hyperammonemia DMAYL0T ID DMAYL0T DMAYL0T DN Phenylbutazone DMAYL0T HS Approved DMAYL0T SN Alindor; Alkabutazona; Alqoverin; Anerval; Anpuzone; Antadol; Anuspiramin; Arthrizon; Artizin; Artrizin; Artrizone; Artropan; Azdid; Azobutyl; Azolid; Benzone; Betazed; Bizolin; Bunetzone; Busone; Butacompren; Butacote; Butadion; Butadiona; Butadione; Butadionum; Butagesic; Butalgina; Butalidon; Butaluy; Butaphen; Butapirazol; Butapirazole; Butapyrazole; Butarecbon; Butartril; Butartrina; Butatron; Butazina; Butazolidin; Butazolidine; Butazona; Bute; Butidiona; Butone; Butoz; Butylpyrin; Buvetzone; Buzon;Chembutazone; Cotylbutazone; Digibutina; Diossidone; Diozol; Diphebuzol; Diphenylbutazone; Ecobutazone; Elmedal; Equipalazone; Equiphen; Eributazone; Esteve; Febuzina; Fenartil; Fenibutal; Fenibutasan; Fenibutazona; Fenibutol; Fenilbutazon; Fenilbutazona; Fenilbutazone; Fenilbutina; Fenilbutine; Fenilidina; Fenotone; Fenylbutazon; Flexazone; Intalbut; Intrabutazone; Intrazone; Ipsoflame; Kadol; Lingel; Malgesic; Mephabutazon; Mephabutazone; Merizone; Nadazone; Nadozone; Novophenyl; Phebuzin; Phebuzine; Phenbutazol; Phenbutazone; Phenopyrine; Phenylbutaz; Phenylbutazon; Phenylbutazonum; Phenyzene; Phenyzone; Praecirheumin; Pyrabutol; Pyrazolidin; Rectofasa; Reudo; Reudox; Reumasyl; Reumazin; Reumazol; Reumune; Reumuzol; Reupolar; Robizone; Rubatone; Scanbutazone; Schemergen; Schemergin; Shigrodin; Tazone; Tencodyne; Tetnor; Tevcodyne; Therazone; Ticinil; Todalgil; Uzone; Wescozone; Zolaphen; Zolidinum; Alka Butazolidin; Art rizin; Buta phen; Butyl pyrin; Equi bute; Exrheudon N; Fe nilbutine; Fenilbutazone [DCIT]; Phenyl butazone; Phenylbutazon [German]; Pirarreumol B; A 7514; Bizolin 200; G 13871; P 8386; P1686; P1Z; AZOLID (TN); Apo-Phenylbutazone; Butiwas-Simple; Component of Azolid-A; DA-192; Fenilbutazona [INN-Spanish]; G 13,871; Ia-But; Mepha-Butazon; Neo-zoline; Phenyl-Mobuzon; Phenylbutazonum [INN-Latin]; Robizon-V; Robizone-V; Usaf ge-15; VAC-10; B.T.Z; Phen-Buta-Vet; R-3-ZON; B.t.z.; Bute, Butazolidin, Butatron, Phenylbutazone; Phenylbutazone (JP15/USP/INN); Phenylbutazone [USAN:INN:BAN:JAN]; 1,2-Diphenyl-2,3-dioxo-4-N-butylpyrazoline; 1,2-Diphenyl-3,5-dioxo-4-butylpyrazolidine; 1,2-Diphenyl-4-butyl-3,5-dioxopyrazolidine; 1,2-Diphenyl-4-butyl-3,5-pyrazolidinedione; 1,2-diphenyl-3,5-dioxo-4-n-butylpyrazoline; 3,5-Dioxe-4 buty-1, diphenyl-pyrazolidine; 3,5-Dioxo-1,2-diphenyl-4-N-butylpyrazolidine; 3,5-Dioxo-1,2-diphenyl-4-n-butyl-pyrazolidin; 3,5-dioxo-4-butyl-1-diphenyl-pyrazolidine; 4-BUTYL-1,2-DIPHENYL-PYRAZOLIDINE-3,5-DIONE; 4-Butyl-1,2-diphenyl-3,5-dioxopyrazolidine; 4-Butyl-1,2-diphenyl-3,5-pyrazolidinedione; 4-Butyl-1,2-diphenylpyrazolidine-3,5-dione; 4-n-Butyl-1,2-diphenyl-3,5-pyrazolidinedione DMAYL0T TC Analgesics DMAYL0T DT Small molecular drug DMAYL0T PC 4781 DMAYL0T MW 308.4 DMAYL0T FM C19H20N2O2 DMAYL0T IC InChI=1S/C19H20N2O2/c1-2-3-14-17-18(22)20(15-10-6-4-7-11-15)21(19(17)23)16-12-8-5-9-13-16/h4-13,17H,2-3,14H2,1H3 DMAYL0T CS CCCCC1C(=O)N(N(C1=O)C2=CC=CC=C2)C3=CC=CC=C3 DMAYL0T IK VYMDGNCVAMGZFE-UHFFFAOYSA-N DMAYL0T IU 4-butyl-1,2-diphenylpyrazolidine-3,5-dione DMAYL0T CA CAS 50-33-9 DMAYL0T CB CHEBI:48574 DMAYL0T DE Chronic pain DMZHUO5 ID DMZHUO5 DMZHUO5 DN Phenylephrine DMZHUO5 HS Approved DMZHUO5 SN Cyclomydril; Dilatair; Dionephrine; Doktors; Duration; Fenilefrina; Isophrim; Isophrin; Mesaton; Mesatone; Mesatonum; Metaoxedrin; Metaoxedrine; Metaoxedrinum; Metasympatol; Metasynephrine; Metsatonum; Mezaton; Mydfrin; Neofrin; Neosynephrine; Nostril; Ocugestrin; Phenoptic; Phenylephrinum; Spersaphrine; Visadron; Alcon Efrin; Isopto Frin; Minims Phenylephrine; Nostril Spray Pump; Nostril Spray Pump Mild; Phenylephrine Minims; Prefrin Liquifilm; Relief Eye Drops for Red Eyes; Alconefrin Nasal Drops 12; Alconefrin Nasal Drops 25; Alconefrin Nasal Drops 50; Alconefrin Nasal Spray 25; Ah-Chew; Ak-dilate; Ak-nefrin; Fenilefrina [INN-Spanish]; I-Phrine; L-Phenylephedrine; L-Phenylephrine; M-Methylaminoethanolphenol; M-Oxedrine; M-Sympathol; M-Sympatol; M-Synephrine; Mydfrin (TN); Neo-Synephrine; Neo-Synephrine Nasal Drops; Neo-Synephrine Nasal Jelly; Neo-Synephrine Nasal Spray; Ocu-Phrin Sterile Eye Drops; Phenylephrine (INN); Phenylephrine Minims (TN); Phenylephrine [INN:BAN]; Phenylephrinum [INN-Latin]; R(-)-Phenylephrine; L-(3-Hydroxyphenyl)-N-methylethanolamine; L-1-(m-Hydroxyphenyl)-2-methylaminoethanol; L-m-Hydroxy-alpha-((methylamino)methyl)benzyl alcohol; L-alpha-Hydroxy-beta-methylamino-3-hydroxy-L-ethylbenzene; Tannins, compds. with (R)-3-hydroxy-alpha-((methylamino)methyl)benzenemethanol; Benzenemethanol, 3-hydroxy-alpha-((methylamino)methyl)-, (R)-(9CI); (-)-m-Hydroxy-alpha-(methylaminomethyl)benzyl alcohol; (R)-2-Hydroxy-2-(3-hydroxyphenyl)-N-methylethylamine; (R)-3-Hydroxy-alpha-((methylamino)methyl)benzenemethanol; 3-[(1R)-1-hydroxy-2-(methylamino)ethyl]phenol DMZHUO5 CP Alcon Canada Inc DMZHUO5 TC Ophthalmologicals DMZHUO5 DT Small molecular drug DMZHUO5 PC 6041 DMZHUO5 MW 167.2 DMZHUO5 FM C9H13NO2 DMZHUO5 IC InChI=1S/C9H13NO2/c1-10-6-9(12)7-3-2-4-8(11)5-7/h2-5,9-12H,6H2,1H3/t9-/m0/s1 DMZHUO5 CS CNC[C@@H](C1=CC(=CC=C1)O)O DMZHUO5 IK SONNWYBIRXJNDC-VIFPVBQESA-N DMZHUO5 IU 3-[(1R)-1-hydroxy-2-(methylamino)ethyl]phenol DMZHUO5 CA CAS 61-76-7 DMZHUO5 CB CHEBI:8093 DMZHUO5 DE Fecal incontinence; Ophthalmic graves disease DMKAEQW ID DMKAEQW DMKAEQW DN Phenyltoloxamine DMKAEQW HS Approved DMKAEQW SN Bristamin hydrochloride; Phenyltoloxamine hydrochloride; HL 2153; (2-(Dimethylamino)ethyl) (o-benzylphenoxy)ether hydrochloride; N,N-Dimethyl-2-(alpha-phenyl-o-toloxy)-ethylamine hydrochloride; ETHYLAMINE, 2-(o-BENZYLPHENOXY)-N,N-DIMETHYL-, HYDROCHLORIDE; Ethylamine, N,N-dimethyl-2-((alpha-phenyl-o-tolyl)oxy)-, hydrochloride; N-(2'-Dimethylaminoaethyl)-(o-benzylphenol)-aether hydrochlorid [German]; AC1L2KJQ; 92-12-6 (Parent); LS-67923; 2-(2-benzylphenoxy)ethyl-dimethylazanium chloride DMKAEQW DT Small molecular drug DMKAEQW PC 7077 DMKAEQW MW 255.35 DMKAEQW FM C17H21NO DMKAEQW IC InChI=1S/C17H21NO/c1-18(2)12-13-19-17-11-7-6-10-16(17)14-15-8-4-3-5-9-15/h3-11H,12-14H2,1-2H3 DMKAEQW CS CN(C)CCOC1=CC=CC=C1CC2=CC=CC=C2 DMKAEQW IK IZRPKIZLIFYYKR-UHFFFAOYSA-N DMKAEQW IU 2-(2-benzylphenoxy)-N,N-dimethylethanamine DMKAEQW CA CAS 92-12-6 DMKAEQW CB CHEBI:135047 DMKAEQW DE Allergy DMNOKBV ID DMNOKBV DMNOKBV DN Phenytoin DMNOKBV HS Approved DMNOKBV SN Aleviatin; Antisacer; Auranile; Causoin; Citrullamon; Citrulliamon; Comital; Comitoina; Convul; Danten; Dantinal; Dantoinal; Dantoine; Denyl; Difenilhidantoina; Difenin; Difetoin; Difhydan; Dihycon; Dihydantoin; Dilabid; Dilantin; Dilantine; Dillantin; Dintoin; Dintoina; Diphantoin; Diphedal; Diphedan; Diphenat; Diphenin; Diphenine; Diphentoin; Diphentyn; Diphenylan; Diphenylhydantoin; Diphenylhydantoine; Diphenylhydatanoin; Ditoinate; Ekko; Elepsindon; Enkelfel; Epamin; Epanutin; Epelin; Epifenyl; Epihydan; Epilantin; Epinat; Epised; Eptal; Eptoin; Fenitoin; Fenitoina; Fentoin; Fenylepsin; Fenytoine; Hidan; Hidantal; Hidantilo; Hidantina; Hidantomin; Hindatal; Hydantal; Hydantin; Hydantoinal; Hydantol; Idantoil; Idantoin; Iphenylhydantoin; Kessodanten; Labopal; Lehydan; Lepitoin; Lepsin; Minetoin; Neosidantoina; Novantoina; Novophenytoin; Oxylan; PHENYTEK; Phanantin; Phanatine; Phenatine; Phenatoine; Phenhydan; Phenhydanin; Phenitoin; Phentoin; Phentytoin; Phenytex; Phenytoine; Phenytoinum; Ritmenal; Saceril; Sanepil; Silantin; Sinergina; Sodanthon; Sodantoin; Sodanton; Solantin; Solantoin; Solantyl; Sylantoic;TOIN; Tacosal; Thilophenyl; Zentronal; Zentropil; Component of Mebroin; Dantoinal klinos; Difenilhidantoina [Spanish]; Dihydan toin; Dilantin acid; Diphenylhydantoine [French]; Ekko capsules; Elepsi ndon; Epdantoin Simple; Epdantoine simple; Epilan D; Extended Phenytoin Sodium; Fen toin; Fenantoin Mn Pharma; Fenidantoin s; Fenytoin Dak; Hidantina senosian; Hidantina vitoria; Ictalis simp le; Ictalis simple; Om hidantoina simple; Phenat ine; Phenytoin AWD; Sodium Diphenylhydantoinate; Taco sal; Toin unicelles; CL12003; D 4007; D4007_SIGMA; Didan TDC 250; Epasmir 5; IFLab1_000214; DILANTIN-30; DPH (VAN); Di-Hydan; Di-Lan; Di-Phetine; Dilantin (TN); Dilantin Infatabs (TN); Dilantin Kapseals (TN); Dilantin-125; Diphenylhydantoin (VAN); Epanutin (TN); Epasmir (5); Epilan-D; Eptoin (TN); Fenidantoin (s); Fenitoina [INN-Spanish]; Neos-Hidantoina; Om-Hydantoine; PHENYTOIN SODIUM, EXTENDED; Phenytek (TN); Phenytoin (PHN); Phenytoin-Gerot; Phenytoine [INN-French]; Phenytoinum [INN-Latin]; Di-Lan (VAN); Didan-tdc-250; Gerot-epilan-D; PHENYTOIN (5,5-DIPHENYLHYDANTOIN); Phenytoin (JP15/USP/INN); Phenytoin [USAN:INN:BAN:JAN]; Hydantoin, 5,5-diphenyl-(8CI); 2,4-Imidazolidinedione, 5,5-diphenyl-(9CI); 2-hydroxy-5,5-diphenyl-3,5-dihydro-4H-imidazol-4-one; 5,5-DIPHENYLHYDANTOIN; 5,5-Diphenyl-2,4-imidazolidinedione; 5,5-Diphenyl-imidazolidine-2,4-dione; 5,5-Diphenylhydantoin (IUPAC); 5,5-Diphenylhydantoin (phenytoin); 5,5-Diphenylimidazolidin-2,4-dione; 5,5-Dwufenylohydantoina; 5,5-Dwufenylohydantoina [Polish]; 5,5-diphenylimidazolidine-2,4-dione DMNOKBV CP Mylan Laboratories DMNOKBV TC Anticonvulsants DMNOKBV DT Small molecular drug DMNOKBV PC 1775 DMNOKBV MW 252.27 DMNOKBV FM C15H12N2O2 DMNOKBV IC InChI=1S/C15H12N2O2/c18-13-15(17-14(19)16-13,11-7-3-1-4-8-11)12-9-5-2-6-10-12/h1-10H,(H2,16,17,18,19) DMNOKBV CS C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3 DMNOKBV IK CXOFVDLJLONNDW-UHFFFAOYSA-N DMNOKBV IU 5,5-diphenylimidazolidine-2,4-dione DMNOKBV CA CAS 57-41-0 DMNOKBV CB CHEBI:8107 DMNOKBV DE Epilepsy DMUKMC8 ID DMUKMC8 DMUKMC8 DN Phloroglucinol DMUKMC8 HS Approved DMUKMC8 SN phloroglucinol; 108-73-6; Benzene-1,3,5-triol; 1,3,5-trihydroxybenzene; 1,3,5-benzenetriol; Phloroglucin; Phloroglucine; Spasfon-Lyoc; s-Trihydroxybenzene; 5-Hydroxyresorcinol; Benzene-s-triol; 3,5-Dihydroxyphenol; Benzene, trihydroxy; sym-Trihydroxybenzene; 5-Oxyresorcinol; Dilospan S; Floroglucinol; Floroglucin; Phloroglucinol anhydrous; 5-Oxyresorcinolphloroglucin; 1,3,5-THB; 1,3,5-Trihydroxycyclohexatriene; 1,3,5-Triol; Floroglucin [Czech]; Floroglucinol [Czech]; Benzene, 1,3,5-trihydroxy-; UNII-DHD7FFG6YS; 5-Benzenetriol; NSC 157 DMUKMC8 DT Small molecular drug DMUKMC8 PC 359 DMUKMC8 MW 126.11 DMUKMC8 FM C6H6O3 DMUKMC8 IC InChI=1S/C6H6O3/c7-4-1-5(8)3-6(9)2-4/h1-3,7-9H DMUKMC8 CS C1=C(C=C(C=C1O)O)O DMUKMC8 IK QCDYQQDYXPDABM-UHFFFAOYSA-N DMUKMC8 IU benzene-1,3,5-triol DMUKMC8 CA CAS 108-73-6 DMUKMC8 CB CHEBI:16204 DMUKMC8 DE Urinary tract disease DMUXQG7 ID DMUXQG7 DMUXQG7 DN Phosphate DMUXQG7 HS Approved DMUXQG7 SN orthophosphate; Phosphate ion; 14265-44-2; O-Phosphate; UNII-NK08V8K8HR; NK08V8K8HR; Phosphates; Phosphate ions; PO4; a phosphate group; tetraoxophosphate(V); tetraoxophosphate(3-); Phosphoric acid trianion; tetraoxidophosphate(3-); phosphoric acid, ion(3-); AC1L1AN2; DTXSID7039672; CHEBI:18367; CTK0H5978; NBIIXXVUZAFLBC-UHFFFAOYSA-K; BDBM50155537; AKOS015903596; PO4(3-); CREATINE PHOSPHATE; N-PHOSPHOCREATINE; [PO4](3-); I14-18227 DMUXQG7 DT Small molecular drug DMUXQG7 PC 1061 DMUXQG7 MW 94.971 DMUXQG7 FM O4P-3 DMUXQG7 IC InChI=1S/H3O4P/c1-5(2,3)4/h(H3,1,2,3,4)/p-3 DMUXQG7 CS [O-]P(=O)([O-])[O-] DMUXQG7 IK NBIIXXVUZAFLBC-UHFFFAOYSA-K DMUXQG7 IU phosphate DMUXQG7 CA CAS 14265-44-2 DMUXQG7 CB CHEBI:18367 DMUXQG7 DE Constipation DM8HDOL ID DM8HDOL DM8HDOL DN Phytonadione DM8HDOL HS Approved DM8HDOL SN Phyllochinon; Phyllohydroquinone; Phytomenadione; Fitomenadione [DCIT]; Phyllochinon [German]; LT00452032; Fitomenadiona [INN-Spanish]; Mephyton (TN); Phylloquinone (8CI); Phytomenadione (INN); Phytomenadionum [INN-Latin]; Phytonadione [USAN:JAN]; Vitamin K1 (TN); Vitamin K1 (VAN); Vitamin K1 (generic); Phythyl-menadion (GERMAN); Phytonadione (JP15/USP); 1,4-Naphthalenedione, 2-methyl-3-((2E,7R,11R)-3,7,11,15-tetramethyl-2-hexadecenyl)-, radical ion(1-); 2-(3,7,11,15-Tetramethylhexadec-2-enyl)-3-methylnaphthalene-1,4-dione; 2-Methyl-3-(3,7,11,15-tetramethyl-2-hexadecenyl)-1,4-naphthalened-ione; 2-Methyl-3-(3,7,11,15-tetramethyl-2-hexadecenyl)-1,4-naphthalenedione; 2-Methyl-3-(3,7,11,15-tetramethylhexadec-2-enyl)-1,4-naphthoquinone; 2-Methyl-3-phythyl-1,4-naphthochinon; 2-Methyl-3-phytyl-1,4-naphthochinon; 2-Methyl-3-phytyl-1,4-naphthochinon [German]; 2-methyl-3-(3,7,11,15-tetramethylhexadec-2-en-1-yl)naphthalene-1,4-dione; 2-methyl-3-[(E)-3,7,11,15-tetramethylhexadec-2-enyl]naphthalene-1,4-dione; 3-Phytylmenadione DM8HDOL TC Vitamins DM8HDOL DT Small molecular drug DM8HDOL PC 5284607 DM8HDOL MW 450.7 DM8HDOL FM C31H46O2 DM8HDOL IC InChI=1S/C31H46O2/c1-22(2)12-9-13-23(3)14-10-15-24(4)16-11-17-25(5)20-21-27-26(6)30(32)28-18-7-8-19-29(28)31(27)33/h7-8,18-20,22-24H,9-17,21H2,1-6H3/b25-20+/t23-,24-/m1/s1 DM8HDOL CS CC1=C(C(=O)C2=CC=CC=C2C1=O)C/C=C(\\C)/CCC[C@H](C)CCC[C@H](C)CCCC(C)C DM8HDOL IK MBWXNTAXLNYFJB-NKFFZRIASA-N DM8HDOL IU 2-methyl-3-[(E,7R,11R)-3,7,11,15-tetramethylhexadec-2-enyl]naphthalene-1,4-dione DM8HDOL CA CAS 79083-00-4 DM8HDOL CB CHEBI:18067 DM8HDOL DE Bleeding disorder; Vitamin K deficiency DM27BL1 ID DM27BL1 DM27BL1 DN Pibrentasvir DM27BL1 HS Approved DM27BL1 SN 2WU922TK3L; A-1325912.0; ABT 530; ABT-530; ABT-530;Pibrentasvir; CHEMBL3545123; CS-8135; D10816; DB13878; Dimethyl N,N'-(((2R,5R)-1-(3,5-difluoro-4-(4-(4-fluorophenyl)piperidin-1-yl)phenyl)pyrrolidine-2,5-diyl)bis((6-fluoro-1H-benzimidazole-5,2-diyl)((2S)-pyrrolidine-2,1-diyl)((2S,3R)-3-methoxy-1-oxobutane-1,2-diyl)))biscarbamate; EX-A865; J-690144; J3.646.121G; Pibrentasvir; Pibrentasvir (JAN/USAN/INN); Pibrentasvir [USAN]; SCHEMBL17639956; SCHEMBL2756579; UNII-2WU922TK3L DM27BL1 TC Antiviral Agent DM27BL1 DT Small molecular drug DM27BL1 PC 58031952 DM27BL1 MW 1113.201 DM27BL1 FM C57H65F5N10O8 DM27BL1 IC InChI=1S/C57H65F5N10O8/c1-29(77-3)49(67-56(75)79-5)54(73)70-19-7-9-47(70)52-63-41-25-35(37(59)27-43(41)65-52)45-15-16-46(72(45)34-23-39(61)51(40(62)24-34)69-21-17-32(18-22-69)31-11-13-33(58)14-12-31)36-26-42-44(28-38(36)60)66-53(64-42)48-10-8-20-71(48)55(74)50(30(2)78-4)68-57(76)80-6/h11-14,23-30,32,45-50H,7-10,15-22H2,1-6H3,(H,63,65)(H,64,66)(H,67,75)(H,68,76)/t29-,30-,45-,46-,47+,48+,49+,50+/m1/s1 DM27BL1 CS CC(C(C(=O)N1CCCC1C2=NC3=C(N2)C=C(C(=C3)F)C4CCC(N4C5=CC(=C(C(=C5)F)N6CCC(CC6)C7=CC=C(C=C7)F)F)C8=CC9=C(C=C8F)N=C(N9)C1CCCN1C(=O)C(C(C)OC)NC(=O)OC)NC(=O)OC)OC DM27BL1 IK VJYSBPDEJWLKKJ-NLIMODCCSA-N DM27BL1 IU methyl N-[(2S,3R)-1-[(2S)-2-[6-[(2R,5R)-1-[3,5-difluoro-4-[4-(4-fluorophenyl)piperidin-1-yl]phenyl]-5-[6-fluoro-2-[(2S)-1-[(2S,3R)-3-methoxy-2-(methoxycarbonylamino)butanoyl]pyrrolidin-2-yl]-3H-benzimidazol-5-yl]pyrrolidin-2-yl]-5-fluoro-1H-benzimidazol-2-yl]pyrrolidin-1-yl]-3-methoxy-1-oxobutan-2-yl]carbamate DM27BL1 CA CAS 1353900-92-1 DM27BL1 DE Hepatitis C virus infection DMIBNG2 ID DMIBNG2 DMIBNG2 DN Picrotoxin DMIBNG2 HS Approved DMIBNG2 SN Cocculin; Cocculus; Picrotox; Picrotoxine; Picrotoxinum; Sesquiterpene; Coques du levant; Coques du levant [French];Fish berry; Indian berry; Oriental berry; P 1675; Picrotin-Picrotoxinin; Picrotoxin (Compound of one mole Picrotoxinin and one mole Picrotin); Picrotoxinin-picrotin; Picrotin, compound with picrotoxinin (1:1); Picrotin, compd. with picrotoxinin (1:1); Picrotoxinin, compd. with picrotin (1:1); 3,6-Methano-8H-1,5,7-trioxacyclopenta(ij)cycloprop(a)azulene-4,8(3H)-dione, hexahydro-2a-hydroxy-9-(1-hydroxy-1-methylethyl)-8b-methyl-, (1aR-(1aalpha,2abeta,3beta,6beta,6abeta,8aS*,8bbeta,9S*))-, compd. with (1aR-(1aalpha,2abeta,3beta,6beta,6; 3,6-Methano-8H-1,5,7-trioxacyclopenta[ij]cycloprop[a]azulene-4,8(3H)-dione, hexahydro-2a-hydroxy-9-(1-hydroxy-1-methylethyl)-8b-methyl-, (1aR,2aR,3S,6R,6aS,8aS,8bR,9S)-& (1aR,2aR,3S,6R,6aS,8aS,8bR,9R; 3,6-Methano-8H-1,5,7-trioxacyclopenta[ij]cycloprop[a]azulene-4,8(3H)-dione, hexahydro-2a-hydroxy-9-(1-hydroxy-1-methylethyl)-8b-methyl-, [1aR-(1a.alpha.,2 DMIBNG2 TC Central Nervous System Stimulants DMIBNG2 DT Small molecular drug DMIBNG2 PC 31304 DMIBNG2 MW 602.6 DMIBNG2 FM C30H34O13 DMIBNG2 IC InChI=1S/C15H18O7.C15H16O6/c1-12(2,18)6-7-10(16)20-8(6)9-13(3)14(7,19)4-5-15(13,22-5)11(17)21-9;1-5(2)7-8-11(16)19-9(7)10-13(3)14(8,18)4-6-15(13,21-6)12(17)20-10/h5-9,18-19H,4H2,1-3H3;6-10,18H,1,4H2,2-3H3/t5-,6+,7?,8?,9-,13-,14-,15+;6?,7-,8?,9?,10+,13+,14+,15-/m10/s1 DMIBNG2 CS CC(=C)[C@@H]1C2[C@@H]3[C@@]4([C@](C1C(=O)O2)(CC5[C@]4(O5)C(=O)O3)O)C.C[C@@]12[C@H]3C4[C@H](C([C@@]1(C[C@@H]5[C@]2(O5)C(=O)O3)O)C(=O)O4)C(C)(C)O DMIBNG2 IK VJKUPQSHOVKBCO-ZTYBEOBUSA-N DMIBNG2 IU (1R,3R,5S,8S,13R,14S)-1-hydroxy-14-(2-hydroxypropan-2-yl)-13-methyl-4,7,10-trioxapentacyclo[6.4.1.19,12.03,5.05,13]tetradecane-6,11-dione;(1R,5S,8S,13R,14R)-1-hydroxy-13-methyl-14-prop-1-en-2-yl-4,7,10-trioxapentacyclo[6.4.1.19,12.03,5.05,13]tetradecane-6,11-dione DMIBNG2 CA CAS 124-87-8 DMIBNG2 DE Respiratory distress syndrome DMV9ADG ID DMV9ADG DMV9ADG DN Pilocarpine DMV9ADG HS Approved DMV9ADG SN Adsorbocarpine; Almocarpine; Epicar; Isopilocarpine; Isoptocarpine; Miocarpine; Ocusert; Pilagan; Pilocarpin; Pilocarpol; Pilokarpin; Pilokarpol; Pilostat; Salagen; Spersacarpine; Syncarpine; Amistura P; Isopto carpine; Minims Pilocarpine; Ocusert pilo; Pilocarpine HCl; Pilocarpine chloride; Pilocarpine nitrate; Ocusert P 20;Beta-Pilocarpine hydrochloride; Diocarpine (TN); Isopto Carpine (TN); Mi-Pilo; Miocarpine (TN); Ocu-Carpine; Ocusert Pilo-40; Ocusert pilo-20; Pilocarpine (TN); Pilopine HS (TN); Piloptic-1; Piloptic-2; Piloptic-3; Piloptic-4; Piloptic-6; Salagen (TN); Scheinpharm (TN); Timpilo (TN); Ocusert Pilo-20 (TN); Ocusert pilo-20 (TN); P.V. Carpine Liquifilm; Pilocarpine (JAN/USP); Pilocarpine [USAN:BAN:JAN]; Piloptic-1/2; Pilocarpine Mononitrate, (3S-cis)-Isomer; Pilocarpine, Monohydrochloride, (3S-cis)-Isomer; Imidazole-5-butyric acid, alpha-ethyl-beta-(hydroxymethyl)-1-methyl-, gamma-lactone; (+)-Pilocarpine; (3S,4R)-3-ethyl-4-[(1-methyl-1H-imidazol-5-yl)methyl]dihydrofuran-2(3H)-one; (3S,4R)-3-ethyl-4-[(3-methylimidazol-4-yl)methyl]oxolan-2-one; (3S,4R)-3-ethyldihydro-4-((1-methyl-1H-imidazol-5-yl)methyl)-2(3H)-furanone; (3S-cis)-3-Ethyldihydro-4-((1-methyl-1H-imidazol-5-yl)methyl)-2(3H)-furanone; (3S-cis)-3-ethyldihydro-4-[(1-methyl-1H-imidazol-5-yl)methyl]-2(3H)-furanone; 3-Ethyl-4-(3-methyl-3H-imidazol-4-ylmethyl)dihydrofuran-2-one; 3-Ethyl-4-[(1-methyl-1H-imidazol-5-yl)methyl]dihydro-2(3H)-furanone; 3-Ethyl-4-[(1-methyl-1H-imidazol-5-yl)methyl]dihydrofuran-2(3H)-one; 3-ethyl-4-((1-methyl-1H-imidazol-5-yl)methyl)dihydro-2(3H)-furanone; 3-ethyl-4-[(3-methylimidazol-4-yl)methyl]oxolan-2-one DMV9ADG CP Alcon Laboratories DMV9ADG TC Cholinergic Agents DMV9ADG DT Small molecular drug DMV9ADG PC 5910 DMV9ADG MW 208.26 DMV9ADG FM C11H16N2O2 DMV9ADG IC InChI=1S/C11H16N2O2/c1-3-10-8(6-15-11(10)14)4-9-5-12-7-13(9)2/h5,7-8,10H,3-4,6H2,1-2H3/t8-,10-/m0/s1 DMV9ADG CS CC[C@H]1[C@H](COC1=O)CC2=CN=CN2C DMV9ADG IK QCHFTSOMWOSFHM-WPRPVWTQSA-N DMV9ADG IU (3S,4R)-3-ethyl-4-[(3-methylimidazol-4-yl)methyl]oxolan-2-one DMV9ADG CA CAS 92-13-7 DMV9ADG CB CHEBI:8207 DMV9ADG DE Glaucoma/ocular hypertension DMZ65K8 ID DMZ65K8 DMZ65K8 DN Pilsicainide DMZ65K8 HS Approved DMZ65K8 SN SUNRYTHM; Sunrhythm; Pilsicainide hydrochloride; DU-6552; SUN-1165; SUN-1165i DMZ65K8 CP Suntory Ltd DMZ65K8 DT Small molecular drug DMZ65K8 PC 4820 DMZ65K8 MW 272.4 DMZ65K8 FM C17H24N2O DMZ65K8 IC InChI=1S/C17H24N2O/c1-13-6-3-7-14(2)16(13)18-15(20)12-17-8-4-10-19(17)11-5-9-17/h3,6-7H,4-5,8-12H2,1-2H3,(H,18,20) DMZ65K8 CS CC1=C(C(=CC=C1)C)NC(=O)CC23CCCN2CCC3 DMZ65K8 IK BCQTVJKBTWGHCX-UHFFFAOYSA-N DMZ65K8 IU N-(2,6-dimethylphenyl)-2-(1,2,3,5,6,7-hexahydropyrrolizin-8-yl)acetamide DMZ65K8 CA CAS 88069-67-4 DMZ65K8 CB CHEBI:135127 DMZ65K8 DE Heart arrhythmia DMR7IVC ID DMR7IVC DMR7IVC DN Pimavanserin DMR7IVC HS Approved DMR7IVC SN ST51054136; AC-5273; I14-1981; 1-[(4-fluorophenyl)methyl]-1-(1-methyl-4-piperidyl)-3-[[4-(2-methylpropoxy)phenyl]methyl]urea DMR7IVC CP Acadia Pharmaceuticals DMR7IVC DT Small molecular drug DMR7IVC PC 10071196 DMR7IVC MW 427.6 DMR7IVC FM C25H34FN3O2 DMR7IVC IC InChI=1S/C25H34FN3O2/c1-19(2)18-31-24-10-6-20(7-11-24)16-27-25(30)29(23-12-14-28(3)15-13-23)17-21-4-8-22(26)9-5-21/h4-11,19,23H,12-18H2,1-3H3,(H,27,30) DMR7IVC CS CC(C)COC1=CC=C(C=C1)CNC(=O)N(CC2=CC=C(C=C2)F)C3CCN(CC3)C DMR7IVC IK RKEWSXXUOLRFBX-UHFFFAOYSA-N DMR7IVC IU 1-[(4-fluorophenyl)methyl]-1-(1-methylpiperidin-4-yl)-3-[[4-(2-methylpropoxy)phenyl]methyl]urea DMR7IVC CA CAS 706779-91-1 DMR7IVC CB CHEBI:133017 DMR7IVC DE Parkinson disease DMZLGRB ID DMZLGRB DMZLGRB DN Pimecrolimus DMZLGRB HS Approved DMZLGRB SN Elidel; ASM 981; SDZ ASM 981; ASM-981; ASM-998; Elidel (TN); SDZ-ASM 981; Pimecrolimus [USAN:INN:BAN]; SDZ-ASM-981; Pimecrolimus (JAN/USAN/INN); 33-epi-Chloro-33-desoxyascomycin DMZLGRB CP Norvatis Phamaceuticals Corporation DMZLGRB TC Dermatologic Agents DMZLGRB DT Small molecular drug DMZLGRB PC 6509979 DMZLGRB MW 810.4 DMZLGRB FM C43H68ClNO11 DMZLGRB IC InChI=1S/C43H68ClNO11/c1-10-30-18-24(2)17-25(3)19-36(53-8)39-37(54-9)21-27(5)43(51,56-39)40(48)41(49)45-16-12-11-13-32(45)42(50)55-38(28(6)33(46)23-34(30)47)26(4)20-29-14-15-31(44)35(22-29)52-7/h18,20,25,27-33,35-39,46,51H,10-17,19,21-23H2,1-9H3/b24-18+,26-20+/t25-,27+,28+,29-,30+,31-,32-,33-,35+,36-,37-,38+,39+,43+/m0/s1 DMZLGRB CS CC[C@@H]1/C=C(/C[C@@H](C[C@@H]([C@@H]2[C@H](C[C@H]([C@@](O2)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@@H]([C@@H]([C@H](CC1=O)O)C)/C(=C/[C@@H]4CC[C@@H]([C@@H](C4)OC)Cl)/C)O)C)OC)OC)C)\\C DMZLGRB IK KASDHRXLYQOAKZ-XDSKOBMDSA-N DMZLGRB IU (1R,9S,12S,13R,14S,17R,18E,21S,23S,24R,25S,27R)-12-[(E)-1-[(1R,3R,4S)-4-chloro-3-methoxycyclohexyl]prop-1-en-2-yl]-17-ethyl-1,14-dihydroxy-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.04,9]octacos-18-ene-2,3,10,16-tetrone DMZLGRB CA CAS 137071-32-0 DMZLGRB CB CHEBI:135888 DMZLGRB DE Atopic dermatitis DMW83TP ID DMW83TP DMW83TP DN Pimozide DMW83TP HS Approved DMW83TP SN Antalon; Neoperidole; Opiran; Orap; Pimozida; Pimozidum; Primozida; ASTA Medica Brand of Pimozide; Janssen Brand of Pimozide;Orap forte; Pharmascience Brand of Pimozide; P 1793; R 6238; McN-JR 6238; Orap (TN); Pimozida [INN-Spanish]; Pimozidum [INN-Latin]; Primozida [INN-Spanish]; R-6238; McN-JR-6238; Pimozide (JAN/USP/INN); Pimozide [USAN:INN:BAN:JAN]; 1-(1-(4,4-Bis(p-fluorophenyl)butyl)-4-piperidyl)-2-benzimidazolinone; 1-(4,4-Bis(p-fluorophenyl)butyl)-4-(2-oxo-1-benzimidazolinyl)piperidine; 1-[1-[4,4-Bis(4-fluorophenyl)butyl]-4-piperidinyl]-1,3-dihydro-2H-benzimidazol-2-one; 1-[1-[4,4-Bis(p-fluorophenyl)butyl]-4-piperidyl]-2-benzimidazolinone; 1-[1-[4,4-bis(4-Fluorophenyl)butyl]-4-piperidinyl]-1,3-dihydro-2H-benzimidazol-2-one; 1-[4,4-Bis(p-fluorophenyl)butyl]-4-(2-oxo-1-benzimidazolinyl)piperidine; 1-{1-[4,4-bis(4-fluorophenyl)butyl]piperidin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one; 1-{1-[4,4-bis(4-fluorophenyl)butyl]piperidin-4-yl}-2,3-dihydro-1H-1,3-benzodiazol-2-one; 3-[1-[4,4-bis(4-fluorophenyl)butyl]piperidin-4-yl]-1H-benzimidazol-2-one DMW83TP CP Janssen Pharmaceutica DMW83TP TC Antipsychotic Agents DMW83TP DT Small molecular drug DMW83TP PC 16362 DMW83TP MW 461.5 DMW83TP FM C28H29F2N3O DMW83TP IC InChI=1S/C28H29F2N3O/c29-22-11-7-20(8-12-22)25(21-9-13-23(30)14-10-21)4-3-17-32-18-15-24(16-19-32)33-27-6-2-1-5-26(27)31-28(33)34/h1-2,5-14,24-25H,3-4,15-19H2,(H,31,34) DMW83TP CS C1CN(CCC1N2C3=CC=CC=C3NC2=O)CCCC(C4=CC=C(C=C4)F)C5=CC=C(C=C5)F DMW83TP IK YVUQSNJEYSNKRX-UHFFFAOYSA-N DMW83TP IU 3-[1-[4,4-bis(4-fluorophenyl)butyl]piperidin-4-yl]-1H-benzimidazol-2-one DMW83TP CA CAS 2062-78-4 DMW83TP CB CHEBI:8212 DMW83TP DE Schizophrenia DMRADYL ID DMRADYL DMRADYL DN Pinacidil DMRADYL HS Approved DMRADYL SN Pinacidilum; P 1134; S 1230; P-154; Pinacidil (anhydrous); Pinacidilum [INN-Latin]; S-1230; N-Cyano-N'-4-pyridinyl-N''-(1,2,2-trimethylpropyl)guanidine; Guanidine, 2-cyano-3-(4-pyridyl)-1-(1,2,2-trimethylpropyl)-, monohydrate; Guanidine, N-cyano-N'-4-pyridinyl-N''-(1,2,2-trimethylpropyl)-, monohydrate; (+-)-Pinacidil; (+/-)-N-Cyano-N'-4-pyridinyl-N"-(1,2,2-trimethylpropyl)guanidine; (R,S)-Pinacidil; (inverted question mark)-N-Cyano-N'-4-pyridinyl-N''-(1,2,2-trimethylpropyl)-guanidine; 1-cyano-2-(3,3-dimethylbutan-2-yl)-3-pyridin-4-ylguanidine; 2-Cyano-3-(4-pyridinyl)-1-(1,2,2-trimethylpropyl)guanidine; 2-Cyano-3-(4-pyridyl)-1-(1,2,2-trimethylpropyl)guanidine monohydrate DMRADYL TC Antihypertensive Agents DMRADYL DT Small molecular drug DMRADYL PC 4826 DMRADYL MW 245.32 DMRADYL FM C13H19N5 DMRADYL IC InChI=1S/C13H19N5/c1-10(13(2,3)4)17-12(16-9-14)18-11-5-7-15-8-6-11/h5-8,10H,1-4H3,(H2,15,16,17,18) DMRADYL CS CC(C(C)(C)C)N=C(NC#N)NC1=CC=NC=C1 DMRADYL IK IVVNZDGDKPTYHK-UHFFFAOYSA-N DMRADYL IU 1-cyano-2-(3,3-dimethylbutan-2-yl)-3-pyridin-4-ylguanidine DMRADYL CA CAS 60560-33-0 DMRADYL CB CHEBI:91706 DMRADYL DE High blood pressure DMD2NV7 ID DMD2NV7 DMD2NV7 DN Pindolol DMD2NV7 HS Approved DMD2NV7 SN Betapindol; Blocklin; Calvisken; Carvisken; Decreten; Durapindol; Pectobloc; Pinbetol; Pindololum; Prindolol; Prinodolol; Pynastin; Visken; Blockin L; Blocklin L; LB 46; LB46; P 0778; Betapindol (TN); Blockin L (TN); Blocklin L (TN); Blocklin-L; Calvisken (TN); Cardilate (TN); Carvisken (TN); DL-LB 46; DL-Pindolol; Decreten (TN); Durapindol (TN); Glauco-Viskin; Glauco-visken; LB-46; P-6820; Pectobloc (TN); Pinbetol (TN); Pindololum [INN-Latin]; Prindolol (TN); Pynastin (TN); Visken (TN); Blocklin-L (TN); Glauco-Visken (TN); Pindolol (JP15/USP/INN); Pindolol [USAN:INN:BAN:JAN]; DL-4-[2-Hydroxy-3-(isopropylamino)propoxy]indole; (+-)-Pindolol; (1)-1-(1H-Indol-4-yloxy)-3-(isopropylamino)propan-2-ol; 1-((1-Methylethyl)amino)-3-(4-indolyloxy)-2-propanol; 1-(1H-Indol-4-yloxy)-3-((1-methylethyl)amino)-2-propanol; 1-(1H-Indol-4-yloxy)-3-(isopropylamino)-2-propanol; 1-(1H-Indol-4-yloxy)-3-[(1-methylethyl)amino]-2-propanol; 1-(1H-indol-4-yloxy)-3-(isopropylamino)propan-2-ol; 1-(1H-indol-4-yloxy)-3-(propan-2-ylamino)-propan-2-ol; 1-(1H-indol-4-yloxy)-3-(propan-2-ylamino)propan-2-ol; 1-(1H-indol-4-yloxy)-3-[(1-methylethyl)amino]propan-2-ol; 1-(1H-indol-4-yloxy)-3-[(propan-2-yl)amino]propan-2-ol; 1-(Indol-4-yloxy)-3-(isopropylamino)-2-propanol; 4-(2-Hydroxy-3-isopropylaminopropoxy)-indole; 4-(3-(Isopropylamino)-2-hydroxypropoxy)indole DMD2NV7 CP Tocris Bioscience DMD2NV7 TC Antihypertensive Agents DMD2NV7 DT Small molecular drug DMD2NV7 PC 4828 DMD2NV7 MW 248.32 DMD2NV7 FM C14H20N2O2 DMD2NV7 IC InChI=1S/C14H20N2O2/c1-10(2)16-8-11(17)9-18-14-5-3-4-13-12(14)6-7-15-13/h3-7,10-11,15-17H,8-9H2,1-2H3 DMD2NV7 CS CC(C)NCC(COC1=CC=CC2=C1C=CN2)O DMD2NV7 IK JZQKKSLKJUAGIC-UHFFFAOYSA-N DMD2NV7 IU 1-(1H-indol-4-yloxy)-3-(propan-2-ylamino)propan-2-ol DMD2NV7 CA CAS 13523-86-9 DMD2NV7 CB CHEBI:8214 DMD2NV7 DE Hypertension DMKJ485 ID DMKJ485 DMKJ485 DN Pioglitazone DMKJ485 HS Approved DMKJ485 SN 111025-46-8; Actos; Pioglitazona; Pioglitazonum; Glustin; Zactos; 105355-27-9; Pioglitazonum [INN-Latin]; Pioglitazona [INN-Spanish]; Duetact; Pioglitazone [INN:BAN]; Pioglitazone [BAN:INN]; 5-(4-(2-(5-ethylpyridin-2-yl)ethoxy)benzyl)thiazolidine-2,4-dione; AD-4833; U 72107; CHEBI:8228; Pioglitazone (Actos); HSDB 7322; Actos (TN); 5-{4-[2-(5-ethylpyridin-2-yl)ethoxy]benzyl}-1,3-thiazolidine-2,4-dione; C19H20N2O3S; AD 4833; 5-[4-[2-(5-ETHYL-2-PYRIDYL)ETHOXY]BENZYL]-2,4-THIAZOLIDINEDIONE; U 72107A; Actos; Actost; Glustin (TN); HS-0047; Pioglitazone (INN); U-72107; U72,107A; Zactos (TN); (+-)-5-((4-(2-(5-ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-2,4-thiazolidinedione; (+/-)-5-[[4-[2-(5-Ethyl-2-pyridinyl)-ethoxy]phenyl]methyl]-2,4-thiazolidinedione; (+/-)-5-[p-[2-(ethyl-2-pyridyl)ethoxy]benzyl]-2,4-thiazolidinedione; 2,4-Thiazolidinedione, 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-(9CI); 5-((4-(2-(5-Ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-2,4-thiazolidinedione; 5-(4-(2-(5-ethyl-2-pyridyl)ethoxy)benzyl)-2,4-thiazolidinedione; 5-[4-[2-(5-Ethyl-2-pyridyl)ethoxy]benzyl]thiazolidine-2,4-dione; 5-[[4-[2-(5-Ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-2,4-thiazolidinedione; 5-[[4-[2-(5-ethylpyridin-2-yl)ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione; 5-[[4-[2-(5-ethylpyridin-2-yl)ethoxy]phenyl]methyl]thiazolidine-2,4-dione; 5-[[4-[2-[(5-ethyl-2-pyridyl)]ethoxy]phenyl]methyl]thiazolidine-2,4-dione; Linagliptin + pioglitazone; PCG1 DMKJ485 CP Takeda Pharmaceuticals DMKJ485 TC Hypoglycemic Agents DMKJ485 DT Small molecular drug DMKJ485 PC 4829 DMKJ485 MW 356.4 DMKJ485 FM C19H20N2O3S DMKJ485 IC InChI=1S/C19H20N2O3S/c1-2-13-3-6-15(20-12-13)9-10-24-16-7-4-14(5-8-16)11-17-18(22)21-19(23)25-17/h3-8,12,17H,2,9-11H2,1H3,(H,21,22,23) DMKJ485 CS CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3 DMKJ485 IK HYAFETHFCAUJAY-UHFFFAOYSA-N DMKJ485 IU 5-[[4-[2-(5-ethylpyridin-2-yl)ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione DMKJ485 CA CAS 111025-46-8 DMKJ485 CB CHEBI:8228 DMKJ485 DE Diabetic complication; Obesity; Type-2 diabetes DM5F84A ID DM5F84A DM5F84A DN Pipecuronium DM5F84A HS Approved DM5F84A SN Arduan; Pipecurium; Arduan (TN); Piperazinium, 4,4'-((2beta,3alpha,5alpha,16beta,17beta)-3,17-bis(acetyloxy)androstane-2,16-diyl)bis(1,1-dimethyl); [(2S,3S,5S,8R,9S,10S,13S,14S,16S,17R)-17-acetyloxy-2,16-bis(4,4-dimethylpiperazin-4-ium-1-yl)-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl] acetate DM5F84A TC Analgesics DM5F84A DT Small molecular drug DM5F84A PC 50192 DM5F84A MW 602.9 DM5F84A FM C35H62N4O4+2 DM5F84A IC InChI=1S/C35H62N4O4/c1-24(40)42-32-21-26-9-10-27-28(35(26,4)23-31(32)37-15-19-39(7,8)20-16-37)11-12-34(3)29(27)22-30(33(34)43-25(2)41)36-13-17-38(5,6)18-14-36/h26-33H,9-23H2,1-8H3/q+2/t26-,27+,28-,29-,30-,31-,32-,33-,34-,35-/m0/s1 DM5F84A CS CC(=O)O[C@H]1C[C@@H]2CC[C@@H]3[C@@H]([C@]2(C[C@@H]1N4CC[N+](CC4)(C)C)C)CC[C@]5([C@H]3C[C@@H]([C@@H]5OC(=O)C)N6CC[N+](CC6)(C)C)C DM5F84A IK OWWLUIWOFHMHOQ-XGHATYIMSA-N DM5F84A IU [(2S,3S,5S,8R,9S,10S,13S,14S,16S,17R)-17-acetyloxy-2,16-bis(4,4-dimethylpiperazin-4-ium-1-yl)-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl] acetate DM5F84A CA CAS 68399-58-6 DM5F84A CB CHEBI:8230 DM5F84A DE Spasm DMGQU0Y ID DMGQU0Y DMGQU0Y DN Piperacetazine DMGQU0Y HS Approved DMGQU0Y SN Quide DMGQU0Y CP Dow Pharmaceutical Corp Sub Dow Chemical Co DMGQU0Y DT Small molecular drug DMGQU0Y PC 19675 DMGQU0Y MW 410.6 DMGQU0Y FM C24H30N2O2S DMGQU0Y IC InChI=1S/C24H30N2O2S/c1-18(28)20-7-8-24-22(17-20)26(21-5-2-3-6-23(21)29-24)13-4-12-25-14-9-19(10-15-25)11-16-27/h2-3,5-8,17,19,27H,4,9-16H2,1H3 DMGQU0Y CS CC(=O)C1=CC2=C(C=C1)SC3=CC=CC=C3N2CCCN4CCC(CC4)CCO DMGQU0Y IK BTFMCMVEUCGQDX-UHFFFAOYSA-N DMGQU0Y IU 1-[10-[3-[4-(2-hydroxyethyl)piperidin-1-yl]propyl]phenothiazin-2-yl]ethanone DMGQU0Y CA CAS 3819-00-9 DMGQU0Y CB CHEBI:92293 DMGQU0Y DE Schizophrenia DMTBKF3 ID DMTBKF3 DMTBKF3 DN Piperacillin DMTBKF3 HS Approved DMTBKF3 SN PIPC; Peperacillin; Peracin; Pipercillin; Pipracil; Pipril; PIPERACILLIN SODIUM; Piperacillin Monosodium Salt; Piperacillin anhydrous; Cl-227193; Peracin (TN); Piperacillin (INN); Piperacillin (anhydrous); Pipracil, Piper; T-1220; Zobactin (TN); (2S,5R,6R)-6-[[(2R)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-{[(2R)-2-{[(4-ethyl-2,3-dioxopiperazin-1-yl)carbonyl]amino}-2-phenylacetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S-(2alpha,5alpha,6beta(S*)))-6-(((((4-Ethyl-2,3-dioxopiperazin-1-yl)carbonyl)amino)phenylacetyl)amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid; 4-ethyl-2,3-dioxopiperazine carbonyl ampicillin; 6-(D-(-)-alpha-(4-Ethyl-2,3-dioxo-1-piperazinecarboxamido)phenylacetamido)penicillanicacid; 6beta-{(2R)-2-[(4-ethyl-2,3-dioxopiperazin-1-yl)carboxamido]-2-phenylacetamido}-2,2-dimethylpenam-3alpha-carboxylic acid DMTBKF3 CP Wyeth DMTBKF3 TC Antibiotics DMTBKF3 DT Small molecular drug DMTBKF3 PC 43672 DMTBKF3 MW 517.6 DMTBKF3 FM C23H27N5O7S DMTBKF3 IC InChI=1S/C23H27N5O7S/c1-4-26-10-11-27(19(32)18(26)31)22(35)25-13(12-8-6-5-7-9-12)16(29)24-14-17(30)28-15(21(33)34)23(2,3)36-20(14)28/h5-9,13-15,20H,4,10-11H2,1-3H3,(H,24,29)(H,25,35)(H,33,34)/t13-,14-,15+,20-/m1/s1 DMTBKF3 CS CCN1CCN(C(=O)C1=O)C(=O)N[C@H](C2=CC=CC=C2)C(=O)N[C@H]3[C@@H]4N(C3=O)[C@H](C(S4)(C)C)C(=O)O DMTBKF3 IK IVBHGBMCVLDMKU-GXNBUGAJSA-N DMTBKF3 IU (2S,5R,6R)-6-[[(2R)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid DMTBKF3 CA CAS 61477-96-1 DMTBKF3 CB CHEBI:8232 DMTBKF3 DE Bacterial infection DMT70RC ID DMT70RC DMT70RC DN Piperaquine DMT70RC HS Approved DMT70RC SN Piperaquinoline; Quinoline, 4,4'-(1,3-propanediyldi-4,1-piperazinediyl)bis(7-chloro-); Quinoline, 4,4'-(1,3-propanediyldi-4,1-piperazinediyl)bis(7-chloro-(9CI); 1,3-bis(1-(7-chloro-4'-quinolyl)-4'-piperazinyl)propane; 1,3-bis(4-(7'-chloro-4'-quinoline)-1-piperazine); 4,4'-(propane-1,3-diyldipiperazine-4,1-diyl)bis(7-chloroquinoline); 7-chloro-4-[4-[3-[4-(7-chloroquinolin-4-yl)piperazin-1-yl]propyl]piperazin-1-yl]quinoline DMT70RC DT Small molecular drug DMT70RC PC 122262 DMT70RC MW 535.5 DMT70RC FM C29H32Cl2N6 DMT70RC IC InChI=1S/C29H32Cl2N6/c30-22-2-4-24-26(20-22)32-8-6-28(24)36-16-12-34(13-17-36)10-1-11-35-14-18-37(19-15-35)29-7-9-33-27-21-23(31)3-5-25(27)29/h2-9,20-21H,1,10-19H2 DMT70RC CS C1CN(CCN1CCCN2CCN(CC2)C3=C4C=CC(=CC4=NC=C3)Cl)C5=C6C=CC(=CC6=NC=C5)Cl DMT70RC IK UCRHFBCYFMIWHC-UHFFFAOYSA-N DMT70RC IU 7-chloro-4-[4-[3-[4-(7-chloroquinolin-4-yl)piperazin-1-yl]propyl]piperazin-1-yl]quinoline DMT70RC CA CAS 4085-31-8 DMT70RC CB CHEBI:91231 DMT70RC DE Malaria DMTY9LU ID DMTY9LU DMTY9LU DN Piperazine DMTY9LU HS Approved DMTY9LU SN Anthalazine; Antiren; Diethylenediamine; Diethyleneimine; Dispermine; Eraverm; Hexahydropyrazine; Lumbrical; PZE; Piperazidine; Piperazin; Pipersol; Upixon; Uvilon; Vermex; Vermizine; Wurmirazin; Piperazin [German]; Piperazin [Germany]; Piperazine Dihydrochloride Dihydrochloride Hydrate; Piperazine [USAN]; Piperazine anhydrous; Piperazinium oleate; Pyrazine hexahydride; LTBB000432; Piperazine [UN2579] [Corrosive]; Eraverm (VAN); PIPERAZINE (HEXAHYDRATE); Piperazine (USP); Piperazine Hexa-Hydrate; Piperazine, anhydrous; Pyrazine, hexahy; Vermizine (TN); Worm-away; Asca-Trol No. 3; Worm-A-Ton; Hexahydro-1,4-diazine; 1,4-Diazacyclohexane; 1,4-Diethylenediamine; 1,4-Piperazine DMTY9LU CP Glaxosmithkline DMTY9LU TC Antinematodal Agents DMTY9LU DT Small molecular drug DMTY9LU PC 4837 DMTY9LU MW 86.14 DMTY9LU FM C4H10N2 DMTY9LU IC InChI=1S/C4H10N2/c1-2-6-4-3-5-1/h5-6H,1-4H2 DMTY9LU CS C1CNCCN1 DMTY9LU IK GLUUGHFHXGJENI-UHFFFAOYSA-N DMTY9LU IU piperazine DMTY9LU CA CAS 110-85-0 DMTY9LU CB CHEBI:28568 DMTY9LU DE Enterobiasis; Ascariasis DMNL0E6 ID DMNL0E6 DMNL0E6 DN Pipobroman DMNL0E6 HS Approved DMNL0E6 SN Amedel; Pipobromanum; Vercyte; A 1803; A-8103; Pipobroman [USAN:INN]; Pipobromanum [INN-Latin]; VERCYTE (TN); Pipobroman (JAN/USAN/INN); N,N'-Bis(3-bromopropionyl)piperazine; N,N-Bis-(3-bromopropionyl)-piperazine; 1,4-Bis(3-bromopropanoyl)piperazine; 1,4-Bis(3-bromopropionyl)piperazine; 3-bromo-1-[4-(3-bromopropanoyl)piperazin-1-yl]propan-1-one DMNL0E6 TC Anticancer Agents DMNL0E6 DT Small molecular drug DMNL0E6 PC 4842 DMNL0E6 MW 356.05 DMNL0E6 FM C10H16Br2N2O2 DMNL0E6 IC InChI=1S/C10H16Br2N2O2/c11-3-1-9(15)13-5-7-14(8-6-13)10(16)2-4-12/h1-8H2 DMNL0E6 CS C1CN(CCN1C(=O)CCBr)C(=O)CCBr DMNL0E6 IK NJBFOOCLYDNZJN-UHFFFAOYSA-N DMNL0E6 IU 3-bromo-1-[4-(3-bromopropanoyl)piperazin-1-yl]propan-1-one DMNL0E6 CA CAS 54-91-1 DMNL0E6 CB CHEBI:8242 DMNL0E6 DE Refractory chronic myeloid leukaemia DMC68DF ID DMC68DF DMC68DF DN Pipotiazine DMC68DF HS Approved DMC68DF SN Pipotiazine; Pipothiazine; Pipotiazina; Pipotiazinum; 39860-99-6; Piportil; Pipotiazinum [INN-Latin]; Pipotiazina [INN-Spanish]; UNII-L903J9JPYV; L903J9JPYV; 10-[3-[4-(2-hydroxyethyl)piperidin-1-yl]propyl]-N,N-dimethylphenothiazine-2-sulfonamide; Pipotiazine [INN:BAN]; Piportil depot; Piportil (TN); Pipotiazine (INN); EINECS 254-659-6; Pipotiazine; ; ; Piportil; AC1L1XY4; SCHEMBL123275; GTPL7557; CHEMBL398880; BDBM81798; DTXSID40192913; ZINC3813024; BCP23973; PDSP2_000525; PDSP1_000527; NSC_62867; AKOS030527554; DB01621; ACM39860996 DMC68DF DT Small molecular drug DMC68DF PC 62867 DMC68DF MW 475.7 DMC68DF FM C24H33N3O3S2 DMC68DF IC InChI=1S/C24H33N3O3S2/c1-25(2)32(29,30)20-8-9-24-22(18-20)27(21-6-3-4-7-23(21)31-24)14-5-13-26-15-10-19(11-16-26)12-17-28/h3-4,6-9,18-19,28H,5,10-17H2,1-2H3 DMC68DF CS CN(C)S(=O)(=O)C1=CC2=C(C=C1)SC3=CC=CC=C3N2CCCN4CCC(CC4)CCO DMC68DF IK JOMHSQGEWSNUKU-UHFFFAOYSA-N DMC68DF IU 10-[3-[4-(2-hydroxyethyl)piperidin-1-yl]propyl]-N,N-dimethylphenothiazine-2-sulfonamide DMC68DF CA CAS 39860-99-6 DMC68DF DE Schizophrenia DMGTW1I ID DMGTW1I DMGTW1I DN Pirarubicin DMGTW1I HS Approved DMGTW1I SN Pinorubicin (TN); Therarubucin (TN) DMGTW1I CP Sanraku and Meiji Seika DMGTW1I DT Small molecular drug DMGTW1I PC 636397 DMGTW1I MW 627.6 DMGTW1I FM C32H37NO12 DMGTW1I IC InChI=1S/C32H37NO12/c1-14-31(45-21-8-3-4-9-42-21)17(33)10-22(43-14)44-19-12-32(40,20(35)13-34)11-16-24(19)30(39)26-25(28(16)37)27(36)15-6-5-7-18(41-2)23(15)29(26)38/h5-7,14,17,19,21-22,31,34,37,39-40H,3-4,8-13,33H2,1-2H3/t14-,17-,19-,21-,22-,31+,32-/m0/s1 DMGTW1I CS C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O[C@H]6CCCCO6 DMGTW1I IK KMSKQZKKOZQFFG-HSUXVGOQSA-N DMGTW1I IU (7S,9S)-7-[(2R,4S,5S,6S)-4-amino-6-methyl-5-[(2S)-oxan-2-yl]oxyoxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione DMGTW1I CA CAS 72496-41-4 DMGTW1I CB CHEBI:32011 DMGTW1I DE Breast cancer DMI5678 ID DMI5678 DMI5678 DN Pirbuterol DMI5678 HS Approved DMI5678 SN Maxair; Pirbuterolum; Pyrbuterol; Pirbuterol acetate salt; CP 24315-1; Maxair (TN); Pirbuterol (INN); Pirbuterol [INN:BAN]; Pirbuterolum [INN-Latin]; CP-24315-1; CP-24,314-1; CP-24,314-14; 2-hydroxymethyl-3-hydroxy-6-(1-hydroxy-2-tert-butylamino ethyl)pyridine, dihydrochloride; 2-tert-Butylamino-1-(5-hydroxy-6-hydroxymethyl-2-pyridyl)ethanol; 6-(2-(tert-butylamino)-1-hydroxyethyl)-2-(hydroxymethyl)-3-pyridinol; 6-[2-(tert-butylamino)-1-hydroxyethyl]-2-(hydroxymethyl)pyridin-3-ol DMI5678 CP 3M Pharmaceuticals DMI5678 TC Bronchodilator Agents DMI5678 DT Small molecular drug DMI5678 PC 4845 DMI5678 MW 240.3 DMI5678 FM C12H20N2O3 DMI5678 IC InChI=1S/C12H20N2O3/c1-12(2,3)13-6-11(17)8-4-5-10(16)9(7-15)14-8/h4-5,11,13,15-17H,6-7H2,1-3H3 DMI5678 CS CC(C)(C)NCC(C1=NC(=C(C=C1)O)CO)O DMI5678 IK VQDBNKDJNJQRDG-UHFFFAOYSA-N DMI5678 IU 6-[2-(tert-butylamino)-1-hydroxyethyl]-2-(hydroxymethyl)pyridin-3-ol DMI5678 CA CAS 38677-81-5 DMI5678 CB CHEBI:8245 DMI5678 DE Asthma DMP6M1N ID DMP6M1N DMP6M1N DN Pirenzepine DMP6M1N HS Approved DMP6M1N SN Gasteril; Gastrotsepin; Gastrozepin; Pirenzepin; Pirenzepina; Pirenzepinum; Pyrenzepine; Ulcosan; Pirenzepine Gastrozepin; Gastrozepin (TN); L-S 519; Pirenzepina [INN-Spanish]; Pirenzepine (INN); Pirenzepine [INN:BAN]; Pirenzepinum [INN-Latin]; 11-((4-Methyl-1-piperazinyl)acetyl)-5,11-dihydro-6H-pyrido(2,3-b)(1,4)benzodiazepin-6-one; 11-[(4-methylpiperazin-1-yl)acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one; 11-[2-(4-methylpiperazin-1-yl)acetyl]-5H-pyrido[2,3-b][1,4]benzodiazepin-6-one; 5,11-Dihydro-11-((4-methyl-1-piperazinyl)acetyl)-6H-pyrido(2,3-b)(1,4)benzodiazepin-6-one DMP6M1N CP Boehringer Ingelheim DMP6M1N TC Antiulcer Agents DMP6M1N DT Small molecular drug DMP6M1N PC 4848 DMP6M1N MW 351.4 DMP6M1N FM C19H21N5O2 DMP6M1N IC InChI=1S/C19H21N5O2/c1-22-9-11-23(12-10-22)13-17(25)24-16-7-3-2-5-14(16)19(26)21-15-6-4-8-20-18(15)24/h2-8H,9-13H2,1H3,(H,21,26) DMP6M1N CS CN1CCN(CC1)CC(=O)N2C3=CC=CC=C3C(=O)NC4=C2N=CC=C4 DMP6M1N IK RMHMFHUVIITRHF-UHFFFAOYSA-N DMP6M1N IU 11-[2-(4-methylpiperazin-1-yl)acetyl]-5H-pyrido[2,3-b][1,4]benzodiazepin-6-one DMP6M1N CA CAS 28797-61-7 DMP6M1N CB CHEBI:8247 DMP6M1N DE Peptic ulcer DM6VZFQ ID DM6VZFQ DM6VZFQ DN Pirfenidone DM6VZFQ HS Approved DM6VZFQ SN Deskar; Esbriet; Pirespa; Pirfenidona; Pirfenidonum; AMR 69; P 2116; AMR-69; F-647; KS-5041; Pirfenidona [INN-Spanish]; Pirfenidone (Deskar); Pirfenidone [USAN:INN]; Pirfenidonum [INN-Latin]; S-7701; Pirfenidone (JAN/USAN/INN); 5-Methyl-1-phenyl-1H-pyridin-2-one; 5-Methyl-1-phenyl-2(1H)-pyridone; 5-Methyl-1-phenyl-2-(1H)-pyridone; 5-methyl-1-phenylpyridin-2(1H)-one; 5-methyl-1-phenylpyridin-2-one DM6VZFQ CP InterMune DM6VZFQ DT Small molecular drug DM6VZFQ PC 40632 DM6VZFQ MW 185.22 DM6VZFQ FM C12H11NO DM6VZFQ IC InChI=1S/C12H11NO/c1-10-7-8-12(14)13(9-10)11-5-3-2-4-6-11/h2-9H,1H3 DM6VZFQ CS CC1=CN(C(=O)C=C1)C2=CC=CC=C2 DM6VZFQ IK ISWRGOKTTBVCFA-UHFFFAOYSA-N DM6VZFQ IU 5-methyl-1-phenylpyridin-2-one DM6VZFQ CA CAS 53179-13-8 DM6VZFQ CB CHEBI:32016 DM6VZFQ DE Idiopathic pulmonary fibrosis DMBCYF5 ID DMBCYF5 DMBCYF5 DN Pirmenol DMBCYF5 HS Approved DMBCYF5 SN Pimenol; Pirmavar; Pirmenol hydrochloride DMBCYF5 CP Pfizer Inc DMBCYF5 DT Small molecular drug DMBCYF5 PC 65502 DMBCYF5 MW 338.5 DMBCYF5 FM C22H30N2O DMBCYF5 IC InChI=1S/C22H30N2O/c1-18-10-8-11-19(2)24(18)17-9-15-22(25,20-12-4-3-5-13-20)21-14-6-7-16-23-21/h3-7,12-14,16,18-19,25H,8-11,15,17H2,1-2H3/t18-,19+,22? DMBCYF5 CS C[C@@H]1CCC[C@@H](N1CCCC(C2=CC=CC=C2)(C3=CC=CC=N3)O)C DMBCYF5 IK APUDBKTWDCXQJA-QIDMFYOTSA-N DMBCYF5 IU 4-[(2S,6R)-2,6-dimethylpiperidin-1-yl]-1-phenyl-1-pyridin-2-ylbutan-1-ol DMBCYF5 CA CAS 68252-19-7 DMBCYF5 CB CHEBI:135436 DMBCYF5 DE Heart arrhythmia DMTK234 ID DMTK234 DMTK234 DN Piroxicam DMTK234 HS Approved DMTK234 SN Akten; Artroxicam; Bruxicam; Caliment; Erazon; Felden; Feldene; Flogobene; Geldene; Improntal; Larapam; Pipoxicam; Pirkam; Piroflex; Piroftal; Piroxicamum; Pyroxycam; Reudene; Riacen; Roxicam; Roxiden; Sasulen; Solocalm; Zunden; Feldene Fast; Feldene Gel; Piroxicam usp; AK1015; CHF 1251; CP 16171; CP16171; P 5654; Apo-Piroxicam; Brexidol (TN); Brexin (TN); CP-16171; Erazon (TN); Exipan (TN); Felden (TN); Feldene (TN); Feldoral (TN); Hotemin (TN); Mobilis (TN); Pirox von ct (TN); Piroxicamum [INN-Latin]; Proponol (TN); Reumador (TN); Tracam (TN); Veral (TN); Vurdon (TN); Feldene, Roxam, Piroxicam; Piroxicam (JP15/USP/INN); Piroxicam [USAN:BAN:INN:JAN]; (3E)-3-[hydroxy-(pyridin-2-ylamino)methylidene]-2-methyl-1,1-dioxo-1; (4-Hydroxy-2-methyl-1,1-dioxobenzo[e]1,2-thiazin-3-yl)-N-(2-pyridyl)carboxamide; 2H-1,2-Benzothiazine-3-carboxamide, 4-hydroxy-2-methyl-N-2-pyridinyl-, 1,1-dioxide; 3-[hydroxy(pyridin-2-ylamino)methylidene]-2-methyl-3,4-dihydro-2H-1; 4-Hydroxy-2-methyl-3-(pyrid-2-yl-carbamoyl)-2H-1,2-benzothiazine 1,1-dioxide; 4-Hydroxy-2-methyl-N-(2-pyridyl)-2H-1,2-benzothiazin-3-caboxyamid-1,1-dioxid; 4-Hydroxy-2-methyl-N-(2-pyridyl)-2H-1,2-benzothiazin-3-caboxyamid-1,1-dioxid [German]; 4-Hydroxy-2-methyl-N-(2-pyridyl)-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide; 4-Hydroxy-2-methyl-N-2-pyridyl-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide; 4-hydroxy-2-methyl-N-(pyridin-2-yl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide; 4-hydroxy-2-methyl-N-pyridin-2-yl-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide DMTK234 CP Pfizer Pharmaceuticals DMTK234 TC Analgesics DMTK234 DT Small molecular drug DMTK234 PC 54676228 DMTK234 MW 331.3 DMTK234 FM C15H13N3O4S DMTK234 IC InChI=1S/C15H13N3O4S/c1-18-13(15(20)17-12-8-4-5-9-16-12)14(19)10-6-2-3-7-11(10)23(18,21)22/h2-9,19H,1H3,(H,16,17,20) DMTK234 CS CN1C(=C(C2=CC=CC=C2S1(=O)=O)O)C(=O)NC3=CC=CC=N3 DMTK234 IK QYSPLQLAKJAUJT-UHFFFAOYSA-N DMTK234 IU 4-hydroxy-2-methyl-1,1-dioxo-N-pyridin-2-yl-1lambda6,2-benzothiazine-3-carboxamide DMTK234 CA CAS 36322-90-4 DMTK234 CB CHEBI:8249 DMTK234 DE Pain DMMOFHT ID DMMOFHT DMMOFHT DN Pirprofen DMMOFHT HS Approved DMMOFHT SN Pirprofen; Rengasil; 31793-07-4; Pirprofenum [INN-Latin]; Pirprofene [INN-French]; Pirprofeno [INN-Spanish]; SU-21524; EINECS 250-805-8; BRN 1686438; SU 21524; Hydratropic acid, 3-chloro-4-(3-pyrrolin-1-yl)-; 3-CHLORO-4-(3-PYRROLIN-1-YL)HYDRATROPIC ACID; C13H14ClNO2; Pirprofenum; Pirprofeno; Pirprofene; Benzeneacetic acid, 3-chloro-4-(2,5-dihydro-1H-pyrrol-1-yl)-alpha-methyl-; Pirprofen [USAN:INN:BAN]; Pirprofen [USAN:BAN:INN]; pirprofen[usan:ban:inn]; Pirprofen (USAN/INN); AC1Q5RRJ; AC1L1UQD; SCHEMBL24311; 5-20-04-00276 (Beilstei DMMOFHT DT Small molecular drug DMMOFHT PC 35935 DMMOFHT MW 251.71 DMMOFHT FM C13H14ClNO2 DMMOFHT IC InChI=1S/C13H14ClNO2/c1-9(13(16)17)10-4-5-12(11(14)8-10)15-6-2-3-7-15/h2-5,8-9H,6-7H2,1H3,(H,16,17) DMMOFHT CS CC(C1=CC(=C(C=C1)N2CC=CC2)Cl)C(=O)O DMMOFHT IK PIDSZXPFGCURGN-UHFFFAOYSA-N DMMOFHT IU 2-[3-chloro-4-(2,5-dihydropyrrol-1-yl)phenyl]propanoic acid DMMOFHT CA CAS 31793-07-4 DMMOFHT CB CHEBI:135028 DMMOFHT DE Dysmenorrhea DMJH792 ID DMJH792 DMJH792 DN Pitavastatin DMJH792 HS Approved DMJH792 SN Pitavastatin; Itavastatin; Livalo; NK 104; Pitavastatin [INN]; Pitavastatin calcium; UNII-M5681Q5F9P; NK-104; C25H24FNO4; M5681Q5F9P; Zypitamag; Flovas; (3R,5S,6E)-7-(2-Cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl)-3,5-dihydroxyhept-6-enoic acid; P 872441; P-872441; (3R,5S,6E)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxyhept-6-enoic acid; ( )-(3R,5S,6E)-7-(2-Cyclopropyl-4-(4-fluorophenyl)-3-quinolyl)-3,5-dihydroxy-6-heptenoic acid; NK 104 (acid); Pitavastatin calcium (JAN) DMJH792 PC 5282452 DMJH792 MW 421.5 DMJH792 FM C25H24FNO4 DMJH792 IC InChI=1S/C25H24FNO4/c26-17-9-7-15(8-10-17)24-20-3-1-2-4-22(20)27-25(16-5-6-16)21(24)12-11-18(28)13-19(29)14-23(30)31/h1-4,7-12,16,18-19,28-29H,5-6,13-14H2,(H,30,31)/b12-11+/t18-,19-/m1/s1 DMJH792 CS C1CC1C2=NC3=CC=CC=C3C(=C2C=CC(CC(CC(=O)O)O)O)C4=CC=C(C=C4)F DMJH792 IK VGYFMXBACGZSIL-MCBHFWOFSA-N DMJH792 IU (E,3R,5S)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxyhept-6-enoic acid DMJH792 CA CAS 147511-69-1 DMJH792 CB CHEBI:32020 DMJH792 DE Primary hyperlipidemia and mixed dyslipidemia DM1UJO0 ID DM1UJO0 DM1UJO0 DN Pitavastatin calcium DM1UJO0 HS Approved DM1UJO0 SN Livalo; Pitavastatin calcium; 147526-32-7; Pitavastatin hemicalcium; NK-104; Nisvastatin; UNII-IYD54XEG3W; Flovas; IYD54XEG3W; 2C25H23FNO4Ca; CHEBI:71258; NK 104 (acid); Calcium (3R,5S,E)-7-(2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl)-3,5-dihydroxyhept-6-enoate; AK-50694; Itavastatin calcium; Bis((3R,5S,6E)-7-(2-cyclopropyl-4-(4-fluorophenyl)-3-quinolyl)-3,5-dihydroxy-6-heptenoate), monocalcium salt; Pitavastatin calcium (JAN); Alipza; Livazo; P-872441; P 872441; 6-Heptenoic acid, DM1UJO0 DT Small molecular drug DM1UJO0 PC 5282451 DM1UJO0 MW 881 DM1UJO0 FM C50H46CaF2N2O8 DM1UJO0 IC InChI=1S/2C25H24FNO4.Ca/c2*26-17-9-7-15(8-10-17)24-20-3-1-2-4-22(20)27-25(16-5-6-16)21(24)12-11-18(28)13-19(29)14-23(30)31;/h2*1-4,7-12,16,18-19,28-29H,5-6,13-14H2,(H,30,31);/q;;+2/p-2/b2*12-11+;/t2*18-,19-;/m11./s1 DM1UJO0 CS C1C(C1)C2=NC3=CC=CC=C3C(=C2/C=C/[C@@H](O)C[C@@H](O)CC(=O)[O-])C4=CC=C(C=C4)F.C1C(C1)C2=NC3=CC=CC=C3C(=C2/C=C/[C@@H](O)C[C@@H](O)CC(=O)[O-])C4=CC=C(C=C4)F.[Ca+2] DM1UJO0 IK RHGYHLPFVJEAOC-FFNUKLMVSA-L DM1UJO0 IU calcium;(E,3R,5S)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxyhept-6-enoate DM1UJO0 CA CAS 147526-32-7 DM1UJO0 CB CHEBI:71258 DM1UJO0 DE Dyslipidemia DM8RFNJ ID DM8RFNJ DM8RFNJ DN Pitolisant DM8RFNJ HS Approved DM8RFNJ SN Pitolisant; 362665-56-3; TIPROLISANT; BF2.649; UNII-4BC83L4PIY; 1-[3-[3-(4-chlorophenyl)propoxy]propyl]piperidine; Pitolisant (BF2.649); 1-(3-(3-(4-Chlorophenyl)propoxy)propyl)piperidine; 4BC83L4PIY; Piperidine, 1-[3-[3-(4-chlorophenyl)propoxy]propyl]-; CHEMBL462605; wakix; 1-[3-[3-(4-Chlorophenyl)propoxy]propyl]-piperidinehydrochloride; 1-{3-[3-(4-chlorophenyl)propoxy]propyl}piperidine; Tirolisant; Pitolisant (INN); tiprolisant [USAN]; Wakix (TN); Pitolisant [USAN:INN]; SCHEMBL117648; GTPL8924; CTK1B6404; HBS-101 DM8RFNJ CP Bioprojet; Ferrer DM8RFNJ DT Small molecular drug DM8RFNJ PC 9948102 DM8RFNJ MW 295.8 DM8RFNJ FM C17H26ClNO DM8RFNJ IC InChI=1S/C17H26ClNO/c18-17-9-7-16(8-10-17)6-4-14-20-15-5-13-19-11-2-1-3-12-19/h7-10H,1-6,11-15H2 DM8RFNJ CS C1CCN(CC1)CCCOCCCC2=CC=C(C=C2)Cl DM8RFNJ IK NNACHAUCXXVJSP-UHFFFAOYSA-N DM8RFNJ IU 1-[3-[3-(4-chlorophenyl)propoxy]propyl]piperidine DM8RFNJ CA CAS 362665-56-3 DM8RFNJ CB CHEBI:134709 DM8RFNJ DE Schizophrenia; Excessive daytime sleepiness DMX8CVY ID DMX8CVY DMX8CVY DN Pivampicillin DMX8CVY HS Approved DMX8CVY SN Pivaloylampicillin; Pivampicilina; Pivampicilline; Pivampicillinum; Pondocillin; Ampicillin Pivaloyl Ester; Ampicillin pivaloyloxymethyl ester; Pivaloyloxymethyl ampicillinate; Pivampicillin Monohydrochloride; MK 191; Pivampicilina [INN-Spanish]; Pivampicillin (INN); Pivampicillin [INN:BAN]; Pivampicilline [INN-French]; Pivampicillinum [INN-Latin]; Pondocillin (TN); [(2,2-dimethylpropanoyl)oxy]methyl 6beta-[(2R)-2-amino-2-phenylacetamido]-2,2-dimethylpenam-3alpha-carboxylate; 2,2-dimethylpropanoyloxymethyl (2S,5R,6R)-6-[[(2R)-2-amino-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate DMX8CVY TC Antibiotics DMX8CVY DT Small molecular drug DMX8CVY PC 33478 DMX8CVY MW 463.5 DMX8CVY FM C22H29N3O6S DMX8CVY IC InChI=1S/C22H29N3O6S/c1-21(2,3)20(29)31-11-30-19(28)15-22(4,5)32-18-14(17(27)25(15)18)24-16(26)13(23)12-9-7-6-8-10-12/h6-10,13-15,18H,11,23H2,1-5H3,(H,24,26)/t13-,14-,15+,18-/m1/s1 DMX8CVY CS CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)N)C(=O)OCOC(=O)C(C)(C)C)C DMX8CVY IK ZEMIJUDPLILVNQ-ZXFNITATSA-N DMX8CVY IU 2,2-dimethylpropanoyloxymethyl (2S,5R,6R)-6-[[(2R)-2-amino-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate DMX8CVY CA CAS 33817-20-8 DMX8CVY CB CHEBI:8255 DMX8CVY DE Bacterial infection DMDU0BV ID DMDU0BV DMDU0BV DN Pivmecillinam DMDU0BV HS Approved DMDU0BV SN Coactabs; PMPC; Pivamdinocillin; Pivmecilinamo; Pivmecillinamum; Selexid; Amdinocillin Pivoxil; Amdinocillin pivoxil [USAN]; Mecillinam Pivaloyl Ester; Amdinocillin pivoxil (USAN); Amdinocillin, pivaloyloxymethyl ester; Coactabs (TN); Penomax (TN); Pivmecilinamo [INN-Spanish]; Pivmecillinam (INN); Pivmecillinamum [INN-Latin]; Ro 10-9071; Selexid (TN); [(2,2-dimethylpropanoyl)oxy]methyl 6beta-[(azepan-1-ylmethylidene)amino]-2,2-dimethylpenam-3alpha-carboxylate; [(2,2-dimethylpropanoyl)oxy]methyl (2S,5R,6R)-6-[(azepan-1-ylmethylidene)amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate; [(2,2-dimethylpropanoyl)oxy]methyl(2s,5r,6r)-6-{[(e)-azepan-1-ylmethylidene]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate; Hydroxymethyl (2S,5R,6R)-6-(((hexahydro-1H-azepin-1-yl)methylene)amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylate pivalate (ester); 2,2-dimethylpropanoyloxymethyl (2S,5R,6R)-6-(azepan-1-ylmethylideneamino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate; 2,2-dimethylpropanoyloxymethyl (5R,6R)-6-(azepan-1-ylmethylideneamino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate DMDU0BV TC Antibiotics DMDU0BV DT Small molecular drug DMDU0BV PC 115163 DMDU0BV MW 439.6 DMDU0BV FM C21H33N3O5S DMDU0BV IC InChI=1S/C21H33N3O5S/c1-20(2,3)19(27)29-13-28-18(26)15-21(4,5)30-17-14(16(25)24(15)17)22-12-23-10-8-6-7-9-11-23/h12,14-15,17H,6-11,13H2,1-5H3/t14-,15+,17-/m1/s1 DMDU0BV CS CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)N=CN3CCCCCC3)C(=O)OCOC(=O)C(C)(C)C)C DMDU0BV IK NPGNOVNWUSPMDP-HLLBOEOZSA-N DMDU0BV IU 2,2-dimethylpropanoyloxymethyl (2S,5R,6R)-6-(azepan-1-ylmethylideneamino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate DMDU0BV CA CAS 32886-97-8 DMDU0BV CB CHEBI:51210 DMDU0BV DE Urinary tract infection DMV74ZH ID DMV74ZH DMV74ZH DN Pizotyline DMV74ZH HS Approved DMV74ZH SN Pizotifen; PIZOTYLINE; 15574-96-6; Sandomigran; Litec; Sandomygran; Pizotifenum; Pizotifeno; Polomigran; Pizotifene; BC-105; BC 105; Pizotyline [USAN]; Pizotifan; Pizotifene [INN-French]; Pizotifenum [INN-Latin]; Pizotifeno [INN-Spanish]; UNII-0BY8440V3N; EINECS 239-632-9; BRN 0753534; C19H21NS; CHEBI:50212; FIADGNVRKBPQEU-UHFFFAOYSA-N; Pizotifen (INN); Pizotifen [INN]; 0BY8440V3N; Pizotyline (USAN); 4-(9,10-dihydro-4H-benzo[4,5]cyclohepta[1,2-b]thiophen-4-ylidene)-1-methylpiperidine DMV74ZH DT Small molecular drug DMV74ZH PC 27400 DMV74ZH MW 295.4 DMV74ZH FM C19H21NS DMV74ZH IC InChI=1S/C19H21NS/c1-20-11-8-15(9-12-20)19-16-5-3-2-4-14(16)6-7-18-17(19)10-13-21-18/h2-5,10,13H,6-9,11-12H2,1H3 DMV74ZH CS CN1CCC(=C2C3=C(CCC4=CC=CC=C42)SC=C3)CC1 DMV74ZH IK FIADGNVRKBPQEU-UHFFFAOYSA-N DMV74ZH IU 1-methyl-4-(6-thiatricyclo[8.4.0.03,7]tetradeca-1(14),3(7),4,10,12-pentaen-2-ylidene)piperidine DMV74ZH CA CAS 15574-96-6 DMV74ZH CB CHEBI:50212 DMV74ZH DE Headache DMKMBES ID DMKMBES DMKMBES DN Plazomicin DMKMBES HS Approved DMKMBES SN ACHN-490; UNII-LYO9XZ250J; 1154757-24-0; LYO9XZ250J; Plazomicin [USAN:INN]; Plazomicin (USAN); ZINC68150640; DB12615; D10151; D-Streptamine, DMKMBES CP Achaogen DMKMBES DT Small molecular drug DMKMBES PC 42613186 DMKMBES MW 592.7 DMKMBES FM C25H48N6O10 DMKMBES IC InChI=1S/C25H48N6O10/c1-25(37)11-38-24(18(35)21(25)29-2)41-20-15(31-22(36)16(33)5-6-26)9-14(28)19(17(20)34)40-23-13(27)4-3-12(39-23)10-30-7-8-32/h3,13-21,23-24,29-30,32-35,37H,4-11,26-28H2,1-2H3,(H,31,36)/t13-,14+,15-,16+,17+,18-,19-,20+,21-,23-,24-,25+/m1/s1 DMKMBES CS C[C@@]1(CO[C@@H]([C@@H]([C@H]1NC)O)O[C@H]2[C@@H](C[C@@H]([C@H]([C@@H]2O)O[C@@H]3[C@@H](CC=C(O3)CNCCO)N)N)NC(=O)[C@H](CCN)O)O DMKMBES IK IYDYFVUFSPQPPV-PEXOCOHZSA-N DMKMBES IU (2S)-4-amino-N-[(1R,2S,3S,4R,5S)-5-amino-4-[[(2S,3R)-3-amino-6-[(2-hydroxyethylamino)methyl]-3,4-dihydro-2H-pyran-2-yl]oxy]-2-[(2R,3R,4R,5R)-3,5-dihydroxy-5-methyl-4-(methylamino)oxan-2-yl]oxy-3-hydroxycyclohexyl]-2-hydroxybutanamide DMKMBES CA CAS 1154757-24-0 DMKMBES DE Urinary tract infection; Prostate disease; Bronchitis; Pancreatic cancer DMKEX7O ID DMKEX7O DMKEX7O DN Plecanatide DMKEX7O HS Approved DMKEX7O SN Trulance DMKEX7O CP Synergy Pharmaceuticals DMKEX7O DT Small molecular drug DMKEX7O PC 70693500 DMKEX7O MW 1681.9 DMKEX7O FM C65H104N18O26S4 DMKEX7O IC InChI=1S/C65H104N18O26S4/c1-25(2)15-34-55(98)80-41-24-113-110-21-38(58(101)77-37(65(108)109)16-26(3)4)71-44(87)20-69-62(105)50(30(10)84)83-61(104)40(78-51(94)29(9)70-63(106)48(27(5)6)81-57(100)35(18-43(68)86)76-64(107)49(28(7)8)82-60(41)103)23-112-111-22-39(59(102)73-32(53(96)75-34)11-13-45(88)89)79-54(97)33(12-14-46(90)91)72-56(99)36(19-47(92)93)74-52(95)31(66)17-42(67)85/h25-41,48-50,84H,11-24,66H2,1-10H3,(H2,67,85)(H2,68,86)(H,69,105)(H,70,106)(H,71,87)(H,72,99)(H,73,102)(H,74,95)(H,75,96)(H,76,107)(H,77,101)(H,78,94)(H,79,97)(H,80,98)(H,81,100)(H,82,103)(H,83,104)(H,88,89)(H,90,91)(H,92,93)(H,108,109)/t29-,30+,31-,32-,33-,34-,35-,36-,37-,38-,39-,40-,41-,48-,49-,50-/m0/s1 DMKEX7O CS C[C@H]1C(=O)N[C@H]2CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](NC(=O)CNC(=O)[C@@H](NC2=O)[C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)O)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)C(C)C)CC(=O)N)C(C)C)CC(C)C)CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)N)N DMKEX7O IK NSPHQWLKCGGCQR-DLJDZFDSSA-N DMKEX7O IU (2S)-2-[[(1R,4S,7S,10S,13S,16R,19S,22S,25R,32S,38R)-10-(2-amino-2-oxoethyl)-25-[[(2S)-4-carboxy-2-[[(2S)-3-carboxy-2-[[(2S)-2,4-diamino-4-oxobutanoyl]amino]propanoyl]amino]butanoyl]amino]-22-(2-carboxyethyl)-32-[(1R)-1-hydroxyethyl]-4-methyl-19-(2-methylpropyl)-3,6,9,12,15,18,21,24,30,33,36-undecaoxo-7,13-di(propan-2-yl)-27,28,40,41-tetrathia-2,5,8,11,14,17,20,23,31,34,37-undecazabicyclo[14.13.13]dotetracontane-38-carbonyl]amino]-4-methylpentanoic acid DMKEX7O CA CAS 467426-54-6 DMKEX7O DE Irritable bowel syndrome; Chronic idiopathic constipation; Crohn disease DMAKXW9 ID DMAKXW9 DMAKXW9 DN PLEGRIDY DMAKXW9 HS Approved DMAKXW9 SN Peginterferon beta-1a DMAKXW9 CP Biogen Idec DMAKXW9 SQ Sequence: MSYNLLGFLQRSSNFQCQKLLWQLNGRLEYCLKDRMNFDIPEEIKQLQQFQKEDAALTIYEMLQNIFAIFRQDSSSTGWNETIVENLLANVYHQINHLKTVLEEKLEKEDFTRGKLMSSLHLKRYYGRILHYLKAKEYSHCAWTIVRVEILRNFYFINRLTGYLRN DMAKXW9 DE Multiple sclerosis DMCJN1P ID DMCJN1P DMCJN1P DN Plerixafor DMCJN1P HS Approved DMCJN1P SN Mozobil; AMD3100; Amd 3100; JM 2987; JM 3100; JM3100; SDZ SID 791; SID791; AMD-3100; Bicyclam JM-2987; JM-3100; Mozobil (TN); GNA & AMD-3100; HHA & AMD-3100; Plerixafor (INN/USAN); 1,1'-[1,4-Phenylenebis(methylene)]bis[1,4,8,11-tetraazacyclotetradecane]; 1,1'-[1,4-Phenylenebis(methylene)]bis[1,4,8,11-tetraazacyclotetradecane] & Galanthus nivalis agglutinin (GNA); 1,1'-[1,4-Phenylenebis(methylene)]bis[1,4,8,11-tetraazacyclotetradecane] & Hippeastrum hybrid agglutinin(HHA); 1,1'-{1,4-phenylenebis(methylene)}-bis{1,4,8,11-tetraaza-cyclotetradecane}; 1-[[4-(1,4,8,11-tetrazacyclotetradec-1-ylmethyl)phenyl]methyl]-1,4,8,11-tetrazacyclotetradecane DMCJN1P CP Genzyme DMCJN1P DT Small molecular drug DMCJN1P PC 65015 DMCJN1P MW 502.8 DMCJN1P FM C28H54N8 DMCJN1P IC InChI=1S/C28H54N8/c1-9-29-15-17-31-13-3-21-35(23-19-33-11-1)25-27-5-7-28(8-6-27)26-36-22-4-14-32-18-16-30-10-2-12-34-20-24-36/h5-8,29-34H,1-4,9-26H2 DMCJN1P CS C1CNCCNCCCN(CCNC1)CC2=CC=C(C=C2)CN3CCCNCCNCCCNCC3 DMCJN1P IK YIQPUIGJQJDJOS-UHFFFAOYSA-N DMCJN1P IU 1-[[4-(1,4,8,11-tetrazacyclotetradec-1-ylmethyl)phenyl]methyl]-1,4,8,11-tetrazacyclotetradecane DMCJN1P CA CAS 110078-46-1 DMCJN1P CB CHEBI:125354 DMCJN1P DE Non-hodgkin lymphoma DM7C8YV ID DM7C8YV DM7C8YV DN Plicamycin DM7C8YV HS Approved DM7C8YV SN A-2371; NSC24559; PA-144; MTM A; AC1O3EQZ; CHEMBL413720; SCHEMBL14066059; NSC-24559; AKOS030213136; EC-7071; CCG-208236; NCGC00160390-01; NCI60_004287; AB01273958-01 DM7C8YV DT Small molecular drug DM7C8YV PC 163659 DM7C8YV MW 1085.1 DM7C8YV FM C52H76O24 DM7C8YV IC InChI=1S/C52H76O24/c1-18-29(72-34-14-30(43(58)21(4)68-34)73-33-13-28(54)42(57)20(3)67-33)12-26-10-25-11-27(49(66-9)48(63)41(56)19(2)53)50(47(62)39(25)46(61)38(26)40(18)55)76-36-16-31(44(59)23(6)70-36)74-35-15-32(45(60)22(5)69-35)75-37-17-52(8,65)51(64)24(7)71-37/h10,12,19-24,27-28,30-37,41-45,49-51,53-61,64-65H,11,13-17H2,1-9H3/t19-,20-,21-,22-,23-,24-,27+,28-,30-,31-,32-,33+,34+,35+,36+,37+,41+,42-,43-,44-,45+,49+,50+,51-,52+/m1/s1 DM7C8YV CS C[C@@H]1[C@H]([C@@H](C[C@@H](O1)O[C@@H]2C[C@@H](O[C@@H]([C@H]2O)C)OC3=CC4=CC5=C(C(=O)[C@H]([C@@H](C5)[C@@H](C(=O)[C@H]([C@@H](C)O)O)OC)O[C@H]6C[C@H]([C@@H]([C@H](O6)C)O)O[C@H]7C[C@H]([C@H]([C@H](O7)C)O)O[C@H]8C[C@]([C@@H]([C@H](O8)C)O)(C)O)C(=C4C(=C3C)O)O)O)O DM7C8YV IK CFCUWKMKBJTWLW-BKHRDMLASA-N DM7C8YV IU (2S,3S)-2-[(2S,4R,5R,6R)-4-[(2S,4R,5S,6R)-4-[(2S,4S,5R,6R)-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy-5-hydroxy-6-methyloxan-2-yl]oxy-5-hydroxy-6-methyloxan-2-yl]oxy-3-[(1S,3S,4R)-3,4-dihydroxy-1-methoxy-2-oxopentyl]-6-[(2S,4R,5R,6R)-4-[(2S,4R,5S,6R)-4,5-dihydroxy-6-methyloxan-2-yl]oxy-5-hydroxy-6-methyloxan-2-yl]oxy-8,9-dihydroxy-7-methyl-3,4-dihydro-2H-anthracen-1-one DM7C8YV CA CAS 18378-89-7 DM7C8YV CB CHEBI:31856 DM7C8YV DE Lung cancer; Ovarian cancer; Testicular cancer; Hypercalcaemia; Solid tumour/cancer DMG8MLJ ID DMG8MLJ DMG8MLJ DN Pneumococcal 13-valent conjugate vaccine DMG8MLJ HS Approved DMG8MLJ SN Prevnar 13 (TN) DMG8MLJ CP Pfizer DMG8MLJ DE Streptococcus infection DMT2EJP ID DMT2EJP DMT2EJP DN Podofilox DMT2EJP HS Approved DMT2EJP SN podophyllotoxin; 518-28-5; Condylox; Condyline; Wartec; Podophyllotoxin 7; Podophyllinic acid lactone; Warticon; (-)-Podophyllotoxin; Podofilox [USAN]; CCRIS 565; UNII-L36H50F353; Podophyllotoxin, 95%; HSDB 7238; NSC24818; CHEMBL61; EINECS 208-250-4; NSC 24818; (5R,5aR,8aR,9R)-9-hydroxy-5-(3,4,5-trimethoxyphenyl)-5,8,8a,9-tetrahydrofuro[3',4':6,7]naphtho[2,3-d][1,3]dioxol-6(5aH)-one; MLS000069495; AI3-50456; CHEBI:50305; Podofilox (USAN); L36H50F353; Furo(3',4':6,7)naphtho(2,3-d)-1,3-dioxol-6(5aH)-one,; Podophyllotoxin DMT2EJP CP Actavis Laboratories Ut Inc DMT2EJP DT Small molecular drug DMT2EJP PC 10607 DMT2EJP MW 414.4 DMT2EJP FM C22H22O8 DMT2EJP IC InChI=1S/C22H22O8/c1-25-16-4-10(5-17(26-2)21(16)27-3)18-11-6-14-15(30-9-29-14)7-12(11)20(23)13-8-28-22(24)19(13)18/h4-7,13,18-20,23H,8-9H2,1-3H3/t13-,18+,19-,20-/m0/s1 DMT2EJP CS COC1=CC(=CC(=C1OC)OC)[C@H]2[C@@H]3[C@H](COC3=O)[C@H](C4=CC5=C(C=C24)OCO5)O DMT2EJP IK YJGVMLPVUAXIQN-XVVDYKMHSA-N DMT2EJP IU (5R,5aR,8aR,9R)-5-hydroxy-9-(3,4,5-trimethoxyphenyl)-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[5,6-f][1,3]benzodioxol-8-one DMT2EJP CA CAS 518-28-5 DMT2EJP CB CHEBI:50305 DMT2EJP DE External genital and perianal wart; Condyloma; Verruca vulgaris DMF6Y0L ID DMF6Y0L DMF6Y0L DN Polatuzumab vedotin DMF6Y0L HS Approved DMF6Y0L CP Genentech DMF6Y0L DT Antibody DMF6Y0L DE Follicular lymphoma; Haematological malignancy; Diffuse large B-cell lymphoma DMH1KMT ID DMH1KMT DMH1KMT DN Polidocanol DMH1KMT HS Approved DMH1KMT SN Asclera (TN) DMH1KMT CP Chemisch FBRK KRSSLR DMH1KMT DT Small molecular drug DMH1KMT PC 656641 DMH1KMT MW 582.8 DMH1KMT FM C30H62O10 DMH1KMT IC InChI=1S/C30H62O10/c1-2-3-4-5-6-7-8-9-10-11-13-32-15-17-34-19-21-36-23-25-38-27-29-40-30-28-39-26-24-37-22-20-35-18-16-33-14-12-31/h31H,2-30H2,1H3 DMH1KMT CS CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO DMH1KMT IK ONJQDTZCDSESIW-UHFFFAOYSA-N DMH1KMT IU 2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol DMH1KMT CA CAS 3055-99-0 DMH1KMT CB CHEBI:46859 DMH1KMT DE Reticular veins; Spider veins DMUCWEX ID DMUCWEX DMUCWEX DN Polidocanol - BioForm Medical/Chemische Fabrik Kreussler & Co DMUCWEX HS Approved DMUCWEX SN Aethoxysklerol; Asclera DMUCWEX DT Small molecular drug DMUCWEX PC 24750 DMUCWEX MW 230.39 DMUCWEX FM C14H30O2 DMUCWEX IC InChI=1S/C14H30O2/c1-2-3-4-5-6-7-8-9-10-11-13-16-14-12-15/h15H,2-14H2,1H3 DMUCWEX CS CCCCCCCCCCCCOCCO DMUCWEX IK SFNALCNOMXIBKG-UHFFFAOYSA-N DMUCWEX IU 2-dodecoxyethanol DMUCWEX CA CAS 4536-30-5 DMUCWEX CB CHEBI:78770 DMUCWEX DE Varicose veins DM0PMGJ ID DM0PMGJ DM0PMGJ DN Polyestradiol Phosphate DM0PMGJ HS Approved DM0PMGJ SN Estradurin DM0PMGJ CP Wyeth Ayerst Laboratories DM0PMGJ TC Anticancer Agents DM0PMGJ DT Small molecular drug DM0PMGJ PC 66435 DM0PMGJ MW 352.4 DM0PMGJ FM C18H25O5P DM0PMGJ IC InChI=1S/C18H25O5P/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)23-24(20,21)22/h3,5,10,14-17,19H,2,4,6-9H2,1H3,(H2,20,21,22)/t14-,15-,16+,17+,18+/m1/s1 DM0PMGJ CS C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2OP(=O)(O)O)CCC4=C3C=CC(=C4)O DM0PMGJ IK BBWXLCKRYRQQPL-ZBRFXRBCSA-N DM0PMGJ IU [(8R,9S,13S,14S,17S)-3-hydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl] dihydrogen phosphate DM0PMGJ CA CAS 4995-43-1 DM0PMGJ DE Prostate cancer DM4I1JP ID DM4I1JP DM4I1JP DN Polyethylene glycol DM4I1JP HS Approved DM4I1JP SN ETHYLENE GLYCOL; Ethane-1,2-diol; 1,2-ethanediol; 107-21-1; glycol; monoethylene glycol; 1,2-Dihydroxyethane; 2-hydroxyethanol; Glycol alcohol; polyethylene glycol; Ethylene alcohol; Macrogol; Fridex; Tescol; Ethylene dihydrate; Norkool; Macrogol 400 BPC; Dowtherm SR 1; Zerex; Ucar 17; Lutrol-9; ethyleneglycol; ethanediol; Aethylenglykol; Polyethylene glycol 200; Glycol, ethylene-; 1,2-Ethandiol; Glycols, polyethylene; Caswell No. 441; Ethylenglycol; Lutrol; Aethylenglykol [German]; Polyethylene glycol 600; 146AR; UNII-FC72KVT52F DM4I1JP DT Small molecular drug DM4I1JP PC 174 DM4I1JP MW 62.07 DM4I1JP FM C2H6O2 DM4I1JP IC InChI=1S/C2H6O2/c3-1-2-4/h3-4H,1-2H2 DM4I1JP CS C(CO)O DM4I1JP IK LYCAIKOWRPUZTN-UHFFFAOYSA-N DM4I1JP IU ethane-1,2-diol DM4I1JP CA CAS 107-21-1 DM4I1JP CB CHEBI:30742 DM4I1JP DE Constipation DMN0LP8 ID DMN0LP8 DMN0LP8 DN Polymyxin B Sulfate DMN0LP8 HS Approved DMN0LP8 SN Aerosporin; Polimixina B; Polymixin B sulfate; Polymxin B sulfate; Polymyxin b; Polymyxine B; Polymyxinum B; Terramycin Ophthalmic; Polimixina B [INN-Spanish]; Polymyxin B Sulfate [USAN:JAN]; Polymyxin B, sulfate; Polymyxine B [INN-French]; Polymyxinum B [INN-Latin]; Aerosporin, PMB, Poly-RX,Polymyxin B sulphate; 4-amino-N-[1-[[4-amino-1-oxo-1-[[6,9,18-tris(2-aminoethyl)-15-benzyl-3-(2-hydroxyethyl)-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-4-hydroxy-1-oxobutan-2-yl]-2-formamidobutanamide DMN0LP8 TC Antibiotics DMN0LP8 DT Small molecular drug DMN0LP8 PC 5702105 DMN0LP8 MW 1301.6 DMN0LP8 FM C56H100N16O17S DMN0LP8 IC InChI=1S/C56H98N16O13.H2O4S/c1-7-32(4)13-11-12-16-44(75)63-36(17-23-57)51(80)72-46(34(6)74)56(85)68-39(20-26-60)48(77)67-41-22-28-62-55(84)45(33(5)73)71-52(81)40(21-27-61)65-47(76)37(18-24-58)66-53(82)42(29-31(2)3)69-54(83)43(30-35-14-9-8-10-15-35)70-49(78)38(19-25-59)64-50(41)79;1-5(2,3)4/h8-10,14-15,31-34,36-43,45-46,73-74H,7,11-13,16-30,57-61H2,1-6H3,(H,62,84)(H,63,75)(H,64,79)(H,65,76)(H,66,82)(H,67,77)(H,68,85)(H,69,83)(H,70,78)(H,71,81)(H,72,80);(H2,1,2,3,4) DMN0LP8 CS CCC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC1=O)CCN)CC2=CC=CC=C2)CC(C)C)CCN)CCN)C(C)O.OS(=O)(=O)O DMN0LP8 IK HFMDLUQUEXNBOP-UHFFFAOYSA-N DMN0LP8 IU N-[4-amino-1-[[1-[[4-amino-1-oxo-1-[[6,9,18-tris(2-aminoethyl)-15-benzyl-3-(1-hydroxyethyl)-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-6-methyloctanamide;sulfuric acid DMN0LP8 CA CAS 1405-20-5 DMN0LP8 DE Pseudomonas infection DMJAOT1 ID DMJAOT1 DMJAOT1 DN Polyoxidonium DMJAOT1 HS Approved DMJAOT1 CP Immutic Group DMJAOT1 DE Infectious disease DMCH80F ID DMCH80F DMCH80F DN Polythiazide DMCH80F HS Approved DMCH80F SN Drenusil; Nephril; Politiazida; Polythiazidum; Renese; P 2525; P-2525; Politiazida [INN-Spanish]; Polythiazidum [INN-Latin]; Renese (TN); Polythiazide (JAN/USAN/INN); Polythiazide [USAN:INN:BAN:JAN]; 2-Methyl-3-(beta,beta,beta-trifluoroethylthiomethyl)-6-chloro-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine 1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3,4-dihydro-2-methyl-3-(((2,2,2-trifluoroethyl)thio)methyl)-, 1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3,4-dihydro-2-methyl-3-(((2,2,2-trifluoroethyl)thio)methyl)-, 1,1-dioxide (8CI, 9CI); 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3,4-dihydro-2-methyl-3-[[(2,2,2-trifluoroethyl)thio]methyl]-, 1,1-dioxide; 6-Chloro-3,4-dihydro-2-methyl-3-(((2,2,2-trifluoroethyl)thio)methyl)-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 6-Chloro-3,4-dihydro-2-methyl-3-[[(2,2,2-trifluoroethyl)thio]methyl]-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 6-Chloro-3,4-dihydro-2-methyl-7-sulphamoyl-3-(2,2,2-trifluoroethylthiomethyl)-2H-benzo-1,2,4-thiadiazine 1,1-dioxide; 6-chloro-2-methyl-1,1-dioxo-3-(2,2,2-trifluoroethylsulfanylmethyl)-3,4-dihydro-1; 6-chloro-2-methyl-3-{[(2,2,2-trifluoroethyl)thio]methyl}-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide DMCH80F TC Antihypertensive Agents DMCH80F DT Small molecular drug DMCH80F PC 4870 DMCH80F MW 439.9 DMCH80F FM C11H13ClF3N3O4S3 DMCH80F IC InChI=1S/C11H13ClF3N3O4S3/c1-18-10(4-23-5-11(13,14)15)17-7-2-6(12)8(24(16,19)20)3-9(7)25(18,21)22/h2-3,10,17H,4-5H2,1H3,(H2,16,19,20) DMCH80F CS CN1C(NC2=CC(=C(C=C2S1(=O)=O)S(=O)(=O)N)Cl)CSCC(F)(F)F DMCH80F IK CYLWJCABXYDINA-UHFFFAOYSA-N DMCH80F IU 6-chloro-2-methyl-1,1-dioxo-3-(2,2,2-trifluoroethylsulfanylmethyl)-3,4-dihydro-1lambda6,2,4-benzothiadiazine-7-sulfonamide DMCH80F CA CAS 346-18-9 DMCH80F CB CHEBI:8327 DMCH80F DE Edema; Hypertension DMTGBAX ID DMTGBAX DMTGBAX DN Pomalidomide DMTGBAX HS Approved DMTGBAX SN Actimid (TN); Pomalidomide (Immunomodulator) DMTGBAX CP Celgene DMTGBAX DT Small molecular drug DMTGBAX PC 134780 DMTGBAX MW 273.24 DMTGBAX FM C13H11N3O4 DMTGBAX IC InChI=1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18) DMTGBAX CS C1CC(=O)NC(=O)C1N2C(=O)C3=C(C2=O)C(=CC=C3)N DMTGBAX IK UVSMNLNDYGZFPF-UHFFFAOYSA-N DMTGBAX IU 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione DMTGBAX CA CAS 19171-19-8 DMTGBAX CB CHEBI:72690 DMTGBAX DE Systemic sclerosis DMYGJQO ID DMYGJQO DMYGJQO DN Ponatinib DMYGJQO HS Approved DMYGJQO SN Iclusig (TN) DMYGJQO CP ARIAD Pharmaceuticals DMYGJQO DT Small molecular drug DMYGJQO PC 24826799 DMYGJQO MW 532.6 DMYGJQO FM C29H27F3N6O DMYGJQO IC InChI=1S/C29H27F3N6O/c1-20-5-6-22(16-21(20)8-10-25-18-33-27-4-3-11-34-38(25)27)28(39)35-24-9-7-23(26(17-24)29(30,31)32)19-37-14-12-36(2)13-15-37/h3-7,9,11,16-18H,12-15,19H2,1-2H3,(H,35,39) DMYGJQO CS CC1=C(C=C(C=C1)C(=O)NC2=CC(=C(C=C2)CN3CCN(CC3)C)C(F)(F)F)C#CC4=CN=C5N4N=CC=C5 DMYGJQO IK PHXJVRSECIGDHY-UHFFFAOYSA-N DMYGJQO IU 3-(2-imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]benzamide DMYGJQO CA CAS 943319-70-8 DMYGJQO CB CHEBI:78543 DMYGJQO DE Acute lymphoblastic leukaemia DMEAOYJ ID DMEAOYJ DMEAOYJ DN Ponesimod DMEAOYJ HS Approved DMEAOYJ SN 854107-55-4; UNII-5G7AKV2MKP; 5G7AKV2MKP; CHEMBL1096146; Ponesimod [USAN:INN]; Ponesimod,ACT-128800; Ponesimod (ACT-128800); GTPL9320; SCHEMBL15477937; SCHEMBL15477934; DTXSID50234631; MolPort-035-681-391; MolPort-046-033-541; EX-A1417; ZINC34509627; s8241; BDBM50316768; AKOS022180266; DB12016; Compound 8bo [PMID:20446681]; HY-10569; KB-72962; AS-35140; AJ-89002; (2Z,5Z)-5-(3-Chloro-4-((2R)-2,3-dihydroxypropoxy)phenylmethylidene)-3-(2-methylphenyl)-2-(propylimino)-1,3-thiazolidin- DMEAOYJ CP Actelion Pharmaceuticals South San Francisco, CA DMEAOYJ DT Small molecular drug DMEAOYJ PC 11363176 DMEAOYJ MW 461 DMEAOYJ FM C23H25ClN2O4S DMEAOYJ IC InChI=1S/C23H25ClN2O4S/c1-3-10-25-23-26(19-7-5-4-6-15(19)2)22(29)21(31-23)12-16-8-9-20(18(24)11-16)30-14-17(28)13-27/h4-9,11-12,17,27-28H,3,10,13-14H2,1-2H3/b21-12-,25-23?/t17-/m1/s1 DMEAOYJ CS CCCN=C1N(C(=O)/C(=C/C2=CC(=C(C=C2)OC[C@@H](CO)O)Cl)/S1)C3=CC=CC=C3C DMEAOYJ IK LPAUOXUZGSBGDU-ULCCENQXSA-N DMEAOYJ IU (5Z)-5-[[3-chloro-4-[(2R)-2,3-dihydroxypropoxy]phenyl]methylidene]-3-(2-methylphenyl)-2-propylimino-1,3-thiazolidin-4-one DMEAOYJ CA CAS 854107-55-4 DMEAOYJ DE Psoriasis vulgaris; Multiple sclerosis DM7ZWNY ID DM7ZWNY DM7ZWNY DN Porfimer Sodium DM7ZWNY HS Approved DM7ZWNY SN Photofrin DM7ZWNY CP Concordia Laboratories Inc DM7ZWNY DT Small molecular drug DM7ZWNY DE Non-small-cell lung cancer DMUL5EW ID DMUL5EW DMUL5EW DN Posaconazole DMUL5EW HS Approved DMUL5EW SN Noxafil; Spriafil; Posaconazole SP; Posaconazole in combination with MGCD290; SCH56592; Sch 56592; X2N; Noxafil (TN); Noxafil, Posaconazole; SCH-56592; Posaconazole (USAN/INN); Posaconazole [USAN:INN:BAN]; 1-((1S,2S)-1-Ethyl-2-hydroxypropyl)-4-{4-[4-(4-{[(5S,3R)-5-(2,4-difluorophenyl)-5-(1,2,4-triazolylmethyl)oxolan-3-yl]methoxy}phenyl)piperazinyl]phenyl}-1,2,4-triazolin-5-one; 4-(p-(4-(p-(((3R,5R)-5-(2,4-Difluorophenyl)tetrahydro-5-(1H-1,2,4-triazol-1-ylmethyl)-3-furyl)methoxy)phenyl)-1-piperazinyl)phenyl)-1-((1S,2S)-1-ethyl-2-hydroxypropyl)-delta(sup 2)-1,2,4-triazolin-5-one; 4-[4-[4-[4-[[(3R,5R)-5-(2,4-difluorophenyl)-5-(1,2,4-triazol-1-ylmethyl)oxolan-3-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-2-[(2S,3S)-2-hydroxypentan-3-yl]-1,2,4-triazol-3-one; 4-[4-[4-[4-[[(5R)-5-(2,4-difluorophenyl)-5-(1,2,4-triazol-1-ylmethyl)oxolan-3-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-2-[(2S,3S)-2-hydroxypentan-3-yl]-1,2,4-triazol-3-one DMUL5EW CP Schering-Plough DMUL5EW TC Antifungal Agents DMUL5EW DT Small molecular drug DMUL5EW PC 468595 DMUL5EW MW 700.8 DMUL5EW FM C37H42F2N8O4 DMUL5EW IC InChI=1S/C37H42F2N8O4/c1-3-35(26(2)48)47-36(49)46(25-42-47)31-7-5-29(6-8-31)43-14-16-44(17-15-43)30-9-11-32(12-10-30)50-20-27-19-37(51-21-27,22-45-24-40-23-41-45)33-13-4-28(38)18-34(33)39/h4-13,18,23-27,35,48H,3,14-17,19-22H2,1-2H3/t26-,27+,35-,37-/m0/s1 DMUL5EW CS CC[C@@H]([C@H](C)O)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5C[C@](OC5)(CN6C=NC=N6)C7=C(C=C(C=C7)F)F DMUL5EW IK RAGOYPUPXAKGKH-XAKZXMRKSA-N DMUL5EW IU 4-[4-[4-[4-[[(3R,5R)-5-(2,4-difluorophenyl)-5-(1,2,4-triazol-1-ylmethyl)oxolan-3-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-2-[(2S,3S)-2-hydroxypentan-3-yl]-1,2,4-triazol-3-one DMUL5EW CA CAS 171228-49-2 DMUL5EW CB CHEBI:64355 DMUL5EW DE Aspergillosis DMMTAJC ID DMMTAJC DMMTAJC DN Potassium chloride DMMTAJC HS Approved DMMTAJC SN Acronitol; Celeka; Chloropotassuril; Chlorvescent; Durekal; Durules; Enpott; Enseal; Infalyte; KCL; KSR; Kadalex; Kalcorid; Kaleorid; Kaleorod; Kaliduron; Kaliglutol; Kalilente; Kalinorm; Kaliolite; Kalipor; Kalipoz; Kalitabs; Kaliumchlorid; Kaochlor; Kaskay; Kato; Kayback; Kayciel; Kaysiel; Keylyte; Kloren; Klorvess; Klotrix; Kolyum; Miopotasio; Neobakasal; Pfiklor; Potasion; Potasol; Potavescent; Rekawan; Selora; Steropotassium; Sylvite; [KCl]; Chlorid draselny; Chlorid draselny [Czech]; Chloride of potash; Conductance standard solution; Dipotassium dichloride; Emplets potassium chloride; K Tab; KCL Retard; KM potassium chloride; Kalinorm Depottab; Kalitrans Retard; Kalium Duriles; Kalium Durules; Kalium Retard; Kalium SR; Kaon Cl; Kaon Ultra; Kay Ciel; Kelp salt; Leo K; Monopotassium chloride; Muriate of potash; Natural sylvite; Plus Kalium Retard; Potassium Chloride BP; Potassium Chloride in Plastic Container; Potassium Cl; Potassium chloride [JAN]; Potassium chloride solution; Potassium chloride standard; Potassium monochloride; Potassium muriate; Rekawan Retard; Repone K; Sal digestnum sylvii; Super K; Tripotassium trichloride; Trona muriate of potash; Trona potassium chloride; Ultra K Chlor; IN2900; Potassium Chloride 10meq in Plastic Container; Potassium chloride 20meq inplastic container; Potassium chloride 30meq in plastic container; Potassium chloride 40meq in plastic container; Addi-K; Apo-K; Cena-K; Chloride, Potassium; Chloropotassuril diffu-K; Diffu-K; Duffi-K; Durules-K; K+10; K+8; K-10; K-Care; K-Contin; K-Dur; K-Grad; K-Lease; K-Lor; K-Lyte Cl; K-Norm; K-SR; K-Sol; K-Tab; K. tab; KCL (TN); KCl-retard Zyma; Kalinor-Retard P; Kalium S.R; Kalium-Durettes; Kalium-R; Kalium-duriles; Kaon Cl-10; Kaon-Cl; Kaon-Cl 10; Kaon-Cl TABS; Kaon-ci; Kay-Ciel; Kay-EM; Klor-Con; Klor-Con M10; Klor-Con M15; Klor-Con M20; Klor-Lyte; Klotrix (TN); Lento-K; Lento-Kalium; Leo-K; Micro-K; Micro-K 10; Micro-K Extentcaps; Micro-K LS; Micro-Kalium Retard; Nu-K; POTASSIUM CHLORIDE, ACS; Peter-kal; Potassium atomic spectroscopy standard concentrate 1.00 g K; Potassium chloride (K3Cl3); Potassium chloride (KCl); Potassium standard concentrate 10.00 g K; Potassium thallium chloride (KTlCl); Repone-K; Rum-K; Sando-K; Slow-K; Slow-K tablets; Span-K; Super K (salt); Ten-K; Clor-K-Zaf; Hydrochloric acid potassium salt (1:1); ISA (ionic strength adjustment solution: 1 M KCl); K-Lyte/Cl; K-Predne-Dome; K-dur (TN); K-lyte/C1; Kalium S.R.; Kaon-Cl (TN); Kay-Cee-L; Klor-con (TN); Potassium chloride (JP15/USP); Ultra-K-Chlor; Conductivity Standard Solution, 1413-S/cm; Conductivity Standard Solution, 500-S/cm; POTASSIUM CHLORIDE, U.S.P.; 11118_FLUKA DMMTAJC TC Dietary supplement DMMTAJC DT Small molecular drug DMMTAJC PC 4873 DMMTAJC MW 74.55 DMMTAJC FM ClK DMMTAJC IC InChI=1S/ClH.K/h1H;/q;+1/p-1 DMMTAJC CS [Cl-].[K+] DMMTAJC IK WCUXLLCKKVVCTQ-UHFFFAOYSA-M DMMTAJC IU potassium;chloride DMMTAJC CA CAS 7447-40-7 DMMTAJC CB CHEBI:32588 DMMTAJC DE Hypokalemia DMGLZ26 ID DMGLZ26 DMGLZ26 DN Practolol DMGLZ26 HS Approved DMGLZ26 SN Dalzic; Eraldin; Practololo; Practololum; Praktololu; Teranol; Eralzdin Practolol; Practololo [DCIT]; Praktololu [Polish]; AY 21011; Cardiol (TN); Cordialina (TN); Dalzic (TN); Eraldin (TN); Eraldina (TN); Practololum [INN-Latin]; Praktol (TN); Pralon (TN); Teranol (TN); Practolol [USAN:BAN:INN]; N-{4-[2-hydroxy-3-(isopropylamino)propoxy]phenyl}acetamide; N-[4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]acetamide; N-[4-({2-hydroxy-3-[(1-methylethyl)amino]propyl}oxy)phenyl]acetamide; N-{4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl}acetamide; N-(4-(2-Hydroxy-3-((1-methylethyl)amino)propoxy)phenyl)acetamide; (+-)-Practolol; 1-(4-Acetamidophenoxy)-3-isopropylamino-2-propanol; 4'-(2-Hydroxy-3-(isopropylamino)propoxy)acetanilide DMGLZ26 TC Antiarrhythmic Agents DMGLZ26 DT Small molecular drug DMGLZ26 PC 4883 DMGLZ26 MW 266.34 DMGLZ26 FM C14H22N2O3 DMGLZ26 IC InChI=1S/C14H22N2O3/c1-10(2)15-8-13(18)9-19-14-6-4-12(5-7-14)16-11(3)17/h4-7,10,13,15,18H,8-9H2,1-3H3,(H,16,17) DMGLZ26 CS CC(C)NCC(COC1=CC=C(C=C1)NC(=O)C)O DMGLZ26 IK DURULFYMVIFBIR-UHFFFAOYSA-N DMGLZ26 IU N-[4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]acetamide DMGLZ26 CA CAS 6673-35-4 DMGLZ26 CB CHEBI:258351 DMGLZ26 DE Cardiac arrhythmias DMAO80I ID DMAO80I DMAO80I DN Pralatrexate DMAO80I HS Approved DMAO80I SN Folotyn (TN) DMAO80I CP Allos Therapeutics DMAO80I DT Small molecular drug DMAO80I PC 148121 DMAO80I MW 477.5 DMAO80I FM C23H23N7O5 DMAO80I IC InChI=1S/C23H23N7O5/c1-2-3-14(10-15-11-26-20-18(27-15)19(24)29-23(25)30-20)12-4-6-13(7-5-12)21(33)28-16(22(34)35)8-9-17(31)32/h1,4-7,11,14,16H,3,8-10H2,(H,28,33)(H,31,32)(H,34,35)(H4,24,25,26,29,30)/t14?,16-/m0/s1 DMAO80I CS C#CCC(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O DMAO80I IK OGSBUKJUDHAQEA-WMCAAGNKSA-N DMAO80I IU (2S)-2-[[4-[1-(2,4-diaminopteridin-6-yl)pent-4-yn-2-yl]benzoyl]amino]pentanedioic acid DMAO80I CA CAS 146464-95-1 DMAO80I CB CHEBI:71223 DMAO80I DE Breast cancer; Peripheral T-cell lymphoma DMGQ0ZI ID DMGQ0ZI DMGQ0ZI DN Pralidoxime chloride DMGQ0ZI HS Approved DMGQ0ZI SN Protopam Chloride DMGQ0ZI CP Baxter Healthcare Corp Anesthesia And Critical Care DMGQ0ZI DT Small molecular drug DMGQ0ZI PC 135445761 DMGQ0ZI MW 172.61 DMGQ0ZI FM C7H9ClN2O DMGQ0ZI IC InChI=1S/C7H8N2O.ClH/c1-9-5-3-2-4-7(9)6-8-10;/h2-6H,1H3;1H DMGQ0ZI CS C[N+]1=CC=CC=C1/C=N/O.[Cl-] DMGQ0ZI IK HIGSLXSBYYMVKI-UHFFFAOYSA-N DMGQ0ZI IU (NE)-N-[(1-methylpyridin-1-ium-2-yl)methylidene]hydroxylamine;chloride DMGQ0ZI CA CAS 51-15-0 DMGQ0ZI CB CHEBI:8355 DMGQ0ZI DE Poisoning due to pesticides and chemicals DMWU0I2 ID DMWU0I2 DMWU0I2 DN Pralsetinib DMWU0I2 HS Approved DMWU0I2 SN GBLBJPZSROAGMF-SIYOEGHHSA-N; Blu667; 2097132-94-8; SCHEMBL18806610; SCHEMBL18789229; SCHEMBL18789228; GTPL10033; BLU-668; EX-A1944; HY-112301; CS-0044766; N-[(1S)-1-[6-(4-fluoropyrazol-1-yl)pyridin-3-yl]ethyl]-1-methoxy-4-[4-methyl-6-[(5-methyl-1H-pyrazol-3-yl)amino]pyrimidin-2-yl]cyclohexane-1-carboxamide DMWU0I2 CP Blueprint Medicines Cambridge, MA DMWU0I2 PC 129073603 DMWU0I2 MW 533.6 DMWU0I2 FM C27H32FN9O2 DMWU0I2 IC InChI=1S/C27H32FN9O2/c1-16-11-22(33-23-12-17(2)35-36-23)34-25(31-16)19-7-9-27(39-4,10-8-19)26(38)32-18(3)20-5-6-24(29-13-20)37-15-21(28)14-30-37/h5-6,11-15,18-19H,7-10H2,1-4H3,(H,32,38)(H2,31,33,34,35,36)/t18-,19?,27?/m0/s1 DMWU0I2 CS CC1=CC(=NN1)NC2=NC(=NC(=C2)C)C3CCC(CC3)(C(=O)N[C@@H](C)C4=CN=C(C=C4)N5C=C(C=N5)F)OC DMWU0I2 IK GBLBJPZSROAGMF-SIYOEGHHSA-N DMWU0I2 IU N-[(1S)-1-[6-(4-fluoropyrazol-1-yl)pyridin-3-yl]ethyl]-1-methoxy-4-[4-methyl-6-[(5-methyl-1H-pyrazol-3-yl)amino]pyrimidin-2-yl]cyclohexane-1-carboxamide DMWU0I2 CA CAS 2097132-94-8 DMWU0I2 DE Solid tumour/cancer; Non-small-cell lung cancer DMNMW9R ID DMNMW9R DMNMW9R DN Pramipexole DMNMW9R HS Approved DMNMW9R SN Mirapex; Pramipexol; Pramipexolum; SUD919CL2Y; Mirapex (TN); Mirapexin (TN); Pramipexole [USAN:INN]; SND-919; Sifrol(TN); U-98528E; Pramipexole (USAN/INN); (-)-Pramipexole; (6S)-6-N-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine; (6S)-N(6)-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine; (6S)-N6-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine; (S)-2-Amino-4,5,6,7-tetrahydro-6-(propylamino)benzothiazole; 111GE001; 2-amino-4,5,6,7-tetrahydro-6-propylaminobenzothiazole; 2-amino-6-propylaminotetrahydrobenzothiazole DMNMW9R CP Intas Pharma DMNMW9R TC Antiparkinson Agents DMNMW9R DT Small molecular drug DMNMW9R PC 119570 DMNMW9R MW 211.33 DMNMW9R FM C10H17N3S DMNMW9R IC InChI=1S/C10H17N3S/c1-2-5-12-7-3-4-8-9(6-7)14-10(11)13-8/h7,12H,2-6H2,1H3,(H2,11,13)/t7-/m0/s1 DMNMW9R CS CCCN[C@H]1CCC2=C(C1)SC(=N2)N DMNMW9R IK FASDKYOPVNHBLU-ZETCQYMHSA-N DMNMW9R IU (6S)-6-N-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine DMNMW9R CA CAS 104632-26-0 DMNMW9R CB CHEBI:8356 DMNMW9R DE Parkinson disease DM2FHG3 ID DM2FHG3 DM2FHG3 DN Pramiracetam DM2FHG3 HS Approved (orphan drug) DM2FHG3 SN Amacetam; Ectapram; Neupramir; Remen; Amacetam hydrochloride; Amacetam sulfate; Pramiracetam hydrochloride; Pramiracetam sulfate; CNS-1879 DM2FHG3 CP Warner-Lambert Co DM2FHG3 DT Small molecular drug DM2FHG3 PC 51712 DM2FHG3 MW 269.38 DM2FHG3 FM C14H27N3O2 DM2FHG3 IC InChI=1S/C14H27N3O2/c1-11(2)17(12(3)4)9-7-15-13(18)10-16-8-5-6-14(16)19/h11-12H,5-10H2,1-4H3,(H,15,18) DM2FHG3 CS CC(C)N(CCNC(=O)CN1CCCC1=O)C(C)C DM2FHG3 IK ZULJGOSFKWFVRX-UHFFFAOYSA-N DM2FHG3 IU N-[2-[di(propan-2-yl)amino]ethyl]-2-(2-oxopyrrolidin-1-yl)acetamide DM2FHG3 CA CAS 68497-62-1 DM2FHG3 CB CHEBI:135110 DM2FHG3 DE Brain disease DM0EZ9Q ID DM0EZ9Q DM0EZ9Q DN Pramlintide DM0EZ9Q HS Approved DM0EZ9Q SN Symlin; Triproamylin; Pramlintide [USAN]; Pramlintide acetate; Pramlintide acetate [USAN]; Pramlintide acetate hydrate; AC 0137 DM0EZ9Q CP Amylin Pharmaceuticals DM0EZ9Q DT Small molecular drug DM0EZ9Q SQ Pramlintide: KCNTATCATQRLANFLVHSSNNFGPILPPTNVGSNTY DM0EZ9Q PC 70691388 DM0EZ9Q MW 3949 DM0EZ9Q FM C171H267N51O53S2 DM0EZ9Q IC InChI=1S/C171H267N51O53S2/c1-21-81(12)130(163(268)207-110(56-78(6)7)169(274)222-53-33-42-118(222)170(275)221-52-32-41-117(221)160(265)219-135(89(20)230)167(272)206-109(66-125(180)238)151(256)212-128(79(8)9)161(266)186-68-126(239)192-111(70-223)154(259)203-107(64-123(178)236)152(257)218-134(88(19)229)166(271)195-98(136(181)241)57-92-43-45-94(231)46-44-92)214-159(264)116-40-31-51-220(116)127(240)69-187-141(246)101(58-90-34-24-22-25-35-90)199-148(253)105(62-121(176)234)201-149(254)106(63-122(177)235)202-155(260)112(71-224)209-156(261)113(72-225)208-146(251)103(60-93-67-184-75-188-93)205-162(267)129(80(10)11)213-150(255)100(55-77(4)5)198-145(250)102(59-91-36-26-23-27-37-91)200-147(252)104(61-120(175)233)196-137(242)82(13)189-144(249)99(54-76(2)3)197-142(247)96(39-30-50-185-171(182)183)193-143(248)97(47-48-119(174)232)194-165(270)132(86(17)227)215-138(243)83(14)190-157(262)114-73-276-277-74-115(210-140(245)95(173)38-28-29-49-172)158(263)204-108(65-124(179)237)153(258)217-131(85(16)226)164(269)191-84(15)139(244)216-133(87(18)228)168(273)211-114/h22-27,34-37,43-46,67,75-89,95-118,128-135,223-231H,21,28-33,38-42,47-66,68-74,172-173H2,1-20H3,(H2,174,232)(H2,175,233)(H2,176,234)(H2,177,235)(H2,178,236)(H2,179,237)(H2,180,238)(H2,181,241)(H,184,188)(H,186,266)(H,187,246)(H,189,249)(H,190,262)(H,191,269)(H,192,239)(H,193,248)(H,194,270)(H,195,271)(H,196,242)(H,197,247)(H,198,250)(H,199,253)(H,200,252)(H,201,254)(H,202,260)(H,203,259)(H,204,263)(H,205,267)(H,206,272)(H,207,268)(H,208,251)(H,209,261)(H,210,245)(H,211,273)(H,212,256)(H,213,255)(H,214,264)(H,215,243)(H,216,244)(H,217,258)(H,218,257)(H,219,265)(H4,182,183,185)/t81-,82-,83-,84-,85+,86+,87+,88+,89+,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,128-,129-,130-,131-,132-,133-,134-,135-/m0/s1 DM0EZ9Q CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N2CCC[C@H]2C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)N)NC(=O)[C@@H]4CCCN4C(=O)CNC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CC6=CNC=N6)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC7=CC=CC=C7)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C)NC(=O)[C@@H]8CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N8)[C@@H](C)O)C)[C@@H](C)O)CC(=O)N)NC(=O)[C@H](CCCCN)N DM0EZ9Q IK TZIRZGBAFTZREM-MKAGXXMWSA-N DM0EZ9Q IU (2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-4-amino-1-[[(2S)-1-[[2-[(2S)-2-[[(2S,3S)-1-[[(2S)-1-[(2S)-2-[(2S)-2-[[(2S,3R)-1-[[(2S)-4-amino-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-1-amino-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]carbamoyl]pyrrolidine-1-carbonyl]pyrrolidin-1-yl]-4-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]-2-[[(2S,3R)-2-[[(2S)-2-[[(4R,7S,10S,13S,16S,19R)-16-(2-amino-2-oxoethyl)-19-[[(2S)-2,6-diaminohexanoyl]amino]-7,13-bis[(1R)-1-hydroxyethyl]-10-methyl-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]amino]propanoyl]amino]-3-hydroxybutanoyl]amino]pentanediamide DM0EZ9Q CA CAS 151126-32-8 DM0EZ9Q CB CHEBI:135922 DM0EZ9Q DE Type-1/2 diabetes DMYHDCA ID DMYHDCA DMYHDCA DN Pranlukast DMYHDCA HS Approved DMYHDCA SN Azlaire; Azlaire (TN); Pranlukast (INN); N-[4-oxo-2-(2H-tetrazol-5-yl)chromen-8-yl]-4-(4-phenylbutoxy)benzamide DMYHDCA TC Antiasthmatic Agents DMYHDCA DT Small molecular drug DMYHDCA PC 4887 DMYHDCA MW 481.5 DMYHDCA FM C27H23N5O4 DMYHDCA IC InChI=1S/C27H23N5O4/c33-23-17-24(26-29-31-32-30-26)36-25-21(23)10-6-11-22(25)28-27(34)19-12-14-20(15-13-19)35-16-5-4-9-18-7-2-1-3-8-18/h1-3,6-8,10-15,17H,4-5,9,16H2,(H,28,34)(H,29,30,31,32) DMYHDCA CS C1=CC=C(C=C1)CCCCOC2=CC=C(C=C2)C(=O)NC3=CC=CC4=C3OC(=CC4=O)C5=NNN=N5 DMYHDCA IK NBQKINXMPLXUET-UHFFFAOYSA-N DMYHDCA IU N-[4-oxo-2-(2H-tetrazol-5-yl)chromen-8-yl]-4-(4-phenylbutoxy)benzamide DMYHDCA CA CAS 103177-37-3 DMYHDCA CB CHEBI:94810 DMYHDCA DE Asthma DM67VKL ID DM67VKL DM67VKL DN Prasterone DM67VKL HS Approved DM67VKL SN Dehydroepiandrosterone; DHEA; 53-43-0; PRASTERONE; Dehydroisoandrosterone; Androstenolone; trans-Dehydroandrosterone; Psicosterone; Diandrone; Diandron; 3beta-hydroxyandrost-5-en-17-one; 17-Hormoforin; Prestara; 17-Chetovis; Andrestenol; 5-Dehydroepiandrosterone; Intrarosa; Siscelar plus; 5,6-Didehydroisoandrosterone; Dehydro-epi-androsterone; Prasteronum; 5,6-Dehydroisoandrosterone; Prasterona; Epiandrosterone, 5-dehydro-; Caswell No 051F; 5,6-Dehydroisoandrostorone DM67VKL DT Small molecular drug DM67VKL PC 5881 DM67VKL MW 288.4 DM67VKL FM C19H28O2 DM67VKL IC InChI=1S/C19H28O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h3,13-16,20H,4-11H2,1-2H3/t13-,14-,15-,16-,18-,19-/m0/s1 DM67VKL CS C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CC=C4[C@@]3(CC[C@@H](C4)O)C DM67VKL IK FMGSKLZLMKYGDP-USOAJAOKSA-N DM67VKL IU (3S,8R,9S,10R,13S,14S)-3-hydroxy-10,13-dimethyl-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-one DM67VKL CA CAS 53-43-0 DM67VKL CB CHEBI:28689 DM67VKL DE Chronic obstructive pulmonary disease; Cardiovascular disease DM7MT6E ID DM7MT6E DM7MT6E DN Prasugrel DM7MT6E HS Approved DM7MT6E SN Effient (TN) DM7MT6E CP Lilly; Daiichi Sankyo DM7MT6E DT Small molecular drug DM7MT6E PC 6918456 DM7MT6E MW 373.4 DM7MT6E FM C20H20FNO3S DM7MT6E IC InChI=1S/C20H20FNO3S/c1-12(23)25-18-10-14-11-22(9-8-17(14)26-18)19(20(24)13-6-7-13)15-4-2-3-5-16(15)21/h2-5,10,13,19H,6-9,11H2,1H3 DM7MT6E CS CC(=O)OC1=CC2=C(S1)CCN(C2)C(C3=CC=CC=C3F)C(=O)C4CC4 DM7MT6E IK DTGLZDAWLRGWQN-UHFFFAOYSA-N DM7MT6E IU [5-[2-cyclopropyl-1-(2-fluorophenyl)-2-oxoethyl]-6,7-dihydro-4H-thieno[3,2-c]pyridin-2-yl] acetate DM7MT6E CA CAS 150322-43-3 DM7MT6E CB CHEBI:87723 DM7MT6E DE Acute coronary syndrome DM6A0X7 ID DM6A0X7 DM6A0X7 DN Pravastatin DM6A0X7 HS Approved DM6A0X7 SN Eptastatin; Oliprevin; Pravastatina; Pravastatine; Pravastatinum; Pravator; Vasten; Pravastatin Sodium Salt; Pravastatina [Spanish]; Pravastatine [French]; Pravastatinum [Latin]; KS-5015; Pravachol (TN); Pravastatin (INN); Pravastatin [INN:BAN]; Pravastatin tert-Octylamine Salt; Pravator (TN); RMS-431; Selektine (TN); SQ-31,000; (3R,5R)-3,5-dihydroxy-7-[(1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-{[(2S)-2-methylbutanoyl]oxy}-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]heptanoic acid; (3R,5R)-7-[(1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-[(2S)-2-methylbutanoyl]oxy-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid; 1,2,6,7,8,8a-hexahydro-beta,delta,6-trihydroxy-2-methyl-8-(2-methyl-1-oxobutoxy)-, (1S-(1alpha(betaS*,deltaS*),2alpha,6alpha,8beta(R*),8aalpha))-1-Naphthaleneheptanoic acid DM6A0X7 CP Bristol-Myers Squibb DM6A0X7 TC Anticholesteremic Agents DM6A0X7 DT Small molecular drug DM6A0X7 PC 54687 DM6A0X7 MW 424.5 DM6A0X7 FM C23H36O7 DM6A0X7 IC InChI=1S/C23H36O7/c1-4-13(2)23(29)30-20-11-17(25)9-15-6-5-14(3)19(22(15)20)8-7-16(24)10-18(26)12-21(27)28/h5-6,9,13-14,16-20,22,24-26H,4,7-8,10-12H2,1-3H3,(H,27,28)/t13-,14-,16+,17+,18+,19-,20-,22-/m0/s1 DM6A0X7 CS CC[C@H](C)C(=O)O[C@H]1C[C@@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@H](C[C@H](CC(=O)O)O)O)O DM6A0X7 IK TUZYXOIXSAXUGO-PZAWKZKUSA-N DM6A0X7 IU (3R,5R)-7-[(1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-[(2S)-2-methylbutanoyl]oxy-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid DM6A0X7 CA CAS 81093-37-0 DM6A0X7 CB CHEBI:63618 DM6A0X7 DE Hypercholesterolaemia DMEWC7N ID DMEWC7N DMEWC7N DN Prazepam DMEWC7N HS Approved DMEWC7N SN Centrax; Demetrin; Lysanxia; Prazeene; Prazene; Prazepamum; Sedapran; Settima; Trepidan; Verstran; W 4020; Centrac (TN); Centrax (TN); Demetrin (TN); K-373; Lysanxia (TN); Mono Demetrin (TN); Pozapam (TN); Prasepine (TN); Prazene (TN); Prazepamum [INN-Latin]; Reapam (TN); Trepidan (TN); W-4020; Prazepam (JP15/USAN/INN); Prazepam [USAN:INN:BAN:JAN]; 7-Chloro-1-(cyclopropylmethyl)-1,3-dihydro-5-phenyl-2H-1,4-benzodiazepin-2-one; 7-Chloro-1-(cyclopropylmethyl)-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one; 7-Chloro-1-cyclopropylmethyl-5-phenyl-1H-1,4-benzodiazepin-2(3H)-one; 7-chloro-1-(cyclopropylmethyl)-5-phenyl-3H-1,4-benzodiazepin-2-one DMEWC7N TC Antianxiety Agents DMEWC7N DT Small molecular drug DMEWC7N PC 4890 DMEWC7N MW 324.8 DMEWC7N FM C19H17ClN2O DMEWC7N IC InChI=1S/C19H17ClN2O/c20-15-8-9-17-16(10-15)19(14-4-2-1-3-5-14)21-11-18(23)22(17)12-13-6-7-13/h1-5,8-10,13H,6-7,11-12H2 DMEWC7N CS C1CC1CN2C(=O)CN=C(C3=C2C=CC(=C3)Cl)C4=CC=CC=C4 DMEWC7N IK MWQCHHACWWAQLJ-UHFFFAOYSA-N DMEWC7N IU 7-chloro-1-(cyclopropylmethyl)-5-phenyl-3H-1,4-benzodiazepin-2-one DMEWC7N CA CAS 2955-38-6 DMEWC7N CB CHEBI:8362 DMEWC7N DE Anxiety disorder DMOU1PK ID DMOU1PK DMOU1PK DN Praziquantel DMOU1PK HS Approved DMOU1PK SN Azinox; Biliricide; Biltricide; Cesol; Cisticid; Cutter; Cysticide; Droncit; Drontsit; Prasiquantel; Praziquantelum; Pyquiton; Traziquantel; Bayer Brand of Praziquantel; Cutter Tape Tabs; Merck Brand of Praziquantel; Embay 8440; P 4668; Bay-8440; Biltricide (TN); EMBAY-8440; NPFAPI-02; Praziquantelum [INN-Latin]; Biltricide, Droncit, Praziquantel; Praziquantel (JAN/USP/INN); Praziquantel [USAN:INN:BAN:JAN]; Praziquantel, (R)-Isomer; Praziquantel, (S)-Isomer; Praziquantel, (+-)-Isomer; (+-)-2-(Cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro-4H-pyrazino(2,1a)isoquinolin-4-one; (11bS)-2-(cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro-4H-pyrazino[2,1-a]isoquinolin-4-one; 2-(Cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro-4H-pyrazino(2,1-a)isoquinolin-4-one; 2-(Cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro-4H-pyrazino[2,1-a]-isoquinolin-4-one; 2-(Cyclohexylcarbonyl)-1,2,3,6,7-11b-hexahydro-4H-pyrazino(2,1a)isoquinolin-4-one; 2-(Cyclohexylcarbonyl)-1,2,3,6,7-11b-hexahydro-4H-pyrazinoe(2,1a)isoquinolin-4-one; 2-(cyclohexanecarbonyl)-3,6,7,11b-tetrahydro-1H-pyrazino[2,1-a]isoquinolin-4-one; 2-(cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro-4H-pyrazino[2,1-a]isoquinolin-4-one; 2-Cyclohexanecarbonyl-1,2,3,6,7,11b-hexahydro-pyrazino[2,1-a]isoquinolin-4-one; 2-Cyclohexylcarbonyl-1,2,3,6,7,11b-hexahydro-4H-pyrazino(2,1-a) isoquinolin-4-one; 8440, EMBAY DMOU1PK CP Bayer Pharmaceuticals Corporation DMOU1PK TC Anthelmintics DMOU1PK DT Small molecular drug DMOU1PK PC 4891 DMOU1PK MW 312.4 DMOU1PK FM C19H24N2O2 DMOU1PK IC InChI=1S/C19H24N2O2/c22-18-13-20(19(23)15-7-2-1-3-8-15)12-17-16-9-5-4-6-14(16)10-11-21(17)18/h4-6,9,15,17H,1-3,7-8,10-13H2 DMOU1PK CS C1CCC(CC1)C(=O)N2CC3C4=CC=CC=C4CCN3C(=O)C2 DMOU1PK IK FSVJFNAIGNNGKK-UHFFFAOYSA-N DMOU1PK IU 2-(cyclohexanecarbonyl)-3,6,7,11b-tetrahydro-1H-pyrazino[2,1-a]isoquinolin-4-one DMOU1PK CA CAS 55268-74-1 DMOU1PK CB CHEBI:91583 DMOU1PK DE Flatworm infection DMCD9YG ID DMCD9YG DMCD9YG DN Prazosin DMCD9YG HS Approved DMCD9YG SN Furazosin; Justac; Lentopres; Prazocin; Prazosina; Prazosine; Prazosinum; Prazosin HCl; TNP00312; CP-12299; Hypovase (TN); Minipress (TN); Prazosin (INN); Prazosin [INN:BAN]; Prazosina [INN-Spanish]; Prazosine [INN-French]; Prazosinum [INN-Latin]; Vasoflex (TN); [3H]-Prazosin; [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl](furan-2-yl)methanone; [4-(4-amino-6,7-dimethoxy-quinazolin-2-yl)piperazin-1-yl]-(2-furyl)methanone; [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(furan-2-yl)methanone; Piperazine,1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)-(9CI); Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furoyl)-(8CI); 1-(3-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanyl-carbonyl)piperazine hydrochloride; 1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl) piperazine; 1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)piperazine; 2-(4-(2-Furoyl)piperazin-1-yl)-4-amino-6,7-dimethoxyquinazoline; 2-[4-(2-furoyl)piperazin-1-yl]-6,7-dimethoxyquinazolin-4-amine; 4-(4-Amino-6,7-dimethoxyquinazolin-2-yl)piperazinyl 2-furyl ketone DMCD9YG CP Pfizer Pharmaceuticals DMCD9YG TC Antihypertensive Agents DMCD9YG DT Small molecular drug DMCD9YG PC 4893 DMCD9YG MW 383.4 DMCD9YG FM C19H21N5O4 DMCD9YG IC InChI=1S/C19H21N5O4/c1-26-15-10-12-13(11-16(15)27-2)21-19(22-17(12)20)24-7-5-23(6-8-24)18(25)14-4-3-9-28-14/h3-4,9-11H,5-8H2,1-2H3,(H2,20,21,22) DMCD9YG CS COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4=CC=CO4)N)OC DMCD9YG IK IENZQIKPVFGBNW-UHFFFAOYSA-N DMCD9YG IU [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(furan-2-yl)methanone DMCD9YG CA CAS 19216-56-9 DMCD9YG CB CHEBI:8364 DMCD9YG DE Congestive heart failure; Benign prostatic hyperplasia; Hypertension DMBUNVW ID DMBUNVW DMBUNVW DN Prednicarbate DMBUNVW HS Approved DMBUNVW SN Dermatop; Peitel; Dermatop (TN); Hoe-777; S-77 0777; S-770777; Prednicarbate (USP/INN); [2-[(8S,9S,10R,11S,13S,14S,17R)-17-ethoxycarbonyloxy-11-hydroxy-10,13-dimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-yl]-2-oxoethyl] propanoate DMBUNVW TC Antiinflammatory Agents DMBUNVW DT Small molecular drug DMBUNVW PC 6714002 DMBUNVW MW 488.6 DMBUNVW FM C27H36O8 DMBUNVW IC InChI=1S/C27H36O8/c1-5-22(31)34-15-21(30)27(35-24(32)33-6-2)12-10-19-18-8-7-16-13-17(28)9-11-25(16,3)23(18)20(29)14-26(19,27)4/h9,11,13,18-20,23,29H,5-8,10,12,14-15H2,1-4H3/t18-,19-,20-,23+,25-,26-,27-/m0/s1 DMBUNVW CS CCC(=O)OCC(=O)[C@]1(CC[C@@H]2[C@@]1(C[C@@H]([C@H]3[C@H]2CCC4=CC(=O)C=C[C@]34C)O)C)OC(=O)OCC DMBUNVW IK FNPXMHRZILFCKX-KAJVQRHHSA-N DMBUNVW IU [2-[(8S,9S,10R,11S,13S,14S,17R)-17-ethoxycarbonyloxy-11-hydroxy-10,13-dimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-yl]-2-oxoethyl] propanoate DMBUNVW CA CAS 73771-04-7 DMBUNVW CB CHEBI:135791 DMBUNVW DE Inflammation DMQ8FR2 ID DMQ8FR2 DMQ8FR2 DN Prednisolone DMQ8FR2 HS Approved DMQ8FR2 SN Nanocort; Prednisolone (injectable liposome formulation, rheumatoid arthritis); Prednisolone (injectable liposome formulation, rheumatoid arthritis), Enceladus; Prednisolone (injectable liposome formulation, rheumatoid arthritis), Galapagos DMQ8FR2 CP Schering Corp Sub Schering Plough Corp DMQ8FR2 TC Anticancer Agents DMQ8FR2 DT Small molecular drug DMQ8FR2 PC 5755 DMQ8FR2 MW 360.4 DMQ8FR2 FM C21H28O5 DMQ8FR2 IC InChI=1S/C21H28O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h5,7,9,14-16,18,22,24,26H,3-4,6,8,10-11H2,1-2H3/t14-,15-,16-,18+,19-,20-,21-/m0/s1 DMQ8FR2 CS C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)CO)O)CCC4=CC(=O)C=C[C@]34C)O DMQ8FR2 IK OIGNJSKKLXVSLS-VWUMJDOOSA-N DMQ8FR2 IU (8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one DMQ8FR2 CA CAS 50-24-8 DMQ8FR2 CB CHEBI:8378 DMQ8FR2 DE Solid tumour/cancer; Multiple sclerosis DM2HG4X ID DM2HG4X DM2HG4X DN Prednisone DM2HG4X HS Approved DM2HG4X SN Adasone; Ancortone; Bicortone; Cartancyl; Colisone; Cortan; Cortidelt; Cotone; Dacorten; Dacortin; Decortancyl; Decortin; Decortisyl; Dehydrocortisone; Dekortin; Dellacort; Deltacortene; Deltacortisone; Deltacortone; Deltasone; Deltison; Deltisona; Deltisone; Deltra; Diadreson; Econosone; Encorton; Encortone; Enkortolon; Enkorton; Fiasone; Hostacortin; Incocortyl; Juvason; Kortancyl; Lisacort; Lodotra; Metacortandracin; Meticorten; Nisona; Nizon; Novoprednisone; Nurison; Orasone; Panafcort; Panasol; Paracort; Parmenison; Pehacort; Precort; Predeltin; Prednicorm; Prednicort; Prednicot; Prednidib; Prednilonga; Prednison; Prednisona; Prednisonum; Prednitone; Prednizon; Prednovister; Presone; Pronison; Pronisone; Rectodelt; Retrocortine; Servisone; Sone; Sterapred; Supercortil; Ultracorten; Ultracortene; Winpred; Wojtab; Zenadrid; Dellacort A; Delta E; Delta cortelan; Liquid Pred; Origen Prednisone; Prednisone Intensol; Zenadrid [veterinary]; P1276; U 6020; Apo-Prednisone; Delta E.; Delta-Cortelan; Delta-Cortisone; Delta-Cortone; Delta-Dome; Delta-E; Delta1-Cortisone; Delta1-Dehydrocortisone; Di-Adreson; In-Sone; Me-Korti; Meticortelone (TN); Meticorten (TN); Meticorten (Veterinary); Metrevet (Veterinary); Prednicen-M; Prednisona [INN-Spanish]; Prednisone [INN:BAN]; Prednisonum [INN-Latin]; SK-Prednisone; Zenadrid (veterinary); Delta(sup 1)-Cortisone; Delta(sup 1)-Dehydrocortisone; Delta(sup1)-Cortisone; Delta-1-Cortisone; Delta-1-Dehydrocortisone; Deltasone, Liquid Pred, Orasone, Adasone, Deltacortisone,Prednisone; (1S,2R,10S,11S,14R,15S)-14-hydroxy-14-(2-hydroxyacetyl)-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-3,6-diene-5,17-dione; (8S,9S,10R,13S,14S,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,9,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,11-dione; (8xi,9xi,14xi)-17,21-dihydroxypregna-1,4-diene-3,11,20-trione; 1,2-Dehydrocortisone; 1,4-Pregnadiene-17-alpha,21-diol-3,11,20-trione; 1,4-Pregnadiene-17.alpha.,21-diol-3,11,20-trione; 1,4-Pregnadiene-17alpha,21-diol-3,11,20-trione; 1-Cortisone; 1-Dehydrocortisone; 17,21-Dihydroxypregna-1,4-diene-3,11,20-trione; 17alpha,21-Dihydroxy-1,4-pregnadiene-3,11,20-trione DM2HG4X CP Schering-Plough DM2HG4X TC Antiinflammatory Agents DM2HG4X DT Small molecular drug DM2HG4X PC 5865 DM2HG4X MW 358.4 DM2HG4X FM C21H26O5 DM2HG4X IC InChI=1S/C21H26O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h5,7,9,14-15,18,22,26H,3-4,6,8,10-11H2,1-2H3/t14-,15-,18+,19-,20-,21-/m0/s1 DM2HG4X CS C[C@]12CC(=O)[C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)CO)O)CCC4=CC(=O)C=C[C@]34C DM2HG4X IK XOFYZVNMUHMLCC-ZPOLXVRWSA-N DM2HG4X IU (8S,9S,10R,13S,14S,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,9,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,11-dione DM2HG4X CA CAS 53-03-2 DM2HG4X CB CHEBI:8382 DM2HG4X DE Atopic dermatitis; Eczema; Inflammation DMDVP3B ID DMDVP3B DMDVP3B DN Pregabalin DMDVP3B HS Approved DMDVP3B SN Pregabalin CR; Pregabalin (controlled-release, oral); Pregabalin (controlled-release, oral), Pfizer DMDVP3B CP Pfizer DMDVP3B DT Small molecular drug DMDVP3B PC 5486971 DMDVP3B MW 159.23 DMDVP3B FM C8H17NO2 DMDVP3B IC InChI=1S/C8H17NO2/c1-6(2)3-7(5-9)4-8(10)11/h6-7H,3-5,9H2,1-2H3,(H,10,11)/t7-/m0/s1 DMDVP3B CS CC(C)C[C@@H](CC(=O)O)CN DMDVP3B IK AYXYPKUFHZROOJ-ZETCQYMHSA-N DMDVP3B IU (3S)-3-(aminomethyl)-5-methylhexanoic acid DMDVP3B CA CAS 148553-50-8 DMDVP3B CB CHEBI:64356 DMDVP3B DE Chronic obstructive pulmonary disease DMYQVGN ID DMYQVGN DMYQVGN DN Premarin/Trimegestone DMYQVGN HS Approved DMYQVGN SN Conjugated estrogen tablets DMYQVGN CP Wyeth DMYQVGN DE Menopause symptom DMDYA31 ID DMDYA31 DMDYA31 DN Pretomanid DMDYA31 HS Approved DMDYA31 SN PA-824; 187235-37-6; Pretomanid; PA 824; PA824; UNII-2XOI31YC4N; (S)-PA 824; (S)-2-Nitro-6-((4-(trifluoromethoxy)benzyl)oxy)-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine; 2XOI31YC4N; CHEMBL227875; MMV688755; AK161427; (6S)-2-nitro-6-[[4-(trifluoromethoxy)phenyl]methoxy]-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine; (6S)-6,7-Dihydro-2-nitro-6-[[4-(trifluoromethoxy)phenyl]methoxy]-5H-imidazo[2,1-b][1,3]oxazine; Pretomanid [USAN:INN]; C14H12F3N3O5; PA-824(Pretomanid); AC1L9UFX; Pretomanid (USAN/INN); MLS006011141; SCHEMBL2983011 DMDYA31 DT Small molecular drug DMDYA31 PC 456199 DMDYA31 MW 359.26 DMDYA31 FM C14H12F3N3O5 DMDYA31 IC InChI=1S/C14H12F3N3O5/c15-14(16,17)25-10-3-1-9(2-4-10)7-23-11-5-19-6-12(20(21)22)18-13(19)24-8-11/h1-4,6,11H,5,7-8H2/t11-/m0/s1 DMDYA31 CS C1[C@@H](COC2=NC(=CN21)[N+](=O)[O-])OCC3=CC=C(C=C3)OC(F)(F)F DMDYA31 IK ZLHZLMOSPGACSZ-NSHDSACASA-N DMDYA31 IU (6S)-2-nitro-6-[[4-(trifluoromethoxy)phenyl]methoxy]-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine DMDYA31 CA CAS 187235-37-6 DMDYA31 DE Mycobacterium infection; Tuberculosis DMQ0C2Z ID DMQ0C2Z DMQ0C2Z DN Prevnar DMQ0C2Z HS Approved DMQ0C2Z SN Prevenar; PNCRM7; PCV-7; Polyvalent pneumococcal vaccine, Praxis; Pneumococcus/CRM-197 conjugate vaccine, Pfizer; Vaccine (pneumococcal), Praxis/American Home Products; 7vPnC, Pfizer DMQ0C2Z CP Pfizer Vaccines DMQ0C2Z DT Vaccine DMQ0C2Z DE Otitis media DMMZB0K ID DMMZB0K DMMZB0K DN Prifinium DMMZB0K HS Approved DMMZB0K SN Prifinium; 10236-81-4; 3-(Benzhydrylidene)-1,1-diethyl-2-methylpyrrolidinium; Prifinum; NCGC00183859-01; EINECS 233-568-5; AC1Q1ITK; AC1L1J7T; SCHEMBL14672576; 3-benzhydrylidene-1,1-diethyl-2-methylpyrrolidin-1-ium; CHEMBL1229214; CTK4A0968; 3-Diphenylmethylene-1,1-diethyl-2-methylpyrrolidinium DMMZB0K DT Small molecular drug DMMZB0K PC 4905 DMMZB0K MW 306.5 DMMZB0K FM C22H28N+ DMMZB0K IC InChI=1S/C22H28N/c1-4-23(5-2)17-16-21(18(23)3)22(19-12-8-6-9-13-19)20-14-10-7-11-15-20/h6-15,18H,4-5,16-17H2,1-3H3/q+1 DMMZB0K CS CC[N+]1(CCC(=C(C2=CC=CC=C2)C3=CC=CC=C3)C1C)CC DMMZB0K IK ZYEPZINLLPPBMI-UHFFFAOYSA-N DMMZB0K IU 3-benzhydrylidene-1,1-diethyl-2-methylpyrrolidin-1-ium DMMZB0K CA CAS 10236-81-4 DMMZB0K DE Irritable bowel syndrome DMI7DZ2 ID DMI7DZ2 DMI7DZ2 DN Prilocaine DMI7DZ2 HS Approved DMI7DZ2 SN Citanest; Prilocaina; Prilocainum; Propitocaine; Prilocaine [USAN]; Prilocaine base; Astra 1512; Astra 1515; L 67; Citanest (TN); Prilocaina [INN-Spanish]; Prilocainum [INN-Latin]; Propitocaine (JAN); Prilocaine (USP/INN); O-Methyl-2-propylaminopropionanilide; O-Methyl-alpha-propylaminopropionanilide; Alpha-n-Propylamino-2-methylpropionanilide; N-[2-Methylphenyl]-2-[propylamino]propanamide; N-(2-methylphenyl)-N2-propylalaninamide; N-(2-Methylphenyl)-2-(propylamino)propanamide; N-(2-methylphenyl)-N(2)-propylalaninamide; Propanamide, N-(2-methylphenyl)-2-(propylamino)-(9CI); 2-(Propylamino)-o-propionotoluidide; 2-Methyl-.alpha.-propylaminopropionanilide; 2-Methyl-alpha-propylaminopropionanilide DMI7DZ2 CP Astrazeneca Lp DMI7DZ2 TC Anesthetics DMI7DZ2 DT Small molecular drug DMI7DZ2 PC 4906 DMI7DZ2 MW 220.31 DMI7DZ2 FM C13H20N2O DMI7DZ2 IC InChI=1S/C13H20N2O/c1-4-9-14-11(3)13(16)15-12-8-6-5-7-10(12)2/h5-8,11,14H,4,9H2,1-3H3,(H,15,16) DMI7DZ2 CS CCCNC(C)C(=O)NC1=CC=CC=C1C DMI7DZ2 IK MVFGUOIZUNYYSO-UHFFFAOYSA-N DMI7DZ2 IU N-(2-methylphenyl)-2-(propylamino)propanamide DMI7DZ2 CA CAS 721-50-6 DMI7DZ2 CB CHEBI:8404 DMI7DZ2 DE Pain DMWQ16I ID DMWQ16I DMWQ16I DN Primaquine DMWQ16I HS Approved DMWQ16I SN Kanaprim; Primachin; Primachina; Primachinum; Primaquin; Primaquina; Primaquinum; Primachina [DCIT]; SN 13272; WR 2975; Dl-Primaquine; Kanaprim (TN); Neo-Quipenyl; Primaquina [INN-Spanish]; Primaquine (INN); Primaquine Bis-Phosphoric Acid; Primaquine [INN:BAN]; Primaquinum [INN-Latin]; SN 13,272; TG1-296; TG1-297; Ethylbutylamino)-6-methoxyquinoline; S. N. 13272; N4-(6-Methoxy-8-quinolinyl)-1,4-pentanediamine; Quinoline, 8-(4-amino-1-methylbutylamino)-6-methoxy; N(4)-(6-methoxyquinolin-8-yl)pentane-1,4-diamine; N-(5-aminopentan-2-yl)-6-methoxyquinolin-8-amine; N~4~-[6-(methyloxy)quinolin-8-yl]pentane-1,4-diamine; Quinoline, 8-[(4-amino-1-methylbutyl)amino]-6-methoxy-(6CI,8CI); (+)-N4-(6-Methoxy-8-quinolinyl)-1,4-pentanediamine; (+)-Primaquine; (+/-)-Primaquine; (-)-N4-(6-Methoxy-8-quinolinyl)-1,4-pentanediamine; (-)-Primaquine; 1,4-Pentanediamine, N4-(6-methoxy-8-quinolinyl)-(9CI); 4-N-(6-methoxyquinolin-8-yl)pentane-1,4-diamine; 6-Methoxy-8-(4-amino-1-methylbutylamino)quinoline; 6-Methoxy-8-[(4-amino-1-methylbutyl)amino]quinoline; 6-Methoxy-8-[4-amino-1-methylbutylamino]quinoline; 8-((4-Amino-1-methylbutyl)amino)-6-methoxyquinoline; 8-(4-Amino-1-m; 8-(4-Amino-1-methylbutylamino)-6-methoxyquinoline; 8-[(4-Amino-1-methylbutyl)amino]-6-methoxyquinoline DMWQ16I CP Sanofi-Aventis DMWQ16I TC Antimalarials DMWQ16I DT Small molecular drug DMWQ16I PC 4908 DMWQ16I MW 259.35 DMWQ16I FM C15H21N3O DMWQ16I IC InChI=1S/C15H21N3O/c1-11(5-3-7-16)18-14-10-13(19-2)9-12-6-4-8-17-15(12)14/h4,6,8-11,18H,3,5,7,16H2,1-2H3 DMWQ16I CS CC(CCCN)NC1=C2C(=CC(=C1)OC)C=CC=N2 DMWQ16I IK INDBQLZJXZLFIT-UHFFFAOYSA-N DMWQ16I IU 4-N-(6-methoxyquinolin-8-yl)pentane-1,4-diamine DMWQ16I CA CAS 90-34-6 DMWQ16I CB CHEBI:8405 DMWQ16I DE Malaria DM0WX6I ID DM0WX6I DM0WX6I DN Primidone DM0WX6I HS Approved DM0WX6I SN Cyral; Desoxyphenobarbital; Desoxyphenobarbitone; Hexadiona; Lepimidin; Lepsiral; Liskantin; Majsolin; Midone; Milepsin; Misodine; Misolyne; Mizodin; Mizolin; Myidone; Mylepsin; Mylepsinum; Mysedon; Mysoline; Neurosyn; Prilepsin; Primacione; Primaclone; Primacone; Primakton; Primidon; Primidona; Primidonum; Primoline; Prysoline; Resimatil; Sertan; Apotex Brand of Primidone; Astra Brand of Primidone; AstraZeneca Brand of Primidone; Desitin Brand of Primidone; Draxis Brand of Primidone; Holsten Brand of Primidone; Pms Primidone; Primidon Holsten; Primidone Methanol Solution; Xcel Brand of Primidone; Zeneca Brand of Primidone; P 7295; Roe 101; Apo-Primidone; Hexamidine (the antispasmodic); Hexamidine(the antispasmodic); Liskantin (TN); Medi-Pets; Mylepsinum (TN); Mysoline (TN); Primidona [INN-Spanish]; Primidone (primaclone); Primidonum [INN-Latin]; Prysoline (TN); Pyrimidone Medi-pets; Resimatil (TN); Sanofi-Synthelabo Brand of Primidone; Sertan (TN); Apo-Primidone (TN); Pyrimidone (Medi-pets); Primidone (JP15/USP/INN); Primidone [USAN:INN:BAN:JAN]; 2-Deoxyphenobarbital; 2-Desoxyphenobarbital; 4,4'-(Hexamethylenedioxy)dibenzamidine; 5-Aethyl-5-phenyl-hexahydropyrimidin-4,6-dion; 5-Aethyl-5-phenyl-hexahydropyrimidin-4,6-dion [German]; 5-Ethyl-5-phenylhexahydropyrimidine-4,6-dione; 5-Ethyldihydro-5-phenyl-4,6(1H,5H)-pyrimidinedione; 5-Ethylhexahydro-4,6-dioxo-5-phenylpyrimidine; 5-Ethylhexahydro-5-phenylpyrimidine-4,6-dione; 5-Phenyl-5-aethylhexahydropyrimidindion-(4,6); 5-Phenyl-5-aethylhexahydropyrimidindion-(4,6) [German]; 5-Phenyl-5-ethyl-hexahydropyrimidine-4,6-dione; 5-ethyl-5-phenyl-1,3-diazinane-4,6-dione; 5-ethyl-5-phenyldihydropyrimidine-4,6(1H,5H)-dione; 5-ethylhe xahydro-4,6-dioxo-5-phenylpyrimidine DM0WX6I CP Rekah Pharmaceutical DM0WX6I TC Anticonvulsants DM0WX6I DT Small molecular drug DM0WX6I PC 4909 DM0WX6I MW 218.25 DM0WX6I FM C12H14N2O2 DM0WX6I IC InChI=1S/C12H14N2O2/c1-2-12(9-6-4-3-5-7-9)10(15)13-8-14-11(12)16/h3-7H,2,8H2,1H3,(H,13,15)(H,14,16) DM0WX6I CS CCC1(C(=O)NCNC1=O)C2=CC=CC=C2 DM0WX6I IK DQMZLTXERSFNPB-UHFFFAOYSA-N DM0WX6I IU 5-ethyl-5-phenyl-1,3-diazinane-4,6-dione DM0WX6I CA CAS 125-33-7 DM0WX6I CB CHEBI:8412 DM0WX6I DE Epilepsy DM9HOKG ID DM9HOKG DM9HOKG DN Prinomastat DM9HOKG HS Approved DM9HOKG SN AG-3354; AG-3362; Prinomastat (USAN/INN); (3S)-N-hydroxy-2,2-dimethyl-4-(4-pyridin-4-yloxyphenyl)sulfonylthiomorpholine-3-carboxamide DM9HOKG CP Pfizer DM9HOKG TC Anticancer Agents DM9HOKG DT Small molecular drug DM9HOKG PC 466151 DM9HOKG MW 423.5 DM9HOKG FM C18H21N3O5S2 DM9HOKG IC InChI=1S/C18H21N3O5S2/c1-18(2)16(17(22)20-23)21(11-12-27-18)28(24,25)15-5-3-13(4-6-15)26-14-7-9-19-10-8-14/h3-10,16,23H,11-12H2,1-2H3,(H,20,22)/t16-/m0/s1 DM9HOKG CS CC1([C@@H](N(CCS1)S(=O)(=O)C2=CC=C(C=C2)OC3=CC=NC=C3)C(=O)NO)C DM9HOKG IK YKPYIPVDTNNYCN-INIZCTEOSA-N DM9HOKG IU (3S)-N-hydroxy-2,2-dimethyl-4-(4-pyridin-4-yloxyphenyl)sulfonylthiomorpholine-3-carboxamide DM9HOKG CA CAS 192329-42-3 DM9HOKG CB CHEBI:138885 DM9HOKG DE Lung cancer; Brain cancer DMMFWOJ ID DMMFWOJ DMMFWOJ DN Probenecid DMMFWOJ HS Approved DMMFWOJ SN Apurina; Bencid; Benecid; Benemid; Benemide; Benuryl; Panuric; Parabenem; Probalan; Probampacin; Probecid; Proben; Probenecida; Probenecide; Probenecidum; Probenemid; Probenicid; Probenid; Probexin; Prolongine; Robenecid; Sulprin; Tubophan; Uricosid; Urocid; Biokanol Brand of Probenecid; ICN Brand of Probenecid; IDIS Brand of Probenecid; Major Brand of Probenecid; Martec Brand of Probenecid; Merck Brand of Probenecid; Ophthalmic Brand of Probenecid; Parmed Brand of Probenecid; Probenecid Major Brand; Probenecid Martec Brand; Probenecid Parmed Brand; Probenecid Weimer; Probenecid Zenith Brand; Probenecid acid; Synergid R; Valdecasas Brand of Probenecid; Zenith Brand of Probenecid; Benemid (TN); Benuryl (TN); Col-BENEMID; ColBenemid (co mponent of); ColBenemid (component of); P-[Dipropylsulfamoyl]benzoic acid; Polycillin-BRB; Pro-Cid; Probenecida [INN-Spanish]; Probenecide [INN-French]; Probenecidum [INN-Latin]; P-(Dipropylsulfamoyl)benzoic acid; P-(Dipropylsulfamyl)benzoic acid; Polycillin-PRB (component of); Probenecid [INN:BAN:JAN]; Probenecid (JP15/USP/INN); 4-((Dipropylamino)sulfonyl)benzoic acid;4-(Di-n-propylsulfamoyl)benzoesaeure; 4-(Dipropylsulfamoyl)benzoic acid; 4-(N,N-Dipropylsulfamoyl)benzoesaeure; 4-[(dipropylamino)sulfonyl]benzoic acid DMMFWOJ TC Uricosuric Agents DMMFWOJ DT Small molecular drug DMMFWOJ PC 4911 DMMFWOJ MW 285.36 DMMFWOJ FM C13H19NO4S DMMFWOJ IC InChI=1S/C13H19NO4S/c1-3-9-14(10-4-2)19(17,18)12-7-5-11(6-8-12)13(15)16/h5-8H,3-4,9-10H2,1-2H3,(H,15,16) DMMFWOJ CS CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(=O)O DMMFWOJ IK DBABZHXKTCFAPX-UHFFFAOYSA-N DMMFWOJ IU 4-(dipropylsulfamoyl)benzoic acid DMMFWOJ CA CAS 57-66-9 DMMFWOJ CB CHEBI:8426 DMMFWOJ DE Hyperuricaemia; Gout DMVZQ2M ID DMVZQ2M DMVZQ2M DN Probucol DMVZQ2M HS Approved DMVZQ2M SN Biphenabid; Bisbid; Bisphenabid; Lesterol; Lorelco; Lursell; Lurselle; Panavir; Probucolum; Sinlestal; Superlipid; Almirall Brand of Probucol; Aventis Brand of Probucol; Hoechst Brand of Probucol; DH 581; DH581; DE-3872; DH-581; LORELCO (TN); Probucolum [INN-Latin]; ZERO/001429; Probucol (JAN/USP/INN); Probucol [USAN:BAN:INN:JAN]; Acetone bis(3,5-di-tert-butyl-4-hydroxyphenyl) mercaptole; Acetone, bis (3,5-di-tert-butyl-4-hydroxyphenyl) mercaptole; Acetone, bis(3,5-di-tert-butyl-4-hydroxyphenyl) mercaptole; 2,6-ditert-butyl-4-[2-(3,5-ditert-butyl-4-hydroxyphenyl)sulfanylpropan-2-ylsulfanyl]phenol; 4,4'-(Isopropylidenedithio)bis(2, 6-di-tert-butylphenol); 4,4'-(Isopropylidenedithio)bis(2,6-di-tert-butylphenol); 4,4'-(Isopropylidenedithio)bis[2, 6-di-tert-butylphenol]; 4,4'-(Isopropylidenedithio)bis[2,6-di-tert-butylphenol]; 4,4'-(propane-2,2-diyldisulfanediyl)bis(2,6-di-tert-butylphenol); 4,4'-[(1-Methylethylidene)bis(thio)]bis-[2,6-bis(1,1-dimethylethyl)phenol] DMVZQ2M TC Anticholesteremic Agents DMVZQ2M DT Small molecular drug DMVZQ2M PC 4912 DMVZQ2M MW 516.799 DMVZQ2M FM C31H48O2S2 DMVZQ2M IC InChI=1S/C31H48O2S2/c1-27(2,3)21-15-19(16-22(25(21)32)28(4,5)6)34-31(13,14)35-20-17-23(29(7,8)9)26(33)24(18-20)30(10,11)12/h15-18,32-33H,1-14H3 DMVZQ2M CS CC(C)(C)C1=CC(=CC(=C1O)C(C)(C)C)SC(C)(C)SC2=CC(=C(C(=C2)C(C)(C)C)O)C(C)(C)C DMVZQ2M IK FYPMFJGVHOHGLL-UHFFFAOYSA-N DMVZQ2M IU 2,6-ditert-butyl-4-[2-(3,5-ditert-butyl-4-hydroxyphenyl)sulfanylpropan-2-ylsulfanyl]phenol DMVZQ2M CA CAS 23288-49-5 DMVZQ2M CB CHEBI:8427 DMVZQ2M DE Coronary artery disease DMNMXR8 ID DMNMXR8 DMNMXR8 DN Procainamide DMNMXR8 HS Approved DMNMXR8 SN Biocoryl; Novocainamid; Novocainamide; Novocamid; Procainamida; Procainamidum; Procamide; Procan; Procanbid; Procapan; Pronestyl; Novocaine amide; Procaine amide; P-Aminobenzoic diethylaminoethylamide; Procainamida [INN-Spanish]; Procainamide (INN); Procainamide [INN:BAN]; Procainamidum [INN-Latin]; Procan (TN); Procanbid (TN); Procapan (free base); Pronestyl (TN); Pronestyl-Sr; P-Amino-N-(2-diethylaminoethyl)benzamide; Benzamide, 4-amino-N-(2-(diethylamino)ethyl)-(9CI); 2-Diethylaminoethylamid kyseliny p-aminobenzoove; 2-Diethylaminoethylamid kyseliny p-aminobenzoove [Czech]; 4-Amino-N-(2-(Diethylamino)Ethyl)Benzamide Sulfate; 4-Amino-N-(2-(diethylamino)ethyl)benzamide; 4-Amino-N-[2-(diethylamino)ethyl]benzamide; 4-amino-N-(2-diethylaminoethyl)-benzamide; 4-amino-N-(2-diethylaminoethyl)benzamide DMNMXR8 TC Antiarrhythmic Agents DMNMXR8 DT Small molecular drug DMNMXR8 PC 4913 DMNMXR8 MW 235.33 DMNMXR8 FM C13H21N3O DMNMXR8 IC InChI=1S/C13H21N3O/c1-3-16(4-2)10-9-15-13(17)11-5-7-12(14)8-6-11/h5-8H,3-4,9-10,14H2,1-2H3,(H,15,17) DMNMXR8 CS CCN(CC)CCNC(=O)C1=CC=C(C=C1)N DMNMXR8 IK REQCZEXYDRLIBE-UHFFFAOYSA-N DMNMXR8 IU 4-amino-N-[2-(diethylamino)ethyl]benzamide DMNMXR8 CA CAS 51-06-9 DMNMXR8 CB CHEBI:8428 DMNMXR8 DE Ventricular arrhythmias DM4LSNE ID DM4LSNE DM4LSNE DN Procaine DM4LSNE HS Approved DM4LSNE SN Allocaine; Anticort; Anuject; Duracaine; Gerokit; Gerovital; Jenacain; Jenacaine; Nissocaine; Norocaine; Novocain; Novocaine; Procain; Procaina; Procainum; Scurocaine; Spinocaine; Solution of novocain; Factor H3; SP01; SP01A; Stoff H3; Vitamin H3; Anticort (TM); Diethylaminoethyl p-aminobenzoate; Gerovital H-3; Novocain (TN); P-Aminobenzoyldiethylaminoethanol; P-Aminobenzyoyldiethylaminoethanol; Procaina [INN-Spanish]; Procaine (INN); Procaine [INN:BAN]; Procaine, base; Procainum [INN-Latin]; SP-01A; Solution of novocain (TN); Beta-Diethylaminoethyl 4-aminobenzoate; P-Aminobenzoic acid 2-diethylaminoethyl ester; Beta-(Diethylamino)ethyl 4-aminobenzoate; Beta-(Diethylamino)ethyl p-aminobenzoate; BENZOIC ACID,4-AMINO,2-DIETHYLAMINOETHYL ESTER PROCAIN BASE; Benzoic acid, 4-amino-, 2-(diethylamino)ethyl ester; Benzoic acid, p-amino-, 2-(diethylamino)ethyl ester; 2-(Diethylamino)ethyl 4-aminobenzoate; 2-(Diethylamino)ethyl p-aminobenzoate; 2-(Diethylamino)ethyl-4-aminobenzoate; 2-Diethylaminoethyl 4-aminobenzoate; 2-Diethylaminoethyl p-aminobenzoate; 2-Diethylaminoethylester kyseliny p-aminobenzoove; 2-Diethylaminoethylester kyseliny p-aminobenzoove [Czech]; 4-Aminobenzoesaeure-beta-diethylaminoethylester; 4-Aminobenzoic acid 2-(diethylamino) ethyl ester; 4-Aminobenzoic acid diethylaminoethyl ester DM4LSNE CP Wyeth Pharmaceuticals DM4LSNE TC Anesthetics DM4LSNE DT Small molecular drug DM4LSNE PC 4914 DM4LSNE MW 236.31 DM4LSNE FM C13H20N2O2 DM4LSNE IC InChI=1S/C13H20N2O2/c1-3-15(4-2)9-10-17-13(16)11-5-7-12(14)8-6-11/h5-8H,3-4,9-10,14H2,1-2H3 DM4LSNE CS CCN(CC)CCOC(=O)C1=CC=C(C=C1)N DM4LSNE IK MFDFERRIHVXMIY-UHFFFAOYSA-N DM4LSNE IU 2-(diethylamino)ethyl 4-aminobenzoate DM4LSNE CA CAS 59-46-1 DM4LSNE CB CHEBI:8430 DM4LSNE DE Anaesthesia DMIK367 ID DMIK367 DMIK367 DN Procarbazine DMIK367 HS Approved DMIK367 SN Ibenzmethyzin; Ibenzmethyzine; MBH; MIH; Natulan; Natulanar; PCX; Procarbazin; Procarbazina; Procarbazinum; Procarbazin [German]; Procarbazine Monohydrochloride; CB 400-497; Indicarb (TN); Matulane (TN); Natulan (TN); Procarbazina [INN-Spanish]; Procarbazine (INN); Procarbazine [INN:BAN]; Procarbazinum [INN-Latin];Ro 4-6467; SRI-10847; Ro 4-6467/1; N-4-Isopropylcarbamoylbenzyl-N'-methylhydrazine; N-Isopropyl-4-[(2-methylhydrazino)methyl]benzamide; P-(2-Methylhydrazinomethyl)-N-isopropylbenzamide; N-Isopropyl-p-(2-methylhydrazinomethyl)-benzamide; P-(N'-Methylhydrazinomethyl)-N-isopropylbenzamide; N-(1-Methylethyl)-4-[(2-methylhydrazino)methyl]benzamide; N-Isopropyl-alpha-(2-methylhydrazino)-p-toluamide; N-(1-Methylethyl)-4-((2-methylhydrazino)methyl)benzamide; Benzamide, N-(1-methylethyl)-4-((2-methylhydrazino)methyl)-(9CI); 1-Methyl-2-(p-(isopropylcarbamoyl)benzyl)hydrazine; 2-(p-Isopropylcarbamoylbenzyl)-1-methylhydrazine; 4-((2-Methylhydrazino)methyl)-N-isopropylbenzamide; 4-[(2-methylhydrazinyl)methyl]-N-propan-2-ylbenzamide DMIK367 CP Sigma-Tau Pharmaceuticals DMIK367 TC Anticancer Agents DMIK367 DT Small molecular drug DMIK367 PC 4915 DMIK367 MW 221.3 DMIK367 FM C12H19N3O DMIK367 IC InChI=1S/C12H19N3O/c1-9(2)15-12(16)11-6-4-10(5-7-11)8-14-13-3/h4-7,9,13-14H,8H2,1-3H3,(H,15,16) DMIK367 CS CC(C)NC(=O)C1=CC=C(C=C1)CNNC DMIK367 IK CPTBDICYNRMXFX-UHFFFAOYSA-N DMIK367 IU 4-[(2-methylhydrazinyl)methyl]-N-propan-2-ylbenzamide DMIK367 CA CAS 671-16-9 DMIK367 CB CHEBI:71417 DMIK367 DE Hodgkin lymphoma DM1M0Q4 ID DM1M0Q4 DM1M0Q4 DN Procaterol DM1M0Q4 HS Approved DM1M0Q4 SN Meptin; Procaterolo; Procaterolum; Procaterol Monohydrochloride; Procaterolo [DCIT]; Procaterolum [Latin]; Meptin (TN); OPC-2009; Procaterol (INN); Procaterol [INN:BAN]; Procaterolum [INN-Latin]; (R*,S*)-(+-)-8-Hydroxy-5-(1-hydroxy-2-((1-methylethyl)amino)butyl)-2(1H)-quinolinone; 5-[1-hydroxy-2-(propan-2-ylamino)butyl]quinoline-2,8-diol; 8-Hydroxy-5-(1-hydroxy-2-((1-methylethyl)amino)butyl)-2(1H)-quinolinone; 8-hydroxy-5-[1-hydroxy-2-(propan-2-ylamino)butyl]-1H-quinolin-2-one DM1M0Q4 TC Bronchodilator Agents DM1M0Q4 DT Small molecular drug DM1M0Q4 PC 4916 DM1M0Q4 MW 290.36 DM1M0Q4 FM C16H22N2O3 DM1M0Q4 IC InChI=1S/C16H22N2O3/c1-4-12(17-9(2)3)16(21)11-5-7-13(19)15-10(11)6-8-14(20)18-15/h5-9,12,16-17,19,21H,4H2,1-3H3,(H,18,20) DM1M0Q4 CS CCC(C(C1=C2C=CC(=O)NC2=C(C=C1)O)O)NC(C)C DM1M0Q4 IK FKNXQNWAXFXVNW-UHFFFAOYSA-N DM1M0Q4 IU 8-hydroxy-5-[1-hydroxy-2-(propan-2-ylamino)butyl]-1H-quinolin-2-one DM1M0Q4 CA CAS 60443-17-6 DM1M0Q4 CB CHEBI:91585 DM1M0Q4 DE Asthma DM53SRA ID DM53SRA DM53SRA DN Prochlorperazine DM53SRA HS Approved DM53SRA SN CHLOPERAZINE; Capazine; Chlormeprazine; Chlorperazine; Combid; Compazine; Compro; Emelent; Eskatrol; Kronocin; Meterazin; Meterazine; Nipodal; Novamin; Prochloroperazine; Prochlorpemazine; Prochlorperazin; Prochlorperazinum; Prochlorpermazine; Prochlorpromazine; Procloperazine; Proclorperazina; Proclorperazine; Stemetil; Tementil; Temetid; Vertigon; Compazine Suppositories; Prochlorperazine Edisylate Salt; Prochlorperazine dihydrobromide; Prochlorperazine dimaleate; Prochlorperazine maleate; Prochlorperazine mesilate; Bayer A 173; P77; RP 6140; SKF 4657; Buccastem (TN); Compazine (TN); Compro (TN); Phenotil (TN); Prochlorperazinum [INN-Latin]; Proclorperazina [INN-Spanish]; Stemetil (TN); Stemzine (TN); Compazine (*Maleate*); Prochlorperazine (JAN/USP/INN); Prochlorperazine [USAN:INN:BAN:JAN]; Chloro-3 (N-methylpiperazinyl-3 propyl)-10 phenothiazine; Chloro-3 (N-methylpiperazinyl-3 propyl)-10 phenothiazine [French]; N-(gamma-(4'-Methylpiperazinyl-1')propyl)-3-chlorophenothiazine; 2-Chloro-10-(3-(1-methyl-4-piperazinyl)propyl)-phenothiazine; 2-Chloro-10-(3-(4-methyl-1-piperazinyl)propyl)-10H-phenothiazine; 2-Chloro-10-(3-(4-methyl-1-piperazinyl)propyl)phenothiazine; 2-Chloro-10-[3-(4-methyl-1-piper-azinyl)propyl]-10H-pheno-thiazine dimaleate; 2-chloro-10-[3-(4-methylpiperazin-1-yl)propyl]-10H-phenothiazine; 2-chloro-10-[3-(4-methylpiperazin-1-yl)propyl]phenothiazine; 3-Chloro-10-(3-(1-methyl-4-piperazinyl)propyl)phenothiazine; 3-Chloro-10-(3-(4-methyl-1-piperazinyl)propyl)phenothiazine; 6140 RP DM53SRA CP GlaxoSmithKline DM53SRA TC Antipsychotic Agents DM53SRA DT Small molecular drug DM53SRA PC 4917 DM53SRA MW 373.9 DM53SRA FM C20H24ClN3S DM53SRA IC InChI=1S/C20H24ClN3S/c1-22-11-13-23(14-12-22)9-4-10-24-17-5-2-3-6-19(17)25-20-8-7-16(21)15-18(20)24/h2-3,5-8,15H,4,9-14H2,1H3 DM53SRA CS CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl DM53SRA IK WIKYUJGCLQQFNW-UHFFFAOYSA-N DM53SRA IU 2-chloro-10-[3-(4-methylpiperazin-1-yl)propyl]phenothiazine DM53SRA CA CAS 58-38-8 DM53SRA CB CHEBI:8435 DM53SRA DE Nausea DMHFJDT ID DMHFJDT DMHFJDT DN Procyclidine DMHFJDT HS Approved DMHFJDT SN Arpicolin; Elorine; Kemadrin; Kemadrine; Lergine; Metanin; Osnervan; Prociclidina; Procidlidina; Procyclid; Procyclidinum; Procyklidin; Prosyklidin; Spamol; Triciclidina; Triciloid; Tricoloid; Tricyclamol; Vagosin; Prociclidina [INN-Spanish]; Procyclidine (INN); Procyclidine [INN:BAN]; Procyclidinum [INN-Latin]; 1-Cyclohexyl-1-phenyl-3-(1-pyrrolidinyl)-1-propanol; 1-Cyclohexyl-1-phenyl-3-pyrrolidino-1-propanol; 1-cyclohexyl-1-phenyl-3-pyrrolidin-1-ylpropan-1-ol DMHFJDT TC Antiparkinson Agents DMHFJDT DT Small molecular drug DMHFJDT PC 4919 DMHFJDT MW 287.4 DMHFJDT FM C19H29NO DMHFJDT IC InChI=1S/C19H29NO/c21-19(17-9-3-1-4-10-17,18-11-5-2-6-12-18)13-16-20-14-7-8-15-20/h1,3-4,9-10,18,21H,2,5-8,11-16H2 DMHFJDT CS C1CCC(CC1)C(CCN2CCCC2)(C3=CC=CC=C3)O DMHFJDT IK WYDUSKDSKCASEF-UHFFFAOYSA-N DMHFJDT IU 1-cyclohexyl-1-phenyl-3-pyrrolidin-1-ylpropan-1-ol DMHFJDT CA CAS 77-37-2 DMHFJDT CB CHEBI:8448 DMHFJDT DE Parkinson disease DMF1X5P ID DMF1X5P DMF1X5P DN Proflavine DMF1X5P HS Approved DMF1X5P SN PRL; Proflavin; Proflavina; Proflavinum; Profura; Progarmed; Isoflav base; Proflavine [INN]; Proflavine hemisulfate; Proflavina [INN-Spanish]; Proflavine Hemi-Sulfate; Proflavinum [INN-Latin]; AE-562/12222295; Acridine-3,6-diamine; 2,8-Diaminoacridine; 2,8-Diaminoacridine (European); 2,8-Diaminoacridinium; 3,6-ACRIDINEDIAMINE; 3,6-Acridinediamine hydrochloride; 3,6-Diamino-acridinium; 3,6-Diaminoacridine; 3,6-Diaminoacridine sulfate; 3,6-Diaminoacridinium; 3,7-Diamino-5-azaanthracene DMF1X5P TC Antiinfective Agents DMF1X5P DT Small molecular drug DMF1X5P PC 7099 DMF1X5P MW 209.25 DMF1X5P FM C13H11N3 DMF1X5P IC InChI=1S/C13H11N3/c14-10-3-1-8-5-9-2-4-11(15)7-13(9)16-12(8)6-10/h1-7H,14-15H2 DMF1X5P CS C1=CC(=CC2=NC3=C(C=CC(=C3)N)C=C21)N DMF1X5P IK WDVSHHCDHLJJJR-UHFFFAOYSA-N DMF1X5P IU acridine-3,6-diamine DMF1X5P CA CAS 92-62-6 DMF1X5P CB CHEBI:8452 DMF1X5P DE Sepsis DM671NG ID DM671NG DM671NG DN Progabide DM671NG HS Approved DM671NG SN Gabren; Gabrene; Halogabide; Progabida; Progabidum; SL 76002; Gabren (TN); Gabrene (TN); Progabida [INN-Spanish]; Progabidum [INN-Latin]; SL 76-002; SL-76002; Progabide (USAN/INN); Progabide [USAN:BAN:INN]; Progabide [USAN:INN:BAN]; 4-(((4-Chlorophenyl)(5-fluoro-2-hydroxyphenyl)methylene)amino)butanamide; 4-((alpha-(p-Chlorophenyl)-5-fluorosalicylidene)amino)butyramide; 4-(alpha-(p-Chlorophenyl)-5-fluoro-2-hydroxybenzylideneamino)butyramide; 4-[[(4-chlorophenyl)-(3-fluoro-6-oxocyclohexa-2,4-dien-1-ylidene)methyl]amino]butanamide; 4-[[(E)-(4-chlorophenyl)-(3-fluoro-6-oxocyclohexa-2,4-dien-1-ylidene)methyl]amino]butanamide; 4-[[(Z)-(4-chlorophenyl)-(3-fluoro-6-oxocyclohexa-2,4-dien-1-ylidene)methyl]amino]butanamide DM671NG CP Sanofi-Aventis DM671NG TC Antidepressants DM671NG DT Small molecular drug DM671NG PC 44115 DM671NG MW 334.8 DM671NG FM C17H16ClFN2O2 DM671NG IC InChI=1S/C17H16ClFN2O2/c18-12-5-3-11(4-6-12)17(21-9-1-2-16(20)23)14-10-13(19)7-8-15(14)22/h3-8,10,22H,1-2,9H2,(H2,20,23) DM671NG CS C1=CC(=CC=C1C(=NCCCC(=O)N)C2=C(C=CC(=C2)F)O)Cl DM671NG IK IBALRBWGSVJPAP-UHFFFAOYSA-N DM671NG IU 4-[[(4-chlorophenyl)-(5-fluoro-2-hydroxyphenyl)methylidene]amino]butanamide DM671NG CA CAS 62666-20-0 DM671NG CB CHEBI:135422 DM671NG DE Depression DMUY35B ID DMUY35B DMUY35B DN Progesterone DMUY35B HS Approved DMUY35B SN progesterone; 57-83-0; Agolutin; Pregn-4-ene-3,20-dione; Luteohormone; Crinone; 4-Pregnene-3,20-dione; Utrogestan; Syngesterone; Progestin; Luteol; Corpus luteum hormone; Progesterol; Progesteronum; Pregnenedione; Glanducorpin; Prometrium; Corlutin; Cyclogest; Progestron; Gestormone; Progestone; Gestone; Progestasert; Progestronol; Methylpregnone; Hormoflaveine; Syngestrets; Proluton; Progekan; Nalutron; Lutoform; Gynlutin; Gesterol; Fologenon; Corporin; Corlutina; Syntolutan; Prolidon; Membrettes; Lutocyclin; Luteodyn; Lucorteum; Corluvite; LPCN-1107; Progesterone (oral, preterm labor); Progesterone (oral, preterm labor), Lipocine DMUY35B CP Lipocine Inc DMUY35B DT Small molecular drug DMUY35B PC 5994 DMUY35B MW 314.5 DMUY35B FM C21H30O2 DMUY35B IC InChI=1S/C21H30O2/c1-13(22)17-6-7-18-16-5-4-14-12-15(23)8-10-20(14,2)19(16)9-11-21(17,18)3/h12,16-19H,4-11H2,1-3H3/t16-,17+,18-,19-,20-,21+/m0/s1 DMUY35B CS CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C DMUY35B IK RJKFOVLPORLFTN-LEKSSAKUSA-N DMUY35B IU (8S,9S,10R,13S,14S,17S)-17-acetyl-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one DMUY35B CA CAS 57-83-0 DMUY35B CB CHEBI:17026 DMUY35B DE Premature labour; Contraception DMBL79I ID DMBL79I DMBL79I DN Proguanil DMBL79I HS Approved DMBL79I SN Bigumal; Chlorguanid; Chlorguanide; Chloriguane; Chloroguanide; Paludrin; Proguanile; Proguanilum; Proguanile [DCIT]; Diguanyl (hydrochloride); Drinupal (hydrochloride); Paludrine (TN); Paludrine (hydrochloride); Palusil (hydrochloride); Proguanil [INN:BAN]; Proguanilum [INN-Latin]; RP-3359; Tirian (hydrochloride); M-4888 (hydrochloride); SN-12837 (hydrochloride); N1-p-Chlorophenyl-N5-isopropylbiguanide; N-(4-Chlorophenyl)-N'-(1-methylethyl)imidodicarbonimidic diamide; N-(4-Chlorophenyl)-N'-(isopropyl)-imidodicarbonimidic diamide; N-(4-chlorophenyl)-N'-(propan-2-yl)imidodicarbonimidic diamide; (1E)-1-[amino-(4-chloroanilino)methylidene]-2-propan-2-ylguanidine; 1-(p-Chlorophenyl)-5-isopropylbiguanide; 1-Isopropyl-5-(4-chlorophenyl)biguanide DMBL79I CP AstraZeneca DMBL79I TC Antimalarials DMBL79I DT Small molecular drug DMBL79I PC 6178111 DMBL79I MW 253.73 DMBL79I FM C11H16ClN5 DMBL79I IC InChI=1S/C11H16ClN5/c1-7(2)15-10(13)17-11(14)16-9-5-3-8(12)4-6-9/h3-7H,1-2H3,(H5,13,14,15,16,17) DMBL79I CS CC(C)N=C(N)/N=C(\\N)/NC1=CC=C(C=C1)Cl DMBL79I IK SSOLNOMRVKKSON-UHFFFAOYSA-N DMBL79I IU (1E)-1-[amino-(4-chloroanilino)methylidene]-2-propan-2-ylguanidine DMBL79I CA CAS 500-92-5 DMBL79I CB CHEBI:8455 DMBL79I DE Malaria DMYSCIL ID DMYSCIL DMYSCIL DN Prolastin DMYSCIL HS Approved DMYSCIL SN Prolastin-C; TAL-6004; Alpha-1 antitrypsin, Bayer; Alpha-1 antitrypsin, Talecris/Crucell; Alpha-1 proteinaseinhibitor (human), Bayer DMYSCIL CP Bayer AG DMYSCIL DE Alpha-1 antitrypsin deficiency DMMJ1IS ID DMMJ1IS DMMJ1IS DN Prolixin decanoate DMMJ1IS HS Approved DMMJ1IS SN Modecate; Dapotum D; Flufenazine decanoate; Fluorophenazine decanoate; Fluphenaline decanoate; Fluphenazine decanoate; Fluphenazine depot; Moditen depot; Fluphenazine O-decanoate; Moditen-depo; Prolixin decanoate (TN); SQ 10,733; Fluphenazine decanoate (JAN/USP); Decanoic acid, 2-[4-[3-[2-(trifluoromethyl)phenothiazin-10-yl]propyl]-1-piperazinyl]ethyl ester; Decanoic acid, 2-[4-[3-[2-(trifluoromethyl)-10H-phenothiazin-10-yl]propyl]-1-piperazinyl]ethyl ester; Decanoic acid, 2-(4-(3-(2-(trifluoromethyl)phenothiazin-10-yl)propyl)-1-piperazinyl)ethyl ester; Decanoic acid, 2-(4-(3-(2-(trifluoromethyl)-10H-phenothiazin-10-yl)propyl)-1-piperazinyl)ethyl ester; 2-(4-(3-(2-(Trifluoromethyl)phenothiazin-10-yl)propyl)-1-piperazinyl)ethyl decanoate; 2-(4-{3-[2-(trifluoromethyl)-10H-phenothiazin-10-yl]propyl}piperazin-1-yl)ethyl decanoate; 2-[4-[3-[2-(trifluoromethyl)phenothiazin-10-yl]propyl]piperazin-1-yl]ethyl decanoate DMMJ1IS TC Antipsychotic Agents DMMJ1IS DT Small molecular drug DMMJ1IS PC 3388 DMMJ1IS MW 591.8 DMMJ1IS FM C32H44F3N3O2S DMMJ1IS IC InChI=1S/C32H44F3N3O2S/c1-2-3-4-5-6-7-8-14-31(39)40-24-23-37-21-19-36(20-22-37)17-11-18-38-27-12-9-10-13-29(27)41-30-16-15-26(25-28(30)38)32(33,34)35/h9-10,12-13,15-16,25H,2-8,11,14,17-24H2,1H3 DMMJ1IS CS CCCCCCCCCC(=O)OCCN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F DMMJ1IS IK VIQCGTZFEYDQMR-UHFFFAOYSA-N DMMJ1IS IU 2-[4-[3-[2-(trifluoromethyl)phenothiazin-10-yl]propyl]piperazin-1-yl]ethyl decanoate DMMJ1IS CA CAS 5002-47-1 DMMJ1IS CB CHEBI:5124 DMMJ1IS DE Schizophrenia DMZAL7W ID DMZAL7W DMZAL7W DN Promazine DMZAL7W HS Approved DMZAL7W SN Ampazine; Berophen; Esparin; Liranol; Prazin; Prazine; Promazin; Promazina; Promazinum; Promwill; Propazinum; Protactyl; Romtiazin; Sinophenin; Tomil; Verophen; Combelen [veterinary]; Promazina [Italian]; A 145; RP 3276; WY 1094; Combelen [veterinary] (TN); Neo-Hibernex; Promazina [INN-Spanish]; Promazine (INN); Promazine [INN:BAN]; Promazinum [INN-Latin]; Sparine (TN); Wy-1094; N-(3-Dimethylaminopropyl)phenothiazine; N-Dimethylamino-1-methylethyl thiodiphenylamine; Dimethyl(3-phenothiazin-10-ylpropyl)amine; N,N-dimethyl-3-phenothiazin-10-ylpropan-1-amine; N,N-dimethyl-3-(10H-phenothiazin-10-yl)propan-1-amine; 10-(3-(Dimethylamino)propyl)phenothiazine; 10-[3-(Dimethylamino)propyl]phenothiazine; 10H-Phenothiazine-10-propanamine, N,N-dimethyl-(9CI); 10H-Phenothiazine-10-propanamine, N,N-dimethyl-, monohydrochloride DMZAL7W CP Wyeth Pharmaceuticals DMZAL7W TC Antipsychotic Agents DMZAL7W DT Small molecular drug DMZAL7W PC 4926 DMZAL7W MW 284.4 DMZAL7W FM C17H20N2S DMZAL7W IC InChI=1S/C17H20N2S/c1-18(2)12-7-13-19-14-8-3-5-10-16(14)20-17-11-6-4-9-15(17)19/h3-6,8-11H,7,12-13H2,1-2H3 DMZAL7W CS CN(C)CCCN1C2=CC=CC=C2SC3=CC=CC=C31 DMZAL7W IK ZGUGWUXLJSTTMA-UHFFFAOYSA-N DMZAL7W IU N,N-dimethyl-3-phenothiazin-10-ylpropan-1-amine DMZAL7W CA CAS 58-40-2 DMZAL7W CB CHEBI:8459 DMZAL7W DE Psychomotor agitation DMK4S8I ID DMK4S8I DMK4S8I DN Promegestone DMK4S8I HS Approved DMK4S8I SN Surgestone (TN) DMK4S8I CP Labs. Cassenne DMK4S8I DT Small molecular drug DMK4S8I PC 36709 DMK4S8I MW 326.5 DMK4S8I FM C22H30O2 DMK4S8I IC InChI=1S/C22H30O2/c1-4-20(24)22(3)12-10-19-18-7-5-14-13-15(23)6-8-16(14)17(18)9-11-21(19,22)2/h13,18-19H,4-12H2,1-3H3/t18-,19+,21+,22-/m1/s1 DMK4S8I CS CCC(=O)[C@]1(CC[C@@H]2[C@@]1(CCC3=C4CCC(=O)C=C4CC[C@@H]23)C)C DMK4S8I IK QFFCYTLOTYIJMR-XMGTWHOFSA-N DMK4S8I IU (8S,13S,14S,17S)-13,17-dimethyl-17-propanoyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one DMK4S8I CA CAS 34184-77-5 DMK4S8I CB CHEBI:73390 DMK4S8I DE Gynecological disease DMU92F8 ID DMU92F8 DMU92F8 DN Promestriene DMU92F8 HS Approved DMU92F8 SN BCP9000134; VA11593; A824465; I06-0300 DMU92F8 DT Small molecular drug DMU92F8 PC 9883915 DMU92F8 MW 328.5 DMU92F8 FM C22H32O2 DMU92F8 IC InChI=1S/C22H32O2/c1-4-13-24-16-6-8-17-15(14-16)5-7-19-18(17)11-12-22(2)20(19)9-10-21(22)23-3/h6,8,14,18-21H,4-5,7,9-13H2,1-3H3/t18-,19-,20+,21+,22+/m1/s1 DMU92F8 CS CCCOC1=CC2=C(C=C1)[C@H]3CC[C@]4([C@H]([C@@H]3CC2)CC[C@@H]4OC)C DMU92F8 IK IUWKNLFTJBHTSD-AANPDWTMSA-N DMU92F8 IU (8R,9S,13S,14S,17S)-17-methoxy-13-methyl-3-propoxy-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene DMU92F8 CA CAS 39219-28-8 DMU92F8 CB CHEBI:135402 DMU92F8 DE Acne vulgaris DM6I5GR ID DM6I5GR DM6I5GR DN Promethazine DM6I5GR HS Approved DM6I5GR SN Antiallersin; Aprobit; Avomine; Camergan; Dimapp; Diphergan; Diprazin; Diprazine; Diprozin; Fargan; Fenazil; Fenetazina; Fenetazine; Genphen; Hiberna; Histargan; Iergigan; Isophenergan; Isopromethazine; Lercigan; Lergigan; Metaryl; Pelpica; Phargan; Phenargan; Phenerzine; Phensedyl; Pilothia; Pilpophen; Pipolphene; Proazaimine; Proazamine; Procit; Promacot; Promazinamide; Promergan; Promesan; Prometasin; Prometazin; Prometazina; Prometazine; Prometh; Promethacon; Promethaine; Promethazin; PromethazineHcl; Promethazinum; Promethegan; Promethiazine; Promezathine; Prorex; Protazine; Prothazin; Prothazine; Provigan; Pyrethia; Pyrethiazine; Remsed; Romergan; Rumergan; Tanidil; Thiergan; Valergine; Vallergine; Lilly 01516; Lilly 1516; RP 3277; SKF 1498; WY 509; A-91033; Atosil (TN); Avomine (TN); Fargan (TN); Farganesse (TN); Lergigan (TN); Phenergan (TN); Phenoject-50; Pro-50; Prometazina [INN-Spanish]; Promethazine [INN:BAN]; Promethazinum [INN-Latin]; Promethegan (TN); Prothiazine (TN); Receptozine (TN); Romergan (TN); Zipan-25; Dimethylamino-isopropyl-phenthiazin; Dimethylamino-isopropyl-phenthiazin [German]; Promethazine (JAN/INN) DM6I5GR CP Wyeth Pharmaceuticals DM6I5GR TC Antiallergic Agents DM6I5GR DT Small molecular drug DM6I5GR PC 4927 DM6I5GR MW 284.4 DM6I5GR FM C17H20N2S DM6I5GR IC InChI=1S/C17H20N2S/c1-13(18(2)3)12-19-14-8-4-6-10-16(14)20-17-11-7-5-9-15(17)19/h4-11,13H,12H2,1-3H3 DM6I5GR CS CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C DM6I5GR IK PWWVAXIEGOYWEE-UHFFFAOYSA-N DM6I5GR IU N,N-dimethyl-1-phenothiazin-10-ylpropan-2-amine DM6I5GR CA CAS 60-87-7 DM6I5GR CB CHEBI:8461 DM6I5GR DE Nausea DMPIBJK ID DMPIBJK DMPIBJK DN Propafenone DMPIBJK HS Approved DMPIBJK SN Propafenona; Propafenonum; Rythmol; Propafenon Hexal; Propafenon hexal (TN); Propafenona [INN-Spanish]; Propafenone (INN); Propafenone [INN:BAN]; Propafenone-HCl; Propafenonum [INN-Latin]; Rythmol SR (TN); Rytmonorm (TN); 1-(2-(2-Hydroxy-3-(propylamino)propoxy)phenyl)-3-phenyl-1-propanone; 1-(2-(2-Hydroxy-3-propylaminopropoxy)phenyl)-3-phenylpropan-1-one; 1-[2-(2-Hydroxy-3-(propylamino)propoxy)phenyl]-3-phenyl-1-propanone hydrochloride; 1-[2-(2-Hydroxy-3-[propylamino]-propoxy)phenyl]-3-phenyl-1-propanone; 1-[2-[2-hydroxy-3-(propylamino)propoxy]phenyl]-3-phenylpropan-1-one DMPIBJK CP Reliant Pharmaceuticals DMPIBJK TC Antiarrhythmic Agents DMPIBJK DT Small molecular drug DMPIBJK PC 4932 DMPIBJK MW 341.4 DMPIBJK FM C21H27NO3 DMPIBJK IC InChI=1S/C21H27NO3/c1-2-14-22-15-18(23)16-25-21-11-7-6-10-19(21)20(24)13-12-17-8-4-3-5-9-17/h3-11,18,22-23H,2,12-16H2,1H3 DMPIBJK CS CCCNCC(COC1=CC=CC=C1C(=O)CCC2=CC=CC=C2)O DMPIBJK IK JWHAUXFOSRPERK-UHFFFAOYSA-N DMPIBJK IU 1-[2-[2-hydroxy-3-(propylamino)propoxy]phenyl]-3-phenylpropan-1-one DMPIBJK CA CAS 54063-53-5 DMPIBJK CB CHEBI:63619 DMPIBJK DE Tachyarrhythmias DM2EN6G ID DM2EN6G DM2EN6G DN Propantheline DM2EN6G HS Approved DM2EN6G SN Corrigast; Ercorax; Ercotina; Ketaman; Kivatin; Neometantyl; Neopepulsan; Pantas; Pantheline; Pervagal; Probanthine; Probantine; Prodixamon; Propantel; Propanthel; Propanthelinium; Propanthelinum; Bromure de propantheline; Bromuro de proantelina; PROPANTHELINE BROMIDE; Propantelina bromuro; Propantelina bromuro [DCIT];Propanthelini bromidum; P 8891; Bromure de propantheline [INN-French]; Bromuro de proantelina [INN-Spanish]; Pro-Banthine; Pro-Gastron; Propanthelini bromidum [INN-Latin]; SC-3171; Pro-Banthine (TN);Propantheline bromide (JP15/USP/INN); Propantheline bromide [USAN:INN:BAN:JAN]; Diisopropyl(2-hydroxyethyl)methylammonium bromide xanthene-9-carboxylate; Xanthene-9-carboxylic acid, ester with (2-hydroxyethyl)diisopropylmethylammonium bromide; Ammonium, (2-hydroxyethyl)diisopropylmethyl-, xanthene-9-carboxylate (ester); Ammonium, diisopropyl(2-hydroxyethyl)methyl-, bromide, xanthene-9-carboxylate; Methyl-di(propan-2-yl)-[2-(9H-xanthene-9-carbonyloxy)ethyl]azanium; Methyl-di(propan-2-yl)-[2-(9H-xanthene-9-carbonyloxy)ethyl]azanium bromide; N-methyl-N-(1-methylethyl)-N-{2-[(9H-xanthen-9-ylcarbonyl)oxy]ethyl}propan-2-aminium bromide; (2-Hydroxyethyl)diisopropylmethylammonium bromide xanthene-9-carboxylate; (2-Hydroxyethyl)diisopropylmethylammonium bromide xanthene-9-carboxylate bromide; 2-Hydroxyethyl]diisopropylmethyl-ammonium bromide xanthene-9-carboxylate; 2-Propanaminium, N-methyl-N-(1-methylethyl)-N-(2-((9H-xanthen-9-ylcarbonyl)oxy)ethyl)-, bromide; 2-Propanaminium, N-methyl-N-(1-methylethyl)-N-(2-((9H-xanthen-9-ylcarbonyl)oxy)ethyl)-, bromide (1:1) DM2EN6G TC Antispasmodics DM2EN6G DT Small molecular drug DM2EN6G PC 4934 DM2EN6G MW 368.5 DM2EN6G FM C23H30NO3+ DM2EN6G IC InChI=1S/C23H30NO3/c1-16(2)24(5,17(3)4)14-15-26-23(25)22-18-10-6-8-12-20(18)27-21-13-9-7-11-19(21)22/h6-13,16-17,22H,14-15H2,1-5H3/q+1 DM2EN6G CS CC(C)[N+](C)(CCOC(=O)C1C2=CC=CC=C2OC3=CC=CC=C13)C(C)C DM2EN6G IK VVWYOYDLCMFIEM-UHFFFAOYSA-N DM2EN6G IU methyl-di(propan-2-yl)-[2-(9H-xanthene-9-carbonyloxy)ethyl]azanium DM2EN6G CA CAS 298-50-0 DM2EN6G CB CHEBI:8481 DM2EN6G DE Stomach ulcer; Excessive sweating DMLS39E ID DMLS39E DMLS39E DN Proparacaine DMLS39E HS Approved DMLS39E SN Alcaine; Diocaine; Kainair; Ophthaine; Ophthetic; Paracaine; Prossimetacaina; Proximetacaina; Proximetacainum; Proxymetacaine; Proxymetacainum; Prossimetacaina [DCIT]; Proxymetacaine Hcl; Ak-taine; Alcaine (TN); Ocu-Caine; Proximetacaina [INN-Spanish]; Proxymetacaine (INN); Proxymetacaine [INN:BAN]; Proxymetacainum [INN-Latin]; Spectro-Caine; Ak-Taine (TN); Beta-(Diethylamino)ethyl 4-n-propoxybenzoate; BENZOIC ACID, 3-AMINO-4-PROPOXY-, 2-(DIETHYLAMINO)ETHYL ESTER; 2-(Diethylamino)ethyl 3-amino-4-propoxybenzoate; 2-diethylaminoethyl 3-amino-4-propoxybenzoate; 3-Amino-4-propoxybenzoic acid 2-(diethylamino)ethyl ester DMLS39E TC Anesthetics DMLS39E DT Small molecular drug DMLS39E PC 4935 DMLS39E MW 294.39 DMLS39E FM C16H26N2O3 DMLS39E IC InChI=1S/C16H26N2O3/c1-4-10-20-15-8-7-13(12-14(15)17)16(19)21-11-9-18(5-2)6-3/h7-8,12H,4-6,9-11,17H2,1-3H3 DMLS39E CS CCCOC1=C(C=C(C=C1)C(=O)OCCN(CC)CC)N DMLS39E IK KCLANYCVBBTKTO-UHFFFAOYSA-N DMLS39E IU 2-(diethylamino)ethyl 3-amino-4-propoxybenzoate DMLS39E CA CAS 499-67-2 DMLS39E CB CHEBI:8485 DMLS39E DE Anaesthesia DM6JQ2I ID DM6JQ2I DM6JQ2I DN Propentofylline propionate DM6JQ2I HS Approved DM6JQ2I SN Hextol (TN) DM6JQ2I DT Small molecular drug DM6JQ2I PC 4938 DM6JQ2I MW 306.36 DM6JQ2I FM C15H22N4O3 DM6JQ2I IC InChI=1S/C15H22N4O3/c1-4-8-18-10-16-13-12(18)14(21)19(15(22)17(13)3)9-6-5-7-11(2)20/h10H,4-9H2,1-3H3 DM6JQ2I CS CCCN1C=NC2=C1C(=O)N(C(=O)N2C)CCCCC(=O)C DM6JQ2I IK RBQOQRRFDPXAGN-UHFFFAOYSA-N DM6JQ2I IU 3-methyl-1-(5-oxohexyl)-7-propylpurine-2,6-dione DM6JQ2I CA CAS 55242-55-2 DM6JQ2I CB CHEBI:32061 DM6JQ2I DE Alzheimer disease DME9JNL ID DME9JNL DME9JNL DN Propericiazine DME9JNL HS Approved DME9JNL SN Aolept; Nemactil; Neulactil; Neuleptil; PERICYAZINE; Periciazina; Periciazine; Periciazinum; Piperocyanomazine;Periciazine [INN]; Bayer 1409; IC 6002; RP 8908; WH 7508; Neulactil (TN); Neuleptil (TN); Periciazina [INN-Spanish]; Periciazinum [INN-Latin]; Propericiazine (JAN); Propericiazine(jan); SKF 20,716; Cyano-3 ((hydroxy-4 piperidyl-1)-3 propyl)-10 phenothiazine; Cyano-3 ((hydroxy-4 piperidyl-1)-3 propyl)-10 phenothiazine [French]; 10-(3-(4-Hydroxypiperidino)propyl)phenothiazine-2-carbonitrile; 10-[3-(4-hydroxypiperidin-1-yl)propyl]-10H-phenothiazine-2-carbonitrile; 10-[3-(4-hydroxypiperidin-1-yl)propyl]phenothiazine-2-carbonitrile; 2-Cyano-10-(3-(4-hydroxy-1-piperidyl)propyl)phenothiazine; 2-Cyano-10-(3-(4-hydroxypiperidino)propyl)phenothiazine; 6909 RP DME9JNL CP Sanofi-Aventis DME9JNL TC Antipsychotic Agents DME9JNL DT Small molecular drug DME9JNL PC 4747 DME9JNL MW 365.5 DME9JNL FM C21H23N3OS DME9JNL IC InChI=1S/C21H23N3OS/c22-15-16-6-7-21-19(14-16)24(18-4-1-2-5-20(18)26-21)11-3-10-23-12-8-17(25)9-13-23/h1-2,4-7,14,17,25H,3,8-13H2 DME9JNL CS C1CN(CCC1O)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C#N DME9JNL IK LUALIOATIOESLM-UHFFFAOYSA-N DME9JNL IU 10-[3-(4-hydroxypiperidin-1-yl)propyl]phenothiazine-2-carbonitrile DME9JNL CA CAS 2622-26-6 DME9JNL CB CHEBI:31981 DME9JNL DE Psychiatric disorder DMWDHUZ ID DMWDHUZ DMWDHUZ DN Propicillin DMWDHUZ HS Approved DMWDHUZ SN Propicillin; propicilline; Propicilina; Propicillinum; 551-27-9; UNII-8X1R260V33; phenoxypropylpenicillin; CHEBI:52429; 8X1R260V33; 6beta-(2-phenoxybutanamido)-2,2-dimethylpenam-3alpha-carboxylic acid; (2S,5R,6R)-3,3-dimethyl-7-oxo-6-[(2-phenoxybutanoyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (1-Phenoxypropyl)penicillin; Propicillinum [INN-Latin]; Propicilina [INN-Spanish]; Propicilline [INN-French]; Propicillin [INN:BAN:DCF]; Propicillin (BAN); EINECS 208-995-5; AC1Q5QWR; NCGC00160673-01; AC1L3P0Y DMWDHUZ DT Small molecular drug DMWDHUZ PC 92879 DMWDHUZ MW 378.4 DMWDHUZ FM C18H22N2O5S DMWDHUZ IC InChI=1S/C18H22N2O5S/c1-4-11(25-10-8-6-5-7-9-10)14(21)19-12-15(22)20-13(17(23)24)18(2,3)26-16(12)20/h5-9,11-13,16H,4H2,1-3H3,(H,19,21)(H,23,24)/t11?,12-,13+,16-/m1/s1 DMWDHUZ CS CCC(C(=O)N[C@H]1[C@@H]2N(C1=O)[C@H](C(S2)(C)C)C(=O)O)OC3=CC=CC=C3 DMWDHUZ IK HOCWPKXKMNXINF-XQERAMJGSA-N DMWDHUZ IU (2S,5R,6R)-3,3-dimethyl-7-oxo-6-(2-phenoxybutanoylamino)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid DMWDHUZ CA CAS 551-27-9 DMWDHUZ CB CHEBI:52429 DMWDHUZ DE Bacterial infection DMKY8V1 ID DMKY8V1 DMKY8V1 DN Propiomazine DMKY8V1 HS Approved DMKY8V1 SN Phenoctyl; Propiomazina; Propiomazinum; Propionylpromethazine; Dorevan (TN); Dorevane (TN); Indorm (TN); Largon (TN); Propavan (TN); Propiomazina [INN-Spanish]; Propiomazinum [INN-Latin]; Serentin (TN); Wy-1359; Propiomazine (USAN/INN); Propiomazine [USAN:BAN:INN]; Propiomazine [USAN:INN:BAN]; 1-(10-(2-(Dimethylamino)propyl)phenothiazin-2-yl)-1-propanone; 1-[10-[2-(dimethylamino)propyl]phenothiazin-2-yl]propan-1-one; 1-{10-[2-(dimethylamino)propyl]-10H-phenothiazin-2-yl}propan-1-one; 10-(2-Dimethylaminopropyl)-2-propionylphenothiazine; 10-Dimethylaminoisopropyl-2-propionylphenothiazine; 2-Propionyl-10-(2-(dimethylamino)propyl)phenothiazine; 3-Propionyl-10-dimethylaminoisopropylphenothiazine DMKY8V1 CP Hikma Maple Ltd DMKY8V1 TC Sedatives and Hypnotics DMKY8V1 DT Small molecular drug DMKY8V1 PC 4940 DMKY8V1 MW 340.5 DMKY8V1 FM C20H24N2OS DMKY8V1 IC InChI=1S/C20H24N2OS/c1-5-18(23)15-10-11-20-17(12-15)22(13-14(2)21(3)4)16-8-6-7-9-19(16)24-20/h6-12,14H,5,13H2,1-4H3 DMKY8V1 CS CCC(=O)C1=CC2=C(C=C1)SC3=CC=CC=C3N2CC(C)N(C)C DMKY8V1 IK UVOIBTBFPOZKGP-UHFFFAOYSA-N DMKY8V1 IU 1-[10-[2-(dimethylamino)propyl]phenothiazin-2-yl]propan-1-one DMKY8V1 CA CAS 362-29-8 DMKY8V1 CB CHEBI:8491 DMKY8V1 DE Insomnia DMUWBIJ ID DMUWBIJ DMUWBIJ DN Propiverine DMUWBIJ HS Approved DMUWBIJ SN propiverine hydrochloride; 54556-98-8; Propiverine HCl; Mictonorm; Propiverine Hydrochlorride; UNII-DC4GZD10H3; (1-methylpiperidin-4-yl) 2,2-diphenyl-2-propoxyacetate hydrochloride; DSSTox_RID_81957; DSSTox_CID_26847; DSSTox_GSID_46847; C23H29NO3.HCl; DC4GZD10H3; CAS-54556-98-8; NCGC00181103-01; Mictonetten; Pollarine; Mictonorm (TN); propiverin hydrochloride; Bup-4 (TN); AC1L9B4A; CHEBI:8494; SCHEMBL1034248; DTXSID1046847; CHEMBL2359059; Propiverine hydrochloride (JP17); KFUJMHHNLGCTIJ-UHFFFAOYSA-N; BCP09576; Tox21_112719; NSC172140 DMUWBIJ DT Small molecular drug DMUWBIJ PC 4942 DMUWBIJ MW 367.5 DMUWBIJ FM C23H29NO3 DMUWBIJ IC InChI=1S/C23H29NO3/c1-3-18-26-23(19-10-6-4-7-11-19,20-12-8-5-9-13-20)22(25)27-21-14-16-24(2)17-15-21/h4-13,21H,3,14-18H2,1-2H3 DMUWBIJ CS CCCOC(C1=CC=CC=C1)(C2=CC=CC=C2)C(=O)OC3CCN(CC3)C DMUWBIJ IK QPCVHQBVMYCJOM-UHFFFAOYSA-N DMUWBIJ IU (1-methylpiperidin-4-yl) 2,2-diphenyl-2-propoxyacetate DMUWBIJ CA CAS 60569-19-9 DMUWBIJ CB CHEBI:8493 DMUWBIJ DE Urinary incontinence DMB4OLE ID DMB4OLE DMB4OLE DN Propofol DMB4OLE HS Approved DMB4OLE SN Ampofol; Aquafol; Diisopropylphenol; Dipravan; Diprivan; Disoprivan; Disoprofol; Fresofol; Ivofol; PFL; Propofolum; Rapinovet; Recofol; Abbott Brand of Propofol; Alpha Brand of Propofol; Astra Brand of Propofol; AstraZeneca Brand of Propofol; Braun Brand of Propofol; Curamed Brand of Propofol; Diprivan Injectable emulsion; Fresenius Brand of Propofol; Fresenius Kabi Brand of Propofol; Juste Brand of Propofol; Parnell Brand of Propofol; Pisa Brand of Propofol; Propofol Abbott; Propofol Fresenius; Propofol MCT; Propofol Rovi; Propofolum [Latin]; Rovi Brand of Propofol; Schering Brand of Propofol; Zeneca Brand of Propofol; AM-149; DDS-04F; Diprivan (TN); Propofol IDD-D; Propofol-Lipuro; ZD-0859; Ghl.PD_Mitscher_leg0.558; Propofol [USAN:INN:BAN]; Propofol (JAN/USAN/INN); Propofol(2,6-Diisopropylphenol); 2, 6-Diisopropylphenol; 2,6 Diisopropylphenol; 2,6-Bis(1-methylethyl)phenol; 2,6-Bis(Isopropyl)-phenol; 2,6-DIISOPROPYLPHENOL; 2,6-Diisopropyl phenol; 2,6-Diisopropylphenol; 2,6-bis(1-methylethyl)-phenol; 2,6-di(propan-2-yl)phenol DMB4OLE CP AstraZeneca DMB4OLE TC Hypnotics and Sedatives DMB4OLE DT Small molecular drug DMB4OLE PC 4943 DMB4OLE MW 178.27 DMB4OLE FM C12H18O DMB4OLE IC InChI=1S/C12H18O/c1-8(2)10-6-5-7-11(9(3)4)12(10)13/h5-9,13H,1-4H3 DMB4OLE CS CC(C)C1=C(C(=CC=C1)C(C)C)O DMB4OLE IK OLBCVFGFOZPWHH-UHFFFAOYSA-N DMB4OLE IU 2,6-di(propan-2-yl)phenol DMB4OLE CA CAS 2078-54-8 DMB4OLE CB CHEBI:44915 DMB4OLE DE Anaesthesia DMMSOLA ID DMMSOLA DMMSOLA DN Propoxyphene Hydrochloride DMMSOLA HS Approved DMMSOLA SN Darvon; Dolene; Kesso-gesic; Prophene 65; Propoxyphene Hydrochloride 65; Darvon-n; Propoxyphene Napsylate DMMSOLA CP Xanodyne Pharmaceutics Inc DMMSOLA TC Neurology Agents DMMSOLA DT Small molecular drug DMMSOLA PC 15424 DMMSOLA MW 375.9 DMMSOLA FM C22H30ClNO2 DMMSOLA IC InChI=1S/C22H29NO2.ClH/c1-5-21(24)25-22(18(2)17-23(3)4,20-14-10-7-11-15-20)16-19-12-8-6-9-13-19;/h6-15,18H,5,16-17H2,1-4H3;1H/t18-,22+;/m1./s1 DMMSOLA CS CCC(=O)O[C@](CC1=CC=CC=C1)(C2=CC=CC=C2)[C@H](C)CN(C)C.Cl DMMSOLA IK QMQBBUPJKANITL-MYXGOWFTSA-N DMMSOLA IU [(2S,3R)-4-(dimethylamino)-3-methyl-1,2-diphenylbutan-2-yl] propanoate;hydrochloride DMMSOLA CA CAS 1639-60-7 DMMSOLA CB CHEBI:8498 DMMSOLA DE Pain DM79NTF ID DM79NTF DM79NTF DN Propranolol DM79NTF HS Approved DM79NTF SN Anaprilin; Anapriline; Avlocardyl; Bedranol; Berkolol; Betachron; Betadren; Betalong; Caridolol; Corpendol; Dociton; Efektolol; Etalong; Euprovasin; Herzbase; Ikopal; Inderal; Inderalici; Inderex; Inderol; Intermigran; Kemi; Migrastat; Naprilin; Obsidan; Obzidan; Pranolol; Pronovan; Propanalol; Propanix; Propanolol; Propranalol; Propranololo; Propranololum; Proprasylyt; Reducor; Sawatal; Servanolol; Sumial; Beta Neg; Inderal hydrochloride; Kemi S; Propranolol Hcl Intensol; Propranololo [DCIT]; Racemic propranolol; Reducorline; AY 64043; AY-20694; Anaprilinum (TN); Avlocardyl (TN); Beta-Propranolol; Beta-Tablinen; Beta-Timelets; DL-Propranolol hydrochloride; Deralin (TN); Dociton (TN); Inderal (TN); Inderal LA (TN); Inderalici (TN); InnoPran XL (TN); Propanolol [INN-Spanish]; Propranolol (INN); Propranolol (TN); Propranolol [INN:BAN]; Propranololum [INN-Latin]; Sumial (TN); D,L-Propranolol; INDERIDE-40/25; R,S-Propranolol Hydrochloride; (+-)-Propranolol; (1)-1-(Isopropylamino)-3-(naphthyloxy)propan-2-ol; (R)-(+)-propranolol; (S)-(-)-PROPRANOLOL; 1-((1-Methylethyl)amino)-3-(1-naphthalenyloxy)-2-propanol; 1-(1-Naphthyloxy)-2-hydroxy-3-(isopropylamino)propane; 1-(Isopropylamino)-3-(1-naphthoxy)-propan-2-ol; 1-(Isopropylamino)-3-(1-naphthyloxy)-2-propanol; 1-(isopropylamino)-3-(1-naphthyloxy)propan-2-ol; 1-(naphthalen-1-yloxy)-3-(propan-2-ylamino)propan-2-ol; 1-Isopropylamino-3-(1-naphthyloxy)-2-propanol; 1-[(1-methylethyl)amino]-3-(naphthalen-1-yloxy)propan-2-ol; 1-naphthalen-1-yloxy-3-(propan-2-ylamino)propan-2-ol; 2-Propanol, 1-((1-methylethyl)amino)-3-(1-naphthalenyloxy)-(9CI); 2-Propanol, 1-((1-methylethyl)amino)-3-(1-naphthalenyloxy)-, (+-)-(9CI); 3-(naphthalen-1-yloxy)-1-(propan-2-ylamino)propan-2-ol DM79NTF CP AstraZeneca plc DM79NTF TC Antianxiety Agents DM79NTF DT Small molecular drug DM79NTF PC 4946 DM79NTF MW 259.339 DM79NTF FM C16H21NO2 DM79NTF IC InChI=1S/C16H21NO2/c1-12(2)17-10-14(18)11-19-16-9-5-7-13-6-3-4-8-15(13)16/h3-9,12,14,17-18H,10-11H2,1-2H3 DM79NTF CS CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O DM79NTF IK AQHHHDLHHXJYJD-UHFFFAOYSA-N DM79NTF IU 1-naphthalen-1-yloxy-3-(propan-2-ylamino)propan-2-ol DM79NTF CA CAS 525-66-6 DM79NTF CB CHEBI:8499 DM79NTF DE Migraine DMTBW2O ID DMTBW2O DMTBW2O DN Propylhexedrine DMTBW2O HS Approved DMTBW2O SN Propylhexedrine hydrochloride; Eggobesin; Eventin hydrochloride; Benzedrex hydrochloride; Pernsator-wirkstoff; dl-Propylhexedrine Hydrochloride; 1007-33-6; Cyclohexylisopropylmethylamine hydrochloride; NSC 27110; NSC 170998; Cyclohexyl(isopropyl)methylammonium chloride; 1-Cyclohexyl-2-methylaminopropane hydrochloride; EINECS 213-753-7; (+-)-Propylhexedrine hydrochloride; N,alpha-Dimethylcyclohexaneethylamine hydrochloride; Propylhexedrine dl-form hydrochloride; Cyclohexaneethylamine, N,alpha-dimethyl-, hydrochloride DMTBW2O DT Small molecular drug DMTBW2O PC 7558 DMTBW2O MW 155.28 DMTBW2O FM C10H21N DMTBW2O IC InChI=1S/C10H21N/c1-9(11-2)8-10-6-4-3-5-7-10/h9-11H,3-8H2,1-2H3 DMTBW2O CS CC(CC1CCCCC1)NC DMTBW2O IK JCRIVQIOJSSCQD-UHFFFAOYSA-N DMTBW2O IU 1-cyclohexyl-N-methylpropan-2-amine DMTBW2O CA CAS 101-40-6 DMTBW2O CB CHEBI:134783 DMTBW2O DE Obesity DM6D7N8 ID DM6D7N8 DM6D7N8 DN Propylthiouracil DM6D7N8 HS Approved DM6D7N8 SN propylthiouracil; 51-52-5; 6-Propyl-2-thiouracil; Propacil; Prothyran; Prothiurone; Procasil; Propycil; Thiuragyl; Protiural; Prothiucil; Prothycil; Propyl-Thiorist; Propyl-Thyracil; 2-Mercapto-6-propylpyrimidin-4-ol; 6-N-Propylthiouracil; Propythiouracil; Propilthiouracil; Propyl-Thiorit; Propylthiorit; 6-Propylthiouracil; Propylthiouracile; Thyreostat II; 6-propyl-2-thioxo-2,3-dihydropyrimidin-4(1H)-one; Propiltiouracilo; 6-N-Propyl-2-thiouracil; 6-Thio-4-propyluracil; PTU (thyreostatic); Propylthiouracilum; 4-Propyl-2-thiouracil; Procasil; Propiltiouracile; PROPYL THIOURACIL; Propiltiouracile [DCIT]; Thyreos tat ii; HC210060; Propiltiouracilo [INN-Spanish]; Propylthiouracil (TN); Propylthiouracile [INN-French]; Propylthiouracilum [INN-Latin]; Ptu(thyreostatic); T0517-6237; Thyreostat propyl-thyracil; Propylthiouracil [INN:BAN:JAN]; Propylthiouracil (JP15/USP/INN); 2,3-Dihydro-6-propyl-2-thioxo-4(1H)-pyrimidinone; 2-Mercapto-4-hydroxy-6-n-propylpyrimidine; 2-Mercapto-6-propyl-4-pyrimidone; 2-Mercapto-6-propylpyrimid-4-one; 2-Thio-4-oxo-6-propyl-1,3-pyrimidine; 2-Thio-6-propyl-1,3-pyrimidin-4-one; 4-Hydroxy-2-mercapto-6-propylpyrimidine; 6 Propyl 2 Thiouracil; 6-(n-Propyl)-2-thiouracil; 6-Prop yl-2-thiouracil; 6-Propil-tiouracile; 6-Propil-tiouracile [Italian]; 6-Propyl-2-thio-2,4(1H,3H)-pyrimidinedione; 6-Propyl-2-thio-2,4(1H,3H)pyrimidinedione; 6-n-PROPYL-2-MERCAPTO-4-HYDROXYPYRIMIDINE; 6-propyl-2 thiouracil; 6-propyl-2-sulfanylidene-1H-pyrimidin-4-one; 6-propyl-2-sulfanylidene-2,3-dihydropyrimidin-4(1H)-one; 6-propyl-2-thiopyrimidine-2,4(1H,3H)-dione; Propyl thiouracile DM6D7N8 TC Antithyroid Agents DM6D7N8 DT Small molecular drug DM6D7N8 PC 657298 DM6D7N8 MW 170.23 DM6D7N8 FM C7H10N2OS DM6D7N8 IC InChI=1S/C7H10N2OS/c1-2-3-5-4-6(10)9-7(11)8-5/h4H,2-3H2,1H3,(H2,8,9,10,11) DM6D7N8 CS CCCC1=CC(=O)NC(=S)N1 DM6D7N8 IK KNAHARQHSZJURB-UHFFFAOYSA-N DM6D7N8 IU 6-propyl-2-sulfanylidene-1H-pyrimidin-4-one DM6D7N8 CA CAS 51-52-5 DM6D7N8 CB CHEBI:8502 DM6D7N8 DE Hyperthyroidism DMX0EZJ ID DMX0EZJ DMX0EZJ DN Prothionamide DMX0EZJ HS Approved DMX0EZJ SN Ektebin; Peteha; Prothionamidum; Protionamid; Protionamida; Protionamide; Protionamidum; Protionizina; Tebeform; Trevintix; Tuberex; RP 9778; TH 1321; Prothionamide (JP15); Protionamida [INN-Spanish]; Protionamide (INN); Protionamide [INN:DCF]; Protionamidum [INN-Latin]; TH-1321; Trevintix (TN); 2-Propyl-4-pyridinecarbothioamide; 2-Propyl-4-thiocarbamoylpyridine; 2-Propyl-thioisonicotinamide; 2-Propylisonicotinylthioamide; 2-Propylthioisonicotinamide; 2-propylpyridine-4-carbothioamide; 4-Pyridinecarbothioamide, 2-propyl-(9CI); 9778 R.P; 9778 R.P. DMX0EZJ TC Antituberculosis Agents DMX0EZJ DT Small molecular drug DMX0EZJ PC 666418 DMX0EZJ MW 180.27 DMX0EZJ FM C9H12N2S DMX0EZJ IC InChI=1S/C9H12N2S/c1-2-3-8-6-7(9(10)12)4-5-11-8/h4-6H,2-3H2,1H3,(H2,10,12) DMX0EZJ CS CCCC1=NC=CC(=C1)C(=S)N DMX0EZJ IK VRDIULHPQTYCLN-UHFFFAOYSA-N DMX0EZJ IU 2-propylpyridine-4-carbothioamide DMX0EZJ CA CAS 14222-60-7 DMX0EZJ CB CHEBI:32066 DMX0EZJ DE Tuberculosis DMGN5QD ID DMGN5QD DMGN5QD DN Protirelin DMGN5QD HS Approved DMGN5QD SN 24305-27-9; Hirtonin; TRH-SR, Takeda; protirelin DMGN5QD CP Abbott Laboratories Pharmaceutical Products Div DMGN5QD TC Neurology Agents DMGN5QD DT Small molecular drug DMGN5QD PC 638678 DMGN5QD MW 362.38 DMGN5QD FM C16H22N6O4 DMGN5QD IC InChI=1S/C16H22N6O4/c17-14(24)12-2-1-5-22(12)16(26)11(6-9-7-18-8-19-9)21-15(25)10-3-4-13(23)20-10/h7-8,10-12H,1-6H2,(H2,17,24)(H,18,19)(H,20,23)(H,21,25)/t10-,11-,12-/m0/s1 DMGN5QD CS C1C[C@H](N(C1)C(=O)[C@H](CC2=CN=CN2)NC(=O)[C@@H]3CCC(=O)N3)C(=O)N DMGN5QD IK XNSAINXGIQZQOO-SRVKXCTJSA-N DMGN5QD IU (2S)-N-[(2S)-1-[(2S)-2-carbamoylpyrrolidin-1-yl]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide DMGN5QD CA CAS 24305-27-9 DMGN5QD CB CHEBI:35940 DMGN5QD DE Central nervous system disease DMAHZKR ID DMAHZKR DMAHZKR DN Protokylol Hydrochloride DMAHZKR HS Approved DMAHZKR SN Ventaire DMAHZKR CP Sanofi Aventis Us Llc DMAHZKR DT Small molecular drug DMAHZKR PC 8699 DMAHZKR MW 367.8 DMAHZKR FM C18H22ClNO5 DMAHZKR IC InChI=1S/C18H21NO5.ClH/c1-11(6-12-2-5-17-18(7-12)24-10-23-17)19-9-16(22)13-3-4-14(20)15(21)8-13;/h2-5,7-8,11,16,19-22H,6,9-10H2,1H3;1H DMAHZKR CS CC(CC1=CC2=C(C=C1)OCO2)NCC(C3=CC(=C(C=C3)O)O)O.Cl DMAHZKR IK LOVXREQUMZKFCM-UHFFFAOYSA-N DMAHZKR IU 4-[2-[1-(1,3-benzodioxol-5-yl)propan-2-ylamino]-1-hydroxyethyl]benzene-1,2-diol;hydrochloride DMAHZKR CA CAS 136-69-6 DMAHZKR DE Asthma DMNHTZI ID DMNHTZI DMNHTZI DN Protriptyline DMNHTZI HS Approved DMNHTZI SN Amimetilina; Impril; Maximed; Novopramine; Protriptilina; Protriptylinum; Protryptyline; Rhotrimine; Triptil; Triptyl; Vivactil; Vivactyl; Triptil hydrochloride; Normethyl EX4442; Triadapin 5; Apo-Imipramine; Apo-Trimip; Novo-Doxepin; Novo-Tripramine; Protriptilina [INN-Spanish]; Protriptyline (INN); Protriptyline [INN:BAN]; Protriptylinum [INN-Latin]; Vivactil (TN); N-Methyl-5H-dibenzo[a,d]cycloheptene-5-propanamine; N-Methyl-5H-dibenzo[a,d]cycloheptene-5-propylamine; N-Methyl-5H-dibenzo(a,d)cycloheptene-5-propylamine; N-3-(5H-Dibenzo(a,d)cyclohepten-5-yl)propyl-N-methylamine; 3-(5H-Dibenzo[a,d]cyclohepten-5-yl)-N-methyl-1-propanamine; 3-(5H-dibenzo[a,d][7]annulen-5-yl)-N-methylpropan-1-amine; 5-(3-Methylaminopropyl)-5H-Dibenzo[a,d]cycloheptene; 5-(3-Methylaminopropyl)-5H-dibenzo(a,d)cycloheptene; 5H-Dibenzo[a, d]cycloheptene-5-propanamine, N-methyl-, hydrochloride; 7-(3-Methylaminopropyl)-1,2:5,6-dibenzocycloheptatriene DMNHTZI CP Teva Womens Health Inc DMNHTZI TC Antidepressants DMNHTZI DT Small molecular drug DMNHTZI PC 4976 DMNHTZI MW 263.4 DMNHTZI FM C19H21N DMNHTZI IC InChI=1S/C19H21N/c1-20-14-6-11-19-17-9-4-2-7-15(17)12-13-16-8-3-5-10-18(16)19/h2-5,7-10,12-13,19-20H,6,11,14H2,1H3 DMNHTZI CS CNCCCC1C2=CC=CC=C2C=CC3=CC=CC=C13 DMNHTZI IK BWPIARFWQZKAIA-UHFFFAOYSA-N DMNHTZI IU N-methyl-3-(2-tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,9,11,13-heptaenyl)propan-1-amine DMNHTZI CA CAS 438-60-8 DMNHTZI CB CHEBI:8597 DMNHTZI DE Depression DMGKT2L ID DMGKT2L DMGKT2L DN Pro-urokinase DMGKT2L HS Approved DMGKT2L SN Thrombolyse (TN) DMGKT2L DE Thrombin deficiency DMOK965 ID DMOK965 DMOK965 DN Prulifloxacin DMOK965 HS Approved DMOK965 SN 123447-62-1; NM441; NM 441; NM-441; Prulifloxacin (hydrochloride); 6-fluoro-1-methyl-7-(4-((5-methyl-2-oxo-1,3-dioxol-4-yl)methyl)piperazin-1-yl)-4-oxo-1,4-dihydro-[1,3]thiazeto[3,2-a]quinoline-3-carboxylic acid; NCGC00164615-01; Quisnon; DSSTox_CID_26480; DSSTox_RID_81651; DSSTox_GSID_46480; 1H,4H-(1,3)Thiazeto(3,2-a)quinoline-3-carboxylic acid, 6-fluoro-1-methyl-7-(4-((5-methyl-2-oxo-1,3-dioxol-4-yl)methyl)-1-piperazinyl)-4-oxo-; 1H,4H-[1,3]Thiazeto[3,2-a]quinoline-3-carboxylic acid, 6-fluoro-1-methyl-7-[4-[(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl]-1-piperazinyl]-4-oxo-; 6-fluoro-1-methyl-7-[4-[(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl]piperazin-1-yl]-4-oxo-1H-[1,3]thiazeto[3,2-a]quinoline-3-carboxylic acid; Prulifloxacin [INN]; Pruvel; Sword; 6-fluoro-1-methyl-7-(4-((5-methyl-2-oxo-1,3-dioxol-4-yl)methyl)piperazin-1-yl)-4-oxo-1H,4H-[1,3]thiazeto[3,2-a]quinoline-3-carboxylic acid; CCRIS 7686; CAS-123447-62-1; Pufloxacin dioxolil; 6-fluoro-1-methyl-7-{4-[(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl]piperazin-1-yl}-4-oxo-4H-[1,3]thiazeto[3,2-a]quinoline-3-carboxylic acid; MLS006011767; CHEMBL422648; NAD-441A; OPT-99; SCHEMBL1650794; DTXSID0046480; CHEBI:32071; AOB5600; BCP12727; HY-B0024; Tox21_112235; BBL034010; MFCD00864847; s2071; STK626148; AKOS005559236; Prulifloxacin (NM441, AF 3013); Tox21_112235_1; AC-2012; DB11892; MCULE-8435182996; SB18983; NCGC00164615-02; NCGC00164615-03; (+-)-7-(4-((Z)-2,3-Dihydroxy-2-butenyl)-1-piperazinyl)-6-fluoro-1-methyl-4-oxo-1H,4H-(1,3)thiazeto(3,2-a)quinoline-3-carboxylic acid, cyclic carbonate; AK144730; AS-13607; I926; SMR000046722; AB0013936; FT-0651733; P2058; Prulifloxacin 100 microg/mL in Acetonitrile; K-1771; 447P621; Prulifloxacin, >=98% (perchloric acid titration); SR-01000872596; Prulifloxacin, Antibiotic for Culture Media Use Only; Q-101929; Q3924793; SR-01000872596-1; BRD-A92341659-001-01-6 DMOK965 DT Small molecular drug DMOK965 PC 65947 DMOK965 MW 461.5 DMOK965 FM C21H20FN3O6S DMOK965 IC InChI=1S/C21H20FN3O6S/c1-10-16(31-21(29)30-10)9-23-3-5-24(6-4-23)15-8-14-12(7-13(15)22)18(26)17(20(27)28)19-25(14)11(2)32-19/h7-8,11H,3-6,9H2,1-2H3,(H,27,28) DMOK965 CS CC1N2C3=CC(=C(C=C3C(=O)C(=C2S1)C(=O)O)F)N4CCN(CC4)CC5=C(OC(=O)O5)C DMOK965 IK PWNMXPDKBYZCOO-UHFFFAOYSA-N DMOK965 IU 6-fluoro-1-methyl-7-[4-[(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl]piperazin-1-yl]-4-oxo-1H-[1,3]thiazeto[3,2-a]quinoline-3-carboxylic acid DMOK965 CA CAS 123447-62-1 DMOK965 CB CHEBI:32071 DMOK965 DE Urinary tract infection DMIVJ0D ID DMIVJ0D DMIVJ0D DN Pseudoephedrine DMIVJ0D HS Approved DMIVJ0D SN Balminil Decongestant Syrup; Dimetapp Decongestant; Dimetapp Decongestant Pediatric Drops; Drixoral Nasal Decongestant; Pseudoephedrine Ephedrine; Sudafed Decongestant Extra Strength; Triaminic AM Decongestant Formula; Triaminic Infant Oral Decongestant Drops; Efidac 24 PseudoephedrineHcl; Sudafed Decongestant 12 Hour; Pseudoefedrina [INN-Spanish]; Pseudoephedrine (INN); Pseudoephedrine [INN:BAN]; Pseudoephedrine d-form; Pseudoephedrinum [INN-Latin]; Sudafed (TN); Alpha-(1-(Methylamino)ethyl)benzyl alcohol; D-psi-2-Methylamino-1-phenyl-1-propanol; Benzenemethanol, alpha-((1S)-1-(methylamino)ethyl)-, (alpha-S)-(9CI); (+)-(1S,2S)-Pseudoephedrine; (1S,2S)-(+)-Pseudoephedrine; (1S,2S)-2-(methylamino)-1-phenylpropan-1-ol; (1S,2S)-2-Methylamino-1-phenyl-1-propanol; (1S,2S)-Pseudoephedrine; (1S,2S)-Pseudoephedrine, polymer-bound DMIVJ0D CP Pfizer Pharmaceuticals DMIVJ0D DT Small molecular drug DMIVJ0D PC 7028 DMIVJ0D MW 165.23 DMIVJ0D FM C10H15NO DMIVJ0D IC InChI=1S/C10H15NO/c1-8(11-2)10(12)9-6-4-3-5-7-9/h3-8,10-12H,1-2H3/t8-,10+/m0/s1 DMIVJ0D CS C[C@@H]([C@H](C1=CC=CC=C1)O)NC DMIVJ0D IK KWGRBVOPPLSCSI-WCBMZHEXSA-N DMIVJ0D IU (1S,2S)-2-(methylamino)-1-phenylpropan-1-ol DMIVJ0D CA CAS 90-82-4 DMIVJ0D CB CHEBI:51209 DMIVJ0D DE Nasal congestion DMLSUWZ ID DMLSUWZ DMLSUWZ DN PSI-7977 DMLSUWZ HS Approved DMLSUWZ SN 1190307-88-0; SOVALDI; PSI 7977; GS-7977; GS 7977; UNII-WJ6CA3ZU8B; WJ6CA3ZU8B; CHEBI:85083; Sofosbuvir (PSI-7977, GS-7977); Hepcvir; Hepcinat; HSDB 8226; 2-((5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-ylmethoxy)phenoxyphosphorylamino)propionic acid isopropyl ester; Sofosbuvir [USAN:INN]; Resof; SoviHep; Sovaldi (TN); Sofosbuvir (JAN/USAN); Sofosbuvir(PSI-7977); GTPL7368; SCHEMBL2010114; CHEMBL1259059; AMMD00019; EX-A389; MolPort-028-720-482; isopropyl (2S)-2-[[[(2R, DMLSUWZ CP Gilead Sciences DMLSUWZ DT Small molecular drug DMLSUWZ PC 45375808 DMLSUWZ MW 529.5 DMLSUWZ FM C22H29FN3O9P DMLSUWZ IC InChI=1S/C22H29FN3O9P/c1-13(2)33-19(29)14(3)25-36(31,35-15-8-6-5-7-9-15)32-12-16-18(28)22(4,23)20(34-16)26-11-10-17(27)24-21(26)30/h5-11,13-14,16,18,20,28H,12H2,1-4H3,(H,25,31)(H,24,27,30)/t14-,16+,18+,20+,22+,36-/m0/s1 DMLSUWZ CS C[C@@H](C(=O)OC(C)C)N[P@](=O)(OC[C@@H]1[C@H]([C@@]([C@@H](O1)N2C=CC(=O)NC2=O)(C)F)O)OC3=CC=CC=C3 DMLSUWZ IK TTZHDVOVKQGIBA-IQWMDFIBSA-N DMLSUWZ IU propan-2-yl (2S)-2-[[[(2R,3R,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyloxolan-2-yl]methoxy-phenoxyphosphoryl]amino]propanoate DMLSUWZ CA CAS 1190307-88-0 DMLSUWZ CB CHEBI:85083 DMLSUWZ DE HCV 1-6 infection; Hepatitis C virus infection DMWLTU2 ID DMWLTU2 DMWLTU2 DN PSMA-11 Ga-68 DMWLTU2 HS Approved DMWLTU2 SN UNII-ZJ0EKR6M10; ZJ0EKR6M10; Prostamedix; (68Ga)Hbed-psma; 68ga-psma-hbed-cc; (68ga)psma-hbed-cc; 68Ga-Psma-11; Gallium Ga-68 gozetotide; Gallium gozetotide Ga-68; Ga-Psma-hbed-CC Ga-68; Gallium (68Ga) gozetotide; Ga-68-Labeled PSMA-11; Ga-68 PSMA-11; PSMA-11 Ga 68; DKFZ-PSMA-11 GA-68; Gallium (68Ga) gozetotide [INN]; Glu-urea-Lys(ahx)-hbed-CC Ga-68; (68Ga)Glu-urea-Lys(Ahx)-HBED-CC; 68Ga-Labelled Glu-urea-Lys(ahx)-hbed-CC; Glu-NH-CO-NH-Lys-(ahx)-(68Ga(hbed-CC)); (68)Ga Labeled Glu-NH-CO-NH-Lys(ahx)-hbed-CC; Gallium Ga 68-labeled psma ligand Glu-urea-Lys(ahx)-hbed-CC; 1906894-20-9 DMWLTU2 DT Radioactive diagnostic agent DMWLTU2 PC 154572876 DMWLTU2 MW 1011.9 DMWLTU2 FM C44H59GaN6O17 DMWLTU2 IC InChI=1S/C44H62N6O17.Ga/c51-34-13-8-28(22-30(34)24-49(26-40(59)60)20-21-50(27-41(61)62)25-31-23-29(9-14-35(31)52)11-16-38(55)56)10-15-37(54)46-18-4-1-2-7-36(53)45-19-5-3-6-32(42(63)64)47-44(67)48-33(43(65)66)12-17-39(57)58;/h8-9,13-14,22-23,32-33,51-52H,1-7,10-12,15-21,24-27H2,(H,45,53)(H,46,54)(H,55,56)(H,57,58)(H,59,60)(H,61,62)(H,63,64)(H,65,66)(H2,47,48,67);/q;+3/p-3/t32-,33-;/m0./s1/i;1-2 DMWLTU2 CS [H+].C1=CC(=C(C=C1CCC(=O)NCCCCCC(=O)NCCCC[C@@H](C(=O)O)NC(=O)N[C@@H](CCC(=O)O)C(=O)O)CN(CCN(CC2=C(C=CC(=C2)CCC(=O)O)[O-])CC(=O)[O-])CC(=O)[O-])[O-].[68Ga+3] DMWLTU2 IK AEBYHKKMCWUMKX-LNTZDJBBSA-K DMWLTU2 IU 2-[[5-[3-[[6-[[(5S)-5-carboxy-5-[[(1S)-1,3-dicarboxypropyl]carbamoylamino]pentyl]amino]-6-oxohexyl]amino]-3-oxopropyl]-2-oxidophenyl]methyl-[2-[[5-(2-carboxyethyl)-2-oxidophenyl]methyl-(carboxylatomethyl)amino]ethyl]amino]acetate;gallium-68(3+);hydron DMWLTU2 CA CAS 1906894-20-9 DMWLTU2 DE Diagnostic imaging DMG2X3E ID DMG2X3E DMG2X3E DN Pyrantel DMG2X3E HS Approved DMG2X3E SN PYRANTEL; Pyrequan; 15686-83-6; Strongid; Pirantele [DCIT]; Pyrantelum; Pirantel; Pyrantel [INN:BAN]; Pyrantelum [INN-Latin]; Pirantel [INN-Spanish]; UNII-4QIH0N49E7; HSDB 3252; EINECS 239-774-1; CHEBI:8654; 4QIH0N49E7; (E)-1-Methyl-2-(2-(thiophen-2-yl)vinyl)-1,4,5,6-tetrahydropyrimidine; E-1,4,5,6-Tetrahydro-1-methyl-2-(2-(2-thienyl)vinyl)pyrimidine; Pirantele; 1-methyl-2-[(E)-2-(2-thienyl)vinyl]-5,6-dihydro-4H-pyrimidine; Pyrimidine, 1,4,5,6-tetrahydro-1-methyl-2-(2-(2-thienyl)vinyl)-, (E)-; Pin-X DMG2X3E DT Small molecular drug DMG2X3E PC 708857 DMG2X3E MW 206.31 DMG2X3E FM C11H14N2S DMG2X3E IC InChI=1S/C11H14N2S/c1-13-8-3-7-12-11(13)6-5-10-4-2-9-14-10/h2,4-6,9H,3,7-8H2,1H3/b6-5+ DMG2X3E CS CN1CCCN=C1/C=C/C2=CC=CS2 DMG2X3E IK YSAUAVHXTIETRK-AATRIKPKSA-N DMG2X3E IU 1-methyl-2-[(E)-2-thiophen-2-ylethenyl]-5,6-dihydro-4H-pyrimidine DMG2X3E CA CAS 15686-83-6 DMG2X3E CB CHEBI:8654 DMG2X3E DE Worm infection DM4IF32 ID DM4IF32 DM4IF32 DN Pyrazinamide DM4IF32 HS Approved DM4IF32 SN Aldinamid; Aldinamide; Braccopiral; Corsazinmid; Dipimide; Eprazin; Farmizina; Isopas; Lynamide; Novamid; Pezetamid; Pharozinamide; Piraldina; Pirazimida; Pirazinamid; Pirazinamida; Pirazinamide; Prazina; Pyrafat; Pyramide; Pyrazide; Pyrazinamdie; Pyrazinamidum; Pyrazineamide; Pyrazinecarboxamide; Rozide; Tebrazid; Tebrazio; Tisamid; Unipyranamide; Zinamide; Zinastat; P ezetamid; Pirazinamide [DCIT]; Pyrazine carboxamide; Pyrazine carboxylamide; Pyrazinecarboxylic acid amide; Pyrazinoic acid am ide; Pyrazinoic acid amide; DRG 0124; MK 56; P 7136; Pyrazinamide BP 2000; T 165; AZT + Pyrazinamide combination; D-50; Pirazinamida [INN-Spanish]; Pms-Pyrazinamide; Pyrazinamide (TN); Pyrazinamidum [INN-Latin]; D-50 (VAN); Pyrazinamide [INN:BAN:JAN]; Pyrazine-2-carboxamide; Pyrazinamide (JP15/USP/INN); Pyrazinoic acid amide, Pezetamid, Pyrafat, Zinamide, Tebrazid, Pyrafat, Pyrazinamide; 2-Carbamylpyrazine; 2-carbamyl pyrazine DM4IF32 TC Antitubercular Agents DM4IF32 DT Small molecular drug DM4IF32 PC 1046 DM4IF32 MW 123.11 DM4IF32 FM C5H5N3O DM4IF32 IC InChI=1S/C5H5N3O/c6-5(9)4-3-7-1-2-8-4/h1-3H,(H2,6,9) DM4IF32 CS C1=CN=C(C=N1)C(=O)N DM4IF32 IK IPEHBUMCGVEMRF-UHFFFAOYSA-N DM4IF32 IU pyrazine-2-carboxamide DM4IF32 CA CAS 98-96-4 DM4IF32 CB CHEBI:45285 DM4IF32 DE Mycobacterium infection DM8HO1L ID DM8HO1L DM8HO1L DN Pyridostigmine DM8HO1L HS Approved DM8HO1L SN Pyridostigminum; Pyridostigmine Bromine; Mestinon (TN); Mestinon-SR; Regonol (TN); AQ-776/42801589; Pyridinium, 3-hydroxy-1-methyl-, dimethylcarbamate (ester); Pyridinium, 3-(((dimethylamino)carbonyl)oxy)-1-methyl-(9CI); (1-methylpyridin-1-ium-3-yl) N,N-dimethylcarbamate; 1-methyl-3-pyridiniumyl dimethylcarbamate; 3-(((Dimethylamino)carbonyl)oxy)-1-methylpyridinium DM8HO1L CP Valeant Pharmaceuticals DM8HO1L TC Parasympathomimetics DM8HO1L DT Small molecular drug DM8HO1L PC 4991 DM8HO1L MW 181.21 DM8HO1L FM C9H13N2O2+ DM8HO1L IC InChI=1S/C9H13N2O2/c1-10(2)9(12)13-8-5-4-6-11(3)7-8/h4-7H,1-3H3/q+1 DM8HO1L CS C[N+]1=CC=CC(=C1)OC(=O)N(C)C DM8HO1L IK RVOLLAQWKVFTGE-UHFFFAOYSA-N DM8HO1L IU (1-methylpyridin-1-ium-3-yl) N,N-dimethylcarbamate DM8HO1L CA CAS 155-97-5 DM8HO1L CB CHEBI:8665 DM8HO1L DE Myasthenia gravis DMO2K0J ID DMO2K0J DMO2K0J DN Pyridoxal Phosphate DMO2K0J HS Approved DMO2K0J SN Pyridoxal phosphate; pyridoxal phosphate; Codecarboxylase; pyridoxal 5-phosphate; 54-47-7; pyridoxal 5'-phosphate; Pyridoxal P; Pyromijin; Hairoxal; Vitazechs; Biosechs; Pyridoxal-5'-phosphate; Hiadelon; Pidopidon; Himitan; Phosphopyridoxal; Sechvitan; Pydoxal; Piodel; Pyridoxyl phosphate; Apolon B6; (4-formyl-5-hydroxy-6-methylpyridin-3-yl)methyl dihydrogen phosphate; HI-Pyridoxin; Pal-P; PYRIDOXAL-5-PHOSPHATE; pyridoxal-P; Phosphopyridoxal coenzyme; Vitahexin P; Hexermin P; Coenzyme B6; Pyridoxal monophosphate; Pyridoxaldehyde phosphate; Apolon B(sub 6); Biosechs; PLP; Pyrido; Phosphoridoxal coenzyme; Pyridoxal phosphate [JAN]; SRI 2392; VITAMIN B6 COMPLEX; Vitamin B6 phosphate; Hexermin-P; Pyridoxal 5-monophosphoric acid ester; Pyridoxal 5-phosphate; Pyridoxal phosphate (6CI); Pyridoxal-5P; Pyridoxal-P; Sechvitan, Vitahexin P; Vitahexin-P; Vitamin B6 phosphate (ester); Pyridoxal 5'-phosphate; Pyridoxal 5'-phosphate hydrate; Pyridoxal-5-Phosphate Hydrate; Pyridoxal-5-monophosphate; P-5'-P; Pyridoxal 5'-(dihydrogen phosphate); Pyridoxal 5'-phosphate monohydrate, vitamin B6; Pyridoxal 5'-phosphate monohydrate-Vitamin B6; Pyridoxal phosphate treated beta-lactoglobulin from bovine whey; Pyridoxal, 5-(dihydrogen phosphate); Pyridoxal, 5-(dihydrogenphosphate); Pyridoxal, 5-(dihydrogen phosphate) (8CI); Phosphoric acid mono-(4-formyl-5-hydroxy-6-methyl-pyridin-3-ylmethyl) ester; Isonicotinaldehyde, 3-hydroxy-5-(hydroxymethyl)-2-methyl-, 5-(dihydrogen phosphate); (4-Formyl-5-hydroxy-6-methyl(3-pyridyl))methyl dihydrogen phosphate; (4-formyl-5-hydroxy-6-methyl-3-pyridinyl)methyl dihydrogen phosphate; 2-Methyl-3-hydroxy-4-formyl-5-hydroxymethylpyridine-5-calcium phosphate; 2-Methyl-3-hydroxy-4-formyl-5-hydroxymethylpyridine-5-calcium phosphate trihydrate; 2-Methyl-3-hydroxy-4-formyl-5-pyridylmethylphosphoric acid; 3-Hydroxy-2-methyl-5-((phosphonooxy)methyl)-4-pyridinecarboxaldehyde; 3-Hydroxy-5-(hydroxymethyl)-2-methylisonicotinaldehyde 5-phosphate; 3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]-4-pyridinecarboxaldehyde; 4-Formyl-5-hydroxy-6-methyl-pyridin-3-yl)methoxyphosphonic acid; 4-Pyridinecarboxaldehyde, 3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]-(9CI); Lepirudine DMO2K0J TC Dietary supplement DMO2K0J DT Small molecular drug DMO2K0J PC 1051 DMO2K0J MW 247.14 DMO2K0J FM C8H10NO6P DMO2K0J IC InChI=1S/C8H10NO6P/c1-5-8(11)7(3-10)6(2-9-5)4-15-16(12,13)14/h2-3,11H,4H2,1H3,(H2,12,13,14) DMO2K0J CS CC1=NC=C(C(=C1O)C=O)COP(=O)(O)O DMO2K0J IK NGVDGCNFYWLIFO-UHFFFAOYSA-N DMO2K0J IU (4-formyl-5-hydroxy-6-methylpyridin-3-yl)methyl dihydrogen phosphate DMO2K0J CA CAS 54-47-7 DMO2K0J CB CHEBI:18405 DMO2K0J DE Malnutrition DM5X7VY ID DM5X7VY DM5X7VY DN Pyrimethamine DM5X7VY HS Approved DM5X7VY SN Chloridin; Chloridine; Chloridyn; Darachlor; Daraclor; Darapram; Daraprim; Daraprime; Daraprin; Diaminopyritamin; Erbaprelina; Ethylpyrimidine; Khloridin; Malacid; Malocid; Malocide; Maloprim; Pirimecidan; Pirimetamin; Pirimetamina; Primethamine; Pyremethamine; Pyrimethamin; Pyrimethaminum; Tindurin; Tindurine; Tinduring; Aventis Brand of Pyrimethamine; Glaxo Wellcome Brand of Pyrimethamine; GlaxoSmithKline Brand of Pyrimethamine; M alocid; Pirimetamina [Spanish]; Pyrimethamine Hcl; Wellcome Brand of Pyrimethamine; BW 5063; RP 4753; WR 2978; AZT + Pyrimethamine combination; BW 50-63; Daraprim (TN); EXR-101; Lactoferrin B & Pyrimethamine; Lactoferrin H & Pyrimethamine; Pirimetamina [INN-Spanish]; Pyrimethamine (Pyr); Pyrimethaminum [INN-Latin]; TCMDC-123831; TCMDC-125860; CRL-8131 & Pyrimethamine; CRL-8142 & Pyrimethamine; Fansidar (Pyrimethamine/Sulfadoxine); Pyrimethamine (JAN/USP/INN); Pyrimethamine [USAN:INN:BAN:JAN]; 2,4-Diamino-5-(4-chlorophenyl)-6-ethylpyrimidine; 2,4-Diamino-5-(p-chlorophenyl)-6-ethylpyrimidine; 2,4-Diamino-5-chlorophenyl-6-ethylpyrimidine; 5-(4'-Chlorophenyl)-2,4-diamino-6-ethylpyrimidine; 5-(4-CHLORO-PHENYL)-6-ETHYL-PYRIMIDINE-2,4-DIAMINE; 5-(4-CHLOROPHENYL)-6-ETHYL-2,4-PYRIMIDINEDIAMINE; 5-(4-Chlorophenyl)-6-ethyl-2,4-diaminopyrimidine; 5-(4-Chlorophenyl)-6-ethyl-2,4-pyrimidi nediamine; 5-(4-chlorophenyl)-2,4-diamino-6-ethylpyrimidine; 5-(4-chlorophenyl)-6-ethylpyrimidine-2,4-diamine; 5-(p-chlorophenyl)-6-ethyl-2,4-diaminopyrimidine; 5-[4-Chlorophenyl]-6-ethyl-2,4-pyrimidinediamine DM5X7VY TC Antimalarials DM5X7VY DT Small molecular drug DM5X7VY PC 4993 DM5X7VY MW 248.71 DM5X7VY FM C12H13ClN4 DM5X7VY IC InChI=1S/C12H13ClN4/c1-2-9-10(11(14)17-12(15)16-9)7-3-5-8(13)6-4-7/h3-6H,2H2,1H3,(H4,14,15,16,17) DM5X7VY CS CCC1=C(C(=NC(=N1)N)N)C2=CC=C(C=C2)Cl DM5X7VY IK WKSAUQYGYAYLPV-UHFFFAOYSA-N DM5X7VY IU 5-(4-chlorophenyl)-6-ethylpyrimidine-2,4-diamine DM5X7VY CA CAS 58-14-0 DM5X7VY CB CHEBI:8673 DM5X7VY DE Malaria DMNA8HM ID DMNA8HM DMNA8HM DN Pyrithione Zinc DMNA8HM HS Approved DMNA8HM SN Head & Shoulders Conditioner DMNA8HM CP Warner Chilcott Co Llc DMNA8HM DT Small molecular drug DMNA8HM PC 3005837 DMNA8HM MW 317.7 DMNA8HM FM C10H8N2O2S2Zn DMNA8HM IC InChI=1S/2C5H4NOS.Zn/c2*7-6-4-2-1-3-5(6)8;/h2*1-4H;/q2*-1;+2 DMNA8HM CS C1=CC(=S)N(C=C1)[O-].C1=CC(=S)N(C=C1)[O-].[Zn+2] DMNA8HM IK PICXIOQBANWBIZ-UHFFFAOYSA-N DMNA8HM IU zinc;1-oxidopyridine-2-thione DMNA8HM CA CAS 13463-41-7 DMNA8HM CB CHEBI:32076 DMNA8HM DE Seborrhoeic dermatitis DMUWAM2 ID DMUWAM2 DMUWAM2 DN Pyronaridine DMUWAM2 HS Approved DMUWAM2 SN Malaridine; Pyronaridine phosphate salt; Benzonaphthyridine 7351; 2-Methoxy-7-chloro-10-(3',5'-bis(pyrrolin-1-ylmethyl)-4'-hydroxyphenylamino)benzo(b)-1,5-naphthyridine; 4-((7-Chloro-2-methoxybenzo(b)-1,5-naphthyridin-10-yl)amino)-2,6-bis(1-pyrrolidinylmethyl)phenol; 4-[(7-chloro-2-methoxy-1,5-dihydrobenzo[b][1,5]naphthyridin-10-yl)imino]-2,6-bis(pyrrolidin-1-ylmethyl)cyclohexa-2,5-dien-1-one; 4-[(7-chloro-2-methoxybenzo[b][1,5]naphthyridin-10-yl)amino]-2,6-bis(pyrrolidin-1-ylmethyl)phenol DMUWAM2 DT Small molecular drug DMUWAM2 PC 107771 DMUWAM2 MW 518 DMUWAM2 FM C29H32ClN5O2 DMUWAM2 IC InChI=1S/C29H32ClN5O2/c1-37-26-9-8-24-28(33-26)27(23-7-6-21(30)16-25(23)32-24)31-22-14-19(17-34-10-2-3-11-34)29(36)20(15-22)18-35-12-4-5-13-35/h6-9,14-16,36H,2-5,10-13,17-18H2,1H3,(H,31,32) DMUWAM2 CS COC1=NC2=C(C3=C(C=C(C=C3)Cl)N=C2C=C1)NC4=CC(=C(C(=C4)CN5CCCC5)O)CN6CCCC6 DMUWAM2 IK DJUFPMUQJKWIJB-UHFFFAOYSA-N DMUWAM2 IU 4-[(7-chloro-2-methoxybenzo[b][1,5]naphthyridin-10-yl)amino]-2,6-bis(pyrrolidin-1-ylmethyl)phenol DMUWAM2 CA CAS 74847-35-1 DMUWAM2 CB CHEBI:135951 DMUWAM2 DE Malaria DM7Q41G ID DM7Q41G DM7Q41G DN Pyruvic acid DM7Q41G HS Approved DM7Q41G SN BTS; Brenztraubensaeure; Acetylformic acid; Acide pyruvique; Pyroracemic acid; CH3COCOOH; A-Ketopropionic acid; Alpha-Ketopropionic acid; Alpha-Oxopropionsaeure; Alpha-keto propionic acid; Alpha-ketopropionic acid; P-9250; Pyruvic acid (8CI); Pyruvic acid (natural); Propanoic acid, 2-oxo-(9CI); 2-Ketopropionic acid; 2-Oxopropanoate; 2-Oxopropanoic acid; 2-Oxopropansaeure; 2-Oxopropionic acid; 2-Oxopropionsaeure; 2-oxo(1-14c)propanoic acid; 2-oxo-propionic acid DM7Q41G TC Dietary supplement DM7Q41G DT Small molecular drug DM7Q41G PC 1060 DM7Q41G MW 88.06 DM7Q41G FM C3H4O3 DM7Q41G IC InChI=1S/C3H4O3/c1-2(4)3(5)6/h1H3,(H,5,6) DM7Q41G CS CC(=O)C(=O)O DM7Q41G IK LCTONWCANYUPML-UHFFFAOYSA-N DM7Q41G IU 2-oxopropanoic acid DM7Q41G CA CAS 127-17-3 DM7Q41G CB CHEBI:32816 DM7Q41G DE Malnutrition DMGAZHU ID DMGAZHU DMGAZHU DN Quattvaxem DMGAZHU HS Approved DMGAZHU SN DTwPHib-CRM197 conjugate vaccine; DPT-Hib vaccine, Chiron; DTP-Hib vaccine, Chiron; Diphtheria, tetanus, pertussis, Haemophilus influenzae b vaccine (CRM-197 adjuvant), Chiron DMGAZHU CP Chiron Corp DMGAZHU DT Vaccine DMGAZHU DE Bordetella pertussis infection DMY4D87 ID DMY4D87 DMY4D87 DN Quazepam DMY4D87 HS Approved DMY4D87 SN Cetrane; Doral; Dormalin; Oniria; Prosedar; Quazapam; Quazepamum; Quazium; Selepam; Sch 16134; Doral (TN); Dormalin (TN); Quazepamum [INN-Latin]; Sch-161; Sch-16134; Quazepam (JAN/USP); Quazepam [USAN:BAN:INN]; Quazepam (JAN/USP/INN); 7-Chloro-5-(2-fluorophenyl)-1,3-dihydro-1-(2,2,2-trifluoroethyl)-2H-1,4-benzodiazepine-2-thione; 7-Chloro-5-(o-fluorophenyl)-1,3-dihydro-1-(2,2,2-trifluoroethyl)-2H-1,4-benzodiazepine-2-thione; 7-chloro-5-(2-fluorophenyl)-1-(2,2,2-trifluoroethyl)-3H-1,4-benzodiazepine-2-thione DMY4D87 CP Schering-Plough DMY4D87 TC Hypnotics and Sedatives DMY4D87 DT Small molecular drug DMY4D87 PC 4999 DMY4D87 MW 386.8 DMY4D87 FM C17H11ClF4N2S DMY4D87 IC InChI=1S/C17H11ClF4N2S/c18-10-5-6-14-12(7-10)16(11-3-1-2-4-13(11)19)23-8-15(25)24(14)9-17(20,21)22/h1-7H,8-9H2 DMY4D87 CS C1C(=S)N(C2=C(C=C(C=C2)Cl)C(=N1)C3=CC=CC=C3F)CC(F)(F)F DMY4D87 IK IKMPWMZBZSAONZ-UHFFFAOYSA-N DMY4D87 IU 7-chloro-5-(2-fluorophenyl)-1-(2,2,2-trifluoroethyl)-3H-1,4-benzodiazepine-2-thione DMY4D87 CA CAS 36735-22-5 DMY4D87 CB CHEBI:8694 DMY4D87 DE Insomnia DM3NC4M ID DM3NC4M DM3NC4M DN Quercetin DM3NC4M HS Approved DM3NC4M SN Kvercetin; Meletin; QUE; Quercetine; Quercetol; Quercitin; Quertin; Quertine; Sophoretin; Xanthaurine; Flavin meletin; Kvercetin [Czech]; Quercetin content; Quercetin dihydrate; CI Natural Yellow 10; Cyanidelonon 1522; KUC104418N; KUC107684N; MixCom3_000183; Natural Yellow 10; P0042; Q 0125; TNP00070; TNP00089; LIM-5662; LNS-5662; C.I . natural yellow 10; C.I. 75670; C.I. Natural Yellow 10; C.I. Natural red 1; CU-01000012502-3; KSC-10-126; KSC-23-76; T-Gelb bzw. grun 1; C.I. Natural yellow 10 & 13; 2-(3,4-Dihydroxy-phenyl)-3,5,7-trihydroxy-chromen-4-one; 2-(3,4-Dihydroxyphenyl)-3,5,7-trihydroxy-4H-1-benzopyran-4-one; 2-(3,4-Dihydroxyphenyl)-3,5,7-trihydroxy-4H-1-benzopyran-4-one dihydrate; 2-(3,4-Dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4-one; 2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxychromen-4-one; 3',4',5,7-Tetrahydroxyflavan-3-ol; 3',4',5,7-tetrahydroxyflavon-3-ol; 3,3',4',5,7-Pentahydroxyflavone dihydrate; 3,5,7,3',4'-Pentahydroxyflavone; 3,5,7-Trihydroxy-2-(3,4-dihydroxyphenyl)-4H-chromen-4-on; 3,5,7-trihydroxy-2-(3,4-dihydroxyphenyl)-4H-chromen-4-one DM3NC4M TC Hypoglycemic Agents DM3NC4M DT Small molecular drug DM3NC4M PC 5280343 DM3NC4M MW 302.23 DM3NC4M FM C15H10O7 DM3NC4M IC InChI=1S/C15H10O7/c16-7-4-10(19)12-11(5-7)22-15(14(21)13(12)20)6-1-2-8(17)9(18)3-6/h1-5,16-19,21H DM3NC4M CS C1=CC(=C(C=C1C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O)O)O DM3NC4M IK REFJWTPEDVJJIY-UHFFFAOYSA-N DM3NC4M IU 2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxychromen-4-one DM3NC4M CA CAS 117-39-5 DM3NC4M CB CHEBI:16243 DM3NC4M DE Obesity DM1N62C ID DM1N62C DM1N62C DN Quetiapine DM1N62C HS Approved DM1N62C SN quetiapine; 111974-69-7; Quetiapine [INN:BAN]; UNII-BGL0JSY5SI; BGL0JSY5SI; CHEMBL716; 2-[2-(4-Dibenzo[b,f][1,4]thiazepin-11-yl-1-piperazinyl)ethoxy]ethanol; CHEBI:8707; C21H25N3O2S; URKOMYMAXPYINW-UHFFFAOYSA-N; 2-(2-(4-Dibenzo(b,f)(1,4)thiazepin-11-yl-1-piperazinyl)ethoxy)ethanol; Ethanol, 2-[2-(4-dibenzo[b,f][1,4]thiazepin-11-yl-1-piperazinyl)ethoxy]-; NCGC00095911-03; Co-Quetiapine; Norsic; Quetiapina; Quetiapinum; Quetiapine hemifumarate; Ketipinor (TN); Norsic (TN); Quetiapine (INN); Seroquel (Fumarate); Seroquel (TN); 2-[2-(4-dibenzo[b,f][1,4]thiazepin-11-ylpiperazin-1-yl)ethoxy]ethanol; 2-{[2-(4-dibenzo[b,f][1,4]thiazepin-11-ylpiperazin-1-yl)ethyl]oxy}ethanol; PD-172760 DM1N62C CP AstraZeneca DM1N62C TC Antipsychotic Agents DM1N62C DT Small molecular drug DM1N62C PC 5002 DM1N62C MW 383.5 DM1N62C FM C21H25N3O2S DM1N62C IC InChI=1S/C21H25N3O2S/c25-14-16-26-15-13-23-9-11-24(12-10-23)21-17-5-1-3-7-19(17)27-20-8-4-2-6-18(20)22-21/h1-8,25H,9-16H2 DM1N62C CS C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42 DM1N62C IK URKOMYMAXPYINW-UHFFFAOYSA-N DM1N62C IU 2-[2-(4-benzo[b][1,4]benzothiazepin-6-ylpiperazin-1-yl)ethoxy]ethanol DM1N62C CA CAS 111974-69-7 DM1N62C CB CHEBI:8707 DM1N62C DE Schizophrenia; Alcohol dependence DM7WI4Q ID DM7WI4Q DM7WI4Q DN Quinagolide DM7WI4Q HS Approved DM7WI4Q SN Norprolac; 87056-78-8; Quinagolidum; SDZ 205-502; Quinagolide (INN/BAN); AC1MJ64J; SCHEMBL143485; CHEMBL290962; CHEBI:135627; ZINC3778441; BDBM50225362; DB09097; D07217; 056Q788; UNII-80Q9QWN15M component GDFGTRDCCWFXTG-ZIFCJYIRSA-N; (3S,4aS,10aR)-3-(diethylsulfamoylamino)-6-hydroxy-1-propyl-3,4,4a,5,10,10a-hexahydro-2H-benzo[g]quinoline DM7WI4Q CP Ferring Pharmaceuticals DM7WI4Q TC Fertility Agents DM7WI4Q DT Small molecular drug DM7WI4Q PC 3086401 DM7WI4Q MW 395.6 DM7WI4Q FM C20H33N3O3S DM7WI4Q IC InChI=1S/C20H33N3O3S/c1-4-10-22-14-17(21-27(25,26)23(5-2)6-3)11-16-12-18-15(13-19(16)22)8-7-9-20(18)24/h7-9,16-17,19,21,24H,4-6,10-14H2,1-3H3/t16-,17+,19-/m1/s1 DM7WI4Q CS CCCN1C[C@H](C[C@H]2[C@H]1CC3=C(C2)C(=CC=C3)O)NS(=O)(=O)N(CC)CC DM7WI4Q IK GDFGTRDCCWFXTG-ZIFCJYIRSA-N DM7WI4Q IU (3S,4aS,10aR)-3-(diethylsulfamoylamino)-6-hydroxy-1-propyl-3,4,4a,5,10,10a-hexahydro-2H-benzo[g]quinoline DM7WI4Q CA CAS 87056-78-8 DM7WI4Q CB CHEBI:135627 DM7WI4Q DE Hyperprolactinaemia DMR8H31 ID DMR8H31 DMR8H31 DN Quinapril DMR8H31 HS Approved DMR8H31 SN Ectren; Koretic; Quinaprilum; QUINAPRIL HCL; Quinaprilum [Latin]; Accupril (TN); Quinapril [INN:BAN]; Quinapril (USP/INN); [3S-[2[R*(R*)],3R*]]-2-[2-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-3-Isoquinolinecarboxylic acid; (3S)-2-(N-{(1S)-1-[(ethyloxy)carbonyl]-3-phenylpropyl}-L-alanyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid; (3S)-2-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-3,4-dihydro-1H-isoquinoline-3-carboxylic acid; (3S)-2-{(2S)-2-[(1S)-1-ethoxycarbonyl-3-phenylpropylamino]propanoyl}-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid; (3S)-2-{N-((S)-1-Ethoxycarbonyl-3-phenylpropyl)-L-alanyl}-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid DMR8H31 CP Pfizer Pharmaceuticals DMR8H31 TC Antihypertensive Agents DMR8H31 DT Small molecular drug DMR8H31 PC 54892 DMR8H31 MW 438.5 DMR8H31 FM C25H30N2O5 DMR8H31 IC InChI=1S/C25H30N2O5/c1-3-32-25(31)21(14-13-18-9-5-4-6-10-18)26-17(2)23(28)27-16-20-12-8-7-11-19(20)15-22(27)24(29)30/h4-12,17,21-22,26H,3,13-16H2,1-2H3,(H,29,30)/t17-,21-,22-/m0/s1 DMR8H31 CS CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2CC3=CC=CC=C3C[C@H]2C(=O)O DMR8H31 IK JSDRRTOADPPCHY-HSQYWUDLSA-N DMR8H31 IU (3S)-2-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-3,4-dihydro-1H-isoquinoline-3-carboxylic acid DMR8H31 CA CAS 85441-61-8 DMR8H31 CB CHEBI:8713 DMR8H31 DE Hypertension DMJ6H1Z ID DMJ6H1Z DMJ6H1Z DN Quinestrol DMJ6H1Z HS Approved DMJ6H1Z SN EECPE; Eston; Estrovis; Estrovister; Plestrovis; Quilea; Quinestrolo; Quinestrolum; Quinestrolo [DCIT]; Estrovis 4000; W 3566; Estrovis (TN); Ethinyl Estradiol 3-Cyclopentyl Ether; Qui-Lea; Quinestrolum [INN-Latin]; W-3566; Quinestrol (USAN/INN); Quinestrol [USAN:INN:BAN]; Estradiol-17-beta 3-cyclopentyl ether; (8R,9S,13S,14S,17R)-3-cyclopentyloxy-17-ethynyl-13-methyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-ol; 17-alpha-Ethinylestradiol 3-cyclopentyl ether; 17ALPHA-ETHYLNYL-1,3,5[10]ESTRATRIENE-3,17BETA-DIOL 3-CYCLOPENTYL ETHER; 17alpha-Ethynyl-1,3,5(10)-estratriene-3,17beta-diol 3-cyclopentyl ether; 17alpha-Ethynylestradiol 3-cyclopentyl ether; 3-(Cyclopentyloxy)-19-nor-17-alpha-pregna-1,3,5(10)-trien-20-yn-17-ol; 3-(Cyclopentyloxy)-19-nor-17alpha-pregna-1,3,5(10)-trien-20-yn-17-ol; 3-(cyclopentyloxy)-17beta-ethynylestra-1,3,5(10)-trien-17-ol; 3-Cyclopentyloxy-17alpha-ethynylestra-1,3,5(10)-trien-17beta-ol DMJ6H1Z TC Anticancer Agents DMJ6H1Z DT Small molecular drug DMJ6H1Z PC 9046 DMJ6H1Z MW 364.5 DMJ6H1Z FM C25H32O2 DMJ6H1Z IC InChI=1S/C25H32O2/c1-3-25(26)15-13-23-22-10-8-17-16-19(27-18-6-4-5-7-18)9-11-20(17)21(22)12-14-24(23,25)2/h1,9,11,16,18,21-23,26H,4-8,10,12-15H2,2H3/t21-,22-,23+,24+,25+/m1/s1 DMJ6H1Z CS C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)OC5CCCC5 DMJ6H1Z IK PWZUUYSISTUNDW-VAFBSOEGSA-N DMJ6H1Z IU (8R,9S,13S,14S,17R)-3-cyclopentyloxy-17-ethynyl-13-methyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-ol DMJ6H1Z CA CAS 152-43-2 DMJ6H1Z CB CHEBI:8716 DMJ6H1Z DE Breast cancer DMWCOSR ID DMWCOSR DMWCOSR DN Quinethazone DMWCOSR HS Approved DMWCOSR SN Aquamox; Chinetazone; Chinethazone; Chinethazonum; Hydromox; Idrokin; Quinetazona; Quinethazon; Quinethazonum; Chinetazone[DCIT]; CL 36010; Hydromox (TN); Quinetazona [INN-Spanish]; Quinethazone (aquamox); Quinethazonum [INN-Latin]; Quinethazone (JAN/INN); Quinethazone [INN:BAN:JAN]; 2-Ethyl-7-chloro-1,2,3,4-tetrahydro-4-oxochinazolin-6-sulfonamid; 7-Chloro-2-ethyl-1,2,3,4-tetrahydro-4-oxo-6-quinazolinesulfonamide; 7-Chloro-2-ethyl-1,2,3,4-tetrahydro-4-oxo-6-sulfamoylquinazoline; 7-Chloro-2-ethyl-6-sulfamoyl-1,2,3,4-tetrahydro-4-quinazolinone; 7-chloro-2-ethyl-4-oxo-1,2,3,4-tetrahydroquinazoline-6-sulfonamide; 7-chloro-2-ethyl-4-oxo-2,3-dihydro-1H-quinazoline-6-sulfonamide DMWCOSR TC Antihypertensive Agents DMWCOSR DT Small molecular drug DMWCOSR PC 6307 DMWCOSR MW 289.74 DMWCOSR FM C10H12ClN3O3S DMWCOSR IC InChI=1S/C10H12ClN3O3S/c1-2-9-13-7-4-6(11)8(18(12,16)17)3-5(7)10(15)14-9/h3-4,9,13H,2H2,1H3,(H,14,15)(H2,12,16,17) DMWCOSR CS CCC1NC2=CC(=C(C=C2C(=O)N1)S(=O)(=O)N)Cl DMWCOSR IK AGMMTXLNIQSRCG-UHFFFAOYSA-N DMWCOSR IU 7-chloro-2-ethyl-4-oxo-2,3-dihydro-1H-quinazoline-6-sulfonamide DMWCOSR CA CAS 73-49-4 DMWCOSR CB CHEBI:8717 DMWCOSR DE Hypertension DMLPICK ID DMLPICK DMLPICK DN Quinidine DMLPICK HS Approved DMLPICK SN Quinact; Quinaglute; Quinalan; Quinatime; Quindine; Quinicardine; Quinidex; Quinidine sulfate; Quiniduran; Quinora; beta-Quinine; Cardioquin; Chinidin; Chinidine; Cin-Quin; Cinchonan-9-ol, 6'-methoxy-, (9S)-; Conchinin; Conchinine; Conquinine; Duraquin; ITX08688JL; Kinidin; Pitayine; chinidinum; quinidina; quinidine; (+)-Quinidine; (8R,9S)-Quinidine; (9S)-6'-Methoxycinchonan-9-ol; (S)-[(2R,4S,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl](6-methoxyquinolin-4-yl)methanol; 56-54-2; CHEBI:28593; CHEMBL1294; MFCD00135581; UNII-ITX08688JL DMLPICK PC 441074 DMLPICK MW 324.4 DMLPICK FM C20H24N2O2 DMLPICK IC LOUPRKONTZGTKE-LHHVKLHASA-N DMLPICK CS COC1=CC2=C(C=CN=C2C=C1)C(C3CC4CCN3CC4C=C)O DMLPICK IK 1S/C20H24N2O2/c1-3-13-12-22-9-7-14(13)10-19(22)20(23)16-6-8-21-18-5-4-15(24-2)11-17(16)18/h3-6,8,11,13-14,19-20,23H,1,7,9-10,12H2,2H3/t13-,14-,19+,20-/m0/s1 DMLPICK IU (S)-[(2R,4S,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol DMLPICK CA CAS 56-54-2 DMLPICK CB CHEBI:28593 DMLPICK DE Ventricular tachyarrhythmia DMSWYF5 ID DMSWYF5 DMSWYF5 DN Quinine DMSWYF5 HS Approved DMSWYF5 SN Aflukin; Chinin; Chinine; Chininum; Conchinin; Conquinine; Quindan; Quinidex; Quinidine; Quinimax; Quinina; Quinineanhydrous; Quinora; Quniacridine; Chinin [German]; Kinder Quinina; QUININE MONO HCL; Quinine Dab; Quinine [BAN]; Quinine anhydrous; Quinine bisulfate; Quinine sulfate; Quinine sulphate; Quinoline alkaloid; LT00645788;Q0028; SB01652; Beta-Quinine; Cin-Quin; Coco-Quinine; IBS-L0034250; Kinder Quinina (TN); Legatrin (TN); Quinine (BAN); Quinine, Anhydrous; Quinine, polymers; Quinine, tannate; Biquinate (*Bisulfate heptathydrate*); Dentojel (*Bisulfate heptathydrate*); Quinamm (*2:1 Sulfate salt*), dihydrate; Quine (*2:1 Sulfate salt*, dihydrate); Quinsan (*2:1 Sulfate salt*), dihydrate; Alpha-(6-Methoxy-4-quinoyl)-5-vinyl-2-quinclidinemethanol; Cinchonan-9-ol, 6'-methoxy-, (8.alpha.,9R)-, sulfate; (+)-Quinidine; (-)-Quinine; (1R)-(6-Methoxyquinolin-4-yl)((1S,4S,5R)-5-vinylquinuclidin-2-yl)methanol; (3A,8A,9r)-6'-methoxycinchonan-9-ol; (5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl)-(6-methoxyquinolin-4-yl)methanol; (8-alpha,9R)-6'-Methoxycinchonan-9-ol; (8.alpha.,9R)-6'-Methoxycinchonan-9-ol; (8S,9R)-6'-Methoxycinchonan-9-ol; (8S,9R)-Quinine; (9R)-6'-methoxy-8alpha-cinchonan-9-ol; (R)-(-)-Quinine, 6-methoxycinchonidine; (R)-(-)-quinine; (R)-(6-Methoxy-quinolin-4-yl)-((2S,5S)-5-vinyl-1-aza-bicyclo[2.2.2]oct-2-yl)-methanol; (R)-(6-methoxyquinolin-4-yl)((2S,4S,8R)-8-vinylquinuclidin-2-yl)methanol; (R)-[(2S,4R,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol; (R)-[(2S,4S,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol; (R)-[(2S,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol; (S)-(5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl)-(6-methoxyquinolin-4-yl)methanol; (S)-[(2R,4R,5S)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol; 6'-Methoxycinchonan-9-ol; 6'-Methoxycinchonidine; 6'-Methoxycinchonine; 6-Methoxycinchonine DMSWYF5 CP Pfizer Pharmaceuticals DMSWYF5 TC Antimalarials DMSWYF5 DT Small molecular drug DMSWYF5 PC 3034034 DMSWYF5 MW 324.4 DMSWYF5 FM C20H24N2O2 DMSWYF5 IC InChI=1S/C20H24N2O2/c1-3-13-12-22-9-7-14(13)10-19(22)20(23)16-6-8-21-18-5-4-15(24-2)11-17(16)18/h3-6,8,11,13-14,19-20,23H,1,7,9-10,12H2,2H3/t13-,14-,19-,20+/m0/s1 DMSWYF5 CS COC1=CC2=C(C=CN=C2C=C1)[C@H]([C@@H]3C[C@@H]4CCN3C[C@@H]4C=C)O DMSWYF5 IK LOUPRKONTZGTKE-WZBLMQSHSA-N DMSWYF5 IU (R)-[(2S,4S,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol DMSWYF5 CA CAS 72402-53-0 DMSWYF5 CB CHEBI:15854 DMSWYF5 DE Malaria DM5GVHU ID DM5GVHU DM5GVHU DN Quinolones DM5GVHU HS Approved DM5GVHU SN AC1MI0KP DM5GVHU DT Small molecular drug DM5GVHU PC 6038 DM5GVHU MW 145.16 DM5GVHU FM C9H7NO DM5GVHU IC InChI=1S/C9H7NO/c11-9-6-5-7-3-1-2-4-8(7)10-9/h1-6H,(H,10,11) DM5GVHU CS C1=CC=C2C(=C1)C=CC(=O)N2 DM5GVHU IK LISFMEBWQUVKPJ-UHFFFAOYSA-N DM5GVHU IU 1H-quinolin-2-one DM5GVHU CA CAS 59-31-4 DM5GVHU CB CHEBI:16365 DM5GVHU DE Bacterial infection; Tuberculosis DMLKFC4 ID DMLKFC4 DMLKFC4 DN Quinupristin DMLKFC4 HS Approved DMLKFC4 SN Quinupristina; Quinupristine; Quinupristinum; SYB; RP 57669; Quinupristin [USAN:INN]; Quinupristina [INN-Spanish]; Quinupristine [INN-French]; Quinupristinum [INN-Latin]; RP-57669; Synercid (TN); Quinupristin (JAN/USAN/INN); 4-[4-(DIMETHYLAMINO)-N-METHYL-L-PHENYLALANINE]-5-[(2S,5R)-5-[[[(3S)-1-AZABICYCLO-[2.2.2]OCT-3-YL]THIO]METHYL]-4-OXO-2-PIPERIDINECARBOXYLIC ACID]VIRGINIAMYCIN; 5delta-(3-quinuclidinyl)thiomethylpristinamycin IA DMLKFC4 TC Antibiotics DMLKFC4 DT Small molecular drug DMLKFC4 PC 5388937 DMLKFC4 MW 1022.2 DMLKFC4 FM C53H67N9O10S DMLKFC4 IC InChI=1S/C53H67N9O10S/c1-6-37-50(68)61-23-11-14-38(61)51(69)59(5)40(26-32-16-18-36(19-17-32)58(3)4)52(70)62-28-35(30-73-43-29-60-24-20-33(43)21-25-60)42(64)27-39(62)47(65)57-45(34-12-8-7-9-13-34)53(71)72-31(2)44(48(66)55-37)56-49(67)46-41(63)15-10-22-54-46/h7-10,12-13,15-19,22,31,33,35,37-40,43-45,63H,6,11,14,20-21,23-30H2,1-5H3,(H,55,66)(H,56,67)(H,57,65)/t31-,35+,37-,38+,39+,40+,43-,44+,45+/m1/s1 DMLKFC4 CS CC[C@@H]1C(=O)N2CCC[C@H]2C(=O)N([C@H](C(=O)N3C[C@H](C(=O)C[C@H]3C(=O)N[C@H](C(=O)O[C@@H]([C@@H](C(=O)N1)NC(=O)C4=C(C=CC=N4)O)C)C5=CC=CC=C5)CS[C@@H]6CN7CCC6CC7)CC8=CC=C(C=C8)N(C)C)C DMLKFC4 IK WTHRRGMBUAHGNI-LCYNINFDSA-N DMLKFC4 IU N-[(3S,6S,12R,15S,16R,19S,22S,25R)-25-[[(3S)-1-azabicyclo[2.2.2]octan-3-yl]sulfanylmethyl]-3-[[4-(dimethylamino)phenyl]methyl]-12-ethyl-4,16-dimethyl-2,5,11,14,18,21,24-heptaoxo-19-phenyl-17-oxa-1,4,10,13,20-pentazatricyclo[20.4.0.06,10]hexacosan-15-yl]-3-hydroxypyridine-2-carboxamide DMLKFC4 CA CAS 120138-50-3 DMLKFC4 DE Bacterial infection DMM4U9G ID DMM4U9G DMM4U9G DN R0-93877 DMM4U9G HS Approved DMM4U9G SN Prucalopride; 179474-81-8; UNII-0A09IUW5TP; 4-Amino-5-chloro-2,3-dihydro-N-[1-(3-methoxypropyl)-4-piperidinyl]-7-benzofurancarboxamide; 0A09IUW5TP; C18H26ClN3O3; CHEMBL117287; R-093877; 4-amino-5-chloro-N-[1-(3-methoxypropyl)piperidin-4-yl]-2,3-dihydro-1-benzofuran-7-carboxamide; R 093877; 4-Amino-5-chloro-N-(1-(3-methoxypropyl)piperidin-4-yl)-2,3-dihydrobenzofuran-7-carboxamide; 4-Amino-5-chloro-2,3-dihydro-N-(1-(3-methoxypropyl)-4-piperidyl)-7-benzofurancarboxamide; R093877; Motegrity; Prucalopride [USAN:INN:BAN] DMM4U9G CP Shire/Takeda DMM4U9G DT Small molecular drug DMM4U9G PC 3052762 DMM4U9G MW 367.9 DMM4U9G FM C18H26ClN3O3 DMM4U9G IC InChI=1S/C18H26ClN3O3/c1-24-9-2-6-22-7-3-12(4-8-22)21-18(23)14-11-15(19)16(20)13-5-10-25-17(13)14/h11-12H,2-10,20H2,1H3,(H,21,23) DMM4U9G CS COCCCN1CCC(CC1)NC(=O)C2=CC(=C(C3=C2OCC3)N)Cl DMM4U9G IK ZPMNHBXQOOVQJL-UHFFFAOYSA-N DMM4U9G IU 4-amino-5-chloro-N-[1-(3-methoxypropyl)piperidin-4-yl]-2,3-dihydro-1-benzofuran-7-carboxamide DMM4U9G CA CAS 179474-81-8 DMM4U9G CB CHEBI:135552 DMM4U9G DE Irritable bowel syndrome; Constipation DMMZXIW ID DMMZXIW DMMZXIW DN Rabeprazole DMMZXIW HS Approved DMMZXIW SN Dexrabeprazole; Eraloc; Rebeprazole sodium; CL23619; LY307640; Aciphex (TN); Eraloc (TN); Pariet (TN); Rabeprazole (INN); Rabeprazole [BAN:INN]; Rabeprazole [INN:BAN]; Rablet (TN); 2-(((4-(3-Methoxypropoxy)-3-methyl-2-pyridinyl)methyl)sulfinyl)-1H-benzimidazole; 2-((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methylsulfinyl)-1H-benzimidazole; 2-({[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methyl}sulfinyl)-1H-benzimidazole; 2-[[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methylsulfinyl]-1H-benzimidazole DMMZXIW CP Eisai; Johnson & Johnson DMMZXIW TC Antiulcer Agents DMMZXIW DT Small molecular drug DMMZXIW PC 5029 DMMZXIW MW 359.4 DMMZXIW FM C18H21N3O3S DMMZXIW IC InChI=1S/C18H21N3O3S/c1-13-16(19-9-8-17(13)24-11-5-10-23-2)12-25(22)18-20-14-6-3-4-7-15(14)21-18/h3-4,6-9H,5,10-12H2,1-2H3,(H,20,21) DMMZXIW CS CC1=C(C=CN=C1CS(=O)C2=NC3=CC=CC=C3N2)OCCCOC DMMZXIW IK YREYEVIYCVEVJK-UHFFFAOYSA-N DMMZXIW IU 2-[[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methylsulfinyl]-1H-benzimidazole DMMZXIW CA CAS 117976-89-3 DMMZXIW CB CHEBI:8768 DMMZXIW DE Bacterial infection DMFOTZ7 ID DMFOTZ7 DMFOTZ7 DN Racecadotril DMFOTZ7 HS Approved DMFOTZ7 SN Acetorphan; Hidrasec; Tiorfan DMFOTZ7 CP BioProjet; Societe Civile de Recherche DMFOTZ7 DT Small molecular drug DMFOTZ7 PC 107751 DMFOTZ7 MW 385.5 DMFOTZ7 FM C21H23NO4S DMFOTZ7 IC InChI=1S/C21H23NO4S/c1-16(23)27-15-19(12-17-8-4-2-5-9-17)21(25)22-13-20(24)26-14-18-10-6-3-7-11-18/h2-11,19H,12-15H2,1H3,(H,22,25) DMFOTZ7 CS CC(=O)SCC(CC1=CC=CC=C1)C(=O)NCC(=O)OCC2=CC=CC=C2 DMFOTZ7 IK ODUOJXZPIYUATO-UHFFFAOYSA-N DMFOTZ7 IU benzyl 2-[[2-(acetylsulfanylmethyl)-3-phenylpropanoyl]amino]acetate DMFOTZ7 CA CAS 81110-73-8 DMFOTZ7 CB CHEBI:91508 DMFOTZ7 DE Diarrhea DMXTCVF ID DMXTCVF DMXTCVF DN Radium-223-Dichloride DMXTCVF HS Approved DMXTCVF CP Bayer HealthCare Pharmaceuticals DMXTCVF DE Prostate cancer DMDKF3M ID DMDKF3M DMDKF3M DN Raloxifene DMDKF3M HS Approved DMDKF3M SN Raloxifene (extended-release, CDT) DMDKF3M CP SCOLR Pharma Inc DMDKF3M DT Small molecular drug DMDKF3M PC 5035 DMDKF3M MW 473.6 DMDKF3M FM C28H27NO4S DMDKF3M IC InChI=1S/C28H27NO4S/c30-21-8-4-20(5-9-21)28-26(24-13-10-22(31)18-25(24)34-28)27(32)19-6-11-23(12-7-19)33-17-16-29-14-2-1-3-15-29/h4-13,18,30-31H,1-3,14-17H2 DMDKF3M CS C1CCN(CC1)CCOC2=CC=C(C=C2)C(=O)C3=C(SC4=C3C=CC(=C4)O)C5=CC=C(C=C5)O DMDKF3M IK GZUITABIAKMVPG-UHFFFAOYSA-N DMDKF3M IU [6-hydroxy-2-(4-hydroxyphenyl)-1-benzothiophen-3-yl]-[4-(2-piperidin-1-ylethoxy)phenyl]methanone DMDKF3M CA CAS 84449-90-1 DMDKF3M CB CHEBI:8772 DMDKF3M DE Osteoporosis DMYURI6 ID DMYURI6 DMYURI6 DN Raltegravir DMYURI6 HS Approved DMYURI6 SN RGV; MK 0518; Isentress(TM); K-0518; MK-0518; Raltegravir (INN); N-(2-(4-(4-fluorobenzylcarbamoyl); N-((4-Fluorophenyl)methyl)-1,6-dihydro-5-hydroxy-1-methyl-2-(1-methyl-1-(((5-methyl-1,3,4-oxadiazol-2-yl)carbonyl)amino)ethyl)-6-oxo-4-pyrimidinecarboxamide; RAL DMYURI6 CP Merck DMYURI6 DT Small molecular drug DMYURI6 PC 54671008 DMYURI6 MW 444.4 DMYURI6 FM C20H21FN6O5 DMYURI6 IC InChI=1S/C20H21FN6O5/c1-10-25-26-17(32-10)16(30)24-20(2,3)19-23-13(14(28)18(31)27(19)4)15(29)22-9-11-5-7-12(21)8-6-11/h5-8,28H,9H2,1-4H3,(H,22,29)(H,24,30) DMYURI6 CS CC1=NN=C(O1)C(=O)NC(C)(C)C2=NC(=C(C(=O)N2C)O)C(=O)NCC3=CC=C(C=C3)F DMYURI6 IK CZFFBEXEKNGXKS-UHFFFAOYSA-N DMYURI6 IU N-[2-[4-[(4-fluorophenyl)methylcarbamoyl]-5-hydroxy-1-methyl-6-oxopyrimidin-2-yl]propan-2-yl]-5-methyl-1,3,4-oxadiazole-2-carboxamide DMYURI6 CA CAS 518048-05-0 DMYURI6 DE Human immunodeficiency virus infection DMT9K8G ID DMT9K8G DMT9K8G DN Raltitrexed DMT9K8G HS Approved DMT9K8G SN Tomudex; 112887-68-0; ZD1694; ZD-1694; ICI-D1694; D-1694; ZD 1694; ICI D1694; UNII-FCB9EGG971; D1694; D 1694; CHEBI:5847; Raltitrexed (Tomudex); C21H22N4O6S; ZD-16; (2S)-2-[[5-[methyl-[(2-methyl-4-oxo-1H-quinazolin-6-yl)methyl]amino]thiophene-2-carbonyl]amino]pentanedioic acid; FCB9EGG971; CHEMBL225071; N-(5-(N-(3,4-Dihydro-2-methyl-4-oxoquinazolin-6-ylmethyl)-N-methylamino)-2-thenoyl)-L-glutamic acid; ICI-D-1694; NSC-639186; NCGC00229704-01; DSSTox_RID_81653; DSSTox_CID_26482; DSSTox_GSID_46482 DMT9K8G CP AstraZeneca DMT9K8G TC Anticancer Agents DMT9K8G DT Small molecular drug DMT9K8G PC 135400182 DMT9K8G MW 458.5 DMT9K8G FM C21H22N4O6S DMT9K8G IC InChI=1S/C21H22N4O6S/c1-11-22-14-4-3-12(9-13(14)19(28)23-11)10-25(2)17-7-6-16(32-17)20(29)24-15(21(30)31)5-8-18(26)27/h3-4,6-7,9,15H,5,8,10H2,1-2H3,(H,24,29)(H,26,27)(H,30,31)(H,22,23,28)/t15-/m0/s1 DMT9K8G CS CC1=NC2=C(C=C(C=C2)CN(C)C3=CC=C(S3)C(=O)N[C@@H](CCC(=O)O)C(=O)O)C(=O)N1 DMT9K8G IK IVTVGDXNLFLDRM-HNNXBMFYSA-N DMT9K8G IU (2S)-2-[[5-[methyl-[(2-methyl-4-oxo-3H-quinazolin-6-yl)methyl]amino]thiophene-2-carbonyl]amino]pentanedioic acid DMT9K8G CA CAS 112887-68-0 DMT9K8G CB CHEBI:5847 DMT9K8G DE Rectal adenocarcinoma DM7IW9J ID DM7IW9J DM7IW9J DN Ramelteon DM7IW9J HS Approved DM7IW9J SN Rozerem; Ramelteon [USAN]; Rozerem (TN); TAK-375; Ramelteon (JAN/USAN/INN); Rozerem, TAK-375, Ramelteon; N-[2-[(8S)-2,6,7,8-tetrahydro-1H-cyclopenta[e][1]benzofuran-8-yl]ethyl]propanamide; N-{2-[(8s)-1,6,7,8-tetrahydro-2h-indeno[5,4-b]fur-8-yl]ethyl}propanamid; (-)-N-(2-(((8S)-1,6,7,8-Tetrahydro-2H-indeno(5,4-b)furan-8-yl)ethyl)propanamide; (S)-N-(2-(1,6,7,8-tetrahydro-2H-indeno-(5,4)furan-8-yl)ethyl)propionamide DM7IW9J CP Takeda DM7IW9J TC Hypnotics and Sedatives DM7IW9J DT Small molecular drug DM7IW9J PC 208902 DM7IW9J MW 259.339 DM7IW9J FM C16H21NO2 DM7IW9J IC InChI=1S/C16H21NO2/c1-2-15(18)17-9-7-12-4-3-11-5-6-14-13(16(11)12)8-10-19-14/h5-6,12H,2-4,7-10H2,1H3,(H,17,18)/t12-/m0/s1 DM7IW9J CS CCC(=O)NCC[C@@H]1CCC2=C1C3=C(C=C2)OCC3 DM7IW9J IK YLXDSYKOBKBWJQ-LBPRGKRZSA-N DM7IW9J IU N-[2-[(8S)-2,6,7,8-tetrahydro-1H-cyclopenta[e][1]benzofuran-8-yl]ethyl]propanamide DM7IW9J CA CAS 196597-26-9 DM7IW9J CB CHEBI:109549 DM7IW9J DE Insomnia; Circadian rhythm sleep disorder DM2R68E ID DM2R68E DM2R68E DN Ramipril DM2R68E HS Approved DM2R68E SN Acovil; Altace; Carasel; Cardace; Delix; Hypren; Hytren; Lostapres; Naprix; Pramace; Quark; Ramace; Ramiprilum; Triatec; Tritace; Vesdil; Zabien; Almirall Brand of Ramipril; Astra Brand of Ramipril; AstraZeneca Brand of Ramipril; Aventis Brand of Ramipril; Aventis Pharma Brand of Ramipril; Hoechst Brand of Ramipril; Monarch Brand of Ramipril; Promed Brand of Ramipril; Ramiprilum [Latin]; HOE 498; HOE498; Altace (TN); Hoe-498; Pramace (discontinued); Tritace (TN); Ramipril (USP/INN); Ramipril [USAN:INN:BAN]; Ramipro, Tritace, Altace, Prilace, Ramipril; N-(1S-carboethoxy-3-phenylpropyl)-S-alanyl-cis,endo-2-azabicyclo[3.3.0]octane-3S-carboxylic Acid; [2s,3as,6as]-1-[(2s)-2-[[(1s)-1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]octahydrocyclopen; [2S,3aS,6aS]-1-[(2S)-2-[[(1S)-1-(Ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]octahydrocyclopenta[b]pyrrole-2-carboxylic acid; (2 S ,3 aS,6 aS)-1[(S)-N-[(S)-1-Carboxy-3-phenylpropyl] alanyl] octahydrocyclopenta [ b ]pyrrole-2-carboxylic acid, 1-ethyl ester; (2S,3aS,6aS)-1-((S)-2-((S)-1-ethoxy-1-oxo-4-phenylbutan-2-ylamino)propanoyl) octahydrocyclopenta[b]pyrrole-2-carboxylic acid; (2S,3aS,6aS)-1-((S)-N-((S)-1-Carboxy-3-phenylpropyl)alanyl)octahydrocyclopenta(b)pyrrole-2-carboxylic acid, 1-ethyl ester; (2S,3aS,6aS)-1-((S)-N-((S)-1-Ethoxycarbonyl-3-phenylpropyl)alanyl)octahydrocyclopenta(b)pyrrol-2-carbonsaeure; (2S,3aS,6aS)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-3,3a,4,5,6,6a-hexahydro-2H-cyclopenta[b]pyrrole-2-carboxylic acid; (2S,3aS,6aS)-1-[(2S)-2-{[(1S)-1-ethoxycarbonyl-3-phenylpropyl]amino}propanoyl]octahydrocyclopenta[b]pyrrole-2-carboxylic acid; (2S,3aS,6aS)-1-[(2S)-2-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}propanoyl]octahydrocyclopenta[b]pyrrole-2-carboxylic acid (non-preferred name); (2S-(1(R*(R*)),2alpha,3abeta,6abeta))-1-(2-((1-(Ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)octahydrocyclopenta(b)pyrrole-2-carboxylic acid; (2s,3as,6as)-1((s)-n-((s)-1-carboxy-3-phenylpropyl)alanyl)octahydrocyclopenta(b)pyrrole-2-carboxylic; (2s,3as,6as)-1-((s)-2-((s)-1-ethoxy-1-oxo-4-phenylbutan-2-ylamino)propanoyl)-octahydrocyclopenta[b]p; (2s,3as,6as)-1-[(s)-2-((s)-1-ethoxycarbonyl-3-phenyl-propylamino)-propionyl]-octahydro-cyclopenta[b] DM2R68E CP Sanofi-Aventis DM2R68E TC Antihypertensive Agents DM2R68E DT Small molecular drug DM2R68E PC 5362129 DM2R68E MW 416.5 DM2R68E FM C23H32N2O5 DM2R68E IC InChI=1S/C23H32N2O5/c1-3-30-23(29)18(13-12-16-8-5-4-6-9-16)24-15(2)21(26)25-19-11-7-10-17(19)14-20(25)22(27)28/h4-6,8-9,15,17-20,24H,3,7,10-14H2,1-2H3,(H,27,28)/t15-,17-,18-,19-,20-/m0/s1 DM2R68E CS CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2[C@H]3CCC[C@H]3C[C@H]2C(=O)O DM2R68E IK HDACQVRGBOVJII-JBDAPHQKSA-N DM2R68E IU (2S,3aS,6aS)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-3,3a,4,5,6,6a-hexahydro-2H-cyclopenta[b]pyrrole-2-carboxylic acid DM2R68E CA CAS 87333-19-5 DM2R68E CB CHEBI:8774 DM2R68E DE Congestive heart failure DMH7GN8 ID DMH7GN8 DMH7GN8 DN Ramosetron DMH7GN8 HS Approved DMH7GN8 SN 132036-88-5; UNII-7ZRO0SC54Y; Ramosetron [INN]; 7ZRO0SC54Y; CHEMBL1643895; Ramosetron (INN); (1-methylindol-3-yl)-[(5R)-4,5,6,7-tetrahydro-3H-benzimidazol-5-yl]methanone; Nor-YM 060; SCHEMBL16701; GTPL2301; DTXSID0043842; NTHPAPBPFQJABD-LLVKDONJSA-N; MolPort-019-991-383; CHEBI:135156; ZINC5116719; AC1L3355; BDBM50334454; 8235AH; AKOS015896003; SB19072; DB09290; SC-92398; AJ-53160; LS-187182; TL8000762; R-146; FT-0651831; D08466; A806353; (-)-(R)-1-Methylindol-3-yl-4,5,6,7-tetrahydro-5-benzimidazolyl ketone; Nasea (TN); YM060 DMH7GN8 DT Small molecular drug DMH7GN8 PC 108000 DMH7GN8 MW 279.34 DMH7GN8 FM C17H17N3O DMH7GN8 IC InChI=1S/C17H17N3O/c1-20-9-13(12-4-2-3-5-16(12)20)17(21)11-6-7-14-15(8-11)19-10-18-14/h2-5,9-11H,6-8H2,1H3,(H,18,19)/t11-/m1/s1 DMH7GN8 CS CN1C=C(C2=CC=CC=C21)C(=O)[C@@H]3CCC4=C(C3)NC=N4 DMH7GN8 IK NTHPAPBPFQJABD-LLVKDONJSA-N DMH7GN8 IU (1-methylindol-3-yl)-[(5R)-4,5,6,7-tetrahydro-3H-benzimidazol-5-yl]methanone DMH7GN8 CA CAS 132036-88-5 DMH7GN8 CB CHEBI:135156 DMH7GN8 DE Nausea and vomiting; Irritable bowel syndrome DMWUFQ4 ID DMWUFQ4 DMWUFQ4 DN Ramucirumab DMWUFQ4 HS Approved DMWUFQ4 SN LY3009806 DMWUFQ4 CP Lilly DMWUFQ4 DT Monoclonal antibody DMWUFQ4 SQ 9098_H|ramucirumab|Homo sapiens||H-GAMMA-1 (VH(1-116)+CH1(117-214)+HINGE-REGION(215-229)+CH2(230-339)+CH3(340-446))|||||||446||||MW 48696.0|MW 48696.0|: EVQLVQSGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSSYIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARVTDAFDIWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK >9098_L|ramucirumab|Homo sapiens||L-KAPPA (V-KAPPA(1-107)+C-KAPPA(109-214))|||||||214||||MW 23124.7|MW 23124.7|DIQMTQSPSSVSASIGDRVTITCRASQGIDNWLGWYQQKPGKAPKLLIYDASNLDTGVPSRFSGSGSGTYFTLTISSLQAEDFAVYFCQQAKAFPPTFGGGTKVDIKGTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC DMWUFQ4 DE Gastric adenocarcinoma DMSYPNW ID DMSYPNW DMSYPNW DN Ranibizumab DMSYPNW HS Approved DMSYPNW SN Ranibizumab (nasal spray, hereditary hemorrhagic telangiectasia) DMSYPNW CP Genentech Inc DMSYPNW DT Antibody DMSYPNW SQ Ranibizumab Light Chain: DIQLTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSTVPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC >Ranibizumab Heavy ChainEVQLVESGGGLVQPGGSLRLSCAASGYDFTHYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPYYYGTSHWYFDVWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHL DMSYPNW DE Hereditary hemorrhagic telangiectasia DM0GUSX ID DM0GUSX DM0GUSX DN Ranitidine DM0GUSX HS Approved DM0GUSX SN Achedos; Acidex; Alquen; Atural; Axoban; Biotidin; Coralen; Curan; Duractin; Ezopta; Fendibina; Gastrial; Gastridina; Gastrolav; Gastrosedol; Istomar; Kuracid; Logast; Mauran; Melfax; Microtid; Noctone; Ptinolin; Quantor; Quicran; RND; Radinat; Randin; Raniben; Raniberl; Ranibloc; Ranidine; Ranifur; Ranin; Raniogas; Raniplex; Ranisen; Raniter; Ranitidin; Ranitidina; Ranitidinum; Ranitiget; Ranitin; Rantacid; Rantidine; Ratic; Raticina; Sampep; Sostril; Taural; Terposen; Ulceranin; Ulcex; Ultidine; Urantac; Verlost; Vesyca; Vizerul; Weichilin; Weidos; Xanidine; ZANTAC; Zantab; Zantadin; Zantic; Ranitidine HCL; Rantidine HCL; Nu-Ranit; Rani-Q; Rani-nerton; Ranitidina [INN-Spanish]; Ranitidine (TN); Ranitidinum [INN-Latin]; Ul-Pep; Zantac (TN); Ranitidine (USAN/INN); Ranitidine [USAN:BAN:INN]; N-(2-((5-((Dimethylamino)methyl)furfuryl)thio)ethyl)-N'-methyl-2-nitro-1,1-ethenediamine; N (2-(((5-((Dimethylamino)methyl)-2-furanyl)methyl)thio)ethyl)-N'-methyl-2-nitro-1,1-ethenediamine; (E)-1-N'-[2-[[5-(dimethylaminomethyl)furan-2-yl]methylsulfanyl]ethyl]-1-N-methyl-2-nitroethene-1,1-diamine; (E)-N-{2-[({5-[(dimethylamino)methyl]-2-furyl}methyl)sulfanyl]ethyl}-N'-methyl-2-nitroethene-1,1-diamine; (E)-N-{2-[({5-[(dimethylamino)methyl]furan-2-yl}methyl)sulfanyl]ethyl}-N'-methyl-2-nitroethene-1,1-diamine DM0GUSX CP GlaxoSmithKline DM0GUSX TC Antiulcer Agents DM0GUSX DT Small molecular drug DM0GUSX PC 3001055 DM0GUSX MW 314.41 DM0GUSX FM C13H22N4O3S DM0GUSX IC InChI=1S/C13H22N4O3S/c1-14-13(9-17(18)19)15-6-7-21-10-12-5-4-11(20-12)8-16(2)3/h4-5,9,14-15H,6-8,10H2,1-3H3/b13-9+ DM0GUSX CS CN/C(=C\\[N+](=O)[O-])/NCCSCC1=CC=C(O1)CN(C)C DM0GUSX IK VMXUWOKSQNHOCA-UKTHLTGXSA-N DM0GUSX IU (E)-1-N'-[2-[[5-[(dimethylamino)methyl]furan-2-yl]methylsulfanyl]ethyl]-1-N-methyl-2-nitroethene-1,1-diamine DM0GUSX CA CAS 82530-72-1 DM0GUSX CB CHEBI:8776 DM0GUSX DE Peptic ulcer DM0C9IL ID DM0C9IL DM0C9IL DN Ranolazine DM0C9IL HS Approved DM0C9IL SN RANOLAZINE; 95635-55-5; Ranexa; N-(2,6-dimethylphenyl)-2-(4-(2-hydroxy-3-(2-methoxyphenoxy)propyl)piperazin-1-yl)acetamide; CVT-303; (-)-Ranolazine; Ranolazine (Ranexa); Ranolazine 2HCl; RS-43285-003; 142387-99-3; N-(2,6-dimethylphenyl)-2-[4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl]acetamide; CHEBI:87690; N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide; C24H33N3O4; NCGC00015897-02; DSSTox_RID_80743; DSSTox_CID_25196; DSSTox_GSID_45196; Ran4; CVT 303; Latixa; RAN D; Latixa; Ranolazine dihydrochloride; KEG-1295; RS-43285; Ranexa (TN); Ranexa, Ranolazine; Ranolazine (USAN/INN); Ranolazine extended-release; Ranolazine/Dronedarone Fixed-Dose Combination DM0C9IL CP CV Therapeutics DM0C9IL TC Analgesics DM0C9IL DT Small molecular drug DM0C9IL PC 56959 DM0C9IL MW 427.5 DM0C9IL FM C24H33N3O4 DM0C9IL IC InChI=1S/C24H33N3O4/c1-18-7-6-8-19(2)24(18)25-23(29)16-27-13-11-26(12-14-27)15-20(28)17-31-22-10-5-4-9-21(22)30-3/h4-10,20,28H,11-17H2,1-3H3,(H,25,29) DM0C9IL CS CC1=C(C(=CC=C1)C)NC(=O)CN2CCN(CC2)CC(COC3=CC=CC=C3OC)O DM0C9IL IK XKLMZUWKNUAPSZ-UHFFFAOYSA-N DM0C9IL IU N-(2,6-dimethylphenyl)-2-[4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl]acetamide DM0C9IL CA CAS 95635-55-5 DM0C9IL CB CHEBI:87690 DM0C9IL DE Chronic/stable angina; Paroxysmal atrial fibrillation DM3WKQ4 ID DM3WKQ4 DM3WKQ4 DN Rasagiline DM3WKQ4 HS Approved DM3WKQ4 SN RAS; Rasagiline [INN]; Azilect (TN); Rasagiline (INN); (1R)-N-(prop-2-yn-1-yl)-2,3-dihydro-1H-inden-1-amine; (1R)-N-prop-2-ynyl-2,3-dihydro-1H-inden-1-amine; (R)-N-2-Propynyl-1-indanamine; 1H-Inden-1-amine, 2,3-dihydro-N-2-propynyl-, (1R) DM3WKQ4 CP Teva Pharmaceutical Industries Ltd DM3WKQ4 TC Antiparkinson Agents DM3WKQ4 DT Small molecular drug DM3WKQ4 PC 3052776 DM3WKQ4 MW 171.24 DM3WKQ4 FM C12H13N DM3WKQ4 IC InChI=1S/C12H13N/c1-2-9-13-12-8-7-10-5-3-4-6-11(10)12/h1,3-6,12-13H,7-9H2/t12-/m1/s1 DM3WKQ4 CS C#CCN[C@@H]1CCC2=CC=CC=C12 DM3WKQ4 IK RUOKEQAAGRXIBM-GFCCVEGCSA-N DM3WKQ4 IU (1R)-N-prop-2-ynyl-2,3-dihydro-1H-inden-1-amine DM3WKQ4 CA CAS 136236-51-6 DM3WKQ4 CB CHEBI:63620 DM3WKQ4 DE Skin cancer; Skin imperfections; Parkinson disease DMWTVAN ID DMWTVAN DMWTVAN DN Rauwolfia serpentina root DMWTVAN HS Approved DMWTVAN SN Raubasine; 483-04-5; Ajmalicin; Circolene; Sarpan; py-Tetrahydroserpentine; Tetrahydroserpentine; UNII-4QJL8OX71Z; EINECS 207-589-5; BRN 0097268; 4QJL8OX71Z; CHEBI:2524; CHEMBL123325; Methyl 16,17-didehydro-19alpha-methyl-18-oxayohimban-16-carboxylat; 16,17-Didehydro-19-methyloxayohimban-16-carboxylic acid m DMWTVAN DT Small molecular drug DMWTVAN DE Discovery agent DMSWNJF ID DMSWNJF DMSWNJF DN Ravulizumab DMSWNJF HS Approved DMSWNJF SN Ravulizumab [USAN]; UNII-C3VX249T6L; C3VX249T6L; ALXN1210 DMSWNJF CP Alexion DMSWNJF DT Antibody DMSWNJF DE Paroxysmal nocturnal haemoglobinuria DM7QG0M ID DM7QG0M DM7QG0M DN Raxibacumab DM7QG0M HS Approved DM7QG0M CP GlaxoSmithKline DM7QG0M DT Monoclonal antibody DM7QG0M DE Anthrax DM26PRD ID DM26PRD DM26PRD DN Reboxetine DM26PRD HS Approved DM26PRD SN 71620-89-8; (2r)-2-[(R)-(2-Ethoxyphenoxy)(Phenyl)methyl]morpholine; Morpholine, 2-[(2-ethoxyphenoxy)phenylmethyl]-, (R*,R*)-; Morpholine, 2-[(R)-(2-ethoxyphenoxy)phenylmethyl]-, (2R)-rel-; Reboxetine [INN:BAN]; Morpholine, 2-((R)-(2-ethoxyphenoxy)phenylmethyl)-, (2R)-rel-; HSDB 7701; Edronax (TN); (R,R)-Reboxetine; AC1L2RJ0; SCHEMBL34533; CHEMBL383921; DTXSID1048257; MolPort-005-943-618; CHEBI:135342; ZINC3996032; BCP12060; AKOS015966368; DB00234; AN-34535; AK431803; AJ-47614 DM26PRD CP Pfizer Pharmaceuticals DM26PRD TC Antidepressants DM26PRD DT Small molecular drug DM26PRD PC 127151 DM26PRD MW 313.4 DM26PRD FM C19H23NO3 DM26PRD IC InChI=1S/C19H23NO3/c1-2-21-16-10-6-7-11-17(16)23-19(15-8-4-3-5-9-15)18-14-20-12-13-22-18/h3-11,18-20H,2,12-14H2,1H3/t18-,19-/m1/s1 DM26PRD CS CCOC1=CC=CC=C1O[C@@H]([C@H]2CNCCO2)C3=CC=CC=C3 DM26PRD IK CBQGYUDMJHNJBX-RTBURBONSA-N DM26PRD IU (2R)-2-[(R)-(2-ethoxyphenoxy)-phenylmethyl]morpholine DM26PRD CA CAS 71620-89-8 DM26PRD CB CHEBI:135342 DM26PRD DE Depression DMY7ESM ID DMY7ESM DMY7ESM DN Recombinant Factor IX DMY7ESM HS Approved DMY7ESM SN RFIX, Baxter; Recombinant Factor IX, Baxter DMY7ESM CP Baxter 1nternational DMY7ESM DE Factor IX deficiency; Bleeding disorder DMMPCFX ID DMMPCFX DMMPCFX DN Recombinant human endostatin DMMPCFX HS Approved DMMPCFX SN Endostar; Endu; Recombinant human endostatin (cancer); YH-16; Recombinant human endostatin (cancer), Shandong Simcere Medgenn DMMPCFX CP Shandong Simcere Medgenn Bio- Pharmaceutical Co Ltd DMMPCFX DE Solid tumour/cancer DM76VHG ID DM76VHG DM76VHG DN Regadenoson DM76VHG HS Approved DM76VHG SN Lexiscan (TN) DM76VHG CP CV Therapeutics DM76VHG DT Small molecular drug DM76VHG PC 219024 DM76VHG MW 390.35 DM76VHG FM C15H18N8O5 DM76VHG IC InChI=1S/C15H18N8O5/c1-17-13(27)6-2-19-23(3-6)15-20-11(16)8-12(21-15)22(5-18-8)14-10(26)9(25)7(4-24)28-14/h2-3,5,7,9-10,14,24-26H,4H2,1H3,(H,17,27)(H2,16,20,21)/t7-,9-,10-,14-/m1/s1 DM76VHG CS CNC(=O)C1=CN(N=C1)C2=NC(=C3C(=N2)N(C=N3)[C@H]4[C@@H]([C@@H]([C@H](O4)CO)O)O)N DM76VHG IK LZPZPHGJDAGEJZ-AKAIJSEGSA-N DM76VHG IU 1-[6-amino-9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]purin-2-yl]-N-methylpyrazole-4-carboxamide DM76VHG CA CAS 313348-27-5 DM76VHG CB CHEBI:135613 DM76VHG DE Radionuclide imaging DM87XSN ID DM87XSN DM87XSN DN REGN-727 DM87XSN HS Approved DM87XSN SN Alirocumab; Alirocumab); RENG-727; Anti-PCSK9 antibody (hypercholesterolemia), Regeneron/sanofi-aventis DM87XSN CP Sanofi; Novo Nordisk DM87XSN DT Antibody DM87XSN DE Familial hypercholesterolemia; Hypercholesterolaemia DMHSY1I ID DMHSY1I DMHSY1I DN Regorafenib DMHSY1I HS Approved DMHSY1I SN Regorafenib; 755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN] DMHSY1I CP Bayer HealthCare Pharmaceuticals DMHSY1I DT Small molecular drug DMHSY1I PC 11167602 DMHSY1I MW 482.8 DMHSY1I FM C21H15ClF4N4O3 DMHSY1I IC InChI=1S/C21H15ClF4N4O3/c1-27-19(31)18-10-13(6-7-28-18)33-12-3-5-17(16(23)9-12)30-20(32)29-11-2-4-15(22)14(8-11)21(24,25)26/h2-10H,1H3,(H,27,31)(H2,29,30,32) DMHSY1I CS CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F DMHSY1I IK FNHKPVJBJVTLMP-UHFFFAOYSA-N DMHSY1I IU 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]-3-fluorophenoxy]-N-methylpyridine-2-carboxamide DMHSY1I CA CAS 755037-03-7 DMHSY1I CB CHEBI:68647 DMHSY1I DE Metastatic colorectal cancer DMK7IWL ID DMK7IWL DMK7IWL DN Relugolix DMK7IWL HS Approved DMK7IWL SN 737789-87-6; TAK-385; TAK 385; UNII-P76B05O5V6; CHEMBL1800159; TAK-385/TAK385; P76B05O5V6; 1-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-3-methoxyurea; Relugolix [USAN:INN]; TAK385; Relugolix (JAN/INN); SCHEMBL778416; GTPL5586; DTXSID40224167; MolPort-044-567-649; AOMXMOCNKJTRQP-UHFFFAOYSA-N; EX-A1083; BCP21587; ZINC43206033; BDBM50347982; AKOS027440398; SB16721; DB11853; CS-5917 DMK7IWL CP Takeda DMK7IWL DT Small molecular drug DMK7IWL PC 10348973 DMK7IWL MW 623.6 DMK7IWL FM C29H27F2N7O5S DMK7IWL IC InChI=1S/C29H27F2N7O5S/c1-36(2)14-19-24-26(39)38(22-12-13-23(42-3)34-33-22)29(41)37(15-18-20(30)6-5-7-21(18)31)27(24)44-25(19)16-8-10-17(11-9-16)32-28(40)35-43-4/h5-13H,14-15H2,1-4H3,(H2,32,35,40) DMK7IWL CS CN(C)CC1=C(SC2=C1C(=O)N(C(=O)N2CC3=C(C=CC=C3F)F)C4=NN=C(C=C4)OC)C5=CC=C(C=C5)NC(=O)NOC DMK7IWL IK AOMXMOCNKJTRQP-UHFFFAOYSA-N DMK7IWL IU 1-[4-[1-[(2,6-difluorophenyl)methyl]-5-[(dimethylamino)methyl]-3-(6-methoxypyridazin-3-yl)-2,4-dioxothieno[2,3-d]pyrimidin-6-yl]phenyl]-3-methoxyurea DMK7IWL CA CAS 737789-87-6 DMK7IWL DE Endometriosis; Prostate cancer DMBFZ6L ID DMBFZ6L DMBFZ6L DN Remdesivir DMBFZ6L HS Approved DMBFZ6L SN L-Alanine, N-((S)-hydroxyphenoxyp; RWWYLEGWBNMMLJ-YSOARWBDSA-N; Remdesivir [USAN]; 1809249-37-3; 3QKI37EEHE; AKOS032946252; SB19838; SCHEMBL17712225; UNII-3QKI37EEHE DMBFZ6L CP Gilead Sciences, Foster City, CA DMBFZ6L DT Small molecular drug DMBFZ6L PC 121304016 DMBFZ6L MW 602.6 DMBFZ6L FM C27H35N6O8P DMBFZ6L IC InChI=1S/C27H35N6O8P/c1-4-18(5-2)13-38-26(36)17(3)32-42(37,41-19-9-7-6-8-10-19)39-14-21-23(34)24(35)27(15-28,40-21)22-12-11-20-25(29)30-16-31-33(20)22/h6-12,16-18,21,23-24,34-35H,4-5,13-14H2,1-3H3,(H,32,37)(H2,29,30,31)/t17-,21+,23+,24+,27-,42-/m0/s1 DMBFZ6L CS CCC(CC)COC(=O)[C@H](C)N[P@](=O)(OC[C@@H]1[C@H]([C@H]([C@](O1)(C#N)C2=CC=C3N2N=CN=C3N)O)O)OC4=CC=CC=C4 DMBFZ6L IK RWWYLEGWBNMMLJ-YSOARWBDSA-N DMBFZ6L IU 2-ethylbutyl (2S)-2-[[[(2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxyoxolan-2-yl]methoxy-phenoxyphosphoryl]amino]propanoate DMBFZ6L CA CAS 1809249-37-3 DMBFZ6L CB CHEBI:145994 DMBFZ6L DE Ebola virus infection; Coronavirus Disease 2019 (COVID-19) DMZTXCH ID DMZTXCH DMZTXCH DN Remifentanil DMZTXCH HS Approved DMZTXCH SN Remifentanyl; Ultiva; GI 87084B; GI 87084X; GI87084B; Remifentanil (INN); Remifentanil [INN:BAN]; Ultiva (TN); Methyl 1-(3-methoxy-3-oxopropyl)-4-(N-propanoylanilino)piperidine-4-carboxylate; 1-Piperidinepropanoic acid, 4-(methoxy-carbonyl)-4-((1-oxopropyl)phenylamino)-, methyl ester; 3-(4-methoxycarbonyl-4-((1-oxopropyl)phenylamino)-1-piperidine)propanoic acid methyl ester; 4-carboxy-4-(n-phenylpropionamido)-1-piperidinepropionic acid dimethyl ester DMZTXCH CP Abbott Laboratories DMZTXCH TC Hypnotics and Sedatives DMZTXCH DT Small molecular drug DMZTXCH PC 60815 DMZTXCH MW 376.4 DMZTXCH FM C20H28N2O5 DMZTXCH IC InChI=1S/C20H28N2O5/c1-4-17(23)22(16-8-6-5-7-9-16)20(19(25)27-3)11-14-21(15-12-20)13-10-18(24)26-2/h5-9H,4,10-15H2,1-3H3 DMZTXCH CS CCC(=O)N(C1=CC=CC=C1)C2(CCN(CC2)CCC(=O)OC)C(=O)OC DMZTXCH IK ZTVQQQVZCWLTDF-UHFFFAOYSA-N DMZTXCH IU methyl 1-(3-methoxy-3-oxopropyl)-4-(N-propanoylanilino)piperidine-4-carboxylate DMZTXCH CA CAS 132875-61-7 DMZTXCH CB CHEBI:8802 DMZTXCH DE Anaesthesia DMNAKLY ID DMNAKLY DMNAKLY DN Remikiren DMNAKLY HS Approved DMNAKLY SN REM; Remikiren [INN]; Remikiren (INN); Ro 42-5892; Ro-42-5892; (2R)-2-benzyl-3-tert-butylsulfonyl-N-[(2S)-1-[[(2R,3S,4R)-1-cyclohexyl-4-cyclopropyl-3,4-dihydroxybutan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]propanamide; (2S)-2-benzyl-3-tert-butylsulfonyl-N-[(2S)-1-[[(2S,3R,4S)-1-cyclohexyl-4-cyclopropyl-3,4-dihydroxybutan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]propanamide; (S)-alpha-((S)-alpha-((t-butylsulfonyl)methyl)hydrocinnamamido)-N-((1S,2R,3S)-1-(cyclohexylmethyl)-3-cyclopropyl-2,3-dihydroxypropyl)imidazole-4-propionamide; (alphaS)-alpha-((alphaS)-alpha-((tert-Butylsulfonyl)methyl)hydrocinnamamido)-N-((1S,2R,3S)-1-(cyclohexylmethyl)-3-cyclopropyl-2,3-dihydroxypropyl)imidazole-4-propionamide; 2-benzyl-3-tert-butylsulfonyl-N-[1-[(1-cyclohexyl-4-cyclopropyl-3,4-dihydroxybutan-2-yl)amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]propanamide DMNAKLY CP Hoffmann-La Roche pharmaceutical company DMNAKLY TC Antihypertensive Agents DMNAKLY DT Small molecular drug DMNAKLY PC 6324659 DMNAKLY MW 630.8 DMNAKLY FM C33H50N4O6S DMNAKLY IC InChI=1S/C33H50N4O6S/c1-33(2,3)44(42,43)20-25(16-22-10-6-4-7-11-22)31(40)37-28(18-26-19-34-21-35-26)32(41)36-27(17-23-12-8-5-9-13-23)30(39)29(38)24-14-15-24/h4,6-7,10-11,19,21,23-25,27-30,38-39H,5,8-9,12-18,20H2,1-3H3,(H,34,35)(H,36,41)(H,37,40)/t25-,27+,28+,29+,30-/m1/s1 DMNAKLY CS CC(C)(C)S(=O)(=O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC2=CN=CN2)C(=O)N[C@@H](CC3CCCCC3)[C@H]([C@H](C4CC4)O)O DMNAKLY IK UXIGZRQVLGFTOU-VQXQMPIVSA-N DMNAKLY IU (2S)-2-benzyl-3-tert-butylsulfonyl-N-[(2S)-1-[[(2S,3R,4S)-1-cyclohexyl-4-cyclopropyl-3,4-dihydroxybutan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]propanamide DMNAKLY CA CAS 126222-34-2 DMNAKLY CB CHEBI:8803 DMNAKLY DE Hypertension DMLVSYX ID DMLVSYX DMLVSYX DN Remimazolam DMLVSYX HS Approved DMLVSYX SN CNS-7054; CNS-7056; CNS-7056B; CNS-7056X; GW-351564X; GW-418259X; GW-457837A; GW-502056X; ONO-2745; Short-acting sedatives, Therasci; GABA A agonist (anesthesia, sedation) CeNeS/Ono; Sedatives (short acting), CeNeS/Ono; Sedatives (short acting), PAION/Ono; Sedatives (short-acting), TheraSci; Short-acting sedatives, Therasci/GSK; Sedatives (short-acting), TheraSci/GSK DMLVSYX CP GlaxoSmithKline plc DMLVSYX DT Small molecular drug DMLVSYX PC 9867812 DMLVSYX MW 439.3 DMLVSYX FM C21H19BrN4O2 DMLVSYX IC InChI=1S/C21H19BrN4O2/c1-13-12-24-21-17(7-9-19(27)28-2)25-20(16-5-3-4-10-23-16)15-11-14(22)6-8-18(15)26(13)21/h3-6,8,10-12,17H,7,9H2,1-2H3/t17-/m0/s1 DMLVSYX CS CC1=CN=C2N1C3=C(C=C(C=C3)Br)C(=N[C@H]2CCC(=O)OC)C4=CC=CC=N4 DMLVSYX IK CYHWMBVXXDIZNZ-KRWDZBQOSA-N DMLVSYX IU methyl 3-[(4S)-8-bromo-1-methyl-6-pyridin-2-yl-4H-imidazo[1,2-a][1,4]benzodiazepin-4-yl]propanoate DMLVSYX CA CAS 308242-62-8 DMLVSYX DE Anaesthesia; Procedural sedation DM5SXUV ID DM5SXUV DM5SXUV DN Repaglinide DM5SXUV HS Approved DM5SXUV SN Actulin; GlucoNorm; NovoNorm; Prandin; Repaglinida; Repaglinidum; Glaxo Wellcome brand of replaginide; Novo Nordisk brand of repaglinide; Repaglinide [USAN]; Novo Nordisk brand 2 of repaglinide; AG-EE 388; AG-EE 388 ZW; AG-EE 623 ZW; AGEE-623ZW; GlucoNorm (TN); NN-623; NovoNorm (TN); Prandin (TN); Repa-glinide; Repaglinida [INN-Spanish]; Repaglinidum [INN-Latin]; SMP-508; AG-EE-388; AG-EE-623 ZW; Prandin, GlucoNorm, NovoNorm, Repaglinide; Repaglinide (JAN/USP/INN); Repaglinide, (+-)-isomer; (+)-2-Ethoxy-alpha-(((S)-alpha-isobutyl-o-piperidinobenzyl)carbamoyl)-p-toluic acid; (S)-(+)-2-Ethoxy-4-[N-[1-(2-piperidinophenyl)-3-methyl-1-butyl]aminocarbonylmethyl]benzoic acid; (S)-2-Ethoxy-4-(2-((methyl-1-(2-(1-piperidinyl)phenyl)butyl)amino)-2-oxoethyl)-benzoic acid; (S)-2-ethoxy-4-(2-((3-methyl-1-(2-(1-piperidinyl)-phenyl)butyl)amino)-2-oxoethyl)-benzoic acid; 111GE012; 2-ethoxy-4-(2-((3-methyl-1-(2-(1-piperidinyl)phenyl)butyl)amino)-2-oxoethyl)benzoic acid; 2-ethoxy-4-(2-{[(1S)-3-methyl-1-(2-piperidin-1-ylphenyl)butyl]amino}-2-oxoethyl)benzoic acid; 2-ethoxy-4-[2-({(1S)-3-methyl-1-[2-(piperidin-1-yl)phenyl]butyl}amino)-2-oxoethyl]benzoic acid; 2-ethoxy-4-[2-[[(1S)-3-methyl-1-(2-piperidin-1-ylphenyl)butyl]amino]-2-oxoethyl]benzoic acid; 2-ethoxy-N-(alpha-(2-methyl-1-propyl)-2-piperidinobenzyl)-4-carbamoylmethylbenzoic acid DM5SXUV CP Novo Nordisk DM5SXUV TC Hypoglycemic Agents DM5SXUV DT Small molecular drug DM5SXUV PC 65981 DM5SXUV MW 452.6 DM5SXUV FM C27H36N2O4 DM5SXUV IC InChI=1S/C27H36N2O4/c1-4-33-25-17-20(12-13-22(25)27(31)32)18-26(30)28-23(16-19(2)3)21-10-6-7-11-24(21)29-14-8-5-9-15-29/h6-7,10-13,17,19,23H,4-5,8-9,14-16,18H2,1-3H3,(H,28,30)(H,31,32)/t23-/m0/s1 DM5SXUV CS CCOC1=C(C=CC(=C1)CC(=O)N[C@@H](CC(C)C)C2=CC=CC=C2N3CCCCC3)C(=O)O DM5SXUV IK FAEKWTJYAYMJKF-QHCPKHFHSA-N DM5SXUV IU 2-ethoxy-4-[2-[[(1S)-3-methyl-1-(2-piperidin-1-ylphenyl)butyl]amino]-2-oxoethyl]benzoic acid DM5SXUV CA CAS 135062-02-1 DM5SXUV CB CHEBI:8805 DM5SXUV DE Diabetic complication DM6KI0D ID DM6KI0D DM6KI0D DN Repirinast DM6KI0D HS Approved DM6KI0D SN MY-1250; MY-5116; MY-6116 DM6KI0D CP Mitsubishi-Tokyo Pharmaceuticals Inc DM6KI0D DT Small molecular drug DM6KI0D PC 5050 DM6KI0D MW 355.4 DM6KI0D FM C20H21NO5 DM6KI0D IC InChI=1S/C20H21NO5/c1-10(2)7-8-25-20(24)15-9-14(22)16-18(26-15)13-6-5-11(3)12(4)17(13)21-19(16)23/h5-6,9-10H,7-8H2,1-4H3,(H,21,23) DM6KI0D CS CC1=C(C2=C(C=C1)C3=C(C(=O)C=C(O3)C(=O)OCCC(C)C)C(=O)N2)C DM6KI0D IK NFQIAEMCQGTTIR-UHFFFAOYSA-N DM6KI0D IU 3-methylbutyl 7,8-dimethyl-4,5-dioxo-6H-pyrano[3,2-c]quinoline-2-carboxylate DM6KI0D CA CAS 73080-51-0 DM6KI0D CB CHEBI:32092 DM6KI0D DE Asthma DMG7SQK ID DMG7SQK DMG7SQK DN Rescinnamine DMG7SQK HS Approved DMG7SQK SN Anapral; Anaprel; Apolon; Apoterin; Cartric; Cinamine; Cinatabs; Cinnaloid; Cinnasil; Moderil; Normorescina; Paresinan; Raupyrol; Raurescin; Raurescine; Recinnamine; Recitensina; Rescaloid; Rescamin; Rescidan; Rescin; Rescinamina; Rescinnamin; Rescinnamina; Rescinnaminum; Rescinpal; Rescisan; Rescitens; Resealoid; Reserpinene; Reserpinin; Reserpinine; Resipal; Reskinnamin; Rozex; Scinnamina; Tenamine; Tuareg; Apoterin S; Methyl trimethoxycinnamoylreserpate; Rescinnamina [DCIT]; Trimethoxy cinnamoyl reserpate de methyl; Trimethoxy cinnamoyl reserpate de methyl [French]; Trimethoxycinnamoyl methyl reserpate; Tsuruselpi S; Anaprel (TN); Cinnasil (TN); Moderil (TN); NP-011016; Rescinamina [INN-Spanish]; Rescinnamine (VAN); Rescinnaminum [INN-Latin]; Resepinine (C35 alkaloid); Reserpinine (C35 alkaloid); Reserpinine (VAN); Tsuruselpi S (TN); Rescinnamine (JAN/INN); Rescinnamine [BAN:INN:JAN]; Methyl reserpate 3,4,5-trimethoxycinnamic acid ester; Reserpic acid methyl ester 3,4,5-trimethoxycinnamate; Methyl 18-O-(3,4,5-trimethoxycinnamoyl)reserpate; O-(3,4,5-Trimethoxy-trans-cinnamoyl) methyl reserpate; 3,4,5-Trimethoxycinnamic acid, methyl reserpate; 3,4,5-Trimethoxycinnamoyl methyl reserpate; 3,4,5-Trimethylcinnamic acid, ester with methyl reserpate; 3,4,5-Trimethylcinnamoyl methyl reserpate DMG7SQK TC Antihypertensive Agents DMG7SQK DT Small molecular drug DMG7SQK PC 5280954 DMG7SQK MW 634.7 DMG7SQK FM C35H42N2O9 DMG7SQK IC InChI=1S/C35H42N2O9/c1-40-21-8-9-22-23-11-12-37-18-20-15-29(46-30(38)10-7-19-13-27(41-2)33(43-4)28(14-19)42-3)34(44-5)31(35(39)45-6)24(20)17-26(37)32(23)36-25(22)16-21/h7-10,13-14,16,20,24,26,29,31,34,36H,11-12,15,17-18H2,1-6H3/b10-7+/t20-,24+,26-,29-,31+,34+/m1/s1 DMG7SQK CS CO[C@H]1[C@@H](C[C@@H]2CN3CCC4=C([C@H]3C[C@@H]2[C@@H]1C(=O)OC)NC5=C4C=CC(=C5)OC)OC(=O)/C=C/C6=CC(=C(C(=C6)OC)OC)OC DMG7SQK IK SZLZWPPUNLXJEA-QEGASFHISA-N DMG7SQK IU methyl (1R,15S,17R,18R,19S,20S)-6,18-dimethoxy-17-[(E)-3-(3,4,5-trimethoxyphenyl)prop-2-enoyl]oxy-1,3,11,12,14,15,16,17,18,19,20,21-dodecahydroyohimban-19-carboxylate DMG7SQK CA CAS 24815-24-5 DMG7SQK CB CHEBI:28572 DMG7SQK DE Hypertension DM6VM38 ID DM6VM38 DM6VM38 DN Reserpine DM6VM38 HS Approved DM6VM38 SN Abesta; Abicol; Adelfan; Adelphin; Alkarau; Alkaserp; Alserin; Apoplon; Apsical; Ascoserp; Ascoserpina; Austrapine; Banasil; Banisil; Benazyl; Bioserpine; Brinderdin; Briserine; Broserpine; Cardioserpin; Carditivo; Carpacil; Carrserp; Darebon; Deserpine; Dralserp; Eberpine; Eberspine; Ebserpine; Elfanex; Elserpine; Enipresser; Escaspere; Eserpine; Eskaserp; Eskaserpine; Gammaserpine; Gilucard; Helfoserpin; Hexaplin; Hiposerpil; Hiserpia; Hydropine; Hydroserp; Hypersil; Hypersine; Hypertensan; Idoserp; Idsoserp; Interpina; Kitine; Klimanosid; Lemiserp; Loweserp; Mallopress; Maviserpin; Mayserpine; Mephaserpin; Modenol; Naquival; Nembuserpin; Neoserfin; Neoserp; Neoslowten; Orthoserpina; Perskleran; Pressimedin; Purserpine; Quiescin; Raucap; Raudiford; Raudixin; Raudixoid; Raugal; Raulen; Rauloydin; Raumorine; Raunervil; Raunorine; Raunova; Raupasil; Raupoid; Raurine; Rausan; Rausedan; Rausedil; Rausedyl; Rauserpin; Rauserpine; Rauserpol; Rausingle; Rautrin; Rauvlid; Rauwasedin; Rauwilid; Rauwiloid; Rauwipur; Rauwita; Rauwoleaf; Rawilid; Recipin; Regroton; Resaltex; Resedrex; Resedril; Reserbal; Resercaps; Resercen; Reserfia; Reserjen; Reserlor; Reserp; Reserpal; Reserpamed; Reserpanca; Reserpene; Reserpex; Reserpidefe; Reserpil; Reserpin; Reserpina; Reserpinum; Reserpka; Reserpoid; Reserpur; Reserutin; Resiatric; Residin; Residine; Resine; Resocalm; Resperin; Resperine; Respital; Restran; Rezerpin; Riserpa; Rivased; Rivasin; Rolserp; Roxel; Roxinoid; Roxynoid; Ryser; Salupres; Sandril; Sandron; Sedaraupin; Sedaraupina; Sederaupin; Sedserp; Seominal; Serfin; Serfolia; Serolfia; Serpalan; Serpaloid; Serpaneurona; Serpanray; Serpasil; Serpasol; Serpate; Serpazil; Serpazol; Serpedin; Serpen; Serpena; Serpentil; Serpentin; Serpentina; Serpicon; Serpil; Serpiloid; Serpilum; Serpine; Serpipur; Serpivate; Serpivite; Serpogen; Serpoid; Serpone; Serpyrit; Sertabs; Sertens; Sertensin; Sertina; Supergan; Tefaserpina; Temposerpine; Tensanyl; Tenserpinie; Tensional; Tensionorme; Tepserpine; Terbolan; Transerpin; Triserpin; Tylandril; Unilord; Unipres; VIXO; Esc aspere; Hydromox R; Hypercal B; Loweser p; Neose rfin; Rau sedyl; Renese R; Rese rpamed; Se rpate; V Serp; VI XO; Diupres 250; Diupres 500; ENT 50146; H 520; Hydropres 25; Hydropres 50; Hydrosine 25; R 0875; Apoplon (TN); Diupres-250; Diupres-500; Diurese-R; Diutensen-R; HYDRO-RESERP; Hydrap-ES; Hydromox-R; Key-serpine; L-Carpserp; Neo-serp; Rau-Sed; Renese-R; Rese-lar; Reser-ar; SK-Reserpine; T-Serp; Usaf cb-27; V-Serp; Vio-Serpine; Cam-Ap-Es; L"-Carpserp; R-e-s; Ser-A-Gen; 3P Reserp DM6VM38 TC Antihypertensive Agents DM6VM38 DT Small molecular drug DM6VM38 PC 5770 DM6VM38 MW 608.7 DM6VM38 FM C33H40N2O9 DM6VM38 IC InChI=1S/C33H40N2O9/c1-38-19-7-8-20-21-9-10-35-16-18-13-27(44-32(36)17-11-25(39-2)30(41-4)26(12-17)40-3)31(42-5)28(33(37)43-6)22(18)15-24(35)29(21)34-23(20)14-19/h7-8,11-12,14,18,22,24,27-28,31,34H,9-10,13,15-16H2,1-6H3/t18-,22+,24-,27-,28+,31+/m1/s1 DM6VM38 CS CO[C@H]1[C@@H](C[C@@H]2CN3CCC4=C([C@H]3C[C@@H]2[C@@H]1C(=O)OC)NC5=C4C=CC(=C5)OC)OC(=O)C6=CC(=C(C(=C6)OC)OC)OC DM6VM38 IK QEVHRUUCFGRFIF-MDEJGZGSSA-N DM6VM38 IU methyl (1R,15S,17R,18R,19S,20S)-6,18-dimethoxy-17-(3,4,5-trimethoxybenzoyl)oxy-1,3,11,12,14,15,16,17,18,19,20,21-dodecahydroyohimban-19-carboxylate DM6VM38 CA CAS 50-55-5 DM6VM38 CB CHEBI:28487 DM6VM38 DE Hypertension DM0AUCH ID DM0AUCH DM0AUCH DN Reslizumab DM0AUCH HS Approved DM0AUCH CP Teva DM0AUCH DT Monoclonal antibody DM0AUCH DE Severe asthma; Asthma; Eosinophilic asthma DM9JXB7 ID DM9JXB7 DM9JXB7 DN Retapamulin DM9JXB7 HS Approved DM9JXB7 SN Altabax; Altargo; SB 275833; Altabax (Glaxo); Altabax (TN); Altargo (TN); Retapamulin (USAN/INN) DM9JXB7 CP GlaxoSmithKline DM9JXB7 TC Antibiotics DM9JXB7 DT Small molecular drug DM9JXB7 PC 6918462 DM9JXB7 MW 517.799 DM9JXB7 FM C30H47NO4S DM9JXB7 IC InChI=1S/C30H47NO4S/c1-7-28(4)16-24(35-25(33)17-36-22-14-20-8-9-21(15-22)31(20)6)29(5)18(2)10-12-30(19(3)27(28)34)13-11-23(32)26(29)30/h7,18-22,24,26-27,34H,1,8-17H2,2-6H3/t18-,19+,20-,21+,22?,24-,26+,27+,28-,29+,30+/m1/s1 DM9JXB7 CS C[C@@H]1CC[C@@]23CCC(=O)[C@H]2[C@@]1([C@@H](C[C@@]([C@H]([C@@H]3C)O)(C)C=C)OC(=O)CSC4C[C@H]5CC[C@@H](C4)N5C)C DM9JXB7 IK STZYTFJPGGDRJD-FJJJPKKESA-N DM9JXB7 IU [(1S,2R,3S,4S,6R,7R,8R,14R)-4-ethenyl-3-hydroxy-2,4,7,14-tetramethyl-9-oxo-6-tricyclo[5.4.3.01,8]tetradecanyl] 2-[[(1R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl]sulfanyl]acetate DM9JXB7 CA CAS 224452-66-8 DM9JXB7 CB CHEBI:166679 DM9JXB7 DE Impetigo DML0D1P ID DML0D1P DML0D1P DN Reteplase DML0D1P HS Approved DML0D1P SN Retevase; Rapilysin (TN); Retavase (TN); Retevase (TN); Reteplase (USAN/INN) DML0D1P TC Thrombolytic Agents DML0D1P SQ DB00015 sequence: SYQGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP DML0D1P DE Heart attack DMGNYIH ID DMGNYIH DMGNYIH DN Retigabine DMGNYIH HS Approved DMGNYIH SN Ezogabine; Potiga; Trobalt; Retigabine [USAN]; D 20443; D 23129; ADD-230001; D-20443; D-23129; GKE-841; KE-0201; Ethyl 2-amino-4-((p-fluorobenzyl)amino)carbanilate; Ethyl N-[2-amino-4-[(4-fluorophenyl)methylamino]phenyl]carbamate; [2-Amino-4-[[(4-fluorophenyl)methyl]amino]phenyl]-carbamate; Ethyl N-(2-amino-4-(4-fluorobenzylamino)phenyl)carbamate hydrochloride; N-(2-Amino-4-(4-fluorobenzylamino)phenyl)carbamic acid ethyl ester; Ethyl (2-amino-4-(((4-fluorophenyl)methyl)amino)phenyl)carbamate; N-(2-Amino-4-(4-fluorobenzylamino)-phenyl) carbamic acid ethyl ester; Carbamic acid, (2-amino-4-(((4-fluorophenyl)methyl)amino)phenyl)-, ethyl ester DMGNYIH CP GSK DMGNYIH TC Anticonvulsants DMGNYIH DT Small molecular drug DMGNYIH PC 121892 DMGNYIH MW 303.33 DMGNYIH FM C16H18FN3O2 DMGNYIH IC InChI=1S/C16H18FN3O2/c1-2-22-16(21)20-15-8-7-13(9-14(15)18)19-10-11-3-5-12(17)6-4-11/h3-9,19H,2,10,18H2,1H3,(H,20,21) DMGNYIH CS CCOC(=O)NC1=C(C=C(C=C1)NCC2=CC=C(C=C2)F)N DMGNYIH IK PCOBBVZJEWWZFR-UHFFFAOYSA-N DMGNYIH IU ethyl N-[2-amino-4-[(4-fluorophenyl)methylamino]phenyl]carbamate DMGNYIH CA CAS 150812-12-7 DMGNYIH CB CHEBI:68584 DMGNYIH DE Epilepsy; Behcet disease DMMP5SI ID DMMP5SI DMMP5SI DN Revefenacin DMMP5SI HS Approved DMMP5SI SN UNII-G2AE2VE07O; G2AE2VE07O; Revefenacin [INN]; Revefenacin [WHO-DD]; Revefenacin [USAN:INN]; Revefenacin (USAN/INN); SCHEMBL356480; EX-A1722; DB11855; GSK1160724; CS-7743; GSK-1160724; HY-15851; D10978; 1211931-83-7 DMMP5SI CP Theravance Biopharma/Mylan DMMP5SI PC 11753673 DMMP5SI MW 597.7 DMMP5SI FM C35H43N5O4 DMMP5SI IC InChI=1S/C35H43N5O4/c1-38(34(42)29-13-11-26(12-14-29)25-40-19-15-28(16-20-40)33(36)41)23-24-39-21-17-30(18-22-39)44-35(43)37-32-10-6-5-9-31(32)27-7-3-2-4-8-27/h2-14,28,30H,15-25H2,1H3,(H2,36,41)(H,37,43) DMMP5SI CS CN(CCN1CCC(CC1)OC(=O)NC2=CC=CC=C2C3=CC=CC=C3)C(=O)C4=CC=C(C=C4)CN5CCC(CC5)C(=O)N DMMP5SI IK FYDWDCIFZSGNBU-UHFFFAOYSA-N DMMP5SI IU [1-[2-[[4-[(4-carbamoylpiperidin-1-yl)methyl]benzoyl]-methylamino]ethyl]piperidin-4-yl] N-(2-phenylphenyl)carbamate DMMP5SI CA CAS 864750-70-9 DMMP5SI DE Chronic obstructive pulmonary disease DM8LRU2 ID DM8LRU2 DM8LRU2 DN Revolade/Promacta DM8LRU2 HS Approved DM8LRU2 SN AC1OC7GM DM8LRU2 CP GSK DM8LRU2 DT Small molecular drug DM8LRU2 PC 6913084 DM8LRU2 MW 330.9 DM8LRU2 FM C22H31Cl DM8LRU2 IC InChI=1S/C22H31Cl/c23-22-17-19(12-8-11-18-9-4-1-2-5-10-18)15-16-21(22)20-13-6-3-7-14-20/h8,12,15-18,20H,1-7,9-11,13-14H2/b12-8- DM8LRU2 CS C1CCCC(CC1)C/C=C\\C2=CC(=C(C=C2)C3CCCCC3)Cl DM8LRU2 IK NDXQJQCGBAIFER-WQLSENKSSA-N DM8LRU2 IU [(Z)-3-(3-chloro-4-cyclohexylphenyl)prop-2-enyl]cycloheptane DM8LRU2 DE Idiopathic thrombocytopenic purpura; Thrombocytopenia; Chronic liver disease DM69XMQ ID DM69XMQ DM69XMQ DN RG-7446 DM69XMQ HS Approved DM69XMQ CP Genentech DM69XMQ DT Monoclonal antibody DM69XMQ DE Urothelial carcinoma; Bladder cancer DMNF0G8 ID DMNF0G8 DMNF0G8 DN Rh-alphaglucosidase DMNF0G8 HS Approved DMNF0G8 SN Pompase (TN) DMNF0G8 DE Pompe disease DM3ADGP ID DM3ADGP DM3ADGP DN Rhucin DM3ADGP HS Approved DM3ADGP SN sildenafil; 139755-83-2; VIAGRA; Sildenafil [INN:BAN]; UK-92480; UNII-3M7OB98Y7H; UK-92,480-10; C22H30N6O4S; HSDB 7305; CHEMBL192; UK 92480-10; CHEBI:9139; 3M7OB98Y7H; 1-((3-(4,7-Dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo(4,3-d)pyrimidin-5-yl)-4-ethoxyphenyl)sulfonyl)-4-methylpiperazine; BNRNXUUZRGQAQC-UHFFFAOYSA-N; 5-(2-Ethoxy-5-((4-methylpiperazin-1-yl)sulfonyl)phenyl)-1-methyl-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-7(6H)-one; Sildenafil DM3ADGP CP Pfizer DM3ADGP DT Small molecular drug DM3ADGP PC 135398744 DM3ADGP MW 474.6 DM3ADGP FM C22H30N6O4S DM3ADGP IC InChI=1S/C22H30N6O4S/c1-5-7-17-19-20(27(4)25-17)22(29)24-21(23-19)16-14-15(8-9-18(16)32-6-2)33(30,31)28-12-10-26(3)11-13-28/h8-9,14H,5-7,10-13H2,1-4H3,(H,23,24,29) DM3ADGP CS CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C DM3ADGP IK BNRNXUUZRGQAQC-UHFFFAOYSA-N DM3ADGP IU 5-[2-ethoxy-5-(4-methylpiperazin-1-yl)sulfonylphenyl]-1-methyl-3-propyl-6H-pyrazolo[4,3-d]pyrimidin-7-one DM3ADGP CA CAS 139755-83-2 DM3ADGP CB CHEBI:9139 DM3ADGP DE Hereditary angioedema; Erectile dysfunction DMALNG0 ID DMALNG0 DMALNG0 DN RHuEPO DMALNG0 HS Approved DMALNG0 CP Bio-Gal Advanced Biotechnology DMALNG0 DE Solid tumour/cancer DMEYLH9 ID DMEYLH9 DMEYLH9 DN Ribavirin DMEYLH9 HS Approved DMEYLH9 SN ribavirin; 36791-04-5; Tribavirin; Rebetol; Virazole; Ribavirine; Copegus; Vilona; Ribamide; Ribasphere; Ribamidil; Viramid; Ribamidyl; Ribavirinum; Ribavirina; Rebetron; Varazid; RTCA; Ribavirin Capsules; Ribavirinum [INN-Latin]; Ribavirine [INN-French]; Ribavirina [INN-Spanish]; ICN-1229; Rebretron; Virazid; Ribav; 1-beta-D-Ribofuranosyl-1,2,4-triazole-3-carboxamide; DRG-0028; 1-beta-D-Ribofuranosyl-1H-1,2,4-triazole-3-carboxamide; UNII-49717AWG6K; Ribavirin (Copegus); Copegus; Cotronak; RBV; RTC; Ravanex; Ribacine; Ribovirin; Viramide; Virazide; R 9644; SCH 18908; C-Virin; Copegus (TN); Drug: Ribavirin; KS-1104; R-964; RG-964; Rebetol (TN); Ribasphere (TN); Ribavirin [USAN:INN]; Vilona (TN); Virazole (Ribavirin) Inhalation Solution; Virazole (TN); AA-504/07617051; Ro 20-9963/000; Ro-20-9963; Ribavirin (JAN/USP/INN); 1-beta-D-Ribofuranosyl-1,2,4-triazolo-3-carboxamide; 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,4-triazole-3-carboxamide; 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-1,2,4-triazole-3-carboxamide; 1-beta-D-ribofuranosyl-1-H-1,2,4-triazole-3-carboxamide; RBI034 (2-5A antisense compound) + Ribavirin DMEYLH9 CP Hoffmann-La Roche pharmaceutical company DMEYLH9 TC Antiviral Agents DMEYLH9 DT Small molecular drug DMEYLH9 PC 37542 DMEYLH9 MW 244.2 DMEYLH9 FM C8H12N4O5 DMEYLH9 IC InChI=1S/C8H12N4O5/c9-6(16)7-10-2-12(11-7)8-5(15)4(14)3(1-13)17-8/h2-5,8,13-15H,1H2,(H2,9,16)/t3-,4-,5-,8-/m1/s1 DMEYLH9 CS C1=NC(=NN1[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O)C(=O)N DMEYLH9 IK IWUCXVSUMQZMFG-AFCXAGJDSA-N DMEYLH9 IU 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,4-triazole-3-carboxamide DMEYLH9 CA CAS 36791-04-5 DMEYLH9 CB CHEBI:63580 DMEYLH9 DE Hepatitis C virus infection DM9CIUW ID DM9CIUW DM9CIUW DN Ribociclib succinate DM9CIUW HS Approved DM9CIUW SN 1374639-75-4; LEE011 succinate; LEE011 (succinate); UNII-BG7HLX2919; LEE011-BBA; Ribociclib succinate [USAN]; BG7HLX2919; Kisqali (TN); Ribociclib succinate (USAN); LEE-011 succinate; SCHEMBL2684999; EX-A1586; HY-15777B; 1374639-75-4 (succinate); AKOS030526460; CS-2277; ACN-040739 DM9CIUW CP Novartis DM9CIUW DT Small molecular drug DM9CIUW PC 57334219 DM9CIUW MW 552.6 DM9CIUW FM C27H36N8O5 DM9CIUW IC InChI=1S/C23H30N8O.C4H6O4/c1-29(2)22(32)19-13-16-14-26-23(28-21(16)31(19)17-5-3-4-6-17)27-20-8-7-18(15-25-20)30-11-9-24-10-12-30;5-3(6)1-2-4(7)8/h7-8,13-15,17,24H,3-6,9-12H2,1-2H3,(H,25,26,27,28);1-2H2,(H,5,6)(H,7,8) DM9CIUW CS CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5.C(CC(=O)O)C(=O)O DM9CIUW IK NHANOMFABJQAAH-UHFFFAOYSA-N DM9CIUW IU butanedioic acid;7-cyclopentyl-N,N-dimethyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrrolo[2,3-d]pyrimidine-6-carboxamide DM9CIUW CA CAS 1374639-75-4 DM9CIUW DE Hormone receptor positive and HER2-negative advanced or metastatic breast cancer; Breast cancer DM8YMWE ID DM8YMWE DM8YMWE DN Riboflavin DM8YMWE HS Approved DM8YMWE SN riboflavin; vitamin B2; Lactoflavin; Riboflavine; Vitamin G; 83-88-5; Lactoflavine; (-)-riboflavin; Beflavine; Beflavin; Riboflavina; Flavaxin; Vitaflavine; Riboflavinum; Ribocrisina; Ribovel; Lactobene; Ribotone; Flaxain; Ribosyn; Riboderm; Ribipca; Flavin BB; Vitasan B2; Fiboflavin; Dermadram; Hyflavin; HYRE; Vitamin Bi; Aqua-Flave; 7,8-Dimethyl-10-ribitylisoalloxazine; Russupteridine Yellow III; 6,7-Dimethyl-9-D-ribitylisoalloxazine; Riboflavinequinone; Riboflavinum [INN-Latin]; Riboflavine [INN-French]; Riboflavina [INN-Spanish] DM8YMWE DT Small molecular drug DM8YMWE PC 493570 DM8YMWE MW 376.4 DM8YMWE FM C17H20N4O6 DM8YMWE IC InChI=1S/C17H20N4O6/c1-7-3-9-10(4-8(7)2)21(5-11(23)14(25)12(24)6-22)15-13(18-9)16(26)20-17(27)19-15/h3-4,11-12,14,22-25H,5-6H2,1-2H3,(H,20,26,27)/t11-,12+,14-/m0/s1 DM8YMWE CS CC1=CC2=C(C=C1C)N(C3=NC(=O)NC(=O)C3=N2)C[C@@H]([C@@H]([C@@H](CO)O)O)O DM8YMWE IK AUNGANRZJHBGPY-SCRDCRAPSA-N DM8YMWE IU 7,8-dimethyl-10-[(2S,3S,4R)-2,3,4,5-tetrahydroxypentyl]benzo[g]pteridine-2,4-dione DM8YMWE CA CAS 83-88-5 DM8YMWE CB CHEBI:17015 DM8YMWE DE Acne vulgaris DMWH9CN ID DMWH9CN DMWH9CN DN Ridogrel DMWH9CN HS Approved DMWH9CN SN Ibidel; R-68070; Ridogrel (USAN/INN); 5-[(E)-[pyridin-3-yl-[3-(trifluoromethyl)phenyl]methylidene]amino]oxypentanoic acid DMWH9CN TC Gastrointestinal Agents DMWH9CN DT Small molecular drug DMWH9CN PC 5362391 DMWH9CN MW 366.3 DMWH9CN FM C18H17F3N2O3 DMWH9CN IC InChI=1S/C18H17F3N2O3/c19-18(20,21)15-7-3-5-13(11-15)17(14-6-4-9-22-12-14)23-26-10-2-1-8-16(24)25/h3-7,9,11-12H,1-2,8,10H2,(H,24,25)/b23-17+ DMWH9CN CS C1=CC(=CC(=C1)C(F)(F)F)/C(=N\\OCCCCC(=O)O)/C2=CN=CC=C2 DMWH9CN IK GLLPUTYLZIKEGF-HAVVHWLPSA-N DMWH9CN IU 5-[(E)-[pyridin-3-yl-[3-(trifluoromethyl)phenyl]methylidene]amino]oxypentanoic acid DMWH9CN CA CAS 110140-89-1 DMWH9CN CB CHEBI:135542 DMWH9CN DE Acute myocardial infarction DM1YBHK ID DM1YBHK DM1YBHK DN Rifabutin DM1YBHK HS Approved DM1YBHK SN Alfacid; Ansamycin; Ansatipin; Ansatipine; Assatipin; Mycobutin; RBT; Rifabutina; Rifabutine; Rifabutinum; Grunenthal Brand of Rifabutin; Kenfarma Brand of Rifabutin; Pfizer Brand of Rifabutin; Rifabutin Pfizer Brand; Rifabutina [Spanish]; Rifabutine [French]; Rifabutinum [Latin]; Antibiotic LM 427; LM 427; LM427; DRG-0085; LM-427; Mycobutin (TN); Rifabutin [USAN:BAN:INN]; Rifabutin (JAN/USP/INN); Mycobutin, Ansamycin, LM 427, Ansatipine, Rifabutin; (9S,12E,14S,15R,16S,17R,18R,19R,20S,21S,22E,24Z)-6,18,20-trihydroxy-1'-isobutyl-14-methoxy-7,9,15,17,19,21,25-heptamethyl-5,10,26-trioxo-3,5,9,10-tetrahydrospiro[9,4-(epoxypentadeca[1,11,13]trienoimino)furo[2',3':7,8]naphtho[1,2-d]imidazole-2,4'-piperidin; Spiro[9,4-(epoxypentadeca[1,11,13]trienimino)-2H-furo[2',3':7,8]naphth[1,2-d]imidazole-2,4'-piperidine]-5,10,26(3H,9H)-trione, 16-(acetyloxy)-6,18,20-trihydroxy-14-methoxy-7,9,15,17,19,21,25-heptameth; 1,4-Dihydro-1-deoxy-1',4-didehydro-5'-(2-methylpropyl)-1-oxorifamycin XIV; 4-Deoxo-3,4-(2-spiro(N-isobutyl-4-piperidyl)-2,5-dihydro-1H-imidazo)-rifamycin S; 4-N-isobutylspiropiperidylrifamycin S DM1YBHK CP Adria Laboratories DM1YBHK TC Antibiotics DM1YBHK DT Small molecular drug DM1YBHK PC 135398743 DM1YBHK MW 847 DM1YBHK FM C46H62N4O11 DM1YBHK IC InChI=1S/C46H62N4O11/c1-22(2)21-50-18-16-46(17-19-50)48-34-31-32-39(54)28(8)42-33(31)43(56)45(10,61-42)59-20-15-30(58-11)25(5)41(60-29(9)51)27(7)38(53)26(6)37(52)23(3)13-12-14-24(4)44(57)47-36(40(32)55)35(34)49-46/h12-15,20,22-23,25-27,30,37-38,41,48,52-55H,16-19,21H2,1-11H3/b13-12+,20-15+,24-14-,47-36?/t23-,25+,26+,27+,30-,37-,38+,41+,45-/m0/s1 DM1YBHK CS C[C@H]1/C=C/C=C(\\C(=O)N=C2C(=C3C(=C4C2=NC5(N4)CCN(CC5)CC(C)C)C6=C(C(=C3O)C)O[C@@](C6=O)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)O)/C DM1YBHK IK ZWBTYMGEBZUQTK-PVLSIAFMSA-N DM1YBHK IU [(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,32-tetrahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-1'-(2-methylpropyl)-6,23-dioxospiro[8,33-dioxa-24,27,29-triazapentacyclo[23.6.1.14,7.05,31.026,30]tritriaconta-1(32),2,4,9,19,21,24,26,30-nonaene-28,4'-piperidine]-13-yl] acetate DM1YBHK CA CAS 72559-06-9 DM1YBHK DE Mycobacterium infection; Tuberculosis DM5DSFZ ID DM5DSFZ DM5DSFZ DN Rifampicin DM5DSFZ HS Approved DM5DSFZ SN Rifadin; Rifadine; Rifagen; Rifaldazin; Rifaldazine; Rifaldin; Rifamor; Rifampicin; Rifampicin SV; Rifampicina; Rifampicina [INN-Spanish]; Rifampicine [French]; Rifampicinum; Rifampicinum [INN-Latin]; Rifamycin AMP; Rifaprodin; Rifcin; Rifinah; Rifobac; Rifoldin; Rifoldine; Riforal; Rimactan; Rimactane; Rimactazid; Rimactizid; Rimazid; Sinerdol; Tubocin; Archidyn; Arficin; Arzide; Benemicin; Dione 21-acetate; Doloresum; Eremfat; Fenampicin; L-5103 Lepetit; rifampin; 13292-46-1; Abrifam; Ba 41166/E; R/AMP; Rifa; Rifam DM5DSFZ PC 135398735 DM5DSFZ MW 822.9 DM5DSFZ FM C43H58N4O12 DM5DSFZ IC JQXXHWHPUNPDRT-WLSIYKJHSA-N DM5DSFZ CS CC1C=CC=C(C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)C(O4)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)C=NN5CCN(CC5)C)C DM5DSFZ IK 1S/C43H58N4O12/c1-21-12-11-13-22(2)42(55)45-33-28(20-44-47-17-15-46(9)16-18-47)37(52)30-31(38(33)53)36(51)26(6)40-32(30)41(54)43(8,59-40)57-19-14-29(56-10)23(3)39(58-27(7)48)25(5)35(50)24(4)34(21)49/h11-14,19-21,23-25,29,34-35,39,49-53H,15-18H2,1-10H3,(H,45,55)/b12-11+,19-14+,22-13-,44-20+/t21-,23+,24+,25+,29-,34-,35+,39+,43-/m0/s1 DM5DSFZ IU [(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate DM5DSFZ CA CAS 13292-46-1 DM5DSFZ CB CHEBI:27470 DM5DSFZ DE Osteoporosis DMA8J1G ID DMA8J1G DMA8J1G DN Rifampin DMA8J1G HS Approved DMA8J1G SN Abrifam; Archidyn; Arficin; Arzide; Benemicin; Benemycin; Dipicin; Doloresum; Eremfat; Famcin; Fenampicin; RFP; RMP; Ramp; Rifa; Rifadin; Rifadine; Rifagen; Rifaldazin; Rifaldazine; Rifaldin; Rifam; Rifamor; Rifampicin; Rifampicina; Rifampicine; Rifampicinum; Rifamsolin; Rifaprodin; Rifcin; Rifinah; Rifobac; Rifoldin; Rifoldine; Riforal; Rimactan; Rimactane; Rimactazid; Rimactizid; Rimazid; Rimycin; Sinerdol; Tubocin; Rifamicin AMP; Rifampicin SV; Rifampicine [French]; Rifampin [USAN]; Rifamycin AMP; Ba 41166; AZT + Rifampin; BA-41166E; Ba 41166/E; DRG-0109; Dione 21-acetate; L-5103; L-5103 Lepetit; Piperine & Rifampicin; R-Cin; R/AMP; Reserpine & Rifampicin; Rifadin (TN); Rifadin I.V; Rifampicin & EEP; Rifampicin & Propolis; Rifampicina [INN-Spanish]; Rifampicinum [INN-Latin]; Rifampin (USP); Rimactan (TN); Rimactane (TN); Rimycin (TN); Sinerdol (TN); Tubocin (TN); Rifadin I.V.; Rifampicin (JP15/INN); Rifampicin[INN:BAN:JAN]; Rifadin, Rimactane, Rifampicin, Rifampin; 1-b]furan-21-yl acetate; 3-(((4-Methyl-1-piperazinyl)imino)-methyl)rifamycin; 3-(((4-Methyl-1-piperazinyl)imino)methyl)rifamycin SV; 3-(4-Methylpiperazinyliminomethyl)-rifamycin SV; 3-(4-Methylpiperazinyliminomethyl)rifamycin SV; 3-([(4-Methyl-1-piperazinyl)imino]methyl)rifamycin SV; 3-[(4-Methyl-1-piperazinyl)iminomethyl]rifamycin SV; 3-[[(4-Methyl-1-piperazinyl)imino]-methyl]rifamycin; 8-(((4-Methyl-1-piperazinyl)imino)methyl)rifamycin SV; 8-(4-Methylpiperazinyliminomethyl) rifamycin SV; 8-[[(4-Methyl-1-piperazinyl)imino[methyl]rifamycin; 8-[[(4-Methyl-1-piperazinyl)imino]methyl]rifamycin sv; 8-[[(4-Methylpiperazinyl)imino]methyl]rifamycin sv; 8CI) DMA8J1G CP Norvatis Phamaceuticals Corporation DMA8J1G TC Antituberculosis Agents DMA8J1G DT Small molecular drug DMA8J1G PC 135398735 DMA8J1G MW 822.9 DMA8J1G FM C43H58N4O12 DMA8J1G IC InChI=1S/C43H58N4O12/c1-21-12-11-13-22(2)42(55)45-33-28(20-44-47-17-15-46(9)16-18-47)37(52)30-31(38(33)53)36(51)26(6)40-32(30)41(54)43(8,59-40)57-19-14-29(56-10)23(3)39(58-27(7)48)25(5)35(50)24(4)34(21)49/h11-14,19-21,23-25,29,34-35,39,49-53H,15-18H2,1-10H3,(H,45,55)/b12-11+,19-14+,22-13-,44-20+/t21-,23+,24+,25+,29-,34-,35+,39+,43-/m0/s1 DMA8J1G CS C[C@H]1/C=C/C=C(\\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C DMA8J1G IK JQXXHWHPUNPDRT-WLSIYKJHSA-N DMA8J1G IU [(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate DMA8J1G CA CAS 13292-46-1 DMA8J1G CB CHEBI:28077 DMA8J1G DE Tuberculosis DMEH3O7 ID DMEH3O7 DMEH3O7 DN Rifamycin DMEH3O7 HS Approved DMEH3O7 SN Rifamycin SV; Rifamycin SV MMX; Rifamycin sodium; CB-01-11; Rifamycin (oral controlled-release, gastrointestinal-specific); Rifamycin (oral controlled-release, gastrointestinal-specific), Cosmo/Dr Falk/Santarus DMEH3O7 CP Cosmo Technologies DMEH3O7 DT Small molecular drug DMEH3O7 PC 6324616 DMEH3O7 MW 697.8 DMEH3O7 FM C37H47NO12 DMEH3O7 IC InChI=1S/C37H47NO12/c1-16-11-10-12-17(2)36(46)38-23-15-24(40)26-27(32(23)44)31(43)21(6)34-28(26)35(45)37(8,50-34)48-14-13-25(47-9)18(3)33(49-22(7)39)20(5)30(42)19(4)29(16)41/h10-16,18-20,25,29-30,33,40-44H,1-9H3,(H,38,46)/b11-10+,14-13+,17-12-/t16-,18+,19+,20+,25-,29-,30+,33+,37-/m0/s1 DMEH3O7 CS C[C@H]1/C=C/C=C(\\C(=O)NC2=CC(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C DMEH3O7 IK HJYYPODYNSCCOU-ODRIEIDWSA-N DMEH3O7 IU [(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate DMEH3O7 CA CAS 6998-60-3 DMEH3O7 CB CHEBI:29673 DMEH3O7 DE Diarrhea; Infectious disease DMCHV4I ID DMCHV4I DMCHV4I DN Rifapentine DMCHV4I HS Approved DMCHV4I SN RIFAPENTINE; Rifapentina; Rifapentinum; Cyclopentylrifampicin; Rifamycin AF/ACPP; Antibiotic DL 473IT; KTC 1; 61379-65-5; MDL 473; DRG-0283; DL 473; R-773; R 77-3; 3-(N-(4-Cyclopentyl-1-piperazinyl)formimidoyl)rifamycin; 3-(4-Cyclopentyl-1-piperazinyl)iminomethylrifamycin SV; 3-(((4-Cyclopentyl-1-piperazinyl)imino)methyl)rifamycin; Rifapentin,(S); NCGC00167431-01; ZINC169621228; NCGC00167431-03; AN-15578; RPE DMCHV4I CP Sanofi-Aventis DMCHV4I TC Antituberculosis Agents DMCHV4I DT Small molecular drug DMCHV4I PC 135403821 DMCHV4I MW 877 DMCHV4I FM C47H64N4O12 DMCHV4I IC InChI=1S/C47H64N4O12/c1-24-13-12-14-25(2)46(59)49-37-32(23-48-51-20-18-50(19-21-51)31-15-10-11-16-31)41(56)34-35(42(37)57)40(55)29(6)44-36(34)45(58)47(8,63-44)61-22-17-33(60-9)26(3)43(62-30(7)52)28(5)39(54)27(4)38(24)53/h12-14,17,22-24,26-28,31,33,38-39,43,53-57H,10-11,15-16,18-21H2,1-9H3,(H,49,59)/b13-12+,22-17+,25-14-,48-23+/t24-,26+,27+,28+,33-,38-,39+,43+,47-/m0/s1 DMCHV4I CS C[C@H]1/C=C/C=C(\\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C6CCCC6)/C DMCHV4I IK WDZCUPBHRAEYDL-GZAUEHORSA-N DMCHV4I IU [(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-26-[(E)-(4-cyclopentylpiperazin-1-yl)iminomethyl]-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate DMCHV4I CA CAS 61379-65-5 DMCHV4I CB CHEBI:45304 DMCHV4I DE Tuberculosis; Macular degeneration DMW1TV2 ID DMW1TV2 DMW1TV2 DN Rifaximin DMW1TV2 HS Approved DMW1TV2 SN RCIFAX; Rifaximin (bioadhesive/ gastrointestinal extended release); Rifaximin (bioadhesive/ gastrointestinal extended release), Salix Pharmaceuticals DMW1TV2 CP Salix Pharmaceuticals Ltd DMW1TV2 DT Small molecular drug DMW1TV2 PC 6436173 DMW1TV2 MW 785.9 DMW1TV2 FM C43H51N3O11 DMW1TV2 IC InChI=1S/C43H51N3O11/c1-19-14-16-46-28(18-19)44-32-29-30-37(50)25(7)40-31(29)41(52)43(9,57-40)55-17-15-27(54-10)22(4)39(56-26(8)47)24(6)36(49)23(5)35(48)20(2)12-11-13-21(3)42(53)45-33(34(32)46)38(30)51/h11-18,20,22-24,27,35-36,39,48-51H,1-10H3,(H,45,53)/b12-11+,17-15+,21-13-/t20-,22+,23+,24+,27-,35-,36+,39+,43-/m0/s1 DMW1TV2 CS C[C@H]1/C=C/C=C(\\C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)O[C@@](C4=O)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)/C DMW1TV2 IK NZCRJKRKKOLAOJ-XRCRFVBUSA-N DMW1TV2 IU [(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,36-tetrahydroxy-11-methoxy-3,7,12,14,16,18,22,30-octamethyl-6,23-dioxo-8,37-dioxa-24,27,33-triazahexacyclo[23.10.1.14,7.05,35.026,34.027,32]heptatriaconta-1(35),2,4,9,19,21,25(36),26(34),28,30,32-undecaen-13-yl] acetate DMW1TV2 CA CAS 80621-81-4 DMW1TV2 CB CHEBI:75246 DMW1TV2 DE Bacterial infection DM13PQW ID DM13PQW DM13PQW DN Rilmenidine DM13PQW HS Approved DM13PQW SN Rilmenidine phosphate; 85409-38-7; Rilmenidine dihydrogen phosphate; UNII-59QD64Q32M; EINECS 287-106-2; 59QD64Q32M; S 3341-3; 4,5-Dihydro-N-(dicyclopropylmethyl)-2-oxazolamine phosphate (1:1); 2-Oxazolamine, 4,5-dihydro-N-(dicyclopropylmethyl)-, phosphate (1:1); (Dicyclopropylmethyl)(4,5-dihydro-2-oxazolyl)ammonium dihydrogen phosphate; W-104082; 2-Oxazolamine, N-(dicyclopropylmethyl)-4,5-dihydro-, phosphate (1:1); N-(dicyclopropylmethyl)-4,5-dihydrooxazol-2-amine; phosphoric acid DM13PQW DT Small molecular drug DM13PQW PC 68712 DM13PQW MW 180.25 DM13PQW FM C10H16N2O DM13PQW IC InChI=1S/C10H16N2O/c1-2-7(1)9(8-3-4-8)12-10-11-5-6-13-10/h7-9H,1-6H2,(H,11,12) DM13PQW CS C1CC1C(C2CC2)NC3=NCCO3 DM13PQW IK CQXADFVORZEARL-UHFFFAOYSA-N DM13PQW IU N-(dicyclopropylmethyl)-4,5-dihydro-1,3-oxazol-2-amine DM13PQW CA CAS 54187-04-1 DM13PQW CB CHEBI:8862 DM13PQW DE Hypertension DMGLUQS ID DMGLUQS DMGLUQS DN Rilonacept DMGLUQS HS Approved DMGLUQS SN Rilonacept (USAN/INN) DMGLUQS CP Regeneron DMGLUQS SQ 8750_M|rilonacept|Homo sapiens||FUSION-IL1RAP-IL1R1-GAMMA-1 (IL1RAP+(Pr21-359)(1-339)+IL1R1+(Pr22-333)(340-651)+HINGE-REGION(652-663)+CH2(664-773)+CH3(774-880))|||||||880||||MW 100630.6|MW 100630.6|: SERCDDWGLDTMRQIQVFEDEPARIKCPLFEHFLKFNYSTAHSAGLTLIWYWTRQDRDLEEPINFRLPENRISKEKDVLWFRPTLLNDTGNYTCMLRNTTYCSKVAFPLEVVQKDSCFNSPMKLPVHKLYIEYGIQRITCPNVDGYFPSSVKPTITWYMGCYKIQNFNNVIPEGMNLSFLIALISNNGNYTCVVTYPENGRTFHLTRTLTVKVVGSPKNAVPPVIHSPNDHVVYEKEPGEELLIPCTVYFSFLMDSRNEVWWTIDGKKPDDITIDVTINESISHSRTEDETRTQILSIKKVTSEDLKRSYVCHARSAKGEVAKAAKVKQKVPAPRYTVEKCKEREEKIILVSSANEIDVRPCPLNPNEHKGTITWYKDDSKTPVSTEQASRIHQHKEKLWFVPAKVEDSGHYYCVVRNSSYCLRIKISAKFVENEPNLCYNAQAIFKQKLPVAGDGGLVCPYMEFFKNENNELPKLQWYKDCKPLLLDNIHFSGVKDRLIVMNVAEKHRGNYTCHASYTYLGKQYPITRVIEFITLEENKPTRPVIVSPANETMEVDLGSQIQLICNVTGQLSDIAYWKWNGSVIDEDDPVLGEDYYSVENPANKRRSTLITVLNISEIESRFYKHPFTCFAKNTHGIDAAYIQLIYPVTNSGDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK DMGLUQS DE Arthritis; Acute gout flare DMJ0QOW ID DMJ0QOW DMJ0QOW DN Rilpivirine DMJ0QOW HS Approved DMJ0QOW SN 500287-72-9; TMC278; Edurant; TMC 278; UNII-FI96A8X663; R278474; TMC-278; 4-{[4-({4-[(E)-2-Cyanoethenyl]-2,6-Dimethylphenyl}amino)pyrimidin-2-Yl]amino}benzonitrile; CHEBI:68606; FI96A8X663; R 278474; 4-{[4-({4-[(E)-2-cyanovinyl]-2,6-dimethylphenyl}amino)pyrimidin-2-yl]amino}benzonitrile; (E)-4-((4-((4-(2-cyanovinyl)-2,6-dimethylphenyl)amino)pyrimidin-2-yl)amino)benzonitrile; (E)-4-(4-(4-(2-cyanovinyl)-2,6-dimethylphenylamino)pyrimidin-2-ylamino)benzonitrile; W-202888; RPV; Mu O-conotoxin DMJ0QOW DT Small molecular drug DMJ0QOW PC 6451164 DMJ0QOW MW 366.4 DMJ0QOW FM C22H18N6 DMJ0QOW IC InChI=1S/C22H18N6/c1-15-12-18(4-3-10-23)13-16(2)21(15)27-20-9-11-25-22(28-20)26-19-7-5-17(14-24)6-8-19/h3-9,11-13H,1-2H3,(H2,25,26,27,28)/b4-3+ DMJ0QOW CS CC1=CC(=CC(=C1NC2=NC(=NC=C2)NC3=CC=C(C=C3)C#N)C)/C=C/C#N DMJ0QOW IK YIBOMRUWOWDFLG-ONEGZZNKSA-N DMJ0QOW IU 4-[[4-[4-[(E)-2-cyanoethenyl]-2,6-dimethylanilino]pyrimidin-2-yl]amino]benzonitrile DMJ0QOW CA CAS 500287-72-9 DMJ0QOW CB CHEBI:68606 DMJ0QOW DE Human immunodeficiency virus infection; Pain DMECBWN ID DMECBWN DMECBWN DN Riluzole DMECBWN HS Approved DMECBWN SN Rilutek; Riluzol; Riluzolum; Riluzole HCl; RP 54274; ALBB-006046; BF-37; PK-26124; R-116; RP-54274; Rilutek (TN); Riluzol [INN-Spanish]; Riluzole [USAN:INN]; Riluzolum [INN-Latin]; ZERO/001785; Amino-2 trifluoromethoxy-6 benzothiazole; Amino-2 trifluoromethoxy-6 benzothiazole [French]; Riluzole (JAN/USAN/INN); PK-26124, RP-54274, Rilutek, Riluzole; 2-Amino-6-(trifluoromethoxy)-benzothiazole; 2-Amino-6-(trifluoromethoxy)benzothiazole; 2-Amino-6-trifluoro-methoxybenzothiazole; 2-amino-6-(trifluoromethoxy)-1,3-benzothiazole; 2-amino-6-(trifluoromethoxy)benzo[d]thiazole; 2-amino-6-(trifluoromethoxyl)benzothiazole; 2-amino-6-trifluoromethoxybenzothiazole; 6-(trifluoromethoxy)-1,3-benzothiazol-2-amine; 6-(trifluoromethoxy)benzo[d]thiazol-2-amine; 6-Trifluoromethoxy-benzothiazol-2-ylamine; 6-trifluoromethoxybenzothiazole-2-yl-amine DMECBWN CP Sanofi-Aventis DMECBWN TC Anticonvulsants DMECBWN DT Small molecular drug DMECBWN PC 5070 DMECBWN MW 234.2 DMECBWN FM C8H5F3N2OS DMECBWN IC InChI=1S/C8H5F3N2OS/c9-8(10,11)14-4-1-2-5-6(3-4)15-7(12)13-5/h1-3H,(H2,12,13) DMECBWN CS C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N DMECBWN IK FTALBRSUTCGOEG-UHFFFAOYSA-N DMECBWN IU 6-(trifluoromethoxy)-1,3-benzothiazol-2-amine DMECBWN CA CAS 1744-22-5 DMECBWN CB CHEBI:8863 DMECBWN DE Amyotrophic lateral sclerosis DM5DWMU ID DM5DWMU DM5DWMU DN Rimantadine DM5DWMU HS Approved DM5DWMU SN Remantadine; Riamantadine; Rimant; Rimantadina; Rimantadinum; Enamine_005755; Alpha-Methyladamantanemethylamine; Flumadine (TN); Rimantadina [INN-Spanish]; Rimantadine (INN); Rimantadine [INN:BAN]; Rimantadinum [INN-Latin]; Alpha-Methyl-1-adamantanemethylamine; Rimant & .alpha. IFN; Rimantidine & .alpha.IFN; Tricyclo(3.3.1.1^3,7)decane-1-methanamine, .alpha.-methyl-& IFN.alpha; 1-(1-Adamantyl)ethanamine; 1-(1-Adamantyl)ethylamin; 1-(1-adamantyl)-ethylamine; 1-(1-adamantyl)ethylamine; 1-(adamantan-1-yl)ethan-1-amine; 1-(tricyclo[3.3.1.1~3,7~]dec-1-yl)ethanamine; 1-Adamantan-1-yl-ethylamine; 1-Adamantan-1-ylethylamine; 1-tricyclo[3.3.1.1~3,7~]dec-1-ylethanamine DM5DWMU CP Forest Laboratories Inc DM5DWMU TC Antiviral Agents DM5DWMU DT Small molecular drug DM5DWMU PC 5071 DM5DWMU MW 179.3 DM5DWMU FM C12H21N DM5DWMU IC InChI=1S/C12H21N/c1-8(13)12-5-9-2-10(6-12)4-11(3-9)7-12/h8-11H,2-7,13H2,1H3 DM5DWMU CS CC(C12CC3CC(C1)CC(C3)C2)N DM5DWMU IK UBCHPRBFMUDMNC-UHFFFAOYSA-N DM5DWMU IU 1-(1-adamantyl)ethanamine DM5DWMU CA CAS 13392-28-4 DM5DWMU CB CHEBI:94440 DM5DWMU DE Influenza A virus infection DMHOAUG ID DMHOAUG DMHOAUG DN Rimegepant DMHOAUG HS Approved DMHOAUG SN BMS-927711; 1289023-67-1; UNII-997WVV895X; BMS 927711; CHEMBL2178422; 997WVV895X; (5S,6S,9R)-5-Amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl 4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate; Rimegepant [USAN:INN]; Rimegepant (USAN/INN); SCHEMBL1670580; DTXSID70156003; C28H28F2N6O3; EX-A1922; 3504AH; ZINC68267814; BDBM50400098; AKOS030526382; DB12457; CS-1027; NCGC00378677-01; HY-15498; KB-145921; W-5991 DMHOAUG CP Labrys Biologics DMHOAUG DT Small molecular drug DMHOAUG PC 51049968 DMHOAUG MW 534.6 DMHOAUG FM C28H28F2N6O3 DMHOAUG IC InChI=1S/C28H28F2N6O3/c29-20-6-1-4-17(23(20)30)18-8-9-22(25-19(24(18)31)5-2-12-32-25)39-28(38)35-14-10-16(11-15-35)36-21-7-3-13-33-26(21)34-27(36)37/h1-7,12-13,16,18,22,24H,8-11,14-15,31H2,(H,33,34,37)/t18-,22+,24-/m0/s1 DMHOAUG CS C1C[C@H](C2=C(C=CC=N2)[C@H]([C@@H]1C3=C(C(=CC=C3)F)F)N)OC(=O)N4CCC(CC4)N5C6=C(NC5=O)N=CC=C6 DMHOAUG IK KRNAOFGYEFKHPB-ANJVHQHFSA-N DMHOAUG IU [(5S,6S,9R)-5-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl] 4-(2-oxo-3H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate DMHOAUG CA CAS 1289023-67-1 DMHOAUG DE Migraine DMTAREC ID DMTAREC DMTAREC DN Rimexolone DMTAREC HS Approved DMTAREC SN Rimexolone (sustained release intra-articular steroid suspension, Plexis, arthritis) DMTAREC CP Auritec Pharmaceuticals Inc DMTAREC DT Small molecular drug DMTAREC PC 5311412 DMTAREC MW 370.5 DMTAREC FM C24H34O3 DMTAREC IC InChI=1S/C24H34O3/c1-6-20(27)24(5)14(2)11-18-17-8-7-15-12-16(25)9-10-22(15,3)21(17)19(26)13-23(18,24)4/h9-10,12,14,17-19,21,26H,6-8,11,13H2,1-5H3/t14-,17+,18+,19+,21-,22+,23+,24-/m1/s1 DMTAREC CS CCC(=O)[C@]1([C@@H](C[C@@H]2[C@@]1(C[C@@H]([C@H]3[C@H]2CCC4=CC(=O)C=C[C@]34C)O)C)C)C DMTAREC IK QTTRZHGPGKRAFB-OOKHYKNYSA-N DMTAREC IU (8S,9S,10R,11S,13S,14S,16R,17S)-11-hydroxy-10,13,16,17-tetramethyl-17-propanoyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one DMTAREC CA CAS 49697-38-3 DMTAREC CB CHEBI:135566 DMTAREC DE Arthritis DMA47C6 ID DMA47C6 DMA47C6 DN Rimiterol DMA47C6 HS Approved DMA47C6 SN Rimiterol Hydrobromide; EINECS 250-834-6; WG-253; 31842-61-2; R 798; (R*,S*)-4-(Hydroxypiperidin-2-ylmethyl)pyrocatechol hydrobromide; erythro-alpha-(3,4-Dihydroxyphenyl)-2-piperidinemethanol hydrobromide; 4-[(S)-hydroxy-[(2R)-piperidin-2-yl]methyl]benzene-1,2-diol hydrobromide; 2-Piperidinemethanol, alpha-(3,4-dihydroxyphenyl)-, (R*,S*)-, hydrobromide; API0025612; UNII-I29DRR8S3R component QPYZEEKXUYXZBK-PKKHVXKMSA-N; 1,2-Benzenediol, 4-(hydroxy-2-piperidinylmethyl)-, hydrobromide, (R*,S*)- (9CI) DMA47C6 DT Small molecular drug DMA47C6 PC 36283 DMA47C6 MW 223.27 DMA47C6 FM C12H17NO3 DMA47C6 IC InChI=1S/C12H17NO3/c14-10-5-4-8(7-11(10)15)12(16)9-3-1-2-6-13-9/h4-5,7,9,12-16H,1-3,6H2/t9-,12+/m1/s1 DMA47C6 CS C1CCN[C@H](C1)[C@H](C2=CC(=C(C=C2)O)O)O DMA47C6 IK IYMMESGOJVNCKV-SKDRFNHKSA-N DMA47C6 IU 4-[(S)-hydroxy-[(2R)-piperidin-2-yl]methyl]benzene-1,2-diol DMA47C6 CA CAS 32953-89-2 DMA47C6 DE Asthma DMXBLMP ID DMXBLMP DMXBLMP DN Riociguat DMXBLMP HS Approved DMXBLMP SN Riociguat; 625115-55-1; Adempas; Riociguat (BAY 63-2521); BAY 63-2521; riociguatum; UNII-RU3FE2Y4XI; RU3FE2Y4XI; CHEBI:76018; Methyl (4,6-diamino-2-(1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)pyrimidin-5-yl)(methyl)carbamate; Methyl N-(4,6-diamino-2-{1-((2-fluorophenyl)methyl)-1H-pyrazolo(3,4-b)pyridin-3-yl}pyrimidin-5-yl)-N-methylcarbamate; N-[4,6-Diamino-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-pyrimidinyl]-N-methylcarbamic acid methyl ester DMXBLMP CP Bayer HealthCare Pharmaceuticals DMXBLMP DT Small molecular drug DMXBLMP PC 11304743 DMXBLMP MW 422.4 DMXBLMP FM C20H19FN8O2 DMXBLMP IC InChI=1S/C20H19FN8O2/c1-28(20(30)31-2)15-16(22)25-18(26-17(15)23)14-12-7-5-9-24-19(12)29(27-14)10-11-6-3-4-8-13(11)21/h3-9H,10H2,1-2H3,(H4,22,23,25,26) DMXBLMP CS CN(C1=C(N=C(N=C1N)C2=NN(C3=C2C=CC=N3)CC4=CC=CC=C4F)N)C(=O)OC DMXBLMP IK WXXSNCNJFUAIDG-UHFFFAOYSA-N DMXBLMP IU methyl N-[4,6-diamino-2-[1-[(2-fluorophenyl)methyl]pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl]-N-methylcarbamate DMXBLMP CA CAS 625115-55-1 DMXBLMP CB CHEBI:76018 DMXBLMP DE Pulmonary arterial hypertension DM958QB ID DM958QB DM958QB DN Ripretinib DM958QB HS Approved DM958QB SN 1442472-39-0; Ripretinib [USAN]; UNII-9XW757O13D; GTPL9175; SCHEMBL14999718; 9XW757O13D; HY-112306; CS-0044835; N-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-N'-phenylurea; 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea; Urea, N-(4-bromo-5-(1-ethyl-1,2-dihydro-7-(methylamino)-2-oxo-1,6-naphthyridin-3-yl)-2-fluorophenyl)-N'-phenyl- DM958QB CP Deciphera Pharmaceuticals Waltham, MA DM958QB PC 71584930 DM958QB MW 510.4 DM958QB FM C24H21BrFN5O2 DM958QB IC InChI=1S/C24H21BrFN5O2/c1-3-31-21-12-22(27-2)28-13-14(21)9-17(23(31)32)16-10-20(19(26)11-18(16)25)30-24(33)29-15-7-5-4-6-8-15/h4-13H,3H2,1-2H3,(H,27,28)(H2,29,30,33) DM958QB CS CCN1C2=CC(=NC=C2C=C(C1=O)C3=CC(=C(C=C3Br)F)NC(=O)NC4=CC=CC=C4)NC DM958QB IK CEFJVGZHQAGLHS-UHFFFAOYSA-N DM958QB IU 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea DM958QB CA CAS 1442472-39-0 DM958QB DE Glioma; Solid tumour/cancer; Systemic mastocytosis; Gastrointestinal stromal tumour DMM32GT ID DMM32GT DMM32GT DN Risankizumab DMM32GT HS Approved DMM32GT CP AbbVie North Chicago, IL Boehringer Ingelheim Pharmaceuticals Ridgefield, CT DMM32GT DE Psoriatic arthritis; Plaque psoriasis DMIMF8J ID DMIMF8J DMIMF8J DN Risdiplam DMIMF8J HS Approved DMIMF8J SN UNII-76RS4S2ET1; 76RS4S2ET1; 1825352-65-5; Risdiplam [INN]; SCHEMBL17260852; EX-A2074; RG-7916; HY-109101; RO7034067; CS-0039501; 4H-Pyrido(1,2-a)pyrimidin-4-one, 7-(4,7-diazaspiro(2.5)oct-7-yl)-2-(2,8-dimethylimidazo(1,2-b)pyridazin-6-yl)-; 2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-7-(4,7-diazaspiro[2.5]octan-7-yl)-4H-pyrido[1,2-a]pyrimidin-4-one DMIMF8J CP PTC Therapeutics South Plainfield, NJ Roche Basel, Switzerland DMIMF8J PC 118513932 DMIMF8J MW 401.5 DMIMF8J FM C22H23N7O DMIMF8J IC InChI=1S/C22H23N7O/c1-14-9-18(26-29-11-15(2)24-21(14)29)17-10-20(30)28-12-16(3-4-19(28)25-17)27-8-7-23-22(13-27)5-6-22/h3-4,9-12,23H,5-8,13H2,1-2H3 DMIMF8J CS CC1=CC(=NN2C1=NC(=C2)C)C3=CC(=O)N4C=C(C=CC4=N3)N5CCNC6(C5)CC6 DMIMF8J IK ASKZRYGFUPSJPN-UHFFFAOYSA-N DMIMF8J IU 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one DMIMF8J CA CAS 1825352-65-5 DMIMF8J DE Spinal muscular atrophy DM5FLTY ID DM5FLTY DM5FLTY DN Risedronate DM5FLTY HS Approved DM5FLTY SN Risedronic acid; 105462-24-6; Actonel; Atelvia; Acido risedronico; Acidum risedronicum; Benet; Risedronic acid [INN:BAN]; Acidum risedronicum [INN-Latin]; Acido risedronico [INN-Spanish]; Acide risedronique [INN-French]; Risedronic acid monohydrate; NE-58095; UNII-KM2Z91756Z; C7H11NO7P2; NE 58019; HSDB 7326; [1-hydroxy-1-phosphono-2-(pyridin-3-yl)ethyl]phosphonic acid; (1-hydroxy-1-phosphono-2-pyridin-3-yl-ethyl)phosphonic acid; Risedronic acid (Actonel); CHEMBL923; CHEBI:8869; Phosphonic acid,; Benet; RIS; Ridron; Acide risedronique; Bisphosphonate 1; Actonel (TN); Ridron (TN); Risedronic acid (INN); (1-Hydroxy-2-(3-pyridyl)ethylidene)diphosphonic acid; (1-hydroxy-1-phosphono-2-pyridin-3-ylethyl)phosphonic acid; (1-hydroxy-2-pyridin-3-ylethane-1,1-diyl)bis(phosphonic acid); 1-HYDROXY-2-(3-PYRIDINYL)ETHYLIDENE BIS-PHOSPHONIC ACID DM5FLTY CP Procter & Gamble; Sanofi-Aventis DM5FLTY TC Bone Density Conservation Agents DM5FLTY DT Small molecular drug DM5FLTY PC 5245 DM5FLTY MW 283.11 DM5FLTY FM C7H11NO7P2 DM5FLTY IC InChI=1S/C7H11NO7P2/c9-7(16(10,11)12,17(13,14)15)4-6-2-1-3-8-5-6/h1-3,5,9H,4H2,(H2,10,11,12)(H2,13,14,15) DM5FLTY CS C1=CC(=CN=C1)CC(O)(P(=O)(O)O)P(=O)(O)O DM5FLTY IK IIDJRNMFWXDHID-UHFFFAOYSA-N DM5FLTY IU (1-hydroxy-1-phosphono-2-pyridin-3-ylethyl)phosphonic acid DM5FLTY CA CAS 105462-24-6 DM5FLTY CB CHEBI:8869 DM5FLTY DE Paget's disease DMN6DXL ID DMN6DXL DMN6DXL DN Risperidone DMN6DXL HS Approved DMN6DXL SN Belivon; Risperdal; Risperdone; Risperidal; Risperidona; Risperidonum; Risperin; Rispolept; Rispolin; Sequinan; Risperdal Consta; Risperidona [Spanish]; Risperidonum [Latin]; R 62 766; R 64766; R64766; Consta, Risperdal; KS-1106; R 64,766; R-118; R-64766; R64,766; Risperdal (TN); Risperdal M-Tab; Risperidal M-Tab; Risperidone (RIS); Risperidone, placebo; R 64 766, Risperdal, Risperidone; R-64,766; R-64-766; Risperidone [USAN:BAN:INN]; Risperidone (JAN/USAN/INN); 3-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)ethyl)-6,7,8,9-tetrahydro-2-methyl-4H-pyrido(1,2-a)pyrimidin-4-one; 3-[2-[-4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one; 3-[2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido [1,2-a] pyrimidin-4-one; 3-[2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperi-dino]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]-pyrimidin-4-one; 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one; 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one; 3-{2-[4-(6-Fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl}-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one; 3-{2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)piperidin-1-yl]ethyl}-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one; 3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one DMN6DXL CP Janssen-Cilag DMN6DXL TC Antipsychotic Agents DMN6DXL DT Small molecular drug DMN6DXL PC 5073 DMN6DXL MW 410.5 DMN6DXL FM C23H27FN4O2 DMN6DXL IC InChI=1S/C23H27FN4O2/c1-15-18(23(29)28-10-3-2-4-21(28)25-15)9-13-27-11-7-16(8-12-27)22-19-6-5-17(24)14-20(19)30-26-22/h5-6,14,16H,2-4,7-13H2,1H3 DMN6DXL CS CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F DMN6DXL IK RAPZEAPATHNIPO-UHFFFAOYSA-N DMN6DXL IU 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one DMN6DXL CB CHEBI:8871 DMN6DXL DE Schizophrenia DM4V6RL ID DM4V6RL DM4V6RL DN Ritodrine DM4V6RL HS Approved DM4V6RL SN Prepar; Ritodrina; Ritodrinium; Utopar; Yutopar; RITODRINE HCL; DU-21220; Ritodrina [INN-Spanish]; Ritodrinium [INN-Latin]; Yutopar (TN); Yutopar S.R; Ritodrine (USAN/INN); Ritodrine [USAN:BAN:INN]; P-Hydroxy-alpha-(1-((p-hydroxyphenethyl)amino)ethyl)benzyl alcohol; Erythro-p-Hydroxy-alpha-(1-((p-hydroxyphenethyl)amino)ethyl)benzyl alcohol; 2-(4-Hydroxyphenethylamino)-1-(4-hydroxyphenyl)propanol; 4-[2-[[(1R,2R)-1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]phenol; 4-[2-[[(1R,2S)-1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]phenol; 4-[2-[[(1S,2R)-1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]phenol; 4-[2-[[(1S,2S)-1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]phenol; 4-[2-[[1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]phenol DM4V6RL TC Sympathomimetics DM4V6RL DT Small molecular drug DM4V6RL PC 33572 DM4V6RL MW 287.35 DM4V6RL FM C17H21NO3 DM4V6RL IC InChI=1S/C17H21NO3/c1-12(17(21)14-4-8-16(20)9-5-14)18-11-10-13-2-6-15(19)7-3-13/h2-9,12,17-21H,10-11H2,1H3/t12-,17-/m0/s1 DM4V6RL CS C[C@@H]([C@@H](C1=CC=C(C=C1)O)O)NCCC2=CC=C(C=C2)O DM4V6RL IK IOVGROKTTNBUGK-SJCJKPOMSA-N DM4V6RL IU 4-[2-[[(1R,2S)-1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]phenol DM4V6RL CA CAS 26652-09-5 DM4V6RL CB CHEBI:8872 DM4V6RL DE Premature labour DMU764S ID DMU764S DMU764S DN Ritonavir DMU764S HS Approved DMU764S SN Norvir; RIT; RTV; Norvir Sec; Ritonavir [USAN]; ABT 538; ABT 84538; ABT538; Abbott 84538; A-84538; ABBOTT-84538; ABT-538; DRG-0244; Norvir (TM); Norvir (TN); Ritonavir (JAN/USAN/INN); N-[(2S,4S,5S)-4-hydroxy-1,6-diphenyl-5-{[(1,3-thiazol-5-ylmethoxy)carbonyl]amino}hexan-2-yl]-N~2~-(methyl{[2-(propan-2-yl)-1,3-thiazol-4-yl]methyl}carbamoyl)-L-valinamide; 1,3-thiazol-5-ylmethyl N-[(2S,3S,5S)-3-hydroxy-5-[[(2S)-3-methyl-2-[[methyl-[(2-propan-2-yl-1,3-thiazol-4-yl)methyl]carbamoyl]amino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate; 5-Thiazolylmethyl ((alphaS)-alpha-((1S,3S)-1-hydroxy-3-((2S)-2-(3-((2-isopropyl-4-thiazolyl)methyl)-3-methylureido)-3-methylbutyramido)-4-phenylbutyl)phenethyl)carbamate; 5-Thiazolylmethyl ((alphaS)-alpha-((1S,3S-1-hydroxy-3-((2S)-2-(3-((2-isopropyl-4-thiazolyl)methyl)-3-methylureido)-3-methylbutyramido)-4-phenylbutyl)phenethyl)carbamate; 538, ABT DMU764S CP Abbott Laboratories DMU764S TC Anti-HIV Agents DMU764S DT Small molecular drug DMU764S PC 392622 DMU764S MW 720.9 DMU764S FM C37H48N6O5S2 DMU764S IC InChI=1S/C37H48N6O5S2/c1-24(2)33(42-36(46)43(5)20-29-22-49-35(40-29)25(3)4)34(45)39-28(16-26-12-8-6-9-13-26)18-32(44)31(17-27-14-10-7-11-15-27)41-37(47)48-21-30-19-38-23-50-30/h6-15,19,22-25,28,31-33,44H,16-18,20-21H2,1-5H3,(H,39,45)(H,41,47)(H,42,46)/t28-,31-,32-,33-/m0/s1 DMU764S CS CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O DMU764S IK NCDNCNXCDXHOMX-XGKFQTDJSA-N DMU764S IU 1,3-thiazol-5-ylmethyl N-[(2S,3S,5S)-3-hydroxy-5-[[(2S)-3-methyl-2-[[methyl-[(2-propan-2-yl-1,3-thiazol-4-yl)methyl]carbamoyl]amino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate DMU764S CA CAS 155213-67-5 DMU764S CB CHEBI:45409 DMU764S DE Human immunodeficiency virus infection DM1YVZT ID DM1YVZT DM1YVZT DN Rituximab DM1YVZT HS Approved DM1YVZT CP Genentech DM1YVZT DT Antibody DM1YVZT DE Non-hodgkin lymphoma; Pemphigus vulgaris DMBUH26 ID DMBUH26 DMBUH26 DN Rituximab DMBUH26 HS Approved DMBUH26 SN MAbThera (TN) DMBUH26 CP Roche DMBUH26 TC Anticancer Agents DMBUH26 DT Antibody DMBUH26 SQ Rituximab heavy chain chimeric: QVQLQQPGAELVKPGASVKMSCKASGYTFTSYNMHWVKQTPGRGLEWIGAIYPGNGDTSYNQKFKGKATLTADKSSSTAYMQLSSLTSEDSAVYYCARSTYYGGDWYFNVWGAGTTVTVSAASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKAEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK >Rituximab light chain chimericQIVLSQSPAILSASPGEKVTMTCRASSSVSYIHWFQQKPGSSPKPWIYATSNLASGVPVRFSGSGSGTSYSLTISRVEAEDAATYYCQQWTSNPPTFGGGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC DMBUH26 DE Non-hodgkin lymphoma; Haematological malignancy DMQMBZ1 ID DMQMBZ1 DMQMBZ1 DN Rivaroxaban DMQMBZ1 HS Approved DMQMBZ1 SN XARELTO (TN) DMQMBZ1 CP Bayer HealthCare Pharmaceuticals; Johnson & Johnson Pharmaceutical Research & Development DMQMBZ1 DT Small molecular drug DMQMBZ1 PC 9875401 DMQMBZ1 MW 435.9 DMQMBZ1 FM C19H18ClN3O5S DMQMBZ1 IC InChI=1S/C19H18ClN3O5S/c20-16-6-5-15(29-16)18(25)21-9-14-10-23(19(26)28-14)13-3-1-12(2-4-13)22-7-8-27-11-17(22)24/h1-6,14H,7-11H2,(H,21,25)/t14-/m0/s1 DMQMBZ1 CS C1COCC(=O)N1C2=CC=C(C=C2)N3C[C@@H](OC3=O)CNC(=O)C4=CC=C(S4)Cl DMQMBZ1 IK KGFYHTZWPPHNLQ-AWEZNQCLSA-N DMQMBZ1 IU 5-chloro-N-[[(5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl]methyl]thiophene-2-carboxamide DMQMBZ1 CA CAS 366789-02-8 DMQMBZ1 CB CHEBI:68579 DMQMBZ1 DE Deep vein thrombosis DMG629M ID DMG629M DMG629M DN Rivastigmine DMG629M HS Approved DMG629M SN Rivastigmine (transdermal patch) DMG629M CP Samyang Corp DMG629M DT Small molecular drug DMG629M PC 77991 DMG629M MW 250.34 DMG629M FM C14H22N2O2 DMG629M IC InChI=1S/C14H22N2O2/c1-6-16(5)14(17)18-13-9-7-8-12(10-13)11(2)15(3)4/h7-11H,6H2,1-5H3/t11-/m0/s1 DMG629M CS CCN(C)C(=O)OC1=CC=CC(=C1)[C@H](C)N(C)C DMG629M IK XSVMFMHYUFZWBK-NSHDSACASA-N DMG629M IU [3-[(1S)-1-(dimethylamino)ethyl]phenyl] N-ethyl-N-methylcarbamate DMG629M CA CAS 123441-03-2 DMG629M CB CHEBI:8874 DMG629M DE Alzheimer disease DMDJMA3 ID DMDJMA3 DMDJMA3 DN Rizatriptan DMDJMA3 HS Approved DMDJMA3 SN Risatriptan; Rizatriptanum; Rizatriptan benzoat; MK 462 free base; Maxalt (TN); Rizaliv (TN); Rizalt (TN); Rizatriptan (INN); Rizatriptan [INN:BAN]; N,N-Dimethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-1H-indole-3-ethanamine; N,N-dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethanamine; N,N-Dimethyl-2-[5-(1H-1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethylamine; N,N-dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]-ethanamine; N,N-dimethyl-2-[5-(1H-1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethanamine DMDJMA3 CP Merck & Co DMDJMA3 TC Antiinflammatory Agents DMDJMA3 DT Small molecular drug DMDJMA3 PC 5078 DMDJMA3 MW 269.34 DMDJMA3 FM C15H19N5 DMDJMA3 IC InChI=1S/C15H19N5/c1-19(2)6-5-13-8-17-15-4-3-12(7-14(13)15)9-20-11-16-10-18-20/h3-4,7-8,10-11,17H,5-6,9H2,1-2H3 DMDJMA3 CS CN(C)CCC1=CNC2=C1C=C(C=C2)CN3C=NC=N3 DMDJMA3 IK ULFRLSNUDGIQQP-UHFFFAOYSA-N DMDJMA3 IU N,N-dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethanamine DMDJMA3 CA CAS 144034-80-0 DMDJMA3 CB CHEBI:48273 DMDJMA3 DE Migraine DMY9BMK ID DMY9BMK DMY9BMK DN Rocuronium DMY9BMK HS Approved DMY9BMK SN Esmeron (TN); Zemuron (TN); (2beta,3alpha,5alpha,16beta,17beta)-17-acetoxy-16-(1-allylpyrrolidinium-1-yl)-3-hydroxy-2-(morpholin-4-yl)androstane; [(2S,3S,5S,8R,9S,10S,13S,14S,16S,17R)-3-hydroxy-10,13-dimethyl-2-morpholin-4-yl-16-(1-prop-2-enylpyrrolidin-1-ium-1-yl)-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl] acetate DMY9BMK CP Gland Pharma Ltd DMY9BMK TC Neuromuscular Nondepolarizing Agents DMY9BMK DT Small molecular drug DMY9BMK PC 441290 DMY9BMK MW 529.8 DMY9BMK FM C32H53N2O4+ DMY9BMK IC InChI=1S/C32H53N2O4/c1-5-14-34(15-6-7-16-34)28-20-26-24-9-8-23-19-29(36)27(33-12-17-37-18-13-33)21-32(23,4)25(24)10-11-31(26,3)30(28)38-22(2)35/h5,23-30,36H,1,6-21H2,2-4H3/q+1/t23-,24+,25-,26-,27-,28-,29-,30-,31-,32-/m0/s1 DMY9BMK CS CC(=O)O[C@H]1[C@H](C[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC[C@@H]4[C@@]3(C[C@@H]([C@H](C4)O)N5CCOCC5)C)C)[N+]6(CCCC6)CC=C DMY9BMK IK YXRDKMPIGHSVRX-OOJCLDBCSA-N DMY9BMK IU [(2S,3S,5S,8R,9S,10S,13S,14S,16S,17R)-3-hydroxy-10,13-dimethyl-2-morpholin-4-yl-16-(1-prop-2-enylpyrrolidin-1-ium-1-yl)-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl] acetate DMY9BMK CA CAS 143558-00-3 DMY9BMK CB CHEBI:8884 DMY9BMK DE Muscle spasm DM3P5DA ID DM3P5DA DM3P5DA DN Rofecoxib DM3P5DA HS Approved DM3P5DA SN Ceoxx; Refecoxib; Vioxx; Cahill May Roberts brand of rofecoxib; MSD brand of rofecoxib; Merck Frosst brandof rofecoxib; Merck brand of rofecoxib; Vioxx Dolor; MK 0966; MK 0996; MK 966; MK0966; Ceeoxx (TN); Ceoxx (TN); KS-1107; MK-0966; MK-966; Merck Sharp & Dhome brand of rofecoxib; Vioxx (TN); Vioxx (trademark); Rofecoxib (JAN/USAN/INN); 3-(4-methylsulfonylphenyl)-4-phenyl-2H-furan-5-one; 3-Phenyl-4-(4-(methylsulfonyl)phenyl))-2(5H)-furanone; 3-phenyl-4-[4-(methylsulfonyl)phenyl]-2(5H)-furanone; 4-(4-(Methylsulfonyl)phenyl)-3-phenyl-2(5H)-furanone; 4-(4-methylsulfonylphenyl)-3-phenyl-5H-furan-2-one; 4-(p-(Methylsulfonyl)phenyl)-3-phenyl-2(5H)-furanone; 4-[4-(methylsulfonyl)phenyl]-3-phenyl-2(5H)-furanone; 4-[4-(methylsulfonyl)phenyl]-3-phenylfuran-2(5H)-one DM3P5DA CP Merck & Co DM3P5DA TC Antiinflammatory Agents DM3P5DA DT Small molecular drug DM3P5DA PC 5090 DM3P5DA MW 314.4 DM3P5DA FM C17H14O4S DM3P5DA IC InChI=1S/C17H14O4S/c1-22(19,20)14-9-7-12(8-10-14)15-11-21-17(18)16(15)13-5-3-2-4-6-13/h2-10H,11H2,1H3 DM3P5DA CS CS(=O)(=O)C1=CC=C(C=C1)C2=C(C(=O)OC2)C3=CC=CC=C3 DM3P5DA IK RZJQGNCSTQAWON-UHFFFAOYSA-N DM3P5DA IU 3-(4-methylsulfonylphenyl)-4-phenyl-2H-furan-5-one DM3P5DA CA CAS 162011-90-7 DM3P5DA CB CHEBI:8887 DM3P5DA DE Osteoarthritis DMPGHY8 ID DMPGHY8 DMPGHY8 DN Roflumilast DMPGHY8 HS Approved DMPGHY8 SN 162401-32-3; DAXAS; Daliresp; 3-(CYCLOPROPYLMETHOXY)-N-(3,5-DICHLOROPYRIDIN-4-YL)-4-(DIFLUOROMETHOXY)BENZAMIDE; BY217; BYK20869; UNII-0P6C6ZOP5U; BY-217; Roflumilast (Daxas); B9302-107; 0P6C6ZOP5U; 3-(Cyclopropylmethoxy)-N-(3,5-dichloro-4-pyridinyl)-4-(difluoromethoxy)benzamide; Benzamide, 3-(cyclopropylmethoxy)-N-(3,5-dichloro-4-pyridinyl)-4-(difluoromethoxy)-; CHEMBL193240; CHEBI:47657; BYK-20869; ROF; Libertek; AK110425; 3-Cyclopropylmethoxy-N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)benzamide; DAXAS; Roflumilast [USAN]; APTA-2217; Roflumilast (JAN/USAN/INN); 3-cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-di-chloropyrid-4-yl)benzamide; Alogliptin/roflumilast DMPGHY8 CP Nycomed US Inc; Altana DMPGHY8 DT Small molecular drug DMPGHY8 PC 449193 DMPGHY8 MW 403.2 DMPGHY8 FM C17H14Cl2F2N2O3 DMPGHY8 IC InChI=1S/C17H14Cl2F2N2O3/c18-11-6-22-7-12(19)15(11)23-16(24)10-3-4-13(26-17(20)21)14(5-10)25-8-9-1-2-9/h3-7,9,17H,1-2,8H2,(H,22,23,24) DMPGHY8 CS C1CC1COC2=C(C=CC(=C2)C(=O)NC3=C(C=NC=C3Cl)Cl)OC(F)F DMPGHY8 IK MNDBXUUTURYVHR-UHFFFAOYSA-N DMPGHY8 IU 3-(cyclopropylmethoxy)-N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)benzamide DMPGHY8 CA CAS 162401-32-3 DMPGHY8 CB CHEBI:47657 DMPGHY8 DE Asthma; Atopic dermatitis; Type-2 diabetes; Chronic obstructive pulmonary disease DMCZWOK ID DMCZWOK DMCZWOK DN Rokitamycin DMCZWOK HS Approved DMCZWOK SN Ricamycin (TN) DMCZWOK CP Toyo Jozo Co Ltd DMCZWOK DT Small molecular drug DMCZWOK PC 5282211 DMCZWOK MW 828 DMCZWOK FM C42H69NO15 DMCZWOK IC InChI=1S/C42H69NO15/c1-11-16-32(48)55-40-27(6)53-34(23-42(40,7)58-31(47)12-2)56-37-26(5)54-41(36(50)35(37)43(8)9)57-38-28(19-20-44)21-24(3)29(45)18-15-13-14-17-25(4)52-33(49)22-30(46)39(38)51-10/h13-15,18,20,24-30,34-41,45-46,50H,11-12,16-17,19,21-23H2,1-10H3/b14-13+,18-15+/t24-,25-,26-,27+,28+,29+,30-,34+,35-,36-,37-,38+,39+,40+,41+,42-/m1/s1 DMCZWOK CS CCCC(=O)O[C@H]1[C@@H](O[C@H](C[C@@]1(C)OC(=O)CC)O[C@@H]2[C@H](O[C@H]([C@@H]([C@H]2N(C)C)O)O[C@H]3[C@H](C[C@H]([C@H](/C=C/C=C/C[C@H](OC(=O)C[C@H]([C@@H]3OC)O)C)O)C)CC=O)C)C DMCZWOK IK VYWWNRMSAPEJLS-MDWYKHENSA-N DMCZWOK IU [(2S,3S,4R,6S)-6-[(2R,3S,4R,5R,6S)-6-[[(4R,5S,6S,7R,9R,10R,11E,13E,16R)-4,10-dihydroxy-5-methoxy-9,16-dimethyl-2-oxo-7-(2-oxoethyl)-1-oxacyclohexadeca-11,13-dien-6-yl]oxy]-4-(dimethylamino)-5-hydroxy-2-methyloxan-3-yl]oxy-2,4-dimethyl-4-propanoyloxyoxan-3-yl] butanoate DMCZWOK CA CAS 74014-51-0 DMCZWOK CB CHEBI:32103 DMCZWOK DE Bacterial infection DM8XP26 ID DM8XP26 DM8XP26 DN Rolapitant DM8XP26 HS Approved DM8XP26 SN Rolapitant; 552292-08-7; Sch 619734; Varubi; UNII-NLE429IZUC; SCH-619734; NLE429IZUC; 914462-92-3; (5S,8S)-8-(((R)-1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)methyl)-8-phenyl-1,7-diazaspiro[4.5]decan-2-one; (5S,8S)-8-[[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]methyl]-8-phenyl-1,9-diazaspiro[4.5]decan-2-one; Rolapitant [USAN:INN]; Varuby; Varubi (TN); Rolapitant (USAN/INN); Rolapitant(sch619734); SCHEMBL354305; GTPL5749; CHEMBL3707331; CHEBI:90908; DTXSID90203740; MolPort-035-942-975; EX-A1288; BCP09609; ZINC3816514 DM8XP26 CP TESARO DM8XP26 DT Small molecular drug DM8XP26 PC 10311306 DM8XP26 MW 500.5 DM8XP26 FM C25H26F6N2O2 DM8XP26 IC InChI=1S/C25H26F6N2O2/c1-16(17-11-19(24(26,27)28)13-20(12-17)25(29,30)31)35-15-23(18-5-3-2-4-6-18)10-9-22(14-32-23)8-7-21(34)33-22/h2-6,11-13,16,32H,7-10,14-15H2,1H3,(H,33,34)/t16-,22-,23-/m1/s1 DM8XP26 CS C[C@H](C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)OC[C@]2(CC[C@]3(CCC(=O)N3)CN2)C4=CC=CC=C4 DM8XP26 IK FIVSJYGQAIEMOC-ZGNKEGEESA-N DM8XP26 IU (5S,8S)-8-[[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]methyl]-8-phenyl-1,9-diazaspiro[4.5]decan-2-one DM8XP26 CA CAS 552292-08-7 DM8XP26 CB CHEBI:90908 DM8XP26 DE Chemotherapy-induced nausea DMBR5Q7 ID DMBR5Q7 DMBR5Q7 DN Rolitetracycline DMBR5Q7 HS Approved DMBR5Q7 SN Bristacin; Kinteto; Pyrrolidinomethyltetracycline; Reverin; Revrin; Rolitetraciclina; Rolitetracyclinum; Solvocillin; Superciclin; Synotodecin; Synterin; Syntetrex; Syntetrin; Tetraverin; Transcycline; Velacicline; Velacycline; AAT 4; SQ 15659; Pirrolidinometil-tetraciclina; Pirrolidinometil-tetraciclina [Italian]; Prm-TC; Rolitetraciclina [INN-Spanish]; Rolitetracyclinum [INN-Latin]; SQ 15,659; Synterin (TN); N-(Pyrrolidinomethyl)tetracycline; Pyrrolidino-methyl-tetracycline; N-Pyrrolidino-methyl-tetracycline; Rolitetracycline (JAN/USAN/INN); Rolitetracycline [USAN:INN:BAN:JAN]; N-(1-Pyrrolidinylmethyl)-tetracycline; (2Z,4S,4aS,5aS,6S,12aS)-4-(dimethylamino)-6,10,11,12a-tetrahydroxy-2-[hydroxy-(pyrrolidin-1-ylmethylamino)methylidene]-6-methyl-4,4a,5,5a-tetrahydrotetracene-1,3,12-trione; (2Z,4S,4aS,6S,12aS)-4-(dimethylamino)-6,10,11,12a-tetrahydroxy-2-[hydroxy-(pyrrolidin-1-ylmethylamino)methylidene]-6-methyl-4,4a,5,5a-tetrahydrotetracene-1,3,12-trione; (2Z,4S,6S,12aS)-4-(dimethylamino)-6,10,11,12a-tetrahydroxy-2-[hydroxy-(pyrrolidin-1-ylmethylamino)methylidene]-6-methyl-4,4a,5,5a-tetrahydrotetracene-1,3,12-trione; (4S,4aS,6S,12aS)-4-(dimethylamino)-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-N-(pyrrolidin-1-ylmethyl)-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide; 4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-N-(1-pyrrolidinylmethyl)-2-naphthacenecarboxamide DMBR5Q7 TC Antibiotics DMBR5Q7 DT Small molecular drug DMBR5Q7 PC 54682938 DMBR5Q7 MW 527.6 DMBR5Q7 FM C27H33N3O8 DMBR5Q7 IC InChI=1S/C27H33N3O8/c1-26(37)13-7-6-8-16(31)17(13)21(32)18-14(26)11-15-20(29(2)3)22(33)19(24(35)27(15,38)23(18)34)25(36)28-12-30-9-4-5-10-30/h6-8,14-15,20,31-32,35,37-38H,4-5,9-12H2,1-3H3,(H,28,36)/t14-,15-,20-,26+,27-/m0/s1 DMBR5Q7 CS C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)NCN5CCCC5)N(C)C)O DMBR5Q7 IK IKQRPFTXKQQLJF-IAHYZSEUSA-N DMBR5Q7 IU (4S,4aS,5aS,6S,12aR)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-N-(pyrrolidin-1-ylmethyl)-4,4a,5,5a-tetrahydrotetracene-2-carboxamide DMBR5Q7 CA CAS 751-97-3 DMBR5Q7 CB CHEBI:63334 DMBR5Q7 DE Acne vulgaris DMT5GNL ID DMT5GNL DMT5GNL DN Romidepsin DMT5GNL HS Approved DMT5GNL SN Chromadax; Istodax; Antibiotic FR 901228; FK 228; FK228; FR 901228; FR901228; HDInhib_000006; Chromadax (TN); FK-228; FK-901228; FR-901228; Istodax (TN); Romidepsin (USAN); Cyclo((2Z)-2-amino-2-butenoyl-L-valyl-(3S,4E)-3-hydroxy-7-mercapto-4-heptenoyl-D-valyl-D-cysteinyl), cyclic (35)-disulfide; L-Valine, N-((3S,4E)-3-hydroxy-7-mercapto-1-oxo-4-heptenyl)-D-valyl-D-cysteinyl-(2Z)-2-amino-2-butenoxyl-, (4-1)-lactone, cyclic (1-2)-disulfide; (1S,4S,7Z,10S,16E,21R)-7-Ethylidene-4,21-bis(1-methylethyl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo(8.7.6)tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetrazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone DMT5GNL CP Gloucester Pharmaceuticals; Fujisawa Pharmaceutical Ltd. DMT5GNL DT Small molecular drug DMT5GNL PC 5352062 DMT5GNL MW 540.7 DMT5GNL FM C24H36N4O6S2 DMT5GNL IC InChI=1S/C24H36N4O6S2/c1-6-16-21(30)28-20(14(4)5)24(33)34-15-9-7-8-10-35-36-12-17(22(31)25-16)26-23(32)19(13(2)3)27-18(29)11-15/h6-7,9,13-15,17,19-20H,8,10-12H2,1-5H3,(H,25,31)(H,26,32)(H,27,29)(H,28,30)/b9-7+,16-6-/t15-,17-,19-,20+/m1/s1 DMT5GNL CS C/C=C\\1/C(=O)N[C@H](C(=O)O[C@H]\\2CC(=O)N[C@@H](C(=O)N[C@H](CSSCC/C=C2)C(=O)N1)C(C)C)C(C)C DMT5GNL IK OHRURASPPZQGQM-GCCNXGTGSA-N DMT5GNL IU (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetrazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone DMT5GNL CA CAS 128517-07-7 DMT5GNL CB CHEBI:61080 DMT5GNL DE Cutaneous T-cell lymphoma; Peripheral T-cell lymphoma; Renal cell carcinoma DM3U7SZ ID DM3U7SZ DM3U7SZ DN Romiplostim DM3U7SZ HS Approved DM3U7SZ CP Amgen DM3U7SZ DT Small molecular drug DM3U7SZ SQ Thrombopoietin receptor binding domain amino acid sequence : IEGPTLRQWLAARA >Amino acid sequence for Fc fusion compoundMDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGGGGGIEGPTLRQWLAARAGGGGGGGGIEGPTLRQWLAARA DM3U7SZ PC 5329098 DM3U7SZ MW 238.28 DM3U7SZ FM C15H14N2O DM3U7SZ IC InChI=1S/C15H14N2O/c1-9-7-10(2)16-14(9)8-12-11-5-3-4-6-13(11)17-15(12)18/h3-8,16H,1-2H3,(H,17,18)/b12-8- DM3U7SZ CS CC1=CC(=C(N1)/C=C\\2/C3=CC=CC=C3NC2=O)C DM3U7SZ IK WUWDLXZGHZSWQZ-WQLSENKSSA-N DM3U7SZ IU (3Z)-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylidene]-1H-indol-2-one DM3U7SZ CA CAS 194413-58-6 DM3U7SZ CB CHEBI:91083 DM3U7SZ DE Thrombocytopenia; Multiple myeloma; Myelodysplastic syndrome DMFJZN0 ID DMFJZN0 DMFJZN0 DN Romosozumab DMFJZN0 HS Approved DMFJZN0 SN AMG 785 DMFJZN0 CP Amgen DMFJZN0 DT Antibody DMFJZN0 DE Postmenopausal osteoporosis DMA6S1D ID DMA6S1D DMA6S1D DN Ropinirole DMA6S1D HS Approved DMA6S1D SN Ropinirol; Ropinirolum; Ropitor; ReQuip CR; ReQuip XL; SKF 101468; Adartrel (TN); Requip (TN); Ropark (TN); Ropinirol[INN-Spanish]; Ropinirole (INN); Ropinirole [INN:BAN]; Ropinirolum [INN-Latin]; Ropitor (TN); SK&F 101468; SK&F-101,468; 4-[2-(Dipropylamino)ethyl]-1,3-dihydro-2H-indol-2-one; 4-[2-(Dipropylamino)ethyl]indoline-2-one; 4-[2-(dipropylamino)ethyl]-1,3-dihydro-2H-indol-2-one; 4-[2-(dipropylamino)ethyl]-1,3-dihydroindol-2-one DMA6S1D CP GlaxoSmithKline plc DMA6S1D TC Antiparkinson Agents DMA6S1D DT Small molecular drug DMA6S1D PC 5095 DMA6S1D MW 260.37 DMA6S1D FM C16H24N2O DMA6S1D IC InChI=1S/C16H24N2O/c1-3-9-18(10-4-2)11-8-13-6-5-7-15-14(13)12-16(19)17-15/h5-7H,3-4,8-12H2,1-2H3,(H,17,19) DMA6S1D CS CCCN(CCC)CCC1=C2CC(=O)NC2=CC=C1 DMA6S1D IK UHSKFQJFRQCDBE-UHFFFAOYSA-N DMA6S1D IU 4-[2-(dipropylamino)ethyl]-1,3-dihydroindol-2-one DMA6S1D CA CAS 91374-21-9 DMA6S1D CB CHEBI:8888 DMA6S1D DE Parkinson disease DMSPJG2 ID DMSPJG2 DMSPJG2 DN Ropivacaine DMSPJG2 HS Approved DMSPJG2 SN Naropin; ROPIVACAINE HCl; Ropivacaine hydrochloride; Ropivacaine monohydrochloride; Naropin (TN); Ropivacaine monohydrochloride, (S)-isomer; (2S)-N-(2,6-dimethylphenyl)-1-propylpiperidine-2-carboxamide; (2S)-N-(2,6-dimethylphenyl)-1-propylpiperidine-2-carboxamide hydrochloride DMSPJG2 CP AstraZeneca DMSPJG2 TC Anesthetics DMSPJG2 DT Small molecular drug DMSPJG2 PC 175805 DMSPJG2 MW 274.4 DMSPJG2 FM C17H26N2O DMSPJG2 IC InChI=1S/C17H26N2O/c1-4-11-19-12-6-5-10-15(19)17(20)18-16-13(2)8-7-9-14(16)3/h7-9,15H,4-6,10-12H2,1-3H3,(H,18,20)/t15-/m0/s1 DMSPJG2 CS CCCN1CCCC[C@H]1C(=O)NC2=C(C=CC=C2C)C DMSPJG2 IK ZKMNUMMKYBVTFN-HNNXBMFYSA-N DMSPJG2 IU (2S)-N-(2,6-dimethylphenyl)-1-propylpiperidine-2-carboxamide DMSPJG2 CA CAS 84057-95-4 DMSPJG2 CB CHEBI:8890 DMSPJG2 DE Anaesthesia DMILWZR ID DMILWZR DMILWZR DN Rosiglitazone DMILWZR HS Approved DMILWZR PC 77999 DMILWZR FM C18H19N3O3S DMILWZR IC InChI=1S/C18H19N3O3S/c1-21(16-4-2-3-9-19-16)10-11-24-14-7-5-13(6-8-14)12-15-17(22)20-18(23)25-15/h2-9,15H,10-12H2,1H3,(H,20,22,23) DMILWZR CS CN(CCOC1=CC=C(C=C1)CC2C(=O)NC(=O)S2)C3=CC=CC=N3 DMILWZR IK YASAKCUCGLMORW-UHFFFAOYSA-N DMILWZR IU 5-[[4-[2-[methyl(pyridin-2-yl)amino]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione DMILWZR CA CAS 122320-73-4 DMILWZR CB CHEBI:50122 DMILWZR DE Type 2 diabetes DMY6EAO ID DMY6EAO DMY6EAO DN Rosiglitazone DMY6EAO HS Approved DMY6EAO SN Rosigilitazone; Rosiglitazone [INN:BAN]; Rosiglitazone maleate; Rosiglizole; TDZ 01; YASAKCUCGLMORW-UHFFFAOYSA-N; Avandamet; Avandaryl; Avandia; rosiglitazona; rosiglitazone; rosiglitazone (Avandia); rosiglitazonum; 122320-73-4; 5-((4-(2-Methyl-2-(pyridinylamino)ethoxy)phenyl)methyl)-2,4-thiazolidinedione-2-butenedioate; 5-(4-(2-(Methyl(pyridin-2-yl)amino)ethoxy)benzyl)thiazolidine-2,4-dione; 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-2,4-thiazolidinedione; BRL49653; Brl 49653; Brl-49653; C18H19N3O3S; CHEBI:50122 DMY6EAO PC 77999 DMY6EAO MW 357.4 DMY6EAO FM C18H19N3O3S DMY6EAO IC YASAKCUCGLMORW-UHFFFAOYSA-N DMY6EAO CS CN(CCOC1=CC=C(C=C1)CC2C(=O)NC(=O)S2)C3=CC=CC=N3 DMY6EAO IK 1S/C18H19N3O3S/c1-21(16-4-2-3-9-19-16)10-11-24-14-7-5-13(6-8-14)12-15-17(22)20-18(23)25-15/h2-9,15H,10-12H2,1H3,(H,20,22,23) DMY6EAO IU 5-[[4-[2-[methyl(pyridin-2-yl)amino]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione DMY6EAO CA CAS 122320-73-4 DMY6EAO CB CHEBI:50122 DMY6EAO DE Diabetes mellitus DMT45MU ID DMT45MU DMT45MU DN Rosiglitazone XR DMT45MU HS Approved DMT45MU SN Avandia; Nyracta; Venvia; Rosiglitazone Maleate [USAN]; Rosiglitazone maleate; BRL 49653C; Avandia (TN); Avandiaadministration for 6-12 weeks; BRL 49653-C; BRL-49653C; SB-206846; SB-210232; Rosiglitazone maleate (JAN/USAN); (+-)-5-(p-(2-(Methyl-2-pyridylamino)ethoxy)benzyl)-2,4-thiazolidinedione maleate (1:1); (+-)-5-[[4-2-(methyl]-2-pyridinylamino)ethoxy]phenyl]methyl]-2,4-thiazolidinedione,(Z)-2-butenedioate (1:1); 2,4-Thiazolidinedione, 5-((4-(2-(methyl-2-pyridinylamino)ethoxy)phenyl)methyl)-, (2Z)-2-butenedioate (1:1); 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino) ethoxy]phenyl]methyl]-, (2Z)-2-butenedioate (1:1); 2,4-Thiazolidinedione,5-((4-(2-(methyl-2-pyridinylamino)ethoxy)phenyl)methyl)-,(2Z)-2-butenedioate; 5-[[4-[2-[methyl(pyridin-2-yl)amino]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione; 5-{[4-({2-[methyl(pyridin-2-yl)amino]ethyl}oxy)phenyl]methyl}-1,3-thiazolidine-2,4-dione (2Z)-but-2-enedioate DMT45MU CP GSK DMT45MU DT Small molecular drug DMT45MU PC 5281055 DMT45MU MW 473.5 DMT45MU FM C22H23N3O7S DMT45MU IC InChI=1S/C18H19N3O3S.C4H4O4/c1-21(16-4-2-3-9-19-16)10-11-24-14-7-5-13(6-8-14)12-15-17(22)20-18(23)25-15;5-3(6)1-2-4(7)8/h2-9,15H,10-12H2,1H3,(H,20,22,23);1-2H,(H,5,6)(H,7,8)/b;2-1- DMT45MU CS CN(CCOC1=CC=C(C=C1)CC2C(=O)NC(=O)S2)C3=CC=CC=N3.C(=C\\C(=O)O)\\C(=O)O DMT45MU IK SUFUKZSWUHZXAV-BTJKTKAUSA-N DMT45MU IU (Z)-but-2-enedioic acid;5-[[4-[2-[methyl(pyridin-2-yl)amino]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione DMT45MU CA CAS 155141-29-0 DMT45MU CB CHEBI:8892 DMT45MU DE Type-2 diabetes; Alzheimer disease DMVOIK1 ID DMVOIK1 DMVOIK1 DN Rosoxacin DMVOIK1 HS Approved DMVOIK1 SN Acrosoxacin; Eracine; Eradacil; Eradacin; Rosoxacine; Rosoxacino; Rosoxacinum; Roxadyl; Winuron; PD 107522; WIN 35213;Eradacil (TN); Rosoxacin [USAN:INN]; Rosoxacine [INN-French]; Rosoxacino [INN-Spanish]; Rosoxacinum [INN-Latin]; Roxadyl (TN); Win 35,213; Win-35123; Rosoxacin (USAN/INN); 1-Ethyl-1,4-dihydro-4-oxo-7-(4-pyridinyl)-3-quinolinecarboxylic acid; 1-Ethyl-1,4-dihydro-4-oxo-7-(4-pyridyl)-3-quinolinecarboxylic acid; 1-ethyl-4-oxo-7-(pyridin-4-yl)-1,4-dihydroquinoline-3-carboxylic acid; 1-ethyl-4-oxo-7-pyridin-4-ylquinoline-3-carboxylic acid DMVOIK1 CP Sanofi-Aventis DMVOIK1 TC Antiinfective Agents DMVOIK1 DT Small molecular drug DMVOIK1 PC 287180 DMVOIK1 MW 294.3 DMVOIK1 FM C17H14N2O3 DMVOIK1 IC InChI=1S/C17H14N2O3/c1-2-19-10-14(17(21)22)16(20)13-4-3-12(9-15(13)19)11-5-7-18-8-6-11/h3-10H,2H2,1H3,(H,21,22) DMVOIK1 CS CCN1C=C(C(=O)C2=C1C=C(C=C2)C3=CC=NC=C3)C(=O)O DMVOIK1 IK XBPZXDSZHPDXQU-UHFFFAOYSA-N DMVOIK1 IU 1-ethyl-4-oxo-7-pyridin-4-ylquinoline-3-carboxylic acid DMVOIK1 CA CAS 40034-42-2 DMVOIK1 CB CHEBI:131715 DMVOIK1 DE Bacterial infection DMMIQ7G ID DMMIQ7G DMMIQ7G DN Rosuvastatin DMMIQ7G HS Approved DMMIQ7G SN Astende; Cirantan; Cresadex; Creston; Crestor; Provisacor; Razel; Rosedex; Rosimol; Rosumed; Rosustatin; Rosuvas; Rosuvast; Rosvel; Rovartal; Simestat; Sinlip; Vivacor; Rosuvastatin [INN]; Rosuvastatin calcium; Rosuvastatin calcium [USAN]; Rosuvastatin hemicalcium; S 4522; ZD 4522; ZD4522; AZD-4522; Creston (TN);Crestor (TN); Pyrimidine Compound, 26; Rosuvastatin (INN); S-4522; ZD 4522, calcium salt; ZD-4522; Rosuvastatin calcium (JAN/USAN); Bis[(E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino] pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhelpt-6-enoic acid] calcium salt; Calcium (E,3R,5S)-7-[4-(4-fluorophenyl)-2-[methyl(methylsulfonyl)amino]-6-propan-2-ylpyrimidin-5-yl]-3,5-dihydroxyhept-6-enoate; (3R,5S,6E)-7-(4-(4-fluorophenyl)-6-(1-methylethyl)-2-(ethyl(methylsulfonyl)amino)-5-pyrimidinyl)-3,5-dihydroxy-6-heptenoic acid; (3R,5S,6E)-7-{4-(4-fluorophenyl)-2-[methyl(methylsulfonyl)amino]-6-(propan-2-yl)pyrimidin-5-yl}-3,5-dihydroxyhept-6-enoic acid; (3R,5S,6E)-7-{4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl}-3,5-dihydroxyhept-6-enoic acid; (E,3R,5R)-7-[4-(4-fluorophenyl)-2-[methyl(methylsulfonyl)amino]-6-propan-2-ylpyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic acid; (E,3R,5S)-7-[4-(4-fluorophenyl)-2-[methyl(methylsulfonyl)amino]-6-propan-2-ylpyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic acid; (S-((R*,S*-(E)))-7-(4-(4-fluorophenyl)-6-(1-methylethyl)-2-(methyl(methylsulfonyl) amino)-5-pyrimidinyl)-3,5-dihydroxy-6-heptenoic acid, calcium salt (2:1); (S-(R*,S*-(E)))-7-(4-(4-Fluorophenyl)-6-(1-methylethyl)-2-(methyl(methylsulfonyl)amino)-5-pyrimidinyl)-3,5-dihydroxy-6-heptenoic acid, calcium salt (2:1); 6-Heptenoic acid, 7-(4-(4-fluorophenyl)-6-(1-methylethyl)-2-(ethyl(methylsulfonyl)amino)-5-pyrimidinyl)-3,5-dihydroxy-, (3R,5S,6E); 6-Heptenoic acid, 7-(4-(4-fluorophenyl)-6-(1-methylethyl)-2-(methyl(methylsulfonyl)amino)-5-pyrimidinyl)-3,5-dihydroxy-, calcium salt (2:1), (3R,5S,6E) DMMIQ7G CP AstraZeneca DMMIQ7G TC Anticholesteremic Agents DMMIQ7G DT Small molecular drug DMMIQ7G PC 446157 DMMIQ7G MW 481.5 DMMIQ7G FM C22H28FN3O6S DMMIQ7G IC InChI=1S/C22H28FN3O6S/c1-13(2)20-18(10-9-16(27)11-17(28)12-19(29)30)21(14-5-7-15(23)8-6-14)25-22(24-20)26(3)33(4,31)32/h5-10,13,16-17,27-28H,11-12H2,1-4H3,(H,29,30)/b10-9+/t16-,17-/m1/s1 DMMIQ7G CS CC(C)C1=NC(=NC(=C1/C=C/[C@H](C[C@H](CC(=O)O)O)O)C2=CC=C(C=C2)F)N(C)S(=O)(=O)C DMMIQ7G IK BPRHUIZQVSMCRT-VEUZHWNKSA-N DMMIQ7G IU (E,3R,5S)-7-[4-(4-fluorophenyl)-2-[methyl(methylsulfonyl)amino]-6-propan-2-ylpyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic acid DMMIQ7G CA CAS 287714-41-4 DMMIQ7G CB CHEBI:38545 DMMIQ7G DE Hypercholesterolaemia; Elevated C-reactive protein DMP7X6Q ID DMP7X6Q DMP7X6Q DN Rotigotine DMP7X6Q HS Approved DMP7X6Q SN Rotigotine; Rotigotine CDS; Rotigotine CDS Patch; SPM 962; SPM-962; (-)-(S)-5,6,7,8-Tetrahydro-6-(propyl(2-(2-thienyl)ethyl)amino)-1-naphthol; Leganto; N 0923; Neupro; (6S)-6-(Propyl(2-(2-thienyl)ethyl)amino)-5,6,7,8-tetrahydro-1-naphthalenol; (6S)-6-[propyl(2-thiophen-2-ylethyl)amino]-5,6,7,8-tetrahydronaphthalen-1-ol; (S)-6-(propyl(2-(thiophen-2-yl)ethyl)amino)-5,6,7,8-tetrahydronaphthalen-1-ol; 87T4T8BO2E; 99755-59-6; C19H25NOS; CHEMBL1303; DSSTox_CID_26772; DSSTox_RID_81893; NCGC00168748-01; UNII-87T4T8BO2E DMP7X6Q PC 59227 DMP7X6Q MW 315.5 DMP7X6Q FM C19H25NOS DMP7X6Q IC KFQYTPMOWPVWEJ-INIZCTEOSA-N DMP7X6Q CS CCCN(CCC1=CC=CS1)C2CCC3=C(C2)C=CC=C3O DMP7X6Q IK 1S/C19H25NOS/c1-2-11-20(12-10-17-6-4-13-22-17)16-8-9-18-15(14-16)5-3-7-19(18)21/h3-7,13,16,21H,2,8-12,14H2,1H3/t16-/m0/s1 DMP7X6Q IU (6S)-6-[propyl(2-thiophen-2-ylethyl)amino]-5,6,7,8-tetrahydronaphthalen-1-ol DMP7X6Q CA CAS 99755-59-6 DMP7X6Q CB CHEBI:135351 DMP7X6Q DE Parkinsonism DM9PVX8 ID DM9PVX8 DM9PVX8 DN Rucaparib DM9PVX8 HS Approved DM9PVX8 SN RUCAPARIB; 283173-50-2; Rubraca; AG-14447; UNII-8237F3U7EH; 8237F3U7EH; AK317822; 8-Fluoro-1,3,4,5-tetrahydro-2-[4-[(methylamino)methyl]phenyl]-6H-pyrrolo[4,3,2-ef][2]benzazepin-6-one; 8-FLUORO-2-(4-((METHYLAMINO)METHYL)PHENYL)-4,5-DIHYDRO-1H-AZEPINO[5,4,3-CD]INDOL-6(3H)-ONE; 6H-Pyrrolo[4,3,2-ef][2]benzazepin-6-one,8-fluoro-1,3,4,5-tetrahydro-2-[4-[(methylamino)methyl]phenyl]-; 8-fluoro-2-(4-methylaminomethyl-phenyl)-1,3,4,5-tetrahydro-azepino[5,4,3-cd]indol-6-one DM9PVX8 CP Clovis Oncology DM9PVX8 DT Small molecular drug DM9PVX8 PC 9931954 DM9PVX8 MW 323.4 DM9PVX8 FM C19H18FN3O DM9PVX8 IC InChI=1S/C19H18FN3O/c1-21-10-11-2-4-12(5-3-11)18-14-6-7-22-19(24)15-8-13(20)9-16(23-18)17(14)15/h2-5,8-9,21,23H,6-7,10H2,1H3,(H,22,24) DM9PVX8 CS CNCC1=CC=C(C=C1)C2=C3CCNC(=O)C4=C3C(=CC(=C4)F)N2 DM9PVX8 IK HMABYWSNWIZPAG-UHFFFAOYSA-N DM9PVX8 IU 6-fluoro-2-[4-(methylaminomethyl)phenyl]-3,10-diazatricyclo[6.4.1.04,13]trideca-1,4,6,8(13)-tetraen-9-one DM9PVX8 CA CAS 283173-50-2 DM9PVX8 CB CHEBI:94311 DM9PVX8 DE Ovarian cancer DMWE60C ID DMWE60C DMWE60C DN Rufinamide DMWE60C HS Approved DMWE60C SN 106308-44-5; Inovelon; Banzel; 1-(2,6-Difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide; CGP-33101; Cgp 33101; Xilep; 1-[(2,6-difluorophenyl)methyl]-1H-1,2,3-Triazole-4-carboxamide; RUF-331; UNII-WFW942PR79; RUF 331; 1-[(2,6-difluorophenyl)methyl]triazole-4-carboxamide; WFW942PR79; C10H8F2N4O; E 2080; POGQSBRIGCQNEG-UHFFFAOYSA-N; 1H-1,2,3-Triazole-4-carboxamide, 1-[(2,6-difluorophenyl)methyl]-; NCGC00165883-02; E2080; DSSTox_CID_26506; DSSTox_RID_81675; DSSTox_GSID_46506; Banzel; Banzel, Rufinamide; E-2080; SYN-111; Rufinamide (USAN/INN); Inovelon/Banzel DMWE60C CP Eisai DMWE60C DT Small molecular drug DMWE60C PC 129228 DMWE60C MW 238.19 DMWE60C FM C10H8F2N4O DMWE60C IC InChI=1S/C10H8F2N4O/c11-7-2-1-3-8(12)6(7)4-16-5-9(10(13)17)14-15-16/h1-3,5H,4H2,(H2,13,17) DMWE60C CS C1=CC(=C(C(=C1)F)CN2C=C(N=N2)C(=O)N)F DMWE60C IK POGQSBRIGCQNEG-UHFFFAOYSA-N DMWE60C IU 1-[(2,6-difluorophenyl)methyl]triazole-4-carboxamide DMWE60C CA CAS 106308-44-5 DMWE60C CB CHEBI:134966 DMWE60C DE Seizure disorder; Pediatric lennox-gastaut syndrome; Epilepsy DM7Q98D ID DM7Q98D DM7Q98D DN Ruxolitinib DM7Q98D HS Approved DM7Q98D SN Ruxolitinib (JAK inhibitor) DM7Q98D CP Incyte DM7Q98D DT Small molecular drug DM7Q98D PC 25126798 DM7Q98D MW 306.4 DM7Q98D FM C17H18N6 DM7Q98D IC InChI=1S/C17H18N6/c18-7-5-15(12-3-1-2-4-12)23-10-13(9-22-23)16-14-6-8-19-17(14)21-11-20-16/h6,8-12,15H,1-5H2,(H,19,20,21)/t15-/m1/s1 DM7Q98D CS C1CCC(C1)[C@@H](CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3 DM7Q98D IK HFNKQEVNSGCOJV-OAHLLOKOSA-N DM7Q98D IU (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile DM7Q98D CA CAS 941678-49-5 DM7Q98D CB CHEBI:66919 DM7Q98D DE High-risk myelofibrosis; Pancreatic cancer; Essential thrombocythemia; Atopic dermatitis; Vitiligo DMOFP18 ID DMOFP18 DMOFP18 DN Ryzodeq DMOFP18 HS Approved DMOFP18 CP Novo nordisk DMOFP18 DE Type-2 diabetes DM0YWJC ID DM0YWJC DM0YWJC DN Safinamide DM0YWJC HS Approved DM0YWJC SN 133865-89-1; Xadago; (S)-2-((4-((3-Fluorobenzyl)oxy)benzyl)amino)propanamide; Fce-26743; UNII-90ENL74SIG; (2S)-2-[[4-[(3-Fluorophenyl)methoxy]phenyl]methylamino]propanamide; EMD 1195686; 90ENL74SIG; CHEMBL396778; EMD-1195686; AK-77847; 2(s)-(4-(3-fluorobenzyloxy)benzylamino)propionamide; CHEMBL48582; Safinamide [USAN:INN]; 2-(4-(3-Fluorobenzyloxy)benzylamino)propionamide; AC1L2ZLK; Safinamide (USAN/INN); (S)-2-(((4-((3-Fluorophenyl)methoxy)phenyl)methyl)amino)propanamide; EC 603-772-2; SCHEMBL69350; Fce 26743; ON 019190.Na DM0YWJC CP Us Worldmeds DM0YWJC DT Small molecular drug DM0YWJC PC 131682 DM0YWJC MW 302.34 DM0YWJC FM C17H19FN2O2 DM0YWJC IC InChI=1S/C17H19FN2O2/c1-12(17(19)21)20-10-13-5-7-16(8-6-13)22-11-14-3-2-4-15(18)9-14/h2-9,12,20H,10-11H2,1H3,(H2,19,21)/t12-/m0/s1 DM0YWJC CS C[C@@H](C(=O)N)NCC1=CC=C(C=C1)OCC2=CC(=CC=C2)F DM0YWJC IK NEMGRZFTLSKBAP-LBPRGKRZSA-N DM0YWJC IU (2S)-2-[[4-[(3-fluorophenyl)methoxy]phenyl]methylamino]propanamide DM0YWJC CA CAS 133865-89-1 DM0YWJC CB CHEBI:134718 DM0YWJC DE Parkinson disease; Idiopathic parkinson disease DM0J2ZT ID DM0J2ZT DM0J2ZT DN Safinamide mesylate DM0J2ZT HS Approved DM0J2ZT SN Safinamide mesylate; Safinamide mesilate; PNU-151774E; UNII-YS90V3DTX0; FCE-28073; NW-1015; Safinamide mesylate [USAN]; YS90V3DTX0; FCE-28073(R-isomer); Safinamide mesylate (USAN); safinamide methanesulfonate; PNU 151774E; Xadago (TN); NW 1015; AC1MI4YU; Safinamide mesilate (JAN) DM0J2ZT CP US WorldMeds DM0J2ZT PC 3038502 DM0J2ZT MW 398.5 DM0J2ZT FM C18H23FN2O5S DM0J2ZT IC InChI=1S/C17H19FN2O2.CH4O3S/c1-12(17(19)21)20-10-13-5-7-16(8-6-13)22-11-14-3-2-4-15(18)9-14;1-5(2,3)4/h2-9,12,20H,10-11H2,1H3,(H2,19,21);1H3,(H,2,3,4)/t12-;/m0./s1 DM0J2ZT CS C[C@@H](C(=O)N)NCC1=CC=C(C=C1)OCC2=CC(=CC=C2)F.CS(=O)(=O)O DM0J2ZT IK YKOCHIUQOBQIAC-YDALLXLXSA-N DM0J2ZT IU (2S)-2-[[4-[(3-fluorophenyl)methoxy]phenyl]methylamino]propanamide;methanesulfonic acid DM0J2ZT CA CAS 202825-46-5 DM0J2ZT DE Parkinson disease DMN9CWF ID DMN9CWF DMN9CWF DN Salbutamol DMN9CWF HS Approved DMN9CWF SN Aerolin; Airomir; Almotex; Anebron; Asmadil; Asmanil; Asmasal; Asmatol; Asmaven; Asmidon; Asmol; Asthalin; Asthavent; Broncovaleas; Bronter; Bugonol; Bumol; Butamol; Butohaler; Butotal; Butovent; Buventol; Cetsim; Cobutolin; Dilatamol; Ecovent; Farcolin; Gerivent; Grafalin; Libretin; Medolin; Mozal; Novosalmol; Parasma; Pneumolat; Proventil; Respax; Respolin; Rotahaler; Sabutal; Sabutamol; Salamol; Salbetol; Salbron; Salbuhexal; Salbulin; Salbupur; Salbusian; Salbutalan; Salbutamolum; Salbutan; Salbutard; Salbutine; Salbutol; Salbuven; Salbuvent; Sallbupp; Salmaplon; Salomol; Salvent; Saventol; Servitamol; Solbutamol; Spreor; Sultanol; Suprasma; Suxar; Theosal; Tobybron; Vencronyl; Ventamol; Ventilan; Ventiloboi; Ventodisks; Ventoline; Volma; Volmax; Zaperin; Albuterol Sulphate; Albuterol [USAN]; Albuterol hemisulfate; Proventil HFA; Proventil Inhaler; Salbutamol Sulphate; Salbutamol sulfate; Sultanol N; Ventalin inhaler; Ventolin Inhaler; Ventolin Rotacaps; Volare albuterol HFA; AH 3365; S 8260; Aerolin (TN); Albuterol (USP); Alti-Salbutamol; Arubendol-Salbutamol; Asmol Uni-Dose; Asthalin (TN); Broncho-Spray; Buto-Asma; Dl-Albuterol; Dl-Salbutamol; ProAi (TN); Proventil (TN); Racemic-Salbutamol; Salbu-BASF; Salbu-Fatol; Salbutamolum [INN-Latin]; Ventolin (TN); Volare easi-breathe; R,S-Albuterol; Alpha-[(t-Butylamino)methyl]-4-hydroxy-m-xylene-alpha,alpha-diol; Alpha-[(tert-Butylamino)methyl]-4-hydroxy-m-xylene-alpha,alpha'-diol; DL-N-tert-Butyl-2-(4-hydroxy-3-hydroxymethylphenyl)-2-hydroxyethylamine; Alpha'-((tert-Butylamino)methyl)-4-hydroxy-m-xylene-alpha,alpha'-diol; Alpha(sup 1)-((tert-Butylamino)methyl)-4-hydroxy-m-xylene-alpha,alpha'-diol; (alpha1-((tert-butylamino)methyl)-4-hydroxy-m-xylene-alpha,alpha-diol); 1-(tert-Butylaminomethyl)-4-hydroxy-m-xylene-alpha1,alpha3-diol; 2-(tert-Butylamino)-1-(4-hydroxy-3-hydroxymethylphenyl)ethanol; 2-t-Butylamino-1-(4-hydroxy-3-hydroxy-3-hydroxymethyl)phenylethanol; 4-Hydroxy-3-hydroxymethyl-alpha-((tert-butylamino)methyl)benzyl alcohol; 4-[2-(tert-Butylamino)-1-hydroxyethyl]-2-(hydroxymethyl)phenol; 4-{2-[(1,1-dimethylethyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol DMN9CWF CP GlaxoSmithKline DMN9CWF TC Bronchodilator Agents DMN9CWF DT Small molecular drug DMN9CWF PC 2083 DMN9CWF MW 239.31 DMN9CWF FM C13H21NO3 DMN9CWF IC InChI=1S/C13H21NO3/c1-13(2,3)14-7-12(17)9-4-5-11(16)10(6-9)8-15/h4-6,12,14-17H,7-8H2,1-3H3 DMN9CWF CS CC(C)(C)NCC(C1=CC(=C(C=C1)O)CO)O DMN9CWF IK NDAUXUAQIAJITI-UHFFFAOYSA-N DMN9CWF IU 4-[2-(tert-butylamino)-1-hydroxyethyl]-2-(hydroxymethyl)phenol DMN9CWF CA CAS 18559-94-9 DMN9CWF CB CHEBI:2549 DMN9CWF DE Acute asthma DM1T2LS ID DM1T2LS DM1T2LS DN Salicin DM1T2LS HS Approved DM1T2LS SN salicin; 138-52-3; Salicoside; Salicine; Salicyl alcohol glucoside; D-(-)-Salicin; (2R,3S,4S,5R,6S)-2-(Hydroxymethyl)-6-(2-(hydroxymethyl)phenoxy)tetrahydro-2H-pyran-3,4,5-triol; 2-(Hydroxymethyl)phenyl beta-D-glucopyranoside; Saligenin beta-D-glucopyranoside; D-Salicin; Saligenin-beta-D-glucopyranoside; 2-(Hydroxymethyl)phenyl-beta-d-glucopyranoside; Salicin (6CI,8CI); D(-)-Salicin; o-(Hydroxymethyl)phenyl beta-D-glucopyranoside; Benzyl alcohol, o-hydroxy-, o-glucoside; UNII-4649620TBZ; AI3-19099; alpha-Hydroxy-o-tolyl beta DM1T2LS DT Small molecular drug DM1T2LS PC 439503 DM1T2LS MW 286.28 DM1T2LS FM C13H18O7 DM1T2LS IC InChI=1S/C13H18O7/c14-5-7-3-1-2-4-8(7)19-13-12(18)11(17)10(16)9(6-15)20-13/h1-4,9-18H,5-6H2/t9-,10-,11+,12-,13-/m1/s1 DM1T2LS CS C1=CC=C(C(=C1)CO)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O DM1T2LS IK NGFMICBWJRZIBI-UJPOAAIJSA-N DM1T2LS IU (2R,3S,4S,5R,6S)-2-(hydroxymethyl)-6-[2-(hydroxymethyl)phenoxy]oxane-3,4,5-triol DM1T2LS CA CAS 138-52-3 DM1T2LS CB CHEBI:17814 DM1T2LS DE Analgesia DM2F8XZ ID DM2F8XZ DM2F8XZ DN Salicyclic acid DM2F8XZ HS Approved DM2F8XZ SN Salicylic acid; salicylic acid; 2-Hydroxybenzoic acid; 69-72-7; o-hydroxybenzoic acid; 2-Carboxyphenol; o-Carboxyphenol; Salonil; Rutranex; Retarder W; Keralyt; Freezone; Duoplant; Saligel; Ionil; Psoriacid-S-stift; salicylate; Stri-Dex; Salicylic acid soap; Benzoic acid, 2-hydroxy-; Salicylic acid collodion; Verrugon; Phenol-2-carboxylic acid; Acidum salicylicum; Trans-Ver-Sal; Orthohydroxybenzoic acid; 2-Hydroxybenzenecarboxylic acid; Acido salicilico; Ionil-Plus; Salicylic acid, tech; Kyselina salicylova; Clear away wart remover; Duofil wart; Domerine; Duofilm; Occlusal; SAX; Salicylate; Sebucare; Sebulex; Acido salicilico [Italian]; Advanced pain relief callus removers; Advanced pain relief corn removers; Akurza Cream; Akurza Lotion; DHS Sal Shampoo; DuoPlant Gel; Duofil wart remover; Hydrisalic Gel; Ionil plus; Kyselina salicylova [Czech]; Mediplast pads; O Hydroxybenzoic Acid; Ortho Hydroxybenzoic Acid; Retarder SAX; Salex Cream; Salex Lotion; CMC_13852; K 537; ATA fraction 10, ammonium salt; Acid, Salicylic; Acido o-idrossibenzoico; Acido o-idrossibenzoico [Italian]; Kyselina 2-hydroxybenzoova; Kyselina 2-hydroxybenzoova [Czech]; O-Carboxyphenol; O-hydroxybenzoic acid; Ortho-Hydroxybenzoic Acid; P&S Shampoo; Phenol derivative, 7; Propa pH Peel-Off Acne Mask; SALICYLIC ACID (SEE ALSO ALPHA HYDROXY ACIDS); SALICYLIC ACID, ACS; Salicylic acid & Sulfur Soap; Salicylic acid (TN); Salicylic acid [USAN:JAN]; Acid, 2-Hydroxybenzoic; Acid, o-Hydroxybenzoic; Acid, ortho-Hydroxybenzoic; BENZOIC ACID,2-HYDROXY SALICYLIC ACID; Dr Scholl's callus removers; Dr Scholl's corn removers; Dr Scholl's wart remover kit; Salicylic acid (6CI,8CI); Salicylic acid (JP15/USP); Alpha/Beta Hydroxy Acids (Glycolic Acid, Salicylic Acid); Salicylic acid-ring-UL-14C; ALPHA/BETA HYDROXY ACIDS (SALICYLIC ACID) (SEE ALPHA/BETA HYDROXY ACIDS); Benzoic acid, 2-hydroxy-(9CI); E9A559BE-383B-4F83-BC02-3031D03D558A; 2 Hydroxybenzoic Acid; 2-hydroxy(1-14c)benzoic acid; SALICYLATE DM2F8XZ TC Antiinflammatory Agents DM2F8XZ DT Small molecular drug DM2F8XZ PC 338 DM2F8XZ MW 138.12 DM2F8XZ FM C7H6O3 DM2F8XZ IC InChI=1S/C7H6O3/c8-6-4-2-1-3-5(6)7(9)10/h1-4,8H,(H,9,10) DM2F8XZ CS C1=CC=C(C(=C1)C(=O)O)O DM2F8XZ IK YGSDEFSMJLZEOE-UHFFFAOYSA-N DM2F8XZ IU 2-hydroxybenzoic acid DM2F8XZ CA CAS 69-72-7 DM2F8XZ CB CHEBI:16914 DM2F8XZ DE Seborrhoeic dermatitis DMIEU69 ID DMIEU69 DMIEU69 DN Salmeterol DMIEU69 HS Approved DMIEU69 SN Aeromax; Astmerole; SALMATEROL; Salmeterolum; Serevent; Glaxo Wellcome brand of salmeterol xinafoate; Salmeterolum [Latin]; GR 33343X; S 2692; GR-33343X; Serevent (TN); Salmeterol (USAN/INN); Salmeterol [USAN:BAN:INN]; (+-)-4-Hydroxy-alpha'-(((6-(4-phenylbutoxy)hexyl)amino)methyl)-m-xylene-alpha,alpha'-diol; (+-)-4-Hydroxy-alpha1-(((6-(4-phenylbutoxy)hexyl)amino)methyl)-1,3-benzenedimethanol; (inverted question mark) 4-Hydroxy-a1-[[[6-(4-phenylbutoxy)hexyl]amino]m-ethyl]-1,3-benzenedimethanol; 2-(hydroxymethyl)-4-(1-hydroxy-2-{[6-(4-phenylbutoxy)hexyl]amino}ethyl)phenol; 2-(hydroxymethyl)-4-[1-hydroxy-2-({6-[(4-phenylbutyl)oxy]hexyl}amino)ethyl]phenol; 2-(hydroxymethyl)-4-[1-hydroxy-2-[6-(4-phenylbutoxy)hexylamino]ethyl]phenol DMIEU69 CP GlaxoSmithKline DMIEU69 TC Bronchodilator Agents DMIEU69 DT Small molecular drug DMIEU69 PC 5152 DMIEU69 MW 415.6 DMIEU69 FM C25H37NO4 DMIEU69 IC InChI=1S/C25H37NO4/c27-20-23-18-22(13-14-24(23)28)25(29)19-26-15-7-1-2-8-16-30-17-9-6-12-21-10-4-3-5-11-21/h3-5,10-11,13-14,18,25-29H,1-2,6-9,12,15-17,19-20H2 DMIEU69 CS C1=CC=C(C=C1)CCCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O DMIEU69 IK GIIZNNXWQWCKIB-UHFFFAOYSA-N DMIEU69 IU 2-(hydroxymethyl)-4-[1-hydroxy-2-[6-(4-phenylbutoxy)hexylamino]ethyl]phenol DMIEU69 CA CAS 89365-50-4 DMIEU69 CB CHEBI:64064 DMIEU69 DE Chronic obstructive pulmonary disease DMEWUPF ID DMEWUPF DMEWUPF DN Salmon Calcitonin DMEWUPF HS Approved DMEWUPF SN Astronin; Biocalcin; Bionocalcin; Cadens; Calciben; Calcihexal; Calcimar; Calcimonta; Calcinil; Calcioton; Calcitonina; Calcitoran; Calco; Calogen; Calsynar; Caltine; Casalm; Catonin; Cibacalcine; Citonina; Eptacalcin; Forcaltonin; Fortical; Ipocalcin; Kalsimin; Karil; Miacalcic; Miacalcin; Miracalcic; Oseototal; Osseocalcina; Osteobion; Osteovis; Ostosalm; Ostostabil; Porostenina; Prontocalcin; Quosten; Riostin; Rulicalcin; Salcat; Salcatonin; Salcatyn; Salmocalcin; Salmofar; Sical; Stalcin; Staporos; Steocin; Tonocalcin; Ucecal; Calcitonin salmon; Calcitonin vom lachs; Calcitonine de saumon; Calsynar Lyo L; Recombinant salmon calcitonin; Salmon calcitonin I; Synthetic salmon calcitonin; CALCITONIN, SALMON; Calcimar (TN); Calcitonin (salmon); Calcitonin salmon (synthesis); Calcitonin, salmar; Calcitonin,salmon; Calcitonin-salmon; Fortical (TN); Isi-calcin; Miacalcin (TN); TZ-CT; Thyrocalcitonin (salmon); Calcitonin salmon (USAN/INN); Calcitonin salmon (synthesis) (JAN); Calcitonin, salmon, for bioassay; Salmon calcitonin (1-32); Calcitonin [USAN:INN:BAN:JAN]; Salmon calcitonin-(I-32) DMEWUPF TC Antiosteporotic Agents DMEWUPF DT Small molecular drug DMEWUPF SQ DB00017 sequence: CSNLSTCVLGKLSQELHKLQTYPRTNTGSGTP DMEWUPF PC 16129616 DMEWUPF MW 3431.9 DMEWUPF FM C145H240N44O48S2 DMEWUPF IC InChI=1S/C145H240N44O48S2/c1-65(2)45-86(175-139(232)110(70(11)12)183-136(229)99-63-239-238-62-79(148)117(210)178-96(59-191)134(227)174-92(52-104(151)202)131(224)172-90(49-69(9)10)129(222)180-98(61-193)135(228)187-114(74(16)197)142(235)181-99)118(211)158-55-106(204)162-80(25-18-20-40-146)120(213)169-89(48-68(7)8)128(221)179-97(60-192)133(226)167-83(34-37-102(149)200)122(215)165-85(36-39-109(207)208)123(216)171-88(47-67(5)6)127(220)173-91(51-77-54-156-64-161-77)130(223)164-81(26-19-21-41-147)121(214)170-87(46-66(3)4)126(219)166-84(35-38-103(150)201)125(218)186-113(73(15)196)141(234)177-94(50-76-30-32-78(199)33-31-76)143(236)189-44-24-29-101(189)137(230)168-82(27-22-42-157-145(154)155)124(217)185-112(72(14)195)140(233)176-93(53-105(152)203)132(225)184-111(71(13)194)138(231)160-56-107(205)163-95(58-190)119(212)159-57-108(206)182-115(75(17)198)144(237)188-43-23-28-100(188)116(153)209/h30-33,54,64-75,79-101,110-115,190-199H,18-29,34-53,55-63,146-148H2,1-17H3,(H2,149,200)(H2,150,201)(H2,151,202)(H2,152,203)(H2,153,209)(H,156,161)(H,158,211)(H,159,212)(H,160,231)(H,162,204)(H,163,205)(H,164,223)(H,165,215)(H,166,219)(H,167,226)(H,168,230)(H,169,213)(H,170,214)(H,171,216)(H,172,224)(H,173,220)(H,174,227)(H,175,232)(H,176,233)(H,177,234)(H,178,210)(H,179,221)(H,180,222)(H,181,235)(H,182,206)(H,183,229)(H,184,225)(H,185,217)(H,186,218)(H,187,228)(H,207,208)(H4,154,155,157) DMEWUPF CS CC(C)CC1C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)N1)CC(=O)N)CO)N)C(=O)NC(C(C)C)C(=O)NC(CC(C)C)C(=O)NCC(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)NC(CO)C(=O)NC(CCC(=O)N)C(=O)NC(CCC(=O)O)C(=O)NC(CC(C)C)C(=O)NC(CC2=CN=CN2)C(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)NC(CCC(=O)N)C(=O)NC(C(C)O)C(=O)NC(CC3=CC=C(C=C3)O)C(=O)N4CCCC4C(=O)NC(CCCNC(=N)N)C(=O)NC(C(C)O)C(=O)NC(CC(=O)N)C(=O)NC(C(C)O)C(=O)NCC(=O)NC(CO)C(=O)NCC(=O)NC(C(C)O)C(=O)N5CCCC5C(=O)N)C(C)O)CO DMEWUPF IK BBBFJLBPOGFECG-UHFFFAOYSA-N DMEWUPF IU 4-[[5-amino-2-[[2-[[2-[[6-amino-2-[[2-[[2-[[2-[[22-amino-16-(2-amino-2-oxoethyl)-7-(1-hydroxyethyl)-10,19-bis(hydroxymethyl)-13-(2-methylpropyl)-6,9,12,15,18,21-hexaoxo-1,2-dithia-5,8,11,14,17,20-hexazacyclotricosane-4-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-[[1-[[1-[[6-amino-1-[[1-[[5-amino-1-[[1-[[1-[2-[[1-[[1-[[4-amino-1-[[1-[[2-[[1-[[2-[[1-(2-carbamoylpyrrolidin-1-yl)-3-hydroxy-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-oxopentanoic acid DMEWUPF CA CAS 9007-12-9 DMEWUPF DE Osteoporosis DM13P4C ID DM13P4C DM13P4C DN Salsalate DM13P4C HS Approved DM13P4C SN Diacesal; Diplosal; Disalcid; Disalicylsaeure; Disalyl; Nobacid; Salflex; Salical; Salina; Saloxium; Salsalato; Salsalatum;Salysal; Sasapirin; Sasapyrin; Sasapyrine; Sasapyrinum; Disalicylic acid; Sal Ester Sal; Salicylic Acid Salicylate; Salicyloylsalicylic acid; Salicylsalicylic acid; Disalcid (TN); O-Salicylcylsalicylsaeure; O-Salicyloylsalicylic Acid; O-Salicylsalicylic acid; Salflex (TN); Salicylic acid, bimolecular ester; Salicylic acid, salicylate; Salsalato [INN-Spanish]; Salsalatum [INN-Latin]; Salsitab (TN); Sasapyrine (JAN); Mono-Gesic (TN); Salsalate (USP/INN); Salsalate [USAN:INN:BAN]; Benzoic acid, 2-hydroxy-, 2-carboxyphenyl ester; 2-((2-Hydroxybenzoyl)oxy)benzoic acid; 2-(2-hydroxybenzoyl)oxybenzoic acid; 2-Carboxyphenyl salicylate; 2-Salicyloyloxybenzoic Acid; 2-{[(2-hydroxyphenyl)carbonyl]oxy}benzoic acid DM13P4C TC Antiinflammatory Agents DM13P4C DT Small molecular drug DM13P4C PC 5161 DM13P4C MW 258.23 DM13P4C FM C14H10O5 DM13P4C IC InChI=1S/C14H10O5/c15-11-7-3-1-5-9(11)14(18)19-12-8-4-2-6-10(12)13(16)17/h1-8,15H,(H,16,17) DM13P4C CS C1=CC=C(C(=C1)C(=O)OC2=CC=CC=C2C(=O)O)O DM13P4C IK WVYADZUPLLSGPU-UHFFFAOYSA-N DM13P4C IU 2-(2-hydroxybenzoyl)oxybenzoic acid DM13P4C CA CAS 552-94-3 DM13P4C CB CHEBI:9014 DM13P4C DE Rheumatoid arthritis DM62MUZ ID DM62MUZ DM62MUZ DN Samarium Sm-153 Lexidronam Pentasodium DM62MUZ HS Approved DM62MUZ CP Lantheus Medical Imaging Inc DM62MUZ TC Neurology Agents DM62MUZ DT Small molecular drug DM62MUZ PC 9810246 DM62MUZ MW 695.93 DM62MUZ FM C6H12N2Na5O12P4Sm DM62MUZ IC InChI=1S/C6H20N2O12P4.5Na.Sm/c9-21(10,11)3-7(4-22(12,13)14)1-2-8(5-23(15,16)17)6-24(18,19)20;;;;;;/h1-6H2,(H2,9,10,11)(H2,12,13,14)(H2,15,16,17)(H2,18,19,20);;;;;;/q;5*+1;+3/p-8/i;;;;;;1+3 DM62MUZ CS C(CN(CP(=O)([O-])[O-])CP(=O)([O-])[O-])N(CP(=O)([O-])[O-])CP(=O)([O-])[O-].[Na+].[Na+].[Na+].[Na+].[Na+].[153Sm+3] DM62MUZ IK SZZACTGRBZTAKY-NKNBZPHVSA-F DM62MUZ IU pentasodium;samarium-153(3+);N,N,N',N'-tetrakis(phosphonatomethyl)ethane-1,2-diamine DM62MUZ DE Cancer related pain DMDINFS ID DMDINFS DMDINFS DN Sanguinarine DMDINFS HS Approved DMDINFS SN SANGUINARINE; 2447-54-3; Pseudochelerythrine; Sanguinarin; sangvinarin; Veadent; Sanguiritrin; SANGUINARIUM; Dimethylenedioxy benzphenanthridine; UNII-AV9VK043SS; C20H14NO4; EINECS 219-503-3; Benzophenanthridine alkaloid; BRN 3915507; AV9VK043SS; CHEBI:17183; NCGC00015959-03; CAS-2447-54-3; [1,3]Benzodioxolo[5,6-c]-1,3-dioxolo[4,5-i]phenanthridinium, 13-methyl-; DSSTox_RID_80748; DSSTox_CID_25204; DSSTox_GSID_45204; 13-Methyl[1,3]benzodioxolo[5,6-C][1,3]dioxolo[4,5-I]phenanthridin-13-Ium; Sangrovit; y-Chelerythrine; SR-01000075650 DMDINFS DT Small molecular drug DMDINFS PC 5154 DMDINFS MW 332.3 DMDINFS FM C20H14NO4+ DMDINFS IC InChI=1S/C20H14NO4/c1-21-8-15-12(4-5-16-20(15)25-10-22-16)13-3-2-11-6-17-18(24-9-23-17)7-14(11)19(13)21/h2-8H,9-10H2,1H3/q+1 DMDINFS CS C[N+]1=C2C(=C3C=CC4=C(C3=C1)OCO4)C=CC5=CC6=C(C=C52)OCO6 DMDINFS IK INVGWHRKADIJHF-UHFFFAOYSA-N DMDINFS IU 24-methyl-5,7,18,20-tetraoxa-24-azoniahexacyclo[11.11.0.02,10.04,8.014,22.017,21]tetracosa-1(24),2,4(8),9,11,13,15,17(21),22-nonaene DMDINFS CA CAS 2447-54-3 DMDINFS CB CHEBI:17183 DMDINFS DE Dental plaque DM5VP0F ID DM5VP0F DM5VP0F DN Saphris DM5VP0F HS Approved DM5VP0F SN Asenapine maleate; Saphris; Asenapine (maleate); Org 5222; Sycrest; Org-5222; Asenapine maleate [USAN]; C17H16ClNO.C4H4O4; Asenapine/; Saphris (TN); EINECS 288-064-8; Org 5222 maleate; trans-5-Chloro-2,3,3a,12b-tetrahydro-2-methyl-1H-dibenz(2,3:6,7)oxepino(4,5-c)pyrrole maleate; (S,S)-Asenapine Maleate; SCHEMBL175228; Asenapine maleate (JAN/USAN); CHEBI:71248; GMDCDXMAFMEDAG-CHHFXETESA-N; ABP000604; s1283; MFCD00900588; Asenapine maleate, >=98% (HPLC); AKOS015951084; SCH-900274; MK-8274; CS-0859; HY-11100; AC-24116 DM5VP0F PC 6917875 DM5VP0F MW 401.8 DM5VP0F FM C21H20ClNO5 DM5VP0F IC InChI=1S/C17H16ClNO.C4H4O4/c1-19-9-14-12-4-2-3-5-16(12)20-17-7-6-11(18)8-13(17)15(14)10-19;5-3(6)1-2-4(7)8/h2-8,14-15H,9-10H2,1H3;1-2H,(H,5,6)(H,7,8)/b;2-1-/t14-,15-;/m1./s1 DM5VP0F CS CN1CC2C(C1)C3=C(C=CC(=C3)Cl)OC4=CC=CC=C24.C(=CC(=O)O)C(=O)O DM5VP0F IK GMDCDXMAFMEDAG-CHHFXETESA-N DM5VP0F IU (Z)-but-2-enedioic acid;(2S,6S)-9-chloro-4-methyl-13-oxa-4-azatetracyclo[12.4.0.02,6.07,12]octadeca-1(18),7(12),8,10,14,16-hexaene DM5VP0F CA CAS 85650-56-2 DM5VP0F CB CHEBI:71248 DM5VP0F DE Schizophrenia DM4087K ID DM4087K DM4087K DN Saprisartan DM4087K HS Approved DM4087K SN Saprisartan potassium; GR 138950; GR-138950; GR-138950C; GR-138950X; 3-[[3-bromo-2-[2-(trifluoromethylsulfonylamino)phenyl]-1-benzofuran-5-yl]methyl]-5-cyclopropyl-2-ethylimidazole-4-carboxamide DM4087K TC Antihypertensive Agents DM4087K DT Small molecular drug DM4087K PC 60921 DM4087K MW 611.4 DM4087K FM C25H22BrF3N4O4S DM4087K IC InChI=1S/C25H22BrF3N4O4S/c1-2-19-31-21(14-8-9-14)22(24(30)34)33(19)12-13-7-10-18-16(11-13)20(26)23(37-18)15-5-3-4-6-17(15)32-38(35,36)25(27,28)29/h3-7,10-11,14,32H,2,8-9,12H2,1H3,(H2,30,34) DM4087K CS CCC1=NC(=C(N1CC2=CC3=C(C=C2)OC(=C3Br)C4=CC=CC=C4NS(=O)(=O)C(F)(F)F)C(=O)N)C5CC5 DM4087K IK DUEWVPTZCSAMNB-UHFFFAOYSA-N DM4087K IU 3-[[3-bromo-2-[2-(trifluoromethylsulfonylamino)phenyl]-1-benzofuran-5-yl]methyl]-5-cyclopropyl-2-ethylimidazole-4-carboxamide DM4087K CA CAS 146623-69-0 DM4087K DE Hypertension DM90TJP ID DM90TJP DM90TJP DN Sapropterin hydrochloride DM90TJP HS Approved DM90TJP SN Biopten (TN) DM90TJP DT Small molecular drug DM90TJP PC 135409471 DM90TJP MW 314.17 DM90TJP FM C9H17Cl2N5O3 DM90TJP IC InChI=1S/C9H15N5O3.2ClH/c1-3(15)6(16)4-2-11-7-5(12-4)8(17)14-9(10)13-7;;/h3-4,6,12,15-16H,2H2,1H3,(H4,10,11,13,14,17);2*1H/t3-,4+,6-;;/m0../s1 DM90TJP CS C[C@@H]([C@@H]([C@H]1CNC2=C(N1)C(=O)NC(=N2)N)O)O.Cl.Cl DM90TJP IK RKSUYBCOVNCALL-NTVURLEBSA-N DM90TJP IU (6R)-2-amino-6-[(1R,2S)-1,2-dihydroxypropyl]-5,6,7,8-tetrahydro-3H-pteridin-4-one;dihydrochloride DM90TJP CA CAS 69056-38-8 DM90TJP CB CHEBI:32120 DM90TJP DE Hyperphenylalaninemia DMG814N ID DMG814N DMG814N DN Saquinavir DMG814N HS Approved DMG814N SN Fortovase; Invirase; ROC; SQV; Saguinavir; Ro 318959; Fortovase (TN); Fortovase(TM); Invirase (TN); Ro 31-8959; Invirase(TM)(monomesylate); Ro-31-8959; Saquinavir (JAN/USP/INN); QNC-ASN-HPH-DIQ-NTB; CIS-N-TERT-BUTYL-DECAHYDRO-2-[2(R)-HYDROXY-4-PHENYL-3(S)-[[N-2-QUINOLYLCARBONYL-L-ASPARAGINYL]AMINO]BUTYL]-(4AS)-ISOQUINOLINE-3(S)-CARBOXAMIDE; (2S)-N-[(2S,3R)-4-[(3S,4aS,8aS)-3-(tert-butylcarbamoyl)-3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinolin-2-yl]-3-hydroxy-1-phenylbutan-2-yl]-2-(quinoline-2-carbonylamino)butanediamide; (2s)-N-[(2s,3r)-4-[(2s,3s,4as,8as)-3-(Tert-Butylcarbamoyl)-3,4,4a,5,6,7,8,8a-Octahydro-1h-Isoquinolin-2-Yl]-3-Hydroxy-1-Phenyl-Butan-2-Yl]-2-(Quinolin-2-Ylcarbonylamino)butanediamide DMG814N CP Hoffmann-La Roche pharmaceutical company DMG814N TC Anti-HIV Agents DMG814N DT Small molecular drug DMG814N PC 441243 DMG814N MW 670.8 DMG814N FM C38H50N6O5 DMG814N IC InChI=1S/C38H50N6O5/c1-38(2,3)43-37(49)32-20-26-14-7-8-15-27(26)22-44(32)23-33(45)30(19-24-11-5-4-6-12-24)41-36(48)31(21-34(39)46)42-35(47)29-18-17-25-13-9-10-16-28(25)40-29/h4-6,9-13,16-18,26-27,30-33,45H,7-8,14-15,19-23H2,1-3H3,(H2,39,46)(H,41,48)(H,42,47)(H,43,49)/t26-,27+,30-,31-,32-,33+/m0/s1 DMG814N CS CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O DMG814N IK QWAXKHKRTORLEM-UGJKXSETSA-N DMG814N IU (2S)-N-[(2S,3R)-4-[(3S,4aS,8aS)-3-(tert-butylcarbamoyl)-3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinolin-2-yl]-3-hydroxy-1-phenylbutan-2-yl]-2-(quinoline-2-carbonylamino)butanediamide DMG814N CA CAS 127779-20-8 DMG814N CB CHEBI:63621 DMG814N DE Human immunodeficiency virus infection DMKS1DV ID DMKS1DV DMKS1DV DN SARALASIN DMKS1DV HS Approved DMKS1DV SN Saralasin; 34273-10-4; UNII-H2AFV2HE66; (Sar1,Val5,Ala8)-Angiotensin II; CHEMBL938; H2AFV2HE66; Saralasinum [INN-Latin]; Saralasin [INN:BAN]; Saralasine [INN-French]; Saralasina [INN-Spanish]; Saralasinum; Saralasine; Saralasina; (1-(N-Methylglycin) 5-L-valin, 8-L-alanin)angiotensin II; Angiotensin II, 1-(N-methylglycine)-5-L-valine-8-L-alanine-; NCGC00166135-01; N-(1-(N-(N-(N-(N-(N2-(N-methylglycly)-L-arginyl)-L-valyl)-L-tyrosyl)-L-valyl)-L-histidyl)-L-prolyl)-L-alanine; SCHEMBL23; AC1O44IX; DSSTox_RID_81710 DMKS1DV DT Small molecular drug DMKS1DV PC 6324663 DMKS1DV MW 912 DMKS1DV FM C42H65N13O10 DMKS1DV IC InChI=1S/C42H65N13O10/c1-22(2)33(53-35(58)28(50-32(57)20-45-6)9-7-15-47-42(43)44)38(61)51-29(17-25-11-13-27(56)14-12-25)36(59)54-34(23(3)4)39(62)52-30(18-26-19-46-21-48-26)40(63)55-16-8-10-31(55)37(60)49-24(5)41(64)65/h11-14,19,21-24,28-31,33-34,45,56H,7-10,15-18,20H2,1-6H3,(H,46,48)(H,49,60)(H,50,57)(H,51,61)(H,52,62)(H,53,58)(H,54,59)(H,64,65)(H4,43,44,47)/t24-,28-,29-,30-,31-,33-,34-/m0/s1 DMKS1DV CS C[C@@H](C(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC2=CN=CN2)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC3=CC=C(C=C3)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CNC DMKS1DV IK PFGWGEPQIUAZME-NXSMLHPHSA-N DMKS1DV IU (2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-(diaminomethylideneamino)-2-[[2-(methylamino)acetyl]amino]pentanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylbutanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]pyrrolidine-2-carbonyl]amino]propanoic acid DMKS1DV CA CAS 34273-10-4 DMKS1DV CB CHEBI:135894 DMKS1DV DE Hypertension DMKZROL ID DMKZROL DMKZROL DN Saralasin Acetate DMKZROL HS Approved DMKZROL SN Saralasin acetate; Sarenin; Saralasin acetate [USAN]; Saralasin acetate (USAN); 39698-78-7; UNII-FO21Z580M4; Sarenin (TN); SCHEMBL2200145; CHEMBL1200670; FO21Z580M4; 34273-10-4 (Parent); D04126; [Sar1, Val5, Ala8]-Angiotensin II acetate salt hydrate; [Sar1, Val5, Ala8]-Angiotensin II acetate salt hydrate, > DMKZROL CP Procter And Gamble Pharmaceuticals Inc Sub Procter And Gamble Co DMKZROL DT Small molecular drug DMKZROL PC 11954381 DMKZROL MW 990.1 DMKZROL FM C44H71N13O13 DMKZROL IC InChI=1S/C42H65N13O10.C2H4O2.H2O/c1-22(2)33(53-35(58)28(50-32(57)20-45-6)9-7-15-47-42(43)44)38(61)51-29(17-25-11-13-27(56)14-12-25)36(59)54-34(23(3)4)39(62)52-30(18-26-19-46-21-48-26)40(63)55-16-8-10-31(55)37(60)49-24(5)41(64)65;1-2(3)4;/h11-14,19,21-24,28-31,33-34,45,56H,7-10,15-18,20H2,1-6H3,(H,46,48)(H,49,60)(H,50,57)(H,51,61)(H,52,62)(H,53,58)(H,54,59)(H,64,65)(H4,43,44,47);1H3,(H,3,4);1H2/t24-,28-,29-,30-,31-,33-,34-;;/m0../s1 DMKZROL CS C[C@@H](C(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC2=CN=CN2)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC3=CC=C(C=C3)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CNC.CC(=O)O.O DMKZROL IK YBZYNINTWCLDQA-UHKVWXOHSA-N DMKZROL IU acetic acid;(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-(diaminomethylideneamino)-2-[[2-(methylamino)acetyl]amino]pentanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylbutanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]pyrrolidine-2-carbonyl]amino]propanoic acid;hydrate DMKZROL CA CAS 39698-78-7 DMKZROL DE Hypertension DMLZNIQ ID DMLZNIQ DMLZNIQ DN Sarecycline DMLZNIQ HS Approved DMLZNIQ SN Sarecycline; UNII-94O110CX2E; 94O110CX2E; Sarecycline [USAN:INN]; Sarecycline (USAN/INN); P005672; SCHEMBL2699170; ZINC72319783; ZINC198637385; DB12035; FT-0772434; D10666 DMLZNIQ CP Allergan DMLZNIQ PC 54681908 DMLZNIQ MW 487.5 DMLZNIQ FM C24H29N3O8 DMLZNIQ IC InChI=1S/C24H29N3O8/c1-26(2)18-13-8-11-7-12-10(9-27(3)35-4)5-6-14(28)16(12)19(29)15(11)21(31)24(13,34)22(32)17(20(18)30)23(25)33/h5-6,11,13,18,28-29,32,34H,7-9H2,1-4H3,(H2,25,33)/t11-,13-,18-,24-/m0/s1 DMLZNIQ CS CN(C)[C@H]1[C@@H]2C[C@@H]3CC4=C(C=CC(=C4C(=C3C(=O)[C@@]2(C(=C(C1=O)C(=O)N)O)O)O)O)CN(C)OC DMLZNIQ IK AYUMVPHUMFKFPJ-SBAJWEJLSA-N DMLZNIQ IU (4S,4aS,5aR,12aR)-4-(dimethylamino)-1,10,11,12a-tetrahydroxy-7-[[methoxy(methyl)amino]methyl]-3,12-dioxo-4a,5,5a,6-tetrahydro-4H-tetracene-2-carboxamide DMLZNIQ CA CAS 1035654-66-0 DMLZNIQ DE Acne vulgaris DMY0M8J ID DMY0M8J DMY0M8J DN Sargramostim DMY0M8J HS Approved DMY0M8J SN Leukine; Leukine (TN); Sargramostim (genetical recombination); Sargramostim (USAN/INN); Sargramostim (genetical recombination) (JAN) DMY0M8J CP Bayer Pharmaceuticals Corporation DMY0M8J TC Immunomodulatory Agents DMY0M8J SQ DB00020 sequence: APARSPSPSTQPWEHVNAIQEALRLLNLSRDTAAEMNETVEVISEMFDLQEPTCLQTRLELYKQGLRGSLTKLKGPLTMMASHYKQHCPPTPETSCATQIITFESFKENLKDFLLVIPFDCWEPVQE DMY0M8J DE Bone marrow transplantation DMOGNXY ID DMOGNXY DMOGNXY DN Sarilumab DMOGNXY HS Approved DMOGNXY SN Kevzara DMOGNXY CP Sanofi/Regeneron DMOGNXY DT Monoclonal antibody DMOGNXY SQ Heavy chain: EVQLVESGGGLVQPGRSLRLSCAASRFTFDDYAMHWVRQAPGKGLEWVSGISWNSGRIGYADSVKGRFTISRDNAENSLFLQMNGLRAEDTALYYCAKGRDSFDIWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK >Light chainDIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLIYGASSLESGVPSRFSGSGSGTDFTLTISSLQPEDFASYYCQQANSFPYTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC DMOGNXY DE Rheumatoid arthritis DMGLP6S ID DMGLP6S DMGLP6S DN Sarpogrelate DMGLP6S HS Approved DMGLP6S SN Sarpogrelate [INN]; Sarpogrelate (INN); Butanedioic acid, mono[2-(dimethylamino)-1-[[2-[2-(3-methoxyphenyl)ethyl]phenoxy]methyl]ethyl] ester; 4-[1-(dimethylamino)-3-[2-[2-(3-methoxyphenyl)ethyl]phenoxy]propan-2-yl]oxy-4-oxobutanoic acid; 4-{[1-(dimethylamino)-3-{2-[2-(3-methoxyphenyl)ethyl]phenoxy}propan-2-yl]oxy}-4-oxobutanoic acid DMGLP6S TC Hypoglycemic Agents DMGLP6S DT Small molecular drug DMGLP6S PC 5160 DMGLP6S MW 429.5 DMGLP6S FM C24H31NO6 DMGLP6S IC InChI=1S/C24H31NO6/c1-25(2)16-21(31-24(28)14-13-23(26)27)17-30-22-10-5-4-8-19(22)12-11-18-7-6-9-20(15-18)29-3/h4-10,15,21H,11-14,16-17H2,1-3H3,(H,26,27) DMGLP6S CS CN(C)CC(COC1=CC=CC=C1CCC2=CC(=CC=C2)OC)OC(=O)CCC(=O)O DMGLP6S IK FFYNAVGJSYHHFO-UHFFFAOYSA-N DMGLP6S IU 4-[1-(dimethylamino)-3-[2-[2-(3-methoxyphenyl)ethyl]phenoxy]propan-2-yl]oxy-4-oxobutanoic acid DMGLP6S CA CAS 125926-17-2 DMGLP6S CB CHEBI:135697 DMGLP6S DE Diabetic complication DMRSKMZ ID DMRSKMZ DMRSKMZ DN Satumomab Pendetide DMRSKMZ HS Approved DMRSKMZ TC Imaging Agents DMRSKMZ DT Monoclonal antibody DMRSKMZ DE Breast cancer DMGXENV ID DMGXENV DMGXENV DN Saxagliptin DMGXENV HS Approved DMGXENV SN Onglyza; BMS 477118-11; BMS-477118; Kombiglyze XR (TN); OPC-262; Onglyza (TN); BMS-477118-11; (1S,5S)-2-[2-amino-2-(3-hydroxy-1-adamantyl)acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile; 2-Azabicyclo[3.1.0]hexane-3-carbonitrile, 2-[(2S)-amino(3-hydroxytricyclo[3.3 DMGXENV CP Bristol-Myers Squibb; AstraZeneca DMGXENV DT Small molecular drug DMGXENV PC 11243969 DMGXENV MW 315.4 DMGXENV FM C18H25N3O2 DMGXENV IC InChI=1S/C18H25N3O2/c19-8-13-2-12-3-14(12)21(13)16(22)15(20)17-4-10-1-11(5-17)7-18(23,6-10)9-17/h10-15,23H,1-7,9,20H2/t10?,11?,12-,13+,14+,15-,17?,18?/m1/s1 DMGXENV CS C1[C@@H]2C[C@@H]2N([C@@H]1C#N)C(=O)[C@H](C34CC5CC(C3)CC(C5)(C4)O)N DMGXENV IK QGJUIPDUBHWZPV-SGTAVMJGSA-N DMGXENV IU (1S,3S,5S)-2-[(2S)-2-amino-2-(3-hydroxy-1-adamantyl)acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile DMGXENV CA CAS 361442-04-8 DMGXENV CB CHEBI:71272 DMGXENV DE Type-2 diabetes DMDK7T9 ID DMDK7T9 DMDK7T9 DN SBC-102 DMDK7T9 HS Approved DMDK7T9 SN Sebelipase alfa; Enzyme replacement therapy (protein recombinant, lysosomal acid lipase deficiency), Synageva BioPharma DMDK7T9 CP Synageva biopharma DMDK7T9 SQ Sebelipase alfa protein sequence: SGGKLTAVDPETNMNVSEIISYWGFPSEEYLVETEDGYILCLNRIPHGRKNHSDKGPKPVVFLQHGLLADSSNWVTNLANSSLGFILADAGFDVWMGNSRGNTWSRKHKTLSVSQDEFWAFSYDEMAKYDLPASINFILNKTGQEQVYYVGHSQGTTIGFIAFSQIPELAKRIKMFFALGPVASVAFCTSPMAKLGRLPDHLIKDLFGDKEFLPQSAFLKWLGTHVCTHVILKELCGNLCFLLCGFNERNLNMSRVDVYTTHSPAGTSVQNMLHWSQAVKFQKFQAFDWGSSAKNYFHYNQSYPPTYNVKDMLVPTAVWSGGHDWLADVYDVNILLTQITNLVFHESIPEWEHLDFIWGLDAPWRLYNKIINLMRKYQ DMDK7T9 DE Enzyme deficiency DMOM8AL ID DMOM8AL DMOM8AL DN Scopolamine DMOM8AL HS Approved DMOM8AL SN Atroscine; Euscopol; Hyosceine; Hysco; Isoscopil; Kwells; SEE; Scop; Scopamin; Scopolaminhydrobromid; Scopos; Sereen; Tranaxine; Transcop; Triptone; Atroscine Hydrobromide; Hydroscine hydrobromide; Hyocine F hydrobromide; Hyoscine bromide; Hyoscyine hydrobromide; SCOPOLAMINE BROMIDE; Scopolamine Hyoscine; Scopolaminium bromide; Scopolammonium bromide; Tropane alkaloid; MOLI001381; NCI61806; Borrachero (TN); Burundanga (TN); Hyoscine (TN); L-Hyoscine hydrobromide; Scopoderm-TTS; Scopolamine (INN); Transderm scop (TN); Levo-duboisine (TN); Xy-, (-)-tropate (ester); (-)-Scopolamine hydrobromide trihydrate; 1alphaH,5alphaH-Tropan-3alpha-ol, 6beta,7beta-epo; 1alphaH,5alphaH-Tropan-3alpha-ol, 6beta,7beta-epoxy-, (-)-tropate (ester); 3-Oxa-9-azatricyclo(3.3.1.O(sup 2,4))nonan-7-ol, 9-methyl-, tropate (ester); 9-methyl-3-oxa-9-azatricyclo[3.3.1.0~2,4~]non-7-yl tropate DMOM8AL CP Norvatis Phamaceuticals Corporation DMOM8AL TC Antispasmodics DMOM8AL DT Small molecular drug DMOM8AL PC 3000322 DMOM8AL MW 303.35 DMOM8AL FM C17H21NO4 DMOM8AL IC InChI=1S/C17H21NO4/c1-18-13-7-11(8-14(18)16-15(13)22-16)21-17(20)12(9-19)10-5-3-2-4-6-10/h2-6,11-16,19H,7-9H2,1H3/t11?,12-,13-,14+,15-,16+/m1/s1 DMOM8AL CS CN1[C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4 DMOM8AL IK STECJAGHUSJQJN-USLFZFAMSA-N DMOM8AL IU [(1R,2R,4S,5S)-9-methyl-3-oxa-9-azatricyclo[3.3.1.02,4]nonan-7-yl] (2S)-3-hydroxy-2-phenylpropanoate DMOM8AL CA CAS 114-49-8 DMOM8AL CB CHEBI:16794 DMOM8AL DE Addictive disorder; Nausea DMJ18YL ID DMJ18YL DMJ18YL DN Secnidazole DMJ18YL HS Approved DMJ18YL SN 3366-95-8; Secnidazol; Secnidazolum; Flagentyl; Secnidazolum [INN-Latin]; Solosec; RP 14539; Secnidazol [INN-Spanish]; PM 185184;Secnidazole (Flagentyl); SYM-1219; EINECS 222-134-0; seknidazol; MLS000559043; PM-185184; NCGC00095158-01; SMR000149359; RP-14539 DMJ18YL CP Lupin DMJ18YL DT Small molecular drug DMJ18YL PC 71815 DMJ18YL MW 185.18 DMJ18YL FM C7H11N3O3 DMJ18YL IC InChI=1S/C7H11N3O3/c1-5(11)4-9-6(2)8-3-7(9)10(12)13/h3,5,11H,4H2,1-2H3 DMJ18YL CS CC1=NC=C(N1CC(C)O)[N+](=O)[O-] DMJ18YL IK KPQZUUQMTUIKBP-UHFFFAOYSA-N DMJ18YL IU 1-(2-methyl-5-nitroimidazol-1-yl)propan-2-ol DMJ18YL CA CAS 3366-95-8 DMJ18YL CB CHEBI:94433 DMJ18YL DE Bacterial vaginosis; Amoebiasis DM14RF5 ID DM14RF5 DM14RF5 DN Secobarbital DM14RF5 HS Approved DM14RF5 SN Barbosec; Evronal; Hypotrol; Hyptran; Meballymal; Meballymalum; Pramil; Quinalbarbital; Quinalbarbitone; Secobarbitale; Secobarbitalum; Secobarbitone; Seconal; Seotal; Somosal; Secobarbital solution; Secobarbital suppository dosage form; Secobarbitale [DCIT]; Secobarbital [USAN:INN]; Secobarbitalum [INN-Latin]; Seconal (TN);Secobarbital (USP/INN); (+-)-5-Allyl-5-(1-methylbutyl)-barbituric acid; (+-)-Secobarbital; 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-(1-methylbutyl)-5-(2-propenyl)-, (+-)-(9CI); 5-(1-methylbutyl)-5-(2-propenyl)-2,4,6(1H,3H,5H)-pyrimidinetrione; 5-(pentan-2-yl)-5-(prop-2-en-1-yl)-pyrimidine-2,4,6(1H,3H,5H)-trione; 5-ALLYL-5-(1-METHYLBUTYL)BARBITURIC ACID; 5-Allyl-5-(1-methylbutyl)-2,4,6(1H,3H,5H)-pyrimidinetrione; 5-Allyl-5-(1-methylbutyl)barbiturate; 5-Allyl-5-(1-methylbutyl)malonylurea; 5-allyl-5-(1-methylbutyl)pyrimidine-2,4,6(1H,3H,5H)-trione; 5-pentan-2-yl-5-prop-2-enyl-1,3-diazinane-2,4,6-trione DM14RF5 CP Eli Lilly DM14RF5 TC Hypnotics and Sedatives DM14RF5 DT Small molecular drug DM14RF5 PC 5193 DM14RF5 MW 238.28 DM14RF5 FM C12H18N2O3 DM14RF5 IC InChI=1S/C12H18N2O3/c1-4-6-8(3)12(7-5-2)9(15)13-11(17)14-10(12)16/h5,8H,2,4,6-7H2,1,3H3,(H2,13,14,15,16,17) DM14RF5 CS CCCC(C)C1(C(=O)NC(=O)NC1=O)CC=C DM14RF5 IK KQPKPCNLIDLUMF-UHFFFAOYSA-N DM14RF5 IU 5-pentan-2-yl-5-prop-2-enyl-1,3-diazinane-2,4,6-trione DM14RF5 CA CAS 76-73-3 DM14RF5 CB CHEBI:9073 DM14RF5 DE Intractable insomnia DMDKE4N ID DMDKE4N DMDKE4N DN Secretin DMDKE4N HS Approved DMDKE4N SN SECREFLO; SecreFlow; Secrepan; Secretina; Secretine; Secretinum; Secretolin; Vitrum; Hormone of the duodenal mucosa that activates pancreatic secretion and lowers the blood sugar level; Human secretin; RG 1068; L-Valinamide; SECRETIN-FERRING; Secretin (human); Secretin (porcine); Secretin-Kabi; Secretina [INN-Spanish]; Secretine [INN-French]; Secretinum [INN-Latin]; Secretin [INN:BAN:DCF:JAN] DMDKE4N TC Diagnostic Agents DMDKE4N DT Small molecular drug DMDKE4N SQ DB00021 sequence: HSDGTFTSELSRLRDSARLQRLLQGLV DMDKE4N PC 16129665 DMDKE4N MW 3056.4 DMDKE4N FM C130H219N43O42 DMDKE4N IC InChI=1S/C130H219N43O42/c1-59(2)43-78(118(206)172-99(65(13)14)126(214)215)151-94(182)53-148-104(192)75(31-34-91(132)180)156-113(201)81(46-62(7)8)163-115(203)82(47-63(9)10)161-107(195)72(28-22-38-145-128(136)137)153-110(198)76(32-35-92(133)181)157-114(202)80(45-61(5)6)159-106(194)71(27-21-37-144-127(134)135)152-102(190)66(15)150-120(208)87(55-174)168-117(205)86(52-98(188)189)165-109(197)73(29-23-39-146-129(138)139)154-112(200)79(44-60(3)4)160-108(196)74(30-24-40-147-130(140)141)155-121(209)89(57-176)169-116(204)83(48-64(11)12)162-111(199)77(33-36-96(184)185)158-122(210)90(58-177)170-125(213)101(68(17)179)173-119(207)84(49-69-25-19-18-20-26-69)166-124(212)100(67(16)178)171-95(183)54-149-105(193)85(51-97(186)187)164-123(211)88(56-175)167-103(191)70(131)50-93-142-41-42-143-93/h18-20,25-26,41-42,59-68,70-90,99-101,174-179H,21-24,27-40,43-58,131H2,1-17H3,(H2,132,180)(H2,133,181)(H,142,143)(H,148,192)(H,149,193)(H,150,208)(H,151,182)(H,152,190)(H,153,198)(H,154,200)(H,155,209)(H,156,201)(H,157,202)(H,158,210)(H,159,194)(H,160,196)(H,161,195)(H,162,199)(H,163,203)(H,164,211)(H,165,197)(H,166,212)(H,167,191)(H,168,205)(H,169,204)(H,170,213)(H,171,183)(H,172,206)(H,173,207)(H,184,185)(H,186,187)(H,188,189)(H,214,215)(H4,134,135,144)(H4,136,137,145)(H4,138,139,146)(H4,140,141,147) DMDKE4N CS CC(C)CC(C(=O)NC(C(C)C)C(=O)O)NC(=O)CNC(=O)C(CCC(=O)N)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(CCC(=O)N)NC(=O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(C)NC(=O)C(CO)NC(=O)C(CC(=O)O)NC(=O)C(CCCNC(=N)N)NC(=O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CCC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC1=CC=CC=C1)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(CC2=NC=CN2)N DMDKE4N IK KKNIUBFRGPFELP-UHFFFAOYSA-N DMDKE4N IU 5-[[1-[[1-[[1-[[1-[[1-[[1-[[1-[[1-[[1-[[1-[[5-amino-1-[[1-[[1-[[1-[[5-amino-1-[[2-[[1-[(1-carboxy-2-methylpropyl)amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-amino-3-(1H-imidazol-2-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoic acid DMDKE4N CA CAS 1393-25-5 DMDKE4N DE Pancreatic exocrine dysfunction; Gastrinoma DMFEGB0 ID DMFEGB0 DMFEGB0 DN Segesterone acetate; ethinyl estradiol DMFEGB0 HS Approved DMFEGB0 CP TherapeuticsMD DMFEGB0 DE Contraception DM6034S ID DM6034S DM6034S DN Selegiline DM6034S HS Approved DM6034S SN selegiline; L-Deprenalin; Emsam; (-)-selegiline; Selegilinum; Selegilina; Carbex; 14611-51-9; Selegilinum [INN-Latin]; Selegilina [INN-Spanish]; UNII-2K1V7GP655; l-E 250; CHEMBL972; CHEBI:9086; N-methyl-N-[(2R)-1-phenylpropan-2-yl]prop-2-yn-1-amine; 2K1V7GP655; (R)-(-)-N,alpha-Dimethyl-N-2-propinylphenethylamine; Benzeneethanamine, N,alpha-dimethyl-N-2-propynyl-, (R)-; selgene; (R)-(-)-N-Methyl-N-(1-phenyl-2-propyl)-2-propinylamin; Selegyline; Zalapar; Selegiline (transdermal, Parkinson's/depression); Zunrisa/Rezonic DM6034S CP Syntropharma DM6034S DT Small molecular drug DM6034S PC 26757 DM6034S MW 187.28 DM6034S FM C13H17N DM6034S IC InChI=1S/C13H17N/c1-4-10-14(3)12(2)11-13-8-6-5-7-9-13/h1,5-9,12H,10-11H2,2-3H3/t12-/m1/s1 DM6034S CS C[C@H](CC1=CC=CC=C1)N(C)CC#C DM6034S IK MEZLKOACVSPNER-GFCCVEGCSA-N DM6034S IU (2R)-N-methyl-1-phenyl-N-prop-2-ynylpropan-2-amine DM6034S CA CAS 14611-51-9 DM6034S CB CHEBI:9086 DM6034S DE Skin imperfections; Major depressive disorder; Chemotherapy-induced nausea DM3VR1L ID DM3VR1L DM3VR1L DN Selegiline hydrochloride DM3VR1L HS Approved DM3VR1L SN Selegiline hydrochloride; 14611-52-0; Selegiline Hcl; (-)-Deprenyl hydrochloride; l-Deprenyl hydrochloride; Jumex hydrochloride; Eldepryl hydrochloride; (-)-Deprenil hydrochloride; (R)-N-Methyl-N-(1-phenylpropan-2-yl)prop-2-yn-1-amine hydrochloride; (-)-E-250 hydrochloride; UNII-6W731X367Q; HSDB 7183; R-(-)-Deprenyl (hydrochloride); FPF1100; (-)-Phenylisopropylmethylpropynylamine; 6W731X367Q; (-)-(R)-N,alpha-Dimethyl-N-2-propynylphenethylamine hydrochloride; Zydis selegiline DM3VR1L CP Somerset Pharmaceuticals Inc DM3VR1L TC Neurology Agents DM3VR1L DT Small molecular drug DM3VR1L PC 26758 DM3VR1L MW 223.74 DM3VR1L FM C13H18ClN DM3VR1L IC InChI=1S/C13H17N.ClH/c1-4-10-14(3)12(2)11-13-8-6-5-7-9-13;/h1,5-9,12H,10-11H2,2-3H3;1H/t12-;/m1./s1 DM3VR1L CS C[C@H](CC1=CC=CC=C1)N(C)CC#C.Cl DM3VR1L IK IYETZZCWLLUHIJ-UTONKHPSSA-N DM3VR1L IU (2R)-N-methyl-1-phenyl-N-prop-2-ynylpropan-2-amine;hydrochloride DM3VR1L CA CAS 14611-52-0 DM3VR1L CB CHEBI:9087 DM3VR1L DE Parkinson disease; Motor symptoms DM25CGV ID DM25CGV DM25CGV DN Selenium DM25CGV HS Approved DM25CGV SN Selenium; Selenium alloy; Selenium and compounds; Selenium anhydride; Selenium base; Selenium dihydride; Selenium dust; Selenium elemental; Selenium homopolymer; Selenium hydride; Selenium metallicum; Selenium, colloidal; Selenium, elemental; Selenium, metallic; Vandex; selenio; 7782-49-2; CCRIS 4250; Caswell No. 732; EINECS 231-957-4; Colloidal selenium; Electronic E-2; Elemental selenium; Gray selenium; Hydrogen selenide (H2Se); SELENIUM ATOM; SELENIUM COMPOUNDS; SELENIUM POWDER; Selen [Polish]; HSDB 4493; Se; Selen; UNII-H6241UJ22B DM25CGV PC 6326970 DM25CGV MW 78.97 DM25CGV FM Se DM25CGV IC BUGBHKTXTAQXES-UHFFFAOYSA-N DM25CGV CS [Se] DM25CGV IK 1S/Se DM25CGV IU selenium DM25CGV CA CAS 7782-49-2 DM25CGV CB CHEBI:27568 DM25CGV DE Seborrhoeic dermatitis DMAHSU0 ID DMAHSU0 DMAHSU0 DN Selexipag DMAHSU0 HS Approved DMAHSU0 SN Selexipag; NS-304; 475086-01-2; Uptravi; NS 304; ACT-293987; UNII-5EXC0E384L; Selexipag(NS-304); ACT 293987; 5EXC0E384L; 2-(4-((5,6-diphenylpyrazin-2-yl)(isopropyl)amino)butoxy)-N-(methylsulfonyl)acetamide; 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide; 2-(4-((5,6-Diphenylpyrazin-2-yl)(propan-2-yl)amino)butoxy}-n-(methanesulfonyl)acetamide; Selexipag [USAN:INN]; 2-{4-[(5,6-diphenylpyrazin-2-yl)(propan-2-yl)amino]butoxy}-N-(methanesulfonyl)acetamide; Uptravi (TN) DMAHSU0 CP Actelion Pharmaceuticals DMAHSU0 DT Small molecular drug DMAHSU0 PC 9913767 DMAHSU0 MW 496.6 DMAHSU0 FM C26H32N4O4S DMAHSU0 IC InChI=1S/C26H32N4O4S/c1-20(2)30(16-10-11-17-34-19-24(31)29-35(3,32)33)23-18-27-25(21-12-6-4-7-13-21)26(28-23)22-14-8-5-9-15-22/h4-9,12-15,18,20H,10-11,16-17,19H2,1-3H3,(H,29,31) DMAHSU0 CS CC(C)N(CCCCOCC(=O)NS(=O)(=O)C)C1=CN=C(C(=N1)C2=CC=CC=C2)C3=CC=CC=C3 DMAHSU0 IK QXWZQTURMXZVHJ-UHFFFAOYSA-N DMAHSU0 IU 2-[4-[(5,6-diphenylpyrazin-2-yl)-propan-2-ylamino]butoxy]-N-methylsulfonylacetamide DMAHSU0 CA CAS 475086-01-2 DMAHSU0 CB CHEBI:90844 DMAHSU0 DE Pulmonary arterial hypertension DMZR15V ID DMZR15V DMZR15V DN Selpercatinib DMZR15V HS Approved DMZR15V SN MFOVQWYFURMVKU-IWAAJCSBSA-N; 2222755-14-6; LOXO292; ARRY-192; LOXO 292; EX-A2636 DMZR15V CP Loxo Oncology Stamford, CT DMZR15V PC 134823904 DMZR15V MW 542.6 DMZR15V FM C29H34N8O3 DMZR15V IC InChI=1S/C29H34N8O3/c1-19-9-34-37-17-23(40-18-24-11-30-5-6-39-24)8-25(29(19)37)26-12-32-27(13-31-26)35-15-21-7-22(16-35)36(21)14-20-3-4-28(38-2)33-10-20/h3-4,8-10,12-13,17,21-22,24,30H,5-7,11,14-16,18H2,1-2H3/t21?,22?,24-/m0/s1 DMZR15V CS CC1=C2C(=CC(=CN2N=C1)OC[C@@H]3CNCCO3)C4=CN=C(C=N4)N5CC6CC(C5)N6CC7=CN=C(C=C7)OC DMZR15V IK MFOVQWYFURMVKU-IWAAJCSBSA-N DMZR15V IU (2S)-2-[[4-[5-[6-[(6-methoxypyridin-3-yl)methyl]-3,6-diazabicyclo[3.1.1]heptan-3-yl]pyrazin-2-yl]-3-methylpyrazolo[1,5-a]pyridin-6-yl]oxymethyl]morpholine DMZR15V DE Non-small-cell lung cancer; Colon cancer; Thyroid cancer DMAGFOD ID DMAGFOD DMAGFOD DN Semaglutide DMAGFOD HS Approved DMAGFOD SN NN9535 DMAGFOD CP Novo Nordisk DMAGFOD DT Small molecular drug DMAGFOD PC 56843331 DMAGFOD MW 4114 DMAGFOD FM C187H291N45O59 DMAGFOD IC InChI=1S/C187H291N45O59/c1-18-105(10)154(180(282)208-108(13)159(261)216-133(86-114-89-200-119-50-40-39-49-117(114)119)170(272)218-129(82-102(4)5)171(273)228-152(103(6)7)178(280)215-121(53-44-72-199-186(192)193)162(264)201-91-141(242)209-120(52-43-71-198-185(190)191)161(263)204-94-151(257)258)230-172(274)131(83-111-45-33-31-34-46-111)219-167(269)126(64-69-149(253)254)214-166(268)122(51-41-42-70-195-144(245)98-290-79-78-289-76-74-197-145(246)99-291-80-77-288-75-73-196-139(240)66-61-127(183(285)286)211-140(241)54-37-29-27-25-23-21-19-20-22-24-26-28-30-38-55-146(247)248)212-158(260)107(12)206-157(259)106(11)207-165(267)125(60-65-138(189)239)210-142(243)92-202-163(265)123(62-67-147(249)250)213-168(270)128(81-101(2)3)217-169(271)130(85-113-56-58-116(238)59-57-113)220-175(277)135(95-233)223-177(279)137(97-235)224-179(281)153(104(8)9)229-174(276)134(88-150(255)256)221-176(278)136(96-234)225-182(284)156(110(15)237)231-173(275)132(84-112-47-35-32-36-48-112)222-181(283)155(109(14)236)227-143(244)93-203-164(266)124(63-68-148(251)252)226-184(287)187(16,17)232-160(262)118(188)87-115-90-194-100-205-115/h31-36,39-40,45-50,56-59,89-90,100-110,118,120-137,152-156,200,233-238H,18-30,37-38,41-44,51-55,60-88,91-99,188H2,1-17H3,(H2,189,239)(H,194,205)(H,195,245)(H,196,240)(H,197,246)(H,201,264)(H,202,265)(H,203,266)(H,204,263)(H,206,259)(H,207,267)(H,208,282)(H,209,242)(H,210,243)(H,211,241)(H,212,260)(H,213,270)(H,214,268)(H,215,280)(H,216,261)(H,217,271)(H,218,272)(H,219,269)(H,220,277)(H,221,278)(H,222,283)(H,223,279)(H,224,281)(H,225,284)(H,226,287)(H,227,244)(H,228,273)(H,229,276)(H,230,274)(H,231,275)(H,232,262)(H,247,248)(H,249,250)(H,251,252)(H,253,254)(H,255,256)(H,257,258)(H,285,286)(H4,190,191,198)(H4,192,193,199)/t105-,106-,107-,108-,109+,110+,118-,120-,121-,122-,123-,124-,125-,126-,127+,128-,129-,130-,131-,132-,133-,134-,135-,136-,137-,152-,153-,154-,155-,156-/m0/s1 DMAGFOD CS CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CC[C@H](C(=O)O)NC(=O)CCCCCCCCCCCCCCCCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)N)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)C(C)(C)NC(=O)[C@H](CC6=CN=CN6)N DMAGFOD IK DLSWIYLPEUIQAV-CCUURXOWSA-N DMAGFOD IU 18-[[(1R)-4-[2-[2-[2-[2-[2-[2-[[(5S)-5-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]-2-methylpropanoyl]amino]-4-carboxybutanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-4-carboxybutanoyl]amino]acetyl]amino]-5-oxopentanoyl]amino]propanoyl]amino]propanoyl]amino]-6-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-carbamimidamido-1-[[2-[[(2S)-5-carbamimidamido-1-(carboxymethylamino)-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-6-oxohexyl]amino]-2-oxoethoxy]ethoxy]ethylamino]-2-oxoethoxy]ethoxy]ethylamino]-1-carboxy-4-oxobutyl]amino]-18-oxooctadecanoic acid DMAGFOD CA CAS 910463-68-2 DMAGFOD DE Type-2 diabetes DM25HP1 ID DM25HP1 DM25HP1 DN Sermorelin DM25HP1 HS Approved DM25HP1 SN Sermorelina; Sermoreline; Sermorelinum; Sermorelina [Spanish]; Sermoreline [French]; Sermorelinum [Latin]; Geref (TN); Sermorelin (INN); Sermorelin [INN:BAN]; GROWTH HORMONE RELEASING FACTOR, Fragment 1-29 Amide; Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2 DM25HP1 CP Emd Serono Inc DM25HP1 TC Hormone Replacement Agents DM25HP1 DT Small molecular drug DM25HP1 SQ DB00010 sequence: YADAIFTNSYRKVLGQLSARKLLQDIMSRQ DM25HP1 PC 16132413 DM25HP1 MW 3357.9 DM25HP1 FM C149H246N44O42S DM25HP1 IC InChI=1S/C149H246N44O42S/c1-20-77(13)116(191-122(211)81(17)168-132(221)104(66-113(204)205)178-121(210)79(15)167-123(212)88(152)62-84-39-43-86(198)44-40-84)145(234)185-102(63-83-32-23-22-24-33-83)138(227)193-118(82(18)197)146(235)186-103(65-111(155)202)137(226)189-108(71-196)142(231)182-101(64-85-41-45-87(199)46-42-85)136(225)175-93(38-31-56-165-149(161)162)126(215)174-91(35-26-28-53-151)131(220)190-115(76(11)12)143(232)184-97(58-72(3)4)124(213)166-68-112(203)170-94(47-49-109(153)200)128(217)180-100(61-75(9)10)135(224)188-106(69-194)140(229)169-80(16)120(209)172-92(37-30-55-164-148(159)160)125(214)173-90(34-25-27-52-150)127(216)179-99(60-74(7)8)134(223)181-98(59-73(5)6)133(222)176-95(48-50-110(154)201)129(218)183-105(67-114(206)207)139(228)192-117(78(14)21-2)144(233)177-96(51-57-236-19)130(219)187-107(70-195)141(230)171-89(119(156)208)36-29-54-163-147(157)158/h22-24,32-33,39-46,72-82,88-108,115-118,194-199H,20-21,25-31,34-38,47-71,150-152H2,1-19H3,(H2,153,200)(H2,154,201)(H2,155,202)(H2,156,208)(H,166,213)(H,167,212)(H,168,221)(H,169,229)(H,170,203)(H,171,230)(H,172,209)(H,173,214)(H,174,215)(H,175,225)(H,176,222)(H,177,233)(H,178,210)(H,179,216)(H,180,217)(H,181,223)(H,182,231)(H,183,218)(H,184,232)(H,185,234)(H,186,235)(H,187,219)(H,188,224)(H,189,226)(H,190,220)(H,191,211)(H,192,228)(H,193,227)(H,204,205)(H,206,207)(H4,157,158,163)(H4,159,160,164)(H4,161,162,165)/t77-,78-,79-,80-,81-,82+,88-,89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,115-,116-,117-,118-/m0/s1 DM25HP1 CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](CC3=CC=C(C=C3)O)N DM25HP1 IK WGWPRVFKDLAUQJ-MITYVQBRSA-N DM25HP1 IU (3S)-4-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-4-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-2-oxoethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-[[(2S)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]-4-oxobutanoic acid DM25HP1 CA CAS 86168-78-7 DM25HP1 DE Pediatric growth disorder DM1A9XO ID DM1A9XO DM1A9XO DN Sertaconazole DM1A9XO HS Approved DM1A9XO SN Sertaconazol; Sertaconazolum; Sertaconazol [Spanish]; Sertaconazole [INN]; Sertaconazolum [Latin]; FI-7045; Sertaconazole (INN); (+-)-1-(2,4-Dichloro-beta-((7-chlorobenzo(b)thien-3-yl)methoxy)phenethyl)imidazole; (inverted exclamation markA)-1-[2,4-dichloro-b-[(7-chlorobenzo[b]thien-3-yl)methoxy]phenethyl]imidazole;1-(2-((7-Chlorobenzo(b)thien-3-yl)methoxy)-2-(2,4-dichlorophenyl)ethyl)-1H-imidazole; 1-[2-[(7-chloro-1-benzothiophen-3-yl)methoxy]-2-(2,4-dichlorophenyl)ethyl]imidazole; 7-Chloro-3-(1-(2,4-dichlorophenyl)-2-(1H-imidazol-1-yl)ethoxy-methyl)benzo(b)thiophene; 7-Chloro-3-[1-(2,4-dichlorophenyl)-2-(1H-imidazol-1-yl)ethoxy-methyl]benzo[b]thiophene; 7-Cloro-3-(1-(2,4-diclorofenil)-2-(1H-imidazol-1-il)etoxi-metil)benzo(b)tiofeno; 7-Cloro-3-(1-(2,4-diclorofenil)-2-(1H-imidazol-1-il)etoxi-metil)benzo(b)tiofeno [Spanish] DM1A9XO TC Antifungal Agents DM1A9XO DT Small molecular drug DM1A9XO PC 65863 DM1A9XO MW 437.8 DM1A9XO FM C20H15Cl3N2OS DM1A9XO IC InChI=1S/C20H15Cl3N2OS/c21-14-4-5-16(18(23)8-14)19(9-25-7-6-24-12-25)26-10-13-11-27-20-15(13)2-1-3-17(20)22/h1-8,11-12,19H,9-10H2 DM1A9XO CS C1=CC2=C(C(=C1)Cl)SC=C2COC(CN3C=CN=C3)C4=C(C=C(C=C4)Cl)Cl DM1A9XO IK JLGKQTAYUIMGRK-UHFFFAOYSA-N DM1A9XO IU 1-[2-[(7-chloro-1-benzothiophen-3-yl)methoxy]-2-(2,4-dichlorophenyl)ethyl]imidazole DM1A9XO CA CAS 99592-32-2 DM1A9XO CB CHEBI:83682 DM1A9XO DE Fungal infection DM0FB1J ID DM0FB1J DM0FB1J DN Sertraline DM0FB1J HS Approved DM0FB1J SN Lustral; SRE; Sertralina; Sertralinum; Sertralina [Spanish]; Sertraline [Zoloft]; Sertralinum [Latin]; CP 51974; Cp 51974; Apo-Sertraline; Lustral (TN); Sertraline (INN); Sertraline (Zoloft); Sertraline [INN:BAN]; Zoloft (TN); (+)-Sertraline; (1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalen-1-amine; (1S-cis)-1,2,3,4-Tetrahydro-4-(3,4-dichlorophenyl)-N-methyl-1-naphthalenamine; (1S-cis)-4-(3,4-Dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenamine DM0FB1J CP Pfizer Inc DM0FB1J TC Antidepressants DM0FB1J DT Small molecular drug DM0FB1J PC 68617 DM0FB1J MW 306.2 DM0FB1J FM C17H17Cl2N DM0FB1J IC InChI=1S/C17H17Cl2N/c1-20-17-9-7-12(13-4-2-3-5-14(13)17)11-6-8-15(18)16(19)10-11/h2-6,8,10,12,17,20H,7,9H2,1H3/t12-,17-/m0/s1 DM0FB1J CS CN[C@H]1CC[C@H](C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl DM0FB1J IK VGKDLMBJGBXTGI-SJCJKPOMSA-N DM0FB1J IU (1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalen-1-amine DM0FB1J CA CAS 79617-96-2 DM0FB1J CB CHEBI:9123 DM0FB1J DE Depression DMPVRN9 ID DMPVRN9 DMPVRN9 DN Setmelanotide DMPVRN9 HS Approved DMPVRN9 SN RM-493; UNII-N7T15V1FUY; BIM-22493; N7T15V1FUY; 920014-72-8; Setmelanotide [USAN:INN]; GTPL9272; CHEMBL3301624; CS-6399; DB11700; HY-19870; L-Cysteinamide, N2-acetyl-L-arginyl-L-cysteinyl-D-alanyl-L-histidyl-D-phenylalanyl-L-arginyl-L-tryptophyl-, cyclic (2-> 8)-disulfide; (4R,7S,10S,13R,16S,19R,22R)-22-[[(2S)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-13-benzyl-10-[3-(diaminomethylideneamino)propyl]-16-(1H-imidazol-5-ylmethyl)-7-(1H-indol-3-ylmethyl)-19-methyl-6,9,12,15,18,21-hexaoxo-1,2-d DMPVRN9 CP Rhythm Metabolics Boston, MA DMPVRN9 PC 11993702 DMPVRN9 MW 1117.3 DMPVRN9 FM C49H68N18O9S2 DMPVRN9 IC InChI=1S/C49H68N18O9S2/c1-26-41(70)63-37(20-30-22-55-25-59-30)46(75)64-35(18-28-10-4-3-5-11-28)44(73)62-34(15-9-17-57-49(53)54)43(72)65-36(19-29-21-58-32-13-7-6-12-31(29)32)45(74)66-38(40(50)69)23-77-78-24-39(47(76)60-26)67-42(71)33(61-27(2)68)14-8-16-56-48(51)52/h3-7,10-13,21-22,25-26,33-39,58H,8-9,14-20,23-24H2,1-2H3,(H2,50,69)(H,55,59)(H,60,76)(H,61,68)(H,62,73)(H,63,70)(H,64,75)(H,65,72)(H,66,74)(H,67,71)(H4,51,52,56)(H4,53,54,57)/t26-,33+,34+,35-,36+,37+,38+,39+/m1/s1 DMPVRN9 CS C[C@@H]1C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)C)C(=O)N)CC2=CNC3=CC=CC=C32)CCCN=C(N)N)CC4=CC=CC=C4)CC5=CN=CN5 DMPVRN9 IK HDHDTKMUACZDAA-PHNIDTBTSA-N DMPVRN9 IU (4R,7S,10S,13R,16S,19R,22R)-22-[[(2S)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-13-benzyl-10-[3-(diaminomethylideneamino)propyl]-16-(1H-imidazol-5-ylmethyl)-7-(1H-indol-3-ylmethyl)-19-methyl-6,9,12,15,18,21-hexaoxo-1,2-dithia-5,8,11,14,17,20-hexazacyclotricosane-4-carboxamide DMPVRN9 CA CAS 920014-72-8 DMPVRN9 DE Diabetic complication; Obesity; Prader-Willi syndrome; Bardet biedl syndrome DMC9O43 ID DMC9O43 DMC9O43 DN Sevoflurane DMC9O43 HS Approved DMC9O43 SN Sevofluran; Sevoflurano; Sevofluranum; Sevofrane; Sevorane; Sojourn; Ultane; Fluoromethyl hexafluoroisopropyl ether; Bax 3084; F0691; MR6S4; MR_6S4; PC4681; Sevoflurano [INN-Spanish]; Sevofluranum [INN-Latin]; Ultane (TN); Sevoflurane (JAN/USAN/INN); Sevoflurane [USAN:INN:BAN:JAN]; Fluoromethyl 1,1,1,3,3,3-Hexafluoroisopropyl Ether; Fluoromethyl 2,2,2-trifluoro-1-(trifluoromethyl)ethyl ether; Fluoromethyl-2,2,2-trifluoro-1-(trifluoromethyl)ethyl ether; 1,1,1,3,3,3-Hexafluoro-2-(fluoromethoxy)propane DMC9O43 CP Abbott Laboratories DMC9O43 TC Anesthetics DMC9O43 DT Small molecular drug DMC9O43 PC 5206 DMC9O43 MW 200.05 DMC9O43 FM C4H3F7O DMC9O43 IC InChI=1S/C4H3F7O/c5-1-12-2(3(6,7)8)4(9,10)11/h2H,1H2 DMC9O43 CS C(OC(C(F)(F)F)C(F)(F)F)F DMC9O43 IK DFEYYRMXOJXZRJ-UHFFFAOYSA-N DMC9O43 IU 1,1,1,3,3,3-hexafluoro-2-(fluoromethoxy)propane DMC9O43 CA CAS 28523-86-6 DMC9O43 CB CHEBI:9130 DMC9O43 DE Anaesthesia DMFJTDI ID DMFJTDI DMFJTDI DN Sibutramine DMFJTDI HS Approved DMFJTDI SN Butramin; Medaria; Meridia; Reductil; Sibutramina; Sibutraminum; Sibutramina [Spanish]; Sibutraminum [Latin]; BTS-54524; Butramin (TN); Ectiva (TN); Meridia (TN); Reductil (TN); Sibutramine (INN); Sibutramine [INN:BAN]; N-1-(1-(4-chlorophenyl)cyclobutyl)-3-methylbutyl-N,N-dimethylamine HCl; 1-[1-(4-chlorophenyl)cyclobutyl]-N,N,3-trimethylbutan-1-amine DMFJTDI CP Abbott Laboratories DMFJTDI TC Appetite Depressants DMFJTDI DT Small molecular drug DMFJTDI PC 5210 DMFJTDI MW 279.8 DMFJTDI FM C17H26ClN DMFJTDI IC InChI=1S/C17H26ClN/c1-13(2)12-16(19(3)4)17(10-5-11-17)14-6-8-15(18)9-7-14/h6-9,13,16H,5,10-12H2,1-4H3 DMFJTDI CS CC(C)CC(C1(CCC1)C2=CC=C(C=C2)Cl)N(C)C DMFJTDI IK UNAANXDKBXWMLN-UHFFFAOYSA-N DMFJTDI IU 1-[1-(4-chlorophenyl)cyclobutyl]-N,N,3-trimethylbutan-1-amine DMFJTDI CA CAS 106650-56-0 DMFJTDI CB CHEBI:9137 DMFJTDI DE Obesity DM1BS03 ID DM1BS03 DM1BS03 DN Sifalimumab DM1BS03 HS Approved DM1BS03 SN Cci 779; CHEBI:79699; Torisel (TN); 42-[3-Hydroxy-2-(hydroxymethyl)-2-methylpropanoate]rapamycin; Temsirolimus (JAN/USAN/INN); 162635-04-3; DB06287; C15182; D06068; J-524319; (1R,2R,4S)-4-[(2R)-2-[(1R,9S,12S,15R,18R,19R,21R,23S,30S,32S,35R)-1,18-dihydroxy-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-2,3,10,14,20-pentaoxo-11,36-dioxa-4-azatricyclo[30.3.1.0; {4,9}]hexatriaconta-16,24,26,28-tetraen-12-yl]propyl]-2-methoxycyclohexyl 3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate DM1BS03 CP AstraZeneca; MedImmune DM1BS03 DT Antibody DM1BS03 DE Renal cell carcinoma; Systemic lupus erythematosus DMSWJ5X ID DMSWJ5X DMSWJ5X DN Sildenafil citrate DMSWJ5X HS Approved DMSWJ5X SN Sildenafil (citrate); Sildenafil citrate; Sildenafil citrate [USAN]; Sildenafil citrate salt; UK 92480; UK-92480-10; UNII-BW9B0ZE037; Sildenafilcitrate; Sildenafil; 1-((3-(4,7-Dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo(4,3-d)pyrimidin-5-yl)-4-ethoxyphenyl)sulfonyl)-4-methylpiperazine; 139755-83-2; 3M7OB98Y7H; 5-(2-Ethoxy-5-((4-methylpiperazin-1-yl)sulfonyl)phenyl)-1-methyl-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-7(6H)-one; BNRNXUUZRGQAQC-UHFFFAOYSA-N; C22H30N6O4S; CHEBI:9139; CHEMBL192; HSDB 7305; Sildenafil [INN:BAN]; UK-92,480-10; UK-92480; UNII-3M7OB98Y7H; 1-((3-(6,7-Dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo(4,3-d)pyrimidin-5-yl)-4-ethoxyphenyl)sulfonyl)-4-methylpiperazine citrate (1:1); 171599-83-0; BW9B0ZE037; CHEBI:58987; Caverta; DSSTox_CID_26076; DSSTox_GSID_46076; DSSTox_RID_81321 DMSWJ5X PC 135413523 DMSWJ5X MW 666.7 DMSWJ5X FM C28H38N6O11S DMSWJ5X IC DEIYFTQMQPDXOT-UHFFFAOYSA-N DMSWJ5X CS CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C.C(C(=O)O)C(CC(=O)O)(C(=O)O)O DMSWJ5X IK 1S/C22H30N6O4S.C6H8O7/c1-5-7-17-19-20(27(4)25-17)22(29)24-21(23-19)16-14-15(8-9-18(16)32-6-2)33(30,31)28-12-10-26(3)11-13-28;7-3(8)1-6(13,5(11)12)2-4(9)10/h8-9,14H,5-7,10-13H2,1-4H3,(H,23,24,29);13H,1-2H2,(H,7,8)(H,9,10)(H,11,12) DMSWJ5X IU 5-[2-ethoxy-5-(4-methylpiperazin-1-yl)sulfonylphenyl]-1-methyl-3-propyl-6H-pyrazolo[4,3-d]pyrimidin-7-one;2-hydroxypropane-1,2,3-tricarboxylic acid DMSWJ5X CA CAS 171599-83-0 DMSWJ5X CB CHEBI:31307 DMSWJ5X DE Erectile dysfunction DMJSBT6 ID DMJSBT6 DMJSBT6 DN Silodosin DMJSBT6 HS Approved DMJSBT6 SN Silodosin; 160970-54-7; Rapaflo; Urief; Silodyx; Urorec; KMD-3213; Silodosin-d6; UNII-CUZ39LUY82; KMD 3213; KAD 3213; CUZ39LUY82; CHEMBL24778; KAD-3213; (R)-1-(3-hydroxypropyl)-5-(2-((2-(2-(2,2,2-trifluoroethoxy)phenoxy)ethyl)amino)propyl)indoline-7-carboxamide; 1-(3-hydroxypropyl)-5-[(2R)-2-[2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethylamino]propyl]-2,3-dihydroindole-7-carboxamide; 160970-64-9; Q-102517; Rapflo DMJSBT6 DT Small molecular drug DMJSBT6 PC 5312125 DMJSBT6 MW 495.5 DMJSBT6 FM C25H32F3N3O4 DMJSBT6 IC InChI=1S/C25H32F3N3O4/c1-17(30-8-12-34-21-5-2-3-6-22(21)35-16-25(26,27)28)13-18-14-19-7-10-31(9-4-11-32)23(19)20(15-18)24(29)33/h2-3,5-6,14-15,17,30,32H,4,7-13,16H2,1H3,(H2,29,33)/t17-/m1/s1 DMJSBT6 CS C[C@H](CC1=CC2=C(C(=C1)C(=O)N)N(CC2)CCCO)NCCOC3=CC=CC=C3OCC(F)(F)F DMJSBT6 IK PNCPYILNMDWPEY-QGZVFWFLSA-N DMJSBT6 IU 1-(3-hydroxypropyl)-5-[(2R)-2-[2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethylamino]propyl]-2,3-dihydroindole-7-carboxamide DMJSBT6 CA CAS 160970-54-7 DMJSBT6 CB CHEBI:135929 DMJSBT6 DE Benign prostatic hyperplasia DMGEATB ID DMGEATB DMGEATB DN Siltuximab DMGEATB HS Approved DMGEATB CP Janssen Biotech DMGEATB DT Antibody DMGEATB SQ Heavy Chain Sequence: EVQLVESGGKLLKPGGSLKLSCAASGFTFSSFAMSWFRQSPEKRLEWVAEISSGGSYTYYPDTVTGRFTISRDNAKNTLYLEMSSLRSEDTAMYYCARGLWGYYALDYWGQGTSVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK >Light Chain SequenceQIVLIQSPAIMSASPGEKVTMTCSASSSVSYMYWYQQKPGSSPRLLIYDTSNLASGVPVRFSGSGSGTSYSLTISRMEAEDAATYYCQQWSGYPYTFGGGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC DMGEATB DE Anemia; Multiple myeloma DMVTHWQ ID DMVTHWQ DMVTHWQ DN Silver sulfadiazine DMVTHWQ HS Approved DMVTHWQ SN Brandiazin; Dermazin; Dermazine; Flamazine; Flammazine; Geben; Sicazine; Silbertone; Silvederma; Silver; Sulfargen; Abbott Brand of Silver Sulfadiazine; Aldo Brand of Silver Sulfadiazine; Major Brand of Silver Sulfadiazine; Medphano Brand of Silver Sulfadiazine; MonarchBrand of Silver Sulfadiazine; Pharmascience Brand of Silver Sulfadiazine; Rhone Poulenc Rorer Brand of Silver Sulfadiazine; SSD AF; SULFADIAZINE SILVER; Sherwood Brand of Silver Sulfadiazine; Silver Sulfafdiazine; Silver sulfadiazinate; Silver sulphadiazine; Solvay Brand of Silver Sulfadiazine; Sulfadiazin silber; Sulfadiazine silver salt; Sulfadiazine silverSilvadene; Zenith Brand of Silver Sulfadiazine; Par Brand 1 of Silver Sulfadiazine; Par Brand 2 of Silver Sulfadiazine; Par Brand 3 of Silver Sulfadiazine; Flamazine (TN); Rhone-Poulenc Rorer Brand of Silver Sulfadiazine; Silvadene (TN); Silver(I) sulfadiazine; Smith & Nephew Brand of Silver Sulfadiazine; Sulfadiazin, silbersalz; Sulfadiazine silver (JP15); Sulfadiazine, Silver [USAN]; Sulfadiazine, silver; Sulfafdiazine, Silver; Thermazene (TN); SSD (1% Silver Sulfadiazine Cream USP); Sulfadiazine, silver (USP); N1-2-Pyrimidinylsulfanilamide monosilver(1+) salt; N(sup 1)-2-Pyrimidinylsulfanilamide monosilver(1+) salt; Silver (4-aminophenyl)sulfonyl-pyrimidin-2-ylazanide; Silver 4-amino-N-pyrimidin-2-ylbenzenesulfonamide; Benzenesulfonamide,4-amino-N-2-pyrimidinyl-, silver complex; Silver(1+) [(4-aminophenyl)sulfonyl](pyrimidin-2-yl)azanide; Sulfanilamide,N1-2-pyrimidinyl-, monosilver(1+) salt; Sulfanilamide, N(sup 1)-2-pyrimidinyl-, monosilver(1+) salt; Benzenesulfonamide, 4-amino-N-2-pyrimidinyl-, monosilver(1+) salt; (4-Amino-N-pyrimidin-2-ylbenzenesulphonamidato-NN,O1)silver; 4-Amino-N-(2-pyrimidinyl)benzenesulfonamide silver salt DMVTHWQ TC Antiinfective Agents DMVTHWQ DT Small molecular drug DMVTHWQ PC 441244 DMVTHWQ MW 357.14 DMVTHWQ FM C10H9AgN4O2S DMVTHWQ IC InChI=1S/C10H9N4O2S.Ag/c11-8-2-4-9(5-3-8)17(15,16)14-10-12-6-1-7-13-10;/h1-7H,11H2;/q-1;+1 DMVTHWQ CS C1=CN=C(N=C1)[N-]S(=O)(=O)C2=CC=C(C=C2)N.[Ag+] DMVTHWQ IK UEJSSZHHYBHCEL-UHFFFAOYSA-N DMVTHWQ IU silver;(4-aminophenyl)sulfonyl-pyrimidin-2-ylazanide DMVTHWQ CA CAS 22199-08-2 DMVTHWQ CB CHEBI:9142 DMVTHWQ DE Bacterial infection DMLUA9D ID DMLUA9D DMLUA9D DN Simeprevir DMLUA9D HS Approved DMLUA9D SN TMC436 DMLUA9D CP Johnson & Johnson DMLUA9D TC Antiinfective Agents DMLUA9D DT Small molecular drug DMLUA9D PC 24873435 DMLUA9D MW 749.9 DMLUA9D FM C38H47N5O7S2 DMLUA9D IC InChI=1S/C38H47N5O7S2/c1-21(2)30-20-51-35(40-30)29-18-32(26-13-14-31(49-5)22(3)33(26)39-29)50-24-16-27-28(17-24)36(45)43(4)15-9-7-6-8-10-23-19-38(23,41-34(27)44)37(46)42-52(47,48)25-11-12-25/h8,10,13-14,18,20-21,23-25,27-28H,6-7,9,11-12,15-17,19H2,1-5H3,(H,41,44)(H,42,46)/b10-8-/t23-,24-,27-,28-,38-/m1/s1 DMLUA9D CS CC1=C(C=CC2=C1N=C(C=C2O[C@@H]3C[C@@H]4[C@@H](C3)C(=O)N(CCCC/C=C\\[C@@H]5C[C@]5(NC4=O)C(=O)NS(=O)(=O)C6CC6)C)C7=NC(=CS7)C(C)C)OC DMLUA9D IK JTZZSQYMACOLNN-VDWJNHBNSA-N DMLUA9D IU (1R,4R,6S,7Z,15R,17R)-N-cyclopropylsulfonyl-17-[7-methoxy-8-methyl-2-(4-propan-2-yl-1,3-thiazol-2-yl)quinolin-4-yl]oxy-13-methyl-2,14-dioxo-3,13-diazatricyclo[13.3.0.04,6]octadec-7-ene-4-carboxamide DMLUA9D CA CAS 923604-59-5 DMLUA9D CB CHEBI:134743 DMLUA9D DE Chronic HCV-1 infection DM30SGU ID DM30SGU DM30SGU DN Simvastatin DM30SGU HS Approved DM30SGU SN Cholestat; Coledis; Colemin; Corolin; Denan; Labistatin; Lipex; Lipovas; Lodales; Medipo; Nivelipol; Pantok; Rendapid; Simovil; Simvastatina; Simvastatine; Simvastatinum; Sinvacor; Sivastin; Synvinolin; Vasotenal; Zocor; Zocord; Simvast CR; Simvastatina [Spanish]; Simvastatine [French]; Simvastatinum [Latin]; MK 0733; MK 733; MK733; TNP00259; DRG-0320; KS-1113; L 644128-000U; MK-0733; MK-733; Simcard (TN); Simlup (TN); Simvacor (TN); Simvastatin & Primycin; Simvastatin, Compactin; Zocor (TN); Simvastatin [USAN:INN:BAN]; Simvastatin (JAN/USP/INN); Zocor, Simlup, Simcard, Simvacor, Simvoget, Zorced, Simvastatin; [(1S,3R,7S,8S,8aR)-8-[2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] 2,2-dimethylbutanoate; Butanoic acid, 2,2-dimethyl-, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester; Butanoic acid, 2,2-dimethyl-, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-((2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl ester; Butanoic acid, 2,2-dimethyl-, (1S,3R,7S,8S,*aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-((2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl ester; (1S,3R,7S,8S,8aR)-8-{2-[(2R,4R)-4-hydroxy-6-oxotetrahydro-2H-pyran-2-yl]ethyl}-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl 2,2-dimethylbutanoate; Butanoic acid, 2,2-dimethyl-,1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)-ethyl]-1-naphthalenyl ester, [1S-[1 alpha,3 alpha,7 beta,8 beta(2S*,4S*),-8a beta; 2,2-Dimethylbutanoic acid (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester; 2,2-Dimethylbutyric acid, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8aR)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one DM30SGU CP Merck & Co DM30SGU TC Anticholesteremic Agents DM30SGU DT Small molecular drug DM30SGU PC 54454 DM30SGU MW 418.6 DM30SGU FM C25H38O5 DM30SGU IC InChI=1S/C25H38O5/c1-6-25(4,5)24(28)30-21-12-15(2)11-17-8-7-16(3)20(23(17)21)10-9-19-13-18(26)14-22(27)29-19/h7-8,11,15-16,18-21,23,26H,6,9-10,12-14H2,1-5H3/t15-,16-,18+,19+,20-,21-,23-/m0/s1 DM30SGU CS CCC(C)(C)C(=O)O[C@H]1C[C@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@@H]3C[C@H](CC(=O)O3)O)C DM30SGU IK RYMZZMVNJRMUDD-HGQWONQESA-N DM30SGU IU [(1S,3R,7S,8S,8aR)-8-[2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] 2,2-dimethylbutanoate DM30SGU CA CAS 79902-63-9 DM30SGU CB CHEBI:9150 DM30SGU DE Hypercholesterolaemia DMGWR0C ID DMGWR0C DMGWR0C DN Sintilimab DMGWR0C HS Approved DMGWR0C SN Tyvyt DMGWR0C CP Innovent Biologics DMGWR0C DT Antibody DMGWR0C DE Hodgkin lymphoma DM2R86O ID DM2R86O DM2R86O DN Siponimod DM2R86O HS Approved DM2R86O SN BAF312 DM2R86O CP Novartis DM2R86O DT Small molecular drug DM2R86O PC 44599207 DM2R86O MW 516.6 DM2R86O FM C29H35F3N2O3 DM2R86O IC InChI=1S/C29H35F3N2O3/c1-3-21-14-23(10-11-24(21)15-34-16-25(17-34)28(35)36)19(2)33-37-18-20-9-12-26(22-7-5-4-6-8-22)27(13-20)29(30,31)32/h9-14,22,25H,3-8,15-18H2,1-2H3,(H,35,36)/b33-19+ DM2R86O CS CCC1=C(C=CC(=C1)/C(=N/OCC2=CC(=C(C=C2)C3CCCCC3)C(F)(F)F)/C)CN4CC(C4)C(=O)O DM2R86O IK KIHYPELVXPAIDH-HNSNBQBZSA-N DM2R86O IU 1-[[4-[(E)-N-[[4-cyclohexyl-3-(trifluoromethyl)phenyl]methoxy]-C-methylcarbonimidoyl]-2-ethylphenyl]methyl]azetidine-3-carboxylic acid DM2R86O CA CAS 1230487-00-9 DM2R86O DE Hepatocellular carcinoma; Rheumatoid arthritis; Multiple sclerosis DMVCMUJ ID DMVCMUJ DMVCMUJ DN Siponimod DMVCMUJ HS Approved DMVCMUJ SN Siponimod; Siponimod [INN]; Siponimod [WHO-DD]; BAF-312; BAF312; BAF312 (Siponimod); RR6P8L282I; 1-[[4-[(E)-N-[[4-cyclohexyl-3-(trifluoromethyl)phenyl]methoxy]-C-methylcarbonimidoyl]-2-ethylphenyl]methyl]azetidine-3-carboxylic acid; 1230487-00-9; 3-Azetidinecarboxylic acid, 1-((4-((1E)-1-(((4-cyclohexyl-3-(trifluoromethyl)phenyl)methoxy)imino)ethyl)-2-ethylphenyl)methyl)-; CHEMBL2336071; UNII-RR6P8L282I DMVCMUJ PC 44599207 DMVCMUJ MW 516.6 DMVCMUJ FM C29H35F3N2O3 DMVCMUJ IC KIHYPELVXPAIDH-HNSNBQBZSA-N DMVCMUJ CS CCC1=C(C=CC(=C1)C(=NOCC2=CC(=C(C=C2)C3CCCCC3)C(F)(F)F)C)CN4CC(C4)C(=O)O DMVCMUJ IK 1S/C29H35F3N2O3/c1-3-21-14-23(10-11-24(21)15-34-16-25(17-34)28(35)36)19(2)33-37-18-20-9-12-26(22-7-5-4-6-8-22)27(13-20)29(30,31)32/h9-14,22,25H,3-8,15-18H2,1-2H3,(H,35,36)/b33-19+ DMVCMUJ IU 1-[[4-[(E)-N-[[4-cyclohexyl-3-(trifluoromethyl)phenyl]methoxy]-C-methylcarbonimidoyl]-2-ethylphenyl]methyl]azetidine-3-carboxylic acid DMVCMUJ CA CAS 1230487-00-9 DMVCMUJ DE Multiple sclerosis DMGW1ID ID DMGW1ID DMGW1ID DN Sirolimus DMGW1ID HS Approved DMGW1ID SN 53123-88-9; Rapamune; Rapamycin (Sirolimus); AY-22989; Rapammune; sirolimusum; WY-090217; RAPA; Antibiotic AY 22989; AY 22989; UNII-W36ZG6FT64; CCRIS 9024; CHEBI:9168; SILA 9268A; W36ZG6FT64; HSDB 7284; C51H79NO13; NSC 226080; DE-109; NCGC00021305-05; DSSTox_CID_3582; DSSTox_RID_77091; DSSTox_GSID_23582; Cypher; Supralimus; Wy 090217; Perceiva; RAP; RPM; Rapamycin from Streptomyces hygroscopicus; SIIA 9268A; LCP-Siro; MS-R001; Rapamune (TN); Rapamycin (TN); Sirolimus (RAPAMUNE); Rapamycin C-7, analog 4; Sirolimus (USAN/INN); Sirolimus [USAN:BAN:INN]; Sirolimus, Rapamune,Rapamycin; Heptadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy; 23,27-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine; 23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine; 23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29; 3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone; Sirolimus (MTOR inhibitor) DMGW1ID CP Wyeth DMGW1ID TC Immunosuppressive Agents DMGW1ID DT Small molecular drug DMGW1ID PC 5284616 DMGW1ID MW 914.2 DMGW1ID FM C51H79NO13 DMGW1ID IC InChI=1S/C51H79NO13/c1-30-16-12-11-13-17-31(2)42(61-8)28-38-21-19-36(7)51(60,65-38)48(57)49(58)52-23-15-14-18-39(52)50(59)64-43(33(4)26-37-20-22-40(53)44(27-37)62-9)29-41(54)32(3)25-35(6)46(56)47(63-10)45(55)34(5)24-30/h11-13,16-17,25,30,32-34,36-40,42-44,46-47,53,56,60H,14-15,18-24,26-29H2,1-10H3/b13-11+,16-12+,31-17+,35-25+/t30-,32-,33-,34-,36-,37+,38+,39+,40-,42+,43+,44-,46-,47+,51-/m1/s1 DMGW1ID CS C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC DMGW1ID IK QFJCIRLUMZQUOT-HPLJOQBZSA-N DMGW1ID IU (1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-[(2R)-1-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]propan-2-yl]-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone DMGW1ID CA CAS 53123-88-9 DMGW1ID CB CHEBI:9168 DMGW1ID DE Organ transplant rejection; Dutch elm disease; Multiple myeloma DM92P0F ID DM92P0F DM92P0F DN Sisomicin DM92P0F HS Approved DM92P0F SN Siseptin; Sisomicin sulfate; Sisomicina [INN-Spanish]; Sisomicine; Sisomicine [INN-French]; Sisomicinum; Sisomicinum [INN-Latin]; Sisomin; Sisomycin; Sissomicin; X55XSL74YQ; sisomicin; 32385-11-8; BRN 1357913; C19H37N5O7; Antibiotic 66-40; Antibiotic 6640; Dehydrogentamicin Cla; Rickamicin; Sch 13475; Sch-13475; CHEBI:9169; D-Streptamine, O-3-deoxy-4-C-methyl-3-(methylamino)-beta-L-arabinopyranosyl-(1-6)-O-(2,6-diamino-2,3,4,6-tetradeoxy-alpha-D-glycero-hex-4-enopyranosyl-(1-4))-2-deoxy-; EINECS 251-018-2; UNII-X55XSL74YQ DM92P0F PC 36119 DM92P0F MW 447.5 DM92P0F FM C19H37N5O7 DM92P0F IC URWAJWIAIPFPJE-YFMIWBNJSA-N DM92P0F CS CC1(COC(C(C1NC)O)OC2C(CC(C(C2O)OC3C(CC=C(O3)CN)N)N)N)O DM92P0F IK 1S/C19H37N5O7/c1-19(27)7-28-18(13(26)16(19)24-2)31-15-11(23)5-10(22)14(12(15)25)30-17-9(21)4-3-8(6-20)29-17/h3,9-18,24-27H,4-7,20-23H2,1-2H3/t9-,10+,11-,12+,13-,14-,15+,16-,17-,18-,19+/m1/s1 DM92P0F IU (2R,3R,4R,5R)-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[[(2S,3R)-3-amino-6-(aminomethyl)-3,4-dihydro-2H-pyran-2-yl]oxy]-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol DM92P0F CA CAS 32385-11-8 DM92P0F CB CHEBI:9169 DM92P0F DE Infectious cystitis DMGDKXN ID DMGDKXN DMGDKXN DN Sitagliptin DMGDKXN HS Approved DMGDKXN SN 486460-32-6; Januvia; Xelevia; Sitagliptan; MK-0431; UNII-QFP0P1DV7Z; Tesavel; QFP0P1DV7Z; (3R)-3-AMINO-1-[3-(TRIFLUOROMETHYL)-5H,6H,7H,8H-[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7-YL]-4-(2,4,5-TRIFLUOROPHENYL)BUTAN-1-ONE; (2R)-4-OXO-4-[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]-1-(2,4,5-TRIFLUOROPHENYL)BUTAN-2-AMINE; CHEBI:40237; (R)-3-AMINO-1-(3-(TRIFLUOROMETHYL)-5,6-DIHYDRO-[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL)-4-(2,4,5-TRIFLUOROPHENYL)BUTAN-1-ONE; Janumet; Sitagliptin phosphate; Januvia (TN); Sitagliptin (PropINN); Januvia (merck & Co); (3R)-3-Amino-1-[3-(trifluoromethyl)-5,6,7,8-tetrahydro-1,2,4-triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butan-1-one; (3R)-3-amino-1-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-4-(2,4,5-trifluorophenyl)butan-1-one; (3R)-3-amino-1-[3-(trifluoromethyl)-6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butan-1-one; Sitagliptin/atovastatin DMGDKXN CP Merck & Co DMGDKXN TC Hypoglycemic Agents DMGDKXN DT Small molecular drug DMGDKXN PC 4369359 DMGDKXN MW 407.31 DMGDKXN FM C16H15F6N5O DMGDKXN IC InChI=1S/C16H15F6N5O/c17-10-6-12(19)11(18)4-8(10)3-9(23)5-14(28)26-1-2-27-13(7-26)24-25-15(27)16(20,21)22/h4,6,9H,1-3,5,7,23H2/t9-/m1/s1 DMGDKXN CS C1CN2C(=NN=C2C(F)(F)F)CN1C(=O)C[C@@H](CC3=CC(=C(C=C3F)F)F)N DMGDKXN IK MFFMDFFZMYYVKS-SECBINFHSA-N DMGDKXN IU (3R)-3-amino-1-[3-(trifluoromethyl)-6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butan-1-one DMGDKXN CA CAS 486460-32-6 DMGDKXN CB CHEBI:40237 DMGDKXN DE Type-2 diabetes; Peripheral arterial disease DMQ8E9R ID DMQ8E9R DMQ8E9R DN SKI-758 DMQ8E9R HS Approved DMQ8E9R SN SCHEMBL3992463; CHEMBL219557; BDBM13047; SKI-758; 3-quinolinecarbonitrile analog 10; ANUHLKPVOXDYSK-UHFFFAOYSA-N; 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-{5-[(4-methylpiperazin-1-yl)methyl]furan-3-yl}quinoline-3-carbonitrile; 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6 methoxy-7-{5-[(4-methylpiperazin-1-yl)methyl]-3-furyl}-3-quinolinecarbonitrile DMQ8E9R DT Small molecular drug DMQ8E9R PC 11341869 DMQ8E9R MW 552.4 DMQ8E9R FM C28H27Cl2N5O3 DMQ8E9R IC InChI=1S/C28H27Cl2N5O3/c1-34-4-6-35(7-5-34)15-19-8-17(16-38-19)20-9-24-21(10-26(20)36-2)28(18(13-31)14-32-24)33-25-12-27(37-3)23(30)11-22(25)29/h8-12,14,16H,4-7,15H2,1-3H3,(H,32,33) DMQ8E9R CS CN1CCN(CC1)CC2=CC(=CO2)C3=C(C=C4C(=C3)N=CC(=C4NC5=CC(=C(C=C5Cl)Cl)OC)C#N)OC DMQ8E9R IK ANUHLKPVOXDYSK-UHFFFAOYSA-N DMQ8E9R IU 4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-[5-[(4-methylpiperazin-1-yl)methyl]furan-3-yl]quinoline-3-carbonitrile DMQ8E9R DE Ischemia DMDIZCS ID DMDIZCS DMDIZCS DN S-licarbazepine DMDIZCS HS Approved DMDIZCS SN Eslicarbazepine; (S)-10-Hydroxy-10,11-dihydro-5H-dibenzo[b,f]azepine-5-carboxamide; S-licarbazepine; UNII-S5VXA428R4; BIA 2-194; S-10-Monohydroxy-dihydro-carbamazepin; S5VXA428R4; S-(+)-10,11-Dihydro-10-hydroxy-5H-dibenz[b,f]azepine-5-carboxamide; (5S)-5-hydroxy-5,6-dihydrobenzo[b][1]benzazepine-11-carboxamide; (10S)-10,11-Dihydro-10-hydroxy-5H-Dibenz[b,f]azepine-5-carboxamide; (S)-Licarbazepine; S(+)-Liscarbazepine; (10S)-10,11-Dihydro-10-hydroxy-5H-dibenz(b,f)azepine-5-carboxamide DMDIZCS PC 9881504 DMDIZCS MW 254.28 DMDIZCS FM 15H14N2O2 DMDIZCS IC InChI=1S/C15H14N2O2/c16-15(19)17-12-7-3-1-5-10(12)9-14(18)11-6-2-4-8-13(11)17/h1-8,14,18H,9H2,(H2,16,19)/t14-/m0/s1 DMDIZCS CS C1C(C2=CC=CC=C2N(C3=CC=CC=C31)C(=O)N)O DMDIZCS IK BMPDWHIDQYTSHX-AWEZNQCLSA-N DMDIZCS IU (5S)-5-hydroxy-5,6-dihydrobenzo[b][1]benzazepine-11-carboxamide DMDIZCS CA CAS 104746-04-5 DMDIZCS DE Partial seizures DMFX9O6 ID DMFX9O6 DMFX9O6 DN SM-101 DMFX9O6 HS Approved (orphan drug) DMFX9O6 SN SMP-534 DMFX9O6 CP SuppreMol DMFX9O6 DT Small molecular drug DMFX9O6 PC 445629 DMFX9O6 DE Idiopathic thrombocytopenic purpura; Diabetic nephropathy; Systemic lupus erythematosus DM1I93C ID DM1I93C DM1I93C DN SMT-D002 DM1I93C HS Approved DM1I93C SN DL-06003 DM1I93C CP DanioLabs Ltd DM1I93C DE Seborrhea DMH21E0 ID DMH21E0 DMH21E0 DN Sodium acetate anhydrous DMH21E0 HS Approved DMH21E0 SN Sodium Acetate In Plastic Container DMH21E0 CP Hospira Inc DMH21E0 DT Small molecular drug DMH21E0 PC 517045 DMH21E0 MW 82.03 DMH21E0 FM C2H3NaO2 DMH21E0 IC InChI=1S/C2H4O2.Na/c1-2(3)4;/h1H3,(H,3,4);/q;+1/p-1 DMH21E0 CS CC(=O)[O-].[Na+] DMH21E0 IK VMHLLURERBWHNL-UHFFFAOYSA-M DMH21E0 IU sodium;acetate DMH21E0 CA CAS 127-09-3 DMH21E0 CB CHEBI:32954 DMH21E0 DE Hyponatraemia DMMU6BJ ID DMMU6BJ DMMU6BJ DN Sodium bicarbonate DMMU6BJ HS Approved DMMU6BJ SN Acidosan; Colovage; Glycoprep; Golytely; Jusonin; Meylon; Natriumhydrogenkarbonat; Natron; Neut; Nulytely; Soludal; BSS plus; Baking soda; Bicarbonate of soda; Carbonic acid monosodium salt; Gripe water; Lithium bicarbonate; Monosodium hydrogen carbonate; Natrii hydrogencarbonas; Natrium bicarbonicum; Natrium hydrogencarbonicum; Natrum bicarbonicum; Sandoz sodium bicarbonate; Sel De vichy; Soda Mint; Sodium acid carbonate; Sodium bicarbonate in plastic container; Sodium bicarbonate liquid concentrate; Sodium bicarbonate solution; Sodium hydrocarbonate; Sodium hydrogen carbonate; Sodium hydrogencarbonate; NaHCO3; Bicarbonate, Sodium; Carbonic acid, monosodium salt; Co-lav; Col-evac; Go-evac; Hema BP-38; Hydrogen Carbonate, Sodium; Meylon (TN); Neut (TN); Peg-lyte; Soda (van); Soda, Baking; Sodium bicarbonate [USAN:JAN]; Carbonic acid sodium salt (1:1); E-Z-EM Prep Lyte; Sodium bicarbonate (1:1); Sodium bicarbonate (JP15/USP); Sodium carbonate (Na(HCO3)); 800 Sodium Bicarbonate Powder DMMU6BJ TC Antidiarrheals DMMU6BJ DT Small molecular drug DMMU6BJ PC 516892 DMMU6BJ MW 84.007 DMMU6BJ FM CHNaO3 DMMU6BJ IC InChI=1S/CH2O3.Na/c2-1(3)4;/h(H2,2,3,4);/q;+1/p-1 DMMU6BJ CS C(=O)(O)[O-].[Na+] DMMU6BJ IK UIIMBOGNXHQVGW-UHFFFAOYSA-M DMMU6BJ IU sodium;hydrogen carbonate DMMU6BJ CA CAS 144-55-8 DMMU6BJ CB CHEBI:32139 DMMU6BJ DE Metabolic acidosis DMM3950 ID DMM3950 DMM3950 DN Sodium chloride DMM3950 HS Approved DMM3950 SN sodium chloride; 7647-14-5; Halite; Salt; Table salt; Saline; Rock salt; Common salt; Dendritis; Purex; Sodium chloric; Top flake; Sodium chloride (NaCl); Hyposaline; Flexivial; Gingivyl; Iodized salt; Slow Sodium; Sea salt; SS salt; Sodium monochloride; Natriumchlorid; Hypersal; Adsorbanac; Trisodium trichloride; White crystal; NaCl; HG blending; Salt (ingredient); sodiumchloride; Colyte; Sodium chloride (Na4Cl4); Caswell No 754; Extra Fine 325 Salt; Extra Fine 200 Salt; Sodium chloride brine, purified; Arm-A-Vial; CCRIS 982; sterling DMM3950 DT Small molecular drug DMM3950 PC 5234 DMM3950 MW 58.44 DMM3950 FM ClNa DMM3950 IC InChI=1S/ClH.Na/h1H;/q;+1/p-1 DMM3950 CS [Na+].[Cl-] DMM3950 IK FAPWRFPIFSIZLT-UHFFFAOYSA-M DMM3950 IU sodium;chloride DMM3950 CA CAS 7647-14-5 DMM3950 CB CHEBI:26710 DMM3950 DE Skin burns DMLJ634 ID DMLJ634 DMLJ634 DN Sodium lauryl sulfate DMLJ634 HS Approved DMLJ634 SN Anticerumen; Dreft; Dupanal; Duponal; Duponol; Gardinol; Irium; NALS; Natriumlaurylsulfat; Neutrazyme; SDS; SLS; Syntapon; WAQE; Akyposal SDS; Aquarex ME; Aquarex methyl; Carsonol SLS; Carsonol SLS Paste B; Carsonol SLS Special; Conco Sulfate WAG; Conco Sulfate WAN; Conco Sulfate WAS; Conco sulfate WA; Conco sulfate WN; DODECYL SULFATE; Dupanol WAQ; Duponal WAQE; Duponol C; Duponol Me; Duponol QC; Duponol WA; Duponol WA dry; Duponol WAQ; Duponol WAQE; Duponol WAQM; Duponol methyl; Duponol qx; Duponol waqa; EMAL O; Empicol LPZ; Hexamol SLS; Incronol SLS; Laurylsiran sodny; Lauyl sodium sulfate; Maprobix NEU; Maprofix LK; Maprofix NEU; Maprofix WAC; Melanol CL; Montopol La Paste; Nikkol SLS; Orvus WA Paste; Perlandrol L; Perlankrol L; Richonol A; Richonol C; Richonol af; SDS Running Buffer; Sintapon L; Sipex OP; Sipex SP; Sipex UB; Sipex sb; Sipex sd; Sipon LS; Sipon LSB; Sipon PD; Sipon WD; Sodium Laurylsulfate; Solsol needles; Standapol WAQ; Stepanol ME; Stepanol ME Dry AW; Stepanol WA; Stepanol WA Paste; Stepanol me dry; Stepanol methyl; Stepanol wac; Stepanol waq; Sterling wa paste; Sulfotex wa; Texapon DL; Trepenol WA; Avirol 101; Avirol 118; Avirol 118 conc; Berol 452; CP 75424; Cycloryl 21; Cycloryl 31; Cycloryl 580; Cycloryl 585N; Detergent 66; Emal 10; Emersal 6400; Empicol LS 30; Empicol LX 28; Finasol osr2; MP SILICA RP 18; Maprofix 563; Melanol CL 30; Monagen Y 100; Monogen Y 100; Odoripon Al 95; Perklankrol ESD 60; Rewopol NLS 30; Sinnopon LS 100; Sinnopon LS 95; Sipon LS 100; Standapol 112; Standapol 112 conc; Standapol was 100; Steinapol NLS 90; Stepanol T 28; Sulfetal L 95; Sulfopon wa 1; Swascol 3L; Tarapon K 12; Tvm 474; Emulsifier no. 104; Finasol osr(sub 2); IPC-SDS;Jordanol SL-300; Lanette Wax-S; Maprofix WAC-LA; Product no. 161; Product no. 75; Quolac EX-UB; S-4600; Standapol wa-ac; Stepanol WA-100; Sterling WAQ-CH; Ultra sulfate sl-1 DMLJ634 DT Small molecular drug DMLJ634 PC 3423265 DMLJ634 MW 288.38 DMLJ634 FM C12H25NaO4S DMLJ634 IC InChI=1S/C12H26O4S.Na/c1-2-3-4-5-6-7-8-9-10-11-12-16-17(13,14)15;/h2-12H2,1H3,(H,13,14,15);/q;+1/p-1 DMLJ634 CS CCCCCCCCCCCCOS(=O)(=O)[O-].[Na+] DMLJ634 IK DBMJMQXJHONAFJ-UHFFFAOYSA-M DMLJ634 IU sodium;dodecyl sulfate DMLJ634 CA CAS 151-21-3 DMLJ634 CB CHEBI:8984 DMLJ634 DE Constipation DMGA9X0 ID DMGA9X0 DMGA9X0 DN Sodium nitroprusside DMGA9X0 HS Approved DMGA9X0 SN Nitroprusside (Sodium); Sodium nitroprusside anhydrous; 14402-89-2; C5FeN6O.2Na; Nitropruss; Nitroprusid-natrium; Sodium nitroprussate; Nitroprussidnatrium [German]; C5FeN6O.2H2O.2Na; Sodium nitroprusside [USAN]; Na2[Fe(CN)5(NO)]; Sodium nitroprussiate dihydrate; Sodium nitrosylpentacyanoferrate; SCHEMBL3020702; CCRIS 1912; Sodium Nitroprusside (anhydrous); Disodium nitrosylpentacyanoferrate; Disodium pentacyanonitrosylferrate; CHEBI:29321; Nitroprussiate de sodium [French]; MolPort-003-926-312; disodium pentacyanidonitrosylfer DMGA9X0 DT Small molecular drug DMGA9X0 PC 11953895 DMGA9X0 MW 297.95 DMGA9X0 FM C5H4FeN6Na2O3 DMGA9X0 IC InChI=1S/5CN.Fe.NO.2Na.2H2O/c5*1-2;;1-2;;;;/h;;;;;;;;;2*1H2/q5*-1;+4;-1;2*+1;; DMGA9X0 CS [C-]#N.[C-]#N.[C-]#N.[C-]#N.[C-]#N.[N-]=O.O.O.[Na+].[Na+].[Fe+4] DMGA9X0 IK XRKMNJXYOFSTBE-UHFFFAOYSA-N DMGA9X0 IU disodium;iron(4+);nitroxyl anion;pentacyanide;dihydrate DMGA9X0 CA CAS 13755-38-9 DMGA9X0 CB CHEBI:9179 DMGA9X0 DE Hypertension DMCIWZL ID DMCIWZL DMCIWZL DN Sodium oxybate DMCIWZL HS Approved DMCIWZL SN Sodium Oxybate [USAN]; Sodium gamma-hydroxybutyrate; Sodium oxybate; Sodium-4-hydroxybutyrate; Somsanit; gamma-Hydroxy sodium butyrate; Anetamin; Gamma OH; Natrium 4-hydroxybutyrat; Oxybate (sodium); Oxybate sodium; Sodium 4-hydroxybutyrate; gamma-Hydroxybutyrate sodium; gamma-Hydroxybutyrate sodium salt; sodium 4-hydroxybutanoate; 4-Hydroxybuttersaeure natriumsalz; 4-Hydroxybutyrate sodium; 4-Hydroxybutyric acid sodium salt; 502-85-2; Butanoic acid, 4-hydroxy-, monosodium salt; EINECS 207-953-3; NSC 84223; UNII-7G33012534 DMCIWZL PC 23663870 DMCIWZL MW 126.09 DMCIWZL FM C4H7NaO3 DMCIWZL IC XYGBKMMCQDZQOZ-UHFFFAOYSA-M DMCIWZL CS C(CC(=O)[O-])CO.[Na+] DMCIWZL IK 1S/C4H8O3.Na/c5-3-1-2-4(6)7;/h5H,1-3H2,(H,6,7);/q;+1/p-1 DMCIWZL IU sodium;4-hydroxybutanoate DMCIWZL CA CAS 502-85-2 DMCIWZL DE Narcolepsy DMXLBCQ ID DMXLBCQ DMXLBCQ DN Sodium phenylbutyrate DMXLBCQ HS Approved DMXLBCQ SN Ammonaps; Buphenyl; EL-532; Sodium 4-phenylbutyrate; Sodium phenylbutyrate, Elan; Sodium phenylbutyrate, Medicis; Sodium phenylbutyrate, Ucyclyd; VP-101; Sodium 4-phenylbutyrate, Elan; Sodium 4-phenylbutyrate, Ucyclyd; Sodium phenylbutyrate (cancer), MacroChem/Access; Sodium phenylbutyrate (cancer), Virium/ Somanta; Sodium phenylbutyrate (cancer), Virium/Access Pharmaceuticals; Sodium 4-phenyibutyrate (cancer), MacroChem/Access; Sodium 4-phenylbutyrate (cancer), Virium/ Somanta; Sodium 4-phenylbutyrate (cancer), Virium/Access Pharmaceuticals DMXLBCQ CP Ucyclyd Pharma Inc; Elan Corp plc DMXLBCQ DT Small molecular drug DMXLBCQ PC 5258 DMXLBCQ MW 186.18 DMXLBCQ FM C10H11NaO2 DMXLBCQ IC InChI=1S/C10H12O2.Na/c11-10(12)8-4-7-9-5-2-1-3-6-9;/h1-3,5-6H,4,7-8H2,(H,11,12);/q;+1/p-1 DMXLBCQ CS C1=CC=C(C=C1)CCCC(=O)[O-].[Na+] DMXLBCQ IK VPZRWNZGLKXFOE-UHFFFAOYSA-M DMXLBCQ IU sodium;4-phenylbutanoate DMXLBCQ CA CAS 1716-12-7 DMXLBCQ CB CHEBI:75316 DMXLBCQ DE Spinal muscular atrophy DMKY27B ID DMKY27B DMKY27B DN Sodium phosphate dibasic/sodium phosphate monobasic DMKY27B HS Approved DMKY27B SN Anhydrous sodium acid phosphate; Dipotassium phosphate anhydrous; Monobasic potassium acid phosphate; Monobasic sodium phosphate; Potassium phosphate; Sodium phosphate DMKY27B DE Multiple sclerosis DM4QFXJ ID DM4QFXJ DM4QFXJ DN Sodium Tetradecyl Sulfate DM4QFXJ HS Approved DM4QFXJ SN STDS; Trombavar; Monotetradecylsulfate sodium salt; Natri tetradecylsulfas; Natrii tetradecyclis sulfas; Sodium myristyl sulfate; Sodium tetradecyl sulphate; Sodium tetradecylsulfate; Sotradecol Sodium; Tetradecyl sodium sulfate; Niaproof 4; Tesapon K 14; Texapon K 14; Myristyl sulfate, sodium salt; Natrii tetradecyclis sulfas [INN-Latin]; Tetradecilsulfato sodico [INN-Spanish]; Tetradecyl sulfate de sodium [INN-French]; Tetradecyl sulfate, sodium salt; Fibro-Vein (TN); S.T.D; Sulfuric acid, monotetradecyl ester, sodium salt; Sulfuric acid, myristyl ester, sodium salt; S.T.D.; 1-Tetradecanol, 1-(hydrogen sulfate), sodium salt (1:1); 1-Tetradecanol, hydrogen sulfate, sodium salt DM4QFXJ TC Sclerosing Agents DM4QFXJ DT Small molecular drug DM4QFXJ PC 23665770 DM4QFXJ MW 316.43 DM4QFXJ FM C14H29NaO4S DM4QFXJ IC InChI=1S/C14H30O4S.Na/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-18-19(15,16)17;/h2-14H2,1H3,(H,15,16,17);/q;+1/p-1 DM4QFXJ CS CCCCCCCCCCCCCCOS(=O)(=O)[O-].[Na+] DM4QFXJ IK UPUIQOIQVMNQAP-UHFFFAOYSA-M DM4QFXJ IU sodium;tetradecyl sulfate DM4QFXJ CA CAS 1191-50-0 DM4QFXJ DE Hemangioma; Varicose and spider veins of leg DMCSLZ4 ID DMCSLZ4 DMCSLZ4 DN Sodium zirconium cyclosilicate DMCSLZ4 HS Approved DMCSLZ4 SN UZSi 9; ZS-9 compound; Sodium zirconium silicate (Na2ZrSi3O9); UZSi-9; CBTCHTJSGLCFMY-UHFFFAOYSA-N; 543686-27-7 DMCSLZ4 CP AstraZeneca DMCSLZ4 PC 91799284 DMCSLZ4 MW 371.5 DMCSLZ4 FM H6Na2O9Si3Zr+2 DMCSLZ4 IC InChI=1S/2Na.H6O9Si3.Zr/c;;1-10(2)7-11(3,4)9-12(5,6)8-10;/h;;1-6H;/q2*+1;; DMCSLZ4 CS O[Si]1(O[Si](O[Si](O1)(O)O)(O)O)O.[Na+].[Na+].[Zr] DMCSLZ4 IK CBTCHTJSGLCFMY-UHFFFAOYSA-N DMCSLZ4 IU disodium;2,2,4,4,6,6-hexahydroxy-1,3,5,2,4,6-trioxatrisilinane;zirconium DMCSLZ4 CA CAS 17141-74-1 DMCSLZ4 DE Hyperkalemia DMQI86A ID DMQI86A DMQI86A DN Sofosbuvir DMQI86A HS Approved DMQI86A SN HSDB 8226; Hepcinat; Hepcvir; Resof; SOFOSBUVIR; Sofosbuvir (PSI-7977, GS-7977); Sofosbuvir [USAN:INN]; Sovaldi (TN); SoviHep DMQI86A TC Antiviral Agents DMQI86A DT Small molecular drug DMQI86A PC 45375808 DMQI86A MW 529.458 DMQI86A FM C22H29FN3O9P DMQI86A IC InChI=1S/C22H29FN3O9P/c1-13(2)33-19(29)14(3)25-36(31,35-15-8-6-5-7-9-15)32-12-16-18(28)22(4,23)20(34-16)26-11-10-17(27)24-21(26)30/h5-11,13-14,16,18,20,28H,12H2,1-4H3,(H,25,31)(H,24,27,30)/t14-,16+,18+,20+,22+,36-/m0/s1 DMQI86A CS CC(C)OC(=O)C(C)NP(=O)(OCC1C(C(C(O1)N2C=CC(=O)NC2=O)(C)F)O)OC3=CC=CC=C3 DMQI86A IK TTZHDVOVKQGIBA-IQWMDFIBSA-N DMQI86A IU propan-2-yl (2S)-2-[[[(2R,3R,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyloxolan-2-yl]methoxy-phenoxyphosphoryl]amino]propanoate DMQI86A CA CAS 1190307-88-0 DMQI86A CB CHEBI:85083 DMQI86A DE Chronic hepatitis C infection DM5F47O ID DM5F47O DM5F47O DN Sofosbuvir + velpatasvir + voxilaprevir DM5F47O HS Approved DM5F47O SN Vosevi; Sofosbuvir / velpatasvir / voxilaprevir; Sofosbuvir mixture with velpatasvir and voxilaprevir; S900007740 DM5F47O CP Gilead Sciences DM5F47O PC 129011857 DM5F47O MW 2281.4 DM5F47O FM C111H135F5N17O26PS DM5F47O IC InChI=1S/C49H54N8O8.C40H52F4N6O9S.C22H29FN3O9P/c1-26(2)41(54-48(60)63-5)47(59)57-27(3)12-17-38(57)45-51-36-16-14-30-20-35-33-15-13-31(19-32(33)25-65-40(35)21-34(30)43(36)53-45)37-22-50-44(52-37)39-18-28(24-62-4)23-56(39)46(58)42(55-49(61)64-6)29-10-8-7-9-11-29;1-7-22-27-19-50(28(22)32(51)48-39(18-23(39)31(41)42)35(53)49-60(55,56)38(5)14-15-38)34(52)30(37(2,3)4)47-36(54)59-26-16-20(26)10-8-9-13-40(43,44)29-33(58-27)46-25-17-21(57-6)11-12-24(25)45-29;1-13(2)33-19(29)14(3)25-36(31,35-15-8-6-5-7-9-15)32-12-16-18(28)22(4,23)20(34-16)26-11-10-17(27)24-21(26)30/h7-11,13-16,19-22,26-28,38-39,41-42H,12,17-18,23-25H2,1-6H3,(H,50,52)(H,51,53)(H,54,60)(H,55,61);11-12,17,20,22-23,26-28,30-31H,7-10,13-16,18-19H2,1-6H3,(H,47,54)(H,48,51)(H,49,53);5-11,13-14,16,18,20,28H,12H2,1-4H3,(H,25,31)(H,24,27,30)/t27-,28-,38-,39-,41-,42+;20-,22-,23+,26-,27+,28+,30-,39-;14-,16+,18+,20+,22+,36-/m010/s1 DM5F47O CS CC[C@@H]1[C@@H]2CN([C@@H]1C(=O)N[C@@]3(C[C@H]3C(F)F)C(=O)NS(=O)(=O)C4(CC4)C)C(=O)[C@@H](NC(=O)O[C@@H]5C[C@H]5CCCCC(C6=NC7=C(C=C(C=C7)OC)N=C6O2)(F)F)C(C)(C)C.C[C@H]1CC[C@H](N1C(=O)[C@H](C(C)C)NC(=O)OC)C2=NC3=C(N2)C=CC4=CC5=C(C=C43)OCC6=C5C=CC(=C6)C7=CN=C(N7)[C@@H]8C[C@@H](CN8C(=O)[C@@H](C9=CC=CC=C9)NC(=O)OC)COC.C[C@@H](C(=O)OC(C)C)N[P@](=O)(OC[C@@H]1[C@H]([C@@]([C@@H](O1)N2C=CC(=O)NC2=O)(C)F)O)OC3=CC=CC=C3 DM5F47O IK FMWRYUBVSONSCK-ZYTFCPLVSA-N DM5F47O IU (1R,18R,20R,24S,27S,28S)-24-tert-butyl-N-[(1R,2R)-2-(difluoromethyl)-1-[(1-methylcyclopropyl)sulfonylcarbamoyl]cyclopropyl]-28-ethyl-13,13-difluoro-7-methoxy-22,25-dioxo-2,21-dioxa-4,11,23,26-tetrazapentacyclo[24.2.1.03,12.05,10.018,20]nonacosa-3,5(10),6,8,11-pentaene-27-carboxamide;methyl N-[(1R)-2-[(2S,4S)-2-[5-[6-[(2S,5S)-1-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]-5-methylpyrrolidin-2-yl]-21-oxa-5,7-diazapentacyclo[11.8.0.03,11.04,8.014,19]henicosa-1(13),2,4(8),5,9,11,14(19),15,17-nonaen-17-yl]-1H-imidazol-2-yl]-4-(methoxymethyl)pyrrolidin-1-yl]-2-oxo-1-phenylethyl]carbamate;propan-2-yl (2S)-2-[[[(2R,3R,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyloxolan-2-yl]methoxy-phenoxyphosphoryl]amino]propanoate DM5F47O DE Hepatitis C virus infection DMG592Q ID DMG592Q DMG592Q DN Solifenacin DMG592Q HS Approved DMG592Q SN Vesicare; Vesikur; Solifenacin succinate; Solifenacin succinate [USAN]; YM 905; Solifenacin (INN); Solifenacin [INN:BAN]; Vesicare (TN); YM-53705; YM-67905; YM-905; Quinuclidin-3'-yl-1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylatemonosuccinate; [(3R)-1-azabicyclo[2.2.2]octan-3-yl] (1S)-1-phenyl-3,4-dihydro-1H-isoquinoline-2-carboxylate; Butanedioic acid, compd with (1S)-(3R)-1-azabicyclo(2.2.2)oct-3-yl 3,4-dihydro-1-phenyl-2(1H)-isoquinolinecarboxylate (1:1); Butanedioic acid, cmpd. with (1S)-(3R)-1-azabicyclo(2.2.2)oct-3-yl 3,4-dihydro-1-phenyl-2(1H)-isoquinolinecarboxylate (1:1); 1-azabicyclo[2.2.2]oct-8-yl (1S)-1-phenyl-3,4-dihydro-1H-isoquinoline-2-carboxylate; 1-azabicyclo[2.2.2]octan-3-yl (1S)-1-phenyl-3,4-dihydro-1H-isoquinoline-2-carboxylate; 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-1-phenyl-, (3R)-1-azabicyclo(2.2.2)oct-3-yl ester, (1S)-, butanedioate (1:1) DMG592Q CP GlaxoSmithKline DMG592Q TC Antispasmodics DMG592Q DT Small molecular drug DMG592Q PC 154059 DMG592Q MW 362.5 DMG592Q FM C23H26N2O2 DMG592Q IC InChI=1S/C23H26N2O2/c26-23(27-21-16-24-13-10-18(21)11-14-24)25-15-12-17-6-4-5-9-20(17)22(25)19-7-2-1-3-8-19/h1-9,18,21-22H,10-16H2/t21-,22-/m0/s1 DMG592Q CS C1CN2CCC1[C@H](C2)OC(=O)N3CCC4=CC=CC=C4[C@@H]3C5=CC=CC=C5 DMG592Q IK FBOUYBDGKBSUES-VXKWHMMOSA-N DMG592Q IU [(3R)-1-azabicyclo[2.2.2]octan-3-yl] (1S)-1-phenyl-3,4-dihydro-1H-isoquinoline-2-carboxylate DMG592Q CA CAS 242478-37-1 DMG592Q CB CHEBI:135530 DMG592Q DE Overactive bladder DMZ9FAO ID DMZ9FAO DMZ9FAO DN Somatomedin-1 DMZ9FAO HS Approved DMZ9FAO SN Igef (TN) DMZ9FAO DE Hormone deficiency DMF3GM2 ID DMF3GM2 DMF3GM2 DN Somatropin recombinant DMF3GM2 HS Approved DMF3GM2 SN Genotropin (TN); Humatrope (TN); Norditropin (TN); Nutropin (TN); Saizen (TN) DMF3GM2 CP Pfizer Pharmaceuticals DMF3GM2 TC Hormone Replacement Agents DMF3GM2 DE Growth hormone deficiency DM72409 ID DM72409 DM72409 DN Sonidegib phosphate DM72409 HS Approved DM72409 SN Sonidegib phosphate; Sonidegib phosphate (USAN); Sonidegib phosphate [USAN:INN]; UNII-W421AI34UW; W421AI34UW; sonidegib bisphosphate; sonidegib diphosphate; 1218778-77-8; 3888AH; AKOS015994565; AOB87343; BCP11860; C26H26F3N3O3.2H3O4P; CHEBI:90864; CHEMBL3137317; CS-1175; DTXSID90669468; EX-A1556; Erismodegib Diphosphate; FE-0016; HY-16582; KS-00002WSZ; LDE-225 Diphosphate; LDE225 (Diphosphate); LDE225 Diphosphate; NVP-LDE225 Diphosphate; NVP-LDE225 Diphosphate salt; Odomzo (TN); SB16677 DM72409 PC 45138699 DM72409 MW 681.5 DM72409 FM C26H32F3N3O11P2 DM72409 IC RWIVSVMMGFFZIJ-VWDRLOGHSA-N DM72409 CS CC1CN(CC(O1)C)C2=NC=C(C=C2)NC(=O)C3=CC=CC(=C3C)C4=CC=C(C=C4)OC(F)(F)F.OP(=O)(O)O.OP(=O)(O)O DM72409 IK 1S/C26H26F3N3O3.2H3O4P/c1-16-14-32(15-17(2)34-16)24-12-9-20(13-30-24)31-25(33)23-6-4-5-22(18(23)3)19-7-10-21(11-8-19)35-26(27,28)29;2*1-5(2,3)4/h4-13,16-17H,14-15H2,1-3H3,(H,31,33);2*(H3,1,2,3,4)/t16-,17+;; DM72409 IU N-[6-[(2R,6S)-2,6-dimethylmorpholin-4-yl]pyridin-3-yl]-2-methyl-3-[4-(trifluoromethoxy)phenyl]benzamide;phosphoric acid DM72409 CA CAS 1218778-77-8 DM72409 CB CHEBI:90864 DM72409 DE Basal cell carcinoma DMS8IFC ID DMS8IFC DMS8IFC DN Sorafenib DMS8IFC HS Approved DMS8IFC SN Nexavar; Sorafenibum; Sorafenib [INN]; Nexavar (TN); Sorafenib (INN); N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea; N-(4-Chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea; N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcar bamoyl)-4-pyridyloxy)phenyl)urea; 4(4-{3-[4-Chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide; 4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide; 4-(4-(3-(4-chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxyllic acid methyamide-4-methylbenzenesulfonate; 4-(4-{3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide; 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide; 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide; 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide; 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide; 4-{4-[({[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL]AMINO}CARBONYL)AMINO]PHENOXY}-N-METHYLPYRIDINE-2-CARBOXAMIDE; Sorafenib (Pan-TK inhibitor) DMS8IFC CP Bayer AG; Onyx Pharmaceuticals DMS8IFC TC Anticancer Agents DMS8IFC DT Small molecular drug DMS8IFC PC 216239 DMS8IFC MW 464.8 DMS8IFC FM C21H16ClF3N4O3 DMS8IFC IC InChI=1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31) DMS8IFC CS CNC(=O)C1=NC=CC(=C1)OC2=CC=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F DMS8IFC IK MLDQJTXFUGDVEO-UHFFFAOYSA-N DMS8IFC IU 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide DMS8IFC CA CAS 284461-73-0 DMS8IFC CB CHEBI:50924 DMS8IFC DE Renal cell carcinoma; Myelodysplastic syndrome; Hepatocellular carcinoma DMAN0DE ID DMAN0DE DMAN0DE DN Sorbitol DMAN0DE HS Approved DMAN0DE SN D-Sorbitol; sorbitol; D-Glucitol; 50-70-4; glucitol; L-Gulitol; (-)-Sorbitol; Glucarine; Sorbilande; Diakarmon; Sorbostyl; Multitol; Nivitin; Karion; Esasorb; Neosorb; D-(-)-Sorbitol; Sorbol; Cholaxine; Sorbite; Sionit; Sionite; Siosan; Sionon; Karion instant; Sorbitol F; Sorbitol FP; Sorbex Rp; Sorbitol syrup C; Sorbex X; Sorbex R; Sorbex M; Sorbex S; Sionit K; D-Sorbol; Hexahydric alcohol; Sorbicolan; Sorvilande; Neosorb P 60; D-Sorbite; Foodol D 70; Neosorb 20/60DC; Neosorb 70/70; Neosorb 70/02; Neosorb P 20/60; d-Sorbit; Karion (carbohydrate) DMAN0DE CP Pharmaxis DMAN0DE DT Small molecular drug DMAN0DE PC 5780 DMAN0DE MW 182.17 DMAN0DE FM C6H14O6 DMAN0DE IC InChI=1S/C6H14O6/c7-1-3(9)5(11)6(12)4(10)2-8/h3-12H,1-2H2/t3-,4+,5-,6-/m1/s1 DMAN0DE CS C([C@H]([C@H]([C@@H]([C@H](CO)O)O)O)O)O DMAN0DE IK FBPFZTCFMRRESA-JGWLITMVSA-N DMAN0DE IU (2R,3R,4R,5S)-hexane-1,2,3,4,5,6-hexol DMAN0DE CA CAS 50-70-4 DMAN0DE CB CHEBI:17924 DMAN0DE DE Constipation DMUJGR1 ID DMUJGR1 DMUJGR1 DN Sorivudine DMUJGR1 HS Approved DMUJGR1 SN Usevir (TN) DMUJGR1 DT Small molecular drug DMUJGR1 PC 5282192 DMUJGR1 MW 349.13 DMUJGR1 FM C11H13BrN2O6 DMUJGR1 IC InChI=1S/C11H13BrN2O6/c12-2-1-5-3-14(11(19)13-9(5)18)10-8(17)7(16)6(4-15)20-10/h1-3,6-8,10,15-17H,4H2,(H,13,18,19)/b2-1+/t6-,7-,8+,10-/m1/s1 DMUJGR1 CS C1=C(C(=O)NC(=O)N1[C@H]2[C@H]([C@@H]([C@H](O2)CO)O)O)/C=C/Br DMUJGR1 IK GCQYYIHYQMVWLT-HQNLTJAPSA-N DMUJGR1 IU 5-[(E)-2-bromoethenyl]-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione DMUJGR1 CA CAS 77181-69-2 DMUJGR1 CB CHEBI:32152 DMUJGR1 DE Virus infection DML60TN ID DML60TN DML60TN DN Sotalol DML60TN HS Approved DML60TN SN Sotalolum; Darob mite; Sotalol Monohydrochloride; Beta-Cardone; Betapace (TN); Betapace AF (TN); Darob mite (TN); MJ-1999; Sotacor (TN); Sotalex (TN); Sotalol (INN); Sotalol [INN:BAN]; Sotalolum [INN-Latin]; D,l-Sotalol; N-[4-[1-hydroxy-2-(propan-2-ylamino)ethyl]phenyl]methanesulfonamide; N-(4-{1-hydroxy-2-[(1-methylethyl)amino]ethyl}phenyl)methanesulfonamide; N-{4-[1-hydroxy-2-(propan-2-ylamino)ethyl]phenyl}methanesulfonamide; Methanesulfonamide, N-(4-(1-hydroxy-2-((1-methylethyl)amino)ethyl)phenyl)-(9CI); 4'-(1-Hydroxy-2-(isopropylamino)ethyl)methane sulfonanilide; 4'-(1-Hydroxy-2-isopropylaminoethyl)methanesulfonanilid DML60TN CP Bristol-Myers Squibb DML60TN TC Antiarrhythmic Agents DML60TN DT Small molecular drug DML60TN PC 5253 DML60TN MW 272.37 DML60TN FM C12H20N2O3S DML60TN IC InChI=1S/C12H20N2O3S/c1-9(2)13-8-12(15)10-4-6-11(7-5-10)14-18(3,16)17/h4-7,9,12-15H,8H2,1-3H3 DML60TN CS CC(C)NCC(C1=CC=C(C=C1)NS(=O)(=O)C)O DML60TN IK ZBMZVLHSJCTVON-UHFFFAOYSA-N DML60TN IU N-[4-[1-hydroxy-2-(propan-2-ylamino)ethyl]phenyl]methanesulfonamide DML60TN CA CAS 3930-20-9 DML60TN CB CHEBI:63622 DML60TN DE Sinus rhythm disorder DMB4HCT ID DMB4HCT DMB4HCT DN Sparfloxacin DMB4HCT HS Approved DMB4HCT SN Esparfloxacino; SPFX; Spara; Sparfloxacine; Sparfloxacinum; Zagam; AT 4140; CP 103826; PD 131501; PD131501; AT-4140; CP-103826; DRG-0143; Esparfloxacino [INN-Spanish]; Liposome-encapsulated sparfloxacin; PD 1315-1; PD-131501; RP-64206; Respipac (TN); Sparfloxacin & RU 40555; Sparfloxacine [INN-French]; Sparfloxacinum [INN-Latin]; Zagam (TN); Sparfloxacin, cis-isomer; Sparfloxacin (JAN/USAN/INN); Sparfloxacin [USAN:BAN:INN:JAN]; Cis-5-Amino-1-cyclopropyl-7-(3,5-dimethyl-1-piperazinyl)-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid; (cis)-5-amino-1-cyclopropyl-7-(3,5-dimethyl-1-piperazinyl)-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid; 5-Amino-1-cyclohexyl-7-(cis-3,5-dimethylpiperazino)-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid; 5-Amino-1-cyclopropyl-7-(cis-3,5-dimethyl)-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid & RU 40555; 5-Amino-1-cyclopropyl-7-(cis-3,5-dimethyl-1-piperazinyl)-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid; 5-amino-1-cyclopropyl-7-[(3R,5S)-3,5-dimethylpiperazin-1-yl]-6,8-difluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 5-amino-1-cyclopropyl-7-[(3R,5S)-3,5-dimethylpiperazin-1-yl]-6,8-difluoro-4-oxoquinoline-3-carboxylic acid DMB4HCT CP Square pharma DMB4HCT TC Antibiotics DMB4HCT DT Small molecular drug DMB4HCT PC 60464 DMB4HCT MW 392.4 DMB4HCT FM C19H22F2N4O3 DMB4HCT IC InChI=1S/C19H22F2N4O3/c1-8-5-24(6-9(2)23-8)17-13(20)15(22)12-16(14(17)21)25(10-3-4-10)7-11(18(12)26)19(27)28/h7-10,23H,3-6,22H2,1-2H3,(H,27,28)/t8-,9+ DMB4HCT CS C[C@@H]1CN(C[C@@H](N1)C)C2=C(C(=C3C(=C2F)N(C=C(C3=O)C(=O)O)C4CC4)N)F DMB4HCT IK DZZWHBIBMUVIIW-DTORHVGOSA-N DMB4HCT IU 5-amino-1-cyclopropyl-7-[(3R,5S)-3,5-dimethylpiperazin-1-yl]-6,8-difluoro-4-oxoquinoline-3-carboxylic acid DMB4HCT CA CAS 110871-86-8 DMB4HCT CB CHEBI:9212 DMB4HCT DE Bacterial infection DM0MQ35 ID DM0MQ35 DM0MQ35 DN Spectinomycin DM0MQ35 HS Approved DM0MQ35 SN Actinospectacin; Actinospectacina; Adspec; Espectinomicina; Prospec; SCM; SPCM; Spectam; Spectinomicina; Spectinomycine; Spectinomycinum; Spectogard; Stanilo; Togamycin; Trobicin; Actinospectacina [Italian]; Spectam Scour Halt; Spectinomicina [Italian]; Spectinomycin Di HCl; Spectinomycin HCl; Spectinomycin dihydrochloride; Spectinomycin hydrochloride; Spectinomycin hydrochloride anhydrous; Spectinomycin monohydrochloride; Spectinomycin sulfate; Antibiotic 2233wp; M 141; U 18409; U 18409 E; Actinospectacin, hydrochloride; Adspec (TN); Espectinomicina [INN-Spanish]; M-141; Prospec (TN); Spectinomycin (INN); Spectinomycin Dihydrochloride, Anhydrous; Spectinomycin Dihydrochloride, Pentahydrate; SpectinomycinHCl/ Sulphate; Spectinomycin Hydrochloride (anhydrous); Spectinomycin [INN:BAN]; Spectinomycine [INN-French]; Spectinomycinum [INN-Latin]; Trobicin (TN); U-18409AE; XK 43-1; Togamycin sulfate (1:1); ACTINOSPECTACIN, ESPECTINOMICINA, CHX-3101; (2R,4aR,5aR,6S,7S,8R,9S,9aR,10aS)-4a,7,9-trihydroxy-2-methyl-6,8-bis(methylamino)decahydro-4H-pyrano[2,3-b][1,4]benzodioxin-4-one; (2R-(2alpha,4abeta,5abeta,6beta,7beta,8beta,9alpha,9aalpha,10abeta))-Decahydro-4a,7,9-trihydroxy-2-methyl-6,8-bis(methylamino)-4H-pyrano(2,3-b)(1,4)benzodioxin-4-one monohydrochloride; 4H-Pyrano[2,3-b][1,4]benzodioxin-4-one, decahydro-4a,7,9-trihydroxy-2-methyl-6,8-bis(methylamino)-, [2R-(2.alpha.,4a.beta.,5a.beta.,6.beta.,7.beta.,8.beta.,9.alpha.,9a.alpha.,10a.beta.)]-, sulfate (1:1) (salt) DM0MQ35 CP Pharmacia & Upjohn Company DM0MQ35 TC Antibiotics DM0MQ35 DT Small molecular drug DM0MQ35 PC 15541 DM0MQ35 MW 332.35 DM0MQ35 FM C14H24N2O7 DM0MQ35 IC InChI=1S/C14H24N2O7/c1-5-4-6(17)14(20)13(21-5)22-12-10(19)7(15-2)9(18)8(16-3)11(12)23-14/h5,7-13,15-16,18-20H,4H2,1-3H3/t5-,7-,8+,9+,10+,11-,12-,13+,14+/m1/s1 DM0MQ35 CS C[C@@H]1CC(=O)[C@]2([C@@H](O1)O[C@@H]3[C@H]([C@@H]([C@@H]([C@@H]([C@H]3O2)NC)O)NC)O)O DM0MQ35 IK UNFWWIHTNXNPBV-WXKVUWSESA-N DM0MQ35 IU (1R,3S,5R,8R,10R,11S,12S,13R,14S)-8,12,14-trihydroxy-5-methyl-11,13-bis(methylamino)-2,4,9-trioxatricyclo[8.4.0.03,8]tetradecan-7-one DM0MQ35 CA CAS 1695-77-8 DM0MQ35 CB CHEBI:9215 DM0MQ35 DE Bacterial infection DM6CMJD ID DM6CMJD DM6CMJD DN Spectinomycin DM6CMJD HS Approved DM6CMJD SN Specitinomycin; Spectam; Spectinomicina; Spectinomicina [Italian]; Spectinomycin; Spectinomycin [INN:BAN]; Spectinomycin hydrochloride; Spectinomycine; Spectinomycine [INN-French]; Spectinomycinum; Spectinomycinum [INN-Latin]; Togamycin; Actinospectacina [Italian]; Antibiotic 2233wp; CHX-3101; Espectinomicina; Espectinomicina [INN-Spanish]; Trobicin; U 18409 E; UNFWWIHTNXNPBV-WXKVUWSESA-N; actinospectacin; 1695-77-8; 93AKI1U6QF; BRN 2171701; C14H24N2O7; CHEBI:9215; EINECS 216-911-3; M-141; SCM; UNII-93AKI1U6QF DM6CMJD PC 15541 DM6CMJD MW 332.35 DM6CMJD FM C14H24N2O7 DM6CMJD IC UNFWWIHTNXNPBV-WXKVUWSESA-N DM6CMJD CS CC1CC(=O)C2(C(O1)OC3C(C(C(C(C3O2)NC)O)NC)O)O DM6CMJD IK 1S/C14H24N2O7/c1-5-4-6(17)14(20)13(21-5)22-12-10(19)7(15-2)9(18)8(16-3)11(12)23-14/h5,7-13,15-16,18-20H,4H2,1-3H3/t5-,7-,8+,9+,10+,11-,12-,13+,14+/m1/s1 DM6CMJD IU (1R,3S,5R,8R,10R,11S,12S,13R,14S)-8,12,14-trihydroxy-5-methyl-11,13-bis(methylamino)-2,4,9-trioxatricyclo[8.4.0.03,8]tetradecan-7-one DM6CMJD CA CAS 1695-77-8 DM6CMJD CB CHEBI:9215 DM6CMJD DE Gonococcal infection DM6XFHS ID DM6XFHS DM6XFHS DN SPI-1005 DM6XFHS HS Approved DM6XFHS SN Ebselen [INN]; Ebselene; Ebselene [French]; Ebseleno; Ebseleno [Spanish]; Ebselenum; Ebselenum [Latin]; Harmokisane; PZ 51; PZ-51; PZ51; RP 60931; SPI-1005; SPI-3005; 2-Phenyl-1,2-benzisoselenazol-3(2H)-one; 2-Phenyl-1,2-benzisoselenazolin-3-one; 2-phenyl-1,2-benzoisoselenazol-3(2H)-one; 2-phenyl-1,2-benzoselenazol-3-one; DR 3305; DR-3305; E 3520 DM6XFHS TC Fibrinolytic Agents DM6XFHS DT Small molecular drug DM6XFHS PC 3194 DM6XFHS MW 274.19 DM6XFHS FM C13H9NOSe DM6XFHS IC InChI=1S/C13H9NOSe/c15-13-11-8-4-5-9-12(11)16-14(13)10-6-2-1-3-7-10/h1-9H DM6XFHS CS C1=CC=C(C=C1)N2C(=O)C3=CC=CC=C3[Se]2 DM6XFHS IK DYEFUKCXAQOFHX-UHFFFAOYSA-N DM6XFHS IU 2-phenyl-1,2-benzoselenazol-3-one DM6XFHS CA CAS 60940-34-3 DM6XFHS CB CHEBI:77543 DM6XFHS DE Reperfusion injury DM0BQRS ID DM0BQRS DM0BQRS DN Spinosad DM0BQRS HS Approved DM0BQRS SN Natroba (TN) DM0BQRS CP ParaPRO DM0BQRS DT Small molecular drug DM0BQRS PC 24721309 DM0BQRS MW 732 DM0BQRS FM C41H65NO10 DM0BQRS IC InChI=1S/C41H65NO10/c1-10-26-12-11-13-34(52-36-17-16-33(42(5)6)23(3)48-36)22(2)37(44)32-20-30-28(31(32)21-35(43)50-26)15-14-25-18-27(19-29(25)30)51-41-40(47-9)39(46-8)38(45-7)24(4)49-41/h14-15,20,22-31,33-34,36,38-41H,10-13,16-19,21H2,1-9H3/t22-,23-,24+,25-,26+,27-,28+,29-,30-,31?,33+,34+,36+,38+,39-,40-,41+/m1/s1 DM0BQRS CS CC[C@H]1CCC[C@@H]([C@H](C(=O)C2=C[C@H]3[C@@H]4C[C@@H](C[C@H]4C=C[C@@H]3C2CC(=O)O1)O[C@H]5[C@@H]([C@@H]([C@H]([C@@H](O5)C)OC)OC)OC)C)O[C@H]6CC[C@@H]([C@H](O6)C)N(C)C DM0BQRS IK SRJQTHAZUNRMPR-MGGCLMNKSA-N DM0BQRS IU (2S,5S,7R,9R,10S,14R,15S,19S)-15-[(2R,5S,6R)-5-(dimethylamino)-6-methyloxan-2-yl]oxy-19-ethyl-14-methyl-7-[(2R,3R,4R,5S,6S)-3,4,5-trimethoxy-6-methyloxan-2-yl]oxy-20-oxatetracyclo[10.10.0.02,10.05,9]docosa-3,11-diene-13,21-dione DM0BQRS CA CAS 168316-95-8 DM0BQRS DE Head and body lice DM20R5F ID DM20R5F DM20R5F DN Spiramycin DM20R5F HS Approved DM20R5F SN spiramycin; 8025-81-8; ST075006; Spiramycinum; Spiramycine; Provamycin; Sequamycin; Espiramicin; Rovamycin; Antibiotic 799; NSC-64393; RP 5337; Rovamycine; Prestwick_121; 5337 R.P.; Prestwick2_000745; Prestwick3_000745; AC1O4WG0; Spiramycin antibiotic complex; BPBio1_000804; SCHEMBL5032756; AKOS015896378; K430; SR-01000872632; SR-01000872632-1; I06-1973; Spiramycin, European Pharmacopoeia (EP) Reference Standard; Spiramycin from Streptomyces sp., VETRANAL(TM), analytical standard; Spiramycin, Pharmaceutical Secondary Standard DM20R5F DT Small molecular drug DM20R5F PC 6419898 DM20R5F MW 843.1 DM20R5F FM C43H74N2O14 DM20R5F IC InChI=1S/C43H74N2O14/c1-24-21-29(19-20-46)39(59-42-37(49)36(45(9)10)38(27(4)56-42)58-35-23-43(6,51)41(50)28(5)55-35)40(52-11)31(47)22-33(48)53-25(2)15-13-12-14-16-32(24)57-34-18-17-30(44(7)8)26(3)54-34/h12-14,16,20,24-32,34-42,47,49-51H,15,17-19,21-23H2,1-11H3/b13-12+,16-14+/t24-,25-,26?,27?,28?,29+,30?,31-,32+,34?,35?,36?,37?,38?,39+,40+,41?,42?,43?/m1/s1 DM20R5F CS C[C@@H]1C/C=C/C=C/[C@@H]([C@@H](C[C@@H]([C@@H]([C@H]([C@@H](CC(=O)O1)O)OC)OC2C(C(C(C(O2)C)OC3CC(C(C(O3)C)O)(C)O)N(C)C)O)CC=O)C)OC4CCC(C(O4)C)N(C)C DM20R5F IK ACTOXUHEUCPTEW-JMRHEKERSA-N DM20R5F IU 2-[(4R,5S,6S,7R,9R,10R,11E,13E,16R)-6-[5-(4,5-dihydroxy-4,6-dimethyloxan-2-yl)oxy-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-10-[5-(dimethylamino)-6-methyloxan-2-yl]oxy-4-hydroxy-5-methoxy-9,16-dimethyl-2-oxo-1-oxacyclohexadeca-11,13-dien-7-yl]acetaldehyde DM20R5F CA CAS 8025-81-8 DM20R5F DE Bacterial infection DM5XLTY ID DM5XLTY DM5XLTY DN Spirapril DM5XLTY HS Approved DM5XLTY SN Renormax; Sandopril; Setrilan; Espirapril [Spanish]; Not established; Spiraprilum [Latin]; Sch-33844; Spirapril (INN); Spirapril [INN:BAN]; TI-211-950; (2S)-3-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-6,9-dithia-3-azaspiro[4.4]nonane-2-carboxylic acid DM5XLTY TC Antihypertensive Agents DM5XLTY DT Small molecular drug DM5XLTY PC 5311447 DM5XLTY MW 466.6 DM5XLTY FM C22H30N2O5S2 DM5XLTY IC InChI=1S/C22H30N2O5S2/c1-3-29-21(28)17(10-9-16-7-5-4-6-8-16)23-15(2)19(25)24-14-22(30-11-12-31-22)13-18(24)20(26)27/h4-8,15,17-18,23H,3,9-14H2,1-2H3,(H,26,27)/t15-,17-,18-/m0/s1 DM5XLTY CS CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2CC3(C[C@H]2C(=O)O)SCCS3 DM5XLTY IK HRWCVUIFMSZDJS-SZMVWBNQSA-N DM5XLTY IU (8S)-7-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-1,4-dithia-7-azaspiro[4.4]nonane-8-carboxylic acid DM5XLTY CA CAS 83647-97-6 DM5XLTY CB CHEBI:135756 DM5XLTY DE Hypertension DM2AQ5N ID DM2AQ5N DM2AQ5N DN Spironolactone DM2AQ5N HS Approved DM2AQ5N SN Abbolactone; Acelat; Aldace; Aldactazide; Aldactide; Aldactone; Alderon; Aldopur; Almatol; Altex; Aquareduct; Deverol; Diatensec; Dira; Duraspiron; Espironolactona; Euteberol; Flumach; Frumikal; Jenaspiron; Lacalmin; Lacdene; Laractone; Melarcon; Nefurofan; NovoSpiroton; Osyrol; Practon; SNL; Sagisal; Sincomen; Spiractin; Spiresis; Spiretic; Spiridon; Spirobeta; Spiroctan; Spiroctanie; Spiroderm; Spirogamma; Spirolactone; Spirolakton; Spirolang; Spirolone; Spirone; Spironocompren; Spironolactonum; Spironolattone; Spironone; Spirospare; Sprioderm; Suracton; Uractone; Urusonin; Veroshpiron; Verospiron; Verospirone; Xenalon; Aldactone A; Alphapharm Brand of Spironolactone; Alpharma Brand of Spironolactone; Alter Brand of Spironolactone; Ashbourne Brand of Spironolactone; Azupharma Brand of Spironolactone; Betapharm Brand of Spironolactone; Cardel Brand of Spironolactone; Ct Arzneimittel Brand of Spironolactone; Dexo Brand of Spironolactone; Espironolactona Alter; Espironolactona Mundogen; Generosan Brand of Spironolactone; Hormosan Brand of Spironolactone; Jenapharm Brand of Spironolactone; Merck dura Brand of Spironolactone; Mundogen Brand of Spironolactone; Novo Spiroton; Novopharm Brand of Spironolactone; Pfizer Brand of Spironolactone; Pharmafrid Brand of Spironolactone; Roche Brand of Spironolactone; Searle Brand of Spironolactone; Spiro von ct; Spirono Isis; Spironolactone A; Spironolattone [DCIT]; Verospirone Opianin; Worwag Brand of Spironolactone; LT00772287; SC 9420; SC9420; Aldactazide (TN); Aldactone (TN); Berlactone (TN); Ct-Arzneimittel Brand of Spironolactone; Espironolactona [INN-Spanish]; Mayoly-Spindler Brand of Spironolactone; Novo-Spiroton; SC-9420; Spiractin (TN); Spiro-Tablinen; Spirono-Isis; Spironolactonum [INN-Latin]; Spirotone (TN); Supra-puren; Verospiron (TN); Von ct, spiro; Novo-Spiroton (TN); Spironolactone [BAN:INN:JAN]; Spironolactone [INN:BAN:JAN]; Spiro L.U.T.; Spironolactone (JP15/USP/INN); Spiro[17H-cyclopenta[a]phenauthrene-17,2'-(3'H)-furan]; Spiro(17H-cyclopenta(a)phenauthrene-17,2'-(3'H)-furan); 4-Pregnen-21-oic acid-17alpha-ol-3-one-7alpha-thiol gamma-lactone 7-acetate; 7-alpha-Acetylthio-3-oxo-17-alpha-pregn-4-ene-21,17-beta-carbolactone; 7alpha-(acetylsulfanyl)-3-oxo-17alpha-pregn-4-ene-21,17-carbolactone DM2AQ5N CP Pfizer Pharmaceuticals DM2AQ5N TC Diuretics DM2AQ5N DT Small molecular drug DM2AQ5N PC 5833 DM2AQ5N MW 416.6 DM2AQ5N FM C24H32O4S DM2AQ5N IC InChI=1S/C24H32O4S/c1-14(25)29-19-13-15-12-16(26)4-8-22(15,2)17-5-9-23(3)18(21(17)19)6-10-24(23)11-7-20(27)28-24/h12,17-19,21H,4-11,13H2,1-3H3/t17-,18-,19+,21+,22-,23-,24+/m0/s1 DM2AQ5N CS CC(=O)S[C@@H]1CC2=CC(=O)CC[C@@]2([C@@H]3[C@@H]1[C@@H]4CC[C@]5([C@]4(CC3)C)CCC(=O)O5)C DM2AQ5N IK LXMSZDCAJNLERA-ZHYRCANASA-N DM2AQ5N IU S-[(7R,8R,9S,10R,13S,14S,17R)-10,13-dimethyl-3,5'-dioxospiro[2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthrene-17,2'-oxolane]-7-yl] ethanethioate DM2AQ5N CA CAS 52-01-7 DM2AQ5N CB CHEBI:9241 DM2AQ5N DE Congestive heart failure DMCO5JZ ID DMCO5JZ DMCO5JZ DN SR141716A DMCO5JZ HS Approved DMCO5JZ SN Riobant; Slimona; [3H]SR141716A; Acomplia (TN); Bethin (TN); Monaslim (TN); Remonabent (TN); Rimonabant [USAN:INN]; Rimoslim (TN); Riobant (TN); Riomont (TN); Slimona (TN); Zimulti (TN); Rimonabant (JAN/USAN/INN); 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-piperidin-1-ylpyrazole-3-carboxamide; 5-(p-Chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-piperidinopyrazole-3-carboxamide DMCO5JZ CP Sanofi-Aventis DMCO5JZ TC Antiobesity Agents DMCO5JZ DT Small molecular drug DMCO5JZ PC 104850 DMCO5JZ MW 463.8 DMCO5JZ FM C22H21Cl3N4O DMCO5JZ IC InChI=1S/C22H21Cl3N4O/c1-14-20(22(30)27-28-11-3-2-4-12-28)26-29(19-10-9-17(24)13-18(19)25)21(14)15-5-7-16(23)8-6-15/h5-10,13H,2-4,11-12H2,1H3,(H,27,30) DMCO5JZ CS CC1=C(N(N=C1C(=O)NN2CCCCC2)C3=C(C=C(C=C3)Cl)Cl)C4=CC=C(C=C4)Cl DMCO5JZ IK JZCPYUJPEARBJL-UHFFFAOYSA-N DMCO5JZ IU 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-piperidin-1-ylpyrazole-3-carboxamide DMCO5JZ CA CAS 168273-06-1 DMCO5JZ CB CHEBI:34967 DMCO5JZ DE Obesity DM6DEK9 ID DM6DEK9 DM6DEK9 DN Stavudine DM6DEK9 HS Approved DM6DEK9 SN DdeThd; DdeTyd; Dideoxydidehydrothymidine; Estavudina; STV; Sanilvudine; Stavudinum; Zent; Zerit; Zerit Xr; Zerut XR; BMY 27857; BMY27857; D 1413; D 4T; BMY-27857; Bristol-Myers Brand of Stavudine; Bristol-Myers Squibb Brand of Stavudine; D 4T (nucleoside); Estavudina [INN-Spanish]; Sanilvudine (JAN); Stavudine, Monosodium Salt; Stavudinum [INN-Latin]; Zerit (TN); Zerit(TM); D4T & GM-CSF; D4TMBY-27857-3; Stavudine (USAN/INN); Stavudine [USAN:BAN:INN]; Stavudine [USAN:INN:BAN]; Thymine, 1-(2,3-dideoxy-beta-D-glycero-pent-2-enofuranosyl)-(7CI,8CI); 1-(2,3-Dideoxy-beta-D-glycero-2-pentenofuranosyl)thymine; 1-(2,3-Dideoxy-beta-D-glycero-pent-2-enofuranosyl)thymine; 1-[(2R,5S)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]-5-methylpyrimidine-2,4(1H,3H)-dione; 1-[(2R,5S)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]-5-methylpyrimidine-2,4-dione; 1-[5-(hydroxymethyl)-2,5-dihydro-2-furanyl]-5-methyl-2,4(1H,3H)-pyrimidinedione & Colony-stimulating factor 2; 2',3' Didehydro 3' deoxythymidine; 2',3'-Anhydrothymidine; 2',3'-DIDEHYDRO-3'-DEOXYTHYMIDINE (DDI); 2',3'-Didehydro-2',3'-dideoxythmidine; 2',3'-Didehydro-3'-deoxythimidine; 2',3'-Didehydro-3'-deoxythymidine; 3'-Azido-3'-deoxythymidine & Granulocyte-macrophage colony-stimulating factor; 3'-Deoxy-2',3'-didehydrothymidine; 3'-Deoxy-2'-thymidinene; D4T DM6DEK9 CP Aurobindo Pharma DM6DEK9 TC Anti-HIV Agents DM6DEK9 DT Small molecular drug DM6DEK9 PC 18283 DM6DEK9 MW 224.21 DM6DEK9 FM C10H12N2O4 DM6DEK9 IC InChI=1S/C10H12N2O4/c1-6-4-12(10(15)11-9(6)14)8-3-2-7(5-13)16-8/h2-4,7-8,13H,5H2,1H3,(H,11,14,15)/t7-,8+/m0/s1 DM6DEK9 CS CC1=CN(C(=O)NC1=O)[C@H]2C=C[C@H](O2)CO DM6DEK9 IK XNKLLVCARDGLGL-JGVFFNPUSA-N DM6DEK9 IU 1-[(2R,5S)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]-5-methylpyrimidine-2,4-dione DM6DEK9 CA CAS 3056-17-5 DM6DEK9 CB CHEBI:63581 DM6DEK9 DE Human immunodeficiency virus infection DMMSDOY ID DMMSDOY DMMSDOY DN Stiripentol DMMSDOY HS Approved DMMSDOY SN Diacomit; ME-2080; Stiripentol (oral); Stiripentol (oral), Laboratoires Biocodex DMMSDOY CP Biocodex DMMSDOY DT Small molecular drug DMMSDOY PC 5311454 DMMSDOY MW 234.29 DMMSDOY FM C14H18O3 DMMSDOY IC InChI=1S/C14H18O3/c1-14(2,3)13(15)7-5-10-4-6-11-12(8-10)17-9-16-11/h4-8,13,15H,9H2,1-3H3/b7-5+ DMMSDOY CS CC(C)(C)C(/C=C/C1=CC2=C(C=C1)OCO2)O DMMSDOY IK IBLNKMRFIPWSOY-FNORWQNLSA-N DMMSDOY IU (E)-1-(1,3-benzodioxol-5-yl)-4,4-dimethylpent-1-en-3-ol DMMSDOY CA CAS 49763-96-4 DMMSDOY CB CHEBI:94435 DMMSDOY DE Dravet syndrome; Epilepsy DM5JQ0D ID DM5JQ0D DM5JQ0D DN Streptokinase DM5JQ0D HS Approved DM5JQ0D SN Awelysin; Estreptoquinasa; Kabikinase; Streptase; Streptochinasi; Streptokinasum; Streptochinasi [DCIT]; Streptococcal fibrinolysin; Estreptoquinasa [INN-Spanish]; Streptase (TN); Streptokinasum [INN-Latin]; 4-cyclohexylpyrrolidine-2-carboxylic Acid DM5JQ0D CP Alpes Selection DM5JQ0D TC Thrombolytic Agents DM5JQ0D DT Small molecular drug DM5JQ0D SQ Streptokinase Sequence DB00086: MKNYLSFGMFALLFALTFGTVNSVQAIAGPEWLLDRPSVNNSQLVVSVAGTVEGTNQDISLKFFEIDLTSRPAHGGKTEQGLSPKSKPFATDSGAMSHKLEKADLLKAIQEQLIANVHSNDDYFEVIDFASDATITDRNGKVYFADKDGSVTLPTQPVQEFLLSGHVRVRPYKEKPIQNQAKSVDVEYTVQFTPLNPDDDFRPGLKDTKLLKTLAIGDTITSQELLAQAQSILNKNHPGYTIYERDSSIVTHDNDIFRTILPMDQEFTYRVKNREQAYRINKKSGLNEEINNTDLISEKYYVLKKGEKPYDPFDRSHLKLFTIKYVDVDTNELLKSEQLLTASERNLDFRDLYDPRDKAKLLYNNLDAFGIMDYTLTGKVEDNHDDTNRIITVYMGKRPEGENASYHLAYDKDRYTEEEREVYSYLRYTGTPIPDNPNDK DM5JQ0D PC 9815560 DM5JQ0D MW 197.27 DM5JQ0D FM C11H19NO2 DM5JQ0D IC InChI=1S/C11H19NO2/c13-11(14)10-6-9(7-12-10)8-4-2-1-3-5-8/h8-10,12H,1-7H2,(H,13,14) DM5JQ0D CS C1CCC(CC1)C2CC(NC2)C(=O)O DM5JQ0D IK XRZWVSXEDRYQGC-UHFFFAOYSA-N DM5JQ0D IU 4-cyclohexylpyrrolidine-2-carboxylic acid DM5JQ0D CA CAS 9002-01-1 DM5JQ0D DE Pulmonary embolism DME1LQN ID DME1LQN DME1LQN DN Streptomycin DME1LQN HS Approved DME1LQN SN Agrept; Agrimycin; Gerox; Neodiestreptopab; SRY; Strepcen; Streptomicina; Streptomycine; Streptomycinum; Streptomyzin; Liposomal Streptomycin; Streptomicina [Italian]; Streptomycin A; Streptomycin A sulfate; Streptomycin Sesquisulfate Hydrate; Streptomycin sulfate; Streptomycin sulphate; Streptomyzin [German]; Agrept (TN); Estreptomicina [INN-Spanish]; Hokko-mycin; Plantomycin (TN); Rimosidin (TN); Streptomycin & EEP; Streptomycin & Propolis; Streptomycin (INN); Streptomycin (TN); Streptomycin [INN:BAN]; Streptomycin, Sulfate Salt; AS-50 (TN); STREPTOMYCIN SULFATE (2:3) SALT; Agri-mycin-17 (TN); O-2-Deoxy-2-(methylamino)-.alpha.-L-glucopyranosyl-(1->2)-O-5-deoxy-3-C-formyl-.alpha.-L-lyxofuranosyl-(1->4)-N,N'-bis(aminoiminomethyl)-D-streptamine and Liposome; N,N'''-[(1R,2R,3S,4R,5R,6S)-4-{5-deoxy-2-O-[2-deoxy-2-(methylamino)-alpha-L-glucopyranosyl]-3-C-formyl-alpha-L-lyxofuranosyloxy}-2,5,6-trihydroxycyclohexane-1,3-diyl]diguanidine; N,N'''-[(1R,2R,3S,4R,5R,6S)-4-({5-deoxy-2-O-[2-deoxy-2-(methylamino)-alpha-L-glucopyranosyl]-3-C-formyl-alpha-L-lyxofuranosyl}oxy)-2,5,6-trihydroxycyclohexane-1,3-diyl]diguanidine; 2,4-Diguanidino-3,5,6-trihydroxycyclohexyl 5-deoxy-2-O-(2-deoxy-2-methylamino-alpha-L-glucopyranosyl)-3-C-formyl-beta-L-lyxopentanofuranoside; 2-[(1R,2R,3S,4R,5R,6S)-3-(diaminomethylideneamino)-4-[(2R,3R,4R,5S)-3-[(2S,3S,4S,5R,6S)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy-4-formyl-4-hydroxy-5-methyloxolan-2-yl]oxy-2,5,6-trihydroxycyclohexyl]guanidine; 2-[(1R,2R,3S,4R,5R,6S)-3-(diaminomethylideneamino)-4-[(2S,3S,4S,5R)-3-[(2R,3R,4R,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy-4-formyl-4-hydroxy-5-methyloxolan-2-yl]oxy-2,5,6-trihydroxycyclohexyl]guanidine; 2-[(1S,2S,3R,4S,5S,6R)-3-(diaminomethylideneamino)-4-[(2R,3R,4R,5S)-3-[(2S,3S,4S,5R,6S)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy-4-formyl-4-hydroxy-5-methyloxolan-2-yl]oxy-2,5,6-trihydroxycyclohexyl]guanidine; 2-[(1S,4S)-5-(diaminomethylideneamino)-2-[(2R,5S)-3-[(2S,5R)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy-4-formyl-4-hydroxy-5-methyloxolan-2-yl]oxy-3,4,6-trihydroxycyclohexyl]guanidine; [2-deoxy-2-(dimethylamino)-alpha-L-glucopyranosyl]-(1->2)-[5-deoxy-3-C-formyl-alpha-L-lyxofuranosyl]-(1->4)-{N',N'''-[(1,3,5/2,4,6)-2,4,5,6-tetrahydroxycyclohexane-1,3-diyl]diguanidine} DME1LQN CP Merck & Co DME1LQN TC Antibiotics DME1LQN DT Small molecular drug DME1LQN PC 19649 DME1LQN MW 581.6 DME1LQN FM C21H39N7O12 DME1LQN IC InChI=1S/C21H39N7O12/c1-5-21(36,4-30)16(40-17-9(26-2)13(34)10(31)6(3-29)38-17)18(37-5)39-15-8(28-20(24)25)11(32)7(27-19(22)23)12(33)14(15)35/h4-18,26,29,31-36H,3H2,1-2H3,(H4,22,23,27)(H4,24,25,28)/t5-,6-,7+,8-,9-,10-,11+,12-,13-,14+,15+,16-,17-,18-,21+/m0/s1 DME1LQN CS C[C@H]1[C@@]([C@H]([C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H]([C@@H]([C@H]2O)O)N=C(N)N)O)N=C(N)N)O[C@H]3[C@H]([C@@H]([C@H]([C@@H](O3)CO)O)O)NC)(C=O)O DME1LQN IK UCSJYZPVAKXKNQ-HZYVHMACSA-N DME1LQN IU 2-[(1R,2R,3S,4R,5R,6S)-3-(diaminomethylideneamino)-4-[(2R,3R,4R,5S)-3-[(2S,3S,4S,5R,6S)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy-4-formyl-4-hydroxy-5-methyloxolan-2-yl]oxy-2,5,6-trihydroxycyclohexyl]guanidine DME1LQN CA CAS 57-92-1 DME1LQN CB CHEBI:17076 DME1LQN DE Bacterial infection DMSRXVM ID DMSRXVM DMSRXVM DN Streptomycin DMSRXVM HS Approved DMSRXVM SN Streptomicina [Italian]; Streptomycin A; Streptomycin A sulfate; Streptomycin [INN:BAN]; Streptomycin sulfate; Streptomycin sulphate; Streptomycine; Streptomycinum; Streptomyzin [German]; Agrept; Agrimycin; Chemform; Estreptomicina [INN-Spanish]; Hokko-mycin; Neodiestreptopab; Strepcen; Y45QSO73OB; streptomycin; 2,4-Diguanidino-3,5,6-trihydroxycyclohexyl 5-deoxy-2-O-(2-deoxy-2-methylamino-alpha-L-glucopyranosyl)-3-C-formyl-beta-L-lyxopentanofuranoside; 57-92-1; CHEBI:17076; Caswell No. 804; Gerox; NSC-14083; UNII-Y45QSO73OB DMSRXVM PC 19649 DMSRXVM MW 581.6 DMSRXVM FM C21H39N7O12 DMSRXVM IC UCSJYZPVAKXKNQ-HZYVHMACSA-N DMSRXVM CS CC1C(C(C(O1)OC2C(C(C(C(C2O)O)N=C(N)N)O)N=C(N)N)OC3C(C(C(C(O3)CO)O)O)NC)(C=O)O DMSRXVM IK 1S/C21H39N7O12/c1-5-21(36,4-30)16(40-17-9(26-2)13(34)10(31)6(3-29)38-17)18(37-5)39-15-8(28-20(24)25)11(32)7(27-19(22)23)12(33)14(15)35/h4-18,26,29,31-36H,3H2,1-2H3,(H4,22,23,27)(H4,24,25,28)/t5-,6-,7+,8-,9-,10-,11+,12-,13-,14+,15+,16-,17-,18-,21+/m0/s1 DMSRXVM IU 2-[(1R,2R,3S,4R,5R,6S)-3-(diaminomethylideneamino)-4-[(2R,3R,4R,5S)-3-[(2S,3S,4S,5R,6S)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy-4-formyl-4-hydroxy-5-methyloxolan-2-yl]oxy-2,5,6-trihydroxycyclohexyl]guanidine DMSRXVM CA CAS 57-92-1 DMSRXVM CB CHEBI:17076 DMSRXVM DE Infectious endocarditis DMOF7AT ID DMOF7AT DMOF7AT DN Streptozocin DMOF7AT HS Approved DMOF7AT SN Estreptozocina; STREPTOZOTOCIN; STRZ; Streptozocine; Streptozocinium; Streptozocinum; Streptozosin; Zanosar; Alkylating agent; Binds to DNA; Streptozocinium [Latin]; Streptozocine [INN-French]; Streptozocinum [INN-Latin]; Zanosar (TN); Streptozocin (USAN/INN); Streptozocin, Zanosar, STZ,Streptozotocin;N-(Methylnitrosocarbamoyl)-alpha-D-glucosamine; N-D-Glucosyl-(2)-N'-nitrosomethylharnstoff; N-D-Glucosyl-(2)-N'-nitrosomethylurea; D-Glucose, 2-deoxy-2-(((methylnitrosoamino)carbonyl)amino)-(9CI); 1-methyl-1-nitroso-3-[(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]urea; 2-Deoxy-2-(((methylnitrosoamino)carbonyl)amino)-D-glucopyranose; 2-Deoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose; 2-Deoxy-2[[(methylnitrosoamino)-carbonyl]amino]-D-glucopyranose; 2-deoxy-2-{[methyl(nitroso)carbamoyl]amino}-alpha-D-glucopyranose DMOF7AT CP Pfizer Pharmaceuticals DMOF7AT TC Anticancer Agents DMOF7AT DT Small molecular drug DMOF7AT PC 29327 DMOF7AT MW 265.22 DMOF7AT FM C8H15N3O7 DMOF7AT IC InChI=1S/C8H15N3O7/c1-11(10-17)8(16)9-4-6(14)5(13)3(2-12)18-7(4)15/h3-7,12-15H,2H2,1H3,(H,9,16)/t3-,4-,5-,6-,7+/m1/s1 DMOF7AT CS CN(C(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@@H]1O)CO)O)O)N=O DMOF7AT IK ZSJLQEPLLKMAKR-GKHCUFPYSA-N DMOF7AT IU 1-methyl-1-nitroso-3-[(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]urea DMOF7AT CA CAS 18883-66-4 DMOF7AT CB CHEBI:9288 DMOF7AT DE Pancreatic cancer DME81IY ID DME81IY DME81IY DN Succimer DME81IY HS Approved DME81IY SN Succimer; meso-2,3-Dimercaptosuccinic acid; 304-55-2; DMSA; (2R,3S)-rel-2,3-Dimercaptosuccinic acid; meso-Dimercaptosuccinic acid; Chemet; Dim-sa; Succimerum; Succimero; Dimercaptosuccinic acid; Succimerum [INN-Latin]; Succimero [INN-Spanish]; (R*,S*)-2,3-Dimercaptobutanedioic acid; Butanedioic acid, 2,3-dimercapto-, (2R,3S)-rel-; UNII-DX1U2629QE; Succimer [USAN:INN:BAN]; HSDB 6783; EINECS 206-155-2; Ro 1-7977; BRN 1725150; DX1U2629QE; CHEBI:63623; Butanedioic acid, 2,3-dimercapto-, (R*,S*)-; meso-2,3-Dimercaptobernsteinsaeure DME81IY DT Small molecular drug DME81IY PC 2724354 DME81IY MW 182.2 DME81IY FM C4H6O4S2 DME81IY IC InChI=1S/C4H6O4S2/c5-3(6)1(9)2(10)4(7)8/h1-2,9-10H,(H,5,6)(H,7,8)/t1-,2+ DME81IY CS [C@@H]([C@@H](C(=O)O)S)(C(=O)O)S DME81IY IK ACTRVOBWPAIOHC-XIXRPRMCSA-N DME81IY IU (2S,3R)-2,3-bis(sulfanyl)butanedioic acid DME81IY CA CAS 304-55-2 DME81IY CB CHEBI:63623 DME81IY DE Metal intoxication DMDWICP ID DMDWICP DMDWICP DN Succinic acid DMDWICP HS Approved DMDWICP SN Asuccin; Bernsteinsaeure; Bernsteinsaure; Butandisaeure; Katasuccin; SIN; Succ; Succinellite; Wormwood; Acid of amber; Acide butanedioique; Acide succinique; Acidum succinicum; Amber acid; Bernsteinsaure [German]; Butanedioic acid diammonium salt; Butanedionic acid; Dihydrofumaric acid; Ethanedicarboxylic acid; Ethylene dicarboxylic acid; Ethylene succinic acid; Ethylenesuccinic acid; Kyselina jantarova; Kyselina jantarova [Czech]; Potassium Succinate; Sal succini; Spirit of amber; Succinicum acidum; Succinicun acidum; Wormwood acid; A 12084; Butanedioic acid (9CI); SUCCINIC ACID, ACS; Succinate, 9; Succinic acid (8CI); Amber acid, Butanedioic acid, Ethylenesuccinic acid; 1,2-Ethanedicarboxylic acid; 1,4-BUTANEDIOIC ACID (SUCCINIC ACID); 1,4-Butanedioic acid DMDWICP TC Dietary supplement DMDWICP DT Small molecular drug DMDWICP PC 1110 DMDWICP MW 118.09 DMDWICP FM C4H6O4 DMDWICP IC InChI=1S/C4H6O4/c5-3(6)1-2-4(7)8/h1-2H2,(H,5,6)(H,7,8) DMDWICP CS C(CC(=O)O)C(=O)O DMDWICP IK KDYFGRWQOYBRFD-UHFFFAOYSA-N DMDWICP IU butanedioic acid DMDWICP CA CAS 110-15-6 DMDWICP CB CHEBI:15741 DMDWICP DE Malnutrition DM2ET1M ID DM2ET1M DM2ET1M DN Succinylcholine DM2ET1M HS Approved DM2ET1M SN Anectine; Diacetylcholine; Ditilin; Ditiline; Listenon; Lysthenon; Quelicin; SCK; Succicuran; Succinocholine; Succinoylcholine; Succinylbischoline; Succinyldicholine; Sucostrin; Suxamethonium; Dicholine succinate; Succinyl choline; Anectine (TN); Scoline (TN); Succinic acid, diester with choline; Succinic acid, diester with choline chloride; Choline, succinate (ester); Choline, succinate (2:1) (ester); Trimethyl-[2-[4-oxo-4-(2-trimethylazaniumylethoxy)butanoyl]oxyethyl]azanium diio; Trimethyl-[2-[4-oxo-4-[2-(trimethylazaniumyl)ethoxy]butanoyl]oxyethyl]azanium; 2,2'-[(1,4-DIOXOBUTANE-1,4-DIYL)BIS(OXY)]BIS(N,N,N-TRIMETHYLETHANAMINIUM) DM2ET1M CP Sandoz Canada Inc DM2ET1M TC Analgesics DM2ET1M DT Small molecular drug DM2ET1M PC 5314 DM2ET1M MW 290.4 DM2ET1M FM C14H30N2O4+2 DM2ET1M IC InChI=1S/C14H30N2O4/c1-15(2,3)9-11-19-13(17)7-8-14(18)20-12-10-16(4,5)6/h7-12H2,1-6H3/q+2 DM2ET1M CS C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C DM2ET1M IK AXOIZCJOOAYSMI-UHFFFAOYSA-N DM2ET1M IU trimethyl-[2-[4-oxo-4-[2-(trimethylazaniumyl)ethoxy]butanoyl]oxyethyl]azanium DM2ET1M CA CAS 306-40-1 DM2ET1M CB CHEBI:45652 DM2ET1M DE Spasm DMP9HBO ID DMP9HBO DMP9HBO DN Sucralfate DMP9HBO HS Approved DMP9HBO SN SUL; Ulcerlmin; Sucralfate, Chugai; Sucralfate, Scios Nova DMP9HBO CP Scios Inc DMP9HBO PC 121494085 DMP9HBO MW 1577.9 DMP9HBO FM C12H54Al9O55S8 DMP9HBO IC InChI=1S/C12H22O35S8.9Al.20H2O/c13-48(14,15)37-1-4-6(43-51(22,23)24)8(45-53(28,29)30)9(46-54(31,32)33)11(40-4)42-12(3-39-50(19,20)21)10(47-55(34,35)36)7(44-52(25,26)27)5(41-12)2-38-49(16,17)18;;;;;;;;;;;;;;;;;;;;;;;;;;;;;/h4-11H,1-3H2,(H,13,14,15)(H,16,17,18)(H,19,20,21)(H,22,23,24)(H,25,26,27)(H,28,29,30)(H,31,32,33)(H,34,35,36);;;;;;;;;;20*1H2/q;;8*+1;;;;;;;;;;;;;;;;;;;;/p-8/t4-,5-,6-,7-,8+,9-,10+,11-,12+;;;;;;;;;;;;;;;;;;;;;;;;;;;;;/m1............................./s1 DMP9HBO CS C([C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)O[C@]2([C@H]([C@@H]([C@H](O2)COS(=O)(=O)O[Al])OS(=O)(=O)O[Al])OS(=O)(=O)O[Al])COS(=O)(=O)O[Al])OS(=O)(=O)O[Al])OS(=O)(=O)O[Al])OS(=O)(=O)O[Al])OS(=O)(=O)O[Al].O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.[Al] DMP9HBO IK YZPQNHUVIVIUCT-JTJNLBSYSA-F DMP9HBO CA CAS 54182-58-0 DMP9HBO DE Acne vulgaris DMU7YEL ID DMU7YEL DMU7YEL DN Sufentanil DMU7YEL HS Approved DMU7YEL SN Chronogesic; Sufentanilum; Sufentanyl; Sulfentanil; Sulfentanyl; R 30730; R-30730; Sufenta (TN); Sufentanilum [INN-Latin]; Sufentil (TN); Sufentanil (USAN/INN); Sufentanil [USAN:BAN:INN]; N-(4-(Methoxymethyl)-1-(2-(2-thienyl)ethyl)-4-piperidyl)propionanilide; N-[4-(methoxymethyl)-1-(2-thiophen-2-ylethyl)piperidin-4-yl]-N-phenylpropanamide; N-{4-(methoxymethyl)-1-[2-(2-thienyl)ethyl]piperidin-4-yl}-N-phenylpropanamide; N-{4-[(methyloxy)methyl]-1-[2-(2-thienyl)ethyl]piperidin-4-yl}-N-phenylpropanamide; N-(4-(Methoxymethyl)-1-(2-(2-thienyl)ethyl)-4-piperidinyl)-N-phenylpropanamide DMU7YEL CP Janssen Pharmaceutica DMU7YEL TC Anesthetics DMU7YEL DT Small molecular drug DMU7YEL PC 41693 DMU7YEL MW 386.6 DMU7YEL FM C22H30N2O2S DMU7YEL IC InChI=1S/C22H30N2O2S/c1-3-21(25)24(19-8-5-4-6-9-19)22(18-26-2)12-15-23(16-13-22)14-11-20-10-7-17-27-20/h4-10,17H,3,11-16,18H2,1-2H3 DMU7YEL CS CCC(=O)N(C1=CC=CC=C1)C2(CCN(CC2)CCC3=CC=CS3)COC DMU7YEL IK GGCSSNBKKAUURC-UHFFFAOYSA-N DMU7YEL IU N-[4-(methoxymethyl)-1-(2-thiophen-2-ylethyl)piperidin-4-yl]-N-phenylpropanamide DMU7YEL CA CAS 56030-54-7 DMU7YEL CB CHEBI:9316 DMU7YEL DE Analgesia DMZ6VEY ID DMZ6VEY DMZ6VEY DN Sulfacetamide DMZ6VEY HS Approved DMZ6VEY SN Acetocid; Acetosulfamin; Acetosulfamine; Albamine; Albucid; Alesten; Cetamide; Formosulfacetamide; Klaron; Oclucid; Ophthacet; Region; SULSTER; Sebizon; Solfacetamide; Steramide; Sulamyd; Sulfacet; Sulfacetamida; Sulfacetamidum; Sulfacetimide; Sulfacil; Sulfacyl; Sulfacylum; Sulfair; Sulfanilacetamide; Sulfanilazetamid; Sulphacetamide; Sulphacetamidum; Sulphasil; Sultrin; Urosulfon; Urosulfone; Isopto cetamide; Sodium sulamyd; Sodium sulfacetamide; Solfacetamide [DCIT]; Sulfacetamide Monosodium Salt; Sulfacetamide Sodium Usp; Sulfacetamide sodium; Sulfacetamide sodium anhydrous; Sulfanilazetamid [German]; Sulphacetamide sodium; Sulfair 15; A-500; Ak-Sulf; Bleph-10; Bleph-10 liquifilm; FML-S; I-Sulfacet; Isopto-Cetamide; Klaron (TN); N-Acetylsulfanilamide; N-Acetylsulfanilamine; N-Sulfanilylacetamide; N-Sulphanilylacetamide; N1-Acetylsulfanilamide; OP-Sulfa 30; Ocusulf-10; Ophthel-S; P-Aminobenzenesulfonacetamide; P-Aminobenzenesulfonoacetamide; Steri-Units Sulfacetamide; Sulf-10; Sulf-15; Sulfacel-15; Sulfacetamida [INN-Spanish]; Sulfacetamide [USAN:INN]; Sulfacetamidum [INN-Latin]; Sulfacyl (VAN); Sulfair-15; Sulten-10; N'-Acetylsulfanilamide; N(sup 1)-Acetylsulfanilamide; N(sup1)-Acetylsulfanilamide; Sulfacetamide (USP/INN); N-(4-Aminobenzenesulfonyl)acetamide; N-(4-Aminophenylsulfonyl)acetamide; N-(4-aminophenyl)sulfonylacetamide; N-Acetyl-4-aminobenzenesulfonamide; N-[(4-Aminophenyl)sulfonyl]acetamide; N-[(p-Aminophenyl)sulfonyl]acetamide; N(sup 1)-Acetyl-4-aminophenylsulfonamide; N-((4-Aminophenyl)sulfonyl)acetamide; N-((p-Aminophenyl)sulfonyl)acetamide DMZ6VEY TC Antibiotics DMZ6VEY DT Small molecular drug DMZ6VEY PC 5320 DMZ6VEY MW 214.24 DMZ6VEY FM C8H10N2O3S DMZ6VEY IC InChI=1S/C8H10N2O3S/c1-6(11)10-14(12,13)8-4-2-7(9)3-5-8/h2-5H,9H2,1H3,(H,10,11) DMZ6VEY CS CC(=O)NS(=O)(=O)C1=CC=C(C=C1)N DMZ6VEY IK SKIVFJLNDNKQPD-UHFFFAOYSA-N DMZ6VEY IU N-(4-aminophenyl)sulfonylacetamide DMZ6VEY CA CAS 144-80-9 DMZ6VEY CB CHEBI:63845 DMZ6VEY DE Acne vulgaris DMKI2XC ID DMKI2XC DMKI2XC DN Sulfacytine DMKI2XC HS Approved DMKI2XC SN Renoquid; Sulfacitina; Sulfacitine; Sulfacitinum; CL 636; Renoquid (TN); Sulfacitina [INN-Spanish]; Sulfacitinum [INN-Latin]; Sulfacytine (USAN); Sulfacytine [USAN:BAN]; N-Sulfanilyl-l-ethylcytosine; Nl-sulfanilyl-1-ethylcytosine; N(sup 1)-(1-Ethyl-1,2-dihydro-2-oxo-4-pyrimidinyl)sulfanilamide; N(sup1)-(1-Ethyl-1,2-dihydro-2-oxo-4-pyrimidinyl)sulfanilamide; Sulfanilamide, N1-(1-ethyl-1,2-dihydro-2-oxo-4-pyrimidinyl)-(8CI); 1-Ethyl N4-sulfanilylcytosin; 1-Ethyl-N-sulfanilylcytosine; 4-amino-N-(1-ethyl-2-oxo-1,2-dihydropyrimidin-4-yl)benzenesulfonamide; 4-amino-N-(1-ethyl-2-oxopyrimidin-4-yl)benzenesulfonamide DMKI2XC TC Antiinfective Agents DMKI2XC DT Small molecular drug DMKI2XC PC 5322 DMKI2XC MW 294.33 DMKI2XC FM C12H14N4O3S DMKI2XC IC InChI=1S/C12H14N4O3S/c1-2-16-8-7-11(14-12(16)17)15-20(18,19)10-5-3-9(13)4-6-10/h3-8H,2,13H2,1H3,(H,14,15,17) DMKI2XC CS CCN1C=CC(=NC1=O)NS(=O)(=O)C2=CC=C(C=C2)N DMKI2XC IK SIBQAECNSSQUOD-UHFFFAOYSA-N DMKI2XC IU 4-amino-N-(1-ethyl-2-oxopyrimidin-4-yl)benzenesulfonamide DMKI2XC CA CAS 17784-12-2 DMKI2XC CB CHEBI:135230 DMKI2XC DE Cystitis; Urinary tract infection DMTW3R8 ID DMTW3R8 DMTW3R8 DN Sulfadiazine DMTW3R8 HS Approved DMTW3R8 SN Adiazin; Adiazine; CocoDiazine; Codiazine; Cremodiazine; Cremotres; Debenal; Deltazina; Diazin; Diazolone; Diazovit; Diazyl; Eskadiazine; Liquadiazine; Microsulfon; Neazine; Neotrizine; Palatrize; Piridisir; Pirimal; Pyrimal; Quadetts; Quadramoid; Sanodiazine; Solfadiazina; Spofadrizine; Sterazine; Sulfadiazene; Sulfadiazin; Sulfadiazina; Sulfadiazinum; Sulfanilamidopyrimidine; Sulfapirimidin; Sulfapyrimidin; Sulfapyrimidine; Sulfatryl; Sulfazine; Sulfolex; Sulfonsol; Sulfose; Sulphadiazine; Terfonyl; Theradiazine; Trifonamide; Trisem; Truozine; Honey diazine; Solfadiazina [DCIT]; Sulfapyrimidin [German]; Sulfonamides Duplex; Sulphadiazine E; Triple Sulfas; Zinc Sulfadiazine; A 306; RP 2616; A-306; Coco-Diazine; Lantrisul (TN); Lipo-Diazine; Lipo-Levazine; Metha-Meridiazine; Neotrizine (TN); Pecta-Diazine; RBPI21 & Sulfa; Sulfadiazina [INN-Spanish]; Sulfadiazine (TN); Sulfadiazine, Zinc; Sulfadiazinum [INN-Latin]; Sulfaloid (TN); Sulfonamides Duplex (TN); Sulfose (TN); Terfonyl (TN); Tri-Sulfameth; Triple Sulfa (TN); Triple Sulfas (TN); Triple Sulfoid (TN); Trisulfapyrimidine, oral suspension; A-306 (VAN); CRL-8131 & Sulfadiazine; Di-Azo-Mul; Mixture of sulfadiazine, sulfamerazine, and sulfamethazine; Pecta-diazine, suspension; S. N. 112; S.N. 112; Sulfadiazine [USAN:INN:JAN]; Thi-Di-Mer; N(1)-2-pyrimidinylsulfanilamide; N(1)-2-pyrimidylsulfanilamide; N(sup 1)-2-Pyrimidinylsulfanilamide; N(sup1)-2-Pyrimidinylsulfanilamide; N(sup1)-2-Pyrimidylsulfanilamide; N-(2-Pyrimidinyl)sulfanilamide; Recombinant bactericidal/permeability-increasing protein & Sulfadiazine; Sulfa-Triple #2 (TN); Sulfadiazine (JAN/USP/INN); N1-(Pyrimidin-2-yl)sulfanilamide; Sulfanilamide, N1-2-pyrimidinyl-(8CI); Adiazin, Adiazine, Debenal, Liquadiazine, Microsulfon, Sulfazine, Sulfolex, Sulfadiazine; 2-Sulfanilamido-pyrimidine; 2-Sulfanilamidopyrimidin; 2-Sulfanilamidopyrimidin [German]; 2-Sulfanilamidopyrimidine; 2-Sulfanilylaminopyrimidine; 2-Sulfapyrimidine; 4-AMINO-N-2-PYRIMIDINYLBENZENESULFONAMIDE; 4-Amino-N-(2-pyrimidinyl)benzenesulfonamide; 4-Amino-N-2-pyrimidinyl-benzenesulfonamide; SDZ DMTW3R8 CP Lilly DMTW3R8 TC Antiinfective Agents DMTW3R8 DT Small molecular drug DMTW3R8 PC 5215 DMTW3R8 MW 250.28 DMTW3R8 FM C10H10N4O2S DMTW3R8 IC InChI=1S/C10H10N4O2S/c11-8-2-4-9(5-3-8)17(15,16)14-10-12-6-1-7-13-10/h1-7H,11H2,(H,12,13,14) DMTW3R8 CS C1=CN=C(N=C1)NS(=O)(=O)C2=CC=C(C=C2)N DMTW3R8 IK SEEPANYCNGTZFQ-UHFFFAOYSA-N DMTW3R8 IU 4-amino-N-pyrimidin-2-ylbenzenesulfonamide DMTW3R8 CA CAS 68-35-9 DMTW3R8 CB CHEBI:9328 DMTW3R8 DE Rheumatic fever DMKM3SX ID DMKM3SX DMKM3SX DN Sulfamerazine DMKM3SX HS Approved DMKM3SX SN Cremomerazine; Kelamerazine; Mebacid; Mesulfa; Methylpyrimal; Methylsulfadiazine; Methylsulfazin; Methylsulfazine;Metilsulfadiazin; Metilsulfazin; Percoccide; Pyralcid; Romezin; Septacil; Septosyl; Solfamerazina; Solumedin; Sulfameradine; Sulfamerazin; Sulfamerazina; Sulfamerazinum; Sulfamethyldiazine; Sulphamerazine; Sumedine; Pyrimal M; Solfamerazina [DCIT]; RP 2632; A-310; Debenal-M; Pirimal-M; Sulfamerazina [INN-Spanish]; Sulfamerazine (INN); Sulfamerazinum [INN-Latin]; Veta-Merazine; Sulfamerazine [USAN:INN:BAN]; N-(4-Methyl-2-pyrimidyl)sulfanilamide; N1-(4-Methyl-2-pyrimidinyl)sulfanilamide; N1-(4-Methylpyrimidin-2-yl)sulfanilamide; N(1)-(4-Methyl-2-pyrimidinyl)sulfanilamide; N(sup 1)-(4-Methyl-2-pyrimidinyl)sulfanilamide; N(sup1)-(4-Methyl-2-pyrimidinyl)sulfanilamide; Sulfanilamide, N1-(4-methyl-2-pyrimidinyl)-(8CI); (p-Aminobenzolsulfonyl)-2-amino-4-methylpyrimidin; (p-Aminobenzolsulfonyl)-2-amino-4-methylpyrimidin [German]; 2(p-Aminobenzolsulfonamido)-4-methylpyrimidin; 2-(4-Aminobenzenesulfonamido)-4-methylpyrimidine; 2-(Sulfanilamido)-4-methylpyrimidine; 2-(p-Aminobenzolsulfonamido)-4-methylpyrimidine; 2-Sulfa-4-methylpyrimidine; 2-Sulfanilamido-4-methylpyrimidine; 2643-RP; 4-Amino-N-(4-methyl-2-pyrimidinyl)-benzenesulfonamide; 4-Amino-N-(4-methyl-2-pyrimidinyl)-benzenesulfonamide (9CI); 4-Amino-N-(4-methyl-2-pyrimidinyl)benzenesulfonamide; 4-Amino-N-(4-methyl-pyrimidin-2-yl)-benzenesulfonamide; 4-amino-N-(4-methylpyrimidin-2-yl)benzene-1-sulfonamide; 4-amino-N-(4-methylpyrimidin-2-yl)benzenesulfonamide DMKM3SX TC Antiinfective Agents DMKM3SX DT Small molecular drug DMKM3SX PC 5325 DMKM3SX MW 264.31 DMKM3SX FM C11H12N4O2S DMKM3SX IC InChI=1S/C11H12N4O2S/c1-8-6-7-13-11(14-8)15-18(16,17)10-4-2-9(12)3-5-10/h2-7H,12H2,1H3,(H,13,14,15) DMKM3SX CS CC1=NC(=NC=C1)NS(=O)(=O)C2=CC=C(C=C2)N DMKM3SX IK QPPBRPIAZZHUNT-UHFFFAOYSA-N DMKM3SX IU 4-amino-N-(4-methylpyrimidin-2-yl)benzenesulfonamide DMKM3SX CA CAS 127-79-7 DMKM3SX CB CHEBI:102130 DMKM3SX DE Bacterial infection DMRGZ16 ID DMRGZ16 DMRGZ16 DN Sulfamethazine DMRGZ16 HS Approved DMRGZ16 SN Azolmetazin; Cremomethazine; Diazil; Dimezathine; Intradine; Kelametazine; Mermeth; Neasina; Neazina; Pirmazin; Primazin; Solfadimidina; Spanbolet; Sulfadimerazine; Sulfadimesin; Sulfadimesine; Sulfadimethyldiazine; Sulfadimethylpyrimidine; Sulfadimezin; Sulfadimezine; Sulfadimezinum; Sulfadimidin; Sulfadimidina; Sulfadimidine; Sulfadimidinum; Sulfadine; Sulfametazina; Sulfametazyny; Sulfamethiazine; Sulfamezathine; Sulfodimesin; Sulfodimezine; Sulphadimethylpyrimidine; Sulphadimidine; Sulphamethasine; Sulphamethazine; Sulphamezathine; Sulphamidine; Sulphodimezine; Superseptil; Superseptyl; Vertolan; Calfspan Tablets; Sa III; Solfadimidina [DCIT]; SulfaSURE SR Bolus; Sulfadimidine solution; Sulfametazina[Italian]; Sulfametazyny [Polish]; Sulfamethazine solution; Sulka S Boluses; BN 2409; HC210279; A-502; Diazil (the sulfanilamide); Dimidin-R; Hava-Span; Sulfa-Isodimerazine; Sulfadimidina [INN-Spanish]; Sulfadimidine (INN); Sulfadimidine [INN:BAN]; Sulfadimidinum [INN-Latin]; Sulfamethazine (USP); Sulfamezathine (TN); N-(4,6-Dimethyl-2-pyrimidyl)sulfanilamide; N(1)-(4,6-Dimethyl-2-pyrimidinyl)sulfanilamide; N(1)-(4,6-Dimethyl-2-pyrimidyl)sulfanilamide; N(Sup1)-(4,6-Dimethyl-2-pyrimidinyl)sulfanilamide; N(Sup1)-(4,6-Dimethyl-2-pyrimidyl)sulfanilamide; N(sup 1)-(4,6-Dimethyl-2-pyrimidinyl)sulfanilamide; N(sup 1)-(4,6-Dimethyl-2-pyrimidyl)sulfanilamide; N(sup1)-(2,6-Dimethylpyrimid-4-yl)sulfanilamide; [(4-Aminophenyl)sulfonyl](4,6-dimethylpyrimidin-2-yl)amine; (p-Aminobenzolsulfonyl)-2-amino-4,6-dimethylpyrimidin; (p-Aminobenzolsulfonyl)-2-amino-4,6-dimethylpyrimidin [German]; 2-(4-Aminobenzenesulfonamido)-4,6-dimethylpyrimidine; 2-(p-Aminobenzenesulfonamido)-4,6-dimethylpyrimidine; 2-Sulfanilamido-4,6-dimethylpyrimidine; 4,6-Dimethyl-2-sulfanilamidopyrimidine; 4,6-Dimethylsulfadiazine; 4-Amino-N-(2,6-dimethyl-4-pyrimidinyl)benzenesulfonamide; 4-Amino-N-(4,6-dimethyl-2-pyrimidinyl)benzenesulfonamide; 4-Amino-N-(4,6-dimethyl-2-pyrimidyl)benzenesulfonamide; 4-Amino-N-(4,6-dimethyl-pyrimidin-2-yl)-benzenesulfonamide; 4-Amino-N-[4,6-dimethyl-2-pyrimidinyl]-benzenesulfonamide; 4-amino-N-(4,6-dimethylpyrimidin-2-yl)benzene-1-sulfonamide; 4-amino-N-(4,6-dimethylpyrimidin-2-yl)benzenesulfonamide; 6-(4'-Aminobenzol-sulfonamido)-2,4-dimethylpyrimidin; 6-(4'-Aminobenzol-sulfonamido)-2,4-dimethylpyrimidin [German] DMRGZ16 TC Antiinfective Agents DMRGZ16 DT Small molecular drug DMRGZ16 PC 5327 DMRGZ16 MW 278.33 DMRGZ16 FM C12H14N4O2S DMRGZ16 IC InChI=1S/C12H14N4O2S/c1-8-7-9(2)15-12(14-8)16-19(17,18)11-5-3-10(13)4-6-11/h3-7H,13H2,1-2H3,(H,14,15,16) DMRGZ16 CS CC1=CC(=NC(=N1)NS(=O)(=O)C2=CC=C(C=C2)N)C DMRGZ16 IK ASWVTGNCAZCNNR-UHFFFAOYSA-N DMRGZ16 IU 4-amino-N-(4,6-dimethylpyrimidin-2-yl)benzenesulfonamide DMRGZ16 CA CAS 57-68-1 DMRGZ16 CB CHEBI:102265 DMRGZ16 DE Bacterial infection DMGCHDS ID DMGCHDS DMGCHDS DN Sulfamethizole DMGCHDS HS Approved DMGCHDS SN Ayerlucil; Famet; Lucosil; Methazol; Microsul; Proklar; Renasul; Rufol; SULFAMETHIAZOLE; Salimol; Solfametizolo; Sulamethizole; Sulfamethazole; Sulfamethizol; Sulfamethizolum; Sulfamethylthiadiazole; Sulfametizol; Sulfapyelon; Sulfstat; Sulfurine; Sulphamethizole; Sulphamethyltiadiazole; Tetracid; Thidicur;Thiosulfil; Ultrasul; Urocydal; Urodiaton; Urolucosil; Urosulfin; Uroz; Solfametizolo [DCIT]; Sulfa gram; Thiosulfil Forte; RP 2145; VK 53; Sulfamethizolum [INN-Latin]; Sulfametizol [INN-Spanish]; Thiosulfil (TN); Sulfamethizole [USAN:INN:JAN]; Thiosulfil-A-Forte; Sulfamethizole (JP15/USP/INN); N1-(5-Methyl-1,3,4-thiadiazol-2-yl)sulfanilamide; N(1)-(5-Methyl-1,3,4-thiadiazol-2-yl)sulfanilamide; N(sup 1)-(5-Methyl-1,3,4-thiadiazol-2-yl)sulfanilamide; N(sup 1)-(5-Methyl-1,3,4-thiadiazol-2-yl)-sulfanilamide; 2-(p-Aminobenzenesulfonamido)-5-methylthiadiazole; 2-Methyl-5-sulfanilamido-1,3,4-thiadiazole; 2-Sulfanilamido-5-methyl-1,3,4-thiadiazole; 4-Amino-N-(5-Methyl-1,3,4-Thiadiazol-2-Yl)Benzene-1-Sulfonamide; 4-Amino-N-(5-methyl-1,3,4-thiadiazol-2-yl)benzenesulfonamide; 4-Amino-N-[5-methyl-1,3,4-thiadiazol-2-yl]benzenesulfonamide; 5-Methyl-2-sulfanilamido-1,3,4-thiadiazole DMGCHDS TC Antiinfective Agents DMGCHDS DT Small molecular drug DMGCHDS PC 5328 DMGCHDS MW 270.3 DMGCHDS FM C9H10N4O2S2 DMGCHDS IC InChI=1S/C9H10N4O2S2/c1-6-11-12-9(16-6)13-17(14,15)8-4-2-7(10)3-5-8/h2-5H,10H2,1H3,(H,12,13) DMGCHDS CS CC1=NN=C(S1)NS(=O)(=O)C2=CC=C(C=C2)N DMGCHDS IK VACCAVUAMIDAGB-UHFFFAOYSA-N DMGCHDS IU 4-amino-N-(5-methyl-1,3,4-thiadiazol-2-yl)benzenesulfonamide DMGCHDS CA CAS 144-82-1 DMGCHDS CB CHEBI:9331 DMGCHDS DE Urinary tract infection DMB08GE ID DMB08GE DMB08GE DN Sulfamethoxazole DMB08GE HS Approved DMB08GE SN sulfamethoxazole; 723-46-6; Gantanol; Sulphamethoxazole; Sulfisomezole; Sulfamethoxazol; Metoxal; Sulfamethylisoxazole; Simsinomin; Radonil; Sinomin; Sulphamethoxazol; 4-Amino-N-(5-methyl-3-isoxazolyl)benzenesulfonamide; Sulpha-methoxizole; Sulfamethalazole; Azo-gantanol; Sulphamethylisoxazole; Urobak; Sulfamethoxizole; 3-Sulfanilamido-5-methylisoxazole; Gantanol-DS; 4-amino-N-(5-methylisoxazol-3-yl)benzenesulfonamide; Bactrimel; Gamazole; Sulphisomezole; Sulfametoxazol; Solfametossazolo; Sulfamethoxazolum; Ro 4-2130; SMX; Septran; Sulphamethalazole; Trib; Solfametossazolo [DCIT]; Sulfamethoxazole sodium; MS 53; Sulphamethoxazole BP 98; ALBB-002089; Apo-Sulfamethoxazole; Bactrim (TN); Septra (TN); Septrin (TN); Sulfamethoxazolum [INN-Latin]; Sulfametoxazol [INN-Spanish]; Ro 6-2580/11; Ro-4-2130; Sulfamethoxazole [USAN:INN:JAN]; Sulfamethoxazole (JP15/USP/INN); N1-(5-Methyl-3-isoxazolyl)sulfanilamide; N1-(5-Methylisoxazol-3-yl)sulfanilamide; SULFAMETHOXAZOLE (8064-90-2 (TRIMETHOPRIM/SULFAMETHOXAZOLE); N'-(5-Methyl-3-isoxazole)sulfanilamide; N'-(5-Methyl-3-isoxazolyl)sulfanilamide; N'-(5-Methylisoxazol-3-yl)sulphanilamide; N(sup 1)-(5-Methyl-3-isoxazolyl)sulfanilamide; N(sup 1)-(5-Methyl-3-isoxazolyl)sulphanilamide; N(sup1)-(5-Methyl-3-isoxazolyl)sulfanilamide; Sulfanilamide, N1-(5-methyl-3-isoxazolyl)-(8CI); 3-(p-Aminophenylsulfonamido)-5-methylisoxazole; 3-(para-Aminophenylsulphonamido)-5-methylisoxazole; 3-Sulphanilamido-5-methylisoxazole; 4-Amino-N-(5-methyl-isoxazol-3-yl)-benzenesulfonamide; 4-Amino-N-[5-methyl-3-isoxazolyl]benzenesulfonamide; 4-amino-N-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide; 5-Methyl-3-sulfanilamidoisoxazole; 5-Methyl-3-sulfanylamidoisoxazole; 5-Methyl-3-sulphanil-amidoisoxazole; Sulphameth oxazole DMB08GE TC Antiinfective Agents DMB08GE DT Small molecular drug DMB08GE PC 5329 DMB08GE MW 253.28 DMB08GE FM C10H11N3O3S DMB08GE IC InChI=1S/C10H11N3O3S/c1-7-6-10(12-16-7)13-17(14,15)9-4-2-8(11)3-5-9/h2-6H,11H2,1H3,(H,12,13) DMB08GE CS CC1=CC(=NO1)NS(=O)(=O)C2=CC=C(C=C2)N DMB08GE IK JLKIGFTWXXRPMT-UHFFFAOYSA-N DMB08GE IU 4-amino-N-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide DMB08GE CA CAS 723-46-6 DMB08GE CB CHEBI:9332 DMB08GE DE Bacterial infection; Infection of P. falciparum DMIO1K0 ID DMIO1K0 DMIO1K0 DN Sulfamylon DMIO1K0 HS Approved DMIO1K0 SN Mafenide; mafenide; 138-39-6; 4-(Aminomethyl)benzenesulfonamide; 4-Aminomethylbenzenesulfonamide; Ambamide; Emilene; Maphenide; Maphenid; Malfamin; Homosul; Homonal; Benzamsulfonamide; Homosulfanilamide; Marprontil; Mesudrin; Septicid; Neofamid; Mesudin; Paramenyl; 4-Homosulfanilamide; Benzenesulfonamide, 4-(aminomethyl)-; Homosulfaminum; 4-(aminomethyl)benzene-1-sulfonamide; p-(Aminomethyl)benzenesulfonamide; 4-sulfamoylbenzylamine; Bensulfamide; Mafenidum [INN-Latin]; Mafenida [INN-Spanish]; 4-(aminosulfonyl)benzylamine; Mafenide acetate; MAFENIDE DMIO1K0 CP Mylan Inc DMIO1K0 DT Small molecular drug DMIO1K0 PC 3998 DMIO1K0 MW 186.23 DMIO1K0 FM C7H10N2O2S DMIO1K0 IC InChI=1S/C7H10N2O2S/c8-5-6-1-3-7(4-2-6)12(9,10)11/h1-4H,5,8H2,(H2,9,10,11) DMIO1K0 CS C1=CC(=CC=C1CN)S(=O)(=O)N DMIO1K0 IK TYMRLRRVMHJFTF-UHFFFAOYSA-N DMIO1K0 IU 4-(aminomethyl)benzenesulfonamide DMIO1K0 CA CAS 138-39-6 DMIO1K0 CB CHEBI:6633 DMIO1K0 DE Bacterial infection DMABVE9 ID DMABVE9 DMABVE9 DN Sulfanilamide DMABVE9 HS Approved DMABVE9 SN AAS; AVC; Albexan; Albosal; Ambeside; Antistrept; Astreptine; Astrocid; Bactesid; Collomide; Colsulanyde; Copticide; Deseptyl; Desseptyl; Dipron; Ergaseptine; Gerison; Gombardol; Infepan; Lusil; Lysococcine; Neococcyl; Orgaseptine; PABS; Prontalbin; Prontylin; Proseptal; Proseptine; Pysococcine; SAN; Sanamid; Septanilam; Septolix; Septoplex; Septoplix; Solfanilamide; Stramid; Strepamide; Streptagol; Streptamid; Streptocid; Streptocide; Streptocidum; Streptocom; Streptol; Strepton; Streptopan; Streptrocide; Sulfanilamida; Sulfanilamidum; Sulfocidin; Therapol; Tolder; Prontosil I; Prontosil White; Pronzin Album; Rubiazol A; Septamide Album; Solfanilamide [DCIT]; Stopton Album; Streptocid album; Streptocide White; Sulfanilamide Vaginal Cream; Sulphanilamide Extra Pure; Sulphanilamide Gr; White streptocide; F 1162; Fourneau 1162; Ro13354; A-349; AVC (TN); Aromatic/heteroaromatic sulfonamide 2; F-1162; P-Aminobenzenesulfonylamide; P-Aminobenzensulfonamide; Streptocid (TN); Streptocide (VAN); Sulfanilamida [INN-Spanish]; Sulfanilamide (INN); Sulfanilamide [INN:DCF]; Sulfanilamidum [INN-Latin]; Aniline-p-sulfonic amide; I.C. 56; BENZENESULFONIC ACID,4-AMINO,AMIDE SULFANILAMIDE; N4,N4-Bis(2-bromoethyl)sulfanilamide; N(sup 4),N(sup 4)-Bis(2-bromoethyl)sulfanilamide; N(sup4),N(sup4)-Bis(2-bromoethyl)sulfanilamide; Benzenesulfonamide, 4-(bis(2-bromoethyl)amino)-(9CI); Sulfanilamide, N4,N4-bis(2-bromoethyl)-(8CI); 1162 F; 4-(Bis(2-bromoethyl)amino)benzenesulfonamide; 4-Aminobenzene-1-Sulfonamide; 4-Aminophenylsulfonamide; 4-Sulfamoylaniline; 4-[bis(2-bromoethyl)amino]benzenesulfonamide DMABVE9 TC Antibiotics DMABVE9 DT Small molecular drug DMABVE9 PC 5333 DMABVE9 MW 172.21 DMABVE9 FM C6H8N2O2S DMABVE9 IC InChI=1S/C6H8N2O2S/c7-5-1-3-6(4-2-5)11(8,9)10/h1-4H,7H2,(H2,8,9,10) DMABVE9 CS C1=CC(=CC=C1N)S(=O)(=O)N DMABVE9 IK FDDDEECHVMSUSB-UHFFFAOYSA-N DMABVE9 IU 4-aminobenzenesulfonamide DMABVE9 CA CAS 63-74-1 DMABVE9 CB CHEBI:45373 DMABVE9 DE Bacterial infection DMFNAEM ID DMFNAEM DMFNAEM DN Sulfaphenazole DMFNAEM HS Approved DMFNAEM SN Sulfabid DMFNAEM CP Pharmaceutical Research Assoc Inc DMFNAEM TC Antiinfective Agents DMFNAEM DT Small molecular drug DMFNAEM PC 5335 DMFNAEM MW 314.4 DMFNAEM FM C15H14N4O2S DMFNAEM IC InChI=1S/C15H14N4O2S/c16-12-6-8-14(9-7-12)22(20,21)18-15-10-11-17-19(15)13-4-2-1-3-5-13/h1-11,18H,16H2 DMFNAEM CS C1=CC=C(C=C1)N2C(=CC=N2)NS(=O)(=O)C3=CC=C(C=C3)N DMFNAEM IK QWCJHSGMANYXCW-UHFFFAOYSA-N DMFNAEM IU 4-amino-N-(2-phenylpyrazol-3-yl)benzenesulfonamide DMFNAEM CA CAS 526-08-9 DMFNAEM CB CHEBI:77780 DMFNAEM DE Bacterial infection DMIUYFH ID DMIUYFH DMIUYFH DN Sulfapyridine DMIUYFH HS Approved DMIUYFH SN Adiplon; Coccoclase; Dagenan; Eubasin; Eubasinum; Haptocil; Piridazol; Plurazol; Pyriamid; Pyridazol; Relbapiridina; Ronin;Septipulmon; Solfapiridina; Streptosilpyridine; Sulfapiridina; Sulfapyridinum; Sulfidin; Sulfidine; Sulphapyridin; Sulphapyridine; Thioseptal; Trianon; Solfapiridina [DCIT]; M and B 693; A-499; ALBB-006215; M + B 693; M&B 693; M+B 693; Sulfapiridina [INN-Spanish]; Sulfapyridine (TN); Sulfapyridinum [INN-Latin]; AO-801/41077453; N(1)-Pyridylsulfanilamide; N(sup1)-Pyridylsulfanilamide; N-2-Pyridylsulfanilamide; N1-2-Pyridylsulfanilamide; Sulfapyridine (USP/INN); Sulfapyridine [USAN:INN:BAN]; N'-2-Pyridylsulfanilide; N(1)-2-Pyridylsulfanilamide; N(sup 1)-2-Pyridylsulfanilamide; N1-(Pyridin-2-yl)sulfanilamide; Sulfanilamide, N1-2-pyridyl-(8CI); 2-(4-Aminobenzenesulfonamido)pyridine; 2-(p-Aminobenzenesulphonamido)pyridine; 2-Sulfanilamidopyridin; 2-Sulfanilamidopyridin [German]; 2-Sulfanilamidopyridine; 2-Sulfanilyl aminopyridine; 2-Sulfanilylaminopyridine; 2-Sulfapyridine; 4-(2-Pyridinylsulfonyl)aniline; 4-AMINO-N-2-PYRIDINYLBENZENESULFONAMIDE; 4-Amino-N,2-pyridinylbenzenesulfonamide; 4-Amino-N-2-pyridinyl-benzenesulfonamide; 4-Amino-N-[2-pyridyl]benzene sulfonamide; 4-[(2-Pyridylamino)sulfonyl]aniline; 4-amino-N-(pyridin-2-yl)benzenesulfonamide; 4-amino-N-pyridin-2-yl-benzenesulfonamide; 4-amino-N-pyridin-2-ylbenzenesulfonamide DMIUYFH TC Dermatologic Agents DMIUYFH DT Small molecular drug DMIUYFH PC 5336 DMIUYFH MW 249.29 DMIUYFH FM C11H11N3O2S DMIUYFH IC InChI=1S/C11H11N3O2S/c12-9-4-6-10(7-5-9)17(15,16)14-11-3-1-2-8-13-11/h1-8H,12H2,(H,13,14) DMIUYFH CS C1=CC=NC(=C1)NS(=O)(=O)C2=CC=C(C=C2)N DMIUYFH IK GECHUMIMRBOMGK-UHFFFAOYSA-N DMIUYFH IU 4-amino-N-pyridin-2-ylbenzenesulfonamide DMIUYFH CA CAS 144-83-2 DMIUYFH CB CHEBI:132842 DMIUYFH DE Dermatitis herpetiformis DMICA9H ID DMICA9H DMICA9H DN Sulfasalazine DMICA9H HS Approved DMICA9H SN sulfasalazine; 599-79-1; Salicylazosulfapyridine; Salazosulfapyridine; Azulfidine; Asulfidine; Salazopyridin; Sulcolon; Azopyrin; Accucol; Colo-Pleon; Salazopiridazin; Salisulf; Reupirin; Benzosulfa; Azopyrine; Salazosulfapyridin; Sulfasalazina; w-t Sasp oral; Sulfasalazinum; Sulfasalazin; Azulfidine EN; Sulfazalazine; Azulfidine EN-tabs; Salazosulfapiridina; Sas-500; Salazosulfapyridinum; Azosulfidin; SASP; Salazo-sulfapyridinum; 5-(p-(2-Pyridylsulfamyl)phenylazo)salicylic acid; SAS-500; Sulfasalizine DMICA9H CP Watson Laboratories DMICA9H TC Antiinflammatory Agents DMICA9H DT Small molecular drug DMICA9H PC 5339 DMICA9H MW 398.4 DMICA9H FM C18H14N4O5S DMICA9H IC InChI=1S/C18H14N4O5S/c23-16-9-6-13(11-15(16)18(24)25)21-20-12-4-7-14(8-5-12)28(26,27)22-17-3-1-2-10-19-17/h1-11,23H,(H,19,22)(H,24,25) DMICA9H CS C1=CC=NC(=C1)NS(=O)(=O)C2=CC=C(C=C2)N=NC3=CC(=C(C=C3)O)C(=O)O DMICA9H IK NCEXYHBECQHGNR-UHFFFAOYSA-N DMICA9H IU 2-hydroxy-5-[[4-(pyridin-2-ylsulfamoyl)phenyl]diazenyl]benzoic acid DMICA9H CA CAS 599-79-1 DMICA9H CB CHEBI:9334 DMICA9H DE Rheumatoid arthritis; Irritable bowel syndrome DMEV954 ID DMEV954 DMEV954 DN Sulfinpyrazone DMEV954 HS Approved DMEV954 SN Anturan; Anturane; Anturanil; Anturano; Anturen; Anturidin; Diphenylpyrazone; Enturan; Enturen; Novopyrazone; Sulfinpirazona; Sulfinpyrazine; Sulfinpyrazon; Sulfinpyrazonum; Sulfoxyphenylpyrazolidin; Sulfoxyphenylpyrazolidine; Sulphinpyrazone; Apo Sulfinpyrazone; Apotex Brand of Sulfinpyrazone; Novartis Brand of Sulfinpyrazone; Nu Pharm Brand of Sulfinpyrazone; Nu Sulfinpyrazone; G 28315; Anturane (TN); Apo-Sulfinpyrazone; G 28,315; Nu-Pharm Brand of Sulfinpyrazone; Nu-Sulfinpyrazone; Sulfinpirazona [INN-Spanish]; Sulfinpyrazone (SPZ); Sulfinpyrazonum [INN-Latin]; USAF GE-13; Sulfinpyrazone [USAN:INN:JAN]; Sulfinpyrazone (JP15/USP/INN); (+/-)-SULFINPYRAZONE; 1,2-Diphenyl-3,5-dioxo-4-(2'-phenyl-sulfinyl-aethyl)-pyrazolidin; 1,2-Diphenyl-3,5-dioxo-4-(2'-phenyl-sulfinyl-aethyl)-pyrazolidin [German]; 1,2-Diphenyl-3,5-dioxo-4-(2-phenylsulfinylethyl) pyrazolidine; 1,2-Diphenyl-3,5-dioxo-4-(2-phenylsulfinylethyl)pyrazolidine; 1,2-Diphenyl-4-(2'-phenylsulfinethyl)-3,5-pyrazolidinedione; 1,2-Diphenyl-4-(2-(phenylsulfinyl)ethyl)-3,5-pyrazolidinedione; 1,2-Diphenyl-4-(phenylsulfinylethyl)-3,5-pyrazolidinedione; 1,2-Diphenyl-4-[2-(phenylsulfinyl)ethyl-3,5-pyrazolidinedione; 1,2-diphenyl-4-[2-(phenylsulfinyl)ethyl]pyrazolidine-3,5-dione; 4-(2-Benzenesulfinylethyl)-1,2-diphenylpyrazolidine-3,5-dione; 4-(Phenylsulfoxyethyl)-1,2-diphenyl-3,5-pyrazolidinedione; 4-[2-(benzenesulfinyl)ethyl]-1,2-diphenylpyrazolidine-3,5-dione DMEV954 TC Uricosuric Agents DMEV954 DT Small molecular drug DMEV954 PC 5342 DMEV954 MW 404.5 DMEV954 FM C23H20N2O3S DMEV954 IC InChI=1S/C23H20N2O3S/c26-22-21(16-17-29(28)20-14-8-3-9-15-20)23(27)25(19-12-6-2-7-13-19)24(22)18-10-4-1-5-11-18/h1-15,21H,16-17H2 DMEV954 CS C1=CC=C(C=C1)N2C(=O)C(C(=O)N2C3=CC=CC=C3)CCS(=O)C4=CC=CC=C4 DMEV954 IK MBGGBVCUIVRRBF-UHFFFAOYSA-N DMEV954 IU 4-[2-(benzenesulfinyl)ethyl]-1,2-diphenylpyrazolidine-3,5-dione DMEV954 CA CAS 57-96-5 DMEV954 CB CHEBI:9342 DMEV954 DE Gout DMXLT8C ID DMXLT8C DMXLT8C DN Sulfisoxazole DMXLT8C HS Approved DMXLT8C SN Accuzole; Alphazole; Amidoxal; Astrazolo; Azosulfizin; Bactesulf; Barazae; Chemouag; Cosoxazole; Dorsulfan; ERYZOLE; Entusil; Entusul; Ganda; Gantrisin; Gantrisine; Gantrisona; Gantrosan; Isoxamin; Neazolin; Neoxazoi; Neoxazol; Novazolo; Novosaxazole; Pancid; Renosulfan; Resoxol; Roxosul; Roxoxol; SOXO; Saxosozine; Sodizole; Solfafurazolo; Sosol; Soxamide; Soxazole; Soxisol; Soxitabs; Soxomide; Stansin; Sulbio; Sulfadimethylisoxazole; Sulfafurazol; Sulfafurazole; Sulfafurazolum; Sulfagan; Sulfagen; Sulfaisoxazole; Sulfalar; Sulfapolar; Sulfasol; Sulfasoxazole; Sulfasoxizole; Sulfazin; Sulfisin; Sulfisonazole; Sulfisoxasole; Sulfisoxazol; Sulfisoxazolum; Sulfizin; Sulfizol; Sulfizole; Sulfofurazole; Sulfoxol; Suloxsol; Sulphadimethylisoxazole; Sulphafuraz; Sulphafurazol; Sulphafurazole; Sulphafurazolum; Sulphaisoxazole; Sulphisoxazol; Sulphisoxazole; Sulphofurazole; Sulsoxin; Thiasin; Unisulf; Urisoxin; Uritrisin; Urogan; Vagilia; Azo Gantrisin; Component of Azo Gantrisin; Component of Azo Gantrisin Accuzole; Dorsulfan warthausen; Roxosul tablets; Solfafurazolo [DCIT]; Sulfafuraz ole; Sulfisoxazole [USAN]; Sulfisoxazole dialamine; NU 445; Component of Azo-Sulfizin; G-sox; Gantrisin (TN); J-Sul; Koro-sulf; Norilgan-S; SK-Soxazole; Sulfafurazole (INN); Sulfafurazolum [INN-Latin]; Sulfazin (VAN); Sulfisoxazole-Carc; Tl-azole; US-67; V-Sul; Sulfisoxazole (JP15/USP); U.S.-67; 3,4-Dimethyl-5-sulfanilamidoisoxazole; 3,4-Dimethyl-5-sulfonamidoisoxazole; 3,4-Dimethyl-5-sulphanilamidoisoxazole; 3,4-Dimethyl-5-sulphonamidoisoxazole; 3,4-Dimethylisoxale-5-sulfanilamide; 3,4-Dimethylisoxazole-5-sulfanilamide; 3,4-Dimethylisoxazole-5-sulphanilamide; 3,4-dimethylisoaxazole-5-sulfanilimide; 5-Sulfanilamido-3,4-dimethyl-isoxazole; 5-Sulfanilamido-3,4-dimethylisoxazole; 5-Sulphanilamido-3,4-dimethyl-isoxazole DMXLT8C CP Hoffmann La Roche Inc DMXLT8C TC Antiinfective Agents DMXLT8C DT Small molecular drug DMXLT8C PC 5344 DMXLT8C MW 267.31 DMXLT8C FM C11H13N3O3S DMXLT8C IC InChI=1S/C11H13N3O3S/c1-7-8(2)13-17-11(7)14-18(15,16)10-5-3-9(12)4-6-10/h3-6,14H,12H2,1-2H3 DMXLT8C CS CC1=C(ON=C1C)NS(=O)(=O)C2=CC=C(C=C2)N DMXLT8C IK NHUHCSRWZMLRLA-UHFFFAOYSA-N DMXLT8C IU 4-amino-N-(3,4-dimethyl-1,2-oxazol-5-yl)benzenesulfonamide DMXLT8C CA CAS 127-69-5 DMXLT8C CB CHEBI:102484 DMXLT8C DE Urinary tract infection DM1YA7M ID DM1YA7M DM1YA7M DN Sulfonamides DM1YA7M HS Approved DM1YA7M SN Sulfonamide Mixtures; Mixtures, Sulfonamide DM1YA7M DT Small molecular drug DM1YA7M PC 91392493 DM1YA7M MW 347.4 DM1YA7M FM C17H17NO5S DM1YA7M IC InChI=1S/C17H17NO5S/c1-2-23-17(20)12-18(16-11-7-6-8-14(16)13-19)24(21,22)15-9-4-3-5-10-15/h3-11,13H,2,12H2,1H3 DM1YA7M CS CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2 DM1YA7M IK DFRPGUIKXDWHSA-UHFFFAOYSA-N DM1YA7M IU ethyl 2-[N-(benzenesulfonyl)-2-formylanilino]acetate DM1YA7M DE Bacterial infection DMAYX6P ID DMAYX6P DMAYX6P DN Sulfoxone DMAYX6P HS Approved DMAYX6P SN Aldapsone; Aldesulfon; Diamidin; Diason; Diazon; Novotrone; Adesulfone sodium; Diasone sodium enterab; Sodium aldesulphone; Sodium sulfoxone; [4-[4-(sulfinomethylamino)phenyl]sulfonylanilino]methanesulfinic acid; [sulfonylbis(4,1-phenyleneimino)]dimethanesulfinic acid DMAYX6P CP Abbvie Inc DMAYX6P TC Antibiotics DMAYX6P DT Small molecular drug DMAYX6P PC 5351 DMAYX6P MW 404.5 DMAYX6P FM C14H16N2O6S3 DMAYX6P IC InChI=1S/C14H16N2O6S3/c17-23(18)9-15-11-1-5-13(6-2-11)25(21,22)14-7-3-12(4-8-14)16-10-24(19)20/h1-8,15-16H,9-10H2,(H,17,18)(H,19,20) DMAYX6P CS C1=CC(=CC=C1NCS(=O)O)S(=O)(=O)C2=CC=C(C=C2)NCS(=O)O DMAYX6P IK NEDPPCHNEOMTJV-UHFFFAOYSA-N DMAYX6P IU [4-[4-(sulfinomethylamino)phenyl]sulfonylanilino]methanesulfinic acid DMAYX6P CA CAS 144-76-3 DMAYX6P CB CHEBI:135651 DMAYX6P DE Dermatitis herpetiformis DM2QHZU ID DM2QHZU DM2QHZU DN Sulindac DM2QHZU HS Approved DM2QHZU SN Aclin; Aflodac; Arthrobid; Arthrocine; Chibret; Clinoril; Copal; Copals; Kenalin; Klinoril; Mobilin; Sulindaco; Sulindacum; Sulindal; Alphapharm Brand of Sulindac; Apo Sulin; Apotex Brand of Sulindac; Cahill May Roberts Brand of Sulindac; Chemia Brand of Sulindac; Copal resin; Copal rosin varnish; Gum copal; KendrickBrand of Sulindac; Merck Brand of Sulindac; Novo Sundac; Novopharm Brand of Sulindac; Nu Pharm Brand of Sulindac; Nu Sulindac; Resin copal; Sulindac sulfoxide; MK 231; MK231; S 8139; Apo-Sulin; Clinoril (TN); MK-231; Merck Sharp & Dohme Brand of Sulindac; Novo-Sundac; Nu-Pharm Brand of Sulindac; Nu-Sulindac; Sulindaco [INN-Spanish]; Sulindacum [INN-Latin]; Sulindac (JAN/USP/INN); Sulindac [USAN:BAN:INN:JAN]; Z-5-Fluoro-2-methyl-1-[p-(methlsulfinyl)benzylidene]indene-3-acetic acid; Cis-5-Fluoro-2-methyl-1-((p-methylsulfinyl)benzylidene)indene-3-acetic acid; {5-fluoro-2-methyl-1-[4-(methylsulfinyl)benzylidene]-1h-inden-3-yl}acetic acid; Cis-5-Fluoro-2-methyl-1-((4-(methylsulfinyl)phenyl)methylene)-1H-indene-3-acetic acid; [(1E)-5-fluoro-2-methyl-1-{[4-(methylsulfinyl)phenyl]methylidene}-1H-inden-3-yl]acetic acid; {(1E)-5-fluoro-2-methyl-1-[4-(methylsulfinyl)benzylidene]-1H-inden-3-yl}acetic acid; {(1Z)-5-fluoro-2-methyl-1-[4-(methylsulfinyl)benzylidene]-1H-inden-3-yl}acetic acid; (E)-(1)-5-Fluoro-2-methyl-1-((4-(methylsulphinyl)phenyl)methylene)-1H-indene-3-acetic acid; (Z)-5-Fluoro-2-methyl-1-((p-(methylsulfinyl)phenyl)methylene)-1H-indene-3-acetic acid; (Z)-5-Fluoro-2-methyl-1-[[4-(methyl-sulfinyl)phenyl]methylene]-1H-indene-3-acetic acid; (Z)-5-Fluoro-2-methyl-1-[p-(methylsulfinyl)benzylidene]indene-3-acetic acid; 2-[(3E)-6-fluoro-2-methyl-3-[(4-methylsulfinylphenyl)methylidene]inden-1-yl]acetic acid; 2-[(3Z)-6-fluoro-2-methyl-3-[(4-methylsulfinylphenyl)methylidene]inden-1-yl]acetic acid; 2-[6-fluoro-2-methyl-3-[(4-methylsulfinylphenyl)methylidene]inden-1-yl]acetic acid; 5-Fluoro-2-methyl-1-((4-(methylsulphinyl)phenyl)methylene)-1H-indene-3-acetic acid DM2QHZU CP Merck & Co DM2QHZU TC Antiinflammatory Agents DM2QHZU DT Small molecular drug DM2QHZU PC 1548887 DM2QHZU MW 356.4 DM2QHZU FM C20H17FO3S DM2QHZU IC InChI=1S/C20H17FO3S/c1-12-17(9-13-3-6-15(7-4-13)25(2)24)16-8-5-14(21)10-19(16)18(12)11-20(22)23/h3-10H,11H2,1-2H3,(H,22,23)/b17-9- DM2QHZU CS CC\\1=C(C2=C(/C1=C\\C3=CC=C(C=C3)S(=O)C)C=CC(=C2)F)CC(=O)O DM2QHZU IK MLKXDPUZXIRXEP-MFOYZWKCSA-N DM2QHZU IU 2-[(3Z)-6-fluoro-2-methyl-3-[(4-methylsulfinylphenyl)methylidene]inden-1-yl]acetic acid DM2QHZU CA CAS 38194-50-2 DM2QHZU CB CHEBI:9352 DM2QHZU DE Rheumatoid arthritis DMNUC42 ID DMNUC42 DMNUC42 DN Sulodexide DMNUC42 HS Approved DMNUC42 TC Antithrombotic Agents DMNUC42 PC 6453528 DMNUC42 MW 295.29 DMNUC42 FM C12H17N5O4 DMNUC42 IC InChI=1S/C12H17N5O4/c1-13-10-7-11(15-4-14-10)17(5-16-7)12-9(20-2)8(19)6(3-18)21-12/h4-6,8-9,12,18-19H,3H2,1-2H3,(H,13,14,15)/t6-,8-,9-,12-/m1/s1 DMNUC42 CS CNC1=C2C(=NC=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)OC DMNUC42 IK GRYSXUXXBDSYRT-WOUKDFQISA-N DMNUC42 IU (2R,3R,4R,5R)-2-(hydroxymethyl)-4-methoxy-5-[6-(methylamino)purin-9-yl]oxolan-3-ol DMNUC42 CA CAS 57817-83-1 DMNUC42 DE Tinnitus DMZI2UF ID DMZI2UF DMZI2UF DN Sulphadoxine DMZI2UF HS Approved DMZI2UF SN 2447-57-6; Sulforthomidine; Fanasil; Sulphormethoxine; 4-amino-N-(5,6-dimethoxypyrimidin-4-yl)benzenesulfonamide; Sulfadoxinum; Sulfadoxina; Sulfadoxin; Fanzil; Solfadossina; Ro 4-4393; Solfadossina [DCIT]; Sulfadoxinum [INN-Latin]; Sulfadoxina [INN-Spanish]; 4-Sulfanilamido-5,6-dimethoxypyrimidine; 4-Amino-N-(5,6-dimethoxy-4-pyrimidinyl)benzenesulfonamide; Benzenesulfonamide, 4-amino-N-(5,6-dimethoxy-4-pyrimidinyl)-; WR 4873; N'-(5,6-Dimethoxy-4-pyrimidyl)sulfanilamide; UNII-88463U4SM5; Orthosulfin; Sulformethoxine; Sulformetoxine; Sulphormetoxin; Sulphorthodimethoxine; WR 4073; Ro-4-4393; Sanasil: Sulfadoxine: Sulformetoxin; Sulfadoxine (JAN/USP/INN); Sulfadoxine [USAN:INN:BAN:JAN]; N1-(5,6-Dimethoxy-4-pyrimidinyl)sulfanilamide; N(sup 1)-(5,6-Dimethoxy-4-pyrimidinyl)sulfanilamide; 4-amino-N-[5,6-bis(methyloxy)pyrimidin-4-yl]benzenesulfonamide; 6-(4-Aminobenzenesulfonamido)-4,5-dimethoxypyrimidine; RS-1653 DMZI2UF DT Small molecular drug DMZI2UF PC 17134 DMZI2UF MW 310.33 DMZI2UF FM C12H14N4O4S DMZI2UF IC InChI=1S/C12H14N4O4S/c1-19-10-11(14-7-15-12(10)20-2)16-21(17,18)9-5-3-8(13)4-6-9/h3-7H,13H2,1-2H3,(H,14,15,16) DMZI2UF CS COC1=C(N=CN=C1OC)NS(=O)(=O)C2=CC=C(C=C2)N DMZI2UF IK PJSFRIWCGOHTNF-UHFFFAOYSA-N DMZI2UF IU 4-amino-N-(5,6-dimethoxypyrimidin-4-yl)benzenesulfonamide DMZI2UF CA CAS 2447-57-6 DMZI2UF CB CHEBI:9329 DMZI2UF DE Malaria DMF54ZG ID DMF54ZG DMF54ZG DN Sulpiride DMF54ZG HS Approved DMF54ZG SN Abilit; Aiglonyl; Alimoral; Arminol; Calmoflorine; Championyl; Coolspan; Darleton; Deponerton; Desisulpid; Desmenat; Digton; Dobren; Dogmatil; Dogmatyl; Dolmatil; Dresent; Eglonil; Eglonyl; Ekilid; Enimon; Equilid; Eusulpid; Fardalan; Fidelan; Guastil; Isnamide; Kylistro; Lebopride; Levobren; Levopraid; Levosulpirida; Levosulpiridum; Lisopiride; Mariastel; Meresa; Miradol; Mirbanil; Misulvan; Neogama; Norestran; Normum; Nufarol; Omiryl; Omperan; Ozoderpin; Pontiride; Psicocen; Pyrikappl; Pyrkappl; Restful; Sernevin; Splotin; Stamonevrol; Sulp; Sulperide; Sulpirid; Sulpirida; Sulpiridum; Sulpitil; Sulpivert; Sulpor; Sulpride; Sulpyrid; Suprium; Sursumid; Synedil; Tepavil; Valirem; Zemorcon; Allphar Brand of Sulpiride; Almirall Brand of Sulpiride; Areu Brand of Sulpiride; Centrum Brand of Sulpiride; Desitin Brand of Sulpiride; Dolorgiet Brand of Sulpiride; Erempharma Brand of Sulpiride; Fumouzer Brand of Sulpiride; Hennig Brand of Sulpiride; Hexal Brand of Sulpiride; Hoechst Brand of Sulpiride; Hormosan Brand of Sulpiride; Krewel Brand of Sulpiride; Levosulpiride [INN]; Magnetic resonance imaging sulpiride; Pharmacia Brand of Sulpiride; Psicofarma Brand of Sulpiride; Rosemont Brand of Sulpiride; Sanofi Synthelabo Brand of Sulpiride; Spyfarma Brand of Sulpiride; Uriach Brand of Sulpiride; Vertigo Meresa; Vertigo neogama; RD 1403; S 8010; Bosnyl (TN); Dogmatil (TN); Dogmatyl (TN); Eglonyl (TN); Levosulpirida [INN-Spanish]; Levosulpiridum [INN-Latin]; Meresa (TN); Neuraxpharm (TN); RV-12309; Ratiopharm (TN); Sanofi-Synthelabo Brand of Sulpiride; Sulpirid (TN); Sulpirida [INN-Spanish]; Sulpiridum [INN-Latin]; Sulpiryd (TN); Vertigo-Meresa; Vertigo-neogama; R. D. 1403; R.D. 1403; Sulpiride (JP15/USAN/INN); Sulpiride [USAN:INN:BAN:JAN]; N-((1-Ethyl-2-pyrrolidinyl)methyl)-5-sulfamoyl-o-anisamide; (+/-)-Sulpiride; (RS)-(+/-)-sulpiride; (inverted question mark)-Sulpiride DMF54ZG CP Arrow Generics DMF54ZG TC Antipsychotic Agents DMF54ZG DT Small molecular drug DMF54ZG PC 5355 DMF54ZG MW 341.4 DMF54ZG FM C15H23N3O4S DMF54ZG IC InChI=1S/C15H23N3O4S/c1-3-18-8-4-5-11(18)10-17-15(19)13-9-12(23(16,20)21)6-7-14(13)22-2/h6-7,9,11H,3-5,8,10H2,1-2H3,(H,17,19)(H2,16,20,21) DMF54ZG CS CCN1CCCC1CNC(=O)C2=C(C=CC(=C2)S(=O)(=O)N)OC DMF54ZG IK BGRJTUBHPOOWDU-UHFFFAOYSA-N DMF54ZG IU N-[(1-ethylpyrrolidin-2-yl)methyl]-2-methoxy-5-sulfamoylbenzamide DMF54ZG CA CAS 15676-16-1 DMF54ZG CB CHEBI:32168 DMF54ZG DE Schizophrenia DMVYXR8 ID DMVYXR8 DMVYXR8 DN Sumatriptan DMVYXR8 HS Approved DMVYXR8 SN Sumatran; Sumatriptanum; Sumax; GR 43175; GR 43175X; NP101; GR-43175; Imigran (TN); Imitrex (TN); KS-1116; Sumatriptanum [INN-Latin]; Sumatriptan (JAN/USP/INN); (3-[2-(Dimethylamino)ethyl]-1H-indol-5-yl)-N-methylmethanesulfonamide; 1-[3-(2-dimethylaminoethyl)-1H-indol-5-yl]-N-methyl-methanesulfonamide; 1-[3-(2-dimethylaminoethyl)-1H-indol-5-yl]-N-methylmethanesulfonamide; 1-{3-[2-(dimethylamino)ethyl]-1H-indol-5-yl}-N-methylmethanesulfonamide; 3-(2-(Dimethylamino)ethyl)-N-methyl-1H-indole-5-methanesulfonamide; 3-[2-(Dimethylamino)ethyl]-N-methyl-1H-indole-5-methanesulfonamide; 3-[2-(Dimethylamino)ethyl]-N-methylindole-5-methanesulfonamide DMVYXR8 CP GlaxoSmithKline DMVYXR8 TC Vasoconstrictor Agents DMVYXR8 DT Small molecular drug DMVYXR8 PC 5358 DMVYXR8 MW 295.4 DMVYXR8 FM C14H21N3O2S DMVYXR8 IC InChI=1S/C14H21N3O2S/c1-15-20(18,19)10-11-4-5-14-13(8-11)12(9-16-14)6-7-17(2)3/h4-5,8-9,15-16H,6-7,10H2,1-3H3 DMVYXR8 CS CNS(=O)(=O)CC1=CC2=C(C=C1)NC=C2CCN(C)C DMVYXR8 IK KQKPFRSPSRPDEB-UHFFFAOYSA-N DMVYXR8 IU 1-[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]-N-methylmethanesulfonamide DMVYXR8 CA CAS 103628-46-2 DMVYXR8 CB CHEBI:10650 DMVYXR8 DE Migraine DMCBJSR ID DMCBJSR DMCBJSR DN Sunitinib DMCBJSR HS Approved DMCBJSR SN Sunitanib; Sunitinibum; Sutent; PDGF TK antagonist; SU 11248; SU11248; KS-5022; SU-11248; SU-11248J; SU-12662; Su-011248; Sunitinib (INN); Sunitinib (free base); Sutent (TN); N-(2-diethylaminoethyl)-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; 5-(5-FLUORO-2-OXO-1,2-DIHYDRO-INDOL-3-YLIDENEMETHYL)-2,4-DIMETHYL-1H-PYRROLE-3-CARBOXYLIC ACID (2-DIETHYLAMINO-ETHYL)-AMIDE; Sunitinib (Pan-TK inhibitor) DMCBJSR CP Pfizer DMCBJSR TC Anticancer Agents DMCBJSR DT Small molecular drug DMCBJSR PC 5329102 DMCBJSR MW 398.5 DMCBJSR FM C22H27FN4O2 DMCBJSR IC InChI=1S/C22H27FN4O2/c1-5-27(6-2)10-9-24-22(29)20-13(3)19(25-14(20)4)12-17-16-11-15(23)7-8-18(16)26-21(17)28/h7-8,11-12,25H,5-6,9-10H2,1-4H3,(H,24,29)(H,26,28)/b17-12- DMCBJSR CS CCN(CC)CCNC(=O)C1=C(NC(=C1C)/C=C\\2/C3=C(C=CC(=C3)F)NC2=O)C DMCBJSR IK WINHZLLDWRZWRT-ATVHPVEESA-N DMCBJSR IU N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide DMCBJSR CA CAS 557795-19-4 DMCBJSR CB CHEBI:38940 DMCBJSR DE Gastrointestinal stromal tumour; Gastrointestinal cancer DMN8E5D ID DMN8E5D DMN8E5D DN Sunitinib malate DMN8E5D HS Approved DMN8E5D SN (Z)-N-(2-(diethylamino)ethyl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (S)-2-hydroxysuccinate; LVX8N1UT73; MFCD08282795; N-(2-(Diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (2S)-hydroxybutanedioate; PHA-290940AD; SU 011248; SU010398; SU011248; SU011248 L-malate salt; SUNITINIB MALEATE; Sunitinib malate; Sunitinib malate [USAN]; UNII-LVX8N1UT73 DMN8E5D TC Anticancer Agents DMN8E5D DT Small molecular drug DMN8E5D PC 6456015 DMN8E5D MW 532.569 DMN8E5D FM C26H33FN4O7 DMN8E5D IC InChI=1S/C22H27FN4O2.C4H6O5/c1-5-27(6-2)10-9-24-22(29)20-13(3)19(25-14(20)4)12-17-16-11-15(23)7-8-18(16)26-21(17)28;5-2(4(8)9)1-3(6)7/h7-8,11-12,25H,5-6,9-10H2,1-4H3,(H,24,29)(H,26,28);2,5H,1H2,(H,6,7)(H,8,9)/b17-12-;/t;2-/m.0/s1 DMN8E5D CS CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C.C(C(C(=O)O)O)C(=O)O DMN8E5D IK LBWFXVZLPYTWQI-IPOVEDGCSA-N DMN8E5D IU N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide;(2S)-2-hydroxybutanedioic acid DMN8E5D CA CAS 341031-54-7 DMN8E5D DE Gastrointestinal stromal tumor; Renal cell carcinoma DMOGREH ID DMOGREH DMOGREH DN Suplatast tosilate DMOGREH HS Approved DMOGREH SN IPD; IPD-1151T; YM-672 DMOGREH CP Taiho Pharmaceutical Co Ltd DMOGREH DT Small molecular drug DMOGREH PC 71773 DMOGREH MW 499.6 DMOGREH FM C23H33NO7S2 DMOGREH IC InChI=1S/C16H25NO4S.C7H8O3S/c1-4-20-11-14(18)12-21-15-7-5-13(6-8-15)17-16(19)9-10-22(2)3;1-6-2-4-7(5-3-6)11(8,9)10/h5-8,14,18H,4,9-12H2,1-3H3;2-5H,1H3,(H,8,9,10) DMOGREH CS CCOCC(COC1=CC=C(C=C1)NC(=O)CC[S+](C)C)O.CC1=CC=C(C=C1)S(=O)(=O)[O-] DMOGREH IK RYVJQEZJUFRANT-UHFFFAOYSA-N DMOGREH IU [3-[4-(3-ethoxy-2-hydroxypropoxy)anilino]-3-oxopropyl]-dimethylsulfanium;4-methylbenzenesulfonate DMOGREH CA CAS 94055-76-2 DMOGREH DE Allergy DMKXJZ7 ID DMKXJZ7 DMKXJZ7 DN Suprofen DMKXJZ7 HS Approved DMKXJZ7 SN Maldocil; Masterfen; Profenal; Srendam; Sulproltin; Suprocil; Suprofene; Suprofenum; Suprol; Sutoprofen; R 25061; R25061; TN 762; TN762; Profenal (TN); R-25061; Suprofene [INN-French]; Suprofenum [INN-Latin]; TN-762; TYN-762P; P-2-Thenoylhydratropic acid; R-25,061; Suprofen (JAN/USP/INN); Suprofen [USAN:BAN:INN:JAN]; Alpha-Methyl-4-(2-thienylcarbonyl)benzeneacetic acid; (+-)-2-(p-(2-Thenoyl)phenyl)propionic acid; (-)-alpha-Methyl-4-(2-thienylcarbonyl)benzeneacetic acid; (R)-(Thien-2-ylcarbonyl)propionic acid; (S)-2-(4-(Thien-2-ylcarbonyl)phenyl)butyric acid; 2-(4-(2-Thenoyl)phenyl)propionsaeure; 2-(4-(2-Thienylcarbonyl)phenyl)propanoic acid; 2-[4-(thiophen-2-ylcarbonyl)phenyl]propanoic acid; 2-[4-(thiophene-2-carbonyl)phenyl]propanoic acid; 4-(2-Thenoyl)hydratropsaeure DMKXJZ7 TC Antiinflammatory Agents DMKXJZ7 DT Small molecular drug DMKXJZ7 PC 5359 DMKXJZ7 MW 260.31 DMKXJZ7 FM C14H12O3S DMKXJZ7 IC InChI=1S/C14H12O3S/c1-9(14(16)17)10-4-6-11(7-5-10)13(15)12-3-2-8-18-12/h2-9H,1H3,(H,16,17) DMKXJZ7 CS CC(C1=CC=C(C=C1)C(=O)C2=CC=CS2)C(=O)O DMKXJZ7 IK MDKGKXOCJGEUJW-UHFFFAOYSA-N DMKXJZ7 IU 2-[4-(thiophene-2-carbonyl)phenyl]propanoic acid DMKXJZ7 CA CAS 40828-46-4 DMKXJZ7 CB CHEBI:9362 DMKXJZ7 DE Miosis DM0E6S3 ID DM0E6S3 DM0E6S3 DN Suvorexant DM0E6S3 HS Approved DM0E6S3 SN Suvorexant; 1030377-33-3; MK-4305; BELSOMRA; MK 4305; MK4305; UNII-081L192FO9; Suvorexant (MK-4305); [(7R)-4-(5-Chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone; (R)-(4-(5-Chlorobenzo[d]oxazol-2-yl)-7-methyl-1,4-diazepan-1-yl)(5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone; CHEMBL1083659; CHEBI:82698; 081L192FO9; C23H23ClN6O2; ((7R)-4-(5-Chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl)(5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone DM0E6S3 DT Small molecular drug DM0E6S3 PC 24965990 DM0E6S3 MW 450.9 DM0E6S3 FM C23H23ClN6O2 DM0E6S3 IC InChI=1S/C23H23ClN6O2/c1-15-3-5-20(30-25-8-9-26-30)18(13-15)22(31)29-12-11-28(10-7-16(29)2)23-27-19-14-17(24)4-6-21(19)32-23/h3-6,8-9,13-14,16H,7,10-12H2,1-2H3/t16-/m1/s1 DM0E6S3 CS C[C@@H]1CCN(CCN1C(=O)C2=C(C=CC(=C2)C)N3N=CC=N3)C4=NC5=C(O4)C=CC(=C5)Cl DM0E6S3 IK JYTNQNCOQXFQPK-MRXNPFEDSA-N DM0E6S3 IU [(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl]-[5-methyl-2-(triazol-2-yl)phenyl]methanone DM0E6S3 CA CAS 1030377-33-3 DM0E6S3 CB CHEBI:82698 DM0E6S3 DE Insomnia DM6S0HB ID DM6S0HB DM6S0HB DN TachoComb DM6S0HB HS Approved DM6S0HB SN Collagen fleece, Nycomed; Collagen fleece, Torii; TO-193; Fibrin/thrombin/aprotinin collagen fleece, Nycomed/Torii DM6S0HB CP Nycomed DM6S0HB DE Wound healing DM51FY6 ID DM51FY6 DM51FY6 DN Tacrine DM51FY6 HS Approved DM51FY6 SN Cognex; Romotal; Tacrina; Tacrinal; Tacrinum; Tenakrin; Tetrahydroaminacrine; Tetrahydroaminoacridine; Tetrahydroaminocrin; Tetrahydroaminocrine; Tha; Tacrine hydrochloride; BBL001044; CS 12602; Cognex (TN); Tacrina [INN-Spanish]; Tacrinal (TN); Tacrine (INN); Tacrine [INN:BAN]; Tacrinum [INN-Latin]; 1,2,3,4-TETRAHYDRO-9-ACRIDINAMINE; 1,2,3,4-TETRAHYDRO-9-ACRIDINAMINE (SEE ALSO 1684-40-8); 1,2,3,4-Tetrahydro-9-acridineamine; 1,2,3,4-Tetrahydro-acridin-9-ylamine; 1,2,3,4-Tetrahydroaminoacridine; 1,2,3,4-tetrahydroacridin-9-amine; 5-Amino-6,7,8,9-tetrahydroacridine (European); 9-AMINOTETRAHYDROACRIDINE; 9-Acridinamine, 1,2,3,4-tetrahydro-(9CI); 9-Amino-1,2,3,4-Tetrahydroacridine Hydrate Hydrochloride Hydrate; 9-amino-1,2,3,4-tetrahydroacridine DM51FY6 TC Parasympathomimetics DM51FY6 DT Small molecular drug DM51FY6 PC 1935 DM51FY6 MW 198.26 DM51FY6 FM C13H14N2 DM51FY6 IC InChI=1S/C13H14N2/c14-13-9-5-1-3-7-11(9)15-12-8-4-2-6-10(12)13/h1,3,5,7H,2,4,6,8H2,(H2,14,15) DM51FY6 CS C1CCC2=NC3=CC=CC=C3C(=C2C1)N DM51FY6 IK YLJREFDVOIBQDA-UHFFFAOYSA-N DM51FY6 IU 1,2,3,4-tetrahydroacridin-9-amine DM51FY6 CA CAS 321-64-2 DM51FY6 CB CHEBI:45980 DM51FY6 DE Alzheimer disease DMZ7XNQ ID DMZ7XNQ DMZ7XNQ DN Tacrolimus DMZ7XNQ HS Approved DMZ7XNQ SN Advagraf; Fujimycin; Graceptor; Modigraf; Prograf; Protopic; Protopy; Tacarolimus; Tsukubaenolide; Tacrolimus anhydrous; FK 506; FK5; FK506; FR 900506; FR900506; K506; L 679934; Advagraf (TN); FR-900506; Fk-506; L-679934; LCP-Tacro; Prograf (TN); Protopic (TN); Tacrolimus (INN); Tacrolimus (Prograf); Tacrolimus (anhydrous); (-)-FK 506; 15,19-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclotricosine-1,7,20,21(23H)-tetrone; 8-DEETHYL-8-[BUT-3-ENYL]-ASCOMYCIN DMZ7XNQ CP Fujisawa; Sucampo DMZ7XNQ TC Immunosuppressive Agents DMZ7XNQ DT Small molecular drug DMZ7XNQ PC 445643 DMZ7XNQ MW 804 DMZ7XNQ FM C44H69NO12 DMZ7XNQ IC InChI=1S/C44H69NO12/c1-10-13-31-19-25(2)18-26(3)20-37(54-8)40-38(55-9)22-28(5)44(52,57-40)41(49)42(50)45-17-12-11-14-32(45)43(51)56-39(29(6)34(47)24-35(31)48)27(4)21-30-15-16-33(46)36(23-30)53-7/h10,19,21,26,28-34,36-40,46-47,52H,1,11-18,20,22-24H2,2-9H3/b25-19+,27-21+/t26-,28+,29+,30-,31+,32-,33+,34-,36+,37-,38-,39+,40+,44+/m0/s1 DMZ7XNQ CS C[C@@H]1C[C@@H]([C@@H]2[C@H](C[C@H]([C@@](O2)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@@H]([C@@H]([C@H](CC(=O)[C@@H](/C=C(/C1)\\C)CC=C)O)C)/C(=C/[C@@H]4CC[C@H]([C@@H](C4)OC)O)/C)O)C)OC)OC DMZ7XNQ IK QJJXYPPXXYFBGM-LFZNUXCKSA-N DMZ7XNQ IU (1R,9S,12S,13R,14S,17R,18E,21S,23S,24R,25S,27R)-1,14-dihydroxy-12-[(E)-1-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]prop-1-en-2-yl]-23,25-dimethoxy-13,19,21,27-tetramethyl-17-prop-2-enyl-11,28-dioxa-4-azatricyclo[22.3.1.04,9]octacos-18-ene-2,3,10,16-tetrone DMZ7XNQ CA CAS 104987-11-3 DMZ7XNQ CB CHEBI:61049 DMZ7XNQ DE Organ transplant rejection; Ocular allergy DMJZHT1 ID DMJZHT1 DMJZHT1 DN Tadalafil DMJZHT1 HS Approved DMJZHT1 SN ADCIRCA; Acdirca; Cialis; Tadanafil; Lilly brand of tadalafil; Tadalafil [USAN]; GF 196960; IC 351; ICOS 351; Ic351; Cialis (TN); GF-196960; IC-351; KS-1117; Tadalafil (JAN/USAN/INN); Cialis, GF 196960, IC 351, ICOS 351, Tadalafil; (6R,12aR)-2,3,6,7,12,12a-Hexahydro-2-methyl-6-(3,4-(methylenedioxy)phenyl) pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione; (6R,12aR)-2,3,6,7,12,12a-Hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl)pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione; (6R-trans)-6-(1,3-Benzodioxol-5-yl)-2,3,6,7,12,12a-hexahydro-2-methyl-pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione DMJZHT1 CP Eli Lilly DMJZHT1 TC Antiimpotence Agents DMJZHT1 DT Small molecular drug DMJZHT1 PC 110635 DMJZHT1 MW 389.4 DMJZHT1 FM C22H19N3O4 DMJZHT1 IC InChI=1S/C22H19N3O4/c1-24-10-19(26)25-16(22(24)27)9-14-13-4-2-3-5-15(13)23-20(14)21(25)12-6-7-17-18(8-12)29-11-28-17/h2-8,16,21,23H,9-11H2,1H3/t16-,21-/m1/s1 DMJZHT1 CS CN1CC(=O)N2[C@@H](C1=O)CC3=C([C@H]2C4=CC5=C(C=C4)OCO5)NC6=CC=CC=C36 DMJZHT1 IK WOXKDUGGOYFFRN-IIBYNOLFSA-N DMJZHT1 IU (2R,8R)-2-(1,3-benzodioxol-5-yl)-6-methyl-3,6,17-triazatetracyclo[8.7.0.03,8.011,16]heptadeca-1(10),11,13,15-tetraene-4,7-dione DMJZHT1 CA CAS 171596-29-5 DMJZHT1 CB CHEBI:71940 DMJZHT1 DE Erectile dysfunction DM1XT4N ID DM1XT4N DM1XT4N DN Tafenoquine DM1XT4N HS Approved DM1XT4N SN 106635-80-7; WR-238605; WR 238605; Etaquine; WR238605; Tafenoquine [INN:BAN DM1XT4N CP Medicines for Malaria Venture/GlaxoSmithKline DM1XT4N DT Small molecular drug DM1XT4N PC 115358 DM1XT4N MW 463.5 DM1XT4N FM C24H28F3N3O3 DM1XT4N IC InChI=1S/C24H28F3N3O3/c1-14-11-20(32-4)30-22-18(29-15(2)7-6-10-28)13-19(31-3)23(21(14)22)33-17-9-5-8-16(12-17)24(25,26)27/h5,8-9,11-13,15,29H,6-7,10,28H2,1-4H3 DM1XT4N CS CC1=CC(=NC2=C1C(=C(C=C2NC(C)CCCN)OC)OC3=CC=CC(=C3)C(F)(F)F)OC DM1XT4N IK LBHLFPGPEGDCJG-UHFFFAOYSA-N DM1XT4N IU 4-N-[2,6-dimethoxy-4-methyl-5-[3-(trifluoromethyl)phenoxy]quinolin-8-yl]pentane-1,4-diamine DM1XT4N CA CAS 106635-80-7 DM1XT4N CB CHEBI:141487 DM1XT4N DE Plasmodium vivax malaria; Malaria DMFC41K ID DMFC41K DMFC41K DN Tafluprost DMFC41K HS Approved DMFC41K SN Zioptan (TN) DMFC41K CP Merck DMFC41K DT Small molecular drug DMFC41K PC 9868491 DMFC41K MW 452.5 DMFC41K FM C25H34F2O5 DMFC41K IC InChI=1S/C25H34F2O5/c1-18(2)32-24(30)13-9-4-3-8-12-20-21(23(29)16-22(20)28)14-15-25(26,27)17-31-19-10-6-5-7-11-19/h3,5-8,10-11,14-15,18,20-23,28-29H,4,9,12-13,16-17H2,1-2H3/b8-3-,15-14+/t20-,21-,22+,23-/m1/s1 DMFC41K CS CC(C)OC(=O)CCC/C=C\\C[C@H]1[C@H](C[C@H]([C@@H]1/C=C/C(COC2=CC=CC=C2)(F)F)O)O DMFC41K IK WSNODXPBBALQOF-VEJSHDCNSA-N DMFC41K IU propan-2-yl (Z)-7-[(1R,2R,3R,5S)-2-[(E)-3,3-difluoro-4-phenoxybut-1-enyl]-3,5-dihydroxycyclopentyl]hept-5-enoate DMFC41K CA CAS 209860-87-7 DMFC41K CB CHEBI:66899 DMFC41K DE Glaucoma/ocular hypertension DM9HQ5U ID DM9HQ5U DM9HQ5U DN Tagraxofusp DM9HQ5U HS Approved DM9HQ5U SN Tagraxofusp [INN]; Molecule 129; Tagraxofusp [USAN]; UNII-8ZHS5657EH; 8ZHS5657EH; Diphtheria toxin-il-3 fusion protein targeting IL-3 receptor DM9HQ5U CP Stemline Therapeutics DM9HQ5U DE Blastic plasmacytoid dendritic cell neoplasm; Acute myeloid leukaemia DM1KS78 ID DM1KS78 DM1KS78 DN Talazoparib DM1KS78 HS Approved DM1KS78 SN Talazoparib (BMN 673); UNII-9QHX048FRV; 9QHX048FRV; Talazoparib [USAN:INN]; Talzenna; 4pjt; 2YQ DM1KS78 CP Pfizer DM1KS78 DT Small molecular drug DM1KS78 PC 135565082 DM1KS78 MW 380.4 DM1KS78 FM C19H14F2N6O DM1KS78 IC InChI=1S/C19H14F2N6O/c1-27-18(22-8-23-27)15-16(9-2-4-10(20)5-3-9)24-13-7-11(21)6-12-14(13)17(15)25-26-19(12)28/h2-8,15-16,24H,1H3,(H,26,28)/t15-,16-/m1/s1 DM1KS78 CS CN1C(=NC=N1)[C@@H]2[C@H](NC3=CC(=CC4=C3C2=NNC4=O)F)C5=CC=C(C=C5)F DM1KS78 IK HWGQMRYQVZSGDQ-HZPDHXFCSA-N DM1KS78 IU (11S,12R)-7-fluoro-11-(4-fluorophenyl)-12-(2-methyl-1,2,4-triazol-3-yl)-2,3,10-triazatricyclo[7.3.1.05,13]trideca-1,5(13),6,8-tetraen-4-one DM1KS78 CA CAS 1207456-01-6 DM1KS78 DE Breast cancer; Psoriatic arthritis DM2M3OC ID DM2M3OC DM2M3OC DN Talazoparib DM2M3OC HS Approved DM2M3OC SN (8S,9R)-5-Fluoro-8-(4-fluorophenyl)-2,7,8,9-tetrahydro-9-(1-methyl-1H-1,2,4-triazol-5-yl)-3H-pyrido[4,3,2-de]phthalazine-3-one; (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one; (8s,9r)-5-Fluoro-8-(4-Fluorophenyl)-9-(1-Methyl-1h-1,2,4-Triazol-5-Yl)-2,7,8,9-Tetrahydro-3h-Pyrido[4,3,2-De]phthalazin-3-One; LT-673; Talazoparib; Talazoparib (BMN 673); Talazoparib [USAN:INN] DM2M3OC TC Poly (ADP-ribose) polymerase (PARP) inhibitor DM2M3OC DT Small molecular drug DM2M3OC PC 135565082 DM2M3OC MW 380.359 DM2M3OC FM C19H14F2N6O DM2M3OC IC InChI=1S/C19H14F2N6O/c1-27-18(22-8-23-27)15-16(9-2-4-10(20)5-3-9)24-13-7-11(21)6-12-14(13)17(15)25-26-19(12)28/h2-8,15-16,24H,1H3,(H,26,28)/t15-,16-/m1/s1 DM2M3OC CS CN1C(=NC=N1)C2C(NC3=C4C2=NNC(=O)C4=CC(=C3)F)C5=CC=C(C=C5)F DM2M3OC IK HWGQMRYQVZSGDQ-HZPDHXFCSA-N DM2M3OC IU (11S,12R)-7-fluoro-11-(4-fluorophenyl)-12-(2-methyl-1,2,4-triazol-3-yl)-2,3,10-triazatricyclo[7.3.1.05,13]trideca-1,5(13),6,8-tetraen-4-one DM2M3OC CA CAS 1207456-01-6 DM2M3OC DE Breast cancer DM214Q8 ID DM214Q8 DM214Q8 DN Talbutal DM214Q8 HS Approved DM214Q8 SN Lotusate; Profundol; Talbumalum; Talbutale; Talbutalum; Talbutal [INN]; Talbutale [DCIT]; WIN 5095; Lotusate (TN); Sec-Butyl allylbarbituric acid; Talbutal (INN); Talbutalum [INN-Latin]; 5-(1-Methylpropyl)-5-(2-propenyl)-2,4,6(1H,3H,5H)-pyrimidinetrione; 5-(1-methylpropyl)-5-prop-2-en-1-ylpyrimidine-2,4,6(1H,3H,5H)-trione; 5-Allyl-5-(1-methylpropyl) barbituric acid; 5-Allyl-5-sec-butylbarbituric acid; 5-Isobutyl-5-allylbarbituric acid; 5-butan-2-yl-5-prop-2-enyl-1,3-diazinane-2,4,6-trione DM214Q8 TC Hypnotics and Sedatives DM214Q8 DT Small molecular drug DM214Q8 PC 8275 DM214Q8 MW 224.26 DM214Q8 FM C11H16N2O3 DM214Q8 IC InChI=1S/C11H16N2O3/c1-4-6-11(7(3)5-2)8(14)12-10(16)13-9(11)15/h4,7H,1,5-6H2,2-3H3,(H2,12,13,14,15,16) DM214Q8 CS CCC(C)C1(C(=O)NC(=O)NC1=O)CC=C DM214Q8 IK BJVVMKUXKQHWJK-UHFFFAOYSA-N DM214Q8 IU 5-butan-2-yl-5-prop-2-enyl-1,3-diazinane-2,4,6-trione DM214Q8 CA CAS 115-44-6 DM214Q8 CB CHEBI:134923 DM214Q8 DE Irritability DM3PZXN ID DM3PZXN DM3PZXN DN Taliglucerase alfa DM3PZXN HS Approved DM3PZXN SN Elelyso (TN) DM3PZXN CP Pfizer DM3PZXN DE Metabolic disorder DMKBW5C ID DMKBW5C DMKBW5C DN Talimogene Laherparepvec DMKBW5C HS Approved DMKBW5C SN IMLYGIC DMKBW5C CP Amgen DMKBW5C TC Anticancer Agents DMKBW5C DT Vaccine DMKBW5C DE Melanoma DMLB0EZ ID DMLB0EZ DMLB0EZ DN Tamoxifen DMLB0EZ HS Approved DMLB0EZ SN tamoxifen; 10540-29-1; trans-Tamoxifen; Crisafeno; Soltamox; Tamoxifene; Diemon; Tamoxifenum; Tamoxifeno; Tamizam; Istubol; Tamoxen; Citofen; Oncomox; Valodex; Retaxim; Tamoxifene [INN-French]; Tamoxifenum [INN-Latin]; Tamoxifeno [INN-Spanish]; Tamoxifen (Z); Tamoxifen and its salts; Tamoxifen [INN:BAN]; ICI-46474; ICI 47699; TRANS FORM OF TAMOXIFEN; CCRIS 3275; UNII-094ZI81Y45; HSDB 6782; CHEMBL83; EINECS 234-118-0; 1-p-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene; Citofen; Nourytam; Novaldex; Tamone; Tamoxifeno;Tamoxifenum; Tomaxithen; Gen-Tamoxifen; Istubal (TN); Nolvadex (TN); Nolvadex-D; Novo-Tamoxifen; Pms-Tamoxifen; Tamoplex (TN); Tamoxifen (INN); Tamoxifen (TN); Trans-Tamoxifen; Valodex (TN); TAMOXIFEN (TAMOXIFEN CITRATE (54965-24-1)); Trans-2-[4-(1,2-Diphenyl-1-butenyl)phenoxy]-N,N-dimethylethylamine; (Z)-1-(p-Dimethylaminoethoxyphenyl)-1,2-diphenyl-1-butene; (Z)-2-(4-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylethanamine; (Z)-2-(4-(1,2-diphenylbut-1-enyl)phenoxy)-N,N-dimethylethanamine; (Z)-2-(para-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylamine (IUPAC); (Z)-2-[4-(1,2)-DIPHENYL-1-BUTENYL)-PHENOXY]-N,N-DIMETHYLETHANAMINE; (Z)-2-[p-(1,2-Diphenyl-1-butenyl)phenoxy]-N,N-dimethylethylamine; 1-p-beta-Dimethylamino-ethoxyphenyl-trans-1,2-diphenylbut-1-ene; 1-para-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene; 2-[4-[(Z)-1,2-diphenylbut-1-enyl]phenoxy]-N,N-dimethylethanamine; 2-{4-[(1Z)-1,2-diphenylbut-1-en-1-yl]phenoxy}-N,N-dimethylethanamine; Tamoxifen (Hormonal therapy); [3H]tamoxifen DMLB0EZ CP AstraZeneca plc DMLB0EZ TC Anticancer Agents DMLB0EZ DT Small molecular drug DMLB0EZ PC 2733526 DMLB0EZ MW 371.5 DMLB0EZ FM C26H29NO DMLB0EZ IC InChI=1S/C26H29NO/c1-4-25(21-11-7-5-8-12-21)26(22-13-9-6-10-14-22)23-15-17-24(18-16-23)28-20-19-27(2)3/h5-18H,4,19-20H2,1-3H3/b26-25- DMLB0EZ CS CC/C(=C(\\C1=CC=CC=C1)/C2=CC=C(C=C2)OCCN(C)C)/C3=CC=CC=C3 DMLB0EZ IK NKANXQFJJICGDU-QPLCGJKRSA-N DMLB0EZ IU 2-[4-[(Z)-1,2-diphenylbut-1-enyl]phenoxy]-N,N-dimethylethanamine DMLB0EZ CA CAS 10540-29-1 DMLB0EZ CB CHEBI:41774 DMLB0EZ DE Breast cancer DM5QF9V ID DM5QF9V DM5QF9V DN Tamsulosin DM5QF9V HS Approved DM5QF9V SN Flomax; Flowmax; Harnal; Tamsolusin; Tamsulon; Tamsulosina; Tamsulosine; Tamsulosinum; Flomax (TN); Flomaxtra (TN); Tamsulon (TN); Tamsulosin (INN); Tamsulosin [INN:BAN]; Tamsulosina [INN-Spanish]; Tamsulosine [INN-French]; Tamsulosinum [INN-Latin]; Urimax (TN); (R)-5-(2-((2-(2-Ethoxyphenoxy)ethyl)amino)propyl)-2-methoxybenzenesulfonamide; 5-(2-((2-(2-ethoxyphenoxy)ethyl)amino)propyl)-2-methoxybenzenesulfonamide; 5-[(2R)-2-[2-(2-ethoxyphenoxy)ethylamino]propyl]-2-methoxybenzenesulfonamide; 5-[(2R)-2-{[2-(2-ethoxyphenoxy)ethyl]amino}propyl]-2-methoxybenzenesulfonamide; 5-[2-[2-(2-ethoxyphenoxy)ethylamino]propyl]-2-methoxy-benzenesulfonamide; 5-{(2R)-2-[(2-{[2-(ethyloxy)phenyl]oxy}ethyl)amino]propyl}-2-(methyloxy)benzenesulfonamide DM5QF9V CP Yamanouchi Pharmaceuticals DM5QF9V TC Anticancer Agents DM5QF9V DT Small molecular drug DM5QF9V PC 129211 DM5QF9V MW 408.5 DM5QF9V FM C20H28N2O5S DM5QF9V IC InChI=1S/C20H28N2O5S/c1-4-26-17-7-5-6-8-18(17)27-12-11-22-15(2)13-16-9-10-19(25-3)20(14-16)28(21,23)24/h5-10,14-15,22H,4,11-13H2,1-3H3,(H2,21,23,24)/t15-/m1/s1 DM5QF9V CS CCOC1=CC=CC=C1OCCN[C@H](C)CC2=CC(=C(C=C2)OC)S(=O)(=O)N DM5QF9V IK DRHKJLXJIQTDTD-OAHLLOKOSA-N DM5QF9V IU 5-[(2R)-2-[2-(2-ethoxyphenoxy)ethylamino]propyl]-2-methoxybenzenesulfonamide DM5QF9V CA CAS 106133-20-4 DM5QF9V CB CHEBI:9398 DM5QF9V DE Benign prostatic hyperplasia DMPHWU6 ID DMPHWU6 DMPHWU6 DN Tandospirone DMPHWU6 HS Approved DMPHWU6 SN Sediel (TN) DMPHWU6 DT Small molecular drug DMPHWU6 PC 91273 DMPHWU6 MW 383.5 DMPHWU6 FM C21H29N5O2 DMPHWU6 IC InChI=1S/C21H29N5O2/c27-19-17-15-4-5-16(14-15)18(17)20(28)26(19)9-2-1-8-24-10-12-25(13-11-24)21-22-6-3-7-23-21/h3,6-7,15-18H,1-2,4-5,8-14H2/t15-,16+,17+,18- DMPHWU6 CS C1C[C@H]2C[C@@H]1[C@H]3[C@@H]2C(=O)N(C3=O)CCCCN4CCN(CC4)C5=NC=CC=N5 DMPHWU6 IK CEIJFEGBUDEYSX-FZDBZEDMSA-N DMPHWU6 IU (1S,2R,6S,7R)-4-[4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]-4-azatricyclo[5.2.1.02,6]decane-3,5-dione DMPHWU6 CA CAS 87760-53-0 DMPHWU6 CB CHEBI:145673 DMPHWU6 DE Anxiety disorder DMXLSH3 ID DMXLSH3 DMXLSH3 DN Tapentadol hydrochloride DMXLSH3 HS Approved DMXLSH3 SN Tapentadol; 175591-23-8; Nucynta; Palexia; UNII-H8A007M585; 3-((1R,2R)-3-(Dimethylamino)-1-ethyl-2-methylpropyl)phenol; 3-((2R,3R)-1-(dimethylamino)-2-methylpentan-3-yl)phenol; phenol, 3-[(1r,2r)-3-(dimethylamino)-1-ethyl-2-methylpropyl]-; BN-200; H8A007M585; CG-5503; (R,R)-Tapentadol; Tapentadol [USAN:INN]; 3-[(2R,3R)-1-(dimethylamino)-2-methylpentan-3-yl]phenol; Phenol, 3-((1R,2R)-3-(dimethylamino)-1-ethyl-2-methylpropyl)-; CG5503; BN 200; CG 5503; Tapentadol (USAN/INN); 3-(1-DIMETHYLAMINO-2-METHYL-PENTAN-3-YL)PHENOL DMXLSH3 CP Ortho-McNell Pharmaceutical DMXLSH3 DT Small molecular drug DMXLSH3 PC 9838021 DMXLSH3 MW 257.8 DMXLSH3 FM C14H24ClNO DMXLSH3 IC InChI=1S/C14H23NO.ClH/c1-5-14(11(2)10-15(3)4)12-7-6-8-13(16)9-12;/h6-9,11,14,16H,5,10H2,1-4H3;1H/t11-,14+;/m0./s1 DMXLSH3 CS CC[C@@H](C1=CC(=CC=C1)O)[C@@H](C)CN(C)C.Cl DMXLSH3 IK ZELFLGGRLLOERW-YECZQDJWSA-N DMXLSH3 IU 3-[(2R,3R)-1-(dimethylamino)-2-methylpentan-3-yl]phenol;hydrochloride DMXLSH3 CA CAS 175591-09-0 DMXLSH3 DE Acute pain DMLOQ1V ID DMLOQ1V DMLOQ1V DN Tasimelteon DMLOQ1V HS Approved DMLOQ1V SN Tasimelteon; 609799-22-6; Hetlioz; VEC-162; BMS-214778; VEC 162; UNII-SHS4PU80D9; BMS 214778; SHS4PU80D9; CHEBI:79042; N-{[(1R,2R)-2-(2,3-dihydro-1-benzofuran-4-yl)cyclopropyl]methyl}propanamide; Tasimelteon [USAN:INN]; tasimelteonum; N-([(1r,2r)-2-(2,3-dihydro-1-benzofuran-4-yl)cyclopropyl]methyl)propanamide; N-[[(1R,2R)-2-(2,3-dihydro-1-benzofuran-4-yl)cyclopropyl]methyl]propanamide; N-(((1R,2R)-2-(2,3-Dihydro-1-benzofuran-4-yl)cyclopropyl)methyl)propanamide; Hetlioz (TN); Tasimelteon (USAN/INN); SCHEMBL3505912; GTPL7393 DMLOQ1V CP Vanda Pharmaceuticals DMLOQ1V DT Small molecular drug DMLOQ1V PC 10220503 DMLOQ1V MW 245.32 DMLOQ1V FM C15H19NO2 DMLOQ1V IC InChI=1S/C15H19NO2/c1-2-15(17)16-9-10-8-13(10)11-4-3-5-14-12(11)6-7-18-14/h3-5,10,13H,2,6-9H2,1H3,(H,16,17)/t10-,13+/m0/s1 DMLOQ1V CS CCC(=O)NC[C@@H]1C[C@H]1C2=C3CCOC3=CC=C2 DMLOQ1V IK PTOIAAWZLUQTIO-GXFFZTMASA-N DMLOQ1V IU N-[[(1R,2R)-2-(2,3-dihydro-1-benzofuran-4-yl)cyclopropyl]methyl]propanamide DMLOQ1V CA CAS 609799-22-6 DMLOQ1V CB CHEBI:79042 DMLOQ1V DE Insomnia DMM13DI ID DMM13DI DMM13DI DN Tasosartan DMM13DI HS Approved DMM13DI SN Verdia; ANA-756; WAY-126756; Tasosartan (USAN/INN); WAY-ANA-756; 2,4-dimethyl-8-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-5,6-dihydropyrido[2,3-d]pyrimidin-7-one; 2,4-dimethyl-8-{[2'-(2h-tetrazol-5-yl)biphenyl-4-yl]methyl}-5,8-dihydropyrido[2,3-d]pyrimidin-7(6h)-one DMM13DI TC Antihypertensive Agents DMM13DI DT Small molecular drug DMM13DI PC 60919 DMM13DI MW 411.5 DMM13DI FM C23H21N7O DMM13DI IC InChI=1S/C23H21N7O/c1-14-18-11-12-21(31)30(23(18)25-15(2)24-14)13-16-7-9-17(10-8-16)19-5-3-4-6-20(19)22-26-28-29-27-22/h3-10H,11-13H2,1-2H3,(H,26,27,28,29) DMM13DI CS CC1=C2CCC(=O)N(C2=NC(=N1)C)CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5 DMM13DI IK ADXGNEYLLLSOAR-UHFFFAOYSA-N DMM13DI IU 2,4-dimethyl-8-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-5,6-dihydropyrido[2,3-d]pyrimidin-7-one DMM13DI CA CAS 145733-36-4 DMM13DI CB CHEBI:135666 DMM13DI DE Hypertension DM3ED1A ID DM3ED1A DM3ED1A DN Tavaborole DM3ED1A HS Approved DM3ED1A SN Kerydin; AN2690; AN-2690; AN-2690); SCH-900340; Topical antifungal (onychomycosis), Merck & Co; Trichophyton-targeting antifungal (onychomycosis), Merck & Co; Fungal leucyl-tRNA synthetase inhibitor (onychomycosis), Anacor Pharmaceuticals/Schering-Plough; Fungal leucyl-tRNA synthetase inhibitor (onychomycosis), Merck & Co/Anacor; Trichophyton-targeting antifungal (onychomycosis), Anacor Pharmaceuticals/Schering-Plough DM3ED1A CP Anacor; Anacor Pharmaceuticals Inc DM3ED1A DT Small molecular drug DM3ED1A PC 11499245 DM3ED1A MW 151.93 DM3ED1A FM C7H6BFO2 DM3ED1A IC InChI=1S/C7H6BFO2/c9-6-1-2-7-5(3-6)4-11-8(7)10/h1-3,10H,4H2 DM3ED1A CS B1(C2=C(CO1)C=C(C=C2)F)O DM3ED1A IK LFQDNHWZDQTITF-UHFFFAOYSA-N DM3ED1A IU 5-fluoro-1-hydroxy-3H-2,1-benzoxaborole DM3ED1A CA CAS 174671-46-6 DM3ED1A CB CHEBI:77942 DM3ED1A DE Onychomycosis DMUOT9V ID DMUOT9V DMUOT9V DN Taxol DMUOT9V HS Approved DMUOT9V SN C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))- DMUOT9V DT Small molecular drug DMUOT9V PC 36314 DMUOT9V MW 853.9 DMUOT9V FM C47H51NO14 DMUOT9V IC InChI=1S/C47H51NO14/c1-25-31(60-43(56)36(52)35(28-16-10-7-11-17-28)48-41(54)29-18-12-8-13-19-29)23-47(57)40(61-42(55)30-20-14-9-15-21-30)38-45(6,32(51)22-33-46(38,24-58-33)62-27(3)50)39(53)37(59-26(2)49)34(25)44(47,4)5/h7-21,31-33,35-38,40,51-52,57H,22-24H2,1-6H3,(H,48,54)/t31-,32-,33+,35-,36+,37+,38-,40-,45+,46-,47+/m0/s1 DMUOT9V CS CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C DMUOT9V IK RCINICONZNJXQF-MZXODVADSA-N DMUOT9V IU [(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,12-diacetyloxy-15-[(2R,3S)-3-benzamido-2-hydroxy-3-phenylpropanoyl]oxy-1,9-dihydroxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl] benzoate DMUOT9V CA CAS 33069-62-4 DMUOT9V CB CHEBI:45863 DMUOT9V DE Gastric adenocarcinoma; Ovarian cancer; Solid tumour/cancer; Breast cancer; Pancreatic cancer DM8SMD1 ID DM8SMD1 DM8SMD1 DN Tazarotene DM8SMD1 HS Approved DM8SMD1 SN Avage; Suretin; Tazaroteno; Tazarotenum; Tazorac; Tazoral; Zorac; AGN 190168; AGN-190168; Avage (TN); Tazarotene [USAN:INN]; Tazorac (TN); Zorac (TN); Tazarotene (JAN/USAN/INN); Tazorac, Avage, Zora, Tazarotene; Ethyl 6-((4,4-dimethylthiochroman-6-yl)ethynyl)nicotinate; Ethyl 6-(2-(4,4-dimethylthiochroman-6-yl)ethynyl)nicotinate; Ethyl 6-[(4,4-dimethyl-3,4-dihydro-2H-thiochromen-6-yl)ethynyl]nicotinate; Ethyl 6-[2-(4,4-dimethyl-2,3-dihydrothiochromen-6-yl)ethynyl]pyridine-3-carboxylate; 3-Pyridinecarboxylic acid, 6-((3,4-dihydro-4,4-dimethyl-2H-1-benzothiopyran-6-yl)ethynyl)-, ethyl ester; 3-Pyridinecarboxylic acid, 6-((3,4-dihydro-4,4-dimethyl-2H-1-benzothiopyran-6-yl)ethynyl)-,ethyl ester DM8SMD1 CP Allergan Pharmaceuticals DM8SMD1 TC Dermatologic Agents DM8SMD1 DT Small molecular drug DM8SMD1 PC 5381 DM8SMD1 MW 351.5 DM8SMD1 FM C21H21NO2S DM8SMD1 IC InChI=1S/C21H21NO2S/c1-4-24-20(23)16-7-9-17(22-14-16)8-5-15-6-10-19-18(13-15)21(2,3)11-12-25-19/h6-7,9-10,13-14H,4,11-12H2,1-3H3 DM8SMD1 CS CCOC(=O)C1=CN=C(C=C1)C#CC2=CC3=C(C=C2)SCCC3(C)C DM8SMD1 IK OGQICQVSFDPSEI-UHFFFAOYSA-N DM8SMD1 IU ethyl 6-[2-(4,4-dimethyl-2,3-dihydrothiochromen-6-yl)ethynyl]pyridine-3-carboxylate DM8SMD1 CA CAS 118292-40-3 DM8SMD1 CB CHEBI:32184 DM8SMD1 DE Psoriasis vulgaris DMWP1BH ID DMWP1BH DMWP1BH DN Tazemetostat DMWP1BH HS Approved DMWP1BH SN EPZ-6438; 1403254-99-8; EPZ6438; UNII-Q40W93WPE1; N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide; Q40W93WPE1; EPZ 6438; E7438; (1,1'-Biphenyl)-3-carboxamide, N-((1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(4-morpholinylmethyl)- DMWP1BH CP Epizyme DMWP1BH DT Small molecular drug DMWP1BH PC 66558664 DMWP1BH MW 572.7 DMWP1BH FM C34H44N4O4 DMWP1BH IC InChI=1S/C34H44N4O4/c1-5-38(29-10-14-41-15-11-29)32-20-28(27-8-6-26(7-9-27)22-37-12-16-42-17-13-37)19-30(25(32)4)33(39)35-21-31-23(2)18-24(3)36-34(31)40/h6-9,18-20,29H,5,10-17,21-22H2,1-4H3,(H,35,39)(H,36,40) DMWP1BH CS CCN(C1CCOCC1)C2=CC(=CC(=C2C)C(=O)NCC3=C(C=C(NC3=O)C)C)C4=CC=C(C=C4)CN5CCOCC5 DMWP1BH IK NSQSAUGJQHDYNO-UHFFFAOYSA-N DMWP1BH IU N-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-3-[ethyl(oxan-4-yl)amino]-2-methyl-5-[4-(morpholin-4-ylmethyl)phenyl]benzamide DMWP1BH CA CAS 1403254-99-8 DMWP1BH DE Malignant rhabdoid tumour; Brain and central nervous system tumour; Diffuse large B-cell lymphoma; Mesothelioma; Solid tumour/cancer; Synovial sarcoma; Follicular lymphoma DM3XNUI ID DM3XNUI DM3XNUI DN Tazobactam DM3XNUI HS Approved DM3XNUI SN TAZ; CL298741; YTR830H; CL-298741; Piprataz (TN); YTR-830H; Tazobactam (JAN/USAN/INN); (2S,3S,5R)-3-methyl-4,4,7-trioxo-3-(triazol-1-ylmethyl)-4; (2S,3S,5R)-3-methyl-7-oxo-3-(1H-1,2,3-triazol-1-ylmethyl)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid 4,4-dioxide DM3XNUI CP Gepach International DM3XNUI TC Antiinfective Agents DM3XNUI DT Small molecular drug DM3XNUI PC 123630 DM3XNUI MW 300.29 DM3XNUI FM C10H12N4O5S DM3XNUI IC InChI=1S/C10H12N4O5S/c1-10(5-13-3-2-11-12-13)8(9(16)17)14-6(15)4-7(14)20(10,18)19/h2-3,7-8H,4-5H2,1H3,(H,16,17)/t7-,8+,10+/m1/s1 DM3XNUI CS C[C@@]1([C@@H](N2[C@H](S1(=O)=O)CC2=O)C(=O)O)CN3C=CN=N3 DM3XNUI IK LPQZKKCYTLCDGQ-WEDXCCLWSA-N DM3XNUI IU (2S,3S,5R)-3-methyl-4,4,7-trioxo-3-(triazol-1-ylmethyl)-4lambda6-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid DM3XNUI CA CAS 89786-04-9 DM3XNUI CB CHEBI:9421 DM3XNUI DE Bacterial infection DML6OE7 ID DML6OE7 DML6OE7 DN Tbo-Filgrastim DML6OE7 HS Approved DML6OE7 SN Neutroval (TN) DML6OE7 CP Sicor Biotech DML6OE7 DE Neutropenia DMQ5S6C ID DMQ5S6C DMQ5S6C DN Tebipenem pivoxil DMQ5S6C HS Approved DMQ5S6C SN 161715-24-8; Orapenem; TBPM-PI; L-084; ME1211; UNII-95AK1A52I8; LJC 11,084; 95AK1A52I8; LJC-11084; ME-1211; 2,2-dimethylpropanoyloxymethyl (4R,5S,6S)-3-[1-(4,5-dihydro-1,3-thiazol-2-yl)azetidin-3-yl]sulfanyl-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate; Tebipenempivoxil; Tebipenem [INN]; (4R,5S,6S)-(Pivaloyloxy)methyl 3-((1-(4,5-dihydrothiazol-2-yl)azetidin-3-yl)thio)-6-((R)-1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate; 1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 3-[[1-(4,5-dihydro-2-thiazolyl)-3-azetidinyl]thio]-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-, (2,2-dimethyl-1-oxopropoxy)methyl ester, (4R,5S,6S)-; Tebipenem pivoxil (L-084); Tebipenem pivoxil(L-084); Orapenem (TN); (1R,5S,6S)-6-[1(R)-Hydroxyethyl]-1-methyl-2-[1-(2-thiazolin-2-yl)azetidin-3-ylsulfanyl]-1-carba-2-penem-3-carboxylic acid pivaloyloxymethyl ester; MLS006011128; SCHEMBL305541; Tebipenem pivoxil [USAN:INN]; CHEMBL2107486; GTPL10864; DTXSID00167228; CHEBI:135799; EX-A1256; HY-B0396; WHO 7924; ZINC4217736; Tebipenem pivoxil (JAN/USAN/INN); 2748AH; CT0255; LJC 11084; MFCD17215369; s2159; AKOS015899532; CCG-269673; LJC-11,084; NCGC00346570-01; NCGC00346570-04; (pivaloyloxy)methyl (4R,5S,6S)-3-((1-(4,5-dihydrothiazol-2-yl)azetidin-3-yl)thio)-6-((R)-1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate; [(4R,5S,6S)-3-{[1-(4,5-dihydro-1,3-thiazol-2-yl)azetidin-3-yl]sulfanyl}-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carbonyloxy]methyl 2,2-dimethylpropanoate; AC-22712; AS-75334; L-084;ME1211; SMR004702908; L 084; D09598; AB01566835_01; Q1623593; (4R,5R,6S)-3-((1-(4,5-Dihydro-2-thiazolyl)-3-azetidinyl)thio)-6-((1R)-1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid (2,2-dimethyl-1-oxopropoxy) methyl ester; 2,2-dimethylpropanoyloxymethyl (4R,5S,6S)-3-[1-(4,5-dihydrothiazol-2-yl)azetidin-3-yl]sulfanyl-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate DMQ5S6C CP Meiji Seika Pharma DMQ5S6C DT Small molecular drug DMQ5S6C PC 9892071 DMQ5S6C MW 497.6 DMQ5S6C FM C22H31N3O6S2 DMQ5S6C IC InChI=1S/C22H31N3O6S2/c1-11-15-14(12(2)26)18(27)25(15)16(19(28)30-10-31-20(29)22(3,4)5)17(11)33-13-8-24(9-13)21-23-6-7-32-21/h11-15,26H,6-10H2,1-5H3/t11-,12-,14-,15-/m1/s1 DMQ5S6C CS C[C@@H]1[C@@H]2[C@H](C(=O)N2C(=C1SC3CN(C3)C4=NCCS4)C(=O)OCOC(=O)C(C)(C)C)[C@@H](C)O DMQ5S6C IK SNUDIPVBUUXCDG-QHSBEEBCSA-N DMQ5S6C IU 2,2-dimethylpropanoyloxymethyl (4R,5S,6S)-3-[1-(4,5-dihydro-1,3-thiazol-2-yl)azetidin-3-yl]sulfanyl-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate DMQ5S6C CA CAS 161715-24-8 DMQ5S6C CB CHEBI:135799 DMQ5S6C DE Respiratory tract infection DMYQCWT ID DMYQCWT DMYQCWT DN Tecartus DMYQCWT HS Approved DMYQCWT SN Brexucabtagene autoleucel; KTE-X19 DMYQCWT CP Gilead Sciences; Kite Pharma DMYQCWT DT CAR T Cell Therapy DMYQCWT DE Mantle cell lymphoma DM2OVDT ID DM2OVDT DM2OVDT DN Tecfidera DM2OVDT HS Approved DM2OVDT SN DIMETHYL FUMARATE DM2OVDT CP Biogen Idec DM2OVDT DT Small molecular drug DM2OVDT PC 637568 DM2OVDT MW 144.12 DM2OVDT FM C6H8O4 DM2OVDT IC InChI=1S/C6H8O4/c1-9-5(7)3-4-6(8)10-2/h3-4H,1-2H3/b4-3+ DM2OVDT CS COC(=O)/C=C/C(=O)OC DM2OVDT IK LDCRTTXIJACKKU-ONEGZZNKSA-N DM2OVDT IU dimethyl (E)-but-2-enedioate DM2OVDT CA CAS 624-49-7 DM2OVDT CB CHEBI:76004 DM2OVDT DE Multiple sclerosis DMUEWM3 ID DMUEWM3 DMUEWM3 DN Technetium (99MTC) mebrofenin DMUEWM3 HS Approved DMUEWM3 SN F2NQ468L52; Glycine, N-(2-((3-bromo-2,4,6-trimethylphenyl)amino)-2-oxoethyl)-N-(carboxymethyl)-, technetium-99Tc salt; Mebrofenin / 99Tc; Mebrofenin / technetium-99Tc; Mebrofenin mixture with technetium-99Tc; TECHNETIUM TC-99M MEBROFENIN KIT; Technetium (99Mtc) Mebrofenin; Technetium TC-99M mebrofenin kit; Technetium Tc 99m DISIDA; Technetium Tc 99m diisopropyl-iminodiacetic acid; Technetium Tc 99m mebrofenin; Technetium Tc-99m mebrofenin; UNII-F2NQ468L52 DMUEWM3 TC Diagnostic Radiopharmaceutical Agents DMUEWM3 DT Small molecular drug DMUEWM3 PC 11431716 DMUEWM3 MW 486.136 DMUEWM3 FM C15H19BrN2O5Tc DMUEWM3 IC InChI=1S/C15H19BrN2O5.Tc/c1-8-4-9(2)15(10(3)14(8)16)17-11(19)5-18(6-12(20)21)7-13(22)23;/h4H,5-7H2,1-3H3,(H,17,19)(H,20,21)(H,22,23);/i;1+1 DMUEWM3 CS CC1=CC(=C(C(=C1NC(=O)CN(CC(=O)O)CC(=O)O)C)Br)C.[Tc] DMUEWM3 IK JLJSYHOPCNWUNE-IEOVAKBOSA-N DMUEWM3 IU 2-[[2-(3-bromo-2,4,6-trimethylanilino)-2-oxoethyl]-(carboxymethyl)amino]acetic acid;technetium-99 DMUEWM3 CA CAS 1415247-71-0 DMUEWM3 DE Imaging of liver and gallbladder DMW5ML9 ID DMW5ML9 DMW5ML9 DN Tecovirimat DMW5ML9 HS Approved DMW5ML9 SN Tecovirimat; ST 246; SIGA-246; UNII-F925RR824R; 816458-31-8; F925RR824R; ST-246; TPOXX; Tecovirimat [USAN:INN]; SIGA 246 DMW5ML9 CP SIGA Technologies DMW5ML9 PC 16124688 DMW5ML9 MW 376.3 DMW5ML9 FM C19H15F3N2O3 DMW5ML9 IC InChI=1S/C19H15F3N2O3/c20-19(21,22)9-3-1-8(2-4-9)16(25)23-24-17(26)14-10-5-6-11(13-7-12(10)13)15(14)18(24)27/h1-6,10-15H,7H2,(H,23,25)/t10-,11+,12+,13-,14-,15+ DMW5ML9 CS C1[C@@H]2[C@H]1[C@@H]3C=C[C@H]2[C@@H]4[C@H]3C(=O)N(C4=O)NC(=O)C5=CC=C(C=C5)C(F)(F)F DMW5ML9 IK CSKDFZIMJXRJGH-VWLPUNTISA-N DMW5ML9 IU N-[(1S,2S,6R,7R,8R,10S)-3,5-dioxo-4-azatetracyclo[5.3.2.02,6.08,10]dodec-11-en-4-yl]-4-(trifluoromethyl)benzamide DMW5ML9 CA CAS 869572-92-9 DMW5ML9 DE Virus infection; Smallpox DMG2SKR ID DMG2SKR DMG2SKR DN Tedizolid DMG2SKR HS Approved DMG2SKR SN Tedizolid; Torezolid; 856866-72-3; TR-700; Da 7157; UNII-97HLQ82NGL; DA-7157; TR 700; 97HLQ82NGL; CHEBI:82717; (5R)-3-[3-fluoro-4-[6-(2-methyltetrazol-5-yl)-3-pyridyl]phenyl]-5-(hydroxymethyl)oxazolidin-2-one; Tedizolid [USAN:INN]; Tedizolid (USAN/INN); SCHEMBL440398; CHEMBL1257051; DTXSID10234975; XFALPSLJIHVRKE-GFCCVEGCSA-N; MolPort-042-624-220; AI025; BCP02830; ZINC43100956; AKOS025401974; CS-0687; NCGC00379072-02; AN-27109; AK322133; AC-27738; BC600578; HY-14855 DMG2SKR CP Bayer HealthCare Pharmaceuticals DMG2SKR DT Small molecular drug DMG2SKR PC 11234049 DMG2SKR MW 370.3 DMG2SKR FM C17H15FN6O3 DMG2SKR IC InChI=1S/C17H15FN6O3/c1-23-21-16(20-22-23)15-5-2-10(7-19-15)13-4-3-11(6-14(13)18)24-8-12(9-25)27-17(24)26/h2-7,12,25H,8-9H2,1H3/t12-/m1/s1 DMG2SKR CS CN1N=C(N=N1)C2=NC=C(C=C2)C3=C(C=C(C=C3)N4C[C@@H](OC4=O)CO)F DMG2SKR IK XFALPSLJIHVRKE-GFCCVEGCSA-N DMG2SKR IU (5R)-3-[3-fluoro-4-[6-(2-methyltetrazol-5-yl)pyridin-3-yl]phenyl]-5-(hydroxymethyl)-1,3-oxazolidin-2-one DMG2SKR CA CAS 856866-72-3 DMG2SKR CB CHEBI:82717 DMG2SKR DE Skin infection DMYOAKS ID DMYOAKS DMYOAKS DN Teduglutide DMYOAKS HS Approved DMYOAKS SN Gattex (TN) DMYOAKS CP NPS DMYOAKS DT Small molecular drug DMYOAKS SQ Protein sequence for teduglutide: HGDGSFSDEMNTILDNLAARDFINWLIQTKITD DMYOAKS PC 16139605 DMYOAKS MW 3752.1 DMYOAKS FM C164H252N44O55S DMYOAKS IC InChI=1S/C164H252N44O55S/c1-21-77(11)126(156(255)187-95(44-46-114(167)214)141(240)206-130(83(17)211)160(259)186-93(42-33-34-49-165)140(239)202-129(80(14)24-4)159(258)208-131(84(18)212)161(260)200-111(163(262)263)66-125(230)231)203-151(250)100(54-76(9)10)189-145(244)103(57-88-67-175-92-41-32-31-40-90(88)92)192-147(246)105(60-116(169)216)199-157(256)127(78(12)22-2)204-152(251)102(56-87-38-29-26-30-39-87)190-149(248)109(64-123(226)227)195-137(236)94(43-35-50-174-164(171)172)183-134(233)82(16)179-133(232)81(15)180-142(241)98(52-74(5)6)188-146(245)104(59-115(168)215)194-150(249)110(65-124(228)229)196-143(242)99(53-75(7)8)198-158(257)128(79(13)23-3)205-162(261)132(85(19)213)207-153(252)106(61-117(170)217)193-139(238)97(48-51-264-20)185-138(237)96(45-47-120(220)221)184-148(247)108(63-122(224)225)197-155(254)113(72-210)201-144(243)101(55-86-36-27-25-28-37-86)191-154(253)112(71-209)182-119(219)70-177-136(235)107(62-121(222)223)181-118(218)69-176-135(234)91(166)58-89-68-173-73-178-89/h25-32,36-41,67-68,73-85,91,93-113,126-132,175,209-213H,21-24,33-35,42-66,69-72,165-166H2,1-20H3,(H2,167,214)(H2,168,215)(H2,169,216)(H2,170,217)(H,173,178)(H,176,234)(H,177,235)(H,179,232)(H,180,241)(H,181,218)(H,182,219)(H,183,233)(H,184,247)(H,185,237)(H,186,259)(H,187,255)(H,188,245)(H,189,244)(H,190,248)(H,191,253)(H,192,246)(H,193,238)(H,194,249)(H,195,236)(H,196,242)(H,197,254)(H,198,257)(H,199,256)(H,200,260)(H,201,243)(H,202,239)(H,203,250)(H,204,251)(H,205,261)(H,206,240)(H,207,252)(H,208,258)(H,220,221)(H,222,223)(H,224,225)(H,226,227)(H,228,229)(H,230,231)(H,262,263)(H4,171,172,174)/t77-,78-,79-,80-,81-,82-,83+,84+,85+,91-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,126-,127-,128-,129-,130-,131-,132-/m0/s1 DMYOAKS CS CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC4=CC=CC=C4)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(=O)O)NC(=O)CNC(=O)[C@H](CC5=CN=CN5)N DMYOAKS IK CILIXQOJUNDIDU-ASQIGDHWSA-N DMYOAKS IU (2S)-2-[[(2S,3R)-2-[[(2S,3S)-2-[[(2S)-6-amino-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S,3R)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]acetyl]amino]-3-carboxypropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-4-carboxybutanoyl]amino]-4-methylsulfanylbutanoyl]amino]-4-oxobutanoyl]amino]-3-hydroxybutanoyl]amino]-3-methylpentanoyl]amino]-4-methylpentanoyl]amino]-3-carboxypropanoyl]amino]-4-oxobutanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-carboxypropanoyl]amino]-3-phenylpropanoyl]amino]-3-methylpentanoyl]amino]-4-oxobutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-methylpentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]hexanoyl]amino]-3-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]butanedioic acid DMYOAKS CA CAS 197922-42-2 DMYOAKS DE Short bowel syndrome DM31ZQM ID DM31ZQM DM31ZQM DN Tegafur DM31ZQM HS Approved DM31ZQM SN Tegafur (Fluoropyrimidine) DM31ZQM DT Small molecular drug DM31ZQM PC 5386 DM31ZQM MW 200.17 DM31ZQM FM C8H9FN2O3 DM31ZQM IC InChI=1S/C8H9FN2O3/c9-5-4-11(6-2-1-3-14-6)8(13)10-7(5)12/h4,6H,1-3H2,(H,10,12,13) DM31ZQM CS C1CC(OC1)N2C=C(C(=O)NC2=O)F DM31ZQM IK WFWLQNSHRPWKFK-UHFFFAOYSA-N DM31ZQM IU 5-fluoro-1-(oxolan-2-yl)pyrimidine-2,4-dione DM31ZQM CA CAS 17902-23-7 DM31ZQM CB CHEBI:32188 DM31ZQM DE Solid tumour/cancer DM3XYD1 ID DM3XYD1 DM3XYD1 DN Tegaserod DM3XYD1 HS Approved DM3XYD1 SN Tegaserod (USAN/INN); 1-[[(Z)-(5-methoxyindol-3-ylidene)methyl]amino]-2-pentylguanidine DM3XYD1 CP Novartis DM3XYD1 DT Small molecular drug DM3XYD1 PC 135409453 DM3XYD1 MW 301.39 DM3XYD1 FM C16H23N5O DM3XYD1 IC InChI=1S/C16H23N5O/c1-3-4-5-8-18-16(17)21-20-11-12-10-19-15-7-6-13(22-2)9-14(12)15/h6-7,9-11,19H,3-5,8H2,1-2H3,(H3,17,18,21)/b20-11+ DM3XYD1 CS CCCCCN=C(N)N/N=C/C1=CNC2=C1C=C(C=C2)OC DM3XYD1 IK IKBKZGMPCYNSLU-RGVLZGJSSA-N DM3XYD1 IU 1-[(E)-(5-methoxy-1H-indol-3-yl)methylideneamino]-2-pentylguanidine DM3XYD1 CA CAS 145158-71-0 DM3XYD1 CB CHEBI:51043 DM3XYD1 DE Irritable bowel syndrome; Gastro-oesophageal reflux; Dyspepsia DMAQ2LK ID DMAQ2LK DMAQ2LK DN Teicoplanin DMAQ2LK HS Approved DMAQ2LK SN Targocid (TN) DMAQ2LK CP Sanofi-Aventis DMAQ2LK DT Small molecular drug DMAQ2LK PC 133065662 DMAQ2LK MW 1879.7 DMAQ2LK FM C88H97Cl2N9O33 DMAQ2LK IC InChI=1S/C88H97Cl2N9O33/c1-3-4-5-6-7-8-9-10-60(108)94-68-74(113)71(110)58(32-101)129-87(68)132-78-55-26-40-27-56(78)126-52-18-14-38(24-47(52)90)77(131-86-67(92-34(2)103)73(112)70(109)57(31-100)128-86)69-84(121)98-66(85(122)123)45-29-42(105)30-54(127-88-76(115)75(114)72(111)59(33-102)130-88)61(45)44-23-37(13-15-49(44)106)63(81(118)99-69)96-83(120)65(40)97-82(119)64-39-21-41(104)28-43(22-39)124-53-25-36(12-16-50(53)107)62(91)80(117)93-48(79(116)95-64)20-35-11-17-51(125-55)46(89)19-35/h11-19,21-30,48,57-59,62-77,86-88,100-102,104-107,109-115H,3-10,20,31-33,91H2,1-2H3,(H,92,103)(H,93,117)(H,94,108)(H,95,116)(H,96,120)(H,97,119)(H,98,121)(H,99,118)(H,122,123)/t48-,57-,58-,59-,62-,63-,64+,65-,66+,67-,68-,69+,70-,71-,72-,73-,74-,75+,76+,77-,86+,87+,88?/m1/s1 DMAQ2LK CS CCCCCCCCCC(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@H]1OC2=C3C=C4C=C2OC5=C(C=C(C=C5)[C@H]([C@H]6C(=O)N[C@@H](C7=C(C(=CC(=C7)O)OC8[C@H]([C@H]([C@@H]([C@H](O8)CO)O)O)O)C9=C(C=CC(=C9)[C@H](C(=O)N6)NC(=O)[C@@H]4NC(=O)[C@@H]1C2=CC(=CC(=C2)OC2=C(C=CC(=C2)[C@H](C(=O)N[C@H](CC2=CC(=C(O3)C=C2)Cl)C(=O)N1)N)O)O)O)C(=O)O)O[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)NC(=O)C)Cl)CO)O)O DMAQ2LK IK BJNLLBUOHPVGFT-CAYRISATSA-N DMAQ2LK IU (1S,2R,19R,22R,34S,37R,40R,52S)-2-[(2R,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-22-amino-5,15-dichloro-64-[(2S,3R,4R,5S,6R)-3-(decanoylamino)-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-26,31,44,49-tetrahydroxy-21,35,38,54,56,59-hexaoxo-47-[(3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-7,13,28-trioxa-20,36,39,53,55,58-hexazaundecacyclo[38.14.2.23,6.214,17.219,34.18,12.123,27.129,33.141,45.010,37.046,51]hexahexaconta-3,5,8,10,12(64),14,16,23(61),24,26,29(60),30,32,41(57),42,44,46(51),47,49,62,65-henicosaene-52-carboxylic acid DMAQ2LK CA CAS 61036-62-2 DMAQ2LK DE Bacterial infection DMMRV29 ID DMMRV29 DMMRV29 DN Telaprevir DMMRV29 HS Approved DMMRV29 SN 402957-28-2; VX-950; Incivek; Telaprevir (VX-950); Incivo; MP-424; VX 950; Telavic; VX-950(Telaprevir); LY-570310; UNII-655M5O3W0U; VRT-111950; CHEMBL231813; CHEBI:68595; 655M5O3W0U; S-Telaprevir; (1S,3aR,6aS)-2-((S)-2-((S)-2-cyclohexyl-2-(pyrazine-6-carboxamido)acetamido)-3,3-dimethylbutanoyl)-N-((S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl)-octahydrocyclopenta[c]pyrrole-1-carboxamide DMMRV29 DT Small molecular drug DMMRV29 PC 3010818 DMMRV29 MW 679.8 DMMRV29 FM C36H53N7O6 DMMRV29 IC InChI=1S/C36H53N7O6/c1-5-10-25(29(44)34(48)39-23-15-16-23)40-33(47)28-24-14-9-13-22(24)20-43(28)35(49)30(36(2,3)4)42-32(46)27(21-11-7-6-8-12-21)41-31(45)26-19-37-17-18-38-26/h17-19,21-25,27-28,30H,5-16,20H2,1-4H3,(H,39,48)(H,40,47)(H,41,45)(H,42,46)/t22-,24-,25-,27-,28-,30+/m0/s1 DMMRV29 CS CCC[C@@H](C(=O)C(=O)NC1CC1)NC(=O)[C@@H]2[C@H]3CCC[C@H]3CN2C(=O)[C@H](C(C)(C)C)NC(=O)[C@H](C4CCCCC4)NC(=O)C5=NC=CN=C5 DMMRV29 IK BBAWEDCPNXPBQM-GDEBMMAJSA-N DMMRV29 IU (3S,3aS,6aR)-2-[(2S)-2-[[(2S)-2-cyclohexyl-2-(pyrazine-2-carbonylamino)acetyl]amino]-3,3-dimethylbutanoyl]-N-[(3S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-3-carboxamide DMMRV29 CA CAS 402957-28-2 DMMRV29 CB CHEBI:68595 DMMRV29 DE Hepatitis C virus infection DM58VQX ID DM58VQX DM58VQX DN Telavancin DM58VQX HS Approved DM58VQX SN telavancinum; telavancina; telavancine; 372151-71-8; UNII-XK134822Z0; CHEBI:71229; XK134822Z0; Telavancin [INN]; HSDB 8194; AC1MIWRX; SCHEMBL8287015; CHEMBL507870; DB06402; LS-192933; T-1455; Telavancin, Antibiotic for Culture Media Use Only; Vancomycin, N3''-(2-(decylamino)ethyl)-29-(((phosphonomethyl)amino)methyl)- DM58VQX DT Small molecular drug DM58VQX PC 3081362 DM58VQX MW 1755.6 DM58VQX FM C80H106Cl2N11O27P DM58VQX IC InChI=1S/C80H106Cl2N11O27P/c1-7-8-9-10-11-12-13-14-21-85-22-23-87-80(5)32-57(115-37(4)71(80)103)119-70-68(102)67(101)55(34-94)118-79(70)120-69-53-28-41-29-54(69)117-52-20-17-40(27-46(52)82)65(99)63-77(109)91-61(78(110)111)43-30-50(96)44(33-86-35-121(112,113)114)66(100)58(43)42-25-38(15-18-49(42)95)59(74(106)93-63)90-75(107)60(41)89-73(105)48(31-56(83)97)88-76(108)62(92-72(104)47(84-6)24-36(2)3)64(98)39-16-19-51(116-53)45(81)26-39/h15-20,25-30,36-37,47-48,55,57,59-65,67-68,70-71,79,84-87,94-96,98-103H,7-14,21-24,31-35H2,1-6H3,(H2,83,97)(H,88,108)(H,89,105)(H,90,107)(H,91,109)(H,92,104)(H,93,106)(H,110,111)(H2,112,113,114)/t37-,47+,48-,55+,57-,59+,60+,61-,62+,63-,64+,65+,67+,68-,70+,71+,79-,80-/m0/s1 DM58VQX CS CCCCCCCCCCNCCN[C@]1(C[C@@H](O[C@H]([C@H]1O)C)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2OC3=C4C=C5C=C3OC6=C(C=C(C=C6)[C@H]([C@H](C(=O)N[C@H](C(=O)N[C@H]5C(=O)N[C@@H]7C8=CC(=C(C=C8)O)C9=C(C(=C(C=C9[C@H](NC(=O)[C@H]([C@@H](C1=CC(=C(O4)C=C1)Cl)O)NC7=O)C(=O)O)O)CNCP(=O)(O)O)O)CC(=O)N)NC(=O)[C@@H](CC(C)C)NC)O)Cl)CO)O)O)C DM58VQX IK ONUMZHGUFYIKPM-MXNFEBESSA-N DM58VQX IU (1S,2R,18R,19R,22S,25R,28R,40S)-22-(2-amino-2-oxoethyl)-5,15-dichloro-48-[(2S,3R,4S,5S,6R)-3-[(2S,4S,5S,6S)-4-[2-(decylamino)ethylamino]-5-hydroxy-4,6-dimethyloxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2,18,32,35,37-pentahydroxy-19-[[(2R)-4-methyl-2-(methylamino)pentanoyl]amino]-20,23,26,42,44-pentaoxo-36-[(phosphonomethylamino)methyl]-7,13-dioxa-21,24,27,41,43-pentazaoctacyclo[26.14.2.23,6.214,17.18,12.129,33.010,25.034,39]pentaconta-3,5,8(48),9,11,14,16,29(45),30,32,34,36,38,46,49-pentadecaene-40-carboxylic acid DM58VQX CA CAS 372151-71-8 DM58VQX CB CHEBI:71229 DM58VQX DE Staphylococcus infection DMSWUGE ID DMSWUGE DMSWUGE DN Telbivudine DMSWUGE HS Approved DMSWUGE SN Epavudine; LLT; LdT; Sebivo; Telbivudin; Tyzeka; Telbivudine [USAN]; LDT600; NB 02B; NV 02B; L-Deoxythymidine; L-Thymidine; L-dT; LDT-600; NV-02B; Tyzeka (TN); Beta-L-Thymidine; Telbivudine (USAN/INN); Tyzake/Sebivo (TN); Tyzeka, Sebivo, Telbivudine; 1-(2-Deoxy-beta-L-erythro-pentofuranosyl)-5-methylpyrimidine-2,4(1H,3H)-dione; 1-(2-Deoxy-beta-L-erythropentafuranosyl)-5-methyl-2,4(1H,3H)-pyrimidinedione; 1-[(2S,4R,5S)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione; 2'-Deoxy-L-thymidine DMSWUGE CP Idenix DMSWUGE TC Antiviral Agents DMSWUGE DT Small molecular drug DMSWUGE PC 159269 DMSWUGE MW 242.23 DMSWUGE FM C10H14N2O5 DMSWUGE IC InChI=1S/C10H14N2O5/c1-5-3-12(10(16)11-9(5)15)8-2-6(14)7(4-13)17-8/h3,6-8,13-14H,2,4H2,1H3,(H,11,15,16)/t6-,7+,8+/m1/s1 DMSWUGE CS CC1=CN(C(=O)NC1=O)[C@@H]2C[C@H]([C@@H](O2)CO)O DMSWUGE IK IQFYYKKMVGJFEH-CSMHCCOUSA-N DMSWUGE IU 1-[(2S,4R,5S)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione DMSWUGE CA CAS 3424-98-4 DMSWUGE CB CHEBI:63624 DMSWUGE DE Hepatitis B virus infection DMZ4P3A ID DMZ4P3A DMZ4P3A DN Telithromycin DMZ4P3A HS Approved DMZ4P3A SN Ketek; Levviax; TEL; HMR 3647; HMR3647; RU 66647; RU66647; HMR-3647; Ketek (TN); RU-66647; Telithromycin [USAN:BAN:INN]; Telithromycin (JAN/USAN/INN); (1R,2R,4R,6R,7R,8R,10R,13R,14S)-7-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-13-ethyl-6-methoxy-2,4,6,8,10,14-hexamethyl-17-[4-(4-pyridin-3-ylimidazol-1-yl)butyl]-12,15-dioxa-17-azabicyclo[12.3.0]heptadecane-3,9,11,16-tetrone; (1R,2R,4R,6R,7R,8R,10S,13R,14S)-7-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-13-ethyl-6-methoxy-2,4,6,8,10,14-hexamethyl-17-[4-(4-pyridin-3-ylimidazol-1-yl)butyl]-12,15-dioxa-17-azabicyclo[12.3.0]heptadecane-3,9,11,16-tetrone; (1R,2R,4R,6S,7R,8R,10R,13R,14S)-7-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-13-ethyl-6-methoxy-2,4,6,8,10,14-hexamethyl-17-[4-(4-pyridin-3-ylimidazol-1-yl)butyl]-12,15-dioxa-17-azabicyclo[12.3.0]heptadecane-3,9,11,16-tetrone; (1R,2S,4R,6R,7R,8R,10R,13R,14S)-7-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-13-ethyl-6-methoxy-2,4,6,8,10,14-hexamethyl-17-[4-(4-pyridin-3-ylimidazol-1-yl)butyl]-12,15-dioxa-17-azabicyclo[12.3.0]heptadecane-3,9,11,16-tetrone; 11,12-Dideoxy-3-des(2,6-dideoxy-3-C,3-O-dimethyl-alpha-L-altropyranosyloxy)-6-O-methyl-3-oxo-12,11-(oxycarbonylimino)-N11-[4-[4-(3-pyridyl)imidazol-1-yl]butyl]erythromycin A DMZ4P3A CP Sanofi-Aventis DMZ4P3A TC Antibiotics DMZ4P3A DT Small molecular drug DMZ4P3A PC 3002190 DMZ4P3A MW 812 DMZ4P3A FM C43H65N5O10 DMZ4P3A IC InChI=1S/C43H65N5O10/c1-12-33-43(8)37(48(41(53)58-43)19-14-13-18-47-23-31(45-24-47)30-16-15-17-44-22-30)27(4)34(49)25(2)21-42(7,54-11)38(28(5)35(50)29(6)39(52)56-33)57-40-36(51)32(46(9)10)20-26(3)55-40/h15-17,22-29,32-33,36-38,40,51H,12-14,18-21H2,1-11H3/t25-,26-,27+,28+,29-,32+,33-,36-,37-,38-,40+,42-,43-/m1/s1 DMZ4P3A CS CC[C@@H]1[C@@]2([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H](C(=O)[C@H](C(=O)O1)C)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)N(C(=O)O2)CCCCN4C=C(N=C4)C5=CN=CC=C5)C DMZ4P3A IK LJVAJPDWBABPEJ-PNUFFHFMSA-N DMZ4P3A IU (1S,2R,5R,7R,8R,9R,11R,13R,14R)-8-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-2-ethyl-9-methoxy-1,5,7,9,11,13-hexamethyl-15-[4-(4-pyridin-3-ylimidazol-1-yl)butyl]-3,17-dioxa-15-azabicyclo[12.3.0]heptadecane-4,6,12,16-tetrone DMZ4P3A CA CAS 191114-48-4 DMZ4P3A CB CHEBI:29688 DMZ4P3A DE Bacterial infection DMS3GX2 ID DMS3GX2 DMS3GX2 DN Telmisartan DMS3GX2 HS Approved DMS3GX2 SN Kinzal; Kinzalmono; Micardis; Pritor; Abbott brand of telmisartan; Boehringer Ingelheim brand of telmisartan; Glaxo Wellcome brand of telmisartan; GlaxoSmithKline brand of telmisartan; BIBR 277; BIBR 277SE; BIBR-277; BIBR-277SE; Bay 68-9291; Micardis (TN); Telmisartan [USAN:INN]; YM-086; BIBR-277-SE; Telmisartan (JAN/USAN/INN); Micardis, Targit, Temax, BIBR277, Telmisartan; 2-[4-[[4-methyl-6-(1-methylbenzimidazol-2-yl)-2-propylbenzimidazol-1-yl]methyl]phenyl]benzoic acid; 4'-((1,4'-dimethyl-2'-propyl(2,6'-bi-1H-benzimidazol)-1'-yl)methyl)-(1,1'-biphenyl)-2-carboxylic acid; 4'-((4-Methyl-6-(1-methyl-2-benzimidazolyl)-2-propyl-1-benzimidazolyl)methyl)-2-biphenylcarboxylic acid; 4'-((4-mehtyl-6-(1-methyl-2-benzimidazolyl)-2-propyl-1-benzimmidazolyl)methyl)-2-biphenylcarboxylic acid; 4'-[(1,4'-dimethyl-2'propyl[2,6'-bi-1H-benzimidazol]-1'-yl)methyl]-[1,1'-biphenyl]-2-carboxylic acid; 4'-[(1,7'-dimethyl-2'-propyl-1H,3'H-2,5'-bibenzimidazol-3'-yl)methyl][1,1'-biphenyl]-2-carboxylic acid; 4'-[(1,7'-dimethyl-2'-propyl-1H,3'H-2,5'-bibenzimidazol-3'-yl)methyl]biphenyl-2-carboxylic acid DMS3GX2 CP Boehringer Ingelheim DMS3GX2 TC Antihypertensive Agents DMS3GX2 DT Small molecular drug DMS3GX2 PC 65999 DMS3GX2 MW 514.6 DMS3GX2 FM C33H30N4O2 DMS3GX2 IC InChI=1S/C33H30N4O2/c1-4-9-30-35-31-21(2)18-24(32-34-27-12-7-8-13-28(27)36(32)3)19-29(31)37(30)20-22-14-16-23(17-15-22)25-10-5-6-11-26(25)33(38)39/h5-8,10-19H,4,9,20H2,1-3H3,(H,38,39) DMS3GX2 CS CCCC1=NC2=C(N1CC3=CC=C(C=C3)C4=CC=CC=C4C(=O)O)C=C(C=C2C)C5=NC6=CC=CC=C6N5C DMS3GX2 IK RMMXLENWKUUMAY-UHFFFAOYSA-N DMS3GX2 IU 2-[4-[[4-methyl-6-(1-methylbenzimidazol-2-yl)-2-propylbenzimidazol-1-yl]methyl]phenyl]benzoic acid DMS3GX2 CA CAS 144701-48-4 DMS3GX2 CB CHEBI:9434 DMS3GX2 DE Hypertension DMDIYFZ ID DMDIYFZ DMDIYFZ DN Telotristat ethyl DMDIYFZ HS Approved DMDIYFZ SN Telotristat; Telotristat etiprate; LP-778902; LX-1032; LX-1606; Serotonin modulator (oral, GI disorder/hypertension/carcinoid syndrome), Lexicon; Tryptophan hydroxylase inhibitor (oral, GI disorder/hypertension/carcinoid syndrome), Lexicon DMDIYFZ CP Lexicon Pharmaceuticals DMDIYFZ DT Small molecular drug DMDIYFZ PC 25181577 DMDIYFZ MW 575 DMDIYFZ FM C27H26ClF3N6O3 DMDIYFZ IC InChI=1S/C27H26ClF3N6O3/c1-3-39-25(38)20(32)12-16-4-6-17(7-5-16)21-14-23(35-26(33)34-21)40-24(27(29,30)31)19-9-8-18(28)13-22(19)37-11-10-15(2)36-37/h4-11,13-14,20,24H,3,12,32H2,1-2H3,(H2,33,34,35)/t20-,24+/m0/s1 DMDIYFZ CS CCOC(=O)[C@H](CC1=CC=C(C=C1)C2=CC(=NC(=N2)N)O[C@H](C3=C(C=C(C=C3)Cl)N4C=CC(=N4)C)C(F)(F)F)N DMDIYFZ IK MDSQOJYHHZBZKA-GBXCKJPGSA-N DMDIYFZ IU ethyl (2S)-2-amino-3-[4-[2-amino-6-[(1R)-1-[4-chloro-2-(3-methylpyrazol-1-yl)phenyl]-2,2,2-trifluoroethoxy]pyrimidin-4-yl]phenyl]propanoate DMDIYFZ CA CAS 1033805-22-9 DMDIYFZ DE Carcinoid syndrome diarrhea; Carcinoid syndrome DM02A65 ID DM02A65 DM02A65 DN Temazepam DM02A65 HS Approved DM02A65 SN Cerepax; Crisonar; Dasuen; Euhypnos; Euipnos; Gelthix; Hydroxydiazepam; Lenal; Levanxene; Levanxol; Levanzene; Mabertin; Methyloxazepam; Nocturne; Nomapam; Normison; Normitab; Nortem; Oxydiazepam; Perdorm; Planum; Remestan; Restoril; Signopam; Temador; Temaz; Temaze; Temazepamum; Temtabs; Tenox; AHP Brand of Temazepam; Alphapharm Brand of Temazepam; Apo Temazepam; Apotex Brand of Temazepam; Ct Arzneimittel Brand of Temazepam; Desitin Brand of Temazepam; Gen Temazepam; Genopharm Brand of Temazepam; Genpharm Brand of Temazepam; ICN Brand of Temazepam; Katwijk Brand of Temazepam; Knoll Brand of Temazepam; Mallinckrodt Brand of Temazepam; Neodorm SP; Norkotral Tema; Norton Brand of Temazepam; Novartis Brand of Temazepam; Novo Temazepam; Novopharm Brand of Temazepam; Nu Pharm Brand of Temazepam; Nu Temazepam; Orion Brand of Temazepam; PMS Temazepam; Pharmascience Brand of Temazepam; Pronervon T; Scheffler Brand of Temazepam; Sigma Brand of Temazepam; Temazep von ct; Uvamin Retard; Wyeth Brand of Temazepam; ER 115; K3917; Pfizer Brand 1 of Temazepam; Pfizer Brand 2 of Temazepam; Ro 5 5345; Ro55345; SaH 47 603; SaH 47603; WY 2917; WY 3917; WY3917; Apo-Temazepam; Ct-Arzneimittel Brand of Temazepam; Euhypnos (TN); Gen-Temazepam; K-3917; N-Methyloxazepam; Norkotral (TN); Normison (TN); Novo-Temazepam; Nu-Pharm Brand of Temazepam; Nu-Temazepam; PMS-Temazepam; Remestan (TN); Restoril (TN); Ro 5-5345; SaH 47-603; Tema, Norkotral; Temazepam, pharmaceutical grade; Temazepamum [INN-Latin]; Temtabs (TN); Tenox (TN); Wy-3917; Ro-5-5345; Temazepam (USP/INN); Temazepam [USAN:INN:BAN]; 1,3-Dihydro-7-chloro-3-hydroxy-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one; 3 Hydroxydiazepam; 3-Hydroxydiazepam; 7-CHLORO-1,3-DIHYDRO-3-HYDROXY-1-METHYL-5-PHENYL-2H-1,4-BENZODIAZEPIN-2-ONE; 7-Chloro-3-hydroxy-1-methyl-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one; 7-chloro-3-hydroxy-1-methyl-5-phenyl-3H-1,4-benzodiazepin-2-one DM02A65 CP Mylan Inc DM02A65 TC Hypnotics and Sedatives DM02A65 DT Small molecular drug DM02A65 PC 5391 DM02A65 MW 300.74 DM02A65 FM C16H13ClN2O2 DM02A65 IC InChI=1S/C16H13ClN2O2/c1-19-13-8-7-11(17)9-12(13)14(18-15(20)16(19)21)10-5-3-2-4-6-10/h2-9,15,20H,1H3 DM02A65 CS CN1C2=C(C=C(C=C2)Cl)C(=NC(C1=O)O)C3=CC=CC=C3 DM02A65 IK SEQDDYPDSLOBDC-UHFFFAOYSA-N DM02A65 IU 7-chloro-3-hydroxy-1-methyl-5-phenyl-3H-1,4-benzodiazepin-2-one DM02A65 CA CAS 846-50-4 DM02A65 CB CHEBI:9435 DM02A65 DE Insomnia DM1A79H ID DM1A79H DM1A79H DN Temocapril DM1A79H HS Approved DM1A79H SN Temocapril; Temocaprilum; 2-((2S,6R)-6-(((S)-1-Ethoxy-1-oxo-4-phenylbutan-2-yl)amino)-5-oxo-2-(thiophen-2-yl)-1,4-thiazepan-4-yl)acetic acid; UNII-18IZ008EU6; 18IZ008EU6; Temocapril [INN:BAN]; Temocaprilum [INN-Latin]; C23H28N2O5S2; 2-((2S,6R)-6-((S)-1-ETHOXY-1-OXO-4-PHENYLBUTAN-2-YLAMINO)-5-OXO-2-(THIOPHEN-2-YL)-1,4-THIAZEPAN-4-YL)ACETIC ACID; (2S-(2alpha,6beta(R*)))-6-((1-(Ethoxycarbonyl)-3-phenylpropyl)amino)tetrahydro-5-oxo-2-(2-thienyl)-1,4-thiazepine-4(5H)-acetic acid; Temocapril (INN); AC1L9FDI DM1A79H PC 443874 DM1A79H MW 476.6 DM1A79H FM C23H28N2O5S2 DM1A79H IC InChI=1S/C23H28N2O5S2/c1-2-30-23(29)17(11-10-16-7-4-3-5-8-16)24-18-15-32-20(19-9-6-12-31-19)13-25(22(18)28)14-21(26)27/h3-9,12,17-18,20,24H,2,10-11,13-15H2,1H3,(H,26,27)/t17-,18-,20-/m0/s1 DM1A79H CS CCOC(=O)C(CCC1=CC=CC=C1)NC2CSC(CN(C2=O)CC(=O)O)C3=CC=CS3 DM1A79H IK FIQOFIRCTOWDOW-BJLQDIEVSA-N DM1A79H IU 2-[(2S,6R)-6-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]-5-oxo-2-thiophen-2-yl-1,4-thiazepan-4-yl]acetic acid DM1A79H CA CAS 111902-57-9 DM1A79H CB CHEBI:135771 DM1A79H DE High blood pressure DM0JXFL ID DM0JXFL DM0JXFL DN Temocapril hydrochloride DM0JXFL HS Approved DM0JXFL SN Acecol (TN) DM0JXFL CP Sankyo DM0JXFL DT Small molecular drug DM0JXFL PC 443873 DM0JXFL MW 513.1 DM0JXFL FM C23H29ClN2O5S2 DM0JXFL IC InChI=1S/C23H28N2O5S2.ClH/c1-2-30-23(29)17(11-10-16-7-4-3-5-8-16)24-18-15-32-20(19-9-6-12-31-19)13-25(22(18)28)14-21(26)27;/h3-9,12,17-18,20,24H,2,10-11,13-15H2,1H3,(H,26,27);1H/t17-,18-,20-;/m0./s1 DM0JXFL CS CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@H]2CS[C@@H](CN(C2=O)CC(=O)O)C3=CC=CS3.Cl DM0JXFL IK XDDQNOKKZKHBIX-ASBZXGSUSA-N DM0JXFL IU 2-[(2S,6R)-6-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]-5-oxo-2-thiophen-2-yl-1,4-thiazepan-4-yl]acetic acid;hydrochloride DM0JXFL CA CAS 110221-44-8 DM0JXFL CB CHEBI:32190 DM0JXFL DE Cardiovascular disease DMNX2QI ID DMNX2QI DMNX2QI DN Temocaprilate DMNX2QI HS Approved DMNX2QI SN (+)-(2S,6R)-6-(((1S)-1-carboxy-3-phenylpropyl)amino)tetrahydro-5-oxo-2-(2-thienyl)-1,4-thiazepine-4(5H)-acetic acid; 2-(4-Carboxymethyl-5-oxo-2-thiophen-2-yl-[1,4]thiazepan-6-ylamino)-4-phenyl-butyric acid; 2D6A12Q12R; AC1L9E45; AJ-48035; AK116088; AKOS016010295; API0000849; AX8152551; BDBM50024710; O437; RNH 5139; RNH-5139; RS 5139; RS-5139; RT-015901; SCHEMBL498916; TL8000320; Temocapril Diacid; Temocaprilat; Temocaprilat [INN:BAN]; ZINC4099102; temocaprilate DMNX2QI PC 443151 DMNX2QI MW 448.552 DMNX2QI FM C21H24N2O5S2 DMNX2QI IC InChI=1S/C21H24N2O5S2/c24-19(25)12-23-11-18(17-7-4-10-29-17)30-13-16(20(23)26)22-15(21(27)28)9-8-14-5-2-1-3-6-14/h1-7,10,15-16,18,22H,8-9,11-13H2,(H,24,25)(H,27,28)/t15-,16-,18-/m0/s1 DMNX2QI CS C1C(SCC(C(=O)N1CC(=O)O)NC(CCC2=CC=CC=C2)C(=O)O)C3=CC=CS3 DMNX2QI IK KZVWEOXAPZXAFB-BQFCYCMXSA-N DMNX2QI IU (2S)-2-[[(2S,6R)-4-(carboxymethyl)-5-oxo-2-thiophen-2-yl-1,4-thiazepan-6-yl]amino]-4-phenylbutanoic acid DMNX2QI CA CAS 110221-53-9 DMNX2QI CB CHEBI:9436 DMNX2QI DE High blood pressure DMKECZD ID DMKECZD DMKECZD DN Temozolomide DMKECZD HS Approved DMKECZD SN Methazolastone; Temodal; Temodar; Temozolamide; Temozolodida; Temozolomidum; Essex brand of temozolomide; Scheringbrand of temozolomide; Temozolodida [Spanish]; Temozolomidum [Latin]; M B 39831; MB 39831; Sch 52365; M & B 39831; M&B 39831; M-39831; Sch-52365; Schering-Plough brand of temozolomide; TMZ-Bioshuttle; Temodal (TN); Temodar (TN); Temozolomide [INN:BAN]; M&B-39831; Temozolomide (JAN/USAN/INN); 3,4-Dihydro-3-methyl-4-oxoimidazo(5,1-d)-1,2,3,5-tetrazine-8-carboxamide; 3,4-Dihydro-3-methyl-4-oxoimidazo(5,1-d)-as-tetrazine-8-carboxamide; 3-Methyl-4-oxo-3,4-dihydroimidazo(5,1-d)(1,2,3,5)tetrazine-8-carboxamide; 3-Methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetraazine-8-carboxamide; 3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide; 3-methyl-4-oxoimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide; 8-Carbamoyl-3-methylimidazo(5,1-d)-1,2,3,5-tetrazin-4(3H)-one; TMZ DMKECZD CP Schering-Plough DMKECZD TC Anticancer Agents DMKECZD DT Small molecular drug DMKECZD PC 5394 DMKECZD MW 194.15 DMKECZD FM C6H6N6O2 DMKECZD IC InChI=1S/C6H6N6O2/c1-11-6(14)12-2-8-3(4(7)13)5(12)9-10-11/h2H,1H3,(H2,7,13) DMKECZD CS CN1C(=O)N2C=NC(=C2N=N1)C(=O)N DMKECZD IK BPEGJWRSRHCHSN-UHFFFAOYSA-N DMKECZD IU 3-methyl-4-oxoimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide DMKECZD CA CAS 85622-93-1 DMKECZD CB CHEBI:72564 DMKECZD DE Grade IV astrocytoma DMS104F ID DMS104F DMS104F DN Temsirolimus DMS104F HS Approved DMS104F SN Torisel DMS104F CP Wyeth DMS104F DT Small molecular drug DMS104F PC 6918289 DMS104F MW 1030.3 DMS104F FM C56H87NO16 DMS104F IC InChI=1S/C56H87NO16/c1-33-17-13-12-14-18-34(2)45(68-9)29-41-22-20-39(7)56(67,73-41)51(63)52(64)57-24-16-15-19-42(57)53(65)71-46(30-43(60)35(3)26-38(6)49(62)50(70-11)48(61)37(5)25-33)36(4)27-40-21-23-44(47(28-40)69-10)72-54(66)55(8,31-58)32-59/h12-14,17-18,26,33,35-37,39-42,44-47,49-50,58-59,62,67H,15-16,19-25,27-32H2,1-11H3/b14-12+,17-13+,34-18+,38-26+/t33-,35-,36-,37-,39-,40+,41+,42+,44-,45+,46+,47-,49-,50+,56-/m1/s1 DMS104F CS C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)OC(=O)C(C)(CO)CO)C)/C)O)OC)C)C)/C)OC DMS104F IK CBPNZQVSJQDFBE-FUXHJELOSA-N DMS104F IU [(1R,2R,4S)-4-[(2R)-2-[(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-2,3,10,14,20-pentaoxo-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraen-12-yl]propyl]-2-methoxycyclohexyl] 3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate DMS104F CA CAS 162635-04-3 DMS104F CB CHEBI:79699 DMS104F DE Renal cell carcinoma DMCOZJY ID DMCOZJY DMCOZJY DN Tenapanor DMCOZJY HS Approved DMCOZJY SN 1234423-95-0; UNII-WYD79216A6; AZD 1722; WYD79216A6; AZD-1722; 3-((S)-6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)-N-(26-((3-((S)-6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl)sulfonamido)-10,17-dioxo-3,6,21,24-tetraoxa-9,11,16,18-tetraazahexacosyl)benzenesulfonamide; Tenapanor [USAN:INN]; Tenapanor(free base); GTPL8449; CHEMBL3304485; SCHEMBL15267600; DTXSID40154016; BCP24892; BCP28554; EX-A2506 DMCOZJY CP AstraZeneca DMCOZJY DT Small molecular drug DMCOZJY PC 71587953 DMCOZJY MW 1145 DMCOZJY FM C50H66Cl4N8O10S2 DMCOZJY IC InChI=1S/C50H66Cl4N8O10S2/c1-61-31-43(41-27-37(51)29-47(53)45(41)33-61)35-7-5-9-39(25-35)73(65,66)59-15-19-71-23-21-69-17-13-57-49(63)55-11-3-4-12-56-50(64)58-14-18-70-22-24-72-20-16-60-74(67,68)40-10-6-8-36(26-40)44-32-62(2)34-46-42(44)28-38(52)30-48(46)54/h5-10,25-30,43-44,59-60H,3-4,11-24,31-34H2,1-2H3,(H2,55,57,63)(H2,56,58,64)/t43-,44-/m0/s1 DMCOZJY CS CN1C[C@H](C2=C(C1)C(=CC(=C2)Cl)Cl)C3=CC(=CC=C3)S(=O)(=O)NCCOCCOCCNC(=O)NCCCCNC(=O)NCCOCCOCCNS(=O)(=O)C4=CC=CC(=C4)[C@@H]5CN(CC6=C5C=C(C=C6Cl)Cl)C DMCOZJY IK DNHPDWGIXIMXSA-CXNSMIOJSA-N DMCOZJY IU 1-[2-[2-[2-[[3-[(4S)-6,8-dichloro-2-methyl-3,4-dihydro-1H-isoquinolin-4-yl]phenyl]sulfonylamino]ethoxy]ethoxy]ethyl]-3-[4-[2-[2-[2-[[3-[(4S)-6,8-dichloro-2-methyl-3,4-dihydro-1H-isoquinolin-4-yl]phenyl]sulfonylamino]ethoxy]ethoxy]ethylcarbamoylamino]butyl]urea DMCOZJY CA CAS 1234423-95-0 DMCOZJY DE Kidney disease; Constipation; Irritable bowel syndrome DMJYN25 ID DMJYN25 DMJYN25 DN Tenecteplase DMJYN25 HS Approved DMJYN25 SN Tnkase; Tnkase (TN); Tenecteplase (USAN/INN) DMJYN25 TC Thrombolytic Agents DMJYN25 SQ DB00031 sequence: SYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGNWSTAESGAECTNWQSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAAAAASPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP DMJYN25 DE Myocardial infarction DMLW57T ID DMLW57T DMLW57T DN Teniposide DMLW57T HS Approved DMLW57T SN PTG; Teniposido; Teniposidum; Vehem; Vumon; Demethyl Epipodophyllotoxin Thenylidine Glucoside; VM 26; Teniposido [INN-Spanish]; Teniposidum [INN-Latin]; VM-26; Vee M-26; Veham-Sandoz; Vumon (TN); Teniposide (USAN/INN); Teniposide [USAN:BAN:INN]; VM-26 (TN); Vumon, VM-26, Vehem, NSC 122819, Teniposide; Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-2-thenylidene-beta-D-glucopyranoside); 4'-Demethyl-epipodophyllotoxin-beta-D-thenylidene-glucoside; 4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-2-thenylidene-beta-D-glucopyranoside); 4'-Demethylepipodophyllotoxin 9-(4,6-O-2-thenylidene-beta-D-glucopyranoside); 4'-Demethylepipodophyllotoxin thenylidene glucoside; 4'-Demethylepipodophyllotoxin-beta-D-thenylidine glucoside; 4'-Dimethyl-9-(4,6-O-2-thenyid)-epipodophyllotoxin; 4-Demethylepipodophyllotoxin-.beta.-D-thenylideneglucoside DMLW57T TC Anticancer Agents DMLW57T DT Small molecular drug DMLW57T PC 452548 DMLW57T MW 656.7 DMLW57T FM C32H32O13S DMLW57T IC InChI=1S/C32H32O13S/c1-37-19-6-13(7-20(38-2)25(19)33)23-14-8-17-18(42-12-41-17)9-15(14)28(16-10-39-30(36)24(16)23)44-32-27(35)26(34)29-21(43-32)11-40-31(45-29)22-4-3-5-46-22/h3-9,16,21,23-24,26-29,31-35H,10-12H2,1-2H3/t16-,21+,23+,24-,26+,27+,28+,29+,31+,32-/m0/s1 DMLW57T CS COC1=CC(=CC(=C1O)OC)[C@H]2[C@@H]3[C@H](COC3=O)[C@@H](C4=CC5=C(C=C24)OCO5)O[C@H]6[C@@H]([C@H]([C@H]7[C@H](O6)CO[C@H](O7)C8=CC=CS8)O)O DMLW57T IK NRUKOCRGYNPUPR-QBPJDGROSA-N DMLW57T IU (5S,5aR,8aR,9R)-5-[[(2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-thiophen-2-yl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-9-(4-hydroxy-3,5-dimethoxyphenyl)-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[6,5-f][1,3]benzodioxol-8-one DMLW57T CA CAS 29767-20-2 DMLW57T DE Acute lymphoblastic leukaemia DM1IS6U ID DM1IS6U DM1IS6U DN Tenofovir DM1IS6U HS Approved DM1IS6U SN Apropovir; PMPA; TFV; Tenefovir; GS 1275; GS 1278; GS1278; GNA & Tenofovir; HHA & Tenofovir; KS-5021; Viread (TN); Viread, Tenofovir; D,L-Tenofovir; PMPA-(R); Phosphonic acid, [[2-(6-amino-9H-purin-9; [(2R)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethylphosphonic acid; Phosphonic acid, [[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]-(9CI); Phosphonic acid, [[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]-& Galanthus nivalis agglutinin (GNA); Phosphonic acid, [[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]-& Hippeastrum hybrid agglutinin(HHA); (R)-9-(2-Phosphonomethoxypropyl)adenine; (R)-9-(2-Phosphonylmethoxypropyl)adenine; (R)-PMPA DM1IS6U CP Gilead Sciences DM1IS6U TC Anti-HIV Agents DM1IS6U DT Small molecular drug DM1IS6U PC 464205 DM1IS6U MW 287.21 DM1IS6U FM C9H14N5O4P DM1IS6U IC InChI=1S/C9H14N5O4P/c1-6(18-5-19(15,16)17)2-14-4-13-7-8(10)11-3-12-9(7)14/h3-4,6H,2,5H2,1H3,(H2,10,11,12)(H2,15,16,17)/t6-/m1/s1 DM1IS6U CS C[C@H](CN1C=NC2=C(N=CN=C21)N)OCP(=O)(O)O DM1IS6U IK SGOIRFVFHAKUTI-ZCFIWIBFSA-N DM1IS6U IU [(2R)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethylphosphonic acid DM1IS6U CA CAS 147127-20-6 DM1IS6U CB CHEBI:63625 DM1IS6U DE Human immunodeficiency virus infection DMTQF4A ID DMTQF4A DMTQF4A DN Tenofovir alafenamide DMTQF4A HS Approved DMTQF4A SN Tenofovir Alafenamide (GS-7340); Tenofovir Alafenamide [USAN:INN]; UNII-EL9943AG5J; UNII-J4414G3BUK; Vemlidy; Tenofovir; UNII-W4HFE001U5; W4HFE001U5; (R)-(((1-(6-AMINO-9H-PURIN-9-YL)PROPAN-2-YL)OXY)METHYL)PHOSPHONIC ACID; (R)-(1-(6-amino-9H-purin-9-yl)propan-2-yloxy)methylphosphonic acid; (R)-9-(2-Phosphonomethoxypropyl)adenine; (R)-9-[2-(Phosphonomethoxy)propyl]adenine; (R)-PMPA; ({[(2R)-1-(6-amino-9H-purin-9-yl)propan-2-yl]oxy}methyl)phosphonic acid; 147127-20-6; 9-[(R)-2-(phosphonomethoxy)propyl]adenine; Apropovir; CHEBI:63625; D,L-Tenofovir; GS-1278; PMPA; PMPA gel; (S)-Isopropyl 2-(((S)-((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(phenoxy)phosphoryl)amino)propanoate; 379270-37-8; AK109983; EL9943AG5J; GS 7340; GS-7339; GS-7340; GS7340; J4414G3BUK; L-Alanine, N-((S)-(((1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy)methyl)phenoxyphosphinyl)-, 1-methylethyl ester; TENOFOVIR ALAFENAMIDE DMTQF4A PC 9574768 DMTQF4A MW 476.5 DMTQF4A FM C21H29N6O5P DMTQF4A IC LDEKQSIMHVQZJK-CAQYMETFSA-N DMTQF4A CS CC(C)OC(=O)C(C)NP(=O)(COC(C)CN1C=NC2=C(N=CN=C21)N)OC3=CC=CC=C3 DMTQF4A IK 1S/C21H29N6O5P/c1-14(2)31-21(28)16(4)26-33(29,32-17-8-6-5-7-9-17)13-30-15(3)10-27-12-25-18-19(22)23-11-24-20(18)27/h5-9,11-12,14-16H,10,13H2,1-4H3,(H,26,29)(H2,22,23,24)/t15-,16+,33+/m1/s1 DMTQF4A IU propan-2-yl (2S)-2-[[[(2R)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethyl-phenoxyphosphoryl]amino]propanoate DMTQF4A CA CAS 379270-37-8 DMTQF4A CB CHEBI:90926 DMTQF4A DE Viral hepatitis DMSY4ZG ID DMSY4ZG DMSY4ZG DN Tenofovir disoproxil fumarate DMSY4ZG HS Approved DMSY4ZG SN Bis-POC-PMPA; GSK548470; PMPA-oral; Tenofovir DF; Tenozet; Viread DMSY4ZG TC Antiinfective Agents DMSY4ZG DT Small molecular drug DMSY4ZG PC 6398764 DMSY4ZG MW 635.5 DMSY4ZG FM C23H34N5O14P DMSY4ZG IC InChI=1S/C19H30N5O10P.C4H4O4/c1-12(2)33-18(25)28-9-31-35(27,32-10-29-19(26)34-13(3)4)11-30-14(5)6-24-8-23-15-16(20)21-7-22-17(15)24;5-3(6)1-2-4(7)8/h7-8,12-14H,6,9-11H2,1-5H3,(H2,20,21,22);1-2H,(H,5,6)(H,7,8)/b;2-1+/t14-;/m1./s1 DMSY4ZG CS C[C@H](CN1C=NC2=C(N=CN=C21)N)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C.C(=C/C(=O)O)\\C(=O)O DMSY4ZG IK VCMJCVGFSROFHV-WZGZYPNHSA-N DMSY4ZG IU [[(2R)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethyl-(propan-2-yloxycarbonyloxymethoxy)phosphoryl]oxymethyl propan-2-yl carbonate;(E)-but-2-enedioic acid DMSY4ZG CA CAS 202138-50-9 DMSY4ZG CB CHEBI:63718 DMSY4ZG DE Discovery agent DMVAZP9 ID DMVAZP9 DMVAZP9 DN Tenoxicam DMVAZP9 HS Approved DMVAZP9 SN Artriunic; Liman; Mobiflex; Reutenox; Tenoxicamum; Tilcotil; Apotex brand of tenoxicam; Novag brand of tenoxicam; Novopharm brand of tenoxicam; Roche brand of tenoxicam; Solvay brand of tenoxicam; Apo-Tenoxicam; Mobiflex (TN); Novo-Tenoxicam; Ro 12-0068; Ro-120068; Tenoxicamum [INN-Latin]; Tilcotil (TN); Ro 12-0068/000; Ro-12-0068; Tenoxicam (JAN/USAN/INN); Tenoxicam [USAN:BAN:INN:JAN]; (3E)-3-[hydroxy-(pyridin-2-ylamino)methylidene]-2-methyl-1,1-dioxothieno[2,3-e]thiazin-4-one; (3Z)-3-[hydroxy-(pyridin-2-ylamino)methylidene]-2-methyl-1,1-dioxothieno[2,3-e]thiazin-4-one; 2H-Thieno(2,3-e)-1,2-thiazine-3-carboxamide, 4-hydroxy-2-methyl-N-2-pyridinyl-, 1,1-dioxide; 3-[hydroxy-(pyridin-2-ylamino)methylidene]-2-methyl-1,1-dioxothieno[2,3-e]thiazin-4-one; 4-HYDROXY-2-METHYL-N-2-PYRIDINYL-2H-THIENO[2,3-E]-1,2-THIAZINE-3-CARBOXAMIDE 1,1-DIOXIDE; 4-Hydroxy-2-methyl-N-2-pyridinyl-2H-thieno(2,3-e)-1,2-thiazine-3-carboxamide1,1-dioxide; 4-Hydroxy-2-methyl-N-2-pyridyl-2H-thieno(2,3-e)-1,2-thiazine-3-carboxamide 1,1-dioxide; 4-hydroxy-2-methyl-N-(pyridin-2-yl)-2H-thieno[2,3-e][1,2]thiazine-3-carboxamide 1,1-dioxide DMVAZP9 CP Roche Laboratories Inc DMVAZP9 TC Antiinflammatory Agents DMVAZP9 DT Small molecular drug DMVAZP9 PC 54677971 DMVAZP9 MW 337.4 DMVAZP9 FM C13H11N3O4S2 DMVAZP9 IC InChI=1S/C13H11N3O4S2/c1-16-10(13(18)15-9-4-2-3-6-14-9)11(17)12-8(5-7-21-12)22(16,19)20/h2-7,17H,1H3,(H,14,15,18) DMVAZP9 CS CN1C(=C(C2=C(S1(=O)=O)C=CS2)O)C(=O)NC3=CC=CC=N3 DMVAZP9 IK LZNWYQJJBLGYLT-UHFFFAOYSA-N DMVAZP9 IU 4-hydroxy-2-methyl-1,1-dioxo-N-pyridin-2-ylthieno[2,3-e]thiazine-3-carboxamide DMVAZP9 CA CAS 59804-37-4 DMVAZP9 CB CHEBI:32192 DMVAZP9 DE Rheumatoid arthritis DMUQ0E8 ID DMUQ0E8 DMUQ0E8 DN Tepotinib DMUQ0E8 HS Approved DMUQ0E8 SN 1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo DMUQ0E8 CP EMD Serono DMUQ0E8 DT Small molecular drug DMUQ0E8 PC 25171648 DMUQ0E8 MW 492.6 DMUQ0E8 FM C29H28N6O2 DMUQ0E8 IC InChI=1S/C29H28N6O2/c1-34-12-10-21(11-13-34)20-37-26-17-31-29(32-18-26)25-7-3-5-23(15-25)19-35-28(36)9-8-27(33-35)24-6-2-4-22(14-24)16-30/h2-9,14-15,17-18,21H,10-13,19-20H2,1H3 DMUQ0E8 CS CN1CCC(CC1)COC2=CN=C(N=C2)C3=CC=CC(=C3)CN4C(=O)C=CC(=N4)C5=CC=CC(=C5)C#N DMUQ0E8 IK AHYMHWXQRWRBKT-UHFFFAOYSA-N DMUQ0E8 IU 3-[1-[[3-[5-[(1-methylpiperidin-4-yl)methoxy]pyrimidin-2-yl]phenyl]methyl]-6-oxopyridazin-3-yl]benzonitrile DMUQ0E8 CA CAS 1100598-32-0 DMUQ0E8 DE Solid tumour/cancer; Hepatocellular carcinoma; Non-small cell lung cancer DM4L59B ID DM4L59B DM4L59B DN Teprotumumab DM4L59B HS Approved DM4L59B SN RV001 DM4L59B CP River vision DM4L59B DE Diabetic macular edema; Graves disease DM3JCVS ID DM3JCVS DM3JCVS DN Terazosin DM3JCVS HS Approved DM3JCVS SN Blavin; Flumarc; Fosfomic; Hytracin; Hytrin; Terazosabb; Terazosina; Terazosine; Terazosinum; Vasomet; Trazosin HCl; A 45975; Abbott 45975; A-45975; Hytrin (TN); Terazosabb (TN); Terazosin (INN); Terazosin [INN:BAN]; Terazosina [INN-Spanish]; Terazosine [INN-French]; Terazosinum [INN-Latin]; [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl](tetrahydrofuran-2-yl)methanone; [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(oxolan-2-yl)methanone; 1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-((tetrahydro-2-furanyl)carbonyl)piperazine; 1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(tetrahydro-2-furoyl)piperazine; 6,7-bis(methyloxy)-2-[4-(tetrahydrofuran-2-ylcarbonyl)piperazin-1-yl]quinazolin-4-amine; 6,7-dimethoxy-2-[4-(tetrahydrofuran-2-ylcarbonyl)piperazin-1-yl]quinazolin-4-amine DM3JCVS CP Abbott Laboratories DM3JCVS TC Anticancer Agents DM3JCVS DT Small molecular drug DM3JCVS PC 5401 DM3JCVS MW 387.4 DM3JCVS FM C19H25N5O4 DM3JCVS IC InChI=1S/C19H25N5O4/c1-26-15-10-12-13(11-16(15)27-2)21-19(22-17(12)20)24-7-5-23(6-8-24)18(25)14-4-3-9-28-14/h10-11,14H,3-9H2,1-2H3,(H2,20,21,22) DM3JCVS CS COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4CCCO4)N)OC DM3JCVS IK VCKUSRYTPJJLNI-UHFFFAOYSA-N DM3JCVS IU [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(oxolan-2-yl)methanone DM3JCVS CA CAS 63590-64-7 DM3JCVS CB CHEBI:9445 DM3JCVS DE Benign prostatic hyperplasia DMI6HUW ID DMI6HUW DMI6HUW DN Terbinafine DMI6HUW HS Approved DMI6HUW SN Bramazil; Lamasil; TerbiFoam; Terbina; Lamisil AT; Lamisil Tablet; Ternbinafine HCl; Lamasil (TN); Lamisil (TN); SF 86-327; Terbisil (TN); Zabel (TN); SF-86-327; Terbinafine (USAN/INN); Terbinafine [USAN:BAN:INN]; Lamisil, Terbinex, Corbinal, Zabel, Terbinafine; Terbinafine, SF-86-327, Lamisil, TBNF; (2E)-N,6,6-trimethyl-N-(1-naphthylmethyl)-2-hepten-4-yn-1-amine; (2E)-N,6,6-trimethyl-N-(naphthalen-1-ylmethyl)hept-2-en-4-yn-1-amine; (E)-N,6,6-trimethyl-N-(naphthalen-1-ylmethyl)hept-2-en-4-yn-1-amine; (E)-N-(6,6-Dimethyl-2-hepten-4-ynyl)-N-methyl-1-naphthalene methanamine; (E)-N-(6,6-Dimethyl-2-hepten-4-ynyl)-N-methyl-1-naphthalenemethylamine; (E)-N-(6,6-dimethyl-2-heptenynyl)-N-methyl-1-naphthalenementhamin hydrochloride DMI6HUW CP Celtic Pharma DMI6HUW TC Antifungal Agents DMI6HUW DT Small molecular drug DMI6HUW PC 1549008 DMI6HUW MW 291.4 DMI6HUW FM C21H25N DMI6HUW IC InChI=1S/C21H25N/c1-21(2,3)15-8-5-9-16-22(4)17-19-13-10-12-18-11-6-7-14-20(18)19/h5-7,9-14H,16-17H2,1-4H3/b9-5+ DMI6HUW CS CC(C)(C)C#C/C=C/CN(C)CC1=CC=CC2=CC=CC=C21 DMI6HUW IK DOMXUEMWDBAQBQ-WEVVVXLNSA-N DMI6HUW IU (E)-N,6,6-trimethyl-N-(naphthalen-1-ylmethyl)hept-2-en-4-yn-1-amine DMI6HUW CA CAS 91161-71-6 DMI6HUW CB CHEBI:9448 DMI6HUW DE Fungal infection; Onychomycosis DMD4381 ID DMD4381 DMD4381 DN Terbutaline DMD4381 HS Approved DMD4381 SN Asthmasian; Brethaire; Brethine; Brican; Bricanyl; Bricar; Bricaril; Bricyn; Terbutalin; Terbutalina; Terbutalino; Terbutalinum; Terbutalina [DCIT]; Terbutaline sulfate; KWD 2019; Asthmasian (TN); Brethaire (TN); Brethine (TN); Bricanyl (TN); KWD-2019; Terbutaline (INN); Terbutaline [INN:BAN]; Terbutalino [INN-Spanish]; Terbutalinum [INN-Latin]; (+-)-5-(2-((1,1-Dimethylethyl)amino)-1-hydroxyethyl)-1,3-benzenediol; (+-)-Terbutaline; 1,3-Benzenediol, 5-(2-((1,1-dimethylethyl)amino)-1-hydroxyethyl)-(9CI); 5-(2-((1,1-DIMETHYLETHYL)AMINO)-1-HYDROXYETHYL)-1,3-BENZENEDIOL; 5-[2-(tert-butylamino)-1-hydroxyethyl]benzene-1,3-diol; 5-{2-[(1,1-dimethylethyl)amino]-1-hydroxyethyl}benzene-1,3-diol DMD4381 CP Ben Venue Laboratories DMD4381 TC Bronchodilator Agents DMD4381 DT Small molecular drug DMD4381 PC 5403 DMD4381 MW 225.28 DMD4381 FM C12H19NO3 DMD4381 IC InChI=1S/C12H19NO3/c1-12(2,3)13-7-11(16)8-4-9(14)6-10(15)5-8/h4-6,11,13-16H,7H2,1-3H3 DMD4381 CS CC(C)(C)NCC(C1=CC(=CC(=C1)O)O)O DMD4381 IK XWTYSIMOBUGWOL-UHFFFAOYSA-N DMD4381 IU 5-[2-(tert-butylamino)-1-hydroxyethyl]benzene-1,3-diol DMD4381 CA CAS 23031-25-6 DMD4381 CB CHEBI:9449 DMD4381 DE Asthma DMVPWLZ ID DMVPWLZ DMVPWLZ DN Terbutyline DMVPWLZ HS Approved DMVPWLZ DE Hypertension DMJ13KI ID DMJ13KI DMJ13KI DN Terconazole DMJ13KI HS Approved DMJ13KI SN Fungistat; Terazol; Terconazol; Terconazolum; Tercospor; Triaconazole; Zazole; R 42470; Terazol 3; Terazol 7; Terazol 73; Tetrazol 3; Tetrazol 7; Gyno-Terazol; R 42,470; R-42470; Terazol 3 (TN); Terazol 7 & 3; Terazol Cream & Suppositories; Terconazol [INN-Spanish]; Terconazolum [INN-Latin]; Terconazole (USAN/INN); Terconazole [USAN:INN:BAN]; Cis-1-(p-((2-(2,4-Dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl)methoxy)phenyl)-4-isopropylpiperazine; Piperazine, 1-[4-[[2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-4-(1-methylethyl)-, rel-(2R,4S); 1-(4-((2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl)methoxy)phenyl)-4-(1-methylethyl)piperazine; 1-[4-[[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-4-propan-2-ylpiperazine; 1-[4-[[(2S,4R)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-4-propan-2-ylpiperazine; 1-[4-[[(4S)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-4-propan-2-ylpiperazine; 1-[4-[[2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-4-propan-2-ylpiperazine DMJ13KI TC Antifungal Agents DMJ13KI DT Small molecular drug DMJ13KI PC 441383 DMJ13KI MW 532.5 DMJ13KI FM C26H31Cl2N5O3 DMJ13KI IC InChI=1S/C26H31Cl2N5O3/c1-19(2)31-9-11-32(12-10-31)21-4-6-22(7-5-21)34-14-23-15-35-26(36-23,16-33-18-29-17-30-33)24-8-3-20(27)13-25(24)28/h3-8,13,17-19,23H,9-12,14-16H2,1-2H3/t23-,26-/m0/s1 DMJ13KI CS CC(C)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=NC=N4)C5=C(C=C(C=C5)Cl)Cl DMJ13KI IK BLSQLHNBWJLIBQ-OZXSUGGESA-N DMJ13KI IU 1-[4-[[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-4-propan-2-ylpiperazine DMJ13KI CA CAS 67915-31-5 DMJ13KI CB CHEBI:82980 DMJ13KI DE Candidiasis DMQ2FKJ ID DMQ2FKJ DMQ2FKJ DN Teriflunomide DMQ2FKJ HS Approved DMQ2FKJ CP Sanofi-Aventis DMQ2FKJ DT Small molecular drug DMQ2FKJ PC 54684141 DMQ2FKJ MW 270.21 DMQ2FKJ FM C12H9F3N2O2 DMQ2FKJ IC InChI=1S/C12H9F3N2O2/c1-7(18)10(6-16)11(19)17-9-4-2-8(3-5-9)12(13,14)15/h2-5,18H,1H3,(H,17,19)/b10-7- DMQ2FKJ CS C/C(=C(\\C#N)/C(=O)NC1=CC=C(C=C1)C(F)(F)F)/O DMQ2FKJ IK UTNUDOFZCWSZMS-YFHOEESVSA-N DMQ2FKJ IU (Z)-2-cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]but-2-enamide DMQ2FKJ CA CAS 163451-81-8 DMQ2FKJ CB CHEBI:68540 DMQ2FKJ DE Hyperlipidaemia; Multiple sclerosis; Hepatitis B virus infection; Rheumatoid arthritis DMMC45B ID DMMC45B DMMC45B DN Teriparatide DMMC45B HS Approved DMMC45B SN Forteo; Forteo (TN); Teriparatide (genetical recombination); Teriparatide (USAN/INN); Teriparatide (genetical recombination) (JAN) DMMC45B CP Eli Lilly DMMC45B TC Bone Density Conservation Agents DMMC45B DT Peptide DMMC45B SQ Parathyroid hormone precursor - Homo sapiens (1-34): SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNF DMMC45B PC 16133850 DMMC45B MW 4118 DMMC45B FM C181H291N55O51S2 DMMC45B IC InChI=1S/C181H291N55O51S2/c1-21-96(18)146(236-160(267)114(48-53-141(250)251)212-174(281)132(84-239)232-177(284)143(93(12)13)233-147(254)103(185)82-237)178(285)216-111(45-50-134(187)241)155(262)219-119(65-90(6)7)163(270)213-116(55-62-289-20)158(265)224-124(71-100-79-196-86-203-100)167(274)226-126(73-135(188)242)169(276)217-117(63-88(2)3)148(255)201-81-138(245)205-105(39-27-30-56-182)149(256)223-123(70-99-78-195-85-202-99)166(273)221-121(67-92(10)11)164(271)225-128(75-137(190)244)171(278)231-131(83-238)173(280)214-115(54-61-288-19)157(264)210-112(46-51-139(246)247)153(260)208-109(43-34-60-199-181(193)194)159(266)234-144(94(14)15)175(282)215-113(47-52-140(248)249)156(263)222-122(69-98-77-200-104-38-26-25-37-102(98)104)165(272)220-120(66-91(8)9)161(268)209-108(42-33-59-198-180(191)192)151(258)206-106(40-28-31-57-183)150(257)207-107(41-29-32-58-184)152(259)218-118(64-89(4)5)162(269)211-110(44-49-133(186)240)154(261)228-129(76-142(252)253)172(279)235-145(95(16)17)176(283)229-125(72-101-80-197-87-204-101)168(275)227-127(74-136(189)243)170(277)230-130(179(286)287)68-97-35-23-22-24-36-97/h22-26,35-38,77-80,85-96,103,105-132,143-146,200,237-239H,21,27-34,39-76,81-84,182-185H2,1-20H3,(H2,186,240)(H2,187,241)(H2,188,242)(H2,189,243)(H2,190,244)(H,195,202)(H,196,203)(H,197,204)(H,201,255)(H,205,245)(H,206,258)(H,207,257)(H,208,260)(H,209,268)(H,210,264)(H,211,269)(H,212,281)(H,213,270)(H,214,280)(H,215,282)(H,216,285)(H,217,276)(H,218,259)(H,219,262)(H,220,272)(H,221,273)(H,222,263)(H,223,256)(H,224,265)(H,225,271)(H,226,274)(H,227,275)(H,228,261)(H,229,283)(H,230,277)(H,231,278)(H,232,284)(H,233,254)(H,234,266)(H,235,279)(H,236,267)(H,246,247)(H,248,249)(H,250,251)(H,252,253)(H,286,287)(H4,191,192,198)(H4,193,194,199)/t96-,103-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,127-,128-,129-,130-,131-,132-,143-,144-,145-,146-/m0/s1 DMMC45B CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC2=CNC=N2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC5=CNC=N5)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC6=CC=CC=C6)C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CO)N DMMC45B IK OGBMKVWORPGQRR-UMXFMPSGSA-N DMMC45B IU (4S)-4-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-hydroxypropanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-4-carboxybutanoyl]amino]-3-methylpentanoyl]amino]-5-oxopentanoyl]amino]-4-methylpentanoyl]amino]-4-methylsulfanylbutanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-4-oxobutanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]hexanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-3-hydroxypropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(1S)-1-carboxy-2-phenylethyl]amino]-1,4-dioxobutan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-oxopentanoic acid DMMC45B CA CAS 52232-67-4 DMMC45B CB CHEBI:135983 DMMC45B DE Osteogenesis imperfecta; Psoriatic disorder DMT9FH3 ID DMT9FH3 DMT9FH3 DN Terlipressin DMT9FH3 HS Approved DMT9FH3 SN Glypressin; Lucassin; Terlipressina; Terlipressine; Terlipressinum; Glypressin (TN); HS-2028; Terlipressin [BAN:INN]; Terlipressina [INN-Spanish]; Terlipressine [INN-French]; Terlipressinum [INN-Latin]; N-(N-(N-Glycylglycyl)glycyl)-8-L-lysinevasopressin DMT9FH3 CP Ferring Pharmaceuticals DMT9FH3 TC Vasoconstrictor Agents DMT9FH3 DT Small molecular drug DMT9FH3 PC 72081 DMT9FH3 MW 1227.4 DMT9FH3 FM C52H74N16O15S2 DMT9FH3 IC InChI=1S/C52H74N16O15S2/c53-17-5-4-9-31(45(76)60-23-41(57)72)63-51(82)38-10-6-18-68(38)52(83)37-27-85-84-26-36(61-44(75)25-59-43(74)24-58-42(73)22-54)50(81)65-34(20-29-11-13-30(69)14-12-29)48(79)64-33(19-28-7-2-1-3-8-28)47(78)62-32(15-16-39(55)70)46(77)66-35(21-40(56)71)49(80)67-37/h1-3,7-8,11-14,31-38,69H,4-6,9-10,15-27,53-54H2,(H2,55,70)(H2,56,71)(H2,57,72)(H,58,73)(H,59,74)(H,60,76)(H,61,75)(H,62,78)(H,63,82)(H,64,79)(H,65,81)(H,66,77)(H,67,80)/t31-,32-,33-,34-,35-,36-,37-,38-/m0/s1 DMT9FH3 CS C1C[C@H](N(C1)C(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)NC(=O)CNC(=O)CNC(=O)CN)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N DMT9FH3 IK BENFXAYNYRLAIU-QSVFAHTRSA-N DMT9FH3 IU (2S)-1-[(4R,7S,10S,13S,16S,19R)-19-[[2-[[2-[(2-aminoacetyl)amino]acetyl]amino]acetyl]amino]-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]-N-[(2S)-6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]pyrrolidine-2-carboxamide DMT9FH3 CA CAS 14636-12-5 DMT9FH3 CB CHEBI:135905 DMT9FH3 DE Hypertension DM2L3D5 ID DM2L3D5 DM2L3D5 DN Tertatolol DM2L3D5 HS Approved DM2L3D5 SN (-)-tertatolol; (+)-Tertatolol; GTPL64; ZINC748; PDSP2_001696; PDSP1_001713; 117305-34-7; UNII-9ZO341YQXP component HTWFXPCUFWKXOP-CYBMUJFWSA-N DM2L3D5 DT Small molecular drug DM2L3D5 PC 36920 DM2L3D5 MW 295.4 DM2L3D5 FM C16H25NO2S DM2L3D5 IC InChI=1S/C16H25NO2S/c1-16(2,3)17-10-13(18)11-19-14-8-4-6-12-7-5-9-20-15(12)14/h4,6,8,13,17-18H,5,7,9-11H2,1-3H3 DM2L3D5 CS CC(C)(C)NCC(COC1=CC=CC2=C1SCCC2)O DM2L3D5 IK HTWFXPCUFWKXOP-UHFFFAOYSA-N DM2L3D5 IU 1-(tert-butylamino)-3-(3,4-dihydro-2H-thiochromen-8-yloxy)propan-2-ol DM2L3D5 CA CAS 83688-84-0 DM2L3D5 CB CHEBI:135244 DM2L3D5 DE Hypertension DM9GP85 ID DM9GP85 DM9GP85 DN Tesamorelin DM9GP85 HS Approved DM9GP85 SN Egrifta (TN) DM9GP85 CP Theratechnologies DM9GP85 DT Small molecular drug DM9GP85 PC 16137828 DM9GP85 MW 5136 DM9GP85 FM C221H366N72O67S DM9GP85 IC InChI=1S/C221H366N72O67S/c1-25-28-30-53-163(308)260-145(92-120-54-58-122(299)59-55-120)198(343)255-116(21)179(324)276-150(96-169(316)317)199(344)256-117(22)180(325)291-172(111(16)26-2)214(359)284-147(91-119-43-31-29-32-44-119)206(351)293-174(118(23)298)215(360)285-149(95-162(230)307)205(350)289-155(104-297)210(355)280-146(93-121-56-60-123(300)61-57-121)203(348)267-130(51-41-83-248-220(240)241)186(331)266-126(46-34-36-78-223)197(342)290-171(110(14)15)212(357)283-141(87-106(6)7)183(328)252-100-166(311)258-133(63-70-157(225)302)190(335)278-144(90-109(12)13)202(347)288-152(101-294)208(353)257-115(20)178(323)262-128(49-39-81-246-218(236)237)185(330)265-125(45-33-35-77-222)189(334)277-143(89-108(10)11)201(346)279-142(88-107(8)9)200(345)272-137(66-73-160(228)305)195(340)282-151(97-170(318)319)207(352)292-173(112(17)27-3)213(358)274-139(76-85-361-24)196(341)287-153(102-295)209(354)268-131(52-42-84-249-221(242)243)187(332)270-135(64-71-158(226)303)192(337)269-132(62-69-156(224)301)182(327)251-99-165(310)259-134(67-74-167(312)313)191(336)286-154(103-296)211(356)281-148(94-161(229)306)204(349)273-136(65-72-159(227)304)193(338)271-138(68-75-168(314)315)194(339)264-124(47-37-79-244-216(232)233)181(326)250-98-164(309)253-113(18)176(321)261-127(48-38-80-245-217(234)235)184(329)254-114(19)177(322)263-129(50-40-82-247-219(238)239)188(333)275-140(175(231)320)86-105(4)5/h28-32,43-44,54-61,105-118,124-155,171-174,294-300H,25-27,33-42,45-53,62-104,222-223H2,1-24H3,(H2,224,301)(H2,225,302)(H2,226,303)(H2,227,304)(H2,228,305)(H2,229,306)(H2,230,307)(H2,231,320)(H,250,326)(H,251,327)(H,252,328)(H,253,309)(H,254,329)(H,255,343)(H,256,344)(H,257,353)(H,258,311)(H,259,310)(H,260,308)(H,261,321)(H,262,323)(H,263,322)(H,264,339)(H,265,330)(H,266,331)(H,267,348)(H,268,354)(H,269,337)(H,270,332)(H,271,338)(H,272,345)(H,273,349)(H,274,358)(H,275,333)(H,276,324)(H,277,334)(H,278,335)(H,279,346)(H,280,355)(H,281,356)(H,282,340)(H,283,357)(H,284,359)(H,285,360)(H,286,336)(H,287,341)(H,288,347)(H,289,350)(H,290,342)(H,291,325)(H,292,352)(H,293,351)(H,312,313)(H,314,315)(H,316,317)(H,318,319)(H4,232,233,244)(H4,234,235,245)(H4,236,237,246)(H4,238,239,247)(H4,240,241,248)(H4,242,243,249)/b30-28+/t111-,112-,113-,114-,115-,116-,117-,118+,124-,125-,126-,127-,128-,129-,130-,131-,132-,133-,134-,135-,136-,137-,138-,139-,140-,141-,142-,143-,144-,145-,146-,147-,148-,149-,150-,151-,152-,153-,154-,155-,171-,172-,173-,174-/m0/s1 DM9GP85 CS CC/C=C/CC(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(=O)N DM9GP85 IK QBEPNUQJQWDYKU-BMGKTWPMSA-N DM9GP85 IU (4S)-4-[[2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-3-carboxy-2-[[(2S)-2-[[(2S)-2-[[(E)-hex-3-enoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]propanoyl]amino]propanoyl]amino]-3-methylpentanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-4-oxobutanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]hexanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-5-oxopentanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]-5-carbamimidamidopentanoyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-5-oxopentanoyl]amino]-3-carboxypropanoyl]amino]-3-methylpentanoyl]amino]-4-methylsulfanylbutanoyl]amino]-3-hydroxypropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]acetyl]amino]-5-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-5-oxopentanoic acid DM9GP85 CA CAS 804475-66-9 DM9GP85 DE HIV-associated lipodystrophy DMVY4GN ID DMVY4GN DMVY4GN DN Testolactone DMVY4GN HS Approved DMVY4GN SN Fludestrin; Teolit; Teslac; Teslak; Testolacton; Testolactona; Testolactonum; Testolattone; Bristol Myers SquibbBrand of Testolactone; Testolattone [DCIT]; SQ 9538; Bristol-Myers Squibb Brand of Testolactone; DELTA1-Dehydrotestolactone; DELTA1-Dehydrotestololactone; DELTA1-Testololactone; SQ-9538; TESLAC (TN);Teslac (TN); Testolactona [INN-Spanish]; Testolactone [USAN:INN]; Testolactonum [INN-Latin]; Delta(1)-Dehydrotestolactone; Delta(1)-Testolactone; Delta(1)-Testololactone; Delta(1)-testololactone; Delta-1-testololactone; Testolactone (USP/INN); D-Homo-17A-oxaandrosta-1,4-diene-3,17-dione; D-homo-17a-oxaandrosta-1,4-diene-3,17-dione; (4aS,4bR,10aR,10bS,12aS)-10a,12a-dimethyl-3,4,4a,5,6,10a,10b,11,12,12a-decahydro-2H-naphtho[2,1-f]chromene-2,8(4bH)-dione; (4aS,4bR,10aR,10bS,12aS)-10a,12a-dimethyl-4,4a,4b,5,6,10b,11,12-octahydro-3H-naphtho[2,1-f]chromene-2,8-dione; 1 Dehydrotestolactone; 1,2,3,4,4a,4b,7,9,10,10a-Decahydro-2-hydroxy-2,4b-dimethyl-7-oxo-1-phenanthrenepropionic acid delta-lactone; 1,2-Dehydrotestololactone; 1,2-Didehydrotestololactone; 1,2-didehydrotestololactone; 1-Dehydrotestolactone; 1-Dehydrotestololactone; 1-dehydrotestololactone; 13,17-Secoandrosta-1,4-dien-17-oic acid, 13-hydroxy-3-oxo-, .delta.-lactone; 13,17-Secoandrosta-1,4-dien-17-oic acid, 13-hydroxy-3-oxo-, delta-lactone; 13,17-Secoandrosta-1,4-dien-17-oic acid, 13-hydroxy-3-oxo-, delta-lactone (8CI); 13,17-Secoandrosta-1,4-dien-17-oic acid, 13-hydroxy-3-oxo-, lactone; 13,17-Secoandrosta-1,4-dien-17-oic acid, 13.alpha.-hydroxy-3-oxo-, .delta.-lactone; 13-Hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oic acid .delta.-lactone; 13-Hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oic acid delta-lactone; 13-hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oic acid delta-lactone; 17a-Oxa-D-homoandrosta-1,4-diene-3,17-dione; 17alpha-Oxo-D-homo-1,4-androstadiene-3,17-dione; 2H-Phenanthro[2,1-b]pyran-2,8(4bH)-dione, 3,4,4a,5,6,10a,10b,11,12,12a-decahydro-10a,12a-dimethyl-, lactone; 3-oxo-13,17-secoandrosta-1,4-dieno-17,13alpha-lactone DMVY4GN TC Anticancer Agents DMVY4GN DT Small molecular drug DMVY4GN PC 13769 DMVY4GN MW 300.4 DMVY4GN FM C19H24O3 DMVY4GN IC InChI=1S/C19H24O3/c1-18-9-7-13(20)11-12(18)3-4-14-15(18)8-10-19(2)16(14)5-6-17(21)22-19/h7,9,11,14-16H,3-6,8,10H2,1-2H3/t14-,15+,16+,18+,19+/m1/s1 DMVY4GN CS C[C@]12CC[C@H]3[C@H]([C@@H]1CCC(=O)O2)CCC4=CC(=O)C=C[C@]34C DMVY4GN IK BPEWUONYVDABNZ-DZBHQSCQSA-N DMVY4GN IU (4aS,4bR,10aR,10bS,12aS)-10a,12a-dimethyl-4,4a,4b,5,6,10b,11,12-octahydro-3H-naphtho[2,1-f]chromene-2,8-dione DMVY4GN CA CAS 968-93-4 DMVY4GN CB CHEBI:9460 DMVY4GN DE Breast cancer DM7HUNW ID DM7HUNW DM7HUNW DN Testosterone DM7HUNW HS Approved DM7HUNW SN AndroGel; Androderm; Androlin; Andronaq; Andropatch; Androsorb; Andrusol; Depotest; Halotensin; Homosteron; Homosterone; Intrinsa; LibiGel; Malerone; Mertestate; Neotestis; Oreton; Orquisteron; Perandren; Primotest; Primoteston; Relibra; Striant; Sustanon; Sustanone; Teslen; Testandrone; Testaqua; Testiculosterone; Testim; Testobase; Testoderm; Testogel; Testolin; Testopropon; Testosteroid; Testosteron; Testosterona; Testosteronum; Testostosterone; Testoviron; Testrone; Testryl; Virormone; Virosterone; Beta testosterone; Cristerona T; Cristerone T; Malogen in Oil; Oreton F; Percutacrine androgenique; Synandrol F; Testoderm Tts; Testopel Pellets; Testosterone and its esters; Testosterone hydrate; Testosterone solution; Testoviron Schering; Testoviron T; Testro AQ; Virilon IM; AA 2500; Andro 100; Andronate 100; Andronate 200; Andropository 200; Andryl 200; CDB 111C; CMC_13449; COL 1621; CP 601B; Everone 200; Sustason 250; Testamone 100; Testred Cypionate 200; Androderm (TN); Androgel (TN); Geno-cristaux gremy; Malestrone (amps); Malogen, aquaspension injection; Neo-Hombreol F; Neo-testis; Oreton-F; Scheinpharm Testone-Cyp; Striant (TN); T-Cypionate; Testim (TN); Testoject-50; Testosterona [INN-Spanish]; Testosterone [Androgenic steroids, anabolic]; Testosterone [INN:BAN]; Testosteronum [INN-Latin]; Trans-Testosterone; Testosterone (JAN/USP); Testrin-P.A; Delta4-Androsten-17beta-ol-3-one; Delta4-androsten-17b-ol-3-one; Androst-4-en-17beta-ol-3-one; Delta(sup 4)-Androsten-17(beta)-ol-3-one; (17beta)-17-Hydroxyandrost-4-en-3-one; (8R,9S,10R,13S,14S,17S)-17-hydroxy-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one; 17-Hydroxy-(17-beta)-androst-4-en-3-one; 17-Hydroxy-(17beta)-androst-4-en-3-one; 17-Hydroxy-4-androsten-3-one; 17-beta-Hydroxy-delta(sup 4)-androsten-3-one; 17-beta-Hydroxyandrost-4-en-3-one; 17b-hydroxy-4-androsten-3-one; 17beta-Hydroxy-3-oxo-4-androstene; 17beta-Hydroxy-4-androsten-3-one; 17beta-Hydroxy-delta(sup4)-androsten-3-one; 17beta-Hydroxyandrost-4-en-3-one; 17beta-Hydroxyandrost-4-ene-3-one; 4-Androsten-17-ol-3-one; 4-Androsten-17beta-ol-3-one; 4-androstene-17beta-ol-3-one; 7-beta-Hydroxyandrost-4-en-3-one DM7HUNW CP Ardana Bioscience DM7HUNW DT Small molecular drug DM7HUNW PC 6013 DM7HUNW MW 288.4 DM7HUNW FM C19H28O2 DM7HUNW IC InChI=1S/C19H28O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h11,14-17,21H,3-10H2,1-2H3/t14-,15-,16-,17-,18-,19-/m0/s1 DM7HUNW CS C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CCC4=CC(=O)CC[C@]34C DM7HUNW IK MUMGGOZAMZWBJJ-DYKIIFRCSA-N DM7HUNW IU (8R,9S,10R,13S,14S,17S)-17-hydroxy-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one DM7HUNW CA CAS 58-22-0 DM7HUNW CB CHEBI:17347 DM7HUNW DE Osteoporosis; Male hormonal deficiency; Hormone deficiency DMC1TEV ID DMC1TEV DMC1TEV DN Testosterone cypionate DMC1TEV HS Approved DMC1TEV SN Testodrin prolongatum; Testosterone 17beta-cyclopentylpropionate; Testosterone 17beta-cypionate; Testosterone cyclopentanepropionate; Testosterone cyclopentylpropionate; Testosterone cypionate [USP]; Testandrone; Testiculosterone; Testim; Testobase; Testoderm; Testogel; Testopropon; Testosteroid; Testosteron; Testosterona; Testosteronum; Testostosterone; Testoviron; Testoviron Schering; Testoviron T; Testrone; Testryl; Virormone; Virosterone; testosterone; trans-Testosterone; 58-22-0; AndroGel; Androderm; Androlin; Andronaq; Andropatch; Andrusol; Cristerona T; Cristerone T; Homosteron; Homosterone; LibiGel; Malerone; Mertestate; Neotestis; Oreton; Orquisteron; Perandren; Primotest; Primoteston; Relibra; Sustanon; Sustanone; Synandrol F; Teslen; UNII-M0XW1UBI14; depAndro 100; depAndro 200; 58-20-8; Andro-Cyp; Androst-4-en-3-one, 17-(3-cyclopentyl-1-oxopropoxy)-, (17b)-; CHEBI:9463; DEPO; Dep-Test; Depo-Testadiol; Depo-Testosterone; Depotest; Depovirin; Durandro; Jectatest; M0XW1UBI14; Malogen CYP; NSC 9157; Pertestis; T-Ionate-P.A; TESTOSTERONE CYPIONATE DMC1TEV PC 441404 DMC1TEV MW 412.6 DMC1TEV FM C27H40O3 DMC1TEV IC HPFVBGJFAYZEBE-ZLQWOROUSA-N DMC1TEV CS CC12CCC3C(C1CCC2OC(=O)CCC4CCCC4)CCC5=CC(=O)CCC35C DMC1TEV IK 1S/C27H40O3/c1-26-15-13-20(28)17-19(26)8-9-21-22-10-11-24(27(22,2)16-14-23(21)26)30-25(29)12-7-18-5-3-4-6-18/h17-18,21-24H,3-16H2,1-2H3/t21-,22-,23-,24-,26-,27-/m0/s1 DMC1TEV IU [(8R,9S,10R,13S,14S,17S)-10,13-dimethyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl] 3-cyclopentylpropanoate DMC1TEV CA CAS 58-20-8 DMC1TEV CB CHEBI:9463 DMC1TEV DE Testosterone deficiency DMB6871 ID DMB6871 DMB6871 DN Testosterone enanthate DMB6871 HS Approved DMB6871 SN Testanthate; Testate; Testenate; Testinon; Testoenant; Testonenant; Testosterone 17-enanthate; Testosterone enantate; Testosterone heptanoate; Testosterone heptoate; Testosterone heptylate; Testosterone oenanthate; Testostroval; testosterone enanthate; 17-Hydroxyandrost-4-en-3-one, 17-heptanoate; 315-37-7; Andro L.A. 200; Andropository; Androtardyl; Atlatest; DePatestrye; Delatest; Depo-Testro Med; Ditate; Durathate; Everone; Exten test; Malogen L.A.; Malogen L.A.200; NSC-17591; Orquisteron-E; Primotestone; Reposo TMD; Reposo-TMD DMB6871 PC 9416 DMB6871 MW 400.6 DMB6871 FM C26H40O3 DMB6871 IC VOCBWIIFXDYGNZ-IXKNJLPQSA-N DMB6871 CS CCCCCCC(=O)OC1CCC2C1(CCC3C2CCC4=CC(=O)CCC34C)C DMB6871 IK 1S/C26H40O3/c1-4-5-6-7-8-24(28)29-23-12-11-21-20-10-9-18-17-19(27)13-15-25(18,2)22(20)14-16-26(21,23)3/h17,20-23H,4-16H2,1-3H3/t20-,21-,22-,23-,25-,26-/m0/s1 DMB6871 IU [(8R,9S,10R,13S,14S,17S)-10,13-dimethyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl] heptanoate DMB6871 CA CAS 315-37-7 DMB6871 CB CHEBI:9464 DMB6871 DE Testosterone deficiency DMZO10Y ID DMZO10Y DMZO10Y DN Testosterone Undecanoate DMZO10Y HS Approved DMZO10Y SN Restandol (TN) DMZO10Y CP Organon Greece DMZO10Y DT Small molecular drug DMZO10Y PC 65157 DMZO10Y MW 456.7 DMZO10Y FM C30H48O3 DMZO10Y IC InChI=1S/C30H48O3/c1-4-5-6-7-8-9-10-11-12-28(32)33-27-16-15-25-24-14-13-22-21-23(31)17-19-29(22,2)26(24)18-20-30(25,27)3/h21,24-27H,4-20H2,1-3H3/t24-,25-,26-,27-,29-,30-/m0/s1 DMZO10Y CS CCCCCCCCCCC(=O)O[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C DMZO10Y IK UDSFVOAUHKGBEK-CNQKSJKFSA-N DMZO10Y IU [(8R,9S,10R,13S,14S,17S)-10,13-dimethyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl] undecanoate DMZO10Y CA CAS 5949-44-0 DMZO10Y CB CHEBI:135741 DMZO10Y DE Hypogonadism DMYWQ0O ID DMYWQ0O DMYWQ0O DN Tetrabenazine DMYWQ0O HS Approved DMYWQ0O SN Nitoman; Rubigen; Tetrabenazina; Tetrabenazinum; Tetrabenzaine; Tetrabenzine; Xenazine; Tetra Benazin; Nitoman (TN); Ro 1-9569; Tetrabenazina [INN-Spanish]; Tetrabenazine (INN); Tetrabenazine [INN:BAN]; Tetrabenazinum [INN-Latin]; Xenazine (TN); Nitoman, Xenazine, Tetrabenazine; Ro 1-9569/12; 1,3,4,6,7,11b-Hexahydro-3-isobutyl-9,10-dimethoxy-2H-benzo(a)quinolizin-2-one; 1,3,4,6,7,11b-Hexahydro-3-isobutyl-9,10-dimethoxy-2H-benzo[a]quinolizin-2-one; 1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-2H-Benzo[a]quinolizin-2-one; 2-Oxo-3-isobutyl-9,10-dimethoxy-1,2,3,4,6,7-hexahydro-11bH-benzo[a]quinolizine; 2-Oxo-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11-beta-hexahydro-2H-benzoquinolizine; 2-Oxo-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11.beta.-hexahydro-2H-benzoquinolizine; 2H-Benzo(a)quinolizin-2-one, 1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-(9CI); 9,10-dimethoxy-3-(2-methylpropyl)-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-one; 9,10-dimethoxy-3-(2-methylpropyl)-1,3,4,6,7,11b-hexahydrobenzo[a]quinolizin-2-one DMYWQ0O TC Nephropathic cystinosis therapy DMYWQ0O DT Small molecular drug DMYWQ0O PC 6018 DMYWQ0O MW 317.4 DMYWQ0O FM C19H27NO3 DMYWQ0O IC InChI=1S/C19H27NO3/c1-12(2)7-14-11-20-6-5-13-8-18(22-3)19(23-4)9-15(13)16(20)10-17(14)21/h8-9,12,14,16H,5-7,10-11H2,1-4H3 DMYWQ0O CS CC(C)CC1CN2CCC3=CC(=C(C=C3C2CC1=O)OC)OC DMYWQ0O IK MKJIEFSOBYUXJB-UHFFFAOYSA-N DMYWQ0O IU 9,10-dimethoxy-3-(2-methylpropyl)-1,3,4,6,7,11b-hexahydrobenzo[a]quinolizin-2-one DMYWQ0O CA CAS 718635-93-9 DMYWQ0O CB CHEBI:64028 DMYWQ0O DE Hyperkinetic movement disorder; Huntington disease DM9J6C2 ID DM9J6C2 DM9J6C2 DN Tetracaine DM9J6C2 HS Approved DM9J6C2 SN Amethocaine; Anetain; Contralgin; Dicain; Dicaine; Dikain; Fissucain; Intercain; Laudocaine; Medicaine; Meethobalm; Metraspray; Mucaesthin; Niphanoid; Pontocaine; Rexocaine; Tetracaina; Tetracainum; Tetrakain; Uromucaesthin; Tetrakain [Czech]; Amethocaine (TN); Diaethylaminoaethanol ester der p-butylaminobenzoesaeure;Diaethylaminoaethanol ester der p-butylaminobenzoesaeure [German]; Medihaler-Tetracaine; Pontocaine (TN); Tetracaina [INN-Spanish]; Tetracaine [USAN:INN]; Tetracainum [INN-Latin]; Dimethylaminoethyl p-butyl-aminobenzoate; Tetracaine (USP/INN); P-Butylaminobenzoyl-2-dimethylaminoethanol; BENZOIC ACID,4-BUTYLAMINO,2-DIMETHYLAMINOETHYL ESTER PANTOCAIN BASE; P-(Butylamino)benzoic acid, 2-(dimethylamino)ethyl ester; BENZOIC ACID, p-(BUTYLAMINO)-, 2-(DIMETHYLAMINO)ETHYL ESTER; Benzoic acid, 4-(butylamino)-, 2-(dimethylamino)ethyl ester; 2-(Dimethylamino)ethyl 4-(butylamino)benzoate; 2-(Dimethylamino)ethyl p-(butylamino)benzoate; 2-Dimethylaminoethylester kyseliny p-butylaminobenzoove; 2-Dimethylaminoethylester kyseliny p-butylaminobenzoove [Czech]; 2-dimethylaminoethyl 4-(butylamino)benzoate; 4-(Butylamino)benzoic acid 2-(dimethylamino)ethyl ester; 4-[Butylamino]benzoic acid-2-[dimethylamino]ethyl ester DM9J6C2 TC Anesthetics DM9J6C2 DT Small molecular drug DM9J6C2 PC 5411 DM9J6C2 MW 264.36 DM9J6C2 FM C15H24N2O2 DM9J6C2 IC InChI=1S/C15H24N2O2/c1-4-5-10-16-14-8-6-13(7-9-14)15(18)19-12-11-17(2)3/h6-9,16H,4-5,10-12H2,1-3H3 DM9J6C2 CS CCCCNC1=CC=C(C=C1)C(=O)OCCN(C)C DM9J6C2 IK GKCBAIGFKIBETG-UHFFFAOYSA-N DM9J6C2 IU 2-(dimethylamino)ethyl 4-(butylamino)benzoate DM9J6C2 CA CAS 94-24-6 DM9J6C2 CB CHEBI:9468 DM9J6C2 DE Spinal anesthesia; Pain DMZA017 ID DMZA017 DMZA017 DN Tetracycline DMZA017 HS Approved DMZA017 SN Amycin; Biocycline; Bristaciclin; Bristaciclina; Bristacycline; Ciclibion; Copharlan; Cyclomycin; Cytome; Dumocyclin; Enterocycline; Medocycline; Resteclin; Robitet; Sanclomycine; Tetrachel; Veracin; Bristaciclin alpha; Cefracycline suspension; Component of Tetrastatin; Sumycin syrup; Tetracycline Free Base; Tetracycline I; Tetracycline II; Tetracycline Monohydrochloride; Achromycin (naphthacene derivative); Achromycin, naphthacene derivative; Centet (base); Lemtrex (base); Liquamycin (Veterinary); Liquamycin, veterinary; Panmycin (TN); Piracaps (base); Polycycline (VAN); Polycycline (antibiotic); Polycycline, antibiotic; SK-Tetracycline; Sumycin (TN); T-125; Tetra-Co; Tetraciclina [INN-Spanish]; Tetracycline & VRC3375; Tetracycline (internal use); Tetracyclinum [INN-Latin]; Tetracyn (TN); Vetquamycin-324 (free base); Tetracycline (JAN/USP/INN); Tetracycline [USAN:INN:BAN:JAN]; Methyl-1,11-dioxo-2-naphthacenecarboxamide; 6-Methyl-1,11-dioxy-2-naphthacenecarboxamide DMZA017 CP Pfizer Inc DMZA017 TC Antibiotics DMZA017 DT Small molecular drug DMZA017 PC 54675776 DMZA017 MW 444.4 DMZA017 FM C22H24N2O8 DMZA017 IC InChI=1S/C22H24N2O8/c1-21(31)8-5-4-6-11(25)12(8)16(26)13-9(21)7-10-15(24(2)3)17(27)14(20(23)30)19(29)22(10,32)18(13)28/h4-6,9-10,15,25-26,29,31-32H,7H2,1-3H3,(H2,23,30)/t9-,10-,15-,21+,22-/m0/s1 DMZA017 CS C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O DMZA017 IK NWXMGUDVXFXRIG-WESIUVDSSA-N DMZA017 IU (4S,4aS,5aS,6S,12aR)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide DMZA017 CA CAS 60-54-8 DMZA017 CB CHEBI:27902 DMZA017 DE Bacterial infection DMINZ4W ID DMINZ4W DMINZ4W DN Tetrahydrobiopterin DMINZ4W HS Approved DMINZ4W SN tetrahydrobiopterin; 17528-72-2; 5,6,7,8-tetrahydrobiopterin; BRN 0544742; CHEBI:15372; 5,6,7,8-Tetrahydro-2-amino-6-(1,2-dihydroxypropyl)-4(1H)-pteridinone; L-erythro-2-Amino-6-(1,2-dihydroxypropyl)-5,6,7,8-tetrahydro-4(3H)-pteridinon; (1R,2S)-(2-Amino-3,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)-1,2-propandiol; 5,6,7,8-erythro-tetrahydrobiopterin; 2-amino-6-(1,2-dihydroxypropyl)-5,6,7,8-tetrahydropteridin-4(3H)-one; Dapropterin; Phenoptin DMINZ4W TC Dietary supplement DMINZ4W DT Small molecular drug DMINZ4W PC 135402045 DMINZ4W MW 241.25 DMINZ4W FM C9H15N5O3 DMINZ4W IC InChI=1S/C9H15N5O3/c1-3(15)6(16)4-2-11-7-5(12-4)8(17)14-9(10)13-7/h3-4,6,12,15-16H,2H2,1H3,(H4,10,11,13,14,17) DMINZ4W CS CC(C(C1CNC2=C(N1)C(=O)NC(=N2)N)O)O DMINZ4W IK FNKQXYHWGSIFBK-UHFFFAOYSA-N DMINZ4W IU 2-amino-6-(1,2-dihydroxypropyl)-5,6,7,8-tetrahydro-3H-pteridin-4-one DMINZ4W CA CAS 17528-72-2 DMINZ4W CB CHEBI:15372 DMINZ4W DE Malnutrition DMH15UV ID DMH15UV DMH15UV DN Tetrahydrofolic acid DMH15UV HS Approved DMH15UV SN Tetrahydrafolate; Tetrahydrofolate; Tetrahydropteroylglutamate; Tetrahydropteroylglutamic acid; BIT3012; FH4; H4PteGlu; Folate-H4; Th-folate; Tetra-H-folate; Tetrahydropteroyl mono-L-glutamate; N-(5,6,7,8-tetrahydropteroyl)-L-glutamic acid; N-(4-(((2-Amino-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)glutamic acid; N-[4-{[(2-amino-4-oxo-3,4,5,6,7,8-hexahydropteridin-6-yl)methyl]amino}benzoyl]-L-glutamic acid; N-(4-(((2-Amino-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid; N-[4-({[(6S)-2-AMINO-4-OXO-1,4,5,6,7,8-HEXAHYDROPTERIDIN-6-YL]METHYL}AMINO)BENZOYL]-L-GLUTAMIC ACID; N-[4-({[(6S)-2-amino-4-oxo-3,4,5,6,7,8-hexahydropteridin-6-yl]methyl}amino)benzoyl]-L-glutamic acid; (2S)-2-[[4-[(2-amino-4-oxo-5,6,7,8-tetrahydro-1H-pteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid; (2S)-2-[[4-[[(6S)-2-amino-4-oxo-5,6,7,8-tetrahydro-1H-pteridin-6-yl]methylamino]benzoyl]amino]pentanedioic acid; (6S)-5,6,7,8-tetrahydropteroylglutamate; (6S)-H4folate; (6S)-THFA; (6S)-Tetrahydrofolic acid; (6S)-tetrahydrofolate; 2-[[4-[(2-amino-4-oxo-5,6,7,8-tetrahydro-1H-pteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid; 5,6,7,8-Tetrahydropteroyl-L-glutamic acid; 5,6,7,8-tetrahydrofolate; 5,6,7,8-tetrahydrofolic acid DMH15UV TC Dietary supplement DMH15UV DT Small molecular drug DMH15UV PC 135444742 DMH15UV MW 445.4 DMH15UV FM C19H23N7O6 DMH15UV IC InChI=1S/C19H23N7O6/c20-19-25-15-14(17(30)26-19)23-11(8-22-15)7-21-10-3-1-9(2-4-10)16(29)24-12(18(31)32)5-6-13(27)28/h1-4,11-12,21,23H,5-8H2,(H,24,29)(H,27,28)(H,31,32)(H4,20,22,25,26,30)/t11?,12-/m0/s1 DMH15UV CS C1C(NC2=C(N1)N=C(NC2=O)N)CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O DMH15UV IK MSTNYGQPCMXVAQ-KIYNQFGBSA-N DMH15UV IU (2S)-2-[[4-[(2-amino-4-oxo-5,6,7,8-tetrahydro-3H-pteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid DMH15UV CA CAS 135-16-0 DMH15UV CB CHEBI:20506 DMH15UV DE Malnutrition DMT57WC ID DMT57WC DMT57WC DN Tetrahydrozoline DMT57WC HS Approved DMT57WC SN Tyzine DMT57WC CP Fougera Pharmaceuticals Inc DMT57WC DT Small molecular drug DMT57WC PC 5419 DMT57WC MW 200.28 DMT57WC FM C13H16N2 DMT57WC IC InChI=1S/C13H16N2/c1-2-6-11-10(4-1)5-3-7-12(11)13-14-8-9-15-13/h1-2,4,6,12H,3,5,7-9H2,(H,14,15) DMT57WC CS C1CC(C2=CC=CC=C2C1)C3=NCCN3 DMT57WC IK BYJAVTDNIXVSPW-UHFFFAOYSA-N DMT57WC IU 2-(1,2,3,4-tetrahydronaphthalen-1-yl)-4,5-dihydro-1H-imidazole DMT57WC CA CAS 84-22-0 DMT57WC CB CHEBI:28674 DMT57WC DE Ocular disease DMWMPRG ID DMWMPRG DMWMPRG DN Tetrodotoxin DMWMPRG HS Approved DMWMPRG SN Maculotoxin; Spheroidine; TTX; Tarichatoxin; Tetradotoxin; Tetrodontoxin; Tetrodotoxine; Tetrodoxin; Fugu Toxin; Fugu poison; BJT 1; Babylonia japonica toxin 1; Octahydro-12-(hydroxymethyl)-2-imino-5,9:7,10adimethano-10aH-(1,3)dioxocino(6,5-d)pyrimidine-4,7,10,11,12-pentol; Octahydro-12-(hydroxymethyl)-2-imino-5,9:7,10a-dimethano-10aH-(1,3)dioxocino(6,5-d)pyrimidine-4,7,10,11,12-pentol; (1R,5R,6R,7R,9S,11R,12R,13S,14S)-14-(hydroxymethyl)-3-imino-8,10-dioxa-2,4-diazatetracyclo[7.3.1.1(7,11).0(1,6)]tetradecane-5,9,12,13,14-pentol; (1r,5r,6r,9r,11s,13s,14s)-3-amino-14-(hydroxymethyl)-8,10-dioxa-2,4-diazatetracyclo[7.3.1.17,11.01,6]tetradec-3-ene-5,9,12,13,14-pentol(non-preferred name); (4R-(4alpha,4aalpha,5alpha,7alpha,9alpha,10alpha,10abeta,11S*,12S*))-Octahydro-12-(hydroxymethyl)-2-imino-5,9:7,10a-dimethano-10aH-(1,3)dioxocino(6,5-d) pyrimidine-4,7,10,11,12-pentol DMWMPRG TC Antibiotics DMWMPRG DT Small molecular drug DMWMPRG PC 11174599 DMWMPRG MW 319.27 DMWMPRG FM C11H17N3O8 DMWMPRG IC InChI=1S/C11H17N3O8/c12-8-13-6(17)2-4-9(19,1-15)5-3(16)10(2,14-8)7(18)11(20,21-4)22-5/h2-7,15-20H,1H2,(H3,12,13,14)/t2-,3-,4-,5+,6-,7+,9+,10-,11+/m1/s1 DMWMPRG CS C([C@@]1([C@H]2[C@@H]3[C@H](N=C(N[C@@]34[C@@H]([C@@H]1O[C@]([C@H]4O)(O2)O)O)N)O)O)O DMWMPRG IK CFMYXEVWODSLAX-QOZOJKKESA-N DMWMPRG IU (1R,5R,6R,7R,9S,11S,12S,13S,14S)-3-amino-14-(hydroxymethyl)-8,10-dioxa-2,4-diazatetracyclo[7.3.1.17,11.01,6]tetradec-3-ene-5,9,12,13,14-pentol DMWMPRG CA CAS 4368-28-9 DMWMPRG DE Bacterial infection DMY62FC ID DMY62FC DMY62FC DN Tezacaftor And Ivacaftor DMY62FC HS Approved DMY62FC SN Ivacaftor / Tezacaftor; Tezacaftor / Ivacaftor; Ivacaftor and Tezacaftor; Ivacaftor regimen with Tezacaftor DMY62FC CP Vertex Pharmaceuticals DMY62FC PC 72722243 DMY62FC MW 913 DMY62FC FM C50H55F3N4O9 DMY62FC IC InChI=1S/C26H27F3N2O6.C24H28N2O3/c1-24(2,13-33)22-8-14-7-18(17(27)10-19(14)31(22)11-16(34)12-32)30-23(35)25(5-6-25)15-3-4-20-21(9-15)37-26(28,29)36-20;1-23(2,3)16-11-17(24(4,5)6)20(27)12-19(16)26-22(29)15-13-25-18-10-8-7-9-14(18)21(15)28/h3-4,7-10,16,32-34H,5-6,11-13H2,1-2H3,(H,30,35);7-13,27H,1-6H3,(H,25,28)(H,26,29)/t16-;/m1./s1 DMY62FC CS CC(C)(C)C1=CC(=C(C=C1NC(=O)C2=CNC3=CC=CC=C3C2=O)O)C(C)(C)C.CC(C)(CO)C1=CC2=CC(=C(C=C2N1C[C@H](CO)O)F)NC(=O)C3(CC3)C4=CC5=C(C=C4)OC(O5)(F)F DMY62FC IK NETGOEWJJZQLCO-PKLMIRHRSA-N DMY62FC IU N-(2,4-ditert-butyl-5-hydroxyphenyl)-4-oxo-1H-quinoline-3-carboxamide;1-(2,2-difluoro-1,3-benzodioxol-5-yl)-N-[1-[(2R)-2,3-dihydroxypropyl]-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)indol-5-yl]cyclopropane-1-carboxamide DMY62FC CA CAS 1969264-35-4 DMY62FC DE Acute lung injury DM70BU5 ID DM70BU5 DM70BU5 DN Thalidomide DM70BU5 HS Approved DM70BU5 SN Algosediv; Asmadion; Asmaval; Bonbrain; Bonbrrin; Calmore; Calmorex; Contergan; Corronarobetin; Distaval; Distaxal; Distoval; Ectiluran; Enterosediv; Gastrinide; Glupan; Glutanon; Grippex; Hippuzon; Imidene; Isomin; Kedavon; Kevadon; Neaufatin; Neosedyn; Neosydyn; Nerosedyn; Neufatin; Neurodyn; Neurosedin; Neurosedym; Neurosedyn; Nevrodyn; Nibrol; Noctosediv; Noxodyn; Pangul; Pantosediv; Polygripan; Profarmil; Psycholiquid; Psychotablets; Quetimid; Quietoplex; Sandormin; Sedalis; Sedimide; Sedin; Sedisperil; Sedoval; Shinnibrol; Sleepan; Slipro; Softenil; Softenon; Synovir; Talargan; Talidomida; Talidomide; Talimol; Talismol; Talizer; Telagan; Telargan; Telargean; Tensival; Thaled; Thalidomidum; Thalin; Thalinette; Thalomid; Thalomide; Theophilcholine; Valgis; Valgraine; Yodomin; Celgene Brand of Thalidomide; Talidomide [DCIT]; Thalidomide Celgene; Thalidomide Pharmion; Asidon 3; ENMD 0995; IN1061; Thalidomine USP26; Alpha-Phthalimidoglutarimide; E-217; Imida-lab; Imidan (peyta); N-Phthalimidoglutamic acid imide; N-Phthaloylglutamimide; N-Phthalylglutamic acid imide; Poly-Giron; Predni-Sediv; Pro-Bam M; Pro-ban M; Sedalis sedi-lab; Shin-naito S; THALIDOMIDE (AIDS INITIATIVE); Talidomida [INN-Spanish]; Thaled (TN); Thalidomide (soluble form); Thalidomidum [INN-Latin]; Thalomid (TM); Thalomid (TN); Thalomid, Thalidomide; Alpha-N-Phthalylglutaramide; Thalidomide [USAN:INN:BAN]; Alpha-(N-Phthalimido)glutarimide; N-Phthalyl-glutaminsaeure-imid; N-Phthalyl-glutaminsaeure-imid [German]; Thalidomide (+ and-); Thalidomide (JAN/USP/INN); N-(2,6-Dioxo-3-piperidyl)phthalimide; (+)-Thalidomide; (+-)-Thalidomide; (+/-)-THALIDOMIDE; (inverted question mark)-Thalidomide; 2,6-Dioxo-3-phthalimidopiperidine; 3-Phthalimidoglutarimide DM70BU5 TC Immunosuppressive Agents DM70BU5 DT Small molecular drug DM70BU5 PC 5426 DM70BU5 MW 258.23 DM70BU5 FM C13H10N2O4 DM70BU5 IC InChI=1S/C13H10N2O4/c16-10-6-5-9(11(17)14-10)15-12(18)7-3-1-2-4-8(7)13(15)19/h1-4,9H,5-6H2,(H,14,16,17) DM70BU5 CS C1CC(=O)NC(=O)C1N2C(=O)C3=CC=CC=C3C2=O DM70BU5 IK UEJJHQNACJXSKW-UHFFFAOYSA-N DM70BU5 IU 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione DM70BU5 CA CAS 50-35-1 DM70BU5 CB CHEBI:74947 DM70BU5 DE Multiple myeloma DMM8D3F ID DMM8D3F DMM8D3F DN Theobromine DMM8D3F HS Approved DMM8D3F SN theobromine; 83-67-0; 3,7-Dimethylxanthine; Diurobromine; Teobromin; Theostene; Theosalvose; Santheose; Thesodate; Thesal; 3,7-dimethylpurine-2,6-dione; 3,7-Dimethyl-3,7-dihydro-1H-purine-2,6-dione; Theobromin; Xanthine, 3,7-dimethyl-; 3,7-Dihydro-3,7-dimethyl-1H-purine-2,6-dione; 1H-Purine-2,6-dione, 3,7-dihydro-3,7-dimethyl-; SC 15090; 2,6-Dihydroxy-3,7-dimethylpurine; Theobromine (natural); UNII-OBD445WZ5P; NSC 5039; 7-Dimethylxanthine; 2,6-Dihydroxy-3,7-dimethyl-purine; BRN 0016464; FEMA No. 3591; CCRIS 2350; HSDB 7332 DMM8D3F DT Small molecular drug DMM8D3F PC 5429 DMM8D3F MW 180.16 DMM8D3F FM C7H8N4O2 DMM8D3F IC InChI=1S/C7H8N4O2/c1-10-3-8-5-4(10)6(12)9-7(13)11(5)2/h3H,1-2H3,(H,9,12,13) DMM8D3F CS CN1C=NC2=C1C(=O)NC(=O)N2C DMM8D3F IK YAPQBXQYLJRXSA-UHFFFAOYSA-N DMM8D3F IU 3,7-dimethylpurine-2,6-dione DMM8D3F CA CAS 83-67-0 DMM8D3F CB CHEBI:28946 DMM8D3F DE Asthma DMRJFN9 ID DMRJFN9 DMRJFN9 DN Theophylline DMRJFN9 HS Approved DMRJFN9 SN Bronchoretard; Cetraphylline; Chronophyllin; Dimethylxanthine; Elixophylline; Liquophylline; Pseudotheophylline; Afonilum Retard; Bronchodid Duracap; Elixophyllin SR; Somophyllin CRT; Spophyllin retard; Telbans DrySyrup; Teofilina [Polish]; Theal tablets; Theobid Duracap; Theodur Dry Syrup; Uniphyllin continus; Elixophyllin (TN); Elixophyllin(e); Pulmo-Timelets; Somophyllin-CRT; Somophyllin-DF; Theo-Organidin; Theoclear-200; Theodur G (TN); Theolair (TN); Theophylline (JP15); Theophylline-SR; Quibron-t (TN); Theo-Dur-Sprinkle; Theophylline-[8-3H; Theoclear L.A.-130; 1,3 Dimethylxanthine; 1,3-Dimethylxanthine; 1H-purine-2,6-dione DMRJFN9 CP Purdue Pharma DMRJFN9 TC Bronchodilator Agents DMRJFN9 DT Small molecular drug DMRJFN9 PC 2153 DMRJFN9 MW 180.16 DMRJFN9 FM C7H8N4O2 DMRJFN9 IC InChI=1S/C7H8N4O2/c1-10-5-4(8-3-9-5)6(12)11(2)7(10)13/h3H,1-2H3,(H,8,9) DMRJFN9 CS CN1C2=C(C(=O)N(C1=O)C)NC=N2 DMRJFN9 IK ZFXYFBGIUFBOJW-UHFFFAOYSA-N DMRJFN9 IU 1,3-dimethyl-7H-purine-2,6-dione DMRJFN9 CA CAS 58-55-9 DMRJFN9 CB CHEBI:28177 DMRJFN9 DE Chronic obstructive pulmonary disease DM7YCK3 ID DM7YCK3 DM7YCK3 DN Thiabendazole DM7YCK3 HS Approved DM7YCK3 SN Biogard; Bioguard; Bovizole; Cropasal; Drawipas; Eprofil; Equizole; Hymush; Lombristop; Mertec; Mertect; Mintesol; Mintezol; Mintezole; Minzolum; Mycozol; Nemacin; Nemapan; Omnizole; Ormogal; Pitrizet; Polival; RPH; Sistesan; Storite; Tbdz; Tebuzate; Tecto; Testo; Thiaben; Thiabendazol; Thiabendazolum; Thiabendole; Thiabenzazole; Thiabenzole; Thibendole; Thibenzol; Thibenzole; Thiprazole; Tiabenda; Tiabendazol; Tiabendazole; Tiabendazolum; Tobaz; Tresaderm; Triasox; Tubazole; Captan T; Equivet TZ; Equizole A; Helmindrax octelmin; Hokustar HP; Mertect lsp; RTU Flowable Fungicide; Tecto B; Tecto rph; Thibenzole att; Top Form Wormer; Chemviron TK 100; G 491; MK 360; Mertect 160; Mertect 340f; Metasol TK 100; Metasol tk 10; PS1057_SUPELCO; Sanaizol 100; Syntol M100; TBZ 6; TBZ 60W; Tecto 10P; Tecto 40F; Tecto 60; Thibenzole 200; Tibimix 20; APL-luster; Arbotect (TN); MK-360; Metasol TK-100; Mintezol (TN); TBZ-6; Thiabendazole (USP); Thiabendazole [BSI:ISO]; Thiabendazole [USAN:BAN]; Tiabendazolum [INN-Latin]; Tresaderm (TN); E-Z-Ex; Mintezol, Equizole, Thiabendazole; Tiabendazol [INN-Spanish, French]; Tiabendazole (JAN/INN); 2-(1,3-Thiazol-4-yl)-1H-benzimidazole; 2-(1,3-Thiazol-4-yl)benzimidazole; 2-(1,3-thiazol-4-yl)-1H-1,3-benzodiazole; 2-(4'-Thiazolyl)benzimidazole; 2-(4-Thiazolyl)-1H-benzimidazole; 2-(4-Thiazolyl)benzimidazole; 2-(Thiazol-4-yl)benzimidazole; 2-Thiazol-4-yl-1H-benzoimidazole; 2-Thiazole-4-ylbenzimidazole; 2-[4-Thiazoly]benzimidazole; 4-(1H-benzimidazol-2-yl)-1,3-thiazole; 4-(2-Benzimidazolyl)thiazole DM7YCK3 TC Antinematodal Agents DM7YCK3 DT Small molecular drug DM7YCK3 PC 5430 DM7YCK3 MW 201.25 DM7YCK3 FM C10H7N3S DM7YCK3 IC InChI=1S/C10H7N3S/c1-2-4-8-7(3-1)12-10(13-8)9-5-14-6-11-9/h1-6H,(H,12,13) DM7YCK3 CS C1=CC=C2C(=C1)NC(=N2)C3=CSC=N3 DM7YCK3 IK WJCNZQLZVWNLKY-UHFFFAOYSA-N DM7YCK3 IU 4-(1H-benzimidazol-2-yl)-1,3-thiazole DM7YCK3 CA CAS 148-79-8 DM7YCK3 CB CHEBI:45979 DM7YCK3 DE Helminth infection; Dutch elm disease DMDRKH2 ID DMDRKH2 DMDRKH2 DN Thiamphenicol DMDRKH2 HS Approved DMDRKH2 SN thiamphenicol; 15318-45-3; Thiophenicol; Thiamcol; (+)-Thiamphenicol; Raceophenidol; Dextrosulphenidol; Thiamphenicolum; D-Thiocymetin; D-Thiophenicol; Thiocymetin (TN); Armai (TN); Thiocymetin; Tiamfenicolo [DCIT]; UNII-FLQ7571NPM; Tiamfenicol [INN-Spanish]; Thiamphenicol (Thiophenicol); Macphenicol; C12H15Cl2NO5S; Urfamycine; Igralin; Hyrazin; Dexawin; Rincrol; Neomyson; Urfamicina; Thiamphenicolum [INN-Latin]; Descocin; Masatirin; Efnicol; SW 5063; Unaseran-D; Thiamphenicol [USAN:INN:BAN:JAN]; EINECS 239-355-3; RACEPHENICOL; WIN-5063-2 DMDRKH2 DT Small molecular drug DMDRKH2 PC 27200 DMDRKH2 MW 356.2 DMDRKH2 FM C12H15Cl2NO5S DMDRKH2 IC InChI=1S/C12H15Cl2NO5S/c1-21(19,20)8-4-2-7(3-5-8)10(17)9(6-16)15-12(18)11(13)14/h2-5,9-11,16-17H,6H2,1H3,(H,15,18)/t9-,10-/m1/s1 DMDRKH2 CS CS(=O)(=O)C1=CC=C(C=C1)[C@H]([C@@H](CO)NC(=O)C(Cl)Cl)O DMDRKH2 IK OTVAEFIXJLOWRX-NXEZZACHSA-N DMDRKH2 IU 2,2-dichloro-N-[(1R,2R)-1,3-dihydroxy-1-(4-methylsulfonylphenyl)propan-2-yl]acetamide DMDRKH2 CA CAS 15318-45-3 DMDRKH2 CB CHEBI:32215 DMDRKH2 DE Bacterial infection DMHDF7B ID DMHDF7B DMHDF7B DN Thiamylal DMHDF7B HS Approved DMHDF7B SN Surital; Thioquinalbarbitone; Thioseconal; Thiamylal [USAN]; Surital (TN); Barbituric acid, 5-allyl-5-(1-methylbutyl)-2-thio-(VAN); Barbituric acid, 5-allyl-5-(1-methylbutyl)-2-thio-(VAN) (8CI); Dihydro-5-(1-methylbutyl)-5-(2-propenyl)-2-thioxo-4,6(1H,5H)-pyrimidinedione; Dihydro-5-(1-methylbutyl)-5-(2-propenyl)-2-thioxo-4,6-(1H,5H)-pyrimidinedione; 4,6(1H,5H)-Pyrimidinedione, dihydro-5-(1-methylbutyl)-5-(2-propenyl)-2-thioxo-(9CI); 5-(pentan-2-yl)-5-(prop-2-en-1-yl)-2-sulfanylidenedihydropyrimidine-4,6(1H,5H)-dione; 5-Allyl-5-(1-methylbutyl)-2-thiobarbituric acid; 5-Allyl-5-(1-methylbutyl)-2-thiobarbitursaeure; 5-Allyl-5-(1-methylbutyl)-2-thioxodihydro-4,6(1H,5H)-pyrimidinedione; 5-allyl-5-(1-methylbutyl)-2-thioxodihydropyrimidine-4,6(1H,5H)-dione; 5-pentan-2-yl-5-prop-2-enyl-2-sulfanylidene-1,3-diazinane-4,6-dione DMHDF7B TC Hypnotics and Sedatives DMHDF7B DT Small molecular drug DMHDF7B PC 3032285 DMHDF7B MW 254.35 DMHDF7B FM C12H18N2O2S DMHDF7B IC InChI=1S/C12H18N2O2S/c1-4-6-8(3)12(7-5-2)9(15)13-11(17)14-10(12)16/h5,8H,2,4,6-7H2,1,3H3,(H2,13,14,15,16,17) DMHDF7B CS CCCC(C)C1(C(=O)NC(=S)NC1=O)CC=C DMHDF7B IK XLOMZPUITCYLMJ-UHFFFAOYSA-N DMHDF7B IU 5-pentan-2-yl-5-prop-2-enyl-2-sulfanylidene-1,3-diazinane-4,6-dione DMHDF7B CA CAS 77-27-0 DMHDF7B CB CHEBI:9536 DMHDF7B DE Anaesthesia DMC1NBW ID DMC1NBW DMC1NBW DN Thiazolidinedione DMC1NBW HS Approved DMC1NBW SN 2295-31-0; 1,3-Thiazolidine-2,4-dione; thiazolidine-2,4-dione; 2,4-Dioxothiazolidine; 2,4(3H,5H)-Thiazoledione; USAF EK-5496; Thiazolidindione; UNII-AA68LXK93C; Thiazolidinedione-2,4; NSC 6745; EINECS 218-941-2; BRN 0110700; AA68LXK93C; AI3-61185; CHEBI:50992; NSC6745; ZOBPZXTWZATXDG-UHFFFAOYSA-N; MFCD00005478; 2,4-Thiazolidinedione, 99%; C3H3NO2S; thiazolidine-dione; 2,4-thiazolidindione; 2,5H)-Thiazoledione; PubChem17487 DMC1NBW DT Small molecular drug DMC1NBW PC 5437 DMC1NBW MW 117.13 DMC1NBW FM C3H3NO2S DMC1NBW IC InChI=1S/C3H3NO2S/c5-2-1-7-3(6)4-2/h1H2,(H,4,5,6) DMC1NBW CS C1C(=O)NC(=O)S1 DMC1NBW IK ZOBPZXTWZATXDG-UHFFFAOYSA-N DMC1NBW IU 1,3-thiazolidine-2,4-dione DMC1NBW CA CAS 2295-31-0 DMC1NBW CB CHEBI:50992 DMC1NBW DE Alzheimer disease DMU3IET ID DMU3IET DMU3IET DN Thiethylperazine DMU3IET HS Approved DMU3IET SN ETHYLTHIOPERAZINE; Theithylperazine; Thiethylperazinum; Thiethylpipezazine; Thioethylperazine; Tietilperazina; Torecan; Tietilperazina [DCIT]; Thiethylperazinum [INN-Latin]; Torecan (TN); Thiethylperazine (USAN/INN); Thiethylperazine [USAN:INN:BAN]; Norzine (*Dimaleate*); GS-95 (*Dimaleate*) DMU3IET CP Norvatis Phamaceuticals Corporation DMU3IET TC Antiemetics DMU3IET DT Small molecular drug DMU3IET PC 5440 DMU3IET MW 399.6 DMU3IET FM C22H29N3S2 DMU3IET IC InChI=1S/C22H29N3S2/c1-3-26-18-9-10-22-20(17-18)25(19-7-4-5-8-21(19)27-22)12-6-11-24-15-13-23(2)14-16-24/h4-5,7-10,17H,3,6,11-16H2,1-2H3 DMU3IET CS CCSC1=CC2=C(C=C1)SC3=CC=CC=C3N2CCCN4CCN(CC4)C DMU3IET IK XCTYLCDETUVOIP-UHFFFAOYSA-N DMU3IET IU 2-ethylsulfanyl-10-[3-(4-methylpiperazin-1-yl)propyl]phenothiazine DMU3IET CA CAS 1420-55-9 DMU3IET CB CHEBI:9544 DMU3IET DE Nausea DMEPWYA ID DMEPWYA DMEPWYA DN THIOCOLCHICOSIDE DMEPWYA HS Approved DMEPWYA SN Thiocolchicoside; 602-41-5; Coltramyl; UNII-T1X8S697GT; Thiocolchicine 2-glucoside analog; NSC 147755; Musco-ril; T1X8S697GT; 10-Thiocolchicoside; Tiocolchicoside [DCIT]; Colchicoside, 10-thio-; Thiocolchicoside [INN:DCF]; Q-201823; Thiocolchicosidum [INN-Latin]; Tiocolchicosido [INN-Spanish]; C27H33NO10S; Tiocolchicosido; Tiocolchicoside; Muscoril; Thiocolchicosidum; EINECS 210-017-7; BRN 0072205; R. 271; 2-10-Di(demethoxy)-2-glucosyloxy-10-methylthiocolchicine; Miotens; Coltrax; NSC147755; Coltramyl (TN); NCGC00016519-01 DMEPWYA DT Small molecular drug DMEPWYA PC 9915886 DMEPWYA MW 563.6 DMEPWYA FM C27H33NO10S DMEPWYA IC InChI=1S/C27H33NO10S/c1-12(30)28-16-7-5-13-9-18(37-27-24(34)23(33)22(32)19(11-29)38-27)25(35-2)26(36-3)21(13)14-6-8-20(39-4)17(31)10-15(14)16/h6,8-10,16,19,22-24,27,29,32-34H,5,7,11H2,1-4H3,(H,28,30)/t16-,19+,22+,23-,24+,27+/m0/s1 DMEPWYA CS CC(=O)N[C@H]1CCC2=CC(=C(C(=C2C3=CC=C(C(=O)C=C13)SC)OC)OC)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O DMEPWYA IK LEQAKWQJCITZNK-AXHKHJLKSA-N DMEPWYA IU N-[(7S)-1,2-dimethoxy-10-methylsulfanyl-9-oxo-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6,7-dihydro-5H-benzo[a]heptalen-7-yl]acetamide DMEPWYA CA CAS 602-41-5 DMEPWYA CB CHEBI:94557 DMEPWYA DE Muscle spasm DM7NKEV ID DM7NKEV DM7NKEV DN Thioguanine DM7NKEV HS Approved DM7NKEV SN 6-thioguanine; Lanvis; THG; Tabloid; ThioguaninGSK; Tioguanin; Tioguanina; Tioguanine; Tioguaninum; Glaxo Wellcome Brand of Thioguanine; Glaxo Wellcome Brand of Tioguanine; GlaxoSmithKline Brand of Thioguanine; GlaxoSmithKline Brand of Tioguanine; Thioguanin GSK; Thioguanine Hemihydrate; Thioguanine Monosodium Salt; Thioguanine Tabloid; Tioguanina Wellcome; Tioguanine GlaxoSmithKline Brand; Wellcome Brand of Thioguanine; BW 5071; DX4; LT00455187; Wellcome U3B; Lanvis (TN); Thioguanin-GSK; Thioguanine [USAN:BAN]; Tioguanina[INN-Spanish]; Tioguanine (INN); Tioguaninum [INN-Latin]; Purine antimetabolite: antimetabolite: inhibits nucleic acid replication; Guanine, thio-(VAN); 2 Amino 6 Purinethiol; 2-Amino 6MP; 2-Amino-1,7-dihydro-6H-purin-6-thion; 2-Amino-1,7-dihydro-6H-purin-6-thion [Czech]; 2-Amino-1,7-dihydro-6H-purine-6-thione; 2-Amino-6-MP; 2-Amino-6-mercaptopurine; 2-Amino-6-merkaptopurin; 2-Amino-6-merkaptopurin [Czech]; 2-Amino-6-purinethiol; 2-Amino-9H-purine-6-thiol; 2-Aminopurin-6-thiol; 2-Aminopurin-6-thiol [Czech]; 2-Aminopurine-6(1H)-thione; 2-Aminopurine-6-thiol; 2-Thioguanine; 2-amino-3,7-dihydropurine-6-thione; 6 Thioguanine; 6-Mercapto-2-aminopurine; 6-Mercaptoguanine; 6-TG; 6-Thioguanine; 6-Thioguanine (6-TG); 6-Thioguanine, Thioguanine; Thioguanine (Guanine analog) DM7NKEV CP Glaxo Smith Kline Pharmaceuticals DM7NKEV TC Anticancer Agents DM7NKEV DT Small molecular drug DM7NKEV PC 2723601 DM7NKEV MW 167.19 DM7NKEV FM C5H5N5S DM7NKEV IC InChI=1S/C5H5N5S/c6-5-9-3-2(4(11)10-5)7-1-8-3/h1H,(H4,6,7,8,9,10,11) DM7NKEV CS C1=NC2=C(N1)C(=S)N=C(N2)N DM7NKEV IK WYWHKKSPHMUBEB-UHFFFAOYSA-N DM7NKEV IU 2-amino-3,7-dihydropurine-6-thione DM7NKEV CA CAS 154-42-7 DM7NKEV CB CHEBI:9555 DM7NKEV DE Acute myeloid leukaemia DMGP8AX ID DMGP8AX DMGP8AX DN Thiopental DMGP8AX HS Approved DMGP8AX SN Intraval; Penthiobarbital; Pentothiobarbital; Thiomebumal; Thionembutal; Thiopentobarbital; Thiopentobarbitone; Thiopentone; Thiothal; Tiopentale; Trapanal; Thiopental [BAN]; Thiopental solution; Thiopentobarbituric acid; Tiopentale [Italian]; Sodium Pentothal (TN); Thiopental (TN); Thiopentone sodium (TN); Trapanal (TN); (+-)-Thiopental; (+/-)-THIOPENTAL; (+/-)-Thiopental solution; 2-Thio-5-ethyl-5-sec-pentylbarbituric acid; 4,6,(1H,5H)-Pyrimidinedione, 5-ethyldihydro-5-(1-methylbutyl)-2-thioxo-(9CI); 5-Ethyl-5-(1-methyl-butyl)-2-thioxo-dihydro-pyrimidine-4,6-dione; 5-Ethyl-5-(1-methylbutyl)-2-thiobarbituric acid; 5-ethyl-2-mercapto-5-(1-methylbutyl)pyrimidine-4,6(1H,5H)-dione; 5-ethyl-5-(1-methylbutyl)-2-thioxodihydropyrimidine-4,6(1H,5H)-dione; 5-ethyl-5-pentan-2-yl-2-sulfanylidene-1,3-diazinane-4,6-dione DMGP8AX CP Abbott Laboratories DMGP8AX TC Hypnotics and Sedatives DMGP8AX DT Small molecular drug DMGP8AX PC 3000715 DMGP8AX MW 242.34 DMGP8AX FM C11H18N2O2S DMGP8AX IC InChI=1S/C11H18N2O2S/c1-4-6-7(3)11(5-2)8(14)12-10(16)13-9(11)15/h7H,4-6H2,1-3H3,(H2,12,13,14,15,16) DMGP8AX CS CCCC(C)C1(C(=O)NC(=S)NC1=O)CC DMGP8AX IK IUJDSEJGGMCXSG-UHFFFAOYSA-N DMGP8AX IU 5-ethyl-5-pentan-2-yl-2-sulfanylidene-1,3-diazinane-4,6-dione DMGP8AX CA CAS 76-75-5 DMGP8AX CB CHEBI:102166 DMGP8AX DE Anaesthesia DM35M8J ID DM35M8J DM35M8J DN Thioridazine DM35M8J HS Approved DM35M8J SN Aldazine; Mallorol; Malloryl; Meleril; Mellaril; Mellarit; Mellerets; Mellerette; Melleretten; Melleril; Melleryl; Metlaril; Novoridazine; Orsanil; Ridazine; Sonapax; Stalleril; Thioridazin; Thioridazinum; Thioxidazine; Tioridazin; Tioridazina; Thioridazine Hcl; Thioridazine Hcl Intensol; Thioridazine prolongatum; Thoridazine hydrochloride; Dl-Thioridazine; Mellaril (TN); Mellaril-S; Melleril (liquid); Novoridazine (TN); TP-21; Thioridazine, prolongatum; Thioridazinum [INN-Latin]; Thioril (TN); Tioridazina [INN-Spanish]; Mellaril-S (TN); Thioridazine (USP/INN); Thioridazine [USAN:INN:BAN]; Mellaril (*Hydrochloride*); (+-)-Thioridazine; 10-(2-(1-Methyl-2-piperidyl)ethyl)-2-(methylthio)phenothiazine; 10-[2-(1-methyl-2-piperidyl)ethyl]-2-methylsulfanyl-phenothiazine; 10-[2-(1-methylpiperidin-2-yl)ethyl]-2-(methylsulfanyl)-10H-phenothiazine; 10-[2-(1-methylpiperidin-2-yl)ethyl]-2-(methylthio)-10H-phenothiazine; 10-[2-(1-methylpiperidin-2-yl)ethyl]-2-methylsulfanylphenothiazine; 2-Methylmercapto-10-(2-(N-methyl-2-piperidyl)ethyl)phenothiazine; 3-Methylmercapto-N-(2'-(N-methyl-2-piperidyl)ethyl)phenothiazine DM35M8J CP Norvatis Phamaceuticals Corporation DM35M8J TC Antipsychotic Agents DM35M8J DT Small molecular drug DM35M8J PC 5452 DM35M8J MW 370.6 DM35M8J FM C21H26N2S2 DM35M8J IC InChI=1S/C21H26N2S2/c1-22-13-6-5-7-16(22)12-14-23-18-8-3-4-9-20(18)25-21-11-10-17(24-2)15-19(21)23/h3-4,8-11,15-16H,5-7,12-14H2,1-2H3 DM35M8J CS CN1CCCCC1CCN2C3=CC=CC=C3SC4=C2C=C(C=C4)SC DM35M8J IK KLBQZWRITKRQQV-UHFFFAOYSA-N DM35M8J IU 10-[2-(1-methylpiperidin-2-yl)ethyl]-2-methylsulfanylphenothiazine DM35M8J CA CAS 50-52-2 DM35M8J CB CHEBI:9566 DM35M8J DE Schizophrenia DMIZKOP ID DMIZKOP DMIZKOP DN Thiotepa DMIZKOP HS Approved DMIZKOP SN thiotepa; THIO-TEPA; 52-24-4; Triethylenethiophosphoramide; Thiophosphamide; Tiofosyl; Tiofosfamid; Thiofozil; Tiofozil; Thioplex; Tespamin; Oncotepa; Tespamine; Girostan; Thiotef; Stepa; Tio-tef; Thio-Tep; Oncotiotepa; Tifosyl; Oncothio-tepa; TESPA; TSPA; Thio-tepa S; Ledertepa; Thiotriethylenephosphoramide; TIO TEF; N,N',N''-Triethylenethiophosphoramide; Tris(1-aziridinyl)phosphine sulfide; Thiophosphamidum; 1,1',1''-phosphorothioyltriaziridine; Triethylene thiophosphoramide; Triaziridinylphosphine sulfide DMIZKOP DT Small molecular drug DMIZKOP PC 5453 DMIZKOP MW 189.22 DMIZKOP FM C6H12N3PS DMIZKOP IC InChI=1S/C6H12N3PS/c11-10(7-1-2-7,8-3-4-8)9-5-6-9/h1-6H2 DMIZKOP CS C1CN1P(=S)(N2CC2)N3CC3 DMIZKOP IK FOCVUCIESVLUNU-UHFFFAOYSA-N DMIZKOP IU tris(aziridin-1-yl)-sulfanylidene-lambda5-phosphane DMIZKOP CA CAS 52-24-4 DMIZKOP CB CHEBI:9570 DMIZKOP DE Breast cancer DMDINC4 ID DMDINC4 DMDINC4 DN Thiothixene DMDINC4 HS Approved DMDINC4 SN Navan; Navane; Navaron; Orbinamon; Thiothixine; Tiotixene; Tiotixeno; Tiotixenum; Thiothixene hydrochloride; P 4657B; CP 12252-1; Cis-Thiothixene; Navane (TN); P-4657 B; P-4657A; P-4657B; Thiothixene (USP); Thiothixene (Z); Thiothixene Hydrochloride (base); Thiothixene [USAN:BAN]; Tiotixene (JAN); Tiotixeno [INN-Spanish]; Tiotixenum [INN-Latin]; Trans-Thiothixene; P-4657-B; CP-12,252-1; CP-12,252-1 base; {2-(Dimethylsulfamoyl)-[9-(4-methyl-1-piperazinyl)propylidene]thiox} anthene; N,N-Dimethyl-9-[3-(4-methyl-1-piperazinyl)propylidene]thiaxanthene-2-sulfonamide; N,N-Dimethyl-9-[3-(4-methyl-1-piperazinyl)propylidene]thioxanthene-2-sulfonamide; N,N-dimethyl-9-[3-(4-methylpiperazin-1-yl)propylidene]thioxanthene-2-sulfonamide; N,N-Dimethyl-9-(3-(4-methyl-1-piperazinyl)propylidene)thioxanthene-2-sulfonamide; Trans-N,N-Dimethyl-9-(3-(4-methyl-piperazinyl)propylidene)thioxanthene-2-sulfonamide; Cis-N,N-Dimethyl-9-(3-(4-methyl-1-piperazinyl)propylidene)thioxanthene-2-sulfonamide; N,N-Dimethyl-9-(3-(4-methylpiperazin-1-yl)propylidene)-9H-thioxanthene-2-sulphonamide; (9E)-N,N-dimethyl-9-[3-(4-methylpiperazin-1-yl)propylidene]-9H-thioxanthene-2-sulfonamide; (9E)-N,N-dimethyl-9-[3-(4-methylpiperazin-1-yl)propylidene]thioxanthene-2-sulfonamide; (9Z)-N,N-dimethyl-9-[3-(4-methylpiperazin-1-yl)propylidene]thioxanthene-2-sulfonamide; (E)-Thiothixene; 2-(Dimethylsulfamoyl)-(9-(4-methyl-1-piperazinyl)propylidene)thioxanthene DMDINC4 CP Pfizer Pharmaceuticals DMDINC4 TC Antipsychotic Agents DMDINC4 DT Small molecular drug DMDINC4 PC 941651 DMDINC4 MW 443.6 DMDINC4 FM C23H29N3O2S2 DMDINC4 IC InChI=1S/C23H29N3O2S2/c1-24(2)30(27,28)18-10-11-23-21(17-18)19(20-7-4-5-9-22(20)29-23)8-6-12-26-15-13-25(3)14-16-26/h4-5,7-11,17H,6,12-16H2,1-3H3/b19-8- DMDINC4 CS CN1CCN(CC1)CC/C=C\\2/C3=CC=CC=C3SC4=C2C=C(C=C4)S(=O)(=O)N(C)C DMDINC4 IK GFBKORZTTCHDGY-UWVJOHFNSA-N DMDINC4 IU (9Z)-N,N-dimethyl-9-[3-(4-methylpiperazin-1-yl)propylidene]thioxanthene-2-sulfonamide DMDINC4 CA CAS 3313-26-6 DMDINC4 CB CHEBI:9571 DMDINC4 DE Schizophrenia DM2P6VD ID DM2P6VD DM2P6VD DN Thrombin/fibrinogen matrix patch DM2P6VD HS Approved DM2P6VD SN Evicel; Thrombin; Biological Hemostatic Dressing; Fibrin Fleece; Fibrin Pad; Fibrin Patch; Fleece Fibrin Patch; Fibrin sealant, Omrix/ Ethicon; Fibrinogen, Omrix/Ethicon; Thrombin/fibrinogen matrix patch (surgical bleeding); Fibrin matrix patch (surgical bleeding), Omrix/Ethicon; Thrombin/fibrinogen matrixpatch (surgical bleeding), Omrix/Ethicon DM2P6VD CP OMRIX Biopharmaceuticals SA DM2P6VD DE Bleeding disorder DMJ47QC ID DMJ47QC DMJ47QC DN Thyrotropin DMJ47QC HS Approved DMJ47QC SN Thytropar DMJ47QC CP Sanofi Aventis Us Llc DMJ47QC DE Hypothyroidism DMMYLTI ID DMMYLTI DMMYLTI DN Thyrotropin Alfa DMMYLTI HS Approved DMMYLTI TC Diagnostic Agents DMMYLTI SQ Alpha chain: APDVQDCPECTLQENPFFSQPGAPILQCMGCCFSRAYPTPLRSKKTMLVQKNVTSESTCCVAKSYNRVTVMGGFKVENHTACHCSTCYYHKS >Beta chainFCIPTEYTMHIERRECAYCLTINTTICAGYCMTRDINGKLFLPKYALSQDVCTYRDFIYRTVEIPGCPLHVAPYFSYPVALSCKCGKCNTDYSDCIHEAIKTNYCTKPQKSY DMMYLTI DE Thyroid cancer DMKSQG0 ID DMKSQG0 DMKSQG0 DN Tiagabine DMKSQG0 HS Approved DMKSQG0 SN tiagabine; 115103-54-3; Gabitril; Tiagabinum; Tiagabina; (R)-Tiagabine; Tiagabinum [INN-Latin]; Tiagabina [INN-Spanish]; Tiagabine [INN:BAN]; Tiagabine [INN]; Abbott-70569; UNII-Z80I64HMNP; Tiagabine (INN); ABBOTT-70569-1; Gabitril (TN); CHEMBL1027; Z80I64HMNP; ABT-569; CHEBI:9586; NO-328; (-)-(R)-1-(4,4-Bis(3-methyl-2-thienyl)-3-butenyl)nipecotic acid; A-70569-1; (R)-1-(4,4-Bis(3-methylthiophen-2-yl)but-3-en-1-yl)piperidine-3-carboxylic acid; Gabatril; NO 329; Gabitril; NO-329; Tiagabina [INN-Spanish];Tiagabine (INN); N-(4,4-di(3-methylthien-2-yl)but-3-enyl)nipecotic acid; (3R)-1-[4,4-bis(3-methyl-2-thienyl)but-3-en-1-yl]piperidine-3-carboxylic acid; (3R)-1-[4,4-bis(3-methylthiophen-2-yl)but-3-enyl]piperidine-3-carboxylic acid; [3H]tiagabine DMKSQG0 CP Cephalon DMKSQG0 TC Anticonvulsants DMKSQG0 DT Small molecular drug DMKSQG0 PC 60648 DMKSQG0 MW 375.6 DMKSQG0 FM C20H25NO2S2 DMKSQG0 IC InChI=1S/C20H25NO2S2/c1-14-7-11-24-18(14)17(19-15(2)8-12-25-19)6-4-10-21-9-3-5-16(13-21)20(22)23/h6-8,11-12,16H,3-5,9-10,13H2,1-2H3,(H,22,23)/t16-/m1/s1 DMKSQG0 CS CC1=C(SC=C1)C(=CCCN2CCC[C@H](C2)C(=O)O)C3=C(C=CS3)C DMKSQG0 IK PBJUNZJWGZTSKL-MRXNPFEDSA-N DMKSQG0 IU (3R)-1-[4,4-bis(3-methylthiophen-2-yl)but-3-enyl]piperidine-3-carboxylic acid DMKSQG0 CA CAS 115103-54-3 DMKSQG0 CB CHEBI:9586 DMKSQG0 DE Epilepsy; Anxiety disorder DMYN8MA ID DMYN8MA DMYN8MA DN Tianeptine DMYN8MA HS Approved DMYN8MA SN Tianeptina; Tianeptinum; Tianeptine Acid; Tianeptine [INN]; Stablon (TN); Tianeptine (INN); (1)-7-((3-Chloro-6,11-dihydro-6-methyldibenzo(c,f)(1,2)thiazepin-11-yl)amino)heptanoic acid S,S-dioxide; 7-[(3-chloro-6-methyl-5,5-dioxido-6,11-dihydrodibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid; 7-[(3-chloro-6-methyl-5,5-dioxo-11H-benzo[c][2,1]benzothiazepin-11-yl)amino]heptanoic acid DMYN8MA DT Small molecular drug DMYN8MA PC 68870 DMYN8MA MW 437 DMYN8MA FM C21H25ClN2O4S DMYN8MA IC InChI=1S/C21H25ClN2O4S/c1-24-18-9-6-5-8-16(18)21(23-13-7-3-2-4-10-20(25)26)17-12-11-15(22)14-19(17)29(24,27)28/h5-6,8-9,11-12,14,21,23H,2-4,7,10,13H2,1H3,(H,25,26) DMYN8MA CS CN1C2=CC=CC=C2C(C3=C(S1(=O)=O)C=C(C=C3)Cl)NCCCCCCC(=O)O DMYN8MA IK JICJBGPOMZQUBB-UHFFFAOYSA-N DMYN8MA IU 7-[(3-chloro-6-methyl-5,5-dioxo-11H-benzo[c][2,1]benzothiazepin-11-yl)amino]heptanoic acid DMYN8MA CA CAS 72797-41-2 DMYN8MA CB CHEBI:91749 DMYN8MA DE Major depressive disorder DMN6CAG ID DMN6CAG DMN6CAG DN Tiapride DMN6CAG HS Approved DMN6CAG SN tiapride; 51012-32-9; Thiapride; Tiapridal; N-(2-(Diethylamino)ethyl)-2-methoxy-5-(methylsulfonyl)benzamide; Tiapridum [INN-Latin]; Tiaprida [INN-Spanish]; UNII-LAH70H9JPH; FLO 1347; Tiapride [INN:BAN:DCF]; Tiapride HCl; EINECS 256-907-9; LAH70H9JPH; BRN 2390588; JTVPZMFULRWINT-UHFFFAOYSA-N; BENZAMIDE, N-(2-(DIETHYLAMINO)ETHYL)-2-METHOXY-5-(METHYLSULFONYL)-; N-(2-(Diethylamino)ethyl)-5-(methylsulfonyl)-o-anisamide; Tiapridum; Tiaprida; Benzamide, N-[2-(diethylamino)ethyl]-2-methoxy-5-(methylsulfonyl)-; NCGC00015996-02; SPI-860 DMN6CAG DT Small molecular drug DMN6CAG PC 5467 DMN6CAG MW 328.4 DMN6CAG FM C15H24N2O4S DMN6CAG IC InChI=1S/C15H24N2O4S/c1-5-17(6-2)10-9-16-15(18)13-11-12(22(4,19)20)7-8-14(13)21-3/h7-8,11H,5-6,9-10H2,1-4H3,(H,16,18) DMN6CAG CS CCN(CC)CCNC(=O)C1=C(C=CC(=C1)S(=O)(=O)C)OC DMN6CAG IK JTVPZMFULRWINT-UHFFFAOYSA-N DMN6CAG IU N-[2-(diethylamino)ethyl]-2-methoxy-5-methylsulfonylbenzamide DMN6CAG CA CAS 51012-32-9 DMN6CAG CB CHEBI:94666 DMN6CAG DE Alcohol dependence; Neuropathic pain DM23D7J ID DM23D7J DM23D7J DN Tiaprofenic acid DM23D7J HS Approved DM23D7J SN Surgam; Tiaprofensaeure; Acide tiaprofenique; Acido tiaprofenico; Acidum tiaprofenicum; Surgam SR; FC 3001; RU 15060; Acide tiaprofenique [INN-French]; Acido tiaprofenico [INN-Spanish]; Acidum tiaprofenicum [INN-Latin]; Apo-Tiaprofenic Tablets; Dom-tiaprofenic; Surgam (TN); Surgamyl (TN); Tiaprofen (TN); Tiaprofenic acid (JAN/INN); Tiaprofenic-200-Tab; Tiaprofenic-300-Tab; Tiaprofenic acid [INN:BAN:DCF:JAN]; Alpha-methyl-5-benzoyl-2-thienylacetic acid; 2-(5-Benzyl-2-thienyl)propionsaeure; 2-(5-benzoylthiophen-2-yl)propanoic acid; 2-[5-(phenylcarbonyl)-2-thienyl]propanoic acid; 5-Benzoyl-alpha-methyl-2-thiopheneacetic acid; 5-benzoyl-alpha-methylthiophene-2-acetic acid DM23D7J TC Analgesics DM23D7J DT Small molecular drug DM23D7J PC 5468 DM23D7J MW 260.31 DM23D7J FM C14H12O3S DM23D7J IC InChI=1S/C14H12O3S/c1-9(14(16)17)11-7-8-12(18-11)13(15)10-5-3-2-4-6-10/h2-9H,1H3,(H,16,17) DM23D7J CS CC(C1=CC=C(S1)C(=O)C2=CC=CC=C2)C(=O)O DM23D7J IK GUHPRPJDBZHYCJ-UHFFFAOYSA-N DM23D7J IU 2-(5-benzoylthiophen-2-yl)propanoic acid DM23D7J CA CAS 33005-95-7 DM23D7J CB CHEBI:32221 DM23D7J DE Pain DM5JWV9 ID DM5JWV9 DM5JWV9 DN Tiazofurin DM5JWV9 HS Approved DM5JWV9 SN Riboxamide; TCAR; TIZ; Tiazofurina; Tiazofurine; Tiazofurinum; Tiazole; Tiazofurin [USAN]; Tiazofurina [Spanish]; Tiazofurinum [Latin]; Cpd-5825; Tiazofurin (USAN); Tiazofurine (INN); 2-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3-thiazole-4-carboxamide; 2-beta-D-Ribofuranosyl-4-thiazolecarboxamide; 2-ribofuranosylthiazole-4-carboxamide DM5JWV9 TC Anticancer Agents DM5JWV9 DT Small molecular drug DM5JWV9 PC 457954 DM5JWV9 MW 260.269 DM5JWV9 FM C9H12N2O5S DM5JWV9 IC InChI=1S/C9H12N2O5S/c10-8(15)3-2-17-9(11-3)7-6(14)5(13)4(1-12)16-7/h2,4-7,12-14H,1H2,(H2,10,15)/t4-,5-,6-,7-/m1/s1 DM5JWV9 CS C1=C(N=C(S1)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O)C(=O)N DM5JWV9 IK FVRDYQYEVDDKCR-DBRKOABJSA-N DM5JWV9 IU 2-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3-thiazole-4-carboxamide DM5JWV9 CA CAS 60084-10-8 DM5JWV9 CB CHEBI:90239 DM5JWV9 DE Solid tumour/cancer DM78XFG ID DM78XFG DM78XFG DN Tibolone DM78XFG HS Approved DM78XFG SN Livial (TN) DM78XFG DT Small molecular drug DM78XFG PC 444008 DM78XFG MW 312.4 DM78XFG FM C21H28O2 DM78XFG IC InChI=1S/C21H28O2/c1-4-21(23)10-8-18-19-13(2)11-14-12-15(22)5-6-16(14)17(19)7-9-20(18,21)3/h1,13,17-19,23H,5-12H2,2-3H3/t13-,17-,18+,19-,20+,21+/m1/s1 DM78XFG CS C[C@@H]1CC2=C(CCC(=O)C2)[C@@H]3[C@@H]1[C@@H]4CC[C@]([C@]4(CC3)C)(C#C)O DM78XFG IK WZDGZWOAQTVYBX-XOINTXKNSA-N DM78XFG IU (7R,8R,9S,13S,14S,17R)-17-ethynyl-17-hydroxy-7,13-dimethyl-1,2,4,6,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-one DM78XFG CA CAS 5630-53-5 DM78XFG CB CHEBI:32223 DM78XFG DE Anabolic metabolism DM4ME02 ID DM4ME02 DM4ME02 DN Ticarcillin DM4ME02 HS Approved DM4ME02 SN TIPC; Ticarcilina; Ticarcilline; Ticarcillinum; Ticarcillin Supplement; Ticillin [veterinary]; BRL-2288; Ticarcilina[INN-Spanish]; Ticarcillin (INN); Ticarcillin [INN:BAN]; Ticarcilline [INN-French]; Ticarcillinum [INN-Latin]; Ticillin [veterinary] (TN); Timentin (TN); A-carboxy-3-thienylmethylpenicillin; Alpha-carboxy-3-thienylmethylpenicillin; (2S,5R,6R)-6-[[(2R)-3-hydroxy-3-oxo-2-thiophen-3-ylpropanoyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-{[(2R)-2-carboxy-2-(3-thienyl)acetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-{[(2R)-2-carboxy-2-thiophen-3-ylacetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 6beta-{[(2R)-2-carboxy-2-thiophen-3-ylacetyl]amino}-2,2-dimethylpenam-3alpha-carboxylic acid DM4ME02 CP GlaxoSmithKline DM4ME02 TC Antibiotics DM4ME02 DT Small molecular drug DM4ME02 PC 36921 DM4ME02 MW 384.4 DM4ME02 FM C15H16N2O6S2 DM4ME02 IC InChI=1S/C15H16N2O6S2/c1-15(2)9(14(22)23)17-11(19)8(12(17)25-15)16-10(18)7(13(20)21)6-3-4-24-5-6/h3-5,7-9,12H,1-2H3,(H,16,18)(H,20,21)(H,22,23)/t7-,8-,9+,12-/m1/s1 DM4ME02 CS CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CSC=C3)C(=O)O)C(=O)O)C DM4ME02 IK OHKOGUYZJXTSFX-KZFFXBSXSA-N DM4ME02 IU (2S,5R,6R)-6-[[(2R)-2-carboxy-2-thiophen-3-ylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid DM4ME02 CA CAS 34787-01-4 DM4ME02 CB CHEBI:9587 DM4ME02 DE Bacterial infection DMO946V ID DMO946V DMO946V DN Ticlopidine DMO946V HS Approved DMO946V SN Ticlid; Ticlopidina; Ticlopidinum; PCR 5332; Ticlid (TN); Ticlopidin-Puren; Ticlopidina [INN-Spanish]; Ticlopidine (INN); Ticlopidine [INN:BAN]; Ticlopidinum [INN-Latin]; Ticlopidin-Puren (TN); 5-((2-Chlorophenyl)methyl)-4,5,6,7-tetrahydrothieno(3,2-c)pyridine; 5-(2-Chlorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine; 5-[(2-chlorophenyl)methyl]-4,5,6,7-tetrahydrothieno[3,2-c]pyridine; 5-[(2-chlorophenyl)methyl]-6,7-dihydro-4H-thieno[3,2-c]pyridine DMO946V TC Fibrinolytic Agents DMO946V DT Small molecular drug DMO946V PC 5472 DMO946V MW 263.8 DMO946V FM C14H14ClNS DMO946V IC InChI=1S/C14H14ClNS/c15-13-4-2-1-3-11(13)9-16-7-5-14-12(10-16)6-8-17-14/h1-4,6,8H,5,7,9-10H2 DMO946V CS C1CN(CC2=C1SC=C2)CC3=CC=CC=C3Cl DMO946V IK PHWBOXQYWZNQIN-UHFFFAOYSA-N DMO946V IU 5-[(2-chlorophenyl)methyl]-6,7-dihydro-4H-thieno[3,2-c]pyridine DMO946V CA CAS 55142-85-3 DMO946V CB CHEBI:9588 DMO946V DE Stroke DMLE7IO ID DMLE7IO DMLE7IO DN Tigecycline DMLE7IO HS Approved DMLE7IO SN Tigilcycline; Tygacil; Tigecycline [USAN]; GAR 936; GAR-936; TBG-MINO; Tygacil (TN); Tygacil(TM); GAR-936,Tigecycline; Tigecycline (JAN/USAN); WAY-GAR-936; Tygacil, GAR-936, WAY-GAR-936, TBG-MINO, Tigecycline; N-[(5aR,6aS,7S,9Z,10aS)-9-[amino(hydroxy)methylidene]-4,7-bis(dimethylamino)-1,10a,12-trihydroxy-8,10,11-trioxo-5a,6,6a,7-tetrahydro-5H-tetracen-2-yl]-2-(tert-butylamino)acetamide; (4S,12aS)-4,7-Bis(dimethylamino)-9-{2-[(tert-butyl)amino]acetylamino}-3,10,12,12a-tetrahydroxy-1,11-dioxo-4,5,6,12a,4a,5a-hexahydronaphthacene-2-carboxamide; (4S,4aS,5aR,12aS)-9-(2-(tert-butylamino)acetamido)-4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide; (4S,4aS,5aR,12aS)-9-[(N-tert-butylglycyl)amino]-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide; 9-t-Butylglycylamido minocycline DMLE7IO CP Wyeth Pharmaceuticals DMLE7IO TC Antibiotics DMLE7IO DT Small molecular drug DMLE7IO PC 54686904 DMLE7IO MW 585.6 DMLE7IO FM C29H39N5O8 DMLE7IO IC InChI=1S/C29H39N5O8/c1-28(2,3)31-11-17(35)32-15-10-16(33(4)5)13-8-12-9-14-21(34(6)7)24(38)20(27(30)41)26(40)29(14,42)25(39)18(12)23(37)19(13)22(15)36/h10,12,14,21,31,36-37,40,42H,8-9,11H2,1-7H3,(H2,30,41)(H,32,35)/t12-,14-,21-,29-/m0/s1 DMLE7IO CS CC(C)(C)NCC(=O)NC1=CC(=C2C[C@H]3C[C@H]4[C@@H](C(=O)C(=C([C@]4(C(=O)C3=C(C2=C1O)O)O)O)C(=O)N)N(C)C)N(C)C DMLE7IO IK SOVUOXKZCCAWOJ-HJYUBDRYSA-N DMLE7IO IU (4S,4aS,5aR,12aR)-9-[[2-(tert-butylamino)acetyl]amino]-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4H-tetracene-2-carboxamide DMLE7IO CA CAS 220620-09-7 DMLE7IO CB CHEBI:149836 DMLE7IO DE Skin infection DMLW9HG ID DMLW9HG DMLW9HG DN Tildrakizumab DMLW9HG HS Approved DMLW9HG SN UNII-DEW6X41BEK; DEW6X41BEK; Tildrakizumab [USAN:INN]; SCH 900222 DMLW9HG CP Sun Pharma DMLW9HG DT Antibody DMLW9HG DE Plaque psoriasis DMJW0VS ID DMJW0VS DMJW0VS DN Tilidine DMJW0VS HS Approved DMJW0VS SN Valoron; Tilidine hydrochloride hemihydrate; 255733-17-6; Tilidine hydrochloride hemihydrate [EP]; DTXSID70180262; Ethyl (1RS,2SR)-2-(dimethylamino)-1-phenylcyclohex-3-enecarboxylate hydrochloride hemihydrate; 3-Cyclohexene-1-carboxylic acid, 2-(dimethylamino)-1-phenyl-, ethyl ester, hydrochloride, hydrate (2:2:1), (1R,2S)-rel-; UNII-Y757T3419R component WHYVWQHDUOALSV-UMJMSJQKSA-N DMJW0VS DT Small molecular drug DMJW0VS PC 30131 DMJW0VS MW 273.37 DMJW0VS FM C17H23NO2 DMJW0VS IC InChI=1S/C17H23NO2/c1-4-20-16(19)17(14-10-6-5-7-11-14)13-9-8-12-15(17)18(2)3/h5-8,10-12,15H,4,9,13H2,1-3H3/t15-,17+/m1/s1 DMJW0VS CS CCOC(=O)[C@@]1(CCC=C[C@H]1N(C)C)C2=CC=CC=C2 DMJW0VS IK WDEFBBTXULIOBB-WBVHZDCISA-N DMJW0VS IU ethyl (1S,2R)-2-(dimethylamino)-1-phenylcyclohex-3-ene-1-carboxylate DMJW0VS CA CAS 51931-66-9 DMJW0VS CB CHEBI:77822 DMJW0VS DE Pain DM3NXRU ID DM3NXRU DM3NXRU DN Timolol DM3NXRU HS Approved DM3NXRU SN Aquanil; Betim; Betimol; Blocadren; Istalol; Optimol; Proflax; TIM; Temserin; Tenopt; Timacar; Timololum; Timopic; Timoptol; Timolol GFS; Timolol [USAN]; Timoptic OcuDose; Apo-Timol; Apo-Timop; Betimol (TN); Blocadren (TN); Istalol (TN); MK-950; Novo-Timol; Nu-Timolol; Phoxal-timolol; Tim-AK; Timolol (INN); Timolol (TN); Timololum [INN-Latin]; Timoptic (TN); Timoptic-XE; Apo-Timol (TN); Apo-Timop (TN); Gen-Timolol (TN); L-714,465; Nu-Timolol (TN); PMS-Timolol (TN); Phoxal-timolol (TN); Tim-AK (TN); Timoptic OcuDose. (TN); Timoptic-XE (TN); S(-)-Timolol maleate; Timolol Maleate, (1:1) Salt; S-(-)-3-(3-tert-Butylamino-2-hydroxypropoxy)-4-morpholino-1,2,5-thiadiazole; (-)-3-Morpholino-4-(3-tert-butylamino-2-hydroxypropoxy)-1,2,5-thiadiazole; (2S)-1-((1,1-dimethylethyl)amino)-3-((4-(4-morpholinyl)-1,2,5-thiadiazol-3-yl)oxy)-2-propanol; (2S)-1-(tert-butylamino)-3-[(4-morpholin-4-yl-1,2,5-thiadiazol-3-yl)oxy]propan-2-ol; (2S)-1-[(1,1-dimethylethyl)amino]-3-[(4-morpholin-4-yl-1,2,5-thiadiazol-3-yl)oxy]propan-2-ol; (S)-1-(1,1-(Dimethylethyl)amino)-3-((4-(4-morpholinyl)-1,2,5-thiadiazol-3-yl)oxy)-2-propanol; (S)-1-(tert-Butylamino)-3-((4-morpholino-1,2,5-thiadiazol-3-yl)oxy)propan-2-ol; (S)-timolol DM3NXRU CP Merck Frosst DM3NXRU TC Antiarrhythmic Agents DM3NXRU DT Small molecular drug DM3NXRU PC 33624 DM3NXRU MW 316.42 DM3NXRU FM C13H24N4O3S DM3NXRU IC InChI=1S/C13H24N4O3S/c1-13(2,3)14-8-10(18)9-20-12-11(15-21-16-12)17-4-6-19-7-5-17/h10,14,18H,4-9H2,1-3H3/t10-/m0/s1 DM3NXRU CS CC(C)(C)NC[C@@H](COC1=NSN=C1N2CCOCC2)O DM3NXRU IK BLJRIMJGRPQVNF-JTQLQIEISA-N DM3NXRU IU (2S)-1-(tert-butylamino)-3-[(4-morpholin-4-yl-1,2,5-thiadiazol-3-yl)oxy]propan-2-ol DM3NXRU CA CAS 26839-75-8 DM3NXRU CB CHEBI:9599 DM3NXRU DE High blood pressure DM3OWT4 ID DM3OWT4 DM3OWT4 DN Tindamax DM3OWT4 HS Approved DM3OWT4 SN Tinidazole (oral), Mission Pharmacal DM3OWT4 CP Presutti Laboratories DM3OWT4 DT Small molecular drug DM3OWT4 PC 5479 DM3OWT4 MW 247.27 DM3OWT4 FM C8H13N3O4S DM3OWT4 IC InChI=1S/C8H13N3O4S/c1-3-16(14,15)5-4-10-7(2)9-6-8(10)11(12)13/h6H,3-5H2,1-2H3 DM3OWT4 CS CCS(=O)(=O)CCN1C(=NC=C1[N+](=O)[O-])C DM3OWT4 IK HJLSLZFTEKNLFI-UHFFFAOYSA-N DM3OWT4 IU 1-(2-ethylsulfonylethyl)-2-methyl-5-nitroimidazole DM3OWT4 CA CAS 148159-84-6 DM3OWT4 CB CHEBI:63627 DM3OWT4 DE Bacterial infection DMNYPGS ID DMNYPGS DMNYPGS DN Tioconazole DMNYPGS HS Approved DMNYPGS SN Fungibacid; GyneCure; Tioconazol; Tioconazolum; Trosyd; Trosyl; Vagistat; Zoniden; Trosyd AF; Trosyd J; Monistat 1; UK 20349; Gyno-trosyd; Tioconazol [INN-Spanish]; Tioconazolum [INN-Latin]; Tz-3; UK 20,349; UK-20349; Vagistat-1; Vagistat-1 (TN); Tioconazole (JAN/USP/INN); Tioconazole [USAN:BAN:INN:JAN]; (+-)-1-(2,4-Dichloro-beta-((2-chloro-3-ethenyl)oxy)phenethyl)imidazole; (+-)-1-[2-[(2-Chloro-3-thienyl)methoxy]-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole; 1-(2,4-Dichloro-(beta-(2-chloro-3-thenyl)oxy)phenethyl)imidazole; 1-(2,4-Dichloro-beta-((2-chloro-3-thenyl)-oxy)phenethyl)imidazole; 1-[2-[(2-chlorothiophen-3-yl)methoxy]-2-(2,4-dichlorophenyl)ethyl]imidazole DMNYPGS TC Antifungal Agents DMNYPGS DT Small molecular drug DMNYPGS PC 5482 DMNYPGS MW 387.7 DMNYPGS FM C16H13Cl3N2OS DMNYPGS IC InChI=1S/C16H13Cl3N2OS/c17-12-1-2-13(14(18)7-12)15(8-21-5-4-20-10-21)22-9-11-3-6-23-16(11)19/h1-7,10,15H,8-9H2 DMNYPGS CS C1=CC(=C(C=C1Cl)Cl)C(CN2C=CN=C2)OCC3=C(SC=C3)Cl DMNYPGS IK QXHHHPZILQDDPS-UHFFFAOYSA-N DMNYPGS IU 1-[2-[(2-chlorothiophen-3-yl)methoxy]-2-(2,4-dichlorophenyl)ethyl]imidazole DMNYPGS CA CAS 65899-73-2 DMNYPGS CB CHEBI:77898 DMNYPGS DE Onychomycosis DMFDC0Q ID DMFDC0Q DMFDC0Q DN Tiotropium DMFDC0Q HS Approved DMFDC0Q SN 186691-13-4; UNII-0EB439235F; 0EB439235F; [3H]tiotropium; (1r,2r,4s,5s,7s)-7-{[hydroxy(Dithiophen-2-Yl)acetyl]oxy}-9,9-Dimethyl-3-Oxa-9-Azoniatricyclo[3310~2,4~]nonane; NCGC00167971-01; 0HK; (1R,2R,4S,5S)-7-{[2-hydroxy-2,2-bis(thiophen-2-yl)acetyl]oxy}-9,9-dimethyl-3-oxa-9-azatricyclo[3310^{2,4}]nonan-9-ium; GTPL367; SCHEMBL4662461; GTPL8592; DTXSID5044281; CHEMBL3305968; Spiriva (TN); Tiotropium bromide [USAN:INN]; (1A,2A,4A,5A,7A)-7-[(Hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatri-cyclo[331024]nonane bromide; (1a,2,4,5a,7)-7-[(2-Hydroxy-2,2-di-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo[33102,4]nonane bromide; 7-{[hydroxy(dithiophen-2-yl)acetyl]oxy}-9,9-dimethyl-3-oxa-9-azoniatricyclo[33102,4]nonane bromide DMFDC0Q CP Boehringer Ingelheim DMFDC0Q TC Bronchodilator Agents DMFDC0Q DT Small molecular drug DMFDC0Q PC 5487427 DMFDC0Q MW 392.5 DMFDC0Q FM C19H22NO4S2+ DMFDC0Q IC InChI=1S/C19H22NO4S2/c1-20(2)12-9-11(10-13(20)17-16(12)24-17)23-18(21)19(22,14-5-3-7-25-14)15-6-4-8-26-15/h3-8,11-13,16-17,22H,9-10H2,1-2H3/q+1/t11?,12-,13+,16-,17+ DMFDC0Q CS C[N+]1([C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)C(C4=CC=CS4)(C5=CC=CS5)O)C DMFDC0Q IK LERNTVKEWCAPOY-FPISHFTHSA-N DMFDC0Q IU [(1S,2S,4R,5R)-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonan-7-yl] 2-hydroxy-2,2-dithiophen-2-ylacetate DMFDC0Q CA CAS 186691-13-4 DMFDC0Q CB CHEBI:90960 DMFDC0Q DE Chronic obstructive pulmonary disease DM8HJX6 ID DM8HJX6 DM8HJX6 DN Tipranavir DM8HJX6 HS Approved DM8HJX6 SN Aptivus; TPV; PNU 140690; U 140690; Aptivus (Boehringer Ingelheim); Aptivus (TN); Aptivus(TM); PNU-140690; PNU-140690E; Tipranavir (INN); U-140690; N-[3-[(1R)-1-[(2R)-6-hydroxy-4-oxo-2-phenethyl-2-propyl-3H-pyran-5-yl]propyl]phenyl]-5-(trifluoromethyl)pyridine-2-sulfonamide; N-(3-{(1R)-1-[(6R)-4-HYDROXY-2-OXO-6-PHENETHYL-6-PROPYL-5,6-DIHYDRO-2H-PYRAN-3-YL]PROPYL}PHENYL)-5-(TRIFLUOROMETHYL)-2-PYRIDINESULFONAMIDE DM8HJX6 CP Boehriger Ingelheim DM8HJX6 TC Anti-HIV Agents DM8HJX6 DT Small molecular drug DM8HJX6 PC 54682461 DM8HJX6 MW 602.7 DM8HJX6 FM C31H33F3N2O5S DM8HJX6 IC InChI=1S/C31H33F3N2O5S/c1-3-16-30(17-15-21-9-6-5-7-10-21)19-26(37)28(29(38)41-30)25(4-2)22-11-8-12-24(18-22)36-42(39,40)27-14-13-23(20-35-27)31(32,33)34/h5-14,18,20,25,36-37H,3-4,15-17,19H2,1-2H3/t25-,30-/m1/s1 DM8HJX6 CS CCC[C@]1(CC(=C(C(=O)O1)[C@H](CC)C2=CC(=CC=C2)NS(=O)(=O)C3=NC=C(C=C3)C(F)(F)F)O)CCC4=CC=CC=C4 DM8HJX6 IK SUJUHGSWHZTSEU-FYBSXPHGSA-N DM8HJX6 IU N-[3-[(1R)-1-[(2R)-4-hydroxy-6-oxo-2-(2-phenylethyl)-2-propyl-3H-pyran-5-yl]propyl]phenyl]-5-(trifluoromethyl)pyridine-2-sulfonamide DM8HJX6 CA CAS 174484-41-4 DM8HJX6 CB CHEBI:63628 DM8HJX6 DE Human immunodeficiency virus infection DMJNV4O ID DMJNV4O DMJNV4O DN Tirbanibulin DMJNV4O HS Approved DMJNV4O SN KX2-391; 897016-82-9; KX-01; UNII-4V9848RS5G; N-benzyl-2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)acetamide; KX-2-391; CHEMBL571546; 4V9848RS5G; KX2391; KX 01; KX-2391; MLS006011272; SCHEMBL153779; KX01; GTPL7957; DTXSID30237862; MolPort-023-293-512; HUNGUWOZPQBXGX-UHFFFAOYSA-N; HMS3656J15; EX-A2434; BCP02845; ZINC43152787; s2700; BDBM50303801; AKOS027276392; KX2-391; KX-01; SB16619; CS-0248; KX2-391 (KX01); BCP9000828; 2-Pyridineacetamide, 5-(4-(2-(4-morpholinyl)ethoxy)phenyl)-n-(phenylmethyl)-; NCGC00346644-05; NCGC00346644-01; KX 2 DMJNV4O CP Kinex Pharmaceuticals DMJNV4O DT Small molecular drug DMJNV4O PC 23635314 DMJNV4O MW 431.5 DMJNV4O FM C26H29N3O3 DMJNV4O IC InChI=1S/C26H29N3O3/c30-26(28-19-21-4-2-1-3-5-21)18-24-9-6-23(20-27-24)22-7-10-25(11-8-22)32-17-14-29-12-15-31-16-13-29/h1-11,20H,12-19H2,(H,28,30) DMJNV4O CS C1COCCN1CCOC2=CC=C(C=C2)C3=CN=C(C=C3)CC(=O)NCC4=CC=CC=C4 DMJNV4O IK HUNGUWOZPQBXGX-UHFFFAOYSA-N DMJNV4O IU N-benzyl-2-[5-[4-(2-morpholin-4-ylethoxy)phenyl]pyridin-2-yl]acetamide DMJNV4O CA CAS 897016-82-9 DMJNV4O DE Prostate cancer; Actinic keratosis DMQG17S ID DMQG17S DMQG17S DN Tirofiban DMQG17S HS Approved DMQG17S SN AGG; Aggrastat; Agrastat; Tirofibanum; Aggrastat (TN); Agrastat (TN); L-700462; MK-383; Tirofiban (INN); Tirofiban[BAN:INN]; Tirofiban [INN:BAN]; L-700,462; N-(BUTYLSULFONYL)-O-[4-(4-PIPERIDINYL)BUTYL]-L-TYROSINE; N-(Butylsulfonyl)-O-(4-(4-piperidyl)butyl)-L-tyrosine; N-(butylsulfonyl)-O-(4-piperidin-4-ylbutyl)-L-tyrosine; N-(butylsulfonyl)-o-[4-(piperidin-4-yl)butyl]-l-tyrosine; (2S)-2-(butylsulfonylamino)-3-[4-(4-piperidin-4-ylbutoxy)phenyl]propanoic acid DMQG17S CP Medicure Pharma DMQG17S TC Fibrinolytic Agents DMQG17S DT Small molecular drug DMQG17S PC 60947 DMQG17S MW 440.6 DMQG17S FM C22H36N2O5S DMQG17S IC InChI=1S/C22H36N2O5S/c1-2-3-16-30(27,28)24-21(22(25)26)17-19-7-9-20(10-8-19)29-15-5-4-6-18-11-13-23-14-12-18/h7-10,18,21,23-24H,2-6,11-17H2,1H3,(H,25,26)/t21-/m0/s1 DMQG17S CS CCCCS(=O)(=O)N[C@@H](CC1=CC=C(C=C1)OCCCCC2CCNCC2)C(=O)O DMQG17S IK COKMIXFXJJXBQG-NRFANRHFSA-N DMQG17S IU (2S)-2-(butylsulfonylamino)-3-[4-(4-piperidin-4-ylbutoxy)phenyl]propanoic acid DMQG17S CA CAS 144494-65-5 DMQG17S CB CHEBI:9605 DMQG17S DE Acute coronary syndrome DMM9BJD ID DMM9BJD DMM9BJD DN Tisagenlecleucel DMM9BJD HS Approved DMM9BJD SN Tisagenlecleucel-T DMM9BJD CP Novartis Pharmaceuticals East Hanover, NJ DMM9BJD DT CAR T Cell Therapy DMM9BJD DE Diffuse large B-cell lymphoma; Chronic lymphocytic leukaemia; Follicular lymphoma; Acute lymphoblastic leukaemia; Acute myeloid leukaemia DMGVUO5 ID DMGVUO5 DMGVUO5 DN Tislelizumab DMGVUO5 HS Approved DMGVUO5 CP BeiGene DMGVUO5 DT Monoclonal antibody DMGVUO5 DE Hepatocellular carcinoma; Hodgkin lymphoma DMUKC5L ID DMUKC5L DMUKC5L DN Tivozanib DMUKC5L HS Approved DMUKC5L SN ASP4130/AV-951 DMUKC5L CP Astellas Pharma US; AVEO Pharmaceuticals DMUKC5L DT Small molecular drug DMUKC5L PC 9911830 DMUKC5L MW 454.9 DMUKC5L FM C22H19ClN4O5 DMUKC5L IC InChI=1S/C22H19ClN4O5/c1-12-8-21(27-32-12)26-22(28)25-16-5-4-13(9-15(16)23)31-18-6-7-24-17-11-20(30-3)19(29-2)10-14(17)18/h4-11H,1-3H3,(H2,25,26,27,28) DMUKC5L CS CC1=CC(=NO1)NC(=O)NC2=C(C=C(C=C2)OC3=C4C=C(C(=CC4=NC=C3)OC)OC)Cl DMUKC5L IK SPMVMDHWKHCIDT-UHFFFAOYSA-N DMUKC5L IU 1-[2-chloro-4-(6,7-dimethoxyquinolin-4-yl)oxyphenyl]-3-(5-methyl-1,2-oxazol-3-yl)urea DMUKC5L CA CAS 475108-18-0 DMUKC5L CB CHEBI:91327 DMUKC5L DE Renal cell carcinoma DMR2IQ4 ID DMR2IQ4 DMR2IQ4 DN Tizanidine DMR2IQ4 HS Approved DMR2IQ4 SN Sirdalud; Ternelin; Tizanidina; Tizanidinum; Sirdalud (TN); Tizanidina [INN-Spanish]; Tizanidine (INN); Tizanidine [INN:BAN]; Tizanidinum [INN-Latin]; Zanaflex (TN); 5-Chloro-4-(2-imidazolin-2-ylamino)-2,1,3-benzothiadiazole; 5-chloro-4-(2-imidazolin-2-yl-amino)-2,1,3-benzothiadiazole; 5-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-2,1,3-benzothiadiazol-4-amine DMR2IQ4 CP Elan Pharmaceuticals DMR2IQ4 TC Analgesics DMR2IQ4 DT Small molecular drug DMR2IQ4 PC 5487 DMR2IQ4 MW 253.71 DMR2IQ4 FM C9H8ClN5S DMR2IQ4 IC InChI=1S/C9H8ClN5S/c10-5-1-2-6-8(15-16-14-6)7(5)13-9-11-3-4-12-9/h1-2H,3-4H2,(H2,11,12,13) DMR2IQ4 CS C1CN=C(N1)NC2=C(C=CC3=NSN=C32)Cl DMR2IQ4 IK XFYDIVBRZNQMJC-UHFFFAOYSA-N DMR2IQ4 IU 5-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-2,1,3-benzothiadiazol-4-amine DMR2IQ4 CA CAS 51322-75-9 DMR2IQ4 CB CHEBI:63629 DMR2IQ4 DE Spasm DMUI0CH ID DMUI0CH DMUI0CH DN Tobramycin DMUI0CH HS Approved DMUI0CH SN Aktob; Brulamycin; Distobram; Gotabiotic; NEBRAMYCIN; Nebcin; Nebicin; Obracin; Obramycin; Sybryx; TOY; Tenebrimycin;Tenemycin; Tobacin; Tobi; Tobracin; Tobradex; Tobradistin; Tobralex; Tobramaxin; Tobramicin; Tobramicina; Tobramitsetin; Tobramycetin; Tobramycine; Tobramycinum; Tobrased; Tobrasone; Tobrex; Deoxykanamycin B; Nebramycin VI; TOBRAMYCIN SULFATE; Tobramycin for Inhalation; Tobramycin solution for inhalation; A 12253A; Lilly 47663; NF 6; Nebramycin 6; Nebramycin factir 6; Nebramycin factor 6; Nebcin (Sulfate); SPRC-AB01; TobraDex (TN); Tobracin (TN); Tobramicina [INN-Spanish]; Tobramycin, Free Base; Tobramycine [INN-French]; Tobramycinum [INN-Latin]; Tobrex (TN); Tobramycin (JP15/USP); Tobramycin[USAN:BAN:INN:JAN]; TOA-(1-6)2TB-(4-1)TOC; TOA-(1-6)TOB-(4-1)TOC; 1-Epitobramycin; 3'-Deoxykanamycin B DMUI0CH CP Bausch & Lomb Pharmaceuticals, Inc. DMUI0CH TC Antibiotics DMUI0CH DT Small molecular drug DMUI0CH PC 36294 DMUI0CH MW 467.5 DMUI0CH FM C18H37N5O9 DMUI0CH IC InChI=1S/C18H37N5O9/c19-3-9-8(25)2-7(22)17(29-9)31-15-5(20)1-6(21)16(14(15)28)32-18-13(27)11(23)12(26)10(4-24)30-18/h5-18,24-28H,1-4,19-23H2/t5-,6+,7+,8-,9+,10+,11-,12+,13+,14-,15+,16-,17+,18+/m0/s1 DMUI0CH CS C1[C@@H]([C@H]([C@@H]([C@H]([C@@H]1N)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)N)O)O)O[C@@H]3[C@@H](C[C@@H]([C@H](O3)CN)O)N)N DMUI0CH IK NLVFBUXFDBBNBW-PBSUHMDJSA-N DMUI0CH IU (2S,3R,4S,5S,6R)-4-amino-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[(2R,3R,5S,6R)-3-amino-6-(aminomethyl)-5-hydroxyoxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-6-(hydroxymethyl)oxane-3,5-diol DMUI0CH CA CAS 32986-56-4 DMUI0CH CB CHEBI:28864 DMUI0CH DE Bacterial infection DMYNMDP ID DMYNMDP DMYNMDP DN Tocainide DMYNMDP HS Approved DMYNMDP SN Taquidil; Tocainida; Tocainidum; Tonocard; Astra W 36095; Tocainida [INN-Spanish]; Tocainidum [INN-Latin]; W-36095; Tocainide (USAN/INN); Tocainide [USAN:BAN:INN]; Alanyl-2,6-xylidide; N-(2,6-dimethylphenyl)alaninamide; (-)-2-Amino-N-(2,6-dimethylphenyl)propanamide; 2-AMINO-N-(2,6-DIMETHYLPHENYL)PROPANAMIDE; 2-Amino-2',6'-propionoxylidide; 2-Amino-N-(2,6-dimethylphenyl)propionamid DMYNMDP TC Antiarrhythmic Agents DMYNMDP DT Small molecular drug DMYNMDP PC 38945 DMYNMDP MW 192.26 DMYNMDP FM C11H16N2O DMYNMDP IC InChI=1S/C11H16N2O/c1-7-5-4-6-8(2)10(7)13-11(14)9(3)12/h4-6,9H,12H2,1-3H3,(H,13,14) DMYNMDP CS CC1=C(C(=CC=C1)C)NC(=O)C(C)N DMYNMDP IK BUJAGSGYPOAWEI-UHFFFAOYSA-N DMYNMDP IU 2-amino-N-(2,6-dimethylphenyl)propanamide DMYNMDP CA CAS 41708-72-9 DMYNMDP CB CHEBI:9611 DMYNMDP DE Ventricular arrhythmias DM7J6OR ID DM7J6OR DM7J6OR DN Tocilizumab DM7J6OR HS Approved DM7J6OR SN Actemra; Actemra (TN); Tocilizumab (USAN/INN); Tocilizumab (genetical recombination); Tocilizumab (genetical recombination) (JAN); humanized IgG1 monoclonal antibody DM7J6OR CP Roche; Genentech DM7J6OR DT Monoclonal antibody DM7J6OR DE Rheumatoid arthritis; Juvenile idiopathic arthritis DM1UE67 ID DM1UE67 DM1UE67 DN TOCOTRIENOL DM1UE67 HS Approved DM1UE67 SN 2-Methyl-2-[[4,8,12-trimethyl-3(E),7(E),11(E)]-tridecatrienyl]-3,4-dihydro-2H-benzo[b]pyran-6-ol DM1UE67 DT Small molecular drug DM1UE67 PC 9929901 DM1UE67 MW 382.6 DM1UE67 FM C26H38O2 DM1UE67 IC InChI=1S/C26H38O2/c1-20(2)9-6-10-21(3)11-7-12-22(4)13-8-17-26(5)18-16-23-19-24(27)14-15-25(23)28-26/h9,11,13-15,19,27H,6-8,10,12,16-18H2,1-5H3/b21-11+,22-13+ DM1UE67 CS CC(=CCC/C(=C/CC/C(=C/CCC1(CCC2=C(O1)C=CC(=C2)O)C)/C)/C)C DM1UE67 IK GJJVAFUKOBZPCB-ZGRPYONQSA-N DM1UE67 IU 2-methyl-2-[(3E,7E)-4,8,12-trimethyltrideca-3,7,11-trienyl]-3,4-dihydrochromen-6-ol DM1UE67 CA CAS 6829-55-6 DM1UE67 DE Hyperlipidaemia DMBS370 ID DMBS370 DMBS370 DN Tofacitinib DMBS370 HS Approved DMBS370 SN Tasocitinib; 477600-75-2; 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile; CP-690550; CP 690550; racemic-tofacitinib; 1259404-17-5; tofacitinibum; CP-690,550; UNII-87LA6FU830; 3-((3R,4R)-rel-4-Methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile; 3-{(3R,4R)-4-methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl}-3-oxopropanenitrile; Tofacitinib (CP-690550,Tasocitinib); CHEMBL221959; CHEBI:71200; Xeljanz (TN) DMBS370 CP Pfizer DMBS370 DT Small molecular drug DMBS370 PC 9926791 DMBS370 MW 312.37 DMBS370 FM C16H20N6O DMBS370 IC InChI=1S/C16H20N6O/c1-11-5-8-22(14(23)3-6-17)9-13(11)21(2)16-12-4-7-18-15(12)19-10-20-16/h4,7,10-11,13H,3,5,8-9H2,1-2H3,(H,18,19,20)/t11-,13+/m1/s1 DMBS370 CS C[C@@H]1CCN(C[C@@H]1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N DMBS370 IK UJLAWZDWDVHWOW-YPMHNXCESA-N DMBS370 IU 3-[(3R,4R)-4-methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-3-oxopropanenitrile DMBS370 CA CAS 477600-75-2 DMBS370 CB CHEBI:71200 DMBS370 DE Rheumatoid arthritis DMIHRNA ID DMIHRNA DMIHRNA DN Tolazamide DMIHRNA HS Approved DMIHRNA SN Diabewas; Norglycin; Tolamide; Tolanase; Tolazamida; Tolazamidum; Tolazolamide; Tolinase; Pharmacia Brand of Tolazamide; T 2408; U 17835; Tolazamida [INN-Spanish]; Tolazamidum [INN-Latin]; Tolinase (TN); U-17835; Tolazamide (JP15/USP/INN); Tolazamide [USAN:INN:BAN:JAN]; N-(p-Toluenesulfonyl)-N'-hexamethyleniminourea; N-[(azepan-1-ylamino)carbonyl]-4-methylbenzenesulfonamide; N-(((hexahydro-1H-azepin-1-yl)amino)carbonyl)-4-methylbenzenesulfonamide; Benzenesulfonamide, {N-[[(hexahydro-1H-azepin-1-yl)amino]carbonyl]-4-methyl-}; N-(((Hexahydro-1H-azepin-1-yl)-amino)carbonyl)-4-methylbenzenesulfonamide; 1-(((((4-Methylphenyl)sulfonyl)amino)carbonyl)amino)azepane; 1-(Hexahydro-1-azepinyl)-3-p-tolylsulfonylurea; 1-(Hexahydro-1H-azepin-1-yl)-3-(p-toluenesulfonyl)urea; 1-(Hexahydro-1H-azepin-1-yl)-3-(p-tolylsulfonyl)urea; 1-(azepan-1-yl)-3-(4-methylphenyl)sulfonylurea; 3-azepan-1-yl-1-(4-methylphenyl)sulfonyl-urea; 4-(p-Tolylsulfonyl)-1,1-hexamethylene; 4-(p-Tolylsulfonyl)-1,1-hexamethylenesemicarbazide; 59866P DMIHRNA TC Hypoglycemic Agents DMIHRNA DT Small molecular drug DMIHRNA PC 5503 DMIHRNA MW 311.4 DMIHRNA FM C14H21N3O3S DMIHRNA IC InChI=1S/C14H21N3O3S/c1-12-6-8-13(9-7-12)21(19,20)16-14(18)15-17-10-4-2-3-5-11-17/h6-9H,2-5,10-11H2,1H3,(H2,15,16,18) DMIHRNA CS CC1=CC=C(C=C1)S(=O)(=O)NC(=O)NN2CCCCCC2 DMIHRNA IK OUDSBRTVNLOZBN-UHFFFAOYSA-N DMIHRNA IU 1-(azepan-1-yl)-3-(4-methylphenyl)sulfonylurea DMIHRNA CA CAS 1156-19-0 DMIHRNA CB CHEBI:9613 DMIHRNA DE Diabetic complication DMI40NL ID DMI40NL DMI40NL DN Tolazoline DMI40NL HS Approved DMI40NL SN Artonil; Benzalolin; Benzazoline; Benzidazol; Benzolin; Benzylimidazoline; Divascol; Imidalin; Imidaline; Kasimid;Lambril; Olitensol; Peripherine; Phenylmethylimidazoline; Prefaxil; Pridazole; Priscol; Priscoline; Tolazolin; Tolazolina; Tolazolinum; Vasimid; Vasodil; Vasodilatan; Dilatol ASI; Tolazine [veterinary]; Tolazoline Monohydrochloride; Ciba 3259; Benzolin (VAN); Benzolin (vasodilator); Tolazine [veterinary] (TN); Tolazolina [INN-Spanish]; Tolazoline (INN); Tolazoline [INN:BAN]; Tolazolinum [INN-Latin]; Benzolin (vasodilator) (VAN); 1H-Imidazole, 4,5-dihydro-2-(phenylmethyl)-(9CI); 2-(phenylmethyl)-4,5-dihydro-1H-imidazole; 2-BENZYL-4,5-IMIDAZOLINE HCl; 2-Benzyl-2-imidazoline; 2-Benzyl-4,5-dihydro-1H-imidazole; 2-Benzyl-4,5-imidazoline; 2-Benzylimidazoline; 4,5-Dihydro-2-(phenylmethyl)-1H-imidazole DMI40NL TC Vasodilator Agents DMI40NL DT Small molecular drug DMI40NL PC 5504 DMI40NL MW 160.22 DMI40NL FM C10H12N2 DMI40NL IC InChI=1S/C10H12N2/c1-2-4-9(5-3-1)8-10-11-6-7-12-10/h1-5H,6-8H2,(H,11,12) DMI40NL CS C1CN=C(N1)CC2=CC=CC=C2 DMI40NL IK JIVZKJJQOZQXQB-UHFFFAOYSA-N DMI40NL IU 2-benzyl-4,5-dihydro-1H-imidazole DMI40NL CA CAS 59-98-3 DMI40NL CB CHEBI:28502 DMI40NL DE Pulmonary hypertension DM02AWV ID DM02AWV DM02AWV DN Tolbutamide DM02AWV HS Approved DM02AWV SN Aglicid; Arcosal; Arkozal; Artosin; Artozin; Beglucin; Butamid; Butamide; Butamidum; Diaben; Diabesan; Diabetamid; Diabetol; Diabuton; Diasulfon; Diaval; Dirastan; Dolipol; Drabet; Glyconon; Ipoglicone; Mobenol; Orabet; Oralin; Oramide; Orezan; Orinase; Orinaz; Oterben; Pramidex; Rastinon; Restinon; Tarasina; Tolbet;Tolbusal; Tolbutamid; Tolbutamida; Tolbutamidum; Tolbutone; Toluina; Tolumid; Toluran; Toluvan; Tolylsulfonylbutylurea; Willbutamide; Apotex Brand of Tolbutamide; Aventis Brand of Tolbutamide; BerlinChemie Brand of Tolbutamide; Butamide Brand of Tolbutamide; Hoechst Brand of Tolbutamide; Pfizer Brand of Tolbutamide; TOLBUTAMIDE USP; Tolbutamide Aventis Brand; Tolbutamide Butamide Brand; Tolbutamide Hoechst Brand; Tolbutamide Pfizer Brand; Valdecasas Brand of Tolbutamide; Yamanouchi Brand of Tolbutamide; D 860; HLS 831; T 0891; U 2043; Apo-Tolbutamide; Berlin-Chemie Brand of Tolbutamide; Novo-Butamide; Orinase (TN); Sk-tolbutamide; Tol-Tab; Tolbutamida [INN-Spanish]; Tolbutamidum [INN-Latin]; Tolbutamide [INN:BAN:JAN]; R.A.N. Brand of Tolbutamide; Tolbutamid R.A.N.; Tolbutamide (JP15/USP/INN); N-4-Methylbenzolsulfonyl-N-butylurea; N-4-(Methylbenzolsulfonyl)-n-butylurea; N-Butyl-N'-p-toluenesulfonylurea; N-n-Butyl-N'-tosylurea; N-(4-Methylbenzenesulfonyl)-N'-butylurea; N-(4-Methylphenylsulfonyl)-N'-butylurea; N-(p-Tolylsulfonyl)-N'-butylcarbamide; N-Butyl-N'-(4-methylphenylsulfonyl)urea; N-Butyl-N'-(p-tolylsulfonyl)urea; N-Butyl-N'-toluene-p-sulfonylurea; N-(p-tolylsulfonyl)-N'-n-butylurea; 1-Butyl-3-(4-methylphenylsulfonyl)urea; 1-Butyl-3-(p-methylphenylsulfonyl)urea; 1-Butyl-3-(p-tolylsulfonyl)urea; 1-Butyl-3-(para-tolylsulfonyl) urea; 1-Butyl-3-tosylurea; 1-butyl-3-(4-methylphenyl)sulfonylurea; 1-p-Toluenesulfonyl-3-butylurea; 3-(p-Tolyl-4-sulfonyl)-1-butylurea; 3-(p-tolylsulfonyl)-1-butylurea; 3-[p-Tolyl-4-sulfonyl]-1-butylurea DM02AWV CP Pharmacia And Upjohn Co DM02AWV TC Hypoglycemic Agents DM02AWV DT Small molecular drug DM02AWV PC 5505 DM02AWV MW 270.35 DM02AWV FM C12H18N2O3S DM02AWV IC InChI=1S/C12H18N2O3S/c1-3-4-9-13-12(15)14-18(16,17)11-7-5-10(2)6-8-11/h5-8H,3-4,9H2,1-2H3,(H2,13,14,15) DM02AWV CS CCCCNC(=O)NS(=O)(=O)C1=CC=C(C=C1)C DM02AWV IK JLRGJRBPOGGCBT-UHFFFAOYSA-N DM02AWV IU 1-butyl-3-(4-methylphenyl)sulfonylurea DM02AWV CA CAS 64-77-7 DM02AWV CB CHEBI:27999 DM02AWV DE Non-insulin dependent diabetes DM8MNVO ID DM8MNVO DM8MNVO DN Tolcapone DM8MNVO HS Approved DM8MNVO SN Tasmar; Roche brand of tolcapone; Ro 40-7592; Tasmar (TN); Tolcapone [USAN:INN]; Ro-40-7592; Tolcapone (JAN/USAN/INN); Methanone,(3,4-dihydroxy-5-nitrophenyl)(4-methylphenyl); (3,4-Dihydroxy-5-nitrophenyl)(4-methylphenyl)methanone; (3,4-dihydroxy-5-nitrophenyl)-(4-methylphenyl)methanone; 3,4-Dihydroxy-4'-methyl-5-nitrobenzophenone; 3,4-dihydroxy-5'-methyl-5-nitrobenzophenone DM8MNVO TC Antiparkinson Agents DM8MNVO DT Small molecular drug DM8MNVO PC 4659569 DM8MNVO MW 273.24 DM8MNVO FM C14H11NO5 DM8MNVO IC InChI=1S/C14H11NO5/c1-8-2-4-9(5-3-8)13(17)10-6-11(15(19)20)14(18)12(16)7-10/h2-7,16,18H,1H3 DM8MNVO CS CC1=CC=C(C=C1)C(=O)C2=CC(=C(C(=C2)O)O)[N+](=O)[O-] DM8MNVO IK MIQPIUSUKVNLNT-UHFFFAOYSA-N DM8MNVO IU (3,4-dihydroxy-5-nitrophenyl)-(4-methylphenyl)methanone DM8MNVO CA CAS 134308-13-7 DM8MNVO CB CHEBI:63630 DM8MNVO DE Parkinson disease DMWUIJE ID DMWUIJE DMWUIJE DN Tolmetin DMWUIJE HS Approved DMWUIJE SN Tolectin; Tolmetina; Tolmetine; Tolmetino; Tolmetinum; Tolmetina [DCIT]; MCN 2559; McN-2559; Tolectin (TN); Tolmetin Sodium, Dihydrate; Tolmetine [INN-French]; Tolmetino [INN-Spanish]; Tolmetinum [INN-Latin]; Tolmetin (USAN/INN); Tolmetin [USAN:BAN:INN]; Acido 1-metil-5-(p-tolnil)-pirrol-2-acetico; Acido 1-metil-5-(p-tolnil)-pirrol-2-acetico [Spanish]; 1-Methyl-5-(4-methylbenzoyl)-1H-pyrrole-2-acetic acid; 1-Methyl-5-(4-methylbenzoyl)-pyrrole-2-acetic acid; 1-Methyl-5-p-toluoylpyrrole-2-acetic acid; 2-[1-methyl-5-(4-methylbenzoyl)pyrrol-2-yl]acetic acid; 5-(p-Toluoyl)-1-methylpyrrole-2-acetic acid DMWUIJE CP Ortho Mcneil Janssen Pharmaceuticals Inc DMWUIJE TC Antiinflammatory Agents DMWUIJE DT Small molecular drug DMWUIJE PC 5509 DMWUIJE MW 257.279 DMWUIJE FM C15H15NO3 DMWUIJE IC InChI=1S/C15H15NO3/c1-10-3-5-11(6-4-10)15(19)13-8-7-12(16(13)2)9-14(17)18/h3-8H,9H2,1-2H3,(H,17,18) DMWUIJE CS CC1=CC=C(C=C1)C(=O)C2=CC=C(N2C)CC(=O)O DMWUIJE IK UPSPUYADGBWSHF-UHFFFAOYSA-N DMWUIJE IU 2-[1-methyl-5-(4-methylbenzoyl)pyrrol-2-yl]acetic acid DMWUIJE CA CAS 26171-23-3 DMWUIJE CB CHEBI:71941 DMWUIJE DE Rheumatoid arthritis DM28MU7 ID DM28MU7 DM28MU7 DN Tolnaftate DM28MU7 HS Approved DM28MU7 SN Aftate; Breezee; Chinofungin; Dermoxin; Dungistop; Focusan; Fungistop; Genaspor; Micoisdin; Phytoderm; Pitrex; Separin; Sorgoa; Sporiline; Timoped; Tinactin; Tinaderm; Tinatox; Tinavet; Ting; Tniaderm; Tolnaftato; Tolnaftatum; Tolnaphthate; Tolsanil; Tonoftal; Tritin; ZeaSorb; Aftate for jock itch aerosol spray powder; Aftate for jock itch gel; Aftate for jock itch sprinkle powder; Bioglan Brand of Tolnaftate; Carter Wallace Brand of Tolnaftate; Chinosol Brand of Tolnaftate; Douglas Brand of Tolnaftate; Essex Brand of Tolnaftate; Genaspore cream; Insight Brand of Tolnaftate; Isdin Brand of Tolnaftate; Naphthiomate T; Ony Clear; Pitrex cream; Schering Brand of Tolnaftate; Stiefel Brand of Tolnaftate; Thompson Brand of Tolnaftate; Tinactin aerosol liquid; Tinactin aerosol powder; Tinactin antifungal deodorant powder aerosol; Tinactin cream; Tinactin jock itch aerosol powder; Tinactin jock itch cream;Tinactin jock itch spray powder; Tinactin plus aerosol powder; Tinactin plus powder; Tinactin powder; Tinactin solution; Ting Products; Ting antifungal cream; Ting antifungal powder; Ting antifungal spray liquid; Ting antifungal spray powder; Tolnaftat Purder N; Tolnaftate Douglas Brand; Tolnaftate Schering Brand; Tolnaftato [DCIT]; Wernigerode Brand of Tolnaftate; Zenith Brand of Tolnaftate; NP 27; NP27; Pedinol Brand 1 of Tolnaftate; Pedinol Brand 2 of Tolnaftate; Sch 10144; Absorbine (TN); Aftate (TN); Aftate for athlete's foot aerosol spray liquid; Aftate for athlete's foot aerosol spray powder; Aftate for athlete's foot gel; Aftate for athlete's foot sprinkle powder; Genaspor (TN); HI-Alazin; Hi-alarzin; Lamasil AF (TN); NP 27 (TN); NP-27 Cream; NP-27 Powder; NP-27 Solution; NP-27 Spray Powder; Naphthiomate-T; Odor Eaters (TN); Ony-Clear; Purder N, Tolnaftat; Schering-Plough Brand 1 of Tolnaftate; Schering-Plough Brand 2 of Tolnaftate; Scholl (TN); Separin (TN); Tinactin (TN); Tinavet (Veterinary); Ting (TN); Tolnaftate(USAN); Tolnaftato [INN-Spanish]; Tolnaftatum [INN-Latin]; Zeasorb-AF powder; Tolnaftate (JP14/USP); Tolnaftate (JP15/USP); Dr. Scholl's athlete's foot spray; Tolnaftate (JP15/USP/INN); Tolnaftate [USAN:BAN:INN:JAN]; Tolnaftate [USAN:INN:BAN:JAN]; M,N-Dimethylthiocarbanilic acid O-2-naphthyl ester; Methyl (3-methylphenyl)carbamothioic acid O-2-naphthalenyl ester; O-2-Naphthyl N,N-dimethylthiocarbanilate; O-2-Naphthyl m,N-dimethylthiocarbanilate; Methyl-(3-methylphenyl)carbamothioic acid O-2-naphthyl ester; Methyl-[3-methylphenyl]-carbamothioic acid O-2-naphthyl ester; O-(2-Naphthyl) methyl(3-methylphenyl)thiocarbamate; O-naphthalen-2-yl methyl(3-methylphenyl)carbamothioate; Carbamothioic acid, methyl(3-methylphenyl)-, O-2-naphthalenyl ester; Carbanilic acid, N,m-dimethylthio-, O-2-naphthyl ester; Carbanilic acid, m,N-dimethylthio-, O-2-naphthyl ester; N-Methyl-(3-methylphenyl)-carbamothioic acid, O-2-naphthalenyl ester; O-naphthalen-2-yl N-methyl-N-(3-methylphenyl)carbamothioate; Carbamothioic acid, N-methyl-N-(3-methylphenyl)-, O-2-naphthalenyl ester; 2-Naphthyl N-methyl-N-(3-tolyl)thionocarbamate DM28MU7 CP Schering-Plough DM28MU7 TC Antifungal Agents DM28MU7 DT Small molecular drug DM28MU7 PC 5510 DM28MU7 MW 307.4 DM28MU7 FM C19H17NOS DM28MU7 IC InChI=1S/C19H17NOS/c1-14-6-5-9-17(12-14)20(2)19(22)21-18-11-10-15-7-3-4-8-16(15)13-18/h3-13H,1-2H3 DM28MU7 CS CC1=CC(=CC=C1)N(C)C(=S)OC2=CC3=CC=CC=C3C=C2 DM28MU7 IK FUSNMLFNXJSCDI-UHFFFAOYSA-N DM28MU7 IU O-naphthalen-2-yl N-methyl-N-(3-methylphenyl)carbamothioate DM28MU7 CA CAS 2398-96-1 DM28MU7 CB CHEBI:9620 DM28MU7 DE Dermatophytosis; Jock itch DMA2GHJ ID DMA2GHJ DMA2GHJ DN Tolperisone DMA2GHJ HS Approved DMA2GHJ SN Agileo; Viveo; AV-650; SPH-3047; Tolperisone (controlled-release); Tolperisone (controlled-release), Sanochemia; Tolperisone (controlled-release), Sanochemia/Avigen DMA2GHJ CP Sanochemia Pharmazeutika AG DMA2GHJ DT Small molecular drug DMA2GHJ PC 5511 DMA2GHJ MW 245.36 DMA2GHJ FM C16H23NO DMA2GHJ IC InChI=1S/C16H23NO/c1-13-6-8-15(9-7-13)16(18)14(2)12-17-10-4-3-5-11-17/h6-9,14H,3-5,10-12H2,1-2H3 DMA2GHJ CS CC1=CC=C(C=C1)C(=O)C(C)CN2CCCCC2 DMA2GHJ IK FSKFPVLPFLJRQB-UHFFFAOYSA-N DMA2GHJ IU 2-methyl-1-(4-methylphenyl)-3-piperidin-1-ylpropan-1-one DMA2GHJ CA CAS 728-88-1 DMA2GHJ CB CHEBI:93835 DMA2GHJ DE Muscle spasm DMSHPW8 ID DMSHPW8 DMSHPW8 DN Tolterodine DMSHPW8 HS Approved DMSHPW8 SN Tolterodina; Tolterodinum; Detrol (TN); Detrusitol (TN); Kabi-2234; 2-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-methylphenol; 2-[(1R)-3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-methylphenol; 2-[3-[Bis(1-methylethyl)amino]-1-phenylpropyl]-4-methylphenol; 2-{(1R)-3-[bis(1-methylethyl)amino]-1-phenylpropyl}-4-methylphenol DMSHPW8 CP Pfizer Pharmaceuticals DMSHPW8 TC Antispasmodics DMSHPW8 DT Small molecular drug DMSHPW8 PC 443879 DMSHPW8 MW 325.5 DMSHPW8 FM C22H31NO DMSHPW8 IC InChI=1S/C22H31NO/c1-16(2)23(17(3)4)14-13-20(19-9-7-6-8-10-19)21-15-18(5)11-12-22(21)24/h6-12,15-17,20,24H,13-14H2,1-5H3/t20-/m1/s1 DMSHPW8 CS CC1=CC(=C(C=C1)O)[C@H](CCN(C(C)C)C(C)C)C2=CC=CC=C2 DMSHPW8 IK OOGJQPCLVADCPB-HXUWFJFHSA-N DMSHPW8 IU 2-[(1R)-3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-methylphenol DMSHPW8 CA CAS 124937-51-5 DMSHPW8 CB CHEBI:9622 DMSHPW8 DE Overactive bladder DMIWFRL ID DMIWFRL DMIWFRL DN Tolvaptan DMIWFRL HS Approved DMIWFRL SN Samsca; OPC 41061; Benzazepine derivative, 32; OPC-41061; Samsca (TN); N-[4-(7-chloro-5-hydroxy-2,3,4,5-tetrahydro-1-benzazepine-1-carbonyl)-3-methylphenyl]-2-methylbenzamide; (-)-4'-((7-Chloro-2,3,4,5-tetrahydro-5-hydroxy-1H-1-benzazepin-1-yl)carbonyl)-o-tolu-m-toluidide; 7-Chloro-5-hydroxy-1-(2-methyl-4-(2-methylbenzoylamino)benzoyl)2,3,4,5-tetrahydro-1H-1-benzazepine DMIWFRL CP Otsuka; Winston Laboratories & Otsuka DMIWFRL DT Small molecular drug DMIWFRL PC 216237 DMIWFRL MW 448.9 DMIWFRL FM C26H25ClN2O3 DMIWFRL IC InChI=1S/C26H25ClN2O3/c1-16-6-3-4-7-20(16)25(31)28-19-10-11-21(17(2)14-19)26(32)29-13-5-8-24(30)22-15-18(27)9-12-23(22)29/h3-4,6-7,9-12,14-15,24,30H,5,8,13H2,1-2H3,(H,28,31) DMIWFRL CS CC1=CC=CC=C1C(=O)NC2=CC(=C(C=C2)C(=O)N3CCCC(C4=C3C=CC(=C4)Cl)O)C DMIWFRL IK GYHCTFXIZSNGJT-UHFFFAOYSA-N DMIWFRL IU N-[4-(7-chloro-5-hydroxy-2,3,4,5-tetrahydro-1-benzazepine-1-carbonyl)-3-methylphenyl]-2-methylbenzamide DMIWFRL CA CAS 150683-30-0 DMIWFRL CB CHEBI:32246 DMIWFRL DE Hyponatraemia; Heart failure DMAE6LK ID DMAE6LK DMAE6LK DN Topetecan DMAE6LK HS Approved DMAE6LK SN TOPOTECAN HYDROCHLORIDE; 119413-54-6; Topotecan Hcl; Hycamptamine hydrochloride; Topotecan (Hydrochloride); Topotecan monohydrochloride; UNII-956S425ZCY; Topotecan hydrochloride [USAN]; Nogitecan hydrochloride; DRG-0288; F S-104864-A; NSC-609699; NSC 609699; NSC609699; 956S425ZCY; (S)-10-((Dimethylamino)methyl)-4-ethyl-4,9-dihydroxy-1H-pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione monohydrochloride; NCGC00095189-01; AK-48920; DSSTox_RID_81248; DSSTox_CID_25952 DMAE6LK CP GSK DMAE6LK DT Small molecular drug DMAE6LK PC 60699 DMAE6LK MW 457.9 DMAE6LK FM C23H24ClN3O5 DMAE6LK IC InChI=1S/C23H23N3O5.ClH/c1-4-23(30)16-8-18-20-12(9-26(18)21(28)15(16)11-31-22(23)29)7-13-14(10-25(2)3)19(27)6-5-17(13)24-20;/h5-8,27,30H,4,9-11H2,1-3H3;1H/t23-;/m0./s1 DMAE6LK CS CC[C@@]1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl DMAE6LK IK DGHHQBMTXTWTJV-BQAIUKQQSA-N DMAE6LK IU (19S)-8-[(dimethylamino)methyl]-19-ethyl-7,19-dihydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaene-14,18-dione;hydrochloride DMAE6LK CA CAS 119413-54-6 DMAE6LK DE Small-cell lung cancer DM82Z30 ID DM82Z30 DM82Z30 DN Topiramate DM82Z30 HS Approved DM82Z30 SN Epitoma; Epitomax; TOR; Tipiramate; Tipiramato; Topamac; Topamax; Topimax; Topina; Topiramato; Topiramatum; Topomax; Cilag brandof topiramate; Janssen brand of topiramate; Ortho brand of topiramate; Tipiramate [French]; Tipiramato [Spanish]; Topamax Sprinkle; Topiramate tablet; Topiramatum [Latin]; Topiramic acid; McN 4853; RWJ 17021; KS-1122; KW-6485; McN-4853; RWJ-17021; Topamax (TN); Topamax, Topiramate; Topiramate (TPM); Topiramate / Placebo; Topiramato [INN-Spanish]; Topiramatum [INN-Latin]; USL-255; RWJ-17021-000; Topiramate [USAN:BAN:INN]; Topiramate (JAN/USAN/INN); Beta-D-Fructopyranose, 2,3:4,5-bis-O-(1-methylethylidene)-, sulfamate; Beta-D-Fructopyranose, 2,3:4,5-bis-O-(1-methylethylidene)-, sulfamate (9CI);Beta.-D-Fructopyranose, 2,3:4,5-bis-O-(1-methylethylidene)-, 1-sulfamate; [(3aS,5aR,8aR,8bS)-2,2,7,7-tetramethyltetrahydro-3aH-bis[1,3]dioxolo[4,5-b:4',5'-d]pyran-3a-yl]methyl sulfamate; 2,3-4,5-bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate; 2,3:4,5-Bis-O-(1-methylethylidene) .beta.-D-fructopyranose sulfamate; 2,3:4,5-Bis-O-(1-methylethylidene)-36-D-fructo-pyranose sulfamate; 2,3:4,5-Bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate; 2,3:4,5-Di-O-isopropylidene-(beta)-D-fructopyranose sulfamate; 2,3:4,5-Di-O-isopropylidene-beta-D-fructopyranose sulfamate; 5H-Bis[1,3]dioxolo[4,5-b:4',5'-d]pyran, beta DM82Z30 CP Ortho-McNell Pharmaceutical DM82Z30 TC Anticonvulsants DM82Z30 DT Small molecular drug DM82Z30 PC 5284627 DM82Z30 MW 339.36 DM82Z30 FM C12H21NO8S DM82Z30 IC InChI=1S/C12H21NO8S/c1-10(2)18-7-5-16-12(6-17-22(13,14)15)9(8(7)19-10)20-11(3,4)21-12/h7-9H,5-6H2,1-4H3,(H2,13,14,15)/t7-,8-,9+,12+/m1/s1 DM82Z30 CS CC1(O[C@@H]2CO[C@@]3([C@H]([C@@H]2O1)OC(O3)(C)C)COS(=O)(=O)N)C DM82Z30 IK KJADKKWYZYXHBB-XBWDGYHZSA-N DM82Z30 IU [(1R,2S,6S,9R)-4,4,11,11-tetramethyl-3,5,7,10,12-pentaoxatricyclo[7.3.0.02,6]dodecan-6-yl]methyl sulfamate DM82Z30 CA CAS 97240-79-4 DM82Z30 CB CHEBI:63631 DM82Z30 DE Alcohol dependence; Epilepsy; Seizure disorder DMP6G8T ID DMP6G8T DMP6G8T DN Topotecan DMP6G8T HS Approved DMP6G8T SN Hycamptamine; Hycamptin; Hycamtamine; Topotecane; Topotecanum; Topotecan lactone; SKF 104864; SKF-S 104864; TOPOTECAN, HYCAMTIN; Topotecan (BAN); Topotecan [INN:BAN]; Topotecane [INN-French]; Topotecanum [INN-Latin]; Topotecan Monohydrochloride, (S)-Isomer; (4S)-10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; (S)-10-((Dimethylamino)methyl)-4-ethyl-4,9-dihydroxy-1H-pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione; (S)-10-[(DIMETHYLAMINO)METHYL]-4-ETHYL-4,9-DIHYDROXY-1H-PYRANO[3',4':6,7]INOLIZINO[1,2-B]-QUINOLINE-3,14(4H,12H)-DIONE; (S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]-quinoline-3,14(4H,12H)-dione; (S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; 9-Dimethylaminomethyl-10-hydroxycamptothecin DMP6G8T CP GlaxoSmithKline DMP6G8T TC Anticancer Agents DMP6G8T DT Small molecular drug DMP6G8T PC 60700 DMP6G8T MW 421.4 DMP6G8T FM C23H23N3O5 DMP6G8T IC InChI=1S/C23H23N3O5/c1-4-23(30)16-8-18-20-12(9-26(18)21(28)15(16)11-31-22(23)29)7-13-14(10-25(2)3)19(27)6-5-17(13)24-20/h5-8,27,30H,4,9-11H2,1-3H3/t23-/m0/s1 DMP6G8T CS CC[C@@]1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O DMP6G8T IK UCFGDBYHRUNTLO-QHCPKHFHSA-N DMP6G8T IU (19S)-8-[(dimethylamino)methyl]-19-ethyl-7,19-dihydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaene-14,18-dione DMP6G8T CA CAS 123948-87-8 DMP6G8T CB CHEBI:63632 DMP6G8T DE Small-cell lung cancer; Ovarian cancer; Solid tumour/cancer DMXKJ6C ID DMXKJ6C DMXKJ6C DN Torasemide DMXKJ6C HS Approved DMXKJ6C SN Demadex; Dilutol; Luprac; Presoril; Sutril; TORSEMIDE; Toradiur; Torasemida; Torasemidum; Torem; Torocard; Torrem; Unat; Torasemide N; Torsemide [USAN]; AC 4464; BM 02015; JDL 464; BM-02015; Demadex (TN); Demadex, Torsemide; GJ-1090; JDL-464; KS-1123; Luprac (TN); PW-2132; Torasemida [INN-Spanish]; Torasemidum [INN-Latin]; Torsemide (USP); Torasemide (JAN/INN); N-(Isopropylcarbamoyl)-4-(m-tolylamino)pyridine-3-sulfonamide; N-{[(1-methylethyl)amino]carbonyl}-4-[(3-methylphenyl)amino]pyridine-3-sulfonamide; N-(((1-Methylethyl)amino)carbonyl)-4-((3-methylphenyl)amino)-3-pyridinesulfonamide; 1-Isopropyl-3-((4-m-toluidino-3-pyridyl)sulfonyl)urea; 1-[4-(3-methylanilino)pyridin-3-yl]sulfonyl-3-propan-2-ylurea; 1-isopropyl-3-((4-(3-methylphenylamino)pyridine)-3-sulfonyl)urea; 1-isopropyl-3-[(4-m-toluidino-3-pyridyl) sulfonyl]urea DMXKJ6C TC Diuretics DMXKJ6C DT Small molecular drug DMXKJ6C PC 41781 DMXKJ6C MW 348.4 DMXKJ6C FM C16H20N4O3S DMXKJ6C IC InChI=1S/C16H20N4O3S/c1-11(2)18-16(21)20-24(22,23)15-10-17-8-7-14(15)19-13-6-4-5-12(3)9-13/h4-11H,1-3H3,(H,17,19)(H2,18,20,21) DMXKJ6C CS CC1=CC(=CC=C1)NC2=C(C=NC=C2)S(=O)(=O)NC(=O)NC(C)C DMXKJ6C IK NGBFQHCMQULJNZ-UHFFFAOYSA-N DMXKJ6C IU 1-[4-(3-methylanilino)pyridin-3-yl]sulfonyl-3-propan-2-ylurea DMXKJ6C CA CAS 56211-40-6 DMXKJ6C CB CHEBI:9637 DMXKJ6C DE Congestive heart failure DMQYUWG ID DMQYUWG DMQYUWG DN Toremifene DMQYUWG HS Approved DMQYUWG SN Acapodene; Estrimex; Farestone; Toremifeno; Toremifenum; Toremifene Base; Toremifeno [Spanish]; Toremifenum [Latin]; GTx 006; Acapodene (TN); FC-1157a; Fareston (TN); GTx-006; Toremifene (INN); Toremifene [INN:BAN]; Z-Toremifene; GTX-006 (Acapodene); Toremifene Citrate (1:1); {2-[4-(4-Chloro-1,2-diphenyl-but-1-enyl)-phenoxy]-ethyl}-dimethyl-amine; (Z)-2-(4-(4-Chloro-1,2-diphenyl-1-butenyl)phenoxy)-N,N-dimethylethanamine; 2-(p-[(Z)-4-chloro-1,2-diphenyl-1-butenyl]-phenoxy)-N,N-dimethyl-ethylamine citrate(1:1); 2-(para-((Z)-4-Chloro-1,2-diphenyl-1-butenyl)phenoxy)-N,N-dimethylethylamine (IUPAC); 2-({4-[(1Z)-4-chloro-1,2-diphenylbut-1-en-1-yl]phenyl}oxy)-N,N-dimethylethanamine; 2-[4-[(Z)-4-chloro-1,2-diphenylbut-1-enyl]phenoxy]-N,N-dimethylethanamine; 2-{4-[(1Z)-4-chloro-1,2-diphenylbut-1-en-1-yl]phenoxy}-N,N-dimethylethanamine DMQYUWG CP Prostrakan Inc DMQYUWG TC Anticancer Agents DMQYUWG DT Small molecular drug DMQYUWG PC 3005573 DMQYUWG MW 406 DMQYUWG FM C26H28ClNO DMQYUWG IC InChI=1S/C26H28ClNO/c1-28(2)19-20-29-24-15-13-23(14-16-24)26(22-11-7-4-8-12-22)25(17-18-27)21-9-5-3-6-10-21/h3-16H,17-20H2,1-2H3/b26-25- DMQYUWG CS CN(C)CCOC1=CC=C(C=C1)/C(=C(/CCCl)\\C2=CC=CC=C2)/C3=CC=CC=C3 DMQYUWG IK XFCLJVABOIYOMF-QPLCGJKRSA-N DMQYUWG IU 2-[4-[(Z)-4-chloro-1,2-diphenylbut-1-enyl]phenoxy]-N,N-dimethylethanamine DMQYUWG CA CAS 89778-26-7 DMQYUWG CB CHEBI:9635 DMQYUWG DE Breast cancer DMMYZ3D ID DMMYZ3D DMMYZ3D DN Tositumomab DMMYZ3D HS Approved DMMYZ3D SN Bexxar (TN) DMMYZ3D CP GlaxoSmithKline DMMYZ3D TC Anticancer Agents DMMYZ3D DT Antibody DMMYZ3D SQ Mouse-Human chimeric Anti-CD20 Heavy Chain 1: QAYLQQSGAELVRPGASVKMSCKASGYTFTSYNMHWVKQTPRQGLEWIGAIYPGNGDTSYNQKFKGKATLTVDKSSSTAYMQLSSLTSEDSAVYFCARVVYYSNSYWYFDVWGTGTTVTVSGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKAEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK >Mouse-Human chimeric Anti-CD20 Light Chain 1QIVLSQSPAILSASPGEKVTMTCRASSSVSYMHWYQQKPGSSPKPWIYAPSNLASGVPARFSGSGSGTSYSLTISRVEAEDAATYYCQQWSFNPPTFGAGTKLELKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR >Mouse-Human chimeric Anti-CD20 Heavy Chain 2QAYLQQSGAELVRPGASVKMSCKASGYTFTSYNMHWVKQTPRQGLEWIGAIYPGNGDTSYNQKFKGKATLTVDKSSSTAYMQLSSLTSEDSAVYFCARVVYYSNSYWYFDVWGTGTTVTVSGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKAEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK >Mouse-Human chimeric Anti-CD20 Light Chain 2QIVLSQSPAILSASPGEKVTMTCRASSSVSYMHWYQQKPGSSPKPWIYAPSNLASGVPARFSGSGSGTSYSLTISRVEAEDAATYYCQQWSFNPPTFGAGTKLELKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR DMMYZ3D DE Non-hodgkin lymphoma DM5A31S ID DM5A31S DM5A31S DN TP-434 DM5A31S HS Approved DM5A31S SN TP-038; TP-120; TP-170; TP-221; TP-271; TP-787; Tetracycline analogs (bacterial infection), Tetraphase Pharmaceuticals; Tetracycline derivatives (bacterial infection), Tetraphase Pharmaceuticals; Fluorocycline antibiotic (oral, bacterial infection), Tetraphase Pharmaceuticals; Tetracycline analogs (iv, antibiotic), Tetraphase Pharmaceuticals; TP-434 (oral, multidrug-resistant bacterial infections); TP-434 (oral, multidrug-resistant bacterial infections), Tetraphase Pharmaceuticals DM5A31S CP Tetraphase Pharmaceuticals DM5A31S DT Small molecular drug DM5A31S PC 54726192 DM5A31S MW 558.6 DM5A31S FM C27H31FN4O8 DM5A31S IC InChI=1S/C27H31FN4O8/c1-31(2)20-13-8-11-7-12-14(28)9-15(30-16(33)10-32-5-3-4-6-32)21(34)18(12)22(35)17(11)24(37)27(13,40)25(38)19(23(20)36)26(29)39/h9,11,13,20,34-35,38,40H,3-8,10H2,1-2H3,(H2,29,39)(H,30,33)/t11-,13-,20-,27-/m0/s1 DM5A31S CS CN(C)[C@H]1[C@@H]2C[C@@H]3CC4=C(C=C(C(=C4C(=C3C(=O)[C@@]2(C(=C(C1=O)C(=O)N)O)O)O)O)NC(=O)CN5CCCC5)F DM5A31S IK AKLMFDDQCHURPW-ISIOAQNYSA-N DM5A31S IU (4S,4aS,5aR,12aR)-4-(dimethylamino)-7-fluoro-1,10,11,12a-tetrahydroxy-3,12-dioxo-9-[(2-pyrrolidin-1-ylacetyl)amino]-4a,5,5a,6-tetrahydro-4H-tetracene-2-carboxamide DM5A31S CA CAS 1207283-85-9 DM5A31S DE Intra-abdominal infection; Influenza virus infection DMG3Y89 ID DMG3Y89 DMG3Y89 DN Trabectedin DMG3Y89 HS Approved DMG3Y89 SN Ecteinascidin; Ecteinascidin-743; Et-743; Yondelis (TN) DMG3Y89 CP PharmaMar DMG3Y89 DT Small molecular drug DMG3Y89 PC 108150 DMG3Y89 MW 761.8 DMG3Y89 FM C39H43N3O11S DMG3Y89 IC InChI=1S/C39H43N3O11S/c1-16-9-20-10-22-37(46)42-23-13-50-38(47)39(21-12-25(48-5)24(44)11-19(21)7-8-40-39)14-54-36(30(42)29(41(22)4)26(20)31(45)32(16)49-6)28-27(23)35-34(51-15-52-35)17(2)33(28)53-18(3)43/h9,11-12,22-23,29-30,36-37,40,44-46H,7-8,10,13-15H2,1-6H3/t22-,23-,29+,30+,36+,37-,39+/m0/s1 DMG3Y89 CS CC1=CC2=C([C@@H]3[C@@H]4[C@H]5C6=C(C(=C7C(=C6[C@@H](N4[C@H]([C@H](C2)N3C)O)COC(=O)[C@@]8(CS5)C9=CC(=C(C=C9CCN8)O)OC)OCO7)C)OC(=O)C)C(=C1OC)O DMG3Y89 IK PKVRCIRHQMSYJX-AIFWHQITSA-N DMG3Y89 IU [(1R,2R,3R,11S,12S,14R,26R)-5,6',12-trihydroxy-6,7'-dimethoxy-7,21,30-trimethyl-27-oxospiro[17,19,28-trioxa-24-thia-13,30-diazaheptacyclo[12.9.6.13,11.02,13.04,9.015,23.016,20]triaconta-4(9),5,7,15,20,22-hexaene-26,1'-3,4-dihydro-2H-isoquinoline]-22-yl] acetate DMG3Y89 CA CAS 114899-77-3 DMG3Y89 CB CHEBI:84050 DMG3Y89 DE Solid tumour/cancer; Ovarian cancer DMRQD04 ID DMRQD04 DMRQD04 DN Tramadol DMRQD04 HS Approved DMRQD04 SN Conzip; Ryzolt; Tramadol Hydrochloride; Ultram Er; Rybix Odt; Ultram DMRQD04 CP Chemie Grunenthal of Stolberg-am-Rhein DMRQD04 TC Analgesics DMRQD04 DT Small molecular drug DMRQD04 PC 33741 DMRQD04 MW 263.37 DMRQD04 FM C16H25NO2 DMRQD04 IC InChI=1S/C16H25NO2/c1-17(2)12-14-7-4-5-10-16(14,18)13-8-6-9-15(11-13)19-3/h6,8-9,11,14,18H,4-5,7,10,12H2,1-3H3/t14-,16+/m1/s1 DMRQD04 CS CN(C)C[C@H]1CCCC[C@@]1(C2=CC(=CC=C2)OC)O DMRQD04 IK TVYLLZQTGLZFBW-ZBFHGGJFSA-N DMRQD04 IU (1R,2R)-2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexan-1-ol DMRQD04 CA CAS 123154-38-1 DMRQD04 CB CHEBI:75725 DMRQD04 DE Pain DM2JGQ3 ID DM2JGQ3 DM2JGQ3 DN Trametinib DM2JGQ3 HS Approved DM2JGQ3 SN GSK 1120212; GSK-1120212; GSK1120212; JTP 74057; JTP-74057; Mekinist; Trametinib (GSK1120212); Trametinib (GSK1120212JTP 74057); Trametinib (MEK inhibitor); 33E86K87QN; A1-01871; AK174783; CHEBI:75998; UNII-33E86K87QN DM2JGQ3 CP GlaxoSmithKline DM2JGQ3 DT Small molecular drug DM2JGQ3 PC 11707110 DM2JGQ3 MW 615.4 DM2JGQ3 FM C26H23FIN5O4 DM2JGQ3 IC InChI=1S/C26H23FIN5O4/c1-13-22-21(23(31(3)24(13)35)30-20-10-7-15(28)11-19(20)27)25(36)33(17-8-9-17)26(37)32(22)18-6-4-5-16(12-18)29-14(2)34/h4-7,10-12,17,30H,8-9H2,1-3H3,(H,29,34) DM2JGQ3 CS CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5 DM2JGQ3 IK LIRYPHYGHXZJBZ-UHFFFAOYSA-N DM2JGQ3 IU N-[3-[3-cyclopropyl-5-(2-fluoro-4-iodoanilino)-6,8-dimethyl-2,4,7-trioxopyrido[4,3-d]pyrimidin-1-yl]phenyl]acetamide DM2JGQ3 CA CAS 871700-17-3 DM2JGQ3 CB CHEBI:75998 DM2JGQ3 DE Melanoma DM4L6EU ID DM4L6EU DM4L6EU DN Trandolapril DM4L6EU HS Approved DM4L6EU SN Gopten; Mavik; Odric; Odrik; Preran; Trandolaprilum; Udrik; Trandolaprilum [Latin]; RU 44570; RU44570; Mavik (TN); RU-44570; Trandolapril [INN:BAN]; Trandolapril (JAN/INN); (2S,3aR,7aS)-1-((S)-N-((S)-1-Carboxy-3-phenylpropyl)alanyl)hexahydro-2-indolinecarboxylic acid, 1-ethyl ester; (2S,3aR,7aS)-1-(N-((1S)-1-((Ethyloxy)carbonyl)-3-phenylpropyl)-L-alanyl)octahydro-1H-indole-2-carboxylic Acid; (2S,3aR,7aS)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carboxylicacid; 1-(2-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)octahydro-1H-indol-2-carboxylic acid DM4L6EU CP Abbott Laboratories DM4L6EU TC Antihypertensive Agents DM4L6EU DT Small molecular drug DM4L6EU PC 5484727 DM4L6EU MW 430.5 DM4L6EU FM C24H34N2O5 DM4L6EU IC InChI=1S/C24H34N2O5/c1-3-31-24(30)19(14-13-17-9-5-4-6-10-17)25-16(2)22(27)26-20-12-8-7-11-18(20)15-21(26)23(28)29/h4-6,9-10,16,18-21,25H,3,7-8,11-15H2,1-2H3,(H,28,29)/t16-,18+,19-,20-,21-/m0/s1 DM4L6EU CS CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2[C@H]3CCCC[C@@H]3C[C@H]2C(=O)O DM4L6EU IK VXFJYXUZANRPDJ-WTNASJBWSA-N DM4L6EU IU (2S,3aR,7aS)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carboxylic acid DM4L6EU CA CAS 87679-37-6 DM4L6EU CB CHEBI:9649 DM4L6EU DE Hypertension DMFI8A7 ID DMFI8A7 DMFI8A7 DN Tranexamic acid DMFI8A7 HS Approved DMFI8A7 SN AMCA; AMCHA; AMH; Amikapron; Amstat; Anvitoff; Carxamin; Cyclocapron; Cyklokapron; Emorhalt; Exacyl; Frenolyse; Hexapromin; Hexatron; Mastop; Rikavarin; Spiramin; Tamcha; Tranex; Tranexamsaeure; Tranexan; Transamin; Transamlon; Trasamlon; Ugurol; Acide tranexamique; Acido tranexamico; Acidum tranexamicum; Tranexmic acid; Tranhexamic acid; Trans AMCHA; CL 65336; DV 79; DV79; KABI 2161; LT00159441; ALBB-006013; Acide tranexamique [INN-French]; Acido tranexamico [INN-Spanish]; Acidum tranexamicum [INN-Latin]; CL-65336; Cis-AMCHA; Cyklokapron (TN); DV-79; RP 18,429; Rikavarin (TN); Rikavarin-S; T-AMCHA; Tranexamic acid cis-form; Trans-Amcha; Trans-Tranexamic acid; Cis-4-(Aminomethyl)cyclohexanecarboxylic acid; Tranexamic acid (JP15/USAN/INN); Tranexamic acid [USAN:INN:BAN:JAN]; Trans-4-(Aminomethyl)cyclohexanecarboxylic acid; Trans-4-(Aminomethyl)cyclohexanecarboxylic acid ester; Trans-p-(Aminomethyl)cyclohexanecarboxylic; Trans-p-(Aminomethyl)cyclohexanecarboxylic acid; Cis-4-Aminomethylcyclohexane-1-carboxylic acid; Trans-1-Aminomethylcyclohexane-4-carboxylic acid; Trans-4-(Aminomethyl)cyclohexane-carboxylic acid; Trans-4-Aminomethylcyclohexane-1-carboxylic acid; Trans-1-(Aminomethyl)cyclohexane-4-carboxylic acid; Trans-4-(Aminomethyl)-1-cyclohexanecarboxylic acid; Trans-4-(Aminomethyl)cyclohexane-1-carboxylic acid; 4-(Aminomethyl)-Cyclohexanecarboxylic Acid; 4-(Aminomethyl)cyclohexanecarboxylic acid; 4-(aminomethyl)cyclohexane-1-carboxylic acid DMFI8A7 CP Daiichi Sankyo Pharma Development DMFI8A7 TC Antifibrinolytic Agents DMFI8A7 DT Small molecular drug DMFI8A7 PC 5526 DMFI8A7 MW 157.21 DMFI8A7 FM C8H15NO2 DMFI8A7 IC InChI=1S/C8H15NO2/c9-5-6-1-3-7(4-2-6)8(10)11/h6-7H,1-5,9H2,(H,10,11) DMFI8A7 CS C1CC(CCC1CN)C(=O)O DMFI8A7 IK GYDJEQRTZSCIOI-UHFFFAOYSA-N DMFI8A7 IU 4-(aminomethyl)cyclohexane-1-carboxylic acid DMFI8A7 CA CAS 701-54-2 DMFI8A7 CB CHEBI:48669 DMFI8A7 DE Excessive bleeding DME5Y64 ID DME5Y64 DME5Y64 DN Tranilast DME5Y64 HS Approved DME5Y64 SN tranilast; 53902-12-8; Rizaben; trans-Tranilast; Tranilastum; 70806-55-2; MK 341; N-(3,4-Dimethoxycinnamoyl)anthranilic acid; Tranilastum [INN-Latin]; Tranilast [USAN:INN:JAN]; Tranpro; UNII-HVF50SMY6E; SB-252218; MK-341; Tranilast (SB 252218); 3,4-DAA; n-(3',4'-dimethoxycinnamoyl) anthranilic acid; HVF50SMY6E; MLS000028468; CHEBI:77572; C18H17NO5; Anthranilic acid, N-(3,4-dimethoxycinnamoyl)-; NZHGWWWHIYHZNX-CSKARUKUSA-N; 2-((3-(3,4-Dimethoxyphenyl)-1-oxo-2-propenyl)amino)benzoic acid; MFCD00864787; T 0318; NU-3450; Rizaben (TN); Tranilast (JAN/USAN/INN); Rizaben, SB 252218, MK 341, Tranpro ,Tranilast; N-(3',4'-dimethoxycinnamoyl) anthranilic acid; N-(3′ -Dimethoxycinnamoyl)anthranilic Acid; 2-({(2E)-3-[3,4-bis(methyloxy)phenyl]prop-2-enoyl}amino)benzoic acid; 2-[[(E)-3-(3,4-dimethoxyphenyl)prop-2-enoyl]amino]benzoic acid; 2-[[3-(3,4-Dimethoxyphenyl)-1-oxo-2-propenyl]amino] benzoic acid; Molecule 20 DME5Y64 CP Kissei DME5Y64 DT Small molecular drug DME5Y64 PC 5282230 DME5Y64 MW 327.3 DME5Y64 FM C18H17NO5 DME5Y64 IC InChI=1S/C18H17NO5/c1-23-15-9-7-12(11-16(15)24-2)8-10-17(20)19-14-6-4-3-5-13(14)18(21)22/h3-11H,1-2H3,(H,19,20)(H,21,22)/b10-8+ DME5Y64 CS COC1=C(C=C(C=C1)/C=C/C(=O)NC2=CC=CC=C2C(=O)O)OC DME5Y64 IK NZHGWWWHIYHZNX-CSKARUKUSA-N DME5Y64 IU 2-[[(E)-3-(3,4-dimethoxyphenyl)prop-2-enoyl]amino]benzoic acid DME5Y64 CA CAS 53902-12-8 DME5Y64 CB CHEBI:77572 DME5Y64 DE Ocular allergy DMGB5RE ID DMGB5RE DMGB5RE DN Tranylcypromine DMGB5RE HS Approved DMGB5RE SN GJZ; Jatrosom; Parnate; Parnitene; Tranilcipromina; Transamine; Tranylcyprominum; Allphar Brand of Tranylcypromine Sulfate; Esparma Brand of Tranylcypromine Sulfate; GlaxoSmithKline Brand of Tranylcypromine Sulfate; Goldshield Brand of Tranylcypromine Sulfate; Link Brand of Tranylcypromine Sulfate; Racemic Tranylcypromine; SmithKline Brand of Tranylcypromine Sulfate; SKF 385; Trans 2 Phenylcyclopropylamine; D-Tranylcypromine; Dl-Tranylcypromine; Jatrosom (TN); L-Tranylcypromine; Parmodalin (TN); Parnate (TN); Parstelin (TN); SKF Trans-385; Sicoton (TN); Sulfate, Tranylcypromine; Tranilcipromina [INN-Spanish]; Transamine (TN); Transapin (TN); Tranylcypromine (INN); Tranylcypromine [INN:BAN]; Tranylcyprominum [INN-Latin]; Tylciprine (TN); Trans-2-Phenylcyclopropylamine; Trans-DL-2-Phenylcyclopropylamine; Trans-(-)-2-Phenylcyclopropanamine; Cyclopropanamine, 2-phenyl-, (1R-trans)-(9CI); (+)-(R)-Tranylcypromine; (+)-Tranylcypromine; (+)-trans-2-Phenylcyclopropylamine; (-)-Tranylcypromine; (1R)-2-phenylcyclopropan-1-amine; (1R,2R)-2-phenylcyclopropan-1-amine; (1R,2S)-2-phenylcyclopropan-1-amine; (1R,2S)-2-phenylcyclopropanamine; (1S)-2-phenylcyclopropan-1-amine; (1S,2R)-2-phenylcyclopropan-1-amine; (1S,2S)-2-phenylcyclopropan-1-amine; (2S)-2-phenylcyclopropan-1-amine; 2-Phenylcyclopropanamine; 2-phenylcyclopropan-1-amine DMGB5RE CP GlaxoSmithKline plc DMGB5RE TC Antidepressants DMGB5RE DT Small molecular drug DMGB5RE PC 19493 DMGB5RE MW 133.19 DMGB5RE FM C9H11N DMGB5RE IC InChI=1S/C9H11N/c10-9-6-8(9)7-4-2-1-3-5-7/h1-5,8-9H,6,10H2/t8-,9+/m0/s1 DMGB5RE CS C1[C@H]([C@@H]1N)C2=CC=CC=C2 DMGB5RE IK AELCINSCMGFISI-DTWKUNHWSA-N DMGB5RE IU (1R,2S)-2-phenylcyclopropan-1-amine DMGB5RE CA CAS 3721-26-4 DMGB5RE CB CHEBI:94631 DMGB5RE DE Prostate cancer; Major depressive disorder DMZQOUX ID DMZQOUX DMZQOUX DN Trastuzumab DMZQOUX HS Approved DMZQOUX SN Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor) DMZQOUX CP Roche; Genentech DMZQOUX TC Anticancer Agents DMZQOUX DT Antibody DMZQOUX SQ Anti-HER2 Light chain (1 and 2): DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC >Anti-HER2 Heavy chain (1 and 2)EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK DMZQOUX DE Breast cancer; Gastric adenocarcinoma; HER2-positive breast cancer DM20K91 ID DM20K91 DM20K91 DN Travoprost DM20K91 HS Approved DM20K91 SN Travatan; Travatanz; Travatan Alcon; Travatan Z; Travoprost [USAN]; AL6221; AL-6221; Travatan (TN); Travatan Z (TN); Travatan, Travoprost; Travoprost (JAN/USAN/INN); Propan-2-yl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3R)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]but-1-enyl]cyclopentyl]hept-5-enoate; Propan-2-yl (5Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-{(1E,3R)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]but-1-en-1-yl}cyclopentyl]hept-5-enoate; Isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-{(1E,3R)-3-hydroxy-4-[(alpha,alpha,alpha-trifluoro-m-tolyl)oxy]-1-butenyl}cyclopentyl)-5-heptenoate; (((1R)-(1alpha(Z),2beta(1E,3R*),3alpha,5alpha))-7-(3,5-dihydroxy-2-(3-hydroxy-4-(3-trifluoromethyl)phenoxy)-1-butenyl)cyclopentyl)-5-heptenoic acid, 1-methylethyl ester; (+)-Fluprostenol isopropyl ester; (1R-(1alpha(Z),2beta(1E,3R*),3alpha,5alpha))-7-(3,5-Dihydroxy-2-(3-hydroxy-4-(3-(trifluoromethyl)phenoxy)-1-butenyl)cyclopentyl)-5-heptenoic acid, 1-methylethyl ester; (Z)-7-((1R,2R,3R,5S)-3,5-Dihydroxy-2-((1E,3R)-3-hydroxy-4-((alpha,alpha,alpha-trifluoro-m-isopropyl-tolyl)oxy)-1-butenyl)cyclopentyl)-5-heptenoate; 5-Heptenoic acid,7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((1E,3R)-3-hydroxy-4-(3-(trifluoromethyl)phenoxy)-1-butenyl)cyclopentyl)-,1-methylethyl ester,(5Z) DM20K91 CP Alcon Canada Inc DM20K91 TC Ophthalmologicals DM20K91 DT Small molecular drug DM20K91 PC 5282226 DM20K91 MW 500.5 DM20K91 FM C26H35F3O6 DM20K91 IC InChI=1S/C26H35F3O6/c1-17(2)35-25(33)11-6-4-3-5-10-21-22(24(32)15-23(21)31)13-12-19(30)16-34-20-9-7-8-18(14-20)26(27,28)29/h3,5,7-9,12-14,17,19,21-24,30-32H,4,6,10-11,15-16H2,1-2H3/b5-3-,13-12+/t19-,21-,22-,23+,24-/m1/s1 DM20K91 CS CC(C)OC(=O)CCC/C=C\\C[C@H]1[C@H](C[C@H]([C@@H]1/C=C/[C@H](COC2=CC=CC(=C2)C(F)(F)F)O)O)O DM20K91 IK MKPLKVHSHYCHOC-AHTXBMBWSA-N DM20K91 IU propan-2-yl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3R)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]but-1-enyl]cyclopentyl]hept-5-enoate DM20K91 CA CAS 157283-68-6 DM20K91 CB CHEBI:746859 DM20K91 DE Open-angle glaucoma DMK1GBJ ID DMK1GBJ DMK1GBJ DN Trazodone DMK1GBJ HS Approved DMK1GBJ SN Beneficat; Desirel; Sideril; Tradozone; Trazalon; Trazodil; Trazodon; Trazodona; Trazodonum; Trazolan; Trazonil; Trialodine; Trittico; Desyrel Dividose; Trazodona [Spanish]; Trazodone Hcl; Trazodonum [Latin]; Beneficat (TN); Deprax (TN); Desirel (TN); Desyrel (TN); Desyrel(trazodone hcl salt); Molipaxin (TN); Thombran (TN); Trazodona [INN-Spanish]; Trazodone (Desyrel); Trazodone (INN); Trazodone [INN:BAN]; Trazodonum [INN-Latin]; Trazorel (TN); Trialodine (TN); Trittico (TN); 2-(3-[4-(3-Chlorophenyl)-1-piperazinyl]propyl)[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one; 2-[3-[4-(3-chlorophenyl)piperazin-1-yl]propyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one; 2-{3-[4-(3-chlorophenyl)piperazin-1-yl]propyl}[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one; 8-[3-[4-(3-Chlorophenyl)piperazin-1-yl]propyl]-1,7,8-triazabicyclo[4.3.0]nona-2,4,6-trien-9-one hydrochloride DMK1GBJ CP Angelini research laboratories DMK1GBJ TC Antidepressants DMK1GBJ DT Small molecular drug DMK1GBJ PC 5533 DMK1GBJ MW 371.9 DMK1GBJ FM C19H22ClN5O DMK1GBJ IC InChI=1S/C19H22ClN5O/c20-16-5-3-6-17(15-16)23-13-11-22(12-14-23)8-4-10-25-19(26)24-9-2-1-7-18(24)21-25/h1-3,5-7,9,15H,4,8,10-14H2 DMK1GBJ CS C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl DMK1GBJ IK PHLBKPHSAVXXEF-UHFFFAOYSA-N DMK1GBJ IU 2-[3-[4-(3-chlorophenyl)piperazin-1-yl]propyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one DMK1GBJ CA CAS 19794-93-5 DMK1GBJ CB CHEBI:9654 DMK1GBJ DE Depression DMTIQF3 ID DMTIQF3 DMTIQF3 DN Treprostinil DMTIQF3 HS Approved DMTIQF3 SN Treprostinilo; Treprostinilum; Uniprost; Viveta; Treprostinil sodium; LRX 15; U 62840; Remodulin (TN); Treprostinil [USAN:INN]; UT-15; Treprostinil (USAN/INN); U-62,840; ((1R,2R,3aS,9aS)-2-hydroxy-1-((3S)-3-hydroxyoctyl)-2,3,3a,4,9,9a-hexahydro-1H-cylopent(b)naphthalen-5-yl)oxy)acetate; ({(1R,2R,3aS,9aS)-2-hydroxy-1-[(3S)-3-hydroxyoctyl]-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]naphthalen-5-yl}oxy)acetic acid; 15 AU81; 2-[[(1R,2R,3aS,9aS)-2-hydroxy-1-[(3S)-3-hydroxyoctyl]-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[g]naphthalen-5-yl]oxy]acetic acid; 2-[[(1S,2S,3aR,9aR)-2-hydroxy-1-[(3R)-3-hydroxyoctyl]-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[g]naphthalen-5-yl]oxy]acetic acid DMTIQF3 TC Antihypertensive Agents DMTIQF3 DT Small molecular drug DMTIQF3 PC 6918140 DMTIQF3 MW 390.5 DMTIQF3 FM C23H34O5 DMTIQF3 IC InChI=1S/C23H34O5/c1-2-3-4-7-17(24)9-10-18-19-11-15-6-5-8-22(28-14-23(26)27)20(15)12-16(19)13-21(18)25/h5-6,8,16-19,21,24-25H,2-4,7,9-14H2,1H3,(H,26,27)/t16-,17-,18+,19-,21+/m0/s1 DMTIQF3 CS CCCCC[C@@H](CC[C@H]1[C@@H](C[C@H]2[C@@H]1CC3=C(C2)C(=CC=C3)OCC(=O)O)O)O DMTIQF3 IK PAJMKGZZBBTTOY-ZFORQUDYSA-N DMTIQF3 IU 2-[[(1R,2R,3aS,9aS)-2-hydroxy-1-[(3S)-3-hydroxyoctyl]-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[g]naphthalen-5-yl]oxy]acetic acid DMTIQF3 CA CAS 81846-19-7 DMTIQF3 CB CHEBI:50861 DMTIQF3 DE Pulmonary arterial hypertension DM49DUI ID DM49DUI DM49DUI DN Tretinoin DM49DUI HS Approved DM49DUI SN Retinoic acid; tretinoin; 302-79-4; Vitamin A acid; all-trans-Retinoic acid; trans-Retinoic acid; ATRA; Airol; Retin-A; Vesanoid; Renova; Dermairol; Aknoten; Eudyna; Aberel; all-trans-Vitamin A acid; Aknefug; All-trans Retinoic Acid; Cordes vas; Epi-aberel; Atralin; Vitamin A1 acid, all-trans-; Tretin M; Retin-A Micro; all-trans-Vitamin A1 acid; Vitamin A acid, all-trans-; all-trans-Tretinoin; Effederm; Retionic acid; TRETINON; Retinoic acid, all-trans-; Alltrans-retinoic acid; beta-Ra; all-(E)-Retinoic acid; beta-Retinoic acid; Avitoin; Aberela; Acnavit; Atragen; Betarretin; Lsotretinoin; Nexret; Panretyn; REA; Retacnyl; Retinoate; Retinova; Solage; Tretinoina; Tretinoine; Tretinoino; Tretinoinum; Vesnaroid; Vitinoin; Aberela [Norway]; Accutane Roche; Acnavit [Denmark]; All Trans Retinoic Acid; Avita Gel; Avitoin [Norway]; Beta all trans Retinoic Acid; Cordes VAS [Germany]; Effederm [France]; Panretin Gel; Retin A; Trans Retinoic Acid; Tretinoin Potassium Salt; Tretinoin Sodium Salt; Tretinoin Zinc Salt; Tretinoin liposome; AGN100335; AGN 192013; ALRT 1057; BAL4079; LGD 100057; R 2625; [3H]Retinoic acid; A-Vitaminsyre; A-Vitaminsyre [Denmark]; AT-RA; Aberela (TN); Acid, Retinoic; Acid, Vitamin A; All trans-Retinoic acid; Atra-IV; Avita (TN); B-Retinoic acid; BML2-E05; Beta-Ra; Beta-Retinoic acid; Potassium Salt, Tretinoin; RETINOIC ACID, ALL TRANS; Renova (TN); Retin A (TN); Retisol-A; Ro 1-5488; Salt, Tretinoin Potassium; Salt, Tretinoin Sodium; Salt, Tretinoin Zinc; Sodium Salt, Tretinoin; Stieva-A; Stieva-a Forte; Trans-Retinoicacid; Tretinoin (TN); Tretinoina [INN-Spanish]; Tretinoine [INN-French]; Tretinoino [INN-Spanish]; Tretinoinum [INN-Latin]; Tri-Luma; Vesanoid (TN); Zinc Salt, Tretinoin; A-Acido (Argentina); Acid A Vit (Belgium, Netherlands); Acid, trans-Retinoic; Acide retinoique (French) (DSL); All-trans-Retinoic acid; All-trans-Tretinoin; All-trans-Vitamin A acid; All-trans-Vitamin A1 acid; PDT-002-002; Retin-A (TN); Stieva-A (TN); Tretinoin 01% cream or placebo; Tretinoin [USAN:INN:BAN]; Tretinoin/All-Trans Retinoic Acid; Tretinoine (French) (EINECS); Acid, all-trans-Retinoic; All-(E)-Retinoic acid; All-trans-b-Retinoic acid; All-trans-beta-Retinoic acid; Beta-all-trans-Retinoic acid; Tretinoin (JAN/USP/INN); Acid, beta-all-trans-Retinoic; Retinoic acid, all-trans-(8CI); Vesanoid, Airol, Renova, Atralin, Retin-A, Avita, Tretinoin; 15-Apo-beta-caroten-15-oic acid; 3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid; 9(Z)-Retinoic acid; 9-cis-RA; 9-trans-retinoic acid DM49DUI CP Roche Pharmaceuticals DM49DUI TC Keratolytic Agents DM49DUI DT Small molecular drug DM49DUI PC 444795 DM49DUI MW 300.4 DM49DUI FM C20H28O2 DM49DUI IC InChI=1S/C20H28O2/c1-15(8-6-9-16(2)14-19(21)22)11-12-18-17(3)10-7-13-20(18,4)5/h6,8-9,11-12,14H,7,10,13H2,1-5H3,(H,21,22)/b9-6+,12-11+,15-8+,16-14+ DM49DUI CS CC1=C(C(CCC1)(C)C)/C=C/C(=C/C=C/C(=C/C(=O)O)/C)/C DM49DUI IK SHGAZHPCJJPHSC-YCNIQYBTSA-N DM49DUI IU (2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenoic acid DM49DUI CA CAS 302-79-4 DM49DUI CB CHEBI:15367 DM49DUI DE Acne vulgaris; Acute promyelocytic leukaemia DMU54QB ID DMU54QB DMU54QB DN Treximet DMU54QB HS Approved DMU54QB SN Trexima; Naproxen mixture with sumatriptan; Naproxen sodium mixture with sumatriptan succinate; Sumatriptan mixture with naproxen;Sumatriptan succinate and naproxen sodium; Sumatriptan succinate mixture with naproxen sodium; Naproxen / sumatriptan DMU54QB CP GSK DMU54QB DT Small molecular drug DMU54QB PC 23709079 DMU54QB MW 665.7 DMU54QB FM C32H40N3NaO9S DMU54QB IC InChI=1S/C14H21N3O2S.C14H14O3.C4H6O4.Na/c1-15-20(18,19)10-11-4-5-14-13(8-11)12(9-16-14)6-7-17(2)3;1-9(14(15)16)10-3-4-12-8-13(17-2)6-5-11(12)7-10;5-3(6)1-2-4(7)8;/h4-5,8-9,15-16H,6-7,10H2,1-3H3;3-9H,1-2H3,(H,15,16);1-2H2,(H,5,6)(H,7,8);/q;;;+1/p-1/t;9-;;/m.0../s1 DMU54QB CS C[C@@H](C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)[O-].CNS(=O)(=O)CC1=CC2=C(C=C1)NC=C2CCN(C)C.C(CC(=O)O)C(=O)O.[Na+] DMU54QB IK IGRAQVLKCQVBQA-DBQHITQZSA-M DMU54QB IU sodium;butanedioic acid;1-[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]-N-methylmethanesulfonamide;(2S)-2-(6-methoxynaphthalen-2-yl)propanoate DMU54QB CA CAS 811794-26-0 DMU54QB DE Migraine DM0AEPG ID DM0AEPG DM0AEPG DN Triacetin DM0AEPG HS Approved DM0AEPG SN triacetin; 102-76-1; Glyceryl triacetate; Glycerol triacetate; Enzactin; Glycerin triacetate; Triacetine; Triacetylglycerol; Fungacetin; Glyped; Triacetyl glycerine; Vanay; Kesscoflex TRA; Kodaflex triacetin; 1,2,3-Propanetriol, triacetate; Acetin, tri-; Triacetinum; Triacetina; 1,2,3-triacetoxypropane; 1,2,3-Propanetriol triacetate; propane-1,2,3-triyl triacetate; Triacetyl glycerin; Triacetyl glycerol; 1,2,3-Propanetriyl triacetate; Triacetin [INN]; 1,2,3-Triacetylglycerol; 1,2,3-Propanetriol, 1,2,3-triacetate; FEMA Number 2007 DM0AEPG DT Small molecular drug DM0AEPG PC 5541 DM0AEPG MW 218.2 DM0AEPG FM C9H14O6 DM0AEPG IC InChI=1S/C9H14O6/c1-6(10)13-4-9(15-8(3)12)5-14-7(2)11/h9H,4-5H2,1-3H3 DM0AEPG CS CC(=O)OCC(COC(=O)C)OC(=O)C DM0AEPG IK URAYPUMNDPQOKB-UHFFFAOYSA-N DM0AEPG IU 2,3-diacetyloxypropyl acetate DM0AEPG CA CAS 102-76-1 DM0AEPG CB CHEBI:9661 DM0AEPG DE Onychomycosis DM98IXF ID DM98IXF DM98IXF DN Triamcinolone DM98IXF HS Approved DM98IXF SN Adcortyl; Aristocort; Celeste; Cinolone; Delphicort; Fluoxiprednisolone; Fluoxyprednisolone; Fougera; Ione; Kenacort; Ledercort; Mycolog; Omcilon; Omicilon; Orion; Rodinolone; Tiamcinolonum; Triamcet; Triamcinalone; Triamcinlon; Triamcinolon; Triamcinolona; Triamcinolonum; Tricortale; Trilone; Tristoject; Volon; Aristocort Tablets; Triamcinolonum [INN]; CL 19823; Aristocort (TN); Azmacort (TN); Cinolone-T; Fougera (TN); Kenacort (TN); Kenacort-AG; Kenalog (TN); Nasacort (TN); SK-Triamcinolone; Tiamcinolonum [INN-Latin]; Triam-Tablinen; Triamcinolona [INN-Spanish]; Tricortone (TN); Triderm (TN); Triesence (TN); Trilone (TN); Tristoject (TN); Volon A (TN); Tri-Nasal (TN); Triamcinolone (JP15/USP/INN); Triamcinolone [USAN:INN:BAN:JAN]; Droxypregna-1,4-diene-3,20-dione; Pregna-1,4-diene-3,20-dio; TRIAMCINOLONE (SEE ALSO TRIAMCINOLONE ACETONIDE (76-25-5) AND TRIAMCINOLONE DIACETATE (67-78-7)); Pregna-1,4-diene-3,20-dione, 9-fluoro-11beta,16alpha,17,21-tetrahydroxy-(8CI); Pregna-1,4-diene-3,20-dione, 9-fluoro-11,16,17,21-tetrahydroxy-, (11beta,16alpha); (8S,9R,10S,11S,13S,14S,16R,17S)-9-fluoro-11,16,17-trihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; 11-beta,16-alpha,17-alpha,21-Tetrahydroxy-9-alpha-fluoro-1,4-pregnadiene-3,20-dione; 11.Beta.,16.alpha.,17.alpha., 21-Tetrahydroxy-9.alpha.-fluoro-1,4-pregnadiene-3,20-dione; 11.beta.,16.alpha.,17.alpha.,21-Tetrahydroxy-9.alpha.-fluoro-1,4-pregnadiene-3,20-dione; 9-Fluoro-11,16,17,21-tetrahydroxypregna-1,4-diene-3,20-dione; 9-Fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione; 9-alpha-Fluoro-11-beta,16-alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione; 9-alpha-Fluoro-16-alpha-hydroxyprednisolone; 9.Alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahy; 9.Alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahydroxy-1,4-pregnadiene-3,20-dione; 9.Alpha.-Fluoro-11.beta.,16.alpha.,17.alpha., 21-tetrahydroxypregna-1,4-diene-3,20-d; 9.Alpha.-Fluoro-16.alpha.-hydroxyprednisolone; 9.alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahydroxy-1,4-pregnadiene-3,20-dione; 9.alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahydroxypregna-1,4-diene-3,20-dione; 9.alpha.-Fluoro-11.beta.,16.alpha.,17.alpha.,21-tetrahydroxypregna-1,4-diene-3,20-dione; 9.alpha.-Fluoro-16.alpha.-hydroxyprednisolone; 9alpha-Fluoro-11beta,16alpha,17,21-tetrahydroxy-1,4-pregnadiene-3,20-dione; 9alpha-Fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione; 9alpha-Fluoro-16alpha-hydroxyprednisolone DM98IXF CP Aventis Pharmaceuticals Inc. DM98IXF TC Antiinflammatory Agents DM98IXF DT Small molecular drug DM98IXF PC 31307 DM98IXF MW 394.4 DM98IXF FM C21H27FO6 DM98IXF IC InChI=1S/C21H27FO6/c1-18-6-5-12(24)7-11(18)3-4-13-14-8-15(25)21(28,17(27)10-23)19(14,2)9-16(26)20(13,18)22/h5-7,13-16,23,25-26,28H,3-4,8-10H2,1-2H3/t13-,14-,15+,16-,18-,19-,20-,21-/m0/s1 DM98IXF CS C[C@]12C[C@@H]([C@]3([C@H]([C@@H]1C[C@H]([C@@]2(C(=O)CO)O)O)CCC4=CC(=O)C=C[C@@]43C)F)O DM98IXF IK GFNANZIMVAIWHM-OBYCQNJPSA-N DM98IXF IU (8S,9R,10S,11S,13S,14S,16R,17S)-9-fluoro-11,16,17-trihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one DM98IXF CA CAS 124-94-7 DM98IXF CB CHEBI:9667 DM98IXF DE Allergic rhinitis DM7LRKD ID DM7LRKD DM7LRKD DN Triamcinolone diacetate DM7LRKD HS Approved DM7LRKD SN Aristocort diacetate; Polcortolon; Tedarol; Aristocort Forte; Triamcinolone 16,21-diacetate; Orion; Aristocort Parenterals; Kenacort Diacetate Syrup; Aristocort diacetate forte; Aristocort Forte Parenteral; TRIAMCINOLONE DIACETATE; UNII-A73MM2Q32P; Kenacourt; Aristocort syrup; CHEBI:9669; 357RP; EINECS 200-669-0; Triamcinolone 16-alpha,21-di(acetate); A73MM2Q32P; 16alpha-Hydroxy-9alpha-fluoroprednisolone diacetate; 9-alpha-Fluoro-16-alpha-hydroxyprednisolone diacetate; NCGC00159320-03; delta1,9alpha-Fluoro-16alpha-hydroxyhydrocortisone diacetate; delta11,16alpha-Hydroxy-9alpha-fluorohydrocortisone diacetate; 16alpha,21-Diacetoxy-9alpha-fluoro-11beta,17alpha-dihydroxy-1,4-pregnadiene-3,20-dione; 9-Fluoro-11-beta,16-alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione 16,21-diacetate; 9-Fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione 16,21-diacetate; DSSTox_CID_28639; DSSTox_RID_82909; DSSTox_GSID_48713; Pregna-1,4-diene-3,20-dione, 16,21-bis(acetyloxy)-9-fluoro-11,17-dihydroxy-, (11beta,16alpha)-; Polcartolone; CAS-67-78-7; Triamcinolone diacetate [JAN]; Triamcinolone diacetate [USP:JAN]; SCHEMBL12549; 67-78-7 DM7LRKD PC 6216 DM7LRKD MW 478.5 DM7LRKD FM C25H31FO8 DM7LRKD IC XGMPVBXKDAHORN-RBWIMXSLSA-N DM7LRKD CS CC(=O)OCC(=O)C1(C(CC2C1(CC(C3(C2CCC4=CC(=O)C=CC43C)F)O)C)OC(=O)C)O DM7LRKD IK 1S/C25H31FO8/c1-13(27)33-12-20(31)25(32)21(34-14(2)28)10-18-17-6-5-15-9-16(29)7-8-22(15,3)24(17,26)19(30)11-23(18,25)4/h7-9,17-19,21,30,32H,5-6,10-12H2,1-4H3/t17-,18-,19-,21+,22-,23-,24-,25+/m0/s1 DM7LRKD IU [2-[(8S,9R,10S,11S,13S,14S,16R,17S)-16-acetyloxy-9-fluoro-11,17-dihydroxy-10,13-dimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] acetate DM7LRKD CA CAS 67-78-7 DM7LRKD CB CHEBI:9669 DM7LRKD DE Allergy DM2HU9I ID DM2HU9I DM2HU9I DN Triamterene DM2HU9I HS Approved DM2HU9I SN Ademin; Ademine; Amteren; Anjal; Dazid; Diarol; Dinazide; Diren; Ditak; Diucelpin; Diurene; Diutensat; Diuteren; Dyberzide; Dyren; Dyrenium; Dytac; Dytenzide; Esiteren; Hidiurese; Hydrene; Hypertorr; Isobar; Jatropur; Jenateren; Kalspare; Masuharmin; Nephral; Noridil; Noridyl; Pterofen; Pterophene; Renezide; Reviten; Taturil; Teriam; Teridin; Triamizide; Triampur; Triamteren; Triamterena; Triamterenum; Triamteril; Triamterine; Triamthiazid; Tricilone; Trispan; Triteren; Triurene; Trizid; Turfa; Uretren; Urocaudal; Goldshield Brand of Triamterene; Jorba Brand of Triamterene; Pter ophene; SmithKline Beecham Brand of Triamterene; TRIAMTERENE USP; Thiazid Wolff; Triamteril complex; Wellspring Brand of Triamterene; Fluss 40; SKF 8542; T 4143; Ademin(e); Apo-triazide; Dyrenium (TN); Pteridine deriv. 11; SALI-PUREN; SK&F 8542; SK-8542; Tri-Span; Triamterena [INN-Spanish]; Triamterenum [INN-Latin]; SK&F-8542; Triamterene (JP15/USP/INN); Triamterene [USAN:INN:BAN:JAN]; 2,4,7-Triamino-6-fenilpteridina; 2,4,7-Triamino-6-fenilpteridina [Italian]; 2,4,7-Triamino-6-phenylpteridine; 6-PHENYL-2,4,7-TRIAMINO PTERIDINE; 6-Phenyl-2,4,7-pteridinetriamine; 6-Phenyl-2,4,7-triaminopteridine; 6-phenylpteridine-2,4,7-triamine DM2HU9I TC Diuretics DM2HU9I DT Small molecular drug DM2HU9I PC 5546 DM2HU9I MW 253.26 DM2HU9I FM C12H11N7 DM2HU9I IC InChI=1S/C12H11N7/c13-9-7(6-4-2-1-3-5-6)16-8-10(14)18-12(15)19-11(8)17-9/h1-5H,(H6,13,14,15,17,18,19) DM2HU9I CS C1=CC=C(C=C1)C2=NC3=C(N=C(N=C3N=C2N)N)N DM2HU9I IK FNYLWPVRPXGIIP-UHFFFAOYSA-N DM2HU9I IU 6-phenylpteridine-2,4,7-triamine DM2HU9I CA CAS 396-01-0 DM2HU9I CB CHEBI:9671 DM2HU9I DE Congestive heart failure; Edema; Hypertension DMETYK5 ID DMETYK5 DMETYK5 DN Triazolam DMETYK5 HS Approved DMETYK5 SN Clorazolam; Halcion; Hypnostat; Novidorm; Novodorm; Songar; Triazolamum; Trilam; Apo Triazo; Apotex Brand of Triazolam; Gen Triazolam; Genpharm Brand of Triazolam; Gerard Brand of Triazolam; Pfizer Brand of Triazolam; Triazolam Pfizer Brand; TGAR01H; U 33030; Alti-Triazolam; Apo-Triazo; Gen-Triazolam; Halcion (TN); Halcion (triazolam); Hypam (TN); Novo-Triolam; Triazolamum [INN-Latin]; Trilam (TN); U 33,030; U-33030; U33,030; Apo-Triazo (TN); U-33,030; Triazolam (JAN/USP/INN); Triazolam [USAN:BAN:INN:JAN]; 8-Chloro-6-(2-chlorophenyl)-1-methyl-4H-(1,2,4)triazolo(4,3-a)(1,4)benzodiazepine; 8-Chloro-6-(2-chlorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine; 8-Chloro-6-(o-chlorophenyl)-1-methyl-4H-s-triazolo(4,3-a)(1,4)benzodiazepine; 8-Chloro-6-(o-chlorophenyl)-1-methyl-4H-s-triazolo[4,3-a][1,4]benzodiazepine; 8-Chloro-6-[2-chlorophenyl]-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine DMETYK5 CP Upjohn Corporation DMETYK5 TC Hypnotics and Sedatives DMETYK5 DT Small molecular drug DMETYK5 PC 5556 DMETYK5 MW 343.2 DMETYK5 FM C17H12Cl2N4 DMETYK5 IC InChI=1S/C17H12Cl2N4/c1-10-21-22-16-9-20-17(12-4-2-3-5-14(12)19)13-8-11(18)6-7-15(13)23(10)16/h2-8H,9H2,1H3 DMETYK5 CS CC1=NN=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4Cl DMETYK5 IK JOFWLTCLBGQGBO-UHFFFAOYSA-N DMETYK5 IU 8-chloro-6-(2-chlorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine DMETYK5 CA CAS 28911-01-5 DMETYK5 CB CHEBI:9674 DMETYK5 DE Insomnia DMHAQCO ID DMHAQCO DMHAQCO DN Trichlormethiazide DMHAQCO HS Approved DMHAQCO SN Achletin; Anistadin; Aponorin; Aquazide; Carvacron; Chlopolidine; Cretonin; Diurazida; Diurese; Diuroral;Esmarin; Eurinol; Fluitran; Flurese; Flutra; Gangesol; Hydrotrichlorothiazide; Intromene; Isestran; Kubacron; Metahydrin; Metatensin; Nakva; Naqua; Naquasone; Schebitran; Tachionin; Tolcasone; Trichlordiuride; Trichlorex; Trichlormas; Trichlormetazid; Trichlormethiazid; Trichlormethiazidum; Trichloromethiadiazide; Trichloromethiazide; Triclordiuride; Triclormetiazida; Triclormetiazide; Triflumen;American Urologicals Brand of Trichloromethiazide; Jones Brand of Trichloromethiazide; Schering Brand of Trichlormethiazide; Triclormetiazide [DCIT]; Triclormetiazide [Italian]; Achletin (TN); Ciba 7057-Su; Diu-Hydrin; Flurese (VAN); Naqua (TN); Salurin (wadel); Trichlormethiazide W/ Reserpine; Trichlormethiazide [INN:JAN]; Trichlormethiazidum [INN-Latin]; Trichloromethiazide, 6; Triclormetiazida[INN-Spanish]; Triflumen (TN); Diu-Hydrin (TN); Trichlormethiazide (JP15/USP/INN); (+-)-6-Chloro-3-(dichloromethyl)-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3-(dichloromethyl)-3,4-dihydro-, 1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3-(dichloromethyl)-3,4-dihydro-,1,1-dioxide; 3-(Dichloromethyl)-6-chloro-7-sulfamoyl-3,4-dihydro-1,2,4-benzothiadiazine 1,1-dioxide; 3-(Dichloromethyl)-6-chloro-7-sulfamoyl-3,4-dihydro-1,2,4-benzothiadiazine-1,1-dioxide; 3-Dichloromethyl-6-chloro-7-sulfamoyl-3,4-dihydro-1,2,4-benzothiadiazine-1,1-dioxide; 3-Dichloromethyl-6-chloro-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine 1,1-dioxide; 3-Dichloromethyl-6-chloro-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine1,1-dioxide; 3-Dichloromethylhydrochlorothiazide; 6-Chloro-3-(dichloromethyl)-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 6-Chloro-3-(dichloromethyl)-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide1,1-dioxide; 6-Chloro-3-(dichloromethyl)3,4-dihydro-7-sulfamoyl-1,2,4-benzothiadiazine-1,1-dioxide; 6-Chloro-3-(dichloromethyl)3,4-dihydro-7-sulfamyl-1,2,4-benzothiadiazine-1,1-dioxide; 6-Chloro-3-[dichloromethyl]-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide-1,1-dioxide; 6-Chloro-3-dichloromethyl-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-Dioxide; 6-Chloro-3-dichloromethyl-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine1,1-dioxide DMHAQCO CP Hoechst Marion Roussel DMHAQCO TC Antihypertensive Agents DMHAQCO DT Small molecular drug DMHAQCO PC 5560 DMHAQCO MW 380.7 DMHAQCO FM C8H8Cl3N3O4S2 DMHAQCO IC InChI=1S/C8H8Cl3N3O4S2/c9-3-1-4-6(2-5(3)19(12,15)16)20(17,18)14-8(13-4)7(10)11/h1-2,7-8,13-14H,(H2,12,15,16) DMHAQCO CS C1=C2C(=CC(=C1Cl)S(=O)(=O)N)S(=O)(=O)NC(N2)C(Cl)Cl DMHAQCO IK LMJSLTNSBFUCMU-UHFFFAOYSA-N DMHAQCO IU 6-chloro-3-(dichloromethyl)-1,1-dioxo-3,4-dihydro-2H-1lambda6,2,4-benzothiadiazine-7-sulfonamide DMHAQCO CA CAS 133-67-5 DMHAQCO CB CHEBI:9683 DMHAQCO DE Hypertension DMPWGBR ID DMPWGBR DMPWGBR DN Triclabendazole DMPWGBR HS Approved DMPWGBR SN Triclabendazole; 68786-66-3; Fasinex; 6-Chloro-5-(2,3-dichlorophenoxy)-2-(methylthio)-1H-benzo[d]imidazole; C14H9Cl3N2OS; Triclabendazolum [INN-Latin]; Triclabendazol [INN-Spanish]; CCRIS 8988; UNII-4784C8E03O; CGA 89317; 5-Chloro-6-(2,3-dichlorophenoxy)-2-(methylthio)-1H-benzimidazole; CPD000466357; MLS001424101; CHEMBL1086440; 6-Chloro-5-(2,3-dichlorophenoxy)-2-methylthio-benzimidazole; 4784C8E03O; NCGC00164610-01; Triclabendazole, 98%; SMR000466357; AK-68238; 5-Chloro-6-(2,3-dichlorophenoxy)-2-(methylthio)benzimidazole DMPWGBR DT Small molecular drug DMPWGBR PC 50248 DMPWGBR MW 359.7 DMPWGBR FM C14H9Cl3N2OS DMPWGBR IC InChI=1S/C14H9Cl3N2OS/c1-21-14-18-9-5-8(16)12(6-10(9)19-14)20-11-4-2-3-7(15)13(11)17/h2-6H,1H3,(H,18,19) DMPWGBR CS CSC1=NC2=CC(=C(C=C2N1)Cl)OC3=C(C(=CC=C3)Cl)Cl DMPWGBR IK NQPDXQQQCQDHHW-UHFFFAOYSA-N DMPWGBR IU 6-chloro-5-(2,3-dichlorophenoxy)-2-methylsulfanyl-1H-benzimidazole DMPWGBR CA CAS 68786-66-3 DMPWGBR CB CHEBI:94759 DMPWGBR DE Helminth infection DMZUR4N ID DMZUR4N DMZUR4N DN Triclosan DMZUR4N HS Approved DMZUR4N SN triclosan; 3380-34-5; 5-CHLORO-2-(2,4-DICHLOROPHENOXY)PHENOL; 2,4,4'-Trichloro-2'-hydroxydiphenyl ether; Irgasan; Cloxifenolum; Triclosanum; Irgasan DP300; Stri-Dex Face Wash; Phenol, 5-chloro-2-(2,4-dichlorophenoxy)-; Lexol 300; Stri-Dex Cleansing Bar; 5-Chloro-2-(2,4-dichloro-phenoxy)-phenol; Triclosanum [INN-Latin]; CH 3565; DP-300; Caswell No 186A; C12H7Cl3O2; UNII-4NM5039Y5X; HSDB 7194; CHEBI:164200; Ether, 2'-hydroxy-2,4,4'-trichlorodiphenyl; Phenyl ether, 2'-hydroxy-2,4,4'-trichloro-; EINECS 222-182-2; CHEMBL849; EPA; Aquasept; Cliniclean; Cloxifenol; Manusept; Sapoderm; TCL; Trisan; Clearasil DailyFace Wash; Dermtek Brand of Triclosan; GlaxoSmithKline Brand of Triclosan; Microshield T; Oxy Skin Wash; Pharmachem Brand of Triclosan; Reckitt Brand of Triclosan; SSL Brand of Triclosan; Ster Zac Bath Concentrate; SterZac Bath Concentrate; Trans Canaderm Brand of Triclosan; Triclosan Pharmachem Brand; Triclosan Reckitt Brand; IN1424; Irgasan DP 300; CH-3565; Johnson & Johnson Brand of Triclosan; Procter & Gamble Brand of Triclosan; Ster-Zac Bath Concentrate; Stri-Dex cleansing bar (TN); Triclosan (USP/INN); Triclosan [USAN:BAN:INN]; 2,4,4'-Trichloro-2'-hydroxy diphenyl ether; 2-Hydroxy-2',4,4'-trichlorodiphenyl Ether; WL-1001 DMZUR4N TC Antibiotics DMZUR4N DT Small molecular drug DMZUR4N PC 5564 DMZUR4N MW 289.5 DMZUR4N FM C12H7Cl3O2 DMZUR4N IC InChI=1S/C12H7Cl3O2/c13-7-1-3-11(9(15)5-7)17-12-4-2-8(14)6-10(12)16/h1-6,16H DMZUR4N CS C1=CC(=C(C=C1Cl)O)OC2=C(C=C(C=C2)Cl)Cl DMZUR4N IK XEFQLINVKFYRCS-UHFFFAOYSA-N DMZUR4N IU 5-chloro-2-(2,4-dichlorophenoxy)phenol DMZUR4N CA CAS 3380-34-5 DMZUR4N CB CHEBI:164200 DMZUR4N DE Trypanosomiasis; Infection of P. falciparum; Malaria DMVLHNI ID DMVLHNI DMVLHNI DN Tridihexethyl DMVLHNI HS Approved DMVLHNI SN Pathilon; Propethonum; (3-cyclohexyl-3-hydroxy-3-phenylpropyl)-triethylazanium; 3-cyclohexyl-N,N,N-triethyl-3-hydroxy-3-phenylpropan-1-aminium DMVLHNI TC Anticholinergic Agents DMVLHNI DT Small molecular drug DMVLHNI PC 20299 DMVLHNI MW 318.5 DMVLHNI FM C21H36NO+ DMVLHNI IC InChI=1S/C21H36NO/c1-4-22(5-2,6-3)18-17-21(23,19-13-9-7-10-14-19)20-15-11-8-12-16-20/h7,9-10,13-14,20,23H,4-6,8,11-12,15-18H2,1-3H3/q+1 DMVLHNI CS CC[N+](CC)(CC)CCC(C1CCCCC1)(C2=CC=CC=C2)O DMVLHNI IK NPRHVSBSZMAEIN-UHFFFAOYSA-N DMVLHNI IU (3-cyclohexyl-3-hydroxy-3-phenylpropyl)-triethylazanium DMVLHNI CA CAS 60-49-1 DMVLHNI CB CHEBI:9701 DMVLHNI DE Acquired nystagmus DMD2WPG ID DMD2WPG DMD2WPG DN Trientine DMD2WPG HS Approved DMD2WPG SN Trientine HCl; 21121-06-2; triethylenetetramine HCl; SMR000058543; AC1NUQ0M; MLS000069683; SCHEMBL205201; CHEMBL1200783; CTK0I9735; DTXSID80419994; XPVOJYDIBHYVFL-UHFFFAOYSA-N; Pharmakon1600-01505675; NSC759164; NSC158271; AKOS027276425; NSC-158271; NSC-759164; 1, N,N'-bis(2-aminoethyl)-, tetrahydrochloride; 1,2-Ethanediamine, N,N'-bis(2-aminoethyl)-, hydrochloride; N'-[2-(2-aminoethylamino)ethyl]ethane-1,2-diamine hydrochloride DMD2WPG DT Small molecular drug DMD2WPG PC 5565 DMD2WPG MW 146.23 DMD2WPG FM C6H18N4 DMD2WPG IC InChI=1S/C6H18N4/c7-1-3-9-5-6-10-4-2-8/h9-10H,1-8H2 DMD2WPG CS C(CNCCNCCN)N DMD2WPG IK VILCJCGEZXAXTO-UHFFFAOYSA-N DMD2WPG IU N'-[2-(2-aminoethylamino)ethyl]ethane-1,2-diamine DMD2WPG CA CAS 112-24-3 DMD2WPG CB CHEBI:39501 DMD2WPG DE Inborn error of metabolism DMOL793 ID DMOL793 DMOL793 DN Trifarotene DMOL793 HS Approved DMOL793 SN Trifarotene; UNII-0J8RN2W0HK; 895542-09-3; CD5789; 0J8RN2W0HK; Trifarotene [USAN:INN]; CD 5789; SCHEMBL381493; GTPL9962; CHEMBL3707313; DTXSID30237781; EX-A2704; DB12808; compound 15b [PMID: 29706423]; 3''-Tert-butyl-4'-(2-hydroxyethoxy)-4''-(pyrrolidin-1-yl)(1,1':3',1'')terphenyl-4-carboxylic acid; HY-100256; CS-0018407; 4-[3-(3-tert-butyl-4-pyrrolidin-1-ylphenyl)-4-(2-hydroxyethoxy)phenyl]benzoic acid; [1,1':3',1''-Terphenyl]-4-carboxylic acid, 3''-(1,1-dimethylethyl)-4'-(2-hydroxyethoxy)-4''-(1-pyrrolidinyl)- DMOL793 CP Galderma DMOL793 DT Small molecular drug DMOL793 PC 11518241 DMOL793 MW 459.6 DMOL793 FM C29H33NO4 DMOL793 IC InChI=1S/C29H33NO4/c1-29(2,3)25-19-23(10-12-26(25)30-14-4-5-15-30)24-18-22(11-13-27(24)34-17-16-31)20-6-8-21(9-7-20)28(32)33/h6-13,18-19,31H,4-5,14-17H2,1-3H3,(H,32,33) DMOL793 CS CC(C)(C)C1=C(C=CC(=C1)C2=C(C=CC(=C2)C3=CC=C(C=C3)C(=O)O)OCCO)N4CCCC4 DMOL793 IK MFBCDACCJCDGBA-UHFFFAOYSA-N DMOL793 IU 4-[3-(3-tert-butyl-4-pyrrolidin-1-ylphenyl)-4-(2-hydroxyethoxy)phenyl]benzoic acid DMOL793 CA CAS 895542-09-3 DMOL793 DE Acne vulgaris DMKBYWI ID DMKBYWI DMKBYWI DN Trifluoperazine DMKBYWI HS Approved DMKBYWI SN Calmazine; Eskazine; Fluoperazine; Flurazine; Modalina; Stelazine; Stellazine; TFP; Trifluoperazin; Trifluoperazina; Trifluoperazinum; Trifluoromethylperazine; Trifluoroperazine; Trifluperazine; Triflurin; Trifluroperizine; Triftazin; Triftazine; Triperazine; Triphtazin; Triphtazine; Triphthasine; PMS Trifluoperazine; Stelazine Concentrate; Trifluoperazina [Italian]; Trifluoperazine HCl; Trifluoperazine dihydrochloride; Trifluoroperazine dihydrochloride; Tripfluoperazine Hydrochloride; NCI17474; RP 7623; SKF 5019; Apo-Trifluoperazine; Eskazine (TN); Eskazinyl (TN); Jatroneural (TN); Modalina (TN); Novo-Trifluzine; Stelazine (TN); Terfluzine (TN); Trifluoperaz (TN); Trifluoperazina [INN-Spanish]; Trifluoperazine (INN); Trifluoperazine [INN:BAN]; Trifluoperazinum [INN-Latin]; Apo-trifluoperazine (TN); Stelazine (*Dihydrochloride*); Trifluoromethyl-10-(3'-(1-methyl-4-piperazinyl)propyl)phenothiazine; 10-(3-(4-Methyl-1-piperazinyl)propyl)-2-(trifluoromethyl)phenothiazine; 10-(3-(4-methyl-1-piperazinyl)propyl)-2-(trifluoromethyl)-10H-phenothiazine; 10-(3-(4-methyl-1-piperazinyl)propyl)-2-(trifluoromethyl)-phenothiazine; 10-(gamma-(N'-Methylpiperazino)propyl)-2-trifluoromethylphenothiazine; 10-[3-(4-METHYL-PIPERAZIN-1-YL)-PROPYL]-2-TRIFLUOROMETHYL-10H-PHENOTHIAZINE; 10-[3-(4-Methyl-1-piperazinyl)propyl]-2-(trifluoromethyl)-10H-phenothiazine; 10-[3-(4-methylpiperazin-1-yl)propyl]-2-(trifluoromethyl)-10H-phenothiazine; 10-[3-(4-methylpiperazin-1-yl)propyl]-2-(trifluoromethyl)phenothiazine; 10-[3-(4-methylpiperazin-1-yl)propyl]-2-(trifluoromethyl)phenothiazine dihydrochloride; 2-Trifluoromethyl-10-(3'-(1-methyl-4-piperazinyl)propyl)phenothiazine DMKBYWI CP GlaxoSmithKline plc DMKBYWI TC Antipsychotic Agents DMKBYWI DT Small molecular drug DMKBYWI PC 5566 DMKBYWI MW 407.5 DMKBYWI FM C21H24F3N3S DMKBYWI IC InChI=1S/C21H24F3N3S/c1-25-11-13-26(14-12-25)9-4-10-27-17-5-2-3-6-19(17)28-20-8-7-16(15-18(20)27)21(22,23)24/h2-3,5-8,15H,4,9-14H2,1H3 DMKBYWI CS CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F DMKBYWI IK ZEWQUBUPAILYHI-UHFFFAOYSA-N DMKBYWI IU 10-[3-(4-methylpiperazin-1-yl)propyl]-2-(trifluoromethyl)phenothiazine DMKBYWI CA CAS 117-89-5 DMKBYWI CB CHEBI:45951 DMKBYWI DE Schizophrenia DMKFQJP ID DMKFQJP DMKFQJP DN Triflupromazine DMKFQJP HS Approved DMKFQJP SN Adazine; Fluopromazine; Fluorofen; Neoprin; Nivoman; Psyquil; Siquil; Trifluopromazine; Triflupromazina; Triflupromazinum;Vesprin; Vetame; Fluopromazine monohydrochloride; Trifluopromazine hydrochloride; Triflupromazine [INN]; Triflupromazina [INN-Spanish]; Triflupromazinum [INN-Latin]; Vesprin (TN); Triflupromazine (USP/INN) DMKFQJP CP Bristol-Myers Squibb DMKFQJP TC Antipsychotic Agents DMKFQJP DT Small molecular drug DMKFQJP PC 5568 DMKFQJP MW 352.4 DMKFQJP FM C18H19F3N2S DMKFQJP IC InChI=1S/C18H19F3N2S/c1-22(2)10-5-11-23-14-6-3-4-7-16(14)24-17-9-8-13(12-15(17)23)18(19,20)21/h3-4,6-9,12H,5,10-11H2,1-2H3 DMKFQJP CS CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)C(F)(F)F DMKFQJP IK XSCGXQMFQXDFCW-UHFFFAOYSA-N DMKFQJP IU N,N-dimethyl-3-[2-(trifluoromethyl)phenothiazin-10-yl]propan-1-amine DMKFQJP CA CAS 146-54-3 DMKFQJP CB CHEBI:9711 DMKFQJP DE Psychotic disorder DMG2YBD ID DMG2YBD DMG2YBD DN Trifluridine DMG2YBD HS Approved DMG2YBD SN Fluridine; TFDU; TRIFLUOROTHYMIDINE; Trifluoridine; Trifluoromethyldeoxyuridine; Trifluridina; Trifluridinum; Virophta; Viroptic; Trifluorothymine deoxyriboside; CF3dUrd; F3DThd; F3T; F3TDR; HS-0007; Trifluridina [INN-Spanish]; Trifluridine [USAN:INN]; Trifluridinum [INN-Latin]; Viroptic (TN); Trifluridine (USP/INN);Viroptic, Trifluorothymidine, Trifluridine; Alpha,alpha,alpha-Trifluorothymidine; 1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-(trifluoromethyl)pyrimidine-2,4-dione; 2'-Deoxy-5-(trifluoromethyl)uridine; 2'-Deoxy-5-trifluoromethyluridine; 5-(Trifluoromethyl)-2'-deoxyuridine; 5-(Trifluoromethyl)deoxyuridine; 5-Trifluoro-2'-deoxythymidine; 5-Trifluoromethyl-2'-deoxyuridine; 5-Trifluoromethyl-2-deoxyuridine; 5-Trifluorothymidine DMG2YBD CP Monarch Pharmaceuticals DMG2YBD TC Antiviral Agents DMG2YBD DT Small molecular drug DMG2YBD PC 6256 DMG2YBD MW 296.2 DMG2YBD FM C10H11F3N2O5 DMG2YBD IC InChI=1S/C10H11F3N2O5/c11-10(12,13)4-2-15(9(19)14-8(4)18)7-1-5(17)6(3-16)20-7/h2,5-7,16-17H,1,3H2,(H,14,18,19)/t5-,6+,7+/m0/s1 DMG2YBD CS C1[C@@H]([C@H](O[C@H]1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O DMG2YBD IK VSQQQLOSPVPRAZ-RRKCRQDMSA-N DMG2YBD IU 1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-(trifluoromethyl)pyrimidine-2,4-dione DMG2YBD CA CAS 70-00-8 DMG2YBD CB CHEBI:75179 DMG2YBD DE Virus infection DMB19L8 ID DMB19L8 DMB19L8 DN Trihexyphenidyl DMB19L8 HS Approved DMB19L8 SN trihexyphenidyl; Benzhexol; Triphenidyl; Trihexyphenidyle; Parkinane retard; Benzhexolum; 144-11-6; Trihexyphenidylum; Sedrena (free base); Trihexifenidilo; Trihexyphenidyle [INN-French]; Trihexifenidilo [INN-Spanish]; Trihexyphenidylum [INN-Latin]; Artane; Trihexylphenizyl; Trihexylphenidyl; Trihexylphenidyle; Trihexyphenidyl [INN:BAN]; Trihexylphenedyl; HSDB 3196; EINECS 205-614-4; NSC 12268; 1-Piperidinepropanol, alpha-cyclohexyl-alpha-phenyl-; 1-cyclohexyl-1-phenyl-3-piperidin-1-ylpropan-1-ol; BRN 0088959; Benzhexol; Trihexane; Trihexy; Artane Sequels; PMS Trihexyphenidyl; Apo-Trihex; Artane (TN); Trihexyphenidyl (INN); Apo-Trihex (TN); Apo-trihex (TN); SWR-0342SA DMB19L8 CP Lederle Laboratories Div American Cyanamid Co DMB19L8 TC Antiparkinson Agents DMB19L8 DT Small molecular drug DMB19L8 PC 5572 DMB19L8 MW 301.5 DMB19L8 FM C20H31NO DMB19L8 IC InChI=1S/C20H31NO/c22-20(18-10-4-1-5-11-18,19-12-6-2-7-13-19)14-17-21-15-8-3-9-16-21/h1,4-5,10-11,19,22H,2-3,6-9,12-17H2 DMB19L8 CS C1CCC(CC1)C(CCN2CCCCC2)(C3=CC=CC=C3)O DMB19L8 IK HWHLPVGTWGOCJO-UHFFFAOYSA-N DMB19L8 IU 1-cyclohexyl-1-phenyl-3-piperidin-1-ylpropan-1-ol DMB19L8 CA CAS 144-11-6 DMB19L8 CB CHEBI:9720 DMB19L8 DE Dystonia; Parkinson disease; Obesity DMP5A4T ID DMP5A4T DMP5A4T DN Trilaciclib DMP5A4T HS Approved DMP5A4T SN G1T28; 1374743-00-6; Trilaciclib [USAN]; G1T28(Trilaciclib); GTPL9626; CHEMBL3894860; SCHEMBL10082028; BDBM253928; US9464092, T; HY-101467; CS-0021431; 2'-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)-7',8'-dihydro-6'H-spiro(cyclohexane-1,9'-pyrazino(1',2':1,5)pyrrolo(2,3-d)pyrimidin)-6'-one; Spiro(cyclohexane-1,9'(6'H)-pyrazino(1',2':1,5)pyrrolo(2,3-d)pyrimidin)-6'-one, 7',8'-dihydro-2'-((5-(4-methyl-1-piperazinyl)-2-pyridinyl)amino)-; 2-[[5-(4-methylpiperazin-1-yl)pyridin-2-yl]amino]spiro[7,8-dihydropyra DMP5A4T CP G1 Therapeutics Research Triangle Park, NC DMP5A4T PC 68029831 DMP5A4T MW 446.5 DMP5A4T FM C24H30N8O DMP5A4T IC InChI=1S/C24H30N8O/c1-30-9-11-31(12-10-30)18-5-6-20(25-15-18)28-23-26-14-17-13-19-22(33)27-16-24(7-3-2-4-8-24)32(19)21(17)29-23/h5-6,13-15H,2-4,7-12,16H2,1H3,(H,27,33)(H,25,26,28,29) DMP5A4T CS CN1CCN(CC1)C2=CN=C(C=C2)NC3=NC=C4C=C5C(=O)NCC6(N5C4=N3)CCCCC6 DMP5A4T IK PDGKHKMBHVFCMG-UHFFFAOYSA-N DMP5A4T IU 4-[[5-(4-methylpiperazin-1-yl)pyridin-2-yl]amino]spiro[1,3,5,11-tetrazatricyclo[7.4.0.02,7]trideca-2,4,6,8-tetraene-13,1'-cyclohexane]-10-one DMP5A4T CA CAS 1374743-00-6 DMP5A4T DE Triple negative breast cancer; Small-cell lung cancer DMQZ9GF ID DMQZ9GF DMQZ9GF DN Trilostane DMQZ9GF HS Approved DMQZ9GF SN Desopan; Desopan (TN); Modrenal (TN); Vetoryl (TN); Vetoryl, Trilostane; Win-24540; Trilostane (JAN/USAN); (4alpha,5alpha,17beta)-3,17-dihydroxy-4,5-epoxyandrost-2-ene-2-carbonitrile; 3,17beta-dihydroxy-4alpha,5-epoxy-5alpha-androst-2-ene-2-carbonitrile DMQZ9GF CP Dechra Pharmaceuticals DMQZ9GF DT Small molecular drug DMQZ9GF PC 656583 DMQZ9GF MW 329.4 DMQZ9GF FM C20H27NO3 DMQZ9GF IC InChI=1S/C20H27NO3/c1-18-7-6-14-12(13(18)3-4-15(18)22)5-8-20-17(24-20)16(23)11(10-21)9-19(14,20)2/h12-15,17,22-23H,3-9H2,1-2H3/t12-,13-,14-,15-,17+,18-,19+,20+/m0/s1 DMQZ9GF CS C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CC[C@]45[C@@]3(CC(=C([C@H]4O5)O)C#N)C DMQZ9GF IK KVJXBPDAXMEYOA-CXANFOAXSA-N DMQZ9GF IU (1S,2R,6R,8S,11S,12S,15S,16S)-5,15-dihydroxy-2,16-dimethyl-7-oxapentacyclo[9.7.0.02,8.06,8.012,16]octadec-4-ene-4-carbonitrile DMQZ9GF CA CAS 13647-35-3 DMQZ9GF CB CHEBI:32260 DMQZ9GF DE Cushing disease DM1QLST ID DM1QLST DM1QLST DN Trimazosin DM1QLST HS Approved DM1QLST SN Trimazosin hydrochloride; Trimazosin HCl; 53746-46-6; UNII-827T79ILE7; Trimazosin hydrochloride [USAN]; 827T79ILE7; Trimazosin hydrochloride monohydrate; Trimazosin hydrochloride (USAN); 35795-16-5 (Parent); Cardovar; Supres; Trimazosin hydrochlorid-1-wasser; AC1Q3ECH; CP 19106-1; AC1L21UN; SCHEMBL10363255; CHEMBL3989848; DTXSID40202021; Trimazosin monohydrochloride monohydrate; 2-Hydroxy-2-methylpropyl 4-(4-amino-6,7,8-trimethoxy-2-quinazolinyl)-1-piperazinecarboxylate monohydrochloride monohydrate; 1-Piperazinecarboxylic aci DM1QLST DT Small molecular drug DM1QLST PC 37264 DM1QLST MW 435.5 DM1QLST FM C20H29N5O6 DM1QLST IC InChI=1S/C20H29N5O6/c1-20(2,27)11-31-19(26)25-8-6-24(7-9-25)18-22-14-12(17(21)23-18)10-13(28-3)15(29-4)16(14)30-5/h10,27H,6-9,11H2,1-5H3,(H2,21,22,23) DM1QLST CS CC(C)(COC(=O)N1CCN(CC1)C2=NC3=C(C(=C(C=C3C(=N2)N)OC)OC)OC)O DM1QLST IK YNZXWQJZEDLQEG-UHFFFAOYSA-N DM1QLST IU (2-hydroxy-2-methylpropyl) 4-(4-amino-6,7,8-trimethoxyquinazolin-2-yl)piperazine-1-carboxylate DM1QLST CA CAS 35795-16-5 DM1QLST CB CHEBI:135710 DM1QLST DE Congestive heart failure DMPYQ7B ID DMPYQ7B DMPYQ7B DN Trimebutine DMPYQ7B HS Approved DMPYQ7B SN Trimebutine maleate; Trimedat; Dromostat; Ibutin; Digerent polifarma; EINECS 251-845-9; TM 906; (1-Ethyl-1-phenyl-2-(3,4,5-trimethoxybenzoyloxy)ethyl)dimethylammonium hydrogen maleate; AC1O5HFA; Benzoic acid, 3,4,5-trimethoxy-, beta-(dimethylamino)-beta-ethylphenethyl ester, maleate (1:1); 34140-59-5; SCHEMBL1652810; C22H29NO5.C4H4O4; AKOS026750056; LS-38470; dimethyl-[2-phenyl-1-(3,4,5-trimethoxybenzoyl)oxybutan-2-yl]azanium; (E)-4-hydroxy-4-oxobut-2-enoate; Benzoic acid, 3,4,5-trimethoxy-, beta-(dimethylamino)-beta-ethyl DMPYQ7B DT Small molecular drug DMPYQ7B PC 5573 DMPYQ7B MW 387.5 DMPYQ7B FM C22H29NO5 DMPYQ7B IC InChI=1S/C22H29NO5/c1-7-22(23(2)3,17-11-9-8-10-12-17)15-28-21(24)16-13-18(25-4)20(27-6)19(14-16)26-5/h8-14H,7,15H2,1-6H3 DMPYQ7B CS CCC(COC(=O)C1=CC(=C(C(=C1)OC)OC)OC)(C2=CC=CC=C2)N(C)C DMPYQ7B IK LORDFXWUHHSAQU-UHFFFAOYSA-N DMPYQ7B IU [2-(dimethylamino)-2-phenylbutyl] 3,4,5-trimethoxybenzoate DMPYQ7B CA CAS 58997-89-0 DMPYQ7B CB CHEBI:94458 DMPYQ7B DE Irritable bowel syndrome DMEMV9D ID DMEMV9D DMEMV9D DN Trimeprazine DMEMV9D HS Approved DMEMV9D SN Alimemazina; Alimemazine; Alimemazinum; Alimezine; Isobutrazine; Methylpromazine; Oxomemazin; Repetin; Teralen; Trimeperazine; Trimeprazine Tartrat; Bayer 1219; Alimemazina [INN-Spanish]; Alimemazine (INN); Alimemazine [INN:BAN]; Alimemazinum [INN-Latin]; Dl-Trimeprazine; Nedeltran (TN); Oxomemazine [DCF:INN]; Panectyl (TN); Repeltin (TN); Temaril (TN); Therafene (TN); Theralen (TN); Theralene (TN); Trimeprazine (BAN); Vallergan (TN); Vanectyl (TN); Trimeprazine 5,5-dioxide; Trimeprazine hemi-(+)-tartrate; N,N,beta-Trimethyl-10H-phenothiazine-10-propanamine; N,N,2-trimethyl-3-phenothiazin-10-ylpropan-1-amine; N,N,2-trimethyl-3-(10H-phenothiazin-10-yl)propan-1-amine; (+-)-Alimemazine; (+-)-Trimeprazine; 10-(2-Methyl-3-dimethylaminopropyl)-phenothiazine; 10-(3-(Dimethylamino)-2-methylpropyl)phenothiazine; 10-(3-Dimethylamino-2-methylpropyl)phenothiazine DMEMV9D CP Allergan Herbert Skin Care Div Allergan Inc DMEMV9D TC Antihistamines DMEMV9D DT Small molecular drug DMEMV9D PC 5574 DMEMV9D MW 298.4 DMEMV9D FM C18H22N2S DMEMV9D IC InChI=1S/C18H22N2S/c1-14(12-19(2)3)13-20-15-8-4-6-10-17(15)21-18-11-7-5-9-16(18)20/h4-11,14H,12-13H2,1-3H3 DMEMV9D CS CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)CN(C)C DMEMV9D IK ZZHLYYDVIOPZBE-UHFFFAOYSA-N DMEMV9D IU N,N,2-trimethyl-3-phenothiazin-10-ylpropan-1-amine DMEMV9D CA CAS 84-96-8 DMEMV9D CB CHEBI:9725 DMEMV9D DE Allergic rhinitis DM0Q8MZ ID DM0Q8MZ DM0Q8MZ DN Trimethadione DM0Q8MZ HS Approved DM0Q8MZ SN Absentol; Absetil; Convenixa; Convexina; Edion; Epidione; Epidone; Epixal; Etydion; Minoaleuiatin; Minoaleviatin; Petidion; Petidon; Petilep; Petimalin; Pitmal; Ptimal; Tioxanona; Tredione; Tricione; Tridilona; Tridion; Tridione; Tridone; Trilidona; Trimedal; Trimedone; Trimetadiona; Trimetadione; Trimethadion; Trimethadionum; Trimethdione; Trimethin; Trimethinum; Trimetin; Trioksal; Trioxanona; Triozanona; Tromedone; Troxidone; Abbott Brand of Trimethadione; Trimetadione [DCIT]; A 2297; Mino-Aleviatin; Neo-Absentol; Tridione (TN); Trimetadiona [INN-Spanish]; Trimethadione [INN:JAN]; Trimethadionum [INN-Latin]; Trimethadione (JP15/INN); 3,3,5-Trimethyl-2,4-diketooxazolidine; 3,5,5,-Trimethyloxazolidine-2,4-dione; 3,5,5-TRIMETHYL-OXAZOLIDINE-2,4-DIONE; 3,5,5-Trimethyl-1,3-oxazolidine-2,4-dione; 3,5,5-Trimethyl-2,4-oxazolidinedione; 3,5,5-Trojmetylooksazolidyno-2,4-dion; 3,5,5-Trojmetylooksazolidyno-2,4-dion [Polish] DM0Q8MZ TC Anticonvulsants DM0Q8MZ DT Small molecular drug DM0Q8MZ PC 5576 DM0Q8MZ MW 143.14 DM0Q8MZ FM C6H9NO3 DM0Q8MZ IC InChI=1S/C6H9NO3/c1-6(2)4(8)7(3)5(9)10-6/h1-3H3 DM0Q8MZ CS CC1(C(=O)N(C(=O)O1)C)C DM0Q8MZ IK IRYJRGCIQBGHIV-UHFFFAOYSA-N DM0Q8MZ IU 3,5,5-trimethyl-1,3-oxazolidine-2,4-dione DM0Q8MZ CA CAS 127-48-0 DM0Q8MZ CB CHEBI:9727 DM0Q8MZ DE Pancreatic cancer; Epilepsy DMHF4IQ ID DMHF4IQ DMHF4IQ DN Trimethaphan DMHF4IQ HS Approved DMHF4IQ SN Thimethaphan; Trimetaphan; Trimetaphanum; Arfonad (TN); Thieno(1',2':1,2)thieno(3,4-d)imidazol-5-ium, decahydro-2-oxo-1,3-bis(phenylmethyl)-(VAN); 1,3-dibenzyl-2-oxodecahydrothieno[1',2':1,2]thieno[3,4-d]imidazol-5-ium DMHF4IQ CP Hoffmann La Roche Inc DMHF4IQ TC Antihypertensive Agents DMHF4IQ DT Small molecular drug DMHF4IQ PC 23576 DMHF4IQ MW 365.5 DMHF4IQ FM C22H25N2OS+ DMHF4IQ IC InChI=1S/C22H25N2OS/c25-22-23(14-17-8-3-1-4-9-17)19-16-26-13-7-12-20(26)21(19)24(22)15-18-10-5-2-6-11-18/h1-6,8-11,19-21H,7,12-16H2/q+1 DMHF4IQ CS C1CC2C3C(C[S+]2C1)N(C(=O)N3CC4=CC=CC=C4)CC5=CC=CC=C5 DMHF4IQ IK CHQOEHPMXSHGCL-UHFFFAOYSA-N DMHF4IQ IU 3,5-dibenzyl-8-thionia-3,5-diazatricyclo[6.3.0.02,6]undecan-4-one DMHF4IQ CA CAS 7187-66-8 DMHF4IQ CB CHEBI:9728 DMHF4IQ DE Aneurysm; Hypertensive emergency DMM7CHK ID DMM7CHK DMM7CHK DN Trimethoprim DMM7CHK HS Approved DMM7CHK SN Abaprim; Alprim; Anitrim; Antrima; Antrimox; Bacdan; Bacidal; Bacide; Bacin; Bacta; Bacterial; Bacticel; Bactin; Bactoprim; Bactramin; Bencole; Bethaprim; Biosulten; Briscotrim; Chemotrin; Cidal; Colizole; Conprim; Cotrimel; Deprim; Duocide; Esbesul; Espectrin; Euctrim; Exbesul; Fermagex; Fortrim; Futin; Idotrim; Ikaprim; Instalac; Kombinax; Lagatrim; Lastrim; Methoprim; Metoprim; Monoprim; Monotrim; Monotrimin; Novotrimel; Omstat; Oraprim; Pancidim; Polytrim; Priloprim; Primosept; Primsol; Proloprim; Protrin; Purbal; Resprim; Roubac; Roubal; Salvatrim; Setprin; Sinotrim; Stopan; Streptoplus; Sugaprim; Sulfamar; Sulfamethoprim; Sulfoxaprim; Sulmeprim; Sulthrim; Sultrex; Syraprim; Tiempe; Toprim; Trimanyl; Trimethioprim; Trimethoprime; Trimethoprimum; Trimethopriom; Trimetoprim; Trimetoprima; Trimexazole; Trimexol; Trimezol; Trimogal; Trimono; Trimopan; Trimpex; Triprim; Trisul; Trisulcom; Trisulfam; Trisural; Uretrim; Urobactrim; Utetrin; Velaten; Wellcoprim; Wellcoprin; Xeroprim; Zamboprim; Bacterial [Antibiotic]; Colizole DS; Component of Bactrim; Component of Septra; Lagatrim Forte; ResprimForte; Septrin DS; Septrin Forte; Septrin S; Trimetoprim [DCIT]; Trimetoprim [Polish]; BW 5672; KUC103659N; NIH 204; T 7883; Trimpex 200; WR 5949; Alcorim-F; Apo-Sulfatrim; BW 56-72; Co-Trimoxizole; Monotrim (TN); NIH 204 (VAN); Proloprim (TN); Smz-Tmp; Sulfamethoxazole & Trimethoprim; TCMDC-125538; Tmp-Ratiopharm; Trimeth/Sulfa; Trimethopim(TMP); Trimethoprim & VRC3375; Trimethoprime [INN-French]; Trimethoprimum [INN-Latin]; Trimetoprima [INN-Spanish]; Trimez-IFSA; Trimpex (TN); Triprim (TN); U-Prin; Uro-D S; BW-56-72; KSC-4-158; AZT + TMP/SMX (mixture) combination; Trimethoprim (JAN/USP/INN); Trimethoprim [USAN:BAN:INN:JAN] DMM7CHK CP GlaxoSmithKline DMM7CHK TC Antiinfective Agents DMM7CHK DT Small molecular drug DMM7CHK PC 5578 DMM7CHK MW 290.32 DMM7CHK FM C14H18N4O3 DMM7CHK IC InChI=1S/C14H18N4O3/c1-19-10-5-8(6-11(20-2)12(10)21-3)4-9-7-17-14(16)18-13(9)15/h5-7H,4H2,1-3H3,(H4,15,16,17,18) DMM7CHK CS COC1=CC(=CC(=C1OC)OC)CC2=CN=C(N=C2N)N DMM7CHK IK IEDVJHCEMCRBQM-UHFFFAOYSA-N DMM7CHK IU 5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-2,4-diamine DMM7CHK CA CAS 738-70-5 DMM7CHK CB CHEBI:45924 DMM7CHK DE Urinary tract infection DMDEA85 ID DMDEA85 DMDEA85 DN Trimetrexate DMDEA85 HS Approved DMDEA85 SN TMQ; Trimetrexato; Trimetrexatum; JB 11; Jb-11; Trimetrexato [INN-Spanish]; Trimetrexatum [INN-Latin]; Trimetrexate (USAN/INN); Trimetrexate [USAN:BAN:INN]; 2,4-Diamino-5-methyl-6-((3,4,5-trimethoxyanilino)methyl)quinazoline; 5-Methyl-6-(((3,4,5-trimethoxyphenyl)amino)methyl)-2,4-quinazolinediamine; 5-methyl-6-({[3,4,5-tris(methyloxy)phenyl]amino}methyl)quinazoline-2,4-diamine; 5-methyl-6-[(3,4,5-trimethoxyanilino)methyl]quinazoline-2,4-diamine; 6-[((3,4,5-Trimethoxyphenyl)amino)methyl]-5-methyl-2,4-quinazolinediamine DMDEA85 CP Medimmune Oncology Inc DMDEA85 TC Antifungal Agents DMDEA85 DT Small molecular drug DMDEA85 PC 5583 DMDEA85 MW 369.4 DMDEA85 FM C19H23N5O3 DMDEA85 IC InChI=1S/C19H23N5O3/c1-10-11(5-6-13-16(10)18(20)24-19(21)23-13)9-22-12-7-14(25-2)17(27-4)15(8-12)26-3/h5-8,22H,9H2,1-4H3,(H4,20,21,23,24) DMDEA85 CS CC1=C(C=CC2=C1C(=NC(=N2)N)N)CNC3=CC(=C(C(=C3)OC)OC)OC DMDEA85 IK NOYPYLRCIDNJJB-UHFFFAOYSA-N DMDEA85 IU 5-methyl-6-[(3,4,5-trimethoxyanilino)methyl]quinazoline-2,4-diamine DMDEA85 CA CAS 52128-35-5 DMDEA85 CB CHEBI:9737 DMDEA85 DE Toxoplasmosis DM1SC8M ID DM1SC8M DM1SC8M DN Trimipramine DM1SC8M HS Approved DM1SC8M SN Sapilent; Stangyl; Surmontil; Surmontyl; Trimeprimina; Trimeprimine; Trimeproprimin; Trimeproprimine; Trimipramina; Trimipraminum; Trimeprimina [Italian]; FI 6120; IL 6001; Beta-Methylimipramine; IL-6001; RP-7162; Rhotrimine (TN); Stangyl (TN); Surmontil (TN); Trimipramina [INN-Spanish]; Trimipraminum [INN-Latin]; Trimipramine (USAN/INN); Trimipramine [USAN:INN:BAN]; Trimipramine, (-)-Isomer; (+)-Trimipramine; (-)-Trimipramine; 1-(3-Dimethylamino-2-methylpropyl)-4,5-dihydro-2,3:6,7-dibenzazepine; 10,11 Dihydro-N,N,beta-trimethyl-5H-dibenz(b,f)azepine-5-propanamine; 10,11-Dihydro-5-(3-dimethylamino-2-methylpropyl)-5H-dibenz(b,f)azepine; 10,11-dihydro-N,N,beta-trimethyl-5H-dibenz[b,f]azepine-5-propanamine; 2'-Metil-3'-dimetilamino-propil-5-iminodibenzile; 2'-Metil-3'-dimetilamino-propil-5-iminodibenzile [Italian]; 3-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N,2-trimethylpropan-1-amine; 3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N,N,2-trimethylpropan-1-amine; 5-(3-(Dimethylamino)-2-methylpropyl)-10,11-dihydro-5H-dibenz(b,f)azepine; 5-(gamma-Dimethylamino-beta-methylpropyl)-10,11-dihydro-5H-dibenzo(b,f)azepine; 5-(gamma-dimethylamino-beta-methylpropyl)-10,11-dihydro-5H-dibenzo[b,f]azepine; 5-[3-(dimethylamino)-2-methylpropyl]-10,11-dihydro-5H-dibenz[b,f]azepine; 5H-Dibenz(b,f)azepine-5-propanamine, 10,11-dihydro-N,N,beta-trimethyl-, (+)-(9CI); 5H-Dibenz(b,f)azepine-5-propanamine, 10,11-dihydro-N,N,beta-trimethyl-, (-)-(9CI); 7162 RP DM1SC8M CP Odyssey Pharmaceuticals Inc DM1SC8M TC Antidepressants DM1SC8M DT Small molecular drug DM1SC8M PC 5584 DM1SC8M MW 294.4 DM1SC8M FM C20H26N2 DM1SC8M IC InChI=1S/C20H26N2/c1-16(14-21(2)3)15-22-19-10-6-4-8-17(19)12-13-18-9-5-7-11-20(18)22/h4-11,16H,12-15H2,1-3H3 DM1SC8M CS CC(CN1C2=CC=CC=C2CCC3=CC=CC=C31)CN(C)C DM1SC8M IK ZSCDBOWYZJWBIY-UHFFFAOYSA-N DM1SC8M IU 3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N,N,2-trimethylpropan-1-amine DM1SC8M CA CAS 3564-75-8 DM1SC8M CB CHEBI:9738 DM1SC8M DE Major depressive disorder DMZBU15 ID DMZBU15 DMZBU15 DN Tripelennamine DMZBU15 HS Approved DMZBU15 SN Benzoxale; Cizaron; Dehistin; Piribenzil; Pyribenzamin; Pyribenzamine; Pyridbenzamine; Resistamine; Tonaril; Tripelannamine; Tripelenamina; Tripelenamine; Tripelennamin; Tripelennamina; Tripelennaminum; Tripellenamine; Triplennamine; Vetibenzamina; Pyrinamine base; Tripelennamina [Italian]; Tripelennamine [BAN]; Tripelennamine [INN]; Ts and Blues; Pyribenzamine (TN); Pyristine (piristina); Tripelenamina [INN-Spanish]; Tripelennamine (INN); Tripelennaminum [INN-Latin]; Tripelennamine Citrate (1:1); Beta-Dimethylaminoethyl-2-pyridylaminotoluene; Beta-Dimethylaminoethyl-2-pyridylbenzylamine; Benzyl-(alpha-pyridyl)-dimethylaethylendiamin; Benzyl-(alpha-pyridyl)-dimethylaethylendiamin [German]; Benzyl-(alpha.-pyridyl)-dimethylaethylendiamin; Benzyl-.alpha.-pyridyl-dimethyl-aethylendiamin; N-benzyl-N-[2-(dimethylamino)ethyl]pyridin-2-amine; N-Benzyl-N',N'-dimethyl-N-2-pyridylethylenediamine; N,N-Dimethyl-N'-benzyl-N'-(2-pyridyl)ethylenediamine; N,N-Dimethyl-N'-benzyl-N'-(alpha-pyridyl)ethylenediamine; N-Benzyl-N',N'-dimethyl-N-(2-pyridyl)ethylenediamine; N-Benzyl-N',N'-dimethyl-N-2-(pyridylethylene)diamine; N-Benzyl-N-(2-pyridyl)-N',N'-dimethyl ethylenediamine; N,N-Dimethyl-N'-benzyl-N'-(alpha.-pyridyl)ethylenediamine; N'-benzyl-N,N-dimethyl-N'-pyridin-2-ylethane-1,2-diamine; N,N-Dimethyl-N'-(phenylmethyl)-N'-2-pyridinyl-1,2-ethanediamine; N,N-dimethyl-N'-(phenylmethyl)-N'-pyridin-2-ylethane-1,2-diamine; N-Benzyl-N',N'-Dimethyl-N-Pyridin-2-Yl-Ethane-1,2-Diamine Hydrochloride; 1,2-Ethanediamine, N,N-dimethyl-N'-(phenylmethyl)-N'-2-pyridinyl-(9CI); 2-(Benzyl(2-dimethylaminoethyl)amino)pyridine; 2-(N-Benzyl-N-(2-dimethylaminoethyl)amino)pyridine; 2-(benzyl(2-(dimethylamino)ethyl)amino)pyridine; 2-[Benzyl(2-dimethylaminoethyl)amino]pyridine; 2-[N-Benzyl-N-(2-dimethylaminoethyl)amino]pyridine DMZBU15 CP Norvatis Phamaceuticals Corporation DMZBU15 TC Antiallergic Agents DMZBU15 DT Small molecular drug DMZBU15 PC 5587 DMZBU15 MW 255.36 DMZBU15 FM C16H21N3 DMZBU15 IC InChI=1S/C16H21N3/c1-18(2)12-13-19(16-10-6-7-11-17-16)14-15-8-4-3-5-9-15/h3-11H,12-14H2,1-2H3 DMZBU15 CS CN(C)CCN(CC1=CC=CC=C1)C2=CC=CC=N2 DMZBU15 IK UFLGIAIHIAPJJC-UHFFFAOYSA-N DMZBU15 IU N'-benzyl-N,N-dimethyl-N'-pyridin-2-ylethane-1,2-diamine DMZBU15 CA CAS 91-81-6 DMZBU15 CB CHEBI:9741 DMZBU15 DE Hypersensitivity DM7SWIA ID DM7SWIA DM7SWIA DN Triprolidine DM7SWIA HS Approved DM7SWIA SN Actidil; Actidilat; Entra; Histafed; Myidyl; Tripolidina; Triprolidin; Triprolidinum; Venen; Triprolidine HCL; Triprolidine Monohydrochloride; Triprolidine hydrochloride; Triprolidine hydrochloride anhydrous; T 6764; Actidil (TN); Myidil (TN); Pro-Actidil; Pro-Entra; Tripolidina [INN-Spanish]; Triprolidine (INN); Triprolidine Hydrochloride (anhydrous); Triprolidine Monohydrochloride, Monohydrate; Triprolidine [INN:BAN]; Triprolidinum [INN-Latin]; Venen (TN); Trans-2-(3-(1-Pyrrolidinyl)-1-p-tolylpropenyl)pyridine; Trans-2-(3-(1-Pyrrolidinyl)-1-p-tolylpropenyl)pyridine monohydrochloride; Trans-1-(2-Pyridyl)-3-pyrrolidino-1-p-tolylprop-1-ene; Trans-1-(4-Methylphenyl)-1-(2-pyridyl)-3-pyrrolidinoprop-1-ene; Pyridine, 2-(3-(1-pyrrolidinyl)-1-p-tolylpropenyl)-, monohydrochloride, monohydrate, stereoisomer; Pyridine, 2-((1E)-1-(4-methylphenyl)-3-(1-pyrrolidinyl)-1-propenyl)-, monohydrochloride; Pyridine, 2-((1E)-1-(4-methylphenyl)-3-(1-pyrrolidinyl)-1-propen-1-yl)-, hydrochloride (1:1); (E)-2-(1-(4-Methylphenyl)-3-(1-pyrrolidinyl)-1-propenyl)pyridine; (E)-2-[3-(1-Pyrrolidinyl)-1-p-tolylpropenyl]pyridine hydrochloride; 2-[(E)-1-(4-methylphenyl)-3-pyrrolidin-1-ium-1-ylprop-1-enyl]pyridine chloride; 2-[(E)-1-(4-methylphenyl)-3-pyrrolidin-1-ylprop-1-enyl]pyridine; 2-[(E)-1-(4-methylphenyl)-3-pyrrolidin-1-ylprop-1-enyl]pyridine hydrochloride DM7SWIA TC Antiallergic Agents DM7SWIA DT Small molecular drug DM7SWIA PC 5282443 DM7SWIA MW 278.4 DM7SWIA FM C19H22N2 DM7SWIA IC InChI=1S/C19H22N2/c1-16-7-9-17(10-8-16)18(19-6-2-3-12-20-19)11-15-21-13-4-5-14-21/h2-3,6-12H,4-5,13-15H2,1H3/b18-11+ DM7SWIA CS CC1=CC=C(C=C1)/C(=C\\CN2CCCC2)/C3=CC=CC=N3 DM7SWIA IK CBEQULMOCCWAQT-WOJGMQOQSA-N DM7SWIA IU 2-[(E)-1-(4-methylphenyl)-3-pyrrolidin-1-ylprop-1-enyl]pyridine DM7SWIA CA CAS 486-12-4 DM7SWIA CB CHEBI:84116 DM7SWIA DE Hay fever DMTK4LS ID DMTK4LS DMTK4LS DN Triptorelin DMTK4LS HS Approved DMTK4LS SN Gonapeptyl depot (TN) DMTK4LS CP Tulane University DMTK4LS DT Small molecular drug DMTK4LS PC 25074470 DMTK4LS MW 1311.4 DMTK4LS FM C64H82N18O13 DMTK4LS IC InChI=1S/C64H82N18O13/c1-34(2)23-46(56(88)75-45(13-7-21-69-64(66)67)63(95)82-22-8-14-52(82)62(94)72-31-53(65)85)76-58(90)48(25-36-28-70-42-11-5-3-9-40(36)42)78-57(89)47(24-35-15-17-39(84)18-16-35)77-61(93)51(32-83)81-59(91)49(26-37-29-71-43-12-6-4-10-41(37)43)79-60(92)50(27-38-30-68-33-73-38)80-55(87)44-19-20-54(86)74-44/h3-6,9-12,15-18,28-30,33-34,44-52,70-71,83-84H,7-8,13-14,19-27,31-32H2,1-2H3,(H2,65,85)(H,68,73)(H,72,94)(H,74,86)(H,75,88)(H,76,90)(H,77,93)(H,78,89)(H,79,92)(H,80,87)(H,81,91)(H4,66,67,69)/t44-,45-,46-,47-,48+,49-,50-,51-,52-/m0/s1 DMTK4LS CS CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N)NC(=O)[C@@H](CC2=CNC3=CC=CC=C32)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC5=CNC6=CC=CC=C65)NC(=O)[C@H](CC7=CN=CN7)NC(=O)[C@@H]8CCC(=O)N8 DMTK4LS IK VXKHXGOKWPXYNA-PGBVPBMZSA-N DMTK4LS IU (2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[(2-amino-2-oxoethyl)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide DMTK4LS CA CAS 57773-63-4 DMTK4LS CB CHEBI:63633 DMTK4LS DE Solid tumour/cancer; Prostate cancer DMHB2C3 ID DMHB2C3 DMHB2C3 DN Trofosfamide DMHB2C3 HS Approved DMHB2C3 SN Trofosfamide; Trophosphamide; Ixoten; 22089-22-1; Trofosfamid; Triphosphamide; Trilofosfamida; Trifosfamide; Trisfosfamide; Trilophosphamide; Trofosfamidum; Z 4828; Trofosfamide [INN]; ASTA Z 4828; Trofosfamida [Spanish]; A-4828; Trofosfamidum [INN-Latin]; NSC 109723; Trofosfamido [INN-Spanish]; MLS002704177; CCRIS 4442; Z-4828; EINECS 244-770-8; Trofosfamide (INN); BRN 0532530; N,N,3-Tris(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide; N,N-3'-Tris(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine, 2-oxide DMHB2C3 DT Small molecular drug DMHB2C3 PC 65702 DMHB2C3 MW 323.6 DMHB2C3 FM C9H18Cl3N2O2P DMHB2C3 IC InChI=1S/C9H18Cl3N2O2P/c10-2-6-13-5-1-9-16-17(13,15)14(7-3-11)8-4-12/h1-9H2 DMHB2C3 CS C1CN(P(=O)(OC1)N(CCCl)CCCl)CCCl DMHB2C3 IK UMKFEPPTGMDVMI-UHFFFAOYSA-N DMHB2C3 IU N,N,3-tris(2-chloroethyl)-2-oxo-1,3,2lambda5-oxazaphosphinan-2-amine DMHB2C3 CA CAS 22089-22-1 DMHB2C3 CB CHEBI:135381 DMHB2C3 DE Non-hodgkin lymphoma DM3VFPD ID DM3VFPD DM3VFPD DN Troglitazone DM3VFPD HS Approved DM3VFPD SN Noscal; Prelay; Resulin; Rezulin; Romglizone; Romozin; Troglitazona; Troglitazonum; Parke Davis brand of troglitazone; CS 045; GR 92132X; CS-045; GR-92132X; Resulin (TN); Rezulin (TN); Romozin (TN); Warner-Lambert brand of troglitazone; Troglitazone [USAN:BAN:INN]; Troglitazone (JAN/USAN/INN); (+-)-all-rac-5-(p-((6-Hydroxy-2,5,7,8-tetramethyl-2-chromanyl)methoxy)benzyl)-2,4-thiazolidinedione; (+/-)-5-[4-[(6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)methoxy]benzyl]-2,4-thiazolidinedione; 2,4-Thiazolidinedione, 5-[[4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy]phenyl]methyl]-(9CI); 5-(4-((6-hydroxy-2,5,7,8-tetramethylchroman-2-yl-methoxy)benzyl)-2,4-thiazolidinedione); 5-(4-(6-Hydroxy-2,5,7,8-tetramethylchroman-2-ylmethoxy)benzyl)thiazolidine-2,4-dione; 5-[(4-{[(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-chromen-2-yl)methyl]oxy}phenyl)methyl]-1,3-thiazolidine-2,4-dione; 5-[[4-[(3,4-Dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy]phenyl]methyl]-2,4-thiazolidinedione; 5-[[4-[(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydrochromen-2-yl)methoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione; 5-{4-[(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-chromen-2-yl)methoxy]benzyl}-1,3-thiazolidine-2,4-dione DM3VFPD CP Daiichi Sankyo Pharma Development DM3VFPD TC Antiinflammatory Agents DM3VFPD DT Small molecular drug DM3VFPD PC 5591 DM3VFPD MW 441.5 DM3VFPD FM C24H27NO5S DM3VFPD IC InChI=1S/C24H27NO5S/c1-13-14(2)21-18(15(3)20(13)26)9-10-24(4,30-21)12-29-17-7-5-16(6-8-17)11-19-22(27)25-23(28)31-19/h5-8,19,26H,9-12H2,1-4H3,(H,25,27,28) DM3VFPD CS CC1=C(C2=C(CCC(O2)(C)COC3=CC=C(C=C3)CC4C(=O)NC(=O)S4)C(=C1O)C)C DM3VFPD IK GXPHKUHSUJUWKP-UHFFFAOYSA-N DM3VFPD IU 5-[[4-[(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydrochromen-2-yl)methoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione DM3VFPD CA CAS 97322-87-7 DM3VFPD CB CHEBI:9753 DM3VFPD DE Diabetic complication DMUZNIG ID DMUZNIG DMUZNIG DN Troleandomycin DMUZNIG HS Approved DMUZNIG SN Aovine; Cyclamycin; Evramicina; Matromicina; Oleandocetin; Oleandocetine; TAO; Treolmicina; Triacetyloleandomycin; Triacetyloleandomycinum; Tribiocillina; Triocetin; Triolan; Troleandomicina; Troleandomycine; Troleandomycinum; Viamicina; Wytrion; Matromycin T; Oleandomycin triacetate; Oleandomycin triacetyl ester; Triacetyl ester of oleandomycin; WY 651; Tao (TN); Tao (VAN); Tekmisin (TN); Treis-Micina; Triacetyloleandomycin (JAN); Triocetin (TN); Troleandomicina [INN-Spanish]; Troleandomycin (TAO); Troleandomycin [USAN:INN]; Troleandomycine [INN-French]; Troleandomycinum [INN-Latin]; Oleandomycin, triacetate (ester); T.A.O; Troleandomycin (USP/INN); T.A.O. DMUZNIG CP Bayer Pharmaceuticals Corporation DMUZNIG TC Antibiotics DMUZNIG DT Small molecular drug DMUZNIG PC 202225 DMUZNIG MW 814 DMUZNIG FM C41H67NO15 DMUZNIG IC InChI=1S/C41H67NO15/c1-19-17-41(18-49-41)38(46)23(5)34(53-27(9)43)21(3)25(7)52-39(47)24(6)35(56-32-16-31(48-14)36(26(8)51-32)54-28(10)44)22(4)33(19)57-40-37(55-29(11)45)30(42(12)13)15-20(2)50-40/h19-26,30-37,40H,15-18H2,1-14H3/t19-,20+,21-,22+,23+,24+,25+,26-,30-,31-,32-,33-,34-,35-,36-,37+,40-,41+/m0/s1 DMUZNIG CS C[C@@H]1C[C@@H]([C@H]([C@@H](O1)O[C@H]2[C@H](C[C@@]3(CO3)C(=O)[C@@H]([C@H]([C@H]([C@H](OC(=O)[C@@H]([C@H]([C@@H]2C)O[C@H]4C[C@@H]([C@H]([C@@H](O4)C)OC(=O)C)OC)C)C)C)OC(=O)C)C)C)OC(=O)C)N(C)C DMUZNIG IK LQCLVBQBTUVCEQ-QTFUVMRISA-N DMUZNIG IU [(3R,5S,6S,7R,8S,9R,12R,13S,14S,15R)-6-[(2S,3R,4S,6R)-3-acetyloxy-4-(dimethylamino)-6-methyloxan-2-yl]oxy-8-[(2R,4S,5S,6S)-5-acetyloxy-4-methoxy-6-methyloxan-2-yl]oxy-5,7,9,12,13,15-hexamethyl-10,16-dioxo-1,11-dioxaspiro[2.13]hexadecan-14-yl] acetate DMUZNIG CA CAS 2751-09-9 DMUZNIG CB CHEBI:45735 DMUZNIG DE Bacterial infection DMOBLGK ID DMOBLGK DMOBLGK DN Tromethamine DMOBLGK HS Approved DMOBLGK SN Trometamol; 77-86-1; TROMETHAMINE; Tris; Tris(Hydroxymethyl)aminomethane; Tham; Trisamine; 2-Amino-2-(hydroxymethyl)-1,3-propanediol; Trizma; Tris buffer; Tris base; Tromethane; Trisaminol; Talatrol; Trispuffer; Trisamin; Pehanorm; Tutofusin tris; Tris-steril; Apiroserum Tham; Addex-tham; Tris-base; Tris, free base; Trimethylolaminomethane; 1,3-Propanediol, 2-amino-2-(hydroxymethyl)-; Tris Amino; Aminotrimethylolmethane; Aminotris(hydroxymethyl)methane; THAM-E; Tris (buffering agent); Tris(Hydroxymethyl)Aminomethane DMOBLGK DT Small molecular drug DMOBLGK PC 6503 DMOBLGK MW 121.14 DMOBLGK FM C4H11NO3 DMOBLGK IC InChI=1S/C4H11NO3/c5-4(1-6,2-7)3-8/h6-8H,1-3,5H2 DMOBLGK CS C(C(CO)(CO)N)O DMOBLGK IK LENZDBCJOHFCAS-UHFFFAOYSA-N DMOBLGK IU 2-amino-2-(hydroxymethyl)propane-1,3-diol DMOBLGK CA CAS 77-86-1 DMOBLGK CB CHEBI:9754 DMOBLGK DE Acidosis DM1D90W ID DM1D90W DM1D90W DN Tropicamide DM1D90W HS Approved DM1D90W SN Bistropamide; Epitromina; Mydral; Mydriacyl; Mydriafair; Mydriaticum; Mydrum; OcuTropic; Opticyl; Paremyd; Tropicacyl; Tropicamida; Tropicamidum; Tropikamid; Tropimil; Visumidriatic; Akorn Brand of Tropicamide; Alcon Brand of Tropicamide; Bournonville Brand of Tropicamide; Cahill May Roberts Brand of Tropicamide; Chauvin Brand of Tropicamide; Colircusi Tropicamida; Medical Ophthalmics Brand of Tropicamide; Minims tropicamide; Novartis Brand of Tropicamide; Ocu Tropic; Ocumed Brand of Tropicamide; Ocusoft Brand of Tropicamide; Pharmafair Brand of Tropicamide; Rivex Brand of Tropicamide; Triaminic DM; Tropicamide Alcon Brand; Tropicamide Chauvin Brand; Tropicamide Faure; Tropicamide Minims; Tropicamide Monofree; Tropicamide Novartis Brand; Tropicamide Ocumed Brand; Tropicamide Pharmafair Brand; Tropicamide Rivex Brand; Stulln Brand 1 of Tropicamide; Stulln Brand 2 of Tropicamide; T 9778; I-Picamide; Mydriacyl (TN); Ocu-Tropic; Ro 1-7683; Spectro-Cyl; Tropicamida [INN-Spanish]; Tropicamidum [INN-Latin]; Tropicamide [USAN:INN:BANJAN]; Tropicamide (JP15/USP/INN); Tropicamide Monohydrochloride, (R)-Isomer; Tropicamide Monohydrochloride, (S)-Isomer; Tropicamide, (R)-Isomer; Tropicamide, (S)-Isomer; N-Ethyl-N-(4-pyridylmethyl)tropamid; N-Ethyl-N-(4-pyridylmethyl)tropamide; N-ethyl-n-(g-picolyl)tropamide; Tropicamide, (+-)-Isomer; N-Ethyl-2-phenyl-N-(4-pyridylmethyl)hydracrylamide; N-Ethyl-2-phenyl-N-4-[-pyridyl-methyl]hydracrylamide; N-Ethyl-alpha-(hydroxymethyl)-N-(4-pyridinylmethyl)benzeneacetamide; N-ethyl-3-hydroxy-2-phenyl-N-(pyridin-4-ylmethyl)propanamide; (+-)-N-Ethyl-2-phenyl-N-(4-pyridylmethyl)hydracrylamide DM1D90W CP Alcon Laboratories Inc DM1D90W TC Diagnostic Agents DM1D90W DT Small molecular drug DM1D90W PC 5593 DM1D90W MW 284.35 DM1D90W FM C17H20N2O2 DM1D90W IC InChI=1S/C17H20N2O2/c1-2-19(12-14-8-10-18-11-9-14)17(21)16(13-20)15-6-4-3-5-7-15/h3-11,16,20H,2,12-13H2,1H3 DM1D90W CS CCN(CC1=CC=NC=C1)C(=O)C(CO)C2=CC=CC=C2 DM1D90W IK BGDKAVGWHJFAGW-UHFFFAOYSA-N DM1D90W IU N-ethyl-3-hydroxy-2-phenyl-N-(pyridin-4-ylmethyl)propanamide DM1D90W CA CAS 1508-75-4 DM1D90W CB CHEBI:9757 DM1D90W DE Mydriasis DMNSJ7V ID DMNSJ7V DMNSJ7V DN Tropisetron DMNSJ7V HS Approved DMNSJ7V SN Navoban; Novaban; TKT; ICS-205930; Navoban (TN); Tropisetron (INN); [(1R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] 1H-indole-3-carboxylate; (3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl 1H-indole-3-carboxylate DMNSJ7V CP Novartis International AG DMNSJ7V DT Small molecular drug DMNSJ7V PC 656665 DMNSJ7V MW 284.35 DMNSJ7V FM C17H20N2O2 DMNSJ7V IC InChI=1S/C17H20N2O2/c1-19-11-6-7-12(19)9-13(8-11)21-17(20)15-10-18-16-5-3-2-4-14(15)16/h2-5,10-13,18H,6-9H2,1H3/t11-,12+,13? DMNSJ7V CS CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C3=CNC4=CC=CC=C43 DMNSJ7V IK ZNRGQMMCGHDTEI-FUNVUKJBSA-N DMNSJ7V IU [(1R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] 1H-indole-3-carboxylate DMNSJ7V CA CAS 89565-68-4 DMNSJ7V CB CHEBI:32269 DMNSJ7V DE Fibromyalgia DMX6RTG ID DMX6RTG DMX6RTG DN Trospium DMX6RTG HS Approved DMX6RTG SN Spasmex; Spasmoplex; Trosec; Regurin (TN); Sanctura (TN); Spasmex (TN); Spasmoplex (TN); Trosec (TN); Trospium chloride (JAN/USAN/INN); Spiro(8-azoniabicyclo(3.2.1)octane-8,1'-pyrrolidinium), 3-hydroxy-, chloride, benzilate; Spiro[8-azoniabicyclo[3.2.1]octane-8,1'-azolidin-1-ium]-3-yl 2-hydroxy-2,2-diphenylacetate; Spiro[8-azoniabicyclo[3.2.1]octane-8,1'-azolidin-1-ium]-3-yl 2-hydroxy-2,2-diphenylacetate chloride; 3-Hydroxyspiro(8-azoniabicyclo(3.2.1)octane-8,1'-pyrrolidinium) chloride benzilate; 6,10-Ethano-5-azoniaspiro(4.5)decan-8-ol, chloride, benzilate; 8-Benziloyloxy-6,10-ethano-5-azoniaspiro(4.5)decane chloride DMX6RTG CP Allergan Pharmaceuticals DMX6RTG TC Parasympatholytics DMX6RTG DT Small molecular drug DMX6RTG PC 5284632 DMX6RTG MW 392.5 DMX6RTG FM C25H30NO3+ DMX6RTG IC InChI=1S/C25H30NO3/c27-24(25(28,19-9-3-1-4-10-19)20-11-5-2-6-12-20)29-23-17-21-13-14-22(18-23)26(21)15-7-8-16-26/h1-6,9-12,21-23,28H,7-8,13-18H2/q+1/t21-,22+,23? DMX6RTG CS C1CC[N+]2(C1)[C@@H]3CC[C@H]2CC(C3)OC(=O)C(C4=CC=CC=C4)(C5=CC=CC=C5)O DMX6RTG IK OYYDSUSKLWTMMQ-AIZNXBIQSA-N DMX6RTG IU [(1R,5S)-spiro[8-azoniabicyclo[3.2.1]octane-8,1'-azolidin-1-ium]-3-yl] 2-hydroxy-2,2-diphenylacetate DMX6RTG CA CAS 47608-32-2 DMX6RTG CB CHEBI:145791 DMX6RTG DE Spasm; Overactive bladder DM32XZT ID DM32XZT DM32XZT DN Trospium chloride DM32XZT HS Approved DM32XZT SN Regurin; Sanctura DM32XZT TC Respiratory Agents DM32XZT DT Small molecular drug DM32XZT PC 5284631 DM32XZT MW 428 DM32XZT FM C25H30ClNO3 DM32XZT IC InChI=1S/C25H30NO3.ClH/c27-24(25(28,19-9-3-1-4-10-19)20-11-5-2-6-12-20)29-23-17-21-13-14-22(18-23)26(21)15-7-8-16-26;/h1-6,9-12,21-23,28H,7-8,13-18H2;1H/q+1;/p-1/t21-,22+,23?; DM32XZT CS C1CC[N+]2(C1)[C@@H]3CC[C@H]2CC(C3)OC(=O)C(C4=CC=CC=C4)(C5=CC=CC=C5)O.[Cl-] DM32XZT IK RVCSYOQWLPPAOA-DHWZJIOFSA-M DM32XZT IU [(1R,5S)-spiro[8-azoniabicyclo[3.2.1]octane-8,1'-azolidin-1-ium]-3-yl] 2-hydroxy-2,2-diphenylacetate;chloride DM32XZT CA CAS 10405-02-4 DM32XZT CB CHEBI:32270 DM32XZT DE Discovery agent DM6AN32 ID DM6AN32 DM6AN32 DN Trovafloxacin DM6AN32 HS Approved DM6AN32 SN TVFX; Trovan; Fluorinated quinolone; Trovafloxacin [INN]; CP 99219; CP99219; CP 99,219; CP-99219;Trovafloxacin (INN); Trovan (TN); Trovan (oral); Turvel (TN); CP-99,219; (1alpha,5alpha,6alpha)-7-(6-Amino-3-azabicyclo[3.1.0]hex-3-yl)-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid; 7-((1R,5S)-6-Amino-3-aza-bicyclo[3.1.0]hex-3-yl)-1-(2,4-difluoro-phenyl)-6-fluoro-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid; 7-[(1R,5S)-6-amino-3-azabicyclo[3.1.0]hexan-3-yl]-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acid; 7-[(1R,5S,6s)-6-amino-3-azabicyclo[3.1.0]hex-3-yl]-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid; 7-[(1r,5s)-6-amino-3-azabicyclo[3.1.0]hex-3-yl]-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid DM6AN32 CP Pfizer Pharmaceuticals DM6AN32 TC Antiinfective Agents DM6AN32 DT Small molecular drug DM6AN32 PC 62959 DM6AN32 MW 416.4 DM6AN32 FM C20H15F3N4O3 DM6AN32 IC InChI=1S/C20H15F3N4O3/c21-8-1-2-15(13(22)3-8)27-7-12(20(29)30)17(28)9-4-14(23)19(25-18(9)27)26-5-10-11(6-26)16(10)24/h1-4,7,10-11,16H,5-6,24H2,(H,29,30)/t10-,11+,16? DM6AN32 CS C1[C@@H]2[C@@H](C2N)CN1C3=C(C=C4C(=O)C(=CN(C4=N3)C5=C(C=C(C=C5)F)F)C(=O)O)F DM6AN32 IK WVPSKSLAZQPAKQ-SOSAQKQKSA-N DM6AN32 IU 7-[(1R,5S)-6-amino-3-azabicyclo[3.1.0]hexan-3-yl]-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acid DM6AN32 CA CAS 147059-72-1 DM6AN32 CB CHEBI:9763 DM6AN32 DE Bacterial infection DMDHCK9 ID DMDHCK9 DMDHCK9 DN Trumenba DMDHCK9 HS Approved DMDHCK9 SN Meningococcal Group B Vaccine DMDHCK9 CP Wyeth; pfizer DMDHCK9 DT Vaccine DMDHCK9 DE Meningitis DM4NTMO ID DM4NTMO DM4NTMO DN TRYPAN BLUE DM4NTMO HS Approved DM4NTMO SN AC1O6WJ7; tetrasodium (3E)-5-amino-3-[[4-[4-[(2Z)-2-(8-amino-1-oxo-3,6-disulfonatonaphthalen-2-ylidene)hydrazinyl]-3-methylphenyl]-2-methylphenyl]hydrazinylidene]-4-oxonaphthalene-2,7-disulfonate; 3,3',3,3'-[(3,3'-Dimethylbiphenyl-4,4'-diyl)bis(iminonitrilo)]bis(3,4-dihydro-4-oxo-5-amino-2,7-naphthalenedisulfonic acid disodium) salt DM4NTMO DT Small molecular drug DM4NTMO PC 6296 DM4NTMO MW 960.8 DM4NTMO FM C34H24N6Na4O14S4 DM4NTMO IC InChI=1S/C34H28N6O14S4.4Na/c1-15-7-17(3-5-25(15)37-39-31-27(57(49,50)51)11-19-9-21(55(43,44)45)13-23(35)29(19)33(31)41)18-4-6-26(16(2)8-18)38-40-32-28(58(52,53)54)12-20-10-22(56(46,47)48)14-24(36)30(20)34(32)42;;;;/h3-14,41-42H,35-36H2,1-2H3,(H,43,44,45)(H,46,47,48)(H,49,50,51)(H,52,53,54);;;;/q;4*+1/p-4 DM4NTMO CS CC1=C(C=CC(=C1)C2=CC(=C(C=C2)N=NC3=C(C4=C(C=C(C=C4C=C3S(=O)(=O)[O-])S(=O)(=O)[O-])N)O)C)N=NC5=C(C6=C(C=C(C=C6C=C5S(=O)(=O)[O-])S(=O)(=O)[O-])N)O.[Na+].[Na+].[Na+].[Na+] DM4NTMO IK GLNADSQYFUSGOU-UHFFFAOYSA-J DM4NTMO IU tetrasodium;5-amino-3-[[4-[4-[(8-amino-1-hydroxy-3,6-disulfonatonaphthalen-2-yl)diazenyl]-3-methylphenyl]-2-methylphenyl]diazenyl]-4-hydroxynaphthalene-2,7-disulfonate DM4NTMO CA CAS 72-57-1 DM4NTMO CB CHEBI:78897 DM4NTMO DE Ophthalmic surgery injury DMBZIVP ID DMBZIVP DMBZIVP DN Tubocurarine DMBZIVP HS Approved DMBZIVP SN Amelizol; Delacurarine; Jexin; Tubadil; Tubaine; Tubarine; Tubocurarin; Tubocurarinum; Chlorure de tubocurarine; Cloruro de tubocurarina; Dextrotubocurarine chloride; Intocostrine T; Isoquinoline alkaloid; Tubocurarina cloruro; Tubocurarina cloruro [DCIT]; Tubocurarine chloride; Tubocurarine hydrochloride; Tubocurarini chloridum; Chlorure de tubocurarine [INN-French]; Cloruro de tubocurarina [INN-Spanish]; Curarin-haf; D-Paracurarine chloride; D-Tubocurarine; D-Tubocurarine chloride; D-Tubocurarine dichloride; D-Tubocurarine hydrochloride; Delacurarine (TN); Jex (TN); Metubine (TN); Tubaine (TN); Tubarine (TN); Tubocurarine chloride (INN); Tubocurarine chloride (TN); Tubocurarine chloride (anhydrous); Tubocurarini chloridum [INN-Latin]; Tubocurarinum (TN); D-(+)-Tubocurarine chloride; Tubocurarine, chloride, hydrochloride, (+)-(8CI); D-7',12'-Dihydroxy-6,6'-dimethoxy-2,2',2'-trimethyltubocuraranium chloride; Tubocuraranium, 7',12'-dihydroxy-6,6'-dimethoxy-2,2',2'-trimethyl-, chloride, hydrochloride; (+)-Tubocurarine; (+)-Tubocurarine chloride; (+)-Tubocurarine chloride hydrochloride; 2,2',2'-trimethyl-6,6'-bis(methyloxy)tubocuraran-2,2'-diium-7',12'-diol dichloride; 7',12'-Dihydroxy-6,6'-dimethoxy-2,2',2'-trimethyltubocuraranium; 7',12'-dihydroxy-6,6'-dimethoxy-2,2',2'-trimethyltubocuraran-2'-ium DMBZIVP TC Neuromuscular Nondepolarizing Agents DMBZIVP DT Small molecular drug DMBZIVP PC 6000 DMBZIVP MW 609.7 DMBZIVP FM C37H41N2O6+ DMBZIVP IC InChI=1S/C37H40N2O6/c1-38-14-12-24-19-32(42-4)33-21-27(24)28(38)16-22-6-9-26(10-7-22)44-37-35-25(20-34(43-5)36(37)41)13-15-39(2,3)29(35)17-23-8-11-30(40)31(18-23)45-33/h6-11,18-21,28-29H,12-17H2,1-5H3,(H-,40,41)/p+1/t28-,29+/m0/s1 DMBZIVP CS CN1CCC2=CC(=C3C=C2[C@@H]1CC4=CC=C(C=C4)OC5=C6[C@@H](CC7=CC(=C(C=C7)O)O3)[N+](CCC6=CC(=C5O)OC)(C)C)OC DMBZIVP IK JFJZZMVDLULRGK-URLMMPGGSA-O DMBZIVP IU (1S,16R)-10,25-dimethoxy-15,15,30-trimethyl-7,23-dioxa-30-aza-15-azoniaheptacyclo[22.6.2.23,6.18,12.118,22.027,31.016,34]hexatriaconta-3(36),4,6(35),8(34),9,11,18(33),19,21,24,26,31-dodecaene-9,21-diol DMBZIVP CA CAS 57-95-4 DMBZIVP CB CHEBI:9774 DMBZIVP DE Anaesthesia; Smoking dependence DMBESUA ID DMBESUA DMBESUA DN Tucatinib DMBESUA HS Approved DMBESUA SN Irbinitinib; 937263-43-9; ONT-380; UNII-234248D0HH; 234248D0HH; N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine; 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-; ONT 380; 4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; Tucatinib [USAN:INN]; 6-DIAMINE DMBESUA CP Seattle Genetics Bothell, WA DMBESUA PC 51039094 DMBESUA MW 480.5 DMBESUA FM C26H24N8O2 DMBESUA IC InChI=1S/C26H24N8O2/c1-16-10-17(5-7-22(16)36-19-8-9-34-23(12-19)28-15-30-34)31-24-20-11-18(4-6-21(20)27-14-29-24)32-25-33-26(2,3)13-35-25/h4-12,14-15H,13H2,1-3H3,(H,32,33)(H,27,29,31) DMBESUA CS CC1=C(C=CC(=C1)NC2=NC=NC3=C2C=C(C=C3)NC4=NC(CO4)(C)C)OC5=CC6=NC=NN6C=C5 DMBESUA IK SDEAXTCZPQIFQM-UHFFFAOYSA-N DMBESUA IU 6-N-(4,4-dimethyl-5H-1,3-oxazol-2-yl)-4-N-[3-methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]quinazoline-4,6-diamine DMBESUA CA CAS 937263-43-9 DMBESUA DE Gastric adenocarcinoma; HER2-positive breast cancer DM749I3 ID DM749I3 DM749I3 DN Ubrogepant DM749I3 HS Approved DM749I3 SN 1374248-77-7; UNII-AD0O8X2QJR; MK-1602; AD0O8X2QJR; Ubrogepant [USAN:INN]; Ubrogepant (USAN/INN); SCHEMBL3698428; CHEMBL2364638; GTPL10176; DTXSID00160178; DDOOFTLHJSMHLN-ZQHRPCGSSA-N; MK1602; ZINC95598454; SB19741; HY-12366; CS-0011109; D10673; (3S)-N-[(3S,5S,6R)-6-methyl-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)piperidin-3-yl]-2-oxospiro[1H-pyrrolo[2,3-b]pyridine-3,6'-5,7-dihydrocyclopenta[b]pyridine]-3'-carboxamide DM749I3 CP Merck DM749I3 DT Small molecular drug DM749I3 PC 68748835 DM749I3 MW 549.5 DM749I3 FM C29H26F3N5O3 DM749I3 IC InChI=1S/C29H26F3N5O3/c1-16-20(17-6-3-2-4-7-17)11-22(26(39)37(16)15-29(30,31)32)35-25(38)19-10-18-12-28(13-23(18)34-14-19)21-8-5-9-33-24(21)36-27(28)40/h2-10,14,16,20,22H,11-13,15H2,1H3,(H,35,38)(H,33,36,40)/t16-,20-,22+,28+/m1/s1 DM749I3 CS C[C@@H]1[C@@H](C[C@@H](C(=O)N1CC(F)(F)F)NC(=O)C2=CC3=C(C[C@@]4(C3)C5=C(NC4=O)N=CC=C5)N=C2)C6=CC=CC=C6 DM749I3 IK DDOOFTLHJSMHLN-ZQHRPCGSSA-N DM749I3 IU (3S)-N-[(3S,5S,6R)-6-methyl-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)piperidin-3-yl]-2-oxospiro[1H-pyrrolo[2,3-b]pyridine-3,6'-5,7-dihydrocyclopenta[b]pyridine]-3'-carboxamide DM749I3 CA CAS 1374248-77-7 DM749I3 DE Migraine DM1IQRP ID DM1IQRP DM1IQRP DN Udenafil DM1IQRP HS Approved DM1IQRP SN Zydena; DA 8159; DA-8159; Zydena (TN); 3-(1-methyl-7-oxo-3-propyl-4H-pyrazolo[4,3-d]pyrimidin-5-yl)-N-[2-(1-methylpyrrolidin-2-yl)ethyl]-4-propoxybenzenesulfonamide; 5-(2-Propyloxy-5-(1-methyl-2-pyrollidinylethylamidosulfonyl)phenyl)-1-methyl-3-propyl-1,6-dihydro-7H-pyrazolo(4,3-d)pyrimidine-7-one DM1IQRP CP Dong-A Pharmaceutical DM1IQRP TC Vasodilator Agents DM1IQRP DT Small molecular drug DM1IQRP PC 135413547 DM1IQRP MW 516.7 DM1IQRP FM C25H36N6O4S DM1IQRP IC InChI=1S/C25H36N6O4S/c1-5-8-20-22-23(31(4)29-20)25(32)28-24(27-22)19-16-18(10-11-21(19)35-15-6-2)36(33,34)26-13-12-17-9-7-14-30(17)3/h10-11,16-17,26H,5-9,12-15H2,1-4H3,(H,27,28,32) DM1IQRP CS CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)NCCC4CCCN4C)OCCC)C DM1IQRP IK IYFNEFQTYQPVOC-UHFFFAOYSA-N DM1IQRP IU 3-(1-methyl-7-oxo-3-propyl-6H-pyrazolo[4,3-d]pyrimidin-5-yl)-N-[2-(1-methylpyrrolidin-2-yl)ethyl]-4-propoxybenzenesulfonamide DM1IQRP CA CAS 268203-93-6 DM1IQRP CB CHEBI:135926 DM1IQRP DE Erectile dysfunction DMX3O0D ID DMX3O0D DMX3O0D DN UFT DMX3O0D HS Approved DMX3O0D SN Futraful; Orzel; UFUR; Tegafur + uracil; UFT + leucovorin; BMS-200604-01; Tegafur + uracil, Taiho/Bristol-Myers Squibb DMX3O0D CP Taiho Pharmaceutical Co Ltd DMX3O0D DT Small molecular drug DMX3O0D PC 104747 DMX3O0D MW 312.25 DMX3O0D FM C12H13FN4O5 DMX3O0D IC InChI=1S/C8H9FN2O3.C4H4N2O2/c9-5-4-11(6-2-1-3-14-6)8(13)10-7(5)12;7-3-1-2-5-4(8)6-3/h4,6H,1-3H2,(H,10,12,13);1-2H,(H2,5,6,7,8) DMX3O0D CS C1CC(OC1)N2C=C(C(=O)NC2=O)F.C1=CNC(=O)NC1=O DMX3O0D IK DHMYGZIEILLVNR-UHFFFAOYSA-N DMX3O0D IU 5-fluoro-1-(oxolan-2-yl)pyrimidine-2,4-dione;1H-pyrimidine-2,4-dione DMX3O0D CA CAS 74578-38-4 DMX3O0D DE Solid tumour/cancer DMBNI20 ID DMBNI20 DMBNI20 DN Ulipristal DMBNI20 HS Approved DMBNI20 SN Ella (TN) DMBNI20 CP HRA Pharma DMBNI20 DT Small molecular drug DMBNI20 PC 13559281 DMBNI20 MW 433.6 DMBNI20 FM C28H35NO3 DMBNI20 IC InChI=1S/C28H35NO3/c1-17(30)28(32)14-13-25-23-11-7-19-15-21(31)10-12-22(19)26(23)24(16-27(25,28)2)18-5-8-20(9-6-18)29(3)4/h5-6,8-9,15,23-25,32H,7,10-14,16H2,1-4H3/t23-,24+,25-,27-,28-/m0/s1 DMBNI20 CS CC(=O)[C@]1(CC[C@@H]2[C@@]1(C[C@@H](C3=C4CCC(=O)C=C4CC[C@@H]23)C5=CC=C(C=C5)N(C)C)C)O DMBNI20 IK HKDLNTKNLJPAIY-WKWWZUSTSA-N DMBNI20 IU (8S,11R,13S,14S,17R)-17-acetyl-11-[4-(dimethylamino)phenyl]-17-hydroxy-13-methyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one DMBNI20 CA CAS 159811-51-5 DMBNI20 DE Contraception DMYRBO1 ID DMYRBO1 DMYRBO1 DN Umbralisib DMYRBO1 HS Approved DMYRBO1 SN RP5264; TGR-1202 DMYRBO1 CP Tg therapeutics DMYRBO1 PC 72950888 DMYRBO1 MW 571.5 DMYRBO1 FM C31H24F3N5O3 DMYRBO1 IC InChI=1S/C31H24F3N5O3/c1-15(2)41-24-9-7-18(12-22(24)34)27-26-30(35)36-14-37-31(26)39(38-27)16(3)29-25(17-5-4-6-19(32)11-17)28(40)21-13-20(33)8-10-23(21)42-29/h4-16H,1-3H3,(H2,35,36,37)/t16-/m0/s1 DMYRBO1 CS C[C@@H](C1=C(C(=O)C2=C(O1)C=CC(=C2)F)C3=CC(=CC=C3)F)N4C5=NC=NC(=C5C(=N4)C6=CC(=C(C=C6)OC(C)C)F)N DMYRBO1 IK IUVCFHHAEHNCFT-INIZCTEOSA-N DMYRBO1 IU 2-[(1S)-1-[4-amino-3-(3-fluoro-4-propan-2-yloxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-6-fluoro-3-(3-fluorophenyl)chromen-4-one DMYRBO1 CA CAS 1532533-67-7 DMYRBO1 DE Chronic lymphocytic leukaemia; Non-hodgkin lymphoma; Diffuse large B-cell lymphoma; Follicular lymphoma; Marginal zone lymphoma DM4E8O9 ID DM4E8O9 DM4E8O9 DN Umeclidinium DM4E8O9 HS Approved DM4E8O9 SN 573719 DM4E8O9 CP GlaxoSmithKline DM4E8O9 DT Small molecular drug DM4E8O9 PC 11519070 DM4E8O9 MW 428.6 DM4E8O9 FM C29H34NO2+ DM4E8O9 IC InChI=1S/C29H34NO2/c31-29(26-12-6-2-7-13-26,27-14-8-3-9-15-27)28-16-19-30(20-17-28,21-18-28)22-23-32-24-25-10-4-1-5-11-25/h1-15,31H,16-24H2/q+1 DM4E8O9 CS C1C[N+]2(CCC1(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)CCOCC5=CC=CC=C5 DM4E8O9 IK FVTWTVQXNAJTQP-UHFFFAOYSA-N DM4E8O9 IU diphenyl-[1-(2-phenylmethoxyethyl)-1-azoniabicyclo[2.2.2]octan-4-yl]methanol DM4E8O9 CA CAS 869185-19-3 DM4E8O9 CB CHEBI:79041 DM4E8O9 DE Chronic obstructive pulmonary disease DMXNR04 ID DMXNR04 DMXNR04 DN Unoprostone DMXNR04 HS Approved DMXNR04 DT Small molecular drug DMXNR04 PC 5311236 DMXNR04 MW 382.5 DMXNR04 FM C22H38O5 DMXNR04 IC InChI=1S/C22H38O5/c1-2-3-4-5-8-11-17(23)14-15-19-18(20(24)16-21(19)25)12-9-6-7-10-13-22(26)27/h6,9,18-21,24-25H,2-5,7-8,10-16H2,1H3,(H,26,27)/b9-6-/t18-,19-,20+,21-/m1/s1 DMXNR04 CS CCCCCCCC(=O)CC[C@H]1[C@@H](C[C@@H]([C@@H]1C/C=C\\CCCC(=O)O)O)O DMXNR04 IK TVHAZVBUYQMHBC-SNHXEXRGSA-N DMXNR04 IU (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-(3-oxodecyl)cyclopentyl]hept-5-enoic acid DMXNR04 CA CAS 120373-36-6 DMXNR04 CB CHEBI:39455 DMXNR04 DE Glaucoma/ocular hypertension DM32B5U ID DM32B5U DM32B5U DN Upadacitinib DM32B5U HS Approved DM32B5U SN ABT-494 DM32B5U CP Abbvie DM32B5U PC 58557659 DM32B5U MW 380.4 DM32B5U FM C17H19F3N6O DM32B5U IC InChI=1S/C17H19F3N6O/c1-2-10-7-25(16(27)24-9-17(18,19)20)8-11(10)13-5-22-14-6-23-15-12(26(13)14)3-4-21-15/h3-6,10-11,21H,2,7-9H2,1H3,(H,24,27)/t10-,11+/m1/s1 DM32B5U CS CC[C@@H]1CN(C[C@@H]1C2=CN=C3N2C4=C(NC=C4)N=C3)C(=O)NCC(F)(F)F DM32B5U IK WYQFJHHDOKWSHR-MNOVXSKESA-N DM32B5U IU (3S,4R)-3-ethyl-4-(1,5,7,10-tetrazatricyclo[7.3.0.02,6]dodeca-2(6),3,7,9,11-pentaen-12-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide DM32B5U CA CAS 1310726-60-3 DM32B5U DE Atopic dermatitis; Psoriatic arthritis; Crohn disease; Ulcerative colitis; Rheumatoid arthritis DM8T2OI ID DM8T2OI DM8T2OI DN Upadacitinib DM8T2OI HS Approved DM8T2OI SN Upadacitinib, ABT-494; J3.590.729G; Rinvoq; SB19218; SCHEMBL9991056; Upadacitinib; Upadacitinib (USAN/INN); Upadacitinib [USAN:INN]; 1-Pyrrolidinecarboxamide, 3-ethyl-4-(3H-imidazo(1,2-a)pyrrolo(2,3-e)pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)-, (3S,4R)-; 1310726-59-0; 1310726-60-3; 4RA0KN46E0; ABT 494; ABT-494; ABT-494 enantiomer; AC-30326; BCP19011; CHEMBL3622821; CS-6150; D10994; EX-A1628; GTPL9246; HY-19569; MFCD30502663; UNII-4RA0KN46E0 DM8T2OI PC 58557659 DM8T2OI MW 380.4 DM8T2OI FM C17H19F3N6O DM8T2OI IC WYQFJHHDOKWSHR-MNOVXSKESA-N DM8T2OI CS CCC1CN(CC1C2=CN=C3N2C4=C(NC=C4)N=C3)C(=O)NCC(F)(F)F DM8T2OI IK 1S/C17H19F3N6O/c1-2-10-7-25(16(27)24-9-17(18,19)20)8-11(10)13-5-22-14-6-23-15-12(26(13)14)3-4-21-15/h3-6,10-11,21H,2,7-9H2,1H3,(H,24,27)/t10-,11+/m1/s1 DM8T2OI IU (3S,4R)-3-ethyl-4-(1,5,7,10-tetrazatricyclo[7.3.0.02,6]dodeca-2(6),3,7,9,11-pentaen-12-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide DM8T2OI CA CAS 1310726-60-3 DM8T2OI DE Rheumatoid arthritis DMHL7OB ID DMHL7OB DMHL7OB DN Uracil mustard DMHL7OB HS Approved DMHL7OB SN Chlorethaminacil; Demethyldopan; Desmethyldopan; Nordopan; Uracillost; Uracilmostaza; Uramustin; Uramustina; Uramustine; Uramustinum; Aminouracil mustard; Uracil lost; Uracil lost [German]; Uracil mustard [USAN]; Uracil nitrogen mustard; ENT 50439; U 8344; CB-4835; SK-19849; U-8344; Uracil mustard (TN); Uracil mustard (USAN); Uramustina [INN-Spanish]; Uramustine (INN); Uramustinum [INN-Latin]; URACIL MUSTARD (500 MG) (FOR U.S. SALE ONLY); 2,6-Dihydroxy-5-bis(2-chloroethyl)aminopyrimidine; 2,6-Dihydroxy-5-bis[2-chloroethyl]aminopyrimidine; 5-(Bis(2-chlorethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4-(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)uracil; 5-(Di-(beta-chloroethyl)amino)uracil; 5-(Di-2-chloroethyl)aminouracil; 5-Aminouracil mustard; 5-N,N-Bis(2-chloroethyl)aminouracil; 5-[Bis(2-chlorethyl)amino]-2,4(1H,3H)pyrimidinedione; 5-[Bis(2-chloroethyl)amino]uracil; 5-[Di(2-chloroethyl)amino]uracil; 5-[Di(beta-chloroethyl)amino]uracil; 5-[Di(beta.-chloroethyl)amino]uracil; 5-[bis(2-chloroethyl)amino]-1H-pyrimidine-2,4-dione; 5-[bis(2-chloroethyl)amino]-2,4(1H,3H)-pyrimidinedione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4(1H,3H)-dione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4-diol DMHL7OB TC Anticancer Agents DMHL7OB DT Small molecular drug DMHL7OB PC 6194 DMHL7OB MW 252.09 DMHL7OB FM C8H11Cl2N3O2 DMHL7OB IC InChI=1S/C8H11Cl2N3O2/c9-1-3-13(4-2-10)6-5-11-8(15)12-7(6)14/h5H,1-4H2,(H2,11,12,14,15) DMHL7OB CS C1=C(C(=O)NC(=O)N1)N(CCCl)CCCl DMHL7OB IK IDPUKCWIGUEADI-UHFFFAOYSA-N DMHL7OB IU 5-[bis(2-chloroethyl)amino]-1H-pyrimidine-2,4-dione DMHL7OB CA CAS 66-75-1 DMHL7OB CB CHEBI:9884 DMHL7OB DE Acute myeloid leukaemia DMD59GI ID DMD59GI DMD59GI DN Urapidil DMD59GI HS Approved DMD59GI SN urapidil; 34661-75-1; Ebrantil; Eupressyl; Mediatensyl; Uraprene; Urapidilum [INN-Latin]; UNII-A78GF17HJS; NSC 310405; B-66256; C20H29N5O3; EINECS 252-130-4; BRN 0725782; A78GF17HJS; MLS003115907; 6-(3-(4-(o-Methoxyphenyl)-1-piperazinyl)propylamino)-1,3-dimethyluracil; 6-[[3-[4-(2-Methoxyphenyl)-1-piperazinyl]propyl]amino]-1,3-dimethyluracil; NCGC00016066-07; Ebrantil (TN); 6-((3-(4-(o-Methoxyphenyl)-1-piperazinyl)propyl)amino)-1,3-dimethyluracil; W-106718; Urapidilum; urapidil(jan); TgAAV-TNFR:Fc DMD59GI DT Small molecular drug DMD59GI PC 5639 DMD59GI MW 387.5 DMD59GI FM C20H29N5O3 DMD59GI IC InChI=1S/C20H29N5O3/c1-22-18(15-19(26)23(2)20(22)27)21-9-6-10-24-11-13-25(14-12-24)16-7-4-5-8-17(16)28-3/h4-5,7-8,15,21H,6,9-14H2,1-3H3 DMD59GI CS CN1C(=CC(=O)N(C1=O)C)NCCCN2CCN(CC2)C3=CC=CC=C3OC DMD59GI IK ICMGLRUYEQNHPF-UHFFFAOYSA-N DMD59GI IU 6-[3-[4-(2-methoxyphenyl)piperazin-1-yl]propylamino]-1,3-dimethylpyrimidine-2,4-dione DMD59GI CA CAS 34661-75-1 DMD59GI CB CHEBI:32278 DMD59GI DE Hypertension; Inflammation DMUK75B ID DMUK75B DMUK75B DN Urea DMUK75B HS Approved DMUK75B SN carbamide; 57-13-6; Isourea; Carbonyldiamide; Ureophil; Carbonyldiamine; Carbamimidic acid; Pseudourea; Ureaphil; Urevert; Carbaderm; Alphadrate; Keratinamin; Calmurid; Aquadrate; Carbonyl diamide; Pastaron; Urepearl; Carbamide resin; Ultra Mide; Varioform ii; Aqua Care; Prespersion, 75 urea; carmol; basodexan; Harnstoff; Nutraplus; Mocovina; Urea solution; Supercel 3000; Aqua Care HP; Ureacin-20; Ureacin-40 Creme; Ureacin-10 lotion; Polyurea; Panafil; Onychomal; Hyanit; Caswell No. 902; Carbonyl Diamine; Mocovina [Czech]; Harnstoff [Ge DMUK75B DT Small molecular drug DMUK75B PC 1176 DMUK75B MW 60.056 DMUK75B FM CH4N2O DMUK75B IC InChI=1S/CH4N2O/c2-1(3)4/h(H4,2,3,4) DMUK75B CS C(=O)(N)N DMUK75B IK XSQUKJJJFZCRTK-UHFFFAOYSA-N DMUK75B IU urea DMUK75B CA CAS 57-13-6 DMUK75B CB CHEBI:16199 DMUK75B DE Dermatological disease DMQTREB ID DMQTREB DMQTREB DN Uridine DMQTREB HS Approved DMQTREB SN uridine; 58-96-8; Uridin; Uracil riboside; beta-Uridine; d-uridine; CHEBI:16704; b-Uridine; UNII-WHI7HQ7H85; Urd; AI3-52690; EINECS 200-407-5; WHI7HQ7H85; MLS000069625; Uracil-1-beta-d-ribofuranoside; C9H12N2O6; DRTQHJPVMGBUCF-XVFCMESISA-N; SMR000058222; 1-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dione; 1-beta-D-ribofuranosylpyrimidine-2,4(1H,3H)-dione DMQTREB DT Small molecular drug DMQTREB PC 6029 DMQTREB MW 244.2 DMQTREB FM C9H12N2O6 DMQTREB IC InChI=1S/C9H12N2O6/c12-3-4-6(14)7(15)8(17-4)11-2-1-5(13)10-9(11)16/h1-2,4,6-8,12,14-15H,3H2,(H,10,13,16)/t4-,6-,7-,8-/m1/s1 DMQTREB CS C1=CN(C(=O)NC1=O)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O DMQTREB IK DRTQHJPVMGBUCF-XVFCMESISA-N DMQTREB IU 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione DMQTREB CA CAS 58-96-8 DMQTREB CB CHEBI:16704 DMQTREB DE Depression DMG9HIA ID DMG9HIA DMG9HIA DN Urofollitropin DMG9HIA HS Approved DMG9HIA SN Bravelle; Fertinex; Metrodin; Urofollitrophin; Fertinorm HP; Bravelle (TN); Fertinex (TN); Follistim (TN); Gonal-F(TN); (4-Threonine)oxytocin; 1,2-Dithia-5,8,11,14,17-penaazacycloeicosane, cyclic peptide deriv.; 4-(L-Threonine)oxytocin DMG9HIA TC Fertility Agents DMG9HIA DT Small molecular drug DMG9HIA SQ Alpha chain: APDVQDCPECTLQENPFFSQPGAPILQCMGCCFSRAYPTPLRSKKTMLVQKNVTSESTCCVAKSYNRVTVMGGFKVENHTACHCSTCYYHKS >Beta chainNSCELTNITIAIEKEECRFCISINTTWCAGYCYTRDLVYKDPARPKIQKTCTFKELVYETVRVPGCAHHADSLYTYPVATQCHCGKCDSDSTDCTVRGLGPSYCSFGEMKE DMG9HIA PC 62819 DMG9HIA MW 980.2 DMG9HIA FM C42H65N11O12S2 DMG9HIA IC InChI=1S/C42H65N11O12S2/c1-6-21(4)33-40(63)52-34(22(5)54)41(64)49-28(16-31(44)56)37(60)50-29(19-67-66-18-25(43)35(58)47-27(38(61)51-33)15-23-9-11-24(55)12-10-23)42(65)53-13-7-8-30(53)39(62)48-26(14-20(2)3)36(59)46-17-32(45)57/h9-12,20-22,25-30,33-34,54-55H,6-8,13-19,43H2,1-5H3,(H2,44,56)(H2,45,57)(H,46,59)(H,47,58)(H,48,62)(H,49,64)(H,50,60)(H,51,61)(H,52,63) DMG9HIA CS CCC(C)C1C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(C(=O)NC(C(=O)N1)CC2=CC=C(C=C2)O)N)C(=O)N3CCCC3C(=O)NC(CC(C)C)C(=O)NCC(=O)N)CC(=O)N)C(C)O DMG9HIA IK ZDRRIRUAESZNIH-UHFFFAOYSA-N DMG9HIA IU 1-[19-amino-7-(2-amino-2-oxoethyl)-13-butan-2-yl-10-(1-hydroxyethyl)-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]-N-[1-[(2-amino-2-oxoethyl)amino]-4-methyl-1-oxopentan-2-yl]pyrrolidine-2-carboxamide DMG9HIA DE Female infertility DM0GOUD ID DM0GOUD DM0GOUD DN Urokinase DM0GOUD HS Approved DM0GOUD TC Thrombolytic Agents DM0GOUD SQ DB00013 sequence: KPSSPPEELKFQCGQKTLRPRFKIIGGEFTTIENQPWFAAIYRRHRGGSVTYVCGGSLMSPCWVISATHCFIDYPKKEDYIVYLGRSRLNSNTQGEMKFEVENLILHKDYSADTLAHHNDIALLKIRSKEGRCAQPSRTIQTICLPSMYNDPQFGTSCEITGFGKENSTDYLYPEQLKMTVVKLISHRECQQPHYYGSEVTTKMLCAADPQWKTDSCQGDSGGPLVCSLQGRMTLTGIVSWGRGCALKDKPGVYTRVSHFLPWIRSHTKEENGLAL DM0GOUD DE Myocardial infarction DMCUT21 ID DMCUT21 DMCUT21 DN Ursodeoxycholic acid DMCUT21 HS Approved DMCUT21 SN Actigall; Antigall; Arsacol; Delursan; Destolit; Deursil; Litursol; Lyeton; Peptarom; Solutrat; UDCA; UDCS; UrSO; Urosiol; Ursacol; Ursobilin; Ursochol; Ursodamor; Ursodeoxycholate; Ursodiol; Ursofalk; Ursolvan; Ursosan; Acide ursodesoxycholique; Acido ursodeossicolico; Acido ursodeossicolico [Italian]; Acido ursodeoxicolico; Acidum ursodeoxycholicum; Deoxyursocholic Acid; Sodium Ursodeoxycholate; Ursacholic Acid; Urso DS; Urso Forte; Ursodeoxy cholic acid; Ursodesoxycholicacid; Ursodexycholic Acid; Ursodiol [USAN]; IU5; U0030; Urso 250; Acide ursodesoxycholique [INN-French]; Acido ursodeoxicolico [INN-Spanish]; Acidum ursodeoxycholicum [INN-Latin]; Actigall (TN); Cholit-ursan; Deursil (TN); Dom-ursodiol c; ISO-URSODEOXYCHOLIC ACID; PHL-ursodiol c; PMS-ursodiol c; U-9000; Urso (TN); Urso Forte (TN); Ursodiol (USP); Ursosan (TN); Ursodeoxycholic acid (JP15/INN); Ursodeoxycholic acid, UDCA, Ursosan, Ursofalk, Urso Forte, Udiliv, Ursodiol; Cholan-24-oic acid, 3,7-dihydroxy-, (3-alpha,5-beta,7-beta)-(9CI); (3alpha,5beta,7beta)-3,7-dihydroxycholan-24-oic acid; (3alpha,5beta,7beta,8xi)-3,7-dihydroxycholan-24-oic acid; (4R)-4-[(3R,5S,7S,8R,9S,10S,13R,14S,17R)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid; 17-beta-(1-Methyl-3-carboxypropyl)etiocholane-3-alpha,7-beta-diol; 3 alpha,7 beta-Dihydroxy-5 beta-cholan-24-oic Acid; 3,7-Dihydroxycholan-24-oic acid; 3-alpha,7-beta-Dihydroxy-5-beta-cholanoic acid; 3-alpha,7-beta-Dihydroxycholanic acid; 3-alpha,7-beta-Dioxycholanic acid; 3alpha,7beta-Dihydroxy-5beta-cholan-24-oic acid; 3alpha,7beta-Dihydroxy-5beta-cholanic acid; 5beta-Cholan-24-oic acid-3alpha,7beta-diol; 5beta-Cholanic Acid-3alpha,7beta-diol; 7-beta-Hydroxylithocholic acid; 7beta-Hydroxylithocholic acid DMCUT21 CP Axcan Pharma DMCUT21 TC Cholagogues and Choleretics DMCUT21 DT Small molecular drug DMCUT21 PC 31401 DMCUT21 MW 392.6 DMCUT21 FM C24H40O4 DMCUT21 IC InChI=1S/C24H40O4/c1-14(4-7-21(27)28)17-5-6-18-22-19(9-11-24(17,18)3)23(2)10-8-16(25)12-15(23)13-20(22)26/h14-20,22,25-26H,4-13H2,1-3H3,(H,27,28)/t14-,15+,16-,17-,18+,19+,20+,22+,23+,24-/m1/s1 DMCUT21 CS C[C@H](CCC(=O)O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2[C@H](C[C@H]4[C@@]3(CC[C@H](C4)O)C)O)C DMCUT21 IK RUDATBOHQWOJDD-UZVSRGJWSA-N DMCUT21 IU (4R)-4-[(3R,5S,7S,8R,9S,10S,13R,14S,17R)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid DMCUT21 CA CAS 128-13-2 DMCUT21 CB CHEBI:9907 DMCUT21 DE Primary biliary cirrhosis DMHTYK3 ID DMHTYK3 DMHTYK3 DN Ustekinumab DMHTYK3 HS Approved DMHTYK3 SN 6,6-Dimethyl-1-[3-(2,4,5-trichlorophenoxy)propoxy]-1,6-dihydro-1,3,5-triazine-2,4-diamine; WR99210; WR-99210; 6,6-DIMETHYL-1-[3-(2,4,5-TRICHLOROPHENOXY)PROPOXY]-1,6-DIHYDRO-1,3,5-TRIAZINE-2,4-DIAMINE; 47326-86-3; BRN 0629517; WR 99210; 1,3,5-Triazine-2,4-diamine, 1,6-dihydro-6,6-dimethyl-1-[3-(2,4,5-trichlorophenoxy)propoxy]-; WR-99,210; CHEMBL129788; BRL 6231; 1,6-Dihydro-6,6-dimethyl-1-(3-(2,4,5-trichlorophenoxy)-propoxy)-1,3,5-triazine-2 ,4-diamine; 1-(2',4',5'-Trichlorophenoxypropoxy)-1,2-dihydro-2,2-dimethyl-4,6-diamino-s-triazine; Stelara (TN) DMHTYK3 CP Centocor Ortho Biotech DMHTYK3 DT Antibody DMHTYK3 DE Plaque psoriasis; Malaria; Inflammatory bowel disease; Psoriasis vulgaris DMA630M ID DMA630M DMA630M DN Vaccinia immune globulin DMA630M HS Approved DMA630M CP DynPort Vaccine Company LLC DMA630M DE Vaccination DMHKS94 ID DMHKS94 DMHKS94 DN Valaciclovir DMHKS94 HS Approved DMHKS94 SN Talavir; VACV; ValACV; Valacyclovir; Virval; Zelitrex; Valaciclovir Hcl; Valacyclover Hydrochloric; Valacyclover Hydrochloride; BW256U87; TBB067866; Acyclovir-valine; BW-256U; Valaciclovir (INN); Valaciclovir [INN:BAN]; Valaciclovir, Valtrex; Valtrex (TN); Zelitrex (TN); Valacyclovir, (L)-isomer; L-Valine ester with 9-((2-hydroxyethoxy)methyl)guanine; L-Valine, 2-((2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methoxy)ethyl ester; L-valine, 2-[(2-amino-1,6-dihydro-6-oxo-9 H-purin-9-yl)methoxy]ethyl ester, monohydrochloride; 2-[(2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl)methoxy]ethyl L-valinate; 2-[(2-amino-6-oxo-3H-purin-9-yl)methoxy]ethyl (2S)-2-amino-3-methylbutanoate; 2-{[(2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl)methyl]oxy}ethyl L-valinate DMHKS94 CP GlaxoSmithKline DMHKS94 TC Antiviral Agents DMHKS94 DT Small molecular drug DMHKS94 PC 135398742 DMHKS94 MW 324.34 DMHKS94 FM C13H20N6O4 DMHKS94 IC InChI=1S/C13H20N6O4/c1-7(2)8(14)12(21)23-4-3-22-6-19-5-16-9-10(19)17-13(15)18-11(9)20/h5,7-8H,3-4,6,14H2,1-2H3,(H3,15,17,18,20)/t8-/m0/s1 DMHKS94 CS CC(C)[C@@H](C(=O)OCCOCN1C=NC2=C1N=C(NC2=O)N)N DMHKS94 IK HDOVUKNUBWVHOX-QMMMGPOBSA-N DMHKS94 IU 2-[(2-amino-6-oxo-1H-purin-9-yl)methoxy]ethyl (2S)-2-amino-3-methylbutanoate DMHKS94 CA CAS 124832-26-4 DMHKS94 CB CHEBI:35854 DMHKS94 DE Virus infection DM5I1CE ID DM5I1CE DM5I1CE DN Valacyclovir Hydrochloride DM5I1CE HS Approved DM5I1CE CP Glaxosmithkline DM5I1CE TC Antiinfective Agents DM5I1CE DT Small molecular drug DM5I1CE PC 135398741 DM5I1CE MW 360.8 DM5I1CE FM C13H21ClN6O4 DM5I1CE IC InChI=1S/C13H20N6O4.ClH/c1-7(2)8(14)12(21)23-4-3-22-6-19-5-16-9-10(19)17-13(15)18-11(9)20;/h5,7-8H,3-4,6,14H2,1-2H3,(H3,15,17,18,20);1H/t8-;/m0./s1 DM5I1CE CS CC(C)[C@@H](C(=O)OCCOCN1C=NC2=C1N=C(NC2=O)N)N.Cl DM5I1CE IK ZCDDBUOENGJMLV-QRPNPIFTSA-N DM5I1CE IU 2-[(2-amino-6-oxo-1H-purin-9-yl)methoxy]ethyl (2S)-2-amino-3-methylbutanoate;hydrochloride DM5I1CE CA CAS 124832-27-5 DM5I1CE CB CHEBI:9919 DM5I1CE DE Herpes simplex virus infection DMQSA2V ID DMQSA2V DMQSA2V DN Valbenazine tosylate DMQSA2V HS Approved DMQSA2V SN Valbenazine ditosylate; UNII-5SML1T733B; 5SML1T733B; Valbenazine tosylate [USAN]; Valbenazine tosylate (USAN); 1639208-54-0; NBI-98854 ditosylate DMQSA2V CP Neurocrine Biosciences DMQSA2V DT Small molecular drug DMQSA2V PC 92042922 DMQSA2V MW 763 DMQSA2V FM C38H54N2O10S2 DMQSA2V IC InChI=1S/C24H38N2O4.2C7H8O3S/c1-14(2)9-17-13-26-8-7-16-10-21(28-5)22(29-6)11-18(16)19(26)12-20(17)30-24(27)23(25)15(3)4;2*1-6-2-4-7(5-3-6)11(8,9)10/h10-11,14-15,17,19-20,23H,7-9,12-13,25H2,1-6H3;2*2-5H,1H3,(H,8,9,10)/t17-,19-,20-,23+;;/m1../s1 DMQSA2V CS CC1=CC=C(C=C1)S(=O)(=O)O.CC1=CC=C(C=C1)S(=O)(=O)O.CC(C)C[C@@H]1CN2CCC3=CC(=C(C=C3[C@H]2C[C@H]1OC(=O)[C@H](C(C)C)N)OC)OC DMQSA2V IK BXGKAGLZHGYAMW-TZYFFPFWSA-N DMQSA2V IU [(2R,3R,11bR)-9,10-dimethoxy-3-(2-methylpropyl)-2,3,4,6,7,11b-hexahydro-1H-benzo[a]quinolizin-2-yl] (2S)-2-amino-3-methylbutanoate;4-methylbenzenesulfonic acid DMQSA2V CA CAS 1639208-54-0 DMQSA2V DE Tardive dyskinesia DMAY7H4 ID DMAY7H4 DMAY7H4 DN Valdecoxib DMAY7H4 HS Approved DMAY7H4 SN Bextra; COX; Kudeq; Valdyn; Pfizer brand of valdecoxib; Valdecoxib [USAN]; SC 65872; ND-0214; SC-65872; YM-974; Valdecoxib (USAN/INN); P-(5-Methyl-3-phenyl-4-isoxazolyl)benzenesulfonamide; Benzenesulfonamide, 4-(5-methyl-3-phenyl-4-isoxazolyl)-(9CI); 4-(5-Methyl-3-phenyl-4-isoxazolyl)benzenesulfonamide; 4-(5-methyl-3-phenyl-1,2-oxazol-4-yl)benzenesulfonamide; 4-(5-methyl-3-phenyl-4-isoxazolyl) benzenesulfonamide; 4-(5-methyl-3-phenyl-isoxazol-4-yl)benzenesulfonamide; 4-(5-methyl-3-phenylisoxazol-4-yl)benzenesulfonamide; 4-(Methyl-3-phenyl-isoxazol-4-yl)-benzenesulfonamide DMAY7H4 TC Antiinflammatory Agents DMAY7H4 DT Small molecular drug DMAY7H4 PC 119607 DMAY7H4 MW 314.4 DMAY7H4 FM C16H14N2O3S DMAY7H4 IC InChI=1S/C16H14N2O3S/c1-11-15(12-7-9-14(10-8-12)22(17,19)20)16(18-21-11)13-5-3-2-4-6-13/h2-10H,1H3,(H2,17,19,20) DMAY7H4 CS CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N DMAY7H4 IK LNPDTQAFDNKSHK-UHFFFAOYSA-N DMAY7H4 IU 4-(5-methyl-3-phenyl-1,2-oxazol-4-yl)benzenesulfonamide DMAY7H4 CA CAS 181695-72-7 DMAY7H4 CB CHEBI:63634 DMAY7H4 DE Osteoarthritis DMS2IUH ID DMS2IUH DMS2IUH DN Valganciclovir DMS2IUH HS Approved DMS2IUH SN Cymeval; RS 79070; RO1079070/194; Valcyte (TN); Valganciclovir (INN); Valganciclovir (Oral); Valganciclovir [INN:BAN]; L-Valine, ester with ganciclovir; [2-[(2-amino-6-oxo-3H-purin-9-yl)methoxy]-3-hydroxypropyl] (2S)-2-amino-3-methylbutanoate; L-Valine, 2-((2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methoxy)-3-hydroxypropyl ester; 5-Amino-3-[1-(hydroxymethyl)-2-(L-valyloxy)ethoxymethyl]-6,7-dihydro-3H-imidazo[4,5-d]pyrimidin-7-one DMS2IUH CP Roche Laboratories Inc DMS2IUH TC Antiviral Agents DMS2IUH DT Small molecular drug DMS2IUH PC 135413535 DMS2IUH MW 354.36 DMS2IUH FM C14H22N6O5 DMS2IUH IC InChI=1S/C14H22N6O5/c1-7(2)9(15)13(23)24-4-8(3-21)25-6-20-5-17-10-11(20)18-14(16)19-12(10)22/h5,7-9,21H,3-4,6,15H2,1-2H3,(H3,16,18,19,22)/t8?,9-/m0/s1 DMS2IUH CS CC(C)[C@@H](C(=O)OCC(CO)OCN1C=NC2=C1N=C(NC2=O)N)N DMS2IUH IK WPVFJKSGQUFQAP-GKAPJAKFSA-N DMS2IUH IU [2-[(2-amino-6-oxo-1H-purin-9-yl)methoxy]-3-hydroxypropyl] (2S)-2-amino-3-methylbutanoate DMS2IUH CA CAS 175865-60-8 DMS2IUH CB CHEBI:63635 DMS2IUH DE Virus infection DMCFE9I ID DMCFE9I DMCFE9I DN Valproate DMCFE9I HS Approved DMCFE9I SN 99-66-1; Dipropylacetic acid; Depakine; Depakene; 2-Propylvaleric acid; Ergenyl; Di-n-propylacetic acid; Mylproin; Pentanoic acid, 2-propyl-; 4-Heptanecarboxylic acid; Propylvaleric acid; n-Dipropylacetic acid; Myproic Acid; Di-n-propylessigsaure; n-DPA; Dipropylacetate; Convulex; Depakin; Vupral; Acido valproico; Acide valproique; Acidum valproicum; Stavzor; Avugane; Baceca; Kyselina 2-propylvalerova; 2-n-Propyl-n-valeric acid; Acetic acid, dipropyl-; Abbott 44090; Valproinsaeure; Savicol; Convulsofin; Deproic; VPA; Depakin chrono; Dipropyl Acetate; Med Valproic; Valproic acid USP; Valproic acid USP24; Acide valproique [INN-French]; Acido valproico [INN-Spanish]; Acidum valproicum [INN-Latin]; Alti-Valproic; Depakote (TM); Dom-Valproic; G2M-777; Kyselina 2-propylvalerova [Czech]; N-DPA; N-Dipropylacetic acid; Novo-Valproic; Nu-Valproic; PMS-Valproic Acid; Penta-Valproic; Valproic acid (USP); Di-n-propylessigsaeure; Di-n-propylessigsaure [German]; Valproic acid [USAN:INN:BAN]; Valproic Acid, SodiumSalt (2:1); 2 PP (base) DMCFE9I CP Abbot Phamaceuticals DMCFE9I TC Neurology Agents DMCFE9I DT Small molecular drug DMCFE9I PC 3121 DMCFE9I MW 144.21 DMCFE9I FM C8H16O2 DMCFE9I IC InChI=1S/C8H16O2/c1-3-5-7(6-4-2)8(9)10/h7H,3-6H2,1-2H3,(H,9,10) DMCFE9I CS CCCC(CCC)C(=O)O DMCFE9I IK NIJJYAXOARWZEE-UHFFFAOYSA-N DMCFE9I IU 2-propylpentanoic acid DMCFE9I CA CAS 99-66-1 DMCFE9I CB CHEBI:39867 DMCFE9I DE Epilepsy; Alcohol dependence DMOYJFK ID DMOYJFK DMOYJFK DN Valrubicin DMOYJFK HS Approved DMOYJFK SN Valstar; Valrubicin [USAN]; Valstar Preservative Free; AD 32; Antibiotic AD 32; Valstar (TN); N-Trifluoroacetyladriamycin 14-valerate; N-Trifluoroacetyldoxorubicin 14-valerate; Trifluoroacetyladriamycin-14-valerate; Valrubicin (USP/INN); N-Trifluoroacetyladriamycin-14-valerate; Adriamycin, trifluoroacetyl-, 14-valerate; [2-oxo-2-[(2S,4S)-2,5,12-trihydroxy-4-[5-hydroxy-6-methyl-4-[(2,2,2-trifluoroacetyl)amino]oxan-2-yl]oxy-7-methoxy-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]ethyl] pentanoate; (2S-cis)-2-(1,2,3,4,6,11-Hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-((2,3,6-trideoxy-3-((trifluoroacetyl)amino)-alpha-L-lyxo-hexopyranosyl)oxy)-2-naphthacenyl)-2-oxoethyl pentanoate; (2S-cis)-Pentanoic acid, 2-(1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-((2,3,6-trideoxy-3-((trifluoroacetyl)amino)-alpha-L-lyxo-hexopyranosyl)oxy)-2-naphth acenyl)-2-oxoethyl ester; (8S,10S)-8-Glycoloyl-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-10-((2,3,6-trideoxy-3-(2,2,2-trifluoroacetamido)-alpha-L-lyxo-hexopyranosyl)oxy)-5,12-naphthacenedione 8(sup 2)-valerate; Pentanoic acid, 2-((2S,4S)-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-((2,3,6-trideoxy-3-((trifluoroacetylamino)-, alpha-L-lysohexopyranoxyl)oxy)-2-naphthacenyl)-2-oxoethyl ester DMOYJFK TC Anticancer Agents DMOYJFK DT Small molecular drug DMOYJFK PC 454216 DMOYJFK MW 723.6 DMOYJFK FM C34H36F3NO13 DMOYJFK IC InChI=1S/C34H36F3NO13/c1-4-5-9-21(40)49-13-20(39)33(47)11-16-24(19(12-33)51-22-10-17(27(41)14(2)50-22)38-32(46)34(35,36)37)31(45)26-25(29(16)43)28(42)15-7-6-8-18(48-3)23(15)30(26)44/h6-8,14,17,19,22,27,41,43,45,47H,4-5,9-13H2,1-3H3,(H,38,46)/t14-,17-,19-,22-,27+,33-/m0/s1 DMOYJFK CS CCCCC(=O)OCC(=O)[C@]1(C[C@@H](C2=C(C1)C(=C3C(=C2O)C(=O)C4=C(C3=O)C=CC=C4OC)O)O[C@H]5C[C@@H]([C@@H]([C@@H](O5)C)O)NC(=O)C(F)(F)F)O DMOYJFK IK ZOCKGBMQLCSHFP-KQRAQHLDSA-N DMOYJFK IU [2-oxo-2-[(2S,4S)-2,5,12-trihydroxy-4-[(2R,4S,5S,6S)-5-hydroxy-6-methyl-4-[(2,2,2-trifluoroacetyl)amino]oxan-2-yl]oxy-7-methoxy-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]ethyl] pentanoate DMOYJFK CA CAS 56124-62-0 DMOYJFK CB CHEBI:135876 DMOYJFK DE Bladder cancer; Psoriasis vulgaris DMREUQ6 ID DMREUQ6 DMREUQ6 DN Valsartan DMREUQ6 HS Approved DMREUQ6 SN valsartan; 137862-53-4; Diovan; Tareg; Provas; L-Valsartan; CGP 48933; Exforge; CGP-48933; (S)-2-(N-((2'-(1H-Tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)pentanamido)-3-methylbutanoic acid; UNII-80M03YXJ7I; N-(p-(o-1H-Tetrazol-5-ylphenyl)benzyl)-N-valeryl-L-valine; CHEMBL1069; 80M03YXJ7I; CHEBI:9927; C24H29N5O3; (2S)-3-methyl-2-[pentanoyl-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]amino]butanoic acid; N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-L-valine; 137863-60-6; AK-58790; Kalpress; Miten; Nisis; Diovan; Vals; Valsarran; Walsartan; Aventis brand of valsartan; CEPA brand of valsartan; Esteve brand of valsartan; Lacer brand of valsartan; Novartis brand of valsartan; Sanol brand of valsartan; Schwarz brand of valsartan; Diovan (TN); Diovan, Valsartan; Valsartan [USAN:INN]; Valtan (TN); Valzaar (TN); Valsartan (JAN/USAN/INN); N-valeryl-N-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)valine; N-pentanoyl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-L-valine; N-pentanoyl-N-{[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl}-L-valine; L-Valine, N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-(9CI); (S)-N-valeryl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]-methyl}-valine; (s)-2-(n-((2'-(1h-tetrazol-5-yl)biphenyl-4-yl)methyl)pentanamido)-3-methylbutanoic acid; [3H]valsartan DMREUQ6 CP Norvatis Phamaceuticals Corporation DMREUQ6 TC Antihypertensive Agents DMREUQ6 DT Small molecular drug DMREUQ6 PC 60846 DMREUQ6 MW 435.5 DMREUQ6 FM C24H29N5O3 DMREUQ6 IC InChI=1S/C24H29N5O3/c1-4-5-10-21(30)29(22(16(2)3)24(31)32)15-17-11-13-18(14-12-17)19-8-6-7-9-20(19)23-25-27-28-26-23/h6-9,11-14,16,22H,4-5,10,15H2,1-3H3,(H,31,32)(H,25,26,27,28)/t22-/m0/s1 DMREUQ6 CS CCCCC(=O)N(CC1=CC=C(C=C1)C2=CC=CC=C2C3=NNN=N3)[C@@H](C(C)C)C(=O)O DMREUQ6 IK ACWBQPMHZXGDFX-QFIPXVFZSA-N DMREUQ6 IU (2S)-3-methyl-2-[pentanoyl-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]amino]butanoic acid DMREUQ6 CA CAS 137862-53-4 DMREUQ6 CB CHEBI:9927 DMREUQ6 DE Hypertension DMK7T1Q ID DMK7T1Q DMK7T1Q DN Vancomycin DMK7T1Q HS Approved DMK7T1Q SN Vancocin; Vancoled; Vancomicina; Vancomicina [INN-Spanish]; Vancomycin (USP); Vancomycin [USAN:INN:BAN]; Vancomycin [USP:INN:BAN]; Vancomycine; Vancomycine [INN-French]; Vancomycinum; Vancomycinum [INN-Latin]; Viomycin derivative; VANCOMYCIN; VANCOR; vancomicin; vanomycin; 1404-90-6; 6Q205EH1VU; C66H75Cl2N9O24; CHEBI:28001; CHEMBL262777; EINECS 215-772-6; HSDB 3262; UNII-6Q205EH1VU; Vancomycin hydrochloride from Streptomyces orientalis DMK7T1Q PC 14969 DMK7T1Q MW 1449.2 DMK7T1Q FM C66H75Cl2N9O24 DMK7T1Q IC MYPYJXKWCTUITO-LYRMYLQWSA-N DMK7T1Q CS CC1C(C(CC(O1)OC2C(C(C(OC2OC3=C4C=C5C=C3OC6=C(C=C(C=C6)C(C(C(=O)NC(C(=O)NC5C(=O)NC7C8=CC(=C(C=C8)O)C9=C(C=C(C=C9O)O)C(NC(=O)C(C(C1=CC(=C(O4)C=C1)Cl)O)NC7=O)C(=O)O)CC(=O)N)NC(=O)C(CC(C)C)NC)O)Cl)CO)O)O)(C)N)O DMK7T1Q IK 1S/C66H75Cl2N9O24/c1-23(2)12-34(71-5)58(88)76-49-51(83)26-7-10-38(32(67)14-26)97-40-16-28-17-41(55(40)101-65-56(54(86)53(85)42(22-78)99-65)100-44-21-66(4,70)57(87)24(3)96-44)98-39-11-8-27(15-33(39)68)52(84)50-63(93)75-48(64(94)95)31-18-29(79)19-37(81)45(31)30-13-25(6-9-36(30)80)46(60(90)77-50)74-61(91)47(28)73-59(89)35(20-43(69)82)72-62(49)92/h6-11,13-19,23-24,34-35,42,44,46-54,56-57,65,71,78-81,83-87H,12,20-22,70H2,1-5H3,(H2,69,82)(H,72,92)(H,73,89)(H,74,91)(H,75,93)(H,76,88)(H,77,90)(H,94,95)/t24-,34+,35-,42+,44-,46+,47+,48-,49+,50-,51+,52+,53+,54-,56+,57+,65-,66-/m0/s1 DMK7T1Q IU (1S,2R,18R,19R,22S,25R,28R,40S)-48-[(2S,3R,4S,5S,6R)-3-[(2S,4S,5S,6S)-4-amino-5-hydroxy-4,6-dimethyloxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-22-(2-amino-2-oxoethyl)-5,15-dichloro-2,18,32,35,37-pentahydroxy-19-[[(2R)-4-methyl-2-(methylamino)pentanoyl]amino]-20,23,26,42,44-pentaoxo-7,13-dioxa-21,24,27,41,43-pentazaoctacyclo[26.14.2.23,6.214,17.18,12.129,33.010,25.034,39]pentaconta-3,5,8(48),9,11,14,16,29(45),30,32,34(39),35,37,46,49-pentadecaene-40-carboxylic acid DMK7T1Q CA CAS 1404-90-6 DMK7T1Q CB CHEBI:28001 DMK7T1Q DE Methicillin-resistant staphylococcus infection DMRICNP ID DMRICNP DMRICNP DN Vandetanib DMRICNP HS Approved DMRICNP SN Zactima; Vandetanib [INN]; CH 331; ZD 6474; ZD6474; AZD-6474; CH-331; F9995-0087; ZD-6474; Zactima, ZD6474; Vandetanib (JAN/INN); Vandetanib, Zactima, ZD6474; N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazolin-4-amine; N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methyl-4-piperidinyl)methoxy)-4-quinazolinamine; N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine; 4-(4-Bromo-2-fluoroanilino)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazoline; Vandetanib (Pan-TK inhibitor) DMRICNP CP AstraZeneca DMRICNP TC Anticancer Agents DMRICNP DT Small molecular drug DMRICNP PC 3081361 DMRICNP MW 475.4 DMRICNP FM C22H24BrFN4O2 DMRICNP IC InChI=1S/C22H24BrFN4O2/c1-28-7-5-14(6-8-28)12-30-21-11-19-16(10-20(21)29-2)22(26-13-25-19)27-18-4-3-15(23)9-17(18)24/h3-4,9-11,13-14H,5-8,12H2,1-2H3,(H,25,26,27) DMRICNP CS CN1CCC(CC1)COC2=C(C=C3C(=C2)N=CN=C3NC4=C(C=C(C=C4)Br)F)OC DMRICNP IK UHTHHESEBZOYNR-UHFFFAOYSA-N DMRICNP IU N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazolin-4-amine DMRICNP CA CAS 443913-73-3 DMRICNP CB CHEBI:49960 DMRICNP DE Solid tumour/cancer DMTBGW8 ID DMTBGW8 DMTBGW8 DN Vardenafil DMTBGW8 HS Approved DMTBGW8 SN VDN; Levitra (TN); VARDENAFIL, LEVITRA; Vardenafil (INN); 1-((3-(3,4-Dihydro-5-methyl-4-oxo-7-propylimidazo(5,1-f)-as-triazin-2-yl)-4-ethoxyphenyl)sulfonyl)-4-ethylpiperazine; 2-(2-Ethoxy-5-(4-ethylpiperazin-1-yl-1-sulfonyl)phenyl)-5-methyl-7-propyl-3H-imidazo(5,1-f)(1,2,4)triazin-4-one; 2-[2-ethoxy-5-(4-ethylpiperazin-1-yl)sulfonylphenyl]-5-methyl-7-propyl-1H-imidazo[5,1-f][1,2,4]triazin-4-one; 2-{2-ETHOXY-5-[(4-ETHYLPIPERAZIN-1-YL)SULFONYL]PHENYL}-5-METHYL-7-PROPYLIMIDAZO[5,1-F][1,2,4]TRIAZIN-4(1H)-ONE; 2-{2-ethoxy-5-[(4-ethylpiperazin-1-yl)sulfonyl]phenyl}-5-methyl-7-propylimidazo[5,1-f][1,2,4]triazin-4-ol DMTBGW8 CP Bayer Pharmaceuticals Corporation DMTBGW8 TC Antiimpotence Agents DMTBGW8 DT Small molecular drug DMTBGW8 PC 135400189 DMTBGW8 MW 488.6 DMTBGW8 FM C23H32N6O4S DMTBGW8 IC InChI=1S/C23H32N6O4S/c1-5-8-20-24-16(4)21-23(30)25-22(26-29(20)21)18-15-17(9-10-19(18)33-7-3)34(31,32)28-13-11-27(6-2)12-14-28/h9-10,15H,5-8,11-14H2,1-4H3,(H,25,26,30) DMTBGW8 CS CCCC1=NC(=C2N1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)CC)OCC)C DMTBGW8 IK SECKRCOLJRRGGV-UHFFFAOYSA-N DMTBGW8 IU 2-[2-ethoxy-5-(4-ethylpiperazin-1-yl)sulfonylphenyl]-5-methyl-7-propyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one DMTBGW8 CA CAS 224785-90-4 DMTBGW8 CB CHEBI:46295 DMTBGW8 DE Erectile dysfunction DMMUOLJ ID DMMUOLJ DMMUOLJ DN Varenicline DMMUOLJ HS Approved DMMUOLJ SN CP 526555; Champix (TN); Chantix (TN); Varenicline (INN); 7,8,9,10-Tetrahydro-6,10-methano-6H-pyrazino(2,3-h)(3)benzazepine; 7,8,9,10-tetrahydro-6h-6,10-methanoazepino[4,5-g]quinoxaline DMMUOLJ CP Pfizer Pharmaceuticals DMMUOLJ DT Small molecular drug DMMUOLJ PC 170361 DMMUOLJ MW 211.26 DMMUOLJ FM C13H13N3 DMMUOLJ IC InChI=1S/C13H13N3/c1-2-16-13-5-11-9-3-8(6-14-7-9)10(11)4-12(13)15-1/h1-2,4-5,8-9,14H,3,6-7H2 DMMUOLJ CS C1C2CNCC1C3=CC4=NC=CN=C4C=C23 DMMUOLJ IK JQSHBVHOMNKWFT-UHFFFAOYSA-N DMMUOLJ IU 5,8,14-triazatetracyclo[10.3.1.02,11.04,9]hexadeca-2,4,6,8,10-pentaene DMMUOLJ CA CAS 249296-44-4 DMMUOLJ DE Smoking dependence DMQ2FPC ID DMQ2FPC DMQ2FPC DN Vasopressin DMQ2FPC HS Approved DMQ2FPC SN Leiormone; Pitressin; Pituitrin; Tonephin; Vasopressina; Vasopressine; Vasopressins; Vasopressinum; American Pharmaceutical Brand of Vasopressin; American Regent Brand of Vasopressin; Antidiuretic Hormones; Antidiuretic hormone; Beta Hypophamine; Inyectable de vasopresina; Monarch Brand of Vasopressin; Solute injectable de vasopressine; Vasopressin Monarch Brand; Vasopressin injection; Vasopressina [DCIT]; Vasopressini injectio; ADH (hormone); Beta-Hypophamine; Inyectable de vasopresina [INN-Spanish]; Pitressin (TN); Solute injectable de vasopressine [INN-French]; Vasopressin (USP); Vasopressini injectio [INN-Latin]; Parke-Davis Brand of Vasopressin (USP); Vasopressin (JP15/USP) DMQ2FPC CP Astellas Pharma DMQ2FPC TC Vasoconstrictor Agents DMQ2FPC DT Small molecular drug DMQ2FPC PC 644077 DMQ2FPC MW 1084.2 DMQ2FPC FM C46H65N15O12S2 DMQ2FPC IC InChI=1S/C46H65N15O12S2/c47-27-22-74-75-23-33(45(73)61-17-5-9-34(61)44(72)56-28(8-4-16-53-46(51)52)39(67)54-21-37(50)65)60-43(71)32(20-36(49)64)59-40(68)29(14-15-35(48)63)55-41(69)31(18-24-6-2-1-3-7-24)58-42(70)30(57-38(27)66)19-25-10-12-26(62)13-11-25/h1-3,6-7,10-13,27-34,62H,4-5,8-9,14-23,47H2,(H2,48,63)(H2,49,64)(H2,50,65)(H,54,67)(H,55,69)(H,56,72)(H,57,66)(H,58,70)(H,59,68)(H,60,71)(H4,51,52,53)/t27-,28-,29-,30-,31-,32-,33-,34-/m0/s1 DMQ2FPC CS C1C[C@H](N(C1)C(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N DMQ2FPC IK KBZOIRJILGZLEJ-LGYYRGKSSA-N DMQ2FPC IU (2S)-1-[(4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]-N-[(2S)-1-[(2-amino-2-oxoethyl)amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]pyrrolidine-2-carboxamide DMQ2FPC CA CAS 113-79-1 DMQ2FPC CB CHEBI:34543 DMQ2FPC DE Diabetes insipidus; Polyuria; Enuresis DMP0UK2 ID DMP0UK2 DMP0UK2 DN Vecuronium DMP0UK2 HS Approved DMP0UK2 SN Norcuron (TN); (2A,3A,5A,16A,17A)-3,17-diacetoxy-16-(1-methylpiperidinium-1-yl)-2-(piperidin-1-yl)androstane; (2beta,3alpha,5alpha,16beta,17beta)-3,17-diacetoxy-16-(1-methylpiperidinium-1-yl)-2-(piperidin-1-yl)androstane; [(2S,3S,5S,8R,9S,10S,13S,14S,16S,17R)-17-acetyloxy-10,13-dimethyl-16-(1-methylpiperidin-1-ium-1-yl)-2-piperidin-1-yl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl] acetate DMP0UK2 CP Bedford Laboratories DMP0UK2 TC Analgesics DMP0UK2 DT Small molecular drug DMP0UK2 PC 39765 DMP0UK2 MW 557.8 DMP0UK2 FM C34H57N2O4+ DMP0UK2 IC InChI=1S/C34H57N2O4/c1-23(37)39-31-20-25-12-13-26-27(34(25,4)22-29(31)35-16-8-6-9-17-35)14-15-33(3)28(26)21-30(32(33)40-24(2)38)36(5)18-10-7-11-19-36/h25-32H,6-22H2,1-5H3/q+1/t25-,26+,27-,28-,29-,30-,31-,32-,33-,34-/m0/s1 DMP0UK2 CS CC(=O)O[C@H]1C[C@@H]2CC[C@@H]3[C@@H]([C@]2(C[C@@H]1N4CCCCC4)C)CC[C@]5([C@H]3C[C@@H]([C@@H]5OC(=O)C)[N+]6(CCCCC6)C)C DMP0UK2 IK BGSZAXLLHYERSY-XQIGCQGXSA-N DMP0UK2 IU [(2S,3S,5S,8R,9S,10S,13S,14S,16S,17R)-17-acetyloxy-10,13-dimethyl-16-(1-methylpiperidin-1-ium-1-yl)-2-piperidin-1-yl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl] acetate DMP0UK2 CA CAS 86029-43-8 DMP0UK2 CB CHEBI:9939 DMP0UK2 DE Spasm DMV3YMX ID DMV3YMX DMV3YMX DN Vedolizmab DMV3YMX HS Approved DMV3YMX SN 4168-17-6 DMV3YMX CP Millennium Pharmaceuticals DMV3YMX DT Monoclonal antibody DMV3YMX DE Crohn disease; Ulcerative colitis DM4BOAS ID DM4BOAS DM4BOAS DN Velaglucerase alfa DM4BOAS HS Approved DM4BOAS SN Vpriv (TN) DM4BOAS CP Shire DM4BOAS SQ VPRIV Sequence: ARPCIPKSFGYSSVVCVCNATYCDSFDPPTFPALGTFSRYESTRSGRRMELSMGPIQANHTGTGLLLTLQPEQKFQKVKGFGGAMTDAAALNILALSPPAQNLLLKSYFSEEGIGYNIIRVPMASCDFSIRTYTYADTPDDFQLHNFSLPEEDTKLKIPLIHRALQLAQRPVSLLASPWTSPTWLKTNGAVNGKGSLKGQPGDIYHQTWARYFVKFLDAYAEHKLQFWAVTAENEPSAGLLSGYPFQCLGFTPEHQRDFIARDLGPTLANSTHHNVRLLMLDDQRLLLPHWAKVVLTDPEAAKYVHGIAVHWYLDFLAPAKATLGETHRLFPNTMLFASEACVGSKFWEQSVRLGSWDRGMQYSHSIITNLLYHVVGWTDWNLALNPEGGPNWVRNFVDSPIIVDITKDTFYKQPMFYHLGHFSKFIPEGSQRVGLVASQKNDLDAVALMHPDGSAVVVVLNRSSKDVPLTIKDPAVGFLETISPGYSIHTYLWRRQ DM4BOAS DE Metabolic disorder DMGF8ZQ ID DMGF8ZQ DMGF8ZQ DN Velpatasvir DMGF8ZQ HS Approved DMGF8ZQ SN Velpatasvir; Velpatasvir [USAN:INN]; Verpatasvir; KCU0C7RS7Z; 1377049-84-7; GS 5816; GS-5816; GS5816; UNII-KCU0C7RS7Z; methyl {(2S)-1-[(2S,5S)-2-(9-{2-[(2S,4S)-1-{(2R)-2-[(methoxycarbonyl)amino]-2-phenylacetyl}-4-(methoxymethyl)pyrrolidin-2-yl]-1H-imidazol-4-yl}-1,11-dihydro[2]benzopyrano[4',3':6,7]naphtho[1,2-d]imidazol-2-yl)-5-methylpyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl}carbamate DMGF8ZQ PC 67683363 DMGF8ZQ MW 883 DMGF8ZQ FM C49H54N8O8 DMGF8ZQ IC FHCUMDQMBHQXKK-CDIODLITSA-N DMGF8ZQ CS CC1CCC(N1C(=O)C(C(C)C)NC(=O)OC)C2=NC3=C(N2)C=CC4=CC5=C(C=C43)OCC6=C5C=CC(=C6)C7=CN=C(N7)C8CC(CN8C(=O)C(C9=CC=CC=C9)NC(=O)OC)COC DMGF8ZQ IK 1S/C49H54N8O8/c1-26(2)41(54-48(60)63-5)47(59)57-27(3)12-17-38(57)45-51-36-16-14-30-20-35-33-15-13-31(19-32(33)25-65-40(35)21-34(30)43(36)53-45)37-22-50-44(52-37)39-18-28(24-62-4)23-56(39)46(58)42(55-49(61)64-6)29-10-8-7-9-11-29/h7-11,13-16,19-22,26-28,38-39,41-42H,12,17-18,23-25H2,1-6H3,(H,50,52)(H,51,53)(H,54,60)(H,55,61)/t27-,28-,38-,39-,41-,42+/m0/s1 DMGF8ZQ IU methyl N-[(1R)-2-[(2S,4S)-2-[5-[6-[(2S,5S)-1-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]-5-methylpyrrolidin-2-yl]-21-oxa-5,7-diazapentacyclo[11.8.0.03,11.04,8.014,19]henicosa-1(13),2,4(8),5,9,11,14(19),15,17-nonaen-17-yl]-1H-imidazol-2-yl]-4-(methoxymethyl)pyrrolidin-1-yl]-2-oxo-1-phenylethyl]carbamate DMGF8ZQ CA CAS 1377049-84-7 DMGF8ZQ CB CHEBI:133009 DMGF8ZQ DE Viral hepatitis DM62UG5 ID DM62UG5 DM62UG5 DN Vemurafenib DM62UG5 HS Approved DM62UG5 SN PLX4032; RG7204; RO5185426; Zelboraf (TN); Vemurafenib (BRAF inhibitor) DM62UG5 CP Daiichi Sankyo group; Genentech DM62UG5 DT Small molecular drug DM62UG5 PC 42611257 DM62UG5 MW 489.9 DM62UG5 FM C23H18ClF2N3O3S DM62UG5 IC InChI=1S/C23H18ClF2N3O3S/c1-2-9-33(31,32)29-19-8-7-18(25)20(21(19)26)22(30)17-12-28-23-16(17)10-14(11-27-23)13-3-5-15(24)6-4-13/h3-8,10-12,29H,2,9H2,1H3,(H,27,28) DM62UG5 CS CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F DM62UG5 IK GPXBXXGIAQBQNI-UHFFFAOYSA-N DM62UG5 IU N-[3-[5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluorophenyl]propane-1-sulfonamide DM62UG5 CA CAS 918504-65-1 DM62UG5 CB CHEBI:63637 DM62UG5 DE Melanoma DM8I94Y ID DM8I94Y DM8I94Y DN Venetoclax DM8I94Y HS Approved DM8I94Y SN Venclexta DM8I94Y DT Small molecular drug DM8I94Y PC 49846579 DM8I94Y MW 868.447 DM8I94Y FM C45H50ClN7O7S DM8I94Y IC InChI=1S/C45H50ClN7O7S/c1-45(2)15-11-33(39(26-45)31-3-5-34(46)6-4-31)29-51-17-19-52(20-18-51)35-7-9-38(42(24-35)60-36-23-32-12-16-47-43(32)49-28-36)44(54)50-61(57,58)37-8-10-40(41(25-37)53(55)56)48-27-30-13-21-59-22-14-30/h3-10,12,16,23-25,28,30,48H,11,13-15,17-22,26-27,29H2,1-2H3,(H,47,49)(H,50,54) DM8I94Y CS CC1(CCC(=C(C1)C2=CC=C(C=C2)Cl)CN3CCN(CC3)C4=CC(=C(C=C4)C(=O)NS(=O)(=O)C5=CC(=C(C=C5)NCC6CCOCC6)[N+](=O)[O-])OC7=CN=C8C(=C7)C=CN8)C DM8I94Y IK LQBVNQSMGBZMKD-UHFFFAOYSA-N DM8I94Y IU 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-N-[3-nitro-4-(oxan-4-ylmethylamino)phenyl]sulfonyl-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide DM8I94Y CA CAS 1257044-40-8 DM8I94Y CB CHEBI:133021 DM8I94Y DE Chronic lymphocytic leukemia DMR6QH0 ID DMR6QH0 DMR6QH0 DN Venlafaxine DMR6QH0 HS Approved DMR6QH0 SN Efectin; Elafax; Venlafaxina; VenlafaxineXR; Venlafaxinum; Venlafaxine ER; Wy 45030; Efectin (TN); Venlafaxina [INN-Spanish];Venlafaxine (Effexor); Venlafaxine (INN); Venlafaxine [BAN:INN]; Venlafaxine [INN:BAN]; Venlafaxinum [INN-Latin]; N,N-dimethyl-2-(1-hydroxycyclohexyl)-2-(4-methoxyphenyl)ethylamine; 1-[(1R)-2-(Dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexanol; 1-[2-(Dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexanol; 1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexan-1-ol; 1-[2-dimethylamino-1-(4-methoxyphenyl)ethyl]cyclohexan-1-ol; 1-{2-(dimethylamino)-1-[4-(methyloxy)phenyl]ethyl}cyclohexanol DMR6QH0 CP Wyeth DMR6QH0 TC Antidepressants DMR6QH0 DT Small molecular drug DMR6QH0 PC 5656 DMR6QH0 MW 277.4 DMR6QH0 FM C17H27NO2 DMR6QH0 IC InChI=1S/C17H27NO2/c1-18(2)13-16(17(19)11-5-4-6-12-17)14-7-9-15(20-3)10-8-14/h7-10,16,19H,4-6,11-13H2,1-3H3 DMR6QH0 CS CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O DMR6QH0 IK PNVNVHUZROJLTJ-UHFFFAOYSA-N DMR6QH0 IU 1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexan-1-ol DMR6QH0 CA CAS 93413-69-5 DMR6QH0 CB CHEBI:9943 DMR6QH0 DE Depression DMA7PEW ID DMA7PEW DMA7PEW DN Verapamil DMA7PEW HS Approved DMA7PEW SN Arpamyl; Calan; Calcan; Cordilox; Dexverapamil; Dilacoran; Drosteakard; Iproveratril; Isoptimo; Isoptin; Isotopin; Vasolan; Veracim; Verapamilo; Verapamilum; Veraptin; Verexamil; Bosoptin (TN); Calan (TN); D-365; Isoptin (TN); Verapamilo [INN-Spanish]; Verapamilum [INN-Latin]; Verelan (TN); CP-16533-1; Covera-HS (TN); Verapamil (USAN/INN); Verapamil [USAN:BAN:INN]; Verapamil [USAN:INN:BAN]; Alpha-((N-Methyl-N-homoveratryl)-gamma-aminopropyl)-3,4-dimethoxyphenylacetonitrile; Alpha-Isopropyl-alpha-((N-methyl-N-homoveratryl)-gamma-aminopropyl)-3,4-dimethoxyphenylacetonitrile; Alpha-(3-((2-(3,4-Dimethoxyphenyl)ethyl)-methylamino)propyl)-3,4-dimethoxy-alpha-(1-methylethyl)benzeneacetonitrile; (+-)-Verapamil; (+/-)-VERAPAMIL; (1)-3-(3,4-Dimethoxyphenyl)-6-((5,6-dimethoxyphenethyl)methylamino)hexane-3-carbonitrile; 2-(3,4-Dimethoxyphenyl)-5-[2-(3,4-dimethoxyphenyl)ethyl-methyl-amino]-2-(1-methylethyl) pentanenitrile; 2-(3,4-dimethoxyphenyl)-5-[2-(3,4-dimethoxyphenyl)ethyl-methylamino]-2-propan-2-ylpentanenitrile; 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile; 5-((3,4-Dimethoxyphenethyl)methylamino)-2-(3,4-dimethoxyphenyl)-2-isopropylvaleronitrile; 5-[(3,4-Dimethoxyphenethyl)methylamino]-2-(3,4-dimethoxyphenyl)-2-isopropylvaleronitrile; Verapamil (Na-Ca chanel blocker) DMA7PEW CP Pfizer Inc DMA7PEW TC Analgesics DMA7PEW DT Small molecular drug DMA7PEW PC 2520 DMA7PEW MW 454.6 DMA7PEW FM C27H38N2O4 DMA7PEW IC InChI=1S/C27H38N2O4/c1-20(2)27(19-28,22-10-12-24(31-5)26(18-22)33-7)14-8-15-29(3)16-13-21-9-11-23(30-4)25(17-21)32-6/h9-12,17-18,20H,8,13-16H2,1-7H3 DMA7PEW CS CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC DMA7PEW IK SGTNSNPWRIOYBX-UHFFFAOYSA-N DMA7PEW IU 2-(3,4-dimethoxyphenyl)-5-[2-(3,4-dimethoxyphenyl)ethyl-methylamino]-2-propan-2-ylpentanenitrile DMA7PEW CA CAS 52-53-9 DMA7PEW CB CHEBI:77733 DMA7PEW DE Hypertension DM7MDBE ID DM7MDBE DM7MDBE DN Vericiguat DM7MDBE HS Approved DM7MDBE SN Vericiguat; 1350653-20-1; UNII-LV66ADM269; BAY-1021189; Methyl (4,6-diamino-2-(5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)pyrimidin-5-yl)carbamate; BAY1021189; LV66ADM269; MK-1242; Methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate; methyl N-[4,6-diamino-2-[5-fluoro-1-[(2-fluorophenyl)methyl]pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl]carbamate; Methyl (4,6-diamino-2-(5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo(3,4-b)pyridin-3-yl)pyrimidin-5-yl)carbam DM7MDBE CP Bayer HealthCare Pharmaceuticals DM7MDBE DT Small molecular drug DM7MDBE PC 54674461 DM7MDBE MW 426.4 DM7MDBE FM C19H16F2N8O2 DM7MDBE IC InChI=1S/C19H16F2N8O2/c1-31-19(30)25-14-15(22)26-17(27-16(14)23)13-11-6-10(20)7-24-18(11)29(28-13)8-9-4-2-3-5-12(9)21/h2-7H,8H2,1H3,(H,25,30)(H4,22,23,26,27) DM7MDBE CS COC(=O)NC1=C(N=C(N=C1N)C2=NN(C3=C2C=C(C=N3)F)CC4=CC=CC=C4F)N DM7MDBE IK QZFHIXARHDBPBY-UHFFFAOYSA-N DM7MDBE IU methyl N-[4,6-diamino-2-[5-fluoro-1-[(2-fluorophenyl)methyl]pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl]carbamate DM7MDBE CA CAS 1350653-20-1 DM7MDBE CB CHEBI:142432 DM7MDBE DE Heart failure DMIY6DB ID DMIY6DB DMIY6DB DN Verteporfin DMIY6DB HS Approved DMIY6DB SN Visudyne (TN) DMIY6DB DT Small molecular drug DMIY6DB PC 11980904 DMIY6DB MW 1437.6 DMIY6DB FM C82H84N8O16 DMIY6DB IC InChI=1S/2C41H42N4O8/c1-9-23-20(2)29-17-34-27-13-10-26(39(49)52-7)38(40(50)53-8)41(27,5)35(45-34)19-30-22(4)24(11-14-36(46)47)32(44-30)18-33-25(12-15-37(48)51-6)21(3)28(43-33)16-31(23)42-29;1-9-23-20(2)29-17-34-27-13-10-26(39(49)52-7)38(40(50)53-8)41(27,5)35(45-34)19-30-22(4)25(12-15-37(48)51-6)33(44-30)18-32-24(11-14-36(46)47)21(3)28(43-32)16-31(23)42-29/h2*9-10,13,16-19,38,42,44H,1,11-12,14-15H2,2-8H3,(H,46,47)/t2*38-,41+/m00/s1 DMIY6DB CS CC1=C(C2=CC3=NC(=CC4=C(C(=C(N4)C=C5[C@@]6([C@@H](C(=CC=C6C(=N5)C=C1N2)C(=O)OC)C(=O)OC)C)C)CCC(=O)OC)C(=C3C)CCC(=O)O)C=C.CC1=C(C2=CC3=NC(=CC4=C(C(=C(N4)C=C5[C@@]6([C@@H](C(=CC=C6C(=N5)C=C1N2)C(=O)OC)C(=O)OC)C)C)CCC(=O)O)C(=C3C)CCC(=O)OC)C=C DMIY6DB IK NJLRKAMQPVVOIU-IDLGWYNRSA-N DMIY6DB IU 3-[(23S,24R)-14-ethenyl-22,23-bis(methoxycarbonyl)-5-(3-methoxy-3-oxopropyl)-4,10,15,24-tetramethyl-25,26,27,28-tetrazahexacyclo[16.6.1.13,6.18,11.113,16.019,24]octacosa-1,3,5,7,9,11(27),12,14,16,18(25),19,21-dodecaen-9-yl]propanoic acid;3-[(23S,24R)-14-ethenyl-22,23-bis(methoxycarbonyl)-9-(3-methoxy-3-oxopropyl)-4,10,15,24-tetramethyl-25,26,27,28-tetrazahexacyclo[16.6.1.13,6.18,11.113,16.019,24]octacosa-1,3,5,7,9,11(27),12,14,16,18(25),19,21-dodecaen-5-yl]propanoic acid DMIY6DB DE Psoriasis vulgaris DMBKX3C ID DMBKX3C DMBKX3C DN VESNARINONE DMBKX3C HS Approved DMBKX3C SN vesnarinone; 81840-15-5; Arkin-Z; Piteranometozine; OPC-8212; Arkin; Vesnarinonum [Latin]; Vesnarinona [Spanish]; UNII-5COW40EV8M; OPC 8212; Vesnarinone [USAN:INN:JAN]; CCRIS 1451; DRG-0210; BRN 5644229; 5COW40EV8M; CHEMBL17423; 6-(4-(3,4-Dimethoxybenzoyl)-1-piperazinyl)-3,4-dihydro-2(1H)-; 1-(1,2,3,4-Tetrahydro-2-oxo-6-quinolyl)-4-veratroylpiperazine; 6-[4-(3,4-dimethoxybenzoyl)piperazin-1-yl]-3,4-dihydro-1H-quinolin-2-one; 3,4-Dihydro-6-(4-(3,4-dimethoxybenzoyl)-1-piperazinyl)-2(1H)-quinolinone DMBKX3C DT Small molecular drug DMBKX3C PC 5663 DMBKX3C MW 395.5 DMBKX3C FM C22H25N3O4 DMBKX3C IC InChI=1S/C22H25N3O4/c1-28-19-7-3-16(14-20(19)29-2)22(27)25-11-9-24(10-12-25)17-5-6-18-15(13-17)4-8-21(26)23-18/h3,5-7,13-14H,4,8-12H2,1-2H3,(H,23,26) DMBKX3C CS COC1=C(C=C(C=C1)C(=O)N2CCN(CC2)C3=CC4=C(C=C3)NC(=O)CC4)OC DMBKX3C IK ZVNYJIZDIRKMBF-UHFFFAOYSA-N DMBKX3C IU 6-[4-(3,4-dimethoxybenzoyl)piperazin-1-yl]-3,4-dihydro-1H-quinolin-2-one DMBKX3C CA CAS 81840-15-5 DMBKX3C CB CHEBI:31237 DMBKX3C DE Cardiac failure DM4UHZF ID DM4UHZF DM4UHZF DN Vestronidase alfa DM4UHZF HS Approved DM4UHZF CP Ultragenyx DM4UHZF DE Mucopolysaccharidosis DMFR201 ID DMFR201 DMFR201 DN Vibegron DMFR201 HS Approved DMFR201 SN MK-4618 DMFR201 CP Merck DMFR201 PC 44472635 DMFR201 MW 444.5 DMFR201 FM C26H28N4O3 DMFR201 IC InChI=1S/C26H28N4O3/c31-24-14-15-27-23-13-12-22(30(23)24)26(33)29-19-8-6-17(7-9-19)16-20-10-11-21(28-20)25(32)18-4-2-1-3-5-18/h1-9,14-15,20-22,25,28,32H,10-13,16H2,(H,29,33)/t20-,21+,22-,25+/m0/s1 DMFR201 CS C1C[C@@H](N[C@@H]1CC2=CC=C(C=C2)NC(=O)[C@@H]3CCC4=NC=CC(=O)N34)[C@@H](C5=CC=CC=C5)O DMFR201 IK DJXRIQMCROIRCZ-XOEOCAAJSA-N DMFR201 IU (6S)-N-[4-[[(2S,5R)-5-[(R)-hydroxy(phenyl)methyl]pyrrolidin-2-yl]methyl]phenyl]-4-oxo-7,8-dihydro-6H-pyrrolo[1,2-a]pyrimidine-6-carboxamide DMFR201 CA CAS 1190389-15-1 DMFR201 CB CHEBI:142418 DMFR201 DE Overactive bladder DM0N85H ID DM0N85H DM0N85H DN Vidarabine DM0N85H HS Approved DM0N85H SN Araadenosine; Arabinosyladenine; Armes; RAB; Spongoadenosine; VIRDARABINE; Vidarabin; Vidarabina; Vidarabinum; Xylosyladenine; Adenine arabinoside; Adenine xyloside; Adenosine arabinose; Ara A; Arabinoside adenine; Arabinosyl adenine; Vidarabina [DCIT]; Vidarabine anhydrous; Vira ATM; Xylosyl A; A 9251; ARA-A NSC 247519; Alpha-Ara A; Ara-A; Arabinosyl-adenine; Arasena-A; Armes (TN); Beta-Ara A; Vidarabine (JAN); Vira-A; Adenosine-8-14C; Vira-A, Vidarabine; ADENOSINE, U.S.P.; (+)-Cyclaradine; 9-Arabinosyladenine DM0N85H TC Antiviral Agents DM0N85H DT Small molecular drug DM0N85H PC 21704 DM0N85H MW 267.24 DM0N85H FM C10H13N5O4 DM0N85H IC InChI=1S/C10H13N5O4/c11-8-5-9(13-2-12-8)15(3-14-5)10-7(18)6(17)4(1-16)19-10/h2-4,6-7,10,16-18H,1H2,(H2,11,12,13)/t4-,6-,7+,10-/m1/s1 DM0N85H CS C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@H]([C@@H]([C@H](O3)CO)O)O)N DM0N85H IK OIRDTQYFTABQOQ-UHTZMRCNSA-N DM0N85H IU (2R,3S,4S,5R)-2-(6-aminopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol DM0N85H CA CAS 5536-17-4 DM0N85H CB CHEBI:45327 DM0N85H DE Herpes simplex virus infection DMYT0OG ID DMYT0OG DMYT0OG DN Vigabatrin DMYT0OG HS Approved DMYT0OG SN GVG; Sabril; Sabrilex; Vigabatrina; Vigabatrine; Vigabatrinum; Aventis Brand of Vigabatrin; Gamma Vinyl GABA; Gamma Vinyl gamma Aminobutyric Acid; Hoechst Brand of Vigabatrin; Vigabatrin Aventis Brand; Vigabatrin Hoechst Brand; Vigabatrin Yamanouchi Brand; Vigabatrina [Spanish]; Vigabatrine [French]; Vigabatrinum [Latin]; Yamanouchi Brand of Vigabatrin; M071754; MDL 71754; RMI 71754; V 8261; V8261_SIGMA; CPP-109; Gamma-Vinyl GABA; MDL 71,754; MDL-71754; RMI-71754; RMI-71890; Sabril (TN); Sabrilex (TN); Gamma-Vinyl-GABA; Hexenoic acid, 4-amino; Vigabatrin [USAN:BAN:INN]; Vigabatrin [USAN:INN:BAN]; Gamma-Vinyl-gamma-Aminobutyric Acid; Gamma-Vinyl-gamma-aminobutyric acid; Vigabatrin (JAN/USAN/INN); Acid, gamma-Vinyl-gamma-Aminobutyric; (R,S)-4-Amino-5-hexenoic acid; (inverted question mark)-gamma-Vinyl GABA; 4-Amino-5-hexenoic acid; 4-Aminohexenoic acid; 4-aminohex-5-enoic acid DMYT0OG CP Ovation Pharma; Lundbeck DMYT0OG TC Anticonvulsants DMYT0OG DT Small molecular drug DMYT0OG PC 5665 DMYT0OG MW 129.16 DMYT0OG FM C6H11NO2 DMYT0OG IC InChI=1S/C6H11NO2/c1-2-5(7)3-4-6(8)9/h2,5H,1,3-4,7H2,(H,8,9) DMYT0OG CS C=CC(CCC(=O)O)N DMYT0OG IK PJDFLNIOAUIZSL-UHFFFAOYSA-N DMYT0OG IU 4-aminohex-5-enoic acid DMYT0OG CA CAS 68506-86-5 DMYT0OG CB CHEBI:63638 DMYT0OG DE Complex partial seizure; Infantile spasm; Epilepsy DMF5EK1 ID DMF5EK1 DMF5EK1 DN Vilanterol DMF5EK1 HS Approved DMF5EK1 SN 503068-34-6; GW642444x; UNII-028LZY775B; GW-642444x; CHEBI:75037; 028LZY775B; Vilanterol (GW642444; GW 642444X); 4-((1R)-2-((6-(2-((2,6-dichlorophenyl)methoxy)ethoxy)hexyl)amino)-1-hydroxyethyl)-2-(hydroxymethyl)phenol; 4-[(1R)-2-[(6-{2-[(2,6-dichlorophenyl)methoxy]ethoxy}hexyl)amino]-1-hydroxyethyl]-2-(hydroxymethyl)phenol; Vilanterol [USAN:INN]; vilanterolum; Vilanterol base; Vilanterol (USAN); SCHEMBL142630; GTPL7353; CHEMBL1198857; DTXSID80198318; DAFYYTQWSAWIGS-DEOSSOPVSA-N; MolPort-044-560-195; Relovair DMF5EK1 CP GlaxoSmithKline DMF5EK1 DT Small molecular drug DMF5EK1 PC 10184665 DMF5EK1 MW 486.4 DMF5EK1 FM C24H33Cl2NO5 DMF5EK1 IC InChI=1S/C24H33Cl2NO5/c25-21-6-5-7-22(26)20(21)17-32-13-12-31-11-4-2-1-3-10-27-15-24(30)18-8-9-23(29)19(14-18)16-28/h5-9,14,24,27-30H,1-4,10-13,15-17H2/t24-/m0/s1 DMF5EK1 CS C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNC[C@@H](C2=CC(=C(C=C2)O)CO)O)Cl DMF5EK1 IK DAFYYTQWSAWIGS-DEOSSOPVSA-N DMF5EK1 IU 4-[(1R)-2-[6-[2-[(2,6-dichlorophenyl)methoxy]ethoxy]hexylamino]-1-hydroxyethyl]-2-(hydroxymethyl)phenol DMF5EK1 CA CAS 503068-34-6 DMF5EK1 CB CHEBI:75037 DMF5EK1 DE Chronic obstructive pulmonary disease DM4LECQ ID DM4LECQ DM4LECQ DN Vilazodone DM4LECQ HS Approved DM4LECQ SN Vilazodone [INN]; Vilazodone (TN); 5-[4-[4-(5-cyano-1H-indol-3-yl)butyl]piperazin-1-yl]-1-benzofuran-2-carboxamide; 5-[4-[4-(5-cyano-1H-indol-3-yl)butyl]piperazin-1-yl]benzofuran-2-carboxamide DM4LECQ CP Genaissance and Merck KGaA DM4LECQ DT Small molecular drug DM4LECQ PC 6918314 DM4LECQ MW 441.5 DM4LECQ FM C26H27N5O2 DM4LECQ IC InChI=1S/C26H27N5O2/c27-16-18-4-6-23-22(13-18)19(17-29-23)3-1-2-8-30-9-11-31(12-10-30)21-5-7-24-20(14-21)15-25(33-24)26(28)32/h4-7,13-15,17,29H,1-3,8-12H2,(H2,28,32) DM4LECQ CS C1CN(CCN1CCCCC2=CNC3=C2C=C(C=C3)C#N)C4=CC5=C(C=C4)OC(=C5)C(=O)N DM4LECQ IK SGEGOXDYSFKCPT-UHFFFAOYSA-N DM4LECQ IU 5-[4-[4-(5-cyano-1H-indol-3-yl)butyl]piperazin-1-yl]-1-benzofuran-2-carboxamide DM4LECQ CA CAS 163521-12-8 DM4LECQ CB CHEBI:70707 DM4LECQ DE Major depressive disorder DMYN59P ID DMYN59P DMYN59P DN Vildagliptin DMYN59P HS Approved DMYN59P SN Equa; Galvu; Galvus; Jalra; Xiliarx; Galvus (TN); Vidagliptin (see Vildagliptin); Vildagliptin (JAN/USAN/INN); (2S)-(((3-hydroxyadamantan-1-yl)amino)acetyl)pyrrolidine-2-carbonitrile; (2S)-1-[2-[(3-hydroxy-1-adamantyl)amino]acetyl]pyrrolidine-2-carbonitrile; 1-[2-[(3-hydroxy-1-adamantyl)amino]acetyl]pyrrolidine-2-carbonitrile; 2-Pyrrolidinecarbonitrile, 1-[[(3-hydroxytricyclo[3.3.1.13,7]dec-1-yl)amino]acetyl]-, (2S)-(9CI) DMYN59P CP Novartis DMYN59P DT Small molecular drug DMYN59P PC 6918537 DMYN59P MW 303.4 DMYN59P FM C17H25N3O2 DMYN59P IC InChI=1S/C17H25N3O2/c18-9-14-2-1-3-20(14)15(21)10-19-16-5-12-4-13(6-16)8-17(22,7-12)11-16/h12-14,19,22H,1-8,10-11H2/t12?,13?,14-,16?,17?/m0/s1 DMYN59P CS C1C[C@H](N(C1)C(=O)CNC23CC4CC(C2)CC(C4)(C3)O)C#N DMYN59P IK SYOKIDBDQMKNDQ-XWTIBIIYSA-N DMYN59P IU (2S)-1-[2-[(3-hydroxy-1-adamantyl)amino]acetyl]pyrrolidine-2-carbonitrile DMYN59P CA CAS 274901-16-5 DMYN59P CB CHEBI:135285 DMYN59P DE Type-2 diabetes DM5TVS3 ID DM5TVS3 DM5TVS3 DN Vinblastine DM5TVS3 HS Approved DM5TVS3 SN Nincaluicolflastine; Rozevin; VLB; Vinblastin; Vinblastina; Vinblastinum; Vincaleucoblastin; Vincaleucoblastine; Vincaleukoblastine; Vincoblastine; Vinblastina [DCIT]; VR-8; Vinblastina (TN); Vinblastine (INN); Vinblastine [INN:BAN]; Vinblastinum [INN-Latin]; NDC 0002-1452-01; (2ALPHA,2'BETA,3BETA,4ALPHA,5BETA)-VINCALEUKOBLASTINE; (2xi,3beta,4'beta,19xi)-vincaleukoblastine; 1H-Indolizino(8,1-cd)carbazole-5-carboxylic acid DM5TVS3 CP Eli Lilly And Co DM5TVS3 TC Anticancer Agents DM5TVS3 DT Small molecular drug DM5TVS3 PC 13342 DM5TVS3 MW 811 DM5TVS3 FM C46H58N4O9 DM5TVS3 IC InChI=1S/C46H58N4O9/c1-8-42(54)23-28-24-45(40(52)57-6,36-30(15-19-49(25-28)26-42)29-13-10-11-14-33(29)47-36)32-21-31-34(22-35(32)56-5)48(4)38-44(31)17-20-50-18-12-16-43(9-2,37(44)50)39(59-27(3)51)46(38,55)41(53)58-7/h10-14,16,21-22,28,37-39,47,54-55H,8-9,15,17-20,23-26H2,1-7H3/t28-,37-,38+,39+,42-,43+,44+,45-,46-/m0/s1 DM5TVS3 CS CC[C@@]1(C[C@H]2C[C@@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O DM5TVS3 IK JXLYSJRDGCGARV-CFWMRBGOSA-N DM5TVS3 IU methyl (1R,9R,10S,11R,12R,19R)-11-acetyloxy-12-ethyl-4-[(13S,15R,17S)-17-ethyl-17-hydroxy-13-methoxycarbonyl-1,11-diazatetracyclo[13.3.1.04,12.05,10]nonadeca-4(12),5,7,9-tetraen-13-yl]-10-hydroxy-5-methoxy-8-methyl-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraene-10-carboxylate DM5TVS3 CA CAS 865-21-4 DM5TVS3 DE Solid tumour/cancer DMK1ZOR ID DMK1ZOR DMK1ZOR DN Vincamine DMK1ZOR HS Approved DMK1ZOR SN vincamine; 1617-90-9; Pervincamine; Devincan; Minorine; Vincamidol; Novicet; Monorin; Methyl vincaminate; Arteriovinca; Vincasaunier; Vinkametrin; Devinkan; Decincan; Vincapront; Vincafolina; Vincadar; Tripervan; Angiopac; Anasclerol; (+)-Vincamine; Equipur; Pervone; Oxygeron; Vincafor; Perval; Ocu-vinc; Vincamina [DCIT]; Vincimax; Vincamine base; Vincaminum [INN-Latin]; UNII-996XVD0JHT; Vincamine [INN:BAN:DCF]; Minorin; Vincachron; Vincapan; Vincamin; Vincagil; Vinca; Vinodrel retard; Vinca-Minor; Vinca-Ecobi; HSDB 7150; Anasclerol (base) DMK1ZOR DT Small molecular drug DMK1ZOR PC 15376 DMK1ZOR MW 354.4 DMK1ZOR FM C21H26N2O3 DMK1ZOR IC InChI=1S/C21H26N2O3/c1-3-20-10-6-11-22-12-9-15-14-7-4-5-8-16(14)23(17(15)18(20)22)21(25,13-20)19(24)26-2/h4-5,7-8,18,25H,3,6,9-13H2,1-2H3/t18-,20+,21+/m1/s1 DMK1ZOR CS CC[C@@]12CCCN3[C@@H]1C4=C(CC3)C5=CC=CC=C5N4[C@](C2)(C(=O)OC)O DMK1ZOR IK RXPRRQLKFXBCSJ-GIVPXCGWSA-N DMK1ZOR IU methyl (15S,17S,19S)-15-ethyl-17-hydroxy-1,11-diazapentacyclo[9.6.2.02,7.08,18.015,19]nonadeca-2,4,6,8(18)-tetraene-17-carboxylate DMK1ZOR CA CAS 1617-90-9 DMK1ZOR CB CHEBI:9985 DMK1ZOR DE Cerebrovascular disease DMINOX3 ID DMINOX3 DMINOX3 DN Vincristine DMINOX3 HS Approved DMINOX3 SN LCR; Leurocristine; Marqibo; Oncovine; Tecnocris; VCR; VIN; Vincasar; Vincristina; Vincristinum; Vincrstine; Vincrystine; Vinkristin; Indole alkaloid; Liposomal Vincristine; Onco TCS; Vincristina [DCIT]; Oncovin (TN); Tecnocris (TN); Vincristine (INN); Vincristine [INN:BAN]; Vincristinum [INN-Latin]; Lilly37231 (1:1 sulfate salt); Oncovin (1:1 sulfate salt); Vincasar (1:1 sulfate salt); Vincrex (1:1 sulfate salt); Vincaleukoblastine, 22-oxo-22-Oxovincaleukoblastine; Z-D-Val-Lys(Z)-OH; 22-Oxovincaleukoblastine DMINOX3 CP Mayne Pharma Limited DMINOX3 TC Anticancer Agents DMINOX3 DT Small molecular drug DMINOX3 PC 5978 DMINOX3 MW 825 DMINOX3 FM C46H56N4O10 DMINOX3 IC InChI=1S/C46H56N4O10/c1-7-42(55)22-28-23-45(40(53)58-5,36-30(14-18-48(24-28)25-42)29-12-9-10-13-33(29)47-36)32-20-31-34(21-35(32)57-4)50(26-51)38-44(31)16-19-49-17-11-15-43(8-2,37(44)49)39(60-27(3)52)46(38,56)41(54)59-6/h9-13,15,20-21,26,28,37-39,47,55-56H,7-8,14,16-19,22-25H2,1-6H3/t28-,37+,38-,39-,42+,43-,44-,45+,46+/m1/s1 DMINOX3 CS CC[C@@]1(C[C@@H]2C[C@@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O DMINOX3 IK OGWKCGZFUXNPDA-XQKSVPLYSA-N DMINOX3 IU methyl (1R,9R,10S,11R,12R,19R)-11-acetyloxy-12-ethyl-4-[(13S,15S,17S)-17-ethyl-17-hydroxy-13-methoxycarbonyl-1,11-diazatetracyclo[13.3.1.04,12.05,10]nonadeca-4(12),5,7,9-tetraen-13-yl]-8-formyl-10-hydroxy-5-methoxy-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraene-10-carboxylate DMINOX3 CA CAS 57-22-7 DMINOX3 CB CHEBI:28445 DMINOX3 DE Acute lymphoblastic leukaemia DMVR628 ID DMVR628 DMVR628 DN Vindesine DMVR628 HS Approved DMVR628 SN DAVA; Vindesin; Vindesina; Vindesinum; Desacetylvinblastine amide; Lilly 112531; Vindesina [INN-Spanish]; Vindesinum [INN-Latin]; Vindesine (USAN/INN); Vindesine [USAN:BAN:INN]; Vindesine [USAN:INN:BAN]; 3-(Aminocarbonyl)-O(sup 4)-deacetyl-3-de(methoxycarbonyl)vincaleukoblastine; 3-(aminocarbonyl)-O(4)-deacetyl-3-de(methoxycarbonyl)vincaleukoblastine; 3-Carbamoyl-4-deacetyl-3-de(methoxycarbonyl)vincaleukoblastine; 3-carbamoyl-O(4)-deacetyl-3-de(methoxycarbonyl)vincaleukoblastine; Methyl (5S,7S,9S)-9-[(2b,3b,4b,5a,12b,19a)-3-carbamoyl-3,4-dihydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidin-15-yl]-5-ethyl-5-hydroxy-1,4,5,6,7,8,9,10-octahydro-2H-3,7-methanoazacycloundecino[5,4-b]indole-9-carboxylate; Methyl (5S,7S,9S)-9-[(2beta,3beta,4beta,5alpha,12beta,19alpha)-3-carbamoyl-3,4-dihydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidin-15-yl]-5-ethyl-5-hydroxy-1,4,5,6,7,8,9,10-octahydro-2H-3,7-methanoazacycloundecino[5,4-b]indole-9-carboxylate DMVR628 TC Anticancer Agents DMVR628 DT Small molecular drug DMVR628 PC 40839 DMVR628 MW 753.9 DMVR628 FM C43H55N5O7 DMVR628 IC InChI=1S/C43H55N5O7/c1-6-39(52)21-25-22-42(38(51)55-5,33-27(13-17-47(23-25)24-39)26-11-8-9-12-30(26)45-33)29-19-28-31(20-32(29)54-4)46(3)35-41(28)15-18-48-16-10-14-40(7-2,34(41)48)36(49)43(35,53)37(44)50/h8-12,14,19-20,25,34-36,45,49,52-53H,6-7,13,15-18,21-24H2,1-5H3,(H2,44,50)/t25-,34+,35-,36-,39+,40-,41-,42+,43+/m1/s1 DMVR628 CS CC[C@@]1(C[C@@H]2C[C@@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)N)O)O)CC)OC)C(=O)OC)O DMVR628 IK HHJUWIANJFBDHT-KOTLKJBCSA-N DMVR628 IU methyl (13S,15S,17S)-13-[(1R,9R,10S,11R,12R,19R)-10-carbamoyl-12-ethyl-10,11-dihydroxy-5-methoxy-8-methyl-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraen-4-yl]-17-ethyl-17-hydroxy-1,11-diazatetracyclo[13.3.1.04,12.05,10]nonadeca-4(12),5,7,9-tetraene-13-carboxylate DMVR628 CA CAS 53643-48-4 DMVR628 CB CHEBI:36373 DMVR628 DE Acute lymphoblastic leukaemia DMVXFYE ID DMVXFYE DMVXFYE DN Vinorelbine DMVXFYE HS Approved DMVXFYE SN Eunades; Exelbine; NVB; Navelbine; Vinorelbin; Vinorelbina; Vinorelbinum; Navelbine base; Vinorelbina [Spanish]; Vinorelbine Ditartarate; Vinorelbine ditartrate; Vinorelbine tartrate; Vinorelbinum [Latin]; KW 2307; KW 2307 base; ANX-530; KW-2307; Navelbine (TN); SDP-012; Vinorelbine (INN); Vinorelbine [INN:BAN]; Aspidospermidine-3-carboxylic acid; Nor-5'-anhydrovinblastine; Methyl (2beta,3beta,4beta,5alpha,12beta,19alpha)-4-acetoxy-15-[(6R,8S)-4-ethyl-8-(methoxycarbonyl)-1,3,6,7,8,9-hexahydro-2,6-methanoazecino[4,3-b]indol-8-yl]-3-hydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidine-3-carboxylate; Methyl (2b,3b,4b,5a,12b,19a)-4-(acetyloxy)-15-[(6R,8S)-4-ethyl-8-(methoxycarbonyl)-1,3,6,7,8,9-hexahydro-2,6-methanoazecino[4,3-b]indol-8-yl]-3-hydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidine-3-carboxylate DMVXFYE CP GlaxoSmithKline DMVXFYE TC Anticancer Agents DMVXFYE DT Small molecular drug DMVXFYE PC 5311497 DMVXFYE MW 778.9 DMVXFYE FM C45H54N4O8 DMVXFYE IC InChI=1S/C45H54N4O8/c1-8-27-19-28-22-44(40(51)55-6,36-30(25-48(23-27)24-28)29-13-10-11-14-33(29)46-36)32-20-31-34(21-35(32)54-5)47(4)38-43(31)16-18-49-17-12-15-42(9-2,37(43)49)39(57-26(3)50)45(38,53)41(52)56-7/h10-15,19-21,28,37-39,46,53H,8-9,16-18,22-25H2,1-7H3/t28-,37-,38+,39+,42+,43+,44-,45-/m0/s1 DMVXFYE CS CCC1=C[C@H]2C[C@@](C3=C(CN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC DMVXFYE IK GBABOYUKABKIAF-IELIFDKJSA-N DMVXFYE IU methyl (1R,9R,10S,11R,12R,19R)-11-acetyloxy-12-ethyl-4-[(12S,14R)-16-ethyl-12-methoxycarbonyl-1,10-diazatetracyclo[12.3.1.03,11.04,9]octadeca-3(11),4,6,8,15-pentaen-12-yl]-10-hydroxy-5-methoxy-8-methyl-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraene-10-carboxylate DMVXFYE CA CAS 71486-22-1 DMVXFYE CB CHEBI:480999 DMVXFYE DE Solid tumour/cancer DMVN2E6 ID DMVN2E6 DMVN2E6 DN Vinpocetine DMVN2E6 HS Approved DMVN2E6 SN Bravinton; Cavinton; Ceractin; Vinpocetinum; Apovincaminic acid ethyl ester; AY 27255; RGH 4405; TCV 3B; V 6383; V6383_SIGMA; AY 27,255; Apovincaminate d'ethyle; Apovincaminate d'ethyle [French]; Cavinton (TN); Cis-Apovincaminic acid ethyl ester; Intelectol (TN); RGH-4405; TCV-3B; Ultra-Vinca; Vinpocetine-ethyl apovincaminate; Vinpocetinum [INN-Latin]; Eburnamenine-14-carboxylic acid ethyl ester; Ethyl apovincamin-22-oate; Vinpocetine [USAN:INN:JAN]; Ethyl (+)-apovincaminate; Vinpocetine (JAN/USAN/INN); Ethyl(+)-cis-apovincaminate; Ethyl apovincaminate, (3alpha,16alpha)-isomer; Ethyl (3alpha,16alpha)-eburnamenine-14-carboxylate; (+)-Apovincaminic acid ethyl ester; (+)-cis-Apovincaminic acid ethyl ester; (3alpha, 16alpha)-Eburnamenine-14-carboxylic acid ethyl ester; 1H-Indolo[3,2,1-de]pyrido[3,2,1-ij][1,5]naphthyridine, eburnamenine-14-carboxylic acid deriv.; 3-alpha,16-alpha-Apovincaminic acid ethyl ester DMVN2E6 TC Vasodilator Agents DMVN2E6 DT Small molecular drug DMVN2E6 PC 443955 DMVN2E6 MW 350.5 DMVN2E6 FM C22H26N2O2 DMVN2E6 IC InChI=1S/C22H26N2O2/c1-3-22-11-7-12-23-13-10-16-15-8-5-6-9-17(15)24(19(16)20(22)23)18(14-22)21(25)26-4-2/h5-6,8-9,14,20H,3-4,7,10-13H2,1-2H3/t20-,22+/m1/s1 DMVN2E6 CS CC[C@@]12CCCN3[C@@H]1C4=C(CC3)C5=CC=CC=C5N4C(=C2)C(=O)OCC DMVN2E6 IK DDNCQMVWWZOMLN-IRLDBZIGSA-N DMVN2E6 IU ethyl (15S,19S)-15-ethyl-1,11-diazapentacyclo[9.6.2.02,7.08,18.015,19]nonadeca-2,4,6,8(18),16-pentaene-17-carboxylate DMVN2E6 CA CAS 42971-09-5 DMVN2E6 CB CHEBI:32297 DMVN2E6 DE Ischemic stroke DMZYLFC ID DMZYLFC DMZYLFC DN Viomycin sulfate DMZYLFC HS Approved DMZYLFC SN Viocin (TN) DMZYLFC DT Small molecular drug DMZYLFC PC 135524783 DMZYLFC MW 783.8 DMZYLFC FM C25H45N13O14S DMZYLFC IC InChI=1S/C25H43N13O10.H2O4S/c26-3-1-2-10(27)4-16(41)32-12-6-30-23(47)18(11-5-17(42)37-24(28)36-11)38-20(44)13(7-31-25(29)48)33-21(45)14(8-39)35-22(46)15(9-40)34-19(12)43;1-5(2,3)4/h7,10-12,14-15,17-18,39-40,42H,1-6,8-9,26-27H2,(H,30,47)(H,32,41)(H,33,45)(H,34,43)(H,35,46)(H,38,44)(H3,28,36,37)(H3,29,31,48);(H2,1,2,3,4)/b13-7-;/t10-,11+,12-,14-,15-,17-,18-;/m0./s1 DMZYLFC CS C1[C@@H](N=C(N[C@H]1O)N)[C@H]2C(=O)NC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N/C(=C\\NC(=O)N)/C(=O)N2)CO)CO)NC(=O)C[C@H](CCCN)N.OS(=O)(=O)O DMZYLFC IK AQONYROJHRNYQQ-QMAPKBLTSA-N DMZYLFC IU (3S)-3,6-diamino-N-[(3S,6Z,9S,12S,15S)-3-[(4R,6S)-2-amino-6-hydroxy-1,4,5,6-tetrahydropyrimidin-4-yl]-6-[(carbamoylamino)methylidene]-9,12-bis(hydroxymethyl)-2,5,8,11,14-pentaoxo-1,4,7,10,13-pentazacyclohexadec-15-yl]hexanamide;sulfuric acid DMZYLFC CA CAS 37883-00-4 DMZYLFC DE Bacterial infection DM0REZS ID DM0REZS DM0REZS DN Virulizin DM0REZS HS Approved DM0REZS SN Virulizin (TN) DM0REZS CP Lorus Therapeutics DM0REZS DE Breast cancer DM5IXKQ ID DM5IXKQ DM5IXKQ DN Vismodegib DM5IXKQ HS Approved DM5IXKQ SN 879085-55-9; GDC-0449; Erivedge; 2-chloro-N-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(methylsulfonyl)benzamide; Vismodegib (GDC-0449); HhAntag691; GDC0449; GDC 0449; UNII-25X868M3DS; CHEMBL473417; CHEBI:66903; 25X868M3DS; NSC755986; AK-77261; 2-chloro-N-[4-chloro-3-(pyridin-2-yl)phenyl]-4-(methylsulfonyl)benzamide; C19H14Cl2N2O3S; 2-chloro-N-(4-chloro-3-pyridin-2-ylphenyl)-4-methylsulfonylbenzamide; 2-chloro-n-(4-chloro-3-(2-pyridinyl)phenyl)-4-(methylsulfonyl)benzamide; Erivedge (TN); Vismodegib (SHH inhibitor); Gdc-0449 DM5IXKQ CP Genentech DM5IXKQ DT Small molecular drug DM5IXKQ PC 24776445 DM5IXKQ MW 421.3 DM5IXKQ FM C19H14Cl2N2O3S DM5IXKQ IC InChI=1S/C19H14Cl2N2O3S/c1-27(25,26)13-6-7-14(17(21)11-13)19(24)23-12-5-8-16(20)15(10-12)18-4-2-3-9-22-18/h2-11H,1H3,(H,23,24) DM5IXKQ CS CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl DM5IXKQ IK BPQMGSKTAYIVFO-UHFFFAOYSA-N DM5IXKQ IU 2-chloro-N-(4-chloro-3-pyridin-2-ylphenyl)-4-methylsulfonylbenzamide DM5IXKQ CA CAS 879085-55-9 DM5IXKQ CB CHEBI:66903 DM5IXKQ DE Basal cell carcinoma; Primitive neuroectodermal tumour medulloblastoma DMJ2AH4 ID DMJ2AH4 DMJ2AH4 DN Vitamin A DMJ2AH4 HS Approved DMJ2AH4 SN Retinol; retinol; all-trans-Retinol; 68-26-8; Vitamin A1; Alphalin; Axerophthol; Afaxin; Oleovitamin A; Chocola A; Ophthalamin; Epiteliol; Biosterol; Aquasynth; Apostavit; Alphasterol; Veroftal; Testavol; Anatola; Prepalin; Myvpack; Agoncal; Agiolan; Vogan; Axerol; Vitpex; Avibon; Apexol; Aoral; Vaflol; Dofsol; Avitol; Vitamin A alcohol; Disatabs Tabs; Lard Factor; Bentavit A; Dohyfral A; all-trans-Retinyl alcohol; Alcovit A; Vogan-Neu; Anatola A; Plivit A; A-Mulsal; Vi-Alpha; A-Vitan; All-trans retinol; Atars; Vafol; trans-retinol; all-trans-Vitamin A; ACON; ATAV; Alin; Avita; Axerophtholum; Cylasphere; LPK; Retinolo; Retinolum; TROL; Thalasphere; Wachstumsvitamin; All Trans Retinol; Antixerophthalmic vitamin; Antixerophthalmisches Vitamin; Aquasol A Parenteral; Homagenets Aoral; Homagenets aorl; Hydrovit A; Mvc Plus; Retinol solution; Retinolo [DCIT]; Retrovitamin A; Sehkraft A; Super A; Testavol S; Vitamin A cryst; Vitamine A; Vitaminum A; Vitavel A; Zinosan N; Rovimix A 500; Vitamin A1 alcohol; A-Sol; Anti-infective vitamin; Beta-Retinol; Retinol [INN:BAN]; Retinolum [INN-Latin]; Solu-A; Trans-Vitamin A alcohol; Trans-retinol; Vi-a; Vi-alpha; Vio-A; Vitamin A (Feed); Vitamin A (USP); Vitamin A alcohol (VAN); Vitamin A1 alcohol, all trans; Vitamin-A; Vitamin-A alcohol; Vitamin-A alcohol solution; Vitamin-A1; Vitavel-A; Vogan-nu; A-Vi-Pel; ALL-TRANS RETINOL (SEE ALSO RETINOID PROJECT 1); All-trans-Retinol; All-trans-Retinyl alcohol; All-trans-Vitamin A; All-trans-Vitamin A alcohol; All-trans-Vitamin A1; Del-VI-A; Hi-A-Vita; Nio-A-Let; Ro-a-vit; Trans-Retinol acid (Vitamin A); Vi-Dom-A; [11,12-3H]-Retinol; MVC 9+3; MVI-12; Retinol, all-trans-(8CI); Retin-11,12-t2-ol (9CI); Retinol-(cellular-retinol-binding-protein); Alcohol 9,13-dimethyl-7-(1,1,5-trimethyl-6-cyclohexen-5-yl)-7,9,11,13-nonatetraen-15-ol; All-trans-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraen-1-ol; (2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraen-1-ol; (2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraen-1-ol; (all-E)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraen-1-ol; 3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclchexen-1-yl)-2,4,6,8-nonatetraen-1-ol; 3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonate-traen-1-ol; 3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraen-1-ol; 3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexenyl)-2,4,6,8-nonatetraen-1-ol; 3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraen-1-ol, (all-E)-Isomer; Tricyclics DMJ2AH4 TC Vitamins DMJ2AH4 DT Small molecular drug DMJ2AH4 PC 445354 DMJ2AH4 MW 286.5 DMJ2AH4 FM C20H30O DMJ2AH4 IC InChI=1S/C20H30O/c1-16(8-6-9-17(2)13-15-21)11-12-19-18(3)10-7-14-20(19,4)5/h6,8-9,11-13,21H,7,10,14-15H2,1-5H3/b9-6+,12-11+,16-8+,17-13+ DMJ2AH4 CS CC1=C(C(CCC1)(C)C)/C=C/C(=C/C=C/C(=C/CO)/C)/C DMJ2AH4 IK FPIPGXGPPPQFEQ-OVSJKPMPSA-N DMJ2AH4 IU (2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraen-1-ol DMJ2AH4 CA CAS 11103-57-4 DMJ2AH4 CB CHEBI:17336 DMJ2AH4 DE Night blindness; Kinetoplastids DMZ1WXJ ID DMZ1WXJ DMZ1WXJ DN Vitamin B1 DMZ1WXJ HS Approved DMZ1WXJ SN 59-43-8; Thiamine monochloride; Aneurine; 3-((4-Amino-2-methylpyrimidin-5-yl)methyl)-5-(2-hydroxyethyl)-4-methylthiazol-3-ium chloride; Tiamina; Oryzanin; Thiaminum; Oryzanine; Bethiamin; Vitaneurin; Beivon; Apatate drape; Thiamine, chloride; B-Amin; Thiamine [INN:BAN]; Tiamina [INN-Spanish]; Thiaminum [INN-Latin]; UNII-X66NSO3N35; CCRIS 5823; HSDB 220; thiamine(1+) chloride; EINECS 200-425-3; X66NSO3N35; CHEBI:33283; AK109288; Thiamine (Vit B1); Thiazolium, DMZ1WXJ TC Vitamins DMZ1WXJ DT Small molecular drug DMZ1WXJ PC 6042 DMZ1WXJ MW 300.81 DMZ1WXJ FM C12H17ClN4OS DMZ1WXJ IC InChI=1S/C12H17N4OS.ClH/c1-8-11(3-4-17)18-7-16(8)6-10-5-14-9(2)15-12(10)13;/h5,7,17H,3-4,6H2,1-2H3,(H2,13,14,15);1H/q+1;/p-1 DMZ1WXJ CS CC1=C(SC=[N+]1CC2=CN=C(N=C2N)C)CCO.[Cl-] DMZ1WXJ IK MYVIATVLJGTBFV-UHFFFAOYSA-M DMZ1WXJ IU 2-[3-[(4-amino-2-methylpyrimidin-5-yl)methyl]-4-methyl-1,3-thiazol-3-ium-5-yl]ethanol;chloride DMZ1WXJ CA CAS 59-43-8 DMZ1WXJ CB CHEBI:33283 DMZ1WXJ DE Vitamin B1 deficiency DMQVRZH ID DMQVRZH DMQVRZH DN Vitamin B3 DMQVRZH HS Approved DMQVRZH SN Niacin (TN); Niacinamide (TN); Nicotinamide (TN) DMQVRZH CP Anmar DMQVRZH DT Small molecular drug DMQVRZH PC 938 DMQVRZH MW 123.11 DMQVRZH FM C6H5NO2 DMQVRZH IC InChI=1S/C6H5NO2/c8-6(9)5-2-1-3-7-4-5/h1-4H,(H,8,9) DMQVRZH CS C1=CC(=CN=C1)C(=O)O DMQVRZH IK PVNIIMVLHYAWGP-UHFFFAOYSA-N DMQVRZH IU pyridine-3-carboxylic acid DMQVRZH CA CAS 59-67-6 DMQVRZH CB CHEBI:15940 DMQVRZH DE Lipid metabolism disorder DMDBZMV ID DMDBZMV DMDBZMV DN Vitamin B6 DMDBZMV HS Approved DMDBZMV SN Aderoxin; Alestrol; Becilan; Beesix; Benadon; Bonasanit; Godabion; Hexavibex; Hexermin; Hexermine; Hexobion; Nestrex; Paxadon; Pydox; Pyridipca; Pyridox; Spondylonal; Vitaped; Adermin hydrochloride; Adermine hydrochloride; Aderomine hydrochloride; Component of Alestrol; Hexabione hydrochloride; PN HCl; PYRIDOXINE HYDROCHLORIDE; Pyridoxin hydrochloride; Pyridoxine HCl; Pyridoxine chloride; Pyridoxine hydrogen chloride; Pyridoxine monohydrochloride; Pyridoxinium chloride; Pyridoxinum hydrochloricum; Pyridoxol hydrochloride; Rodex TD; AIDS006784; Campoviton 6; Vitamin V6; AIDS-006784; Cernevit-12; Pyridoxine (INN); Pyridoxine Hydrochloride (B6); Pyridoxine hydrochloride[USAN:JAN]; Pyridoxine, hydrochloride; Pyridoxine-HCl Microencapsulated; Pyridoxinum hydrochloricum (Hungarian); Pyridoxol, hydrochloride; Rodex (R); Vitamin B6-hydrochloride; Vitamin V6 (TN); Vitamin-B6 hydrochloride; Hexa-Betalin (R); Hexa-betalin (TN); Pyridoxine hydrochloride (JP15/USP); Tex Six T.R.; PYRIDOXINE HYDROCHLORIDE, U.S.P.; (5-hydroxy-4,6-dimethylpyridin-3-yl)methyl phosphate; 2-Methyl-3-hydroxy-4,5-bis(hydroxymethyl)pyridine; 2-Methyl-3-hydroxy-4,5-di(hydroxymethyl)pyridine; 2-Methyl-3-hydroxy-4,5-dihydroxymethyl-pyridin; 2-Methyl-3-hydroxy-4,5-dihydroxymethyl-pyridin [German]; 2-Methyl-4,5-bis(hydroxymethyl)-3-hydroxypyridine; 2-methyl-3-hydroxy-4,5-bis(hydroxy-methyl) pyridine; 2-methyl-3-hydroxy-4,5-dihydroxymethylpyridine; 2-methyl-4,5-dimethylol-pyridin-3-ol; 3,4-Pyridinedimethanol, 5-hydroxy-6-methyl-, hydrochloride; 3-Hydroxy-4,5-dihydroxymethyl-2-methylpyridine hydrochloride; 3-Hydroxy-4,5-dimethylol-.alpha.-picoline hydrochloride; 3-Hydroxy-4,5-dimethylol-alpha-picoline hydrochloride; 4,5-Bis(hydroxymethyl)-2-methyl-3-pyridinol; 4,5-Bis(hydroxymethyl)-2-methylpyridin-3-ol hydrochloride; 4,5-bis(hydroxymethyl)-2-methyl-3-pyridinol hydrochloride; 4,5-bis(hydroxymethyl)-2-methylpyridine-3-ol; 4-Deoxypyridoxine 5'-phosphate; 5-Hydroxy-6-methyl-3,4-pyridinedicarbinol hydrochloride; 5-Hydroxy-6-methyl-3,4-pyridinedimethanol hydrochloride; 5-Hydroxy-6-methyl-3,4-pyridinedimethanol, hydrochloride DMDBZMV TC Vitamins DMDBZMV DT Small molecular drug DMDBZMV PC 1054 DMDBZMV MW 169.18 DMDBZMV FM C8H11NO3 DMDBZMV IC InChI=1S/C8H11NO3/c1-5-8(12)7(4-11)6(3-10)2-9-5/h2,10-12H,3-4H2,1H3 DMDBZMV CS CC1=NC=C(C(=C1O)CO)CO DMDBZMV IK LXNHXLLTXMVWPM-UHFFFAOYSA-N DMDBZMV IU 4,5-bis(hydroxymethyl)-2-methylpyridin-3-ol DMDBZMV CA CAS 65-23-6 DMDBZMV CB CHEBI:16709 DMDBZMV DE Vitamin B6 deficiency DMXJ7O8 ID DMXJ7O8 DMXJ7O8 DN Vitamin C DMXJ7O8 HS Approved DMXJ7O8 SN l-ascorbic acid; vitamin C; 50-81-7; L(+)-Ascorbic acid; Ascorbicap; Cevitamic acid; Ascoltin; Hybrin; Secorbate; Proscorbin; Lemascorb; Ascorteal; Ascorbajen; Vitascorbol; Vitamisin; Natrascorb; Citriscorb; Cescorbat; Ascorbutina; Testascorbic; Cevitamin; Cetemican; Allercorb; Vitacimin; Roscorbic; Laroscorbine; Viscorin; Redoxon; Cenetone; Cegiolan; Cebicure; Ascorvit; Viforcit; Concemin; Cevital; Cergona; Cemagyl; Cebione; Cantaxin; Ascorin; Vitacee; Vicelat; Cevimin; Cetamid; Cenolate; Celaskon; Vitacin; Adenex; Ascorb; Ascorbicab; Ascorbicin; Ascorbinsaeure; Cantan; Cebid; Cebion; Cecon; Ceglion; Celin; Cemill; Cereon; Cetebe; Cevalin; Cevatine; Cevex; Cevibid; Cevitan; Cevitex; Cewin; Ciamin; Cipca; Colascor; Cortalex; Duoscorb; Ferancee; Hicee; Magnorbin; Ribena; Scorbacid; Semidehydroascorbate; Sodascorbate; Stuartinic; Sunkist; Tolfrinic; Vitace; Xitix; Acid Ascorbic; Acide ascorbique; Acido ascorbico; Acidum ascorbicum; Acidum ascorbinicum; Antiscorbic vita min; Antiscorbic vitamin; Antiscorbutic factor; Antiscorbutic vitamin; Ascorbyl radical; Catavin C; Ce lent; Component of Cortalex; Component of Endoglobin Forte; Component of Ferancee; Davitamon C; Ferrous ascorbate; Kyselina askorbova; Kyselina askorbova [Czech]; Magnesium Ascorbicum; Monodehydroascorbic acid; Natrascorb injectable; Oral Vitamin C; Planavit C; Roscorbi c; Vicomin C; Acide ascorbique [INN-French]; Acido ascorbico [INN-Spanish]; Acidum ascorbicum [INN-Latin]; Arco-cee; Ascoltin (TN); Ascorbic Acid, Monosodium Salt; Ascorbicap (TN); C-Level; C-Long; C-Quin; C-Span; C-Vimin; Cee-Caps TD; Cee-Vite; Cee-caps td; Cetane-Caps TC; Cetane-Caps TD; Cevi-Bid; Component of E and C-Level; IDO-C; Iron(II) ascorbate; Iron-ascorbic acid complexes; L-Ascorbic acid; L-Lyxoascorbic acid; L-Xyloascorbic acid; L-ascorbic acid; Liqui-Cee; Meri-C; Sodium Ascorbate (Ascorbic Acid); Vitamin-C; Ascorbic acid [BAN:INN:JAN]; Ascorbic acid [INN:BAN:JAN]; CE-VI-Sol; Ce-Mi-Lin; Dora-C-500; L-3-Ketothreohexuronic acid lactone; L-3-ketothreohexuronic acid; L-Ascorbic acid, free radical form; Ascor-bid; Ascorbic acid (JP15/USP/INN); Ascor-BID; L-(+)-Ascorbic Acid; L-threo-Hex-2-enonic acid, gamma-lactone; L-threo-hex-1-eofuranos-3-ulose; L-threo-hex-2-enono-1,4-lactone; (2R)-2-[(1S)-1,2-Dihydroxyethyl]-4,5-dihydroxy-furan-3-one; (2R)-2-[(1S)-1,2-dihydroxyethyl]-4,5-dihydroxyfuran-3-one; (5R)-5-[(1S)-1,2-dihydroxyethyl]-3,4-dihydroxyfuran-2(5H)-one; 2-(1,2-Dihydroxyethyl)-4,5-dihydroxyfuran-3-one; 3-Keto-L-gulofuranolactone; 3-Oxo-L-gulofuranolactone; 3-Oxo-L-gulofuranolactone (enol form); [14C]ascorbic acid DMXJ7O8 TC Vitamins DMXJ7O8 DT Small molecular drug DMXJ7O8 PC 54670067 DMXJ7O8 MW 176.12 DMXJ7O8 FM C6H8O6 DMXJ7O8 IC InChI=1S/C6H8O6/c7-1-2(8)5-3(9)4(10)6(11)12-5/h2,5,7-10H,1H2/t2-,5+/m0/s1 DMXJ7O8 CS C([C@@H]([C@@H]1C(=C(C(=O)O1)O)O)O)O DMXJ7O8 IK CIWBSHSKHKDKBQ-JLAZNSOCSA-N DMXJ7O8 IU (2R)-2-[(1S)-1,2-dihydroxyethyl]-3,4-dihydroxy-2H-furan-5-one DMXJ7O8 CA CAS 50-81-7 DMXJ7O8 CB CHEBI:29073 DMXJ7O8 DE Vitamin C deficiency; Urinary tract infection DMWQUC9 ID DMWQUC9 DMWQUC9 DN Vitamin D DMWQUC9 HS Approved DMWQUC9 SN Vigantol; Vigorsan; Vitamin D3; Vitinc Dan-Dee-3; cholecalciferol; vitamin d-3; (+)-Vitamin D3; Activated 7-dehydrocholesterol; Arachitol; Calciol; Cholecalciferol, D3; Cholecalciferolum; Colecalciferol; Colecalciferolo [DCIT]; Colecalciferolum; Colecalciferolum [INN-Latin]; Colecalcipherol; D3-Vicotrat; D3-Vigantol; Delsterol; Deparal; Duphafral D3 1000; Ebivit; FeraCol; NEO Dohyfral D3; Oleovitamin D3; Quintox; Rampage; Ricketon; Trivitan; VITAMIN D; Vi-De3; Vi-de-3-hydrosol; 1406-16-2; 67-97-0; 7-Dehydrocholestrol, activated;; MFCD00078131 DMWQUC9 PC 5280795 DMWQUC9 MW 384.6 DMWQUC9 FM C27H44O DMWQUC9 IC QYSXJUFSXHHAJI-YRZJJWOYSA-N DMWQUC9 CS CC(C)CCCC(C)C1CCC2C1(CCCC2=CC=C3CC(CCC3=C)O)C DMWQUC9 IK 1S/C27H44O/c1-19(2)8-6-9-21(4)25-15-16-26-22(10-7-17-27(25,26)5)12-13-23-18-24(28)14-11-20(23)3/h12-13,19,21,24-26,28H,3,6-11,14-18H2,1-2,4-5H3/b22-12+,23-13-/t21-,24+,25-,26+,27-/m1/s1 DMWQUC9 IU (1S,3Z)-3-[(2E)-2-[(1R,3aS,7aR)-7a-methyl-1-[(2R)-6-methylheptan-2-yl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol DMWQUC9 CA CAS 67-97-0 DMWQUC9 CB CHEBI:28940 DMWQUC9 DE Hyperparathyroidism DMZC90K ID DMZC90K DMZC90K DN Vitamin E DMZC90K HS Approved DMZC90K SN Covi-ox; VITAMIN E; E-Vimin; Syntopherol; Profecundin; Evitaminum; Viprimol; Vascuals; Etamican; Viteolin; Tokopharm; Vitayonon; Epsilan; Emipherol; Denamone; Almefrol; Verrol; Ilitia; Etavit; 77171-98-3; Evion; Esorb; alpha-Tokoferol; alpha Tocopherol; Vitaplex E; Vitamin E alpha; Eprolin S; Viterra E; E Prolin; Spavit E; Vita E; Endo E; Med-E; Lan-E; Antisterility vitamin; alpha-Tocopherol acid; Tenox GT 1; (R)-2,5,7,8-tetramethyl-2-((4S,8S)-4,8,12-trimethyltridecyl)chroman-6-ol; Rhenogran Ronotec 50; Vi-E; Covitol F 1000; E 307 (tocopherol) DMZC90K DT Small molecular drug DMZC90K PC 14985 DMZC90K MW 430.7 DMZC90K FM C29H50O2 DMZC90K IC InChI=1S/C29H50O2/c1-20(2)12-9-13-21(3)14-10-15-22(4)16-11-18-29(8)19-17-26-25(7)27(30)23(5)24(6)28(26)31-29/h20-22,30H,9-19H2,1-8H3/t21-,22-,29-/m1/s1 DMZC90K CS CC1=C(C2=C(CC[C@@](O2)(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)C(=C1O)C)C DMZC90K IK GVJHHUAWPYXKBD-IEOSBIPESA-N DMZC90K IU (2R)-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-ol DMZC90K CA CAS 59-02-9 DMZC90K CB CHEBI:18145 DMZC90K DE Cardiovascular disease DMWIJTN ID DMWIJTN DMWIJTN DN Voclosporin DMWIJTN HS Approved DMWIJTN SN Luveniq; ISAtx-247; ISA-247; UNII-2PN063X6B1; ISATX247; 515814-01-4; ISA247; 2PN063X6B1; ISA 247; trans-ISA-247; LX211; Voclosporin (USAN/INN); Voclosporin [USAN:INN]; Voclera; 3odi; LX-211; LX-214; ISA247, Luveniq; AC1OCFHS; R-1524; SCHEMBL12632344; CHEBI:135957; (E)-ISA-247; DB11693; 515814-00-3; HY-106638; CS-0026210; D09033; Cyclosporin A, 6-((2S,3R,4R)-3-hydroxy-4-methyl-2-(methylamino)-6,8-nonadienoic acid)-; 368455-04-3; Luveniq; Voclosporin [USAN]; R 1524; Trans-ISA 247; Trans-ISA-247; TrkA-IgG DMWIJTN CP Isotechnika DMWIJTN DT Small molecular drug DMWIJTN PC 6918486 DMWIJTN MW 1214.6 DMWIJTN FM C63H111N11O12 DMWIJTN IC InChI=1S/C63H111N11O12/c1-25-27-28-29-41(15)53(76)52-57(80)66-44(26-2)59(82)68(18)34-49(75)69(19)45(30-35(3)4)56(79)67-50(39(11)12)62(85)70(20)46(31-36(5)6)55(78)64-42(16)54(77)65-43(17)58(81)71(21)47(32-37(7)8)60(83)72(22)48(33-38(9)10)61(84)73(23)51(40(13)14)63(86)74(52)24/h25,27-28,35-48,50-53,76H,1,26,29-34H2,2-24H3,(H,64,78)(H,65,77)(H,66,80)(H,67,79)/b28-27+/t41-,42+,43-,44+,45+,46+,47+,48+,50+,51+,52+,53-/m1/s1 DMWIJTN CS CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C=C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C DMWIJTN IK BICRTLVBTLFLRD-PTWUADNWSA-N DMWIJTN IU (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(1R,2R,4E)-1-hydroxy-2-methylhepta-4,6-dienyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone DMWIJTN CA CAS 515814-00-3 DMWIJTN CB CHEBI:135957 DMWIJTN DE Kidney disease; Psoriasis vulgaris; Lupus nephritis DMUBP9O ID DMUBP9O DMUBP9O DN Voglibose DMUBP9O HS Approved DMUBP9O SN Basen; Glustat; Vocarb; Basen OD; A-71100; AO-128; Basen (TN); Basen (Takeda Chemical Industries); Volix (Ranbaxy labs);Voglibose (JP15/USAN/INN); N-(1,3-Dihydroxyprop-2-yl)valiolamine; (1S,2S,3R,4S,5S)-5-(1,3-dihydroxypropan-2-ylamino)-1-(hydroxymethyl)cyclohexane-1,2,3,4-tetrol; (1S,2S,3R,4S,5S)-5-{[2-hydroxy-1-(hydroxymethyl)ethyl]amino}-1-(hydroxymethyl)cyclohexane-1,2,3,4-tetrol; 3,4-Dideoxy-4-{[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-2-D-epi-inositol DMUBP9O CP Takeda DMUBP9O TC Hypoglycemic Agents DMUBP9O DT Small molecular drug DMUBP9O PC 444020 DMUBP9O MW 267.28 DMUBP9O FM C10H21NO7 DMUBP9O IC InChI=1S/C10H21NO7/c12-2-5(3-13)11-6-1-10(18,4-14)9(17)8(16)7(6)15/h5-9,11-18H,1-4H2/t6-,7-,8+,9-,10-/m0/s1 DMUBP9O CS C1[C@@H]([C@@H]([C@H]([C@@H]([C@]1(CO)O)O)O)O)NC(CO)CO DMUBP9O IK FZNCGRZWXLXZSZ-CIQUZCHMSA-N DMUBP9O IU (1S,2S,3R,4S,5S)-5-(1,3-dihydroxypropan-2-ylamino)-1-(hydroxymethyl)cyclohexane-1,2,3,4-tetrol DMUBP9O CA CAS 83480-29-9 DMUBP9O CB CHEBI:32300 DMUBP9O DE Diabetic complication DM1YEPS ID DM1YEPS DM1YEPS DN Volanesorsen DM1YEPS HS Approved DM1YEPS CP Akcea Therapeutics Cambridge, MA, Ionis Pharmaceuticals Carlsbad, CA DM1YEPS DT Antisense oligonucleotide DM1YEPS PC 121494123 DM1YEPS MW 7165 DM1YEPS FM C230H320N63O125P19S19 DM1YEPS IC InChI=1S/C230H320N63O125P19S19/c1-98-55-274(217(308)254-178(98)231)142-45-112(400-419(322,438)361-70-124-113(46-143(381-124)275-56-99(2)179(232)255-218(275)309)401-423(326,442)367-76-130-119(52-149(387-130)288-92-248-152-183(236)242-89-245-186(152)288)407-427(330,446)369-78-132-121(54-151(389-132)290-94-252-156-190(290)260-215(240)263-202(156)306)408-425(328,444)365-72-125-114(47-144(382-125)276-57-100(3)180(233)256-219(276)310)406-428(331,447)372-81-134-160(171(354-38-28-344-18)206(393-134)283-64-107(10)196(300)269-226(283)317)412-432(335,451)375-84-137-163(173(356-40-30-346-20)208(395-137)285-66-109(12)198(302)271-228(285)319)415-435(338,454)377-86-139-165(175(358-42-32-348-22)210(397-139)287-68-111(14)200(304)273-230(287)321)416-436(339,455)379-87-140-166(176(359-43-33-349-23)212(398-140)292-96-250-154-185(238)244-91-247-188(154)292)417-430(333,449)371-80-133-158(295)168(351-35-25-341-15)204(391-133)282-63-106(9)195(299)268-225(282)316)123(380-142)71-362-421(324,440)403-117-50-147(279-61-104(7)193(297)266-223(279)314)386-128(117)75-366-426(329,445)409-120-53-150(289-93-251-155-189(289)259-214(239)262-201(155)305)388-131(120)77-368-424(327,443)405-118-51-148(280-62-105(8)194(298)267-224(280)315)385-127(118)74-364-422(325,441)404-116-49-146(278-60-103(6)192(296)265-222(278)313)384-126(116)73-363-420(323,439)402-115-48-145(277-58-101(4)181(234)257-220(277)311)383-129(115)79-370-429(332,448)411-162-136(394-207(172(162)355-39-29-345-19)284-65-108(11)197(301)270-227(284)318)83-374-434(337,453)414-164-138(396-209(174(164)357-41-31-347-21)286-67-110(13)199(303)272-229(286)320)85-376-433(336,452)413-161-135(392-205(170(161)353-37-27-343-17)281-59-102(5)182(235)258-221(281)312)82-378-437(340,456)418-167-141(399-213(177(167)360-44-34-350-24)293-97-253-157-191(293)261-216(241)264-203(157)307)88-373-431(334,450)410-159-122(69-294)390-211(169(159)352-36-26-342-16)291-95-249-153-184(237)243-90-246-187(153)291/h55-68,89-97,112-151,158-177,204-213,294-295H,25-54,69-88H2,1-24H3,(H,322,438)(H,323,439)(H,324,440)(H,325,441)(H,326,442)(H,327,443)(H,328,444)(H,329,445)(H,330,446)(H,331,447)(H,332,448)(H,333,449)(H,334,450)(H,335,451)(H,336,452)(H,337,453)(H,338,454)(H,339,455)(H,340,456)(H2,231,254,308)(H2,232,255,309)(H2,233,256,310)(H2,234,257,311)(H2,235,258,312)(H2,236,242,245)(H2,237,243,246)(H2,238,244,247)(H,265,296,313)(H,266,297,314)(H,267,298,315)(H,268,299,316)(H,269,300,317)(H,270,301,318)(H,271,302,319)(H,272,303,320)(H,273,304,321)(H3,239,259,262,305)(H3,240,260,263,306)(H3,241,261,264,307)/t112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122+,123+,124+,125+,126+,127+,128+,129+,130+,131+,132+,133+,134+,135+,136+,137+,138+,139+,140+,141+,142+,143+,144+,145+,146+,147+,148+,149+,150+,151+,158+,159+,160+,161+,162+,163+,164+,165+,166+,167+,168+,169+,170+,171+,172+,173+,174+,175+,176+,177+,204+,205+,206+,207+,208+,209+,210+,211+,212+,213+,419?,420?,421?,422?,423?,424?,425?,426?,427?,428?,429?,430?,431?,432?,433?,434?,435?,436?,437?/m0/s1 DM1YEPS CS CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)COP(=S)(O)O[C@H]3C[C@@H](O[C@@H]3COP(=S)(O)O[C@H]4C[C@@H](O[C@@H]4COP(=S)(O)O[C@@H]5[C@H](O[C@H]([C@@H]5OCCOC)N6C=C(C(=O)NC6=O)C)COP(=S)(O)O[C@@H]7[C@H](O[C@H]([C@@H]7OCCOC)N8C=C(C(=O)NC8=O)C)COP(=S)(O)O[C@@H]9[C@H](O[C@H]([C@@H]9OCCOC)N1C=C(C(=NC1=O)N)C)COP(=S)(O)O[C@@H]1[C@H](O[C@H]([C@@H]1OCCOC)N1C=NC2=C1N=C(NC2=O)N)COP(=S)(O)O[C@@H]1[C@H](O[C@H]([C@@H]1OCCOC)N1C=NC2=C(N=CN=C21)N)CO)N1C=C(C(=NC1=O)N)C)N1C=C(C(=O)NC1=O)C)OP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N1C=NC2=C1N=C(NC2=O)N)OP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N1C=C(C(=O)NC1=O)C)OP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N1C=C(C(=NC1=O)N)C)OP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N1C=C(C(=NC1=O)N)C)OP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N1C=NC2=C(N=CN=C21)N)OP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N1C=NC2=C1N=C(NC2=O)N)OP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N1C=C(C(=NC1=O)N)C)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=C(C(=O)NC1=O)C)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=C(C(=O)NC1=O)C)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=C(C(=O)NC1=O)C)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=NC2=C(N=CN=C21)N)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=C(C(=O)NC1=O)C)OCCOC)O DM1YEPS IK IJUQCWMZCMFFJP-GQSLRNSLSA-N DM1YEPS IU 1-[(2R,4S,5R)-4-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[(2R,3S,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[(2R,3R,4R,5R)-3-[[(2R,3R,4R,5R)-3-[[(2R,3R,4R,5R)-3-[[(2R,3R,4R,5R)-5-(6-aminopurin-9-yl)-3-[hydroxy-[[(2R,3R,4R,5R)-3-hydroxy-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy]phosphinothioyl]oxy-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(2-amino-6-oxo-1H-purin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(2-amino-6-oxo-1H-purin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-2-[[[(2R,3R,4R,5R)-2-[[[(2R,3R,4R,5R)-2-[[[(2R,3R,4R,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-2-[[[(2R,3R,4R,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[(2R,3R,4R,5R)-5-(6-aminopurin-9-yl)-2-(hydroxymethyl)-4-(2-methoxyethoxy)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-4-(2-methoxyethoxy)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-4-(2-methoxyethoxy)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]oxolan-2-yl]-5-methylpyrimidine-2,4-dione DM1YEPS DE Familial chylomicronemia syndrome; Hyperlipoproteinemia; Hypertriglyceridemia DMO6315 ID DMO6315 DMO6315 DN Vonoprazan DMO6315 HS Approved DMO6315 SN TAK-438 DMO6315 CP Takeda DMO6315 DT Small molecular drug DMO6315 PC 45375887 DMO6315 MW 461.5 DMO6315 FM C21H20FN3O6S DMO6315 IC InChI=1S/C17H16FN3O2S.C4H4O4/c1-19-10-13-9-17(15-6-2-3-7-16(15)18)21(12-13)24(22,23)14-5-4-8-20-11-14;5-3(6)1-2-4(7)8/h2-9,11-12,19H,10H2,1H3;1-2H,(H,5,6)(H,7,8)/b;2-1+ DMO6315 CS CNCC1=CN(C(=C1)C2=CC=CC=C2F)S(=O)(=O)C3=CN=CC=C3.C(=C/C(=O)O)\\C(=O)O DMO6315 IK ROGSHYHKHPCCJW-WLHGVMLRSA-N DMO6315 IU (E)-but-2-enedioic acid;1-[5-(2-fluorophenyl)-1-pyridin-3-ylsulfonylpyrrol-3-yl]-N-methylmethanamine DMO6315 CA CAS 881681-01-2 DMO6315 DE Gastroesophageal reflux disease; Helicobacter infection DMI783H ID DMI783H DMI783H DN Vonvendi DMI783H HS Approved DMI783H SN Vonicog alfa DMI783H CP Vonvendi DMI783H DT Recombinant protein DMI783H DE Von willebrand disease DMA16BR ID DMA16BR DMA16BR DN Vorapaxar DMA16BR HS Approved DMA16BR SN Vorapaxar; 618385-01-6; Zontivity; SCH-530348; SCH530348; UNII-ZCE93644N2; CHEMBL493982; CHEBI:82702; ZCE93644N2; MK-5348; ethyl ((1R,3aR,4aR,6R,8aR,9S,9aS)-9-((E)-2-(5-(3-fluorophenyl)pyridin-2-yl)vinyl)-1-methyl-3-oxododecahydronaphtho[2,3-c]furan-6-yl)carbamate; Ethyl [(1r,3ar,4ar,6r,8ar,9s,9as)-9-{(E)-2-[5-(3-Fluorophenyl)pyridin-2-Yl]ethenyl}-1-Methyl-3-Oxododecahydronaphtho[2,3-C]furan-6-Yl]carbamate; Vorapaxar [USAN:INN]; Carbamic acid, [(1R,3aR,4aR,6R,8aR,9S,9aS)-9-[(1E)-2-[5-(3-fluorophenyl)-2- pyridinyl]etheny DMA16BR CP Schering-Plough DMA16BR DT Small molecular drug DMA16BR PC 10077130 DMA16BR MW 492.6 DMA16BR FM C29H33FN2O4 DMA16BR IC InChI=1S/C29H33FN2O4/c1-3-35-29(34)32-23-10-11-24-20(14-23)15-26-27(17(2)36-28(26)33)25(24)12-9-22-8-7-19(16-31-22)18-5-4-6-21(30)13-18/h4-9,12-13,16-17,20,23-27H,3,10-11,14-15H2,1-2H3,(H,32,34)/b12-9+/t17-,20+,23-,24-,25+,26-,27+/m1/s1 DMA16BR CS CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@@H]3[C@H]([C@H]2/C=C/C4=NC=C(C=C4)C5=CC(=CC=C5)F)[C@H](OC3=O)C DMA16BR IK ZBGXUVOIWDMMJE-QHNZEKIYSA-N DMA16BR IU ethyl N-[(1R,3aR,4aR,6R,8aR,9S,9aS)-9-[(E)-2-[5-(3-fluorophenyl)pyridin-2-yl]ethenyl]-1-methyl-3-oxo-3a,4,4a,5,6,7,8,8a,9,9a-decahydro-1H-benzo[f][2]benzofuran-6-yl]carbamate DMA16BR CA CAS 618385-01-6 DMA16BR CB CHEBI:82702 DMA16BR DE Myocardial infarction DMAOL2S ID DMAOL2S DMAOL2S DN Voriconazole DMAOL2S HS Approved DMAOL2S SN VCZ; Vfend; Pfizer brand of voriconazole; UK 109496; Voriconazole in combination with MGCD290; DRG-0301; UK 109,496; UK-109496; VFEND (TN); Vfend (TN); Vfend, Voriconazole; UK-109,496; Voriconazole [USAN:INN:BAN]; Voriconazole (JAN/USAN/INN); (2R,3S)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1,2,4-triazol-1-yl)butan-2-ol; (2R,3S)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol; (R-(R*,S*))-alpha-(2,4-difluorophenyl)-5-fluoro-beta-methyl-alpha-(1H-1,2,4-triazol-1-ylmethyl)-4-pyrimidineethanol; (alphaR,betaS)-alpha-(2,4-Difluorophenyl)-5-fluoro-beta-methyl-alpha-(1H-1,2,4-triazol-1-ylmethyl)-4-pyrimidineethanol; (alphaR,betaS)-alpha-(2,4-difluorophenyl)-5-fluoro-beta-methyl-alpha(1H-1,2,4-triazol-1-ylmethyl)-4-pyrimidineethanol; VRC DMAOL2S CP Pfizer DMAOL2S TC Antifungal Agents DMAOL2S DT Small molecular drug DMAOL2S PC 71616 DMAOL2S MW 349.31 DMAOL2S FM C16H14F3N5O DMAOL2S IC InChI=1S/C16H14F3N5O/c1-10(15-14(19)5-20-7-22-15)16(25,6-24-9-21-8-23-24)12-3-2-11(17)4-13(12)18/h2-5,7-10,25H,6H2,1H3/t10-,16+/m0/s1 DMAOL2S CS C[C@@H](C1=NC=NC=C1F)[C@](CN2C=NC=N2)(C3=C(C=C(C=C3)F)F)O DMAOL2S IK BCEHBSKCWLPMDN-MGPLVRAMSA-N DMAOL2S IU (2R,3S)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1,2,4-triazol-1-yl)butan-2-ol DMAOL2S CA CAS 188416-29-7 DMAOL2S CB CHEBI:10023 DMAOL2S DE Invasive aspergillosis DMWMPD4 ID DMWMPD4 DMWMPD4 DN Vorinostat DMWMPD4 HS Approved DMWMPD4 SN NHNPODA; SAHA; SHH; Zolinza; Merck brand of Vorinostat; OCTANEDIOIC ACID HYDROXYAMIDE PHENYLAMIDE; SAHA cpd; Suberanilohydroxamic acid; Suberoylanilide hydroxamic acid; Vorinostat MSD; Vorinostat [USAN]; M344; MK0683; SKI390; WIN64652; MK-0683; SAHA, Suberoylanilide hydroxamic acid; SW-064652; Zolinza (TN); Vorinostat (JAN/USAN); N1-hydroxy-N8-phenyloctanediamide; Zolinza, MK-0683, SAHA; N'-hydroxy-N-phenyloctanediamide; N-Hydroxy-N'-phenyl octanediamide; N-Hyrdroxy-N'-phenyloctanediamide; N-hydroxy-N'-phenyloctanediamide; N-hydroxy-N'-phenyl-octane-1,8-diotic acid diamide; Vorinostat (HDAC inhibitor) DMWMPD4 CP Merck DMWMPD4 TC Anticancer Agents DMWMPD4 DT Small molecular drug DMWMPD4 PC 5311 DMWMPD4 MW 264.32 DMWMPD4 FM C14H20N2O3 DMWMPD4 IC InChI=1S/C14H20N2O3/c17-13(15-12-8-4-3-5-9-12)10-6-1-2-7-11-14(18)16-19/h3-5,8-9,19H,1-2,6-7,10-11H2,(H,15,17)(H,16,18) DMWMPD4 CS C1=CC=C(C=C1)NC(=O)CCCCCCC(=O)NO DMWMPD4 IK WAEXFXRVDQXREF-UHFFFAOYSA-N DMWMPD4 IU N'-hydroxy-N-phenyloctanediamide DMWMPD4 CA CAS 149647-78-9 DMWMPD4 CB CHEBI:45716 DMWMPD4 DE Cutaneous T-cell lymphoma DM6F1PU ID DM6F1PU DM6F1PU DN Vortioxetine DM6F1PU HS Approved DM6F1PU SN VORTIOXETINE; 508233-74-7; 1-(2-((2,4-Dimethylphenyl)thio)phenyl)piperazine; Lu AA21004; UNII-3O2K1S3WQV; 3O2K1S3WQV; CHEBI:76016; Trintellix; 1-{2-[(2,4-dimethylphenyl)sulfanyl]phenyl}piperazine; Piperazine, 1-[2-[(2,4-dimethylphenyl)thio]phenyl]-; Brintellix (TN); 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine; 1-[2-(2,4-dimethylphenyl)sulfanylphenyl]piperazine; 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]-piperazine; CHEMBL2204360; 1-[2-[(2,4-Dimethylphenyl)thio]phenyl]piperazine; Lu-AA21004 DM6F1PU CP Lundbeck; Takeda Pharmaceuticals DM6F1PU DT Small molecular drug DM6F1PU PC 9966051 DM6F1PU MW 298.4 DM6F1PU FM C18H22N2S DM6F1PU IC InChI=1S/C18H22N2S/c1-14-7-8-17(15(2)13-14)21-18-6-4-3-5-16(18)20-11-9-19-10-12-20/h3-8,13,19H,9-12H2,1-2H3 DM6F1PU CS CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C DM6F1PU IK YQNWZWMKLDQSAC-UHFFFAOYSA-N DM6F1PU IU 1-[2-(2,4-dimethylphenyl)sulfanylphenyl]piperazine DM6F1PU CA CAS 508233-74-7 DM6F1PU CB CHEBI:76016 DM6F1PU DE Major depressive disorder; Mood disorder DMCS6M5 ID DMCS6M5 DMCS6M5 DN Voxelotor DMCS6M5 HS Approved DMCS6M5 SN Hemoglobin Modulators-1; 1446321-46-5; UNII-3ZO554A4Q8; GBT 440; 3ZO554A4Q8; 2-hydroxy-6-([2-[1-(propan-2-yl)-1H-pyrazol-5-yl]pyridin-3-yl]methoxy)benzaldehyde; 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde; 2-hydroxy-6-((2-(1-(propan-2-yl)-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde; Voxelotor [USAN]; SCHEMBL15065529; Voxelotor(GBT440, GTx011); GTX-011; GBT-440; MolPort-044-830-677; FWCVZAQENIZVMY-UHFFFAOYSA-N; AKOS030526545; ZINC145969085; CS-5317; HY-18681; DA-44587; S DMCS6M5 CP Global Blood Therapeutics South San Francisco, CA DMCS6M5 PC 71602803 DMCS6M5 MW 337.4 DMCS6M5 FM C19H19N3O3 DMCS6M5 IC InChI=1S/C19H19N3O3/c1-13(2)22-16(8-10-21-22)19-14(5-4-9-20-19)12-25-18-7-3-6-17(24)15(18)11-23/h3-11,13,24H,12H2,1-2H3 DMCS6M5 CS CC(C)N1C(=CC=N1)C2=C(C=CC=N2)COC3=CC=CC(=C3C=O)O DMCS6M5 IK FWCVZAQENIZVMY-UHFFFAOYSA-N DMCS6M5 IU 2-hydroxy-6-[[2-(2-propan-2-ylpyrazol-3-yl)pyridin-3-yl]methoxy]benzaldehyde DMCS6M5 CA CAS 1446321-46-5 DMCS6M5 DE Sickle-cell disorder DMAI83D ID DMAI83D DMAI83D DN Voxilaprevir DMAI83D HS Approved DMAI83D SN Voxilaprevir; Voxilaprevir (USAN/INN); Voxilaprevir [USAN:INN]; 0570F37359;J3.665.048F; 1535212-07-7; CS-0017027; D10899; DB12026; GS-9857; HY-19840; L9P; SCHEMBL15412621; UNII-0570F37359 DMAI83D PC 89921642 DMAI83D MW 868.9 DMAI83D FM C40H52F4N6O9S DMAI83D IC MZBLZLWXUBZHSL-FZNJKFJKSA-N DMAI83D CS CCC1C2CN(C1C(=O)NC3(CC3C(F)F)C(=O)NS(=O)(=O)C4(CC4)C)C(=O)C(NC(=O)OC5CC5CCCCC(C6=NC7=C(C=C(C=C7)OC)N=C6O2)(F)F)C(C)(C)C DMAI83D IK 1S/C40H52F4N6O9S/c1-7-22-27-19-50(28(22)32(51)48-39(18-23(39)31(41)42)35(53)49-60(55,56)38(5)14-15-38)34(52)30(37(2,3)4)47-36(54)59-26-16-20(26)10-8-9-13-40(43,44)29-33(58-27)46-25-17-21(57-6)11-12-24(25)45-29/h11-12,17,20,22-23,26-28,30-31H,7-10,13-16,18-19H2,1-6H3,(H,47,54)(H,48,51)(H,49,53)/t20-,22-,23+,26-,27+,28+,30-,39-/m1/s1 DMAI83D IU (1R,18R,20R,24S,27S,28S)-24-tert-butyl-N-[(1R,2R)-2-(difluoromethyl)-1-[(1-methylcyclopropyl)sulfonylcarbamoyl]cyclopropyl]-28-ethyl-13,13-difluoro-7-methoxy-22,25-dioxo-2,21-dioxa-4,11,23,26-tetrazapentacyclo[24.2.1.03,12.05,10.018,20]nonacosa-3,5(10),6,8,11-pentaene-27-carboxamide DMAI83D CA CAS 1535212-07-7 DMAI83D DE Viral hepatitis DMIO4V5 ID DMIO4V5 DMIO4V5 DN VRX496 DMIO4V5 HS Approved DMIO4V5 SN Nelfinavir; nelfinavir; 159989-64-7; Viracept; Nelfinavir [INN:BAN]; AG1343; UNII-HO3OGH5D7I; AG-1343; C32H45N3O4S; NELFINAVIR MESYLATE AG1343; Viracept (TN); HO3OGH5D7I; CHEBI:7496; AG 1343; NLF; 1UN; 2-[2-HYDROXY-3-(3-HYDROXY-2-METHYL-BENZOYLAMINO)-4-PHENYL SULFANYL-BUTYL]-DECAHYDRO-ISOQUINOLINE-3-CARBOXYLIC ACID TERT-BUTYLAMIDE; (3S-(2(2S*,3S*),3alpha,4abeta,8abeta))-N-(1,1-Dimethylethyl)decahydro-2-(2-hydroxy-3-((3-hydroxy-2-methylbenzoyl)amino)-4-(phenylthio)butyl)-3-isoquinolinecarboxamide; NFV; NFV; Nelfinavir Monomethane Sulfonate; AG1346; Nelfinavir (INN); Nelfinavir [BAN:INN]; AG1343 (*Mesylate salt*); Viracept (TM)(*Mesylate salt*); Met-SDF-1beta & Nelfinavir; Met-Stromal Cell-derived Factor-1beta (Human) & Nelfinavir; (3S,4aS,8aS)-N-tert-butyl-2-[(2R,3R)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-phenylsulfanylbutyl]-3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinoline-3-carboxamide DMIO4V5 CP VIRxSYS Corporation DMIO4V5 TC Antisense DMIO4V5 DT Antisense drug DMIO4V5 DE Acquired immune deficiency syndrome; Coronavirus infection DMJYCVW ID DMJYCVW DMJYCVW DN Warfarin DMJYCVW HS Approved DMJYCVW SN Brumolin; Choice; Coumadin; Coumafen; Coumafene; Coumaphen; Coumaphene; Coumarins; Coumefene; Dethmor; Dethnel; Kumader; Kumadu; Kumatox; Kypfarin; Maveran; Panwarfin; Prothromadin; RAX; Ratorex; Ratoxin; Ratron; Rattentraenke; Rattunal; Rodafarin; Rosex; Sofarin; Solfarin; Warfarat; Warfarina; Warfarine; Warfarinum; Warficide; Zoocoumarin; Arab Rat Death; Arab rat deth; Coumafene [French]; Dicusat E; Eastern states duocide; Fasco fascrat powder; Maag Rattentod Cum; Mouse pak; Ratron G; Rattenstreupulver Neu Schacht; Rattenstreupulver new schacht; Rodafarin C; Rodex blox; Sorexa plus; Temus W; Twin light rat away; Vampirinip II; Vampirinip iii; Warfarin Q; Warfarin plus; Warfarin plus [discontinued]; Zoocoumarin [Netherlands and USSR]; Zoocoumarin [Russian]; CBKinase1_000192; CBKinase1_012592; Latka 42; Latka 42 [Czech]; PS104_SUPELCO; WARF compound 42; Warf 10; Warf 42; Athrombine-K; CO-Rax; Choice (TN); Coumadin (TN); D-Con; Frass-Ratron; Jantoven (TN); Liqua-tox; Mar-Frin; Marevan (TN); Place-pax; Rac-Warfarin; Rat & mice bait; Rat-Gard; Rat-Kill; Rat-Mix; Rat-Ola; Rat-Trol; Ratten-Koederrohr; Ro-Deth; Rough & ready mouse mix; Tox-hid; Waran (TN); Warfarin (INN); Warfarin (and salts of); Warfarin [BSI:ISO]; Warfarin [INN:BAN]; Warfarin(R); Warfarina [INN-Spanish]; Warfarine [INN-French]; Warfarine [ISO-French]; Warfarinum [INN-Latin]; Cov-R-Tox; Martin's mar-frin; Rat-B-gon; Rat-a-way; Rats-no-more; Spray-trol brand roden-trol; Rat-o-cide #2; Warfarin titrated to an INR of 2.5-3.0; W.A.R.F. 42; (-)-Warfarin; (S)-Warfarin; 200 coumarin DMJYCVW CP Pharmaceutical Research Assoc Inc DMJYCVW TC Anticoagulants DMJYCVW DT Small molecular drug DMJYCVW PC 54678486 DMJYCVW MW 308.3 DMJYCVW FM C19H16O4 DMJYCVW IC InChI=1S/C19H16O4/c1-12(20)11-15(13-7-3-2-4-8-13)17-18(21)14-9-5-6-10-16(14)23-19(17)22/h2-10,15,21H,11H2,1H3 DMJYCVW CS CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O DMJYCVW IK PJVWKTKQMONHTI-UHFFFAOYSA-N DMJYCVW IU 4-hydroxy-3-(3-oxo-1-phenylbutyl)chromen-2-one DMJYCVW CA CAS 81-81-2 DMJYCVW CB CHEBI:87732 DMJYCVW DE Atrial fibrillation; Thrombosis DMLHOA0 ID DMLHOA0 DMLHOA0 DN Xatral DMLHOA0 HS Approved DMLHOA0 SN Alfetim; Alfoten; Urion; Uroxatral; Alfuzosin HCl; Alfuzosin Hydrochloride; Alfuzosin hydrochloride [USAN]; Xatral OD; Xatral Retard; Xatral SR; Xatral XL; SL 77 499-10; SL 77499-10; SL-7749910; Uroxatral, Alfuzosin hydrochloride; Alfuzosin hydrochloride (JAN/USAN); SL-77499-10; SL-77.0499-10; N-[3-[4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino]propyl]tetrahydro-2-furancarboxamide hydrochloride; N-[3-[(4-amino-6,7-dimethoxyquinazolin-2-yl)-methylamino]propyl]oxolane-2-carboxamide hydrochloride; N-{3-[(4-amino-6,7-dimethoxychinazolin-2-yl)(methyl)amino]propyl}tetrahydrofuran-2-carboxamidhydrochlorid; (+-)-N-(3-((4-Amino-6,7-dimethoxy-2-quinazolinyl)methylamino)propyl)tetrahydro-2-furamide monohydrochloride DMLHOA0 CP Sanofi-Aventis DMLHOA0 DT Small molecular drug DMLHOA0 PC 71764 DMLHOA0 MW 425.9 DMLHOA0 FM C19H28ClN5O4 DMLHOA0 IC InChI=1S/C19H27N5O4.ClH/c1-24(8-5-7-21-18(25)14-6-4-9-28-14)19-22-13-11-16(27-3)15(26-2)10-12(13)17(20)23-19;/h10-11,14H,4-9H2,1-3H3,(H,21,25)(H2,20,22,23);1H DMLHOA0 CS CN(CCCNC(=O)C1CCCO1)C2=NC3=CC(=C(C=C3C(=N2)N)OC)OC.Cl DMLHOA0 IK YTNKWDJILNVLGX-UHFFFAOYSA-N DMLHOA0 IU N-[3-[(4-amino-6,7-dimethoxyquinazolin-2-yl)-methylamino]propyl]oxolane-2-carboxamide;hydrochloride DMLHOA0 CA CAS 81403-68-1 DMLHOA0 CB CHEBI:32286 DMLHOA0 DE Benign prostatic hyperplasia DMU8ANS ID DMU8ANS DMU8ANS DN Ximelegatran DMU8ANS HS Approved DMU8ANS SN Cyclohexanecarboxamide, 4-[(1R)-1-aminoethyl]-N-4-pyridinyl-, trans-; y-27632; 146986-50-7; Y-27632 dihydrochloride; Y27632; UNII-0X370ROP6H; Y 27632; cyclohexanecarboxamide, 4-[(1R)-1-aminoethyl]-N-4-pyridinyl-, trans-; 0X370ROP6H; CHEBI:75393; 4-[(1R)-1-aminoethyl]-N-(pyridin-4-yl)cyclohexane-1-carboxamide; (R)-TRANS-4-(1-AMINOETHYL)-N-(4-PYRIDYL) CYCLOHEXANECARBOXAMIDE; 4-[(1R)-1-aminoethyl]-N-(4-pyridyl)cyclohexanecarboxamide; 4-[(1R)-1-aminoethyl]-N-pyridin-4-ylcyclohexane-1-carboxamide; (R)-(+)-trans-N-(4-pyridyl)-4-(1-aminoethyl)-cyclohexanecarboxamide; Y-27632 DMU8ANS CP AstraZeneca DMU8ANS DT Small molecular drug DMU8ANS PC 448042 DMU8ANS MW 247.34 DMU8ANS FM C14H21N3O DMU8ANS IC InChI=1S/C14H21N3O/c1-10(15)11-2-4-12(5-3-11)14(18)17-13-6-8-16-9-7-13/h6-12H,2-5,15H2,1H3,(H,16,17,18)/t10-,11?,12?/m1/s1 DMU8ANS CS C[C@H](C1CCC(CC1)C(=O)NC2=CC=NC=C2)N DMU8ANS IK IYOZTVGMEWJPKR-VOMCLLRMSA-N DMU8ANS IU 4-[(1R)-1-aminoethyl]-N-pyridin-4-ylcyclohexane-1-carboxamide DMU8ANS CA CAS 146986-50-7 DMU8ANS CB CHEBI:75393 DMU8ANS DE Myocardial infarction; Asthma DMAR467 ID DMAR467 DMAR467 DN Xylose DMAR467 HS Approved DMAR467 SN D-Xylose; D-Xylopyranose; Xyloside; D-xylopentose; (3R,4S,5R)-oxane-2,3,4,5-tetrol; 7261-26-9; CHEBI:53455; Xylopyranoside; D-Xylopyranoside; Xylomed; D-Xyl; 10257-31-5; (3R,4S,5R)-tetrahydro-2H-pyran-2,3,4,5-tetrol; (3R,4S,5R)-Tetrahydro-2H-pyran-2,3,4,5-tetraol; D-(+)-Xylose, > Xyl; Xylose (USP); Xylo-Pfan (TN); DSSTox_CID_3745; Epitope ID:114701; AC1L35YW; DSSTox_RID_77180; SCHEMBL39891; DSSTox_GSID_23745; MLS001361339; cid_135191; CHEMBL502135; DTXSID0023745; CTK0H1735; BDBM16234; MolPort-003-934-029; D-xylose DMAR467 DT Small molecular drug DMAR467 PC 135191 DMAR467 MW 150.13 DMAR467 FM C5H10O5 DMAR467 IC InChI=1S/C5H10O5/c6-2-1-10-5(9)4(8)3(2)7/h2-9H,1H2/t2-,3+,4-,5?/m1/s1 DMAR467 CS C1[C@H]([C@@H]([C@H](C(O1)O)O)O)O DMAR467 IK SRBFZHDQGSBBOR-IOVATXLUSA-N DMAR467 IU (3R,4S,5R)-oxane-2,3,4,5-tetrol DMAR467 CA CAS 10257-31-5 DMAR467 CB CHEBI:53455 DMAR467 DE Gastrointestinal disease DMDPM7R ID DMDPM7R DMDPM7R DN Y-25130 DMDPM7R HS Approved DMDPM7R SN Azasetron; Nazasetron; Azasetron [INN]; C17H20ClN3O3; 123039-99-6; WUKZPHOXUVCQOR-UHFFFAOYSA-N; Azasetron (INN); 6-Chloro-4-methyl-3-oxo-N-(quinuclidin-3-yl)-3,4-dihydro-2H-benzo[b][1,4]oxazine-8-carboxamide; NCGC00024563-02; DSSTox_RID_81029; DSSTox_CID_25651; DSSTox_GSID_45651; (- )-6-Chloro-3,4-dihydro-4-methyl-3-oxo-N-3-quinuclidinyl-2H-1,4-benzoxazine-8-carboxamide; N-(1-azabicyclo[2.2.2]octan-3-yl)-6-chloro-4-methyl-3-oxo-1,4-benzoxazine-8-carboxamide DMDPM7R DT Small molecular drug DMDPM7R PC 2264 DMDPM7R MW 349.8 DMDPM7R FM C17H20ClN3O3 DMDPM7R IC InChI=1S/C17H20ClN3O3/c1-20-14-7-11(18)6-12(16(14)24-9-15(20)22)17(23)19-13-8-21-4-2-10(13)3-5-21/h6-7,10,13H,2-5,8-9H2,1H3,(H,19,23) DMDPM7R CS CN1C(=O)COC2=C(C=C(C=C21)Cl)C(=O)NC3CN4CCC3CC4 DMDPM7R IK WUKZPHOXUVCQOR-UHFFFAOYSA-N DMDPM7R IU N-(1-azabicyclo[2.2.2]octan-3-yl)-6-chloro-4-methyl-3-oxo-1,4-benzoxazine-8-carboxamide DMDPM7R CA CAS 123040-69-7 DMDPM7R CB CHEBI:91712 DMDPM7R DE Nausea and vomiting DMNZCI1 ID DMNZCI1 DMNZCI1 DN YM443 DMNZCI1 HS Approved DMNZCI1 SN Acofide; Acotiamide DMNZCI1 CP Astellas DMNZCI1 DT Small molecular drug DMNZCI1 PC 6918406 DMNZCI1 MW 541.1 DMNZCI1 FM C21H37ClN4O8S DMNZCI1 IC InChI=1S/C21H30N4O5S.ClH.3H2O/c1-12(2)25(13(3)4)8-7-22-20(28)15-11-31-21(23-15)24-19(27)14-9-17(29-5)18(30-6)10-16(14)26;;;;/h9-13,26H,7-8H2,1-6H3,(H,22,28)(H,23,24,27);1H;3*1H2 DMNZCI1 CS CC(C)N(CCNC(=O)C1=CSC(=N1)NC(=O)C2=CC(=C(C=C2O)OC)OC)C(C)C.O.O.O.Cl DMNZCI1 IK NPTDXIXCQCFGKC-UHFFFAOYSA-N DMNZCI1 IU N-[2-[di(propan-2-yl)amino]ethyl]-2-[(2-hydroxy-4,5-dimethoxybenzoyl)amino]-1,3-thiazole-4-carboxamide;trihydrate;hydrochloride DMNZCI1 CA CAS 773092-05-0 DMNZCI1 DE Functional dyspepsia DMMP3Y2 ID DMMP3Y2 DMMP3Y2 DN Yn-968D1 DMMP3Y2 HS Approved DMMP3Y2 SN Apatinib; Apatinib mesylate; VEGF receptor inhibitor (cancer), Advenchen; VEGFR2 receptor inhibitor (cancer), LSK/ Jiangsu Henrui/ Bukwang DMMP3Y2 CP Advenchen Laboratories LLC DMMP3Y2 DT Small molecular drug DMMP3Y2 PC 45139106 DMMP3Y2 MW 493.6 DMMP3Y2 FM C25H27N5O4S DMMP3Y2 IC InChI=1S/C24H23N5O.CH4O3S/c25-17-24(11-1-2-12-24)19-5-7-20(8-6-19)29-23(30)21-4-3-13-27-22(21)28-16-18-9-14-26-15-10-18;1-5(2,3)4/h3-10,13-15H,1-2,11-12,16H2,(H,27,28)(H,29,30);1H3,(H,2,3,4) DMMP3Y2 CS CS(=O)(=O)O.C1CCC(C1)(C#N)C2=CC=C(C=C2)NC(=O)C3=C(N=CC=C3)NCC4=CC=NC=C4 DMMP3Y2 IK FYJROXRIVQPKRY-UHFFFAOYSA-N DMMP3Y2 IU N-[4-(1-cyanocyclopentyl)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide;methanesulfonic acid DMMP3Y2 CA CAS 1218779-75-9 DMMP3Y2 DE Breast cancer DMJCP1Y ID DMJCP1Y DMJCP1Y DN Yohimbine DMJCP1Y HS Approved DMJCP1Y SN APHRODINE; Actibine; Aphrodyne; Aphrosol; Corynine; Johimbin; Quebrachin; Quebrachine; Thybine; Yocon; Yohimar; Yohimbin; Yohimex; Yoman; Yovital; Dayto himbin; Yohimbic acid methyl ester; Baron-X; Trans-Quinolizidine yohimbine; Yohimbine (DCF); Methyl 17alpha-hydroxyyohimban-16alpha-carboxylate; Yohimbol-16alpha-carboxylic acid, methyl ester (6CI); Benz[g]indolo[2,3-a]quinolizine, yohimban-16-carboxylic acid deriv.; Methyl (16alpha,17alpha)-17-hydroxyyohimban-16-carboxylate; Yohimban-16alpha-carboxylic acid, 17alpha-hydroxy-, methyl ester (8CI); Yohimban-16-alpha-carboxylic acid, 17-alpha-hydroxy-, methyl ester; Yohimban-16-carboxylic acid, 17-hydroxy-, methyl ester, (16alpha,17alpha)-(9CI); Yohimban-16-.alpha.-carboxylic acid, 17-.alpha.-hydroxy-, methyl ester; (+)-Yohimbin; (+)-Yohimbine; (16alpha,17alpha)-17-Hydroxy-yohimban-16-carboxylic acid methyl ester; (16alpha,17alpha)-17-hydroxyyohimban-16-carboxylic acid methyl ester; 17-Hydroxy-yohimbane-16-carboxylic acid methyl ester; 17-Hydroxyyohimban-16-carboxylic acid methyl ester; 17alpha-hydroxyyohimban-16alpha-carboxylic acid methyl ester; 2-Hydroxy-1,2,3,4,4a,5,7,8,13,13b,14,14a-dodecahydro-indolo[2',3':3,4]pyrido[1,2-b]isoquinoline-1-carboxylic acid methyl ester DMJCP1Y CP Palisades Pharmaceuticals Inc DMJCP1Y TC Mydriatics DMJCP1Y DT Small molecular drug DMJCP1Y PC 8969 DMJCP1Y MW 354.4 DMJCP1Y FM C21H26N2O3 DMJCP1Y IC InChI=1S/C21H26N2O3/c1-26-21(25)19-15-10-17-20-14(13-4-2-3-5-16(13)22-20)8-9-23(17)11-12(15)6-7-18(19)24/h2-5,12,15,17-19,22,24H,6-11H2,1H3/t12-,15-,17-,18-,19+/m0/s1 DMJCP1Y CS COC(=O)[C@H]1[C@H](CC[C@@H]2[C@@H]1C[C@H]3C4=C(CCN3C2)C5=CC=CC=C5N4)O DMJCP1Y IK BLGXFZZNTVWLAY-SCYLSFHTSA-N DMJCP1Y IU methyl (1S,15R,18S,19R,20S)-18-hydroxy-1,3,11,12,14,15,16,17,18,19,20,21-dodecahydroyohimban-19-carboxylate DMJCP1Y CA CAS 146-48-5 DMJCP1Y CB CHEBI:10093 DMJCP1Y DE Erectile dysfunction DMHNQOG ID DMHNQOG DMHNQOG DN Zafirlukast DMHNQOG HS Approved DMHNQOG SN Accolate; Accoleit; Aeronix; Olmoran; Respix; Zafirst; AstraZeneca brand of zafirlukast; Menarini brand of zafirlukast; Novartis brand of zafirlukast; Zeneca brand of zafirkulast; Accolate (TN); Accoleit (TN); Vanticon (TN); Zafirlukast [USAN:BAN:INN]; Accolate, Accoleit, Vanticon, Zafirlukast; Zafirlukast (JAN/USAN/INN); Cyclopentyl N-[3-[[2-methoxy-4-[(2-methylphenyl)sulfonylcarbamoyl]phenyl]methyl]-1-methylindol-5-yl]carbamate; Cyclopentyl 3-(2-methoxy-4-((o-tolylsulfonyl)carbamoyl)benzyl)-1-methylindole-5-carbamate; Cyclopentyl 3-[2-methoxy-4-(2-methylphenylsulfonylcarbamoyl)benzyl]-1-methyl-1H-indol-5-ylcarbamate; Cyclopentyl [3-(2-methoxy-4-{[(2-methylphenyl)sulfonyl]carbamoyl}benzyl)-1-methyl-1H-indol-5-yl]carbamate; Cyclopentyl (1-methyl-3-{[2-(methyloxy)-4-({[(2-methylphenyl)sulfonyl]amino}carbonyl)phenyl]methyl}-1H-indol-5-yl)carbamate; Carbamic acid, (3-((2-methoxy-4-((((2-methylphenyl)sulfonyl)amino)carbonyl)phenyl)methyl)-1-methyl-1H-indol-5-yl)-, cyclopentyl ester; 4-(5-cyclopentyloxy-carbonylamino-1-methyl-indol-3-ylmethyl)-3-methoxy-N-o-tolylsulfonylbenzamide; 4-(5-cyclopentyloxycarbonylamino-1-methyl-1H-indol-3-ylmethyl)-3-methoxy-N-o-tolylsulfonylbenzamide; 4-(5-cyclopentyloxycarbonylamino-2-methylindol-3-yl-methyl)-3-methoxy-N-O-tolylsulfonylbenzamide DMHNQOG CP AstraZeneca plc DMHNQOG TC Antiasthmatic Agents DMHNQOG DT Small molecular drug DMHNQOG PC 5717 DMHNQOG MW 575.7 DMHNQOG FM C31H33N3O6S DMHNQOG IC InChI=1S/C31H33N3O6S/c1-20-8-4-7-11-29(20)41(37,38)33-30(35)22-13-12-21(28(17-22)39-3)16-23-19-34(2)27-15-14-24(18-26(23)27)32-31(36)40-25-9-5-6-10-25/h4,7-8,11-15,17-19,25H,5-6,9-10,16H2,1-3H3,(H,32,36)(H,33,35) DMHNQOG CS CC1=CC=CC=C1S(=O)(=O)NC(=O)C2=CC(=C(C=C2)CC3=CN(C4=C3C=C(C=C4)NC(=O)OC5CCCC5)C)OC DMHNQOG IK YEEZWCHGZNKEEK-UHFFFAOYSA-N DMHNQOG IU cyclopentyl N-[3-[[2-methoxy-4-[(2-methylphenyl)sulfonylcarbamoyl]phenyl]methyl]-1-methylindol-5-yl]carbamate DMHNQOG CA CAS 107753-78-6 DMHNQOG CB CHEBI:10100 DMHNQOG DE Asthma DMH7MUV ID DMH7MUV DMH7MUV DN Zalcitabine DMH7MUV HS Approved DMH7MUV SN zalcitabine; Dideoxycytidine; 7481-89-2; 2',3'-DIDEOXYCYTIDINE; ddCyd; HIVID; ddC; Cytidine, 2',3'-dideoxy-; Zalcitibine; 4-Amino-1-((2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one; 2,3-dideoxycytidine; NSC 606170; UNII-6L3XT8CB3I; CCRIS 692; HSDB 7156; C9H13N3O3; Ro-24-2027/000; Ro 24-2027/000; CHEMBL853; BRN 0654956; 6L3XT8CB3I; CHEBI:10101; 1-(2,3-Dideoxy-beta-D-ribofuranosyl)cytosine; WREGKURFCTUGRC-POYBYMJQSA-N; 4-amino-1-[(2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2(1H)-one; MFCD00012188; DdC; DdCyd; D 5782; DDC (DDC); DdC & Interferon alpha; DdC & sCD4; DdC (Antiviral); Hivid (TN); Hivid(TM); Interferon AD + ddC; KS-1130; SRI-7707; Beta-D-DDC; DS-4152 & ddC; DdC & GM-CSF; DdC & IFN-alpha; DdC & NP (from PHCA or HSA); PC-SOD & ddC; Zalcitabine [USAN:INN:BAN]; Hivid, Dideoxycytidine, NSC 606170, Zalcitabine; Zalcitabine (JAN/USP/INN); Beta-D-2',3'-Dideoxycytidine; Cytidine, 2',3'-dideoxy & Interferon alpha; Sulfated polysaccharide-peptidoglycan DS-4152 & 2',3'-Dideoxycytidine; Cytidine, 2',3'-dideoxy-& Colony-stimulating factor; Beta-D-2',3'-Dideoxycytidine & Granulocyte-macrophage colony-stimulating factor; Lecithinized superoxide dismutase & beta-D-2',3'-Dideoxycytidine; 2',3'-Dideoxycytidine & Interferon-alpha; 2',3'-Dideoxycytidine & Nanoparticles (from human serum albumin or polyhexylcyanoacrylate); 2',3'-Dideoxycytidine & sCD4(soluble recombinant protein); 3'-Azido-3'-deoxythymidine/2',3'-Dideoxycytidine; 4-amino-1-[(2R,5S)-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one; DdC DMH7MUV CP Hoffmann-La Roche pharmaceutical company DMH7MUV TC Anti-HIV Agents DMH7MUV DT Small molecular drug DMH7MUV PC 24066 DMH7MUV MW 211.22 DMH7MUV FM C9H13N3O3 DMH7MUV IC InChI=1S/C9H13N3O3/c10-7-3-4-12(9(14)11-7)8-2-1-6(5-13)15-8/h3-4,6,8,13H,1-2,5H2,(H2,10,11,14)/t6-,8+/m0/s1 DMH7MUV CS C1C[C@@H](O[C@@H]1CO)N2C=CC(=NC2=O)N DMH7MUV IK WREGKURFCTUGRC-POYBYMJQSA-N DMH7MUV IU 4-amino-1-[(2R,5S)-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one DMH7MUV CA CAS 7481-89-2 DMH7MUV CB CHEBI:10101 DMH7MUV DE Human immunodeficiency virus infection DMGFWSM ID DMGFWSM DMGFWSM DN Zaleplon DMGFWSM HS Approved DMGFWSM SN Sonata; Zalaplon; Zerene; CL 284846; L 846; L846; LJC 10846; ZAL 846; AZ-007; CL 284,846; CL-284846; CL284,846; L-846; LJC-10846; SKP-1041; Sonata (TN); Staccato-zaleplon; Starnoc (TN); ZAL-846; Zaleplon [USAN:INN]; Zaleplon (JAN/USAN/INN); N-[3-(3-cyanopyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-N-ethylacetamide; N-(3-(3-Cyanopyrazolo(1,5-a)pyrimidin-7-yl)phenyl)-N-ethylacetamide; 3'-(3-Cyanopyrazolo(1,5-a)pyrimidin-7-yl)-N-ethylacetanilide; 3'-(3-Cyanopyrazolo(1,5-alpha)pyrimidin-7-yl)-N-ethylacetanilide DMGFWSM CP King Pharm DMGFWSM TC Hypnotics and Sedatives DMGFWSM DT Small molecular drug DMGFWSM PC 5719 DMGFWSM MW 305.33 DMGFWSM FM C17H15N5O DMGFWSM IC InChI=1S/C17H15N5O/c1-3-21(12(2)23)15-6-4-5-13(9-15)16-7-8-19-17-14(10-18)11-20-22(16)17/h4-9,11H,3H2,1-2H3 DMGFWSM CS CCN(C1=CC=CC(=C1)C2=CC=NC3=C(C=NN23)C#N)C(=O)C DMGFWSM IK HUNXMJYCHXQEGX-UHFFFAOYSA-N DMGFWSM IU N-[3-(3-cyanopyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-N-ethylacetamide DMGFWSM CA CAS 151319-34-5 DMGFWSM CB CHEBI:10102 DMGFWSM DE Insomnia DMFMBZ4 ID DMFMBZ4 DMFMBZ4 DN Zanamivir DMFMBZ4 HS Approved DMFMBZ4 SN zanamivir; 139110-80-8; Relenza; 4-Guanidino-Neu5Ac2en; GANA; Zanamavir; MODIFIED SIALIC ACID; GG167; UNII-L6O3XI777I; GG 167; GR-121167X; Zanamivir (Relenza); Relenza (TN); 4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid; GR 121167X; CHEMBL222813; L6O3XI777I; ZMR; CHEBI:50663; GANA (inhibitor); 5-Acetamido-2,6-anhydro-3,4,5-trideoxy-4-guanidino-D-glycero-D-galacto-non-2-enonic acid; GNA; AK163166; GG-167; DSSTox_CID_3749; DSSTox_RID_77184; DSSTox_GSID_23749; Zanamivir [USAN:INN:BAN]; HSDB 7437; C12H20N4O7; GANA; Zanamivir hydrate; GR121167X; Zanamivir (USAN/INN); (2R,3R,4S)-3-acetamido-4-(diaminomethylideneamino)-2-[(1R,2R)-1,2,3-trihydroxypropyl]-3,4-dihydro-2H-pyran-6-carboxylic acid; 4-Guanidino-NeueAc2en; 5-(acetylamino)-4-{[amino(imino)methyl]amino}-2,6-anhydro-3,4,5-trideoxy-D-glycero-D-galacto-non-2-enonic acid; ZNV; 4-guanidino-Neu5Ac2en; BAC-zanamivir DMFMBZ4 CP GlaxoSmithKline DMFMBZ4 TC Antiviral Agents DMFMBZ4 DT Small molecular drug DMFMBZ4 PC 60855 DMFMBZ4 MW 332.31 DMFMBZ4 FM C12H20N4O7 DMFMBZ4 IC InChI=1S/C12H20N4O7/c1-4(18)15-8-5(16-12(13)14)2-7(11(21)22)23-10(8)9(20)6(19)3-17/h2,5-6,8-10,17,19-20H,3H2,1H3,(H,15,18)(H,21,22)(H4,13,14,16)/t5-,6+,8+,9+,10+/m0/s1 DMFMBZ4 CS CC(=O)N[C@@H]1[C@H](C=C(O[C@H]1[C@@H]([C@@H](CO)O)O)C(=O)O)N=C(N)N DMFMBZ4 IK ARAIBEBZBOPLMB-UFGQHTETSA-N DMFMBZ4 IU (2R,3R,4S)-3-acetamido-4-(diaminomethylideneamino)-2-[(1R,2R)-1,2,3-trihydroxypropyl]-3,4-dihydro-2H-pyran-6-carboxylic acid DMFMBZ4 CA CAS 139110-80-8 DMFMBZ4 CB CHEBI:50663 DMFMBZ4 DE Influenza virus infection DMJWRQP ID DMJWRQP DMJWRQP DN Zanubrutinib DMJWRQP HS Approved DMJWRQP SN RNOAOAWBMHREKO-UHFFFAOYSA-N; 1633350-06-7; ( inverted exclamation markA)-Zanubrutinib; CHEMBL3973435; SCHEMBL19742851; SCHEMBL16208602; BGB3111; BDBM249900; BCP29110; BCP25045; BCP25838; AKOS032946689; SB18877; CS-6366; ( inverted exclamation markA)-BGB-3111; HY-101474; US9447106, 27 DMJWRQP CP BeiGene Cambridge, MA DMJWRQP PC 135905454 DMJWRQP MW 471.5 DMJWRQP FM C27H29N5O3 DMJWRQP IC InChI=1S/C27H29N5O3/c1-2-23(33)31-16-13-18(14-17-31)22-12-15-29-27-24(26(28)34)25(30-32(22)27)19-8-10-21(11-9-19)35-20-6-4-3-5-7-20/h2-11,18,22,29H,1,12-17H2,(H2,28,34) DMJWRQP CS C=CC(=O)N1CCC(CC1)C2CCNC3=C(C(=NN23)C4=CC=C(C=C4)OC5=CC=CC=C5)C(=O)N DMJWRQP IK RNOAOAWBMHREKO-UHFFFAOYSA-N DMJWRQP IU 2-(4-phenoxyphenyl)-7-(1-prop-2-enoylpiperidin-4-yl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide DMJWRQP DE B-cell lymphoma; Chronic lymphocytic leukaemia; Small lymphocytic lymphoma; Waldenstrom macroglobulinemia; Mantle cell lymphoma DMUR5NG ID DMUR5NG DMUR5NG DN Zanubrutinib DMUR5NG HS Approved DMUR5NG SN Zanubrutinib; Zanubrutinib (USAN/INN); Zanubrutinib [INN]; Zanubrutinib [USAN]; compound 27b [US9447106]; (7S)-2-(4-phenoxyphenyl)-7-(1-prop-2-enoylpiperidin-4-yl)-1,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide; 1691249-45-2; BDBM250082; BGB3111; CHEMBL3936761; CS-0021869; D11422; GTPL9861; HY-101474A; Pyrazolo(1,5-a)pyrimidine-3-carboxamide, 4,5,6,7-tetrahydro-7-(1-(1-oxo-2-propen-1-yl)-4-piperidinyl)-2-(4-phenoxyphenyl)-, (7S)-; SCHEMBL17842597; AG9MHG098Z; US9447106, 27b (peak 2); ZINC584641430; UNII-AG9MHG098Z DMUR5NG PC 135565884 DMUR5NG MW 471.5 DMUR5NG FM C27H29N5O3 DMUR5NG IC RNOAOAWBMHREKO-QFIPXVFZSA-N DMUR5NG CS C=CC(=O)N1CCC(CC1)C2CCNC3=C(C(=NN23)C4=CC=C(C=C4)OC5=CC=CC=C5)C(=O)N DMUR5NG IK 1S/C27H29N5O3/c1-2-23(33)31-16-13-18(14-17-31)22-12-15-29-27-24(26(28)34)25(30-32(22)27)19-8-10-21(11-9-19)35-20-6-4-3-5-7-20/h2-11,18,22,29H,1,12-17H2,(H2,28,34)/t22-/m0/s1 DMUR5NG IU (7S)-2-(4-phenoxyphenyl)-7-(1-prop-2-enoylpiperidin-4-yl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide DMUR5NG CA CAS 1691249-45-2 DMUR5NG DE Mantle cell lymphoma DMA5QPM ID DMA5QPM DMA5QPM DN Zemaira DMA5QPM HS Approved DMA5QPM SN Alpha-1-antitrypsin DMA5QPM CP CSL Behring DMA5QPM DT Recombinant protein DMA5QPM DE Emphysema DMSLJP4 ID DMSLJP4 DMSLJP4 DN Ziconotide DMSLJP4 HS Approved DMSLJP4 SN Prialt; Ziconotide [USAN]; SNX 111; DRG-0250; Omega-Conotoxin M VIIA; Omega-conotoxin MVIIA; Prialt (TN); SNX-111; Omega-ConopeptideMVIIA (Conus); Omega-Conotoxin mviia, conus magus; Omega-Conotoxin M VIIA (reduced), cyclic (1-16),(8-20),(15-25)-tris(disulfide) DMSLJP4 CP Neurox/Parke Davis DMSLJP4 TC Analgesics DMSLJP4 DT Small molecular drug DMSLJP4 PC 16135415 DMSLJP4 MW 2639.2 DMSLJP4 FM C102H172N36O32S7 DMSLJP4 IC InChI=1S/C102H172N36O32S7/c1-50(2)34-63-91(161)127-62(26-33-171-5)90(160)129-64(35-53-22-24-54(143)25-23-53)92(162)130-65(36-78(148)149)93(163)135-72-48-175-173-45-69(80(108)150)133-86(156)58(18-8-12-29-105)121-76(146)39-117-85(155)66(41-139)131-88(158)61(21-15-32-114-102(111)112)126-96(166)70-46-176-177-47-71(97(167)132-68(43-141)95(165)125-60(87(157)128-63)20-14-31-113-101(109)110)134-89(159)59(19-9-13-30-106)123-81(151)51(3)119-74(144)37-115-83(153)56(16-6-10-27-103)120-75(145)38-116-84(154)57(17-7-11-28-104)124-82(152)55(107)44-172-174-49-73(137-98(72)168)99(169)138-79(52(4)142)100(170)118-40-77(147)122-67(42-140)94(164)136-70/h22-25,50-52,55-73,79,139-143H,6-21,26-49,103-107H2,1-5H3,(H2,108,150)(H,115,153)(H,116,154)(H,117,155)(H,118,170)(H,119,144)(H,120,145)(H,121,146)(H,122,147)(H,123,151)(H,124,152)(H,125,165)(H,126,166)(H,127,161)(H,128,157)(H,129,160)(H,130,162)(H,131,158)(H,132,167)(H,133,156)(H,134,159)(H,135,163)(H,136,164)(H,137,168)(H,138,169)(H,148,149)(H4,109,110,113)(H4,111,112,114)/t51-,52+,55-,56-,57-,58-,59-,60-,61-,62-,63-,64-,65-,66-,67-,68-,69-,70-,71-,72-,73-,79-/m0/s1 DMSLJP4 CS C[C@H]1C(=O)N[C@H](C(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)NCC(=O)N1)CCCCN)CCCCN)N)C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N3)CO)[C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC2=O)CO)CCCNC(=N)N)CC(C)C)CCSC)CC4=CC=C(C=C4)O)CC(=O)O)C(=O)N)CCCCN)CO)CCCNC(=N)N)CCCCN DMSLJP4 IK BPKIMPVREBSLAJ-QTBYCLKRSA-N DMSLJP4 IU 2-[(1R,4S,7S,13S,16R,21R,24S,27S,30S,33S,36S,39S,42R,45S,48S,54S,60S,63R,68R,71S,77S)-63-amino-13,45,54,60-tetrakis(4-aminobutyl)-4,36-bis(3-carbamimidamidopropyl)-16-carbamoyl-71-[(1R)-1-hydroxyethyl]-7,39,77-tris(hydroxymethyl)-27-[(4-hydroxyphenyl)methyl]-48-methyl-33-(2-methylpropyl)-30-(2-methylsulfanylethyl)-2,5,8,11,14,23,26,29,32,35,38,41,44,47,50,53,56,59,62,69,72,75,78,85-tetracosaoxo-18,19,65,66,81,82-hexathia-3,6,9,12,15,22,25,28,31,34,37,40,43,46,49,52,55,58,61,70,73,76,79,84-tetracosazatricyclo[40.37.4.221,68]pentaoctacontan-24-yl]acetic acid DMSLJP4 CA CAS 107452-89-1 DMSLJP4 CB CHEBI:135912 DMSLJP4 DE Pain; Traumatic brain injury DM4KI7O ID DM4KI7O DM4KI7O DN Zidovudine DM4KI7O HS Approved DM4KI7O SN zidovudine; Azidothymidine; 30516-87-1; 3'-Azido-3'-deoxythymidine; Retrovir; AZT; Zidovudinum; Compound S; Thymidine, 3'-azido-3'-deoxy-; ZIDOVUDINE [AZT]; zidovudin; BW A509U; Zidovudinum [Latin]; Zidovudina [Spanish]; BWA509U; DRG-0004; 3'-Azido-2',3'-Dideoxythymidine; ZDV; UNII-4B9XT59T7S; 3'-Deoxy-3'-azidothymidine; CCRIS 105; Aztec; BW-A509U; BW-A-509U; HSDB 6515; 3'-Azido-3'-deoxythymidine (AIDS); CHEMBL129; NSC 602670; BW-A 509U; MLS000028548; 4B9XT59T7S; AZT; Antiviral; Azidodeoxythymidine; ZVD; Zidovudin; Zidovudina; AZT Antiviral; AZT TRANSPLACENTAL CARCINOGENESIS STUDY; Antiviral AZT; Cpd S; Racemic Liposomal AZT; Zidovudine EP III; BWA 509U; K7 [P Ti2 W10 O40]; AZT & EPO; AZT & HPA; AZT & Lymphoblastoid Interferon; AZT & SST; AZT & rsT4; AZT & sCD4; AZT & srCD4; AZT (Antiviral); AZT+PRO 140; AZT, Antiviral; Apo-Zidovudine; BWA-509U; Intron A & AZT; Novo-Azt; Propolis+AZT; Retrovir (TN); Retrovir(TM); Retrovis (TN); Zidovudine+PRO 140; AZT & Colony-stimulating factor 2; AZT & Concanavalin A (ConA); AZT & GM-CSF; AZT & IFN-alpha; AZT & IL-1; AZT & IL-2; AZT & IL-6; AZT & Li & EPO; AZT & NP (from PHCA or HSA); AZT & PM-19; DS-4152 & AZT; Liposomal AZT-SN-1; Liposomal AZT-SN-3; PC-SOD+AZT;RIFN-beta seron & AZT; AZT & CD4(178)-PE 40; AZT & Li & GM-CSF; AZT & Li & IL-1; AZT & Li & IL-6; AZT & rIFNalpha2; Racemic-dipalmitoylglycerophospho-AZT (in a lipid vesicle); Zidovudine (JAN/USP/INN); Zidovudine [USAN:INN:BAN:JAN]; AZT & rsCD4 & rIFNalphaA; SN-1-dipalmitoylglycerophospho-AZT (in a lipid vesicle); SN-3-dipalmitoylglycerophospho-AZT (in a lipid vesicle); AZT & Interferon-alpha-2; Met-SDF-1beta & AZT; Met-SDF-1beta & Zidovudine; Interferon AD + 3'-azido-3'-deoxythymidine; 1-(3-Azido-2,3-dideoxy-beta-D-ribofuranosyl)thymine; 3′-Azido-3′-deoxythymidine; 3' Azido 2',3' Dideoxythymidine; 3' Azido 3' deoxythymidine; 3'-Azido-3'-deoxythymidine & Concanavalin A; 3'-Azido-3'-deoxythymidine & Erythropoietin; 3'-Azido-3'-deoxythymidine & Heteropolyoxotungstate PM-19; 3'-Azido-3'-deoxythymidine & Interleukin-1; 3'-Azido-3'-deoxythymidine & Interleukin-2; 3'-Azido-3'-deoxythymidine & Interleukin-6; 3'-Azido-3'-deoxythymidine & Lithium & Erythropoietin; 3'-Azido-3'-deoxythymidine & Lithium & Interleukin-1; 3'-Azido-3'-deoxythymidine & Lithium & Interleukin-6; 3'-Azido-3'-deoxythymidine & Lymphoblastoid Interferon; 3'-Azido-3'-deoxythymidine & Sho-Saiko-To; 3'-Azido-3'deoxythymidine & Interferon-alpha; 3'-Azidothymidine; 3'-azido-3'-deoxythymidine, AZT; 3-Azido-3-deoxythymidine; Dendrigen; CTCE-0422 DM4KI7O CP GlaxoSmithKline DM4KI7O TC Anti-HIV Agents DM4KI7O DT Small molecular drug DM4KI7O PC 35370 DM4KI7O MW 267.24 DM4KI7O FM C10H13N5O4 DM4KI7O IC InChI=1S/C10H13N5O4/c1-5-3-15(10(18)12-9(5)17)8-2-6(13-14-11)7(4-16)19-8/h3,6-8,16H,2,4H2,1H3,(H,12,17,18)/t6-,7+,8+/m0/s1 DM4KI7O CS CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)CO)N=[N+]=[N-] DM4KI7O IK HBOMLICNUCNMMY-XLPZGREQSA-N DM4KI7O IU 1-[(2R,4S,5S)-4-azido-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione DM4KI7O CA CAS 30516-87-1 DM4KI7O CB CHEBI:10110 DM4KI7O DE Human immunodeficiency virus infection; Virus infection DMVRIC2 ID DMVRIC2 DMVRIC2 DN Zileuton DMVRIC2 HS Approved DMVRIC2 SN Leutrol; Zileutonum; Ziluton; Zyflo; Abbott brand of zileuton; Zyflo CR; Zyflo Filmtab; A 64077; Abbot 64077; Abbott 64077; A-64077; ABBOTT-64077; ABT-077; CTI-02; ZYFLO (TN); ZYFLO, Zileuton; Zileutonum [INN-Latin]; Zyflo (TN); Zileuton (USP/INN); Zileuton [USAN:INN:BAN]; N-[1-(benzo[b]thiophen-2-yl)ethyl]-N-hydroxyurea; N-(1-Benzo(b)thien-2-ylethyl)-N-hydroxyurea; (+-)-1-(1-Benzo(b)thien-2-ylethyl)-1-hydroxyurea; (+-)-1-(1-Benzo[b]thien-2-ylethyl)-1-hydroxyurea; (+/-)-1-(1-Benzo[b]thien-2-ylethyl)-1-hydroxyurea; 1-[1-(1-benzothien-2-yl)ethyl]-1-hydroxyurea; 1-[1-(1-benzothiophen-2-yl)ethyl]-1-hydroxyurea DMVRIC2 CP Cornerstone Therapeutics Inc DMVRIC2 TC Antiinflammatory Agents DMVRIC2 DT Small molecular drug DMVRIC2 PC 60490 DMVRIC2 MW 236.29 DMVRIC2 FM C11H12N2O2S DMVRIC2 IC InChI=1S/C11H12N2O2S/c1-7(13(15)11(12)14)10-6-8-4-2-3-5-9(8)16-10/h2-7,15H,1H3,(H2,12,14) DMVRIC2 CS CC(C1=CC2=CC=CC=C2S1)N(C(=O)N)O DMVRIC2 IK MWLSOWXNZPKENC-UHFFFAOYSA-N DMVRIC2 IU 1-[1-(1-benzothiophen-2-yl)ethyl]-1-hydroxyurea DMVRIC2 CA CAS 111406-87-2 DMVRIC2 CB CHEBI:10112 DMVRIC2 DE Asthma DMZ4R3Q ID DMZ4R3Q DMZ4R3Q DN Zinc salts DMZ4R3Q HS Approved DMZ4R3Q DE Arthritis DMK4OL7 ID DMK4OL7 DMK4OL7 DN Zinostatin stimalamer DMK4OL7 HS Approved DMK4OL7 SN Smancs (TN) DMK4OL7 DT Small molecular drug DMK4OL7 PC 70682998 DMK4OL7 MW 657.7 DMK4OL7 FM C36H35NO11 DMK4OL7 IC InChI=1S/C36H35NO11/c1-17-9-10-22-18(2)13-21(42-5)15-24(22)28(17)33(40)45-25-14-20-11-12-36(27-16-43-35(41)46-27)26(48-36)8-6-7-23(20)32(25)47-34-29(37-4)31(39)30(38)19(3)44-34/h7,9-10,13-15,19,25-27,29-32,34,37-39H,16H2,1-5H3/b23-7+/t19-,25-,26-,27+,29-,30+,31-,32?,34-,36+/m1/s1 DMK4OL7 CS C[C@@H]1[C@@H]([C@@H]([C@H]([C@H](O1)OC\\2[C@@H](C=C3/C2=C\\C#C[C@@H]4[C@@](O4)(C#C3)[C@@H]5COC(=O)O5)OC(=O)C6=C(C=CC7=C6C=C(C=C7C)OC)C)NC)O)O DMK4OL7 IK FYQZGCBXYVWXSP-STTFAQHVSA-N DMK4OL7 IU [(4S,6R,9E,12R)-11-[(2R,3R,4R,5R,6R)-4,5-dihydroxy-6-methyl-3-(methylamino)oxan-2-yl]oxy-4-[(4S)-2-oxo-1,3-dioxolan-4-yl]-5-oxatricyclo[8.3.0.04,6]trideca-1(13),9-dien-2,7-diyn-12-yl] 7-methoxy-2,5-dimethylnaphthalene-1-carboxylate DMK4OL7 DE Brain cancer DMM58JY ID DMM58JY DMM58JY DN Ziprasidone DMM58JY HS Approved DMM58JY SN 146939-27-7; Geodon; Zeldox; Ziprasidone hydrochloride; Ziprasidone [INN:BAN]; UNII-6UKA5VEJ6X; CP 88059; Ziprasidone mesylate trihydrate; 6UKA5VEJ6X; CHEMBL708; C21H21ClN4OS; CHEBI:10119; CP-88,059-1; ziprazidone; DSSTox_CID_3753; DSSTox_RID_77186; 5-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-6-chloro-1,3-dihydroindol-2-one; DSSTox_GSID_23753; ziprasidonum; ziprasidona; 5-(2-(4-(benzo[d]isothiazol-3-yl)piperazin-1-yl)ethyl)-6-chloroindolin-2-one; Geodon; Zipradon; Ziprasidona; Ziprasidonum; Ziprazidone; CP 88059-01; Geodon (TN); Zeldox (TN); Zipradon (TN); Ziprasidone (INN); CP-88,059; CP-88059-1; CP-88,059-01; 5-{2-[4-(1,2-benzisothiazol-3-yl)piperazin-1-yl]ethyl}-6-chloro-1,3-dihydro-2H-indol-2-one; 5-{2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl}-6-chloro-1,3-dihydro-2H-indol-2-one; 6-chloro-5-[2-[4-(7-thia-8-azabicyclo[430]nona-1,3,5,8-tetraen-9-yl)piperazin-1-yl]ethyl]-1,3-dihydroindol-2-one; TC-5280 DMM58JY CP Pfizer DMM58JY TC Antipsychotic Agents DMM58JY DT Small molecular drug DMM58JY PC 60854 DMM58JY MW 412.9 DMM58JY FM C21H21ClN4OS DMM58JY IC InChI=1S/C21H21ClN4OS/c22-17-13-18-15(12-20(27)23-18)11-14(17)5-6-25-7-9-26(10-8-25)21-16-3-1-2-4-19(16)28-24-21/h1-4,11,13H,5-10,12H2,(H,23,27) DMM58JY CS C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54 DMM58JY IK MVWVFYHBGMAFLY-UHFFFAOYSA-N DMM58JY IU 5-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-6-chloro-1,3-dihydroindol-2-one DMM58JY CA CAS 146939-27-7 DMM58JY CB CHEBI:10119 DMM58JY DE Schizophrenia DMN4H2O ID DMN4H2O DMN4H2O DN Zithromax DMN4H2O HS Approved DMN4H2O SN azithromycin; Zithromax; 83905-01-5; Azithromycinum; Azithromycine; Sumamed; Zitromax; Zmax; Hemomycin; Azitrocin; Azasite; Azenil; Aritromicina; Zitrotek; Zithrax; Mixoterin; Setron; Aziwok; Zitrim; Aztrin; Zifin; Tobil; Zmas; Zeto; Azithromycinum [Latin]; Azithromycine [French]; Zithromax IV; AZITHROMYCIN DIHYDRATE; Misultina; Azitromax; Z-Pak; Tromix; Aritromicina [Spanish]; Azitromicina; CP-62993; UNII-J2KLZ20U1M; DRG-0104; CCRIS 1961; HSDB 7205; Azithromycin (anhydrous); C38H72N2O12; BRN 5387583; J2KLZ20U1M; Azythromycin; CHEBI:2955 DMN4H2O DT Small molecular drug DMN4H2O PC 447043 DMN4H2O MW 749 DMN4H2O FM C38H72N2O12 DMN4H2O IC InChI=1S/C38H72N2O12/c1-15-27-38(10,46)31(42)24(6)40(13)19-20(2)17-36(8,45)33(52-35-29(41)26(39(11)12)16-21(3)48-35)22(4)30(23(5)34(44)50-27)51-28-18-37(9,47-14)32(43)25(7)49-28/h20-33,35,41-43,45-46H,15-19H2,1-14H3/t20-,21-,22+,23-,24-,25+,26+,27-,28+,29-,30+,31-,32+,33-,35+,36-,37-,38-/m1/s1 DMN4H2O CS CC[C@@H]1[C@@]([C@@H]([C@H](N(C[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)C)O)(C)O DMN4H2O IK MQTOSJVFKKJCRP-BICOPXKESA-N DMN4H2O IU (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-11-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-2-ethyl-3,4,10-trihydroxy-13-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,6,8,10,12,14-heptamethyl-1-oxa-6-azacyclopentadecan-15-one DMN4H2O CA CAS 83905-01-5 DMN4H2O CB CHEBI:2955 DMN4H2O DE Syphilis infection DMIXC7G ID DMIXC7G DMIXC7G DN Zoledronate DMIXC7G HS Approved DMIXC7G SN Aclasta; Reclast; ZOL; Zometa; Novartis brand of zoledronic acid; Zoledronic acid; Zometa Concentrate; Bisphosphonate 3; CGP 42446; CGP 42446A; Aclasta (TN); CGP 42'446; CGP-42446; KS-1132; Reclast (TN); Zoledronic acid (INN); Zoledronic acid [USAN:INN]; Zomera (TN); Zometa (Novartis); Zometa (TN); CGP-42'446; Zometa, Zomera, Aclasta and Reclast, Zoledronic Acid; [1-hydroxy-2-(1H-imidazol-1-yl)ethane-1,1-diyl]bis(phosphonic acid); (1-Hydroxy-2-imidazol-1-ylethylidene)diphosphonic acid; (1-hydroxy-2-(1H-imidazol-1-yl)ethylidene)bisphosphonic acid; (1-hydroxy-2-imidazol-1-yl-1-phosphonoethyl)phosphonic acid; (1-hydroxy-2-imidazol-1-yl-phosphonoethyl)phosphonic acid monohydrate; 2-(imidazol-1-yl)-1-hydroxyethane-1,1-diphosphonic acid; 2-(imidazol-1-yl)-1-hydroxyethylidene-1,1-bisphosphonic acid DMIXC7G CP Norvatis Phamaceuticals Corporation DMIXC7G TC Bone Density Conservation Agents DMIXC7G DT Small molecular drug DMIXC7G PC 68740 DMIXC7G MW 272.09 DMIXC7G FM C5H10N2O7P2 DMIXC7G IC InChI=1S/C5H10N2O7P2/c8-5(15(9,10)11,16(12,13)14)3-7-2-1-6-4-7/h1-2,4,8H,3H2,(H2,9,10,11)(H2,12,13,14) DMIXC7G CS C1=CN(C=N1)CC(O)(P(=O)(O)O)P(=O)(O)O DMIXC7G IK XRASPMIURGNCCH-UHFFFAOYSA-N DMIXC7G IU (1-hydroxy-2-imidazol-1-yl-1-phosphonoethyl)phosphonic acid DMIXC7G CA CAS 118072-93-8 DMIXC7G CB CHEBI:46557 DMIXC7G DE Hypercalcaemia DM57O90 ID DM57O90 DM57O90 DN Zolgensma DM57O90 HS Approved DM57O90 SN Onasemnogene abeparvovec-xioi DM57O90 CP AveXis DM57O90 DT Gene therapy DM57O90 DE Spinal muscular atrophy DM1IB4Q ID DM1IB4Q DM1IB4Q DN Zolmitriptan DM1IB4Q HS Approved DM1IB4Q SN AscoTop; Flezol; Zolmitriptane; Zolmitriptanum; Zomig; Zomigon; Zolmitriptan RapidFilm; Zolmitriptan [USAN]; Zomig Nasal Spray; Zomig ZMT; AscoTop (TN); BW-311C90; KS-5072; Zomig (TN); Zomig-ZMT; Zomigon (TN); Zomigoro (TN); Zomig, Zomigon, AscoTopand, Zomigoro, Zolmitriptan; (4S)-4-({3-[2-(dimethylamino)ethyl]-1H-indol-5-yl}methyl)-1,3-oxazolidin-2-one; (4S)-4-[[3-(2-dimethylaminoethyl)-1H-indol-5-yl]methyl]-1,3-oxazolidin-2-one; (S)-4-((3-(2-(Dimethylamino)ethyl)-1H-indol-5-yl)methyl)-2-oxazolidinone; (S)-4-((3-(2-(Dimethylamino)ethyl)indol-5-yl)methyl)-2-oxazolidinone; (S)-4-[3-(2-Dimethylamino-ethyl)-1H-indol-5-ylmethyl]-oxazolidin-2-one; (S)-4-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-2-oxazolidinone; 4-((3-(2-(Dimethylamino)ethyl)-1H-indol-5-yl)methyl)-2-oxazolidinone; 4-[[3-(2-dimethylaminoethyl)-1H-indol-5-yl]methyl]oxazolidin-2-one DM1IB4Q CP AstraZeneca DM1IB4Q TC Antimigraine Agents DM1IB4Q DT Small molecular drug DM1IB4Q PC 60857 DM1IB4Q MW 287.36 DM1IB4Q FM C16H21N3O2 DM1IB4Q IC InChI=1S/C16H21N3O2/c1-19(2)6-5-12-9-17-15-4-3-11(8-14(12)15)7-13-10-21-16(20)18-13/h3-4,8-9,13,17H,5-7,10H2,1-2H3,(H,18,20)/t13-/m0/s1 DM1IB4Q CS CN(C)CCC1=CNC2=C1C=C(C=C2)C[C@H]3COC(=O)N3 DM1IB4Q IK ULSDMUVEXKOYBU-ZDUSSCGKSA-N DM1IB4Q IU (4S)-4-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-1,3-oxazolidin-2-one DM1IB4Q CA CAS 139264-17-8 DM1IB4Q CB CHEBI:10124 DM1IB4Q DE Migraine DMWOSKJ ID DMWOSKJ DMWOSKJ DN Zolpidem DMWOSKJ HS Approved DMWOSKJ SN zolpidem; 82626-48-0; Ambien; Zolpidemum; Lorex; Zolpidemum [Latin]; Zolpidem [INN:BAN]; UNII-7K383OQI23; N,N-Dimethyl-2-[6-methyl-2-(4-methylphenyl)imidazo[1,2-a]pyridin-3-yl]acetamide; CHEMBL911; N,N,6-Trimethyl-2-(4-methylphenyl)imidazo(1,2-a)pyridine-3-acetamide; DEA No 2783; CHEBI:10125; ZAFYATHCZYHLPB-UHFFFAOYSA-N; 7K383OQI23; NCGC00095179-01; N,N,6-Trimethyl-2-p-tolylimidazo[1,2-a]pyridine-3-acetamide; SL-800750; N,N,6-Trimethyl-2-(4-methylphenyl)imidazo[1,2-a]pyridine-3-acetamide; ZolpiMist; Zolpidem tartrate; Zolpidem (low-dose oral spray, middle-of-the-night awakenings); Zolpidem (low-dose oral spray, middle-of-the-night awakenings), NovaDel; [3H]zolpidem DMWOSKJ CP NovaDel Pharma Inc DMWOSKJ DT Small molecular drug DMWOSKJ PC 5732 DMWOSKJ MW 307.4 DMWOSKJ FM C19H21N3O DMWOSKJ IC InChI=1S/C19H21N3O/c1-13-5-8-15(9-6-13)19-16(11-18(23)21(3)4)22-12-14(2)7-10-17(22)20-19/h5-10,12H,11H2,1-4H3 DMWOSKJ CS CC1=CC=C(C=C1)C2=C(N3C=C(C=CC3=N2)C)CC(=O)N(C)C DMWOSKJ IK ZAFYATHCZYHLPB-UHFFFAOYSA-N DMWOSKJ IU N,N-dimethyl-2-[6-methyl-2-(4-methylphenyl)imidazo[1,2-a]pyridin-3-yl]acetamide DMWOSKJ CA CAS 82626-48-0 DMWOSKJ CB CHEBI:10125 DMWOSKJ DE Insomnia DM0DTF7 ID DM0DTF7 DM0DTF7 DN Zonisamide DM0DTF7 HS Approved DM0DTF7 SN Exceglan; Excegram; Excegran; Tremode; Trerief; Zonegran; Zonisamida; Zonisamidum; Elan brand of zonisamide; Zonisamida [Spanish]; Zonisamide monosodium; Zonisamidum [Latin]; AD 810; PD 110843; SPR_2; AD-810; AD-810N; E-2090; Excegran (TN); PD-110843; Zonegran (TN); Zonegran, Zonisamide; Zonisamide (ZNS); Zonisamide (JAN/USAN/INN); Zonisamide [USAN:BAN:INN:JAN]; 1,2-Benzisoxazole-3-methanesulfonamide; 1,2-benzoxazol-3-ylmethanesulfonamide; 1-(1,2-Benzoxazol-3-Yl)methanesulfonamide; 1-(1,2-benzisoxazol-3-yl)methanesulfonamide; 3-(Sulfamoylmethyl)-1,2-benzisoxazole; 3-sulfamoylmethyl-1,2-benzisoxazole DM0DTF7 CP Eisai DM0DTF7 TC Analgesics DM0DTF7 DT Small molecular drug DM0DTF7 PC 5734 DM0DTF7 MW 212.23 DM0DTF7 FM C8H8N2O3S DM0DTF7 IC InChI=1S/C8H8N2O3S/c9-14(11,12)5-7-6-3-1-2-4-8(6)13-10-7/h1-4H,5H2,(H2,9,11,12) DM0DTF7 CS C1=CC=C2C(=C1)C(=NO2)CS(=O)(=O)N DM0DTF7 IK UBQNRHZMVUUOMG-UHFFFAOYSA-N DM0DTF7 IU 1,2-benzoxazol-3-ylmethanesulfonamide DM0DTF7 CA CAS 68291-97-4 DM0DTF7 DE Epilepsy DMPI6Z0 ID DMPI6Z0 DMPI6Z0 DN Zopiclone DMPI6Z0 HS Approved DMPI6Z0 SN Amoban; Amovane; Imovance; Imovane; Limovan; Optidorm; Rhovane; Siaten; Sopivan; Ximovan; Zileze; Zimoclone; Zimovane; Zopicalm; Zopicalma; Zopiclodura; Zopiclona; Zopiclonum; Zopitan; Zorclone; AbZ brand of zopiclone; Aliud brand of zopiclone; Alpharma brand of zopiclone; Aventis Pharma brand of zopiclone; Aventis brand of zopiclone; Azupharma brand of zopiclone; Betapharm brand of zopiclone; Ciclum brand of zopiclone; Clonmel brand of zopiclone; Dolorgeit brand of zopiclone; Gerard brand of zopiclone; Hexal brand of zopiclone; Hormosan brand of zopiclone; Italfarmaco brand of zopiclone; Merck dura brand of zopiclone; Neuraxpharm brand of zopiclone; Norton brand of zopiclone; Opus brand of zopiclone; Pinewood brand of zopiclone; Ratiopharm brand of zopiclone; Rhodiapharm brand of zopiclone; Stadapharm brand of zopiclone; TAD brand of zopiclone; Temmler brand of zopiclone; Teva brand of zopiclone; Zopiclon AL; Zopiclon AZU; Zopiclon AbZ; Zopiclon Stada; Zopiclon TAD; Zopiclon beta; Zopiclon von ct; RP 27 267; RP 27267; Z 4900; Z4900_SIGMA; Amoban (TN); Ct-Arzneimittel brand of zopiclone; Imovane (TN); Novo-zopiclone; Nu-Pharm brand of zopiclone; Nu-Zopiclone; RP-27267; Ran-zopiclone; Ratio-Zopiclone; Rhone-Poulenc Rorer brand of zopiclone; Zimovane (TN); Zopi-Puren; Zopiclon-TEVA; Zopiclon-neuraxpharm; Zopiclon-ratiopharm; Zopiclona [INN-Spanish]; Zopiclone (TN); Zopiclonum [INN-Latin]; Zopinox (TN); Zopiclone (JAN/INN); Zopiclone [BAN:INN:JAN]; Zopiclone, Imovane, Zimovane, Lunesta; [6-(5-chloropyridin-2-yl)-5-oxo-7H-pyrrolo[3,4-b]pyrazin-7-yl] 4-methylpiperazine-1-carboxylate; 1-Piperazinecarboxylic acid, 4-methyl-, 6-(5-chloro-2-pyridinyl)-6,7-dihydro-7-oxo-5H-pyrrolo(3,4-b)pyrazin-5-yl ester; 1-Piperazinecarboxylic acid, 4-methyl-, 6-(5-chloro-2-pyridinyl)-6,7-dihydro-7-oxo-5H-pyrrolo[3,4-b]pyrazin-5-yl ester; 4-Methyl-1-piperazinecarboxylic acid 6-(5-chloro-2-pyridinyl)-6,7-dihydro-7-oxo-5H-pyrrolo[3,4-b]pyrazin-5-yl ester; 4-Methyl-1-piperazinecarboxylic acid ester with 6-(5-chloro-2-pyridyl)-6,7-dihydro-7-hydroxy-5H-pyrrolo(3,4-b)pyrazin-5-one; 6-(5-Chloro-2-pyridinyl)-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazin-5-yl 4-methyl-1-piperazinecarboxylate; 6-(5-chloro-2-pyridyl)-6,7-dihydro-7-oxo-5H-pyrrolo(3,4-b)pyrazin-5-yl 4-methyl-1-piperazinecarboxylate; 6-(5-chloropyrid-2-yl)-5-(4-methylpiperazin-1-yl)carbonyloxy-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine; 6-(5-chloropyridin-2-yl)-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazin-5-yl 4-methylpiperazine-1-carboxylate DMPI6Z0 CP Sanofi-Aventis DMPI6Z0 TC Hypnotics and Sedatives DMPI6Z0 DT Small molecular drug DMPI6Z0 PC 5735 DMPI6Z0 MW 388.8 DMPI6Z0 FM C17H17ClN6O3 DMPI6Z0 IC InChI=1S/C17H17ClN6O3/c1-22-6-8-23(9-7-22)17(26)27-16-14-13(19-4-5-20-14)15(25)24(16)12-3-2-11(18)10-21-12/h2-5,10,16H,6-9H2,1H3 DMPI6Z0 CS CN1CCN(CC1)C(=O)OC2C3=NC=CN=C3C(=O)N2C4=NC=C(C=C4)Cl DMPI6Z0 IK GBBSUAFBMRNDJC-UHFFFAOYSA-N DMPI6Z0 IU [6-(5-chloropyridin-2-yl)-5-oxo-7H-pyrrolo[3,4-b]pyrazin-7-yl] 4-methylpiperazine-1-carboxylate DMPI6Z0 CA CAS 43200-80-2 DMPI6Z0 CB CHEBI:32315 DMPI6Z0 DE Insomnia DMRMCXW ID DMRMCXW DMRMCXW DN Zotarolimus DMRMCXW HS Approved DMRMCXW SN Abt-578; Zotarolimus (TN) DMRMCXW CP Medtronic DMRMCXW DT Small molecular drug DMRMCXW PC 9876378 DMRMCXW MW 966.2 DMRMCXW FM C52H79N5O12 DMRMCXW IC InChI=1S/C52H79N5O12/c1-31-16-12-11-13-17-32(2)43(65-8)28-39-21-19-37(7)52(64,69-39)49(61)50(62)56-23-15-14-18-41(56)51(63)68-44(34(4)26-38-20-22-40(45(27-38)66-9)57-30-53-54-55-57)29-42(58)33(3)25-36(6)47(60)48(67-10)46(59)35(5)24-31/h11-13,16-17,25,30-31,33-35,37-41,43-45,47-48,60,64H,14-15,18-24,26-29H2,1-10H3/b13-11+,16-12+,32-17+,36-25+/t31-,33-,34-,35-,37-,38+,39+,40+,41+,43+,44+,45-,47-,48+,52-/m1/s1 DMRMCXW CS C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@@H]([C@@H](C4)OC)N5C=NN=N5)C)/C)O)OC)C)C)/C)OC DMRMCXW IK CGTADGCBEXYWNE-JUKNQOCSSA-N DMRMCXW IU (1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-19,30-dimethoxy-12-[(2R)-1-[(1S,3R,4S)-3-methoxy-4-(tetrazol-1-yl)cyclohexyl]propan-2-yl]-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone DMRMCXW CA CAS 221877-54-9 DMRMCXW CB CHEBI:135897 DMRMCXW DE Solid tumour/cancer DMF3VXA ID DMF3VXA DMF3VXA DN Zotepine DMF3VXA HS Approved DMF3VXA SN zotepine; 26615-21-4; Nipolept; Lodopin; Zoleptil; Zotepina; Zotepinum; Compound-4; Zotepina [Spanish]; Zotepinum [INN-Latin]; Zotepina [INN-Spanish]; UNII-U29O83JAZW; 2-Chloro-11-(2-(dimethylamino)ethoxy)dibenzo(b,f)thiepin; 2-Chlor-11-(2-dimethylaminoaethoxy)-dibenzo(b,f)-thiepin; C18H18ClNOS; BRN 1435710; U29O83JAZW; CHEMBL285802; CHEBI:32316; HDOZVRUNCMBHFH-UHFFFAOYSA-N; 2-[(8-chlorodibenzo[b,f]thiepin-10-yl)oxy]-N,N-dimethylethanamine; 2-Chloro-11-(2-dimethylaminoethoxy)-dibenzo(b,f)thiepine; NCGC00182081-02 DMF3VXA DT Small molecular drug DMF3VXA PC 5736 DMF3VXA MW 331.9 DMF3VXA FM C18H18ClNOS DMF3VXA IC InChI=1S/C18H18ClNOS/c1-20(2)9-10-21-16-11-13-5-3-4-6-17(13)22-18-8-7-14(19)12-15(16)18/h3-8,11-12H,9-10H2,1-2H3 DMF3VXA CS CN(C)CCOC1=CC2=CC=CC=C2SC3=C1C=C(C=C3)Cl DMF3VXA IK HDOZVRUNCMBHFH-UHFFFAOYSA-N DMF3VXA IU 2-(3-chlorobenzo[b][1]benzothiepin-5-yl)oxy-N,N-dimethylethanamine DMF3VXA CA CAS 26615-21-4 DMF3VXA CB CHEBI:32316 DMF3VXA DE Anxiety disorder DMKYD5N ID DMKYD5N DMKYD5N DN Zuclopenthixol DMKYD5N HS Approved DMKYD5N SN Acuphase; CLOPENTHIXOL; Cisordinol; Clopenthixolum; Clopentixol; Clopixol; Zuclopenthixolum; Zuclopentixol; Alpha Clopenthixol; Zuclopenthixolum [Latin]; Zuclopentixol [Spanish]; Acuphase (TN); Alpha-Clopenthixol; Cisordinol (TN); Clopenthixol (USAN); Clopixol (TN); Zuclopenthixol (INN); Zuclopenthixol [BAN:INN]; (Z)-4-(3-(2-Chlorothioxanthen-9-ylidene)propyl)-1-piperazineethanol; 2-[4-[(3Z)-3-(2-chlorothioxanthen-9-ylidene)propyl]piperazin-1-yl]ethanol; 2-{4-[(3Z)-3-(2-chloro-10H-dibenzo[b,e]thiopyran-10-ylidene)propyl]piperazin-1-yl}ethanol; 2-{4-[3-(2-chloro-10H-dibenzo[b,e]thiopyran-10-ylidene)propyl]piperazin-1-yl}ethanol; 4-(3-(2-Chlorothioxanthen-9-ylidene)propyl)-1-piperazineethanol DMKYD5N CP Lundbeck pharmaceutical company DMKYD5N TC Antipsychotic Agents DMKYD5N DT Small molecular drug DMKYD5N PC 5311507 DMKYD5N MW 401 DMKYD5N FM C22H25ClN2OS DMKYD5N IC InChI=1S/C22H25ClN2OS/c23-17-7-8-22-20(16-17)18(19-4-1-2-6-21(19)27-22)5-3-9-24-10-12-25(13-11-24)14-15-26/h1-2,4-8,16,26H,3,9-15H2/b18-5- DMKYD5N CS C1CN(CCN1CC/C=C\\2/C3=CC=CC=C3SC4=C2C=C(C=C4)Cl)CCO DMKYD5N IK WFPIAZLQTJBIFN-DVZOWYKESA-N DMKYD5N IU 2-[4-[(3Z)-3-(2-chlorothioxanthen-9-ylidene)propyl]piperazin-1-yl]ethanol DMKYD5N CA CAS 53772-83-1 DMKYD5N CB CHEBI:51364 DMKYD5N DE Schizophrenia DMRCOU5 ID DMRCOU5 DMRCOU5 DN Dicycloplatin DMRCOU5 HS Registered DMRCOU5 CP Peking University DMRCOU5 PC 44475103 DMRCOU5 MW 515.38 DMRCOU5 FM C12H20N2O8Pt DMRCOU5 IC InChI=1S/2C6H8O4.2H3N.Pt/c2*7-4(8)6(5(9)10)2-1-3-6;;;/h2*1-3H2,(H,7,8)(H,9,10);2*1H3;/q;;;;+2/p-2 DMRCOU5 CS C1CC(C1)(C(=O)O)C(=O)O.C1CC(C1)(C(=O)[O-])C(=O)[O-].N.N.[Pt+2] DMRCOU5 IK IIJQICKYWPGJDT-UHFFFAOYSA-L DMRCOU5 IU azane;cyclobutane-1,1-dicarboxylate;cyclobutane-1,1-dicarboxylic acid;platinum(2+) DMRCOU5 CA CAS 287402-09-9 DMRCOU5 DE Prostate cancer DMBZ27L ID DMBZ27L DMBZ27L DN Favipiravir DMBZ27L HS Registered DMBZ27L SN AIDS121660; Favipiravir (JAN/INN); 3-bromo-5-hydroxy-4-methyl-2,6-dinitro-benzoic Acid; T705 DMBZ27L CP Toyama Chemical DMBZ27L DT Small molecular drug DMBZ27L PC 492405 DMBZ27L MW 157.1 DMBZ27L FM C5H4FN3O2 DMBZ27L IC InChI=1S/C5H4FN3O2/c6-2-1-8-5(11)3(9-2)4(7)10/h1H,(H2,7,10)(H,8,11) DMBZ27L CS C1=C(N=C(C(=O)N1)C(=O)N)F DMBZ27L IK ZCGNOVWYSGBHAU-UHFFFAOYSA-N DMBZ27L IU 5-fluoro-2-oxo-1H-pyrazine-3-carboxamide DMBZ27L CA CAS 259793-96-9 DMBZ27L CB CHEBI:134722 DMBZ27L DE Influenza virus infection DMDWYUN ID DMDWYUN DMDWYUN DN HBI-8000 DMDWYUN HS Registered DMDWYUN SN CS055; SCHEMBL5500152; GTPL8305; AKOS026750315; N-(2-amino-5-fluorophenyl)-4-{[3-(pyridin-3-yl)prop-2-enamido]methyl}benzamide DMDWYUN CP HUYA Bioscience International; Quintiles DMDWYUN DT Small molecular drug DMDWYUN PC 12136798 DMDWYUN MW 390.4 DMDWYUN FM C22H19FN4O2 DMDWYUN IC InChI=1S/C22H19FN4O2/c23-18-8-9-20(19(24)12-18)27-22(29)17-6-3-16(4-7-17)14-26-21(28)10-5-15-2-1-11-25-13-15/h1-13H,14,24H2,(H,26,28)(H,27,29)/b10-5+ DMDWYUN CS C1=CC(=CN=C1)/C=C/C(=O)NCC2=CC=C(C=C2)C(=O)NC3=C(C=C(C=C3)F)N DMDWYUN IK SZMJVTADHFNAIS-BJMVGYQFSA-N DMDWYUN IU N-(2-amino-4-fluorophenyl)-4-[[[(E)-3-pyridin-3-ylprop-2-enoyl]amino]methyl]benzamide DMDWYUN CA CAS 1616493-44-7 DMDWYUN CB CHEBI:135918 DMDWYUN DE Solid tumour/cancer; Melanoma; Merkel cell carcinoma; Renal cell carcinoma; Non-small-cell lung cancer DM5GFIK ID DM5GFIK DM5GFIK DN Icotinib hydrochloride DM5GFIK HS Registered DM5GFIK SN Conmana; Conmanna; Icotinib; BPI-2009-H DM5GFIK CP Beta Pharma Inc DM5GFIK DT Small molecular drug DM5GFIK PC 44609731 DM5GFIK MW 427.9 DM5GFIK FM C22H22ClN3O4 DM5GFIK IC InChI=1S/C22H21N3O4.ClH/c1-2-16-4-3-5-17(12-16)25-22-18-13-20-21(14-19(18)23-15-24-22)29-11-9-27-7-6-26-8-10-28-20;/h1,3-5,12-15H,6-11H2,(H,23,24,25);1H DM5GFIK CS C#CC1=CC(=CC=C1)NC2=NC=NC3=CC4=C(C=C32)OCCOCCOCCO4.Cl DM5GFIK IK PNNGXMJMUUJHAV-UHFFFAOYSA-N DM5GFIK IU N-(3-ethynylphenyl)-2,5,8,11-tetraoxa-15,17-diazatricyclo[10.8.0.014,19]icosa-1(12),13,15,17,19-pentaen-18-amine;hydrochloride DM5GFIK CA CAS 1204313-51-8 DM5GFIK DE Non-small-cell lung cancer DM5GIWZ ID DM5GIWZ DM5GIWZ DN Mirogabalin DM5GIWZ HS Registered DM5GIWZ SN Mirogabalin; 1138245-13-2; UNII-S7LK2KDM5U; DS-5565; S7LK2KDM5U; Bicyclo[3.2.0]hept-3-ene-6-acetic acid, 6-(aminomethyl)-3-ethyl-, (1R,5S,6S)-; Bicyclo(3.2.0)hept-3-ene-6-acetic acid, 6-(aminomethyl)-3-ethyl-, (1R,5S,6S)-; 2-((1R,5S,6S)-6-(aminomethyl)-3-ethylbicyclo[3.2.0]hept-3-en-6-yl)acetic acid; ((1R,5S,6S)-6-(Aminomethyl)-3-ethylbicyclo(3.2.0)hept-3-en-6-yl)acetic acid; Mirogabalin [INN]; Mirogabalin [USAN:INN]; [(1R,5S,6S)-6-(Aminomethyl)-3-ethylbicyclo[3.2.0]hept-3-en-6-yl]acetic acid; DS5565; DS 5565; GTPL8303 DM5GIWZ DT Small molecular drug DM5GIWZ PC 59509752 DM5GIWZ MW 209.28 DM5GIWZ FM C12H19NO2 DM5GIWZ IC InChI=1S/C12H19NO2/c1-2-8-3-9-5-12(7-13,6-11(14)15)10(9)4-8/h4,9-10H,2-3,5-7,13H2,1H3,(H,14,15)/t9-,10-,12-/m1/s1 DM5GIWZ CS CCC1=C[C@@H]2[C@H](C1)C[C@@]2(CC(=O)O)CN DM5GIWZ IK FTBQORVNHOIASH-CKYFFXLPSA-N DM5GIWZ IU 2-[(1R,5S,6S)-6-(aminomethyl)-3-ethyl-6-bicyclo[3.2.0]hept-3-enyl]acetic acid DM5GIWZ CA CAS 1138245-13-2 DM5GIWZ DE Fibromyalgia; Cancer related pain; Cardiovascular disease; Peripheral neuropathy DMY67U8 ID DMY67U8 DMY67U8 DN Trapidil DMY67U8 HS Phase 4 DMY67U8 SN trapidil; Trapymin; Rocornal; 15421-84-8; Avantrin; Trapymine; N,N-diethyl-5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine; AR 12008; Trapidilum [INN-Latin]; UNII-EYG5Y6355E; EINECS 239-434-2; BRN 0186842; 7-Diethylamino-5-methyl-s-triazolo(1,5-a)pyrimidine; MLS000567667; EYG5Y6355E; N,N-Diethyl-5-methyl-(1,2,4)triazolo(1,5-a)pyrimidine-7-amine; (1,2,4)Triazolo(1,5-a)pyrimidin-7-amine, N,N-diethyl-5-methyl-; 5-Methyl-7-diethylamino-s-triazolo-(1,5-a)-pyrimidine; NCGC00016715-01; AR-12008; SMR000154170; SU10991 DMY67U8 DT Small molecular drug DMY67U8 PC 5531 DMY67U8 MW 205.26 DMY67U8 FM C10H15N5 DMY67U8 IC InChI=1S/C10H15N5/c1-4-14(5-2)9-6-8(3)13-10-11-7-12-15(9)10/h6-7H,4-5H2,1-3H3 DMY67U8 CS CCN(CC)C1=CC(=NC2=NC=NN12)C DMY67U8 IK GSNOZLZNQMLSKJ-UHFFFAOYSA-N DMY67U8 IU N,N-diethyl-5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine DMY67U8 CA CAS 15421-84-8 DMY67U8 CB CHEBI:32254 DMY67U8 DE Multiple myeloma; Coronary artery disease; Acute coronary syndrome DMVZL26 ID DMVZL26 DMVZL26 DN 3,4-Dihydroxycinnamic Acid DMVZL26 HS Phase 4 DMVZL26 SN Caffeic acid; caffeic acid; 3,4-Dihydroxycinnamic acid; 331-39-5; 3-(3,4-dihydroxyphenyl)acrylic acid; 501-16-6; (E)-3-(3,4-dihydroxyphenyl)acrylic acid; 3,4-Dihydroxybenzeneacrylic acid; (2E)-3-(3,4-dihydroxyphenyl)prop-2-enoic acid; trans-caffeic acid; trans-Caffeate; 3,4-Dihydroxy-trans-cinnamate; 2-Propenoic acid, 3-(3,4-dihydroxyphenyl)-; Cinnamic acid, 3,4-dihydroxy-; 3-(3,4-Dihydroxyphenyl)propenoic acid; UNII-U2S3A33KVM; 3-(3,4-Dihydroxyphenyl)-2-propenoic acid; 4-(2-Carboxyethenyl)-1,2-dihydroxybenzene DMVZL26 DT Small molecular drug DMVZL26 PC 689043 DMVZL26 MW 180.16 DMVZL26 FM C9H8O4 DMVZL26 IC InChI=1S/C9H8O4/c10-7-3-1-6(5-8(7)11)2-4-9(12)13/h1-5,10-11H,(H,12,13)/b4-2+ DMVZL26 CS C1=CC(=C(C=C1/C=C/C(=O)O)O)O DMVZL26 IK QAIPRVGONGVQAS-DUXPYHPUSA-N DMVZL26 IU (E)-3-(3,4-dihydroxyphenyl)prop-2-enoic acid DMVZL26 CA CAS 331-39-5 DMVZL26 CB CHEBI:16433 DMVZL26 DE Thrombocytopenia DML6CN4 ID DML6CN4 DML6CN4 DN Acemetacin DML6CN4 HS Phase 4 DML6CN4 SN Acemetacina; Acemetacina [INN-Spanish]; Acemetacine; Acemetacine [INN-French]; Acemetacinum; Acemetacinum [INN-Latin]; Acemix; Aximeixin; Emflex; Rantudil; Rheumibis; TVX 3322; indometacin carboxymethyl ester; indometacin glycolic ester; indomethacin carboxymethyl ester; indomethacin glycolic ester; 1H-Indole-3-acetic acid, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl-, carboxymethyl ester; 53164-05-9; BRN 0501672; Bay f 4975; C21H18ClNO6; CHEBI:31162; CHEMBL189171; EINECS 258-403-4; K 708; K-708; UNII-5V141XK28X; acemetacin DML6CN4 PC 1981 DML6CN4 MW 415.8 DML6CN4 FM C21H18ClNO6 DML6CN4 IC FSQKKOOTNAMONP-UHFFFAOYSA-N DML6CN4 CS CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)OCC(=O)O DML6CN4 IK 1S/C21H18ClNO6/c1-12-16(10-20(26)29-11-19(24)25)17-9-15(28-2)7-8-18(17)23(12)21(27)13-3-5-14(22)6-4-13/h3-9H,10-11H2,1-2H3,(H,24,25) DML6CN4 IU 2-[2-[1-(4-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]acetyl]oxyacetic acid DML6CN4 CA CAS 53164-05-9 DML6CN4 CB CHEBI:31162 DML6CN4 DE Osteoarthritis DM4UE3K ID DM4UE3K DM4UE3K DN Acetylcarnitine DM4UE3K HS Phase 4 DM4UE3K SN (-)-Acetylcarnitine; (3R)-3-acetyloxy-4-(trimethylazaniumyl)butanoate; (R)-Acetylcarnitine; 3040-38-8; 6DH1W9VH8Q; ALCAR; Acetyl-L-(-)-carnitine; Acetyl-L-carnitine; Acetylcarnitine, L-; CAR(2:0); CHEBI:57589; Carnitine, acetyl-, L-; HSDB 7587; L-ACETYLCARNITINE; L-Acetyl carnitine; L-Carnitine acetyl ester; L-O-Acetylcarnitine; Levocarnitine acetyl; Nicetile; O-Acetyl-L-carnitine; R-Acetylcarnitine; RDHQFKQIGNGIED-MRVPVSSYSA-N; UNII-6DH1W9VH8Q; acetyl l-carnitine; acetyl-carnitine; acetylcarnitine DM4UE3K DT Small molecular drug DM4UE3K PC 7045767 DM4UE3K MW 203.238 DM4UE3K FM C9H17NO4 DM4UE3K IC InChI=1S/C9H17NO4/c1-7(11)14-8(5-9(12)13)6-10(2,3)4/h8H,5-6H2,1-4H3/t8-/m1/s1 DM4UE3K CS CC(=O)OC(CC(=O)[O-])C[N+](C)(C)C DM4UE3K IK RDHQFKQIGNGIED-MRVPVSSYSA-N DM4UE3K IU (3R)-3-acetyloxy-4-(trimethylazaniumyl)butanoate DM4UE3K CA CAS 3040-38-8 DM4UE3K CB CHEBI:57589 DM4UE3K DE Migraine DM1237M ID DM1237M DM1237M DN Alfacalcidol DM1237M HS Phase 4 DM1237M SN Alfacalcidol [INN:BAN:JAN]; Alfacalcidolum; Alfacalcidolum [INN-Latin]; Alfarol; Alpha D 3; Alphacalcidol; Alsiodol; Bondiol; EinsAlpha; One-Alpha; Oxydevit; Sinovul; URQ2517572; Un-Alpha; Vitamin D3, 1alpha-Hydroxy-; alfacalcidol; alpha-Calcidol; (5Z,7E)-9,10-Seco-5,7,10(19)-cholestatrien-1alpha,3beta-diol; 1-Hydroxycholecalciferol; 1-Hydroxyvitamin D3; 1alpha-Hydroxy-vitamin D3; 1alpha-Hydroxycholecalciferol; 1alpha-Hydroxyvitamin D3; 1alpha-OH-D3; 41294-56-8; CCRIS 3341; CHEBI:31186; UNII-URQ2517572 DM1237M PC 5282181 DM1237M MW 400.6 DM1237M FM C27H44O2 DM1237M IC OFHCOWSQAMBJIW-AVJTYSNKSA-N DM1237M CS CC(C)CCCC(C)C1CCC2C1(CCCC2=CC=C3CC(CC(C3=C)O)O)C DM1237M IK 1S/C27H44O2/c1-18(2)8-6-9-19(3)24-13-14-25-21(10-7-15-27(24,25)5)11-12-22-16-23(28)17-26(29)20(22)4/h11-12,18-19,23-26,28-29H,4,6-10,13-17H2,1-3,5H3/b21-11+,22-12-/t19-,23-,24-,25+,26+,27-/m1/s1 DM1237M IU (1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-7a-methyl-1-[(2R)-6-methylheptan-2-yl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol DM1237M CA CAS 41294-56-8 DM1237M CB CHEBI:31186 DM1237M DE Diabetes mellitus DMY2AH1 ID DMY2AH1 DMY2AH1 DN Aminophenazone DMY2AH1 HS Phase 4 DMY2AH1 SN AMINOPYRINE; Amidazofen; Amidazophen; Amidazophene; Amidofebrin; Amidofen; Amidophen; Amidophenazone; Amidopyrazoline; Amidopyrin; Amidopyrine; Aminofenazone; Aminophenazon; Aminopyrin; Anafebrina; Brufaneuxol; Dereuma; Dimapyrin; Dimethylaminoantipyrine; Dimethylaminoazophene; Dimethylaminophenazone; Dipirin; Dipyrin; Dipyrine; Eufibron; Febrinina; Febron; Hyparon; Itamidone; Mamallet-A; Novamidon; Piramidon; Pirazon; Piridol; Piromidina; Polinalin; Pyradone; Pyramidon; Pyramidone; aminophenazone; 4-Dimethylaminoantipyrine; 58-15-1 DMY2AH1 PC 6009 DMY2AH1 MW 231.29 DMY2AH1 FM C13H17N3O DMY2AH1 IC RMMXTBMQSGEXHJ-UHFFFAOYSA-N DMY2AH1 CS CC1=C(C(=O)N(N1C)C2=CC=CC=C2)N(C)C DMY2AH1 IK 1S/C13H17N3O/c1-10-12(14(2)3)13(17)16(15(10)4)11-8-6-5-7-9-11/h5-9H,1-4H3 DMY2AH1 IU 4-(dimethylamino)-1,5-dimethyl-2-phenylpyrazol-3-one DMY2AH1 CA CAS 58-15-1 DMY2AH1 CB CHEBI:160246 DMY2AH1 DE Anaesthesia DMWDEN0 ID DMWDEN0 DMWDEN0 DN Amylin DMWDEN0 HS Phase 4 DMWDEN0 SN Amlintide; Pancreatic amylin; IAPP; Islet amyloid polypeptide; Insulinoma amyloid peptide; Diabetes-associated peptide; Insulinoma amyloid polypeptide; Amylin (human); Amlintide [USAN:INN]; 122384-88-7; Human islet amyloid peptide; AC001; AC 001; SCHEMBL374892; C8H16N2O4.C4H10; LS-172011; FT-0688968 DMWDEN0 DT Small molecular drug DMWDEN0 PC 16132430 DMWDEN0 MW 3903.3 DMWDEN0 FM C165H261N51O55S2 DMWDEN0 IC InChI=1S/C165H261N51O55S2/c1-22-75(12)124(159(266)200-95(47-71(4)5)140(247)203-108(64-219)153(260)206-110(66-221)154(261)216-129(84(21)226)163(270)202-105(58-119(174)234)147(254)209-122(73(8)9)157(264)181-61-121(236)187-106(62-217)150(257)198-103(56-117(172)232)148(255)215-128(83(20)225)162(269)190-93(130(175)237)49-87-38-40-89(227)41-39-87)211-132(239)76(13)183-120(235)60-180-136(243)97(50-85-32-25-23-26-33-85)194-144(251)101(54-115(170)230)196-145(252)102(55-116(171)231)197-151(258)107(63-218)205-152(259)109(65-220)204-142(249)99(52-88-59-178-69-182-88)201-158(265)123(74(10)11)210-146(253)96(48-72(6)7)193-141(248)98(51-86-34-27-24-28-35-86)195-143(250)100(53-114(169)229)191-131(238)77(14)184-139(246)94(46-70(2)3)192-137(244)91(37-31-45-179-165(176)177)188-138(245)92(42-43-113(168)228)189-161(268)126(81(18)223)212-133(240)78(15)185-155(262)111-67-272-273-68-112(207-135(242)90(167)36-29-30-44-166)156(263)199-104(57-118(173)233)149(256)214-125(80(17)222)160(267)186-79(16)134(241)213-127(82(19)224)164(271)208-111/h23-28,32-35,38-41,59,69-84,90-112,122-129,217-227H,22,29-31,36-37,42-58,60-68,166-167H2,1-21H3,(H2,168,228)(H2,169,229)(H2,170,230)(H2,171,231)(H2,172,232)(H2,173,233)(H2,174,234)(H2,175,237)(H,178,182)(H,180,243)(H,181,264)(H,183,235)(H,184,246)(H,185,262)(H,186,267)(H,187,236)(H,188,245)(H,189,268)(H,190,269)(H,191,238)(H,192,244)(H,193,248)(H,194,251)(H,195,250)(H,196,252)(H,197,258)(H,198,257)(H,199,263)(H,200,266)(H,201,265)(H,202,270)(H,203,247)(H,204,249)(H,205,259)(H,206,260)(H,207,242)(H,208,271)(H,209,254)(H,210,253)(H,211,239)(H,212,240)(H,213,241)(H,214,256)(H,215,255)(H,216,261)(H4,176,177,179)/t75-,76-,77-,78-,79-,80+,81+,82+,83+,84+,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,122-,123-,124-,125-,126-,127-,128-,129-/m0/s1 DMWDEN0 CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CC3=CN=CN3)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC4=CC=CC=C4)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C)NC(=O)[C@@H]5CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N5)[C@@H](C)O)C)[C@@H](C)O)CC(=O)N)NC(=O)[C@H](CCCCN)N DMWDEN0 IK PLOPBXQQPZYQFA-AXPWDRQUSA-N DMWDEN0 IU (2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-4-amino-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-4-amino-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-1-amino-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]-2-[[(2S,3R)-2-[[(2S)-2-[[(4R,7S,10S,13S,16S,19R)-16-(2-amino-2-oxoethyl)-19-[[(2S)-2,6-diaminohexanoyl]amino]-7,13-bis[(1R)-1-hydroxyethyl]-10-methyl-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]amino]propanoyl]amino]-3-hydroxybutanoyl]amino]pentanediamide DMWDEN0 CA CAS 106602-62-4 DM8EKSV ID DM8EKSV DM8EKSV DN Anti-MIF antibodies DM8EKSV HS Phase 4 DM8EKSV SN Antimacrophage inhibitory factor, Baxter; Anti-MIF antibodies (inflammation); Anti-MIF antibodies (inflammation), Baxter; Anti-MIF technology, Cytokine/IDEC; Anti-inflammatories, Cytokine/IDEC; Anti-macrophage inhibitory factor, Cytokine/IDEC DM8EKSV CP Baxter healthcare DM8EKSV DE Autoimmune diabetes DML1VXW ID DML1VXW DML1VXW DN Arotinolol DML1VXW HS Phase 4 DML1VXW SN Arotinolol; Arotinolol (INN); Arotinolol [INN]; Arotinololum; Arotinololum [Latin]; (+-)-5-(2-((3-(tert-Butylamino)-2-hydroxypropyl)thio)-4-thiazolyl)-2-thiophenecarboxamide; 2-(3-tert-Butylamino-2-hydroxypropylthio)-4-(5-carbamoyl-2-thienyl)thiazole; 5-(2-((3-(tert-Butylamino)-2-hydroxypropyl)thio)thiazol-4-yl)thiophene-2-carboxamide; 5-[2-[3-(tert-butylamino)-2-hydroxypropyl]sulfanyl-1,3-thiazol-4-yl]thiophene-2-carboxamide; 68377-92-4; AK129719; C15H21N3O2S3; S-596 DML1VXW PC 2239 DML1VXW MW 371.5 DML1VXW FM C15H21N3O2S3 DML1VXW IC BHIAIPWSVYSKJS-UHFFFAOYSA-N DML1VXW CS CC(C)(C)NCC(CSC1=NC(=CS1)C2=CC=C(S2)C(=O)N)O DML1VXW IK 1S/C15H21N3O2S3/c1-15(2,3)17-6-9(19)7-21-14-18-10(8-22-14)11-4-5-12(23-11)13(16)20/h4-5,8-9,17,19H,6-7H2,1-3H3,(H2,16,20) DML1VXW IU 5-[2-[3-(tert-butylamino)-2-hydroxypropyl]sulfanyl-1,3-thiazol-4-yl]thiophene-2-carboxamide DML1VXW CA CAS 68377-92-4 DML1VXW CB CHEBI:135569 DML1VXW DE Essential tremor DMB7WYM ID DMB7WYM DMB7WYM DN ATOSIBAN DMB7WYM HS Phase 4 DMB7WYM SN Atosiban; Tractocile; 90779-69-4; Atosiban acetate; Antocin; UNII-081D12SI0Z; Rwj 22164; Orf-22164; RWJ-22164; CHEMBL382301; 1-Deamino-2D-tyr-(OEt)-4-thr-8-orn-oxytocin; dTVT; 081D12SI0Z; 1-Deamino-2-D-Tyr-(O-ethyl)-4-Thr-8-ornoxytocin; 1-(3-Mercaptopropanoic acid)-2-(O-ethyl-D-tyrosine)-4-L-threonine-8-L-ornithineoxytocin; NCGC00165718-01; Atosibanum [INN-Latin]; ORF 22164; deTVT; Atosibanum; Antocin II; Atosiban [USAN:INN:BAN]; RWJ22164; 1-(3-Mercaptopropionic acid)-2-(3-(p-ethoxyphenyl)-D-alanine)-4-L-threonine-8-L-ornithineox DMB7WYM DT Small molecular drug DMB7WYM PC 5311010 DMB7WYM MW 994.2 DMB7WYM FM C43H67N11O12S2 DMB7WYM IC InChI=1S/C43H67N11O12S2/c1-5-23(3)35-41(63)53-36(24(4)55)42(64)50-29(20-32(45)56)38(60)51-30(43(65)54-17-8-10-31(54)40(62)49-27(9-7-16-44)37(59)47-21-33(46)57)22-68-67-18-15-34(58)48-28(39(61)52-35)19-25-11-13-26(14-12-25)66-6-2/h11-14,23-24,27-31,35-36,55H,5-10,15-22,44H2,1-4H3,(H2,45,56)(H2,46,57)(H,47,59)(H,48,58)(H,49,62)(H,50,64)(H,51,60)(H,52,61)(H,53,63)/t23-,24+,27-,28+,29-,30-,31-,35-,36-/m0/s1 DMB7WYM CS CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSCCC(=O)N[C@@H](C(=O)N1)CC2=CC=C(C=C2)OCC)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CCCN)C(=O)NCC(=O)N)CC(=O)N)[C@@H](C)O DMB7WYM IK VWXRQYYUEIYXCZ-OBIMUBPZSA-N DMB7WYM IU (2S)-N-[(2S)-5-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxopentan-2-yl]-1-[(4R,7S,10S,13S,16R)-7-(2-amino-2-oxoethyl)-13-[(2S)-butan-2-yl]-16-[(4-ethoxyphenyl)methyl]-10-[(1R)-1-hydroxyethyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]pyrrolidine-2-carboxamide DMB7WYM CA CAS 90779-69-4 DMB7WYM CB CHEBI:135899 DMA12HL ID DMA12HL DMA12HL DN Azelnidipine DMA12HL HS Phase 4 DMA12HL SN Azelnidipine; Azelnidipine [INN]; Calblock; RS-9054; 123524-52-7; 3,5-PYRIDINEDICARBOXYLIC ACID, 2-AMINO-1,4-DIHYDRO-6-METHYL-4-(3-NITROPHENYL)-, 3-[1-(DIPHENYLMETHYL)-3-AZETIDINYL] 5-(1-METHYLETHYL) ESTER; 3-(1-Benzhydrylazetidin-3-yl) 5-isopropyl 2-amino-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; C33H34N4O6; CS 905; CS-905; DSSTox_CID_120; DSSTox_GSID_20120; DSSTox_RID_75382; MFCD00865803; NCGC00167436-01; NCGC00167436-02 DMA12HL PC 65948 DMA12HL MW 582.6 DMA12HL FM C33H34N4O6 DMA12HL IC ZKFQEACEUNWPMT-UHFFFAOYSA-N DMA12HL CS CC1=C(C(C(=C(N1)N)C(=O)OC2CN(C2)C(C3=CC=CC=C3)C4=CC=CC=C4)C5=CC(=CC=C5)[N+](=O)[O-])C(=O)OC(C)C DMA12HL IK 1S/C33H34N4O6/c1-20(2)42-32(38)27-21(3)35-31(34)29(28(27)24-15-10-16-25(17-24)37(40)41)33(39)43-26-18-36(19-26)30(22-11-6-4-7-12-22)23-13-8-5-9-14-23/h4-17,20,26,28,30,35H,18-19,34H2,1-3H3 DMA12HL IU 3-O-(1-benzhydrylazetidin-3-yl) 5-O-propan-2-yl 2-amino-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate DMA12HL CA CAS 123524-52-7 DMA12HL CB CHEBI:31247 DMA12HL DE Essential hypertension DMJSDBE ID DMJSDBE DMJSDBE DN Barnidipine DMJSDBE HS Phase 4 DMJSDBE SN Barnidipine [INN]; Barnidipine HCl; Barnidipino; Barnidipino [INN-Spanish]; Barnidipinum; Barnidipinum [INN-Latin]; Libradin; Mepirodipine; VXMOONUMYLCFJD-DHLKQENFSA-N; Vasexten (TN); YM 09730; barnidipine; (S)-3-((S)-1-Benzylpyrrolidin-3-yl) 5-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; 104713-75-9; 2VBY96ASWJ; AC1L9FD3; BCP07244; C27H29N3O6; CHEBI:135793; CHEMBL2103761; CHEMBL2110040; CTK8B6661; SCHEMBL49302; UNII-2VBY96ASWJ DMJSDBE PC 443869 DMJSDBE MW 491.5 DMJSDBE FM C27H29N3O6 DMJSDBE IC VXMOONUMYLCFJD-DHLKQENFSA-N DMJSDBE CS CC1=C(C(C(=C(N1)C)C(=O)OC2CCN(C2)CC3=CC=CC=C3)C4=CC(=CC=C4)[N+](=O)[O-])C(=O)OC DMJSDBE IK 1S/C27H29N3O6/c1-17-23(26(31)35-3)25(20-10-7-11-21(14-20)30(33)34)24(18(2)28-17)27(32)36-22-12-13-29(16-22)15-19-8-5-4-6-9-19/h4-11,14,22,25,28H,12-13,15-16H2,1-3H3/t22-,25-/m0/s1 DMJSDBE IU 5-O-[(3S)-1-benzylpyrrolidin-3-yl] 3-O-methyl (4S)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate DMJSDBE CA CAS 104713-75-9 DMJSDBE CB CHEBI:135793 DMJSDBE DE Essential hypertension DMLKUG7 ID DMLKUG7 DMLKUG7 DN Beclabuvir DMLKUG7 HS Phase 4 DMLKUG7 SN Beclabuvir; Beclabuvir (USAN/INN); Beclabuvir(BMS-791325); SB16521; 958002-33-0; BDBM50448498; BMS-791325; CHEMBL3126842; CS-6041; HY-12429; SCHEMBL11951525; cyclohexyl-N-(dimethylsulfamoyl)-methoxy-(3-methyl-3,8-diazabicyclo[3.2.1]octane-8-carbonyl)[?]carboxamide DMLKUG7 PC 49773361 DMLKUG7 MW 659.8 DMLKUG7 FM C36H45N5O5S DMLKUG7 IC ZTTKEBYSXUCBSE-VSBZUFFNSA-N DMLKUG7 CS CN1CC2CCC(C1)N2C(=O)C34CC3C5=C(C=CC(=C5)OC)C6=C(C7=C(N6C4)C=C(C=C7)C(=O)NS(=O)(=O)N(C)C)C8CCCCC8 DMLKUG7 IK 1S/C36H45N5O5S/c1-38(2)47(44,45)37-34(42)23-10-14-28-31(16-23)40-21-36(35(43)41-24-11-12-25(41)20-39(3)19-24)18-30(36)29-17-26(46-4)13-15-27(29)33(40)32(28)22-8-6-5-7-9-22/h10,13-17,22,24-25,30H,5-9,11-12,18-21H2,1-4H3,(H,37,42)/t24?,25?,30-,36-/m0/s1 DMLKUG7 IU (8S,10R)-19-cyclohexyl-N-(dimethylsulfamoyl)-5-methoxy-10-(3-methyl-3,8-diazabicyclo[3.2.1]octane-8-carbonyl)-12-azapentacyclo[10.7.0.02,7.08,10.013,18]nonadeca-1(19),2(7),3,5,13(18),14,16-heptaene-15-carboxamide DMLKUG7 CA CAS 958002-33-0 DMLKUG7 DE Viral hepatitis DM5NW1E ID DM5NW1E DM5NW1E DN Beclomethasone dipropionate DM5NW1E HS Phase 4 DM5NW1E SN BECLOMETHASONE DIPROPIONATE; Beclometasone dipropionate; Beconase; Beclovent; Vancenase; Beclorhinol; Becloforte; Sanasthmyl; Beclazone; Sanasthmax; Propaderm; Beclomet; Vanceril; Aerobec; Becloturmant; Beclacin; Respocort; Entyderma; Korbutone; Viarox; Rino-clenil; Clenil-A; Beclometasone 17,21-dipropionate; Becotide; Aldecin; Turbinal; Aldecina; Rhinosol; Beclate; Atomase; Alanase; Benconase; Aldecine; Clenil; Spir; Beclocort Nasel; Beclomet Nasal; Propaderm Forte; Rhino Clenil; Inalone O; Inalone R; Qvar; QNASL; Beconase AQ; Qvar 80 DM5NW1E PC 21700 DM5NW1E MW 521 DM5NW1E FM C28H37ClO7 DM5NW1E IC InChI=1S/C28H37ClO7/c1-6-23(33)35-15-22(32)28(36-24(34)7-2)16(3)12-20-19-9-8-17-13-18(30)10-11-25(17,4)27(19,29)21(31)14-26(20,28)5/h10-11,13,16,19-21,31H,6-9,12,14-15H2,1-5H3/t16-,19-,20-,21-,25-,26-,27-,28-/m0/s1 DM5NW1E CS CCC(=O)OCC(=O)C1(C(CC2C1(CC(C3(C2CCC4=CC(=O)C=CC43C)Cl)O)C)C)OC(=O)CC DM5NW1E IK KUVIULQEHSCUHY-XYWKZLDCSA-N DM5NW1E IU [2-[(8S,9R,10S,11S,13S,14S,16S,17R)-9-chloro-11-hydroxy-10,13,16-trimethyl-3-oxo-17-propanoyloxy-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] propanoate DM5NW1E CA CAS 5534-09-8 DM5NW1E CB CHEBI:3002 DM5NW1E DE Allergic rhinitis DMWNP6B ID DMWNP6B DMWNP6B DN Benidipine DMWNP6B HS Phase 4 DMWNP6B SN Benidipene; Benidipine; Benidipine (INN); Benidipine [INN]; Benidipino; Benidipino [Spanish]; Benidipinum; Benidipinum [Latin]; ZINC100014880; ZINC21992076; (+-)-(R*)-3-((R*)-1-Benzyl-3-piperidyl) methyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate; 105979-17-7; 5-O-[(3R)-1-benzylpiperidin-3-yl] 3-O-methyl (4R)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; AC1LCVDP; AKOS015895389; C28H31N3O6; CHEMBL2105555; CHEMBL3303980; CTK8E8626; DTXSID0022648; NCGC00185768-01; SCHEMBL24516 DMWNP6B PC 656668 DMWNP6B MW 505.6 DMWNP6B FM C28H31N3O6 DMWNP6B IC QZVNQOLPLYWLHQ-ZEQKJWHPSA-N DMWNP6B CS CC1=C(C(C(=C(N1)C)C(=O)OC2CCCN(C2)CC3=CC=CC=C3)C4=CC(=CC=C4)[N+](=O)[O-])C(=O)OC DMWNP6B IK 1S/C28H31N3O6/c1-18-24(27(32)36-3)26(21-11-7-12-22(15-21)31(34)35)25(19(2)29-18)28(33)37-23-13-8-14-30(17-23)16-20-9-5-4-6-10-20/h4-7,9-12,15,23,26,29H,8,13-14,16-17H2,1-3H3/t23-,26-/m1/s1 DMWNP6B IU 5-O-[(3R)-1-benzylpiperidin-3-yl] 3-O-methyl (4R)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate DMWNP6B CA CAS 105979-17-7 DMWNP6B DE Diabetic nephropathy DMHKZX1 ID DMHKZX1 DMHKZX1 DN Benzethonium DMHKZX1 HS Phase 4 DMHKZX1 SN Benzethonii chloridum [INN-Latin]; Benzetonio cloruro [DCIT]; Formula 144; Inactisol; Phemerol; Phemersol chloride; Sanizol; Antiseptol (quarternary compound); Solamin; benzethonium; 10172-60-8; 1VU15B70BP; 498-77-1; BZT (VAN); CCRIS 4748; CHEMBL221753; Caswell No. 614B; Chlorure de benzethonium [INN-French]; Cloruro de benzetonio [INN-Spanish]; EINECS 204-479-9; HSDB 567; NCI-C61494; NSC 20200; NSC20200; UNII-1VU15B70BP; benzyl-dimethyl-[2-[2-[4-(1,1,3,3-tetramethylbutyl)phenoxy]ethoxy]ethyl]ammonium DMHKZX1 PC 2335 DMHKZX1 MW 412.6 DMHKZX1 FM C27H42NO2+ DMHKZX1 IC SIYLLGKDQZGJHK-UHFFFAOYSA-N DMHKZX1 CS CC(C)(C)CC(C)(C)C1=CC=C(C=C1)OCCOCC[N+](C)(C)CC2=CC=CC=C2 DMHKZX1 IK 1S/C27H42NO2/c1-26(2,3)22-27(4,5)24-13-15-25(16-14-24)30-20-19-29-18-17-28(6,7)21-23-11-9-8-10-12-23/h8-16H,17-22H2,1-7H3/q+1 DMHKZX1 IU benzyl-dimethyl-[2-[2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethoxy]ethyl]azanium DMHKZX1 CA CAS 10172-60-8 DMHKZX1 CB CHEBI:94725 DMHKZX1 DE Methicillin-resistant staphylococcus infection DML634R ID DML634R DML634R DN Beraprost DML634R HS Phase 4 DML634R SN Beraprost [USAN:INN]; Beraprostum; Beraprostum [INN-Latin]; MDL-201229; ML-1229; beraprost; (+-)-(1R,2R,3aS,8bS)-2,3,3a,8b-Tetrahydro-2-hydroxy-1-((E)-(3S,4RS)-3-hydroxy-4-methyl-1-octen-6-ynyl)-1H-cyclopenta(b)benzofuran-5-butyric acid; 2-Hydroxy-1-(3-hydroxy-4-methyl-1-octen-6-ynyl)-2,3,3a,8b-tetrahydro-1H-cyclopenta(b)benzofuran-5-butanoic acid; 88430-50-6; AC1OCEUA; CHEBI:135633; CHEMBL1207745; CTPOHARTNNSRSR-APJZLKAGSA-N; DTXSID7049136; SCHEMBL16904620; SCHEMBL34593 DML634R PC 6917951 DML634R MW 398.5 DML634R FM C24H30O5 DML634R IC CTPOHARTNNSRSR-APJZLKAGSA-N DML634R CS CC#CCC(C)C(C=CC1C(CC2C1C3=CC=CC(=C3O2)CCCC(=O)O)O)O DML634R IK 1S/C24H30O5/c1-3-4-7-15(2)19(25)13-12-17-20(26)14-21-23(17)18-10-5-8-16(24(18)29-21)9-6-11-22(27)28/h5,8,10,12-13,15,17,19-21,23,25-26H,6-7,9,11,14H2,1-2H3,(H,27,28)/b13-12+/t15?,17-,19+,20+,21-,23-/m0/s1 DML634R IU 4-[(1R,2R,3aS,8bS)-2-hydroxy-1-[(E,3S)-3-hydroxy-4-methyloct-1-en-6-ynyl]-2,3,3a,8b-tetrahydro-1H-cyclopenta[b][1]benzofuran-5-yl]butanoic acid DML634R CA CAS 88430-50-6 DML634R CB CHEBI:135633 DML634R DE Influenza virus infection DMWL182 ID DMWL182 DMWL182 DN Beraprost DMWL182 HS Phase 4 DMWL182 SN beraprost; 88430-50-6; 88430-50-6 (free acid); 1H-Cyclopenta(b)benzofuran-5-butanoic acid, 2,3,3a,8b-tetrahydro-2-hydroxy-1-(3-hydroxy-4-methyl-1-octen-6-ynyl)-; Beraprost (USAN); GTPL1967; SCHEMBL1554142; SCHEMBL1554145; BDBM85181; CAS_2352; NSC_2352; 4-[2-hydroxy-1-[(E)-3-hydroxy-4-methyloct-1-en-6-ynyl]-2,3,3a,8b-tetrahydro-1H-cyclopenta[b][1]benzofuran-5-yl]butanoic acid; K578; D02720; L024061; Q5977854; (E)-4-(2-hydroxy-1-(3-hydroxy-4-methyloct-1-en-6-ynyl)-2,3,3a,8b-tetrahydro-1H-benzo[d]cyclopenta[b]furan-5-yl)butanoic acid; 4-(2-Hydroxy-1-(3-hydroxy-4-methyloct-1-en-6-yn-1-yl)-2,3,3a,8b-tetrahydro-1H-cyclopenta[b]benzofuran-5-yl)butanoic acid; 4-{4-hydroxy-3-[(1E)-3-hydroxy-4-methyloct-1-en-6-yn-1-yl]-7-oxatricyclo[6.4.0.0^{2,6}]dodeca-1(12),8,10-trien-9-yl}butanoic acid DMWL182 DT Small molecular drug DMWL182 PC 5282428 DMWL182 MW 398.5 DMWL182 FM C24H30O5 DMWL182 IC InChI=1S/C24H30O5/c1-3-4-7-15(2)19(25)13-12-17-20(26)14-21-23(17)18-10-5-8-16(24(18)29-21)9-6-11-22(27)28/h5,8,10,12-13,15,17,19-21,23,25-26H,6-7,9,11,14H2,1-2H3,(H,27,28)/b13-12+ DMWL182 CS CC#CCC(C)C(/C=C/C1C(CC2C1C3=CC=CC(=C3O2)CCCC(=O)O)O)O DMWL182 IK CTPOHARTNNSRSR-OUKQBFOZSA-N DMWL182 IU 4-[2-hydroxy-1-[(E)-3-hydroxy-4-methyloct-1-en-6-ynyl]-2,3,3a,8b-tetrahydro-1H-cyclopenta[b][1]benzofuran-5-yl]butanoic acid DMWL182 CA CAS 88430-50-6 DMWL182 DE Pulmonary hypertension DMC5Q8X ID DMC5Q8X DMC5Q8X DN Berberine DMC5Q8X HS Phase 4 DMC5Q8X SN berberine; 2086-83-1; Berberin; Umbellatine; UNII-0I8Y3P32UF; 0I8Y3P32UF; CHEBI:16118; EINECS 218-229-1; Berberal; BRN 3570374; ST055798; 9,10-Dimethoxy-2,3-(methylenedioxy)-7,8,13,13a-tetrahydroberbinium; Benzo(g)-1,3-benzodioxolo(5,6-a)quinolizinium, 5,6-dihydro-9,10-dimethoxy-; 9,10-dimethoxy-5,6-dihydro[1,3]dioxolo[4,5-g]isoquino[3,2-a]isoquinolin-7-ium; Berbamine sulphate acid; CHEMBL12089; 7,8,13,13a-tetradehydro-9,10-dimethoxy-2,3-(methylenedioxy)berbinium; BERBINIUM, 7,8,13,13a-TETRAHYDRO-9,10-DIMETHOXY-2,3-(METHYLE DMC5Q8X DT Small molecular drug DMC5Q8X PC 2353 DMC5Q8X MW 336.4 DMC5Q8X FM C20H18NO4+ DMC5Q8X IC InChI=1S/C20H18NO4/c1-22-17-4-3-12-7-16-14-9-19-18(24-11-25-19)8-13(14)5-6-21(16)10-15(12)20(17)23-2/h3-4,7-10H,5-6,11H2,1-2H3/q+1 DMC5Q8X CS COC1=C(C2=C[N+]3=C(C=C2C=C1)C4=CC5=C(C=C4CC3)OCO5)OC DMC5Q8X IK YBHILYKTIRIUTE-UHFFFAOYSA-N DMC5Q8X IU 16,17-dimethoxy-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaene DMC5Q8X CA CAS 2086-83-1 DMC5Q8X CB CHEBI:16118 DMGXD5T ID DMGXD5T DMGXD5T DN Brotizolam DMGXD5T HS Phase 4 DMGXD5T SN Brotizolamum; Brotizolamum [INN-Latin]; Lendorm; Lendormin; Mederantil; Sintonal; UMSGKTJDUHERQW-UHFFFAOYSA-N; WE 941; WE-941; brotizolam; 2-Bromo-4-(2-chlorophenyl)-9-methyl-6H-thieno(3,2-f)(1,2,4)triazolo(4,3-a)(1,4)diazepine; 2-Bromo-4-(o-chlorophenyl)-9-methyl-6H-thieno(3,2-f)-s-triazolo(4,3-a)(1,4)diazepine; 2-bromo-4-(2-chlorophenyl)-9-methyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine; 57801-81-7; 5XZM1R3DKF; BRN 0839277; C15H10BrClN4S; CHEMBL32479; EINECS 260-964-5; NCGC00183872-01; UNII-5XZM1R3DKF DMGXD5T PC 2451 DMGXD5T MW 393.7 DMGXD5T FM C15H10BrClN4S DMGXD5T IC UMSGKTJDUHERQW-UHFFFAOYSA-N DMGXD5T CS CC1=NN=C2N1C3=C(C=C(S3)Br)C(=NC2)C4=CC=CC=C4Cl DMGXD5T IK 1S/C15H10BrClN4S/c1-8-19-20-13-7-18-14(9-4-2-3-5-11(9)17)10-6-12(16)22-15(10)21(8)13/h2-6H,7H2,1H3 DMGXD5T IU 4-bromo-7-(2-chlorophenyl)-13-methyl-3-thia-1,8,11,12-tetrazatricyclo[8.3.0.02,6]trideca-2(6),4,7,10,12-pentaene DMGXD5T CA CAS 57801-81-7 DMGXD5T CB CHEBI:31308 DMGXD5T DE Insomnia DMXZU73 ID DMXZU73 DMXZU73 DN Carbapenem DMXZU73 HS Phase 4 DMXZU73 SN Carbapenem; Cis-carbapenem; (5R)-1-azabicyclo[3.2.0]hept-2-en-7-one; 2,3-didehydro-1-carbapenam; 67836-EP2275424A1; 67836-EP2295402A2; 67836-EP2305219A1; 67836-EP2308874A1; CHEBI:46765; SCHEMBL37243 DMXZU73 PC 13293131 DMXZU73 MW 109.13 DMXZU73 FM C6H7NO DMXZU73 IC YZBQHRLRFGPBSL-RXMQYKEDSA-N DMXZU73 CS C1C=CN2C1CC2=O DMXZU73 IK 1S/C6H7NO/c8-6-4-5-2-1-3-7(5)6/h1,3,5H,2,4H2/t5-/m1/s1 DMXZU73 IU (5R)-1-azabicyclo[3.2.0]hept-2-en-7-one DMXZU73 CB CHEBI:46765 DMXZU73 DE Infectious cystitis DMJKWPZ ID DMJKWPZ DMJKWPZ DN Cefpirome DMJKWPZ HS Phase 4 DMJKWPZ SN Cefpiroma; Cefpiroma [Spanish]; Cefpirome (INN); Cefpirome [INN:BAN]; Cefpiromum; Cefpiromum [Latin]; Cefrom; Cerfpirome; Keiten; Broact; CEFPIROME; S72Q2F09HY; cefpirome sulfate; cefpirome sulphate; (6R,7R)-7-{[(2Z)-2-(2-Amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-(6,7-dihydro-5H-cyclopenta[b]pyridinium-1-ylmethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; 84957-29-9; C22H22N6O5S2; CHEBI:3503; HR 810; HR-810; NCGC00181339-01; UNII-S72Q2F09HY DMJKWPZ PC 5479539 DMJKWPZ MW 514.6 DMJKWPZ FM C22H22N6O5S2 DMJKWPZ IC DKOQGJHPHLTOJR-WHRDSVKCSA-N DMJKWPZ CS CON=C(C1=CSC(=N1)N)C(=O)NC2C3N(C2=O)C(=C(CS3)C[N+]4=CC=CC5=C4CCC5)C(=O)[O-] DMJKWPZ IK 1S/C22H22N6O5S2/c1-33-26-15(13-10-35-22(23)24-13)18(29)25-16-19(30)28-17(21(31)32)12(9-34-20(16)28)8-27-7-3-5-11-4-2-6-14(11)27/h3,5,7,10,16,20H,2,4,6,8-9H2,1H3,(H3-,23,24,25,29,31,32)/b26-15-/t16-,20-/m1/s1 DMJKWPZ IU (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-(6,7-dihydro-5H-cyclopenta[b]pyridin-1-ium-1-ylmethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate DMJKWPZ CA CAS 84957-29-9 DMJKWPZ CB CHEBI:3503 DMJKWPZ DE Pseudomonas infection DMPZTRC ID DMPZTRC DMPZTRC DN Ceftazidine DMPZTRC HS Phase 4 DMPZTRC SN Ceftazidine [INN]; Ceftazidine [USAN]; Ceftazidine [IBAN]; (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2-carboxypropan-2-yloxyimino)acetyl]amino]-8-oxo-3-(pyridin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;hydroxide DMPZTRC PC 13505813 DMPZTRC MW 564.6 DMPZTRC FM C22H24N6O8S2 DMPZTRC IC GCZOCVAKBHTGOL-ROMZVAKDSA-N DMPZTRC CS CC(C)(C(=O)O)ON=C(C1=CSC(=N1)N)C(=O)NC2C3N(C2=O)C(=C(CS3)C[N+]4=CC=CC=C4)C(=O)O.[OH-] DMPZTRC IK 1S/C22H22N6O7S2.H2O/c1-22(2,20(33)34)35-26-13(12-10-37-21(23)24-12)16(29)25-14-17(30)28-15(19(31)32)11(9-36-18(14)28)8-27-6-4-3-5-7-27;/h3-7,10,14,18H,8-9H2,1-2H3,(H4-,23,24,25,29,31,32,33,34);1H2/b26-13-;/t14-,18-;/m1./s1 DMPZTRC IU (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2-carboxypropan-2-yloxyimino)acetyl]amino]-8-oxo-3-(pyridin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;hydroxide DMPZTRC DE Meningitis DMYGEH7 ID DMYGEH7 DMYGEH7 DN Ceftolozane sulfate DMYGEH7 HS Phase 4 DMYGEH7 SN Ceftolozane; CXA-101; CXA-301; CXA-301); Cephalosporin derivatives, Astellas; Cephalosporinderivatives, Calixa Therapeutics; FR-193879; FR-264205; FR-295389; CXA-101 (inhaled), Calixa; CXA-101 (inhaled), Cubist; Cephalosporin derivative (H pylori/P aeruginosa infection), Astellas; CXA-101 (inhaled, bacterial lung infection), Cubist DMYGEH7 CP Fujisawa Pharmaceutical Co Ltd; Calixa Therapeutics Inc DMYGEH7 DT Small molecular drug DMYGEH7 PC 11592969 DMYGEH7 MW 764.8 DMYGEH7 FM C23H32N12O12S3 DMYGEH7 IC InChI=1S/C23H30N12O8S2.H2O4S/c1-23(2,20(40)41)43-31-11(15-30-21(26)45-32-15)16(36)29-12-17(37)35-13(19(38)39)9(8-44-18(12)35)6-34-7-10(14(25)33(34)3)28-22(42)27-5-4-24;1-5(2,3)4/h7,12,18,25H,4-6,8,24H2,1-3H3,(H7,26,27,28,29,30,32,36,38,39,40,41,42);(H2,1,2,3,4)/b31-11+;/t12-,18-;/m1./s1 DMYGEH7 CS CC(C)(C(=O)O)O/N=C(\\C1=NSC(=N1)N)/C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C[N+]4=CC(=C(N4C)N)NC(=O)NCCN)C(=O)O.OS(=O)(=O)[O-] DMYGEH7 IK UJDQGRLTPBVSFN-GZGOMJRCSA-N DMYGEH7 IU (6R,7R)-3-[[3-amino-4-(2-aminoethylcarbamoylamino)-2-methylpyrazol-1-ium-1-yl]methyl]-7-[[(2E)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(2-carboxypropan-2-yloxyimino)acetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;hydrogen sulfate DMYGEH7 DE Respiratory tract infection DMYTGW0 ID DMYTGW0 DMYTGW0 DN Celiprolol DMYTGW0 HS Phase 4 DMYTGW0 SN Celectol; Celiprolol [INN:BAN]; Celiprololum; Celiprololum [INN-Latin]; RHC 5320 A; RHC-5320A; ST-1396; Selectol; UL/1677; celiprolol; 3-[3-acetyl-4-[3-(tert-butylamino)-2-hydroxypropoxy]phenyl]-1,1-diethylurea; 56980-93-9; BRN 2776298; CCRIS 3400; EINECS 260-497-7; N'-(3-Acetyl-4-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)phenyl)-N,N-diethylurea; Urea, N'-(3-acetyl-4-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)phenyl)-N,N-diethyl- DMYTGW0 PC 2663 DMYTGW0 MW 379.5 DMYTGW0 FM C20H33N3O4 DMYTGW0 IC JOATXPAWOHTVSZ-UHFFFAOYSA-N DMYTGW0 CS CCN(CC)C(=O)NC1=CC(=C(C=C1)OCC(CNC(C)(C)C)O)C(=O)C DMYTGW0 IK 1S/C20H33N3O4/c1-7-23(8-2)19(26)22-15-9-10-18(17(11-15)14(3)24)27-13-16(25)12-21-20(4,5)6/h9-11,16,21,25H,7-8,12-13H2,1-6H3,(H,22,26) DMYTGW0 IU 3-[3-acetyl-4-[3-(tert-butylamino)-2-hydroxypropoxy]phenyl]-1,1-diethylurea DMYTGW0 CA CAS 56980-93-9 DMYTGW0 CB CHEBI:94461 DMYTGW0 DE Essential hypertension DM6C4YJ ID DM6C4YJ DM6C4YJ DN Chlorphenamine DM6C4YJ HS Phase 4 DM6C4YJ SN Chloropheniramine; Chlorophenylpyridamine; Chloropiril; Chloroprophenpyridamine; Chlorphenamin; Chlorphenamine; Chlorphenaminum; Chlorpheniramine maleate; Chlorpheniramine polistirex; Chlorpheniraminum; Chlorprophenpyridamine; Clorfenamina; Clorfeniramina; Clorfeniramina [Italian]; Cloropiril; Aller-Chlor; Allergican; Allergisan; Antagonate; Chlor-trimeton; Haynon; Histadur; Kloromin; Phenetron; Polaramine; Polaronil; Telachlor; Teldrin; chlorpheniramine; 132-22-9; 4-Chloropheniramine DM6C4YJ PC 2725 DM6C4YJ MW 274.79 DM6C4YJ FM C16H19ClN2 DM6C4YJ IC SOYKEARSMXGVTM-UHFFFAOYSA-N DM6C4YJ CS CN(C)CCC(C1=CC=C(C=C1)Cl)C2=CC=CC=N2 DM6C4YJ IK 1S/C16H19ClN2/c1-19(2)12-10-15(16-5-3-4-11-18-16)13-6-8-14(17)9-7-13/h3-9,11,15H,10,12H2,1-2H3/t15-/m1/s1 DM6C4YJ IU 3-(4-chlorophenyl)-N,N-dimethyl-3-pyridin-2-ylpropan-1-amine DM6C4YJ CA CAS 132-22-9 DM6C4YJ CB CHEBI:52010 DM6C4YJ DE Allergy DM0N19Y ID DM0N19Y DM0N19Y DN Chondroitin sulfate DM0N19Y HS Phase 4 DM0N19Y SN Chondritinsulfate; Chondritinsulphate; Chondroitin 4 and 6 sulfate; Chondroitin 4-sulfate; Chondroitin 6-sulfate; Chondroitin polysulfate; Chondroitin sulfate; Chondroitin sulfuric acid; Chondroitin sulfuric acids; Chondroitin sulphate; Chondroitin, CHONDROITIN SULFATES; hydrogen sulfate; Chondroitine sulfate; Chondroitinsulfate C; Chondroitinsulfuric acids; Chondron; Chonsurid; Condrosan; Condrosulf; Sodium chondroitin sulfate; Structum; Uropol S; chondroitin sulfate C; 9007-28-7; EINECS 232-696-9; Gepan; UNII-6IC1M3OG5Z DM0N19Y PC 24766 DM0N19Y MW 463.37 DM0N19Y FM C13H21NO15S DM0N19Y IC KXKPYJOVDUMHGS-OSRGNVMNSA-N DM0N19Y CS CC(=O)NC1C(C(C(OC1O)OS(=O)(=O)O)O)OC2C(C(C(C(O2)C(=O)O)O)O)O DM0N19Y IK 1S/C13H21NO15S/c1-2(15)14-3-8(7(19)13(28-11(3)22)29-30(23,24)25)26-12-6(18)4(16)5(17)9(27-12)10(20)21/h3-9,11-13,16-19,22H,1H3,(H,14,15)(H,20,21)(H,23,24,25)/t3-,4+,5+,6-,7-,8-,9+,11-,12-,13-/m1/s1 DM0N19Y IU (2S,3S,4S,5R,6R)-6-[(2R,3R,4R,5R,6R)-3-acetamido-2,5-dihydroxy-6-sulfooxyoxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid DM0N19Y CA CAS 9007-28-7 DM0N19Y DE Osteoarthritis DMBG0N4 ID DMBG0N4 DMBG0N4 DN Cibenzoline DMBG0N4 HS Phase 4 DMBG0N4 SN Cibenzolina; Cibenzolina [INN-Spanish]; Cibenzoline; Cibenzoline (INN); Cibenzoline [INN]; Cibenzolinum; Cibenzolinum [INN-Latin]; Cifenline; Cifenline (USAN); Cifenline [USAN]; Ro 22-7796; Ro 227796; UP 33901; (+-)-2-(2,2-Diphenylcyclopropyl)-2-imidazoline; 1H-Imidazole, 2-(2,2-diphenylcyclopropyl)-4,5-dihydro-, (+-)-; 2-(2,2-Diphenyl-cyclopropyl)-4,5-dihydro-1H-imidazole; 2-(2,2-diphenylcyclopropyl)-2-imidazoline; 2-(2,2-diphenylcyclopropyl)-4,5-dihydro-1H-imidazole; 53267-01-9; C18H18N2; CHEMBL87045; EINECS 258-453-7 DMBG0N4 PC 2747 DMBG0N4 MW 262.3 DMBG0N4 FM C18H18N2 DMBG0N4 IC IPOBOOXFSRWSHL-UHFFFAOYSA-N DMBG0N4 CS C1CN=C(N1)C2CC2(C3=CC=CC=C3)C4=CC=CC=C4 DMBG0N4 IK 1S/C18H18N2/c1-3-7-14(8-4-1)18(15-9-5-2-6-10-15)13-16(18)17-19-11-12-20-17/h1-10,16H,11-13H2,(H,19,20) DMBG0N4 IU 2-(2,2-diphenylcyclopropyl)-4,5-dihydro-1H-imidazole DMBG0N4 CA CAS 53267-01-9 DMBG0N4 CB CHEBI:135083 DMBG0N4 DE Atrial fibrillation DMSW5QP ID DMSW5QP DMSW5QP DN Cotrimoxazole DMSW5QP HS Phase 4 DMSW5QP SN Centran; Centrin; Cotrim.L.U.T; Eslectin; Insozalin; Biseptol-480; LS-2191; Metomide; Trimedin; Trimethoprim/Sulfamethoxazol; Trimezole; CHEMBL195591; Sulfamethoxazole-Trimethoprim Combination DMSW5QP PC 24719 DMSW5QP MW 542.6 DMSW5QP FM C25H30N6O6S DMSW5QP IC CTNTUFQBOKZSPI-UHFFFAOYSA-N DMSW5QP CS CC1=CC(=NO1)CS(=O)(=O)C2=CC=C(C=C2)N.COC1=CC(=CC(=C1OC)OC)CC2=CN=C(N=C2N)N DMSW5QP IK 1S/C14H18N4O3.C11H12N2O3S/c1-19-10-5-8(6-11(20-2)12(10)21-3)4-9-7-17-14(16)18-13(9)15;1-8-6-10(13-16-8)7-17(14,15)11-4-2-9(12)3-5-11/h5-7H,4H2,1-3H3,(H4,15,16,17,18);2-6H,7,12H2,1H3 DMSW5QP IU 4-[(5-methyl-1,2-oxazol-3-yl)methylsulfonyl]aniline;5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-2,4-diamine DMSW5QP DE Human immunodeficiency virus infection DMLMOIJ ID DMLMOIJ DMLMOIJ DN Cyproterone acetate DMLMOIJ HS Phase 4 DMLMOIJ SN Cyprosterone acetate; Cyproteron acetate; Cyproteron-R acetate; Cyproterone 17-O-acetate; Cyproterone 17.alpha.-acetate; Cyproterone 17alpha-acetate; Cyproterone acetate [USAN:JAN]; Androcur; CYPROTERONE ACETATE; Cyproteroneacetate; SH 714; SH 80714; SH-714; 3'H-Cyclopropa(1,2)pregna-1,4,6-triene-3,20-dione, 17-(acetyloxy)-6-chloro-1,2-dihydro-, (1beta,2beta)-; 427-51-0; 4KM2BN5JHF; C24H29ClO4; CCRIS 4385; CHEBI:50743; CHEMBL139835; EINECS 207-048-3; HSDB 3592; MLS000859908; NSC 81430; NSC-81430; UNII-4KM2BN5JHF DMLMOIJ PC 9880 DMLMOIJ MW 416.9 DMLMOIJ FM C24H29ClO4 DMLMOIJ IC UWFYSQMTEOIJJG-FDTZYFLXSA-N DMLMOIJ CS CC(=O)C1(CCC2C1(CCC3C2C=C(C4=CC(=O)C5CC5C34C)Cl)C)OC(=O)C DMLMOIJ IK 1S/C24H29ClO4/c1-12(26)24(29-13(2)27)8-6-16-14-10-20(25)19-11-21(28)15-9-18(15)23(19,4)17(14)5-7-22(16,24)3/h10-11,14-18H,5-9H2,1-4H3/t14-,15+,16-,17-,18-,22-,23-,24-/m0/s1 DMLMOIJ IU [(1S,2S,3S,5R,11R,12S,15R,16S)-15-acetyl-9-chloro-2,16-dimethyl-6-oxo-15-pentacyclo[9.7.0.02,8.03,5.012,16]octadeca-7,9-dienyl] acetate DMLMOIJ CA CAS 427-51-0 DMLMOIJ CB CHEBI:50743 DMLMOIJ DE Polycystic ovary syndrome DMV6KFY ID DMV6KFY DMV6KFY DN Dapoxetine DMV6KFY HS Phase 4 DMV6KFY SN Priligy (TN) DMV6KFY CP Furiex pharmaceuticals DMV6KFY DT Small molecular drug DMV6KFY PC 71353 DMV6KFY MW 305.4 DMV6KFY FM C21H23NO DMV6KFY IC InChI=1S/C21H23NO/c1-22(2)20(18-10-4-3-5-11-18)15-16-23-21-14-8-12-17-9-6-7-13-19(17)21/h3-14,20H,15-16H2,1-2H3/t20-/m0/s1 DMV6KFY CS CN(C)[C@@H](CCOC1=CC=CC2=CC=CC=C21)C3=CC=CC=C3 DMV6KFY IK USRHYDPUVLEVMC-FQEVSTJZSA-N DMV6KFY IU (1S)-N,N-dimethyl-3-naphthalen-1-yloxy-1-phenylpropan-1-amine DMV6KFY CA CAS 119356-77-3 DMV6KFY CB CHEBI:135962 DMV6KFY DE Premature ejaculation DMV5KTJ ID DMV5KTJ DMV5KTJ DN Demegestone DMV5KTJ HS Phase 4 DMV5KTJ SN Demegestona; Demegestona [INN-Spanish]; Demegestone; Demegestone (INN); Demegestone [INN:DCF]; Demegestonum; Demegestonum [INN-Latin]; Lutionex; R 2453; R-2453; RU 2453; SCHEMBL146550; ZINC4215548; 10116-22-0; 17-Methyl-19-norpregna-4,9-diene-3,20-dione; 17alpha-Methyl-19-demethylpregna-4,9-diene-3,20-dione; 19-Norpregna-4,9-diene-3,20-dione, 17-methyl- (8CI)(9CI); 6E89AM91SZ; AC1L3PEV; CHEBI:135339; CHEMBL2104231; D07223; DTXSID20878581; EINECS 233-320-6; NSC 118189; UNII-6E89AM91SZ DMV5KTJ PC 93057 DMV5KTJ MW 312.4 DMV5KTJ FM C21H28O2 DMV5KTJ IC JWAHBTQSSMYISL-MHTWAQMVSA-N DMV5KTJ CS CC(=O)C1(CCC2C1(CCC3=C4CCC(=O)C=C4CCC23)C)C DMV5KTJ IK 1S/C21H28O2/c1-13(22)20(2)11-9-19-18-6-4-14-12-15(23)5-7-16(14)17(18)8-10-21(19,20)3/h12,18-19H,4-11H2,1-3H3/t18-,19+,20-,21+/m1/s1 DMV5KTJ IU (8S,13S,14S,17S)-17-acetyl-13,17-dimethyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one DMV5KTJ CA CAS 10116-22-0 DMV5KTJ CB CHEBI:135339 DMV5KTJ DE Corpus luteum cyst DMN2Q5I ID DMN2Q5I DMN2Q5I DN Diacerein DMN2Q5I HS Phase 4 DMN2Q5I SN Diacerein; 13739-02-1; Diacetylrhein; Diacerhein; Fisiodar; Artrodar; 1,8-DIACETOXY-3-CARBOXYANTHRAQUINONE; DIACERIN; 4,5-Diacetylrhein; Diacereinum [Latin]; Diacereine [French]; Diacereina [Spanish]; UNII-4HU6J11EL5; Diacerein [INN]; SF-277; C19H12O8; EINECS 237-310-2; BRN 2184909; 4,5-diacetyloxy-9,10-dioxoanthracene-2-carboxylic acid; MLS000028577; 4HU6J11EL5; 1,8-Diacetoxyanthraquinone-3-carboxylic acid; Diacerein (INN); 4,5-diacetyloxy-9,10-dioxo-2-anthracenecarboxylic acid; NCGC00018274-04; SMR000058958; AK468692 DMN2Q5I DT Small molecular drug DMN2Q5I PC 26248 DMN2Q5I MW 368.3 DMN2Q5I FM C19H12O8 DMN2Q5I IC InChI=1S/C19H12O8/c1-8(20)26-13-5-3-4-11-15(13)18(23)16-12(17(11)22)6-10(19(24)25)7-14(16)27-9(2)21/h3-7H,1-2H3,(H,24,25) DMN2Q5I CS CC(=O)OC1=CC=CC2=C1C(=O)C3=C(C2=O)C=C(C=C3OC(=O)C)C(=O)O DMN2Q5I IK TYNLGDBUJLVSMA-UHFFFAOYSA-N DMN2Q5I IU 4,5-diacetyloxy-9,10-dioxoanthracene-2-carboxylic acid DMN2Q5I CA CAS 13739-02-1 DMN2Q5I CB CHEBI:94708 DMTX0PZ ID DMTX0PZ DMTX0PZ DN Dibekacin DMTX0PZ HS Phase 4 DMTX0PZ SN Debecacin; Dibekacin sulfate; Dibekacina; Dibekacina [INN-Spanish]; Dibekacine; Dibekacine [INN-French]; Dibekacinum; Dibekacinum [INN-Latin]; Dideoxykanamycin B; Kappati; Panamicin; dibekacin; 3',4'-Dideoxykanamycin B; 34493-98-6; 45ZFO9E525; BRN 1441606; CHEBI:37945; DKB; DKM; EINECS 252-064-6; O-3-Amino-3-deoxy-alpha-D-glucopyranosyl-(1-4)-O-(2,6-diamino-2,3,4,6-tetradeoxy-alpha-D-erythro-hexopyranosyl-(1-6))-2-deoxy-L-streptamine; UNII-45ZFO9E525 DMTX0PZ PC 470999 DMTX0PZ MW 451.5 DMTX0PZ FM C18H37N5O8 DMTX0PZ IC JJCQSGDBDPYCEO-XVZSLQNASA-N DMTX0PZ CS C1CC(C(OC1CN)OC2C(CC(C(C2O)OC3C(C(C(C(O3)CO)O)N)O)N)N)N DMTX0PZ IK 1S/C18H37N5O8/c19-4-6-1-2-7(20)17(28-6)30-15-8(21)3-9(22)16(14(15)27)31-18-13(26)11(23)12(25)10(5-24)29-18/h6-18,24-27H,1-5,19-23H2/t6-,7+,8-,9+,10+,11-,12+,13+,14-,15+,16-,17+,18+/m0/s1 DMTX0PZ IU (2S,3R,4S,5S,6R)-4-amino-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[(2R,3R,6S)-3-amino-6-(aminomethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-6-(hydroxymethyl)oxane-3,5-diol DMTX0PZ CA CAS 34493-98-6 DMTX0PZ CB CHEBI:37945 DMTX0PZ DE Acute lower respiratory infection DMZ5Y1P ID DMZ5Y1P DMZ5Y1P DN Dichloroacetate DMZ5Y1P HS Phase 4 DMZ5Y1P SN 2,2-dichloroacetate; Dichloracetate; Dichloroacetate ion; 13425-80-4; Dichloroacetic acid ion(1-); DCA; BRN 3903873; 2q8h; ACETIC ACID, DICHLORO-, ION(1-); 2,2-bis(chloranyl)ethanoate; GTPL4518; CHEBI:28240; DTXSID40158610; STL483470; NCGC00241105-01; 68626-EP2292227A2; 68626-EP2292628A2; 68626-EP2298776A1; 68626-EP2308861A1; 68626-EP2374454A1; A839686; Q27077050 DMZ5Y1P DT Small molecular drug DMZ5Y1P PC 25975 DMZ5Y1P MW 127.93 DMZ5Y1P FM C2HCl2O2- DMZ5Y1P IC InChI=1S/C2H2Cl2O2/c3-1(4)2(5)6/h1H,(H,5,6)/p-1 DMZ5Y1P CS C(C(=O)[O-])(Cl)Cl DMZ5Y1P IK JXTHNDFMNIQAHM-UHFFFAOYSA-M DMZ5Y1P IU 2,2-dichloroacetate DMZ5Y1P CA CAS 13425-80-4 DMZ5Y1P CB CHEBI:28240 DMZ5Y1P DE Pulmonary fibrosis; Pyruvate dehydrogenase complex deficiency; Insulin-resistant disorder DMB0FWL ID DMB0FWL DMB0FWL DN Dihydrocodeine DMB0FWL HS Phase 4 DMB0FWL SN Dihydrocodeine bitartrate; DF 118; Dihydrocodeine (oral); S-8115; Dihydrocodeine (oral), Shionogi; (-)-Dihydrocodeine DMB0FWL CP Mundipharma AG DMB0FWL DT Small molecular drug DMB0FWL PC 5284543 DMB0FWL MW 301.4 DMB0FWL FM C18H23NO3 DMB0FWL IC InChI=1S/C18H23NO3/c1-19-8-7-18-11-4-5-13(20)17(18)22-16-14(21-2)6-3-10(15(16)18)9-12(11)19/h3,6,11-13,17,20H,4-5,7-9H2,1-2H3/t11-,12+,13-,17-,18-/m0/s1 DMB0FWL CS CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)OC)O[C@H]3[C@H](CC4)O DMB0FWL IK RBOXVHNMENFORY-DNJOTXNNSA-N DMB0FWL IU (4R,4aR,7S,7aR,12bS)-9-methoxy-3-methyl-2,4,4a,5,6,7,7a,13-octahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-ol DMB0FWL CA CAS 125-28-0 DMB0FWL CB CHEBI:135276 DMB0FWL DE Cancer related pain DM3S8XC ID DM3S8XC DM3S8XC DN Dihydrotestosterone DM3S8XC HS Phase 4 DM3S8XC SN Androstanolone; STANOLONE; dihydrotestosterone; 521-18-6; Andractim; Androlone; Proteina; Anaboleen; Stanaprol; Anabolex; Protona; Neodrol; Cristerona MB; 4-Dihydrotestosterone; 17beta-Hydroxy-5alpha-androstan-3-one; 5alpha-Dihydrotestosterone; Androstanolonum; Androstanolona; DHT; 5-alpha-Dihydrotestosterone; Dihydrotestosteron; Testosterone, dihydro-; 4,5alpha-Dihydrotestosterone; 5alpha-Androstan-17beta-ol-3-one; Stanorone; Stanolon; 17beta-Hydroxyandrostan-3-one; 5alpha-DHT; LG 152; 17beta-Hydroxy-3-androstanone; [3H]dihydrotestosterone DM3S8XC DT Small molecular drug DM3S8XC PC 10635 DM3S8XC MW 290.4 DM3S8XC FM C19H30O2 DM3S8XC IC InChI=1S/C19H30O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h12,14-17,21H,3-11H2,1-2H3/t12-,14-,15-,16-,17-,18-,19-/m0/s1 DM3S8XC CS C[C@]12CCC(=O)C[C@@H]1CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC[C@@H]4O)C DM3S8XC IK NVKAWKQGWWIWPM-ABEVXSGRSA-N DM3S8XC IU (5S,8R,9S,10S,13S,14S,17S)-17-hydroxy-10,13-dimethyl-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-one DM3S8XC CA CAS 521-18-6 DM3S8XC CB CHEBI:16330 DM3S8XC DE Prostate hyperplasia DM3YH4I ID DM3YH4I DM3YH4I DN D-Serine DM3YH4I HS Phase 4 DM3YH4I SN D-serine; 312-84-5; (R)-2-amino-3-hydroxypropanoic acid; (2R)-2-amino-3-hydroxypropanoic acid; Serine D-form; (R)-Serine; Serine, D-; d-(+)-serine; D-2-Amino-3-hydroxypropionic Acid; D-Serin; D-Ser; UNII-1K77H2Z9B1; EINECS 206-229-4; MFCD00004269; NSC 77689; (2R)-2-amino-3-hydroxy-propanoic acid; AI3-18476; CHEMBL285123; CHEBI:16523; MTCFGRXMJLQNBG-UWTATZPHSA-N; 1K77H2Z9B1; (R)-2-Amino-3-hydroxypropionic acid; DSN; NCGC00094363-03; D-Serine, 98%; D-2-Amino-3-hydroxypropanoic acid; NSC77689; serine d-; [3h]-d-serine; (2R)-serine DM3YH4I DT Small molecular drug DM3YH4I PC 71077 DM3YH4I MW 105.09 DM3YH4I FM C3H7NO3 DM3YH4I IC InChI=1S/C3H7NO3/c4-2(1-5)3(6)7/h2,5H,1,4H2,(H,6,7)/t2-/m1/s1 DM3YH4I CS C([C@H](C(=O)O)N)O DM3YH4I IK MTCFGRXMJLQNBG-UWTATZPHSA-N DM3YH4I IU (2R)-2-amino-3-hydroxypropanoic acid DM3YH4I CA CAS 312-84-5 DM3YH4I CB CHEBI:16523 DMH21D9 ID DMH21D9 DMH21D9 DN Ebastine DMH21D9 HS Phase 4 DMH21D9 SN ebastine; Kestine; Ebastel; Ebastin; Evastel; Kestin; Bactil; Ebastinum [Latin]; LAS W-090; Ebastina [Spanish]; Estivan; UNII-TQD7Q784P1; RP 64305; 1-(4-tert-butylphenyl)-4-[4-(diphenylmethoxy)piperidin-1-yl]butan-1-one; TQD7Q784P1; CHEMBL305660; 4-Diphenylmethoxy-1-(3-(4-tert-butylbenzoyl)propyl)piperidine; C32H39NO2; MFCD00865661; 1-[4-(1,1-Dimethylethyl)phenyl]-4-[4-(diphenylmethoxy)-1-piperidinyl]-1-butanone; NCGC00164603-01; RP-64305; 4'-tert-Butyl-4-(4-(diphenylmethoxy)piperidino)butyrophenone DMH21D9 PC 3191 DMH21D9 MW 469.7 DMH21D9 FM C32H39NO2 DMH21D9 IC InChI=1S/C32H39NO2/c1-32(2,3)28-18-16-25(17-19-28)30(34)15-10-22-33-23-20-29(21-24-33)35-31(26-11-6-4-7-12-26)27-13-8-5-9-14-27/h4-9,11-14,16-19,29,31H,10,15,20-24H2,1-3H3 DMH21D9 CS CC(C)(C)C1=CC=C(C=C1)C(=O)CCCN2CCC(CC2)OC(C3=CC=CC=C3)C4=CC=CC=C4 DMH21D9 IK MJJALKDDGIKVBE-UHFFFAOYSA-N DMH21D9 IU 4-(4-benzhydryloxypiperidin-1-yl)-1-(4-tert-butylphenyl)butan-1-one DMH21D9 CA CAS 90729-43-4 DMH21D9 CB CHEBI:31528 DMH21D9 DE Irritable bowel syndrome DMQRX24 ID DMQRX24 DMQRX24 DN Ebastine DMQRX24 HS Phase 4 DMQRX24 SN Ebastel; Ebastin; Ebastina [Spanish]; Ebastinum [Latin]; Estivan; Evastel; Kestin; Kestine; LAS W-090; RP 64305; Bactil; RP-64305; TQD7Q784P1; ebastine; 1-(4-tert-butylphenyl)-4-[4-(diphenylmethoxy)piperidin-1-yl]butan-1-one; 1-[4-(1,1-Dimethylethyl)phenyl]-4-[4-(diphenylmethoxy)-1-piperidinyl]-1-butanone; 4'-tert-Butyl-4-(4-(diphenylmethoxy)piperidino)butyrophenone; 4-Diphenylmethoxy-1-(3-(4-tert-butylbenzoyl)propyl)piperidine; 90729-43-4; C32H39NO2; CHEMBL305660; MFCD00865661; NCGC00164603-01; UNII-TQD7Q784P1 DMQRX24 PC 3191 DMQRX24 MW 469.7 DMQRX24 FM C32H39NO2 DMQRX24 IC MJJALKDDGIKVBE-UHFFFAOYSA-N DMQRX24 CS CC(C)(C)C1=CC=C(C=C1)C(=O)CCCN2CCC(CC2)OC(C3=CC=CC=C3)C4=CC=CC=C4 DMQRX24 IK 1S/C32H39NO2/c1-32(2,3)28-18-16-25(17-19-28)30(34)15-10-22-33-23-20-29(21-24-33)35-31(26-11-6-4-7-12-26)27-13-8-5-9-14-27/h4-9,11-14,16-19,29,31H,10,15,20-24H2,1-3H3 DMQRX24 IU 4-(4-benzhydryloxypiperidin-1-yl)-1-(4-tert-butylphenyl)butan-1-one DMQRX24 CA CAS 90729-43-4 DMQRX24 CB CHEBI:31528 DMQRX24 DE Irritable bowel syndrome DM9WPIH ID DM9WPIH DM9WPIH DN Ergonovine maleate DM9WPIH HS Phase 4 DM9WPIH SN Ergomet; Ergometrin maleate; Ergometrine acid maleate; Ergometrine hydrogen maleate; Ergometrine maleate (1:1); Ergonovine hydrogen maleate; Ergonovine maleate; Ergonovine maleate (USP); Ergonovine maleate [USP]; Ergonovine maleate salt; Ergonovine, maleate (1:1); Ergonovine, maleate (1:1) (salt); Ergotocin maleate; Ermetrin; Metriclavin; Oxytocic; Cornocentin; Crude ergot; D-Ergonovine maleate; YMH3D0ZJWV; ergometrine maleate; 129-51-1; CHEBI:31554; EINECS 204-953-5; NSC 93752; UNII-YMH3D0ZJWV DM9WPIH PC 6437065 DM9WPIH MW 441.5 DM9WPIH FM C23H27N3O6 DM9WPIH IC YREISLCRUMOYAY-IIPCNOPRSA-N DM9WPIH CS CC(CO)NC(=O)C1CN(C2CC3=CNC4=CC=CC(=C34)C2=C1)C.C(=CC(=O)O)C(=O)O DM9WPIH IK 1S/C19H23N3O2.C4H4O4/c1-11(10-23)21-19(24)13-6-15-14-4-3-5-16-18(14)12(8-20-16)7-17(15)22(2)9-13;5-3(6)1-2-4(7)8/h3-6,8,11,13,17,20,23H,7,9-10H2,1-2H3,(H,21,24);1-2H,(H,5,6)(H,7,8)/b;2-1-/t11-,13+,17+;/m0./s1 DM9WPIH IU (6aR,9R)-N-[(2S)-1-hydroxypropan-2-yl]-7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide;(Z)-but-2-enedioic acid DM9WPIH CA CAS 129-51-1 DM9WPIH CB CHEBI:31554 DM9WPIH DE Abnormal vaginal bleeding DMKEGI3 ID DMKEGI3 DMKEGI3 DN Esmirtazapine DMKEGI3 HS Phase 4 DMKEGI3 SN Esmirtazapine; Esmirtazapine [INN]; Org 44-20; Org-44-20; ZINC968310; (+)-Mirtazapine; (S)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino(2,1-a)pyrido(2,3-c)(2)benzazepine; 4685R51V7M; 61337-87-9; AC1MJ43F; BIDD:PXR0200; CHEMBL1366933; DB06678; EINECS 262-714-0; PDSP1_001530; PDSP2_001514; SCHEMBL49330; UNII-4685R51V7M DMKEGI3 PC 3085218 DMKEGI3 MW 265.35 DMKEGI3 FM C17H19N3 DMKEGI3 IC RONZAEMNMFQXRA-MRXNPFEDSA-N DMKEGI3 CS CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4 DMKEGI3 IK 1S/C17H19N3/c1-19-9-10-20-16(12-19)15-7-3-2-5-13(15)11-14-6-4-8-18-17(14)20/h2-8,16H,9-12H2,1H3/t16-/m1/s1 DMKEGI3 IU (7S)-5-methyl-2,5,19-triazatetracyclo[13.4.0.02,7.08,13]nonadeca-1(15),8,10,12,16,18-hexaene DMKEGI3 CA CAS 61337-87-9 DMKEGI3 DE Depression DM7ITZK ID DM7ITZK DM7ITZK DN Ethinylestradiol propanesulfonate DM7ITZK HS Phase 4 DM7ITZK SN Ethinylestradiol propanesulfonate; Ethinyl estradiol isopropylsulfonate; SCHEMBL457480; Turisteron; Turisteron (TN); XF48685MYR; ethinylestradiol sulfonate; (17; 17-Hydroxy-19-norpregna-1(10),2,4-trien-20-yn-3-yl propane-2-sulfonate; 17alpha-Ethinyl-3-isopropylsulfonyloxyestradiol; 19-Norpregna-1,3,5(10)-trien-20-yne-3,17-diol, 3-(2-propanesulfonate), (17alpha)-; 28913-23-7; A)-17-ethynyl-17-hydroxyestra-1,3,5(10)-trien-3-yl propane-2-sulfonate; AC1L2A1G; AC1Q6XYI; CHEBI:135643; D07928; DTXSID20951545; J-96; UNII-XF48685MYR DM7ITZK PC 68582 DM7ITZK MW 402.5 DM7ITZK FM C23H30O4S DM7ITZK IC KPEUDULLQDHKAZ-VROINQGHSA-N DM7ITZK CS CC(C)S(=O)(=O)OC1=CC2=C(C=C1)C3CCC4(C(C3CC2)CCC4(C#C)O)C DM7ITZK IK 1S/C23H30O4S/c1-5-23(24)13-11-21-20-8-6-16-14-17(27-28(25,26)15(2)3)7-9-18(16)19(20)10-12-22(21,23)4/h1,7,9,14-15,19-21,24H,6,8,10-13H2,2-4H3/t19-,20-,21+,22+,23+/m1/s1 DM7ITZK IU [(8R,9S,13S,14S,17R)-17-ethynyl-17-hydroxy-13-methyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-yl] propane-2-sulfonate DM7ITZK CA CAS 28913-23-7 DM7ITZK CB CHEBI:135643 DM7ITZK DE Prostate cancer DM8TNX3 ID DM8TNX3 DM8TNX3 DN Etizolam DM8TNX3 HS Phase 4 DM8TNX3 SN Etizolam [INN:JAN]; Etizolamum [INN-Latin]; VMZUTJCNQWMAGF-UHFFFAOYSA-N; Y 7131; Y-7131; etizolam; 4-(2-chlorophenyl)-2-ethyl-9-methyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine; 40054-69-1; 6-(o-Chlorophenyl)-8-ethyl-1-methyl-4H-s-triazolo(3,4-c)thieno(2,3-e)(1,4)-diazepine; 8-Ethyl-6-(o-chlorophenyl)-1-methyl-4H-s-triazolo(3,4c)thieno(2,3e)-1,4-diazepine; A76XI0HL37; AHR 3219; BRN 0572740; C17H15ClN4S; Depas; NCGC00182031-01; UNII-A76XI0HL37 DM8TNX3 PC 3307 DM8TNX3 MW 342.8 DM8TNX3 FM C17H15ClN4S DM8TNX3 IC VMZUTJCNQWMAGF-UHFFFAOYSA-N DM8TNX3 CS CCC1=CC2=C(S1)N3C(=NN=C3CN=C2C4=CC=CC=C4Cl)C DM8TNX3 IK 1S/C17H15ClN4S/c1-3-11-8-13-16(12-6-4-5-7-14(12)18)19-9-15-21-20-10(2)22(15)17(13)23-11/h4-8H,3,9H2,1-2H3 DM8TNX3 IU 7-(2-chlorophenyl)-4-ethyl-13-methyl-3-thia-1,8,11,12-tetrazatricyclo[8.3.0.02,6]trideca-2(6),4,7,10,12-pentaene DM8TNX3 CA CAS 40054-69-1 DM8TNX3 CB CHEBI:31583 DM8TNX3 DE Insomnia DMR7U8F ID DMR7U8F DMR7U8F DN Etoperidone DMR7U8F HS Phase 4 DMR7U8F SN Etoperidona; Etoperidona [INN-Spanish]; Etoperidona [Spanish]; Etoperidone [INN]; Etoperidonum; Etoperidonum [INN-Latin]; ETOPERIDONE; IZBNNCFOBMGTQX-UHFFFAOYSA-N; KAI6MVO39Z; L001188; ZINC3830815; 2-[3-[4-(3-chlorophenyl)piperazin-1-yl]propyl]-4,5-diethyl-1,2,4-triazol-3-one; 52942-31-1; AC1L242J; AC1Q3SR1; ACM52942311; BDBM82438; CAS_52942-31-1; CHEBI:135589; CHEMBL1743259; DB09194; DTXSID0023034; NSC_40589; PDSP1_000523; PDSP2_000521; SCHEMBL49314; UNII-KAI6MVO39Z DMR7U8F PC 40589 DMR7U8F MW 377.9 DMR7U8F FM C19H28ClN5O DMR7U8F IC IZBNNCFOBMGTQX-UHFFFAOYSA-N DMR7U8F CS CCC1=NN(C(=O)N1CC)CCCN2CCN(CC2)C3=CC(=CC=C3)Cl DMR7U8F IK 1S/C19H28ClN5O/c1-3-18-21-25(19(26)24(18)4-2)10-6-9-22-11-13-23(14-12-22)17-8-5-7-16(20)15-17/h5,7-8,15H,3-4,6,9-14H2,1-2H3 DMR7U8F IU 2-[3-[4-(3-chlorophenyl)piperazin-1-yl]propyl]-4,5-diethyl-1,2,4-triazol-3-one DMR7U8F CA CAS 52942-31-1 DMR7U8F CB CHEBI:135589 DMR7U8F DE Depression DM9R1YU ID DM9R1YU DM9R1YU DN Gestodene DM9R1YU HS Phase 4 DM9R1YU SN Gestinol; Gestoden; Gestodene [USAN:INN:BAN]; Gestodeno; Gestodeno [INN-Spanish]; Gestodenum; Gestodenum [INN-Latin]; SH B 331; GESTODENE; 13-Ethyl-17-hydroxy-18,19-dinor-17alpha-pregna-4,15-dien-20-yn-3-one; 1664P6E6MI; 17-alpha-Ethinyl-13-ethyl-17-beta-hydroxy-4,15-gonadien-3-one; 18,19-Dinorpregna-4,15-dien-20-yn-3-one, 13-ethyl-17-hydroxy-, (17-alpha)-; 60282-87-3; BRN 4237181; CCRIS 9189; DSSTox_CID_26478; DSSTox_GSID_46478; DSSTox_RID_81649; EINECS 262-145-8; HSDB 3594; UNII-1664P6E6MI DM9R1YU PC 3033968 DM9R1YU MW 310.4 DM9R1YU FM C21H26O2 DM9R1YU IC SIGSPDASOTUPFS-XUDSTZEESA-N DM9R1YU CS CCC12CCC3C(C1C=CC2(C#C)O)CCC4=CC(=O)CCC34 DM9R1YU IK 1S/C21H26O2/c1-3-20-11-9-17-16-8-6-15(22)13-14(16)5-7-18(17)19(20)10-12-21(20,23)4-2/h2,10,12-13,16-19,23H,3,5-9,11H2,1H3/t16-,17+,18+,19-,20-,21-/m0/s1 DM9R1YU IU (8R,9S,10R,13S,14S,17R)-13-ethyl-17-ethynyl-17-hydroxy-1,2,6,7,8,9,10,11,12,14-decahydrocyclopenta[a]phenanthren-3-one DM9R1YU CA CAS 60282-87-3 DM9R1YU CB CHEBI:135323 DM9R1YU DE Contraception DMDN4A1 ID DMDN4A1 DMDN4A1 DN Glitazone DMDN4A1 HS Phase 4 DMDN4A1 SN 74772-78-4; 5-(4-Hydroxybenzyl)thiazolidine-2,4-dione; 5-(4-Hydroxybenzyl)-2,4-thiazolidinedione; 5-(4-HYDROXYBENZYL)-1,3-THIAZOLIDINE-2,4-DIONE; U-90441; 2,4-dioxo-5-[(p-hydroxyphenyl)-methyl]thiazolidine; 5-[(4-Hydroxyphenyl)methyl]-2,4-thiazolidinedione; 2,4-Thiazolidinedione, 5-[(4-hydroxyphenyl)methyl]-; Glitazone; 5-(4-Hydroxybenzyl)thiazolidin-2,4-dione; ACMC-1BF0J; Pioglitazone Metabolite M1; SCHEMBL623021; SCHEMBL18174924; CTK5E0483; MolPort-006-394-329; NKOHRVBBQISBSB-UHFFFAOYSA-N; ZX-AT015682; KM1640; CH-087 DMDN4A1 DT Small molecular drug DMDN4A1 PC 10198397 DMDN4A1 MW 223.25 DMDN4A1 FM C10H9NO3S DMDN4A1 IC InChI=1S/C10H9NO3S/c12-7-3-1-6(2-4-7)5-8-9(13)11-10(14)15-8/h1-4,8,12H,5H2,(H,11,13,14) DMDN4A1 CS C1=CC(=CC=C1CC2C(=O)NC(=O)S2)O DMDN4A1 IK NKOHRVBBQISBSB-UHFFFAOYSA-N DMDN4A1 IU 5-[(4-hydroxyphenyl)methyl]-1,3-thiazolidine-2,4-dione DMDN4A1 CA CAS 74772-78-4 DMF72W3 ID DMF72W3 DMF72W3 DN Glyceryl trinitrate DMF72W3 HS Phase 4 DMF72W3 SN Gilustenon; Glycerol trinitrate; Glyceryl trinitrate; Lenitral; Minitran; Natispray; Nitro-Bid; Nitro-dur; Nitrocine; Nitroderm; Cordipatch; Corditrine; Epinitril; Nitroderm TTS; Nitroglicerina; Nitroglycerine; Nitroglycerol; Nitroglyn; Nitrolan; Nitrolingual; Nitronet; Nitrong; Nitroplast; Nitrorectal; Nitroretard; Nitrospan; Nitrostat; Perglottal; Perlinganit; Rectogesic; Susadrin; Sustonit; Transderm Nitro; Transderm-nitro; Tridil; Trinitrin; Trinitroglycerin; Trinitroglycerol; Trinitrolong; Trinitrosan; nitroglycerin; 55-63-0; Niong DMF72W3 PC 4510 DMF72W3 MW 227.09 DMF72W3 FM C3H5N3O9 DMF72W3 IC SNIOPGDIGTZGOP-UHFFFAOYSA-N DMF72W3 CS C(C(CO[N+](=O)[O-])O[N+](=O)[O-])O[N+](=O)[O-] DMF72W3 IK 1S/C3H5N3O9/c7-4(8)13-1-3(15-6(11)12)2-14-5(9)10/h3H,1-2H2 DMF72W3 IU 1,3-dinitrooxypropan-2-yl nitrate DMF72W3 CA CAS 55-63-0 DMF72W3 CB CHEBI:28787 DMF72W3 DE Acute coronary syndrome DM0OX31 ID DM0OX31 DM0OX31 DN Glypromate DM0OX31 HS Phase 4 DM0OX31 SN Glypromate; Glycyl-prolyl-glutamic acid; Gly-Pro-Glu, >=98% (HPLC); Gly-pro-glu; SCHEMBL1170125; ZINC3776571; ZYK4RVV5LS; glycyl-l-prolyl-l-glutamic acid; 32302-76-4; CHEMBL371315; DB05633; DTXSID80186038; UNII-ZYK4RVV5LS DM0OX31 PC 3080768 DM0OX31 MW 301.3 DM0OX31 FM C12H19N3O6 DM0OX31 IC JJGBXTYGTKWGAT-YUMQZZPRSA-N DM0OX31 CS C1CC(N(C1)C(=O)CN)C(=O)NC(CCC(=O)O)C(=O)O DM0OX31 IK 1S/C12H19N3O6/c13-6-9(16)15-5-1-2-8(15)11(19)14-7(12(20)21)3-4-10(17)18/h7-8H,1-6,13H2,(H,14,19)(H,17,18)(H,20,21)/t7-,8-/m0/s1 DM0OX31 IU (2S)-2-[[(2S)-1-(2-aminoacetyl)pyrrolidine-2-carbonyl]amino]pentanedioic acid DM0OX31 CA CAS 32302-76-4 DM0OX31 DE Epilepsy DM9BPLW ID DM9BPLW DM9BPLW DN Grazoprevir DM9BPLW HS Phase 4 DM9BPLW SN Grazoprevir; Grazoprevir [INN]; Grazoprevir anhydrous; MK 5172; MK-5172; MK5172; OBMNJSNZOWALQB-NCQNOWPTSA-N; SCHEMBL2175313; (1aR,5S,8S,10R,22aR)-5-tert-butyl-N-{(1R,2S)-1-[(cyclopropanesulfonyl)carbamoyl]-2-ethenylcyclopropyl}-14-methoxy-3,6-dioxo-1,1a,3,4,5,6,9,10,18,19,20,21,22,22a-tetradecahydro-8H-7,10-methanocyclopropa[18,19][1,10,3,6]dioxadiazacyclononadecino[11,12-b]quinoxaline-8-carboxamide; 1350514-68-9; 8YE81R1X1J; CHEBI:132975; CHEMBL2063090; DTXSID50159234; EX-A2253; UNII-8YE81R1X1J DM9BPLW PC 44603531 DM9BPLW MW 766.9 DM9BPLW FM C38H50N6O9S DM9BPLW IC OBMNJSNZOWALQB-NCQNOWPTSA-N DM9BPLW CS CC(C)(C)C1C(=O)N2CC(CC2C(=O)NC3(CC3C=C)C(=O)NS(=O)(=O)C4CC4)OC5=NC6=C(C=CC(=C6)OC)N=C5CCCCCC7CC7OC(=O)N1 DM9BPLW IK 1S/C38H50N6O9S/c1-6-22-19-38(22,35(47)43-54(49,50)25-13-14-25)42-32(45)29-18-24-20-44(29)34(46)31(37(2,3)4)41-36(48)53-30-16-21(30)10-8-7-9-11-27-33(52-24)40-28-17-23(51-5)12-15-26(28)39-27/h6,12,15,17,21-22,24-25,29-31H,1,7-11,13-14,16,18-20H2,2-5H3,(H,41,48)(H,42,45)(H,43,47)/t21-,22-,24-,29+,30-,31-,38-/m1/s1 DM9BPLW IU (1R,18R,20R,24S,27S)-24-tert-butyl-N-[(1R,2S)-1-(cyclopropylsulfonylcarbamoyl)-2-ethenylcyclopropyl]-7-methoxy-22,25-dioxo-2,21-dioxa-4,11,23,26-tetrazapentacyclo[24.2.1.03,12.05,10.018,20]nonacosa-3,5(10),6,8,11-pentaene-27-carboxamide DM9BPLW CA CAS 1350514-68-9 DM9BPLW CB CHEBI:132975 DM9BPLW DE Viral hepatitis DMPN5IH ID DMPN5IH DMPN5IH DN Guanfacine DMPN5IH HS Phase 4 DMPN5IH SN GUANFACINE; Tenex; Guanfacinum [INN-Latin]; Guanfacina [INN-Spanish]; Estulic; Intuniv; N-amidino-2-(2,6-dichlorophenyl)acetamide; CHEBI:5558; INJOMKTZOLKMBF-UHFFFAOYSA-N; SPD 503; C9H9Cl2N3O; N-carbamimidoyl-2-(2,6-dichlorophenyl)acetamide; N-(diaminomethylidene)-2-(2,6-dichlorophenyl)acetamide; Guanfacine Monohydrochloride; NCGC00015469-05; Lon798; Guanfacine (INN); Estulic (TN); Tenex (Salt/Mix); Estulic (Salt/Mix); Tocris-1030; Prestwick1_000339; Prestwick3_000339; Prestwick2_000339; Prestwick0_000339; Lopac-G-1043 DMPN5IH PC 3519 DMPN5IH MW 246.09 DMPN5IH FM C9H9Cl2N3O DMPN5IH IC InChI=1S/C9H9Cl2N3O/c10-6-2-1-3-7(11)5(6)4-8(15)14-9(12)13/h1-3H,4H2,(H4,12,13,14,15) DMPN5IH CS C1=CC(=C(C(=C1)Cl)CC(=O)N=C(N)N)Cl DMPN5IH IK INJOMKTZOLKMBF-UHFFFAOYSA-N DMPN5IH IU N-(diaminomethylidene)-2-(2,6-dichlorophenyl)acetamide DMPN5IH CA CAS 29110-47-2 DMPN5IH CB CHEBI:5558 DMPN5IH DE Primary liver cancer DMLYXBF ID DMLYXBF DMLYXBF DN Guanoxan DMLYXBF HS Phase 4 DMLYXBF SN Guanoxan; Guanoxan [INN:BAN]; Guanoxane; Guanoxano; Guanoxano [INN-Spanish]; Guanoxanum; Guanoxanum [INN-Latin]; Guanoxon; ((2,3-Dihydro-1,4-benzodioxin-2-yl)methyl)guanidine; (1,4-Benzodioxan-2-ylmethyl)guanidine; 2165-19-7; Envacar (Salt/Mix); BRN 1251616; DSSTox_CID_26166; DSSTox_RID_81397; GUANIDINE, (1,4-BENZODIOXAN-2-YLMETHYL)-; Guanidine, ((2,3-dihydro-1,4-benzodioxin-2-yl)methyl)-; N-((2,3-Dihydro-1,4-benzodioxin-2-yl)methyl)guanidine; N-[(2,3-Dihydro-1,4-benzodioxin-2-yl)methyl]guanidine; NCGC00160462-01 DMLYXBF PC 16564 DMLYXBF MW 207.23 DMLYXBF FM C10H13N3O2 DMLYXBF IC HIUVKVDQFXDZHU-UHFFFAOYSA-N DMLYXBF CS C1C(OC2=CC=CC=C2O1)CN=C(N)N DMLYXBF IK 1S/C10H13N3O2/c11-10(12)13-5-7-6-14-8-3-1-2-4-9(8)15-7/h1-4,7H,5-6H2,(H4,11,12,13) DMLYXBF IU 2-(2,3-dihydro-1,4-benzodioxin-3-ylmethyl)guanidine DMLYXBF CA CAS 2165-19-7 DMLYXBF CB CHEBI:134871 DMLYXBF DE Essential hypertension DM4OQRD ID DM4OQRD DM4OQRD DN HIF-1alpha DM4OQRD HS Phase 4 DM4OQRD SN Unii-NA856793UT; 192705-79-6; PD-166866; PD166866; PD 166866; UNII-NA856793UT; CHEMBL299763; NA856793UT; 1-[2-amino-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]-3-tert-butylurea; 1-(2-Amino-6-(3,5-dimethoxyphenyl)-pyrido(2,3-d)pyrimidin-7-yl)-3-tert-butyl urea; Urea,N-[2-amino-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]-N'-(1,1-dimethylethyl)-; 1-[2-Amino-6-(3,5-dimethoxyphenyl)-pyrido[2,3-d]pyrimidin-7-yl]-3-tert-butyl urea; 6-arylpyrido[2,3-d]pyrimidine deriv 25; AC1NS3U5; SCHEMBL1248489; BDBM3443; CTK4E1060 DM4OQRD CP Enzon DM4OQRD TC Anticancer Agents DM4OQRD DT Small molecular drug DM4OQRD PC 5328127 DM4OQRD MW 396.4 DM4OQRD FM C20H24N6O3 DM4OQRD IC InChI=1S/C20H24N6O3/c1-20(2,3)26-19(27)25-17-15(8-12-10-22-18(21)24-16(12)23-17)11-6-13(28-4)9-14(7-11)29-5/h6-10H,1-5H3,(H4,21,22,23,24,25,26,27) DM4OQRD CS CC(C)(C)NC(=O)NC1=C(C=C2C=NC(=NC2=N1)N)C3=CC(=CC(=C3)OC)OC DM4OQRD IK NHJSWORVNIOXIT-UHFFFAOYSA-N DM4OQRD IU 1-[2-amino-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]-3-tert-butylurea DM4OQRD CA CAS 192705-79-6 DM4OQRD CB CHEBI:156259 DM4OQRD DE Lymphoma DMYOC29 ID DMYOC29 DMYOC29 DN Hirudin DMYOC29 HS Phase 4 DMYOC29 SN Hirudin (53-64); 135546-61-1; Hirudin 53-64; DTXSID20159463; L-Alanine, L-asparaginylglycyl-L-alpha-aspartyl-L-pheylalanyl-L-alpha-glutamyl-L-alpha-glutamyl-L-isoleucyl-L-prolyl-L-alpha-glutamyl-L-alpha-glutamyl-L-tyrosyl-L-leucyl- DMYOC29 DT Small molecular drug DMYOC29 PC 72941487 DMYOC29 MW 7044 DMYOC29 FM C287H440N80O113S7 DMYOC29 IC InChI=1S/C287H440N80O113S7/c1-25-133(19)226-281(469)345-161(87-125(3)4)235(423)306-111-208(394)320-180(116-370)266(454)344-175(101-219(414)415)237(425)307-105-202(388)316-151(62-75-212(400)401)242(430)321-145(41-30-33-81-288)240(428)339-170(96-197(297)383)258(446)326-152(57-70-193(293)379)249(437)351-185(121-484-481-118-182-239(427)310-107-201(387)313-147(55-68-191(291)377)232(420)303-108-205(391)317-169(95-196(296)382)257(445)322-146(42-31-34-82-289)241(429)350-186(271(459)360-226)122-485-482-119-183(268(456)323-149(61-74-211(398)399)234(422)304-110-207(393)319-179(115-369)265(453)342-173(99-200(300)386)264(452)357-223(130(13)14)279(467)355-182)352-253(441)164(90-128(9)10)335-269(457)184-120-483-486-123-187(354-262(450)177(103-221(418)419)347-283(471)230(137(23)374)362-263(451)167(92-140-47-51-143(376)52-48-140)346-278(466)224(131(15)16)359-276(464)222(301)129(11)12)272(460)363-229(136(22)373)282(470)330-157(66-79-216(408)409)248(436)348-178(114-368)238(426)309-106-203(389)315-150(56-69-192(292)378)243(431)340-171(97-198(298)384)259(447)334-163(89-127(7)8)252(440)353-184)270(458)358-225(132(17)18)280(468)364-228(135(21)372)277(465)311-112-204(390)314-148(60-73-210(396)397)233(421)305-113-209(395)356-231(138(24)375)286(474)367-86-38-46-190(367)275(463)331-159(43-32-35-83-290)284(472)365-84-36-44-188(365)273(461)328-153(58-71-194(294)380)247(435)349-181(117-371)267(455)338-168(94-142-104-302-124-312-142)256(444)341-172(98-199(299)385)260(448)343-174(100-218(412)413)236(424)308-109-206(392)318-176(102-220(416)417)261(449)337-165(91-139-39-28-27-29-40-139)254(442)327-154(63-76-213(402)403)244(432)325-158(67-80-217(410)411)250(438)361-227(134(20)26-2)285(473)366-85-37-45-189(366)274(462)329-156(65-78-215(406)407)245(433)324-155(64-77-214(404)405)246(434)336-166(93-141-49-53-144(54-50-141)480-487(477,478)479)255(443)333-162(88-126(5)6)251(439)332-160(287(475)476)59-72-195(295)381/h27-29,39-40,47-54,104,124-138,145-190,222-231,368-376H,25-26,30-38,41-46,55-103,105-123,288-290,301H2,1-24H3,(H2,291,377)(H2,292,378)(H2,293,379)(H2,294,380)(H2,295,381)(H2,296,382)(H2,297,383)(H2,298,384)(H2,299,385)(H2,300,386)(H,302,312)(H,303,420)(H,304,422)(H,305,421)(H,306,423)(H,307,425)(H,308,424)(H,309,426)(H,310,427)(H,311,465)(H,313,387)(H,314,390)(H,315,389)(H,316,388)(H,317,391)(H,318,392)(H,319,393)(H,320,394)(H,321,430)(H,322,445)(H,323,456)(H,324,433)(H,325,432)(H,326,446)(H,327,442)(H,328,461)(H,329,462)(H,330,470)(H,331,463)(H,332,439)(H,333,443)(H,334,447)(H,335,457)(H,336,434)(H,337,449)(H,338,455)(H,339,428)(H,340,431)(H,341,444)(H,342,453)(H,343,448)(H,344,454)(H,345,469)(H,346,466)(H,347,471)(H,348,436)(H,349,435)(H,350,429)(H,351,437)(H,352,441)(H,353,440)(H,354,450)(H,355,467)(H,356,395)(H,357,452)(H,358,458)(H,359,464)(H,360,459)(H,361,438)(H,362,451)(H,363,460)(H,364,468)(H,396,397)(H,398,399)(H,400,401)(H,402,403)(H,404,405)(H,406,407)(H,408,409)(H,410,411)(H,412,413)(H,414,415)(H,416,417)(H,418,419)(H,475,476)(H,477,478,479)/t133-,134-,135+,136+,137+,138+,145-,146-,147-,148-,149-,150-,151-,152-,153-,154-,155-,156-,157-,158-,159-,160-,161-,162-,163-,164-,165-,166-,167-,168-,169-,170-,171-,172-,173-,174-,175-,176-,177-,178-,179-,180-,181-,182-,183-,184-,185-,186-,187-,188-,189-,190-,222-,223-,224-,225-,226-,227-,228-,229-,230-,231-/m0/s1 DMYOC29 CS CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H]2C(=O)NCC(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)C(C)C)CC(=O)N)CO)CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]3CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N3)CC(C)C)CC(=O)N)CCC(=O)N)CO)CCC(=O)O)[C@@H](C)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)N)C(=O)N1)CCCCN)CC(=O)N)CCC(=O)N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N5CCC[C@H]5C(=O)N[C@@H](CCCCN)C(=O)N6CCC[C@H]6C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC7=CN=CN7)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)NCC(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC8=CC=CC=C8)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N9CCC[C@H]9C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CC=C(C=C1)OS(=O)(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)O)CCC(=O)N)CC(=O)N)CCCCN)CCC(=O)O)CC(=O)O)CO)CC(C)C DMYOC29 IK WQPDUTSPKFMPDP-OUMQNGNKSA-N DMYOC29 IU (2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2S,3R)-2-[[2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2S)-2-[[(1R,6R,9S,12S,15S,18S,24S,27S,33S,36S,39R,44R,47S,53S,56S,59S,67S,73S,76S)-15,76-bis(4-aminobutyl)-44-[[(2S)-2-[[(4R,7S,10S,13S,19S,22S,25S,28R)-28-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxybutanoyl]amino]-3-carboxypropanoyl]amino]-10-(2-amino-2-oxoethyl)-13-(3-amino-3-oxopropyl)-22-(2-carboxyethyl)-25-[(1R)-1-hydroxyethyl]-19-(hydroxymethyl)-7-(2-methylpropyl)-6,9,12,15,18,21,24,27-octaoxo-1,2-dithia-5,8,11,14,17,20,23,26-octazacyclononacosane-4-carbonyl]amino]-4-methylpentanoyl]amino]-12,56,73-tris(2-amino-2-oxoethyl)-9,67-bis(3-amino-3-oxopropyl)-36-[(2S)-butan-2-yl]-18,47-bis(2-carboxyethyl)-24-(carboxymethyl)-27,53-bis(hydroxymethyl)-33-(2-methylpropyl)-8,11,14,17,20,23,26,29,32,35,38,45,48,51,54,57,60,62,65,68,71,74,77-tricosaoxo-59-propan-2-yl-3,4,41,42-tetrathia-7,10,13,16,19,22,25,28,31,34,37,46,49,52,55,58,61,63,66,69,72,75,78-tricosazabicyclo[37.22.17]octaheptacontane-6-carbonyl]amino]-3-methylbutanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]-4-carboxybutanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-oxobutanoyl]amino]-3-carboxypropanoyl]amino]acetyl]amino]-3-carboxypropanoyl]amino]-3-phenylpropanoyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbonyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-3-(4-sulfooxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-5-oxopentanoic acid DMYOC29 CA CAS 8001-27-2 DM0WD1V ID DM0WD1V DM0WD1V DN Human calcitonin DM0WD1V HS Phase 4 DM0WD1V SN Calcitonin (human synthetic); Calcitonin (human); Calcitonin human; Calcitonin, human; Calcitonin, human synthetic DM0WD1V PC 16220016 DM0WD1V IU (4S)-4-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[2-[[(2S)-2-[[(2S)-2-[[(4R,7S,10S,13S,16S,19S,22R)-22-amino-16-(2-amino-2-oxoethyl)-7-[(1R)-1-hydroxyethyl]-10,19-bis(hydroxymethyl)-13-(2-methylpropyl)-6,9,12,15,18,21-hexaoxo-1,2-dithia-5,8,11,14,17,20-hexazacyclotricosane-4-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S,3R)-1-[[(2S)-1-[(2S)-2-[[(2S)-1-[[(2S,3R)-1-[[(2S)-4-amino-1-[[(2S,3R)-1-[[2-[[(2S)-1-[[2-[[(2S,3R)-1-[(2S)-2-carbamoylpyrrolidin-1-yl]-3-hydroxy-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-oxopentanoic acid DM0WD1V DE Hyperparathyroidism DMABXOZ ID DMABXOZ DMABXOZ DN Hyaluronic acid DMABXOZ HS Phase 4 DMABXOZ SN Hyaluronic Acid [BAN]; Hylan G-F 20; Hyvisc; Luronit; Mucoitin; Amo Vitrax; Amvisc; Biolon; Etamucine; Sepracoat; Sofast; Synvisc; C33H54N2O23; EINECS 232-678-0; HSDB 7240; Hyaluronate Sodium (hyaluronic acid) DMABXOZ PC 24847767 DMABXOZ MW 846.8 DMABXOZ FM C33H54N2O23 DMABXOZ IC BVOZFCOTOYGLGD-VPQOAABJSA-N DMABXOZ CS CC(=O)NC1C(C(C(OC1COCC2C(OC(C(C2O)(C)O)OCC3C(C(OC(C3O)CO)O)NC(=O)C)C(=O)O)CO)O)COC4C(C(C(C(O4)C(=O)O)O)O)O DMABXOZ IK 1S/C33H54N2O23/c1-10(38)34-18-12(7-53-31-24(44)22(42)23(43)26(57-31)29(48)49)20(40)15(4-36)55-17(18)9-52-6-14-25(28(46)47)58-32(33(3,51)27(14)45)54-8-13-19(35-11(2)39)30(50)56-16(5-37)21(13)41/h12-27,30-32,36-37,40-45,50-51H,4-9H2,1-3H3,(H,34,38)(H,35,39)(H,46,47)(H,48,49)/t12-,13-,14+,15?,16?,17-,18?,19?,20-,21-,22+,23-,24?,25?,26?,27+,30+,31+,32+,33?/m0/s1 DMABXOZ IU (3S,4R,6R)-3-[[(2R,4R,5S)-3-acetamido-4-[[(2R,4R,5S)-6-carboxy-3,4,5-trihydroxyoxan-2-yl]oxymethyl]-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]methoxymethyl]-6-[[(2R,4R,5S)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]methoxy]-4,5-dihydroxy-5-methyloxane-2-carboxylic acid DMABXOZ DE Osteoarthritis DM8NWFD ID DM8NWFD DM8NWFD DN Hypericum DM8NWFD HS Phase 4 DM8NWFD SN 6-formamidopenicillanic acid; UNII-2TC14ZH3A5; CHEBI:59004; CTK2F8101; 6-formamido-2,2-dimethylpenam-3alpha-carboxylic acid; 2TC14ZH3A5; 64527-04-4; (2S,5R,6R)-6-formamido-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-Formamido-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid; PAB 141; 141a/2A; HIS-1201; Epitope ID:119700; SCHEMBL11176911; DTXSID90429524; 6beta-formylaminopenicillanic acid; 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylicacid, 6-(formylamino)-3,3-d DM8NWFD DT Small molecular drug DM8NWFD PC 9548591 DM8NWFD MW 244.27 DM8NWFD FM C9H12N2O4S DM8NWFD IC InChI=1S/C9H12N2O4S/c1-9(2)5(8(14)15)11-6(13)4(10-3-12)7(11)16-9/h3-5,7H,1-2H3,(H,10,12)(H,14,15)/t4-,5+,7-/m1/s1 DM8NWFD CS CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC=O)C(=O)O)C DM8NWFD IK MDQGTDMBVJCTBN-JCGDXUMPSA-N DM8NWFD IU (2S,5R,6R)-6-formamido-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid DM8NWFD CA CAS 64527-04-4 DM8NWFD CB CHEBI:59004 DMVXLOD ID DMVXLOD DMVXLOD DN Imrecoxib DMVXLOD HS Phase 4 DMVXLOD SN Imrecoxib; UNII-SGW6W5758V; SGW6W5758V; CHEMBL504535; 395683-14-4; Imricoxib; BAP-909; SCHEMBL3034253; BDBM50293282; AKOS032954049; DB12354; LS-194053; 2H-Pyrrol-2-one, 1,5-dihydro-3-(4-methylphenyl)-4-(4-(methylsulfonyl)phenyl)-1-propyl-; BAP-909; ; DMVXLOD DT Small molecular drug DMVXLOD PC 11682175 DMVXLOD MW 369.5 DMVXLOD FM C21H23NO3S DMVXLOD IC InChI=1S/C21H23NO3S/c1-4-13-22-14-19(16-9-11-18(12-10-16)26(3,24)25)20(21(22)23)17-7-5-15(2)6-8-17/h5-12H,4,13-14H2,1-3H3 DMVXLOD CS CCCN1CC(=C(C1=O)C2=CC=C(C=C2)C)C3=CC=C(C=C3)S(=O)(=O)C DMVXLOD IK AXMZZGKKZDJGAZ-UHFFFAOYSA-N DMVXLOD IU 4-(4-methylphenyl)-3-(4-methylsulfonylphenyl)-1-propyl-2H-pyrrol-5-one DMVXLOD CA CAS 395683-14-4 DM2R496 ID DM2R496 DM2R496 DN Indenolol DM2R496 HS Phase 4 DM2R496 SN Indenolol; Indenolol [INN]; Indenolol [BAN:INN]; Indenolol [INN:BAN]; Indenololum; Indenololum [INN-Latin]; Sch 28316 Z; Sch 28316Z; Securpres; 1-(4-Indenyloxy)-3-isopropylamino-2-propanol; 1-(Inden-4(or 7)-yloxy)-3-(isopropylamino)-2-propanol; 106656-86-4; 2-Propanol, 1-(1H-inden-4-yloxy)-3-((1-methylethyl)amino)-; 2-Propanol, 1-(1H-inden-4-yloxy)-3-[(1-methylethyl)amino]-; 4-(2-Hydroxy-3-isopropylaminopropoxy)indene; 60607-68-3; AC1L2H51; AC1Q77JA; ACMC-20macf; C15H27NO2; CHEMBL153585; EINECS 262-323-5; SCHEMBL79021; YB-2 DM2R496 PC 71955 DM2R496 MW 247.33 DM2R496 FM C15H21NO2 DM2R496 IC MPGBPFMOOXKQRX-UHFFFAOYSA-N DM2R496 CS CC(C)NCC(COC1=CC=CC2=C1C=CC2)O DM2R496 IK 1S/C15H21NO2/c1-11(2)16-9-13(17)10-18-15-8-4-6-12-5-3-7-14(12)15/h3-4,6-8,11,13,16-17H,5,9-10H2,1-2H3 DM2R496 IU 1-(1H-inden-4-yloxy)-3-(propan-2-ylamino)propan-2-ol DM2R496 CA CAS 60607-68-3 DM2R496 DE Cardiac arrhythmia DMVPLNC ID DMVPLNC DMVPLNC DN Ingrezza DMVPLNC HS Phase 4 DMVPLNC SN Valbenazine; 1025504-45-3; UNII-54K37P50KH; Valbenazine free base; NBI 98854; 54K37P50KH; 1025504-45-3 (free base); (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl L-valinate; L-Valine, (2R,3R,11bR)-1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-2H-benzo[a]quinolizin-2-yl ester; Valbenazine [USAN:INN]; L-Valine, (2R,3R,11bR)-1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-2H-benzo(a)quinolizin-2-yl ester; ValbenazineNBI-98854; Valbenazine (USAN/INN); GTPL8694; CHEMBL2364639; SCHEMBL15932979; EX-A2002; MFCD28963976; ZINC43195697; CS-5908; DB11915; SB17456; NCGC00522306-02; [(2R,3R,11bR)-9,10-dimethoxy-3-(2-methylpropyl)-2,3,4,6,7,11b-hexahydro-1H-benzo[a]quinolizin-2-yl] (2S)-2-amino-3-methylbutanoate; AC-30929; AS-35294; HY-16771; D10675; NBI-98854;NBI98854;NBI 98854; Q27089118; (2R,3R,11bR)-9,10-Dimethoxy-3-(2-methylpropyl)-1,3,4,6,7,11b-hexahydro-2H- benzo(a)quinolizin-2-yl L-valinate; (S)-2-amino-3-methyl-butyric acid (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl ester; [(2R,3R,11bR)-9,10-dimethoxy-3-(2-methylpropyl)-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1-a]isoquinolin-2-yl] (2S)-2-amino-3-methylbutanoate; Valine 1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-2H-benzo(a)quinolizin-2-yl ester DMVPLNC CP Neurocrine Biosciences DMVPLNC DT Small molecular drug DMVPLNC PC 24795069 DMVPLNC MW 418.6 DMVPLNC FM C24H38N2O4 DMVPLNC IC InChI=1S/C24H38N2O4/c1-14(2)9-17-13-26-8-7-16-10-21(28-5)22(29-6)11-18(16)19(26)12-20(17)30-24(27)23(25)15(3)4/h10-11,14-15,17,19-20,23H,7-9,12-13,25H2,1-6H3/t17-,19-,20-,23+/m1/s1 DMVPLNC CS CC(C)C[C@@H]1CN2CCC3=CC(=C(C=C3[C@H]2C[C@H]1OC(=O)[C@H](C(C)C)N)OC)OC DMVPLNC IK GEJDGVNQKABXKG-CFKGEZKQSA-N DMVPLNC IU [(2R,3R,11bR)-9,10-dimethoxy-3-(2-methylpropyl)-2,3,4,6,7,11b-hexahydro-1H-benzo[a]quinolizin-2-yl] (2S)-2-amino-3-methylbutanoate DMVPLNC CA CAS 1025504-45-3 DMVPLNC DE Tourette syndrome; Tardive dyskinesia DM7U58J ID DM7U58J DM7U58J DN Isoflavone DM7U58J HS Phase 4 DM7U58J SN Isoflavone; Isoflavone (8CI); Isoflavone skeleton; LS-191186; MCULE-2586547916; OVO2KUW8H8; SBB068618; SCHEMBL8028; ST098957; VN10014; ZINC895390; isoflavon; 3-Phenylchromone; 3-phenyl-4H-1-benzopyran-4-one; 3-phenyl-4H-chromen-4-one; 3-phenylchromen-4-one; 4H-1-Benzopyran-4-one, 3-phenyl-; 574-12-9; AC-12802; AK114020; AKOS015918505; AX8135136; BCP22856; BCP9000133; CCG-214095; CHEBI:18220; CHEMBL366460; CS-W006405; DB12007; DS-6374; DTXSID90205986; KS-00000GFW; NSC 135405; NSC-135405; NSC135405; GOMNOOKGLZYEJT-UHFFFAOYSA-N; UNII-OVO2KUW8H8 DM7U58J PC 72304 DM7U58J MW 222.24 DM7U58J FM C15H10O2 DM7U58J IC GOMNOOKGLZYEJT-UHFFFAOYSA-N DM7U58J CS C1=CC=C(C=C1)C2=COC3=CC=CC=C3C2=O DM7U58J IK 1S/C15H10O2/c16-15-12-8-4-5-9-14(12)17-10-13(15)11-6-2-1-3-7-11/h1-10H DM7U58J IU 3-phenylchromen-4-one DM7U58J CA CAS 574-12-9 DM7U58J CB CHEBI:18220 DM7U58J DE Asthma DM170OH ID DM170OH DM170OH DN Ketazolam DM170OH HS Phase 4 DM170OH SN Ketazolamum; Ketazolamum [INN-Latin]; Loftran; U 28774; U-28,774; Unakalm; Anseren; Ansieten; KETAZOLAM; 11-Chloro-8,12b-dihydro-2,8-dimethyl-12b-phenyl-4H-(1,3)-oxazino(3,2-d)(1,4)benzodiazepine-4,7(6H)dione; 27223-35-4; 4H-(1,3)Oxazino(3,2-d)(1,4)benzodiazepine-4,7(6H)-dione, 8,12b-dihydro-11-chloro-2,8-dimethyl-12b-phenyl-; 4H-[1,3]Oxazino[3,2-d][1,4]benzodiazepine-4,7(6H)-dione, 11-chloro-8,12b-dihydro-2,8-dimethyl-12b-phenyl-; Anxon; EINECS 248-346-3; NSC 338158 DM170OH PC 33746 DM170OH MW 368.8 DM170OH FM C20H17ClN2O3 DM170OH IC PWAJCNITSBZRBL-UHFFFAOYSA-N DM170OH CS CC1=CC(=O)N2CC(=O)N(C3=C(C2(O1)C4=CC=CC=C4)C=C(C=C3)Cl)C DM170OH IK 1S/C20H17ClN2O3/c1-13-10-18(24)23-12-19(25)22(2)17-9-8-15(21)11-16(17)20(23,26-13)14-6-4-3-5-7-14/h3-11H,12H2,1-2H3 DM170OH IU 11-chloro-2,8-dimethyl-12b-phenyl-6H-[1,3]oxazino[3,2-d][1,4]benzodiazepine-4,7-dione DM170OH CA CAS 27223-35-4 DM170OH CB CHEBI:135556 DM170OH DE Anxiety disorder DMQP5I3 ID DMQP5I3 DMQP5I3 DN Lacidipine DMQP5I3 HS Phase 4 DMQP5I3 SN Lacidipine; Lacidipine (Lacipil, Motens); Lacidipino; Lacidipino [Spanish]; Lacidipinum [Latin]; Lacimen; Lacipil; Motens; trans Lacidipine; 103890-78-4; 260080034N; 4-(o-((E)-2-Carboxyvinyl)phenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid, 4-tert-butyl diethyl ester; C26H33NO6; DSSTox_CID_26429; DSSTox_GSID_46429; DSSTox_RID_81607; GR 43659 X; GR 43659X; GR-43659X; GX-1048; UNII-260080034N; diethyl 2,6-dimethyl-4-[2-[(E)-3-[(2-methylpropan-2-yl)oxy]-3-oxoprop-1-enyl]phenyl]-1,4-dihydropyridine-3,5-dicarboxylate DMQP5I3 PC 5311217 DMQP5I3 MW 455.5 DMQP5I3 FM C26H33NO6 DMQP5I3 IC GKQPCPXONLDCMU-CCEZHUSRSA-N DMQP5I3 CS CCOC(=O)C1=C(NC(=C(C1C2=CC=CC=C2C=CC(=O)OC(C)(C)C)C(=O)OCC)C)C DMQP5I3 IK 1S/C26H33NO6/c1-8-31-24(29)21-16(3)27-17(4)22(25(30)32-9-2)23(21)19-13-11-10-12-18(19)14-15-20(28)33-26(5,6)7/h10-15,23,27H,8-9H2,1-7H3/b15-14+ DMQP5I3 IU diethyl 2,6-dimethyl-4-[2-[(E)-3-[(2-methylpropan-2-yl)oxy]-3-oxoprop-1-enyl]phenyl]-1,4-dihydropyridine-3,5-dicarboxylate DMQP5I3 CA CAS 103890-78-4 DMQP5I3 CB CHEBI:94480 DMQP5I3 DE Essential hypertension DM5FABJ ID DM5FABJ DM5FABJ DN LAROPIPRANT DM5FABJ HS Phase 4 DM5FABJ SN Laropiprant; 571170-77-9; MK 0524; Cardaptive; MK-0524; UNII-G7N11T8O78; CHEMBL426559; G7N11T8O78; 2-[(3R)-4-[(4-chlorophenyl)methyl]-7-fluoro-5-methylsulfonyl-2,3-dihydro-1H-cyclopenta[b]indol-3-yl]acetic acid; 2-[(3R)-4-[(4-chlorophenyl)methyl]-7-fluoro-5-methanesulfonyl-1H,2H,3H,4H-cyclopenta[b]indol-3-yl]acetic acid; Tedaptive; Laropiprant [USAN:INN:BAN]; [14C]-Laropiprant; Laropiprant/MK-0524; Laropiprant (INN/USAN); Laropiprant (MK-0524); SCHEMBL991107; AMOT0189; GTPL3356; KS-00000XIE; CTK8F0660; MK-0524B DM5FABJ DT Small molecular drug DM5FABJ PC 9867642 DM5FABJ MW 435.9 DM5FABJ FM C21H19ClFNO4S DM5FABJ IC InChI=1S/C21H19ClFNO4S/c1-29(27,28)18-10-15(23)9-17-16-7-4-13(8-19(25)26)20(16)24(21(17)18)11-12-2-5-14(22)6-3-12/h2-3,5-6,9-10,13H,4,7-8,11H2,1H3,(H,25,26)/t13-/m1/s1 DM5FABJ CS CS(=O)(=O)C1=CC(=CC2=C1N(C3=C2CC[C@@H]3CC(=O)O)CC4=CC=C(C=C4)Cl)F DM5FABJ IK NXFFJDQHYLNEJK-CYBMUJFWSA-N DM5FABJ IU 2-[(3R)-4-[(4-chlorophenyl)methyl]-7-fluoro-5-methylsulfonyl-2,3-dihydro-1H-cyclopenta[b]indol-3-yl]acetic acid DM5FABJ CA CAS 571170-77-9 DM5FABJ CB CHEBI:135942 DM5FABJ DE Arteriosclerosis; Coronary heart disease DM92S6N ID DM92S6N DM92S6N DN Levamlodipine DM92S6N HS Phase 4 DM92S6N SN Levamlodipine (hypertension); S-amlodipine gentisate; Levamlodipine (hypertension), SK Chemicals; S-amlodipine (hypertension), SK Chemicals DM92S6N CP SK Chemicals Co Ltd DM92S6N DT Small molecular drug DM92S6N PC 9822750 DM92S6N MW 408.9 DM92S6N FM C20H25ClN2O5 DM92S6N IC InChI=1S/C20H25ClN2O5/c1-4-28-20(25)18-15(11-27-10-9-22)23-12(2)16(19(24)26-3)17(18)13-7-5-6-8-14(13)21/h5-8,17,23H,4,9-11,22H2,1-3H3/t17-/m0/s1 DM92S6N CS CCOC(=O)C1=C(NC(=C([C@@H]1C2=CC=CC=C2Cl)C(=O)OC)C)COCCN DM92S6N IK HTIQEAQVCYTUBX-KRWDZBQOSA-N DM92S6N IU 3-O-ethyl 5-O-methyl (4S)-2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate DM92S6N CA CAS 103129-82-4 DM92S6N CB CHEBI:53796 DM92S6N DE Hypertension DM82JP0 ID DM82JP0 DM82JP0 DN Lynestrenol DM82JP0 HS Phase 4 DM82JP0 SN Linestrenol; Linestrenol [INN-Spanish]; Linestrenolo [DCIT]; Lynenol; Lynestrenolum [INN-Latin]; Lynoestrenol; Lynoestrenol [Progestins]; Lynstranol; Endometril; Ethinyl oestrenol; Ethinylestrenol; Ethinyloestranol; Ethynloestrenol; Ethynylestrenol; Exluten; Exlution; Exluton; Exlutona; IND 1006; LYNESTRENOL; Org 485-50; Orgametil; Orgametril; Orgametrol; 17-alpha-Ethynylestrenol; 17-alpha-Ethynyloestrenol; 17alpha-Ethynylestrenol; 3-Desoxynorlutin; 52-76-6; CCRIS 9093; EINECS 200-151-4; NSC 37725; NSC-37725; UNII-N2Z8ALG4U5 DM82JP0 PC 5857 DM82JP0 MW 284.4 DM82JP0 FM C20H28O DM82JP0 IC YNVGQYHLRCDXFQ-XGXHKTLJSA-N DM82JP0 CS CC12CCC3C(C1CCC2(C#C)O)CCC4=CCCCC34 DM82JP0 IK 1S/C20H28O/c1-3-20(21)13-11-18-17-9-8-14-6-4-5-7-15(14)16(17)10-12-19(18,20)2/h1,6,15-18,21H,4-5,7-13H2,2H3/t15-,16+,17+,18-,19-,20-/m0/s1 DM82JP0 IU (8R,9S,10R,13S,14S,17R)-17-ethynyl-13-methyl-2,3,6,7,8,9,10,11,12,14,15,16-dodecahydro-1H-cyclopenta[a]phenanthren-17-ol DM82JP0 CA CAS 52-76-6 DM82JP0 CB CHEBI:31790 DM82JP0 DE Transsexualism DM0UGYX ID DM0UGYX DM0UGYX DN Medifoxamine DM0UGYX HS Phase 4 DM0UGYX SN Medifoxamina; Medifoxamina [INN-Spanish]; Medifoxamine; Medifoxamine (INN); Medifoxamine [INN:DCF]; Medifoxaminum; Medifoxaminum [INN-Latin]; KWU7C2A1NT; ZX-AT022754; (Dimethylamino)acetaldehyde diphenyl acetal; 32359-34-5; AC1L1V3V; Acetaldehyde, (dimethylamino)-, diphenyl acetal; BRN 2054310; C16H19NO2; CHEBI:135061; CHEMBL85231; CTK4G8876; DTXSID80186078; EINECS 251-011-4; Ethanamine, N,N-dimethyl-2,2-diphenoxy-; N,N-Dimethyl-2,2-diphenoxyethanamine; N,N-Dimethyl-2,2-diphenoxyethylamine; SCHEMBL49319; UNII-KWU7C2A1NT DM0UGYX PC 36109 DM0UGYX MW 257.329 DM0UGYX FM C16H19NO2 DM0UGYX IC QNMGHBMGNRQPNL-UHFFFAOYSA-N DM0UGYX CS CN(C)CC(OC1=CC=CC=C1)OC2=CC=CC=C2 DM0UGYX IK 1S/C16H19NO2/c1-17(2)13-16(18-14-9-5-3-6-10-14)19-15-11-7-4-8-12-15/h3-12,16H,13H2,1-2H3 DM0UGYX IU N,N-dimethyl-2,2-diphenoxyethanamine DM0UGYX CA CAS 32359-34-5 DM0UGYX CB CHEBI:135061 DM0UGYX DE Depression DME1X96 ID DME1X96 DME1X96 DN Mexazolam DME1X96 HS Phase 4 DME1X96 SN Melex (TN); Mexazolam (JAN/INN); Mexazolam [INN:JAN]; Mexazolamum; Mexazolamum [INN-Latin]; Sedoxil; mexazolam; 10-Chloro-11b-(2-chlorophenyl)-2,3,7,11b-tetrahydro-3-methyloxazolo(3,2-d)(1,4)benzodiazepin-6(5H)-one; 10-Chloro-11b-(o-chlorophenyl)-2,3,7,11b-tetrahydro-3-methyloxazolo(3,2-d)(1,4)benzodiazepin-6(5H)-one; 31868-18-5; AC1L1HL4; BRN 1091849; C18H16Cl2N2O2; CHEBI:31842; CS 386; CS-386; DSSTox_CID_31504; Melex; Oxazolo(3,2-d)(1,4)benzodiazepin-6(5H)-one, 10-chloro-11b-(2-chlorophenyl)-2,3,7,11b-tetrahydro-3-methyl- DME1X96 PC 4177 DME1X96 MW 363.2 DME1X96 FM C18H16Cl2N2O2 DME1X96 IC ANUCDXCTICZJRH-UHFFFAOYSA-N DME1X96 CS CC1COC2(N1CC(=O)NC3=C2C=C(C=C3)Cl)C4=CC=CC=C4Cl DME1X96 IK 1S/C18H16Cl2N2O2/c1-11-10-24-18(13-4-2-3-5-15(13)20)14-8-12(19)6-7-16(14)21-17(23)9-22(11)18/h2-8,11H,9-10H2,1H3,(H,21,23) DME1X96 IU 10-chloro-11b-(2-chlorophenyl)-3-methyl-2,3,5,7-tetrahydro-[1,3]oxazolo[3,2-d][1,4]benzodiazepin-6-one DME1X96 CA CAS 31868-18-5 DME1X96 CB CHEBI:31842 DME1X96 DE Anxiety disorder DM2VOQ3 ID DM2VOQ3 DM2VOQ3 DN Mosapride DM2VOQ3 HS Phase 4 DM2VOQ3 SN Mosapride; 112885-41-3; 4-amino-5-chloro-2-ethoxy-N-((4-(4-fluorobenzyl)-2-morpholinyl)methyl)benzamide; Mosapride [INN]; CHEMBL60889; Mosapride (INN); 4-amino-5-chloro-2-ethoxy-N-[[4-[(4-fluorophenyl)methyl]-2-morpholinyl]methyl]benzamide; AK-41276; 4-amino-5-chloro-2-ethoxy-N-[[4-[(4-fluorophenyl)methyl]morpholin-2-yl]methyl]benzamide; Q-201413; 4-amino-5-chloro-2-ethoxy-N-({4-[(4-fluorophenyl)methyl]morpholin-2-yl}methyl)benzamide DM2VOQ3 DT Small molecular drug DM2VOQ3 PC 119584 DM2VOQ3 MW 421.9 DM2VOQ3 FM C21H25ClFN3O3 DM2VOQ3 IC InChI=1S/C21H25ClFN3O3/c1-2-28-20-10-19(24)18(22)9-17(20)21(27)25-11-16-13-26(7-8-29-16)12-14-3-5-15(23)6-4-14/h3-6,9-10,16H,2,7-8,11-13,24H2,1H3,(H,25,27) DM2VOQ3 CS CCOC1=CC(=C(C=C1C(=O)NCC2CN(CCO2)CC3=CC=C(C=C3)F)Cl)N DM2VOQ3 IK YPELFRMCRYSPKZ-UHFFFAOYSA-N DM2VOQ3 IU 4-amino-5-chloro-2-ethoxy-N-[[4-[(4-fluorophenyl)methyl]morpholin-2-yl]methyl]benzamide DM2VOQ3 CA CAS 112885-41-3 DM2VOQ3 CB CHEBI:94373 DMVILAD ID DMVILAD DMVILAD DN MOTILIN DMVILAD HS Phase 4 DMVILAD SN Motilin (human, porcine); UNII-D85V250YSI; D85V250YSI; 9072-41-7; Human motilin; 52906-92-0; Motilin (swine); Motilin (human); Motilin (porcine); Motilin [MI]; Human motilin [MI]; Motilin porcine; h-Motilin; Phe-Val-Pro-Ile-Phe-Thr-Tyr-Gly-Glu-Leu-Gln-Arg-Met-Gln-Glu-Lys-Glu-Arg-Asn-Lys-Gly-Gln; GTPL1458; CHEMBL525634; Motilin porcine, > DMVILAD DT Small molecular drug DMVILAD PC 16136567 DMVILAD MW 2699.1 DMVILAD FM C120H188N34O35S DMVILAD IC InChI=1S/C120H188N34O35S/c1-9-64(6)97(152-114(184)86-31-22-53-154(86)117(187)96(63(4)5)151-99(169)70(123)56-66-23-12-10-13-24-66)115(185)150-84(57-67-25-14-11-15-26-67)113(183)153-98(65(7)155)116(186)149-83(58-68-32-34-69(156)35-33-68)101(171)135-60-91(161)136-75(39-45-93(163)164)105(175)147-82(55-62(2)3)111(181)145-77(37-43-88(125)158)106(176)140-73(29-20-51-132-119(128)129)103(173)146-80(48-54-190-8)110(180)142-76(36-42-87(124)157)107(177)144-79(41-47-95(167)168)108(178)139-72(28-17-19-50-122)102(172)143-78(40-46-94(165)166)109(179)141-74(30-21-52-133-120(130)131)104(174)148-85(59-90(127)160)112(182)138-71(27-16-18-49-121)100(170)134-61-92(162)137-81(118(188)189)38-44-89(126)159/h10-15,23-26,32-35,62-65,70-86,96-98,155-156H,9,16-22,27-31,36-61,121-123H2,1-8H3,(H2,124,157)(H2,125,158)(H2,126,159)(H2,127,160)(H,134,170)(H,135,171)(H,136,161)(H,137,162)(H,138,182)(H,139,178)(H,140,176)(H,141,179)(H,142,180)(H,143,172)(H,144,177)(H,145,181)(H,146,173)(H,147,175)(H,148,174)(H,149,186)(H,150,185)(H,151,169)(H,152,184)(H,153,183)(H,163,164)(H,165,166)(H,167,168)(H,188,189)(H4,128,129,132)(H4,130,131,133)/t64-,65+,70-,71-,72-,73-,74-,75-,76-,77-,78-,79-,80-,81-,82-,83-,84-,85-,86-,96-,97-,98-/m0/s1 DMVILAD CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@@H]3CCCN3C(=O)[C@H](C(C)C)NC(=O)[C@H](CC4=CC=CC=C4)N DMVILAD IK LVRVABPNVHYXRT-BQWXUCBYSA-N DMVILAD IU (2S)-5-amino-2-[[2-[[(2S)-6-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-amino-3-phenylpropanoyl]amino]-3-methylbutanoyl]pyrrolidine-2-carbonyl]amino]-3-methylpentanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]-4-carboxybutanoyl]amino]-4-methylpentanoyl]amino]-5-oxopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-oxopentanoyl]amino]-4-carboxybutanoyl]amino]hexanoyl]amino]-4-carboxybutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-4-oxobutanoyl]amino]hexanoyl]amino]acetyl]amino]-5-oxopentanoic acid DMVILAD CA CAS 9072-41-7 DMHEAB1 ID DMHEAB1 DMHEAB1 DN Neupro DMHEAB1 HS Phase 4 DMHEAB1 SN Rotigotine; 99755-59-6; Leganto; SPM 962; (S)-6-(propyl(2-(thiophen-2-yl)ethyl)amino)-5,6,7,8-tetrahydronaphthalen-1-ol; (6S)-rotigotine; UNII-87T4T8BO2E; (6S)-6-[propyl(2-thiophen-2-ylethyl)amino]-5,6,7,8-tetrahydronaphthalen-1-ol; SPM-962; N 0923; CHEMBL1303; 87T4T8BO2E; 99755-59-6 (free base); (6S)-6-(Propyl(2-(2-thienyl)ethyl)amino)-5,6,7,8-tetrahydro-1-naphthalenol; NCGC00168748-01; Rotigotine CDS Patch; (6s)-5,6,7,8-tetrahydro-6-[propyl[2-(2-thienyl)ethyl]amino]-1-naphthalenol; DSSTox_CID_26772; DSSTox_RID_81893; DSSTox_GSID_46772; C19H25NOS; Rotigotine CDS; (S)-5,6,7,8-Tetrahydro-6-(propyl(2-(2-thienyl)ethyl)amino)-1-naphthol; (S)-6-[Propyl-(2-thiophen-2-yl-ethyl)-amino]-5,6,7,8-tetrahydro-naphthalen-1-ol; CAS-99755-59-6; Neupro (TN); N-0923; Rotigotine [USAN:INN:BAN]; (S)-5,6,7,8-tetrahydro-6-[propyl[2-(2-thienyl)ethyl]amino]-1-naphthol; (S)-6-[Propyl[2-(thiophen-2-yl)ethyl]amino]-5,6,7,8-tetrahydronaphthalen-1-ol; SPM-936; SPM-937; PubChem16423; (-)-(S)-5,6,7,8-Tetrahydro-6-(propyl(2-(2-thienyl)ethyl)amino)-1-naphthol; GTPL941; cc-129; Rotigotine (JAN/USAN/INN); (-)-N-0437; SCHEMBL1088585; ZINC4028; DTXSID5046772; HSDB 8254; (2S)-2-[propyl-[2-(2-thienyl)ethyl]amino]tetralin-5-ol; CHEBI:135351; HMS3885D17; EX-A1164; Tox21_112627; 2696AH; BDBM50123626; MFCD00870193; s4274; AKOS016340728; Tox21_112627_1; AC-3547; CCG-267650; CS-0376; DB05271; SB19528; SS-4572; 1-naphthalenol, 5,6,7,8-tetrahydro-6-(propyl (2-(2-thienyl)ethyl)amino-(6S)-; NCGC00168748-02; HY-75502; AB0088886; SW220014-1; D05768; W-5179; 572R932; A846076; Q411985; J-502471; UNII-5QTR54Z0E1 component KFQYTPMOWPVWEJ-INIZCTEOSA-N; (6S)-6-(propyl-(2-thiophen-2-ylethyl)amino)-5,6,7,8-tetrahydronaphthalen-1-ol; 1-Naphthalenol, 5,6,7,8-tetrahydro-6-(propyl(2-(2-thienyl)ethyl)amino)-, (6S)- DMHEAB1 CP UCB DMHEAB1 DT Small molecular drug DMHEAB1 PC 59227 DMHEAB1 MW 315.5 DMHEAB1 FM C19H25NOS DMHEAB1 IC InChI=1S/C19H25NOS/c1-2-11-20(12-10-17-6-4-13-22-17)16-8-9-18-15(14-16)5-3-7-19(18)21/h3-7,13,16,21H,2,8-12,14H2,1H3/t16-/m0/s1 DMHEAB1 CS CCCN(CCC1=CC=CS1)[C@H]2CCC3=C(C2)C=CC=C3O DMHEAB1 IK KFQYTPMOWPVWEJ-INIZCTEOSA-N DMHEAB1 IU (6S)-6-[propyl(2-thiophen-2-ylethyl)amino]-5,6,7,8-tetrahydronaphthalen-1-ol DMHEAB1 CA CAS 99755-59-6 DMHEAB1 CB CHEBI:135351 DMHEAB1 DE Parkinson disease; Restless legs syndrome DMRP8XB ID DMRP8XB DMRP8XB DN Nomegestrol DMRP8XB HS Phase 4 DMRP8XB SN Nomegestrol; Nomegestrol (USAN/INN); Nomegestrol [USAN:INN:BAN]; Nomegestrolum; Nomegestrolum [Latin]; SCHEMBL139763; Thermex; nomegestrol[inn]; Monaco; (8S,9S,10R,13S,14S,17R)-17-acetyl-17-hydroxy-6,13-dimethyl-1,2,8,9,10,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one; 10F89177CO; 17-Hydroxy-6-methyl-19-nor-4,6-pregnadiene-3,20-dione; 17-Hydroxy-6-methyl-19-norpregna-4,6-diene-3,20-dione; 58691-88-6; AC1L2AFS; AC1Q6OH0; CHEBI:135993; CHEMBL2105722; UNII-10F89177CO DMRP8XB PC 68783 DMRP8XB MW 328.4 DMRP8XB FM C21H28O3 DMRP8XB IC KZUIYQJTUIACIG-YBZCJVABSA-N DMRP8XB CS CC1=CC2C(CCC3(C2CCC3(C(=O)C)O)C)C4C1=CC(=O)CC4 DMRP8XB IK 1S/C21H28O3/c1-12-10-18-16(15-5-4-14(23)11-17(12)15)6-8-20(3)19(18)7-9-21(20,24)13(2)22/h10-11,15-16,18-19,24H,4-9H2,1-3H3/t15-,16-,18-,19+,20+,21+/m1/s1 DMRP8XB IU (8S,9S,10R,13S,14S,17R)-17-acetyl-17-hydroxy-6,13-dimethyl-1,2,8,9,10,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one DMRP8XB CA CAS 58691-88-6 DMRP8XB CB CHEBI:135993 DMRP8XB DE Hypercoagulability DMVAOME ID DMVAOME DMVAOME DN Oleandomycin DMVAOME HS Phase 4 DMVAOME SN Oleandomycin A; Amimycin; Landomycin; Matromycin; Antibiotic PA 105; LMPK04000007; P8ZQ646136; PA 105; Prestwick3_000152; RZPAKFUAFGMUPI-QESOVKLGSA-N; Romicil; SCHEMBL3717; ZINC85432018; oleandomycin; 3922-90-5; AB00513809; AC1L2I65; BDBM234401; BPBio1_000314; BSPBio_000284; C01946; CHEBI:16869; CHEMBL606258; CS-0063452; E704; HY-116010; NCGC00179617-01; UNII-P8ZQ646136 DMVAOME PC 72493 DMVAOME MW 687.9 DMVAOME FM C35H61NO12 DMVAOME IC RZPAKFUAFGMUPI-QESOVKLGSA-N DMVAOME CS CC1CC(C(C(O1)OC2C(CC3(CO3)C(=O)C(C(C(C(OC(=O)C(C(C2C)OC4CC(C(C(O4)C)O)OC)C)C)C)O)C)C)O)N(C)C DMVAOME IK 1S/C35H61NO12/c1-16-14-35(15-43-35)32(40)19(4)27(37)18(3)22(7)46-33(41)21(6)31(47-26-13-25(42-11)28(38)23(8)45-26)20(5)30(16)48-34-29(39)24(36(9)10)12-17(2)44-34/h16-31,34,37-39H,12-15H2,1-11H3/t16-,17+,18-,19+,20+,21+,22+,23-,24-,25-,26-,27-,28-,29+,30-,31-,34-,35+/m0/s1 DMVAOME IU (3R,5S,6S,7R,8S,9R,12R,13R,14S,15R)-6-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-hydroxy-8-[(2R,4S,5S,6S)-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy-5,7,9,12,13,15-hexamethyl-1,11-dioxaspiro[2.13]hexadecane-10,16-dione DMVAOME CA CAS 3922-90-5 DMVAOME CB CHEBI:16869 DMVAOME DE Acute upper respiratory infection DMQIMTK ID DMQIMTK DMQIMTK DN Ombitasvir DMQIMTK HS Phase 4 DMQIMTK SN 2302768XJ8; ABT 267; ABT-267; ABT-267;ABT267;ABT 267; ABT267; CHEBI:85183; CHEMBL3127326; CS-5330; DB09296; Ombitasvir; Ombitasvir (USAN); Ombitasvir [USAN:INN]; Ombitasvir pound>>ABT-267; Ombitasvir(ABT-267); SB16895; SCHEMBL8542284; UNII-2302768XJ8; ZINC150601177; dimethyl ([(2S,5S)-1-(4-tert-butylphenyl)pyrrolidine-2,5-diyl]bis{(4,1-phenylene)carbamoyl(2S)pyrrolidine-2,1-diyl[(2S)-3-methyl-1-oxobutane-1,2-diyl]})biscarbamate DMQIMTK TC Antiviral Agent DMQIMTK DT Small molecular drug DMQIMTK PC 54767916 DMQIMTK MW 894.127 DMQIMTK FM C50H67N7O8 DMQIMTK IC InChI=1S/C50H67N7O8/c1-30(2)42(53-48(62)64-8)46(60)55-28-10-12-40(55)44(58)51-35-20-14-32(15-21-35)38-26-27-39(57(38)37-24-18-34(19-25-37)50(5,6)7)33-16-22-36(23-17-33)52-45(59)41-13-11-29-56(41)47(61)43(31(3)4)54-49(63)65-9/h14-25,30-31,38-43H,10-13,26-29H2,1-9H3,(H,51,58)(H,52,59)(H,53,62)(H,54,63)/t38-,39-,40-,41-,42-,43-/m0/s1 DMQIMTK CS CC(C)C(C(=O)N1CCCC1C(=O)NC2=CC=C(C=C2)C3CCC(N3C4=CC=C(C=C4)C(C)(C)C)C5=CC=C(C=C5)NC(=O)C6CCCN6C(=O)C(C(C)C)NC(=O)OC)NC(=O)OC DMQIMTK IK PIDFDZJZLOTZTM-KHVQSSSXSA-N DMQIMTK IU methyl N-[(2S)-1-[(2S)-2-[[4-[(2S,5S)-1-(4-tert-butylphenyl)-5-[4-[[(2S)-1-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]pyrrolidine-2-carbonyl]amino]phenyl]pyrrolidin-2-yl]phenyl]carbamoyl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate DMQIMTK CA CAS 1258226-87-7 DMQIMTK CB CHEBI:85183 DMQIMTK DE Hepatitis C virus infection DMPSKA5 ID DMPSKA5 DMPSKA5 DN Ortho-phosphate DMPSKA5 HS Phase 4 DMPSKA5 SN Acide phosphorique; Acide phosphorique [French]; Acido fosforico; Acido fosforico [Italian]; Acidum phosphoricum; Fosforzuuroplossingen; Fosforzuuroplossingen [Dutch]; ORTHOPHOSPHORIC ACID; POLYPHOSPHORIC ACID; Phosphoric acid; Phosphoric acid 75%; Phosphoric acid, ortho-; Phosphorsaeure; Phosphorsaeureloesungen; Phosphorsaeureloesungen [German]; Superphosphoric acid; Wc-reiniger; White phosphoric acid; o-Phosphoric acid; ortho-phosphoric acid; 7664-38-2; Caswell No. 662; Evits; FEMA No. 2900; Sonac; UNII-E4GA8884NN DMPSKA5 PC 1004 DMPSKA5 MW 97.995 DMPSKA5 FM H3O4P DMPSKA5 IC NBIIXXVUZAFLBC-UHFFFAOYSA-N DMPSKA5 CS OP(=O)(O)O DMPSKA5 IK 1S/H3O4P/c1-5(2,3)4/h(H3,1,2,3,4) DMPSKA5 IU phosphoric acid DMPSKA5 CA CAS 7664-38-2 DMPSKA5 CB CHEBI:26078. DMPSKA5 DE Thyroid cancer DMU1JVW ID DMU1JVW DMU1JVW DN Otilonium DMU1JVW HS Phase 4 DMU1JVW SN LS-187100; OTILONIUM; ZINC8214636; 105360-89-2; 6330179ARU; AB01566869_01; AC1L2HEM; AC1Q65RN; CHEBI:135780; CHEMBL1433361; CTK8G5037; DTXSID0048391; Diethyl-methyl-[2-[4-[(2-octoxybenzoyl)amino]benzoyl]oxyethyl]azanium; Ethanaminium, N,N-diethyl-N-methyl-2-((4-((2-(octyloxy)benzoyl)amino)benzoyl)oxy)-; N,N-Diethyl-N-methyl-2-(4-(2-(octyloxy)benzamido)benzoyloxy)ethanaminium; NCGC00163507-01; NCGC00163507-02; SCHEMBL20352274; UNII-6330179ARU DMU1JVW PC 72093 DMU1JVW MW 483.7 DMU1JVW FM C29H43N2O4+ DMU1JVW IC NQHNLNLJPDMBFN-UHFFFAOYSA-O DMU1JVW CS CCCCCCCCOC1=CC=CC=C1C(=O)NC2=CC=C(C=C2)C(=O)OCC[N+](C)(CC)CC DMU1JVW IK 1S/C29H42N2O4/c1-5-8-9-10-11-14-22-34-27-16-13-12-15-26(27)28(32)30-25-19-17-24(18-20-25)29(33)35-23-21-31(4,6-2)7-3/h12-13,15-20H,5-11,14,21-23H2,1-4H3/p+1 DMU1JVW IU diethyl-methyl-[2-[4-[(2-octoxybenzoyl)amino]benzoyl]oxyethyl]azanium DMU1JVW CA CAS 105360-89-2 DMU1JVW CB CHEBI:135780 DMU1JVW DE Irritable bowel syndrome DMIGKA1 ID DMIGKA1 DMIGKA1 DN Ozagrel DMIGKA1 HS Phase 4 DMIGKA1 SN Ozagrel (ophthalmic, eye disorders); Ozagrel (ophthalmic, eye disorders), Kissei/ Teika DMIGKA1 CP Kissei Pharmaceutical Co Ltd DMIGKA1 DT Small molecular drug DMIGKA1 PC 5282440 DMIGKA1 MW 228.25 DMIGKA1 FM C13H12N2O2 DMIGKA1 IC InChI=1S/C13H12N2O2/c16-13(17)6-5-11-1-3-12(4-2-11)9-15-8-7-14-10-15/h1-8,10H,9H2,(H,16,17)/b6-5+ DMIGKA1 CS C1=CC(=CC=C1CN2C=CN=C2)/C=C/C(=O)O DMIGKA1 IK SHZKQBHERIJWAO-AATRIKPKSA-N DMIGKA1 IU (E)-3-[4-(imidazol-1-ylmethyl)phenyl]prop-2-enoic acid DMIGKA1 CA CAS 82571-53-7 DMIGKA1 CB CHEBI:92359 DMIGKA1 DE Chronic obstructive pulmonary disease; Xerophthalmia DMY2AEF ID DMY2AEF DMY2AEF DN PAI-1 DMY2AEF HS Phase 4 DMY2AEF SN PA Autoinducer; Pseudomonas aeruginosa autoinducer; N-(3-Oxododecanoyl)homoserine lactone; 3-Oxo-N-(tetrahydro-2-oxo-3-furanyl)dodecanamide; 152833-54-0; CHEBI:29639; 3-oxo-N-(2-oxotetrahydrofuran-3-yl)dodecanamide; N-(3-ketododecanoyl)homoserine lactone; 3-oxo-C12-AHL; 3-oxo-N-(2-oxooxolan-3-yl)dodecanamide; AC1L2SRN; CHEMBL482476; SCHEMBL10076544; BCP19350; AN-30880; RT-014202; 3-(3-Oxododecanoylamino)tetrahydrofuran-2-one; C11840; Dodecanamide, 3-oxo-N-(tetrahydro-2-oxo-3-furanyl)- DMY2AEF DT Small molecular drug DMY2AEF PC 3246941 DMY2AEF MW 297.39 DMY2AEF FM C16H27NO4 DMY2AEF IC InChI=1S/C16H27NO4/c1-2-3-4-5-6-7-8-9-13(18)12-15(19)17-14-10-11-21-16(14)20/h14H,2-12H2,1H3,(H,17,19)/t14-/m0/s1 DMY2AEF CS CCCCCCCCCC(=O)CC(=O)N[C@H]1CCOC1=O DMY2AEF IK PHSRRHGYXQCRPU-AWEZNQCLSA-N DMY2AEF IU 3-oxo-N-[(3S)-2-oxooxolan-3-yl]dodecanamide DMY2AEF CA CAS 168982-69-2 DMY2AEF CB CHEBI:44534 DMIV8CT ID DMIV8CT DMIV8CT DN Parecoxib DMIV8CT HS Phase 4 DMIV8CT SN Parecoxib; SC-69124; Dynastat; Valus-P; Vorth-P; SC 69124; UNII-9TUW81Y3CE; 9TUW81Y3CE; Parecoxib [USAN:INN:BAN]; CHEBI:73038; N-((p-(5-methyl-3-phenyl-4-isoxazolyl)phenyl)sulfonyl)propionamide; Parocoxib; N-[4-(5-methyl-3-phenyl-1,2-oxazol-4-yl)phenyl]sulfonylpropanamide; Propanamide, N-((4-(5-methyl-3-phenyl-4-isoxazolyl)phenyl)sulfonyl)-; N-[4-(5-methyl-3-phenyl-1,2-oxazol-4-yl)benzenesulfonyl]propanamide; N-{[4-(5-methyl-3-phenyl-1,2-oxazol-4-yl)phenyl]sulfonyl}propanamide; parecoxibum; Valdecoxib Impurity J; Parecoxib ( DMIV8CT DT Small molecular drug DMIV8CT PC 119828 DMIV8CT MW 370.4 DMIV8CT FM C19H18N2O4S DMIV8CT IC InChI=1S/C19H18N2O4S/c1-3-17(22)21-26(23,24)16-11-9-14(10-12-16)18-13(2)25-20-19(18)15-7-5-4-6-8-15/h4-12H,3H2,1-2H3,(H,21,22) DMIV8CT CS CCC(=O)NS(=O)(=O)C1=CC=C(C=C1)C2=C(ON=C2C3=CC=CC=C3)C DMIV8CT IK TZRHLKRLEZJVIJ-UHFFFAOYSA-N DMIV8CT IU N-[4-(5-methyl-3-phenyl-1,2-oxazol-4-yl)phenyl]sulfonylpropanamide DMIV8CT CA CAS 198470-84-7 DMIV8CT CB CHEBI:73038 DMQY873 ID DMQY873 DMQY873 DN Pentifylline DMQY873 HS Phase 4 DMQY873 SN Pentifilina [INN-Spanish]; Pentifyllin; Pentifylline; Pentifylline [INN:BAN:DCF]; Pentifyllinum [INN-Latin]; Cosadon; Cosaldon; Hexyltheobromine; MBM1C4K26S; SK 7 (Pharmaceutical); Theobromine, 1-hexyl-; 1-Hexyl-3,7-dihydro-3,7-dimethyl-1H-purine-2,6-dione; 1-Hexyl-3,7-dimethyl-1H-purine-2,6(3H,7H)-dione; 1-Hexyl-3,7-dimethylxanthine; 1-Hexyltheobromine; 1-n-hexyltheobromine; 1028-33-7; 3,7-Dimethyl-1-hexyl-1H,3H-purin-2,6-dione; BRN 0270632; C13H20N4O2; EINECS 213-842-0; MFCD00041424; SK 7; UNII-MBM1C4K26S DMQY873 PC 70569 DMQY873 MW 264.32 DMQY873 FM C13H20N4O2 DMQY873 IC MRWQRJMESRRJJB-UHFFFAOYSA-N DMQY873 CS CCCCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C DMQY873 IK 1S/C13H20N4O2/c1-4-5-6-7-8-17-12(18)10-11(14-9-15(10)2)16(3)13(17)19/h9H,4-8H2,1-3H3 DMQY873 IU 1-hexyl-3,7-dimethylpurine-2,6-dione DMQY873 CA CAS 1028-33-7 DMQY873 CB CHEBI:135091 DMQY873 DE Cerebrovascular dementia DM4OIMZ ID DM4OIMZ DM4OIMZ DN Pinaverium DM4OIMZ HS Phase 4 DM4OIMZ SN Pinaverium; LS-176056; SCHEMBL312166; U2368VVE7O; 59995-65-2; AC1L24AP; BDBM50101975; C26H41BrNO4; CHEBI:135811; CHEMBL1909324; DB09090; Morpholinium, 4-((2-bromo-4,5-dimethoxyphenyl)methyl)-4-(2-(2-(6,6-dimethylbicyclo(3.1.1)hept-2-yl)ethoxy)ethyl)-; NCGC00181763-01; UNII-U2368VVE7O DM4OIMZ PC 40704 DM4OIMZ MW 511.5 DM4OIMZ FM C26H41BrNO4+ DM4OIMZ IC DDHUTBKXLWCZCO-UHFFFAOYSA-N DM4OIMZ CS CC1(C2CCC(C1C2)CCOCC[N+]3(CCOCC3)CC4=CC(=C(C=C4Br)OC)OC)C DM4OIMZ IK 1S/C26H41BrNO4/c1-26(2)21-6-5-19(22(26)16-21)7-11-31-12-8-28(9-13-32-14-10-28)18-20-15-24(29-3)25(30-4)17-23(20)27/h15,17,19,21-22H,5-14,16,18H2,1-4H3/q+1 DM4OIMZ IU 4-[(2-bromo-4,5-dimethoxyphenyl)methyl]-4-[2-[2-(6,6-dimethyl-2-bicyclo[3.1.1]heptanyl)ethoxy]ethyl]morpholin-4-ium DM4OIMZ CA CAS 59995-65-2 DM4OIMZ CB CHEBI:135811 DM4OIMZ DE Irritable bowel syndrome DMWRYUH ID DMWRYUH DMWRYUH DN Prasterone sulfate DMWRYUH HS Phase 4 DMWRYUH SN Prasterone sulfate; Prasterone sulphate; 17-Ketoandrost-5-en-3beta-yl sulfate; 3-O-Sulfodehydroepiandrosterone; 3beta-Hydroxyandrost-5-en-17-one 3-sulfate; 651-48-9; DEHYDROEPIANDROSTERONE SULFATE; DHEA sulfate; DHEA sulphate; DHEA-S; Dehydroandrosterone sulfate; Dehydroepiandrosterone 3-sulfate; Dehydroepiandrosterone monosulfate; Dehydroepiandrosterone sulphate; Dehydroisoandrosterone sulfate; Dehydroisoandrosterone-3-sulfate; Androst-5-en-17-on-3beta-yl sulfuric acid; CCRIS 6746; DHEAS; UNII-57B09Q7FJR DMWRYUH PC 12594 DMWRYUH MW 368.5 DMWRYUH FM C19H28O5S DMWRYUH IC CZWCKYRVOZZJNM-USOAJAOKSA-N DMWRYUH CS CC12CCC3C(C1CCC2=O)CC=C4C3(CCC(C4)OS(=O)(=O)O)C DMWRYUH IK 1S/C19H28O5S/c1-18-9-7-13(24-25(21,22)23)11-12(18)3-4-14-15-5-6-17(20)19(15,2)10-8-16(14)18/h3,13-16H,4-11H2,1-2H3,(H,21,22,23)/t13-,14-,15-,16-,18-,19-/m0/s1 DMWRYUH IU [(3S,8R,9S,10R,13S,14S)-10,13-dimethyl-17-oxo-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-yl] hydrogen sulfate DMWRYUH CA CAS 651-48-9 DMWRYUH CB CHEBI:16814 DMWRYUH DE Adrenocortical deficiency DM6VFO1 ID DM6VFO1 DM6VFO1 DN Pregnenolone DM6VFO1 HS Phase 4 DM6VFO1 SN Pregnenolone (schizophrenia); Neurosteroid (schizophrenia), Neuroscience; Pregnenolone (schizophrenia), Neuroscience DM6VFO1 CP Duke University DM6VFO1 DT Small molecular drug DM6VFO1 PC 8955 DM6VFO1 MW 316.5 DM6VFO1 FM C21H32O2 DM6VFO1 IC InChI=1S/C21H32O2/c1-13(22)17-6-7-18-16-5-4-14-12-15(23)8-10-20(14,2)19(16)9-11-21(17,18)3/h4,15-19,23H,5-12H2,1-3H3/t15-,16-,17+,18-,19-,20-,21+/m0/s1 DM6VFO1 CS CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C DM6VFO1 IK ORNBQBCIOKFOEO-QGVNFLHTSA-N DM6VFO1 IU 1-[(3S,8S,9S,10R,13S,14S,17S)-3-hydroxy-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]ethanone DM6VFO1 CA CAS 145-13-1 DM6VFO1 CB CHEBI:16581 DM6VFO1 DE Schizophrenia DM8PTSY ID DM8PTSY DM8PTSY DN Prenylamine DM8PTSY HS Phase 4 DM8PTSY SN Prenilamina; Prenilamina [INN-Spanish]; Prenylamine (vasodilator); Prenylamine [USAN:INN:BAN]; Prenylaminum; Prenylaminum [INN-Latin]; Bismethin; Carditin; Corontin; Corpax; DL-Prenylamine; Difril; Elecor; Falliocor; Hostaginan; PRENYLAMINE; SAN 13-194; Sandoz 13-194; Segontin; Synadrin; Valecor; 1-Phenyl-2-(1',1'-diphenylpropyl-3'-amino)propane; 390-64-7; B-436; BRN 2060323; CHEMBL24072; EINECS 206-869-4; N-(1-Methyl-2-phenylethyl)-gamma-phenylbenzenepropanamine; N-(3,3-Diphenylpropyl)-alpha-methylphenethylamine DM8PTSY PC 9801 DM8PTSY MW 329.5 DM8PTSY FM C24H27N DM8PTSY IC IFFPICMESYHZPQ-UHFFFAOYSA-N DM8PTSY CS CC(CC1=CC=CC=C1)NCCC(C2=CC=CC=C2)C3=CC=CC=C3 DM8PTSY IK 1S/C24H27N/c1-20(19-21-11-5-2-6-12-21)25-18-17-24(22-13-7-3-8-14-22)23-15-9-4-10-16-23/h2-16,20,24-25H,17-19H2,1H3 DM8PTSY IU 3,3-diphenyl-N-(1-phenylpropan-2-yl)propan-1-amine DM8PTSY CA CAS 390-64-7 DM8PTSY CB CHEBI:8397 DM8PTSY DE Angina pectoris DM37FKA ID DM37FKA DM37FKA DN Primovist DM37FKA HS Phase 4 DM37FKA SN Eovist; Primovist; gadoxate disodium; AC1L9OPS; gadolinium ethoxybenzyl-DTPA; MOLI000482; 2-[[2-[bis(carboxymethyl)amino]-3-(4-ethoxyphenyl)propyl]-[2-[bis(carboxymethyl)amino]ethyl]amino]acetic acid; gadolinium(3+) DM37FKA PC 450096 DM37FKA MW 684.8 DM37FKA FM C23H33GdN3O11+3 DM37FKA IC InChI=1S/C23H33N3O11.Gd/c1-2-37-18-5-3-16(4-6-18)9-17(26(14-22(33)34)15-23(35)36)10-24(11-19(27)28)7-8-25(12-20(29)30)13-21(31)32;/h3-6,17H,2,7-15H2,1H3,(H,27,28)(H,29,30)(H,31,32)(H,33,34)(H,35,36);/q;+3 DM37FKA CS CCOC1=CC=C(C=C1)CC(CN(CCN(CC(=O)O)CC(=O)O)CC(=O)O)N(CC(=O)O)CC(=O)O.[Gd+3] DM37FKA IK PCZHWPSNPWAQNF-UHFFFAOYSA-N DM37FKA IU 2-[[2-[bis(carboxymethyl)amino]-3-(4-ethoxyphenyl)propyl]-[2-[bis(carboxymethyl)amino]ethyl]amino]acetic acid;gadolinium(3+) DM37FKA DE Lung cancer DMXL43T ID DMXL43T DMXL43T DN Prulifloxacin DMXL43T HS Phase 4 DMXL43T SN Prulifloxacin; Prulifloxacin [INN]; Pruvel; Q-101929; Quisnon; NM 441; NM-441; 123447-62-1; 1H,4H-(1,3)Thiazeto(3,2-a)quinoline-3-carboxylic acid, 6-fluoro-1-methyl-7-(4-((5-methyl-2-oxo-1,3-dioxol-4-yl)methyl)-1-piperazinyl)-4-oxo-; 6-fluoro-1-methyl-7-(4-((5-methyl-2-oxo-1,3-dioxol-4-yl)methyl)piperazin-1-yl)-4-oxo-1,4-dihydro-[1,3]thiazeto[3,2-a]quinoline-3-carboxylic acid; AK144730; CCRIS 7686; DSSTox_CID_26480; DSSTox_GSID_46480; DSSTox_RID_81651; NCGC00164615-01; NM441; Sword DMXL43T PC 65947 DMXL43T MW 461.5 DMXL43T FM C21H20FN3O6S DMXL43T IC PWNMXPDKBYZCOO-UHFFFAOYSA-N DMXL43T CS CC1N2C3=CC(=C(C=C3C(=O)C(=C2S1)C(=O)O)F)N4CCN(CC4)CC5=C(OC(=O)O5)C DMXL43T IK 1S/C21H20FN3O6S/c1-10-16(31-21(29)30-10)9-23-3-5-24(6-4-23)15-8-14-12(7-13(15)22)18(26)17(20(27)28)19-25(14)11(2)32-19/h7-8,11H,3-6,9H2,1-2H3,(H,27,28) DMXL43T IU 6-fluoro-1-methyl-7-[4-[(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl]piperazin-1-yl]-4-oxo-1H-[1,3]thiazeto[3,2-a]quinoline-3-carboxylic acid DMXL43T CA CAS 123447-62-1 DMXL43T CB CHEBI:32071 DMXL43T DE Chronic obstructive pulmonary disease DMF8CJ9 ID DMF8CJ9 DMF8CJ9 DN Pyridine DMF8CJ9 HS Phase 4 DMF8CJ9 SN Azabenzene; 110-86-1; Azine; Pyridin; Pirydyna; Piridina; Pyridin [German]; Pirydyna [Polish]; Piridina [Italian]; RCRA waste number U196; NCI-C55301; Caswell No. 717; CCRIS 2926; HSDB 118; pyridine-ring; CHEBI:16227; FEMA Number 2966; CP 32; UNII-NH9L3PP67S; EINECS 203-809-9; UN1282; NSC 406123; FEMA No. 2966; RCRA waste no. U196; EPA Pesticide Chemical Code 069202; NH9L3PP67S; AI3-01240; pyridine fraction; JUJWROOIHBZHMG-UHFFFAOYSA-N; MFCD00011732; Pentadeuteropyridine; Pyridine [UN1282] [Flammable liquid]; 7291-22-7 DMF8CJ9 DT Small molecular drug DMF8CJ9 PC 1049 DMF8CJ9 MW 79.1 DMF8CJ9 FM C5H5N DMF8CJ9 IC InChI=1S/C5H5N/c1-2-4-6-5-3-1/h1-5H DMF8CJ9 CS C1=CC=NC=C1 DMF8CJ9 IK JUJWROOIHBZHMG-UHFFFAOYSA-N DMF8CJ9 IU pyridine DMF8CJ9 CA CAS 110-86-1 DMF8CJ9 CB CHEBI:16227 DMBPN7T ID DMBPN7T DMBPN7T DN Rupatadine DMBPN7T HS Phase 4 DMBPN7T SN Rupatadine trihydrochloride; UNII-G61C8NZY2T; G61C8NZY2T; 156611-76-6; Rupatadine HCl; Rupatadine hydrochloride; UR 12592; AC1L320L; DTXSID90166109; BQFOTHHRVVHLEW-UHFFFAOYSA-N; 8-Chloro-6,11-dihydro-11-(1-((5-methyl-3-pyridinyl)methyl)-4-piperidinylidene)-5H-benzo(5,6)cyclohepta(1,2-b)pyridine trihydrochloride; 5H-Benzo(5,6)cyclohepta(1,2-b)pyridine, 8-chloro-6,11-dihydro-11-(1-((5-methyl-3-pyridinyl)methyl)-4-piperidinylidene)-, trihydrochloride DMBPN7T DT Small molecular drug DMBPN7T PC 133017 DMBPN7T MW 416 DMBPN7T FM C26H26ClN3 DMBPN7T IC InChI=1S/C26H26ClN3/c1-18-13-19(16-28-15-18)17-30-11-8-20(9-12-30)25-24-7-6-23(27)14-22(24)5-4-21-3-2-10-29-26(21)25/h2-3,6-7,10,13-16H,4-5,8-9,11-12,17H2,1H3 DMBPN7T CS CC1=CC(=CN=C1)CN2CCC(=C3C4=C(CCC5=C3N=CC=C5)C=C(C=C4)Cl)CC2 DMBPN7T IK WUZYKBABMWJHDL-UHFFFAOYSA-N DMBPN7T IU 13-chloro-2-[1-[(5-methylpyridin-3-yl)methyl]piperidin-4-ylidene]-4-azatricyclo[9.4.0.03,8]pentadeca-1(11),3(8),4,6,12,14-hexaene DMBPN7T CA CAS 158876-82-5 DMBPN7T CB CHEBI:135673 DMXBYQR ID DMXBYQR DMXBYQR DN Silymarin DMXBYQR HS Phase 4 DMXBYQR SN Milk thistle extract; Sabal serrulata extract; 84604-20-6; AN-35849; FT-0656490; A835184; (2S)-3,5,7-trihydroxy-2-[(2S,3R)-3-(4-hydroxy-3-methoxyphenyl)-2-(hydroxymethyl)-2,3-dihydro-1,4-benzodioxin-6-yl]-3,4-dihydro-2H-1-benzopyran-4-one; (2S)-3,5,7-trihydroxy-2-[(2S,3R)-3-(4-hydroxy-3-methoxy-phenyl)-2-(hydroxymethyl)-2,3-dihydro-1,4-benzodioxin-6-yl]chroman-4-one DMXBYQR DT Small molecular drug DMXBYQR PC 5213 DMXBYQR MW 482.4 DMXBYQR FM C25H22O10 DMXBYQR IC InChI=1S/C25H22O10/c1-32-17-6-11(2-4-14(17)28)24-20(10-26)33-16-5-3-12(7-18(16)34-24)25-23(31)22(30)21-15(29)8-13(27)9-19(21)35-25/h2-9,20,23-29,31H,10H2,1H3 DMXBYQR CS COC1=C(C=CC(=C1)C2C(OC3=C(O2)C=C(C=C3)C4C(C(=O)C5=C(C=C(C=C5O4)O)O)O)CO)O DMXBYQR IK SEBFKMXJBCUCAI-UHFFFAOYSA-N DMXBYQR IU 3,5,7-trihydroxy-2-[3-(4-hydroxy-3-methoxyphenyl)-2-(hydroxymethyl)-2,3-dihydro-1,4-benzodioxin-6-yl]-2,3-dihydrochromen-4-one DMXBYQR CA CAS 65666-07-1 DMXBYQR CB CHEBI:125451 DMOSJD0 ID DMOSJD0 DMOSJD0 DN Sivelestat sodium hydrate DMOSJD0 HS Phase 4 DMOSJD0 SN sivelestat sodium hydrate; Sivelestat sodium tetrahydrate; 201677-61-4; Elaspol; Sodium sivelestat; EI546 sodium; UNII-737RR8Y409; Sivelestat (sodium tetrahydrate); LY544349 sodium; Sivelestat sodium [USAN]; Sivelestat sodium (USAN); 737RR8Y409; DSSTox_CID_26727; DSSTox_RID_81857; DSSTox_GSID_46727; sodium 2-[[2-[[4-(2,2-dimethylpropanoyloxy)phenyl]sulfonylamino]benzoyl]amino]acetate tetrahydrate; LY544349 Sodium Hydrate; Elaspol (TN); CAS-201677-61-4; NCGC00167577-01; AC1L4KMF; Sivelestat sodium hydrate (JAN); Sodium 2-[[2-[[4-(2,2-dimethylpropanoyloxy)phenyl]sulfonylamino]benzoyl]amino]acetate tetrahydrate; Sodium ((2-(((4-((2,2-dimethylpropanoyl)oxy)phenyl)sulfonyl)amino)benzoyl)amino)acetate tetrahydrate; Glycine, N-(2-(((4-(2,2-dimethyl-1-oxopropoxy)phenyl)sulfonyl)amino)benzoyl)-, monosodium salt, tetrahydrate DMOSJD0 CP ONO Pharmaceuticals DMOSJD0 DT Small molecular drug DMOSJD0 PC 23663985 DMOSJD0 MW 528.5 DMOSJD0 FM C20H29N2NaO11S DMOSJD0 IC InChI=1S/C20H22N2O7S.Na.4H2O/c1-20(2,3)19(26)29-13-8-10-14(11-9-13)30(27,28)22-16-7-5-4-6-15(16)18(25)21-12-17(23)24;;;;;/h4-11,22H,12H2,1-3H3,(H,21,25)(H,23,24);;4*1H2/q;+1;;;;/p-1 DMOSJD0 CS CC(C)(C)C(=O)OC1=CC=C(C=C1)S(=O)(=O)NC2=CC=CC=C2C(=O)NCC(=O)[O-].O.O.O.O.[Na+] DMOSJD0 IK PLHREJBSQUSUCW-UHFFFAOYSA-M DMOSJD0 IU sodium;2-[[2-[[4-(2,2-dimethylpropanoyloxy)phenyl]sulfonylamino]benzoyl]amino]acetate;tetrahydrate DMOSJD0 CA CAS 201677-61-4 DMOSJD0 CB CHEBI:32133 DMOSJD0 DE Community-acquired pneumonia; Acute lung injury DMTV7XH ID DMTV7XH DMTV7XH DN SPN-812 DMTV7XH HS Phase 4 DMTV7XH SN Viloxazine hydrochloride; 35604-67-2; 2-((2-Ethoxyphenoxy)methyl)morpholine hydrochloride; Emovit; 2-[(2-ethoxyphenoxy)methyl]morpholine hydrochloride; ICI 58,834; Viloxazine hydrochloride [USAN]; 2-((2-ethoxyphenoxy)methyl)morpholinehydrochloride; 2-[(2-ethoxyphenoxy)methyl]morpholine;hydrochloride; Morpholine, 2-[(2-ethoxyphenoxy)methyl]-, hydrochloride; Vicilan; Vivalan; 2-[(2-ethoxy phenoxy)methyl]morpholine hydrochloride; Morpholine, 2-((2-ethoxyphenoxy)methyl)-, hydrochloride; Viloxazine hydrochloride (USAN); Viloxazine HCl; CCRIS 1915; Viloxacina clorhidrato; ICI-58834; Viloxacina clorhidrato [Spanish]; EINECS 252-638-6; Prestwick_734; 2-((o-Ethoxyphenoxy)methyl)morpholine hydrochloride; Vivalan (TN); 2-(2-Ethoxyphenoxymethyl)tetrahydro-1,4-oxazine hydrochloride; 2-(2-Ethoxyphenoxymethyl)-2,3,5,6-tetrahydro-1,4-oxazine hydrochloride; rac Viloxazine Hydrochloride; DSSTox_CID_31511; DSSTox_RID_97396; DSSTox_GSID_57722; SCHEMBL300741; CHEMBL2106483; DTXSID8057722; Tox21_113955; 1478AE; AKOS015847050; CCG-220828; NCGC00262964-01; CAS-35604-67-2; A6217; FT-0675815; FT-0675816; FT-0675817; FT-0675818; FT-0675819; D02572; Z-1958; 2-(o-ethoxyphenoxymethyl)morpholine hydrochloride; 604E672; SR-01000872636; SR-01000872636-1; W-110863; 2-(2-Ethoxy-phenoxymethyl)-morpholine; hydrochloride; 2-[(2-Ethoxyphenoxy)-methyl]morpholine hydrochloride; Q27285797; 2-(2-ethoxy-phenoxymethyl)-tetra-hydro-1,4-oxazine hydrochloride DMTV7XH CP Supernus Pharmaceuticals DMTV7XH DT Small molecular drug DMTV7XH PC 71424 DMTV7XH MW 273.75 DMTV7XH FM C13H20ClNO3 DMTV7XH IC InChI=1S/C13H19NO3.ClH/c1-2-15-12-5-3-4-6-13(12)17-10-11-9-14-7-8-16-11;/h3-6,11,14H,2,7-10H2,1H3;1H DMTV7XH CS CCOC1=CC=CC=C1OCC2CNCCO2.Cl DMTV7XH IK HJOCKFVCMLCPTP-UHFFFAOYSA-N DMTV7XH IU 2-[(2-ethoxyphenoxy)methyl]morpholine;hydrochloride DMTV7XH CA CAS 35604-67-2 DMTV7XH DE Attention deficit hyperactivity disorder DM4TX7J ID DM4TX7J DM4TX7J DN Talipexole DM4TX7J HS Phase 4 DM4TX7J SN Talipexole; 101626-70-4; Talipexole [INN]; Talipexolum [Latin]; Talipexol [Spanish]; UNII-7AM2J46Z1Y; Domin; 7AM2J46Z1Y; CHEMBL279085; Talipexole (INN); NCGC00163160-01; DSSTox_CID_26321; DSSTox_RID_81537; DSSTox_GSID_46321; Talipexolum; Talipexol; 6-Allyl-2-amino-5,6,7,8-tetrahydro-4H-thiazolo(4,5-d)azepine; 6-allyl-5,6,7,8-tetrahydro-4H-thiazolo[4,5-d]azepin-2-amine; 6-prop-2-enyl-4,5,7,8-tetrahydro-[1,3]thiazolo[4,5-d]azepin-2-amine; 4H-Thiazolo[4,5-d]azepin-2-amine,5,6,7,8-tetrahydro-6-(2-propen-1-yl)-; BHT920 DM4TX7J DT Small molecular drug DM4TX7J PC 5374 DM4TX7J MW 209.31 DM4TX7J FM C10H15N3S DM4TX7J IC InChI=1S/C10H15N3S/c1-2-5-13-6-3-8-9(4-7-13)14-10(11)12-8/h2H,1,3-7H2,(H2,11,12) DM4TX7J CS C=CCN1CCC2=C(CC1)SC(=N2)N DM4TX7J IK DHSSDEDRBUKTQY-UHFFFAOYSA-N DM4TX7J IU 6-prop-2-enyl-4,5,7,8-tetrahydro-[1,3]thiazolo[4,5-d]azepin-2-amine DM4TX7J CA CAS 101626-70-4 DM4TX7J CB CHEBI:93327 DM62IPN ID DM62IPN DM62IPN DN Tenofovir disoproxil DM62IPN HS Phase 4 DM62IPN SN Tenofovir (Disoproxil); Tenofovir disoproxil; 201341-05-1; 9-((R)-2-((Bis(((isopropoxycarbonyl)oxy)methoxy)phosphinyl)methoxy)propyl)adenine; Bis(POC)PMPA; PMPA prodrug; CHEBI:63717; F4YU4LON7I; UNII-F4YU4LON7I; [[(1R)-2-(6-aminopurin-9-yl)-1-methyl-ethoxy]methyl-(isopropoxycarbonyloxymethoxy)phosphoryl]oxymethyl isopropyl carbonate; tenofovir bis(isopropyloxycarbonyloxymethyl) ester DM62IPN PC 5481350 DM62IPN MW 519.4 DM62IPN FM C19H30N5O10P DM62IPN IC JFVZFKDSXNQEJW-CQSZACIVSA-N DM62IPN CS CC(C)OC(=O)OCOP(=O)(COC(C)CN1C=NC2=C(N=CN=C21)N)OCOC(=O)OC(C)C DM62IPN IK 1S/C19H30N5O10P/c1-12(2)33-18(25)28-9-31-35(27,32-10-29-19(26)34-13(3)4)11-30-14(5)6-24-8-23-15-16(20)21-7-22-17(15)24/h7-8,12-14H,6,9-11H2,1-5H3,(H2,20,21,22)/t14-/m1/s1 DM62IPN IU [[(2R)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethyl-(propan-2-yloxycarbonyloxymethoxy)phosphoryl]oxymethyl propan-2-yl carbonate DM62IPN CA CAS 201341-05-1 DM62IPN CB CHEBI:63717 DM62IPN DE Human immunodeficiency virus infection DMC40UY ID DMC40UY DMC40UY DN Tenofovir disoproxil DMC40UY HS Phase 4 DMC40UY SN Tenofovir disoproxil; PMPA prodrug; Bis(POC)PMPA; Tenofovir (Disoproxil); UNII-F4YU4LON7I; 9-((R)-2-((Bis(((isopropoxycarbonyl)oxy)methoxy)phosphinyl)methoxy)propyl)adenine; F4YU4LON7I; CHEBI:63717; tenofovir bis(isopropyloxycarbonyloxymethyl) ester; Tenofovir Disoproxil Fumarate; [[(1R)-2-(6-aminopurin-9-yl)-1-methyl-ethoxy]methyl-(isopropoxycarbonyloxymethoxy)phosphoryl]oxymethyl isopropyl carbonate DMC40UY PC 5481350 DMC40UY MW 519.4 DMC40UY FM C19H30N5O10P DMC40UY IC InChI=1S/C19H30N5O10P/c1-12(2)33-18(25)28-9-31-35(27,32-10-29-19(26)34-13(3)4)11-30-14(5)6-24-8-23-15-16(20)21-7-22-17(15)24/h7-8,12-14H,6,9-11H2,1-5H3,(H2,20,21,22)/t14-/m1/s1 DMC40UY CS CC(C)OC(=O)OCOP(=O)(COC(C)CN1C=NC2=C(N=CN=C21)N)OCOC(=O)OC(C)C DMC40UY IK JFVZFKDSXNQEJW-CQSZACIVSA-N DMC40UY IU [[(2R)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethyl-(propan-2-yloxycarbonyloxymethoxy)phosphoryl]oxymethyl propan-2-yl carbonate DMC40UY CA CAS 201341-05-1 DMC40UY CB CHEBI:63717 DMC40UY DE Chronic hepatitis B infection DM2M47Y ID DM2M47Y DM2M47Y DN TKM-ApoB DM2M47Y HS Phase 4 DM2M47Y CP Tekmira Pharmaceuticals DM2M47Y DT siRNA drug DM2M47Y DE Hypercholesterolaemia DM7NSI0 ID DM7NSI0 DM7NSI0 DN Urethane DM7NSI0 HS Phase 4 DM7NSI0 SN Uretan; Uretan etylowy; Uretano [DCIT]; Urethan; Urethanum; Urethanum [INN-Latin]; Aethylcarbamat; Aethylcarbamat [German]; Aethylurethan; Aethylurethan [German]; Carbamic acid ethyl ester; Carbamic acid, ethyl ester; Carbamidsaeure-aethylester; ETHYL CARBAMATE; Estane 5703; Ethyl urethan; Ethyl urethane; Ethylcarbamate; Ethylester kyseliny karbaminove; Ethylurethan; Ethylurethane; Leucethane; Leucothane; O-Ethyl urethane; O-Ethylurethane; Pracarbamin; Pracarbamine; U-Compound; ethyl aminoformate; urethane; 51-79-6; NSC 746 DM7NSI0 PC 5641 DM7NSI0 MW 89.09 DM7NSI0 FM C3H7NO2 DM7NSI0 IC JOYRKODLDBILNP-UHFFFAOYSA-N DM7NSI0 CS CCOC(=O)N DM7NSI0 IK 1S/C3H7NO2/c1-2-6-3(4)5/h2H2,1H3,(H2,4,5) DM7NSI0 IU ethyl carbamate DM7NSI0 CA CAS 51-79-6 DM7NSI0 CB CHEBI:17967 DM7NSI0 DE Lung cancer DMCOJPS ID DMCOJPS DMCOJPS DN Vonoprazan DMCOJPS HS Phase 4 DMCOJPS SN Vonoprazan; Vonoprazan [INN]; TAK-438 (free base); TAK-438 free base; SCHEMBL194487; 1-(5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamine; 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1h-pyrrol-3-yl]-n-methylmethanamine; 1-[5-(2-fluorophenyl)-1-pyridin-3-ylsulfonyl-pyrrol-3-yl]-~{N}-methyl-methanamine; 1-[5-(2-fluorophenyl)-1-pyridin-3-ylsulfonylpyrrol-3-yl]-N-methylmethanamine; 1R5L3J156G; 881681-00-1; BCP13240; CHEBI:136048; CHEMBL2079130; DTXSID20236869; KS-00000TU1; UNII-1R5L3J156G DMCOJPS PC 15981397 DMCOJPS MW 345.4 DMCOJPS FM C17H16FN3O2S DMCOJPS IC BFDBKMOZYNOTPK-UHFFFAOYSA-N DMCOJPS CS CNCC1=CN(C(=C1)C2=CC=CC=C2F)S(=O)(=O)C3=CN=CC=C3 DMCOJPS IK 1S/C17H16FN3O2S/c1-19-10-13-9-17(15-6-2-3-7-16(15)18)21(12-13)24(22,23)14-5-4-8-20-11-14/h2-9,11-12,19H,10H2,1H3 DMCOJPS IU 1-[5-(2-fluorophenyl)-1-pyridin-3-ylsulfonylpyrrol-3-yl]-N-methylmethanamine DMCOJPS CA CAS 881681-00-1 DMCOJPS CB CHEBI:136048 DMCOJPS DE Gastro-oesophageal reflux disease DMKV32D ID DMKV32D DMKV32D DN Xylometazoline DMKV32D HS Phase 4 DMKV32D SN Xylometazoline (nasal mucoadhesive/MucoAd, congestion); Decongestant (nasal mucoadhesive/MucoAd, congestion), Strategic BioSciences; Xylometazoline (nasal mucoadhesive/MucoAd, congestion), Strategic BioSciences DMKV32D CP Fortune Apex Development Ltd DMKV32D DT Small molecular drug DMKV32D PC 5709 DMKV32D MW 244.37 DMKV32D FM C16H24N2 DMKV32D IC InChI=1S/C16H24N2/c1-11-8-13(16(3,4)5)9-12(2)14(11)10-15-17-6-7-18-15/h8-9H,6-7,10H2,1-5H3,(H,17,18) DMKV32D CS CC1=CC(=CC(=C1CC2=NCCN2)C)C(C)(C)C DMKV32D IK HUCJFAOMUPXHDK-UHFFFAOYSA-N DMKV32D IU 2-[(4-tert-butyl-2,6-dimethylphenyl)methyl]-4,5-dihydro-1H-imidazole DMKV32D CA CAS 526-36-3 DMKV32D CB CHEBI:10082 DMKV32D DE Allergic rhinitis DM9RJH7 ID DM9RJH7 DM9RJH7 DN Zaltoprofen DM9RJH7 HS Phase 4 DM9RJH7 SN Zaltoprofen (unspecified); Zaltoprofene; Zaltoprofeno; Zaltoprofenum; CN 100; CN-100; Soleton; zaltoprofen; (+-)-2-(10,11-Dihydro-10-oxodibenzo(b,f)thiepin-2-yl)propionic acid; 10,11-Dihydro-alpha-methyl-10-oxodibenzo(b,f)thiepin-2-acetic acid; 2-(10,11-Dihydro-10-oxodibenzo[b,f]thiepin-2-yl)propionic Acid; 2-(10-oxo-10,11-dihydrodibenzo[b,f]thiepin-2-yl)propanoic acid; 2-(6-oxo-5H-benzo[b][1]benzothiepin-3-yl)propanoic acid; 74711-43-6; 89482-00-8; AK-77321; C17H14O3S; EINECS 277-973-5; NCGC00183878-01; Peon DM9RJH7 PC 5720 DM9RJH7 MW 298.4 DM9RJH7 FM C17H14O3S DM9RJH7 IC MUXFZBHBYYYLTH-UHFFFAOYSA-N DM9RJH7 CS CC(C1=CC2=C(C=C1)SC3=CC=CC=C3C(=O)C2)C(=O)O DM9RJH7 IK 1S/C17H14O3S/c1-10(17(19)20)11-6-7-15-12(8-11)9-14(18)13-4-2-3-5-16(13)21-15/h2-8,10H,9H2,1H3,(H,19,20) DM9RJH7 IU 2-(6-oxo-5H-benzo[b][1]benzothiepin-3-yl)propanoic acid DM9RJH7 CA CAS 74711-43-6 DM9RJH7 CB CHEBI:32306 DM9RJH7 DE Anaesthesia DMXIRA0 ID DMXIRA0 DMXIRA0 DN RLX030 DMXIRA0 HS Approval submitted DMXIRA0 SN Serelaxin DMXIRA0 CP Novartis DMXIRA0 DT Small molecular drug DMXIRA0 PC 71300755 DMXIRA0 MW 5963 DMXIRA0 FM C256H408N74O74S8 DMXIRA0 IC InChI=1S/C256H408N74O74S8/c1-32-128(20)198-246(396)286-135(27)207(357)326-199(129(21)33-2)248(398)321-180(210(360)279-106-189(343)289-161(79-88-405-30)221(371)315-177(111-334)239(389)329-202(137(29)337)250(400)312-171(232(382)317-178(112-335)251(401)402)98-141-103-277-148-57-41-39-55-145(141)148)114-408-412-118-184(252(403)404)322-230(380)168(95-138-52-36-35-37-53-138)308-215(365)154(63-50-86-274-255(267)268)291-203(353)132(24)283-226(376)164(91-121(6)7)307-238(388)176(110-333)314-216(366)155(64-51-87-275-256(269)270)293-213(363)151(59-43-46-82-258)301-249(399)201(136(28)336)330-242(392)181-115-409-411-117-183(319-217(367)150(58-42-45-81-257)294-233(383)173(101-186(262)340)303-206(356)133(25)284-225(375)163(90-120(4)5)302-205(355)134(26)285-236(386)174(108-331)316-229(379)169(96-139-65-67-143(338)68-66-139)309-227(377)165(92-122(8)9)305-218(368)156-70-75-187(341)287-156)241(391)320-182(240(390)311-172(99-142-104-271-119-281-142)235(385)323-195(125(14)15)243(393)280-107-190(344)290-181)116-410-407-113-179(209(359)278-105-188(342)288-149(61-48-84-272-253(263)264)212(362)295-159(72-77-192(347)348)220(370)306-167(94-124(12)13)234(384)325-196(126(16)17)244(394)299-153(62-49-85-273-254(265)266)211(361)282-131(23)204(354)292-157(224(374)327-198)69-74-185(261)339)318-228(378)166(93-123(10)11)304-214(364)152(60-44-47-83-259)300-247(397)200(130(22)34-3)328-245(395)197(127(18)19)324-223(373)160(73-78-193(349)350)297-219(369)158(71-76-191(345)346)296-222(372)162(80-89-406-31)298-231(381)170(97-140-102-276-147-56-40-38-54-144(140)147)310-237(387)175(109-332)313-208(358)146(260)100-194(351)352/h35-41,52-57,65-68,102-104,119-137,146,149-184,195-202,276-277,331-338H,32-34,42-51,58-64,69-101,105-118,257-260H2,1-31H3,(H2,261,339)(H2,262,340)(H,271,281)(H,278,359)(H,279,360)(H,280,393)(H,282,361)(H,283,376)(H,284,375)(H,285,386)(H,286,396)(H,287,341)(H,288,342)(H,289,343)(H,290,344)(H,291,353)(H,292,354)(H,293,363)(H,294,383)(H,295,362)(H,296,372)(H,297,369)(H,298,381)(H,299,394)(H,300,397)(H,301,399)(H,302,355)(H,303,356)(H,304,364)(H,305,368)(H,306,370)(H,307,388)(H,308,365)(H,309,377)(H,310,387)(H,311,390)(H,312,400)(H,313,358)(H,314,366)(H,315,371)(H,316,379)(H,317,382)(H,318,378)(H,319,367)(H,320,391)(H,321,398)(H,322,380)(H,323,385)(H,324,373)(H,325,384)(H,326,357)(H,327,374)(H,328,395)(H,329,389)(H,330,392)(H,345,346)(H,347,348)(H,349,350)(H,351,352)(H,401,402)(H,403,404)(H4,263,264,272)(H4,265,266,273)(H4,267,268,274)(H4,269,270,275)/t128-,129-,130-,131-,132-,133-,134-,135-,136+,137+,146-,149-,150-,151-,152-,153-,154-,155-,156-,157-,158-,159-,160-,161-,162-,163-,164-,165-,166-,167-,168-,169-,170-,171-,172-,173-,174-,175-,176-,177-,178-,179-,180-,181-,182-,183-,184-,195-,196-,197-,198-,199-,200-,201-,202-/m0/s1 DMXIRA0 CS CC[C@H](C)[C@H]1C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)C)[C@@H](C)CC)CCC(=O)N)C)CCCNC(=N)N)C(C)C)CC(C)C)CCC(=O)O)CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)O)N)C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N2)C(C)C)CC5=CN=CN5)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC6=CC=C(C=C6)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]7CCC(=O)N7)[C@@H](C)O)CCCCN)CCCNC(=N)N)CO)CC(C)C)C)CCCNC(=N)N)CC8=CC=CC=C8)C(=O)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC9=CNC1=CC=CC=C19)C(=O)N[C@@H](CO)C(=O)O DMXIRA0 IK DTLOVISJEFBXLX-REAFJZEQSA-N DMXIRA0 IU (1R,6R,12S,15S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,50S,53S,56S,59S,62S,65S,68S,71S,74R,80S,83S,88R)-6-[[(2S)-2-[[(2S)-6-amino-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-methylsulfanylbutanoyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-3-methylbutanoyl]amino]-3-methylpentanoyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]-88-[[(2S)-6-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-3-hydroxy-2-[[(2S)-3-(4-hydroxyphenyl)-2-[[(2S)-4-methyl-2-[[(2S)-5-oxopyrrolidine-2-carbonyl]amino]pentanoyl]amino]propanoyl]amino]propanoyl]amino]propanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-4-oxobutanoyl]amino]hexanoyl]amino]-68-(4-aminobutyl)-30-(3-amino-3-oxopropyl)-50-benzyl-33,39-bis[(2S)-butan-2-yl]-12,24,53,65-tetrakis(3-carbamimidamidopropyl)-15-(2-carboxyethyl)-42-[[2-[[(2S)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-1-[[(1S)-1-carboxy-2-hydroxyethyl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-2-oxoethyl]carbamoyl]-71-[(1R)-1-hydroxyethyl]-62-(hydroxymethyl)-83-(1H-imidazol-5-ylmethyl)-27,36,56-trimethyl-18,59-bis(2-methylpropyl)-7,10,13,16,19,22,25,28,31,34,37,40,49,52,55,58,61,64,67,70,73,76,79,82,85,87-hexacosaoxo-21,80-di(propan-2-yl)-3,4,44,45,90,91-hexathia-8,11,14,17,20,23,26,29,32,35,38,41,48,51,54,57,60,63,66,69,72,75,78,81,84,86-hexacosazabicyclo[72.11.7]dononacontane-47-carboxylic acid DMXIRA0 CA CAS 99489-94-8 DMXIRA0 DE Acute heart failure DMOML9Q ID DMOML9Q DMOML9Q DN Pancrecarb DMOML9Q HS NDA filed DMOML9Q SN Pancrelipase (Digestive Care) DMOML9Q CP Digestive Care Inc DMOML9Q SQ Pancreatic alpha amylase: QYSPNTQQGRTSIVHLFEWRWVDIALECERYLAPKGFGGVQVSPPNENVAIYNPFRPWWERYQPVSYKLCTRSGNEDEFRNMVTRCNNVGVRIYVDAVINHMCGNAVSAGTSSTCGSYFNPGSRDFPAVPYSGWDFNDGKCKTGSGDIENYNDATQVRDCRLTGLLDLALEKDYVRSKIAEYMNHLIDIGVAGFRLDASKHMWPGDIKAILDKLHNLNSNWFPAGSKPFIYQEVIDLGGEPIKSSDYFGNGRVTEFKYGAKLGTVIRKWNGEKMSYLKNWGEGWGFVPSDRALVFVDNHDNQRGHGAGGASILTFWDARLYKMAVGFMLAHPYGFTRVMSSYRWPRQFQNGNDVNDWVGPPNNNGVIKEVTINPDTTCGNDWVCEHRWRQIRNMVIFRNVVDGQPFTNWYDNGSNQVAFGRGNRGFIVFNNDDWSFSLTLQTGLPAGTYCDVISGDKINGNCTGIKIYVSDDGKAHFSISNSAEDPFIAIHAESKL >Chymotrypsin BGVPAIHPVLSGLSRIVNGEDAVPGSWPWQVSLQDKTGFHFCGGSLISEDWVVTAAHCGVRTSDVVVAGEFDQGSDEENIQVLKIAKVFKNPKFSILTVNNDITLLKLATPARFSQTVSAVCLPSADDDFPAGTLCATTGWGKTKYNANKTPDKLQQAALPLLSNAECKKSWGRRITDVMICAGASGVSSCMGDSGGPLVCQKDGAWTLVGIVSWGSDTCSTSSPGVYARVTKLIPWVQKILAAN >pancreatic triacylglycerol lipaseMLPLWTLSLLLGAVAGKEVCYERLGCFSDDSPWSGITERPLHILPWSPKDVNTRFLLYTNENPNNFQEVAADSSSISGSNFKTNRKTRFIIHGFIDKGEENWLANVCKNLFKVESVNCICVDWKGGSRTGYTQASQNIRIVGAEVAYFVEFLQSAFGYSPSNVHVIGHSLGAHAAGEAGRRTNGTIGRITGLDPAEPCFQGTPELVRLDPSDAKFVDVIHTDGAPIVPNLGFGMSQVVGHLDFFPNGGVEMPGCKKNILSQIVDIDGIWEGTRDFAACNHLRSYKYYTDSIVNPDGFAGFPCASYNVFTANKCFPCPSGGCPQMGHYADRYPGKTNDVGQKFYLDTGDASNFARWRYKVSVTLSGKKVTGHILVSLFGNKGNSKQYEIFKGTLKPDSTHSNEFDSDVDVGDLQMVKFIWYNNVINPTLPRVGASKIIVETNVGKQFNFCSPETVREEVLLTLTPC DMOML9Q DE Pancreatic malfunction DMF2O4T ID DMF2O4T DMF2O4T DN (S)-FLURBIPROFEN DMF2O4T HS Preregistration DMF2O4T SN 51543-39-6; esflurbiprofen; (S)-(+)-2-Fluoro-alpha-methyl-4-biphenylacetic acid; UNII-J5ZZK9P7MX; (S)-2-(2-fluorobiphenyl-4-yl)propanoic acid; (S)-2-(2-Fluoro-[1,1'-biphenyl]-4-yl)propanoic acid; (2S)-2-(2-fluorobiphenyl-4-yl)propanoic acid; J5ZZK9P7MX; CHEMBL435298; CHEBI:42446; SYTBZMRGLBWNTM-JTQLQIEISA-N; (2S)-2-(3-fluoro-4-phenylphenyl)propanoic acid; BTS-24332; (S)-2-Fluoro-alpha-methyl-4-biphenylacetic acid; (S)-2-Fluoro-alpha-methyl(1,1'-biphenyl)-4-acetic ac DMF2O4T CP Taisho Pharmaceutical; TOKUHON DMF2O4T DT Small molecular drug DMF2O4T PC 72099 DMF2O4T MW 244.26 DMF2O4T FM C15H13FO2 DMF2O4T IC InChI=1S/C15H13FO2/c1-10(15(17)18)12-7-8-13(14(16)9-12)11-5-3-2-4-6-11/h2-10H,1H3,(H,17,18)/t10-/m0/s1 DMF2O4T CS C[C@@H](C1=CC(=C(C=C1)C2=CC=CC=C2)F)C(=O)O DMF2O4T IK SYTBZMRGLBWNTM-JTQLQIEISA-N DMF2O4T IU (2S)-2-(3-fluoro-4-phenylphenyl)propanoic acid DMF2O4T CA CAS 51543-39-6 DMF2O4T CB CHEBI:42446 DMF2O4T DE Myalgia; Scapulohumeral periarthritis; Osteoarthritis DMBRFUQ ID DMBRFUQ DMBRFUQ DN B-cell lymphoma vaccine DMBRFUQ HS Preregistration DMBRFUQ SN BiovaxID (TN) DMBRFUQ CP BioVest International DMBRFUQ DT Vaccine DMBRFUQ DE Follicular lymphoma DMP5O1U ID DMP5O1U DMP5O1U DN GSK2696273 DMP5O1U HS Preregistration DMP5O1U CP Glaxosmithkline; molmed DMP5O1U DE Chronic pain; Immunodeficiency DMXSDJU ID DMXSDJU DMXSDJU DN MPL-containing Pollinex allergy desensitization vaccine DMXSDJU HS Preregistration DMXSDJU SN Pollinex Quattro (ragweed allergy vaccine); Quattro MPL (ragweed allergy vaccine); MPL-containing Pollinex allergy desensitization vaccine (ragweed); Ragweed SC vaccine, Allergy Therapeutics/AllerPharma; MPL-containing Pollinex allergy desensitization vaccine (ragweed), AllergyTherapeutics/AllerPharma DMXSDJU CP Allergy therapeutics DMXSDJU DT Vaccine DMXSDJU DE Allergy DMLRKJX ID DMLRKJX DMLRKJX DN Neugranin DMLRKJX HS Preregistration DMLRKJX SN Albugranin; CG-10639; Granulocyte colony stimulating factor (long-acting), CoGenesys; Granulocyte colony stimulating factor (long-acting), Teva Pharmaceutical; Long-acting G-CSF, HGS; Long-acting G-CSF, Teva Pharmaceutical; G-SCF (long-acting), CoGenesys DMLRKJX CP Aventis Behring LLC DMLRKJX DE Neutropenia DMUY09W ID DMUY09W DMUY09W DN SK-NBP601 DMUY09W HS Preregistration DMUY09W SN NBP-601 DMUY09W CP SK Chemicals Co Ltd DMUY09W DE Hemophilia DM26I8H ID DM26I8H DM26I8H DN TK-DLI DM26I8H HS Preregistration DM26I8H SN TBI-0301; Herpes simplex thymidine kinase suicide gene therapy, MolMed/Takara Bio; HSV thymidine kinase gene therapy (GvH, retroviral vector), Istituto Scientifico H San Raffaele; HSV-TK suicide gene therapy, MolMed/Takara Bio; TK cell therapy (haploidentical haematopoietic stem cell transplantation), MolMed/Takara Bio; HSV-TK gene therapy (haematological malignancies), MolMed/Takara Bio; TK-DLI, San Raffaele/MolMed/Takara Bio; TK gene/cell therapy (bone marrow transplantation-associated GvHD prevention), MolMed/Takara Bio; TK-expressing donor T-cells (bone marrow transplantation-associated GvHD prevention), San Raffaele/MolMed; Thymidine kinase expressing donor T-cells (bone marrow transplantation-associated GvHD prevention), San Raffaele/MolMed/Takara DM26I8H CP Molmed DM26I8H DE Graft-versus-host disease DMYA6TR ID DMYA6TR DMYA6TR DN Human coagulation factor X DMYA6TR HS BLA submitted DMYA6TR CP Bio products laboratory DMYA6TR DE Renal cell carcinoma DMNCY1I ID DMNCY1I DMNCY1I DN (-)-Phenserine DMNCY1I HS Phase 3 DMNCY1I SN (-)-Phenserine; CHEMBL54727; SCHEMBL5464366; BDBM10622; (3aS)-1,3a,8-trimethyl-1H,2H,3H,3aH,8H,8aH-pyrrolo[2,3-b]indol-5-yl N-phenylcarbamate DMNCY1I DT Small molecular drug DMNCY1I PC 192706 DMNCY1I MW 337.4 DMNCY1I FM C20H23N3O2 DMNCY1I IC InChI=1S/C20H23N3O2/c1-20-11-12-22(2)18(20)23(3)17-10-9-15(13-16(17)20)25-19(24)21-14-7-5-4-6-8-14/h4-10,13,18H,11-12H2,1-3H3,(H,21,24)/t18-,20+/m1/s1 DMNCY1I CS C[C@@]12CCN([C@@H]1N(C3=C2C=C(C=C3)OC(=O)NC4=CC=CC=C4)C)C DMNCY1I IK PBHFNBQPZCRWQP-QUCCMNQESA-N DMNCY1I IU [(3aR,8bS)-3,4,8b-trimethyl-2,3a-dihydro-1H-pyrrolo[2,3-b]indol-7-yl] N-phenylcarbamate DMNCY1I CA CAS 101246-66-6 DMNCY1I DE Alzheimer disease DMLRHM5 ID DMLRHM5 DMLRHM5 DN [3H](R)-(-)-baclofen DMLRHM5 HS Phase 3 DMLRHM5 SN AC1OCG0F; ZB000014 DMLRHM5 DT Small molecular drug DMLRHM5 PC 44602 DMLRHM5 MW 213.66 DMLRHM5 FM C10H12ClNO2 DMLRHM5 IC InChI=1S/C10H12ClNO2/c11-9-3-1-7(2-4-9)8(6-12)5-10(13)14/h1-4,8H,5-6,12H2,(H,13,14)/t8-/m0/s1 DMLRHM5 CS C1=CC(=CC=C1[C@@H](CC(=O)O)CN)Cl DMLRHM5 IK KPYSYYIEGFHWSV-QMMMGPOBSA-N DMLRHM5 IU (3R)-4-amino-3-(4-chlorophenyl)butanoic acid DMLRHM5 CA CAS 69308-37-8 DMLRHM5 DE Multiple sclerosis DM3YEV0 ID DM3YEV0 DM3YEV0 DN 131I-labelled aCD45 DM3YEV0 HS Phase 3 DM3YEV0 CP Actinium Pharmaceuticals DM3YEV0 DT Radiopharmaceutical therapy agent DM3YEV0 DE Acute myeloid leukaemia DMTZ1A5 ID DMTZ1A5 DMTZ1A5 DN 13-cis-retinoic acid DMTZ1A5 HS Phase 3 DMTZ1A5 SN CRA, UCSD DMTZ1A5 CP University of California San Diego DMTZ1A5 DE Glioma; Infertility; Azoospermia DMP5L8S ID DMP5L8S DMP5L8S DN 177Lu-DOTA-octreotate DMP5L8S HS Phase 3 DMP5L8S SN Lutate; Octreotate [177Lu]; Lutetium-177 octreotate; 177-Lu octreotate; 177-Lu-radiolabeled somatostatin receptor-targeted peptide (neuroendocrine tumor), Biosynthema; 177-lutetium-radiolabeled somatostatin receptor-targeted peptide (neuroendocrinetumor), Biosynthema; 177Lutetium DOTA0-Tyr3-Octreotate DMP5L8S CP Advanced accelerator applications DMP5L8S DE Melanoma; Neuroendocrine cancer DMQ0IZ6 ID DMQ0IZ6 DMQ0IZ6 DN 177Lu-labelled PSMA-617 DMQ0IZ6 HS Phase 3 DMQ0IZ6 CP Novartis/Endocyte DMQ0IZ6 DT Radiopharmaceutical therapy agent DMQ0IZ6 DE Prostate cancer DMMZS2T ID DMMZS2T DMMZS2T DN 177-Lu-oxodotreotide DMMZS2T HS Phase 3 DMMZS2T CP Millburn DMMZS2T DT Small molecular drug DMMZS2T DE Neuroendocrine cancer DMX178V ID DMX178V DMX178V DN 177-Lu-PSMA-617 DMX178V HS Phase 3 DMX178V CP Advanced Accelerator Applications DMX178V DT Small molecular drug DMX178V DE Prostate cancer DME2A8X ID DME2A8X DME2A8X DN 5-methoxypsoralen DME2A8X HS Phase 3 DME2A8X SN 5-MOP DME2A8X CP Oclassen Pharmaceuticals Inc DME2A8X DT Small molecular drug DME2A8X PC 2355 DME2A8X MW 216.19 DME2A8X FM C12H8O4 DME2A8X IC InChI=1S/C12H8O4/c1-14-12-7-2-3-11(13)16-10(7)6-9-8(12)4-5-15-9/h2-6H,1H3 DME2A8X CS COC1=C2C=CC(=O)OC2=CC3=C1C=CO3 DME2A8X IK BGEBZHIAGXMEMV-UHFFFAOYSA-N DME2A8X IU 4-methoxyfuro[3,2-g]chromen-7-one DME2A8X CA CAS 484-20-8 DME2A8X CB CHEBI:18293 DME2A8X DE Psoriasis vulgaris DM4OHMP ID DM4OHMP DM4OHMP DN A-3309 DM4OHMP HS Phase 3 DM4OHMP SN Elobixibat; ALBI-3309; Ileal bile acid transporter inhibitors, AstraZeneca; ASBT inhibitor (oral, chronic idiopathic constipation), Albireo; IBAT inhibitor (oral, chronic idiopathic constipation), Albireo; Apical sodium-dependent bile acid transporter inhibitor (oral, chronic idiopathic constipation), Albireo; IBAT inhibitors (1,5-benzothiazepine derivatives), AstraZeneca DM4OHMP CP AstraZeneca plc DM4OHMP DE Lipid metabolism disorder DMJNSLU ID DMJNSLU DMJNSLU DN AAV2-hRPE65v2 DMJNSLU HS Phase 3 DMJNSLU SN RPE65 AAV gene therapy (Leber's congenital amaurosis), Children's Hospital of Philadelphia/Second University of Naples; RPE65 adeno-associated viral vector gene therapy (Leber's congenital amaurosis), Children's Hospital of Philadelphia/Second Univerity of Naples DMJNSLU CP Childrens Hospital of Philadelphia DMJNSLU DE Ocular disease DMPDQ8T ID DMPDQ8T DMPDQ8T DN AB-103 DMPDQ8T HS Phase 3 DMPDQ8T SN Superantigen toxin antagonist (iv/infusion, septic shock/toxic shock), Atox Bio/Hebrew University of Jerusalem DMPDQ8T CP Atoxbio; fast-track drugs & biologics DMPDQ8T DT Small molecular drug DMPDQ8T PC 16111 DMPDQ8T MW 281.25 DMPDQ8T FM C12H16N3O3P DMPDQ8T IC InChI=1S/C12H16N3O3P/c16-12(18-10-11-4-2-1-3-5-11)13-19(17,14-6-7-14)15-8-9-15/h1-5H,6-10H2,(H,13,16,17) DMPDQ8T CS C1CN1P(=O)(NC(=O)OCC2=CC=CC=C2)N3CC3 DMPDQ8T IK VFIUCBTYGKMLCM-UHFFFAOYSA-N DMPDQ8T IU benzyl N-[bis(aziridin-1-yl)phosphoryl]carbamate DMPDQ8T CA CAS 1980-45-6 DMPDQ8T DE Necrotizing soft tissue infection DMUES7Y ID DMUES7Y DMUES7Y DN AB154 DMUES7Y HS Phase 3 DMUES7Y SN Domvanalimab DMUES7Y CP Arcus Biosciences; Gilead Sciences DMUES7Y DT Antibody DMUES7Y DE Solid tumour/cancer; Non-small cell lung cancer DMMWO7V ID DMMWO7V DMMWO7V DN ABBV-951 DMMWO7V HS Phase 3 DMMWO7V SN Foslevodopa; UNII-37NQZ0J76I; 37NQZ0J76I; 3-hydroxy-O-phosphono-L-tyrosine; 101141-95-1; 97321-87-4; Dopa 4-phosphate; Levodopa-4'-monophosphate; 3-Hydroxy-O-phosphonotyrosine; Foslevodopa (JAN/USAN/INN); CHEMBL4594379; SCHEMBL17685899; DTXSID70905957; HY-109132; CS-0086774; D11839; (S)-2-amino-3-(3-hydroxy-4-(phosphonooxy)phenyl)propanoic acid DMMWO7V CP AbbVie DMMWO7V DT Small molecular drug DMMWO7V PC 127766 DMMWO7V MW 277.17 DMMWO7V FM C9H12NO7P DMMWO7V IC InChI=1S/C9H12NO7P/c10-6(9(12)13)3-5-1-2-8(7(11)4-5)17-18(14,15)16/h1-2,4,6,11H,3,10H2,(H,12,13)(H2,14,15,16)/t6-/m0/s1 DMMWO7V CS C1=CC(=C(C=C1C[C@@H](C(=O)O)N)O)OP(=O)(O)O DMMWO7V IK YNDMEEULGSTYJT-LURJTMIESA-N DMMWO7V IU (2S)-2-amino-3-(3-hydroxy-4-phosphonooxyphenyl)propanoic acid DMMWO7V CA CAS 97321-87-4 DMMWO7V DE Parkinson disease DMCKPG4 ID DMCKPG4 DMCKPG4 DN ABC294640 DMCKPG4 HS Phase 3 DMCKPG4 SN ABC294640; 915385-81-8; Opaganib; ABC-294640; CHEMBL2158685; ABC 294640; UNII-DRG21OQ517; DRG21OQ517; Yeliva; SCHEMBL1548333; GTPL6624; CHEBI:124965; MolPort-044-560-286; HMS3402P05; BCP08959; EX-A1962; BDBM50393642; 3-(4-chlorophenyl)-N-(pyridin-4-ylmethyl)adamantane-1-carboxamide; AKOS027327311; CS-0877; SB17167; DB12764; API0017247; HY-16015; S7174; BRD-A70814879-003-01-8; ABC294640; 915385-81-8; ABC-294640 DMCKPG4 CP Apogee Biotechnology DMCKPG4 DT Small molecular drug DMCKPG4 PC 15604015 DMCKPG4 MW 380.9 DMCKPG4 FM C23H25ClN2O DMCKPG4 IC InChI=1S/C23H25ClN2O/c24-20-3-1-19(2-4-20)22-10-17-9-18(11-22)13-23(12-17,15-22)21(27)26-14-16-5-7-25-8-6-16/h1-8,17-18H,9-15H2,(H,26,27) DMCKPG4 CS C1C2CC3(CC1CC(C2)(C3)C(=O)NCC4=CC=NC=C4)C5=CC=C(C=C5)Cl DMCKPG4 IK CAOTVXGYTWCKQE-UHFFFAOYSA-N DMCKPG4 IU 3-(4-chlorophenyl)-N-(pyridin-4-ylmethyl)adamantane-1-carboxamide DMCKPG4 CA CAS 915385-81-8 DMCKPG4 CB CHEBI:124965 DMCKPG4 DE Advanced solid tumour; Hepatocellular carcinoma; Cholangiocarcinoma; Multiple myeloma DM91LGU ID DM91LGU DM91LGU DN Abexinostat DM91LGU HS Phase 3 DM91LGU SN PCI-24781; 783355-60-2; ABEXINOSTAT; PCI 24781; CRA-024781; CRA 024781; UNII-IYO470654U; 3-((dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)phenoxy)ethyl)benzofuran-2-carboxamide; CRA-02478; Abexinostat(PCI-24781); PCI-24781 (Abexinostat); Abexinostat (PCI-24781); IYO470654U; 3-[(Dimethylamino)methyl]-N-[2-[4-[(hydroxyamino)carbonyl]phenoxy]ethyl]-2-benzofurancarboxamide; 3-((Dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)-phenoxy)ethyl)benzofuran-2-carboxamide DM91LGU CP Pharmacyclics DM91LGU DT Small molecular drug DM91LGU PC 11749858 DM91LGU MW 397.4 DM91LGU FM C21H23N3O5 DM91LGU IC InChI=1S/C21H23N3O5/c1-24(2)13-17-16-5-3-4-6-18(16)29-19(17)21(26)22-11-12-28-15-9-7-14(8-10-15)20(25)23-27/h3-10,27H,11-13H2,1-2H3,(H,22,26)(H,23,25) DM91LGU CS CN(C)CC1=C(OC2=CC=CC=C21)C(=O)NCCOC3=CC=C(C=C3)C(=O)NO DM91LGU IK MAUCONCHVWBMHK-UHFFFAOYSA-N DM91LGU IU 3-[(dimethylamino)methyl]-N-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]-1-benzofuran-2-carboxamide DM91LGU CA CAS 783355-60-2 DM91LGU CB CHEBI:92223 DM91LGU DE Acute myeloid leukaemia; Breast cancer; Diffuse large B-cell lymphoma; Follicular lymphoma; Gynecologic cancer; Peripheral T-cell lymphoma; Solid tumour/cancer; Renal cell carcinoma DMMF5K4 ID DMMF5K4 DMMF5K4 DN ABL 001 DMMF5K4 HS Phase 3 DMMF5K4 CP Novartis pharmaceuticals DMMF5K4 DE leukaemia; Chronic myeloid leukaemia; Promyelocytic leukaemia DM7EVUF ID DM7EVUF DM7EVUF DN ABL001 DM7EVUF HS Phase 3 DM7EVUF SN asciminib; ABL-001; 1492952-76-7; Asciminib free base; ABL001-NX; UNII-L1F3R18W77; L1F3R18W77; NVP-ABL001; (R)-N-(4-(Chlorodifluoromethoxy)phenyl)-6-(3-hydroxypyrrolidin-1-yl)-5-(1H-pyrazol-5-yl)nicotinamide; 1492952-76-7 (free base); N-[4-[chloro(difluoro)methoxy]phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-5-yl)pyridine-3-carboxamide; Asciminib [USAN]; Asciminib (ABL001); Asciminib (USAN/INN); GTPL8962; CHEMBL4208229; SCHEMBL15388306; TQP0925; EX-A3030; BDBM50459091; NSC789925; s8555; ZINC150275965; CCG-269232; CS-7655; DB12597; NSC-789925; SB18878; BS-15538; HY-104010; D11403; Q27074535; (R)-N-(4-(Chloro difluoromethoxy)phenyl)-6-(3-hydroxypyrrolidin-1-yl)-5-(1H-pyrazol-5-yl)nicotinamide; AY7 DM7EVUF CP Novartis DM7EVUF DT Small molecular drug DM7EVUF PC 72165228 DM7EVUF MW 449.8 DM7EVUF FM C20H18ClF2N5O3 DM7EVUF IC InChI=1S/C20H18ClF2N5O3/c21-20(22,23)31-15-3-1-13(2-4-15)26-19(30)12-9-16(17-5-7-25-27-17)18(24-10-12)28-8-6-14(29)11-28/h1-5,7,9-10,14,29H,6,8,11H2,(H,25,27)(H,26,30)/t14-/m1/s1 DM7EVUF CS C1CN(C[C@@H]1O)C2=C(C=C(C=N2)C(=O)NC3=CC=C(C=C3)OC(F)(F)Cl)C4=CC=NN4 DM7EVUF IK VOVZXURTCKPRDQ-CQSZACIVSA-N DM7EVUF IU N-[4-[chloro(difluoro)methoxy]phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-5-yl)pyridine-3-carboxamide DM7EVUF CA CAS 1492952-76-7 DM7EVUF DE Chronic myeloid leukaemia DM2J4YB ID DM2J4YB DM2J4YB DN ABP 501 DM2J4YB HS Phase 3 DM2J4YB CP Amgen DM2J4YB DT Antibody DM2J4YB DE Rheumatoid arthritis; Plaque psoriasis DMDXE4I ID DMDXE4I DMDXE4I DN ABP959 DMDXE4I HS Phase 3 DMDXE4I CP Amgen DMDXE4I DT Small molecular drug DMDXE4I DE Paroxysmal nocturnal haemoglobinuria DMNE56X ID DMNE56X DMNE56X DN ABT-263 DMNE56X HS Phase 3 DMNE56X SN Navitoclax; ABT 263; S1001_Selleck; ABT263, Navitoclax; 4-(4-{[2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({4-({(1R)-3-morpholin-4-yl-1-[(phenylsulfanyl)methyl]propyl}amino)-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)benzamide DMNE56X CP Roche; Genentech DMNE56X DT Small molecular drug DMNE56X PC 24978538 DMNE56X MW 974.6 DMNE56X FM C47H55ClF3N5O6S3 DMNE56X IC InChI=1S/C47H55ClF3N5O6S3/c1-46(2)20-18-42(34-8-12-37(48)13-9-34)36(31-46)32-55-22-24-56(25-23-55)39-14-10-35(11-15-39)45(57)53-65(60,61)41-16-17-43(44(30-41)64(58,59)47(49,50)51)52-38(19-21-54-26-28-62-29-27-54)33-63-40-6-4-3-5-7-40/h3-17,30,38,52H,18-29,31-33H2,1-2H3,(H,53,57)/t38-/m1/s1 DMNE56X CS CC1(CCC(=C(C1)CN2CCN(CC2)C3=CC=C(C=C3)C(=O)NS(=O)(=O)C4=CC(=C(C=C4)N[C@H](CCN5CCOCC5)CSC6=CC=CC=C6)S(=O)(=O)C(F)(F)F)C7=CC=C(C=C7)Cl)C DMNE56X IK JLYAXFNOILIKPP-KXQOOQHDSA-N DMNE56X IU 4-[4-[[2-(4-chlorophenyl)-5,5-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-N-[4-[[(2R)-4-morpholin-4-yl-1-phenylsulfanylbutan-2-yl]amino]-3-(trifluoromethylsulfonyl)phenyl]sulfonylbenzamide DMNE56X CA CAS 923564-51-6 DMNE56X CB CHEBI:94128 DMNE56X DE Relapsed or refractory chronic lymphocytic leukaemia; Solid tumour/cancer; Myelofibrosis DMNQ869 ID DMNQ869 DMNQ869 DN ABT-267 DMNQ869 HS Phase 3 DMNQ869 SN HCV therapeutic, Abbott DMNQ869 CP Abbott Laboratories DMNQ869 DT Small molecular drug DMNQ869 PC 54767916 DMNQ869 MW 894.1 DMNQ869 FM C50H67N7O8 DMNQ869 IC InChI=1S/C50H67N7O8/c1-30(2)42(53-48(62)64-8)46(60)55-28-10-12-40(55)44(58)51-35-20-14-32(15-21-35)38-26-27-39(57(38)37-24-18-34(19-25-37)50(5,6)7)33-16-22-36(23-17-33)52-45(59)41-13-11-29-56(41)47(61)43(31(3)4)54-49(63)65-9/h14-25,30-31,38-43H,10-13,26-29H2,1-9H3,(H,51,58)(H,52,59)(H,53,62)(H,54,63)/t38-,39-,40-,41-,42-,43-/m0/s1 DMNQ869 CS CC(C)[C@@H](C(=O)N1CCC[C@H]1C(=O)NC2=CC=C(C=C2)[C@@H]3CC[C@H](N3C4=CC=C(C=C4)C(C)(C)C)C5=CC=C(C=C5)NC(=O)[C@@H]6CCCN6C(=O)[C@H](C(C)C)NC(=O)OC)NC(=O)OC DMNQ869 IK PIDFDZJZLOTZTM-KHVQSSSXSA-N DMNQ869 IU methyl N-[(2S)-1-[(2S)-2-[[4-[(2S,5S)-1-(4-tert-butylphenyl)-5-[4-[[(2S)-1-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]pyrrolidine-2-carbonyl]amino]phenyl]pyrrolidin-2-yl]phenyl]carbamoyl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate DMNQ869 CA CAS 1258226-87-7 DMNQ869 CB CHEBI:85183 DMNQ869 DE Hepatitis C virus infection DMJFD2I ID DMJFD2I DMJFD2I DN ABT-492 DMJFD2I HS Phase 3 DMJFD2I SN Delafloxacin; 189279-58-1; ABT-492; WQ-3034; Abt 492; 1-(6-AMINO-3,5-DIFLUOROPYRIDIN-2-YL)-8-CHLORO-6-FLUORO-7-(3-HYDROXYAZETIDIN-1-YL)-4-OXO-1,4-DIHYDROQUINOLINE-3-CARBOXYLIC ACID; ABT492; RX-3341; UNII-6315412YVF; 6315412YVF; 1-(6-amino-3,5-difluoro-2-pyridyl)-8-chloro-6-fluoro-7-(3-hydroxyazetidin-1-yl)-4-oxo-quinoline-3-carboxylic acid; 1-(6-amino-3,5-difluoropyridin-2-yl)-8-chloro-6-fluoro-7-(3-hydroxyazetidin-1-yl)-4-oxoquinoline-3-carboxylic acid; Delafloxacin [USAN:INN]; Delafloxacinum; Delafloxacin (USAN) DMJFD2I DT Small molecular drug DMJFD2I PC 487101 DMJFD2I MW 440.8 DMJFD2I FM C18H12ClF3N4O4 DMJFD2I IC InChI=1S/C18H12ClF3N4O4/c19-12-13-7(1-9(20)14(12)25-3-6(27)4-25)15(28)8(18(29)30)5-26(13)17-11(22)2-10(21)16(23)24-17/h1-2,5-6,27H,3-4H2,(H2,23,24)(H,29,30) DMJFD2I CS C1C(CN1C2=C(C=C3C(=C2Cl)N(C=C(C3=O)C(=O)O)C4=C(C=C(C(=N4)N)F)F)F)O DMJFD2I IK DYDCPNMLZGFQTM-UHFFFAOYSA-N DMJFD2I IU 1-(6-amino-3,5-difluoropyridin-2-yl)-8-chloro-6-fluoro-7-(3-hydroxyazetidin-1-yl)-4-oxoquinoline-3-carboxylic acid DMJFD2I CA CAS 189279-58-1 DMJFD2I DE Bacterial infection DM3FIC2 ID DM3FIC2 DM3FIC2 DN ABT-761 DM3FIC2 HS Phase 3 DM3FIC2 SN Atreleuton; Atreleuton [USAN]; ABT 761; A-85761; Atreleuton (USAN/INN); 1-[(2R)-4-[5-[(4-fluorophenyl)methyl]thiophen-2-yl]but-3-yn-2-yl]-1-hydroxyurea DM3FIC2 CP Abbott Laboratories DM3FIC2 DT Small molecular drug DM3FIC2 PC 3086671 DM3FIC2 MW 318.4 DM3FIC2 FM C16H15FN2O2S DM3FIC2 IC InChI=1S/C16H15FN2O2S/c1-11(19(21)16(18)20)2-7-14-8-9-15(22-14)10-12-3-5-13(17)6-4-12/h3-6,8-9,11,21H,10H2,1H3,(H2,18,20)/t11-/m1/s1 DM3FIC2 CS C[C@H](C#CC1=CC=C(S1)CC2=CC=C(C=C2)F)N(C(=O)N)O DM3FIC2 IK MMSNEKOTSJRTRI-LLVKDONJSA-N DM3FIC2 IU 1-[(2R)-4-[5-[(4-fluorophenyl)methyl]thiophen-2-yl]but-3-yn-2-yl]-1-hydroxyurea DM3FIC2 CA CAS 154355-76-7 DM3FIC2 DE Asthma DMREDYP ID DMREDYP DMREDYP DN ABT-869 DMREDYP HS Phase 3 DMREDYP SN Linifanib; ABT 869; S1003_Selleck; AL-39324; RG-3635; ABT869, Linifanib, AL-39324, RG3635; N-(4-(3-Amino-1H-indazol-4-yl)phenyl)-N1-(2-fluoro-5-methylphenyl)urea; N-(4-(3-Amino-1H-indazol-4-yl)phenyl)-N'-(2-fluoro-5-methylphenyl)urea DMREDYP CP Abbott Laboratories DMREDYP TC Anticancer Agents DMREDYP DT Small molecular drug DMREDYP PC 11485656 DMREDYP MW 375.4 DMREDYP FM C21H18FN5O DMREDYP IC InChI=1S/C21H18FN5O/c1-12-5-10-16(22)18(11-12)25-21(28)24-14-8-6-13(7-9-14)15-3-2-4-17-19(15)20(23)27-26-17/h2-11H,1H3,(H3,23,26,27)(H2,24,25,28) DMREDYP CS CC1=CC(=C(C=C1)F)NC(=O)NC2=CC=C(C=C2)C3=C4C(=CC=C3)NN=C4N DMREDYP IK MPVGZUGXCQEXTM-UHFFFAOYSA-N DMREDYP IU 1-[4-(3-amino-1H-indazol-4-yl)phenyl]-3-(2-fluoro-5-methylphenyl)urea DMREDYP CA CAS 796967-16-3 DMREDYP CB CHEBI:91435 DMREDYP DE Solid tumour/cancer DMYHSO2 ID DMYHSO2 DMYHSO2 DN ABT-874 DMYHSO2 HS Phase 3 DMYHSO2 CP Abbott; Astra Zeneca DMYHSO2 DE Crohn disease; Rheumatoid arthritis; Plaque psoriasis DM4HYMS ID DM4HYMS DM4HYMS DN ABT-888 DM4HYMS HS Phase 3 DM4HYMS SN Veliparib; 912444-00-9; ABT-888; ABT 888; ABT-888 (Veliparib); Veliparib (ABT-888); ABT888; UNII-01O4K0631N; 2-[(2R)-2-Methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide; CHEBI:62880; 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide; (R)-2-(2-methylpyrrolidin-2-yl)-1H-benzo[d]imidazole-4-carboxamide; 01O4K0631N; 2-[(2R)-2-Methylpyrrolidin-2-yl]-1H-benimidazole-4-; (2r)-2-(7-Carbamoyl-1h-Benzimidazol-2-Yl)-2-Methylpyrrolidinium; Veliparib dihydrochloride DM4HYMS DT Small molecular drug DM4HYMS PC 45480520 DM4HYMS MW 317.21 DM4HYMS FM C13H18Cl2N4O DM4HYMS IC InChI=1S/C13H16N4O.2ClH/c1-13(6-3-7-15-13)12-16-9-5-2-4-8(11(14)18)10(9)17-12;;/h2,4-5,15H,3,6-7H2,1H3,(H2,14,18)(H,16,17);2*1H/t13-;;/m1../s1 DM4HYMS CS C[C@@]1(CCCN1)C2=NC3=C(C=CC=C3N2)C(=O)N.Cl.Cl DM4HYMS IK DSBSVDCHFMEYBX-FFXKMJQXSA-N DM4HYMS IU 2-[(2R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide;dihydrochloride DM4HYMS CA CAS 912445-05-7 DM4HYMS DE Breast cancer; Epithelial ovarian cancer; Melanoma; Ovarian cancer; Non-small-cell lung cancer DMQRL2Y ID DMQRL2Y DMQRL2Y DN AC0010 DMQRL2Y HS Phase 3 DMQRL2Y SN Avitinib; 1557267-42-1; N-(3-((2-((3-Fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)phenyl)acrylamide; Avitinib free base; SCHEMBL15453394; KS-00000TON; EX-A783; MolPort-042-663-560; Avitinib(AC0010/AC0010MA); ZINC142081723; AKOS030632728; CS-W008904; N-(3-{2-[3-Fluoro-4-(4-methyl-piperazin-1-yl)-phenylamino]-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy}-phenyl)-acrylamide; DS-19269; AK543905; 2-Propenamide, N-[3-[[2-[[3-fluoro-4-(4-methyl-1-piperazinyl)phenyl]amino]-7H-pyrrolo[2,3-d]pyrimidin-4- DMQRL2Y CP ACEA BiosciencesSan Diego, CA DMQRL2Y PC 72734520 DMQRL2Y MW 487.5 DMQRL2Y FM C26H26FN7O2 DMQRL2Y IC InChI=1S/C26H26FN7O2/c1-3-23(35)29-17-5-4-6-19(15-17)36-25-20-9-10-28-24(20)31-26(32-25)30-18-7-8-22(21(27)16-18)34-13-11-33(2)12-14-34/h3-10,15-16H,1,11-14H2,2H3,(H,29,35)(H2,28,30,31,32) DMQRL2Y CS CN1CCN(CC1)C2=C(C=C(C=C2)NC3=NC4=C(C=CN4)C(=N3)OC5=CC=CC(=C5)NC(=O)C=C)F DMQRL2Y IK UOFYSRZSLXWIQB-UHFFFAOYSA-N DMQRL2Y IU N-[3-[[2-[3-fluoro-4-(4-methylpiperazin-1-yl)anilino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenyl]prop-2-enamide DMQRL2Y CA CAS 1557267-42-1 DMQRL2Y DE Non-small-cell lung cancer DMXZ9T3 ID DMXZ9T3 DMXZ9T3 DN AC-170 DMXZ9T3 HS Phase 3 DMXZ9T3 SN 88139-91-7; 5-Bromo-2-hydroxymethylpyridine; (5-Bromopyridin-2-yl)methanol; 2-hydroxymethyl-5-bromopyridine; 5-Bromo-2-(hydroxymethyl)pyridine; (5-bromopyrid-2-yl)methanol; 5-Bromo-2-pyridinemethanol; (5-Bromo-pyridin-2-yl)-methanol; 2-PYRIDINEMETHANOL, 5-BROMO-; 5-BROMOPYRIDINE-2-METHANOL; (5-bromo-2-pyridyl)methanol; (5-bromo-2-pyridyl)methan-1-ol; AC-170; (5-Bromo-pyridin-2-yl)methanol (5-Bromo-2-hydroxymethylpyridine); zlchem 391; PubChem7710; PubChem12387; ACMC-209qrb; AC1NP90H; 5-bromo-2-pyridine methanol; KSC494K9D DMXZ9T3 CP Aciex Therapeutics Inc DMXZ9T3 DT Small molecular drug DMXZ9T3 PC 5200169 DMXZ9T3 MW 188.02 DMXZ9T3 FM C6H6BrNO DMXZ9T3 IC InChI=1S/C6H6BrNO/c7-5-1-2-6(4-9)8-3-5/h1-3,9H,4H2 DMXZ9T3 CS C1=CC(=NC=C1Br)CO DMXZ9T3 IK RUCZFWMEACWFER-UHFFFAOYSA-N DMXZ9T3 IU (5-bromopyridin-2-yl)methanol DMXZ9T3 CA CAS 88139-91-7 DMXZ9T3 DE Allergic conjunctivitis DM8Y4JS ID DM8Y4JS DM8Y4JS DN AC220 DM8Y4JS HS Phase 3 DM8Y4JS SN Quizartinib DM8Y4JS CP Ambit Biosciences; Astellas Pharma US DM8Y4JS DT Small molecular drug DM8Y4JS PC 24889392 DM8Y4JS MW 560.7 DM8Y4JS FM C29H32N6O4S DM8Y4JS IC InChI=1S/C29H32N6O4S/c1-29(2,3)25-17-26(33-39-25)32-27(36)30-20-6-4-19(5-7-20)22-18-35-23-9-8-21(16-24(23)40-28(35)31-22)38-15-12-34-10-13-37-14-11-34/h4-9,16-18H,10-15H2,1-3H3,(H2,30,32,33,36) DM8Y4JS CS CC(C)(C)C1=CC(=NO1)NC(=O)NC2=CC=C(C=C2)C3=CN4C5=C(C=C(C=C5)OCCN6CCOCC6)SC4=N3 DM8Y4JS IK CVWXJKQAOSCOAB-UHFFFAOYSA-N DM8Y4JS IU 1-(5-tert-butyl-1,2-oxazol-3-yl)-3-[4-[6-(2-morpholin-4-ylethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl]urea DM8Y4JS CA CAS 950769-58-1 DM8Y4JS CB CHEBI:90217 DM8Y4JS DE leukaemia; Acute myeloid leukaemia DM1RMF5 ID DM1RMF5 DM1RMF5 DN Acadesine DM1RMF5 HS Phase 3 DM1RMF5 SN AICAR; Acadra; ADV-P1; ATH-001; Acadesine (intravenous formulation, leukemia); Acadesine (intravenous formulation, leukemia), Advanced In Vitro Cell Technologies DM1RMF5 CP Schering-Plough DM1RMF5 DT Small molecular drug DM1RMF5 PC 17513 DM1RMF5 MW 258.23 DM1RMF5 FM C9H14N4O5 DM1RMF5 IC InChI=1S/C9H14N4O5/c10-7-4(8(11)17)12-2-13(7)9-6(16)5(15)3(1-14)18-9/h2-3,5-6,9,14-16H,1,10H2,(H2,11,17)/t3-,5-,6-,9-/m1/s1 DM1RMF5 CS C1=NC(=C(N1[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O)N)C(=O)N DM1RMF5 IK RTRQQBHATOEIAF-UUOKFMHZSA-N DM1RMF5 IU 5-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]imidazole-4-carboxamide DM1RMF5 CA CAS 2627-69-2 DM1RMF5 CB CHEBI:28498 DM1RMF5 DE Diabetic complication DMY96O3 ID DMY96O3 DMY96O3 DN acelarin DMY96O3 HS Phase 3 DMY96O3 SN NUC-1031 DMY96O3 DT Small molecular drug DMY96O3 PC 11169170 DMY96O3 MW 580.5 DMY96O3 FM C25H27F2N4O8P DMY96O3 IC InChI=1S/C25H27F2N4O8P/c1-16(22(33)36-14-17-8-4-2-5-9-17)30-40(35,39-18-10-6-3-7-11-18)37-15-19-21(32)25(26,27)23(38-19)31-13-12-20(28)29-24(31)34/h2-13,16,19,21,23,32H,14-15H2,1H3,(H,30,35)(H2,28,29,34)/t16-,19+,21+,23+,40?/m0/s1 DMY96O3 CS C[C@@H](C(=O)OCC1=CC=CC=C1)NP(=O)(OC[C@@H]2[C@H](C([C@@H](O2)N3C=CC(=NC3=O)N)(F)F)O)OC4=CC=CC=C4 DMY96O3 IK NHTKGYOMICWFQZ-KKQYNPQSSA-N DMY96O3 IU benzyl (2S)-2-[[[(2R,3R,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-4,4-difluoro-3-hydroxyoxolan-2-yl]methoxy-phenoxyphosphoryl]amino]propanoate DMY96O3 CA CAS 840506-29-8 DMY96O3 DE Alzheimer disease; Ovarian cancer; Biliary tract cancer DM3UQ9K ID DM3UQ9K DM3UQ9K DN Acolbifene DM3UQ9K HS Phase 3 DM3UQ9K SN Acolbifene; EM-652; 182167-02-8; UNII-815LJ9X0D1; 815LJ9X0D1; EM 652; Acolbifene [INN:BAN]; SCH 57068; AC1L4EAA; SCHEMBL406183; CHEMBL68055; CTK4F5320; SCH-57068; HY-16023A; ( )-(2S)-3-(4-Hydroxyphenyl)-4-methyl-2-(4-(2-(piperidin-1-yl)ethoxy)phenyl)-2H-1-benzopyran-7-ol; CS-0007143; (2S)-3-(4-hydroxyphenyl)-4-methyl-2-[4-(2-piperidin-1-ylethoxy)phenyl]-2H-chromen-7-ol; (S)-3-(4-hydroxyphenyl)-4-methyl-2-(4-(2-(piperidin-1-yl)ethoxy)phenyl)-2H-chromen-7-ol DM3UQ9K CP EndoCeutics DM3UQ9K DT Small molecular drug DM3UQ9K PC 155435 DM3UQ9K MW 457.6 DM3UQ9K FM C29H31NO4 DM3UQ9K IC InChI=1S/C29H31NO4/c1-20-26-14-11-24(32)19-27(26)34-29(28(20)21-5-9-23(31)10-6-21)22-7-12-25(13-8-22)33-18-17-30-15-3-2-4-16-30/h5-14,19,29,31-32H,2-4,15-18H2,1H3/t29-/m0/s1 DM3UQ9K CS CC1=C([C@@H](OC2=C1C=CC(=C2)O)C3=CC=C(C=C3)OCCN4CCCCC4)C5=CC=C(C=C5)O DM3UQ9K IK DUYNJNWVGIWJRI-LJAQVGFWSA-N DM3UQ9K IU (2S)-3-(4-hydroxyphenyl)-4-methyl-2-[4-(2-piperidin-1-ylethoxy)phenyl]-2H-chromen-7-ol DM3UQ9K CA CAS 182167-02-8 DM3UQ9K DE Breast cancer DMXYRPO ID DMXYRPO DMXYRPO DN Act1 DMXYRPO HS Phase 3 DMXYRPO SN 51-34-3; UNII-DL48G20X8X; alpha-(Hydroxymethyl)benzeneacetic acid 9-methyl-3-oxa-9-azatricyclo(3.3.1.0(2.4))non-7-yl ester; DL48G20X8X; CHEBI:16794 DMXYRPO DT Small molecular drug DMXYRPO DE Wound healing DMVLWG7 ID DMVLWG7 DMVLWG7 DN Ad5FGF-4 DMVLWG7 HS Phase 3 DMVLWG7 DE Angina pectoris DMFIP35 ID DMFIP35 DMFIP35 DN Adhexil DMFIP35 HS Phase 3 DMFIP35 CP OMRIX Biopharmaceuticals SA DMFIP35 DE Injury DMLBYRA ID DMLBYRA DMLBYRA DN ADX N05 DMLBYRA HS Phase 3 DMLBYRA CP Aerial BioPharma DMLBYRA DE Excessive daytime sleepiness; Mood disorder DMAYO46 ID DMAYO46 DMAYO46 DN AEZS-108 DMAYO46 HS Phase 3 DMAYO46 SN Zoptarelin doxorubicin; AEZS-108; AN-152; UNII-27844X2J29; ZEN-008; 27844X2J29; Zoptrex; Zoptarelin doxorubicin [INN]; Zoptarelin doxorubicin [USAN]; AEZS 108; CHEMBL3544954; AN 152; Luteinizing hormone-releasing factor (pig), 6-(N6-(5-(2-(4-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-2-naphthacenyl)-2-oxoethoxy)-1,5-dioxopentyl)-D-lysine)-, (2S-cis)- DMAYO46 CP AEterna Zentaris DMAYO46 DT Small molecular drug DMAYO46 PC 16134409 DMAYO46 MW 1893 DMAYO46 FM C91H117N19O26 DMAYO46 IC InChI=1S/C91H117N19O26/c1-44(2)31-58(83(125)104-57(17-11-29-98-90(94)95)89(131)110-30-12-18-63(110)88(130)100-40-67(93)114)105-81(123)55(16-7-8-28-97-68(115)20-10-21-70(117)134-42-66(113)91(132)36-52-73(65(37-91)136-71-35-53(92)76(118)45(3)135-71)80(122)75-74(78(52)120)77(119)51-14-9-19-64(133-4)72(51)79(75)121)103-84(126)59(32-46-22-24-49(112)25-23-46)106-87(129)62(41-111)109-85(127)60(33-47-38-99-54-15-6-5-13-50(47)54)107-86(128)61(34-48-39-96-43-101-48)108-82(124)56-26-27-69(116)102-56/h5-6,9,13-15,19,22-25,38-39,43-45,53,55-63,65,71,76,99,111-112,118,120,122,132H,7-8,10-12,16-18,20-21,26-37,40-42,92H2,1-4H3,(H2,93,114)(H,96,101)(H,97,115)(H,100,130)(H,102,116)(H,103,126)(H,104,125)(H,105,123)(H,106,129)(H,107,128)(H,108,124)(H,109,127)(H4,94,95,98)/t45-,53-,55+,56-,57-,58-,59-,60-,61-,62-,63-,65-,71-,76+,91-/m0/s1 DMAYO46 CS C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)COC(=O)CCCC(=O)NCCCC[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N6CCC[C@H]6C(=O)NCC(=O)N)NC(=O)[C@H](CC7=CC=C(C=C7)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC8=CNC9=CC=CC=C98)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@@H]1CCC(=O)N1)O)N)O DMAYO46 IK OOUACICUAVTCEC-LZHWUUGESA-N DMAYO46 IU [2-[(2S,4S)-4-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]-2-oxoethyl] 5-[[(5R)-6-[[(2S)-1-[[(2S)-1-[(2S)-2-[(2-amino-2-oxoethyl)carbamoyl]pyrrolidin-1-yl]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-[[(2S)-2-[[(2S)-3-hydroxy-2-[[(2S)-2-[[(2S)-3-(1H-imidazol-5-yl)-2-[[(2S)-5-oxopyrrolidine-2-carbonyl]amino]propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]propanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-6-oxohexyl]amino]-5-oxopentanoate DMAYO46 CA CAS 139570-93-7 DMAYO46 DE Acute lymphoblastic leukaemia DMS0ZBI ID DMS0ZBI DMS0ZBI DN Ag-221 DMS0ZBI HS Phase 3 DMS0ZBI SN AG-221 (IDH2 inhibitor) DMS0ZBI CP Agios pharmaceuticals; celgene DMS0ZBI PC 89683805 DMS0ZBI MW 473.4 DMS0ZBI FM C19H17F6N7O DMS0ZBI IC InChI=1S/C19H17F6N7O/c1-17(2,33)9-27-15-30-14(11-4-3-5-12(29-11)18(20,21)22)31-16(32-15)28-10-6-7-26-13(8-10)19(23,24)25/h3-8,33H,9H2,1-2H3,(H2,26,27,28,30,31,32) DMS0ZBI CS CC(C)(CNC1=NC(=NC(=N1)C2=NC(=CC=C2)C(F)(F)F)NC3=CC(=NC=C3)C(F)(F)F)O DMS0ZBI IK DYLUUSLLRIQKOE-UHFFFAOYSA-N DMS0ZBI IU 2-methyl-1-[[4-[6-(trifluoromethyl)pyridin-2-yl]-6-[[2-(trifluoromethyl)pyridin-4-yl]amino]-1,3,5-triazin-2-yl]amino]propan-2-ol DMS0ZBI CA CAS 1446502-11-9 DMS0ZBI CB CHEBI:145374 DMS0ZBI DE Acute myeloid leukaemia; Acute myelogenous leukaemia DMIE1WY ID DMIE1WY DMIE1WY DN AG-881 DMIE1WY HS Phase 3 DMIE1WY SN Vorasidenib; 1644545-52-7; UNII-789Q85GA8P; 789Q85GA8P; AG881; 9UO; 6-(6-chloropyridin-2-yl)-N2,N4-bis[(2R)-1,1,1-trifluoropropan-2-yl]-1,3,5-triazine-2,4-diamine; Vorasidenib [INN]; Vorasidenib (AG-881); SCHEMBL16393139; AG 881 [WHO-DD]; QCZAWDGAVJMPTA-RNFRBKRXSA-N; BDBM279948; EX-A2574; US10028961, Compound 101; AG 881; s8611; CS-8033; HY-104042; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoro propan-2-yl)-1,3,5-triazine-2,4-diamine; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoroprop DMIE1WY CP Agios Pharmaceuticals Cambridge, MA Celgene Summit, NJ DMIE1WY PC 117817422 DMIE1WY MW 414.74 DMIE1WY FM C14H13ClF6N6 DMIE1WY IC InChI=1S/C14H13ClF6N6/c1-6(13(16,17)18)22-11-25-10(8-4-3-5-9(15)24-8)26-12(27-11)23-7(2)14(19,20)21/h3-7H,1-2H3,(H2,22,23,25,26,27)/t6-,7-/m1/s1 DMIE1WY CS C[C@H](C(F)(F)F)NC1=NC(=NC(=N1)C2=NC(=CC=C2)Cl)N[C@H](C)C(F)(F)F DMIE1WY IK QCZAWDGAVJMPTA-RNFRBKRXSA-N DMIE1WY IU 6-(6-chloropyridin-2-yl)-2-N,4-N-bis[(2R)-1,1,1-trifluoropropan-2-yl]-1,3,5-triazine-2,4-diamine DMIE1WY CA CAS 1644545-52-7 DMIE1WY DE Acute myeloid leukaemia; Glioma DMYN3IH ID DMYN3IH DMYN3IH DN AGI-1067 DMYN3IH HS Phase 3 DMYN3IH SN AGZ-1067; Succinic acid 2,6-di-tert-butyl-4-[1-(3,5-di-tert-butyl-4-hydroxyphenylsulfanyl)-1-methylethylsulfanyl]phenyl monoester DMYN3IH CP AtheroGenics DMYN3IH DT Small molecular drug DMYN3IH PC 216325 DMYN3IH MW 616.9 DMYN3IH FM C35H52O5S2 DMYN3IH IC InChI=1S/C35H52O5S2/c1-31(2,3)23-17-21(18-24(29(23)39)32(4,5)6)41-35(13,14)42-22-19-25(33(7,8)9)30(26(20-22)34(10,11)12)40-28(38)16-15-27(36)37/h17-20,39H,15-16H2,1-14H3,(H,36,37) DMYN3IH CS CC(C)(C)C1=CC(=CC(=C1O)C(C)(C)C)SC(C)(C)SC2=CC(=C(C(=C2)C(C)(C)C)OC(=O)CCC(=O)O)C(C)(C)C DMYN3IH IK RKSMVPNZHBRNNS-UHFFFAOYSA-N DMYN3IH IU 4-[2,6-ditert-butyl-4-[2-(3,5-ditert-butyl-4-hydroxyphenyl)sulfanylpropan-2-ylsulfanyl]phenoxy]-4-oxobutanoic acid DMYN3IH CA CAS 216167-82-7 DMYN3IH DE Artery stenosis DMJRQDG ID DMJRQDG DMJRQDG DN AG-SPT201 DMJRQDG HS Phase 3 DMJRQDG SN SPT201; S-pantoprazole sodium trihydrate (ulcer), Ahn-Gook; (S)-pantoprazole sodium trihydrate DMJRQDG CP Ahn-Gook Pharmaceuticals Co Ltd DMJRQDG DE Ulcerative colitis DMS2WV3 ID DMS2WV3 DMS2WV3 DN AIDSVAX DMS2WV3 HS Phase 3 DMS2WV3 SN AIDSVAX B/B; AIDSVAX B/E; Bivalent gp120 HIV vaccines, GSID; Bivalent gp120 HIV vaccines, Global Solutions for Infectious Diseases; Bivalent gp120 HIV vaccines, VaxGen DMS2WV3 CP DiaDexus Inc DMS2WV3 DT Vaccine DMS2WV3 DE Human immunodeficiency virus infection DM8SYTE ID DM8SYTE DM8SYTE DN AIR-insulin DM8SYTE HS Phase 3 DM8SYTE SN HIIP DM8SYTE CP Alkermes DM8SYTE DE Diabetic complication DM5K6J4 ID DM5K6J4 DM5K6J4 DN AJM-300 DM5K6J4 HS Phase 3 DM5K6J4 SN Alpha-4 integrin antagonist (inflammatory bowel disease), Ajinomoto DM5K6J4 CP Ajinomoto Co Inc DM5K6J4 DE Crohn disease; Ulcerative colitis DM2EJM3 ID DM2EJM3 DM2EJM3 DN AKB-6548 DM2EJM3 HS Phase 3 DM2EJM3 CP Akebia therapeutics DM2EJM3 PC 23634441 DM2EJM3 MW 306.7 DM2EJM3 FM C14H11ClN2O4 DM2EJM3 IC InChI=1S/C14H11ClN2O4/c15-10-3-1-2-8(4-10)9-5-11(18)13(16-6-9)14(21)17-7-12(19)20/h1-6,18H,7H2,(H,17,21)(H,19,20) DM2EJM3 CS C1=CC(=CC(=C1)Cl)C2=CC(=C(N=C2)C(=O)NCC(=O)O)O DM2EJM3 IK JGRXMPYUTJLTKT-UHFFFAOYSA-N DM2EJM3 IU 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid DM2EJM3 CA CAS 1000025-07-9 DM2EJM3 DE Anaemia DM3WP0N ID DM3WP0N DM3WP0N DN Al3818 DM3WP0N HS Phase 3 DM3WP0N SN Anlotinib; 1058156-90-3; UNII-GKF8S4C432; GKF8S4C432; AL-3818; SCHEMBL2063386; GTPL9601; KSMZEXLVHXZPEF-UHFFFAOYSA-N; MolPort-044-567-604; ZINC117924202; AKOS030526233; DB11885; CS-5396; AL 3818; HY-19716; 1-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxyquinolin-7-yl]oxymethyl]cyclopropan-1-amine; 1-((4-(4-fluoro-2-methyl-1h-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl)cyclopropan-amine; Cyclopropanamine, 1-(((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxy-7-quinolinyl)oxy)methyl)- DM3WP0N CP Advenchen Laboratories Moorpark, CA DM3WP0N PC 25017411 DM3WP0N MW 407.4 DM3WP0N FM C23H22FN3O3 DM3WP0N IC InChI=1S/C23H22FN3O3/c1-13-9-15-16(27-13)3-4-19(22(15)24)30-18-5-8-26-17-11-21(20(28-2)10-14(17)18)29-12-23(25)6-7-23/h3-5,8-11,27H,6-7,12,25H2,1-2H3 DM3WP0N CS CC1=CC2=C(N1)C=CC(=C2F)OC3=C4C=C(C(=CC4=NC=C3)OCC5(CC5)N)OC DM3WP0N IK KSMZEXLVHXZPEF-UHFFFAOYSA-N DM3WP0N IU 1-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxyquinolin-7-yl]oxymethyl]cyclopropan-1-amine DM3WP0N CA CAS 1058156-90-3 DM3WP0N DE Alveolar soft part sarcoma; Cervical cancer; Endometrial cancer; Fallopian tube cancer; Leiomyosarcoma; Ovarian cancer; Peritoneal cavity cancer; Synovial sarcoma DMK0QW6 ID DMK0QW6 DMK0QW6 DN Albinterferon alfa-2b DMK0QW6 HS Phase 3 DMK0QW6 SN Albuferon; Joulferon; Zalbin; ABF-656; Albuferon-alpha; Interferon alpha-albumin fusion protein, HGS; Albumin-based fusion protein (viral disease), Principia; Interferon alpha-albumin fusion protein, HGS/Novartis DMK0QW6 CP Human Genome Sciences DMK0QW6 DE Hepatitis C virus infection DMWAL73 ID DMWAL73 DMWAL73 DN Albutropin DMWAL73 HS Phase 3 DMWAL73 SN Albumin-based fusion protein (growth deficiency), Teva Pharmaceutical; Recombinant human growth hormone (HGH, long acting),Human Genome Sciences; Albumin-based fusion protein (growth deficiency), Principia (HGS); Recombinant human growth hormone (HGH, long-acting), Teva Pharmaceutical DMWAL73 CP Aventis Behring LLC DMWAL73 DE Growth failure DMHKCIS ID DMHKCIS DMHKCIS DN Aldoxorubicin DMHKCIS HS Phase 3 DMHKCIS SN 1361644-26-9; ALDOXORUBICIN; Doxorubicin-EMCH; 151038-96-9; Aldoxorubicin (USAN); CHEMBL2107818; SCHEMBL15221892; OBMJQRLIQQTJLR-LBMCFUDOSA-N; ZINC163337436; AKOS030526452; CS-1186; HY-16261; D10383; W-5595; (8S)-1-Methoxy-6,8alpha,11-trihydroxy-8-[1-[2-[6-(2,5-dioxo-3-pyrroline-1-yl)hexanoyl]hydrazono]-2-hydroxyethyl]-10alpha-(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyloxy)-7,8,9,10-tetrahydronaphthacene-5,12-dione DMHKCIS CP CytRx, Los Angeles, CA DMHKCIS PC 9810709 DMHKCIS MW 750.7 DMHKCIS FM C37H42N4O13 DMHKCIS IC InChI=1S/C37H42N4O13/c1-17-32(46)20(38)13-27(53-17)54-22-15-37(51,23(16-42)39-40-24(43)9-4-3-5-12-41-25(44)10-11-26(41)45)14-19-29(22)36(50)31-30(34(19)48)33(47)18-7-6-8-21(52-2)28(18)35(31)49/h6-8,10-11,17,20,22,27,32,42,46,48,50-51H,3-5,9,12-16,38H2,1-2H3,(H,40,43)/b39-23+/t17-,20-,22-,27-,32+,37-/m0/s1 DMHKCIS CS C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(/C(=N/NC(=O)CCCCCN6C(=O)C=CC6=O)/CO)O)N)O DMHKCIS IK OBMJQRLIQQTJLR-USGQOSEYSA-N DMHKCIS IU N-[(E)-[1-[(2S,4S)-4-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]-2-hydroxyethylidene]amino]-6-(2,5-dioxopyrrol-1-yl)hexanamide DMHKCIS CA CAS 1361644-26-9 DMHKCIS DE Soft tissue sarcoma; Pancreatic ductal carcinoma; Glioblastoma multiforme; Small-cell lung cancer; Solid tumour/cancer DMPH1RK ID DMPH1RK DMPH1RK DN Alferminogene tadenovec DMPH1RK HS Phase 3 DMPH1RK SN Generx (TN) DMPH1RK CP Cardium Therapeutics DMPH1RK DE Heart disease; Angina pectoris DMVHRL8 ID DMVHRL8 DMVHRL8 DN Alfimeprase DMVHRL8 HS Phase 3 DMVHRL8 SN Thrombolytic fibrolase derivative (cardiovascular diseases), Nuvelo; Thrombolytic fibrolase derivative (cerebrovascular ischemia), Nuvelo; Thrombolytic fibrolase derivative (peripheral arterial occlusive diseases), Nuvelo DMVHRL8 CP Nuvelo DMVHRL8 SQ Alfimeprase Sequence: SFPQRYVQLVIVADHRMNTKYNGDSDKIRQWVHQIVNTINEIYRPLNIQFTLVGLEIWSNQDLITVTSVSHDTLASFGNWRETDLLRRQRHDNAQLLTAIDFDGDTVGLAYVGGMCQLKHSTGVIQDHSAINLLVALTMAHELGHNLGMNHDGNQCHCGANSCVMAAMLSDQPSKLFSDCSKKDYQTFLTVNNPQCILNKP DMVHRL8 DE Peripheral vascular disease DMBQK0X ID DMBQK0X DMBQK0X DN Algenpantucel-L DMBQK0X HS Phase 3 DMBQK0X SN HyperAcute pancreas (TN) DMBQK0X CP NewLink Genetics DMBQK0X DT Vaccine DMBQK0X DE Pancreatic cancer DMQ509J ID DMQ509J DMQ509J DN Alicaforsen DMQ509J HS Phase 3 DMQ509J SN Alicaforsen [INN]; ISIS 2302; ISIS-2302; Intercellular adhesion molecule-1 antisense oligodeoxynucleotide; DNA, d((R)-P-thio)(G-C-C-A-A-G-C-T-G-G-C-A-T-C-C-G-T-C-A); Deoxyribonucleic acid, d((R)-P-thio)(G-C-C-C-A-A-G-C-T-G-G-C-A-T-C-C-G-T-C-A) DMQ509J CP ISIS & Atlantic Healthcare DMQ509J TC Antisense DMQ509J DT Antisense drug DMQ509J PC 16197725 DMQ509J MW 6349 DMQ509J FM C192H225N75O98P19S19-19 DMQ509J IC InChI=1S/C192H244N75O98P19S19/c1-76-40-256(190(286)245-169(76)270)136-30-89(357-376(299,395)314-50-106-84(25-131(334-106)251-15-7-122(196)230-185(251)281)351-370(293,389)312-49-105-87(28-134(333-105)254-18-10-125(199)233-188(254)284)355-374(297,393)323-59-115-97(38-145(343-115)266-74-225-154-167(266)238-180(208)243-175(154)276)364-381(304,400)319-55-111-90(31-137(339-111)257-41-77(2)170(271)246-191(257)287)356-375(298,394)313-46-102-81(22-128(330-102)248-12-4-119(193)227-182(248)278)348-366(289,385)308-44-100-79(269)20-127(328-100)259-67-218-147-156(201)210-63-214-160(147)259)110(338-136)54-318-380(303,399)359-92-33-139(260-68-219-148-157(202)211-64-215-161(148)260)340-112(92)56-320-373(296,392)354-88-29-135(255-19-11-126(200)234-189(255)285)336-108(88)52-316-379(302,398)363-96-37-144(265-73-224-153-166(265)237-179(207)242-174(153)275)346-118(96)62-326-384(307,403)365-98-39-146(267-75-226-155-168(267)239-181(209)244-176(155)277)344-116(98)60-324-377(300,396)358-91-32-138(258-42-78(3)171(272)247-192(258)288)337-109(91)53-317-371(294,390)352-85-26-132(252-16-8-123(197)231-186(252)282)335-107(85)51-315-378(301,397)362-95-36-143(264-72-223-152-165(264)236-178(206)241-173(152)274)345-117(95)61-325-383(306,402)361-94-35-141(262-70-221-150-159(204)213-66-217-163(150)262)342-114(94)58-322-382(305,401)360-93-34-140(261-69-220-149-158(203)212-65-216-162(149)261)341-113(93)57-321-372(295,391)353-86-27-133(253-17-9-124(198)232-187(253)283)332-104(86)48-311-369(292,388)350-83-24-130(250-14-6-121(195)229-184(250)280)331-103(83)47-310-368(291,387)349-82-23-129(249-13-5-120(194)228-183(249)279)329-101(82)45-309-367(290,386)347-80-21-142(327-99(80)43-268)263-71-222-151-164(263)235-177(205)240-172(151)273/h4-19,40-42,63-75,79-118,127-146,268-269H,20-39,43-62H2,1-3H3,(H,289,385)(H,290,386)(H,291,387)(H,292,388)(H,293,389)(H,294,390)(H,295,391)(H,296,392)(H,297,393)(H,298,394)(H,299,395)(H,300,396)(H,301,397)(H,302,398)(H,303,399)(H,304,400)(H,305,401)(H,306,402)(H,307,403)(H2,193,227,278)(H2,194,228,279)(H2,195,229,280)(H2,196,230,281)(H2,197,231,282)(H2,198,232,283)(H2,199,233,284)(H2,200,234,285)(H2,201,210,214)(H2,202,211,215)(H2,203,212,216)(H2,204,213,217)(H,245,270,286)(H,246,271,287)(H,247,272,288)(H3,205,235,240,273)(H3,206,236,241,274)(H3,207,237,242,275)(H3,208,238,243,276)(H3,209,239,244,277)/p-19/t79-,80-,81-,82-,83-,84-,85-,86-,87-,88-,89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99+,100+,101+,102+,103+,104+,105+,106+,107+,108+,109+,110+,111+,112+,113+,114+,115+,116+,117+,118+,127+,128+,129+,130+,131+,132+,133+,134+,135+,136+,137+,138+,139+,140+,141+,142+,143+,144+,145+,146+,366?,367?,368?,369?,370?,371?,372?,373?,374?,375?,376?,377?,378?,379?,380?,381?,382?,383?,384?/m0/s1 DMQ509J CS CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)COP(=S)([O-])O[C@H]3C[C@@H](O[C@@H]3COP(=S)([O-])O[C@H]4C[C@@H](O[C@@H]4COP(=S)([O-])O[C@H]5C[C@@H](O[C@@H]5COP(=S)([O-])O[C@H]6C[C@@H](O[C@@H]6COP(=S)([O-])O[C@H]7C[C@@H](O[C@@H]7COP(=S)([O-])O[C@H]8C[C@@H](O[C@@H]8COP(=S)([O-])O[C@H]9C[C@@H](O[C@@H]9COP(=S)([O-])O[C@H]1C[C@@H](O[C@@H]1CO)N1C=NC2=C1N=C(NC2=O)N)N1C=CC(=NC1=O)N)N1C=CC(=NC1=O)N)N1C=CC(=NC1=O)N)N1C=NC2=C(N=CN=C21)N)N1C=NC2=C(N=CN=C21)N)N1C=NC2=C1N=C(NC2=O)N)N1C=CC(=NC1=O)N)OP(=S)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=NC2=C1N=C(NC2=O)N)OP(=S)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=NC2=C1N=C(NC2=O)N)OP(=S)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=CC(=NC1=O)N)OP(=S)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=NC2=C(N=CN=C21)N)OP(=S)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=C(C(=O)NC1=O)C)OP(=S)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=CC(=NC1=O)N)OP(=S)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=CC(=NC1=O)N)OP(=S)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=NC2=C1N=C(NC2=O)N)OP(=S)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=C(C(=O)NC1=O)C)OP(=S)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=CC(=NC1=O)N)OP(=S)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=NC2=C(N=CN=C21)N)O DMQ509J IK ZMJWRJKGPUDEOX-LMXUULCNSA-A DMQ509J IU 1-[(2R,4S,5R)-4-[[(2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[(2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-3-[[(2R,3S,5R)-5-(6-aminopurin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-oxidophosphinothioyl]oxyoxolan-2-yl]methoxy-oxidophosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-oxidophosphinothioyl]oxyoxolan-2-yl]methoxy-oxidophosphinothioyl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-oxidophosphinothioyl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-oxidophosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-oxidophosphinothioyl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-oxidophosphinothioyl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-oxidophosphinothioyl]oxyoxolan-2-yl]methoxy-oxidophosphinothioyl]oxyoxolan-2-yl]methoxy-oxidophosphinothioyl]oxy-5-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-2-(hydroxymethyl)oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]-5-(6-aminopurin-9-yl)oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]-5-(6-aminopurin-9-yl)oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]oxolan-2-yl]-5-methylpyrimidine-2,4-dione DMQ509J CA CAS 185229-68-9 DMQ509J DE Ulcerative colitis; Crohn disease; Lleum inflammation DM9R2SD ID DM9R2SD DM9R2SD DN Alilusem DM9R2SD HS Phase 3 DM9R2SD SN M-12285; M-17000; M-17055; MD-31 DM9R2SD CP Mochida Pharmaceutical Co Ltd DM9R2SD DT Small molecular drug DM9R2SD PC 6338015 DM9R2SD MW 394.8 DM9R2SD FM C17H15ClN2O5S DM9R2SD IC InChI=1S/C17H15ClN2O5S/c1-11-4-2-3-5-13(11)17(21)20-9-8-15(19-25-26(22,23)24)14-7-6-12(18)10-16(14)20/h2-7,10H,8-9H2,1H3,(H,22,23,24)/b19-15+ DM9R2SD CS CC1=CC=CC=C1C(=O)N2CC/C(=N\\OS(=O)(=O)O)/C3=C2C=C(C=C3)Cl DM9R2SD IK QQCSUWGQBREWRO-XDJHFCHBSA-N DM9R2SD IU [(E)-[7-chloro-1-(2-methylbenzoyl)-2,3-dihydroquinolin-4-ylidene]amino] hydrogen sulfate DM9R2SD CA CAS 791024-52-7 DM9R2SD DE Diuretic vasodilator DM83EBP ID DM83EBP DM83EBP DN Alisporivir DM83EBP HS Phase 3 DM83EBP SN DEB-025; Debio-025; HCV infection therapy, Debiopharm/Novartis; HIV infection therapy, Debiopharm DM83EBP CP Novartis pharmaceuticals DM83EBP DT Protein/peptide drug DM83EBP PC 11513676 DM83EBP MW 1216.6 DM83EBP FM C63H113N11O12 DM83EBP IC InChI=1S/C63H113N11O12/c1-26-29-30-40(16)52(75)51-56(79)66-44(27-2)59(82)68(20)43(19)58(81)74(28-3)49(38(12)13)55(78)67-48(37(10)11)62(85)69(21)45(31-34(4)5)54(77)64-41(17)53(76)65-42(18)57(80)70(22)46(32-35(6)7)60(83)71(23)47(33-36(8)9)61(84)72(24)50(39(14)15)63(86)73(51)25/h26,29,34-52,75H,27-28,30-33H2,1-25H3,(H,64,77)(H,65,76)(H,66,79)(H,67,78)/b29-26+/t40-,41+,42-,43-,44+,45+,46+,47+,48+,49+,50+,51+,52-/m1/s1 DM83EBP CS CC[C@H]1C(=O)N([C@@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)C(C)C)CC)C)C DM83EBP IK OLROWHGDTNFZBH-XEMWPYQTSA-N DM83EBP IU (3S,6S,9S,12R,15S,18S,21S,24S,27R,30S,33S)-25,30-diethyl-33-[(E,1R,2R)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,27,28-nonamethyl-6,9,18-tris(2-methylpropyl)-3,21,24-tri(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone DM83EBP CA CAS 254435-95-5 DM83EBP DE Duchenne dystrophy DMCHA27 ID DMCHA27 DMCHA27 DN Almonertinib DMCHA27 HS Phase 3 DMCHA27 SN HS-10296; Ameile; 1899921-05-1; Egfr T790M inhibitor HS-10296; N-(5-((4-(1-Cyclopropyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide; UNII-T4RS462G19; SCHEMBL17683063; GTPL11136; T4RS462G19; EX-A3721; HS 10296 [WHO-DD]; s8817; HS10296; example 26 [WO2016054987A1]; HY-112823; CS-0066162; 2-Propenamide, N-(5-((4-(1-cyclopropyl-1H-indol-3-yl)-2-pyrimidinyl)amino)-2-((2-(dimethylamino)ethyl)methylamino)-4-methoxyphenyl)-; C1(CC1)N1C=C(C2=CC=CC=C12)C1=NC(=NC=C1)NC=1C(=CC(=C(C=1)NC(C=C)=O)N(C)CCN(C)C)OC; N-[5-[[4-(1-cyclopropylindol-3-yl)pyrimidin-2-yl]amino]-2-[2-(dimethylamino)ethyl-methylamino]-4-methoxyphenyl]prop-2-enamide DMCHA27 CP EQRx DMCHA27 DT Small molecular drug DMCHA27 PC 121280087 DMCHA27 MW 525.6 DMCHA27 FM C30H35N7O2 DMCHA27 IC InChI=1S/C30H35N7O2/c1-6-29(38)32-24-17-25(28(39-5)18-27(24)36(4)16-15-35(2)3)34-30-31-14-13-23(33-30)22-19-37(20-11-12-20)26-10-8-7-9-21(22)26/h6-10,13-14,17-20H,1,11-12,15-16H2,2-5H3,(H,32,38)(H,31,33,34) DMCHA27 CS CN(C)CCN(C)C1=CC(=C(C=C1NC(=O)C=C)NC2=NC=CC(=N2)C3=CN(C4=CC=CC=C43)C5CC5)OC DMCHA27 IK DOEOECWDNSEFDN-UHFFFAOYSA-N DMCHA27 IU N-[5-[[4-(1-cyclopropylindol-3-yl)pyrimidin-2-yl]amino]-2-[2-(dimethylamino)ethyl-methylamino]-4-methoxyphenyl]prop-2-enamide DMCHA27 CA CAS 1899921-05-1 DMCHA27 DE Non-small-cell lung cancer DMFUOM7 ID DMFUOM7 DMFUOM7 DN ALN-TTRsc DMFUOM7 HS Phase 3 DMFUOM7 SN SAR438714 DMFUOM7 CP Alnylam pharmaceuticals DMFUOM7 DE Cardiomyopathy DMKLBHX ID DMKLBHX DMKLBHX DN ALO-02 DMKLBHX HS Phase 3 DMKLBHX SN ALO-02 Oxycodone-naltrexone core DMKLBHX CP Elite Pharmaceuticals; pfizer DMKLBHX DE Pain DM2RTGP ID DM2RTGP DM2RTGP DN Alpha-glucosidase DM2RTGP HS Phase 3 DM2RTGP SN Pompes disease therapy, Pharming; Alpha-glucosidase (transgenic); Alpha-glucosidase, Pharming; GD-halpha-GLU; Alpha-glucosidase (transgenic), Pharming/Genzyme DM2RTGP CP Pharming Group NV DM2RTGP DE Muscle disease DM7EBH9 ID DM7EBH9 DM7EBH9 DN ALX-0081 DM7EBH9 HS Phase 3 DM7EBH9 CP Ablynx DM7EBH9 DE Thrombocytopenia; Thrombotic thrombocytopenic purpura DMG5BTD ID DMG5BTD DMG5BTD DN ALZT-OP1 DMG5BTD HS Phase 3 DMG5BTD SN ALZT-OP1a+ALZT-OP1b; cromolyn + ibuprofen DMG5BTD CP AZTherapies Boston, MA DMG5BTD DE Alzheimer disease DMGMNUE ID DMGMNUE DMGMNUE DN AM0010 DMGMNUE HS Phase 3 DMGMNUE CP Armo biosciences DMGMNUE DE Solid tumour/cancer; Pancreatic ductal carcinoma; Renal cell carcinoma; Non-small-cell lung cancer; Pancreatic cancer DM4E9PK ID DM4E9PK DM4E9PK DN AM-111 DM4E9PK HS Phase 3 DM4E9PK SN UNII-FU288768DP; FU288768DP; XG102 peptide; AM111 peptide; D-JNKI-1; D-JNKI 1 peptide; XG 102; AM 111; D-JNKI 1; TAT-IB1 fusion peptide XG-102 (synthetic); HIV TAT-JIP-1 fusion peptide XG-102 (synthetic); 1198367-70-2; 1148126-36-6; Glycine, D-alpha-aspartyl-D-glutaminyl-D-seryl-D-arginyl-D-prolyl-D-valyl-D-glutaminyl-D-prolyl-D-phenylalanyl-D-leucyl-D-asparaginyl-D-leucyl-D-threonyl-D-threonyl-D-prolyl-D-arginyl-D-lysyl-D-prolyl-D-arginyl-D-prolyl-D-prolyl-D-arginyl-D-arginyl-D-arginyl-D-glutaminyl-D-arginyl-D-arginyl- DM4E9PK CP Auris Medical DM4E9PK PC 72941992 DM4E9PK MW 3823.4 DM4E9PK FM C164H285N65O41 DM4E9PK IC InChI=1S/C164H285N65O41/c1-84(2)77-106(216-139(254)108(79-89-33-10-9-11-34-89)219-146(261)112-48-28-72-225(112)153(268)105(55-58-119(171)235)215-148(263)123(86(5)6)221-147(262)115-51-29-73-226(115)151(266)103(45-25-69-198-163(187)188)213-142(257)110(83-230)220-137(252)100(53-56-117(169)233)201-126(241)90(168)80-121(237)238)138(253)218-109(81-120(172)236)140(255)217-107(78-85(3)4)141(256)222-124(87(7)231)149(264)223-125(88(8)232)155(270)228-75-31-50-114(228)144(259)211-99(44-24-68-197-162(185)186)135(250)212-102(37-14-17-61-167)150(265)224-71-27-47-111(224)145(260)214-104(46-26-70-199-164(189)190)152(267)229-76-32-52-116(229)154(269)227-74-30-49-113(227)143(258)210-98(43-23-67-196-161(183)184)134(249)207-95(40-20-64-193-158(177)178)131(246)206-97(42-22-66-195-160(181)182)133(248)209-101(54-57-118(170)234)136(251)208-96(41-21-65-194-159(179)180)132(247)205-94(39-19-63-192-157(175)176)130(245)204-93(36-13-16-60-166)129(244)203-92(35-12-15-59-165)128(243)202-91(38-18-62-191-156(173)174)127(242)200-82-122(239)240/h9-11,33-34,84-88,90-116,123-125,230-232H,12-32,35-83,165-168H2,1-8H3,(H2,169,233)(H2,170,234)(H2,171,235)(H2,172,236)(H,200,242)(H,201,241)(H,202,243)(H,203,244)(H,204,245)(H,205,247)(H,206,246)(H,207,249)(H,208,251)(H,209,248)(H,210,258)(H,211,259)(H,212,250)(H,213,257)(H,214,260)(H,215,263)(H,216,254)(H,217,255)(H,218,253)(H,219,261)(H,220,252)(H,221,262)(H,222,256)(H,223,264)(H,237,238)(H,239,240)(H4,173,174,191)(H4,175,176,192)(H4,177,178,193)(H4,179,180,194)(H4,181,182,195)(H4,183,184,196)(H4,185,186,197)(H4,187,188,198)(H4,189,190,199)/t87-,88-,90+,91+,92+,93+,94+,95+,96+,97+,98+,99+,100+,101+,102+,103+,104+,105+,106+,107+,108+,109+,110+,111+,112+,113+,114+,115+,116+,123+,124+,125+/m0/s1 DM4E9PK CS C[C@@H]([C@H](C(=O)N[C@H]([C@H](C)O)C(=O)N1CCC[C@@H]1C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCCN)C(=O)N2CCC[C@@H]2C(=O)N[C@H](CCCNC(=N)N)C(=O)N3CCC[C@@H]3C(=O)N4CCC[C@@H]4C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCC(=O)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCNC(=N)N)C(=O)NCC(=O)O)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](CC(=O)N)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](CC5=CC=CC=C5)NC(=O)[C@H]6CCCN6C(=O)[C@@H](CCC(=O)N)NC(=O)[C@@H](C(C)C)NC(=O)[C@H]7CCCN7C(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CO)NC(=O)[C@@H](CCC(=O)N)NC(=O)[C@@H](CC(=O)O)N)O DM4E9PK IK HRMVIAFZYCCHGF-BMCUWHFPSA-N DM4E9PK IU (3R)-3-amino-4-[[(2R)-5-amino-1-[[(2R)-1-[[(2R)-1-[(2R)-2-[[(2R)-1-[[(2R)-5-amino-1-[(2R)-2-[[(2R)-1-[[(2R)-1-[[(2R)-4-amino-1-[[(2R)-1-[[(2R,3S)-1-[[(2R,3S)-1-[(2R)-2-[[(2R)-1-[[(2R)-6-amino-1-[(2R)-2-[[(2R)-1-[(2R)-2-[(2R)-2-[[(2R)-1-[[(2R)-1-[[(2R)-1-[[(2R)-5-amino-1-[[(2R)-1-[[(2R)-1-[[(2R)-6-amino-1-[[(2R)-6-amino-1-[[(2R)-5-carbamimidamido-1-(carboxymethylamino)-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]carbamoyl]pyrrolidine-1-carbonyl]pyrrolidin-1-yl]-5-carbamimidamido-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-3-hydroxy-1-oxobutan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]carbamoyl]pyrrolidin-1-yl]-1,5-dioxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]carbamoyl]pyrrolidin-1-yl]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-oxobutanoic acid DM4E9PK CA CAS 1198367-70-2 DM4E9PK DE Neurological disorder DMVOY6B ID DMVOY6B DMVOY6B DN AMD-070 DMVOY6B HS Phase 3 DMVOY6B SN AMD 070; AMD070; AMD11070; S14-0353; N-(1H-benzoimidazol-2-ylmethyl)-N-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine; N'-(1H-Benzo[d]imidazol-2-ylmethyl)-N'-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine Trihydrobromide Dihydrate DMVOY6B CP Genzyme DMVOY6B DT Small molecular drug DMVOY6B PC 11256587 DMVOY6B MW 349.5 DMVOY6B FM C21H27N5 DMVOY6B IC InChI=1S/C21H27N5/c22-12-3-4-14-26(15-20-24-17-9-1-2-10-18(17)25-20)19-11-5-7-16-8-6-13-23-21(16)19/h1-2,6,8-10,13,19H,3-5,7,11-12,14-15,22H2,(H,24,25)/t19-/m0/s1 DMVOY6B CS C1C[C@@H](C2=C(C1)C=CC=N2)N(CCCCN)CC3=NC4=CC=CC=C4N3 DMVOY6B IK WVLHHLRVNDMIAR-IBGZPJMESA-N DMVOY6B IU N'-(1H-benzimidazol-2-ylmethyl)-N'-[(8S)-5,6,7,8-tetrahydroquinolin-8-yl]butane-1,4-diamine DMVOY6B CA CAS 558447-26-0 DMVOY6B CB CHEBI:138865 DMVOY6B DE Human immunodeficiency virus infection; Renal cell carcinoma; Melanoma; Merkel cell carcinoma; Solid tumour/cancer; Whim syndrome DM4FPM3 ID DM4FPM3 DM4FPM3 DN Amediplase DM4FPM3 HS Phase 3 DM4FPM3 SN Amediplase [INN]; Trans,trans-3,4:12,13-Tetrahydroxy-3,4,12,13-tetrahydro-dibenz(a,h)anthracene; (3S,4S,12S,13S)-3,4,12,13-tetrahydronaphtho[1,2-b]phenanthrene-3,4,12,13-tetrol DM4FPM3 CP Menarini DM4FPM3 DT Small molecular drug DM4FPM3 PC 154656 DM4FPM3 MW 346.4 DM4FPM3 FM C22H18O4 DM4FPM3 IC InChI=1S/C22H18O4/c23-19-8-7-13-15(20(19)24)6-5-11-9-17-12-3-1-2-4-14(12)21(25)22(26)18(17)10-16(11)13/h1-10,19-26H/t19-,20-,21-,22-/m0/s1 DM4FPM3 CS C1=CC=C2C(=C1)[C@@H]([C@H](C3=C2C=C4C=CC5=C(C4=C3)C=C[C@@H]([C@H]5O)O)O)O DM4FPM3 IK YQINXCSNGCDFCQ-CMOCDZPBSA-N DM4FPM3 IU (3S,4S,12S,13S)-3,4,12,13-tetrahydronaphtho[1,2-b]phenanthrene-3,4,12,13-tetrol DM4FPM3 CA CAS 151910-75-7 DM4FPM3 DE Thrombosis; Myocardial infarction DMG324Y ID DMG324Y DMG324Y DN AMG 145 DMG324Y HS Phase 3 DMG324Y CP Amgen Thousand DMG324Y DE Hypercholesterolaemia DMQJXL4 ID DMQJXL4 DMQJXL4 DN AMG 386 DMQJXL4 HS Phase 3 DMQJXL4 SN 7440-23-5; Natrium; Sodium-23; Sodio; Sodium metal; Sodio [Spanish]; Sodium (liquid alloy); UNII-9NEZ333N27; HSDB 687; EINECS 231-132-9; UN1428; UNII-23J3BHR95O; Sodium, dry stick; 9NEZ333N27; MFCD00085307; Sodium, 998%, oiled sticks, wrapped in aluminium foil; monosodium; sodium atom; mono sodium; mono-sodium; Sodium, CP; SodiuR4733m hydride, CP; AC1NSENP; ACMC-1BKTZ; Sodium, ACS reagent, dry; 11Na; EC 231-132-9; AC1Q1W6R; SODIUM, LARGE PIECES; Sodium hydride, dry, 95%; NAH 80; HSDB 745; CTK2H7876; CHEBI:26708; Oravescent fentanyl; R3487; PT-15; R4930 DMQJXL4 CP Amgen DMQJXL4 DT Small molecular drug DMQJXL4 PC 5360545 DMQJXL4 MW 22.989 DMQJXL4 FM Na DMQJXL4 IC InChI=1S/Na DMQJXL4 CS [Na] DMQJXL4 IK KEAYESYHFKHZAL-UHFFFAOYSA-N DMQJXL4 IU sodium DMQJXL4 CA CAS 7440-23-5 DMQJXL4 CB CHEBI:26708 DMQJXL4 DE Alzheimer disease; Neuropathic pain; Sexual dysfunction; Breast cancer; Asthma DMS1X67 ID DMS1X67 DMS1X67 DN Amitifadine DMS1X67 HS Phase 3 DMS1X67 SN EB-1010 DMS1X67 CP Euthymics Bioscience DMS1X67 DT Small molecular drug DMS1X67 PC 11658655 DMS1X67 MW 228.11 DMS1X67 FM C11H11Cl2N DMS1X67 IC InChI=1S/C11H11Cl2N/c12-9-2-1-7(3-10(9)13)11-4-8(11)5-14-6-11/h1-3,8,14H,4-6H2/t8-,11+/m1/s1 DMS1X67 CS C1[C@H]2[C@@]1(CNC2)C3=CC(=C(C=C3)Cl)Cl DMS1X67 IK BSMNRYCSBFHEMQ-KCJUWKMLSA-N DMS1X67 IU (1R,5S)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane DMS1X67 CA CAS 410074-73-6 DMS1X67 DE Obesity; Alcohol dependence; Mood disorder DMF50XJ ID DMF50XJ DMF50XJ DN Amitriptyline+ketamine DMF50XJ HS Phase 3 DMF50XJ SN AmiKet DMF50XJ CP EpiCept Pharmaceuticals DMF50XJ TC Analgesics DMF50XJ DT Small molecular drug DMF50XJ PC 24784105 DMF50XJ MW 412.9 DMF50XJ FM C20H17ClN4O2S DMF50XJ IC InChI=1S/C20H16N4O2S.ClH/c1-13(25)23(2)15-6-3-5-14(11-15)17-8-9-21-20-16(12-22-24(17)20)19(26)18-7-4-10-27-18;/h3-12H,1-2H3;1H DMF50XJ CS CC(=O)N(C)C1=CC=CC(=C1)C2=CC=NC3=C(C=NN23)C(=O)C4=CC=CS4.Cl DMF50XJ IK HPYLZBPCIBFRAI-UHFFFAOYSA-N DMF50XJ IU N-methyl-N-[3-[3-(thiophene-2-carbonyl)pyrazolo[1,5-a]pyrimidin-7-yl]phenyl]acetamide;hydrochloride DMF50XJ DE Neuropathic pain; Diabetic neuropathy; Postherpetic neuralgia DMZ7AMY ID DMZ7AMY DMZ7AMY DN Amivantamab DMZ7AMY HS Phase 3 DMZ7AMY CP Janssen DMZ7AMY DT Antibody DMZ7AMY DE Non-small-cell lung cancer DMB9587 ID DMB9587 DMB9587 DN Amocarzine DMB9587 HS Phase 3 DMB9587 SN Phenthiourezine; Thiocarbamazine; CGP-6140; S-80016 DMB9587 CP Novartis AG DMB9587 DT Small molecular drug DMB9587 PC 5464102 DMB9587 MW 371.5 DMB9587 FM C18H21N5O2S DMB9587 IC InChI=1S/C18H21N5O2S/c1-21-10-12-22(13-11-21)18(26)20-16-4-2-14(3-5-16)19-15-6-8-17(9-7-15)23(24)25/h2-9,19H,10-13H2,1H3,(H,20,26) DMB9587 CS CN1CCN(CC1)C(=S)NC2=CC=C(C=C2)NC3=CC=C(C=C3)[N+](=O)[O-] DMB9587 IK UFLRJROFPAGRPN-UHFFFAOYSA-N DMB9587 IU 4-methyl-N-[4-(4-nitroanilino)phenyl]piperazine-1-carbothioamide DMB9587 CA CAS 36590-19-9 DMB9587 CB CHEBI:38946 DMB9587 DE Helminth infection DM6SGUB ID DM6SGUB DM6SGUB DN Amrubicin DM6SGUB HS Phase 3 DM6SGUB SN 110267-81-7; Amrubicin [INN]; SCHEMBL119022; AC1L4374; (+-)-(7S,9S)-9-Acetyl-9-amino-7-((2-deoxy-beta-D-erythro-pentopyranosyl)oxy)-7,8,9,10-tetrahydro-6,11-dihydroxy-5,12-naphthacenedione; BC677604; AN-16624; LS-183761; FT-0662134; ( -)-(7S,9S)-9-Acetyl-9-amino-7-((2-deoxy-beta-D-erythro-pentopyranosyl)oxy)-7,8,9,10-tetrahydro-6,11-dihydroxy-5,12-naphthacenedione; (7S,9S)-9-acetyl-9-amino-7-(4,5-dihydroxytetrahydropyran-2-yl)oxy-6,11-dihydroxy-8,10-dihydro-7H-tetracene-5,12-dione DM6SGUB CP Celgene DM6SGUB DT Small molecular drug DM6SGUB PC 3035016 DM6SGUB MW 483.5 DM6SGUB FM C25H25NO9 DM6SGUB IC InChI=1S/C25H25NO9/c1-10(27)25(26)7-13-18(16(8-25)35-17-6-14(28)15(29)9-34-17)24(33)20-19(23(13)32)21(30)11-4-2-3-5-12(11)22(20)31/h2-5,14-17,28-29,32-33H,6-9,26H2,1H3/t14-,15+,16-,17-,25-/m0/s1 DM6SGUB CS CC(=O)[C@]1(C[C@@H](C2=C(C1)C(=C3C(=C2O)C(=O)C4=CC=CC=C4C3=O)O)O[C@H]5C[C@@H]([C@@H](CO5)O)O)N DM6SGUB IK VJZITPJGSQKZMX-XDPRQOKASA-N DM6SGUB IU (7S,9S)-9-acetyl-9-amino-7-[(2S,4S,5R)-4,5-dihydroxyoxan-2-yl]oxy-6,11-dihydroxy-8,10-dihydro-7H-tetracene-5,12-dione DM6SGUB CA CAS 110267-81-7 DM6SGUB CB CHEBI:135779 DM6SGUB DE Small-cell lung cancer DM8QIRN ID DM8QIRN DM8QIRN DN AMT-011 DM8QIRN HS Phase 3 DM8QIRN SN Alipogene tiparvovec DM8QIRN CP Amsterdam Molecular Therapeutics DM8QIRN DE Blood forming organ disorder DMSO02K ID DMSO02K DMSO02K DN AMT-061 DMSO02K HS Phase 3 DMSO02K SN etranacogene dezaparvovec DMSO02K CP uniQure DMSO02K DT Gene therapy DMSO02K DE Haemophilia B DMP2BFG ID DMP2BFG DMP2BFG DN Anacetrapib DMP2BFG HS Phase 3 DMP2BFG SN MK0859; Anacetrapib (USAN); MK-0859 DMP2BFG CP Merck DMP2BFG DT Small molecular drug DMP2BFG PC 11556427 DMP2BFG MW 637.5 DMP2BFG FM C30H25F10NO3 DMP2BFG IC InChI=1S/C30H25F10NO3/c1-14(2)22-11-23(25(43-4)12-24(22)31)21-6-5-18(28(32,33)34)9-17(21)13-41-15(3)26(44-27(41)42)16-7-19(29(35,36)37)10-20(8-16)30(38,39)40/h5-12,14-15,26H,13H2,1-4H3/t15-,26-/m0/s1 DMP2BFG CS C[C@H]1[C@H](OC(=O)N1CC2=C(C=CC(=C2)C(F)(F)F)C3=CC(=C(C=C3OC)F)C(C)C)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F DMP2BFG IK MZZLGJHLQGUVPN-HAWMADMCSA-N DMP2BFG IU (4S,5R)-5-[3,5-bis(trifluoromethyl)phenyl]-3-[[2-(4-fluoro-2-methoxy-5-propan-2-ylphenyl)-5-(trifluoromethyl)phenyl]methyl]-4-methyl-1,3-oxazolidin-2-one DMP2BFG CA CAS 875446-37-0 DMP2BFG DE Hyperlipidaemia; Arteriosclerosis DM2F9YO ID DM2F9YO DM2F9YO DN Anakinra DM2F9YO HS Phase 3 DM2F9YO SN Antril DM2F9YO TC Antiviral Agents DM2F9YO DT Protein/peptide drug DM2F9YO DE Coronavirus Disease 2019 (COVID-19) DM6HXTS ID DM6HXTS DM6HXTS DN Anamorelin DM6HXTS HS Phase 3 DM6HXTS SN 249921-19-5; UNII-DD5RBA1NKF; DD5RBA1NKF; RC 1291; Anamorelin [INN]; ONO-7643; SCHEMBL935751; CHEMBL2110579; EX-A154; DTXSID20179702; C31H42N6O3; BCP06108; 3444AH; ZINC43130908; AKOS030526752; SB16911; API0008642; RC-1291; NCGC00378854-01; KB-80338; HY-14734; BC600755; (3R)-1-(2-Methylalanyl-D-tryptophyl)-3-(phenylmethyl)-3-piperidinecarboxylic acid 1,2,2-trimethylhydrazide; AB0165721; FT-0773543; W-5500; 921A195; CS 1036 DM6HXTS CP Sapphire Therape. DM6HXTS DT Small molecular drug DM6HXTS PC 9828911 DM6HXTS MW 546.7 DM6HXTS FM C31H42N6O3 DM6HXTS IC InChI=1S/C31H42N6O3/c1-30(2,32)28(39)34-26(18-23-20-33-25-15-10-9-14-24(23)25)27(38)37-17-11-16-31(21-37,29(40)36(5)35(3)4)19-22-12-7-6-8-13-22/h6-10,12-15,20,26,33H,11,16-19,21,32H2,1-5H3,(H,34,39)/t26-,31-/m1/s1 DM6HXTS CS CC(C)(C(=O)N[C@H](CC1=CNC2=CC=CC=C21)C(=O)N3CCC[C@](C3)(CC4=CC=CC=C4)C(=O)N(C)N(C)C)N DM6HXTS IK VQPFSIRUEPQQPP-MXBOTTGLSA-N DM6HXTS IU 2-amino-N-[(2R)-1-[(3R)-3-benzyl-3-[dimethylamino(methyl)carbamoyl]piperidin-1-yl]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]-2-methylpropanamide DM6HXTS CA CAS 249921-19-5 DM6HXTS DE Carbohydrate metabolism disorder DMK2Y4V ID DMK2Y4V DMK2Y4V DN Ancrod DMK2Y4V HS Phase 3 DMK2Y4V SN Arvin; Arwin; Venacil; Viprinex; Agkistrodon rhodostoma venom proteinase; Agkistrodon serine proteinase; Snake venom, Knoll DMK2Y4V CP Knoll GmbH; Neurobiological Technologies DMK2Y4V DE Blood forming organ disorder DMLDB1X ID DMLDB1X DMLDB1X DN Andecaliximab DMLDB1X HS Phase 3 DMLDB1X CP Gilead Sciences Foster City, CA DMLDB1X DE Solid tumour/cancer; Gastric adenocarcinoma DMX36BH ID DMX36BH DMX36BH DN Andolast DMX36BH HS Phase 3 DMX36BH SN Dizolast; CR-2039; Calcium-activated potassium channel opener (inhaled powder, asthma), Rottapharm DMX36BH CP Rottapharm Madaus DMX36BH DT Small molecular drug DMX36BH PC 65970 DMX36BH MW 333.31 DMX36BH FM C15H11N9O DMX36BH IC InChI=1S/C15H11N9O/c25-15(11-3-1-9(2-4-11)13-17-21-22-18-13)16-12-7-5-10(6-8-12)14-19-23-24-20-14/h1-8H,(H,16,25)(H,17,18,21,22)(H,19,20,23,24) DMX36BH CS C1=CC(=CC=C1C2=NNN=N2)C(=O)NC3=CC=C(C=C3)C4=NNN=N4 DMX36BH IK VXEBMQZDPONDFB-UHFFFAOYSA-N DMX36BH IU 4-(2H-tetrazol-5-yl)-N-[4-(2H-tetrazol-5-yl)phenyl]benzamide DMX36BH CA CAS 132640-22-3 DMX36BH DE Rhinitis DMITJAK ID DMITJAK DMITJAK DN Androsterone DMITJAK HS Phase 3 DMITJAK SN androsterone; 53-41-8; Androkinine; Androtine; 5alpha-Androsterone; Atromide ICI; 3alpha-Hydroxy-5alpha-androstan-17-one; 3-Epihydroxyetioallocholan-17-one; cis-Androsterone; 3alpha-Hydroxyetioallocholan-17-one; 5alpha-Androstane-3alpha-ol-17-one; 3alpha-Hydroxy-17-androstanone; Androstanon-3-alpha-ol-17-one; 3-alpha-Hydroxy-17-androstanone; 3-alpha-Hydroxyetioallocholan-17-one; 3-alpha-Hydroxy-5-alpha-androstan-17-one; 5-alpha-Androstan-3-alpha-ol-17-one; Caswell No. 051G; Androstan-17-one, 3-hydroxy-, (3alpha,5alpha)- DMITJAK DT Small molecular drug DMITJAK PC 5879 DMITJAK MW 290.4 DMITJAK FM C19H30O2 DMITJAK IC InChI=1S/C19H30O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h12-16,20H,3-11H2,1-2H3/t12-,13+,14-,15-,16-,18-,19-/m0/s1 DMITJAK CS C[C@]12CC[C@H](C[C@@H]1CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CCC4=O)C)O DMITJAK IK QGXBDMJGAMFCBF-HLUDHZFRSA-N DMITJAK IU (3R,5S,8R,9S,10S,13S,14S)-3-hydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,14,15,16-tetradecahydrocyclopenta[a]phenanthren-17-one DMITJAK CA CAS 53-41-8 DMITJAK CB CHEBI:16032 DM76GZ0 ID DM76GZ0 DM76GZ0 DN Angiotensin-(1-7) DM76GZ0 HS Phase 3 DM76GZ0 SN Ang (1-7); Angiotensin (1-7); Angiotensin-(1-7) (cancer); Angiotensin-(1-7) (cancer), Wake Forest University DM76GZ0 CP Tarix pharmaceuticals DM76GZ0 DT Small molecular drug DM76GZ0 PC 123805 DM76GZ0 MW 899 DM76GZ0 FM C41H62N12O11 DM76GZ0 IC InChI=1S/C41H62N12O11/c1-5-22(4)33(38(61)50-29(17-24-19-45-20-47-24)39(62)53-15-7-9-30(53)40(63)64)52-36(59)28(16-23-10-12-25(54)13-11-23)49-37(60)32(21(2)3)51-35(58)27(8-6-14-46-41(43)44)48-34(57)26(42)18-31(55)56/h10-13,19-22,26-30,32-33,54H,5-9,14-18,42H2,1-4H3,(H,45,47)(H,48,57)(H,49,60)(H,50,61)(H,51,58)(H,52,59)(H,55,56)(H,63,64)(H4,43,44,46)/t22-,26-,27-,28-,29-,30-,32-,33-/m0/s1 DM76GZ0 CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N2CCC[C@H]2C(=O)O)NC(=O)[C@H](CC3=CC=C(C=C3)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(=O)O)N DM76GZ0 IK PVHLMTREZMEJCG-GDTLVBQBSA-N DM76GZ0 IU (2S)-1-[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-carboxypropanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]pyrrolidine-2-carboxylic acid DM76GZ0 CA CAS 39386-80-6 DM76GZ0 CB CHEBI:55438 DM76GZ0 DE Lymphoma; Chemotherapy-induced nausea; Sarcoma; Duchenne dystrophy; Muscular dystrophy DM3FPAQ ID DM3FPAQ DM3FPAQ DN Anifrolumab DM3FPAQ HS Phase 3 DM3FPAQ CP MedImmune Gaithersburg, MD DM3FPAQ DE Systemic lupus erythematosus DMX0PWV ID DMX0PWV DMX0PWV DN Anti-IL-23 DMX0PWV HS Phase 3 DMX0PWV SN Anti-IL-23 (chronic inflammation); Anti-IL-23 (chronic inflammation), Merck & Co; Anti-IL-23 (chronic inflammation), Schering-Plough; Anti-interleukin-23 antibody (chronic inflammation), Merck & Co DMX0PWV CP Schering-Plough Corp DMX0PWV DT Antibody DMX0PWV DE Inflammation DMUYOC8 ID DMUYOC8 DMUYOC8 DN AP12009 DMUYOC8 HS Phase 3 DMUYOC8 CP Antisense therapeutics DMUYOC8 TC Antisense DMUYOC8 DT Antisense drug DMUYOC8 DE Colorectal cancer DMD8QTC ID DMD8QTC DMD8QTC DN Apadenoson DMD8QTC HS Phase 3 DMD8QTC SN Stedivaze (TN) DMD8QTC CP PGx Health DMD8QTC DT Small molecular drug DMD8QTC PC 9805430 DMD8QTC MW 486.5 DMD8QTC FM C23H30N6O6 DMD8QTC IC InChI=1S/C23H30N6O6/c1-3-25-21(32)18-16(30)17(31)22(35-18)29-11-26-15-19(24)27-14(28-20(15)29)6-4-5-12-7-9-13(10-8-12)23(33)34-2/h11-13,16-18,22,30-31H,3,5,7-10H2,1-2H3,(H,25,32)(H2,24,27,28)/t12?,13?,16-,17+,18-,22+/m0/s1 DMD8QTC CS CCNC(=O)[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=C(N=C32)C#CCC4CCC(CC4)C(=O)OC)N)O)O DMD8QTC IK FLEVIENZILQUKB-DMJMAAGCSA-N DMD8QTC IU methyl 4-[3-[6-amino-9-[(2R,3R,4S,5S)-5-(ethylcarbamoyl)-3,4-dihydroxyoxolan-2-yl]purin-2-yl]prop-2-ynyl]cyclohexane-1-carboxylate DMD8QTC CA CAS 250386-15-3 DMD8QTC DE Coronary artery disease DMVY0BU ID DMVY0BU DMVY0BU DN Apaziquone DMVY0BU HS Phase 3 DMVY0BU SN EOquin; 114560-48-4; Apaziquonum; NOR-701; EO 9 (pharmaceutical); EO-9; Apaziquone [USAN:INN]; NSC-382459; Apaziquonum [INN-Latin]; E 09; NSC 382459; UNII-H464ZO600O; E-85/053; E-09; EO9; NSC 382456; H464ZO600O; 5-(Azridin-1-yl)-3-(hydroxymethyl)-2-((1E)-3-hydroxyprop-1-enyl)-methyl-1H-indole-4,7-dione; (E)-5-(1-Azirinyl)-3-(hydroxymethyl)-2-(3-hydroxy-1-propenyl)-1-methyl-1H-indole-4,7-dione; E09; 1H-Indole-4,7-dione, 5-(1-aziridinyl)-3-(hydroxymethyl)-2-(3-hydroxy-1-propenyl)-1-methyl-, (E)-; Neoquin; Qapzola; Apaziquonum; EO 9; Eoquin (TN); Apaziquone (USAN/INN); E-85/050; 3-hydroxymethyl-5-aziridinyl-1-methyl-2-(1H-indole-4,7-dione)prop-beta-en-alpha-ol; 5-(aziridin-1-yl)-3-(hydroxymethyl)-2-[(E)-3-hydroxyprop-1-enyl]-1-methylindole-4,7-dione; Apaziquone/EOquin DMVY0BU CP Spectrum DMVY0BU DT Small molecular drug DMVY0BU PC 5813717 DMVY0BU MW 288.3 DMVY0BU FM C15H16N2O4 DMVY0BU IC InChI=1S/C15H16N2O4/c1-16-10(3-2-6-18)9(8-19)13-14(16)12(20)7-11(15(13)21)17-4-5-17/h2-3,7,18-19H,4-6,8H2,1H3/b3-2+ DMVY0BU CS CN1C(=C(C2=C1C(=O)C=C(C2=O)N3CC3)CO)/C=C/CO DMVY0BU IK MXPOCMVWFLDDLZ-NSCUHMNNSA-N DMVY0BU IU 5-(aziridin-1-yl)-3-(hydroxymethyl)-2-[(E)-3-hydroxyprop-1-enyl]-1-methylindole-4,7-dione DMVY0BU CA CAS 114560-48-4 DMVY0BU DE Non-muscle invasive bladder cancer; Bladder cancer DMT0A3Y ID DMT0A3Y DMT0A3Y DN APD-334 DMT0A3Y HS Phase 3 DMT0A3Y SN S1P1 receptor agonists (autoimmune diseases), Arena Pharmaceuticals DMT0A3Y CP Arena Pharmaceuticals Inc DMT0A3Y PC 44623998 DMT0A3Y MW 457.5 DMT0A3Y FM C26H26F3NO3 DMT0A3Y IC InChI=1S/C26H26F3NO3/c27-26(28,29)22-11-15(5-8-19(22)16-3-1-2-4-16)14-33-18-7-10-23-21(13-18)20-9-6-17(12-24(31)32)25(20)30-23/h5,7-8,10-11,13,16-17,30H,1-4,6,9,12,14H2,(H,31,32)/t17-/m1/s1 DMT0A3Y CS C1CCC(C1)C2=C(C=C(C=C2)COC3=CC4=C(C=C3)NC5=C4CC[C@@H]5CC(=O)O)C(F)(F)F DMT0A3Y IK MVGWUTBTXDYMND-QGZVFWFLSA-N DMT0A3Y IU 2-[(3R)-7-[[4-cyclopentyl-3-(trifluoromethyl)phenyl]methoxy]-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]acetic acid DMT0A3Y CA CAS 1206123-37-6 DMT0A3Y DE Autoimmune diabetes; Pyoderma gangrenosum; Ulcerative colitis DM4HQ52 ID DM4HQ52 DM4HQ52 DN APL-2 DM4HQ52 HS Phase 3 DM4HQ52 CP Apellis Pharmaceuticals DM4HQ52 DE Paroxysmal nocturnal haemoglobinuria DMBRQF5 ID DMBRQF5 DMBRQF5 DN ApoC-III DMBRQF5 HS Phase 3 DM1K78U ID DM1K78U DM1K78U DN Apricitabine DM1K78U HS Phase 3 DM1K78U SN Apricitabine; 160707-69-7; AVX754; AVX 754; UNII-K1YX059ML1; BCH 10618; (-)-dOTC; (-)-BCH 10652; K1YX059ML1; AVX-754; SPD-754; BCH-10618; 4-amino-1-[(2R,4R)-2-(hydroxymethyl)-1,3-oxathiolan-4-yl]pyrimidin-2-one; 4-Amino-1-[(2R,4R)-2-(hydroxymethyl)-1,3-oxathiolan-4-yl]-2(1H)-pyrimidinone; BCH-10652; 2(1H)-Pyrimidinone, 4-amino-1-((2R,4R)-2-(hydroxymethyl)-1,3-oxathiolan-4-yl)-; 2(1H)-Pyrimidinone, 4-amino-1-(2-(hydroxymethyl)-1,3-oxathiolan-4-yl)-, (2R-cis)-; Apricitabine [INN]; SPD754; BCH-10619; SPD 754; AC1L9S1I; (+/-)dOTC DM1K78U DT Small molecular drug DM1K78U PC 455041 DM1K78U MW 229.26 DM1K78U FM C8H11N3O3S DM1K78U IC InChI=1S/C8H11N3O3S/c9-5-1-2-11(8(13)10-5)6-4-14-7(3-12)15-6/h1-2,6-7,12H,3-4H2,(H2,9,10,13)/t6-,7-/m1/s1 DM1K78U CS C1[C@@H](S[C@@H](O1)CO)N2C=CC(=NC2=O)N DM1K78U IK RYMCFYKJDVMSIR-RNFRBKRXSA-N DM1K78U IU 4-amino-1-[(2R,4R)-2-(hydroxymethyl)-1,3-oxathiolan-4-yl]pyrimidin-2-one DM1K78U CA CAS 160707-69-7 DM1K78U DE Human immunodeficiency virus infection DM2YQK8 ID DM2YQK8 DM2YQK8 DN AR-301 DM2YQK8 HS Phase 3 DM2YQK8 CP Aridis Pharmaceuticals DM2YQK8 DT Antibody DM2YQK8 DE Ventilator-associated pneumonia; Hospital-acquired pneumonia; Pneumonia DMZB9RI ID DMZB9RI DMZB9RI DN Arabaclofen DMZB9RI HS Phase 3 DMZB9RI DT Small molecular drug DMZB9RI DE Fragile X syndrome DMO628K ID DMO628K DMO628K DN Arbaclofen placarbil DMO628K HS Phase 3 DMO628K SN AP; R-baclofen - XenoPort; XP-19986 DMO628K CP Genentech DMO628K DT Small molecular drug DMO628K PC 11281011 DMO628K MW 399.9 DMO628K FM C19H26ClNO6 DMO628K IC InChI=1S/C19H26ClNO6/c1-11(2)17(24)26-18(12(3)4)27-19(25)21-10-14(9-16(22)23)13-5-7-15(20)8-6-13/h5-8,11-12,14,18H,9-10H2,1-4H3,(H,21,25)(H,22,23)/t14-,18-/m0/s1 DMO628K CS CC(C)[C@@H](OC(=O)C(C)C)OC(=O)NC[C@H](CC(=O)O)C1=CC=C(C=C1)Cl DMO628K IK JXTAALBWJQJLGN-KSSFIOAISA-N DMO628K IU (3R)-3-(4-chlorophenyl)-4-[[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino]butanoic acid DMO628K CA CAS 847353-30-4 DMO628K DE Fragile X syndrome; Alcohol dependence DMYNJHI ID DMYNJHI DMYNJHI DN Arc029 DMYNJHI HS Phase 3 DMYNJHI SN Nilvadipine; nilvadipine; 75530-68-6; Escor; Nivadil; Nivadipine; FR-34235; Nilvadipinum [Latin]; Nilvadipino [Spanish]; FR 34235; FK 235; Nilvadipine [USAN:INN:JAN]; Nilvadipine (ARC029); FK-235; F-102362; BRN 3572609; F 102,362; CL-287389; CL 287,389; FAIIFDPAEUKBEP-UHFFFAOYSA-N; C19H19N3O6; NCGC00167435-01; 5-Isopropyl 3-methyl 2-cyano-1,4-dihydro-6-methyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate; 3,5-Pyridinedicarboxylic acid, 2-cyano-1,4-dihydro-6-methyl-4-(3-nitrophenyl)-, 3-methyl 5-(1-methylethyl) ester; Nilvadipino; NILVADIPINE DMYNJHI CP Archer Pharmaceuticals DMYNJHI DT Small molecular drug DMYNJHI PC 4494 DMYNJHI MW 385.4 DMYNJHI FM C19H19N3O6 DMYNJHI IC InChI=1S/C19H19N3O6/c1-10(2)28-19(24)15-11(3)21-14(9-20)17(18(23)27-4)16(15)12-6-5-7-13(8-12)22(25)26/h5-8,10,16,21H,1-4H3 DMYNJHI CS CC1=C(C(C(=C(N1)C#N)C(=O)OC)C2=CC(=CC=C2)[N+](=O)[O-])C(=O)OC(C)C DMYNJHI IK FAIIFDPAEUKBEP-UHFFFAOYSA-N DMYNJHI IU 3-O-methyl 5-O-propan-2-yl 2-cyano-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate DMYNJHI CA CAS 75530-68-6 DMYNJHI CB CHEBI:31911 DMYNJHI DE Alzheimer disease DM180DM ID DM180DM DM180DM DN ARGX-113 DM180DM HS Phase 3 DM180DM CP Argenx DM180DM DT Small molecular drug DM180DM DE Myasthenia gravis DM84AD1 ID DM84AD1 DM84AD1 DN Arofylline DM84AD1 HS Phase 3 DM84AD1 SN Arofyllin; KM09088; Arofylline (USAN/INN); 3-(4-chlorophenyl)-1-propyl-3,7-dihydro-1H-purine-2,6-dione; 3-(4-chlorophenyl)-1-propyl-7H-purine-2,6-dione DM84AD1 CP Almiral Prodesfarma DM84AD1 DT Small molecular drug DM84AD1 PC 166553 DM84AD1 MW 304.73 DM84AD1 FM C14H13ClN4O2 DM84AD1 IC InChI=1S/C14H13ClN4O2/c1-2-7-18-13(20)11-12(17-8-16-11)19(14(18)21)10-5-3-9(15)4-6-10/h3-6,8H,2,7H2,1H3,(H,16,17) DM84AD1 CS CCCN1C(=O)C2=C(N=CN2)N(C1=O)C3=CC=C(C=C3)Cl DM84AD1 IK GVTLDPJNRVMCAL-UHFFFAOYSA-N DM84AD1 IU 3-(4-chlorophenyl)-1-propyl-7H-purine-2,6-dione DM84AD1 CA CAS 136145-07-8 DM84AD1 DE Chronic obstructive pulmonary disease DM02BVQ ID DM02BVQ DM02BVQ DN ARQ-087 DM02BVQ HS Phase 3 DM02BVQ CP ArQule Inc DM02BVQ PC 46834118 DM02BVQ MW 468.6 DM02BVQ FM C29H29FN4O DM02BVQ IC InChI=1S/C29H29FN4O/c1-35-16-15-31-14-13-20-7-6-8-22(17-20)33-29-32-19-21-18-26(24-10-4-5-12-27(24)30)23-9-2-3-11-25(23)28(21)34-29/h2-12,17,19,26,31H,13-16,18H2,1H3,(H,32,33,34)/t26-/m1/s1 DM02BVQ CS COCCNCCC1=CC(=CC=C1)NC2=NC=C3C[C@H](C4=CC=CC=C4C3=N2)C5=CC=CC=C5F DM02BVQ IK KPJDVVCDVBFRMU-AREMUKBSSA-N DM02BVQ IU (6R)-6-(2-fluorophenyl)-N-[3-[2-(2-methoxyethylamino)ethyl]phenyl]-5,6-dihydrobenzo[h]quinazolin-2-amine DM02BVQ CA CAS 1234356-69-4 DM02BVQ DE Solid tumour/cancer; Cholangiocarcinoma; Intrahepatic cholangiocarcinoma DML61S4 ID DML61S4 DML61S4 DN ARQ-151 DML61S4 HS Phase 3 DML61S4 CP Arcutis Biotherapeutics DML61S4 DT Small molecular drug DML61S4 DE Plaque psoriasis; Psoriasis vulgaris; Atopic dermatitis DMD7XWS ID DMD7XWS DMD7XWS DN AS-013 DMD7XWS HS Phase 3 DMD7XWS SN Circulase; Ecraprost; Prostaglandin E1 (liposomal), Mitsubishi Pharma/Asahi Glass DMD7XWS CP Taisho Pharmaceutical Co Ltd DMD7XWS DT Small molecular drug DMD7XWS PC 6917049 DMD7XWS MW 480.7 DMD7XWS FM C28H48O6 DMD7XWS IC InChI=1S/C28H48O6/c1-4-7-11-15-22(29)18-19-23-24(26(21-25(23)30)34-28(32)14-6-3)16-12-9-10-13-17-27(31)33-20-8-5-2/h18-19,22-23,25,29-30H,4-17,20-21H2,1-3H3/b19-18+/t22-,23+,25+/m0/s1 DMD7XWS CS CCCCC[C@@H](/C=C/[C@H]1[C@@H](CC(=C1CCCCCCC(=O)OCCCC)OC(=O)CCC)O)O DMD7XWS IK HITYEEHTEOQBAC-OSIGYOHNSA-N DMD7XWS IU butyl 7-[(4R,5R)-2-butanoyloxy-4-hydroxy-5-[(E,3S)-3-hydroxyoct-1-enyl]cyclopenten-1-yl]heptanoate DMD7XWS CA CAS 136892-64-3 DMD7XWS DE Thrombosis DMIV1WR ID DMIV1WR DMIV1WR DN AS-12141 DMIV1WR HS Phase 3 DMIV1WR SN D-GalNAc; GalNAc; N-Acetyl-D-Galactosamine; N-acetyl-galactosamine; N-Acetyl-Galactosamine; 14215-68-0; 2-Acetamido-2-Deoxy-D-Galactopyranose; 2-Acetamido-2-Deoxy-D-Galactopyranoside; 2-Acetamido-2-Deoxy-D-Galactose; 2-Acetamido-2-Deoxy-Galactopyranose; 2-Acetamido-2-Deoxy-Galactopyranoside; 2-Acetamido-2-Deoxy-Galactose; 2-Deoxy-2-Acetamido-D-Galactopyranose; 2-Deoxy-2-Acetamido-D-Galactopyranoside; 2-Deoxy-2-Acetamido-D-Galactose; 2-Deoxy-2-Acetamido-Galactopyranose; 2-Deoxy-2-Acetamido-Galactopyranoside; 2-Deoxy-2-Acetamido-Galactose DMIV1WR PC 35717 DMIV1WR MW 221.21 DMIV1WR FM C8H15NO6 DMIV1WR IC OVRNDRQMDRJTHS-KEWYIRBNSA-N DMIV1WR CS CC(=O)NC1C(C(C(OC1O)CO)O)O DMIV1WR IK 1S/C8H15NO6/c1-3(11)9-5-7(13)6(12)4(2-10)15-8(5)14/h4-8,10,12-14H,2H2,1H3,(H,9,11)/t4-,5-,6+,7-,8?/m1/s1 DMIV1WR IU N-[(3R,4R,5R,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide DMIV1WR CA CAS 1136-42-1 DMIV1WR CB CHEBI:28037 DMIV1WR DE Gaucher disease DMK09D4 ID DMK09D4 DMK09D4 DN ASC09 + ritonavir DMK09D4 HS Phase 3 DMK09D4 SN TMC-310911 + norvir; ASC09F DMK09D4 TC Antiviral Agents DMK09D4 DT Combination drug DMK09D4 DE Coronavirus Disease 2019 (COVID-19) DMWE3SC ID DMWE3SC DMWE3SC DN ASC09 + ritonavir + oseltamivir DMWE3SC HS Phase 3 DMWE3SC SN TMC-310911 + norvir + tamiflu DMWE3SC TC Antiviral Agents DMWE3SC DT Combination drug DMWE3SC DE Coronavirus Disease 2019 (COVID-19) DMND3AB ID DMND3AB DMND3AB DN Asimadoline DMND3AB HS Phase 3 DMND3AB SN Asimadoline [INN]; EMD 61753; N-[(1S)-2-[(3S)-3-hydroxypyrrolidin-1-yl]-1-phenylethyl]-N-methyl-2,2-diphenylacetamide DMND3AB CP Merck DMND3AB DT Small molecular drug DMND3AB PC 179340 DMND3AB MW 414.5 DMND3AB FM C27H30N2O2 DMND3AB IC InChI=1S/C27H30N2O2/c1-28(25(21-11-5-2-6-12-21)20-29-18-17-24(30)19-29)27(31)26(22-13-7-3-8-14-22)23-15-9-4-10-16-23/h2-16,24-26,30H,17-20H2,1H3/t24-,25+/m0/s1 DMND3AB CS CN([C@H](CN1CC[C@@H](C1)O)C2=CC=CC=C2)C(=O)C(C3=CC=CC=C3)C4=CC=CC=C4 DMND3AB IK JHLHNYVMZCADTC-LOSJGSFVSA-N DMND3AB IU N-[(1S)-2-[(3S)-3-hydroxypyrrolidin-1-yl]-1-phenylethyl]-N-methyl-2,2-diphenylacetamide DMND3AB CA CAS 153205-46-0 DMND3AB DE Diarrhea-predominant irritable bowel syndrome; Pruritus DMVA8KU ID DMVA8KU DMVA8KU DN ASP0113 DMVA8KU HS Phase 3 DMVA8KU SN VCL-CB01 DMVA8KU CP Astellas DMVA8KU DT Vaccine DMVA8KU DE Cytomegalovirus infection DMZ1UOI ID DMZ1UOI DMZ1UOI DN Asp-015K DMZ1UOI HS Phase 3 DMZ1UOI SN Peficitinib; ASP015K; UNII-HPH1166CKX; 944118-01-8; ASP-015K; HPH1166CKX; 4-[[(1R,3S)-5-hydroxy-2-adamantyl]amino]-1H-pyrrolo[2,3-b]pyridine-5-carboxamide; 4-[[(1S,3R)-5-oxidanyl-2-adamantyl]amino]-1H-pyrrolo[2,3-b]pyridine-5-carboxamide; Peficitinib [USAN:INN]; ASP 015K; JNJ-54781532; 9T6; Peficitinib (USAN/INN); SCHEMBL1154421; SCHEMBL9990248; SCHEMBL4447032; GTPL8315; SCHEMBL9990240; SCHEMBL1154418; CHEMBL3137308; SCHEMBL17645135; BCP18465; BDBM50124208; SB16834; DB11708; SC-17960; ASP015K; JNJ-54781532; D10653; Peficitinib pound A DMZ1UOI CP Astellas Pharma Inc DMZ1UOI DT Small molecular drug DMZ1UOI PC 57928403 DMZ1UOI MW 326.4 DMZ1UOI FM C18H22N4O2 DMZ1UOI IC InChI=1S/C18H22N4O2/c19-16(23)13-8-21-17-12(1-2-20-17)15(13)22-14-10-3-9-4-11(14)7-18(24,5-9)6-10/h1-2,8-11,14,24H,3-7H2,(H2,19,23)(H2,20,21,22)/t9?,10-,11+,14?,18? DMZ1UOI CS C1[C@@H]2CC3(C[C@@H](C2NC4=C5C=CNC5=NC=C4C(=O)N)CC1C3)O DMZ1UOI IK DREIJXJRTLTGJC-JQCLMNFQSA-N DMZ1UOI IU 4-[[(1S,3R)-5-hydroxy-2-adamantyl]amino]-1H-pyrrolo[2,3-b]pyridine-5-carboxamide DMZ1UOI CA CAS 944118-01-8 DMZ1UOI DE Psoriasis vulgaris; Rheumatoid arthritis DMR71ST ID DMR71ST DMR71ST DN ASP1929 DMR71ST HS Phase 3 DMR71ST SN Cetuximab sarotalocan DMR71ST CP Rakuten Medical DMR71ST DT Antibody DMR71ST DE Solid tumour/cancer; Head and neck cancer DMGQ1TV ID DMGQ1TV DMGQ1TV DN ASP1941 DMGQ1TV HS Phase 3 DMGQ1TV SN Ipragliflozin L-proline; 951382-34-6; UNII-M6N3GK48A4; Suglat (TN); Ipragliflozin (L-Proline); M6N3GK48A4; Ipragliflozin L-proline [JAN]; Ipragliflozin L-proline (JAN); Ipragliflozin mixture with proline; DTXSID20241771; EX-A2771; L-Proline compd. with (1S)-1,5-anhydro-1-C-[3-(benzo[b]thien-2-ylmethyl)-4-fluorophenyl]-D-glucitol (1:1); HY-14894A; AKOS027321043; L-Proline, compd. with (1S)-1,5-anhydro-1-C-(3-(benzo(b)thien-2-ylmethyl)-4-fluorophenyl)-D-glucitol (1:1); AK310367; DS-11639; AC-29892; CS-0019749; D10200 DMGQ1TV CP Astellas Pharma US DMGQ1TV DT Small molecular drug DMGQ1TV PC 10453870 DMGQ1TV MW 404.5 DMGQ1TV FM C21H21FO5S DMGQ1TV IC InChI=1S/C21H21FO5S/c22-15-6-5-12(21-20(26)19(25)18(24)16(10-23)27-21)7-13(15)9-14-8-11-3-1-2-4-17(11)28-14/h1-8,16,18-21,23-26H,9-10H2/t16-,18-,19+,20-,21+/m1/s1 DMGQ1TV CS C1=CC=C2C(=C1)C=C(S2)CC3=C(C=CC(=C3)[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)F DMGQ1TV IK AHFWIQIYAXSLBA-RQXATKFSSA-N DMGQ1TV IU (2S,3R,4R,5S,6R)-2-[3-(1-benzothiophen-2-ylmethyl)-4-fluorophenyl]-6-(hydroxymethyl)oxane-3,4,5-triol DMGQ1TV CA CAS 761423-87-4 DMGQ1TV CB CHEBI:134724 DMGQ1TV DE Liver disease DM5N1OB ID DM5N1OB DM5N1OB DN Asp-2151 DM5N1OB HS Phase 3 DM5N1OB SN Helicase-primase inhibitor (herpes infection), Astellas DM5N1OB CP Astellas Pharma Inc DM5N1OB DT Small molecular drug DM5N1OB PC 11397521 DM5N1OB MW 482.6 DM5N1OB FM C24H26N4O5S DM5N1OB IC InChI=1S/C24H26N4O5S/c1-16-4-3-5-17(2)22(16)28(24(30)19-10-12-34(31,32)13-11-19)14-21(29)26-20-8-6-18(7-9-20)23-25-15-33-27-23/h3-9,15,19H,10-14H2,1-2H3,(H,26,29) DM5N1OB CS CC1=C(C(=CC=C1)C)N(CC(=O)NC2=CC=C(C=C2)C3=NOC=N3)C(=O)C4CCS(=O)(=O)CC4 DM5N1OB IK MNHNIVNAFBSLLX-UHFFFAOYSA-N DM5N1OB IU N-(2,6-dimethylphenyl)-N-[2-[4-(1,2,4-oxadiazol-3-yl)anilino]-2-oxoethyl]-1,1-dioxothiane-4-carboxamide DM5N1OB CA CAS 841301-32-4 DM5N1OB DE Herpes simplex virus infection DMLY0H5 ID DMLY0H5 DMLY0H5 DN Astuprotimut-R DMLY0H5 HS Phase 3 DMLY0H5 CP GlaxoSmithKline DMLY0H5 DE Non-small-cell lung cancer DM4HK8Z ID DM4HK8Z DM4HK8Z DN ASTX727 DM4HK8Z HS Phase 3 DM4HK8Z CP Astex Pharmaceuticals Pleasanton, CA DM4HK8Z DE Chronic myelogenous leukaemia; Myelodysplastic syndrome DMRV4DT ID DMRV4DT DMRV4DT DN AT1001 DMRV4DT HS Phase 3 DMRV4DT SN Larazotide acetate; Larazotide acetate [USAN]; AT-1001; 881851-50-9; Larazotide acetate (USAN); UNII-FO8S2IW40N; AT 1001; FO8S2IW40N; CHEMBL2103815; NYGCNONRVCGHAT-UFIKZEAMSA-N; HY-106268A; CS-8047; D09352; Glycylglycyl-L-valyl-L-leucyl-L-valyl-L-glutaminyl-L-prolylglycine acetate; Glycine, glycylglycyl-L-valyl-L-leucyl-L-valyl-L-glutaminyl-L-prolyl-, monoacetate DMRV4DT DT Small molecular drug DMRV4DT PC 44146842 DMRV4DT MW 785.9 DMRV4DT FM C34H59N9O12 DMRV4DT IC InChI=1S/C32H55N9O10.C2H4O2/c1-16(2)12-20(38-30(49)26(17(3)4)39-24(44)14-35-23(43)13-33)28(47)40-27(18(5)6)31(50)37-19(9-10-22(34)42)32(51)41-11-7-8-21(41)29(48)36-15-25(45)46;1-2(3)4/h16-21,26-27H,7-15,33H2,1-6H3,(H2,34,42)(H,35,43)(H,36,48)(H,37,50)(H,38,49)(H,39,44)(H,40,47)(H,45,46);1H3,(H,3,4)/t19-,20-,21-,26-,27-;/m0./s1 DMRV4DT CS CC(C)C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N1CCC[C@H]1C(=O)NCC(=O)O)NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)CN.CC(=O)O DMRV4DT IK NYGCNONRVCGHAT-UFIKZEAMSA-N DMRV4DT IU acetic acid;2-[[(2S)-1-[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[(2-aminoacetyl)amino]acetyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-3-methylbutanoyl]amino]-5-oxopentanoyl]pyrrolidine-2-carbonyl]amino]acetic acid DMRV4DT CA CAS 881851-50-9 DMRV4DT DE Autoimmune diabetes DMVJW0S ID DMVJW0S DMVJW0S DN AT-406 DMVJW0S HS Phase 3 DMVJW0S SN 1071992-99-8; SM 406; (5S,8S,10aR)-N-benzhydryl-5-((S)-2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; CHEMBL2158051; QCR-136; UNII-N65WC8PXDD; N65WC8PXDD; AT406 (SM-406, ARRY-334543); J-501625; (5S,8S,10aR)-N-(Diphenylmethyl)-5-[(N-methyl-L-alanyl)amino]-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; AT-406/Debio-1143 DMVJW0S CP Ascenta Therapeutics; Debiopharm DMVJW0S DT Small molecular drug DMVJW0S PC 25022340 DMVJW0S MW 561.7 DMVJW0S FM C32H43N5O4 DMVJW0S IC InChI=1S/C32H43N5O4/c1-21(2)19-28(38)36-18-17-25-15-16-27(37(25)32(41)26(20-36)34-30(39)22(3)33-4)31(40)35-29(23-11-7-5-8-12-23)24-13-9-6-10-14-24/h5-14,21-22,25-27,29,33H,15-20H2,1-4H3,(H,34,39)(H,35,40)/t22-,25+,26-,27-/m0/s1 DMVJW0S CS C[C@@H](C(=O)N[C@H]1CN(CC[C@H]2CC[C@H](N2C1=O)C(=O)NC(C3=CC=CC=C3)C4=CC=CC=C4)C(=O)CC(C)C)NC DMVJW0S IK LSXUTRRVVSPWDZ-MKKUMYSQSA-N DMVJW0S IU (5S,8S,10aR)-N-benzhydryl-5-[[(2S)-2-(methylamino)propanoyl]amino]-3-(3-methylbutanoyl)-6-oxo-1,2,4,5,8,9,10,10a-octahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide DMVJW0S CA CAS 1071992-99-8 DMVJW0S DE Acute myeloid leukaemia; Lymphoma; Solid tumour/cancer; Squamous head and neck cell carcinom DMQ94CT ID DMQ94CT DMQ94CT DN AT9283 DMQ94CT HS Phase 3 DMQ94CT CP Astex Therape. DMQ94CT TC Anticancer Agents DMQ94CT DT Small molecular drug DMQ94CT PC 135398495 DMQ94CT MW 381.4 DMQ94CT FM C19H23N7O2 DMQ94CT IC InChI=1S/C19H23N7O2/c27-19(21-13-2-3-13)24-16-10-20-25-17(16)18-22-14-4-1-12(9-15(14)23-18)11-26-5-7-28-8-6-26/h1,4,9-10,13H,2-3,5-8,11H2,(H,20,25)(H,22,23)(H2,21,24,27) DMQ94CT CS C1CC1NC(=O)NC2=C(NN=C2)C3=NC4=C(N3)C=C(C=C4)CN5CCOCC5 DMQ94CT IK LOLPPWBBNUVNQZ-UHFFFAOYSA-N DMQ94CT IU 1-cyclopropyl-3-[5-[6-(morpholin-4-ylmethyl)-1H-benzimidazol-2-yl]-1H-pyrazol-4-yl]urea DMQ94CT CA CAS 896466-04-9 DMQ94CT CB CHEBI:125514 DMQ94CT DE Solid tumour/cancer DM8GFEV ID DM8GFEV DM8GFEV DN Atacicept DM8GFEV HS Phase 3 DM8GFEV CP ZymoGenetics; Serono DM8GFEV DE Multiple sclerosis; Rheumatoid arthritis; Lymphoma; Systemic lupus erythematosus; Lupus DM4GXW3 ID DM4GXW3 DM4GXW3 DN Ataluren DM4GXW3 HS Phase 3 DM4GXW3 SN Ataluren; 775304-57-9; PTC124; 3-(5-(2-fluorophenyl)-1,2,4-oxadiazol-3-yl)benzoic acid; PTC-124; 3-[5-(2-Fluorophenyl)-1,2,4-oxadiazol-3-yl]benzoic acid; PTC124 (Ataluren); PTC 124; UNII-K16AME9I3V; Ataluren (PTC124); K16AME9I3V; NCGC00168759-02; Translarna; AK-31904; Benzoic acid, 3-[5-(2-fluorophenyl)-1,2,4-oxadiazol-3-yl]-; DSSTox_CID_26776; DSSTox_RID_81895; DSSTox_GSID_46776; Benzoic acid, 3-(5-(2-fluorophenyl)-1,2,4-oxadiazol-3-yl)-; CAS-775304-57-9; Ataluren [USAN:INN]; Translarna (TN); PTC124,Ataluren; Ataluren(ptc124) DM4GXW3 CP Genzyme; PTC Therapeutics DM4GXW3 DT Small molecular drug DM4GXW3 PC 11219835 DM4GXW3 MW 284.24 DM4GXW3 FM C15H9FN2O3 DM4GXW3 IC InChI=1S/C15H9FN2O3/c16-12-7-2-1-6-11(12)14-17-13(18-21-14)9-4-3-5-10(8-9)15(19)20/h1-8H,(H,19,20) DM4GXW3 CS C1=CC=C(C(=C1)C2=NC(=NO2)C3=CC(=CC=C3)C(=O)O)F DM4GXW3 IK OOUGLTULBSNHNF-UHFFFAOYSA-N DM4GXW3 IU 3-[5-(2-fluorophenyl)-1,2,4-oxadiazol-3-yl]benzoic acid DM4GXW3 CA CAS 775304-57-9 DM4GXW3 CB CHEBI:94805 DM4GXW3 DE Aniridia; Cystic fibrosis; Mucopolysaccharidosis; Dravet syndrome; Duchenne dystrophy; Muscular dystrophy DM3QLK2 ID DM3QLK2 DM3QLK2 DN Atamestane + Toremifene DM3QLK2 HS Phase 3 DM3QLK2 SN Atamestane-plus-toremifene DM3QLK2 CP Intarcia Therapeutics DM3QLK2 DE Breast cancer DM4VJ5Q ID DM4VJ5Q DM4VJ5Q DN ATG-Fresenius S DM4VJ5Q HS Phase 3 DM4VJ5Q CP Enzon DM4VJ5Q DT Antibody DM4VJ5Q DE Transplant rejection DMBR0QK ID DMBR0QK DMBR0QK DN Atorvastatin DMBR0QK HS Phase 3 DMBR0QK SN atorvastatin; 134523-00-5; Cardyl; Xavator; Tozalip; Lipitor; Torvast; Sotis; ATORVASTATIN CALCIUM; Atorvastatin [INN:BAN]; 110862-48-1; UNII-A0JWA85V8F; CCRIS 7159; C33H35FN2O5; HSDB 7039; CI 981; Lipitor (TN); CHEMBL1487; A0JWA85V8F; CHEBI:39548; (betaR,deltaR)-2-(p-Fluorophenyl)-b; Atorvastatin DMBR0QK TC Antiviral Agents DMBR0QK DT Small molecular drug DMBR0QK PC 60823 DMBR0QK MW 558.6 DMBR0QK FM C33H35FN2O5 DMBR0QK IC InChI=1S/C33H35FN2O5/c1-21(2)31-30(33(41)35-25-11-7-4-8-12-25)29(22-9-5-3-6-10-22)32(23-13-15-24(34)16-14-23)36(31)18-17-26(37)19-27(38)20-28(39)40/h3-16,21,26-27,37-38H,17-20H2,1-2H3,(H,35,41)(H,39,40)/t26-,27-/m1/s1 DMBR0QK CS CC(C)C1=C(C(=C(N1CC[C@H](C[C@H](CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4 DMBR0QK IK XUKUURHRXDUEBC-KAYWLYCHSA-N DMBR0QK IU (3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid DMBR0QK CA CAS 134523-00-5 DMBR0QK CB CHEBI:39548 DMBR0QK DE Coronavirus Disease 2019 (COVID-19) DMM74PK ID DMM74PK DMM74PK DN Atrasentan DMM74PK HS Phase 3 DMM74PK SN Xinlay; Atrasentan [INN]; A 127722; A 147627; ABT 627; A-127722; A-147627; ABT-627; Xinlay (TN); A-127722.5; (+)-A 127722; (+)-A-127722; (11C)ABT-627; (2R,3R,4S)-4-(1,3-benzodioxol-5-yl)-1-[2-(dibutylamino)-2-oxoethyl]-2-(4-methoxyphenyl)pyrrolidine-3-carboxylic acid; 2-(4-methoxyphenyl)-4-(1,3-benzodioxol-5-yl)-1-(((dibutylamino)carbonyl)methyl)pyrrolidine-3-carboxylic acid; 2R-(4-methoxyphenyl)-4S(1,3-benzodioxol-5-yl)-1-(N,N-di(n-butyl)aminocarbonyl-methyl)-pyrrolidine-3R-carboxylic acid DMM74PK CP Abbott DMM74PK DT Small molecular drug DMM74PK PC 159594 DMM74PK MW 510.6 DMM74PK FM C29H38N2O6 DMM74PK IC InChI=1S/C29H38N2O6/c1-4-6-14-30(15-7-5-2)26(32)18-31-17-23(21-10-13-24-25(16-21)37-19-36-24)27(29(33)34)28(31)20-8-11-22(35-3)12-9-20/h8-13,16,23,27-28H,4-7,14-15,17-19H2,1-3H3,(H,33,34)/t23-,27-,28+/m1/s1 DMM74PK CS CCCCN(CCCC)C(=O)CN1C[C@@H]([C@H]([C@@H]1C2=CC=C(C=C2)OC)C(=O)O)C3=CC4=C(C=C3)OCO4 DMM74PK IK MOTJMGVDPWRKOC-QPVYNBJUSA-N DMM74PK IU (2R,3R,4S)-4-(1,3-benzodioxol-5-yl)-1-[2-(dibutylamino)-2-oxoethyl]-2-(4-methoxyphenyl)pyrrolidine-3-carboxylic acid DMM74PK CA CAS 173937-91-2 DMM74PK CB CHEBI:135810 DMM74PK DE Prostate cancer; Diabetic nephropathy DM64WYC ID DM64WYC DM64WYC DN Atx-101 DM64WYC HS Phase 3 DM64WYC SN ATX-101, APIM Therapeutics; Proliferating cell nuclear antigen (peptide, cancer), APIM DM64WYC CP Bayer HealthCare Pharmaceuticals DM64WYC PC 222528 DM64WYC MW 392.6 DM64WYC FM C24H40O4 DM64WYC IC InChI=1S/C24H40O4/c1-14(4-9-22(27)28)18-7-8-19-17-6-5-15-12-16(25)10-11-23(15,2)20(17)13-21(26)24(18,19)3/h14-21,25-26H,4-13H2,1-3H3,(H,27,28)/t14-,15-,16-,17+,18-,19+,20+,21+,23+,24-/m1/s1 DM64WYC CS C[C@H](CCC(=O)O)[C@H]1CC[C@@H]2[C@@]1([C@H](C[C@H]3[C@H]2CC[C@H]4[C@@]3(CC[C@H](C4)O)C)O)C DM64WYC IK KXGVEGMKQFWNSR-LLQZFEROSA-N DM64WYC IU (4R)-4-[(3R,5R,8R,9S,10S,12S,13R,14S,17R)-3,12-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid DM64WYC CA CAS 83-44-3 DM64WYC CB CHEBI:28834 DM64WYC DE Obesity DM0EQ9X ID DM0EQ9X DM0EQ9X DN Av 133 DM0EQ9X HS Phase 3 DM0EQ9X CP Avid Radiopharmaceuticals DM0EQ9X DE Alzheimer disease DMPW5UF ID DMPW5UF DMPW5UF DN Avalglucosidase alfa DMPW5UF HS Phase 3 DMPW5UF CP Sanofi DMPW5UF DT Recombinant protein DMPW5UF DE Pompe disease DMA86FL ID DMA86FL DMA86FL DN Avastin+/-Tarceva DMA86FL HS Phase 3 DMA86FL SN Juglone; juglone; 481-39-0; 5-Hydroxy-1,4-naphthoquinone; 5-Hydroxy-1,4-naphthalenedione; Regianin; Juglon; Nucin; 5-Hydroxynaphthalene-1,4-dione; Walnut extract; 5-Hydroxynaphthoquinone; Akhnot; Yuglon; 8-Hydroxy-1,4-naphthoquinone; CI Natural Brown 7; 1,4-NAPHTHALENEDIONE, 5-HYDROXY-; 5-Hydroxy-p-naphthoquinone; 1,4-Naphthoquinone, 5-hydroxy-; CI 75500; Juglane; Jugnlon; Iuglon; Caswell No 515AA; 1,4-Naphthoquinone, 8-hydroxy-; 5-Hydroxy-1,4-naphthosemiquinone; 5-Hydroxy-1,4-naftochinon; UNII-W6Q80SK9L6; NSC 622948; NSC 153189; CCRIS; JUGLONE DMA86FL CP Genentech DMA86FL DT Small molecular drug DMA86FL PC 3806 DMA86FL MW 174.15 DMA86FL FM C10H6O3 DMA86FL IC InChI=1S/C10H6O3/c11-7-4-5-9(13)10-6(7)2-1-3-8(10)12/h1-5,12H DMA86FL CS C1=CC2=C(C(=O)C=CC2=O)C(=C1)O DMA86FL IK KQPYUDDGWXQXHS-UHFFFAOYSA-N DMA86FL IU 5-hydroxynaphthalene-1,4-dione DMA86FL CA CAS 481-39-0 DMA86FL CB CHEBI:15794 DMA86FL DE Non-small-cell lung cancer; Nasopharyngeal carcinoma DMRJK3U ID DMRJK3U DMRJK3U DN Avotermin DMRJK3U HS Phase 3 DMRJK3U SN Juvista; RN-1001; SPD-538; TGF3, Renovo; RN-1, Renovo DMRJK3U CP Renovo, UK (Shire, UK) DMRJK3U DE Sarcoidosis DMV1SOR ID DMV1SOR DMV1SOR DN AVP-786 DMV1SOR HS Phase 3 DMV1SOR CP Avanir pharmaceuticals DMV1SOR PC 25052519 DMV1SOR MW 277.4 DMV1SOR FM C18H25NO DMV1SOR IC InChI=1S/C18H25NO/c1-19-10-9-18-8-4-3-5-15(18)17(19)11-13-6-7-14(20-2)12-16(13)18/h6-7,12,15,17H,3-5,8-11H2,1-2H3/t15-,17+,18+/m1/s1/i1D3,2D3 DMV1SOR CS [2H]C([2H])([2H])N1CC[C@@]23CCCC[C@@H]2[C@@H]1CC4=C3C=C(C=C4)OC([2H])([2H])[2H] DMV1SOR IK MKXZASYAUGDDCJ-QNNIAVNKSA-N DMV1SOR IU (1S,9S,10S)-4-(trideuteriomethoxy)-17-(trideuteriomethyl)-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-triene DMV1SOR CA CAS 1079043-55-2 DMV1SOR DE Pain; Alzheimer disease; Neurobehavioral disorder; Schizophrenia DM6WZG8 ID DM6WZG8 DM6WZG8 DN AXS-05 DM6WZG8 HS Phase 3 DM6WZG8 CP Axsome Therapeutics DM6WZG8 DT Small molecular drug DM6WZG8 DE Alzheimer disease; Depression DMM6G5D ID DMM6G5D DMM6G5D DN AZD0914 DMM6G5D HS Phase 3 DMM6G5D SN Zoliflodacin DMM6G5D CP Astrazeneca DMM6G5D PC 76685216 DMM6G5D MW 487.4 DMM6G5D FM C22H22FN5O7 DMM6G5D IC InChI=1S/C22H22FN5O7/c1-8-7-33-21(32)28(8)17-12-4-11-5-22(18(29)24-20(31)25-19(22)30)16-10(3)34-9(2)6-27(16)14(11)13(23)15(12)35-26-17/h4,8-10,16H,5-7H2,1-3H3,(H2,24,25,29,30,31)/t8-,9+,10-,16+/m0/s1 DMM6G5D CS C[C@@H]1CN2[C@H]([C@@H](O1)C)C3(CC4=CC5=C(C(=C42)F)ON=C5N6[C@H](COC6=O)C)C(=O)NC(=O)NC3=O DMM6G5D IK ZSWMIFNWDQEXDT-ZESJGQACSA-N DMM6G5D IU (4'R,6'S,7'S)-17'-fluoro-4',6'-dimethyl-13'-[(4S)-4-methyl-2-oxo-1,3-oxazolidin-3-yl]spiro[1,3-diazinane-5,8'-5,15-dioxa-2,14-diazatetracyclo[8.7.0.02,7.012,16]heptadeca-1(17),10,12(16),13-tetraene]-2,4,6-trione DMM6G5D CA CAS 1620458-09-4 DMM6G5D DE Bacterial infection; Neisseria gonorrhoeae infection DM9SKW8 ID DM9SKW8 DM9SKW8 DN AZD5363 DM9SKW8 HS Phase 3 DM9SKW8 SN AZD5363; 1143532-39-1; AZD-5363; capivasertib; AZD 5363; UNII-WFR23M21IE; WFR23M21IE; cc-638; 4-Amino-N-[(1s)-1-(4-Chlorophenyl)-3-Hydroxypropyl]-1-(7h-Pyrrolo[2,3-D]pyrimidin-4-Yl)piperidine-4-Carboxamide; C21H25ClN6O2; (S)-4-AMINO-N-(1-(4-CHLOROPHENYL)-3-HYDROXYPROPYL)-1-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)PIPERIDINE-4-CARBOXAMIDE; 4-Amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4-piperidinecarboxamide; 4-Piperidinecarboxamide, 4-amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1 DM9SKW8 CP Astex Pharmaceuticals DM9SKW8 DT Small molecular drug DM9SKW8 PC 25227436 DM9SKW8 MW 428.9 DM9SKW8 FM C21H25ClN6O2 DM9SKW8 IC InChI=1S/C21H25ClN6O2/c22-15-3-1-14(2-4-15)17(6-12-29)27-20(30)21(23)7-10-28(11-8-21)19-16-5-9-24-18(16)25-13-26-19/h1-5,9,13,17,29H,6-8,10-12,23H2,(H,27,30)(H,24,25,26)/t17-/m0/s1 DM9SKW8 CS C1CN(CCC1(C(=O)N[C@@H](CCO)C2=CC=C(C=C2)Cl)N)C3=NC=NC4=C3C=CN4 DM9SKW8 IK JDUBGYFRJFOXQC-KRWDZBQOSA-N DM9SKW8 IU 4-amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide DM9SKW8 CA CAS 1143532-39-1 DM9SKW8 DE Solid tumour/cancer; Triple negative breast cancer DMLY9F1 ID DMLY9F1 DMLY9F1 DN Azetirelin DMLY9F1 HS Phase 3 DMLY9F1 SN Azetirelin; YM-14673 (dihydrate); Nalpha-[(S)-2-Azetidinone-4-carbonyl]-L-histidyl-L-prolinamide DMLY9F1 DT Small molecular drug DMLY9F1 PC 65841 DMLY9F1 MW 348.36 DMLY9F1 FM C15H20N6O4 DMLY9F1 IC InChI=1S/C15H20N6O4/c16-13(23)11-2-1-3-21(11)15(25)10(4-8-6-17-7-18-8)20-14(24)9-5-12(22)19-9/h6-7,9-11H,1-5H2,(H2,16,23)(H,17,18)(H,19,22)(H,20,24)/t9-,10-,11-/m0/s1 DMLY9F1 CS C1C[C@H](N(C1)C(=O)[C@H](CC2=CN=CN2)NC(=O)[C@@H]3CC(=O)N3)C(=O)N DMLY9F1 IK WBGUMUGCONUXFK-DCAQKATOSA-N DMLY9F1 IU (2S)-1-[(2S)-3-(1H-imidazol-5-yl)-2-[[(2S)-4-oxoazetidine-2-carbonyl]amino]propanoyl]pyrrolidine-2-carboxamide DMLY9F1 CA CAS 95729-65-0 DMLY9F1 DE Pain DMUIBV8 ID DMUIBV8 DMUIBV8 DN Azimilide DMUIBV8 HS Phase 3 DMUIBV8 SN Azimilide [INN:BAN]; 1-({[5-(4-chlorophenyl)furan-2-yl]methylidene}amino)-3-[4-(4-methylpiperazin-1-yl)butyl]imidazolidine-2,4-dione DMUIBV8 CP Procter & Gamble DMUIBV8 DT Small molecular drug DMUIBV8 PC 9571004 DMUIBV8 MW 458 DMUIBV8 FM C23H28ClN5O3 DMUIBV8 IC InChI=1S/C23H28ClN5O3/c1-26-12-14-27(15-13-26)10-2-3-11-28-22(30)17-29(23(28)31)25-16-20-8-9-21(32-20)18-4-6-19(24)7-5-18/h4-9,16H,2-3,10-15,17H2,1H3/b25-16+ DMUIBV8 CS CN1CCN(CC1)CCCCN2C(=O)CN(C2=O)/N=C/C3=CC=C(O3)C4=CC=C(C=C4)Cl DMUIBV8 IK MREBEPTUUMTTIA-PCLIKHOPSA-N DMUIBV8 IU 1-[(E)-[5-(4-chlorophenyl)furan-2-yl]methylideneamino]-3-[4-(4-methylpiperazin-1-yl)butyl]imidazolidine-2,4-dione DMUIBV8 CA CAS 149908-53-2 DMUIBV8 CB CHEBI:34545 DMUIBV8 DE Atrial fibrillation DM5Y4Q2 ID DM5Y4Q2 DM5Y4Q2 DN Azithromycin + hydroxychloroquine DM5Y4Q2 HS Phase 3 DM5Y4Q2 SN Zithromax + oxichloroquine DM5Y4Q2 TC Antiviral Agents DM5Y4Q2 DT Combination drug DM5Y4Q2 DE Coronavirus Disease 2019 (COVID-19) DMPV6B2 ID DMPV6B2 DMPV6B2 DN BA-058 DMPV6B2 HS Phase 3 DMPV6B2 SN BA-058 Microneedle Patch; BA-058 (transdermal microneedle patch, osteoporosis); BA-058 (transdermal microneedle patch, osteoporosis), Radius Health DMPV6B2 CP Radius Health Inc DMPV6B2 DE Osteoporosis DMXBHR6 ID DMXBHR6 DMXBHR6 DN Balaglitazone DMXBHR6 HS Phase 3 DMXBHR6 SN DRF-2593; NN-2344; DRF-2593-307; NNC-61-0645 DMXBHR6 CP Dr Reddy's Research Foundation DMXBHR6 DT Small molecular drug DMXBHR6 PC 9889200 DMXBHR6 MW 395.4 DMXBHR6 FM C20H17N3O4S DMXBHR6 IC InChI=1S/C20H17N3O4S/c1-23-17(21-15-5-3-2-4-14(15)19(23)25)11-27-13-8-6-12(7-9-13)10-16-18(24)22-20(26)28-16/h2-9,16H,10-11H2,1H3,(H,22,24,26) DMXBHR6 CS CN1C(=NC2=CC=CC=C2C1=O)COC3=CC=C(C=C3)CC4C(=O)NC(=O)S4 DMXBHR6 IK IETKPTYAGKZLKY-UHFFFAOYSA-N DMXBHR6 IU 5-[[4-[(3-methyl-4-oxoquinazolin-2-yl)methoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione DMXBHR6 CA CAS 199113-98-9 DMXBHR6 DE Type-1 diabetes DMUOFAC ID DMUOFAC DMUOFAC DN Balixafortide DMUOFAC HS Phase 3 DMUOFAC SN 1051366-32-5; Balixafortide [INN]; UNII-PRC974M49B; PRC974M49B; Ala-cys-ser-ala-pro-arg-tyr-cys-tyr-gln-lys-pro-pro-tyr-his cyclic (2->9)-disulfide; Cyclo(L-alanyl-L-cysteinyl-L-seryl-L-alanyl-D-prolyl-(2S)-2,4-diaminobutanoyl-L-arginyl-L-tyrosyl-L-cysteinyl-L-tyrosyl-L-glutaminyl-L-lysyl-D-prolyl-L-prolyl-L-tyrosyl-L-histidyl), cyclic (2->9)-disulfide DMUOFAC CP Polyphor DMUOFAC DT Peptide DMUOFAC PC 91864511 DMUOFAC MW 1782 DMUOFAC FM C80H112N22O21S2 DMUOFAC IC InChI=1S/C80H112N22O21S2/c1-42(82)65(108)98-59-39-124-125-40-60(99-70(113)55(34-45-16-22-49(105)23-17-45)93-66(109)51(10-5-29-87-80(84)85)91-74(117)61-11-6-30-100(61)76(119)43(2)89-71(114)58(38-103)97-73(59)116)72(115)94-54(33-44-14-20-48(104)21-15-44)68(111)90-52(26-27-64(83)107)67(110)92-53(9-3-4-28-81)77(120)102-32-8-13-63(102)78(121)101-31-7-12-62(101)75(118)95-56(35-46-18-24-50(106)25-19-46)69(112)96-57(79(122)123)36-47-37-86-41-88-47/h14-25,37,41-43,51-63,103-106H,3-13,26-36,38-40,81-82H2,1-2H3,(H2,83,107)(H,86,88)(H,89,114)(H,90,111)(H,91,117)(H,92,110)(H,93,109)(H,94,115)(H,95,118)(H,96,112)(H,97,116)(H,98,108)(H,99,113)(H,122,123)(H4,84,85,87)/t42-,43-,51-,52-,53-,54-,55-,56-,57-,58-,59-,60-,61-,62-,63-/m0/s1 DMUOFAC CS C[C@H]1C(=O)N2CCC[C@H]2C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N1)CO)NC(=O)[C@H](C)N)C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCCN)C(=O)N4CCC[C@H]4C(=O)N5CCC[C@H]5C(=O)N[C@@H](CC6=CC=C(C=C6)O)C(=O)N[C@@H](CC7=CNC=N7)C(=O)O)CC8=CC=C(C=C8)O)CCCNC(=N)N DMUOFAC IK UUTLJGUXRVWOSI-YYXAXUJHSA-N DMUOFAC IU (2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-1-[(2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(3S,6S,9R,14R,17S,20S,23S)-9-[[(2S)-2-aminopropanoyl]amino]-20-(3-carbamimidamidopropyl)-6-(hydroxymethyl)-17-[(4-hydroxyphenyl)methyl]-3-methyl-2,5,8,16,19,22-hexaoxo-11,12-dithia-1,4,7,15,18,21-hexazabicyclo[21.3.0]hexacosane-14-carbonyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-5-oxopentanoyl]amino]hexanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-(1H-imidazol-4-yl)propanoic acid DMUOFAC DE Metastatic breast cancer DMKMTDG ID DMKMTDG DMKMTDG DN Balovaptan DMKMTDG HS Phase 3 DMKMTDG SN 1228088-30-9; UNII-RAX5D5AGV6; RG7314; RAX5D5AGV6; RO5285119; 8-chloro-5-methyl-1-(4-pyridin-2-yloxycyclohexyl)-4,6-dihydro-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine; 8-chloro-5-methyl-1-{trans-4-[(pyridin-2-yl)oxy]cyclohexyl}-5,6-dihydro-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine; Balovaptan [INN]; Balovaptan [USAN]; Balovaptan (USAN/INN); Balovaptan [USAN:INN]; SCHEMBL2471320; SCHEMBL3329710; SCHEMBL3332136; CHEMBL4297183; GTPL10615; compound 1 [PMID: 31951127]; DB14823; RG-7314; SB19643; Ro-5285119; BS-14780; HY-109024; CS-0030526; D11476; 12-chloro-8-methyl-3-[(1r,4r)-4-(pyridin-2-yloxy)cyclohexyl]-2,4,5,8-tetraazatricyclo[8.4.0.0,tetradeca-1(10),3,5,11,13-pentaene; 4H-(1,2,4)Triazolo(4,3-a)(1,4)benzodiazepine, 8-chloro-5,6-dihydro-5-methyl-1-(trans-4-(2-pyridinyloxy)cyclohexyl)-; 8-Chloro-5-methyl-1-(trans-4-(2-pyridinyloxy)cyclohexyl)-5,6-dihydro-4H-(1,2,4)triazolo(4,3-a)(1,4)benzodiazepine DMKMTDG CP Genentech DMKMTDG DT Small molecular drug DMKMTDG PC 46200932 DMKMTDG MW 409.9 DMKMTDG FM C22H24ClN5O DMKMTDG IC InChI=1S/C22H24ClN5O/c1-27-13-16-12-17(23)7-10-19(16)28-20(14-27)25-26-22(28)15-5-8-18(9-6-15)29-21-4-2-3-11-24-21/h2-4,7,10-12,15,18H,5-6,8-9,13-14H2,1H3 DMKMTDG CS CN1CC2=C(C=CC(=C2)Cl)N3C(=NN=C3C4CCC(CC4)OC5=CC=CC=N5)C1 DMKMTDG IK GMPZPHGHNDMRKL-UHFFFAOYSA-N DMKMTDG IU 8-chloro-5-methyl-1-(4-pyridin-2-yloxycyclohexyl)-4,6-dihydro-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine DMKMTDG CA CAS 1228088-30-9 DMKMTDG DE Autism spectrum disorder DMHQ5GK ID DMHQ5GK DMHQ5GK DN Bapineuzumab DMHQ5GK HS Phase 3 DMHQ5GK SN AAB-001; Monoclonal antibody (Alzheimer's disease), Elan/Pfizer; Monoclonal antibody (Alzheimer's disease), Elan/Wyeth; Monoclonal antibody (Alzheimer's disease), Wyeth/Elan DMHQ5GK CP Elan Corp plc DMHQ5GK DT Antibody DMHQ5GK DE Alzheimer disease DMODA2X ID DMODA2X DMODA2X DN Bardoxolone methyl DMODA2X HS Phase 3 DMODA2X SN BARD; WPTTVJLTNAWYAO-OYWPANLISA-N; 218600-53-4 DMODA2X CP Reata Pharmaceuticals Irving, TX DMODA2X DT Small molecular drug DMODA2X PC 400769 DMODA2X MW 505.7 DMODA2X FM C32H43NO4 DMODA2X IC InChI=1S/C32H43NO4/c1-27(2)11-13-32(26(36)37-8)14-12-31(7)24(20(32)17-27)21(34)15-23-29(5)16-19(18-33)25(35)28(3,4)22(29)9-10-30(23,31)6/h15-16,20,22,24H,9-14,17H2,1-8H3/t20-,22-,24-,29-,30+,31+,32-/m0/s1 DMODA2X CS C[C@@]12CC[C@]3(CCC(C[C@H]3[C@H]1C(=O)C=C4[C@]2(CC[C@@H]5[C@@]4(C=C(C(=O)C5(C)C)C#N)C)C)(C)C)C(=O)OC DMODA2X IK WPTTVJLTNAWYAO-KPOXMGGZSA-N DMODA2X IU methyl (4aS,6aR,6bS,8aR,12aS,14aR,14bS)-11-cyano-2,2,6a,6b,9,9,12a-heptamethyl-10,14-dioxo-1,3,4,5,6,7,8,8a,14a,14b-decahydropicene-4a-carboxylate DMODA2X CA CAS 218600-53-4 DMODA2X DE Mixed connective tissue disease; Pulmonary arterial hypertension; Pulmonary hypertension DMPRI14 ID DMPRI14 DMPRI14 DN Baricitinib DMPRI14 HS Phase 3 DMPRI14 SN Baricitinib (LY3009104, INCB028050); Baricitinib [USAN:INN]; C16H17N7O2S; INCB 028050; INCB-028050; INCB028050; ISP4442I3Y; J-503551; LY-3009104; LY3009104; Olumiant (TN); UNII-ISP4442I3Y; olumiant DMPRI14 CP Incyte/Eli Lilly DMPRI14 TC Antiviral Agents DMPRI14 DT Small molecular drug DMPRI14 PC 44205240 DMPRI14 MW 371.4 DMPRI14 FM C16H17N7O2S DMPRI14 IC InChI=1S/C16H17N7O2S/c1-2-26(24,25)22-9-16(10-22,4-5-17)23-8-12(7-21-23)14-13-3-6-18-15(13)20-11-19-14/h3,6-8,11H,2,4,9-10H2,1H3,(H,18,19,20) DMPRI14 CS CCS(=O)(=O)N1CC(C1)(CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3 DMPRI14 IK XUZMWHLSFXCVMG-UHFFFAOYSA-N DMPRI14 IU 2-[1-ethylsulfonyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile DMPRI14 CA CAS 1187594-09-7 DMPRI14 CB CHEBI:95341 DMPRI14 DE Asthma; Atopic dermatitis; Psoriatic arthritis; Rheumatoid arthritis; Systemic lupus erythematosus; Coronavirus Disease 2019 (COVID-19) DMB147A ID DMB147A DMB147A DN BAX-817 DMB147A HS Phase 3 DMB147A CP Baxter International Inc DMB147A DE Hemophilia DM407I6 ID DM407I6 DM407I6 DN BAY 853934 DM407I6 HS Phase 3 DM407I6 SN Molidustat; 1154028-82-6; BAY 85-3934; Molidustat (BAY85-3934); BAY85-3934; UNII-9JH486CZ13; Molidustat(BAY 85-3934); 9JH486CZ13; 2-(6-morpholin-4-ylpyrimidin-4-yl)-4-(triazol-1-yl)-1H-pyrazol-3-one; 3H-Pyrazol-3-one, 1,2-dihydro-2-[6-(4-morpholinyl)-4-pyrimidinyl]-4-(1H-1,2,3-triazol-1-yl)-; 2-(6-Morpholinopyrimidin-4-yl)-4-(1H-1,2,3-triazol-1-yl)-1H-pyrazol-3(2H)-one; 2-[6-(4-Morpholinyl)-4-pyrimidinyl]-4-(1H-1,2,3-triazol-1-yl)-1,2-dihydro-3H-pyrazol-3-one; 2-(6-morpholin-4-ylpyrimidin-4-yl)-4-(1,2,3-triazol-1-yl)pyrazol-3-ol; 2-(6-Morpholin-4-Ylpyrimidin-4-Yl)-4-(1,2,3-Triazol-1-Yl)-1~{h}-Pyrazol-3-One; Molidustat [INN]; Molidustat(BAY85-3934); Molidustat (BAY 85-3934); QEQ; GTPL8456; SCHEMBL2569970; SCHEMBL6114312; CHEMBL3646118; CHEMBL3991036; DTXSID80151089; EX-A562; BDBM118339; AOB87194; BCP14477; MFCD28411428; AKOS026750584; ZINC167006010; BAY-853934; CCG-267626; SB17156; NCGC00388364-04; AK323698; AS-74456; HY-12654; QC-11791; DB-092822; B5861; S8138; A14404; BAY 85-3934;BAY-85-3934; US8653111, 72; Q27087553; OC1=C(N2N=NC=C2)C=NN1C(N=CN=1)=CC=1N1CCOCC1; 1-(6-morpholinopyrimidin-4-yl)-4-(1H-1,2,3-triazol-1-yl)-1H-pyrazol-5-ol; Molidustat;BAY 85-3934;BAY-85-3934; BAY 853934; BAY-853934; BAY853934; 2-(6-(Morpholin-4-yl)pyrimidin-4-yl)-4-(1H-1,2,3-triazol-1-yl)-1,2-dihydro-3H-pyrazol-3-one; 2-(6-Morpholin-4-ylpyrimidin-4-yl)-4-(1H-1,2,3-triazol-1-yl)-1,2-dihydro-3H-pyrazol-3-one; 2-[6-(morpholin-4-yl)pyrimidin-4-yl]-4-(1H-1,2,3-triazol-1-yl)-2,3-dihydro-1H-pyrazol-3-one; A1H DM407I6 CP Bayer DM407I6 DT Small molecular drug DM407I6 PC 59603622 DM407I6 MW 314.3 DM407I6 FM C13H14N8O2 DM407I6 IC InChI=1S/C13H14N8O2/c22-13-10(20-2-1-16-18-20)8-17-21(13)12-7-11(14-9-15-12)19-3-5-23-6-4-19/h1-2,7-9,17H,3-6H2 DM407I6 CS C1COCCN1C2=NC=NC(=C2)N3C(=O)C(=CN3)N4C=CN=N4 DM407I6 IK IJMBOKOTALXLKS-UHFFFAOYSA-N DM407I6 IU 2-(6-morpholin-4-ylpyrimidin-4-yl)-4-(triazol-1-yl)-1H-pyrazol-3-one DM407I6 CA CAS 1154028-82-6 DM407I6 DE Anaemia DMPW5SB ID DMPW5SB DMPW5SB DN Bay 86-9766 DMPW5SB HS Phase 3 DMPW5SB SN 923032-37-5; RDEA119; BAY 869766; RDEA 119; UNII-JPX07AFM0N; RDEA-119; Refametinib (RDEA119, Bay 86-9766); JPX07AFM0N; (S)-N-(3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide; N-[3,4-difluoro-2-(2-fluoro-4-iodoanilino)-6-methoxyphenyl]-1-[(2S)-2,3-dihydroxypropyl]cyclopropane-1-sulfonamide; Refametinib [INN]; 923032-38-6; BAY-869766; BAY 8697661; 3e8n; Refametinib R enantiomer; Refametinib (RDEA119); SCHEMBL345333 DMPW5SB CP Ardea Biosciences DMPW5SB DT Small molecular drug DMPW5SB PC 44182295 DMPW5SB MW 572.3 DMPW5SB FM C19H20F3IN2O5S DMPW5SB IC InChI=1S/C19H20F3IN2O5S/c1-30-15-7-13(21)16(22)18(24-14-3-2-10(23)6-12(14)20)17(15)25-31(28,29)19(4-5-19)8-11(27)9-26/h2-3,6-7,11,24-27H,4-5,8-9H2,1H3/t11-/m0/s1 DMPW5SB CS COC1=CC(=C(C(=C1NS(=O)(=O)C2(CC2)C[C@@H](CO)O)NC3=C(C=C(C=C3)I)F)F)F DMPW5SB IK RDSACQWTXKSHJT-NSHDSACASA-N DMPW5SB IU N-[3,4-difluoro-2-(2-fluoro-4-iodoanilino)-6-methoxyphenyl]-1-[(2S)-2,3-dihydroxypropyl]cyclopropane-1-sulfonamide DMPW5SB CA CAS 923032-37-5 DMPW5SB DE Solid tumour/cancer DM09M3H ID DM09M3H DM09M3H DN BAY 94-9027 DM09M3H HS Phase 3 DM09M3H SN Peg rFVIII DM09M3H CP Bayer HealthCare Pharmaceuticals DM09M3H DE Stroke; Hemophilia DMWYPZF ID DMWYPZF DMWYPZF DN BAY-35-3377 DMWYPZF HS Phase 3 DMWYPZF SN BY-377; Gastroquinolone antibacterial, Altana; Gastroquinolone antibacterial, Bayer; Quinolone antibacterials, Bayer DMWYPZF CP Bayer AG DMWYPZF DT Small molecular drug DMWYPZF PC 11662028 DMWYPZF MW 434.8 DMWYPZF FM C20H20ClFN4O4 DMWYPZF IC InChI=1S/C20H19FN4O4.ClH/c21-14-5-11-17(25(10-1-2-10)7-13(19(11)26)20(27)28)12(6-22)18(14)24-8-15-16(9-24)29-4-3-23-15;/h5,7,10,15-16,23H,1-4,8-9H2,(H,27,28);1H/t15-,16-;/m0./s1 DMWYPZF CS C1CC1N2C=C(C(=O)C3=CC(=C(C(=C32)C#N)N4C[C@H]5[C@H](C4)OCCN5)F)C(=O)O.Cl DMWYPZF IK CQMSQUOHWYYEKM-MOGJOVFKSA-N DMWYPZF IU 7-[(4aS,7aS)-3,4,4a,5,7,7a-hexahydro-2H-pyrrolo[3,4-b][1,4]oxazin-6-yl]-8-cyano-1-cyclopropyl-6-fluoro-4-oxoquinoline-3-carboxylic acid;hydrochloride DMWYPZF CA CAS 209342-41-6 DMWYPZF DE Otitis media DMQG7ZM ID DMQG7ZM DMQG7ZM DN Belagenpumatucel-L DMQG7ZM HS Phase 3 DMQG7ZM SN Lucanix (TN) DMQG7ZM CP NovaRx DMQG7ZM DT Vaccine DMQG7ZM DE Small-cell lung cancer; Non-small-cell lung cancer DM71CK8 ID DM71CK8 DM71CK8 DN Beloranib DM71CK8 HS Phase 3 DM71CK8 SN 251111-30-5; CKD-732; UNII-FI471K8BU6; ZGN-433; FI471K8BU6; O-(4-(2-Dimethylaminoethoxy)-trans-cinnamoyl)fumagillol; Beloranib [INN]; ZGN 433; AC1OCFID; ZGN-440(Beloranib); US9682965, Compound A; GTPL8445; SCHEMBL14648763; DTXSID40179800; BDBM148430; ZINC3982162; AKOS027326543; DB12671; (3R,4S,5S,6R)-5-Methoxy-4-((2R,3R)-2-methyl-3-(3-methylbut-2-en-1-yl)oxiran-2-yl)-1-oxaspiro(25)octan-6-yl (2E)-3-(4-(2-(dimethylamino)ethoxy)phenyl)prop-2-enoate; O-(4-Dimethylaminoethoxycinnamoyl)fumagillol; CKD-731; Fumagillin analogs, Chong Kun Dang; HRK-429; HRK-512 DM71CK8 CP Zafgen DM71CK8 DT Small molecular drug DM71CK8 PC 6918502 DM71CK8 MW 499.6 DM71CK8 FM C29H41NO6 DM71CK8 IC InChI=1S/C29H41NO6/c1-20(2)7-13-24-28(3,36-24)27-26(32-6)23(15-16-29(27)19-34-29)35-25(31)14-10-21-8-11-22(12-9-21)33-18-17-30(4)5/h7-12,14,23-24,26-27H,13,15-19H2,1-6H3/b14-10+/t23-,24-,26-,27-,28+,29+/m1/s1 DM71CK8 CS CC(=CC[C@@H]1[C@@](O1)(C)[C@H]2[C@@H]([C@@H](CC[C@]23CO3)OC(=O)/C=C/C4=CC=C(C=C4)OCCN(C)C)OC)C DM71CK8 IK ZEZFKUBILQRZCK-MJSCXXSSSA-N DM71CK8 IU [(3R,4S,5S,6R)-5-methoxy-4-[(2R,3R)-2-methyl-3-(3-methylbut-2-enyl)oxiran-2-yl]-1-oxaspiro[2.5]octan-6-yl] (E)-3-[4-[2-(dimethylamino)ethoxy]phenyl]prop-2-enoate DM71CK8 CA CAS 251111-30-5 DM71CK8 DE Obesity; Solid tumour/cancer DMLU8NX ID DMLU8NX DMLU8NX DN Benserazide DMLU8NX HS Phase 3 DMLU8NX SN benserazide; Serazide; 322-35-0; Benseraszide; Benserazida; Benserazidum; Ro 4-4602; Ro 44602; DL-Serine 2-(2,3,4-trihydroxybenzyl)hydrazide; Benserazidum [INN-Latin]; Benserazida [INN-Spanish]; Benserazide [USAN:INN:BAN]; DL-Seryltrihydroxybenzylhydrazine; C10H15N3O5; BRN 3984490; DL-Serine, 2-((2,3,4-trihydroxyphenyl)methyl)hydrazide; CHEBI:64187; DL-Serine 2-((2,3,4-trihydroxyphenyl)methyl)hydrazide; Serine, 2-(2,3,4-trihydroxybenzyl)hyrazide, DL-; DL-serine 2-[(2,3,4-trihydroxyphenyl)methyl]hydrazide DMLU8NX DT Small molecular drug DMLU8NX PC 2327 DMLU8NX MW 257.24 DMLU8NX FM C10H15N3O5 DMLU8NX IC InChI=1S/C10H15N3O5/c11-6(4-14)10(18)13-12-3-5-1-2-7(15)9(17)8(5)16/h1-2,6,12,14-17H,3-4,11H2,(H,13,18) DMLU8NX CS C1=CC(=C(C(=C1CNNC(=O)C(CO)N)O)O)O DMLU8NX IK BNQDCRGUHNALGH-UHFFFAOYSA-N DMLU8NX IU 2-amino-3-hydroxy-N'-[(2,3,4-trihydroxyphenyl)methyl]propanehydrazide DMLU8NX CA CAS 322-35-0 DMLU8NX CB CHEBI:64187 DMS9503 ID DMS9503 DMS9503 DN Benzylpenicillin DMS9503 HS Phase 3 DMS9503 SN penicillin g; Benzylpenicillinic acid; Free penicillin II; Pencillin G; 61-33-6; Benzylpenicillin G; Bencilpenicilina; Benzylpenicillinum; Benzyl penicillin; Free penicillin G; Dropcillin; Pharmacillin; Gelacillin; Liquacillin; Benzopenicillin; Cilopen; Pradupen; Benzylpenicilline; Specilline G; Cilloral; Cosmopen; Ursopen; Galofak; Free benzylpenicillin; Compocillin G; Phenylacetamidopenicillanic acid; 6-(2-Phenylacetamido)penicillanic acid; Pfizerpen; Benzyl-6-aminopenicillinic acid DMS9503 DT Small molecular drug DMS9503 PC 5904 DMS9503 MW 334.4 DMS9503 FM C16H18N2O4S DMS9503 IC InChI=1S/C16H18N2O4S/c1-16(2)12(15(21)22)18-13(20)11(14(18)23-16)17-10(19)8-9-6-4-3-5-7-9/h3-7,11-12,14H,8H2,1-2H3,(H,17,19)(H,21,22)/t11-,12+,14-/m1/s1 DMS9503 CS CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)CC3=CC=CC=C3)C(=O)O)C DMS9503 IK JGSARLDLIJGVTE-MBNYWOFBSA-N DMS9503 IU (2S,5R,6R)-3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid DMS9503 CA CAS 61-33-6 DMS9503 CB CHEBI:18208 DM6RWBN ID DM6RWBN DM6RWBN DN Beperminogene perplasmid DM6RWBN HS Phase 3 DM6RWBN CP AnGes; Daiichi DM6RWBN DE Heart disease; Critical limb ischemia DMLVNTA ID DMLVNTA DMLVNTA DN Besipirdine DMLVNTA HS Phase 3 DMLVNTA SN Besipirdine hydrochloride; HP-749; P86-7480 DMLVNTA CP Hoechst Marion Roussel Inc DMLVNTA DT Small molecular drug DMLVNTA PC 60691 DMLVNTA MW 251.33 DMLVNTA FM C16H17N3 DMLVNTA IC InChI=1S/C16H17N3/c1-2-12-18(15-7-10-17-11-8-15)19-13-9-14-5-3-4-6-16(14)19/h3-11,13H,2,12H2,1H3 DMLVNTA CS CCCN(C1=CC=NC=C1)N2C=CC3=CC=CC=C32 DMLVNTA IK OTPPJICEBWOCKD-UHFFFAOYSA-N DMLVNTA IU N-propyl-N-pyridin-4-ylindol-1-amine DMLVNTA CA CAS 119257-34-0 DMLVNTA DE Cognitive impairment DM0MI81 ID DM0MI81 DM0MI81 DN Bevacizumab + Erlotinib DM0MI81 HS Phase 3 DM0MI81 CP Roche DM0MI81 DE Metastatic colorectal cancer; Non-small-cell lung cancer; Hypopharyngeal squamous cell carcinoma; Hepatocellular carcinoma DM9EXGI ID DM9EXGI DM9EXGI DN Bevacizumab + Rituximab DM9EXGI HS Phase 3 DM9EXGI CP Roche DM9EXGI DT Combination drug (Antibody) DM9EXGI PC 24801580 DM9EXGI MW 396.2 DM9EXGI FM C14H18ILiN2O3 DM9EXGI IC InChI=1S/C14H19IN2O3.Li/c1-3-17(4-2)8-7-16-13(18)10-5-6-11(14(19)20)12(15)9-10;/h5-6,9H,3-4,7-8H2,1-2H3,(H,16,18)(H,19,20);/q;+1/p-1 DM9EXGI CS [Li+].CCN(CC)CCNC(=O)C1=CC(=C(C=C1)C(=O)[O-])I DM9EXGI IK CNMYRBKJCDLCHB-UHFFFAOYSA-M DM9EXGI IU lithium;4-[2-(diethylamino)ethylcarbamoyl]-2-iodobenzoate DM9EXGI DE Non-hodgkin lymphoma; Lymphoma DM9CEI5 ID DM9CEI5 DM9CEI5 DN Bevacizumab + Trastuzumab DM9CEI5 HS Phase 3 DM9CEI5 SN Lithocholic acid; LITHOCHOLIC ACID; 434-13-9; Lithocolic acid; Lithocholate; 3alpha-Hydroxy-5beta-cholanic acid; 3alpha-Hydroxy-5beta-cholan-24-oic acid; 3-Hydroxycholan-24-oic acid; 3alpha-Hydroxycholanic acid; 3-alpha-Hydroxycholanic acid; 5beta-Cholanic acid-3alpha-ol; NCI-C03861; 3alpha-Hydroxy-5beta-cholanoic acid; (3alpha,5beta)-3-hydroxycholan-24-oic acid; 3-alpha-Hydroxy-5-beta-cholanic acid; CCRIS 363; UNII-5QU0I8393U; 3alpha-Hydroxy-5beta-cholanate; 5-beta-Cholanic acid, 3-alpha-hydroxy-; Cholan-24-oic acid, 3-hydroxy-, DM9CEI5 CP Roche DM9CEI5 DT Combination drug (Antibody) DM9CEI5 PC 9903 DM9CEI5 MW 376.6 DM9CEI5 FM C24H40O3 DM9CEI5 IC InChI=1S/C24H40O3/c1-15(4-9-22(26)27)19-7-8-20-18-6-5-16-14-17(25)10-12-23(16,2)21(18)11-13-24(19,20)3/h15-21,25H,4-14H2,1-3H3,(H,26,27)/t15-,16-,17-,18+,19-,20+,21+,23+,24-/m1/s1 DM9CEI5 CS C[C@H](CCC(=O)O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC[C@H]4[C@@]3(CC[C@H](C4)O)C)C DM9CEI5 IK SMEROWZSTRWXGI-HVATVPOCSA-N DM9CEI5 IU (4R)-4-[(3R,5R,8R,9S,10S,13R,14S,17R)-3-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid DM9CEI5 CA CAS 434-13-9 DM9CEI5 DE Breast cancer DMK56G0 ID DMK56G0 DMK56G0 DN Bexagliflozin DMK56G0 HS Phase 3 DMK56G0 SN UNII-EY00JF42FV; EGT-1442; Bexagliflozin [USAN]; THR-1442; EY00JF42FV; CHEMBL1808388; 1118567-05-7; Bexagliflozin (USAN); D-Glucitol, 1,5-anhydro-1-C-(4-chloro-3-((4-(2-(cyclopropyloxy)ethoxy)phenyl)methyl)phenyl)-, (1S)-; (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-(2-cyclopropoxyethoxy)benzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol; (1S)-1,5-Anhydro-1-C-[4-chloro-3-[[4-[2-(cyclopropyloxy)ethoxy]phenyl]methyl]phenyl]-D-glucitol; EGT1442; D-Glucitol, 1,5-anhydro-1-C-[4-chloro-3-[[4-[2-(cyclopropylo DMK56G0 CP Theracos Marlborough, MA DMK56G0 PC 25195624 DMK56G0 MW 464.9 DMK56G0 FM C24H29ClO7 DMK56G0 IC InChI=1S/C24H29ClO7/c25-19-8-3-15(24-23(29)22(28)21(27)20(13-26)32-24)12-16(19)11-14-1-4-17(5-2-14)30-9-10-31-18-6-7-18/h1-5,8,12,18,20-24,26-29H,6-7,9-11,13H2/t20-,21-,22+,23-,24+/m1/s1 DMK56G0 CS C1CC1OCCOC2=CC=C(C=C2)CC3=C(C=CC(=C3)[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)Cl DMK56G0 IK BTCRKOKVYTVOLU-SJSRKZJXSA-N DMK56G0 IU (2S,3R,4R,5S,6R)-2-[4-chloro-3-[[4-(2-cyclopropyloxyethoxy)phenyl]methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol DMK56G0 CA CAS 1118567-05-7 DMK56G0 DE Type-2 diabetes DM7NJYC ID DM7NJYC DM7NJYC DN BGB-A317 DM7NJYC HS Phase 3 DM7NJYC CP BeiGene Cambridge, MA DM7NJYC DE Hepatocellular carcinoma; Solid tumour/cancer; Squamous cell carcinoma DMNKBEC ID DMNKBEC DMNKBEC DN BGJ398 DMNKBEC HS Phase 3 DMNKBEC SN Infigratinib DMNKBEC DT Small molecular drug DMNKBEC PC 53235510 DMNKBEC MW 560.5 DMNKBEC FM C26H31Cl2N7O3 DMNKBEC IC InChI=1S/C26H31Cl2N7O3/c1-5-34-10-12-35(13-11-34)18-8-6-17(7-9-18)31-21-15-22(30-16-29-21)33(2)26(36)32-25-23(27)19(37-3)14-20(38-4)24(25)28/h6-9,14-16H,5,10-13H2,1-4H3,(H,32,36)(H,29,30,31) DMNKBEC CS CCN1CCN(CC1)C2=CC=C(C=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl DMNKBEC IK QADPYRIHXKWUSV-UHFFFAOYSA-N DMNKBEC IU 3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-[6-[4-(4-ethylpiperazin-1-yl)anilino]pyrimidin-4-yl]-1-methylurea DMNKBEC CA CAS 872511-34-7 DMNKBEC CB CHEBI:63451 DMNKBEC DE Solid tumour/cancer; Cholangiocarcinoma DM3MXT8 ID DM3MXT8 DM3MXT8 DN BI 201335 DM3MXT8 HS Phase 3 DM3MXT8 SN Faldaprevir; BI-201335; UNII-958X4J301A; CHEMBL1241348; 958X4J301A; N-[(Cyclopentyloxy)carbonyl]-3-Methyl-L-Valyl-(4r)-4-[(8-Bromo-7-Methoxy-2-{2-[(2-Methylpropanoyl)amino]-1,3-Thiazol-4-Yl}quinolin-4-Yl)oxy]-N-[(1r,2s)-1-Carboxy-2-Ethenylcyclopropyl]-L-Prolinamide; BI 201335; 801283-95-4; BI201335; Faldaprevir [USAN:INN]; SCHEMBL222429; BDBM50336545; SB16712; DB11808 DM3MXT8 CP Boehringer Ingelheim Pharma DM3MXT8 DT Small molecular drug DM3MXT8 PC 42601552 DM3MXT8 MW 869.8 DM3MXT8 FM C40H49BrN6O9S DM3MXT8 IC InChI=1S/C40H49BrN6O9S/c1-8-21-17-40(21,36(51)52)46-34(49)27-15-23(18-47(27)35(50)32(39(4,5)6)44-38(53)56-22-11-9-10-12-22)55-29-16-25(26-19-57-37(43-26)45-33(48)20(2)3)42-31-24(29)13-14-28(54-7)30(31)41/h8,13-14,16,19-23,27,32H,1,9-12,15,17-18H2,2-7H3,(H,44,53)(H,46,49)(H,51,52)(H,43,45,48)/t21-,23-,27+,32-,40-/m1/s1 DM3MXT8 CS CC(C)C(=O)NC1=NC(=CS1)C2=NC3=C(C=CC(=C3Br)OC)C(=C2)O[C@@H]4C[C@H](N(C4)C(=O)[C@H](C(C)(C)C)NC(=O)OC5CCCC5)C(=O)N[C@@]6(C[C@H]6C=C)C(=O)O DM3MXT8 IK LLGDPTDZOVKFDU-XUHJSTDZSA-N DM3MXT8 IU (1R,2S)-1-[[(2S,4R)-4-[8-bromo-7-methoxy-2-[2-(2-methylpropanoylamino)-1,3-thiazol-4-yl]quinolin-4-yl]oxy-1-[(2S)-2-(cyclopentyloxycarbonylamino)-3,3-dimethylbutanoyl]pyrrolidine-2-carbonyl]amino]-2-ethenylcyclopropane-1-carboxylic acid DM3MXT8 CA CAS 801283-95-4 DM3MXT8 DE Hepatitis C virus infection DMH3XDR ID DMH3XDR DMH3XDR DN BI 425809 DMH3XDR HS Phase 3 DMH3XDR CP Boehringer Ingelheim DMH3XDR DT Small molecular drug DMH3XDR DE Schizophrenia DMBH4FL ID DMBH4FL DMBH4FL DN BI 655066 DMBH4FL HS Phase 3 DMBH4FL CP Boehringer ingelheim pharmaceuticals DMBH4FL DT Antibody DMBH4FL DE Ankylosing spondylitis; Chronic plaque psoriasis; Crohn disease; Psoriatic arthritis DM42GP9 ID DM42GP9 DM42GP9 DN Bicifadine DM42GP9 HS Phase 3 DM42GP9 SN BICIFADINE; 71195-57-8; 1-(4-methylphenyl)-3-azabicyclo[3.1.0]hexane; 1-(p-Tolyl)-3-azabicyclo[3.1.0]hexane; 1-p-tolyl-3-azabicyclo[3.1.0]hexane; 5-(4-methylphenyl)-3-azabicyclo[3.1.0]hexane; 3-Azabicyclo[3.1.0]hexane, 1-(4-methylphenyl)-; CL-220075; PubChem18323; AC1L2J2O; SCHEMBL38793; AZA001; CHEMBL511099; OFYVIGTWSQPCLF-UHFFFAOYSA-N; NIH-9542; MCV-4147; BDBM50417944; AKOS006271730; DOV-220075; AN-3206; DB04889; KB-13207; 5-(p-tolyl)-3-azabicyclo[3.1.0]hexane; AM20041063; FT-0718156; 1-(p-tolyl)-3-azabicyclo[3.1.0]-hexane DM42GP9 CP Dov Pharmaceutical DM42GP9 TC Analgesics DM42GP9 DT Small molecular drug DM42GP9 PC 47953 DM42GP9 MW 173.25 DM42GP9 FM C12H15N DM42GP9 IC InChI=1S/C12H15N/c1-9-2-4-10(5-3-9)12-6-11(12)7-13-8-12/h2-5,11,13H,6-8H2,1H3 DM42GP9 CS CC1=CC=C(C=C1)C23CC2CNC3 DM42GP9 IK OFYVIGTWSQPCLF-UHFFFAOYSA-N DM42GP9 IU 1-(4-methylphenyl)-3-azabicyclo[3.1.0]hexane DM42GP9 CA CAS 71195-57-8 DM42GP9 DE Neuropathic pain; Chronic low back pain DM57B9J ID DM57B9J DM57B9J DN Biferonex DM57B9J HS Phase 3 DM57B9J SN Beneferon; Beneserin; Interferon beta 1a, BioPartners; Interferon beta 1a, Rentschler/Berlex/Schering; Beta-interferon (1a), Schering/Dr Rentschler DM57B9J CP Dr Rentschler Biotechnologie GmbH DM57B9J DE Multiple sclerosis DM51JW4 ID DM51JW4 DM51JW4 DN BIIB037 DM51JW4 HS Phase 3 DM51JW4 CP Biogen Idec DM51JW4 DE Alzheimer disease DM0AEDT ID DM0AEDT DM0AEDT DN BIIB067 DM0AEDT HS Phase 3 DM0AEDT SN IONIS-SOD1RX; Tofersen DM0AEDT CP Ionis Pharmaceuticals DM0AEDT DT Antisense oligonucleotide DM0AEDT DE Amyotrophic lateral sclerosis DMR9TF1 ID DMR9TF1 DMR9TF1 DN Bimekizumab DMR9TF1 HS Phase 3 DMR9TF1 CP UCB Atlanta, GA DMR9TF1 DE Psoriatic arthritis; Plaque psoriasis DMS2GA1 ID DMS2GA1 DMS2GA1 DN Bindarit DMS2GA1 HS Phase 3 DMS2GA1 SN Bindarit, Angelini Pharmaceuticals; CCL2 inhibitor (inflammatory disorders/kidney disease), Angelini Pharmaceuticals; MCP-1 inhibitor (inflammatory disorder/kidney disease), Angelini Pharmaceuticals DMS2GA1 CP Angelini Pharmaceuticals SpA DMS2GA1 DT Small molecular drug DMS2GA1 PC 71354 DMS2GA1 MW 324.4 DMS2GA1 FM C19H20N2O3 DMS2GA1 IC InChI=1S/C19H20N2O3/c1-19(2,18(22)23)24-13-16-15-10-6-7-11-17(15)21(20-16)12-14-8-4-3-5-9-14/h3-11H,12-13H2,1-2H3,(H,22,23) DMS2GA1 CS CC(C)(C(=O)O)OCC1=NN(C2=CC=CC=C21)CC3=CC=CC=C3 DMS2GA1 IK MTHORRSSURHQPZ-UHFFFAOYSA-N DMS2GA1 IU 2-[(1-benzylindazol-3-yl)methoxy]-2-methylpropanoic acid DMS2GA1 CA CAS 130641-38-2 DMS2GA1 DE Nephritis DMVHF8G ID DMVHF8G DMVHF8G DN Binodenoson DMVHF8G HS Phase 3 DMVHF8G SN CorVue; MRE-0470; MRE-0479; MRE-470; SHA-174; WRC-0470 DMVHF8G CP Aderis Pharmaceuticals Inc DMVHF8G DT Small molecular drug DMVHF8G PC 9576912 DMVHF8G MW 391.4 DMVHF8G FM C17H25N7O4 DMVHF8G IC InChI=1S/C17H25N7O4/c18-14-11-15(22-17(21-14)23-20-6-9-4-2-1-3-5-9)24(8-19-11)16-13(27)12(26)10(7-25)28-16/h6,8-10,12-13,16,25-27H,1-5,7H2,(H3,18,21,22,23)/b20-6+/t10-,12-,13-,16-/m1/s1 DMVHF8G CS C1CCC(CC1)/C=N/NC2=NC(=C3C(=N2)N(C=N3)[C@H]4[C@@H]([C@@H]([C@H](O4)CO)O)O)N DMVHF8G IK XJFMHMFFBSOEPR-DNZQAUTHSA-N DMVHF8G IU (2R,3R,4S,5R)-2-[6-amino-2-[(2E)-2-(cyclohexylmethylidene)hydrazinyl]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol DMVHF8G CA CAS 144348-08-3 DMVHF8G DE Hypertension DME76AP ID DME76AP DME76AP DN Bis(olanzapine) pamoate monohydrate DME76AP HS Phase 3 DME76AP SN Bis[2-methyl-4-(4-methylpiperazin-1-yl)-10H-thieno[2,3-b][1,5]benzodiazepine] 4,4'-methylenebis(3-hydroxynaphthalen-2-carboxylic acid) salt monohydrate DME76AP DE Psychotic disorder DMW34B1 ID DMW34B1 DMW34B1 DN BL-8040 DMW34B1 HS Phase 3 DMW34B1 CP BioLineRx DMW34B1 DT Peptide DMW34B1 PC 91865076 DMW34B1 MW 2159.5 DMW34B1 FM C97H144FN33O19S2 DMW34B1 IC InChI=1S/C97H144FN33O19S2/c98-60-33-31-58(32-34-60)78(135)119-65(19-8-42-113-93(104)105)79(136)121-68(21-10-44-115-95(108)109)83(140)126-73(51-56-25-30-57-14-1-2-15-59(57)48-56)87(144)130-75-53-152-151-52-74(88(145)118-63(77(101)134)18-7-41-112-92(102)103)129-84(141)69(23-12-46-117-97(111)150)122-81(138)66(20-9-43-114-94(106)107)124-86(143)72(50-55-28-37-62(133)38-29-55)128-90(147)76-24-13-47-131(76)91(148)70(17-4-6-40-100)125-82(139)64(16-3-5-39-99)120-80(137)67(22-11-45-116-96(110)149)123-85(142)71(127-89(75)146)49-54-26-35-61(132)36-27-54/h1-2,14-15,25-38,48,63-76,132-133H,3-13,16-24,39-47,49-53,99-100H2,(H2,101,134)(H,118,145)(H,119,135)(H,120,137)(H,121,136)(H,122,138)(H,123,142)(H,124,143)(H,125,139)(H,126,140)(H,127,146)(H,128,147)(H,129,141)(H,130,144)(H4,102,103,112)(H4,104,105,113)(H4,106,107,114)(H4,108,109,115)(H3,110,116,149)(H3,111,117,150)/t63-,64-,65-,66-,67-,68-,69-,70-,71-,72-,73-,74-,75-,76-/m0/s1 DMW34B1 CS C1C[C@H]2C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2C1)CCCCN)CCCCN)CCCNC(=O)N)CC3=CC=C(C=C3)O)NC(=O)[C@H](CC4=CC5=CC=CC=C5C=C4)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)C6=CC=C(C=C6)F)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N)CCCNC(=O)N)CCCNC(=N)N)CC7=CC=C(C=C7)O DMW34B1 IK JJVZSYKFCOBILL-MKMRYRNGSA-N DMW34B1 IU (3S,6S,9S,12S,15R,20R,23S,26S,29S,32S)-3,6-bis(4-aminobutyl)-N-[(2S)-1-amino-5-carbamimidamido-1-oxopentan-2-yl]-15-[[(2S)-2-[[(2S)-5-carbamimidamido-2-[[(2S)-5-carbamimidamido-2-[(4-fluorobenzoyl)amino]pentanoyl]amino]pentanoyl]amino]-3-naphthalen-2-ylpropanoyl]amino]-26-(3-carbamimidamidopropyl)-9,23-bis[3-(carbamoylamino)propyl]-12,29-bis[(4-hydroxyphenyl)methyl]-2,5,8,11,14,22,25,28,31-nonaoxo-17,18-dithia-1,4,7,10,13,21,24,27,30-nonazabicyclo[30.3.0]pentatriacontane-20-carboxamide DMW34B1 CA CAS 664334-36-5 DMW34B1 CB CHEBI:145536 DMW34B1 DE Acute myeloid leukaemia; Pancreatic cancer; Myelodysplastic syndrome; Multiple myeloma DM7V9LH ID DM7V9LH DM7V9LH DN Blisibimod DM7V9LH HS Phase 3 DM7V9LH CP Anthera Pharmaceuticals Hayward, CA DM7V9LH DE Systemic lupus erythematosus DM36C17 ID DM36C17 DM36C17 DN Blonanserin DM36C17 HS Phase 3 DM36C17 SN Lonasen; Blonanserin [INN]; AD 5423; AD-5423; Blonanserin (JAN/INN); 2-(4-Ethyl-1-piperazinyl)-4-(4-fluorophenyl)-5,6,7,8,9,10-hexahydrocycloocta(b)pyridine; 2-(4-Ethyl-1-piperazinyl)-4-(p-fluorophenyl)-5,6,7,8,9,10-hexahydrocycloocta(b)pyridine; 2-(4-ethylpiperazin-1-yl)-4-(4-fluorophenyl)-5,6,7,8,9,10-hexahydrocycloocta[b]pyridine DM36C17 CP Dainippon DM36C17 DT Small molecular drug DM36C17 PC 125564 DM36C17 MW 367.5 DM36C17 FM C23H30FN3 DM36C17 IC InChI=1S/C23H30FN3/c1-2-26-13-15-27(16-14-26)23-17-21(18-9-11-19(24)12-10-18)20-7-5-3-4-6-8-22(20)25-23/h9-12,17H,2-8,13-16H2,1H3 DM36C17 CS CCN1CCN(CC1)C2=NC3=C(CCCCCC3)C(=C2)C4=CC=C(C=C4)F DM36C17 IK XVGOZDAJGBALKS-UHFFFAOYSA-N DM36C17 IU 2-(4-ethylpiperazin-1-yl)-4-(4-fluorophenyl)-5,6,7,8,9,10-hexahydrocycloocta[b]pyridine DM36C17 CA CAS 132810-10-7 DM36C17 CB CHEBI:31296 DM36C17 DE Schizophrenia DMBXR23 ID DMBXR23 DMBXR23 DN BMN-110 DMBXR23 HS Phase 3 DMBXR23 SN Enzyme replacement therapy (iv infusion, MPS IVA), BioMarin; Enzyme replacement therapy (iv infusion, Morquio A syndrome), BioMarin; Enzyme replacement therapy (iv infusion, mucopolysaccharidosis IVA), BioMarin; N-acetylgalactosamine-6-sulfatase (GALNS) (Morquio A syndrome), BioMarin DMBXR23 CP Biomarin pharmaceutical DMBXR23 DE Morquio syndrome DMM9XL2 ID DMM9XL2 DMM9XL2 DN BMN-111 DMM9XL2 HS Phase 3 DMM9XL2 SN C-type natriuretic peptide analog (achondroplasia), BioMarin DMM9XL2 CP Biomarin pharmaceutical DMM9XL2 PC 119058036 DMM9XL2 MW 4103 DMM9XL2 FM C176H290N56O51S3 DMM9XL2 IC InChI=1S/C176H290N56O51S3/c1-14-95(10)143-172(280)201-84-138(245)209-125(86-234)168(276)221-113(54-65-284-13)159(267)229-124(85-233)152(260)200-81-135(242)206-114(66-91(2)3)150(258)198-83-140(247)211-128(174(282)283)89-286-285-88-127(170(278)224-118(70-98-34-16-15-17-35-98)151(259)199-80-137(244)207-115(67-92(4)5)162(270)217-108(41-23-29-60-182)155(263)223-117(69-94(8)9)164(272)226-122(75-142(250)251)167(275)219-110(160(268)231-143)44-32-63-193-176(188)189)210-139(246)82-197-149(257)105(38-20-26-57-179)215-169(277)126(87-235)230-163(271)116(68-93(6)7)208-136(243)79-196-147(255)103(36-18-24-55-177)213-153(261)106(39-21-27-58-180)218-166(274)121(74-132(185)239)222-144(252)96(11)203-133(240)77-195-148(256)104(37-19-25-56-178)214-165(273)119(71-99-46-48-101(236)49-47-99)225-156(264)107(40-22-28-59-181)216-154(262)109(43-31-62-192-175(186)187)212-145(253)97(12)204-161(269)120(73-131(184)238)227-171(279)129-45-33-64-232(129)173(281)123(72-100-76-190-90-202-100)228-158(266)112(51-53-141(248)249)220-157(265)111(50-52-130(183)237)205-134(241)78-194-146(254)102-42-30-61-191-102/h15-17,34-35,46-49,76,90-97,102-129,143,191,233-236H,14,18-33,36-45,50-75,77-89,177-182H2,1-13H3,(H2,183,237)(H2,184,238)(H2,185,239)(H,190,202)(H,194,254)(H,195,256)(H,196,255)(H,197,257)(H,198,258)(H,199,259)(H,200,260)(H,201,280)(H,203,240)(H,204,269)(H,205,241)(H,206,242)(H,207,244)(H,208,243)(H,209,245)(H,210,246)(H,211,247)(H,212,253)(H,213,261)(H,214,273)(H,215,277)(H,216,262)(H,217,270)(H,218,274)(H,219,275)(H,220,265)(H,221,276)(H,222,252)(H,223,263)(H,224,278)(H,225,264)(H,226,272)(H,227,279)(H,228,266)(H,229,267)(H,230,271)(H,231,268)(H,248,249)(H,250,251)(H,282,283)(H4,186,187,192)(H4,188,189,193)/t95-,96-,97-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,127-,128-,129-,143-/m0/s1 DMM9XL2 CS CC[C@H](C)[C@H]1C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CCCNC(=N)N)CC(=O)O)CC(C)C)CCCCN)CC(C)C)CC2=CC=CC=C2)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@H](CC3=CC=C(C=C3)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)N)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CC5=CN=CN5)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)CNC(=O)[C@@H]6CCCN6)C(=O)O)CC(C)C)CO)CCSC)CO DMM9XL2 IK IGYWDDBBJPSOTG-WBAGYEQSSA-N DMM9XL2 IU (4R,10S,16S,19S,22S,28S,31S,34S,37S,40S,43S,49S,52R)-52-[[2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-6-amino-2-[[(2S)-6-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-5-amino-5-oxo-2-[[2-[[(2S)-pyrrolidine-2-carbonyl]amino]acetyl]amino]pentanoyl]amino]-4-carboxybutanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]pyrrolidine-2-carbonyl]amino]-4-oxobutanoyl]amino]propanoyl]amino]-5-carbamimidamidopentanoyl]amino]hexanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]hexanoyl]amino]acetyl]amino]propanoyl]amino]-4-oxobutanoyl]amino]hexanoyl]amino]hexanoyl]amino]acetyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]acetyl]amino]-40-(4-aminobutyl)-49-benzyl-28-[(2S)-butan-2-yl]-31-(3-carbamimidamidopropyl)-34-(carboxymethyl)-16,22-bis(hydroxymethyl)-10,37,43-tris(2-methylpropyl)-19-(2-methylsulfanylethyl)-6,9,12,15,18,21,24,27,30,33,36,39,42,45,48,51-hexadecaoxo-1,2-dithia-5,8,11,14,17,20,23,26,29,32,35,38,41,44,47,50-hexadecazacyclotripentacontane-4-carboxylic acid DMM9XL2 CA CAS 1480724-61-5 DMM9XL2 DE Achondroplasia DM94Y6O ID DM94Y6O DM94Y6O DN BMN-701 DM94Y6O HS Phase 3 DM94Y6O SN IGF2-GAA; XC-701; ZC-701; Enzyme replacement therapy (GILT, Pompe disease), BioMarin/ZyStor DM94Y6O CP Biomarin pharmaceutical DM94Y6O DE Pompe disease; Type 2 glycogen storage disease DMDAN8H ID DMDAN8H DMDAN8H DN BMS-582664 DMDAN8H HS Phase 3 DMDAN8H SN Brivanib alaninate; BMS 582664; BMS582664; BMS-582664, Brivanib alaninate; Brivanib alaninate (INN/USAN); L-Alanine, (1R)-2-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-5-methylpyrrolo(2,1-f)(1,2,4)triazin-6-yl)oxy)-1-methylethyl ester DMDAN8H CP Bristol Myers Squibb DMDAN8H TC Anticancer Agents DMDAN8H DT Small molecular drug DMDAN8H PC 11154925 DMDAN8H MW 441.5 DMDAN8H FM C22H24FN5O4 DMDAN8H IC InChI=1S/C22H24FN5O4/c1-11-7-15-16(27-11)5-6-17(19(15)23)32-21-20-13(3)18(8-28(20)26-10-25-21)30-9-12(2)31-22(29)14(4)24/h5-8,10,12,14,27H,9,24H2,1-4H3/t12-,14+/m1/s1 DMDAN8H CS CC1=CC2=C(N1)C=CC(=C2F)OC3=NC=NN4C3=C(C(=C4)OC[C@@H](C)OC(=O)[C@H](C)N)C DMDAN8H IK LTEJRLHKIYCEOX-OCCSQVGLSA-N DMDAN8H IU [(2R)-1-[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxypropan-2-yl] (2S)-2-aminopropanoate DMDAN8H CA CAS 649735-63-7 DMDAN8H DE Hepatocellular carcinoma DMAR1YS ID DMAR1YS DMAR1YS DN BMS-986165 DMAR1YS HS Phase 3 DMAR1YS CP Bristol-Myers Squibb Princeton, NJ DMAR1YS PC 134821691 DMAR1YS MW 425.5 DMAR1YS FM C20H22N8O3 DMAR1YS IC InChI=1S/C20H22N8O3/c1-21-20(30)16-14(9-15(25-26-16)24-19(29)11-7-8-11)23-13-6-4-5-12(17(13)31-3)18-22-10-28(2)27-18/h4-6,9-11H,7-8H2,1-3H3,(H,21,30)(H2,23,24,25,29)/i1D3 DMAR1YS CS [2H]C([2H])([2H])NC(=O)C1=NN=C(C=C1NC2=CC=CC(=C2OC)C3=NN(C=N3)C)NC(=O)C4CC4 DMAR1YS IK BZZKEPGENYLQSC-FIBGUPNXSA-N DMAR1YS IU 6-(cyclopropanecarbonylamino)-4-[2-methoxy-3-(1-methyl-1,2,4-triazol-3-yl)anilino]-N-(trideuteriomethyl)pyridazine-3-carboxamide DMAR1YS CA CAS 1609392-27-9 DMAR1YS DE Plaque psoriasis; Psoriasis vulgaris DM3MAYQ ID DM3MAYQ DM3MAYQ DN BMS-986205 DM3MAYQ HS Phase 3 DM3MAYQ SN KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)- DM3MAYQ CP Bristol-Myers Squibb Princeton, NJ DM3MAYQ PC 121328278 DM3MAYQ MW 410.9 DM3MAYQ FM C24H24ClFN2O DM3MAYQ IC InChI=1S/C24H24ClFN2O/c1-15(24(29)28-20-9-6-18(25)7-10-20)16-2-4-17(5-3-16)21-12-13-27-23-11-8-19(26)14-22(21)23/h6-17H,2-5H2,1H3,(H,28,29)/t15-,16?,17?/m1/s1 DM3MAYQ CS C[C@H](C1CCC(CC1)C2=C3C=C(C=CC3=NC=C2)F)C(=O)NC4=CC=C(C=C4)Cl DM3MAYQ IK KRTIYQIPSAGSBP-KLAILNCOSA-N DM3MAYQ IU (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide DM3MAYQ CA CAS 1923833-60-6 DM3MAYQ DE Advanced cancer; Gastric adenocarcinoma; Melanoma; Renal cell carcinoma; Solid tumour/cancer DM2OBNW ID DM2OBNW DM2OBNW DN Bococizumab DM2OBNW HS Phase 3 DM2OBNW CP Pfizer DM2OBNW DT Antibody DM2OBNW DE Chronic obstructive pulmonary disease DM6KRLW ID DM6KRLW DM6KRLW DN BQ788 DM6KRLW HS Phase 3 DM6KRLW SN (2R)-2-[[(2R)-2-amino-3-(1-methoxycarbonylindol-3-yl)propanoyl]-[(2S)-2-[[(2R,6S)-2,6-dimethylpiperidine-1-carbonyl]amino]-4,4-dimethylpentanoyl]amino]hexanoic acid; BQ 788; AC1MIWQ3; GTPL1010; SCHEMBL18429752 DM6KRLW DT Small molecular drug DM6KRLW PC 16759603 DM6KRLW MW 663.8 DM6KRLW FM C34H50N5NaO7 DM6KRLW IC InChI=1S/C34H51N5O7.Na/c1-8-9-16-25(31(42)43)35-29(40)26(18-23-20-38(33(45)46-7)28-17-11-10-15-24(23)28)36-30(41)27(19-34(4,5)6)37-32(44)39-21(2)13-12-14-22(39)3;/h10-11,15,17,20-22,25-27H,8-9,12-14,16,18-19H2,1-7H3,(H,35,40)(H,36,41)(H,37,44)(H,42,43);/q;+1/p-1/t21-,22+,25-,26-,27+;/m1./s1 DM6KRLW CS CCCC[C@H](C(=O)[O-])NC(=O)[C@@H](CC1=CN(C2=CC=CC=C21)C(=O)OC)NC(=O)[C@H](CC(C)(C)C)NC(=O)N3[C@@H](CCC[C@@H]3C)C.[Na+] DM6KRLW IK QCVIFBRTTLMEOV-FUKQNADPSA-M DM6KRLW IU sodium;(2R)-2-[[(2R)-2-[[(2S)-2-[[(2R,6S)-2,6-dimethylpiperidine-1-carbonyl]amino]-4,4-dimethylpentanoyl]amino]-3-(1-methoxycarbonylindol-3-yl)propanoyl]amino]hexanoate DM6KRLW CA CAS 156161-89-6 DM6KRLW DE Hypertension; Acute kidney injury; Encephalopathy; Myasthenia gravis; Neuromyelitis optica DM942HP ID DM942HP DM942HP DN Brivanib DM942HP HS Phase 3 DM942HP SN Brivanib; 649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol DM942HP CP Bristol-Myers Squibb DM942HP DT Small molecular drug DM942HP PC 11234052 DM942HP MW 370.4 DM942HP FM C19H19FN4O3 DM942HP IC InChI=1S/C19H19FN4O3/c1-10-6-13-14(23-10)4-5-15(17(13)20)27-19-18-12(3)16(26-8-11(2)25)7-24(18)22-9-21-19/h4-7,9,11,23,25H,8H2,1-3H3/t11-/m1/s1 DM942HP CS CC1=CC2=C(N1)C=CC(=C2F)OC3=NC=NN4C3=C(C(=C4)OC[C@@H](C)O)C DM942HP IK WCWUXEGQKLTGDX-LLVKDONJSA-N DM942HP IU (2R)-1-[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxypropan-2-ol DM942HP CA CAS 649735-46-6 DM942HP CB CHEBI:94562 DM942HP DE Liver cancer; Breast cancer DMM0VO3 ID DMM0VO3 DMM0VO3 DN BSI-201 DMM0VO3 HS Phase 3 DMM0VO3 SN Iniparib; NIBA; INO2BA; IND-71677; SAR-240550; Iniparib, NSC-746045, IND-71677, BSI201, BSI-201; 4-Iodo-3-nitrobenzamide; 4-iodo-3-nitro-benzamide DMM0VO3 CP Sanofi-Aventis DMM0VO3 DT Small molecular drug DMM0VO3 PC 9796068 DMM0VO3 MW 292.03 DMM0VO3 FM C7H5IN2O3 DMM0VO3 IC InChI=1S/C7H5IN2O3/c8-5-2-1-4(7(9)11)3-6(5)10(12)13/h1-3H,(H2,9,11) DMM0VO3 CS C1=CC(=C(C=C1C(=O)N)[N+](=O)[O-])I DMM0VO3 IK MDOJTZQKHMAPBK-UHFFFAOYSA-N DMM0VO3 IU 4-iodo-3-nitrobenzamide DMM0VO3 CA CAS 160003-66-7 DMM0VO3 CB CHEBI:95067 DMM0VO3 DE Solid tumour/cancer DM50SNX ID DM50SNX DM50SNX DN Bucelipase alfa DM50SNX HS Phase 3 DM50SNX SN Exinalda; Kiobrina; BSSL, Biovitrum; Bile salt stimulated lipase, Arexis; Bile salt stimulated lipase, Biovitrum; Bile salt stimulated lipase, PPL Therapeutics; HrBSSL, Biovitrum; Human recombinant bile salt stimulated lipase, Biovitrum; TgBSSL, PPL Therapeutics DM50SNX CP Astra Hassle AB DM50SNX DE Exocrine pancreatic insufficiency DM1WEHC ID DM1WEHC DM1WEHC DN Buparlisib DM1WEHC HS Phase 3 DM1WEHC SN BKM120 DM1WEHC CP Novartis DM1WEHC DT Small molecular drug DM1WEHC PC 16654980 DM1WEHC MW 410.4 DM1WEHC FM C18H21F3N6O2 DM1WEHC IC InChI=1S/C18H21F3N6O2/c19-18(20,21)13-9-15(22)23-11-12(13)14-10-16(26-1-5-28-6-2-26)25-17(24-14)27-3-7-29-8-4-27/h9-11H,1-8H2,(H2,22,23) DM1WEHC CS C1COCCN1C2=NC(=NC(=C2)C3=CN=C(C=C3C(F)(F)F)N)N4CCOCC4 DM1WEHC IK CWHUFRVAEUJCEF-UHFFFAOYSA-N DM1WEHC IU 5-(2,6-dimorpholin-4-ylpyrimidin-4-yl)-4-(trifluoromethyl)pyridin-2-amine DM1WEHC CA CAS 944396-07-0 DM1WEHC CB CHEBI:71954 DM1WEHC DE Breast cancer DMAR9ND ID DMAR9ND DMAR9ND DN Bupropion+Naltrexone DMAR9ND HS Phase 3 DMAR9ND SN Mysimba; Contrave; Naltrexone/bupropion; Naltrexone / bupropion; Bupropion / naltrexone; Bupropion mixture with naltrexone; SCHEMBL15633271; 1201668-08-7 DMAR9ND CP Orexigen Therapeutics DMAR9ND DT Small molecular drug DMAR9ND PC 11556075 DMAR9ND MW 581.1 DMAR9ND FM C33H41ClN2O5 DMAR9ND IC InChI=1S/C20H23NO4.C13H18ClNO/c22-13-4-3-12-9-15-20(24)6-5-14(23)18-19(20,16(12)17(13)25-18)7-8-21(15)10-11-1-2-11;1-9(15-13(2,3)4)12(16)10-6-5-7-11(14)8-10/h3-4,11,15,18,22,24H,1-2,5-10H2;5-9,15H,1-4H3/t15-,18+,19+,20-;/m1./s1 DMAR9ND CS CC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C.C1CC1CN2CC[C@]34[C@@H]5C(=O)CC[C@]3([C@H]2CC6=C4C(=C(C=C6)O)O5)O DMAR9ND IK KVNBDVQGENTICK-ITLPAZOVSA-N DMAR9ND IU (4R,4aS,7aR,12bS)-3-(cyclopropylmethyl)-4a,9-dihydroxy-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one;2-(tert-butylamino)-1-(3-chlorophenyl)propan-1-one DMAR9ND CA CAS 1201668-08-7 DMAR9ND DE Obesity DM6RUKX ID DM6RUKX DM6RUKX DN BVT.2733 DM6RUKX HS Phase 3 DM6RUKX SN CHEMBL553071; AC1OCFOV; 376641-65-5; SCHEMBL5692696; MolPort-042-665-756; 3-chloro-2-methyl-N-[4-[2-(4-methylpiperazin-1-yl)-2-oxoethyl]-1,3-thiazol-2-yl]benzenesulfonamide hydrochloride DM6RUKX DT Small molecular drug DM6RUKX PC 6918651 DM6RUKX MW 429 DM6RUKX FM C17H21ClN4O3S2 DM6RUKX IC InChI=1S/C17H21ClN4O3S2/c1-12-14(18)4-3-5-15(12)27(24,25)20-17-19-13(11-26-17)10-16(23)22-8-6-21(2)7-9-22/h3-5,11H,6-10H2,1-2H3,(H,19,20) DM6RUKX CS CC1=C(C=CC=C1Cl)S(=O)(=O)NC2=NC(=CS2)CC(=O)N3CCN(CC3)C DM6RUKX IK YDPRNGAPPNPYQQ-UHFFFAOYSA-N DM6RUKX IU 3-chloro-2-methyl-N-[4-[2-(4-methylpiperazin-1-yl)-2-oxoethyl]-1,3-thiazol-2-yl]benzenesulfonamide DM6RUKX CA CAS 376640-41-4 DM6RUKX DE Non-insulin dependent diabetes; Lupus; Myasthenia gravis; Systemic lupus erythematosus DM1ARHT ID DM1ARHT DM1ARHT DN BYM338 DM1ARHT HS Phase 3 DM1ARHT CP Novartis DM1ARHT DE Acute myeloid leukaemia; Inclusion body myositis; Muscle atrophy DMPTCYB ID DMPTCYB DMPTCYB DN Cadi-05 DMPTCYB HS Phase 3 DMPTCYB SN Mycobacterium w; Poly-TLR agonist polyantigenic vaccine (cancer), Cadila; Poly-toll-like receptor agonist polyantigenic vaccine (cancer), Cadila DMPTCYB CP Cadila Pharmaceuticals Ltd DMPTCYB DT Vaccine DMPTCYB DE Prostate cancer DM6CHNJ ID DM6CHNJ DM6CHNJ DN Camptothecin DM6CHNJ HS Phase 3 DM6CHNJ SN camptothecin; Camptothecine; 7689-03-4; (S)-(+)-Camptothecin; Campathecin; d-Camptothecin; (+)-Camptothecine; (+)-Camptothecin; 20(S)-Camptothecine; 21,22-Secocamptothecin-21-oic acid lactone; NSC94600; (S)-Camptothecin; Camptothecine (8CI); 20(S)-Camptothecin; Camptothecine (S,+); CHEMBL65; UNII-XT3Z54Z28A; MLS000766223; (4S)-4-ethyl-4-hydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; XT3Z54Z28A; CHEBI:27656; VSJKWCGYPAHWDS-FQEVSTJZSA-N; Camptothecin, Camptotheca acuminata; NSC-94600; Camptothecin derivat DM6CHNJ DT Small molecular drug DM6CHNJ PC 24360 DM6CHNJ MW 348.4 DM6CHNJ FM C20H16N2O4 DM6CHNJ IC InChI=1S/C20H16N2O4/c1-2-20(25)14-8-16-17-12(7-11-5-3-4-6-15(11)21-17)9-22(16)18(23)13(14)10-26-19(20)24/h3-8,25H,2,9-10H2,1H3/t20-/m0/s1 DM6CHNJ CS CC[C@@]1(C2=C(COC1=O)C(=O)N3CC4=CC5=CC=CC=C5N=C4C3=C2)O DM6CHNJ IK VSJKWCGYPAHWDS-FQEVSTJZSA-N DM6CHNJ IU (19S)-19-ethyl-19-hydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4,6,8,10,15(20)-heptaene-14,18-dione DM6CHNJ CA CAS 7689-03-4 DM6CHNJ CB CHEBI:27656 DM6CHNJ DE Solid tumour/cancer DMHJCGV ID DMHJCGV DMHJCGV DN Candoxatril DMHJCGV HS Phase 3 DMHJCGV SN UK 79300; Candoxatril [USAN:INN:BAN]; UK-79,300; Candoxatril (JAN/USAN/INN); Cyclohexanecarboxylic acid, 4-(((1-(2-carboxy-3-(2-methoxyethoxy)propyl)cyclopentyl)carbonyl)-amino)-, (4(S)-cis); [4(S)-cis]-4-[[[1-[3-[(2,3-dihydro-1H-indeb5-yl)oxy]-2-[(2-methoxyethoxy)methyl]-3-oxopropyl]cyclopentyl]carbonyl]amino]cyclohexanecarboxylic acid; Cis-4-{[(1-{(2S)-3-(2,3-dihydro-1H-inden-5-yloxy)-2-[(2-methoxyethoxy)methyl]-3-oxopropyl}cyclopentyl)carbonyl]amino}cyclohexanecarboxylic acid; (alphaS)-1-((cis-4-Carboxycyclohexyl)carbamoyl)-alpha-((2-methoxyethoxy)methyl)cyclopentanepropionic acid; 3-(1-((4-Carboxycyclohexyl)carbamoyl)cyclopentyl)-2-(2-methoxyethoxymethyl)propanoic acid 5-indanyl ester; 4-[[1-[(2S)-3-(2,3-dihydro-1H-inden-5-yloxy)-2-(2-methoxyethoxymethyl)-3-oxopropyl]cyclopentanecarbonyl]amino]cyclohexane-1-carboxylic acid; 4-[[1-[3-(2,3-dihydro-1H-inden-5-yloxy)-2-(2-methoxyethoxymethyl)-3-oxopropyl]cyclopentanecarbonyl]amino]cyclohexane-1-carboxylic acid DMHJCGV TC Antihypertensive Agents DMHJCGV DT Small molecular drug DMHJCGV PC 5362417 DMHJCGV MW 515.6 DMHJCGV FM C29H41NO7 DMHJCGV IC InChI=1S/C29H41NO7/c1-35-15-16-36-19-23(27(33)37-25-12-9-20-5-4-6-22(20)17-25)18-29(13-2-3-14-29)28(34)30-24-10-7-21(8-11-24)26(31)32/h9,12,17,21,23-24H,2-8,10-11,13-16,18-19H2,1H3,(H,30,34)(H,31,32)/t21?,23-,24?/m0/s1 DMHJCGV CS COCCOC[C@H](CC1(CCCC1)C(=O)NC2CCC(CC2)C(=O)O)C(=O)OC3=CC4=C(CCC4)C=C3 DMHJCGV IK ZTWZVMIYIIVABD-RZMWZJFBSA-N DMHJCGV IU 4-[[1-[(2S)-3-(2,3-dihydro-1H-inden-5-yloxy)-2-(2-methoxyethoxymethyl)-3-oxopropyl]cyclopentanecarbonyl]amino]cyclohexane-1-carboxylic acid DMHJCGV CA CAS 123122-55-4 DMHJCGV CB CHEBI:3353 DMHJCGV DE Hypertension DM4FHQR ID DM4FHQR DM4FHQR DN Canfosfamide DM4FHQR HS Phase 3 DM4FHQR SN Telcyta (TN) DM4FHQR CP Telik DM4FHQR DT Small molecular drug DM4FHQR PC 5312109 DM4FHQR MW 787.5 DM4FHQR FM C26H40Cl4N5O10PS DM4FHQR IC InChI=1S/C26H40Cl4N5O10PS/c27-8-12-34(13-9-28)46(42,35(14-10-29)15-11-30)45-16-17-47(43,44)18-21(32-22(36)7-6-20(31)25(38)39)24(37)33-23(26(40)41)19-4-2-1-3-5-19/h1-5,20-21,23H,6-18,31H2,(H,32,36)(H,33,37)(H,38,39)(H,40,41)/t20-,21-,23+/m0/s1 DM4FHQR CS C1=CC=C(C=C1)[C@H](C(=O)O)NC(=O)[C@H](CS(=O)(=O)CCOP(=O)(N(CCCl)CCCl)N(CCCl)CCCl)NC(=O)CC[C@@H](C(=O)O)N DM4FHQR IK OJLHWPALWODJPQ-QNWVGRARSA-N DM4FHQR IU (2S)-2-amino-5-[[(2R)-3-[2-[bis[bis(2-chloroethyl)amino]phosphoryloxy]ethylsulfonyl]-1-[[(R)-carboxy(phenyl)methyl]amino]-1-oxopropan-2-yl]amino]-5-oxopentanoic acid DM4FHQR CA CAS 158382-37-7 DM4FHQR CB CHEBI:135883 DM4FHQR DE Solid tumour/cancer DMMZDJ6 ID DMMZDJ6 DMMZDJ6 DN Captopril DMMZDJ6 HS Phase 3 DMMZDJ6 SN captopril; 62571-86-2; Capoten; L-Captopril; Lopirin; Captopryl; Cesplon; Captolane; Tensoprel; Dilabar; Acepress; Captoril; Tenosbon; Hypertil; Garranil; Alopresin; Lopril; Acepril; Captoprilum; Aceplus; Acediur; Tensobon; Isopresol;Apopril; Asisten; Captoprilum [INN-Latin]; SQ 14225; SQ-14225; SQ 14,225; SA 333; Captopril DMMZDJ6 TC Antiviral Agents DMMZDJ6 DT Small molecular drug DMMZDJ6 PC 44093 DMMZDJ6 MW 217.29 DMMZDJ6 FM C9H15NO3S DMMZDJ6 IC InChI=1S/C9H15NO3S/c1-6(5-14)8(11)10-4-2-3-7(10)9(12)13/h6-7,14H,2-5H2,1H3,(H,12,13)/t6-,7+/m1/s1 DMMZDJ6 CS C[C@H](CS)C(=O)N1CCC[C@H]1C(=O)O DMMZDJ6 IK FAKRSMQSSFJEIM-RQJHMYQMSA-N DMMZDJ6 IU (2S)-1-[(2S)-2-methyl-3-sulfanylpropanoyl]pyrrolidine-2-carboxylic acid DMMZDJ6 CA CAS 62571-86-2 DMMZDJ6 CB CHEBI:3380 DMMZDJ6 DE Coronavirus Disease 2019 (COVID-19) DMUVMWZ ID DMUVMWZ DMUVMWZ DN Carebastine DMUVMWZ HS Phase 3 DMUVMWZ SN Carebastina; Carebastinum; Carebastina [Spanish]; Carebastine [INN]; Carebastinum [Latin]; E00013; P-(4-(4-(Diphenylmethoxy)piperidino)butyryl)-alpha-methylhydratropic acid; 2-(4-(4-(4-Benzhydryloxypiperidino)butyryl)phenyl)-2-methylpropionsaeure; 2-[4-[4-(4-benzhydryloxypiperidin-1-yl)butanoyl]phenyl]-2-methylpropanoic acid DMUVMWZ CP Almirall Prodesfarma DMUVMWZ DT Small molecular drug DMUVMWZ PC 65820 DMUVMWZ MW 499.6 DMUVMWZ FM C32H37NO4 DMUVMWZ IC InChI=1S/C32H37NO4/c1-32(2,31(35)36)27-17-15-24(16-18-27)29(34)14-9-21-33-22-19-28(20-23-33)37-30(25-10-5-3-6-11-25)26-12-7-4-8-13-26/h3-8,10-13,15-18,28,30H,9,14,19-23H2,1-2H3,(H,35,36) DMUVMWZ CS CC(C)(C1=CC=C(C=C1)C(=O)CCCN2CCC(CC2)OC(C3=CC=CC=C3)C4=CC=CC=C4)C(=O)O DMUVMWZ IK XGHOVGYJHWQGCC-UHFFFAOYSA-N DMUVMWZ IU 2-[4-[4-(4-benzhydryloxypiperidin-1-yl)butanoyl]phenyl]-2-methylpropanoic acid DMUVMWZ CA CAS 90729-42-3 DMUVMWZ DE Ocular allergy DM4Y1SP ID DM4Y1SP DM4Y1SP DN Carisbamate DM4Y1SP HS Phase 3 DM4Y1SP SN Comfyde; JNJ 10234094; RWJ 333369; YKP 509; Carisbamate (USAN); JNJ-10234094; RWJ-333369; YKP-509; S-2-O-Carbamoyl-1-o-chlorophenyl-ethanol; [(2S)-2-(2-chlorophenyl)-2-hydroxyethyl] carbamate DM4Y1SP CP Johnson & Johnson DM4Y1SP DT Small molecular drug DM4Y1SP PC 6918474 DM4Y1SP MW 215.63 DM4Y1SP FM C9H10ClNO3 DM4Y1SP IC InChI=1S/C9H10ClNO3/c10-7-4-2-1-3-6(7)8(12)5-14-9(11)13/h1-4,8,12H,5H2,(H2,11,13)/t8-/m1/s1 DM4Y1SP CS C1=CC=C(C(=C1)[C@@H](COC(=O)N)O)Cl DM4Y1SP IK OLBWFRRUHYQABZ-MRVPVSSYSA-N DM4Y1SP IU [(2S)-2-(2-chlorophenyl)-2-hydroxyethyl] carbamate DM4Y1SP CA CAS 194085-75-1 DM4Y1SP CB CHEBI:135966 DM4Y1SP DE Seizure disorder; Focal dystonia; Epilepsy DMPG4OM ID DMPG4OM DMPG4OM DN CAZ AVI DMPG4OM HS Phase 3 DMPG4OM SN CAZ104 DMPG4OM CP AstraZeneca DMPG4OM DE Serious infection DM097UP ID DM097UP DM097UP DN CBT-1 DM097UP HS Phase 3 DM097UP CP National Institutes of Health Clinical Center (CC) DM097UP DE Non-small-cell lung cancer; Solid tumour/cancer DMV7WSN ID DMV7WSN DMV7WSN DN CC-25430 DMV7WSN HS Phase 3 DMV7WSN SN Caroverin; Caroverina; Caroverina [INN-Spanish]; Caroverine; Caroverine (INN); Caroverine [INN]; Caroverinum; Caroverinum [INN-Latin]; P 201-1; Spasmium; Spasmium (TN); Tox21_113512; XJ73B0K6KB; ZINC4212360; 1-Diethylaminoethyl-3-(p-methoxybenzyl)quinoxalone-2; 23465-76-1; AC1L23SW; BRD-K70161083-003-01-4; C-23692; CAS-23465-76-1; CC-25430; CHEBI:135541; CHEMBL1729803; D07098; DSSTox_CID_28936; DSSTox_GSID_49010; DSSTox_RID_83202; DTXSID6049010; FT-0716182; MFCD00865257; NCGC00186046-01; NCGC00186046-02; SCHEMBL25946; UNII-XJ73B0K6KB; P-201 DMV7WSN PC 65709 DMV7WSN MW 365.5 DMV7WSN FM C22H27N3O2 DMV7WSN IC MSPRUJDUTKRMLM-UHFFFAOYSA-N DMV7WSN CS CCN(CC)CCN1C2=CC=CC=C2N=C(C1=O)CC3=CC=C(C=C3)OC DMV7WSN IK 1S/C22H27N3O2/c1-4-24(5-2)14-15-25-21-9-7-6-8-19(21)23-20(22(25)26)16-17-10-12-18(27-3)13-11-17/h6-13H,4-5,14-16H2,1-3H3 DMV7WSN IU 1-[2-(diethylamino)ethyl]-3-[(4-methoxyphenyl)methyl]quinoxalin-2-one DMV7WSN CA CAS 23465-76-1 DMV7WSN CB CHEBI:135541 DMV7WSN DE Tinnitus DMTNQB0 ID DMTNQB0 DMTNQB0 DN CC-486 DMTNQB0 HS Phase 3 DMTNQB0 SN AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue DMTNQB0 CP Celgene DMTNQB0 DT Small molecular drug DMTNQB0 PC 9840076 DMTNQB0 MW 320.4 DMTNQB0 FM C19H20N4O DMTNQB0 IC InChI=1S/C19H20N4O/c1-22(2)12-13-6-8-14(9-7-13)18-21-16-5-3-4-15-17(16)23(18)11-10-20-19(15)24/h3-9H,10-12H2,1-2H3,(H,20,24) DMTNQB0 CS CN(C)CC1=CC=C(C=C1)C2=NC3=CC=CC4=C3N2CCNC4=O DMTNQB0 IK SEKJSSBJKFLZIT-UHFFFAOYSA-N DMTNQB0 IU 2-[4-[(dimethylamino)methyl]phenyl]-1,3,10-triazatricyclo[6.4.1.04,13]trideca-2,4,6,8(13)-tetraen-9-one DMTNQB0 CA CAS 328543-09-5 DMTNQB0 CB CHEBI:92015 DMTNQB0 DE Myelodysplastic syndrome; Acute myeloid leukaemia; Diffuse large B-cell lymphoma DM5LQHB ID DM5LQHB DM5LQHB DN CCX-168 DM5LQHB HS Phase 3 DM5LQHB SN Avacopan DM5LQHB CP ChemoCentryx DM5LQHB PC 49841217 DM5LQHB MW 581.6 DM5LQHB FM C33H35F4N3O2 DM5LQHB IC InChI=1S/C33H35F4N3O2/c1-20-12-15-25(19-27(20)33(35,36)37)39-31(41)26-10-6-18-40(32(42)29-21(2)7-5-11-28(29)34)30(26)22-13-16-24(17-14-22)38-23-8-3-4-9-23/h5,7,11-17,19,23,26,30,38H,3-4,6,8-10,18H2,1-2H3,(H,39,41)/t26-,30-/m0/s1 DM5LQHB CS CC1=C(C(=CC=C1)F)C(=O)N2CCC[C@@H]([C@@H]2C3=CC=C(C=C3)NC4CCCC4)C(=O)NC5=CC(=C(C=C5)C)C(F)(F)F DM5LQHB IK PUKBOVABABRILL-YZNIXAGQSA-N DM5LQHB IU (2R,3S)-2-[4-(cyclopentylamino)phenyl]-1-(2-fluoro-6-methylbenzoyl)-N-[4-methyl-3-(trifluoromethyl)phenyl]piperidine-3-carboxamide DM5LQHB CA CAS 1346623-17-3 DM5LQHB DE Eosinophilic granulomatosis with polyangiitis; Hereditary haemolytic anemia; Anca-associated vasculitis DMWO5ZR ID DMWO5ZR DMWO5ZR DN Cediranib DMWO5ZR HS Phase 3 DMWO5ZR SN Recentin; AZD 2171; AZD2171; M6294; AZD-2171; ZD-2171; AZD2171, Recentin, Cediranib; Cediranib (USAN/INN); 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazoline; 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline DMWO5ZR CP AstraZeneca DMWO5ZR TC Anticancer Agents DMWO5ZR DT Small molecular drug DMWO5ZR PC 9933475 DMWO5ZR MW 450.5 DMWO5ZR FM C25H27FN4O3 DMWO5ZR IC InChI=1S/C25H27FN4O3/c1-16-12-17-19(29-16)6-7-21(24(17)26)33-25-18-13-22(31-2)23(14-20(18)27-15-28-25)32-11-5-10-30-8-3-4-9-30/h6-7,12-15,29H,3-5,8-11H2,1-2H3 DMWO5ZR CS CC1=CC2=C(N1)C=CC(=C2F)OC3=NC=NC4=CC(=C(C=C43)OC)OCCCN5CCCC5 DMWO5ZR IK XXJWYDDUDKYVKI-UHFFFAOYSA-N DMWO5ZR IU 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazoline DMWO5ZR CA CAS 288383-20-0 DMWO5ZR CB CHEBI:94782 DMWO5ZR DE Peritoneal cavity cancer DMLWIU4 ID DMLWIU4 DMLWIU4 DN Cefluprenam DMLWIU4 HS Phase 3 DMLWIU4 SN E-1077 DMLWIU4 CP Eisai Co Ltd DMLWIU4 DT Small molecular drug DMLWIU4 PC 6536774 DMLWIU4 MW 556.6 DMLWIU4 FM C20H25FN8O6S2 DMLWIU4 IC InChI=1S/C20H25FN8O6S2/c1-3-29(2,7-11(22)30)6-4-5-10-8-36-18-13(17(32)28(18)14(10)19(33)34)24-16(31)12(26-35-9-21)15-25-20(23)37-27-15/h4-5,13,18H,3,6-9H2,1-2H3,(H5-,22,23,24,25,27,30,31,33,34)/b5-4+,26-12-/t13-,18-,29?/m1/s1 DMLWIU4 CS CC[N+](C)(C/C=C/C1=C(N2[C@@H]([C@@H](C2=O)NC(=O)/C(=N\\OCF)/C3=NSC(=N3)N)SC1)C(=O)[O-])CC(=O)N DMLWIU4 IK XAKKNLNAJBNLPC-MAYKBZFQSA-N DMLWIU4 IU (6R,7R)-3-[(E)-3-[(2-amino-2-oxoethyl)-ethyl-methylazaniumyl]prop-1-enyl]-7-[[(2Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(fluoromethoxyimino)acetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate DMLWIU4 CA CAS 116853-25-9 DMLWIU4 CB CHEBI:3488 DMLWIU4 DE Bacterial infection DMM76GL ID DMM76GL DMM76GL DN Ceftobiprole DMM76GL HS Phase 3 DMM76GL SN BAL 9141; BAL 9141-000; BAL-9141; Ro 63-9141; Ro-63-9141; Ro-63-9141/000; (6R,7R)-7-[[(2Z)-2-(5-amino-1,2,4-thiadiazol-3-ylidene)-2-nitrosoacetyl]amino]-8-oxo-3-[(E)-[2-oxo-1-[(3R)-pyrrolidin-3-yl]pyrrolidin-3-ylidene]methyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid DMM76GL CP Johnson & Johnson DMM76GL DT Small molecular drug DMM76GL PC 135413542 DMM76GL MW 534.6 DMM76GL FM C20H22N8O6S2 DMM76GL IC InChI=1S/C20H22N8O6S2/c21-20-24-14(26-36-20)11(25-34)15(29)23-12-17(31)28-13(19(32)33)9(7-35-18(12)28)5-8-2-4-27(16(8)30)10-1-3-22-6-10/h5,10,12,18,22,34H,1-4,6-7H2,(H,23,29)(H,32,33)(H2,21,24,26)/b8-5+,25-11-/t10-,12-,18-/m1/s1 DMM76GL CS C1CNC[C@@H]1N2CC/C(=C\\C3=C(N4[C@@H]([C@@H](C4=O)NC(=O)/C(=N\\O)/C5=NSC(=N5)N)SC3)C(=O)O)/C2=O DMM76GL IK VOAZJEPQLGBXGO-SDAWRPRTSA-N DMM76GL IU (6R,7R)-7-[[(2Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-hydroxyiminoacetyl]amino]-8-oxo-3-[(E)-[2-oxo-1-[(3R)-pyrrolidin-3-yl]pyrrolidin-3-ylidene]methyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid DMM76GL CA CAS 209467-52-7 DMM76GL CB CHEBI:140407 DMM76GL DE Community-acquired pneumonia; Skin and skin-structure infection DMWLF2X ID DMWLF2X DMWLF2X DN Ceftobiprole medocaril DMWLF2X HS Phase 3 DMWLF2X SN UNII-YXV28V1B07; YXV28V1B07; BAL5788; 376653-43-9; ceftobiprolemedocaril; Ceftobiprole Medocaril [INN]; SCHEMBL2671859; SCHEMBL19236293; CHEBI:135968; DB14733; 653C439; (6R,7R)-7-((2Z)-2-(5-Amino-1,2,4-thiadiazol-3-yl)-2-(hydroxyimino)acetamido)-3-((E)((3'R)-1'-((5-methyl-2-oxo-1,3-dioxol-4-yl)methoxycarbonyl)-2-oxo-(1,3'-bipyrrolidin)-3-ylidene)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid DMWLF2X CP Basilea Pharmaceutica DMWLF2X DT Small molecular drug DMWLF2X PC 135413544 DMWLF2X MW 690.7 DMWLF2X FM C26H26N8O11S2 DMWLF2X IC InChI=1S/C26H26N8O11S2/c1-10-14(45-26(41)44-10)8-43-25(40)32-4-3-13(7-32)33-5-2-11(20(33)36)6-12-9-46-22-16(21(37)34(22)17(12)23(38)39)28-19(35)15(30-42)18-29-24(27)47-31-18/h6,13,16,22,42H,2-5,7-9H2,1H3,(H,28,35)(H,38,39)(H2,27,29,31)/b11-6+,30-15-/t13-,16-,22-/m1/s1 DMWLF2X CS CC1=C(OC(=O)O1)COC(=O)N2CC[C@H](C2)N3CC/C(=C\\C4=C(N5[C@@H]([C@@H](C5=O)NC(=O)/C(=N\\O)/C6=NSC(=N6)N)SC4)C(=O)O)/C3=O DMWLF2X IK HFTSMHTWUFCYMJ-YIOMYIDASA-N DMWLF2X IU (6R,7R)-7-[[(2Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-hydroxyiminoacetyl]amino]-3-[(E)-[1-[(3R)-1-[(5-methyl-2-oxo-1,3-dioxol-4-yl)methoxycarbonyl]pyrrolidin-3-yl]-2-oxopyrrolidin-3-ylidene]methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid DMWLF2X CA CAS 376653-43-9 DMWLF2X CB CHEBI:135968 DMWLF2X DE Skin and skin-structure infection DMIGX84 ID DMIGX84 DMIGX84 DN Cethromycin DMIGX84 HS Phase 3 DMIGX84 SN Restanza; Cethromycin [USAN]; ABT 773; A-195773; ABT-773; Abbott-195773; A-195773.0; Cethromycin (USAN/INN); (1R,2R,4R,6R,7R,8R,10R,13R,14S)-7-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-13-ethyl-2,4,6,8,10,14-hexamethyl-6-[(E)-3-quinolin-3-ylprop-2-enoxy]-12,15-dioxa-17-azabicyclo[12.3.0]heptadecane-3,9,11,16-tetrone; (1R,2R,4R,6S,7R,8R,10R,13R,14S)-7-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-13-ethyl-2,4,6,8,10,14-hexamethyl-6-[(E)-3-quinolin-3-ylprop-2-enoxy]-12,15-dioxa-17-azabicyclo[12.3.0]heptadecane-3,9,11,16-tetrone; (1S,2R,5R,7R,8R,9R,11R,13R,14R)-2-Ethyl-1,5,7,9,11,13-Hexamethyl-9-[3-(3-quinolyl)-2(E)-propenyloxy]-8-[3,4,6-trideoxy-3-(dimethylamino)-beta-D-glucopyranosyloxy]-3,17-dioxa-15-azabicyclo[12.3.0]hepta; (3aS,4R,7R,9R,10R,11R,13R,15R,15aR)-4-Ethyl-3a,7,9,11,13,15 hexamethyl-11-((3-(quinolin-3-yl)prop-2-enyl)oxy)-10-((3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl)oxy)octahydro-2H-oxacyclotetradecino(4,3-d)oxazole-2,6,8,14(1H,7H,9H)-tetrone; (3aS,4R,7R,9R,10R,11R,13R,15R,15aR)-4-Ethyl-3a,7,9,11,13,15-hexamethyl-11-((3-(quinolin-3-yl)prop-2-enyl)oxy)-10-((3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl)oxy)octahydro-2H-oxacyclotetradecino(4,3-d)oxazole-2,6,8,14(1H,7H,9H)-tetrone DMIGX84 CP Advanced life sciences DMIGX84 DT Small molecular drug DMIGX84 PC 447451 DMIGX84 MW 765.9 DMIGX84 FM C42H59N3O10 DMIGX84 IC InChI=1S/C42H59N3O10/c1-11-32-42(8)36(44-40(50)55-42)25(4)33(46)23(2)21-41(7,51-18-14-15-28-20-29-16-12-13-17-30(29)43-22-28)37(26(5)34(47)27(6)38(49)53-32)54-39-35(48)31(45(9)10)19-24(3)52-39/h12-17,20,22-27,31-32,35-37,39,48H,11,18-19,21H2,1-10H3,(H,44,50)/b15-14+/t23-,24-,25+,26+,27-,31+,32-,35-,36-,37-,39+,41-,42-/m1/s1 DMIGX84 CS CC[C@@H]1[C@@]2([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H](C(=O)[C@H](C(=O)O1)C)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC/C=C/C4=CC5=CC=CC=C5N=C4)C)C)NC(=O)O2)C DMIGX84 IK PENDGIOBPJLVBT-ONLVEXIXSA-N DMIGX84 IU (1S,2R,5R,7R,8R,9R,11R,13R,14R)-8-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-2-ethyl-1,5,7,9,11,13-hexamethyl-9-[(E)-3-quinolin-3-ylprop-2-enoxy]-3,17-dioxa-15-azabicyclo[12.3.0]heptadecane-4,6,12,16-tetrone DMIGX84 CA CAS 205110-48-1 DMIGX84 CB CHEBI:29506 DMIGX84 DE Bacterial infection; Pneumonia DMWAHTN ID DMWAHTN DMWAHTN DN Cetilistat DMWAHTN HS Phase 3 DMWAHTN SN Cametor; Cetilistat [INN]; ATL 962; ATL962; ATL-962; Cetilistat (JAN/USAN/INN); 2-(Hexadecyloxy)-6-methyl-4H-3,1-benzoxazin-4-one DMWAHTN CP Alizyme; Takeda; Norgine B.V. DMWAHTN DT Small molecular drug DMWAHTN PC 9952916 DMWAHTN MW 401.6 DMWAHTN FM C25H39NO3 DMWAHTN IC InChI=1S/C25H39NO3/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-16-19-28-25-26-23-18-17-21(2)20-22(23)24(27)29-25/h17-18,20H,3-16,19H2,1-2H3 DMWAHTN CS CCCCCCCCCCCCCCCCOC1=NC2=C(C=C(C=C2)C)C(=O)O1 DMWAHTN IK MVCQKIKWYUURMU-UHFFFAOYSA-N DMWAHTN IU 2-hexadecoxy-6-methyl-3,1-benzoxazin-4-one DMWAHTN CA CAS 282526-98-1 DMWAHTN CB CHEBI:134721 DMWAHTN DE Obesity; Diabetic complication DMX9K3W ID DMX9K3W DMX9K3W DN Cetraxal Otic DMX9K3W HS Phase 3 DMX9K3W SN Ciprofloxacin otic DMX9K3W CP Salvat Laboratories DMX9K3W DE Otitis externa DMIKMA9 ID DMIKMA9 DMIKMA9 DN CG-100649 DMIKMA9 HS Phase 3 DMIKMA9 SN Polmacoxib; 301692-76-2; UNII-IJ34D6YPAO; CG100649; IJ34D6YPAO; 4-(3-(3-fluorophenyl)-5,5-dimethyl-4-oxo-4,5-dihydrofuran-2-yl)benzenesulfonamide; 4-[3-(3-Fluorophenyl)-5,5-Dimethyl-4-Oxidanylidene-Furan-2-Yl]benzenesulfonamide; 4-(3-(3-Fluorophenyl)-5,5-dimethyl-4-oxo-4,5-dihydrofuran-2-yl)-benzenesulfonamide; Polmacoxib [USAN:INN]; CG-100649; Acelex (S. Korea); CG 100649; Polmacoxib (USAN/INN); SCHEMBL3233093; CHEMBL166863; GTPL8316; EX-A601; IJWPAFMIFNSIGD-UHFFFAOYSA-N; ZINC589683; BCP15550; AKOS025149767; SB17177; DB12399 DMIKMA9 CP CG Pharmaceuticals DMIKMA9 DT Small molecular drug DMIKMA9 PC 9841854 DMIKMA9 MW 361.4 DMIKMA9 FM C18H16FNO4S DMIKMA9 IC InChI=1S/C18H16FNO4S/c1-18(2)17(21)15(12-4-3-5-13(19)10-12)16(24-18)11-6-8-14(9-7-11)25(20,22)23/h3-10H,1-2H3,(H2,20,22,23) DMIKMA9 CS CC1(C(=O)C(=C(O1)C2=CC=C(C=C2)S(=O)(=O)N)C3=CC(=CC=C3)F)C DMIKMA9 IK IJWPAFMIFNSIGD-UHFFFAOYSA-N DMIKMA9 IU 4-[3-(3-fluorophenyl)-5,5-dimethyl-4-oxofuran-2-yl]benzenesulfonamide DMIKMA9 CA CAS 301692-76-2 DMIKMA9 DE Arthritis DM1TJXA ID DM1TJXA DM1TJXA DN Chloride DM1TJXA HS Phase 3 DM1TJXA SN chloride ion; 16887-00-6; Chloride(1-); Chloride anion; Chlorine, ion; UNII-Q32ZN48698; Hydrochloric acid, ion(1-); Chlorid; CHEMBL19429; Cl-; CHEBI:17996; Q32ZN48698; Chlorides; Chloride ions; Chloride (ion); Perchloride; Chlorine anion; Chlorine ion; Chloride (Cl-); Chlorine(1-); Chlorine ion(1-); Chloride ion (1-); Chlorine, ion (Cl1-); AC1L18YJ; Cl(-); CTK0H5734; BDBM26979; VEXZGXHMUGYJMC-UHFFFAOYSA-M; c0884; AKOS015903642; FT-0755769; 3-Carbamoyl-1-ethoxymethylpyridinium chloride; 1-Butoxymethyl-3-carbamoyl-pyridinium DM1TJXA DT Small molecular drug DM1TJXA PC 312 DM1TJXA MW 35.45 DM1TJXA FM Cl- DM1TJXA IC InChI=1S/ClH/h1H/p-1 DM1TJXA CS [Cl-] DM1TJXA IK VEXZGXHMUGYJMC-UHFFFAOYSA-M DM1TJXA IU chloride DM1TJXA CA CAS 16887-00-6 DM1TJXA CB CHEBI:17996 DM1TJXA DE Solid tumour/cancer DMORSFB ID DMORSFB DMORSFB DN Chloroquine DMORSFB HS Phase 3 DMORSFB SN Amokin; Aralen; Aralen HCl; Arechin; Arechine; Arequin; Arolen; Arthrochin; Artrichin; Avlochlor; Avloclor; Bemaco; Bemaphate; Bemasulph; Benaquin; Bipiquin; CU-01000012392-2; Capquin; Chemochin; Chingamin; Chloraquine; Chlorochin; Chlorochine; Chlorochinum; Chloroin; Chloroquin; Chloroquina; Chloroquine (USP/INN); Chloroquine (VAN); Chloroquine Bis-Phosphoric Acid; Chloroquine FNA (TN); Chloroquine [USAN:INN:BAN]; Chloroquine phosphate; Chloroquinium; Chloroquinum; Chloroquinum [INN-Latin]; Chlorquin; Cidanchin; Clorochina; Clorochina [DCIT]; Cloroquina; Cloroquina [INN-Spanish]; Cocartrit; Dawaquin (TN); Delagil; Dichinalex; Elestol; Gontochin; Gontochin phosphate; Heliopar; Imagon; Ipsen 225; Iroquine; Khingamin; Klorokin; Lapaquin; Malaquin; Malaquin (*Diphosphate*); Malaren; Malarex; Mesylith; Miniquine; Neochin; Nivachine; Nivaquine B; Pfizerquine; Quinachlor; Quinagamin; Quinagamine; Quinercyl; Quingamine; Quinilon; Quinoscan; RP 3377; RP-3377; Resochen; Resochin; Resochin (TN); Resoquina; Resoquine; Reumachlor; Reumaquin; Rivoquine; Ro 01-6014/N2; Ronaquine; Roquine; SN 6718; SN-7618; ST 21; ST 21 (pharmaceutical); Sanoquin; Silbesan;Siragan; Solprina; Sopaquin; Tanakan; Tanakene; Tresochin; Trochin; W 7618;WIN 244 DMORSFB CP Medreich Sterilab Ltd DMORSFB TC Antiviral Agents DMORSFB DT Small molecular drug DMORSFB PC 2719 DMORSFB MW 319.9 DMORSFB FM C18H26ClN3 DMORSFB IC InChI=1S/C18H26ClN3/c1-4-22(5-2)12-6-7-14(3)21-17-10-11-20-18-13-15(19)8-9-16(17)18/h8-11,13-14H,4-7,12H2,1-3H3,(H,20,21) DMORSFB CS CCN(CC)CCCC(C)NC1=C2C=CC(=CC2=NC=C1)Cl DMORSFB IK WHTVZRBIWZFKQO-UHFFFAOYSA-N DMORSFB IU 4-N-(7-chloroquinolin-4-yl)-1-N,1-N-diethylpentane-1,4-diamine DMORSFB CA CAS 54-05-7 DMORSFB CB CHEBI:3638 DMORSFB DE Malaria; Coronavirus Disease 2019 (COVID-19); Middle East Respiratory Syndrome (MERS); Severe acute respiratory syndrome (SARS) DM5X7DJ ID DM5X7DJ DM5X7DJ DN Chlorpromazine DM5X7DJ HS Phase 3 DM5X7DJ SN Aminasine; Aminazin; Aminazine; Ampliactil; Amplicitil; Amplictil; BC 135; Chlor-PZ; Chlor-Promanyl; Chlordelazine; Chlorderazin; Chloropromazine; Chlorpromados; Chlorpromanyl (discontinued); Chlorpromazin; Chlorpromazine (USP/INN); Chlorpromazine Tannate; Chlorpromazine [USAN:INN:BAN]; Chlorpromazinum; Chlorpromazinum [INN-Latin]; Clorpromazina; Clorpromazina [INN-Spanish]; Clorpromazina [Italian]; Contomin; Cromedazine; Elmarin; Esmind; Fenactil; Fenaktyl; Fraction AB; HL 5746; JHICC02042; Largactil; Largactil (TN); Largactil Liquid; Largactil Oral Drops; Largactilothiazine; Largactyl; Megaphen; Novo-Chlorpromazine; Novomazina; Phenactyl; Phenathyl; Phenothiazine hydrochloride; Plegomasine; Plegomazin; Prazilpromactil; Proma; Promactil; Promazil; Propaphen; Propaphenin; Prozil; Psychozine; SKF 2601-A; SKF 2601A; SKF-2601; Sanopron; Thorazine; Thorazine (TN); Thorazine Spansule; Thorazine Suppositories; Thorazine hydrochloride; Torazina; Wintermin; Z80 DM5X7DJ CP GlaxoSmithKline DM5X7DJ TC Antiviral Agents DM5X7DJ DT Small molecular drug DM5X7DJ PC 2726 DM5X7DJ MW 318.9 DM5X7DJ FM C17H19ClN2S DM5X7DJ IC InChI=1S/C17H19ClN2S/c1-19(2)10-5-11-20-14-6-3-4-7-16(14)21-17-9-8-13(18)12-15(17)20/h3-4,6-9,12H,5,10-11H2,1-2H3 DM5X7DJ CS CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl DM5X7DJ IK ZPEIMTDSQAKGNT-UHFFFAOYSA-N DM5X7DJ IU 3-(2-chlorophenothiazin-10-yl)-N,N-dimethylpropan-1-amine DM5X7DJ CA CAS 34468-21-8 DM5X7DJ CB CHEBI:3647 DM5X7DJ DE Schizophrenia; Middle East Respiratory Syndrome (MERS); Severe acute respiratory syndrome (SARS) DM0Q6CM ID DM0Q6CM DM0Q6CM DN CIGB-300 DM0Q6CM HS Phase 3 DM0Q6CM SN P15; IGBC-300; P15-Tat DM0Q6CM CP Center for Genetic Engineering and Biotechnology DM0Q6CM PC 86290205 DM0Q6CM MW 3060.6 DM0Q6CM FM C127H215N53O30S3 DM0Q6CM IC InChI=1S/C127H215N53O30S3/c1-66(2)55-84-100(189)157-61-97(187)177-98(67(3)182)116(205)176-89(120(209)210)64-213-212-63-88(113(202)173-85(56-68-59-156-71-22-6-5-21-70(68)71)111(200)168-82(40-54-211-4)110(199)175-87(62-181)118(207)178-51-18-32-90(178)114(203)169-79(30-16-48-154-126(143)144)108(197)174-86(112(201)172-84)57-69-60-147-65-158-69)160-95(185)39-50-148-99(188)80(35-37-93(131)183)170-115(204)91-33-19-52-179(91)119(208)92-34-20-53-180(92)117(206)83(31-17-49-155-127(145)146)171-107(196)78(29-15-47-153-125(141)142)165-105(194)76(27-13-45-151-123(137)138)166-109(198)81(36-38-94(132)184)167-106(195)77(28-14-46-152-124(139)140)164-104(193)75(26-12-44-150-122(135)136)163-103(192)74(24-8-10-42-129)162-102(191)73(23-7-9-41-128)161-101(190)72(159-96(186)58-130)25-11-43-149-121(133)134/h5-6,21-22,59-60,65-67,72-92,98,156,181-182H,7-20,23-58,61-64,128-130H2,1-4H3,(H2,131,183)(H2,132,184)(H,147,158)(H,148,188)(H,157,189)(H,159,186)(H,160,185)(H,161,190)(H,162,191)(H,163,192)(H,164,193)(H,165,194)(H,166,198)(H,167,195)(H,168,200)(H,169,203)(H,170,204)(H,171,196)(H,172,201)(H,173,202)(H,174,197)(H,175,199)(H,176,205)(H,177,187)(H,209,210)(H4,133,134,149)(H4,135,136,150)(H4,137,138,151)(H4,139,140,152)(H4,141,142,153)(H4,143,144,154)(H4,145,146,155)/t67-,72+,73+,74+,75+,76+,77+,78+,79+,80+,81+,82+,83+,84+,85+,86+,87+,88+,89+,90+,91+,92+,98+/m1/s1 DM0Q6CM CS C[C@H]([C@H]1C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2CCC[C@H]2C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N1)CC(C)C)CC3=CNC=N3)CCCNC(=N)N)CO)CCSC)CC4=CNC5=CC=CC=C54)NC(=O)CCNC(=O)[C@H](CCC(=O)N)NC(=O)[C@@H]6CCCN6C(=O)[C@@H]7CCCN7C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)CN)C(=O)O)O DM0Q6CM IK RNELHWXSRSKXRD-QNKYCTLBSA-N DM0Q6CM IU (3S,6S,9S,12R,17R,20S,26S,29S,32S,35S)-12-[3-[[(2S)-5-amino-2-[[(2S)-1-[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-6-amino-2-[[(2S)-2-[(2-aminoacetyl)amino]-5-carbamimidamidopentanoyl]amino]hexanoyl]amino]hexanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]propanoylamino]-32-(3-carbamimidamidopropyl)-20-[(1R)-1-hydroxyethyl]-3-(hydroxymethyl)-29-(1H-imidazol-4-ylmethyl)-9-(1H-indol-3-ylmethyl)-26-(2-methylpropyl)-6-(2-methylsulfanylethyl)-2,5,8,11,19,22,25,28,31,34-decaoxo-14,15-dithia-1,4,7,10,18,21,24,27,30,33-decazabicyclo[33.3.0]octatriacontane-17-carboxylic acid DM0Q6CM CB CHEBI:83696 DM0Q6CM DE Cervical cancer DMP0NGX ID DMP0NGX DMP0NGX DN Cilansetron DMP0NGX HS Phase 3 DMP0NGX SN Calmactin; DU-123265; KC-9946; Cilansetron (USAN/INN) DMP0NGX CP Solvay Pharma DMP0NGX DT Small molecular drug DMP0NGX PC 6918107 DMP0NGX MW 319.4 DMP0NGX FM C20H21N3O DMP0NGX IC InChI=1S/C20H21N3O/c1-13-21-9-11-22(13)12-15-7-8-17-18(20(15)24)16-6-2-4-14-5-3-10-23(17)19(14)16/h2,4,6,9,11,15H,3,5,7-8,10,12H2,1H3/t15-/m1/s1 DMP0NGX CS CC1=NC=CN1C[C@H]2CCC3=C(C2=O)C4=CC=CC5=C4N3CCC5 DMP0NGX IK NCNFDKWULDWJDS-OAHLLOKOSA-N DMP0NGX IU (12R)-12-[(2-methylimidazol-1-yl)methyl]-1-azatetracyclo[7.6.1.05,16.010,15]hexadeca-5(16),6,8,10(15)-tetraen-11-one DMP0NGX CA CAS 120635-74-7 DMP0NGX DE Irritable bowel syndrome DMEAOZ0 ID DMEAOZ0 DMEAOZ0 DN Cilengitide DMEAOZ0 HS Phase 3 DMEAOZ0 SN Cilengitide; 188968-51-6; EMD-121974; Cilengitide [USAN:INN]; UNII-4EDF46E4GI; EMD121974; EMD-12192; EMD 121974; 4EDF46E4GI; CHEMBL429876; 2-[(2S,5R,8S,11S)-5-benzyl-11-[3-(diaminomethylideneamino)propyl]-7-methyl-3,6,9,12,15-pentaoxo-8-propan-2-yl-1,4,7,10,13-pentazacyclopentadec-2-yl]acetic acid; Cyclo(L-arginylglycyl-L-aspartyl-D-phenylalanyl-N-methyl-L-valyl); Cyclo(L-arginylglycyl-L-alpha-aspartyl-D-phenylalanyl-N-methyl-L-valyl); Cilengitide (TFA salt) DMEAOZ0 DT Small molecular drug DMEAOZ0 PC 176873 DMEAOZ0 MW 588.7 DMEAOZ0 FM C27H40N8O7 DMEAOZ0 IC InChI=1S/C27H40N8O7/c1-15(2)22-25(41)33-17(10-7-11-30-27(28)29)23(39)31-14-20(36)32-18(13-21(37)38)24(40)34-19(26(42)35(22)3)12-16-8-5-4-6-9-16/h4-6,8-9,15,17-19,22H,7,10-14H2,1-3H3,(H,31,39)(H,32,36)(H,33,41)(H,34,40)(H,37,38)(H4,28,29,30)/t17-,18-,19+,22-/m0/s1 DMEAOZ0 CS CC(C)[C@H]1C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](C(=O)N1C)CC2=CC=CC=C2)CC(=O)O)CCCN=C(N)N DMEAOZ0 IK AMLYAMJWYAIXIA-VWNVYAMZSA-N DMEAOZ0 IU 2-[(2S,5R,8S,11S)-5-benzyl-11-[3-(diaminomethylideneamino)propyl]-7-methyl-3,6,9,12,15-pentaoxo-8-propan-2-yl-1,4,7,10,13-pentazacyclopentadec-2-yl]acetic acid DMEAOZ0 CA CAS 188968-51-6 DMEAOZ0 DE Rheumatoid arthritis DM1975O ID DM1975O DM1975O DN Cilnidipine DM1975O HS Phase 3 DM1975O SN Atelec; Cinaldipine; Cinalong; Siscard; Cilnidipine [INN]; FRC 8653; Atelec (TN); FRC-8653; Cilnidipine (JAN/INN); (+-)-(E)-Cinnamyl 2-methoxyethyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate; 1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 2-methoxyethyl (2E)-3-phenyl-2-propenyl ester; 2-methoxyethyl (2E)-3-phenylprop-2-en-1-yl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; 3-O-(2-methoxyethyl) 5-O-[(E)-3-phenylprop-2-enyl] 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate DM1975O CP Fuji Viscera Pharmaceutical DM1975O DT Small molecular drug DM1975O PC 5282138 DM1975O MW 492.5 DM1975O FM C27H28N2O7 DM1975O IC InChI=1S/C27H28N2O7/c1-18-23(26(30)35-14-8-11-20-9-5-4-6-10-20)25(21-12-7-13-22(17-21)29(32)33)24(19(2)28-18)27(31)36-16-15-34-3/h4-13,17,25,28H,14-16H2,1-3H3/b11-8+ DM1975O CS CC1=C(C(C(=C(N1)C)C(=O)OC/C=C/C2=CC=CC=C2)C3=CC(=CC=C3)[N+](=O)[O-])C(=O)OCCOC DM1975O IK KJEBULYHNRNJTE-DHZHZOJOSA-N DM1975O IU 3-O-(2-methoxyethyl) 5-O-[(E)-3-phenylprop-2-enyl] 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate DM1975O CA CAS 132203-70-4 DM1975O CB CHEBI:31399 DM1975O DE High blood pressure DMU2J7Y ID DMU2J7Y DMU2J7Y DN Ciltacabtagene autoleucel DMU2J7Y HS Phase 3 DMU2J7Y SN JNJ-68284528 DMU2J7Y CP Janssen DMU2J7Y DT CAR T Cell Therapy DMU2J7Y DE Multiple myeloma DMEGFYD ID DMEGFYD DMEGFYD DN Cinitapride DMEGFYD HS Phase 3 DMEGFYD SN Cinitapride; 66564-14-5; Cidine; cinitapride tartrate; Blaston; Cinitapride [INN]; C21H30N4O4; Cinitapride hydrogen tartrate; Cinitapride (INN); 4-amino-N-[1-(cyclohex-3-en-1-ylmethyl)piperidin-4-yl]-2-ethoxy-5-nitrobenzamide; Cinitapridum; Cinitaprida; Paxapride; Cinitapridum [INN-Latin]; Cinitaprida [INN-Spanish]; cidin; Cintapro; Cinmove; UNII-R8I97I2L24; Paxapride (TN); AC1Q1YMD; AC1L2AM4; (non-labelled)Cinitapride-d5; SCHEMBL476454; SCHEMBL19235643; CHEMBL2104523; CHEBI:135642; R8I97I2L24; BCP04096; AKOS015909742; DB08810 DMEGFYD CP Eisai DMEGFYD DT Small molecular drug DMEGFYD PC 68867 DMEGFYD MW 402.5 DMEGFYD FM C21H30N4O4 DMEGFYD IC InChI=1S/C21H30N4O4/c1-2-29-20-13-18(22)19(25(27)28)12-17(20)21(26)23-16-8-10-24(11-9-16)14-15-6-4-3-5-7-15/h3-4,12-13,15-16H,2,5-11,14,22H2,1H3,(H,23,26) DMEGFYD CS CCOC1=CC(=C(C=C1C(=O)NC2CCN(CC2)CC3CCC=CC3)[N+](=O)[O-])N DMEGFYD IK ZDLBNXXKDMLZMF-UHFFFAOYSA-N DMEGFYD IU 4-amino-N-[1-(cyclohex-3-en-1-ylmethyl)piperidin-4-yl]-2-ethoxy-5-nitrobenzamide DMEGFYD CA CAS 66564-14-5 DMEGFYD CB CHEBI:135642 DMEGFYD DE Functional dyspepsia DM803GL ID DM803GL DM803GL DN CIPEMASTAT DM803GL HS Phase 3 DM803GL SN Cipemastat; Trocade; Ro 32-3555; 190648-49-8; UNII-02HQ4TYQ60; 02HQ4TYQ60; GFUITADOEPNRML-SJORKVTESA-N; Cipemastat [USAN:INN]; Ro 32-3555/000; Trocade (TN); Cipemastat (USAN/INN); GTPL6466; CHEMBL115653; SCHEMBL7088217; CTK8F1312; BDBM30344; MolPort-023-276-601; ZINC600699; (alphaR,betaR)-beta-(Cyclopentylmethyl)-gamma-oxo-alpha-((3,4,4-piperidinebutyrohydroxamic acid; AKOS024457333; HY-19677; Ro-32-03555; Ro-323555000; RT-015421; RO32-3555; CS-0016192; D03517; J-012306 DM803GL DT Small molecular drug DM803GL PC 9824350 DM803GL MW 436.5 DM803GL FM C22H36N4O5 DM803GL IC InChI=1S/C22H36N4O5/c1-22(2)20(29)26(21(30)24(22)3)14-17(18(27)23-31)16(13-15-9-5-6-10-15)19(28)25-11-7-4-8-12-25/h15-17,31H,4-14H2,1-3H3,(H,23,27)/t16-,17+/m1/s1 DM803GL CS CC1(C(=O)N(C(=O)N1C)C[C@@H]([C@@H](CC2CCCC2)C(=O)N3CCCCC3)C(=O)NO)C DM803GL IK GFUITADOEPNRML-SJORKVTESA-N DM803GL IU (2R,3R)-3-(cyclopentylmethyl)-N-hydroxy-4-oxo-4-piperidin-1-yl-2-[(3,4,4-trimethyl-2,5-dioxoimidazolidin-1-yl)methyl]butanamide DM803GL CA CAS 190648-49-8 DM803GL DE Rheumatoid arthritis DMJ9ZIY ID DMJ9ZIY DMJ9ZIY DN CK-2017357 DMJ9ZIY HS Phase 3 DMJ9ZIY SN Tirasemtiv; 1005491-05-3; Tirasemtiv(CK-2017357); CK-2017357; UNII-G8WSM7R635; G8WSM7R635; 5-ethynyl-3-pentan-3-yl-1H-imidazo[4,5-b]pyrazin-2-one; CK 2017357; 6-ethynyl-1-(pentan-3-yl)-1H-imidazo[4,5-b]pyrazin-2-ol; 2H-Imidazo[4,5-b]pyrazin-2-one, 1-(1-ethylpropyl)-6-ethynyl-1,3-dihydro-;2H-Imidazo[4,5-b]pyrazin-2-one, 1-(1-ethylpropyl)-6-ethynyl-1,3-dihydro-; Tirasemtiv [USAN:INN]; Tirasemtiv (USAN/INN); SCHEMBL976988; GTPL8280; tiraseMtiv (CK-2017357); CHEMBL3039529; EX-A367; DTXSID90143379; RSQGZEAXODVTOL-UHFFFAOYSA-N DMJ9ZIY CP Cytokinetics DMJ9ZIY DT Small molecular drug DMJ9ZIY PC 23729157 DMJ9ZIY MW 230.27 DMJ9ZIY FM C12H14N4O DMJ9ZIY IC InChI=1S/C12H14N4O/c1-4-8-7-13-10-11(14-8)16(12(17)15-10)9(5-2)6-3/h1,7,9H,5-6H2,2-3H3,(H,13,15,17) DMJ9ZIY CS CCC(CC)N1C2=NC(=CN=C2NC1=O)C#C DMJ9ZIY IK RSQGZEAXODVTOL-UHFFFAOYSA-N DMJ9ZIY IU 5-ethynyl-3-pentan-3-yl-1H-imidazo[4,5-b]pyrazin-2-one DMJ9ZIY CA CAS 1005491-05-3 DMJ9ZIY DE Muscle fatigue; Amyotrophic lateral sclerosis DMTSONL ID DMTSONL DMTSONL DN Claritin/Singulair DMTSONL HS Phase 3 DMTSONL SN Loratadine/montelukast sodium DMTSONL CP Schering-Plough DMTSONL DE Allergic rhinitis DMPQR1D ID DMPQR1D DMPQR1D DN Claudiximab DMPQR1D HS Phase 3 DMPQR1D SN IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed DMPQR1D CP Ganymed Pharmaceuticals AG DMPQR1D DT Antibody DMPQR1D DE Esophageal cancer; Gastric adenocarcinoma DMQSBX4 ID DMQSBX4 DMQSBX4 DN Clazosentan DMQSBX4 HS Phase 3 DMQSBX4 SN Clazosentan; 180384-56-9; Ro-61-1790; VML-588; UNII-3DRR0X4728; AXV-343434; CHEMBL109648; 3DRR0X4728; Clazosentan [INN]; VML 588; AXV 034; AXV-034343; Ro 61-1790; AXV-034; AXV 034343; AC1O5FK3; SCHEMBL1652657; CTK4D7597; DTXSID60170955; ZINC3939238; BDBM50066370; AKOS032946377; SB18855; N-[6-(2-HYDROXYETHOXY)-5-(2-METHOXYPHENOXY)-2-[2-(2H-TETRAZOL-5-YL)-4-PYRIDINYL]-4-PYRIMIDINYL]-5-METHYL-2-PYRIDINESULFONAMIDE; DB-065318; FT-0765561 DMQSBX4 CP Actelion Pharmaceuticals DMQSBX4 DT Small molecular drug DMQSBX4 PC 6433095 DMQSBX4 MW 577.6 DMQSBX4 FM C25H23N9O6S DMQSBX4 IC InChI=1S/C25H23N9O6S/c1-15-7-8-20(27-14-15)41(36,37)32-24-21(40-19-6-4-3-5-18(19)38-2)25(39-12-11-35)29-22(28-24)16-9-10-26-17(13-16)23-30-33-34-31-23/h3-10,13-14,35H,11-12H2,1-2H3,(H,28,29,32)(H,30,31,33,34) DMQSBX4 CS CC1=CN=C(C=C1)S(=O)(=O)NC2=C(C(=NC(=N2)C3=CC(=NC=C3)C4=NNN=N4)OCCO)OC5=CC=CC=C5OC DMQSBX4 IK LFWCJABOXHSRGC-UHFFFAOYSA-N DMQSBX4 IU N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-[2-(2H-tetrazol-5-yl)pyridin-4-yl]pyrimidin-4-yl]-5-methylpyridine-2-sulfonamide DMQSBX4 CA CAS 180384-56-9 DMQSBX4 DE Vasospasm; Cerebral vasospasm DMR21Q3 ID DMR21Q3 DMR21Q3 DN Clevudine DMR21Q3 HS Phase 3 DMR21Q3 SN Clevudine; 163252-36-6; Levovir; L-FMAU; UNII-IN51MVP5F1; Clevudine (Levovir); IN51MVP5F1; 1-(2-Deoxy-2-fluoro-beta-L-arabinofuranosyl)thymine; 1-((2S,3R,4S,5S)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione; AK106264; 1-[(2S,3R,4S,5S)-3-fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-5-methyl-pyrimidine-2,4-dione; 1-[(2S,3R,4S,5S)-3-fluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione; Clevudine [USAN:INN]; Revovir; Clevudine (USAN) DMR21Q3 CP Bukwang; Eisai DMR21Q3 DT Small molecular drug DMR21Q3 PC 73115 DMR21Q3 MW 260.22 DMR21Q3 FM C10H13FN2O5 DMR21Q3 IC InChI=1S/C10H13FN2O5/c1-4-2-13(10(17)12-8(4)16)9-6(11)7(15)5(3-14)18-9/h2,5-7,9,14-15H,3H2,1H3,(H,12,16,17)/t5-,6+,7-,9-/m0/s1 DMR21Q3 CS CC1=CN(C(=O)NC1=O)[C@@H]2[C@@H]([C@H]([C@@H](O2)CO)O)F DMR21Q3 IK GBBJCSTXCAQSSJ-XQXXSGGOSA-N DMR21Q3 IU 1-[(2S,3R,4S,5S)-3-fluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione DMR21Q3 CA CAS 163252-36-6 DMR21Q3 CB CHEBI:135964 DMR21Q3 DE Hepatitis B virus infection DMSPN58 ID DMSPN58 DMSPN58 DN Clomethiazole DMSPN58 HS Phase 3 DMSPN58 SN Clomethiazole; 533-45-9; Chlormethiazole; 5-(2-CHLOROETHYL)-4-METHYLTHIAZOLE; Distraneurin; Emineurina; Clomethiazolum; Chlormethiazol; Chlorethiazol; Chlorethiazole; Somnevrin; Clometiazole; Clomethiazol; 5-(2-Chloroethyl)-4-methyl-1,3-thiazole; Thiazole, 5-(2-chloroethyl)-4-methyl-; Clometiazolo [DCIT]; Chloro-S.C.T.Z.; C6H8ClNS; UNII-0C5DBZ19HV; Clometiazol [INN-Spanish]; Clomethiazolum [INN-Latin]; WY 1485; Clomethiazole [INN]; SCTZ [as edisylate]; EINECS 208-565-7; 4-Methyl-5-(beta-chloroethyl)thiazole; BRN 0114244; 0C5DBZ19HV DMSPN58 DT Small molecular drug DMSPN58 PC 10783 DMSPN58 MW 161.65 DMSPN58 FM C6H8ClNS DMSPN58 IC InChI=1S/C6H8ClNS/c1-5-6(2-3-7)9-4-8-5/h4H,2-3H2,1H3 DMSPN58 CS CC1=C(SC=N1)CCCl DMSPN58 IK PCLITLDOTJTVDJ-UHFFFAOYSA-N DMSPN58 IU 5-(2-chloroethyl)-4-methyl-1,3-thiazole DMSPN58 CA CAS 533-45-9 DMSPN58 CB CHEBI:92875 DMSPN58 DE Stroke DMFQ1WX ID DMFQ1WX DMFQ1WX DN CLS006 DMFQ1WX HS Phase 3 DMFQ1WX CP Cutanea Wayne, PA DMFQ1WX DE Verruca vulgaris DMASPWR ID DMASPWR DMASPWR DN CM-2395 DMASPWR HS Phase 3 DMASPWR CP Cenomed BioSciences DMASPWR DE Schizophrenia DMLMN2F ID DMLMN2F DMLMN2F DN CM-AT DMLMN2F HS Phase 3 DMLMN2F DE Autism spectrum disorder; Attention deficit hyperactivity disorder DMC4X7L ID DMC4X7L DMC4X7L DN CMS-024-02 DMC4X7L HS Phase 3 DMC4X7L SN Tyroserleutide; Tyroservatide; CMS-024; CMS-024); Tyroserleutide (iv, cancer), China Medical System; Tyroserleutide (iv, cancer), Shenzhen Kangzhe Pharmaceuticals; Tyroservatide (cancer), Shenzhen Kangzhe Pharmaceuticals/ China Medical System Holdings; Tyroserleutide (iv, cancer), Shenzhen Kangzhe Pharmaceuticals/ China Medical System; Tyrosyl-seryl-leucine (cancer), Tianjin Medical University/Shenzhen Kangzhe Pharmaceutical DMC4X7L CP Shenzhen Kangzhe Pharmaceutical Co Ltd DMC4X7L PC 11303106 DMC4X7L MW 367.4 DMC4X7L FM C17H25N3O6 DMC4X7L IC InChI=1S/C17H25N3O6/c1-9(2)14(17(25)26)20-16(24)13(8-21)19-15(23)12(18)7-10-3-5-11(22)6-4-10/h3-6,9,12-14,21-22H,7-8,18H2,1-2H3,(H,19,23)(H,20,24)(H,25,26)/t12-,13-,14-/m0/s1 DMC4X7L CS CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CC=C(C=C1)O)N DMC4X7L IK TYFLVOUZHQUBGM-IHRRRGAJSA-N DMC4X7L IU (2S)-2-[[(2S)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]-3-methylbutanoic acid DMC4X7L CA CAS 154039-16-4 DMC4X7L CB CHEBI:165974 DMC4X7L DE Solid tumour/cancer DM9Y3B5 ID DM9Y3B5 DM9Y3B5 DN CMX-001 DM9Y3B5 HS Phase 3 DM9Y3B5 SN Brincidofovir; CMX001; 444805-28-1; Hexadecyloxypropyl-cidofovir; CMX 001; Hexadecyloxypropyl cidofovir; UNII-6794O900AX; 6794O900AX; HDP-Cidofovir; Cidofovir-HDP; [(2S)-1-(4-amino-2-oxopyrimidin-1-yl)-3-hydroxypropan-2-yl]oxymethyl-(3-hexadecoxypropoxy)phosphinic acid; Brincidofovir [USAN:INN]; Hexadecyloxypropyl - cidofovir; Cidofovir prodrug; HDP-HPMPC; Brincidofovir (USAN); AC1LA8GF; 3-(hexadecyloxy)propyl hydrogen ((((S)-1-(4-amino-2-oxopyrimidin-1(2H)-yl)-3-hydroxypropan-2-yl)oxy) DM9Y3B5 CP Chimerix DM9Y3B5 DT Small molecular drug DM9Y3B5 PC 483477 DM9Y3B5 MW 561.7 DM9Y3B5 FM C27H52N3O7P DM9Y3B5 IC InChI=1S/C27H52N3O7P/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-19-35-20-16-21-37-38(33,34)24-36-25(23-31)22-30-18-17-26(28)29-27(30)32/h17-18,25,31H,2-16,19-24H2,1H3,(H,33,34)(H2,28,29,32)/t25-/m0/s1 DM9Y3B5 CS CCCCCCCCCCCCCCCCOCCCOP(=O)(CO[C@@H](CN1C=CC(=NC1=O)N)CO)O DM9Y3B5 IK WXJFKKQWPMNTIM-VWLOTQADSA-N DM9Y3B5 IU [(2S)-1-(4-amino-2-oxopyrimidin-1-yl)-3-hydroxypropan-2-yl]oxymethyl-(3-hexadecoxypropoxy)phosphinic acid DM9Y3B5 CA CAS 444805-28-1 DM9Y3B5 DE Solid tumour/cancer DMB4JPG ID DMB4JPG DMB4JPG DN CNTX-4975 DMB4JPG HS Phase 3 DMB4JPG CP Centrexion Therapeutics Boston, MA DMB4JPG DE Pain; Morton neuroma; Knee osteoarthritis DMWZ2TU ID DMWZ2TU DMWZ2TU DN CO-1686 DMWZ2TU HS Phase 3 DMWZ2TU SN 1374640-70-6; AVL-301; CO1686; UNII-72AH61702G; CNX-419; CO-1686 (AVL-301); Rociletinib(AVL-301,CNX-419,CO-1686); 72AH61702G; N-(3-((2-((4-(4-acetylpiperazin-1-yl)-2-methoxyphenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)phenyl)acrylamide; CO 1686; Rociletinib (CO-1686, AVL-301); Rociletinib [USAN:INN]; Tube721; Rociletinib (USAN/INN); Rociletinib (CO-1686); SCHEMBL4177736; GTPL7966; CHEMBL3545308; EX-A228; MolPort-035-395-816; C27H28F3N7O3; HMS3653G08; BDBM149404; BCP07085; AOB87314; ZINC98043800; s7284 DMWZ2TU CP Clovis Oncology DMWZ2TU DT Small molecular drug DMWZ2TU PC 57335384 DMWZ2TU MW 555.6 DMWZ2TU FM C27H28F3N7O3 DMWZ2TU IC InChI=1S/C27H28F3N7O3/c1-4-24(39)32-18-6-5-7-19(14-18)33-25-21(27(28,29)30)16-31-26(35-25)34-22-9-8-20(15-23(22)40-3)37-12-10-36(11-13-37)17(2)38/h4-9,14-16H,1,10-13H2,2-3H3,(H,32,39)(H2,31,33,34,35) DMWZ2TU CS CC(=O)N1CCN(CC1)C2=CC(=C(C=C2)NC3=NC=C(C(=N3)NC4=CC(=CC=C4)NC(=O)C=C)C(F)(F)F)OC DMWZ2TU IK HUFOZJXAKZVRNJ-UHFFFAOYSA-N DMWZ2TU IU N-[3-[[2-[4-(4-acetylpiperazin-1-yl)-2-methoxyanilino]-5-(trifluoromethyl)pyrimidin-4-yl]amino]phenyl]prop-2-enamide DMWZ2TU CA CAS 1374640-70-6 DMWZ2TU DE Lung cancer; Non-small-cell lung cancer DMN9ETB ID DMN9ETB DMN9ETB DN Contusugene ladenovec DMN9ETB HS Phase 3 DMN9ETB SN Advexin; Ad5CMV-p53; INGN-004; INGN-201; Ad-p53, Introgen; Gene therapy (p53/adenovirus), University of Texas; Gene therapy (p53/adenoviral), Introgen/Aventis; Gene therapy (p53/adenoviral), Introgen/RPR DMN9ETB CP Introgen Therapeutics DMN9ETB DE Oral cancer; Liver metastasis DMA0WEK ID DMA0WEK DMA0WEK DN Coprexa DMA0WEK HS Phase 3 DMA0WEK SN Tetrathiomolybdate DMA0WEK CP Pipex Pharmaceuticals DMA0WEK DT Small molecular drug DMA0WEK PC 5245480 DMA0WEK MW 226.2 DMA0WEK FM H2MoS4-2 DMA0WEK IC InChI=1S/Mo.2H2S.2S/h;2*1H2;;/p-2 DMA0WEK CS [SH-].[SH-].S=[Mo]=S DMA0WEK IK VVRHUOPINLMZBL-UHFFFAOYSA-L DMA0WEK IU bis(sulfanylidene)molybdenum;sulfanide DMA0WEK CA CAS 16330-92-0 DMA0WEK CB CHEBI:30703 DMA0WEK DE Neurological disorder DMBS3UG ID DMBS3UG DMBS3UG DN CORT-125134 DMBS3UG HS Phase 3 DMBS3UG SN relacorilant; Relacorilant; UNII-2158753C7E; 2158753C7E; 1496510-51-0; Relacorilant [INN]; Relacorilant [WHO-DD]; Relacorilant [USAN:INN]; SCHEMBL15454999; WANIDIGFXJFFEL-SANMLTNESA-N; CORT125134; ZINC141949519; AKOS032945759; J3.651.009I; ((4aR)-1-(4-fluorophenyl)-6-(1-methyl-1H-pyrazole-4-sulfonyl)-1,4,5,6,7,8-hexahydro-4aH-pyrazolo(3,4-g)isoquinolin-4a-yl)(4-(trifluoromethyl)pyridin-2-yl)methanone; Methanone, ((4aR)-1-(4-fluorophenyl)-1,4,5,6,7,8-hexahydro-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)-4ah-pyrazolo(3,4-g)isoqui DMBS3UG CP Corcept TherapeuticsMenlo Park, CA DMBS3UG PC 73051463 DMBS3UG MW 586.6 DMBS3UG FM C27H22F4N6O3S DMBS3UG IC InChI=1S/C27H22F4N6O3S/c1-35-15-22(14-33-35)41(39,40)36-9-7-18-11-24-17(13-34-37(24)21-4-2-20(28)3-5-21)12-26(18,16-36)25(38)23-10-19(6-8-32-23)27(29,30)31/h2-6,8,10-11,13-15H,7,9,12,16H2,1H3/t26-/m0/s1 DMBS3UG CS CN1C=C(C=N1)S(=O)(=O)N2CCC3=CC4=C(C[C@@]3(C2)C(=O)C5=NC=CC(=C5)C(F)(F)F)C=NN4C6=CC=C(C=C6)F DMBS3UG IK WANIDIGFXJFFEL-SANMLTNESA-N DMBS3UG IU [(4aR)-1-(4-fluorophenyl)-6-(1-methylpyrazol-4-yl)sulfonyl-4,5,7,8-tetrahydropyrazolo[3,4-g]isoquinolin-4a-yl]-[4-(trifluoromethyl)pyridin-2-yl]methanone DMBS3UG CA CAS 1496510-51-0 DMBS3UG DE Alcohol dependence; Solid tumour/cancer; Cushing disease DMMEAOL ID DMMEAOL DMMEAOL DN Coversin DMMEAOL HS Phase 3 DMMEAOL CP Akari Therapeutics DMMEAOL DT Recombinant?protein DMMEAOL DE Paroxysmal nocturnal haemoglobinuria DMZIM37 ID DMZIM37 DMZIM37 DN CP-868596 DMZIM37 HS Phase 3 DMZIM37 SN Crenolanib; 670220-88-9; Crenolanib (CP-868596); ARO-002; UNII-LQF7I567TQ; LQF7I567TQ; CP-868596 (Crenolanib); CP-868,596; [1-[2-[5-(3-Methyloxetan-3-ylmethoxy)benzimidazol-1-yl]quinolin-8-yl]piperidin-4-yl]amine; 1-(2-(5-((3-Methyloxetan-3-yl)methoxy)-1H-benzo-[d]imidazol-1-yl)quinolin-8-yl)piperidin-4-amine; CP868569; 1-[2-[5-[(3-Methyl-3-oxetanyl)methoxy]-1-benzimidazolyl]-8-quinolyl]-4-piperidinamine; J-502712; 1-[2-[5-[(3-methyloxetan-3-yl)methoxy]benzimidazol-1-yl]quinolin-8-yl]piperidin-4-amine DMZIM37 CP Pfizer DMZIM37 TC Anticancer Agents DMZIM37 DT Small molecular drug DMZIM37 PC 10366136 DMZIM37 MW 443.5 DMZIM37 FM C26H29N5O2 DMZIM37 IC InChI=1S/C26H29N5O2/c1-26(14-32-15-26)16-33-20-6-7-22-21(13-20)28-17-31(22)24-8-5-18-3-2-4-23(25(18)29-24)30-11-9-19(27)10-12-30/h2-8,13,17,19H,9-12,14-16,27H2,1H3 DMZIM37 CS CC1(COC1)COC2=CC3=C(C=C2)N(C=N3)C4=NC5=C(C=CC=C5N6CCC(CC6)N)C=C4 DMZIM37 IK DYNHJHQFHQTFTP-UHFFFAOYSA-N DMZIM37 IU 1-[2-[5-[(3-methyloxetan-3-yl)methoxy]benzimidazol-1-yl]quinolin-8-yl]piperidin-4-amine DMZIM37 CA CAS 670220-88-9 DMZIM37 CB CHEBI:145365 DMZIM37 DE Gastrointestinal cancer; Acute myelogenous leukaemia; Malignant glioma; Acute myeloid leukaemia; Gastrointestinal stromal tumour DM2EO5M ID DM2EO5M DM2EO5M DN CPC-211 DM2EO5M HS Phase 3 DM2EO5M SN Dichloracetate; Dichloroacetate; Dichloroacetate ion; Dichloroacetic acid ion(1-); LS-11597; STL483470; 13425-80-4; 2,2-bis(chloranyl)ethanoate; 2,2-dichloroacetate; 2q8h; 68626-EP2292227A2; 68626-EP2292628A2; 68626-EP2298776A1; 68626-EP2308861A1; 68626-EP2374454A1; A839686; ACETIC ACID, DICHLORO-, ION(1-); Acetic acid,2,2-dichloro-, ion(1-); BRN 3903873; CHEBI:28240; CTK4B9070; DCA; DTXSID40158610; GTPL4518; NCGC00241105-01 DM2EO5M PC 25975 DM2EO5M MW 127.93 DM2EO5M FM C2HCl2O2- DM2EO5M IC JXTHNDFMNIQAHM-UHFFFAOYSA-M DM2EO5M CS C(C(=O)[O-])(Cl)Cl DM2EO5M IK 1S/C2H2Cl2O2/c3-1(4)2(5)6/h1H,(H,5,6)/p-1 DM2EO5M IU 2,2-dichloroacetate DM2EO5M CA CAS 13425-80-4 DM2EO5M CB CHEBI:28240 DM2EO5M DE Dehydrogenase PDC deficiency DMPXOYJ ID DMPXOYJ DMPXOYJ DN CPI-0610 DMPXOYJ HS Phase 3 DMPXOYJ CP Constellation pharmaceuticals DMPXOYJ PC 57389999 DMPXOYJ MW 365.8 DMPXOYJ FM C20H16ClN3O2 DMPXOYJ IC InChI=1S/C20H16ClN3O2/c1-11-18-14-4-2-3-5-15(14)19(12-6-8-13(21)9-7-12)23-16(10-17(22)25)20(18)26-24-11/h2-9,16H,10H2,1H3,(H2,22,25)/t16-/m0/s1 DMPXOYJ CS CC1=NOC2=C1C3=CC=CC=C3C(=N[C@H]2CC(=O)N)C4=CC=C(C=C4)Cl DMPXOYJ IK GCWIQUVXWZWCLE-INIZCTEOSA-N DMPXOYJ IU 2-[(4S)-6-(4-chlorophenyl)-1-methyl-4H-[1,2]oxazolo[5,4-d][2]benzazepin-4-yl]acetamide DMPXOYJ CA CAS 1380087-89-7 DMPXOYJ DE Acute myeloid leukaemia; Myelodysplastic neoplasm; Myeloproliferative neoplasm; Myelofibrosis DM5XUQL ID DM5XUQL DM5XUQL DN CPI-613 DM5XUQL HS Phase 3 DM5XUQL SN CPI-613; 95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874 DM5XUQL CP Cornerstone Pharmaceuticals DM5XUQL DT Small molecular drug DM5XUQL PC 24770514 DM5XUQL MW 388.6 DM5XUQL FM C22H28O2S2 DM5XUQL IC InChI=1S/C22H28O2S2/c23-22(24)14-8-7-13-21(26-18-20-11-5-2-6-12-20)15-16-25-17-19-9-3-1-4-10-19/h1-6,9-12,21H,7-8,13-18H2,(H,23,24) DM5XUQL CS C1=CC=C(C=C1)CSCCC(CCCCC(=O)O)SCC2=CC=CC=C2 DM5XUQL IK ZYRLHJIMTROTBO-UHFFFAOYSA-N DM5XUQL IU 6,8-bis(benzylsulfanyl)octanoic acid DM5XUQL CA CAS 95809-78-2 DM5XUQL DE Acute myeloid leukaemia; Myelodysplastic syndrome; B-cell lymphoma; Metastatic colorectal cancer; Recurrent adult burkitt lymphoma; T-cell lymphoma; Pancreatic cancer DM62E7C ID DM62E7C DM62E7C DN CPL-7075 DM62E7C HS Phase 3 DM62E7C SN Ajulemic acid; Lenabasum; IP-751; CT-3; 137945-48-3; IP 751; UNII-OGN7X90BT8; CPL7075; JBT-101; OGN7X90BT8; Resunab; (6aR,10aR)-1-hydroxy-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene-9-carboxylic acid; (6ar,10ar)-3-(1,1-Dimethylheptyl)-1-Hydroxy-6,6-Dimethyl-6a,7,10,10a-Tetrahydro-6h-Benzo[c]chromene-9-Carboxylic Acid; DMH-THC-11-OIC; AB-III-56; CT 3; CPL 7075; Lenabasum [USAN]; HU-239; AC1MJ0SY; SCHEMBL26441; CHEMBL456341; GTPL9772; IP751; Mixed CB agonist/sodim channel blocker (pain), Cervelo DM62E7C CP Cervelo Pharmaceuticals Ltd DM62E7C DT Small molecular drug DM62E7C PC 3083542 DM62E7C MW 400.5 DM62E7C FM C25H36O4 DM62E7C IC InChI=1S/C25H36O4/c1-6-7-8-9-12-24(2,3)17-14-20(26)22-18-13-16(23(27)28)10-11-19(18)25(4,5)29-21(22)15-17/h10,14-15,18-19,26H,6-9,11-13H2,1-5H3,(H,27,28)/t18-,19-/m1/s1 DM62E7C CS CCCCCCC(C)(C)C1=CC(=C2[C@@H]3CC(=CC[C@H]3C(OC2=C1)(C)C)C(=O)O)O DM62E7C IK YCHYFHOSGQABSW-RTBURBONSA-N DM62E7C IU (6aR,10aR)-1-hydroxy-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene-9-carboxylic acid DM62E7C CA CAS 137945-48-3 DM62E7C DE Cystic fibrosis; Rheumatoid arthritis; Systemic lupus erythematosus; Systemic sclerosis; Diffuse systemic sclerosis DM60TVK ID DM60TVK DM60TVK DN CQA 206-291 DM60TVK HS Phase 3 DM60TVK SN Cqa 206-291; Cqa-206-291; 93822-42-5; UNII-9I4I0M95U7; 9I4I0M95U7; N,N-Diethyl-N-(1-ethyl-6-methylergoline-8-yl)sulfamide; AC1L3TWB; SCHEMBL8195741; Sulfamide, N,N-diethyl-N'-((8alpha)-1-ethyl-6-methylergolin-8-yl)- DM60TVK DT Small molecular drug DM60TVK PC 9953076 DM60TVK MW 404.6 DM60TVK FM C21H32N4O2S DM60TVK IC InChI=1S/C21H32N4O2S/c1-5-24-13-15-11-20-18(17-9-8-10-19(24)21(15)17)12-16(14-23(20)4)22-28(26,27)25(6-2)7-3/h8-10,13,16,18,20,22H,5-7,11-12,14H2,1-4H3/t16-,18+,20+/m0/s1 DM60TVK CS CCN1C=C2C[C@@H]3[C@H](C[C@@H](CN3C)NS(=O)(=O)N(CC)CC)C4=C2C1=CC=C4 DM60TVK IK ARTRTLXKTHJPRW-ILZDJORESA-N DM60TVK IU (6aR,9S,10aR)-9-(diethylsulfamoylamino)-4-ethyl-7-methyl-6,6a,8,9,10,10a-hexahydroindolo[4,3-fg]quinoline DM60TVK CA CAS 93822-42-5 DM60TVK DE Parkinson disease DMKD2BQ ID DMKD2BQ DMKD2BQ DN Creatine ALS-08 DMKD2BQ HS Phase 3 DMKD2BQ SN Creatine; ALS-02; ALS-05; ALS-08; HD-02; PD-02; PD-04; PD-06; Creatine (ALS), Avicena; Creatine (amyotrophic lateral sclerosis), Avicena; PD-01, Avicena; AL-02 (ALS), Avicena; AL-08 (ALS), Avicena; Creatine (Huntington's disease), Avicena; Creatine (Parkinson's disease), Avicena DMKD2BQ CP Avicena Group Inc; Avicena DMKD2BQ DT Small molecular drug DMKD2BQ PC 586 DMKD2BQ MW 131.13 DMKD2BQ FM C4H9N3O2 DMKD2BQ IC InChI=1S/C4H9N3O2/c1-7(4(5)6)2-3(8)9/h2H2,1H3,(H3,5,6)(H,8,9) DMKD2BQ CS CN(CC(=O)O)C(=N)N DMKD2BQ IK CVSVTCORWBXHQV-UHFFFAOYSA-N DMKD2BQ IU 2-[carbamimidoyl(methyl)amino]acetic acid DMKD2BQ CA CAS 57-00-1 DMKD2BQ CB CHEBI:16919 DMKD2BQ DE Motor neurone disease DM7QI29 ID DM7QI29 DM7QI29 DN Crenezumab DM7QI29 HS Phase 3 DM7QI29 SN MABT5102A; RG7412 DM7QI29 CP Genentech DM7QI29 DT Monoclonal antibody DM7QI29 DE Alzheimer disease DM5F24X ID DM5F24X DM5F24X DN Crocin DM5F24X HS Phase 3 DM5F24X DE Knee osteoarthritis DM67P0F ID DM67P0F DM67P0F DN CS-038 DM67P0F HS Phase 3 DM67P0F SN Chiglitazar; CS-00098; PPAR alpha/gamma agonist (diabetes), Chipscreen Biosciences DM67P0F CP Shenzhen Chipscreen Biosciences Ltd DM67P0F DT Small molecular drug DM67P0F PC 71402018 DM67P0F MW 572.6 DM67P0F FM C36H29FN2O4 DM67P0F IC InChI=1S/C36H29FN2O4/c37-26-17-15-25(16-18-26)35(40)30-9-1-4-10-31(30)38-32(36(41)42)23-24-13-19-27(20-14-24)43-22-21-39-33-11-5-2-7-28(33)29-8-3-6-12-34(29)39/h1-20,32,38H,21-23H2,(H,41,42)/t32-/m0/s1 DM67P0F CS C1=CC=C2C(=C1)C3=CC=CC=C3N2CCOC4=CC=C(C=C4)C[C@@H](C(=O)O)NC5=CC=CC=C5C(=O)C6=CC=C(C=C6)F DM67P0F IK QNLWMPLUWMWDMQ-YTTGMZPUSA-N DM67P0F IU (2S)-3-[4-(2-carbazol-9-ylethoxy)phenyl]-2-[2-(4-fluorobenzoyl)anilino]propanoic acid DM67P0F CA CAS 743438-45-1 DM67P0F DE Type-2 diabetes DMSY0NE ID DMSY0NE DMSY0NE DN CS1001 DMSY0NE HS Phase 3 DMSY0NE CP CStone Pharmaceuticals DMSY0NE DT Antibody DMSY0NE DE Non-small cell lung cancer DM1PV4Y ID DM1PV4Y DM1PV4Y DN CS-600G DM1PV4Y HS Phase 3 DM1PV4Y SN Koloxo; Loxoprofen; Loxoprofen (INN); Loxoprofen [INN]; Loxoprofen sodium hydrate; Loxoprofene; Loxoprofene [French]; Loxoprofeno; Loxoprofeno [Spanish]; Loxoprofenum; Loxoprofenum [Latin]; YMBXTVYHTMGZDW-UHFFFAOYSA-N; sodium loxoprofen; yl]-propionic acid; 2-(4-((2-Oxocyclopentyl)methyl)phenyl)propanoic acid; 2-[4-(2-Oxo-cyclopentylmethyl)-phen; 2-[4-[(2-oxocyclopentyl)methyl]phenyl]propanoic acid; 2-{4-[(2-oxocyclopentyl)methyl]phenyl}propanoic acid; 68767-14-6; CHEBI:76172; CHEMBL19299; CS-600; MFCD00864331; Oxeno DM1PV4Y PC 3965 DM1PV4Y MW 246.3 DM1PV4Y FM C15H18O3 DM1PV4Y IC YMBXTVYHTMGZDW-UHFFFAOYSA-N DM1PV4Y CS CC(C1=CC=C(C=C1)CC2CCCC2=O)C(=O)O DM1PV4Y IK 1S/C15H18O3/c1-10(15(17)18)12-7-5-11(6-8-12)9-13-3-2-4-14(13)16/h5-8,10,13H,2-4,9H2,1H3,(H,17,18) DM1PV4Y IU 2-[4-[(2-oxocyclopentyl)methyl]phenyl]propanoic acid DM1PV4Y CA CAS 68767-14-6 DM1PV4Y CB CHEBI:76172 DM1PV4Y DE Epilepsy DM4CSDH ID DM4CSDH DM4CSDH DN CS-8958 DM4CSDH HS Phase 3 DM4CSDH SN Inavir; Laninamivir octanoate; R-118958 DM4CSDH CP Biota DM4CSDH DT Small molecular drug DM4CSDH PC 9847629 DM4CSDH MW 472.5 DM4CSDH FM C21H36N4O8 DM4CSDH IC InChI=1S/C21H36N4O8/c1-4-5-6-7-8-9-16(28)32-11-14(27)18(31-3)19-17(24-12(2)26)13(25-21(22)23)10-15(33-19)20(29)30/h10,13-14,17-19,27H,4-9,11H2,1-3H3,(H,24,26)(H,29,30)(H4,22,23,25)/t13-,14+,17+,18+,19+/m0/s1 DM4CSDH CS CCCCCCCC(=O)OC[C@H]([C@H]([C@H]1[C@@H]([C@H](C=C(O1)C(=O)O)N=C(N)N)NC(=O)C)OC)O DM4CSDH IK UKTIJASCFRNWCB-RMIBSVFLSA-N DM4CSDH IU (2R,3R,4S)-3-acetamido-4-(diaminomethylideneamino)-2-[(1R,2R)-2-hydroxy-1-methoxy-3-octanoyloxypropyl]-3,4-dihydro-2H-pyran-6-carboxylic acid DM4CSDH CA CAS 203120-46-1 DM4CSDH CB CHEBI:134741 DM4CSDH DE Influenza virus infection DMV574J ID DMV574J DMV574J DN CSL312 DMV574J HS Phase 3 DMV574J SN Garadacimab DMV574J CP CSL Behring DMV574J DT Antibody DMV574J DE Hereditary angioedema DMZJGVL ID DMZJGVL DMZJGVL DN CSL-654 DMZJGVL HS Phase 3 DMZJGVL SN RIX-FP; Recombinant coagulation factor IX (iv, hemophilia B), CSL Behring; Recombinant coagulation factor IX (extended half-life, hemophilia B), CSL Behring DMZJGVL CP Csl behring DMZJGVL SQ DB00100 sequence: YNSGKLEEFVQGNLERECMEEKCSFEEAREVFENTERTTEFWKQYVDGDQCESNPCLNGGSCKDDINSYECWCPFGFEGKNCELDVTCNIKNGRCEQFCKNSADNKVVCSCTEGYRLAENQKSCEPAVPFPCGRVSVSQTSKLTRAEAVFPDVDYVNSTEAETILDNITQSTQSFNDFTRVVGGEDAKPGQFPWQVVLNGKVDAFCGGSIVNEKWIVTAAHCVETGVKITVVAGEHNIEETEHTEQKRNVIRIIPHHNYNAAINKYNHDIALLELDEPLVLNSYVTPICIADKEYTNIFLKFGSGYVSGWGRVFHKGRSALVLQYLRVPLVDRATCLRSTKFTIYNNMFCAGFHEGGRDSCQGDSGGPHVTEVEGTSFLTGIISWGEECAMKGKYGIYTKVSRYVNWIKEKTKLT DMZJGVL DE Factor IX deficiency DMU2ZFK ID DMU2ZFK DMU2ZFK DN CT-2584 DMU2ZFK HS Phase 3 DMU2ZFK SN Apra (Cell Therapeutics, US, US); 1-[11-(Dodecylamino)-10-hydroxyundecyl]-3,7-dimethylxanthine DMU2ZFK CP Cell Therapeutics DMU2ZFK DT Small molecular drug DMU2ZFK PC 3081346 DMU2ZFK MW 533.8 DMU2ZFK FM C30H55N5O3 DMU2ZFK IC InChI=1S/C30H55N5O3/c1-4-5-6-7-8-9-10-13-16-19-22-31-24-26(36)21-18-15-12-11-14-17-20-23-35-29(37)27-28(32-25-33(27)2)34(3)30(35)38/h25-26,31,36H,4-24H2,1-3H3 DMU2ZFK CS CCCCCCCCCCCCNCC(CCCCCCCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C)O DMU2ZFK IK MZNMZWZGUGFQJP-UHFFFAOYSA-N DMU2ZFK IU 1-[11-(dodecylamino)-10-hydroxyundecyl]-3,7-dimethylpurine-2,6-dione DMU2ZFK CA CAS 166981-13-1 DMU2ZFK DE Solid tumour/cancer DMQPH29 ID DMQPH29 DMQPH29 DN Curcumin DMQPH29 HS Phase 3 DMQPH29 SN curcumin; 458-37-7; Diferuloylmethane; Natural yellow 3; Turmeric yellow; Turmeric; Curcuma; Kacha haldi; Gelbwurz; Indian saffron; Curcumin I; Souchet; Halud; Halad; Haidr; Haldar; Merita earth; Yellow Ginger; Terra Merita; Yellow Root; Safran d'Inde; Yo-Kin; Golden seal; Curcuma oil; Orange Root; Oils, curcuma; CI Natural Yellow 3; Curcumine; Hydrastis; Indian turmeric; Yellow puccoon; Turmeric extract; Diferaloylmethane; Kurkumin [Czech]; (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione; Tumeric yellow; Turmeric oil DMQPH29 DT Small molecular drug DMQPH29 PC 969516 DMQPH29 MW 368.4 DMQPH29 FM C21H20O6 DMQPH29 IC InChI=1S/C21H20O6/c1-26-20-11-14(5-9-18(20)24)3-7-16(22)13-17(23)8-4-15-6-10-19(25)21(12-15)27-2/h3-12,24-25H,13H2,1-2H3/b7-3+,8-4+ DMQPH29 CS COC1=C(C=CC(=C1)/C=C/C(=O)CC(=O)/C=C/C2=CC(=C(C=C2)O)OC)O DMQPH29 IK VFLDPWHFBUODDF-FCXRPNKRSA-N DMQPH29 IU (1E,6E)-1,7-bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione DMQPH29 CA CAS 458-37-7 DMQPH29 CB CHEBI:3962 DMQPH29 DE Solid tumour/cancer DMIQ31Y ID DMIQ31Y DMIQ31Y DN Custirsen DMIQ31Y HS Phase 3 DMIQ31Y SN OGX-001/TV-1011; OGX-011 DMIQ31Y CP OncoGenex Pharmaceuticals DMIQ31Y DT Small molecular drug DMIQ31Y PC 72941942 DMIQ31Y MW 7346 DMIQ31Y FM C231H312N78O119P20S20 DMIQ31Y IC InChI=1S/C231H312N78O119P20S20/c1-97-52-295(224(324)273-181(97)235)210-174(361-32-24-353-10)166(118(60-310)401-210)422-444(347,464)383-78-136-171(179(366-37-29-358-15)215(406-136)308-95-265-160-189(243)253-86-259-195(160)308)427-448(351,468)387-80-138-172(180(367-38-30-359-16)216(408-138)309-96-269-164-199(309)279-220(247)283-208(164)320)428-447(350,467)385-76-134-168(175(362-33-25-354-11)211(403-134)296-53-98(2)182(236)274-225(296)325)423-442(345,462)380-73-131-114(48-151(397-131)303-90-263-158-187(241)251-84-257-193(158)303)417-439(342,459)379-72-128-115(49-152(398-128)304-91-266-161-196(304)276-217(244)280-205(161)317)418-435(338,455)370-63-121-107(41-144(390-121)291-22-19-141(234)272-223(291)323)411-430(333,450)374-67-125-111(45-148(394-125)300-87-260-155-184(238)248-81-254-190(155)300)415-437(340,457)378-71-130-117(51-154(400-130)306-93-268-163-198(306)278-219(246)282-207(163)319)420-440(343,460)376-68-126-112(46-149(395-126)301-88-261-156-185(239)249-82-255-191(156)301)416-438(341,458)377-70-129-116(50-153(399-129)305-92-267-162-197(305)277-218(245)281-206(162)318)419-436(339,456)373-66-124-109(43-146(393-124)293-56-101(5)201(313)285-228(293)328)413-433(336,453)368-61-119-105(39-142(388-119)289-20-17-139(232)270-221(289)321)409-429(332,449)371-64-122-110(44-147(391-122)294-57-102(6)202(314)286-229(294)329)414-434(337,454)372-65-123-108(42-145(392-123)292-55-100(4)200(312)284-227(292)327)412-432(335,452)369-62-120-106(40-143(389-120)290-21-18-140(233)271-222(290)322)410-431(334,451)375-69-127-113(47-150(396-127)302-89-262-157-186(240)250-83-256-192(157)302)421-441(344,461)382-75-133-167(177(364-35-27-356-13)213(405-133)299-59-104(8)204(316)288-231(299)331)424-445(348,465)384-77-135-169(176(363-34-26-355-12)212(404-135)297-54-99(3)183(237)275-226(297)326)425-446(349,466)386-79-137-170(178(365-36-28-357-14)214(407-137)307-94-264-159-188(242)252-85-258-194(159)307)426-443(346,463)381-74-132-165(311)173(360-31-23-352-9)209(402-132)298-58-103(7)203(315)287-230(298)330/h17-22,52-59,81-96,105-138,142-154,165-180,209-216,310-311H,23-51,60-80H2,1-16H3,(H,332,449)(H,333,450)(H,334,451)(H,335,452)(H,336,453)(H,337,454)(H,338,455)(H,339,456)(H,340,457)(H,341,458)(H,342,459)(H,343,460)(H,344,461)(H,345,462)(H,346,463)(H,347,464)(H,348,465)(H,349,466)(H,350,467)(H,351,468)(H2,232,270,321)(H2,233,271,322)(H2,234,272,323)(H2,235,273,324)(H2,236,274,325)(H2,237,275,326)(H2,238,248,254)(H2,239,249,255)(H2,240,250,256)(H2,241,251,257)(H2,242,252,258)(H2,243,253,259)(H,284,312,327)(H,285,313,328)(H,286,314,329)(H,287,315,330)(H,288,316,331)(H3,244,276,280,317)(H3,245,277,281,318)(H3,246,278,282,319)(H3,247,279,283,320)/t105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118+,119+,120+,121+,122+,123+,124+,125+,126+,127+,128+,129+,130+,131+,132+,133+,134+,135+,136+,137+,138+,142+,143+,144+,145+,146+,147+,148+,149+,150+,151+,152+,153+,154+,165+,166+,167+,168+,169+,170+,171+,172+,173+,174+,175+,176+,177+,178+,179+,180+,209+,210+,211+,212+,213+,214+,215+,216+,429?,430?,431?,432?,433?,434?,435?,436?,437?,438?,439?,440?,441?,442?,443?,444?,445?,446?,447?,448?/m0/s1 DMIQ31Y CS CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)COP(=S)(O)O[C@H]3C[C@@H](O[C@@H]3COP(=S)(O)O[C@H]4C[C@@H](O[C@@H]4COP(=S)(O)O[C@H]5C[C@@H](O[C@@H]5COP(=S)(O)O[C@H]6C[C@@H](O[C@@H]6COP(=S)(O)O[C@H]7C[C@@H](O[C@@H]7COP(=S)(O)O[C@H]8C[C@@H](O[C@@H]8COP(=S)(O)O[C@H]9C[C@@H](O[C@@H]9COP(=S)(O)O[C@H]1C[C@@H](O[C@@H]1COP(=S)(O)O[C@H]1C[C@@H](O[C@@H]1COP(=S)(O)O[C@@H]1[C@H](O[C@H]([C@@H]1OCCOC)N1C=C(C(=NC1=O)N)C)COP(=S)(O)O[C@@H]1[C@H](O[C@H]([C@@H]1OCCOC)N1C=NC2=C1N=C(NC2=O)N)COP(=S)(O)O[C@@H]1[C@H](O[C@H]([C@@H]1OCCOC)N1C=NC2=C(N=CN=C21)N)COP(=S)(O)O[C@@H]1[C@H](O[C@H]([C@@H]1OCCOC)N1C=C(C(=NC1=O)N)C)CO)N1C=NC2=C(N=CN=C21)N)N1C=NC2=C1N=C(NC2=O)N)N1C=CC(=NC1=O)N)N1C=NC2=C(N=CN=C21)N)N1C=NC2=C1N=C(NC2=O)N)N1C=NC2=C(N=CN=C21)N)N1C=NC2=C1N=C(NC2=O)N)N1C=C(C(=O)NC1=O)C)N1C=CC(=NC1=O)N)OP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N1C=C(C(=O)NC1=O)C)OP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N1C=CC(=NC1=O)N)OP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N1C=NC2=C(N=CN=C21)N)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=C(C(=O)NC1=O)C)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=C(C(=NC1=O)N)C)OCCOC)OP(=O)(OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=NC2=C(N=CN=C21)N)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=C(C(=O)NC1=O)C)OCCOC)O)S DMIQ31Y IK RCFZILUHCNXXFY-DEDWCYLFSA-N DMIQ31Y IU 1-[(2R,4S,5R)-5-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-2-[[[(2R,3R,4R,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-2-[[[(2R,3R,4R,5R)-2-[[[(2R,3R,4R,5R)-2-[[[(2R,3R,4R,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-2-(hydroxymethyl)-4-(2-methoxyethoxy)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(6-aminopurin-9-yl)-4-(2-methoxyethoxy)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(2-amino-6-oxo-1H-purin-9-yl)-4-(2-methoxyethoxy)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-4-(2-methoxyethoxy)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(6-aminopurin-9-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(2-amino-6-oxo-1H-purin-9-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(6-aminopurin-9-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(2-amino-6-oxo-1H-purin-9-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(6-aminopurin-9-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(2-amino-6-oxo-1H-purin-9-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-4-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3R,4R,5R)-3-[[(2R,3R,4R,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[(2R,3R,4R,5R)-5-(6-aminopurin-9-yl)-3-[hydroxy-[[(2R,3R,4R,5R)-3-hydroxy-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy]phosphinothioyl]oxy-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-sulfanylphosphoryl]oxy-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]-5-methylpyrimidine-2,4-dione DMIQ31Y CA CAS 890056-27-6 DMIQ31Y DE Lung cancer; Breast cancer; Prostate cancer DM0JA9N ID DM0JA9N DM0JA9N DN Cyrtominetin DM0JA9N HS Phase 3 DM0JA9N SN IdB-1031; D,L-5,7,3',4'-Tetrahydroxy-6,8-dimethylflavanone; Rac-5,7-Dihydroxy-2-(3,4-dihydroxyphenyl)-6,8-dimethyl-2,3-dihydro-4H-1-benzopyran-4-one DM0JA9N DT Small molecular drug DM0JA9N PC 125309 DM0JA9N MW 316.3 DM0JA9N FM C17H16O6 DM0JA9N IC InChI=1S/C17H16O6/c1-7-15(21)8(2)17-14(16(7)22)12(20)6-13(23-17)9-3-4-10(18)11(19)5-9/h3-5,13,18-19,21-22H,6H2,1-2H3 DM0JA9N CS CC1=C(C(=C2C(=C1O)C(=O)CC(O2)C3=CC(=C(C=C3)O)O)C)O DM0JA9N IK AESMRHCYHARBLU-UHFFFAOYSA-N DM0JA9N IU 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-6,8-dimethyl-2,3-dihydrochromen-4-one DM0JA9N CA CAS 95272-99-4 DM0JA9N DE Phlegmy cough DMUF0BJ ID DMUF0BJ DMUF0BJ DN CYTISINE DMUF0BJ HS Phase 3 DMUF0BJ SN CYTISINE; 485-35-8; Sophorine; Baptitoxine; (-)-Cytisine; Laburnin; Baptitoxin; Tabex; Ulexin; Cytiton; Ulexine; Tsitizin; Cytitone; Cystisine; Cytizin; Citizin; Tabax; (1R,5S)-3,4,5,6-Tetrahydro-1H-1,5-methanopyrido[1,2-a][1,5]diazocin-8(2H)-one; Baphitoxine; UNII-53S5U404NU; Cytisine (-); HSDB 3560; EINECS 207-616-0; NSC 407282; BRN 0083882; Cytisin; (1r,5s)-1,2,3,4,5,6-Hexahydro-8h-1,5-Methanopyrido[1,2-A][1,5]diazocin-8-One; CHEBI:4055; CHEMBL497939; 53S5U404NU; Cytisine, 98% DMUF0BJ DT Small molecular drug DMUF0BJ PC 10235 DMUF0BJ MW 190.24 DMUF0BJ FM C11H14N2O DMUF0BJ IC InChI=1S/C11H14N2O/c14-11-3-1-2-10-9-4-8(5-12-6-9)7-13(10)11/h1-3,8-9,12H,4-7H2/t8-,9+/m0/s1 DMUF0BJ CS C1[C@H]2CNC[C@@H]1C3=CC=CC(=O)N3C2 DMUF0BJ IK ANJTVLIZGCUXLD-DTWKUNHWSA-N DMUF0BJ IU (1R,9S)-7,11-diazatricyclo[7.3.1.02,7]trideca-2,4-dien-6-one DMUF0BJ CA CAS 485-35-8 DMUF0BJ CB CHEBI:4055 DMUF0BJ DE Tobacco dependence DMYJ2QB ID DMYJ2QB DMYJ2QB DN D2A21 DMYJ2QB HS Phase 3 DMYJ2QB SN Demegel (Demegen, US, US); Alanyl-L-phenylalanyl-L-alanyl-L-phenylalanine DMYJ2QB PC 16199213 DMYJ2QB MW 2775.4 DMYJ2QB FM C144H212N32O24 DMYJ2QB IC InChI=1S/C144H212N32O24/c1-91(155-128(183)105(154)83-97-49-15-7-16-50-97)122(177)161-106(65-31-40-74-145)129(184)165-111(70-36-45-79-150)134(189)172-117(86-100-55-21-10-22-56-100)139(194)156-93(3)124(179)163-108(67-33-42-76-147)131(186)167-114(73-39-48-82-153)137(192)175-120(89-103-61-27-13-28-62-103)143(198)169-110(69-35-44-78-149)132(187)168-113(72-38-47-81-152)136(191)174-119(88-102-59-25-12-26-60-102)140(195)157-92(2)123(178)162-107(66-32-41-75-146)130(185)166-112(71-37-46-80-151)135(190)173-118(87-101-57-23-11-24-58-101)141(196)158-94(4)125(180)164-109(68-34-43-77-148)133(188)171-116(85-99-53-19-9-20-54-99)142(197)159-95(5)126(181)170-115(84-98-51-17-8-18-52-98)138(193)160-96(6)127(182)176-121(144(199)200)90-104-63-29-14-30-64-104/h7-30,49-64,91-96,105-121H,31-48,65-90,145-154H2,1-6H3,(H,155,183)(H,156,194)(H,157,195)(H,158,196)(H,159,197)(H,160,193)(H,161,177)(H,162,178)(H,163,179)(H,164,180)(H,165,184)(H,166,185)(H,167,186)(H,168,187)(H,169,198)(H,170,181)(H,171,188)(H,172,189)(H,173,190)(H,174,191)(H,175,192)(H,176,182)(H,199,200)/t91-,92-,93-,94-,95-,96-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-/m0/s1 DMYJ2QB CS C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC4=CC=CC=C4)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC5=CC=CC=C5)C(=O)N[C@@H](C)C(=O)N[C@@H](CC6=CC=CC=C6)C(=O)N[C@@H](C)C(=O)N[C@@H](CC7=CC=CC=C7)C(=O)O)NC(=O)[C@H](CC8=CC=CC=C8)N DMYJ2QB IK WVRNJUBRGDUHNI-CPOCOYSOSA-N DMYJ2QB IU (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-amino-3-phenylpropanoyl]amino]propanoyl]amino]hexanoyl]amino]hexanoyl]amino]-3-phenylpropanoyl]amino]propanoyl]amino]hexanoyl]amino]hexanoyl]amino]-3-phenylpropanoyl]amino]hexanoyl]amino]hexanoyl]amino]-3-phenylpropanoyl]amino]propanoyl]amino]hexanoyl]amino]hexanoyl]amino]-3-phenylpropanoyl]amino]propanoyl]amino]hexanoyl]amino]-3-phenylpropanoyl]amino]propanoyl]amino]-3-phenylpropanoyl]amino]propanoyl]amino]-3-phenylpropanoic acid DMYJ2QB DE Burn and burn infection DM9FAJM ID DM9FAJM DM9FAJM DN D-5519 DM9FAJM HS Phase 3 DM9FAJM DE Asthma DM6S4R2 ID DM6S4R2 DM6S4R2 DN DA-3031 DM6S4R2 HS Phase 3 DM6S4R2 SN Long-acting agent (neutropenia), Dong-A; PEG-GCSF (neutropenia), Dong-A; PEG-granulocyte colony stimulating factor (neutropenia),Dong-A DM6S4R2 CP Dong-A Pharmaceutical Co Ltd DM6S4R2 DT Small molecular drug DM6S4R2 PC 168302 DM6S4R2 MW 185.26 DM6S4R2 FM C10H19NO2 DM6S4R2 IC InChI=1S/C8H15NO2.C2H4/c1-7(2)8(10)11-6-5-9(3)4;1-2/h1,5-6H2,2-4H3;1-2H2 DM6S4R2 CS CC(=C)C(=O)OCCN(C)C.C=C DM6S4R2 IK PNMYDOBPCBCQIA-UHFFFAOYSA-N DM6S4R2 IU 2-(dimethylamino)ethyl 2-methylprop-2-enoate;ethene DM6S4R2 CA CAS 25134-54-7 DM6S4R2 DE Neutropenia DMP2SGN ID DMP2SGN DMP2SGN DN Dabelotine DMP2SGN HS Phase 3 DMP2SGN SN Dabelotine mesilate; S-12024; S-12024-2 DMP2SGN CP Servier DMP2SGN DT Small molecular drug DMP2SGN PC 177949 DMP2SGN MW 262.35 DMP2SGN FM C15H22N2O2 DMP2SGN IC InChI=1S/C15H22N2O2/c1-17-8-3-5-12-4-2-6-14(15(12)17)19-11-13-10-16-7-9-18-13/h2,4,6,13,16H,3,5,7-11H2,1H3 DMP2SGN CS CN1CCCC2=C1C(=CC=C2)OCC3CNCCO3 DMP2SGN IK VXQWMLATWQSCBE-UHFFFAOYSA-N DMP2SGN IU 2-[(1-methyl-3,4-dihydro-2H-quinolin-8-yl)oxymethyl]morpholine DMP2SGN CA CAS 118976-38-8 DMP2SGN DE Cognitive impairment DMRDZ4X ID DMRDZ4X DMRDZ4X DN Dabigatran etexilate DMRDZ4X HS Phase 3 DMRDZ4X SN BIBR-1048; 211915-06-9; Dabigatran etexilate mesilate; ethyl N-[(2-{[(4-{N'-[(hexyloxy)carbonyl]carbamimidoyl}phenyl)amino]methyl}-1-methyl-1H-benzimidazol-5-yl)carbonyl]-N-pyridin-2-yl-beta-alaninate; Dabigatran etexilate methanesulfonate; BIBR-1048 (Dabigatran); UNII-2E18WX195X; BIBR1048; BIBR-1048-BS-RS1; CHEBI:70746; 2E18WX195X; cc-72; DSSTox_CID_31470; DSSTox_RID_97355; DSSTox_GSID_57681; SCHEMBL505829; DTXSID4057681; Dabigatran etexilate (USAN/INN); MolPort-016-633-287; EBD35035; Tox21_113924; BDBM504 DMRDZ4X CP Boehringer Ingelheim Ridgefield, CT DMRDZ4X PC 135565674 DMRDZ4X MW 627.7 DMRDZ4X FM C34H41N7O5 DMRDZ4X IC InChI=1S/C34H41N7O5/c1-4-6-7-10-21-46-34(44)39-32(35)24-12-15-26(16-13-24)37-23-30-38-27-22-25(14-17-28(27)40(30)3)33(43)41(20-18-31(42)45-5-2)29-11-8-9-19-36-29/h8-9,11-17,19,22,37H,4-7,10,18,20-21,23H2,1-3H3,(H2,35,39,44) DMRDZ4X CS CCCCCCOC(=O)NC(=N)C1=CC=C(C=C1)NCC2=NC3=C(N2C)C=CC(=C3)C(=O)N(CCC(=O)OCC)C4=CC=CC=N4 DMRDZ4X IK KSGXQBZTULBEEQ-UHFFFAOYSA-N DMRDZ4X IU ethyl 3-[[2-[[4-(N-hexoxycarbonylcarbamimidoyl)anilino]methyl]-1-methylbenzimidazole-5-carbonyl]-pyridin-2-ylamino]propanoate DMRDZ4X CA CAS 211915-06-9 DMRDZ4X DE Venous thromboembolism DMKNCVM ID DMKNCVM DMKNCVM DN Dalcetrapib DMKNCVM HS Phase 3 DMKNCVM SN JTT 705; JTT-705; R-1658; RG-1658; RO-4607381; S-[2-[[1-(2-ethylbutyl)cyclohexanecarbonyl]amino]phenyl] 2-methylpropanethioate DMKNCVM CP Roche DMKNCVM DT Small molecular drug DMKNCVM PC 6918540 DMKNCVM MW 389.6 DMKNCVM FM C23H35NO2S DMKNCVM IC InChI=1S/C23H35NO2S/c1-5-18(6-2)16-23(14-10-7-11-15-23)22(26)24-19-12-8-9-13-20(19)27-21(25)17(3)4/h8-9,12-13,17-18H,5-7,10-11,14-16H2,1-4H3,(H,24,26) DMKNCVM CS CCC(CC)CC1(CCCCC1)C(=O)NC2=CC=CC=C2SC(=O)C(C)C DMKNCVM IK YZQLWPMZQVHJED-UHFFFAOYSA-N DMKNCVM IU S-[2-[[1-(2-ethylbutyl)cyclohexanecarbonyl]amino]phenyl] 2-methylpropanethioate DMKNCVM CA CAS 211513-37-0 DMKNCVM CB CHEBI:95001 DMKNCVM DE Hyperlipidaemia; Acute coronary syndrome DM1C95G ID DM1C95G DM1C95G DN DARE-BV1 DM1C95G HS Phase 3 DM1C95G CP Dare Bioscience DM1C95G DT Small molecular drug DM1C95G DE Bacterial vaginosis DMR2JD4 ID DMR2JD4 DMR2JD4 DN Darotropium + 642444 DMR2JD4 HS Phase 3 DMR2JD4 CP GSK DMR2JD4 DT Combination drug DMR2JD4 PC 25195533; 642444 DMR2JD4 DE Chronic obstructive pulmonary disease DM2FV5N ID DM2FV5N DM2FV5N DN Darunavir + cobicistat DM2FV5N HS Phase 3 DM2FV5N SN Prezcobix; Prezista + GS-9350 DM2FV5N TC Antiviral Agents DM2FV5N DT Combination drug DM2FV5N DE Coronavirus Disease 2019 (COVID-19) DMF3V01 ID DMF3V01 DMF3V01 DN Darunavir + ritonavir + favipiravir + hydroxychloroquine DMF3V01 HS Phase 3 DMF3V01 SN Prezista + norvir + T-705 + oxichloroquine DMF3V01 TC Antiviral Agents DMF3V01 DT Combination drug DMF3V01 DE Coronavirus Disease 2019 (COVID-19) DMN9BO3 ID DMN9BO3 DMN9BO3 DN Darunavir + ritonavir + oseltamivir + hydroxychloroquine DMN9BO3 HS Phase 3 DMN9BO3 SN Prezista + norvir + rseltamivir + oxichloroquine DMN9BO3 TC Antiviral Agents DMN9BO3 DT Combination drug DMN9BO3 DE Coronavirus Disease 2019 (COVID-19) DMN8DQH ID DMN8DQH DMN8DQH DN Darusentan DMN8DQH HS Phase 3 DMN8DQH SN Endothelin antagonist, BASF; HMR-4005; LU-127043; LU-135252 DMN8DQH CP Gilead Sciences; Knoll GmbH DMN8DQH DT Small molecular drug DMN8DQH PC 177236 DMN8DQH MW 410.4 DMN8DQH FM C22H22N2O6 DMN8DQH IC InChI=1S/C22H22N2O6/c1-27-17-14-18(28-2)24-21(23-17)30-19(20(25)26)22(29-3,15-10-6-4-7-11-15)16-12-8-5-9-13-16/h4-14,19H,1-3H3,(H,25,26)/t19-/m1/s1 DMN8DQH CS COC1=CC(=NC(=N1)O[C@H](C(=O)O)C(C2=CC=CC=C2)(C3=CC=CC=C3)OC)OC DMN8DQH IK FEJVSJIALLTFRP-LJQANCHMSA-N DMN8DQH IU (2S)-2-(4,6-dimethoxypyrimidin-2-yl)oxy-3-methoxy-3,3-diphenylpropanoic acid DMN8DQH CA CAS 171714-84-4 DMN8DQH DE Hypotension DMD7K9X ID DMD7K9X DMD7K9X DN Davunetide DMD7K9X HS Phase 3 DMD7K9X SN Davunetide; NAP; AL-108; AL-208; Davunetide (intranasal spray), Allon; NAPVSIPQ eight amino acid peptide (intranasal spray), Allon; Davunetide (intravenous-infused), Allon Therapeutics; NAP eight amino acid peptide (neuroprotection/cognitive impairment), Allon; NAPVSIPQ eight amino acid peptide (neuroprotection/cognitive impairment), Allon; Central nervous system therapeutic (Alzheimer's disease/schizophrenia), Allon; Central nervous system therapeutic (post-cardiac artery bypass graft/mild cognitive impairment), Allon; NAPVSIPQ eight amino acid peptide (intravenous-infused/subcutaneous depot formulation), Allon Therapeutics; Davunetide (iv/sc, Alzheimer's disease), Allon Therapeutics DMD7K9X CP Allon Therapeutics Inc DMD7K9X DE Cognitive impairment; Alzheimer disease DMUX7Z8 ID DMUX7Z8 DMUX7Z8 DN DE-117 DMUX7Z8 HS Phase 3 DMUX7Z8 PC 44230999 DMUX7Z8 MW 520.6 DMUX7Z8 FM C26H28N6O4S DMUX7Z8 IC InChI=1S/C26H28N6O4S/c1-20(2)36-26(33)17-28-25-8-3-6-22(30-25)19-31(37(34,35)24-7-4-13-27-16-24)18-21-9-11-23(12-10-21)32-15-5-14-29-32/h3-16,20H,17-19H2,1-2H3,(H,28,30) DMUX7Z8 CS CC(C)OC(=O)CNC1=CC=CC(=N1)CN(CC2=CC=C(C=C2)N3C=CC=N3)S(=O)(=O)C4=CN=CC=C4 DMUX7Z8 IK VIQCWEGEHRBLAC-UHFFFAOYSA-N DMUX7Z8 IU propan-2-yl 2-[[6-[[(4-pyrazol-1-ylphenyl)methyl-pyridin-3-ylsulfonylamino]methyl]pyridin-2-yl]amino]acetate DMUX7Z8 CA CAS 1187451-19-9 DMUX7Z8 DE Glaucoma/ocular hypertension DM0GUV2 ID DM0GUV2 DM0GUV2 DN DE-766 DM0GUV2 HS Phase 3 DM0GUV2 CP Daiichi Sankyo DM0GUV2 DE Non-small-cell lung cancer; Gastric adenocarcinoma; Nasopharyngeal carcinoma DM2R15Q ID DM2R15Q DM2R15Q DN DENBUFYLLINE DM2R15Q HS Phase 3 DM2R15Q SN denbufylline; 57076-71-8; Denbufyllinum [Latin]; Denbufilina [Spanish]; BRL 30892; BRL-30892; UNII-04B949KO6F; 1,3-Di-n-butyl-7-(2-oxopropyl)xanthine; CHEMBL277465; 7-Acetonyl-1,3-dibutylxanthine; C16H24N4O3; 04B949KO6F; 3,7-Dihydro-1,3-dibutyl-7-(2-oxopropyl)-1H-purine-2,6-dione; 1,3-Di-n-butyl-7-(2& -oxopropyl)xanthine; Denbufyllinum; Denbufilina; 1H-Purine-2,6-dione,1,3-dibutyl-3,7-dihydro-7-(2-oxopropyl)-; 1H-Purine-2,6-dione, 3,7-dihydro-1,3-dibutyl-7-(2-oxopropyl)-; Denbufylline [INN:BAN]; Denbufylline [BAN:INN DM2R15Q DT Small molecular drug DM2R15Q PC 2984 DM2R15Q MW 320.39 DM2R15Q FM C16H24N4O3 DM2R15Q IC InChI=1S/C16H24N4O3/c1-4-6-8-19-14-13(18(11-17-14)10-12(3)21)15(22)20(16(19)23)9-7-5-2/h11H,4-10H2,1-3H3 DM2R15Q CS CCCCN1C2=C(C(=O)N(C1=O)CCCC)N(C=N2)CC(=O)C DM2R15Q IK HJPRDDKCXVCFOH-UHFFFAOYSA-N DM2R15Q IU 1,3-dibutyl-7-(2-oxopropyl)purine-2,6-dione DM2R15Q CA CAS 57076-71-8 DM2R15Q CB CHEBI:92669 DM2R15Q DE Cognitive impairment DM2ATZB ID DM2ATZB DM2ATZB DN Deoxynojirimycin DM2ATZB HS Phase 3 DM2ATZB SN 1-DEOXYNOJIRIMYCIN; 19130-96-2; DUVOGLUSTAT; deoxynojirimycin; Moranoline; (2R,3R,4R,5S)-2-(hydroxymethyl)piperidine-3,4,5-triol; 1,5-Deoxy-1,5-imino-D-mannitol; Moranolin; UNII-FZ56898FLE; D-1-deoxynojirimycin; 1,5-Dideoxy-1,5-imino-D-glucitol; CHEMBL307429; C6H13NO4; FZ56898FLE; CHEBI:44369; 1-Deoxy-Nojirimycin; 5-Amino-1,5-dideoxy-D-glucopyranose; DNJ; AK151410; 3,4,5-Piperidinetriol, 2-(hydroxymethyl)-, (2R,3R,4R,5S)-; 3,4,5-Piperidinetriol, 2-(hydroxymethyl)-, (2R-(2alpha,3beta,4alpha,5beta))- DM2ATZB DT Small molecular drug DM2ATZB PC 29435 DM2ATZB MW 163.17 DM2ATZB FM C6H13NO4 DM2ATZB IC InChI=1S/C6H13NO4/c8-2-3-5(10)6(11)4(9)1-7-3/h3-11H,1-2H2/t3-,4+,5-,6-/m1/s1 DM2ATZB CS C1[C@@H]([C@H]([C@@H]([C@H](N1)CO)O)O)O DM2ATZB IK LXBIFEVIBLOUGU-JGWLITMVSA-N DM2ATZB IU (2R,3R,4R,5S)-2-(hydroxymethyl)piperidine-3,4,5-triol DM2ATZB CA CAS 19130-96-2 DM2ATZB CB CHEBI:44369 DM2ATZB DE Pompe disease DMDLU4Z ID DMDLU4Z DMDLU4Z DN Desmoteplase DMDLU4Z HS Phase 3 DMDLU4Z CP Lundbeck Research DMDLU4Z SQ P98119|URT1_DESRO Salivary plasminogen activator alpha 1 precursor - Desmodus rotundus: MVNTMKTKLLCVLLLCGAVFSLPRQETYRQLARGSRAYGVACKDEITQMTYRRQESWLRPEVRSKRVEHCQCDRGQARCHTVPVNSCSEPRCFNGGTCWQAVYFSDFVCQCPAGYTGKRCEVDTRATCYEGQGVTYRGTWSTAESRVECINWNSSLLTRRTYNGRMPDAFNLGLGNHNYCRNPNGAPKPWCYVIKAGKFTSESCSVPVCSKATCGLRKYKEPQLHSTGGLFTDITSHPWQAAIFAQNRRSSGERFLCGGILISSCWVLTAAHCFQESYLPDQLKVVLGRTYRVKPGEEEQTFKVKKYIVHKEFDDDTYNNDIALLQLKSDSPQCAQESDSVRAICLPEANLQLPDWTECELSGYGKHKSSSPFYSEQLKEGHVRLYPSSRCAPKFLFNKTVTNNMLCAGDTRSGEIYPNVHDACQGDSGGPLVCMNDNHMTLLGIISWGVGCGEKDVPGVYTKVTNYLGWIRDNMHL DMDLU4Z DE Ischemic stroke DMRH291 ID DMRH291 DMRH291 DN Dexanabinol DMRH291 HS Phase 3 DMRH291 SN Sinnabidiol; HU 211; HU-211; PRS 211007-000; (6aS,10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol; 1,1-Dimethylheptyl-11-hydroxytetrahydrocannabinol; 1,1-Dimethylheptyl-7-hydroxy-delta(6)-tetrahydrocannabinol; 11-Hydroxy-delta(8)-tetrahydrocannabinol-dimethylheptyl; 11-Hydroxy-delta-8-dmh-thc; 11-Hydroxymethyl-delta(8)-tetrahydrocannabinol-dimethylheptyl; 11-OH-delta(8)-Thc-dmh; 5'(1,1-Dimethylheptyl)-7-hydroxyhexahydrocannabinol; 7-Hydroxy-delta-6-tetrahydrocannabinoldimethylheptyl DMRH291 CP Pharmos DMRH291 DT Small molecular drug DMRH291 PC 107778 DMRH291 MW 386.6 DMRH291 FM C25H38O3 DMRH291 IC InChI=1S/C25H38O3/c1-6-7-8-9-12-24(2,3)18-14-21(27)23-19-13-17(16-26)10-11-20(19)25(4,5)28-22(23)15-18/h10,14-15,19-20,26-27H,6-9,11-13,16H2,1-5H3/t19-,20-/m0/s1 DMRH291 CS CCCCCCC(C)(C)C1=CC(=C2[C@H]3CC(=CC[C@@H]3C(OC2=C1)(C)C)CO)O DMRH291 IK SSQJFGMEZBFMNV-PMACEKPBSA-N DMRH291 IU (6aS,10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol DMRH291 CA CAS 112924-45-5 DMRH291 DE Traumatic brain injury DM1WNGJ ID DM1WNGJ DM1WNGJ DN DFP-10917 DM1WNGJ HS Phase 3 DM1WNGJ CP Delta-Fly Pharma DM1WNGJ DT Small molecular drug DM1WNGJ PC 119184 DM1WNGJ MW 252.23 DM1WNGJ FM C10H12N4O4 DM1WNGJ IC InChI=1S/C10H12N4O4/c11-3-5-8(16)6(4-15)18-9(5)14-2-1-7(12)13-10(14)17/h1-2,5-6,8-9,15-16H,4H2,(H2,12,13,17)/t5-,6+,8-,9+/m0/s1 DM1WNGJ CS C1=CN(C(=O)N=C1N)[C@H]2[C@H]([C@@H]([C@H](O2)CO)O)C#N DM1WNGJ IK DCYBPMFXJCWXNB-JWIUVKOKSA-N DM1WNGJ IU (2R,3S,4S,5R)-2-(4-amino-2-oxopyrimidin-1-yl)-4-hydroxy-5-(hydroxymethyl)oxolane-3-carbonitrile DM1WNGJ CA CAS 135598-68-4 DM1WNGJ CB CHEBI:145435 DM1WNGJ DE Acute lymphoblastic leukaemia; Solid tumour/cancer; Acute myeloid leukaemia DMOUGX1 ID DMOUGX1 DMOUGX1 DN Diamyd DMOUGX1 HS Phase 3 DMOUGX1 SN Oramyd; Human glutamate decarboxylase 65 kDa isoform; RhGAD-65; GAD65 (diabetes), Biosyn; GAD65 (diabetes), Diamyd; GAD65 (diabetes), OMJPI; GAD65 antigen-based therapy (diabetes), Johnson and Johnson; GAD65 (diabetes), Ortho-McNeil-Janssen Pharmaceuticals DMOUGX1 CP Diamyd medical DMOUGX1 DE Type-1 diabetes DM4XBM7 ID DM4XBM7 DM4XBM7 DN DiaPep-277 DM4XBM7 HS Phase 3 DM4XBM7 SN Diaccine; AVE-0277; AVE-277; Antidiabetic, Peptor DM4XBM7 CP Andromeda biotech DM4XBM7 DT Small molecular drug DM4XBM7 PC 16138701 DM4XBM7 MW 2390.7 DM4XBM7 FM C106H180N28O34 DM4XBM7 IC InChI=1S/C106H180N28O34/c1-23-55(18)83(131-102(164)82(54(16)17)130-90(152)60(27-24-32-111-106(109)110)118-91(153)65(38-50(8)9)123-92(154)63(36-48(4)5)121-87(149)58(21)117-101(163)81(53(14)15)129-76(140)45-113-74(138)43-112-75(139)44-114-88(150)62(35-47(2)3)126-100(162)80(108)52(12)13)103(165)133-33-25-28-71(133)98(160)115-56(19)85(147)120-64(37-49(6)7)93(155)125-68(41-78(143)144)95(157)128-70(46-135)97(159)124-66(39-51(10)11)96(158)132-84(59(22)136)104(166)134-34-26-29-72(134)99(161)116-57(20)86(148)122-67(40-73(107)137)94(156)119-61(30-31-77(141)142)89(151)127-69(105(167)168)42-79(145)146/h47-72,80-84,135-136H,23-46,108H2,1-22H3,(H2,107,137)(H,112,139)(H,113,138)(H,114,150)(H,115,160)(H,116,161)(H,117,163)(H,118,153)(H,119,156)(H,120,147)(H,121,149)(H,122,148)(H,123,154)(H,124,159)(H,125,155)(H,126,162)(H,127,151)(H,128,157)(H,129,140)(H,130,152)(H,131,164)(H,132,158)(H,141,142)(H,143,144)(H,145,146)(H,167,168)(H4,109,110,111)/t55-,56-,57-,58-,59+,60-,61-,62-,63-,64-,65-,66-,67-,68-,69-,70-,71-,72-,80-,81-,82-,83-,84-/m0/s1 DM4XBM7 CS CC[C@H](C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N2CCC[C@H]2C(=O)N[C@@H](C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)N DM4XBM7 IK VGGRNGOEDNBLPH-YJHCMWSWSA-N DM4XBM7 IU (2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[2-[[2-[[(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]acetyl]amino]acetyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbonyl]amino]propanoyl]amino]-4-methylpentanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]propanoyl]amino]-4-oxobutanoyl]amino]-4-carboxybutanoyl]amino]butanedioic acid DM4XBM7 CA CAS 179822-83-4 DM4XBM7 DE Autoimmune diabetes DMHZBEO ID DMHZBEO DMHZBEO DN Difelikefalin DMHZBEO HS Phase 3 DMHZBEO SN UNII-NA1U919MRO; NA1U919MRO; MR13A9; 1024828-77-0; FE202845; Difelikefalin [INN]; Difelikefalin [USAN:INN]; SEQ ID NO: 2; GTPL9044; CHEMBL3989915; SCHEMBL10316464; BDBM235785; DB11938; FE-202845; US9359399, 2; D-Phe-D-Phe-D-Leu-D-Lys-[gamma-(4-N-piperidinyl)amino carboxylic acid]; 4-Piperidinecarboylic acid, 4-amino-1-(D-phenylalanyl-D-phenylalanyl-D-leucyl-D-lysyl)-; 4-Piperidinecarboxylic acid, N1-(D-phenylalanyl-D-phenylalanyl-D-leucyl-D-lysyl)-4-amino-; 4-Piperidinecarboxylic acid, N1-(D DMHZBEO CP Cara Therapeutics Stamford, CT DMHZBEO PC 24794466 DMHZBEO MW 679.8 DMHZBEO FM C36H53N7O6 DMHZBEO IC InChI=1S/C36H53N7O6/c1-24(2)21-29(32(45)40-28(15-9-10-18-37)34(47)43-19-16-36(39,17-20-43)35(48)49)42-33(46)30(23-26-13-7-4-8-14-26)41-31(44)27(38)22-25-11-5-3-6-12-25/h3-8,11-14,24,27-30H,9-10,15-23,37-39H2,1-2H3,(H,40,45)(H,41,44)(H,42,46)(H,48,49)/t27-,28-,29-,30-/m1/s1 DMHZBEO CS CC(C)C[C@H](C(=O)N[C@H](CCCCN)C(=O)N1CCC(CC1)(C(=O)O)N)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CC3=CC=CC=C3)N DMHZBEO IK FWMNVWWHGCHHJJ-SKKKGAJSSA-N DMHZBEO IU 4-amino-1-[(2R)-6-amino-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid DMHZBEO CA CAS 1024828-77-0 DMHZBEO DE Pruritus DMU4T9Y ID DMU4T9Y DMU4T9Y DN Dimesna DMU4T9Y HS Phase 3 DMU4T9Y SN Tavocept (TN) DMU4T9Y CP BioNumerik Pharmaceuticals DMU4T9Y DT Small molecular drug DMU4T9Y PC 65625 DMU4T9Y MW 326.4 DMU4T9Y FM C4H8Na2O6S4 DMU4T9Y IC InChI=1S/C4H10O6S4.2Na/c5-13(6,7)3-1-11-12-2-4-14(8,9)10;;/h1-4H2,(H,5,6,7)(H,8,9,10);;/q;2*+1/p-2 DMU4T9Y CS C(CS(=O)(=O)[O-])SSCCS(=O)(=O)[O-].[Na+].[Na+] DMU4T9Y IK KQYGMURBTJPBPQ-UHFFFAOYSA-L DMU4T9Y IU disodium;2-(2-sulfonatoethyldisulfanyl)ethanesulfonate DMU4T9Y CA CAS 16208-51-8 DMU4T9Y DE Diabetic nephropathy; Lung cancer DM19CFZ ID DM19CFZ DM19CFZ DN DIMS-0150 DM19CFZ HS Phase 3 DM19CFZ SN Kappaproct; Antisense NF-kBp65 oligonucleotide (IBD), InDex Pharmaceuticals; Antisense NF-kBp65 oligonucleotide (IBD), Serono; Antisense NF-kBp65 oligonucleotide (inflammatory bowel disease), Serono DM19CFZ CP Karolinska Institute DM19CFZ DT Antisense drug DM19CFZ DE Ulcerative colitis DMG8U6M ID DMG8U6M DMG8U6M DN DIPROTEVERINE HYDROCHLORIDE DMG8U6M HS Phase 3 DMG8U6M SN UNII-T587ZFV6UM; T587ZFV6UM; Isoquinoline, 3,4-dihydro-6,7-bis(1-methylethoxy)-1-((3,4-diethoxyphenyl)methyl)-, hydrochloride; 69373-88-2; 1-(3',4'-Diethoxybenzyl)-6,7-diisoprooxy-3,4-dihydroisoquinoline hydrochloride; DIPROTEVERINE HYDROCHLORIDE; AC1MHK6D; SCHEMBL7313181; DTXSID30219461; AWQPJKUSDUHYIX-UHFFFAOYSA-N; 69373-95-1 (Parent); LS-85505; 1-(3'4'-diethoxybenzyl)-6,7-diisopropoxy-3,4-dihydroisoquinoline hydrochloride; 1-[(3,4-diethoxyphenyl)methyl]-6,7-di(propan-2-yloxy)-3,4-dihydroisoquinoline hydrochloride DMG8U6M DT Small molecular drug DMG8U6M PC 3052867 DMG8U6M MW 462 DMG8U6M FM C26H36ClNO4 DMG8U6M IC InChI=1S/C26H35NO4.ClH/c1-7-28-23-10-9-19(14-24(23)29-8-2)13-22-21-16-26(31-18(5)6)25(30-17(3)4)15-20(21)11-12-27-22;/h9-10,14-18H,7-8,11-13H2,1-6H3;1H DMG8U6M CS CCOC1=C(C=C(C=C1)CC2=NCCC3=CC(=C(C=C32)OC(C)C)OC(C)C)OCC.Cl DMG8U6M IK AWQPJKUSDUHYIX-UHFFFAOYSA-N DMG8U6M IU 1-[(3,4-diethoxyphenyl)methyl]-6,7-di(propan-2-yloxy)-3,4-dihydroisoquinoline;hydrochloride DMG8U6M CA CAS 69373-88-2 DMG8U6M DE Angina pectoris DM64QG9 ID DM64QG9 DM64QG9 DN Diquafosol DM64QG9 HS Phase 3 DM64QG9 SN UppppU; Diquafosol [INN]; KPY 998; Diquafosol [INN:BAN]; INS-365; P1,P4-Bis(5'-uridyl) tetrahydrogen tetraphosphate; P1,P4-Bis(5'-uridyl) tetraphosphate; [[(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate DM64QG9 CP Santen Pharmaceutical DM64QG9 DT Small molecular drug DM64QG9 PC 148197 DM64QG9 MW 790.3 DM64QG9 FM C18H26N4O23P4 DM64QG9 IC InChI=1S/C18H26N4O23P4/c23-9-1-3-21(17(29)19-9)15-13(27)11(25)7(41-15)5-39-46(31,32)43-48(35,36)45-49(37,38)44-47(33,34)40-6-8-12(26)14(28)16(42-8)22-4-2-10(24)20-18(22)30/h1-4,7-8,11-16,25-28H,5-6H2,(H,31,32)(H,33,34)(H,35,36)(H,37,38)(H,19,23,29)(H,20,24,30)/t7-,8-,11-,12-,13-,14-,15-,16-/m1/s1 DM64QG9 CS C1=CN(C(=O)NC1=O)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)OP(=O)(O)OP(=O)(O)OC[C@@H]3[C@H]([C@H]([C@@H](O3)N4C=CC(=O)NC4=O)O)O)O)O DM64QG9 IK NMLMACJWHPHKGR-NCOIDOBVSA-N DM64QG9 IU [[(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate DM64QG9 CA CAS 59985-21-6 DM64QG9 CB CHEBI:27791 DM64QG9 DE Dry eye disease DMJS8V3 ID DMJS8V3 DMJS8V3 DN Disufenton sodium DMJS8V3 HS Phase 3 DMJS8V3 SN Cerovive; ARL-16556; CPI-22; CXY-059; HPN-07; NXY-059; NXY-059G; OKN-007; S-PBN; Nitrones (cancer), Oklahoma Medical Research Foundation; Nitrones, Renovis/AstraZeneca; PBN derivatives, Renovis/AstraZeneca; Spin trap agents, Renovis/AstraZeneca DMJS8V3 CP AstraZeneca DMJS8V3 DT Small molecular drug DMJS8V3 PC 6440181 DMJS8V3 MW 381.3 DMJS8V3 FM C11H13NNa2O7S2 DMJS8V3 IC InChI=1S/C11H15NO7S2.2Na/c1-11(2,3)12(13)7-8-4-5-9(20(14,15)16)6-10(8)21(17,18)19;;/h4-7H,1-3H3,(H,14,15,16)(H,17,18,19);;/q;2*+1/p-2/b12-7-;; DMJS8V3 CS CC(C)(C)/[N+](=C/C1=C(C=C(C=C1)S(=O)(=O)[O-])S(=O)(=O)[O-])/[O-].[Na+].[Na+] DMJS8V3 IK XLZOVRYBVCMCGL-BPNVQINPSA-L DMJS8V3 IU disodium;4-[(Z)-[tert-butyl(oxido)azaniumylidene]methyl]benzene-1,3-disulfonate DMJS8V3 DE Ischemia; Recurrent glioblastoma DMMKGBP ID DMMKGBP DMMKGBP DN D-Methionine DMMKGBP HS Phase 3 DMMKGBP SN D-Methionine-(methyl-13C); D-Methionine-(methyl-13C), 99 atom % 13C DMMKGBP DT Small molecular drug DMMKGBP PC 84815 DMMKGBP MW 149.21 DMMKGBP FM C5H11NO2S DMMKGBP IC InChI=1S/C5H11NO2S/c1-9-3-2-4(6)5(7)8/h4H,2-3,6H2,1H3,(H,7,8)/t4-/m1/s1 DMMKGBP CS CSCC[C@H](C(=O)O)N DMMKGBP IK FFEARJCKVFRZRR-SCSAIBSYSA-N DMMKGBP IU (2R)-2-amino-4-methylsulfanylbutanoic acid DMMKGBP CA CAS 348-67-4 DMMKGBP CB CHEBI:16867 DMO7BQS ID DMO7BQS DMO7BQS DN DMP-444 DMO7BQS HS Phase 3 DMO7BQS CP Bristol-Myers Squibb Pharma Co DMO7BQS DE Coronary artery disease DMQLSMB ID DMQLSMB DMQLSMB DN Dociparstat sodium DMQLSMB HS Phase 3 DMQLSMB SN DSTAT DMQLSMB CP Chimerix DMQLSMB DE Acute myeloid leukaemia DMH8IT5 ID DMH8IT5 DMH8IT5 DN Donaperminogene seltoplasmid DMH8IT5 HS Phase 3 DMH8IT5 SN VM202 DMH8IT5 CP ViroMed DMH8IT5 DT Gene therapy DMH8IT5 DE Amyotrophic lateral sclerosis; Diabetic foot ulcer; Diabetic neuropathy DM97S10 ID DM97S10 DM97S10 DN DP-b99 DM97S10 HS Phase 3 DM97S10 SN DP-b99; 343340-21-6; 222315-88-0; SCHEMBL720046; DP-b 99; DTXSID20187908; DP-BAPTA-99, DP-b99; ZINC162948634; 2,2'-(((ethane-1,2-diylbis(oxy))bis(2,1-phenylene))bis((2-(2-(octyloxy)ethoxy)-2-oxoethyl)azanediyl))diacetic acid DM97S10 CP D-Pharm DM97S10 DT Small molecular drug DM97S10 PC 9810955 DM97S10 MW 789 DM97S10 FM C42H64N2O12 DM97S10 IC InChI=1S/C42H64N2O12/c1-3-5-7-9-11-17-23-51-25-27-55-41(49)33-43(31-39(45)46)35-19-13-15-21-37(35)53-29-30-54-38-22-16-14-20-36(38)44(32-40(47)48)34-42(50)56-28-26-52-24-18-12-10-8-6-4-2/h13-16,19-22H,3-12,17-18,23-34H2,1-2H3,(H,45,46)(H,47,48) DM97S10 CS CCCCCCCCOCCOC(=O)CN(CC(=O)O)C1=CC=CC=C1OCCOC2=CC=CC=C2N(CC(=O)O)CC(=O)OCCOCCCCCCCC DM97S10 IK FTGBVHPWUIHWRH-UHFFFAOYSA-N DM97S10 IU 2-[2-[2-[2-[carboxymethyl-[2-(2-octoxyethoxy)-2-oxoethyl]amino]phenoxy]ethoxy]-N-[2-(2-octoxyethoxy)-2-oxoethyl]anilino]acetic acid DM97S10 CA CAS 343340-21-6 DM97S10 DE Stroke DMWUN1S ID DMWUN1S DMWUN1S DN Drisapersen DMWUN1S HS Phase 3 DMWUN1S SN 2402968 DMWUN1S CP GlaxoSmithKline DMWUN1S DT Antisense drug DMWUN1S PC 121494119 DMWUN1S MW 6978 DMWUN1S FM C211H275N76O119P19S19 DMWUN1S IC InChI=1S/C211H275N76O119P19S19/c1-329-136-116(295)77(369-178(136)271-33-24-99(289)252-206(271)304)40-349-407(310,426)389-118-79(371-180(138(118)331-3)268-30-21-96(212)249-203(268)301)42-351-409(312,428)392-121-81(373-183(141(121)334-6)273-35-26-101(291)254-208(273)306)44-352-410(313,429)393-122-82(374-184(142(122)335-7)274-36-27-102(292)255-209(274)307)45-353-411(314,430)394-123-83(375-185(143(123)336-8)275-37-28-103(293)256-210(275)308)46-355-415(318,434)396-125-85(377-187(145(125)338-10)277-65-238-105-156(215)226-59-232-162(105)277)48-358-413(316,432)391-120-80(372-182(140(120)333-5)270-32-23-98(214)251-205(270)303)43-354-417(320,436)402-131-94(386-193(151(131)344-16)283-71-244-111-168(283)258-198(221)263-173(111)296)57-366-424(327,443)405-132-91(383-194(152(132)345-17)284-72-245-112-169(284)259-199(222)264-174(112)297)54-363-414(317,433)395-124-84(376-186(144(124)337-9)276-38-29-104(294)257-211(276)309)47-356-416(319,435)397-126-89(381-188(146(126)339-11)278-66-239-106-157(216)227-60-233-163(106)278)52-361-422(325,441)403-133-92(384-195(153(133)346-18)285-73-246-113-170(285)260-200(223)265-175(113)298)55-364-420(323,439)400-130-88(380-192(150(130)343-15)282-70-243-110-161(220)231-64-237-167(110)282)51-360-419(322,438)399-128-90(382-190(148(128)341-13)280-68-241-108-159(218)229-62-235-165(108)280)53-362-423(326,442)404-134-95(387-196(154(134)347-19)286-74-247-114-171(286)261-201(224)266-176(114)299)58-367-425(328,444)406-135-93(385-197(155(135)348-20)287-75-248-115-172(287)262-202(225)267-177(115)300)56-365-421(324,440)401-129-87(379-191(149(129)342-14)281-69-242-109-160(219)230-63-236-166(109)281)50-359-418(321,437)398-127-86(378-189(147(127)340-12)279-67-240-107-158(217)228-61-234-164(107)279)49-357-412(315,431)390-119-78(370-181(139(119)332-4)269-31-22-97(213)250-204(269)302)41-350-408(311,427)388-117-76(39-288)368-179(137(117)330-2)272-34-25-100(290)253-207(272)305/h21-38,59-95,116-155,178-197,288,295H,39-58H2,1-20H3,(H,310,426)(H,311,427)(H,312,428)(H,313,429)(H,314,430)(H,315,431)(H,316,432)(H,317,433)(H,318,434)(H,319,435)(H,320,436)(H,321,437)(H,322,438)(H,323,439)(H,324,440)(H,325,441)(H,326,442)(H,327,443)(H,328,444)(H2,212,249,301)(H2,213,250,302)(H2,214,251,303)(H2,215,226,232)(H2,216,227,233)(H2,217,228,234)(H2,218,229,235)(H2,219,230,236)(H2,220,231,237)(H,252,289,304)(H,253,290,305)(H,254,291,306)(H,255,292,307)(H,256,293,308)(H,257,294,309)(H3,221,258,263,296)(H3,222,259,264,297)(H3,223,260,265,298)(H3,224,261,266,299)(H3,225,262,267,300)/t76-,77-,78-,79-,80-,81-,82-,83-,84-,85-,86-,87-,88-,89-,90-,91-,92-,93-,94-,95-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,127-,128-,129-,130-,131-,132-,133-,134-,135-,136-,137-,138-,139-,140-,141-,142-,143-,144-,145-,146-,147-,148-,149-,150-,151-,152-,153-,154-,155-,178-,179-,180-,181-,182-,183-,184-,185-,186-,187-,188-,189-,190-,191-,192-,193-,194-,195-,196-,197-,407?,408?,409?,410?,411?,412?,413?,414?,415?,416?,417?,418?,419?,420?,421?,422?,423?,424?,425?/m1/s1 DMWUN1S CS CO[C@@H]1[C@@H]([C@H](O[C@H]1N2C=CC(=O)NC2=O)COP(=S)(O)O[C@@H]3[C@H](O[C@H]([C@@H]3OC)N4C=CC(=NC4=O)N)COP(=S)(O)O[C@@H]5[C@H](O[C@H]([C@@H]5OC)N6C=CC(=O)NC6=O)COP(=S)(O)O[C@@H]7[C@H](O[C@H]([C@@H]7OC)N8C=CC(=O)NC8=O)COP(=S)(O)O[C@@H]9[C@H](O[C@H]([C@@H]9OC)N1C=CC(=O)NC1=O)COP(=S)(O)O[C@@H]1[C@H](O[C@H]([C@@H]1OC)N1C=NC2=C(N=CN=C21)N)COP(=S)(O)O[C@@H]1[C@H](O[C@H]([C@@H]1OC)N1C=CC(=NC1=O)N)COP(=S)(O)O[C@@H]1[C@H](O[C@H]([C@@H]1OC)N1C=NC2=C1N=C(NC2=O)N)COP(=S)(O)O[C@@H]1[C@H](O[C@H]([C@@H]1OC)N1C=NC2=C1N=C(NC2=O)N)COP(=S)(O)O[C@@H]1[C@H](O[C@H]([C@@H]1OC)N1C=CC(=O)NC1=O)COP(=S)(O)O[C@@H]1[C@H](O[C@H]([C@@H]1OC)N1C=NC2=C(N=CN=C21)N)COP(=S)(O)O[C@@H]1[C@H](O[C@H]([C@@H]1OC)N1C=NC2=C1N=C(NC2=O)N)COP(=S)(O)O[C@@H]1[C@H](O[C@H]([C@@H]1OC)N1C=NC2=C(N=CN=C21)N)COP(=S)(O)O[C@@H]1[C@H](O[C@H]([C@@H]1OC)N1C=NC2=C(N=CN=C21)N)COP(=S)(O)O[C@@H]1[C@H](O[C@H]([C@@H]1OC)N1C=NC2=C1N=C(NC2=O)N)COP(=S)(O)O[C@@H]1[C@H](O[C@H]([C@@H]1OC)N1C=NC2=C1N=C(NC2=O)N)COP(=S)(O)O[C@@H]1[C@H](O[C@H]([C@@H]1OC)N1C=NC2=C(N=CN=C21)N)COP(=S)(O)O[C@@H]1[C@H](O[C@H]([C@@H]1OC)N1C=NC2=C(N=CN=C21)N)COP(=O)(O[C@@H]1[C@H](O[C@H]([C@@H]1OC)N1C=CC(=NC1=O)N)COP(=S)(O)O[C@@H]1[C@H](O[C@H]([C@@H]1OC)N1C=CC(=O)NC1=O)CO)S)O DMWUN1S IK HUGILZFVSVLCAO-XVKRXUDYSA-N DMWUN1S IU 1-[(2R,3R,4R,5R)-5-[[[(2R,3R,4R,5R)-2-[[[(2R,3R,4R,5R)-2-[[[(2R,3R,4R,5R)-2-[[[(2R,3R,4R,5R)-2-[[[(2R,3R,4R,5R)-2-[[[(2R,3R,4R,5R)-2-[[[(2R,3R,4R,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[(2R,3R,4R,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[(2R,3R,4R,5R)-2-[[[(2R,3R,4R,5R)-2-[[[(2R,3R,4R,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[(2R,3R,4R,5R)-2-[[[(2R,3R,4R,5R)-2-[[[(2R,3R,4R,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[(2R,3R,4R,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[(2R,3R,4R,5R)-2-[[[(2R,3R,4R,5R)-2-[[[(2R,3R,4R,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-2-[[[(2R,3R,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-2-(hydroxymethyl)-4-methoxyoxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-4-methoxyoxolan-3-yl]oxy-sulfanylphosphoryl]oxymethyl]-5-(6-aminopurin-9-yl)-4-methoxyoxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(6-aminopurin-9-yl)-4-methoxyoxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-4-methoxyoxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-4-methoxyoxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(6-aminopurin-9-yl)-4-methoxyoxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(6-aminopurin-9-yl)-4-methoxyoxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-4-methoxyoxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(6-aminopurin-9-yl)-4-methoxyoxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(2,4-dioxopyrimidin-1-yl)-4-methoxyoxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-4-methoxyoxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-4-methoxyoxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(4-amino-2-oxopyrimidin-1-yl)-4-methoxyoxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(6-aminopurin-9-yl)-4-methoxyoxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(2,4-dioxopyrimidin-1-yl)-4-methoxyoxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(2,4-dioxopyrimidin-1-yl)-4-methoxyoxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(2,4-dioxopyrimidin-1-yl)-4-methoxyoxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(4-amino-2-oxopyrimidin-1-yl)-4-methoxyoxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-4-hydroxy-3-methoxyoxolan-2-yl]pyrimidine-2,4-dione DMWUN1S CA CAS 1251830-50-8 DMWUN1S DE Duchenne dystrophy DMM0HAE ID DMM0HAE DMM0HAE DN DSC-127 DMM0HAE HS Phase 3 DMM0HAE SN aclerastide; UNII-YYD6UT8T47; YYD6UT8T47; Aclerastide [INN]; DSC-127; Norleu3-a(1-7); Asp-arg-nle-tyr-ile-his-pro; DSC127; USB-001; 227803-63-6; 1-7-Angiotensin II, 3-L-norleucine-5-L-isoleucine DMM0HAE CP Derma Sciences DMM0HAE DT Small molecular drug DMM0HAE PC 9811551 DMM0HAE MW 913 DMM0HAE FM C42H64N12O11 DMM0HAE IC InChI=1S/C42H64N12O11/c1-4-6-9-28(50-36(59)29(10-7-16-47-42(44)45)49-35(58)27(43)20-33(56)57)37(60)51-30(18-24-12-14-26(55)15-13-24)38(61)53-34(23(3)5-2)39(62)52-31(19-25-21-46-22-48-25)40(63)54-17-8-11-32(54)41(64)65/h12-15,21-23,27-32,34,55H,4-11,16-20,43H2,1-3H3,(H,46,48)(H,49,58)(H,50,59)(H,51,60)(H,52,62)(H,53,61)(H,56,57)(H,64,65)(H4,44,45,47)/t23-,27-,28-,29-,30-,31-,32-,34-/m0/s1 DMM0HAE CS CCCC[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC2=CN=CN2)C(=O)N3CCC[C@H]3C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(=O)O)N DMM0HAE IK RUBMHAHMIJSMHA-LBWFYSSPSA-N DMM0HAE IU (2S)-1-[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-carboxypropanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]pyrrolidine-2-carboxylic acid DMM0HAE CA CAS 227803-63-6 DMM0HAE DE Diabetic foot ulcer DM6P8HU ID DM6P8HU DM6P8HU DN Dutasteride + tamsulosin DM6P8HU HS Phase 3 DM6P8HU SN Jalyn; Dutasteride / tamsulosin; Tamsulosin / Dutasteride; Dutasteride mixture with tamsulosin DM6P8HU CP GSK DM6P8HU DT Combination drug (small molecular drug) DM6P8HU PC 11679580 DM6P8HU MW 937 DM6P8HU FM C47H58F6N4O7S DM6P8HU IC InChI=1S/C27H30F6N2O2.C20H28N2O5S/c1-24-11-9-17-15(4-8-21-25(17,2)12-10-22(36)35-21)16(24)6-7-19(24)23(37)34-20-13-14(26(28,29)30)3-5-18(20)27(31,32)33;1-4-26-17-7-5-6-8-18(17)27-12-11-22-15(2)13-16-9-10-19(25-3)20(14-16)28(21,23)24/h3,5,10,12-13,15-17,19,21H,4,6-9,11H2,1-2H3,(H,34,37)(H,35,36);5-10,14-15,22H,4,11-13H2,1-3H3,(H2,21,23,24)/t15-,16-,17-,19+,21+,24-,25+;15-/m01/s1 DM6P8HU CS CCOC1=CC=CC=C1OCCN[C@H](C)CC2=CC(=C(C=C2)OC)S(=O)(=O)N.C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2C(=O)NC4=C(C=CC(=C4)C(F)(F)F)C(F)(F)F)CC[C@@H]5[C@@]3(C=CC(=O)N5)C DM6P8HU IK SHHCJPKACHSWFP-NMXGMQNUSA-N DM6P8HU IU (1S,3aS,3bS,5aR,9aR,9bS,11aS)-N-[2,5-bis(trifluoromethyl)phenyl]-9a,11a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,5a,6,9b,10,11-dodecahydroindeno[5,4-f]quinoline-1-carboxamide;5-[(2R)-2-[2-(2-ethoxyphenoxy)ethylamino]propyl]-2-methoxybenzenesulfonamide DM6P8HU DE Benign prostatic hyperplasia; Prostate cancer DMM5VTA ID DMM5VTA DMM5VTA DN Dutogliptin DMM5VTA HS Phase 3 DMM5VTA SN Dutogliptin tartrate; PHX-1004; PHX-1149; PHX-1149T; DPP IV inhibitors (diabetes), Phenomix; DPP IV program (diabetes), Phenomix DMM5VTA CP Phenomix Corp DMM5VTA PC 11253490 DMM5VTA MW 241.1 DMM5VTA FM C10H20BN3O3 DMM5VTA IC InChI=1S/C10H20BN3O3/c15-10(7-13-8-3-4-12-6-8)14-5-1-2-9(14)11(16)17/h8-9,12-13,16-17H,1-7H2/t8-,9+/m1/s1 DMM5VTA CS B([C@@H]1CCCN1C(=O)CN[C@@H]2CCNC2)(O)O DMM5VTA IK DVJAMEIQRSHVKC-BDAKNGLRSA-N DMM5VTA IU [(2R)-1-[2-[[(3R)-pyrrolidin-3-yl]amino]acetyl]pyrrolidin-2-yl]boronic acid DMM5VTA CA CAS 852329-66-9 DMM5VTA DE Type-2 diabetes DMAFUIR ID DMAFUIR DMAFUIR DN DWP-431 DMAFUIR HS Phase 3 DMAFUIR SN Recombinant bone morphogenetic protein 2 (bone synthesis), Daewoong; RBMP-2 (bone synthesis), Daewoong DMAFUIR CP Daewoong Pharmaceutical Co Ltd DMAFUIR DE Bone development disorder DMM1YC4 ID DMM1YC4 DMM1YC4 DN E-101 DMM1YC4 HS Phase 3 DMM1YC4 SN Myeloperoxidase; Glucose oxidase; Human myeloperoxidase, dimer; E-101 (infections); Myeloperoxidase formulations (nosocomial infections), Exoxemis; E-101 (infections), Exoxemis; MPO enzyme system (hospital-acquiredl infections), Exoxemis; Myeloperoxidase + glucose oxidase (infections), Exoxemis DMM1YC4 CP Exoxemis DMM1YC4 DT Small molecular drug DMM1YC4 PC 11973707 DMM1YC4 MW 377.3 DMM1YC4 FM C17H26Cl2N2O3 DMM1YC4 IC InChI=1S/C17H25ClN2O3.ClH/c1-4-12-8-13(18)16(23-3)14(15(12)21)17(22)19-9-11-6-7-20(5-2)10-11;/h8,11,21H,4-7,9-10H2,1-3H3,(H,19,22);1H/t11-;/m0./s1 DMM1YC4 CS CCC1=CC(=C(C(=C1O)C(=O)NC[C@@H]2CCN(C2)CC)OC)Cl.Cl DMM1YC4 IK RDZXYWICCLALQM-MERQFXBCSA-N DMM1YC4 IU 5-chloro-3-ethyl-N-[[(3S)-1-ethylpyrrolidin-3-yl]methyl]-2-hydroxy-6-methoxybenzamide;hydrochloride DMM1YC4 DE Infectious disease DMTNUJ8 ID DMTNUJ8 DMTNUJ8 DN E-2609 DMTNUJ8 HS Phase 3 DMTNUJ8 SN Beta secretase inhibitor (Alzheimer's disease), Eisai DMTNUJ8 CP Eisai Co Ltd DMTNUJ8 PC 57827330 DMTNUJ8 MW 437.4 DMTNUJ8 FM C19H18F3N5O2S DMTNUJ8 IC InChI=1S/C19H18F3N5O2S/c1-9-12-7-30-18(23)27-19(12,8-29-9)11-4-10(2-3-13(11)20)26-17(28)15-6-24-14(5-25-15)16(21)22/h2-6,9,12,16H,7-8H2,1H3,(H2,23,27)(H,26,28)/t9-,12-,19-/m1/s1 DMTNUJ8 CS C[C@@H]1[C@H]2CSC(=N[C@]2(CO1)C3=C(C=CC(=C3)NC(=O)C4=NC=C(N=C4)C(F)F)F)N DMTNUJ8 IK AACUJFVOHGRMTR-DPXNYUHVSA-N DMTNUJ8 IU N-[3-[(4aS,5R,7aS)-2-amino-5-methyl-4,4a,5,7-tetrahydrofuro[3,4-d][1,3]thiazin-7a-yl]-4-fluorophenyl]-5-(difluoromethyl)pyrazine-2-carboxamide DMTNUJ8 CA CAS 1388651-30-6 DMTNUJ8 DE Alzheimer disease DM42PFT ID DM42PFT DM42PFT DN E-3810 DM42PFT HS Phase 3 DM42PFT SN Lucitanib; AL-3810; E-3810, EOS DM42PFT CP Clovis oncology DM42PFT DT Small molecular drug DM42PFT PC 25031915 DM42PFT MW 443.5 DM42PFT FM C26H25N3O4 DM42PFT IC InChI=1S/C26H25N3O4/c1-28-25(30)19-5-3-4-16-12-17(6-7-18(16)19)33-22-8-11-29-21-14-24(23(31-2)13-20(21)22)32-15-26(27)9-10-26/h3-8,11-14H,9-10,15,27H2,1-2H3,(H,28,30) DM42PFT CS CNC(=O)C1=CC=CC2=C1C=CC(=C2)OC3=C4C=C(C(=CC4=NC=C3)OCC5(CC5)N)OC DM42PFT IK CUDVHEFYRIWYQD-UHFFFAOYSA-N DM42PFT IU 6-[7-[(1-aminocyclopropyl)methoxy]-6-methoxyquinolin-4-yl]oxy-N-methylnaphthalene-1-carboxamide DM42PFT CA CAS 1058137-23-7 DM42PFT CB CHEBI:65209 DM42PFT DE Solid tumour/cancer DMUHS5Q ID DMUHS5Q DMUHS5Q DN E-913 DMUHS5Q HS Phase 3 DMUHS5Q SN E913; E 913; 342394-93-8; 1,4,9-Triazaspiro(5.5)undecane-2,5-dione, 1-butyl-3-(cyclohexylmethyl)-9-((2,3-dihydro-1,4-benzodioxin-6-yl)methyl)-; 11-butyl-9-(cyclohexylmethyl)-3-(2,3-dihydro-1,4-benzodioxin-6-ylmethyl)-3,8,11-triazaspiro[5.5]undecane-7,10-dione; 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-(cyclohexylmethyl)-9-[(2,3-dihydro-1,4-benzodioxin-6-yl)methyl]-; AC1LANMM; E-913; SCHEMBL1649664; GTPL3500; CHEMBL1196395; e9-13; BDBM50190513; LS-184716 DMUHS5Q DT Small molecular drug DMUHS5Q PC 491774 DMUHS5Q MW 483.6 DMUHS5Q FM C28H41N3O4 DMUHS5Q IC InChI=1S/C28H41N3O4/c1-2-3-13-31-26(32)23(18-21-7-5-4-6-8-21)29-27(33)28(31)11-14-30(15-12-28)20-22-9-10-24-25(19-22)35-17-16-34-24/h9-10,19,21,23H,2-8,11-18,20H2,1H3,(H,29,33) DMUHS5Q CS CCCCN1C(=O)C(NC(=O)C12CCN(CC2)CC3=CC4=C(C=C3)OCCO4)CC5CCCCC5 DMUHS5Q IK VBONNDPACFTZMX-UHFFFAOYSA-N DMUHS5Q IU 1-butyl-3-(cyclohexylmethyl)-9-(2,3-dihydro-1,4-benzodioxin-6-ylmethyl)-1,4,9-triazaspiro[5.5]undecane-2,5-dione DMUHS5Q CA CAS 342394-93-8 DMUHS5Q DE Human immunodeficiency virus infection DMLA1ER ID DMLA1ER DMLA1ER DN EC20 DMLA1ER HS Phase 3 DMLA1ER SN Technetium Tc-99m etarfolatide DMLA1ER CP Endocyte DMLA1ER DT Small molecular drug DMLA1ER PC 135428923 DMLA1ER MW 745.7 DMLA1ER FM C29H35N11O11S DMLA1ER IC InChI=1S/C29H35N11O11S/c30-15(24(45)37-17(7-20(42)43)25(46)38-18(11-52)28(50)51)10-33-19(41)6-5-16(27(48)49)36-23(44)12-1-3-13(4-2-12)32-8-14-9-34-22-21(35-14)26(47)40-29(31)39-22/h1-4,9,15-18,32,52H,5-8,10-11,30H2,(H,33,41)(H,36,44)(H,37,45)(H,38,46)(H,42,43)(H,48,49)(H,50,51)(H3,31,34,39,40,47)/t15-,16+,17-,18-/m0/s1 DMLA1ER CS C1=CC(=CC=C1C(=O)N[C@H](CCC(=O)NC[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CS)C(=O)O)N)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N DMLA1ER IK RKGPQAGUQDVJHG-MHORFTMASA-N DMLA1ER IU (2R)-5-[[(2S)-2-amino-3-[[(2S)-3-carboxy-1-[[(1R)-1-carboxy-2-sulfanylethyl]amino]-1-oxopropan-2-yl]amino]-3-oxopropyl]amino]-2-[[4-[(2-amino-4-oxo-3H-pteridin-6-yl)methylamino]benzoyl]amino]-5-oxopentanoic acid DMLA1ER CA CAS 479578-27-3 DMLA1ER DE Ovarian cancer DMS9R43 ID DMS9R43 DMS9R43 DN Ecopipam DMS9R43 HS Phase 3 DMS9R43 SN Sch-39166; Sch 39166; 112108-01-7; Ecopipam [INN]; Sch39166; UNII-0X748O646K; CHEMBL298406; 0X748O646K; DSSTox_RID_80075; DSSTox_CID_23814; 6,7,7a,8,9,13b-Hexahydro-3-chloro-2-hydroxy-N-methyl-5H-benzo(d)naphtho(2,1b)azepine; DSSTox_GSID_43814; 5H-Benzo(d)naphth(2,1-b)azepin-12-ol, 11-chloro-6,6a,7,8,9,13b-hexahydro-7-methyl-, trans-(-)-; (6aS,13bR)-11-chloro-7-methyl-6,6a,7,8,9,13b-hexahydro-5H-benzo[d]naphtho[2,1-b]azepin-12-ol; 5H-Benzo[d]naphth[2,1-b]azepin-12-ol,; ecopipam (controlled-release, Lesch Nyhan syndrome/Tourette's syndrome/compulsive gambling). Psyadon Pharmaceuticals DMS9R43 DT Small molecular drug DMS9R43 PC 107930 DMS9R43 MW 313.8 DMS9R43 FM C19H20ClNO DMS9R43 IC InChI=1S/C19H20ClNO/c1-21-9-8-13-10-16(20)18(22)11-15(13)19-14-5-3-2-4-12(14)6-7-17(19)21/h2-5,10-11,17,19,22H,6-9H2,1H3/t17-,19+/m0/s1 DMS9R43 CS CN1CCC2=CC(=C(C=C2[C@@H]3[C@@H]1CCC4=CC=CC=C34)O)Cl DMS9R43 IK DMJWENQHWZZWDF-PKOBYXMFSA-N DMS9R43 IU (6aS,13bR)-11-chloro-7-methyl-5,6,6a,8,9,13b-hexahydronaphtho[1,2-a][3]benzazepin-12-ol DMS9R43 CA CAS 112108-01-7 DMS9R43 CB CHEBI:93645 DMS9R43 DE Cocaine addiction; Tourette syndrome DMRLXAI ID DMRLXAI DMRLXAI DN ED-71 DMRLXAI HS Phase 3 DMRLXAI SN Edirol; Eldecalcitol; (5Z,7E)-(1R,2R,3R)-2-(3-hydroxypropoxy)-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol; 104121-92-8; 1alpha,25-dihydroxy-2beta-(3-hydroxypropoxy)cholecalciferol; 1alpha,25-dihydroxy-2beta-(3-hydroxypropoxy)vitamin D3; 2-(3-Hydroxypropoxy)-1,25-dihydroxyvitamin D3; ED 71; ED-71; I2JP8UE90H; UNII-I2JP8UE90H DMRLXAI PC 6918141 DMRLXAI MW 490.7 DMRLXAI FM C30H50O5 DMRLXAI IC FZEXGDDBXLBRTD-AYIMTCTASA-N DMRLXAI CS CC(CCCC(C)(C)O)C1CCC2C1(CCCC2=CC=C3CC(C(C(C3=C)O)OCCCO)O)C DMRLXAI IK 1S/C30H50O5/c1-20(9-6-15-29(3,4)34)24-13-14-25-22(10-7-16-30(24,25)5)11-12-23-19-26(32)28(27(33)21(23)2)35-18-8-17-31/h11-12,20,24-28,31-34H,2,6-10,13-19H2,1,3-5H3/b22-11+,23-12-/t20-,24-,25+,26-,27-,28-,30-/m1/s1 DMRLXAI IU (1R,2R,3R,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(2R)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-2-(3-hydroxypropoxy)-4-methylidenecyclohexane-1,3-diol DMRLXAI CA CAS 104121-92-8 DMRLXAI CB CHEBI:73927 DMRLXAI DE Osteoporosis DMYVBF6 ID DMYVBF6 DMYVBF6 DN Edasalonexent DMYVBF6 HS Phase 3 DMYVBF6 SN UNII-AF3Z6434KS; AF3Z6434KS; 1204317-86-1; Edasalonexent [INN]; SCHEMBL1823117; CHEMBL3786673; JQLBBYLGWHUHRW-KUBAVDMBSA-N; N-(2-(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenamidoethyl)-2-hydroxybenzamide; Benzamide, 2-hydroxy-N-(2-(((4Z,7Z,10Z,13Z,16Z,19Z)-1-oxo-4,7,10,13,16,19-docosahexaen-1-yl)amino)ethyl)-; N-(2-(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16, 19-hexaenamidoethyl)-2-hydroxybenzamide DMYVBF6 CP Catabasis Pharmaceuticals Cambridge, MA DMYVBF6 PC 44626120 DMYVBF6 MW 490.7 DMYVBF6 FM C31H42N2O3 DMYVBF6 IC InChI=1S/C31H42N2O3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-25-30(35)32-26-27-33-31(36)28-23-21-22-24-29(28)34/h3-4,6-7,9-10,12-13,15-16,18-19,21-24,34H,2,5,8,11,14,17,20,25-27H2,1H3,(H,32,35)(H,33,36)/b4-3-,7-6-,10-9-,13-12-,16-15-,19-18- DMYVBF6 CS CC/C=C\\C/C=C\\C/C=C\\C/C=C\\C/C=C\\C/C=C\\CCC(=O)NCCNC(=O)C1=CC=CC=C1O DMYVBF6 IK JQLBBYLGWHUHRW-KUBAVDMBSA-N DMYVBF6 IU N-[2-[[(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoyl]amino]ethyl]-2-hydroxybenzamide DMYVBF6 CA CAS 1204317-86-1 DMYVBF6 DE Duchenne dystrophy DM3ZL7D ID DM3ZL7D DM3ZL7D DN Edotecarin DM3ZL7D HS Phase 3 DM3ZL7D SN ED-749; Edotecarin < Prop INN; J-107088; PF-804950; 12-(beta-D-Glucopyranosyl)-2,10-dihydroxy-6-[2-hydroxy-1-(hydroxymethyl)ethylamino]-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione DM3ZL7D CP Pfizer DM3ZL7D DT Small molecular drug DM3ZL7D PC 9808998 DM3ZL7D MW 608.6 DM3ZL7D FM C29H28N4O11 DM3ZL7D IC InChI=1S/C29H28N4O11/c34-7-10(8-35)31-33-27(42)20-18-13-3-1-11(37)5-15(13)30-22(18)23-19(21(20)28(33)43)14-4-2-12(38)6-16(14)32(23)29-26(41)25(40)24(39)17(9-36)44-29/h1-6,10,17,24-26,29-31,34-41H,7-9H2/t17-,24-,25+,26-,29-/m1/s1 DM3ZL7D CS C1=CC2=C(C=C1O)NC3=C4C(=C5C(=C23)C(=O)N(C5=O)NC(CO)CO)C6=C(N4[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO)O)O)O)C=C(C=C6)O DM3ZL7D IK QMVPQBFHUJZJCS-NTKFZFFISA-N DM3ZL7D IU 13-(1,3-dihydroxypropan-2-ylamino)-6,20-dihydroxy-3-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]-3,13,23-triazahexacyclo[14.7.0.02,10.04,9.011,15.017,22]tricosa-1,4(9),5,7,10,15,17(22),18,20-nonaene-12,14-dione DM3ZL7D CA CAS 174402-32-5 DM3ZL7D DE Gastric adenocarcinoma DMX7BM4 ID DMX7BM4 DMX7BM4 DN Efaproxyn DMX7BM4 HS Phase 3 DMX7BM4 SN Efaproxiral; RSR13 DMX7BM4 CP Allos Therapeutics DMX7BM4 DT Small molecular drug DMX7BM4 PC 122335 DMX7BM4 MW 341.4 DMX7BM4 FM C20H23NO4 DMX7BM4 IC InChI=1S/C20H23NO4/c1-13-9-14(2)11-16(10-13)21-18(22)12-15-5-7-17(8-6-15)25-20(3,4)19(23)24/h5-11H,12H2,1-4H3,(H,21,22)(H,23,24) DMX7BM4 CS CC1=CC(=CC(=C1)NC(=O)CC2=CC=C(C=C2)OC(C)(C)C(=O)O)C DMX7BM4 IK BNFRJXLZYUTIII-UHFFFAOYSA-N DMX7BM4 IU 2-[4-[2-(3,5-dimethylanilino)-2-oxoethyl]phenoxy]-2-methylpropanoic acid DMX7BM4 CA CAS 131179-95-8 DMX7BM4 DE Lung cancer DMKA2PI ID DMKA2PI DMKA2PI DN Efpeglenatide DMKA2PI HS Phase 3 DMKA2PI SN Langlenatide; Efpeglenatide [INN]; Langlenatide [WHO-DD]; UNII-3M1V5Z2270; SCHEMBL19712179; 3M1V5Z2270; 1296200-77-5 DMKA2PI CP Sanofi US Bridgewater, NJ DMKA2PI PC 86278345 DMKA2PI MW 403.5 DMKA2PI FM C19H37N3O6 DMKA2PI IC InChI=1S/C19H37N3O6/c20-16(18(23)24)6-1-2-8-21-9-4-12-27-14-15-28-13-5-11-22-10-3-7-17(22)19(25)26/h16-17,21H,1-15,20H2,(H,23,24)(H,25,26)/t16-,17-/m0/s1 DMKA2PI CS C1C[C@H](N(C1)CCCOCCOCCCNCCCC[C@@H](C(=O)O)N)C(=O)O DMKA2PI IK OJQLGILETRTDGQ-IRXDYDNUSA-N DMKA2PI IU (2S)-1-[3-[2-[3-[[(5S)-5-amino-5-carboxypentyl]amino]propoxy]ethoxy]propyl]pyrrolidine-2-carboxylic acid DMKA2PI DE Type-2 diabetes DMCMJRA ID DMCMJRA DMCMJRA DN EGF816 DMCMJRA HS Phase 3 DMCMJRA CP Novartis pharmaceuticals DMCMJRA PC 72703790 DMCMJRA MW 495 DMCMJRA FM C26H31ClN6O2 DMCMJRA IC InChI=1S/C26H31ClN6O2/c1-18-16-19(12-13-28-18)25(35)30-26-29-22-10-6-9-21(27)24(22)33(26)20-8-4-5-15-32(17-20)23(34)11-7-14-31(2)3/h6-7,9-13,16,20H,4-5,8,14-15,17H2,1-3H3,(H,29,30,35)/b11-7+/t20-/m1/s1 DMCMJRA CS CC1=NC=CC(=C1)C(=O)NC2=NC3=C(N2[C@@H]4CCCCN(C4)C(=O)/C=C/CN(C)C)C(=CC=C3)Cl DMCMJRA IK IOMMMLWIABWRKL-WUTDNEBXSA-N DMCMJRA IU N-[7-chloro-1-[(3R)-1-[(E)-4-(dimethylamino)but-2-enoyl]azepan-3-yl]benzimidazol-2-yl]-2-methylpyridine-4-carboxamide DMCMJRA CA CAS 1508250-71-2 DMCMJRA DE Non-small-cell lung cancer DMB2C0E ID DMB2C0E DMB2C0E DN Elagolix DMB2C0E HS Phase 3 DMB2C0E SN Elagolix; 834153-87-6; UNII-5B2546MB5Z; NBI-56418; 5B2546MB5Z; NBI56418; NBI 56418; Elagolix [USAN:INN]; Orilissa; ELA gOLIX; Elagolix (USAN/INN); SCHEMBL1642523; GTPL8362; CHEMBL1208155; DTXSID40232348; ABT-620; 4-[[(1R)-2-[5-(2-fluoro-3-methoxyphenyl)-3-[[2-fluoro-6-(trifluoromethyl)phenyl]methyl]-4-methyl-2,6-dioxopyrimidin-1-yl]-1-phenylethyl]amino]butanoic acid; EX-A1765; BCP08827; ZINC49888891; CS-5329; SB16700; DB11979; compound 10b [PMID 19006286]; HY-14789; AN-27202; D09335; Z-3253; 153E876; Butanoic acid, 4-(((1R)-2-(5-(2-flu DMB2C0E CP Abbott Laboratories Abbott; Neurocrine Biosciences DMB2C0E DT Small molecular drug DMB2C0E PC 11250647 DMB2C0E MW 631.6 DMB2C0E FM C32H30F5N3O5 DMB2C0E IC InChI=1S/C32H30F5N3O5/c1-19-28(21-11-6-14-26(45-2)29(21)34)30(43)40(18-25(20-9-4-3-5-10-20)38-16-8-15-27(41)42)31(44)39(19)17-22-23(32(35,36)37)12-7-13-24(22)33/h3-7,9-14,25,38H,8,15-18H2,1-2H3,(H,41,42)/t25-/m0/s1 DMB2C0E CS CC1=C(C(=O)N(C(=O)N1CC2=C(C=CC=C2F)C(F)(F)F)C[C@@H](C3=CC=CC=C3)NCCCC(=O)O)C4=C(C(=CC=C4)OC)F DMB2C0E IK HEAUOKZIVMZVQL-VWLOTQADSA-N DMB2C0E IU 4-[[(1R)-2-[5-(2-fluoro-3-methoxyphenyl)-3-[[2-fluoro-6-(trifluoromethyl)phenyl]methyl]-4-methyl-2,6-dioxopyrimidin-1-yl]-1-phenylethyl]amino]butanoic acid DMB2C0E CA CAS 834153-87-6 DMB2C0E DE Uterine fibroids DMW6C81 ID DMW6C81 DMW6C81 DN Eltoprazine DMW6C81 HS Phase 3 DMW6C81 SN Piperazine derivative (ADHD), PsychoGenics/ReqMed Company; 5-HT1A/5-HT1B agonist and 5-HT2C antagonist (ADHD), PsychoGenics/ReqMed Company DMW6C81 CP Amarantus bioscience; psychogenics DMW6C81 DT Small molecular drug DMW6C81 PC 65853 DMW6C81 MW 220.27 DMW6C81 FM C12H16N2O2 DMW6C81 IC InChI=1S/C12H16N2O2/c1-2-10(14-6-4-13-5-7-14)12-11(3-1)15-8-9-16-12/h1-3,13H,4-9H2 DMW6C81 CS C1CN(CCN1)C2=C3C(=CC=C2)OCCO3 DMW6C81 IK WVLHGCRWEHCIOT-UHFFFAOYSA-N DMW6C81 IU 1-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazine DMW6C81 CA CAS 98224-03-4 DMW6C81 DE Non-hodgkin lymphoma; Alzheimer disease; Attention deficit hyperactivity disorder; Dyskinesia; Parkinson disease DMZKTYJ ID DMZKTYJ DMZKTYJ DN Enmetazobactam DMZKTYJ HS Phase 3 DMZKTYJ SN AAI-101; AAI101; 1001404-83-6; UNII-80VUN7L00C; 80VUN7L00C; (2S,3S,5R)-3-methyl-3-((3-methyl-1H-1,2,3-triazol-3-ium-1-yl)methyl)-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate 4,4-dioxide; CHEMBL4458276; SCHEMBL18110082; OCID-5090; CS-7557; HY-103095; J3.628.087E; (2S,3S,5R)-3-Methyl-3-((3-methyltriazol-3-ium-1-yl)methyl)-4,4,7-trioxo-4^6-thia-1-azabicyclo(3.2.0)heptane-2-carboxylate; (2S,3S,5R)-3-methyl-3-[(3-methyltriazol-3-ium-1-yl)methyl]-4,4,7-trioxo-4$l^{6}-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate; 1H-1,2,3-Triazolium, 3-(((2S,3S,5R)-2-carboxy-3-methyl-4,4-dioxido-7-oxo-4-thia-1-azabicyclo(3.2.0)hept-3-yl)methyl)-1-methyl-, inner salt DMZKTYJ CP Allecra Therapeutics DMZKTYJ DT Small molecular drug DMZKTYJ PC 23653540 DMZKTYJ MW 314.32 DMZKTYJ FM C11H14N4O5S DMZKTYJ IC InChI=1S/C11H14N4O5S/c1-11(6-14-4-3-13(2)12-14)9(10(17)18)15-7(16)5-8(15)21(11,19)20/h3-4,8-9H,5-6H2,1-2H3/t8-,9+,11+/m1/s1 DMZKTYJ CS C[C@@]1([C@@H](N2[C@H](S1(=O)=O)CC2=O)C(=O)[O-])CN3C=C[N+](=N3)C DMZKTYJ IK HFZITXBUTWITPT-YWVKMMECSA-N DMZKTYJ IU (2S,3S,5R)-3-methyl-3-[(3-methyltriazol-3-ium-1-yl)methyl]-4,4,7-trioxo-4lambda6-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate DMZKTYJ CA CAS 1001404-83-6 DMZKTYJ DE Urinary tract infection DMIKDCQ ID DMIKDCQ DMIKDCQ DN Ensartinib DMIKDCQ HS Phase 3 DMIKDCQ CP Xcovery Palm Beach Gardens, FL DMIKDCQ PC 56960363 DMIKDCQ MW 561.4 DMIKDCQ FM C26H27Cl2FN6O3 DMIKDCQ IC InChI=1S/C26H27Cl2FN6O3/c1-13-11-35(12-14(2)31-13)26(37)16-4-6-17(7-5-16)32-25(36)20-10-21(24(30)34-33-20)38-15(3)22-18(27)8-9-19(29)23(22)28/h4-10,13-15,31H,11-12H2,1-3H3,(H2,30,34)(H,32,36)/t13-,14+,15-/m1/s1 DMIKDCQ CS C[C@@H]1CN(C[C@@H](N1)C)C(=O)C2=CC=C(C=C2)NC(=O)C3=NN=C(C(=C3)O[C@H](C)C4=C(C=CC(=C4Cl)F)Cl)N DMIKDCQ IK GLYMPHUVMRFTFV-QLFBSQMISA-N DMIKDCQ IU 6-amino-5-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-N-[4-[(3S,5R)-3,5-dimethylpiperazine-1-carbonyl]phenyl]pyridazine-3-carboxamide DMIKDCQ CA CAS 1370651-20-9 DMIKDCQ DE Non-small-cell lung cancer DM7EOBQ ID DM7EOBQ DM7EOBQ DN Entacapone+levodopa+carbidopa DM7EOBQ HS Phase 3 DM7EOBQ CP Orion; Novartis DM7EOBQ DE Restless legs syndrome; Parkinson disease DMTWLXY ID DMTWLXY DMTWLXY DN Entresto DMTWLXY HS Phase 3 DMTWLXY SN Sacubitril valsartan sodium hydrate; UNII-WB8FT61183; Sacubitril mixture with valsartan; WB8FT61183; Entresto (TN); Valsartan mixture with AHU-377; MolPort-042-624-138; C96H120N12Na6O21; 9052AF; AKOS026670199; ACN-036829; 3-(1-Biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl)propionate-3'-methyl-2'-(pentanoyl(2'-(tetrazol-5-ylate)biphenyl-4'-ylmethyl)amino)butyrate; AK198922; AC-29037; Sacubitril valsartan sodium hydrate (JAN); FT-0700025; D10226; L-Valine, N-(1-oxopentyl)-N-((2'-(2H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-, compd. wi DMTWLXY CP Novartis East Hanover, NJ DMTWLXY PC 71449007 DMTWLXY MW 1916 DMTWLXY FM C96H120N12Na6O21 DMTWLXY IC InChI=1S/2C24H29N5O3.2C24H29NO5.6Na.5H2O/c2*1-4-5-10-21(30)29(22(16(2)3)24(31)32)15-17-11-13-18(14-12-17)19-8-6-7-9-20(19)23-25-27-28-26-23;2*1-3-30-24(29)17(2)15-21(25-22(26)13-14-23(27)28)16-18-9-11-20(12-10-18)19-7-5-4-6-8-19;;;;;;;;;;;/h2*6-9,11-14,16,22H,4-5,10,15H2,1-3H3,(H2,25,26,27,28,31,32);2*4-12,17,21H,3,13-16H2,1-2H3,(H,25,26)(H,27,28);;;;;;;5*1H2/q;;;;6*+1;;;;;/p-6/t2*22-;2*17-,21+;;;;;;;;;;;/m0011.........../s1 DMTWLXY CS CCCCC(=O)N(CC1=CC=C(C=C1)C2=CC=CC=C2C3=NN=N[N-]3)[C@@H](C(C)C)C(=O)[O-].CCCCC(=O)N(CC1=CC=C(C=C1)C2=CC=CC=C2C3=NN=N[N-]3)[C@@H](C(C)C)C(=O)[O-].CCOC(=O)[C@H](C)C[C@@H](CC1=CC=C(C=C1)C2=CC=CC=C2)NC(=O)CCC(=O)[O-].CCOC(=O)[C@H](C)C[C@@H](CC1=CC=C(C=C1)C2=CC=CC=C2)NC(=O)CCC(=O)[O-].O.O.O.O.O.[Na+].[Na+].[Na+].[Na+].[Na+].[Na+] DMTWLXY IK ZASXKEGREHRXDL-CAWNUZPDSA-H DMTWLXY IU hexasodium;4-[[(2S,4R)-5-ethoxy-4-methyl-5-oxo-1-(4-phenylphenyl)pentan-2-yl]amino]-4-oxobutanoate;(2S)-3-methyl-2-[pentanoyl-[[4-[2-(1,2,3-triaza-4-azanidacyclopenta-2,5-dien-5-yl)phenyl]phenyl]methyl]amino]butanoate;pentahydrate DMTWLXY CA CAS 936623-90-4 DMTWLXY DE Acute myocardial infarction; Heart failure DM5H0R9 ID DM5H0R9 DM5H0R9 DN Enzastaurin DM5H0R9 HS Phase 3 DM5H0R9 SN LY317615; LE-0014; LY317615, Enzastaurin; 3-(1-methyl-1H-indol-3-yl)-4-{1-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1H-indol-3-yl}-1H-pyrrole-2,5-dione; 3-(1-methylindol-3-yl)-4-[1-[1-(pyridin-2-ylmethyl)piperidin-4-yl]indol-3-yl]pyrrole-2,5-dione DM5H0R9 CP Eli Lilly DM5H0R9 TC Anticancer Agents DM5H0R9 DT Small molecular drug DM5H0R9 PC 176167 DM5H0R9 MW 515.6 DM5H0R9 FM C32H29N5O2 DM5H0R9 IC InChI=1S/C32H29N5O2/c1-35-19-25(23-9-2-4-11-27(23)35)29-30(32(39)34-31(29)38)26-20-37(28-12-5-3-10-24(26)28)22-13-16-36(17-14-22)18-21-8-6-7-15-33-21/h2-12,15,19-20,22H,13-14,16-18H2,1H3,(H,34,38,39) DM5H0R9 CS CN1C=C(C2=CC=CC=C21)C3=C(C(=O)NC3=O)C4=CN(C5=CC=CC=C54)C6CCN(CC6)CC7=CC=CC=N7 DM5H0R9 IK AXRCEOKUDYDWLF-UHFFFAOYSA-N DM5H0R9 IU 3-(1-methylindol-3-yl)-4-[1-[1-(pyridin-2-ylmethyl)piperidin-4-yl]indol-3-yl]pyrrole-2,5-dione DM5H0R9 CA CAS 170364-57-5 DM5H0R9 CB CHEBI:91368 DM5H0R9 DE Central nervous system disease; Glioblastoma multiforme; Non-hodgkin lymphoma; Diffuse large B-cell lymphoma DMEX86V ID DMEX86V DMEX86V DN Epcoritamab DMEX86V HS Phase 3 DMEX86V CP Genmab DMEX86V DT Antibody DMEX86V DE Diffuse large B-cell lymphoma DM1SMAI ID DM1SMAI DM1SMAI DN Eperisone DM1SMAI HS Phase 3 DM1SMAI SN EMPP; Myonal; Myorelark; E-0646; E-2000; E-646; Eperisone (transdermal patch); Eperisone (oral), Eisai; Eperisone (transdermalpatch), Eisai; E-2000 (oral), Eisai; E-2000 (transdermal patch), Eisai DM1SMAI CP Eisai Co Ltd DM1SMAI DT Small molecular drug DM1SMAI PC 3236 DM1SMAI MW 259.399 DM1SMAI FM C17H25NO DM1SMAI IC InChI=1S/C17H25NO/c1-3-15-7-9-16(10-8-15)17(19)14(2)13-18-11-5-4-6-12-18/h7-10,14H,3-6,11-13H2,1-2H3 DM1SMAI CS CCC1=CC=C(C=C1)C(=O)C(C)CN2CCCCC2 DM1SMAI IK SQUNAWUMZGQQJD-UHFFFAOYSA-N DM1SMAI IU 1-(4-ethylphenyl)-2-methyl-3-piperidin-1-ylpropan-1-one DM1SMAI CA CAS 64840-90-0 DM1SMAI CB CHEBI:77070 DM1SMAI DE Muscle spasm DM08XIN ID DM08XIN DM08XIN DN EPIANDROSTERONE DM08XIN HS Phase 3 DM08XIN SN EPIANDROSTERONE; 481-29-8; trans-Androsterone; Isoandrosterone; 3Beta-hydroxy-5alpha-androstan-17-one; 3beta-Hydroxyetioallocholan-17-one; epi-andosterone; 5alpha-Androstan-3beta-ol-17-one; iso-Androsterone; d-Epiandrosterone; UNII-8TR252Z538; 3-Epiandrosterone; (3beta,5alpha)-3-hydroxyandrostan-17-one; CHEMBL272195; 3beta-Hydroxy-androstan-17-one; CHEBI:541975; QGXBDMJGAMFCBF-LUJOEAJASA-N; Androsterone, epi-; NSC 93996; MFCD00064134; 8TR252Z538; ST072176; Androstan-17-one, 3-hydroxy-, (3b,5a)-; epi-Androsterone; C19H30O2 DM08XIN DT Small molecular drug DM08XIN PC 441302 DM08XIN MW 290.4 DM08XIN FM C19H30O2 DM08XIN IC InChI=1S/C19H30O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h12-16,20H,3-11H2,1-2H3/t12-,13-,14-,15-,16-,18-,19-/m0/s1 DM08XIN CS C[C@]12CC[C@@H](C[C@@H]1CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CCC4=O)C)O DM08XIN IK QGXBDMJGAMFCBF-LUJOEAJASA-N DM08XIN IU (3S,5S,8R,9S,10S,13S,14S)-3-hydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,14,15,16-tetradecahydrocyclopenta[a]phenanthren-17-one DM08XIN CA CAS 481-29-8 DM08XIN CB CHEBI:541975 DMCGWBJ ID DMCGWBJ DMCGWBJ DN Epigallocatechin gallate DMCGWBJ HS Phase 3 DMCGWBJ SN (-)-Epigallocatechin gallate; EGCG; 989-51-5; Epigallocatechin 3-gallate; Epigallocatechin-3-gallate; Tea catechin; (-)-Epigallocatechin-3-o-gallate; Teavigo; Epigallocatechin-3-monogallate; (-)-Epigallocatechol gallate; (2R,3R)-5,7-Dihydroxy-2-(3,4,5-trihydroxyphenyl)chroman-3-yl 3,4,5-trihydroxybenzoate; Catechin deriv; UNII-BQM438CTEL; Green tea extract; CCRIS 3729; (-)-epigallocatechin 3-gallate; C22H18O11; BQM438CTEL; (2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl; EGCG analogs; EGCG, Anagen; Epigallocatechin gallate analogs, Anagen; Epigallocatechin gallate, Anagen; GTPs,Anagen; Green tea polyphenols, Anagen; EPIGALOCATECHIN GALLATE DMCGWBJ CP Anagen Therapeutics Inc; Enzo Life Sciences DMCGWBJ DT Small molecular drug DMCGWBJ PC 65064 DMCGWBJ MW 458.4 DMCGWBJ FM C22H18O11 DMCGWBJ IC InChI=1S/C22H18O11/c23-10-5-12(24)11-7-18(33-22(31)9-3-15(27)20(30)16(28)4-9)21(32-17(11)6-10)8-1-13(25)19(29)14(26)2-8/h1-6,18,21,23-30H,7H2/t18-,21-/m1/s1 DMCGWBJ CS C1[C@H]([C@H](OC2=CC(=CC(=C21)O)O)C3=CC(=C(C(=C3)O)O)O)OC(=O)C4=CC(=C(C(=C4)O)O)O DMCGWBJ IK WMBWREPUVVBILR-WIYYLYMNSA-N DMCGWBJ IU [(2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl] 3,4,5-trihydroxybenzoate DMCGWBJ CA CAS 989-51-5 DMCGWBJ CB CHEBI:4806 DMCGWBJ DE Hepatic fibrosis DM9QPOU ID DM9QPOU DM9QPOU DN Epoetin zeta DM9QPOU HS Phase 3 DM9QPOU CP Hospira DM9QPOU DE Anemia DMITJRU ID DMITJRU DMITJRU DN Epothilon DMITJRU HS Phase 3 DMITJRU CP Bayer AG DMITJRU DE Ovarian cancer DMI1ZXV ID DMI1ZXV DMI1ZXV DN Epratuzumab DMI1ZXV HS Phase 3 DMI1ZXV SN LymphoCide; Lymphocide (TN); Epratuzumab (USAN/INN) DMI1ZXV CP Immunomedics DMI1ZXV DT Antibody DMI1ZXV DE Graft rejection in heart transplantation; Systemic lupus erythematosus; Acute lymphoblastic leukaemia DM35T1O ID DM35T1O DM35T1O DN Epristeride DM35T1O HS Phase 3 DM35T1O SN Zariflo; ONO-9302; SKB-105657; SKF-105657 DM35T1O CP SmithKline Beecham plc DM35T1O DT Small molecular drug DM35T1O PC 68741 DM35T1O MW 399.6 DM35T1O FM C25H37NO3 DM35T1O IC InChI=1S/C25H37NO3/c1-23(2,3)26-21(27)20-9-8-18-17-7-6-16-14-15(22(28)29)10-12-24(16,4)19(17)11-13-25(18,20)5/h6,14,17-20H,7-13H2,1-5H3,(H,26,27)(H,28,29)/t17-,18-,19-,20+,24-,25-/m0/s1 DM35T1O CS C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2C(=O)NC(C)(C)C)CC=C4[C@@]3(CCC(=C4)C(=O)O)C DM35T1O IK VAPSMQAHNAZRKC-PQWRYPMOSA-N DM35T1O IU (8S,9S,10R,13S,14S,17S)-17-(tert-butylcarbamoyl)-10,13-dimethyl-2,7,8,9,11,12,14,15,16,17-decahydro-1H-cyclopenta[a]phenanthrene-3-carboxylic acid DM35T1O CA CAS 119169-78-7 DM35T1O CB CHEBI:31552 DM35T1O DE Hirsutism DMTV7ZM ID DMTV7ZM DMTV7ZM DN Eptastigmine DMTV7ZM HS Phase 3 DMTV7ZM SN heptastigmine; Heptylphysostigmine; Physostigmine heptyl; Eptastigmine [INN]; (-)-Heptylphysostigmine; Eptastigminum [INN-Latin]; Eptastigmina [INN-Spanish]; UNII-6PZZ52D76Q; N-Demethyl-N-heptylphysostigmine; 101246-68-8; BRN 4883778; CHEMBL433041; 6PZZ52D76Q; Heptylstigmine; heptyl-physostigmine; Eptastigminum; Eptastigmina; heptyl physostigmine; Carbamic acid, heptyl-, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo(2,3-b)indol-5-yl ester, (3aS-cis)-; AC1Q60XA; SCHEMBL195028; BDBM10972; Epiastigmine; Eptastigmine tartrate; Heptylstigmine tartrate; Heptyl-physostigmine; L-693487; MF-201; HEPTYPHYSOSTIGMINE DMTV7ZM CP Consiglio Nazionale delle Ricerche DMTV7ZM DT Small molecular drug DMTV7ZM PC 65872 DMTV7ZM MW 359.5 DMTV7ZM FM C21H33N3O2 DMTV7ZM IC InChI=1S/C21H33N3O2/c1-5-6-7-8-9-13-22-20(25)26-16-10-11-18-17(15-16)21(2)12-14-23(3)19(21)24(18)4/h10-11,15,19H,5-9,12-14H2,1-4H3,(H,22,25)/t19-,21+/m1/s1 DMTV7ZM CS CCCCCCCNC(=O)OC1=CC2=C(C=C1)N([C@@H]3[C@]2(CCN3C)C)C DMTV7ZM IK RRGMXBQMCUKRLH-CTNGQTDRSA-N DMTV7ZM IU [(3aR,8bS)-3,4,8b-trimethyl-2,3a-dihydro-1H-pyrrolo[2,3-b]indol-7-yl] N-heptylcarbamate DMTV7ZM CA CAS 101246-68-8 DMTV7ZM DE Cognitive impairment DM6BU57 ID DM6BU57 DM6BU57 DN Eraxis/Vfend DM6BU57 HS Phase 3 DM6BU57 CP Pfizer DM6BU57 DE Fungal infection DM9YI2C ID DM9YI2C DM9YI2C DN ErepoXen DM9YI2C HS Phase 3 DM9YI2C CP Lipoxen plc DM9YI2C DE Anemia DMKQZ0L ID DMKQZ0L DMKQZ0L DN ERITORAN DMKQZ0L HS Phase 3 DMKQZ0L SN ERITORAN; UNII-551541VI0Y; E5564; CHEMBL501259; CHEBI:68609; 185955-34-4; 551541VI0Y; Eritoran [INN]; 3-O-decyl-2-deoxy-6-O-{2-deoxy-3-O-[(3R)-3-methoxydecyl]-6-O-methyl-2-[(11E)-octadec-11-enoylamino]-4-O-phosphonato-beta-D-glucopyranosyl}-2-[(3-oxotetradecanoyl)amino]-1-O-phosphono-alpha-D-glucopyranose; 3-O-Decyl-2-Deoxy-6-O-{2-Deoxy-3-O-[(3r)-3-Methoxydecyl]-6-O-Methyl-2-[(11z)-Octadec-11-Enoylamino]-4-O-Phosphono-Beta-D-Glucopyranosyl}-2-[(3-Oxotetradecanoyl)amino]-1-O-Phosphono-Alpha-D-Glucopyranose; B1287 DMKQZ0L DT Small molecular drug DMKQZ0L PC 6912404 DMKQZ0L MW 1313.7 DMKQZ0L FM C66H126N2O19P2 DMKQZ0L IC InChI=1S/C66H126N2O19P2/c1-7-11-15-19-22-25-26-27-28-29-30-32-34-38-42-46-57(70)67-60-64(82-49-47-54(80-6)45-41-36-18-14-10-4)62(86-88(73,74)75)56(51-79-5)85-65(60)83-52-55-61(72)63(81-48-43-39-35-24-21-17-13-9-3)59(66(84-55)87-89(76,77)78)68-58(71)50-53(69)44-40-37-33-31-23-20-16-12-8-2/h25-26,54-56,59-66,72H,7-24,27-52H2,1-6H3,(H,67,70)(H,68,71)(H2,73,74,75)(H2,76,77,78)/b26-25-/t54-,55-,56-,59-,60-,61-,62-,63-,64-,65-,66-/m1/s1 DMKQZ0L CS CCCCCCCCCCCC(=O)CC(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@@H]1OP(=O)(O)O)CO[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)COC)OP(=O)(O)O)OCC[C@@H](CCCCCCC)OC)NC(=O)CCCCCCCCC/C=C\\CCCCCC)O)OCCCCCCCCCC DMKQZ0L IK BPSMYQFMCXXNPC-MFCPCZTFSA-N DMKQZ0L IU [(2R,3R,4R,5S,6R)-4-decoxy-5-hydroxy-6-[[(2R,3R,4R,5S,6R)-4-[(3R)-3-methoxydecoxy]-6-(methoxymethyl)-3-[[(Z)-octadec-11-enoyl]amino]-5-phosphonooxyoxan-2-yl]oxymethyl]-3-(3-oxotetradecanoylamino)oxan-2-yl] dihydrogen phosphate DMKQZ0L CA CAS 185955-34-4 DMKQZ0L CB CHEBI:68609 DMKQZ0L DE Sepsis DMVU687 ID DMVU687 DMVU687 DN Esketamine DMVU687 HS Phase 3 DMVU687 SN (S)-Ketamine; l-Ketamine; (S)-(-)-Ketamine; 33643-46-8; S-Ketamine; UNII-50LFG02TXD; 50LFG02TXD; (S)-2-(o-chlorophenyl)-2-(methylamino)cyclohexanone; CHEBI:60799; esketamine HCl; (2S)-2-(2-chlorophenyl)-2-(methylamino)cyclohexanone; cyclohexanone, 2-(2-chlorophenyl)-2-(methylamino)-, (2S)-; 6740-88-1 (Parent); Esketamine [USAN:INN:BAN]; S-Ketamin; S-(-)-Ketamine; Esketamine (USAN/INN); AC1L4AD8; DSSTox_CID_27787; DSSTox_RID_82562; DSSTox_GSID_47810; SCHEMBL5512024; GTPL9152; CHEMBL395091; DTXSID6047810; YQEZ DMVU687 CP Janssen Research & Development Raritan, NJ DMVU687 PC 182137 DMVU687 MW 237.72 DMVU687 FM C13H16ClNO DMVU687 IC InChI=1S/C13H16ClNO/c1-15-13(9-5-4-8-12(13)16)10-6-2-3-7-11(10)14/h2-3,6-7,15H,4-5,8-9H2,1H3/t13-/m0/s1 DMVU687 CS CN[C@@]1(CCCCC1=O)C2=CC=CC=C2Cl DMVU687 IK YQEZLKZALYSWHR-ZDUSSCGKSA-N DMVU687 IU (2S)-2-(2-chlorophenyl)-2-(methylamino)cyclohexan-1-one DMVU687 CA CAS 33643-46-8 DMVU687 CB CHEBI:60799 DMVU687 DE Depression DM8RBHJ ID DM8RBHJ DM8RBHJ DN Esomeprazole magnesium + Aspirin DM8RBHJ HS Phase 3 DM8RBHJ CP AstraZeneca DM8RBHJ DE Peptic ulcer DM4YGWA ID DM4YGWA DM4YGWA DN Esonarimod DM4YGWA HS Phase 3 DM4YGWA SN Sonatimod; KE-298; KE-749; KE-758; NE-298; (R)-KE-298; (S)-KE-298 DM4YGWA CP Taisho Pharmaceutical Co Ltd DM4YGWA DT Small molecular drug DM4YGWA PC 127998 DM4YGWA MW 280.34 DM4YGWA FM C14H16O4S DM4YGWA IC InChI=1S/C14H16O4S/c1-9-3-5-11(6-4-9)13(16)7-12(14(17)18)8-19-10(2)15/h3-6,12H,7-8H2,1-2H3,(H,17,18) DM4YGWA CS CC1=CC=C(C=C1)C(=O)CC(CSC(=O)C)C(=O)O DM4YGWA IK YRSSFEUQNAXQMX-UHFFFAOYSA-N DM4YGWA IU 2-(acetylsulfanylmethyl)-4-(4-methylphenyl)-4-oxobutanoic acid DM4YGWA CA CAS 101973-77-7 DM4YGWA CB CHEBI:31559 DM4YGWA DE Arthritis DMXLGED ID DMXLGED DMXLGED DN esuberaprost DMXLGED HS Phase 3 DMXLGED SN APS-314D free acid; BPS-314d DMXLGED DT Small molecular drug DMXLGED PC 10501053 DMXLGED MW 398.5 DMXLGED FM C24H30O5 DMXLGED IC InChI=1S/C24H30O5/c1-3-4-7-15(2)19(25)13-12-17-20(26)14-21-23(17)18-10-5-8-16(24(18)29-21)9-6-11-22(27)28/h5,8,10,12-13,15,17,19-21,23,25-26H,6-7,9,11,14H2,1-2H3,(H,27,28)/b13-12+/t15-,17-,19+,20+,21-,23-/m0/s1 DMXLGED CS CC#CC[C@H](C)[C@@H](/C=C/[C@H]1[C@@H](C[C@H]2[C@@H]1C3=CC=CC(=C3O2)CCCC(=O)O)O)O DMXLGED IK CTPOHARTNNSRSR-NOQAJONNSA-N DMXLGED IU 4-[(1R,2R,3aS,8bS)-2-hydroxy-1-[(E,3S,4S)-3-hydroxy-4-methyloct-1-en-6-ynyl]-2,3,3a,8b-tetrahydro-1H-cyclopenta[b][1]benzofuran-5-yl]butanoic acid DMXLGED CA CAS 94132-88-4 DMXLGED DE Gout; Pulmonary arterial hypertension DMQHX1Y ID DMQHX1Y DMQHX1Y DN Etirinotecan pegol DMQHX1Y HS Phase 3 DMQHX1Y SN NKTR-102 DMQHX1Y CP Nektar Therapeutics DMQHX1Y DT Small molecular drug DMQHX1Y PC 56935717 DMQHX1Y MW 3047.4 DMQHX1Y FM C161H192N20O40 DMQHX1Y IC InChI=1S/C161H192N20O40/c1-9-105-109-69-101(214-153(198)174-53-37-97(38-54-174)170-45-21-17-22-46-170)29-33-125(109)166-141-113(105)81-178-129(141)73-121-117(145(178)190)85-210-149(194)158(121,13-5)218-137(186)77-162-133(182)89-202-61-65-206-93-157(94-207-66-62-203-90-134(183)163-78-138(187)219-159(14-6)122-74-130-142-114(82-179(130)146(191)118(122)86-211-150(159)195)106(10-2)110-70-102(30-34-126(110)167-142)215-154(199)175-55-39-98(40-56-175)171-47-23-18-24-48-171,95-208-67-63-204-91-135(184)164-79-139(188)220-160(15-7)123-75-131-143-115(83-180(131)147(192)119(123)87-212-151(160)196)107(11-3)111-71-103(31-35-127(111)168-143)216-155(200)176-57-41-99(42-58-176)172-49-25-19-26-50-172)96-209-68-64-205-92-136(185)165-80-140(189)221-161(16-8)124-76-132-144-116(84-181(132)148(193)120(124)88-213-152(161)197)108(12-4)112-72-104(32-36-128(112)169-144)217-156(201)177-59-43-100(44-60-177)173-51-27-20-28-52-173/h29-36,69-76,97-100H,9-28,37-68,77-96H2,1-8H3,(H,162,182)(H,163,183)(H,164,184)(H,165,185)/t158-,159-,160-,161-/m0/s1 DMQHX1Y CS CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)[C@@]4(CC)OC(=O)CNC(=O)COCCOCC(COCCOCC(=O)NCC(=O)O[C@]5(C6=C(COC5=O)C(=O)N7CC8=C(C9=C(C=CC(=C9)OC(=O)N3CCC(CC3)N3CCCCC3)N=C8C7=C6)CC)CC)(COCCOCC(=O)NCC(=O)O[C@]3(C4=C(COC3=O)C(=O)N3CC5=C(C6=C(C=CC(=C6)OC(=O)N6CCC(CC6)N6CCCCC6)N=C5C3=C4)CC)CC)COCCOCC(=O)NCC(=O)O[C@]3(C4=C(COC3=O)C(=O)N3CC5=C(C6=C(C=CC(=C6)OC(=O)N6CCC(CC6)N6CCCCC6)N=C5C3=C4)CC)CC)C2=NC2=C1C=C(C=C2)OC(=O)N1CCC(CC1)N1CCCCC1 DMQHX1Y IK SELCJVNOEBVTAC-HLDPIHRNSA-N DMQHX1Y IU [(19S)-19-[2-[[2-[2-[3-[2-[2-[[2-[[(19S)-10,19-diethyl-14,18-dioxo-7-(4-piperidin-1-ylpiperidine-1-carbonyl)oxy-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaen-19-yl]oxy]-2-oxoethyl]amino]-2-oxoethoxy]ethoxy]-2,2-bis[2-[2-[[2-[[(19S)-10,19-diethyl-14,18-dioxo-7-(4-piperidin-1-ylpiperidine-1-carbonyl)oxy-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaen-19-yl]oxy]-2-oxoethyl]amino]-2-oxoethoxy]ethoxymethyl]propoxy]ethoxy]acetyl]amino]acetyl]oxy-10,19-diethyl-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaen-7-yl] 4-piperidin-1-ylpiperidine-1-carboxylate DMQHX1Y DE Breast cancer; Ovarian cancer DMCDZ15 ID DMCDZ15 DMCDZ15 DN Evacetrapib DMCDZ15 HS Phase 3 DMCDZ15 SN LY2484595 DMCDZ15 CP Lilly DMCDZ15 DT Small molecular drug DMCDZ15 PC 49836058 DMCDZ15 MW 638.6 DMCDZ15 FM C31H36F6N6O2 DMCDZ15 IC InChI=1S/C31H36F6N6O2/c1-18-11-19(2)27-25(12-18)26(5-4-10-42(27)16-20-6-8-22(9-7-20)28(44)45)43(29-38-40-41(3)39-29)17-21-13-23(30(32,33)34)15-24(14-21)31(35,36)37/h11-15,20,22,26H,4-10,16-17H2,1-3H3,(H,44,45)/t20?,22?,26-/m0/s1 DMCDZ15 CS CC1=CC(=C2C(=C1)[C@H](CCCN2CC3CCC(CC3)C(=O)O)N(CC4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F)C5=NN(N=N5)C)C DMCDZ15 IK IHIUGIVXARLYHP-UXNJHFGPSA-N DMCDZ15 IU 4-[[(5S)-5-[[3,5-bis(trifluoromethyl)phenyl]methyl-(2-methyltetrazol-5-yl)amino]-7,9-dimethyl-2,3,4,5-tetrahydro-1-benzazepin-1-yl]methyl]cyclohexane-1-carboxylic acid DMCDZ15 CA CAS 1186486-62-3 DMCDZ15 DE Cardiovascular disease DMG4UJ6 ID DMG4UJ6 DMG4UJ6 DN EVK-001 DMG4UJ6 HS Phase 3 DMG4UJ6 CP Evoke Pharma DMG4UJ6 DE Diabetic gastroparesis DMLQO7F ID DMLQO7F DMLQO7F DN EVP-6124 DMLQO7F HS Phase 3 DMLQO7F SN Encenicline; EVP-6124; 550999-75-2; UNII-5FI5376A0X; EVP6124; EVP 6124; CHEMBL2151572; (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide; 5FI5376A0X; C16H17ClN2OS; 550999-74-1; Encenicline [USAN:INN]; FRM-6124; Encenicline (USAN/INN); SCHEMBL744767; GTPL6926; SSRDSYXGYPJKRR-ZDUSSCGKSA-N; ZINC95579362; BDBM50393255; 3662AH; AKOS027322165; DB11726; CS-0933; MT-4666; Benzo(b)thiophene-2-carboxamide, N-(3R)-1-azabicyclo(2.2.2)oct-3-yl-7-chloro-; NCGC00378871-01; HY-15430; W-5978; D10626 DMLQO7F CP EnVivo Pharmaceuticals DMLQO7F DT Small molecular drug DMLQO7F PC 46196517 DMLQO7F MW 320.8 DMLQO7F FM C16H17ClN2OS DMLQO7F IC InChI=1S/C16H17ClN2OS/c17-12-3-1-2-11-8-14(21-15(11)12)16(20)18-13-9-19-6-4-10(13)5-7-19/h1-3,8,10,13H,4-7,9H2,(H,18,20)/t13-/m0/s1 DMLQO7F CS C1CN2CCC1[C@H](C2)NC(=O)C3=CC4=C(S3)C(=CC=C4)Cl DMLQO7F IK SSRDSYXGYPJKRR-ZDUSSCGKSA-N DMLQO7F IU N-[(3R)-1-azabicyclo[2.2.2]octan-3-yl]-7-chloro-1-benzothiophene-2-carboxamide DMLQO7F CA CAS 550999-75-2 DMLQO7F DE Schizophrenia; Alzheimer disease DMCA7FN ID DMCA7FN DMCA7FN DN Exatecan DMCA7FN HS Phase 3 DMCA7FN SN Exatecan mesylate; DX-8951; DX-8951a; DX-8951f; UM-1; UM-2 DMCA7FN CP Daiichi Seiyaku Co Ltd DMCA7FN DT Small molecular drug DMCA7FN PC 151115 DMCA7FN MW 435.4 DMCA7FN FM C24H22FN3O4 DMCA7FN IC InChI=1S/C24H22FN3O4/c1-3-24(31)14-6-18-21-12(8-28(18)22(29)13(14)9-32-23(24)30)19-16(26)5-4-11-10(2)15(25)7-17(27-21)20(11)19/h6-7,16,31H,3-5,8-9,26H2,1-2H3/t16-,24-/m0/s1 DMCA7FN CS CC[C@@]1(C2=C(COC1=O)C(=O)N3CC4=C5[C@H](CCC6=C5C(=CC(=C6C)F)N=C4C3=C2)N)O DMCA7FN IK ZVYVPGLRVWUPMP-FYSMJZIKSA-N DMCA7FN IU (10S,23S)-23-amino-10-ethyl-18-fluoro-10-hydroxy-19-methyl-8-oxa-4,15-diazahexacyclo[14.7.1.02,14.04,13.06,11.020,24]tetracosa-1,6(11),12,14,16,18,20(24)-heptaene-5,9-dione DMCA7FN CA CAS 171335-80-1 DMCA7FN CB CHEBI:135709 DMCA7FN DE Solid tumour/cancer DMBY56U ID DMBY56U DMBY56U DN EXISULIND DMBY56U HS Phase 3 DMBY56U SN Aposulind; Aptosyn; Sulindac sulfone; FGN-1; Prevatac (former Brand Name); Exisulind; (Z)-5-Fluoro-2-methyl-1-[4-(methylsulfonyl)benzylidene]-1H-indene-3-acetic acid DMBY56U CP OSI Pharmaceuticals DMBY56U DT Small molecular drug DMBY56U PC 5472495 DMBY56U MW 372.4 DMBY56U FM C20H17FO4S DMBY56U IC InChI=1S/C20H17FO4S/c1-12-17(9-13-3-6-15(7-4-13)26(2,24)25)16-8-5-14(21)10-19(16)18(12)11-20(22)23/h3-10H,11H2,1-2H3,(H,22,23)/b17-9- DMBY56U CS CC\\1=C(C2=C(/C1=C\\C3=CC=C(C=C3)S(=O)(=O)C)C=CC(=C2)F)CC(=O)O DMBY56U IK MVGSNCBCUWPVDA-MFOYZWKCSA-N DMBY56U IU 2-[(3Z)-6-fluoro-2-methyl-3-[(4-methylsulfonylphenyl)methylidene]inden-1-yl]acetic acid DMBY56U CA CAS 59973-80-7 DMBY56U CB CHEBI:64212 DMBY56U DE Colorectal cancer DMOKT7Y ID DMOKT7Y DMOKT7Y DN FARGLITAZAR DMOKT7Y HS Phase 3 DMOKT7Y SN Farglitazar; GI-262570; GI262570; 196808-45-4; GI 262570; UNII-3433GY7132; CHEMBL107367; GI-262570X; 2-(2-BENZOYL-PHENYLAMINO)-3-{4-[2-(5-METHYL-2-PHENYL-OXAZOL-4-YL)-ETHOXY]-PHENYL}-PROPIONIC ACID; 3433GY7132; L-Tyrosine, N-(2-benzoylphenyl)-o-(2-(5-methyl-2-phenyl-4-oxazolyl)ethyl)-; L-Tyrosine, N-(2-benzoylphenyl)-o-(2-(5-methyl-2-phenyl-4-oxazolyl)ethyl); N-(o-Benzoylphenyl)-O-(2-(5-methyl-2-phenyl-4-oxazolyl)ethyl)-L-tyrosine; Farglitazar [USAN]; Farglitazar [USAN:INN]; L-tyrosine, N-(2-benzoylphenyl)-O-[2-(5-methyl- DMOKT7Y DT Small molecular drug DMOKT7Y PC 170364 DMOKT7Y MW 546.6 DMOKT7Y FM C34H30N2O5 DMOKT7Y IC InChI=1S/C34H30N2O5/c1-23-29(36-33(41-23)26-12-6-3-7-13-26)20-21-40-27-18-16-24(17-19-27)22-31(34(38)39)35-30-15-9-8-14-28(30)32(37)25-10-4-2-5-11-25/h2-19,31,35H,20-22H2,1H3,(H,38,39)/t31-/m0/s1 DMOKT7Y CS CC1=C(N=C(O1)C2=CC=CC=C2)CCOC3=CC=C(C=C3)C[C@@H](C(=O)O)NC4=CC=CC=C4C(=O)C5=CC=CC=C5 DMOKT7Y IK ZZCHHVUQYRMYLW-HKBQPEDESA-N DMOKT7Y IU (2S)-2-(2-benzoylanilino)-3-[4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl]propanoic acid DMOKT7Y CA CAS 196808-45-4 DMOKT7Y DE Type-1 diabetes DM83SEB ID DM83SEB DM83SEB DN Faricimab DM83SEB HS Phase 3 DM83SEB SN RO6867461; RG7716 DM83SEB DT Antibody DM83SEB DE Diabetic macular edema DMFLWX1 ID DMFLWX1 DMFLWX1 DN Farletuzumab DMFLWX1 HS Phase 3 DMFLWX1 CP Morphotek DMFLWX1 DT Monoclonal antibody DMFLWX1 SQ 9067_H|farletuzumab|||H-GAMMA-1 (VH(1-119)+CH1(120-217)+HINGE-REGION(218-232)+CH2(233-342)+CH3(343-449))|||||||449||||MW 48946.2|MW 48946.2|: EVQLVESGGGVVQPGRSLRLSCSASGFTFSGYGLSWVRQAPGKGLEWVAMISSGGSYTYYADSVKGRFAISRDNAKNTLFLQMDSLRPEDTGVYFCARHGDDPAWFAYWGQGTPVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK >9067_L|farletuzumab|||L-KAPPA (V-KAPPA(1-110)+C-KAPPA(111-217))|||||||217||||MW 23755.2|MW 23755.2|DIQLTQSPSSLSASVGDRVTITCSVSSSISSNNLHWYQQKPGKAPKPWIYGTSNLASGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQQWSSYPYMYTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC DMFLWX1 DE Ovarian cancer; Non-small-cell lung cancer DMTGYSO ID DMTGYSO DMTGYSO DN Fasiglifam hemihydrate DMTGYSO HS Phase 3 DMTGYSO SN Fasiglifam hemihydrate; 1374598-80-7; UNII-8LDT91CH8A; 8LDT91CH8A; TAK-875 Hemihydrate; Fasiglifam hydrate (JAN); DTXSID80160191; MolPort-035-395-707; EX-A2165; s2637; AKOS025404925; 3-Benzofuranacetic acid, 6-((2',6'-dimethyl-4'-(3-(methylsulfonyl)propoxy)(1,1'-biphenyl)-3-yl)methoxy)-2,3-dihydro-, hydrate (2:1), (3S)-; (3S)-6-((2',6'-Dimethyl-4'-(3-(methylsulfonyl)propoxy) biphenyl-3-yl)methoxy)-2,3-dihydro-l-benzofuran-3-yl)acetic acid hydrate; SC-95595; BC600332; (3S)-6-((2',6'-Dimethyl-4'-(3-(methylsulfonyl)propoxy) DMTGYSO CP Apollo Scientific DMTGYSO DT Small molecular drug DMTGYSO PC 57339446 DMTGYSO MW 1067.3 DMTGYSO FM C58H66O15S2 DMTGYSO IC InChI=1S/2C29H32O7S.H2O/c2*1-19-12-25(34-10-5-11-37(3,32)33)13-20(2)29(19)22-7-4-6-21(14-22)17-35-24-8-9-26-23(15-28(30)31)18-36-27(26)16-24;/h2*4,6-9,12-14,16,23H,5,10-11,15,17-18H2,1-3H3,(H,30,31);1H2/t2*23-;/m11./s1 DMTGYSO CS CC1=CC(=CC(=C1C2=CC=CC(=C2)COC3=CC4=C(C=C3)[C@@H](CO4)CC(=O)O)C)OCCCS(=O)(=O)C.CC1=CC(=CC(=C1C2=CC=CC(=C2)COC3=CC4=C(C=C3)[C@@H](CO4)CC(=O)O)C)OCCCS(=O)(=O)C.O DMTGYSO IK OJXYMYYDAVXPIK-IWKNALKQSA-N DMTGYSO IU 2-[(3S)-6-[[3-[2,6-dimethyl-4-(3-methylsulfonylpropoxy)phenyl]phenyl]methoxy]-2,3-dihydro-1-benzofuran-3-yl]acetic acid;hydrate DMTGYSO CA CAS 1374598-80-7 DMTGYSO DE Type-2 diabetes DM5PRLA ID DM5PRLA DM5PRLA DN Fasinumab DM5PRLA HS Phase 3 DM5PRLA CP Regeneron Pharmaceuticals Tarrytown, NY Teva Pharmaceuticals USA North Wales, PA DM5PRLA DE Neuropathic pain; Chronic low back pain; Pain; Osteoarthritis DM8E51L ID DM8E51L DM8E51L DN FASORACETAM DM8E51L HS Phase 3 DM8E51L SN LAM-105; NS-105; Fasoracetam; (R)-1-[(5-Oxo-2-pyrrolidinyl)carbonyl]piperidine; (R)-5-(Piperidin-1-ylcarbonyl)pyrrolidin-2-one DM8E51L DT Small molecular drug DM8E51L PC 198695 DM8E51L MW 196.25 DM8E51L FM C10H16N2O2 DM8E51L IC InChI=1S/C10H16N2O2/c13-9-5-4-8(11-9)10(14)12-6-2-1-3-7-12/h8H,1-7H2,(H,11,13)/t8-/m1/s1 DM8E51L CS C1CCN(CC1)C(=O)[C@H]2CCC(=O)N2 DM8E51L IK GOWRRBABHQUJMX-MRVPVSSYSA-N DM8E51L IU (5R)-5-(piperidine-1-carbonyl)pyrrolidin-2-one DM8E51L CA CAS 110958-19-5 DM8E51L CB CHEBI:31592 DM8E51L DE Cognitive impairment DM35GBS ID DM35GBS DM35GBS DN Favipiravir DM35GBS HS Phase 3 DM35GBS SN AIDS121660; Favipiravir (JAN/INN); 3-bromo-5-hydroxy-4-methyl-2,6-dinitro-benzoic Acid; T705 DM35GBS CP Toyama Chemical DM35GBS TC Antiviral Agents DM35GBS DT Small molecular drug DM35GBS PC 492405 DM35GBS MW 157.1 DM35GBS FM C5H4FN3O2 DM35GBS IC InChI=1S/C5H4FN3O2/c6-2-1-8-5(11)3(9-2)4(7)10/h1H,(H2,7,10)(H,8,11) DM35GBS CS C1=C(N=C(C(=O)N1)C(=O)N)F DM35GBS IK ZCGNOVWYSGBHAU-UHFFFAOYSA-N DM35GBS IU 5-fluoro-2-oxo-1H-pyrazine-3-carboxamide DM35GBS CA CAS 259793-96-9 DM35GBS CB CHEBI:134722 DM35GBS DE Influenza virus infection; Coronavirus Disease 2019 (COVID-19) DM0762O ID DM0762O DM0762O DN Fenfluramine DM0762O HS Phase 3 DM0762O SN Acino; Adifax; Adipomin; Fenfluramina; Fenfluraminum; Isomeride; Obedrex; Pesos; Ponderex; Rotondin; Dexfenfluramina [Spanish]; Dexfenfluraminum [Latin]; Fenfluramina [DCIT]; Fenfluramine hydrochloride; Levofenfluramine [INN]; Ponderax PA; S 768; D-Fenfluramine; Dexfenfluramine [INN:BAN]; Fenfluramine (INN); Fenfluramine [INN:BAN]; Fenfluraminum [INN-Latin]; Ponderax (TN); Fenfluramine, (+-)-Isomer; N-Ethyl-alpha-methyl-3-trifluoromethylphenethylamine; D-N-Ethyl-alpha-methyl-m-trifluoromethylphenethylamine; N-Ethyl-alpha-methyl-3-(trifluoromethyl)benzeneethanamine; N-Ethyl-alpha-methyl-m-(trifluoromethyl)phenethylamine; N-ethyl-1-[3-(trifluoromethyl)phenyl]propan-2-amine; Benzeneethanamine, N-ethyl-alpha-methyl-3-(trifluoromethyl)-(9CI); Benzeneethanamine, N-ethyl-alpha-methyl-3-(trifluoromethyl)-, (S)-(9CI);Benzeneethanamine, N-ethyl-alpha-methyl-3-(trifluoromethyl)-, (+-)-(9CI); (+)-Fenfluramine; (+-)-Fenfluramine; (+/-)-Fenfluramine hydrochloride; (S)-Fenfluramine; 1-(m-trifluoromethyl-phenyl)-2-ethylaminopropane; 1-(meta-Trifluoromethyl-phenyl)-2 ethylaminopropane; 2-Ethylamino-1-(3-trifluoromethylphenyl)propane; 3-(Trifluoromethyl)-N-ethyl-alpha-methylphenethylamine DM0762O CP Zogenix Emeryville, CA DM0762O DT Small molecular drug DM0762O PC 3337 DM0762O MW 231.26 DM0762O FM C12H16F3N DM0762O IC InChI=1S/C12H16F3N/c1-3-16-9(2)7-10-5-4-6-11(8-10)12(13,14)15/h4-6,8-9,16H,3,7H2,1-2H3 DM0762O CS CCNC(C)CC1=CC(=CC=C1)C(F)(F)F DM0762O IK DBGIVFWFUFKIQN-UHFFFAOYSA-N DM0762O IU N-ethyl-1-[3-(trifluoromethyl)phenyl]propan-2-amine DM0762O CA CAS 458-24-2 DM0762O CB CHEBI:5000 DM0762O DE Dravet syndrome; LennoxGastaut syndrome; Obesity DMRD5SP ID DMRD5SP DMRD5SP DN Fenretinide DMRD5SP HS Phase 3 DMRD5SP SN RT-101; ST-602; SYT-101; Fenretinide (pulmonary Pseudomonas aeruginosa infections in cystic fibrosis), McGill University; LXS/4-HPR; Fenretinide (Ewing's sarcoma), Cancer Research UK; Fenretinide (ILE formulation), Children's Hospital LA; Fenretinide (intralipid emulsion formulation), Children's Hospital of Los Angeles; Fenretinide (intravenous, cancer), SciTech Development; Fenretinide (iv), Children's Hospital LA; Fenretinide (oral, AMD), Sytera; Fenretinide (soft gel capsule, AMD), ReVision Therapeutics; Fenretinide (soft gel capsule, AMD), Sirion; Fenretinide (topical, actinic keratosis and cancer), SciTech Development; N-(4-hydroxyphenyl)retinamide; Fenretinide (intravenous emulsion, lymphoma/solid tumors/pediatric neuroblastomas/pediatric leukemia), CerRx; Fenretinide (oral powder/Lym-X-Sorb, neuroblastoma), BioMolecular Products; 4-HPR DMRD5SP CP Sirion Therapeutics; cerrx; Sytera Inc DMRD5SP DT Small molecular drug DMRD5SP PC 5288209 DMRD5SP MW 391.5 DMRD5SP FM C26H33NO2 DMRD5SP IC InChI=1S/C26H33NO2/c1-19(11-16-24-21(3)10-7-17-26(24,4)5)8-6-9-20(2)18-25(29)27-22-12-14-23(28)15-13-22/h6,8-9,11-16,18,28H,7,10,17H2,1-5H3,(H,27,29)/b9-6+,16-11+,19-8+,20-18+ DMRD5SP CS CC1=C(C(CCC1)(C)C)/C=C/C(=C/C=C/C(=C/C(=O)NC2=CC=C(C=C2)O)/C)/C DMRD5SP IK AKJHMTWEGVYYSE-FXILSDISSA-N DMRD5SP IU (2E,4E,6E,8E)-N-(4-hydroxyphenyl)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenamide DMRD5SP CA CAS 65646-68-6 DMRD5SP CB CHEBI:42588 DMRD5SP DE Lymphoma; Peripheral T-cell lymphoma; Solid tumour/cancer; Tumour; Macular degeneration DM4NX0C ID DM4NX0C DM4NX0C DN Fevipiprant DM4NX0C HS Phase 3 DM4NX0C SN 872365-14-5; NVP-QAW039; QAW039; UNII-2PEX5N7DQ4; 2PEX5N7DQ4; 2-[2-methyl-1-[[4-methylsulfonyl-2-(trifluoromethyl)phenyl]methyl]pyrrolo[2,3-b]pyridin-3-yl]acetic acid; 2-(2-methyl-1-(4-(methylsulfonyl)-2-(trifluoromethyl)benzyl)-1H-pyrrolo[2,3-b]pyridin-3-yl)acetic acid; 2-Methyl-1-[[4-(methylsulfonyl)-2-(trifluoromethyl)phenyl]methyl]-1H-pyrrolo[2,3-b]pyridine-3-acetic acid; Fevipiprant [INN]; Fevipiprant [USAN:INN]; QAW 039; Fevipiprant (JAN/USAN/INN); GTPL8995; SCHEMBL1940595; CHEMBL3137332; QAW-039; HMS3743E19; BCP25015; EX-A2495; BDBM50233520; ZINC43101772; AB85348; CS-5956; DB12011; Fevipiprant; NVP-QAW039; QAW039; SB16897; (1-(4-((Methane)sulfonyl)-2-trifluoromethylbenzyl)-2-methyl-1H-pyrrolo(2,3-b)pyridin-3-yl)acetic acid; 2-(1-((4-Methanesulfonyl-2-(trifluoromethyl)phenyl)methyl(-2-methyl-1H-pyrrolo(2,3-b)pyridin-3-yl)acetic acid; AC-31956; AS-74870; HY-16768; DS-022511; FT-0774596; D10631; Q27077292; 1-(4-methanesulfonylbenzyl)-2-methyl-1H-pyrrolo(2,3-b)pyridin-3-yl)acetic acid; (2-methyl-1-{[4-(methylsulfonyl)-2-(trifluoromethyl)phenyl]methyl}-1H-pyrrolo[2,3-b]pyridin-3-yl)acetic acid; [1-(4-Methanesulfonyl-2-trifluoromethyl-benzyl)-2-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl]-acetic acid; [2-METHYL-1-[4-(METHYLSULFONYL)-2-(TRIFLUOROMETHYL)BENZYL]-1H-PYRROLO[2,3-B]PYRIDIN-3-YL]ACETIC ACID; 2-(1-{[4-methanesulfonyl-2-(trifluoromethyl)phenyl]methyl}-2-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)acetic acid; 2-[2-methyl-1-[[4-methylsulfonyl-2-(trifluoromethyl)phenyl]methyl]pyrrolo[5,4-b]pyridin-3-yl]acetic acid; FSY DM4NX0C CP Novartis DM4NX0C DT Small molecular drug DM4NX0C PC 23582412 DM4NX0C MW 426.4 DM4NX0C FM C19H17F3N2O4S DM4NX0C IC InChI=1S/C19H17F3N2O4S/c1-11-15(9-17(25)26)14-4-3-7-23-18(14)24(11)10-12-5-6-13(29(2,27)28)8-16(12)19(20,21)22/h3-8H,9-10H2,1-2H3,(H,25,26) DM4NX0C CS CC1=C(C2=C(N1CC3=C(C=C(C=C3)S(=O)(=O)C)C(F)(F)F)N=CC=C2)CC(=O)O DM4NX0C IK GFPPXZDRVCSVNR-UHFFFAOYSA-N DM4NX0C IU 2-[2-methyl-1-[[4-methylsulfonyl-2-(trifluoromethyl)phenyl]methyl]pyrrolo[2,3-b]pyridin-3-yl]acetic acid DM4NX0C CA CAS 872365-14-5 DM4NX0C DE Asthma DM4XSQ2 ID DM4XSQ2 DM4XSQ2 DN FG-4592 DM4XSQ2 HS Phase 3 DM4XSQ2 SN FG-4592; 808118-40-3; Roxadustat; Roxadustat (FG-4592); UNII-X3O30D9YMX; N-[(4-Hydroxy-1-methyl-7-phenoxy-3-isoquinolinyl)carbonyl]glycine; FG4592; ASP1517; Glycine, N-[(4-hydroxy-1-methyl-7-phenoxy-3-isoquinolinyl)carbonyl]-; X3O30D9YMX; CHEMBL2338329; 2-[(4-hydroxy-1-methyl-7-phenoxyisoquinoline-3-carbonyl)amino]acetic acid; FG 4592; AK198953; n-((4-hydroxy-1-methyl-7-phenoxy-3-isoquinolinyl)carbonyl)glycine; [[(4-Hydroxy-1-methyl-7-phenoxyisoquinolin-3-yl)carbonyl]amino]acetic Acid DM4XSQ2 CP FibroGen DM4XSQ2 DT Small molecular drug DM4XSQ2 PC 11256664 DM4XSQ2 MW 352.3 DM4XSQ2 FM C19H16N2O5 DM4XSQ2 IC InChI=1S/C19H16N2O5/c1-11-15-9-13(26-12-5-3-2-4-6-12)7-8-14(15)18(24)17(21-11)19(25)20-10-16(22)23/h2-9,24H,10H2,1H3,(H,20,25)(H,22,23) DM4XSQ2 CS CC1=C2C=C(C=CC2=C(C(=N1)C(=O)NCC(=O)O)O)OC3=CC=CC=C3 DM4XSQ2 IK YOZBGTLTNGAVFU-UHFFFAOYSA-N DM4XSQ2 IU 2-[(4-hydroxy-1-methyl-7-phenoxyisoquinoline-3-carbonyl)amino]acetic acid DM4XSQ2 CA CAS 808118-40-3 DM4XSQ2 CB CHEBI:132774 DM4XSQ2 DE Kidney disease; Anaemia DMFZ81T ID DMFZ81T DMFZ81T DN Fidanacogene elaparvovec DMFZ81T HS Phase 3 DMFZ81T SN AAV8-hFIX19 DMFZ81T CP Pfizer DMFZ81T DT Gene therapy DMFZ81T DE Haemophilia B DMZL1I8 ID DMZL1I8 DMZL1I8 DN Fidarestat DMZL1I8 HS Phase 3 DMZL1I8 SN Aldos; FID; Fidaresstat; SK 860; Snk 860; Aldos (TN); SNK-860; Fidarestat (JAN/INN); (+)-(2S,4S)-6-Fluoro-2',5'-dioxospiro(chroman-4,4'-imidazolidine)-2-carboxamide; (+)-(2s,4s)-6-fluoro-2',5'-dioxospiro[chroman-4,4'-imidazolidine]-2-carboxamide; (2S,4S)-2-AMINOFORMYL-6-FLUORO-SPIRO[CHROMAN-4,4'-IMIDAZOLIDINE]-2',5'-DIONE; (2S,4S)-6-Fluoro-2',5'-dioxospiro(3,4-dihydro-2H-1-benzopyran-4,4'-imidazolidine)-2-carboxamide; (2S,4S)-6-fluoro-2',5'-dioxospiro(chroman-4,4'-imidazolidine)-2-carboxamide; (2S,4S)-6-fluoro-2',5'-dioxospiro[2,3-dihydrochromene-4,4'-imidazolidine]-2-carboxamide DMZL1I8 CP Sanwa Kagaku DMZL1I8 DT Small molecular drug DMZL1I8 PC 160024 DMZL1I8 MW 279.22 DMZL1I8 FM C12H10FN3O4 DMZL1I8 IC InChI=1S/C12H10FN3O4/c13-5-1-2-7-6(3-5)12(4-8(20-7)9(14)17)10(18)15-11(19)16-12/h1-3,8H,4H2,(H2,14,17)(H2,15,16,18,19)/t8-,12-/m0/s1 DMZL1I8 CS C1[C@H](OC2=C([C@]13C(=O)NC(=O)N3)C=C(C=C2)F)C(=O)N DMZL1I8 IK WAAPEIZFCHNLKK-UFBFGSQYSA-N DMZL1I8 IU (2S,4S)-6-fluoro-2',5'-dioxospiro[2,3-dihydrochromene-4,4'-imidazolidine]-2-carboxamide DMZL1I8 CA CAS 136087-85-9 DMZL1I8 DE Diabetic complication DMM4FJ3 ID DMM4FJ3 DMM4FJ3 DN Finerenone DMM4FJ3 HS Phase 3 DMM4FJ3 SN UNII-DE2O63YV8R; BAY 94-8862; 1050477-31-0; BAY94-8862; DE2O63YV8R; Finerenone [USAN:INN]; Finerenone (JAN/USAN/INN); SCHEMBL8157011; GTPL8678; DTXSID10146928; J3.584.878I; D10633; 1,6-Naphthyridine-3-carboxamide, 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-1,4-dihydro-2,8-dimethyl-, (4S)-;1,6-Naphthyridine-3-carboxamide, 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-1,4-dihydro-2,8-dimethyl-, (4S)-; 1,6-Naphthyridine-3-carboxamide, 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-1,4-dihydro-2,8-dimethyl-, (4S)-; (4S)-4-(4-cyano-2-metho DMM4FJ3 CP Bayer HealthCare Pharmaceuticals, Plainsboro, NJ DMM4FJ3 PC 60150535 DMM4FJ3 MW 378.4 DMM4FJ3 FM C21H22N4O3 DMM4FJ3 IC InChI=1S/C21H22N4O3/c1-5-28-21-18-17(14-7-6-13(9-22)8-15(14)27-4)16(20(23)26)12(3)25-19(18)11(2)10-24-21/h6-8,10,17,25H,5H2,1-4H3,(H2,23,26)/t17-/m1/s1 DMM4FJ3 CS CCOC1=NC=C(C2=C1[C@@H](C(=C(N2)C)C(=O)N)C3=C(C=C(C=C3)C#N)OC)C DMM4FJ3 IK BTBHLEZXCOBLCY-QGZVFWFLSA-N DMM4FJ3 IU (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide DMM4FJ3 CA CAS 1050477-31-0 DMM4FJ3 DE Diabetic nephropathy DMMQ7BY ID DMMQ7BY DMMQ7BY DN Fitusiran DMMQ7BY HS Phase 3 DMMQ7BY SN ALN-AT3SC DMMQ7BY CP Sanofi DMMQ7BY DT Small interfering RNA DMMQ7BY DE Hemophilia DM6R2XF ID DM6R2XF DM6R2XF DN FKB238 DM6R2XF HS Phase 3 DM6R2XF CP Fujifilm; Centus Biotherapeutics DM6R2XF DT Antibody DM6R2XF DE Non-small-cell lung cancer DMPSG4D ID DMPSG4D DMPSG4D DN Flobufen DMPSG4D HS Phase 3 DMPSG4D SN VUFB-16066; VUFB-17203 DMPSG4D CP VUFB DMPSG4D DT Small molecular drug DMPSG4D PC 159476 DMPSG4D MW 304.29 DMPSG4D FM C17H14F2O3 DMPSG4D IC InChI=1S/C17H14F2O3/c1-10(17(21)22)8-16(20)12-4-2-11(3-5-12)14-7-6-13(18)9-15(14)19/h2-7,9-10H,8H2,1H3,(H,21,22) DMPSG4D CS CC(CC(=O)C1=CC=C(C=C1)C2=C(C=C(C=C2)F)F)C(=O)O DMPSG4D IK FIKVYIRIUOFLLR-UHFFFAOYSA-N DMPSG4D IU 4-[4-(2,4-difluorophenyl)phenyl]-2-methyl-4-oxobutanoic acid DMPSG4D CA CAS 112344-52-2 DMPSG4D DE Rheumatoid arthritis DMKL5AT ID DMKL5AT DMKL5AT DN Flurpiridaz F 18 DMKL5AT HS Phase 3 DMKL5AT SN Flurpiridaz (18F); PET myocardial perfusion imaging agents, Bristol-Myers Squibb Medical Imaging; RP-1003-18; RP-1004-18; RP-1005-18; [18F]-RP-1003; [18F]-RP-1004; [18F]-RP-1005; [18F]-labeled PET myocardial perfusion imaging agents, Lantheus Medical Imaging; BMS-747158-02-[18F]; Fluorine-18-BMS-747158; [18F]-labeled MC-1 inhibitors (MPIAs), Lantheus Medical Imaging; [18F]-labeled MC-1 inhibitors, Bristol-Myers Squibb Medical Imaging; [18fluorine]-labeled mitochondrial complex-1 inhibitors, Bristol-Myers Squibb Medical Imaging; 18F-BMS-747158-02 DMKL5AT CP Lantheus medical imaging DMKL5AT DT Small molecular drug DMKL5AT PC 11405965 DMKL5AT MW 367.8 DMKL5AT FM C18H22ClFN2O3 DMKL5AT IC InChI=1S/C18H22ClFN2O3/c1-18(2,3)22-17(23)16(19)15(10-21-22)25-12-14-6-4-13(5-7-14)11-24-9-8-20/h4-7,10H,8-9,11-12H2,1-3H3/i20-1 DMKL5AT CS CC(C)(C)N1C(=O)C(=C(C=N1)OCC2=CC=C(C=C2)COCC[18F])Cl DMKL5AT IK RMXZKEPDYBTFOS-LRFGSCOBSA-N DMKL5AT IU 2-tert-butyl-4-chloro-5-[[4-(2-(18F)fluoranylethoxymethyl)phenyl]methoxy]pyridazin-3-one DMKL5AT CA CAS 863887-89-2 DMKL5AT DE Myocardial disease DM5S4DL ID DM5S4DL DM5S4DL DN Forigerimod DM5S4DL HS Phase 3 DM5S4DL SN CEP-33457 DM5S4DL CP Cephalon DM5S4DL DT Small molecular drug DM5S4DL PC 56841982 DM5S4DL MW 2638.9 DM5S4DL FM C117H181N34O32PS DM5S4DL IC InChI=1S/C117H181N34O32PS/c1-9-64(5)94(148-99(163)75(120)24-18-47-128-115(121)122)112(176)144-85(56-71-57-127-62-132-71)106(170)139-80(44-51-185-8)103(167)147-93(63(3)4)110(174)143-83(54-69-32-38-73(154)39-33-69)105(169)146-87(60-152)108(172)138-78(25-14-16-45-118)101(165)137-76(27-19-48-129-116(123)124)96(160)97(161)88(150-184(180,181)182)61-183-133-59-91(157)135-81(26-15-17-46-119)113(177)151-50-21-29-89(151)109(173)140-77(28-20-49-130-117(125)126)100(164)131-58-90(156)136-82(53-68-30-36-72(153)37-31-68)104(168)134-66(7)98(162)142-84(52-67-22-12-11-13-23-67)107(171)149-95(65(6)10-2)111(175)141-79(42-43-92(158)159)102(166)145-86(114(178)179)55-70-34-40-74(155)41-35-70/h11-13,22-23,30-41,57,62-66,75-89,93-95,133,152-155H,9-10,14-21,24-29,42-56,58-61,118-120H2,1-8H3,(H,127,132)(H,131,164)(H,134,168)(H,135,157)(H,136,156)(H,137,165)(H,138,172)(H,139,170)(H,140,173)(H,141,175)(H,142,162)(H,143,174)(H,144,176)(H,145,166)(H,146,169)(H,147,167)(H,148,163)(H,149,171)(H,158,159)(H,178,179)(H4,121,122,128)(H4,123,124,129)(H4,125,126,130)(H3,150,180,181,182)/t64-,65-,66-,75-,76-,77-,78-,79-,80-,81-,82-,83-,84-,85-,86-,87-,88-,89-,93-,94-,95-/m0/s1 DM5S4DL CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)C(=O)[C@H](CONCC(=O)N[C@@H](CCCCN)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CC4=CC=C(C=C4)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC5=CC=CC=C5)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC6=CC=C(C=C6)O)C(=O)O)NP(=O)(O)O)NC(=O)[C@H](CCCNC(=N)N)N DM5S4DL IK LSLBZWAEEUGETG-GGVFYUGVSA-N DM5S4DL IU (4S)-4-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-1-[(2S)-6-amino-2-[[2-[[(2S,5S)-5-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-amino-5-carbamimidamidopentanoyl]amino]-3-methylpentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylsulfanylbutanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]-8-carbamimidamido-3,4-dioxo-2-(phosphonoamino)octoxy]amino]acetyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-carbamimidamidopentanoyl]amino]acetyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]-3-phenylpropanoyl]amino]-3-methylpentanoyl]amino]-5-[[(1S)-1-carboxy-2-(4-hydroxyphenyl)ethyl]amino]-5-oxopentanoic acid DM5S4DL CA CAS 497156-60-2 DM5S4DL DE Systemic lupus erythematosus DM8L3JU ID DM8L3JU DM8L3JU DN Fosclin DM8L3JU HS Phase 3 DM8L3JU SN Fosmidomycin + clindamycin (oral, malaria), Jomaa; Fosmidomycin + clindamycin fixed-dose combination (oral, malaria), Jomaa DM8L3JU CP Jomaa Pharma GmbH DM8L3JU DE Malaria DM3274D ID DM3274D DM3274D DN Fostamatinib disodium DM3274D HS Phase 3 DM3274D SN 1025687-58-4; R788(prodrug of R406); R788 (Fostamatinib) Disodium; UNII-X9417132K8; R 788 sodium; R788(Fostamatinib disodium); R 935788 sodium; R935788 (Fostamatinib disodium, R788); R788 disodium; X9417132K8; R788 disodium hexahydrate; R788 SODIUM; R-788 disodium; R788, Fostamatinib; Tube731; sodium (6-((5-fluoro-2-((3,4,5-trimethoxyphenyl)amino)pyrimidin-4-yl)amino)-2,2-dimethyl-3-oxo-2,3-dihydro-4H-pyrido[3,2-b][1,4]oxazin-4-yl)methyl phosphate; Disodium (6-(5-fluoro-2-(3 DM3274D CP Rigel Pharmaceuticals South San Francisco, CA DM3274D PC 25008120 DM3274D MW 624.4 DM3274D FM C23H24FN6Na2O9P DM3274D IC InChI=1S/C23H26FN6O9P.2Na/c1-23(2)21(31)30(11-38-40(32,33)34)20-14(39-23)6-7-17(28-20)27-19-13(24)10-25-22(29-19)26-12-8-15(35-3)18(37-5)16(9-12)36-4;;/h6-10H,11H2,1-5H3,(H2,32,33,34)(H2,25,26,27,28,29);;/q;2*+1/p-2 DM3274D CS CC1(C(=O)N(C2=C(O1)C=CC(=N2)NC3=NC(=NC=C3F)NC4=CC(=C(C(=C4)OC)OC)OC)COP(=O)([O-])[O-])C.[Na+].[Na+] DM3274D IK HSYBQXDGYCYSGA-UHFFFAOYSA-L DM3274D IU disodium;[6-[[5-fluoro-2-(3,4,5-trimethoxyanilino)pyrimidin-4-yl]amino]-2,2-dimethyl-3-oxopyrido[3,2-b][1,4]oxazin-4-yl]methyl phosphate DM3274D CA CAS 1025687-58-4 DM3274D DE Thrombocytopenia DM823WQ ID DM823WQ DM823WQ DN FP-1201 DM823WQ HS Phase 3 DM823WQ SN Traumagen; Traumakine; MR-11-A-8; CD73 agonist (intravenous, ALI/ARDS/neonatal RDS/ischemia), Faron Pharmaceuticals/MaruishiPharmaceutical; Interferon beta-1a (intravenous, ALI/ARDS/neonatal RDS/ischemia), Faron Pharmaceuticals/Maruishi Pharmaceutical DM823WQ CP Faron Pharmaceuticals Ltd DM823WQ DE Acute lung injury DMGF8MZ ID DMGF8MZ DMGF8MZ DN FPL-62064 DMGF8MZ HS Phase 3 DMGF8MZ SN N-(4-Methoxyphenyl)-1-phenyl-1H-pyrazol-3-amine DMGF8MZ DT Small molecular drug DMGF8MZ PC 128268 DMGF8MZ MW 265.31 DMGF8MZ FM C16H15N3O DMGF8MZ IC InChI=1S/C16H15N3O/c1-20-15-9-7-13(8-10-15)17-16-11-12-19(18-16)14-5-3-2-4-6-14/h2-12H,1H3,(H,17,18) DMGF8MZ CS COC1=CC=C(C=C1)NC2=NN(C=C2)C3=CC=CC=C3 DMGF8MZ IK WKLGNFJHVJIZPK-UHFFFAOYSA-N DMGF8MZ IU N-(4-methoxyphenyl)-1-phenylpyrazol-3-amine DMGF8MZ CA CAS 103141-09-9 DMGF8MZ DE Inflammation DMHOSCQ ID DMHOSCQ DMHOSCQ DN Fruquintinib DMHOSCQ HS Phase 3 DMHOSCQ SN HMPL-013 DMHOSCQ CP Hutchison Medipharma Enterprises Ltd DMHOSCQ PC 44480399 DMHOSCQ MW 393.4 DMHOSCQ FM C21H19N3O5 DMHOSCQ IC InChI=1S/C21H19N3O5/c1-11-19(20(25)22-2)13-6-5-12(7-16(13)28-11)29-21-14-8-17(26-3)18(27-4)9-15(14)23-10-24-21/h5-10H,1-4H3,(H,22,25) DMHOSCQ CS CC1=C(C2=C(O1)C=C(C=C2)OC3=NC=NC4=CC(=C(C=C43)OC)OC)C(=O)NC DMHOSCQ IK BALLNEJQLSTPIO-UHFFFAOYSA-N DMHOSCQ IU 6-(6,7-dimethoxyquinazolin-4-yl)oxy-N,2-dimethyl-1-benzofuran-3-carboxamide DMHOSCQ CA CAS 1194506-26-7 DMHOSCQ DE Solid tumour/cancer DM1YVLM ID DM1YVLM DM1YVLM DN FST-201 DM1YVLM HS Phase 3 DM1YVLM SN Dexamethasone + povidone iodine (otitis), Foresight Biotherapeutics; Otic anti-infective (otitis), Foresight Biotherapeutics DM1YVLM CP Foresight Biotherapeutics Inc DM1YVLM DE Otitis externa DMDKYVE ID DMDKYVE DMDKYVE DN FT-0624878 DMDKYVE HS Phase 3 DMDKYVE SN Cellulosepulver; DEAE-CELLULOSE; DEAE-Sephacel(R); Diethylaminoethyl cellulose; Diethylaminoethyl-Sephacel(R); SBB058705; SC-21746; cellulose; 9004-34-6; AKOS015895024; Cellulose, 2-(diethylamino)ethyl ether; Diethylaminoethyl-Sephacel(R), aqueous ethanol suspension, 40-160 mum (wet), exclusion limit ~1,000,000 Da; Express-Ion(TM) exchanger?? D free base, 60-130 mum; FT-0624878; M158 DMDKYVE PC 16211032 DMDKYVE MW 342.3 DMDKYVE FM C12H22O11 DMDKYVE IC GUBGYTABKSRVRQ-WFVLMXAXSA-N DMDKYVE CS C(C1C(C(C(C(O1)OC2C(OC(C(C2O)O)O)CO)O)O)O)O DMDKYVE IK 1S/C12H22O11/c13-1-3-5(15)6(16)9(19)12(22-3)23-10-4(2-14)21-11(20)8(18)7(10)17/h3-20H,1-2H2/t3?,4?,5?,6?,7?,8?,9?,10-,11?,12+/m1/s1 DMDKYVE IU (6S)-2-(hydroxymethyl)-6-[(3S)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol DMDKYVE CA CAS 9004-34-6 DMDKYVE DE Human immunodeficiency virus infection DMF4I1V ID DMF4I1V DMF4I1V DN FT-0710230 DMF4I1V HS Phase 3 DMF4I1V SN Meconic acid; Mekonsaure; NSC 805; NSC-805; NSC805; Opium acid; Poppy acid; Q421116; SCHEMBL546968; SCHEMBL600257; UNII-V502I79516; V502I79516; ZEGRKMXCOCRTCS-UHFFFAOYSA-N; ZINC1587602; Opio; Papaver somniferum exudate; Papaver somniferum resin; 3-HYDROXY-4-OXO-4H-PYRAN-2,6-DICARBOXYLIC ACID; 3-Hydroxy-4-oxo-1,4-pyran-2,6-dicarboxylic acid; 3-Hydroxy-4-oxopyran-2,6-dicarboxylic acid; 3-hydroxy-4-oxo-pyran-2,6-dicarboxylic acid; 3-hydroxy-4-pyrone-2,6-dicarboxylic acid; 497-59-6; 4H-Pyran-2, 3-hydroxy-4-oxo-; 4H-Pyran-2,6-dicarboxylic acid, 3-hydroxy-4-oxo-; 4H-Pyran-2,6-dicarboxylicacid, 3-hydroxy-4-oxo-; BDBM50147502; C20209; CHEMBL109516; CTK1D7773; DB-083476; DTXSID2060096; EINECS 207-848-2 DMF4I1V PC 10347 DMF4I1V IU 3-hydroxy-4-oxopyran-2,6-dicarboxylic acid DMF4I1V DE Opiate dependence DMK38MV ID DMK38MV DMK38MV DN Fulranumab DMK38MV HS Phase 3 DMK38MV CP Johnson & Johnson Pharmaceutical Research & Development DMK38MV DT Monoclonal antibody DMK38MV DE Cancer related pain; Back pain; Arthralgia DMP83UZ ID DMP83UZ DMP83UZ DN Fumaric acid DMP83UZ HS Phase 3 DMP83UZ SN Fum; Fumarsaeure; Acidum fumaricum; Allomaleic acid; Allomalenic acid; Ammonium fumarate; Boletic acid; Butenedioic acid; Kyselina fumarova; Kyselina fumarova [Czech]; Lichenic acid; Tumaric acid; F0067; OR17920; FC 33 (acid); Fumarate, 10; Fumaric acid (8CI); Fumaric acid (NF); Lichenic acid (VAN); S04-0167; Trans-Butenedioic acid; U-1149; E-2-Butenedioic acid; Trans-2-Butenedioic acid; USAF EK-P-583; Trans-1,2-Ethylenedicarboxylic acid; Trans-but-2-enedioic acid; (2E)-2-butenedioic acid; (2E)-but-2-enedioic acid; (E)-2-Butenedioic acid; 1,2-Ethylenedicarboxylic acid, (E); 2-(E)-Butenedioic acid; 2-Butenedioic acid; 2-Butenedioic acid (2E-(9CI) DMP83UZ CP Biogen Idec DMP83UZ DT Small molecular drug DMP83UZ PC 444972 DMP83UZ MW 116.07 DMP83UZ FM C4H4O4 DMP83UZ IC InChI=1S/C4H4O4/c5-3(6)1-2-4(7)8/h1-2H,(H,5,6)(H,7,8)/b2-1+ DMP83UZ CS C(=C/C(=O)O)\\C(=O)O DMP83UZ IK VZCYOOQTPOCHFL-OWOJBTEDSA-N DMP83UZ IU (E)-but-2-enedioic acid DMP83UZ CA CAS 110-17-8 DMP83UZ CB CHEBI:18012 DMP83UZ DE Multiple sclerosis; Pustular palmoplantar psoriasis DMZARP1 ID DMZARP1 DMZARP1 DN FV-100 DMZARP1 HS Phase 3 DMZARP1 SN CF-1001; CF-1094; CF-1368; CF-1369; CF-1449; CF-1452; CF-1698; CF-1712; CF-1743; CF-1821; CF-1835; CF-1837; CF-1838; CF-1851; CF-2004; CF-2160; CF-2161; CF-2200; BCNAs (antiviral), FermaVir Pharmaceuticals; Bicyclic nucleoside analogs (VZV infection), FermaVir; Bicyclic nucleoside analogs (VZV infection), Inhibitex; Antivirals (nucleoside derivatives), Welsh School of Pharmacy/Rega; BCNAs (antiviral), Rega/Welsh School of Pharmacy; Bicyclic nucleoside analogs (antiviral), Rega/Welsh School of Pharmacy DMZARP1 CP Welsh School of Pharmacy DMZARP1 DT Small molecular drug DMZARP1 PC 71587897 DMZARP1 MW 534 DMZARP1 FM C27H36ClN3O6 DMZARP1 IC InChI=1S/C27H35N3O6.ClH/c1-4-5-6-7-17-8-10-18(11-9-17)21-12-19-14-30(27(33)29-25(19)36-21)23-13-20(31)22(35-23)15-34-26(32)24(28)16(2)3;/h8-12,14,16,20,22-24,31H,4-7,13,15,28H2,1-3H3;1H/t20-,22+,23+,24-;/m0./s1 DMZARP1 CS CCCCCC1=CC=C(C=C1)C2=CC3=CN(C(=O)N=C3O2)[C@H]4C[C@@H]([C@H](O4)COC(=O)[C@H](C(C)C)N)O.Cl DMZARP1 IK CAHTYTZOAVUCIU-ZMQZINMSSA-N DMZARP1 IU [(2R,3S,5R)-3-hydroxy-5-[2-oxo-6-(4-pentylphenyl)furo[2,3-d]pyrimidin-3-yl]oxolan-2-yl]methyl (2S)-2-amino-3-methylbutanoate;hydrochloride DMZARP1 CA CAS 956483-03-7 DMZARP1 DE Varicella zoster virus infection DMMNP2F ID DMMNP2F DMMNP2F DN G17DT DMMNP2F HS Phase 3 DMMNP2F SN Gastrimmune; Insegia DMMNP2F CP Receptor Biologix DMMNP2F DT Antibody DMMNP2F DE Gastric adenocarcinoma DMXJMKF ID DMXJMKF DMXJMKF DN Ganaxolone DMXJMKF HS Phase 3 DMXJMKF SN Ganaxolone [USAN]; CCD 1042; CCD-1042; Ganaxolone (USAN/INN); (3alpha,5alpha)-3-Hydroxy-3-methylpregnan-20-one; 1-[(3R,5S,10S,13S,17S)-3-hydroxy-3,10,13-trimethyl-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]ethanone; 1-[(3R,5S,8R,9S,10S,13S,14S,17S)-3-hydroxy-3,10,13-trimethyl-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]ethanone; 3alpha-Hydroxy-3-methyl-5alpha-pregnan-20-one; 3alpha-Hydroxy-3beta-methyl-5alpha-pregnan-20-one DMXJMKF CP Marinus DMXJMKF DT Small molecular drug DMXJMKF PC 6918305 DMXJMKF MW 332.5 DMXJMKF FM C22H36O2 DMXJMKF IC InChI=1S/C22H36O2/c1-14(23)17-7-8-18-16-6-5-15-13-20(2,24)11-12-21(15,3)19(16)9-10-22(17,18)4/h15-19,24H,5-13H2,1-4H3/t15-,16-,17+,18-,19-,20+,21-,22+/m0/s1 DMXJMKF CS CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC[C@@H]4[C@@]3(CC[C@@](C4)(C)O)C)C DMXJMKF IK PGTVWKLGGCQMBR-FLBATMFCSA-N DMXJMKF IU 1-[(3R,5S,8R,9S,10S,13S,14S,17S)-3-hydroxy-3,10,13-trimethyl-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]ethanone DMXJMKF CA CAS 38398-32-2 DMXJMKF DE Postpartum depression; Complex partial seizure DMWX90U ID DMWX90U DMWX90U DN Gantenerumab DMWX90U HS Phase 3 DMWX90U SN RG1450 DMWX90U CP Roche DMWX90U DT Monoclonal antibody DMWX90U DE Alzheimer disease DMO3ITF ID DMO3ITF DMO3ITF DN GASTRAZOLE DMO3ITF HS Phase 3 DMO3ITF SN JB-95008; 5-[N-[5-[N-(Cycloheptylmethyl)carbamoyl]-1H-benzimidazol-6-ylcarbonyl]-2-fluoro-L-phenylalanylamino]isophthalic acid DMO3ITF DT Small molecular drug DMO3ITF PC 71587829 DMO3ITF MW 687.6 DMO3ITF FM C34H32FN5Na2O7 DMO3ITF IC InChI=1S/C34H34FN5O7.2Na/c35-26-10-6-5-9-20(26)14-29(32(43)39-23-12-21(33(44)45)11-22(13-23)34(46)47)40-31(42)25-16-28-27(37-18-38-28)15-24(25)30(41)36-17-19-7-3-1-2-4-8-19;;/h5-6,9-13,15-16,18-19,29H,1-4,7-8,14,17H2,(H,36,41)(H,37,38)(H,39,43)(H,40,42)(H,44,45)(H,46,47);;/q;2*+1/p-2/t29-;;/m0../s1 DMO3ITF CS C1CCCC(CC1)CNC(=O)C2=CC3=C(C=C2C(=O)N[C@@H](CC4=CC=CC=C4F)C(=O)NC5=CC(=CC(=C5)C(=O)[O-])C(=O)[O-])N=CN3.[Na+].[Na+] DMO3ITF IK VHAXHRARUCKASM-UJXPALLWSA-L DMO3ITF IU disodium;5-[[(2S)-2-[[6-(cycloheptylmethylcarbamoyl)-1H-benzimidazole-5-carbonyl]amino]-3-(2-fluorophenyl)propanoyl]amino]benzene-1,3-dicarboxylate DMO3ITF CA CAS 862583-15-1 DMO3ITF DE Duodenal ulcer DMT4QHD ID DMT4QHD DMT4QHD DN GDC-0032 DMT4QHD HS Phase 3 DMT4QHD SN Taselisib; 1282512-48-4; GDC 0032; UNII-L08J2O299M; 2-(4-(2-(1-isopropyl-3-methyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)-1H-pyrazol-1-yl)-2-methylpropanamide; CHEMBL2387080; GDC0032; L08J2O299M; Taselisib [INN]; 2-Methyl-2-(4-{2-[3-Methyl-1-(Propan-2-Yl)-1h-1,2,4-Triazol-5-Yl]-5,6-Dihydroimidazo[1,2-D][1,4]benzoxazepin-9-Yl}-1h-Pyrazol-1-Yl)propanamide; Taselisib [USAN:INN]; GTPL7794; SCHEMBL1485247; SYN1202; DTXSID00155842; BEUQXVWXFDOSAQ-UHFFFAOYSA-N DMT4QHD CP Genentech DMT4QHD DT Small molecular drug DMT4QHD PC 51001932 DMT4QHD MW 460.5 DMT4QHD FM C24H28N8O2 DMT4QHD IC InChI=1S/C24H28N8O2/c1-14(2)32-22(27-15(3)29-32)19-13-30-8-9-34-20-10-16(6-7-18(20)21(30)28-19)17-11-26-31(12-17)24(4,5)23(25)33/h6-7,10-14H,8-9H2,1-5H3,(H2,25,33) DMT4QHD CS CC1=NN(C(=N1)C2=CN3CCOC4=C(C3=N2)C=CC(=C4)C5=CN(N=C5)C(C)(C)C(=O)N)C(C)C DMT4QHD IK BEUQXVWXFDOSAQ-UHFFFAOYSA-N DMT4QHD IU 2-methyl-2-[4-[2-(5-methyl-2-propan-2-yl-1,2,4-triazol-3-yl)-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepin-9-yl]pyrazol-1-yl]propanamide DMT4QHD CA CAS 1282512-48-4 DMT4QHD DE Solid tumour/cancer; Breast cancer DMWBZJD ID DMWBZJD DMWBZJD DN GDC-0068 DMWBZJD HS Phase 3 DMWBZJD SN RG7440 DMWBZJD CP Genentech DMWBZJD DT Small molecular drug DMWBZJD PC 24788740 DMWBZJD MW 458 DMWBZJD FM C24H32ClN5O2 DMWBZJD IC InChI=1S/C24H32ClN5O2/c1-15(2)26-13-19(17-4-6-18(25)7-5-17)24(32)30-10-8-29(9-11-30)23-21-16(3)12-20(31)22(21)27-14-28-23/h4-7,14-16,19-20,26,31H,8-13H2,1-3H3/t16-,19-,20-/m1/s1 DMWBZJD CS C[C@@H]1C[C@H](C2=C1C(=NC=N2)N3CCN(CC3)C(=O)[C@H](CNC(C)C)C4=CC=C(C=C4)Cl)O DMWBZJD IK GRZXWCHAXNAUHY-NSISKUIASA-N DMWBZJD IU (2S)-2-(4-chlorophenyl)-1-[4-[(5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl]piperazin-1-yl]-3-(propan-2-ylamino)propan-1-one DMWBZJD CA CAS 1001264-89-6 DMWBZJD CB CHEBI:95089 DMWBZJD DE Solid tumour/cancer; Breast cancer; Colorectal cancer; Gastric adenocarcinoma; Prostate cancer DMBEL3Q ID DMBEL3Q DMBEL3Q DN GDC-0853 DMBEL3Q HS Phase 3 DMBEL3Q SN Fenebrutinib DMBEL3Q CP GenentechSouth San Francisco, CA DMBEL3Q PC 86567195 DMBEL3Q MW 664.8 DMBEL3Q FM C37H44N8O4 DMBEL3Q IC InChI=1S/C37H44N8O4/c1-23-18-42(27-21-49-22-27)9-10-43(23)26-5-6-33(39-17-26)40-30-13-25(19-41(4)35(30)47)28-7-8-38-34(29(28)20-46)45-12-11-44-31(36(45)48)14-24-15-37(2,3)16-32(24)44/h5-8,13-14,17,19,23,27,46H,9-12,15-16,18,20-22H2,1-4H3,(H,39,40)/t23-/m0/s1 DMBEL3Q CS C[C@H]1CN(CCN1C2=CN=C(C=C2)NC3=CC(=CN(C3=O)C)C4=C(C(=NC=C4)N5CCN6C7=C(CC(C7)(C)C)C=C6C5=O)CO)C8COC8 DMBEL3Q IK WNEODWDFDXWOLU-QHCPKHFHSA-N DMBEL3Q IU 10-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2S)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl]amino]-6-oxopyridin-3-yl]pyridin-2-yl]-4,4-dimethyl-1,10-diazatricyclo[6.4.0.02,6]dodeca-2(6),7-dien-9-one DMBEL3Q CA CAS 1434048-34-6 DMBEL3Q DE Solid tumour/cancer; Autoimmune disease; Chronic idiopathic urticaria; Multiple sclerosis DMTUV7L ID DMTUV7L DMTUV7L DN GED-0301 DMTUV7L HS Phase 3 DMTUV7L SN SMAD-7 inhibitor (oligonucleotide, Crohn's disease), Giuliani DMTUV7L CP Giuliani SpA DMTUV7L DE Crohn disease; Ulcerative colitis DM4GWL7 ID DM4GWL7 DM4GWL7 DN Gefapixant DM4GWL7 HS Phase 3 DM4GWL7 SN UNII-6K6L7E3F1L; 6K6L7E3F1L; MK-7264; 1015787-98-0; Gefapixant [USAN]; GTPL9540; SCHEMBL1493905; CHEMBL3716057; HLWURFKMDLAKOD-UHFFFAOYSA-N; ZINC116342482; J3.556.891C; 5-(2,4-diaminopyrimidin-5-yl)oxy-2-methoxy-4-propan-2-ylbenzenesulfonamide; 2-Methoxy-4-isopropyl-5-(2,4-diamino-5-pyrimidinyloxy)benzenesulfonamide; 5-(2,4-diamino-pyrimidin-5-yloxy)-4-isopropyl-2-methoxy-benzenesulfonamide; 5-((2,4-Diaminopyrimidin-5-yl)oxy)-2-methoxy-4-(propan-2-yl)benzenesulfonamid DM4GWL7 CP Merck, Roche DM4GWL7 PC 24764487 DM4GWL7 MW 353.4 DM4GWL7 FM C14H19N5O4S DM4GWL7 IC InChI=1S/C14H19N5O4S/c1-7(2)8-4-10(22-3)12(24(17,20)21)5-9(8)23-11-6-18-14(16)19-13(11)15/h4-7H,1-3H3,(H2,17,20,21)(H4,15,16,18,19) DM4GWL7 CS CC(C)C1=CC(=C(C=C1OC2=CN=C(N=C2N)N)S(=O)(=O)N)OC DM4GWL7 IK HLWURFKMDLAKOD-UHFFFAOYSA-N DM4GWL7 IU 5-(2,4-diaminopyrimidin-5-yl)oxy-2-methoxy-4-propan-2-ylbenzenesulfonamide DM4GWL7 CA CAS 1015787-98-0 DM4GWL7 DE Overactive bladder; Cough DMZKGPV ID DMZKGPV DMZKGPV DN Gemigliptin DMZKGPV HS Phase 3 DMZKGPV SN 911637-19-9; UNII-5DHU18M5D6; 5DHU18M5D6; (S)-1-(2-Amino-4-(2,4-bis(trifluoromethyl)-5,6-dihydropyrido[3,4-d]pyrimidin-7(8H)-yl)-4-oxobutyl)-5,5-difluoropiperidin-2-one; (S)-1-(2-amino-4-(2,4-bis(trifluoromethyl)-5,8-dihydropyrido[3,4-d]pyrimidin-7(6H)-yl)-4-oxobutyl)-5,5-difluoropiperidin-2-one; Gemigliptin [INN]; Gemigliptin (prop.INN); SCHEMBL1262740; CHEMBL3707235; CHEBI:134731; ZINC68245464; AKOS025290873; PB11419; DB12412; API0013914; AK170799; 2-Piperidinone, 1-((2S)-2-amino-4-(5,8-dihydro-2,4- DMZKGPV CP LG Life Sciences Ltd DMZKGPV DT Small molecular drug DMZKGPV PC 11953153 DMZKGPV MW 489.4 DMZKGPV FM C18H19F8N5O2 DMZKGPV IC InChI=1S/C18H19F8N5O2/c19-16(20)3-1-12(32)31(8-16)6-9(27)5-13(33)30-4-2-10-11(7-30)28-15(18(24,25)26)29-14(10)17(21,22)23/h9H,1-8,27H2/t9-/m0/s1 DMZKGPV CS C1CC(CN(C1=O)C[C@H](CC(=O)N2CCC3=C(C2)N=C(N=C3C(F)(F)F)C(F)(F)F)N)(F)F DMZKGPV IK ZWPRRQZNBDYKLH-VIFPVBQESA-N DMZKGPV IU 1-[(2S)-2-amino-4-[2,4-bis(trifluoromethyl)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-7-yl]-4-oxobutyl]-5,5-difluoropiperidin-2-one DMZKGPV CA CAS 911637-19-9 DMZKGPV CB CHEBI:134731 DMZKGPV DE Diabetic complication; Type-2 diabetes DM1WMOK ID DM1WMOK DM1WMOK DN Generx DM1WMOK HS Phase 3 DM1WMOK SN Alferminogene tadenovec DM1WMOK CP Angionetics DM1WMOK DT Gene therapy DM1WMOK DE Angina pectoris DM7ZOAE ID DM7ZOAE DM7ZOAE DN GFT-505 DM7ZOAE HS Phase 3 DM7ZOAE SN GFT-1007; PPAR activator (dyslipidemia/type 2 diabetes), Genfit DM7ZOAE CP Genfit SA DM7ZOAE PC 9864881 DM7ZOAE MW 384.5 DM7ZOAE FM C22H24O4S DM7ZOAE IC InChI=1S/C22H24O4S/c1-14-12-16(13-15(2)20(14)26-22(3,4)21(24)25)6-11-19(23)17-7-9-18(27-5)10-8-17/h6-13H,1-5H3,(H,24,25)/b11-6+ DM7ZOAE CS CC1=CC(=CC(=C1OC(C)(C)C(=O)O)C)/C=C/C(=O)C2=CC=C(C=C2)SC DM7ZOAE IK AFLFKFHDSCQHOL-IZZDOVSWSA-N DM7ZOAE IU 2-[2,6-dimethyl-4-[(E)-3-(4-methylsulfanylphenyl)-3-oxoprop-1-enyl]phenoxy]-2-methylpropanoic acid DM7ZOAE CA CAS 923978-27-2 DM7ZOAE DE Type-2 diabetes; Non-alcoholic steatohepatitis DMR6YH3 ID DMR6YH3 DMR6YH3 DN GLP-1 DMR6YH3 HS Phase 3 DMR6YH3 SN Glucagon-like peptide 1; Glucagon-like-peptide-1; Glucagon-like peptide-1; Proglucagon (72-108); Proglucagon (78-107)amide; Glucagon-related peptide I; 89750-14-1; GLP-1 (7-36) amide (human, bovine, guinea pig, mouse,; Oral GLP (diabetes, eligen), Emisphere; GLP-1 (oral tablet, Eligen, diabetes); Glucagon-like peptides (oral, eligen), Emisphere; GLP-1 (oral tablet, Eligen, diabetes), Emisphere; NH2-HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR-CONH2 DMR6YH3 CP Emisphere Technologies Inc DMR6YH3 PC 16135499 DMR6YH3 MW 3297.6 DMR6YH3 FM C149H226N40O45 DMR6YH3 IC InChI=1S/C149H226N40O45/c1-17-76(10)119(146(232)167-80(14)126(212)175-104(60-86-63-159-91-36-25-24-35-89(86)91)136(222)177-100(56-73(4)5)137(223)186-117(74(6)7)144(230)174-93(37-26-28-52-150)128(214)160-65-110(197)168-92(122(154)208)39-30-54-158-149(155)156)188-138(224)102(57-83-31-20-18-21-32-83)178-133(219)98(47-51-115(204)205)173-132(218)94(38-27-29-53-151)170-124(210)78(12)164-123(209)77(11)166-131(217)97(44-48-109(153)196)169-111(198)66-161-130(216)96(46-50-114(202)203)172-134(220)99(55-72(2)3)176-135(221)101(59-85-40-42-88(195)43-41-85)179-141(227)106(68-190)182-143(229)108(70-192)183-145(231)118(75(8)9)187-140(226)105(62-116(206)207)180-142(228)107(69-191)184-148(234)121(82(16)194)189-139(225)103(58-84-33-22-19-23-34-84)181-147(233)120(81(15)193)185-112(199)67-162-129(215)95(45-49-113(200)201)171-125(211)79(13)165-127(213)90(152)61-87-64-157-71-163-87/h18-25,31-36,40-43,63-64,71-82,90,92-108,117-121,159,190-195H,17,26-30,37-39,44-62,65-70,150-152H2,1-16H3,(H2,153,196)(H2,154,208)(H,157,163)(H,160,214)(H,161,216)(H,162,215)(H,164,209)(H,165,213)(H,166,217)(H,167,232)(H,168,197)(H,169,198)(H,170,210)(H,171,211)(H,172,220)(H,173,218)(H,174,230)(H,175,212)(H,176,221)(H,177,222)(H,178,219)(H,179,227)(H,180,228)(H,181,233)(H,182,229)(H,183,231)(H,184,234)(H,185,199)(H,186,223)(H,187,226)(H,188,224)(H,189,225)(H,200,201)(H,202,203)(H,204,205)(H,206,207)(H4,155,156,158)/t76-,77-,78-,79-,80-,81+,82+,90-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,117-,118-,119-,120-,121-/m0/s1 DMR6YH3 CS CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)N)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)N)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](CC6=CN=CN6)N DMR6YH3 IK DTHNMHAUYICORS-KTKZVXAJSA-N DMR6YH3 IU (4S)-5-[[2-[[(2S,3R)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[2-[[(2S)-1-amino-5-carbamimidamido-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-2-oxoethyl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-4-[[(2S)-2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]propanoyl]amino]-5-oxopentanoic acid DMR6YH3 CA CAS 89750-14-1 DMR6YH3 DE Diabetic complication DMEFCTP ID DMEFCTP DMEFCTP DN Glufosfamide DMEFCTP HS Phase 3 DMEFCTP SN Glucosylifostamide mustard; D 19575; D-19575; Glc-IPM; Glucosyl-ifosfamide mustard; Beta-D-Glucopyranose 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate; Beta-D-Glucopyranose, 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate); (2S,3R,4S,5S,6R)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol DMEFCTP CP Threshold Pharmaceuticals DMEFCTP DT Small molecular drug DMEFCTP PC 123628 DMEFCTP MW 383.16 DMEFCTP FM C10H21Cl2N2O7P DMEFCTP IC InChI=1S/C10H21Cl2N2O7P/c11-1-3-13-22(19,14-4-2-12)21-10-9(18)8(17)7(16)6(5-15)20-10/h6-10,15-18H,1-5H2,(H2,13,14,19)/t6-,7-,8+,9-,10+/m1/s1 DMEFCTP CS C(CCl)NP(=O)(NCCCl)O[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O DMEFCTP IK PSVUJBVBCOISSP-SPFKKGSWSA-N DMEFCTP IU (2S,3R,4S,5S,6R)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol DMEFCTP CA CAS 132682-98-5 DMEFCTP DE Ovarian cancer; Pancreatic cancer DMOUT89 ID DMOUT89 DMOUT89 DN Glutamic acid DMOUT89 HS Phase 3 DMOUT89 SN D(-)-Glutamic acid; D-(-)-Glutamic acid; D-2-Aminoglutaric acid; D-2-Aminopentanedioic acid; D-Glutamicacid; D-Glutaminic acid; D-Glutaminsaeure; D-glutamate; D-glutamic acid; Gamma-D-Glutamic Acid; Glutamic acid D-form; Glutamic acid, D-; H-D-Glu-OH; L(+)-Glutamic acid; Lopac-G-2128; Q479989WEA; R-(-)-Glutamic acid; Tocris-0217; WHUUTDBJXJRKMK-GSVOUGTGSA-N; glutamate; (2R)-2-aminopentanedioic acid; (R)-2-aminopentanedioic acid; (r)-glutamic acid; 6893-26-1; CHEBI:15966; CHEMBL76232; D-Glu; DGL; MFCD00063112; UNII-Q479989WEA DMOUT89 PC 23327 DMOUT89 MW 147.13 DMOUT89 FM C5H9NO4 DMOUT89 IC WHUUTDBJXJRKMK-GSVOUGTGSA-N DMOUT89 CS C(CC(=O)O)C(C(=O)O)N DMOUT89 IK 1S/C5H9NO4/c6-3(5(9)10)1-2-4(7)8/h3H,1-2,6H2,(H,7,8)(H,9,10)/t3-/m1/s1 DMOUT89 IU (2R)-2-aminopentanedioic acid DMOUT89 CA CAS 6893-26-1 DMOUT89 CB CHEBI:15966 DMOUT89 DE Follicular lymphoma DM8M2N3 ID DM8M2N3 DM8M2N3 DN Glycyrrhizin DM8M2N3 HS Phase 3 DM8M2N3 SN Glycyrrhizic acid; glycyrrhizin; Glycyrrhizinic acid; 1405-86-3; Glycyron; Glycyrrhetinic acid glycoside; glyzyrrhizin; 18-beta-Glycyrrhizic acid; Glycyrrizin; Liquorice; UNII-6FO62043WK; Rizinsan K2 A2 (free acid); HSDB 496; EINECS 215-785-7; C42H62O16; Glycyrrhizin [JAN]; NSC 167409; NSC 234419; BRN 0077922; CHEMBL441687; NSC 2800; beta-Glycyrrhizin; CHEBI:15939; 6FO62043WK; DSSTox_RID_82047; DSSTox_CID_27006; DSSTox_GSID_47006; Glycyram; alpha-D-Glucopyranosiduronic acid, (3beta,20beta)-20-carboxy-11-oxo-30-norolean-12-en-3-yl 2-O- DM8M2N3 DT Small molecular drug DM8M2N3 PC 14982 DM8M2N3 MW 822.9 DM8M2N3 FM C42H62O16 DM8M2N3 IC InChI=1S/C42H62O16/c1-37(2)21-8-11-42(7)31(20(43)16-18-19-17-39(4,36(53)54)13-12-38(19,3)14-15-41(18,42)6)40(21,5)10-9-22(37)55-35-30(26(47)25(46)29(57-35)33(51)52)58-34-27(48)23(44)24(45)28(56-34)32(49)50/h16,19,21-31,34-35,44-48H,8-15,17H2,1-7H3,(H,49,50)(H,51,52)(H,53,54)/t19-,21-,22-,23-,24-,25-,26-,27+,28-,29-,30+,31+,34-,35-,38+,39-,40-,41+,42+/m0/s1 DM8M2N3 CS C[C@]12CC[C@](C[C@H]1C3=CC(=O)[C@@H]4[C@]5(CC[C@@H](C([C@@H]5CC[C@]4([C@@]3(CC2)C)C)(C)C)O[C@@H]6[C@@H]([C@H]([C@@H]([C@H](O6)C(=O)O)O)O)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)C(=O)O)O)O)O)C)(C)C(=O)O DM8M2N3 IK LPLVUJXQOOQHMX-QWBHMCJMSA-N DM8M2N3 IU (2S,3S,4S,5R,6R)-6-[(2S,3R,4S,5S,6S)-2-[[(3S,4aR,6aR,6bS,8aS,11S,12aR,14aR,14bS)-11-carboxy-4,4,6a,6b,8a,11,14b-heptamethyl-14-oxo-2,3,4a,5,6,7,8,9,10,12,12a,14a-dodecahydro-1H-picen-3-yl]oxy]-6-carboxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid DM8M2N3 CA CAS 1405-86-3 DM8M2N3 CB CHEBI:15939 DM8M2N3 DE Influenza virus infection DMQCZ4N ID DMQCZ4N DMQCZ4N DN Glyminox DMQCZ4N HS Phase 3 DMQCZ4N SN Savvy DMQCZ4N CP Biosyn Inc DMQCZ4N DT Small molecular drug DMQCZ4N PC 56842993 DMQCZ4N MW 599 DMQCZ4N FM C36H74N2O4 DMQCZ4N IC InChI=1S/C20H39NO3.C16H35NO/c1-4-5-6-7-8-9-10-11-12-13-14-15-16-17-19(22)21(2,3)18-20(23)24;1-4-5-6-7-8-9-10-11-12-13-14-15-16-17(2,3)18/h4-18H2,1-3H3;4-16H2,1-3H3 DMQCZ4N CS CCCCCCCCCCCCCCCC(=O)[N+](C)(C)CC(=O)[O-].CCCCCCCCCCCCCC[N+](C)(C)[O-] DMQCZ4N IK KALYGJOYPFFBRF-UHFFFAOYSA-N DMQCZ4N IU N,N-dimethyltetradecan-1-amine oxide;2-[hexadecanoyl(dimethyl)azaniumyl]acetate DMQCZ4N CA CAS 664323-11-9 DMQCZ4N DE Sexually transmitted infection DMOHUR2 ID DMOHUR2 DMOHUR2 DN GLYX-13 DMOHUR2 HS Phase 3 DMOHUR2 SN Rapastinel; 117928-94-6; GLYX-13; GLYX 13; GLYX13; UNII-6A1X56B95E; L-Threoninamide, L-threonyl-L-prolyl-L-prolyl-; 6A1X56B95E; (S)-N-((2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl)-1-((S)-1-((2S,3R)-2-amino-3-hydroxybutanoyl)pyrrolidine-2-carbonyl)pyrrolidine-2-carboxamide; GLYX-13 trifluoroacetate; TPPT-amide trifluoroacetate; TPPT-amide; GLYX-13 peptide; Rapastinel [USAN:INN]; GLYX13;Rapastinel; Rapastinel(GLYX-13); L-Threonyl-L-prolyl-L-prolyl-L-threoninamide trifluoroacetate; Thr-Pro-Pro-Thr-NH2 trifluoroacetate DMOHUR2 CP Naurex DMOHUR2 DT Small molecular drug DMOHUR2 PC 14539800 DMOHUR2 MW 413.5 DMOHUR2 FM C18H31N5O6 DMOHUR2 IC InChI=1S/C18H31N5O6/c1-9(24)13(19)18(29)23-8-4-6-12(23)17(28)22-7-3-5-11(22)16(27)21-14(10(2)25)15(20)26/h9-14,24-25H,3-8,19H2,1-2H3,(H2,20,26)(H,21,27)/t9-,10-,11+,12+,13+,14+/m1/s1 DMOHUR2 CS C[C@H]([C@@H](C(=O)N1CCC[C@H]1C(=O)N2CCC[C@H]2C(=O)N[C@@H]([C@@H](C)O)C(=O)N)N)O DMOHUR2 IK GIBQQARAXHVEGD-BSOLPCOYSA-N DMOHUR2 IU (2S)-1-[(2S)-1-[(2S,3R)-2-amino-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]-N-[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]pyrrolidine-2-carboxamide DMOHUR2 CA CAS 117928-94-6 DMOHUR2 DE Major depressive disorder DMQIE7U ID DMQIE7U DMQIE7U DN GMA102 DMQIE7U HS Phase 3 DMQIE7U CP Gmax Biopharm DMQIE7U DT Antibody DMQIE7U DE Type-2 diabetes; Obesity DM2XSG0 ID DM2XSG0 DM2XSG0 DN GMA105 DM2XSG0 HS Phase 3 DM2XSG0 CP Gmax Biopharm DM2XSG0 DT Antibody DM2XSG0 DE Type-2 diabetes; Obesity DMJ432G ID DMJ432G DMJ432G DN GMI-1070 DMJ432G HS Phase 3 DMJ432G SN GMI-1010; GMI-1011; GMI-1040 series; GMI-1077; Glyosin, GlycoMimetics; Heterobifunctional glycomimetic pan-selectin inhibitors (smallmolecule therapeutic), GlycoMimetics; Selectin inhibitors (asthma/sickle cell anemia/hematological neoplasm), GlycoMimetics DMJ432G CP Glycomimetics; pfizer DMJ432G DT Small molecular drug DMJ432G PC 44232546 DMJ432G MW 1447.4 DMJ432G FM C58H74N6O31S3 DMJ432G IC InChI=1S/C58H74N6O31S3/c1-27-45(69)47(71)48(72)56(90-27)95-49-35(62-53(74)36-23-41(66)64-58(78)63-36)19-31(20-37(49)92-57-51(94-55(77)29-10-6-3-7-11-29)50(46(70)39(24-65)93-57)91-38(54(75)76)16-28-8-4-2-5-9-28)52(73)60-13-12-59-42(67)25-88-14-15-89-26-43(68)61-34-21-32(96(79,80)81)17-30-18-33(97(82,83)84)22-40(44(30)34)98(85,86)87/h3,6-7,10-11,17-18,21-23,27-28,31,35,37-39,45-51,56-57,65,69-72H,2,4-5,8-9,12-16,19-20,24-26H2,1H3,(H,59,67)(H,60,73)(H,61,68)(H,62,74)(H,75,76)(H,79,80,81)(H,82,83,84)(H,85,86,87)(H2,63,64,66,78)/t27-,31+,35-,37+,38-,39+,45+,46-,47+,48-,49+,50-,51+,56-,57+/m0/s1 DMJ432G CS C[C@H]1[C@H]([C@H]([C@@H]([C@@H](O1)O[C@@H]2[C@H](C[C@H](C[C@H]2O[C@H]3[C@@H]([C@H]([C@H]([C@H](O3)CO)O)O[C@@H](CC4CCCCC4)C(=O)O)OC(=O)C5=CC=CC=C5)C(=O)NCCNC(=O)COCCOCC(=O)NC6=C7C(=CC(=C6)S(=O)(=O)O)C=C(C=C7S(=O)(=O)O)S(=O)(=O)O)NC(=O)C8=CC(=O)NC(=O)N8)O)O)O DMJ432G IK VXBNTHRZPJLRSS-PTCSXESPSA-N DMJ432G IU (2S)-2-[(2R,3R,4S,5S,6R)-3-benzoyloxy-2-[(1R,2R,3S,5R)-3-[(2,4-dioxo-1H-pyrimidine-6-carbonyl)amino]-5-[2-[[2-[2-[2-oxo-2-[(3,6,8-trisulfonaphthalen-1-yl)amino]ethoxy]ethoxy]acetyl]amino]ethylcarbamoyl]-2-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxycyclohexyl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3-cyclohexylpropanoic acid DMJ432G CA CAS 927881-99-0 DMJ432G DE Asthma; Vaso-occlusive crisis DMDTGWQ ID DMDTGWQ DMDTGWQ DN GMI-1271 DMDTGWQ HS Phase 3 DMDTGWQ SN Uproleselan DMDTGWQ CP Glycomimetics DMDTGWQ DT ? DMDTGWQ PC 71600085 DMDTGWQ MW 1304.5 DMDTGWQ FM C60H109N3O27 DMDTGWQ IC InChI=1S/C60H109N3O27/c1-5-44-38-45(39-46(55(44)90-60-54(70)53(69)51(67)41(2)86-60)88-59-50(63-42(3)65)56(52(68)48(40-64)89-59)87-47(58(72)73)37-43-9-7-6-8-10-43)57(71)62-13-12-61-49(66)11-14-75-17-18-77-21-22-79-25-26-81-29-30-83-33-34-85-36-35-84-32-31-82-28-27-80-24-23-78-20-19-76-16-15-74-4/h41,43-48,50-56,59-60,64,67-70H,5-40H2,1-4H3,(H,61,66)(H,62,71)(H,63,65)(H,72,73)/t41-,44-,45+,46+,47-,48+,50+,51+,52-,53+,54-,55+,56+,59+,60-/m0/s1 DMDTGWQ CS CC[C@H]1C[C@H](C[C@H]([C@@H]1O[C@H]2[C@H]([C@@H]([C@@H]([C@@H](O2)C)O)O)O)O[C@H]3[C@@H]([C@H]([C@H]([C@H](O3)CO)O)O[C@@H](CC4CCCCC4)C(=O)O)NC(=O)C)C(=O)NCCNC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOC DMDTGWQ IK LYSYOXNOOPBOSC-NGSKMYNLSA-N DMDTGWQ IU (2S)-2-[(2R,3R,4R,5R,6R)-3-acetamido-2-[(1R,2R,3S,5R)-3-ethyl-5-[2-[3-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]propanoylamino]ethylcarbamoyl]-2-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxycyclohexyl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3-cyclohexylpropanoic acid DMDTGWQ CA CAS 1983970-12-2 DMDTGWQ DE Multiple myeloma; Acute myeloid leukaemia DM0LQ94 ID DM0LQ94 DM0LQ94 DN GnRH DM0LQ94 HS Phase 3 DM0LQ94 SN Lutrepatch; GnRH (Lutrepatch, female fertility); GnRH (Lutrepatch, female fertility), Ferring; GnRH (Lutrepatch, female infertility), Ferring/Vyteris; GnRH (Smart Patch, female infertility), Ferring/Vyteris; GnRH (Smart Patch, female infertility), Vyteris/Ferring; Iontophoretic anti-infertility peptide (Smart Patch), Ferring/Vyteris; Iontophoretic anti-infertility peptide (Smart Patch), Vyteris/Ferring; Anti-infertility peptide (iontophoretic/Smart Patch), Ferring/Vyteris; Anti-infertility peptide (iontophoretic/Smart Patch), Vyteris/Ferring; Gonadotropin-releasing hormone (Smart Patch, female infertility), Ferring/Vyteris; Gonadotropin-releasing hormone (Smart Patch, female infertility), Vyteris/Ferring DM0LQ94 CP Ferring Pharmaceuticals Inc DM0LQ94 PC 16132914 DM0LQ94 MW 1212.3 DM0LQ94 FM C60H73N15O13 DM0LQ94 IC InChI=1S/C60H73N15O13/c1-32(2)20-47(60(88)75-19-7-12-49(75)59(87)65-28-50(61)78)73-55(83)44(22-34-25-63-40-10-5-3-8-38(34)40)69-52(80)29-66-53(81)43(21-33-13-15-37(77)16-14-33)70-58(86)48(30-76)74-56(84)45(23-35-26-64-41-11-6-4-9-39(35)41)71-57(85)46(24-36-27-62-31-67-36)72-54(82)42-17-18-51(79)68-42/h3-6,8-11,13-16,25-27,31-32,42-49,63-64,76-77H,7,12,17-24,28-30H2,1-2H3,(H2,61,78)(H,62,67)(H,65,87)(H,66,81)(H,68,79)(H,69,80)(H,70,86)(H,71,85)(H,72,82)(H,73,83)(H,74,84) DM0LQ94 CS CC(C)CC(C(=O)N1CCCC1C(=O)NCC(=O)N)NC(=O)C(CC2=CNC3=CC=CC=C32)NC(=O)CNC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CC5=CNC6=CC=CC=C65)NC(=O)C(CC7=CN=CN7)NC(=O)C8CCC(=O)N8 DM0LQ94 IK NMJREATYWWNIKX-UHFFFAOYSA-N DM0LQ94 IU N-[1-[[1-[[1-[[1-[[2-[[1-[[1-[2-[(2-amino-2-oxoethyl)carbamoyl]pyrrolidin-1-yl]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide DM0LQ94 DE Female infertility DMKWV4B ID DMKWV4B DMKWV4B DN Golnerminogene pradenovac DMKWV4B HS Phase 3 DMKWV4B SN TNFerade (TN) DMKWV4B CP GenVec DMKWV4B DE Esophageal cancer DMZS2R7 ID DMZS2R7 DMZS2R7 DN Granexin gel DMZS2R7 HS Phase 3 DMZS2R7 SN alphaCT1 DMZS2R7 CP FirstString Research DMZS2R7 DE Diabetic foot ulcer; Keloidal surgical scar; Radiation syndrome DM4Y7WV ID DM4Y7WV DM4Y7WV DN GRASPA DM4Y7WV HS Phase 3 DM4Y7WV SN L-asparaginase (erythrocyte-encapsulated, acute lymphoblastic leukemia/solid tumor), ERYtech DM4Y7WV CP Erytech Pharma DM4Y7WV DT Protein DM4Y7WV SQ Elspar Sequence: QMSLQQELRYIEALSAIVETGQKMLEAGESALDVVTEAVRLLEECPLFNAGIGAVFTRDETHELDACVMDGNTLKAGAVAGVSHLRNPVLAARLVMEQSPHVMMIGEGAENFAFARGMERVSPEIFSTSLRYEQLLAARKEGATVLDHSGAPLDEKQKMGTVGAVALDLDGNLAAATSTGGMTNKLPGRVGDSPLVGAGCYANNASVAVSCTGTGEVFIRALAAYDIAALMDYGGLSLAEACERVVMEKLPTLGGSGGLIAIDHEGNVALPFNTEGMYRAWGYAGDTPTTGIYREKGDTVATQ >sp|P00805|ASPG2_ECOLI L-asparaginase 2 OS=Escherichia coli (strain K12) GN=ansB PE=1 SV=2MEFFKKTALAALVMGFSGAALALPNITILATGGTIAGGGDSATKSNYTVGKVGVENLVNAVPQLKDIANVKGEQVVNIGSQDMNDNVWLTLAKKINTDCDKTDGFVITHGTDTMEETAYFLDLTVKCDKPVVMVGAMRPSTSMSADGPFNLYNAVVTAADKASANRGVLVVMNDTVLDGRDVTKTNTTDVATFKSVNYGPLGYIHNGKIDYQRTPARKHTSDTPFDVSKLNELPKVGIVYNYANASDLPAKALVDAGYDGIVSAGVGNGNLYKSVFDTLATAAKTGTAVVRSSRVPTGATTQDAEVDDAKYGFVASGTLNPQKARVLLQLALTQTKDPQQIQQIFNQY DM4Y7WV DE Pancreatic cancer; Acute lymphoblastic leukaemia DM71GPM ID DM71GPM DM71GPM DN Grippol Plus DM71GPM HS Phase 3 DM71GPM SN Egg-based adjuvanted seasonal influenza vaccine, Solvay DM71GPM CP Solvay SA DM71GPM DT Vaccine DM71GPM DE Influenza virus infection DMB34TZ ID DMB34TZ DMB34TZ DN Grippol TC DMB34TZ HS Phase 3 DMB34TZ SN Grippol; Grippol Neo; Cell-based adjuvanted seasonal influenza vaccine, Solvay/Petrovax; Seasonal influenza vaccine (tissue culture), Solvay/Petrovax DMB34TZ CP Solvay SA DMB34TZ DT Vaccine DMB34TZ DE Influenza virus infection DMHN3PG ID DMHN3PG DMHN3PG DN GRT-6005 DMHN3PG HS Phase 3 DMHN3PG SN Cebranopadol; 863513-91-1; GRT6005; UNII-7GDW9S3GN3; GRT 6005; 7GDW9S3GN3; Cebranopadol [USAN:INN]; Cebranopadol (USAN/INN); Cebranopadol(GRT-6005); SCHEMBL566256; SCHEMBL154336; GTPL8866; CHEMBL3545616; CHEMBL2364605; SCHEMBL10035739; CHEMBL3962932; SCHEMBL19336241; SCHEMBL14183935; MolPort-039-063-422; BDBM177926; ZINC3950145; EX-A1095; BCP09612; BDBM50101095; BDBM50101112; AKOS032953927; AKOS025402576; AKOS025290738; DB12830; CS-1323; SB16531; NCGC00378895-01; AK170452; HY-15536; AS-35183; Centrally-acting nociceptin agonist analgesic (oral liquid, pain/diabetic neuropathy), Grunenthal; GRT 6005/06 DMHN3PG CP Forest laboratories DMHN3PG DT Small molecular drug DMHN3PG PC 11848225 DMHN3PG MW 378.5 DMHN3PG FM C24H27FN2O DMHN3PG IC InChI=1S/C24H27FN2O/c1-27(2)23(17-6-4-3-5-7-17)11-13-24(14-12-23)22-19(10-15-28-24)20-16-18(25)8-9-21(20)26-22/h3-9,16,26H,10-15H2,1-2H3 DMHN3PG CS CN(C)C1(CCC2(CC1)C3=C(CCO2)C4=C(N3)C=CC(=C4)F)C5=CC=CC=C5 DMHN3PG IK CSMVOZKEWSOFER-UHFFFAOYSA-N DMHN3PG IU 6-fluoro-N,N-dimethyl-1'-phenylspiro[4,9-dihydro-3H-pyrano[3,4-b]indole-1,4'-cyclohexane]-1'-amine DMHN3PG CA CAS 863513-91-1 DMHN3PG DE Diabetic neuropathy DMNZO7M ID DMNZO7M DMNZO7M DN GS-441524 DMNZO7M HS Phase 3 DMNZO7M SN EVO984; EVO-984; EVO 984; GS 441524; GS441524 DMNZO7M TC Antiviral Agents DMNZO7M DT Small molecular drug DMNZO7M PC 44468216 DMNZO7M MW 291.26 DMNZO7M FM C12H13N5O4 DMNZO7M IC InChI=1S/C12H13N5O4/c13-4-12(10(20)9(19)7(3-18)21-12)8-2-1-6-11(14)15-5-16-17(6)8/h1-2,5,7,9-10,18-20H,3H2,(H2,14,15,16)/t7-,9-,10-,12+/m1/s1 DMNZO7M CS C1=C2C(=NC=NN2C(=C1)[C@]3([C@@H]([C@@H]([C@H](O3)CO)O)O)C#N)N DMNZO7M IK BRDWIEOJOWJCLU-LTGWCKQJSA-N DMNZO7M IU (2R,3R,4S,5R)-2-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-3,4-dihydroxy-5-(hydroxymethyl)oxolane-2-carbonitrile DMNZO7M CA CAS 1191237-69-0 DMNZO7M CB CHEBI:147281 DMNZO7M DE Coronavirus Disease 2019 (COVID-19) DMP8MDW ID DMP8MDW DMP8MDW DN GS-5745 DMP8MDW HS Phase 3 DMP8MDW CP GILEAD DMP8MDW PC 56776542 DMP8MDW MW 250.02 DMP8MDW FM C7H5BrFNO3 DMP8MDW IC InChI=1S/C7H5BrFNO3/c1-13-5-3-2-4(8)6(9)7(5)10(11)12/h2-3H,1H3 DMP8MDW CS COC1=C(C(=C(C=C1)Br)F)[N+](=O)[O-] DMP8MDW IK LJJAOMRFFXQENV-UHFFFAOYSA-N DMP8MDW IU 1-bromo-2-fluoro-4-methoxy-3-nitrobenzene DMP8MDW CA CAS 1352317-80-6 DMP8MDW DE Ulcerative colitis; Solid tumour/cancer; Crohn disease; Gastric adenocarcinoma; Rheumatoid arthritis DMGJQVI ID DMGJQVI DMGJQVI DN GS-6615 DMGJQVI HS Phase 3 DMGJQVI SN Eleclazine; 1443211-72-0; GS-6615; UNII-PUY08529FK; PUY08529FK; 4-(pyrimidin-2-ylmethyl)-7-(4-(trifluoromethoxy)phenyl)-3,4-dihydrobenzo[f][1,4]oxazepin-5(2H)-one; Eleclazine [INN]; Eleclazine [USAN:INN]; Eleclazine (USAN/INN); Eleclazine(GS-6615); GTPL8413; CHEMBL3707392; SCHEMBL14480722; MolPort-044-723-855; YNUAEEJQYHYLMS-UHFFFAOYSA-N; GS6615; ZINC206191652; AKOS030627706; DB12394; SB19622; KS-000006B4; 1,4-Benzoxazepin-5(2H)-one, 3,4-dihydro-4-(2-pyrimidinylmethyl)-7-(4-(trifluoromethoxy)phenyl)-; AS-35245; J3.563.176C DMGJQVI CP GILEAD DMGJQVI DT Small molecular drug DMGJQVI PC 71183216 DMGJQVI MW 415.4 DMGJQVI FM C21H16F3N3O3 DMGJQVI IC InChI=1S/C21H16F3N3O3/c22-21(23,24)30-16-5-2-14(3-6-16)15-4-7-18-17(12-15)20(28)27(10-11-29-18)13-19-25-8-1-9-26-19/h1-9,12H,10-11,13H2 DMGJQVI CS C1COC2=C(C=C(C=C2)C3=CC=C(C=C3)OC(F)(F)F)C(=O)N1CC4=NC=CC=N4 DMGJQVI IK YNUAEEJQYHYLMS-UHFFFAOYSA-N DMGJQVI IU 4-(pyrimidin-2-ylmethyl)-7-[4-(trifluoromethoxy)phenyl]-2,3-dihydro-1,4-benzoxazepin-5-one DMGJQVI CA CAS 1443211-72-0 DMGJQVI DE Ischemic heart disease; Long QT syndrome DM936V7 ID DM936V7 DM936V7 DN GS-9674 DM936V7 HS Phase 3 DM936V7 SN Cilofexor; 1418274-28-8; UNII-YUN2306954; PX104; 1418274-28-8 (free acid); YUN2306954; 2-(3-(2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)-3-hydroxyazetidin-1-yl)isonicotinic acid; GS 9674; 2-[3-[2-chloro-4-[[5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methoxy]phenyl]-3-hydroxyazetidin-1-yl]pyridine-4-carboxylic acid; Cilofexor [INN]; Cilofexor (GS(c)\\9674); CHEMBL4297613; SCHEMBL14641986; GTPL10644; BCP29283; BDBM50511109; GS9674; s6547; DB15168; example 13/9 [US10485795B2]; HY-109083; CS-0039260; 2-(3-(2-Chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)-4-isoxazolyl)methoxy)phenyl)-3-hydroxy-1-azetidinyl)-4-pyridinecarboxylic acid; 4-Pyridinecarboxylic acid, 2-(3-(2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)-4-isoxazolyl)methoxy)phenyl)-3-hydroxy-1-azetidinyl)- DM936V7 DT Small molecular drug DM936V7 PC 71228883 DM936V7 MW 586.8 DM936V7 FM C28H22Cl3N3O5 DM936V7 IC InChI=1S/C28H22Cl3N3O5/c29-20-2-1-3-21(30)24(20)25-18(26(39-33-25)15-4-5-15)12-38-17-6-7-19(22(31)11-17)28(37)13-34(14-28)23-10-16(27(35)36)8-9-32-23/h1-3,6-11,15,37H,4-5,12-14H2,(H,35,36) DM936V7 CS C1CC1C2=C(C(=NO2)C3=C(C=CC=C3Cl)Cl)COC4=CC(=C(C=C4)C5(CN(C5)C6=NC=CC(=C6)C(=O)O)O)Cl DM936V7 IK KZSKGLFYQAYZCO-UHFFFAOYSA-N DM936V7 IU 2-[3-[2-chloro-4-[[5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methoxy]phenyl]-3-hydroxyazetidin-1-yl]pyridine-4-carboxylic acid DM936V7 CA CAS 1418274-28-8 DM936V7 DE Non-alcoholic steatohepatitis; Primary sclerosing cholangitis DMT8J0I ID DMT8J0I DMT8J0I DN GSK1265744 DMT8J0I HS Phase 3 DMT8J0I SN Cabotegravir; 1051375-10-0; GSK1265744; UNII-HMH0132Z1Q; GSK744; GSK1265744A; GSK-1265744; HMH0132Z1Q; Cabotegravir (GSK744, GSK1265744); CAB; Oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide, N-[(2,4-difluorophenyl)methyl]-2,3,5,7,11,11a-hexahydro-6-hydroxy-3-methyl-5,7-dioxo-, (3S,11aR)-;Oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide, N-[(2,4-difluorophenyl)methyl]-2,3,5,7,11,11a-hexahydro-6-hydroxy-3-methyl-5,7-dioxo-, (3S,11aR)-; Cabotegravir [USAN:INN]; GSK744 LAP; GSK744 LA; S/GSK1265744; GSK 744; 744 LA; GSK 1265 DMT8J0I CP GSK DMT8J0I DT Small molecular drug DMT8J0I PC 54713659 DMT8J0I MW 405.4 DMT8J0I FM C19H17F2N3O5 DMT8J0I IC InChI=1S/C19H17F2N3O5/c1-9-8-29-14-7-23-6-12(16(25)17(26)15(23)19(28)24(9)14)18(27)22-5-10-2-3-11(20)4-13(10)21/h2-4,6,9,14,26H,5,7-8H2,1H3,(H,22,27)/t9-,14+/m0/s1 DMT8J0I CS C[C@H]1CO[C@H]2N1C(=O)C3=C(C(=O)C(=CN3C2)C(=O)NCC4=C(C=C(C=C4)F)F)O DMT8J0I IK WCWSTNLSLKSJPK-LKFCYVNXSA-N DMT8J0I IU (3R,6S)-N-[(2,4-difluorophenyl)methyl]-10-hydroxy-6-methyl-8,11-dioxo-4-oxa-1,7-diazatricyclo[7.4.0.03,7]trideca-9,12-diene-12-carboxamide DMT8J0I CA CAS 1051375-10-0 DMT8J0I DE Human immunodeficiency virus infection DMRNGD2 ID DMRNGD2 DMRNGD2 DN GSK1278863 DMRNGD2 HS Phase 3 DMRNGD2 SN Daprodustat; 960539-70-2; GSK1278863; UNII-JVR38ZM64B; GSK-1278863; JVR38ZM64B; N-((1,3-Dicyclohexylhexahydro-2,4,6-trioxopyrimidin-5-yl)carbonyl)glycine; Daprodustat [USAN:INN]; GSK 1278863; Daprodustat(GSK1278863); Daprodustat; GSK1278863; Daprodustat (JAN/USAN/INN); GTPL8455; Daprodustat (GSK1278863); CHEMBL3544988; KS-00000M8Z; EX-A1121; BCP16766; s8171; AKOS027439964; Glycine, N-((1,3-dicyclohexylhexahydro-2,4,6-trioxo-5-pyrimidinyl)carbonyl)-; ZINC231226004; CS-5453; SB19761; DB11682; HY-17608; J3.560.573H; D10874 DMRNGD2 CP GSK DMRNGD2 DT Small molecular drug DMRNGD2 PC 91617630 DMRNGD2 MW 393.4 DMRNGD2 FM C19H27N3O6 DMRNGD2 IC InChI=1S/C19H27N3O6/c23-14(24)11-20-16(25)15-17(26)21(12-7-3-1-4-8-12)19(28)22(18(15)27)13-9-5-2-6-10-13/h12-13,15H,1-11H2,(H,20,25)(H,23,24) DMRNGD2 CS C1CCC(CC1)N2C(=O)C(C(=O)N(C2=O)C3CCCCC3)C(=O)NCC(=O)O DMRNGD2 IK RUEYEZADQJCKGV-UHFFFAOYSA-N DMRNGD2 IU 2-[(1,3-dicyclohexyl-2,4,6-trioxo-1,3-diazinane-5-carbonyl)amino]acetic acid DMRNGD2 CA CAS 960539-70-2 DMRNGD2 DE Autism spectrum disorder; Diabetic foot ulcer; Anaemia DMSMFN2 ID DMSMFN2 DMSMFN2 DN GSK2140944 DMSMFN2 HS Phase 3 DMSMFN2 SN Gepotidacin DMSMFN2 CP Glaxosmithkline DMSMFN2 PC 25101874 DMSMFN2 MW 448.5 DMSMFN2 FM C24H28N6O3 DMSMFN2 IC InChI=1S/C24H28N6O3/c31-22-4-3-20-24-29(22)15-19(30(24)23(32)13-27-20)14-28-7-5-17(6-8-28)25-11-18-10-16-2-1-9-33-21(16)12-26-18/h3-4,10,12-13,17,19,25H,1-2,5-9,11,14-15H2/t19-/m1/s1 DMSMFN2 CS C1CC2=CC(=NC=C2OC1)CNC3CCN(CC3)C[C@@H]4CN5C(=O)C=CC6=C5N4C(=O)C=N6 DMSMFN2 IK PZFAZQUREQIODZ-LJQANCHMSA-N DMSMFN2 IU (3R)-3-[[4-(3,4-dihydro-2H-pyrano[2,3-c]pyridin-6-ylmethylamino)piperidin-1-yl]methyl]-1,4,7-triazatricyclo[6.3.1.04,12]dodeca-6,8(12),9-triene-5,11-dione DMSMFN2 CA CAS 1075236-89-3 DMSMFN2 DE Acute bacterial skin infection; Urinary tract infection; Neisseria gonorrhoeae infection DMWL2XD ID DMWL2XD DMWL2XD DN GSK2402968 DMWL2XD HS Phase 3 DMWL2XD CP GlaxoSmithKline; Prosensa DMWL2XD DE Duchenne dystrophy DMUVZAO ID DMUVZAO DMUVZAO DN GSK642444 DMUVZAO HS Phase 3 DMUVZAO SN threo isoleucyl thiazolidide, 1; BDBM17299 DMUVZAO CP Theravance; GlaxoSmithKline DMUVZAO DT Small molecular drug DMUVZAO PC 23647689 DMUVZAO MW 203.33 DMUVZAO FM C9H19N2OS+ DMUVZAO IC InChI=1S/C9H18N2OS/c1-3-7(2)8(10)9(12)11-4-5-13-6-11/h7-8H,3-6,10H2,1-2H3/p+1/t7-,8-/m0/s1 DMUVZAO CS CC[C@H](C)[C@@H](C(=O)N1CCSC1)[NH3+] DMUVZAO IK WCRLBFHWFPELKW-YUMQZZPRSA-O DMUVZAO IU [(2S,3S)-3-methyl-1-oxo-1-(1,3-thiazolidin-3-yl)pentan-2-yl]azanium DMUVZAO DE Chronic obstructive pulmonary disease DMPS7U2 ID DMPS7U2 DMPS7U2 DN GTPL-9088 DMPS7U2 HS Phase 3 DMPS7U2 SN Clobetasona; Clobetasona [INN-Spanish]; Clobetasone; Clobetasone (INN); Clobetasone [INN:BAN]; Clobetasonum; Clobetasonum [INN-Latin]; LT69WY1J6D; SCHEMBL3581; XXIFVOHLGBURIG-OZCCCYNHSA-N; ZINC5752185; (8S,9R,10S,13S,14S,16S,17R)-17-(2-chloroacetyl)-9-fluoro-17-hydroxy-10,13,16-trimethyl-7,8,12,14,15,16-hexahydro-6H-cyclopenta[a]phenanthrene-3,11-dione; 21-Chlor-9-fluor-17-hydroxy-16beta-methyl-1,4-pregnadien-3,11,20-trion; 54063-32-0; AC1L2G2H; API0002061; D07717; DB13158; EINECS 258-953-5; GTPL9088; UNII-LT69WY1J6D DMPS7U2 PC 71387 DMPS7U2 MW 408.9 DMPS7U2 FM C22H26ClFO4 DMPS7U2 IC XXIFVOHLGBURIG-OZCCCYNHSA-N DMPS7U2 CS CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(=O)CC2(C1(C(=O)CCl)O)C)F)C DMPS7U2 IK 1S/C22H26ClFO4/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,24)17(26)10-20(16,3)22(12,28)18(27)11-23/h6-7,9,12,15-16,28H,4-5,8,10-11H2,1-3H3/t12-,15-,16-,19-,20-,21-,22-/m0/s1 DMPS7U2 IU (8S,9R,10S,13S,14S,16S,17R)-17-(2-chloroacetyl)-9-fluoro-17-hydroxy-10,13,16-trimethyl-7,8,12,14,15,16-hexahydro-6H-cyclopenta[a]phenanthrene-3,11-dione DMPS7U2 CA CAS 54063-32-0 DMPS7U2 DE Atopic dermatitis DM9Y3EG ID DM9Y3EG DM9Y3EG DN Guadecitabine DM9Y3EG HS Phase 3 DM9Y3EG SN UNII-2KT4YN1DP7; 929901-49-5; 2KT4YN1DP7; SGI-110 free acid; Guadecitabine [USAN:INN]; GuadecitabineSGI-110; Guadecitabine (USAN/INN); CHEMBL3544916; Guanosine, 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxy-; ZINC43203165; AKOS027321496; AKOS030238181; DB11918; CS-3089; HY-13542; D10877; 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxyguanosine DM9Y3EG CP Astex Pharmaceuticals Pleasanton, CA DM9Y3EG PC 135564655 DM9Y3EG MW 557.4 DM9Y3EG FM C18H24N9O10P DM9Y3EG IC InChI=1S/C18H24N9O10P/c19-16-22-6-27(18(31)25-16)12-2-8(9(3-28)35-12)37-38(32,33)34-4-10-7(29)1-11(36-10)26-5-21-13-14(26)23-17(20)24-15(13)30/h5-12,28-29H,1-4H2,(H,32,33)(H2,19,25,31)(H3,20,23,24,30)/t7-,8-,9+,10+,11+,12+/m0/s1 DM9Y3EG CS C1[C@@H]([C@H](O[C@H]1N2C=NC3=C2N=C(NC3=O)N)COP(=O)(O)O[C@H]4C[C@@H](O[C@@H]4CO)N5C=NC(=NC5=O)N)O DM9Y3EG IK GUWXKKAWLCENJA-WGWHJZDNSA-N DM9Y3EG IU [(2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methyl [(2R,3S,5R)-5-(4-amino-2-oxo-1,3,5-triazin-1-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate DM9Y3EG CA CAS 929901-49-5 DM9Y3EG DE Myelodysplastic syndrome DMN4E7T ID DMN4E7T DMN4E7T DN Guaiacol DMN4E7T HS Phase 3 DMN4E7T SN guaiacol; 2-Methoxyphenol; 90-05-1; o-Methoxyphenol; 2-Hydroxyanisole; Phenol, 2-methoxy-; Pyrocatechol monomethyl ether; Methylcatechol; Guaiastil; Guaicol; 1-Hydroxy-2-methoxybenzene; Pyroguaiac acid; o-Guaiacol; o-Hydroxyanisole; Guaicolina; Guajol; Guasol; Anastil; Phenol, o-methoxy-; Catechol monomethyl ether; O-Methyl catechol; CREOSOTE, WOOD; Methoxyphenol; Guajakol; Wood creosote; 2-Methoxy-Phenol; Creosote, beechwood; Guajacol; Methyl Catechol; Phenol, methoxy-; Guajakol [Czech]; Guaiacol (natural); 8021-39-4; Methylcatachol DMN4E7T DT Small molecular drug DMN4E7T PC 460 DMN4E7T MW 124.14 DMN4E7T FM C7H8O2 DMN4E7T IC InChI=1S/C7H8O2/c1-9-7-5-3-2-4-6(7)8/h2-5,8H,1H3 DMN4E7T CS COC1=CC=CC=C1O DMN4E7T IK LHGVFZTZFXWLCP-UHFFFAOYSA-N DMN4E7T IU 2-methoxyphenol DMN4E7T CA CAS 8021-39-4 DMN4E7T CB CHEBI:28591 DMIWLJE ID DMIWLJE DMIWLJE DN Guanine DMIWLJE HS Phase 3 DMIWLJE DT Small molecular drug DMIWLJE PC 135398634 DMIWLJE MW 151.13 DMIWLJE FM C5H5N5O DMIWLJE IC InChI=1S/C5H5N5O/c6-5-9-3-2(4(11)10-5)7-1-8-3/h1H,(H4,6,7,8,9,10,11) DMIWLJE CS C1=NC2=C(N1)C(=O)NC(=N2)N DMIWLJE IK UYTPUPDQBNUYGX-UHFFFAOYSA-N DMIWLJE IU 2-amino-1,7-dihydropurin-6-one DMIWLJE CA CAS 73-40-5 DMIWLJE CB CHEBI:16235 DMHULRK ID DMHULRK DMHULRK DN GV1001 DMHULRK HS Phase 3 DMHULRK SN GV1001 DMHULRK CP KAEL-GemVax DMHULRK DT Vaccine DMHULRK DE Pancreatic cancer DMAXTFO ID DMAXTFO DMAXTFO DN H1N1 influenza vaccine DMAXTFO HS Phase 3 DMAXTFO SN Humenza; H1N1 influenza vaccine (AF-03-adjuvanted, EU market); H1N1 influenza vaccine (AF-03-adjuvanted, EU market), Sanofi Pasteur DMAXTFO CP Sanofi Pasteur DMAXTFO DT Vaccine DMAXTFO DE Influenza virus infection DM9CMI3 ID DM9CMI3 DM9CMI3 DN H5N1 influenza vaccine DM9CMI3 HS Phase 3 DM9CMI3 SN KIB-PIA; H5N1 influenza vaccine (inactivated whole virion, egg-cultured, alum-adjuvanted); Avian influenza vaccine (inactivated whole virion, egg-cultured, alum-adjuvanted), Kitasato; H5N1 influenza vaccine (inactivated whole virion, egg-cultured, alum-adjuvanted), Kitasato DM9CMI3 CP Kitasato Institute DM9CMI3 DT Vaccine DM9CMI3 DE Influenza virus infection DMQ38JZ ID DMQ38JZ DMQ38JZ DN HB-AS02V DMQ38JZ HS Phase 3 DMQ38JZ SN HBV vaccine (adjuvanted), Henogen; Hepatitis B virus vaccine (adjuvanted), Henogen DMQ38JZ CP Henogen SA DMQ38JZ DT Vaccine DMQ38JZ DE Hepatitis B virus infection DMB06MU ID DMB06MU DMB06MU DN HC-1119 DMB06MU HS Phase 3 DMB06MU SN Enzalutamide D3; UNII-3OKI556HC2; 3OKI556HC2; HC 1119; 1443331-82-5; CHEMBL4594421; SCHEMBL18789402; HY-70002S; CS-0019855; 4-(3-(4-Cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl)-2-fluoro-N-(methyl-d3)benzamide; Benzamide, 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl)-2-fluoro-N-(methyl-d3)- DMB06MU CP Hinova Pharmaceuticals DMB06MU DT Small molecular drug DMB06MU PC 71580408 DMB06MU MW 467.5 DMB06MU FM C21H16F4N4O2S DMB06MU IC InChI=1S/C21H16F4N4O2S/c1-20(2)18(31)28(12-5-4-11(10-26)15(8-12)21(23,24)25)19(32)29(20)13-6-7-14(16(22)9-13)17(30)27-3/h4-9H,1-3H3,(H,27,30)/i3D3 DMB06MU CS [2H]C([2H])([2H])NC(=O)C1=C(C=C(C=C1)N2C(=S)N(C(=O)C2(C)C)C3=CC(=C(C=C3)C#N)C(F)(F)F)F DMB06MU IK WXCXUHSOUPDCQV-HPRDVNIFSA-N DMB06MU IU 4-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-sulfanylideneimidazolidin-1-yl]-2-fluoro-N-(trideuteriomethyl)benzamide DMB06MU CA CAS 1443331-82-5 DMB06MU DE Prostate cancer DMB9U5E ID DMB9U5E DMB9U5E DN HE3286 DMB9U5E HS Phase 3 DMB9U5E SN Triolex; HE3286; UNII-PH8858757I; PH8858757I; 1004264-32-7; HE 3286; HE-3286; 1001100-69-1; SCHEMBL512549; 3beta,7beta,17beta-Trihydroxy-17alpha-ethynylandrost-5-ene; DB05212; Pregn-5-en-20-yne-3,7,17-triol, (3beta,7beta,17alpha)- DMB9U5E CP Hollis-Eden Pharmaceuticals DMB9U5E DT Small molecular drug DMB9U5E PC 16739648 DMB9U5E MW 330.5 DMB9U5E FM C21H30O3 DMB9U5E IC InChI=1S/C21H30O3/c1-4-21(24)10-7-16-18-15(6-9-20(16,21)3)19(2)8-5-14(22)11-13(19)12-17(18)23/h1,12,14-18,22-24H,5-11H2,2-3H3/t14-,15-,16-,17-,18+,19-,20-,21-/m0/s1 DMB9U5E CS C[C@]12CC[C@@H](CC1=C[C@@H]([C@@H]3[C@@H]2CC[C@]4([C@H]3CC[C@]4(C#C)O)C)O)O DMB9U5E IK JJKOQZHWYLMASZ-FJWDNACWSA-N DMB9U5E IU (3S,7R,8R,9S,10R,13S,14S,17R)-17-ethynyl-10,13-dimethyl-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthrene-3,7,17-triol DMB9U5E CA CAS 1001100-69-1 DMB9U5E DE Type-2 diabetes DMQTLVB ID DMQTLVB DMQTLVB DN Hebergel DMQTLVB HS Phase 3 DMQTLVB SN Interferon alpha 2b gel (viral infection), CIGB DMQTLVB CP Center for Genetic Engineering and Biotechnology DMQTLVB DE Virus infection DMUE843 ID DMUE843 DMUE843 DN Hematide DMUE843 HS Phase 3 DMUE843 CP Affymax Inc; Takeda Pharmaceutical Co Ltd. DMUE843 DE Anemia DMGFULM ID DMGFULM DMGFULM DN Heparin low molecular weight DMGFULM HS Phase 3 DMGFULM SN Heparin low molecular weight, Watson Laboratories; Heparin transmucosal, TheraTech DMGFULM CP Watson Laboratories Inc DMGFULM DE Thrombosis DMXAZ47 ID DMXAZ47 DMXAZ47 DN HGH-CTP DMXAZ47 HS Phase 3 DMXAZ47 SN MOD-401; MOD-4023; Human growth hormone (injectable, CTP, growth disorder), Modigene; Long-acting hGH (injectable, CTP, growth disorder), Modigene DMXAZ47 CP Prolor biotech; chiasma DMXAZ47 DE Growth hormone deficiency DM6QOVN ID DM6QOVN DM6QOVN DN HKI-272 DM6QOVN HS Phase 3 DM6QOVN SN Neratinib (ERBB2 inhibitor) DM6QOVN CP Wyeth Research DM6QOVN TC Anticancer Agents DM6QOVN DT Small molecular drug DM6QOVN PC 9915743 DM6QOVN MW 557 DM6QOVN FM C30H29ClN6O3 DM6QOVN IC InChI=1S/C30H29ClN6O3/c1-4-39-28-16-25-23(15-26(28)36-29(38)9-7-13-37(2)3)30(20(17-32)18-34-25)35-21-10-11-27(24(31)14-21)40-19-22-8-5-6-12-33-22/h5-12,14-16,18H,4,13,19H2,1-3H3,(H,34,35)(H,36,38)/b9-7+ DM6QOVN CS CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)/C=C/CN(C)C DM6QOVN IK JWNPDZNEKVCWMY-VQHVLOKHSA-N DM6QOVN IU (E)-N-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]-3-cyano-7-ethoxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide DM6QOVN CA CAS 698387-09-6 DM6QOVN CB CHEBI:61397 DM6QOVN DE Breast cancer DM29XGY ID DM29XGY DM29XGY DN HMPL-004 DM29XGY HS Phase 3 DM29XGY SN Nuclear factor kappa B inhibitor (oral, IBD/ulcerative colitis/Crohns disease), Hutchson Medipharma; TNF alpha ligand inhibitor (oral, IBD/ulcerative colitis/Crohns disease), Hutchson Medipharma; IL-1 beta modulator (oral, IBD/ulcerative colitis/Crohns disease), Hutchson Medipharma; IL-6 antagonist (oral, IBD/ulcerative colitis/Crohns disease), Hutchson Medipharma DM29XGY CP Hutchison Medipharma Enterprises Ltd DM29XGY DE Inflammatory bowel disease DMAVIPZ ID DMAVIPZ DMAVIPZ DN HSR-803 DMAVIPZ HS Phase 3 DMAVIPZ SN Ganaton; ITOPRIDE HCl; Itopride (hydrochloride); Q-201260; itopride hydrochloride; 122892-31-3; 2H9NV66W0I; C20H27ClN2O4; DSSTox_CID_26693; DSSTox_GSID_46693; DSSTox_RID_81827; HSR-803; HSR803; Hsr 803; Itax; MFCD00881710; N-((4-(2-(Dimethylamino)ethoxy)phenyl)methyl)-3,4-dimethoxybenzamide monohydrochloride; N-(4-(2-(Dimethylamino)ethoxy)benzyl)-3,4-dimethoxidebenzamide hydrochloride; N-(4-(2-(dimethylamino)ethoxy)benzyl)-3,4-dimethoxybenzmide; UNII-2H9NV66W0I; n-[4-(2-dimethylaminoethoxy)benzyl]-3,4-dimethoxybenzamide hcl DMAVIPZ PC 129791 DMAVIPZ MW 394.9 DMAVIPZ FM C20H27ClN2O4 DMAVIPZ IC ZTOUXLLIPWWHSR-UHFFFAOYSA-N DMAVIPZ CS CN(C)CCOC1=CC=C(C=C1)CNC(=O)C2=CC(=C(C=C2)OC)OC.Cl DMAVIPZ IK 1S/C20H26N2O4.ClH/c1-22(2)11-12-26-17-8-5-15(6-9-17)14-21-20(23)16-7-10-18(24-3)19(13-16)25-4;/h5-10,13H,11-12,14H2,1-4H3,(H,21,23);1H DMAVIPZ IU N-[[4-[2-(dimethylamino)ethoxy]phenyl]methyl]-3,4-dimethoxybenzamide;hydrochloride DMAVIPZ CA CAS 122892-31-3 DMAVIPZ DE Functional nausea/vomiting DMBER0Q ID DMBER0Q DMBER0Q DN Hu5F9-G4 DMBER0Q HS Phase 3 DMBER0Q CP Forty Seven Menlo Park, CA DMBER0Q DE Solid tumour/cancer; Acute myeloid leukaemia; Colorectal cancer; B-cell non-hodgkin lymphoma; Myelodysplastic syndrome DMXZAL2 ID DMXZAL2 DMXZAL2 DN Hydroxychloroquine DMXZAL2 HS Phase 3 DMXZAL2 SN Hidroxicloroquina; Hidroxicloroquina [INN-Spanish]; Hydroxychlorochin; Gen-Hydroxychloroquine 200mg Tablets; HCQ; Hydroxychloroguine; Hydroxychloroquine (INN);Hydroxychloroquine [INN:BAN]; Hydroxychloroquine Sulfate (1:1) Salt; Hydroxychloroquinum; Hydroxychloroquinum [INN-Latin]; Idrossiclorochina; Idrossiclorochina [DCIT]; Oxichlorochinum; Oxichloroquine; Oxychlorochin; Oxychloroquine; Plaquenil (TN); Polirreumin; Polirreumin (TN); Quensyl; WIN 1258 DMXZAL2 CP Concordia Pharmaceuticals Inc DMXZAL2 TC Antiviral Agents DMXZAL2 DT Small molecular drug DMXZAL2 PC 3652 DMXZAL2 MW 335.9 DMXZAL2 FM C18H26ClN3O DMXZAL2 IC InChI=1S/C18H26ClN3O/c1-3-22(11-12-23)10-4-5-14(2)21-17-8-9-20-18-13-15(19)6-7-16(17)18/h6-9,13-14,23H,3-5,10-12H2,1-2H3,(H,20,21) DMXZAL2 CS CCN(CCCC(C)NC1=C2C=CC(=CC2=NC=C1)Cl)CCO DMXZAL2 IK XXSMGPRMXLTPCZ-UHFFFAOYSA-N DMXZAL2 IU 2-[4-[(7-chloroquinolin-4-yl)amino]pentyl-ethylamino]ethanol DMXZAL2 CA CAS 118-42-3 DMXZAL2 CB CHEBI:5801 DMXZAL2 DE Malaria; Coronavirus Disease 2019 (COVID-19) DMIGFOR ID DMIGFOR DMIGFOR DN I3C DMIGFOR HS Phase 3 DMIGFOR SN Indole-3-carbinol; 700-06-1; 3-Indolemethanol; INDOLE-3-METHANOL; (1H-Indol-3-yl)methanol; 1H-indol-3-ylmethanol; 3-Hydroxymethylindole; 1H-Indole-3-methanol; 3-Indolylcarbinol; Indinol; 3-(Hydroxymethyl)indole; 3-Indole methanol; Indole 3 carbinol; (1H-Indol-3-yl)-methanol; MFCD00005632; UNII-C11E72455F; CHEBI:24814; C11E72455F; NSC-525801; NCGC00090701-06; indol-3-ylmethan-1-ol; I0496; Indole-3-carbinol, 97%; SMR000385784; CCRIS 3261; EINECS 211-836-2; 1H-Indol-3-Yl-Methanol; NSC 525801; BRN 0121323; AI3-60090; 3-Indolecarbinol; 3-Indolylmethanol; Prevention 4 (indole-3-carbinol); indole-3-carbinole; zlchem 356; PubChem7265; 3-hydroxymethyl indole; Spectrum2_001710; Spectrum3_001973; ACMC-209oc7; DSSTox_CID_11458; DSSTox_RID_78876; DSSTox_GSID_31458; BSPBio_003573; MLS001333161; MLS001333162; SCHEMBL195520; SPECTRUM1505320; SPBio_001700; CHEMBL155625; 1H-Indole-3-methanol (9CI); 3-Phenoxybenzylaminehydrochloride; DTXSID7031458; GTPL10047; KBio3_002949; ZLC0198; HMS1789O22; HMS2235E10; HMS3369B02; HMS3651I18; HMS3749E07; ZINC158743; ACN-S002804; ACT03591; BCP00087; HY-N0170; INDOLE-3-CARBINOL (I3C); Tox21_400055; 9344AF; ANW-35813; CCG-38786; HSCI1_000097; NSC525801; s2313; SBB004095; AKOS001075120; AC-7583; CS-7780; DB12881; GS-0916; LS20980; MCULE-6344603304; SB14958; SDCCGMLS-0065970.P001; SDCCGMLS-0065970.P002; VI30396; Indole-3-methanol (Indole-3-carbinol); SMP2_000172; NCGC00090701-01; NCGC00090701-02; NCGC00090701-03; NCGC00090701-04; NCGC00090701-05; NCGC00090701-07; AK-53373; CAS-700-06-1; SY015976; AB0008317; DB-011567; A9256; FT-0615875; ST50308202; SW219849-1; I-2100; M-3233; A836732; SR-01000838318; Q1770257; SR-01000838318-3; BRD-K01815685-001-02-3; BRD-K01815685-001-07-2; Z85923165 DMIGFOR DT Small molecular drug DMIGFOR PC 3712 DMIGFOR MW 147.17 DMIGFOR FM C9H9NO DMIGFOR IC InChI=1S/C9H9NO/c11-6-7-5-10-9-4-2-1-3-8(7)9/h1-5,10-11H,6H2 DMIGFOR CS C1=CC=C2C(=C1)C(=CN2)CO DMIGFOR IK IVYPNXXAYMYVSP-UHFFFAOYSA-N DMIGFOR IU 1H-indol-3-ylmethanol DMIGFOR CA CAS 700-06-1 DMIGFOR CB CHEBI:24814 DMIGFOR DE Breast cancer DM5KL8E ID DM5KL8E DM5KL8E DN IBI-308 DM5KL8E HS Phase 3 DM5KL8E CP Innovent Biologics DM5KL8E DT Monoclonal antibody DM5KL8E DE Bronchioalveolar carcinoma DM9G5XD ID DM9G5XD DM9G5XD DN IB-MECA DM9G5XD HS Phase 3 DM9G5XD SN IB-Meca; 152918-18-8; piclidenoson; CF-101; 3-IB-Meca; N(6)-Ibamu; CF 101; Cf101; N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine; UNII-30679UMI0N; N(6)-(3-Iodobenzyl)adenosine-5'-N-methyluronamide; 1-Deoxy-1-(6-(((3-iodophenyl)methyl)amino)-9H-purin-9-yl)-N-methyl-beta-D-ribofuranuronamide; CHEMBL119709; CHEBI:73286; 30679UMI0N; RPR-113090; 3-iodobenzyl-5'-N-methylcarboxamidoadenosine; N(6)-(3-iodo-benzyl)adenosine-5'-N-methyluronamide; 3-IB-MECA DM9G5XD DT Small molecular drug DM9G5XD PC 123683 DM9G5XD MW 510.3 DM9G5XD FM C18H19IN6O4 DM9G5XD IC InChI=1S/C18H19IN6O4/c1-20-17(28)14-12(26)13(27)18(29-14)25-8-24-11-15(22-7-23-16(11)25)21-6-9-3-2-4-10(19)5-9/h2-5,7-8,12-14,18,26-27H,6H2,1H3,(H,20,28)(H,21,22,23)/t12-,13+,14-,18+/m0/s1 DM9G5XD CS CNC(=O)[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)NCC4=CC(=CC=C4)I)O)O DM9G5XD IK HUJXGQILHAUCCV-MOROJQBDSA-N DM9G5XD IU (2S,3S,4R,5R)-3,4-dihydroxy-5-[6-[(3-iodophenyl)methylamino]purin-9-yl]-N-methyloxolane-2-carboxamide DM9G5XD CA CAS 152918-18-8 DM9G5XD CB CHEBI:73286 DM9G5XD DE Solid tumour/cancer; Plaque psoriasis; Psoriasis vulgaris; Rheumatoid arthritis DMT67EH ID DMT67EH DMT67EH DN Ibodutant DMT67EH HS Phase 3 DMT67EH SN MEN-15596; Tachykinin NK2 receptor antagonist (irritable bowel syndrome), Menarini DMT67EH CP The Menarini Group DMT67EH DT Small molecular drug DMT67EH PC 11527495 DMT67EH MW 644.9 DMT67EH FM C37H48N4O4S DMT67EH IC InChI=1S/C37H48N4O4S/c1-26-9-10-30-23-33(46-32(30)21-26)35(43)40-37(15-5-6-16-37)36(44)39-31(22-27-7-3-2-4-8-27)34(42)38-24-28-11-17-41(18-12-28)25-29-13-19-45-20-14-29/h2-4,7-10,21,23,28-29,31H,5-6,11-20,22,24-25H2,1H3,(H,38,42)(H,39,44)(H,40,43)/t31-/m1/s1 DMT67EH CS CC1=CC2=C(C=C1)C=C(S2)C(=O)NC3(CCCC3)C(=O)N[C@H](CC4=CC=CC=C4)C(=O)NCC5CCN(CC5)CC6CCOCC6 DMT67EH IK YQYSVMKCMIUCHY-WJOKGBTCSA-N DMT67EH IU 6-methyl-N-[1-[[(2R)-1-[[1-(oxan-4-ylmethyl)piperidin-4-yl]methylamino]-1-oxo-3-phenylpropan-2-yl]carbamoyl]cyclopentyl]-1-benzothiophene-2-carboxamide DMT67EH CA CAS 522664-63-7 DMT67EH DE Irritable bowel syndrome DMOJQGT ID DMOJQGT DMOJQGT DN ICARIIN DMOJQGT HS Phase 3 DMOJQGT SN Icariin; 489-32-7; Ieariline; UNII-VNM47R2QSQ; CHEBI:78420; VNM47R2QSQ; Icariine; 3-((6-Deoxymannopyranosyl)oxy)-7-(glucopyranosyloxy)-5-hydroxy-2-(4-methoxyphenyl)-8-(3-methyl-2-butenyl)-4H-1-benzopyran-4-one; Icarin; 5-hydroxy-2-(4-methoxyphenyl)-8-(3-methylbut-2-en-1-yl)-7-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-3-(((2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-4H-chromen-4-one; 4H-1-Benzopyran-4-one, 3-((6-deoxy-alpha-L-mannopyranosyl)oxy)-7-(be DMOJQGT DT Small molecular drug DMOJQGT PC 5318997 DMOJQGT MW 676.7 DMOJQGT FM C33H40O15 DMOJQGT IC InChI=1S/C33H40O15/c1-13(2)5-10-17-19(45-33-28(42)26(40)23(37)20(12-34)46-33)11-18(35)21-24(38)31(48-32-27(41)25(39)22(36)14(3)44-32)29(47-30(17)21)15-6-8-16(43-4)9-7-15/h5-9,11,14,20,22-23,25-28,32-37,39-42H,10,12H2,1-4H3/t14-,20+,22-,23+,25+,26-,27+,28+,32-,33+/m0/s1 DMOJQGT CS C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OC2=C(OC3=C(C2=O)C(=CC(=C3CC=C(C)C)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)O)C5=CC=C(C=C5)OC)O)O)O DMOJQGT IK TZJALUIVHRYQQB-XLRXWWTNSA-N DMOJQGT IU 5-hydroxy-2-(4-methoxyphenyl)-8-(3-methylbut-2-enyl)-7-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxychromen-4-one DMOJQGT CA CAS 489-32-7 DMOJQGT CB CHEBI:78420 DM3OU54 ID DM3OU54 DM3OU54 DN ICI 118,551 DM3OU54 HS Phase 3 DM3OU54 SN Ici 118551; (2R,3S)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol; CHEMBL198059; CHEBI:73289; ICI-118551; ICI118551; erythro-DL-1-(7-Methylindan-4-yloxy)-3-isopropylaminobutan-2-ol; (2R,3S)-3-(isopropylamino)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]butan-2-ol; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (2R,3S)-rel-; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (R*,S*)-(+-)-; ICI-118,551; Ici 111,581; AC1NUNSO DM3OU54 DT Small molecular drug DM3OU54 PC 3682 DM3OU54 MW 277.4 DM3OU54 FM C17H27NO2 DM3OU54 IC InChI=1S/C17H27NO2/c1-11(2)18-13(4)16(19)10-20-17-9-8-12(3)14-6-5-7-15(14)17/h8-9,11,13,16,18-19H,5-7,10H2,1-4H3 DM3OU54 CS CC1=C2CCCC2=C(C=C1)OCC(C(C)NC(C)C)O DM3OU54 IK VFIDUCMKNJIJTO-UHFFFAOYSA-N DM3OU54 IU 1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol DM3OU54 CB CHEBI:91879 DM3OU54 DE Gastric adenocarcinoma; HER2-positive breast cancer DM7YNV9 ID DM7YNV9 DM7YNV9 DN Iclaprim DM7YNV9 HS Phase 3 DM7YNV9 SN 192314-93-5; AR-100; 5-[(2-cyclopropyl-7,8-dimethoxy-2h-chromen-5-yl)methyl]pyrimidine-2,4-diamine; RO-48-2622; Mersarex; 5-((2-Cyclopropyl-7,8-dimethoxy-2H-chromen-5-yl)methyl)pyrimidine-2,4-diamine; Iclaprim [USAN:INN]; Iclaprim (USAN/INN); 2,4-Pyrimidinediamine, 5-((2-cyclopropyl-7,8-dimethoxy-2H-1-benzopyran-5-yl)methyl)-; 2,4-Pyrimidinediamine, 5-[(2-cyclopropyl-7,8-dimethoxy-2H-1-benzopyran-5-yl)methyl]-; AR 100; AC1Q4WM5; SCHEMBL379386; CHEMBL134561; AC1L4U54; SCHEMBL12899446; CTK4E0971; BDBM18070; Iclaprim [INN]; AR-102; AR-100001; 5-((2RS)-2-cyclopropyl-7,8-dimethoxy-2H-chromen-5-ylmethyl)pyrimidine-2,4-diamine DM7YNV9 CP Arpida DM7YNV9 DT Small molecular drug DM7YNV9 PC 213043 DM7YNV9 MW 354.4 DM7YNV9 FM C19H22N4O3 DM7YNV9 IC InChI=1S/C19H22N4O3/c1-24-15-8-11(7-12-9-22-19(21)23-18(12)20)13-5-6-14(10-3-4-10)26-16(13)17(15)25-2/h5-6,8-10,14H,3-4,7H2,1-2H3,(H4,20,21,22,23) DM7YNV9 CS COC1=C(C2=C(C=CC(O2)C3CC3)C(=C1)CC4=CN=C(N=C4N)N)OC DM7YNV9 IK HWJPWWYTGBZDEG-UHFFFAOYSA-N DM7YNV9 IU 5-[(2-cyclopropyl-7,8-dimethoxy-2H-chromen-5-yl)methyl]pyrimidine-2,4-diamine DM7YNV9 CA CAS 192314-93-5 DM7YNV9 CB CHEBI:131751 DM7YNV9 DE Pneumonia; Bacterial infection; Acute bacterial skin infection DMU72KL ID DMU72KL DMU72KL DN ICP-022 DMU72KL HS Phase 3 DMU72KL SN Orelabrutinib; 1655504-04-3; UNII-WJA5UO9E10; WJA5UO9E10; 4-yl]pyridine-3-carboxamide; ICP022; 2-(4-phenoxyphenyl)-6-[1-(prop-2-enoyl)piperidin-; 6-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)nicotinamide; Orelabrutinib [INN]; orelabrutinib (proposed INN); SCHEMBL16597834; US9951056, Example 3; GTPL10629; BDBM389631; EX-A3442; NSC826039; s9600; NSC-826039; example 3 [WO2015048662A2]; DB-091042; HY-129390; CS-0105163; 2-(4-phenoxyphenyl)-6-(1-prop-2-enoylpiperidin-4-yl)pyridine-3-carboxamide; 3-Pyridinecarboxamide, 6-(1-(1-oxo-2-propen-1-yl)-4-piperidinyl)-2-(4-phenoxyphenyl)-; 6-(1-(1-Oxo-2-propen-1-yl)-4-piperidinyl)-2-(4-phenoxyphenyl)-3-pyridinecarboxamide DMU72KL CP InnoCare Pharma DMU72KL DT Small molecular drug DMU72KL PC 91667513 DMU72KL MW 427.5 DMU72KL FM C26H25N3O3 DMU72KL IC InChI=1S/C26H25N3O3/c1-2-24(30)29-16-14-18(15-17-29)23-13-12-22(26(27)31)25(28-23)19-8-10-21(11-9-19)32-20-6-4-3-5-7-20/h2-13,18H,1,14-17H2,(H2,27,31) DMU72KL CS C=CC(=O)N1CCC(CC1)C2=NC(=C(C=C2)C(=O)N)C3=CC=C(C=C3)OC4=CC=CC=C4 DMU72KL IK MZPVEMOYADUARK-UHFFFAOYSA-N DMU72KL IU 2-(4-phenoxyphenyl)-6-(1-prop-2-enoylpiperidin-4-yl)pyridine-3-carboxamide DMU72KL CA CAS 1655504-04-3 DMU72KL DE Diffuse large B-cell lymphoma; Chronic lymphocytic leukaemia; Small lymphocytic lymphoma DMBIZ7H ID DMBIZ7H DMBIZ7H DN ICT-107 DMBIZ7H HS Phase 3 DMBIZ7H CP ImmunoCellular Therapeutics DMBIZ7H DT Vaccine DMBIZ7H DE Glioblastoma multiforme; Brain cancer; Recurrent glioblastoma DMSP0X8 ID DMSP0X8 DMSP0X8 DN IDAZOXAN HYDROCHLORIDE DMSP0X8 HS Phase 3 DMSP0X8 SN IDAZOXAN HYDROCHLORIDE; 79944-56-2; Idazoxan HCl; RX 781094; MLS000069708; SMR000058458; SR-01000000206; Opera_ID_847; Idazoxan (hydrochloride); AC1L4CEL; MLS001148081; SCHEMBL707367; CHEMBL543467; CTK8G0263; MolPort-003-941-824; MYUBYOVCLMEAOH-UHFFFAOYSA-N; (+/-)-Idazoxan Monohydrochloride; Pharmakon1600-01506073; HMS1570J14; Tox21_500652; NSC759867; MFCD00069293; BN0267; AKOS024458652; NSC-759867; RX 781094A; LP00652; CCG-214002; 1H-Imidazole, 2-(2,3-dihydro-1,4-benzodioxin-2-yl)-4,5-dihydro-,monohydrochloride; 1H-Imidazole, 2-(2,3-d DMSP0X8 DT Small molecular drug DMSP0X8 PC 154494 DMSP0X8 MW 240.68 DMSP0X8 FM C11H13ClN2O2 DMSP0X8 IC InChI=1S/C11H12N2O2.ClH/c1-2-4-9-8(3-1)14-7-10(15-9)11-12-5-6-13-11;/h1-4,10H,5-7H2,(H,12,13);1H DMSP0X8 CS C1CN=C(N1)C2COC3=CC=CC=C3O2.Cl DMSP0X8 IK MYUBYOVCLMEAOH-UHFFFAOYSA-N DMSP0X8 IU 2-(2,3-dihydro-1,4-benzodioxin-3-yl)-4,5-dihydro-1H-imidazole;hydrochloride DMSP0X8 CA CAS 79944-56-2 DMSP0X8 DE Neurological disorder DMV3DHQ ID DMV3DHQ DMV3DHQ DN IDDBCP161883 DMV3DHQ HS Phase 3 DMV3DHQ CP Mitsubishi Tanabe DMV3DHQ DE Type-2 diabetes DM3A701 ID DM3A701 DM3A701 DN IDP-122 DM3A701 HS Phase 3 DM3A701 CP Valeant Pharmaceuticals Bridgewater, NJ DM3A701 DE Plaque psoriasis DMRLVUD ID DMRLVUD DMRLVUD DN Imagabalin DMRLVUD HS Phase 3 DMRLVUD SN Imagabalin hydrochloride; PD-0332334; PD-332334; PF-00195889 DMRLVUD CP Pfizer Inc DMRLVUD DT Small molecular drug DMRLVUD PC 10236037 DMRLVUD MW 173.25 DMRLVUD FM C9H19NO2 DMRLVUD IC InChI=1S/C9H19NO2/c1-3-4-7(2)5-8(10)6-9(11)12/h7-8H,3-6,10H2,1-2H3,(H,11,12)/t7-,8+/m1/s1 DMRLVUD CS CCC[C@@H](C)C[C@@H](CC(=O)O)N DMRLVUD IK JXEHXYFSIOYTAH-SFYZADRCSA-N DMRLVUD IU (3S,5R)-3-amino-5-methyloctanoic acid DMRLVUD CA CAS 610300-07-7 DMRLVUD DE Generalized anxiety disorder DMM9JEF ID DMM9JEF DMM9JEF DN Imatinib DMM9JEF HS Phase 3 DMM9JEF SN Cgp 57148; Glamox; Glamox (TN); Gleevec (TN); Glivec (TN); Imatinib (INN); Imatinib (STI571); Imatinib Methansulfonate; Imatinib [INN:BAN]; 112GI019; 152459-95-5; BKJ8M8G5HI; CCRIS 9076; CGP-57148; CHEMBL941; Imatinib free base; STI; UNII-BKJ8M8G5HI DMM9JEF CP Novartis AG DMM9JEF TC Antiviral Agents DMM9JEF DT Small molecular drug DMM9JEF PC 5291 DMM9JEF MW 493.6 DMM9JEF FM C29H31N7O DMM9JEF IC InChI=1S/C29H31N7O/c1-21-5-10-25(18-27(21)34-29-31-13-11-26(33-29)24-4-3-12-30-19-24)32-28(37)23-8-6-22(7-9-23)20-36-16-14-35(2)15-17-36/h3-13,18-19H,14-17,20H2,1-2H3,(H,32,37)(H,31,33,34) DMM9JEF CS CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5 DMM9JEF IK KTUFNOKKBVMGRW-UHFFFAOYSA-N DMM9JEF IU 4-[(4-methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide DMM9JEF CA CAS 152459-95-5 DMM9JEF CB CHEBI:45783 DMM9JEF DE Chronic myelogenous leukaemia; Intestinal cancer; Lung cancer; Systemic mastocytosis; Middle East Respiratory Syndrome (MERS); Severe acute respiratory syndrome (SARS) DM7BCWT ID DM7BCWT DM7BCWT DN Imiglitazar DM7BCWT HS Phase 3 DM7BCWT SN TAK-559 DM7BCWT CP Takeda Pharmaceutical Co Ltd DM7BCWT DT Small molecular drug DM7BCWT PC 9890879 DM7BCWT MW 470.5 DM7BCWT FM C28H26N2O5 DM7BCWT IC InChI=1S/C28H26N2O5/c1-20-26(29-28(35-20)23-10-6-3-7-11-23)19-33-24-14-12-21(13-15-24)18-34-30-25(16-17-27(31)32)22-8-4-2-5-9-22/h2-15H,16-19H2,1H3,(H,31,32)/b30-25+ DM7BCWT CS CC1=C(N=C(O1)C2=CC=CC=C2)COC3=CC=C(C=C3)CO/N=C(\\CCC(=O)O)/C4=CC=CC=C4 DM7BCWT IK ULVDFHLHKNJICZ-QCWLDUFUSA-N DM7BCWT IU (4E)-4-[[4-[(5-methyl-2-phenyl-1,3-oxazol-4-yl)methoxy]phenyl]methoxyimino]-4-phenylbutanoic acid DM7BCWT CA CAS 250601-04-8 DM7BCWT DE Type-2 diabetes DM735FA ID DM735FA DM735FA DN IMO-2125 DM735FA HS Phase 3 DM735FA CP Idera Pharmaceuticals DM735FA DE Hepatitis C virus infection; Melanoma; Solid tumour/cancer DMIJGT9 ID DMIJGT9 DMIJGT9 DN INCB24360 DMIJGT9 HS Phase 3 DMIJGT9 SN Epacadostat DMIJGT9 CP Incyte DMIJGT9 DT Small molecular drug DMIJGT9 PC 135564890 DMIJGT9 MW 438.24 DMIJGT9 FM C11H13BrFN7O4S DMIJGT9 IC InChI=1S/C11H13BrFN7O4S/c12-7-5-6(1-2-8(7)13)17-11(18-21)9-10(20-24-19-9)15-3-4-16-25(14,22)23/h1-2,5,16,21H,3-4H2,(H,15,20)(H,17,18)(H2,14,22,23) DMIJGT9 CS C1=CC(=C(C=C1N=C(C2=NON=C2NCCNS(=O)(=O)N)NO)Br)F DMIJGT9 IK FBKMWOJEPMPVTQ-UHFFFAOYSA-N DMIJGT9 IU N'-(3-bromo-4-fluorophenyl)-N-hydroxy-4-[2-(sulfamoylamino)ethylamino]-1,2,5-oxadiazole-3-carboximidamide DMIJGT9 CA CAS 1204669-58-8 DMIJGT9 DE Recurrent glioblastoma; Melanoma; B-cell lymphoma; Colorectal cancer; Head and neck cancer; Lung cancer; Lymphoma; Merkel cell carcinoma; Ovarian cancer; Solid tumour/cancer; Urothelial carcinoma DMZA2K0 ID DMZA2K0 DMZA2K0 DN INCSHR1210 DMZA2K0 HS Phase 3 DMZA2K0 SN Camrelizumab DMZA2K0 CP Incyte Wilmington, DE DMZA2K0 DT Monoclonal antibody DMZA2K0 DE Solid tumour/cancer; Bronchioalveolar carcinoma; Esophageal squamous cell carcinoma DMLG96Z ID DMLG96Z DMLG96Z DN INM-176 DMLG96Z HS Phase 3 DMLG96Z SN WIN-026; Win-025; Alzheimer's therapeutic, Whanin Pharmaceuticals; KR-WAP-026; Anti-beta amyloid/AChE inhibitor (Alzheimer's), WhanIn; Anti-beta amyloid/acetylcholinesterase inhibitor (Alzheimer's), WhanIn DMLG96Z CP Scigenic & Scigen Harvest Co Ltd DMLG96Z DE Alzheimer disease DM5L8QT ID DM5L8QT DM5L8QT DN INO-1001 DM5L8QT HS Phase 3 DM5L8QT SN Hypoxanthine arabinoside; LT00454797; 9-[(3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3H-purin-6-one DM5L8QT CP Inotek Pharma. DM5L8QT TC Anticancer Agents DM5L8QT DT Small molecular drug DM5L8QT PC 6708742 DM5L8QT DE Brain cancer DMUS1F8 ID DMUS1F8 DMUS1F8 DN Inolimomab DMUS1F8 HS Phase 3 DMUS1F8 CP EUSA Pharma DMUS1F8 DT Monoclonal antibody DMUS1F8 DE Heart transplant rejection DMOTH6V ID DMOTH6V DMOTH6V DN Interferon alpha 2a DMOTH6V HS Phase 3 DMOTH6V SN LBSI-5535; Interferon alpha 2a (Biohydrix sustained release/weekly dosing, HCV); Interferon alpha 2a (Biohydrix sustained release/weekly dosing, HCV), LG Life Sciences; Sr-IFN alpha (Biohydrix sustained release/weekly dosing, HCV), LGLS DMOTH6V CP LG Life Sciences Ltd DMOTH6V DE Hepatitis C virus infection DMZA47Y ID DMZA47Y DMZA47Y DN Iomab-B DMZA47Y HS Phase 3 DMZA47Y SN Iomab-B (TN) DMZA47Y CP Actinium Pharmaceuticals DMZA47Y DT Antibody DMZA47Y DE Acute myeloid leukaemia; Bone marrow transplantation DMSV12M ID DMSV12M DMSV12M DN Isavuconazole DMSV12M HS Phase 3 DMSV12M SN Isavuconazole; 241479-67-4; isavuconazol; BAL 4815; BAL-4815; UNII-60UTO373KE; Isavuconazole [INN]; 60UTO373KE; Isavuconazole(BAL-4815; RO-0094815); RO 0094815; CHEBI:85979; Isavuconazole (INN); RO-0094815; 4-[2-[(1R,2R)-2-(2,5-Difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-4-thiazolyl]benzonitrile; 1286730-05-9; 4-[2-[(2R,3R)-3-(2,5-difluorophenyl)-3-hydroxy-4-(1,2,4-triazol-1-yl)butan-2-yl]-1,3-thiazol-4-yl]benzonitrile DMSV12M CP Astellas DMSV12M DT Small molecular drug DMSV12M PC 6918485 DMSV12M MW 437.5 DMSV12M FM C22H17F2N5OS DMSV12M IC InChI=1S/C22H17F2N5OS/c1-14(21-28-20(10-31-21)16-4-2-15(9-25)3-5-16)22(30,11-29-13-26-12-27-29)18-8-17(23)6-7-19(18)24/h2-8,10,12-14,30H,11H2,1H3/t14-,22+/m0/s1 DMSV12M CS C[C@@H](C1=NC(=CS1)C2=CC=C(C=C2)C#N)[C@](CN3C=NC=N3)(C4=C(C=CC(=C4)F)F)O DMSV12M IK DDFOUSQFMYRUQK-RCDICMHDSA-N DMSV12M IU 4-[2-[(2R,3R)-3-(2,5-difluorophenyl)-3-hydroxy-4-(1,2,4-triazol-1-yl)butan-2-yl]-1,3-thiazol-4-yl]benzonitrile DMSV12M CA CAS 241479-67-4 DMSV12M CB CHEBI:85979 DMSV12M DE Invasive aspergillosis; Invasive candidiasis; Candidemia DMQZI7K ID DMQZI7K DMQZI7K DN ISIS 23722 DMQZI7K HS Phase 3 DMQZI7K CP Isis Pharmaceuticals DMQZI7K SQ TGTGCTATTCTGTGAATT DMQZI7K DE Solid tumour/cancer DMKWBJR ID DMKWBJR DMKWBJR DN ISIS-PKK DMKWBJR HS Phase 3 DMKWBJR SN ISIS-PKKRx DMKWBJR DT Antisense drug DMKWBJR DE Amyloid cardiomyopathy DM4U5NF ID DM4U5NF DM4U5NF DN ISIS-TTR DM4U5NF HS Phase 3 DM4U5NF CP ISIS Pharm DM4U5NF DT Antisense drug DM4U5NF DE Amyloidosis DMBJTVL ID DMBJTVL DMBJTVL DN Isotretinoin DMBJTVL HS Phase 3 DMBJTVL SN Accutane; 13-cis-Retinoic acid; Roaccutane; Neovitamin A acid; 13-cis-Vitamin A acid; 13-cis retinoic acid; Claravis; Amnesteem; Isotrex; Teriosal; Sotret; isotretinoino; Isotretinoinum; Isotretinoine; Roaccutan; 13-RA; Roacutan; Absorica; ISOTRETINON; Isotretinoine [INN-French]; Isotretinoinum [INN-Latin]; Isotretinoino [INN-Spanish]; CIP-Isotretinoin; Accutane (TN); Isotretinoin (USP); Ro-4-3780; UNII-EH28UP18IF; CCRIS 4286; HSDB 3929 DMBJTVL TC Antiviral Agents DMBJTVL DT Small molecular drug DMBJTVL PC 5282379 DMBJTVL MW 300.4 DMBJTVL FM C20H28O2 DMBJTVL IC InChI=1S/C20H28O2/c1-15(8-6-9-16(2)14-19(21)22)11-12-18-17(3)10-7-13-20(18,4)5/h6,8-9,11-12,14H,7,10,13H2,1-5H3,(H,21,22)/b9-6+,12-11+,15-8+,16-14- DMBJTVL CS CC1=C(C(CCC1)(C)C)/C=C/C(=C/C=C/C(=C\\C(=O)O)/C)/C DMBJTVL IK SHGAZHPCJJPHSC-XFYACQKRSA-N DMBJTVL IU (2Z,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenoic acid DMBJTVL CA CAS 4759-48-2 DMBJTVL CB CHEBI:6067 DMBJTVL DE Coronavirus Disease 2019 (COVID-19) DMP61YB ID DMP61YB DMP61YB DN ISRAPAFANT DMP61YB HS Phase 3 DMP61YB SN Y-24180; Israpafant; Pafnol (Mitsubishi Pharma, JP); Rac-4-(2-Chlorophenyl)-2-[2-(4-isobutylphenyl)ethyl]-6,9-dimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine DMP61YB DT Small molecular drug DMP61YB PC 119175 DMP61YB MW 489.1 DMP61YB FM C28H29ClN4S DMP61YB IC InChI=1S/C28H29ClN4S/c1-17(2)15-21-11-9-20(10-12-21)13-14-22-16-24-26(23-7-5-6-8-25(23)29)30-18(3)27-32-31-19(4)33(27)28(24)34-22/h5-12,16-18H,13-15H2,1-4H3 DMP61YB CS CC1C2=NN=C(N2C3=C(C=C(S3)CCC4=CC=C(C=C4)CC(C)C)C(=N1)C5=CC=CC=C5Cl)C DMP61YB IK RMSWMRJVUJSDGN-UHFFFAOYSA-N DMP61YB IU 7-(2-chlorophenyl)-9,13-dimethyl-4-[2-[4-(2-methylpropyl)phenyl]ethyl]-3-thia-1,8,11,12-tetrazatricyclo[8.3.0.02,6]trideca-2(6),4,7,10,12-pentaene DMP61YB CA CAS 117279-73-9 DMP61YB DE Asthma DMNDGWE ID DMNDGWE DMNDGWE DN IT-101 DMNDGWE HS Phase 3 DMNDGWE CP Insert Therapeutics DMNDGWE DE Solid tumour/cancer DMFZBNE ID DMFZBNE DMFZBNE DN ITF2357 DMFZBNE HS Phase 3 DMFZBNE SN Givinostat; Carbamic acid, N-(4-((hydroxyamino)carbonyl)phenyl)-, (6-((diethylamino)methyl)-2-naphthalenyl)methyl ester, hydrochloride (1:1) DMFZBNE CP Italfarmaco DMFZBNE DT Small molecular drug DMFZBNE PC 9804992 DMFZBNE MW 421.5 DMFZBNE FM C24H27N3O4 DMFZBNE IC InChI=1S/C24H27N3O4/c1-3-27(4-2)15-17-5-7-21-14-18(6-8-20(21)13-17)16-31-24(29)25-22-11-9-19(10-12-22)23(28)26-30/h5-14,30H,3-4,15-16H2,1-2H3,(H,25,29)(H,26,28) DMFZBNE CS CCN(CC)CC1=CC2=C(C=C1)C=C(C=C2)COC(=O)NC3=CC=C(C=C3)C(=O)NO DMFZBNE IK YALNUENQHAQXEA-UHFFFAOYSA-N DMFZBNE IU [6-(diethylaminomethyl)naphthalen-2-yl]methyl N-[4-(hydroxycarbamoyl)phenyl]carbamate DMFZBNE CA CAS 497833-27-9 DMFZBNE CB CHEBI:94187 DMFZBNE DE Polycythemia vera; Essential thrombocythemia; Myelofibrosis; Duchenne dystrophy DMUQ1DO ID DMUQ1DO DMUQ1DO DN ITI-007 DMUQ1DO HS Phase 3 DMUQ1DO CP Intra-Cellular Therapies DMUQ1DO DT Small molecular drug DMUQ1DO PC 21302490 DMUQ1DO MW 393.5 DMUQ1DO FM C24H28FN3O DMUQ1DO IC InChI=1S/C24H28FN3O/c1-26-14-15-28-21-11-13-27(16-20(21)19-4-2-5-22(26)24(19)28)12-3-6-23(29)17-7-9-18(25)10-8-17/h2,4-5,7-10,20-21H,3,6,11-16H2,1H3/t20-,21-/m0/s1 DMUQ1DO CS CN1CCN2[C@H]3CCN(C[C@H]3C4=C2C1=CC=C4)CCCC(=O)C5=CC=C(C=C5)F DMUQ1DO IK HOIIHACBCFLJET-SFTDATJTSA-N DMUQ1DO IU 1-(4-fluorophenyl)-4-[(10R,15S)-4-methyl-1,4,12-triazatetracyclo[7.6.1.05,16.010,15]hexadeca-5,7,9(16)-trien-12-yl]butan-1-one DMUQ1DO CA CAS 313369-37-8 DMUQ1DO DE Insomnia; Schizophrenia; Depression; Major depressive disorder DMGWVLX ID DMGWVLX DMGWVLX DN Itolizumab DMGWVLX HS Phase 3 DMGWVLX SN T-1h-mAb; T-1h-mAb); Anti-CD6 humanized monoclonal antibody, Center of Molecular Immunology/Biocon Biopharmaceuticals; Anti-CD6 humanized monoclonal antibody (rheumatoid arthritis/ psoriasis/ T-cell lymphoma), CIM/Biocon Biopharmaceuticals DMGWVLX CP Dermatology; The Center of Molecular Immunology DMGWVLX DT Antibody DMGWVLX DE Type-1 diabetes DM7MLTR ID DM7MLTR DM7MLTR DN Itopride DM7MLTR HS Phase 3 DM7MLTR SN Itopride; Itopride (INN); Itopride [INN]; QQQIECGTIMUVDS-UHFFFAOYSA-N; SCHEMBL311309; SR-01000763470; 122898-67-3; 81BMQ80QRL; AC1L1GQ2; AC1Q5DLT; DTXSID7048320; N-(4-(2-(Dimethylamino)ethoxy)benzyl)-3,4-dimethoxybenzamide; N-({4-[2-(dimethylamino)ethoxy]phenyl}methyl)-3,4-dimethoxybenzamide; N-[4-[2-(Dimethylamino)ethoxy]benzyl]-3,4-dimethoxybenzamide; N-[[4-[2-(dimethylamino)ethoxy]phenyl]methyl]-3,4-dimethoxybenzamide; NCGC00167529-01; UNII-81BMQ80QRL; n-{4-[2-(dimethylamino)ethoxy]benzyl}-3,4-dimethoxybenzamide DM7MLTR PC 3792 DM7MLTR MW 358.4 DM7MLTR FM C20H26N2O4 DM7MLTR IC QQQIECGTIMUVDS-UHFFFAOYSA-N DM7MLTR CS CN(C)CCOC1=CC=C(C=C1)CNC(=O)C2=CC(=C(C=C2)OC)OC DM7MLTR IK 1S/C20H26N2O4/c1-22(2)11-12-26-17-8-5-15(6-9-17)14-21-20(23)16-7-10-18(24-3)19(13-16)25-4/h5-10,13H,11-12,14H2,1-4H3,(H,21,23) DM7MLTR IU N-[[4-[2-(dimethylamino)ethoxy]phenyl]methyl]-3,4-dimethoxybenzamide DM7MLTR CA CAS 122898-67-3 DM7MLTR CB CHEBI:94809 DM7MLTR DE Functional nausea/vomiting DMNORK8 ID DMNORK8 DMNORK8 DN Jakafi DMNORK8 HS Phase 3 DMNORK8 SN Ruxolitinib phosphate; 1092939-17-7; Ruxolitinib (phosphate); Jakavi; (R)-3-(4-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile phosphate; UNII-436LRU32H5; Ruxolitinib phosphate salt; Ruxolitinib phosphate(INCB018424); CHEBI:66917; 436LRU32H5; J-501793; (betaR)-beta-Cyclopentyl-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazole-1-propanenitrile phosphate; (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile phosphate; Ruxolitinib phosphate [USAN]; Jaka DMNORK8 CP Incyte, Wilmington, DE DMNORK8 PC 25127112 DMNORK8 MW 404.4 DMNORK8 FM C17H21N6O4P DMNORK8 IC InChI=1S/C17H18N6.H3O4P/c18-7-5-15(12-3-1-2-4-12)23-10-13(9-22-23)16-14-6-8-19-17(14)21-11-20-16;1-5(2,3)4/h6,8-12,15H,1-5H2,(H,19,20,21);(H3,1,2,3,4)/t15-;/m1./s1 DMNORK8 CS C1CCC(C1)[C@@H](CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3.OP(=O)(O)O DMNORK8 IK JFMWPOCYMYGEDM-XFULWGLBSA-N DMNORK8 IU (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile;phosphoric acid DMNORK8 CA CAS 1092939-17-7 DMNORK8 CB CHEBI:66917 DMNORK8 DE Essential thrombocythemia DM8FSPV ID DM8FSPV DM8FSPV DN JTZ-951 DM8FSPV HS Phase 3 DM8FSPV PC 50899324 DM8FSPV MW 340.33 DM8FSPV FM C17H16N4O4 DM8FSPV IC InChI=1S/C17H16N4O4/c22-13-8-12(7-6-11-4-2-1-3-5-11)21-16(19-10-20-21)15(13)17(25)18-9-14(23)24/h1-5,8,10H,6-7,9H2,(H,18,25)(H,19,20)(H,23,24) DM8FSPV CS C1=CC=C(C=C1)CCC2=CC(=O)C(=C3N2NC=N3)C(=O)NCC(=O)O DM8FSPV IK FJYRBJKWDXVHHO-UHFFFAOYSA-N DM8FSPV IU 2-[[7-oxo-5-(2-phenylethyl)-3H-[1,2,4]triazolo[1,5-a]pyridine-8-carbonyl]amino]acetic acid DM8FSPV CA CAS 1262132-81-9 DM8FSPV DE Anaemia DM5WCV4 ID DM5WCV4 DM5WCV4 DN JX-594 DM5WCV4 HS Phase 3 DM5WCV4 SN Pexastimogene devacirepvec DM5WCV4 CP Jennerex Biotherapeutics DM5WCV4 DE Liver cancer; Colorectal cancer; Hepatocellular carcinoma DM9J0KD ID DM9J0KD DM9J0KD DN K-103-IP DM9J0KD HS Phase 3 DM9J0KD DE Pain DMCRGY4 ID DMCRGY4 DMCRGY4 DN Karenitecin DMCRGY4 HS Phase 3 DMCRGY4 SN Karenitecin (TN) DMCRGY4 CP BioNumerik Pharmaceuticals DMCRGY4 DT Small molecular drug DMCRGY4 PC 148202 DMCRGY4 MW 448.6 DMCRGY4 FM C25H28N2O4Si DMCRGY4 IC InChI=1S/C25H28N2O4Si/c1-5-25(30)19-12-21-22-17(13-27(21)23(28)18(19)14-31-24(25)29)15(10-11-32(2,3)4)16-8-6-7-9-20(16)26-22/h6-9,12,30H,5,10-11,13-14H2,1-4H3/t25-/m0/s1 DMCRGY4 CS CC[C@@]1(C2=C(COC1=O)C(=O)N3CC4=C(C5=CC=CC=C5N=C4C3=C2)CC[Si](C)(C)C)O DMCRGY4 IK POADTFBBIXOWFJ-VWLOTQADSA-N DMCRGY4 IU (19S)-19-ethyl-19-hydroxy-10-(2-trimethylsilylethyl)-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4,6,8,10,15(20)-heptaene-14,18-dione DMCRGY4 CA CAS 203923-89-1 DMCRGY4 DE Lung cancer; Ovarian cancer DM8VO16 ID DM8VO16 DM8VO16 DN KH-902 DM8VO16 HS Phase 3 DM8VO16 SN Fumintide; KH-902 (intravitreal, AMD/DME), Kanghong Biotechnologies DM8VO16 CP Chengdu Kanghong Biotechnologies Co Ltd DM8VO16 DE Diabetic macular edema DMSDBPG ID DMSDBPG DMSDBPG DN KN046 DMSDBPG HS Phase 3 DMSDBPG CP Alphamab Oncology DMSDBPG DT Antibody DMSDBPG DE Non-small-cell lung cancer DMP5G1K ID DMP5G1K DMP5G1K DN KPS-0373 DMP5G1K HS Phase 3 DMP5G1K SN S-0373; TSH release modulator (spinocerebellar ataxia), Kissei; Thyrotropin-releasing hormone derivative (spinocerebellarataxia), Shionogi; Thyrotropin-releasing hormone derivative (Parkinson's disease), Shionogi DMP5G1K CP Shionogi & Co Ltd DMP5G1K DE Parkinson disease DMM2LTC ID DMM2LTC DMM2LTC DN KSI-301 DMM2LTC HS Phase 3 DMM2LTC CP Kodiak Sciences DMM2LTC DT Antibody biopolymer conjugate DMM2LTC DE Diabetic macular edema DMP3GI2 ID DMP3GI2 DMP3GI2 DN KW-3357 DMP3GI2 HS Phase 3 DMP3GI2 SN Coagulation factor inhibitor (iv, blood clotting disorder), Kyowa; Recombinant antithrombin (iv, blooding clottingdisorder), Kyowa Hakko Kirin DMP3GI2 CP Kyowa Hakko Kogyo Co Ltd DMP3GI2 DE Coagulation defect DMF0NA9 ID DMF0NA9 DMF0NA9 DN KX-01 DMF0NA9 HS Phase 3 DMF0NA9 CP Athenex Buffalo, NY DMF0NA9 DE Actinic keratosis DMWTPCA ID DMWTPCA DMWTPCA DN L-651582 DMWTPCA HS Phase 3 DMWTPCA SN Carboxyamidotriazole (CAI) DMWTPCA CP National Cancer Institute DMWTPCA DT Small molecular drug DMWTPCA PC 108144 DMWTPCA MW 424.7 DMWTPCA FM C17H12Cl3N5O2 DMWTPCA IC InChI=1S/C17H12Cl3N5O2/c18-10-3-1-9(2-4-10)15(26)13-11(19)5-8(6-12(13)20)7-25-16(21)14(17(22)27)23-24-25/h1-6H,7,21H2,(H2,22,27) DMWTPCA CS C1=CC(=CC=C1C(=O)C2=C(C=C(C=C2Cl)CN3C(=C(N=N3)C(=O)N)N)Cl)Cl DMWTPCA IK WNRZHQBJSXRYJK-UHFFFAOYSA-N DMWTPCA IU 5-amino-1-[[3,5-dichloro-4-(4-chlorobenzoyl)phenyl]methyl]triazole-4-carboxamide DMWTPCA CA CAS 99519-84-3 DMWTPCA DE Solid tumour/cancer DMI3YLK ID DMI3YLK DMI3YLK DN LA-EP2006 DMI3YLK HS Phase 3 DMI3YLK CP Sandoz DMI3YLK DE Neutropenia DMA2NYS ID DMA2NYS DMA2NYS DN Lampalizumab DMA2NYS HS Phase 3 DMA2NYS CP Genentech DMA2NYS DT Antibody DMA2NYS DE Geographic retinal atrophy DMFJLB6 ID DMFJLB6 DMFJLB6 DN Lanabecestat DMFJLB6 HS Phase 3 DMFJLB6 SN 1383982-64-6; UNII-X8SPJ492VF; X8SPJ492VF; LY3314814; Lanabecestat [USAN]; Lanabecestat (USAN); SCHEMBL9947930; GTPL7789; SCHEMBL9947926; CHEMBL3261045; SCHEMBL10249890; CHEMBL3989948; CHEMBL3349234; BDBM41542; BDBM41537; MolPort-044-560-403; BDBM136733; EX-A1471; s8193; ZINC95576075; BDBM50012629; US8865911, 20a Isomer 1; CS-7494; Lanabecestat(AZD3293,LY-3314814); HY-100740; LY 3314814; D10946; US8865911, 122; US8865911, 114; 4-methoxy-5'-methyl-6'-(5-(prop-1-yn-1-yl)pyridin-3-yl)-3'H-dispiro(cyclohexane DMFJLB6 CP AstraZeneca Wilmington, DE; Eli Lilly Indianapolis, IN DMFJLB6 PC 67979346 DMFJLB6 MW 412.5 DMFJLB6 FM C26H28N4O DMFJLB6 IC InChI=1S/C26H28N4O/c1-4-5-18-12-21(16-28-15-18)19-6-7-20-14-25(10-8-22(31-3)9-11-25)26(23(20)13-19)29-17(2)24(27)30-26/h6-7,12-13,15-16,22H,8-11,14H2,1-3H3,(H2,27,30)/t22?,25?,26-/m0/s1 DMFJLB6 CS CC#CC1=CC(=CN=C1)C2=CC3=C(CC4([C@]35N=C(C(=N5)N)C)CCC(CC4)OC)C=C2 DMFJLB6 IK WKDNQONLGXOZRG-BOPKNSRXSA-N DMFJLB6 CA CAS 1383982-64-6 DMFJLB6 DE Alzheimer disease DM4EGPN ID DM4EGPN DM4EGPN DN Lanperisone DM4EGPN HS Phase 3 DM4EGPN SN NK-433 DM4EGPN CP Nippon Kayaku Co Ltd DM4EGPN DT Small molecular drug DM4EGPN PC 198707 DM4EGPN MW 285.3 DM4EGPN FM C15H18F3NO DM4EGPN IC InChI=1S/C15H18F3NO/c1-11(10-19-8-2-3-9-19)14(20)12-4-6-13(7-5-12)15(16,17)18/h4-7,11H,2-3,8-10H2,1H3/t11-/m1/s1 DM4EGPN CS C[C@H](CN1CCCC1)C(=O)C2=CC=C(C=C2)C(F)(F)F DM4EGPN IK RYZCWZZJFAKYHX-LLVKDONJSA-N DM4EGPN IU (2R)-2-methyl-3-pyrrolidin-1-yl-1-[4-(trifluoromethyl)phenyl]propan-1-one DM4EGPN CA CAS 116287-14-0 DM4EGPN DE Musculoskeletal disorder DMMA0C7 ID DMMA0C7 DMMA0C7 DN Laquinamod DMMA0C7 HS Phase 3 DMMA0C7 SN Laquinimod sodium; Laquinimod Sodium Salt; 248282-07-7; UNII-4H914M0CSP; Laquinimod sodium [USAN]; TV-5600; 4H914M0CSP; ABR-215062 SODIUM; Laquinimod sodium (USAN); sodium 5-chloro-3-(ethyl(phenyl)carbamoyl)-1-methyl-2-oxo-1,2-dihydroquinolin-4-olate; SAIK-MS compound; ABR 215062 Sodium; SCHEMBL1991182; CHEMBL2103814; DTXSID50179538; QCR-166; JWHPPWBIIQMBQC-UHFFFAOYSA-M; AKOS027326368; TV 5600; FT-0670730; D08938; Sodium 5-chloro-3-(ethylphenylcarbamoyl)-1-methyl-2-oxo-1,2-dihydroquinolin- 4-olate; 3-Quinolinecarboxamide, 5-chlo DMMA0C7 CP Active Biotech; Teva DMMA0C7 DT Small molecular drug DMMA0C7 PC 23697158 DMMA0C7 MW 378.8 DMMA0C7 FM C19H16ClN2NaO3 DMMA0C7 IC InChI=1S/C19H17ClN2O3.Na/c1-3-22(12-8-5-4-6-9-12)19(25)16-17(23)15-13(20)10-7-11-14(15)21(2)18(16)24;/h4-11,23H,3H2,1-2H3;/q;+1/p-1 DMMA0C7 CS CCN(C1=CC=CC=C1)C(=O)C2=C(C3=C(C=CC=C3Cl)N(C2=O)C)[O-].[Na+] DMMA0C7 IK JWHPPWBIIQMBQC-UHFFFAOYSA-M DMMA0C7 IU sodium;5-chloro-3-[ethyl(phenyl)carbamoyl]-1-methyl-2-oxoquinolin-4-olate DMMA0C7 CA CAS 248282-07-7 DMMA0C7 DE Multiple sclerosis DM3IWS8 ID DM3IWS8 DM3IWS8 DN Laquinimod DM3IWS8 HS Phase 3 DM3IWS8 SN Laquinimod; 248281-84-7; 5-CHLORO-N-ETHYL-4-HYDROXY-1-METHYL-2-OXO-N-PHENYL-1,2-DIHYDROQUINOLINE-3-CARBOXAMIDE; ABR-215062; ABR 215062; 5-Chloro-4-hydroxy-1-methyl-2-oxo-1,2-dihydro-quinoline-3-carboxylic acid ethyl-phenyl-amide; UNII-908SY76S4G; CIVENTICHEM CV-4057; Laquinimod (ABR-215062); 908SY76S4G; N-Ethyl-N-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide; 5-chloro-n-ethyl-2-hydroxy-1-methyl-4-oxo-n-phenyl-1,4-dihydroquinoline-3-carboxamide; C19H17ClN2O3 DM3IWS8 CP Teva Neuroscience DM3IWS8 DT Small molecular drug DM3IWS8 PC 54677946 DM3IWS8 MW 356.8 DM3IWS8 FM C19H17ClN2O3 DM3IWS8 IC InChI=1S/C19H17ClN2O3/c1-3-22(12-8-5-4-6-9-12)19(25)16-17(23)15-13(20)10-7-11-14(15)21(2)18(16)24/h4-11,23H,3H2,1-2H3 DM3IWS8 CS CCN(C1=CC=CC=C1)C(=O)C2=C(C3=C(C=CC=C3Cl)N(C2=O)C)O DM3IWS8 IK GKWPCEFFIHSJOE-UHFFFAOYSA-N DM3IWS8 IU 5-chloro-N-ethyl-4-hydroxy-1-methyl-2-oxo-N-phenylquinoline-3-carboxamide DM3IWS8 CA CAS 248281-84-7 DM3IWS8 CB CHEBI:134738 DM3IWS8 DE Lupus; Multiple sclerosis; Huntington disease; Primary progressive multiple sclerosis DMH2EA1 ID DMH2EA1 DMH2EA1 DN Laromustine DMH2EA1 HS Phase 3 DMH2EA1 SN Cloretazine; Onrigin; Alkylating agents, Vion; SHP, Vion; Sulfonyl hydrazine prodrugs, Vion; VN-40101M; VNP-40101M; VNP-4090-CE; 90CE DMH2EA1 CP Vion Pharmaceuticals Inc DMH2EA1 DT Small molecular drug DMH2EA1 PC 3081349 DMH2EA1 MW 307.8 DMH2EA1 FM C6H14ClN3O5S2 DMH2EA1 IC InChI=1S/C6H14ClN3O5S2/c1-8-6(11)10(17(3,14)15)9(5-4-7)16(2,12)13/h4-5H2,1-3H3,(H,8,11) DMH2EA1 CS CNC(=O)N(N(CCCl)S(=O)(=O)C)S(=O)(=O)C DMH2EA1 IK PVCULFYROUOVGJ-UHFFFAOYSA-N DMH2EA1 IU 1-[2-chloroethyl(methylsulfonyl)amino]-3-methyl-1-methylsulfonylurea DMH2EA1 CA CAS 173424-77-6 DMH2EA1 DE Solid tumour/cancer DMAJM12 ID DMAJM12 DMAJM12 DN LATIN T1D DMAJM12 HS Phase 3 DMAJM12 SN NN9211 DMAJM12 CP Novo Nordisk DMAJM12 DE Type-1 diabetes DM09RKB ID DM09RKB DM09RKB DN LC-150444 DM09RKB HS Phase 3 DM09RKB SN LCD15-0444; Dipeptidyl peptidase IV inhibitors (oral, type 2 diabetes), LG Life Sciences DM09RKB CP LG Life Sciences Ltd DM09RKB DE Type-2 diabetes DMT4K0Z ID DMT4K0Z DMT4K0Z DN L-citrulline DMT4K0Z HS Phase 3 DMT4K0Z SN L-citrulline; citrulline; 372-75-8; H-cit-oh; delta-Ureidonorvaline; Sitrulline; N5-Carbamoyl-L-ornithine; L-Cytrulline; L(+)-citrulline; N5-(Aminocarbonyl)ornithine; N(delta)-Carbamylornithine; Citrulline, L-; alpha-Amino-delta-ureidovaleric acid; (S)-2-Amino-5-ureidopentanoic acid; N5-carbamoylornithine; d-ureidonorvaline; Ornithine, N5-(aminocarbonyl)-; L-2-Amino-5-ureidovaleric acid; L-Ornithine, N5-(aminocarbonyl)-; L-(+)-Citrulline; 2-Amino-5-ureidovaleric acid; L-citrullin; (2S)-2-amino-5-(carbamoylamino)pentanoic acid DMT4K0Z DT Small molecular drug DMT4K0Z PC 9750 DMT4K0Z MW 175.19 DMT4K0Z FM C6H13N3O3 DMT4K0Z IC InChI=1S/C6H13N3O3/c7-4(5(10)11)2-1-3-9-6(8)12/h4H,1-3,7H2,(H,10,11)(H3,8,9,12)/t4-/m0/s1 DMT4K0Z CS C(C[C@@H](C(=O)O)N)CNC(=O)N DMT4K0Z IK RHGKLRLOHDJJDR-BYPYZUCNSA-N DMT4K0Z IU (2S)-2-amino-5-(carbamoylamino)pentanoic acid DMT4K0Z CA CAS 372-75-8 DMT4K0Z CB CHEBI:16349 DMT4K0Z DE Acute lung injury DMFLJHQ ID DMFLJHQ DMFLJHQ DN LCQ908 DMFLJHQ HS Phase 3 DMFLJHQ SN Pradigastat; LCQ-908; 956136-95-1; UNII-2U23G6VNUZ; LCQ908; 2U23G6VNUZ; LCQ 908; Pradigastat [USAN:INN]; LCQ 908NXA; 2-[4-[4-[5-[[6-(trifluoromethyl)pyridin-3-yl]amino]pyridin-2-yl]phenyl]cyclohexyl]acetic acid; 2-{4-[4-(5-{[6-(trifluoromethyl)pyridin-3-yl]amino}pyridin-2-yl)phenyl]cyclohexyl}acetic acid; Pradigastat (USAN); LCQ908-NXA; SCHEMBL180536; GTPL7830; SCHEMBL1289309; CHEMBL2364624; SCHEMBL18286769; SCHEMBL16104874; GXALXAKNHIROPE-UHFFFAOYSA-N; BCP21089; ZINC253387875; AKOS027338695; DB12866; SB16971; CS-1222 DMFLJHQ CP Novartis DMFLJHQ DT Small molecular drug DMFLJHQ PC 53387035 DMFLJHQ MW 455.5 DMFLJHQ FM C25H24F3N3O2 DMFLJHQ IC InChI=1S/C25H24F3N3O2/c26-25(27,28)23-12-10-21(15-30-23)31-20-9-11-22(29-14-20)19-7-5-18(6-8-19)17-3-1-16(2-4-17)13-24(32)33/h5-12,14-17,31H,1-4,13H2,(H,32,33) DMFLJHQ CS C1CC(CCC1CC(=O)O)C2=CC=C(C=C2)C3=NC=C(C=C3)NC4=CN=C(C=C4)C(F)(F)F DMFLJHQ IK GXALXAKNHIROPE-UHFFFAOYSA-N DMFLJHQ IU 2-[4-[4-[5-[[6-(trifluoromethyl)pyridin-3-yl]amino]pyridin-2-yl]phenyl]cyclohexyl]acetic acid DMFLJHQ CA CAS 956136-95-1 DMFLJHQ DE Hepatitis C virus infection; Familial chylomicronemia syndrome; Hypertriglyceridemia DMQP0X5 ID DMQP0X5 DMQP0X5 DN Lebrikizumab DMQP0X5 HS Phase 3 DMQP0X5 SN RG3637 DMQP0X5 CP Aerovance DMQP0X5 DT Monoclonal antibody DMQP0X5 DE Chronic obstructive pulmonary disease; Severe asthma; Atopic dermatitis; Idiopathic pulmonary fibrosis DMMX75K ID DMMX75K DMMX75K DN LEE011 DMMX75K HS Phase 3 DMMX75K SN Ribociclib; LEE011; 1211441-98-3; LEE-011; Kisqali; Ribociclib(LEE011); UNII-TK8ERE8P56; LEE 011; 7-cyclopentyl-N,N-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide; TK8ERE8P56; Ribociclib (LEE011); AK174906; 7-cyclopentyl-N,N-dimethyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide; 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo [2,3-d]pyrimidine-6-carboxylic acid dimethylamide; Ribociclib [USAN:INN]; LEE011A; Tube013 DMMX75K CP Novartis AG DMMX75K DT Small molecular drug DMMX75K PC 44631912 DMMX75K MW 434.5 DMMX75K FM C23H30N8O DMMX75K IC InChI=1S/C23H30N8O/c1-29(2)22(32)19-13-16-14-26-23(28-21(16)31(19)17-5-3-4-6-17)27-20-8-7-18(15-25-20)30-11-9-24-10-12-30/h7-8,13-15,17,24H,3-6,9-12H2,1-2H3,(H,25,26,27,28) DMMX75K CS CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5 DMMX75K IK RHXHGRAEPCAFML-UHFFFAOYSA-N DMMX75K IU 7-cyclopentyl-N,N-dimethyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrrolo[2,3-d]pyrimidine-6-carboxamide DMMX75K CA CAS 1211441-98-3 DMMX75K DE Solid tumour/cancer; Breast cancer DMSCGM8 ID DMSCGM8 DMSCGM8 DN LentiGlobin DMSCGM8 HS Phase 3 DMSCGM8 SN Globin gene therapy (LentiPak, sickle cell/beta-thalassemia), Genetix; Globin gene therapy (LentiPak, sickle cell/beta-thalassemia), bluebird DMSCGM8 CP Bluebird bio DMSCGM8 DE Sickle-cell disorder; Beta thalassemia DMSRIT4 ID DMSRIT4 DMSRIT4 DN Lenzilumab DMSRIT4 HS Phase 3 DMSRIT4 SN lenzilumab; GTPL8935; KB003; KB-003 DMSRIT4 TC Antiviral Agents DMSRIT4 DT Monoclonal antibody DMSRIT4 DE Coronavirus Disease 2019 (COVID-19) DMOTCIU ID DMOTCIU DMOTCIU DN Lerisetron DMOTCIU HS Phase 3 DMOTCIU SN Lerisetron[inn]; 1-benzyl-2-piperazin-1-ylbenzimidazole DMOTCIU CP FAES Farma DMOTCIU DT Small molecular drug DMOTCIU PC 65997 DMOTCIU MW 292.4 DMOTCIU FM C18H20N4 DMOTCIU IC InChI=1S/C18H20N4/c1-2-6-15(7-3-1)14-22-17-9-5-4-8-16(17)20-18(22)21-12-10-19-11-13-21/h1-9,19H,10-14H2 DMOTCIU CS C1CN(CCN1)C2=NC3=CC=CC=C3N2CC4=CC=CC=C4 DMOTCIU IK PWWDCRQZITYKDV-UHFFFAOYSA-N DMOTCIU IU 1-benzyl-2-piperazin-1-ylbenzimidazole DMOTCIU CA CAS 143257-98-1 DMOTCIU DE Vomiting; Testicular germ cell tumour; Nausea DMAYC76 ID DMAYC76 DMAYC76 DN Levomequitazine DMAYC76 HS Phase 3 DMAYC76 SN V-0114; V-0114CP DMAYC76 CP Pierre Fabre SA DMAYC76 DT Small molecular drug DMAYC76 PC 6992284 DMAYC76 MW 322.5 DMAYC76 FM C20H22N2S DMAYC76 IC InChI=1S/C20H22N2S/c1-3-7-19-17(5-1)22(18-6-2-4-8-20(18)23-19)14-16-13-21-11-9-15(16)10-12-21/h1-8,15-16H,9-14H2/t16-/m0/s1 DMAYC76 CS C1CN2CCC1[C@@H](C2)CN3C4=CC=CC=C4SC5=CC=CC=C53 DMAYC76 IK HOKDBMAJZXIPGC-INIZCTEOSA-N DMAYC76 IU 10-[[(3S)-1-azabicyclo[2.2.2]octan-3-yl]methyl]phenothiazine DMAYC76 CA CAS 88598-74-7 DMAYC76 DE Seasonal allergic rhinitis DM103O8 ID DM103O8 DM103O8 DN Ligelizumab DM103O8 HS Phase 3 DM103O8 SN QGE031 DM103O8 CP Novartis DM103O8 DT Antibody DM103O8 DE Chronic idiopathic urticaria DMNM93X ID DMNM93X DMNM93X DN Linagliptin DMNM93X HS Phase 3 DMNM93X SN Linagliptin; BI 1356; Ondero; 668270-12-0; Tradjenta; BI-1356; Linagliptin (BI-1356); UNII-3X29ZEJ4R2; BI-1356-BS; CHEMBL237500; 3X29ZEJ4R2; CHEBI:68610; C25H28N8O2; Linagliptin DMNM93X TC Antiviral Agents DMNM93X DT Small molecular drug DMNM93X PC 10096344 DMNM93X MW 472.5 DMNM93X FM C25H28N8O2 DMNM93X IC InChI=1S/C25H28N8O2/c1-4-5-13-32-21-22(29-24(32)31-12-8-9-17(26)14-31)30(3)25(35)33(23(21)34)15-20-27-16(2)18-10-6-7-11-19(18)28-20/h6-7,10-11,17H,8-9,12-15,26H2,1-3H3/t17-/m1/s1 DMNM93X CS CC#CCN1C2=C(N=C1N3CCC[C@H](C3)N)N(C(=O)N(C2=O)CC4=NC5=CC=CC=C5C(=N4)C)C DMNM93X IK LTXREWYXXSTFRX-QGZVFWFLSA-N DMNM93X IU 8-[(3R)-3-aminopiperidin-1-yl]-7-but-2-ynyl-3-methyl-1-[(4-methylquinazolin-2-yl)methyl]purine-2,6-dione DMNM93X CA CAS 668270-12-0 DMNM93X CB CHEBI:68610 DMNM93X DE Coronavirus Disease 2019 (COVID-19) DM0ZOGX ID DM0ZOGX DM0ZOGX DN Linopirdine DM0ZOGX HS Phase 3 DM0ZOGX SN AVIVA; Linopirine; DuP-996 DM0ZOGX CP Bristol-Myers Squibb Pharma Co DM0ZOGX DT Small molecular drug DM0ZOGX PC 3932 DM0ZOGX MW 391.5 DM0ZOGX FM C26H21N3O DM0ZOGX IC InChI=1S/C26H21N3O/c30-25-26(18-20-10-14-27-15-11-20,19-21-12-16-28-17-13-21)23-8-4-5-9-24(23)29(25)22-6-2-1-3-7-22/h1-17H,18-19H2 DM0ZOGX CS C1=CC=C(C=C1)N2C3=CC=CC=C3C(C2=O)(CC4=CC=NC=C4)CC5=CC=NC=C5 DM0ZOGX IK YEJCDKJIEMIWRQ-UHFFFAOYSA-N DM0ZOGX IU 1-phenyl-3,3-bis(pyridin-4-ylmethyl)indol-2-one DM0ZOGX CA CAS 105431-72-9 DM0ZOGX CB CHEBI:34823 DM0ZOGX DE Cognitive impairment DMNF4UH ID DMNF4UH DMNF4UH DN Liprotamase DMNF4UH HS Phase 3 DMNF4UH SN LY3031642 DMNF4UH CP Lilly DMNF4UH DE Cystic fibrosis DMKZRBP ID DMKZRBP DMKZRBP DN Litoxetine DMKZRBP HS Phase 3 DMKZRBP SN Litoxetine; 86811-09-8; 4-(2-Naphthylmethoxy)piperidine; UNII-9980ST005G; CHEMBL471036; 9980ST005G; Litoxetinum; Litoxetina; Litoxetine [INN]; Litoxetinum [INN-Latin]; Litoxetina [INN-Spanish]; AC1L23OW; SCHEMBL119884; ZINC3647; CTK3E8854; DTXSID30235828; BDBM50278564; 4-(naphthalen-2-ylmethoxy)piperidine DMKZRBP DT Small molecular drug DMKZRBP PC 65650 DMKZRBP MW 241.33 DMKZRBP FM C16H19NO DMKZRBP IC InChI=1S/C16H19NO/c1-2-4-15-11-13(5-6-14(15)3-1)12-18-16-7-9-17-10-8-16/h1-6,11,16-17H,7-10,12H2 DMKZRBP CS C1CNCCC1OCC2=CC3=CC=CC=C3C=C2 DMKZRBP IK MJJDYOLPMGIWND-UHFFFAOYSA-N DMKZRBP IU 4-(naphthalen-2-ylmethoxy)piperidine DMKZRBP CA CAS 86811-09-8 DMKZRBP DE Mood disorder DMDN4ZP ID DMDN4ZP DMDN4ZP DN Lixivaptan DMDN4ZP HS Phase 3 DMDN4ZP SN 168079-32-1; VPA-985; WAY-VPA-985; UNII-8F5X4B082E; VPA985; CHEMBL49429; CRTX-080; VPA 985; 8F5X4B082E; N-[3-chloro-4-(6,11-dihydropyrrolo[2,1-c][1,4]benzodiazepine-5-carbonyl)phenyl]-5-fluoro-2-methylbenzamide; Lixar; Lixivaptan [USAN:INN]; Lixivaptan (USAN/INN); WAY VPA-985; Lixivaptan (VPA-985); AC1L59LM; WAY-VPA 985; GTPL2238; SCHEMBL1649340; DTXSID00168472; PPHTXRNHTVLQED-UHFFFAOYSA-N; ZINC600399; EX-A1129; BCP09167; BDBM50065115; AKOS022181388; AN-1842; CS-7512; API0009250; NCGC00485402-01; VPA985; BF-Derm1 DMDN4ZP CP Wyeth-Ayerst; Cardiokine DMDN4ZP DT Small molecular drug DMDN4ZP PC 172997 DMDN4ZP MW 473.9 DMDN4ZP FM C27H21ClFN3O2 DMDN4ZP IC InChI=1S/C27H21ClFN3O2/c1-17-8-9-19(29)13-23(17)26(33)30-20-10-11-22(24(28)14-20)27(34)32-16-21-6-4-12-31(21)15-18-5-2-3-7-25(18)32/h2-14H,15-16H2,1H3,(H,30,33) DMDN4ZP CS CC1=C(C=C(C=C1)F)C(=O)NC2=CC(=C(C=C2)C(=O)N3CC4=CC=CN4CC5=CC=CC=C53)Cl DMDN4ZP IK PPHTXRNHTVLQED-UHFFFAOYSA-N DMDN4ZP IU N-[3-chloro-4-(6,11-dihydropyrrolo[2,1-c][1,4]benzodiazepine-5-carbonyl)phenyl]-5-fluoro-2-methylbenzamide DMDN4ZP CA CAS 168079-32-1 DMDN4ZP DE Skin infection; Congestive heart failure; Hyponatraemia DM4OAIU ID DM4OAIU DM4OAIU DN LMI070 DM4OAIU HS Phase 3 DM4OAIU SN branaplam; Branaplam; 1562338-42-4; NVS-SM1; UNII-P12R69543A; LMI-070; P12R69543A; 5-(1H-pyrazol-4-yl)-2-(6-((2,2,6,6-tetramethylpiperidin-4-yl)oxy)pyridazin-3-yl)phenol; Branaplam [INN]; SCHEMBL15475826; LMI070 (NVS-SM1); STWTUEAWRAIWJG-UHFFFAOYSA-N; BCP19909; ZINC146605125; AKOS030526592; CS-5319; HY-19620; Phenol, 5-(1H-pyrazol-4-yl)-2-(6-((2,2,6,6-tetramethyl-4-piperidinyl)oxy)-3-pyridazinyl)- DM4OAIU CP Novartis Pharmaceuticals East Hanover, NJ DM4OAIU PC 135565042 DM4OAIU MW 393.5 DM4OAIU FM C22H27N5O2 DM4OAIU IC InChI=1S/C22H27N5O2/c1-21(2)10-16(11-22(3,4)27-21)29-20-8-7-18(25-26-20)17-6-5-14(9-19(17)28)15-12-23-24-13-15/h5-9,12-13,16,27-28H,10-11H2,1-4H3,(H,23,24) DM4OAIU CS CC1(CC(CC(N1)(C)C)OC2=NN=C(C=C2)C3=C(C=C(C=C3)C4=CNN=C4)O)C DM4OAIU IK STWTUEAWRAIWJG-UHFFFAOYSA-N DM4OAIU IU 5-(1H-pyrazol-4-yl)-2-[6-(2,2,6,6-tetramethylpiperidin-4-yl)oxypyridazin-3-yl]phenol DM4OAIU CA CAS 1562338-42-4 DM4OAIU DE Spinal muscular atrophy DMOFIBM ID DMOFIBM DMOFIBM DN LMT-X DMOFIBM HS Phase 3 DMOFIBM SN Second-generation tau aggregation inhibitor (Alzheimer's disease); Second-generation tau aggregation inhibitor (Alzheimer's disease), TauRx DMOFIBM CP TauRx Therapeutics Pte Ltd DMOFIBM DE Acute myeloid leukaemia; Alzheimer disease DM9EZM0 ID DM9EZM0 DM9EZM0 DN LNP023 DM9EZM0 HS Phase 3 DM9EZM0 SN Iptacopan; LNP-023; UNII-8E05T07Z6W; 8E05T07Z6W; 1644670-37-0; 4-((2S,4S)-4-ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)piperidin-2-yl)benzoic acid; 4-[(2~{S},4~{S})-4-ethoxy-1-[(5-methoxy-7-methyl-1~{H}-indol-4-yl)methyl]piperidin-2-yl]benzoic acid; 4-[(2S,4S)-4-ethoxy-1-[(5-methoxy-7-methyl-1H-indol-4-yl)methyl]piperidin-2-yl]benzoic acid; Iptacopan [INN]; CHEMBL4594448; SCHEMBL16400416; GTPL10710; US9682968, Example-26a; BDBM160475; ZINC223246892; compound 41 [PMID: 32073845]; HY-127105; CS-0093107; 4-((2S,4S)-(4-ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)piperidin-2-yl))benzoic acid; Benzoic acid, 4-((2S,4S)-4-ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)-2-piperidinyl)-; JGQ DM9EZM0 CP Novartis DM9EZM0 DT Small molecular drug DM9EZM0 PC 90467622 DM9EZM0 MW 422.5 DM9EZM0 FM C25H30N2O4 DM9EZM0 IC InChI=1S/C25H30N2O4/c1-4-31-19-10-12-27(22(14-19)17-5-7-18(8-6-17)25(28)29)15-21-20-9-11-26-24(20)16(2)13-23(21)30-3/h5-9,11,13,19,22,26H,4,10,12,14-15H2,1-3H3,(H,28,29)/t19-,22-/m0/s1 DM9EZM0 CS CCO[C@H]1CCN([C@@H](C1)C2=CC=C(C=C2)C(=O)O)CC3=C(C=C(C4=C3C=CN4)C)OC DM9EZM0 IK RENRQMCACQEWFC-UGKGYDQZSA-N DM9EZM0 IU 4-[(2S,4S)-4-ethoxy-1-[(5-methoxy-7-methyl-1H-indol-4-yl)methyl]piperidin-2-yl]benzoic acid DM9EZM0 CA CAS 1644670-37-0 DM9EZM0 DE IgA nephropathy; Paroxysmal nocturnal haemoglobinuria DMQNVR8 ID DMQNVR8 DMQNVR8 DN Lopinavir + ritonavir DMQNVR8 HS Phase 3 DMQNVR8 SN Aluviran + norvir; Kaletra DMQNVR8 TC Antiviral Agents DMQNVR8 DT Combination drug DMQNVR8 PC 11979606 DMQNVR8 MW 1349.7 DMQNVR8 FM C74H96N10O10S2 DMQNVR8 IC InChI=1S/C37H48N6O5S2.C37H48N4O5/c1-24(2)33(42-36(46)43(5)20-29-22-49-35(40-29)25(3)4)34(45)39-28(16-26-12-8-6-9-13-26)18-32(44)31(17-27-14-10-7-11-15-27)41-37(47)48-21-30-19-38-23-50-30;1-25(2)34(41-20-12-19-38-37(41)45)36(44)39-30(21-28-15-7-5-8-16-28)23-32(42)31(22-29-17-9-6-10-18-29)40-33(43)24-46-35-26(3)13-11-14-27(35)4/h6-15,19,22-25,28,31-33,44H,16-18,20-21H2,1-5H3,(H,39,45)(H,41,47)(H,42,46);5-11,13-18,25,30-32,34,42H,12,19-24H2,1-4H3,(H,38,45)(H,39,44)(H,40,43)/t28-,31-,32-,33-;30-,31-,32-,34-/m00/s1 DMQNVR8 CS CC1=C(C(=CC=C1)C)OCC(=O)N[C@@H](CC2=CC=CC=C2)[C@H](C[C@H](CC3=CC=CC=C3)NC(=O)[C@H](C(C)C)N4CCCNC4=O)O.CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O DMQNVR8 IK OFFWOVJBSQMVPI-RMLGOCCBSA-N DMQNVR8 IU (2S)-N-[(2S,4S,5S)-5-[[2-(2,6-dimethylphenoxy)acetyl]amino]-4-hydroxy-1,6-diphenylhexan-2-yl]-3-methyl-2-(2-oxo-1,3-diazinan-1-yl)butanamide;1,3-thiazol-5-ylmethyl N-[(2S,3S,5S)-3-hydroxy-5-[[(2S)-3-methyl-2-[[methyl-[(2-propan-2-yl-1,3-thiazol-4-yl)methyl]carbamoyl]amino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate DMQNVR8 CA CAS 369372-47-4 DMQNVR8 DE Coronavirus Disease 2019 (COVID-19) DMX0O9U ID DMX0O9U DMX0O9U DN Lopinavir + ritonavir + favipiravir DMX0O9U HS Phase 3 DMX0O9U SN Aluviran + norvir + T-705 DMX0O9U TC Antiviral Agents DMX0O9U DT Combination drug DMX0O9U DE Coronavirus Disease 2019 (COVID-19) DMNY05F ID DMNY05F DMNY05F DN Lopinavir + ritonavir + oseltamivir DMNY05F HS Phase 3 DMNY05F SN Aluviran + norvir + tamiflu DMNY05F TC Antiviral Agents DMNY05F DT Combination drug DMNY05F DE Coronavirus Disease 2019 (COVID-19) DMTL5Q0 ID DMTL5Q0 DMTL5Q0 DN Losartan DMTL5Q0 HS Phase 3 DMTL5Q0 SN Cozaar; Cozaar (TN); DUP 89; DuP 753; DuP-753; Hyzaar; JMS50MPO89; LOSARTAN POTASSIUM; Lortaan; Losartan (INN); 114798-26-4; C22H23ClN6O; CHEBI:6541; CL23623; Losartan [INN:BAN]; Losartan monopotassium salt; Losartic; Losartic (TN); MK-954; MK954; UNII-JMS50MPO89; [3H]losartan DMTL5Q0 CP Merck & Co DMTL5Q0 TC Antiviral Agents DMTL5Q0 DT Small molecular drug DMTL5Q0 PC 3961 DMTL5Q0 MW 422.9 DMTL5Q0 FM C22H23ClN6O DMTL5Q0 IC InChI=1S/C22H23ClN6O/c1-2-3-8-20-24-21(23)19(14-30)29(20)13-15-9-11-16(12-10-15)17-6-4-5-7-18(17)22-25-27-28-26-22/h4-7,9-12,30H,2-3,8,13-14H2,1H3,(H,25,26,27,28) DMTL5Q0 CS CCCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)CO)Cl DMTL5Q0 IK PSIFNNKUMBGKDQ-UHFFFAOYSA-N DMTL5Q0 IU [2-butyl-5-chloro-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol DMTL5Q0 CA CAS 114798-26-4 DMTL5Q0 CB CHEBI:6541 DMTL5Q0 DE Discovery agent; Hypertension; Coronavirus Disease 2019 (COVID-19) DMIL37Z ID DMIL37Z DMIL37Z DN Losmapimod DMIL37Z HS Phase 3 DMIL37Z SN 585543-15-3; GSK-AHAB; GW856553; GW856553X; UNII-F2DQF16BXE; F2DQF16BXE; GW-856553; 6-[5-(cyclopropylcarbamoyl)-3-fluoro-2-methylphenyl]-N-(2,2-dimethylpropyl)pyridine-3-carboxamide; Losmapimod [USAN:INN]; Losmapimod (GW856553X); GSKAHAB; GW 856553X; SB 856553; Losmapimod (USAN/INN); SCHEMBL1070401; GTPL7835; CHEMBL1088752; EX-A486; CHEBI:131167; KKYABQBFGDZVNQ-UHFFFAOYSA-N; MolPort-009-194-138; losmapimod pound> HMS3653G19; BCP09909; AOB87105; ZINC35793138; s7215; BDBM50418610; 2523AH; AKOS015994587 DMIL37Z CP GSK DMIL37Z DT Small molecular drug DMIL37Z PC 11552706 DMIL37Z MW 383.5 DMIL37Z FM C22H26FN3O2 DMIL37Z IC InChI=1S/C22H26FN3O2/c1-13-17(9-15(10-18(13)23)21(28)26-16-6-7-16)19-8-5-14(11-24-19)20(27)25-12-22(2,3)4/h5,8-11,16H,6-7,12H2,1-4H3,(H,25,27)(H,26,28) DMIL37Z CS CC1=C(C=C(C=C1F)C(=O)NC2CC2)C3=NC=C(C=C3)C(=O)NCC(C)(C)C DMIL37Z IK KKYABQBFGDZVNQ-UHFFFAOYSA-N DMIL37Z IU 6-[5-(cyclopropylcarbamoyl)-3-fluoro-2-methylphenyl]-N-(2,2-dimethylpropyl)pyridine-3-carboxamide DMIL37Z CA CAS 585543-15-3 DMIL37Z CB CHEBI:131167 DMIL37Z DE Acute coronary syndrome DMWGRQD ID DMWGRQD DMWGRQD DN LU AE58054 DMWGRQD HS Phase 3 DMWGRQD SN Idalopirdine; Lu AE58054; 467459-31-0; LU-AE58054; UNII-59WCJ0YNWM; LU AE 58054; 59WCJ0YNWM; 2-(6-fluoro-1H-indol-3-yl)-N-[[3-(2,2,3,3-tetrafluoropropoxy)phenyl]methyl]ethanamine; 1H-Indole-3-ethanamine,6-fluoro-N-[[3-(2,2,3,3-tetrafluoropropoxy)phenyl]methyl]-; 1H-Indole-3-ethanamine, 6-fluoro-N-[[3-(2,2,3,3-tetrafluoropropoxy)phenyl]methyl]-; Idalopirdine [USAN:INN]; Idlopirdine; Idalopirdine (USAN/INN); Lu AE58054;Idalopirdine; SCHEMBL762762; Idalopirdine(Lu-AE-58054); GTPL8689; CHEMBL3286580; C20H19F5N2O; EX-A844 DMWGRQD CP Lundbeck DMWGRQD DT Small molecular drug DMWGRQD PC 21071390 DMWGRQD MW 398.4 DMWGRQD FM C20H19F5N2O DMWGRQD IC InChI=1S/C20H19F5N2O/c21-15-4-5-17-14(11-27-18(17)9-15)6-7-26-10-13-2-1-3-16(8-13)28-12-20(24,25)19(22)23/h1-5,8-9,11,19,26-27H,6-7,10,12H2 DMWGRQD CS C1=CC(=CC(=C1)OCC(C(F)F)(F)F)CNCCC2=CNC3=C2C=CC(=C3)F DMWGRQD IK YBAWYTYNMZWMMJ-UHFFFAOYSA-N DMWGRQD IU 2-(6-fluoro-1H-indol-3-yl)-N-[[3-(2,2,3,3-tetrafluoropropoxy)phenyl]methyl]ethanamine DMWGRQD CA CAS 467459-31-0 DMWGRQD DE Schizophrenia DMNAYUJ ID DMNAYUJ DMNAYUJ DN Lu AF35700 DMNAYUJ HS Phase 3 DMNAYUJ CP Lundbeck Deerfield, IL DMNAYUJ DE Schizophrenia DMMLXA9 ID DMMLXA9 DMMLXA9 DN LX-4211 DMMLXA9 HS Phase 3 DMMLXA9 SN Sotagliflozin; 1018899-04-1; LX-4211; LX4211; UNII-6B4ZBS263Y; 6B4ZBS263Y; AK170751; (2s,3r,4r,5s,6r)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2h-pyran-3,4,5-triol; b-L-Xylopyranoside, methyl 5-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-1-thio-, (5S)-;b-L-Xylopyranoside, methyl 5-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-1-thio-, (5S)-; Sotagliflozin [USAN:INN]; beta-l-Xylopyranoside, methyl 5-C-(4-chloro-3-((4-ethoxyphenyl)methyl)phenyl)-1-thio-, (5S)-; LX 4211; Tube103; LP 802034 DMMLXA9 CP Lexicon Pharmaceuticals DMMLXA9 DT Small molecular drug DMMLXA9 PC 24831714 DMMLXA9 MW 424.9 DMMLXA9 FM C21H25ClO5S DMMLXA9 IC InChI=1S/C21H25ClO5S/c1-3-26-15-7-4-12(5-8-15)10-14-11-13(6-9-16(14)22)20-18(24)17(23)19(25)21(27-20)28-2/h4-9,11,17-21,23-25H,3,10H2,1-2H3/t17-,18-,19+,20+,21-/m1/s1 DMMLXA9 CS CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)SC)O)O)O)Cl DMMLXA9 IK QKDRXGFQVGOQKS-CRSSMBPESA-N DMMLXA9 IU (2S,3R,4R,5S,6R)-2-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-6-methylsulfanyloxane-3,4,5-triol DMMLXA9 CA CAS 1018899-04-1 DMMLXA9 DE Type-2 diabetes; Cardiovascular disease; Type-1 diabetes DM1BXMY ID DM1BXMY DM1BXMY DN LY2605541 DM1BXMY HS Phase 3 DM1BXMY SN UNII-6Y83I5F10I; Insulin peglispro [USAN:INN]; INSULIN PEGLISPRO; LY2605541; 6Y83I5F10I; 1200440-65-8; LY 2605541; Polyethylene glycol 20,000 pegylated insulin lispro:(28B-(6-N-((omega-methoxypoly(oxyethylene))carbonyl)-L-lysine),29B-L-proline)human insulin; Poly(oxy-1,2-ethanediyl), alpha-hydro-omega-methoxy-, 28B-ester with 28B-(N6-carboxy-L- lysine)-29B-L-prolineinsulin (human) DM1BXMY CP Boehringer Ingelheim Pharmaceuticals; Eli Lilly DM1BXMY DT Small molecular drug DM1BXMY PC 71301236 DM1BXMY MW 5892 DM1BXMY FM C261H387N65O79S6 DM1BXMY IC InChI=1S/C261H387N65O79S6/c1-30-134(23)208(317-196(343)107-262)255(397)321-207(133(21)22)251(393)290-160(76-83-203(353)354)219(361)285-157(72-79-192(265)339)223(365)312-186-119-409-410-120-187-246(388)309-181(114-328)243(385)297-164(91-126(7)8)226(368)298-170(98-143-54-62-149(333)63-55-143)229(371)286-155(70-77-190(263)337)220(362)293-163(90-125(5)6)224(366)288-159(75-82-202(351)352)222(364)306-177(104-193(266)340)236(378)301-172(100-145-58-66-151(335)67-59-145)232(374)313-185-118-408-407-117-184(216(358)276-110-197(344)281-154(73-80-200(347)348)218(360)284-153(52-43-85-273-260(269)270)214(356)275-111-198(345)282-168(95-140-45-35-32-36-46-140)228(370)300-169(96-141-47-37-33-38-48-141)231(373)302-174(101-146-60-68-152(336)69-61-146)241(383)323-210(137(26)330)256(398)291-161(51-41-42-84-274-261(403)405-88-87-404-29)258(400)326-86-44-53-189(326)249(391)325-212(139(28)332)259(401)402)315-253(395)206(132(19)20)319-238(380)166(93-128(11)12)295-230(372)171(99-144-56-64-150(334)65-57-144)299-225(367)162(89-124(3)4)292-213(355)136(25)280-217(359)158(74-81-201(349)350)289-250(392)204(130(15)16)318-239(381)167(94-129(13)14)296-234(376)176(103-148-109-272-123-279-148)305-242(384)180(113-327)283-199(346)112-277-215(357)183(116-406-411-121-188(314-247(186)389)248(390)324-211(138(27)331)257(399)310-182(115-329)244(386)322-209(135(24)31-2)254(396)316-187)311-227(369)165(92-127(9)10)294-233(375)175(102-147-108-271-122-278-147)304-221(363)156(71-78-191(264)338)287-235(377)179(106-195(268)342)308-252(394)205(131(17)18)320-240(382)173(97-142-49-39-34-40-50-142)303-237(379)178(105-194(267)341)307-245(185)387/h32-40,45-50,54-69,108-109,122-139,153-189,204-212,327-336H,30-31,41-44,51-53,70-107,110-121,262H2,1-29H3,(H2,263,337)(H2,264,338)(H2,265,339)(H2,266,340)(H2,267,341)(H2,268,342)(H,271,278)(H,272,279)(H,274,403)(H,275,356)(H,276,358)(H,277,357)(H,280,359)(H,281,344)(H,282,345)(H,283,346)(H,284,360)(H,285,361)(H,286,371)(H,287,377)(H,288,366)(H,289,392)(H,290,393)(H,291,398)(H,292,355)(H,293,362)(H,294,375)(H,295,372)(H,296,376)(H,297,385)(H,298,368)(H,299,367)(H,300,370)(H,301,378)(H,302,373)(H,303,379)(H,304,363)(H,305,384)(H,306,364)(H,307,387)(H,308,394)(H,309,388)(H,310,399)(H,311,369)(H,312,365)(H,313,374)(H,314,389)(H,315,395)(H,316,396)(H,317,343)(H,318,381)(H,319,380)(H,320,382)(H,321,397)(H,322,386)(H,323,383)(H,324,390)(H,325,391)(H,347,348)(H,349,350)(H,351,352)(H,353,354)(H,401,402)(H4,269,270,273)/t134-,135-,136-,137+,138+,139+,153-,154-,155-,156-,157-,158-,159-,160-,161-,162-,163-,164-,165-,166-,167-,168-,169-,170-,171-,172-,173-,174-,175-,176-,177-,178-,179-,180-,181-,182-,183-,184-,185-,186-,187-,188-,189-,204-,205-,206-,207-,208-,209-,210-,211-,212-/m0/s1 DM1BXMY CS CC[C@H](C)[C@H]1C(=O)N[C@H]2CSSC[C@@H](C(=O)N[C@@H](CSSC[C@H]3C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N3)CC(C)C)CC4=CN=CN4)CCC(=O)N)CC(=O)N)C(C)C)CC5=CC=CC=C5)CC(=O)N)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC2=O)CO)CC(C)C)CC6=CC=C(C=C6)O)CCC(=O)N)CC(C)C)CCC(=O)O)CC(=O)N)CC7=CC=C(C=C7)O)C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CC8=CC=CC=C8)C(=O)N[C@@H](CC9=CC=CC=C9)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCNC(=O)OCCOC)C(=O)N2CCC[C@H]2C(=O)N[C@@H]([C@@H](C)O)C(=O)O)C(C)C)CC(C)C)CC2=CC=C(C=C2)O)CC(C)C)C)CCC(=O)O)C(C)C)CC(C)C)CC2=CN=CN2)CO)C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CO)[C@@H](C)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)CN DM1BXMY IK UFIPGFMPJACHTH-HXDLXPBZSA-N DM1BXMY IU (4S)-4-[[2-[[(aS,1R,3aS,6R,6aS,9S,12S,13aR,15S,18R,21S,24S,27S,30S,33S,36S,39S,42S,45R,50R,53S,56S,59S,62S,65S,68S,71S,74S,77S,80S,88S,91S,94S,97S)-13a-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[(2-aminoacetyl)amino]-3-methylpentanoyl]amino]-3-methylbutanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]-6a,39,97-tris(2-amino-2-oxoethyl)-30,94-bis(3-amino-3-oxopropyl)-3a-benzyl-15-[(2S)-butan-2-yl]-36,68-bis(2-carboxyethyl)-9-[(1R)-1-hydroxyethyl]-12,21,80-tris(hydroxymethyl)-27,42,59-tris[(4-hydroxyphenyl)methyl]-77,91-bis(1H-imidazol-5-ylmethyl)-65-methyl-24,33,56,62,74,88-hexakis(2-methylpropyl)-2a,5a,7,8a,10,13,14a,16,19,22,25,28,31,34,37,40,43,52,55,58,61,64,67,70,73,76,79,82,85,87,90,93,96,99-tetratriacontaoxo-a,53,71-tri(propan-2-yl)-3,4,10a,11a,47,48-hexathia-1a,4a,7a,8,11,14,15a,17,20,23,26,29,32,35,38,41,44,51,54,57,60,63,66,69,72,75,78,81,84,86,89,92,95,98-tetratriacontazatricyclo[43.40.23.76,18]pentadecahectane-50-carbonyl]amino]acetyl]amino]-5-[[(2S)-5-carbamimidamido-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-1-[(2S)-2-[[(1S,2R)-1-carboxy-2-hydroxypropyl]carbamoyl]pyrrolidin-1-yl]-6-(2-methoxyethoxycarbonylamino)-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]amino]-1-oxopentan-2-yl]amino]-5-oxopentanoic acid DM1BXMY DE Type-1/2 diabetes DMEZ0H5 ID DMEZ0H5 DMEZ0H5 DN LY2963016 DMEZ0H5 HS Phase 3 DMEZ0H5 CP Boehringer Ingelheim Pharmaceuticals; Eli Lilly DMEZ0H5 DE Type-1/2 diabetes DMWZIRJ ID DMWZIRJ DMWZIRJ DN LY404039 DMWZIRJ HS Phase 3 DMWZIRJ SN LY 404039; LY-404039; (1R,2S,5R,6R)-2-amino-4,4-dioxo-4$l^{6}-thiabicyclo[3.1.0]hexane-2,6-dicarboxylic Acid; 4-amino-2-thiabicyclo(3.1.0)hexane-4,6-dicarboxylic acid DMWZIRJ CP Eli Lilly DMWZIRJ DT Small molecular drug DMWZIRJ PC 9834591 DMWZIRJ MW 235.22 DMWZIRJ FM C7H9NO6S DMWZIRJ IC InChI=1S/C7H9NO6S/c8-7(6(11)12)1-15(13,14)4-2(3(4)7)5(9)10/h2-4H,1,8H2,(H,9,10)(H,11,12)/t2-,3-,4+,7+/m1/s1 DMWZIRJ CS C1[C@]([C@@H]2[C@H]([C@@H]2S1(=O)=O)C(=O)O)(C(=O)O)N DMWZIRJ IK AVDUGNCTZRCAHH-MDASVERJSA-N DMWZIRJ IU (1R,4S,5S,6S)-4-amino-2,2-dioxo-2lambda6-thiabicyclo[3.1.0]hexane-4,6-dicarboxylic acid DMWZIRJ CA CAS 635318-11-5 DMWZIRJ CB CHEBI:94640 DMWZIRJ DE Schizophrenia DM7WORZ ID DM7WORZ DM7WORZ DN LY-686017 DM7WORZ HS Phase 3 DM7WORZ SN NK1 antagonist (anxiety/alcoholism), Eli Lilly DM7WORZ CP Eli Lilly & Co DM7WORZ DT Small molecular drug DM7WORZ PC 9916461 DM7WORZ MW 587.9 DM7WORZ FM C28H16ClF6N5O DM7WORZ IC InChI=1S/C28H16ClF6N5O/c29-22-6-2-1-4-20(22)26(41)21-5-3-9-37-23(21)24-25(17-7-10-36-11-8-17)40(39-38-24)15-16-12-18(27(30,31)32)14-19(13-16)28(33,34)35/h1-14H,15H2 DM7WORZ CS C1=CC=C(C(=C1)C(=O)C2=C(N=CC=C2)C3=C(N(N=N3)CC4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F)C5=CC=NC=C5)Cl DM7WORZ IK CAVRKWRKTNINFF-UHFFFAOYSA-N DM7WORZ IU [2-[1-[[3,5-bis(trifluoromethyl)phenyl]methyl]-5-pyridin-4-yltriazol-4-yl]pyridin-3-yl]-(2-chlorophenyl)methanone DM7WORZ CA CAS 622370-35-8 DM7WORZ DE Alcohol dependence; Atopic dermatitis DM6LVCQ ID DM6LVCQ DM6LVCQ DN LY-CoV555 DM6LVCQ HS Phase 3 DM6LVCQ SN LY3819253 DM6LVCQ CP Lilly; AbCellera DM6LVCQ DT Antibody DM6LVCQ DE Coronavirus Disease 2019 (COVID-19) DMGNC6T ID DMGNC6T DMGNC6T DN M-0011 DMGNC6T HS Phase 3 DMGNC6T SN N-0011; RhLAMAN, Zymenex; Recombinant human alpha-mannosidase (alpha mannosidosis), Zymenex DMGNC6T CP Zymenex A/S DMGNC6T DE Alpha-mannosidosis DM7ZFBA ID DM7ZFBA DM7ZFBA DN M100907 DM7ZFBA HS Phase 3 DM7ZFBA SN Volinanserin; 139290-65-6; UNII-EW71EE171J; (R)-(2,3-Dimethoxyphenyl)(1-(4-fluorophenethyl)piperidin-4-yl)methanol; CHEMBL74355; EW71EE171J; (R)-(+)-ALPHA-(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUORO-PHENYL)ETHYL]-4-PIPERIDINE METHANOL; M-100907; (R)-(2,3-dimethoxyphenyl)-[1-[2-(4-fluorophenyl)ethyl]piperidin-4-yl]methanol; Volinanserin [INN]; Serotonin 5-HT2 Receptor Antagonists; VOLINANSERIN DM7ZFBA DT Small molecular drug DM7ZFBA PC 5311271 DM7ZFBA MW 373.5 DM7ZFBA FM C22H28FNO3 DM7ZFBA IC InChI=1S/C22H28FNO3/c1-26-20-5-3-4-19(22(20)27-2)21(25)17-11-14-24(15-12-17)13-10-16-6-8-18(23)9-7-16/h3-9,17,21,25H,10-15H2,1-2H3/t21-/m1/s1 DM7ZFBA CS COC1=CC=CC(=C1OC)[C@@H](C2CCN(CC2)CCC3=CC=C(C=C3)F)O DM7ZFBA IK HXTGXYRHXAGCFP-OAQYLSRUSA-N DM7ZFBA IU (R)-(2,3-dimethoxyphenyl)-[1-[2-(4-fluorophenyl)ethyl]piperidin-4-yl]methanol DM7ZFBA CA CAS 139290-65-6 DM7ZFBA DE Sleep-wake disorder DMZ6VD5 ID DMZ6VD5 DMZ6VD5 DN M-518101 DMZ6VD5 HS Phase 3 DMZ6VD5 CP Maruho Co Ltd DMZ6VD5 DE Psoriasis vulgaris; Plaque psoriasis DM1PRT6 ID DM1PRT6 DM1PRT6 DN M710 DM1PRT6 HS Phase 3 DM1PRT6 SN 637-01-4; N,N,N',N'-Tetramethyl-p-phenylenediamine dihydrochloride; N1,N1,N4,N4-tetramethylbenzene-1,4-diamine dihydrochloride; N,N,N',N'-Tetramethyl-1,4-phenylenediamine Dihydrochloride; UNII-66W8HKA51X; MFCD00012482; 66W8HKA51X; tetramethyl-p-phenylenediamine dihydrochloride; 1,4-Benzenediamine, N,N,N',N'-tetramethyl-, dihydrochloride; NSC36730; 1,4-Benzenediamine, N1,N1,N4,N4-tetramethyl-, hydrochloride (1:2); 1-N,1-N,4-N,4-N-tetramethylbenzene-1,4-diamine;dihydrochloride; Wursters Reagent; N,N,N',N'-Tetramethyl-p-phenylenediamine dihydrochloride, 99%; EINECS 211-274-8; NSC 36730; TMPPD; ACMC-1B8O0; SCHEMBL379125; DTXSID2060915; N,N,N',N'-Tetramethyl-para-phenylenediamine dihydrochloride; ANW-34710; AKOS005254702; MCULE-3840175847; VZ32824; AS-14819; SY061584; 3-(4-Bromo-1H-pyrazol-1-yl)propanoicacid; DB-054526; FT-0629355; ST50308398; Tetramethyl-p-phenylene diamine hydrochloride; 1,4-Bis(dimethylamino)benzene dihydrochloride; X-4255; N,N,N',N'-Tetramethyl-p-phenylenediamine 2HCl; N,N,N',N'-Tetramethyl-p-phenylenediamine DiHCl; W-104885; Q27264036; [4-(dimethylamino)phenyl]dimethylamine, chloride, chloride; N,N,N\\',N\\'-Tetramethyl-p-phenylenediamine dihydrochloride; N1,N1,N4,N4-Tetramethyl-1,4-benzenediamine Dihydrochloride; p-Phenylenediamine, N,N,N',N'-tetramethyl-, dihydrochloride (8CI); N,N,N',N'-Tetramethyl-p-phenylenediamine dihydrochloride, >=95%, powder; N,N,N',N'-Tetramethyl-p-phenylenediamine dihydrochloride, >=97.0% (AT) DM1PRT6 CP Momenta Pharmaceuticals; Mylan DM1PRT6 DT Small molecular drug DM1PRT6 PC 71561 DM1PRT6 MW 237.17 DM1PRT6 FM C10H18Cl2N2 DM1PRT6 IC InChI=1S/C10H16N2.2ClH/c1-11(2)9-5-7-10(8-6-9)12(3)4;;/h5-8H,1-4H3;2*1H DM1PRT6 CS CN(C)C1=CC=C(C=C1)N(C)C.Cl.Cl DM1PRT6 IK FBHKTSXMTASXFJ-UHFFFAOYSA-N DM1PRT6 IU 1-N,1-N,4-N,4-N-tetramethylbenzene-1,4-diamine;dihydrochloride DM1PRT6 CA CAS 637-01-4 DM1PRT6 DE Diabetic macular edema DM8D13S ID DM8D13S DM8D13S DN MABp1 DM8D13S HS Phase 3 DM8D13S CP Xbiotech Austin, TX DM8D13S DE Type-2 diabetes; Acne vulgaris; Atopic dermatitis; Hidradenitis suppurativa; Plaque psoriasis; Pyoderma gangrenosum; Colorectal cancer; Peripheral vascular disease DMVXUR0 ID DMVXUR0 DMVXUR0 DN Magrolimab DMVXUR0 HS Phase 3 DMVXUR0 SN GS-4721 DMVXUR0 CP Gilead Sciences DMVXUR0 DT Antibody DMVXUR0 DE Acute myeloid leukaemia; Myelodysplastic syndrome DMJPGUA ID DMJPGUA DMJPGUA DN Manidipine DMJPGUA HS Phase 3 DMJPGUA SN manidipine; 89226-50-6; Franidipine; 120092-68-4; Manidipine 6300; 3-(2-(4-Benzhydrylpiperazin-1-yl)ethyl) 5-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; Iperten; Artedil; Manidipine [INN]; Manidipine (Manyper); C35H38N4O6; CHEMBL312176; Manidipine (INN); 2-(4-Diphenylmethyl-1-piperazinyl)ethyl methyl-1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylate; 2-[4-(diphenylmethyl)piperazin-1-yl]ethyl methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridin DMJPGUA DT Small molecular drug DMJPGUA PC 4008 DMJPGUA MW 610.7 DMJPGUA FM C35H38N4O6 DMJPGUA IC InChI=1S/C35H38N4O6/c1-24-30(34(40)44-3)32(28-15-10-16-29(23-28)39(42)43)31(25(2)36-24)35(41)45-22-21-37-17-19-38(20-18-37)33(26-11-6-4-7-12-26)27-13-8-5-9-14-27/h4-16,23,32-33,36H,17-22H2,1-3H3 DMJPGUA CS CC1=C(C(C(=C(N1)C)C(=O)OCCN2CCN(CC2)C(C3=CC=CC=C3)C4=CC=CC=C4)C5=CC(=CC=C5)[N+](=O)[O-])C(=O)OC DMJPGUA IK ANEBWFXPVPTEET-UHFFFAOYSA-N DMJPGUA IU 5-O-[2-(4-benzhydrylpiperazin-1-yl)ethyl] 3-O-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate DMJPGUA CA CAS 89226-50-6 DMJPGUA CB CHEBI:135849 DMR23M1 ID DMR23M1 DMR23M1 DN Mapracorat DMR23M1 HS Phase 3 DMR23M1 SN BOL-303242X; SEGRA, Intendis; SEGRA, Schering AG; ZK-216348; ZK-238587; ZK-245186; Mapracorat (ophthalmic, ocular inflammation); Mapracorat Ophthalmic Suspension, Bausch & Lomb; SEGRA (atopic dermatitis), Bayer; Selective glucocorticoid receptor agonists (SEGRA) Bayer Schering/AstraZeneca; Selective glucocorticoid receptor agonists (SEGRA) Schering AG/AstraZeneca; Selective glucocorticoid receptor agonists (SEGRA), Schering AG; Selective glucocorticoid receptor agonists (dermatology), Schering AG; Mapracorat (dermatological, atopic dermatitis), Intendis; SEGRA (ophthalmic disease), Bausch & Lomb; Selective glucocorticoid receptor agonist (ophthalmic disease), Bausch & Lomb; Selective glucocorticoid receptor agonists (dermatological, eczema), Intendis; Suppressor of pro-inflammatory mediators (eczema), Intendis; BOL-303242-X Ophthalmic Suspension, Bausch & Lomb; Mapracorat (ophthalmic, ocular inflammation), Bausch & Lomb; ZK-245186 (ophthalmic), Bausch & Lomb DMR23M1 CP Bayer Schering Pharma AG DMR23M1 DT Small molecular drug DMR23M1 PC 24795088 DMR23M1 MW 462.5 DMR23M1 FM C25H26F4N2O2 DMR23M1 IC InChI=1S/C25H26F4N2O2/c1-15-7-8-18-20(5-4-6-21(18)31-15)30-14-24(32,25(27,28)29)13-23(2,3)19-12-17(26)11-16-9-10-33-22(16)19/h4-8,11-12,30,32H,9-10,13-14H2,1-3H3/t24-/m1/s1 DMR23M1 CS CC1=NC2=C(C=C1)C(=CC=C2)NC[C@](CC(C)(C)C3=CC(=CC4=C3OCC4)F)(C(F)(F)F)O DMR23M1 IK VJGFOYBQOIPQFY-XMMPIXPASA-N DMR23M1 IU (2R)-1,1,1-trifluoro-4-(5-fluoro-2,3-dihydro-1-benzofuran-7-yl)-4-methyl-2-[[(2-methylquinolin-5-yl)amino]methyl]pentan-2-ol DMR23M1 CA CAS 887375-26-0 DMR23M1 DE Ocular disease DMJCF1O ID DMJCF1O DMJCF1O DN Maralixibat DMJCF1O HS Phase 3 DMJCF1O SN Lopixibat; UNII-UYB6UOF69L; Maralixibat [USAN]; 716313-53-0; UYB6UOF69L; CHEMBL363392; Maralixibat (USAN); Lopixibat cation; CHEMBL17879; 1-(4-((4-((4R,5R)-3,3-dibutyl-7-(dimethylamino)-4-hydroxy-1,1-dioxido-2,3,4,5-tetrahydrobenzo[b]thiepin-5-yl)phenoxy)methyl)benzyl)-1,4-diazabicyclo[2.2.2]octan-1-ium; LUM001 CATION; LUM-001 CATION; SCHEMBL10013954; BDBM50140282; 4-Aza-1-azoniabicyclo(2.2.2)octane, 1-((4-((4-((4R,5R)-3,3-dibutyl-7-(dimethylamino)-2,3,4,5-tetrahydro-4-hydroxy-1,1-dioxido-1-benzothiepin-5-yl)phenoxy)methyl)phenyl)methyl)-; D10951; Q27291331; (4R,5R)-5-[4-[[4-(1-aza-4-azoniabicyclo[2.2.2]octan-4-ylmethyl)phenyl]methoxy]phenyl]-3,3-dibutyl-7-(dimethylamino)-1,1-dioxo-4,5-dihydro-2H-1$l^{6}-benzothiepin-4-ol; 1-{4-[4-((4R,5R)-3,3-Dibutyl-7-dimethylamino-4-hydroxy-1,1-dioxo-2,3,4,5-tetrahydro-1H-1lambda*6*-benzo[b]thiepin-5-yl)-phenoxymethyl]-benzyl}-4-aza-1-azonia-bicyclo[2.2.2]octane; chloride DMJCF1O CP Mirum Pharmaceuticals DMJCF1O DT Small molecular drug DMJCF1O PC 9831643 DMJCF1O MW 675 DMJCF1O FM C40H56N3O4S+ DMJCF1O IC InChI=1S/C40H56N3O4S/c1-5-7-19-40(20-8-6-2)30-48(45,46)37-18-15-34(41(3)4)27-36(37)38(39(40)44)33-13-16-35(17-14-33)47-29-32-11-9-31(10-12-32)28-43-24-21-42(22-25-43)23-26-43/h9-18,27,38-39,44H,5-8,19-26,28-30H2,1-4H3/q+1/t38-,39-/m1/s1 DMJCF1O CS CCCCC1(CS(=O)(=O)C2=C(C=C(C=C2)N(C)C)[C@H]([C@H]1O)C3=CC=C(C=C3)OCC4=CC=C(C=C4)C[N+]56CCN(CC5)CC6)CCCC DMJCF1O IK STPKWKPURVSAJF-LJEWAXOPSA-N DMJCF1O IU (4R,5R)-5-[4-[[4-(4-aza-1-azoniabicyclo[2.2.2]octan-1-ylmethyl)phenyl]methoxy]phenyl]-3,3-dibutyl-7-(dimethylamino)-1,1-dioxo-4,5-dihydro-2H-1lambda6-benzothiepin-4-ol DMJCF1O CA CAS 716313-53-0 DMJCF1O DE Alagille syndrome; Progressive familial intrahepatic cholestasis DM3GTAL ID DM3GTAL DM3GTAL DN Maribavir DM3GTAL HS Phase 3 DM3GTAL SN 176161-24-3; Benzimidavir; (2S,3S,4R,5S)-2-(5,6-dichloro-2-(isopropylamino)-1H-benzo[d]imidazol-1-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol; 1263W94; UNII-PTB4X93HE1; PTB4X93HE1; 5,6-Dichloro-2-(isopropylamino)-1-(beta-L-ribofuranosyl)-1H-benzimidazole; 5,6-Dichloro-N-(1-methylethyl)-1-beta-L-ribofuranosyl-1H-benzimidazol-2-amine; (2S,3S,4R,5S)-2-[5,6-dichloro-2-(propan-2-ylamino)benzimidazol-1-yl]-5-(hydroxymethyl)oxolane-3,4-diol; Maribavir [USAN:INN:BAN]; Camvia; C15H19Cl2N3O4; Camvia(TM); Camvia (TN); Bzurea DM3GTAL DT Small molecular drug DM3GTAL PC 471161 DM3GTAL MW 376.2 DM3GTAL FM C15H19Cl2N3O4 DM3GTAL IC InChI=1S/C15H19Cl2N3O4/c1-6(2)18-15-19-9-3-7(16)8(17)4-10(9)20(15)14-13(23)12(22)11(5-21)24-14/h3-4,6,11-14,21-23H,5H2,1-2H3,(H,18,19)/t11-,12-,13-,14-/m0/s1 DM3GTAL CS CC(C)NC1=NC2=CC(=C(C=C2N1[C@@H]3[C@H]([C@H]([C@@H](O3)CO)O)O)Cl)Cl DM3GTAL IK KJFBVJALEQWJBS-XUXIUFHCSA-N DM3GTAL IU (2S,3S,4R,5S)-2-[5,6-dichloro-2-(propan-2-ylamino)benzimidazol-1-yl]-5-(hydroxymethyl)oxolane-3,4-diol DM3GTAL CA CAS 176161-24-3 DM3GTAL DE Cytomegalovirus infection DM6V34C ID DM6V34C DM6V34C DN Marimastat DM6V34C HS Phase 3 DM6V34C SN Marimastat [USAN]; BB 2516; BB-2516; Marimastat (USAN/INN); (2R,3S)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N',3-dihydroxy-2-(2-methylpropyl)butanediamide; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoxy)propyl)carboyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoyl)propyl)carbamoyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-N(4)-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N(1),2-dihydroxy-3-(2-methylpropyl)butanediamide DM6V34C CP British Biotech plc; Schering-Plough DM6V34C TC Anticancer Agents DM6V34C DT Small molecular drug DM6V34C PC 119031 DM6V34C MW 331.41 DM6V34C FM C15H29N3O5 DM6V34C IC InChI=1S/C15H29N3O5/c1-8(2)7-9(10(19)13(21)18-23)12(20)17-11(14(22)16-6)15(3,4)5/h8-11,19,23H,7H2,1-6H3,(H,16,22)(H,17,20)(H,18,21)/t9-,10+,11-/m1/s1 DM6V34C CS CC(C)C[C@H]([C@@H](C(=O)NO)O)C(=O)N[C@H](C(=O)NC)C(C)(C)C DM6V34C IK OCSMOTCMPXTDND-OUAUKWLOSA-N DM6V34C IU (2R,3S)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N',3-dihydroxy-2-(2-methylpropyl)butanediamide DM6V34C CA CAS 154039-60-8 DM6V34C CB CHEBI:50662 DM6V34C DE Lung cancer; Pancreatic cancer DME9QGW ID DME9QGW DME9QGW DN Marizomib DME9QGW HS Phase 3 DME9QGW SN MARIZOMIB; salinosporamide A; 437742-34-2; (-)-Salinosporamide A; UNII-703P9YDP7F; NPI-0052; NPI 0052; ML 858; 703P9YDP7F; CHEBI:48045; (1R,4R,5S)-4-(2-chloroethyl)-1-[(S)-(1S)-cyclohex-2-en-1-yl(hydroxy)methyl]-5-methyl-6-oxa-2-azabicyclo[3.2.0]heptane-3,7-dione; Marizomib [USAN:INN]; marizomibum; Marizomib (USAN/INN); Salinosporamide A (NPI-0052, Marizomib); SCHEMBL151667; CHEMBL371405; NGWSFRIPKNWYAO-SHTIJGAHSA-N; ZINC3990364; BDBM50398608; 2531AH; AKOS027323566; DB11762; Z-3093; D09640; 855517-10-1 DME9QGW CP Nereus Pharmaceuticals DME9QGW DT Small molecular drug DME9QGW PC 11347535 DME9QGW MW 313.77 DME9QGW FM C15H20ClNO4 DME9QGW IC InChI=1S/C15H20ClNO4/c1-14-10(7-8-16)12(19)17-15(14,13(20)21-14)11(18)9-5-3-2-4-6-9/h3,5,9-11,18H,2,4,6-8H2,1H3,(H,17,19)/t9-,10+,11+,14+,15+/m1/s1 DME9QGW CS C[C@]12[C@H](C(=O)N[C@]1(C(=O)O2)[C@H]([C@H]3CCCC=C3)O)CCCl DME9QGW IK NGWSFRIPKNWYAO-SHTIJGAHSA-N DME9QGW IU (1R,4R,5S)-4-(2-chloroethyl)-1-[(S)-[(1S)-cyclohex-2-en-1-yl]-hydroxymethyl]-5-methyl-6-oxa-2-azabicyclo[3.2.0]heptane-3,7-dione DME9QGW CA CAS 437742-34-2 DME9QGW CB CHEBI:48045 DME9QGW DE Solid tumour/cancer; Malignant glioma; Multiple myeloma; Glioblastoma of brain DMRSNEU ID DMRSNEU DMRSNEU DN Masitinib DMRSNEU HS Phase 3 DMRSNEU SN Masitinib; 790299-79-5; AB1010; Masatinib; Masitinib (AB1010); Masivet; AB-1010; AB 1010; UNII-M59NC4E26P; Masitinib [INN]; M59NC4E26P; 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]benzamide; CHEMBL1908391; CHEBI:63450; Masitinib (INN); N-(4-Methyl-3-((4-(pyridin-3-yl)thiazol-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide; Q-201339; C28H30N6OS; N-(4-methyl-3-(4-(pyridin-3-yl)thiazol-2-ylamino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide DMRSNEU CP AB Science DMRSNEU DT Small molecular drug DMRSNEU PC 10074640 DMRSNEU MW 498.6 DMRSNEU FM C28H30N6OS DMRSNEU IC InChI=1S/C28H30N6OS/c1-20-5-10-24(16-25(20)31-28-32-26(19-36-28)23-4-3-11-29-17-23)30-27(35)22-8-6-21(7-9-22)18-34-14-12-33(2)13-15-34/h3-11,16-17,19H,12-15,18H2,1-2H3,(H,30,35)(H,31,32) DMRSNEU CS CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC(=CS4)C5=CN=CC=C5 DMRSNEU IK WJEOLQLKVOPQFV-UHFFFAOYSA-N DMRSNEU IU 4-[(4-methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-yl-1,3-thiazol-2-yl)amino]phenyl]benzamide DMRSNEU CA CAS 790299-79-5 DMRSNEU CB CHEBI:63450 DMRSNEU DE Amyotrophic lateral sclerosis; Metastatic gastric or gastroesophageal junction cancer; Multiple sclerosis; Gastrointestinal stromal tumour; Ovarian cancer; Pancreatic cancer DMK9BP2 ID DMK9BP2 DMK9BP2 DN Mavacamten DMK9BP2 HS Phase 3 DMK9BP2 SN SAR-439152; SAR 439152; SAR439152; MYK-461; MYK 461; MYK461 DMK9BP2 CP MyoKardia South San Francisco, CA Sanofi Bridgewater, NJ DMK9BP2 PC 117761397 DMK9BP2 MW 273.33 DMK9BP2 FM C15H19N3O2 DMK9BP2 IC InChI=1S/C15H19N3O2/c1-10(2)18-14(19)9-13(17-15(18)20)16-11(3)12-7-5-4-6-8-12/h4-11,16H,1-3H3,(H,17,20)/t11-/m0/s1 DMK9BP2 CS C[C@@H](C1=CC=CC=C1)NC2=CC(=O)N(C(=O)N2)C(C)C DMK9BP2 IK RLCLASQCAPXVLM-NSHDSACASA-N DMK9BP2 IU 6-[[(1S)-1-phenylethyl]amino]-3-propan-2-yl-1H-pyrimidine-2,4-dione DMK9BP2 CA CAS 1642288-47-8 DMK9BP2 DE Obstructive hypertrophic cardiomyopathy DMBPY9Z ID DMBPY9Z DMBPY9Z DN MBG453 DMBPY9Z HS Phase 3 DMBPY9Z CP Novartis Oncology East Hanover, NJ DMBPY9Z DE Solid tumour/cancer; Myelodysplastic syndrome DMVZ57G ID DMVZ57G DMVZ57G DN MD1003 DMVZ57G HS Phase 3 DMVZ57G CP MedDay Pharmaceuticals Paris, France DMVZ57G DE Multiple sclerosis DM5X849 ID DM5X849 DM5X849 DN MEDI4736 DM5X849 HS Phase 3 DM5X849 CP AstraZeneca DM5X849 DT Monoclonal antibody DM5X849 DE Solid tumour/cancer DM4W8RE ID DM4W8RE DM4W8RE DN Melagatran DM4W8RE HS Phase 3 DM4W8RE SN Melagatran; 159776-70-2; UNII-2A9QP32MD4; Melagatran [INN]; 2A9QP32MD4; CHEBI:43966; MELAGATRAN (ASTRA-ZENECA); C22H31N5O4; Melagatran (INN); N-((R)-(((2S)-2-((-p-Amidobenzyl)carbamoyl)-1-azetidinyl)carbonyl)cyclohexylmethyl)glycine; [((1R)-2-{(2S)-2-[({4-[AMINO(IMINO)METHYL]BENZYL}AMINO)CARBONYL]AZETIDINYL}-1-CYCLOHEXYL-2-OXOETHYL)AMINO]ACETIC ACID; MEL; H-319/68; N-((R)-(((2S)-2-((p-Amidinobenzyl)carbamoyl)-1-azetidinyl)carbonyl)cyclohexylmethyl)glycine DM4W8RE DT Small molecular drug DM4W8RE PC 183797 DM4W8RE MW 429.5 DM4W8RE FM C22H31N5O4 DM4W8RE IC InChI=1S/C22H31N5O4/c23-20(24)16-8-6-14(7-9-16)12-26-21(30)17-10-11-27(17)22(31)19(25-13-18(28)29)15-4-2-1-3-5-15/h6-9,15,17,19,25H,1-5,10-13H2,(H3,23,24)(H,26,30)(H,28,29)/t17-,19+/m0/s1 DM4W8RE CS C1CCC(CC1)[C@H](C(=O)N2CC[C@H]2C(=O)NCC3=CC=C(C=C3)C(=N)N)NCC(=O)O DM4W8RE IK DKWNMCUOEDMMIN-PKOBYXMFSA-N DM4W8RE IU 2-[[(1R)-2-[(2S)-2-[(4-carbamimidoylphenyl)methylcarbamoyl]azetidin-1-yl]-1-cyclohexyl-2-oxoethyl]amino]acetic acid DM4W8RE CA CAS 159776-70-2 DM4W8RE CB CHEBI:43966 DMQEC6Z ID DMQEC6Z DMQEC6Z DN Melanoma vaccine DMQEC6Z HS Phase 3 DMQEC6Z SN NA17.A2 peptides, Institut Curie; Vaccine (melanoma), Institut Curie; Melanoma vaccine (NA17.A2/tyrosinase/MART-1, gp100); Melanoma vaccine (NA17.A2/tyrosinase/MART-1, gp100), Institut Curie DMQEC6Z CP Institut Curie DMQEC6Z DT Vaccine DMQEC6Z DE Melanoma DM8Z0I3 ID DM8Z0I3 DM8Z0I3 DN MF-101 DM8Z0I3 HS Phase 3 DM8Z0I3 SN DW-700; DW-700); Menopause Formula-101; Estrogen receptor beta agonist (menopausal symptoms), Bionovo; Liquiritigenin (menopausal symptoms), Bionovo DM8Z0I3 CP Bionovo Inc; Daewon Pharm Co Ltd DM8Z0I3 DE Hepatitis virus infection DMRKTCP ID DMRKTCP DMRKTCP DN MGA012 DMRKTCP HS Phase 3 DMRKTCP SN INCMGA0012; Retifanlimab DMRKTCP CP MacroGenics DMRKTCP DT Antibody DMRKTCP DE Solid tumour/cancer; Metastatic colorectal cancer; Non-small-cell lung cancer; Merkel cell carcinoma; Penile squamous cancer DMCJRL1 ID DMCJRL1 DMCJRL1 DN MGN-1703 DMCJRL1 HS Phase 3 DMCJRL1 SN TLR-9 agonist (cancer), Mologen DMCJRL1 CP Mologen Holding AG DMCJRL1 DE Colorectal cancer; Solid tumour/cancer DMZHN5B ID DMZHN5B DMZHN5B DN MIM-D3 DMZHN5B HS Phase 3 DMZHN5B SN TrkA agonist (ocular disease/Alzheimer's disease), Mimetogen DMZHN5B CP Mimetogen Pharmaceuticals Inc DMZHN5B DT Small molecular drug DMZHN5B PC 9808372 DMZHN5B MW 580.5 DMZHN5B FM C24H32N6O11 DMZHN5B IC InChI=1S/C24H32N6O11/c25-9-2-1-3-15-23(37)29-17(22(36)26-12-20(33)34)8-10-41-18-6-4-13(30(39)40)11-14(18)21(35)27-16(24(38)28-15)5-7-19(31)32/h4,6,11,15-17H,1-3,5,7-10,12,25H2,(H,26,36)(H,27,35)(H,28,38)(H,29,37)(H,31,32)(H,33,34)/t15-,16-,17-/m0/s1 DMZHN5B CS C1COC2=C(C=C(C=C2)[N+](=O)[O-])C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H]1C(=O)NCC(=O)O)CCCCN)CCC(=O)O DMZHN5B IK DVJXNXPFYJIACK-ULQDDVLXSA-N DMZHN5B IU 3-[(5S,8S,11S)-8-(4-aminobutyl)-5-(carboxymethylcarbamoyl)-16-nitro-7,10,13-trioxo-2-oxa-6,9,12-triazabicyclo[12.4.0]octadeca-1(14),15,17-trien-11-yl]propanoic acid DMZHN5B CA CAS 263251-78-1 DMZHN5B DE Alzheimer disease DMCJY35 ID DMCJY35 DMCJY35 DN MIN-101 DMCJY35 HS Phase 3 DMCJY35 SN Roluperidone DMCJY35 CP Minerva neurosciences DMCJY35 PC 9799284 DMCJY35 MW 366.4 DMCJY35 FM C22H23FN2O2 DMCJY35 IC InChI=1S/C22H23FN2O2/c23-19-7-5-17(6-8-19)21(26)15-24-11-9-16(10-12-24)13-25-14-18-3-1-2-4-20(18)22(25)27/h1-8,16H,9-15H2 DMCJY35 CS C1CN(CCC1CN2CC3=CC=CC=C3C2=O)CC(=O)C4=CC=C(C=C4)F DMCJY35 IK RNRYULFRLCBRQS-UHFFFAOYSA-N DMCJY35 IU 2-[[1-[2-(4-fluorophenyl)-2-oxoethyl]piperidin-4-yl]methyl]-3H-isoindol-1-one DMCJY35 CA CAS 359625-79-9 DMCJY35 DE Schizophrenia DM7R3N5 ID DM7R3N5 DM7R3N5 DN Mirikizumab DM7R3N5 HS Phase 3 DM7R3N5 CP Eli Lilly Indianapolis, IN DM7R3N5 DE Psoriasis vulgaris DM5S4LX ID DM5S4LX DM5S4LX DN Mirvetuximab soravtansine DM5S4LX HS Phase 3 DM5S4LX SN ZOHXWSHGANNQGO-QRVRWUFNSA-N; DB12489 DM5S4LX CP ImmunoGen Waltham, MA DM5S4LX PC 91810695 DM5S4LX MW 977.6 DM5S4LX FM C42H61ClN4O14S3 DM5S4LX IC InChI=1S/C42H61ClN4O14S3/c1-23-12-11-13-31(58-10)42(53)22-29(59-39(52)45-42)24(2)36-41(6,61-36)32(21-34(49)47(8)27-19-26(18-23)20-28(57-9)35(27)43)60-38(51)25(3)46(7)33(48)14-16-40(4,5)63-62-17-15-30(37(44)50)64(54,55)56/h11-13,19-20,24-25,29-32,36,53H,14-18,21-22H2,1-10H3,(H2,44,50)(H,45,52)(H,54,55,56)/b13-11+,23-12+/t24-,25+,29+,30?,31-,32+,36+,41+,42+/m1/s1 DM5S4LX CS C[C@@H]1[C@@H]2C[C@]([C@@H](/C=C/C=C(/CC3=CC(=C(C(=C3)OC)Cl)N(C(=O)C[C@@H]([C@]4([C@H]1O4)C)OC(=O)[C@H](C)N(C)C(=O)CCC(C)(C)SSCCC(C(=O)N)S(=O)(=O)O)C)\\C)OC)(NC(=O)O2)O DM5S4LX IK ZOHXWSHGANNQGO-DSIKUUPMSA-N DM5S4LX IU 1-amino-4-[[5-[[(2S)-1-[[(1S,2R,3S,5S,6S,16E,18E,20R,21S)-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.110,14.03,5]hexacosa-10,12,14(26),16,18-pentaen-6-yl]oxy]-1-oxopropan-2-yl]-methylamino]-2-methyl-5-oxopentan-2-yl]disulfanyl]-1-oxobutane-2-sulfonic acid DM5S4LX DE Endometrial cancer; Ovarian cancer DM3PSUF ID DM3PSUF DM3PSUF DN MK-3102 DM3PSUF HS Phase 3 DM3PSUF SN Omarigliptin DM3PSUF CP Merck DM3PSUF DT Small molecular drug DM3PSUF PC 46209133 DM3PSUF MW 398.4 DM3PSUF FM C17H20F2N4O3S DM3PSUF IC InChI=1S/C17H20F2N4O3S/c1-27(24,25)23-7-10-6-22(8-16(10)21-23)12-5-15(20)17(26-9-12)13-4-11(18)2-3-14(13)19/h2-4,7,12,15,17H,5-6,8-9,20H2,1H3/t12-,15+,17-/m1/s1 DM3PSUF CS CS(=O)(=O)N1C=C2CN(CC2=N1)[C@@H]3C[C@@H]([C@H](OC3)C4=C(C=CC(=C4)F)F)N DM3PSUF IK MKMPWKUAHLTIBJ-ISTRZQFTSA-N DM3PSUF IU (2R,3S,5R)-2-(2,5-difluorophenyl)-5-(2-methylsulfonyl-4,6-dihydropyrrolo[3,4-c]pyrazol-5-yl)oxan-3-amine DM3PSUF CA CAS 1226781-44-7 DM3PSUF CB CHEBI:134735 DM3PSUF DE Type-2 diabetes DMQBF7O ID DMQBF7O DMQBF7O DN MK-3222 DMQBF7O HS Phase 3 DMQBF7O CP Merck DMQBF7O DT Antibody DMQBF7O DE Psoriasis vulgaris; Hairy cell leukaemia; Plaque psoriasis DMGNHC2 ID DMGNHC2 DMGNHC2 DN MK-3415A DMGNHC2 HS Phase 3 DMGNHC2 SN Actoxumab/bezlotoxumab DMGNHC2 CP Merck DMGNHC2 DT Antibody DMGNHC2 DE Malaria; Clostridium infection DMA25NO ID DMA25NO DMA25NO DN MK-4214 DMA25NO HS Phase 3 DMA25NO SN INS-19; Recombinant human GCSF (biosimilar), Insmed DMA25NO CP Insmed Inc DMA25NO DE Neutropenia DMLYGH4 ID DMLYGH4 DMLYGH4 DN MK-4827 DMLYGH4 HS Phase 3 DMLYGH4 SN 1038915-60-4; (S)-2-(4-(piperidin-3-yl)phenyl)-2H-indazole-7-carboxamide; UNII-HMC2H89N35; HMC2H89N35; CHEMBL1094636; 2-{4-[(3s)-piperidin-3-yl]phenyl}-2h-indazole-7-carboxamide; MK4827; MK 4827; Niraparib [USAN:INN]; 2-{4-[(3S)-piperidin-3-yl]phenyl}indazole-7-carboxamide; 2-[4-[(3S)-piperidin-3-yl]phenyl]indazole-7-carboxamide; MK 4827 (Base); Niraparib (USAN); Zejula (TN); MK-4827(Niraparib); SCHEMBL1421875; GTPL8275; CTK8B9123; EX-A290; DTXSID50146129; MolPort-023-219-142; ZINC43206370; BDBM50316226 DMLYGH4 CP Merck DMLYGH4 DT Small molecular drug DMLYGH4 PC 24958200 DMLYGH4 MW 320.4 DMLYGH4 FM C19H20N4O DMLYGH4 IC InChI=1S/C19H20N4O/c20-19(24)17-5-1-3-15-12-23(22-18(15)17)16-8-6-13(7-9-16)14-4-2-10-21-11-14/h1,3,5-9,12,14,21H,2,4,10-11H2,(H2,20,24)/t14-/m1/s1 DMLYGH4 CS C1C[C@H](CNC1)C2=CC=C(C=C2)N3C=C4C=CC=C(C4=N3)C(=O)N DMLYGH4 IK PCHKPVIQAHNQLW-CQSZACIVSA-N DMLYGH4 IU 2-[4-[(3S)-piperidin-3-yl]phenyl]indazole-7-carboxamide DMLYGH4 CA CAS 1038915-60-4 DMLYGH4 DE Ewing sarcoma; Ovarian cancer; Breast cancer DM84LO5 ID DM84LO5 DM84LO5 DN MK-8109 DM84LO5 HS Phase 3 DM84LO5 CP Merck DM84LO5 DE Ovarian cancer DMK301H ID DMK301H DMK301H DN MK-8742 DMK301H HS Phase 3 DMK301H CP Merck DMK301H DE Hepatitis C virus infection DMT8IAJ ID DMT8IAJ DMT8IAJ DN MK-8808 DMT8IAJ HS Phase 3 DMT8IAJ CP Merck DMT8IAJ DE Rheumatoid arthritis; Follicular lymphoma DMP36KD ID DMP36KD DMP36KD DN MLN4924 DMP36KD HS Phase 3 DMP36KD SN Pevonedistat; 905579-51-3; MLN4924; MLN-4924; MLN 4924; UNII-S3AZD8D215; S3AZD8D215; Sulfamic acid [(1S,2S,4R)-4-[4-[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-2-hydroxycyclopentyl]methyl ester; ((1S,2S,4R)-4-(4-(((S)-2,3-dihydro-1H-inden-1-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-hydroxycyclopentyl)methyl sulfamate; C21H25N5O4S; [(1s,2s,4r)-4-{4-[(1s)-2,3-Dihydro-1h-Inden-1-Ylamino]-7h-Pyrrolo[2,3-D]pyrimidin-7-Yl}-2-Hydroxycyclopentyl]methyl Sulfamate; Pevonedistat [USAN:INN]; 3gzn DMP36KD CP Takeda DMP36KD DT Small molecular drug DMP36KD PC 16720766 DMP36KD MW 443.5 DMP36KD FM C21H25N5O4S DMP36KD IC InChI=1S/C21H25N5O4S/c22-31(28,29)30-11-14-9-15(10-19(14)27)26-8-7-17-20(23-12-24-21(17)26)25-18-6-5-13-3-1-2-4-16(13)18/h1-4,7-8,12,14-15,18-19,27H,5-6,9-11H2,(H2,22,28,29)(H,23,24,25)/t14-,15+,18-,19-/m0/s1 DMP36KD CS C1CC2=CC=CC=C2[C@H]1NC3=C4C=CN(C4=NC=N3)[C@@H]5C[C@H]([C@H](C5)O)COS(=O)(=O)N DMP36KD IK MPUQHZXIXSTTDU-QXGSTGNESA-N DMP36KD IU [(1S,2S,4R)-4-[4-[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]pyrrolo[2,3-d]pyrimidin-7-yl]-2-hydroxycyclopentyl]methyl sulfamate DMP36KD CA CAS 905579-51-3 DMP36KD CB CHEBI:95028 DMP36KD DE Advanced malignancy; Myelodysplastic syndrome; Acute myelogenous leukaemia; Nasopharyngeal carcinoma DMO8PT9 ID DMO8PT9 DMO8PT9 DN MLN8237 DMO8PT9 HS Phase 3 DMO8PT9 SN Alisertib DMO8PT9 TC Anticancer Agents DMO8PT9 DT Small molecular drug DMO8PT9 PC 24771867 DMO8PT9 MW 518.9 DMO8PT9 FM C27H20ClFN4O4 DMO8PT9 IC InChI=1S/C27H20ClFN4O4/c1-36-21-5-3-4-20(29)23(21)25-19-10-15(28)6-8-17(19)24-14(12-30-25)13-31-27(33-24)32-16-7-9-18(26(34)35)22(11-16)37-2/h3-11,13H,12H2,1-2H3,(H,34,35)(H,31,32,33) DMO8PT9 CS COC1=C(C(=CC=C1)F)C2=NCC3=CN=C(N=C3C4=C2C=C(C=C4)Cl)NC5=CC(=C(C=C5)C(=O)O)OC DMO8PT9 IK ZLHFILGSQDJULK-UHFFFAOYSA-N DMO8PT9 IU 4-[[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-2-methoxybenzoic acid DMO8PT9 CA CAS 1028486-01-2 DMO8PT9 CB CHEBI:125628 DMO8PT9 DE Solid tumour/cancer; Small-cell lung cancer DMFWE9S ID DMFWE9S DMFWE9S DN Mobocertinib DMFWE9S HS Phase 3 DMFWE9S SN 1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; TAK788; AP32788; AP-32788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate DMFWE9S CP Takeda DMFWE9S DT Small molecular drug DMFWE9S PC 118607832 DMFWE9S MW 585.7 DMFWE9S FM C32H39N7O4 DMFWE9S IC InChI=1S/C32H39N7O4/c1-9-29(40)34-24-16-25(28(42-8)17-27(24)38(6)15-14-37(4)5)35-32-33-18-22(31(41)43-20(2)3)30(36-32)23-19-39(7)26-13-11-10-12-21(23)26/h9-13,16-20H,1,14-15H2,2-8H3,(H,34,40)(H,33,35,36) DMFWE9S CS CC(C)OC(=O)C1=CN=C(N=C1C2=CN(C3=CC=CC=C32)C)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC DMFWE9S IK AZSRSNUQCUDCGG-UHFFFAOYSA-N DMFWE9S IU propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate DMFWE9S CA CAS 1847461-43-1 DMFWE9S DE Non-small cell lung cancer DM2TNJ1 ID DM2TNJ1 DM2TNJ1 DN Molgramostim DM2TNJ1 HS Phase 3 DM2TNJ1 SN Genfulin; Molgramostim (topical, wound healing); Molgramostim (topical, wound healing), GeneScience; GM-CSF (topical, woundhealing), GeneScience; Granulocyte-macrophage colony stimulating factor (topical, wound healing), GeneScience DM2TNJ1 CP GeneScience Pharmaceuticals Co Ltd DM2TNJ1 DE Wound healing; Autoimmune pulmonary alveolar proteinosis DMF98Q0 ID DMF98Q0 DMF98Q0 DN Momelotinib DMF98Q0 HS Phase 3 DMF98Q0 SN Cyt387; 1056634-68-4; MOMELOTINIB; Cyt-387; N-(Cyanomethyl)-4-(2-((4-morpholinophenyl)amino)pyrimidin-4-yl)benzamide; CYT 387; CYT 11387; UNII-6O01GMS00P; N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide; 6O01GMS00P; CHEMBL1078178; AK102858; N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide; N-(cyanomethyl)-4-(2-{[4-(morpholin-4-yl)phenyl]amino}pyrimidin-4-yl)benzamide; CYT387 sulfate salt; N-(Cyanomethyl)-4-(2-((4-morpholinophenyl)-amino)pyrimidin-4-yl)benzamide DMF98Q0 CP Gilead Sciences DMF98Q0 DT Small molecular drug DMF98Q0 PC 25062766 DMF98Q0 MW 414.5 DMF98Q0 FM C23H22N6O2 DMF98Q0 IC InChI=1S/C23H22N6O2/c24-10-12-25-22(30)18-3-1-17(2-4-18)21-9-11-26-23(28-21)27-19-5-7-20(8-6-19)29-13-15-31-16-14-29/h1-9,11H,12-16H2,(H,25,30)(H,26,27,28) DMF98Q0 CS C1COCCN1C2=CC=C(C=C2)NC3=NC=CC(=N3)C4=CC=C(C=C4)C(=O)NCC#N DMF98Q0 IK ZVHNDZWQTBEVRY-UHFFFAOYSA-N DMF98Q0 IU N-(cyanomethyl)-4-[2-(4-morpholin-4-ylanilino)pyrimidin-4-yl]benzamide DMF98Q0 CA CAS 1056634-68-4 DMF98Q0 CB CHEBI:91407 DMF98Q0 DE Myelofibrosis; Polycythemia vera; Thrombocythemia DMQ1FU8 ID DMQ1FU8 DMQ1FU8 DN Montelukast DMQ1FU8 HS Phase 3 DMQ1FU8 SN Singulair; Montelukast [INN:BAN]; UNII-MHM278SD3E; MK 0476; CHEMBL787; MHM278SD3E; CHEBI:50730; 142522-28-9; Aerokast; Brondilat (TN) DMQ1FU8 TC Antiviral Agents DMQ1FU8 DT Small molecular drug DMQ1FU8 PC 5281040 DMQ1FU8 MW 586.2 DMQ1FU8 FM C35H36ClNO3S DMQ1FU8 IC InChI=1S/C35H36ClNO3S/c1-34(2,40)30-9-4-3-7-25(30)13-17-32(41-23-35(18-19-35)22-33(38)39)27-8-5-6-24(20-27)10-15-29-16-12-26-11-14-28(36)21-31(26)37-29/h3-12,14-16,20-21,32,40H,13,17-19,22-23H2,1-2H3,(H,38,39)/b15-10+/t32-/m1/s1 DMQ1FU8 CS CC(C)(C1=CC=CC=C1CC[C@H](C2=CC=CC(=C2)/C=C/C3=NC4=C(C=CC(=C4)Cl)C=C3)SCC5(CC5)CC(=O)O)O DMQ1FU8 IK UCHDWCPVSPXUMX-TZIWLTJVSA-N DMQ1FU8 IU 2-[1-[[(1R)-1-[3-[(E)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl]-3-[2-(2-hydroxypropan-2-yl)phenyl]propyl]sulfanylmethyl]cyclopropyl]acetic acid DMQ1FU8 CA CAS 158966-92-8 DMQ1FU8 CB CHEBI:50730 DMQ1FU8 DE Coronavirus Disease 2019 (COVID-19) DMPVW6H ID DMPVW6H DMPVW6H DN Morphine-6-glucuronide DMPVW6H HS Phase 3 DMPVW6H SN Morphine-6-glucuronide; Morphine 6-glucuronide; 20290-10-2; UNII-64Y9KYM60R; Morphine 6-beta-D-glucopyranosiduronide; 64Y9KYM60R; CHEBI:80581; MORPHINE GLUCURONIDE; MORPHINE 6-GLUCURONIDE(MINOR); beta-D-Glucopyranosiduronic acid, (5alpha,6alpha)-7,8-didehydro-4,5-epoxy-3-hydroxy-17-methylmorphinan-6-yl; Morphine 6-beta-D-Glucuronide; Glucopyranosiduronic acid, 7,8-didehydro-4,5-alpha-epoxy-3-hydroxy-17-methylmorphinan-6-alpha-yl-, beta-D-; Morphine glucuronide [INN]; morphine-glucuronide DMPVW6H TC Analgesics DMPVW6H DT Small molecular drug DMPVW6H PC 5360621 DMPVW6H MW 461.5 DMPVW6H FM C23H27NO9 DMPVW6H IC InChI=1S/C23H27NO9/c1-24-7-6-23-10-3-5-13(31-22-17(28)15(26)16(27)19(33-22)21(29)30)20(23)32-18-12(25)4-2-9(14(18)23)8-11(10)24/h2-5,10-11,13,15-17,19-20,22,25-28H,6-8H2,1H3,(H,29,30)/t10-,11+,13-,15-,16-,17+,19-,20-,22+,23-/m0/s1 DMPVW6H CS CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)O)O[C@H]3[C@H](C=C4)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)C(=O)O)O)O)O DMPVW6H IK GNJCUHZOSOYIEC-GAROZEBRSA-N DMPVW6H IU (2S,3S,4S,5R,6R)-6-[[(4R,4aR,7S,7aR,12bS)-9-hydroxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-yl]oxy]-3,4,5-trihydroxyoxane-2-carboxylic acid DMPVW6H CA CAS 20290-10-2 DMPVW6H CB CHEBI:80581 DMPVW6H DE Pain DM15ZIB ID DM15ZIB DM15ZIB DN Mosunetuzumab DM15ZIB HS Phase 3 DM15ZIB SN RG7828; RO7030816; BTCT4465A DM15ZIB DT Antibody DM15ZIB DE Follicular lymphoma DMB24H7 ID DMB24H7 DMB24H7 DN Motavizumab DMB24H7 HS Phase 3 DMB24H7 SN MEDI-524; Motavizumab (USAN/INN) DMB24H7 CP AstraZeneca DMB24H7 DT Monoclonal antibody DMB24H7 DE Respiratory syncytial virus infection DM8K5Z6 ID DM8K5Z6 DM8K5Z6 DN Motexafin lutetium DM8K5Z6 HS Phase 3 DM8K5Z6 SN Lutetium texaphyrin; Lu-Tex; Motexafin lutetium < USAN; Optrin (Pharmacyclics); PCI-0123; Antrin (Pharmacyclics, US, US); Lutrin (National Cancer Institute (US), US; Pharmacyclics, , , JP); (PB-7-11-233'2'4)-Bis(acetato-O)[9,10-diethyl-20,21-bis[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]-4,15-dimethyl-8,11-imino-3,6:16,13-dinitrilo-1,18-benzodiazacycloeicosine-5,14-dipropanolato-N1,N18,N23,N24 DM8K5Z6 CP Pharmacyclics DM8K5Z6 DT Small molecular drug DM8K5Z6 PC 3081907 DM8K5Z6 MW 1184.1 DM8K5Z6 FM C52H74LuN5O15 DM8K5Z6 IC InChI=1S/C48H66N5O10.2C2H4O2.Lu.H2O/c1-7-35-36(8-2)40-28-42-38(12-10-14-55)34(4)46(53-42)32-50-44-30-48(63-26-24-61-22-20-59-18-16-57-6)47(62-25-23-60-21-19-58-17-15-56-5)29-43(44)49-31-45-33(3)37(11-9-13-54)41(52-45)27-39(35)51-40;2*1-2(3)4;;/h27-32,54-55H,7-26H2,1-6H3;2*1H3,(H,3,4);;1H2/q-1;;;+3;/p-2 DM8K5Z6 CS CCC1=C(C2=CC3=NC(=CN=C4C=C(C(=CC4=NC=C5C(=C(C(=N5)C=C1[N-]2)CCCO)C)OCCOCCOCCOC)OCCOCCOCCOC)C(=C3CCCO)C)CC.CC(=O)[O-].CC(=O)[O-].O.[Lu+3] DM8K5Z6 IK WIQKYZYFTAEWBF-UHFFFAOYSA-L DM8K5Z6 IU 3-[4,5-diethyl-24-(3-hydroxypropyl)-16,17-bis[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]-10,23-dimethyl-13,20,25,26-tetraza-27-azanidapentacyclo[20.2.1.13,6.18,11.014,19]heptacosa-1(25),2,4,6,8(26),9,11,13,15,17,19,21,23-tridecaen-9-yl]propan-1-ol;lutetium(3+);diacetate;hydrate DM8K5Z6 CA CAS 156436-90-7 DM8K5Z6 DE Artery stenosis DM9K3LM ID DM9K3LM DM9K3LM DN MPDL-3280A DM9K3LM HS Phase 3 DM9K3LM CP Genentech DM9K3LM DT Monoclonal antibody DM9K3LM DE Melanoma DMNDCFY ID DMNDCFY DMNDCFY DN MPL-S DMNDCFY HS Phase 3 DMNDCFY CP Ribi ImmunoChem Research Inc DMNDCFY DE Endotoxic shock DMDV4EP ID DMDV4EP DMDV4EP DN MRTX849 DMDV4EP HS Phase 3 DMDV4EP SN 2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX-849; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)- DMDV4EP CP Mirati Therapeutics DMDV4EP DT Small molecular drug DMDV4EP PC 138611145 DMDV4EP MW 604.1 DMDV4EP FM C32H35ClFN7O2 DMDV4EP IC InChI=1S/C32H35ClFN7O2/c1-21(34)31(42)41-17-16-40(18-23(41)11-13-35)30-25-12-15-39(28-10-4-7-22-6-3-9-26(33)29(22)28)19-27(25)36-32(37-30)43-20-24-8-5-14-38(24)2/h3-4,6-7,9-10,23-24H,1,5,8,11-12,14-20H2,2H3/t23-,24-/m0/s1 DMDV4EP CS CN1CCC[C@H]1COC2=NC3=C(CCN(C3)C4=CC=CC5=C4C(=CC=C5)Cl)C(=N2)N6CCN([C@H](C6)CC#N)C(=O)C(=C)F DMDV4EP IK PEMUGDMSUDYLHU-ZEQRLZLVSA-N DMDV4EP IU 2-[(2S)-4-[7-(8-chloronaphthalen-1-yl)-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile DMDV4EP CA CAS 2326521-71-3 DMDV4EP DE Non-small-cell lung cancer DMUNBMA ID DMUNBMA DMUNBMA DN MT-1621 DMUNBMA HS Phase 3 DMUNBMA CP Modis Therapeutics DMUNBMA DT Deoxynucleoside DMUNBMA DE Thymidine kinase 2 deficiency DMZPEHY ID DMZPEHY DMZPEHY DN Multi-epitope peptide melanoma vaccine DMZPEHY HS Phase 3 DMZPEHY SN Multi-epitope peptide melanoma vaccine (MART-1, gp100, tyrosinase); Multi-epitope peptide melanoma vaccine (MART-1, gp100, tyrosinase), University of Pittsburgh; MART-1 (51-73) + MART-1(27-35); MART-1(NSC-672643), gp100(NSC-683472), tyrosinase (NSC-699048); MGT (MART-1 (27-35), gp100(209-217, 210M), tyrosinase (368-376, 370D)); (MART-1, gp100, tyrosinase) + (IFNalfa2b + GM-CSF); (MART-1, gp100, tyrosinase) + GM-CSF; (MART-1, gp100, tyrosinase) + IFNalfa2b DMZPEHY CP University of Pittsburgh DMZPEHY DT Vaccine DMZPEHY DE Melanoma DMG3NFZ ID DMG3NFZ DMG3NFZ DN Muraglitazar DMG3NFZ HS Phase 3 DMG3NFZ SN Muraglitazar; 331741-94-7; Pargluva; BMS-298585; UNII-W1MKM70WQI; BMS 298585; W1MKM70WQI; CHEMBL186179; N-[(4-Methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine; N-((4-methoxyphenoxy)carbonyl)-N-((4-(2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy)phenyl)methyl)glycine; BMS298585; Muraglitazar [USAN:INN]; CCRIS 9258; AC1L4FVP; Muraglitazar (USAN/INN); DSSTox_CID_31508; DSSTox_RID_97393; DSSTox_GSID_57719; SCHEMBL676469; DTXSID9057719; CTK8E8901; MolPort-006-395-259; IRLWJILLXJGJTD-UHFFFAOYSA-N DMG3NFZ DT Small molecular drug DMG3NFZ PC 206044 DMG3NFZ MW 516.5 DMG3NFZ FM C29H28N2O7 DMG3NFZ IC InChI=1S/C29H28N2O7/c1-20-26(30-28(37-20)22-6-4-3-5-7-22)16-17-36-24-10-8-21(9-11-24)18-31(19-27(32)33)29(34)38-25-14-12-23(35-2)13-15-25/h3-15H,16-19H2,1-2H3,(H,32,33) DMG3NFZ CS CC1=C(N=C(O1)C2=CC=CC=C2)CCOC3=CC=C(C=C3)CN(CC(=O)O)C(=O)OC4=CC=C(C=C4)OC DMG3NFZ IK IRLWJILLXJGJTD-UHFFFAOYSA-N DMG3NFZ IU 2-[(4-methoxyphenoxy)carbonyl-[[4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl]methyl]amino]acetic acid DMG3NFZ CA CAS 331741-94-7 DMUQ390 ID DMUQ390 DMUQ390 DN Murepavadin DMUQ390 HS Phase 3 DMUQ390 SN UNII-0D02GRY87Z; 0D02GRY87Z; 944252-63-5; Murepavadin [INN]; Murepavadin [USAN:INN]; Murepavadin (USAN/INN); CHEMBL3946483; Cyclo(L-alanyl-L-seryl-D-prolyl-L-prolyl-L-threonyl-L-tryptophyl-L-isoleucyl-(2S)-2,4-diaminobutanoyl-L-ornithyl-(2R)-2,4-diaminobutanoyl-(2S)-2,4-diaminobutanoyl-L-tryptophyl-(2S)-2,4-diaminobutanoyl-(2S)-2,4-diaminobutanoyl); RO7033877; D10957 DMUQ390 CP Polyphor DMUQ390 PC 91824766 DMUQ390 MW 1553.8 DMUQ390 FM C73H112N22O16 DMUQ390 IC InChI=1S/C73H112N22O16/c1-5-38(2)58-70(108)88-52(24-30-79)65(103)83-47(17-10-25-74)62(100)85-49(21-27-76)63(101)86-51(23-29-78)66(104)89-53(33-41-35-80-45-15-8-6-13-43(41)45)67(105)87-50(22-28-77)64(102)84-48(20-26-75)61(99)82-39(3)60(98)91-55(37-96)72(110)95-32-12-19-57(95)73(111)94-31-11-18-56(94)69(107)93-59(40(4)97)71(109)90-54(68(106)92-58)34-42-36-81-46-16-9-7-14-44(42)46/h6-9,13-16,35-36,38-40,47-59,80-81,96-97H,5,10-12,17-34,37,74-79H2,1-4H3,(H,82,99)(H,83,103)(H,84,102)(H,85,100)(H,86,101)(H,87,105)(H,88,108)(H,89,104)(H,90,109)(H,91,98)(H,92,106)(H,93,107)/t38-,39-,40+,47-,48-,49+,50-,51-,52-,53-,54-,55-,56-,57+,58-,59-/m0/s1 DMUQ390 CS CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2CCC[C@@H]2C(=O)N3CCC[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CC4=CNC5=CC=CC=C54)[C@@H](C)O)CO)C)CCN)CCN)CC6=CNC7=CC=CC=C76)CCN)CCN)CCCN)CCN DMUQ390 IK RIDRXGOBXZLKHZ-NZUANIILSA-N DMUQ390 IU (3R,9S,12S,15S,18S,21S,24S,27R,30S,33S,36S,39S,42S,45S)-15,18,24,27,33-pentakis(2-aminoethyl)-30-(3-aminopropyl)-36-[(2S)-butan-2-yl]-42-[(1R)-1-hydroxyethyl]-9-(hydroxymethyl)-21,39-bis(1H-indol-3-ylmethyl)-12-methyl-1,7,10,13,16,19,22,25,28,31,34,37,40,43-tetradecazatricyclo[43.3.0.03,7]octatetracontane-2,8,11,14,17,20,23,26,29,32,35,38,41,44-tetradecone DMUQ390 CA CAS 944252-63-5 DMUQ390 DE Ventilator-associated pneumonia DMS9GE1 ID DMS9GE1 DMS9GE1 DN MyoCell SDF-1 DMS9GE1 HS Phase 3 DMS9GE1 SN Autologous skeletal myoblast therapy (SDF-1, cardiovascular disease), Bioheart DMS9GE1 CP Bioheart DMS9GE1 DE Heart failure DMY60DT ID DMY60DT DMY60DT DN N8-GP DMY60DT HS Phase 3 DMY60DT SN NN7088 DMY60DT CP Novo Nordisk DMY60DT DE Factor VIII deficiency DMHKJ5I ID DMHKJ5I DMHKJ5I DN Nabiximols DMHKJ5I HS Phase 3 DMHKJ5I SN Nabiximols; Sativex; GW-1000; Cannador; Nabiximols [USAN]; GW1000; GW 1000; Tetrahydrocannabinol-cannabidiol combination; Cannabidiol mixture with Tetrahydrocannabinol; delta-9-Tetrahydrocannabinol and cannabidiol; Cannabidiol and delta-9-tetrahydrocarnabinol; GW-1000-02 DMHKJ5I CP Otsuka America Pharmaceutical DMHKJ5I DT Small molecular drug DMHKJ5I PC 44148067 DMHKJ5I MW 628.9 DMHKJ5I FM C42H60O4 DMHKJ5I IC InChI=1S/2C21H30O2/c1-5-6-7-8-15-12-18(22)20-16-11-14(2)9-10-17(16)21(3,4)23-19(20)13-15;1-5-6-7-8-16-12-19(22)21(20(23)13-16)18-11-15(4)9-10-17(18)14(2)3/h11-13,16-17,22H,5-10H2,1-4H3;11-13,17-18,22-23H,2,5-10H2,1,3-4H3/t16-,17-;17-,18?/m10/s1 DMHKJ5I CS CCCCCC1=CC(=C(C(=C1)O)C2C=C(CC[C@H]2C(=C)C)C)O.CCCCCC1=CC(=C2[C@@H]3C=C(CC[C@H]3C(OC2=C1)(C)C)C)O DMHKJ5I IK SSNHGLKFJISNTR-FWUPRJFYSA-N DMHKJ5I IU (6aR,10aR)-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-ol;2-[(6R)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]-5-pentylbenzene-1,3-diol DMHKJ5I CA CAS 56575-23-6 DMHKJ5I DE Cancer related pain; Muscle spasm DMDZ6Q3 ID DMDZ6Q3 DMDZ6Q3 DN Napabucasin DMDZ6Q3 HS Phase 3 DMDZ6Q3 SN 83280-65-3; UNII-Z1HHM49K7O; 2-acetylnaphtho[2,3-b]furan-4,9-dione; Z1HHM49K7O; 2-Acetylnaphtho(2,3-b)furan-4,9-dione; 2-Acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione; Napabucasin [USAN:INN]; Napabucasin (BBI608); 2-Acetylfuranonaphthoquinone; CHEMBL64130; Napabucasin (JAN/USAN/INN); SCHEMBL1883845; Napabucasin - BBI 608/ FNQ; 2-Acetylfuro-1,4-naphthoquinone; DPHUWDIXHNQOSY-UHFFFAOYSA-N; MolPort-039-101-321; EX-A1314; ZINC13306865; s7977; AKOS027470201; DB12155; CS-1747; ACN-053294; HY-13919 DMDZ6Q3 CP Boston Biomedical Cambridge, MA DMDZ6Q3 PC 10331844 DMDZ6Q3 MW 240.21 DMDZ6Q3 FM C14H8O4 DMDZ6Q3 IC InChI=1S/C14H8O4/c1-7(15)11-6-10-12(16)8-4-2-3-5-9(8)13(17)14(10)18-11/h2-6H,1H3 DMDZ6Q3 CS CC(=O)C1=CC2=C(O1)C(=O)C3=CC=CC=C3C2=O DMDZ6Q3 IK DPHUWDIXHNQOSY-UHFFFAOYSA-N DMDZ6Q3 IU 2-acetylbenzo[f][1]benzofuran-4,9-dione DMDZ6Q3 CA CAS 83280-65-3 DMDZ6Q3 DE Pancreatic cancer; Colorectal cancer; Advanced malignancy; Solid tumour/cancer; Gastrointestinal cancer; Haematological malignancy; Hepatocellular carcinoma; Recurring respiratory infection; Recurrent glioblastoma DMKP45D ID DMKP45D DMKP45D DN Naproxcinod DMKP45D HS Phase 3 DMKP45D SN Beprana; Nitronaproxen; AR-P900758XX; AZD-3582; HCT-3012; Nitronaproxen, NicOx; NO-naproxen, AstraZeneca; NO-naproxen, NicOx; NO-NSAID, NicOx/AstraZeneca; Nitric oxide-donating derivative of naproxen (oral, osteoarthritis), NicOx DMKP45D CP NicOx SA DMKP45D DT Small molecular drug DMKP45D PC 9884642 DMKP45D MW 347.4 DMKP45D FM C18H21NO6 DMKP45D IC InChI=1S/C18H21NO6/c1-13(18(20)24-9-3-4-10-25-19(21)22)14-5-6-16-12-17(23-2)8-7-15(16)11-14/h5-8,11-13H,3-4,9-10H2,1-2H3/t13-/m0/s1 DMKP45D CS C[C@@H](C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)OCCCCO[N+](=O)[O-] DMKP45D IK AKFJWRDCWYYTIG-ZDUSSCGKSA-N DMKP45D IU 4-nitrooxybutyl (2S)-2-(6-methoxynaphthalen-2-yl)propanoate DMKP45D CA CAS 163133-43-5 DMKP45D CB CHEBI:76254 DMKP45D DE Inflammation DMIC56X ID DMIC56X DMIC56X DN NASVAC DMIC56X HS Phase 3 DMIC56X SN NASTERAP; HBV vaccine (intranasal), CIGB DMIC56X CP Center for Genetic Engineering and Biotechnology DMIC56X DT Vaccine DMIC56X DE Hepatitis B virus infection DMRSI1M ID DMRSI1M DMRSI1M DN NAV5001 DMRSI1M HS Phase 3 DMRSI1M CP Navidea biopharmaceuticals DMRSI1M DE Dementia DMVO1C0 ID DMVO1C0 DMVO1C0 DN NBI-98854 DMVO1C0 HS Phase 3 DMVO1C0 SN NBI-98782; Vesicular monoamine transporter 2 inhibitor (CNS indications), Neurocrine; VMAT-2 inhibitor (CNS disease), Neurocrine DMVO1C0 CP Neurocrine biosciences DMVO1C0 DT Small molecular drug DMVO1C0 PC 123836 DMVO1C0 MW 319.4 DMVO1C0 FM C19H29NO3 DMVO1C0 IC InChI=1S/C19H29NO3/c1-12(2)7-14-11-20-6-5-13-8-18(22-3)19(23-4)9-15(13)16(20)10-17(14)21/h8-9,12,14,16-17,21H,5-7,10-11H2,1-4H3 DMVO1C0 CS CC(C)CC1CN2CCC3=CC(=C(C=C3C2CC1O)OC)OC DMVO1C0 IK WEQLWGNDNRARGE-UHFFFAOYSA-N DMVO1C0 IU 9,10-dimethoxy-3-(2-methylpropyl)-2,3,4,6,7,11b-hexahydro-1H-benzo[a]quinolizin-2-ol DMVO1C0 CA CAS 3466-75-9 DMVO1C0 DE Movement disorder; Tourette syndrome DMFD249 ID DMFD249 DMFD249 DN Nebracetam DMFD249 HS Phase 3 DMFD249 SN Memolog; WEB-1881; WEB-1881-FU DMFD249 CP Boehringer Ingelheim Corp DMFD249 DT Small molecular drug DMFD249 PC 65926 DMFD249 MW 204.27 DMFD249 FM C12H16N2O DMFD249 IC InChI=1S/C12H16N2O/c13-7-11-6-12(15)14(9-11)8-10-4-2-1-3-5-10/h1-5,11H,6-9,13H2 DMFD249 CS C1C(CN(C1=O)CC2=CC=CC=C2)CN DMFD249 IK LCAFGJGYCUMTGS-UHFFFAOYSA-N DMFD249 IU 4-(aminomethyl)-1-benzylpyrrolidin-2-one DMFD249 CA CAS 97205-34-0 DMFD249 DE Parkinson disease DMDBY30 ID DMDBY30 DMDBY30 DN Nelipepimut S DMDBY30 HS Phase 3 DMDBY30 SN E75 DMDBY30 CP Galena biopharma DMDBY30 DT Small molecular drug DMDBY30 PC 9941306 DMDBY30 MW 995.2 DMDBY30 FM C50H78N10O11 DMDBY30 IC InChI=1S/C50H78N10O11/c1-8-31(6)42(60-44(64)35(52)21-15-16-22-51)49(69)58-37(25-33-17-11-9-12-18-33)45(65)53-27-41(62)55-40(28-61)48(68)57-36(23-29(2)3)46(66)54-32(7)43(63)56-38(26-34-19-13-10-14-20-34)47(67)59-39(50(70)71)24-30(4)5/h9-14,17-20,29-32,35-40,42,61H,8,15-16,21-28,51-52H2,1-7H3,(H,53,65)(H,54,66)(H,55,62)(H,56,63)(H,57,68)(H,58,69)(H,59,67)(H,60,64)(H,70,71)/t31-,32-,35-,36-,37-,38-,39-,40-,42-/m0/s1 DMDBY30 CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CC(C)C)C(=O)O)NC(=O)[C@H](CCCCN)N DMDBY30 IK AHOKKYCUWBLDST-QYULHYBRSA-N DMDBY30 IU (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2,6-diaminohexanoyl]amino]-3-methylpentanoyl]amino]-3-phenylpropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoic acid DMDBY30 CA CAS 160212-35-1 DMDBY30 DE Non-hodgkin lymphoma; Breast cancer; Gastric adenocarcinoma DMH9EUA ID DMH9EUA DMH9EUA DN Nemolizumab DMH9EUA HS Phase 3 DMH9EUA CP Galderma Fort Worth, TX DMH9EUA DE Atopic dermatitis DMIPNBG ID DMIPNBG DMIPNBG DN Nemonaxacin DMIPNBG HS Phase 3 DMIPNBG CP Warner Chilcott plc DMIPNBG DE Methicillin-resistant staphylococci infection DMVP7HI ID DMVP7HI DMVP7HI DN Nestorone DMVP7HI HS Phase 3 DMVP7HI SN Nestorone; Nestorone MDTS; Nestorone metered dose transdermal system; Nestorone transdermal spray, Acrux; ST-1435; Nestorone transdermal spray, Population Council/Acrux DMVP7HI CP Population Council; Population Council Center for Biomedical Research DMVP7HI DT Small molecular drug DMVP7HI PC 108059 DMVP7HI MW 370.5 DMVP7HI FM C23H30O4 DMVP7HI IC InChI=1S/C23H30O4/c1-13-11-21-20-7-5-16-12-17(26)6-8-18(16)19(20)9-10-22(21,4)23(13,14(2)24)27-15(3)25/h12,18-21H,1,5-11H2,2-4H3/t18-,19+,20+,21-,22-,23-/m0/s1 DMVP7HI CS CC(=O)[C@]1(C(=C)C[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@H]34)C)OC(=O)C DMVP7HI IK CKFBRGLGTWAVLG-GOMYTPFNSA-N DMVP7HI IU [(8R,9S,10R,13S,14S,17R)-17-acetyl-13-methyl-16-methylidene-3-oxo-2,6,7,8,9,10,11,12,14,15-decahydro-1H-cyclopenta[a]phenanthren-17-yl] acetate DMVP7HI CA 7759-35-5 DMVP7HI DE Endometriosis DMTKRY1 ID DMTKRY1 DMTKRY1 DN Netivudine DMTKRY1 HS Phase 3 DMTKRY1 SN Zonavir; BW-882; BW-882C; 882-C-87; 882C DMTKRY1 CP Burroughs Wellcome Inc DMTKRY1 DT Small molecular drug DMTKRY1 PC 55281 DMTKRY1 MW 282.25 DMTKRY1 FM C12H14N2O6 DMTKRY1 IC InChI=1S/C12H14N2O6/c1-2-3-6-4-14(12(19)13-10(6)18)11-9(17)8(16)7(5-15)20-11/h4,7-9,11,15-17H,5H2,1H3,(H,13,18,19)/t7-,8-,9+,11-/m1/s1 DMTKRY1 CS CC#CC1=CN(C(=O)NC1=O)[C@H]2[C@H]([C@@H]([C@H](O2)CO)O)O DMTKRY1 IK QLOCVMVCRJOTTM-SDNRWEOFSA-N DMTKRY1 IU 1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-prop-1-ynylpyrimidine-2,4-dione DMTKRY1 CA CAS 84558-93-0 DMTKRY1 DE Virus infection DMEKAYI ID DMEKAYI DMEKAYI DN Netupitant DMEKAYI HS Phase 3 DMEKAYI SN R-1124; NK1 antagonist (emesis), Roche; Ro-67-3189 DMEKAYI CP Helsinn Therapeutics DMEKAYI DT Small molecular drug DMEKAYI PC 6451149 DMEKAYI MW 578.6 DMEKAYI FM C30H32F6N4O DMEKAYI IC InChI=1S/C30H32F6N4O/c1-19-8-6-7-9-23(19)24-17-26(40-12-10-38(4)11-13-40)37-18-25(24)39(5)27(41)28(2,3)20-14-21(29(31,32)33)16-22(15-20)30(34,35)36/h6-9,14-18H,10-13H2,1-5H3 DMEKAYI CS CC1=CC=CC=C1C2=CC(=NC=C2N(C)C(=O)C(C)(C)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)N4CCN(CC4)C DMEKAYI IK WAXQNWCZJDTGBU-UHFFFAOYSA-N DMEKAYI IU 2-[3,5-bis(trifluoromethyl)phenyl]-N,2-dimethyl-N-[4-(2-methylphenyl)-6-(4-methylpiperazin-1-yl)pyridin-3-yl]propanamide DMEKAYI CA CAS 290297-26-6 DMEKAYI CB CHEBI:85155 DMEKAYI DE Chemotherapy-induced nausea DME617W ID DME617W DME617W DN Neucardin DME617W HS Phase 3 DME617W SN Human neuregulin-1 recombinant peptide fragment (injectable, heart failure/cardiomyopathy), Zensun; RhNRG-1 (injectable, heartfailure/cardiomyopathy), Zensun DME617W CP Zensun (Shanghai) Sci-Tech Co Ltd DME617W DE Heart failure; Chronic heart failure DMYTC4I ID DMYTC4I DMYTC4I DN NeuVax DMYTC4I HS Phase 3 DMYTC4I SN NeuVax (TN) DMYTC4I CP Galena Biopharma DMYTC4I DT Vaccine DMYTC4I DE Breast cancer DMJ2KIE ID DMJ2KIE DMJ2KIE DN NI-101 DMJ2KIE HS Phase 3 DMJ2KIE SN BART; Ch12F6A; MAb (AD), Neurimmune/Biogen Idec; Monoclonal antibodies (Alzheimer! s disease), Neurimmune Therapeutics/Biogen Idec; Anti-beta amyloid mAbs (Alzheimer! s disease), Neurimmune Therapeutics/Biogen Idec DMJ2KIE CP Neurimmune Therapeutics AG DMJ2KIE DT Antibody DMJ2KIE DE Alzheimer disease DMFBNA3 ID DMFBNA3 DMFBNA3 DN Nicaraven DMFBNA3 HS Phase 3 DMFBNA3 SN AVS; Antevan; Antevas DMFBNA3 CP Chugai Pharmaceutical DMFBNA3 DT Small molecular drug DMFBNA3 PC 71234 DMFBNA3 MW 284.31 DMFBNA3 FM C15H16N4O2 DMFBNA3 IC InChI=1S/C15H16N4O2/c1-11(19-15(21)13-5-3-7-17-10-13)8-18-14(20)12-4-2-6-16-9-12/h2-7,9-11H,8H2,1H3,(H,18,20)(H,19,21) DMFBNA3 CS CC(CNC(=O)C1=CN=CC=C1)NC(=O)C2=CN=CC=C2 DMFBNA3 IK KTXBOOWDLPUROC-UHFFFAOYSA-N DMFBNA3 IU N-[2-(pyridine-3-carbonylamino)propyl]pyridine-3-carboxamide DMFBNA3 CA CAS 79455-30-4 DMFBNA3 DE Cerebrovascular disease DM376WT ID DM376WT DM376WT DN NKTR 214 DM376WT HS Phase 3 DM376WT CP Nektar Therapeutics San Francisco, CA DM376WT DE Bladder cancer; Colorectal cancer; Melanoma; Renal cell carcinoma; Solid tumour/cancer; Sarcoma DM45DS8 ID DM45DS8 DM45DS8 DN NKTR-181 DM45DS8 HS Phase 3 DM45DS8 CP Nektar therapeutics DM45DS8 PC 73673720 DM45DS8 MW 595.7 DM45DS8 FM C31H49NO10 DM45DS8 IC InChI=1S/C31H49NO10/c1-32-9-8-30-27-23-4-5-24(35-3)28(27)42-29(30)25(6-7-31(30,33)26(32)22-23)41-21-20-40-19-18-39-17-16-38-15-14-37-13-12-36-11-10-34-2/h4-5,25-26,29,33H,6-22H2,1-3H3/t25-,26+,29-,30-,31+/m0/s1 DM45DS8 CS CN1CC[C@]23[C@@H]4[C@H](CC[C@]2([C@H]1CC5=C3C(=C(C=C5)OC)O4)O)OCCOCCOCCOCCOCCOCCOC DM45DS8 IK RQHILGKAOIGUHU-XPLSERNMSA-N DM45DS8 IU (4R,4aS,7S,7aR,12bS)-9-methoxy-7-[2-[2-[2-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]-3-methyl-1,2,4,5,6,7,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinolin-4a-ol DM45DS8 CA CAS 1211231-76-3 DM45DS8 DE Neuropathic pain; Chronic low back pain; Pain DMACYW6 ID DMACYW6 DMACYW6 DN NKTR-214 DMACYW6 HS Phase 3 DMACYW6 SN bempegaldesleukin DMACYW6 CP Nektar Therapeutics DMACYW6 DT Recombinant protein DMACYW6 DE Melanoma DMDJLY9 ID DMDJLY9 DMDJLY9 DN NM-702 DMDJLY9 HS Phase 3 DMDJLY9 SN NM-702; Parogrelil hydrochloride; UNII-65O9DMS368; 65O9DMS368; NM702; NM 702; 878796-94-2; SCHEMBL1739368; QWGUGDYWUADMGB-UHFFFAOYSA-N; 3(2H)-Pyridazinone, 4-bromo-6-(3-(4-chlorophenyl)propoxy)-5-((3-pyridinylmethyl)amino)-, hydrochloride (1:1); 139145-84-9; 4-bromo-6-(3-(4-chlorophenyl)propoxy)-5-(3-pyridylmethylamino)-3(2H)-pyridazinone hydrochloride DMDJLY9 CP Nissan Chemical America DMDJLY9 DT Small molecular drug DMDJLY9 PC 9848253 DMDJLY9 MW 486.2 DMDJLY9 FM C19H19BrCl2N4O2 DMDJLY9 IC InChI=1S/C19H18BrClN4O2.ClH/c20-16-17(23-12-14-3-1-9-22-11-14)19(25-24-18(16)26)27-10-2-4-13-5-7-15(21)8-6-13;/h1,3,5-9,11H,2,4,10,12H2,(H2,23,24,26);1H DMDJLY9 CS C1=CC(=CN=C1)CNC2=C(C(=O)NN=C2OCCCC3=CC=C(C=C3)Cl)Br.Cl DMDJLY9 IK QWGUGDYWUADMGB-UHFFFAOYSA-N DMDJLY9 IU 5-bromo-3-[3-(4-chlorophenyl)propoxy]-4-(pyridin-3-ylmethylamino)-1H-pyridazin-6-one;hydrochloride DMDJLY9 CA CAS 878796-94-2 DMDJLY9 DE Angina pectoris DMDGK83 ID DMDGK83 DMDGK83 DN NN1841 DMDGK83 HS Phase 3 DMDGK83 SN NovoThirteen (TN) DMDGK83 CP Novo Nordisk DMDGK83 DE Hemophilia DM0QV27 ID DM0QV27 DM0QV27 DN NN5401 DM0QV27 HS Phase 3 DM0QV27 SN Insulin degludec and insulin aspart; Ryzodeg (TN) DM0QV27 CP Novo Nordisk DM0QV27 DE Diabetic complication DM1PI9G ID DM1PI9G DM1PI9G DN NN8717 DM1PI9G HS Phase 3 DM1PI9G CP Novo Nordisk DM1PI9G DE Graft-versus-host disease DMOF0CA ID DMOF0CA DMOF0CA DN Nolatrexed DMOF0CA HS Phase 3 DMOF0CA SN Thymitaq; AG-337; ZX-337; Nolatrexed (intravenous), EXIMIAS DMOF0CA CP Agouron Pharmaceuticals Inc DMOF0CA DT Small molecular drug DMOF0CA PC 135400184 DMOF0CA MW 284.34 DMOF0CA FM C14H12N4OS DMOF0CA IC InChI=1S/C14H12N4OS/c1-8-2-3-10-11(13(19)18-14(15)17-10)12(8)20-9-4-6-16-7-5-9/h2-7H,1H3,(H3,15,17,18,19) DMOF0CA CS CC1=C(C2=C(C=C1)N=C(NC2=O)N)SC3=CC=NC=C3 DMOF0CA IK XHWRWCSCBDLOLM-UHFFFAOYSA-N DMOF0CA IU 2-amino-6-methyl-5-pyridin-4-ylsulfanyl-3H-quinazolin-4-one DMOF0CA CA CAS 147149-76-6 DMOF0CA DE Solid tumour/cancer DMMC3Y8 ID DMMC3Y8 DMMC3Y8 DN NPC-01 DMMC3Y8 HS Phase 3 DMMC3Y8 SN LEP pill; Low dose estrogen progestin pill (dysmenorrhea), Nobelpharma DMMC3Y8 CP Nobelpharma Co Ltd DMMC3Y8 DE Dysmenorrhea DMCMIJ1 ID DMCMIJ1 DMCMIJ1 DN NT0202 DMCMIJ1 HS Phase 3 DMCMIJ1 SN Amphetamine polistirex DMCMIJ1 CP Neos therapeutics DMCMIJ1 DE Attention deficit hyperactivity disorder DMA16IL ID DMA16IL DMA16IL DN NU-100 DMA16IL HS Phase 3 DMA16IL SN BaroFeron; Interferon beta-1b (PreEMT, multiple sclerosis), BaroFold; Interferon beta-1b (PreEMT, multiple sclerosis), NuronBiotech DMA16IL CP Nuron biotech DMA16IL PC 21987656 DMA16IL MW 378.5 DMA16IL FM C24H30N2O2 DMA16IL IC InChI=1S/C24H30N2O2/c27-23(25-21-7-3-1-4-8-21)19-13-11-18-16-20(14-12-17(18)15-19)24(28)26-22-9-5-2-6-10-22/h11-16,21-22H,1-10H2,(H,25,27)(H,26,28) DMA16IL CS C1CCC(CC1)NC(=O)C2=CC3=C(C=C2)C=C(C=C3)C(=O)NC4CCCCC4 DMA16IL IK MBSRTKPGZKQXQR-UHFFFAOYSA-N DMA16IL IU 2-N,6-N-dicyclohexylnaphthalene-2,6-dicarboxamide DMA16IL CA CAS 153250-52-3 DMA16IL DE Multiple sclerosis DM8JWNA ID DM8JWNA DM8JWNA DN NVP-LAQ824 DM8JWNA HS Phase 3 DM8JWNA SN Dacinostat; 404951-53-7; LAQ824; LAQ-824; LAQ824 (Dacinostat); UNII-V10P524501; (E)-N-hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]prop-2-enamide; CHEMBL356066; V10P524501; (2E)-N-hydroxy-3-[4-({(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino}methyl)phenyl]prop-2-enamide; Dacinostat [INN]; (E)-N-Hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]meth yl]phenyl]prop-2-enamide; (2E)-N-hydroxy-3-(4-{[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl}phenyl)prop-2-enamide; Dacinostat; NVP-LAQ 824; NVP-LAQ824, Dacinostat, LAQ824; LBH539 DM8JWNA CP Corcept Therapeutics DM8JWNA DT Small molecular drug DM8JWNA PC 6445533 DM8JWNA MW 379.5 DM8JWNA FM C22H25N3O3 DM8JWNA IC InChI=1S/C22H25N3O3/c26-14-13-25(12-11-19-15-23-21-4-2-1-3-20(19)21)16-18-7-5-17(6-8-18)9-10-22(27)24-28/h1-10,15,23,26,28H,11-14,16H2,(H,24,27)/b10-9+ DM8JWNA CS C1=CC=C2C(=C1)C(=CN2)CCN(CCO)CC3=CC=C(C=C3)/C=C/C(=O)NO DM8JWNA IK BWDQBBCUWLSASG-MDZDMXLPSA-N DM8JWNA IU (E)-N-hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]prop-2-enamide DM8JWNA CA CAS 404951-53-7 DM8JWNA CB CHEBI:94063 DM8JWNA DE leukaemia; Multiple myeloma; Mood disorder DM3L2GT ID DM3L2GT DM3L2GT DN O6-Benzylguanine alkylade DM3L2GT HS Phase 3 DM3L2GT SN KRX-0402; O6-Benzylguanine (BG) DM3L2GT CP Wiley-Liss; Keryx Biopharmaceuticals DM3L2GT DE Sarcoma DMENDP6 ID DMENDP6 DMENDP6 DN OBI-1 DMENDP6 HS Phase 3 DMENDP6 SN Porcine rFVIII, Ipsen/Inspiration; Porcine rFVIII, Octagen/Ipsen; Porcine rFactor VIII, Ipsen/Inspiration; Porcine rFactor VIII, Octagen/Ipsen; Recombinant porcine Factor VIII, Ipsen/Inspiration; Recombinant porcine Factor VIII, Octagen/Ipsen DMENDP6 CP Baxter international; inspiration biopharmaceuticals DMENDP6 DE Factor VIII deficiency DM7KI4E ID DM7KI4E DM7KI4E DN Oblimersen DM7KI4E HS Phase 3 DM7KI4E CP Genta Incorp DM7KI4E PC 118984457 DM7KI4E MW 6058 DM7KI4E FM C172H204N62Na17O91P17S17 DM7KI4E IC InChI=1S/C172H221N62O91P17S17.17Na/c1-69-39-225(169(253)213-149(69)237)117-21-73(236)92(292-117)44-274-326(257,343)320-85-33-129(229-63-191-135-141(181)187-61-189-143(135)229)303-103(85)55-285-332(263,349)314-79-27-122(221-17-9-113(177)201-165(221)249)295-95(79)47-278-330(261,347)312-78-26-121(220-16-8-112(176)200-164(220)248)298-98(78)50-280-338(269,355)322-87-35-131(231-65-193-137-145(231)205-157(183)209-153(137)241)305-105(87)57-287-334(265,351)316-81-29-124(223-19-11-115(179)203-167(223)251)299-99(81)51-281-339(270,356)323-88-36-132(232-66-194-138-146(232)206-158(184)210-154(138)242)307-107(88)59-289-337(268,354)319-84-32-128(228-42-72(4)152(240)216-172(228)256)302-102(84)54-284-341(272,358)325-90-38-134(234-68-196-140-148(234)208-160(186)212-156(140)244)306-106(90)58-288-335(266,352)317-82-30-125(224-20-12-116(180)204-168(224)252)300-100(82)52-282-340(271,357)324-89-37-133(233-67-195-139-147(233)207-159(185)211-155(139)243)308-108(89)60-290-342(273,359)321-86-34-130(230-64-192-136-142(182)188-62-190-144(136)230)304-104(86)56-286-333(264,350)315-80-28-123(222-18-10-114(178)202-166(222)250)296-96(80)48-277-328(259,345)310-76-24-119(218-14-6-110(174)198-162(218)246)294-94(76)46-276-329(260,346)311-77-25-120(219-15-7-111(175)199-163(219)247)297-97(77)49-279-336(267,353)318-83-31-127(227-41-71(3)151(239)215-171(227)255)301-101(83)53-283-331(262,348)313-75-23-118(217-13-5-109(173)197-161(217)245)293-93(75)45-275-327(258,344)309-74-22-126(291-91(74)43-235)226-40-70(2)150(238)214-170(226)254;;;;;;;;;;;;;;;;;/h5-20,39-42,61-68,73-108,117-134,235-236H,21-38,43-60H2,1-4H3,(H,257,343)(H,258,344)(H,259,345)(H,260,346)(H,261,347)(H,262,348)(H,263,349)(H,264,350)(H,265,351)(H,266,352)(H,267,353)(H,268,354)(H,269,355)(H,270,356)(H,271,357)(H,272,358)(H,273,359)(H2,173,197,245)(H2,174,198,246)(H2,175,199,247)(H2,176,200,248)(H2,177,201,249)(H2,178,202,250)(H2,179,203,251)(H2,180,204,252)(H2,181,187,189)(H2,182,188,190)(H,213,237,253)(H,214,238,254)(H,215,239,255)(H,216,240,256)(H3,183,205,209,241)(H3,184,206,210,242)(H3,185,207,211,243)(H3,186,208,212,244);;;;;;;;;;;;;;;;;/q;17*+1/p-17/t73-,74-,75-,76-,77-,78-,79-,80-,81-,82-,83-,84-,85-,86-,87-,88-,89-,90-,91+,92+,93+,94+,95+,96+,97+,98+,99+,100+,101+,102+,103+,104+,105+,106+,107+,108+,117+,118+,119+,120+,121+,122+,123+,124+,125+,126+,127+,128+,129+,130+,131+,132+,133+,134+,326?,327?,328?,329?,330?,331?,332?,333?,334?,335?,336?,337?,338?,339?,340?,341?,342?;;;;;;;;;;;;;;;;;/m0................./s1 DM7KI4E CS CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)COP(=S)([O-])O[C@H]3C[C@@H](O[C@@H]3COP(=O)(O[C@H]4C[C@@H](O[C@@H]4COP(=S)([O-])O[C@H]5C[C@@H](O[C@@H]5COP(=S)([O-])O[C@H]6C[C@@H](O[C@@H]6COP(=S)([O-])O[C@H]7C[C@@H](O[C@@H]7COP(=S)([O-])O[C@H]8C[C@@H](O[C@@H]8COP(=S)([O-])O[C@H]9C[C@@H](O[C@@H]9COP(=S)([O-])O[C@H]1C[C@@H](O[C@@H]1COP(=S)([O-])O[C@H]1C[C@@H](O[C@@H]1COP(=S)([O-])O[C@H]1C[C@@H](O[C@@H]1COP(=S)([O-])O[C@H]1C[C@@H](O[C@@H]1COP(=S)([O-])O[C@H]1C[C@@H](O[C@@H]1COP(=S)([O-])O[C@H]1C[C@@H](O[C@@H]1COP(=S)([O-])O[C@H]1C[C@@H](O[C@@H]1COP(=S)([O-])O[C@H]1C[C@@H](O[C@@H]1COP(=S)([O-])O[C@H]1C[C@@H](O[C@@H]1COP(=S)([O-])O[C@H]1C[C@@H](O[C@@H]1CO)N1C=C(C(=O)NC1=O)C)N1C=CC(=NC1=O)N)N1C=C(C(=O)NC1=O)C)N1C=CC(=NC1=O)N)N1C=CC(=NC1=O)N)N1C=CC(=NC1=O)N)N1C=NC2=C(N=CN=C21)N)N1C=NC2=C1N=C(NC2=O)N)N1C=CC(=NC1=O)N)N1C=NC2=C1N=C(NC2=O)N)N1C=C(C(=O)NC1=O)C)N1C=NC2=C1N=C(NC2=O)N)N1C=CC(=NC1=O)N)N1C=NC2=C1N=C(NC2=O)N)N1C=CC(=NC1=O)N)N1C=CC(=NC1=O)N)[S-])N1C=NC2=C(N=CN=C21)N)O.[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+] DM7KI4E IK IBXPAFBDJCXCDW-MHFPCNPESA-A DM7KI4E IU heptadecasodium;1-[(2R,4S,5R)-5-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-2-[[[(2R,3S,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-2-[[[(2R,3S,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-2-[[[(2R,3S,5R)-2-(hydroxymethyl)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]-5-(6-aminopurin-9-yl)oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-3-yl]oxy-sulfidophosphoryl]oxymethyl]-5-(6-aminopurin-9-yl)oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]-4-hydroxyoxolan-2-yl]-5-methylpyrimidine-2,4-dione DM7KI4E CA CAS 190977-41-4 DM7KI4E DE Multiple myeloma; Melanoma DMEDSVJ ID DMEDSVJ DMEDSVJ DN Ociperlimab DMEDSVJ HS Phase 3 DMEDSVJ SN BGB-A1217 DMEDSVJ CP BeiGene DMEDSVJ DT Antibody DMEDSVJ DE Cervical cancer; Non-small-cell lung cancer DM1EO3G ID DM1EO3G DM1EO3G DN Odanacatib DM1EO3G HS Phase 3 DM1EO3G SN MK 0822; MK0822; MK-0822A; Odanacatib (USAN) DM1EO3G CP Merck DM1EO3G DT Small molecular drug DM1EO3G PC 10152654 DM1EO3G MW 525.6 DM1EO3G FM C25H27F4N3O3S DM1EO3G IC InChI=1S/C25H27F4N3O3S/c1-23(2,26)14-20(22(33)32-24(15-30)12-13-24)31-21(25(27,28)29)18-6-4-16(5-7-18)17-8-10-19(11-9-17)36(3,34)35/h4-11,20-21,31H,12-14H2,1-3H3,(H,32,33)/t20-,21-/m0/s1 DM1EO3G CS CC(C)(C[C@@H](C(=O)NC1(CC1)C#N)N[C@@H](C2=CC=C(C=C2)C3=CC=C(C=C3)S(=O)(=O)C)C(F)(F)F)F DM1EO3G IK FWIVDMJALNEADT-SFTDATJTSA-N DM1EO3G IU (2S)-N-(1-cyanocyclopropyl)-4-fluoro-4-methyl-2-[[(1S)-2,2,2-trifluoro-1-[4-(4-methylsulfonylphenyl)phenyl]ethyl]amino]pentanamide DM1EO3G CA CAS 603139-19-1 DM1EO3G DE Osteoporosis DMYN391 ID DMYN391 DMYN391 DN Odevixibat DMYN391 HS Phase 3 DMYN391 SN 501692-44-0; UNII-2W150K0UUC; 2W150K0UUC; A4250; AZD8294; 501692-44-0 (free base); Odevixibat (USAN); Odevixibat [USAN]; AR-H064974; A-4250; (S)-2-((R)-2-(2-((3,3-Dibutyl-7-(methylthio)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydrobenzo[f][1,2,5]thiadiazepin-8-yl)oxy)acetamido)-2-(4-hydroxyphenyl)acetamido)butanoic acid; SCHEMBL946468; CHEMBL4297588; BDBM77040; GTPL11194; AZD-8294; example 5 [US9694018B1]; WHO 10706; HY-109120; Unk-D-nTyr-Abu-OH (IUPAC condensed name); CS-0078340; D11716; US9694018, 5; (2S)-2-(((2R)-2-((((3,3-Dibutyl-7-(methylthio)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro- 1,2,5-benzothiadiazepin-8-yl)oxy)acetyl)amino)-2-(4-hydroxyphenyl)acetyl)amino)butanoic acid; (2S)-2-[[(2R)-2-[[2-[(3,3-dibutyl-7-methylsulfanyl-1,1-dioxo-5-phenyl-2,4-dihydro-1lambda6,2,5-benzothiadiazepin-8-yl)oxy]acetyl]amino]-2-(4-hydroxyphenyl)acetyl]amino]butanoic acid; Butanoic acid, 2-(((2R)-((((3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl)oxy)acetyl)amino)(4-hydroxyphenyl)acetyl)amino)-, (2S)-; Butanoic acid, 2-(((2R)-2-((2-((3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl)oxy)acetyl)amino)-2-(4-hydroxyphenyl)acetyl)amino)-, (2S)- DMYN391 CP Albireo Pharma DMYN391 DT Small molecular drug DMYN391 PC 10153627 DMYN391 MW 740.9 DMYN391 FM C37H48N4O8S2 DMYN391 IC InChI=1S/C37H48N4O8S2/c1-5-8-19-37(20-9-6-2)24-41(26-13-11-10-12-14-26)29-21-31(50-4)30(22-32(29)51(47,48)40-37)49-23-33(43)39-34(25-15-17-27(42)18-16-25)35(44)38-28(7-3)36(45)46/h10-18,21-22,28,34,40,42H,5-9,19-20,23-24H2,1-4H3,(H,38,44)(H,39,43)(H,45,46)/t28-,34+/m0/s1 DMYN391 CS CCCCC1(CN(C2=CC(=C(C=C2S(=O)(=O)N1)OCC(=O)N[C@H](C3=CC=C(C=C3)O)C(=O)N[C@@H](CC)C(=O)O)SC)C4=CC=CC=C4)CCCC DMYN391 IK XULSCZPZVQIMFM-IPZQJPLYSA-N DMYN391 IU (2S)-2-[[(2R)-2-[[2-[(3,3-dibutyl-7-methylsulfanyl-1,1-dioxo-5-phenyl-2,4-dihydro-1lambda6,2,5-benzothiadiazepin-8-yl)oxy]acetyl]amino]-2-(4-hydroxyphenyl)acetyl]amino]butanoic acid DMYN391 CA CAS 501692-44-0 DMYN391 DE Alagille syndrome DMBWO5T ID DMBWO5T DMBWO5T DN ODT-8 DMBWO5T HS Phase 3 DMBWO5T SN H-c(Cys3-Phe6-Phe7-DTrp8-Lys9-Thr10-Phe11-Cys14)-OH; CHEMBL266477; BDBM50136824; (4R,7S,10S,13S,16R,19S,22S,25R)-16-((1H-indol-3-yl)methyl)-25-amino-13-(4-aminobutyl)-7,19,22-tribenzyl-10-((R)-1-hydroxyethyl)-6,9,12,15,18,21,24-heptaoxo-1,2-dithia-5,8,11,14,17,20,23-heptaazacyclohexacosane-4-carboxylic acid DMBWO5T PC 11251755 DMBWO5T MW 1079.3 DMBWO5T FM C54H66N10O10S2 DMBWO5T IC InChI=1S/C54H66N10O10S2/c1-32(65)46-53(72)62-43(27-35-19-9-4-10-20-35)51(70)63-45(54(73)74)31-76-75-30-38(56)47(66)59-41(25-33-15-5-2-6-16-33)49(68)60-42(26-34-17-7-3-8-18-34)50(69)61-44(28-36-29-57-39-22-12-11-21-37(36)39)52(71)58-40(48(67)64-46)23-13-14-24-55/h2-12,15-22,29,32,38,40-46,57,65H,13-14,23-28,30-31,55-56H2,1H3,(H,58,71)(H,59,66)(H,60,68)(H,61,69)(H,62,72)(H,63,70)(H,64,67)(H,73,74)/t32-,38+,40+,41+,42+,43+,44-,45+,46+/m1/s1 DMBWO5T CS C[C@H]([C@H]1C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)CC5=CC=CC=C5)N)C(=O)O)CC6=CC=CC=C6)O DMBWO5T IK PJRZZHKHLDKTKL-OCZUONHDSA-N DMBWO5T IU (4R,7S,10S,13S,16R,19S,22S,25R)-25-amino-13-(4-aminobutyl)-7,19,22-tribenzyl-10-[(1R)-1-hydroxyethyl]-16-(1H-indol-3-ylmethyl)-6,9,12,15,18,21,24-heptaoxo-1,2-dithia-5,8,11,14,17,20,23-heptazacyclohexacosane-4-carboxylic acid DM1FBZ7 ID DM1FBZ7 DM1FBZ7 DN Olodaterol/tiotropium bromide DM1FBZ7 HS Phase 3 DM1FBZ7 SN 136310-93-5; UNII-XX112XZP0J; XX112XZP0J; (1R,2R,4S,5S,7s)-7-(2-Hydroxy-2,2-di(thiophen-2-yl)acetoxy)-9,9-dimethyl-3-oxa-9-azatricyclo[3.3.1.02,4]nonan-9-ium bromide; AK-72842; (1R,2R,4S,5S,7S)-7-(2-Hydroxy-2,2-di(thiophen-2-yl)acetoxy)-9,9-dimethyl-3-oxa-9-azatricyclo[3.3.1.0 DM1FBZ7 CP Boehringer Ingelheim Pharmaceuticals DM1FBZ7 DT Small molecular drug DM1FBZ7 PC 5487426 DM1FBZ7 MW 472.4 DM1FBZ7 FM C19H22BrNO4S2 DM1FBZ7 IC InChI=1S/C19H22NO4S2.BrH/c1-20(2)12-9-11(10-13(20)17-16(12)24-17)23-18(21)19(22,14-5-3-7-25-14)15-6-4-8-26-15;/h3-8,11-13,16-17,22H,9-10H2,1-2H3;1H/q+1;/p-1/t11?,12-,13+,16-,17+; DM1FBZ7 CS C[N+]1([C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)C(C4=CC=CS4)(C5=CC=CS5)O)C.[Br-] DM1FBZ7 IK DQHNAVOVODVIMG-RGECMCKFSA-M DM1FBZ7 IU [(1R,2R,4S,5S)-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonan-7-yl] 2-hydroxy-2,2-dithiophen-2-ylacetate;bromide DM1FBZ7 CA CAS 136310-93-5 DM1FBZ7 CB CHEBI:90959 DM1FBZ7 DE Chronic obstructive pulmonary disease DM4Z9QI ID DM4Z9QI DM4Z9QI DN Olokizumab DM4Z9QI HS Phase 3 DM4Z9QI CP UCB DM4Z9QI DT Monoclonal antibody DM4Z9QI DE Rheumatoid arthritis DM624TW ID DM624TW DM624TW DN Omecamtiv mecarbil DM624TW HS Phase 3 DM624TW SN Omecamtiv mecarbil; 873697-71-3; Omecamtiv mecarbil (CK-1827452); CK-1827452; CK1827452; UNII-2M19539ERK; CK 1827452; methyl 4-(2-fluoro-3-(3-(6-Methylpyridin-3-yl)ureido)benzyl)piperazine-1-carboxylate; CHEMBL1800955; AMG-423; 2M19539ERK; Methyl 4-(2-Fluoro-3-{[(6-Methylpyridin-3-Yl)carbamoyl]amino}benzyl)piperazine-1-Carboxylate; Methyl 4-[[2-fluoro-3-[n'-(6-methylpyridin-3-yl)ureido]phenyl]methyl]piperazine-1-carboxylate; Omecamtiv mecarbil [USAN:INN]; omecamtiv mercarbil; MLS006011266; SCHEMBL400544; Omecamtiv Mecarbil; DM624TW CP Amgen DM624TW DT Small molecular drug DM624TW PC 11689883 DM624TW MW 401.4 DM624TW FM C20H24FN5O3 DM624TW IC InChI=1S/C20H24FN5O3/c1-14-6-7-16(12-22-14)23-19(27)24-17-5-3-4-15(18(17)21)13-25-8-10-26(11-9-25)20(28)29-2/h3-7,12H,8-11,13H2,1-2H3,(H2,23,24,27) DM624TW CS CC1=NC=C(C=C1)NC(=O)NC2=CC=CC(=C2F)CN3CCN(CC3)C(=O)OC DM624TW IK RFUBTTPMWSKEIW-UHFFFAOYSA-N DM624TW IU methyl 4-[[2-fluoro-3-[(6-methylpyridin-3-yl)carbamoylamino]phenyl]methyl]piperazine-1-carboxylate DM624TW CA CAS 873697-71-3 DM624TW DE Heart failure DMBWY8V ID DMBWY8V DMBWY8V DN Omega-6-FA DMBWY8V HS Phase 3 DMBWY8V SN Fatty Acids, Omega-6; Omega-6 Fatty Acids; Omega-6 Polyunsaturates; N-6 Fatty Acids; SCHEMBL17080398 DMBWY8V PC 56842208 DMBWY8V MW 584.9 DMBWY8V FM C38H64O4 DMBWY8V IC ZCDMRPMKAQLWAO-PZLFCYFRSA-N DMBWY8V CS CCCCCC=CCC=CCCCCCCCC(=O)O.CCCCCC=CCC=CCC=CCC=CCCCC(=O)O DMBWY8V IK 1S/C20H32O2.C18H32O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20(21)22;1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18(19)20/h6-7,9-10,12-13,15-16H,2-5,8,11,14,17-19H2,1H3,(H,21,22);6-7,9-10H,2-5,8,11-17H2,1H3,(H,19,20)/b7-6-,10-9-,13-12-,16-15-;7-6-,10-9- DMBWY8V IU (5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoic acid;(9Z,12Z)-octadeca-9,12-dienoic acid DMBWY8V DE Attention deficit hyperactivity disorder DMK6QBZ ID DMK6QBZ DMK6QBZ DN OMS721 DMK6QBZ HS Phase 3 DMK6QBZ CP Omeros, Seattle, WA DMK6QBZ DE Thrombotic microangiopathy; Glomerulonephritis; Lupus; Atypical hemolytic uremic syndrome DMU86DM ID DMU86DM DMU86DM DN ONO-1101 DMU86DM HS Phase 3 DMU86DM SN Landiolol; Landiolol [INN]; ONO-1101; Ono 1101; (S-(R*,R*))-(2,2-Dimethyl-1,3-dioxolan-4-yl)methyl 4-(2-hydroxy-3-((2-((4-morpholinylcarbonyl)amino)ethyl)amino)propoxy)benzenepropanoate; 133242-30-5; 62NWQ924LH; Benzenepropanoic acid, 4-((2S)-2-hydroxy-3-((2-((4-morpholinylcarbonyl)amino)ethyl)amino)propoxy)-, ((4S)-2,2-dimethyl-1,3-dioxolan-4-yl)methyl ester; UNII-62NWQ924LH; [(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]methyl 3-[4-[(2S)-2-hydroxy-3-[2-(morpholine-4-carbonylamino)ethylamino]propoxy]phenyl]propanoate DMU86DM PC 114905 DMU86DM MW 509.6 DMU86DM FM C25H39N3O8 DMU86DM IC WMDSZGFJQKSLLH-RBBKRZOGSA-N DMU86DM CS CC1(OCC(O1)COC(=O)CCC2=CC=C(C=C2)OCC(CNCCNC(=O)N3CCOCC3)O)C DMU86DM IK 1S/C25H39N3O8/c1-25(2)35-18-22(36-25)17-34-23(30)8-5-19-3-6-21(7-4-19)33-16-20(29)15-26-9-10-27-24(31)28-11-13-32-14-12-28/h3-4,6-7,20,22,26,29H,5,8-18H2,1-2H3,(H,27,31)/t20-,22+/m0/s1 DMU86DM IU [(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]methyl 3-[4-[(2S)-2-hydroxy-3-[2-(morpholine-4-carbonylamino)ethylamino]propoxy]phenyl]propanoate DMU86DM CA CAS 133242-30-5 DMU86DM CB CHEBI:135809 DMU86DM DE Atrial fibrillation DM06KRC ID DM06KRC DM06KRC DN Oregovomab DM06KRC HS Phase 3 DM06KRC CP Quest PharmaTech DM06KRC DT Monoclonal antibody DM06KRC DE Ovarian cancer; Epithelial ovarian cancer DMWD3IV ID DMWD3IV DMWD3IV DN Oseltamivir + hydroxychloroquine DMWD3IV HS Phase 3 DMWD3IV SN Tamiflu + oxichloroquine DMWD3IV TC Antiviral Agents DMWD3IV DT Combination drug DMWD3IV DE Coronavirus Disease 2019 (COVID-19) DMHKZLF ID DMHKZLF DMHKZLF DN OSI-906 DMHKZLF HS Phase 3 DMHKZLF SN Linsitinib; 867160-71-2; OSI-906; Linsitinib(OSI-906); OSI906; OSI 906; OSI-906AA; OSI-906 (Linsitinib); UNII-15A52GPT8T; Kinome_3532; ASP-7487; 3-[8-amino-1-(2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl]-1-methylcyclobutan-1-ol; 15A52GPT8T; CHEMBL1091644; MMV676605; cis-3-[8-Amino-1-(2-phenyl-7-quinolinyl)imidazo[1,5-a]pyrazin-3-yl]-1-methylcyclobutanol; C26H23N5O; cis-3-(8-amino-1-(2-phenyl-7-quinolinyl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanol; Linsitinib [USAN:INN]; OSI906/Linsitinib/; Linsitinib; OSI-906 DMHKZLF DT Small molecular drug DMHKZLF PC 11640390 DMHKZLF MW 421.5 DMHKZLF FM C26H23N5O DMHKZLF IC InChI=1S/C26H23N5O/c1-26(32)14-19(15-26)25-30-22(23-24(27)28-11-12-31(23)25)18-8-7-17-9-10-20(29-21(17)13-18)16-5-3-2-4-6-16/h2-13,19,32H,14-15H2,1H3,(H2,27,28) DMHKZLF CS CC1(CC(C1)C2=NC(=C3N2C=CN=C3N)C4=CC5=C(C=C4)C=CC(=N5)C6=CC=CC=C6)O DMHKZLF IK PKCDDUHJAFVJJB-UHFFFAOYSA-N DMHKZLF IU 3-[8-amino-1-(2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl]-1-methylcyclobutan-1-ol DMHKZLF CA CAS 867160-71-2 DMHKZLF CB CHEBI:91402 DMHKZLF DE Solid tumour/cancer DM7R145 ID DM7R145 DM7R145 DN Otesaconazole DM7R145 HS Phase 3 DM7R145 SN Oteseconazole; 1340593-59-0; VT-1161; UNII-VHH774W97N; VHH774W97N; CHEMBL3311228; (R)-2-(2,4-Difluorophenyl)-1,1-Difluoro-3-(1h-Tetrazol-1-Yl)-1-(5-(4-(2,2,2-Trifluoroethoxy)phenyl)pyridin-2-Yl)propan-2-Ol; Oteseconazole [USAN]; Oteseconazole (USAN/INN); SCHEMBL17113021; BDBM50046187; WHO 10138; DB13055; SB17420; HY-17643; CS-0016914; D11785; Q27291837; (2R)-2-(2,4-difluorophenyl)-1,1-difluoro-3-(1H-tetrazol-1-yl)-1-{5-[4-(2,2,2-trifluoroethoxy)phenyl]pyridin-2-yl}propan-2-ol; (2R)-2-(2,4-difluorophenyl)-1,1-difluoro-3-(tetrazol-1-yl)-1-[5-[4-(2,2,2-trifluoroethoxy)phenyl]pyridin-2-yl]propan-2-ol; 2-Pyridineethanol, alpha-(2,4-difluorophenyl)-beta,beta-difluoro-alpha-(1H-tetrazol-1-ylmethyl)-5-(4-(2,2,2-trifluoroethoxy)phenyl)-, (alphaR)- DM7R145 CP Mycovia Pharmaceuticals DM7R145 DT Small molecular drug DM7R145 PC 77050711 DM7R145 MW 527.4 DM7R145 FM C23H16F7N5O2 DM7R145 IC InChI=1S/C23H16F7N5O2/c24-16-4-7-18(19(25)9-16)21(36,11-35-13-32-33-34-35)23(29,30)20-8-3-15(10-31-20)14-1-5-17(6-2-14)37-12-22(26,27)28/h1-10,13,36H,11-12H2/t21-/m0/s1 DM7R145 CS C1=CC(=CC=C1C2=CN=C(C=C2)C([C@](CN3C=NN=N3)(C4=C(C=C(C=C4)F)F)O)(F)F)OCC(F)(F)F DM7R145 IK IDUYJRXRDSPPRC-NRFANRHFSA-N DM7R145 IU (2R)-2-(2,4-difluorophenyl)-1,1-difluoro-3-(tetrazol-1-yl)-1-[5-[4-(2,2,2-trifluoroethoxy)phenyl]pyridin-2-yl]propan-2-ol DM7R145 CA CAS 1340593-59-0 DM7R145 DE Onychomycosis; Vulvovaginal Candidiasis DMLMS6J ID DMLMS6J DMLMS6J DN OTL-101 DMLMS6J HS Phase 3 DMLMS6J CP Orchard Therapeutics DMLMS6J DT Gene therapy DMLMS6J DE Severe combined immunodeficiency DM3BK2Y ID DM3BK2Y DM3BK2Y DN OTL-103 DM3BK2Y HS Phase 3 DM3BK2Y CP Orchard Therapeutics DM3BK2Y DT Gene therapy DM3BK2Y DE Wiskott-Aldrich syndrome DM5DRMY ID DM5DRMY DM5DRMY DN P1101 DM5DRMY HS Phase 3 DM5DRMY SN N-Phenylethylenediamine; 1664-40-0; N1-Phenylethane-1,2-diamine; N-(2-Aminoethyl)aniline; 1,2-Ethanediamine, N-phenyl-; Ethylenediamine, N-phenyl-; N-Phenyl-1,2-ethanediamine; 1,2-Ethanediamine, N1-phenyl-; Benzenamine, N-(2-aminoethyl)-; N'-phenylethane-1,2-diamine; N-phenylethane-1,2-diamine; n1-phenyl-1,2-ethanediamine; MFCD00008162; (2-aminoethyl)phenylamine; N-Phenylethylenediamine, 99%; NSC84247; phenylethylenediamine; EINECS 216-773-4; NSC 84247; 2-phenylaminoethylamine; phenyl ethylene diamine; ACMC-209duf; N -phenylethylenediamine; N-phenyl ethylenediamine; N-phenyl ethylene diamine; N-phenyl-ethylene-diamine; N-(2-aminoethyl)-aniline; N-phenyl ethyl-ene diamine; n2-phenyl-1,2-ethanediamine; N-phenyl-ethane-1,2-diamine; SCHEMBL307775; N-Phenylethylenediamine, 98%; N'-phenyl-ethane-1,2-diamine; N1-phenyl-ethane-1,2-diamine; DTXSID1061861; OCIDXARMXNJACB-UHFFFAOYSA-; Ethylenediamine, N-phenyl- (8CI); STR05027; ZINC1736738; 8473AA; ANW-22213; NSC-84247; SBB004200; STL257388; AKOS005135725; LS10740; MCULE-5870561171; NE53436; AC-25457; AK122216; SY009366; DB-043652; CS-0045385; FT-0629102; ST45237853; EN300-81504; J-010281 DM5DRMY CP PharmaEssentia DM5DRMY DT Small molecular drug DM5DRMY PC 74270 DM5DRMY MW 136.19 DM5DRMY FM C8H12N2 DM5DRMY IC InChI=1S/C8H12N2/c9-6-7-10-8-4-2-1-3-5-8/h1-5,10H,6-7,9H2 DM5DRMY CS C1=CC=C(C=C1)NCCN DM5DRMY IK OCIDXARMXNJACB-UHFFFAOYSA-N DM5DRMY IU N'-phenylethane-1,2-diamine DM5DRMY CA CAS 1664-40-0 DM5DRMY DE Polycythemia vera DM7WYXJ ID DM7WYXJ DM7WYXJ DN P-1101 DM7WYXJ HS Phase 3 DM7WYXJ SN Pegylated interferon alpha (hepatitis B and C virus infection), PharmaEssentia; Pegylated interferon alpha-2b (polycythemia vera), AOP Orphan; PEG-INF-alpha (hepatitis B and C virus infection), PharmaEssentia; PEG-P-IFN-alpha-2b DM7WYXJ CP Hanall biopharma; medtronic DM7WYXJ DE Hepatitis B virus infection; Essential thrombocythemia; Myelofibrosis DM9PVHX ID DM9PVHX DM9PVHX DN P2B-001 DM9PVHX HS Phase 3 DM9PVHX SN Fixed-dose combination therapy (Parkinsons diease), Pharma Two B DM9PVHX CP Pharma Two B Ltd DM9PVHX DE Parkinson disease DM1T6ZN ID DM1T6ZN DM1T6ZN DN Pacritinib DM1T6ZN HS Phase 3 DM1T6ZN SN JAK inhibitor (alone or in combination)s DM1T6ZN CP Cell Therapeutics DM1T6ZN DT Small molecular drug DM1T6ZN PC 46216796 DM1T6ZN MW 472.6 DM1T6ZN FM C28H32N4O3 DM1T6ZN IC InChI=1S/C28H32N4O3/c1-2-13-32(12-1)14-17-35-27-9-8-25-19-24(27)21-34-16-4-3-15-33-20-22-6-5-7-23(18-22)26-10-11-29-28(30-25)31-26/h3-11,18-19H,1-2,12-17,20-21H2,(H,29,30,31)/b4-3+ DM1T6ZN CS C1CCN(C1)CCOC2=C3COC/C=C/COCC4=CC(=CC=C4)C5=NC(=NC=C5)NC(=C3)C=C2 DM1T6ZN IK HWXVIOGONBBTBY-ONEGZZNKSA-N DM1T6ZN IU (16E)-11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,27-triazatetracyclo[19.3.1.12,6.18,12]heptacosa-1(24),2(27),3,5,8(26),9,11,16,21(25),22-decaene DM1T6ZN CA CAS 937272-79-2 DM1T6ZN DE Myelofibrosis DMFKOR9 ID DMFKOR9 DMFKOR9 DN Pafuramidine DMFKOR9 HS Phase 3 DMFKOR9 SN Pafuramidine maleate; DB-289; DB-290; DB-75 prodrug, Immtech; Pafuramidine maleate (oral formulation), Strativa DMFKOR9 CP Immtech International; University of North Carolina DMFKOR9 DT Small molecular drug DMFKOR9 PC 5480200 DMFKOR9 MW 364.4 DMFKOR9 FM C20H20N4O3 DMFKOR9 IC InChI=1S/C20H20N4O3/c1-25-23-19(21)15-7-3-13(4-8-15)17-11-12-18(27-17)14-5-9-16(10-6-14)20(22)24-26-2/h3-12H,1-2H3,(H2,21,23)(H2,22,24) DMFKOR9 CS CO/N=C(\\N)/C1=CC=C(C=C1)C2=CC=C(O2)C3=CC=C(C=C3)/C(=N/OC)/N DMFKOR9 IK UKOQVLAXCBRRGH-UHFFFAOYSA-N DMFKOR9 IU N'-methoxy-4-[5-[4-[(Z)-N'-methoxycarbamimidoyl]phenyl]furan-2-yl]benzenecarboximidamide DMFKOR9 CA CAS 186953-56-0 DMFKOR9 DE Malaria DMAD2OZ ID DMAD2OZ DMAD2OZ DN Palovarotene DMAD2OZ HS Phase 3 DMAD2OZ SN R-667; RG-667; Retinoid receptor agonist, Roche; Ro-3300074; Ro-330074 DMAD2OZ CP Roche DMAD2OZ DT Small molecular drug DMAD2OZ PC 10295295 DMAD2OZ MW 414.5 DMAD2OZ FM C27H30N2O2 DMAD2OZ IC InChI=1S/C27H30N2O2/c1-26(2)12-13-27(3,4)24-17-22(18-29-15-5-14-28-29)21(16-23(24)26)11-8-19-6-9-20(10-7-19)25(30)31/h5-11,14-17H,12-13,18H2,1-4H3,(H,30,31)/b11-8+ DMAD2OZ CS CC1(CCC(C2=C1C=C(C(=C2)/C=C/C3=CC=C(C=C3)C(=O)O)CN4C=CC=N4)(C)C)C DMAD2OZ IK YTFHCXIPDIHOIA-DHZHZOJOSA-N DMAD2OZ IU 4-[(E)-2-[5,5,8,8-tetramethyl-3-(pyrazol-1-ylmethyl)-6,7-dihydronaphthalen-2-yl]ethenyl]benzoic acid DMAD2OZ CA CAS 410528-02-8 DMAD2OZ DE Emphysema; Fibrodysplasia ossificans progressiva DM4SKYI ID DM4SKYI DM4SKYI DN PAMAQUESIDE DM4SKYI HS Phase 3 DM4SKYI SN CP-148623; Pamaqueside < Prop INN; 11-Ketotigogenyl beta-O-cellobioside DM4SKYI DT Small molecular drug DM4SKYI PC 9918516 DM4SKYI MW 754.9 DM4SKYI FM C39H62O14 DM4SKYI IC InChI=1S/C39H62O14/c1-17-7-10-39(48-16-17)18(2)27-24(53-39)12-22-21-6-5-19-11-20(8-9-37(19,3)28(21)23(42)13-38(22,27)4)49-35-33(47)31(45)34(26(15-41)51-35)52-36-32(46)30(44)29(43)25(14-40)50-36/h17-22,24-36,40-41,43-47H,5-16H2,1-4H3/t17-,18+,19+,20+,21+,22+,24+,25-,26-,27+,28-,29-,30+,31-,32-,33-,34-,35-,36+,37+,38+,39-/m1/s1 DM4SKYI CS C[C@@H]1CC[C@@]2([C@H]([C@H]3[C@@H](O2)C[C@@H]4[C@@]3(CC(=O)[C@H]5[C@H]4CC[C@@H]6[C@@]5(CC[C@@H](C6)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO)O[C@H]8[C@@H]([C@H]([C@@H]([C@H](O8)CO)O)O)O)O)O)C)C)C)OC1 DM4SKYI IK VWMZIGBYZQUQOA-QEEMJVPDSA-N DM4SKYI IU (1S,2S,4S,5'R,6R,7S,8R,9S,12S,13S,16S,18S)-16-[(2R,3R,4R,5S,6R)-3,4-dihydroxy-6-(hydroxymethyl)-5-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-5',7,9,13-tetramethylspiro[5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icosane-6,2'-oxane]-11-one DM4SKYI CA CAS 150332-35-7 DM4SKYI DE Hyperlipidaemia DMIRYU9 ID DMIRYU9 DMIRYU9 DN Pancopride DMIRYU9 HS Phase 3 DMIRYU9 SN LAS-30451 DMIRYU9 CP Almirall Prodesfarma SA DMIRYU9 DT Small molecular drug DMIRYU9 PC 71342 DMIRYU9 MW 349.9 DMIRYU9 FM C18H24ClN3O2 DMIRYU9 IC InChI=1S/C18H24ClN3O2/c19-14-7-13(17(8-15(14)20)24-10-11-1-2-11)18(23)21-16-9-22-5-3-12(16)4-6-22/h7-8,11-12,16H,1-6,9-10,20H2,(H,21,23) DMIRYU9 CS C1CC1COC2=CC(=C(C=C2C(=O)NC3CN4CCC3CC4)Cl)N DMIRYU9 IK DBQMQBCSKXTCIJ-UHFFFAOYSA-N DMIRYU9 IU 4-amino-N-(1-azabicyclo[2.2.2]octan-3-yl)-5-chloro-2-(cyclopropylmethoxy)benzamide DMIRYU9 DE Nausea DMEW5Z8 ID DMEW5Z8 DMEW5Z8 DN PARABEN DMEW5Z8 HS Phase 3 DM3H2U4 ID DM3H2U4 DM3H2U4 DN Patrome DM3H2U4 HS Phase 3 DM3H2U4 CP GlaxoSmithKline DM3H2U4 DE Parkinson disease DMHXTAQ ID DMHXTAQ DMHXTAQ DN Pazufloxacin DMHXTAQ HS Phase 3 DMHXTAQ SN 127045-41-4; T-3761; UNII-4CZ1R38NDI; 4CZ1R38NDI; NCGC00167534-01; DSSTox_CID_26697; DSSTox_RID_81831; DSSTox_GSID_46697; Pazufloxacin [INN]; SMR000466380; CCRIS 7312; CAS-127045-41-4; T 3761; 127046-18-8; PZFX; Pazufloxacin (JAN/INN); SCHEMBL34460; 7H-Pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid, 10-(1-aminocyclopropyl)-9-fluoro-2,3-dihydro-3-methyl-7-oxo-, (S)-; MLS000759513; MLS001424116; CHEMBL240163; DTXSID5046697; CHEBI:94700; HY-B0724B; HMS2051B05; HMS2090H07; BCP12954; LSM-5745; RKL10069; ZINC3779726; Tox21_112531; BDBM50248017; MFCD00865012; AKOS015900451; Tox21_112531_1; AC-3506; CCG-100919; DB11774; GM-1171; KS-5008; NC00169; NCGC00167534-02; (-)-(3S)-10-(1-Aminocyclopropyl)-9-fluoro-2,3-dihydro-3-methyl-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid; 7H-Pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid, 2,3-dihydro-10-(1-aminocyclopropyl)-9-fluoro-3-methyl-7-oxo-, (S)-; AB0012715; D01153; AB00639918-07; AB00639918-09; AB00639918_10; Pazufloxacin, VETRANAL(TM), analytical standard; SR-01000759348; J-005457; Q3898423; SR-01000759348-4; (S)-10-(1-aminocyclopropyl)-9-fluoro-3-methyl-7-oxo-3,7-dihydro-2H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid; (S)-10-(1-aminocyclopropyl)-9-fluoro-3-methyl-7-oxo2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acid; 7H-Pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid,10-(1-aminocyclopropyl)-9-fluoro-2,3-dihydro-3-methyl-7-oxo-, (3S)-; 7H-Pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylicacid,10-(1-aminocyclopropyl)-9-fluoro-2,3-dihydro-3-methyl-7-oxo- DMHXTAQ DT Small molecular drug DMHXTAQ PC 65957 DMHXTAQ MW 318.3 DMHXTAQ FM C16H15FN2O4 DMHXTAQ IC InChI=1S/C16H15FN2O4/c1-7-6-23-14-11(16(18)2-3-16)10(17)4-8-12(14)19(7)5-9(13(8)20)15(21)22/h4-5,7H,2-3,6,18H2,1H3,(H,21,22)/t7-/m0/s1 DMHXTAQ CS C[C@H]1COC2=C3N1C=C(C(=O)C3=CC(=C2C4(CC4)N)F)C(=O)O DMHXTAQ IK XAGMUUZPGZWTRP-ZETCQYMHSA-N DMHXTAQ IU (2S)-6-(1-aminocyclopropyl)-7-fluoro-2-methyl-10-oxo-4-oxa-1-azatricyclo[7.3.1.05,13]trideca-5(13),6,8,11-tetraene-11-carboxylic acid DMHXTAQ CA CAS 127045-41-4 DMHXTAQ CB CHEBI:94700 DMHXTAQ DE Conjunctivitis DMP3G0W ID DMP3G0W DMP3G0W DN Pazufloxacin DMP3G0W HS Phase 3 DMP3G0W SN Pazufloxacin; T-3761; Pazufloxacin [INN]; UNII-4CZ1R38NDI; CCRIS 7312; T 3761; 4CZ1R38NDI; C16H15FN2O4; NCGC00167534-01; DSSTox_CID_26697; DSSTox_RID_81831; DSSTox_GSID_46697; 7H-Pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid, 10-(1-aminocyclopropyl)-9-fluoro-2,3-dihydro-3-methyl-7-oxo-, (S)-; SMR000466380; (-)-(3S)-10-(1-Aminocyclopropyl)-9-fluoro-2,3-dihydro-3-methyl-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid DMP3G0W PC 65957 DMP3G0W MW 318.3 DMP3G0W FM C16H15FN2O4 DMP3G0W IC InChI=1S/C16H15FN2O4/c1-7-6-23-14-11(16(18)2-3-16)10(17)4-8-12(14)19(7)5-9(13(8)20)15(21)22/h4-5,7H,2-3,6,18H2,1H3,(H,21,22)/t7-/m0/s1 DMP3G0W CS CC1COC2=C3N1C=C(C(=O)C3=CC(=C2C4(CC4)N)F)C(=O)O DMP3G0W IK XAGMUUZPGZWTRP-ZETCQYMHSA-N DMP3G0W IU (2S)-6-(1-aminocyclopropyl)-7-fluoro-2-methyl-10-oxo-4-oxa-1-azatricyclo[7.3.1.05,13]trideca-5(13),6,8,11-tetraene-11-carboxylic acid DMP3G0W CA CAS 127045-41-4 DMP3G0W CB CHEBI:94700 DMP3G0W DE Bacterial conjunctivitis DMJBHO0 ID DMJBHO0 DMJBHO0 DN PC-DAC:Insulin DMJBHO0 HS Phase 3 DMJBHO0 SN Capsulin; Intesulin; Macrulin; Nodlin; SuliXen; AERx Diabetes Management System; AERx iDMS; Capsulin IR; Capsulin OAD; Capsulin insulin replacement; Insulin tregopil; Ultrafast Insulin program; HIM2; AERx (insulin); AT-1391; AT-2391; Analog-PH20; CADDYS (insulin); CJC-1530; CJC-1531; CJC-1575; CJC-1576; Capsulin oral anti-diabetic; DTY-001; GW-843362; GW-843362M; Hexyl insulin monoconjugate, Nobex; IN-105; Inhaled insulin, Andaris; Insulin-PH20; Intesulin-1; Intesulin-IVE; NB-058; NIN-058; NN-1998; ORMD-0801; Oral insulin, Emisphere; Oral insulin, Nobex; PC-Insulin; Inhaled insulin, QDose/BMS; Inhaled insulin, Quadrant/MicroDose; Insulin (inhaled), Aradigm; Insulin (inhaled), QDose; Insulin (inhaled),Translational Research; Insulin (oral), Biocon; Insulin (oral), Coremed; Insulin (oral), Protein Delivery Inc; Insulin (pulmonary), Translational Research; MicroPor (insulin), Altea DMJBHO0 CP Lipoxen plc; Aradigm; Translational Research Ltd; Diabetology Ltd; Coremed Inc; Nobex Corp; Altea Therapeutics; ConjuChem Biotechnologies Inc; Bioglan Pharmaceuticals Co; Epic Therapeutics Inc; NOD Pharmaceuticals Inc; Andaris Group Ltd; Emisphere Technologies Inc; halozyme therapeutics DMJBHO0 DE Type-1 diabetes; Type-2 diabetes DMMBC5W ID DMMBC5W DMMBC5W DN PDGF-BB DMMBC5W HS Phase 3 DMMBC5W SN PDGF-BB (BioChaperone technology, diabetic foot ulcer/venous ulcers/burns) DMMBC5W CP Adocia SAS DMMBC5W DE Diabetic foot ulcer DM53J6B ID DM53J6B DM53J6B DN PDR001 DM53J6B HS Phase 3 DM53J6B CP Novartis Oncology East Hanover, NJ DM53J6B DT Antibody DM53J6B DE Lymphoma; Neuroendocrine cancer; Solid tumour/cancer; Melanoma; Esophageal squamous cell carcinoma DMBKWAF ID DMBKWAF DMBKWAF DN Peg-G-CSF DMBKWAF HS Phase 3 DMBKWAF SN Peg-G-CSF (chemotherapy induced side effects) DMBKWAF CP Phage Biotechnology Corp DMBKWAF DE Solid tumour/cancer DMK6OFY ID DMK6OFY DMK6OFY DN Peginterferon lambda-1a DMK6OFY HS Phase 3 DMK6OFY SN BMS-914143; IFN lambda, ZymoGenetics/Novo Nordisk; Interferon lambda 1, ZymoGenetics/Novo Nordisk; PEG-IL-29; PEG-rIL-29; Interleukin-29, ZymoGenetics/Novo Nordisk; PEG-IFN lambda, ZymoGenetics/Novo Nordisk; PEG-interferon lambda, ZymoGenetics/Novo Nordisk; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk; Peginterferon lambda-1a, ZymoGenetics/Bristol-Myers Squibb; PEG-IFN lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; PEG-interferon lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; Recombinant PEG-interferon lambda-1, ZymoGenetics/Bristol-Myers Squibb; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb DMK6OFY CP Bristol-myers squibb DMK6OFY DE Acute myeloid leukaemia DMESAZK ID DMESAZK DMESAZK DN Peretinoin DMESAZK HS Phase 3 DMESAZK SN Polyprenoic acid; E-5166; NIK-333; Peretinoin (oral); Peretinoin (oral), Kowa; Peretinoin (oral formulation, hepatocellular carcinoma), Kowa Pharmaceutical DMESAZK CP Kowa Pharmaceutical Co Ltd; Eisai Co Ltd DMESAZK DT Small molecular drug DMESAZK PC 6437836 DMESAZK MW 302.5 DMESAZK FM C20H30O2 DMESAZK IC InChI=1S/C20H30O2/c1-16(2)9-6-10-17(3)11-7-12-18(4)13-8-14-19(5)15-20(21)22/h8-9,11,13-15H,6-7,10,12H2,1-5H3,(H,21,22)/b14-8+,17-11+,18-13+,19-15+ DMESAZK CS CC(=CCC/C(=C/CC/C(=C/C=C/C(=C/C(=O)O)/C)/C)/C)C DMESAZK IK UUBHZHZSIKRVIV-KCXSXWJSSA-N DMESAZK IU (2E,4E,6E,10E)-3,7,11,15-tetramethylhexadeca-2,4,6,10,14-pentaenoic acid DMESAZK CA CAS 81485-25-8 DMESAZK DE Hepatocellular carcinoma DMUP5Z0 ID DMUP5Z0 DMUP5Z0 DN PF-03084014 DMUP5Z0 HS Phase 3 DMUP5Z0 SN Nirogacestat; 1290543-63-3; PF-03084014; PF-3084014; UNII-QZ62892OFJ; 865773-15-5; PF 3084014; PF-03084014 (PF-3084014); QZ62892OFJ; Z-3181; PF03084014; Nirogacestat [USAN]; Nirogacestat (USAN/INN); GTPL7746; SCHEMBL13184754; CHEMBL1770916; EX-A855; DTXSID60235679; MolPort-039-193-852; (2S)-2-[[(2S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl]amino]-N-[1-[1-(2,2-dimethylpropylamino)-2-methylpropan-2-yl]imidazol-4-yl]pentanamide; ZINC38217837; s8018; AKOS030526383; SB16726; DB12005; CS-1689; NCGC00378713-01 DMUP5Z0 CP Pfizer DMUP5Z0 DT Small molecular drug DMUP5Z0 PC 46224413 DMUP5Z0 MW 489.6 DMUP5Z0 FM C27H41F2N5O DMUP5Z0 IC InChI=1S/C27H41F2N5O/c1-7-8-23(32-20-10-9-18-11-19(28)12-22(29)21(18)13-20)25(35)33-24-14-34(17-31-24)27(5,6)16-30-15-26(2,3)4/h11-12,14,17,20,23,30,32H,7-10,13,15-16H2,1-6H3,(H,33,35)/t20-,23-/m0/s1 DMUP5Z0 CS CCC[C@@H](C(=O)NC1=CN(C=N1)C(C)(C)CNCC(C)(C)C)N[C@H]2CCC3=C(C2)C(=CC(=C3)F)F DMUP5Z0 IK VFCRKLWBYMDAED-REWPJTCUSA-N DMUP5Z0 IU (2S)-2-[[(2S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl]amino]-N-[1-[1-(2,2-dimethylpropylamino)-2-methylpropan-2-yl]imidazol-4-yl]pentanamide DMUP5Z0 CA CAS 1290543-63-3 DMUP5Z0 DE Alzheimer disease; Solid tumour/cancer; Desmoid tumour DM0TWCY ID DM0TWCY DM0TWCY DN PF-04950615 DM0TWCY HS Phase 3 DM0TWCY CP Pfizer New York, NY DM0TWCY DT Antibody DM0TWCY DE Hypercholesterolaemia DM8J29L ID DM8J29L DM8J29L DN PF-04965842 DM8J29L HS Phase 3 DM8J29L PC 78323835 DM8J29L MW 323.42 DM8J29L FM C14H21N5O2S DM8J29L IC InChI=1S/C14H21N5O2S/c1-3-6-22(20,21)18-10-7-11(8-10)19(2)14-12-4-5-15-13(12)16-9-17-14/h4-5,9-11,18H,3,6-8H2,1-2H3,(H,15,16,17) DM8J29L CS CCCS(=O)(=O)NC1CC(C1)N(C)C2=NC=NC3=C2C=CN3 DM8J29L IK IUEWXNHSKRWHDY-UHFFFAOYSA-N DM8J29L IU N-[3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl]propane-1-sulfonamide DM8J29L CA CAS 1622902-68-4 DM8J29L DE Lupus; Atopic dermatitis DM23BUP ID DM23BUP DM23BUP DN PF-05280014 DM23BUP HS Phase 3 DM23BUP CP Pfizer DM23BUP DE Breast cancer DMNZOCK ID DMNZOCK DMNZOCK DN PF-05280586 DMNZOCK HS Phase 3 DMNZOCK CP Pfizer DMNZOCK DE Cluster headache; Follicular lymphoma DM2GF14 ID DM2GF14 DM2GF14 DN PF-06410293 DM2GF14 HS Phase 3 DM2GF14 CP Pfizer DM2GF14 DT Antibody DM2GF14 DE Rheumatoid arthritis DMM4C95 ID DMM4C95 DMM4C95 DN PF-06438179 DMM4C95 HS Phase 3 DMM4C95 CP Pfizer DMM4C95 DE Rheumatoid arthritis DMVHZDP ID DMVHZDP DMVHZDP DN PF-06439535 DMVHZDP HS Phase 3 DMVHZDP CP Pfizer DMVHZDP DT Antibody DMVHZDP DE Solid tumour/cancer; Non-small-cell lung cancer DMW63TQ ID DMW63TQ DMW63TQ DN PF-06741086 DMW63TQ HS Phase 3 DMW63TQ SN marstacimab DMW63TQ CP Pfizer DMW63TQ DT Antibody DMW63TQ DE Hemophilia DMWPA4L ID DMWPA4L DMWPA4L DN PF-07055480 DMWPA4L HS Phase 3 DMWPA4L SN giroctocogene fitelparvovec DMWPA4L CP Pfizer DMWPA4L DT Gene therapy DMWPA4L DE Haemophilia A DMS1EQ7 ID DMS1EQ7 DMS1EQ7 DN PF-1228305 DMS1EQ7 HS Phase 3 DMS1EQ7 SN Sitaxentan sodium; Sitaxsentan sodium DMS1EQ7 CP Pfizer DMS1EQ7 DT Small molecular drug DMS1EQ7 PC 11477084 DMS1EQ7 MW 476.9 DMS1EQ7 FM C18H14ClN2NaO6S2 DMS1EQ7 IC InChI=1S/C18H14ClN2O6S2.Na/c1-9-5-13-14(26-8-25-13)7-11(9)6-12(22)17-15(3-4-28-17)29(23,24)21-18-16(19)10(2)20-27-18;/h3-5,7H,6,8H2,1-2H3;/q-1;+1 DMS1EQ7 CS CC1=CC2=C(C=C1CC(=O)C3=C(C=CS3)S(=O)(=O)[N-]C4=C(C(=NO4)C)Cl)OCO2.[Na+] DMS1EQ7 IK MDTNUYUCUYPIHE-UHFFFAOYSA-N DMS1EQ7 IU sodium;(4-chloro-3-methyl-1,2-oxazol-5-yl)-[2-[2-(6-methyl-1,3-benzodioxol-5-yl)acetyl]thiophen-3-yl]sulfonylazanide DMS1EQ7 CA CAS 210421-74-2 DMS1EQ7 DE Pulmonary hypertension DMJ7IKW ID DMJ7IKW DMJ7IKW DN PF-4494700 DMJ7IKW HS Phase 3 DMJ7IKW SN PF-04494700; TTP-488; TTP-488); Alzheimers therapy, TransTech/Pfizer; Diabetic nephropathy therapy, Transtech/Pfizer; Alzheimer'streatment, TransTech/Pfizer; Alzheimer's therapy (RAGE), Transtech/Pfizer DMJ7IKW CP Transtech pharma DMJ7IKW DT Small molecular drug DMJ7IKW PC 11180124 DMJ7IKW MW 532.1 DMJ7IKW FM C32H38ClN3O2 DMJ7IKW IC InChI=1S/C32H38ClN3O2/c1-4-7-9-32-34-31(25-10-16-28(17-11-25)37-23-8-22-35(5-2)6-3)24-36(32)27-14-20-30(21-15-27)38-29-18-12-26(33)13-19-29/h10-21,24H,4-9,22-23H2,1-3H3 DMJ7IKW CS CCCCC1=NC(=CN1C2=CC=C(C=C2)OC3=CC=C(C=C3)Cl)C4=CC=C(C=C4)OCCCN(CC)CC DMJ7IKW IK KJNNWYBAOPXVJY-UHFFFAOYSA-N DMJ7IKW IU 3-[4-[2-butyl-1-[4-(4-chlorophenoxy)phenyl]imidazol-4-yl]phenoxy]-N,N-diethylpropan-1-amine DMJ7IKW CA CAS 603148-36-3 DMJ7IKW DE Dementia; Alzheimer disease DM5DAP3 ID DM5DAP3 DM5DAP3 DN PGF2ALPHA-IE DM5DAP3 HS Phase 3 DM5DAP3 SN Prostaglandin F2alpha isopropyl ester; (5Z,9alpha,11alpha,13E,15S)-9,11,15-Trihydroxyprosta-5,13-dien-1-oic acid isopropyl ester DM5DAP3 DT Small molecular drug DM5DAP3 PC 5283077 DM5DAP3 MW 396.6 DM5DAP3 FM C23H40O5 DM5DAP3 IC InChI=1S/C23H40O5/c1-4-5-8-11-18(24)14-15-20-19(21(25)16-22(20)26)12-9-6-7-10-13-23(27)28-17(2)3/h6,9,14-15,17-22,24-26H,4-5,7-8,10-13,16H2,1-3H3/b9-6-,15-14+/t18-,19+,20+,21-,22+/m0/s1 DM5DAP3 CS CCCCC[C@@H](/C=C/[C@H]1[C@@H](C[C@@H]([C@@H]1C/C=C\\CCCC(=O)OC(C)C)O)O)O DM5DAP3 IK FPABVZYYTCHNMK-YNRDDPJXSA-N DM5DAP3 IU propan-2-yl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]cyclopentyl]hept-5-enoate DM5DAP3 CA CAS 53764-90-2 DM5DAP3 CB CHEBI:165336 DM5DAP3 DE Glaucoma/ocular hypertension DM8Y12A ID DM8Y12A DM8Y12A DN PH-80 DM8Y12A HS Phase 3 DM8Y12A SN Vomeropherin (premenstrual syndrome), Pherin; Vomeropherin (premenstrual syndrome), Pherin/ Organon DM8Y12A CP Pherin Corp DM8Y12A DE Premenstrual syndrome DMDC7OH ID DMDC7OH DMDC7OH DN PH94B NS DMDC7OH HS Phase 3 DMDC7OH SN Aloradine IN; Aloradine NS DMDC7OH CP Pherin Pharmaceuticals Los Altos, CA DMDC7OH DE Social anxiety disorder DMVEHM4 ID DMVEHM4 DMVEHM4 DN Phentermine+topiramate DMVEHM4 HS Phase 3 DMVEHM4 SN Qnexa (TN) DMVEHM4 CP Vivus DMVEHM4 DT Small molecular drug DMVEHM4 PC 56842108 DMVEHM4 MW 488.6 DMVEHM4 FM C22H36N2O8S DMVEHM4 IC InChI=1S/C12H21NO8S.C10H15N/c1-10(2)18-7-5-16-12(6-17-22(13,14)15)9(8(7)19-10)20-11(3,4)21-12;1-10(2,11)8-9-6-4-3-5-7-9/h7-9H,5-6H2,1-4H3,(H2,13,14,15);3-7H,8,11H2,1-2H3/t7-,8-,9?,12+;/m1./s1 DMVEHM4 CS CC1(O[C@@H]2CO[C@@]3(C([C@@H]2O1)OC(O3)(C)C)COS(=O)(=O)N)C.CC(C)(CC1=CC=CC=C1)N DMVEHM4 IK PWDLDBWXTVILPC-QGGVPXFVSA-N DMVEHM4 IU 2-methyl-1-phenylpropan-2-amine;[(1R,6S,9R)-4,4,11,11-tetramethyl-3,5,7,10,12-pentaoxatricyclo[7.3.0.02,6]dodecan-6-yl]methyl sulfamate DMVEHM4 CA CAS 960078-81-3 DMVEHM4 DE Obesity DMGZPX6 ID DMGZPX6 DMGZPX6 DN PI-88 DMGZPX6 HS Phase 3 DMGZPX6 SN CHEMBL603733 DMGZPX6 CP Progen Industries DMGZPX6 TC Anticancer Agents DMGZPX6 DT Small molecular drug DMGZPX6 PC 46233427 DMGZPX6 MW 2516.5 DMGZPX6 FM C30H35Na15O77PS16-3 DMGZPX6 IC InChI=1S/C30H53O77PS16.15Na/c31-108(32,33)82-1-6-14(99-116(55,56)57)20(102-119(64,65)66)25(106-123(76,77)78)29(87-6)94-17-12(97-114(49,50)51)8(3-84-110(37,38)39)89-27(23(17)104-121(70,71)72)92-16-11(96-113(46,47)48)7(2-83-109(34,35)36)88-26(22(16)103-120(67,68)69)93-18-13(98-115(52,53)54)9(4-85-111(40,41)42)90-28(24(18)105-122(73,74)75)95-21-19(101-118(61,62)63)15(100-117(58,59)60)10(5-86-112(43,44)45)91-30(21)107-124(79,80)81;;;;;;;;;;;;;;;/h6-30H,1-5H2,(H2,31,32,33)(H,34,35,36)(H,37,38,39)(H,40,41,42)(H,43,44,45)(H,46,47,48)(H,49,50,51)(H,52,53,54)(H,55,56,57)(H,58,59,60)(H,61,62,63)(H,64,65,66)(H,67,68,69)(H,70,71,72)(H,73,74,75)(H,76,77,78)(H,79,80,81);;;;;;;;;;;;;;;/q;15*+1/p-18/t6-,7-,8-,9-,10-,11-,12-,13-,14-,15-,16+,17+,18+,19+,20+,21+,22+,23+,24+,25+,26-,27-,28-,29-,30-;;;;;;;;;;;;;;;/m1.............../s1 DMGZPX6 CS C([C@@H]1[C@H]([C@@H]([C@@H]([C@H](O1)O[C@H]2[C@@H]([C@H](O[C@@H]([C@H]2OS(=O)(=O)[O-])O[C@H]3[C@@H]([C@H](O[C@@H]([C@H]3OS(=O)(=O)[O-])O[C@H]4[C@@H]([C@H](O[C@@H]([C@H]4OS(=O)(=O)[O-])O[C@H]5[C@H]([C@@H]([C@H](O[C@@H]5OS(=O)(=O)[O-])COS(=O)(=O)[O-])OS(=O)(=O)[O-])OS(=O)(=O)[O-])COS(=O)(=O)[O-])OS(=O)(=O)[O-])COS(=O)(=O)[O-])OS(=O)(=O)[O-])COS(=O)(=O)[O-])OS(=O)(=O)[O-])OS(=O)(=O)[O-])OS(=O)(=O)[O-])OS(=O)(=O)[O-])OP(=O)([O-])[O-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+] DMGZPX6 IK FIYNUMVQYZZZCH-JSZMYKOGSA-A DMGZPX6 IU pentadecasodium;[(2R,3R,4S,5S,6R)-6-[(2R,3S,4S,5R,6R)-2-[(2R,3S,4S,5R,6R)-2-[(2R,3R,4S,5S,6R)-3,5-disulfonatooxy-2-(sulfonatooxymethyl)-6-[(2R,3S,4R,5R,6R)-2,4,5-trisulfonatooxy-6-(sulfonatooxymethyl)oxan-3-yl]oxyoxan-4-yl]oxy-3,5-disulfonatooxy-6-(sulfonatooxymethyl)oxan-4-yl]oxy-3,5-disulfonatooxy-6-(sulfonatooxymethyl)oxan-4-yl]oxy-3,4,5-trisulfonatooxyoxan-2-yl]methyl phosphate DMGZPX6 DE Prostate cancer; Hepatocellular carcinoma DM7OSHC ID DM7OSHC DM7OSHC DN Pinaverium bromide DM7OSHC HS Phase 3 DM7OSHC SN Dicetel; Bromure de pinaverium; Bromuro de pinaverio; Pinaverii bromidum; Pinaverium bromide [INN]; LAT 1717; Bromure de pinaverium [INN-French]; Bromuro de pinaverio [INN-Spanish]; Dicetel (TN); Pinaverii bromidum [INN-Latin]; Pinaverium bromide (INN); Morpholinium, 4-(2-bromo-4,5-dimethoxy)benzyl-4-(2-(2-(6,6-dimethyl-2-norpinyl)ethoxy)ethyl)-, bromide; 4-(6-Bromoveratryl)-4-(2-(2-(6,6-dimethyl-2-norpinyl)ethoxy)ethyl)morpholinium bromide; 4-[(2-bromo-4,5-dimethoxyphenyl)methyl]-4-[2-[2-(6,6-dimethyl-4-bicyclo[3.1.1]heptanyl)ethoxy]ethyl]morpholin-4-ium bromide DM7OSHC CP Solvay DM7OSHC DT Small molecular drug DM7OSHC PC 40703 DM7OSHC MW 591.4 DM7OSHC FM C26H41Br2NO4 DM7OSHC IC InChI=1S/C26H41BrNO4.BrH/c1-26(2)21-6-5-19(22(26)16-21)7-11-31-12-8-28(9-13-32-14-10-28)18-20-15-24(29-3)25(30-4)17-23(20)27;/h15,17,19,21-22H,5-14,16,18H2,1-4H3;1H/q+1;/p-1 DM7OSHC CS CC1(C2CCC(C1C2)CCOCC[N+]3(CCOCC3)CC4=CC(=C(C=C4Br)OC)OC)C.[Br-] DM7OSHC IK IKGXLCMLVINENI-UHFFFAOYSA-M DM7OSHC IU 4-[(2-bromo-4,5-dimethoxyphenyl)methyl]-4-[2-[2-(6,6-dimethyl-2-bicyclo[3.1.1]heptanyl)ethoxy]ethyl]morpholin-4-ium;bromide DM7OSHC CA CAS 53251-94-8 DM7OSHC DE Irritable bowel syndrome DMRG1X3 ID DMRG1X3 DMRG1X3 DN Pirtobrutinib DMRG1X3 HS Phase 3 DMRG1X3 SN BTK inhibitor 16; 2101700-15-4; Pirtobrutinib [USAN]; UNII-JNA39I7ZVB; JNA39I7ZVB; LOXO-305; SCHEMBL19014257; WHO 11681; HY-131328; LY3527727; CS-0133286; (S)-5-Amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1H-pyrazole-4-carboxamide; 1H-Pyrazole-4-carboxamide, 5-amino-3-(4-(((5-fluoro-2-methoxybenzoyl)amino)methyl)phenyl)-1-((1S)-2,2,2-trifluoro-1-methylethyl)- DMRG1X3 CP LOXO Oncology DMRG1X3 DT Small molecular drug DMRG1X3 PC 129269915 DMRG1X3 MW 479.4 DMRG1X3 FM C22H21F4N5O3 DMRG1X3 IC InChI=1S/C22H21F4N5O3/c1-11(22(24,25)26)31-19(27)17(20(28)32)18(30-31)13-5-3-12(4-6-13)10-29-21(33)15-9-14(23)7-8-16(15)34-2/h3-9,11H,10,27H2,1-2H3,(H2,28,32)(H,29,33)/t11-/m0/s1 DMRG1X3 CS C[C@@H](C(F)(F)F)N1C(=C(C(=N1)C2=CC=C(C=C2)CNC(=O)C3=C(C=CC(=C3)F)OC)C(=O)N)N DMRG1X3 IK FWZAWAUZXYCBKZ-NSHDSACASA-N DMRG1X3 IU 5-amino-3-[4-[[(5-fluoro-2-methoxybenzoyl)amino]methyl]phenyl]-1-[(2S)-1,1,1-trifluoropropan-2-yl]pyrazole-4-carboxamide DMRG1X3 CA CAS 2101700-15-4 DMRG1X3 DE Chronic lymphocytic leukaemia; Small lymphocytic lymphoma DMQGR45 ID DMQGR45 DMQGR45 DN Pixantrone DMQGR45 HS Phase 3 DMQGR45 SN Pixuvri (TN) DMQGR45 CP Cell Therapeutics DMQGR45 DT Small molecular drug DMQGR45 PC 134019 DMQGR45 MW 325.4 DMQGR45 FM C17H19N5O2 DMQGR45 IC InChI=1S/C17H19N5O2/c18-4-7-21-12-1-2-13(22-8-5-19)15-14(12)16(23)10-3-6-20-9-11(10)17(15)24/h1-3,6,9,21-22H,4-5,7-8,18-19H2 DMQGR45 CS C1=CC(=C2C(=C1NCCN)C(=O)C3=C(C2=O)C=NC=C3)NCCN DMQGR45 IK PEZPMAYDXJQYRV-UHFFFAOYSA-N DMQGR45 IU 6,9-bis(2-aminoethylamino)benzo[g]isoquinoline-5,10-dione DMQGR45 CA CAS 144510-96-3 DMQGR45 CB CHEBI:135945 DMQGR45 DE Multiple sclerosis; Follicular lymphoma; Diffuse large B-cell lymphoma; Pediatric cancer DMCA6BW ID DMCA6BW DMCA6BW DN Pixykine DMCA6BW HS Phase 3 DMCA6BW SN Milodistim; Plasmid Immunex yeast 321; PIXY-321 DMCA6BW CP Immunex Corp DMCA6BW DE Human immunodeficiency virus infection DM1RWMY ID DM1RWMY DM1RWMY DN Plasma derived factor VIII PEGylated liposomal DM1RWMY HS Phase 3 DM1RWMY SN LongAte; NecLip-pdFVIII; Plasma derived factor VIII (PEGylated liposomal (NecLip), hemophilia A), Recoly DM1RWMY CP Recoly NV DM1RWMY DE Factor VIII deficiency DMD7L48 ID DMD7L48 DMD7L48 DN Plinabulin DMD7L48 HS Phase 3 DMD7L48 SN NPI-2358 DMD7L48 CP Nereus Pharmaceuticals DMD7L48 DT Small molecular drug DMD7L48 PC 9949641 DMD7L48 MW 336.4 DMD7L48 FM C19H20N4O2 DMD7L48 IC InChI=1S/C19H20N4O2/c1-19(2,3)16-13(20-11-21-16)10-15-18(25)22-14(17(24)23-15)9-12-7-5-4-6-8-12/h4-11H,1-3H3,(H,20,21)(H,22,25)(H,23,24)/b14-9-,15-10- DMD7L48 CS CC(C)(C)C1=C(N=CN1)/C=C\\2/C(=O)N/C(=C\\C3=CC=CC=C3)/C(=O)N2 DMD7L48 IK UNRCMCRRFYFGFX-TYPNBTCFSA-N DMD7L48 IU (3Z,6Z)-3-benzylidene-6-[(5-tert-butyl-1H-imidazol-4-yl)methylidene]piperazine-2,5-dione DMD7L48 CA CAS 714272-27-2 DMD7L48 DE Non-small-cell lung cancer DMJ8AUE ID DMJ8AUE DMJ8AUE DN Plitidepsin DMJ8AUE HS Phase 3 DMJ8AUE SN Aplidin (TN) DMJ8AUE CP PharmaMar DMJ8AUE DT Small molecular drug DMJ8AUE PC 9812534 DMJ8AUE MW 1110.3 DMJ8AUE FM C57H87N7O15 DMJ8AUE IC InChI=1S/C57H87N7O15/c1-15-33(8)46-44(66)29-45(67)79-49(32(6)7)48(68)34(9)50(69)58-39(26-30(2)3)54(73)64-25-17-19-41(64)56(75)62(13)43(28-37-20-22-38(77-14)23-21-37)57(76)78-36(11)47(52(71)59-46)60-51(70)42(27-31(4)5)61(12)55(74)40-18-16-24-63(40)53(72)35(10)65/h20-23,30-34,36,39-44,46-47,49,66H,15-19,24-29H2,1-14H3,(H,58,69)(H,59,71)(H,60,70)/t33-,34-,36+,39-,40-,41-,42+,43-,44-,46+,47-,49-/m0/s1 DMJ8AUE CS CC[C@H](C)[C@@H]1[C@H](CC(=O)O[C@H](C(=O)[C@@H](C(=O)N[C@H](C(=O)N2CCC[C@H]2C(=O)N([C@H](C(=O)O[C@@H]([C@@H](C(=O)N1)NC(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H]3CCCN3C(=O)C(=O)C)C)CC4=CC=C(C=C4)OC)C)CC(C)C)C)C(C)C)O DMJ8AUE IK UUSZLLQJYRSZIS-LXNNNBEUSA-N DMJ8AUE IU (2S)-N-[(2R)-1-[[(3S,6S,8S,12S,13R,16S,17R,20S,23S)-13-[(2S)-butan-2-yl]-12-hydroxy-20-[(4-methoxyphenyl)methyl]-6,17,21-trimethyl-3-(2-methylpropyl)-2,5,7,10,15,19,22-heptaoxo-8-propan-2-yl-9,18-dioxa-1,4,14,21-tetrazabicyclo[21.3.0]hexacosan-16-yl]amino]-4-methyl-1-oxopentan-2-yl]-N-methyl-1-(2-oxopropanoyl)pyrrolidine-2-carboxamide DMJ8AUE CA CAS 137219-37-5 DMJ8AUE CB CHEBI:90205 DMJ8AUE DE Multiple myeloma; Angioimmunoblastic T-cell Lymphoma DMV8EXG ID DMV8EXG DMV8EXG DN PolyHeme DMV8EXG HS Phase 3 DMV8EXG SN Oxygen-carrying blood substitute, Northfield Laboratories DMV8EXG CP Northfield Laboratories DMV8EXG PC 72941846 DMV8EXG MW 347.26 DMV8EXG FM C13H18NO8P DMV8EXG IC InChI=1S/C8H10NO6P.C5H8O2/c1-5-8(11)7(3-10)6(2-9-5)4-15-16(12,13)14;6-4-2-1-3-5-7/h2-3,11H,4H2,1H3,(H2,12,13,14);4-5H,1-3H2 DMV8EXG CS CC1=NC=C(C(=C1O)C=O)COP(=O)(O)O.C(CC=O)CC=O DMV8EXG IK SKKYPUWZZNPUMG-UHFFFAOYSA-N DMV8EXG IU (4-formyl-5-hydroxy-6-methylpyridin-3-yl)methyl dihydrogen phosphate;pentanedial DMV8EXG DE Blood forming organ disorder DMTD7AB ID DMTD7AB DMTD7AB DN Pracinostat DMTD7AB HS Phase 3 DMTD7AB SN Pracinostat; 929016-96-6; SB939; SB 939; Pracinostat (SB939); SB-939; UNII-GPO2JN4UON; GPO2JN4UON; CHEMBL1851943; (E)-3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzo[d]imidazol-5-yl)-N-hydroxyacrylamide; 2-Propenamide, 3-[2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl]-N-hydroxy-, (2E)-; Pracinostat [INN]; (2E)-3-(2-Butyl-1-[2-(diethylamino)ethyl]-1h-1,3-benzodiazol-5-yl)-n-hydroxyprop-2-enamide; 2-Propenamide, 3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzimidazol-5-yl)-N-hydroxy-, (2E)- DMTD7AB CP MEI Pharma DMTD7AB DT Small molecular drug DMTD7AB PC 49855250 DMTD7AB MW 358.5 DMTD7AB FM C20H30N4O2 DMTD7AB IC InChI=1S/C20H30N4O2/c1-4-7-8-19-21-17-15-16(10-12-20(25)22-26)9-11-18(17)24(19)14-13-23(5-2)6-3/h9-12,15,26H,4-8,13-14H2,1-3H3,(H,22,25)/b12-10+ DMTD7AB CS CCCCC1=NC2=C(N1CCN(CC)CC)C=CC(=C2)/C=C/C(=O)NO DMTD7AB IK JHDKZFFAIZKUCU-ZRDIBKRKSA-N DMTD7AB IU (E)-3-[2-butyl-1-[2-(diethylamino)ethyl]benzimidazol-5-yl]-N-hydroxyprop-2-enamide DMTD7AB CA CAS 929016-96-6 DMTD7AB CB CHEBI:95071 DMTD7AB DE Myelofibrosis; Myelodysplastic syndrome; Acute myeloid leukaemia DM2ZYX9 ID DM2ZYX9 DM2ZYX9 DN Pradaxa DM2ZYX9 HS Phase 3 DM2ZYX9 SN Dabigatran etexilate mesylate; 872728-81-9; XETBXHPXHHOLOE-UHFFFAOYSA-N; CP0128; FT-0660872; ethyl 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazole-5-carbonyl)-pyridin-2-yl-amino]-propionate methanesulphonate; 1-methyl-2-[N-[4-(N-n-hexyloxycarbonylamidino)phenyl]-amino-methyl]-benzimidazol-5-yl-carboxylic acid-N-(2-pyridyl)-N-(2-ethoxycarbonylethyl)-amide mesylate DM2ZYX9 CP Boehringer Ingelheim Pharmaceuticals Ridgefield, CT DM2ZYX9 PC 11434065 DM2ZYX9 MW 723.8 DM2ZYX9 FM C35H45N7O8S DM2ZYX9 IC InChI=1S/C34H41N7O5.CH4O3S/c1-4-6-7-10-21-46-34(44)39-32(35)24-12-15-26(16-13-24)37-23-30-38-27-22-25(14-17-28(27)40(30)3)33(43)41(20-18-31(42)45-5-2)29-11-8-9-19-36-29;1-5(2,3)4/h8-9,11-17,19,22,37H,4-7,10,18,20-21,23H2,1-3H3,(H2,35,39,44);1H3,(H,2,3,4) DM2ZYX9 CS CCCCCCOC(=O)/N=C(/C1=CC=C(C=C1)NCC2=NC3=C(N2C)C=CC(=C3)C(=O)N(CCC(=O)OCC)C4=CC=CC=N4)\\N.CS(=O)(=O)O DM2ZYX9 IK XETBXHPXHHOLOE-UHFFFAOYSA-N DM2ZYX9 IU ethyl 3-[[2-[[4-[(Z)-N'-hexoxycarbonylcarbamimidoyl]anilino]methyl]-1-methylbenzimidazole-5-carbonyl]-pyridin-2-ylamino]propanoate;methanesulfonic acid DM2ZYX9 CA CAS 872728-81-9 DM2ZYX9 DE Stroke DMOMDXI ID DMOMDXI DMOMDXI DN Pratosartan DMOMDXI HS Phase 3 DMOMDXI SN KD3-671; KT3-671 DMOMDXI CP Kotobuki Pharmaceutical Co Ltd DMOMDXI DT Small molecular drug DMOMDXI PC 9802561 DMOMDXI MW 426.5 DMOMDXI FM C25H26N6O DMOMDXI IC InChI=1S/C25H26N6O/c1-2-7-23-26-21-10-5-6-11-22(32)24(21)31(23)16-17-12-14-18(15-13-17)19-8-3-4-9-20(19)25-27-29-30-28-25/h3-4,8-9,12-15H,2,5-7,10-11,16H2,1H3,(H,27,28,29,30) DMOMDXI CS CCCC1=NC2=C(N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5)C(=O)CCCC2 DMOMDXI IK KCTFTBCZZUBAKN-UHFFFAOYSA-N DMOMDXI IU 2-propyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-5,6,7,8-tetrahydrocyclohepta[d]imidazol-4-one DMOMDXI CA CAS 153804-05-8 DMOMDXI CB CHEBI:32041 DMOMDXI DE Hypertension DMLSOB7 ID DMLSOB7 DMLSOB7 DN Premarin/Pravachol DMLSOB7 HS Phase 3 DMLSOB7 SN Estrogen/Eptastatin DMLSOB7 CP Bristol-Myers Squibb DMLSOB7 DE Hyperlipidaemia DMX9YLR ID DMX9YLR DMX9YLR DN Pridopidine DMX9YLR HS Phase 3 DMX9YLR SN PRIDOPIDINE; 346688-38-8; 4-[3-(Methylsulfonyl)phenyl]-1-propylpiperidine; 4-(3-(Methylsulfonyl)phenyl)-1-propylpiperidine; ACR-16; UNII-HD4TW8S2VK; ACR16; ACR 16; HD4TW8S2VK; CHEMBL596802; FR310826; Pridopidine [USAN:INN]; Pridopidine (USAN/INN); 4-(3-Methanesulfonyl-phenyl)-1-propyl-piperidine; SCHEMBL166748; CTK4H2809; DTXSID90188225; ASP 2314; ZINC22063703; BDBM50308028; AKOS015891431; DB11947; NCGC00386586-01; HY-10684; AS-50146; AJ-80925; FR 310826; DB-014417; AX8258340; CS-0002733; FT-0672149; Huntexil; Pridopidine hydrochloride; ASP-2314; Dopamine modulator (Huntingtons disease), Carlsson Research; Dopamine modulator (Huntingtons disease), NeuroSearch; Dopamine modulator (schizophrenia), Astellas; Dopamine modulator (schizophrenia), Fujisawa; Dopamine modulator (neurological disorders), Merck & Co DMX9YLR CP Teva pharmaceutical DMX9YLR DT Small molecular drug DMX9YLR PC 9795739 DMX9YLR MW 281.4 DMX9YLR FM C15H23NO2S DMX9YLR IC InChI=1S/C15H23NO2S/c1-3-9-16-10-7-13(8-11-16)14-5-4-6-15(12-14)19(2,17)18/h4-6,12-13H,3,7-11H2,1-2H3 DMX9YLR CS CCCN1CCC(CC1)C2=CC(=CC=C2)S(=O)(=O)C DMX9YLR IK YGKUEOZJFIXDGI-UHFFFAOYSA-N DMX9YLR IU 4-(3-methylsulfonylphenyl)-1-propylpiperidine DMX9YLR CA CAS 346688-38-8 DMX9YLR DE Huntington disease DMD1FTP ID DMD1FTP DMD1FTP DN PRO-140 DMD1FTP HS Phase 3 DMD1FTP SN PRO-140 (sc); Humanized monoclonal anibody (subcutaneous, HIV infection), Progenics; PRO-140 (subcutaneous, HIV); CCR5 antagonist (subcutaneous, humanized mAb, HIV infection), Progenics; PRO-140 (subcutaneous, HIV), Progenics Pharmaceuticals DMD1FTP CP Progenics Pharmaceuticals Inc DMD1FTP DE Human immunodeficiency virus infection DM5FZH4 ID DM5FZH4 DM5FZH4 DN ProstaVac DM5FZH4 HS Phase 3 DM5FZH4 SN Pox virus vector prostate specific antigen vaccine (benign prostatic hyperplasia/prostatitis); Pox virus vector prostate specific antigen vaccine (benign prostatic hyperplasia/prostatitis), AmVac DM5FZH4 CP AmVac AG DM5FZH4 DT Vaccine DM5FZH4 DE Prostate hyperplasia DMVU8RW ID DMVU8RW DMVU8RW DN PRT4445 DMVU8RW HS Phase 3 DMVU8RW CP Portola pharmaceuticals DMVU8RW DE Bleeding disorder DMEH641 ID DMEH641 DMEH641 DN PRX-302 DMEH641 HS Phase 3 DMEH641 CP Sophiris DMEH641 DE Prostate cancer DMIZJ8M ID DMIZJ8M DMIZJ8M DN Psoralen DMIZJ8M HS Phase 3 DMIZJ8M SN Psoralen; 66-97-7; 7H-Furo[3,2-g]chromen-7-one; Ficusin; Furocoumarin; Psoralene; 7H-Furo[3,2-g][1]benzopyran-7-one; Psorline-P; 6,7-Furanocoumarin; furo[3,2-g]chromen-7-one; Furo[3,2-g]coumarin; Furo(4',5',6,7)coumarin; Furo(2',3',7,6)coumarin; Furo(3,2-g)-coumarin; Furo[4',5':6,7]coumarin; Furo[2',3':7,6]coumarin; NSC 404562; UNII-KTZ7ZCN2EX; 7H-Furo(3,2-g)(1)benzopyran-7-one; 7H-Furo[3,2-g]benzopyran-7-one; CCRIS 4343; Furo[2'.3':7.6]coumarin; HSDB 3528; KTZ7ZCN2EX; EINECS 200-639-7; 6-Hydroxy-5-benzofuranacrylic acid beta-lacto DMIZJ8M DT Small molecular drug DMIZJ8M PC 6199 DMIZJ8M MW 186.16 DMIZJ8M FM C11H6O3 DMIZJ8M IC InChI=1S/C11H6O3/c12-11-2-1-7-5-8-3-4-13-9(8)6-10(7)14-11/h1-6H DMIZJ8M CS C1=CC(=O)OC2=CC3=C(C=CO3)C=C21 DMIZJ8M IK ZCCUUQDIBDJBTK-UHFFFAOYSA-N DMIZJ8M IU furo[3,2-g]chromen-7-one DMIZJ8M CA CAS 66-97-7 DMIZJ8M CB CHEBI:27616 DMTSN8L ID DMTSN8L DMTSN8L DN PT005 DMTSN8L HS Phase 3 DMTSN8L SN Perforomist; Atock; Foradil Aerolizer; Foradil Certihaler; YM-08316; Broncoral; Eolus; Oxis Turbuhaler; BD-40A; Eformoterol fumarate; Formoterol Easyhaler; CGP-25827A; AC1OCEVQ; PT-005 DMTSN8L CP Pearl Therapeutics DMTSN8L DT Small molecular drug DMTSN8L PC 6917983 DMTSN8L MW 822.9 DMTSN8L FM C42H54N4O13 DMTSN8L IC InChI=1S/2C19H24N2O4.C4H4O4.H2O/c2*1-13(9-14-3-6-16(25-2)7-4-14)20-11-19(24)15-5-8-18(23)17(10-15)21-12-22;5-3(6)1-2-4(7)8;/h2*3-8,10,12-13,19-20,23-24H,9,11H2,1-2H3,(H,21,22);1-2H,(H,5,6)(H,7,8);1H2/b;;2-1+;/t2*13-,19+;;/m11../s1 DMTSN8L CS C[C@H](CC1=CC=C(C=C1)OC)NC[C@@H](C2=CC(=C(C=C2)O)NC=O)O.C[C@H](CC1=CC=C(C=C1)OC)NC[C@@H](C2=CC(=C(C=C2)O)NC=O)O.C(=C/C(=O)O)\\C(=O)O.O DMTSN8L IK BPXZSHHCUKRDHD-HTLUESNNSA-N DMTSN8L IU (E)-but-2-enedioic acid;N-[2-hydroxy-5-[(1R)-1-hydroxy-2-[[(2R)-1-(4-methoxyphenyl)propan-2-yl]amino]ethyl]phenyl]formamide;hydrate DMTSN8L DE Chronic obstructive pulmonary disease DML1KTO ID DML1KTO DML1KTO DN PT2977 DML1KTO HS Phase 3 DML1KTO SN MK-6482 DML1KTO CP Peloton Therapeutics Dallas, TX DML1KTO PC 117947097 DML1KTO MW 383.3 DML1KTO FM C17H12F3NO4S DML1KTO IC InChI=1S/C17H12F3NO4S/c1-26(23,24)12-3-2-11(13-14(12)17(22)16(20)15(13)19)25-10-5-8(7-21)4-9(18)6-10/h2-6,15-17,22H,1H3/t15-,16-,17+/m1/s1 DML1KTO CS CS(=O)(=O)C1=C2[C@@H]([C@@H]([C@@H](C2=C(C=C1)OC3=CC(=CC(=C3)C#N)F)F)F)O DML1KTO IK LOMMPXLFBTZENJ-ZACQAIPSSA-N DML1KTO IU 3-[[(1S,2S,3R)-2,3-difluoro-1-hydroxy-7-methylsulfonyl-2,3-dihydro-1H-inden-4-yl]oxy]-5-fluorobenzonitrile DML1KTO CA CAS 1672668-24-4 DML1KTO DE Solid tumour/cancer; Von hippel-lindau disease; Renal cell carcinoma DMMJ63A ID DMMJ63A DMMJ63A DN PT-304 DMMJ63A HS Phase 3 DMMJ63A SN 149486-04-4; Thiourea, N-(2-(3-fluorophenyl)ethyl)-N'-2-thiazolyl-; Thiourea, N-[2-(3-fluorophenyl)ethyl]-N'-2-thiazolyl-; PETT Analog 3; AC1MHDMA; SCHEMBL6964163; CHEMBL253995; BDBM1896; DTXSID20164299; 1-[2-(3-fluorophenyl)ethyl]-3-(1,3-thiazol-2-yl)thiourea; AKOS030030941; 1-(2-Thiazolyl)-3-[3-fluorophenethyl]thiourea; N-(2-(3-Fluorophenethyl))-N -(2-thiazolyl)thiourea; 1-[2-(3-fluorophenyl)ethyl]-3-thiazol-2-yl-thiourea DMMJ63A DT Small molecular drug DMMJ63A PC 3001163 DMMJ63A MW 281.4 DMMJ63A FM C12H12FN3S2 DMMJ63A IC InChI=1S/C12H12FN3S2/c13-10-3-1-2-9(8-10)4-5-14-11(17)16-12-15-6-7-18-12/h1-3,6-8H,4-5H2,(H2,14,15,16,17) DMMJ63A CS C1=CC(=CC(=C1)F)CCNC(=S)NC2=NC=CS2 DMMJ63A IK NDHSDDFIIZKISX-UHFFFAOYSA-N DMMJ63A IU 1-[2-(3-fluorophenyl)ethyl]-3-(1,3-thiazol-2-yl)thiourea DMMJ63A CA CAS 149486-04-4 DMVDCGZ ID DMVDCGZ DMVDCGZ DN Pyridoxamine DMVDCGZ HS Phase 3 DMVDCGZ SN Pyridorin (TN) DMVDCGZ CP Nephrogenex DMVDCGZ DT Small molecular drug DMVDCGZ PC 1052 DMVDCGZ MW 168.19 DMVDCGZ FM C8H12N2O2 DMVDCGZ IC InChI=1S/C8H12N2O2/c1-5-8(12)7(2-9)6(4-11)3-10-5/h3,11-12H,2,4,9H2,1H3 DMVDCGZ CS CC1=NC=C(C(=C1O)CN)CO DMVDCGZ IK NHZMQXZHNVQTQA-UHFFFAOYSA-N DMVDCGZ IU 4-(aminomethyl)-5-(hydroxymethyl)-2-methylpyridin-3-ol DMVDCGZ CA CAS 85-87-0 DMVDCGZ CB CHEBI:16410 DMVDCGZ DE Diabetic nephropathy; Diabetic kidney disease DMPCFXN ID DMPCFXN DMPCFXN DN QAW-039 DMPCFXN HS Phase 3 DMPCFXN DE Asthma DMDU5Y2 ID DMDU5Y2 DMDU5Y2 DN QPI-1002 DMDU5Y2 HS Phase 3 DMDU5Y2 CP Quark Pharmaceuticals DMDU5Y2 TC siRNA DMDU5Y2 DT siRNA drug DMDU5Y2 DE Renal artery disease; Renal transplantation DMUWXEB ID DMUWXEB DMUWXEB DN QPI-1007 DMUWXEB HS Phase 3 DMUWXEB SN SiCASP2; SiRNA therapy (caspase-2, ocular injury), Quark Pharmaceuticals DMUWXEB CP Quark pharmaceuticals DMUWXEB DT siRNA drug DMUWXEB DE Glaucoma/ocular hypertension; Ischemic optic neuropathy; Non-arteritic anterior ischemic optic neuropathy DMDCQW0 ID DMDCQW0 DMDCQW0 DN Quinotolast DMDCQW0 HS Phase 3 DMDCQW0 SN Aslock; Quinotalast; FK-021; FR-71021 DMDCQW0 CP Fujisawa Pharmaceutical Co Ltd DMDCQW0 DT Small molecular drug DMDCQW0 PC 65871 DMDCQW0 MW 348.32 DMDCQW0 FM C17H12N6O3 DMDCQW0 IC InChI=1S/C17H12N6O3/c24-15(18-17-19-21-22-20-17)12-10-14(26-11-6-2-1-3-7-11)13-8-4-5-9-23(13)16(12)25/h1-10H,(H2,18,19,20,21,22,24) DMDCQW0 CS C1=CC=C(C=C1)OC2=C3C=CC=CN3C(=O)C(=C2)C(=O)NC4=NNN=N4 DMDCQW0 IK ZUPLNRDTYQWUHP-UHFFFAOYSA-N DMDCQW0 IU 4-oxo-1-phenoxy-N-(2H-tetrazol-5-yl)quinolizine-3-carboxamide DMDCQW0 CA CAS 101193-40-2 DMDCQW0 DE Asthma DMSFX75 ID DMSFX75 DMSFX75 DN QVA-149 DMSFX75 HS Phase 3 DMSFX75 SN Glycopyrrolate mixture with indacaterol; 1262431-94-6; Utibron; Utibron Neohaler; Ultibro Breezhaler; Glycopyrrolate / indacaterol; Indacaterol / glycopyrronium; Indacaterol / glycopyrrolate; QVA149; QVA 149; Glycopyrronium bromide / indacaterol DMSFX75 CP Sosei; Vectura; Novartis DMSFX75 DT Small molecular drug DMSFX75 PC 11564052 DMSFX75 MW 790.8 DMSFX75 FM C43H56BrN3O6 DMSFX75 IC InChI=1S/C24H28N2O3.C19H28NO3.BrH/c1-3-14-9-16-11-18(12-17(16)10-15(14)4-2)25-13-22(28)19-5-7-21(27)24-20(19)6-8-23(29)26-24;1-20(2)13-12-17(14-20)23-18(21)19(22,16-10-6-7-11-16)15-8-4-3-5-9-15;/h5-10,18,22,25,27-28H,3-4,11-13H2,1-2H3,(H,26,29);3-5,8-9,16-17,22H,6-7,10-14H2,1-2H3;1H/q;+1;/p-1/t22-;;/m0../s1 DMSFX75 CS CCC1=C(C=C2CC(CC2=C1)NC[C@@H](C3=C4C=CC(=O)NC4=C(C=C3)O)O)CC.C[N+]1(CCC(C1)OC(=O)C(C2CCCC2)(C3=CC=CC=C3)O)C.[Br-] DMSFX75 IK GCUZFFAPBPDIFM-IKXQUJFKSA-M DMSFX75 IU 5-[(1R)-2-[(5,6-diethyl-2,3-dihydro-1H-inden-2-yl)amino]-1-hydroxyethyl]-8-hydroxy-1H-quinolin-2-one;(1,1-dimethylpyrrolidin-1-ium-3-yl) 2-cyclopentyl-2-hydroxy-2-phenylacetate;bromide DMSFX75 CA CAS 1262431-94-6 DMSFX75 DE Chronic obstructive pulmonary disease DM4K9WH ID DM4K9WH DM4K9WH DN R1678 DM4K9WH HS Phase 3 DM4K9WH SN R-1678; RG-1678 DM4K9WH CP Roche DM4K9WH DT Small molecular drug DM4K9WH PC 137905 DM4K9WH MW 342.3 DM4K9WH FM C22H14O4 DM4K9WH IC InChI=1S/C22H14O4/c23-19(15-7-3-1-4-8-15)21(25)17-11-13-18(14-12-17)22(26)20(24)16-9-5-2-6-10-16/h1-14H DM4K9WH CS C1=CC=C(C=C1)C(=O)C(=O)C2=CC=C(C=C2)C(=O)C(=O)C3=CC=CC=C3 DM4K9WH IK FUEGWHHUYNHBNI-UHFFFAOYSA-N DM4K9WH IU 1-[4-(2-oxo-2-phenylacetyl)phenyl]-2-phenylethane-1,2-dione DM4K9WH CA CAS 3363-97-1 DM4K9WH DE Schizophrenia DM9Z4N5 ID DM9Z4N5 DM9Z4N5 DN RA101495 DM9Z4N5 HS Phase 3 DM9Z4N5 SN Zilucoplan DM9Z4N5 CP Ra Pharmaceuticals Cambridge, MA DM9Z4N5 PC 133083018 DM9Z4N5 MW 3562 DM9Z4N5 FM C172H278N24O55 DM9Z4N5 IC InChI=1S/C172H278N24O55/c1-9-10-11-12-13-14-15-16-17-18-19-20-27-44-146(202)182-136(170(226)227)53-56-144(200)177-64-67-229-69-71-231-73-75-233-77-79-235-81-83-237-85-87-239-89-91-241-93-95-243-97-99-245-101-103-247-105-107-249-109-111-251-113-112-250-110-108-248-106-104-246-102-100-244-98-96-242-94-92-240-90-88-238-86-84-236-82-80-234-78-76-232-74-72-230-70-68-228-66-59-145(201)175-60-31-29-41-135(169(224)225)186-165(220)152(126-37-25-22-26-38-126)193-162(217)142-43-34-65-196(142)168(223)140(116-125-47-51-129(199)52-48-125)190-157(212)133(54-57-148(204)205)184-161(216)139(117-127-120-180-154-130(127)39-32-62-178-154)188-159(214)138(115-124-45-49-128(198)50-46-124)189-166(221)153(172(5,6)7)194-163(218)143(119-150(208)209)195(8)167(222)141-118-147(203)176-61-30-28-40-131(181-122(4)197)158(213)192-151(121(2)3)164(219)185-134(55-58-149(206)207)156(211)183-132(42-33-63-179-171(173)174)155(210)187-137(160(215)191-141)114-123-35-23-21-24-36-123/h21,23-24,32,35-36,39,45-52,62,120-121,126,131-143,151-153,198-199H,9-20,22,25-31,33-34,37-38,40-44,53-61,63-119H2,1-8H3,(H,175,201)(H,176,203)(H,177,200)(H,178,180)(H,181,197)(H,182,202)(H,183,211)(H,184,216)(H,185,219)(H,186,220)(H,187,210)(H,188,214)(H,189,221)(H,190,212)(H,191,215)(H,192,213)(H,193,217)(H,194,218)(H,204,205)(H,206,207)(H,208,209)(H,224,225)(H,226,227)(H4,173,174,179)/t131-,132-,133-,134-,135-,136-,137-,138-,139-,140-,141-,142-,143-,151-,152-,153+/m0/s1 DM9Z4N5 CS CCCCCCCCCCCCCCCC(=O)N[C@@H](CCC(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCC(=O)NCCCC[C@@H](C(=O)O)NC(=O)[C@H](C1CCCCC1)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC3=CC=C(C=C3)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC4=CNC5=C4C=CC=N5)NC(=O)[C@H](CC6=CC=C(C=C6)O)NC(=O)[C@H](C(C)(C)C)NC(=O)[C@H](CC(=O)O)N(C)C(=O)[C@@H]7CC(=O)NCCCC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N7)CC8=CC=CC=C8)CCCNC(=N)N)CCC(=O)O)C(C)C)NC(=O)C)C(=O)O DM9Z4N5 IK JDXCOXKBIGBZSK-PSNKNOTQSA-N DM9Z4N5 IU (2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,5S,8S,11S,14S,22S)-22-acetamido-11-benzyl-8-(3-carbamimidamidopropyl)-5-(2-carboxyethyl)-3,6,9,12,16,23-hexaoxo-2-propan-2-yl-1,4,7,10,13,17-hexazacyclotricosane-14-carbonyl]-methylamino]-3-carboxypropanoyl]amino]-3,3-dimethylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-(1H-pyrrolo[2,3-b]pyridin-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carbonyl]amino]-2-cyclohexylacetyl]amino]-6-[3-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[[(4S)-4-carboxy-4-(hexadecanoylamino)butanoyl]amino]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]propanoylamino]hexanoic acid DM9Z4N5 CA CAS 1841136-73-9 DM9Z4N5 DE Paroxysmal nocturnal haemoglobinuria; Myasthenia gravis DM8RLJ5 ID DM8RLJ5 DM8RLJ5 DN RAD-1901 DM8RLJ5 HS Phase 3 DM8RLJ5 SN ER-306323; ER-308698; SERMs, Eisai/Radius; Selective estrogen receptor modulators, Eisai/Radius DM8RLJ5 CP Eisai Co Ltd DM8RLJ5 PC 23642301 DM8RLJ5 MW 458.6 DM8RLJ5 FM C30H38N2O2 DM8RLJ5 IC InChI=1S/C30H38N2O2/c1-4-31-17-16-22-6-8-23(9-7-22)21-32(5-2)30-20-28(34-3)14-15-29(30)26-11-10-25-19-27(33)13-12-24(25)18-26/h6-9,12-15,19-20,26,31,33H,4-5,10-11,16-18,21H2,1-3H3/t26-/m1/s1 DM8RLJ5 CS CCNCCC1=CC=C(C=C1)CN(CC)C2=C(C=CC(=C2)OC)[C@@H]3CCC4=C(C3)C=CC(=C4)O DM8RLJ5 IK SIFNOOUKXBRGGB-AREMUKBSSA-N DM8RLJ5 IU (6R)-6-[2-[ethyl-[[4-[2-(ethylamino)ethyl]phenyl]methyl]amino]-4-methoxyphenyl]-5,6,7,8-tetrahydronaphthalen-2-ol DM8RLJ5 CA CAS 722533-56-4 DM8RLJ5 DE Breast cancer DMN1ZEU ID DMN1ZEU DMN1ZEU DN Radiosensitizer gene therapy DMN1ZEU HS Phase 3 DMN1ZEU SN Radiosensitizer gene therapy (prostate cancer) DMN1ZEU CP Advantagene DMN1ZEU DE Pancreatic cancer DMWA74Y ID DMWA74Y DMWA74Y DN Radotinib DMWA74Y HS Phase 3 DMWA74Y SN IY-5511; IY-GV50205; Anticancer, Il-yang DMWA74Y CP Il-Yang Pharmaceutical Co DMWA74Y DT Small molecular drug DMWA74Y PC 16063245 DMWA74Y MW 530.5 DMWA74Y FM C27H21F3N8O DMWA74Y IC InChI=1S/C27H21F3N8O/c1-16-3-4-18(9-23(16)37-26-33-6-5-22(36-26)24-13-31-7-8-32-24)25(39)35-20-10-19(27(28,29)30)11-21(12-20)38-14-17(2)34-15-38/h3-15H,1-2H3,(H,35,39)(H,33,36,37) DMWA74Y CS CC1=C(C=C(C=C1)C(=O)NC2=CC(=CC(=C2)C(F)(F)F)N3C=C(N=C3)C)NC4=NC=CC(=N4)C5=NC=CN=C5 DMWA74Y IK DUPWHXBITIZIKZ-UHFFFAOYSA-N DMWA74Y IU 4-methyl-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyrazin-2-ylpyrimidin-2-yl)amino]benzamide DMWA74Y CA CAS 926037-48-1 DMWA74Y DE leukaemia DMFSHEM ID DMFSHEM DMFSHEM DN Ragaglitazar DMFSHEM HS Phase 3 DMFSHEM SN Ragaglitazar; DRF-2725; (2S)-2-ETHOXY-3-{4-[2-(10H-PHENOXAZIN-10-YL)ETHOXY]PHENYL}PROPANOIC ACID; CHEMBL24038; (2S)-2-ethoxy-3-[4-(2-phenoxazin-10-ylethoxy)phenyl]propanoic acid; DRF; 1nyx; DRF2725; AC1L9KVW; 2-Ethoxy-3-[4-(2-phenoxazin-10-yl-ethoxy)-phenyl]-propionic acid; GTPL2664; SCHEMBL4822459; WMUIIGVAWPWQAW-DEOSSOPVSA-N; NN-622; BDBM50109551; DB07675; NNC-61-0029; (-)-DRF-2725; (S)-2-Ethoxy-3-[4-(2-phenoxazin-10-yl-ethoxy)-phenyl]-propionic acid; (2S)-2-ethoxy-3-{4-[2-(phenoxazin-10-yl)ethoxy]phenyl}propanoic acid DMFSHEM DT Small molecular drug DMFSHEM PC 447458 DMFSHEM MW 419.5 DMFSHEM FM C25H25NO5 DMFSHEM IC InChI=1S/C25H25NO5/c1-2-29-24(25(27)28)17-18-11-13-19(14-12-18)30-16-15-26-20-7-3-5-9-22(20)31-23-10-6-4-8-21(23)26/h3-14,24H,2,15-17H2,1H3,(H,27,28)/t24-/m0/s1 DMFSHEM CS CCO[C@@H](CC1=CC=C(C=C1)OCCN2C3=CC=CC=C3OC4=CC=CC=C42)C(=O)O DMFSHEM IK WMUIIGVAWPWQAW-DEOSSOPVSA-N DMFSHEM IU (2S)-2-ethoxy-3-[4-(2-phenoxazin-10-ylethoxy)phenyl]propanoic acid DMFSHEM CA CAS 222834-30-2 DMFSHEM DE Type-1 diabetes DMUNMY0 ID DMUNMY0 DMUNMY0 DN Ralfinamide DMUNMY0 HS Phase 3 DMUNMY0 SN Ralfinamida; Ralfinamide [INN]; NW 1029; NW-1029; Ralfinamida [INN-Spanish]; (2S)-2-(4-(2-Fluorobenzyloxy)benzylamino)propanamide; (2S)-2-[[4-[(2-fluorophenyl)methoxy]phenyl]methylamino]propanamide DMUNMY0 CP Newron DMUNMY0 TC Analgesics DMUNMY0 DT Small molecular drug DMUNMY0 PC 5745207 DMUNMY0 MW 302.34 DMUNMY0 FM C17H19FN2O2 DMUNMY0 IC InChI=1S/C17H19FN2O2/c1-12(17(19)21)20-10-13-6-8-15(9-7-13)22-11-14-4-2-3-5-16(14)18/h2-9,12,20H,10-11H2,1H3,(H2,19,21)/t12-/m0/s1 DMUNMY0 CS C[C@@H](C(=O)N)NCC1=CC=C(C=C1)OCC2=CC=CC=C2F DMUNMY0 IK BHJIBOFHEFDSAU-LBPRGKRZSA-N DMUNMY0 IU (2S)-2-[[4-[(2-fluorophenyl)methoxy]phenyl]methylamino]propanamide DMUNMY0 CA CAS 133865-88-0 DMUNMY0 DE Neuropathic pain DMD5QRS ID DMD5QRS DMD5QRS DN Ranirestat DMD5QRS HS Phase 3 DMD5QRS SN AS-3201 DMD5QRS CP Eisai DMD5QRS DT Small molecular drug DMD5QRS PC 153948 DMD5QRS MW 420.2 DMD5QRS FM C17H11BrFN3O4 DMD5QRS IC InChI=1S/C17H11BrFN3O4/c18-10-4-3-9(11(19)6-10)8-21-14(24)12-2-1-5-22(12)17(16(21)26)7-13(23)20-15(17)25/h1-6H,7-8H2,(H,20,23,25)/t17-/m1/s1 DMD5QRS CS C1C(=O)NC(=O)[C@@]12C(=O)N(C(=O)C3=CC=CN23)CC4=C(C=C(C=C4)Br)F DMD5QRS IK QCVNMNYRNIMDKV-QGZVFWFLSA-N DMD5QRS IU (3R)-2'-[(4-bromo-2-fluorophenyl)methyl]spiro[pyrrolidine-3,4'-pyrrolo[1,2-a]pyrazine]-1',2,3',5-tetrone DMD5QRS CA CAS 147254-64-6 DMD5QRS DE Diabetic neuropathy DMVKL3B ID DMVKL3B DMVKL3B DN Ravulizumab DMVKL3B HS Phase 3 DMVKL3B SN Ultomiris (TN); Ravulizumab (USAN); Ravulizumab (genetical recombination) (JAN); D11054; 1803171-55-2 DMVKL3B TC Antiviral Agents DMVKL3B DT Monoclonal antibody DMVKL3B DE Coronavirus Disease 2019 (COVID-19) DMPJTZ1 ID DMPJTZ1 DMPJTZ1 DN RBP-7000 DMPJTZ1 HS Phase 3 DMPJTZ1 CP Reckitt benckiser pharmaceutical DMPJTZ1 DE Non-small-cell lung cancer; Schizophrenia DMDZW8K ID DMDZW8K DMDZW8K DN RBT-101 DMDZW8K HS Phase 3 DMDZW8K SN RBT-102; RBT-103; RBT-104; Seasonal/pandemic influenza vaccines (VLPs); Seasonal/pandemic influenza vaccines (VLPs), Redbiotec; Seasonal/pandemic influenza vaccines (virus-like-particles), Redbiotec DMDZW8K CP Redbiotec AG DMDZW8K DE Influenza virus infection; Heart failure; Respiratory tract infection DM2GHCR ID DM2GHCR DM2GHCR DN Rebamipide DM2GHCR HS Phase 3 DM2GHCR SN rebamipide; 90098-04-7; Mucosta; Proamipide; 111911-87-6; OPC-12759; Rebamipidum; Pramipide; Rebamipide [INN:JAN]; Rebamipidum [INN-Latin]; Rebamipida [INN-Spanish]; OPC 12759; CCRIS 3585; Rebamipide hydrate; 2-(4-Chlorobenzoylamino)-3-(1,2-dihydro-2-oxo-4-quinolyl)propionic acid; 139344-42-6; 2-[(4-chlorobenzoyl)amino]-3-(2-oxo-1H-quinolin-4-yl)propanoic acid; Mucosta hydrate; NCGC00095161-01; Proamipide hydrate; 2-(4-Chlorobenzamido)-3-[2(1H)-quinolinon-4-yl]propionic Acid DM2GHCR DT Small molecular drug DM2GHCR PC 5042 DM2GHCR MW 370.8 DM2GHCR FM C19H15ClN2O4 DM2GHCR IC InChI=1S/C19H15ClN2O4/c20-13-7-5-11(6-8-13)18(24)22-16(19(25)26)9-12-10-17(23)21-15-4-2-1-3-14(12)15/h1-8,10,16H,9H2,(H,21,23)(H,22,24)(H,25,26) DM2GHCR CS C1=CC=C2C(=C1)C(=CC(=O)N2)CC(C(=O)O)NC(=O)C3=CC=C(C=C3)Cl DM2GHCR IK ALLWOAVDORUJLA-UHFFFAOYSA-N DM2GHCR IU 2-[(4-chlorobenzoyl)amino]-3-(2-oxo-1H-quinolin-4-yl)propanoic acid DM2GHCR CA CAS 90098-04-7 DM2GHCR CB CHEBI:93814 DM2GHCR DE Peptic ulcer DM8HVNR ID DM8HVNR DM8HVNR DN Recombinant acidic fibroblast growth factor DM8HVNR HS Phase 3 DM8HVNR SN AFGF; Rh-aFGF; Recombinant acidic fibroblast growth factor (ulcer/burns); Recombinant acidic fibroblast growth factor (ulcer/burns), SinoBiomed; Recombinant acidic fibroplast growth factor (ulcer/burns), SinoBiomed DM8HVNR CP SinoBiomed Inc DM8HVNR DE Skin burns DMOWQAF ID DMOWQAF DMOWQAF DN Recombinant human iduronate-2-sulfatase DMOWQAF HS Phase 3 DMOWQAF SN GC-1111; Recombinant human iduronate-2-sulfatase (Hunter syndrome); Recombinant human iduronate-2-sulfatase (Hunter syndrome), Green Cross DMOWQAF CP Green Cross Corp DMOWQAF DE Hunter syndrome DM7JFDO ID DM7JFDO DM7JFDO DN Recombinant von Willebrand factor/recombinant Factor VIII complex DM7JFDO HS Phase 3 DM7JFDO SN Willebrand factor/recombinant Factor VIII complex; Recombinant von Willebrand factor/recombinant Factor VIII complex (von Willebrand disease) DM7JFDO CP Csl behring DM7JFDO DE Von willebrand disease DM34GOF ID DM34GOF DM34GOF DN REL-1017 DM34GOF HS Phase 3 DM34GOF SN Dextromethadone; d-Methadone; S-Methadone; (S)-methadone; (+)-Methadone; S-(+)-Methadone; 6S-Methadone; 5653-80-5; L-(+)-Methadone; (6S)-Methadone; l-Methadone; (S)-(+)-Methadone; UNII-S95RZH8AMH; d-6-(Dimethylamino)-4,4-diphenyl-3-heptanone; S95RZH8AMH; (S)-6-(Dimethylamino)-4,4-diphenyl-3-heptanone; CHEMBL350719; (S)-6-(dimethylamino)-4,4-diphenylheptan-3-one; 3-14-00-00279 (Beilstein Handbook Reference); Methadone, (+)-; BRN 3213667; (+)-(S)-Methadone; (+)-(6S)-Methadone; SCHEMBL24294; (6S)-6-(dimethylamino)-4,4-diphenylheptan-3-one; CHEBI:167308; 3-HEPTANONE, 6-(DIMETHYLAMINO)-4,4-DIPHENYL-, (S)-; ZINC1530707; BDBM50223640; DB15198; SB18896; (S)-6-Dimethylamino4,4-diphenylheptan-3-on; Q15634047; (+)-(S)-6-(dimethylamino)-4,4-diphenyl-3-heptanone; 3-heptanone, 6-(dimethylamino)-4,4-diphenyl-, (6S)-; UNII-UC6VBE7V1Z component USSIQXCVUWKGNF-KRWDZBQOSA-N; UNII-UC6VBE7V1Z component USSIQXCVUWKGNF-QGZVFWFLSA-N; 3-Heptanone, 6-(dimethylamino)-4,4-diphenyl-, (6S)- (9CI); 3-Heptanone, 6-(dimethylamino)-4,4-diphenyl-, (S)- (8CI) DM34GOF CP Relmada Therapeutics DM34GOF DT Small molecular drug DM34GOF PC 643985 DM34GOF MW 309.4 DM34GOF FM C21H27NO DM34GOF IC InChI=1S/C21H27NO/c1-5-20(23)21(16-17(2)22(3)4,18-12-8-6-9-13-18)19-14-10-7-11-15-19/h6-15,17H,5,16H2,1-4H3/t17-/m0/s1 DM34GOF CS CCC(=O)C(C[C@H](C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2 DM34GOF IK USSIQXCVUWKGNF-KRWDZBQOSA-N DM34GOF IU (6S)-6-(dimethylamino)-4,4-diphenylheptan-3-one DM34GOF CA CAS 5653-80-5 DM34GOF CB CHEBI:167308 DM34GOF DE Neuropathic pain; Major depressive disorder DMOWINT ID DMOWINT DMOWINT DN Reloxaliase DMOWINT HS Phase 3 DMOWINT SN ALLN-177 DMOWINT CP Allena Pharmaceuticals DMOWINT DT Protein DMOWINT DE Hyperoxaluria DM3YXP8 ID DM3YXP8 DM3YXP8 DN Remacemide DM3YXP8 HS Phase 3 DM3YXP8 SN Remacemida; Remacemidum; Remacemide [INN]; FPL 12924; FPL 12924AA; FPL 14144; FPL 14145; FPL-12944AA; PR 1032-644; PR 934-423; PR1032-646; Remacemida [INN-Spanish]; Remacemidum [INN-Latin]; PR-934-423; Remacemide monohydrochloride, (+-)-isomer; (+)-2-Amino-N-(1-methyl-1,2-diphenylethyl)acetamide; (+-)-2-Amino-N-(1-methyl-1,2-diphenylethyl)acetamide; (-)-2-Amino-N-(1-methyl-1,2-diphenylethyl)acetamide; 2-amino-N-(1,2-diphenylpropan-2-yl)acetamide; 2-amino-N-(1-methyl-1,2-diphenylethyl)acetamide DM3YXP8 CP Astra Zeneca DM3YXP8 DT Small molecular drug DM3YXP8 PC 60511 DM3YXP8 MW 268.35 DM3YXP8 FM C17H20N2O DM3YXP8 IC InChI=1S/C17H20N2O/c1-17(19-16(20)13-18,15-10-6-3-7-11-15)12-14-8-4-2-5-9-14/h2-11H,12-13,18H2,1H3,(H,19,20) DM3YXP8 CS CC(CC1=CC=CC=C1)(C2=CC=CC=C2)NC(=O)CN DM3YXP8 IK YSGASDXSLKIKOD-UHFFFAOYSA-N DM3YXP8 IU 2-amino-N-(1,2-diphenylpropan-2-yl)acetamide DM3YXP8 CA CAS 128298-28-2 DM3YXP8 CB CHEBI:91654 DM3YXP8 DE Pain DM49IGE ID DM49IGE DM49IGE DN Remdesivir DM49IGE HS Phase 3 DM49IGE SN L-Alanine, N-((S)-hydroxyphenoxyp; RWWYLEGWBNMMLJ-YSOARWBDSA-N; Remdesivir [USAN]; 1809249-37-3; 3QKI37EEHE; AKOS032946252; SB19838; SCHEMBL17712225; UNII-3QKI37EEHE DM49IGE CP Gilead Sciences, Foster City, CA DM49IGE TC Antiviral Agents DM49IGE DT Small molecular drug DM49IGE PC 121304016 DM49IGE MW 602.6 DM49IGE FM C27H35N6O8P DM49IGE IC InChI=1S/C27H35N6O8P/c1-4-18(5-2)13-38-26(36)17(3)32-42(37,41-19-9-7-6-8-10-19)39-14-21-23(34)24(35)27(15-28,40-21)22-12-11-20-25(29)30-16-31-33(20)22/h6-12,16-18,21,23-24,34-35H,4-5,13-14H2,1-3H3,(H,32,37)(H2,29,30,31)/t17-,21+,23+,24+,27-,42-/m0/s1 DM49IGE CS CCC(CC)COC(=O)[C@H](C)N[P@](=O)(OC[C@@H]1[C@H]([C@H]([C@](O1)(C#N)C2=CC=C3N2N=CN=C3N)O)O)OC4=CC=CC=C4 DM49IGE IK RWWYLEGWBNMMLJ-YSOARWBDSA-N DM49IGE IU 2-ethylbutyl (2S)-2-[[[(2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxyoxolan-2-yl]methoxy-phenoxyphosphoryl]amino]propanoate DM49IGE CA CAS 1809249-37-3 DM49IGE CB CHEBI:145994 DM49IGE DE Ebola virus infection; Coronavirus Disease 2019 (COVID-19); Coronavirus Disease 2019 (COVID-19); Middle East Respiratory Syndrome (MERS); Severe acute respiratory syndrome (SARS) DM7HQNX ID DM7HQNX DM7HQNX DN Renzapride DM7HQNX HS Phase 3 DM7HQNX SN Renzaprida; Renzapridum; Renzaprida [INN-Spanish]; Renzapridum [INN-Latin]; 4-amino-N-[(4S,5S)-1-azabicyclo[3.3.1]nonan-4-yl]-5-chloro-2-methoxybenzamide DM7HQNX CP Alizyme DM7HQNX DT Small molecular drug DM7HQNX PC 119574 DM7HQNX MW 323.82 DM7HQNX FM C16H22ClN3O2 DM7HQNX IC InChI=1S/C16H22ClN3O2/c1-22-15-8-13(18)12(17)7-11(15)16(21)19-14-4-6-20-5-2-3-10(14)9-20/h7-8,10,14H,2-6,9,18H2,1H3,(H,19,21)/t10-,14+/m0/s1 DM7HQNX CS COC1=CC(=C(C=C1C(=O)N[C@@H]2CCN3CCC[C@H]2C3)Cl)N DM7HQNX IK GZSKEXSLDPEFPT-IINYFYTJSA-N DM7HQNX IU 4-amino-N-[(4R,5S)-1-azabicyclo[3.3.1]nonan-4-yl]-5-chloro-2-methoxybenzamide DM7HQNX CA CAS 112727-80-7 DM7HQNX DE Irritable bowel syndrome DMVBA7I ID DMVBA7I DMVBA7I DN Reparixin DMVBA7I HS Phase 3 DMVBA7I SN reparixin; repertaxin; 266359-83-5; UNII-U604E1NB3K; CHEMBL191413; U604E1NB3K; DF 1681Y; (R)-2-(4-isobutylphenyl)-N-(methylsulfonyl)propanamide; Reparixin [USAN:INN]; (2R)-2-[4-(2-methylpropyl)phenyl]-N-methylsulfonylpropanamide; (2R)-2-(4-(2-Methylpropyl)phenyl)-N-methylsulfonylpropanamide; 2-(4-isobutylphenyl)propionylmethanesulfonamide; Reparixin (USAN/INN); DSSTox_RID_81678; DSSTox_CID_26509; DSSTox_GSID_46509; ZINC8717; SCHEMBL1884299; GTPL8498; DTXSID6046509; EX-A2461; DF-1681Y; BCP10635; Tox21_112272; BDBM50169045; Repertaxin; Reparixin [INN]; Reparixin (INN/USAN); (R)-2-(4-isobutylphenyl)propionylmethanesulfonamide; RAPARIXIN DMVBA7I CP Dompe s.p.a. DMVBA7I DT Small molecular drug DMVBA7I PC 9838712 DMVBA7I MW 283.39 DMVBA7I FM C14H21NO3S DMVBA7I IC InChI=1S/C14H21NO3S/c1-10(2)9-12-5-7-13(8-6-12)11(3)14(16)15-19(4,17)18/h5-8,10-11H,9H2,1-4H3,(H,15,16)/t11-/m1/s1 DMVBA7I CS C[C@H](C1=CC=C(C=C1)CC(C)C)C(=O)NS(=O)(=O)C DMVBA7I IK KQDRVXQXKZXMHP-LLVKDONJSA-N DMVBA7I IU (2R)-2-[4-(2-methylpropyl)phenyl]-N-methylsulfonylpropanamide DMVBA7I CA CAS 266359-83-5 DMVBA7I DE Graft rejection in heart transplantation; lung transplantation; Ischemia-reperfusion injury; Pancreatic islet transplantation failure DMDEJX9 ID DMDEJX9 DMDEJX9 DN Reproxalap DMDEJX9 HS Phase 3 DMDEJX9 SN 2-(3-Amino-6-chloroquinolin-2-yl)propan-2-ol; 2-(3-amino-6-chloroquinolin-2-yl)propan-2-ol; Reproxalap [USAN]; UNII-F0GIZ22IJH; F0GIZ22IJH; SCHEMBL12228833; ALD-102; ADX-102; 2-Quinolinemethanol, 3-amino-6-chloro-alpha,alpha-dimethyl-; NS2 DMDEJX9 CP Aldeyra Therapeutics Lexington, MA DMDEJX9 PC 16088030 DMDEJX9 MW 236.7 DMDEJX9 FM C12H13ClN2O DMDEJX9 IC InChI=1S/C12H13ClN2O/c1-12(2,16)11-9(14)6-7-5-8(13)3-4-10(7)15-11/h3-6,16H,14H2,1-2H3 DMDEJX9 CS CC(C)(C1=C(C=C2C=C(C=CC2=N1)Cl)N)O DMDEJX9 IK GUHFUVLKYSQIOQ-UHFFFAOYSA-N DMDEJX9 IU 2-(3-amino-6-chloroquinolin-2-yl)propan-2-ol DMDEJX9 CA CAS 916056-79-6 DMDEJX9 DE Sjogren-Larsson syndrome DMFMWYC ID DMFMWYC DMFMWYC DN Resatorvid DMFMWYC HS Phase 3 DMFMWYC SN Resatorvid; TAK-242; 243984-11-4; UNII-H2MZ648C31; CHEMBL225157; H2MZ648C31; TAK242; Resatorvid [INN]; TAK-242 (Resatorvid); C15H17ClFNO4S; SCHEMBL872197; GTPL9036; MolPort-035-773-739; BDBM50155929; ZINC13982410; 4003AH; AKOS027250774; CS-0408; KB-80786; AN-16512; HY-11109; A3850; W-5468; P111021; ethyl (6R)-6-[(2-chloro-4-fluorophenyl)sulfamoyl]cyclohexene-1-carboxylate; ethyl (6r)-6-[n-(2-chloro-4-fluorophenyl)sulfamoyl]cyclohex-1-ene-1-carboxylate; ethyl (6R)-6-[(2-chloro-4-fluoro-phenyl)sulfamoyl]cyclohexene-1-carboxylate DMFMWYC CP Takeda DMFMWYC DT Small molecular drug DMFMWYC PC 11703255 DMFMWYC MW 361.8 DMFMWYC FM C15H17ClFNO4S DMFMWYC IC InChI=1S/C15H17ClFNO4S/c1-2-22-15(19)11-5-3-4-6-14(11)23(20,21)18-13-8-7-10(17)9-12(13)16/h5,7-9,14,18H,2-4,6H2,1H3/t14-/m1/s1 DMFMWYC CS CCOC(=O)C1=CCCC[C@H]1S(=O)(=O)NC2=C(C=C(C=C2)F)Cl DMFMWYC IK LEEIJTHMHDMWLJ-CQSZACIVSA-N DMFMWYC IU ethyl (6R)-6-[(2-chloro-4-fluorophenyl)sulfamoyl]cyclohexene-1-carboxylate DMFMWYC CA CAS 243984-11-4 DMFMWYC DE Sepsis DM3RWXL ID DM3RWXL DM3RWXL DN Resveratrol DM3RWXL HS Phase 3 DM3RWXL SN Resveratrol; Resvida; KUC104385N; R 5010; SRT 501; Cis-resveratrol; PREVENTION 8 (RESVERATROL); RM-1812; SRT-501; Trans-resveratrol; CU-01000001503-3; KSC-10-164; Resveratrol-3-sulfate; Trans-3,4',5-trihydroxystilbene; Trans-3,4′,5-Trihydroxystilbene; Trans-1,2-(3,4',5-Trihydroxydiphenyl)ethylene; (E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol DM3RWXL CP Sirtris Pharma DM3RWXL DT Small molecular drug DM3RWXL PC 445154 DM3RWXL MW 228.24 DM3RWXL FM C14H12O3 DM3RWXL IC InChI=1S/C14H12O3/c15-12-5-3-10(4-6-12)1-2-11-7-13(16)9-14(17)8-11/h1-9,15-17H/b2-1+ DM3RWXL CS C1=CC(=CC=C1/C=C/C2=CC(=CC(=C2)O)O)O DM3RWXL IK LUKBXSAWLPMMSZ-OWOJBTEDSA-N DM3RWXL IU 5-[(E)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol DM3RWXL CA CAS 501-36-0 DM3RWXL CB CHEBI:45713 DM3RWXL DE Colorectal cancer; Giant cell arteritis; Rheumatoid arthritis; Systemic sclerosis DMOYGZF ID DMOYGZF DMOYGZF DN Retosiban DMOYGZF HS Phase 3 DMOYGZF SN 820957-38-8; UNII-GIE06H28OX; GSK221149A; GSK-221149A; GIE06H28OX; CHEMBL429736; Retosiban [USAN:INN]; Retosiban (USAN); GSK 221149A; SCHEMBL230301; GTPL8403; DTXSID00231559; PLVGDGRBPMVYPB-FDUHJNRSSA-N; ZINC6718496; BDBM50372608; GSK-221,149-A; SB16762; DB11818; HY-14778; CS-0003555; J3.542.064I; D08986; 2,5-Piperazinedione, 3-(2,3-dihydro-1H-inden-2-yl)-1-[(1R)-1-(2-methyl-4-oxazolyl)-2-(4-morpholinyl)-2-oxoethyl]-6-[(1S)-1-methylpropyl]-, (3R,6R)- DMOYGZF CP GlaxoSmithKline DMOYGZF DT Small molecular drug DMOYGZF PC 11340891 DMOYGZF MW 494.6 DMOYGZF FM C27H34N4O5 DMOYGZF IC InChI=1S/C27H34N4O5/c1-4-16(2)23-25(32)29-22(20-13-18-7-5-6-8-19(18)14-20)26(33)31(23)24(21-15-36-17(3)28-21)27(34)30-9-11-35-12-10-30/h5-8,15-16,20,22-24H,4,9-14H2,1-3H3,(H,29,32)/t16-,22+,23+,24+/m0/s1 DMOYGZF CS CC[C@H](C)[C@@H]1C(=O)N[C@@H](C(=O)N1[C@H](C2=COC(=N2)C)C(=O)N3CCOCC3)C4CC5=CC=CC=C5C4 DMOYGZF IK PLVGDGRBPMVYPB-FDUHJNRSSA-N DMOYGZF IU (3R,6R)-6-[(2S)-butan-2-yl]-3-(2,3-dihydro-1H-inden-2-yl)-1-[(1R)-1-(2-methyl-1,3-oxazol-4-yl)-2-morpholin-4-yl-2-oxoethyl]piperazine-2,5-dione DMOYGZF CA CAS 820957-38-8 DMOYGZF DE Preterm labour DM5E73H ID DM5E73H DM5E73H DN Revusiran DM5E73H HS Phase 3 DM5E73H DT siRNA drug DM5E73H DE Amyloidosis DMQ4CSX ID DMQ4CSX DMQ4CSX DN Rezafungin DMQ4CSX HS Phase 3 DMQ4CSX SN CD-101; CD101; SP-3025; CHEMBL3989945; HY-108009; CS-0027142; J3.555.717B; J3.599.425D; (4R,5R)-N2-[4-(4'-Pentoxy-1,1'-biphenyl-4-yl)benzoyl]-5-[2-(trimethylaminio)ethoxy]-4-hydroxy-cyclo[L-Orn*-[(3R)-3-methyl-L-Ser-]-[(4R)-4-hydroxy-L-Pro-]-2-[(1S,2S)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-L-Gly-[(3R)-3-methyl-L-Ser-]-[(3S,4S)-3-hydroxy-4-methyl-L-Pro-]-] DMQ4CSX CP Cidara Therapeutics DMQ4CSX DT Small molecular drug DMQ4CSX PC 78318119 DMQ4CSX MW 1226.4 DMQ4CSX FM C63H85N8O17+ DMQ4CSX IC InChI=1S/C63H84N8O17/c1-8-9-10-28-87-45-25-21-40(22-26-45)38-13-11-37(12-14-38)39-15-17-42(18-16-39)56(80)64-46-31-48(76)61(88-29-27-71(5,6)7)68-60(84)52-53(77)34(2)32-70(52)63(86)50(36(4)73)66-59(83)51(55(79)54(78)41-19-23-43(74)24-20-41)67-58(82)47-30-44(75)33-69(47)62(85)49(35(3)72)65-57(46)81/h11-26,34-36,44,46-55,61,72-73,75-79H,8-10,27-33H2,1-7H3,(H5-,64,65,66,67,68,74,80,81,82,83,84)/p+1/t34-,35+,36+,44+,46-,47-,48+,49-,50-,51-,52-,53-,54-,55-,61+/m0/s1 DMQ4CSX CS CCCCCOC1=CC=C(C=C1)C2=CC=C(C=C2)C3=CC=C(C=C3)C(=O)N[C@H]4C[C@H]([C@H](NC(=O)[C@@H]5[C@H]([C@H](CN5C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]6C[C@H](CN6C(=O)[C@@H](NC4=O)[C@@H](C)O)O)[C@@H]([C@H](C7=CC=C(C=C7)O)O)O)[C@@H](C)O)C)O)OCC[N+](C)(C)C)O DMQ4CSX IK LNFCWEXGZIEGJW-TXSVMFMRSA-O DMQ4CSX IU 2-[[(3S,6S,9S,11R,15S,18S,20R,21R,24S,25S,26S)-6-[(1S,2S)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-11,20,25-trihydroxy-3,15-bis[(1R)-1-hydroxyethyl]-26-methyl-2,5,8,14,17,23-hexaoxo-18-[[4-[4-(4-pentoxyphenyl)phenyl]benzoyl]amino]-1,4,7,13,16,22-hexazatricyclo[22.3.0.09,13]heptacosan-21-yl]oxy]ethyl-trimethylazanium DMQ4CSX DE Candidiasis DMTQJE0 ID DMTQJE0 DMTQJE0 DN RG3638 DMTQJE0 HS Phase 3 DMTQJE0 SN Onartuzumab DMTQJE0 CP Roche DMTQJE0 DE Non-small-cell lung cancer; Gastric adenocarcinoma DMER75Y ID DMER75Y DMER75Y DN RG6013 DMER75Y HS Phase 3 DMER75Y DT Antibody DMER75Y DE Haemophilia A DMJRFYB ID DMJRFYB DMJRFYB DN RG7201 DMJRFYB HS Phase 3 DMJRFYB CP Roche DMJRFYB DE Type-2 diabetes DMF5GZI ID DMF5GZI DMF5GZI DN RG7388 DMF5GZI HS Phase 3 DMF5GZI SN Idasanutlin; RG7388; 1229705-06-9; Idasanutlin (RG-7388); RG-7388; UNII-QSQ883V35U; QSQ883V35U; CHEMBL2402737; Benzoic acid, 4-((((2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl)carbonyl)amino)-3-methoxy-; RO5503781; Idasanutlin [USAN:INN]; Benzoic acid, 4-[[[(2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl]carbonyl]amino]-3-methoxy-; RG-7388;Idasanutlin; RO-5503781; SCHEMBL442856 DMF5GZI CP Roche DMF5GZI DT Small molecular drug DMF5GZI PC 53358942 DMF5GZI MW 616.5 DMF5GZI FM C31H29Cl2F2N3O4 DMF5GZI IC InChI=1S/C31H29Cl2F2N3O4/c1-30(2,3)14-24-31(15-36,19-10-9-17(32)13-21(19)34)25(18-6-5-7-20(33)26(18)35)27(38-24)28(39)37-22-11-8-16(29(40)41)12-23(22)42-4/h5-13,24-25,27,38H,14H2,1-4H3,(H,37,39)(H,40,41)/t24-,25-,27+,31-/m0/s1 DMF5GZI CS CC(C)(C)C[C@H]1[C@]([C@H]([C@@H](N1)C(=O)NC2=C(C=C(C=C2)C(=O)O)OC)C3=C(C(=CC=C3)Cl)F)(C#N)C4=C(C=C(C=C4)Cl)F DMF5GZI IK TVTXCJFHQKSQQM-LJQIRTBHSA-N DMF5GZI IU 4-[[(2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)pyrrolidine-2-carbonyl]amino]-3-methoxybenzoic acid DMF5GZI CA CAS 1229705-06-9 DMF5GZI DE Haematological malignancy; Solid tumour/cancer; Polycythemia vera; Acute myeloid leukaemia DMDVAFP ID DMDVAFP DMDVAFP DN RG7601 DMDVAFP HS Phase 3 DMDVAFP CP Abbott; Roche DMDVAFP DE Chronic lymphocytic leukaemia DMGOTK4 ID DMGOTK4 DMGOTK4 DN Rhumab Beta7 DMGOTK4 HS Phase 3 DMGOTK4 CP Roche; Genentech DMGOTK4 DT Antibody DMGOTK4 DE Ulcerative colitis DMLHEU7 ID DMLHEU7 DMLHEU7 DN Ridaforolimus DMLHEU7 HS Phase 3 DMLHEU7 SN Deforolimus; AP 23573; MK 8669; AP-23573; MK-8669; AP23573, MK-8669, Ridaforolimus, Deforolimus DMLHEU7 CP Merck DMLHEU7 DT Small molecular drug DMLHEU7 PC 11520894 DMLHEU7 MW 990.2 DMLHEU7 FM C53H84NO14P DMLHEU7 IC InChI=1S/C53H84NO14P/c1-32-18-14-13-15-19-33(2)44(63-8)30-40-23-21-38(7)53(61,67-40)50(58)51(59)54-25-17-16-20-41(54)52(60)66-45(35(4)28-39-22-24-43(46(29-39)64-9)68-69(11,12)62)31-42(55)34(3)27-37(6)48(57)49(65-10)47(56)36(5)26-32/h13-15,18-19,27,32,34-36,38-41,43-46,48-49,57,61H,16-17,20-26,28-31H2,1-12H3/b15-13+,18-14+,33-19+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1 DMLHEU7 CS C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)OP(=O)(C)C)C)/C)O)OC)C)C)/C)OC DMLHEU7 IK BUROJSBIWGDYCN-GAUTUEMISA-N DMLHEU7 IU (1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-12-[(2R)-1-[(1S,3R,4R)-4-dimethylphosphoryloxy-3-methoxycyclohexyl]propan-2-yl]-1,18-dihydroxy-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone DMLHEU7 CA CAS 572924-54-0 DMLHEU7 CB CHEBI:79700 DMLHEU7 DE Sarcoma DMYXOHV ID DMYXOHV DMYXOHV DN Rifalazil DMYXOHV HS Phase 3 DMYXOHV DT Small molecular drug DMYXOHV PC 135431094 DMYXOHV MW 941.1 DMYXOHV FM C51H64N4O13 DMYXOHV IC InChI=1S/C51H64N4O13/c1-24(2)23-54-16-18-55(19-17-54)32-21-33(57)39-35(22-32)67-48-40(52-39)36-37-44(60)30(8)47-38(36)49(62)51(10,68-47)65-20-15-34(64-11)27(5)46(66-31(9)56)29(7)43(59)28(6)42(58)25(3)13-12-14-26(4)50(63)53-41(48)45(37)61/h12-15,20-22,24-25,27-29,34,42-43,46,58-60,62H,16-19,23H2,1-11H3,(H,53,63)/b13-12+,20-15+,26-14-/t25-,27+,28+,29+,34-,42-,43+,46+,51-/m0/s1 DMYXOHV CS C[C@H]1/C=C/C=C(\\C(=O)NC2=C3C(=C4C(=C(C(=C5C4=C([C@](O5)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)O)C)O)C2=O)N=C6C(=CC(=CC6=O)N7CCN(CC7)CC(C)C)O3)/C DMYXOHV IK IXSVOCGZBUJEPI-HTQYORAHSA-N DMYXOHV IU [(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,6,15,17-tetrahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-30-[4-(2-methylpropyl)piperazin-1-yl]-23,32,37-trioxo-8,27,38-trioxa-24,34-diazahexacyclo[23.11.1.14,7.05,36.026,35.028,33]octatriaconta-1,3,5,9,19,21,25,28,30,33,35-undecaen-13-yl] acetate DMYXOHV CA CAS 129791-92-0 DMYXOHV DE Bacterial infection DMKTS2M ID DMKTS2M DMKTS2M DN Rifaximin DR DMKTS2M HS Phase 3 DMKTS2M CP Salix Pharmaceuticals Raleigh, NC DMKTS2M DE Crohn disease DMOSTXF ID DMOSTXF DMOSTXF DN Rigosertib DMOSTXF HS Phase 3 DMOSTXF SN Rigosertib; 592542-59-1; UNII-67DOW7F9GL; 67DOW7F9GL; N-[2-Methoxy-5-({[(E)-2-(2,4,6-Trimethoxyphenyl)ethenyl]sulfonyl}methyl)phenyl]glycine; ON-01910.Na; Rigosertib [USAN:INN]; 6FS; Rigosertib (USAN); AC1OCFT5; SCHEMBL498624; Estybon (proposed trade name); SCHEMBL498623; GTPL7833; CHEMBL1241855; ON01910.Na; DTXSID30207984; CHEBI:124939; OWBFCJROIKNMGD-BQYQJAHWSA-N; 1910 Na; ZINC3942646; BCP08296; BDBM50060917; 4006AH; AKOS015966442; DB12146; SB16468; (E)-2-((2-methoxy-5-(((2,4,6-trimethoxystyryl)sulfonyl)methyl)phenyl)amino)acetic a DMOSTXF CP Onconova Therapeutics DMOSTXF DT Small molecular drug DMOSTXF PC 6918736 DMOSTXF MW 451.5 DMOSTXF FM C21H25NO8S DMOSTXF IC InChI=1S/C21H25NO8S/c1-27-15-10-19(29-3)16(20(11-15)30-4)7-8-31(25,26)13-14-5-6-18(28-2)17(9-14)22-12-21(23)24/h5-11,22H,12-13H2,1-4H3,(H,23,24)/b8-7+ DMOSTXF CS COC1=C(C=C(C=C1)CS(=O)(=O)/C=C/C2=C(C=C(C=C2OC)OC)OC)NCC(=O)O DMOSTXF IK OWBFCJROIKNMGD-BQYQJAHWSA-N DMOSTXF IU 2-[2-methoxy-5-[[(E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonylmethyl]anilino]acetic acid DMOSTXF CA CAS 592542-59-1 DMOSTXF CB CHEBI:124939 DMOSTXF DE Solid tumour/cancer; Myelodysplastic syndrome DMGTCI0 ID DMGTCI0 DMGTCI0 DN Rilimogene galvacirepvec DMGTCI0 HS Phase 3 DMGTCI0 SN Prostvac (TN) DMGTCI0 CP BM ImmunoTherapeutics DMGTCI0 DE Prostate cancer DMP6IMQ ID DMP6IMQ DMP6IMQ DN Rindopepimut DMP6IMQ HS Phase 3 DMP6IMQ CP Celldex Therapeutics DMP6IMQ DE Glioblastoma multiforme; Brain cancer DMYX7VI ID DMYX7VI DMYX7VI DN Rintatolimod DMYX7VI HS Phase 3 DMYX7VI CP Hemispherx Biopharma DMYX7VI DT siRNA drug DMYX7VI DE Human immunodeficiency virus infection DM13V0P ID DM13V0P DM13V0P DN Rivoceranib DM13V0P HS Phase 3 DM13V0P CP Elevar Therapeutics DM13V0P DT Small molecular drug DM13V0P DE Gastric adenocarcinoma; Solid tumour/cancer; Sarcoma DMBY31K ID DMBY31K DMBY31K DN Rivoglitazone DMBY31K HS Phase 3 DMBY31K SN CS-011; DE-101; Rivoglitazone (ophthalmic); Rivoglitazone (ophthalmic), Santen; CS-011 (ophthalmic), Santen DMBY31K CP Sankyo Co Ltd DMBY31K DT Small molecular drug DMBY31K PC 3055168 DMBY31K MW 397.4 DMBY31K FM C20H19N3O4S DMBY31K IC InChI=1S/C20H19N3O4S/c1-23-16-10-14(26-2)7-8-15(16)21-18(23)11-27-13-5-3-12(4-6-13)9-17-19(24)22-20(25)28-17/h3-8,10,17H,9,11H2,1-2H3,(H,22,24,25) DMBY31K CS CN1C2=C(C=CC(=C2)OC)N=C1COC3=CC=C(C=C3)CC4C(=O)NC(=O)S4 DMBY31K IK XMSXOLDPMGMWTH-UHFFFAOYSA-N DMBY31K IU 5-[[4-[(6-methoxy-1-methylbenzimidazol-2-yl)methoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione DMBY31K CA CAS 185428-18-6 DMBY31K DE Ocular inflammation DMVQ5X1 ID DMVQ5X1 DMVQ5X1 DN Roclatan DMVQ5X1 HS Phase 3 DMVQ5X1 SN PG324 DMVQ5X1 CP Aerie pharmaceuticals DMVQ5X1 PC 118984471 DMVQ5X1 MW 886.1 DMVQ5X1 FM C54H67N3O8 DMVQ5X1 IC InChI=1S/C28H27N3O3.C26H40O5/c1-18-3-10-25(19(2)13-18)28(33)34-17-20-4-6-21(7-5-20)26(15-29)27(32)31-24-9-8-23-16-30-12-11-22(23)14-24;1-19(2)31-26(30)13-9-4-3-8-12-22-23(25(29)18-24(22)28)17-16-21(27)15-14-20-10-6-5-7-11-20/h3-14,16,26H,15,17,29H2,1-2H3,(H,31,32);3,5-8,10-11,19,21-25,27-29H,4,9,12-18H2,1-2H3/b;8-3-/t26-;21-,22+,23+,24-,25+/m10/s1 DMVQ5X1 CS CC1=CC(=C(C=C1)C(=O)OCC2=CC=C(C=C2)[C@@H](CN)C(=O)NC3=CC4=C(C=C3)C=NC=C4)C.CC(C)OC(=O)CCC/C=C\\C[C@H]1[C@H](C[C@H]([C@@H]1CC[C@H](CCC2=CC=CC=C2)O)O)O DMVQ5X1 IK QILUCPOIAVKEBG-GCBPXYGZSA-N DMVQ5X1 IU [4-[(2S)-3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl]phenyl]methyl 2,4-dimethylbenzoate;propan-2-yl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]hept-5-enoate DMVQ5X1 DE Glaucoma/ocular hypertension DMSZPR3 ID DMSZPR3 DMSZPR3 DN Rolofylline DMSZPR3 HS Phase 3 DMSZPR3 SN KW 3902; HMR-4902; KW-3902; MK-7418; Rolofylline (USAN); 1,3-Dipropyl-8-(3-noradamantyl)xanthine; 1,3-Dnax; 8-(3-Noradamantyl)-1,3-dipropylxanthine; 8-(Hexahydro-2,5-methanopentalen-3a(1H)-yl)-3,7-dihydro-1,3-dipropyl-1H-purine-2,6-dione; 8-(Noradamantan-3-yl)-1,3-dipropylxanthine; 8-(hexahydro-2,5-methanopentalen-3a(1h)-yl)-1,3-dipropyl-3,7-dihydro-1h-purine-2,6-dione DMSZPR3 CP Merck DMSZPR3 DT Small molecular drug DMSZPR3 PC 64627 DMSZPR3 MW 356.5 DMSZPR3 FM C20H28N4O2 DMSZPR3 IC InChI=1S/C20H28N4O2/c1-3-5-23-16-15(17(25)24(6-4-2)19(23)26)21-18(22-16)20-10-12-7-13(11-20)9-14(20)8-12/h12-14H,3-11H2,1-2H3,(H,21,22) DMSZPR3 CS CCCN1C2=C(C(=O)N(C1=O)CCC)NC(=N2)C34CC5CC(C3)CC4C5 DMSZPR3 IK PJBFVWGQFLYWCB-UHFFFAOYSA-N DMSZPR3 IU 1,3-dipropyl-8-(3-tricyclo[3.3.1.03,7]nonanyl)-7H-purine-2,6-dione DMSZPR3 CA CAS 136199-02-5 DMSZPR3 DE Heart failure DMPIDXT ID DMPIDXT DMPIDXT DN Rosiglitazone + metformin DMPIDXT HS Phase 3 DMPIDXT SN Orantinib; TSU-68; 252916-29-3; SU-6668; SU6668; SU 6668; 210644-62-5; UNII-9RL37ZZ665; Orantinib (TSU-68); NSC 702827; TSU68; CHEMBL274654; 9RL37ZZ665; TSU 68; PDGFR Tyrosine Kinase Inhibitor VI, SU6668; 2,4-Dimethyl-5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-pyrrole-3-propanoic acid; J-502593; Orantinibum; 3-(2,4-dimethyl-5-{[(3Z)-2-oxo-1H-indol-3-ylidene]methyl}-1H-pyrrol-3-yl)propanoic acid; 3-[2,4-dimethyl-5-[(Z)-(2-oxo-1H-indol-3-ylidene)methyl]-1H-pyrrol-3-yl]propanoic acid; Orantinib [INN] DMPIDXT CP GSK DMPIDXT DT Combination drug (small molecular drug) DMPIDXT PC 5329099 DMPIDXT MW 310.3 DMPIDXT FM C18H18N2O3 DMPIDXT IC InChI=1S/C18H18N2O3/c1-10-12(7-8-17(21)22)11(2)19-16(10)9-14-13-5-3-4-6-15(13)20-18(14)23/h3-6,9,19H,7-8H2,1-2H3,(H,20,23)(H,21,22)/b14-9- DMPIDXT CS CC1=C(NC(=C1CCC(=O)O)C)/C=C\\2/C3=CC=CC=C3NC2=O DMPIDXT IK NHFDRBXTEDBWCZ-ZROIWOOFSA-N DMPIDXT IU 3-[2,4-dimethyl-5-[(Z)-(2-oxo-1H-indol-3-ylidene)methyl]-1H-pyrrol-3-yl]propanoic acid DMPIDXT CA CAS 210644-62-5 DMPIDXT DE Advanced solid tumour; Diabetic complication DM18B72 ID DM18B72 DM18B72 DN Rosiglitazone + simvastatin DM18B72 HS Phase 3 DM18B72 CP GSK DM18B72 DT Combination drug (small molecular drug) DM18B72 PC 23644561 DM18B72 MW 241.24 DM18B72 FM C13H11N3O2 DM18B72 IC InChI=1S/C13H11N3O2/c1-18-9-2-3-12-10(5-9)11(13(17)16-12)4-8-6-14-7-15-8/h2-8H,1H3,(H,16,17)/b11-4- DM18B72 CS COC1=CC\\2=C(C=C1)NC(=O)/C2=C\\C3C=NC=N3 DM18B72 IK KKGJVFQBVRACGR-WCIBSUBMSA-N DM18B72 IU (3Z)-3-(4H-imidazol-4-ylmethylidene)-5-methoxy-1H-indol-2-one DM18B72 DE Type-2 diabetes DMNGCAD ID DMNGCAD DMNGCAD DN Rova-T DMNGCAD HS Phase 3 DMNGCAD SN rovalpituzumab tesirine; Rovalpituzumab Tesirine; Rova-t; Rovalpituzumab-Tesirin; UNII-P256HB60FF; Rovalpituzumab tesirine [INN]; P256HB60FF; Rovalpituzumab tesirine [WHO-DD]; Rovalpituzumab tesirine [USAN:INN]; SC0002; 1613313-09-9 DMNGCAD CP StemcentRx South San Francisco, CA DMNGCAD PC 131954443 DMNGCAD MW 1617.8 DMNGCAD FM C78H108N10O25S DMNGCAD IC InChI=1S/C78H108N10O25S/c1-49(2)70(84-68(90)16-21-103-23-25-105-27-29-107-31-33-109-35-36-110-34-32-108-30-28-106-26-24-104-22-17-80-67(89)15-18-85-69(91)43-66(76(85)97)114-48-58(79)77(98)99)72(93)82-52(5)71(92)83-54-13-11-53(12-14-54)47-113-78(100)88-60-42-65(63(102-7)40-57(60)74(95)87-46-51(4)38-61(87)75(88)96)112-20-10-8-9-19-111-64-41-59-56(39-62(64)101-6)73(94)86-45-50(3)37-55(86)44-81-59/h11-14,39-42,44-46,49,52,55,58,61,66,70,75,96H,8-10,15-38,43,47-48,79H2,1-7H3,(H,80,89)(H,82,93)(H,83,92)(H,84,90)(H,98,99)/t52-,55-,58-,61-,66+,70-,75-/m0/s1 DMNGCAD CS CC1=CN2[C@@H](C1)C=NC3=CC(=C(C=C3C2=O)OC)OCCCCCOC4=C(C=C5C(=C4)N([C@H]([C@@H]6CC(=CN6C5=O)C)O)C(=O)OCC7=CC=C(C=C7)NC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCNC(=O)CCN8C(=O)C[C@H](C8=O)SC[C@@H](C(=O)O)N)OC DMNGCAD IK NQUUPTGRJYIXSL-YPDXTJLXSA-N DMNGCAD IU (2R)-3-[(3R)-1-[3-[2-[2-[2-[2-[2-[2-[2-[2-[3-[[(2S)-1-[[(2S)-1-[4-[[(6S,6aS)-3-[5-[[(6aS)-2-methoxy-8-methyl-11-oxo-6a,7-dihydropyrrolo[2,1-c][1,4]benzodiazepin-3-yl]oxy]pentoxy]-6-hydroxy-2-methoxy-8-methyl-11-oxo-6a,7-dihydro-6H-pyrrolo[2,1-c][1,4]benzodiazepine-5-carbonyl]oxymethyl]anilino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-oxopropoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethylamino]-3-oxopropyl]-2,5-dioxopyrrolidin-3-yl]sulfanyl-2-aminopropanoic acid DMNGCAD CA CAS 1613313-09-9 DMNGCAD DE Small-cell lung cancer; Neuroendocrine cancer DM9T8OF ID DM9T8OF DM9T8OF DN RQ-00000004 DM9T8OF HS Phase 3 DM9T8OF SN PF-03716556; RQ-00000774; RQ-4; Acid pump inhibitor (GERD), Pfizer; Acid pump inhibitor (GERD), RaQualia;Acid pump inhibitor (gastroesophageal reflux), Pfizer; Acid pump inhibitor (gastroesophageal reflux), RaQualia DM9T8OF CP Pfizer Inc DM9T8OF DE Gastroesophageal reflux disease DMQM2FH ID DMQM2FH DMQM2FH DN RRx-001 DMQM2FH HS Phase 3 DMQM2FH SN RRX-001; 925206-65-1; 2-BROMO-1-(3,3-DINITROAZETIDIN-1-YL)ETHAN-1-ONE; UNII-7RPW6SU9SC; 2-Bromo-1-(3,3-dinitroazetidin-1-yl)ethanone; 7RPW6SU9SC; RRx001; Ethanone, 2-bromo-1-(3,3-dinitro-1-azetidinyl)-; SCHEMBL2249018; CHEMBL3526802; MolPort-044-559-098; EX-A2006; BCP19228; 1-bromoacetyl-3,3-dinitroazetidine; ZINC34805177; s8405; DB12060; CS-5286; HY-16438; AS-53015 DMQM2FH CP RadioRx DMQM2FH DT Small molecular drug DMQM2FH PC 15950826 DMQM2FH MW 268.02 DMQM2FH FM C5H6BrN3O5 DMQM2FH IC InChI=1S/C5H6BrN3O5/c6-1-4(10)7-2-5(3-7,8(11)12)9(13)14/h1-3H2 DMQM2FH CS C1C(CN1C(=O)CBr)([N+](=O)[O-])[N+](=O)[O-] DMQM2FH IK JODKFOVZURLVTG-UHFFFAOYSA-N DMQM2FH IU 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone DMQM2FH CA CAS 925206-65-1 DMQM2FH DE Lymphoma; Anaplastic glioma; Neuroendocrine cancer; Ovarian epithelial cancer; Solid tumour/cancer; Non-small-cell lung cancer; Small-cell lung cancer DM62QTW ID DM62QTW DM62QTW DN RTB101 DM62QTW HS Phase 3 DM62QTW CP ResTORbio DM62QTW DT Small molecular drug DM62QTW DE Coronavirus Disease 2019 (COVID-19); Respiratory tract infection DMDWU1S ID DMDWU1S DMDWU1S DN Rubitecan DMDWU1S HS Phase 3 DMDWU1S SN 9-Nitrocamptothecin; 91421-42-0; Orathecin; 9-nitro-20(S)-camptothecin; Camptogen; 9-NC; RFS 2000; RFS-2000; UNII-H19C446XXB; Nitrocamptothecin; H19C446XXB; CHEBI:90225; C20H15N3O6; (S)-4-Ethyl-4-hydroxy-10-nitro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; NCGC00167969-01; (s)-4-ethyl-4-hydroxy-10-nitro-1h-pyrano[3',4':6,7]-indolizino[1,2-b]quinoline-3,14(4h,12h)-dione; 9NC; Q-100889; (4s)-4-ethyl-4-hydroxy-10-nitro-1h-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4h,12h)-dione; Inhaled Orathecin; L9NC; Rubitecan (inhaled); Aerosolized liposomal 9 nitro-20 (S) camptothecin; Rubitecan (inhaled), SuperGen; 9-Nitro-20(S)-camptothecin; 9-Nitrocamptothecin (9-NC) DMDWU1S CP SuperGen; Clayton Foundation For Research; MD Anderson Cancer Center DMDWU1S DT Small molecular drug DMDWU1S PC 472335 DMDWU1S MW 393.3 DMDWU1S FM C20H15N3O6 DMDWU1S IC InChI=1S/C20H15N3O6/c1-2-20(26)13-7-16-17-10(8-22(16)18(24)12(13)9-29-19(20)25)6-11-14(21-17)4-3-5-15(11)23(27)28/h3-7,26H,2,8-9H2,1H3/t20-/m0/s1 DMDWU1S CS CC[C@@]1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC=C5[N+](=O)[O-])N=C4C3=C2)O DMDWU1S IK VHXNKPBCCMUMSW-FQEVSTJZSA-N DMDWU1S IU (19S)-19-ethyl-19-hydroxy-8-nitro-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaene-14,18-dione DMDWU1S CA CAS 91421-42-0 DMDWU1S CB CHEBI:90225 DMDWU1S DE Human immunodeficiency virus infection DMQOCD8 ID DMQOCD8 DMQOCD8 DN RUBOXISTAURIN HYDROCHLORIDE DMQOCD8 HS Phase 3 DMQOCD8 SN LY-333531.HCl; Ruboxistaurin hydrochloride; 9(S)-(Dimethylaminomethyl)-5,6,7,9,10,11,12,17,18,19,20,21-dodecahydro-5,21:12,17-dimethenodibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecine-18,20-dione hydrochloride DMQOCD8 PC 9870785 DMQOCD8 MW 505 DMQOCD8 FM C28H29ClN4O3 DMQOCD8 IC InChI=1S/C28H28N4O3.ClH/c1-30(2)15-18-11-12-31-16-21(19-7-3-5-9-23(19)31)25-26(28(34)29-27(25)33)22-17-32(13-14-35-18)24-10-6-4-8-20(22)24;/h3-10,16-18H,11-15H2,1-2H3,(H,29,33,34);1H/t18-;/m0./s1 DMQOCD8 CS CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C32)C4=C(C5=CN(CCO1)C6=CC=CC=C65)C(=O)NC4=O.Cl DMQOCD8 IK NYQIEYDJYFVLPO-FERBBOLQSA-N DMQOCD8 IU (18S)-18-[(dimethylamino)methyl]-17-oxa-4,14,21-triazahexacyclo[19.6.1.17,14.02,6.08,13.022,27]nonacosa-1(28),2(6),7(29),8,10,12,22,24,26-nonaene-3,5-dione;hydrochloride DMQOCD8 CA CAS 169939-93-9 DMQOCD8 DE Lymphoma DM25TMP ID DM25TMP DM25TMP DN Rubraca rucaparib DM25TMP HS Phase 3 DM25TMP CP Clovis Oncology Boulder, CO DM25TMP DE Prostate cancer; Ovarian cancer DM20KYR ID DM20KYR DM20KYR DN Ruxolitinib DM20KYR HS Phase 3 DM20KYR SN Ruxolitinib (JAK inhibitor) DM20KYR CP Incyte DM20KYR TC Antiviral Agents DM20KYR DT Small molecular drug DM20KYR PC 25126798 DM20KYR MW 306.4 DM20KYR FM C17H18N6 DM20KYR IC InChI=1S/C17H18N6/c18-7-5-15(12-3-1-2-4-12)23-10-13(9-22-23)16-14-6-8-19-17(14)21-11-20-16/h6,8-12,15H,1-5H2,(H,19,20,21)/t15-/m1/s1 DM20KYR CS C1CCC(C1)[C@@H](CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3 DM20KYR IK HFNKQEVNSGCOJV-OAHLLOKOSA-N DM20KYR IU (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile DM20KYR CA CAS 941678-49-5 DM20KYR CB CHEBI:66919 DM20KYR DE Essential thrombocythemia; High-risk myelofibrosis; Nasopharyngeal carcinoma; Pancreatic cancer; Coronavirus Disease 2019 (COVID-19) DMAYTIH ID DMAYTIH DMAYTIH DN S-06911 DMAYTIH HS Phase 3 DMAYTIH SN Strontium ranelate + vitamin D3 (osteoporosis), Servier; Strontium ranelate + vitamin D3 (fixed-dose combination, osteoporosis), Servier DMAYTIH CP Servier DMAYTIH DE Osteoporosis DMXY34J ID DMXY34J DMXY34J DN S-110 DMXY34J HS Phase 3 DMXY34J SN DNA demethylating agent (myelodysplastic syndrome), Supergen DMXY34J CP SuperGen Inc DMXY34J DE Acute myeloid leukaemia; Chronic myelogenous leukaemia; Solid tumour/cancer DM408GM ID DM408GM DM408GM DN S-474474 DM408GM HS Phase 3 DM408GM CP Shionogi DM408GM DE Metabolic syndrome x DM7F2VG ID DM7F2VG DM7F2VG DN SA-237 DM7F2VG HS Phase 3 DM7F2VG SN Second generation IL-6 antagonist (mAb, inflammatory disease), Chugai DM7F2VG CP Chugai Pharmaceutical Co Ltd DM7F2VG DE Rheumatoid arthritis; Encephalopathy; Neuromyelitis optica DMGR98T ID DMGR98T DMGR98T DN SAGE-217 DMGR98T HS Phase 3 DMGR98T SN HARRKNSQXBRBGZ-GVKWWOCJSA-N; SCHEMBL16189866; HY-103040; CS-0023489; 1632051-40-1 DMGR98T CP Sage Therapeutics Cambridge, MA DMGR98T PC 86294073 DMGR98T MW 409.6 DMGR98T FM C25H35N3O2 DMGR98T IC InChI=1S/C25H35N3O2/c1-24(30)9-7-18-17(11-24)3-4-20-19(18)8-10-25(2)21(20)5-6-22(25)23(29)15-28-14-16(12-26)13-27-28/h13-14,17-22,30H,3-11,15H2,1-2H3/t17-,18+,19-,20-,21+,22-,24-,25+/m1/s1 DMGR98T CS C[C@]1(CC[C@H]2[C@@H](C1)CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC[C@@H]4C(=O)CN5C=C(C=N5)C#N)C)O DMGR98T IK HARRKNSQXBRBGZ-GVKWWOCJSA-N DMGR98T IU 1-[2-[(3R,5R,8R,9R,10S,13S,14S,17S)-3-hydroxy-3,13-dimethyl-2,4,5,6,7,8,9,10,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-oxoethyl]pyrazole-4-carbonitrile DMGR98T CA CAS 1632051-40-1 DMGR98T DE Essential tremor or related tremors; Major depressive disorder; Parkinson disease; Postpartum depression DMI1R5S ID DMI1R5S DMI1R5S DN SAIT101 DMI1R5S HS Phase 3 DMI1R5S CP Archigen Biotech DMI1R5S DT Antibody DMI1R5S DE Follicular lymphoma DMKHLRT ID DMKHLRT DMKHLRT DN SAND-26 DMKHLRT HS Phase 3 DMKHLRT SN Begedina; CD26-targeting antibody (autoimmunity), ADIENNE DMKHLRT CP ADIENNE Pharma & Biotech DMKHLRT DT Antibody DMKHLRT DE Autoimmune diabetes DMXAO4J ID DMXAO4J DMXAO4J DN SAR153191 DMXAO4J HS Phase 3 DMXAO4J CP Sanofi-Aventis DMXAO4J DE Ankylosing spondylitis DMHFBOG ID DMHFBOG DMHFBOG DN SAR231893 DMHFBOG HS Phase 3 DMHFBOG CP Sanofi DMHFBOG DE Atopic dermatitis; Asthma DMR0EWV ID DMR0EWV DMR0EWV DN SAR342434 DMR0EWV HS Phase 3 DMR0EWV DE Diabetic complication; Type-1 diabetes; Type-2 diabetes DMXGE3O ID DMXGE3O DMXGE3O DN SAR408701 DMXGE3O HS Phase 3 DMXGE3O CP Sanofi DMXGE3O DT Antibody drug conjugate DMXGE3O DE Solid tumour/cancer; Non-small-cell lung cancer DMDMAE4 ID DMDMAE4 DMDMAE4 DN SAR438584 DMDMAE4 HS Phase 3 DMDMAE4 SN REGN2222 DMDMAE4 DT Antibody DMDMAE4 DE Respiratory syncytial virus infection DM8HCFD ID DM8HCFD DM8HCFD DN Sarilumab DM8HCFD HS Phase 3 DM8HCFD SN Kevzara DM8HCFD CP Sanofi/Regeneron DM8HCFD TC Antiviral Agents DM8HCFD DT Monoclonal antibody DM8HCFD SQ Heavy chain: EVQLVESGGGLVQPGRSLRLSCAASRFTFDDYAMHWVRQAPGKGLEWVSGISWNSGRIGYADSVKGRFTISRDNAENSLFLQMNGLRAEDTALYYCAKGRDSFDIWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK >Light chainDIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLIYGASSLESGVPSRFSGSGSGTDFTLTISSLQPEDFASYYCQQANSFPYTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC DM8HCFD DE Rheumatoid arthritis; Severely active rheumatoid arthritis; Coronavirus Disease 2019 (COVID-19) DMUVSG4 ID DMUVSG4 DMUVSG4 DN Sasanlimab DMUVSG4 HS Phase 3 DMUVSG4 SN PF-06801591 DMUVSG4 CP Pfizer DMUVSG4 DT Antibody DMUVSG4 DE Non-muscle invasive bladder cancer DME5PN3 ID DME5PN3 DME5PN3 DN Satavaptan DME5PN3 HS Phase 3 DME5PN3 CP Sanofi-Aventis DME5PN3 DT Small molecular drug DME5PN3 PC 158348 DME5PN3 MW 643.8 DME5PN3 FM C33H45N3O8S DME5PN3 IC InChI=1S/C33H45N3O8S/c1-6-43-25-8-9-27-26(22-25)33(13-11-24(12-14-33)44-20-17-35-15-18-42-19-16-35)31(38)36(27)45(39,40)29-10-7-23(21-28(29)41-5)30(37)34-32(2,3)4/h7-10,21-22,24H,6,11-20H2,1-5H3,(H,34,37) DME5PN3 CS CCOC1=CC2=C(C=C1)N(C(=O)C23CCC(CC3)OCCN4CCOCC4)S(=O)(=O)C5=C(C=C(C=C5)C(=O)NC(C)(C)C)OC DME5PN3 IK QKXJWFOKVQWEDZ-UHFFFAOYSA-N DME5PN3 IU N-tert-butyl-4-[5'-ethoxy-4-(2-morpholin-4-ylethoxy)-2'-oxospiro[cyclohexane-1,3'-indole]-1'-yl]sulfonyl-3-methoxybenzamide DME5PN3 CA CAS 185913-78-4 DME5PN3 DE Acute and chronic heart failure DMALFKX ID DMALFKX DMALFKX DN Savolitinib DMALFKX HS Phase 3 DMALFKX SN 1313725-88-0; AZD-6094; AZD6094; UNII-2A2DA6857R; CHEMBL3334567; 2A2DA6857R; Savolitinib [INN]; Volitinib(Savolitinib); Savolitinib [USAN:INN]; GTPL9918; SCHEMBL12489208; EX-A845; BDBM50023342; ZINC149738712; AKOS030526403; DB12048; compound 28 [PMID: 25148209]; HY-15959; AS-35250; 1H-1,2,3-Triazolo(4,5-b)pyrazine, 1-((1S)-1-imidazo(1,2-a)pyridin-6-ylethyl)-6-(1-methyl-1H-pyrazol-4-yl)-; KB-333895; FT-0700162; J-690125; 4-{1-[(1S)-1-{imidazo[1,2-a]pyri DMALFKX CP AstraZeneca Wilmington, DE DMALFKX PC 68289010 DMALFKX MW 345.4 DMALFKX FM C17H15N9 DMALFKX IC InChI=1S/C17H15N9/c1-11(12-3-4-15-18-5-6-25(15)10-12)26-17-16(22-23-26)19-8-14(21-17)13-7-20-24(2)9-13/h3-11H,1-2H3/t11-/m0/s1 DMALFKX CS C[C@@H](C1=CN2C=CN=C2C=C1)N3C4=NC(=CN=C4N=N3)C5=CN(N=C5)C DMALFKX IK XYDNMOZJKOGZLS-NSHDSACASA-N DMALFKX IU 3-[(1S)-1-imidazo[1,2-a]pyridin-6-ylethyl]-5-(1-methylpyrazol-4-yl)triazolo[4,5-b]pyrazine DMALFKX CA CAS 1313725-88-0 DMALFKX DE Solid tumour/cancer; Renal cell carcinoma DMAPRWV ID DMAPRWV DMAPRWV DN SaxaDapa FDC DMAPRWV HS Phase 3 DMAPRWV CP AstraZeneca DMAPRWV DE Diabetic complication DMME6GJ ID DMME6GJ DMME6GJ DN SB12 DMME6GJ HS Phase 3 DMME6GJ CP Samsung Bioepis DMME6GJ DT Antibody DMME6GJ DE Paroxysmal nocturnal haemoglobinuria DM6L4ZT ID DM6L4ZT DM6L4ZT DN SB-742457 DM6L4ZT HS Phase 3 DM6L4ZT SN GSK 742457; SB 742457; GSK-742457; 3-(benzenesulfonyl)-8-piperazin-1-yl-quinoline DM6L4ZT CP GlaxoSmithKline DM6L4ZT DT Small molecular drug DM6L4ZT PC 11256720 DM6L4ZT MW 353.4 DM6L4ZT FM C19H19N3O2S DM6L4ZT IC InChI=1S/C19H19N3O2S/c23-25(24,16-6-2-1-3-7-16)17-13-15-5-4-8-18(19(15)21-14-17)22-11-9-20-10-12-22/h1-8,13-14,20H,9-12H2 DM6L4ZT CS C1CN(CCN1)C2=CC=CC3=CC(=CN=C32)S(=O)(=O)C4=CC=CC=C4 DM6L4ZT IK JJZFWROHYSMCMU-UHFFFAOYSA-N DM6L4ZT IU 3-(benzenesulfonyl)-8-piperazin-1-ylquinoline DM6L4ZT CA CAS 607742-69-8 DM6L4ZT DE Alzheimer disease DM6XNJR ID DM6XNJR DM6XNJR DN SC-46553 DM6XNJR HS Phase 3 DM6XNJR SN Ginsenoside 20-Glc-Rf; PubChem13034; SC-46553; ZINC238808898; ginsenoside-Rd; 705G938; CHEMBL525935; S597; Ginsenoside Rd DM6XNJR PC 24721561 DM6XNJR MW 963.2 DM6XNJR FM C48H82O19 DM6XNJR IC FBFMBWCLBGQEBU-RXMALORBSA-N DM6XNJR CS CC(=CCCC(C)(C1CCC2(C1C(CC3C2(CC(C4C3(CCC(C4(C)C)O)C)OC5C(C(C(C(O5)CO)O)O)OC6C(C(C(C(O6)CO)O)O)O)C)O)C)OC7C(C(C(C(O7)CO)O)O)O)C DM6XNJR IK 1S/C48H82O19/c1-21(2)10-9-13-48(8,67-42-38(61)35(58)32(55)26(19-50)64-42)22-11-15-46(6)30(22)23(52)16-28-45(5)14-12-29(53)44(3,4)40(45)24(17-47(28,46)7)62-43-39(36(59)33(56)27(20-51)65-43)66-41-37(60)34(57)31(54)25(18-49)63-41/h10,22-43,49-61H,9,11-20H2,1-8H3/t22-,23+,24-,25+,26+,27+,28+,29-,30-,31+,32+,33+,34-,35-,36-,37+,38+,39+,40-,41-,42-,43+,45+,46+,47+,48-/m0/s1 DM6XNJR IU (2S,3R,4S,5S,6R)-2-[(2R,3R,4S,5S,6R)-2-[[(3S,5R,6S,8R,9R,10R,12R,13R,14R,17S)-3,12-dihydroxy-4,4,8,10,14-pentamethyl-17-[(2S)-6-methyl-2-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhept-5-en-2-yl]-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-6-yl]oxy]-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol DM6XNJR DE Cerebral stroke DMK1IPV ID DMK1IPV DMK1IPV DN SCY-078 DMK1IPV HS Phase 3 DMK1IPV SN Ibrexafungerp DMK1IPV CP Scynexis DMK1IPV DT Small molecular drug DMK1IPV PC 46871657 DMK1IPV MW 730 DMK1IPV FM C44H67N5O4 DMK1IPV IC InChI=1S/C44H67N5O4/c1-27(2)28(3)39(7)18-19-41(9)30-12-13-33-40(8)23-52-25-44(33,31(30)14-17-42(41,10)34(39)37(50)51)22-32(35(40)53-24-43(11,45)38(4,5)6)49-36(47-26-48-49)29-15-20-46-21-16-29/h14-16,20-21,26-28,30,32-35H,12-13,17-19,22-25,45H2,1-11H3,(H,50,51)/t28-,30+,32-,33+,34-,35+,39-,40-,41-,42+,43+,44+/m1/s1 DMK1IPV CS C[C@H](C(C)C)[C@]1(CC[C@@]2([C@H]3CC[C@H]4[C@]5(COC[C@]4(C3=CC[C@]2([C@@H]1C(=O)O)C)C[C@H]([C@@H]5OC[C@@](C)(C(C)(C)C)N)N6C(=NC=N6)C7=CC=NC=C7)C)C)C DMK1IPV IK BODYFEUFKHPRCK-ZCZMVWJSSA-N DMK1IPV IU (1R,5S,6R,7R,10R,11R,14R,15S,20R,21R)-21-[(2R)-2-amino-2,3,3-trimethylbutoxy]-5,7,10,15-tetramethyl-7-[(2R)-3-methylbutan-2-yl]-20-(5-pyridin-4-yl-1,2,4-triazol-1-yl)-17-oxapentacyclo[13.3.3.01,14.02,11.05,10]henicos-2-ene-6-carboxylic acid DMK1IPV CA CAS 1207753-03-4 DMK1IPV DE Fungal infection; Invasive candidiasis DMAMTGI ID DMAMTGI DMAMTGI DN SD-101 DMAMTGI HS Phase 3 DMAMTGI SN HCV-ISS; HCV vaccine (ISS), Dynavax/Symphony Dynamo DMAMTGI CP Scioderm DMAMTGI DT Oligonucleotide DMAMTGI DE Hepatitis C virus infection; Melanoma; Skin disease; Squamous cell carcinoma; Squamous head and neck cell carcinom DM9DEYL ID DM9DEYL DM9DEYL DN SD-6010 DM9DEYL HS Phase 3 DM9DEYL CP Pfizer New York, NY DM9DEYL DE Osteoarthritis DMBD4K3 ID DMBD4K3 DMBD4K3 DN Selinexor DMBD4K3 HS Phase 3 DMBD4K3 SN Xpovio; KPT 330; KPT-330; KPT-330(Selinexor); KPT330;Selinexor; 1393477-72-9; 31TZ62FO8F; CHEMBL3545185; SCHEMBL14678327; Selinexor; Selinexor (KPT-330); Selinexor [USAN:INN]; Tube706; UNII-31TZ62FO8F DMBD4K3 CP Karyopharm therapeutics DMBD4K3 DT Small molecular drug DMBD4K3 PC 71481097 DMBD4K3 MW 443.3 DMBD4K3 FM C17H11F6N7O DMBD4K3 IC InChI=1S/C17H11F6N7O/c18-16(19,20)11-5-10(6-12(7-11)17(21,22)23)15-26-9-30(29-15)4-1-14(31)28-27-13-8-24-2-3-25-13/h1-9H,(H,25,27)(H,28,31)/b4-1- DMBD4K3 CS C1=CN=C(C=N1)NNC(=O)/C=C\\N2C=NC(=N2)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F DMBD4K3 IK DEVSOMFAQLZNKR-RJRFIUFISA-N DMBD4K3 IU (Z)-3-[3-[3,5-bis(trifluoromethyl)phenyl]-1,2,4-triazol-1-yl]-N'-pyrazin-2-ylprop-2-enehydrazide DMBD4K3 CA CAS 1393477-72-9 DMBD4K3 DE Solid tumour/cancer; Diffuse large B-cell lymphoma; Acute myeloid leukaemia; Multiple myeloma; Liposarcoma; Neuroendocrine cancer; Recurrent glioblastoma DMC7W6R ID DMC7W6R DMC7W6R DN Selumetinib DMC7W6R HS Phase 3 DMC7W6R SN Selumetinib; AZD-6244; ARRY142886; AZD6244; ARRY142886; AZD 6244; AZD-6244; 6UH91I579U; ARRY 142886; ARRY-142886; AZD6244 (Selumetinib); AZD6244(Selumetinib); CHEBI:90227; CHEMBL1614701; MEK inhibitors; Selumetinib (AZD6244); UNII-6UH91I579U DMC7W6R CP AstraZeneca DMC7W6R DT Small molecular drug DMC7W6R PC 10127622 DMC7W6R MW 457.7 DMC7W6R FM C17H15BrClFN4O3 DMC7W6R IC InChI=1S/C17H15BrClFN4O3/c1-24-8-21-16-13(24)7-10(17(26)23-27-5-4-25)15(14(16)20)22-12-3-2-9(18)6-11(12)19/h2-3,6-8,22,25H,4-5H2,1H3,(H,23,26) DMC7W6R CS CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)Cl)C(=O)NOCCO DMC7W6R IK CYOHGALHFOKKQC-UHFFFAOYSA-N DMC7W6R IU 6-(4-bromo-2-chloroanilino)-7-fluoro-N-(2-hydroxyethoxy)-3-methylbenzimidazole-5-carboxamide DMC7W6R CA CAS 606143-52-6 DMC7W6R CB CHEBI:90227 DMC7W6R DE Non-small-cell lung cancer; Melanoma; Thyroid cancer; Solid tumour/cancer DML83IW ID DML83IW DML83IW DN Semagacestat DML83IW HS Phase 3 DML83IW SN DAPT; AN-37124; AN-44989; LY-374973; LY-411575; LY-424354; LY-450139; LY-4501395; Gamma-secretase inhibitors (Alzheimer's disease), Elan Pharmaceuticals/Eli Lilly DML83IW CP Eli Lilly & Co DML83IW DT Small molecular drug DML83IW PC 9843750 DML83IW MW 361.4 DML83IW FM C19H27N3O4 DML83IW IC InChI=1S/C19H27N3O4/c1-11(2)16(23)18(25)20-12(3)17(24)21-15-14-8-6-5-7-13(14)9-10-22(4)19(15)26/h5-8,11-12,15-16,23H,9-10H2,1-4H3,(H,20,25)(H,21,24)/t12-,15-,16-/m0/s1 DML83IW CS C[C@@H](C(=O)N[C@H]1C2=CC=CC=C2CCN(C1=O)C)NC(=O)[C@H](C(C)C)O DML83IW IK PKXWXXPNHIWQHW-RCBQFDQVSA-N DML83IW IU (2S)-2-hydroxy-3-methyl-N-[(2S)-1-[[(5S)-3-methyl-4-oxo-2,5-dihydro-1H-3-benzazepin-5-yl]amino]-1-oxopropan-2-yl]butanamide DML83IW CA CAS 425386-60-3 DML83IW CB CHEBI:131158 DML83IW DE Parkinson disease DMKL9QO ID DMKL9QO DMKL9QO DN Seocalcitol DMKL9QO HS Phase 3 DMKL9QO SN Seocalcitol; 134404-52-7; UNII-Q0OZ0D9223; EB-1089; Q0OZ0D9223; EB1089; EB 1089; Seocalcitol [INN:BAN]; CB-1089; (22E,24E)-1alpha,25-dihydroxy-26,27-dimethyl-22,23,24,24a-tetradehydro-24a-homovitamin D3 / (22E,24E)-1alpha,25-dihydroxy-26,27-dimethyl-22,23,24,24a-tetradehydro-24a-homocholecalciferol; (1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(2R,3E,5E)-7-ethyl-7-hydroxynona-3,5-dien-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol DMKL9QO DT Small molecular drug DMKL9QO PC 5288149 DMKL9QO MW 454.7 DMKL9QO FM C30H46O3 DMKL9QO IC InChI=1S/C30H46O3/c1-6-30(33,7-2)18-9-8-11-21(3)26-15-16-27-23(12-10-17-29(26,27)5)13-14-24-19-25(31)20-28(32)22(24)4/h8-9,11,13-14,18,21,25-28,31-33H,4,6-7,10,12,15-17,19-20H2,1-3,5H3/b11-8+,18-9+,23-13+,24-14-/t21-,25-,26-,27+,28+,29-/m1/s1 DMKL9QO CS CCC(CC)(/C=C/C=C/[C@@H](C)[C@H]1CC[C@@H]\\2[C@@]1(CCC/C2=C\\C=C/3\\C[C@H](C[C@@H](C3=C)O)O)C)O DMKL9QO IK LVLLALCJVJNGQQ-SEODYNFXSA-N DMKL9QO IU (1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(2R,3E,5E)-7-ethyl-7-hydroxynona-3,5-dien-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol DMKL9QO CA CAS 134404-52-7 DMKL9QO DE Rickets DMG2QP4 ID DMG2QP4 DMG2QP4 DN SEP-363856 DMG2QP4 HS Phase 3 DMG2QP4 CP Sunovion DMG2QP4 PC 89532783 DMG2QP4 MW 183.27 DMG2QP4 FM C9H13NOS DMG2QP4 IC InChI=1S/C9H13NOS/c1-10-6-8-9-7(2-4-11-8)3-5-12-9/h3,5,8,10H,2,4,6H2,1H3/t8-/m0/s1 DMG2QP4 CS CNC[C@H]1C2=C(CCO1)C=CS2 DMG2QP4 IK ABDDQTDRAHXHOC-QMMMGPOBSA-N DMG2QP4 IU 1-[(7S)-5,7-dihydro-4H-thieno[2,3-c]pyran-7-yl]-N-methylmethanamine DMG2QP4 CA CAS 1310426-33-5 DMG2QP4 DE Major depressive disorder; Parkinson disease; Schizophrenia DM5VH6U ID DM5VH6U DM5VH6U DN Serlopitant DM5VH6U HS Phase 3 DM5VH6U SN VPD-737; UNII-277V92K32B; CHEMBL447955; 860642-69-9; 277V92K32B; 3-((3aR,4R,5S,7aS)-5-((R)-1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-4-(4-fluorophenyl)hexahydro-1H-isoindol-2(3H)-yl)cyclopent-2-enone; Serlopitant [USAN:INN]; VPD 737; Serlopitant (USAN); SCHEMBL3183159; GTPL9280; mk-0594; FLNYCRJBCNNHRH-OIYLJQICSA-N; BDBM50277511; compound 17 (Jiang et al. 2009); DB12973; D09378; 3-[(3aR,4R,5S,7aS)-5-{(1R)-1-[3,5-Bis(trifluoromethyl)phenyl]ethoxy}-4-(4-fluorophenyl)octahydro-1H-isoindol-2-yl]cyclopent-2-en-1-one DM5VH6U CP Menlo Therapeutics Redwood City, CA DM5VH6U PC 23653789 DM5VH6U MW 555.5 DM5VH6U FM C29H28F7NO2 DM5VH6U IC InChI=1S/C29H28F7NO2/c1-16(19-10-20(28(31,32)33)12-21(11-19)29(34,35)36)39-26-9-4-18-14-37(23-7-8-24(38)13-23)15-25(18)27(26)17-2-5-22(30)6-3-17/h2-3,5-6,10-13,16,18,25-27H,4,7-9,14-15H2,1H3/t16-,18-,25-,26+,27+/m1/s1 DM5VH6U CS C[C@H](C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)O[C@H]2CC[C@@H]3CN(C[C@H]3[C@@H]2C4=CC=C(C=C4)F)C5=CC(=O)CC5 DM5VH6U IK FLNYCRJBCNNHRH-OIYLJQICSA-N DM5VH6U IU 3-[(3aR,4R,5S,7aS)-5-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-4-(4-fluorophenyl)-1,3,3a,4,5,6,7,7a-octahydroisoindol-2-yl]cyclopent-2-en-1-one DM5VH6U CA CAS 860642-69-9 DM5VH6U DE Prurigo nodularis; Psoriasis vulgaris DMZ61IA ID DMZ61IA DMZ61IA DN Setipiprant DMZ61IA HS Phase 3 DMZ61IA SN ACT-129968 DMZ61IA CP Actelion Pharmaceuticals DMZ61IA DT Small molecular drug DMZ61IA PC 49843471 DMZ61IA MW 402.4 DMZ61IA FM C24H19FN2O3 DMZ61IA IC InChI=1S/C24H19FN2O3/c25-16-8-9-21-19(12-16)20-13-26(11-10-22(20)27(21)14-23(28)29)24(30)18-7-3-5-15-4-1-2-6-17(15)18/h1-9,12H,10-11,13-14H2,(H,28,29) DMZ61IA CS C1CN(CC2=C1N(C3=C2C=C(C=C3)F)CC(=O)O)C(=O)C4=CC=CC5=CC=CC=C54 DMZ61IA IK IHAXLPDVOWLUOS-UHFFFAOYSA-N DMZ61IA IU 2-[8-fluoro-2-(naphthalene-1-carbonyl)-3,4-dihydro-1H-pyrido[4,3-b]indol-5-yl]acetic acid DMZ61IA CA CAS 866460-33-5 DMZ61IA DE Asthma DM1NQDW ID DM1NQDW DM1NQDW DN SGI110 DM1NQDW HS Phase 3 DM1NQDW CP Astex Pharmaceuticals DM1NQDW PC 137295284 DM1NQDW MW 581.4 DM1NQDW FM C18H25N9NaO10P DM1NQDW IC InChI=1S/C18H24N9O10P.Na.H/c19-16-22-6-27(18(31)25-16)12-2-8(9(3-28)35-12)37-38(32,33)34-4-10-7(29)1-11(36-10)26-5-21-13-14(26)23-17(20)24-15(13)30;;/h5-12,28-29H,1-4H2,(H,32,33)(H2,19,25,31)(H3,20,23,24,30);;/q;+1;-1/t7?,8-,9+,10+,11?,12+;;/m0../s1 DM1NQDW CS [H-].C1[C@@H]([C@H](O[C@H]1N2C=NC(=NC2=O)N)CO)OP(=O)(O)OC[C@@H]3C(CC(O3)N4C=NC5=C4N=C(NC5=O)N)O.[Na+] DM1NQDW IK AYXRQJHOBFJIHP-ZWBDGAAVSA-N DM1NQDW IU sodium;[(2R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methyl [(2R,3S,5R)-5-(4-amino-2-oxo-1,3,5-triazin-1-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate;hydride DM1NQDW DE Acute myeloid leukaemia DM4N1SP ID DM4N1SP DM4N1SP DN Shigamabs DM4N1SP HS Phase 3 DM4N1SP SN C-Stx1; C-Stx2; Ca-Stx1; Ca-Stx2; Anti-Shiga toxin monoclonal antibodies, Thallion; Anti-Shiga toxin monoclonals, Sunol;Monoclonal antibodies (HUS), Sunol; Monoclonal antibodies (HUS), Thallion DM4N1SP CP Bellus Health DM4N1SP DT Monoclonal antibody DM4N1SP DE Haemolytic uraemic syndrome; Bacterial infection DMEWRXA ID DMEWRXA DMEWRXA DN SHP647 DMEWRXA HS Phase 3 DMEWRXA CP inhibitor, Lexington, MA DMEWRXA DE Crohn disease; Ulcerative colitis DMMIWCE ID DMMIWCE DMMIWCE DN Sifuvirtide DMMIWCE HS Phase 3 DMMIWCE SN FS-0101; HIV fusion inhibitor (oral), FusoGen; HIV gp41 protein inhibitor (oral), FusoGen; Sifuvirtide (oral, HIV); Sifuvirtide (oral, HIV), FusoGen DMMIWCE CP FusoGen Pharmaceuticals Inc DMMIWCE PC 49769437 DMMIWCE MW 4686 DMMIWCE FM C201H307N59O71 DMMIWCE IC InChI=1S/C201H307N59O71/c1-15-93(10)156(257-177(311)124(54-67-151(285)286)235-162(296)109(31-22-70-219-197(209)210)226-168(302)119(49-62-146(275)276)237-184(318)133(81-101-87-225-108-30-21-19-28-105(101)108)254-195(329)160(97(14)264)259-178(312)125(55-68-152(287)288)239-183(317)132(244-161(295)106(202)88-261)80-100-86-224-107-29-20-18-27-104(100)107)191(325)242-123(53-66-150(283)284)173(307)249-135(83-144(208)272)186(320)247-131(79-99-38-42-103(266)43-39-99)189(323)260-159(96(13)263)194(328)241-112(34-25-73-222-200(215)216)163(297)232-117(47-60-142(206)270)176(310)258-158(95(12)17-3)193(327)253-130(78-98-36-40-102(265)41-37-98)182(316)229-113(35-26-74-223-201(217)218)175(309)256-157(94(11)16-2)192(326)252-129(77-92(8)9)179(313)236-121(51-64-148(279)280)171(305)234-122(52-65-149(281)282)174(308)255-138(89-262)190(324)240-115(45-58-140(204)268)167(301)233-118(48-61-145(273)274)170(304)230-114(44-57-139(203)267)166(300)231-116(46-59-141(205)269)172(306)251-136(84-154(291)292)187(321)228-111(33-24-72-221-199(213)214)164(298)248-134(82-143(207)271)185(319)238-120(50-63-147(277)278)169(303)227-110(32-23-71-220-198(211)212)165(299)250-137(85-155(293)294)188(322)246-128(76-91(6)7)181(315)245-127(75-90(4)5)180(314)243-126(196(330)331)56-69-153(289)290/h18-21,27-30,36-43,86-87,90-97,106,109-138,156-160,224-225,261-266H,15-17,22-26,31-35,44-85,88-89,202H2,1-14H3,(H2,203,267)(H2,204,268)(H2,205,269)(H2,206,270)(H2,207,271)(H2,208,272)(H,226,302)(H,227,303)(H,228,321)(H,229,316)(H,230,304)(H,231,300)(H,232,297)(H,233,301)(H,234,305)(H,235,296)(H,236,313)(H,237,318)(H,238,319)(H,239,317)(H,240,324)(H,241,328)(H,242,325)(H,243,314)(H,244,295)(H,245,315)(H,246,322)(H,247,320)(H,248,298)(H,249,307)(H,250,299)(H,251,306)(H,252,326)(H,253,327)(H,254,329)(H,255,308)(H,256,309)(H,257,311)(H,258,310)(H,259,312)(H,260,323)(H,273,274)(H,275,276)(H,277,278)(H,279,280)(H,281,282)(H,283,284)(H,285,286)(H,287,288)(H,289,290)(H,291,292)(H,293,294)(H,330,331)(H4,209,210,219)(H4,211,212,220)(H4,213,214,221)(H4,215,216,222)(H4,217,218,223)/t93-,94-,95-,96+,97+,106-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,127-,128-,129-,130-,131-,132-,133-,134-,135-,136-,137-,138-,156-,157-,158-,159-,160-/m0/s1 DMMIWCE CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC5=CNC6=CC=CC=C65)NC(=O)[C@H](CO)N DMMIWCE IK WIOOVJJJJQAZGJ-ISHQQBGZSA-N DMMIWCE IU (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-hydroxypropanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-4-carboxybutanoyl]amino]-3-methylpentanoyl]amino]-4-carboxybutanoyl]amino]-4-oxobutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxybutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylpentanoyl]amino]-4-methylpentanoyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-carboxypropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-4-oxobutanoyl]amino]-4-carboxybutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-carboxypropanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]pentanedioic acid DMMIWCE DE Human immunodeficiency virus infection DM4YDAJ ID DM4YDAJ DM4YDAJ DN Sildenafil DM4YDAJ HS Phase 3 DM4YDAJ SN sildenafil; 139755-83-2; VIAGRA; Sildenafil [INN:BAN]; UK-92480; UNII-3M7OB98Y7H; UK-92,480-10; C22H30N6O4S; HSDB 7305; CHEMBL192; UK 92480-10; CHEBI:9139; 3M7OB98Y7H; BNRNXUUZRGQAQC-UHFFFAOYSA-N; Sildenafil DM4YDAJ TC Antiviral Agents DM4YDAJ DT Small molecular drug DM4YDAJ PC 135398744 DM4YDAJ MW 474.6 DM4YDAJ FM C22H30N6O4S DM4YDAJ IC InChI=1S/C22H30N6O4S/c1-5-7-17-19-20(27(4)25-17)22(29)24-21(23-19)16-14-15(8-9-18(16)32-6-2)33(30,31)28-12-10-26(3)11-13-28/h8-9,14H,5-7,10-13H2,1-4H3,(H,23,24,29) DM4YDAJ CS CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C DM4YDAJ IK BNRNXUUZRGQAQC-UHFFFAOYSA-N DM4YDAJ IU 5-[2-ethoxy-5-(4-methylpiperazin-1-yl)sulfonylphenyl]-1-methyl-3-propyl-6H-pyrazolo[4,3-d]pyrimidin-7-one DM4YDAJ CA CAS 139755-83-2 DM4YDAJ CB CHEBI:9139 DM4YDAJ DE Coronavirus Disease 2019 (COVID-19) DMVO7UW ID DMVO7UW DMVO7UW DN Siltuximab DMVO7UW HS Phase 3 DMVO7UW SN Sylvant (TN); Siltuximab (USAN/INN); D09669; 541502-14-1 DMVO7UW TC Antiviral Agents DMVO7UW DT Monoclonal antibody DMVO7UW DE Coronavirus Disease 2019 (COVID-19) DM18QHT ID DM18QHT DM18QHT DN Simvastatin acid DM18QHT HS Phase 3 DM18QHT SN Simvastatin acid; Tenivastatin; UNII-9L6M5TH46B; DIMETHYL-COMPACTIN; 9L6M5TH46B; (3R,5R)-7-[(1S,2S,6R,8S,8aR)-8-(2,2-dimethylbutanoyloxy)-2,6-dimethyl-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid; Tenivastatin [INN]; (3R,5R)-7-{(1S,2S,6R,8S,8aR)-8-[(2,2-dimethylbutanoyl)oxy]-2,6-dimethyl-1,2,6,7,8,8a-hexahydronaphthalen-1-yl}-3,5-dihydroxyheptanoic acid DM18QHT PC 64718 DM18QHT MW 436.6 DM18QHT FM C25H40O6 DM18QHT IC InChI=1S/C25H40O6/c1-6-25(4,5)24(30)31-21-12-15(2)11-17-8-7-16(3)20(23(17)21)10-9-18(26)13-19(27)14-22(28)29/h7-8,11,15-16,18-21,23,26-27H,6,9-10,12-14H2,1-5H3,(H,28,29)/t15-,16-,18+,19+,20-,21-,23-/m0/s1 DM18QHT CS CCC(C)(C)C(=O)OC1CC(C=C2C1C(C(C=C2)C)CCC(CC(CC(=O)O)O)O)C DM18QHT IK XWLXKKNPFMNSFA-HGQWONQESA-N DM18QHT IU (3R,5R)-7-[(1S,2S,6R,8S,8aR)-8-(2,2-dimethylbutanoyloxy)-2,6-dimethyl-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid DM18QHT CA CAS 121009-77-6 DM18QHT DE Chronic obstructive pulmonary disease DMK8AQP ID DMK8AQP DMK8AQP DN Sirukumab DMK8AQP HS Phase 3 DMK8AQP CP GlaxoSmithKline DMK8AQP DT Monoclonal antibody DMK8AQP DE Rheumatoid arthritis; Cutaneous lupus erythematosus; Giant cell arteritis; Major depressive disorder DM6BZCV ID DM6BZCV DM6BZCV DN Sivelestat DM6BZCV HS Phase 3 DM6BZCV SN 127373-66-4; UNII-DWI62G0P59; 2-[[2-[[4-(2,2-dimethylpropanoyloxy)phenyl]sulfonylamino]benzoyl]amino]acetic acid; Elastase Inhibitor IV; C20H22N2O7S; N-(2-(4-(2,2-Dimethylpropionyloxy)phenylsulfonylamino)benzoyl)aminoacetic acid; Sivelestat (ONO-5046); LY544349; CHEMBL76688; LY 544349; DWI62G0P59; Glycine, N-(2-(((4-(2,2-dimethyl-1-oxopropoxy)phenyl)sulfonyl)amino)benzoyl)-; N-(o-(p-Pivaloyloxybenzene)sulfonylaminobenzoyl)glycine DM6BZCV DT Small molecular drug DM6BZCV PC 107706 DM6BZCV MW 434.5 DM6BZCV FM C20H22N2O7S DM6BZCV IC InChI=1S/C20H22N2O7S/c1-20(2,3)19(26)29-13-8-10-14(11-9-13)30(27,28)22-16-7-5-4-6-15(16)18(25)21-12-17(23)24/h4-11,22H,12H2,1-3H3,(H,21,25)(H,23,24) DM6BZCV CS CC(C)(C)C(=O)OC1=CC=C(C=C1)S(=O)(=O)NC2=CC=CC=C2C(=O)NCC(=O)O DM6BZCV IK BTGNGJJLZOIYID-UHFFFAOYSA-N DM6BZCV IU 2-[[2-[[4-(2,2-dimethylpropanoyloxy)phenyl]sulfonylamino]benzoyl]amino]acetic acid DM6BZCV CA CAS 127373-66-4 DM6BZCV CB CHEBI:135704 DM6BZCV DE Anterior uveitis; Pyoderma gangrenosum; Axial spondyloarthritis; Crohn disease; Multiple sclerosis; Psoriatic arthritis; Rheumatoid arthritis; Ulcerative colitis DMWOF1E ID DMWOF1E DMWOF1E DN SKY59 DMWOF1E HS Phase 3 DMWOF1E SN Crovalimab; RO7112689 DMWOF1E CP Roche DMWOF1E DT Antibody DMWOF1E DE Haemolytic uraemic syndrome DMH7W9X ID DMH7W9X DMH7W9X DN SNDX-275 DMH7W9X HS Phase 3 DMH7W9X SN Entinostat; Histone Deacetylase Inhibitor I; IN1470; MS 275; SNDX 275; MS 27-275; Ms-275; Entinostat (USAN/INN); MS-27-275; Pyridin-3-ylmethyl 4-(2-aminophenylcarbamoyl)benzylcarbamate; Pyridin-3-ylmethyl N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate; Pyridin-3-ylmethyl {4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Pyridin-3-ylmethyl{4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Carbamic acid, [[4-[[(2-aminophenyl)amino]carbonyl]phenyl] methyl]-, 3-pyridinylmethyl ester; Carbamic acid, [[4-[[(2-aminophenyl)carbaonyl]phenyl]methyl]-, 3-pyridinylmethyl ester; Entinostat, SNDX-275, MS-27-275, MS-275; N-(2-Aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)aminomethyl]benzamide; N-(2-aminophenyl)-4-(N-(pyridin-3-ylmethoxycarbonyl)aminomethyl)benzamide; Carbamic acid, ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)-, 3-pyridinylmethyl ester; 3-Pyridinylmethyl ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)carbamate DMH7W9X CP Bayer Schering DMH7W9X DT Small molecular drug DMH7W9X PC 4261 DMH7W9X MW 376.4 DMH7W9X FM C21H20N4O3 DMH7W9X IC InChI=1S/C21H20N4O3/c22-18-5-1-2-6-19(18)25-20(26)17-9-7-15(8-10-17)13-24-21(27)28-14-16-4-3-11-23-12-16/h1-12H,13-14,22H2,(H,24,27)(H,25,26) DMH7W9X CS C1=CC=C(C(=C1)N)NC(=O)C2=CC=C(C=C2)CNC(=O)OCC3=CN=CC=C3 DMH7W9X IK INVTYAOGFAGBOE-UHFFFAOYSA-N DMH7W9X IU pyridin-3-ylmethyl N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate DMH7W9X CA CAS 209783-80-2 DMH7W9X CB CHEBI:132082 DMH7W9X DE Colorectal cancer; Melanoma; Ovarian cancer; Non-small-cell lung cancer; Breast cancer DMOQKAD ID DMOQKAD DMOQKAD DN SNF472 DMOQKAD HS Phase 3 DMOQKAD SN Hexasodium phytate; UNII-ZBX50UG81V; 34367-89-0(Hexasodium phytate); ZBX50UG81V; 34367-89-0; sodium cyclohexane-1,2,3,4,5,6-hexayl hexakis(hydrogen phosphate); Inositol, hexakis(dihydrogen phosphate) hexasodium salt, myo-; Myo-inositol, hexakis(dihydrogen phosphate), hexasodium salt; Q27295268; scyllo-inositol,1,2,3,4,5,6-hexakis(dihydrogenphosphate),hexasodiumsalt; (1R,2R,3S,4S,5S,6S)-cyclohexane-(1,2,3,4,5,6)-hexaylhexakis(hydrogenphosphate),hexasodiumsalt DMOQKAD CP Sanifit DMOQKAD DT Small molecular drug DMOQKAD PC 91667962 DMOQKAD MW 791.93 DMOQKAD FM C6H12Na6O24P6 DMOQKAD IC InChI=1S/C6H18O24P6.6Na/c7-31(8,9)25-1-2(26-32(10,11)12)4(28-34(16,17)18)6(30-36(22,23)24)5(29-35(19,20)21)3(1)27-33(13,14)15;;;;;;/h1-6H,(H2,7,8,9)(H2,10,11,12)(H2,13,14,15)(H2,16,17,18)(H2,19,20,21)(H2,22,23,24);;;;;;/q;6*+1/p-6 DMOQKAD CS C1(C(C(C(C(C1OP(=O)(O)[O-])OP(=O)(O)[O-])OP(=O)(O)[O-])OP(=O)(O)[O-])OP(=O)(O)[O-])OP(=O)(O)[O-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+] DMOQKAD IK DHZIAGCFFSRULK-UHFFFAOYSA-H DMOQKAD IU hexasodium;[2,3,4,5,6-pentakis[[hydroxy(oxido)phosphoryl]oxy]cyclohexyl] hydrogen phosphate DMOQKAD CA CAS 34367-89-0 DMOQKAD DE Calciphylaxis; Calcific uremic arteriolopathy DMZE2JO ID DMZE2JO DMZE2JO DN SNS-595 DMZE2JO HS Phase 3 DMZE2JO SN Voreloxin; Vosaroxin; AG 7352; SNS 595; SPC 595; AG 7352 (TN); AG-7352; SNS 595 (TN); SPC 595 (TN); SPC-595; Voreloxin (TN); Voreloxin (USAN); SNS-595 (TN); 1,4-Dihydro-7-(3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid DMZE2JO CP Sunesis Pharmaceuticals Inc DMZE2JO DT Small molecular drug DMZE2JO PC 9952884 DMZE2JO MW 401.4 DMZE2JO FM C18H19N5O4S DMZE2JO IC InChI=1S/C18H19N5O4S/c1-19-12-8-22(9-13(12)27-2)14-4-3-10-15(24)11(17(25)26)7-23(16(10)21-14)18-20-5-6-28-18/h3-7,12-13,19H,8-9H2,1-2H3,(H,25,26)/t12-,13-/m0/s1 DMZE2JO CS CN[C@H]1CN(C[C@@H]1OC)C2=NC3=C(C=C2)C(=O)C(=CN3C4=NC=CS4)C(=O)O DMZE2JO IK XZAFZXJXZHRNAQ-STQMWFEESA-N DMZE2JO IU 7-[(3S,4S)-3-methoxy-4-(methylamino)pyrrolidin-1-yl]-4-oxo-1-(1,3-thiazol-2-yl)-1,8-naphthyridine-3-carboxylic acid DMZE2JO CA CAS 175414-77-4 DMZE2JO DE Ovarian cancer; Acute myeloid leukaemia DMPBA0D ID DMPBA0D DMPBA0D DN Sofpironium bromide DMPBA0D HS Phase 3 DMPBA0D SN BBI-4000; 1628106-94-4; Sofpironium bromide [USAN]; CHEMBL3707223; Sofpironium bromide (JAN/USAN/INN); D10989; Pyrrolidinium, 3-(((2R)-2-cyclopentyl-2-hydroxy-2-phenylacetyl)oxy)-1-(2-ethoxy-2-oxoethyl)-1-methyl-, bromide (1:1), (3R)- DMPBA0D CP Brickell Biotech Boulder, CO DMPBA0D PC 86301316 DMPBA0D MW 470.4 DMPBA0D FM C22H32BrNO5 DMPBA0D IC InChI=1S/C22H32NO5.BrH/c1-3-27-20(24)16-23(2)14-13-19(15-23)28-21(25)22(26,18-11-7-8-12-18)17-9-5-4-6-10-17;/h4-6,9-10,18-19,26H,3,7-8,11-16H2,1-2H3;1H/q+1;/p-1/t19-,22+,23?;/m1./s1 DMPBA0D CS CCOC(=O)C[N+]1(CC[C@H](C1)OC(=O)[C@@](C2CCCC2)(C3=CC=CC=C3)O)C.[Br-] DMPBA0D IK FIAFMTCUJCWADZ-JOFREBOKSA-M DMPBA0D IU [(3R)-1-(2-ethoxy-2-oxoethyl)-1-methylpyrrolidin-1-ium-3-yl] (2R)-2-cyclopentyl-2-hydroxy-2-phenylacetate;bromide DMPBA0D CA CAS 1628106-94-4 DMPBA0D DE Primary axillary hyperhidrosis DM0HIU5 ID DM0HIU5 DM0HIU5 DN Solanezumab DM0HIU5 HS Phase 3 DM0HIU5 CP Eli Lilly DM0HIU5 DT Monoclonal antibody DM0HIU5 DE Alzheimer disease DM6QZIA ID DM6QZIA DM6QZIA DN Solithromycin DM6QZIA HS Phase 3 DM6QZIA SN Solithromycin; CEM-101; OP-1068; OPT-1068; Solithromycin (iv, bacterial pneumonia), Cempra; Solithromycin (malaria), Cempra/Medicines for Malaria Venture; Solithromycin (oral, bacterial pneumonia), Cempra; CEM-101 (iv, bacterial pneumonia), Cempra; CEM-101 (malaria), Cempra/Medicines for Malaria Venture; CEM-101 (oral, bacterial pneumonia), Cempra DM6QZIA CP Cempra pharmaceuticals DM6QZIA DT Small molecular drug DM6QZIA PC 25242512 DM6QZIA MW 845 DM6QZIA FM C43H65FN6O10 DM6QZIA IC InChI=1S/C43H65FN6O10/c1-12-32-43(8)35(50(40(55)60-43)19-14-13-18-49-23-30(46-47-49)28-16-15-17-29(45)21-28)26(4)33(51)24(2)22-41(6,56-11)37(27(5)36(53)42(7,44)39(54)58-32)59-38-34(52)31(48(9)10)20-25(3)57-38/h15-17,21,23-27,31-32,34-35,37-38,52H,12-14,18-20,22,45H2,1-11H3/t24-,25-,26+,27+,31+,32-,34-,35-,37-,38+,41-,42+,43-/m1/s1 DM6QZIA CS CC[C@@H]1[C@@]2([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H](C(=O)[C@](C(=O)O1)(C)F)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)N(C(=O)O2)CCCCN4C=C(N=N4)C5=CC(=CC=C5)N)C DM6QZIA IK IXXFZUPTQVDPPK-ZAWHAJPISA-N DM6QZIA IU (1S,2R,5S,7R,8R,9R,11R,13R,14R)-15-[4-[4-(3-aminophenyl)triazol-1-yl]butyl]-8-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-2-ethyl-5-fluoro-9-methoxy-1,5,7,9,11,13-hexamethyl-3,17-dioxa-15-azabicyclo[12.3.0]heptadecane-4,6,12,16-tetrone DM6QZIA CA 760981-83-7 DM6QZIA DE Bacillus anthracis infection DMLAYTP ID DMLAYTP DMLAYTP DN Soluble ferric pyrophosphate DMLAYTP HS Phase 3 DMLAYTP SN Ferric pyrophosphate; Soluble ferric pyrophosphate (anemia) DMLAYTP CP Rockwell Medical Inc DMLAYTP DT Small molecular drug DMLAYTP PC 24877 DMLAYTP MW 745.21 DMLAYTP FM Fe4O21P6 DMLAYTP IC InChI=1S/4Fe.3H4O7P2/c;;;;3*1-8(2,3)7-9(4,5)6/h;;;;3*(H2,1,2,3)(H2,4,5,6)/q4*+3;;;/p-12 DMLAYTP CS [O-]P(=O)([O-])OP(=O)([O-])[O-].[O-]P(=O)([O-])OP(=O)([O-])[O-].[O-]P(=O)([O-])OP(=O)([O-])[O-].[Fe+3].[Fe+3].[Fe+3].[Fe+3] DMLAYTP IK CADNYOZXMIKYPR-UHFFFAOYSA-B DMLAYTP IU iron(3+);phosphonato phosphate DMLAYTP CA CAS 10058-44-3 DMLAYTP CB CHEBI:132767 DMLAYTP DE Iron-deficiency anemia DMIG4OX ID DMIG4OX DMIG4OX DN SOTB07 DMIG4OX HS Phase 3 DMIG4OX DE Asthma DMLSV74 ID DMLSV74 DMLSV74 DN Sotorasib DMLSV74 HS Phase 3 DMLSV74 SN AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; AMG510 ; AMG 510; AMG-510; AMG510; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)- DMLSV74 CP Amgen DMLSV74 DT Small molecular drug DMLSV74 PC 137278711 DMLSV74 MW 560.6 DMLSV74 FM C30H30F2N6O3 DMLSV74 IC InChI=1S/C30H30F2N6O3/c1-6-23(40)36-12-13-37(18(5)15-36)28-19-14-21(32)26(24-20(31)8-7-9-22(24)39)34-29(19)38(30(41)35-28)27-17(4)10-11-33-25(27)16(2)3/h6-11,14,16,18,39H,1,12-13,15H2,2-5H3/t18-/m0/s1 DMLSV74 CS C[C@H]1CN(CCN1C2=NC(=O)N(C3=NC(=C(C=C32)F)C4=C(C=CC=C4F)O)C5=C(C=CN=C5C(C)C)C)C(=O)C=C DMLSV74 IK NXQKSXLFSAEQCZ-SFHVURJKSA-N DMLSV74 IU 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one DMLSV74 CA CAS 2252403-56-6 DMLSV74 DE Non-small-cell lung cancer DMMP51W ID DMMP51W DMMP51W DN sparsentan DMMP51W HS Phase 3 DMMP51W SN Sparsentan; RE-021; 254740-64-2; UNII-9242RO5URM; PS433540; PS-433540; CHEMBL539423; 9242RO5URM; BMS-346567; retrophin; Sparsentan [USAN]; compound 7 [PMID 15634011]; PS 33540; Sparsentan (RE-021); Sparsentan(PS433540); SCHEMBL535109; GTPL8448; BCP23969; BDBM50175523; SB16876; DB12548; CS-7947; DARA-a (Dual Acting Receptor Antagonist of angiotension and endothelin receptors); HY-17621; L023324; 4'-((2-butyl-4-oxo-1,3-diazaspiro[44]non-1-en-3-yl)methyl)-N-(4,5-dimethylisoxazol-3-yl)-2'-(ethoxymethyl)-[1,1'-biphenyl]-2-sulfonamide; RE-021 DMMP51W DT Small molecular drug DMMP51W PC 10257882 DMMP51W MW 592.8 DMMP51W FM C32H40N4O5S DMMP51W IC InChI=1S/C32H40N4O5S/c1-5-7-14-29-33-32(17-10-11-18-32)31(37)36(29)20-24-15-16-26(25(19-24)21-40-6-2)27-12-8-9-13-28(27)42(38,39)35-30-22(3)23(4)41-34-30/h8-9,12-13,15-16,19H,5-7,10-11,14,17-18,20-21H2,1-4H3,(H,34,35) DMMP51W CS CCCCC1=NC2(CCCC2)C(=O)N1CC3=CC(=C(C=C3)C4=CC=CC=C4S(=O)(=O)NC5=NOC(=C5C)C)COCC DMMP51W IK WRFHGDPIDHPWIQ-UHFFFAOYSA-N DMMP51W IU 2-[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2-(ethoxymethyl)phenyl]-N-(4,5-dimethyl-1,2-oxazol-3-yl)benzenesulfonamide DMMP51W CA CAS 254740-64-2 DMMP51W DE Myocardial infarction; Hypertension; Focal segmental glomerulosclerosis DM4TOEQ ID DM4TOEQ DM4TOEQ DN Spartalizumab DM4TOEQ HS Phase 3 DM4TOEQ CP Novartis DM4TOEQ DT Monoclonal antibody DM4TOEQ DE Melanoma DM7NV1I ID DM7NV1I DM7NV1I DN SPD-465 DM7NV1I HS Phase 3 DM7NV1I SN Triple-bead MAS, Shire; Triple-bead mixed amphetamine salts (oral, attention deficit hyperactivity disorder ADHD), Shire DM7NV1I CP Shire plc DM7NV1I DE Attention deficit hyperactivity disorder DMVJNFI ID DMVJNFI DMVJNFI DN Spermidine DMVJNFI HS Phase 3 DMVJNFI SN Spermidin; UNII-U87FK77H25; BRN 1698591; AI3-26636; EINECS 204-689-0; CHEMBL19612; CHEBI:16610; ATHGHQPFGPMSJY-UHFFFAOYSA-N; U87FK77H25; MFCD00008229; Spermidine hydrochloride; NSC528399; 1pot; Aminopropylbutandiamine; N-(4-Aminobutyl)-1,3-diaminopropane; Spectrum_000005; Tocris-0959; ACMC-20ajn3; AC1L1AQB; Spectrum2_000874; Spectrum3_000977; Spectrum4_001101; Spectrum5_001561; Lopac-S-2501; Biomol-NT_000212; bmse000116; bmse000951; bmse000955; Spermidine 0.1 M solution; Lopac0_001047; SCHEMBL15618; BSPBio_002613; KBioGR_001542; KBioSS_000345; 4-04-00-01300 (Beilstein Handbook Reference); DivK1c_001007; SPBio_000947; Spermidine, > =99% (GC); Spermidine, analytical standard; BPBio1_001276; GTPL2390; DTXSID4036645; CTK3J1693; KBio1_001007; KBio2_000345; KBio2_002913; KBio2_005481; KBio3_001833; MolPort-001-761-230; NINDS_001007; HY-B1776; ZINC1532612; BDBM50009353; PA(34); N-(3-Aminopropyl)-4-aminobutylamine; AKOS006222987; CCG-205124; DB03566; MCULE-8096530192; RTR-003757; SDCCGMLS-0066822.P001; IDI1_001007; NCGC00015937-01; NCGC00015937-02; NCGC00015937-03; NCGC00015937-04; NCGC00015937-05; NCGC00024903-01; NCGC00024903-02; NCGC00024903-03; AJ-26792; AN-22947; LS-45643; M923; NCI60_004294; SC-69371; DB-026892; TR-003757; CS-0013804; FT-0629162; ST24048721; ST45025991; C00315; 124S209; SR0 DMVJNFI DT Small molecular drug DMVJNFI PC 1102 DMVJNFI MW 145.25 DMVJNFI FM C7H19N3 DMVJNFI IC InChI=1S/C7H19N3/c8-4-1-2-6-10-7-3-5-9/h10H,1-9H2 DMVJNFI CS C(CCNCCCN)CN DMVJNFI IK ATHGHQPFGPMSJY-UHFFFAOYSA-N DMVJNFI IU N'-(3-aminopropyl)butane-1,4-diamine DMVJNFI CA CAS 124-20-9 DMVJNFI CB CHEBI:16610 DMVJNFI DE Plaque psoriasis; Rheumatoid arthritis DMACVEI ID DMACVEI DMACVEI DN SPI-2012 DMACVEI HS Phase 3 DMACVEI CP SPECTRUM pharmaceuticals DMACVEI DE Breast cancer DM3PS2E ID DM3PS2E DM3PS2E DN Squalamine DM3PS2E HS Phase 3 DM3PS2E SN Squalamine; 148717-90-2; Squalamine [INN]; UNII-F8PO54Z4V7; F8PO54Z4V7; CHEBI:80765; 3beta-N-1-(N-(3-(4-Aminobutyl))-1,3-diaminopropane)-7alpha,24-dihydroxy-5alpha-cholestane 24-sulfate; (3beta,5alpha,7alpha,24R)-3-((3-(4-(Aminobutyl)amino)propyl)amio)cholestane-7,24-diol 24-(hydrogen sulfate); 3-((3-(4-(Aminobutyl)amino)propyl)amio)cholestane-7,24-diol 24-(hydrogen sulfate), (3beta,5alpha,7alpha,24R)-; Cholestane-7,24-diol, 3-((3-(4-(aminobutyl)amino)propyl)amio)-, 24-(hydrogen sulfate), (3beta,5alpha,7alpha,24R)- DM3PS2E CP OHR Pharmaceutical DM3PS2E DT Small molecular drug DM3PS2E PC 72495 DM3PS2E MW 628 DM3PS2E FM C34H65N3O5S DM3PS2E IC InChI=1S/C34H65N3O5S/c1-23(2)31(42-43(39,40)41)12-9-24(3)27-10-11-28-32-29(14-16-34(27,28)5)33(4)15-13-26(21-25(33)22-30(32)38)37-20-8-19-36-18-7-6-17-35/h23-32,36-38H,6-22,35H2,1-5H3,(H,39,40,41)/t24-,25-,26+,27-,28+,29+,30-,31-,32+,33+,34-/m1/s1 DM3PS2E CS C[C@H](CC[C@H](C(C)C)OS(=O)(=O)O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2[C@@H](C[C@@H]4[C@@]3(CC[C@@H](C4)NCCCNCCCCN)C)O)C DM3PS2E IK UIRKNQLZZXALBI-MSVGPLKSSA-N DM3PS2E IU [(3R,6R)-6-[(3S,5R,7R,8R,9S,10S,13R,14S,17R)-3-[3-(4-aminobutylamino)propylamino]-7-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-methylheptan-3-yl] hydrogen sulfate DM3PS2E CA CAS 148717-90-2 DM3PS2E CB CHEBI:80765 DM3PS2E DE Solid tumour/cancer; Diabetic macular edema DM1ODMR ID DM1ODMR DM1ODMR DN SR46349B DM1ODMR HS Phase 3 DM1ODMR SN Eplivanserin fumarate; SR 46349; SR 46349B; SR-46349B; 2-Propen-1-one, 1-(2-fluorophenyl)-3-(4-hydroxyphenyl)-, O-(2-(dimethylamino)ethyl)oxime, (Z,E)-, (E)-2-butenedioate (2:1) (salt); 4-((3Z)-3-(2-Dimethylaminoethyl)oxyimino-3-(2-fluorophenyl)propen-1-yl)phenol hemifumarate; 4-[(E)-3-(2-dimethylaminoethyloxyamino)-3-(2-fluorophenyl)prop-2-enylidene]cyclohexa-2,5-dien-1-one DM1ODMR CP Sanofi-Aventis DM1ODMR DT Small molecular drug DM1ODMR PC 135456189 DM1ODMR MW 772.8 DM1ODMR FM C42H46F2N4O8 DM1ODMR IC InChI=1S/2C19H21FN2O2.C4H4O4/c2*1-22(2)13-14-24-21-19(17-5-3-4-6-18(17)20)12-9-15-7-10-16(23)11-8-15;5-3(6)1-2-4(7)8/h2*3-12,23H,13-14H2,1-2H3;1-2H,(H,5,6)(H,7,8)/b2*12-9+,21-19-;2-1+ DM1ODMR CS CN(CCO/N=C(\\C1=CC=CC=C1F)/C=C/C2=CC=C(C=C2)O)C.CN(CCO/N=C(\\C1=CC=CC=C1F)/C=C/C2=CC=C(C=C2)O)C.C(=C/C(=O)O)\\C(=O)O DM1ODMR IK RNLKLYQQDLHHBH-ABDBJYMXSA-N DM1ODMR IU (E)-but-2-enedioic acid;4-[(E,3Z)-3-[2-(dimethylamino)ethoxyimino]-3-(2-fluorophenyl)prop-1-enyl]phenol DM1ODMR CA CAS 130580-02-8 DM1ODMR DE Schizophrenia; Primary insomnia; Sleep-wake disorder DMT71EX ID DMT71EX DMT71EX DN SSR-126517E DMT71EX HS Phase 3 DMT71EX CP Sanofi-aventis DMT71EX DE Thrombosis DMVLKDX ID DMVLKDX DMVLKDX DN Streptokinase rectal suppository DMVLKDX HS Phase 3 DMVLKDX SN Proctokinase; Streptokinase rectal suppository (hemorrhoids); Streptokinase rectal suppository (hemorrhoids), CIGB DMVLKDX CP Center for Genetic Engineering and Biotechnology DMVLKDX DE Hemorrhoids DMPOTM4 ID DMPOTM4 DMPOTM4 DN Sulfatinib DMPOTM4 HS Phase 3 DMPOTM4 SN Anticancer agents, Hutchison; HMPL-012; Kinase inhibitors (cancer), Hutchison; VEGFR-1, 2, 3 and FGFR 1 inhibitor (oral, cancer), Hutchison DMPOTM4 CP Hutchison Medipharma Enterprises Ltd DMPOTM4 PC 52920501 DMPOTM4 MW 480.6 DMPOTM4 FM C24H28N6O3S DMPOTM4 IC InChI=1S/C24H28N6O3S/c1-17-13-19-15-21(7-8-22(19)27-17)33-23-9-10-25-24(29-23)28-20-6-4-5-18(14-20)16-34(31,32)26-11-12-30(2)3/h4-10,13-15,26-27H,11-12,16H2,1-3H3,(H,25,28,29) DMPOTM4 CS CC1=CC2=C(N1)C=CC(=C2)OC3=NC(=NC=C3)NC4=CC=CC(=C4)CS(=O)(=O)NCCN(C)C DMPOTM4 IK TTZSNFLLYPYKIL-UHFFFAOYSA-N DMPOTM4 IU N-[2-(dimethylamino)ethyl]-1-[3-[[4-[(2-methyl-1H-indol-5-yl)oxy]pyrimidin-2-yl]amino]phenyl]methanesulfonamide DMPOTM4 CA CAS 1308672-74-3 DMPOTM4 DE Solid tumour/cancer; Neuroendocrine cancer DMMD856 ID DMMD856 DMMD856 DN Sulopenem DMMD856 HS Phase 3 DMMD856 SN CP-70,429; PF-03709270; PF-3,709,270 DMMD856 TC Antiinfective Agents DMMD856 DT Small molecular drug DMMD856 PC 9950244 DMMD856 MW 349.5 DMMD856 FM C12H15NO5S3 DMMD856 IC InChI=1S/C12H15NO5S3/c1-5(14)7-9(15)13-8(11(16)17)12(20-10(7)13)19-6-2-3-21(18)4-6/h5-7,10,14H,2-4H2,1H3,(H,16,17)/t5-,6+,7+,10-,21-/m1/s1 DMMD856 CS C[C@H]([C@@H]1[C@@H]2N(C1=O)C(=C(S2)S[C@H]3CC[S@@](=O)C3)C(=O)O)O DMMD856 IK FLSUCZWOEMTFAQ-PRBGKLEPSA-N DMMD856 IU (5R,6S)-6-[(1R)-1-hydroxyethyl]-7-oxo-3-[(1R,3S)-1-oxothiolan-3-yl]sulfanyl-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid DMMD856 CA CAS 120788-07-0 DMMD856 DE Urinary tract infection DM07653 ID DM07653 DM07653 DN SULTHIAME DM07653 HS Phase 3 DM07653 SN sultiame; SULTHIAME; Ospolot; sultiam; Sulphenyltame; Sulthiamine; Contravul; Trolone; 61-56-3; Sultiamum; Elisal; Conadil; Riker 594; Bayer A-168; Sultiamum [INN-Latin]; Sultiamo [INN-Spanish]; Sulthiame [USAN]; 4-(1,1-dioxothiazinan-2-yl)benzenesulfonamide; UNII-I00Q766CZ2; RP-10284; R-594; EINECS 200-511-0; p-(Tetrahydro-2H-1,2-thiazin-2-yl)benzenesulfonamide, S,S-dioxide; BRN 1222219; Benzenesulfonamide, 4-(tetrahydro-2H-1,2-thiazin-2-yl)-, S,S-dioxide; RP 10284; 4-(1,1-Dioxido-1,2-thiazinan-2-yl)benzenesulfonamide; CHEMBL328560 DM07653 DT Small molecular drug DM07653 PC 5356 DM07653 MW 290.4 DM07653 FM C10H14N2O4S2 DM07653 IC InChI=1S/C10H14N2O4S2/c11-18(15,16)10-5-3-9(4-6-10)12-7-1-2-8-17(12,13)14/h3-6H,1-2,7-8H2,(H2,11,15,16) DM07653 CS C1CCS(=O)(=O)N(C1)C2=CC=C(C=C2)S(=O)(=O)N DM07653 IK HMHVCUVYZFYAJI-UHFFFAOYSA-N DM07653 IU 4-(1,1-dioxothiazinan-2-yl)benzenesulfonamide DM07653 CA CAS 61-56-3 DM07653 CB CHEBI:32171 DMYHV17 ID DMYHV17 DMYHV17 DN Sumanirole DMYHV17 HS Phase 3 DMYHV17 SN PNU 95666; U 95666E; PNU-95666; [2-[(1R)-1-(methylamino)ethyl]phenyl]methanol; Benzenemethanol, alpha-((1R)-1-(methylamino)ethyl)-, (alphaS)-rel-, 2-naphthalenesulfonate (salt); 2-Naphthalenesulfonic acid, compd with (R*,S*)-alpha-(1-(methylamino)ethyl)benzenemethanol (1:1); 2-Naphthalenesulfonic acid, compd with rel-(alphaS)-alpha-((1R)-1-(methylamino)ethyl)benzenemethanol (1:1) DMYHV17 CP Pfizer DMYHV17 DT Small molecular drug DMYHV17 PC 9818479 DMYHV17 MW 203.24 DMYHV17 FM C11H13N3O DMYHV17 IC InChI=1S/C11H13N3O/c1-12-8-5-7-3-2-4-9-10(7)14(6-8)11(15)13-9/h2-4,8,12H,5-6H2,1H3,(H,13,15)/t8-/m1/s1 DMYHV17 CS CN[C@@H]1CC2=C3C(=CC=C2)NC(=O)N3C1 DMYHV17 IK RKZSNTNMEFVBDT-MRVPVSSYSA-N DMYHV17 IU (10R)-10-(methylamino)-1,3-diazatricyclo[6.3.1.04,12]dodeca-4,6,8(12)-trien-2-one DMYHV17 CA CAS 179386-43-7 DMYHV17 DE Parkinson disease DMXNZQK ID DMXNZQK DMXNZQK DN SUN-101 DMXNZQK HS Phase 3 DMXNZQK CP Sunovion DMXNZQK DE Chronic obstructive pulmonary disease DMH2FN1 ID DMH2FN1 DMH2FN1 DN Suronacrine maleate DMH2FN1 HS Phase 3 DMH2FN1 SN HP-128; Suronacrine maleate < Rec INNM; Rac-9-(Benzylamino)-1,2,3,4-tetrahydroacridin-1-ol maleate DMH2FN1 DT Small molecular drug DMH2FN1 PC 9953907 DMH2FN1 MW 420.5 DMH2FN1 FM C24H24N2O5 DMH2FN1 IC InChI=1S/C20H20N2O.C4H4O4/c23-18-12-6-11-17-19(18)20(15-9-4-5-10-16(15)22-17)21-13-14-7-2-1-3-8-14;5-3(6)1-2-4(7)8/h1-5,7-10,18,23H,6,11-13H2,(H,21,22);1-2H,(H,5,6)(H,7,8)/b;2-1- DMH2FN1 CS C1CC(C2=C(C3=CC=CC=C3N=C2C1)NCC4=CC=CC=C4)O.C(=C\\C(=O)O)\\C(=O)O DMH2FN1 IK JRQSVNSUJOFXHC-BTJKTKAUSA-N DMH2FN1 IU 9-(benzylamino)-1,2,3,4-tetrahydroacridin-1-ol;(Z)-but-2-enedioic acid DMH2FN1 CA CAS 113108-86-4 DMH2FN1 DE Cognitive impairment DMY7WH1 ID DMY7WH1 DMY7WH1 DN Sutimlimab DMY7WH1 HS Phase 3 DMY7WH1 CP Sanofi DMY7WH1 DT Antibody DMY7WH1 DE Cold type autoimmune haemolytic anemia DM3BO8G ID DM3BO8G DM3BO8G DN SUVN-G3031 DM3BO8G HS Phase 3 DM3BO8G SN LNXDUSQEXVQFGP-UHFFFAOYSA-N; UNII-65V47O9NOP; 65V47O9NOP; SCHEMBL12484542; N-[4-(1-Cyclobutyl piperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide; 1394808-82-2 DM3BO8G CP Suven Life Sciences Hyderabad, India DM3BO8G PC 60151477 DM3BO8G MW 373.5 DM3BO8G FM C21H31N3O3 DM3BO8G IC InChI=1S/C21H31N3O3/c25-21(16-23-12-14-26-15-13-23)22-17-4-6-19(7-5-17)27-20-8-10-24(11-9-20)18-2-1-3-18/h4-7,18,20H,1-3,8-16H2,(H,22,25) DM3BO8G CS C1CC(C1)N2CCC(CC2)OC3=CC=C(C=C3)NC(=O)CN4CCOCC4 DM3BO8G IK LNXDUSQEXVQFGP-UHFFFAOYSA-N DM3BO8G IU N-[4-(1-cyclobutylpiperidin-4-yl)oxyphenyl]-2-morpholin-4-ylacetamide DM3BO8G CA CAS 1394808-82-2 DM3BO8G DE Cognitive impairment DMOVEDH ID DMOVEDH DMOVEDH DN SYM-004 DMOVEDH HS Phase 3 DMOVEDH SN Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen DMOVEDH CP Symphogen A/S DMOVEDH DT Antibody DMOVEDH DE Head and neck cancer; Colorectal cancer; Metastatic colorectal cancer; Recurrent glioblastoma; Non-small-cell lung cancer DMRUEKC ID DMRUEKC DMRUEKC DN Synthetic conjugated estrogen DMRUEKC HS Phase 3 DMRUEKC SN Bijuva; Bithena; DR-2041; SCE-A Vaginal Cream; Synthetic conjugated estrogen (cream, vulvovaginal atrophy); Synthetic conjugated estrogen (cream, vulvovaginal atrophy), Teva DMRUEKC CP Duramed Pharmaceuticals Inc DMRUEKC DE Vaginal disease DMXU4ON ID DMXU4ON DMXU4ON DN Synthetic hypericin DMXU4ON HS Phase 3 DMXU4ON SN Hypericin; VIMRxyn; Synthetic hypericin, Nexell DMXU4ON CP Nexell Therapeutics Inc DMXU4ON DE Virus infection DM9L1AC ID DM9L1AC DM9L1AC DN SYR-472 DM9L1AC HS Phase 3 DM9L1AC SN Trelagliptin succinate; TRELAGLIPTIN SUCCINATE; 1029877-94-8; Trelagliptin (succinate); UNII-4118932Z90; AK198895; 2-[[6-[(3R)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxopyrimidin-1-yl]methyl]-4-fluorobenzonitrile; 4118932Z90; SYR-472 succinate; (R)-2-((6-(3-aminopiperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl)-4-fluorobenzonitrile succinate; SYR 111472 succinate; Trelagliptin succinate [USAN]; SYR111472 SUCCINATE; SYR 472; SYR472; Zafatek (TN); Trelagliptin succinat; SYR472 succinate; syr; Trelagliptin Succinate DM9L1AC CP Takeda DM9L1AC DT Small molecular drug DM9L1AC PC 15983988 DM9L1AC MW 357.4 DM9L1AC FM C18H20FN5O2 DM9L1AC IC InChI=1S/C18H20FN5O2/c1-22-17(25)8-16(23-6-2-3-15(21)11-23)24(18(22)26)10-13-7-14(19)5-4-12(13)9-20/h4-5,7-8,15H,2-3,6,10-11,21H2,1H3/t15-/m1/s1 DM9L1AC CS CN1C(=O)C=C(N(C1=O)CC2=C(C=CC(=C2)F)C#N)N3CCC[C@H](C3)N DM9L1AC IK IWYJYHUNXVAVAA-OAHLLOKOSA-N DM9L1AC IU 2-[[6-[(3R)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxopyrimidin-1-yl]methyl]-4-fluorobenzonitrile DM9L1AC CA CAS 865759-25-7 DM9L1AC CB CHEBI:134715 DM9L1AC DE Non-insulin dependent diabetes; Metabolic disorder DMR32KN ID DMR32KN DMR32KN DN TA-6366 DMR32KN HS Phase 3 DMR32KN SN Hipertene (TN); Imidapril (INN); Imidapril HCl; Imidapril [BAN:INN]; Imidapril [INN:BAN]; Imidaprilum; Imidaprilum [INN-Latin]; Novaloc; Tanatril; imidapril; lmidaprfil; (4S)-3-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-1-methyl-2-oxoimidazolidine-4-carboxylic acid; (S)-3-(N-((S)-1-Ethoxycarbonyl-3-phenylpropyl)-L-alanyl)-1-methyl-2-oxoimidazoline-4-carboxylic acid; 89371-37-9; BW7H1TJS22; C20H27N3O6; CHEMBL317094; MFCD00923828; NCGC00181342-01; UNII-BW7H1TJS22 DMR32KN PC 5464343 DMR32KN MW 405.4 DMR32KN FM C20H27N3O6 DMR32KN IC KLZWOWYOHUKJIG-BPUTZDHNSA-N DMR32KN CS CCOC(=O)C(CCC1=CC=CC=C1)NC(C)C(=O)N2C(CN(C2=O)C)C(=O)O DMR32KN IK 1S/C20H27N3O6/c1-4-29-19(27)15(11-10-14-8-6-5-7-9-14)21-13(2)17(24)23-16(18(25)26)12-22(3)20(23)28/h5-9,13,15-16,21H,4,10-12H2,1-3H3,(H,25,26)/t13-,15-,16-/m0/s1 DMR32KN IU (4S)-3-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-1-methyl-2-oxoimidazolidine-4-carboxylic acid DMR32KN CA CAS 89371-37-9 DMR32KN CB CHEBI:135654 DMR32KN DE Essential hypertension DMKSAG1 ID DMKSAG1 DMKSAG1 DN Tabalumab DMKSAG1 HS Phase 3 DMKSAG1 SN LY2127399 DMKSAG1 CP Lilly DMKSAG1 DT Monoclonal antibody DMKSAG1 DE Multiple myeloma DMW5PHL ID DMW5PHL DMW5PHL DN Taberminogene vadenovec DMW5PHL HS Phase 3 DMW5PHL SN Trinam (TN) DMW5PHL CP Ark Therapeutics DMW5PHL DE Vascular restinosis DM1NTVQ ID DM1NTVQ DM1NTVQ DN Tadekinig alfa DM1NTVQ HS Phase 3 DM1NTVQ CP AB2 Bio DM1NTVQ DT Recombinant protein DM1NTVQ DE XIAP deficiency DMCF6SX ID DMCF6SX DMCF6SX DN TAK-491 DMCF6SX HS Phase 3 DMCF6SX SN TAK 491 DMCF6SX CP Takeda DMCF6SX DT Small molecular drug DMCF6SX PC 135409642 DMCF6SX MW 568.5 DMCF6SX FM C30H24N4O8 DMCF6SX IC InChI=1S/C30H24N4O8/c1-3-38-28-31-23-10-6-9-22(27(35)39-16-24-17(2)40-30(37)41-24)25(23)34(28)15-18-11-13-19(14-12-18)20-7-4-5-8-21(20)26-32-29(36)42-33-26/h4-14H,3,15-16H2,1-2H3,(H,32,33,36) DMCF6SX CS CCOC1=NC2=CC=CC(=C2N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NOC(=O)N5)C(=O)OCC6=C(OC(=O)O6)C DMCF6SX IK QJFSABGVXDWMIW-UHFFFAOYSA-N DMCF6SX IU (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 2-ethoxy-3-[[4-[2-(5-oxo-4H-1,2,4-oxadiazol-3-yl)phenyl]phenyl]methyl]benzimidazole-4-carboxylate DMCF6SX CA CAS 863031-21-4 DMCF6SX CB CHEBI:68845 DMCF6SX DE Hypertension DM2H8FZ ID DM2H8FZ DM2H8FZ DN TAK-700 DM2H8FZ HS Phase 3 DM2H8FZ SN Orteronel DM2H8FZ CP Millennium Pharmaceuticals DM2H8FZ DT Small molecular drug DM2H8FZ PC 9883029 DM2H8FZ MW 307.3 DM2H8FZ FM C18H17N3O2 DM2H8FZ IC InChI=1S/C18H17N3O2/c1-19-17(22)14-3-2-13-9-15(5-4-12(13)8-14)18(23)6-7-21-11-20-10-16(18)21/h2-5,8-11,23H,6-7H2,1H3,(H,19,22) DM2H8FZ CS CNC(=O)C1=CC2=C(C=C1)C=C(C=C2)C3(CCN4C3=CN=C4)O DM2H8FZ IK OZPFIJIOIVJZMN-UHFFFAOYSA-N DM2H8FZ IU 6-(7-hydroxy-5,6-dihydropyrrolo[1,2-c]imidazol-7-yl)-N-methylnaphthalene-2-carboxamide DM2H8FZ CB CHEBI:94965 DM2H8FZ DE Prostate cancer DMIM5AP ID DMIM5AP DMIM5AP DN TAK-875 DMIM5AP HS Phase 3 DMIM5AP SN TAK-875; Fasiglifam; 1000413-72-8; TAK875; TAK 875; UNII-GLP1W4JXAH; GLP1W4JXAH; (S)-2-(6-((2',6'-Dimethyl-4'-(3-(methylsulfonyl)propoxy)-[1,1'-biphenyl]-3-yl)methoxy)-2,3-dihydrobenzofuran-3-yl)acetic acid; CHEMBL1829174; [(3s)-6-({2',6'-Dimethyl-4'-[3-(Methylsulfonyl)propoxy]biphenyl-3-Yl}methoxy)-2,3-Dihydro-1-Benzofuran-3-Yl]acetic Acid; 3-Benzofuranacetic acid, 6-[[2',6'-diMethyl-4'-[3-(Methylsulfonyl)propoxy][1,1'-biphenyl]-3-yl]Methoxy]-2,3-dihydro-, (3S)-; J-501277 DMIM5AP CP Takeda Pharmaceuticals U.S.A. DMIM5AP DT Small molecular drug DMIM5AP PC 24857286 DMIM5AP MW 524.6 DMIM5AP FM C29H32O7S DMIM5AP IC InChI=1S/C29H32O7S/c1-19-12-25(34-10-5-11-37(3,32)33)13-20(2)29(19)22-7-4-6-21(14-22)17-35-24-8-9-26-23(15-28(30)31)18-36-27(26)16-24/h4,6-9,12-14,16,23H,5,10-11,15,17-18H2,1-3H3,(H,30,31)/t23-/m1/s1 DMIM5AP CS CC1=CC(=CC(=C1C2=CC=CC(=C2)COC3=CC4=C(C=C3)[C@@H](CO4)CC(=O)O)C)OCCCS(=O)(=O)C DMIM5AP IK BZCALJIHZVNMGJ-HSZRJFAPSA-N DMIM5AP IU 2-[(3S)-6-[[3-[2,6-dimethyl-4-(3-methylsulfonylpropoxy)phenyl]phenyl]methoxy]-2,3-dihydro-1-benzofuran-3-yl]acetic acid DMIM5AP CA CAS 1000413-72-8 DMIM5AP DE Type-2 diabetes DM1IZ5D ID DM1IZ5D DM1IZ5D DN Talabostat DM1IZ5D HS Phase 3 DM1IZ5D SN Talabostat mesylate; Boroproline compounds, DARA BioSciences; Boroproline compounds, Point Therapeutics; PT-100; Val-boro-Pro DM1IZ5D CP Point Therapeutics; Tufts University School of Medicine DM1IZ5D DT Small molecular drug DM1IZ5D PC 6918572 DM1IZ5D MW 214.07 DM1IZ5D FM C9H19BN2O3 DM1IZ5D IC InChI=1S/C9H19BN2O3/c1-6(2)8(11)9(13)12-5-3-4-7(12)10(14)15/h6-8,14-15H,3-5,11H2,1-2H3/t7-,8-/m0/s1 DM1IZ5D CS B([C@@H]1CCCN1C(=O)[C@H](C(C)C)N)(O)O DM1IZ5D IK FKCMADOPPWWGNZ-YUMQZZPRSA-N DM1IZ5D IU [(2R)-1-[(2S)-2-amino-3-methylbutanoyl]pyrrolidin-2-yl]boronic acid DM1IZ5D CA CAS 149682-77-9 DM1IZ5D DE Constitutional neutropenia; Solid tumour/cancer DMV7T64 ID DMV7T64 DMV7T64 DN Talactoferrin DMV7T64 HS Phase 3 DMV7T64 SN Talactoferrin (topical) DMV7T64 CP Agennix AG DMV7T64 DE Diabetic foot ulcer DM3G74J ID DM3G74J DM3G74J DN Tamibarotene DM3G74J HS Phase 3 DM3G74J SN Tamibarotene (oral, Alzheimer's disease) DM3G74J CP Research Foundation Itsuu Laboratory DM3G74J DT Small molecular drug DM3G74J PC 108143 DM3G74J MW 351.4 DM3G74J FM C22H25NO3 DM3G74J IC InChI=1S/C22H25NO3/c1-21(2)11-12-22(3,4)18-13-16(9-10-17(18)21)23-19(24)14-5-7-15(8-6-14)20(25)26/h5-10,13H,11-12H2,1-4H3,(H,23,24)(H,25,26) DM3G74J CS CC1(CCC(C2=C1C=CC(=C2)NC(=O)C3=CC=C(C=C3)C(=O)O)(C)C)C DM3G74J IK MUTNCGKQJGXKEM-UHFFFAOYSA-N DM3G74J IU 4-[(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)carbamoyl]benzoic acid DM3G74J CA CAS 94497-51-5 DM3G74J CB CHEBI:32181 DM3G74J DE Alzheimer disease; T-cell leukaemia DMJKWMA ID DMJKWMA DMJKWMA DN Tanezumab DMJKWMA HS Phase 3 DMJKWMA CP Pfizer New York, NY DMJKWMA DT Monoclonal antibody DMJKWMA DE Neuropathic pain; Chronic low back pain; Pain; Osteoarthritis; Cancer related pain DMWM4D0 ID DMWM4D0 DMWM4D0 DN TAS-120 DMWM4D0 HS Phase 3 DMWM4D0 CP Taiho oncology DMWM4D0 PC 71621331 DMWM4D0 MW 418.4 DMWM4D0 FM C22H22N6O3 DMWM4D0 IC InChI=1S/C22H22N6O3/c1-4-19(29)27-8-7-15(12-27)28-22-20(21(23)24-13-25-22)18(26-28)6-5-14-9-16(30-2)11-17(10-14)31-3/h4,9-11,13,15H,1,7-8,12H2,2-3H3,(H2,23,24,25)/t15-/m0/s1 DMWM4D0 CS COC1=CC(=CC(=C1)C#CC2=NN(C3=NC=NC(=C23)N)[C@H]4CCN(C4)C(=O)C=C)OC DMWM4D0 IK KEIPNCCJPRMIAX-HNNXBMFYSA-N DMWM4D0 IU 1-[(3S)-3-[4-amino-3-[2-(3,5-dimethoxyphenyl)ethynyl]pyrazolo[3,4-d]pyrimidin-1-yl]pyrrolidin-1-yl]prop-2-en-1-one DMWM4D0 CA CAS 1448169-71-8 DMWM4D0 DE Multiple myeloma; Solid tumour/cancer; Cholangiocarcinoma DMPYET9 ID DMPYET9 DMPYET9 DN Taspoglutide DMPYET9 HS Phase 3 DMPYET9 SN BIM-51077; BIM-51079; BIM-51182; Glucagon agonists, Ipsen; ITM-077; R-1583; RG-1583; RO-5073031; Glucagon agonists, Beaufour-Ipsen DMPYET9 CP Ipsen DMPYET9 PC 56842233 DMPYET9 MW 3339.7 DMPYET9 FM C152H232N40O45 DMPYET9 IC InChI=1S/C152H232N40O45/c1-20-78(10)119(145(233)168-81(13)125(213)174-105(63-87-66-162-92-39-28-27-38-90(87)92)134(222)176-101(59-75(4)5)135(223)187-117(76(6)7)143(231)173-95(41-30-32-56-154)142(230)192-152(18,19)148(236)184-93(122(157)210)42-33-57-161-150(158)159)189-136(224)103(60-84-34-23-21-24-35-84)177-131(219)99(50-54-115(206)207)172-130(218)94(40-29-31-55-153)170-124(212)80(12)166-123(211)79(11)167-129(217)98(47-51-110(156)199)169-111(200)68-163-127(215)96(48-52-113(202)203)171-132(220)100(58-74(2)3)175-133(221)102(62-86-43-45-89(198)46-44-86)178-139(227)107(70-193)181-141(229)109(72-195)182-144(232)118(77(8)9)188-138(226)106(65-116(208)209)179-140(228)108(71-194)183-147(235)121(83(15)197)190-137(225)104(61-85-36-25-22-26-37-85)180-146(234)120(82(14)196)186-112(201)69-164-128(216)97(49-53-114(204)205)185-149(237)151(16,17)191-126(214)91(155)64-88-67-160-73-165-88/h21-28,34-39,43-46,66-67,73-83,91,93-109,117-121,162,193-198H,20,29-33,40-42,47-65,68-72,153-155H2,1-19H3,(H2,156,199)(H2,157,210)(H,160,165)(H,163,215)(H,164,216)(H,166,211)(H,167,217)(H,168,233)(H,169,200)(H,170,212)(H,171,220)(H,172,218)(H,173,231)(H,174,213)(H,175,221)(H,176,222)(H,177,219)(H,178,227)(H,179,228)(H,180,234)(H,181,229)(H,182,232)(H,183,235)(H,184,236)(H,185,237)(H,186,201)(H,187,223)(H,188,226)(H,189,224)(H,190,225)(H,191,214)(H,192,230)(H,202,203)(H,204,205)(H,206,207)(H,208,209)(H4,158,159,161)/t78-,79-,80-,81-,82+,83+,91-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,117-,118-,119-,120-,121-/m0/s1 DMPYET9 CS CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NC(C)(C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)N)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)C(C)(C)NC(=O)[C@H](CC6=CN=CN6)N DMPYET9 IK WRGVLTAWMNZWGT-VQSPYGJZSA-N DMPYET9 IU (4S)-4-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]-2-methylpropanoyl]amino]-4-carboxybutanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-4-carboxybutanoyl]amino]acetyl]amino]-5-oxopentanoyl]amino]propanoyl]amino]propanoyl]amino]hexanoyl]amino]-5-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[1-[[(2S)-1-amino-5-carbamimidamido-1-oxopentan-2-yl]amino]-2-methyl-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-5-oxopentanoic acid DMPYET9 CA CAS 275371-94-3 DMPYET9 DE Type-1 diabetes DM9GSVQ ID DM9GSVQ DM9GSVQ DN Tasquinimod DM9GSVQ HS Phase 3 DM9GSVQ SN TASQ DM9GSVQ CP Active Biotech DM9GSVQ DT Small molecular drug DM9GSVQ PC 54682876 DM9GSVQ MW 406.4 DM9GSVQ FM C20H17F3N2O4 DM9GSVQ IC InChI=1S/C20H17F3N2O4/c1-24(12-9-7-11(8-10-12)20(21,22)23)18(27)16-17(26)15-13(25(2)19(16)28)5-4-6-14(15)29-3/h4-10,26H,1-3H3 DM9GSVQ CS CN1C2=C(C(=CC=C2)OC)C(=C(C1=O)C(=O)N(C)C3=CC=C(C=C3)C(F)(F)F)O DM9GSVQ IK ONDYALNGTUAJDX-UHFFFAOYSA-N DM9GSVQ IU 4-hydroxy-5-methoxy-N,1-dimethyl-2-oxo-N-[4-(trifluoromethyl)phenyl]quinoline-3-carboxamide DM9GSVQ CA CAS 254964-60-8 DM9GSVQ DE Prostate cancer DMD6AUX ID DMD6AUX DMD6AUX DN Tat-NR2B9c DMD6AUX HS Phase 3 DMD6AUX SN NA-1; NA-1); PSD-95 inhibitor (stroke), NoNO/Arbor Vita; NMDAR NR2 domain-binding protein + HIV-1 Tat protein (Stroke), NoNO/Arbor Vita DMD6AUX CP Nono inc DMD6AUX DT Peptide DMD6AUX PC 44568939 DMD6AUX MW 2518.9 DMD6AUX FM C105H188N42O30 DMD6AUX IC InChI=1S/C105H188N42O30/c1-7-55(6)80(98(175)140-69(34-36-77(154)155)92(169)143-72(50-148)95(172)142-71(48-78(156)157)94(171)146-79(54(4)5)99(176)177)147-97(174)74(52-150)145-96(173)73(51-149)144-93(170)70(46-53(2)3)141-90(167)62(22-10-13-39-108)133-85(162)63(24-15-41-124-101(113)114)135-87(164)65(26-17-43-126-103(117)118)136-88(165)66(27-18-44-127-104(119)120)138-91(168)68(33-35-75(110)152)139-89(166)67(28-19-45-128-105(121)122)137-86(163)64(25-16-42-125-102(115)116)134-84(161)61(21-9-12-38-107)132-83(160)60(20-8-11-37-106)131-82(159)59(23-14-40-123-100(111)112)130-76(153)49-129-81(158)58(109)47-56-29-31-57(151)32-30-56/h29-32,53-55,58-74,79-80,148-151H,7-28,33-52,106-109H2,1-6H3,(H2,110,152)(H,129,158)(H,130,153)(H,131,159)(H,132,160)(H,133,162)(H,134,161)(H,135,164)(H,136,165)(H,137,163)(H,138,168)(H,139,166)(H,140,175)(H,141,167)(H,142,172)(H,143,169)(H,144,170)(H,145,173)(H,146,171)(H,147,174)(H,154,155)(H,156,157)(H,176,177)(H4,111,112,123)(H4,113,114,124)(H4,115,116,125)(H4,117,118,126)(H4,119,120,127)(H4,121,122,128)/t55-,58-,59-,60-,61-,62-,63-,64-,65-,66-,67-,68-,69-,70-,71-,72-,73-,74-,79-,80-/m0/s1 DMD6AUX CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)CNC(=O)[C@H](CC1=CC=C(C=C1)O)N DMD6AUX IK XWQVQFBTSBCKLI-FKXNDIMNSA-N DMD6AUX IU (4S)-4-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-6-amino-2-[[(2S)-2-[[2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]-5-carbamimidamidopentanoyl]amino]hexanoyl]amino]hexanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-methylpentanoyl]amino]-5-[[(2S)-1-[[(2S)-3-carboxy-1-[[(1S)-1-carboxy-2-methylpropyl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-5-oxopentanoic acid DMD6AUX CA CAS 500992-11-0 DMD6AUX DE Cerebrovascular ischaemia; Stroke DML6GAN ID DML6GAN DML6GAN DN Taxol/Paraplatin/Herceptin DML6GAN HS Phase 3 DML6GAN SN Paclitaxel/carboplatin/trastuzumab DML6GAN CP Bristol-Myers Squibb DML6GAN DE Breast cancer DMGKBZH ID DMGKBZH DMGKBZH DN TD-1792 DMGKBZH HS Phase 3 DMGKBZH CP Theravance DMGKBZH DT Small molecular drug DMGKBZH PC 76960417 DMGKBZH MW 1983.3 DMGKBZH FM C87H95Cl3N16O28S2 DMGKBZH IC InChI=1S/C87H95Cl3N16O28S2/c1-33(2)20-45(94-5)74(117)100-62-66(112)36-11-14-49(43(88)22-36)130-51-24-38-25-52(70(51)134-85-71(69(115)68(114)53(31-107)132-85)133-55-29-87(4,93)72(116)34(3)129-55)131-50-15-12-37(23-44(50)89)67(113)63-81(124)99-59(42-26-40(108)27-48(110)56(42)41-21-35(10-13-47(41)109)57(77(120)101-63)98-78(121)58(38)97-75(118)46(28-54(91)111)96-80(62)123)76(119)95-16-9-19-128-104-61(60-73(90)136-86(92)103-60)79(122)102-64-82(125)106-65(84(126)127)39(32-135-83(64)106)30-105-17-7-6-8-18-105/h6-8,10-15,17-18,21-27,33-34,45-46,53,55,57-59,62-64,66-69,71-72,83,85,94,107,112-116H,9,16,19-20,28-32,93H2,1-5H3,(H15-,91,92,95,96,97,98,99,100,101,102,103,104,108,109,110,111,117,118,119,120,121,122,123,124,126,127)/t34-,45+,46-,53+,55-,57+,58+,59-,62+,63-,64+,66+,67+,68+,69-,71+,72+,83+,85-,87-/m0/s1 DMGKBZH CS C[C@H]1[C@H]([C@@](C[C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2OC3=C4C=C5C=C3OC6=C(C=C(C=C6)[C@H]([C@H](C(=O)N[C@H](C(=O)N[C@H]5C(=O)N[C@@H]7C8=CC(=C(C=C8)O)C9=C(C=C(C=C9O)O)[C@H](NC(=O)[C@H]([C@@H](C1=CC(=C(O4)C=C1)Cl)O)NC7=O)C(=O)NCCCO/N=C(/C1=C(SC(=N1)N)Cl)\\C(=O)N[C@H]1[C@@H]2N(C1=O)C(=C(CS2)C[N+]1=CC=CC=C1)C(=O)[O-])CC(=O)N)NC(=O)[C@@H](CC(C)C)NC)O)Cl)CO)O)O)(C)N)O DMGKBZH IK OGUAFUAJSPORAH-KHCCTVBNSA-N DMGKBZH IU (6R,7R)-7-[[(2Z)-2-(2-amino-5-chloro-1,3-thiazol-4-yl)-2-[3-[[(1S,2R,18R,19R,22S,25R,28R,40S)-48-[(2S,3R,4S,5S,6R)-3-[(2S,4S,5S,6S)-4-amino-5-hydroxy-4,6-dimethyloxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-22-(2-amino-2-oxoethyl)-5,15-dichloro-2,18,32,35,37-pentahydroxy-19-[[(2R)-4-methyl-2-(methylamino)pentanoyl]amino]-20,23,26,42,44-pentaoxo-7,13-dioxa-21,24,27,41,43-pentazaoctacyclo[26.14.2.23,6.214,17.18,12.129,33.010,25.034,39]pentaconta-3,5,8(48),9,11,14,16,29(45),30,32,34(39),35,37,46,49-pentadecaene-40-carbonyl]amino]propoxyimino]acetyl]amino]-8-oxo-3-(pyridin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate DMGKBZH CA CAS 722454-12-8 DMGKBZH DE Gram-positive bacterial infection; Skin infection DMVSX6O ID DMVSX6O DMVSX6O DN Tebipenem DMVSX6O HS Phase 3 DMVSX6O SN Tebipenem [INN] DMVSX6O CP Sanofi-Aventis DMVSX6O DT Small molecular drug DMVSX6O PC 9800194 DMVSX6O MW 383.5 DMVSX6O FM C16H21N3O4S2 DMVSX6O IC InChI=1S/C16H21N3O4S2/c1-7-11-10(8(2)20)14(21)19(11)12(15(22)23)13(7)25-9-5-18(6-9)16-17-3-4-24-16/h7-11,20H,3-6H2,1-2H3,(H,22,23)/t7-,8-,10-,11-/m1/s1 DMVSX6O CS C[C@@H]1[C@@H]2[C@H](C(=O)N2C(=C1SC3CN(C3)C4=NCCS4)C(=O)O)[C@@H](C)O DMVSX6O IK GXXLUDOKHXEFBQ-YJFSRANCSA-N DMVSX6O IU (4R,5S,6S)-3-[1-(4,5-dihydro-1,3-thiazol-2-yl)azetidin-3-yl]sulfanyl-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid DMVSX6O CA CAS 161715-21-5 DMVSX6O DE Obesity; Nicotine dependence; Urinary tract infection DMTCR2O ID DMTCR2O DMTCR2O DN Tecarfarin DMTCR2O HS Phase 3 DMTCR2O SN ATI-5923 DMTCR2O CP ARYx Therapeutics DMTCR2O DT Small molecular drug DMTCR2O PC 54718618 DMTCR2O MW 460.3 DMTCR2O FM C21H14F6O5 DMTCR2O IC InChI=1S/C21H14F6O5/c1-19(20(22,23)24,21(25,26)27)32-17(29)12-8-6-11(7-9-12)10-14-16(28)13-4-2-3-5-15(13)31-18(14)30/h2-9,28H,10H2,1H3 DMTCR2O CS CC(C(F)(F)F)(C(F)(F)F)OC(=O)C1=CC=C(C=C1)CC2=C(C3=CC=CC=C3OC2=O)O DMTCR2O IK QFLNTQDOVCLQKW-UHFFFAOYSA-N DMTCR2O IU (1,1,1,3,3,3-hexafluoro-2-methylpropan-2-yl) 4-[(4-hydroxy-2-oxochromen-3-yl)methyl]benzoate DMTCR2O CA CAS 867257-26-9 DMTCR2O DE Cerebrovascular ischaemia; Thrombosis DMKE187 ID DMKE187 DMKE187 DN Telmisartan DMKE187 HS Phase 3 DMKE187 SN Telmisartan; 144701-48-4; Micardis; Pritor; BIBR 277; Kinzalmono; BIBR-277; BIBR 277SE; Telmisattan; Targit; Telmisartan [INN]; UNII-U5SYW473RQ; BIBR-277SE; BIBR-277-SE; U5SYW473RQ; CHEMBL1017; CHEBI:9434; Telmisartan DMKE187 TC Antiviral Agents DMKE187 DT Small molecular drug DMKE187 PC 65999 DMKE187 MW 514.6 DMKE187 FM C33H30N4O2 DMKE187 IC InChI=1S/C33H30N4O2/c1-4-9-30-35-31-21(2)18-24(32-34-27-12-7-8-13-28(27)36(32)3)19-29(31)37(30)20-22-14-16-23(17-15-22)25-10-5-6-11-26(25)33(38)39/h5-8,10-19H,4,9,20H2,1-3H3,(H,38,39) DMKE187 CS CCCC1=NC2=C(N1CC3=CC=C(C=C3)C4=CC=CC=C4C(=O)O)C=C(C=C2C)C5=NC6=CC=CC=C6N5C DMKE187 IK RMMXLENWKUUMAY-UHFFFAOYSA-N DMKE187 IU 2-[4-[[4-methyl-6-(1-methylbenzimidazol-2-yl)-2-propylbenzimidazol-1-yl]methyl]phenyl]benzoic acid DMKE187 CA CAS 144701-48-4 DMKE187 CB CHEBI:9434 DMKE187 DE Coronavirus Disease 2019 (COVID-19) DMHQRYE ID DMHQRYE DMHQRYE DN Tenidap DMHQRYE HS Phase 3 DMHQRYE DT Small molecular drug DMHQRYE PC 60712 DMHQRYE MW 320.8 DMHQRYE FM C14H9ClN2O3S DMHQRYE IC InChI=1S/C14H9ClN2O3S/c15-7-3-4-9-8(6-7)11(13(19)17(9)14(16)20)12(18)10-2-1-5-21-10/h1-6,19H,(H2,16,20) DMHQRYE CS C1=CSC(=C1)C(=O)C2=C(N(C3=C2C=C(C=C3)Cl)C(=O)N)O DMHQRYE IK IZSFDUMVCVVWKW-UHFFFAOYSA-N DMHQRYE IU 5-chloro-2-hydroxy-3-(thiophene-2-carbonyl)indole-1-carboxamide DMHQRYE CA CAS 120210-48-2 DMHQRYE CB CHEBI:35847 DMHQRYE DE Rheumatoid arthritis DMHOV7D ID DMHOV7D DMHOV7D DN Tenofovir alafenamide DMHOV7D HS Phase 3 DMHOV7D SN (S)-Isopropyl 2-(((S)-((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(phenoxy)phosphoryl)amino)propanoate; AK109983; EL9943AG5J; GS 7340; GS-7339; GS-7340; GS7340; J4414G3BUK; L-Alanine, N-((S)-(((1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy)methyl)phenoxyphosphinyl)-, 1-methylethyl ester; TENOFOVIR ALAFENAMIDE; Tenofovir Alafenamide (GS-7340); Tenofovir Alafenamide [USAN:INN]; UNII-EL9943AG5J; UNII-J4414G3BUK; Vemlidy DMHOV7D TC Antiviral Agent DMHOV7D DT Small molecular drug DMHOV7D PC 9574768 DMHOV7D MW 476.474 DMHOV7D FM C21H29N6O5P DMHOV7D IC InChI=1S/C21H29N6O5P/c1-14(2)31-21(28)16(4)26-33(29,32-17-8-6-5-7-9-17)13-30-15(3)10-27-12-25-18-19(22)23-11-24-20(18)27/h5-9,11-12,14-16H,10,13H2,1-4H3,(H,26,29)(H2,22,23,24)/t15-,16+,33+/m1/s1 DMHOV7D CS CC(C)OC(=O)C(C)NP(=O)(COC(C)CN1C=NC2=C1N=CN=C2N)OC3=CC=CC=C3 DMHOV7D IK LDEKQSIMHVQZJK-CAQYMETFSA-N DMHOV7D IU propan-2-yl (2S)-2-[[[(2R)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethyl-phenoxyphosphoryl]amino]propanoate DMHOV7D CA CAS 379270-37-8 DMHOV7D CB CHEBI:90926 DMHOV7D DE Chronic hepatitis B infection; Human immunodeficiency virus infection DMZ3P6C ID DMZ3P6C DMZ3P6C DN Teplizumab DMZ3P6C HS Phase 3 DMZ3P6C CP MacroGenics DMZ3P6C DT Antibody DMZ3P6C DE Type-1 diabetes; Melanoma DM4MZXE ID DM4MZXE DM4MZXE DN Terodiline DM4MZXE HS Phase 3 DM4MZXE SN Bicor; Microl; Mictrol; Micturin; Micturol; Terolin; Terodiline hydrochloride; TD-758 DM4MZXE CP Pharmacia & Upjohn AB DM4MZXE DT Small molecular drug DM4MZXE PC 23480 DM4MZXE MW 281.4 DM4MZXE FM C20H27N DM4MZXE IC InChI=1S/C20H27N/c1-16(21-20(2,3)4)15-19(17-11-7-5-8-12-17)18-13-9-6-10-14-18/h5-14,16,19,21H,15H2,1-4H3 DM4MZXE CS CC(CC(C1=CC=CC=C1)C2=CC=CC=C2)NC(C)(C)C DM4MZXE IK UISARWKNNNHPGI-UHFFFAOYSA-N DM4MZXE IU N-tert-butyl-4,4-diphenylbutan-2-amine DM4MZXE CA CAS 15793-40-5 DM4MZXE CB CHEBI:135168 DM4MZXE DE Urinary incontinence DMGRBN5 ID DMGRBN5 DMGRBN5 DN TESAGLITAZAR DMGRBN5 HS Phase 3 DMGRBN5 SN Tesaglitazar; 251565-85-2; Galida; (S)-2-Ethoxy-3-(4-(4-((methylsulfonyl)oxy)phenethoxy)phenyl)propanoic acid; AZ 242; AZ-242; AR-H039242XX; (S)-2-Ethoxy-3-{4-[2-(4-methanesulfonyloxyphenyl)ethoxy]phenyl}propionic acid; UNII-6734037O3L; (S)-2-Ethoxy-3-{4-[2-(4-methanesulfonyloxy-phenyl)-ethoxy]-phenyl}-propionic acid; (2S)-2-ethoxy-3-[4-[2-(4-methylsulfonyloxyphenyl)ethoxy]phenyl]propanoic acid; BR-44608; 6734037O3L; (S)-2-Ethoxy-3-[4-[2-(4-methanesulfonyloxyphenyl)ethoxy]phenyl]propanoic acid DMGRBN5 DT Small molecular drug DMGRBN5 PC 208901 DMGRBN5 MW 408.5 DMGRBN5 FM C20H24O7S DMGRBN5 IC InChI=1S/C20H24O7S/c1-3-25-19(20(21)22)14-16-6-8-17(9-7-16)26-13-12-15-4-10-18(11-5-15)27-28(2,23)24/h4-11,19H,3,12-14H2,1-2H3,(H,21,22)/t19-/m0/s1 DMGRBN5 CS CCO[C@@H](CC1=CC=C(C=C1)OCCC2=CC=C(C=C2)OS(=O)(=O)C)C(=O)O DMGRBN5 IK CXGTZJYQWSUFET-IBGZPJMESA-N DMGRBN5 IU (2S)-2-ethoxy-3-[4-[2-(4-methylsulfonyloxyphenyl)ethoxy]phenyl]propanoic acid DMGRBN5 CA CAS 251565-85-2 DMGRBN5 DE Type-1 diabetes DMMTKC6 ID DMMTKC6 DMMTKC6 DN TEV-48125 DMMTKC6 HS Phase 3 DMMTKC6 DT Antibody DMMTKC6 DE Migraine DM9R5J6 ID DM9R5J6 DM9R5J6 DN Tezepelumab DM9R5J6 HS Phase 3 DM9R5J6 CP Amgen; AstraZeneca DM9R5J6 DT Antibody DM9R5J6 DE Severe asthma DMLCXPD ID DMLCXPD DMLCXPD DN TG-C DMLCXPD HS Phase 3 DMLCXPD SN 3-Thiaglutaryl-Coa; S-[[(2-Hydroxy-2-oxoethyl)thio]acetyl]coenzyme A; (3R,5S,9R)-1-[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-10,14,19-trioxo-2,4,6-trioxa-18,21-dithia-11,15-diaza-3,5-diphosphatricosan-23-oic acid 3,5-dioxide; TGC DMLCXPD DT Small molecular drug DMLCXPD PC 24768536 DMLCXPD MW 899.7 DMLCXPD FM C25H40N7O19P3S2 DMLCXPD IC InChI=1S/C25H40N7O19P3S2/c1-25(2,20(38)23(39)28-4-3-14(33)27-5-6-56-16(36)9-55-8-15(34)35)10-48-54(45,46)51-53(43,44)47-7-13-19(50-52(40,41)42)18(37)24(49-13)32-12-31-17-21(26)29-11-30-22(17)32/h11-13,18-20,24,37-38H,3-10H2,1-2H3,(H,27,33)(H,28,39)(H,34,35)(H,43,44)(H,45,46)(H2,26,29,30)(H2,40,41,42)/t13-,18-,19-,20+,24-/m1/s1 DMLCXPD CS CC(C)(COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)[C@H](C(=O)NCCC(=O)NCCSC(=O)CSCC(=O)O)O DMLCXPD IK GKSSRSUPHZUOQO-ITIYDSSPSA-N DMLCXPD IU 2-[2-[2-[3-[[(2R)-4-[[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-4-hydroxy-3-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxy-2-hydroxy-3,3-dimethylbutanoyl]amino]propanoylamino]ethylsulfanyl]-2-oxoethyl]sulfanylacetic acid DMLCXPD DE Arthritis DMPGH7N ID DMPGH7N DMPGH7N DN ThermoProfen DMPGH7N HS Phase 3 DMPGH7N CP ZARS Pharma DMPGH7N DE Pain DM3PA8H ID DM3PA8H DM3PA8H DN THVD-201 DM3PA8H HS Phase 3 DM3PA8H SN Tolterodine + pilocarpine (overactive bladder/urinary incontinence), TheraVida DM3PA8H CP TheraVida Inc DM3PA8H DE Overactive bladder DM3DG5C ID DM3DG5C DM3DG5C DN THX-TS01 DM3DG5C HS Phase 3 DM3DG5C CP Therapix Biosciences Givatayim, Israel DM3DG5C DE Tourette syndrome DMMO6P0 ID DMMO6P0 DMMO6P0 DN Tifacogin DMMO6P0 HS Phase 3 DMMO6P0 SN LACI; SC-59735; TFP-561; LACI, Pharmacia/Chiron; LACI, Searle/Chiron; Lipoprotein associated coagulation inhibitor, Pharmacia/Chiron;Lipoprotein associated coagulation inhibitor, Searle/Chiron; RTFPI, Pharmacia/Chiron; RTFPI, Searle/Chiron; Tissue factor pathway inhibitor, Pharmacia/Chiron; Tissue factor pathway inhibitor, Searle/Chiron DMMO6P0 CP GD Searle & Co; Chiron DMMO6P0 DT Small molecular drug DMMO6P0 PC 961320 DMMO6P0 MW 203.31 DMMO6P0 FM C12H13NS DMMO6P0 IC InChI=1S/C12H13NS/c1-2-5-11(6-3-1)9-13-10-12-7-4-8-14-12/h1-8,13H,9-10H2 DMMO6P0 CS C1=CC=C(C=C1)CNCC2=CC=CS2 DMMO6P0 IK GEWKIDGKZRKUFB-UHFFFAOYSA-N DMMO6P0 IU 1-phenyl-N-(thiophen-2-ylmethyl)methanamine DMMO6P0 CA CAS 73325-61-8 DMMO6P0 DE Sepsis DMZBGI8 ID DMZBGI8 DMZBGI8 DN Tilarginine acetate DMZBGI8 HS Phase 3 DMZBGI8 SN 53308-83-1; L-NMMA acetate; UNII-2FL3530AF2; 2FL3530AF2; DSSTox_RID_81122; DSSTox_CID_25780; DSSTox_GSID_45780; SMR000449329; CAS-53308-83-1; N-omega-Monomethyl-L-arginine monoacetate, 99% DMZBGI8 CP ArgiNOx DMZBGI8 DT Small molecular drug DMZBGI8 PC 135242 DMZBGI8 MW 248.28 DMZBGI8 FM C9H20N4O4 DMZBGI8 IC InChI=1S/C7H16N4O2.C2H4O2/c1-10-7(9)11-4-2-3-5(8)6(12)13;1-2(3)4/h5H,2-4,8H2,1H3,(H,12,13)(H3,9,10,11);1H3,(H,3,4)/t5-;/m0./s1 DMZBGI8 CS CC(=O)O.CN=C(N)NCCC[C@@H](C(=O)O)N DMZBGI8 IK IKPNWIGTWUZCKM-JEDNCBNOSA-N DMZBGI8 IU acetic acid;(2S)-2-amino-5-[(N'-methylcarbamimidoyl)amino]pentanoic acid DMZBGI8 CA CAS 53308-83-1 DMZBGI8 DE Angina pectoris; Myocardial infarction DMGYK2N ID DMGYK2N DMGYK2N DN Tilsotolimod DMGYK2N HS Phase 3 DMGYK2N SN IMO-2125 DMGYK2N CP Idera Pharmaceuticals DMGYK2N DT Oligonucleotide DMGYK2N DE Melanoma DMBFE4K ID DMBFE4K DMBFE4K DN Tirapazamine DMBFE4K HS Phase 3 DMBFE4K SN TPZ; Tirazone; SR-259075; SR-4233; SR-4317; SR-4330; SR-4482; Win-59075 DMBFE4K CP Sri international DMBFE4K DT Small molecular drug DMBFE4K PC 135413511 DMBFE4K MW 178.15 DMBFE4K FM C7H6N4O2 DMBFE4K IC InChI=1S/C7H6N4O2/c8-7-9-11(13)6-4-2-1-3-5(6)10(7)12/h1-4H,(H2,8,9) DMBFE4K CS C1=CC=C2C(=C1)[N+](=C(N=[N+]2[O-])N)[O-] DMBFE4K IK ORYDPOVDJJZGHQ-UHFFFAOYSA-N DMBFE4K IU 1,4-dioxido-1,2,4-benzotriazine-1,4-diium-3-amine DMBFE4K CA CAS 27314-97-2 DMBFE4K CB CHEBI:78887 DMBFE4K DE Alzheimer disease; Hepatocellular carcinoma DMQNMAT ID DMQNMAT DMQNMAT DN Tirzepatide DMQNMAT HS Phase 3 DMQNMAT CP Eli Lilly DMQNMAT DE Type 2 diabetes DM95IPS ID DM95IPS DM95IPS DN Tivanisiran DM95IPS HS Phase 3 DM95IPS CP Sylentis DM95IPS DT Small interfering RNA DM95IPS DE Dry eye disease DMNVP8Q ID DMNVP8Q DMNVP8Q DN Tivantinib DMNVP8Q HS Phase 3 DMNVP8Q SN Tivantinib; 905854-02-6; ARQ-197; ARQ197; ARQ 197; Tivantinib (ARQ 197); (3R,4R)-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl)pyrrolidine-2,5-dione; UNII-PJ4H73IL17; PJ4H73IL17; 1000873-98-2; (3R,4R)-3-(5,6-Dihydro-4H-pyrrolo(3,2,1-ij)quinolin-1-yl)-4-(1H-indol-3-yl)pyrrolidine-2,5-dione; Tivantinib [USAN:INN]; 1228508-24-4; Tivantinib; ARQ197; ARQ 197, Tivantinib; Tivantinib (ARQ-197); ARQ 197 (Tivantinib); cc-86; SCHEMBL44944; Tivantinib (JAN/USAN/INN); GTPL7948; CHEMBL2103882; CHEBI:91398; QCR-102 DMNVP8Q CP ArQule; Daiichi Sankyo DMNVP8Q DT Small molecular drug DMNVP8Q PC 11494412 DMNVP8Q MW 369.4 DMNVP8Q FM C23H19N3O2 DMNVP8Q IC InChI=1S/C23H19N3O2/c27-22-19(16-11-24-18-9-2-1-7-14(16)18)20(23(28)25-22)17-12-26-10-4-6-13-5-3-8-15(17)21(13)26/h1-3,5,7-9,11-12,19-20,24H,4,6,10H2,(H,25,27,28)/t19-,20-/m0/s1 DMNVP8Q CS C1CC2=C3C(=CC=C2)C(=CN3C1)[C@H]4[C@@H](C(=O)NC4=O)C5=CNC6=CC=CC=C65 DMNVP8Q IK UCEQXRCJXIVODC-PMACEKPBSA-N DMNVP8Q IU (3R,4R)-3-(1-azatricyclo[6.3.1.04,12]dodeca-2,4,6,8(12)-tetraen-3-yl)-4-(1H-indol-3-yl)pyrrolidine-2,5-dione DMNVP8Q CA CAS 905854-02-6 DMNVP8Q CB CHEBI:91398 DMNVP8Q DE Solid tumour/cancer; Hepatocellular carcinoma DMYLT67 ID DMYLT67 DMYLT67 DN TKI258 DMYLT67 HS Phase 3 DMYLT67 SN Dovitinib; 405169-16-6; CHIR-258; TKI-258; Chir 258; 4-Amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one; CHIR258; Dovitinib (TKI-258, CHIR-258); UNII-I35H55G906; CHEMBL522892; 804551-71-1; I35H55G906; TKI 258; 1027263-12-2; (3Z)-4-Amino-5-fluoro-3-[5-(4-methyl-1-piperazinyl)-1,3-dihydro-2H-benzimidazol-2-ylidene]-2(3H)-quinolinone; C21H21FN6O; 4-Amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one DMYLT67 CP Novartis & Chiron Corp DMYLT67 TC Anticancer Agents DMYLT67 DT Small molecular drug DMYLT67 PC 135611162 DMYLT67 MW 500.5 DMYLT67 FM C24H29FN6O5 DMYLT67 IC InChI=1S/C21H21FN6O.C3H6O3.H2O/c1-27-7-9-28(10-8-27)12-5-6-14-16(11-12)25-20(24-14)18-19(23)17-13(22)3-2-4-15(17)26-21(18)29;1-2(4)3(5)6;/h2-6,11H,7-10H2,1H3,(H,24,25)(H3,23,26,29);2,4H,1H3,(H,5,6);1H2 DMYLT67 CS CC(C(=O)O)O.CN1CCN(CC1)C2=CC3=C(C=C2)N=C(N3)C4=C(C5=C(C=CC=C5F)NC4=O)N.O DMYLT67 IK QDPVYZNVVQQULH-UHFFFAOYSA-N DMYLT67 IU 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one;2-hydroxypropanoic acid;hydrate DMYLT67 CA CAS 915769-50-5 DMYLT67 DE Endometrial cancer; Renal cell carcinoma; Triple negative breast cancer DMO1234 ID DMO1234 DMO1234 DN TNX-102 DMO1234 HS Phase 3 DMO1234 SN Cyclobenzaprine very low dose DMO1234 CP TONIX Pharmaceuticals DMO1234 DT Small molecular drug DMO1234 PC 22576 DMO1234 MW 311.8 DMO1234 FM C20H22ClN DMO1234 IC InChI=1S/C20H21N.ClH/c1-21(2)15-7-12-20-18-10-5-3-8-16(18)13-14-17-9-4-6-11-19(17)20;/h3-6,8-14H,7,15H2,1-2H3;1H DMO1234 CS CN(C)CCC=C1C2=CC=CC=C2C=CC3=CC=CC=C31.Cl DMO1234 IK VXEAYBOGHINOKW-UHFFFAOYSA-N DMO1234 IU N,N-dimethyl-3-(2-tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,9,11,13-heptaenylidene)propan-1-amine;hydrochloride DMO1234 CA CAS 6202-23-9 DMO1234 CB CHEBI:3997 DMO1234 DE Fibromyalgia; Post-traumatic stress disorder DMYA41S ID DMYA41S DMYA41S DN TNX-355 DMYA41S HS Phase 3 DMYA41S CP Tanox; Biogen DMYA41S DE Human immunodeficiency virus infection DMFDNT0 ID DMFDNT0 DMFDNT0 DN Tocilizumab DMFDNT0 HS Phase 3 DMFDNT0 SN Actemra; Actemra (TN); Tocilizumab (USAN/INN); Tocilizumab (genetical recombination); Tocilizumab (genetical recombination) (JAN); humanized IgG1 monoclonal antibody DMFDNT0 CP Roche; Genentech DMFDNT0 TC Antiviral Agents DMFDNT0 DT Monoclonal antibody DMFDNT0 DE Juvenile idiopathic arthritis; Rheumatoid arthritis; Systemic sclerosis; Coronavirus Disease 2019 (COVID-19) DMATC14 ID DMATC14 DMATC14 DN Tozadenant DMATC14 HS Phase 3 DMATC14 SN Ro-2; SYN-115; A2a receptor antagonists (Parkinson's disease), Synosia/Roche; Adenosine A2a receptor antagonists (Parkinson's disease), Synosia/Roche DMATC14 CP Biotie therapies DMATC14 DT Small molecular drug DMATC14 PC 11618368 DMATC14 MW 406.5 DMATC14 FM C19H26N4O4S DMATC14 IC InChI=1S/C19H26N4O4S/c1-19(25)5-7-23(8-6-19)18(24)21-17-20-15-14(26-2)4-3-13(16(15)28-17)22-9-11-27-12-10-22/h3-4,25H,5-12H2,1-2H3,(H,20,21,24) DMATC14 CS CC1(CCN(CC1)C(=O)NC2=NC3=C(C=CC(=C3S2)N4CCOCC4)OC)O DMATC14 IK XNBRWUQWSKXMPW-UHFFFAOYSA-N DMATC14 IU 4-hydroxy-N-(4-methoxy-7-morpholin-4-yl-1,3-benzothiazol-2-yl)-4-methylpiperidine-1-carboxamide DMATC14 CA CAS 870070-55-6 DMATC14 DE Parkinson disease DMLKI2B ID DMLKI2B DMLKI2B DN Trafermin DMLKI2B HS Phase 3 DMLKI2B SN Fiblast; Fiblast (TN); Trafermin (genetical recombination); Trafermin (USAN/INN); Trafermin (genetical recombination) (JAN) DMLKI2B CP Johnson & Johnson Licensee; Kaken Pharmaceutical DMLKI2B DE Periodontitis DM6ENSJ ID DM6ENSJ DM6ENSJ DN Tralokinumab DM6ENSJ HS Phase 3 DM6ENSJ SN CAT-354; Anti-IL 13 monoclonal antibody, CAT/AstraZeneca; IL-13 antagonist, CAT/AstraZeneca; Interleukin-13 antagonist, CAT/AstraZeneca DM6ENSJ CP Ception Therapeutics DM6ENSJ DT Monoclonal antibody DM6ENSJ DE Asthma; Ulcerative colitis; Atopic dermatitis DM7BSRH ID DM7BSRH DM7BSRH DN Tramiprosate DM7BSRH HS Phase 3 DM7BSRH SN Alzhemed; Cerebril; Homotaurine; Vivimind; LU-02659; NC-531; NC-758; Tramiprosate (stroke), Neurochem; Tramiprosate (Alzheimer's disease), Neurochem; 3APS DM7BSRH CP Neurochem DM7BSRH DT Small molecular drug DM7BSRH PC 1646 DM7BSRH MW 139.18 DM7BSRH FM C3H9NO3S DM7BSRH IC InChI=1S/C3H9NO3S/c4-2-1-3-8(5,6)7/h1-4H2,(H,5,6,7) DM7BSRH CS C(CN)CS(=O)(=O)O DM7BSRH IK SNKZJIOFVMKAOJ-UHFFFAOYSA-N DM7BSRH IU 3-aminopropane-1-sulfonic acid DM7BSRH CA CAS 3687-18-1 DM7BSRH CB CHEBI:1457 DM7BSRH DE Alzheimer disease DMLB3I4 ID DMLB3I4 DMLB3I4 DN Trastuzumab-DM1 DMLB3I4 HS Phase 3 DMLB3I4 CP Genentech DMLB3I4 DT Antibody drug conjugate DMLB3I4 DE Breast cancer DM1874J ID DM1874J DM1874J DN TRC105 DM1874J HS Phase 3 DM1874J DT Monoclonal antibody DM1874J DE Breast cancer; Lung cancer; Ovarian cancer; Macular degeneration; Peritoneal cancer; Fallopian tube cancer; Soft tissue sarcoma; Gestational trophoblastic neoplasia; Hemangiosarcoma; Hepatocellular carcinoma; Renal cell carcinoma; Recurrent glioblastoma; Angiosarcoma DMOG2X1 ID DMOG2X1 DMOG2X1 DN Trebananib DMOG2X1 HS Phase 3 DMOG2X1 CP Amgen DMOG2X1 DT Recombinant protein DMOG2X1 DE Solid tumour/cancer; Renal cell carcinoma; Ovarian cancer DMOQ9H1 ID DMOQ9H1 DMOQ9H1 DN Tremelimumab DMOQ9H1 HS Phase 3 DMOQ9H1 CP AstraZeneca DMOQ9H1 DT Monoclonal antibody DMOQ9H1 DE Solid tumour/cancer; Malignant mesothelioma DMS57DJ ID DMS57DJ DMS57DJ DN Trimegestone/ethinyl estradiol DMS57DJ HS Phase 3 DMS57DJ CP Wyeth DMS57DJ DE Contraception DMCMDVR ID DMCMDVR DMCMDVR DN Triptolide DMCMDVR HS Phase 3 DMCMDVR SN triptolide; 38748-32-2; Triptolid; PG490; UNII-19ALD1S53J; NSC 163062; CHEMBL463763; CHEBI:9747; 19ALD1S53J; C20H24O6; PG-490; CPD000466307; Triptolide, Tripterygium wilfordii; (-)-Triptolide; PG 490; Trisoxireno(4b,5:6,7:8a,9)phenanthro(1,2-c)furan-1(3H)-one, 3b,4,4a,6,6a,7a,7b,8b,9,10-decahydro-6-hydroxy-8b-methyl-6a-(1-methylethyl)-, (3bS,4aS,5aS,6R,6aR,7aS,7bS,8aS,8bS)-; SMR000466307; NSC163062; Triptolide, 1; Triptolide(PG490)/; AC1Q6AXN; BSPBio_001595; KBioGR_000315; KBioSS_000315 DMCMDVR DT Small molecular drug DMCMDVR PC 107985 DMCMDVR MW 360.4 DMCMDVR FM C20H24O6 DMCMDVR IC InChI=1S/C20H24O6/c1-8(2)18-13(25-18)14-20(26-14)17(3)5-4-9-10(7-23-15(9)21)11(17)6-12-19(20,24-12)16(18)22/h8,11-14,16,22H,4-7H2,1-3H3/t11-,12-,13-,14-,16+,17-,18-,19+,20+/m0/s1 DMCMDVR CS CC(C)[C@@]12[C@@H](O1)[C@H]3[C@@]4(O3)[C@]5(CCC6=C([C@@H]5C[C@H]7[C@]4([C@@H]2O)O7)COC6=O)C DMCMDVR IK DFBIRQPKNDILPW-CIVMWXNOSA-N DMCMDVR IU (1S,2S,4S,5S,7R,8R,9S,11S,13S)-8-hydroxy-1-methyl-7-propan-2-yl-3,6,10,16-tetraoxaheptacyclo[11.7.0.02,4.02,9.05,7.09,11.014,18]icos-14(18)-en-17-one DMCMDVR CA CAS 38748-32-2 DMCMDVR CB CHEBI:9747 DMCMDVR DE Autoimmune diabetes DMHDNK0 ID DMHDNK0 DMHDNK0 DN TroVax DMHDNK0 HS Phase 3 DMHDNK0 SN TroVax (TN) DMHDNK0 CP Oxford BioMedica DMHDNK0 DT Vaccine DMHDNK0 DE Prostate cancer DM0QNF4 ID DM0QNF4 DM0QNF4 DN TRx0237 DM0QNF4 HS Phase 3 DM0QNF4 SN 951131-15-0; UNII-E79ZM68IOZ; E79ZM68IOZ; Leucomethylene Blue dihydrobromide; TRX0237 dihydrobromide; TRX 0237 dihydrobromide; TRX-0237 dihydrobromide; TRx0237(LMTX); TRX-0237 2HBr; Leukomethylene Blue dihydrobromide; Hydromethylthionine HBr(TRX0237); BCP24159; EX-A4299; Reduced methylene Blue dihydrobromide; N3,N3,N7,N7-Tetramethyl-10H-phenothiazine-3,7-diamine dihydrobromide; Leucomethylene Blue 2HBr;TRX0237 dihydrobromide;TRX 0237 dihydrobromide;TRX-0237 dihydrobromide DM0QNF4 CP TauRx Therapeutics DM0QNF4 DT Small molecular drug DM0QNF4 PC 23651551 DM0QNF4 MW 447.2 DM0QNF4 FM C16H21Br2N3S DM0QNF4 IC InChI=1S/C16H19N3S.2BrH/c1-18(2)11-5-7-13-15(9-11)20-16-10-12(19(3)4)6-8-14(16)17-13;;/h5-10,17H,1-4H3;2*1H DM0QNF4 CS CN(C)C1=CC2=C(C=C1)NC3=C(S2)C=C(C=C3)N(C)C.Br.Br DM0QNF4 IK JAUPSVVTGFBHTN-UHFFFAOYSA-N DM0QNF4 IU 3-N,3-N,7-N,7-N-tetramethyl-10H-phenothiazine-3,7-diamine;dihydrobromide DM0QNF4 CA CAS 951131-15-0 DM0QNF4 DE Alzheimer disease DMAFPHB ID DMAFPHB DMAFPHB DN TRYPTAMINE DMAFPHB HS Phase 3 DMAFPHB SN tryptamine; 61-54-1; 2-(1H-Indol-3-yl)ethanamine; 3-(2-aminoethyl)indole; 1H-Indole-3-ethanamine; 2-(3-Indolyl)ethylamine; Indol-3-ethylamine; Indole, 3-(2-aminoethyl)-; 2-(Indol-3-yl)ethylamine; 2-(1H-Indol-3-Yl)Ethan-1-Amine; 3-Indoleethylamine; Tryptamin; 2-(1H-indol-3-yl)ethylamine; 2-Indol-3-ylethylamine; 2-(1H-INDOL-3-YL)-ETHYLAMINE; UNII-422ZU9N5TV; (Amino-2 ethyl)-3 indole; (Amino-2 ethyl)-3 indole [French]; Tryptamine, 98%; BRN 0125513; EINECS 200-510-5; CHEMBL6640; 422ZU9N5TV; CHEBI:16765; APJYDQYYACXCRM-UHFFFAOYSA-N DMAFPHB DT Small molecular drug DMAFPHB PC 1150 DMAFPHB MW 160.22 DMAFPHB FM C10H12N2 DMAFPHB IC InChI=1S/C10H12N2/c11-6-5-8-7-12-10-4-2-1-3-9(8)10/h1-4,7,12H,5-6,11H2 DMAFPHB CS C1=CC=C2C(=C1)C(=CN2)CCN DMAFPHB IK APJYDQYYACXCRM-UHFFFAOYSA-N DMAFPHB IU 2-(1H-indol-3-yl)ethanamine DMAFPHB CA CAS 61-54-1 DMAFPHB CB CHEBI:16765 DMPBJ8W ID DMPBJ8W DMPBJ8W DN Turoctocog alfa DMPBJ8W HS Phase 3 DMPBJ8W SN NN7008 DMPBJ8W CP Novo Nordisk DMPBJ8W DE Haemophilia A DM71ZL6 ID DM71ZL6 DM71ZL6 DN TZTX-001 DM71ZL6 HS Phase 3 DM71ZL6 SN Teverelix LA; TX 12-001-HR DM71ZL6 CP Ardana Bioscience DM71ZL6 DE Endometriosis DMN72OM ID DMN72OM DMN72OM DN U300 DMN72OM HS Phase 3 DMN72OM SN Methyl 3,5-dinitrobenzoate; 2702-58-1; Benzoic acid, 3,5-dinitro-, methyl ester; POGCCFLNFPIIGW-UHFFFAOYSA-N; 3,5-dinitro-benzoic acid methyl ester; Methyl 3,5-Dinitrobenzoate,99%; Methyl-3,5-dinitrobenzoate; U300; ACMC-1CR6Q; AC1L5B8W; AC1Q5AI0; KSC494Q3H; SCHEMBL418416; Jsp005266; CHEMBL2252127; CTK3J4833; KS-00000ZZJ; NSC7317; MolPort-001-012-121; Methyl 3,5-dinitrobenzoate, 99%; ALBB-024845; NSC-7317; ZINC1683476; METHYL-3,5-DINITRO BENZOATE; BBL000013; ANW-44565; SBB068882; MFCD00017016; STK386186; 3,5-Dinitrobenzoic acid methyl e DMN72OM CP Sanofi us DMN72OM DT Small molecular drug DMN72OM PC 222067 DMN72OM MW 226.14 DMN72OM FM C8H6N2O6 DMN72OM IC InChI=1S/C8H6N2O6/c1-16-8(11)5-2-6(9(12)13)4-7(3-5)10(14)15/h2-4H,1H3 DMN72OM CS COC(=O)C1=CC(=CC(=C1)[N+](=O)[O-])[N+](=O)[O-] DMN72OM IK POGCCFLNFPIIGW-UHFFFAOYSA-N DMN72OM IU methyl 3,5-dinitrobenzoate DMN72OM CA CAS 2702-58-1 DMN72OM DE Type-2 diabetes DMHTY9W ID DMHTY9W DMHTY9W DN Ublituximab DMHTY9W HS Phase 3 DMHTY9W SN TG-1101 DMHTY9W CP TG Therapeutics DMHTY9W DT Antibody DMHTY9W DE Chronic lymphocytic leukaemia; Lymphoma; Multiple sclerosis; Nodal marginal zone lymphoma DMKUOVP ID DMKUOVP DMKUOVP DN Ublituximab + umbralisib DMKUOVP HS Phase 3 DMKUOVP CP TG Therapeutics New York, NY DMKUOVP DE Chronic lymphocytic leukaemia; Non-hodgkin lymphoma DM90AG2 ID DM90AG2 DM90AG2 DN Ularitide DM90AG2 HS Phase 3 DM90AG2 SN Urodilatin; 115966-23-9; Atriopeptin (95-126); Human urodilatin; Urodilatin human; Ularitide [INN]; Urodilatin ularitide; Anf (95-126); Anp (95-126); ANP 95-126; Atrial natriuretic peptide (95-126); CHEMBL2103920; Urodilatin human, > AKOS030213250; DB05034; CDD 95-126; LS-187531; LS-186876; Thr-Ala-Pro-Arg-Atrial Natriuretic Peptide; atrial natriuretic factor prohormone (95-126) DM90AG2 CP EKR Therapeutics DM90AG2 DT Small molecular drug DM90AG2 PC 16132416 DM90AG2 MW 3505.9 DM90AG2 FM C145H234N52O44S3 DM90AG2 IC InChI=1S/C145H234N52O44S3/c1-11-72(6)112-137(238)171-60-106(208)172-73(7)113(214)177-86(40-41-103(146)205)122(223)190-95(63-198)116(217)170-61-108(210)175-88(51-70(2)3)114(215)169-62-109(211)176-100(133(234)187-92(56-104(147)206)127(228)193-97(65-200)130(231)186-91(54-77-27-16-13-17-28-77)126(227)180-82(31-20-45-163-142(153)154)119(220)189-94(139(240)241)55-78-36-38-79(204)39-37-78)68-243-244-69-101(134(235)185-90(53-76-25-14-12-15-26-76)115(216)168-58-105(207)167-59-107(209)174-80(29-18-43-161-140(149)150)117(218)182-87(42-50-242-10)123(224)188-93(57-110(212)213)128(229)181-85(124(225)196-112)34-23-48-166-145(159)160)195-132(233)99(67-202)194-131(232)98(66-201)192-120(221)83(32-21-46-164-143(155)156)178-118(219)81(30-19-44-162-141(151)152)179-125(226)89(52-71(4)5)184-129(230)96(64-199)191-121(222)84(33-22-47-165-144(157)158)183-135(236)102-35-24-49-197(102)138(239)74(8)173-136(237)111(148)75(9)203/h12-17,25-28,36-39,70-75,80-102,111-112,198-204H,11,18-24,29-35,40-69,148H2,1-10H3,(H2,146,205)(H2,147,206)(H,167,207)(H,168,216)(H,169,215)(H,170,217)(H,171,238)(H,172,208)(H,173,237)(H,174,209)(H,175,210)(H,176,211)(H,177,214)(H,178,219)(H,179,226)(H,180,227)(H,181,229)(H,182,218)(H,183,236)(H,184,230)(H,185,235)(H,186,231)(H,187,234)(H,188,224)(H,189,220)(H,190,223)(H,191,222)(H,192,221)(H,193,228)(H,194,232)(H,195,233)(H,196,225)(H,212,213)(H,240,241)(H4,149,150,161)(H4,151,152,162)(H4,153,154,163)(H4,155,156,164)(H4,157,158,165)(H4,159,160,166)/t72-,73-,74-,75+,80-,81-,82-,83-,84-,85-,86-,87-,88-,89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,111-,112-/m0/s1 DM90AG2 CS CC[C@H](C)[C@H]1C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)NCC(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CCCNC(=N)N)CC(=O)O)CCSC)CCCNC(=N)N)CC2=CC=CC=C2)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]3CCCN3C(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)O)N)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC4=CC=CC=C4)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC5=CC=C(C=C5)O)C(=O)O)CC(C)C)CO)CCC(=O)N)C DM90AG2 IK IUCCYQIEZNQWRS-DWWHXVEHSA-N DM90AG2 IU (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(4R,10S,16S,19S,22S,28S,31S,34S,37S,40S,49S,52R)-52-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S,3R)-2-amino-3-hydroxybutanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-19-(3-amino-3-oxopropyl)-49-benzyl-28-[(2S)-butan-2-yl]-31,40-bis(3-carbamimidamidopropyl)-34-(carboxymethyl)-16-(hydroxymethyl)-22-methyl-10-(2-methylpropyl)-37-(2-methylsulfanylethyl)-6,9,12,15,18,21,24,27,30,33,36,39,42,45,48,51-hexadecaoxo-1,2-dithia-5,8,11,14,17,20,23,26,29,32,35,38,41,44,47,50-hexadecazacyclotripentacontane-4-carbonyl]amino]-4-oxobutanoyl]amino]-3-hydroxypropanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(4-hydroxyphenyl)propanoic acid DM90AG2 CA CAS 118812-69-4 DM90AG2 DE Heart failure; Acute heart failure DMIQCFG ID DMIQCFG DMIQCFG DN Ulinastatin DMIQCFG HS Phase 3 DMIQCFG SN Urinastatin; Urinary trypsin inhibitor; Trypsin inhibitor MR-20; MR-20 (Magnetic powder); Uti(68); Acid-stable protease inhibitor; Urinary trypsin inhibitor (68); 2,4-Dioxaspiro[5.5]undec-8-ene, 3-(2-furanyl)-; 80449-31-6; Urinary trypsin inhibitor-like inhibitor (43); Trypsin inhibitor (human urine urinastatin protein moiety); 80449-32-7; 2,4-Dioxaspiro(5.5)undec-8-ene, 3-(2-furanyl)-; Miraclid; AC1L2Y1N; UTI68; 3-(2-Furanyl)-2,4-dioxaspiro(5.5)undec-8-ene; AC1Q70L4; AKOS025401879; CS-7119; MR 20 (magnetic p DMIQCFG DT Small molecular drug DMIQCFG PC 105102 DMIQCFG MW 220.26 DMIQCFG FM C13H16O3 DMIQCFG IC InChI=1S/C13H16O3/c1-2-6-13(7-3-1)9-15-12(16-10-13)11-5-4-8-14-11/h1-2,4-5,8,12H,3,6-7,9-10H2 DMIQCFG CS C1CC2(CC=C1)COC(OC2)C3=CC=CO3 DMIQCFG IK ODVKSTFPQDVPJZ-UHFFFAOYSA-N DMIQCFG IU 3-(furan-2-yl)-2,4-dioxaspiro[5.5]undec-9-ene DMIQCFG CA CAS 80449-32-7 DMIQCFG DE Premature labour DM6PMNR ID DM6PMNR DM6PMNR DN Ulocuplumab DM6PMNR HS Phase 3 DM6PMNR CP Bristol-myers squibb DM6PMNR DT Monoclonal antibody DM6PMNR DE Haematological malignancy; Multiple myeloma DMCWM03 ID DMCWM03 DMCWM03 DN Unfractionated heparin DMCWM03 HS Phase 3 DMCWM03 SN Elaprin; UFH (solid oral), Emisphere; Unfractionated heparin (solid oral, eligen); SNAC/heparin capsule (solid oral), Emisphere; SNAD/heparin tablet (solid oral), Emisphere; Unfractionated heparin (solid oral, eligen), Emisphere DMCWM03 CP Emisphere Technologies Inc DMCWM03 DE Thrombosis DM0DIEZ ID DM0DIEZ DM0DIEZ DN UNI-rhIL-11 DM0DIEZ HS Phase 3 DM0DIEZ SN Recombinant human interleukin 11 (thrombocytopenia), Uni-Bio Science Group; RhIL-11 (thrombocytopenia), Uni-Bio Science Group DM0DIEZ CP Uni-Bio Science Group Limited DM0DIEZ DE Thrombocytopenia DMM2OZH ID DMM2OZH DMM2OZH DN Ushercell DMM2OZH HS Phase 3 DMM2OZH SN Cellulose sulfate gel, Polydex DMM2OZH CP Polydex Pharmaceuticals Ltd DMM2OZH DT Small molecular drug DMM2OZH PC 154413 DMM2OZH MW 457.6 DMM2OZH FM C30H35NO3 DMM2OZH IC InChI=1S/C30H35NO3/c1-30(2)29(23-9-5-4-6-10-23)28(26-16-15-25(32-3)21-27(26)34-30)22-11-13-24(14-12-22)33-20-19-31-17-7-8-18-31/h4-6,9-16,21,28-29H,7-8,17-20H2,1-3H3/t28-,29+/m0/s1 DMM2OZH CS CC1([C@@H]([C@H](C2=C(O1)C=C(C=C2)OC)C3=CC=C(C=C3)OCCN4CCCC4)C5=CC=CC=C5)C DMM2OZH IK XZEUAXYWNKYKPL-URLMMPGGSA-N DMM2OZH IU 1-[2-[4-[(3S,4S)-7-methoxy-2,2-dimethyl-3-phenyl-3,4-dihydrochromen-4-yl]phenoxy]ethyl]pyrrolidine DMM2OZH CA CAS 31477-60-8 DMM2OZH DE Bacterial infection DMD2O0L ID DMD2O0L DMD2O0L DN UX-001 DMD2O0L HS Phase 3 DMD2O0L CP Ultragenyx Pharmaceutical DMD2O0L DT Small molecular drug DMD2O0L PC 656387 DMD2O0L MW 309.27 DMD2O0L FM C11H19NO9 DMD2O0L IC InChI=1S/C11H19NO9/c1-4(14)12-7-5(15)2-11(20,10(18)19)21-9(7)8(17)6(16)3-13/h5-9,13,15-17,20H,2-3H2,1H3,(H,12,14)(H,18,19)/t5-,6-,7+,8-,9+,11+/m0/s1 DMD2O0L CS CC(=O)N[C@@H]1[C@H](C[C@@](O[C@H]1[C@H]([C@H](CO)O)O)(C(=O)O)O)O DMD2O0L IK SQVRNKJHWKZAKO-USOVHJGOSA-N DMD2O0L IU (2R,4S,5R,6R)-5-acetamido-2,4-dihydroxy-6-[(1S,2S)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid DMD2O0L DE Myopathy; Hereditary inclusion body myositis DMDCFXJ ID DMDCFXJ DMDCFXJ DN Vaborbactam DMDCFXJ HS Phase 3 DMDCFXJ SN RPX-7009; 1360457-46-0; RPX7009; UNII-1C75676F8V; 2-((3R,6S)-2-hydroxy-3-(2-(thiophen-2-yl)acetamido)-1,2-oxaborinan-6-yl)acetic acid; CHEMBL3317857; 1C75676F8V; 2-[(3R,6S)-2-hydroxy-3-[(2-thiophen-2-ylacetyl)amino]oxaborinan-6-yl]acetic acid; Vaborbactam [INN]; RPX 7009; Vaborbactam. RPX7009; Vaborbactam (USAN/INN); Vaborbactam [USAN:INN]; SCHEMBL620289; GTPL10871; Vabomere (vaborbactam + meropenem); EX-A2589; BDBM50089084; MFCD28502176; AKOS032961376; CS-6445; DB12107; SB17184; 1,2-Oxaborinane-6-acetic acid, 2-hydroxy-3-((2-(2-thienyl)acetyl)amino)-, (3R,6S)-; compound 9f [PMID: 25782055]; NCGC00510003-01; HY-19930; 2-hydroxy-3-((2-(2-thienyl)acetyl)amino)-; D10998; Q27252228; {(3R,6S)-2-hydroxy-3-[(thiophen-2-ylacetyl)amino]-1,2-oxaborinan-6-yl}acetic acid; 2-((3R,6S)-2-hydroxy-3-(2-(thiophen-2-yl)acetamido)-1,2-oxaborinan-6-yl)acetic acid; 2-[(3R,6S)-2-hydroxy-3-[(2-thiophen-2-ylacetyl)amino]oxaborinan-6-yl]acetic acid; 1,2-Oxaborinane-6-acetic acid DMDCFXJ DT Small molecular drug DMDCFXJ PC 56649692 DMDCFXJ MW 297.14 DMDCFXJ FM C12H16BNO5S DMDCFXJ IC InChI=1S/C12H16BNO5S/c15-11(7-9-2-1-5-20-9)14-10-4-3-8(6-12(16)17)19-13(10)18/h1-2,5,8,10,18H,3-4,6-7H2,(H,14,15)(H,16,17)/t8-,10-/m0/s1 DMDCFXJ CS B1([C@H](CC[C@H](O1)CC(=O)O)NC(=O)CC2=CC=CS2)O DMDCFXJ IK IOOWNWLVCOUUEX-WPRPVWTQSA-N DMDCFXJ IU 2-[(3R,6S)-2-hydroxy-3-[(2-thiophen-2-ylacetyl)amino]oxaborinan-6-yl]acetic acid DMDCFXJ CA CAS 1360457-46-0 DMDCFXJ DE Urinary tract infection DM9LH10 ID DM9LH10 DM9LH10 DN Vadastuximab talirine DM9LH10 HS Phase 3 DM9LH10 SN vadastuximab talirine; Vadastuximab talirine [INN]; Vadastuximab talirine [USAN]; Vadastuximab talirine [WHO-DD]; UNII-T13V17U431; T13V17U431; UNII-X1TW58ZV0U component BNJNAEJASPUJTO-DUOHOMBCSA-N; 1436390-64-5 DM9LH10 CP Seattle Genetics Bothell, WA DM9LH10 PC 122706909 DM9LH10 MW 1210.4 DM9LH10 FM C63H71N9O14S DM9LH10 IC InChI=1S/C63H71N9O14S/c1-35(2)57(69-55(73)11-8-7-9-20-70-56(74)29-54(62(70)79)87-34-47(64)63(80)81)59(76)67-36(3)58(75)68-41-16-12-37(13-17-41)39-23-42-30-65-48-27-52(50(83-5)25-45(48)60(77)71(42)32-39)85-21-10-22-86-53-28-49-46(26-51(53)84-6)61(78)72-33-40(24-43(72)31-66-49)38-14-18-44(82-4)19-15-38/h12-19,25-28,30-33,35-36,42-43,47,54,57H,7-11,20-24,29,34,64H2,1-6H3,(H,67,76)(H,68,75)(H,69,73)(H,80,81)/t36-,42-,43-,47-,54+,57-/m0/s1 DM9LH10 CS C[C@@H](C(=O)NC1=CC=C(C=C1)C2=CN3[C@@H](C2)C=NC4=CC(=C(C=C4C3=O)OC)OCCCOC5=C(C=C6C(=C5)N=C[C@@H]7CC(=CN7C6=O)C8=CC=C(C=C8)OC)OC)NC(=O)[C@H](C(C)C)NC(=O)CCCCCN9C(=O)C[C@H](C9=O)SC[C@@H](C(=O)O)N DM9LH10 IK BNJNAEJASPUJTO-DUOHOMBCSA-N DM9LH10 IU (2R)-3-[(3R)-1-[6-[[(2S)-1-[[(2S)-1-[4-[(6aS)-3-[3-[[(6aS)-2-methoxy-8-(4-methoxyphenyl)-11-oxo-6a,7-dihydropyrrolo[2,1-c][1,4]benzodiazepin-3-yl]oxy]propoxy]-2-methoxy-11-oxo-6a,7-dihydropyrrolo[2,1-c][1,4]benzodiazepin-8-yl]anilino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-6-oxohexyl]-2,5-dioxopyrrolidin-3-yl]sulfanyl-2-aminopropanoic acid DM9LH10 CA CAS 1436390-64-5 DM9LH10 DE Acute myeloid leukaemia; Myelodysplastic syndrome DM9J5Q4 ID DM9J5Q4 DM9J5Q4 DN VAL-083 DM9J5Q4 HS Phase 3 DM9J5Q4 SN VAL-083; Dianhydrogalactitol; 23261-20-3; UNII-4S465RYF7M; 1,2:5,6-DIANHYDROGALACTITOL; Dulcitoldiepoxide; 4S465RYF7M; Dianhydrogalactitol [USAN:INN]; SCHEMBL4306431; Dianhydrogalactitol (USAN/INN); CHEMBL3137322; AAFJXZWCNVJTMK-GUCUJZIJSA-N; ZINC4963497; CS-1358; DB12873; NSC-1323313; HY-16513; BC657197; D10623; W-5268; J-015059; 457899-38-6 DM9J5Q4 CP Del Mar Pharmaceuticals DM9J5Q4 DT Small molecular drug DM9J5Q4 PC 15942827 DM9J5Q4 MW 146.14 DM9J5Q4 FM C6H10O4 DM9J5Q4 IC InChI=1S/C6H10O4/c7-5(3-1-9-3)6(8)4-2-10-4/h3-8H,1-2H2/t3-,4+,5+,6- DM9J5Q4 CS C1[C@@H](O1)[C@@H]([C@@H]([C@@H]2CO2)O)O DM9J5Q4 IK AAFJXZWCNVJTMK-GUCUJZIJSA-N DM9J5Q4 IU (1S,2R)-1-[(2S)-oxiran-2-yl]-2-[(2R)-oxiran-2-yl]ethane-1,2-diol DM9J5Q4 CA CAS 23261-20-3 DM9J5Q4 DE Grade IV malignant glioma; Acute myeloid leukaemia; Recurrent glioblastoma; Recurring respiratory infection DMMKE2H ID DMMKE2H DMMKE2H DN Valoctocogene roxaparvovec DMMKE2H HS Phase 3 DMMKE2H SN BMN 270 DMMKE2H CP BioMarin Pharmaceutical DMMKE2H DT Gene therapy DMMKE2H DE Haemophilia A DMQL0KF ID DMQL0KF DMQL0KF DN Vanadate DMQL0KF HS Phase 3 DMQL0KF SN Ammonium metavanadate; 7803-55-6; Ammonium vanadate(V); UNII-FL85PX638G; FL85PX638G; Ammonium metavanadate, ACS reagent; Ammoniummetavanadate; Ammonium metavanadate, 99.5%, for analysis; Ammonium metavanadate, 99.996%, (trace metal basis); Ammonium meta-Vanadate; Vanadate (VO31-), ammonium (1:1); AC1LANGP; ammonium vanadiumoylolate; H4NO3V; EC 232-261-3; azanium oxido(dioxo)vanadium; KS-00000WUM; UNTBPXHCXVWYOI-UHFFFAOYSA-O; MolPort-044-723-987; MolPort-003-925-733; MFCD00011430; AKOS030228605; AMMONIUM VANADATE (META), NH4VO3 DMQL0KF DT Small molecular drug DMQL0KF PC 516859 DMQL0KF MW 116.978 DMQL0KF FM H4NO3V DMQL0KF IC InChI=1S/H3N.3O.V/h1H3;;;;/q;;;-1;/p+1 DMQL0KF CS [NH4+].[O-][V](=O)=O DMQL0KF IK UNTBPXHCXVWYOI-UHFFFAOYSA-O DMQL0KF IU azanium;oxido(dioxo)vanadium DMQL0KF CA CAS 7803-55-6 DMQL0KF DE Plaque psoriasis; Psoriatic arthritis; Rheumatoid arthritis DMLIMEA ID DMLIMEA DMLIMEA DN Varespladib methyl DMLIMEA HS Phase 3 DMLIMEA SN A-002; LY-333013; S-3013; Varespladib methyl (oral formulation, coronary artery disease); PLA2 inhibitors (inflammation), Lilly/Shionogi; Varespladib (oral formulation, coronary artery disease), Anthera; Varespladib methyl (oral formulation, coronary artery disease), Anthera DMLIMEA CP Shionogi & Co Ltd DMLIMEA DT Small molecular drug DMLIMEA PC 9886917 DMLIMEA MW 394.4 DMLIMEA FM C22H22N2O5 DMLIMEA IC InChI=1S/C22H22N2O5/c1-3-15-20(21(26)22(23)27)19-16(24(15)12-14-8-5-4-6-9-14)10-7-11-17(19)29-13-18(25)28-2/h4-11H,3,12-13H2,1-2H3,(H2,23,27) DMLIMEA CS CCC1=C(C2=C(N1CC3=CC=CC=C3)C=CC=C2OCC(=O)OC)C(=O)C(=O)N DMLIMEA IK VJYDOJXJUCJUHL-UHFFFAOYSA-N DMLIMEA IU methyl 2-(1-benzyl-2-ethyl-3-oxamoylindol-4-yl)oxyacetate DMLIMEA CA CAS 172733-08-3 DMLIMEA DE Rheumatoid arthritis DMANKTO ID DMANKTO DMANKTO DN Vatreptacog alfa (activated) DMANKTO HS Phase 3 DMANKTO SN NN-1731; NNC-0078-0000-0007; Recombinant factor VIIa analog with mutations V158D/E296V/M298Q (bleeding disorders), Novo Nordisk DMANKTO CP Novo Nordisk A/S DMANKTO DE Bleeding disorder DMX04CA ID DMX04CA DMX04CA DN VB-111 DMX04CA HS Phase 3 DMX04CA CP VBL Therapeutics DMX04CA DE Glioblastoma multiforme; Malignant glioma; Ovarian cancer; Recurrent glioblastoma DMXHI89 ID DMXHI89 DMXHI89 DN Velac Gel DMXHI89 HS Phase 3 DMXHI89 SN Clindamycin/tretinoin DMXHI89 CP Stiefel Laboratories DMXHI89 DE Acne vulgaris DMJBU9V ID DMJBU9V DMJBU9V DN Velimogene aliplasmid DMJBU9V HS Phase 3 DMJBU9V SN Allovectin (TN) DMJBU9V CP Vical DMJBU9V DE Melanoma DM6L5ZQ ID DM6L5ZQ DM6L5ZQ DN Vercirnon DM6L5ZQ HS Phase 3 DM6L5ZQ SN 1605786 DM6L5ZQ CP GlaxoSmithKline DM6L5ZQ DT Small molecular drug DM6L5ZQ PC 10343454 DM6L5ZQ MW 444.9 DM6L5ZQ FM C22H21ClN2O4S DM6L5ZQ IC InChI=1S/C22H21ClN2O4S/c1-22(2,3)16-4-7-18(8-5-16)30(28,29)24-20-9-6-17(23)14-19(20)21(26)15-10-12-25(27)13-11-15/h4-14,24H,1-3H3 DM6L5ZQ CS CC(C)(C)C1=CC=C(C=C1)S(=O)(=O)NC2=C(C=C(C=C2)Cl)C(=O)C3=CC=[N+](C=C3)[O-] DM6L5ZQ IK JRWROCIMSDXGOZ-UHFFFAOYSA-N DM6L5ZQ IU 4-tert-butyl-N-[4-chloro-2-(1-oxidopyridin-1-ium-4-carbonyl)phenyl]benzenesulfonamide DM6L5ZQ CA CAS 698394-73-9 DM6L5ZQ DE Crohn disease DMOQ81Y ID DMOQ81Y DMOQ81Y DN Vernakalant DMOQ81Y HS Phase 3 DMOQ81Y SN Vernakalant; 794466-70-9; UNII-9G468C8B13; Vemakalant; RSD1235; 9G468C8B13; (3R)-1-((1R,2R)-2-(2-(3,4-dimethoxyphenyl)ethoxy)cyclohexyl)pyrrolidin-3-ol; 3-Pyrrolidinol,1-[(1R,2R)-2-[2-(3,4-dimethoxyphenyl)ethoxy]cyclohexyl]-, (3R)-; RSD-1235; Vernakalant [INN:BAN]; SCHEMBL410062; CHEMBL2111112; DTXSID60229659; VBHQKCBVWWUUKN-KZNAEPCWSA-N; CHEBI:135956; EX-A2465; ZINC22010910; 4151AH; AKOS027326205; DB06217; SB16873; CS-0276; API0014187; RL05068; 3-Pyrrolidinol, 1-((1R,2R)-2-(2-(3,4-dimethoxyphenyl)ethoxy)cyclohexyl)-, (3R)- DMOQ81Y CP Cardiome Pharma; Merck DMOQ81Y DT Small molecular drug DMOQ81Y PC 9930049 DMOQ81Y MW 349.5 DMOQ81Y FM C20H31NO4 DMOQ81Y IC InChI=1S/C20H31NO4/c1-23-19-8-7-15(13-20(19)24-2)10-12-25-18-6-4-3-5-17(18)21-11-9-16(22)14-21/h7-8,13,16-18,22H,3-6,9-12,14H2,1-2H3/t16-,17-,18-/m1/s1 DMOQ81Y CS COC1=C(C=C(C=C1)CCO[C@@H]2CCCC[C@H]2N3CC[C@H](C3)O)OC DMOQ81Y IK VBHQKCBVWWUUKN-KZNAEPCWSA-N DMOQ81Y IU (3R)-1-[(1R,2R)-2-[2-(3,4-dimethoxyphenyl)ethoxy]cyclohexyl]pyrrolidin-3-ol DMOQ81Y CA CAS 794466-70-9 DMOQ81Y CB CHEBI:135956 DMOQ81Y DE Atrial fibrillation DM4CGH5 ID DM4CGH5 DM4CGH5 DN verubecestat DM4CGH5 HS Phase 3 DM4CGH5 SN example 25 (US8940748) DM4CGH5 DT Small molecular drug DM4CGH5 PC 51352361 DM4CGH5 MW 409.4 DM4CGH5 FM C17H17F2N5O3S DM4CGH5 IC InChI=1S/C17H17F2N5O3S/c1-17(9-28(26,27)24(2)16(20)23-17)12-7-11(4-5-13(12)19)22-15(25)14-6-3-10(18)8-21-14/h3-8H,9H2,1-2H3,(H2,20,23)(H,22,25)/t17-/m0/s1 DM4CGH5 CS C[C@]1(CS(=O)(=O)N(C(=N1)N)C)C2=C(C=CC(=C2)NC(=O)C3=NC=C(C=C3)F)F DM4CGH5 IK YHYKUSGACIYRML-KRWDZBQOSA-N DM4CGH5 IU N-[3-[(5R)-3-amino-2,5-dimethyl-1,1-dioxo-6H-1,2,4-thiadiazin-5-yl]-4-fluorophenyl]-5-fluoropyridine-2-carboxamide DM4CGH5 CA CAS 1286770-55-5 DM4CGH5 DE Alzheimer disease DMMQ2U9 ID DMMQ2U9 DMMQ2U9 DN VGX-3100 DMMQ2U9 HS Phase 3 DMMQ2U9 CP Inovio Pharmaceuticals DMMQ2U9 DE Human papillomavirus infection; Cervical Intraepithelial neoplasia; Vulvar squamous intraepithelial lesion; Dysplasia; Vulvar intraepithelial neoplasia DMCWNZG ID DMCWNZG DMCWNZG DN Vibegron DMCWNZG HS Phase 3 DMCWNZG SN Beova; Beova (TN); VIBEGRON; Vibegron (JAN/USAN); Vibegron [USAN:INN]; compound 7 [PMID: 26709102]; vibegronum DMCWNZG DT Small molecular drug DMCWNZG PC 44472635 DMCWNZG MW 444.535 DMCWNZG FM C26H28N4O3 DMCWNZG IC InChI=1S/C26H28N4O3/c31-24-14-15-27-23-13-12-22(30(23)24)26(33)29-19-8-6-17(7-9-19)16-20-10-11-21(28-20)25(32)18-4-2-1-3-5-18/h1-9,14-15,20-22,25,28,32H,10-13,16H2,(H,29,33)/t20-,21+,22-,25+/m0/s1 DMCWNZG CS C1CC(NC1CC2=CC=C(C=C2)NC(=O)C3CCC4=NC=CC(=O)N34)C(C5=CC=CC=C5)O DMCWNZG IK DJXRIQMCROIRCZ-XOEOCAAJSA-N DMCWNZG IU (6S)-N-[4-[[(2S,5R)-5-[(R)-hydroxy(phenyl)methyl]pyrrolidin-2-yl]methyl]phenyl]-4-oxo-7,8-dihydro-6H-pyrrolo[1,2-a]pyrimidine-6-carboxamide DMCWNZG CA CAS 1190389-15-1 DMCWNZG CB ChEBI:142418 DMCWNZG DE Overactive bladder disorder DMLO0KD ID DMLO0KD DMLO0KD DN Vicineum DMLO0KD HS Phase 3 DMLO0KD SN Oportuzumab monatox DMLO0KD CP Sesen Bio DMLO0KD DT Recombinant protein DMLO0KD DE Bladder cancer DMMTW9K ID DMMTW9K DMMTW9K DN Vicriviroc DMMTW9K HS Phase 3 DMMTW9K SN SchD; Sch 417690; PRO 140 & Vicrivirac; SCH-417690; SCH-D; SCH-D690; Sch-D compound; PRO 140 (Anti-CCR5 monoclonal antibody) & 1-[(4,6-Dimethyl-5-pyrimidinyl)carbonyl]-4-[4-{2-methoxy-1(R)-4-(trifluoromethyl)-phenyl}ethyl-3(S)-methyl-1-piperazinyl]-4-methylpiperidine; (4,6-dimethylpyrimidin-5-yl)-[4-[(3S)-4-[(1R)-2-methoxy-1-[4-(trifluoromethyl)phenyl]ethyl]-3-methylpiperazin-1-yl]-4-methylpiperidin-1-yl]methanone; 1-((4,6-Dimethyl-5-pyrimidinyl)carbonyl)-4-(4-(2-methoxy-4-(trifluoromethyl)phenyl)ethyl-3-methyl-1-piperazinyl)-4-methylpiperidine; 1-[(4,6-Dimethyl-5-pyrimidinyl)carbonyl]-4-[4-{2-methoxy-1(R)-4-(trifluoromethyl)-phenyl}ethyl-3(S)-methyl-1-piperazinyl]-4-methylpiperidine DMMTW9K CP Schering-Plough DMMTW9K DT Small molecular drug DMMTW9K PC 3009355 DMMTW9K MW 533.6 DMMTW9K FM C28H38F3N5O2 DMMTW9K IC InChI=1S/C28H38F3N5O2/c1-19-16-35(14-15-36(19)24(17-38-5)22-6-8-23(9-7-22)28(29,30)31)27(4)10-12-34(13-11-27)26(37)25-20(2)32-18-33-21(25)3/h6-9,18-19,24H,10-17H2,1-5H3/t19-,24-/m0/s1 DMMTW9K CS C[C@H]1CN(CCN1[C@@H](COC)C2=CC=C(C=C2)C(F)(F)F)C3(CCN(CC3)C(=O)C4=C(N=CN=C4C)C)C DMMTW9K IK CNPVJJQCETWNEU-CYFREDJKSA-N DMMTW9K IU (4,6-dimethylpyrimidin-5-yl)-[4-[(3S)-4-[(1R)-2-methoxy-1-[4-(trifluoromethyl)phenyl]ethyl]-3-methylpiperazin-1-yl]-4-methylpiperidin-1-yl]methanone DMMTW9K CA CAS 306296-47-9 DMMTW9K CB CHEBI:94843 DMMTW9K DE Human immunodeficiency virus infection DMJFNR9 ID DMJFNR9 DMJFNR9 DN Viramidine DMJFNR9 HS Phase 3 DMJFNR9 SN Ribamidine; Prodrug of Ribavirin; Ribavirin amidine; Taribavirin hydrochloride; ICN 3142; AVS-000206; AVS-206;ICN-3142; Taribavirin hydrochloride (USAN); Viramidine (TN); 1-.Beta.-D-Ribofuranosyl-1,2,4-triazole-3-carboximidine hydrochloride; 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,4-triazole-3-carboximidamide; 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,4-triazole-3-carboximidamide hydrochloride; 1-beta-D-Ribofuranosyl-1,2,4-triazole-3-carboximidine DMJFNR9 CP Valeant Pharmaceuticals International DMJFNR9 DT Small molecular drug DMJFNR9 PC 451448 DMJFNR9 MW 243.22 DMJFNR9 FM C8H13N5O4 DMJFNR9 IC InChI=1S/C8H13N5O4/c9-6(10)7-11-2-13(12-7)8-5(16)4(15)3(1-14)17-8/h2-5,8,14-16H,1H2,(H3,9,10)/t3-,4-,5-,8-/m1/s1 DMJFNR9 CS C1=NC(=NN1[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O)C(=N)N DMJFNR9 IK NHKZSTHOYNWEEZ-AFCXAGJDSA-N DMJFNR9 IU 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,4-triazole-3-carboximidamide DMJFNR9 CA CAS 119567-79-2 DMJFNR9 CB CHEBI:134989 DMJFNR9 DE Hepatitis C virus infection DMXYM1H ID DMXYM1H DMXYM1H DN Visilizumab DMXYM1H HS Phase 3 DMXYM1H SN Nuvion; Visiluzumab; HuM291; SMART anti-CD3 MAb, PDL; SMART anti-CD3 MAb, Protein Design Labs; Anti-CD3 MAb (humanized), PDL DMXYM1H CP PDL BioPharma Inc; PDL BioPharma DMXYM1H DT Antibody DMXYM1H DE Graft-versus-host disease DMQGV5P ID DMQGV5P DMQGV5P DN VLB-01 DMQGV5P HS Phase 3 DMQGV5P CP Marco Polo Pharmaceuticals SA DMQGV5P DE Epilepsy DMSW80U ID DMSW80U DMSW80U DN VM-202 DMSW80U HS Phase 3 DMSW80U CP ViroMed DMSW80U DE Angina pectoris; Amyotrophic lateral sclerosis; Peripheral neuropathy; Diabetic foot ulcer; Peripheral arterial disease DM4P5UJ ID DM4P5UJ DM4P5UJ DN VM-501 DM4P5UJ HS Phase 3 DM4P5UJ SN IL-11 agonist (thrombocytopenia, small molecule therapeutic/iv/sc), Viromed DM4P5UJ CP ViroMed Co Ltd DM4P5UJ DE Thrombocytopenia DMOFH1M ID DMOFH1M DMOFH1M DN Volasertib DMOFH1M HS Phase 3 DMOFH1M SN Volasertib; 755038-65-4; BI 6727; BI-6727; BI6727 (Volasertib); Volasertib (BI 6727); UNII-6EM57086EA; 6EM57086EA; BI6727; N-{trans-4-[4-(Cyclopropylmethyl)piperazin-1-Yl]cyclohexyl}-4-{[(7r)-7-Ethyl-5-Methyl-8-(1-Methylethyl)-6-Oxo-5,6,7,8-Tetrahydropteridin-2-Yl]amino}-3-Methoxybenzamide; Volasertib [USAN:INN]; IBI; Volasertib (USAN); BI6727,Volasertib; Volasertib(BI6727); BI6727 - Volasertib; Volasertib (BI6727); BI6727 (Volasertib)/; BI 6727 (Volasertib); MLS006011195; SCHEMBL738946; SCHEMBL9888052; SCHEMBL2169101; GTPL7947 DMOFH1M CP Boehringer Ingelheim DMOFH1M DT Small molecular drug DMOFH1M PC 10461508 DMOFH1M MW 618.8 DMOFH1M FM C34H50N8O3 DMOFH1M IC InChI=1S/C34H50N8O3/c1-6-28-33(44)39(4)29-20-35-34(38-31(29)42(28)22(2)3)37-27-14-9-24(19-30(27)45-5)32(43)36-25-10-12-26(13-11-25)41-17-15-40(16-18-41)21-23-7-8-23/h9,14,19-20,22-23,25-26,28H,6-8,10-13,15-18,21H2,1-5H3,(H,36,43)(H,35,37,38)/t25?,26?,28-/m1/s1 DMOFH1M CS CC[C@@H]1C(=O)N(C2=CN=C(N=C2N1C(C)C)NC3=C(C=C(C=C3)C(=O)NC4CCC(CC4)N5CCN(CC5)CC6CC6)OC)C DMOFH1M IK SXNJFOWDRLKDSF-XKHVUIRMSA-N DMOFH1M IU N-[4-[4-(cyclopropylmethyl)piperazin-1-yl]cyclohexyl]-4-[[(7R)-7-ethyl-5-methyl-6-oxo-8-propan-2-yl-7H-pteridin-2-yl]amino]-3-methoxybenzamide DMOFH1M CA CAS 755038-65-4 DMOFH1M DE Acute myeloid leukaemia DM5T4IS ID DM5T4IS DM5T4IS DN VP-102 DM5T4IS HS Phase 3 DM5T4IS CP Verrica Pharmaceuticals West Chester, PA DM5T4IS DE Common wart; Molluscum contagiosum infection DMWMT5N ID DMWMT5N DMWMT5N DN VRS-317 DMWMT5N HS Phase 3 DMWMT5N SN HGH-XTEN; Human growth hormone-XTEN; RPEG HGH (injectable, growth deficiency), Versartis; Recombinant PEGylated human growth hormone (injectable, growth deficiency), Versartis DMWMT5N CP Versartis DMWMT5N DE Growth hormone deficiency DMM1Z9G ID DMM1Z9G DMM1Z9G DN Vutrisiran DMM1Z9G HS Phase 3 DMM1Z9G SN ALN-TTRsc02 DMM1Z9G CP Alnylam Pharmaceuticals DMM1Z9G DT Small interfering RNA DMM1Z9G DE Transthyretin familial amyloid cardiomyopathy DMJBXO3 ID DMJBXO3 DMJBXO3 DN VX-661 DMJBXO3 HS Phase 3 DMJBXO3 CP Vertex Pharmaceuticals Inc DMJBXO3 DT Small molecular drug DMJBXO3 PC 46199646 DMJBXO3 MW 520.5 DMJBXO3 FM C26H27F3N2O6 DMJBXO3 IC InChI=1S/C26H27F3N2O6/c1-24(2,13-33)22-8-14-7-18(17(27)10-19(14)31(22)11-16(34)12-32)30-23(35)25(5-6-25)15-3-4-20-21(9-15)37-26(28,29)36-20/h3-4,7-10,16,32-34H,5-6,11-13H2,1-2H3,(H,30,35)/t16-/m1/s1 DMJBXO3 CS CC(C)(CO)C1=CC2=CC(=C(C=C2N1C[C@H](CO)O)F)NC(=O)C3(CC3)C4=CC5=C(C=C4)OC(O5)(F)F DMJBXO3 IK MJUVRTYWUMPBTR-MRXNPFEDSA-N DMJBXO3 IU 1-(2,2-difluoro-1,3-benzodioxol-5-yl)-N-[1-[(2R)-2,3-dihydroxypropyl]-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)indol-5-yl]cyclopropane-1-carboxamide DMJBXO3 CA CAS 1152311-62-0 DMJBXO3 DE Cystic fibrosis DMM2JXP ID DMM2JXP DMM2JXP DN VX-787 DMM2JXP HS Phase 3 DMM2JXP SN Pimodivir DMM2JXP CP Vertex pharmaceuticals DMM2JXP DT Small molecular drug DMM2JXP PC 67286591 DMM2JXP MW 399.4 DMM2JXP FM C20H19F2N5O2 DMM2JXP IC InChI=1S/C20H19F2N5O2/c21-11-5-12-13(7-24-17(12)23-6-11)18-25-8-14(22)19(27-18)26-16-10-3-1-9(2-4-10)15(16)20(28)29/h5-10,15-16H,1-4H2,(H,23,24)(H,28,29)(H,25,26,27)/t9?,10?,15-,16-/m0/s1 DMM2JXP CS C1CC2CCC1[C@@H]([C@H]2NC3=NC(=NC=C3F)C4=CNC5=C4C=C(C=N5)F)C(=O)O DMM2JXP IK JGPXDNKSIXAZEQ-SBBZOCNPSA-N DMM2JXP IU (2S,3S)-3-[[5-fluoro-2-(5-fluoro-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4-yl]amino]bicyclo[2.2.2]octane-2-carboxylic acid DMM2JXP CA CAS 1629869-44-8 DMM2JXP DE Influenza A virus infection DM1JCW8 ID DM1JCW8 DM1JCW8 DN Xaliproden DM1JCW8 HS Phase 3 DM1JCW8 SN Xaliproden (USAN); 1,2,3,6-tetrahydro-1-(2-(2-naphthalenyl)ethyl)-4-(3-(trifluoromethyl)phenyl)-pyridine; 1,2,3,6-tetrahydro-1-(2-(2-naphthyl)ethyl)-4-(alpha,alpha,alpha-trifluoro-m-tolyl)pyridine; 1-(2-(2-Naphthyl)ethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine; 1-(2-naphthalen-2-ylethyl)-4-[3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-pyridine; 1-[2-(2-naphthyl)ethyl]-4-[3-(trifluoromethyl)phenyl]-1,2,3,6-tetrahydropyridine DM1JCW8 CP Sanofi-Aventis DM1JCW8 DT Small molecular drug DM1JCW8 PC 128919 DM1JCW8 MW 381.4 DM1JCW8 FM C24H22F3N DM1JCW8 IC InChI=1S/C24H22F3N/c25-24(26,27)23-7-3-6-22(17-23)20-11-14-28(15-12-20)13-10-18-8-9-19-4-1-2-5-21(19)16-18/h1-9,11,16-17H,10,12-15H2 DM1JCW8 CS C1CN(CC=C1C2=CC(=CC=C2)C(F)(F)F)CCC3=CC4=CC=CC=C4C=C3 DM1JCW8 IK WJJYZXPHLSLMGE-UHFFFAOYSA-N DM1JCW8 IU 1-(2-naphthalen-2-ylethyl)-4-[3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-pyridine DM1JCW8 CA CAS 135354-02-8 DM1JCW8 CB CHEBI:48520 DM1JCW8 DE Lateral sclerosis; Peripheral sensory neuropathies; Alzheimer disease; Juvenile idiopathic arthritis; Plaque psoriasis DMK34MZ ID DMK34MZ DMK34MZ DN Xilonix DMK34MZ HS Phase 3 DMK34MZ CP Xbiotech DMK34MZ DE Non-small-cell lung cancer; Influenza virus infection; Colorectal cancer DMJ6F5C ID DMJ6F5C DMJ6F5C DN XL019 DMJ6F5C HS Phase 3 DMJ6F5C SN XL019; 945755-56-6; UNII-4L1AM42NVA; (S)-N-(4-(2-((4-morpholinophenyl)amino)pyrimidin-4-yl)phenyl)pyrrolidine-2-carboxamide; 4L1AM42NVA; (2S)-N-[4-[2-[[4-(4-Morpholinyl)phenyl]amino]-4-pyrimidinyl]phenyl]-2-pyrrolidinecarboxamide; 945750-13-0; (2S)-N-[4-[2-(4-morpholin-4-ylanilino)pyrimidin-4-yl]phenyl]pyrrolidine-2-carboxamide; (2S)-N-[4-(2-{[4-(MORPHOLIN-4-YL)PHENYL]AMINO}PYRIMIDIN-4-YL)PHENYL]PYRROLIDINE-2-CARBOXAMIDE; C25H28N6O2; 2-Pyrrolidinecarboxamide, N-(4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)phe DMJ6F5C DT Small molecular drug DMJ6F5C PC 57990869 DMJ6F5C MW 444.5 DMJ6F5C FM C25H28N6O2 DMJ6F5C IC InChI=1S/C25H28N6O2/c32-24(23-2-1-12-26-23)28-19-5-3-18(4-6-19)22-11-13-27-25(30-22)29-20-7-9-21(10-8-20)31-14-16-33-17-15-31/h3-11,13,23,26H,1-2,12,14-17H2,(H,28,32)(H,27,29,30)/t23-/m0/s1 DMJ6F5C CS C1C[C@H](NC1)C(=O)NC2=CC=C(C=C2)C3=NC(=NC=C3)NC4=CC=C(C=C4)N5CCOCC5 DMJ6F5C IK ISOCDPQFIXDIMS-QHCPKHFHSA-N DMJ6F5C IU (2S)-N-[4-[2-(4-morpholin-4-ylanilino)pyrimidin-4-yl]phenyl]pyrrolidine-2-carboxamide DMJ6F5C CA CAS 945755-56-6 DMJ6F5C DE Polycythemia vera; Solid tumour/cancer DMOKQV7 ID DMOKQV7 DMOKQV7 DN XOMA 052 DMOKQV7 HS Phase 3 DMOKQV7 SN Gevokizumab DMOKQV7 CP XOMA DMOKQV7 DT Antibody DMOKQV7 DE Type-2 diabetes DMOLR5W ID DMOLR5W DMOLR5W DN Yttrium (90Y) clivatuzumab tetraxetan DMOLR5W HS Phase 3 DMOLR5W SN PAM4 mAb; Yttrium Y 90 clivatuzumab tetraxetan; Anti-MUC1 PAM4 monoclonal antibody; Clivatuzumab tetraxetan-[90Y]; HPAM4-Cide; IMMU-107; PAM-4; PAM4-Y-90; Yttrium-90-hPAM4; 90Y-clivatuzumab tetraxetan; 90Y-hPAM4 DMOLR5W CP Immunomedics; Garden State Cancer Center; Immunomedics DMOLR5W DT Antibody DMOLR5W DE Pancreatic cancer DMEY1F3 ID DMEY1F3 DMEY1F3 DN Zabofloxacin DMEY1F3 HS Phase 3 DMEY1F3 SN DW-224a; DW-224aa; PB-101; Zabofloxacin (oral), IASO Pharma/DHP DMEY1F3 CP Dong Wha Pharmaceutical Co Ltd DMEY1F3 DT Small molecular drug DMEY1F3 PC 10388396 DMEY1F3 MW 401.4 DMEY1F3 FM C19H20FN5O4 DMEY1F3 IC InChI=1S/C19H20FN5O4/c1-29-23-14-6-24(9-19(14)7-21-8-19)17-13(20)4-11-15(26)12(18(27)28)5-25(10-2-3-10)16(11)22-17/h4-5,10,21H,2-3,6-9H2,1H3,(H,27,28)/b23-14+ DMEY1F3 CS CO/N=C/1\\CN(CC12CNC2)C3=C(C=C4C(=O)C(=CN(C4=N3)C5CC5)C(=O)O)F DMEY1F3 IK ZNPOCLHDJCAZAH-OEAKJJBVSA-N DMEY1F3 IU 1-cyclopropyl-6-fluoro-7-[(8Z)-8-methoxyimino-2,6-diazaspiro[3.4]octan-6-yl]-4-oxo-1,8-naphthyridine-3-carboxylic acid DMEY1F3 DE Pneumonia DM52QEZ ID DM52QEZ DM52QEZ DN Zalutumumab DM52QEZ HS Phase 3 DM52QEZ CP Genmab DM52QEZ DT Antibody DM52QEZ SQ Zalutumumab (A chain): QVQLVESGGGVVQPGRSLRLSCAASGFTFSTYGMHWVRQAPGKGLEWVAVIWDDGSYKYYGDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDGITMVRGVMKDYFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK > Zalutumumab (B chain)AIQLTQSPSSLSASVGDRVTITCRASQDISSALVWYQQKPGKAPKLLIYDASSLESGVPSRFSGSESGTDFTLTISSLQPEDFATYYCQQFNSYPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC DM52QEZ DE Head and neck cancer DMKB4ZY ID DMKB4ZY DMKB4ZY DN Zanolimumab DMKB4ZY HS Phase 3 DMKB4ZY CP Emergent BioSolutions DMKB4ZY DT Antibody DMKB4ZY DE Lymphoma DM9HUYP ID DM9HUYP DM9HUYP DN ZANOTERONE DM9HUYP HS Phase 3 DM9HUYP SN ZANOTERONE; 107000-34-0; UNII-XQ5V1W49JG; XQ5V1W49JG; WIN-49596; Zanoterone [USAN:INN]; Win 49,596; Zanoterone (USAN/INN); win49596; SCHEMBL60980; CHEMBL1908363; DTXSID50147873; BDBM50368314; 1'-(Methylsulfonyl)-1'H-5alpha,17alpha-pregn-20-yno(3,2-c)pyrazol-17-ol; D06357; 34004-EP2305642A2; 34004-EP2298765A1; 34004-EP2275420A1; 34004-EP2311453A1; 34004-EP2298764A1; 34004-EP2298748A2; 34004-EP2295416A2; 34004-EP2295055A2; 1'H-Pregn-20-yno(3,2-c)pyrazol-17-ol, 1'-(methylsulfonyl)-, (5alpha,17alpha)- DM9HUYP DT Small molecular drug DM9HUYP PC 9844827 DM9HUYP MW 416.6 DM9HUYP FM C23H32N2O3S DM9HUYP IC InChI=1S/C23H32N2O3S/c1-5-23(26)11-9-19-17-7-6-16-12-20-15(14-25(24-20)29(4,27)28)13-21(16,2)18(17)8-10-22(19,23)3/h1,14,16-19,26H,6-13H2,2-4H3/t16-,17+,18-,19-,21-,22-,23-/m0/s1 DM9HUYP CS C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CC[C@@H]4[C@@]3(CC5=CN(N=C5C4)S(=O)(=O)C)C DM9HUYP IK MHDDZDPNIDVLNK-ZGIWMXSJSA-N DM9HUYP IU (1S,2S,10S,13R,14S,17R,18S)-17-ethynyl-2,18-dimethyl-6-methylsulfonyl-6,7-diazapentacyclo[11.7.0.02,10.04,8.014,18]icosa-4,7-dien-17-ol DM9HUYP CA CAS 107000-34-0 DM9HUYP DE Prostate hyperplasia DMF30HL ID DMF30HL DMF30HL DN Zarnestra DMF30HL HS Phase 3 DMF30HL SN JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE DMF30HL CP Johnson & Johnson DMF30HL TC Anticancer Agents DMF30HL DT Small molecular drug DMF30HL PC 159324 DMF30HL MW 489.4 DMF30HL FM C27H22Cl2N4O DMF30HL IC InChI=1S/C27H22Cl2N4O/c1-32-16-31-15-25(32)27(30,18-6-9-20(28)10-7-18)19-8-11-24-23(13-19)22(14-26(34)33(24)2)17-4-3-5-21(29)12-17/h3-16H,30H2,1-2H3/t27-/m1/s1 DMF30HL CS CN1C=NC=C1[C@@](C2=CC=C(C=C2)Cl)(C3=CC4=C(C=C3)N(C(=O)C=C4C5=CC(=CC=C5)Cl)C)N DMF30HL IK PLHJCIYEEKOWNM-HHHXNRCGSA-N DMF30HL IU 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one DMF30HL CA CAS 192185-72-1 DMF30HL CB CHEBI:141969 DMF30HL DE Colorectal cancer; Pancreatic cancer; Chronic myelogenous leukaemia; Myelodysplastic syndrome; Human papillomavirus infection; Peripheral T-cell lymphoma; Acute myeloid leukaemia DMWDEFC ID DMWDEFC DMWDEFC DN Zatosetron maleate DMWDEFC HS Phase 3 DMWDEFC SN LY-277359 maleate; Zatosetron maleate < Rec INNM; Endo-5-Chloro-2,2-dimethyl-N-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-2,3-dihydrobenzofuran-7-carboxamide maleate DMWDEFC DT Small molecular drug DMWDEFC PC 6918153 DMWDEFC MW 464.9 DMWDEFC FM C23H29ClN2O6 DMWDEFC IC InChI=1S/C19H25ClN2O2.C4H4O4/c1-19(2)10-11-6-12(20)7-16(17(11)24-19)18(23)21-13-8-14-4-5-15(9-13)22(14)3;5-3(6)1-2-4(7)8/h6-7,13-15H,4-5,8-10H2,1-3H3,(H,21,23);1-2H,(H,5,6)(H,7,8)/b;2-1-/t13?,14-,15+; DMWDEFC CS CC1(CC2=C(O1)C(=CC(=C2)Cl)C(=O)NC3C[C@H]4CC[C@@H](C3)N4C)C.C(=C\\C(=O)O)\\C(=O)O DMWDEFC IK HAFQATMFFHYNPN-BSLJCGBVSA-N DMWDEFC IU (Z)-but-2-enedioic acid;5-chloro-2,2-dimethyl-N-[(1R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl]-3H-1-benzofuran-7-carboxamide DMWDEFC CA CAS 123482-23-5 DMWDEFC DE Anxiety disorder DMP8ESD ID DMP8ESD DMP8ESD DN Zicronapine DMP8ESD HS Phase 3 DMP8ESD SN Zicronapine; 170381-16-5; UNII-QZV11V7G6A; QZV11V7G6A; Zicronapine [USAN:INN]; Zicronapine (USAN/INN); SCHEMBL904402; CHEMBL3039528; DTXSID30168849; Lu31-130; AKOS032946690; DB12188; 4-((1R,3S)-6-Chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl)-1,2,2-trimethylpiperazine; LU-31130; D10329; Piperazine, 4-((1R,3S)-6-chloro-2,3-dihydro-3-phenyl-1H-inden-1-yl)-1,2,2-trimethyl- DMP8ESD CP Lundbeck DMP8ESD DT Small molecular drug DMP8ESD PC 11465618 DMP8ESD MW 354.9 DMP8ESD FM C22H27ClN2 DMP8ESD IC InChI=1S/C22H27ClN2/c1-22(2)15-25(12-11-24(22)3)21-14-19(16-7-5-4-6-8-16)18-10-9-17(23)13-20(18)21/h4-10,13,19,21H,11-12,14-15H2,1-3H3/t19-,21+/m0/s1 DMP8ESD CS CC1(CN(CCN1C)[C@@H]2C[C@H](C3=C2C=C(C=C3)Cl)C4=CC=CC=C4)C DMP8ESD IK BYPMJBXPNZMNQD-PZJWPPBQSA-N DMP8ESD IU 4-[(1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl]-1,2,2-trimethylpiperazine DMP8ESD CA CAS 170381-16-5 DMP8ESD DE Schizophrenia DM09TVB ID DM09TVB DM09TVB DN Zimura DM09TVB HS Phase 3 DM09TVB SN ARC-1905 DM09TVB CP Ophthotech Corp DM09TVB DT Oligonucleotide DM09TVB DE Macular degeneration DMFWMKZ ID DMFWMKZ DMFWMKZ DN ZK-93423 DMFWMKZ HS Phase 3 DMFWMKZ SN ZK 93423; 83910-44-5; ZK93423; ZK 93 423; 6-Benzyloxy-4-methoxymethyl-beta-carboline-3-carboxylic acid ethyl ester; 9H-Pyrido(3,4-b)indole-3-carboxylic acid, 4-(methoxymethyl)-6-(phenylmethoxy)-, ethyl ester; ALBKMJDFBZVHAK-UHFFFAOYSA-N; PDSP1_001754; AC1L3TNV; AC1Q64YI; CHEMBL10947; GTPL4346; SCHEMBL7117282; CHEMBL1518572; BDBM85039; CHEBI:92593; ZINC5857871; PDSP2_001737; PDSP1_001771; ethyl 6-(benzyloxy)-4-(methoxymethyl)-9h-; BDBM50007553; PDSP2_001754; CAS_121926; NSC_121926 DMFWMKZ DT Small molecular drug DMFWMKZ PC 121926 DMFWMKZ MW 390.4 DMFWMKZ FM C23H22N2O4 DMFWMKZ IC InChI=1S/C23H22N2O4/c1-3-28-23(26)22-18(14-27-2)21-17-11-16(29-13-15-7-5-4-6-8-15)9-10-19(17)25-20(21)12-24-22/h4-12,25H,3,13-14H2,1-2H3 DMFWMKZ CS CCOC(=O)C1=NC=C2C(=C1COC)C3=C(N2)C=CC(=C3)OCC4=CC=CC=C4 DMFWMKZ IK ALBKMJDFBZVHAK-UHFFFAOYSA-N DMFWMKZ IU ethyl 4-(methoxymethyl)-6-phenylmethoxy-9H-pyrido[3,4-b]indole-3-carboxylate DMFWMKZ CA CAS 83910-44-5 DMFWMKZ CB CHEBI:92593 DMFWMKZ DE Epileptic seizures DM5ST9Z ID DM5ST9Z DM5ST9Z DN Zolbetuximab DM5ST9Z HS Phase 3 DM5ST9Z SN IMAB362 DM5ST9Z CP Astellas Pharma DM5ST9Z DT Antibody DM5ST9Z DE Pancreatic cancer; Gastric adenocarcinoma; Esophagogastric junction neoplasm DM8L7JD ID DM8L7JD DM8L7JD DN Zoniporide hydrochloride DM8L7JD HS Phase 3 DM8L7JD SN CP-597396; EMD-392426; Zoniporide hydrochloride < Prop INNM; N''-[5-Cyclopropyl-1-(5-quinolyl)-1H-pyrazol-4-ylcarbonyl]guanidine hydrochloride monohydrate DM8L7JD DT Small molecular drug DM8L7JD PC 11962997 DM8L7JD MW 356.8 DM8L7JD FM C17H17ClN6O DM8L7JD IC InChI=1S/C17H16N6O.ClH/c18-17(19)22-16(24)12-9-21-23(15(12)10-6-7-10)14-5-1-4-13-11(14)3-2-8-20-13;/h1-5,8-10H,6-7H2,(H4,18,19,22,24);1H DM8L7JD CS C1CC1C2=C(C=NN2C3=CC=CC4=C3C=CC=N4)C(=O)N=C(N)N.Cl DM8L7JD IK JTEXNYIOROVPIR-UHFFFAOYSA-N DM8L7JD IU 5-cyclopropyl-N-(diaminomethylidene)-1-quinolin-5-ylpyrazole-4-carboxamide;hydrochloride DM8L7JD CA CAS 241800-97-5 DM8L7JD DE Angina pectoris DMMBJYC ID DMMBJYC DMMBJYC DN ZYH-1 DMMBJYC HS Phase 3 DMMBJYC SN Metabolism disorder treatment, Zydus-Cadila; PPAR alpha/gamma modulator (dyslipdemia), Zydus-Cadila DMMBJYC CP Zydus-Cadila Group DMMBJYC DE Lipid metabolism disorder DM12UX6 ID DM12UX6 DM12UX6 DN 131 I-omburtamab DM12UX6 HS Phase 2/3 DM12UX6 CP Y-mAbs Therapeutics DM12UX6 DT Antibody DM12UX6 DE Neuroblastoma; Brain and central nervous system tumour DMZ0T24 ID DMZ0T24 DMZ0T24 DN Abagovomab DMZ0T24 HS Phase 2/3 DMZ0T24 CP Menarini DMZ0T24 DT Monoclonal antibody DMZ0T24 DE Ovarian cancer DMKY9GI ID DMKY9GI DMKY9GI DN Activated recombinant FVII-albumin fusion protein DMKY9GI HS Phase 2/3 DMKY9GI SN CSL-689; Activated recombinant FVII-albumin fusion protein (hemophilia); Activated recombinant FVII-albumin fusion protein (hemophilia), CSL Behring; RVIIa-FP (hemophilia), CSL Behring; Recombinant factor VIIa/human albumin fusion protein (hemophilia), CSL Behring DMKY9GI CP Csl behring DMKY9GI DE Hemophilia DM6GTMD ID DM6GTMD DM6GTMD DN ADX-48621 DM6GTMD HS Phase 2/3 DM6GTMD SN Dipraglurant; 872363-17-2; UNII-CV8JZR21A1; ADX48621; CV8JZR21A1; CHEMBL2346738; 6-fluoro-2-[4-(2-pyridinyl)-3-butyn-1-yl]-Imidazo[1,2-a]pyridine; Dipraglurant [INN]; ADX-48621; SCHEMBL103033; GTPL6452; C16H12FN3; DTXSID90236230; BCP23706; BDBM50431705; ZINC72266314; 3590AH; 6-Fluoro-2-(4-(pyridin-2-yl)but-3-yn-1-yl)imidazo(1,2-a)pyridine; AKOS030526956; SB16993; DB12733; CS-0690; NCGC00351745-02; HY-14859; DB-076892; FT-0705373; J3.560.334D; W-5761; ADX 48621;ADX48621;ADX-48621 DM6GTMD CP Addex Pharma. DM6GTMD DT Small molecular drug DM6GTMD PC 44557636 DM6GTMD MW 265.28 DM6GTMD FM C16H12FN3 DM6GTMD IC InChI=1S/C16H12FN3/c17-13-8-9-16-19-15(12-20(16)11-13)7-2-1-5-14-6-3-4-10-18-14/h3-4,6,8-12H,2,7H2 DM6GTMD CS C1=CC=NC(=C1)C#CCCC2=CN3C=C(C=CC3=N2)F DM6GTMD IK LZXMUJCJAWVHPZ-UHFFFAOYSA-N DM6GTMD IU 6-fluoro-2-(4-pyridin-2-ylbut-3-ynyl)imidazo[1,2-a]pyridine DM6GTMD CA CAS 872363-17-2 DM6GTMD DE Mood disorder; Dyskinesia; Parkinson disease DMMHSLC ID DMMHSLC DMMHSLC DN Afq056 DMMHSLC HS Phase 2/3 DMMHSLC SN Mavoglurant DMMHSLC CP Novartis DMMHSLC DT Small molecular drug DMMHSLC PC 9926832 DMMHSLC MW 313.4 DMMHSLC FM C19H23NO3 DMMHSLC IC InChI=1S/C19H23NO3/c1-14-5-3-6-15(13-14)8-11-19(22)10-4-7-17-16(19)9-12-20(17)18(21)23-2/h3,5-6,13,16-17,22H,4,7,9-10,12H2,1-2H3/t16-,17-,19-/m1/s1 DMMHSLC CS CC1=CC(=CC=C1)C#C[C@@]2(CCC[C@@H]3[C@H]2CCN3C(=O)OC)O DMMHSLC IK ZFPZEYHRWGMJCV-ZHALLVOQSA-N DMMHSLC IU methyl (3aR,4S,7aR)-4-hydroxy-4-[2-(3-methylphenyl)ethynyl]-3,3a,5,6,7,7a-hexahydro-2H-indole-1-carboxylate DMMHSLC CA CAS 543906-09-8 DMMHSLC DE Fragile X syndrome DMGC970 ID DMGC970 DMGC970 DN AG-013 DMGC970 HS Phase 2/3 DMGC970 SN ActoBiotic (oral mucositis), ActoGenix; TFF-producing Lactococci lactis (mucositis), ActoGenix/VIB/University of Ghent; Trefoil factor producing micro-organisms (TopAct, oral, mucositis), ActoGenix DMGC970 CP Flanders Interuniversity Institute for Biotechnology (VIB) DMGC970 DE Oral mucositis DMD741P ID DMD741P DMD741P DN Alagebrium chloride DMD741P HS Phase 2/3 DMD741P SN PTB; Tetrazolium chloride; ALT-711; ALT-766; N-phenacylthiazolium bromide; Advanced glycosylation end product (AGE)breakers, Alteon; Advanced glycosylation end product (AGE) breakers, Synvista DMD741P CP Synvista Therapeutics Inc DMD741P DT Small molecular drug DMD741P PC 216306 DMD741P MW 267.77 DMD741P FM C13H14ClNOS DMD741P IC InChI=1S/C13H14NOS.ClH/c1-10-11(2)16-9-14(10)8-13(15)12-6-4-3-5-7-12;/h3-7,9H,8H2,1-2H3;1H/q+1;/p-1 DMD741P CS CC1=C(SC=[N+]1CC(=O)C2=CC=CC=C2)C.[Cl-] DMD741P IK MKOMESMZHZNBIZ-UHFFFAOYSA-M DMD741P IU 2-(4,5-dimethyl-1,3-thiazol-3-ium-3-yl)-1-phenylethanone;chloride DMD741P CA CAS 341028-37-3 DMD741P DE Hypotension DM36HBS ID DM36HBS DM36HBS DN ALXN1101 DM36HBS HS Phase 2/3 DM36HBS CP Alexion pharmaceuticals DM36HBS DE Molybdenum cofactor deficiency DMBFOAZ ID DMBFOAZ DMBFOAZ DN AMG520 DMBFOAZ HS Phase 2/3 DMBFOAZ SN CNP520 DMBFOAZ CP Amgen Thousand Oaks, CA Novartis East Hanover, NJ DMBFOAZ DE Alzheimer disease DMN6F1W ID DMN6F1W DMN6F1W DN Amiodarone DMN6F1W HS Phase 2/3 DMN6F1W SN amiodarone; 1951-25-3; Cordarone; Amiodarona; Amiodaronum; Amjodaronum; Amiodaronum [INN-Latin]; Amiodarona [INN-Spanish]; Pacerone; L 3428; L-3428; UNII-N3RQ532IUT; C25H29I2NO3; SKF 33134-A; EINECS 217-772-1; CHEMBL633; BRN 1271711; N3RQ532; Amiodarone DMN6F1W TC Antiviral Agents DMN6F1W DT Small molecular drug DMN6F1W PC 2157 DMN6F1W MW 645.3 DMN6F1W FM C25H29I2NO3 DMN6F1W IC InChI=1S/C25H29I2NO3/c1-4-7-11-22-23(18-10-8-9-12-21(18)31-22)24(29)17-15-19(26)25(20(27)16-17)30-14-13-28(5-2)6-3/h8-10,12,15-16H,4-7,11,13-14H2,1-3H3 DMN6F1W CS CCCCC1=C(C2=CC=CC=C2O1)C(=O)C3=CC(=C(C(=C3)I)OCCN(CC)CC)I DMN6F1W IK IYIKLHRQXLHMJQ-UHFFFAOYSA-N DMN6F1W IU (2-butyl-1-benzofuran-3-yl)-[4-[2-(diethylamino)ethoxy]-3,5-diiodophenyl]methanone DMN6F1W CA CAS 1951-25-3 DMN6F1W CB CHEBI:2663 DMN6F1W DE Coronavirus Disease 2019 (COVID-19) DMJRU3A ID DMJRU3A DMJRU3A DN AMO-02 DMJRU3A HS Phase 2/3 DMJRU3A CP AMO Pharma Berwyn, PA DMJRU3A DE Myotonic dystrophy DMDLGRO ID DMDLGRO DMDLGRO DN Aramchol DMDLGRO HS Phase 2/3 DMDLGRO SN Stearoyl CoA desaturase-1 inhibitor (oral, liver/lipid metabolism diseases), Galmed DMDLGRO CP Galmed Medical Research Ltd DMDLGRO DT Small molecular drug DMDLGRO PC 18738120 DMDLGRO MW 702.1 DMDLGRO FM C44H79NO5 DMDLGRO IC InChI=1S/C44H79NO5/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-40(48)45-34-27-28-43(3)33(29-34)30-38(46)42-36-25-24-35(32(2)23-26-41(49)50)44(36,4)39(47)31-37(42)43/h32-39,42,46-47H,5-31H2,1-4H3,(H,45,48)(H,49,50)/t32-,33+,34+,35-,36+,37+,38-,39+,42+,43+,44-/m1/s1 DMDLGRO CS CCCCCCCCCCCCCCCCCCCC(=O)N[C@H]1CC[C@]2([C@@H](C1)C[C@H]([C@@H]3[C@@H]2C[C@@H]([C@]4([C@H]3CC[C@@H]4[C@H](C)CCC(=O)O)C)O)O)C DMDLGRO IK SHKXZIQNFMOPBS-OOMQYRRCSA-N DMDLGRO IU (4R)-4-[(3S,5S,7R,8R,9S,10S,12S,13R,14S,17R)-7,12-dihydroxy-3-(icosanoylamino)-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid DMDLGRO CA CAS 246529-22-6 DMDLGRO DE Lipid metabolism disorder DMS8QF9 ID DMS8QF9 DMS8QF9 DN Arimoclomol DMS8QF9 HS Phase 2/3 DMS8QF9 SN BRX-345 DMS8QF9 CP Biorex Research and Development Co DMS8QF9 DT Small molecular drug DMS8QF9 PC 9568077 DMS8QF9 MW 313.78 DMS8QF9 FM C14H20ClN3O3 DMS8QF9 IC InChI=1S/C14H20ClN3O3/c15-14(12-5-4-8-18(20)9-12)16-21-11-13(19)10-17-6-2-1-3-7-17/h4-5,8-9,13,19H,1-3,6-7,10-11H2/b16-14-/t13-/m1/s1 DMS8QF9 CS C1CCN(CC1)C[C@H](CO/N=C(/C2=C[N+](=CC=C2)[O-])\\Cl)O DMS8QF9 IK SGEIEGAXKLMUIZ-XUVDNFPMSA-N DMS8QF9 IU (3Z)-N-[(2R)-2-hydroxy-3-piperidin-1-ylpropoxy]-1-oxidopyridin-1-ium-3-carboximidoyl chloride DMS8QF9 CA CAS 289893-25-0 DMS8QF9 DE Cerebrovascular ischaemia; Inclusion body myositis DM15VBJ ID DM15VBJ DM15VBJ DN Artemisone DM15VBJ HS Phase 2/3 DM15VBJ SN Artemifone; Artemisone, Medicines For Malaria Venture; MMV-00/1007; Artemisinin derviative, Bayer/WHO/Hong Kong University; Artemisone, Bayer/WHO/Hong Kong University; Semi-synthetic endoperoxide, Bayer/WHO/Hong Kong University DM15VBJ CP Hong Kong University of Science & Technology DM15VBJ DT Small molecular drug DM15VBJ PC 11531457 DM15VBJ MW 401.5 DM15VBJ FM C19H31NO6S DM15VBJ IC InChI=1S/C19H31NO6S/c1-12-4-5-15-13(2)16(20-8-10-27(21,22)11-9-20)23-17-19(15)14(12)6-7-18(3,24-17)25-26-19/h12-17H,4-11H2,1-3H3/t12-,13-,14+,15+,16-,17-,18-,19-/m1/s1 DM15VBJ CS C[C@@H]1CC[C@H]2[C@H]([C@@H](O[C@H]3[C@@]24[C@H]1CC[C@](O3)(OO4)C)N5CCS(=O)(=O)CC5)C DM15VBJ IK FDMUNKXWYMSZIR-NQWKWHCYSA-N DM15VBJ IU 4-[(1R,4S,5R,8S,9R,10R,12R,13R)-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-10-yl]-1,4-thiazinane 1,1-dioxide DM15VBJ CA CAS 255730-18-8 DM15VBJ DE Malaria DMZGKXW ID DMZGKXW DMZGKXW DN Atogepant DMZGKXW HS Phase 2/3 DMZGKXW SN UNII-7CRV8RR151; 7CRV8RR151; AGN-241689; MK-8031; 1374248-81-3; Atogepant [INN]; Atogepant [WHO-DD]; Atogepant [USAN:INN]; SCHEMBL4570348; GTPL9730; CHEMBL3991065; example 4 [US20120122911]; Spiro(6H-cyclopenta(b)pyridine-6,3'-(3H)pyrrolo(2,3-b)pyridine)-3-carboxamide, 1',2',5,7-tetrahydro-N-((3S,5S,6R)-6-methyl-2-oxo-1-(2,2,2-trifluoroethyl)-5-(2,3,6-trifluorophenyl)-3-piperidinyl)-2'-oxo-, (3'S)-; (3S)-N-[(3S,5S,6R)-6-methyl-2-oxo-1-(2,2,2-trifluoroethyl)-5-(2,3,6-trifluorophenyl)piperidin-3-yl]-2-oxospiro[1 DMZGKXW CP Allergan Parsippany, NJ DMZGKXW PC 72163100 DMZGKXW MW 603.5 DMZGKXW FM C29H23F6N5O3 DMZGKXW IC InChI=1S/C29H23F6N5O3/c1-13-16(22-18(30)4-5-19(31)23(22)32)8-20(26(42)40(13)12-29(33,34)35)38-25(41)15-7-14-9-28(10-21(14)37-11-15)17-3-2-6-36-24(17)39-27(28)43/h2-7,11,13,16,20H,8-10,12H2,1H3,(H,38,41)(H,36,39,43)/t13-,16-,20+,28+/m1/s1 DMZGKXW CS C[C@@H]1[C@@H](C[C@@H](C(=O)N1CC(F)(F)F)NC(=O)C2=CC3=C(C[C@@]4(C3)C5=C(NC4=O)N=CC=C5)N=C2)C6=C(C=CC(=C6F)F)F DMZGKXW IK QIVUCLWGARAQIO-OLIXTKCUSA-N DMZGKXW IU (3S)-N-[(3S,5S,6R)-6-methyl-2-oxo-1-(2,2,2-trifluoroethyl)-5-(2,3,6-trifluorophenyl)piperidin-3-yl]-2-oxospiro[1H-pyrrolo[2,3-b]pyridine-3,6'-5,7-dihydrocyclopenta[b]pyridine]-3'-carboxamide DMZGKXW CA CAS 1374248-81-3 DMZGKXW DE Migraine DMVB4OS ID DMVB4OS DMVB4OS DN AVN 211 DMVB4OS HS Phase 2/3 DMVB4OS CP Avineuro Pharmaceuticals DMVB4OS DE Schizophrenia DM5YHU2 ID DM5YHU2 DM5YHU2 DN Avoralstat DM5YHU2 HS Phase 2/3 DM5YHU2 SN TUWMKPVJGGWGNL-UHFFFAOYSA-N; UNII-UX17773O15; UX17773O15; 918407-35-9; Avoralstat [INN]; 3-(2-((4-Carbamimidoylphenyl)carbamoyl)-4-ethenyl-5-methoxyphenyl)-6-((cyclopropylmethyl)carbamoyl)pyridine-2-carboxylic acid; 3-{2-[(4-carbamimidoylphenyl)carbamoyl]-4-ethenyl-5-methoxyphenyl}-6-[(cyclopropylmethyl)carbamoyl]pyridine-2-carboxylic acid; SCHEMBL17513082; AKOS030629101; DB12120; CS-7551; 2-Pyridinecarboxylic acid, 3-(2-(((4-(aminoiminomethyl)phenyl)amino)carbonyl)-4-ethenyl-5-met DM5YHU2 CP BioCryst Pharmaceuticals Durham, NC DM5YHU2 PC 86566678 DM5YHU2 MW 513.5 DM5YHU2 FM C28H27N5O5 DM5YHU2 IC InChI=1S/C28H27N5O5/c1-3-16-12-21(26(34)32-18-8-6-17(7-9-18)25(29)30)20(13-23(16)38-2)19-10-11-22(33-24(19)28(36)37)27(35)31-14-15-4-5-15/h3,6-13,15H,1,4-5,14H2,2H3,(H3,29,30)(H,31,35)(H,32,34)(H,36,37) DM5YHU2 CS COC1=CC(=C(C=C1C=C)C(=O)NC2=CC=C(C=C2)C(=N)N)C3=C(N=C(C=C3)C(=O)NCC4CC4)C(=O)O DM5YHU2 IK TUWMKPVJGGWGNL-UHFFFAOYSA-N DM5YHU2 IU 3-[2-[(4-carbamimidoylphenyl)carbamoyl]-4-ethenyl-5-methoxyphenyl]-6-(cyclopropylmethylcarbamoyl)pyridine-2-carboxylic acid DM5YHU2 CA CAS 918407-35-9 DM5YHU2 DE Hereditary angioedema DMJQHXD ID DMJQHXD DMJQHXD DN AZD3293 DMJQHXD HS Phase 2/3 DMJQHXD SN CHEMBL2152914; SCHEMBL9948518; SCHEMBL9948271; SCHEMBL18562845; BDBM50393099 DMJQHXD CP AstraZeneca DMJQHXD DT Small molecular drug DMJQHXD PC 57404290 DMJQHXD MW 412.5 DMJQHXD FM C26H28N4O DMJQHXD IC InChI=1S/C26H28N4O/c1-4-5-18-12-21(16-28-15-18)19-6-7-20-14-25(10-8-22(31-3)9-11-25)26(23(20)13-19)29-17(2)24(27)30-26/h6-7,12-13,15-16,22H,8-11,14H2,1-3H3,(H2,27,30) DMJQHXD CS CC#CC1=CC(=CN=C1)C2=CC3=C(CC4(C35N=C(C(=N5)N)C)CCC(CC4)OC)C=C2 DMJQHXD IK WKDNQONLGXOZRG-UHFFFAOYSA-N DMJQHXD DE Alzheimer disease DM3827C ID DM3827C DM3827C DN AZD4547 DM3827C HS Phase 2/3 DM3827C SN AZD4547; 1035270-39-3; AZD-4547; AZD 4547; UNII-2167OG1EKJ; 2167OG1EKJ; CHEBI:63453; KB-74810; N-(5-(3,5-Dimethoxyphenethyl)-1H-pyrazol-3-yl)-4-((3R,5S)-rel-3,5-dimethylpiperazin-1-yl)benzamide; N-{5-[2-(3,5-dimethoxyphenyl)ethyl]-1H-pyrazol-3-yl}-4-(cis-3,5-dimethylpiperazin-1-yl)benzamide; rel-N-[5-[2-(3,5-Dimethoxyphenyl)ethyl]-1H-pyrazol-3-yl]-4-[(3R,5S)-3,5-dimethyl-1-piperazinyl]benzamide; N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-1H-pyrazol-3-yl]-4-[(3R,5S)-3,5-dimethylpiperazin-1-yl]benzamide DM3827C CP AstraZeneca DM3827C DT Small molecular drug DM3827C PC 51039095 DM3827C MW 463.6 DM3827C FM C26H33N5O3 DM3827C IC InChI=1S/C26H33N5O3/c1-17-15-31(16-18(2)27-17)22-9-6-20(7-10-22)26(32)28-25-13-21(29-30-25)8-5-19-11-23(33-3)14-24(12-19)34-4/h6-7,9-14,17-18,27H,5,8,15-16H2,1-4H3,(H2,28,29,30,32)/t17-,18+ DM3827C CS C[C@@H]1CN(C[C@@H](N1)C)C2=CC=C(C=C2)C(=O)NC3=NNC(=C3)CCC4=CC(=CC(=C4)OC)OC DM3827C IK VRQMAABPASPXMW-HDICACEKSA-N DM3827C IU N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-1H-pyrazol-3-yl]-4-[(3S,5R)-3,5-dimethylpiperazin-1-yl]benzamide DM3827C CA CAS 1035270-39-3 DM3827C CB CHEBI:63453 DM3827C DE Solid tumour/cancer DMHWE5R ID DMHWE5R DMHWE5R DN Batabulin DMHWE5R HS Phase 2/3 DMHWE5R SN T-138067; T-138068; T-67 DMHWE5R CP Tularik Inc DMHWE5R DT Small molecular drug DMHWE5R PC 216324 DMHWE5R MW 371.26 DMHWE5R FM C13H7F6NO3S DMHWE5R IC InChI=1S/C13H7F6NO3S/c1-23-7-3-2-5(4-6(7)14)20-24(21,22)13-11(18)9(16)8(15)10(17)12(13)19/h2-4,20H,1H3 DMHWE5R CS COC1=C(C=C(C=C1)NS(=O)(=O)C2=C(C(=C(C(=C2F)F)F)F)F)F DMHWE5R IK ROZCIVXTLACYNY-UHFFFAOYSA-N DMHWE5R IU 2,3,4,5,6-pentafluoro-N-(3-fluoro-4-methoxyphenyl)benzenesulfonamide DMHWE5R CA CAS 195533-53-0 DMHWE5R DE Solid tumour/cancer DMKT16N ID DMKT16N DMKT16N DN Bevacizumab DMKT16N HS Phase 2/3 DMKT16N SN Bevacizumab (ophthalmic slow-release tissue tablet); Avastin DMKT16N TC Antiviral Agents DMKT16N DT Monoclonal antibody DMKT16N DE Metastatic colorectal cancer; Coronavirus Disease 2019 (COVID-19) DMUSJ3D ID DMUSJ3D DMUSJ3D DN BIIB-088 DMUSJ3D HS Phase 2/3 DMUSJ3D SN AGTC 501 DMUSJ3D CP Applied Genetic Technologies DMUSJ3D DT Gene therapy DMUSJ3D DE Retinitis pigmentosa DMYFQJL ID DMYFQJL DMYFQJL DN BNV-222 DMYFQJL HS Phase 2/3 DMYFQJL SN Diepalrestat choline; UNII-16AHE7410O; 16AHE7410O; CHEMBL4297277; Q27251797; 1665300-21-9; Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, (5Z)-5-((2E)-2-methyl-3-phenyl-2-propen-1-ylidene)-4-oxo-2-thioxo-3-thiazolidineacetate, (5Z)-5-((2E)-2-methyl-3-phenyl-2-propen-1-ylidene)-4-oxo-2-thioxo-3-thiazolidineacetate (1:1:1) DMYFQJL CP BioNevia Pharmaceuticals DMYFQJL DT Small molecular drug DMYFQJL PC 117587644 DMYFQJL MW 742 DMYFQJL FM C35H39N3O7S4 DMYFQJL IC InChI=1S/2C15H13NO3S2.C5H14NO/c2*1-10(7-11-5-3-2-4-6-11)8-12-14(19)16(9-13(17)18)15(20)21-12;1-6(2,3)4-5-7/h2*2-8H,9H2,1H3,(H,17,18);7H,4-5H2,1-3H3/q;;+1/p-1/b2*10-7+,12-8-; DMYFQJL CS C/C(=C\\C1=CC=CC=C1)/C=C\\2/C(=O)N(C(=S)S2)CC(=O)O.C/C(=C\\C1=CC=CC=C1)/C=C\\2/C(=O)N(C(=S)S2)CC(=O)[O-].C[N+](C)(C)CCO DMYFQJL IK WKSNHZZSMLFYFI-UROVXFGGSA-M DMYFQJL IU 2-hydroxyethyl(trimethyl)azanium;2-[(5Z)-5-[(E)-2-methyl-3-phenylprop-2-enylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]acetate;2-[(5Z)-5-[(E)-2-methyl-3-phenylprop-2-enylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]acetic acid DMYFQJL CA CAS 1665300-21-9 DMYFQJL DE Diabetic neuropathy DMV52CP ID DMV52CP DMV52CP DN Bucindolol DMV52CP HS Phase 2/3 DMV52CP SN Bucindolol; 71119-11-4; Bucindolol [INN:BAN]; Bucindololum [INN-Latin]; CHEMBL321582; C22H25N3O2; NCGC00167817-01; 2-(2-Hydroxy-3-((2-(1H-indol-3-yl)-1,1-dimethylethyl)amino)propoxy)benzonitrile; DSSTox_RID_81872; DSSTox_CID_26744; DSSTox_GSID_46744; Bucindololum; 2-[2-Hydroxy-3-[2-(indol-3-yl)-1,1-dimethylethylamino]propoxy]benzonitrile; Benzonitrile, 2-(2-hydroxy-3-((2-(1H-indol-3-yl)-1,1-dimethylethyl)amino)propoxy)-; 2-[2-Hydroxy-3-[[2-(1H-indol-3-yl)-1,1-dimethylethyl]amino]propoxy]benzonitrile DMV52CP DT Small molecular drug DMV52CP PC 51045 DMV52CP MW 363.5 DMV52CP FM C22H25N3O2 DMV52CP IC InChI=1S/C22H25N3O2/c1-22(2,11-17-13-24-20-9-5-4-8-19(17)20)25-14-18(26)15-27-21-10-6-3-7-16(21)12-23/h3-10,13,18,24-26H,11,14-15H2,1-2H3 DMV52CP CS CC(C)(CC1=CNC2=CC=CC=C21)NCC(COC3=CC=CC=C3C#N)O DMV52CP IK FBMYKMYQHCBIGU-UHFFFAOYSA-N DMV52CP IU 2-[2-hydroxy-3-[[1-(1H-indol-3-yl)-2-methylpropan-2-yl]amino]propoxy]benzonitrile DMV52CP CA CAS 71119-11-4 DMV52CP DE Hypertension; Atrial fibrillation DM31VZT ID DM31VZT DM31VZT DN CAD-106 DM31VZT HS Phase 2/3 DM31VZT SN Amilomotide; Alzheimers disease vaccine, Cytos/Novartis; Immunodrug vaccines (Alzheimers disease), Cytos/Novartis; Beta amyloid 1-6 peptide/Qbeta virus-like particle conjugate (Alzheimer's disease), Cytos/Novartis DM31VZT CP Cytos Biotechnology AG DM31VZT DT Vaccine DM31VZT DE Alzheimer disease DMVLXMG ID DMVLXMG DMVLXMG DN Camostat mesylate DMVLXMG HS Phase 2/3 DMVLXMG SN Camostat (mesylate); Camostat Methanesulfonate; Camostat methanesulfate; DSSTox_CID_238; DSSTox_GSID_20238; DSSTox_RID_75452; FOY 305; FOY-305; FOY305; Foipan; Foipan (TN); Foipan mesylate; NCGC00167526-01; Q-200778; UNII-451M50A1EQ; camostat mesilate; 451M50A1EQ; C21H26N4O8S; CAS-59721-29-8; CHEMBL85164 DMVLXMG TC Antiviral Agents DMVLXMG DT Small molecular drug DMVLXMG PC 5284360 DMVLXMG MW 494.5 DMVLXMG FM C21H26N4O8S DMVLXMG IC InChI=1S/C20H22N4O5.CH4O3S/c1-24(2)17(25)12-28-18(26)11-13-3-9-16(10-4-13)29-19(27)14-5-7-15(8-6-14)23-20(21)22;1-5(2,3)4/h3-10H,11-12H2,1-2H3,(H4,21,22,23);1H3,(H,2,3,4) DMVLXMG CS CN(C)C(=O)COC(=O)CC1=CC=C(C=C1)OC(=O)C2=CC=C(C=C2)N=C(N)N.CS(=O)(=O)O DMVLXMG IK FSEKIHNIDBATFG-UHFFFAOYSA-N DMVLXMG IU [4-[2-[2-(dimethylamino)-2-oxoethoxy]-2-oxoethyl]phenyl] 4-(diaminomethylideneamino)benzoate;methanesulfonic acid DMVLXMG CA CAS 59721-29-8 DMVLXMG CB CHEBI:31347 DMVLXMG DE Middle East Respiratory Syndrome (MERS); Severe acute respiratory syndrome (SARS); Coronavirus Disease 2019 (COVID-19); Middle East Respiratory Syndrome (MERS); Severe acute respiratory syndrome (SARS) DMST3FM ID DMST3FM DMST3FM DN CART-19 DMST3FM HS Phase 2/3 DMST3FM CP Fujian Medical University DMST3FM DT CAR T Cell Therapy DMST3FM DE Acute lymphoblastic leukaemia DM45Z3P ID DM45Z3P DM45Z3P DN CD123/CLL1 CAR-T Cells DM45Z3P HS Phase 2/3 DM45Z3P CP Fujian Medical University DM45Z3P DT CAR T Cell Therapy (Dual specific) DM45Z3P DE Acute myeloid leukaemia DM32148 ID DM32148 DM32148 DN CD19 CAR T cells DM32148 HS Phase 2/3 DM32148 CP Fujian Medical University DM32148 DT CAR T Cell Therapy DM32148 DE Acute lymphoblastic leukaemia; B-cell lymphoma DMFCLT6 ID DMFCLT6 DMFCLT6 DN CE-224535 DMFCLT6 HS Phase 2/3 DMFCLT6 SN CP-23575 DMFCLT6 CP Pfizer Inc DMFCLT6 DT Small molecular drug DMFCLT6 PC 11547499 DMFCLT6 MW 480.9 DMFCLT6 FM C22H29ClN4O6 DMFCLT6 IC InChI=1S/C22H29ClN4O6/c1-33-13-16(28)12-26-19(29)11-25-27(21(26)31)15-6-7-18(23)17(10-15)20(30)24-14-22(32)8-4-2-3-5-9-22/h6-7,10-11,16,28,32H,2-5,8-9,12-14H2,1H3,(H,24,30)/t16-/m1/s1 DMFCLT6 CS COC[C@@H](CN1C(=O)C=NN(C1=O)C2=CC(=C(C=C2)Cl)C(=O)NCC3(CCCCCC3)O)O DMFCLT6 IK FUCKCIVGBCBZNP-MRXNPFEDSA-N DMFCLT6 IU 2-chloro-N-[(1-hydroxycycloheptyl)methyl]-5-[4-[(2R)-2-hydroxy-3-methoxypropyl]-3,5-dioxo-1,2,4-triazin-2-yl]benzamide DMFCLT6 CA CAS 724424-43-5 DMFCLT6 DE Arthralgia DMXCD69 ID DMXCD69 DMXCD69 DN CEP1347 DMXCD69 HS Phase 2/3 DMXCD69 SN AC1L31ZX; SCHEMBL1649555; ZINC103589452; DB05403 DMXCD69 DT Small molecular drug DMXCD69 PC 9917013 DMXCD69 MW 615.8 DMXCD69 FM C33H33N3O5S2 DMXCD69 IC InChI=1S/C33H33N3O5S2/c1-5-42-15-17-7-9-22-19(11-17)26-27-21(14-34-30(27)37)25-20-12-18(16-43-6-2)8-10-23(20)36-29(25)28(26)35(22)24-13-33(39,31(38)40-4)32(36,3)41-24/h7-12,24,39H,5-6,13-16H2,1-4H3,(H,34,37)/t24-,32+,33+/m1/s1 DMXCD69 CS CCSCC1=CC2=C(C=C1)N3[C@H]4C[C@@]([C@](O4)(N5C6=C(C=C(C=C6)CSCC)C7=C8CNC(=O)C8=C2C3=C75)C)(C(=O)OC)O DMXCD69 IK SCMLRESZJCKCTC-KMYQRJGFSA-N DMXCD69 IU methyl (15S,16R,18R)-10,23-bis(ethylsulfanylmethyl)-16-hydroxy-15-methyl-3-oxo-28-oxa-4,14,19-triazaoctacyclo[12.11.2.115,18.02,6.07,27.08,13.019,26.020,25]octacosa-1,6,8(13),9,11,20(25),21,23,26-nonaene-16-carboxylate DMXCD69 CA CAS 156177-65-0 DMXCD69 DE Asthma DMUOMBZ ID DMUOMBZ DMUOMBZ DN CLL1 CAR-T Cell DMUOMBZ HS Phase 2/3 DMUOMBZ CP Fujian Medical University DMUOMBZ DT CAR T Cell Therapy (Dual specific) DMUOMBZ DE Acute myeloid leukaemia DMX9V8K ID DMX9V8K DMX9V8K DN Contigoside B DMX9V8K HS Phase 2/3 DMX9V8K SN Isoquercitrin; Isoquercetin; 482-35-9; Hirsutrin; 3-Glucosylquercetin; Glucosyl 3-quercetin; Quercetin 3-glucoside; Quercetol 3-glucoside; Quercetin 3-o-glucopyranoside; Quercetin 3-D-glucoside; Quercetol 3-monoglucoside; Quercetin 3-monoglucoside; Isotrifoliin; Quercetin 3-beta-glucoside; Quercetin 3-O-glucoside; quercetin-3-glucoside; Quercetin 3-beta-O-glucoside; Quercetin-3-O-glucopyranoside; UNII-6HN2PC637T; quercetin-3-O-glucoside; NSC 115918; BRN 0100989; CHEMBL250450; 6HN2PC637T; CHEBI:68352; quercetin 3-O-beta-D-glucopyran DMX9V8K DT Small molecular drug DMX9V8K PC 5280804 DMX9V8K MW 464.4 DMX9V8K FM C21H20O12 DMX9V8K IC InChI=1S/C21H20O12/c22-6-13-15(27)17(29)18(30)21(32-13)33-20-16(28)14-11(26)4-8(23)5-12(14)31-19(20)7-1-2-9(24)10(25)3-7/h1-5,13,15,17-18,21-27,29-30H,6H2/t13-,15-,17+,18-,21+/m1/s1 DMX9V8K CS C1=CC(=C(C=C1C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)O)O DMX9V8K IK OVSQVDMCBVZWGM-QSOFNFLRSA-N DMX9V8K IU 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-4-one DMX9V8K CA CAS 482-35-9 DMX9V8K CB CHEBI:68352 DMX9V8K DE Thrombosis DMJYTUQ ID DMJYTUQ DMJYTUQ DN CR-845 DMJYTUQ HS Phase 2/3 DMJYTUQ SN Kappa opioid agonist (intravenous, pain), Cara/Ferring; Kappa opioid agonist (oral, pain), Cara/Ferring; Kappa opioid agonist (subcutaneous, pain), Cara/Ferring; CR-845 (iv infusion, pain), Cara/Ferring; CR-845 (oral capsule, pain), Cara/Ferring; CR-845 (subcutaneous, pain), Cara/Ferring; FE-202845 (iv, pain), Cara/Ferring; FE-202845 (oral, pain), Cara/Ferring; FE-202845 (sc, pain), Cara/Ferring DMJYTUQ CP Cara Therapeutics Inc; cara therapeutics DMJYTUQ DE Pain; Chronic pain DMSR7D2 ID DMSR7D2 DMSR7D2 DN CX-516 DMSR7D2 HS Phase 2/3 DMSR7D2 SN Ampalex; BDP 12; CX 516; CX516; BDP-12; SPD-420; Piperidin-1-yl(quinoxalin-6-yl)methanone; 1-(6-Quinoxalinylcarbonyl)piperidine; 1-(6-quinoxalinylcarbonyl)-Piperidine; 1-(quinoxalin-6-ylcarbonyl)piperidine; 6-(piperidin-1-ylcarbonyl)quinoxaline DMSR7D2 CP Cortex DMSR7D2 DT Small molecular drug DMSR7D2 PC 148184 DMSR7D2 MW 241.29 DMSR7D2 FM C14H15N3O DMSR7D2 IC InChI=1S/C14H15N3O/c18-14(17-8-2-1-3-9-17)11-4-5-12-13(10-11)16-7-6-15-12/h4-7,10H,1-3,8-9H2 DMSR7D2 CS C1CCN(CC1)C(=O)C2=CC3=NC=CN=C3C=C2 DMSR7D2 IK ANDGGVOPIJEHOF-UHFFFAOYSA-N DMSR7D2 IU piperidin-1-yl(quinoxalin-6-yl)methanone DMSR7D2 CA CAS 154235-83-3 DMSR7D2 CB CHEBI:34605 DMSR7D2 DE Pervasive developmental disorder; Schizophrenia DML906E ID DML906E DML906E DN CY-1503 DML906E HS Phase 2/3 DML906E SN Cylexin DML906E CP Epimmune Inc DML906E DE Hypertension DMYVKM5 ID DMYVKM5 DMYVKM5 DN Darbufelone DMYVKM5 HS Phase 2/3 DMYVKM5 SN PD-136095 DMYVKM5 CP Parke-Davis & Co DMYVKM5 DT Small molecular drug DMYVKM5 PC 6444826 DMYVKM5 MW 332.5 DMYVKM5 FM C18H24N2O2S DMYVKM5 IC InChI=1S/C18H24N2O2S/c1-17(2,3)11-7-10(8-12(14(11)21)18(4,5)6)9-13-15(22)20-16(19)23-13/h7-9,21H,1-6H3,(H2,19,20,22)/b13-9- DMYVKM5 CS CC(C)(C)C1=CC(=CC(=C1O)C(C)(C)C)/C=C\\2/C(=O)N=C(S2)N DMYVKM5 IK AKTXOQVMWSFEBQ-LCYFTJDESA-N DMYVKM5 IU (5Z)-2-amino-5-[(3,5-ditert-butyl-4-hydroxyphenyl)methylidene]-1,3-thiazol-4-one DMYVKM5 CA CAS 139226-28-1 DMYVKM5 DE Asthma DMZV3SY ID DMZV3SY DMZV3SY DN Denagliptin DMZV3SY HS Phase 2/3 DMZV3SY SN GW 823093; GW823093; (2S,4S)-1-[(2S)-2-amino-3,3-bis(4-fluorophenyl)propanoyl]-4-fluoro-pyrrolidine-2-carbonitrile DMZV3SY CP Glaxo Smithkline DMZV3SY DT Small molecular drug DMZV3SY PC 9887755 DMZV3SY MW 373.4 DMZV3SY FM C20H18F3N3O DMZV3SY IC InChI=1S/C20H18F3N3O/c21-14-5-1-12(2-6-14)18(13-3-7-15(22)8-4-13)19(25)20(27)26-11-16(23)9-17(26)10-24/h1-8,16-19H,9,11,25H2/t16-,17-,19-/m0/s1 DMZV3SY CS C1[C@@H](CN([C@@H]1C#N)C(=O)[C@H](C(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F)N)F DMZV3SY IK URRAHSMDPCMOTH-LNLFQRSKSA-N DMZV3SY IU (2S,4S)-1-[(2S)-2-amino-3,3-bis(4-fluorophenyl)propanoyl]-4-fluoropyrrolidine-2-carbonitrile DMZV3SY CA CAS 483369-58-0 DMZV3SY DE Type-2 diabetes DMVSIN2 ID DMVSIN2 DMVSIN2 DN Emapalumab DMVSIN2 HS Phase 2/3 DMVSIN2 SN emapalumab; Gamifant; emapalumab-lzsg; GTPL9295; Ni-0501; NI0501 DMVSIN2 TC Antiviral Agents DMVSIN2 DT Monoclonal antibody DMVSIN2 DE Coronavirus Disease 2019 (COVID-19) DMH8VMP ID DMH8VMP DMH8VMP DN Emixustat DMH8VMP HS Phase 2/3 DMH8VMP SN EMIXUSTAT; UNII-02DZ1HBF0M; 1141777-14-1; 02DZ1HBF0M; Emixustat [USAN:INN]; (1R)-3-amino-1-[3-(cyclohexylmethoxy)phenyl]propan-1-ol; Incemixustat; ACU 4229; A3V; Emixustat (USAN); SCHEMBL966515; CHEMBL2107821; DTXSID50150665; WJIGGYYSZBWCGC-MRXNPFEDSA-N; ZINC59126886; AKOS032945088; CS-6177; DB12608; HY-19720; D10348; (r)-3-amino-1-(3-(cyclohexylmethoxy)phenyl)propan-1-ol; 3-Amino-1-[3-(cyclohexylmethoxy)phenyl]propan-1(R)-ol hydro -chloride DMH8VMP CP Acucela Seattle, WA DMH8VMP DT Small molecular drug DMH8VMP PC 25221720 DMH8VMP MW 263.37 DMH8VMP FM C16H25NO2 DMH8VMP IC InChI=1S/C16H25NO2/c17-10-9-16(18)14-7-4-8-15(11-14)19-12-13-5-2-1-3-6-13/h4,7-8,11,13,16,18H,1-3,5-6,9-10,12,17H2/t16-/m1/s1 DMH8VMP CS C1CCC(CC1)COC2=CC=CC(=C2)[C@@H](CCN)O DMH8VMP IK WJIGGYYSZBWCGC-MRXNPFEDSA-N DMH8VMP IU (1R)-3-amino-1-[3-(cyclohexylmethoxy)phenyl]propan-1-ol DMH8VMP CA CAS 1141777-14-1 DMH8VMP DE Age-related macular degeneration; Proliferative diabetic retinopathy DMOYE70 ID DMOYE70 DMOYE70 DN Fexinidazole DMOYE70 HS Phase 2/3 DMOYE70 SN Fexinidazole (human African trypanosomiasis); Fexinidazole (African sleeping sickness), Drugs for Neglected Diseases initiative; Fexinidazole (HAT), Drugs for Neglected Diseases initiative; Fexinidazole (human African trypanosomiasis), Drugs for Neglected Diseases initiative DMOYE70 CP Drugs for Neglected Diseases initiative DMOYE70 DT Small molecular drug DMOYE70 PC 68792 DMOYE70 MW 279.32 DMOYE70 FM C12H13N3O3S DMOYE70 IC InChI=1S/C12H13N3O3S/c1-14-11(13-7-12(14)15(16)17)8-18-9-3-5-10(19-2)6-4-9/h3-7H,8H2,1-2H3 DMOYE70 CS CN1C(=CN=C1COC2=CC=C(C=C2)SC)[N+](=O)[O-] DMOYE70 IK MIWWSGDADVMLTG-UHFFFAOYSA-N DMOYE70 IU 1-methyl-2-[(4-methylsulfanylphenoxy)methyl]-5-nitroimidazole DMOYE70 CA CAS 59729-37-2 DMOYE70 DE Trypanosomiasis DMH7CSQ ID DMH7CSQ DMH7CSQ DN Gavilimomab DMH7CSQ HS Phase 2/3 DMH7CSQ SN ABX-CBL; CBL-1 DMH7CSQ CP Abgenix Inc DMH7CSQ DT Antibody DMH7CSQ DE Graft-versus-host disease DM0JETC ID DM0JETC DM0JETC DN Genistein DM0JETC HS Phase 2/3 DM0JETC SN Bonistein; GEN; Genestein; Genisteol; Genisterin; Prunetol; Sophoricol; Differenol A; G 6649; G10000; IN1327; NPI 031L; STO514; TNP00151; GENISTEIN (ENDOCRINE DISRUPTER); Lactoferrin-genistein; PTI G4660 (Genistein); PTI-G4660; SIPI 807-1; C.I. 75610; SIPI-9764-I; ENDOCRINE DISRUPTOR (GENISTEIN) (SEE ALSO GENISTEIN (446-72-0)); 4 inverted exclamation marka,5,7-Trihydroxyisoflavone; ,5,7-Trihydroxyisoflavone; 4',5, 7-Trihydroxyisoflavone; 4',5,7-Trihydroxy isoflavone; 4',5,7-Trihydroxyisoflavone; 4,5,7-Trihydroxyiso-flavone; 4,6,7-Trihydroxyisoflavone; 5,7,4'-Trihydroxyisoflavone; 5,7-Dihydroxy-3-(4-hydroxyphenyl)-4-benzopyrone; 5,7-Dihydroxy-3-(4-hydroxyphenyl)-4H-1-benzopyran-4-one; 5,7-dihydroxy-3-(4-hydroxyphenyl)-4H-chromen-4-one; 5,7-dihydroxy-3-(4-hydroxyphenyl)chromen-4-one DM0JETC CP DSM Nutritional Products DM0JETC DT Small molecular drug DM0JETC PC 5280961 DM0JETC MW 270.24 DM0JETC FM C15H10O5 DM0JETC IC InChI=1S/C15H10O5/c16-9-3-1-8(2-4-9)11-7-20-13-6-10(17)5-12(18)14(13)15(11)19/h1-7,16-18H DM0JETC CS C1=CC(=CC=C1C2=COC3=CC(=CC(=C3C2=O)O)O)O DM0JETC IK TZBJGXHYKVUXJN-UHFFFAOYSA-N DM0JETC IU 5,7-dihydroxy-3-(4-hydroxyphenyl)chromen-4-one DM0JETC CA CAS 446-72-0 DM0JETC CB CHEBI:28088 DM0JETC DE Prostate cancer; Menopause symptom DMW7TZV ID DMW7TZV DMW7TZV DN GS-6207 DMW7TZV HS Phase 2/3 DMW7TZV SN 2189684-45-3; N-[(1R)-1-[3-[4-Chloro-3-(cyclopropylsulfonylamino)-1-(2,2-difluoroethyl)indazol-7-yl]-6-(3-methyl-3-methylsulfonylbut-1-ynyl)pyridin-2-yl]-2-(3,5-difluorophenyl)ethyl]-2-[(2R,4S)-9-(difluoromethyl)-5,5-difluoro-7,8-diazatricyclo[4.3.0.02,4]nona-1(6),8-dien-7-yl]acetamide DMW7TZV CP Gilead Sciences DMW7TZV DT Small molecular drug DMW7TZV PC 138059678 DMW7TZV MW 958.3 DMW7TZV FM C41H36ClF8N7O5S2 DMW7TZV IC InChI=1S/C41H36ClF8N7O5S2/c1-40(2,63(3,59)60)11-10-22-4-7-24(25-8-9-28(42)33-36(25)56(17-30(45)46)54-39(33)55-64(61,62)23-5-6-23)34(51-22)29(14-19-12-20(43)15-21(44)13-19)52-31(58)18-57-37-32(35(53-57)38(47)48)26-16-27(26)41(37,49)50/h4,7-9,12-13,15,23,26-27,29-30,38H,5-6,14,16-18H2,1-3H3,(H,52,58)(H,54,55)/t26-,27+,29-/m1/s1 DMW7TZV CS CC(C)(C#CC1=NC(=C(C=C1)C2=C3C(=C(C=C2)Cl)C(=NN3CC(F)F)NS(=O)(=O)C4CC4)[C@@H](CC5=CC(=CC(=C5)F)F)NC(=O)CN6C7=C([C@@H]8C[C@@H]8C7(F)F)C(=N6)C(F)F)S(=O)(=O)C DMW7TZV IK CPCUUUACFKQOHY-IUAQSZDVSA-N DMW7TZV IU N-[(1R)-1-[3-[4-chloro-3-(cyclopropylsulfonylamino)-1-(2,2-difluoroethyl)indazol-7-yl]-6-(3-methyl-3-methylsulfonylbut-1-ynyl)pyridin-2-yl]-2-(3,5-difluorophenyl)ethyl]-2-[(2R,4S)-9-(difluoromethyl)-5,5-difluoro-7,8-diazatricyclo[4.3.0.02,4]nona-1(6),8-dien-7-yl]acetamide DMW7TZV DE Human immunodeficiency virus infection DMMTL7V ID DMMTL7V DMMTL7V DN Hemoglobin raffimer DMMTL7V HS Phase 2/3 DMMTL7V SN Hemolink; Cross-linked hemoglobin, Hemosol DMMTL7V CP Ontario Inc DMMTL7V DE Anemia DMPLQ1V ID DMPLQ1V DMPLQ1V DN IFX-1 DMPLQ1V HS Phase 2/3 DMPLQ1V SN IFX-1 mab DMPLQ1V TC Antiviral Agents DMPLQ1V DT Monoclonal antibody DMPLQ1V DE Coronavirus Disease 2019 (COVID-19) DMONWJ4 ID DMONWJ4 DMONWJ4 DN Imetelstat DMONWJ4 HS Phase 2/3 DMONWJ4 SN Motesanib diphosphate; 857876-30-3; Motesanib (Diphosphate); Motesanib Diphosphate (AMG-706); UNII-T6Q3060U91; Motesanib diphosphate [USAN]; T6Q3060U91; Motesanib diphosphate (USAN); AMG-706 diphosphate; Motesanib phosphate (JAN); bis(phosphoric acid); Motesanib Diphosphate/AMG-706; CHEMBL2107357; DTXSID30235080; C22H29N5O9P2; MolPort-016-633-170; HMS3654K07; AOB87339; ABP000867; AKOS026750408; CS-0193; API0006359; AN-5306; SB16584; RL05311; AS-17019; HY-10229; SW218300-2; FT-0672543; X7466; D08947; W-5527; A841448 DMONWJ4 CP Geron DMONWJ4 DT Small molecular drug DMONWJ4 PC 71587831 DMONWJ4 MW 4610 DMONWJ4 FM C148H211N68O53P13S13 DMONWJ4 IC InChI=1S/C148H211N68O53P13S13/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18-97(218)160-34-69(217)38-255-282(242,295)256-51-95-74(25-102(261-95)207-37-68(4)136(221)191-148(207)229)195-274(234,287)249-45-89-78(29-106(264-89)212-61-175-115-124(155)165-56-170-129(115)212)199-277(237,290)252-48-92-81(32-109(267-92)215-64-178-118-132(215)183-143(158)187-139(118)224)202-280(240,293)254-50-94-82(33-110(269-94)216-65-179-119-133(216)184-144(159)188-140(119)225)203-281(241,294)253-49-93-79(30-107(268-93)213-62-176-116-130(213)181-141(156)185-137(116)222)200-278(238,291)246-42-86-72(23-100(260-86)205-35-66(2)134(219)189-146(205)227)193-272(232,285)245-41-85-73(24-101(259-85)206-36-67(3)135(220)190-147(206)228)194-273(233,286)248-44-88-77(28-105(263-88)211-60-174-114-123(154)164-55-169-128(114)211)198-276(236,289)251-47-91-80(31-108(266-91)214-63-177-117-131(214)182-142(157)186-138(117)223)201-279(239,292)250-46-90-76(27-104(265-90)210-59-173-113-122(153)163-54-168-127(113)210)197-275(235,288)244-40-84-71(22-99(258-84)204-20-19-96(150)180-145(204)226)192-271(231,284)247-43-87-75(26-103(262-87)209-58-172-112-121(152)162-53-167-126(112)209)196-270(230,283)243-39-83-70(149)21-98(257-83)208-57-171-111-120(151)161-52-166-125(111)208/h19-20,35-37,52-65,69-95,98-110,217H,5-18,21-34,38-51,149H2,1-4H3,(H,160,218)(H,242,295)(H2,150,180,226)(H2,151,161,166)(H2,152,162,167)(H2,153,163,168)(H2,154,164,169)(H2,155,165,170)(H,189,219,227)(H,190,220,228)(H,191,221,229)(H2,192,231,284)(H2,193,232,285)(H2,194,233,286)(H2,195,234,287)(H2,196,230,283)(H2,197,235,288)(H2,198,236,289)(H2,199,237,290)(H2,200,238,291)(H2,201,239,292)(H2,202,240,293)(H2,203,241,294)(H3,156,181,185,222)(H3,157,182,186,223)(H3,158,183,187,224)(H3,159,184,188,225)/t69?,70-,71-,72-,73-,74-,75-,76-,77-,78-,79-,80-,81-,82-,83+,84+,85+,86+,87+,88+,89+,90+,91+,92+,93+,94+,95+,98+,99+,100+,101+,102+,103+,104+,105+,106+,107+,108+,109+,110+,270?,271?,272?,273?,274?,275?,276?,277?,278?,279?,280?,281?,282?/m0/s1 DMONWJ4 CS CCCCCCCCCCCCCCCC(=O)NCC(COP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N2C=C(C(=O)NC2=O)C)NP(=S)(O)OC[C@@H]3[C@H](C[C@@H](O3)N4C=NC5=C(N=CN=C54)N)NP(=S)(O)OC[C@@H]6[C@H](C[C@@H](O6)N7C=NC8=C7N=C(NC8=O)N)NP(=S)(O)OC[C@@H]9[C@H](C[C@@H](O9)N1C=NC2=C1N=C(NC2=O)N)NP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N1C=NC2=C1N=C(NC2=O)N)NP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N1C=C(C(=O)NC1=O)C)NP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N1C=C(C(=O)NC1=O)C)NP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N1C=NC2=C(N=CN=C21)N)NP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N1C=NC2=C1N=C(NC2=O)N)NP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N1C=NC2=C(N=CN=C21)N)NP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N1C=CC(=NC1=O)N)NP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N1C=NC2=C(N=CN=C21)N)NP(=O)(OC[C@@H]1[C@H](C[C@@H](O1)N1C=NC2=C(N=CN=C21)N)N)S)O DMONWJ4 IK LVZYXEALRXBLJZ-ISQYCPACSA-N DMONWJ4 IU N-[3-[[(2S,3S,5R)-3-[[[(2S,3S,5R)-3-[[[(2S,3S,5R)-3-[[[(2S,3S,5R)-3-[[[(2S,3S,5R)-3-[[[(2S,3S,5R)-3-[[[(2S,3S,5R)-3-[[[(2S,3S,5R)-3-[[[(2S,3S,5R)-3-[[[(2S,3S,5R)-3-[[[(2S,3S,5R)-3-[[[(2S,3S,5R)-3-[[[(2S,3S,5R)-3-amino-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-sulfanylphosphoryl]amino]-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]amino]-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]amino]-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]amino]-5-(2-amino-6-oxo-1H-purin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]amino]-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]amino]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]amino]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]amino]-5-(2-amino-6-oxo-1H-purin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]amino]-5-(2-amino-6-oxo-1H-purin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]amino]-5-(2-amino-6-oxo-1H-purin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]amino]-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]amino]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-2-hydroxypropyl]hexadecanamide DMONWJ4 CA CAS 868169-64-6 DMONWJ4 DE Multiple myeloma; Breast cancer; Non-small-cell lung cancer; Essential thrombocythemia; Myelodysplastic syndrome; Myelofibrosis DMIUA3M ID DMIUA3M DMIUA3M DN Imprime PGG DMIUA3M HS Phase 2/3 DMIUA3M SN Imprime PGG (TN) DMIUA3M CP Biothera DMIUA3M DE Breast cancer; Colorectal cancer; Head and neck cancer; Melanoma; Non-hodgkin lymphoma DM5UJ9P ID DM5UJ9P DM5UJ9P DN IMU-838 DM5UJ9P HS Phase 2/3 DM5UJ9P SN Vidofludimus; 717824-30-1; 4SC-101; SC12267; UNII-8Y1PJ3VG81; SC 12267; CHEMBL197194; 8Y1PJ3VG81; Vidofludimus(4SC-101; SC12267); Vidofludimus [INN]; SCHEMBL247888; GTPL9860; KS-00000TTT; BDBM16111; EX-A546; IMU-838; DTXSID50431325; HMS3740I15; AOB87354; BCP14555; ZINC14960644; s7262; AK; Vidofludimus DM5UJ9P TC Antiviral Agents DM5UJ9P DT Small molecular drug DM5UJ9P PC 9820008 DM5UJ9P MW 355.4 DM5UJ9P FM C20H18FNO4 DM5UJ9P IC InChI=1S/C20H18FNO4/c1-26-14-5-2-4-12(10-14)13-8-9-18(17(21)11-13)22-19(23)15-6-3-7-16(15)20(24)25/h2,4-5,8-11H,3,6-7H2,1H3,(H,22,23)(H,24,25) DM5UJ9P CS COC1=CC=CC(=C1)C2=CC(=C(C=C2)NC(=O)C3=C(CCC3)C(=O)O)F DM5UJ9P IK XPRDUGXOWVXZLL-UHFFFAOYSA-N DM5UJ9P IU 2-[[2-fluoro-4-(3-methoxyphenyl)phenyl]carbamoyl]cyclopentene-1-carboxylic acid DM5UJ9P CA CAS 717824-30-1 DM5UJ9P DE Coronavirus Disease 2019 (COVID-19) DMC3794 ID DMC3794 DMC3794 DN Indium-111 DMC3794 HS Phase 2/3 DMC3794 SN ABT-806 DMC3794 CP Abbott Laboratories Abbott DMC3794 DT Antibody DMC3794 DE Solid tumour/cancer DMGPJ5U ID DMGPJ5U DMGPJ5U DN JNJ-54861911 DMGPJ5U HS Phase 2/3 DMGPJ5U CP Janssen research & development DMGPJ5U PC 68254185 DMGPJ5U MW 367.4 DMGPJ5U FM C18H14FN5OS DMGPJ5U IC InChI=1S/C18H14FN5OS/c1-18(6-7-26-17(21)24-18)13-8-12(3-4-14(13)19)23-16(25)15-5-2-11(9-20)10-22-15/h2-8,10H,1H3,(H2,21,24)(H,23,25)/t18-/m0/s1 DMGPJ5U CS C[C@]1(C=CSC(=N1)N)C2=C(C=CC(=C2)NC(=O)C3=NC=C(C=C3)C#N)F DMGPJ5U IK VLLFGVHGKLDDLW-SFHVURJKSA-N DMGPJ5U IU N-[3-[(4S)-2-amino-4-methyl-1,3-thiazin-4-yl]-4-fluorophenyl]-5-cyanopyridine-2-carboxamide DMGPJ5U CA CAS 1200493-78-2 DMGPJ5U DE Alzheimer disease DMBJ4IZ ID DMBJ4IZ DMBJ4IZ DN LECOZOTAN HYDROCHLORIDE DMBJ4IZ HS Phase 2/3 DMBJ4IZ SN Lecozotan hydrochloride < USAN; SRA-333; 4-Cyano-N-[2(R)-[4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]propyl]-N-(2-pyridyl)benzamide hydrochloride DMBJ4IZ DT Small molecular drug DMBJ4IZ PC 11156648 DMBJ4IZ MW 520 DMBJ4IZ FM C28H30ClN5O3 DMBJ4IZ IC InChI=1S/C28H29N5O3.ClH/c1-21(31-13-15-32(16-14-31)24-5-4-6-25-27(24)36-18-17-35-25)20-33(26-7-2-3-12-30-26)28(34)23-10-8-22(19-29)9-11-23;/h2-12,21H,13-18,20H2,1H3;1H/t21-;/m1./s1 DMBJ4IZ CS C[C@H](CN(C1=CC=CC=N1)C(=O)C2=CC=C(C=C2)C#N)N3CCN(CC3)C4=C5C(=CC=C4)OCCO5.Cl DMBJ4IZ IK GXYZREDEYDFJPT-ZMBIFBSDSA-N DMBJ4IZ IU 4-cyano-N-[(2R)-2-[4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]propyl]-N-pyridin-2-ylbenzamide;hydrochloride DMBJ4IZ CA CAS 433282-68-9 DMBJ4IZ DE Cognitive impairment DMEUGZL ID DMEUGZL DMEUGZL DN Legumain-cleavable doxorubicin prodrugs DMEUGZL HS Phase 2/3 DMEUGZL SN Legubicin; LEG-2; LEG-3; Legumain-cleavable doxorubicin prodrugs (cancer); Legumain-cleavabledoxorubicin prodrugs (cancer), Affinity Pharmaceuticals DMEUGZL CP Scripps Research Institute DMEUGZL DE Solid tumour/cancer DM4OYXE ID DM4OYXE DM4OYXE DN LIAROZOLE DM4OYXE HS Phase 2/3 DM4OYXE SN Liarozole; Liazal; 115575-11-6; R-75251; LIAROZOLE FUMARATE; Liarozole [INN:BAN]; Liarozolum [INN-Latin]; Liarozol [INN-Spanish]; R 75251; R-61405; R085246; R 61405; R-085246; R 085246; 6-((3-chlorophenyl)(1H-imidazol-1-yl)methyl)-1H-benzo[d]imidazole; UNII-17NYD2210B; CHEMBL389433; UNII-090Y06W08H; 17NYD2210B; 090Y06W08H; Liarozolum; Liarozol; 1H-Benzimidazole, 5-((3-chlorophenyl)-1H-imidazol-1-ylmethyl)-; NCGC00181034-01; Liarozole, (-)-; Liarozole, (+)-; AC1L1TNN; AC1Q3M3B; SCHEMBL18597; GTPL5210; SCHEMBL15944205; DTXSID9048277 DM4OYXE DT Small molecular drug DM4OYXE PC 60652 DM4OYXE MW 308.8 DM4OYXE FM C17H13ClN4 DM4OYXE IC InChI=1S/C17H13ClN4/c18-14-3-1-2-12(8-14)17(22-7-6-19-11-22)13-4-5-15-16(9-13)21-10-20-15/h1-11,17H,(H,20,21) DM4OYXE CS C1=CC(=CC(=C1)Cl)C(C2=CC3=C(C=C2)N=CN3)N4C=CN=C4 DM4OYXE IK UGFHIPBXIWJXNA-UHFFFAOYSA-N DM4OYXE IU 6-[(3-chlorophenyl)-imidazol-1-ylmethyl]-1H-benzimidazole DM4OYXE CA CAS 115575-11-6 DM4OYXE CB CHEBI:135316 DM4OYXE DE Dermatological disease DMI215P ID DMI215P DMI215P DN Lopinavir + ritonavir + interferon beta-1b DMI215P HS Phase 2/3 DMI215P SN Aluviran + norvir + betaseron DMI215P TC Antiviral Agents DMI215P DT Combination drug DMI215P DE Middle East Respiratory Syndrome (MERS) DMP8HW1 ID DMP8HW1 DMP8HW1 DN LY2157299 DMP8HW1 HS Phase 2/3 DMP8HW1 SN Galunisertib; 700874-72-2; LY2157299; LY 2157299; LY-2157299; UNII-3OKH1W5LZE; 4-(2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 3OKH1W5LZE; Galunisertib (LY2157299); AK-79916; 4-[5,6-Dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-quinolinecarboxamide; 4-(2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo-[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 4-[2-(6-methylpyridin-2-yl)-4H,5H,6H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide DMP8HW1 CP Eli Lilly DMP8HW1 DT Small molecular drug DMP8HW1 PC 10090485 DMP8HW1 MW 369.4 DMP8HW1 FM C22H19N5O DMP8HW1 IC InChI=1S/C22H19N5O/c1-13-4-2-5-18(25-13)21-20(19-6-3-11-27(19)26-21)15-9-10-24-17-8-7-14(22(23)28)12-16(15)17/h2,4-5,7-10,12H,3,6,11H2,1H3,(H2,23,28) DMP8HW1 CS CC1=NC(=CC=C1)C2=NN3CCCC3=C2C4=C5C=C(C=CC5=NC=C4)C(=O)N DMP8HW1 IK IVRXNBXKWIJUQB-UHFFFAOYSA-N DMP8HW1 IU 4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide DMP8HW1 CA CAS 700874-72-2 DMP8HW1 CB CHEBI:137064 DMP8HW1 DE Arteriosclerosis; Glioma; Hepatocellular carcinoma; Pancreatic cancer; Solid tumour/cancer; Non-small-cell lung cancer DMUQWRD ID DMUQWRD DMUQWRD DN LYS-SAF302 DMUQWRD HS Phase 2/3 DMUQWRD SN SRP-9002 DMUQWRD CP Lysogene; Sarepta Therapeutics DMUQWRD DT Gene therapy DMUQWRD DE Mucopolysaccharidosis DM948AP ID DM948AP DM948AP DN MAb114 DM948AP HS Phase 2/3 DM948AP CP Ridgeback Biotherapeutics DM948AP DT Antibody DM948AP DE Ebola virus infection DMONYS9 ID DMONYS9 DMONYS9 DN MBX-102 DMONYS9 HS Phase 2/3 DMONYS9 SN Arhalofenate; Mbx-102; MBX 102; 24136-23-0; UNII-1P01UJR9X1; JNJ-39659100; 1P01UJR9X1; CB-102; M-102; Arhalofenate [USAN:INN]; Arhalofenate (USAN/INN); SCHEMBL3302781; CHEMBL2103824; BJBCSGQLZQGGIQ-QGZVFWFLSA-N; ZINC2012859; BDBM50093473; AKOS032945719; DB11811; CS-6812; SB16866; (-)-2-(Acetylamino)ethyl (2R)-(4-chlorophenyl)(3-(trifluoromethyl)phenoxy)acetate; CJ-31172; Benzeneacetic acid, 4-chloro-alpha-(3-(trifluoromethyl)phenoxy)-, 2-(acetylamino)ethyl ester, (-)-; HY-14831; D09579; UNII-K9TZK4MNO6 component BJBCSGQLZQGGIQ-QGZV DMONYS9 CP Metabolex DMONYS9 DT Small molecular drug DMONYS9 PC 12082259 DMONYS9 MW 415.8 DMONYS9 FM C19H17ClF3NO4 DMONYS9 IC InChI=1S/C19H17ClF3NO4/c1-12(25)24-9-10-27-18(26)17(13-5-7-15(20)8-6-13)28-16-4-2-3-14(11-16)19(21,22)23/h2-8,11,17H,9-10H2,1H3,(H,24,25)/t17-/m1/s1 DMONYS9 CS CC(=O)NCCOC(=O)[C@@H](C1=CC=C(C=C1)Cl)OC2=CC=CC(=C2)C(F)(F)F DMONYS9 IK BJBCSGQLZQGGIQ-QGZVFWFLSA-N DMONYS9 IU 2-acetamidoethyl (2R)-2-(4-chlorophenyl)-2-[3-(trifluoromethyl)phenoxy]acetate DMONYS9 CA CAS 24136-23-0 DMONYS9 DE Gout DMNTCV4 ID DMNTCV4 DMNTCV4 DN MBX-8025 DMNTCV4 HS Phase 2/3 DMNTCV4 SN Ppar; A agonist 2; SCHEMBL4950228; CHEMBL3545019; XJHXZGHPCAKRFK-UHFFFAOYSA-N; HY-100120; CS-0018099; {2-Methyl-4-[5-methyl-2-(4-trifluoromethyl-phenyl)-2H-[1,2,3]triazol-4-ylmethylsulfanyl]-phenoxy}-acetic acid DMNTCV4 CP Metabolex DMNTCV4 DT Small molecular drug DMNTCV4 PC 11236126 DMNTCV4 MW 444.5 DMNTCV4 FM C21H23F3O5S DMNTCV4 IC InChI=1S/C21H23F3O5S/c1-3-27-17(11-28-16-6-4-15(5-7-16)21(22,23)24)13-30-18-8-9-19(14(2)10-18)29-12-20(25)26/h4-10,17H,3,11-13H2,1-2H3,(H,25,26)/t17-/m1/s1 DMNTCV4 CS CCO[C@H](COC1=CC=C(C=C1)C(F)(F)F)CSC2=CC(=C(C=C2)OCC(=O)O)C DMNTCV4 IK JWHYSEDOYMYMNM-QGZVFWFLSA-N DMNTCV4 IU 2-[4-[(2R)-2-ethoxy-3-[4-(trifluoromethyl)phenoxy]propyl]sulfanyl-2-methylphenoxy]acetic acid DMNTCV4 CA CAS 851528-79-5 DMNTCV4 DE Obesity; Familial hypercholesterolemia; Primary biliary cholangitis DMBIO6E ID DMBIO6E DMBIO6E DN Meclinertant DMBIO6E HS Phase 2/3 DMBIO6E SN Reminertant; SR 48692; SR48692; SR-48692; 2-(((1-(7-Chloroquinolin-4-yl)-5-(2,6-dimethoxyphenyl)-1H-pyrazol-3-yl)carbonyl)amino)tricyclo(3.3.1.1(sup 3,7))decane-2-carboxylic acid; 2-((1-(7-Chloro-4-quinolinyl)-5-(2,6-dimethoxyphenyl)pyrazol-3-yl)carbonylamino)tricyclo(3.3.1.1.(3.7))decan-2-carboxylic acid;2-[[1-(7-chloroquinolin-4-yl)-5-(2,6-dimethoxyphenyl)pyrazole-3-carbonyl]amino]adamantane-2-carboxylic acid DMBIO6E CP Sanofi-aventis DMBIO6E TC Anticancer Agents DMBIO6E DT Small molecular drug DMBIO6E PC 119192 DMBIO6E MW 587.1 DMBIO6E FM C32H31ClN4O5 DMBIO6E IC InChI=1S/C32H31ClN4O5/c1-41-27-4-3-5-28(42-2)29(27)26-16-24(36-37(26)25-8-9-34-23-15-21(33)6-7-22(23)25)30(38)35-32(31(39)40)19-11-17-10-18(13-19)14-20(32)12-17/h3-9,15-20H,10-14H2,1-2H3,(H,35,38)(H,39,40) DMBIO6E CS COC1=C(C(=CC=C1)OC)C2=CC(=NN2C3=C4C=CC(=CC4=NC=C3)Cl)C(=O)NC5(C6CC7CC(C6)CC5C7)C(=O)O DMBIO6E IK DYLJVOXRWLXDIG-UHFFFAOYSA-N DMBIO6E IU 2-[[1-(7-chloroquinolin-4-yl)-5-(2,6-dimethoxyphenyl)pyrazole-3-carbonyl]amino]adamantane-2-carboxylic acid DMBIO6E CA CAS 146362-70-1 DMBIO6E CB CHEBI:125516 DMBIO6E DE Inflammatory bowel disease DMFE0P1 ID DMFE0P1 DMFE0P1 DN Metformin glycinate DMFE0P1 HS Phase 2/3 DMFE0P1 SN DMMET-01; Metformin glycinate (diabetes); Type 2 diabetes therapy, Laboratorios Silanes; Metformin glycinate (diabetes), Laboratorios Silanes DMFE0P1 CP Laboratorios Silanes SA De CV DMFE0P1 DT Small molecular drug DMFE0P1 PC 44520175 DMFE0P1 MW 204.23 DMFE0P1 FM C6H16N6O2 DMFE0P1 IC InChI=1S/C4H11N5.C2H5NO2/c1-9(2)4(7)8-3(5)6;3-1-2(4)5/h1-2H3,(H5,5,6,7,8);1,3H2,(H,4,5) DMFE0P1 CS CN(C)C(=N)N=C(N)N.C(C(=O)O)N DMFE0P1 IK KOFRCHIVYXPUNL-UHFFFAOYSA-N DMFE0P1 IU 2-aminoacetic acid;3-(diaminomethylidene)-1,1-dimethylguanidine DMFE0P1 CA CAS 121369-64-0 DMFE0P1 DE Type-2 diabetes DM752PU ID DM752PU DM752PU DN MGCD516 DM752PU HS Phase 2/3 DM752PU SN Sitravatinib DM752PU CP Mirati therapeutics DM752PU PC 25212148 DM752PU MW 629.7 DM752PU FM C33H29F2N5O4S DM752PU IC InChI=1S/C33H29F2N5O4S/c1-43-15-14-36-18-20-2-8-25(38-19-20)29-17-26-30(45-29)28(10-13-37-26)44-27-9-7-23(16-24(27)35)40-32(42)33(11-12-33)31(41)39-22-5-3-21(34)4-6-22/h2-10,13,16-17,19,36H,11-12,14-15,18H2,1H3,(H,39,41)(H,40,42) DM752PU CS COCCNCC1=CN=C(C=C1)C2=CC3=NC=CC(=C3S2)OC4=C(C=C(C=C4)NC(=O)C5(CC5)C(=O)NC6=CC=C(C=C6)F)F DM752PU IK WLAVZAAODLTUSW-UHFFFAOYSA-N DM752PU IU 1-N'-[3-fluoro-4-[2-[5-[(2-methoxyethylamino)methyl]pyridin-2-yl]thieno[3,2-b]pyridin-7-yl]oxyphenyl]-1-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide DM752PU CA CAS 1123837-84-2 DM752PU DE Non-small-cell lung cancer; Solid tumour/cancer; Breast cancer DM2YNMI ID DM2YNMI DM2YNMI DN MK-1654 DM2YNMI HS Phase 2/3 DM2YNMI CP Merck DM2YNMI DT Antibody DM2YNMI DE Respiratory syncytial virus infection DMDQOWT ID DMDQOWT DMDQOWT DN MOR-208 DMDQOWT HS Phase 2/3 DMDQOWT SN XmAb CD19; XENP-5574; XENP-5603; XmAb-5574; Anti-CD19 humanized mAb (cancer/autoimmune disease), Xencor; Anti-CD19 humanized monoclonal antibody (cancer/autoimmune disease), Xencor DMDQOWT CP Morphosys DMDQOWT DT Antibody DMDQOWT DE Autoimmune diabetes; Diffuse large B-cell lymphoma; B-cell chronic lymphocytic leukaemia; Chronic lymphocytic leukaemia; Non-hodgkin lymphoma DMKMZW2 ID DMKMZW2 DMKMZW2 DN MTC-DOX DMKMZW2 HS Phase 2/3 DMKMZW2 SN MTC-doxorubicin DMKMZW2 CP FeRx DMKMZW2 DE Liver cancer DM16PWF ID DM16PWF DM16PWF DN N1-methylnicotinamide DM16PWF HS Phase 2/3 DM16PWF SN Trigonellinamide; 1-methylnicotinamide; N(1)-Methylnicotinamide; N1-Methylnicotinamide; 3-(Aminocarbonyl)-1-methylpyridinium; 1-Methyl nicotinamide; 3-carbamoyl-1-methylpyridinium; 3106-60-3; Pyridinium, 3-carbamoyl-1-methyl-; UNII-UM47085BXC; N(sup 1)-Methylnicotinamide; 3-carbamoyl-1-methylpyridin-1-ium; BRN 3540351; 1-methylpyridine-3-carboxamide; UM47085BXC; CHEBI:16797; 1-methylpyridin-1-ium-3-carboxamide; CHEMBL1209652; Trigonellamide; Pyridinium, 3-(aminocarbonyl)-1-methyl-; 1-methyl-3-carbamoylpyridinium; 8GC; I-methyl n DM16PWF DT Small molecular drug DM16PWF PC 457 DM16PWF MW 137.16 DM16PWF FM C7H9N2O+ DM16PWF IC InChI=1S/C7H8N2O/c1-9-4-2-3-6(5-9)7(8)10/h2-5H,1H3,(H-,8,10)/p+1 DM16PWF CS C[N+]1=CC=CC(=C1)C(=O)N DM16PWF IK LDHMAVIPBRSVRG-UHFFFAOYSA-O DM16PWF IU 1-methylpyridin-1-ium-3-carboxamide DM16PWF CA CAS 3106-60-3 DM16PWF CB CHEBI:16797 DM16PWF DE Hyperlipidemia DM8D6O2 ID DM8D6O2 DM8D6O2 DN Nafamostat DM8D6O2 HS Phase 2/3 DM8D6O2 SN FUT-175; Nafamostat [INN]; Nafamostatum [Latin]; UNII-Y25LQ0H97D; Nafamstat; Nafamstat Mesilate; 6-Amidino2-naphthyl 4-guanidinobenzoate; Y25LQ0H97D; CHEMBL273264; C19H17N5O2; Nafamostat (INN); p-Guanidinobenzoic acid ester with 6-hydroxy-2-naphthamidine; Nafamostatum DM8D6O2 TC Antiviral Agents DM8D6O2 DT Small molecular drug DM8D6O2 PC 4413 DM8D6O2 MW 347.4 DM8D6O2 FM C19H17N5O2 DM8D6O2 IC InChI=1S/C19H17N5O2/c20-17(21)14-2-1-13-10-16(8-5-12(13)9-14)26-18(25)11-3-6-15(7-4-11)24-19(22)23/h1-10H,(H3,20,21)(H4,22,23,24) DM8D6O2 CS C1=CC(=CC=C1C(=O)OC2=CC3=C(C=C2)C=C(C=C3)C(=N)N)N=C(N)N DM8D6O2 IK MQQNFDZXWVTQEH-UHFFFAOYSA-N DM8D6O2 IU (6-carbamimidoylnaphthalen-2-yl) 4-(diaminomethylideneamino)benzoate DM8D6O2 CA CAS 81525-10-2 DM8D6O2 CB CHEBI:135466 DM8D6O2 DE Pancreatitis; Sepsis; Coronavirus Disease 2019 (COVID-19); Middle East Respiratory Syndrome (MERS) DMD5AEB ID DMD5AEB DMD5AEB DN NAL-GLU DMD5AEB HS Phase 2/3 DMD5AEB SN [Ac-D2Nal1,D4ClPhe2,D3Pal3,Arg5,DGlu5(anisole adduct),DAla10]-GnRH; Acetyl-D-2-naphthylalanyl-D-4-chlorophenylalanyl-D-3-pyridylalanyl-L-seryl-L-arginyl-[4-(4-methoxybenzoyl)-D-2-aminobutyryl]-L-leucyl-L-arginyl-L-prolyl-D-alanylamide; N-Acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-L-arginyl-5-(4-methoxyphenyl)-5-oxo-D-norvalyl-L-leucyl-L-arginyl-L-prolyl-D-alanylamide DMD5AEB PC 44412112 DMD5AEB MW 343.4 DMD5AEB FM C18H21N3O4 DMD5AEB IC InChI=1S/C18H21N3O4/c19-14(17(23)21-15(18(24)25)7-8-16(20)22)10-11-5-6-12-3-1-2-4-13(12)9-11/h1-6,9,14-15H,7-8,10,19H2,(H2,20,22)(H,21,23)(H,24,25)/t14-,15-/m0/s1 DMD5AEB CS C1=CC=C2C=C(C=CC2=C1)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)N DMD5AEB IK VSZVSSYQFUFEQG-GJZGRUSLSA-N DMD5AEB IU (2S)-5-amino-2-[[(2S)-2-amino-3-naphthalen-2-ylpropanoyl]amino]-5-oxopentanoic acid DMD5AEB DE Prostate cancer DM901ZW ID DM901ZW DM901ZW DN Naptumomab estafenatox DM901ZW HS Phase 2/3 DM901ZW CP Active Biotech DM901ZW DE Solid tumour/cancer DM3MJUS ID DM3MJUS DM3MJUS DN NBTX-001 DM3MJUS HS Phase 2/3 DM3MJUS CP Nobilis Therapeutics Portland, OR DM3MJUS DE Panic disorder; Post-traumatic stress disorder DM0798Z ID DM0798Z DM0798Z DN NLG8189 DM0798Z HS Phase 2/3 DM0798Z SN 1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189 DM0798Z CP NewLink Genetics DM0798Z DT Small molecular drug DM0798Z PC 405012 DM0798Z MW 218.25 DM0798Z FM C12H14N2O2 DM0798Z IC InChI=1S/C12H14N2O2/c1-14-7-8(6-10(13)12(15)16)9-4-2-3-5-11(9)14/h2-5,7,10H,6,13H2,1H3,(H,15,16)/t10-/m1/s1 DM0798Z CS CN1C=C(C2=CC=CC=C21)C[C@H](C(=O)O)N DM0798Z IK ZADWXFSZEAPBJS-SNVBAGLBSA-N DM0798Z IU (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid DM0798Z CA CAS 110117-83-4 DM0798Z DE Acute myeloid leukaemia; Melanoma; Brain cancer; Pancreatic cancer; Prostate cancer DM4H78P ID DM4H78P DM4H78P DN NT-501 DM4H78P HS Phase 2/3 DM4H78P SN NTC-201E; CNTF cell implant (ECT), Neurotech; CNTF ophthalmic cell implant (retinitis pigmentosa), Neurotech; Cell implant (ciliary neurotrophic factor), Neurotech; Cell implant (retinitis pigmentosa, ECT), Neurotech DM4H78P CP Amgen Inc DM4H78P DE Ocular inflammation; Macular telangiectasia type 2; Retinitis pigmentosa DMT13UA ID DMT13UA DMT13UA DN Olokizumab DMT13UA HS Phase 2/3 DMT13UA SN OLOKIZUMAB; CHEMBL1743050; CDP-6038 DMT13UA TC Antiviral Agents DMT13UA DT Monoclonal antibody DMT13UA DE Coronavirus Disease 2019 (COVID-19) DMTIESG ID DMTIESG DMTIESG DN Omburtamab DMTIESG HS Phase 2/3 DMTIESG CP Y-mAbs Therapeutics DMTIESG DT Antibody DMTIESG DE Neuroblastoma DMPDA17 ID DMPDA17 DMPDA17 DN Omburtamab I-131 DMPDA17 HS Phase 2/3 DMPDA17 CP Y-mAbs Therapeutics New York, NY DMPDA17 DE Small round cell desmoplastic tumour; Neuroblastoma DMCA2PJ ID DMCA2PJ DMCA2PJ DN ONO-2506 DMCA2PJ HS Phase 2/3 DMCA2PJ SN (2R)-2-Propyloctanoic acid; Arundic acid; 185517-21-9; (R)-2-PROPYLOCTANOIC ACID; Proglia; Cereact; ONO 2506; R-(-)-Arundic Acid; UNII-F2628ZD0FO; MK-0724; (R)-(-)-2-Propyloctanoic Acid; F2628ZD0FO; NCGC00183861-01; Acide arundique; Acido arzndico; Acidum arundicum; Arundic acid [INN]; Arocyte; Acide arundique [INN-French]; Acidum arundicum [INN-Latin]; Arundic acid (JAN/INN); Acido arzndico [INN-Spanish]; ONO-2506PO; MK 0724; AC1L4LMD; AC1Q5QIF; SCHEMBL4365; DSSTox_RID_83036; DSSTox_CID_28767; DSSTox_GSID_48841; ONO 2506PO; Arocyte; Ono2506; Acido arundico [INN-Spanish]; 2-Propyloctanoic acid; FR149175 DMCA2PJ CP Ono Pharmaceuticals DMCA2PJ DT Small molecular drug DMCA2PJ PC 208925 DMCA2PJ MW 186.29 DMCA2PJ FM C11H22O2 DMCA2PJ IC InChI=1S/C11H22O2/c1-3-5-6-7-9-10(8-4-2)11(12)13/h10H,3-9H2,1-2H3,(H,12,13)/t10-/m1/s1 DMCA2PJ CS CCCCCC[C@@H](CCC)C(=O)O DMCA2PJ IK YCYMCMYLORLIJX-SNVBAGLBSA-N DMCA2PJ IU (2R)-2-propyloctanoic acid DMCA2PJ CA CAS 185517-21-9 DMCA2PJ DE Stroke; Type-2 diabetes DMCTRLN ID DMCTRLN DMCTRLN DN OT-101 DMCTRLN HS Phase 2/3 DMCTRLN CP Mateon/Oncotelic DMCTRLN DT Antisense oligonucleotide DMCTRLN DE Melanoma; Merkel cell carcinoma; Pancreatic cancer; Recurrent glioblastoma; Coronavirus Disease 2019 (COVID-19) DMURH4X ID DMURH4X DMURH4X DN Oxypurinol DMURH4X HS Phase 2/3 DMURH4X SN Oxypurinol (intravenous) DMURH4X CP Johns Hopkins University DMURH4X DT Small molecular drug DMURH4X PC 135398752 DMURH4X MW 152.11 DMURH4X FM C5H4N4O2 DMURH4X IC InChI=1S/C5H4N4O2/c10-4-2-1-6-9-3(2)7-5(11)8-4/h1H,(H3,6,7,8,9,10,11) DMURH4X CS C1=NNC2=C1C(=O)NC(=O)N2 DMURH4X IK HXNFUBHNUDHIGC-UHFFFAOYSA-N DMURH4X IU 1,7-dihydropyrazolo[3,4-d]pyrimidine-4,6-dione DMURH4X CA CAS 2465-59-0 DMURH4X CB CHEBI:28315 DMURH4X DE Heart failure DM0NZDT ID DM0NZDT DM0NZDT DN Pactimibe DM0NZDT HS Phase 2/3 DM0NZDT SN Pactimibe; 189198-30-9; UNII-D874R9PZ9T; D874R9PZ9T; CHEMBL478858; Pactimibe [INN:BAN]; [7-(2,2-Dimethylpropanamido)-4,6-dimethyl-1-octylindolin-5-yl]acetic acid; (7-(2,2-Dimethylpropanamido)-4,6-dimethyl-1-octylindolin-5-yl)acetic acid; AC1MIXTD; SCHEMBL282098; CTK0H7032; DTXSID80172315; TXIIZHHIOHVWJD-UHFFFAOYSA-N; ZINC1545445; BDBM50263192; DB12971; 2-[7-(2,2-Dimethylpropanoylamino)-4,6-dimethyl-1-octyl-2,3-dihydroindo L-5-yl]acetic acid; AN-30445; 198P309 DM0NZDT DT Small molecular drug DM0NZDT PC 3081927 DM0NZDT MW 416.6 DM0NZDT FM C25H40N2O3 DM0NZDT IC InChI=1S/C25H40N2O3/c1-7-8-9-10-11-12-14-27-15-13-19-17(2)20(16-21(28)29)18(3)22(23(19)27)26-24(30)25(4,5)6/h7-16H2,1-6H3,(H,26,30)(H,28,29) DM0NZDT CS CCCCCCCCN1CCC2=C(C(=C(C(=C21)NC(=O)C(C)(C)C)C)CC(=O)O)C DM0NZDT IK TXIIZHHIOHVWJD-UHFFFAOYSA-N DM0NZDT IU 2-[7-(2,2-dimethylpropanoylamino)-4,6-dimethyl-1-octyl-2,3-dihydroindol-5-yl]acetic acid DM0NZDT CA CAS 189198-30-9 DM0NZDT DE Arteriosclerosis DMRZ1F2 ID DMRZ1F2 DMRZ1F2 DN Padsevonil DMRZ1F2 HS Phase 2/3 DMRZ1F2 SN 1294000-61-5; UNII-0R1HN52K0N; UCB0942; UCB1415943-000; (R)-4-(2-chloro-2,2-difluoroethyl)-1-((2-(methoxymethyl)-6-(trifluoromethyl)imidazo[2,1-b][1,3,4]thiadiazol-5-yl)methyl)pyrrolidin-2-one; (4R)-4-(2-Chloro-2,2-difluoroethyl)-1-((2-(methoxymethyl)-6-(trifluoromethyl)imidazo(2,1-b)(1,3,4)thiadiazol-5-yl)methyl)pyrrolidin-2-one; (4R)-4-(2-chloro-2,2-difluoroethyl)-1-[[2-(methoxymethyl)-6-(trifluoromethyl)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]methyl]pyrrolidin-2-one; Padsevonil [INN]; Padsevonil [USAN]; Padsevonil (JAN/USAN); SCHEMBL1672843; CHEMBL4297521; UCB-0942; WHO 10384; DB14977; SB18725; HY-109009; CS-0030507; D11842; Q27237119; (4R)-4-(2-Chloro-2,2-difluoroethyl)-1-((2-(methoxymethyl)-6-(trifluoromethyl)imidazo(2,1-b)(1,3,4)thiadiazol-5-yl)methyl)-2-pyrrolidinone; 2-Pyrrolidinone, 4-(2-chloro-2,2-difluoroethyl)-1-((2-(methoxymethyl)-6-(trifluoromethyl)imidazo(2,1-b)-1,3,4-thiadiazol-5-yl)methyl)-, (4R)- DMRZ1F2 CP UCB DMRZ1F2 DT Small molecular drug DMRZ1F2 PC 52911611 DMRZ1F2 MW 432.8 DMRZ1F2 FM C14H14ClF5N4O2S DMRZ1F2 IC InChI=1S/C14H14ClF5N4O2S/c1-26-6-9-22-24-8(11(14(18,19)20)21-12(24)27-9)5-23-4-7(2-10(23)25)3-13(15,16)17/h7H,2-6H2,1H3/t7-/m1/s1 DMRZ1F2 CS COCC1=NN2C(=C(N=C2S1)C(F)(F)F)CN3C[C@H](CC3=O)CC(F)(F)Cl DMRZ1F2 IK DCXFIOLWWRXEQH-SSDOTTSWSA-N DMRZ1F2 IU (4R)-4-(2-chloro-2,2-difluoroethyl)-1-[[2-(methoxymethyl)-6-(trifluoromethyl)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]methyl]pyrrolidin-2-one DMRZ1F2 CA CAS 1294000-61-5 DMRZ1F2 DE Epilepsy DMHWY2G ID DMHWY2G DMHWY2G DN Pagoclone DMHWY2G HS Phase 2/3 DMHWY2G SN IP-456; RP-59037; RP-62955 DMHWY2G CP Rhone-Poulenc SA DMHWY2G DT Small molecular drug DMHWY2G PC 131664 DMHWY2G MW 407.9 DMHWY2G FM C23H22ClN3O2 DMHWY2G IC InChI=1S/C23H22ClN3O2/c1-14(2)7-10-16(28)13-19-17-5-3-4-6-18(17)23(29)27(19)21-12-9-15-8-11-20(24)25-22(15)26-21/h3-6,8-9,11-12,14,19H,7,10,13H2,1-2H3 DMHWY2G CS CC(C)CCC(=O)CC1C2=CC=CC=C2C(=O)N1C3=NC4=C(C=C3)C=CC(=N4)Cl DMHWY2G IK HIUPRQPBWVEQJJ-UHFFFAOYSA-N DMHWY2G IU 2-(7-chloro-1,8-naphthyridin-2-yl)-3-(5-methyl-2-oxohexyl)-3H-isoindol-1-one DMHWY2G CA CAS 133737-32-3 DMHWY2G DE Anxiety disorder DMBJ15R ID DMBJ15R DMBJ15R DN Pexacerfont DMBJ15R HS Phase 2/3 DMBJ15R SN PEXACERFONT; 459856-18-9; UNII-LF1VBG4ZUK; CRF1 ANTAGONIST; LF1VBG4ZUK; BMS-562086; Pexacerfont [USAN:INN]; BMS 562086; Pexacerfont (USAN/INN); CHEMBL482950; SCHEMBL5235999; BDBM29490; DTXSID60196675; CS-6630; DB12572; HY-12127; D10022; Pyrazolo[1,5-a]-1,3,5-triazine, 13-15; BMS562086;BMS 562086;BMS-562086; Pyrazolo(1,5-a)-1,3,5-triazin-4-amine, 8-(6-methoxy-2-methyl-3-pyridinyl)-2,7-dimethyl-N-((1R)-1-methylpropyl)- DMBJ15R CP Bristol-Myers Squibb DMBJ15R DT Small molecular drug DMBJ15R PC 9884366 DMBJ15R MW 340.4 DMBJ15R FM C18H24N6O DMBJ15R IC InChI=1S/C18H24N6O/c1-7-10(2)19-18-22-13(5)21-17-16(12(4)23-24(17)18)14-8-9-15(25-6)20-11(14)3/h8-10H,7H2,1-6H3,(H,19,21,22)/t10-/m1/s1 DMBJ15R CS CC[C@@H](C)NC1=NC(=NC2=C(C(=NN21)C)C3=C(N=C(C=C3)OC)C)C DMBJ15R IK LBWQSAZEYIZZCE-SNVBAGLBSA-N DMBJ15R IU N-[(2R)-butan-2-yl]-8-(6-methoxy-2-methylpyridin-3-yl)-2,7-dimethylpyrazolo[1,5-a][1,3,5]triazin-4-amine DMBJ15R CA CAS 459856-18-9 DMBJ15R DE Anxiety disorder DMYKNME ID DMYKNME DMYKNME DN PF-06651600 DMYKNME HS Phase 2/3 DMYKNME SN CBRJPFGIXUFMTM-WDEREUQCSA-N; 1792180-81-4; UNII-2OYE00PC25; 2OYE00PC25; PF06651600; 1-((2S,5R)-5-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one; GTPL9559; SCHEMBL16764638; BCP24778; EX-A2613; ZINC526061581; example 5 [WO2015083028]; ACN-040697; compound 11 [PMID: 28139931]; HY-100754; CS-0020243; 1-[(2S,5R)-2-Methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]-2-propen-1-one malonate; 1-[(2S,5R)-2-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)piperidin-1-yl]prop-2-en-1-one DMYKNME CP Pfizer New York, NY DMYKNME PC 118115473 DMYKNME MW 285.34 DMYKNME FM C15H19N5O DMYKNME IC InChI=1S/C15H19N5O/c1-3-13(21)20-8-11(5-4-10(20)2)19-15-12-6-7-16-14(12)17-9-18-15/h3,6-7,9-11H,1,4-5,8H2,2H3,(H2,16,17,18,19)/t10-,11+/m0/s1 DMYKNME CS C[C@H]1CC[C@H](CN1C(=O)C=C)NC2=NC=NC3=C2C=CN3 DMYKNME IK CBRJPFGIXUFMTM-WDEREUQCSA-N DMYKNME IU 1-[(2S,5R)-2-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)piperidin-1-yl]prop-2-en-1-one DMYKNME CA CAS 1792180-81-4 DMYKNME DE Asthma; Crohn disease; Alopecia DM1QSM3 ID DM1QSM3 DM1QSM3 DN Phenol DM1QSM3 HS Phase 2/3 DM1QSM3 SN carbolic acid; 108-95-2; Hydroxybenzene; Phenic acid; Oxybenzene; Phenylic acid; Benzenol; Phenyl hydrate; Monophenol; Phenyl hydroxide; Phenylic alcohol; PhOH; Monohydroxybenzene; Phenole; Paoscle; Phenyl alcohol; Phenol alcohol; Izal; Phenol, liquefied; Acide carbolique; Fenolo; Phenosmolin; Fenosmoline; Fenosmolin; Carbolsaure; Fenol; Liquid phenol; Carbolic oil; Phenol, pure; Phenol homopolymer; Phenole [German]; Fenolo [Italian]; Benzene, hydroxy-; Rcra waste number U188; Campho-Phenique Gel; Phenic; Carbolsaure [German] DM1QSM3 DT Small molecular drug DM1QSM3 PC 996 DM1QSM3 MW 94.11 DM1QSM3 FM C6H6O DM1QSM3 IC InChI=1S/C6H6O/c7-6-4-2-1-3-5-6/h1-5,7H DM1QSM3 CS C1=CC=C(C=C1)O DM1QSM3 IK ISWSIDIOOBJBQZ-UHFFFAOYSA-N DM1QSM3 IU phenol DM1QSM3 CA CAS 108-95-2 DM1QSM3 CB CHEBI:15882 DM1SV8I ID DM1SV8I DM1SV8I DN PHN-131 DM1SV8I HS Phase 2/3 DM1SV8I SN NALBUPHINE HYDROCHLORIDE; Nalbuphine HCL; Nubain; 23277-43-2; Nalbufina clorhidrato [Spanish]; Nalbuphine hydrochloride [USAN]; En 2234A; UNII-ZU4275277R; EN-2234A; EINECS 245-549-9; ZU4275277R; 17-(Cyclobutylmethyl)-4,5alpha-epoxymorphinan-3,6alpha,14-triol hydrochloride; Morphinan-3,6,14-triol, 17-(cyclobutylmethyl)-4,5-epoxy-, hydrochloride, (5-alpha,6-alpha)-; (5alpha,6alpha)-17-(Cyclobutylmethyl)-4,5-epoxymorphinan-3,6,14-triol hydrochloride; N-Cyclobutylmethyl-14-hydroxydihydronormorphine hydrochloride; Nalbuphine h DM1SV8I CP PhytoHealth Corp DM1SV8I DT Small molecular drug DM1SV8I PC 5360733 DM1SV8I MW 393.9 DM1SV8I FM C21H28ClNO4 DM1SV8I IC InChI=1S/C21H27NO4.ClH/c23-14-5-4-13-10-16-21(25)7-6-15(24)19-20(21,17(13)18(14)26-19)8-9-22(16)11-12-2-1-3-12;/h4-5,12,15-16,19,23-25H,1-3,6-11H2;1H/t15-,16+,19-,20-,21+;/m0./s1 DM1SV8I CS C1CC(C1)CN2CC[C@]34[C@@H]5[C@H](CC[C@]3([C@H]2CC6=C4C(=C(C=C6)O)O5)O)O.Cl DM1SV8I IK YZLZPSJXMWGIFH-BCXQGASESA-N DM1SV8I IU (4R,4aS,7S,7aR,12bS)-3-(cyclobutylmethyl)-1,2,4,5,6,7,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-4a,7,9-triol;hydrochloride DM1SV8I CA CAS 23277-43-2 DM1SV8I CB CHEBI:7455 DM1SV8I DE Pain DMPWH30 ID DMPWH30 DMPWH30 DN Pimagedine HCl DMPWH30 HS Phase 2/3 DMPWH30 CP Synvista Therapeutics DMPWH30 DT Small molecular drug DMPWH30 PC 85468708 DMPWH30 MW 110.55 DMPWH30 FM CH7ClN4 DMPWH30 IC InChI=1S/CH6N4.ClH/c2-1(3)5-4;/h4H2,(H4,2,3,5);1H DMPWH30 CS C(=[NH+]N)(N)N.[Cl-] DMPWH30 IK UBDZFAGVPPMTIT-UHFFFAOYSA-N DMPWH30 IU amino(diaminomethylidene)azanium;chloride DMPWH30 CA CAS 16139-18-7 DMPWH30 DE Diabetic kidney disease DM0EFQS ID DM0EFQS DM0EFQS DN Plasminogen DM0EFQS HS Phase 2/3 DM0EFQS CP Kedrion DM0EFQS DE Alzheimer disease DMCGK6X ID DMCGK6X DMCGK6X DN PRO 140 DMCGK6X HS Phase 2/3 DMCGK6X CP CytoDyn DMCGK6X DT Antibody DMCGK6X DE Human immunodeficiency virus-1 infection DMZI4OV ID DMZI4OV DMZI4OV DN QLT-091001 DMZI4OV HS Phase 2/3 DMZI4OV SN Crystalets; Davitan A 650; Myvak (VAN); Myvax (VAN); O~15~-acetylretinol; RETINYL ACETATE; RO 1-5275; Retinol acetate; Retinol, acetate; Retinol, acetate, all-trans-; Retinyl acetate, all-trans-; Vitamin A acetate; Vitamin A acetate (VAN); Vitamin A alcohol acetate; Vitamin A ester; Vitamin A1 acetate; all-trans-Retinol acetate; all-trans-Retinyl acetate; all-trans-Retinylacetate; all-trans-Vitamin A acetate; trans-Retinol Acetate; 127-47-9; Acetic acid, retinyl ester; CCRIS 1907; NSC 122045; UNII-3LE3D9D6OY DMZI4OV PC 638034 DMZI4OV MW 328.5 DMZI4OV FM C22H32O2 DMZI4OV IC QGNJRVVDBSJHIZ-QHLGVNSISA-N DMZI4OV CS CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CCOC(=O)C)C)C DMZI4OV IK 1S/C22H32O2/c1-17(9-7-10-18(2)14-16-24-20(4)23)12-13-21-19(3)11-8-15-22(21,5)6/h7,9-10,12-14H,8,11,15-16H2,1-6H3/b10-7+,13-12+,17-9+,18-14+ DMZI4OV IU [(2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenyl] acetate DMZI4OV CA CAS 127-47-9 DMZI4OV CB CHEBI:32095 DMZI4OV DE Barrett esophagus DMB8UQ3 ID DMB8UQ3 DMB8UQ3 DN Ramatroban DMB8UQ3 HS Phase 2/3 DMB8UQ3 SN 116649-85-5; Baynas; BAY u3405; Bay u-3405; Bay u 3406; Bay-u-3405; Bay u 3405; BAY-u 3405; UNII-P1ALI72U6C; C21H21FN2O4S; 3-[(3R)-3-[(4-fluorophenyl)sulfonylamino]-1,2,3,4-tetrahydrocarbazol-9-yl]propanoic acid; P1ALI72U6C; 3-(4-Fluorophenylsulfonamido)-1,2,3,4-tetrahydro-9-carbazole propanoic acid; CHEMBL361812; (+)-(3R)-3-(p-Fluorobenzenesulfonamido)-1,2,3,4-tetrahydrocarbazole-9-propionic acid; NCGC00167519-01; EN-137774; DSSTox_RID_81819; Baynas (TN); Ramatroban (JAN/INN); [3H]ramatroban DMB8UQ3 CP Bayer Yakuhin DMB8UQ3 DT Small molecular drug DMB8UQ3 PC 123879 DMB8UQ3 MW 416.5 DMB8UQ3 FM C21H21FN2O4S DMB8UQ3 IC InChI=1S/C21H21FN2O4S/c22-14-5-8-16(9-6-14)29(27,28)23-15-7-10-20-18(13-15)17-3-1-2-4-19(17)24(20)12-11-21(25)26/h1-6,8-9,15,23H,7,10-13H2,(H,25,26)/t15-/m1/s1 DMB8UQ3 CS C1CC2=C(C[C@@H]1NS(=O)(=O)C3=CC=C(C=C3)F)C4=CC=CC=C4N2CCC(=O)O DMB8UQ3 IK LDXDSHIEDAPSSA-OAHLLOKOSA-N DMB8UQ3 IU 3-[(3R)-3-[(4-fluorophenyl)sulfonylamino]-1,2,3,4-tetrahydrocarbazol-9-yl]propanoic acid DMB8UQ3 CA CAS 116649-85-5 DMB8UQ3 CB CHEBI:32087 DMB8UQ3 DE Perennial allergic rhinitis DM1LFUN ID DM1LFUN DM1LFUN DN Ravidasvir DM1LFUN HS Phase 2/3 DM1LFUN SN PPI-668 free base; UNII-AL3G001BI8; AL3G001BI8; 1242087-93-9; Methyl N-[(1S)-1-[[(2S)-2-[5-[6-[2-[(2S)-1-[(2S)-2-[(methoxycarbonyl)amino]-3-methyl-1-oxobutyl]-2-pyrrolidinyl]-1H-benzimidazol-6-yl]-2-naphthalenyl]-1H-imidazol-2-yl]-1-pyrrolidinyl]carbonyl]-2-methylpropyl]carbamate; Ravidasvir [USAN]; Ravidasvir free base; BL-238630; SCHEMBL7603463; CHEMBL3121849; SCHEMBL12075676; BDBM243443; methyl N-[(2S)-1-[(2S)-2-[5-[6-[2-[(2S)-1-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]pyrrolidin-2-yl]-3H-benzimidazol-5-yl]naphthalen-2-yl]-1H-imidazol-2-yl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate; SB19743; Carbamic acid, N-((1S)-1-(((2S)-2-(5-(6-(2-((2S)-1-((2S)-2-((methoxycarbonyl)amino)-3-methyl-1-oxobutyl)-2-pyrrolidinyl)-1H-benzimidazol-6-yl)-2-naphthalenyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)-, methyl ester; Methyl N-((1S)-1-(((2S)-2-(5-(6-(2-((2S)-1-((2S)-2-((methoxycarbonyl)amino)-3- methylbutanoyl)pyrrolidin-2-yl)-1H-imidazol-4-yl)naphthalen-2-yl)-1H-benzimidazol-2-yl)pyrrolidin-1-yl)carbonyl)-2-methylpropyl)carbamate; BI 238630; BI-238630; US9427428, 3; Q27273972; methyl ((1S)-1-(((2S)-2-(4-(6-(2-((2S)-1-((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-benzimidazol-5-yl)-2-naphthyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate; methyl((1S)-1-(((2S)-2-(4-(6-(2-((2S)-1-((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-benzimidazol-5-yl)-2-naphthyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate; methyl((s)-1-((s)-2-(5-(6-(2((s)-1-((methoxycarbonyl)-l-valyl)pyrrolidin-2-yl)-1h-imidazol-4-yl)naphthalen-2-yl)-1h-benzo[d]imidazol-2-yl) pyrrolidin-1-yl)-3-methyl-1-oxobutan-2-yl)carbamate DM1LFUN CP Presidio Pharmaceuticals DM1LFUN DT Small molecular drug DM1LFUN PC 52918888 DM1LFUN MW 762.9 DM1LFUN FM C42H50N8O6 DM1LFUN IC InChI=1S/C42H50N8O6/c1-23(2)35(47-41(53)55-5)39(51)49-17-7-9-33(49)37-43-22-32(46-37)29-14-13-25-19-26(11-12-27(25)20-29)28-15-16-30-31(21-28)45-38(44-30)34-10-8-18-50(34)40(52)36(24(3)4)48-42(54)56-6/h11-16,19-24,33-36H,7-10,17-18H2,1-6H3,(H,43,46)(H,44,45)(H,47,53)(H,48,54)/t33-,34-,35-,36-/m0/s1 DM1LFUN CS CC(C)[C@@H](C(=O)N1CCC[C@H]1C2=NC3=C(N2)C=C(C=C3)C4=CC5=C(C=C4)C=C(C=C5)C6=CN=C(N6)[C@@H]7CCCN7C(=O)[C@H](C(C)C)NC(=O)OC)NC(=O)OC DM1LFUN IK LCHMHYPWGWYXEL-ZYADHFCISA-N DM1LFUN IU methyl N-[(2S)-1-[(2S)-2-[5-[6-[2-[(2S)-1-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]pyrrolidin-2-yl]-3H-benzimidazol-5-yl]naphthalen-2-yl]-1H-imidazol-2-yl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate DM1LFUN CA CAS 1242087-93-9 DM1LFUN DE Hepatitis C DML9FD4 ID DML9FD4 DML9FD4 DN Rinfabate DML9FD4 HS Phase 2/3 DML9FD4 SN RhIGFBP-3; Rinfabate, Insmed; RhIGF-BP3, Insmed; Insulin-like growth factor binding protein-3, Insmed DML9FD4 CP Insmed Inc DML9FD4 DE Solid tumour/cancer DMWZ6DK ID DMWZ6DK DMWZ6DK DN Roledumab DMWZ6DK HS Phase 2/3 DMWZ6DK SN DMATRIA; LFB-R593; R-297; R-593; Anti-D human monoclonal antibody, Laboratoire Francais du Fractionnement et des Biotechnologies; R297 antibody (hematological disease), LFB; R297 antibody (hematological disease), Laboratoire Francais du Fractionnement et des Biotechnologies; Anti-RhD antibody (hematological disease), LFB; Anti-rhesus D mAB (hematological disease), LFB DMWZ6DK CP LFB Biotechnologies DMWZ6DK DT Antibody DMWZ6DK DE Anemia DMNIYSZ ID DMNIYSZ DMNIYSZ DN RP101 DMNIYSZ HS Phase 2/3 DMNIYSZ SN SCHEMBL15589316; CHEMBL3703295; BDBM149820; US8975415, DMNIYSZ CP RESprotect DMNIYSZ DT Small molecular drug DMNIYSZ PC 446727 DMNIYSZ MW 333.13 DMNIYSZ FM C11H13BrN2O5 DMNIYSZ IC InChI=1S/C11H13BrN2O5/c12-2-1-6-4-14(11(18)13-10(6)17)9-3-7(16)8(5-15)19-9/h1-2,4,7-9,15-16H,3,5H2,(H,13,17,18)/b2-1+/t7-,8+,9+/m0/s1 DMNIYSZ CS C1[C@@H]([C@H](O[C@H]1N2C=C(C(=O)NC2=O)/C=C/Br)CO)O DMNIYSZ IK ODZBBRURCPAEIQ-PIXDULNESA-N DMNIYSZ IU 5-[(E)-2-bromoethenyl]-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione DMNIYSZ CA CAS 69304-47-8 DMNIYSZ DE Pancreatic cancer; Infectious disease DMOJLCV ID DMOJLCV DMOJLCV DN SAR164877 DMOJLCV HS Phase 2/3 DMOJLCV CP Sanofi-Aventis DMOJLCV TC Analgesics DMOJLCV DE Pain DMH7IPW ID DMH7IPW DMH7IPW DN Sarizotan DMH7IPW HS Phase 2/3 DMH7IPW SN Sarizotan [INN]; EMD 128130; N-((3,4-Dihydro-2H-1-benzopyran-2-yl)methyl)-5-(4-fluorophenyl)-3-pyridinemethanamine; (-)-3-((((R)-2-Chromanylmethyl)amino)methyl)-5-(p-fluorophenyl)pyridine; 1-(3,4-dihydro-2H-chromen-2-yl)-N-[[5-(4-fluorophenyl)pyridin-3-yl]methyl]methanamine DMH7IPW CP EMD Serono DMH7IPW DT Small molecular drug DMH7IPW PC 6918388 DMH7IPW MW 348.4 DMH7IPW FM C22H21FN2O DMH7IPW IC InChI=1S/C22H21FN2O/c23-20-8-5-17(6-9-20)19-11-16(12-24-14-19)13-25-15-21-10-7-18-3-1-2-4-22(18)26-21/h1-6,8-9,11-12,14,21,25H,7,10,13,15H2/t21-/m1/s1 DMH7IPW CS C1CC2=CC=CC=C2O[C@H]1CNCC3=CC(=CN=C3)C4=CC=C(C=C4)F DMH7IPW IK HKFMQJUJWSFOLY-OAQYLSRUSA-N DMH7IPW IU 1-[(2R)-3,4-dihydro-2H-chromen-2-yl]-N-[[5-(4-fluorophenyl)pyridin-3-yl]methyl]methanamine DMH7IPW CA CAS 351862-32-3 DMH7IPW DE Parkinson disease; Rett syndrome DM31L9K ID DM31L9K DM31L9K DN Sepofarsen DM31L9K HS Phase 2/3 DM31L9K SN QR-110 DM31L9K CP ProQR Therapeutics DM31L9K DT Oligonucleotide DM31L9K DE Leber congenital amaurosis DMTV5XC ID DMTV5XC DMTV5XC DN Sitafloxacin DMTV5XC HS Phase 2/3 DMTV5XC SN Sitafloxacin; Gracevit; Sitafloxacin Sesquihydrate; UNII-3GJC60U4Q8; Sitafloxacin isomer II; DU-6859a; C19H18ClF2N3O3; 3GJC60U4Q8; 7-((S)-7-AMINO-5-AZASPIRO[2.4]HEPTAN-5-YL)-8-CHLORO-6-FLUORO-1-((1R,2S)-2-FLUOROCYCLOPROPYL)-4-OXO-1,4-DIHYDROQUINOLINE-3-CARBOXYLIC ACID; STFX; 7-[(7S)-7-amino-5-azaspiro[2.4]heptan-5-yl]-8-chloro-6-fluoro-1-[(1R,2S)-2-fluorocyclopropyl]-4-oxo-quinoline-3-carboxylic acid DMTV5XC PC 461399 DMTV5XC MW 409.8 DMTV5XC FM C19H18ClF2N3O3 DMTV5XC IC InChI=1S/C19H18ClF2N3O3/c20-14-15-8(17(26)9(18(27)28)5-25(15)12-4-10(12)21)3-11(22)16(14)24-6-13(23)19(7-24)1-2-19/h3,5,10,12-13H,1-2,4,6-7,23H2,(H,27,28)/t10-,12+,13+/m0/s1 DMTV5XC CS C1CC12CN(CC2N)C3=C(C=C4C(=C3Cl)N(C=C(C4=O)C(=O)O)C5CC5F)F DMTV5XC IK PNUZDKCDAWUEGK-CYZMBNFOSA-N DMTV5XC IU 7-[(7S)-7-amino-5-azaspiro[2.4]heptan-5-yl]-8-chloro-6-fluoro-1-[(1R,2S)-2-fluorocyclopropyl]-4-oxoquinoline-3-carboxylic acid DMTV5XC CA CAS 127254-12-0 DMTV5XC CB CHEBI:4304 DMTV5XC DE Escherichia Coli Infections DM30JWZ ID DM30JWZ DM30JWZ DN SM04554 DM30JWZ HS Phase 2/3 DM30JWZ CP Samumed San Diego,CA DM30JWZ DT Small molecular drug DM30JWZ DE Alopecia DMD9ISG ID DMD9ISG DMD9ISG DN SM-88 DMD9ISG HS Phase 2/3 DMD9ISG CP Tyme Technologies New York, NY DMD9ISG PC 3125 DMD9ISG MW 195.21 DMD9ISG FM C10H13NO3 DMD9ISG IC InChI=1S/C10H13NO3/c1-10(11,9(13)14)6-7-2-4-8(12)5-3-7/h2-5,12H,6,11H2,1H3,(H,13,14) DMD9ISG CS CC(CC1=CC=C(C=C1)O)(C(=O)O)N DMD9ISG IK NHTGHBARYWONDQ-UHFFFAOYSA-N DMD9ISG IU 2-amino-3-(4-hydroxyphenyl)-2-methylpropanoic acid DMD9ISG CA CAS 658-48-0 DMD9ISG DE Prostate cancer; Pancreatic cancer DM5WQ2U ID DM5WQ2U DM5WQ2U DN SR-123781A DM5WQ2U HS Phase 2/3 DM5WQ2U CP Sanofi-aventis DM5WQ2U PC 145996625 DM5WQ2U MW 4854 DM5WQ2U FM C127H201Na19O134S17 DM5WQ2U IC InChI=1S/C127H220O134S17.19Na/c1-183-32-46-60(235-114-95(203-21)76(192-10)62(48(223-114)34-185-3)237-116-97(205-23)78(194-12)64(50(225-116)36-187-5)239-118-99(207-25)80(196-14)66(52(227-118)38-189-7)241-120-101(209-27)82(198-16)68(55(229-120)41-216-264(138,139)140)244-124-106(258-275(171,172)173)89(254-271(159,160)161)71(57(231-124)43-218-266(144,145)146)246-125-107(259-276(174,175)176)90(255-272(162,163)164)72(58(232-125)44-219-267(147,148)149)247-126-109(261-278(180,181)182)91(256-273(165,166)167)73(252-269(153,154)155)59(234-126)45-220-268(150,151)152)74(190-8)94(202-20)113(222-46)236-61-47(33-184-2)224-115(96(204-22)75(61)191-9)238-63-49(35-186-4)226-117(98(206-24)77(63)193-11)240-65-51(37-188-6)228-119(100(208-26)79(65)195-13)242-67-54(40-215-263(135,136)137)230-121(102(210-28)81(67)197-15)248-86-84(200-18)104(212-30)123(251-92(86)110(128)129)245-70-56(42-217-265(141,142)143)233-127(108(260-277(177,178)179)88(70)253-270(156,157)158)249-87-85(201-19)103(211-29)122(250-93(87)111(130)131)243-69-53(39-214-262(132,133)134)221-112(213-31)105(83(69)199-17)257-274(168,169)170;;;;;;;;;;;;;;;;;;;/h46-109,112-127H,32-45H2,1-31H3,(H,128,129)(H,130,131)(H,132,133,134)(H,135,136,137)(H,138,139,140)(H,141,142,143)(H,144,145,146)(H,147,148,149)(H,150,151,152)(H,153,154,155)(H,156,157,158)(H,159,160,161)(H,162,163,164)(H,165,166,167)(H,168,169,170)(H,171,172,173)(H,174,175,176)(H,177,178,179)(H,180,181,182);;;;;;;;;;;;;;;;;;;/q;19*+1/p-19/t46-,47-,48-,49-,50-,51-,52-,53-,54-,55-,56-,57-,58-,59-,60-,61-,62-,63-,64-,65-,66-,67+,68-,69-,70-,71-,72-,73-,74+,75+,76+,77+,78+,79+,80+,81+,82+,83+,84+,85+,86+,87+,88+,89+,90+,91+,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103+,104-,105+,106-,107-,108-,109-,112+,113-,114+,115+,116+,117-,118+,119+,120-,121-,122-,123-,124+,125-,126-,127-;;;;;;;;;;;;;;;;;;;/m1.................../s1 DM5WQ2U CS COC[C@@H]1[C@H]([C@@H]([C@H]([C@@H](O1)O[C@@H]2[C@H](O[C@@H]([C@@H]([C@H]2OC)OC)O[C@@H]3[C@H](O[C@H]([C@@H]([C@H]3OC)OC)O[C@H]4[C@H](O[C@@H]([C@@H]([C@H]4OC)OC)O[C@H]5[C@@H]([C@H]([C@@H](O[C@H]5C(=O)[O-])O[C@@H]6[C@H](O[C@@H]([C@@H]([C@H]6OS(=O)(=O)[O-])OS(=O)(=O)[O-])O[C@H]7[C@@H]([C@@H]([C@@H](O[C@H]7C(=O)[O-])O[C@@H]8[C@H](O[C@@H]([C@H]([C@H]8OC)OS(=O)(=O)[O-])OC)COS(=O)(=O)[O-])OC)OC)COS(=O)(=O)[O-])OC)OC)COS(=O)(=O)[O-])COC)COC)OC)OC)O[C@@H]9[C@@H]([C@H]([C@@H]([C@H](O9)COC)O[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)COC)O[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)COC)O[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)COC)O[C@@H]1[C@@H]([C@H]([C@@H]([C@H](O1)COS(=O)(=O)[O-])O[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)COS(=O)(=O)[O-])O[C@@H]1[C@@H]([C@H]([C@@H]([C@H](O1)COS(=O)(=O)[O-])O[C@@H]1[C@@H]([C@H]([C@@H]([C@H](O1)COS(=O)(=O)[O-])OS(=O)(=O)[O-])OS(=O)(=O)[O-])OS(=O)(=O)[O-])OS(=O)(=O)[O-])OS(=O)(=O)[O-])OS(=O)(=O)[O-])OS(=O)(=O)[O-])OC)OC)OC)OC)OC)OC)OC)OC)OC)OC.[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+] DM5WQ2U IK RRHHPXJSGSYSHW-ZURHXDBDSA-A DM5WQ2U IU nonadecasodium;(2R,3S,4S,5R,6R)-6-[(2R,3R,4S,5R,6R)-6-[(2R,3S,4S,5S,6R)-2-carboxylato-6-[(2R,3R,4S,5S,6S)-4,6-dimethoxy-5-sulfonatooxy-2-(sulfonatooxymethyl)oxan-3-yl]oxy-4,5-dimethoxyoxan-3-yl]oxy-4,5-disulfonatooxy-2-(sulfonatooxymethyl)oxan-3-yl]oxy-3-[(2R,3R,4S,5S,6R)-5-[(2S,3R,4S,5R,6R)-5-[(2R,3R,4S,5R,6R)-5-[(2S,3R,4S,5R,6R)-5-[(2R,3R,4S,5R,6R)-5-[(2S,3R,4S,5R,6R)-5-[(2S,3R,4S,5R,6R)-5-[(2S,3R,4S,5R,6R)-5-[(2R,3R,4S,5R,6R)-5-[(2S,3R,4S,5R,6R)-5-[(2R,3R,4S,5R,6R)-3,4-disulfonatooxy-6-(sulfonatooxymethyl)-5-[(2R,3R,4S,5R,6R)-3,4,5-trisulfonatooxy-6-(sulfonatooxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,4-disulfonatooxy-6-(sulfonatooxymethyl)oxan-2-yl]oxy-3,4-dimethoxy-6-(sulfonatooxymethyl)oxan-2-yl]oxy-3,4-dimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-3,4-dimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-3,4-dimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-3,4-dimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-3,4-dimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-3,4-dimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-3,4-dimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-3,4-dimethoxy-6-(sulfonatooxymethyl)oxan-2-yl]oxy-4,5-dimethoxyoxane-2-carboxylate DM5WQ2U CA CAS 232602-93-6 DM5WQ2U DE Venous thrombosis DMKGQF0 ID DMKGQF0 DMKGQF0 DN Suvodirsen DMKGQF0 HS Phase 2/3 DMKGQF0 SN WVE-210201 DMKGQF0 CP Wave Life Sciences DMKGQF0 DT Antisense oligonucleotide DMKGQF0 DE Duchenne dystrophy DMWE3GB ID DMWE3GB DMWE3GB DN TG-4010 DMWE3GB HS Phase 2/3 DMWE3GB SN MVA-Muc1-IL-2; MVA-TG-9931 (frozen suspension); MUC1/IL-2 antigen therapy (gene transfer system, cancer), Transgene DMWE3GB CP Transgene DMWE3GB DE Bipolar disorder; Non-small-cell lung cancer DMVDTR2 ID DMVDTR2 DMVDTR2 DN Thymoquinone DMVDTR2 HS Phase 2/3 DMVDTR2 SN 490-91-5; Thymoquinon; p-Cymene-2,5-dione; 2-Isopropyl-5-methyl-1,4-benzoquinone; 2,5-CYCLOHEXADIENE-1,4-DIONE, 2-METHYL-5-(1-METHYLETHYL)-; 2-Isopropyl-5-methyl-p-benzoquinone; 2-Isopropyl-5-methylbenzoquinone; Polythymoquinone; 5-Isopropyl-2-methyl-1,4-benzoquinone; 2-Isopropyl-5-methylbenzo-1,4-quinone; p-Mentha-3,6-diene-2,5-dione; NSC 2228; 2-Isopropyl-5-methylcyclohexa-2,5-diene-1,4-dione; 2-Methyl-5-isopropyl-p-benzoquinone; 2-methyl-5-propan-2-ylcyclohexa-2,5-diene-1,4-dione; NSC2228; 2-methyl-5-(propan-2-yl)cyclohexa-2,5-diene-1,4-dione; UNII-O60IE26NUF; 2-Methyl-5-isopropyl-1,4-benzoquinone; O60IE26NUF; 2,5-Cyclohexadiene-1,4-dione, 5-isopropyl-2-methyl-; NSC-2228; 5-Isopropyl-2-methyl-p-benzoquinone; MFCD00001602; 2-Methyl-5-(1-methylethyl)-2,5-cyclohexadiene-1,4-dione; p-Mentha-3,6-diene-2,5-dione (8CI); 5-Isopropyl-2-methyl-2,5-Cyclohexadiene-1,4-dione; CCRIS 7152; EINECS 207-721-1; 2-methyl-5-(methylethyl)cyclohexa-2,5-diene-1,4-dione; BRN 1939047; thymolquinone; Thymoil; AI3-17758; 4hco; p-Mentha-3,5-dione; Spectrum_001237; SpecPlus_000457; Thymoquinone, >=98%; Spectrum2_000700; Spectrum3_001345; Spectrum4_001895; Spectrum5_000550; BSPBio_003129; KBioGR_002455; KBioSS_001717; DivK1c_006553; SCHEMBL542535; SPBio_000859; CHEMBL1672002; DTXSID9060079; KBio1_001497; KBio2_001717; KBio2_004285; KBio2_006853; KBio3_002349; Thymoquinone, analytical standard; CHEBI:113532; 2-Methyl-5-iso-propylbenzoquinone; BDBM166686; ZINC164367; BCP16946; HY-D0803; WLN: L6V DVJ B1 EY1&1; 2,4-dione, 5-isopropyl-2-methyl-; ANW-41600; CCG-40027; s4761; SBB008296; AKOS003368628; MCULE-9899033250; NCGC00178250-01; NCGC00178250-05; 73940-92-8; AK101679; AS-11327; 2-Isopropyl-5-methylbenzo-1,4-quinone #; 2,4-dione, 2-methyl-5-(1-methylethyl)-; CS-0012226; FT-0612708; ST45023960; K-9199; SR-05000002192; Q7799650; SR-05000002192-2; W-202869; BRD-K97566842-001-03-5; Thymoquinone; 2-isopropyl-5-methylbenzo-1,4-quinone; 2-methyl-5-(propan-2-yl)cyclohexa-2,5-diene-1,4-dione (F8); 2-Methyl-5-(1-methylethyl)-2,5-cyclohexadiene-1,4-dione, 9CI DMVDTR2 DT Small molecular drug DMVDTR2 PC 10281 DMVDTR2 MW 164.2 DMVDTR2 FM C10H12O2 DMVDTR2 IC InChI=1S/C10H12O2/c1-6(2)8-5-9(11)7(3)4-10(8)12/h4-6H,1-3H3 DMVDTR2 CS CC1=CC(=O)C(=CC1=O)C(C)C DMVDTR2 IK KEQHJBNSCLWCAE-UHFFFAOYSA-N DMVDTR2 IU 2-methyl-5-propan-2-ylcyclohexa-2,5-diene-1,4-dione DMVDTR2 CA CAS 490-91-5 DMVDTR2 CB CHEBI:113532 DMVDTR2 DE Polycystic ovarian syndrome DM23ARP ID DM23ARP DM23ARP DN V-710 DM23ARP HS Phase 2/3 DM23ARP SN Vaccine (Staphylococcus aureus), Intercell; Vaccine (Staphylococcus aureus), Merck & Co; Iron surface determinant B-based vaccine (Staphylococcus aureus infection), Merck & Co; IsdB-based vaccine (Staphylococcus aureus infection), Merck & Co DM23ARP CP Intercell AG DM23ARP DT Vaccine DM23ARP DE Staphylococcus infection DMDG8Q3 ID DMDG8Q3 DMDG8Q3 DN Varlitinib DMDG8Q3 HS Phase 2/3 DMDG8Q3 SN VARLITINIB; 845272-21-1; ARRY-334543; ARRY334543; ARRY 334543; ARRY-543; UNII-846Y8197W1; ASLAN-001; 846Y8197W1; (R)-N4-(3-chloro-4-(thiazol-2-ylmethoxy)phenyl)-N6-(4-methyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine; Varlitinib [USAN:INN]; Varlitinib (ARRY334543); Varlitinib free base; Varlitinib (USAN/INN); MLS006011274; GTPL7645; SCHEMBL1384578; CHEMBL2103842; SYN1192; MolPort-028-720-424; EX-A1005; 4-N-[3-chloro-4-(1,3-thiazol-2-ylmethoxy)phenyl]-6-N-[(4R)-4-methyl-4,5-dihydro-1,3-oxazol-2-yl]quinazoline-4,6-diamine DMDG8Q3 CP ASLAN Pharmaceuticals DMDG8Q3 DT Small molecular drug DMDG8Q3 PC 42642648 DMDG8Q3 MW 466.9 DMDG8Q3 FM C22H19ClN6O2S DMDG8Q3 IC InChI=1S/C22H19ClN6O2S/c1-13-10-31-22(27-13)29-14-2-4-18-16(8-14)21(26-12-25-18)28-15-3-5-19(17(23)9-15)30-11-20-24-6-7-32-20/h2-9,12-13H,10-11H2,1H3,(H,27,29)(H,25,26,28)/t13-/m1/s1 DMDG8Q3 CS C[C@@H]1COC(=N1)NC2=CC3=C(C=C2)N=CN=C3NC4=CC(=C(C=C4)OCC5=NC=CS5)Cl DMDG8Q3 IK UWXSAYUXVSFDBQ-CYBMUJFWSA-N DMDG8Q3 IU 4-N-[3-chloro-4-(1,3-thiazol-2-ylmethoxy)phenyl]-6-N-[(4R)-4-methyl-4,5-dihydro-1,3-oxazol-2-yl]quinazoline-4,6-diamine DMDG8Q3 CA CAS 845272-21-1 DMDG8Q3 DE Breast cancer; Metastatic biliary tract neoplasms DMTROUI ID DMTROUI DMTROUI DN Vazegepant DMTROUI HS Phase 2/3 DMTROUI SN UNII-ODU3ZAZ94J; ODU3ZAZ94J; BHV-3500; BDBM50436107 DMTROUI TC Antiviral Agents DMTROUI DT Small molecular drug DMTROUI PC 53472683 DMTROUI MW 638.8 DMTROUI FM C36H46N8O3 DMTROUI IC InChI=1S/C36H46N8O3/c1-24-19-25(20-28-23-37-40-33(24)28)21-32(35(46)43-17-15-42(16-18-43)29-9-11-41(2)12-10-29)39-36(47)44-13-7-26(8-14-44)30-22-27-5-3-4-6-31(27)38-34(30)45/h3-6,19-20,22-23,26,29,32H,7-18,21H2,1-2H3,(H,37,40)(H,38,45)(H,39,47)/t32-/m1/s1 DMTROUI CS CC1=CC(=CC2=C1NN=C2)C[C@H](C(=O)N3CCN(CC3)C4CCN(CC4)C)NC(=O)N5CCC(CC5)C6=CC7=CC=CC=C7NC6=O DMTROUI IK JJVAPHYEOZSKJZ-JGCGQSQUSA-N DMTROUI IU N-[(2R)-3-(7-methyl-1H-indazol-5-yl)-1-[4-(1-methylpiperidin-4-yl)piperazin-1-yl]-1-oxopropan-2-yl]-4-(2-oxo-1H-quinolin-3-yl)piperidine-1-carboxamide DMTROUI CA CAS 1337918-83-8 DMTROUI DE Coronavirus Disease 2019 (COVID-19) DMGKRAJ ID DMGKRAJ DMGKRAJ DN VB4-845 DMGKRAJ HS Phase 2/3 DMGKRAJ CP Viventia Biotechnologies DMGKRAJ DT Antibody DMGKRAJ SQ 9045_H|oportuzumab monatox|||SCFV-KAPPA-HEAVY-TOXIN (V-KAPPA(7-118)+LINKER(119-144)+VH(145-260)+TOX-DOMAIN(281-637))|||||||647||||MW 69566.3|MW 69566.3|: HHHHHHDIQMTQSPSSLSASVGDRVTITCRSTKSLLHSNGITYLYWYQQKPGKAPKLLIYQMSNLASGVPSRFSSSGSGTDFTLTISSLQPEDFATYYCAQNLEIPRTFGQGTKVELKRATPSHNSHQVPSAGGPTANSGTSGSEVQLVQSGPGLVQPGGSVRISCAASGYTFTNYGMNWVKQAPGKGLEWMGWINTYTGESTYADSFKGRFTFSLDTSASAAYLQINSLRAEDTAVYYCARFAIKGDYWGQGTLLTVSSEFGGAPEFPKPSTPPGSSGLEGGSLAALTAHQACHLPLETFTRHRQPRGWEQLEQCGYPVQRLVALYLAARLSWNQVDQVIRNALASPGSGGDLGEAIREQPEQARLALTLAAAESERFVRQGTGNDEAGAASADVVSLTCPVAAGECAGPADSGDALLERNYPTGAEFLGDGGDVSFSTRGTQNWTVERLLQAHRQLEERGYVFVGYHGTFLEAAQSIVFGGVRARSQDLDAIWRGFYIAGDPALAYGYAQDQEPDARGRIRNGALLRVYVPRSSLPGFYRTGLTLAAPEAAGEVERLIGHPLPLRLDAITGPEEEGGRLETILGWPLAERTVVIPSAIPTDPRNVGGDLDPSSIPDKEQAISALPDYASQPGKPPHHHHHHKDEL DMGKRAJ DE Head and neck cancer DM0ASTP ID DM0ASTP DM0ASTP DN Verapamil DM0ASTP HS Phase 2/3 DM0ASTP SN VERAPAMIL; Iproveratril; 52-53-9; Vasolan; Dilacoran; Isoptin; Falicard; Isoptine; Isoptimo; Finoptin; Calan; Verapamilo; Verapamilum; Verapamilum [INN-Latin]; Lekoptin; Verapamilo [INN-Spanish]; Isotopin; Calcan; Tarka; D-365; Securon; Verelan; Izoptin; Verapamil [USAN:INN:BAN]; CP-16533-1; Covera-HS; Verpamil; CCRIS 6749; Verelan PM; Isoptin SR; C; Verapamil DM0ASTP TC Antiviral Agents DM0ASTP DT Small molecular drug DM0ASTP PC 2520 DM0ASTP MW 454.6 DM0ASTP FM C27H38N2O4 DM0ASTP IC InChI=1S/C27H38N2O4/c1-20(2)27(19-28,22-10-12-24(31-5)26(18-22)33-7)14-8-15-29(3)16-13-21-9-11-23(30-4)25(17-21)32-6/h9-12,17-18,20H,8,13-16H2,1-7H3 DM0ASTP CS CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC DM0ASTP IK SGTNSNPWRIOYBX-UHFFFAOYSA-N DM0ASTP IU 2-(3,4-dimethoxyphenyl)-5-[2-(3,4-dimethoxyphenyl)ethyl-methylamino]-2-propan-2-ylpentanenitrile DM0ASTP CA CAS 52-53-9 DM0ASTP CB CHEBI:77733 DM0ASTP DE Coronavirus Disease 2019 (COVID-19) DM4WQBO ID DM4WQBO DM4WQBO DN VM-1500 DM4WQBO HS Phase 2/3 DM4WQBO SN VM-1500 (topical gel formulation, HIV infection) DM4WQBO CP Viriom Ltd DM4WQBO DE Human immunodeficiency virus infection DM5G1NT ID DM5G1NT DM5G1NT DN VX-210 DM5G1NT HS Phase 2/3 DM5G1NT SN BA-210; VX210 DM5G1NT CP Vertex Pharmaceuticals Boston, MA DM5G1NT DE Spinal cord injury DM2U3MX ID DM2U3MX DM2U3MX DN VX-509 DM2U3MX HS Phase 2/3 DM2U3MX SN Decernotinib; Adelatinib; 944842-54-0; VX-509; UNII-MZK2GP0RHK; Decernotinib(VX-509); VX509; MZK2GP0RHK; VRT-831509; VX 509; (2r)-2-Methyl-2-[[2-(1h-Pyrrolo[2,3-B]pyridin-3-Yl)pyrimidin-4-Yl]amino]-N-[2,2,2-Tris(Fluoranyl)ethyl]butanamide; (R)-2-((2-(1H-Pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4-yl)amino)-2-methyl-N-(2,2,2-trifluoroethyl)butanamide; Decernotinib [USAN:INN]; VRT 831509; Decernotinib,VX-509; Decernotinib (USAN/INN); Decernotinib (VX-509); VX-509 (Decernotinib); SCHEMBL2630387; GTPL8309; CHEMBL3039513; KS-00001CYK DM2U3MX CP Vertex Pharmaceuticals DM2U3MX DT Small molecular drug DM2U3MX PC 59422203 DM2U3MX MW 392.4 DM2U3MX FM C18H19F3N6O DM2U3MX IC InChI=1S/C18H19F3N6O/c1-3-17(2,16(28)25-10-18(19,20)21)27-13-6-8-23-15(26-13)12-9-24-14-11(12)5-4-7-22-14/h4-9H,3,10H2,1-2H3,(H,22,24)(H,25,28)(H,23,26,27)/t17-/m1/s1 DM2U3MX CS CC[C@](C)(C(=O)NCC(F)(F)F)NC1=NC(=NC=C1)C2=CNC3=C2C=CC=N3 DM2U3MX IK ASUGUQWIHMTFJL-QGZVFWFLSA-N DM2U3MX IU (2R)-2-methyl-2-[[2-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4-yl]amino]-N-(2,2,2-trifluoroethyl)butanamide DM2U3MX CA CAS 944842-54-0 DM2U3MX DE Rheumatoid arthritis DMHXJ68 ID DMHXJ68 DMHXJ68 DN WVE-210201 DMHXJ68 HS Phase 2/3 DMHXJ68 CP WaVe Life Sciences Cambridge, MA DMHXJ68 DE Duchenne dystrophy DM78DOT ID DM78DOT DM78DOT DN AllerB DM78DOT HS Phase 2b DM78DOT CP Anergis SA DM78DOT DE Allergy DMJM9LZ ID DMJM9LZ DMJM9LZ DN LB80380 DMJM9LZ HS Phase 2b DMJM9LZ SN LB80380; UNII-S9I9P4J8IU; LB 80380; S9I9P4J8IU; LB-80380; 441785-26-8; PMCDG dipivoxil; AC1O59EP; SCHEMBL4270816; CHEMBL1652128; ANA-380; DTXSID90196062; J3.616.617G; [[1-[(2-aminopurin-9-yl)methyl]cyclopropoxy]methyl-(2,2-dimethylpropanoyloxymethoxy)phosphoryl]oxymethyl 2,2-dimethylpropanoate; [({[(2-Aminopurin-9-yl)methyl]cyclopropoxy}methyl)[(2,2-dimethylpropanoyloxy)methoxy]carbonyloxy]methyl 2,2-dimethylpropanoate; 872968-04-2 DMJM9LZ CP LG Life Sciences DMJM9LZ DT Small molecular drug DMJM9LZ PC 6480442 DMJM9LZ MW 527.5 DMJM9LZ FM C22H34N5O8P DMJM9LZ IC InChI=1S/C22H34N5O8P/c1-20(2,3)17(28)31-12-34-36(30,35-13-32-18(29)21(4,5)6)14-33-22(7-8-22)10-27-11-25-15-9-24-19(23)26-16(15)27/h9,11H,7-8,10,12-14H2,1-6H3,(H2,23,24,26) DMJM9LZ CS CC(C)(C)C(=O)OCOP(=O)(COC1(CC1)CN2C=NC3=CN=C(N=C32)N)OCOC(=O)C(C)(C)C DMJM9LZ IK JLKJXDOWBVVABZ-UHFFFAOYSA-N DMJM9LZ IU [[1-[(2-aminopurin-9-yl)methyl]cyclopropyl]oxymethyl-(2,2-dimethylpropanoyloxymethoxy)phosphoryl]oxymethyl 2,2-dimethylpropanoate DMJM9LZ CA CAS 441785-26-8 DMJM9LZ DE Hepatitis B virus infection DMXB4NL ID DMXB4NL DMXB4NL DN MEDI4893 DMXB4NL HS Phase 2b DMXB4NL CP AstraZeneca DMXB4NL DT Antibody DMXB4NL DE Hospital-acquired pneumonia; Ventilator-associated pneumonia DMEARCM ID DMEARCM DMEARCM DN OrM3 DMEARCM HS Phase 2b DMEARCM CP Merck Research Laboratories DMEARCM DE Chronic obstructive pulmonary disease DMOE582 ID DMOE582 DMOE582 DN TZP-101 DMOE582 HS Phase 2b DMOE582 SN Ulimorelin; TZP-101; TZP 101; UNII-LGI67MCW2S; 842131-33-3; LGI67MCW2S; CHEMBL1923502; Ulimorelin [USAN:INN]; Ulimorelin (USAN/INN); SCHEMBL804500; TZP101; GTPL3535; CHEMBL1963249; DTXSID00233139; BDBM50359256; DB12128; D09981; (3R,6S,9R,12R)-6-cyclopropyl-12-[(4-fluorophenyl)methyl]-3,8,9-trimethyl-2-oxa-5,8,11,14-tetrazabicyclo[16.4.0]docosa-1(22),18,20-triene-7,10,13-trione; D-Phenylalanine, (2S)-N-((2R)-2-(2-(3-aminopropyl)phenoxy)propyl)-2- cyclopropylglycyl-N-methyl-D-alanyl-4-fluoro-, (3-1)-lactam DMOE582 CP Tranzyme DMOE582 DT Small molecular drug DMOE582 PC 11526696 DMOE582 MW 538.7 DMOE582 FM C30H39FN4O4 DMOE582 IC InChI=1S/C30H39FN4O4/c1-19-18-33-27(23-12-13-23)30(38)35(3)20(2)28(36)34-25(17-21-10-14-24(31)15-11-21)29(37)32-16-6-8-22-7-4-5-9-26(22)39-19/h4-5,7,9-11,14-15,19-20,23,25,27,33H,6,8,12-13,16-18H2,1-3H3,(H,32,37)(H,34,36)/t19-,20-,25-,27+/m1/s1 DMOE582 CS C[C@@H]1CN[C@H](C(=O)N([C@@H](C(=O)N[C@@H](C(=O)NCCCC2=CC=CC=C2O1)CC3=CC=C(C=C3)F)C)C)C4CC4 DMOE582 IK WGYPAJVJMXQXTR-ABNZCKJZSA-N DMOE582 IU (3R,6S,9R,12R)-6-cyclopropyl-12-[(4-fluorophenyl)methyl]-3,8,9-trimethyl-2-oxa-5,8,11,14-tetrazabicyclo[16.4.0]docosa-1(22),18,20-triene-7,10,13-trione DMOE582 CA CAS 842131-33-3 DMOE582 DE Gastrointestinal disease; Gastroparesis; Ileus DMUB8WN ID DMUB8WN DMUB8WN DN Aerovant DMUB8WN HS Phase 2a DMUB8WN CP Aerovance DMUB8WN DE Asthma DMSC8YW ID DMSC8YW DMSC8YW DN ANA773 DMSC8YW HS Phase 2a DMSC8YW CP Anadys Pharmaceuticals DMSC8YW DE Hepatitis C virus infection DMJBDL0 ID DMJBDL0 DMJBDL0 DN BIIB104 DMJBDL0 HS Phase 2a DMJBDL0 CP Biogen DMJBDL0 DE Cognitive impairment DM0TH9A ID DM0TH9A DM0TH9A DN Bimosiamose DM0TH9A HS Phase 2a DM0TH9A SN TBC 1269; TBC-1269 DM0TH9A CP Encysive Pharma DM0TH9A DT Small molecular drug DM0TH9A PC 9811353 DM0TH9A MW 862.9 DM0TH9A FM C46H54O16 DM0TH9A IC InChI=1S/C46H54O16/c47-23-35-39(53)41(55)43(57)45(61-35)59-33-15-13-25(19-31(33)29-11-5-9-27(17-29)21-37(49)50)7-3-1-2-4-8-26-14-16-34(60-46-44(58)42(56)40(54)36(24-48)62-46)32(20-26)30-12-6-10-28(18-30)22-38(51)52/h5-6,9-20,35-36,39-48,53-58H,1-4,7-8,21-24H2,(H,49,50)(H,51,52)/t35-,36-,39-,40-,41+,42+,43+,44+,45+,46+/m1/s1 DM0TH9A CS C1=CC(=CC(=C1)C2=C(C=CC(=C2)CCCCCCC3=CC(=C(C=C3)O[C@@H]4[C@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)C5=CC=CC(=C5)CC(=O)O)O[C@@H]6[C@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O)CC(=O)O DM0TH9A IK RYWCQJDEHXJHRI-XJMXIVSISA-N DM0TH9A IU 2-[3-[5-[6-[3-[3-(carboxymethyl)phenyl]-4-[(2R,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]hexyl]-2-[(2R,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]phenyl]acetic acid DM0TH9A CA CAS 187269-40-5 DM0TH9A DE Atopic dermatitis; Psoriatic disorder; Chronic obstructive pulmonary disease; Asthma DMR6LXM ID DMR6LXM DMR6LXM DN CAP-232 DMR6LXM HS Phase 2a DMR6LXM SN TT-232; UNII-49D4Q4254Z; TT 232; 49D4Q4254Z; 147159-51-1; Phe-cys-tyr-trp-lys-cys-thr-NH2 (2-6)-disulfide; TLN 232; CAP-232; CAP 232; Phenylalanyl-cysteinyl-tyrosyl-tryptophyl-lysyl-cysteinyl-threoninamide (2-6)-disulfide; AC1OCF7X; CHEMBL539934; TLN-232; L-Threoninamide, D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-cysteinyl-, cyclic (2-6)-disulfide; TT2-32; ZINC169289417; AKOS024458270; DB12088; NCGC00249606-01 DMR6LXM TC Anticancer Agents DMR6LXM DT Small molecular drug DMR6LXM PC 6918265 DMR6LXM MW 947.1 DMR6LXM FM C45H58N10O9S2 DMR6LXM IC InChI=1S/C45H58N10O9S2/c1-25(56)38(39(48)58)55-45(64)37-24-66-65-23-36(53-40(59)31(47)19-26-9-3-2-4-10-26)44(63)51-34(20-27-14-16-29(57)17-15-27)42(61)52-35(21-28-22-49-32-12-6-5-11-30(28)32)43(62)50-33(41(60)54-37)13-7-8-18-46/h2-6,9-12,14-17,22,25,31,33-38,49,56-57H,7-8,13,18-21,23-24,46-47H2,1H3,(H2,48,58)(H,50,62)(H,51,63)(H,52,61)(H,53,59)(H,54,60)(H,55,64)/t25-,31-,33+,34+,35-,36+,37+,38+/m1/s1 DMR6LXM CS C[C@H]([C@@H](C(=O)N)NC(=O)[C@@H]1CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@@H](CC5=CC=CC=C5)N)O DMR6LXM IK SNAJPQVDGYDQSW-DYCFWDQMSA-N DMR6LXM IU (4R,7S,10R,13S,16R)-7-(4-aminobutyl)-N-[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]-16-[[(2R)-2-amino-3-phenylpropanoyl]amino]-13-[(4-hydroxyphenyl)methyl]-10-(1H-indol-3-ylmethyl)-6,9,12,15-tetraoxo-1,2-dithia-5,8,11,14-tetrazacycloheptadecane-4-carboxamide DMR6LXM CA CAS 147159-51-1 DMR6LXM DE Pain; Renal cell carcinoma DMLQ3PO ID DMLQ3PO DMLQ3PO DN INCB13739 DMLQ3PO HS Phase 2a DMLQ3PO SN Phenylarsine oxide; phenylarsine oxide; Oxophenylarsine; 637-03-6; Arzene; Phenylarsenoxide; Arsenosobenzene; ARSINE, OXOPHENYL-; Phenyl arsine oxide; Benzene, arsenoso-; arsorosobenzene; Fenylarsinoxid; Caswell No 060; Fenylarsinoxid [Czech]; C6H5AsO; Phenyl arsenoxide; UNII-0HUR2WY345; PAO; EINECS 211-275-3; NSC 42470; EPA Pesticide Chemical Code 007101; BRN 2935227; 0HUR2WY345; CHEBI:75253; MFCD00001990; Phenylarsine oxide, 97%; Phenylarsine Oxide Solution; oxo(phenyl)arsan; Phenylarsinoxyd; oxo(phenyl)arsine; oxo(phenyl)arsane; PhAsO; phenylarsenious DMLQ3PO CP Incyte DMLQ3PO DT Small molecular drug DMLQ3PO PC 11502183 DMLQ3PO MW 398.9 DMLQ3PO FM C19H27ClN2O3S DMLQ3PO IC InChI=1S/C19H27ClN2O3S/c1-14-17(20)10-5-11-18(14)26(24,25)22-12-6-7-15(13-22)19(23)21-16-8-3-2-4-9-16/h5,10-11,15-16H,2-4,6-9,12-13H2,1H3,(H,21,23) DMLQ3PO CS CC1=C(C=CC=C1Cl)S(=O)(=O)N2CCCC(C2)C(=O)NC3CCCCC3 DMLQ3PO IK ODRPEKCTTLECBX-UHFFFAOYSA-N DMLQ3PO IU 1-(3-chloro-2-methylphenyl)sulfonyl-N-cyclohexylpiperidine-3-carboxamide DMLQ3PO DE Diabetic complication; Type-2 diabetes DMMWC6F ID DMMWC6F DMMWC6F DN INCB9471 DMMWC6F HS Phase 2a DMMWC6F SN INCB-9471; UNII-C5D4W25708; INCB9471; CHEMBL1688243; INCB009471; C5D4W25708; INCB-009471; INCB 9471; INCB0 09471; 869769-98-2; SCHEMBL3676335; ZINC43171152; BDBM50339033; DB12960; 925701-76-4; Piperidine, 1-((4,6-dimethyl-5-pyrimidinyl)carbonyl)-4-((3S)-4-((1R,2R)-2-ethoxy-2,3-dihydro-5-(trifluoromethyl)-1H-inden-1-yl)-3-methyl-1-piperazinyl)-4-methyl-; 5-((4-(4-(2-Ethoxy-5-(trifluoromethyl)-2,3-dihydro-1H-inden-1-yl)-3-methylpiperazin-1-yl)-4-methylpiperidin-1-yl)carbonyl)-4,6-dimethylpyrimidine DMMWC6F CP Incyte DMMWC6F DT Small molecular drug DMMWC6F PC 49871007 DMMWC6F MW 559.7 DMMWC6F FM C30H40F3N5O2 DMMWC6F IC InChI=1S/C30H40F3N5O2/c1-6-40-25-16-22-15-23(30(31,32)33)7-8-24(22)27(25)38-14-13-37(17-19(38)2)29(5)9-11-36(12-10-29)28(39)26-20(3)34-18-35-21(26)4/h7-8,15,18-19,25,27H,6,9-14,16-17H2,1-5H3/t19-,25+,27+/m0/s1 DMMWC6F CS CCO[C@@H]1CC2=C([C@H]1N3CCN(C[C@@H]3C)C4(CCN(CC4)C(=O)C5=C(N=CN=C5C)C)C)C=CC(=C2)C(F)(F)F DMMWC6F IK ZMCJFJZOSKEMOM-DNKZPPIMSA-N DMMWC6F IU (4,6-dimethylpyrimidin-5-yl)-[4-[(3S)-4-[(1R,2R)-2-ethoxy-5-(trifluoromethyl)-2,3-dihydro-1H-inden-1-yl]-3-methylpiperazin-1-yl]-4-methylpiperidin-1-yl]methanone DMMWC6F CA CAS 869769-98-2 DMMWC6F DE Human immunodeficiency virus infection; Infectious disease DMYZU6G ID DMYZU6G DMYZU6G DN MEM-1003 DMYZU6G HS Phase 2a DMYZU6G SN SCHEMBL1191960; SCHEMBL16332975 DMYZU6G CP Bayer DMYZU6G DT Small molecular drug DMYZU6G PC 9802887 DMYZU6G MW 432.9 DMYZU6G FM C22H25ClN2O5 DMYZU6G IC InChI=1S/C22H25ClN2O5/c1-12(2)30-22(27)18-14(4)25-13(3)17(21(26)29-10-9-28-5)19(18)16-8-6-7-15(11-24)20(16)23/h6-8,12,19,25H,9-10H2,1-5H3 DMYZU6G CS CC1=C(C(C(=C(N1)C)C(=O)OC(C)C)C2=CC=CC(=C2Cl)C#N)C(=O)OCCOC DMYZU6G IK GTIKSQYSAKETQA-UHFFFAOYSA-N DMYZU6G IU 3-O-(2-methoxyethyl) 5-O-propan-2-yl 4-(2-chloro-3-cyanophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate DMYZU6G DE Dementia; Bipolar disorder DMGM1IR ID DMGM1IR DMGM1IR DN RhuDex DMGM1IR HS Phase 2a DMGM1IR CP MediGene AG DMGM1IR DE Rheumatoid arthritis DMKJDR6 ID DMKJDR6 DMKJDR6 DN VX-702 DMKJDR6 HS Phase 2a DMKJDR6 SN ST51054128; I14-1965; EC-000.2363; 6-[carbamoyl-(2,6-difluorophenyl)amino]-2-(2,4-difluorophenyl)pyridine-3-carboxamide DMKJDR6 CP Vertex Pharma DMKJDR6 DT Small molecular drug DMKJDR6 PC 10341154 DMKJDR6 MW 404.3 DMKJDR6 FM C19H12F4N4O2 DMKJDR6 IC InChI=1S/C19H12F4N4O2/c20-9-4-5-10(14(23)8-9)16-11(18(24)28)6-7-15(26-16)27(19(25)29)17-12(21)2-1-3-13(17)22/h1-8H,(H2,24,28)(H2,25,29) DMKJDR6 CS C1=CC(=C(C(=C1)F)N(C2=NC(=C(C=C2)C(=O)N)C3=C(C=C(C=C3)F)F)C(=O)N)F DMKJDR6 IK FYSRKRZDBHOFAY-UHFFFAOYSA-N DMKJDR6 IU 6-(N-carbamoyl-2,6-difluoroanilino)-2-(2,4-difluorophenyl)pyridine-3-carboxamide DMKJDR6 CA CAS 745833-23-2 DMKJDR6 CB CHEBI:94489 DMKJDR6 DE Coronary artery disease; Rheumatoid arthritis; Inflammation DMAV426 ID DMAV426 DMAV426 DN (S)-oxybutynin DMAV426 HS Phase 2 DMAV426 CP Sepracor DMAV426 PC 206530 DMAV426 MW 357.5 DMAV426 FM C22H31NO3 DMAV426 IC InChI=1S/C22H31NO3/c1-3-23(4-2)17-11-12-18-26-21(24)22(25,19-13-7-5-8-14-19)20-15-9-6-10-16-20/h5,7-8,13-14,20,25H,3-4,6,9-10,15-18H2,1-2H3/t22-/m1/s1 DMAV426 CS CCN(CC)CC#CCOC(=O)[C@](C1CCCCC1)(C2=CC=CC=C2)O DMAV426 IK XIQVNETUBQGFHX-JOCHJYFZSA-N DMAV426 IU 4-(diethylamino)but-2-ynyl (2S)-2-cyclohexyl-2-hydroxy-2-phenylacetate DMAV426 CA CAS 119618-22-3 DMAV426 CB CHEBI:51329 DMAV426 DE Urinary incontinence DMGDOS2 ID DMGDOS2 DMGDOS2 DN (Z)-endoxifen DMGDOS2 HS Phase 2 DMGDOS2 SN Endoxifen; Z-Endoxifen; 4-Hydroxy-N-desmethyltamoxifen; (E/Z)-Endoxifen; Endoxifen Z-Isomer; UNII-46AF8680RC; N-Desmethyl-4-hydroxytamoxifen; 110025-28-0; 4-Hydroxy-N-desmethyl-tamoxifen; CHEBI:80555; 46AF8680RC; 4OHNDtam; W-200834; N-Desmethyl-4-hydroxy Tamoxifen (approx. 1:1 E/Z Mixture); (Z)-4-Hydroxy-N-desmethyl Tamoxifen (contains up to 10% E isomer); 4-hydroxy-N-desmethyltamoxifen, (Z)-isomer; (Z)-Endoxifen; Endoxifen(E/Z=1:1); 4-hydroxy-N-desmethyl tamoxifen; SCHEMBL10107920; CHEMBL1093458; GTPL10203; EX-A645 DMGDOS2 PC 10090750 DMGDOS2 MW 373.5 DMGDOS2 FM C25H27NO2 DMGDOS2 IC InChI=1S/C25H27NO2/c1-3-24(19-7-5-4-6-8-19)25(20-9-13-22(27)14-10-20)21-11-15-23(16-12-21)28-18-17-26-2/h4-16,26-27H,3,17-18H2,1-2H3/b25-24- DMGDOS2 CS CCC(=C(C1=CC=C(C=C1)O)C2=CC=C(C=C2)OCCNC)C3=CC=CC=C3 DMGDOS2 IK MHJBZVSGOZTKRH-IZHYLOQSSA-N DMGDOS2 IU 4-[(Z)-1-[4-[2-(methylamino)ethoxy]phenyl]-2-phenylbut-1-enyl]phenol DMGDOS2 CA CAS 112093-28-4 DMGDOS2 CB CHEBI:80555 DMGDOS2 DE Breast cancer DMV86DY ID DMV86DY DMV86DY DN [131I]-BC8 DMV86DY HS Phase 2 DMV86DY DT Antibody DMV86DY DE leukaemia DM4VWXI ID DM4VWXI DM4VWXI DN [131I]-Metuximab DM4VWXI HS Phase 2 DM4VWXI CP Elsevier DM4VWXI DT Antibody DM4VWXI DE Liver cancer DMSLMY7 ID DMSLMY7 DMSLMY7 DN 11C-PBR-28 DMSLMY7 HS Phase 2 DMSLMY7 SN Radiolabeled benzodiazepine receptor ligands, NIH; Carbon-11-PBR-101; Carbon-11-PBR-28; Fluorine-18-PBR-06; 11C-PBR-01; 18F-PBR-06 DMSLMY7 CP National Institutes of Health DMSLMY7 PC 11653141 DMSLMY7 MW 347.4 DMSLMY7 FM C21H20N2O3 DMSLMY7 IC InChI=1S/C21H20N2O3/c1-16(24)23(15-17-8-6-7-11-20(17)25-2)19-14-22-13-12-21(19)26-18-9-4-3-5-10-18/h3-14H,15H2,1-2H3/i2-1 DMSLMY7 CS CC(=O)N(CC1=CC=CC=C1O[11CH3])C2=C(C=CN=C2)OC3=CC=CC=C3 DMSLMY7 IK DHZBNHMEIOBPAE-JVVVGQRLSA-N DMSLMY7 IU N-[(2-(111C)methoxyphenyl)methyl]-N-(4-phenoxypyridin-3-yl)acetamide DMSLMY7 CA CAS 1005325-43-8 DMSLMY7 DE Brain disease DMTIED1 ID DMTIED1 DMTIED1 DN 131I-TM-601 DMTIED1 HS Phase 2 DMTIED1 SN Glioma therapy, Transmolecular; Solid tumor imaging, TransMolecular; TM-602; TM-603; TM-803; Toxin-based anticancers, Transmolecular; Iodine-131-TM-601 DMTIED1 CP TransMolecular Inc DMTIED1 DE Glioma DM4EP6Y ID DM4EP6Y DM4EP6Y DN 13-DEOXYADRIAMYCIN HYDROCHLORIDE DM4EP6Y HS Phase 2 DM4EP6Y SN GPX-100; (8R,10S)-10-(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyloxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyethyl)-1-methoxynaphthacene-5,12-dione hydrochloride; 13-Deoxydoxorubicin hydrochloride DM4EP6Y CP Access Pharmaceuticals DM4EP6Y PC 9829418 DM4EP6Y MW 566 DM4EP6Y FM C27H32ClNO10 DM4EP6Y IC InChI=1S/C27H31NO10.ClH/c1-11-22(30)14(28)8-17(37-11)38-16-10-27(35,6-7-29)9-13-19(16)26(34)21-20(24(13)32)23(31)12-4-3-5-15(36-2)18(12)25(21)33;/h3-5,11,14,16-17,22,29-30,32,34-35H,6-10,28H2,1-2H3;1H/t11-,14-,16-,17-,22+,27-;/m0./s1 DM4EP6Y CS C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(CCO)O)N)O.Cl DM4EP6Y IK YZSQITAPLDJGKS-RYQLBYGJSA-N DM4EP6Y IU (7S,9R)-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyethyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione;hydrochloride DM4EP6Y CA CAS 65360-29-4 DM4EP6Y DE Solid tumour/cancer DMNF38S ID DMNF38S DMNF38S DN 16,16-dimethyl-PGE2 DMNF38S HS Phase 2 DMNF38S SN 16,16-dimethylprostaglandin E2 DMNF38S DT Small molecular drug DMNF38S PC 5283066 DMNF38S MW 380.5 DMNF38S FM C22H36O5 DMNF38S IC InChI=1S/C22H36O5/c1-4-5-14-22(2,3)20(25)13-12-17-16(18(23)15-19(17)24)10-8-6-7-9-11-21(26)27/h6,8,12-13,16-17,19-20,24-25H,4-5,7,9-11,14-15H2,1-3H3,(H,26,27)/b8-6-,13-12+/t16-,17-,19-,20-/m1/s1 DMNF38S CS CCCCC(C)(C)[C@@H](/C=C/[C@H]1[C@@H](CC(=O)[C@@H]1C/C=C\\CCCC(=O)O)O)O DMNF38S IK QAOBBBBDJSWHMU-WMBBNPMCSA-N DMNF38S IU (Z)-7-[(1R,2R,3R)-3-hydroxy-2-[(E,3R)-3-hydroxy-4,4-dimethyloct-1-enyl]-5-oxocyclopentyl]hept-5-enoic acid DMNF38S CA CAS 39746-25-3 DMNF38S CB CHEBI:141046 DMNF38S DE Stem cell engraftment DMT8GVU ID DMT8GVU DMT8GVU DN 177Lu-DOTATATE DMT8GVU HS Phase 2 DMT8GVU CP Advanced accelerator applications DMT8GVU PC 76966897 DMT8GVU MW 1609.5 DMT8GVU FM C65H87LuN14O19S2 DMT8GVU IC InChI=1S/C65H90N14O19S2.Lu/c1-38(80)56-64(96)73-51(63(95)75-57(39(2)81)65(97)98)37-100-99-36-50(72-59(91)47(28-40-10-4-3-5-11-40)68-52(83)32-76-20-22-77(33-53(84)85)24-26-79(35-55(88)89)27-25-78(23-21-76)34-54(86)87)62(94)70-48(29-41-15-17-43(82)18-16-41)60(92)71-49(30-42-31-67-45-13-7-6-12-44(42)45)61(93)69-46(58(90)74-56)14-8-9-19-66;/h3-7,10-13,15-18,31,38-39,46-51,56-57,67,80-82H,8-9,14,19-30,32-37,66H2,1-2H3,(H,68,83)(H,69,93)(H,70,94)(H,71,92)(H,72,91)(H,73,96)(H,74,90)(H,75,95)(H,84,85)(H,86,87)(H,88,89)(H,97,98);/q;+3/p-3/t38-,39-,46+,47-,48+,49-,50+,51+,56+,57+;/m1./s1/i;1+2 DMT8GVU CS C[C@H]([C@H]1C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@@H](CC5=CC=CC=C5)NC(=O)CN6CCN(CCN(CCN(CC6)CC(=O)[O-])CC(=O)[O-])CC(=O)[O-])C(=O)N[C@@H]([C@@H](C)O)C(=O)O)O.[177Lu+3] DMT8GVU IK MXDPZUIOZWKRAA-PRDSJKGBSA-K DMT8GVU IU 2-[4-[2-[[(2R)-1-[[(4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-4-[[(1S,2R)-1-carboxy-2-hydroxypropyl]carbamoyl]-7-[(1R)-1-hydroxyethyl]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicos-19-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]-7,10-bis(carboxylatomethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetate;lutetium-177(3+) DMT8GVU CA CAS 437608-50-9 DMT8GVU DE Hepatitis C virus infection DM2TSMD ID DM2TSMD DM2TSMD DN 177Lu-labelled NeoBOMB1 DM2TSMD HS Phase 2 DM2TSMD CP Novartis/AAA DM2TSMD DT Radiopharmaceutical therapy agent DM2TSMD DE Solid tumour/cancer DM8JVIB ID DM8JVIB DM8JVIB DN 18F-LMI-1195 DM8JVIB HS Phase 2 DM8JVIB SN Flourine-18-LMI-1195; Fluorine-18-based PET imaging agent (intravenous, heart failure), Lantheus; 18F-based PET imaging agent (intravenous, heart failure), Lantheus DM8JVIB CP Lantheus medical imaging DM8JVIB DE Heart failure DMZWNQF ID DMZWNQF DMZWNQF DN 2'3'-Dideoxyinosine DMZWNQF HS Phase 2 DMZWNQF DT Small molecular drug DMZWNQF PC 16219192 DMBOL4K ID DMBOL4K DMBOL4K DN 264W94 DMBOL4K HS Phase 2 DMBOL4K SN GW-264 DMBOL4K CP Glaxo Wellcome plc DMBOL4K DT Small molecular drug DMBOL4K PC 9823277 DMBOL4K MW 417.6 DMBOL4K FM C23H31NO4S DMBOL4K IC InChI=1S/C23H31NO4S/c1-5-7-13-23(6-2)16-29(25,26)21-15-20(28-4)19(27-3)14-18(21)22(24-23)17-11-9-8-10-12-17/h8-12,14-15,22,24H,5-7,13,16H2,1-4H3/t22-,23-/m1/s1 DMBOL4K CS CCCC[C@@]1(CS(=O)(=O)C2=CC(=C(C=C2[C@H](N1)C3=CC=CC=C3)OC)OC)CC DMBOL4K IK CKFWDLFFXXVSBJ-DHIUTWEWSA-N DMBOL4K IU (3R,5R)-3-butyl-3-ethyl-7,8-dimethoxy-5-phenyl-4,5-dihydro-2H-1lambda6,4-benzothiazepine 1,1-dioxide DMBOL4K CA CAS 178259-25-1 DMBOL4K DE Hyperlipidaemia DMGBPME ID DMGBPME DMGBPME DN 2-Methoxyestradiol DMGBPME HS Phase 2 DMGBPME SN ESM; Panzem; PulmoLAR; Panzem NCD; M 6383; (17beta)-2-Methoxyestra-1,3,5(10)-triene-3,17-diol; (17beta)-2-methoxyestra-1(10),2,4-triene-3,17-diol; (8R,9S,13S,14S,17S)-2-methoxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol; 1,3,5(10)-ESTRATRIEN-2,3,17-BETA-TRIOL 2-METHYL ETHER; 1,3,5(10)-Estratriene-2,3,17-triol 2-methyl ether; 2,3,17beta-Trihydroxy-1,3,5(10)-estratriene 2-methyl ether; 2-Hydroxyestradiol 2-methyl ether; 2-Hydroxyestradol 2-methyl ether; 2-ME2, 2-Methoxyestradiol; 2-Methoxyestra-1,3,5(10)-triene-3,17beta-diol; 2-Methoxyestradiol-17beta; 3,17beta-Dihydroxy-2-methoxy-1,3,5(10)-estratriene DMGBPME CP EntreMed DMGBPME DT Small molecular drug DMGBPME PC 66414 DMGBPME MW 302.4 DMGBPME FM C19H26O3 DMGBPME IC InChI=1S/C19H26O3/c1-19-8-7-12-13(15(19)5-6-18(19)21)4-3-11-9-16(20)17(22-2)10-14(11)12/h9-10,12-13,15,18,20-21H,3-8H2,1-2H3/t12-,13+,15-,18-,19-/m0/s1 DMGBPME CS C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CCC4=CC(=C(C=C34)OC)O DMGBPME IK CQOQDQWUFQDJMK-SSTWWWIQSA-N DMGBPME IU (8R,9S,13S,14S,17S)-2-methoxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol DMGBPME CA CAS 362-07-2 DMGBPME CB CHEBI:28955 DMGBPME DE Pulmonary arterial hypertension DMX9MSL ID DMX9MSL DMX9MSL DN 2X-121 DMX9MSL HS Phase 2 DMX9MSL CP 2X Oncology Cambridge, MA DMX9MSL DE Breast cancer DML8M5T ID DML8M5T DML8M5T DN 3,5-diiodothyropropionic acid DML8M5T HS Phase 2 DML8M5T SN DITPA) DML8M5T CP Titan Pharmaceuticals DML8M5T DT Small molecular drug DML8M5T PC 160565 DML8M5T MW 510.06 DML8M5T FM C15H12I2O4 DML8M5T IC InChI=1S/C15H12I2O4/c16-12-7-9(1-6-14(19)20)8-13(17)15(12)21-11-4-2-10(18)3-5-11/h2-5,7-8,18H,1,6H2,(H,19,20) DML8M5T CS C1=CC(=CC=C1O)OC2=C(C=C(C=C2I)CCC(=O)O)I DML8M5T IK WONYMNWUJVKVII-UHFFFAOYSA-N DML8M5T IU 3-[4-(4-hydroxyphenoxy)-3,5-diiodophenyl]propanoic acid DML8M5T CA CAS 1158-10-7 DML8M5T CB CHEBI:134267 DML8M5T DE Cardiovascular disease; Congestive heart failure DMTLR6Y ID DMTLR6Y DMTLR6Y DN 3K3A-APC DMTLR6Y HS Phase 2 DMTLR6Y CP Zz biotech DMTLR6Y DE Cerebrovascular ischaemia; Ischemic stroke DMPFVJB ID DMPFVJB DMPFVJB DN 5-hydroxymethyl-2-furfural DMPFVJB HS Phase 2 DMPFVJB SN Aes-103; 5-HMF; 5-hydroxymethylfurfural DMPFVJB CP Aesrx DMPFVJB DT Small molecular drug DMPFVJB PC 237332 DMPFVJB MW 126.11 DMPFVJB FM C6H6O3 DMPFVJB IC InChI=1S/C6H6O3/c7-3-5-1-2-6(4-8)9-5/h1-3,8H,4H2 DMPFVJB CS C1=C(OC(=C1)C=O)CO DMPFVJB IK NOEGNKMFWQHSLB-UHFFFAOYSA-N DMPFVJB IU 5-(hydroxymethyl)furan-2-carbaldehyde DMPFVJB CA 67-47-0 DMPFVJB DE Anemia DMHBN8X ID DMHBN8X DMHBN8X DN 60P002 DMHBN8X HS Phase 2 DMHBN8X CP 60 Degrees Pharmaceuticals DMHBN8X DT Small molecular drug DMHBN8X DE Dengue DMOV0AP ID DMOV0AP DMOV0AP DN 842166X DMOV0AP HS Phase 2 DMOV0AP SN GW842166X; 666260-75-9; GW 842166X; GW-842166X; UNII-VL1I6P2DZ8; VL1I6P2DZ8; GW842166; GW 842166; CHEMBL225411; 2-((2,4-dichlorophenyl)amino)-N-((tetrahydro-2H-pyran-4-yl)methyl)-4-(trifluoromethyl)pyrimidine-5-carboxamide; TWQYWUXBZHPIIV-UHFFFAOYSA-N; 842166X; MLS006010287; C18H17Cl2F3N4O2; SCHEMBL3015040; DTXSID60216786; MolPort-009-019-316; HMS3656P06; BCP05306; ZINC3947932; BDBM50211843; s2778; 2455AH; AKOS032945128; DB11903; BCP9000755; CS-7768; SB19546; API0013938; GW-842,166X; NCGC00346697-05; NCGC00346697-01; KB-77649; HY-14167 DMOV0AP DT Small molecular drug DMOV0AP PC 10253143 DMOV0AP MW 449.3 DMOV0AP FM C18H17Cl2F3N4O2 DMOV0AP IC InChI=1S/C18H17Cl2F3N4O2/c19-11-1-2-14(13(20)7-11)26-17-25-9-12(15(27-17)18(21,22)23)16(28)24-8-10-3-5-29-6-4-10/h1-2,7,9-10H,3-6,8H2,(H,24,28)(H,25,26,27) DMOV0AP CS C1COCCC1CNC(=O)C2=CN=C(N=C2C(F)(F)F)NC3=C(C=C(C=C3)Cl)Cl DMOV0AP IK TWQYWUXBZHPIIV-UHFFFAOYSA-N DMOV0AP IU 2-(2,4-dichloroanilino)-N-(oxan-4-ylmethyl)-4-(trifluoromethyl)pyrimidine-5-carboxamide DMOV0AP CA CAS 666260-75-9 DMOV0AP DE Pain DML4GU1 ID DML4GU1 DML4GU1 DN 99mTc-MIP-1404 DML4GU1 HS Phase 2 DML4GU1 CP Molecular Insight Pharmaceuticals Inc DML4GU1 DT ? DML4GU1 PC 71300957 DML4GU1 MW 1176.3 DML4GU1 FM C40H53ClN10O23Tc DML4GU1 IC InChI=1S/C37H50N10O20.3CHO.ClH.Tc/c48-26(6-4-22(35(63)64)41-37(67)42-23(36(65)66)5-7-29(51)52)40-21(34(61)62)3-1-2-10-43(13-24-38-8-11-44(24)15-27(49)46(17-30(53)54)18-31(55)56)14-25-39-9-12-45(25)16-28(50)47(19-32(57)58)20-33(59)60;3*1-2;;/h8-9,11-12,21-23H,1-7,10,13-20H2,(H,40,48)(H,51,52)(H,53,54)(H,55,56)(H,57,58)(H,59,60)(H,61,62)(H,63,64)(H,65,66)(H2,41,42,67);3*1H;1H;/q;3*-1;;+4/p-1/t21-,22-,23-;;;;;/m0...../s1/i;;;;;1+1 DML4GU1 CS [CH-]=O.[CH-]=O.[CH-]=O.C1=CN(C(=N1)CN(CCCC[C@@H](C(=O)O)NC(=O)CC[C@@H](C(=O)O)NC(=O)N[C@@H](CCC(=O)O)C(=O)O)CC2=NC=CN2CC(=O)N(CC(=O)O)CC(=O)O)CC(=O)N(CC(=O)O)CC(=O)O.[Cl-].[99Tc+4] DML4GU1 IK XOJYSFPEJAILJZ-LCERUKBVSA-M DML4GU1 IU (2S)-2-[[(1S)-4-[[(1S)-5-[bis[[1-[2-[bis(carboxymethyl)amino]-2-oxoethyl]imidazol-2-yl]methyl]amino]-1-carboxypentyl]amino]-1-carboxy-4-oxobutyl]carbamoylamino]pentanedioic acid;methanone;technetium-99(4+);chloride DML4GU1 CA CAS 1333117-95-5 DML4GU1 DE Prostate cancer DMX2LO3 ID DMX2LO3 DMX2LO3 DN 99mTc-RP-128 DMX2LO3 HS Phase 2 DMX2LO3 SN (SP-5-25)-Hydrogen [N,N-dimethylglycyl-kappaN-L-seryl-kappaN-L-cysteinyl-kappaN,kappaS-glycyl-L-threonyl-L-lysyl-L-prolyl-L-prolyl-L-argininato(4-)]oxotechnetate(1-)-99Tc; 186037-48-9 DMX2LO3 DE Diagnostic imaging DMQXYRG ID DMQXYRG DMQXYRG DN 9-AMINOCAMPTOTHECIN DMQXYRG HS Phase 2 DMQXYRG SN IDEC-132; (S)-10-Amino-4-ethyl-4-hydroxy-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14-dione; 9-Amino-20(S)-camptothecin DMQXYRG DT Small molecular drug DMQXYRG PC 72402 DMQXYRG MW 363.4 DMQXYRG FM C20H17N3O4 DMQXYRG IC InChI=1S/C20H17N3O4/c1-2-20(26)13-7-16-17-10(6-11-14(21)4-3-5-15(11)22-17)8-23(16)18(24)12(13)9-27-19(20)25/h3-7,26H,2,8-9,21H2,1H3/t20-/m0/s1 DMQXYRG CS CC[C@@]1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC=C5N=C4C3=C2)N)O DMQXYRG IK FUXVKZWTXQUGMW-FQEVSTJZSA-N DMQXYRG IU (19S)-8-amino-19-ethyl-19-hydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4,6,8,10,15(20)-heptaene-14,18-dione DMQXYRG CA CAS 91421-43-1 DMQXYRG CB CHEBI:80755 DMQXYRG DE Acquired immune deficiency syndrome DM57TY3 ID DM57TY3 DM57TY3 DN 9-ING-41 DM57TY3 HS Phase 2 DM57TY3 SN 1034895-42-5; ND1SOF0DLU; UNII-ND1SOF0DLU; CHEMBL483465; 3-(5-fluoro-1-benzofuran-3-yl)-4-(5-methyl-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione; 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)-1H-pyrrole-2,5-dione; elraglusib; SCHEMBL3152351; GTPL11412; EX-A4074; BDBM50267716; s9602; SB19735; compound 26 [PMID: 19338355]; HY-113914; CS-0063319; 1H-Pyrrole-2,5-dione, 3-(5-fluoro-3-benzofuranyl)-4-(5-methyl-5H-1,3-dioxolo(4,5-F)indol-7-yl)-; 3-(5-Fluoro-benzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-F)indol-7-yl)-pyrrole-2,5-dione; 3-(5-Fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione; 4-(5-methyl-5H-[1,3]dioxolo[4,5-f]-indol-7-yl)-3-(5-fluoro-1-benzofuran-3-yl)-1 h-pyrrole-2,5-dione DM57TY3 CP Actuate Therapeutics DM57TY3 DT Small molecular drug DM57TY3 PC 44582816 DM57TY3 MW 404.3 DM57TY3 FM C22H13FN2O5 DM57TY3 IC InChI=1S/C22H13FN2O5/c1-25-7-13(11-5-17-18(6-15(11)25)30-9-29-17)19-20(22(27)24-21(19)26)14-8-28-16-3-2-10(23)4-12(14)16/h2-8H,9H2,1H3,(H,24,26,27) DM57TY3 CS CN1C=C(C2=CC3=C(C=C21)OCO3)C4=C(C(=O)NC4=O)C5=COC6=C5C=C(C=C6)F DM57TY3 IK FARXPFGGGGLENU-UHFFFAOYSA-N DM57TY3 IU 3-(5-fluoro-1-benzofuran-3-yl)-4-(5-methyl-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione DM57TY3 CA CAS 1034895-42-5 DM57TY3 DE Solid tumour/cancer; Myelofibrosis DM6ZIES ID DM6ZIES DM6ZIES DN A-6 DM6ZIES HS Phase 2 DM6ZIES SN Angstrom-6; CD44 binding peptide (cancer), Angstrom DM6ZIES CP Angstrom pharmaceuticals DM6ZIES DE Macular degeneration DMHOLB7 ID DMHOLB7 DMHOLB7 DN A-85380 DMHOLB7 HS Phase 2 DMHOLB7 SN A-85380; A 85380; 161416-98-4; CHEMBL59986; (S)-3-(AZETIDIN-2-YLMETHOXY)PYRIDINE; AC1NSJQT; Pyridine, 3-[(2S)-2-azetidinylmethoxy]-; SCHEMBL676026; A-159470; GTPL5460; ZINC3805142; 3-(2(s)-azetidinylmethoxy)pyridine; BDBM50049750; AKOS030230435; NCGC00387223-01; 3-[(2S)-azetidin-2-ylmethoxy]pyridine; 3-[[(2S)-azetidin-2-yl]methoxy]pyridine; 3-((S)-1-Azetidin-2-ylmethoxy)-pyridine; Pyridine, 3-(2-azetidinylmethoxy)-, (S)- DMHOLB7 DT Small molecular drug DMHOLB7 PC 5310969 DMHOLB7 MW 164.2 DMHOLB7 FM C9H12N2O DMHOLB7 IC InChI=1S/C9H12N2O/c1-2-9(6-10-4-1)12-7-8-3-5-11-8/h1-2,4,6,8,11H,3,5,7H2/t8-/m0/s1 DMHOLB7 CS C1CN[C@@H]1COC2=CN=CC=C2 DMHOLB7 IK XKFMBGWHHBCWCD-QMMMGPOBSA-N DMHOLB7 IU 3-[[(2S)-azetidin-2-yl]methoxy]pyridine DMHOLB7 CA CAS 161416-98-4 DMOGDCQ ID DMOGDCQ DMOGDCQ DN Ab-01 DMOGDCQ HS Phase 2 DMOGDCQ SN Ab-02; IL-21 receptor-targeted human monoclonal antibodies (inflammation); Anti-IL-21R mAb (inflammation), Pfizer; IL-21 receptor-targeted human monoclonal antibodies (inflammation), Pfizer DMOGDCQ CP Pfizer Inc DMOGDCQ DT Antibody DMOGDCQ DE Inflammation DMEW62S ID DMEW62S DMEW62S DN AB-106 DMEW62S HS Phase 2 DMEW62S SN DS6051b; GTPL11198; AB106 DMEW62S CP AnHeart Therapeutics DMEW62S DT Small molecular drug DMEW62S PC 154699459 DMEW62S MW 405.5 DMEW62S FM C23H24FN5O DMEW62S IC InChI=1S/C23H24FN5O/c1-15(25)14-30-20-8-6-17(7-9-20)21-13-26-23-11-10-22(28-29(21)23)27-16(2)18-4-3-5-19(24)12-18/h3-13,15-16H,14,25H2,1-2H3,(H,27,28) DMEW62S CS CC(COC1=CC=C(C=C1)C2=CN=C3N2N=C(C=C3)NC(C)C4=CC(=CC=C4)F)N DMEW62S IK HEVHTYMYEMEBPX-UHFFFAOYSA-N DMEW62S IU 3-[4-(2-aminopropoxy)phenyl]-N-[1-(3-fluorophenyl)ethyl]imidazo[1,2-b]pyridazin-6-amine DMEW62S DE Non-small cell lung cancer DM48DPS ID DM48DPS DM48DPS DN AB-729 DM48DPS HS Phase 2 DM48DPS CP Arbutus Biopharma DM48DPS DT Small interfering RNA DM48DPS DE Hepatitis B virus infection DM4ZLTY ID DM4ZLTY DM4ZLTY DN ABBV-2222 DM4ZLTY HS Phase 2 DM4ZLTY SN QVDYQHXNAQHIKH-YMBRHYMPSA-N; ABBV 2222; 1918143-53-9; BCP25130 DM4ZLTY CP AbbVie DM4ZLTY PC 121301049 DM4ZLTY MW 559.5 DM4ZLTY FM C28H21F4NO7 DM4ZLTY IC InChI=1S/C28H21F4NO7/c29-26(30)37-17-6-7-18-19(13-21(38-22(18)12-17)14-1-3-15(4-2-14)24(34)35)33-25(36)27(9-10-27)16-5-8-20-23(11-16)40-28(31,32)39-20/h1-8,11-12,19,21,26H,9-10,13H2,(H,33,36)(H,34,35)/t19-,21-/m1/s1 DM4ZLTY CS C1CC1(C2=CC3=C(C=C2)OC(O3)(F)F)C(=O)N[C@@H]4C[C@@H](OC5=C4C=CC(=C5)OC(F)F)C6=CC=C(C=C6)C(=O)O DM4ZLTY IK QVDYQHXNAQHIKH-TZIWHRDSSA-N DM4ZLTY IU 4-[(2R,4R)-4-[[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropanecarbonyl]amino]-7-(difluoromethoxy)-3,4-dihydro-2H-chromen-2-yl]benzoic acid DM4ZLTY CA CAS 1918143-53-9 DM4ZLTY DE Cystic fibrosis DMT6H3J ID DMT6H3J DMT6H3J DN AbGn-168 DMT6H3J HS Phase 2 DMT6H3J SN AbGn-168H; Antibody 168 (autoimmune diseases), Boehringer Ingelheim/AbGenomics; Anti-CD162 mAb (psoriasis), Boehringer/AbGenomics DMT6H3J CP Abgenomics international DMT6H3J DT Antibody DMT6H3J DE Allergy DMQ6KZM ID DMQ6KZM DMQ6KZM DN ABI-009 DMQ6KZM HS Phase 2 DMQ6KZM CP Celgene DMQ6KZM DE Solid tumour/cancer; Malignant perivascular epithelioid cell tumour; Non-muscle invasive bladder cancer; Pulmonary arterial hypertension DM59OJ2 ID DM59OJ2 DM59OJ2 DN Abicipar pegol DM59OJ2 HS Phase 2 DM59OJ2 CP Allergan Parsippany, NJ Molecular Partners Zurich, Switzerland DM59OJ2 DE Diabetic macular edema DMX1KDM ID DMX1KDM DMX1KDM DN ABI-H0731 DMX1KDM HS Phase 2 DMX1KDM SN Vebicorvir; UNII-16F6055SMG; 16F6055SMG; 11-Oxo-N-((2-(trifluoromethyl)thiazol-5-yl)methyl)-10,11-dihydrodibenzo[b,f][1,4]thiazepine-8-carboxamide 5,5-dioxide; 2090064-66-5; Vebicorvir [INN]; Vebicorvir [USAN]; SCHEMBL21250344; WHO 11201; Dibenzo(b,F)(1,4)thiazepine-8-carboxamide, 10,11-dihydro-11-oxo-N-((2-(trifluoromethyl)-5-thiazolyl)methyl)-, 5,5-dioxide DMX1KDM CP Assembly Biosciences DMX1KDM DT Small molecular drug DMX1KDM PC 139394142 DMX1KDM MW 467.4 DMX1KDM FM C19H12F3N3O4S2 DMX1KDM IC InChI=1S/C19H12F3N3O4S2/c20-19(21,22)18-24-9-11(30-18)8-23-16(26)10-5-6-15-13(7-10)25-17(27)12-3-1-2-4-14(12)31(15,28)29/h1-7,9H,8H2,(H,23,26)(H,25,27) DMX1KDM CS C1=CC=C2C(=C1)C(=O)NC3=C(S2(=O)=O)C=CC(=C3)C(=O)NCC4=CN=C(S4)C(F)(F)F DMX1KDM IK LBJVBJYMZKEREY-UHFFFAOYSA-N DMX1KDM IU 6,11,11-trioxo-N-[[2-(trifluoromethyl)-1,3-thiazol-5-yl]methyl]-5H-benzo[b][1,4]benzothiazepine-3-carboxamide DMX1KDM CA CAS 2090064-66-5 DMX1KDM DE Hepatitis B DM6X70G ID DM6X70G DM6X70G DN ABI-H2158 DM6X70G HS Phase 2 DM6X70G CP Assembly Biosciences DM6X70G DT Small molecular drug DM6X70G DE Hepatitis B DMTCXSG ID DMTCXSG DMTCXSG DN Abituzumab DMTCXSG HS Phase 2 DMTCXSG CP Emd serono DMTCXSG DT Antibody DMTCXSG DE Colorectal cancer DM23UQ9 ID DM23UQ9 DM23UQ9 DN ABT-122 DM23UQ9 HS Phase 2 DM23UQ9 CP AbbVie DM23UQ9 DT Monoclonal antibody DM23UQ9 DE Rheumatoid arthritis; Psoriatic arthritis DM2OS51 ID DM2OS51 DM2OS51 DN ABT-126 DM2OS51 HS Phase 2 DM2OS51 CP Abbott Laboratories DM2OS51 PC 24987875 DM2OS51 MW 313.4 DM2OS51 FM C17H19N3OS DM2OS51 IC InChI=1S/C17H19N3OS/c1-2-4-12(5-3-1)16-18-19-17(22-16)21-15-13-6-11-7-14(15)10-20(8-11)9-13/h1-5,11,13-15H,6-10H2 DM2OS51 CS C1C2CC3CN(C2)CC1C3OC4=NN=C(S4)C5=CC=CC=C5 DM2OS51 IK QZDCYUCETTWCMO-UHFFFAOYSA-N DM2OS51 IU 2-(1-azatricyclo[3.3.1.13,7]decan-4-yloxy)-5-phenyl-1,3,4-thiadiazole DM2OS51 CA CAS 1026687-03-5 DM2OS51 DE Schizophrenia; Alzheimer disease DMN3S1B ID DMN3S1B DMN3S1B DN ABT-229 DMN3S1B HS Phase 2 DMN3S1B SN Alemcinal; ABT-229; UNII-5DS173ODI4; 5DS173ODI4; ABBOTT-81229.0; 150785-53-8; A-81229; Alemcinal (USAN/INN); CHEMBL300049; ABT229; GTPL1444; BDBM86685; ABT 229; D02801; 8,9-didehydro-N-demethyl-9-deoxo-4', 6, 12-trideoxy-6,9-epoxy-N-ethylerythromycin DMN3S1B DT Small molecular drug DMN3S1B PC 9918079 DMN3S1B MW 697.9 DMN3S1B FM C38H67NO10 DMN3S1B IC InChI=1S/C38H67NO10/c1-14-28-23(6)30(40)24(7)32-20(3)17-38(11,49-32)34(48-36-31(41)27(39(12)15-2)16-21(4)45-36)25(8)33(26(9)35(42)46-28)47-29-19-37(10,43-13)18-22(5)44-29/h21-31,33-34,36,40-41H,14-19H2,1-13H3/t21-,22+,23+,24-,25+,26-,27+,28-,29+,30+,31-,33+,34-,36+,37+,38-/m1/s1 DMN3S1B CS CC[C@@H]1[C@@H]([C@@H]([C@H](C2=C(C[C@@](O2)([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]3C[C@@](C[C@@H](O3)C)(C)OC)C)O[C@H]4[C@@H]([C@H](C[C@H](O4)C)N(C)CC)O)C)C)C)O)C DMN3S1B IK IWTSXJNGTTXMFK-KTQUSEMZSA-N DMN3S1B IU (2R,3S,4R,5R,8R,9S,10S,11R,12R)-5-ethyl-11-[(2S,3R,4S,6R)-4-[ethyl(methyl)amino]-3-hydroxy-6-methyloxan-2-yl]oxy-3-hydroxy-9-[(2S,4S,6S)-4-methoxy-4,6-dimethyloxan-2-yl]oxy-2,4,8,10,12,14-hexamethyl-6,15-dioxabicyclo[10.2.1]pentadec-1(14)-en-7-one DMN3S1B CA CAS 150785-53-8 DMN3S1B DE Pain DM7X54F ID DM7X54F DM7X54F DN ABT-288 DM7X54F HS Phase 2 DM7X54F SN ABT-288; UNII-5MEI1M3NHH; 5MEI1M3NHH; ABT 288; GNIRITULTPTAQWKNQAVFIVSAN; SCHEMBL2406947; ABT288; GTPL6927; GNIRITULTPTAQW-KNQAVFIVSA-N; 948845-91-8; J3.497.401B; 2-[4'-(3aR,6aR)-(5-Methylhexahydropyrrolo[3,4-b]pyrrol-1(2H)-yl)-1,1'-biphenyl-4-yl]pyridazin-3(2H)-one; 2-{4'-[(3aR,6aR)-5-Methylhexahydropyrrolo[3,4-b]pyrrol-1(2H)-yl]-1,1-biphenyl-4-yl}pyridazin-3(2H)-one; 2-[4'-(3aR,6aR)-(5-methylhexahydropyrrolo[3,4-b]pyrrol-1(2H)-yl)-1,1'-biphenyl-4-yl ]pyridazin-3(2H)-one; (3aR, 6aR)-2-[4'-(5-Methyl-hexahydro-pyrrolo[3,4 DM7X54F CP Abbott Laboratories DM7X54F DT Small molecular drug DM7X54F PC 24743471 DM7X54F MW 372.5 DM7X54F FM C23H24N4O DM7X54F IC InChI=1S/C23H24N4O/c1-25-15-19-12-14-26(22(19)16-25)20-8-4-17(5-9-20)18-6-10-21(11-7-18)27-23(28)3-2-13-24-27/h2-11,13,19,22H,12,14-16H2,1H3/t19-,22+/m1/s1 DM7X54F CS CN1C[C@H]2CCN([C@H]2C1)C3=CC=C(C=C3)C4=CC=C(C=C4)N5C(=O)C=CC=N5 DM7X54F IK GNIRITULTPTAQW-KNQAVFIVSA-N DM7X54F IU 2-[4-[4-[(3aR,6aR)-5-methyl-2,3,3a,4,6,6a-hexahydropyrrolo[2,3-c]pyrrol-1-yl]phenyl]phenyl]pyridazin-3-one DM7X54F CA CAS 948845-91-8 DM7X54F DE Alzheimer disease DM6WN2D ID DM6WN2D DM6WN2D DN ABT-308 DM6WN2D HS Phase 2 DM6WN2D DE Asthma; Eosinophilic esophagitis DMMZOYN ID DMMZOYN DMMZOYN DN ABT-348 DMMZOYN HS Phase 2 DMMZOYN SN ILORASERTIB; ABT-348; 1227939-82-3; UNII-6L5D03D975; ABT 348; ABT348; 6L5D03D975; A-968660; Abbott-969660; Ilorasertib [USAN:INN]; Ilorasertib (USAN); Kinome_405; GTPL9914; A-968660.0; SCHEMBL3381224; CHEMBL1980297; DTXSID10153718; WPHKIQPVPYJNAX-UHFFFAOYSA-N; BCP07256; ZINC63298074; BDBM50381716; SB16853; CS-6804; DB11694; KB-74395; HY-16018; US8722890, 1; Z-3287; US8722890, 2; D10423; N-(4-{4-amino-7-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]thieno[3,2-c]pyridin-3-yl}phenyl)-N'-(3-fluorophenyl)urea DMMZOYN CP Abbott Laboratories Abbott DMMZOYN DT Small molecular drug DMMZOYN PC 46207586 DMMZOYN MW 488.5 DMMZOYN FM C25H21FN6O2S DMMZOYN IC InChI=1S/C25H21FN6O2S/c26-17-2-1-3-19(10-17)31-25(34)30-18-6-4-15(5-7-18)21-14-35-23-20(12-28-24(27)22(21)23)16-11-29-32(13-16)8-9-33/h1-7,10-14,33H,8-9H2,(H2,27,28)(H2,30,31,34) DMMZOYN CS C1=CC(=CC(=C1)F)NC(=O)NC2=CC=C(C=C2)C3=CSC4=C3C(=NC=C4C5=CN(N=C5)CCO)N DMMZOYN IK WPHKIQPVPYJNAX-UHFFFAOYSA-N DMMZOYN IU 1-[4-[4-amino-7-[1-(2-hydroxyethyl)pyrazol-4-yl]thieno[3,2-c]pyridin-3-yl]phenyl]-3-(3-fluorophenyl)urea DMMZOYN CA CAS 1227939-82-3 DMMZOYN DE Haematological malignancy DM7XW5Y ID DM7XW5Y DM7XW5Y DN ABT-384 DM7XW5Y HS Phase 2 DM7XW5Y SN ABT-384; UNII-R5TH77F919; CHEMBL222670; ABT 384; R5TH77F919; SCHEMBL231595; GTPL7357; ABT384; SCHEMBL20457214; BDBM50195291; DB12501; 868623-40-9; 4-{2-methyl-2-[4-(5-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl]-propionylamino}-adamantane-1-carboxylic acid amide DM7XW5Y CP Abbott Laboratories DM7XW5Y DT Small molecular drug DM7XW5Y PC 11670435 DM7XW5Y MW 493.6 DM7XW5Y FM C25H34F3N5O2 DM7XW5Y IC InChI=1S/C25H34F3N5O2/c1-23(2,33-7-5-32(6-8-33)19-4-3-18(14-30-19)25(26,27)28)22(35)31-20-16-9-15-10-17(20)13-24(11-15,12-16)21(29)34/h3-4,14-17,20H,5-13H2,1-2H3,(H2,29,34)(H,31,35) DM7XW5Y CS CC(C)(C(=O)NC1C2CC3CC1CC(C3)(C2)C(=O)N)N4CCN(CC4)C5=NC=C(C=C5)C(F)(F)F DM7XW5Y IK CLHMYBJIOZXCEX-UHFFFAOYSA-N DM7XW5Y IU 4-[[2-methyl-2-[4-[5-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl]propanoyl]amino]adamantane-1-carboxamide DM7XW5Y CA CAS 868623-40-9 DM7XW5Y DE Alzheimer disease; Hepatitis C virus infection DMGUTPN ID DMGUTPN DMGUTPN DN ABT-414 DMGUTPN HS Phase 2 DMGUTPN CP Abbvie DMGUTPN DT Antibody DMGUTPN DE Glioblastoma multiforme; Brain cancer; Recurrent glioblastoma DMNAU1V ID DMNAU1V DMNAU1V DN ABT-436 DMNAU1V HS Phase 2 DMNAU1V CP Abbott Laboratories DMNAU1V DE Anxiety disorder DMFW860 ID DMFW860 DMFW860 DN ABT-450 DMFW860 HS Phase 2 DMFW860 CP Abbott; Enanta DMFW860 PC 45110509 DMFW860 MW 765.9 DMFW860 FM C40H43N7O7S DMFW860 IC InChI=1S/C40H43N7O7S/c1-24-21-42-33(22-41-24)35(48)43-32-16-6-4-2-3-5-11-25-20-40(25,39(51)46-55(52,53)27-17-18-27)45-36(49)34-19-26(23-47(34)38(32)50)54-37-30-14-8-7-12-28(30)29-13-9-10-15-31(29)44-37/h5,7-15,21-22,25-27,32,34H,2-4,6,16-20,23H2,1H3,(H,43,48)(H,45,49)(H,46,51)/b11-5-/t25-,26-,32+,34+,40-/m1/s1 DMFW860 CS CC1=CN=C(C=N1)C(=O)N[C@H]2CCCCC/C=C\\[C@@H]3C[C@]3(NC(=O)[C@@H]4C[C@H](CN4C2=O)OC5=NC6=CC=CC=C6C7=CC=CC=C75)C(=O)NS(=O)(=O)C8CC8 DMFW860 IK UAUIUKWPKRJZJV-QPLHLKROSA-N DMFW860 IU (1S,4R,6S,7Z,14S,18R)-N-cyclopropylsulfonyl-14-[(5-methylpyrazine-2-carbonyl)amino]-2,15-dioxo-18-phenanthridin-6-yloxy-3,16-diazatricyclo[14.3.0.04,6]nonadec-7-ene-4-carboxamide DMFW860 CA CAS 1216941-48-8 DMFW860 DE Hepatitis C virus infection DMPDVM8 ID DMPDVM8 DMPDVM8 DN ABT-510 DMPDVM8 HS Phase 2 DMPDVM8 SN N-Acetyl-N-methyl-glycyl-glycyl-L-valyl-D-alloisoleucyl-L-threonyl-L-norvalyl-L-isoleucyl-L-argininyl-L-proline N-ethylamide DMPDVM8 CP Abbott Laboratories DMPDVM8 DT Small molecular drug DMPDVM8 PC 6918562 DMPDVM8 MW 994.2 DMPDVM8 FM C46H83N13O11 DMPDVM8 IC InChI=1S/C46H83N13O11/c1-12-18-30(39(64)55-36(26(7)13-2)42(67)53-31(19-16-21-50-46(47)48)45(70)59-22-17-20-32(59)40(65)49-15-4)52-44(69)38(28(9)60)57-43(68)37(27(8)14-3)56-41(66)35(25(5)6)54-33(62)23-51-34(63)24-58(11)29(10)61/h25-28,30-32,35-38,60H,12-24H2,1-11H3,(H,49,65)(H,51,63)(H,52,69)(H,53,67)(H,54,62)(H,55,64)(H,56,66)(H,57,68)(H4,47,48,50)/t26-,27-,28+,30-,31-,32-,35-,36-,37+,38-/m0/s1 DMPDVM8 CS CCC[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NCC)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H]([C@@H](C)CC)NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)CN(C)C(=O)C DMPDVM8 IK RIWLPSIAFBLILR-WVNGMBSFSA-N DMPDVM8 IU (2S)-1-[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2R,3S)-2-[[(2S)-2-[[2-[[2-[acetyl(methyl)amino]acetyl]amino]acetyl]amino]-3-methylbutanoyl]amino]-3-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]pentanoyl]amino]-3-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]-N-ethylpyrrolidine-2-carboxamide DMPDVM8 CA CAS 251579-55-2 DMPDVM8 DE Solid tumour/cancer DMEWQ4X ID DMEWQ4X DMEWQ4X DN ABT-639 DMEWQ4X HS Phase 2 DMEWQ4X SN ABT-639; 1235560-28-7; ABT 639; UNII-0G7D0CQ88I; ABT639; 0G7D0CQ88I; CHEMBL3589557; ABT-639 free base; SCHEMBL400073; GTPL7721; CHEMBL3590674; AGPIHNZOZNKRGT-CYBMUJFWSA-N; MolPort-046-033-584; EX-A1021; BCP17732; BDBM50095309; ZINC113741875; AKOS030526344; SB19105; CS-5515; HY-19721; 4-chloro-2-fluoro-N-(2-fluorophenyl)-5-[[(8aR)-hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl]carbonyl]benzenesulfonamide; 4-chloro-2-fluoro-N-(2-fluorophenyl)-5-[(8aR)-hexahydropyrrolo[1,2-a]pyrazin-2(1H)-ylcarbonyl]benzenesulfonamide DMEWQ4X DT Small molecular drug DMEWQ4X PC 46851313 DMEWQ4X MW 455.9 DMEWQ4X FM C20H20ClF2N3O3S DMEWQ4X IC InChI=1S/C20H20ClF2N3O3S/c21-15-11-17(23)19(30(28,29)24-18-6-2-1-5-16(18)22)10-14(15)20(27)26-9-8-25-7-3-4-13(25)12-26/h1-2,5-6,10-11,13,24H,3-4,7-9,12H2/t13-/m1/s1 DMEWQ4X CS C1C[C@@H]2CN(CCN2C1)C(=O)C3=CC(=C(C=C3Cl)F)S(=O)(=O)NC4=CC=CC=C4F DMEWQ4X IK AGPIHNZOZNKRGT-CYBMUJFWSA-N DMEWQ4X IU 5-[(8aR)-3,4,6,7,8,8a-hexahydro-1H-pyrrolo[1,2-a]pyrazine-2-carbonyl]-4-chloro-2-fluoro-N-(2-fluorophenyl)benzenesulfonamide DMEWQ4X CA CAS 1235560-28-7 DMEWQ4X DE Pain DMLEO2Z ID DMLEO2Z DMLEO2Z DN ABT-652 DMLEO2Z HS Phase 2 DMLEO2Z CP Abbott Laboratories DMLEO2Z DE Musculoskeletal pain; Diabetic neuropathy DMNG35S ID DMNG35S DMNG35S DN ABT-751 DMNG35S HS Phase 2 DMNG35S SN ABT-751; 141430-65-1; ABT 751; E-7010; ABT751; ABT-751 (E7010); UNII-WDT5V5OB9F; E 7010; WDT5V5OB9F; N-[2-[(4-HYDROXYPHENYL)AMINO]-3-PYRIDYL]-4-METHOXYBENZENESULFONAMIDE; CHEMBL20684; N-(2-((4-Hydroxyphenyl)amino)-3-pyridinyl)-4-methoxybenzenesulfonamide; N-{2-[(4-hydroxyphenyl)amino]pyridin-3-yl}-4-methoxybenzenesulfonamide; Benzenesulfonamide,N-[2-[(4-hydroxyphenyl)amino]-3-pyridinyl]-4-methoxy-; N-(2-(4-hydroxyphenylamino)pyridin-3-yl)-4-methoxybenzenesulfonamide DMNG35S DT Small molecular drug DMNG35S PC 3035714 DMNG35S MW 371.4 DMNG35S FM C18H17N3O4S DMNG35S IC InChI=1S/C18H17N3O4S/c1-25-15-8-10-16(11-9-15)26(23,24)21-17-3-2-12-19-18(17)20-13-4-6-14(22)7-5-13/h2-12,21-22H,1H3,(H,19,20) DMNG35S CS COC1=CC=C(C=C1)S(=O)(=O)NC2=C(N=CC=C2)NC3=CC=C(C=C3)O DMNG35S IK URCVCIZFVQDVPM-UHFFFAOYSA-N DMNG35S IU N-[2-(4-hydroxyanilino)pyridin-3-yl]-4-methoxybenzenesulfonamide DMNG35S CA CAS 141430-65-1 DMNG35S CB CHEBI:95043 DMNG35S DE Solid tumour/cancer DM6PTIX ID DM6PTIX DM6PTIX DN ABT-981 DM6PTIX HS Phase 2 DM6PTIX CP AbbVie DM6PTIX DT Monoclonal antibody DM6PTIX DE Osteoarthritis DM9Y1XB ID DM9Y1XB DM9Y1XB DN ABT-RTA-408 DM9Y1XB HS Phase 2 DM9Y1XB CP Abbvie; reata pharmaceuticals DM9Y1XB DE Non-small-cell lung cancer DM91U0R ID DM91U0R DM91U0R DN ABX-EGF DM91U0R HS Phase 2 DM91U0R DT Antibody DMCZFMS ID DMCZFMS DMCZFMS DN ABX-IL8 DMCZFMS HS Phase 2 DMCZFMS DT Antibody DMCZFMS DE Melanoma DMNVFZA ID DMNVFZA DMNVFZA DN AC-1202 DMNVFZA HS Phase 2 DMNVFZA SN Ketasyn DMNVFZA CP Accera DMNVFZA DT Small molecular drug DMNVFZA PC 10850 DMNVFZA MW 470.7 DMNVFZA FM C27H50O6 DMNVFZA IC InChI=1S/C27H50O6/c1-4-7-10-13-16-19-25(28)31-22-24(33-27(30)21-18-15-12-9-6-3)23-32-26(29)20-17-14-11-8-5-2/h24H,4-23H2,1-3H3 DMNVFZA CS CCCCCCCC(=O)OCC(COC(=O)CCCCCCC)OC(=O)CCCCCCC DMNVFZA IK VLPFTAMPNXLGLX-UHFFFAOYSA-N DMNVFZA IU 2,3-di(octanoyloxy)propyl octanoate DMNVFZA CA CAS 538-23-8 DMNVFZA CB CHEBI:76978 DMNVFZA DE Memory loss DMB0TNL ID DMB0TNL DMB0TNL DN AC-201 DMB0TNL HS Phase 2 DMB0TNL CP TWi Biotechnology Taipei, Taiwan DMB0TNL DE Type-2 diabetes DM3TUBR ID DM3TUBR DM3TUBR DN Acalabrutinib DM3TUBR HS Phase 2 DM3TUBR SN Acalabrutinib; 1420477-60-6; ACP-196; Calquence; UNII-I42748ELQW; I42748ELQW; Benzamide; Acalabrutinib [INN]; Acalabrutinib [USAN:INN]; Acalabrutinib (ACP-196); Calquence (TN); Benzamide, ACP-196; Acalabrutinib; Acalabrutinib(ACP196); GTPL8912; CHEMBL3707348; Acalabrutinib (JAN/USAN/INN); SCHEMBL14637368; EX-A881; ACP 196; WDENQI; Acalabrutinib DM3TUBR TC Antiviral Agents DM3TUBR DT Small molecular drug DM3TUBR PC 71226662 DM3TUBR MW 465.5 DM3TUBR FM C26H23N7O2 DM3TUBR IC InChI=1S/C26H23N7O2/c1-2-6-21(34)32-15-5-7-19(32)25-31-22(23-24(27)29-14-16-33(23)25)17-9-11-18(12-10-17)26(35)30-20-8-3-4-13-28-20/h3-4,8-14,16,19H,5,7,15H2,1H3,(H2,27,29)(H,28,30,35)/t19-/m0/s1 DM3TUBR CS CC#CC(=O)N1CCC[C@H]1C2=NC(=C3N2C=CN=C3N)C4=CC=C(C=C4)C(=O)NC5=CC=CC=N5 DM3TUBR IK WDENQIQQYWYTPO-IBGZPJMESA-N DM3TUBR IU 4-[8-amino-3-[(2S)-1-but-2-ynoylpyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1-yl]-N-pyridin-2-ylbenzamide DM3TUBR CA CAS 1420477-60-6 DM3TUBR DE Coronavirus Disease 2019 (COVID-19) DM0FGDO ID DM0FGDO DM0FGDO DN ACCLAIM DM0FGDO HS Phase 2 DM0FGDO SN Depon; Excel; Furore; PUMA; Whip; Fenoxaprop ethyl; Fenoxaprop ethyl ester; Fenoxaprop ethyl ester [ANSI]; Tiller Herbicide; HOE 33171; FENOXAPROP-ETHYL; HOE-A 25-01; Ethyl 2-(4-((6-chlorobenzoxazol-2-yl)oxy)phenoxy)propionate; Ethyl 2-[4-[(6-chloro-1,3-benzoxazol-2-yl)oxy]phenoxy]propanoate; Ethyl (D+)-2-(4-(6-chlor-2-benzoxazolyloxy)phenoxy)propanoate; Ethyl (D+)-2-(4-(6-chlor-2-benzoxazolyloxy)phenoxy)propanoate [French]; Ethyl 2-(4-[(6-chloro-1,3-benzoxazol-2-yl)oxy]phenoxy)propanoate; Ethyl 2-{4-[(6-chloro-1,3-benzoxazol-2-yl)oxy]phenoxy}propanoate; Ethyl-2-((4-(6-chloro-2-benzoxazolyloxy))-phenoxy)propionate; Ethyl (+-)-2-(4-(6-chloro-2-benzoxazolyloxy)phenoxy)propanoate; Propanoic acid, 2-(4-((6-chloro-2-benzoxazolyl)oxy)phenoxy)-, ethyl ester; (+/-)-2-(4-((6-Chloro-2-benzoxazolyl)oxy)phenoxy)propanoic acid ethyl ester; 2-(4-((6-Chloro-2-benzoxazolylen)oxy)phenoxy)propanoic acid, ethyl ester DM0FGDO CP Angiogenix DM0FGDO DT Small molecular drug DM0FGDO PC 47938 DM0FGDO MW 361.8 DM0FGDO FM C18H16ClNO5 DM0FGDO IC InChI=1S/C18H16ClNO5/c1-3-22-17(21)11(2)23-13-5-7-14(8-6-13)24-18-20-15-9-4-12(19)10-16(15)25-18/h4-11H,3H2,1-2H3 DM0FGDO CS CCOC(=O)C(C)OC1=CC=C(C=C1)OC2=NC3=C(O2)C=C(C=C3)Cl DM0FGDO IK PQKBPHSEKWERTG-UHFFFAOYSA-N DM0FGDO IU ethyl 2-[4-[(6-chloro-1,3-benzoxazol-2-yl)oxy]phenoxy]propanoate DM0FGDO CA CAS 66441-23-4 DM0FGDO CB CHEBI:5008 DM0FGDO DE Coronary artery disease; Angina pectoris DMZ8PY0 ID DMZ8PY0 DMZ8PY0 DN ACE-031 DMZ8PY0 HS Phase 2 DMZ8PY0 CP Acceleron Pharma DMZ8PY0 DE Duchenne dystrophy DMIVUFL ID DMIVUFL DMIVUFL DN ACH-1625 DMIVUFL HS Phase 2 DMIVUFL SN SOVAPREVIR; 1001667-23-7; UNII-2ND9V3MN6O; ACH-0141625; 2ND9V3MN6O; Sovaprevir [USAN:INN]; Sovaprevir (USAN); Prodrug of ACH-1095; SCHEMBL1462843; CHEMBL2105750; DTXSID00142994; DB12069; SB16836; D10166; 2-Pyrrolidinecarboxamide, N-((1R,2S)-1-(((cyclopropylsulfonyl)amino)carbonyl)-2- ethenylcyclopropyl)-1-((2S)-3,3-dimethyl-1-oxo-2-(2-oxo-2-(1-piperidinyl)ethyl)butyl)-4- DMIVUFL CP Achillion DMIVUFL DT Small molecular drug DMIVUFL PC 53362096 DMIVUFL MW 800 DMIVUFL FM C43H53N5O8S DMIVUFL IC InChI=1S/C43H53N5O8S/c1-6-28-25-43(28,41(52)46-57(53,54)31-16-17-31)45-39(50)36-22-30(26-48(36)40(51)33(42(2,3)4)23-38(49)47-19-11-8-12-20-47)56-37-24-34(27-13-9-7-10-14-27)44-35-21-29(55-5)15-18-32(35)37/h6-7,9-10,13-15,18,21,24,28,30-31,33,36H,1,8,11-12,16-17,19-20,22-23,25-26H2,2-5H3,(H,45,50)(H,46,52)/t28-,30-,33-,36+,43-/m1/s1 DMIVUFL CS CC(C)(C)[C@H](CC(=O)N1CCCCC1)C(=O)N2C[C@@H](C[C@H]2C(=O)N[C@@]3(C[C@H]3C=C)C(=O)NS(=O)(=O)C4CC4)OC5=CC(=NC6=C5C=CC(=C6)OC)C7=CC=CC=C7 DMIVUFL IK MHFMTUBUVQZIRE-WINRQGAFSA-N DMIVUFL IU (2S,4R)-N-[(1R,2S)-1-(cyclopropylsulfonylcarbamoyl)-2-ethenylcyclopropyl]-1-[(2S)-3,3-dimethyl-2-(2-oxo-2-piperidin-1-ylethyl)butanoyl]-4-(7-methoxy-2-phenylquinolin-4-yl)oxypyrrolidine-2-carboxamide DMIVUFL CA CAS 1001667-23-7 DMIVUFL DE Hepatitis C virus infection DM0RPY5 ID DM0RPY5 DM0RPY5 DN ACH-3102 DM0RPY5 HS Phase 2 DM0RPY5 CP Achillion pharmaceuticals DM0RPY5 PC 71474517 DM0RPY5 MW 1001.3 DM0RPY5 FM C60H72N8O6 DM0RPY5 IC InChI=1S/C60H72N8O6/c1-33(2)53(65-59(71)73-5)57(69)67-49-13-9-7-11-41(49)31-51(67)55-61-45-25-23-39(29-47(45)63-55)43-27-35-15-19-37(43)21-17-36-16-20-38(22-18-35)44(28-36)40-24-26-46-48(30-40)64-56(62-46)52-32-42-12-8-10-14-50(42)68(52)58(70)54(34(3)4)66-60(72)74-6/h15-16,19-20,23-30,33-34,41-42,49-54H,7-14,17-18,21-22,31-32H2,1-6H3,(H,61,63)(H,62,64)(H,65,71)(H,66,72)/t41-,42-,49-,50-,51-,52-,53-,54-/m0/s1 DM0RPY5 CS CC(C)[C@@H](C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C3=NC4=C(N3)C=C(C=C4)C5=C6CCC7=CC(=C(CCC(=C5)C=C6)C=C7)C8=CC9=C(C=C8)N=C(N9)[C@@H]1C[C@@H]2CCCC[C@@H]2N1C(=O)[C@H](C(C)C)NC(=O)OC)NC(=O)OC DM0RPY5 IK LSYBRGMTRKJATA-IVEWBXRVSA-N DM0RPY5 IU methyl N-[(2S)-1-[(2S,3aS,7aS)-2-[6-[11-[2-[(2S,3aS,7aS)-1-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]-2,3,3a,4,5,6,7,7a-octahydroindol-2-yl]-3H-benzimidazol-5-yl]-5-tricyclo[8.2.2.24,7]hexadeca-1(12),4,6,10,13,15-hexaenyl]-1H-benzimidazol-2-yl]-2,3,3a,4,5,6,7,7a-octahydroindol-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate DM0RPY5 CA CAS 1415119-52-6 DM0RPY5 DE Hepatitis C virus infection DMLVCZR ID DMLVCZR DMLVCZR DN ACH-4471 DMLVCZR HS Phase 2 DMLVCZR SN PIBARDGJJAGJAJ-NQIIRXRSSA-N; UNII-JM8C1SFX0U; JM8C1SFX0U; SCHEMBL17024981; 1903768-17-1; (2S,4R)-1-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromopyridin-2-yl)-4-fluoropyrrolidine-2-carboxamide DMLVCZR CP Achillion Pharmaceuticals New Haven, CT DMLVCZR PC 118323590 DMLVCZR MW 580.4 DMLVCZR FM C26H23BrFN7O3 DMLVCZR IC InChI=1S/C26H23BrFN7O3/c1-14(36)25-19-8-16(17-10-29-15(2)30-11-17)6-7-20(19)35(33-25)13-24(37)34-12-18(28)9-21(34)26(38)32-23-5-3-4-22(27)31-23/h3-8,10-11,18,21H,9,12-13H2,1-2H3,(H,31,32,38)/t18-,21+/m1/s1 DMLVCZR CS CC1=NC=C(C=N1)C2=CC3=C(C=C2)N(N=C3C(=O)C)CC(=O)N4C[C@@H](C[C@H]4C(=O)NC5=NC(=CC=C5)Br)F DMLVCZR IK PIBARDGJJAGJAJ-NQIIRXRSSA-N DMLVCZR IU (2S,4R)-1-[2-[3-acetyl-5-(2-methylpyrimidin-5-yl)indazol-1-yl]acetyl]-N-(6-bromopyridin-2-yl)-4-fluoropyrrolidine-2-carboxamide DMLVCZR CA CAS 1903768-17-1 DMLVCZR DE Glomerulonephritis; Anaemia DMPR8E9 ID DMPR8E9 DMPR8E9 DN ACP-001 DMPR8E9 HS Phase 2 DMPR8E9 SN TransCon-PEG Growth Hormone; TransCon-PEG-hGH; Growth hormone (TransCon, subcutaneous sustained-release), Ascendis Pharma DMPR8E9 CP Ascendis Pharma A/S DMPR8E9 DE Growth hormone deficiency DMMG61B ID DMMG61B DMMG61B DN ACT-GRO-777 DMMG61B HS Phase 2 DMMG61B SN AGRO-100; AS-1411; Anticancer aptamers, Aptamera; GRO-26B; AGRO-100 derivatives, Aptamera; Nucleolin inhibitors (cancer), Aptamera; Nucleolin inhibitors (iv, acute myeloid leukemia), Advanced Cancer Therapeutics DMMG61B CP Aptamera Inc DMMG61B DT Aptamer DMMG61B DE Solid tumour/cancer DMKBIPR ID DMKBIPR DMKBIPR DN Actimab-A DMKBIPR HS Phase 2 DMKBIPR CP Actinium Pharmaceuticals New York, NY DMKBIPR DE Acute myeloid leukaemia DM9GRTK ID DM9GRTK DM9GRTK DN ACYLINE DM9GRTK HS Phase 2 DM9GRTK SN Acyline; UNII-S3439D3B35; CHEMBL262747; S3439D3B35; BDBM50102456; DB11906; D-Alaninamide, N-acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-4-(acetylamino)-L-phenylalanyl-4-(acetylamino)-D-phenylalanyl-L-leucyl-N6-(1-methylethyl)-L-lysyl-L-prolyl-; Z-3146; Ac-D-Nal-[D-(pCl)Phe]-D-Pal-Ser-[Aph(Ac)]-D-[Aph(Ac)]-Leu-ILys-Pro-DAla-NH2 DM9GRTK PC 16137348 DM9GRTK MW 1533.2 DM9GRTK FM C80H102ClN15O14 DM9GRTK IC InChI=1S/C80H102ClN15O14/c1-46(2)37-63(72(102)89-62(18-11-12-35-84-47(3)4)80(110)96-36-14-19-70(96)79(109)85-48(5)71(82)101)90-74(104)66(40-53-23-30-60(31-24-53)86-49(6)98)92-76(106)67(41-54-25-32-61(33-26-54)87-50(7)99)94-78(108)69(45-97)95-77(107)68(43-56-15-13-34-83-44-56)93-75(105)65(39-52-21-28-59(81)29-22-52)91-73(103)64(88-51(8)100)42-55-20-27-57-16-9-10-17-58(57)38-55/h9-10,13,15-17,20-34,38,44,46-48,62-70,84,97H,11-12,14,18-19,35-37,39-43,45H2,1-8H3,(H2,82,101)(H,85,109)(H,86,98)(H,87,99)(H,88,100)(H,89,102)(H,90,104)(H,91,103)(H,92,106)(H,93,105)(H,94,108)(H,95,107)/t48-,62+,63+,64-,65-,66-,67+,68-,69+,70+/m1/s1 DM9GRTK CS C[C@H](C(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCNC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=C(C=C2)NC(=O)C)NC(=O)[C@H](CC3=CC=C(C=C3)NC(=O)C)NC(=O)[C@H](CO)NC(=O)[C@@H](CC4=CN=CC=C4)NC(=O)[C@@H](CC5=CC=C(C=C5)Cl)NC(=O)[C@@H](CC6=CC7=CC=CC=C7C=C6)NC(=O)C DM9GRTK IK ZWNUQDJANZGVFO-YHSALVGYSA-N DM9GRTK IU (2S)-1-[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-acetamidophenyl)propanoyl]amino]-3-(4-acetamidophenyl)propanoyl]amino]-4-methylpentanoyl]amino]-6-(propan-2-ylamino)hexanoyl]-N-[(2R)-1-amino-1-oxopropan-2-yl]pyrrolidine-2-carboxamide DM9GRTK CA CAS 170157-13-8 DM9GRTK DE Prostate cancer DMLV9GS ID DMLV9GS DMLV9GS DN AD04 DMLV9GS HS Phase 2 DMLV9GS CP ADial Pharmaceuticals Charlottesville, VA DMLV9GS DE Alcohol dependence; Opioid dependence DMMFLXN ID DMMFLXN DMMFLXN DN AD-452 DMMFLXN HS Phase 2 DMMFLXN SN RS(+)-mefloquine; (+)-erythro-mefloquine DMMFLXN CP Sosei R&D Ltd DMMFLXN DE Rheumatoid arthritis DM8GHIX ID DM8GHIX DM8GHIX DN ADC-3680 DM8GHIX HS Phase 2 DM8GHIX SN ADC-3680B; CRTh2 antagonists (oral, allergic asthma/allergic rhinitis/COPD), Argenta Discovery; CRTh2 antagonists (oral, allergic asthma/allergic rhinitis/COPD), Pulmagen; Prostaglandin D2 receptor antagonists (oral, COPD/allergic asthma/allergic rhinitis), Argenta Discovery DM8GHIX CP Argenta Discovery Ltd DM8GHIX DE Allergic rhinitis DM821BS ID DM821BS DM821BS DN Adipiplon DM821BS HS Phase 2 DM821BS SN GABA modulator (insomnia), Neurogen; NG-2-73 DM821BS CP Neurogen Corporation DM821BS DT Small molecular drug DM821BS PC 11198924 DM821BS MW 351.4 DM821BS FM C18H18FN7 DM821BS IC InChI=1S/C18H18FN7/c1-3-5-13-15(22-11-26-17(13)23-12(2)24-26)10-25-9-8-21-18(25)16-14(19)6-4-7-20-16/h4,6-9,11H,3,5,10H2,1-2H3 DM821BS CS CCCC1=C(N=CN2C1=NC(=N2)C)CN3C=CN=C3C4=C(C=CC=N4)F DM821BS IK UAMAIHOEGLEXSV-UHFFFAOYSA-N DM821BS IU 7-[[2-(3-fluoropyridin-2-yl)imidazol-1-yl]methyl]-2-methyl-8-propyl-[1,2,4]triazolo[1,5-c]pyrimidine DM821BS CA CAS 840486-93-3 DM821BS DE Sleep-wake disorder DMMUPTN ID DMMUPTN DMMUPTN DN ADL-5747 DMMUPTN HS Phase 2 DMMUPTN CP Pfizer DMMUPTN DT Small molecular drug DMMUPTN PC 76967747 DMMUPTN MW 428.9 DMMUPTN FM C24H29ClN2O3 DMMUPTN IC InChI=1S/C24H28N2O3.ClH/c1-3-26(4-2)23(28)17-9-10-18(21(27)15-17)20-16-24(11-13-25-14-12-24)29-22-8-6-5-7-19(20)22;/h5-10,15-16,25,27H,3-4,11-14H2,1-2H3;1H DMMUPTN CS CCN(CC)C(=O)C1=CC(=C(C=C1)C2=CC3(CCNCC3)OC4=CC=CC=C42)O.Cl DMMUPTN IK XROFSGVHHSJMMG-UHFFFAOYSA-N DMMUPTN IU N,N-diethyl-3-hydroxy-4-spiro[chromene-2,4'-piperidine]-4-ylbenzamide;hydrochloride DMMUPTN CA CAS 1187653-56-0 DMMUPTN DE Pain DMDQH9A ID DMDQH9A DMDQH9A DN ADL-5859 DMDQH9A HS Phase 2 DMDQH9A SN PF-04856880 DMDQH9A CP Pfizer DMDQH9A DT Small molecular drug DMDQH9A PC 46931003 DMDQH9A MW 428.9 DMDQH9A FM C24H29ClN2O3 DMDQH9A IC InChI=1S/C24H28N2O3.ClH/c1-3-26(4-2)23(28)18-10-8-17(9-11-18)19-16-24(12-14-25-15-13-24)29-21-7-5-6-20(27)22(19)21;/h5-11,16,25,27H,3-4,12-15H2,1-2H3;1H DMDQH9A CS CCN(CC)C(=O)C1=CC=C(C=C1)C2=CC3(CCNCC3)OC4=CC=CC(=C42)O.Cl DMDQH9A IK ZFNLSWREIULTDO-UHFFFAOYSA-N DMDQH9A IU N,N-diethyl-4-(5-hydroxyspiro[chromene-2,4'-piperidine]-4-yl)benzamide;hydrochloride DMDQH9A CA CAS 850173-95-4 DMDQH9A DE Rheumatoid arthritis DM819CO ID DM819CO DM819CO DN ADMVA DM819CO HS Phase 2 DM819CO SN RMVA vaccine (HIV-1), ADARC; Recombinant modified vaccinia Ankara vaccine (HIV-1), ADARC; Recombinant modified vaccinia Ankaravaccine (HIV-1), Aaron Diamond AIDS Research Center; DNA vaccine (gag, pol, env, tat, nef), ADARC; DNA vaccine (gag, pol, env, tat, nef), Aaron Diamond AIDS Research Center; HIV-1 vaccine (gag, pol, env, tat, nef), ADARC; HIV-1 vaccine (gag, pol, env, tat, nef), Aaron Diamond AIDS Research Center DM819CO CP Aaron Diamond AIDS Research Center DM819CO DT Vaccine DM819CO DE Diabetic complication DMJSWXL ID DMJSWXL DMJSWXL DN Ad-p53 DMJSWXL HS Phase 2 DMJSWXL SN P53 gene therapy, Transgene/Schering-Plough; Ad-p53, Transgene/Schering-Plough DMJSWXL CP Transgene SA DMJSWXL DE Colorectal cancer; Solid tumour/cancer DMRYH3M ID DMRYH3M DMRYH3M DN ADP-A2M4 DMRYH3M HS Phase 2 DMRYH3M CP Adaptimmune DMRYH3M DE Solid tumour/cancer; Synovial sarcoma DME384W ID DME384W DME384W DN AdPEDR DME384W HS Phase 2 DME384W CP GenVec DME384W DT Small molecular drug DME384W PC 11557063 DME384W MW 964.7 DME384W FM C38H41IN14O9 DME384W IC InChI=1S/C20H22N8O5.C18H19IN6O4/c1-28(9-11-8-23-17-15(24-11)16(21)26-20(22)27-17)12-4-2-10(3-5-12)18(31)25-13(19(32)33)6-7-14(29)30;1-20-17(28)14-12(26)13(27)18(29-14)25-8-24-11-15(22-7-23-16(11)25)21-6-9-3-2-4-10(19)5-9/h2-5,8,13H,6-7,9H2,1H3,(H,25,31)(H,29,30)(H,32,33)(H4,21,22,23,26,27);2-5,7-8,12-14,18,26-27H,6H2,1H3,(H,20,28)(H,21,22,23)/t13-;12-,13+,14-,18+/m00/s1 DME384W CS CNC(=O)[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)NCC4=CC(=CC=C4)I)O)O.CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O DME384W IK BDNQEWFVMDIRTE-VXJTWHGRSA-N DME384W IU (2S)-2-[[4-[(2,4-diaminopteridin-6-yl)methyl-methylamino]benzoyl]amino]pentanedioic acid;(2S,3S,4R,5R)-3,4-dihydroxy-5-[6-[(3-iodophenyl)methylamino]purin-9-yl]-N-methyloxolane-2-carboxamide DME384W DE Exudative age-related macular degeneration DMCNTFW ID DMCNTFW DMCNTFW DN Ad-RTS-hIL-12 DMCNTFW HS Phase 2 DMCNTFW CP Ziopharm Oncology DMCNTFW DT Gene therapy DMCNTFW DE Melanoma; Malignant glioma; Recurrent glioblastoma; Glioblastoma of brain DMM6B2Y ID DMM6B2Y DMM6B2Y DN ADU- S100 DMM6B2Y HS Phase 2 DMM6B2Y DT Small molecular drug DMM6B2Y DE Head and neck cancer DM8HBUI ID DM8HBUI DM8HBUI DN ADU-S100 DM8HBUI HS Phase 2 DM8HBUI SN MIW815; IZJJFUQKKZFVLH-LTKSHMRXSA-N; 1638241-89-0; AKOS027321070; HY-12885 DM8HBUI CP Aduro Biotech Berkeley, CANovartis Oncology East Hanover, NJ DM8HBUI PC 135390762 DM8HBUI MW 734.5 DM8HBUI FM C20H22N10Na2O10P2S2 DM8HBUI IC InChI=1S/C20H24N10O10P2S2.2Na/c21-15-9-17(25-3-23-15)29(5-27-9)19-12(32)13-8(38-19)2-36-42(34,44)40-14-11(31)7(1-35-41(33,43)39-13)37-20(14)30-6-28-10-16(22)24-4-26-18(10)30;;/h3-8,11-14,19-20,31-32H,1-2H2,(H,33,43)(H,34,44)(H2,21,23,25)(H2,22,24,26);;/q;2*+1/p-2/t7-,8-,11-,12-,13-,14-,19-,20-,41?,42?;;/m1../s1 DM8HBUI CS C1[C@@H]2[C@H]([C@H]([C@@H](O2)N3C=NC4=C(N=CN=C43)N)OP(=S)(OC[C@@H]5[C@H]([C@H]([C@@H](O5)N6C=NC7=C(N=CN=C76)N)O)OP(=O)(O1)[S-])[O-])O.[Na+].[Na+] DM8HBUI IK GDWOOOCBNOMMTL-QYUKNOIISA-L DM8HBUI IU disodium;(1R,6R,8R,9R,10S,15R,17R,18R)-8,17-bis(6-aminopurin-9-yl)-3-oxido-12-oxo-3-sulfanylidene-12-sulfido-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecane-9,18-diol DM8HBUI CA CAS 1638750-95-4 DM8HBUI DE Solid tumour/cancer; Head and neck cancer DMGVKHQ ID DMGVKHQ DMGVKHQ DN ADX10059 DMGVKHQ HS Phase 2 DMGVKHQ CP Addex Pharma. DMGVKHQ DE Anxiety disorder DMC8NAO ID DMC8NAO DMC8NAO DN ADXS-HPV DMC8NAO HS Phase 2 DMC8NAO CP Advaxis DMC8NAO DT Vaccine DMC8NAO DE Cervical Intraepithelial neoplasia; Cervical cancer DMJVN89 ID DMJVN89 DMJVN89 DN AEB07 DMJVN89 HS Phase 2 DMJVN89 CP Novartis DMJVN89 DT Small molecular drug DMJVN89 PC 9963383 DMJVN89 MW 1078.3 DMJVN89 FM C52H71N9O12S2 DMJVN89 IC InChI=1S/C27H36N4O5S.C24H31N5O4.CH4O3S/c1-26(2,28)25(33)29-22(18-36-17-20-9-5-4-6-10-20)24(32)30-15-13-27(14-16-30)19-31(37(3,34)35)23-12-8-7-11-21(23)27;1-3-16-6-8-19(27-23(16)25-2)9-7-17-10-12-29(24(17)33)15-21(30)28-20(13-22(31)32)18-5-4-11-26-14-18;1-5(2,3)4/h4-12,22H,13-19,28H2,1-3H3,(H,29,33);4-6,8,11,14,17,20H,3,7,9-10,12-13,15H2,1-2H3,(H,25,27)(H,28,30)(H,31,32);1H3,(H,2,3,4)/t22-;17-,20-;/m10./s1 DMJVN89 CS CCC1=C(N=C(C=C1)CC[C@H]2CCN(C2=O)CC(=O)N[C@@H](CC(=O)O)C3=CN=CC=C3)NC.CC(C)(C(=O)N[C@H](COCC1=CC=CC=C1)C(=O)N2CCC3(CC2)CN(C4=CC=CC=C34)S(=O)(=O)C)N.CS(=O)(=O)O DMJVN89 IK XAOWMNBAVQDQSR-WQDYQDSXSA-N DMJVN89 IU 2-amino-2-methyl-N-[(2R)-1-(1-methylsulfonylspiro[2H-indole-3,4'-piperidine]-1'-yl)-1-oxo-3-phenylmethoxypropan-2-yl]propanamide;(3S)-3-[[2-[(3S)-3-[2-[5-ethyl-6-(methylamino)pyridin-2-yl]ethyl]-2-oxopyrrolidin-1-yl]acetyl]amino]-3-pyridin-3-ylpropanoic acid;methanesulfonic acid DMJVN89 DE Transplant rejection DMQ1GH4 ID DMQ1GH4 DMQ1GH4 DN AEF0117 DMQ1GH4 HS Phase 2 DMQ1GH4 CP Aelis Farma DMQ1GH4 DT Small molecular drug DMQ1GH4 DE Marijuana use disorder DMSBLOU ID DMSBLOU DMSBLOU DN AEG-33773 DMSBLOU HS Phase 2 DMSBLOU CP Aegera Therapeutics Inc DMSBLOU DE Diabetic neuropathy DMI5TXZ ID DMI5TXZ DMI5TXZ DN AEM-28 DMI5TXZ HS Phase 2 DMI5TXZ SN Apo-E peptide mimetic (acute coronary syndrome), University of Alabama at Birmingham/LipimetiX DMI5TXZ CP Lipimetix development DMI5TXZ DE Hyperlipidaemia; Familial hypercholesterolemia DMNO7BC ID DMNO7BC DMNO7BC DN AeroLEF DMNO7BC HS Phase 2 DMNO7BC DE Pain DMFO2G5 ID DMFO2G5 DMFO2G5 DN Afabicin DMFO2G5 HS Phase 2 DMFO2G5 SN UNII-DMM8663H2R; DMM8663H2R; 1518800-35-5; Afabicin [INN]; SCHEMBL15479062; SCHEMBL16262317; (6-((1E)-3-(Methyl((3-methyl-1-benzofuran-2-yl)methyl)amino)-3-oxoprop-1-en-1-yl)-2-oxo-3,4-dihydro-1,8-naphthyridin-1(2H)-yl)methyl dihydrogen phosphate; 2-Propenamide, N-methyl-N-((3-methyl-2-benzofuranyl)methyl)-3-(5,6,7,8-tetrahydro-7-oxo-8-((phosphonooxy)methyl)-1,8-naphthyridin-3-yl)-, (2E)- DMFO2G5 CP Debiopharm Lausanne, Switzerland DMFO2G5 PC 72696796 DMFO2G5 MW 485.4 DMFO2G5 FM C23H24N3O7P DMFO2G5 IC InChI=1S/C23H24N3O7P/c1-15-18-5-3-4-6-19(18)33-20(15)13-25(2)21(27)9-7-16-11-17-8-10-22(28)26(23(17)24-12-16)14-32-34(29,30)31/h3-7,9,11-12H,8,10,13-14H2,1-2H3,(H2,29,30,31)/b9-7+ DMFO2G5 CS CC1=C(OC2=CC=CC=C12)CN(C)C(=O)/C=C/C3=CC4=C(N=C3)N(C(=O)CC4)COP(=O)(O)O DMFO2G5 IK HFYMDQMXVPJNTH-VQHVLOKHSA-N DMFO2G5 IU [6-[(E)-3-[methyl-[(3-methyl-1-benzofuran-2-yl)methyl]amino]-3-oxoprop-1-enyl]-2-oxo-3,4-dihydro-1,8-naphthyridin-1-yl]methyl dihydrogen phosphate DMFO2G5 CA CAS 1518800-35-5 DMFO2G5 DE Acute bacterial skin infection DMFORDT ID DMFORDT DMFORDT DN Afimoxifene DMFORDT HS Phase 2 DMFORDT SN 4-Hydroxytamoxifen; Afimoxifene; (Z)-4-Hydroxytamoxifen; Hydroxytamoxifen; 4-Monohydroxytamoxifen; Tamogel; 68047-06-3; trans-4-Hydroxytamoxifen; Ici 79280; 68392-35-8; 65213-48-1; 4-OH-TAM; (Z)-4-(1-(4-(2-(Dimethylamino)ethoxy)phenyl)-2-phenylbut-1-en-1-yl)phenol; Z-4-hydroxytamoxifen; UNII-95K54647BZ; CHEMBL489; ICI 79,280; TAMOXIFEN, 4-HYDROXY-, (Z)-; BRN 4910749; (E/Z)-4-Hydroxy Tamoxifen; MLS000069742; C26H29NO2; CHEBI:44616; 95K54647BZ; SMR000058939; 4-(1-(4-(2-(Dimethylamino)ethoxy)phenyl)-2-phenylbut-1-enyl)phenol DMFORDT CP ASCEND Therapeutics DMFORDT DT Small molecular drug DMFORDT PC 449459 DMFORDT MW 387.5 DMFORDT FM C26H29NO2 DMFORDT IC InChI=1S/C26H29NO2/c1-4-25(20-8-6-5-7-9-20)26(21-10-14-23(28)15-11-21)22-12-16-24(17-13-22)29-19-18-27(2)3/h5-17,28H,4,18-19H2,1-3H3/b26-25- DMFORDT CS CC/C(=C(\\C1=CC=C(C=C1)O)/C2=CC=C(C=C2)OCCN(C)C)/C3=CC=CC=C3 DMFORDT IK TXUZVZSFRXZGTL-QPLCGJKRSA-N DMFORDT IU 4-[(Z)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-2-phenylbut-1-enyl]phenol DMFORDT CA CAS 68047-06-3 DMFORDT CB CHEBI:44616 DMFORDT DE Breast cancer; Ductal carcinoma DMN45IC ID DMN45IC DMN45IC DN AFM13 DMN45IC HS Phase 2 DMN45IC CP Affimed Therapeutics DMN45IC DT Antibody DMN45IC DE Hodgkin lymphoma; Lymphoma; Peripheral T-cell lymphoma; Mycosis fungoides DMTFE9Y ID DMTFE9Y DMTFE9Y DN AFN-1252 DMTFE9Y HS Phase 2 DMTFE9Y SN API-1252; API-1401; Antibacterial therapeutics, Affinium; Antibacterials, Affinium; Bacterial fatty acid biosynthesis inhibitors, Affinium; Galapagos program, Affinium; Antibacterial therapeutics, Affinium/GSK; Antibacterials, Affinium/GSK; FabI inhibitors (antibacterial), Affinium; AFN-1252 (oral, bacterial infection); AFN-1252 (oral, bacterial infection), Affinium DMTFE9Y CP Affinium pharmaceuticals DMTFE9Y DT Small molecular drug DMTFE9Y PC 10407120 DMTFE9Y MW 375.4 DMTFE9Y FM C22H21N3O3 DMTFE9Y IC InChI=1S/C22H21N3O3/c1-14-17-5-3-4-6-18(17)28-19(14)13-25(2)21(27)10-7-15-11-16-8-9-20(26)24-22(16)23-12-15/h3-7,10-12H,8-9,13H2,1-2H3,(H,23,24,26)/b10-7+ DMTFE9Y CS CC1=C(OC2=CC=CC=C12)CN(C)C(=O)/C=C/C3=CC4=C(NC(=O)CC4)N=C3 DMTFE9Y IK QXTWSUQCXCWEHF-JXMROGBWSA-N DMTFE9Y IU (E)-N-methyl-N-[(3-methyl-1-benzofuran-2-yl)methyl]-3-(7-oxo-6,8-dihydro-5H-1,8-naphthyridin-3-yl)prop-2-enamide DMTFE9Y CA CAS 620175-39-5 DMTFE9Y DE Staphylococcus infection DM6AJKC ID DM6AJKC DM6AJKC DN AFN-1720 DM6AJKC HS Phase 2 DM6AJKC CP Affinium pharmaceuticals DM6AJKC DE Bacterial infection DM1FJ2B ID DM1FJ2B DM1FJ2B DN AFP464 DM1FJ2B HS Phase 2 DM1FJ2B SN UNII-73JNH95XPX; AFP464; 73JNH95XPX; 468719-53-1; AFP 464; AFP-464; Hexanamide, 2,6-diamino-N-(4-(5-amino-6,8-difluoro-7-methyl-4-oxo-4H-1-benzopyran-2-yl)-2-fluorophenyl)-, (2S)-, dimethanesulfonate DM1FJ2B CP Kirax DM1FJ2B DT Small molecular drug DM1FJ2B PC 399587 DM1FJ2B MW 544.5 DM1FJ2B FM C23H27F3N4O6S DM1FJ2B IC InChI=1S/C22H23F3N4O3.CH4O3S/c1-10-18(24)20(28)17-15(30)9-16(32-21(17)19(10)25)11-5-6-14(12(23)8-11)29-22(31)13(27)4-2-3-7-26;1-5(2,3)4/h5-6,8-9,13H,2-4,7,26-28H2,1H3,(H,29,31);1H3,(H,2,3,4)/t13-;/m0./s1 DM1FJ2B CS CC1=C(C(=C2C(=O)C=C(OC2=C1F)C3=CC(=C(C=C3)NC(=O)[C@H](CCCCN)N)F)N)F.CS(=O)(=O)O DM1FJ2B IK MJVICFBYAVBBOA-ZOWNYOTGSA-N DM1FJ2B IU (2S)-2,6-diamino-N-[4-(5-amino-6,8-difluoro-7-methyl-4-oxochromen-2-yl)-2-fluorophenyl]hexanamide;methanesulfonic acid DM1FJ2B CA CAS 468719-53-1 DM1FJ2B DE Breast cancer DMD3XMG ID DMD3XMG DMD3XMG DN AFTVac DMD3XMG HS Phase 2 DMD3XMG SN Autologous fixed tumor vaccine (AFTVac) therapy; Autologous vaccine (cancer), Cell-Medicine; GM-CSF agonist/IL-2 agonist containing-vaccine; Fixed autologous tumor derivatives + microparticles encapsulating GM-CSF and IL-2, Cell-Medicine DMD3XMG CP Cell-Medicine Inc DMD3XMG DT Vaccine DMD3XMG DE Glioblastoma multiforme DMA9FKY ID DMA9FKY DMA9FKY DN AG140699 DMA9FKY HS Phase 2 DMA9FKY CP Pfizer DMA9FKY TC Anticancer Agents DMA9FKY DE Melanoma DMNQ5T2 ID DMNQ5T2 DMNQ5T2 DN AG-858 DMNQ5T2 HS Phase 2 DMNQ5T2 SN Chronic myeloid leukemia therapy, Antigenics; HSP-70 cancer vaccine, Antigenics; HSPPC-70 (cancer); HSPPC-70-C DMNQ5T2 CP Agenus Inc; Antigenics DMNQ5T2 DT Vaccine DMNQ5T2 DE leukaemia DMPO7UG ID DMPO7UG DMPO7UG DN AGEN2034 DMPO7UG HS Phase 2 DMPO7UG CP AgenusLexington, MA DMPO7UG DT Monoclonal antibody DMPO7UG DE Solid tumour/cancer; Cervical cancer DMP5Y1A ID DMP5Y1A DMP5Y1A DN AGN-199981 DMP5Y1A HS Phase 2 DMP5Y1A CP Allergan DMP5Y1A TC Analgesics DMP5Y1A DE Neuropathic pain DM4KOAC ID DM4KOAC DM4KOAC DN AGN-241751 DM4KOAC HS Phase 2 DM4KOAC CP Allergan DM4KOAC DT Small molecular drug DM4KOAC DE Major depressive disorder DMLQRFO ID DMLQRFO DMLQRFO DN AGN-2979 DMLQRFO HS Phase 2 DMLQRFO SN BTG-1501; SC-48274; AGN-2979 (free base); 3-[3-(Dimethylamino)propyl]-3-(3-methoxyphenyl)-4,4-dimethylpiperidine-2,6-dione; 3-[3-(Dimethylamino)propyl]-3-(3-methoxyphenyl)-4,4-dimethylpiperidine-2,6-dione monohydrochloride DMLQRFO DT Small molecular drug DMLQRFO PC 40914 DMLQRFO MW 332.4 DMLQRFO FM C19H28N2O3 DMLQRFO IC InChI=1S/C19H28N2O3/c1-18(2)13-16(22)20-17(23)19(18,10-7-11-21(3)4)14-8-6-9-15(12-14)24-5/h6,8-9,12H,7,10-11,13H2,1-5H3,(H,20,22,23) DMLQRFO CS CC1(CC(=O)NC(=O)C1(CCCN(C)C)C2=CC(=CC=C2)OC)C DMLQRFO IK UJFNSGBGJMRZKS-UHFFFAOYSA-N DMLQRFO IU 3-[3-(dimethylamino)propyl]-3-(3-methoxyphenyl)-4,4-dimethylpiperidine-2,6-dione DMLQRFO CA CAS 53873-21-5 DMLQRFO DE Psychotic disorder DMMGAUK ID DMMGAUK DMMGAUK DN AGN-XX/YY DMMGAUK HS Phase 2 DMMGAUK SN Rezatomidine DMMGAUK CP ACADIA Pharmaceuticals DMMGAUK DT Small molecular drug DMMGAUK PC 11287722 DMMGAUK MW 232.35 DMMGAUK FM C13H16N2S DMMGAUK IC InChI=1S/C13H16N2S/c1-8-5-4-6-11(9(8)2)10(3)12-7-14-13(16)15-12/h4-7,10H,1-3H3,(H2,14,15,16)/t10-/m0/s1 DMMGAUK CS CC1=C(C(=CC=C1)[C@H](C)C2=CNC(=S)N2)C DMMGAUK IK WQXVKEDUCPMRRI-JTQLQIEISA-N DMMGAUK IU 4-[(1S)-1-(2,3-dimethylphenyl)ethyl]-1,3-dihydroimidazole-2-thione DMMGAUK CA CAS 847829-38-3 DMMGAUK DE Fibromyalgia; Diabetic nephropathy DM2POHA ID DM2POHA DM2POHA DN AGS-16C3F DM2POHA HS Phase 2 DM2POHA CP AgensysSanta Monica, CA DM2POHA DE Renal cell carcinoma DMMKASG ID DMMKASG DMMKASG DN AGTC-0106 DMMKASG HS Phase 2 DMMKASG SN Alpha-1 antitrypsin deficiency gene therapy, AGTC; RAAV1-CB-hAAT; Gene therapy (alpha-1 antitrypsin deficiency), Applied Genetic Technologies DMMKASG CP Agtc; applied genetic technologies DMMKASG DE Alpha-1 antitrypsin deficiency DMXJ8Z4 ID DMXJ8Z4 DMXJ8Z4 DN AK104 DMXJ8Z4 HS Phase 2 DMXJ8Z4 CP Akeso Biopharma DMXJ8Z4 DT Antibody DMXJ8Z4 DE Cervical cancer; Hepatocellular carcinoma DMKNRYH ID DMKNRYH DMKNRYH DN AKB-9778 DMKNRYH HS Phase 2 DMKNRYH CP Aerpio Therapeutics DMKNRYH PC 46700782 DMKNRYH MW 586.7 DMKNRYH FM C26H26N4O6S3 DMKNRYH IC InChI=1S/C26H26N4O6S3/c1-36-26(32)29-21(15-17-6-3-2-4-7-17)24(31)27-20(22-16-38-25(28-22)23-8-5-13-37-23)14-18-9-11-19(12-10-18)30-39(33,34)35/h2-13,16,20-21,30H,14-15H2,1H3,(H,27,31)(H,29,32)(H,33,34,35)/t20-,21-/m0/s1 DMKNRYH CS COC(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC2=CC=C(C=C2)NS(=O)(=O)O)C3=CSC(=N3)C4=CC=CS4 DMKNRYH IK KWJDHELCGJFUHW-SFTDATJTSA-N DMKNRYH IU [4-[(2S)-2-[[(2S)-2-(methoxycarbonylamino)-3-phenylpropanoyl]amino]-2-(2-thiophen-2-yl-1,3-thiazol-4-yl)ethyl]phenyl]sulfamic acid DMKNRYH CA CAS 1008510-37-9 DMKNRYH DE Peripheral arterial disease; Diabetic macular edema DMR8W7Y ID DMR8W7Y DMR8W7Y DN AKCEA-ANGPTL3-LRX DMR8W7Y HS Phase 2 DMR8W7Y CP Akcea Therapeutics Cambridge, MA DMR8W7Y DE Cardiovascular disease DMCTWIB ID DMCTWIB DMCTWIB DN AL102 DMCTWIB HS Phase 2 DMCTWIB CP Ayala Pharmaceuticals DMCTWIB DT Small molecular drug DMCTWIB DE Desmoid tumour DM3P91Z ID DM3P91Z DM3P91Z DN Alacizumab pegol DM3P91Z HS Phase 2 DM3P91Z SN CDP-791 DM3P91Z CP UCB Celltech DM3P91Z DT Antibody DM3P91Z DE Non-small-cell lung cancer DM2U530 ID DM2U530 DM2U530 DN ALD-401 DM2U530 HS Phase 2 DM2U530 SN ALD-401, Aldagen; ALDH-expressing stem cell therapy (ischemic stroke), Aldagen DM2U530 CP Cytomedix DM2U530 DE Cerebrovascular ischaemia DM6RBYT ID DM6RBYT DM6RBYT DN ALD-403 DM6RBYT HS Phase 2 DM6RBYT SN MAb (migraine), Alder DM6RBYT CP Alder biopharmaceuticals DM6RBYT DE Migraine DMPWSBL ID DMPWSBL DMPWSBL DN ALD-518 DMPWSBL HS Phase 2 DMPWSBL DE Rheumatoid arthritis; Psoriatic arthritis DMUA0XC ID DMUA0XC DMUA0XC DN ALF-5755 DMUA0XC HS Phase 2 DMUA0XC SN HIP/PAP; Hepatocarcinoma-intestine-pancreas/pancreatic-associated protein DMUA0XC CP INSERM DMUA0XC DE Liver failure DMR2YPF ID DMR2YPF DMR2YPF DN ALG-1001 DMR2YPF HS Phase 2 DMR2YPF CP Allegro Ophthalmics DMR2YPF PC 130476723 DMR2YPF MW 637.7 DMR2YPF FM C22H39N9O11S DMR2YPF IC InChI=1S/C22H39N9O11S/c1-11(32)17(20(37)31-7-3-5-14(31)21(38)39)30-19(36)13(10-43(40,41)42)29-16(34)9-27-18(35)12(28-15(33)8-23)4-2-6-26-22(24)25/h11-14,17,32H,2-10,23H2,1H3,(H,27,35)(H,28,33)(H,29,34)(H,30,36)(H,38,39)(H4,24,25,26)(H,40,41,42)/t11-,12+,13+,14+,17+/m1/s1 DMR2YPF CS C[C@H]([C@@H](C(=O)N1CCC[C@H]1C(=O)O)NC(=O)[C@H](CS(=O)(=O)O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)NC(=O)CN)O DMR2YPF IK MYZAXBZLEILEBR-RVFOSREFSA-N DMR2YPF IU (2S)-1-[(2S,3R)-2-[[(2R)-2-[[2-[[(2S)-2-[(2-aminoacetyl)amino]-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]-3-sulfopropanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carboxylic acid DMR2YPF CA CAS 1307293-62-4 DMR2YPF DE Diabetic macular edema DME3ZYC ID DME3ZYC DME3ZYC DN ALKS 4230 DME3ZYC HS Phase 2 DME3ZYC CP Alkermes DME3ZYC DT Protein DME3ZYC DE Solid tumour/cancer DMF3QN1 ID DMF3QN1 DMF3QN1 DN ALKS33 DMF3QN1 HS Phase 2 DMF3QN1 SN Samidorphan DMF3QN1 CP Alkermes DMF3QN1 DT Small molecular drug DMF3QN1 PC 11667832 DMF3QN1 MW 370.4 DMF3QN1 FM C21H26N2O4 DMF3QN1 IC InChI=1S/C21H26N2O4/c22-19(26)15-4-3-13-9-16-21(27)6-5-14(24)10-20(21,17(13)18(15)25)7-8-23(16)11-12-1-2-12/h3-4,12,16,25,27H,1-2,5-11H2,(H2,22,26)/t16-,20-,21-/m1/s1 DMF3QN1 CS C1CC1CN2CC[C@]34CC(=O)CC[C@]3([C@H]2CC5=C4C(=C(C=C5)C(=O)N)O)O DMF3QN1 IK RYIDHLJADOKWFM-MAODMQOUSA-N DMF3QN1 IU (1R,9R,10S)-17-(cyclopropylmethyl)-3,10-dihydroxy-13-oxo-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-triene-4-carboxamide DMF3QN1 CA CAS 852626-89-2 DMF3QN1 DE Alcohol dependence DMWYMJN ID DMWYMJN DMWYMJN DN ALN-CC5 DMWYMJN HS Phase 2 DMWYMJN CP Alnylam Pharmaceuticals: Cemdisiran DMWYMJN DT Antisense oligonucleotide DMWYMJN DE Haemolytic uraemic syndrome DMEYNQA ID DMEYNQA DMEYNQA DN ALN-RSV01 DMEYNQA HS Phase 2 DMEYNQA DT siRNA drug DMEYNQA DE Respiratory infection; Respiratory syncytial virus infection DMJPV5X ID DMJPV5X DMJPV5X DN Alovudine DMJPV5X HS Phase 2 DMJPV5X SN Alovudine; 25526-93-6; FddT; 3'-DEOXY-3'-FLUOROTHYMIDINE; FddThD; 3'-Fluoro-3'-deoxythymidine; Thymidine, 3'-deoxy-3'-fluoro-; 3'F-TdR; 3'-FddT; Alovudine [USAN:INN]; UNII-PG53R0DWDQ; 3'-Fluorothymidine; 3'-FLT; DRG-0097; PG53R0DWDQ; NSC 140025; BRN 0754299; 3'-Fluorodeoxythymidine; CL 184824; CHEMBL105318; FLT; 1-((2R,4S,5R)-4-fluoro-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione; C10H13FN2O4; MIV-310; 1-(3'-Deoxy-3'-fluoro-beta-D-pentofuranosyl)thymine; CL-184824; DSSTox_RID_81738; DSSTox_CID_26579 DMJPV5X DT Small molecular drug DMJPV5X PC 33039 DMJPV5X MW 244.22 DMJPV5X FM C10H13FN2O4 DMJPV5X IC InChI=1S/C10H13FN2O4/c1-5-3-13(10(16)12-9(5)15)8-2-6(11)7(4-14)17-8/h3,6-8,14H,2,4H2,1H3,(H,12,15,16)/t6-,7+,8+/m0/s1 DMJPV5X CS CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)CO)F DMJPV5X IK UXCAQJAQSWSNPQ-XLPZGREQSA-N DMJPV5X IU 1-[(2R,4S,5R)-4-fluoro-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione DMJPV5X CA CAS 25526-93-6 DMJPV5X DE Breast cancer DM5EFXZ ID DM5EFXZ DM5EFXZ DN Alpha-1 antitrypsin DM5EFXZ HS Phase 2 DM5EFXZ SN AAT, Transgene; Alpha-1 antitrypsin, Transgene DM5EFXZ CP Transgene SA DM5EFXZ DE Bacillus anthracis infection; Coagulation defect DMLBWT1 ID DMLBWT1 DMLBWT1 DN ALRN-6924 DMLBWT1 HS Phase 2 DMLBWT1 CP Aileron Therapeutics Cambridge, MA DMLBWT1 DE Acute myeloid leukaemia; Haematological malignancy; Myelodysplastic syndrome; Solid tumour/cancer DM9KL7P ID DM9KL7P DM9KL7P DN ALT-801 DM9KL7P HS Phase 2 DM9KL7P SN ALT-801 (donor lymphocyte infusion, cancer); ALT-801 (donor lymphocyte infusion, cancer), Altor; STAR IL-2 conjugate (donor lymphocyte infusion, cancer), Altor; STAR-Ck (donor lymphocyte infusion, cancer), Altor; Soluble T-cell Antigen Receptor IL-2 conjugate (donor lymphocyte infusion, cancer), Altor DM9KL7P CP Altor bioscience DM9KL7P DE Acute myeloid leukaemia; Bladder cancer; Non-muscle invasive bladder cancer DMK3U1X ID DMK3U1X DMK3U1X DN ALT-803 DMK3U1X HS Phase 2 DMK3U1X SN IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience DMK3U1X CP Altor bioscience DMK3U1X DE Human immunodeficiency virus infection; Solid tumour/cancer; Non-hodgkin lymphoma; Pancreatic cancer; Non-small-cell lung cancer; Bladder cancer; Multiple myeloma; Acute myeloid leukaemia DMGJ71F ID DMGJ71F DMGJ71F DN ALT-836 DMGJ71F HS Phase 2 DMGJ71F CP Altor BioScience DMGJ71F DE Adult respiratory distress syndrome DMLSK01 ID DMLSK01 DMLSK01 DN Altrakincept DMLSK01 HS Phase 2 DMLSK01 CP Novartis DMLSK01 DT Monoclonal antibody DMLSK01 DE Asthma DMXSFA0 ID DMXSFA0 DMXSFA0 DN ALV-003 DMXSFA0 HS Phase 2 DMXSFA0 SN Gluten-detoxifying protease (celiac sprue), Alvine Pharmaceuticals; Glutamine-specific cysteine protease (EP-B2) + proline-specific prolyl endopeptidase (PEP) (celiac disease), Alvine DMXSFA0 CP Alvine Pharmaceuticals Inc DMXSFA0 DE Coeliac disease DMO1VHC ID DMO1VHC DMO1VHC DN ALX-0061 DMO1VHC HS Phase 2 DMO1VHC SN Nanobody therapeutic (autoimmune/inflammatory disease), Ablynx; Anti-IL-6R nanobody therapeutic (autoimmune/inflammatory disease), Ablynx DMO1VHC CP Ablynx NV DMO1VHC DT Antibody DMO1VHC DE Autoimmune diabetes; Rheumatoid arthritis; Systemic lupus erythematosus DMCAFXM ID DMCAFXM DMCAFXM DN ALX-101 DMCAFXM HS Phase 2 DMCAFXM SN Rovazolac; UNII-W51K389XIL; W51K389XIL; Rovazolac [INN]; GTPL9625; SCHEMBL15242823; ZUMNJDGBYXHASJ-UHFFFAOYSA-N; example 36 [WO2013130892]; HY-109073; CS-0033536; A-110; ethyl 2-[5-[4-(3-methylsulfonylphenyl)phenyl]-3-(trifluoromethyl)pyrazol-1-yl]acetate; ethyl 2-(5-(3'-(methylsulfonyl)biphenyl-4-yl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)acetate; ethyl 2-(5-(3'-(methylsulfonyl)-[1,1'-biphenyl]-4-yl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)acetate; Ethyl 2-(5-(3'-(methylsulfonyl)-(1,1'-biphenyl)-4-yl)-3-(trifluoromethy DMCAFXM CP Ralexar Therapeutics Malvern, PA DMCAFXM PC 89792952 DMCAFXM MW 452.4 DMCAFXM FM C21H19F3N2O4S DMCAFXM IC InChI=1S/C21H19F3N2O4S/c1-3-30-20(27)13-26-18(12-19(25-26)21(22,23)24)15-9-7-14(8-10-15)16-5-4-6-17(11-16)31(2,28)29/h4-12H,3,13H2,1-2H3 DMCAFXM CS CCOC(=O)CN1C(=CC(=N1)C(F)(F)F)C2=CC=C(C=C2)C3=CC(=CC=C3)S(=O)(=O)C DMCAFXM IK ZUMNJDGBYXHASJ-UHFFFAOYSA-N DMCAFXM IU ethyl 2-[5-[4-(3-methylsulfonylphenyl)phenyl]-3-(trifluoromethyl)pyrazol-1-yl]acetate DMCAFXM CA CAS 1454288-88-0 DMCAFXM DE Atopic dermatitis DMV934L ID DMV934L DMV934L DN ALX-40-4C DMV934L HS Phase 2 DMV934L SN AV-9 DMV934L CP NPS Allelix Corp DMV934L DT Small molecular drug DMV934L PC 25077385 DMV934L MW 1464.7 DMV934L FM C56H113N37O10 DMV934L IC InChI=1S/C56H113N37O10/c1-29(94)85-31(12-3-21-77-49(60)61)40(96)87-33(14-5-23-79-51(64)65)42(98)89-35(16-7-25-81-53(68)69)44(100)91-37(18-9-27-83-55(72)73)46(102)93-38(19-10-28-84-56(74)75)47(103)92-36(17-8-26-82-54(70)71)45(101)90-34(15-6-24-80-52(66)67)43(99)88-32(13-4-22-78-50(62)63)41(97)86-30(39(57)95)11-2-20-76-48(58)59/h30-38H,2-28H2,1H3,(H2,57,95)(H,85,94)(H,86,97)(H,87,96)(H,88,99)(H,89,98)(H,90,101)(H,91,100)(H,92,103)(H,93,102)(H4,58,59,76)(H4,60,61,77)(H4,62,63,78)(H4,64,65,79)(H4,66,67,80)(H4,68,69,81)(H4,70,71,82)(H4,72,73,83)(H4,74,75,84)/t30-,31-,32-,33-,34-,35-,36-,37-,38-/m1/s1 DMV934L CS CC(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N DMV934L IK LGLVVVCSQBZONM-HCCLCSBVSA-N DMV934L IU (2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanamide DMV934L CA CAS 153127-49-2 DMV934L DE Human immunodeficiency virus infection DMH5LFR ID DMH5LFR DMH5LFR DN ALXN6000 DMH5LFR HS Phase 2 DMH5LFR SN Samalizumab DMH5LFR CP Alexion Pharmaceuticals DMH5LFR DT Antibody DMH5LFR DE Chronic lymphocytic leukaemia; Acute myeloid leukaemia; Solid tumour/cancer DM7ZQAT ID DM7ZQAT DM7ZQAT DN ALZ-801 DM7ZQAT HS Phase 2 DM7ZQAT CP Alzheon DM7ZQAT PC 25008296 DM7ZQAT MW 238.31 DM7ZQAT FM C8H18N2O4S DM7ZQAT IC InChI=1S/C8H18N2O4S/c1-6(2)7(9)8(11)10-4-3-5-15(12,13)14/h6-7H,3-5,9H2,1-2H3,(H,10,11)(H,12,13,14)/t7-/m0/s1 DM7ZQAT CS CC(C)[C@@H](C(=O)NCCCS(=O)(=O)O)N DM7ZQAT IK NRZRFNYKMSAZBI-ZETCQYMHSA-N DM7ZQAT IU 3-[[(2S)-2-amino-3-methylbutanoyl]amino]propane-1-sulfonic acid DM7ZQAT CA CAS 1034190-08-3 DM7ZQAT DE Alzheimer disease DM9UMSJ ID DM9UMSJ DM9UMSJ DN AM001 DM9UMSJ HS Phase 2 DM9UMSJ SN MLS000562506; CHEMBL1407569; HMS2222P08; SMR000453693 DM9UMSJ CP AmDerma Pharmaceuticals DM9UMSJ DT Small molecular drug DM9UMSJ PC 16745944 DM9UMSJ MW 369.4 DM9UMSJ FM C19H19N3O5 DM9UMSJ IC InChI=1S/C19H19N3O5/c1-2-10-26-14-11-17(27-15(14)12-23)22-9-8-16(21-19(22)25)20-18(24)13-6-4-3-5-7-13/h1,3-9,14-15,17,23H,10-12H2,(H,20,21,24,25)/t14-,15-,17-/m1/s1 DM9UMSJ CS C#CCO[C@@H]1C[C@@H](O[C@@H]1CO)N2C=CC(=NC2=O)NC(=O)C3=CC=CC=C3 DM9UMSJ IK VUDFTOHJBXWAGS-BFYDXBDKSA-N DM9UMSJ IU N-[1-[(2R,4R,5R)-5-(hydroxymethyl)-4-prop-2-ynoxyoxolan-2-yl]-2-oxopyrimidin-4-yl]benzamide DM9UMSJ DE Actinic keratosis DMGVQI8 ID DMGVQI8 DMGVQI8 DN AM-001 DMGVQI8 HS Phase 2 DMGVQI8 SN AM-001 (topical); AM-001 (topical), DermAct DMGVQI8 CP DermAct Pharmaceutical Inc DMGVQI8 DE Dermatological disease; Actinic keratosis DMBWNX5 ID DMBWNX5 DMBWNX5 DN AMA-76 DMBWNX5 HS Phase 2 DMBWNX5 CP Amakem DMBWNX5 DE Glaucoma/ocular hypertension DMEB3T9 ID DMEB3T9 DMEB3T9 DN Amdoxovir DMEB3T9 HS Phase 2 DMEB3T9 SN Amdoxovir; DAPD; 145514-04-1; DAPD cpd; UNII-54I81H0M9C; (-)-DAPD; beta-D-2,6-Diaminopurine-dioxolane; 54I81H0M9C; [(2R,4R)-4-(2,6-diaminopurin-9-yl)-1,3-dioxolan-2-yl]methanol; (2R-cis)-4-(2,6-Diamino-9H-purin-9-yl)-1,3-dioxolane-2-methanol; (2R,4R)-4-(2,6-Diamino-9H-purin-9-yl)-1,3-dioxolane-2-methanol; (-)-(2R,4R)-2-Amino-(2-(hydroxymethyl)-1,3-dioxolan-4-yl)adenine; 1,3-Dioxolane-2-methanol, 4-(2,6-diamino-9H-purin-9-yl)-, (2R,4R)-; 1,3-Dioxolane-2-methanol, 4-(2,6-diamino-9H-purin-9-yl)-, (2R-cis)-; Amdoxovir [USAN] DMEB3T9 DT Small molecular drug DMEB3T9 PC 124088 DMEB3T9 MW 252.23 DMEB3T9 FM C9H12N6O3 DMEB3T9 IC InChI=1S/C9H12N6O3/c10-7-6-8(14-9(11)13-7)15(3-12-6)4-2-17-5(1-16)18-4/h3-5,16H,1-2H2,(H4,10,11,13,14)/t4-,5-/m1/s1 DMEB3T9 CS C1[C@@H](O[C@@H](O1)CO)N2C=NC3=C(N=C(N=C32)N)N DMEB3T9 IK RLAHNGKRJJEIJL-RFZPGFLSSA-N DMEB3T9 IU [(2R,4R)-4-(2,6-diaminopurin-9-yl)-1,3-dioxolan-2-yl]methanol DMEB3T9 CA CAS 145514-04-1 DMEB3T9 DE Hepatitis B virus infection DMIVZ3M ID DMIVZ3M DMIVZ3M DN AME-133v DMIVZ3M HS Phase 2 DMIVZ3M SN Ocaratuzumab DMIVZ3M CP MENTRIK Biotech DMIVZ3M DT Antibody DMIVZ3M DE Non-hodgkin lymphoma DMUMCB9 ID DMUMCB9 DMUMCB9 DN Amelubant DMUMCB9 HS Phase 2 DMUMCB9 SN Amelubant [INN]; BIIL 283 BS; BIIL 284; Ethyl ((4-((3-((4-(1-(4-hydroxyphenyl)-1-methylethyl)phenoxy)methyl)benzyl)oxy)phenyl)(imino)methyl)carbamate; Carbamic acid, ((4-((3-((4-(1-(4-hydroxyphenyl)-1-methylethyl)phenoxy)methyl)phenyl)methoxy)phenyl)iminomethyl)-, ethyl ester DMUMCB9 CP Boehringer Ingelheim DMUMCB9 DT Small molecular drug DMUMCB9 PC 135564996 DMUMCB9 MW 538.6 DMUMCB9 FM C33H34N2O5 DMUMCB9 IC InChI=1S/C33H34N2O5/c1-4-38-32(37)35-31(34)25-8-16-29(17-9-25)39-21-23-6-5-7-24(20-23)22-40-30-18-12-27(13-19-30)33(2,3)26-10-14-28(36)15-11-26/h5-20,36H,4,21-22H2,1-3H3,(H2,34,35,37) DMUMCB9 CS CCOC(=O)NC(=N)C1=CC=C(C=C1)OCC2=CC(=CC=C2)COC3=CC=C(C=C3)C(C)(C)C4=CC=C(C=C4)O DMUMCB9 IK SBVYURPQULDJTI-UHFFFAOYSA-N DMUMCB9 IU ethyl N-[4-[[3-[[4-[2-(4-hydroxyphenyl)propan-2-yl]phenoxy]methyl]phenyl]methoxy]benzenecarboximidoyl]carbamate DMUMCB9 CA CAS 346735-24-8 DMUMCB9 DE Cystic fibrosis; Pulmonary disease DMGOFL3 ID DMGOFL3 DMGOFL3 DN AMG 151 DMGOFL3 HS Phase 2 DMGOFL3 CP Amgen DMGOFL3 DE Type-2 diabetes DMPQHOR ID DMPQHOR DMPQHOR DN AMG 208 DMPQHOR HS Phase 2 DMPQHOR SN AMG-208; 1002304-34-8; AMG 208; AMG208; UNII-Y2SR66P7VM; 7-methoxy-4-((6-phenyl-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methoxy)quinoline; Y2SR66P7VM; CHEBI:90626; 7-methoxy-4-[(6-phenyl[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methoxy]quinoline; 7-Methoxy-4-[(6-phenyl-1,2,4-triazolo[4,3-b]pyridazin-3-yl)methoxy]quinoline; C22H17N5O2; 7-methoxy-4-[(6-phenyl-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methoxy]quinoline; 7-methoxy-4-({6-phenyl-[1,2,4]triazolo[4,3-b]pyridazin-3-yl}methoxy)quinoline; Triazolopyridazine, 4; 3cd8 DMPQHOR CP Amgen Thousand DMPQHOR DT Small molecular drug DMPQHOR PC 24864821 DMPQHOR MW 383.4 DMPQHOR FM C22H17N5O2 DMPQHOR IC InChI=1S/C22H17N5O2/c1-28-16-7-8-17-19(13-16)23-12-11-20(17)29-14-22-25-24-21-10-9-18(26-27(21)22)15-5-3-2-4-6-15/h2-13H,14H2,1H3 DMPQHOR CS COC1=CC2=NC=CC(=C2C=C1)OCC3=NN=C4N3N=C(C=C4)C5=CC=CC=C5 DMPQHOR IK HEAIZQNMNCHNFD-UHFFFAOYSA-N DMPQHOR IU 7-methoxy-4-[(6-phenyl-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methoxy]quinoline DMPQHOR CA CAS 1002304-34-8 DMPQHOR CB CHEBI:90626 DMPQHOR DE Solid tumour/cancer DM65PTO ID DM65PTO DM65PTO DN AMG 232 DM65PTO HS Phase 2 DM65PTO SN KRT-232 DM65PTO CP Amgen DM65PTO PC 58573469 DM65PTO MW 568.6 DM65PTO FM C28H35Cl2NO5S DM65PTO IC InChI=1S/C28H35Cl2NO5S/c1-17(2)24(16-37(35,36)18(3)4)31-26(19-9-11-21(29)12-10-19)23(20-7-6-8-22(30)13-20)14-28(5,27(31)34)15-25(32)33/h6-13,17-18,23-24,26H,14-16H2,1-5H3,(H,32,33)/t23-,24-,26-,28-/m1/s1 DM65PTO CS CC(C)[C@@H](CS(=O)(=O)C(C)C)N1[C@@H]([C@H](C[C@](C1=O)(C)CC(=O)O)C2=CC(=CC=C2)Cl)C3=CC=C(C=C3)Cl DM65PTO IK DRLCSJFKKILATL-YWCVFVGNSA-N DM65PTO IU 2-[(3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-3-methyl-1-[(2S)-3-methyl-1-propan-2-ylsulfonylbutan-2-yl]-2-oxopiperidin-3-yl]acetic acid DM65PTO CA CAS 1352066-68-2 DM65PTO DE Solid tumour/cancer; Merkel cell carcinoma DMO72IF ID DMO72IF DMO72IF DN AMG 301 DMO72IF HS Phase 2 DMO72IF CP Amgen Thousand Oaks, CA Novartis Pharmaceuticals East Hanover, NJ DMO72IF DE Migraine; Hyperprolactinaemia DMI3WFG ID DMI3WFG DMI3WFG DN AMG 334 DMI3WFG HS Phase 2 DMI3WFG CP Amgen DMI3WFG DE Migraine DMIOUEY ID DMIOUEY DMIOUEY DN AMG 337 DMIOUEY HS Phase 2 DMIOUEY PC 44181686 DMIOUEY MW 463.5 DMIOUEY FM C23H22FN7O3 DMIOUEY IC InChI=1S/C23H22FN7O3/c1-14(30-5-4-20-18(23(30)32)9-17(11-25-20)34-7-6-33-3)21-27-28-22-19(24)8-15(13-31(21)22)16-10-26-29(2)12-16/h4-5,8-14H,6-7H2,1-3H3/t14-/m1/s1 DMIOUEY CS C[C@H](C1=NN=C2N1C=C(C=C2F)C3=CN(N=C3)C)N4C=CC5=C(C4=O)C=C(C=N5)OCCOC DMIOUEY IK DWHXUGDWKAIASB-CQSZACIVSA-N DMIOUEY IU 6-[(1R)-1-[8-fluoro-6-(1-methylpyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl]ethyl]-3-(2-methoxyethoxy)-1,6-naphthyridin-5-one DMIOUEY CA CAS 1173699-31-4 DMIOUEY DE Solid tumour/cancer; Clear cell sarcoma DM0DRAZ ID DM0DRAZ DM0DRAZ DN AMG 479 DM0DRAZ HS Phase 2 DM0DRAZ CP Amgen DM0DRAZ DE Breast cancer DME6QH1 ID DME6QH1 DME6QH1 DN AMG 557 DME6QH1 HS Phase 2 DME6QH1 CP Amgen Thousand DME6QH1 DE Systemic lupus erythematosus; Sjogren syndrome DMY1XJH ID DMY1XJH DMY1XJH DN AMG 570 DMY1XJH HS Phase 2 DMY1XJH CP Amgen DMY1XJH DT Small molecular drug DMY1XJH DE Systemic lupus erythematosus DMFXN2T ID DMFXN2T DMFXN2T DN AMG 745 DMFXN2T HS Phase 2 DMFXN2T CP Amgen DMFXN2T DE Muscle atrophy DMWPGB8 ID DMWPGB8 DMWPGB8 DN Amg 747 DMWPGB8 HS Phase 2 DMWPGB8 CP Amgen DMWPGB8 DE Schizophrenia DM973N4 ID DM973N4 DM973N4 DN AMG 853 DM973N4 HS Phase 2 DM973N4 SN VIDUPIPRANT; 1169483-24-2; AMG 853; AMG-853; UNII-61OTZ32XNC; 61OTZ32XNC; 2-(4-(4-(tert-butylcarbamoyl)-2-(2-chloro-4-cyclopropylphenylsulfonamido)phenoxy)-5-chloro-2-fluorophenyl)acetic acid; CHEMBL1951575; AMG 853(AMG853;Vidupiprant); Benzeneacetic acid, 5-chloro-4-[2-[[(2-chloro-4-cyclopropylphenyl)sulfonyl]amino]-4-[[(1,1-dimethylethyl)amino]carbonyl]phenoxy]-2-fluoro-; Vidupiprant [USAN:INN]; AMG853;Vidupiprant; Vidupiprant (USAN/INN); AMG853; SCHEMBL4344221; GTPL10169; DTXSID40151606; BCP28132; ZINC43206238 DM973N4 CP Amgen Thousand DM973N4 DT Small molecular drug DM973N4 PC 42641863 DM973N4 MW 609.5 DM973N4 FM C28H27Cl2FN2O6S DM973N4 IC InChI=1S/C28H27Cl2FN2O6S/c1-28(2,3)32-27(36)17-6-8-23(39-24-14-21(31)18(11-19(24)29)13-26(34)35)22(12-17)33-40(37,38)25-9-7-16(10-20(25)30)15-4-5-15/h6-12,14-15,33H,4-5,13H2,1-3H3,(H,32,36)(H,34,35) DM973N4 CS CC(C)(C)NC(=O)C1=CC(=C(C=C1)OC2=C(C=C(C(=C2)F)CC(=O)O)Cl)NS(=O)(=O)C3=C(C=C(C=C3)C4CC4)Cl DM973N4 IK PFWVGKROPKKEDW-UHFFFAOYSA-N DM973N4 IU 2-[4-[4-(tert-butylcarbamoyl)-2-[(2-chloro-4-cyclopropylphenyl)sulfonylamino]phenoxy]-5-chloro-2-fluorophenyl]acetic acid DM973N4 CA CAS 1169483-24-2 DM973N4 DE Asthma DM3H0IX ID DM3H0IX DM3H0IX DN AMG 890 DM3H0IX HS Phase 2 DM3H0IX SN Olpasiran DM3H0IX CP Amgen DM3H0IX DT Small interfering RNA DM3H0IX DE Cardiac fibrosis DMODJTX ID DMODJTX DMODJTX DN AMG-181 DMODJTX HS Phase 2 DMODJTX SN Inflammatory bowel disease therapeutics, Amgen DMODJTX CP Amgen; astrazeneca DMODJTX DT Antibody DMODJTX DE Crohn disease; Ulcerative colitis DM1T3KQ ID DM1T3KQ DM1T3KQ DN AMG-714 DM1T3KQ HS Phase 2 DM1T3KQ CP Genmab; Amgen DM1T3KQ DT Antibody DM1T3KQ DE Rheumatoid arthritis; Coeliac disease DMJ4GPR ID DMJ4GPR DMJ4GPR DN AMP-579 DMJ4GPR HS Phase 2 DMJ4GPR SN RPR-100579; (1S,2R,3S,4R)-4-[7-[1(R)-(3-Chloro-2-thienylmethyl)propylamino]-3H-imidazo[4,5-b]pyridin-3-yl]-N-ethyl-2,3-dihydroxycyclopentane-1-carboxamide DMJ4GPR DT Small molecular drug DMJ4GPR PC 72941762 DMJ4GPR MW 478 DMJ4GPR FM C22H28ClN5O3S DMJ4GPR IC InChI=1S/C22H28ClN5O3S/c1-3-12(9-17-15(23)6-8-32-17)27-20-13-5-7-28(21(13)26-11-25-20)16-10-14(18(29)19(16)30)22(31)24-4-2/h5-8,11-12,14,16,18-19,29-30H,3-4,9-10H2,1-2H3,(H,24,31)(H,25,26,27)/t12-,14+,16-,18-,19+/m1/s1 DMJ4GPR CS CC[C@H](CC1=C(C=CS1)Cl)NC2=C3C=CN(C3=NC=N2)[C@@H]4C[C@@H]([C@H]([C@H]4O)O)C(=O)NCC DMJ4GPR IK CKQOOYMMAAPDKH-QODLLSGVSA-N DMJ4GPR IU (1S,2R,3S,4R)-4-[4-[[(2R)-1-(3-chlorothiophen-2-yl)butan-2-yl]amino]pyrrolo[2,3-d]pyrimidin-7-yl]-N-ethyl-2,3-dihydroxycyclopentane-1-carboxamide DMJ4GPR CA CAS 213453-89-5 DMJ4GPR DE Hyperlipidaemia DMGE8FK ID DMGE8FK DMGE8FK DN AMR-001 DMGE8FK HS Phase 2 DMGE8FK CP Amorcyte; Progenitor Cell Therapy DMGE8FK DE Heart failure DMOB01U ID DMOB01U DMOB01U DN Amsilarotene DMOB01U HS Phase 2 DMOB01U SN Am-555S; TAC-101; Anticancer retinoic acid receptor antagonist (oral), Taiho DMOB01U CP Taiho Pharmaceutical Co Ltd DMOB01U DT Small molecular drug DMOB01U PC 9800306 DMOB01U MW 385.6 DMOB01U FM C20H27NO3Si2 DMOB01U IC InChI=1S/C20H27NO3Si2/c1-25(2,3)17-11-15(12-18(13-17)26(4,5)6)19(22)21-16-9-7-14(8-10-16)20(23)24/h7-13H,1-6H3,(H,21,22)(H,23,24) DMOB01U CS C[Si](C)(C)C1=CC(=CC(=C1)C(=O)NC2=CC=C(C=C2)C(=O)O)[Si](C)(C)C DMOB01U IK VVTNSTLJOVCBDL-UHFFFAOYSA-N DMOB01U IU 4-[[3,5-bis(trimethylsilyl)benzoyl]amino]benzoic acid DMOB01U CA CAS 125973-56-0 DMOB01U DE Solid tumour/cancer DMS0GA6 ID DMS0GA6 DMS0GA6 DN AMY-101 DMS0GA6 HS Phase 2 DMS0GA6 SN UNII-4Z4DFR9BX7; 4Z4DFR9BX7; 1427001-89-5 (free base); Compstatin 40; Compstatin analog peptide CP40; CHEMBL4297260; 1427001-89-5; L-Isoleucinamide, D-tyrosyl-L-isoleucyl-L-cysteinyl-L-valyl-1-methyl-L-tryptophyl-L-glutaminyl-L-alpha-aspartyl-L-tryptophyl-N-methylglycyl-L-alanyl-L-histidyl-L-arginyl-L-cysteinyl-N2-methyl-, cyclic (3->13)-disulfide; S3,S13-Cyclo(D-tyrolsyl-L-isoleucyl-L-cysteinyl-L-valyl-1-methyl-L-tryptophyl-L-glutaminyl-L-aspartyl-L-tryptophyl-N-methyl-L-glycyl-L-alanyl-L-histidyl-L-arginyl-L-cysteinyl-N-methyl-L-isoleucinamide) DMS0GA6 CP Amyndas DMS0GA6 DT Peptide DMS0GA6 PC 131634231 DMS0GA6 MW 1789.1 DMS0GA6 FM C83H117N23O18S2 DMS0GA6 IC InChI=1S/C83H117N23O18S2/c1-11-43(5)68(103-72(114)53(84)30-46-23-25-50(107)26-24-46)80(122)100-61-39-125-126-40-62(82(124)106(10)69(70(86)112)44(6)12-2)101-73(115)55(21-17-29-90-83(87)88)94-76(118)58(33-49-36-89-41-92-49)96-71(113)45(7)93-65(109)38-105(9)81(123)60(31-47-35-91-54-20-15-13-18-51(47)54)99-77(119)59(34-66(110)111)97-74(116)56(27-28-64(85)108)95-75(117)57(98-79(121)67(42(3)4)102-78(61)120)32-48-37-104(8)63-22-16-14-19-52(48)63/h13-16,18-20,22-26,35-37,41-45,53,55-62,67-69,91,107H,11-12,17,21,27-34,38-40,84H2,1-10H3,(H2,85,108)(H2,86,112)(H,89,92)(H,93,109)(H,94,118)(H,95,117)(H,96,113)(H,97,116)(H,98,121)(H,99,119)(H,100,122)(H,101,115)(H,102,120)(H,103,114)(H,110,111)(H4,87,88,90)/t43-,44-,45-,53+,55-,56-,57-,58-,59-,60-,61-,62-,67-,68-,69-/m0/s1 DMS0GA6 CS CC[C@H](C)[C@@H](C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CN(C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC1=O)C(C)C)CC2=CN(C3=CC=CC=C32)C)CCC(=O)N)CC(=O)O)CC4=CNC5=CC=CC=C54)C)C)CC6=CN=CN6)CCCNC(=N)N)C(=O)N(C)[C@@H]([C@@H](C)CC)C(=O)N)NC(=O)[C@@H](CC7=CC=C(C=C7)O)N DMS0GA6 IK MUSGYEMSJUFFHT-UWABRSFTSA-N DMS0GA6 IU 2-[(4R,7S,10S,13S,19S,22S,25S,28S,31S,34R)-34-[[(2S,3S)-2-[[(2R)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]-4-[[(2S,3S)-1-amino-3-methyl-1-oxopentan-2-yl]-methylcarbamoyl]-25-(3-amino-3-oxopropyl)-7-(3-carbamimidamidopropyl)-10-(1H-imidazol-5-ylmethyl)-19-(1H-indol-3-ylmethyl)-13,17-dimethyl-28-[(1-methylindol-3-yl)methyl]-6,9,12,15,18,21,24,27,30,33-decaoxo-31-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacont-22-yl]acetic acid DMS0GA6 CA CAS 1427001-89-5 DMS0GA6 DE Gingivitis DMT3S10 ID DMT3S10 DMT3S10 DN AN0128 DMT3S10 HS Phase 2 DMT3S10 SN Bis(3-chloro-4-methyl-phenyl)boranyl 3-hydroxypyridine-2-carboxylate; 2-Pyridinecarboxylic acid, 3-hydroxy-, anhydride with bis(3-chloro-4-methylphenyl)borinic acid; 3-Hydroxypyridine-2-carbonyloxy-bis(3-chloro-4-methylphenyl)borane DMT3S10 CP Anacor Pharma. DMT3S10 DT Small molecular drug DMT3S10 PC 11704019 DMT3S10 MW 400.1 DMT3S10 FM C20H16BCl2NO3 DMT3S10 IC InChI=1S/C20H16BCl2NO3/c1-12-5-7-14(10-16(12)22)21(15-8-6-13(2)17(23)11-15)27-20(26)19-18(25)4-3-9-24-19/h3-11,25H,1-2H3 DMT3S10 CS B(C1=CC(=C(C=C1)C)Cl)(C2=CC(=C(C=C2)C)Cl)OC(=O)C3=C(C=CC=N3)O DMT3S10 IK ZTLSOLUCMQEGEA-UHFFFAOYSA-N DMT3S10 IU bis(3-chloro-4-methylphenyl)boranyl 3-hydroxypyridine-2-carboxylate DMT3S10 CA CAS 872044-70-7 DMT3S10 DE Psoriatic disorder; Atopic dermatitis DMJ7QP8 ID DMJ7QP8 DMJ7QP8 DN AN-019 DMJ7QP8 HS Phase 2 DMJ7QP8 SN NRC-19; NRC-24; NRC-AN-015; NRC-AN-019; Bcr-Abl inhibitors (CML), Natco DMJ7QP8 CP Natco Pharma Ltd DMJ7QP8 DE Chronic myelogenous leukaemia DM3JNXS ID DM3JNXS DM3JNXS DN AN-1792 DM3JNXS HS Phase 2 DM3JNXS SN Betabloc; AIP-001 DM3JNXS CP Elan Pharmaceutical Research DM3JNXS DT Small molecular drug DM3JNXS PC 15176 DM3JNXS MW 283.83 DM3JNXS FM C16H26ClNO DM3JNXS IC InChI=1S/C16H25NO.ClH/c1-3-12(2)17-11-16(18)15-9-8-13-6-4-5-7-14(13)10-15;/h8-10,12,16-18H,3-7,11H2,1-2H3;1H DM3JNXS CS CCC(C)[NH2+]CC(C1=CC2=C(CCCC2)C=C1)O.[Cl-] DM3JNXS IK KHBXORBAOCQNMC-UHFFFAOYSA-N DM3JNXS IU butan-2-yl-[2-hydroxy-2-(5,6,7,8-tetrahydronaphthalen-2-yl)ethyl]azanium;chloride DM3JNXS CA CAS 1506-12-3 DM3JNXS DE Alzheimer disease DMDK7CL ID DMDK7CL DMDK7CL DN AN-2898 DMDK7CL HS Phase 2 DMDK7CL SN PDE4 inhibitor (topical, psoriasis/atopic dermatitis), Anacor DMDK7CL CP Anacor Pharmaceuticals Inc DMDK7CL PC 24806574 DMDK7CL MW 276.06 DMDK7CL FM C15H9BN2O3 DMDK7CL IC InChI=1S/C15H9BN2O3/c17-7-10-1-2-13(5-11(10)8-18)21-14-3-4-15-12(6-14)9-20-16(15)19/h1-6,19H,9H2 DMDK7CL CS B1(C2=C(CO1)C=C(C=C2)OC3=CC(=C(C=C3)C#N)C#N)O DMDK7CL IK UBMGTTRDNUKZMT-UHFFFAOYSA-N DMDK7CL IU 4-[(1-hydroxy-3H-2,1-benzoxaborol-5-yl)oxy]benzene-1,2-dicarbonitrile DMDK7CL CA CAS 906673-33-4 DMDK7CL DE Atopic dermatitis DMG7IEN ID DMG7IEN DMG7IEN DN Anatibant DMG7IEN HS Phase 2 DMG7IEN SN Anatibant [INN]; (2S)-N-(3-(4-Carbamimidoylbenzamido)propyl)-1-(2,4-dichloro-3-((2,4-dimethyl-8-quinolyloxy)methyl)phenylsulfonyl)pyrrolidine-2-carboxamide DMG7IEN CP Fournier Pharma DMG7IEN DT Small molecular drug DMG7IEN PC 9831652 DMG7IEN MW 711.7 DMG7IEN FM C34H36Cl2N6O5S DMG7IEN IC InChI=1S/C34H36Cl2N6O5S/c1-20-18-21(2)41-31-24(20)6-3-8-28(31)47-19-25-26(35)13-14-29(30(25)36)48(45,46)42-17-4-7-27(42)34(44)40-16-5-15-39-33(43)23-11-9-22(10-12-23)32(37)38/h3,6,8-14,18,27H,4-5,7,15-17,19H2,1-2H3,(H3,37,38)(H,39,43)(H,40,44)/t27-/m0/s1 DMG7IEN CS CC1=CC(=NC2=C1C=CC=C2OCC3=C(C=CC(=C3Cl)S(=O)(=O)N4CCC[C@H]4C(=O)NCCCNC(=O)C5=CC=C(C=C5)C(=N)N)Cl)C DMG7IEN IK XUHBBTKJWIBQMY-MHZLTWQESA-N DMG7IEN IU (2S)-N-[3-[(4-carbamimidoylbenzoyl)amino]propyl]-1-[2,4-dichloro-3-[(2,4-dimethylquinolin-8-yl)oxymethyl]phenyl]sulfonylpyrrolidine-2-carboxamide DMG7IEN CA CAS 209733-45-9 DMG7IEN CB CHEBI:138828 DMG7IEN DE Traumatic brain injury DMTG2O0 ID DMTG2O0 DMTG2O0 DN Anrukinzumab DMTG2O0 HS Phase 2 DMTG2O0 SN Ab13-2; IMA-638; PF-05230917; Anti-IL-13 antibody (asthma), Wyeth; Anti-IL-13 antibody (ulcerative colitis), Pfizer DMTG2O0 CP Genentech DMTG2O0 DT Monoclonal antibody DMTG2O0 DE Ulcerative colitis; Asthma DMHVZ27 ID DMHVZ27 DMHVZ27 DN Anti-CD137 DMHVZ27 HS Phase 2 DMHVZ27 SN BMS-663513 DMHVZ27 CP Bristol-Myers Squibb DMHVZ27 DT Antibody DMHVZ27 DE Solid tumour/cancer DMPRIHK ID DMPRIHK DMPRIHK DN Anti-CD3 and anti-Her2/neu bispecific antibody-armed activated T cells DMPRIHK HS Phase 2 DMPRIHK SN Her2Bi-armed activated T cells (breast cancer), Barbara Ann Karmanos Cancer Institute; Anti-CD3 and anti-Her2/neu bispecific antibody-armed activated T cells (breast cancer); Anti-CD3 and anti-Her2/neu bispecific antibody-armed activated T cells (breast cancer), Barbara Ann Karmanos Cancer Institute DMPRIHK CP Transtarget; barbara ann karmanos cancer institute DMPRIHK DT Antibody DMPRIHK DE Breast cancer DMVQHBK ID DMVQHBK DMVQHBK DN Anti-GD2 CART DMVQHBK HS Phase 2 DMVQHBK CP Zhujiang Hospital DMVQHBK DT CAR T Cell Therapy DMVQHBK DE Neuroblastoma DMVRNAO ID DMVRNAO DMVRNAO DN Anti-IP10 DMVRNAO HS Phase 2 DMVRNAO CP Bristol-myers squibb DMVRNAO DT Antibody DMVRNAO DE Ulcerative colitis; Crohn disease DMJO402 ID DMJO402 DMJO402 DN Anti-LAG3 DMJO402 HS Phase 2 DMJO402 CP Bristol-Myers Squibb Princeton, NJ DMJO402 DE Gastric adenocarcinoma; Renal cell carcinoma; Non-small-cell lung cancer DMQ58YH ID DMQ58YH DMQ58YH DN Anti-LT alpha DMQ58YH HS Phase 2 DMQ58YH CP Genentech DMQ58YH DT Antibody DMQ58YH DE Rheumatoid arthritis DMQFU1R ID DMQFU1R DMQFU1R DN Anti-M1 prime DMQFU1R HS Phase 2 DMQFU1R CP Genentech DMQFU1R DT Antibody DMQFU1R DE Asthma DMJPZDC ID DMJPZDC DMJPZDC DN Anti-PSCA mab DMJPZDC HS Phase 2 DMJPZDC CP Agensys DMJPZDC DT Monoclonal antibody DMJPZDC DE Pancreatic cancer DMDKRS3 ID DMDKRS3 DMDKRS3 DN Antistasin DMDKRS3 HS Phase 2 DMDKRS3 DE Attention deficit hyperactivity disorder DMRGQVZ ID DMRGQVZ DMRGQVZ DN Antroquinonol DMRGQVZ HS Phase 2 DMRGQVZ SN Hocena; Fungal extract (cancer), Golden Biotechnology DMRGQVZ CP Golden biotechnology DMRGQVZ PC 24875259 DMRGQVZ MW 390.6 DMRGQVZ FM C24H38O4 DMRGQVZ IC InChI=1S/C24H38O4/c1-16(2)10-8-11-17(3)12-9-13-18(4)14-15-20-19(5)21(25)23(27-6)24(28-7)22(20)26/h10,12,14,19-20,22,26H,8-9,11,13,15H2,1-7H3/b17-12+,18-14+/t19-,20-,22-/m1/s1 DMRGQVZ CS C[C@@H]1[C@H]([C@H](C(=C(C1=O)OC)OC)O)C/C=C(\\C)/CC/C=C(\\C)/CCC=C(C)C DMRGQVZ IK LJTSIMVOOOLKOL-FNRDIUJOSA-N DMRGQVZ IU (4R,5R,6R)-4-hydroxy-2,3-dimethoxy-6-methyl-5-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]cyclohex-2-en-1-one DMRGQVZ CA CAS 1010081-09-0 DMRGQVZ CB CHEBI:65415 DMRGQVZ DE Non-small-cell lung cancer; Pancreatic cancer DMMJOZD ID DMMJOZD DMMJOZD DN ANW-32821 DMMJOZD HS Phase 2 DMMJOZD SN Cholest-5-en-3-beta-ol; Cholesterol; Cholest-5-en-3-ol (3beta)-; Cholest-5-en-3beta-ol; Cholesterin; Cholesterine; Cholesterol base H; Cholesteryl alcohol; Cholestrin; Cholestrol; Cordulan; Dastar; Dusoline; Dusoran; Dythol; Hydrocerin; Kathro; Lidinit; Lidinite; Nimco cholesterol base H; Provitamin D; Super hartolan; Tegolan; Tegolan (VAN); Wool alcohols B. P.; cholesterol; (-)-Cholesterol; (3beta)-cholest-5-en-3-ol; 3-beta-Hydroxycholest-5-ene; 3beta-Hydroxycholest-5-ene; 5-Cholesten-3beta-ol; 57-88-5; 5:6-Cholesten-3beta-ol; CCRIS 2834; Lanol DMMJOZD PC 5997 DMMJOZD MW 386.664 DMMJOZD FM C27H46O DMMJOZD IC HVYWMOMLDIMFJA-DPAQBDIFSA-N DMMJOZD CS CC(C)CCCC(C)C1CCC2C1(CCC3C2CC=C4C3(CCC(C4)O)C)C DMMJOZD IK InChI=1S/C27H46O/c1-18(2)7-6-8-19(3)23-11-12-24-22-10-9-20-17-21(28)13-15-26(20,4)25(22)14-16-27(23,24)5/h9,18-19,21-25,28H,6-8,10-17H2,1-5H3/t19-,21+,22+,23-,24+,25+,26+,27-/m1/s1 DMMJOZD IU (3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol DMMJOZD CA CAS 17528-72-2 DMMJOZD CB ChEBI:15372 DMMJOZD DE Cone rod dystrophy DMYBQEF ID DMYBQEF DMYBQEF DN AP26113 DMYBQEF HS Phase 2 DMYBQEF SN 1197958-12-5; ALK-IN-1; UNII-3DGD69C6PV; 3DGD69C6PV; CHEMBL3397300; (2-((5-chloro-2-((4-(4-(dimethylamino)piperidin-1-yl)-2-methoxyphenyl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide; 5-Chloro-N~2~-{4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyphenyl}-N~4~-[2-(dimethylphosphoryl)phenyl]pyrimidine-2,4-diamine; 5-chloro-2-N-[4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyphenyl]-4-N-(2-dimethylphosphorylphenyl)pyrimidine-2,4-diamine; AP26113-analog; Tube723; compound 11q [PMID: 27144831] DMYBQEF DT Small molecular drug DMYBQEF PC 57390074 DMYBQEF MW 529 DMYBQEF FM C26H34ClN6O2P DMYBQEF IC InChI=1S/C26H34ClN6O2P/c1-32(2)18-12-14-33(15-13-18)19-10-11-21(23(16-19)35-3)30-26-28-17-20(27)25(31-26)29-22-8-6-7-9-24(22)36(4,5)34/h6-11,16-18H,12-15H2,1-5H3,(H2,28,29,30,31) DMYBQEF CS CN(C)C1CCN(CC1)C2=CC(=C(C=C2)NC3=NC=C(C(=N3)NC4=CC=CC=C4P(=O)(C)C)Cl)OC DMYBQEF IK OVDSPTSBIQCAIN-UHFFFAOYSA-N DMYBQEF IU 5-chloro-2-N-[4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyphenyl]-4-N-(2-dimethylphosphorylphenyl)pyrimidine-2,4-diamine DMYBQEF CA CAS 1197958-12-5 DMYBQEF DE Solid tumour/cancer DM3ICYL ID DM3ICYL DM3ICYL DN AP-301-IH DM3ICYL HS Phase 2 DM3ICYL SN AP-301; AP-301-IRI; AP-301-PN; AP-301-PN); Peptide TNF alpha analog (pneumonia), Apeptico; Peptide TNF alpha modulator (edema in acute lung injury), Apeptico/Medical College of Georgia; Peptide TNF alpha modulator (ischemia/reperfusion injury), Apeptico DM3ICYL CP Apeptico Forschung und Entwicklung GmbH DM3ICYL DE Pneumonia DMISQOZ ID DMISQOZ DMISQOZ DN AP-761 DMISQOZ HS Phase 2 DMISQOZ SN BI-671800 DMISQOZ CP Actimis Pharmaceuticals Inc DMISQOZ DT Small molecular drug DMISQOZ PC 45270144 DMISQOZ MW 501.5 DMISQOZ FM C25H26F3N5O3 DMISQOZ IC InChI=1S/C25H26F3N5O3/c1-32(2)22-19(14-21(34)35)23(33(3)4)31-20(30-22)13-15-5-11-18(12-6-15)29-24(36)16-7-9-17(10-8-16)25(26,27)28/h5-12H,13-14H2,1-4H3,(H,29,36)(H,34,35) DMISQOZ CS CN(C)C1=C(C(=NC(=N1)CC2=CC=C(C=C2)NC(=O)C3=CC=C(C=C3)C(F)(F)F)N(C)C)CC(=O)O DMISQOZ IK XEOSTBFUCNZKGS-UHFFFAOYSA-N DMISQOZ IU 2-[4,6-bis(dimethylamino)-2-[[4-[[4-(trifluoromethyl)benzoyl]amino]phenyl]methyl]pyrimidin-5-yl]acetic acid DMISQOZ CA CAS 1093108-50-9 DMISQOZ DE Asthma DM1B8IT ID DM1B8IT DM1B8IT DN Apadoline DM1B8IT HS Phase 2 DM1B8IT SN ACMC-20mvlw; SCHEMBL7518667; CTK8G8521; 10H-Phenothiazine-2-carboxamide,10-[(1R)-1-methyl-2-(1-pyrrolidinyl)ethyl]-N-propyl-; KXMAIWXPZGQNCR-UHFFFAOYSA-N; L001386; N-propyl-10-[1-(pyrrolidinyl)-2-propyl]-2-phenothiazinecarboxamide; N-propyl-10-[1-(1-pyrrolidinyl)-2-propyl]-2-phenothiazinecarboxamide DM1B8IT CP Rhone-Poulenc SA DM1B8IT DT Small molecular drug DM1B8IT PC 179334 DM1B8IT MW 395.6 DM1B8IT FM C23H29N3OS DM1B8IT IC InChI=1S/C23H29N3OS/c1-3-12-24-23(27)18-10-11-22-20(15-18)26(17(2)16-25-13-6-7-14-25)19-8-4-5-9-21(19)28-22/h4-5,8-11,15,17H,3,6-7,12-14,16H2,1-2H3,(H,24,27)/t17-/m1/s1 DM1B8IT CS CCCNC(=O)C1=CC2=C(C=C1)SC3=CC=CC=C3N2[C@H](C)CN4CCCC4 DM1B8IT IK KXMAIWXPZGQNCR-QGZVFWFLSA-N DM1B8IT IU N-propyl-10-[(2R)-1-pyrrolidin-1-ylpropan-2-yl]phenothiazine-2-carboxamide DM1B8IT CA CAS 135003-30-4 DM1B8IT DE Pain DMQMV9F ID DMQMV9F DMQMV9F DN Apaxifylline DMQMV9F HS Phase 2 DMQMV9F SN BIIP-20; U-98950; BIIP-20-XX DMQMV9F CP Boehringer Ingelheim Corp DMQMV9F DT Small molecular drug DMQMV9F PC 60949 DMQMV9F MW 318.37 DMQMV9F FM C16H22N4O3 DMQMV9F IC InChI=1S/C16H22N4O3/c1-3-7-19-14-12(15(22)20(8-4-2)16(19)23)17-13(18-14)10-5-6-11(21)9-10/h10H,3-9H2,1-2H3,(H,17,18)/t10-/m0/s1 DMQMV9F CS CCCN1C2=C(C(=O)N(C1=O)CCC)NC(=N2)[C@H]3CCC(=O)C3 DMQMV9F IK RUHGOZFOVBMWOO-JTQLQIEISA-N DMQMV9F IU 8-[(1S)-3-oxocyclopentyl]-1,3-dipropyl-7H-purine-2,6-dione DMQMV9F CA CAS 151581-23-6 DMQMV9F DE Cognitive impairment DM3VP19 ID DM3VP19 DM3VP19 DN APC-8015F DM3VP19 HS Phase 2 DM3VP19 SN CD54-postive autologous cell immunotherapy (hormone refractory prostate cancer), Dendreon DM3VP19 CP Dendreon Corp DM3VP19 DE Prostate cancer DMNQ7DV ID DMNQ7DV DMNQ7DV DN APD-209 DMNQ7DV HS Phase 2 DMNQ7DV SN Undisclosed cachexia therapy (oral fixed-dose combination), Acacia DMNQ7DV CP Acacia Pharma Ltd DMNQ7DV PC 49837938 DMNQ7DV MW 1042.3 DMNQ7DV FM C54H95N3O16 DMNQ7DV IC InChI=1S/C54H95N3O16/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23-25-28-48(62)56-31-34-68-36-38-70-40-42-71-41-39-69-37-35-67-33-29-49(63)55-30-26-24-27-32-72-54(53(65)66)43-46(60)50(57-45(2)59)52(73-54)51(64)47(61)44-58/h46-47,50-52,58,60-61,64H,3-13,18-44H2,1-2H3,(H,55,63)(H,56,62)(H,57,59)(H,65,66)/t46-,47+,50+,51+,52+,54+/m0/s1 DMNQ7DV CS CCCCCCCCCCCCC#CC#CCCCCCCCCC(=O)NCCOCCOCCOCCOCCOCCC(=O)NCCCCCO[C@@]1(C[C@@H]([C@H]([C@@H](O1)[C@@H]([C@@H](CO)O)O)NC(=O)C)O)C(=O)O DMNQ7DV IK VRJMVFQLUBTBKF-HBJHFNNESA-N DMNQ7DV IU (2R,4S,5R,6R)-5-acetamido-4-hydroxy-2-[5-[3-[2-[2-[2-[2-[2-(pentacosa-10,12-diynoylamino)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]propanoylamino]pentoxy]-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid DMNQ7DV CA CAS 1261156-82-4 DMNQ7DV DE Cachexia DM3XT5V ID DM3XT5V DM3XT5V DN APD371 DM3XT5V HS Phase 2 DM3XT5V SN Olorinab; UNII-581F7DFA9B; 581F7DFA9B; Olorinab [USAN]; SCHEMBL11995430; 1268881-20-4; (4aS,5aS)-N-((2S)-1-hydroxy-3,3-dimethylbutan-2-yl)-1-(4-oxidopyrazin-2-yl)-4,4a,5,5a-tetrahydro-1H-cyclopropa(4,5)cyclopenta(1,2-c)pyrazole-3-carboxamide; 1H-Cyclopropa(4,5)cyclopenta(1,2-c)pyrazole-3-carboxamide, 4,4a,5,5a-tetrahydro-N-((1S)-1-(hydroxymethyl)-2,2-dimethylpropyl)-1-(4-oxido-2-pyrazinyl)-, (4aS,5aS)-; (1aS,5aS)-2-(4-Oxy-pyrazin-2-yl)-1a,2,5,5a-tetrahydro-1H-2,3-diaza-cyclopropa(a)pentalene-4-carboxylic aci DM3XT5V CP Arena Pharmaceuticals San Diego, CA DM3XT5V PC 60164925 DM3XT5V MW 357.4 DM3XT5V FM C18H23N5O3 DM3XT5V IC InChI=1S/C18H23N5O3/c1-18(2,3)13(9-24)20-17(25)15-12-7-10-6-11(10)16(12)23(21-15)14-8-22(26)5-4-19-14/h4-5,8,10-11,13,24H,6-7,9H2,1-3H3,(H,20,25)/t10-,11-,13+/m0/s1 DM3XT5V CS CC(C)(C)[C@@H](CO)NC(=O)C1=NN(C2=C1C[C@H]3[C@@H]2C3)C4=NC=C[N+](=C4)[O-] DM3XT5V IK ACSQLTBPYZSGBA-GMXVVIOVSA-N DM3XT5V IU (2S,4S)-N-[(2S)-1-hydroxy-3,3-dimethylbutan-2-yl]-9-(4-oxidopyrazin-4-ium-2-yl)-8,9-diazatricyclo[4.3.0.02,4]nona-1(6),7-diene-7-carboxamide DM3XT5V CA CAS 1268881-20-4 DM3XT5V DE Crohn disease DM1VITS ID DM1VITS DM1VITS DN APD-403 DM1VITS HS Phase 2 DM1VITS CP Acacia Pharma Ltd DM1VITS DE Vomiting DM9LZ0M ID DM9LZ0M DM9LZ0M DN APD-515 DM9LZ0M HS Phase 2 DM9LZ0M SN ACA-1515 DM9LZ0M CP Acacia Pharma Ltd DM9LZ0M DE Xerostomia DM0FXMZ ID DM0FXMZ DM0FXMZ DN APG-101 DM0FXMZ HS Phase 2 DM0FXMZ SN CD95 receptor extracellular domain-IgG fused protein (GvHD), Apogenix; CD95 receptor extracellular domain-IgG fused protein (myocardial infarction), Apogenix; CD95 receptor extracellular domain-IgG fused protein (stroke), Apogenix; CD95 receptor extracellular domain-immunoglobulin G fused protein (graft versus hostdisease), Apogenix DM0FXMZ CP Apogenix GmbH DM0FXMZ DE Cerebrovascular ischaemia DMIFA0L ID DMIFA0L DMIFA0L DN APG-115 DMIFA0L HS Phase 2 DMIFA0L SN 15Qau0SI9J; 15QAU0SI9J; UNII-15QAU0SI9J; 1818393-16-6; APG 115 [WHO-DD]; SCHEMBL17189805; Bicyclo(2.2.2)octane-1-carboxylic acid, 4-((((3'R,4'S,5'R)-6''-chloro-4'-(3-chloro-2-fluorophenyl)-1'-ethyl-1'',2''-dihydro-2''-oxodispiro(cyclohexane-1,2'-pyrrolidine-3',3''-(3H)indol)-5'-yl)carbonyl)amino)- DMIFA0L CP Ascentage Pharma Rockville, MD DMIFA0L PC 91972012 DMIFA0L MW 642.6 DMIFA0L FM C34H38Cl2FN3O4 DMIFA0L IC InChI=1S/C34H38Cl2FN3O4/c1-2-40-27(28(41)39-32-16-13-31(14-17-32,15-18-32)30(43)44)25(21-7-6-8-23(36)26(21)37)34(33(40)11-4-3-5-12-33)22-10-9-20(35)19-24(22)38-29(34)42/h6-10,19,25,27H,2-5,11-18H2,1H3,(H,38,42)(H,39,41)(H,43,44)/t25-,27+,31?,32?,34+/m0/s1 DMIFA0L CS CCN1[C@H]([C@@H]([C@]2(C13CCCCC3)C4=C(C=C(C=C4)Cl)NC2=O)C5=C(C(=CC=C5)Cl)F)C(=O)NC67CCC(CC6)(CC7)C(=O)O DMIFA0L IK YJCZPJQGFSSFOL-MNZPCBJKSA-N DMIFA0L CA CAS 1818393-16-6 DMIFA0L DE Solid tumour/cancer; Prolymphocytic leukaemia DM756GE ID DM756GE DM756GE DN APH-0812 DM756GE HS Phase 2 DM756GE SN Bryostatin-1 + HDAC inhibitor combination (HIV-1 infection), Aphios DM756GE CP Aphios Corp DM756GE DE Human immunodeficiency virus-1 infection; Human immunodeficiency virus infection DMHIS6Z ID DMHIS6Z DMHIS6Z DN Apilimod DMHIS6Z HS Phase 2 DMHIS6Z SN Apilimod; STA 5326; STA-5326; GFW2K84S4L; STA5326; Apilimod [INN]; EX-A908 DMHIS6Z TC Antiviral Agents DMHIS6Z DT Small molecular drug DMHIS6Z PC 10173277 DMHIS6Z MW 418.5 DMHIS6Z FM C23H26N6O2 DMHIS6Z IC InChI=1S/C23H26N6O2/c1-18-5-4-6-19(15-18)17-25-28-21-16-22(29-10-13-30-14-11-29)27-23(26-21)31-12-8-20-7-2-3-9-24-20/h2-7,9,15-17H,8,10-14H2,1H3,(H,26,27,28)/b25-17+ DMHIS6Z CS CC1=CC(=CC=C1)/C=N/NC2=CC(=NC(=N2)OCCC3=CC=CC=N3)N4CCOCC4 DMHIS6Z IK HSKAZIJJKRAJAV-KOEQRZSOSA-N DMHIS6Z IU N-[(E)-(3-methylphenyl)methylideneamino]-6-morpholin-4-yl-2-(2-pyridin-2-ylethoxy)pyrimidin-4-amine DMHIS6Z CA CAS 541550-19-0 DMHIS6Z DE Coronavirus Disease 2019 (COVID-19) DM4N2O0 ID DM4N2O0 DM4N2O0 DN Apilimod dimesylate DM4N2O0 HS Phase 2 DM4N2O0 CP LAM Therapeutics Guilford, CT DM4N2O0 PC 11527330 DM4N2O0 MW 610.7 DM4N2O0 FM C25H34N6O8S2 DM4N2O0 IC InChI=1S/C23H26N6O2.2CH4O3S/c1-18-5-4-6-19(15-18)17-25-28-21-16-22(29-10-13-30-14-11-29)27-23(26-21)31-12-8-20-7-2-3-9-24-20;2*1-5(2,3)4/h2-7,9,15-17H,8,10-14H2,1H3,(H,26,27,28);2*1H3,(H,2,3,4)/b25-17+;; DM4N2O0 CS CC1=CC(=CC=C1)/C=N/NC2=CC(=NC(=N2)OCCC3=CC=CC=N3)N4CCOCC4.CS(=O)(=O)O.CS(=O)(=O)O DM4N2O0 IK GAJWNIKZLYZYSY-OKUPSQOASA-N DM4N2O0 IU methanesulfonic acid;N-[(E)-(3-methylphenyl)methylideneamino]-6-morpholin-4-yl-2-(2-pyridin-2-ylethoxy)pyrimidin-4-amine DM4N2O0 CA CAS 870087-36-8 DM4N2O0 DE Non-hodgkin lymphoma DM7IGO9 ID DM7IGO9 DM7IGO9 DN Apimostinel DM7IGO9 HS Phase 2 DM7IGO9 SN UNII-TTT1F11FZB; TTT1F11FZB; 1421866-48-9; Apimostinel [USAN]; SCHEMBL14682282; CHEMBL3989872; DB11784; Threonyl-prolyl-2R-(2-benzyl)-prolyl-threonine amide; L-Threoninamide, L-threonyl-L-prolyl-2-(phenylmethyl)-L-prolyl- DM7IGO9 CP Allergan Parsippany, NJ DM7IGO9 PC 71249967 DM7IGO9 MW 503.6 DM7IGO9 FM C25H37N5O6 DM7IGO9 IC InChI=1S/C25H37N5O6/c1-15(31)19(26)23(35)29-12-6-10-18(29)22(34)30-13-7-11-25(30,14-17-8-4-3-5-9-17)24(36)28-20(16(2)32)21(27)33/h3-5,8-9,15-16,18-20,31-32H,6-7,10-14,26H2,1-2H3,(H2,27,33)(H,28,36)/t15-,16-,18+,19+,20+,25-/m1/s1 DM7IGO9 CS C[C@H]([C@@H](C(=O)N1CCC[C@H]1C(=O)N2CCC[C@@]2(CC3=CC=CC=C3)C(=O)N[C@@H]([C@@H](C)O)C(=O)N)N)O DM7IGO9 IK DVBUEXCIEIAXPM-PJUQSVSOSA-N DM7IGO9 IU (2R)-1-[(2S)-1-[(2S,3R)-2-amino-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]-N-[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]-2-benzylpyrrolidine-2-carboxamide DM7IGO9 CA CAS 1421866-48-9 DM7IGO9 DE Major depressive disorder DMP0LST ID DMP0LST DMP0LST DN APL-101 DMP0LST HS Phase 2 DMP0LST SN Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine DMP0LST CP Apollomics DMP0LST DT Small molecular drug DMP0LST PC 72202701 DMP0LST MW 424.4 DMP0LST FM C20H15F3N8 DMP0LST IC InChI=1S/C20H15F3N8/c1-29-9-11-6-14(15(21)7-17(11)27-29)20(22,23)19-26-25-18-5-4-16(28-31(18)19)12-8-24-30(10-12)13-2-3-13/h4-10,13H,2-3H2,1H3 DMP0LST CS CN1C=C2C=C(C(=CC2=N1)F)C(C3=NN=C4N3N=C(C=C4)C5=CN(N=C5)C6CC6)(F)F DMP0LST IK QHXLXUIZUCJRKV-UHFFFAOYSA-N DMP0LST IU 6-(1-cyclopropylpyrazol-4-yl)-3-[difluoro-(6-fluoro-2-methylindazol-5-yl)methyl]-[1,2,4]triazolo[4,3-b]pyridazine DMP0LST CA CAS 1440964-89-5 DMP0LST DE Non-small cell lung cancer DMGJ1X2 ID DMGJ1X2 DMGJ1X2 DN Aplindore fumarate DMGJ1X2 HS Phase 2 DMGJ1X2 SN Aplindore; Aplindore fumarate (USAN); WAY-DAB-452; (2S)-2-[(benzylamino)methyl]-2,3,7,9-tetrahydro-[1,4]dioxino[2,3-e]indol-8-one; 8H-1,4-Dioxino(2,3-e)indol-8-one,2,3,7,9-tetrahydro-2-(((phenylmethyl)amino)methyl)-,2(S)-, (2E)-2-butenediotate (1:1) DMGJ1X2 CP Wyeth DMGJ1X2 DT Small molecular drug DMGJ1X2 PC 6440763 DMGJ1X2 MW 426.4 DMGJ1X2 FM C22H22N2O7 DMGJ1X2 IC InChI=1S/C18H18N2O3.C4H4O4/c21-17-8-14-15(20-17)6-7-16-18(14)23-13(11-22-16)10-19-9-12-4-2-1-3-5-12;5-3(6)1-2-4(7)8/h1-7,13,19H,8-11H2,(H,20,21);1-2H,(H,5,6)(H,7,8)/b;2-1+/t13-;/m0./s1 DMGJ1X2 CS C1[C@@H](OC2=C(O1)C=CC3=C2CC(=O)N3)CNCC4=CC=CC=C4.C(=C/C(=O)O)\\C(=O)O DMGJ1X2 IK GELJVTSEGKGLDF-QDSMGTAFSA-N DMGJ1X2 IU (2S)-2-[(benzylamino)methyl]-2,3,7,9-tetrahydro-[1,4]dioxino[2,3-e]indol-8-one;(E)-but-2-enedioic acid DMGJ1X2 CA CAS 189681-71-8 DMGJ1X2 DE Schizophrenia DMGNFBC ID DMGNFBC DMGNFBC DN APN301 DMGNFBC HS Phase 2 DMGNFBC SN MAb hu14.18 linked with IL-2 DMGNFBC CP Apeiron Biologics DMGNFBC DT Antibody DMGNFBC DE Neuroblastoma DM32YTJ ID DM32YTJ DM32YTJ DN APN-301 DM32YTJ HS Phase 2 DM32YTJ SN EMD-273063; Ch14.18-IL-2; Hu14.18-IL-2 DM32YTJ CP Apeiron biologics DM32YTJ DE Melanoma; Neuroblastoma DMEXN7V ID DMEXN7V DMEXN7V DN APN401 DMEXN7V HS Phase 2 DMEXN7V SN APN-411; E3 ubiquitin protein ligase Cbl-b silencing siRNA therapeutics (cancer); Cbl-b modulators (cancer), Apeiron Biologics; E3 ubiquitin ligase casitas B cell lymphoma-b silencing siRNA therapeutics (cancer), Apeiron Biologics; E3 ubiquitin protein ligase Cbl-b silencing siRNA therapeutics (cancer), Apeiron Biologics DMEXN7V CP Apeiron Biologics DMEXN7V DT Small interfering RNA DMEXN7V DE Solid tumour/cancer DMKVP7E ID DMKVP7E DMKVP7E DN Apolizumab DMKVP7E HS Phase 2 DMKVP7E SN Remitogen; Hu 1D10; Hu1D10, PDL; SMART 1D10 MAb, Protein Design Labs; SMART anti-B cell lymphoma DMKVP7E CP PDL BioPharma DMKVP7E DT Monoclonal antibody DMKVP7E DE Solid tumour/cancer DM6B9HP ID DM6B9HP DM6B9HP DN Apomine DM6B9HP HS Phase 2 DM6B9HP SN Apomine; SR-45023A; UNII-JQ95208805; JQ95208805; SR-9223i; SR 45023A; APB-231-A2; SKF 99085; F-99085; 126411-13-0; SCHEMBL1648488; AC1L423G; DB12276; 4-[2,2-bis[di(propan-2-yloxy)phosphoryl]ethyl]-2,6-ditert-butylphenol; tetraisopropyl 2-(3,5-di-tert-butyl-4-hydroxyphenyl)ethyl-1,1-biphosphonate; Phosphonic acid, (2-(3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl)ethylidene)bis-, tetrakis(1-methylethyl); SK&F-99085; 2-(3,5-Di-tert-butyl-4-hydroxyphenyl)ethylidene-1,1-diphosphonic acid tetraisopropyl ester; SR-45023A (Apomine) DM6B9HP CP Genzyme DM6B9HP DT Small molecular drug DM6B9HP PC 176405 DM6B9HP MW 562.7 DM6B9HP FM C28H52O7P2 DM6B9HP IC InChI=1S/C28H52O7P2/c1-18(2)32-36(30,33-19(3)4)25(37(31,34-20(5)6)35-21(7)8)17-22-15-23(27(9,10)11)26(29)24(16-22)28(12,13)14/h15-16,18-21,25,29H,17H2,1-14H3 DM6B9HP CS CC(C)OP(=O)(C(CC1=CC(=C(C(=C1)C(C)(C)C)O)C(C)(C)C)P(=O)(OC(C)C)OC(C)C)OC(C)C DM6B9HP IK YLJOVCWVJCDPLN-UHFFFAOYSA-N DM6B9HP IU 4-[2,2-bis[di(propan-2-yloxy)phosphoryl]ethyl]-2,6-ditert-butylphenol DM6B9HP CA CAS 126411-13-0 DM6B9HP DE Osteopetrosis DMNFADH ID DMNFADH DMNFADH DN APR-246 DMNFADH HS Phase 2 DMNFADH SN Eprenetapopt DMNFADH CP Aprea Therapeutics DMNFADH DT Small molecular drug DMNFADH PC 52918385 DMNFADH MW 199.25 DMNFADH FM C10H17NO3 DMNFADH IC InChI=1S/C10H17NO3/c1-14-7-10(6-12)9(13)8-2-4-11(10)5-3-8/h8,12H,2-7H2,1H3 DMNFADH CS COCC1(C(=O)C2CCN1CC2)CO DMNFADH IK BGBNULCRKBVAKL-UHFFFAOYSA-N DMNFADH IU 2-(hydroxymethyl)-2-(methoxymethyl)-1-azabicyclo[2.2.2]octan-3-one DMNFADH CA CAS 5291-32-7 DMNFADH DE Solid tumour/cancer; Ovarian cancer; Esophageal cancer; Myelodysplastic syndrome; Bladder cancer; Gastric adenocarcinoma DM8W4N9 ID DM8W4N9 DM8W4N9 DN Apratastat DM8W4N9 HS Phase 2 DM8W4N9 SN TMI-005; TMI-05; UNII-C6BZ5263BJ; 287405-51-0; C6BZ5263BJ; CHEMBL206815; TMI 005; Apratastat [USAN:INN]; Apratastat (USAN/INN); MLS006010301; SCHEMBL2834310; GTPL6482; TMI005; Apratastat, > MolPort-021-805-014; BCPP000041; ZINC28571311; BDBM50181008; DB13020; API0013699; compound 5h [PMID: 16426848]; SMR004701369; 4CA-0170; D08859; 3-Thiomorpholinecarboxamide,N-hydroxy-4-[[4-[(4-hydroxy-2-butyn-1-yl)oxy]phenyl]sulfonyl]-2,2-dimethyl-,(3S)-; TMI-1; Dual TACE/MMP-13 inhibitors (inflammation), Wyeth; Dual TACE/MMP-13 inhibitors (rheumatoid arthritis), Wyeth; Dual TACE/MMP-13 inhibitors, Wyeth-Ayerst DM8W4N9 CP Wyeth Research DM8W4N9 DT Small molecular drug DM8W4N9 PC 11452716 DM8W4N9 MW 414.5 DM8W4N9 FM C17H22N2O6S2 DM8W4N9 IC InChI=1S/C17H22N2O6S2/c1-17(2)15(16(21)18-22)19(9-12-26-17)27(23,24)14-7-5-13(6-8-14)25-11-4-3-10-20/h5-8,15,20,22H,9-12H2,1-2H3,(H,18,21)/t15-/m0/s1 DM8W4N9 CS CC1([C@@H](N(CCS1)S(=O)(=O)C2=CC=C(C=C2)OCC#CCO)C(=O)NO)C DM8W4N9 IK MAVDNGWEBZTACC-HNNXBMFYSA-N DM8W4N9 IU (3S)-N-hydroxy-4-[4-(4-hydroxybut-2-ynoxy)phenyl]sulfonyl-2,2-dimethylthiomorpholine-3-carboxamide DM8W4N9 CA CAS 287405-51-0 DM8W4N9 DE Rheumatoid arthritis DMEJICQ ID DMEJICQ DMEJICQ DN Aprocitentan DMEJICQ HS Phase 2 DMEJICQ SN ACT-132577; UNII-MZI81HV01P; 1103522-45-7; Despropyl Macitentan; MZI81HV01P; CHEMBL2165326; CHEBI:76609; Macitentan metabolite; ACT 132577; SCHEMBL3646065; ZINC95553608; BDBM50395672; AKOS028114466; CS-2687; HY-15895; BC600808; 5-(4-bromophenyl)-4-[2-(5-bromopyrimidin-2-yl)oxyethoxy]-6-(sulfamoylamino)pyrimidine; N-[5-(4-bromophenyl)-6-{2-[(5-bromopyrimidin-2-yl)oxy]ethoxy}pyrimidin-4-yl]sulfuric diamide DMEJICQ CP Idorsia Pharmaceuticals Allschwil, Switzerland Janssen Biotech Horsham, PA DMEJICQ PC 25099191 DMEJICQ MW 546.2 DMEJICQ FM C16H14Br2N6O4S DMEJICQ IC InChI=1S/C16H14Br2N6O4S/c17-11-3-1-10(2-4-11)13-14(24-29(19,25)26)22-9-23-15(13)27-5-6-28-16-20-7-12(18)8-21-16/h1-4,7-9H,5-6H2,(H2,19,25,26)(H,22,23,24) DMEJICQ CS C1=CC(=CC=C1C2=C(N=CN=C2OCCOC3=NC=C(C=N3)Br)NS(=O)(=O)N)Br DMEJICQ IK DKULOVKANLVDEA-UHFFFAOYSA-N DMEJICQ IU 5-(4-bromophenyl)-4-[2-(5-bromopyrimidin-2-yl)oxyethoxy]-6-(sulfamoylamino)pyrimidine DMEJICQ CA CAS 1103522-45-7 DMEJICQ CB CHEBI:76609 DMEJICQ DE Hypertension DMX2P5G ID DMX2P5G DMX2P5G DN APX005M DMX2P5G HS Phase 2 DMX2P5G CP Apexigen San Carlos, CA DMX2P5G DT Antibody DMX2P5G DE Solid tumour/cancer; Brain cancer; Chronic lymphocytic leukaemia; Melanoma DMU6NBO ID DMU6NBO DMU6NBO DN APX3330 DMU6NBO HS Phase 2 DMU6NBO SN E3330; 136164-66-4; E-3330; E 3330; CHEMBL578390; UNII-11267UI968; 11267UI968; (2E)-2-[(4,5-dimethoxy-2-methyl-3,6-dioxocyclohexa-1,4-dien-1-yl)methylidene]undecanoic acid; (E)-2-((4,5-dimethoxy-2-methyl-3,6-dioxocyclohexa-1,4-dien-1-yl)methylene)undecanoic acid; (2E)-3-(5-(2,3-Dimethoxy-6-methyl-1,4-benzoquinoyl))-2-nonyl-2-propenoic acid; SCHEMBL3758716; SCHEMBL3758719; HMS3886N15; APX 3330; EX-A2212; BDBM50303955; s7445; ZINC14252145; CCG-268389; HY-19357; B5875; CS-0015424; E3330, >=98% (HPLC); A14440; (E)-3-(4,5-dimethoxy-2-methyl-3,6-dioxocyclohexa-1,4-dienyl)-2-nonylpropenoic acid; (E)-3-(5,6-Dimethoxy-3-methyl-14-dioxocyclohexa-25-dienyl)-2-nonylpropenoic Acid; Undecanoic acid, 2-((4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methylene)-, (E)- DMU6NBO CP Apexian Pharmaceuticals DMU6NBO DT Small molecular drug DMU6NBO PC 6439397 DMU6NBO MW 378.5 DMU6NBO FM C21H30O6 DMU6NBO IC InChI=1S/C21H30O6/c1-5-6-7-8-9-10-11-12-15(21(24)25)13-16-14(2)17(22)19(26-3)20(27-4)18(16)23/h13H,5-12H2,1-4H3,(H,24,25)/b15-13+ DMU6NBO CS CCCCCCCCC/C(=C\\C1=C(C(=O)C(=C(C1=O)OC)OC)C)/C(=O)O DMU6NBO IK AALSSIXXBDPENJ-FYWRMAATSA-N DMU6NBO IU (2E)-2-[(4,5-dimethoxy-2-methyl-3,6-dioxocyclohexa-1,4-dien-1-yl)methylidene]undecanoic acid DMU6NBO CA CAS 136164-66-4 DMU6NBO DE Solid tumour/cancer; Diabetic retinopathy DM1USXR ID DM1USXR DM1USXR DN AQ-13 DM1USXR HS Phase 2 DM1USXR SN AQ-13 Dihydrochloride; 169815-40-1; UNII-PKT9732S5K; AQ 13; PKT9732S5K; DTXSID10168761; (N1-(7-Chloroquinolin-4-yl)-3-(N3,N3-diethylamino)propylamine) dihydrochloride; HY-100358; CS-0018673; 1,3-Propanediamine, N'-(7-chloro-4-quinolinyl)-N,N-diethyl-, dihydrochloride DM1USXR CP Tulane University DM1USXR DT Small molecular drug DM1USXR PC 9820475 DM1USXR MW 364.7 DM1USXR FM C16H24Cl3N3 DM1USXR IC InChI=1S/C16H22ClN3.2ClH/c1-3-20(4-2)11-5-9-18-15-8-10-19-16-12-13(17)6-7-14(15)16;;/h6-8,10,12H,3-5,9,11H2,1-2H3,(H,18,19);2*1H DM1USXR CS CCN(CC)CCCNC1=C2C=CC(=CC2=NC=C1)Cl.Cl.Cl DM1USXR IK ZNHBPWZRWNFJPN-UHFFFAOYSA-N DM1USXR IU N-(7-chloroquinolin-4-yl)-N',N'-diethylpropane-1,3-diamine;dihydrochloride DM1USXR CA CAS 169815-40-1 DM1USXR DE Malaria DMD2RFO ID DMD2RFO DMD2RFO DN AQW-051 DMD2RFO HS Phase 2 DMD2RFO SN AQW-051; 669770-29-0; (R)-3-((6-(p-Tolyl)pyridin-3-yl)oxy)quinuclidine; AQW051; NPDLTEZXGWRMLQ-IBGZPJMESA-N; UNII-JQH481R778; SCHEMBL1459285; GTPL7371; SCHEMBL19522679; JQH481R778; ZINC3942685; AKOS030628482; SB17130; AS-35273; (R)-3-(6-p-tolyl-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane DMD2RFO CP Novartis AG DMD2RFO DT Small molecular drug DMD2RFO PC 50914822 DMD2RFO MW 294.4 DMD2RFO FM C19H22N2O DMD2RFO IC InChI=1S/C19H22N2O/c1-14-2-4-15(5-3-14)18-7-6-17(12-20-18)22-19-13-21-10-8-16(19)9-11-21/h2-7,12,16,19H,8-11,13H2,1H3/t19-/m0/s1 DMD2RFO CS CC1=CC=C(C=C1)C2=NC=C(C=C2)O[C@H]3CN4CCC3CC4 DMD2RFO IK NPDLTEZXGWRMLQ-IBGZPJMESA-N DMD2RFO IU (3R)-3-[6-(4-methylphenyl)pyridin-3-yl]oxy-1-azabicyclo[2.2.2]octane DMD2RFO DE Alzheimer disease DMCH3G5 ID DMCH3G5 DMCH3G5 DN AQX-1125 DMCH3G5 HS Phase 2 DMCH3G5 SN AQX-108; AQX-131; AQX-132; AQX-133; AQX-134; AQX-135; AQX-140; AQX-150; SHIP agonists (cancer/inflammation), Aquinox DMCH3G5 CP Aquinox Pharmaceuticals Inc DMCH3G5 DT Small molecular drug DMCH3G5 PC 76965484 DMCH3G5 MW 321.5 DMCH3G5 FM C20H35NO2 DMCH3G5 IC InChI=1S/C20H35NO2/c1-13-4-5-17-16(11-21)18(7-9-19(13,17)2)20(3)8-6-15(23)10-14(20)12-22/h14-18,22-23H,1,4-12,21H2,2-3H3/t14-,15+,16+,17+,18+,19-,20+/m1/s1 DMCH3G5 CS C[C@@]1(CC[C@@H](C[C@@H]1CO)O)[C@H]2CC[C@]3([C@H]([C@@H]2CN)CCC3=C)C DMCH3G5 IK MDEJTPWQNNMAQF-BVMLLJBZSA-N DMCH3G5 IU (1S,3S,4R)-4-[(3aS,4R,5S,7aS)-4-(aminomethyl)-7a-methyl-1-methylidene-3,3a,4,5,6,7-hexahydro-2H-inden-5-yl]-3-(hydroxymethyl)-4-methylcyclohexan-1-ol DMCH3G5 CA CAS 782487-28-9 DMCH3G5 DE Chronic obstructive pulmonary disease DM93CTQ ID DM93CTQ DM93CTQ DN AR08 DM93CTQ HS Phase 2 DM93CTQ CP Arbor pharmaceuticals DM93CTQ DE Attention deficit hyperactivity disorder DM5TC43 ID DM5TC43 DM5TC43 DN AR-12286 DM5TC43 HS Phase 2 DM5TC43 SN AR-11236; AR-12080; AR-12132; CF-286-03; CF-286-04 DM5TC43 CP Aerie Pharmaceuticals Inc DM5TC43 PC 66906051 DM5TC43 MW 327.4 DM5TC43 FM C17H17N3O2S DM5TC43 IC InChI=1S/C17H17N3O2S/c1-20(2)15(12-6-8-23-10-12)17(22)19-13-3-4-14-11(9-13)5-7-18-16(14)21/h3-10,15H,1-2H3,(H,18,21)(H,19,22) DM5TC43 CS CN(C)C(C1=CSC=C1)C(=O)NC2=CC3=C(C=C2)C(=O)NC=C3 DM5TC43 IK VDYRZXYYQMMFJW-UHFFFAOYSA-N DM5TC43 IU 2-(dimethylamino)-N-(1-oxo-2H-isoquinolin-6-yl)-2-thiophen-3-ylacetamide DM5TC43 CA CAS 1414854-42-4 DM5TC43 DE Glaucoma/ocular hypertension DM8A71F ID DM8A71F DM8A71F DN AR-67 DM8A71F HS Phase 2 DM8A71F SN AR-67; Silatecan; 220913-32-6; DB-67; UNII-3YEA04NV6H; 3YEA04NV6H; DB67; AR67; AR 67; (20S)-7-t-Butyldimethylsilyl-10-hydroxycamptothecin; NCI60_038363; C26H30N2O5Si; SCHEMBL1266162; CHEMBL412309; GTPL8919; DTXSID00176592; DB 67; BCP19768; 7555AD; NSC708298; ZINC170020689; AKOS030627314; DB12384; NSC-708298; compound 14 [PMID:11052802]; KB-74723; Z3398; Z-3160; 1H-pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione, 11-((1,1-dimethylethyl)dimethylsilyl)-4-ethyl-4,9-dihydroxy-, (4S)- DM8A71F CP Arno Therapeutics DM8A71F DT Small molecular drug DM8A71F PC 6712744 DM8A71F MW 478.6 DM8A71F FM C26H30N2O5Si DM8A71F IC InChI=1S/C26H30N2O5Si/c1-7-26(32)18-11-20-21-16(12-28(20)23(30)17(18)13-33-24(26)31)22(34(5,6)25(2,3)4)15-10-14(29)8-9-19(15)27-21/h8-11,29,32H,7,12-13H2,1-6H3/t26-/m0/s1 DM8A71F CS CC[C@@]1(C2=C(COC1=O)C(=O)N3CC4=C(C5=C(C=CC(=C5)O)N=C4C3=C2)[Si](C)(C)C(C)(C)C)O DM8A71F IK XUSKJHCMMWAAHV-SANMLTNESA-N DM8A71F IU (19S)-10-[tert-butyl(dimethyl)silyl]-19-ethyl-7,19-dihydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaene-14,18-dione DM8A71F CA CAS 220913-32-6 DM8A71F DE Myelodysplastic syndrome; Glioblastoma multiforme DMJHA6Q ID DMJHA6Q DMJHA6Q DN Ar9281 DMJHA6Q HS Phase 2 DMJHA6Q SN 1-(Adamantane-1-yl)-3-(1-acetylpiperidine-4-yl)urea; UNII-4HA03Q8EZ9; 4HA03Q8EZ9; CHEMBL436774; 1-[(1-Acetylpiperidin-4-yl)-3-adamantan-1-yl]urea; 913548-29-5; Ar9281; AR-9281; Apau (enzyme inhibitor); SCHEMBL654229; 1-(1-Acetyl-piperidin-4-yl)-3-adamantan-1-yl-urea; SCHEMBL18464997; MolPort-023-222-910; HUDQLWBKJOMXSZ-UHFFFAOYSA-N; BDBM100423; BDBM50191854; ZINC36330562; AKOS030231617; J3137087F; US8501783, 1153; 1-(adamant-1-yl)-3-(1-acetylpiperidin-4-yl) urea; N-(1-Acetylpiperidin-4-yl)-N'-(adamant-1-yl) urea; N-(1-acetylpiperidin-4-yl)-N'-(adamant-1-yl)urea DMJHA6Q CP Ar te Therapeutics DMJHA6Q DT Small molecular drug DMJHA6Q PC 12000797 DMJHA6Q MW 319.4 DMJHA6Q FM C18H29N3O2 DMJHA6Q IC InChI=1S/C18H29N3O2/c1-12(22)21-4-2-16(3-5-21)19-17(23)20-18-9-13-6-14(10-18)8-15(7-13)11-18/h13-16H,2-11H2,1H3,(H2,19,20,23) DMJHA6Q CS CC(=O)N1CCC(CC1)NC(=O)NC23CC4CC(C2)CC(C4)C3 DMJHA6Q IK HUDQLWBKJOMXSZ-UHFFFAOYSA-N DMJHA6Q IU 1-(1-acetylpiperidin-4-yl)-3-(1-adamantyl)urea DMJHA6Q CA CAS 913548-29-5 DMJHA6Q DE Hypertension DM7PCLY ID DM7PCLY DM7PCLY DN ARC1779 DM7PCLY HS Phase 2 DM7PCLY CP Archemix DM7PCLY DT Small molecular drug DM7PCLY DE Intracranial embolism DM9LNXS ID DM9LNXS DM9LNXS DN ARI-3037MO DM9LNXS HS Phase 2 DM9LNXS CP Arisaph Pharmaceuticals DM9LNXS DE Dyslipidemia; Cardiovascular disease; Hypertriglyceridemia DML3PJF ID DML3PJF DML3PJF DN ARN-810 DML3PJF HS Phase 2 DML3PJF CP Seragon pharmaceuticals DML3PJF PC 56941241 DML3PJF MW 446.9 DML3PJF FM C26H20ClFN2O2 DML3PJF IC InChI=1S/C26H20ClFN2O2/c1-2-21(22-10-9-20(28)14-23(22)27)26(18-8-11-24-19(13-18)15-29-30-24)17-6-3-16(4-7-17)5-12-25(31)32/h3-15H,2H2,1H3,(H,29,30)(H,31,32)/b12-5+,26-21+ DML3PJF CS CC/C(=C(/C1=CC=C(C=C1)/C=C/C(=O)O)\\C2=CC3=C(C=C2)NN=C3)/C4=C(C=C(C=C4)F)Cl DML3PJF IK BURHGPHDEVGCEZ-KJGLQBJMSA-N DML3PJF IU (E)-3-[4-[(E)-2-(2-chloro-4-fluorophenyl)-1-(1H-indazol-5-yl)but-1-enyl]phenyl]prop-2-enoic acid DML3PJF CA CAS 1365888-06-7 DML3PJF DE Breast cancer DM2UP6Z ID DM2UP6Z DM2UP6Z DN ARO-AAT DM2UP6Z HS Phase 2 DM2UP6Z CP Arrowhead Pharmaceuticals DM2UP6Z DT Small interfering RNA DM2UP6Z DE Alpha-1 antitrypsin deficiency; Alopecia DM5WK0J ID DM5WK0J DM5WK0J DN ARQ 092 DM5WK0J HS Phase 2 DM5WK0J SN Miransertib DM5WK0J CP ArQule; Daiichi DM5WK0J PC 53262401 DM5WK0J MW 432.5 DM5WK0J FM C27H24N6 DM5WK0J IC InChI=1S/C27H24N6/c28-24-21(8-4-17-30-24)25-32-23-14-13-22(18-6-2-1-3-7-18)31-26(23)33(25)20-11-9-19(10-12-20)27(29)15-5-16-27/h1-4,6-14,17H,5,15-16,29H2,(H2,28,30) DM5WK0J CS C1CC(C1)(C2=CC=C(C=C2)N3C4=C(C=CC(=N4)C5=CC=CC=C5)N=C3C6=C(N=CC=C6)N)N DM5WK0J IK HNFMVVHMKGFCMB-UHFFFAOYSA-N DM5WK0J IU 3-[3-[4-(1-aminocyclobutyl)phenyl]-5-phenylimidazo[4,5-b]pyridin-2-yl]pyridin-2-amine DM5WK0J CA CAS 1313881-70-7 DM5WK0J DE Solid tumour/cancer; Proteus syndrome DMRG0A3 ID DMRG0A3 DMRG0A3 DN ARQ 531 DMRG0A3 HS Phase 2 DMRG0A3 SN JSFCZQSJQXFJDS-QAPCUYQASA-N; UNII-JTZ51LIXN4; JTZ51LIXN4; 2095393-15-8; ARQ-531; ARQ531; SCHEMBL18770934; SCHEMBL18756744; EX-A2727; BCP29029; HY-112215; CS-0044154; HRA; (2-Chloro-4-phenoxyphenyl)(4-(((3R,6S)-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl)amino)-7H-pyrrolo(2,3-d)pyrimidin-5-yl)methanone; 1,5-anhydro-2-{[5-(2-chloro-4-phenoxybenzene-1-carbonyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino}-2,3,4-trideoxy-D-erythro-hexitol DMRG0A3 CP ArQule Burlington, MA DMRG0A3 PC 129045720 DMRG0A3 MW 478.9 DMRG0A3 FM C25H23ClN4O4 DMRG0A3 IC InChI=1S/C25H23ClN4O4/c26-21-10-17(34-16-4-2-1-3-5-16)8-9-19(21)23(32)20-11-27-24-22(20)25(29-14-28-24)30-15-6-7-18(12-31)33-13-15/h1-5,8-11,14-15,18,31H,6-7,12-13H2,(H2,27,28,29,30)/t15-,18+/m1/s1 DMRG0A3 CS C1C[C@H](OC[C@@H]1NC2=NC=NC3=C2C(=CN3)C(=O)C4=C(C=C(C=C4)OC5=CC=CC=C5)Cl)CO DMRG0A3 IK JSFCZQSJQXFJDS-QAPCUYQASA-N DMRG0A3 IU (2-chloro-4-phenoxyphenyl)-[4-[[(3R,6S)-6-(hydroxymethyl)oxan-3-yl]amino]-7H-pyrrolo[2,3-d]pyrimidin-5-yl]methanone DMRG0A3 CA CAS 2095393-15-8 DMRG0A3 DE Hematologic tumour DMH5CAL ID DMH5CAL DMH5CAL DN ARQ 761 DMH5CAL HS Phase 2 DMH5CAL CP ArQule DMH5CAL DE Solid tumour/cancer; Pancreatic cancer DMYEIOH ID DMYEIOH DMYEIOH DN ARQ-154 DMYEIOH HS Phase 2 DMYEIOH CP Arcutis Biotherapeutics DMYEIOH DT Small molecular drug DMYEIOH DE Plaque psoriasis DM0VGDC ID DM0VGDC DM0VGDC DN ARRY-382 DM0VGDC HS Phase 2 DM0VGDC CP Array BioPharma; Celgene DM0VGDC DE Solid tumour/cancer DM17469 ID DM17469 DM17469 DN ARRY-502 DM17469 HS Phase 2 DM17469 CP Array BioPharma DM17469 PC 131633366 DM17469 MW 516.4 DM17469 FM C26H23Cl2NO6 DM17469 IC InChI=1S/C26H23Cl2NO6/c1-33-22-12-17(27)5-2-15(22)8-10-29-25(30)16-3-6-18(7-4-16)35-24-14-23-20(13-21(24)28)19(26(31)32)9-11-34-23/h2-7,12-14,19H,8-11H2,1H3,(H,29,30)(H,31,32)/t19-/m0/s1 DM17469 CS COC1=C(C=CC(=C1)Cl)CCNC(=O)C2=CC=C(C=C2)OC3=C(C=C4[C@H](CCOC4=C3)C(=O)O)Cl DM17469 IK QIDYUNXQPQEJEC-IBGZPJMESA-N DM17469 IU (4S)-6-chloro-7-[4-[2-(4-chloro-2-methoxyphenyl)ethylcarbamoyl]phenoxy]-3,4-dihydro-2H-chromene-4-carboxylic acid DM17469 CA CAS 1202891-16-4 DM17469 DE Allergic asthma DMTOI7S ID DMTOI7S DMTOI7S DN ARRY-520 DMTOI7S HS Phase 2 DMTOI7S SN Filanesib; ARRY-520; 885060-09-3; UNII-8A49OSO368; Arry520; CHEMBL2347655; ARRY 520 trifluoroacetate; 8A49OSO368; ARRY 520; (2S)-2-(3-aminopropyl)-5-(2,5-difluorophenyl)-N-methoxy-N-methyl-2-phenyl-1,3,4-thiadiazole-3(2H)-carboxamide; Filanesib [INN]; Filanesib [USAN:INN]; C20H22F2N4O2S; ARRY-520; Filanesib; 1385020-40-5; Filanesib(ARRY-520); SCHEMBL368043; DTXSID50237086; EX-A678; BCP07442; ZINC43204022; 3452AH; BDBM50431893; AKOS030526964; SB19209; RL05514; CS-0867; NCGC00381751-02; NCGC00381751-04 DMTOI7S CP Array BioPharma. DMTOI7S TC Anticancer Agents DMTOI7S DT Small molecular drug DMTOI7S PC 44224257 DMTOI7S MW 420.5 DMTOI7S FM C20H22F2N4O2S DMTOI7S IC InChI=1S/C20H22F2N4O2S/c1-25(28-2)19(27)26-20(11-6-12-23,14-7-4-3-5-8-14)29-18(24-26)16-13-15(21)9-10-17(16)22/h3-5,7-10,13H,6,11-12,23H2,1-2H3/t20-/m0/s1 DMTOI7S CS CN(C(=O)N1[C@](SC(=N1)C2=C(C=CC(=C2)F)F)(CCCN)C3=CC=CC=C3)OC DMTOI7S IK LLXISKGBWFTGEI-FQEVSTJZSA-N DMTOI7S IU (2S)-2-(3-aminopropyl)-5-(2,5-difluorophenyl)-N-methoxy-N-methyl-2-phenyl-1,3,4-thiadiazole-3-carboxamide DMTOI7S CA CAS 885060-09-3 DMTOI7S DE Solid tumour/cancer; Multiple myeloma DMJ48AB ID DMJ48AB DMJ48AB DN ARRY-797 DMJ48AB HS Phase 2 DMJ48AB SN CHEMBL1088750; ARRY-797; SCHEMBL222635; ARRY-371797; BDBM50314072 DMJ48AB CP Array BioPharma. DMJ48AB TC Analgesics DMJ48AB DT Small molecular drug DMJ48AB PC 46883775 DMJ48AB MW 416.5 DMJ48AB FM C22H26F2N4O2 DMJ48AB IC InChI=1S/C22H26F2N4O2/c1-14(2)13-28-19-11-17(22(29)25-7-8-27(3)4)21(9-15(19)12-26-28)30-20-6-5-16(23)10-18(20)24/h5-6,9-12,14H,7-8,13H2,1-4H3,(H,25,29) DMJ48AB CS CC(C)CN1C2=CC(=C(C=C2C=N1)OC3=C(C=C(C=C3)F)F)C(=O)NCCN(C)C DMJ48AB IK IFGWYHGYNVGVRB-UHFFFAOYSA-N DMJ48AB IU 5-(2,4-difluorophenoxy)-N-[2-(dimethylamino)ethyl]-1-(2-methylpropyl)indazole-6-carboxamide DMJ48AB DE Pain; Osteoarthritis; Dilated cardiomyopathy DML27AE ID DML27AE DML27AE DN Arverapamil DML27AE HS Phase 2 DML27AE SN Arverapamil; (R)-norverapamil; Agi-003; UNII-3J8P56R04P; (R)-(+)-Nor Verapamil Hydrochloride; 123932-43-4; 3J8P56R04P; Rezular; (+)-norverapamil; (R)-desmethylverapamil; (+)-desmethylverapamil; CHEBI:134082; ZINC13492624; AKOS030532539; Benzeneacetonitrile, alpha-(3-((2-(3,4-dimethoxyphenyl)ethyl)amino)propyl)-3,4-dimethoxy-alpha-(1-methylethyl)-, (alphaR)-; UNII-957Z3K3R56 component UPKQNCPKPOLASS-AREMUKBSSA-N DML27AE CP AGI Therapeutics DML27AE DT Small molecular drug DML27AE PC 15593907 DML27AE MW 440.6 DML27AE FM C26H36N2O4 DML27AE IC InChI=1S/C26H36N2O4/c1-19(2)26(18-27,21-9-11-23(30-4)25(17-21)32-6)13-7-14-28-15-12-20-8-10-22(29-3)24(16-20)31-5/h8-11,16-17,19,28H,7,12-15H2,1-6H3/t26-/m1/s1 DML27AE CS CC(C)[C@@](CCCNCCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC DML27AE IK UPKQNCPKPOLASS-AREMUKBSSA-N DML27AE IU (2R)-2-(3,4-dimethoxyphenyl)-5-[2-(3,4-dimethoxyphenyl)ethylamino]-2-propan-2-ylpentanenitrile DML27AE CA CAS 123932-43-4 DML27AE CB CHEBI:134082 DML27AE DE Irritable bowel syndrome DMMX1EJ ID DMMX1EJ DMMX1EJ DN AS-1402 DMMX1EJ HS Phase 2 DMMX1EJ SN Therex; R-1550; HuHMFG1 derivative, ICRF/Antisoma/Roche; Anti-mucin MAb, ICRF/Antisoma/Roche DMMX1EJ CP Antisoma DMMX1EJ DT Antibody DMMX1EJ DE Breast cancer DMTUMYX ID DMTUMYX DMTUMYX DN AS-902330 DMTUMYX HS Phase 2 DMTUMYX SN Sprifermin; Zfgf5; FGF-18, Merck Serono; FGF-18, ZymoGenetics DMTUMYX CP Emd serono DMTUMYX DE Arthropathy DMNVU28 ID DMNVU28 DMNVU28 DN ASB17061 DMNVU28 HS Phase 2 DMNVU28 CP Daiichi Sankyo DMNVU28 DE Atopic dermatitis DMMBVCJ ID DMMBVCJ DMMBVCJ DN ASCJ-9 DMMBVCJ HS Phase 2 DMMBVCJ SN Dimethylcurcumin; ASC-JMX1; ASCJ-9; ASCJ-9 (systemic), AndroScience; ASCJ-9 (topical), AndroScience; Androgen antagonist (alopecia/acne), AndroScience; Androgen receptor degradation enhancers (oral, spinal bulbar muscular atrophy), AndroScience DMMBVCJ CP AndroScience DMMBVCJ DE Alopecia; Acne vulgaris DMDQS4W ID DMDQS4W DMDQS4W DN ASC-J9 DMDQS4W HS Phase 2 DMDQS4W SN Dimethylcurcumin; 52328-98-0; 917813-54-8; ASCJ-9; (1E,4Z,6E)-1,7-bis(3,4-dimethoxyphenyl)-5-hydroxyhepta-1,4,6-trien-3-one; 1,7-Bis-(3,4-dimethoxyphenyl)-5-hydroxy-hepta-1,4,6-trien-3-one; 1,7-Bis-(3,4-dimethoxy-phenyl)-5-hydroxy-hepta-1,4,6-trien-3-one; GO-Y-025; (1E,4E,6E)-1,7-Bis(3,4-dimethoxyphenyl)-5-hydroxyhepta-1,4,6-trien-3-one; Dimethylcurcumin (ASC-J9); 1,7-Bis(3,4-dimethoxyphenyl)-5-hydroxyhepta-1,4,6-trien-3-one; SCHEMBL3487103; CHC-004; DTXSID10200352; EX-A927; AMY15692; 3454AH; MFCD12912341; MFCD22123809; NSC734923; RSC004738; s6630; AKOS015891371; AKOS025311328; ZINC100007120; CS-0533; DB06133; LS40141; NSC-734923; SB18767; 1,4,6-Heptatrien-3-one, 1,7-bis(3,4-dimethoxyphenyl)-5-hydroxy-, (1E,4Z,6E)--; 1,4,6-Heptatrien-3-one, 1,7-bis(3,4-dimethoxyphenyl)-5-hydroxy-, (Z,E,E)-; AC-31058; DS-14720; HY-15194; ASC-J9,CAS:52328-98-0; W9512; J3.606.945G; A11300; W-5544; GO-Y025; Dimethylcurcumin; ASC J9; GO Y025; 1, 4-dimethoxyphenyl)-1, 6-heptadiene-3,5-dione; (1E,6E)-1,7-Bis(3,4-dimethoxyphenyl)-5-hydroxy-1,4,6-heptatriene-3-one; 1,7-Bis-(3,4-dimethoxy-phenyl)- 5-hydroxy-hepta-1,4,6-trien-3-one; (1E,4Z,6E)-1,7-bis(3,4-dimethoxyphenyl)-5-hydroxy-1,4,6-heptatrien-3-one; (1E,4Z,6E)-1,7-Bis(3,4-dimethoxyphenyl)-5-hydroxy-1,4,6-heptatriene-3-one; (1E,4Z,6E)-1,7-bis(3,4-dimethoxyphenyl)-5-hydroxy-hepta-1,4,6-trien-3-one; 115851-85-9 DMDQS4W CP AndroScience DMDQS4W DT Small molecular drug DMDQS4W PC 6477182 DMDQS4W MW 396.4 DMDQS4W FM C23H24O6 DMDQS4W IC InChI=1S/C23H24O6/c1-26-20-11-7-16(13-22(20)28-3)5-9-18(24)15-19(25)10-6-17-8-12-21(27-2)23(14-17)29-4/h5-15,24H,1-4H3/b9-5+,10-6+,18-15- DMDQS4W CS COC1=C(C=C(C=C1)/C=C/C(=C/C(=O)/C=C/C2=CC(=C(C=C2)OC)OC)/O)OC DMDQS4W IK ZMGUKFHHNQMKJI-CIOHCNBKSA-N DMDQS4W IU (1E,4Z,6E)-1,7-bis(3,4-dimethoxyphenyl)-5-hydroxyhepta-1,4,6-trien-3-one DMDQS4W CA CAS 52328-98-0 DMDQS4W DE Thrombosis; End-stage renal disease DMZF68E ID DMZF68E DMZF68E DN Ascrolimus DMZF68E HS Phase 2 DMZF68E SN A-86281; ABT-281; ZK-248258 DMZF68E CP Abbott Laboratories DMZF68E PC 9919023 DMZF68E MW 844 DMZF68E FM C44H69N5O11 DMZF68E IC InChI=1S/C44H69N5O11/c1-10-31-18-25(2)17-26(3)19-37(57-8)40-38(58-9)21-28(5)44(55,60-40)41(52)42(53)48-16-12-11-13-33(48)43(54)59-39(29(6)34(50)23-35(31)51)27(4)20-30-14-15-32(36(22-30)56-7)49-24-45-46-47-49/h18,20,24,26,28-34,36-40,50,55H,10-17,19,21-23H2,1-9H3/b25-18+,27-20+/t26-,28+,29+,30-,31+,32-,33-,34-,36+,37-,38-,39+,40+,44+/m0/s1 DMZF68E CS CC[C@@H]1/C=C(/C[C@@H](C[C@@H]([C@@H]2[C@H](C[C@H]([C@@](O2)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@@H]([C@@H]([C@H](CC1=O)O)C)/C(=C/[C@@H]4CC[C@@H]([C@@H](C4)OC)N5C=NN=N5)/C)O)C)OC)OC)C)\\C DMZF68E IK HIEKJRVYXXINKH-ADVKXBNGSA-N DMZF68E IU (1R,9S,12S,13R,14S,17R,18E,21S,23S,24R,25S,27R)-17-ethyl-1,14-dihydroxy-23,25-dimethoxy-12-[(E)-1-[(1R,3R,4S)-3-methoxy-4-(tetrazol-1-yl)cyclohexyl]prop-1-en-2-yl]-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.04,9]octacos-18-ene-2,3,10,16-tetrone DMZF68E CA CAS 148147-65-3 DMZF68E DE Psoriasis vulgaris DM1CLKO ID DM1CLKO DM1CLKO DN ASKP-1240 DM1CLKO HS Phase 2 DM1CLKO SN Anti-CD40 mAb (organ transplant rejection/autoimmune disease), Kirin/Astellas; Anti-CD40 mAb (organ transplant rejection/autoimmune disease), Kyowa Hakko Kirin/Astellas; 4D11 DM1CLKO CP Astellas pharma us; kyowa hakko kirin pharma DM1CLKO DT Antibody DM1CLKO DE Transplant rejection DM35S2I ID DM35S2I DM35S2I DN ASM-024 DM35S2I HS Phase 2 DM35S2I CP Asmacure Lt |e DM35S2I PC 117587641 DM35S2I MW 404.6 DM35S2I FM C22H32N2O3S DM35S2I IC InChI=1S/C15H25N2.C7H8O3S/c1-3-17(4-2)13-8-11-16(12-14-17)15-9-6-5-7-10-15;1-6-2-4-7(5-3-6)11(8,9)10/h5-7,9-10H,3-4,8,11-14H2,1-2H3;2-5H,1H3,(H,8,9,10)/q+1;/p-1 DM35S2I CS CC[N+]1(CCCN(CC1)C2=CC=CC=C2)CC.CC1=CC=C(C=C1)S(=O)(=O)[O-] DM35S2I IK PXRYYARWCNIUKT-UHFFFAOYSA-M DM35S2I IU 1,1-diethyl-4-phenyl-1,4-diazepan-1-ium;4-methylbenzenesulfonate DM35S2I CA CAS 1609534-90-8 DM35S2I DE Asthma DMTHR4U ID DMTHR4U DMTHR4U DN ASM8 DMTHR4U HS Phase 2 DMTHR4U CP Pharmaxis DMTHR4U DT Antisense drug DMTHR4U DE Allergic asthma DM92X7N ID DM92X7N DM92X7N DN ASN002 DM92X7N HS Phase 2 DM92X7N SN POAZPIKWEFFCBP-UHFFFAOYSA-N; GTPL10000; 2-[1-(4-{[4-(4-hydroxypiperazin-1-yl)phenyl]amino}-5-oxo-5H,6H-pyrimido[4,5-d]pyridazin-2-yl)piperidin-4-yl]acetonitrile DM92X7N CP Asana BioSciences Lawrenceville, NJ DM92X7N PC 71269142 DM92X7N MW 460.5 DM92X7N FM C24H28N8O2 DM92X7N IC InChI=1S/C24H28N8O2/c25-10-5-16-6-11-32(12-7-16)24-28-20-15-26-30-23(34)21(20)22(29-24)27-17-1-3-18(4-2-17)31-13-8-19(33)9-14-31/h1-4,15-16,19,33H,5-9,11-14H2,(H,30,34)(H,27,28,29) DM92X7N CS C1CN(CCC1CC#N)C2=NC3=C(C(=O)NN=C3)C(=N2)NC4=CC=C(C=C4)N5CCC(CC5)O DM92X7N IK NLFLXLJXEIUQDL-UHFFFAOYSA-N DM92X7N IU 2-[1-[4-[4-(4-hydroxypiperidin-1-yl)anilino]-5-oxo-6H-pyrimido[4,5-d]pyridazin-2-yl]piperidin-4-yl]acetonitrile DM92X7N CA CAS 1425381-60-7 DM92X7N DE Eczema; Lymphoma; Solid tumour/cancer DMWPGLS ID DMWPGLS DMWPGLS DN ASN100 DMWPGLS HS Phase 2 DMWPGLS CP Arsanis DMWPGLS DT Monoclonal antibody DMWPGLS DE Ventilator-associated pneumonia; Hospital-acquired pneumonia DM6HJ3V ID DM6HJ3V DM6HJ3V DN ASP0819 DM6HJ3V HS Phase 2 DM6HJ3V CP Astellas Pharma DM6HJ3V DT Small molecular drug DM6HJ3V DE Fibromyalgia DME8XD7 ID DME8XD7 DME8XD7 DN ASP-1707 DME8XD7 HS Phase 2 DME8XD7 CP Astellas Pharma Inc DME8XD7 DE Endometriosis DMBADQV ID DMBADQV DMBADQV DN ASP-3291 DMBADQV HS Phase 2 DMBADQV CP Astellas Pharma Inc DMBADQV DE Ulcerative colitis DM4KTN6 ID DM4KTN6 DM4KTN6 DN ASP-3652 DM4KTN6 HS Phase 2 DM4KTN6 SN FK-175; Beta 3 adrenoceptor agonists (overactive bladder), Astellas DM4KTN6 CP Astellas Pharma Inc DM4KTN6 DE Overactive bladder DMZUAH2 ID DMZUAH2 DMZUAH2 DN ASP-4901 DMZUAH2 HS Phase 2 DMZUAH2 CP Astellas Pharma DMZUAH2 DE Genitourinary disease DMTF24A ID DMTF24A DMTF24A DN ASP-7035 DMTF24A HS Phase 2 DMTF24A CP Astellas Pharma Inc DMTF24A PC 11478371 DMTF24A MW 548.4 DMTF24A FM C25H23F7N2O4 DMTF24A IC InChI=1S/C25H23F7N2O4/c1-14(26)13-38-16-3-4-17(20(11-16)25(30,31)32)23(37)34-8-6-24(28,29)19(12-22(36)33-7-9-35)18-10-15(27)2-5-21(18)34/h2-5,10-12,14,35H,6-9,13H2,1H3,(H,33,36)/b19-12-/t14-/m1/s1 DMTF24A CS C[C@H](COC1=CC(=C(C=C1)C(=O)N2CCC(/C(=C\\C(=O)NCCO)/C3=C2C=CC(=C3)F)(F)F)C(F)(F)F)F DMTF24A IK VSXSHTIGQAUGMW-VCRXTVNUSA-N DMTF24A IU (2Z)-N-(2-hydroxyethyl)-2-[4,4,7-trifluoro-1-[4-[(2R)-2-fluoropropoxy]-2-(trifluoromethyl)benzoyl]-2,3-dihydro-1-benzazepin-5-ylidene]acetamide DMTF24A CA CAS 790694-26-7 DMTF24A DE Nocturia DMGDF2X ID DMGDF2X DMGDF2X DN ASP-7147 DMGDF2X HS Phase 2 DMGDF2X CP Astellas Pharma Inc DMGDF2X DE Irritable bowel syndrome DM3TN1A ID DM3TN1A DM3TN1A DN ASP7991 DM3TN1A HS Phase 2 DM3TN1A CP Astellas DM3TN1A DE Hyperparathyroidism DMR1MIV ID DMR1MIV DMR1MIV DN ASP8062 DMR1MIV HS Phase 2 DMR1MIV CP Astellas Northbrook, IL DMR1MIV DE Fibromyalgia DMYK1JU ID DMYK1JU DMYK1JU DN ASP8232 DMYK1JU HS Phase 2 DMYK1JU CP Astellas DMYK1JU DE Diabetic nephropathy; Diabetic macular edema DMHLXUY ID DMHLXUY DMHLXUY DN ASP8273 DMHLXUY HS Phase 2 DMHLXUY CP Astellas pharma us DMHLXUY PC 71667668 DMHLXUY MW 562.7 DMHLXUY FM C30H42N8O3 DMHLXUY IC InChI=1S/C30H42N8O3/c1-4-25-30(41-24-12-15-38(20-24)26(39)5-2)34-29(27(33-25)28(31)40)32-21-6-8-22(9-7-21)36-13-10-23(11-14-36)37-18-16-35(3)17-19-37/h5-9,23-24H,2,4,10-20H2,1,3H3,(H2,31,40)(H,32,34)/t24-/m1/s1 DMHLXUY CS CCC1=C(N=C(C(=N1)C(=O)N)NC2=CC=C(C=C2)N3CCC(CC3)N4CCN(CC4)C)O[C@@H]5CCN(C5)C(=O)C=C DMHLXUY IK QKDCLUARMDUUKN-XMMPIXPASA-N DMHLXUY IU 6-ethyl-3-[4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]anilino]-5-[(3R)-1-prop-2-enoylpyrrolidin-3-yl]oxypyrazine-2-carboxamide DMHLXUY CA CAS 1448232-80-1 DMHLXUY DE Non-small-cell lung cancer DMBZQS7 ID DMBZQS7 DMBZQS7 DN ASP-8477 DMBZQS7 HS Phase 2 DMBZQS7 CP Astellas Pharma Inc DMBZQS7 DE Neuropathic pain DM2MSGF ID DM2MSGF DM2MSGF DN ASP9831 DM2MSGF HS Phase 2 DM2MSGF CP Astellas DM2MSGF DT Small molecular drug DM2MSGF DE Steatohepatitis; Non-alcoholic steatohepatitis DMMKW8L ID DMMKW8L DMMKW8L DN ASTX660 DMMKW8L HS Phase 2 DMMKW8L SN YCXOHEXZVKOGEV-DNRQZRRGSA-N; 1799328-86-1; SCHEMBL16830758; CS-8216; HY-109565; 1-(6-(4-fluorobenzyl)-5-(hydroxymethyl)-3,3-dimethyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)-2-((2R,5R)-5-methyl-2-(((R)-3-methylmorpholino)methyl)piperazin-1-yl)ethan-1-one DMMKW8L CP Astex Pharmaceuticals Pleasanton, CA DMMKW8L PC 118169620 DMMKW8L MW 539.7 DMMKW8L FM C30H42FN5O3 DMMKW8L IC InChI=1S/C30H42FN5O3/c1-20-14-35(25(13-32-20)15-34-9-10-39-18-21(34)2)16-28(38)36-19-30(3,4)29-27(36)12-23(26(17-37)33-29)11-22-5-7-24(31)8-6-22/h5-8,12,20-21,25,32,37H,9-11,13-19H2,1-4H3/t20-,21-,25-/m1/s1 DMMKW8L CS C[C@@H]1CN([C@H](CN1)CN2CCOC[C@H]2C)CC(=O)N3CC(C4=C3C=C(C(=N4)CO)CC5=CC=C(C=C5)F)(C)C DMMKW8L IK YCXOHEXZVKOGEV-DNRQZRRGSA-N DMMKW8L IU 1-[6-[(4-fluorophenyl)methyl]-5-(hydroxymethyl)-3,3-dimethyl-2H-pyrrolo[3,2-b]pyridin-1-yl]-2-[(2R,5R)-5-methyl-2-[[(3R)-3-methylmorpholin-4-yl]methyl]piperazin-1-yl]ethanone DMMKW8L CA CAS 1799328-86-1 DMMKW8L DE Solid tumour/cancer; Lymphoma DMARIQK ID DMARIQK DMARIQK DN AT-527 DMARIQK HS Phase 2 DMARIQK SN AT527; SCHEMBL18061556; GTPL11295; 2241337-84-6; propan-2-yl (2S)-2-[[[(3R,4R,5R)-5-[2-amino-6-(methylamino)purin-9-yl]-4-fluoro-3-hydroxy-4-methyloxolan-2-yl]methoxy-phenoxyphosphoryl]amino]propanoate DMARIQK CP Atea Pharmaceuticals DMARIQK DT Small molecular drug DMARIQK PC 122527270 DMARIQK MW 581.5 DMARIQK FM C24H33FN7O7P DMARIQK IC InChI=1S/C24H33FN7O7P/c1-13(2)37-21(34)14(3)31-40(35,39-15-9-7-6-8-10-15)36-11-16-18(33)24(4,25)22(38-16)32-12-28-17-19(27-5)29-23(26)30-20(17)32/h6-10,12-14,16,18,22,33H,11H2,1-5H3,(H,31,35)(H3,26,27,29,30)/t14-,16?,18+,22+,24+,40-/m0/s1 DMARIQK CS C[C@@H](C(=O)OC(C)C)N[P@](=O)(OCC1[C@H]([C@@]([C@@H](O1)N2C=NC3=C(N=C(N=C32)N)NC)(C)F)O)OC4=CC=CC=C4 DMARIQK IK OISLSHLAXHALQZ-ZXWZJMKMSA-N DMARIQK IU propan-2-yl (2S)-2-[[[(3R,4R,5R)-5-[2-amino-6-(methylamino)purin-9-yl]-4-fluoro-3-hydroxy-4-methyloxolan-2-yl]methoxy-phenoxyphosphoryl]amino]propanoate DMARIQK DE Coronavirus Disease 2019 (COVID-19) DM35KDA ID DM35KDA DM35KDA DN Ataciguat DM35KDA HS Phase 2 DM35KDA SN Ataciguat [INN]; HMR 1766; HMR-1766; 5-Chloro-2-((5-chloro-2-thienyl)sulfonylamino)-N-(4-(morpholin-4-ylsulfonyl)phenyl)benzamide; 5-Chloro-2-(5-chlorothiophene-2-sulfonylamino)-N-(4-(morpholine-4-sulfonyl)phenyl)benzamide; 5-chloro-2-[(5-chlorothiophen-2-yl)sulfonylamino]-N-(4-morpholin-4-ylsulfonylphenyl)benzamide DM35KDA CP Sanofi-Aventis DM35KDA TC Analgesics DM35KDA DT Small molecular drug DM35KDA PC 213037 DM35KDA MW 576.5 DM35KDA FM C21H19Cl2N3O6S3 DM35KDA IC InChI=1S/C21H19Cl2N3O6S3/c22-14-1-6-18(25-34(28,29)20-8-7-19(23)33-20)17(13-14)21(27)24-15-2-4-16(5-3-15)35(30,31)26-9-11-32-12-10-26/h1-8,13,25H,9-12H2,(H,24,27) DM35KDA CS C1COCCN1S(=O)(=O)C2=CC=C(C=C2)NC(=O)C3=C(C=CC(=C3)Cl)NS(=O)(=O)C4=CC=C(S4)Cl DM35KDA IK PQHLRGARXNPFCF-UHFFFAOYSA-N DM35KDA IU 5-chloro-2-[(5-chlorothiophen-2-yl)sulfonylamino]-N-(4-morpholin-4-ylsulfonylphenyl)benzamide DM35KDA CA CAS 254877-67-3 DM35KDA DE Neuropathic pain DM6ABD9 ID DM6ABD9 DM6ABD9 DN ATHX-105 DM6ABD9 HS Phase 2 DM6ABD9 SN ATH-88651; 5-HT2c receptor agonists (obesity), Athersys Inc DM6ABD9 CP Athersys DM6ABD9 DE Obesity DMWP59B ID DMWP59B DMWP59B DN ATI-2042 DMWP59B HS Phase 2 DMWP59B SN Budiodarone DMWP59B CP ARYx Therapeutics DMWP59B DT Small molecular drug DMWP59B PC 9833332 DMWP59B MW 703.3 DMWP59B FM C27H31I2NO5 DMWP59B IC InChI=1S/C27H31I2NO5/c1-5-17(4)34-24(31)16-23-25(19-10-8-9-11-22(19)35-23)26(32)18-14-20(28)27(21(29)15-18)33-13-12-30(6-2)7-3/h8-11,14-15,17H,5-7,12-13,16H2,1-4H3/t17-/m0/s1 DMWP59B CS CC[C@H](C)OC(=O)CC1=C(C2=CC=CC=C2O1)C(=O)C3=CC(=C(C(=C3)I)OCCN(CC)CC)I DMWP59B IK ZXOSVKYCXLTVGS-KRWDZBQOSA-N DMWP59B IU [(2S)-butan-2-yl] 2-[3-[4-[2-(diethylamino)ethoxy]-3,5-diiodobenzoyl]-1-benzofuran-2-yl]acetate DMWP59B CA CAS 335148-45-3 DMWP59B DE Atrial fibrillation DMT5QYJ ID DMT5QYJ DMT5QYJ DN ATI-2173 DMT5QYJ HS Phase 2 DMT5QYJ CP Antios Therapeutics DMT5QYJ DT Small molecular drug DMT5QYJ DE Hepatitis B DMTY6OF ID DMTY6OF DMTY6OF DN ATI-501 DMTY6OF HS Phase 2 DMTY6OF CP Aclaris Therapeutics DMTY6OF DT Small molecular drug DMTY6OF DE Alopecia DM8NODR ID DM8NODR DM8NODR DN ATI-502 DM8NODR HS Phase 2 DM8NODR SN ifidancitinib; UNII-R105E71J13; R105E71J13; A-301; 5-[[2-(4-fluoro-3-methoxy-5-methylanilino)-5-methylpyrimidin-4-yl]amino]-3H-1,3-benzoxazol-2-one; Ifidancitinib [INN]; SCHEMBL342002; CHEMBL4594441; GTPL10638; 2(3H)-Benzoxazolone, 5-((2-((4-fluoro-3-methoxy-5-methylphenyl)amino)-5-methyl-4-pyrimidinyl)amino)-; 5-((2-((4-Fluoro-3-methoxy-5-methylphenyl)amino)-5-methyl-4-pyrimidinyl)amino)-2(3H)-benzoxazolone; 5-((2-(4-Fluoro-3-methoxy-5-methylphenylamino)-5-methylpyrimidin-4-yl)amino)benzo(d)oxazol-2(3H)-one; 5-(2-(4-fluoro-3-methoxy-5-methylphenylamino)-5-methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3h)-one DM8NODR CP Aclaris Therapeutics DM8NODR DT Small molecular drug DM8NODR PC 46851625 DM8NODR MW 395.4 DM8NODR FM C20H18FN5O3 DM8NODR IC InChI=1S/C20H18FN5O3/c1-10-6-13(8-16(28-3)17(10)21)24-19-22-9-11(2)18(26-19)23-12-4-5-15-14(7-12)25-20(27)29-15/h4-9H,1-3H3,(H,25,27)(H2,22,23,24,26) DM8NODR CS CC1=CC(=CC(=C1F)OC)NC2=NC=C(C(=N2)NC3=CC4=C(C=C3)OC(=O)N4)C DM8NODR IK OYFMQDVLFYKOPZ-UHFFFAOYSA-N DM8NODR IU 5-[[2-(4-fluoro-3-methoxy-5-methylanilino)-5-methylpyrimidin-4-yl]amino]-3H-1,3-benzoxazol-2-one DM8NODR CA CAS 1236667-40-5 DM8NODR DE Atopic dermatitis; Alopecia DMK3VYU ID DMK3VYU DMK3VYU DN ATI-502 DMK3VYU HS Phase 2 DMK3VYU CP Aclaris Therapeutics Wayne, PA DMK3VYU DE Atopic dermatitis; Vitiligo DMYAQV2 ID DMYAQV2 DMYAQV2 DN ATL101 DMYAQV2 HS Phase 2 DMYAQV2 CP Atlab pharma; weill medical college DMYAQV2 DE Influenza virus infection DMD0I29 ID DMD0I29 DMD0I29 DN ATL-104 DMD0I29 HS Phase 2 DMD0I29 DE Solid tumour/cancer DM3POT6 ID DM3POT6 DM3POT6 DN ATL1102 DM3POT6 HS Phase 2 DM3POT6 CP ISIS Pharm; Antisense Therapeutics DM3POT6 DE Multiple sclerosis DM7I56B ID DM7I56B DM7I56B DN ATM AVI DM7I56B HS Phase 2 DM7I56B CP AstraZeneca DM7I56B DE Bacterial infection DM4T9RS ID DM4T9RS DM4T9RS DN ATN-161 DM4T9RS HS Phase 2 DM4T9RS SN PHSCN; PHSCN, University of Michigan; Angiogenesis inhibitors (cancer), Attenuon; Integrin antagonists (cancer), Attenuon; Ac-PHSCN-NH2, University of Michigan DM4T9RS CP University of Michigan DM4T9RS DT Small molecular drug DM4T9RS PC 9960285 DM4T9RS MW 597.6 DM4T9RS FM C23H35N9O8S DM4T9RS IC InChI=1S/C23H35N9O8S/c1-11(34)32-4-2-3-17(32)23(40)29-14(5-12-7-26-10-27-12)20(37)30-15(8-33)21(38)31-16(9-41)22(39)28-13(19(25)36)6-18(24)35/h7,10,13-17,33,41H,2-6,8-9H2,1H3,(H2,24,35)(H2,25,36)(H,26,27)(H,28,39)(H,29,40)(H,30,37)(H,31,38)/t13-,14-,15-,16-,17-/m0/s1 DM4T9RS CS CC(=O)N1CCC[C@H]1C(=O)N[C@@H](CC2=CN=CN2)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(=O)N)C(=O)N DM4T9RS IK MMHDBUJXLOFTLC-WOYTXXSLSA-N DM4T9RS IU (2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-acetylpyrrolidine-2-carbonyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-3-sulfanylpropanoyl]amino]butanediamide DM4T9RS CA CAS 262438-43-7 DM4T9RS DE Renal cell carcinoma DMQJ5DV ID DMQJ5DV DMQJ5DV DN ATN-224 DMQJ5DV HS Phase 2 DMQJ5DV SN Angiogenesis inhibitor, Attenuon; Superoxide dismutase 1 inhibitor, Attenuon DMQJ5DV CP University of Michigan DMQJ5DV DT Small molecular drug DMQJ5DV PC 18442052 DMQJ5DV MW 434.6 DMQJ5DV FM C10H30MoN2O2S4 DMQJ5DV IC InChI=1S/2C5H14NO.Mo.2H2S.2S/c2*1-6(2,3)4-5-7;;;;;/h2*7H,4-5H2,1-3H3;;2*1H2;;/q2*+1;;;;;/p-2 DMQJ5DV CS C[N+](C)(C)CCO.C[N+](C)(C)CCO.[SH-].[SH-].S=[Mo]=S DMQJ5DV IK FSWNJZRQQVVVJT-UHFFFAOYSA-L DMQJ5DV IU bis(sulfanylidene)molybdenum;2-hydroxyethyl(trimethyl)azanium;sulfanide DMQJ5DV CA CAS 649749-10-0 DMQJ5DV DE Solid tumour/cancer DMUXO3Z ID DMUXO3Z DMUXO3Z DN AUS-131 DMUXO3Z HS Phase 2 DMUXO3Z SN AUS-131; S-Equol; (-)-(S)-Equol; (-)-Equol; (3S)-3-(4-hydroxyphenyl)-3,4-dihydro-2H-1-benzopyran-7-ol; (3S)-3-(4-hydroxyphenyl)chroman-7-ol; (S)-(-)-4',7-Isoflavandiol; (S)-3,4-Dihydro-3-(4-hydroxyphenyl)-2H-1-benzopyran-7-ol; (S)-3-(4-Hydroxyphenyl)chroman-7-ol; (S)-Equol; 2H-1-Benzopyran-7-ol, 3,4-dihydro-3-(4-hydroxyphenyl)-, (3S)-; 2T6D2HPX7Q; 4',7-Dihydroxyisoflavan; 4',7-Isoflavandiol; 531-95-3; 7,4'-dihydroxyisoflavan; CCRIS 9222; CHEBI:34741; CHEMBL198877; EINECS 208-522-2; Equol; UNII-2T6D2HPX7Q DMUXO3Z PC 91469 DMUXO3Z MW 242.27 DMUXO3Z FM C15H14O3 DMUXO3Z IC ADFCQWZHKCXPAJ-GFCCVEGCSA-N DMUXO3Z IU (3S)-3-(4-hydroxyphenyl)-3,4-dihydro-2H-chromen-7-ol DMUXO3Z DE Prostatic hyperplasia DMZMSQJ ID DMZMSQJ DMZMSQJ DN AUS-131 DMZMSQJ HS Phase 2 DMZMSQJ CP Ausio Pharmaceuticals DMZMSQJ PC 91469 DMZMSQJ MW 242.27 DMZMSQJ FM C15H14O3 DMZMSQJ IC InChI=1S/C15H14O3/c16-13-4-1-10(2-5-13)12-7-11-3-6-14(17)8-15(11)18-9-12/h1-6,8,12,16-17H,7,9H2/t12-/m1/s1 DMZMSQJ CS C1[C@H](COC2=C1C=CC(=C2)O)C3=CC=C(C=C3)O DMZMSQJ IK ADFCQWZHKCXPAJ-GFCCVEGCSA-N DMZMSQJ IU (3S)-3-(4-hydroxyphenyl)-3,4-dihydro-2H-chromen-7-ol DMZMSQJ CA CAS 531-95-3 DMZMSQJ CB CHEBI:34741 DMZMSQJ DE Hot flushes; Alzheimer disease DMN7VK1 ID DMN7VK1 DMN7VK1 DN AV-101 DMN7VK1 HS Phase 2 DMN7VK1 SN Anti-epileptic, VistaGen; L-4-chlorokynurenine; NMDA receptor antagonists, University of Maryland/VistaGen; 4-Cl-kynurenine, NIH/VistaGen; 7-Chlorokynurenic acid; 7-Cl-KYN; 7-Cl-KYNA, NIH DMN7VK1 CP Vistagen therapeutics DMN7VK1 PC 9859632 DMN7VK1 MW 242.66 DMN7VK1 FM C10H11ClN2O3 DMN7VK1 IC InChI=1S/C10H11ClN2O3/c11-5-1-2-6(7(12)3-5)9(14)4-8(13)10(15)16/h1-3,8H,4,12-13H2,(H,15,16)/t8-/m0/s1 DMN7VK1 CS C1=CC(=C(C=C1Cl)N)C(=O)C[C@@H](C(=O)O)N DMN7VK1 IK HQLHZNDJQSRKDT-QMMMGPOBSA-N DMN7VK1 IU (2S)-2-amino-4-(2-amino-4-chlorophenyl)-4-oxobutanoic acid DMN7VK1 CA CAS 153152-32-0 DMN7VK1 DE Neuropathic pain; Major depressive disorder DMDL9WU ID DMDL9WU DMDL9WU DN AV-201 DMDL9WU HS Phase 2 DMDL9WU SN AAV (amino acid decarboxylase), Avigen; AAV (tyrosine hydroxylase), Avigen; AAV gene therapy (Parkinsons), Avigen; AAV vector (AADC), Avigen; AAV vector (TH), Avigen; AAV-hAADC-2; Gene therapy (PD), Avigen; Gene therapy (Parkinsons disease), Avigen; Gene therapy (L-aromatic amino acid decarboxylase), Avigen DMDL9WU CP Avigen Inc DMDL9WU DE Parkinson disease DMASRP3 ID DMASRP3 DMASRP3 DN AVA-101 DMASRP3 HS Phase 2 DMASRP3 CP Avalanche biotechnologies DMASRP3 DE Age-related macular degeneration DMORJD4 ID DMORJD4 DMORJD4 DN AVB-500 DMORJD4 HS Phase 2 DMORJD4 CP Aravive DMORJD4 DT Protein DMORJD4 DE IgA nephropathy DMLAOHX ID DMLAOHX DMLAOHX DN Avdoralimab DMLAOHX HS Phase 2 DMLAOHX SN IPH5401 DMLAOHX TC Antiviral Agents DMLAOHX DT Monoclonal antibody DMLAOHX DE Coronavirus Disease 2019 (COVID-19) DMESMHU ID DMESMHU DMESMHU DN AVE-0657 DMESMHU HS Phase 2 DMESMHU SN IDDBCP219683 DMESMHU CP Sanofi DMESMHU DE Cheyne-stokes respiration DMA42BV ID DMA42BV DMA42BV DN AVE-2268 DMA42BV HS Phase 2 DMA42BV CP Aventis SA DMA42BV DE Diabetic complication DMQGI73 ID DMQGI73 DMQGI73 DN AVI-4557 DMQGI73 HS Phase 2 DMQGI73 CP AVI BioPharma DMQGI73 DT Antisense drug DMQGI73 DE Anxiety disorder DMUOYQR ID DMUOYQR DMUOYQR DN AVI-5126 DMUOYQR HS Phase 2 DMUOYQR SN Resten-CP; NeuGene (CABG), AVI DMUOYQR CP AVI BioPharma DMUOYQR DT Antisense drug DMUOYQR DE Coronary artery disease DMJFLBC ID DMJFLBC DMJFLBC DN AVN 101 DMJFLBC HS Phase 2 DMJFLBC CP Avineuro Pharmaceuticals DMJFLBC DE Anxiety disorder; Alzheimer disease; Cognitive impairment DMK2LGM ID DMK2LGM DMK2LGM DN AVN 322 DMK2LGM HS Phase 2 DMK2LGM CP Avineuro Pharmaceuticals DMK2LGM DE Alzheimer disease; Cognitive impairment DMOGFNI ID DMOGFNI DMOGFNI DN AVN-101 DMOGFNI HS Phase 2 DMOGFNI SN 1061354-48-0; UNII-XML910S5X8; XML910S5X8; 2,8-Dimethyl-5-phenethyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole hydrochloride; AVN-101 hydrochloride; AVN-101 HCl; SB18759; 1H-Pyrido(4,3-b)indole, 2,3,4,5-tetrahydro-2,8-dimethyl-5-(2-phenylethyl)-, hydrochloride (1:1) DMOGFNI CP Avineuro DMOGFNI DT Small molecular drug DMOGFNI PC 126843189 DMOGFNI MW 340.9 DMOGFNI FM C21H25ClN2 DMOGFNI IC InChI=1S/C21H24N2.ClH/c1-16-8-9-20-18(14-16)19-15-22(2)12-11-21(19)23(20)13-10-17-6-4-3-5-7-17;/h3-9,14H,10-13,15H2,1-2H3;1H DMOGFNI CS CC1=CC2=C(C=C1)N(C3=C2CN(CC3)C)CCC4=CC=CC=C4.Cl DMOGFNI IK RKLJJDFIWWRTEJ-UHFFFAOYSA-N DMOGFNI IU 2,8-dimethyl-5-(2-phenylethyl)-3,4-dihydro-1H-pyrido[4,3-b]indole;hydrochloride DMOGFNI CA CAS 1061354-48-0 DMOGFNI DE Cognitive impairment DMVADGZ ID DMVADGZ DMVADGZ DN AWD-12-281 DMVADGZ HS Phase 2 DMVADGZ SN GW-842470; AWD-12-343; AWD-12-281 (COPD), elbion/GlaxoSmithKline; AWD-12-281 (allergic rhinitis), elbion/GlaxoSmithKline; AWD-12-281 (asthma), elbion/GlaxoSmithKline; AWD-12-281 (inhaled), elbion/GlaxoSmithKline; AWD-12-281 (intranasal), elbion/GlaxoSmithKline; 842470 DMVADGZ CP ASTA Medica AG DMVADGZ DT Small molecular drug DMVADGZ PC 6918428 DMVADGZ MW 458.3 DMVADGZ FM C22H14Cl2FN3O3 DMVADGZ IC InChI=1S/C22H14Cl2FN3O3/c23-17-8-26-9-18(24)20(17)27-22(31)21(30)16-11-28(10-12-1-3-13(25)4-2-12)19-6-5-14(29)7-15(16)19/h1-9,11,29H,10H2,(H,26,27,31) DMVADGZ CS C1=CC(=CC=C1CN2C=C(C3=C2C=CC(=C3)O)C(=O)C(=O)NC4=C(C=NC=C4Cl)Cl)F DMVADGZ IK DPHDSIQHVGSITN-UHFFFAOYSA-N DMVADGZ IU N-(3,5-dichloropyridin-4-yl)-2-[1-[(4-fluorophenyl)methyl]-5-hydroxyindol-3-yl]-2-oxoacetamide DMVADGZ CA CAS 257892-33-4 DMVADGZ DE Rhinitis DMTAEMB ID DMTAEMB DMTAEMB DN AX-200 DMTAEMB HS Phase 2 DMTAEMB SN Filgrastim (stroke, ALS), Sygnis; Granulocyte colony stimulating factor (stroke, ALS), Sygnis; Granulocyte colony stimulating factor (intravenous, peripheral arterial occlusive disease/spinal cord injury/stroke/Parkinsons disease), Axaron; G-CSF (protein recombinant/iv, stroke/ALS/PAO/PD/SCI), Sygnis DMTAEMB CP SYGNIS Bioscience GmbH & Co KG DMTAEMB DE Cardiovascular disease DMTQ1Y3 ID DMTQ1Y3 DMTQ1Y3 DN AXL-1717 DMTQ1Y3 HS Phase 2 DMTQ1Y3 SN BVT-51004; IGF-1 inhibitors, Axelar/Biovitrum; IGF-1 inhibitors, Karolinska/Biovitrum; Insulin-like growth factor 1 inhibitors, Axelar/Biovitrum DMTQ1Y3 CP Axelar AB DMTQ1Y3 DT Small molecular drug DMTQ1Y3 PC 72435 DMTQ1Y3 MW 414.4 DMTQ1Y3 FM C22H22O8 DMTQ1Y3 IC InChI=1S/C22H22O8/c1-25-16-4-10(5-17(26-2)21(16)27-3)18-11-6-14-15(30-9-29-14)7-12(11)20(23)13-8-28-22(24)19(13)18/h4-7,13,18-20,23H,8-9H2,1-3H3/t13-,18+,19+,20-/m0/s1 DMTQ1Y3 CS COC1=CC(=CC(=C1OC)OC)[C@H]2[C@H]3[C@H](COC3=O)[C@H](C4=CC5=C(C=C24)OCO5)O DMTQ1Y3 IK YJGVMLPVUAXIQN-HAEOHBJNSA-N DMTQ1Y3 IU (5R,5aR,8aS,9R)-5-hydroxy-9-(3,4,5-trimethoxyphenyl)-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[5,6-f][1,3]benzodioxol-8-one DMTQ1Y3 CA CAS 477-47-4 DMTQ1Y3 CB CHEBI:75251 DMTQ1Y3 DE Solid tumour/cancer DM4CJNE ID DM4CJNE DM4CJNE DN AYX-1 DM4CJNE HS Phase 2 DM4CJNE DE Pain DMHFUJT ID DMHFUJT DMHFUJT DN AZ-01, PEGylated interferon-beta DMHFUJT HS Phase 2 DMHFUJT SN PEGylated interferon-beta (long-acting, multiple sclerosis), Allozyne; AZ-01, PEGylated interferon-beta (long-acting, multiple sclerosis); AZ-01, PEGylated interferon-beta (long-acting, multiple sclerosis), Allozyne DMHFUJT CP Allozyne Inc DMHFUJT DE Multiple sclerosis DM9LKYP ID DM9LKYP DM9LKYP DN AZ-40140 DM9LKYP HS Phase 2 DM9LKYP CP Asahi Kasei DM9LKYP DE Type-2 diabetes; Obesity DMM0N1F ID DMM0N1F DMM0N1F DN AZD-0865 DMM0N1F HS Phase 2 DMM0N1F SN AR-H044277 DMM0N1F CP AstraZeneca plc DMM0N1F DT Small molecular drug DMM0N1F PC 9951066 DMM0N1F MW 366.5 DMM0N1F FM C21H26N4O2 DMM0N1F IC InChI=1S/C21H26N4O2/c1-13-6-5-7-14(2)18(13)11-23-19-10-17(21(27)22-8-9-26)12-25-16(4)15(3)24-20(19)25/h5-7,10,12,23,26H,8-9,11H2,1-4H3,(H,22,27) DMM0N1F CS CC1=C(C(=CC=C1)C)CNC2=CC(=CN3C2=NC(=C3C)C)C(=O)NCCO DMM0N1F IK GHVIMBCFLRTFHI-UHFFFAOYSA-N DMM0N1F IU 8-[(2,6-dimethylphenyl)methylamino]-N-(2-hydroxyethyl)-2,3-dimethylimidazo[1,2-a]pyridine-6-carboxamide DMM0N1F CA CAS 248919-64-4 DMM0N1F DE Gastrointestinal disease DM7B1AR ID DM7B1AR DM7B1AR DN AZD-1446 DM7B1AR HS Phase 2 DM7B1AR SN TC-6683; Alpha-4 beta-2 neuronal nicotinic receptor modulator (oral, cognitive disorder), Targacept/AstraZeneca DM7B1AR CP Targacept Inc DM7B1AR DT Small molecular drug DM7B1AR PC 96568204 DM7B1AR MW 240.68 DM7B1AR FM C11H13ClN2O2 DM7B1AR IC InChI=1S/C11H13ClN2O2/c12-10-2-1-9(16-10)11(15)14-5-7-3-13-4-8(7)6-14/h1-2,7-8,13H,3-6H2/t7-,8+ DM7B1AR CS C1[C@@H]2CN(C[C@@H]2CN1)C(=O)C3=CC=C(O3)Cl DM7B1AR IK GTUIQNHJSXQMKW-OCAPTIKFSA-N DM7B1AR IU [(3aS,6aR)-2,3,3a,4,6,6a-hexahydro-1H-pyrrolo[3,4-c]pyrrol-5-yl]-(5-chlorofuran-2-yl)methanone DM7B1AR CA CAS 1025007-04-8 DM7B1AR DE Alzheimer disease DMLK59M ID DMLK59M DMLK59M DN AZD1480 DMLK59M HS Phase 2 DMLK59M SN RET inhibitors DMLK59M CP AstraZeneca DMLK59M DT Small molecular drug DMLK59M PC 16659841 DMLK59M MW 348.76 DMLK59M FM C14H14ClFN8 DMLK59M IC InChI=1S/C14H14ClFN8/c1-7-3-11(24-23-7)21-13-10(15)6-19-14(22-13)20-8(2)12-17-4-9(16)5-18-12/h3-6,8H,1-2H3,(H3,19,20,21,22,23,24)/t8-/m0/s1 DMLK59M CS CC1=CC(=NN1)NC2=NC(=NC=C2Cl)N[C@@H](C)C3=NC=C(C=N3)F DMLK59M IK PDOQBOJDRPLBQU-QMMMGPOBSA-N DMLK59M IU 5-chloro-2-N-[(1S)-1-(5-fluoropyrimidin-2-yl)ethyl]-4-N-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine DMLK59M CA CAS 935666-88-9 DMLK59M DE Myeloproliferative syndrome DMUE90I ID DMUE90I DMUE90I DN AZD1656 DMUE90I HS Phase 2 DMUE90I SN AZD1656; AZD-1656; FJEJHJINOKKDCW-INIZCTEOSA-N; 3-{[5-(azetidin-1-ylcarbonyl)pyrazin-2-yl]oxy}-5-{[(1S)-1-methyl-2-(methyloxy)ethyl]oxy}-N-(5-methylpyrazin-2-yl)benzamide; SCHEMBL321593; GTPL7701; UNII-660M185X4D; CHEMBL3219124; AZD 1656; 660M185X4D; 89961-EP2305674A1; 89961-EP2301929A1; 89961-EP2301935A1; 3-{[5-(azetidin-1-ylcarbonyl)pyrazin-2-yl]oxy}-5-[(1S)-2-methoxy-1-methylethoxy]-N-(5-methylpyrazin-2-yl)benzamide DMUE90I CP AstraZeneca DMUE90I DT Small molecular drug DMUE90I PC 16039797 DMUE90I MW 478.5 DMUE90I FM C24H26N6O5 DMUE90I IC InChI=1S/C24H26N6O5/c1-15-10-27-21(12-25-15)29-23(31)17-7-18(34-16(2)14-33-3)9-19(8-17)35-22-13-26-20(11-28-22)24(32)30-5-4-6-30/h7-13,16H,4-6,14H2,1-3H3,(H,27,29,31)/t16-/m0/s1 DMUE90I CS CC1=CN=C(C=N1)NC(=O)C2=CC(=CC(=C2)O[C@@H](C)COC)OC3=NC=C(N=C3)C(=O)N4CCC4 DMUE90I IK FJEJHJINOKKDCW-INIZCTEOSA-N DMUE90I IU 3-[5-(azetidine-1-carbonyl)pyrazin-2-yl]oxy-5-[(2S)-1-methoxypropan-2-yl]oxy-N-(5-methylpyrazin-2-yl)benzamide DMUE90I CA CAS 919783-22-5 DMUE90I DE Diabetic complication DMX5SG7 ID DMX5SG7 DMX5SG7 DN AZD1772//RDX5791 DMX5SG7 HS Phase 2 DMX5SG7 CP Ardelyx; astrazeneca DMX5SG7 DE Chronic kidney disease DMMCL9F ID DMMCL9F DMMCL9F DN AZD1981 DMMCL9F HS Phase 2 DMMCL9F SN AZD1981; 802904-66-1; AZD-1981; UNII-2AD53WQ2CX; AZD 1981; 2AD53WQ2CX; CHEMBL1914489; 2-[4-acetamido-3-(4-chlorophenyl)sulfanyl-2-methylindol-1-yl]acetic acid; 1H-Indole-1-acetic acid, 4-(acetylamino)-3-((4-chlorophenyl)thio)-2-methyl-; 1H-Indole-1-acetic acid, 4-(acetylamino)-3-[(4-chlorophenyl)thio]-2-methyl-; JWYIGNODXSRKGP-UHFFFAOYSA-N; GTPL7680; SCHEMBL1053662; EX-A662; MolPort-035-395-811; HMS3653A06; BCP20957; ZINC73196066; s7263; BDBM50357102; AKOS027263775; SB16902; DB11946; CS-4189; NCGC00386290-04; HY-15950; SC-94603 DMMCL9F DT Small molecular drug DMMCL9F PC 11292191 DMMCL9F MW 388.9 DMMCL9F FM C19H17ClN2O3S DMMCL9F IC InChI=1S/C19H17ClN2O3S/c1-11-19(26-14-8-6-13(20)7-9-14)18-15(21-12(2)23)4-3-5-16(18)22(11)10-17(24)25/h3-9H,10H2,1-2H3,(H,21,23)(H,24,25) DMMCL9F CS CC1=C(C2=C(C=CC=C2N1CC(=O)O)NC(=O)C)SC3=CC=C(C=C3)Cl DMMCL9F IK JWYIGNODXSRKGP-UHFFFAOYSA-N DMMCL9F IU 2-[4-acetamido-3-(4-chlorophenyl)sulfanyl-2-methylindol-1-yl]acetic acid DMMCL9F CA CAS 802904-66-1 DMMCL9F DE Chronic obstructive pulmonary disease DMOEARH ID DMOEARH DMOEARH DN Azd2014 DMOEARH HS Phase 2 DMOEARH SN AZD2014; 1009298-59-2; Vistusertib; AZD-2014; AZD 2014; UNII-0BSC3P4H5X; 0BSC3P4H5X; cc-551; 3-[2,4-Bis((3S)-3-methylmorpholin-4-yl)pyrido[5,6-e]pyrimidin-7-yl]-N-methylbenzamide; CHEMBL2336325; 3-[2,4-Bis((3S)-3-methyLmorpholin-4-yl)pyrido-[5,6-e]pyrimidin-7-yl]-N-methylbenzamide; C25H30N6O3; 3-(2,4-bis((S)-3-methylmorpholino)pyrido[2,3-d]pyrimidin-7-yl)-N-methylbenzamide; 3-[2,4-bis[(3S)-3-methylmorpholin-4-yl]pyrido[2,3-d]pyrimidin-7-yl]-N-methylbenzamide; Vistusertib [INN]; Vistusertib [USAN]; Vistusertib (JAN/INN) DMOEARH CP AstraZeneca DMOEARH DT Small molecular drug DMOEARH PC 25262792 DMOEARH MW 462.5 DMOEARH FM C25H30N6O3 DMOEARH IC InChI=1S/C25H30N6O3/c1-16-14-33-11-9-30(16)23-20-7-8-21(18-5-4-6-19(13-18)24(32)26-3)27-22(20)28-25(29-23)31-10-12-34-15-17(31)2/h4-8,13,16-17H,9-12,14-15H2,1-3H3,(H,26,32)/t16-,17-/m0/s1 DMOEARH CS C[C@H]1COCCN1C2=NC(=NC3=C2C=CC(=N3)C4=CC(=CC=C4)C(=O)NC)N5CCOC[C@@H]5C DMOEARH IK JUSFANSTBFGBAF-IRXDYDNUSA-N DMOEARH IU 3-[2,4-bis[(3S)-3-methylmorpholin-4-yl]pyrido[2,3-d]pyrimidin-7-yl]-N-methylbenzamide DMOEARH CA CAS 1009298-59-2 DMOEARH DE Solid tumour/cancer DMGQSVX ID DMGQSVX DMGQSVX DN AZD-2115 DMGQSVX HS Phase 2 DMGQSVX SN Dual action MABA (COPD), AstraZeneca; Dual action muscarinic acetylcholine receptor antagonist/beta 2 adrenoceptor agonist (COPD), AstraZeneca DMGQSVX CP AstraZeneca DMGQSVX DE Chronic obstructive pulmonary disease DM8FZOG ID DM8FZOG DM8FZOG DN AZD-2327 DM8FZOG HS Phase 2 DM8FZOG SN Opioid receptor delta agonist (anxiety, depression), AstraZeneca DM8FZOG CP AstraZeneca plc DM8FZOG DT Small molecular drug DM8FZOG PC 11525765 DM8FZOG MW 474.6 DM8FZOG FM C29H35FN4O DM8FZOG IC InChI=1S/C29H35FN4O/c1-3-33(4-2)29(35)24-12-10-23(11-13-24)28(25-6-5-7-27(31)20-25)34-18-16-32(17-19-34)21-22-8-14-26(30)15-9-22/h5-15,20,28H,3-4,16-19,21,31H2,1-2H3/t28-/m1/s1 DM8FZOG CS CCN(CC)C(=O)C1=CC=C(C=C1)[C@H](C2=CC(=CC=C2)N)N3CCN(CC3)CC4=CC=C(C=C4)F DM8FZOG IK XGFLMBBZEPJGHY-MUUNZHRXSA-N DM8FZOG IU 4-[(R)-(3-aminophenyl)-[4-[(4-fluorophenyl)methyl]piperazin-1-yl]methyl]-N,N-diethylbenzamide DM8FZOG CA CAS 875647-81-7 DM8FZOG DE Anxiety disorder DMF34UY ID DMF34UY DMF34UY DN AZD-2423 DMF34UY HS Phase 2 DMF34UY SN CCR2b antagonist (pain, COPD), AstraZeneca DMF34UY CP AstraZeneca plc DMF34UY DT Small molecular drug DMF34UY PC 46213922 DMF34UY MW 425.9 DMF34UY FM C20H29ClFN5O2 DMF34UY IC InChI=1S/C20H29ClFN5O2/c1-20(2,3)27-7-6-23-17(13-27)18(28)25-8-10-26(11-9-25)19(29)24-14-4-5-15(21)16(22)12-14/h4-5,12,17,23H,6-11,13H2,1-3H3,(H,24,29)/t17-/m1/s1 DMF34UY CS CC(C)(C)N1CCN[C@H](C1)C(=O)N2CCN(CC2)C(=O)NC3=CC(=C(C=C3)Cl)F DMF34UY IK SRWQVWAIVQXPJY-QGZVFWFLSA-N DMF34UY IU 4-[(2R)-4-tert-butylpiperazine-2-carbonyl]-N-(4-chloro-3-fluorophenyl)piperazine-1-carboxamide DMF34UY CA CAS 1229603-37-5 DMF34UY DE Chronic obstructive pulmonary disease DMZLGQV ID DMZLGQV DMZLGQV DN AZD2624 DMZLGQV HS Phase 2 DMZLGQV SN Pavinetant; AZD-2624; MLE4901; 941690-55-7; UNII-3U471ZVC5K; 3U471ZVC5K; AZ124752520; pavinetantum; Pavinetant [USAN]; SCHEMBL3587478; GTPL5775; CHEMBL3545233; CHEBI:140478; QYTBBBAHNIWFOD-NRFANRHFSA-N; BDBM50180193; AKOS032946112; DB11692; CS-7979; 4-Quinolinecarboxamide, 3-((methylsulfonyl)amino)-2-phenyl-N-((1S)-1-phenylpropyl)-; HY-14432; KB-74807; 3-methanesulfonamido-2-phenyl-N-[(1S)-1-phenylpropyl]quinoline-4-carboxamide; 3-[(methanesulfonyl)amino]-2-phenyl-N-[(1S)-1-phenylpropyl]quinoline-4-carboxamide DMZLGQV CP AstraZeneca DMZLGQV DT Small molecular drug DMZLGQV PC 23649245 DMZLGQV MW 459.6 DMZLGQV FM C26H25N3O3S DMZLGQV IC InChI=1S/C26H25N3O3S/c1-3-21(18-12-6-4-7-13-18)28-26(30)23-20-16-10-11-17-22(20)27-24(19-14-8-5-9-15-19)25(23)29-33(2,31)32/h4-17,21,29H,3H2,1-2H3,(H,28,30)/t21-/m0/s1 DMZLGQV CS CC[C@@H](C1=CC=CC=C1)NC(=O)C2=C(C(=NC3=CC=CC=C32)C4=CC=CC=C4)NS(=O)(=O)C DMZLGQV IK QYTBBBAHNIWFOD-NRFANRHFSA-N DMZLGQV IU 3-(methanesulfonamido)-2-phenyl-N-[(1S)-1-phenylpropyl]quinoline-4-carboxamide DMZLGQV CA CAS 941690-55-7 DMZLGQV CB CHEBI:140478 DMZLGQV DE Schizophrenia; Multiple sclerosis; . DMYUNXP ID DMYUNXP DMYUNXP DN AZD2811 DMYUNXP HS Phase 2 DMYUNXP CP AstraZeneca DMYUNXP DT Small molecular drug DMYUNXP DE Small-cell lung cancer DM6AI9N ID DM6AI9N DM6AI9N DN AZD-2927 DM6AI9N HS Phase 2 DM6AI9N SN AZD2927 DM6AI9N CP AstraZenec, UK DM6AI9N DT Small molecular drug DM6AI9N PC 57345449 DM6AI9N MW 308.4 DM6AI9N FM C17H25FN2O2 DM6AI9N IC InChI=1S/C17H25FN2O2/c1-11(2)16(10-20-8-14(21)9-20)19(4)17(22)13-5-6-15(18)12(3)7-13/h5-7,11,14,16,21H,8-10H2,1-4H3/t16-/m1/s1 DM6AI9N CS CC1=C(C=CC(=C1)C(=O)N(C)[C@H](CN2CC(C2)O)C(C)C)F DM6AI9N IK GAHPWXLXWUVMIV-MRXNPFEDSA-N DM6AI9N IU 4-fluoro-N-[(2S)-1-(3-hydroxyazetidin-1-yl)-3-methylbutan-2-yl]-N,3-dimethylbenzamide DM6AI9N DE Atrial fibrillation DME8Z5M ID DME8Z5M DME8Z5M DN AZD-3199 DME8Z5M HS Phase 2 DME8Z5M PC 16035068 DME8Z5M MW 578.8 DME8Z5M FM C32H42N4O4S DME8Z5M IC InChI=1S/C32H42N4O4S/c1-3-35(4-2)20-21-36(19-18-33-17-14-26-12-13-28(37)30-31(26)41-32(39)34-30)29(38)16-23-40-22-15-25-10-7-9-24-8-5-6-11-27(24)25/h5-13,33,37H,3-4,14-23H2,1-2H3,(H,34,39) DME8Z5M CS CCN(CC)CCN(CCNCCC1=C2C(=C(C=C1)O)NC(=O)S2)C(=O)CCOCCC3=CC=CC4=CC=CC=C43 DME8Z5M IK ZVULMJYRVAVKCP-UHFFFAOYSA-N DME8Z5M IU N-[2-(diethylamino)ethyl]-N-[2-[2-(4-hydroxy-2-oxo-3H-1,3-benzothiazol-7-yl)ethylamino]ethyl]-3-(2-naphthalen-1-ylethoxy)propanamide DME8Z5M CA CAS 925243-19-2 DME8Z5M DE Asthma DMANC59 ID DMANC59 DMANC59 DN AZD-3241 DMANC59 HS Phase 2 DMANC59 SN Parkinson's disease therapeutic, AstraZeneca DMANC59 CP AstraZeneca plc DMANC59 PC 11528958 DMANC59 MW 253.32 DMANC59 FM C11H15N3O2S DMANC59 IC InChI=1S/C11H15N3O2S/c1-7(2)16-6-5-14-8-3-4-12-9(8)10(15)13-11(14)17/h3-4,7,12H,5-6H2,1-2H3,(H,13,15,17) DMANC59 CS CC(C)OCCN1C2=C(C(=O)NC1=S)NC=C2 DMANC59 IK FVJCUZCRPIMVLB-UHFFFAOYSA-N DMANC59 IU 1-(2-propan-2-yloxyethyl)-2-sulfanylidene-5H-pyrrolo[3,2-d]pyrimidin-4-one DMANC59 CA CAS 890655-80-8 DMANC59 DE Parkinson disease DML9M5S ID DML9M5S DML9M5S DN AZD-4017 DML9M5S HS Phase 2 DML9M5S SN AZD-4017 (oral tablet, ocular hypertension) DML9M5S CP AstraZeneca plc DML9M5S DT Small molecular drug DML9M5S PC 24946280 DML9M5S MW 419.6 DML9M5S FM C22H33N3O3S DML9M5S IC InChI=1S/C22H33N3O3S/c1-2-13-29-22-18(21(28)23-17-8-4-3-5-9-17)10-11-19(24-22)25-12-6-7-16(15-25)14-20(26)27/h10-11,16-17H,2-9,12-15H2,1H3,(H,23,28)(H,26,27)/t16-/m0/s1 DML9M5S CS CCCSC1=C(C=CC(=N1)N2CCC[C@H](C2)CC(=O)O)C(=O)NC3CCCCC3 DML9M5S IK NCDZABJPWMBMIQ-INIZCTEOSA-N DML9M5S IU 2-[(3S)-1-[5-(cyclohexylcarbamoyl)-6-propylsulfanylpyridin-2-yl]piperidin-3-yl]acetic acid DML9M5S CA CAS 1024033-43-9 DML9M5S DE Ocular hypertension DM8SVIY ID DM8SVIY DM8SVIY DN AZD4635 DM8SVIY HS Phase 2 DM8SVIY SN NCWQLHHDGDXIJN-UHFFFAOYSA-N; AZD-4635; 1321514-06-0; 6-(2-chloro-6-methylpyridin-4-yl)-5-(4-fluorophenyl)-1,2,4-triazin-3-amine; SCHEMBL2320714; EX-A1681; AC-30333; HY-101980; CS-0022379; 5-(4-fluorophenyl)-6-(2-chloro-6-methyl-pyridin-4-yl)-1,2,4-triazin-3-amine DM8SVIY CP AstraZeneca Wilmington, DE DM8SVIY PC 86676119 DM8SVIY MW 315.73 DM8SVIY FM C15H11ClFN5 DM8SVIY IC InChI=1S/C15H11ClFN5/c1-8-6-10(7-12(16)19-8)14-13(20-15(18)22-21-14)9-2-4-11(17)5-3-9/h2-7H,1H3,(H2,18,20,22) DM8SVIY CS CC1=CC(=CC(=N1)Cl)C2=C(N=C(N=N2)N)C3=CC=C(C=C3)F DM8SVIY IK NCWQLHHDGDXIJN-UHFFFAOYSA-N DM8SVIY IU 6-(2-chloro-6-methylpyridin-4-yl)-5-(4-fluorophenyl)-1,2,4-triazin-3-amine DM8SVIY CA CAS 1321514-06-0 DM8SVIY DE Solid tumour/cancer; Prostate cancer DMFVL5J ID DMFVL5J DMFVL5J DN AZD-4877 DMFVL5J HS Phase 2 DMFVL5J SN Anticancer therapeutic (solid tumors), AstraZeneca DMFVL5J CP AstraZeneca plc DMFVL5J DT Small molecular drug DMFVL5J PC 10368812 DMFVL5J MW 503.7 DMFVL5J FM C28H33N5O2S DMFVL5J IC InChI=1S/C28H33N5O2S/c1-18(2)24(32(16-8-15-29)27(34)22-13-11-19(3)12-14-22)25-30-26-23(20(4)31-36-26)28(35)33(25)17-21-9-6-5-7-10-21/h5-7,9-14,18,24H,8,15-17,29H2,1-4H3 DMFVL5J CS CC1=CC=C(C=C1)C(=O)N(CCCN)C(C2=NC3=C(C(=NS3)C)C(=O)N2CC4=CC=CC=C4)C(C)C DMFVL5J IK SMFXSYMLJDHGIE-UHFFFAOYSA-N DMFVL5J IU N-(3-aminopropyl)-N-[1-(5-benzyl-3-methyl-4-oxo-[1,2]thiazolo[5,4-d]pyrimidin-6-yl)-2-methylpropyl]-4-methylbenzamide DMFVL5J CA CAS 1176760-49-8 DMFVL5J DE Acute myeloid leukaemia DM3JSFK ID DM3JSFK DM3JSFK DN AZD-5069 DM3JSFK HS Phase 2 DM3JSFK SN CXCR2 inhibitor (COPD), Astrazeneca DM3JSFK CP AstraZeneca plc DM3JSFK PC 56645576 DM3JSFK MW 476.5 DM3JSFK FM C18H22F2N4O5S2 DM3JSFK IC InChI=1S/C18H22F2N4O5S2/c1-11(14(26)9-25)29-16-8-15(23-31(27,28)24-6-3-7-24)21-18(22-16)30-10-12-4-2-5-13(19)17(12)20/h2,4-5,8,11,14,25-26H,3,6-7,9-10H2,1H3,(H,21,22,23)/t11-,14+/m1/s1 DM3JSFK CS C[C@H]([C@H](CO)O)OC1=NC(=NC(=C1)NS(=O)(=O)N2CCC2)SCC3=C(C(=CC=C3)F)F DM3JSFK IK QZECRCLSIGFCIO-RISCZKNCSA-N DM3JSFK IU N-[2-[(2,3-difluorophenyl)methylsulfanyl]-6-[(2R,3S)-3,4-dihydroxybutan-2-yl]oxypyrimidin-4-yl]azetidine-1-sulfonamide DM3JSFK CA CAS 878385-84-3 DM3JSFK DE Asthma DMOZ04X ID DMOZ04X DMOZ04X DN AZD-5213 DMOZ04X HS Phase 2 DMOZ04X CP AstraZeneca plc DMOZ04X PC 53342708 DMOZ04X MW 327.4 DMOZ04X FM C19H25N3O2 DMOZ04X IC InChI=1S/C19H25N3O2/c20-18(23)14-6-4-13(5-7-14)16-12-17(16)19(24)22-10-8-21(9-11-22)15-2-1-3-15/h4-7,15-17H,1-3,8-12H2,(H2,20,23)/t16-,17+/m1/s1 DMOZ04X CS C1CC(C1)N2CCN(CC2)C(=O)[C@H]3C[C@@H]3C4=CC=C(C=C4)C(=O)N DMOZ04X IK VCQZCDSEWSFTPO-SJORKVTESA-N DMOZ04X IU 4-[(1S,2S)-2-(4-cyclobutylpiperazine-1-carbonyl)cyclopropyl]benzamide DMOZ04X CA CAS 1119807-02-1 DMOZ04X DE Alzheimer disease DMJ8V3K ID DMJ8V3K DMJ8V3K DN AZD5312 DMJ8V3K HS Phase 2 DMJ8V3K CP Astrazeneca; isis pharmaceuticals DMJ8V3K DE Prostate cancer DM0PFNC ID DM0PFNC DM0PFNC DN AZD6738 DM0PFNC HS Phase 2 DM0PFNC CP Astrazeneca; eagle pharmaceuticals DM0PFNC DT Small molecular drug DM0PFNC PC 54761306 DM0PFNC MW 412.5 DM0PFNC FM C20H24N6O2S DM0PFNC IC InChI=1S/C20H24N6O2S/c1-13-12-28-10-9-26(13)17-11-16(20(5-6-20)29(2,21)27)24-19(25-17)15-4-8-23-18-14(15)3-7-22-18/h3-4,7-8,11,13,21H,5-6,9-10,12H2,1-2H3,(H,22,23)/t13-,29-/m1/s1 DM0PFNC CS C[C@@H]1COCCN1C2=NC(=NC(=C2)C3(CC3)[S@](=N)(=O)C)C4=C5C=CNC5=NC=C4 DM0PFNC IK OHUHVTCQTUDPIJ-JYCIKRDWSA-N DM0PFNC IU imino-methyl-[1-[6-[(3R)-3-methylmorpholin-4-yl]-2-(1H-pyrrolo[2,3-b]pyridin-4-yl)pyrimidin-4-yl]cyclopropyl]-oxo-lambda6-sulfane DM0PFNC DE Chronic lymphocytic leukaemia; Solid tumour/cancer; Small-cell lung cancer DMIBXK0 ID DMIBXK0 DMIBXK0 DN AZD-7009 DMIBXK0 HS Phase 2 DMIBXK0 SN AR-H065522XX; AZD-7009 (iv formulation, atrial fibrillation conversion) DMIBXK0 CP AstraZeneca plc DMIBXK0 DT Small molecular drug DMIBXK0 PC 72440971 DMIBXK0 MW 496.9 DMIBXK0 FM C22H23ClF2N4O5 DMIBXK0 IC InChI=1S/C22H23ClF2N4O5/c1-33-28-19(26)13-4-2-12(3-5-13)11-27-20(31)17-6-7-29(17)21(32)18(30)14-8-15(23)10-16(9-14)34-22(24)25/h2-5,8-10,17-18,22,30H,6-7,11H2,1H3,(H2,26,28)(H,27,31) DMIBXK0 CS CON=C(C1=CC=C(C=C1)CNC(=O)C2CCN2C(=O)C(C3=CC(=CC(=C3)Cl)OC(F)F)O)N DMIBXK0 IK XSNMGLZVFNDDPW-UHFFFAOYSA-N DMIBXK0 IU 1-[2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-(N'-methoxycarbamimidoyl)phenyl]methyl]azetidine-2-carboxamide DMIBXK0 DE Atrial fibrillation DMC48SP ID DMC48SP DMC48SP DN AZD-7268 DMC48SP HS Phase 2 DMC48SP SN Enkephalinergic receptor modulator (oral, depression, anxiety), AstraZeneca DMC48SP CP AstraZeneca plc DMC48SP DT Small molecular drug DMC48SP PC 24772484 DMC48SP MW 498.6 DMC48SP FM C29H30N4O2S DMC48SP IC InChI=1S/C29H30N4O2S/c1-32(16-17-34)29(35)24-9-7-21(8-10-24)27(26-6-2-4-23-5-3-13-30-28(23)26)22-11-14-33(15-12-22)18-25-19-36-20-31-25/h2-10,13,19-20,34H,11-12,14-18H2,1H3 DMC48SP CS CN(CCO)C(=O)C1=CC=C(C=C1)C(=C2CCN(CC2)CC3=CSC=N3)C4=CC=CC5=C4N=CC=C5 DMC48SP IK ZJKUETLEJYCOBO-UHFFFAOYSA-N DMC48SP IU N-(2-hydroxyethyl)-N-methyl-4-[quinolin-8-yl-[1-(1,3-thiazol-4-ylmethyl)piperidin-4-ylidene]methyl]benzamide DMC48SP CA CAS 1018988-00-5 DMC48SP DE Anxiety disorder DMXF26Y ID DMXF26Y DMXF26Y DN AZD7325 DMXF26Y HS Phase 2 DMXF26Y SN AZD-7325; UNII-KNM216XOUH; KNM216XOUH; CHEMBL1783282; 942437-37-8; AZD7325; KYDURMHFWXCKMW-UHFFFAOYSA-N; SCHEMBL1962584; GTPL7712; AZD 7325; BDBM50418481; SB17497; 4-amino-8-(2-fluoro-6-methoxyphenyl)-N-propylcinnoline-3-carboxamide; 4-Amino-8-(2-fluoro-6-methoxy-phenyl)-N-propylcinnoline-3-carboxamide DMXF26Y CP AstraZeneca DMXF26Y DT Small molecular drug DMXF26Y PC 23581869 DMXF26Y MW 354.4 DMXF26Y FM C19H19FN4O2 DMXF26Y IC InChI=1S/C19H19FN4O2/c1-3-10-22-19(25)18-16(21)12-7-4-6-11(17(12)23-24-18)15-13(20)8-5-9-14(15)26-2/h4-9H,3,10H2,1-2H3,(H2,21,23)(H,22,25) DMXF26Y CS CCCNC(=O)C1=NN=C2C(=C1N)C=CC=C2C3=C(C=CC=C3F)OC DMXF26Y IK KYDURMHFWXCKMW-UHFFFAOYSA-N DMXF26Y IU 4-amino-8-(2-fluoro-6-methoxyphenyl)-N-propylcinnoline-3-carboxamide DMXF26Y CA CAS 942437-37-8 DMXF26Y DE Anxiety disorder DMEW3K9 ID DMEW3K9 DMEW3K9 DN AZD7624 DMEW3K9 HS Phase 2 DMEW3K9 CP Astrazeneca DMEW3K9 PC 25143624 DMEW3K9 MW 491.6 DMEW3K9 FM C27H30FN5O3 DMEW3K9 IC InChI=1S/C27H30FN5O3/c1-17-21(28)15-18(25(34)31-19-7-8-19)16-22(17)33-13-11-30-24(26(33)35)32-27(9-10-27)20-5-3-4-6-23(20)36-14-12-29-2/h3-6,11,13,15-16,19,29H,7-10,12,14H2,1-2H3,(H,30,32)(H,31,34) DMEW3K9 CS CC1=C(C=C(C=C1F)C(=O)NC2CC2)N3C=CN=C(C3=O)NC4(CC4)C5=CC=CC=C5OCCNC DMEW3K9 IK NNKPHNTWNILINE-UHFFFAOYSA-N DMEW3K9 IU N-cyclopropyl-3-fluoro-4-methyl-5-[3-[[1-[2-[2-(methylamino)ethoxy]phenyl]cyclopropyl]amino]-2-oxopyrazin-1-yl]benzamide DMEW3K9 CA CAS 1095004-78-6 DMEW3K9 DE Chronic obstructive pulmonary disease DMLXFM6 ID DMLXFM6 DMLXFM6 DN AZD-8683 DMLXFM6 HS Phase 2 DMLXFM6 CP AstraZeneca plc DMLXFM6 DE Chronic obstructive pulmonary disease DM0M7QW ID DM0M7QW DM0M7QW DN AZD-8848 DM0M7QW HS Phase 2 DM0M7QW SN AZ-12441970; DSP-3025; SM-324405; TLR7 agonist (allergy), Dainippon/AstraZeneca DM0M7QW CP Dainippon Sumitomo Pharma Co Ltd DM0M7QW PC 11592228 DM0M7QW MW 569.7 DM0M7QW FM C29H43N7O5 DM0M7QW IC InChI=1S/C29H43N7O5/c1-3-4-16-41-28-32-26(30)25-27(33-28)36(29(38)31-25)13-7-12-35(11-6-10-34-14-17-40-18-15-34)21-23-9-5-8-22(19-23)20-24(37)39-2/h5,8-9,19H,3-4,6-7,10-18,20-21H2,1-2H3,(H,31,38)(H2,30,32,33) DM0M7QW CS CCCCOC1=NC(=C2C(=N1)N(C(=O)N2)CCCN(CCCN3CCOCC3)CC4=CC=CC(=C4)CC(=O)OC)N DM0M7QW IK FEFIBEHSXLKJGI-UHFFFAOYSA-N DM0M7QW IU methyl 2-[3-[[3-(6-amino-2-butoxy-8-oxo-7H-purin-9-yl)propyl-(3-morpholin-4-ylpropyl)amino]methyl]phenyl]acetate DM0M7QW CA CAS 866269-28-5 DM0M7QW DE Allergic rhinitis DMFLCW4 ID DMFLCW4 DMFLCW4 DN AZD8931 DMFLCW4 HS Phase 2 DMFLCW4 SN Sapitinib; AZD8931; 848942-61-0; AZD8931 (Sapitinib); AZD-8931; Sapitinib(AZD8931); UNII-3499328002; CHEMBL2408045; 2-(4-((4-((3-Chloro-2-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)-n-methylacetamide; 2-[4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)piperidin-1-yl]-N-methylacetamide; Sapitinib [INN]; 4-(3-chloro-2-fluoroanilino)-7-methoxy-6-((1-(n-methylcarbamoylmethyl)piperidin-4-yl)oxy)quinazoline DMFLCW4 CP AstraZeneca DMFLCW4 DT Small molecular drug DMFLCW4 PC 11488320 DMFLCW4 MW 473.9 DMFLCW4 FM C23H25ClFN5O3 DMFLCW4 IC InChI=1S/C23H25ClFN5O3/c1-26-21(31)12-30-8-6-14(7-9-30)33-20-10-15-18(11-19(20)32-2)27-13-28-23(15)29-17-5-3-4-16(24)22(17)25/h3-5,10-11,13-14H,6-9,12H2,1-2H3,(H,26,31)(H,27,28,29) DMFLCW4 CS CNC(=O)CN1CCC(CC1)OC2=C(C=C3C(=C2)C(=NC=N3)NC4=C(C(=CC=C4)Cl)F)OC DMFLCW4 IK DFJSJLGUIXFDJP-UHFFFAOYSA-N DMFLCW4 IU 2-[4-[4-(3-chloro-2-fluoroanilino)-7-methoxyquinazolin-6-yl]oxypiperidin-1-yl]-N-methylacetamide DMFLCW4 CA CAS 848942-61-0 DMFLCW4 CB CHEBI:132986 DMFLCW4 DE Breast cancer DMJGYPK ID DMJGYPK DMJGYPK DN AZD9056 DMJGYPK HS Phase 2 DMJGYPK SN AZD-9056; AZD9056; 345304-65-6; UNII-F13K378W4L; N-(1-adamantylmethyl)-2-chloro-5-[3-(3-hydroxypropylamino)propyl]benzamide; F13K378W4L; AZD 9056; GTPL7826; SCHEMBL4126642; CHEMBL3545108; HSQAARMBHJCUOK-UHFFFAOYSA-N; MolPort-044-723-510; KS-000000WO; BCP25185; ZINC34356159; AKOS030228502; DB12594; Benzamide, 2-chloro-5-(3-((3-hydroxypropyl)amino)propyl)-N-(tricyclo(3.3.1.13,7)dec-1-ylmethyl)-; 2-Chloro-5-[3-[(3-hydroxypropyl)amino]propyl]-N-(tricyclo[3.3.1.13,7]dec-1-ylmethyl)-benzamide DMJGYPK CP AstraZeneca DMJGYPK DT Small molecular drug DMJGYPK PC 10161381 DMJGYPK MW 419 DMJGYPK FM C24H35ClN2O2 DMJGYPK IC InChI=1S/C24H35ClN2O2/c25-22-5-4-17(3-1-6-26-7-2-8-28)12-21(22)23(29)27-16-24-13-18-9-19(14-24)11-20(10-18)15-24/h4-5,12,18-20,26,28H,1-3,6-11,13-16H2,(H,27,29) DMJGYPK CS C1C2CC3CC1CC(C2)(C3)CNC(=O)C4=C(C=CC(=C4)CCCNCCCO)Cl DMJGYPK IK HSQAARMBHJCUOK-UHFFFAOYSA-N DMJGYPK IU N-(1-adamantylmethyl)-2-chloro-5-[3-(3-hydroxypropylamino)propyl]benzamide DMJGYPK CA CAS 345304-65-6 DMJGYPK DE Chronic obstructive pulmonary disease DMVKPEZ ID DMVKPEZ DMVKPEZ DN AZD-9164 DMVKPEZ HS Phase 2 DMVKPEZ SN IDDBCP239717 DMVKPEZ CP AstraZeneca plc DMVKPEZ PC 44517831 DMVKPEZ MW 465.6 DMVKPEZ FM C29H38FN2O2+ DMVKPEZ IC InChI=1S/C29H38FN2O2/c1-29(25-8-4-2-5-9-25,31-17-6-3-7-18-31)28(33)34-27-22-32(20-15-24(27)16-21-32)19-14-23-10-12-26(30)13-11-23/h2,4-5,8-13,24,27H,3,6-7,14-22H2,1H3/q+1/t24?,27-,29-,32?/m0/s1 DMVKPEZ CS C[C@](C1=CC=CC=C1)(C(=O)O[C@H]2C[N+]3(CCC2CC3)CCC4=CC=C(C=C4)F)N5CCCCC5 DMVKPEZ IK FNYFFCOCVNTJCD-NNMXADRKSA-N DMVKPEZ IU [(3R)-1-[2-(4-fluorophenyl)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] (2S)-2-phenyl-2-piperidin-1-ylpropanoate DMVKPEZ CA CAS 1034978-04-5 DMVKPEZ DE Chronic obstructive pulmonary disease DMB87M3 ID DMB87M3 DMB87M3 DN AZD9668 DMB87M3 HS Phase 2 DMB87M3 SN Alvelestat; 848141-11-7; AZD9668; Alvelestat (AZD9668); AZD 9668; CHEMBL3617964; AZD-9668; KB-105160; Avelestat; 6-Methyl-5-(1-methyl-1H-pyrazol-5-yl)-N-{[5-(methylsulfonyl)pyridin-2-yl]methyl}-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide; 6-methyl-5-(1-methyl-1H-pyrazol-5-yl)-N-((5-(methylsulfonyl)pyridin-2-yl)methyl)-2-oxo-1-(3-(trifluoromethyl)phenyl)-1,2-dihydropyridine-3-carboxamide DMB87M3 CP AstraZeneca DMB87M3 DT Small molecular drug DMB87M3 PC 46861623 DMB87M3 MW 545.5 DMB87M3 FM C25H22F3N5O4S DMB87M3 IC InChI=1S/C25H22F3N5O4S/c1-15-20(22-9-10-31-32(22)2)12-21(23(34)30-13-17-7-8-19(14-29-17)38(3,36)37)24(35)33(15)18-6-4-5-16(11-18)25(26,27)28/h4-12,14H,13H2,1-3H3,(H,30,34) DMB87M3 CS CC1=C(C=C(C(=O)N1C2=CC=CC(=C2)C(F)(F)F)C(=O)NCC3=NC=C(C=C3)S(=O)(=O)C)C4=CC=NN4C DMB87M3 IK QNQZWEGMKJBHEM-UHFFFAOYSA-N DMB87M3 IU 6-methyl-5-(2-methylpyrazol-3-yl)-N-[(5-methylsulfonylpyridin-2-yl)methyl]-2-oxo-1-[3-(trifluoromethyl)phenyl]pyridine-3-carboxamide DMB87M3 CA CAS 848141-11-7 DMB87M3 DE Chronic obstructive pulmonary disease; Bronchiectasis DMQOTHP ID DMQOTHP DMQOTHP DN AZD9833 DMQOTHP HS Phase 2 DMQOTHP SN AZD-9833; UNII-JUP57A8EPZ; JUP57A8EPZ; 2222844-89-3; Camizestrant; Camizestrant [USAN]; SCHEMBL20089710; NSC828717; WHO 11592; NSC-828717; HY-136255; AZ14066724; CS-0121043; 3-Pyridinamine, N-(1-(3-fluoropropyl)-3-azetidinyl)-6-((6S,8R)-6,7,8,9-tetrahydro-8-methyl-7-(2,2,2-trifluoroethyl)-3H-pyrazolo(4,3-F)isoquinolin-6-yl)- DMQOTHP CP AstraZeneca DMQOTHP DT Small molecular drug DMQOTHP PC 134453496 DMQOTHP MW 476.5 DMQOTHP FM C24H28F4N6 DMQOTHP IC InChI=1S/C24H28F4N6/c1-15-9-19-18(4-6-21-20(19)11-30-32-21)23(34(15)14-24(26,27)28)22-5-3-16(10-29-22)31-17-12-33(13-17)8-2-7-25/h3-6,10-11,15,17,23,31H,2,7-9,12-14H2,1H3,(H,30,32)/t15-,23+/m1/s1 DMQOTHP CS C[C@@H]1CC2=C(C=CC3=C2C=NN3)[C@H](N1CC(F)(F)F)C4=NC=C(C=C4)NC5CN(C5)CCCF DMQOTHP IK WDHOIABIERMLGY-CMJOXMDJSA-N DMQOTHP IU N-[1-(3-fluoropropyl)azetidin-3-yl]-6-[(6S,8R)-8-methyl-7-(2,2,2-trifluoroethyl)-3,6,8,9-tetrahydropyrazolo[4,3-f]isoquinolin-6-yl]pyridin-3-amine DMQOTHP CA CAS 2222844-89-3 DMQOTHP DE ER-positive breast cancer DME0JMV ID DME0JMV DME0JMV DN AZX-100 DME0JMV HS Phase 2 DME0JMV CP AzERx Inc DME0JMV DE Asthma DMOMDA4 ID DMOMDA4 DMOMDA4 DN B-701 DMOMDA4 HS Phase 2 DMOMDA4 SN VKRFJPYJBOIVPD-UHFFFAOYSA-N; B 701; NSC 46406; 78218-88-9; Phosphorodiamidic acid, N,N-bis(2-chloroethyl)-N'-(3-hydroxypropyl)-, (3-chloropropyl) ester; AC1L3VIX; AC1Q6T2K; NSC46406; NSC-46406; 3-chloropropyl n,n-bis(2-chloroethyl)-n'-(3-hydroxypropyl)phosphorodiamidate; LS-107974; 3-[[bis(2-chloroethyl)amino-(3-chloropropoxy)phosphoryl]amin; 3-[[bis(2-chloroethyl)amino-(3-chloropropoxy)phosphoryl]amino]propan-1-ol; Phosphorodiamidic acid,N-bis(2-chloroethyl)-N'-(3-hydroxypropyl)-, 3-chloropropyl ester DMOMDA4 CP BioClin Therapeutics San Ramon, CA DMOMDA4 PC 95987 DMOMDA4 MW 355.6 DMOMDA4 FM C10H22Cl3N2O3P DMOMDA4 IC InChI=1S/C10H22Cl3N2O3P/c11-3-1-10-18-19(17,14-6-2-9-16)15(7-4-12)8-5-13/h16H,1-10H2,(H,14,17) DMOMDA4 CS C(CNP(=O)(N(CCCl)CCCl)OCCCCl)CO DMOMDA4 IK VKRFJPYJBOIVPD-UHFFFAOYSA-N DMOMDA4 IU 3-[[bis(2-chloroethyl)amino-(3-chloropropoxy)phosphoryl]amino]propan-1-ol DMOMDA4 CA CAS 78218-88-9 DMOMDA4 DE Bladder cancer; Urothelial carcinoma DM7586F ID DM7586F DM7586F DN Bafetinib DM7586F HS Phase 2 DM7586F SN Bafetinib; 859212-16-1; INNO-406; NS-187; UNII-NVW4Z03I9B; CNS-9; NVW4Z03I9B; INNO406; CHEMBL206834; (S)-N-(3-([4,5'-bipyrimidin]-2-ylamino)-4-methylphenyl)-4-((3-(dimethylamino)pyrrolidin-1-yl)methyl)-3-(trifluoromethyl)benzamide; 4-[[(3S)-3-DIMETHYLAMINOPYRROLIDIN-1-YL]METHYL]-N-[4-METHYL-3-[(4-PYRIMIDIN-5-YLPYRIMIDIN-2-YL)AMINO]PHENYL]-3-(TRIFLUOROMETHYL)BENZAMIDE; INNO 406; NS 187; N-[3-(4,5'-Bipyrimidin-2-Ylamino)-4-Methylphenyl]-4-{[(3s)-3-(Dimethylamino)pyrrolidin-1-Yl]methyl}-3-(Trifluoromethyl)benzamide DM7586F CP CytRx DM7586F DT Small molecular drug DM7586F PC 11387605 DM7586F MW 576.6 DM7586F FM C30H31F3N8O DM7586F IC InChI=1S/C30H31F3N8O/c1-19-4-7-23(13-27(19)39-29-36-10-8-26(38-29)22-14-34-18-35-15-22)37-28(42)20-5-6-21(25(12-20)30(31,32)33)16-41-11-9-24(17-41)40(2)3/h4-8,10,12-15,18,24H,9,11,16-17H2,1-3H3,(H,37,42)(H,36,38,39)/t24-/m0/s1 DM7586F CS CC1=C(C=C(C=C1)NC(=O)C2=CC(=C(C=C2)CN3CC[C@@H](C3)N(C)C)C(F)(F)F)NC4=NC=CC(=N4)C5=CN=CN=C5 DM7586F IK ZGBAJMQHJDFTQJ-DEOSSOPVSA-N DM7586F IU 4-[[(3S)-3-(dimethylamino)pyrrolidin-1-yl]methyl]-N-[4-methyl-3-[(4-pyrimidin-5-ylpyrimidin-2-yl)amino]phenyl]-3-(trifluoromethyl)benzamide DM7586F CA CAS 859212-16-1 DM7586F DE Bone disease DM4C7E6 ID DM4C7E6 DM4C7E6 DN BAICALEIN DM4C7E6 HS Phase 2 DM4C7E6 SN baicalein; 491-67-8; 5,6,7-Trihydroxyflavone; 5,6,7-trihydroxy-2-phenyl-4H-chromen-4-one; Noroxylin; Biacalein; BaiKalein; Baicelein; UNII-49QAH60606; NSC661431; NSC 661431; CHEMBL8260; 5,6,7-trihydroxy-2-phenylchromen-4-one; CHEBI:2979; FXNFHKRTJBSTCS-UHFFFAOYSA-N; MFCD00017459; 4H-1-Benzopyran-4-one, 5,6,7-trihydroxy-2-phenyl-; 49QAH60606; 5,7-Trihydroxyflavone; 5,6,7-trihydroxy-2-phenyl-chromen-4-one; Sho-saiko-to; SMR000112462; SR-01000597499; Baicalein, 8; Baicalein,(S); 3WL; Baicalein, 14; Baicalein, 98%; AC1NQYPP; Tocris-1761 DM4C7E6 DT Small molecular drug DM4C7E6 PC 5281605 DM4C7E6 MW 270.24 DM4C7E6 FM C15H10O5 DM4C7E6 IC InChI=1S/C15H10O5/c16-9-6-11(8-4-2-1-3-5-8)20-12-7-10(17)14(18)15(19)13(9)12/h1-7,17-19H DM4C7E6 CS C1=CC=C(C=C1)C2=CC(=O)C3=C(O2)C=C(C(=C3O)O)O DM4C7E6 IK FXNFHKRTJBSTCS-UHFFFAOYSA-N DM4C7E6 IU 5,6,7-trihydroxy-2-phenylchromen-4-one DM4C7E6 CA CAS 491-67-8 DM4C7E6 CB CHEBI:2979 DM4C7E6 DE Influenza virus infection DM3WCL4 ID DM3WCL4 DM3WCL4 DN Baltaleucel-T DM3WCL4 HS Phase 2 DM3WCL4 CP Cell Medica Houston, TX DM3WCL4 DE Diffuse large B-cell lymphoma; Hodgkin lymphoma; Lymphoma; Post-transplant lymphoproliferative disorder DMSZOXQ ID DMSZOXQ DMSZOXQ DN Baminercept DMSZOXQ HS Phase 2 DMSZOXQ SN BG-9924; Soluble lymphotoxin beta receptor, Biogen; Soluble lymphotoxin beta receptor, Biogen Idec DMSZOXQ CP Biogen Idec DMSZOXQ DE Rheumatoid arthritis DM0TZEP ID DM0TZEP DM0TZEP DN Bamosiran DM0TZEP HS Phase 2 DM0TZEP SN SYL040012 DM0TZEP CP Sylentis DM0TZEP DT Small interfering RNA DM0TZEP DE Glaucoma/ocular hypertension DMW03YD ID DMW03YD DMW03YD DN BAN2401 DMW03YD HS Phase 2 DMW03YD CP BioArtic Neuroscience DMW03YD DE Alzheimer disease DMWI0X3 ID DMWI0X3 DMWI0X3 DN Barusiban DMWI0X3 HS Phase 2 DMWI0X3 SN FE-200440 DMWI0X3 CP Ferring Pharmaceuticals Inc DMWI0X3 DT Small molecular drug DMWI0X3 PC 9832431 DMWI0X3 MW 830.1 DMWI0X3 FM C40H63N9O8S DMWI0X3 IC InChI=1S/C40H63N9O8S/c1-6-23(3)34-38(55)46-31(20-32(42)51)36(53)45-29(40(57)49(5)26(22-50)11-10-16-41)14-17-58-18-15-33(52)44-30(19-25-21-43-28-13-9-8-12-27(25)28)37(54)47-35(24(4)7-2)39(56)48-34/h8-9,12-13,21,23-24,26,29-31,34-35,43,50H,6-7,10-11,14-20,22,41H2,1-5H3,(H2,42,51)(H,44,52)(H,45,53)(H,46,55)(H,47,54)(H,48,56)/t23-,24+,26+,29+,30-,31+,34+,35+/m1/s1 DMWI0X3 CS CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CCSCCC(=O)N[C@@H](C(=O)N1)CC2=CNC3=CC=CC=C32)C(=O)N(C)[C@@H](CCCN)CO)CC(=O)N)[C@H](C)CC DMWI0X3 IK UGNGRKKDUVKQDF-IHOMMZCZSA-N DMWI0X3 IU (4S,7S,10S,13S,16R)-N-[(2S)-5-amino-1-hydroxypentan-2-yl]-7-(2-amino-2-oxoethyl)-13-[(2S)-butan-2-yl]-10-[(2R)-butan-2-yl]-16-(1H-indol-3-ylmethyl)-N-methyl-6,9,12,15,18-pentaoxo-1-thia-5,8,11,14,17-pentazacycloicosane-4-carboxamide DMWI0X3 CA CAS 285571-64-4 DMWI0X3 DE Androgen deficiency DMQ8J0U ID DMQ8J0U DMQ8J0U DN Basmisanil DMQ8J0U HS Phase 2 DMQ8J0U SN 1159600-41-5; UNII-788PET5SUA; 788PET5SUA; (1,1-Dioxidothiomorpholino)(6-((3-(4-fluorophenyl)-5-methylisoxazol-4-yl)methoxy)pyridin-3-yl)methanone; Basmisanil [INN]; Basmisanil [USAN:INN]; Basmisani; Basmisanil(RG1662); Basmisanil (USAN/INN); SCHEMBL2685527; CHEMBL3681419; MolPort-044-561-818; VCGRFBXVSFAGGA-UHFFFAOYSA-N; BDBM133427; EX-A1272; AKOS032947142; ZINC145814743; DB11877; CS-6046; HY-16716; (1,1-Dioxo-4-thiomorpholinyl)(6-((3-(4-fluorophenyl)-5-methylisoxazol-4-yl)methoxy)pyridin-3-yl)metha DMQ8J0U CP Roche DMQ8J0U PC 57336276 DMQ8J0U MW 445.5 DMQ8J0U FM C21H20FN3O5S DMQ8J0U IC InChI=1S/C21H20FN3O5S/c1-14-18(20(24-30-14)15-2-5-17(22)6-3-15)13-29-19-7-4-16(12-23-19)21(26)25-8-10-31(27,28)11-9-25/h2-7,12H,8-11,13H2,1H3 DMQ8J0U CS CC1=C(C(=NO1)C2=CC=C(C=C2)F)COC3=NC=C(C=C3)C(=O)N4CCS(=O)(=O)CC4 DMQ8J0U IK VCGRFBXVSFAGGA-UHFFFAOYSA-N DMQ8J0U IU (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone DMQ8J0U CA CAS 1159600-41-5 DMQ8J0U DE Alzheimer disease; Cognitive impairment; Complete androgen insensitivity syndrome; Immune dysregulation DM6CVZ5 ID DM6CVZ5 DM6CVZ5 DN Bavisant DM6CVZ5 HS Phase 2 DM6CVZ5 SN JNJ-31001074 DM6CVZ5 CP Johnson & Johnson Pharmaceutical Research & Development DM6CVZ5 DT Small molecular drug DM6CVZ5 PC 16061509 DM6CVZ5 MW 329.4 DM6CVZ5 FM C19H27N3O2 DM6CVZ5 IC InChI=1S/C19H27N3O2/c23-19(22-9-7-21(8-10-22)18-5-6-18)17-3-1-16(2-4-17)15-20-11-13-24-14-12-20/h1-4,18H,5-15H2 DM6CVZ5 CS C1CC1N2CCN(CC2)C(=O)C3=CC=C(C=C3)CN4CCOCC4 DM6CVZ5 IK BGBVSGSIXIIREO-UHFFFAOYSA-N DM6CVZ5 IU (4-cyclopropylpiperazin-1-yl)-[4-(morpholin-4-ylmethyl)phenyl]methanone DM6CVZ5 CA CAS 929622-08-2 DM6CVZ5 DE Attention deficit hyperactivity disorder DM4JGNH ID DM4JGNH DM4JGNH DN BAY 1067197 DM4JGNH HS Phase 2 DM4JGNH CP Bayer HealthCare Pharmaceuticals DM4JGNH DE Heart failure DMHKTGX ID DMHKTGX DMHKTGX DN BAY 1142524 DMHKTGX HS Phase 2 DMHKTGX SN Fulacimstat; UNII-VIR72PP4ZU; VIR72PP4ZU; BAY1142524; 1488354-15-9; 1-yl]-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid; 1-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-6-yl)-; 2,4-dioxo-3-[(1R)-4-(trifluoromethyl)-2,3-dihydro-1H-inden-; Fulacimstat [INN]; Fulacimstat; BAY1142524; Fulacimstat(BAY 1142524); CHEMBL4297596; SCHEMBL16701233; EX-A2732; DB15085; BAY-1142524; HY-109059; CS-0032987; (R)-1-(3-methyl-2-oxo-2,3-dihydrobenzo[d]oxazol-6-yl)-2,4-dioxo-3-(4-(trifluoromethyl)-2,3-dihydro-1H-inden-1-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid; 1-(2,3-Dihydro-3-methyl-2-oxo-6-benzoxazolyl)-3-((1R)-2,3-dihydro-4-(trifluoromethyl)-1H-inden-1-yl)-1,2,3,4-tetrahydro-2,4-dioxo-5-pyrimidinecarboxylic acid; 1-(3-methyl-2-oxo-1,3-benzoxazol-6-yl)-2,4-dioxo-3-[(1R)-4-(trifluoromethyl)-2,3-dihydro-1H-inden-1-yl]pyrimidine-5-carboxylic acid; 1-(3-Methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-6-yl)-2,4-dioxo-3-((1R)-4-(trifluoromethyl)-2,3-dihydro-1H-inden-1-yl)-1,2,3,4-tetrahydro-5-pyrimidinecarboxylic acid; 1-(3-Methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-6-yl)-2,4-dioxo-3-[(1R)-4-(trifluoromethyl)-2,3-dihydro-1H-inden-1-yl]-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid; 5-Pyrimidinecarboxylic acid, 1-(2,3-dihydro-3-methyl-2-oxo-6-benzoxazolyl)-3-((1R)-2,3-dihydro-4-(trifluoromethyl)-1H-inden-1-yl)-1,2,3,4-tetrahydro-2,4-dioxo- DMHKTGX CP Bayer DMHKTGX DT Small molecular drug DMHKTGX PC 91758792 DMHKTGX MW 487.4 DMHKTGX FM C23H16F3N3O6 DMHKTGX IC InChI=1S/C23H16F3N3O6/c1-27-17-7-5-11(9-18(17)35-22(27)34)28-10-14(20(31)32)19(30)29(21(28)33)16-8-6-12-13(16)3-2-4-15(12)23(24,25)26/h2-5,7,9-10,16H,6,8H2,1H3,(H,31,32)/t16-/m1/s1 DMHKTGX CS CN1C2=C(C=C(C=C2)N3C=C(C(=O)N(C3=O)[C@@H]4CCC5=C4C=CC=C5C(F)(F)F)C(=O)O)OC1=O DMHKTGX IK JDARDSVOVYVQST-MRXNPFEDSA-N DMHKTGX IU 1-(3-methyl-2-oxo-1,3-benzoxazol-6-yl)-2,4-dioxo-3-[(1R)-4-(trifluoromethyl)-2,3-dihydro-1H-inden-1-yl]pyrimidine-5-carboxylic acid DMHKTGX CA CAS 1488354-15-9 DMHKTGX DE Myocardial infarction DM8SNEM ID DM8SNEM DM8SNEM DN BAY 11-42524 DM8SNEM HS Phase 2 DM8SNEM CP Bayer healthcare pharmaceuticals DM8SNEM DE Heart failure; Left ventricular dysfunction DM450XS ID DM450XS DM450XS DN BAY 2253651 DM450XS HS Phase 2 DM450XS CP Bayer DM450XS DT Small molecular drug DM450XS DE Obstructive sleep apnea DMSUB64 ID DMSUB64 DMSUB64 DN BAY 57-1293 DMSUB64 HS Phase 2 DMSUB64 SN Pritelivir; 348086-71-5; BAY-57-1293; UNII-07HQ1TJ4JE; AIC316; BAY57-1293; 07HQ1TJ4JE; Pritelivir (BAY 57-1293); N-Methyl-N-(4-methyl-5-sulfamoylthiazol-2-yl)-2-(4-(pyridin-2-yl)phenyl)acetamide; N-methyl-N-(4-methyl-5-sulfamoyl-1,3-thiazol-2-yl)-2-(4-pyridin-2-ylphenyl)acetamide; Pritelivir [INN]; AIC-316; AIC 316; AC1LANY1; PritelivirBAY-57-1293; SCHEMBL1074614; Pritelivir(BAY 57-1293); DTXSID70188344; EX-A247; MolPort-029-887-140; IVZKZONQVYTCKC-UHFFFAOYSA-N; HMS3653B15; BCP08742 DMSUB64 DT Small molecular drug DMSUB64 PC 491941 DMSUB64 MW 402.5 DMSUB64 FM C18H18N4O3S2 DMSUB64 IC InChI=1S/C18H18N4O3S2/c1-12-17(27(19,24)25)26-18(21-12)22(2)16(23)11-13-6-8-14(9-7-13)15-5-3-4-10-20-15/h3-10H,11H2,1-2H3,(H2,19,24,25) DMSUB64 CS CC1=C(SC(=N1)N(C)C(=O)CC2=CC=C(C=C2)C3=CC=CC=N3)S(=O)(=O)N DMSUB64 IK IVZKZONQVYTCKC-UHFFFAOYSA-N DMSUB64 IU N-methyl-N-(4-methyl-5-sulfamoyl-1,3-thiazol-2-yl)-2-(4-pyridin-2-ylphenyl)acetamide DMSUB64 CA CAS 348086-71-5 DMSUB64 DE Herpes simplex virus infection DMA75FG ID DMA75FG DMA75FG DN BAY 794980 DMA75FG HS Phase 2 DMA75FG SN BAY-794980; Kogenate FS liposome; Kogenate liposomal; NecLip-rFVIII; PEGLip-formulated exogenous FVIII - Bayer/Zilip-Pharma; PEGLip-FVIII FS - Bayer/Zilip-Pharma; PEGylated octocog alfa sucrose - Bayer/Zilip-Pharma DMA75FG DE Discovery agent DMCPUKG ID DMCPUKG DMCPUKG DN BAY 85-8501 DMCPUKG HS Phase 2 DMCPUKG CP Bayer HealthCare Pharmaceuticals DMCPUKG PC 66601502 DMCPUKG MW 474.5 DMCPUKG FM C22H17F3N4O3S DMCPUKG IC InChI=1S/C22H17F3N4O3S/c1-13-18(12-27)20(17-8-7-14(11-26)9-19(17)33(3,31)32)28(2)21(30)29(13)16-6-4-5-15(10-16)22(23,24)25/h4-10,20H,1-3H3/t20-/m1/s1 DMCPUKG CS CC1=C([C@H](N(C(=O)N1C2=CC=CC(=C2)C(F)(F)F)C)C3=C(C=C(C=C3)C#N)S(=O)(=O)C)C#N DMCPUKG IK YAJWYFPMASPAMM-HXUWFJFHSA-N DMCPUKG IU (4S)-4-(4-cyano-2-methylsulfonylphenyl)-3,6-dimethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-4H-pyrimidine-5-carbonitrile DMCPUKG CA CAS 1161921-82-9 DMCPUKG DE Bronchiectasis DMRZLU4 ID DMRZLU4 DMRZLU4 DN BAY 86-5044 DMRZLU4 HS Phase 2 DMRZLU4 SN Lonaprisan; ZK-230211; 211254-73-8; UNII-F5Z5EL4D26; F5Z5EL4D26; AC1OCFKM; ZK-PRA; Lonaprisan [USAN:INN]; Lonaprisan (USAN/INN); SCHEMBL977182; CHEMBL146032; zk230211; BDBM50409115; BAY86-5044; ZK 230211; ZK 232011; D10016; Z-3103; (8S,11R,13S,14S,17S)-11-(4-ACETYLPHENYL)-17-HYDROXY-13-METHYL-17-(PERFLUOROETHYL)-6,7,8,11,12,13,14,15,16,17-DECAHYDRO-1H-CYCLOPENTA[A]PHENANTHREN-3(2H)-ONE; Lonaprisan DMRZLU4 CP Bayer HealthCare Pharmaceuticals DMRZLU4 DT Small molecular drug DMRZLU4 PC 6918548 DMRZLU4 MW 508.5 DMRZLU4 FM C28H29F5O3 DMRZLU4 IC InChI=1S/C28H29F5O3/c1-15(34)16-3-5-17(6-4-16)22-14-25(2)23(11-12-26(25,36)27(29,30)28(31,32)33)21-9-7-18-13-19(35)8-10-20(18)24(21)22/h3-6,13,21-23,36H,7-12,14H2,1-2H3/t21-,22+,23-,25-,26-/m0/s1 DMRZLU4 CS CC(=O)C1=CC=C(C=C1)[C@H]2C[C@]3([C@@H](CC[C@]3(C(C(F)(F)F)(F)F)O)[C@H]4C2=C5CCC(=O)C=C5CC4)C DMRZLU4 IK VHZPUDNSVGRVMB-RXDLHWJPSA-N DMRZLU4 IU (8S,11R,13S,14S,17S)-11-(4-acetylphenyl)-17-hydroxy-13-methyl-17-(1,1,2,2,2-pentafluoroethyl)-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one DMRZLU4 CA CAS 211254-73-8 DMRZLU4 DE Breast cancer DMCSGJ2 ID DMCSGJ2 DMCSGJ2 DN BAY1163877 DMCSGJ2 HS Phase 2 DMCSGJ2 SN Rogaratinib DMCSGJ2 CP Bayer healthcare pharmaceuticals DMCSGJ2 PC 71611869 DMCSGJ2 MW 466.6 DMCSGJ2 FM C23H26N6O3S DMCSGJ2 IC InChI=1S/C23H26N6O3S/c1-13-6-14-8-18(33-22(14)17(7-13)32-3)20-15(11-31-2)16(9-28-5-4-25-19(30)10-28)29-21(20)23(24)26-12-27-29/h6-8,12H,4-5,9-11H2,1-3H3,(H,25,30)(H2,24,26,27) DMCSGJ2 CS CC1=CC2=C(C(=C1)OC)SC(=C2)C3=C4C(=NC=NN4C(=C3COC)CN5CCNC(=O)C5)N DMCSGJ2 IK HNLRRJSKGXOYNO-UHFFFAOYSA-N DMCSGJ2 IU 4-[[4-amino-6-(methoxymethyl)-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)pyrrolo[2,1-f][1,2,4]triazin-7-yl]methyl]piperazin-2-one DMCSGJ2 CA CAS 1443530-05-9 DMCSGJ2 DE Solid tumour/cancer; Bladder cancer DM83IYE ID DM83IYE DM83IYE DN BAY1193397 DM83IYE HS Phase 2 DM83IYE CP Bayer HealthCare Pharmaceuticals Whippany, NJ DM83IYE DE Peripheral arterial disease DMYSQMW ID DMYSQMW DMYSQMW DN BAY-1902607 DMYSQMW HS Phase 2 DMYSQMW CP Bayer DMYSQMW DE Cough DMM7Q68 ID DMM7Q68 DMM7Q68 DN BAY-2253651 DMM7Q68 HS Phase 2 DMM7Q68 CP Bayer DMM7Q68 DE Obstructive sleep apnea DMVA5NS ID DMVA5NS DMVA5NS DN BAY-57-9352 DMVA5NS HS Phase 2 DMVA5NS SN Telatinib; Bay 57-9352 DMVA5NS CP Bayer AG DMVA5NS TC Anticancer Agents DMVA5NS DT Small molecular drug DMVA5NS PC 9808844 DMVA5NS MW 409.8 DMVA5NS FM C20H16ClN5O3 DMVA5NS IC InChI=1S/C20H16ClN5O3/c1-22-19(27)16-10-12(6-8-23-16)11-29-20-17-15(7-9-28-17)18(25-26-20)24-14-4-2-13(21)3-5-14/h2-10H,11H2,1H3,(H,22,27)(H,24,25) DMVA5NS CS CNC(=O)C1=NC=CC(=C1)COC2=NN=C(C3=C2OC=C3)NC4=CC=C(C=C4)Cl DMVA5NS IK QFCXANHHBCGMAS-UHFFFAOYSA-N DMVA5NS IU 4-[[4-(4-chloroanilino)furo[2,3-d]pyridazin-7-yl]oxymethyl]-N-methylpyridine-2-carboxamide DMVA5NS CA CAS 332012-40-5 DMVA5NS DE Solid tumour/cancer; Gastric adenocarcinoma DM7NHLC ID DM7NHLC DM7NHLC DN BAY-85-3934 DM7NHLC HS Phase 2 DM7NHLC SN Hypoxia-inducible factor prolyl hydroxylase inhibitors (anemia); HIF-PH inhibitors (anemia), Bayer DM7NHLC CP Bayer HealthCare Pharmaceuticals DM7NHLC DT Small molecular drug DM7NHLC PC 69669724 DM7NHLC MW 336.28 DM7NHLC FM C13H13N8NaO2 DM7NHLC IC InChI=1S/C13H14N8O2.Na/c22-13-10(20-2-1-16-18-20)8-17-21(13)12-7-11(14-9-15-12)19-3-5-23-6-4-19;/h1-2,7-9,22H,3-6H2;/q;+1/p-1 DM7NHLC CS C1COCCN1C2=NC=NC(=C2)N3C(=C(C=N3)N4C=CN=N4)[O-].[Na+] DM7NHLC IK VYRQLKYGGSWDNH-UHFFFAOYSA-M DM7NHLC IU sodium;2-(6-morpholin-4-ylpyrimidin-4-yl)-4-(triazol-1-yl)pyrazol-3-olate DM7NHLC DE Anemia DM2XE80 ID DM2XE80 DM2XE80 DN BAY-X-7195 DM2XE80 HS Phase 2 DM2XE80 SN BAY-X-7195; UGWPB2QIT9; UNII-UGWPB2QIT9; BAY X-7195; BAY X 7195; AC1O5X0Q; 143538-27-6; SCHEMBL156423; CHEMBL314115; 4-[(Z,4S)-7-hydroxy-7-oxo-1-[4-(4-phenoxybutoxy)phenyl]hept-2-en-4-yl]sulfanylbenzoic acid DM2XE80 CP Bayer AG DM2XE80 DT Small molecular drug DM2XE80 PC 6442328 DM2XE80 MW 520.6 DM2XE80 FM C30H32O6S DM2XE80 IC InChI=1S/C30H32O6S/c31-29(32)20-19-27(37-28-17-13-24(14-18-28)30(33)34)10-6-7-23-11-15-26(16-12-23)36-22-5-4-21-35-25-8-2-1-3-9-25/h1-3,6,8-18,27H,4-5,7,19-22H2,(H,31,32)(H,33,34)/b10-6-/t27-/m1/s1 DM2XE80 CS C1=CC=C(C=C1)OCCCCOC2=CC=C(C=C2)C/C=C\\[C@H](CCC(=O)O)SC3=CC=C(C=C3)C(=O)O DM2XE80 IK MHKAEITVUICXRN-BPGQXAFDSA-N DM2XE80 IU 4-[(Z,3S)-1-carboxy-6-[4-(4-phenoxybutoxy)phenyl]hex-4-en-3-yl]sulfanylbenzoic acid DM2XE80 CA CAS 143538-27-6 DM2XE80 DE Asthma DMLO18H ID DMLO18H DMLO18H DN BAY-Y-5959 DMLO18H HS Phase 2 DMLO18H CP Bayer AG DMLO18H PC 9910240 DMLO18H MW 424.5 DMLO18H FM C26H24N4O2 DMLO18H IC InChI=1S/C26H24N4O2/c1-15(2)32-26(31)24-23(21(13-27)16(3)30-25(24)28)19-10-7-11-22-20(19)12-18(14-29-22)17-8-5-4-6-9-17/h4-12,14-15,23,30H,28H2,1-3H3/t23-/m1/s1 DMLO18H CS CC1=C([C@H](C(=C(N1)N)C(=O)OC(C)C)C2=C3C=C(C=NC3=CC=C2)C4=CC=CC=C4)C#N DMLO18H IK PHJVBZVDUNTGNR-HSZRJFAPSA-N DMLO18H IU propan-2-yl (4R)-2-amino-5-cyano-6-methyl-4-(3-phenylquinolin-5-yl)-1,4-dihydropyridine-3-carboxylate DMLO18H CA CAS 146136-94-9 DMLO18H DE Cardiovascular disease DMB0UF9 ID DMB0UF9 DMB0UF9 DN Bb2121 DMB0UF9 HS Phase 2 DMB0UF9 CP bluebird bioCambridge, MACelgeneSummit, NJ DMB0UF9 DT CAR T Cell Therapy DMB0UF9 DE Multiple myeloma DMR59I4 ID DMR59I4 DMR59I4 DN BBI-5000 DMR59I4 HS Phase 2 DMR59I4 CP Brickell Biotech DMR59I4 DT Small molecular drug DMR59I4 DE Alopecia DMDSNIR ID DMDSNIR DMDSNIR DN BBI503 DMDSNIR HS Phase 2 DMDSNIR CP Boston Biomedical DMDSNIR PC 25190990 DMDSNIR MW 539.7 DMDSNIR FM C31H33N5O2S DMDSNIR IC InChI=1S/C31H33N5O2S/c1-5-36(6-2)15-14-32-30(38)28-19(3)26(33-20(28)4)17-24-23-16-22(12-13-25(23)34-29(24)37)27-18-39-31(35-27)21-10-8-7-9-11-21/h7-13,16-18,33H,5-6,14-15H2,1-4H3,(H,32,38)(H,34,37)/b24-17- DMDSNIR CS CCN(CC)CCNC(=O)C1=C(NC(=C1C)/C=C\\2/C3=C(C=CC(=C3)C4=CSC(=N4)C5=CC=CC=C5)NC2=O)C DMDSNIR IK QDWKGEFGLQMDAM-ULJHMMPZSA-N DMDSNIR IU N-[2-(diethylamino)ethyl]-2,4-dimethyl-5-[(Z)-[2-oxo-5-(2-phenyl-1,3-thiazol-4-yl)-1H-indol-3-ylidene]methyl]-1H-pyrrole-3-carboxamide DMDSNIR CA CAS 1129403-56-0 DMDSNIR DE Ovarian cancer; Hepatocellular carcinoma; Cholangiocarcinoma; Solid tumour/cancer DMY1UGV ID DMY1UGV DMY1UGV DN Bc-3781 intravenous DMY1UGV HS Phase 2 DMY1UGV SN BC-3781 (intravenous), Nabriva; BC-3781 (oral), Nabriva DMY1UGV CP Nabriva therapeutics DMY1UGV DT Small molecular drug DMY1UGV PC 52918381 DMY1UGV MW 507.7 DMY1UGV FM C28H45NO5S DMY1UGV IC InChI=1S/C28H45NO5S/c1-6-26(4)14-22(34-23(32)15-35-21-8-7-18(29)13-20(21)31)27(5)16(2)9-11-28(17(3)25(26)33)12-10-19(30)24(27)28/h6,16-18,20-22,24-25,31,33H,1,7-15,29H2,2-5H3/t16-,17+,18?,20?,21?,22-,24+,25+,26-,27+,28+/m1/s1 DMY1UGV CS C[C@@H]1CC[C@@]23CCC(=O)[C@H]2[C@@]1([C@@H](C[C@@]([C@H]([C@@H]3C)O)(C)C=C)OC(=O)CSC4CCC(CC4O)N)C DMY1UGV IK KPVIXBKIJXZQJX-IJUBVZAWSA-N DMY1UGV IU [(1S,2R,3S,4S,6R,7R,8R,14R)-4-ethenyl-3-hydroxy-2,4,7,14-tetramethyl-9-oxo-6-tricyclo[5.4.3.01,8]tetradecanyl] 2-(4-amino-2-hydroxycyclohexyl)sulfanylacetate DMY1UGV CA CAS 1061872-97-6 DMY1UGV DE Bacterial infection DMMKCJ6 ID DMMKCJ6 DMMKCJ6 DN BC-7013 DMMKCJ6 HS Phase 2 DMMKCJ6 SN Pleuromutilin (topical, dermatological infection), Nabriva DMMKCJ6 CP Nabriva Therapeutics AG DMMKCJ6 DE Skin infection DM2BO9W ID DM2BO9W DM2BO9W DN BCP-13498 DM2BO9W HS Phase 2 DM2BO9W SN Propacetamol; Pro-Dafalgan; Propacetamol (INN); Propacetamol [INN:BAN]; Propacetamol [INN]; Propacetamolum; Propacetamolum [Latin]; Tox21_113811; ZINC55161176; (4-acetamidophenyl) 2-(diethylamino)acetate; 5CHW4JMR82; 66532-85-2; AC1L2ALY; AC1Q6199; AKOS015890722; BCP13498; CHEBI:135089; CHEMBL1851805; DB09288; DSSTox_CID_31589; DSSTox_GSID_57800; DSSTox_RID_97473; DTXSID3057800; EINECS 266-390-1; Glycine, N,N-diethyl-, 4-(acetylamino)phenyl ester; N,N-Diethylglycine, ester with 4'-hydroxyacetanilide; SCHEMBL26155; UNII-5CHW4JMR82 DM2BO9W PC 68865 DM2BO9W MW 264.32 DM2BO9W FM C14H20N2O3 DM2BO9W IC QTGAJCQTLIRCFL-UHFFFAOYSA-N DM2BO9W CS CCN(CC)CC(=O)OC1=CC=C(C=C1)NC(=O)C DM2BO9W IK 1S/C14H20N2O3/c1-4-16(5-2)10-14(18)19-13-8-6-12(7-9-13)15-11(3)17/h6-9H,4-5,10H2,1-3H3,(H,15,17) DM2BO9W IU (4-acetamidophenyl) 2-(diethylamino)acetate DM2BO9W CA CAS 66532-85-2 DM2BO9W CB CHEBI:135089 DM2BO9W DE Anaesthesia DMUFY4K ID DMUFY4K DMUFY4K DN BCT303 DMUFY4K HS Phase 2 DMUFY4K SN Liothyronine sustained release DMUFY4K CP Intellectual property executives DMUFY4K DE Hypothyroidism DMRSG31 ID DMRSG31 DMRSG31 DN BCX-3408 DMRSG31 HS Phase 2 DMRSG31 SN ULODESINE; 548486-59-5; UNII-JNG8L9460Y; JNG8L9460Y; CHEMBL269864; DADMe-immucillin H; Ulodesine [USAN:INN]; Ulodesine (USAN); DADMe-ImmH,7; 1n3i; AC1L9KNW; 7-[[(3R,4R)-3-(hydroxymethyl)-4-oxidanyl-pyrrolidin-1-ium-1-yl]methyl]-3,5-dihydropyrrolo[3,2-d]pyrimidin-4-one; R-3421; SCHEMBL474735; SCHEMBL16320802; CTK5A2657; BDBM22109; DTXSID00203332; AKOS030554378; DB12353; SB17254; D10431; 4H-Pyrrolo[3,2-d]pyrimidin-4-one,1,5-dihydro-7-[[(3R,4R)-3-hydroxy-4-(hydroxymethyl)-1-pyrrolidinyl]methyl]-; BCX-4208; Ulodesine DMRSG31 DT Small molecular drug DMRSG31 PC 135449518 DMRSG31 MW 264.28 DMRSG31 FM C12H16N4O3 DMRSG31 IC InChI=1S/C12H16N4O3/c17-5-8-3-16(4-9(8)18)2-7-1-13-11-10(7)14-6-15-12(11)19/h1,6,8-9,13,17-18H,2-5H2,(H,14,15,19)/t8-,9+/m1/s1 DMRSG31 CS C1[C@@H]([C@H](CN1CC2=CNC3=C2N=CNC3=O)O)CO DMRSG31 IK AFNHHLILYQEHKK-BDAKNGLRSA-N DMRSG31 IU 7-[[(3R,4R)-3-hydroxy-4-(hydroxymethyl)pyrrolidin-1-yl]methyl]-3,5-dihydropyrrolo[3,2-d]pyrimidin-4-one DMRSG31 CA CAS 548486-59-5 DMRSG31 DE Plaque psoriasis; Gout; Autoimmune diabetes DMKFJXP ID DMKFJXP DMKFJXP DN BDB001 DMKFJXP HS Phase 2 DMKFJXP CP Birdie Biopharmaceuticals; Seven and Eight Biopharmaceuticals DMKFJXP DT Antibody DMKFJXP DE Solid tumour/cancer DM2Q50G ID DM2Q50G DM2Q50G DN Belnacasan DM2Q50G HS Phase 2 DM2Q50G SN Second generation ICE inhibitors, Vertex; VRT-043198; VRT-43198; VX-765; VX-765) DM2Q50G CP MedKoo Biosciences; vertex pharmaceuticals DM2Q50G DT Small molecular drug DM2Q50G PC 11398092 DM2Q50G MW 509 DM2Q50G FM C24H33ClN4O6 DM2Q50G IC InChI=1S/C24H33ClN4O6/c1-5-34-23-16(12-18(30)35-23)27-21(32)17-7-6-10-29(17)22(33)19(24(2,3)4)28-20(31)13-8-9-15(26)14(25)11-13/h8-9,11,16-17,19,23H,5-7,10,12,26H2,1-4H3,(H,27,32)(H,28,31)/t16-,17-,19+,23+/m0/s1 DM2Q50G CS CCO[C@H]1[C@H](CC(=O)O1)NC(=O)[C@@H]2CCCN2C(=O)[C@H](C(C)(C)C)NC(=O)C3=CC(=C(C=C3)N)Cl DM2Q50G IK SJDDOCKBXFJEJB-MOKWFATOSA-N DM2Q50G IU (2S)-1-[(2S)-2-[(4-amino-3-chlorobenzoyl)amino]-3,3-dimethylbutanoyl]-N-[(2R,3S)-2-ethoxy-5-oxooxolan-3-yl]pyrrolidine-2-carboxamide DM2Q50G CA CAS 273404-37-8 DM2Q50G DE Epilepsy DMWNYIE ID DMWNYIE DMWNYIE DN Bemarituzumab DMWNYIE HS Phase 2 DMWNYIE CP Five Prime Therapeutics South San Francisco, CA DMWNYIE DE Gastric adenocarcinoma DM0YCPL ID DM0YCPL DM0YCPL DN Bemcentinib DM0YCPL HS Phase 2 DM0YCPL SN R428; 1037624-75-1; BGB324; R-428; BGB-324; UNII-0ICW2LX8AS; (S)-1-(6,7-dihydro-5H-benzo[6,7]cyclohepta[1,2-c]pyridazin-3-yl)-N3-(7-(pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulen-2-yl)-1H-1,2,4-triazole-3,5-diamine; CHEMBL3809489; SYN1131; CS-1046; HY-15150; QC-11751; R 428; W-5845; Bemcentinib [USAN]; R428 (BGB324); Bemcentinib (USAN/INN); BemcentinibR428BGB324); SCHEMBL1639904; GTPL10478; BGB 324; DTXSID70673109; 1-(6,7-dihydro-5H-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-3-N-[(7S)-7-pyrrolidin-1-yl-6,7,8,9-tetrahydro-5H-benzo[7]annulen-3-yl]-1,2,4-triazole-3,5-diamine; AMY16774; BCP21180; C30H34N8; EX-A1720; SYN-1131; BDBM50172079; NSC824183; s2841; WHO 10631; ZINC51951669; AKOS032947237; ACN-037541; DB12411; NSC-824183; SB16614; NCGC00386665-07; 1-(6,7-Dihydro-5H-benzo[6,7]cyclohepta[1,2-c]pyridazin-3-yl)-N~3~-[(7S)-7-(pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulen-2-yl]-1H-1,2,4-triazole-3,5-diamine; 1H-1,2,4-Triazole-3,5-diamine, 1-(6,7-dihydro-5H-benzo(6,7)cyclohepta(1,2-C)pyridazin-3-yl)-N3-((7S)-6,7,8,9-tetrahydro-7-(1-pyrrolidinyl)-5H-benzocyclohepten-2-yl)-; AC-28444; AS-16270; KB-80319; D11438; Q27236818; BGB324; BGB-324; BGB 324; R 428; R-428; Bemcentinib; 1-(6,7-dihydro-5H-benzo[6,7]cyclohepta[1,2-c]pyridazin-3-yl)-N3-(7-(S)-(pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulene-2-yl)-1H-1,2,4-triazole-3,5-diamine DM0YCPL CP Rigel Pharmaceuticals; BerGen BIO DM0YCPL DT Small molecular drug DM0YCPL PC 46215462 DM0YCPL MW 506.6 DM0YCPL FM C30H34N8 DM0YCPL IC InChI=1S/C30H34N8/c31-29-33-30(32-24-13-10-20-11-14-25(15-12-22(20)18-24)37-16-3-4-17-37)36-38(29)27-19-23-8-5-7-21-6-1-2-9-26(21)28(23)35-34-27/h1-2,6,9-10,13,18-19,25H,3-5,7-8,11-12,14-17H2,(H3,31,32,33,36)/t25-/m0/s1 DM0YCPL CS C1CCN(C1)[C@H]2CCC3=C(CC2)C=C(C=C3)NC4=NN(C(=N4)N)C5=NN=C6C(=C5)CCCC7=CC=CC=C76 DM0YCPL IK KXMZDGSRSGHMMK-VWLOTQADSA-N DM0YCPL IU 1-(3,4-diazatricyclo[9.4.0.02,7]pentadeca-1(15),2,4,6,11,13-hexaen-5-yl)-3-N-[(7S)-7-pyrrolidin-1-yl-6,7,8,9-tetrahydro-5H-benzo[7]annulen-3-yl]-1,2,4-triazole-3,5-diamine DM0YCPL CA CAS 1037624-75-1 DM0YCPL DE Non-small-cell lung cancer; Myelodysplastic syndrome; Triple negative breast cancer DMUL6GY ID DMUL6GY DMUL6GY DN BEMORADAN DMUL6GY HS Phase 2 DMUL6GY SN Orf-22867; RWJ-22867; Bemoradan; Rac-7-(1,4,5,6-Tetrahydro-4-methyl-6-oxo-3-pyridazinyl)-2H-1,4-benzoxazin-3(4H)-one; Rac-5-Methyl-6-(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-7-yl)-2,3,4,5-tetrahydropyridazin-3-one DMUL6GY DT Small molecular drug DMUL6GY PC 5362399 DMUL6GY MW 259.26 DMUL6GY FM C13H13N3O3 DMUL6GY IC InChI=1S/C13H13N3O3/c1-7-4-11(17)15-16-13(7)8-2-3-9-10(5-8)19-6-12(18)14-9/h2-3,5,7H,4,6H2,1H3,(H,14,18)(H,15,17) DMUL6GY CS CC1CC(=O)NN=C1C2=CC3=C(C=C2)NC(=O)CO3 DMUL6GY IK XZPGINPFWXLYNW-UHFFFAOYSA-N DMUL6GY IU 7-(4-methyl-6-oxo-4,5-dihydro-1H-pyridazin-3-yl)-4H-1,4-benzoxazin-3-one DMUL6GY CA CAS 112018-01-6 DMUL6GY DE Heart failure DMRC0EQ ID DMRC0EQ DMRC0EQ DN Bertilimumab DMRC0EQ HS Phase 2 DMRC0EQ SN CAT-213; ICo-008 DMRC0EQ CP Cambridge Antibody Technology DMRC0EQ DT Monoclonal antibody DMRC0EQ DE Ocular allergy; Bullous pemphigoid; Psoriasis vulgaris; Ulcerative colitis DMJ2REU ID DMJ2REU DMJ2REU DN Berubicin DMJ2REU HS Phase 2 DMJ2REU SN Berubicin hydrochloride; RTA-744; RTA-769; WP-744; WP-769; Anthracycline derivative topoisomerase II inhibitor (cancer), MD Anderson; Anthracycline derivative topoisomerase II inhibitor (cancer), Reata; Berubicin (intravenous), Reata Pharmaceuticals; Berubicin (oral, cancer); Anthracycline topoisomerase II inhibitor (oral, cancer), MD Anderson Cancer Center; Anthracycline topoisomerase II inhibitor (oral, cancer), Reata Pharmaceuticals; Berubicin (oral, cancer), Reata Pharmaceuticals DMJ2REU CP MD Anderson Cancer Center DMJ2REU DT Small molecular drug DMJ2REU PC 9874592 DMJ2REU MW 633.6 DMJ2REU FM C34H35NO11 DMJ2REU IC InChI=1S/C34H35NO11/c1-16-33(44-15-17-7-4-3-5-8-17)20(35)11-24(45-16)46-22-13-34(42,23(37)14-36)12-19-26(22)32(41)28-27(30(19)39)29(38)18-9-6-10-21(43-2)25(18)31(28)40/h3-10,16,20,22,24,33,36,39,41-42H,11-15,35H2,1-2H3/t16-,20-,22-,24-,33+,34-/m0/s1 DMJ2REU CS C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)OCC6=CC=CC=C6 DMJ2REU IK FIGNGSHKNAHTSH-JJMFXPFOSA-N DMJ2REU IU (7S,9S)-7-[(2R,4S,5S,6S)-4-amino-6-methyl-5-phenylmethoxyoxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione DMJ2REU CA CAS 677017-23-1 DMJ2REU DE Solid tumour/cancer DM7583A ID DM7583A DM7583A DN Beta-caryophyllene DM7583A HS Phase 2 DM7583A SN BETA-CARYOPHYLLENE; Caryophyllene; (-)-trans-Caryophyllene; 87-44-5; L-Caryophyllene; (-)-beta-caryophyllene; trans-Caryophyllene; (E)-Caryophyllene; (E)-beta-caryophyllene; b-caryophyllene; trans-beta-caryophyllene; Beta-Caryophylene; (-)-Caryophyllene; beta-Caryophyllen; beta-Caryophyllene; CHEBI:10357; (E)-beta-caryophylene; beta-(E)-Caryophyllene; beta-Caryophyllen; (1R,4E,9S)-4,11,11-trimethyl-8-methylidenebicyclo[7.2.0]undec-4-ene; MFCD00075925; UNII-BHW853AU9H; g-Caryophyllene; (1R,9S,E)-4,11,11-trimethyl-8-methylenebicyclo[7.2.0]undec-4-ene; (1S,9R)-6,10,10-trimethyl-2-methylenebicyclo[7.2.0]undec-5-ene; NSC 11906; E-.beta.-caryophyllene; BHW853AU9H; beta-Caryophyllene, (-); Tincturoid; NSC11906; Caryophyllene B; beta-cariofillene; (1R,4E,9S)-4,11,11-trimethyl-8-methylene-bicyclo[7.2.0]undec-4-ene; beta-caryophillene; Bicyclo(7.2.0)undec-4-ene, 8-methylene-4,11,11-trimethyl-, (E)-(1R,9S)-(-)-; Bicyclo[7.2.0]undec-4-ene, 8-methylene-4,11,11-trimethyl-, (E)-(1R,9S)-(-)-; Bicyclo[7.2.0]undec-4-ene, 4,11,11-trimethyl-8-methylene-, [1R-(1R*,4E,9S*)]-; E-beta-caryophyllene; Caryophyllene, (E); beta-(e)-caryophyllene; beta-trans-caryophyllene; (-)- -caryophyllene; (-)-(E)-Caryophyllene; DSSTox_CID_4739; beta-trans-Caryophyllene; trans-.beta.-Caryophyllene; (-)-I(2)-caryophyllene; DSSTox_RID_77517; DSSTox_GSID_24739; 8-Methylene-4,11,11-(trimethyl)bicyclo[7.2.0]undec-4-ene; CHEMBL445740; DTXSID8024739; HY-N1415; ZINC8234282; Tox21_301497; BDBM50529607; s6058; (1R,4E,9S)-4,11,11-trimethyl-8-methylenebicyclo[7.2.0]undec-4-ene; AKOS024283988; trans-(1R,9S)-8-Methylene-4,11,11-trimethylbicyclo[7.2.0]undec-4-ene; LMPR0103120001; beta-Caryophyllene, >=80%, FCC, FG; CAS-87-44-5; NCGC00142620-01; NCGC00255159-01; ST072181; (-)-trans-Caryophyllene, analytical standard; CS-0016839; V0915; C09629; Q421614; W-109317; UNII-K4H93P747O component NPNUFJAVOOONJE-GFUGXAQUSA-N; (-)-trans-Caryophyllene, >=98.5% (sum of enantiomers, GC); trans-(1R,9S)-4,11,11-trimethyl-8-methylenebicyclo[7.2.0]undec-4-ene; 8-Methylene-4,11,11-(trimethyl)bicyclo(7.2.0)undec-4-ene, (1R,4E,9S)-; Bicyclo[7.2.0]undec-4-ene, 4,11,11-trimethyl-8-methylene-, (E)-(1R,9S)-(-)-; Bicyclo[7.2.0]undec-4-ene, 4,11,11-trimethyl-8-methylene-, [1R- (1R*,4E,9S*)]- DM7583A DT Small molecular drug DM7583A PC 5281515 DM7583A MW 204.35 DM7583A FM C15H24 DM7583A IC InChI=1S/C15H24/c1-11-6-5-7-12(2)13-10-15(3,4)14(13)9-8-11/h6,13-14H,2,5,7-10H2,1,3-4H3/b11-6+/t13-,14-/m1/s1 DM7583A CS C/C/1=C\\CCC(=C)[C@H]2CC([C@@H]2CC1)(C)C DM7583A IK NPNUFJAVOOONJE-GFUGXAQUSA-N DM7583A IU (1R,4E,9S)-4,11,11-trimethyl-8-methylidenebicyclo[7.2.0]undec-4-ene DM7583A CA CAS 87-44-5 DM7583A CB CHEBI:10357 DM7583A DE Pain DMMI84K ID DMMI84K DMMI84K DN Beta-lapachone DMMI84K HS Phase 2 DMMI84K SN ARQ 501; SL 11001; A-lapachone; LAPACHONE, BETA; AK-693/21096016; 2,2-dimethyl-3,4-dihydrobenzo[h]chromene-5,6-dione; 3,4-Dihydro-2,2-dimethyl-2H-naphtho(1,2-b)pyran-5,6-dione; 3,4-Dihydro-2,2-dimethyl-2H-naphtho[1,2-B]pyran-5,6-dione DMMI84K CP Roche DMMI84K DT Small molecular drug DMMI84K PC 3885 DMMI84K MW 242.27 DMMI84K FM C15H14O3 DMMI84K IC InChI=1S/C15H14O3/c1-15(2)8-7-11-13(17)12(16)9-5-3-4-6-10(9)14(11)18-15/h3-6H,7-8H2,1-2H3 DMMI84K CS CC1(CCC2=C(O1)C3=CC=CC=C3C(=O)C2=O)C DMMI84K IK QZPQTZZNNJUOLS-UHFFFAOYSA-N DMMI84K IU 2,2-dimethyl-3,4-dihydrobenzo[h]chromene-5,6-dione DMMI84K CA CAS 4707-32-8 DMMI84K CB CHEBI:10429 DMMI84K DE Solid tumour/cancer DML2D8Q ID DML2D8Q DML2D8Q DN Bevirimat DML2D8Q HS Phase 2 DML2D8Q SN DSB; Bevirimat dimeglumine; DSB 2NMG; MPC-4326; PA-457; PA-103001-01; PA-103001-04; PA-457 di-NMG; Viral maturation inhibitor (HIV), Myrexis; Viral maturation inhibitor (HIV), Myriad; Viral maturation inhibitor (HIV), Panacos; YK-FH-312; 3-O-(3' 3'-dimethylsuccinyl)-betulinic acid DML2D8Q CP Panacos DML2D8Q DT Small molecular drug DML2D8Q PC 457928 DML2D8Q MW 584.8 DML2D8Q FM C36H56O6 DML2D8Q IC InChI=1S/C36H56O6/c1-21(2)22-12-17-36(30(40)41)19-18-34(8)23(28(22)36)10-11-25-33(7)15-14-26(42-27(37)20-31(3,4)29(38)39)32(5,6)24(33)13-16-35(25,34)9/h22-26,28H,1,10-20H2,2-9H3,(H,38,39)(H,40,41)/t22-,23+,24-,25+,26-,28+,33-,34+,35+,36-/m0/s1 DML2D8Q CS CC(=C)[C@@H]1CC[C@]2([C@H]1[C@H]3CC[C@@H]4[C@]5(CC[C@@H](C([C@@H]5CC[C@]4([C@@]3(CC2)C)C)(C)C)OC(=O)CC(C)(C)C(=O)O)C)C(=O)O DML2D8Q IK YJEJKUQEXFSVCJ-WRFMNRASSA-N DML2D8Q IU (1R,3aS,5aR,5bR,7aR,9S,11aR,11bR,13aR,13bR)-9-(3-carboxy-3-methylbutanoyl)oxy-5a,5b,8,8,11a-pentamethyl-1-prop-1-en-2-yl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysene-3a-carboxylic acid DML2D8Q CA CAS 174022-42-5 DML2D8Q CB CHEBI:65484 DML2D8Q DE Human immunodeficiency virus infection DMKBRDL ID DMKBRDL DMKBRDL DN BEZ235 DMKBRDL HS Phase 2 DMKBRDL SN BEZ-235; S14-0511; NVP-BEZ-235; NVP-BEZ235, BEZ235; 2-(4-(2,3-dihydro-3-methyl-2-oxo-8-(quinolin-3-yl)imidazo[4,5-c]quinolin-1-yl)phenyl)-2-methylpropanenitrile DMKBRDL CP Novartis DMKBRDL DT Small molecular drug DMKBRDL PC 11977753 DMKBRDL MW 469.5 DMKBRDL FM C30H23N5O DMKBRDL IC InChI=1S/C30H23N5O/c1-30(2,18-31)22-9-11-23(12-10-22)35-28-24-15-19(21-14-20-6-4-5-7-25(20)32-16-21)8-13-26(24)33-17-27(28)34(3)29(35)36/h4-17H,1-3H3 DMKBRDL CS CC(C)(C#N)C1=CC=C(C=C1)N2C3=C4C=C(C=CC4=NC=C3N(C2=O)C)C5=CC6=CC=CC=C6N=C5 DMKBRDL IK JOGKUKXHTYWRGZ-UHFFFAOYSA-N DMKBRDL IU 2-methyl-2-[4-(3-methyl-2-oxo-8-quinolin-3-ylimidazo[4,5-c]quinolin-1-yl)phenyl]propanenitrile DMKBRDL CA CAS 915019-65-7 DMKBRDL CB CHEBI:71952 DMKBRDL DE Solid tumour/cancer DMVUX1C ID DMVUX1C DMVUX1C DN BFH-772 DMVUX1C HS Phase 2 DMVUX1C SN NVP-BFH-772 DMVUX1C CP Novartis AG DMVUX1C PC 24756034 DMVUX1C MW 439.4 DMVUX1C FM C23H16F3N3O3 DMVUX1C IC InChI=1S/C23H16F3N3O3/c24-23(25,26)15-4-2-5-16(10-15)29-22(31)20-6-1-3-14-9-18(7-8-19(14)20)32-21-11-17(12-30)27-13-28-21/h1-11,13,30H,12H2,(H,29,31) DMVUX1C CS C1=CC(=CC(=C1)NC(=O)C2=CC=CC3=C2C=CC(=C3)OC4=NC=NC(=C4)CO)C(F)(F)F DMVUX1C IK JNLSTLQFDDAULK-UHFFFAOYSA-N DMVUX1C IU 6-[6-(hydroxymethyl)pyrimidin-4-yl]oxy-N-[3-(trifluoromethyl)phenyl]naphthalene-1-carboxamide DMVUX1C CA CAS 890128-81-1 DMVUX1C DE Psoriasis vulgaris DMRO6XT ID DMRO6XT DMRO6XT DN BGB-290 DMRO6XT HS Phase 2 DMRO6XT SN Pamiparib DMRO6XT PC 135565554 DMRO6XT MW 298.31 DMRO6XT FM C16H15FN4O DMRO6XT IC InChI=1S/C16H15FN4O/c1-16-3-2-4-21(16)7-11-13-12-9(15(22)20-19-11)5-8(17)6-10(12)18-14(13)16/h5-6,18H,2-4,7H2,1H3,(H,20,22)/t16-/m1/s1 DMRO6XT CS C[C@]12CCCN1CC3=NNC(=O)C4=C5C3=C2NC5=CC(=C4)F DMRO6XT IK DENYZIUJOTUUNY-MRXNPFEDSA-N DMRO6XT IU (2R)-14-fluoro-2-methyl-6,9,10,19-tetrazapentacyclo[14.2.1.02,6.08,18.012,17]nonadeca-1(18),8,12(17),13,15-pentaen-11-one DMRO6XT CA CAS 1446261-44-4 DMRO6XT DE Recurrent glioblastoma; Solid tumour/cancer; Ovarian cancer DMQCFSM ID DMQCFSM DMQCFSM DN BGB-3112 DMQCFSM HS Phase 2 DMQCFSM CP BeiGene Cambridge, MA DMQCFSM DE Follicular lymphoma DMDI43Y ID DMDI43Y DMDI43Y DN BGB-324 DMDI43Y HS Phase 2 DMDI43Y SN BGB-001; SiRNA therapeutic (metastasis cancer), BiobergenBio DMDI43Y CP BergenBio AS DMDI43Y DT siRNA drug DMDI43Y DE Metastatic malignant neoplasm; Acute myeloid leukaemia; Breast cancer; Myelodysplastic syndrome DM1X3L0 ID DM1X3L0 DM1X3L0 DN BGB-3245 DM1X3L0 HS Phase 2 DM1X3L0 CP BeiGene DM1X3L0 DT Small molecular drug DM1X3L0 DE Solid tumour/cancer DMS2MQ5 ID DMS2MQ5 DMS2MQ5 DN BGC-20-1531 DMS2MQ5 HS Phase 2 DMS2MQ5 SN AH-22921; EP4 antagonist, BTG; EP4 antagonist, Pharmagene; Migraine therapy, BTG; Migraine therapy, Pharmagene; PGN-1531; EP4 receptor antagonists (migraine), Asterand; R-4 (migraine), Pharmagene DMS2MQ5 CP Pharmagene plc DMS2MQ5 DT Small molecular drug DMS2MQ5 PC 25209437 DMS2MQ5 MW 514.5 DMS2MQ5 FM C26H23N2NaO6S DMS2MQ5 IC InChI=1S/C26H24N2O6S.Na/c1-17-6-4-5-7-25(17)35(30,31)28-26(29)24-14-20(18(2)34-24)16-33-21-10-8-19(9-11-21)23-13-12-22(32-3)15-27-23;/h4-15H,16H2,1-3H3,(H,28,29);/q;+1/p-1 DMS2MQ5 CS CC1=CC=CC=C1S(=O)(=O)[N-]C(=O)C2=CC(=C(O2)C)COC3=CC=C(C=C3)C4=NC=C(C=C4)OC.[Na+] DMS2MQ5 IK TVDHMDXPKGMXRT-UHFFFAOYSA-M DMS2MQ5 IU sodium;[4-[[4-(5-methoxypyridin-2-yl)phenoxy]methyl]-5-methylfuran-2-carbonyl]-(2-methylphenyl)sulfonylazanide DMS2MQ5 DE Migraine DMYDM68 ID DMYDM68 DMYDM68 DN BGP-15 DMYDM68 HS Phase 2 DMYDM68 SN 66611-37-8; BGP-15 2HCl; 3-Pyridinecarboximidamide, N-(2-hydroxy-3-(1-piperidinyl)propoxy)-, hydrochloride (1:2); BGP 15; BGP15; SCHEMBL3067994; MolPort-039-099-291; MolPort-027-834-918; s8370; AKOS016007888; AKOS026745444; SB17119; CS-6045; 3-Pyridinecarboximidamide, N-(2-hydroxy-3-(1-piperidinyl)propoxy)-, dihydrochloride; BGP-15, > AS-16983; TC-162219; AX8217132; KB-258115; HY-100828; (Z)-N'-(2-hydroxy-3-(piperidin-1-yl)propoxy)nicotinimidamide dihydrochloride DMYDM68 CP N-Gene Research Laboratories DMYDM68 DT Small molecular drug DMYDM68 PC 9884807 DMYDM68 MW 351.3 DMYDM68 FM C14H24Cl2N4O2 DMYDM68 IC InChI=1S/C14H22N4O2.2ClH/c15-14(12-5-4-6-16-9-12)17-20-11-13(19)10-18-7-2-1-3-8-18;;/h4-6,9,13,19H,1-3,7-8,10-11H2,(H2,15,17);2*1H DMYDM68 CS C1CCN(CC1)CC(CO/N=C(/C2=CN=CC=C2)\\N)O.Cl.Cl DMYDM68 IK ISGGVCWFTPTHIX-UHFFFAOYSA-N DMYDM68 IU N'-(2-hydroxy-3-piperidin-1-ylpropoxy)pyridine-3-carboximidamide;dihydrochloride DMYDM68 CA CAS 66611-37-8 DMYDM68 DE Type-2 diabetes DMO4MNQ ID DMO4MNQ DMO4MNQ DN BGS-649 DMO4MNQ HS Phase 2 DMO4MNQ CP Novartis AG DMO4MNQ DE Endometriosis DMSROM4 ID DMSROM4 DMSROM4 DN BHQ880 DMSROM4 HS Phase 2 DMSROM4 SN BHQ-880A; Anti-DKK1 monoclonal antibody (multiple myeloma), Novartis DMSROM4 CP Novartis DMSROM4 DT Antibody DMSROM4 DE Multiple myeloma DM7ZM1H ID DM7ZM1H DM7ZM1H DN BHT-3009 DM7ZM1H HS Phase 2 DM7ZM1H CP Bayhill Therapeutics DM7ZM1H DT Vaccine DM7ZM1H DE Multiple sclerosis DM740BS ID DM740BS DM740BS DN BI 1358894 DM740BS HS Phase 2 DM740BS CP Boehringer Ingelheim DM740BS DT Small molecular drug DM740BS DE Depression DMMSGAT ID DMMSGAT DMMSGAT DN BI 207127 DMMSGAT HS Phase 2 DMMSGAT SN Deleobuvir; UNII-58BU988K90; 58BU988K90; 863884-77-9; Deleobuvir [USAN:INN]; SCHEMBL900174; SCHEMBL900176; CHEMBL2403318; DTXSID40235516; BMAIGAHXAJEULY-UKTHLTGXSA-N; SB16520; BI-207127; 1221574-24-8; (E)-3-(2-(1-(2-(5-Bromopyrimidin-2-yl)-3-cyclopentyl-1-methyl-1H-indole-6-carboxamido)cyclobutyl)-1-methyl-1H-benzo[d]imidazol-6-yl)acrylic; Deleobuvir; (E)-3-(2-(1-(2-(5-Bromopyrimidin-2-yl)-3-cyclopentyl-1-methyl-1H-indole-6-carboxamido)cyclobutyl)-1-methyl-1H-benzo[d]imidazol-6-yl)acrylic acid; 2-Propenoic acid, 3-(2-(1-(((2-(5-bromo-2-pyrimidinyl)-3-cyclopentyl-1-methyl-1H-indol-6-yl)carbonyl)amino)cyclobutyl)-1-methyl-1H-benzimidazol-6-yl)-, (2E)-; (E)-3-(2-(1 DMMSGAT CP Boehringer Ingelheim Pharma DMMSGAT DT Small molecular drug DMMSGAT PC 56948249 DMMSGAT MW 653.6 DMMSGAT FM C34H33BrN6O3 DMMSGAT IC InChI=1S/C34H33BrN6O3/c1-40-26-17-22(10-11-24(26)29(21-6-3-4-7-21)30(40)31-36-18-23(35)19-37-31)32(44)39-34(14-5-15-34)33-38-25-12-8-20(9-13-28(42)43)16-27(25)41(33)2/h8-13,16-19,21H,3-7,14-15H2,1-2H3,(H,39,44)(H,42,43)/b13-9+ DMMSGAT CS CN1C2=C(C=CC(=C2)C(=O)NC3(CCC3)C4=NC5=C(N4C)C=C(C=C5)/C=C/C(=O)O)C(=C1C6=NC=C(C=N6)Br)C7CCCC7 DMMSGAT IK BMAIGAHXAJEULY-UKTHLTGXSA-N DMMSGAT IU (E)-3-[2-[1-[[2-(5-bromopyrimidin-2-yl)-3-cyclopentyl-1-methylindole-6-carbonyl]amino]cyclobutyl]-3-methylbenzimidazol-5-yl]prop-2-enoic acid DMMSGAT CA CAS 863884-77-9 DMMSGAT DE Hepatitis C virus infection DMJSADP ID DMJSADP DMJSADP DN BI 2536 DMJSADP HS Phase 2 DMJSADP SN BI2536, BI 2536 DMJSADP CP Boehringer Ingelheim DMJSADP TC Anticancer Agents DMJSADP DT Small molecular drug DMJSADP PC 11364421 DMJSADP MW 521.7 DMJSADP FM C28H39N7O3 DMJSADP IC InChI=1S/C28H39N7O3/c1-5-22-27(37)34(3)23-17-29-28(32-25(23)35(22)20-8-6-7-9-20)31-21-11-10-18(16-24(21)38-4)26(36)30-19-12-14-33(2)15-13-19/h10-11,16-17,19-20,22H,5-9,12-15H2,1-4H3,(H,30,36)(H,29,31,32)/t22-/m1/s1 DMJSADP CS CC[C@@H]1C(=O)N(C2=CN=C(N=C2N1C3CCCC3)NC4=C(C=C(C=C4)C(=O)NC5CCN(CC5)C)OC)C DMJSADP IK XQVVPGYIWAGRNI-JOCHJYFZSA-N DMJSADP IU 4-[[(7R)-8-cyclopentyl-7-ethyl-5-methyl-6-oxo-7H-pteridin-2-yl]amino]-3-methoxy-N-(1-methylpiperidin-4-yl)benzamide DMJSADP CA CAS 755038-02-9 DMJSADP DE Acute myeloid leukaemia DM1NMGJ ID DM1NMGJ DM1NMGJ DN BI 456906 DM1NMGJ HS Phase 2 DM1NMGJ CP Boehringer Ingelheim; Zealand Pharma DM1NMGJ DT Small molecular drug DM1NMGJ DE Type 2 diabetes DMF86P2 ID DMF86P2 DMF86P2 DN BI 655064 DMF86P2 HS Phase 2 DMF86P2 CP Boehringer ingelheim pharmaceuticals DMF86P2 DT Antibody DMF86P2 DE Rheumatoid arthritis; Lupus; Thrombocytopenia DMJFDS0 ID DMJFDS0 DMJFDS0 DN BI-409306 DMJFDS0 HS Phase 2 DMJFDS0 CP Boehringer Ingelheim Pharmaceuticals DMJFDS0 PC 135908617 DMJFDS0 MW 311.34 DMJFDS0 FM C16H17N5O2 DMJFDS0 IC InChI=1S/C16H17N5O2/c22-16-13-10-18-21(12-4-7-23-8-5-12)15(13)19-14(20-16)9-11-3-1-2-6-17-11/h1-3,6,10,12H,4-5,7-9H2,(H,19,20,22) DMJFDS0 CS C1COCCC1N2C3=C(C=N2)C(=O)NC(=N3)CC4=CC=CC=N4 DMJFDS0 IK BZTIJCSHNVZMES-UHFFFAOYSA-N DMJFDS0 IU 1-(oxan-4-yl)-6-(pyridin-2-ylmethyl)-5H-pyrazolo[3,4-d]pyrimidin-4-one DMJFDS0 CA CAS 1189767-28-9 DMJFDS0 DE Psychiatric disorder; Alzheimer disease; Schizophrenia DMZR9OU ID DMZR9OU DMZR9OU DN BI-44370 DMZR9OU HS Phase 2 DMZR9OU SN BI-44370; Calcitonin gene-related peptide antagonist (migraine), Boehringer Ingelheim DMZR9OU CP Boehringer Ingelheim Corp DMZR9OU DE Migraine DMSZQHX ID DMSZQHX DMSZQHX DN BI-505 DMSZQHX HS Phase 2 DMSZQHX CP BioInvent International DMSZQHX DT Antibody DMSZQHX DE Multiple myeloma DM9FZYT ID DM9FZYT DM9FZYT DN BI-655130 DM9FZYT HS Phase 2 DM9FZYT CP Boehringer Ingelheim Ridgefield, CT DM9FZYT DE Plaque psoriasis; Palmoplantar pustulosis DMWH7Z5 ID DMWH7Z5 DMWH7Z5 DN BI-836826 DMWH7Z5 HS Phase 2 DMWH7Z5 CP Boehringer Ingelheim Pharmaceuticals DMWH7Z5 DT Antibody DMWH7Z5 DE Chronic lymphocytic leukaemia; Solid tumour/cancer; Diffuse large B-cell lymphoma; Non-hodgkin lymphoma DMUVMY9 ID DMUVMY9 DMUVMY9 DN BI-836858 DMUVMY9 HS Phase 2 DMUVMY9 CP Boehringer Ingelheim Pharmaceuticals DMUVMY9 DT Antibody DMUVMY9 DE Acute myeloid leukaemia; Myelodysplastic syndrome DMG3ON2 ID DMG3ON2 DMG3ON2 DN BIA 3-202 DMG3ON2 HS Phase 2 DMG3ON2 SN Nebicapone; 274925-86-9; UNII-NM2KXJ990T; NM2KXJ990T; CHEMBL160038; Ethanone, 1-(3,4-dihydroxy-5-nitrophenyl)-2-phenyl-; BIA 3-202; Nebicapone [INN]; 1-(3,4-dihydroxy-5-nitrophenyl)-2-phenylethanone; SCHEMBL132167; ZINC8750; 1-(3,4-dihydroxy-5-nitro-phenyl)-2-phenyl-ethanone; CTK8H9559; DTXSID30181912; BIA-3-202; BDBM50108878; AKOS028111881; ACM274925869; FT-0703128 DMG3ON2 DT Small molecular drug DMG3ON2 PC 9838389 DMG3ON2 MW 273.24 DMG3ON2 FM C14H11NO5 DMG3ON2 IC InChI=1S/C14H11NO5/c16-12(6-9-4-2-1-3-5-9)10-7-11(15(19)20)14(18)13(17)8-10/h1-5,7-8,17-18H,6H2 DMG3ON2 CS C1=CC=C(C=C1)CC(=O)C2=CC(=C(C(=C2)O)O)[N+](=O)[O-] DMG3ON2 IK MRFOLGFFTUGAEB-UHFFFAOYSA-N DMG3ON2 IU 1-(3,4-dihydroxy-5-nitrophenyl)-2-phenylethanone DMG3ON2 CA CAS 274925-86-9 DMG3ON2 DE Parkinson disease DMHYZEK ID DMHYZEK DMHYZEK DN BIBH 1 DMHYZEK HS Phase 2 DMHYZEK CP Boehringer Ingelheim DMHYZEK DT Antibody DMHYZEK DE Solid tumour/cancer DM9OXEJ ID DM9OXEJ DM9OXEJ DN BIIB 023 DM9OXEJ HS Phase 2 DM9OXEJ CP Biogen Idec DM9OXEJ DE Rheumatoid arthritis DM293JT ID DM293JT DM293JT DN BIIB 033 DM293JT HS Phase 2 DM293JT DT Antibody DM293JT DE Multiple sclerosis DMH7RJ1 ID DMH7RJ1 DMH7RJ1 DN BIIB014 DMH7RJ1 HS Phase 2 DMH7RJ1 SN V2006 DMH7RJ1 CP Biogen Idec DMH7RJ1 DT Small molecular drug DMH7RJ1 PC 21874557 DMH7RJ1 MW 321.34 DMH7RJ1 FM C16H15N7O DMH7RJ1 IC InChI=1S/C16H15N7O/c1-9-7-10(4-5-11(9)17)8-23-15-14(21-22-23)13(19-16(18)20-15)12-3-2-6-24-12/h2-7H,8,17H2,1H3,(H2,18,19,20) DMH7RJ1 CS CC1=C(C=CC(=C1)CN2C3=NC(=NC(=C3N=N2)C4=CC=CO4)N)N DMH7RJ1 IK HQSBCDPYXDGTCL-UHFFFAOYSA-N DMH7RJ1 IU 3-[(4-amino-3-methylphenyl)methyl]-7-(furan-2-yl)triazolo[4,5-d]pyrimidin-5-amine DMH7RJ1 CA CAS 442908-10-3 DMH7RJ1 DE Parkinson disease DMPAJ41 ID DMPAJ41 DMPAJ41 DN BIIB-021 DMPAJ41 HS Phase 2 DMPAJ41 SN CNF-2024; CNF-3647; EC-129; EC-137; EC-138; EC-141; EC-144; EC-146; EC-147; EC-151; EC-78; EC-89; EC-145, Conforma; EC-82, Conforma; Hsp90 inhibitor (cancer), Biogen Idec; Synthetic Hsp90 inhibitors (cancer), Conforma; Hsp90 inhibitors (synthetic, cancer), Conforma DMPAJ41 CP Conforma Therapeutics Corp DMPAJ41 DT Small molecular drug DMPAJ41 PC 16736529 DMPAJ41 MW 318.76 DMPAJ41 FM C14H15ClN6O DMPAJ41 IC InChI=1S/C14H15ClN6O/c1-7-4-17-9(8(2)11(7)22-3)5-21-6-18-10-12(15)19-14(16)20-13(10)21/h4,6H,5H2,1-3H3,(H2,16,19,20) DMPAJ41 CS CC1=CN=C(C(=C1OC)C)CN2C=NC3=C2N=C(N=C3Cl)N DMPAJ41 IK QULDDKSCVCJTPV-UHFFFAOYSA-N DMPAJ41 IU 6-chloro-9-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]purin-2-amine DMPAJ41 CA CAS 848695-25-0 DMPAJ41 CB CHEBI:90687 DMPAJ41 DE Breast cancer DMZO2SY ID DMZO2SY DMZO2SY DN BIIB054 DMZO2SY HS Phase 2 DMZO2SY CP Biogen Cambridge, MA DMZO2SY DE Parkinson disease DMLV1ET ID DMLV1ET DMLV1ET DN BIIB074 DMLV1ET HS Phase 2 DMLV1ET SN CNV1014082; BC600719; HY-12796; B5927; (5R)-5-(4-[2- DMLV1ET CP Biogen DMLV1ET PC 16046068 DMLV1ET MW 314.4 DMLV1ET FM C18H19FN2O2 DMLV1ET IC InChI=1S/C18H19FN2O2/c19-15-4-2-1-3-13(15)11-23-14-7-5-12(6-8-14)16-9-10-17(21-16)18(20)22/h1-8,16-17,21H,9-11H2,(H2,20,22)/t16-,17+/m1/s1 DMLV1ET CS C1C[C@H](N[C@H]1C2=CC=C(C=C2)OCC3=CC=CC=C3F)C(=O)N DMLV1ET IK JESCETIFNOFKEU-SJORKVTESA-N DMLV1ET IU (2S,5R)-5-[4-[(2-fluorophenyl)methoxy]phenyl]pyrrolidine-2-carboxamide DMLV1ET CA CAS 934240-30-9 DMLV1ET DE Lumbosacral radiculopathy; Trigeminal neuralgia; Bipolar disorder DM263RP ID DM263RP DM263RP DN BIIB092 DM263RP HS Phase 2 DM263RP CP Biogen Cambridge, MA DM263RP DE Alzheimer disease; Progressive supranuclear palsy DM2J36F ID DM2J36F DM2J36F DN BILN-2061 DM2J36F HS Phase 2 DM2J36F SN Ciluprevir; BILN-2061; 300832-84-2; BILN 2061; UNII-75C8DU40T0; CHEMBL297884; 75C8DU40T0; Ciluprevir [USAN:INN]; Ciluprevir (BILN-2061); BILN 2061 ZW; BILN2061; SCHEMBL2524642; BILN-2061-ZW; C40H50N6O8S; (cyclopentoxycarbonylamino)-[[2-[2-(isopropylamino)thiazol-4-yl]-7-methoxy-4-quinolyl]oxy]-dioxo-[ ]carboxylic acid; BDBM50142916; 3548AH; ZINC150339466; AKOS024627485; CS-0339; DB05868; BILN 2061; ; ; BILN 2061ZW; HY-10242; W-5515; F2145-0237 DM2J36F TC Antiviral Agents DM2J36F DT Small molecular drug DM2J36F PC 9853710 DM2J36F MW 774.9 DM2J36F FM C40H50N6O8S DM2J36F IC InChI=1S/C40H50N6O8S/c1-23(2)41-38-43-32(22-55-38)31-19-34(28-16-15-26(52-3)17-30(28)42-31)53-27-18-33-35(47)45-40(37(49)50)20-24(40)11-7-5-4-6-8-14-29(36(48)46(33)21-27)44-39(51)54-25-12-9-10-13-25/h7,11,15-17,19,22-25,27,29,33H,4-6,8-10,12-14,18,20-21H2,1-3H3,(H,41,43)(H,44,51)(H,45,47)(H,49,50)/b11-7-/t24-,27-,29+,33+,40-/m1/s1 DM2J36F CS CC(C)NC1=NC(=CS1)C2=NC3=C(C=CC(=C3)OC)C(=C2)O[C@@H]4C[C@H]5C(=O)N[C@@]6(C[C@H]6/C=C\\CCCCC[C@@H](C(=O)N5C4)NC(=O)OC7CCCC7)C(=O)O DM2J36F IK PJZPDFUUXKKDNB-KNINVFKUSA-N DM2J36F IU (1S,4R,6S,7Z,14S,18R)-14-(cyclopentyloxycarbonylamino)-18-[7-methoxy-2-[2-(propan-2-ylamino)-1,3-thiazol-4-yl]quinolin-4-yl]oxy-2,15-dioxo-3,16-diazatricyclo[14.3.0.04,6]nonadec-7-ene-4-carboxylic acid DM2J36F CA CAS 300832-84-2 DM2J36F DE Hepatitis virus infection DMAG4SX ID DMAG4SX DMAG4SX DN BILR-355 DMAG4SX HS Phase 2 DMAG4SX SN BILR-355-BS; 11-Ethyl-5-methyl-8-[2-(1-oxidoquinolin-4-yloxy)ethyl]-6,11-dihydro-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one DMAG4SX DE Human immunodeficiency virus infection DM6EIZG ID DM6EIZG DM6EIZG DN BIM23A760 DM6EIZG HS Phase 2 DM6EIZG SN Lonapalene; LONAPALENE; RS-43179; 91431-42-4; UNII-WIF31Q54NJ; WIF31Q54NJ; CHEMBL36648; Lonapalenum; Lonapaleno; Lonapalenum [Latin]; Lonapaleno [Spanish]; Lonapalene (USAN); Lonapalene [USAN:INN]; RS 43179; 6-Chloro-2,3-dimethoxy-1,4-naphthalenediol diacetate; (4-acetyloxy-6-chloro-2,3-dimethoxynaphthalen-1-yl) acetate; AC1L1KN9; SCHEMBL120134; ZINC1630; DTXSID00238563; IFWMVQUGSGWCRP-UHFFFAOYSA-N; HY-U00156; BDBM50004677; CS-7197; ZB000377; D04770; 6-chloro-1,4-diacetoxy-2,3-dimethoxynaphthalene DM6EIZG CP Ipsen DM6EIZG DT Small molecular drug DM6EIZG PC 56237 DM6EIZG MW 338.74 DM6EIZG FM C16H15ClO6 DM6EIZG IC InChI=1S/C16H15ClO6/c1-8(18)22-13-11-6-5-10(17)7-12(11)14(23-9(2)19)16(21-4)15(13)20-3/h5-7H,1-4H3 DM6EIZG CS CC(=O)OC1=C(C(=C(C2=C1C=CC(=C2)Cl)OC(=O)C)OC)OC DM6EIZG IK IFWMVQUGSGWCRP-UHFFFAOYSA-N DM6EIZG IU (4-acetyloxy-6-chloro-2,3-dimethoxynaphthalen-1-yl) acetate DM6EIZG CA CAS 91431-42-4 DM6EIZG DE Acromegaly; Carcinoid syndrome; Psoriasis vulgaris DMH7Q4E ID DMH7Q4E DMH7Q4E DN Bimagrumab DMH7Q4E HS Phase 2 DMH7Q4E CP Novartis DMH7Q4E DT Antibody DMH7Q4E DE Type 2 diabetes DMBRL19 ID DMBRL19 DMBRL19 DN Bimakalim DMBRL19 HS Phase 2 DMBRL19 SN EMD-52692; SR-44866 DMBRL19 CP Merck KGaA DMBRL19 DT Small molecular drug DMBRL19 PC 60674 DMBRL19 MW 278.3 DMBRL19 FM C17H14N2O2 DMBRL19 IC InChI=1S/C17H14N2O2/c1-17(2)10-14(19-8-4-3-5-16(19)20)13-9-12(11-18)6-7-15(13)21-17/h3-10H,1-2H3 DMBRL19 CS CC1(C=C(C2=C(O1)C=CC(=C2)C#N)N3C=CC=CC3=O)C DMBRL19 IK JTVSKASWNROQQF-UHFFFAOYSA-N DMBRL19 IU 2,2-dimethyl-4-(2-oxopyridin-1-yl)chromene-6-carbonitrile DMBRL19 CA CAS 117545-11-6 DMBRL19 DE Angina pectoris DMB9LRJ ID DMB9LRJ DMB9LRJ DN Bintrafusp alfa DMB9LRJ HS Phase 2 DMB9LRJ CP EMD Serono; GlaxoSmithKline DMB9LRJ DT Recombinant protein DMB9LRJ DE Non-small cell lung cancer DM6N05H ID DM6N05H DM6N05H DN BIO-11006 DM6N05H HS Phase 2 DM6N05H CP BioMarck Pharmaceuticals DM6N05H DE Chronic obstructive pulmonary disease; Non-small-cell lung cancer DMPNYXQ ID DMPNYXQ DMPNYXQ DN BIO-11006 DMPNYXQ HS Phase 2 DMPNYXQ SN UNII-609AWV0US2; 609AWV0US2; DB14886; (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[(2-acetamidoacetyl)amino]propanoyl]amino]-5-amino-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxypropanoyl]amino]-6-aminohexanoyl]amino]-3-hydroxybutanoyl]amino]propanoyl]amino]propanoyl]amino]-6-aminohexanoic acid; 901117-03-1 DMPNYXQ CP BioMarck Pharmaceuticals DMPNYXQ DT Small molecular drug DMPNYXQ PC 11622197 DMPNYXQ MW 1050.2 DMPNYXQ FM C46H75N13O15 DMPNYXQ IC InChI=1S/C46H75N13O15/c1-24(51-36(64)22-50-28(5)62)39(66)54-31(17-18-35(49)63)41(68)57-33(21-29-13-7-6-8-14-29)43(70)58-34(23-60)44(71)55-30(15-9-11-19-47)42(69)59-37(27(4)61)45(72)53-25(2)38(65)52-26(3)40(67)56-32(46(73)74)16-10-12-20-48/h6-8,13-14,24-27,30-34,37,60-61H,9-12,15-23,47-48H2,1-5H3,(H2,49,63)(H,50,62)(H,51,64)(H,52,65)(H,53,72)(H,54,66)(H,55,71)(H,56,67)(H,57,68)(H,58,70)(H,59,69)(H,73,74)/t24-,25-,26-,27+,30-,31-,32-,33-,34-,37-/m0/s1 DMPNYXQ CS C[C@H]([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C)NC(=O)CNC(=O)C)O DMPNYXQ IK KCSNGWMKFYVMKF-HGYIIGRXSA-N DMPNYXQ IU (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[(2-acetamidoacetyl)amino]propanoyl]amino]-5-amino-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxypropanoyl]amino]-6-aminohexanoyl]amino]-3-hydroxybutanoyl]amino]propanoyl]amino]propanoyl]amino]-6-aminohexanoic acid DMPNYXQ CA CAS 901117-03-1 DMPNYXQ DE Non-small-cell lung cancer DMKICA3 ID DMKICA3 DMKICA3 DN BIO-1211 DMKICA3 HS Phase 2 DMKICA3 SN BIO-1211; BIO 1211; 187735-94-0; UNII-61G4E2353I; CHEMBL88478; 61G4E2353I; BIO1211; GTPL6589; SCHEMBL1223367; MolPort-023-276-985; ZINC3930111; BDBM50074661; AKOS024457866; L-Proline, N-(2-(4-((((2-methylphenyl)amino)carbonyl)amino)phenyl)acetyl)-L-leucyl-L-alpha-aspartyl-L-valyl-; L-Proline, N-((4-((((2-methylphenyl)amino)carbonyl)amino)phenyl)acetyl)-L-leucyl-L-alpha-aspartyl-L-valyl- DMKICA3 DT Small molecular drug DMKICA3 PC 9961766 DMKICA3 MW 708.8 DMKICA3 FM C36H48N6O9 DMKICA3 IC InChI=1S/C36H48N6O9/c1-20(2)17-26(38-29(43)18-23-12-14-24(15-13-23)37-36(51)40-25-10-7-6-9-22(25)5)32(46)39-27(19-30(44)45)33(47)41-31(21(3)4)34(48)42-16-8-11-28(42)35(49)50/h6-7,9-10,12-15,20-21,26-28,31H,8,11,16-19H2,1-5H3,(H,38,43)(H,39,46)(H,41,47)(H,44,45)(H,49,50)(H2,37,40,51)/t26-,27-,28-,31-/m0/s1 DMKICA3 CS CC1=CC=CC=C1NC(=O)NC2=CC=C(C=C2)CC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)N3CCC[C@H]3C(=O)O DMKICA3 IK NVVGCQABIHSJSQ-KFZSMJGVSA-N DMKICA3 IU (2S)-1-[(2S)-2-[[(2S)-3-carboxy-2-[[(2S)-4-methyl-2-[[2-[4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]amino]pentanoyl]amino]propanoyl]amino]-3-methylbutanoyl]pyrrolidine-2-carboxylic acid DMKICA3 CA CAS 187735-94-0 DMKICA3 DE Asthma DM7PT8R ID DM7PT8R DM7PT8R DN BioE-743 DM7PT8R HS Phase 2 DM7PT8R CP BioElectron Technology Mountain View, CA DM7PT8R DE Leigh syndrome; Pontocerebellar hypoplasia type 6 DM6PBUM ID DM6PBUM DM6PBUM DN Birinapant DM6PBUM HS Phase 2 DM6PBUM SN Birinapant; 1260251-31-7; Birinapant (TL32711); TL-32711; UNII-6O4Z07B57R; TL 32711; 6O4Z07B57R; (2S)-N-[(2S)-1-[(2R,4S)-2-[[6-fluoro-2-[6-fluoro-3-[[(2R,4S)-4-hydroxy-1-[(2S)-2-[[(2S)-2-(methylamino)propanoyl]amino]butanoyl]pyrrolidin-2-yl]methyl]-1H-indol-2-yl]-1H-indol-3-yl]methyl]-4-hydroxypyrrolidin-1-yl]-1-oxobutan-2-yl]-2-(methylamino)propanamide DM6PBUM CP TetraLogic Pharmaceuticals DM6PBUM DT Small molecular drug DM6PBUM PC 49836020 DM6PBUM MW 806.9 DM6PBUM FM C42H56F2N8O6 DM6PBUM IC InChI=1S/C42H56F2N8O6/c1-7-33(49-39(55)21(3)45-5)41(57)51-19-27(53)15-25(51)17-31-29-11-9-23(43)13-35(29)47-37(31)38-32(30-12-10-24(44)14-36(30)48-38)18-26-16-28(54)20-52(26)42(58)34(8-2)50-40(56)22(4)46-6/h9-14,21-22,25-28,33-34,45-48,53-54H,7-8,15-20H2,1-6H3,(H,49,55)(H,50,56)/t21-,22-,25-,26-,27-,28-,33-,34-/m0/s1 DM6PBUM CS CC[C@@H](C(=O)N1C[C@H](C[C@H]1CC2=C(NC3=C2C=CC(=C3)F)C4=C(C5=C(N4)C=C(C=C5)F)C[C@@H]6C[C@@H](CN6C(=O)[C@H](CC)NC(=O)[C@H](C)NC)O)O)NC(=O)[C@H](C)NC DM6PBUM IK PKWRMUKBEYJEIX-DXXQBUJASA-N DM6PBUM IU (2S)-N-[(2S)-1-[(2R,4S)-2-[[6-fluoro-2-[6-fluoro-3-[[(2R,4S)-4-hydroxy-1-[(2S)-2-[[(2S)-2-(methylamino)propanoyl]amino]butanoyl]pyrrolidin-2-yl]methyl]-1H-indol-2-yl]-1H-indol-3-yl]methyl]-4-hydroxypyrrolidin-1-yl]-1-oxobutan-2-yl]-2-(methylamino)propanamide DM6PBUM CA CAS 1260251-31-7 DM6PBUM DE Lymphoma; Solid tumour/cancer DMW76V0 ID DMW76V0 DMW76V0 DN Bisantrene DMW76V0 HS Phase 2 DMW76V0 SN 39C34M111K; 78186-34-2; 9,10-Anthracendicarbaldehyde bis(2-imidazolin-2-ylhydrazon); 9,10-Anthracenedicarboxaldehyde, bis((4,5-dihydro-1H-imidazol-2-yl)hydrazone)-; BISANTRENE HYDROCHLORIDE; BRN 0966309; Bisantrene; Bisantrene [INN]; Bisantreno; Bisantreno [INN-Spanish]; Bisantrenum; Bisantrenum [INN-Latin]; CHEMBL25336; CL 216942; N-[(E)-[10-[(E)-(4,5-dihydro-1H-imidazol-2-ylhydrazono)methyl]-9-anthryl]methyleneamino]-4,5-dihydro-1H-imidazol-2-amine; NSC 337766; UNII-39C34M111K DMW76V0 DT Small molecular drug DMW76V0 PC 5351322 DMW76V0 MW 398.474 DMW76V0 FM C22H22N8 DMW76V0 IC InChI=1S/C22H22N8/c1-2-6-16-15(5-1)19(13-27-29-21-23-9-10-24-21)17-7-3-4-8-18(17)20(16)14-28-30-22-25-11-12-26-22/h1-8,13-14H,9-12H2,(H2,23,24,29)(H2,25,26,30)/b27-13+,28-14+ DMW76V0 CS C1CN=C(N1)NN=CC2=C3C=CC=CC3=C(C4=CC=CC=C42)C=NNC5=NCCN5 DMW76V0 IK NJSMWLQOCQIOPE-OCHFTUDZSA-N DMW76V0 IU N-[(E)-[10-[(E)-(4,5-dihydro-1H-imidazol-2-ylhydrazinylidene)methyl]anthracen-9-yl]methylideneamino]-4,5-dihydro-1H-imidazol-2-amine DMW76V0 CA CAS 78186-34-2 DMW76V0 DE Acute myelogenous leukemia DMVDO93 ID DMVDO93 DMVDO93 DN BL-1020 DMVDO93 HS Phase 2 DMVDO93 SN BL 1020; Perphenazine 4-aminobutyrate; Butanoic acid, 4-amino-, 2-(4-(3-(2-chloro-10H-phenothiazin-10-yl)propyl)-1-piperazinyl)ethyl ester DMVDO93 CP BioLineRx DMVDO93 DT Small molecular drug DMVDO93 PC 11203271 DMVDO93 MW 489.1 DMVDO93 FM C25H33ClN4O2S DMVDO93 IC InChI=1S/C25H33ClN4O2S/c26-20-8-9-24-22(19-20)30(21-5-1-2-6-23(21)33-24)12-4-11-28-13-15-29(16-14-28)17-18-32-25(31)7-3-10-27/h1-2,5-6,8-9,19H,3-4,7,10-18,27H2 DMVDO93 CS C1CN(CCN1CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl)CCOC(=O)CCCN DMVDO93 IK BABFYCSPNDKXRI-UHFFFAOYSA-N DMVDO93 IU 2-[4-[3-(2-chlorophenothiazin-10-yl)propyl]piperazin-1-yl]ethyl 4-aminobutanoate DMVDO93 CA CAS 751477-01-7 DMVDO93 DE Schizophrenia DM8R71T ID DM8R71T DM8R71T DN BL-22 DM8R71T HS Phase 2 DM8R71T SN CAT-3888; GCR-3888; RFB4(dsFv)-PE38; PE38-conjugated anti-CD22 immunotoxin, NCI/Cambridge Antibody Technology/AstraZeneca DM8R71T CP National Cancer Institute DM8R71T DT Antibody DM8R71T DE Acute lymphoblastic leukaemia DMSBPJI ID DMSBPJI DMSBPJI DN BL-7040 DMSBPJI HS Phase 2 DMSBPJI SN Monarsen; EN-101; TLR-9 activator (oral, inflammatory bowel disease), BioLineRx; TLR-9 activator (oral, inflammatory bowel disease), Hebrew University of Jerusalem DMSBPJI CP Yissum Research Development Co DMSBPJI DT Small molecular drug DMSBPJI PC 56841946 DMSBPJI MW 6375 DMSBPJI FM C194H253N64O106P19S19 DMSBPJI IC InChI=1S/C194H253N64O106P19S19/c1-78-45-248(189(279)233-165(78)261)137-35-91(108(333-137)58-307-365(285,384)346-84-28-130(326-101(84)51-259)239-19-10-121(195)218-180(239)270)357-375(295,394)321-66-116-98(42-144(341-116)255-74-215-149-162(255)227-177(206)230-171(149)267)360-378(298,397)312-56-106-85(29-131(331-106)240-20-11-122(196)219-181(240)271)347-366(286,385)308-52-102-88(32-134(327-102)243-23-14-125(199)222-184(243)274)350-369(289,388)319-64-114-97(41-143(339-114)254-73-213-147-158(204)209-71-211-160(147)254)359-377(297,396)311-55-105-89(33-135(330-105)244-24-15-126(200)223-185(244)275)351-370(290,389)320-65-115-100(44-146(340-115)257-76-217-151-164(257)229-179(208)232-173(151)269)362-380(300,399)318-63-113-95(39-141(338-113)252-49-82(5)169(265)237-193(252)283)356-374(294,393)316-61-111-93(37-139(336-111)250-47-80(3)167(263)235-191(250)281)354-372(292,391)310-54-104-86(30-132(329-104)241-21-12-123(197)220-182(241)272)348-367(287,386)314-59-109-92(36-138(334-109)249-46-79(2)166(262)234-190(249)280)353-371(291,390)309-53-103-87(31-133(328-103)242-22-13-124(198)221-183(242)273)349-368(288,387)315-60-110-94(38-140(335-110)251-48-81(4)168(264)236-192(251)282)355-373(293,392)317-62-112-96(40-142(337-112)253-50-83(6)170(266)238-194(253)284)358-376(296,395)322-67-117-99(43-145(342-117)256-75-216-150-163(256)228-178(207)231-172(150)268)361-379(299,398)313-57-107-90(34-136(332-107)245-25-16-127(201)224-186(245)276)352-381(301,400)324-69-120-154(157(306-9)176(345-120)258-77-214-148-159(205)210-72-212-161(148)258)364-383(303,402)325-70-119-153(156(305-8)175(344-119)247-27-18-129(203)226-188(247)278)363-382(302,401)323-68-118-152(260)155(304-7)174(343-118)246-26-17-128(202)225-187(246)277/h10-27,45-50,71-77,84-120,130-146,152-157,174-176,259-260H,28-44,51-70H2,1-9H3,(H,285,384)(H,286,385)(H,287,386)(H,288,387)(H,289,388)(H,290,389)(H,291,390)(H,292,391)(H,293,392)(H,294,393)(H,295,394)(H,296,395)(H,297,396)(H,298,397)(H,299,398)(H,300,399)(H,301,400)(H,302,401)(H,303,402)(H2,195,218,270)(H2,196,219,271)(H2,197,220,272)(H2,198,221,273)(H2,199,222,274)(H2,200,223,275)(H2,201,224,276)(H2,202,225,277)(H2,203,226,278)(H2,204,209,211)(H2,205,210,212)(H,233,261,279)(H,234,262,280)(H,235,263,281)(H,236,264,282)(H,237,265,283)(H,238,266,284)(H3,206,227,230,267)(H3,207,228,231,268)(H3,208,229,232,269) DMSBPJI CS CC1=CN(C(=O)NC1=O)C2CC(C(O2)COP(=S)(O)OC3CC(OC3CO)N4C=CC(=NC4=O)N)OP(=S)(O)OCC5C(CC(O5)N6C=NC7=C6N=C(NC7=O)N)OP(=S)(O)OCC8C(CC(O8)N9C=CC(=NC9=O)N)OP(=S)(O)OCC1C(CC(O1)N1C=CC(=NC1=O)N)OP(=S)(O)OCC1C(CC(O1)N1C=NC2=C(N=CN=C21)N)OP(=S)(O)OCC1C(CC(O1)N1C=CC(=NC1=O)N)OP(=S)(O)OCC1C(CC(O1)N1C=NC2=C1N=C(NC2=O)N)OP(=S)(O)OCC1C(CC(O1)N1C=C(C(=O)NC1=O)C)OP(=S)(O)OCC1C(CC(O1)N1C=C(C(=O)NC1=O)C)OP(=S)(O)OCC1C(CC(O1)N1C=CC(=NC1=O)N)OP(=S)(O)OCC1C(CC(O1)N1C=C(C(=O)NC1=O)C)OP(=S)(O)OCC1C(CC(O1)N1C=CC(=NC1=O)N)OP(=S)(O)OCC1C(CC(O1)N1C=C(C(=O)NC1=O)C)OP(=S)(O)OCC1C(CC(O1)N1C=C(C(=O)NC1=O)C)OP(=S)(O)OCC1C(CC(O1)N1C=NC2=C1N=C(NC2=O)N)OP(=S)(O)OCC1C(CC(O1)N1C=CC(=NC1=O)N)OP(=S)(O)OCC1C(C(C(O1)N1C=NC2=C(N=CN=C21)N)OC)OP(=S)(O)OCC1C(C(C(O1)N1C=CC(=NC1=O)N)OC)OP(=S)(O)OCC1C(C(C(O1)N1C=CC(=NC1=O)N)OC)O DMSBPJI IK QJYMZHMIZZYHBI-UHFFFAOYSA-N DMSBPJI IU 1-[4-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(4-amino-2-oxopyrimidin-1-yl)-3-[[3-[[5-(4-amino-2-oxopyrimidin-1-yl)-3-[[5-(4-amino-2-oxopyrimidin-1-yl)-3-hydroxy-4-methoxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-methoxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(6-aminopurin-9-yl)-4-methoxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-[[[5-(4-amino-2-oxopyrimidin-1-yl)-2-(hydroxymethyl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]oxolan-2-yl]-5-methylpyrimidine-2,4-dione DMSBPJI DE Inflammatory bowel disease DMKO0BQ ID DMKO0BQ DMKO0BQ DN BLD-2660 DMKO0BQ HS Phase 2 DMKO0BQ SN BLD 2660 DMKO0BQ TC Antiviral Agents DMKO0BQ DT Small molecular drug DMKO0BQ DE Coronavirus Disease 2019 (COVID-19) DMYK1DR ID DMYK1DR DMYK1DR DN BLI-1005 DMYK1DR HS Phase 2 DMYK1DR CP BioLite Taipei, Taiwan DMYK1DR DE Major depressive disorder DMG1LVA ID DMG1LVA DMG1LVA DN BLZ-945 DMG1LVA HS Phase 2 DMG1LVA SN CSF-1R inhibitor (bone cancer); CSF-1R inhibitor (bone cancer), Novartis DMG1LVA CP Novartis Institutes for BioMedical Research Inc DMG1LVA DT Small molecular drug DMG1LVA PC 46184986 DMG1LVA MW 398.5 DMG1LVA FM C20H22N4O3S DMG1LVA IC InChI=1S/C20H22N4O3S/c1-21-19(26)16-10-13(8-9-22-16)27-12-6-7-15-18(11-12)28-20(24-15)23-14-4-2-3-5-17(14)25/h6-11,14,17,25H,2-5H2,1H3,(H,21,26)(H,23,24)/t14-,17-/m1/s1 DMG1LVA CS CNC(=O)C1=NC=CC(=C1)OC2=CC3=C(C=C2)N=C(S3)N[C@@H]4CCCC[C@H]4O DMG1LVA IK ADZBMFGQQWPHMJ-RHSMWYFYSA-N DMG1LVA IU 4-[[2-[[(1R,2R)-2-hydroxycyclohexyl]amino]-1,3-benzothiazol-6-yl]oxy]-N-methylpyridine-2-carboxamide DMG1LVA CA CAS 953769-46-5 DMG1LVA DE Solid tumour/cancer; Amyotrophic lateral sclerosis DMQI43G ID DMQI43G DMQI43G DN BMS 650032 DMQI43G HS Phase 2 DMQI43G SN Asunaprevir; 630420-16-5; BMS-650032; UNII-S9X0KRJ00S; BMS 650032; S9X0KRJ00S; Asunaprevir (BMS-650032); N-(Tert-Butoxycarbonyl)-3-Methyl-L-Valyl-(4r)-4-[(7-Chloro-4-Methoxyisoquinolin-1-Yl)oxy]-N-{(1r,2s)-1-[(Cyclopropylsulfonyl)carbamoyl]-2-Ethenylcyclopropyl}-L-Prolinamide; Asunaprevir [USAN:INN]; Sunvepra (TN); tert-butyl N-[(1S)-1-[(2S,4R)-4-[(7-chloro-4-methoxy-1-isoquinolyl)oxy]-2-[[(1R,2S)-1-(cyclopropylsulfonylcarbamoyl)-2-vinyl-cyclopropyl]carbamoyl]pyrrolidine-1-carbonyl]-2,2-dimethyl-propyl]carbamate; 2R9 DMQI43G CP Bristol-Myers Squibb DMQI43G DT Small molecular drug DMQI43G PC 16076883 DMQI43G MW 748.3 DMQI43G FM C35H46ClN5O9S DMQI43G IC InChI=1S/C35H46ClN5O9S/c1-9-19-16-35(19,31(44)40-51(46,47)22-11-12-22)39-28(42)25-15-21(49-29-24-14-20(36)10-13-23(24)26(48-8)17-37-29)18-41(25)30(43)27(33(2,3)4)38-32(45)50-34(5,6)7/h9-10,13-14,17,19,21-22,25,27H,1,11-12,15-16,18H2,2-8H3,(H,38,45)(H,39,42)(H,40,44)/t19-,21-,25+,27-,35-/m1/s1 DMQI43G CS CC(C)(C)[C@@H](C(=O)N1C[C@@H](C[C@H]1C(=O)N[C@@]2(C[C@H]2C=C)C(=O)NS(=O)(=O)C3CC3)OC4=NC=C(C5=C4C=C(C=C5)Cl)OC)NC(=O)OC(C)(C)C DMQI43G IK XRWSZZJLZRKHHD-WVWIJVSJSA-N DMQI43G IU tert-butyl N-[(2S)-1-[(2S,4R)-4-(7-chloro-4-methoxyisoquinolin-1-yl)oxy-2-[[(1R,2S)-1-(cyclopropylsulfonylcarbamoyl)-2-ethenylcyclopropyl]carbamoyl]pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]carbamate DMQI43G CA CAS 630420-16-5 DMQI43G CB CHEBI:134723 DMQI43G DE Hepatitis C virus infection DMKH4PI ID DMKH4PI DMKH4PI DN BMS 791325 DMKH4PI HS Phase 2 DMKH4PI SN BMS-791325 DMKH4PI CP Bristol-Myers Squibb DMKH4PI DT Small molecular drug DMKH4PI PC 56934415 DMKH4PI MW 659.8 DMKH4PI FM C36H45N5O5S DMKH4PI IC InChI=1S/C36H45N5O5S/c1-38(2)47(44,45)37-34(42)23-10-14-28-31(16-23)40-21-36(35(43)41-24-11-12-25(41)20-39(3)19-24)18-30(36)29-17-26(46-4)13-15-27(29)33(40)32(28)22-8-6-5-7-9-22/h10,13-17,22,24-25,30H,5-9,11-12,18-21H2,1-4H3,(H,37,42)/t24-,25+,30-,36-/m0/s1 DMKH4PI CS CN1C[C@H]2CC[C@@H](C1)N2C(=O)[C@]34C[C@H]3C5=C(C=CC(=C5)OC)C6=C(C7=C(N6C4)C=C(C=C7)C(=O)NS(=O)(=O)N(C)C)C8CCCCC8 DMKH4PI IK ZTTKEBYSXUCBSE-QDFUAKMASA-N DMKH4PI IU (8S,10R)-19-cyclohexyl-N-(dimethylsulfamoyl)-5-methoxy-10-[(1S,5R)-3-methyl-3,8-diazabicyclo[3.2.1]octane-8-carbonyl]-12-azapentacyclo[10.7.0.02,7.08,10.013,18]nonadeca-1(19),2(7),3,5,13(18),14,16-heptaene-15-carboxamide DMKH4PI CA CAS 958002-33-0 DMKH4PI DE Hepatitis C virus infection DMDPLEM ID DMDPLEM DMDPLEM DN BMS-184476 DMDPLEM HS Phase 2 DMDPLEM SN 10,11,12,12a,12b-dodecahydro-1H-7,11-methanocyclodeca[3,4]benz[1,2-b]oxet-9-yl ester; 7-O-(Methylsulfanylmethyl)paclitaxel DMDPLEM DT Small molecular drug DMDPLEM PC 6918461 DMDPLEM MW 914 DMDPLEM FM C49H55NO14S DMDPLEM IC InChI=1S/C49H55NO14S/c1-27-33(62-45(57)38(53)37(30-17-11-8-12-18-30)50-43(55)31-19-13-9-14-20-31)24-49(58)42(63-44(56)32-21-15-10-16-22-32)40-47(6,41(54)39(61-28(2)51)36(27)46(49,4)5)34(60-26-65-7)23-35-48(40,25-59-35)64-29(3)52/h8-22,33-35,37-40,42,53,58H,23-26H2,1-7H3,(H,50,55)/t33-,34-,35+,37-,38+,39+,40-,42-,47+,48-,49+/m0/s1 DMDPLEM CS CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)OCSC)C)OC(=O)C DMDPLEM IK UBJAHGAUPNGZFF-XOVTVWCYSA-N DMDPLEM IU [(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,12-diacetyloxy-15-[(2R,3S)-3-benzamido-2-hydroxy-3-phenylpropanoyl]oxy-1-hydroxy-10,14,17,17-tetramethyl-9-(methylsulfanylmethoxy)-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl] benzoate DMDPLEM CA CAS 160237-25-2 DMDPLEM DE Solid tumour/cancer DML1CK2 ID DML1CK2 DML1CK2 DN BMS-188797 DML1CK2 HS Phase 2 DML1CK2 SN 11,12,12a,12b-dodecahydro-1H-7,11-methanocyclodeca[3,4]benz[1,2-b]oxet-9-yl ester; 4-O-Deacetyl-4-O-(methoxycarbonyl)paclitaxel DML1CK2 DT Small molecular drug DML1CK2 PC 6918494 DML1CK2 MW 869.9 DML1CK2 FM C47H51NO15 DML1CK2 IC InChI=1S/C47H51NO15/c1-25-30(61-42(55)35(51)34(27-16-10-7-11-17-27)48-40(53)28-18-12-8-13-19-28)23-47(57)39(62-41(54)29-20-14-9-15-21-29)37-45(5,38(52)36(60-26(2)49)33(25)44(47,3)4)31(50)22-32-46(37,24-59-32)63-43(56)58-6/h7-21,30-32,34-37,39,50-51,57H,22-24H2,1-6H3,(H,48,53)/t30-,31-,32+,34-,35+,36+,37-,39-,45+,46-,47+/m0/s1 DML1CK2 CS CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)OC)O)C)OC(=O)C DML1CK2 IK GMJWGJSDPOAZTP-MIDYMNAOSA-N DML1CK2 IU [(1S,2S,3R,4S,7R,9S,10S,12R,15S)-12-acetyloxy-15-[(2R,3S)-3-benzamido-2-hydroxy-3-phenylpropanoyl]oxy-1,9-dihydroxy-4-methoxycarbonyloxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl] benzoate DML1CK2 CA CAS 172481-83-3 DML1CK2 DE Solid tumour/cancer DMJUV6C ID DMJUV6C DMJUV6C DN BMS-223131 DMJUV6C HS Phase 2 DMJUV6C SN 4-(5-Chloro-2-hydroxyphenyl)-3-(2-hydroxyethyl)-6-(trifluoromethyl)quinolin-2(1H)-one DMJUV6C PC 9951995 DMJUV6C MW 383.7 DMJUV6C FM C18H13ClF3NO3 DMJUV6C IC InChI=1S/C18H13ClF3NO3/c19-10-2-4-15(25)13(8-10)16-11(5-6-24)17(26)23-14-3-1-9(7-12(14)16)18(20,21)22/h1-4,7-8,24-25H,5-6H2,(H,23,26) DMJUV6C CS C1=CC2=C(C=C1C(F)(F)F)C(=C(C(=O)N2)CCO)C3=C(C=CC(=C3)Cl)O DMJUV6C IK QESHSZWKJULSAR-UHFFFAOYSA-N DMJUV6C IU 4-(5-chloro-2-hydroxyphenyl)-3-(2-hydroxyethyl)-6-(trifluoromethyl)-1H-quinolin-2-one DMJUV6C CA CAS 275375-69-4 DMJUV6C DE Erectile dysfunction DMQL3VS ID DMQL3VS DMQL3VS DN BMS-275183 DMQL3VS HS Phase 2 DMQL3VS SN BMS-198246; Oral taxane (cancer), BMS; Oral taxane (cancer), Bristol-Myers Squibb DMQL3VS CP Bristol-Myers Squibb Co DMQL3VS DT Small molecular drug DMQL3VS PC 6918594 DMQL3VS MW 845.9 DMQL3VS FM C43H59NO16 DMQL3VS IC InChI=1S/C43H59NO16/c1-21-24(57-35(50)28(47)31(38(3,4)5)44-36(51)59-39(6,7)8)19-43(53)33(58-34(49)23-16-14-13-15-17-23)30-41(11,32(48)29(56-22(2)45)27(21)40(43,9)10)25(46)18-26-42(30,20-55-26)60-37(52)54-12/h13-17,24-26,28-31,33,46-47,53H,18-20H2,1-12H3,(H,44,51)/t24-,25-,26+,28+,29+,30-,31+,33-,41+,42-,43+/m0/s1 DMQL3VS CS CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C(C)(C)C)NC(=O)OC(C)(C)C)O)O)OC(=O)C5=CC=CC=C5)(CO4)OC(=O)OC)O)C)OC(=O)C DMQL3VS IK AHXICHPPXIGCBN-GPWPDEGDSA-N DMQL3VS IU [(1S,2S,3R,4S,7R,9S,10S,12R,15S)-12-acetyloxy-1,9-dihydroxy-15-[(2R,3S)-2-hydroxy-4,4-dimethyl-3-[(2-methylpropan-2-yl)oxycarbonylamino]pentanoyl]oxy-4-methoxycarbonyloxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl] benzoate DMQL3VS CA CAS 355113-98-3 DMQL3VS DE Solid tumour/cancer DMGYXFP ID DMGYXFP DMGYXFP DN BMS-582949 DMGYXFP HS Phase 2 DMGYXFP SN BMS-582949; 623152-17-0; BMS 582949; UNII-CR743OME9E; BMS582949; CR743OME9E; PS540446; CHEMBL1230065; PS-540446; 4-{[5-(cyclopropylcarbamoyl)-2-methylphenyl]amino}-5-methyl-N-propylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide; 3mvl; SCHEMBL254996; GTPL7838; DTXSID90211380; MolPort-044-560-326; EX-A1265; BCP14356; ZINC36475284; s8124; BDBM50327009; AKOS030573299; DB12696; Pyrrolo(2,1-f)(1,2,4)triazine-6-carboxamide, 4-((5-((cyclopropylamino)carbonyl)-2-methylphenyl)amino)-5-methyl-n-propyl-; PS540446; BMS582949 free base; PS 540446 DMGYXFP CP Bristol-Myers Squibb DMGYXFP DT Small molecular drug DMGYXFP PC 10409068 DMGYXFP MW 406.5 DMGYXFP FM C22H26N6O2 DMGYXFP IC InChI=1S/C22H26N6O2/c1-4-9-23-22(30)17-11-28-19(14(17)3)20(24-12-25-28)27-18-10-15(6-5-13(18)2)21(29)26-16-7-8-16/h5-6,10-12,16H,4,7-9H2,1-3H3,(H,23,30)(H,26,29)(H,24,25,27) DMGYXFP CS CCCNC(=O)C1=CN2C(=C1C)C(=NC=N2)NC3=C(C=CC(=C3)C(=O)NC4CC4)C DMGYXFP IK GDTQLZHHDRRBEB-UHFFFAOYSA-N DMGYXFP IU 4-[5-(cyclopropylcarbamoyl)-2-methylanilino]-5-methyl-N-propylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide DMGYXFP CA CAS 623152-17-0 DMGYXFP DE Psoriasis vulgaris; Atherosclerosis DMDPQV5 ID DMDPQV5 DMDPQV5 DN BMS-599626 DMDPQV5 HS Phase 2 DMDPQV5 SN BMS-599626; 714971-09-2; AC480; AC-480; BMS 599626; (S)-Morpholin-3-ylmethyl (4-((1-(3-fluorobenzyl)-1H-indazol-5-yl)amino)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl)carbamate; UNII-2252724U5N; CHEMBL1645462; BMS599626; AC480 (BMS-599626); 2252724U5N; J-502499; C27H27FN8O3; AC 480; AC1480 (free base); PubChem22432; GTPL7647; SCHEMBL12065349; CTK8B6780; DTXSID60221714; SYN1142; AOB5594; MolPort-023-279-418; EX-A2296; ZINC6717782; KS-000008GE; BDBM50333373; s1056; C27H44O11; ANW-54337; AKOS015999853; CS-0407; RL05125; BCP9000428; SB21703 DMDPQV5 CP Bristol Myers Squibb DMDPQV5 TC Anticancer Agents DMDPQV5 DT Small molecular drug DMDPQV5 PC 10437018 DMDPQV5 MW 530.6 DMDPQV5 FM C27H27FN8O3 DMDPQV5 IC InChI=1S/C27H27FN8O3/c1-17-23(34-27(37)39-15-22-14-38-8-7-29-22)13-36-25(17)26(30-16-32-36)33-21-5-6-24-19(10-21)11-31-35(24)12-18-3-2-4-20(28)9-18/h2-6,9-11,13,16,22,29H,7-8,12,14-15H2,1H3,(H,34,37)(H,30,32,33)/t22-/m0/s1 DMDPQV5 CS CC1=C2C(=NC=NN2C=C1NC(=O)OC[C@@H]3COCCN3)NC4=CC5=C(C=C4)N(N=C5)CC6=CC(=CC=C6)F DMDPQV5 IK LUJZZYWHBDHDQX-QFIPXVFZSA-N DMDPQV5 IU [(3S)-morpholin-3-yl]methyl N-[4-[[1-[(3-fluorophenyl)methyl]indazol-5-yl]amino]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamate DMDPQV5 CA CAS 714971-09-2 DMDPQV5 DE Solid tumour/cancer DMX302C ID DMX302C DMX302C DN BMS-690514 DMX302C HS Phase 2 DMX302C SN BMS 690514; BMS690514 DMX302C DT Small molecular drug DMX302C PC 11349170 DMX302C MW 368.4 DMX302C FM C19H24N6O2 DMX302C IC InChI=1S/C19H24N6O2/c1-27-15-4-2-3-14(9-15)23-19-18-13(5-8-25(18)22-12-21-19)10-24-7-6-16(20)17(26)11-24/h2-5,8-9,12,16-17,26H,6-7,10-11,20H2,1H3,(H,21,22,23)/t16-,17-/m1/s1 DMX302C CS COC1=CC=CC(=C1)NC2=NC=NN3C2=C(C=C3)CN4CC[C@H]([C@@H](C4)O)N DMX302C IK CSGQVNMSRKWUSH-IAGOWNOFSA-N DMX302C IU (3R,4R)-4-amino-1-[[4-(3-methoxyanilino)pyrrolo[2,1-f][1,2,4]triazin-5-yl]methyl]piperidin-3-ol DMX302C CA CAS 859853-30-8 DMX302C DE Chronic pain DM51LTG ID DM51LTG DM51LTG DN BMS-708163 DM51LTG HS Phase 2 DM51LTG SN Avagacestat DM51LTG CP Bristol-Myers Squibb DM51LTG DT Small molecular drug DM51LTG PC 46883536 DM51LTG MW 520.9 DM51LTG FM C20H17ClF4N4O4S DM51LTG IC InChI=1S/C20H17ClF4N4O4S/c21-14-3-5-15(6-4-14)34(31,32)29(17(18(26)30)7-8-20(23,24)25)10-13-2-1-12(9-16(13)22)19-27-11-33-28-19/h1-6,9,11,17H,7-8,10H2,(H2,26,30)/t17-/m1/s1 DM51LTG CS C1=CC(=CC=C1S(=O)(=O)N(CC2=C(C=C(C=C2)C3=NOC=N3)F)[C@H](CCC(F)(F)F)C(=O)N)Cl DM51LTG IK XEAOPVUAMONVLA-QGZVFWFLSA-N DM51LTG IU (2R)-2-[(4-chlorophenyl)sulfonyl-[[2-fluoro-4-(1,2,4-oxadiazol-3-yl)phenyl]methyl]amino]-5,5,5-trifluoropentanamide DM51LTG CA CAS 1146699-66-2 DM51LTG DE Alzheimer disease DMTVGY7 ID DMTVGY7 DMTVGY7 DN BMS-770767 DMTVGY7 HS Phase 2 DMTVGY7 CP Bristol-Myers Squibb DMTVGY7 DE Hypercholesterolaemia DMKY638 ID DMKY638 DMKY638 DN BMS-813160 DMKY638 HS Phase 2 DMKY638 SN BMS-585059; CCR2/CCR5 chemokine antagonist (immune disorders, cardiovascular disorders), BMS; CCR2/CCR5 dual antagonist (cardiovascular disease), Bristol-Myers Squibb; CCR2/CCR5 dual antagonist (immunology), Bristol-Myers Squibb DMKY638 CP Bristol-myers squibb DMKY638 PC 51039119 DMKY638 MW 484.6 DMKY638 FM C25H40N8O2 DMKY638 IC InChI=1S/C25H40N8O2/c1-15(34)28-18-12-16(30-25(5,6)7)8-9-19(18)32-11-10-17(22(32)35)29-23-27-14-26-21-13-20(24(2,3)4)31-33(21)23/h13-14,16-19,30H,8-12H2,1-7H3,(H,28,34)(H,26,27,29)/t16-,17+,18-,19+/m1/s1 DMKY638 CS CC(=O)N[C@@H]1C[C@@H](CC[C@@H]1N2CC[C@@H](C2=O)NC3=NC=NC4=CC(=NN43)C(C)(C)C)NC(C)(C)C DMKY638 IK CMVHFGNTABZQJU-HCXYKTFWSA-N DMKY638 IU N-[(1R,2S,5R)-5-(tert-butylamino)-2-[(3S)-3-[(7-tert-butylpyrazolo[1,5-a][1,3,5]triazin-4-yl)amino]-2-oxopyrrolidin-1-yl]cyclohexyl]acetamide DMKY638 CA CAS 1286279-29-5 DMKY638 DE Diabetic nephropathy; Solid tumour/cancer DMT8L6P ID DMT8L6P DMT8L6P DN BMS-817399 DMT8L6P HS Phase 2 DMT8L6P CP Bristol-Myers Squibb DMT8L6P PC 44537841 DMT8L6P MW 454 DMT8L6P FM C23H36ClN3O4 DMT8L6P IC InChI=1S/C23H36ClN3O4/c1-15(2)18(26-20(29)25-13-22(5,6)30)19(28)27-12-11-23(31,21(3,4)14-27)16-7-9-17(24)10-8-16/h7-10,15,18,30-31H,11-14H2,1-6H3,(H2,25,26,29)/t18-,23+/m1/s1 DMT8L6P CS CC(C)[C@H](C(=O)N1CC[C@@](C(C1)(C)C)(C2=CC=C(C=C2)Cl)O)NC(=O)NCC(C)(C)O DMT8L6P IK GTDPZONCGOCXOD-JPYJTQIMSA-N DMT8L6P IU 1-[(2R)-1-[(4S)-4-(4-chlorophenyl)-4-hydroxy-3,3-dimethylpiperidin-1-yl]-3-methyl-1-oxobutan-2-yl]-3-(2-hydroxy-2-methylpropyl)urea DMT8L6P CA CAS 1202400-18-7 DMT8L6P DE Rheumatoid arthritis DMF46PD ID DMF46PD DMF46PD DN BMS-911543 DMF46PD HS Phase 2 DMF46PD SN BMS-911543; 1271022-90-2; BMS 911543; BMS911543; UNII-7N03P021J8; 7N03P021J8; N,N-Dicyclopropyl-4-[(1,5-Dimethyl-1h-Pyrazol-3-Yl)amino]-6-Ethyl-1-Methyl-1,6-Dihydroimidazo[4,5-D]pyrrolo[2,3-B]pyridine-7-Carboxamide; N,N-dicyclopropyl-4-((1,5-dimethyl-1H-pyrazol-3-yl)amino)-6-ethyl-1-methyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide; N,N-dicyclopropyl-4-((1,5-dimethyl-1H-pyrazol-3-yl)amino)-6-ethyl-1-methyl-1,6-dihydroimidazo(4,5-d)pyrrolo(2,3b)pyridine-7-carboxamide; JCINBYQJBYJGDM-UHFFFAOYSA-N DMF46PD CP Bristol-Myers Squibb DMF46PD DT Small molecular drug DMF46PD PC 50922691 DMF46PD MW 432.5 DMF46PD FM C23H28N8O DMF46PD IC InChI=1S/C23H28N8O/c1-5-30-17(23(32)31(14-6-7-14)15-8-9-15)11-16-20-19(24-12-28(20)3)21(26-22(16)30)25-18-10-13(2)29(4)27-18/h10-12,14-15H,5-9H2,1-4H3,(H,25,26,27) DMF46PD CS CCN1C(=CC2=C3C(=C(N=C21)NC4=NN(C(=C4)C)C)N=CN3C)C(=O)N(C5CC5)C6CC6 DMF46PD IK JCINBYQJBYJGDM-UHFFFAOYSA-N DMF46PD IU N,N-dicyclopropyl-7-[(1,5-dimethylpyrazol-3-yl)amino]-10-ethyl-3-methyl-3,5,8,10-tetrazatricyclo[7.3.0.02,6]dodeca-1,4,6,8,11-pentaene-11-carboxamide DMF46PD CA CAS 1271022-90-2 DMF46PD DE Myelofibrosis DMN28WK ID DMN28WK DMN28WK DN BMS-919373 DMN28WK HS Phase 2 DMN28WK CP Bristol-myers squibb DMN28WK PC 51030730 DMN28WK MW 468.5 DMN28WK FM C25H20N6O2S DMN28WK IC InChI=1S/C25H20N6O2S/c26-34(32,33)20-13-18(14-27-16-20)24-30-22-11-6-10-21(17-7-2-1-3-8-17)23(22)25(31-24)29-15-19-9-4-5-12-28-19/h1-14,16H,15H2,(H2,26,32,33)(H,29,30,31) DMN28WK CS C1=CC=C(C=C1)C2=C3C(=CC=C2)N=C(N=C3NCC4=CC=CC=N4)C5=CC(=CN=C5)S(=O)(=O)N DMN28WK IK XGKULQQVQWCASY-UHFFFAOYSA-N DMN28WK IU 5-[5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl]pyridine-3-sulfonamide DMN28WK CA CAS 1272353-82-8 DMN28WK DE Atrial fibrillation DMUTS1W ID DMUTS1W DMUTS1W DN BMS-936557 DMUTS1W HS Phase 2 DMUTS1W SN Anti-CXCL10 antibody (iv, ulcerative colitis/ rheumatoid arthritis/ inflammation), Medarex/BMS; Anti-IP-10 antibody (iv, ulcerative colitis/ rheumatoid arthritis/ inflammation), Bristol-Myers Squibb/Medarex DMUTS1W CP Medarex Inc DMUTS1W DT Antibody DMUTS1W DE Immune System disease DM7XV4R ID DM7XV4R DM7XV4R DN BMS-954561 DM7XV4R HS Phase 2 DM7XV4R SN AGN-001; AGN-209323; AGN-2XXXXX; AGN-323; EHT-001; EHT/AGN-0001; EHT/AGN-001; GABA/nicotinic modulator (neuroscience), BMS; Neuropathic pain therapy, ExonHit/Allergan/Bristol-Myers Squibb DM7XV4R CP Exonhit DM7XV4R DE Diabetic neuropathy DMMEAGO ID DMMEAGO DMMEAGO DN BMS-955176 DMMEAGO HS Phase 2 DMMEAGO CP Bristol-myers squibb DMMEAGO DE Human immunodeficiency virus-1 infection DMVJXOH ID DMVJXOH DMVJXOH DN BMS-986012 DMVJXOH HS Phase 2 DMVJXOH CP Bristol-Myers Squibb DMVJXOH DT Antibody DMVJXOH DE Small-cell lung cancer; Solid tumour/cancer DMHMV6E ID DMHMV6E DMHMV6E DN BMS-986020 DMHMV6E HS Phase 2 DMHMV6E SN GQBRZBHEPUQRPL-LJQANCHMSA-N; 1257213-50-5; AP-3152 free acid; UNII-38CTP01B4L; 38CTP01B4L; SCHEMBL344742; GTPL9498; EX-A866; MolPort-044-616-249; ZINC113624125; AKOS030631907; CS-5844; AS-35060; HY-100619; FT-0700148; J-690107; Cyclopropanecarboxylic acid, 1-(4'-(3-methyl-4-((((1R)-1-phenylethoxy)carbonyl)amino)-5-isoxazolyl)(1,1'-biphenyl)-4-yl)-; 1-{4'-[3-Methyl-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid; 1-[4-[4-[3-methyl-4-[[(1R)-1-phenylethoxy]carbonyl DMHMV6E CP Bristol-Myers SquibbPrinceton, NJ DMHMV6E PC 49792850 DMHMV6E MW 482.5 DMHMV6E FM C29H26N2O5 DMHMV6E IC InChI=1S/C29H26N2O5/c1-18-25(30-28(34)35-19(2)20-6-4-3-5-7-20)26(36-31-18)23-10-8-21(9-11-23)22-12-14-24(15-13-22)29(16-17-29)27(32)33/h3-15,19H,16-17H2,1-2H3,(H,30,34)(H,32,33)/t19-/m1/s1 DMHMV6E CS CC1=NOC(=C1NC(=O)O[C@H](C)C2=CC=CC=C2)C3=CC=C(C=C3)C4=CC=C(C=C4)C5(CC5)C(=O)O DMHMV6E IK GQBRZBHEPUQRPL-LJQANCHMSA-N DMHMV6E IU 1-[4-[4-[3-methyl-4-[[(1R)-1-phenylethoxy]carbonylamino]-1,2-oxazol-5-yl]phenyl]phenyl]cyclopropane-1-carboxylic acid DMHMV6E CA CAS 1257213-50-5 DMHMV6E DE Psoriasis vulgaris; Scleroderma DMIZKEC ID DMIZKEC DMIZKEC DN BMS-986036 DMIZKEC HS Phase 2 DMIZKEC CP Bristol-Myers Squibb Princeton, NJ DMIZKEC DE Type-2 diabetes DMTKDIP ID DMTKDIP DMTKDIP DN BMS-986141 DMTKDIP HS Phase 2 DMTKDIP SN UNII-W530IRZ40G; W530IRZ40G; UDM-003183; 1478711-48-6; 4-(4-(((6-Methoxy-2-(2-methoxyimidazo[2,1-b][1,3,4]thiadiazol-6-yl)benzofuran-4-yl)oxy)methyl)thiazol-2-yl)-N,N-dimethylbenzamide; CHEMBL3716552; SCHEMBL15348940; BDBM176003; DB14942; US9688695, 36; 4-[4-[[6-methoxy-2-(2-methoxyimidazo[2,1-b][1,3,4]thiadiazol-6-yl)-1-benzofuran-4-yl]oxymethyl]-1,3-thiazol-2-yl]-N,N-dimethylbenzamide; Benzamide, 4-(4-(((6-methoxy-2-(2-methoxyimidazo(2,1-b)-1,3,4-thiadiazol-6-yl)-4-benzofuranyl)oxy)methyl)-2-thiazolyl)-N,N-dimethyl- DMTKDIP CP Bristol-Myers Squibb DMTKDIP DT Small molecular drug DMTKDIP PC 72188743 DMTKDIP MW 561.6 DMTKDIP FM C27H23N5O5S2 DMTKDIP IC InChI=1S/C27H23N5O5S2/c1-31(2)25(33)16-7-5-15(6-8-16)24-28-17(14-38-24)13-36-21-9-18(34-3)10-22-19(21)11-23(37-22)20-12-32-26(29-20)39-27(30-32)35-4/h5-12,14H,13H2,1-4H3 DMTKDIP CS CN(C)C(=O)C1=CC=C(C=C1)C2=NC(=CS2)COC3=CC(=CC4=C3C=C(O4)C5=CN6C(=N5)SC(=N6)OC)OC DMTKDIP IK KEEBLYWBELVGPQ-UHFFFAOYSA-N DMTKDIP IU 4-[4-[[6-methoxy-2-(2-methoxyimidazo[2,1-b][1,3,4]thiadiazol-6-yl)-1-benzofuran-4-yl]oxymethyl]-1,3-thiazol-2-yl]-N,N-dimethylbenzamide DMTKDIP CA CAS 1478711-48-6 DMTKDIP DE Thrombosis DMZB8AJ ID DMZB8AJ DMZB8AJ DN BMS-986142 DMZB8AJ HS Phase 2 DMZB8AJ SN Unii-pjx9GH268R; UNII-PJX9GH268R; PJX9GH268R; CHEMBL3900554; 1643368-58-4; GTPL9857; SCHEMBL16319712; BMS986142; BDBM50194720; AKOS032954006; compound 14f [PMID: 27583770]; J3.563.199B; 73T; 6-Fluoro-5-(R)-(3-(S)-(8-Fluoro-1-Methyl-2,4-Dioxo-1,2-Dihydroquinazolin-3(4h)-Yl)-2-Methylphenyl)-2-(S)-(2-Hydroxypropan-2-Yl)-2,3,4,9-Tetrahydro-1h-Carbazole-8-Carboxamide; (7S)-3-fluoro-4-[3-(8-fluoro-1-methyl-2,4-dioxoquinazolin-3-yl)-2-methylphenyl]-7-(2-hydroxypropan-2-yl)-6,7,8,9-tetrahydro-5H-carbazole-1-carboxamide DMZB8AJ CP Bristol-Myers SquibbPrinceton, NJ DMZB8AJ PC 86582336 DMZB8AJ MW 572.6 DMZB8AJ FM C32H30F2N4O4 DMZB8AJ IC InChI=1S/C32H30F2N4O4/c1-15-17(7-6-10-24(15)38-30(40)19-8-5-9-21(33)28(19)37(4)31(38)41)25-22(34)14-20(29(35)39)27-26(25)18-12-11-16(32(2,3)42)13-23(18)36-27/h5-10,14,16,36,42H,11-13H2,1-4H3,(H2,35,39)/t16-/m0/s1 DMZB8AJ CS CC1=C(C=CC=C1N2C(=O)C3=C(C(=CC=C3)F)N(C2=O)C)C4=C(C=C(C5=C4C6=C(N5)C[C@H](CC6)C(C)(C)O)C(=O)N)F DMZB8AJ IK ZRYMMWAJAFUANM-INIZCTEOSA-N DMZB8AJ IU (7S)-3-fluoro-4-[3-(8-fluoro-1-methyl-2,4-dioxoquinazolin-3-yl)-2-methylphenyl]-7-(2-hydroxypropan-2-yl)-6,7,8,9-tetrahydro-5H-carbazole-1-carboxamide DMZB8AJ CA CAS 1643368-58-4 DMZB8AJ DE Rheumatoid arthritis DM4QHZS ID DM4QHZS DM4QHZS DN BMS-986177 DM4QHZS HS Phase 2 DM4QHZS SN Milvexian; UNII-0W79NDQ608; Milvexian (USAN); Milvexian [USAN]; BMS 986177; JNJ-70033093; 1802425-99-5; CHEMBL4112929; SCHEMBL16982989; WHO 11401; D11802; (5R,9S)-9-(4-(5-Chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl)-6-oxopyrimidin-1(6H)-yl)-21-(difluoromethyl)-5-methyl-21H-3-aza-1(4,2)-pyridina-2(5,4)-pyrazolacyclonaphan-4-one; (9R,13S)-13-{4-[5-chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-6-oxo-1,6-dihydropyrimidin-1-yl}-3-(difluoromethyl)-9-methyl-3,4,7,15-tetraazatricyclo[12.3.1.02,6]octadeca-1(18),2(6),4,14,16-pentaen-8-one; 11,15-Metheno-15H-pyrazolo(4,3-b)(1,7)diazacyclotetradecin-5(6H)-one, 10-(4-(5-chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl)-6-oxo-1(6H)-pyrimidinyl)-1-(difluoromethyl)-1,4,7,8,9,10-hexahydro-6-methyl-, (6R,10S)-2 DM4QHZS CP Bristol-Myers Squibb DM4QHZS DT Small molecular drug DM4QHZS PC 118277544 DM4QHZS MW 626.4 DM4QHZS FM C28H23Cl2F2N9O2 DM4QHZS IC InChI=1S/C28H23Cl2F2N9O2/c1-15-3-2-4-23(20-9-16(7-8-33-20)26-21(36-27(15)43)12-35-41(26)28(31)32)39-14-34-19(11-25(39)42)18-10-17(29)5-6-22(18)40-13-24(30)37-38-40/h5-15,23,28H,2-4H2,1H3,(H,36,43)/t15-,23+/m1/s1 DM4QHZS CS C[C@@H]1CCC[C@@H](C2=NC=CC(=C2)C3=C(C=NN3C(F)F)NC1=O)N4C=NC(=CC4=O)C5=C(C=CC(=C5)Cl)N6C=C(N=N6)Cl DM4QHZS IK FSWFYCYPTDLKON-CMJOXMDJSA-N DM4QHZS IU (9R,13S)-13-[4-[5-chloro-2-(4-chlorotriazol-1-yl)phenyl]-6-oxopyrimidin-1-yl]-3-(difluoromethyl)-9-methyl-3,4,7,15-tetrazatricyclo[12.3.1.02,6]octadeca-1(18),2(6),4,14,16-pentaen-8-one DM4QHZS CA CAS 1802425-99-5 DM4QHZS DE Thrombosis; Cerebral ischemia DM42B0C ID DM42B0C DM42B0C DN BMS-986253 DM42B0C HS Phase 2 DM42B0C CP Bristol-Myers Squibb DM42B0C DT Antibody DM42B0C DE Solid tumour/cancer; Coronavirus Disease 2019 (COVID-19) DM5OU2W ID DM5OU2W DM5OU2W DN BMS-986253 DM5OU2W HS Phase 2 DM5OU2W SN Humax-inflam; HuMax-IL8; Humax-IL-8; UNII-N0YWS8X3S9; N0YWS8X3S9; MDX-018; BMS-986253; anti-Il-8 monoclonal antibody humax-IL8; 2231258-73-2 DM5OU2W TC Antiviral Agents DM5OU2W DT Monoclonal antibody DM5OU2W DE Coronavirus Disease 2019 (COVID-19) DMSRVXO ID DMSRVXO DMSRVXO DN BMS-986263 DMSRVXO HS Phase 2 DMSRVXO SN ND L02 s0201 DMSRVXO CP Bristol-Myers Squibb DMSRVXO DT Small interfering RNA DMSRVXO DE Hepatic fibrosis DMUM2KA ID DMUM2KA DMUM2KA DN BN82451 DMUM2KA HS Phase 2 DMUM2KA SN UNII-531B661QBY; 335242-75-6; BN-82451; 531B661QBY; 4-(2-(Aminomethyl)-1,3-thiazol-4-yl)-2,6-di(tert-butyl)phenol; Phenol,4-2-(aminomethyl)-4-thiazolyl-2,6-bis(1,1-dimethyl ethyl)-; 4-[2-(aminomethyl)-1,3-thiazol-4-yl]-2,6-di(tert-butyl)phenol; SCHEMBL197161; HAQOEWGSBVQDHB-UHFFFAOYSA-N; Phenol, 4-(2-(aminomethyl)-4-thiazolyl)-2,6-bis(1,1-dimethylethyl)-; SB17395; KB-59536 DMUM2KA CP Ipsen DMUM2KA DT Small molecular drug DMUM2KA PC 72941952 DMUM2KA MW 354.9 DMUM2KA FM C18H27ClN2OS DMUM2KA IC InChI=1S/C18H26N2OS.ClH/c1-17(2,3)12-7-11(14-10-22-15(9-19)20-14)8-13(16(12)21)18(4,5)6;/h7-8,10,21H,9,19H2,1-6H3;1H DMUM2KA CS CC(C)(C)C1=CC(=CC(=C1O)C(C)(C)C)C2=CSC(=N2)CN.Cl DMUM2KA IK WPWBWGUPSJCKKF-UHFFFAOYSA-N DMUM2KA IU 4-[2-(aminomethyl)-1,3-thiazol-4-yl]-2,6-ditert-butylphenol;hydrochloride DMUM2KA CA CAS 918656-59-4 DMUM2KA DE Parkinson disease DMJC8DR ID DMJC8DR DMJC8DR DN BNC-105 DMJC8DR HS Phase 2 DMJC8DR SN BNC-105P; IL-0035; IL-0049; Combretastatin A4 analogs (cancer), Bionomics; VDAs (cancer), Bionomics; Vascular disruption agents (cancer), Bionomics; Vascular targeting agents (cancer), Bionomics DMJC8DR CP Iliad Chemicals Pty Ltd DMJC8DR DT Small molecular drug DMJC8DR PC 24786555 DMJC8DR MW 372.4 DMJC8DR FM C20H20O7 DMJC8DR IC InChI=1S/C20H20O7/c1-10-16(12-6-7-13(23-2)18(22)19(12)27-10)17(21)11-8-14(24-3)20(26-5)15(9-11)25-4/h6-9,22H,1-5H3 DMJC8DR CS CC1=C(C2=C(O1)C(=C(C=C2)OC)O)C(=O)C3=CC(=C(C(=C3)OC)OC)OC DMJC8DR IK RADMJHVVIZTENA-UHFFFAOYSA-N DMJC8DR IU (7-hydroxy-6-methoxy-2-methyl-1-benzofuran-3-yl)-(3,4,5-trimethoxyphenyl)methanone DMJC8DR CA CAS 945771-74-4 DMJC8DR DE Mesothelioma DMEGDWA ID DMEGDWA DMEGDWA DN BNC-210 DMEGDWA HS Phase 2 DMEGDWA SN BNC-10002; GABA-A modulators (oral, anxiety), Bionomics DMEGDWA CP Bionomics Ltd DMEGDWA DE Anxiety disorder DMRWG8B ID DMRWG8B DMRWG8B DN BNT321 DMRWG8B HS Phase 2 DMRWG8B SN MVT-5873 DMRWG8B CP BioNTech DMRWG8B DT Antibody DMRWG8B DE Pancreatic cancer DM8JQZC ID DM8JQZC DM8JQZC DN BNZ-1 DM8JQZC HS Phase 2 DM8JQZC CP Bioniz Therapeutics DM8JQZC DT Peptide DM8JQZC DE Cutaneous T-cell lymphoma; T-cell leukaemia; Large granular lymphocytic leukemia DMZ70GE ID DMZ70GE DMZ70GE DN BOS-228 DMZ70GE HS Phase 2 DMZ70GE CP Boston Pharmaceuticals DMZ70GE DT Small molecular drug DMZ70GE DE Bacterial infection DMKDGI8 ID DMKDGI8 DMKDGI8 DN BP-100-1-01 DMKDGI8 HS Phase 2 DMKDGI8 CP Bio-Path Ogden, Utah DMKDGI8 DE Myelodysplastic syndrome; Hematologic tumour; Chronic myelogenous leukaemia; Acute myeloid leukaemia; Acute lymphoblastic leukaemia DMWVPO0 ID DMWVPO0 DMWVPO0 DN BPN14770 DMWVPO0 HS Phase 2 DMWVPO0 SN KRRGWHSEDYQKDQ-UHFFFAOYSA-N; SCHEMBL15659026; 2-(4-((2-(3-Chlorophenyl)-6-(trifluoromethyl)pyrimidin-4-yl)amino)phenyl)acetamide DMWVPO0 CP Tetra Discovery Partners Grand Rapids, MI DMWVPO0 PC 90111638 DMWVPO0 MW 405.8 DMWVPO0 FM C21H15ClF3NO2 DMWVPO0 IC InChI=1S/C21H15ClF3NO2/c22-17-3-1-2-16(12-17)18-9-15(10-19(26-18)21(23,24)25)8-13-4-6-14(7-5-13)11-20(27)28/h1-7,9-10,12H,8,11H2,(H,27,28) DMWVPO0 CS C1=CC(=CC(=C1)Cl)C2=NC(=CC(=C2)CC3=CC=C(C=C3)CC(=O)O)C(F)(F)F DMWVPO0 IK LTSUMTMGJHPGFX-UHFFFAOYSA-N DMWVPO0 IU 2-[4-[[2-(3-chlorophenyl)-6-(trifluoromethyl)pyridin-4-yl]methyl]phenyl]acetic acid DMWVPO0 CA CAS 1606974-33-7 DMWVPO0 DE Alzheimer disease DMDYZRS ID DMDYZRS DMDYZRS DN BPS-804 DMDYZRS HS Phase 2 DMDYZRS SN Anti-sclerostin antibody (osteoporosis/hypophophatasia), Novartis DMDYZRS CP Novartis AG DMDYZRS DT Antibody DMDYZRS DE Metabolic bone disease DM0MO8I ID DM0MO8I DM0MO8I DN BQ-123 DM0MO8I HS Phase 2 DM0MO8I SN BQ-123; 136553-81-6; BQ123; BQ 123; Cyclo(D-trp-D-asp-pro-D-val-leu); UNII-S2A8YZM151; CHEBI:2965; S2A8YZM151; CHEMBL314691; cyclo[D-Trp-D-Asp-Pro-D-Val-Leu]; cyclo(D-Asp-Pro-D-Val-Leu-D-Trp); cyclo(-D-Trp-D-Asp-Pro-D-Val-Leu); cyclo-[D-Asp-Pro-d-Val-Leu-d-Trp]; cyclo-(D-Asp-Pro-D-Val-Leu-D-Trp); Cyclo(D-trp-D-asp-L-pro-D-val-L-leu); Cyclo[D-trp-D-asp-L-pro-D-val-L-leu]; cyclo[(D)Trp-(D)Asp-Pro-(D)Val-Leu]; cyclo[D-Asp-L-Pro-D-Val-L-Leu-D-Trp]; cyclo(D-Asp-L-Pro-D-Val-L-Leu-D-Trp) DM0MO8I DT Small molecular drug DM0MO8I PC 443289 DM0MO8I MW 610.7 DM0MO8I FM C31H42N6O7 DM0MO8I IC InChI=1S/C31H42N6O7/c1-16(2)12-21-27(40)33-22(13-18-15-32-20-9-6-5-8-19(18)20)28(41)35-23(14-25(38)39)31(44)37-11-7-10-24(37)29(42)36-26(17(3)4)30(43)34-21/h5-6,8-9,15-17,21-24,26,32H,7,10-14H2,1-4H3,(H,33,40)(H,34,43)(H,35,41)(H,36,42)(H,38,39)/t21-,22+,23+,24-,26+/m0/s1 DM0MO8I CS CC(C)C[C@H]1C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](C(=O)N1)C(C)C)CC(=O)O)CC3=CNC4=CC=CC=C43 DM0MO8I IK VYCMAAOURFJIHD-PJNXIOHISA-N DM0MO8I IU 2-[(3R,6R,9S,12R,15S)-6-(1H-indol-3-ylmethyl)-9-(2-methylpropyl)-2,5,8,11,14-pentaoxo-12-propan-2-yl-1,4,7,10,13-pentazabicyclo[13.3.0]octadecan-3-yl]acetic acid DM0MO8I CA CAS 136553-81-6 DM0MO8I CB CHEBI:2965 DM0MO8I DE Pulmonary arterial hypertension DMNFKVW ID DMNFKVW DMNFKVW DN BR-4628 DMNFKVW HS Phase 2 DMNFKVW CP Bayer HealthCare Pharmaceuticals DMNFKVW PC 60168629 DMNFKVW MW 381.4 DMNFKVW FM C22H23NO5 DMNFKVW IC InChI=1S/C22H23NO5/c1-6-27-22(26)19-13(4)23-12(3)18(14(5)24)20(19)16-9-7-8-15-17(25)10-11(2)28-21(15)16/h7-10,20,23H,6H2,1-5H3/t20-/m1/s1 DMNFKVW CS CCOC(=O)C1=C(NC(=C([C@H]1C2=CC=CC3=C2OC(=CC3=O)C)C(=O)C)C)C DMNFKVW IK DXCPBIXBBLLGOZ-HXUWFJFHSA-N DMNFKVW IU ethyl (4R)-5-acetyl-2,6-dimethyl-4-(2-methyl-4-oxochromen-8-yl)-1,4-dihydropyridine-3-carboxylate DMNFKVW DE Heart failure DM3TRF7 ID DM3TRF7 DM3TRF7 DN Brasofensine DM3TRF7 HS Phase 2 DM3TRF7 SN Brasofensine [INN] DM3TRF7 CP Lundbeck DM3TRF7 DT Small molecular drug DM3TRF7 PC 9554198 DM3TRF7 MW 327.2 DM3TRF7 FM C16H20Cl2N2O DM3TRF7 IC InChI=1S/C16H20Cl2N2O/c1-20-11-4-6-16(20)13(9-19-21-2)12(8-11)10-3-5-14(17)15(18)7-10/h3,5,7,9,11-13,16H,4,6,8H2,1-2H3/b19-9+/t11?,12-,13-,16?/m1/s1 DM3TRF7 CS CN1C2CCC1[C@@H]([C@H](C2)C3=CC(=C(C=C3)Cl)Cl)/C=N/OC DM3TRF7 IK NRLIFEGHTNUYFL-MTKJPOGLSA-N DM3TRF7 IU (E)-1-[(2R,3S)-3-(3,4-dichlorophenyl)-8-methyl-8-azabicyclo[3.2.1]octan-2-yl]-N-methoxymethanimine DM3TRF7 CA CAS 171655-91-7 DM3TRF7 DE Parkinson disease DMKGM42 ID DMKGM42 DMKGM42 DN BREQUINAR DMKGM42 HS Phase 2 DMKGM42 SN Brequinar; 96187-53-0; 6-Fluoro-2-(2'-fluoro-[1,1'-biphenyl]-4-yl)-3-methylquinoline-4-carboxylic acid; brequinarum [Latin]; Brequinar [INN]; Biphenquinate; 6-fluoro-2-(2'-fluorobiphenyl-4-yl)-3-methylquinoline-4-carboxylic acid; Brequinarum [INN-Latin]; UNII-5XL19F49H6; C23H15F2NO2; NSC-368390; NSC 368390; 6-fluoro-2-[4-(2-fluorophenyl)phenyl]-3-methylquinoline-4-carboxylic acid; PHEZJEYUWHETKO-UHFFFAOYSA-N; Dup 785; 5XL19F49H6; 6-FLUORO-2-(2'-FLUORO-1,1'-BIPHENYL-4-YL)-3-METHYLQUINOLINE-4-CARBOXYLIC ACID; brequinarum DMKGM42 DT Small molecular drug DMKGM42 PC 57030 DMKGM42 MW 375.4 DMKGM42 FM C23H15F2NO2 DMKGM42 IC InChI=1S/C23H15F2NO2/c1-13-21(23(27)28)18-12-16(24)10-11-20(18)26-22(13)15-8-6-14(7-9-15)17-4-2-3-5-19(17)25/h2-12H,1H3,(H,27,28) DMKGM42 CS CC1=C(C2=C(C=CC(=C2)F)N=C1C3=CC=C(C=C3)C4=CC=CC=C4F)C(=O)O DMKGM42 IK PHEZJEYUWHETKO-UHFFFAOYSA-N DMKGM42 IU 6-fluoro-2-[4-(2-fluorophenyl)phenyl]-3-methylquinoline-4-carboxylic acid DMKGM42 CA CAS 96187-53-0 DMKGM42 DE Acute myeloid leukaemia; Coronavirus Disease 2019 (COVID-19) DMXI9BP ID DMXI9BP DMXI9BP DN Brilacidin DMXI9BP HS Phase 2 DMXI9BP SN UNII-I1679X069H; 1224095-98-0; I1679X069H; Brilacidin [USAN:INN]; Brilacidin (USAN); SCHEMBL2878543; CHEMBL2219413; DTXSID90153594; AKOS030238222; DB12997; CS-6677; HY-19892; D10414; N,N'-Bis(3-((5-(carbamimidoylamino)pentanoyl)amino)-2-((3R)-pyrrolidin-3-yloxy)-5-(trifluoromethyl)phenyl)pyrimidine-4,6-dicarboxamide; 4,6-Pyrimidinedicarboxamide, N4,N6-bis(3-((5-((aminoiminomethyl)amino)-1-oxopentyl)amino)-2-((3R)-3-pyrrolidinyloxy)-5-(trifluoromethyl)phenyl)- DMXI9BP CP Cellceutix DMXI9BP DT Small molecular drug DMXI9BP PC 25023695 DMXI9BP MW 936.9 DMXI9BP FM C40H50F6N14O6 DMXI9BP IC InChI=1S/C40H50F6N14O6/c41-39(42,43)21-13-25(57-31(61)5-1-3-9-53-37(47)48)33(65-23-7-11-51-18-23)27(15-21)59-35(63)29-17-30(56-20-55-29)36(64)60-28-16-22(40(44,45)46)14-26(34(28)66-24-8-12-52-19-24)58-32(62)6-2-4-10-54-38(49)50/h13-17,20,23-24,51-52H,1-12,18-19H2,(H,57,61)(H,58,62)(H,59,63)(H,60,64)(H4,47,48,53)(H4,49,50,54)/t23-,24-/m1/s1 DMXI9BP CS C1CNC[C@@H]1OC2=C(C=C(C=C2NC(=O)C3=CC(=NC=N3)C(=O)NC4=CC(=CC(=C4O[C@@H]5CCNC5)NC(=O)CCCCN=C(N)N)C(F)(F)F)C(F)(F)F)NC(=O)CCCCN=C(N)N DMXI9BP IK QPDYBCZNGUJZDK-DNQXCXABSA-N DMXI9BP IU 4-N,6-N-bis[3-[5-(diaminomethylideneamino)pentanoylamino]-2-[(3R)-pyrrolidin-3-yl]oxy-5-(trifluoromethyl)phenyl]pyrimidine-4,6-dicarboxamide DMXI9BP CA CAS 1224095-98-0 DMXI9BP DE Infectious disease; Acute bacterial skin infection DMLD80M ID DMLD80M DMLD80M DN Brivoligide DMLD80M HS Phase 2 DMLD80M SN AYX1 DMLD80M CP Adynxx DMLD80M DT Oligonucleotide DMLD80M DE Postoperative pain DMLFGHX ID DMLFGHX DMLFGHX DN BRL 35135 DMLFGHX HS Phase 2 DMLFGHX SN Brl35135A; BRL 35135; Methyl 4-(2-(2-hydroxy-2-(3-chlorophenyl)ethylamino)propyl)phenoxyacetate; Brl-35135; 91097-81-3; C20H24ClNO4; Acetic acid, (4-(2-((2-(3-chlorophenyl)-2-hydroxyethyl)amino)propyl)phenoxy)-, methyl ester; AC1Q3M3M; AC1L3U5A; CHEMBL49289; SCHEMBL4611391; CTK5G8940; ZFLBZHXQAMUEFS-UHFFFAOYSA-N; LS-178136; L003499; methyl 4-[2-[(3-chloro-beta-hydroxyphenethyl) amino]propyl]phenoxyacetate; [4-[2-[[2-(3-Chlorophenyl)-2-hydroxyethyl]amino]propyl]phenoxy]acetic acid methyl ester; methyl 2-[4-[2-[[2-(3-chloroph DMLFGHX DT Small molecular drug DMLFGHX PC 122186 DMLFGHX MW 377.9 DMLFGHX FM C20H24ClNO4 DMLFGHX IC InChI=1S/C20H24ClNO4/c1-14(22-12-19(23)16-4-3-5-17(21)11-16)10-15-6-8-18(9-7-15)26-13-20(24)25-2/h3-9,11,14,19,22-23H,10,12-13H2,1-2H3 DMLFGHX CS CC(CC1=CC=C(C=C1)OCC(=O)OC)NCC(C2=CC(=CC=C2)Cl)O DMLFGHX IK ZFLBZHXQAMUEFS-UHFFFAOYSA-N DMLFGHX IU methyl 2-[4-[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]phenoxy]acetate DMLFGHX CA CAS 91097-81-3 DMLFGHX DE Diabetic complication DMUI5PA ID DMUI5PA DMUI5PA DN Brostallicin DMUI5PA HS Phase 2 DMUI5PA SN Brostallicin; UNII-RPC6R41K4I; 203258-60-0; RPC6R41K4I; PNU-166196A; Brostallicin [INN]; AC1OCFEA; SCHEMBL3678233; CHEMBL1189025; DTXSID70174222; ZINC3979512; Z-3228; 4-[[4-[[4-[[4-(2-bromoprop-2-enoylamino)-1-methylpyrrole-2-carbonyl]amino]-1-methylpyrrole-2-carbonyl]amino]-1-methylpyrrole-2-carbonyl]amino]-N-[2-(diaminomethylideneamino)ethyl]-1-methylpyrrole-2-carboxamide DMUI5PA CP Cell Therapeutics DMUI5PA DT Small molecular drug DMUI5PA PC 6918408 DMUI5PA MW 723.6 DMUI5PA FM C30H35BrN12O5 DMUI5PA IC InChI=1S/C30H35BrN12O5/c1-16(31)25(44)36-17-9-22(41(3)12-17)27(46)38-19-11-24(43(5)14-19)29(48)39-20-10-23(42(4)15-20)28(47)37-18-8-21(40(2)13-18)26(45)34-6-7-35-30(32)33/h8-15H,1,6-7H2,2-5H3,(H,34,45)(H,36,44)(H,37,47)(H,38,46)(H,39,48)(H4,32,33,35) DMUI5PA CS CN1C=C(C=C1C(=O)NCCN=C(N)N)NC(=O)C2=CC(=CN2C)NC(=O)C3=CC(=CN3C)NC(=O)C4=CC(=CN4C)NC(=O)C(=C)Br DMUI5PA IK RXOVOXFAAGIKDQ-UHFFFAOYSA-N DMUI5PA IU 4-[[4-[[4-[[4-(2-bromoprop-2-enoylamino)-1-methylpyrrole-2-carbonyl]amino]-1-methylpyrrole-2-carbonyl]amino]-1-methylpyrrole-2-carbonyl]amino]-N-[2-(diaminomethylideneamino)ethyl]-1-methylpyrrole-2-carboxamide DMUI5PA CA CAS 203258-60-0 DMUI5PA DE Breast cancer DM1ZOCK ID DM1ZOCK DM1ZOCK DN Bryostatin-1 DM1ZOCK HS Phase 2 DM1ZOCK SN Bryostatin 1; 83314-01-6 DM1ZOCK DT Small molecular drug DM1ZOCK PC 5280757 DM1ZOCK MW 905 DM1ZOCK FM C47H68O17 DM1ZOCK IC InChI=1S/C47H68O17/c1-10-11-12-13-14-15-39(51)62-43-31(22-41(53)58-9)21-34-25-37(28(2)48)61-42(54)24-32(50)23-35-26-38(59-29(3)49)45(6,7)46(55,63-35)27-36-19-30(20-40(52)57-8)18-33(60-36)16-17-44(4,5)47(43,56)64-34/h12-17,20,22,28,32-38,43,48,50,55-56H,10-11,18-19,21,23-27H2,1-9H3/b13-12+,15-14+,17-16+,30-20+,31-22+/t28-,32-,33+,34+,35-,36+,37-,38+,43+,46+,47-/m1/s1 DM1ZOCK CS CCC/C=C/C=C/C(=O)O[C@H]1/C(=C/C(=O)OC)/C[C@H]2C[C@@H](OC(=O)C[C@@H](C[C@@H]3C[C@@H](C([C@@](O3)(C[C@@H]4C/C(=C/C(=O)OC)/C[C@@H](O4)/C=C/C([C@@]1(O2)O)(C)C)O)(C)C)OC(=O)C)O)[C@@H](C)O DM1ZOCK IK MJQUEDHRCUIRLF-TVIXENOKSA-N DM1ZOCK IU [(1S,3S,5Z,7R,8E,11S,12S,13E,15S,17R,21R,23R,25S)-25-acetyloxy-1,11,21-trihydroxy-17-[(1R)-1-hydroxyethyl]-5,13-bis(2-methoxy-2-oxoethylidene)-10,10,26,26-tetramethyl-19-oxo-18,27,28,29-tetraoxatetracyclo[21.3.1.13,7.111,15]nonacos-8-en-12-yl] (2E,4E)-octa-2,4-dienoate DM1ZOCK CA CAS 83314-01-6 DM1ZOCK CB CHEBI:88353 DM1ZOCK DE Alzheimer disease DM2LZIY ID DM2LZIY DM2LZIY DN BT-061 DM2LZIY HS Phase 2 DM2LZIY CP Biotest DM2LZIY DT Antibody DM2LZIY DE Asthma; Psoriasis vulgaris DMYO185 ID DMYO185 DMYO185 DN BT-062 DMYO185 HS Phase 2 DMYO185 CP Biotest Pharmaceuticals; ImmunoGen DMYO185 DT Antibody DMYO185 DE Multiple myeloma DMDWP0U ID DMDWP0U DMDWP0U DN BTA-798 DMDWP0U HS Phase 2 DMDWP0U SN Capsid-binding inhibitors, Biota; Capsid-binding (anti-rhinovirus) agents, Biota DMDWP0U CP Biota pharmaceuticals DMDWP0U DE Rhinovirus infection DMS6ZA0 ID DMS6ZA0 DMS6ZA0 DN BTD-001 DMS6ZA0 HS Phase 2 DMS6ZA0 CP Balance Therapeutics San Bruno, CA DMS6ZA0 DE Narcolepsy DMY5IX4 ID DMY5IX4 DMY5IX4 DN BTL-TML-001 DMY5IX4 HS Phase 2 DMY5IX4 SN Influenza virus infection, Beech Tree Labs DMY5IX4 CP Beech Tree Labs Inc DMY5IX4 DE Influenza virus infection; Herpes simplex labialis DMA9238 ID DMA9238 DMA9238 DN BTRX-246040 DMA9238 HS Phase 2 DMA9238 CP BlackThorn Therapeutics San Francisco, CA DMA9238 DE Major depressive disorder DMWPDUZ ID DMWPDUZ DMWPDUZ DN BTRX-335140 DMWPDUZ HS Phase 2 DMWPDUZ SN CYM-53093; UNII-XK5ILZ28KI; XK5ILZ28KI; 2244614-14-8; 1-(6-Ethyl-8-fluoro-4-methyl-3-(3-methyl-1,2,4-oxadiazol-5-yl)quinolin-2-yl)-N-(tetrahydro-2H-pyran-4-yl)piperidin-4 amine; CHEMBL4592045; SCHEMBL20670520; GTPL10452; BTRX335140; BCP32121; CYM53093; BDBM50531908; compound 58 [PMID: 30707578]; HY-124754; CS-0087593; BTRX 335140; BTRX335140; CYM-53093; CYM 53093; CYM53093; 1-(6-Ethyl-8-fluoro-4-methyl-3-(3-methyl-1,2,4-oxadiazol-5-yl)quinolin-2-yl)-N-(tetrahydro-2H-pyran-4-yl)piperidin-4-amine; 1-[6-ethyl-8-fluoro-4-methyl-3-(3-methyl-1,2,4-oxadiazol-5-yl)quinolin-2-yl]-N-(oxan-4-yl)piperidin-4-amine; 4-Piperidinamine, 1-(6-ethyl-8-fluoro-4-methyl-3-(3-methyl-1,2,4-oxadiazol-5-yl)-2-quinolinyl)-N-(tetrahydro-2H-pyran-4-yl)- DMWPDUZ CP BlackThorn Therapeutics DMWPDUZ DT Small molecular drug DMWPDUZ PC 137434175 DMWPDUZ MW 453.6 DMWPDUZ FM C25H32FN5O2 DMWPDUZ IC InChI=1S/C25H32FN5O2/c1-4-17-13-20-15(2)22(25-27-16(3)30-33-25)24(29-23(20)21(26)14-17)31-9-5-18(6-10-31)28-19-7-11-32-12-8-19/h13-14,18-19,28H,4-12H2,1-3H3 DMWPDUZ CS CCC1=CC2=C(C(=C(N=C2C(=C1)F)N3CCC(CC3)NC4CCOCC4)C5=NC(=NO5)C)C DMWPDUZ IK CQOJHAJWCDJEAT-UHFFFAOYSA-N DMWPDUZ IU 1-[6-ethyl-8-fluoro-4-methyl-3-(3-methyl-1,2,4-oxadiazol-5-yl)quinolin-2-yl]-N-(oxan-4-yl)piperidin-4-amine DMWPDUZ CA CAS 2244614-14-8 DMWPDUZ DE Major depressive disorder DMIEPJG ID DMIEPJG DMIEPJG DN BTT-1023 DMIEPJG HS Phase 2 DMIEPJG SN SI-3106; SI-636; Fully human VAP-1 mAbs (inflammation), BioTie/Seikagaku; Fully human VAP-1 monoclonal antibody (inflammation), BioTie/Seikagaku; VAP-1 antibody (rheumatoid arthritis/psoriasis), BioTie DMIEPJG CP BioTie Therapies Corp DMIEPJG DT Antibody DMIEPJG DE Psoriasis vulgaris DMZC4V0 ID DMZC4V0 DMZC4V0 DN Buproprion+zonisamide DMZC4V0 HS Phase 2 DMZC4V0 SN Empatic (TN) DMZC4V0 CP Orexigen Therapeutics DMZC4V0 DE Obesity DMNB4XK ID DMNB4XK DMNB4XK DN BVD-523 DMNB4XK HS Phase 2 DMNB4XK CP Biomed valley discoveries DMNB4XK PC 11719003 DMNB4XK MW 433.3 DMNB4XK FM C21H22Cl2N4O2 DMNB4XK IC InChI=1S/C21H22Cl2N4O2/c1-12(2)26-20-8-16(17(23)10-25-20)14-7-18(24-9-14)21(29)27-19(11-28)13-4-3-5-15(22)6-13/h3-10,12,19,24,28H,11H2,1-2H3,(H,25,26)(H,27,29)/t19-/m1/s1 DMNB4XK CS CC(C)NC1=NC=C(C(=C1)C2=CNC(=C2)C(=O)N[C@H](CO)C3=CC(=CC=C3)Cl)Cl DMNB4XK IK KSERXGMCDHOLSS-LJQANCHMSA-N DMNB4XK IU N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]-4-[5-chloro-2-(propan-2-ylamino)pyridin-4-yl]-1H-pyrrole-2-carboxamide DMNB4XK CA CAS 869886-67-9 DMNB4XK DE Solid tumour/cancer; Pancreatic cancer; Melanoma DM8CWL0 ID DM8CWL0 DM8CWL0 DN BVT.28949 DM8CWL0 HS Phase 2 DM8CWL0 CP Biovitrum DM8CWL0 DE Glaucoma/ocular hypertension DMD8GNB ID DMD8GNB DMD8GNB DN BXT-51072 DMD8GNB HS Phase 2 DMD8GNB SN ALT-2074; SYI-2074 DMD8GNB CP Synvista Therapeutics DMD8GNB DT Small molecular drug DMD8GNB PC 130165 DMD8GNB MW 226.19 DMD8GNB FM C10H13NSe DMD8GNB IC InChI=1S/C10H13NSe/c1-10(2)7-11-12-9-6-4-3-5-8(9)10/h3-6,11H,7H2,1-2H3 DMD8GNB CS CC1(CN[Se]C2=CC=CC=C21)C DMD8GNB IK FXRYWOJYVGJZLE-UHFFFAOYSA-N DMD8GNB IU 4,4-dimethyl-2,3-dihydro-1,2-benzoselenazine DMD8GNB CA CAS 173026-17-0 DMD8GNB DE Cardiovascular disease DMTRONK ID DMTRONK DMTRONK DN BZL-101 DMTRONK HS Phase 2 DMTRONK CP Bionovo DMTRONK DE Breast cancer DMGE058 ID DMGE058 DMGE058 DN Cabiralizumab DMGE058 HS Phase 2 DMGE058 CP Bristol-Myers Squibb Princeton, NJFive Prime Therapeutics South San Francisco, CA DMGE058 DE Solid tumour/cancer; Pancreatic cancer DMGXCY9 ID DMGXCY9 DMGXCY9 DN Calcium phosphate DMGXCY9 HS Phase 2 DMGXCY9 SN Bonarka; Calcigenol simple; Calcium orthophosphate; Calcium phosphate; Calcium phosphate (3:2); Calcium phosphate (Ca3(PO4)2); Calcium phosphate tribasic; Calcium tertiary phosphate; Natural whitlockite; Phosphoric acid, calcium salt; Phosphoric acid, calcium salt (2:3); Synthos; TRICALCIUM PHOSPHATE; Tertiary calcium phosphate; Tribasic calcium phosphate; Tricalcium diphosphate; Tricalcium orthophosphate; beta-TCP; beta-Tricalcium phosphate DMGXCY9 DT Small molecular drug DMGXCY9 PC 24456 DMGXCY9 MW 310.174 DMGXCY9 FM Ca3O8P2 DMGXCY9 IC InChI=1S/3Ca.2H3O4P/c;;;2*1-5(2,3)4/h;;;2*(H3,1,2,3,4)/q3*+2;;/p-6 DMGXCY9 CS [O-]P(=O)([O-])[O-].[O-]P(=O)([O-])[O-].[Ca+2].[Ca+2].[Ca+2] DMGXCY9 IK QORWJWZARLRLPR-UHFFFAOYSA-H DMGXCY9 IU tricalcium;diphosphate DMGXCY9 CA CAS 7758-87-410103-46-5 DMGXCY9 CB ChEBI:9679 DMGXCY9 DE Osteoporosis DMDV8MK ID DMDV8MK DMDV8MK DN CALDARET HYDRATE DMDV8MK HS Phase 2 DMDV8MK SN MCC-135; Caldaret hydrate; 5-Methyl-2-(1-piperazinyl)benzenesulfonic acid monohydrate DMDV8MK CP Mitsubishi Pharma DMDV8MK DT Small molecular drug DMDV8MK PC 9816981 DMDV8MK MW 274.34 DMDV8MK FM C11H18N2O4S DMDV8MK IC InChI=1S/C11H16N2O3S.H2O/c1-9-2-3-10(11(8-9)17(14,15)16)13-6-4-12-5-7-13;/h2-3,8,12H,4-7H2,1H3,(H,14,15,16);1H2 DMDV8MK CS CC1=CC(=C(C=C1)N2CCNCC2)S(=O)(=O)O.O DMDV8MK IK ZRQKZWAOIRVBFD-UHFFFAOYSA-N DMDV8MK IU 5-methyl-2-piperazin-1-ylbenzenesulfonic acid;hydrate DMDV8MK CA CAS 192509-24-3 DMDV8MK DE Cardiovascular disease DMAKSMX ID DMAKSMX DMAKSMX DN Camicinal DMAKSMX HS Phase 2 DMAKSMX SN 962040 DMAKSMX CP GlaxoSmithKline DMAKSMX DT Small molecular drug DMAKSMX PC 15984937 DMAKSMX MW 424.6 DMAKSMX FM C25H33FN4O DMAKSMX IC InChI=1S/C25H33FN4O/c1-19-17-29(14-11-27-19)18-21-7-5-20(6-8-21)15-25(31)30-12-9-23(10-13-30)28-24-4-2-3-22(26)16-24/h2-8,16,19,23,27-28H,9-15,17-18H2,1H3/t19-/m0/s1 DMAKSMX CS C[C@H]1CN(CCN1)CC2=CC=C(C=C2)CC(=O)N3CCC(CC3)NC4=CC(=CC=C4)F DMAKSMX IK RZKDEGZIFSJVNA-IBGZPJMESA-N DMAKSMX IU 1-[4-(3-fluoroanilino)piperidin-1-yl]-2-[4-[[(3S)-3-methylpiperazin-1-yl]methyl]phenyl]ethanone DMAKSMX CA CAS 923565-21-3 DMAKSMX DE Delayed gastric emptying; Diabetic gastroparesis DMQ7UL8 ID DMQ7UL8 DMQ7UL8 DN Camostat DMQ7UL8 HS Phase 2 DMQ7UL8 SN Camostat; 59721-28-7; camostate; Camostat [INN]; Camostatum [INN-Latin]; UNII-0FD207WKDU; CCRIS 7219; 4-(2-(2-(Dimethylamino)-2-oxoethoxy)-2-oxoethyl)phenyl 4-guanidinobenzoate; 0FD207WKDU; C20H22N4O5; Camostat (INN); Foipan; FOY 305; FOY-305; Dimethylcarbamoylmethyl 4-(4-guqnidinobenzoyloxy)phenylacetat; foypan; Camostatum; CHEMBL85164; camostate-mesilate; [4-[2-[2-(dimethylamino)-2-oxoethoxy]-2-oxoethyl]phenyl] 4-(diaminomethylideneamino)benzoate; p-Guanidinobenzoic acid, ester with (p-hydroxyphenyl)acetic acid, ester with N DMQ7UL8 DT Small molecular drug DMQ7UL8 PC 2536 DMQ7UL8 MW 398.4 DMQ7UL8 FM C20H22N4O5 DMQ7UL8 IC InChI=1S/C20H22N4O5/c1-24(2)17(25)12-28-18(26)11-13-3-9-16(10-4-13)29-19(27)14-5-7-15(8-6-14)23-20(21)22/h3-10H,11-12H2,1-2H3,(H4,21,22,23) DMQ7UL8 CS CN(C)C(=O)COC(=O)CC1=CC=C(C=C1)OC(=O)C2=CC=C(C=C2)N=C(N)N DMQ7UL8 IK XASIMHXSUQUHLV-UHFFFAOYSA-N DMQ7UL8 IU [4-[2-[2-(dimethylamino)-2-oxoethoxy]-2-oxoethyl]phenyl] 4-(diaminomethylideneamino)benzoate DMQ7UL8 CA CAS 59721-28-7 DMQ7UL8 CB CHEBI:135632 DMQ7UL8 DE Cystic fibrosis DMEZLFT ID DMEZLFT DMEZLFT DN Camsirubicin DMEZLFT HS Phase 2 DMEZLFT SN UNII-VI79RD8VNN; VI79RD8VNN; 236095-26-4; (8R,10S)-10-(((2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,8,11-trihydroxy-8-(2-hydroxyethyl)-12-imino-1-methoxy-7,9,10,12-tetrahydrotetracen-5(8H)-one; 5(8H)-Naphthacenone, 10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,9,10,12-tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyethyl)-12-imino-1-methoxy-, (8R,10S)- DMEZLFT CP Monopar Therapeutics DMEZLFT DT Small molecular drug DMEZLFT PC 135446069 DMEZLFT MW 528.5 DMEZLFT FM C27H32N2O9 DMEZLFT IC InChI=1S/C27H32N2O9/c1-11-23(31)14(28)8-17(37-11)38-16-10-27(35,6-7-30)9-13-19(16)26(34)20-21(25(13)33)24(32)12-4-3-5-15(36-2)18(12)22(20)29/h3-5,11,14,16-17,23,29-31,33-35H,6-10,28H2,1-2H3/t11-,14-,16-,17-,23+,27-/m0/s1 DMEZLFT CS C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=N)C(=CC=C5)OC)O)(CCO)O)N)O DMEZLFT IK GNCWGPLZJLZZPI-KUIJCEFOSA-N DMEZLFT IU (8R,10S)-10-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,8,11-trihydroxy-8-(2-hydroxyethyl)-12-imino-1-methoxy-9,10-dihydro-7H-tetracen-5-one DMEZLFT CA CAS 236095-26-4 DMEZLFT DE Soft tissue sarcoma DMEYIVW ID DMEYIVW DMEYIVW DN CAP1-6D DMEYIVW HS Phase 2 DMEYIVW SN Modified CEA peptide (pancreatic cancer), University of Chicago DMEYIVW CP University of Chicago DMEYIVW DT Small molecular drug DMEYIVW PC 396060 DMEYIVW MW 965.1 DMEYIVW FM C43H68N10O15 DMEYIVW IC InChI=1S/C43H68N10O15/c1-20(2)12-27(49-37(61)26(44)15-24-8-10-25(55)11-9-24)40(64)53-32(19-54)38(62)46-18-34(57)47-23(7)36(60)48-30(17-35(58)59)42(66)50-28(13-21(3)4)39(63)51-29(16-33(45)56)41(65)52-31(43(67)68)14-22(5)6/h8-11,20-23,26-32,54-55H,12-19,44H2,1-7H3,(H2,45,56)(H,46,62)(H,47,57)(H,48,60)(H,49,61)(H,50,66)(H,51,63)(H,52,65)(H,53,64)(H,58,59)(H,67,68) DMEYIVW CS CC(C)CC(C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)NC(CC(=O)O)C(=O)NC(CC(C)C)C(=O)NC(CC(=O)N)C(=O)NC(CC(C)C)C(=O)O)NC(=O)C(CC1=CC=C(C=C1)O)N DMEYIVW IK SNKUSVNHTCUELQ-UHFFFAOYSA-N DMEYIVW IU 2-[[4-amino-2-[[2-[[2-[2-[[2-[[2-[[2-[[2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]propanoylamino]-3-carboxypropanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-4-methylpentanoic acid DMEYIVW DE Pancreatic cancer DMJKLHU ID DMJKLHU DMJKLHU DN CAP-7.1 DMJKLHU HS Phase 2 DMJKLHU CP CellAct Pharma GmbH DMJKLHU PC 154701729 DMJKLHU DE Solid tumour/cancer DMYWO62 ID DMYWO62 DMYWO62 DN Capadenoson DMYWO62 HS Phase 2 DMYWO62 SN Capadenoson; 544417-40-5; UNII-O519NVW73R; O519NVW73R; CHEMBL3235279; BAY 68-4986; 2-amino-6-[[[2-(4-chlorophenyl)-4-thiazolyl]methyl]thio]-4-[4-(2-hydroxyethoxy)phenyl]-3,5-Pyridinedicarbonitrile; C25H18ClN5O2S2; Capadenoson [INN]; 2-amino-6-({(2-(4-chlorophenyl)-1,3-thiazol-4-yl)methyl}sulfanyl)-4-(4-(2-hydroxyethoxy)phenyl)pyridine-3,5-dicarbonitrile; 2-amino-6-({[2-(4-chlorophenyl)-1,3-thiazol-4-yl]methyl}sulfanyl)-4-[4-(2-hydroxyethoxy)phenyl]pyridine-3,5-dicarbonitrile; SCHEMBL174016; Capadenoson;BAY 68-4986 DMYWO62 CP Bayer HealthCare Pharmaceuticals DMYWO62 DT Small molecular drug DMYWO62 PC 9936489 DMYWO62 MW 520 DMYWO62 FM C25H18ClN5O2S2 DMYWO62 IC InChI=1S/C25H18ClN5O2S2/c26-17-5-1-16(2-6-17)24-30-18(13-34-24)14-35-25-21(12-28)22(20(11-27)23(29)31-25)15-3-7-19(8-4-15)33-10-9-32/h1-8,13,32H,9-10,14H2,(H2,29,31) DMYWO62 CS C1=CC(=CC=C1C2=C(C(=NC(=C2C#N)SCC3=CSC(=N3)C4=CC=C(C=C4)Cl)N)C#N)OCCO DMYWO62 IK CITWCLNVRIKQAF-UHFFFAOYSA-N DMYWO62 IU 2-amino-6-[[2-(4-chlorophenyl)-1,3-thiazol-4-yl]methylsulfanyl]-4-[4-(2-hydroxyethoxy)phenyl]pyridine-3,5-dicarbonitrile DMYWO62 CA CAS 544417-40-5 DMYWO62 DE Atrial fibrillation DMY4OMS ID DMY4OMS DMY4OMS DN Carabersat DMY4OMS HS Phase 2 DMY4OMS SN SB-204268; SB-204269; SB-258339 DMY4OMS CP SmithKline Beecham plc DMY4OMS DT Small molecular drug DMY4OMS PC 193943 DMY4OMS MW 357.4 DMY4OMS FM C20H20FNO4 DMY4OMS IC InChI=1S/C20H20FNO4/c1-11(23)13-6-9-16-15(10-13)17(18(24)20(2,3)26-16)22-19(25)12-4-7-14(21)8-5-12/h4-10,17-18,24H,1-3H3,(H,22,25)/t17-,18+/m0/s1 DMY4OMS CS CC(=O)C1=CC2=C(C=C1)OC([C@@H]([C@H]2NC(=O)C3=CC=C(C=C3)F)O)(C)C DMY4OMS IK RCLXAPJEFHPYEG-ZWKOTPCHSA-N DMY4OMS IU N-[(3R,4S)-6-acetyl-3-hydroxy-2,2-dimethyl-3,4-dihydrochromen-4-yl]-4-fluorobenzamide DMY4OMS CA CAS 184653-84-7 DMY4OMS DE Epileptic seizures DMN5JCX ID DMN5JCX DMN5JCX DN Carboxyamidotriazole orotate DMN5JCX HS Phase 2 DMN5JCX CP Tactical Therapeutics DMN5JCX PC 154732136 DMN5JCX DE Glioblastoma multiforme DM7ADGX ID DM7ADGX DM7ADGX DN Carfentanil DM7ADGX HS Phase 2 DM7ADGX SN CARFENTANIL; Carfentanyl; Carfentanila; Carfentanilum; Wildnil; 59708-52-0; Carfentanil [INN]; Carfentanila [Spanish]; UNII-LA9DTA2L8F; Carfentanilum [INN-Latin]; Carfentanila [INN-Spanish]; Methyl 1-phenylethyl-4-(N-phenylpropionamido)isonipecotate; CHEBI:61084; Methyl 4-(N-propionyl-N-phenylamino)-1-(2-phenylethyl)-4-piperidine-carboxylate; Methyl 4-(N-(1-oxopropyl)-N-phenylamino)-1-(2-phenylethyl)-4-piperidinecarboxylate; 4-((1-Oxopropyl)phenylamino)-1-(2-phenylethyl)-4-piperidinecarboxylic acid methyl ester DM7ADGX DT Small molecular drug DM7ADGX PC 62156 DM7ADGX MW 394.5 DM7ADGX FM C24H30N2O3 DM7ADGX IC InChI=1S/C24H30N2O3/c1-3-22(27)26(21-12-8-5-9-13-21)24(23(28)29-2)15-18-25(19-16-24)17-14-20-10-6-4-7-11-20/h4-13H,3,14-19H2,1-2H3 DM7ADGX CS CCC(=O)N(C1=CC=CC=C1)C2(CCN(CC2)CCC3=CC=CC=C3)C(=O)OC DM7ADGX IK YDSDEBIZUNNPOB-UHFFFAOYSA-N DM7ADGX IU methyl 1-(2-phenylethyl)-4-(N-propanoylanilino)piperidine-4-carboxylate DM7ADGX CA CAS 59708-52-0 DM7ADGX CB CHEBI:61084 DMAUN15 ID DMAUN15 DMAUN15 DN Carlumab DMAUN15 HS Phase 2 DMAUN15 SN CCL-2; CNTO-888; Anti-MCP1 monoclonal antibodies, Centocor; CCL2 monoclonal antibody (infusion, cancer), Centocor DMAUN15 CP Janssen biotech DMAUN15 DT Antibody DMAUN15 DE Pulmonary fibrosis DMN6TKI ID DMN6TKI DMN6TKI DN Carmoterol DMN6TKI HS Phase 2 DMN6TKI SN 147568-66-9; 8-Hydroxy-5-((R)-1-hydroxy-2-(((R)-1-(4-methoxyphenyl)propan-2-yl)amino)ethyl)quinolin-2(1H)-one; UNII-9810NUL4D1; CHEMBL1094785; 9810NUL4D1; 2(1h)-quinolinone, 8-hydroxy-5-[(1r)-1-hydroxy-2-[[(1r)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-; 8-hydroxy-5-[(1R)-1-hydroxy-2-{[(2R)-1-(4-methoxyphenyl)propan-2-yl]amino}ethyl]-1,2-dihydroquinolin-2-one; Carmoterol [INN]; 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(2R)-1-(4-methoxyphenyl)propan-2-yl]amino]ethyl]-1H-quinolin-2-one; AC1Q6MT1 DMN6TKI CP Chiesi DMN6TKI DT Small molecular drug DMN6TKI PC 63952 DMN6TKI MW 368.4 DMN6TKI FM C21H24N2O4 DMN6TKI IC InChI=1S/C21H24N2O4/c1-13(11-14-3-5-15(27-2)6-4-14)22-12-19(25)16-7-9-18(24)21-17(16)8-10-20(26)23-21/h3-10,13,19,22,24-25H,11-12H2,1-2H3,(H,23,26)/t13-,19+/m1/s1 DMN6TKI CS C[C@H](CC1=CC=C(C=C1)OC)NC[C@@H](C2=C3C=CC(=O)NC3=C(C=C2)O)O DMN6TKI IK IHOXNOQMRZISPV-YJYMSZOUSA-N DMN6TKI IU 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(2R)-1-(4-methoxyphenyl)propan-2-yl]amino]ethyl]-1H-quinolin-2-one DMN6TKI CA CAS 147568-66-9 DMN6TKI DE Chronic obstructive pulmonary disease DMTBFXW ID DMTBFXW DMTBFXW DN CART 19 DMTBFXW HS Phase 2 DMTBFXW CP University of Pennsylvania DMTBFXW DT CAR T Cell Therapy DMTBFXW DE Acute lymphoblastic leukaemia; Pancreatic cancer DM28A5D ID DM28A5D DM28A5D DN CAR-T cells targeting CD19 DM28A5D HS Phase 2 DM28A5D CP The First Affiliated Hospital of Soochow University DM28A5D DT CAR T Cell Therapy DM28A5D DE Non-hodgkin lymphoma DM3RU0A ID DM3RU0A DM3RU0A DN CAR-T cells targeting CD20 DM3RU0A HS Phase 2 DM3RU0A CP The First Affiliated Hospital of Soochow University DM3RU0A DT CAR T Cell Therapy DM3RU0A DE Non-hodgkin lymphoma DM6XN4C ID DM6XN4C DM6XN4C DN CAR-T cells targeting CD22 DM6XN4C HS Phase 2 DM6XN4C CP The First Affiliated Hospital of Soochow University DM6XN4C DT CAR T Cell Therapy DM6XN4C DE Non-hodgkin lymphoma DML0KWM ID DML0KWM DML0KWM DN CAR-T cells targeting CD30 DML0KWM HS Phase 2 DML0KWM CP The First Affiliated Hospital of Soochow University DML0KWM DT CAR T Cell Therapy DML0KWM DE Non-hodgkin lymphoma DMHQKN6 ID DMHQKN6 DMHQKN6 DN CART-19 DMHQKN6 HS Phase 2 DMHQKN6 CP University of Pennsylvania DMHQKN6 DT CAR T Cell Therapy DMHQKN6 DE Non-hodgkin lymphoma; B-cell lymphoma; leukaemia; Acute lymphoblastic leukaemia; Chronic lymphocytic leukaemia; B-cell chronic lymphocytic leukaemia; Diffuse large B-cell lymphoma; Follicular lymphoma; Haematopoietic/lymphoid cancer; Mantle cell lymphoma; Prolymphocytic leukaemia DMZUV7T ID DMZUV7T DMZUV7T DN CART-19 cells DMZUV7T HS Phase 2 DMZUV7T CP University of Pennsylvania DMZUV7T DT CAR T Cell Therapy DMZUV7T DE Acute lymphocytic leukaemia; Multiple myeloma DMQBP7R ID DMQBP7R DMQBP7R DN CAT 1004 DMQBP7R HS Phase 2 DMQBP7R CP Catabasis Pharmaceuticals DMQBP7R DE Type-2 diabetes; Duchenne dystrophy DM2IFYZ ID DM2IFYZ DM2IFYZ DN CB-10-01 DM2IFYZ HS Phase 2 DM2IFYZ CP Cosmo Pharmaceuticals DM2IFYZ DT Vaccine DM2IFYZ DE Melanoma DM094UH ID DM094UH DM094UH DN CB-839 DM094UH HS Phase 2 DM094UH PC 71577426 DM094UH MW 571.6 DM094UH FM C26H24F3N7O3S DM094UH IC InChI=1S/C26H24F3N7O3S/c27-26(28,29)39-20-9-5-6-17(14-20)15-22(37)31-21-12-11-18(33-34-21)7-1-2-10-24-35-36-25(40-24)32-23(38)16-19-8-3-4-13-30-19/h3-6,8-9,11-14H,1-2,7,10,15-16H2,(H,31,34,37)(H,32,36,38) DM094UH CS C1=CC=NC(=C1)CC(=O)NC2=NN=C(S2)CCCCC3=NN=C(C=C3)NC(=O)CC4=CC(=CC=C4)OC(F)(F)F DM094UH IK PRAAPINBUWJLGA-UHFFFAOYSA-N DM094UH IU N-[6-[4-[5-[(2-pyridin-2-ylacetyl)amino]-1,3,4-thiadiazol-2-yl]butyl]pyridazin-3-yl]-2-[3-(trifluoromethoxy)phenyl]acetamide DM094UH CA CAS 1439399-58-2 DM094UH DE leukaemia; Breast cancer; Renal cell carcinoma; Solid tumour/cancer DMK4FRU ID DMK4FRU DMK4FRU DN CBLB-502 DMK4FRU HS Phase 2 DMK4FRU SN CBLB-501; Mini-flagellin, Cleveland BioLabs; Recombinant flagellin proteins (injury protection), Cleveland BioLabs DMK4FRU CP Cleveland BioLabs Inc DMK4FRU DE Acute radiation syndrome DMSBNTZ ID DMSBNTZ DMSBNTZ DN CBX-129801 DMSBNTZ HS Phase 2 DMSBNTZ SN Ersatta; C-peptide (depot formulation), Cebix; Long-acting synthetic C-peptide, Cebix; PEGylated C-peptide (diabetic complications), Cebix DMSBNTZ CP Cebix DMSBNTZ DE Diabetic complication DMQ874W ID DMQ874W DMQ874W DN CC-1088 DMQ874W HS Phase 2 DMQ874W SN CDC801; CC-1088; CHEMBL88153; SCHEMBL185853; CDC-801; DDYUBCCTNHWSQM-UHFFFAOYSA-N; BDBM50216298; HY-U00179; CS-7247; 192819-27-5 DMQ874W DT Small molecular drug DMQ874W PC 9844338 DMQ874W MW 408.4 DMQ874W FM C23H24N2O5 DMQ874W IC InChI=1S/C23H24N2O5/c1-29-19-11-10-14(12-20(19)30-15-6-2-3-7-15)18(13-21(24)26)25-22(27)16-8-4-5-9-17(16)23(25)28/h4-5,8-12,15,18H,2-3,6-7,13H2,1H3,(H2,24,26) DMQ874W CS COC1=C(C=C(C=C1)C(CC(=O)N)N2C(=O)C3=CC=CC=C3C2=O)OC4CCCC4 DMQ874W IK DDYUBCCTNHWSQM-UHFFFAOYSA-N DMQ874W IU 3-(3-cyclopentyloxy-4-methoxyphenyl)-3-(1,3-dioxoisoindol-2-yl)propanamide DMQ874W CA CAS 192819-27-5 DMQ874W DE Crohn disease DMNE7L3 ID DMNE7L3 DMNE7L3 DN CC-220 DMNE7L3 HS Phase 2 DMNE7L3 SN AC1OEW2H; NPD6561; MCULE-9299015048; BCP9000573; BCP0726000266 DMNE7L3 DT Small molecular drug DMNE7L3 PC 67335295 DMNE7L3 MW 449.5 DMNE7L3 FM C25H27N3O5 DMNE7L3 IC InChI=1S/C25H27N3O5/c29-23-9-8-21(24(30)26-23)28-15-20-19(25(28)31)2-1-3-22(20)33-16-18-6-4-17(5-7-18)14-27-10-12-32-13-11-27/h1-7,21H,8-16H2,(H,26,29,30)/t21-/m0/s1 DMNE7L3 CS C1CC(=O)NC(=O)[C@H]1N2CC3=C(C2=O)C=CC=C3OCC4=CC=C(C=C4)CN5CCOCC5 DMNE7L3 IK IXZOHGPZAQLIBH-NRFANRHFSA-N DMNE7L3 IU (3S)-3-[7-[[4-(morpholin-4-ylmethyl)phenyl]methoxy]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione DMNE7L3 CA CAS 1323403-33-3 DMNE7L3 DE Sarcoidosis; Multiple myeloma; Systemic lupus erythematosus DMJR9H0 ID DMJR9H0 DMJR9H0 DN CC-292 DMJR9H0 HS Phase 2 DMJR9H0 SN AVL-292; 1202757-89-8; spebrutinib; cc-292; UNII-DRU6NG543J; CC-292 (AVL-292); DRU6NG543J; AVL292; N-[3-[[5-fluoro-2-[4-(2-methoxyethoxy)anilino]pyrimidin-4-yl]amino]phenyl]prop-2-enamide; AK198940; N-(3-((5-fluoro-2-((4-(2-methoxyethoxy)phenyl)amino)pyrimidin-4-yl)amino)phenyl)acrylamide; N-[3-[[5-fluoro-2-[[4-(2-methoxyethoxy)phenyl]amino]-4-pyrimidinyl]amino]phenyl]-2-propenamide; Btk inhibitor CC-292; Spebrutinib [USAN:INN]; Spebrutinib (USAN/INN); SCHEMBL626216; GTPL7837; CHEMBL3301625; EX-A255; AVL 292 DMJR9H0 CP Celgene DMJR9H0 DT Small molecular drug DMJR9H0 PC 59174488 DMJR9H0 MW 423.4 DMJR9H0 FM C22H22FN5O3 DMJR9H0 IC InChI=1S/C22H22FN5O3/c1-3-20(29)25-16-5-4-6-17(13-16)26-21-19(23)14-24-22(28-21)27-15-7-9-18(10-8-15)31-12-11-30-2/h3-10,13-14H,1,11-12H2,2H3,(H,25,29)(H2,24,26,27,28) DMJR9H0 CS COCCOC1=CC=C(C=C1)NC2=NC=C(C(=N2)NC3=CC(=CC=C3)NC(=O)C=C)F DMJR9H0 IK KXBDTLQSDKGAEB-UHFFFAOYSA-N DMJR9H0 IU N-[3-[[5-fluoro-2-[4-(2-methoxyethoxy)anilino]pyrimidin-4-yl]amino]phenyl]prop-2-enamide DMJR9H0 CA CAS 1202757-89-8 DMJR9H0 DE Chronic lymphocytic leukaemia DMPMO6G ID DMPMO6G DMPMO6G DN CC-401 DMPMO6G HS Phase 2 DMPMO6G SN CC-401; 395104-30-0; UNII-NOE38VQA1W; NOE38VQA1W; 3-(3-(2-(piperidin-1-yl)ethoxy)phenyl)-5-(1H-1,2,4-triazol-5-yl)-1H-indazole; 3-(3-(2-(piperidin-1-yl)ethoxy)phenyl)-5-(1H-1,2,4-triazol-3-yl)-1H-indazole; 3-[3-[2-(1-PIPERIDINYL)ETHOXY]PHENYL]-5-(1H-1,2,4-TRIAZOL-5-YL)-1H-INDAZOLE; CC 401; C22H24N6O; PubChem22434; SCHEMBL4604749; CHEMBL1614713; CHEBI:91437; DTXSID40192650; MolPort-044-561-531; MolPort-021-804-942; BCPP000298; BCP01960; ZINC38836256; RS0046; HY-13022A; AKOS027251057; AKOS027336636; DB12432; BCP9000495; CS-1955 DMPMO6G TC Anticancer Agents DMPMO6G DT Small molecular drug DMPMO6G PC 10430360 DMPMO6G MW 388.5 DMPMO6G FM C22H24N6O DMPMO6G IC InChI=1S/C22H24N6O/c1-2-9-28(10-3-1)11-12-29-18-6-4-5-16(13-18)21-19-14-17(22-23-15-24-27-22)7-8-20(19)25-26-21/h4-8,13-15H,1-3,9-12H2,(H,25,26)(H,23,24,27) DMPMO6G CS C1CCN(CC1)CCOC2=CC=CC(=C2)C3=NNC4=C3C=C(C=C4)C5=NC=NN5 DMPMO6G IK XDJCLCLBSGGNKS-UHFFFAOYSA-N DMPMO6G IU 3-[3-(2-piperidin-1-ylethoxy)phenyl]-5-(1H-1,2,4-triazol-5-yl)-1H-indazole DMPMO6G CA CAS 395104-30-0 DMPMO6G CB CHEBI:91437 DMPMO6G DE Solid tumour/cancer DM0EDHJ ID DM0EDHJ DM0EDHJ DN CC-90011 DM0EDHJ HS Phase 2 DM0EDHJ SN UNII-W6F4FRQ5QC; W6F4FRQ5QC; CC90011; 1821307-10-1; CC-90011 besylate; 4-[2-(4-aminopiperidin-1-yl)-5-(3-fluoro-4-methoxyphenyl)-1-methyl-6-oxo-1,6-dihydropyrimidin-4-yl]-2-fluorobenzonitrile; Pulrodemstat; 4-(2-(4-Aminopiperidin-1-yl)-5-(3-fluoro-4-methoxyphenyl)-1-methyl-6-oxo-1,6-dihydropyrimidin-4-yl)-2-fluorobenzonitrile; Pulrodemstat [INN]; CC-90011 Free base; SCHEMBL17222702; GTPL11284; US10023543, Example 7; BDBM283216; US10023543, Example 85; US10023543, Example 86; NSC822744; NSC-822744; compound 11 [PMID: 33034194]; Q67009340; NC1CCN(CC1)C=1N(C(C(=C(N1)C1=CC(=C(C#N)C=C1)F)C1=CC(=C(C=C1)OC)F)=O)C; 4-(2-(4-Amino-piperidin-1-yl)-5-(3-fluoro-4-methoxyphenyl)-1-methyl-6-oxo-1,6-dihydropyrimidin-4-yl)-2-fluorobenzonitrile; 4-[2-(4-amino-piperidin-1-yl)-5- (3-fluoro-4-methoxy-phenyl)-1- methyl-6-oxo-1,6-dihydro- pyrimidin-4-yl]-2-fluoro- benzonitrile; Benzonitrile, 4-(2-(4-amino-1-piperidinyl)-5-(3-fluoro-4-methoxyphenyl)-1,6-dihydro-1-methyl-6-oxo-4-pyrimidinyl)-2-fluoro-; V0Y DM0EDHJ CP Bristol-Myers Squibb DM0EDHJ DT Small molecular drug DM0EDHJ PC 118483201 DM0EDHJ MW 451.5 DM0EDHJ FM C24H23F2N5O2 DM0EDHJ IC InChI=1S/C24H23F2N5O2/c1-30-23(32)21(14-5-6-20(33-2)19(26)11-14)22(15-3-4-16(13-27)18(25)12-15)29-24(30)31-9-7-17(28)8-10-31/h3-6,11-12,17H,7-10,28H2,1-2H3 DM0EDHJ CS CN1C(=O)C(=C(N=C1N2CCC(CC2)N)C3=CC(=C(C=C3)C#N)F)C4=CC(=C(C=C4)OC)F DM0EDHJ IK NBAIXBAUHIQQGF-UHFFFAOYSA-N DM0EDHJ IU 4-[2-(4-aminopiperidin-1-yl)-5-(3-fluoro-4-methoxyphenyl)-1-methyl-6-oxopyrimidin-4-yl]-2-fluorobenzonitrile DM0EDHJ CA CAS 1821307-10-1 DM0EDHJ DE Lymphoma; Non-hodgkin lymphoma DMHVEGJ ID DMHVEGJ DMHVEGJ DN CC-930 DMHVEGJ HS Phase 2 DMHVEGJ SN TANZISERTIB; CC-930; 899805-25-5; CC 930; UNII-M5O06306UO; CHEMBL1950289; M5O06306UO; CC930; Trans-4-({9-[(3s)-Tetrahydrofuran-3-Yl]-8-[(2,4,6-Trifluorophenyl)amino]-9h-Purin-2-Yl}amino)cyclohexanol; Tanzisertib [USAN:INN]; 3tti; trans-4-((9-((3S)-Tetrahydrofuran-3-yl)-8-((2,4,6-trifluorophenyl)amino)-9H-purin-2-yl)amino)cyclohexanol; Tanzisertib (USAN); CC-930(Tanzisertib); SCHEMBL2133061; SCHEMBL4760419; SCHEMBL2133055; GTPL9836; SCHEMBL8082102; SCHEMBL15589918; CHEMBL1950305; SCHEMBL10179476; JNK-930; MolPort-044-562-358 DMHVEGJ CP Celgene DMHVEGJ DT Small molecular drug DMHVEGJ PC 11597537 DMHVEGJ MW 448.4 DMHVEGJ FM C21H23F3N6O2 DMHVEGJ IC InChI=1S/C21H23F3N6O2/c22-11-7-15(23)18(16(24)8-11)28-21-27-17-9-25-20(26-12-1-3-14(31)4-2-12)29-19(17)30(21)13-5-6-32-10-13/h7-9,12-14,31H,1-6,10H2,(H,27,28)(H,25,26,29)/t12?,13-,14?/m0/s1 DMHVEGJ CS C1COC[C@H]1N2C3=NC(=NC=C3N=C2NC4=C(C=C(C=C4F)F)F)NC5CCC(CC5)O DMHVEGJ IK IBGLGMOPHJQDJB-MOKVOYLWSA-N DMHVEGJ IU 4-[[9-[(3S)-oxolan-3-yl]-8-(2,4,6-trifluoroanilino)purin-2-yl]amino]cyclohexan-1-ol DMHVEGJ CA CAS 899805-25-5 DMHVEGJ DE Discoid lupus erythematosus; Idiopathic pulmonary fibrosis DMJ9XCO ID DMJ9XCO DMJ9XCO DN CCX-140 DMJ9XCO HS Phase 2 DMJ9XCO SN CCX-140-B; CCR2 receptor antagonist (inflammation/multiple sclerosis/metabolic disease), ChemoCentryx; CCR2 receptor antagonist (inflammation/multiple sclerosis/metabolic disease/chronic kidney disease), ChemoCentryx DMJ9XCO CP Chemocentryx DMJ9XCO PC 25134303 DMJ9XCO MW 495.9 DMJ9XCO FM C20H13ClF3N5O3S DMJ9XCO IC InChI=1S/C20H13ClF3N5O3S/c1-10-6-15(29-33(31,32)11-2-3-14(21)13(7-11)20(22,23)24)17(26-8-10)18(30)16-12-4-5-25-19(12)28-9-27-16/h2-9,29H,1H3,(H,25,27,28) DMJ9XCO CS CC1=CC(=C(N=C1)C(=O)C2=C3C=CNC3=NC=N2)NS(=O)(=O)C4=CC(=C(C=C4)Cl)C(F)(F)F DMJ9XCO IK LUUMLYXKTPBTQR-UHFFFAOYSA-N DMJ9XCO IU 4-chloro-N-[5-methyl-2-(7H-pyrrolo[2,3-d]pyrimidine-4-carbonyl)pyridin-3-yl]-3-(trifluoromethyl)benzenesulfonamide DMJ9XCO CA CAS 1100318-47-5 DMJ9XCO DE Diabetic nephropathy DMSHV9C ID DMSHV9C DMSHV9C DN CCX-354 DMSHV9C HS Phase 2 DMSHV9C SN CCX-354-C; GSK2941266 DMSHV9C CP ChemoCentryx Inc DMSHV9C PC 135565361 DMSHV9C MW 451.9 DMSHV9C FM C22H22ClN7O2 DMSHV9C IC InChI=1S/C22H22ClN7O2/c1-32-18-13-15(4-5-17(18)23)28-9-11-29(12-10-28)19(31)14-30-22-16(3-2-6-26-22)20(27-30)21-24-7-8-25-21/h2-8,13H,9-12,14H2,1H3,(H,24,25) DMSHV9C CS COC1=C(C=CC(=C1)N2CCN(CC2)C(=O)CN3C4=C(C=CC=N4)C(=N3)C5=NC=CN5)Cl DMSHV9C IK ZIMLRKWQDLVPEK-UHFFFAOYSA-N DMSHV9C IU 1-[4-(4-chloro-3-methoxyphenyl)piperazin-1-yl]-2-[3-(1H-imidazol-2-yl)pyrazolo[3,4-b]pyridin-1-yl]ethanone DMSHV9C CA CAS 1010073-75-2 DMSHV9C DE Autoimmune diabetes; Rheumatoid arthritis DMPVAUT ID DMPVAUT DMPVAUT DN CCX872 DMPVAUT HS Phase 2 DMPVAUT CP Chemocentryx DMPVAUT DE Diabetic nephropathy; Pancreatic tumour DMEK580 ID DMEK580 DMEK580 DN CD19 CAR T cells DMEK580 HS Phase 2 DMEK580 CP Southwest Hospital, China DMEK580 DT CAR T Cell Therapy DMEK580 DE B-cell chronic lymphocytic leukaemia; Diffuse large B-cell lymphoma; Non-hodgkin lymphoma DMQJBUK ID DMQJBUK DMQJBUK DN CD19-targeting CAR T cells DMQJBUK HS Phase 2 DMQJBUK CP Uppsala University DMQJBUK DT CAR T Cell Therapy DMQJBUK DE B-cell lymphoma; leukaemia DMQGI8R ID DMQGI8R DMQGI8R DN CD20 CAR T cells DMQGI8R HS Phase 2 DMQGI8R CP Southwest Hospital, China DMQGI8R DT CAR T Cell Therapy DMQGI8R DE B-cell chronic lymphocytic leukaemia; Diffuse large B-cell lymphoma; Non-hodgkin lymphoma DMXYLTI ID DMXYLTI DMXYLTI DN CDP323 DMXYLTI HS Phase 2 DMXYLTI SN Zaurategrast; 455264-31-0; (S)-3-(4-((2,7-Naphthyridin-1-yl)amino)phenyl)-2-((2-bromo-3-oxospiro[3.5]non-1-en-1-yl)amino)propanoic acid; UNII-06A0IC74I3; 06A0IC74I3; C26H25BrN4O3; Zaurategrast [INN]; SCHEMBL2976322; CTK8C0588; DTXSID90196547; MolPort-023-332-826; KS-00001DY0; ANW-64932; 6274AB; ZINC100041912; AKOS016005046; CS-0322; N-(2-Bromo-3-oxospiro[3.5]non-1-en-1-yl)-4-(2,7-naphthyridin-1-ylamino)-L-phenylalanine; NCGC00378753-01 DMXYLTI CP UCB; Biogen Idec DMXYLTI DT Small molecular drug DMXYLTI PC 23394557 DMXYLTI MW 549.5 DMXYLTI FM C28H29BrN4O3 DMXYLTI IC InChI=1S/C28H29BrN4O3/c1-2-36-27(35)22(33-24-23(29)25(34)28(24)12-4-3-5-13-28)16-18-6-8-20(9-7-18)32-26-21-17-30-14-10-19(21)11-15-31-26/h6-11,14-15,17,22,33H,2-5,12-13,16H2,1H3,(H,31,32)/t22-/m0/s1 DMXYLTI CS CCOC(=O)[C@H](CC1=CC=C(C=C1)NC2=NC=CC3=C2C=NC=C3)NC4=C(C(=O)C45CCCCC5)Br DMXYLTI IK QCYAXXZCQKMTMO-QFIPXVFZSA-N DMXYLTI IU ethyl (2S)-2-[(2-bromo-3-oxospiro[3.5]non-1-en-1-yl)amino]-3-[4-(2,7-naphthyridin-1-ylamino)phenyl]propanoate DMXYLTI CA CAS 455264-30-9 DMXYLTI DE Rheumatoid arthritis; Multiple sclerosis DM3YB2C ID DM3YB2C DM3YB2C DN CDP-6038 DM3YB2C HS Phase 2 DM3YB2C DE Rheumatoid arthritis DM8UQJG ID DM8UQJG DM8UQJG DN CDX-1307 DM8UQJG HS Phase 2 DM8UQJG SN BHCG-VAC; BetaHCG-VAC; MDX-1307; Dendritic cell targeted hCG-beta vaccine, Medarex; B11-hCG-beta, Medarex; Antigen-presenting cell-targeted vaccine (injectable, cancer), Celldex Therapeutics; Antigen-presenting cell-targeted vaccine (intradermal, cancer), Celldex Therapeutics; Antigen-presenting cell-targeted vaccine (iv, cancer), Celldex Therapeutics DM8UQJG CP Medarex Inc DM8UQJG DT Vaccine DM8UQJG DE Bladder cancer DMCGNJ6 ID DMCGNJ6 DMCGNJ6 DN CDX-1401 DMCGNJ6 HS Phase 2 DMCGNJ6 CP Celldex Therapeutics DMCGNJ6 DE Solid tumour/cancer; Ovarian cancer DMKRFCO ID DMKRFCO DMKRFCO DN CDX-301 DMKRFCO HS Phase 2 DMKRFCO DE Hematopoietic stem cell transplantation; Solid tumour/cancer; Multiple myeloma DM5GKYD ID DM5GKYD DM5GKYD DN CDX-3379 DM5GKYD HS Phase 2 DM5GKYD CP Celldex Therapeutics Hampton, NJ DM5GKYD DE Solid tumour/cancer; Squamous cell carcinoma DM6Z9BV ID DM6Z9BV DM6Z9BV DN CeaVac DM6Z9BV HS Phase 2 DM6Z9BV SN Idiotypic vaccine (CEA), Titan; Monoclonal antibody (cancer), Titan DM6Z9BV CP Titan Pharmaceuticals DM6Z9BV DT Vaccine DM6Z9BV DE Colorectal cancer DM1S2FZ ID DM1S2FZ DM1S2FZ DN Cemdisiran DM1S2FZ HS Phase 2 DM1S2FZ CP Alnylam Pharmaceuticals DM1S2FZ DT Small interfering RNA DM1S2FZ DE Paroxysmal nocturnal haemoglobinuria; Haemolytic uraemic syndrome DMCT8EY ID DMCT8EY DMCT8EY DN Cenderitide DMCT8EY HS Phase 2 DMCT8EY CP Nile Therapeutics DMCT8EY DE Heart failure; Heart disease DMU3P1K ID DMU3P1K DMU3P1K DN Cenerimod DMU3P1K HS Phase 2 DMU3P1K SN 1262414-04-9; UNII-Y333RS1786; ACT-334441; Y333RS1786; Cenerimod [INN]; Cenerimod [USAN]; SCHEMBL2671193; GTPL9824; MolPort-044-723-844; KS-000006AE; ZINC167253016; AKOS030630068; CS-6364; DB12705; 1,2-Propanediol, 3-(4-(5-(2-cyclopentyl-6-methoxy-4-pyridinyl)-1,2,4-oxadiazol-3-yl)-2-ethyl-6-methylphenoxy)-, (2S)-; (S)-3-((4-(5-(2-Cyclopentyl-6-methoxypyridin-4-yl)(1,2,4)oxadiazol-3-yl)-2-ethyl-6-methylphenyl)oxy)propane-1,2-diol; HY-17606; AS-35045; (S)-3-(4-(5-(2-Cyclopentyl-6-methoxypyridin-4-yl)-1,2,4-oxadiazol DMU3P1K CP Actelion Pharmaceuticals South San Francisco, CA DMU3P1K PC 49871973 DMU3P1K MW 453.5 DMU3P1K FM C25H31N3O5 DMU3P1K IC InChI=1S/C25H31N3O5/c1-4-16-10-18(9-15(2)23(16)32-14-20(30)13-29)24-27-25(33-28-24)19-11-21(17-7-5-6-8-17)26-22(12-19)31-3/h9-12,17,20,29-30H,4-8,13-14H2,1-3H3/t20-/m0/s1 DMU3P1K CS CCC1=C(C(=CC(=C1)C2=NOC(=N2)C3=CC(=NC(=C3)OC)C4CCCC4)C)OC[C@H](CO)O DMU3P1K IK KJKKMMMRWISKRF-FQEVSTJZSA-N DMU3P1K IU (2S)-3-[4-[5-(2-cyclopentyl-6-methoxypyridin-4-yl)-1,2,4-oxadiazol-3-yl]-2-ethyl-6-methylphenoxy]propane-1,2-diol DMU3P1K CA CAS 1262414-04-9 DMU3P1K DE Systemic lupus erythematosus DMMN21R ID DMMN21R DMMN21R DN Cenersen DMMN21R HS Phase 2 DMMN21R CP Eleos DMMN21R DT Antisense drug DMMN21R PC 56841947 DMMN21R MW 6415 DMMN21R FM C195H253N66O106P19S19 DMMN21R IC InChI=1S/C195H253N66O106P19S19/c1-77-43-250(190(282)236-165(77)264)134-32-89(107(336-134)56-317-370(290,389)351-85-28-130(244-20-12-122(198)222-184(244)276)332-103(85)52-313-375(295,394)357-91-34-136(252-45-79(3)167(266)238-192(252)284)340-111(91)60-321-382(302,401)364-99-42-144(260-75-219-150-164(260)231-181(209)235-174(150)273)344-115(99)64-324-378(298,397)360-94-37-139(255-48-82(6)170(269)241-195(255)287)339-110(94)59-320-381(301,400)361-95-38-140(256-71-214-145-157(204)210-69-212-159(145)256)341-112(95)61-322-372(292,391)353-87-30-132(246-22-14-124(200)224-186(246)278)333-104(87)53-314-379(299,398)363-98-41-143(259-74-218-149-163(259)230-180(208)234-173(149)272)345-116(98)65-325-383(303,402)365-96-39-141(257-72-216-147-161(257)228-178(206)232-171(147)270)342-113(96)62-310-368(288,387)349-83-26-128(329-100(83)49-262)242-18-10-120(196)220-182(242)274)355-373(293,392)311-50-101-84(27-129(330-101)243-19-11-121(197)221-183(243)275)350-369(289,388)316-55-106-90(33-135(335-106)251-44-78(2)166(265)237-191(251)283)356-374(294,393)312-51-102-86(29-131(331-102)245-21-13-123(199)223-185(245)277)352-371(291,390)318-57-108-92(35-137(337-108)253-46-80(4)168(267)239-193(253)285)358-376(296,395)319-58-109-93(36-138(338-109)254-47-81(5)169(268)240-194(254)286)359-377(297,396)323-63-114-97(40-142(343-114)258-73-217-148-162(258)229-179(207)233-172(148)271)362-380(300,399)315-54-105-88(31-133(334-105)247-23-15-125(201)225-187(247)279)354-384(304,403)327-67-119-153(156(309-9)177(348-119)261-76-215-146-158(205)211-70-213-160(146)261)367-386(306,405)328-68-118-152(155(308-8)176(347-118)249-25-17-127(203)227-189(249)281)366-385(305,404)326-66-117-151(263)154(307-7)175(346-117)248-24-16-126(202)226-188(248)280/h10-25,43-48,69-76,83-119,128-144,151-156,175-177,262-263H,26-42,49-68H2,1-9H3,(H,288,387)(H,289,388)(H,290,389)(H,291,390)(H,292,391)(H,293,392)(H,294,393)(H,295,394)(H,296,395)(H,297,396)(H,298,397)(H,299,398)(H,300,399)(H,301,400)(H,302,401)(H,303,402)(H,304,403)(H,305,404)(H,306,405)(H2,196,220,274)(H2,197,221,275)(H2,198,222,276)(H2,199,223,277)(H2,200,224,278)(H2,201,225,279)(H2,202,226,280)(H2,203,227,281)(H2,204,210,212)(H2,205,211,213)(H,236,264,282)(H,237,265,283)(H,238,266,284)(H,239,267,285)(H,240,268,286)(H,241,269,287)(H3,206,228,232,270)(H3,207,229,233,271)(H3,208,230,234,272)(H3,209,231,235,273) DMMN21R CS CC1=CN(C(=O)NC1=O)C2CC(C(O2)COP(=S)(O)OC3CC(OC3COP(=S)(O)OC4CC(OC4COP(=S)(O)OC5CC(OC5COP(=S)(O)OC6CC(OC6COP(=S)(O)OC7CC(OC7COP(=S)(O)OC8CC(OC8COP(=S)(O)OC9CC(OC9COP(=S)(O)OC1CC(OC1COP(=S)(O)OC1CC(OC1COP(=S)(O)OC1CC(OC1COP(=S)(O)OC1CC(OC1CO)N1C=CC(=NC1=O)N)N1C=NC2=C1N=C(NC2=O)N)N1C=NC2=C1N=C(NC2=O)N)N1C=CC(=NC1=O)N)N1C=NC2=C(N=CN=C21)N)N1C=C(C(=O)NC1=O)C)N1C=NC2=C1N=C(NC2=O)N)N1C=C(C(=O)NC1=O)C)N1C=CC(=NC1=O)N)N1C=C(C(=O)NC1=O)C)N1C=CC(=NC1=O)N)OP(=S)(O)OCC1C(CC(O1)N1C=CC(=NC1=O)N)OP(=S)(O)OCC1C(CC(O1)N1C=C(C(=O)NC1=O)C)OP(=S)(O)OCC1C(CC(O1)N1C=C(C(=O)NC1=O)C)OP(=S)(O)OCC1C(CC(O1)N1C=NC2=C1N=C(NC2=O)N)OP(=S)(O)OCC1C(CC(O1)N1C=CC(=NC1=O)N)OP(=S)(O)OCC1C(C(C(O1)N1C=NC2=C(N=CN=C21)N)OC)OP(=S)(O)OCC1C(C(C(O1)N1C=CC(=NC1=O)N)OC)OP(=S)(O)OCC1C(C(C(O1)N1C=CC(=NC1=O)N)OC)O DMMN21R IK UTNSIDJKCKLZLN-UHFFFAOYSA-N DMMN21R IU 1-[5-[[[2-[[[2-[[[2-[[[2-[[[5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[2-[[[2-[[[2-[[[5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[5-(4-amino-2-oxopyrimidin-1-yl)-2-(hydroxymethyl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(6-aminopurin-9-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-4-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(4-amino-2-oxopyrimidin-1-yl)-3-[[3-[[5-(4-amino-2-oxopyrimidin-1-yl)-3-[[5-(4-amino-2-oxopyrimidin-1-yl)-3-hydroxy-4-methoxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-methoxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(6-aminopurin-9-yl)-4-methoxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]-5-methylpyrimidine-2,4-dione DMMN21R DE Acute myeloid leukaemia DM4V8WF ID DM4V8WF DM4V8WF DN Cenicriviroc DM4V8WF HS Phase 2 DM4V8WF SN Cenicriviroc; 497223-25-3; TBR-652; TAK-652; Cenicriviroc mesylate; UNII-15C116UA4Y; TAK652; 15C116UA4Y; TBR652; Cenicriviroc (USAN/INN); SCHEMBL3157768; SCHEMBL3157748; CHEMBL2110727; MolPort-044-723-655; MolPort-044-649-359; EX-A1608; BDBM50422828; AKOS027250788; CS-6148; DB11758; SB16976; HY-14882; AS-35184; D09878; UNII-15C116UA4Y component PNDKCRDVVKJPKG-WHERJAGFSA-N; 1-Benzazocine-5-carboxamide, 8-[4-(2-butoxyethoxy)phenyl]-1,2,3,4-tetrahydro-1-(2-methylpropyl)-N-[4-[[(1-propyl-1H-imidazol-5-yl)methyl]sulfinyl]phenyl]-, (5E)- DM4V8WF CP Tobira Therapeutics DM4V8WF DT Small molecular drug DM4V8WF PC 11285792 DM4V8WF MW 696.9 DM4V8WF FM C41H52N4O4S DM4V8WF IC InChI=1S/C41H52N4O4S/c1-5-7-22-48-23-24-49-38-15-10-32(11-16-38)33-12-19-40-35(25-33)26-34(9-8-21-44(40)28-31(3)4)41(46)43-36-13-17-39(18-14-36)50(47)29-37-27-42-30-45(37)20-6-2/h10-19,25-27,30-31H,5-9,20-24,28-29H2,1-4H3,(H,43,46)/b34-26+/t50-/m0/s1 DM4V8WF CS CCCCOCCOC1=CC=C(C=C1)C2=CC/3=C(C=C2)N(CCC/C(=C3)/C(=O)NC4=CC=C(C=C4)[S@@](=O)CC5=CN=CN5CCC)CC(C)C DM4V8WF IK PNDKCRDVVKJPKG-WHERJAGFSA-N DM4V8WF IU (5E)-8-[4-(2-butoxyethoxy)phenyl]-1-(2-methylpropyl)-N-[4-[(S)-(3-propylimidazol-4-yl)methylsulfinyl]phenyl]-3,4-dihydro-2H-1-benzazocine-5-carboxamide DM4V8WF CA CAS 497223-25-3 DM4V8WF CB CHEBI:149636 DM4V8WF DE Human immunodeficiency virus infection; Human immunodeficiency virus-1 infection DMWUQI9 ID DMWUQI9 DMWUQI9 DN CER-001 DMWUQI9 HS Phase 2 DMWUQI9 CP Cerenis Therapeutics DMWUQI9 DE Acute coronary syndrome; Cardiovascular disease DMSABRI ID DMSABRI DMSABRI DN CERC-301 DMSABRI HS Phase 2 DMSABRI CP Cerecor DMSABRI PC 11394238 DMSABRI MW 358.4 DMSABRI FM C19H23FN4O2 DMSABRI IC InChI=1S/C19H23FN4O2/c1-14-3-5-15(6-4-14)13-26-19(25)24-10-7-16(17(20)12-24)11-23-18-21-8-2-9-22-18/h2-6,8-9,16-17H,7,10-13H2,1H3,(H,21,22,23)/t16-,17-/m1/s1 DMSABRI CS CC1=CC=C(C=C1)COC(=O)N2CC[C@@H]([C@@H](C2)F)CNC3=NC=CC=N3 DMSABRI IK RECBFDWSXWAXHY-IAGOWNOFSA-N DMSABRI IU (4-methylphenyl)methyl (3S,4R)-3-fluoro-4-[(pyrimidin-2-ylamino)methyl]piperidine-1-carboxylate DMSABRI CA CAS 808733-05-3 DMSABRI DE Major depressive disorder DM3SZ7P ID DM3SZ7P DM3SZ7P DN CERC-801 DM3SZ7P HS Phase 2 DM3SZ7P SN D-(+)-Galactose Anhydrous; D-Galactopyranose; D-Galactopyranoside; D-Galactose; D-Galactose (9CI); D-Glucose-2-13C; Echocon; Echovist; Galactopyranose; Galactopyranoside; Galactose; Galactose, D- (8CI); Galactose, pure; Shu 450; Shu 454; Shu-454; brain sugar; cerebrose; dl-Galactose; 10257-28-0; AC1L1LNU; AC1Q28DZ; AI3-18440; CHEBI:4139; D-Gal; DSSTox_CID_3088; DSSTox_GSID_23088; DSSTox_RID_76869; EINECS 233-595-2; Epitope ID:141794; Gal; MLS001335983; MLS001335984; NCGC00159442-02; SCHEMBL38935; SMR000857326 DM3SZ7P PC 6036 DM3SZ7P MW 180.16 DM3SZ7P FM C6H12O6 DM3SZ7P IC WQZGKKKJIJFFOK-SVZMEOIVSA-N DM3SZ7P CS C(C1C(C(C(C(O1)O)O)O)O)O DM3SZ7P IK 1S/C6H12O6/c7-1-2-3(8)4(9)5(10)6(11)12-2/h2-11H,1H2/t2-,3+,4+,5-,6?/m1/s1 DM3SZ7P IU (3R,4S,5R,6R)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol DM3SZ7P CA CAS 10257-28-0 DM3SZ7P CB CHEBI:4139 DM3SZ7P DE Glycosylation disorder DMSCR2H ID DMSCR2H DMSCR2H DN Cerdulatinib DMSCR2H HS Phase 2 DMSCR2H SN PRT-062070; Syk + JAK multikinase inhibitor (NHL/CLL/RA), Portola Pharmaceuticals DMSCR2H CP Portola Pharmaceuticals Inc; portola pharmaceuticals DMSCR2H PC 44595079 DMSCR2H MW 445.5 DMSCR2H FM C20H27N7O3S DMSCR2H IC InChI=1S/C20H27N7O3S/c1-2-31(29,30)27-11-9-26(10-12-27)16-7-5-15(6-8-16)24-20-22-13-17(18(21)28)19(25-20)23-14-3-4-14/h5-8,13-14H,2-4,9-12H2,1H3,(H2,21,28)(H2,22,23,24,25) DMSCR2H CS CCS(=O)(=O)N1CCN(CC1)C2=CC=C(C=C2)NC3=NC=C(C(=N3)NC4CC4)C(=O)N DMSCR2H IK BGLPECHZZQDNCD-UHFFFAOYSA-N DMSCR2H IU 4-(cyclopropylamino)-2-[4-(4-ethylsulfonylpiperazin-1-yl)anilino]pyrimidine-5-carboxamide DMSCR2H CA CAS 1198300-79-6 DMSCR2H DE Non-hodgkin lymphoma; Atopic dermatitis; B-cell lymphoma; Vitiligo DMNW5I9 ID DMNW5I9 DMNW5I9 DN CERE-110 DMNW5I9 HS Phase 2 DMNW5I9 CP Ceregene DMNW5I9 DE Alzheimer disease DMS01AX ID DMS01AX DMS01AX DN CERE-120 DMS01AX HS Phase 2 DMS01AX SN Neurturin; NeuroRescue PD; AAV-NTN; AAV2-NRTN; AAV2-Neurturin; NTN gene therapy, Ceregene; Neurological gene therapy, Ceregene; Neurturin gene therapy, Ceregene; Neurturin, Genentech; Parkinsons disease gene therapy, Ceregene; GDNF agonist, StemCells/Genentech; NTN gene-expressing AAV vector-based therapy (Parkinson's disease/other neurological diseases), Ceregene/Genzyme; Neurturin gene-expressing adeno-associated virus vector-based therapy (Parkinson's disease/other neurological diseases), Ceregene/Genzyme DMS01AX CP Ceregene DMS01AX DE Parkinson disease DMAWKSM ID DMAWKSM DMAWKSM DN CetuGEX DMAWKSM HS Phase 2 DMAWKSM CP Glycotope GmbH DMAWKSM DT Antibody DMAWKSM DE Solid tumour/cancer DMP56WJ ID DMP56WJ DMP56WJ DN CF102 DMP56WJ HS Phase 2 DMP56WJ SN 2-Cl-IB-Meca; 163042-96-4; Cl-IB-MECA; Namodenoson; C-Ibza-MU; CF-102; CI-IB-MECA; (2S,3S,4R,5R)-5-(2-Chloro-6-((3-iodobenzyl)amino)-9H-purin-9-yl)-3,4-dihydroxy-N-methyltetrahydrofuran-2-carboxamide; UNII-Z07JR07J6C; 2Cl-IB-MECA; 1-[2-CHLORO-6-[[(3-IODOPHENYL)METHYL]AMINO]-9H-PURIN-9-YL]-1-DEOXY-N-METHYL-BETA-D-RIBOFURANURONAMIDE; CHEMBL431733; Z07JR07J6C; CF102; 2-Chloro-N(6)-(3-iodobenzyl)adenosine-5'-N-methyluronamide DMP56WJ CP Can-Fite BioPharm DMP56WJ DT Small molecular drug DMP56WJ PC 3035850 DMP56WJ MW 544.7 DMP56WJ FM C18H18ClIN6O4 DMP56WJ IC InChI=1S/C18H18ClIN6O4/c1-21-16(29)13-11(27)12(28)17(30-13)26-7-23-10-14(24-18(19)25-15(10)26)22-6-8-3-2-4-9(20)5-8/h2-5,7,11-13,17,27-28H,6H2,1H3,(H,21,29)(H,22,24,25)/t11-,12+,13-,17+/m0/s1 DMP56WJ CS CNC(=O)[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=C(N=C32)Cl)NCC4=CC(=CC=C4)I)O)O DMP56WJ IK IPSYPUKKXMNCNQ-PFHKOEEOSA-N DMP56WJ IU (2S,3S,4R,5R)-5-[2-chloro-6-[(3-iodophenyl)methylamino]purin-9-yl]-3,4-dihydroxy-N-methyloxolane-2-carboxamide DMP56WJ CA CAS 163042-96-4 DMP56WJ DE Hepatitis C virus infection; Hepatocellular carcinoma DM3BN4W ID DM3BN4W DM3BN4W DN CFI-400945 DM3BN4W HS Phase 2 DM3BN4W SN CFI 400945; CFI400945 DM3BN4W DT Small molecular drug DM3BN4W PC 58486178 DM3BN4W MW 534.6 DM3BN4W FM C33H34N4O3 DM3BN4W IC InChI=1S/C33H34N4O3/c1-20-17-37(18-21(2)40-20)19-23-6-4-22(5-7-23)8-12-29-26-11-9-24(14-31(26)36-35-29)28-16-33(28)27-15-25(39-3)10-13-30(27)34-32(33)38/h4-15,20-21,28H,16-19H2,1-3H3,(H,34,38)(H,35,36)/b12-8+/t20-,21+,28-,33-/m0/s1 DM3BN4W CS C[C@@H]1CN(C[C@@H](O1)C)CC2=CC=C(C=C2)/C=C/C3=NNC4=C3C=CC(=C4)[C@@H]5C[C@]56C7=C(C=CC(=C7)OC)NC6=O DM3BN4W IK DADASRPKWOGKCU-FVTQAUBDSA-N DM3BN4W IU (2'S,3R)-2'-[3-[(E)-2-[4-[[(2R,6S)-2,6-dimethylmorpholin-4-yl]methyl]phenyl]ethenyl]-1H-indazol-6-yl]-5-methoxyspiro[1H-indole-3,1'-cyclopropane]-2-one DM3BN4W CA CAS 1338806-73-7 DM3BN4W DE Breast cancer DM1TWIE ID DM1TWIE DM1TWIE DN CFZ533 DM1TWIE HS Phase 2 DM1TWIE CP Novartis pharmaceuticals DM1TWIE DE Rheumatoid arthritis; Graves disease; Myasthenia gravis; Sjogren syndrome DMWY609 ID DMWY609 DMWY609 DN CG201 DMWY609 HS Phase 2 DMWY609 SN Bevonium methyl sulfate; BEVONIUM METILSULFATE; Bevonium methylsulfate; 5205-82-3; Bevonium methylsulphate; Piribenzil methyl sulfate; Bevonii metilsulfas [INN-Latin]; EINECS 226-001-8; CG 201; Metilsulfato de bevonio [INN-Spanish]; Metilsulfate de bevonium [INN-French]; Bevonium metilsulfate [INN]; L-99; 2-(Hydroxymethyl)-1,1-dimethylpiperidinium methyl sulfate benzilate; Piperidinium, 2-(hydroxymethyl)-1,1-dimethyl-, methyl sulfate, benzilate; alpha-Phenylmandelic acid N,N-dimethylpiperidinium-2-methyl ester methylsulfa DMWY609 CP CG Therapeutics DMWY609 DT Small molecular drug DMWY609 PC 31799 DMWY609 MW 465.6 DMWY609 FM C23H31NO7S DMWY609 IC InChI=1S/C22H28NO3.CH4O4S/c1-23(2)16-10-9-15-20(23)17-26-21(24)22(25,18-11-5-3-6-12-18)19-13-7-4-8-14-19;1-5-6(2,3)4/h3-8,11-14,20,25H,9-10,15-17H2,1-2H3;1H3,(H,2,3,4)/q+1;/p-1 DMWY609 CS C[N+]1(CCCCC1COC(=O)C(C2=CC=CC=C2)(C3=CC=CC=C3)O)C.COS(=O)(=O)[O-] DMWY609 IK AXKJGGRSAVLXTE-UHFFFAOYSA-M DMWY609 IU (1,1-dimethylpiperidin-1-ium-2-yl)methyl 2-hydroxy-2,2-diphenylacetate;methyl sulfate DMWY609 CA CAS 5205-82-3 DMWY609 CB CHEBI:31283 DMWY609 DE Solid tumour/cancer DMFAKGR ID DMFAKGR DMFAKGR DN CG-400549 DMFAKGR HS Phase 2 DMFAKGR SN CG-400329; CG-400462; CG-400587; Bacterial enoyl-ACP reductase inhibitors, CrystalGenomics; FabI inhibitors (antibacterial), CrystalGenomics; FabK inhibitors (bacterial infections, oral), CrystalGenomics DMFAKGR CP Cg pharmaceuticals DMFAKGR DT Small molecular drug DMFAKGR PC 11844916 DMFAKGR MW 340.4 DMFAKGR FM C19H20N2O2S DMFAKGR IC InChI=1S/C19H20N2O2S/c1-14-15(4-2-6-18(14)20)13-21-9-7-16(12-19(21)22)23-10-8-17-5-3-11-24-17/h2-7,9,11-12H,8,10,13,20H2,1H3 DMFAKGR CS CC1=C(C=CC=C1N)CN2C=CC(=CC2=O)OCCC3=CC=CS3 DMFAKGR IK YCLREGRRHGLOAK-UHFFFAOYSA-N DMFAKGR IU 1-[(3-amino-2-methylphenyl)methyl]-4-(2-thiophen-2-ylethoxy)pyridin-2-one DMFAKGR CA CAS 934628-27-0 DMFAKGR DE Bacterial infection DM17JSI ID DM17JSI DM17JSI DN CGC-11047 DM17JSI HS Phase 2 DM17JSI SN UNII-2C4Y86R2AX; 2C4Y86R2AX; (Z)-N,N'-bis[3-(ethylamino)propyl]but-2-ene-1,4-diamine; 206991-64-2; CHEMBL3104344; CGC-11047 free base; Pg-11047(free base); AC1O51NW; CHEMBL142464; SCHEMBL2360444; BDBM50445365; 308145-19-9; (Z)-N,N'-Bis[3-(ethylamino)propyl]-2-butene-1,4-diamine; 2-Butene-1,4-diamine, N1,N4-bis(3-(ethylamino)propyl)-, (2Z)-; 2-Butene-1,4-diamine, N,N'-bis(3-(ethylamino)propyl)-, (2Z)-; 2-Butene-1,4-diamine, N,N'-bis[3-(ethylamino)propyl]-, tetrahydrochloride, (2Z)- DM17JSI CP Progen Pharmaceuticals DM17JSI DT Small molecular drug DM17JSI PC 6475492 DM17JSI MW 256.43 DM17JSI FM C14H32N4 DM17JSI IC InChI=1S/C14H32N4/c1-3-15-11-7-13-17-9-5-6-10-18-14-8-12-16-4-2/h5-6,15-18H,3-4,7-14H2,1-2H3/b6-5- DM17JSI CS CCNCCCNC/C=C\\CNCCCNCC DM17JSI IK XFWLTFZLLXVKDY-WAYWQWQTSA-N DM17JSI IU (Z)-N,N'-bis[3-(ethylamino)propyl]but-2-ene-1,4-diamine DM17JSI CA CAS 308145-19-9 DM17JSI DE Prostate cancer DMYNTQV ID DMYNTQV DMYNTQV DN CGP-28014 DMYNTQV HS Phase 2 DMYNTQV SN Cgp 28014; 111757-17-6; Methanimidamide, N'-(1,6-dihydro-6-oxo-2-pyridinyl)-N,N-dipropyl-; N-(2-Oxopyridin-6-yl)-N',N'-di-n-propylformamidine; N'-(1,6-Dihydro-6-oxo-2-pyridinyl)-N,N-dipropylmethanimidamide; CGP-28014; N-(2-pyridone-6-yl)-N',N'-di-n-propylformamidine; cgp28014; CHEBI:79969; LS-90457 DMYNTQV CP Novartis AG DMYNTQV DT Small molecular drug DMYNTQV PC 159470 DMYNTQV MW 221.3 DMYNTQV FM C12H19N3O DMYNTQV IC InChI=1S/C12H19N3O/c1-3-8-15(9-4-2)10-13-11-6-5-7-12(16)14-11/h5-7,10H,3-4,8-9H2,1-2H3,(H,14,16) DMYNTQV CS CCCN(CCC)C=NC1=CC=CC(=O)N1 DMYNTQV IK MEYPAYJYAZKERR-UHFFFAOYSA-N DMYNTQV IU N'-(6-oxo-1H-pyridin-2-yl)-N,N-dipropylmethanimidamide DMYNTQV CA CAS 111757-17-6 DMYNTQV DE Major depressive disorder DMKS7RJ ID DMKS7RJ DMKS7RJ DN CGS-15873A DMKS7RJ HS Phase 2 DMKS7RJ SN Rac-trans-7-Hydroxy-4-propyl-1,2,3,4a,5,10b-hexahydro-4H-[1]benzopyrano[3,4-b]pyridine monohydrochloride DMKS7RJ DT Small molecular drug DMKS7RJ PC 195284 DMKS7RJ MW 283.79 DMKS7RJ FM C15H22ClNO2 DMKS7RJ IC InChI=1S/C15H21NO2.ClH/c1-2-8-16-9-4-6-11-12-5-3-7-14(17)15(12)18-10-13(11)16;/h3,5,7,11,13,17H,2,4,6,8-10H2,1H3;1H/t11-,13-;/m0./s1 DMKS7RJ CS CCCN1CCC[C@@H]2[C@@H]1COC3=C2C=CC=C3O.Cl DMKS7RJ IK CEVXGMUELSDOPY-JZKFLRDJSA-N DMKS7RJ IU (4aR,10bS)-4-propyl-1,2,3,4a,5,10b-hexahydrochromeno[3,4-b]pyridin-7-ol;hydrochloride DMKS7RJ CA CAS 118929-49-0 DMKS7RJ DE Psychotic disorder DMLQRYH ID DMLQRYH DMLQRYH DN CH-4051 DMLQRYH HS Phase 2 DMLQRYH CP Chelsea Therapeutics DMLQRYH PC 11532464 DMLQRYH MW 449.5 DMLQRYH FM C23H23N5O5 DMLQRYH IC InChI=1S/C23H23N5O5/c1-12(21(30)31)10-18(22(32)33)26-20(29)15-7-4-13(5-8-15)2-3-14-6-9-17-16(11-14)19(24)28-23(25)27-17/h4-9,11,18H,1-3,10H2,(H,26,29)(H,30,31)(H,32,33)(H4,24,25,27,28)/t18-/m0/s1 DMLQRYH CS C=C(C[C@@H](C(=O)O)NC(=O)C1=CC=C(C=C1)CCC2=CC3=C(C=C2)N=C(N=C3N)N)C(=O)O DMLQRYH IK NAWXUBYGYWOOIX-SFHVURJKSA-N DMLQRYH IU (2S)-2-[[4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]benzoyl]amino]-4-methylidenepentanedioic acid DMLQRYH DE Rheumatoid arthritis DMQ2O8V ID DMQ2O8V DMQ2O8V DN CHF-3381 DMQ2O8V HS Phase 2 DMQ2O8V SN Indantadol; UNII-Z3867B9SQP; Z3867B9SQP; Indantadol [INN]; CHF 3381; N-(2-Indanyl)glycinamide hydrochloride; 2-(2-indanylamino)acetamide; SCHEMBL399565; ZINC9005; MolPort-015-094-768; MNLULKBKWKTZPE-UHFFFAOYSA-N; AKOS009549166 DMQ2O8V CP Chiesi DMQ2O8V TC Analgesics DMQ2O8V DT Small molecular drug DMQ2O8V PC 10198454 DMQ2O8V MW 226.7 DMQ2O8V FM C11H15ClN2O DMQ2O8V IC InChI=1S/C11H14N2O.ClH/c12-11(14)7-13-10-5-8-3-1-2-4-9(8)6-10;/h1-4,10,13H,5-7H2,(H2,12,14);1H DMQ2O8V CS C1C(CC2=CC=CC=C21)NCC(=O)N.Cl DMQ2O8V IK JPNNIRXUJSPGRM-UHFFFAOYSA-N DMQ2O8V IU 2-(2,3-dihydro-1H-inden-2-ylamino)acetamide;hydrochloride DMQ2O8V CA CAS 202914-18-9 DMQ2O8V DE Neuropathic pain DMTE071 ID DMTE071 DMTE071 DN CHF-5074 DMTE071 HS Phase 2 DMTE071 SN CHF 5074; CHF5074; 749269-83-8; CHF-5074; Itanapraced; UNII-C35RF1MWQZ; GHF-5074; C35RF1MWQZ; CHEMBL196945; 1-(3',4'-dichloro-2-fluoro(1,1'-biphenyl)-4-yl)cyclopropanecarboxylic acid; 1-[4-(3,4-dichlorophenyl)-3-fluorophenyl]cyclopropane-1-carboxylic acid; 1-(3',4'-Dichloro-2-Fluorobiphenyl-4-Yl)cyclopropanecarboxylic Acid; H50; SCHEMBL407631; GTPL7339; DTXSID30225901; AOB5325; LIYLTQQDABRNRX-UHFFFAOYSA-N; ZINC3986651; EX-A1963; BDBM50172482; AKOS026750398; SB16945; CS-5022; NCGC00408905-01; AS-16850; HY-14399; BC600569; FT-0708261 DMTE071 CP Chiesi Pharmaceuticals DMTE071 DT Small molecular drug DMTE071 PC 9996409 DMTE071 MW 325.2 DMTE071 FM C16H11Cl2FO2 DMTE071 IC InChI=1S/C16H11Cl2FO2/c17-12-4-1-9(7-13(12)18)11-3-2-10(8-14(11)19)16(5-6-16)15(20)21/h1-4,7-8H,5-6H2,(H,20,21) DMTE071 CS C1CC1(C2=CC(=C(C=C2)C3=CC(=C(C=C3)Cl)Cl)F)C(=O)O DMTE071 IK LIYLTQQDABRNRX-UHFFFAOYSA-N DMTE071 IU 1-[4-(3,4-dichlorophenyl)-3-fluorophenyl]cyclopropane-1-carboxylic acid DMTE071 CA CAS 749269-83-8 DMTE071 DE Alzheimer disease; Cognitive impairment DMALN2M ID DMALN2M DMALN2M DN Cholyl lysyl fluorescein DMALN2M HS Phase 2 DMALN2M PC 44470395 DMALN2M FM C51H63N3O11S DMALN2M IC InChI=1S/C51H63N3O11S/c1-26(36-14-15-37-46-38(25-43(59)51(36,37)3)50(2)18-17-31(57)20-27(50)21-40(46)58)7-16-44(60)54-39(48(63)64)6-4-5-19-52-49(66)53-28-8-11-32(35(22-28)47(61)62)45-33-12-9-29(55)23-41(33)65-42-24-30(56)10-13-34(42)45/h8-13,22-24,26-27,31,36-40,43,46,55,57-59H,4-7,14-21,25H2,1-3H3,(H,54,60)(H,61,62)(H,63,64)(H2,52,53,66)/t26-,27+,31-,36-,37+,38+,39+,40-,43+,46+,50+,51-/m1/s1 DMALN2M CS CC(CCC(=O)NC(CCCCNC(=S)NC1=CC(=C(C=C1)C2=C3C=CC(=O)C=C3OC4=C2C=CC(=C4)O)C(=O)O)C(=O)O)C5CCC6C5(C(CC7C6C(CC8C7(CCC(C8)O)C)O)O)C DMALN2M IK ZUJFMZPBQQCXQR-TZCNZRNCSA-N DMALN2M IU 5-[[(5S)-5-carboxy-5-[[(4R)-4-[(3R,5S,7R,8R,9S,10S,12S,13R,14S,17R)-3,7,12-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]pentyl]carbamothioylamino]-2-(3-hydroxy-6-oxoxanthen-9-yl)benzoic acid DMALN2M DE Hepatitis virus infection DMULZ4W ID DMULZ4W DMULZ4W DN CHR-2797 DMULZ4W HS Phase 2 DMULZ4W SN Tosedostat; Tosedostat, CHR2797, CHR-2797 DMULZ4W CP Chroma Therape. DMULZ4W TC Anticancer Agents DMULZ4W DT Small molecular drug DMULZ4W PC 15547703 DMULZ4W MW 406.5 DMULZ4W FM C21H30N2O6 DMULZ4W IC InChI=1S/C21H30N2O6/c1-13(2)12-16(18(24)20(26)23-28)19(25)22-17(14-8-4-3-5-9-14)21(27)29-15-10-6-7-11-15/h3-5,8-9,13,15-18,24,28H,6-7,10-12H2,1-2H3,(H,22,25)(H,23,26)/t16-,17+,18+/m1/s1 DMULZ4W CS CC(C)C[C@H]([C@@H](C(=O)NO)O)C(=O)N[C@@H](C1=CC=CC=C1)C(=O)OC2CCCC2 DMULZ4W IK FWFGIHPGRQZWIW-SQNIBIBYSA-N DMULZ4W IU cyclopentyl (2S)-2-[[(2R)-2-[(1S)-1-hydroxy-2-(hydroxyamino)-2-oxoethyl]-4-methylpentanoyl]amino]-2-phenylacetate DMULZ4W CA CAS 238750-77-1 DMULZ4W CB CHEBI:95044 DMULZ4W DE Acute myeloid leukaemia; Myelodysplastic syndrome; Inflammation DMMRKPF ID DMMRKPF DMMRKPF DN CHS-131 DMMRKPF HS Phase 2 DMMRKPF CP Coherus Biosciences Redwood City, CA DMMRKPF DE Multiple sclerosis DMLRTN1 ID DMLRTN1 DMLRTN1 DN CI-1012 DMLRTN1 HS Phase 2 DMLRTN1 SN NCS-675753; PD-161374; HIV replication inhibitor, Parke-Davis/NIAID DMLRTN1 CP Parke-Davis & Co Ltd DMLRTN1 DT Small molecular drug DMLRTN1 PC 72552 DMLRTN1 MW 304.4 DMLRTN1 FM C14H12N2O2S2 DMLRTN1 IC InChI=1S/C14H12N2O2S2/c15-13(17)9-5-1-3-7-11(9)19-20-12-8-4-2-6-10(12)14(16)18/h1-8H,(H2,15,17)(H2,16,18) DMLRTN1 CS C1=CC=C(C(=C1)C(=O)N)SSC2=CC=CC=C2C(=O)N DMLRTN1 IK OEEHSSKRJOGQMP-UHFFFAOYSA-N DMLRTN1 IU 2-[(2-carbamoylphenyl)disulfanyl]benzamide DMLRTN1 CA CAS 2527-57-3 DMLRTN1 DE Acquired immune deficiency syndrome DMSI8N3 ID DMSI8N3 DMSI8N3 DN CI-1033 DMSI8N3 HS Phase 2 DMSI8N3 SN Canertinib; Canertinib HCl; Canertinib dihydrochloride; Canertinib dihydrochloride [USAN]; CI1033; PD 183805; Canertinib dihydrochloride (USAN); PD-0183805; PD-183805; Canertinib, PD-183805, CI1033, PD183805; N-[4-(3-Chloro-4-fluorophenylamino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]acrylamide dihydrochloride; N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-[3-(4-morpholinyl)propoxy]-6-quinazolinyl]-2-propenamide dihydrochloride; N-[4-(3-chloro-4-fluoroanilino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]prop-2-enamide; N-[4-(3-chloro-4-fluoroanilino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]prop-2-enamide dihydrochloride; N-(4-(3-chloro-4-fluorophenyl)amino)-7-(3-morpholin-4-yl)propoxy)quinazolin-6-yl)prop-2-enamide dihydrochloride; N-{4-[(3-chloro-4-fluorophenyl)amino]-7-[3-(morpholin-4-yl)propoxy]quinazolin-6-yl}prop-2-enamide; N-(4-((3-Chloro-4-fluorophenyl)amino)-7-(3-(morpholin-4-yl)propoxy)quinazolin-6-yl)prop-2-enamide; 2-Propenamide, N-(4-((3-chloro-4-fluorophenyl) amino)-7-(3-(4-morpholinyl) propoxy)-6-quinazolinyl)-, dihydrochloride; 2-Propenamide, N-(4-((3-chloro-4-fluorophenyl)amino)-7-(3-(4-morpholinyl)propoxy)-6-quinazolinyl)-, dihydrochloride DMSI8N3 CP Pfizer DMSI8N3 TC Anticancer Agents DMSI8N3 DT Small molecular drug DMSI8N3 PC 156414 DMSI8N3 MW 485.9 DMSI8N3 FM C24H25ClFN5O3 DMSI8N3 IC InChI=1S/C24H25ClFN5O3/c1-2-23(32)30-21-13-17-20(14-22(21)34-9-3-6-31-7-10-33-11-8-31)27-15-28-24(17)29-16-4-5-19(26)18(25)12-16/h2,4-5,12-15H,1,3,6-11H2,(H,30,32)(H,27,28,29) DMSI8N3 CS C=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4 DMSI8N3 IK OMZCMEYTWSXEPZ-UHFFFAOYSA-N DMSI8N3 IU N-[4-(3-chloro-4-fluoroanilino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]prop-2-enamide DMSI8N3 CA CAS 267243-28-7 DMSI8N3 CB CHEBI:61399 DMSI8N3 DE Lymphoma DMCFLRH ID DMCFLRH DMCFLRH DN Cibinetide DMCFLRH HS Phase 2 DMCFLRH SN UNII-9W5677JKDA; 9W5677JKDA; 1208243-50-8; Cibinetide [USAN]; Pglu-glu-gln-leu-glu-arg-ala-leu-asn-ser-ser; Pyr-glu-gln-leu-glu-arg-ala-leu-asn-ser-ser-OH; GTPL9677; CHEMBL3545305; DB13006; L-Serine, 5-oxo-L-prolyl-L-alpha-glutamyl-L-glutaminyl-L-leucyl-L-alpha-glutamyl-L-arginyl-L-alanyl-L-leucyl-L-asparaginyl-L-seryl-; L-Pyroglutamyl-L-glutamyl-L-glutaminyl-L-leucyl-L-glutamyl-L-arginyl-L-alanyl-L-leucyl-L-asparaginyl-L-seryl-L-serine; L-Pyroglutamyl-L-glutamyl-L-glutam DMCFLRH CP Araim Pharmaceuticals Tarrytown, NY DMCFLRH PC 91810664 DMCFLRH MW 1257.3 DMCFLRH FM C51H84N16O21 DMCFLRH IC InChI=1S/C51H84N16O21/c1-22(2)17-30(47(84)65-32(19-36(53)71)48(85)66-33(20-68)49(86)67-34(21-69)50(87)88)63-40(77)24(5)57-41(78)25(7-6-16-56-51(54)55)59-43(80)29(11-15-39(75)76)62-46(83)31(18-23(3)4)64-45(82)27(8-12-35(52)70)60-44(81)28(10-14-38(73)74)61-42(79)26-9-13-37(72)58-26/h22-34,68-69H,6-21H2,1-5H3,(H2,52,70)(H2,53,71)(H,57,78)(H,58,72)(H,59,80)(H,60,81)(H,61,79)(H,62,83)(H,63,77)(H,64,82)(H,65,84)(H,66,85)(H,67,86)(H,73,74)(H,75,76)(H,87,88)(H4,54,55,56)/t24-,25-,26-,27-,28-,29-,30-,31-,32-,33-,34-/m0/s1 DMCFLRH CS C[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H]1CCC(=O)N1 DMCFLRH IK WZTIQQBMSJTRBR-WYKNNRPVSA-N DMCFLRH IU (4S)-5-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-1-[[(1S)-1-carboxy-2-hydroxyethyl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-5-oxo-4-[[(2S)-5-oxopyrrolidine-2-carbonyl]amino]pentanoic acid DMCFLRH CA CAS 1208243-50-8 DMCFLRH DE Depression; Diabetic macular edema; Neuropathic pain; Sarcoidosis; Peripheral neuropathy DMGTZLW ID DMGTZLW DMGTZLW DN Cicletanine DMGTZLW HS Phase 2 DMGTZLW SN Cicletanine; Cycletanide; Tenstaten; 89943-82-8; Justar; BN-1270; Win-90000; cicletanide; BN 1270; Cicletaninum; Cicletanina; Cicletaninum [Latin]; Cicletanina [Spanish]; Cicletanine [USAN:INN:BAN]; Win 90,000; ACMC-20mckj; ACMC-20mcin; AC1Q3NNY; Cicletanine (USAN/INN); (+-)-BN-1270; AC1L1HZ3; SCHEMBL49794; CHEMBL191886; (R)-(-)-CICLETANINE; CHEBI:135078; Furo[3,4-c]pyridin-7-ol, 3-(4-chlorophenyl)-1,3-dihydro-6-methyl-, (S)-; Furo[3,4-c]pyridin-7-ol, 3-(4-chlorophenyl)-1,3-dihydro-6-methyl-, (R)-; CVKNDPRBJVBDSS-UHFFFAOYSA-N DMGTZLW CP Gilead Sciences DMGTZLW DT Small molecular drug DMGTZLW PC 54910 DMGTZLW MW 261.7 DMGTZLW FM C14H12ClNO2 DMGTZLW IC InChI=1S/C14H12ClNO2/c1-8-13(17)12-7-18-14(11(12)6-16-8)9-2-4-10(15)5-3-9/h2-6,14,17H,7H2,1H3 DMGTZLW CS CC1=NC=C2C(OCC2=C1O)C3=CC=C(C=C3)Cl DMGTZLW IK CVKNDPRBJVBDSS-UHFFFAOYSA-N DMGTZLW IU 3-(4-chlorophenyl)-6-methyl-1,3-dihydrofuro[3,4-c]pyridin-7-ol DMGTZLW CA CAS 89943-82-8 DMGTZLW CB CHEBI:135078 DMGTZLW DE Pulmonary arterial hypertension DMTKSVA ID DMTKSVA DMTKSVA DN CIMICOXIB DMTKSVA HS Phase 2 DMTKSVA SN Cimicoxib; 265114-23-6; UNII-W7FHJ107MC; UR-8880; W7FHJ107MC; CHEMBL435381; CHEBI:76127; 4-[4-chloro-5-(3-fluoro-4-methoxyphenyl)imidazol-1-yl]benzenesulfonamide; 4-[4-chloro-5-(3-fluoro-4-methoxyphenyl)-1H-imidazol-1-yl]benzenesulfonamide; 4-(4-chloro-5-(3-fluoro-4-methoxyphenyl)imidazol-1-yl)benzenesulfonamide; Cimicoxib [INN]; 4-(4-Chloro-5-(3-fluoro-4-methoxyphenyl)-1H-imidazol-1-yl)benzenesulfonamide; AC1Q6UZ8; AC1L4U5V; SCHEMBL3123310; CTK4F8038; DTXSID30181093; KYXDNECMRLFQMZ-UHFFFAOYSA-N; BCP24933; ZINC1494105 DMTKSVA DT Small molecular drug DMTKSVA PC 213053 DMTKSVA MW 381.8 DMTKSVA FM C16H13ClFN3O3S DMTKSVA IC InChI=1S/C16H13ClFN3O3S/c1-24-14-7-2-10(8-13(14)18)15-16(17)20-9-21(15)11-3-5-12(6-4-11)25(19,22)23/h2-9H,1H3,(H2,19,22,23) DMTKSVA CS COC1=C(C=C(C=C1)C2=C(N=CN2C3=CC=C(C=C3)S(=O)(=O)N)Cl)F DMTKSVA IK KYXDNECMRLFQMZ-UHFFFAOYSA-N DMTKSVA IU 4-[4-chloro-5-(3-fluoro-4-methoxyphenyl)imidazol-1-yl]benzenesulfonamide DMTKSVA CA CAS 265114-23-6 DMTKSVA CB CHEBI:76127 DMTKSVA DE Pain DMGEAM6 ID DMGEAM6 DMGEAM6 DN Cinaciguat DMGEAM6 HS Phase 2 DMGEAM6 SN Cinaciguat; 329773-35-5; BAY 58-2667; BAY582667; UNII-59K0Y58UAD; BAY-58-2667; 59K0Y58UAD; 4-({(4-carboxybutyl)[2-(2-{[4-(2-phenylethyl)benzyl]oxy}phenyl)ethyl]amino}methyl)benzoic acid; Cinaciguat [INN:JAN]; cinaciguatum; Z90; Cinaciguat (JAN/INN); SCHEMBL249267; GTPL5168; CHEMBL1236936; QCR-279; Cinaciguat (BAY 58-2667); MolPort-039-139-611; CHEBI:142433; ZINC3934935; BCP07942; 3550AH; AKOS026750293; AN-1845; CS-1169; HY-14181; KB-40005; AB0095741; D07577; W-5794 DMGEAM6 DT Small molecular drug DMGEAM6 PC 9808022 DMGEAM6 MW 565.7 DMGEAM6 FM C36H39NO5 DMGEAM6 IC InChI=1S/C36H39NO5/c38-35(39)12-6-7-24-37(26-30-19-21-33(22-20-30)36(40)41)25-23-32-10-4-5-11-34(32)42-27-31-17-15-29(16-18-31)14-13-28-8-2-1-3-9-28/h1-5,8-11,15-22H,6-7,12-14,23-27H2,(H,38,39)(H,40,41) DMGEAM6 CS C1=CC=C(C=C1)CCC2=CC=C(C=C2)COC3=CC=CC=C3CCN(CCCCC(=O)O)CC4=CC=C(C=C4)C(=O)O DMGEAM6 IK WPYWMXNXEZFMAK-UHFFFAOYSA-N DMGEAM6 IU 4-[[4-carboxybutyl-[2-[2-[[4-(2-phenylethyl)phenyl]methoxy]phenyl]ethyl]amino]methyl]benzoic acid DMGEAM6 CA CAS 329773-35-5 DMGEAM6 CB CHEBI:142433 DMGEAM6 DE Acute decompensated heart failure DM98RW0 ID DM98RW0 DM98RW0 DN Cirmtuzumab DM98RW0 HS Phase 2 DM98RW0 SN UC-961 DM98RW0 CP Oncternal Therapeutics San Diego, CA DM98RW0 DE Mantle cell lymphoma; Chronic lymphocytic leukaemia DMNRYPF ID DMNRYPF DMNRYPF DN Cixutumumab DMNRYPF HS Phase 2 DMNRYPF SN LY3012217 DMNRYPF CP Lilly DMNRYPF DT Monoclonal antibody DMNRYPF DE Non-small-cell lung cancer; Liver cancer DMOFTRE ID DMOFTRE DMOFTRE DN Cizolirtine DMOFTRE HS Phase 2 DMOFTRE SN Cizolirtine [INN]; N,N-dimethyl-2-[(2-methylpyrazol-3-yl)-phenylmethoxy]ethanamine; N,N-dimethyl-2-[(R)-(2-methylpyrazol-3-yl)-phenylmethoxy]ethanamine DMOFTRE CP Esteve Laboratories DMOFTRE TC Analgesics DMOFTRE DT Small molecular drug DMOFTRE PC 132412 DMOFTRE MW 259.35 DMOFTRE FM C15H21N3O DMOFTRE IC InChI=1S/C15H21N3O/c1-17(2)11-12-19-15(13-7-5-4-6-8-13)14-9-10-16-18(14)3/h4-10,15H,11-12H2,1-3H3 DMOFTRE CS CN1C(=CC=N1)C(C2=CC=CC=C2)OCCN(C)C DMOFTRE IK DCMJBKFKXGPPMT-UHFFFAOYSA-N DMOFTRE IU N,N-dimethyl-2-[(2-methylpyrazol-3-yl)-phenylmethoxy]ethanamine DMOFTRE CA CAS 142155-43-9 DMOFTRE DE Neuropathic pain DMTSVJM ID DMTSVJM DMTSVJM DN CJM112 DMTSVJM HS Phase 2 DMTSVJM CP Novartis Pharmaceuticals East Hanover, NJ DMTSVJM DE Chronic plaque psoriasis; Multiple myeloma; Plaque psoriasis; Solid tumour/cancer; Acne vulgaris DM9FHV8 ID DM9FHV8 DM9FHV8 DN CK-2127107 DM9FHV8 HS Phase 2 DM9FHV8 CP Cytokinetics DM9FHV8 PC 67454400 DM9FHV8 MW 384.4 DM9FHV8 FM C19H18F2N6O DM9FHV8 IC InChI=1S/C19H18F2N6O/c20-13-6-19(7-13,16-15(21)2-1-4-23-16)11-26-18-24-8-14(9-25-18)27-5-3-12(10-27)17(22)28/h1-5,8-10,13H,6-7,11H2,(H2,22,28)(H,24,25,26) DM9FHV8 CS C1C(CC1(CNC2=NC=C(C=N2)N3C=CC(=C3)C(=O)N)C4=C(C=CC=N4)F)F DM9FHV8 IK MQXWPWOCXGARRK-UHFFFAOYSA-N DM9FHV8 IU 1-[2-[[3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyrimidin-5-yl]pyrrole-3-carboxamide DM9FHV8 CA CAS 1345410-31-2 DM9FHV8 DE Muscle atrophy; Amyotrophic lateral sclerosis; Spinal muscular atrophy DMW9F1G ID DMW9F1G DMW9F1G DN CKD602 DMW9F1G HS Phase 2 DMW9F1G SN Belotecan hydrochloride; 213819-48-8; Belotecan; CKD-602; Belotecan HCl; Camtobell hydrochloride; Belotecan (hydrochloride); CKD 602; UNII-01DZ4127G7; 01DZ4127G7; Belotecan hydrochloride (USAN); Belotecan Hydrochloride [USAN]; CHEMBL2107315; DTXSID60175647; BCP28717; HY-13566A; AKOS027420465; API0009359; CS-6955; (S)-4-ethyl-4-hydroxy-11-(2-(isopropylamino)ethyl)-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione hydrochloride; AN-29684; ACM213819488; FT-0662513; D03225; 819C488; J-014022 DMW9F1G DT Small molecular drug DMW9F1G PC 6456014 DMW9F1G MW 433.5 DMW9F1G FM C25H27N3O4 DMW9F1G IC InChI=1S/C25H27N3O4/c1-4-25(31)19-11-21-22-17(12-28(21)23(29)18(19)13-32-24(25)30)15(9-10-26-14(2)3)16-7-5-6-8-20(16)27-22/h5-8,11,14,26,31H,4,9-10,12-13H2,1-3H3/t25-/m0/s1 DMW9F1G CS CC[C@@]1(C2=C(COC1=O)C(=O)N3CC4=C(C5=CC=CC=C5N=C4C3=C2)CCNC(C)C)O DMW9F1G IK LNHWXBUNXOXMRL-VWLOTQADSA-N DMW9F1G IU (19S)-19-ethyl-19-hydroxy-10-[2-(propan-2-ylamino)ethyl]-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4,6,8,10,15(20)-heptaene-14,18-dione DMW9F1G CA CAS 256411-32-2 DMW9F1G CB CHEBI:135702 DMW9F1G DE Solid tumour/cancer DMXH1KC ID DMXH1KC DMXH1KC DN CL-316,243 DMXH1KC HS Phase 2 DMXH1KC SN UNII-52H8DB0TKX; 52H8DB0TKX; 5-[(2R)-2-[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]-1,3-benzodioxole-2,2-dicarboxylic acid; CL-316243; 5-((2R)-2-(((2R)-2-(3-Chlorophenyl)-2-hydroxyethyl)amino)propyl)-1,3-benzodioxole-2,2-dicarboxylic acid; CL 316243; CL316,243; Cl-316243 Free diacid; AC1NUOLQ; Lopac0_000295; SCHEMBL2345491; GTPL3462; CHEMBL1204876; BDBM25763; ZINC1493298; 183720-02-7; 1,3-Benzodioxole-2,2-dicarboxylic acid, 5-((2R)-2-(((2R)-2-(3-chlorophenyl)-2-hydroxyethyl)amino)propyl)-; LS-187111 DMXH1KC DT Small molecular drug DMXH1KC PC 5312115 DMXH1KC MW 465.8 DMXH1KC FM C20H18ClNNa2O7 DMXH1KC IC InChI=1S/C20H20ClNO7.2Na/c1-11(22-10-15(23)13-3-2-4-14(21)9-13)7-12-5-6-16-17(8-12)29-20(28-16,18(24)25)19(26)27;;/h2-6,8-9,11,15,22-23H,7,10H2,1H3,(H,24,25)(H,26,27);;/q;2*+1/p-2/t11-,15+;;/m1../s1 DMXH1KC CS C[C@H](CC1=CC2=C(C=C1)OC(O2)(C(=O)[O-])C(=O)[O-])NC[C@@H](C3=CC(=CC=C3)Cl)O.[Na+].[Na+] DMXH1KC IK FUZBPOHHSBDTJQ-CFOQQKEYSA-L DMXH1KC IU disodium;5-[(2R)-2-[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]-1,3-benzodioxole-2,2-dicarboxylate DMXH1KC CA CAS 138908-40-4 DMXH1KC DE Obesity DMSF7WJ ID DMSF7WJ DMSF7WJ DN CL-329167 DMSF7WJ HS Phase 2 DMSF7WJ SN 2-Butyl-6-(1-methoxy-1-methylethyl)-3-[2'-(1H-tetrazol-5-yl)biphenyl-4-ylmethyl]quinazolin-4(3H)-one DMSF7WJ DT Small molecular drug DMSF7WJ PC 6918269 DMSF7WJ MW 508.6 DMSF7WJ FM C30H32N6O2 DMSF7WJ IC InChI=1S/C30H32N6O2/c1-5-6-11-27-31-26-17-16-22(30(2,3)38-4)18-25(26)29(37)36(27)19-20-12-14-21(15-13-20)23-9-7-8-10-24(23)28-32-34-35-33-28/h7-10,12-18H,5-6,11,19H2,1-4H3,(H,32,33,34,35) DMSF7WJ CS CCCCC1=NC2=C(C=C(C=C2)C(C)(C)OC)C(=O)N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5 DMSF7WJ IK XZCUIMYYMKTCBA-UHFFFAOYSA-N DMSF7WJ IU 2-butyl-6-(2-methoxypropan-2-yl)-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]quinazolin-4-one DMSF7WJ DE Hypertension DM6ZOUV ID DM6ZOUV DM6ZOUV DN Clazakizumab DM6ZOUV HS Phase 2 DM6ZOUV SN Clazakizumab; ALD518; CHEMBL2108589; BMS-945429 DM6ZOUV TC Antiviral Agents DM6ZOUV DT Monoclonal antibody DM6ZOUV DE Coronavirus Disease 2019 (COVID-19) DMAIW6C ID DMAIW6C DMAIW6C DN Clazakizumab DMAIW6C HS Phase 2 DMAIW6C CP Bristol-myers squibb; alder biopharmaceuticals DMAIW6C DT Monoclonal antibody DMAIW6C DE Crohn disease; Rheumatoid arthritis DMU6R3O ID DMU6R3O DMU6R3O DN CLG561 DMU6R3O HS Phase 2 DMU6R3O CP Alcon DMU6R3O DT Antibody DMU6R3O DE Geographic retinal atrophy DMH2VS0 ID DMH2VS0 DMH2VS0 DN CLP-1001 DMH2VS0 HS Phase 2 DMH2VS0 SN Cross-linked polyelectrolyte polymer (renal disease), Sorbent Therapeutics DMH2VS0 CP Sorbent therapeutics DMH2VS0 DE Chronic heart failure DMAW4EL ID DMAW4EL DMAW4EL DN CLR-1404 DMAW4EL HS Phase 2 DMAW4EL SN CLR-1501; CLR-1502 DMAW4EL CP Cellectar LLC DMAW4EL DE Solid tumour/cancer DM3Z6IQ ID DM3Z6IQ DM3Z6IQ DN CLR-3001 DM3Z6IQ HS Phase 2 DM3Z6IQ CP Clera Inc DM3Z6IQ DE Major depressive disorder DMQSIY1 ID DMQSIY1 DMQSIY1 DN CLS003 DMQSIY1 HS Phase 2 DMQSIY1 SN Furosemide/digoxin; ICVT; Ionic contra viral therapy DMQSIY1 CP Cutanea Wayne, PA DMQSIY1 DE Plantar wart DM1NCUY ID DM1NCUY DM1NCUY DN CMI-392 DM1NCUY HS Phase 2 DM1NCUY SN LDP-392; 3-[2-[2-(4-Chlorophenylsulfanyl)ethoxy]-3-methoxy-5-[trans-5-(3,4,5-trimethoxyphenyl)tetrahydrofuran-2-yl]benzyl]-1-hydroxy-1-methylurea DM1NCUY CP Millennium Pharmaceuticals DM1NCUY DT Small molecular drug DM1NCUY PC 6918268 DM1NCUY MW 633.2 DM1NCUY FM C31H37ClN2O8S DM1NCUY IC InChI=1S/C31H37ClN2O8S/c1-34(36)31(35)33-18-21-14-19(15-26(37-2)29(21)41-12-13-43-23-8-6-22(32)7-9-23)24-10-11-25(42-24)20-16-27(38-3)30(40-5)28(17-20)39-4/h6-9,14-17,24-25,36H,10-13,18H2,1-5H3,(H,33,35)/t24-,25-/m0/s1 DM1NCUY CS CN(C(=O)NCC1=C(C(=CC(=C1)[C@@H]2CC[C@H](O2)C3=CC(=C(C(=C3)OC)OC)OC)OC)OCCSC4=CC=C(C=C4)Cl)O DM1NCUY IK LZVBMKDVEPGGFK-DQEYMECFSA-N DM1NCUY IU 3-[[2-[2-(4-chlorophenyl)sulfanylethoxy]-3-methoxy-5-[(2S,5S)-5-(3,4,5-trimethoxyphenyl)oxolan-2-yl]phenyl]methyl]-1-hydroxy-1-methylurea DM1NCUY DE Psoriasis vulgaris DM7GELO ID DM7GELO DM7GELO DN CMVpp65-A0201 DM7GELO HS Phase 2 DM7GELO SN CMV vaccine (pp65 antigen), City of Hope DM7GELO CP City of Hope DM7GELO DT Vaccine DM7GELO DE Cytomegalovirus infection DMPSCVY ID DMPSCVY DMPSCVY DN CMX-2043 DMPSCVY HS Phase 2 DMPSCVY CP Ischemix DMPSCVY PC 49802864 DMPSCVY MW 406.5 DMPSCVY FM C16H26N2O6S2 DMPSCVY IC InChI=1S/C16H26N2O6S2/c1-10(16(23)24)17-15(22)12(6-7-14(20)21)18-13(19)5-3-2-4-11-8-9-25-26-11/h10-12H,2-9H2,1H3,(H,17,22)(H,18,19)(H,20,21)(H,23,24)/t10-,11+,12-/m0/s1 DMPSCVY CS C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)CCCC[C@@H]1CCSS1 DMPSCVY IK MQXRTCVZPIHBLD-TUAOUCFPSA-N DMPSCVY IU (4S)-5-[[(1S)-1-carboxyethyl]amino]-4-[5-[(3R)-dithiolan-3-yl]pentanoylamino]-5-oxopentanoic acid DMPSCVY CA CAS 910627-26-8 DMPSCVY DE Myocardial reperfusion injury; Cardiac disease DM0MTP8 ID DM0MTP8 DM0MTP8 DN CN-105 DM0MTP8 HS Phase 2 DM0MTP8 SN 5-Nitroisoquinoline; 607-32-9; Isoquinoline, 5-nitro-; 5-Nitro-isoquinoline; MLS002637661; PYGMPFQCCWBTJQ-UHFFFAOYSA-N; 5-nitroisochinolin; EINECS 210-133-8; 5-nitro isoquinoline; PubChem6272; AI3-61887; Maybridge1_001820; ACMC-1AV1Q; AC1Q1X2S; 5-Nitroisoquinoline, 98%; Oprea1_032003; SCHEMBL1010663; AC1Q201M; AC1L2B31; CHEMBL353253; PYGMPFQCCWBTJQ-UHFFFAOYSA-; KS-00000DJC; CTK2F2846; ZINC93213; HMS546K16; DTXSID00209511; NSC3017; MolPort-001-761-771; HMS3078A13; ACT09900; ALBB-021274; NSC-3017; ANW-33564; SBB066313; MFCD00006905 DM0MTP8 CP AegisCN Raleigh, NC DM0MTP8 PC 69085 DM0MTP8 MW 174.16 DM0MTP8 FM C9H6N2O2 DM0MTP8 IC InChI=1S/C9H6N2O2/c12-11(13)9-3-1-2-7-6-10-5-4-8(7)9/h1-6H DM0MTP8 CS C1=CC2=C(C=CN=C2)C(=C1)[N+](=O)[O-] DM0MTP8 IK PYGMPFQCCWBTJQ-UHFFFAOYSA-N DM0MTP8 IU 5-nitroisoquinoline DM0MTP8 CA CAS 607-32-9 DM0MTP8 DE Nontraumatic intracerebral hemorrhage DM16KJ3 ID DM16KJ3 DM16KJ3 DN CNS-5161 DM16KJ3 HS Phase 2 DM16KJ3 SN CNS5161; 2-(2-chloro-5-methylsulfanylphenyl)-1-methyl-1-(3-methylsulfanylphenyl)guanidine; 2-[2-chloro-5-(methylsulfanyl)phenyl]-1-methyl-1-[3-(methylsulfanyl)phenyl]guanidine DM16KJ3 CP CeNeS DM16KJ3 TC Analgesics DM16KJ3 DT Small molecular drug DM16KJ3 PC 192711 DM16KJ3 MW 351.9 DM16KJ3 FM C16H18ClN3S2 DM16KJ3 IC InChI=1S/C16H18ClN3S2/c1-20(11-5-4-6-12(9-11)21-2)16(18)19-15-10-13(22-3)7-8-14(15)17/h4-10H,1-3H3,(H2,18,19) DM16KJ3 CS CN(C1=CC(=CC=C1)SC)C(=NC2=C(C=CC(=C2)SC)Cl)N DM16KJ3 IK JHVHEDNLONERHY-UHFFFAOYSA-N DM16KJ3 IU 2-(2-chloro-5-methylsulfanylphenyl)-1-methyl-1-(3-methylsulfanylphenyl)guanidine DM16KJ3 CA CAS 160754-76-7 DM16KJ3 DE Neuropathic pain DM2PEU5 ID DM2PEU5 DM2PEU5 DN CNSB-001 DM2PEU5 HS Phase 2 DM2PEU5 SN Flupirtine + opioid (fixed dose, diabetic neuropathic pain), CNSBio; Flupirtine + opioid (fixed dose, diabetic neuropathic pain), Relevare DM2PEU5 CP Relevare Pharmaceuticals Ltd DM2PEU5 DE Neuropathic pain DMOR8SY ID DMOR8SY DMOR8SY DN CNT0-1959 DMOR8SY HS Phase 2 DMOR8SY CP Janssen biotech DMOR8SY DT Antibody DMOR8SY DE Rheumatoid arthritis DM6RQXB ID DM6RQXB DM6RQXB DN CNTO-6785 DM6RQXB HS Phase 2 DM6RQXB CP Janssen research & development DM6RQXB DT Antibody DM6RQXB DE Rheumatoid arthritis DMLT7JV ID DMLT7JV DMLT7JV DN CNV-2197944 DMLT7JV HS Phase 2 DMLT7JV SN GSK-2197944; Cav2.2 channel blocker (chronic pain), GlaxoSmithKline/Convergence Pharmaceuticals DMLT7JV CP GlaxoSmithKline plc DMLT7JV PC 44595848 DMLT7JV MW 427.4 DMLT7JV FM C19H20F3N3O3S DMLT7JV IC InChI=1S/C19H20F3N3O3S/c1-13-12-24(10-11-25(13)18(26)17-4-3-9-23-14(17)2)29(27,28)16-7-5-15(6-8-16)19(20,21)22/h3-9,13H,10-12H2,1-2H3/t13-/m0/s1 DMLT7JV CS C[C@H]1CN(CCN1C(=O)C2=C(N=CC=C2)C)S(=O)(=O)C3=CC=C(C=C3)C(F)(F)F DMLT7JV IK BLFJGFDZMABYMY-ZDUSSCGKSA-N DMLT7JV IU (2-methylpyridin-3-yl)-[(2S)-2-methyl-4-[4-(trifluoromethyl)phenyl]sulfonylpiperazin-1-yl]methanone DMLT7JV CA CAS 1204535-44-3 DMLT7JV DE Pain DMH5GQU ID DMH5GQU DMH5GQU DN CO-101 DMH5GQU HS Phase 2 DMH5GQU SN methyl 2-(dimethylcarbamoyl)benzoate; 26593-43-1; Phthalamic acid, N,N-dimethyl-, methyl ester; CO 101; BRN 2504723; N,N-Dimethylphthalamic acid methyl ester; N,N-Dimethylphthalamic acid, methyl ester; AC1Q5ZAU; 2-09-00-00601 (Beilstein Handbook Reference); AC1L4V19; CTK4F8203; DTXSID50181156; 2-methoxycarbonyl-N,N-dimethylbenzamide; LS-109082; Benzoic acid,2-[(dimethylamino)carbonyl]-, methyl ester DMH5GQU CP Clovis Oncology DMH5GQU DT Small molecular drug DMH5GQU PC 9828310 DMH5GQU MW 527.6 DMH5GQU FM C27H43F2N3O5 DMH5GQU IC InChI=1S/C27H43F2N3O5/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-23(33)36-20-21-24(34)27(28,29)25(37-21)32-19-18-22(30)31-26(32)35/h9-10,18-19,21,24-25,34H,2-8,11-17,20H2,1H3,(H2,30,31,35)/b10-9+/t21-,24-,25-/m1/s1 DMH5GQU CS CCCCCCCC/C=C/CCCCCCCC(=O)OC[C@@H]1[C@H](C([C@@H](O1)N2C=CC(=NC2=O)N)(F)F)O DMH5GQU IK HESSNRGIEVBPRB-QDDPNBLJSA-N DMH5GQU IU [(2R,3R,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-4,4-difluoro-3-hydroxyoxolan-2-yl]methyl (E)-octadec-9-enoate DMH5GQU CA CAS 210829-30-4 DMH5GQU DE Pancreatic cancer DMF4MX9 ID DMF4MX9 DMF4MX9 DN Cobomarsen DMF4MX9 HS Phase 2 DMF4MX9 SN MRG-106 DMF4MX9 CP miRagen Therapeutics Boulder, CO DMF4MX9 DE Chronic lymphocytic leukaemia; Diffuse large B-cell lymphoma; Cutaneous T-cell lymphoma DMDWG36 ID DMDWG36 DMDWG36 DN Codrituzumab DMDWG36 HS Phase 2 DMDWG36 CP GenentechSouth San Francisco, CA DMDWG36 DE Hepatic metastasis DMO0VGH ID DMO0VGH DMO0VGH DN Coenzyme Q10 analog DMO0VGH HS Phase 2 DMO0VGH SN Coenzyme Q10 analog (mitochondrial disease); Coenzyme Q10 analog (mitochondrial disease), Edison Pharmaceuticals DMO0VGH CP Edison Pharmaceuticals Inc DMO0VGH DE Huntington disease; Leigh syndrome; Mitochondrial respiratory chain disease; Rett syndrome DMNC76I ID DMNC76I DMNC76I DN COL-1077 DMNC76I HS Phase 2 DMNC76I CP Columbia Laboratories Inc DMNC76I DE Pain DMSGFOY ID DMSGFOY DMSGFOY DN Coltuximab ravtansine DMSGFOY HS Phase 2 DMSGFOY CP ImmunoGen Waltham, MA DMSGFOY DE Diffuse large B-cell lymphoma; Non-hodgkin lymphoma DMI2GSK ID DMI2GSK DMI2GSK DN Coluracetam DMI2GSK HS Phase 2 DMI2GSK SN BCI-540; MKC-231; High-affinity choline uptake facilitator (CNS disorders), Mitsubishi; Neurons growth promoting compound (major depressive disorder/anxiety), BrainCells; High-affinity choline uptake facilitator (depression/ anxiety), BrainCells DMI2GSK CP Mitsubishi Pharma Corp DMI2GSK DT Small molecular drug DMI2GSK PC 214346 DMI2GSK MW 341.4 DMI2GSK FM C19H23N3O3 DMI2GSK IC InChI=1S/C19H23N3O3/c1-11-12(2)25-19-17(11)18(13-6-3-4-7-14(13)20-19)21-15(23)10-22-9-5-8-16(22)24/h3-10H2,1-2H3,(H,20,21,23) DMI2GSK CS CC1=C(OC2=NC3=C(CCCC3)C(=C12)NC(=O)CN4CCCC4=O)C DMI2GSK IK PSPGQHXMUKWNDI-UHFFFAOYSA-N DMI2GSK IU N-(2,3-dimethyl-5,6,7,8-tetrahydrofuro[2,3-b]quinolin-4-yl)-2-(2-oxopyrrolidin-1-yl)acetamide DMI2GSK CA CAS 135463-81-9 DMI2GSK DE Alzheimer disease DMGCTX5 ID DMGCTX5 DMGCTX5 DN Combined PR1/WT1 vaccine DMGCTX5 HS Phase 2 DMGCTX5 SN Combined PR1/WT1 vaccine (leukemia); Combined PR1/WT1 vaccine (leukemia), NIH; Proteinase 1/Wilms tumor 1 vaccine (leukemia), NIH DMGCTX5 CP National Institutes of Health DMGCTX5 DT Vaccine DMGCTX5 DE Myeloid leukaemia DM2UOSN ID DM2UOSN DM2UOSN DN Conatumumab DM2UOSN HS Phase 2 DM2UOSN CP Amgen; Takeda DM2UOSN DT Monoclonal antibody DM2UOSN DE Pain; Colorectal cancer DMZ0F65 ID DMZ0F65 DMZ0F65 DN Contezolid DMZ0F65 HS Phase 2 DMZ0F65 SN MRX-I; UNII-B669M62ELP; B669M62ELP; CHEMBL3287379; 1112968-42-9; 4(1H)-Pyridinone, 2,3-dihydro-1-(2,3,6-trifluoro-4-((5S)-5-((3-isoxazolylamino)methyl)-2-oxo-3-oxazolidinyl)phenyl)-; 4(1H)-Pyridinone, 2,3-dihydro-1-[2,3,6-trifluoro-4-[(5S)-5-[(3-isoxazolylamino)methyl]-2-oxo-3-oxazolidinyl]phenyl]-; Contezolid [USAN]; SCHEMBL5945221; BDBM50017203; DB12796 DMZ0F65 CP MicuRx Pharmaceuticals Hayward, CA DMZ0F65 PC 25184541 DMZ0F65 MW 408.3 DMZ0F65 FM C18H15F3N4O4 DMZ0F65 IC InChI=1S/C18H15F3N4O4/c19-12-7-13(15(20)16(21)17(12)24-4-1-10(26)2-5-24)25-9-11(29-18(25)27)8-22-14-3-6-28-23-14/h1,3-4,6-7,11H,2,5,8-9H2,(H,22,23)/t11-/m0/s1 DMZ0F65 CS C1CN(C=CC1=O)C2=C(C=C(C(=C2F)F)N3C[C@@H](OC3=O)CNC4=NOC=C4)F DMZ0F65 IK SULYVXZZUMRQAX-NSHDSACASA-N DMZ0F65 IU (5S)-5-[(1,2-oxazol-3-ylamino)methyl]-3-[2,3,5-trifluoro-4-(4-oxo-2,3-dihydropyridin-1-yl)phenyl]-1,3-oxazolidin-2-one DMZ0F65 CA CAS 1112968-42-9 DMZ0F65 DE MRSA infection; Skin infection DMMOHUA ID DMMOHUA DMMOHUA DN Contezolid acefosamil DMMOHUA HS Phase 2 DMMOHUA SN JANNTEAGZXJITO-BTQNPOSSSA-M; UNII-T79C086548; T79C086548; Contezolid acefosamil [USAN]; CHEMBL3989966; Acetic acid, anhydride with N-(((5R)-3-(4-(3,4-dihydro-4-oxo-1(2H)-pyridinyl)-2,3,5-trifluorophenyl)-2-oxo-5-oxazolidinyl)methyl)-N-3-isoxazolylphosphoramidic acid, sodium salt (1:1:1); Acetic (5R)-isoxazol-3yl((2-oxo-3-(2,3,5-trifluoro-4-(4-oxo-3,4-dihydropyridin-1(2H)-yl)phenyl)oxazolidin-5-yl)methyl)phosphoramidic anhydride, sodium salt (1:1); 1807365-35-0 DMMOHUA CP MicuRx Pharmaceuticals Hayward, CA DMMOHUA PC 131750213 DMMOHUA MW 552.3 DMMOHUA FM C20H17F3N4NaO8P DMMOHUA IC InChI=1S/C20H18F3N4O8P.Na/c1-11(28)35-36(31,32)27(16-4-7-33-24-16)10-13-9-26(20(30)34-13)15-8-14(21)19(18(23)17(15)22)25-5-2-12(29)3-6-25;/h2,4-5,7-8,13H,3,6,9-10H2,1H3,(H,31,32);/q;+1/p-1/t13-;/m1./s1 DMMOHUA CS CC(=O)OP(=O)(N(C[C@H]1CN(C(=O)O1)C2=CC(=C(C(=C2F)F)N3CCC(=O)C=C3)F)C4=NOC=C4)[O-].[Na+] DMMOHUA IK JANNTEAGZXJITO-BTQNPOSSSA-M DMMOHUA IU sodium;acetyloxy-[1,2-oxazol-3-yl-[[(5R)-2-oxo-3-[2,3,5-trifluoro-4-(4-oxo-2,3-dihydropyridin-1-yl)phenyl]-1,3-oxazolidin-5-yl]methyl]amino]phosphinate DMMOHUA CA CAS 1807365-35-0 DMMOHUA DE Acute bacterial skin infection DMER82Z ID DMER82Z DMER82Z DN COR-1 DMER82Z HS Phase 2 DMER82Z CP Corimmun GmbH DMER82Z DE Heart failure DMHBOUX ID DMHBOUX DMHBOUX DN CORT125281 DMHBOUX HS Phase 2 DMHBOUX SN Exicorilant; UNII-GTB859B7K8; GTB859B7K8; Exicorilant [INN]; SCHEMBL16737057; CORT-125281; 1781244-77-6; Methanone, ((4aR,8aS)-1-(4-fluorophenyl)-1,4,5,6,7,8,8a,9-octahydro-6-((2-methyl-2H-1,2,3-triazol-4-yl)sulfonyl)-4ah-pyrazolo(3,4-g)isoquinolin-4a-yl)(4-(trifluoromethyl)-2-pyridinyl)- DMHBOUX CP Corcept Therapeutics Menlo Park, CA DMHBOUX PC 118092367 DMHBOUX MW 589.6 DMHBOUX FM C26H23F4N7O3S DMHBOUX IC InChI=1S/C26H23F4N7O3S/c1-35-32-14-23(34-35)41(39,40)36-9-7-17-11-22-16(13-33-37(22)20-4-2-19(27)3-5-20)12-25(17,15-36)24(38)21-10-18(6-8-31-21)26(28,29)30/h2-6,8,10,13-14,17H,7,9,11-12,15H2,1H3/t17-,25-/m0/s1 DMHBOUX CS CN1N=CC(=N1)S(=O)(=O)N2CC[C@H]3CC4=C(C[C@@]3(C2)C(=O)C5=NC=CC(=C5)C(F)(F)F)C=NN4C6=CC=C(C=C6)F DMHBOUX IK HWJYJKAURRIWJM-GKVSMKOHSA-N DMHBOUX IU [(4aR,8aS)-1-(4-fluorophenyl)-6-(2-methyltriazol-4-yl)sulfonyl-4,5,7,8,8a,9-hexahydropyrazolo[3,4-g]isoquinolin-4a-yl]-[4-(trifluoromethyl)pyridin-2-yl]methanone DMHBOUX CA CAS 1781244-77-6 DMHBOUX DE Prostate cancer DMVKW0N ID DMVKW0N DMVKW0N DN Coumate DMVKW0N HS Phase 2 DMVKW0N DT Small molecular drug DMVKW0N PC 9859866 DMVKW0N MW 255.25 DMVKW0N FM C10H9NO5S DMVKW0N IC InChI=1S/C10H9NO5S/c1-6-4-10(12)15-9-5-7(2-3-8(6)9)16-17(11,13)14/h2-5H,1H3,(H2,11,13,14) DMVKW0N CS CC1=CC(=O)OC2=C1C=CC(=C2)OS(=O)(=O)N DMVKW0N IK UFGBGFMPBMEVMI-UHFFFAOYSA-N DMVKW0N IU (4-methyl-2-oxochromen-7-yl) sulfamate DMVKW0N CA CAS 136167-05-0 DMVKW0N DE Breast cancer DM2K5VP ID DM2K5VP DM2K5VP DN Coxsackievirus A21 DM2K5VP HS Phase 2 DM2K5VP SN Cavatak (TN) DM2K5VP CP Viralytics DM2K5VP DE Bladder cancer; Lung cancer; Melanoma; Prostate cancer; Glioblastoma multiforme DM8X5Q1 ID DM8X5Q1 DM8X5Q1 DN CP101 DM8X5Q1 HS Phase 2 DM8X5Q1 CP Finch Therapeutics DM8X5Q1 DT Small molecular drug DM8X5Q1 DE Autism spectrum disorder; Clostridium infection DMIU19E ID DMIU19E DMIU19E DN CP-101,606 DMIU19E HS Phase 2 DMIU19E SN SCHEMBL5888841; CHEMBL321758; AKOS030627610; CP-101581; (1R,2R)-1-(4-Hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidino)-1-propanol; 1-((1R,2R)-Rel-1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl)-4-phenylpiperidin-4-ol DMIU19E TC Analgesics DMIU19E DT Small molecular drug DMIU19E PC 219101 DMIU19E MW 327.4 DMIU19E FM C20H25NO3 DMIU19E IC InChI=1S/C20H25NO3/c1-15(19(23)16-7-9-18(22)10-8-16)21-13-11-20(24,12-14-21)17-5-3-2-4-6-17/h2-10,15,19,22-24H,11-14H2,1H3/t15-,19+/m0/s1 DMIU19E CS C[C@@H]([C@H](C1=CC=C(C=C1)O)O)N2CCC(CC2)(C3=CC=CC=C3)O DMIU19E IK QEMSVZNTSXPFJA-HNAYVOBHSA-N DMIU19E IU 1-[(1S,2S)-1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl]-4-phenylpiperidin-4-ol DMIU19E CA CAS 134234-12-1 DMIU19E DE Ischemic stroke; Parkinson disease DMSWLM5 ID DMSWLM5 DMSWLM5 DN CP-122721 DMSWLM5 HS Phase 2 DMSWLM5 SN CP-122721; UNII-R7OYP6N58F; R7OYP6N58F; CHEMBL319118; CHEMBL1917847; DSSTox_CID_27251; DSSTox_RID_82210; DSSTox_GSID_47251; SCHEMBL156646; DTXSID9047251; Tox21_300205; BDBM50067935; ZINC22441997; AKOS030542331; DB05421; NCGC00254228-01; NCGC00247927-01; CAS-145742-28-5; (2S,3S)-N-(2-methoxy-5-(trifluoromethoxy)benzyl)-2-phenylpiperidin-3-amine DMSWLM5 DT Small molecular drug DMSWLM5 PC 9821217 DMSWLM5 MW 380.4 DMSWLM5 FM C20H23F3N2O2 DMSWLM5 IC InChI=1S/C20H23F3N2O2/c1-26-18-10-9-16(27-20(21,22)23)12-15(18)13-25-17-8-5-11-24-19(17)14-6-3-2-4-7-14/h2-4,6-7,9-10,12,17,19,24-25H,5,8,11,13H2,1H3/t17-,19-/m0/s1 DMSWLM5 CS COC1=C(C=C(C=C1)OC(F)(F)F)CN[C@H]2CCCN[C@H]2C3=CC=CC=C3 DMSWLM5 IK ZIWFCOIGUNPHPM-HKUYNNGSSA-N DMSWLM5 IU (2S,3S)-N-[[2-methoxy-5-(trifluoromethoxy)phenyl]methyl]-2-phenylpiperidin-3-amine DMSWLM5 CA CAS 145742-28-5 DMSWLM5 DE Major depressive disorder DMVO5DR ID DMVO5DR DMVO5DR DN CP-331684 DMVO5DR HS Phase 2 DMVO5DR SN 2-[4-[2-[2(R)-(6-Amino-3-pyridinyl)-2-hydroxyethylamino]ethoxy]phenyl]acetic acid DMVO5DR DT Small molecular drug DMVO5DR PC 9840517 DMVO5DR MW 331.4 DMVO5DR FM C17H21N3O4 DMVO5DR IC InChI=1S/C17H21N3O4/c18-16-6-3-13(10-20-16)15(21)11-19-7-8-24-14-4-1-12(2-5-14)9-17(22)23/h1-6,10,15,19,21H,7-9,11H2,(H2,18,20)(H,22,23)/t15-/m0/s1 DMVO5DR CS C1=CC(=CC=C1CC(=O)O)OCCNC[C@@H](C2=CN=C(C=C2)N)O DMVO5DR IK GZJZZQHTBTUBEL-HNNXBMFYSA-N DMVO5DR IU 2-[4-[2-[[(2R)-2-(6-aminopyridin-3-yl)-2-hydroxyethyl]amino]ethoxy]phenyl]acetic acid DMVO5DR CA CAS 207922-70-1 DMVO5DR DE Diabetic complication DMEYMTX ID DMEYMTX DMEYMTX DN CP-461 DMEYMTX HS Phase 2 DMEYMTX SN CP-461; OSI 461; UNII-68OJX9I7DT; CP 461; 68OJX9I7DT; 1H-Indene-3-acetamide, 5-fluoro-2-methyl-N-(phenylmethyl)-1-(4-pyridinylmethylene)-, monohydrochloride, (1Z)-; 227619-96-7; N-benzyl-2-[(3Z)-6-fluoro-2-methyl-3-(pyridin-4-ylmethylidene)inden-1-yl]acetamide hydrochloride; AC1O6379; 279238-68-5 DMEYMTX DT Small molecular drug DMEYMTX PC 6445781 DMEYMTX MW 420.9 DMEYMTX FM C25H22ClFN2O DMEYMTX IC InChI=1S/C25H21FN2O.ClH/c1-17-22(13-18-9-11-27-12-10-18)21-8-7-20(26)14-24(21)23(17)15-25(29)28-16-19-5-3-2-4-6-19;/h2-14H,15-16H2,1H3,(H,28,29);1H/b22-13-; DMEYMTX CS CC\\1=C(C2=C(/C1=C\\C3=CC=NC=C3)C=CC(=C2)F)CC(=O)NCC4=CC=CC=C4.Cl DMEYMTX IK KGXPDNOBLLACKL-BWLGBDCWSA-N DMEYMTX IU N-benzyl-2-[(3Z)-6-fluoro-2-methyl-3-(pyridin-4-ylmethylidene)inden-1-yl]acetamide;hydrochloride DMEYMTX CA CAS 227619-96-7 DMEYMTX DE Inflammatory bowel disease DMZEJLB ID DMZEJLB DMZEJLB DN CP-533536 DMZEJLB HS Phase 2 DMZEJLB SN Evatanepag; CP-533,536; 2-(3-((((4-(1,1-dimethylethyl)phenyl)methyl)(pyridin-3-ylsulfonyl)amino)methyl)phenoxy)acetic acid; 2-[3-[[pyridin-3-ylsulfonyl-[(4-tert-butylphenyl)methyl]amino]methyl]phenoxy]acetic Acid DMZEJLB CP Pfizer DMZEJLB DT Small molecular drug DMZEJLB PC 9890801 DMZEJLB MW 468.6 DMZEJLB FM C25H28N2O5S DMZEJLB IC InChI=1S/C25H28N2O5S/c1-25(2,3)21-11-9-19(10-12-21)16-27(33(30,31)23-8-5-13-26-15-23)17-20-6-4-7-22(14-20)32-18-24(28)29/h4-15H,16-18H2,1-3H3,(H,28,29) DMZEJLB CS CC(C)(C)C1=CC=C(C=C1)CN(CC2=CC(=CC=C2)OCC(=O)O)S(=O)(=O)C3=CN=CC=C3 DMZEJLB IK WOHRHWDYFNWPNG-UHFFFAOYSA-N DMZEJLB IU 2-[3-[[(4-tert-butylphenyl)methyl-pyridin-3-ylsulfonylamino]methyl]phenoxy]acetic acid DMZEJLB CA CAS 223488-57-1 DMZEJLB DE Osteoporosis DMX054A ID DMX054A DMX054A DN CP-547632 DMX054A HS Phase 2 DMX054A SN BFF; CP 547632; CP-547,632; 3-(4-Bromo-2,6-difluorobenzyloxy)-5-(3-(4-pyrrolidin-1-ylbutyl)ureido)isothiazole-4-carboxylic acid amide DMX054A CP OSI Pharmaceuticals DMX054A TC Anticancer Agents DMX054A DT Small molecular drug DMX054A PC 9811611 DMX054A MW 532.4 DMX054A FM C20H24BrF2N5O3S DMX054A IC InChI=1S/C20H24BrF2N5O3S/c21-12-9-14(22)13(15(23)10-12)11-31-18-16(17(24)29)19(32-27-18)26-20(30)25-5-1-2-6-28-7-3-4-8-28/h9-10H,1-8,11H2,(H2,24,29)(H2,25,26,30) DMX054A CS C1CCN(C1)CCCCNC(=O)NC2=C(C(=NS2)OCC3=C(C=C(C=C3F)Br)F)C(=O)N DMX054A IK HXHAJRMTJXHJJZ-UHFFFAOYSA-N DMX054A IU 3-[(4-bromo-2,6-difluorophenyl)methoxy]-5-(4-pyrrolidin-1-ylbutylcarbamoylamino)-1,2-thiazole-4-carboxamide DMX054A CA CAS 252003-65-9 DMX054A DE Solid tumour/cancer; Ovarian cancer; Non-small-cell lung cancer DMKJFDM ID DMKJFDM DMKJFDM DN CP-601927 DMKJFDM HS Phase 2 DMKJFDM SN CP-601932; Alpha4beta2 nAchR partial agonists (depression), Pfizer DMKJFDM CP Pfizer Inc DMKJFDM DT Small molecular drug DMKJFDM PC 11498153 DMKJFDM MW 227.22 DMKJFDM FM C12H12F3N DMKJFDM IC InChI=1S/C12H12F3N/c13-12(14,15)9-1-2-10-7-3-8(6-16-5-7)11(10)4-9/h1-2,4,7-8,16H,3,5-6H2/t7-,8+/m0/s1 DMKJFDM CS C1[C@H]2CNC[C@@H]1C3=C2C=CC(=C3)C(F)(F)F DMKJFDM IK RNOBTWYQAWEZHH-JGVFFNPUSA-N DMKJFDM IU (1S,8R)-4-(trifluoromethyl)-10-azatricyclo[6.3.1.02,7]dodeca-2(7),3,5-triene DMKJFDM CA CAS 357425-02-6 DMKJFDM DE Gastrointestinal disease DMUJ0W7 ID DMUJ0W7 DMUJ0W7 DN CP-724714 DMUJ0W7 HS Phase 2 DMUJ0W7 SN CP 724714; CP-724,714; CP724,714, CP-724,714; 2-Methoxy-N-(3-(4-((3-methyl-4-((6-methyl-3-pyridinyl)oxy)phenyl)amino)-6-quinazolinyl)-2-propenyl)acetamide; 2-Methoxy-N-[(2E)-3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propen-1-yl]acetamide DMUJ0W7 CP Pfizer DMUJ0W7 TC Anticancer Agents DMUJ0W7 DT Small molecular drug DMUJ0W7 PC 9874913 DMUJ0W7 MW 469.5 DMUJ0W7 FM C27H27N5O3 DMUJ0W7 IC InChI=1S/C27H27N5O3/c1-18-13-21(8-11-25(18)35-22-9-6-19(2)29-15-22)32-27-23-14-20(7-10-24(23)30-17-31-27)5-4-12-28-26(33)16-34-3/h4-11,13-15,17H,12,16H2,1-3H3,(H,28,33)(H,30,31,32)/b5-4+ DMUJ0W7 CS CC1=NC=C(C=C1)OC2=C(C=C(C=C2)NC3=NC=NC4=C3C=C(C=C4)/C=C/CNC(=O)COC)C DMUJ0W7 IK LLVZBTWPGQVVLW-SNAWJCMRSA-N DMUJ0W7 IU 2-methoxy-N-[(E)-3-[4-[3-methyl-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]prop-2-enyl]acetamide DMUJ0W7 CA CAS 845680-17-3 DMUJ0W7 CB CHEBI:91331 DMUJ0W7 DE Lymphoma DMT3ORQ ID DMT3ORQ DMT3ORQ DN CP-80794 DMT3ORQ HS Phase 2 DMT3ORQ DT Small molecular drug DMT3ORQ PC 64922 DMT3ORQ MW 620.8 DMT3ORQ FM C31H48N4O7S DMT3ORQ IC InChI=1S/C31H48N4O7S/c1-21(2)42-30(39)27(36)24(18-22-10-6-4-7-11-22)32-29(38)26(20-43-3)33-28(37)25(19-23-12-8-5-9-13-23)34-31(40)35-14-16-41-17-15-35/h5,8-9,12-13,21-22,24-27,36H,4,6-7,10-11,14-20H2,1-3H3,(H,32,38)(H,33,37)(H,34,40)/t24-,25-,26-,27+/m0/s1 DMT3ORQ CS CC(C)OC(=O)[C@@H]([C@H](CC1CCCCC1)NC(=O)[C@H](CSC)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)N3CCOCC3)O DMT3ORQ IK UZQBKCWYZBHBOW-YIPNQBBMSA-N DMT3ORQ IU propan-2-yl (2R,3S)-4-cyclohexyl-2-hydroxy-3-[[(2R)-3-methylsulfanyl-2-[[(2S)-2-(morpholine-4-carbonylamino)-3-phenylpropanoyl]amino]propanoyl]amino]butanoate DMT3ORQ CA CAS 119625-78-4 DMT3ORQ DE Hypertension DM6MUCX ID DM6MUCX DM6MUCX DN CpG-10101 DM6MUCX HS Phase 2 DM6MUCX SN Actilon; Anti-HCV therapy, Coley DM6MUCX CP Coley Pharmaceutical Group Inc; Coley Pharmaceutical DM6MUCX DE Hepatitis C virus infection DMK9NQI ID DMK9NQI DMK9NQI DN CPP-115 DMK9NQI HS Phase 2 DMK9NQI SN GABA aminotransferase inhibitors (oral), Northwestern University/Catalyst Pharmaceutical Partners; Vigabatrin derivatives (oral, neurological diseases), Northwestern University; Vigabatrin derivatives (oral, drug addiction/epilepsy/neuropathic pain), Catalyst Pharmaceutical Partners DMK9NQI CP Catalyst pharmaceutical partners DMK9NQI DT Small molecular drug DMK9NQI PC 9794014 DMK9NQI MW 177.15 DMK9NQI FM C7H9F2NO2 DMK9NQI IC InChI=1S/C7H9F2NO2/c8-6(9)4-1-3(7(11)12)2-5(4)10/h3,5H,1-2,10H2,(H,11,12)/t3-,5-/m0/s1 DMK9NQI CS C1[C@H](CC(=C(F)F)[C@H]1N)C(=O)O DMK9NQI IK CBSRETZPFOBWNG-UCORVYFPSA-N DMK9NQI IU (1S,3S)-3-amino-4-(difluoromethylidene)cyclopentane-1-carboxylic acid DMK9NQI CA CAS 640897-20-7 DMK9NQI DE Substance use disorder; Infantile spasm; Tourette syndrome DMK7DFM ID DMK7DFM DMK7DFM DN CPX-POM DMK7DFM HS Phase 2 DMK7DFM CP CicloMed DMK7DFM DT Small molecular drug DMK7DFM DE Solid tumour/cancer; Bladder cancer DMHJEZS ID DMHJEZS DMHJEZS DN CR-3294 DMHJEZS HS Phase 2 DMHJEZS CP Rottapharm Madaus DMHJEZS DE Diarrhea DMNC1AF ID DMNC1AF DMNC1AF DN CR-665 DMNC1AF HS Phase 2 DMNC1AF SN CR665; UNII-3BX9UG06GG; 3BX9UG06GG; 228546-92-7; CR-665; CR 665; FE 200665; FE-200665; SCHEMBL4451321; DTXSID30177395; jnj-38488502; DB05155; D-Argininamide, D-phenylalanyl-D-phenylalanyl-D-norleucyl-N-(4-pyridinylmethyl)- DMNC1AF CP Ferring Pharmaceuticals Inc DMNC1AF DT Small molecular drug DMNC1AF PC 25030387 DMNC1AF MW 671.8 DMNC1AF FM C36H49N9O4 DMNC1AF IC InChI=1S/C36H49N9O4/c1-2-3-15-30(34(48)43-29(16-10-19-41-36(38)39)33(47)42-24-27-17-20-40-21-18-27)44-35(49)31(23-26-13-8-5-9-14-26)45-32(46)28(37)22-25-11-6-4-7-12-25/h4-9,11-14,17-18,20-21,28-31H,2-3,10,15-16,19,22-24,37H2,1H3,(H,42,47)(H,43,48)(H,44,49)(H,45,46)(H4,38,39,41)/t28-,29-,30-,31-/m1/s1 DMNC1AF CS CCCC[C@H](C(=O)N[C@H](CCCN=C(N)N)C(=O)NCC1=CC=NC=C1)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CC3=CC=CC=C3)N DMNC1AF IK DBOGGOVKHSCMNB-OMRVPHBLSA-N DMNC1AF IU (2R)-2-[[(2R)-2-[[(2R)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-N-[(2R)-5-(diaminomethylideneamino)-1-oxo-1-(pyridin-4-ylmethylamino)pentan-2-yl]hexanamide DMNC1AF CA CAS 228546-92-7 DMNC1AF DE Pain DMQ47U6 ID DMQ47U6 DMQ47U6 DN CR8020 DMQ47U6 HS Phase 2 DMQ47U6 SN H3N2 and H7N7 influenza monoclonal antibody therapy, Crucell DMQ47U6 CP Crucell DMQ47U6 DT Antibody DMQ47U6 DE Influenza A virus infection; Influenza virus infection DMO1ZGX ID DMO1ZGX DMO1ZGX DN CRILVASTATIN DMO1ZGX HS Phase 2 DMO1ZGX SN Crilvastatin < Rec INN; PMD-387; L-Pyroglutamic acid rac-cis-3,3,5-trimethylcyclohexyl ester; 5-Oxo-L-proline rac-cis-3,3,5-trimethylcyclohexyl ester DMO1ZGX DT Small molecular drug DMO1ZGX PC 22845140 DMO1ZGX MW 253.34 DMO1ZGX FM C14H23NO3 DMO1ZGX IC InChI=1S/C14H23NO3/c1-9-6-10(8-14(2,3)7-9)18-13(17)11-4-5-12(16)15-11/h9-11H,4-8H2,1-3H3,(H,15,16)/t9?,10?,11-/m0/s1 DMO1ZGX CS CC1CC(CC(C1)(C)C)OC(=O)[C@@H]2CCC(=O)N2 DMO1ZGX IK FXAAOALUHHXBSO-ILDUYXDCSA-N DMO1ZGX IU (3,3,5-trimethylcyclohexyl) (2S)-5-oxopyrrolidine-2-carboxylate DMO1ZGX CA CAS 120551-59-9 DMO1ZGX DE Hyperlipidaemia DMQUWXY ID DMQUWXY DMQUWXY DN CRLX101 DMQUWXY HS Phase 2 DMQUWXY CP Cerulean Pharma DMQUWXY PC 184196 DMQUWXY MW 348.4 DMQUWXY FM C20H16N2O4 DMQUWXY IC InChI=1S/C20H16N2O4/c1-2-20(25)14-8-16-17-12(7-11-5-3-4-6-15(11)21-17)9-22(16)18(23)13(14)10-26-19(20)24/h3-8,25H,2,9-10H2,1H3/t20-/m1/s1 DMQUWXY CS CC[C@]1(C2=C(COC1=O)C(=O)N3CC4=CC5=CC=CC=C5N=C4C3=C2)O DMQUWXY IK VSJKWCGYPAHWDS-HXUWFJFHSA-N DMQUWXY IU (19R)-19-ethyl-19-hydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4,6,8,10,15(20)-heptaene-14,18-dione DMQUWXY CA CAS 110351-92-3 DMQUWXY DE Solid tumour/cancer; Renal cell carcinoma; Ovarian cancer; Non-small-cell lung cancer DM85WID ID DM85WID DM85WID DN Crobenetine DM85WID HS Phase 2 DM85WID SN CROBENETINE; CROBENETINE); BIII-890-CL; Crobenetine; Crobenetine hydrochloride; (2R,6S)-3-[2(S)-Benzyloxypropyl]-6,11,11-trimethyl-1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin-10-ol; (2R,6S)-3-[2(S)-Benzyloxypropyl]-6,11,11-trimethyl-1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin-10-ol hydrochloride DM85WID DT Small molecular drug DM85WID PC 9886143 DM85WID MW 379.5 DM85WID FM C25H33NO2 DM85WID IC InChI=1S/C25H33NO2/c1-18(28-17-19-9-6-5-7-10-19)16-26-14-13-25(4)21-11-8-12-22(27)20(21)15-23(26)24(25,2)3/h5-12,18,23,27H,13-17H2,1-4H3/t18-,23+,25-/m0/s1 DM85WID CS C[C@@H](CN1CC[C@]2(C3=C(C[C@@H]1C2(C)C)C(=CC=C3)O)C)OCC4=CC=CC=C4 DM85WID IK VCCBCXVFGHTDQN-UODBTFMRSA-N DM85WID IU (1S,9R)-1,13,13-trimethyl-10-[(2S)-2-phenylmethoxypropyl]-10-azatricyclo[7.3.1.02,7]trideca-2(7),3,5-trien-6-ol DM85WID CA 221019-25-6 DM85WID DE Pain DM129T7 ID DM129T7 DM129T7 DN CROMOGLYCATE LISETIL HYDROCHLORIDE DM129T7 HS Phase 2 DM129T7 SN Diethyl L-lysylcromoglycate dihydrochloride; KY-556; N-556; Cromoglycate lisetil hydrochloride DM129T7 DT Small molecular drug DM129T7 PC 196639 DM129T7 MW 652.6 DM129T7 FM C33H36N2O12 DM129T7 IC InChI=1S/C33H36N2O12/c1-3-41-32(39)27-15-21(36)29-23(10-7-12-25(29)46-27)43-17-19(45-31(38)20(35)9-5-6-14-34)18-44-24-11-8-13-26-30(24)22(37)16-28(47-26)33(40)42-4-2/h7-8,10-13,15-16,19-20H,3-6,9,14,17-18,34-35H2,1-2H3/t20-/m0/s1 DM129T7 CS CCOC(=O)C1=CC(=O)C2=C(O1)C=CC=C2OCC(COC3=CC=CC4=C3C(=O)C=C(O4)C(=O)OCC)OC(=O)[C@H](CCCCN)N DM129T7 IK NGJJDHCBOKNREV-FQEVSTJZSA-N DM129T7 IU ethyl 5-[2-[(2S)-2,6-diaminohexanoyl]oxy-3-(2-ethoxycarbonyl-4-oxochromen-5-yl)oxypropoxy]-4-oxochromene-2-carboxylate DM129T7 CA CAS 110816-79-0 DM129T7 CB CHEBI:31438 DM129T7 DE Asthma DMXU5LZ ID DMXU5LZ DMXU5LZ DN CRS-207 DMXU5LZ HS Phase 2 DMXU5LZ CP Aduro BioTech DMXU5LZ DT Vaccine DMXU5LZ DE Pancreatic cancer; Ovarian cancer; Gastric adenocarcinoma; Mesothelioma DM16IMT ID DM16IMT DM16IMT DN CRYPTOPHYCIN 52 DM16IMT HS Phase 2 DM16IMT SN LY-355703; [3S-(3alpha,10beta,13E,16beta)]-10-(3-Chloro-4-methoxybenzyl)-16-[2(R*),3(R*)-epoxy-1(R)-methyl-3-phenylpropyl]-3-isobutyl-6,6-dimethyl-1,4-dioxa-8,11-diazacyclohexadec-13-ene-2,5,9,12-tetraone DM16IMT DT Small molecular drug DM16IMT PC 9939639 DM16IMT MW 669.2 DM16IMT FM C36H45ClN2O8 DM16IMT IC InChI=1S/C36H45ClN2O8/c1-21(2)17-29-34(42)45-27(22(3)31-32(47-31)24-11-8-7-9-12-24)13-10-14-30(40)39-26(19-23-15-16-28(44-6)25(37)18-23)33(41)38-20-36(4,5)35(43)46-29/h7-12,14-16,18,21-22,26-27,29,31-32H,13,17,19-20H2,1-6H3,(H,38,41)(H,39,40)/b14-10+/t22-,26+,27-,29-,31+,32+/m0/s1 DM16IMT CS C[C@@H]([C@@H]1C/C=C/C(=O)N[C@@H](C(=O)NCC(C(=O)O[C@H](C(=O)O1)CC(C)C)(C)C)CC2=CC(=C(C=C2)OC)Cl)[C@@H]3[C@H](O3)C4=CC=CC=C4 DM16IMT IK LSXOBYNBRKOTIQ-RQUBOUMQSA-N DM16IMT IU (3S,10R,13E,16S)-10-[(3-chloro-4-methoxyphenyl)methyl]-6,6-dimethyl-3-(2-methylpropyl)-16-[(1S)-1-[(2R,3R)-3-phenyloxiran-2-yl]ethyl]-1,4-dioxa-8,11-diazacyclohexadec-13-ene-2,5,9,12-tetrone DM16IMT CA CAS 186256-67-7 DM16IMT DE Solid tumour/cancer DMZCG91 ID DMZCG91 DMZCG91 DN CSL-112 DMZCG91 HS Phase 2 DMZCG91 SN Reconstituted HDL (acute coronary syndrome), CSL DMZCG91 CP Csl DMZCG91 DE Arteriosclerosis; Cardiovascular disease DMQXL1T ID DMQXL1T DMQXL1T DN CT 327 DMQXL1T HS Phase 2 DMQXL1T CP Creabilis Therapeutics DMQXL1T DE Psoriasis vulgaris; Plaque psoriasis DMBRKZ7 ID DMBRKZ7 DMBRKZ7 DN CT1812 DMBRKZ7 HS Phase 2 DMBRKZ7 SN Elayta DMBRKZ7 CP Cognition Therapeutics Pittsburgh, PA DMBRKZ7 PC 118278088 DMBRKZ7 MW 431.6 DMBRKZ7 FM C24H33NO4S DMBRKZ7 IC InChI=1S/C24H33NO4S/c1-23(2,3)29-22-13-17(7-10-21(22)26)11-12-24(4,5)25-15-18-8-9-20(30(6,27)28)14-19(18)16-25/h7-10,13-14,26H,11-12,15-16H2,1-6H3 DMBRKZ7 CS CC(C)(C)OC1=C(C=CC(=C1)CCC(C)(C)N2CC3=C(C2)C=C(C=C3)S(=O)(=O)C)O DMBRKZ7 IK ISQAPFMBJFZOLG-UHFFFAOYSA-N DMBRKZ7 IU 4-[3-methyl-3-(5-methylsulfonyl-1,3-dihydroisoindol-2-yl)butyl]-2-[(2-methylpropan-2-yl)oxy]phenol DMBRKZ7 CA CAS 1802632-22-9 DMBRKZ7 DE Alzheimer disease DMSGYNP ID DMSGYNP DMSGYNP DN CTK0H-9987 DMSGYNP HS Phase 2 DMSGYNP SN Neoprontosil; Neoprontosil, disodium salt; Neoprontsil; PRONTOCIL; ZINC261161909; ZINC28863804; AZOSULFAMIDE; 132-38-7; 2,7-Naphthalenedisulfonic acid, 6-(acetylamino)-3-((4-(aminosulfonyl)phenyl)azo)-4-hydroxy-; 2,7-Naphthalenedisulfonic acid, 6-(acetylamino)-3-[[4-(aminosulfonyl)phenyl]azo]-4-hydroxy-; 2,7-Naphthalenedisulfonic acid, 6-(acetylamino)-3-[[4-(aminosulfonyl)phenyl]azo]-4-hydroxy-, disodium salt; AABSSN; BDBM50221406; CHEMBL237251; CTK0H9987; DTXSID0074500 DMSGYNP PC 8625 DMSGYNP MW 544.5 DMSGYNP FM C18H16N4O10S3 DMSGYNP IC RALNLQYPLYWQRT-UHFFFAOYSA-N DMSGYNP CS CC(=O)NC1=C(C=C2C=C(C(=C(C2=C1)O)N=NC3=CC=C(C=C3)S(=O)(=O)N)S(=O)(=O)O)S(=O)(=O)O DMSGYNP IK 1S/C18H16N4O10S3/c1-9(23)20-14-8-13-10(6-15(14)34(27,28)29)7-16(35(30,31)32)17(18(13)24)22-21-11-2-4-12(5-3-11)33(19,25)26/h2-8,24H,1H3,(H,20,23)(H2,19,25,26)(H,27,28,29)(H,30,31,32) DMSGYNP IU 6-acetamido-4-hydroxy-3-[(4-sulfamoylphenyl)diazenyl]naphthalene-2,7-disulfonic acid DMSGYNP DE Trachoma DMMPC6W ID DMMPC6W DMMPC6W DN CTL019 DMMPC6W HS Phase 2 DMMPC6W CP Novartis Pharmaceuticals DMMPC6W DT CAR T Cell Therapy DMMPC6W DE Acute lymphoblastic leukaemia; Diffuse large B-cell lymphoma; Chronic lymphocytic leukaemia DM3SYOK ID DM3SYOK DM3SYOK DN CTP-543 DM3SYOK HS Phase 2 DM3SYOK CP Concert Pharmaceuticals Lexington, MA DM3SYOK DE Asthma DMBT46Y ID DMBT46Y DMBT46Y DN CTP-543 DMBT46Y HS Phase 2 DMBT46Y SN Deuruxolitinib; D8-ruxolitinib; UNII-0CA0VSF91Y; Deuruxolitinib (USAN); Deuruxolitinib [USAN]; C-21543; (3R)-3-(2,2,3,3,4,4,5,5-octadeuteriocyclopentyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile; 1513883-39-0; CTP543; CHEMBL4594381; SCHEMBL19555526; GTPL11410; WHO 11622; D11866; (3R)-3-(2,2,3,3,4,4,5,5-D8)cyclopentyl-3-(4-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)-1Hpyrazol-1-yl)propanenitrile; H-Pyrazole-1-propanenitrile, beta-(cyclopentyl-2,2,3,3,4,4,5,5-d8)-4-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)-, (betaR)- DMBT46Y CP Concert Pharmaceuticals DMBT46Y DT Small molecular drug DMBT46Y PC 72704611 DMBT46Y MW 314.41 DMBT46Y FM C17H18N6 DMBT46Y IC InChI=1S/C17H18N6/c18-7-5-15(12-3-1-2-4-12)23-10-13(9-22-23)16-14-6-8-19-17(14)21-11-20-16/h6,8-12,15H,1-5H2,(H,19,20,21)/t15-/m1/s1/i1D2,2D2,3D2,4D2 DMBT46Y CS [2H]C1(C(C(C(C1([2H])[2H])([2H])[2H])([2H])[2H])[C@@H](CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3)[2H] DMBT46Y IK HFNKQEVNSGCOJV-FBXGHSCESA-N DMBT46Y IU (3R)-3-(2,2,3,3,4,4,5,5-octadeuteriocyclopentyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile DMBT46Y CA CAS 1513883-39-0 DMBT46Y DE Alopecia DMYPXQ2 ID DMYPXQ2 DMYPXQ2 DN CVBT-141H DMYPXQ2 HS Phase 2 DMYPXQ2 SN CVBT-141A; CVBT-141C; CVBT-141C); Cardio Vascu-Grow; FGF-1-141; Recombinant FGF-1 (coronary heart disease), CardioVascular Therapeutics; Recombinant FGF-1 (peripheral vascular disease), CardioVascular biotherapeutics DMYPXQ2 CP CardioVascular BioTherapeutics Inc; CardioVascular Biotherapeutics DMYPXQ2 DE Coronary artery disease; Peripheral arterial disease; Coronary heart disease DMCN9GX ID DMCN9GX DMCN9GX DN CVX-045 DMCN9GX HS Phase 2 DMCN9GX SN CVX-22; CovX-045; PF-4856882; TSP-1 mimetic (cancer), CovX; Thrombospondin-1 mimetic (cancer), CovX; Thrombospondin-1 mimetic (cancer), Pfizer DMCN9GX CP CovX Pharmaceuticals Inc DMCN9GX DE Solid tumour/cancer DMVZT2I ID DMVZT2I DMVZT2I DN CX-072 DMVZT2I HS Phase 2 DMVZT2I CP CytomX Therapeutics South San Francisco, CA DMVZT2I DT Antibody DMVZT2I DE Solid tumour/cancer; Advanced malignancy; Lymphoma; Medulloblastoma DMS2WB5 ID DMS2WB5 DMS2WB5 DN CX157 DMS2WB5 HS Phase 2 DMS2WB5 SN CX157; O6L62LZJ0Q; CX-157; CX 157; 205187-53-7; UNII-O6L62LZJ0Q; SCHEMBL235650; DTXSID40174517; PDIMOTRDGUQMNY-UHFFFAOYSA-N; HY-100178; CS-0018174; 3-fluoro-7-(2,2,2-trifluoroethoxy)phenoxathiin 10,10-dioxide; Phenoxathiin, 3-fluoro-7-(2,2,2-trifluoroethoxy)-, 10,10-dioxide DMS2WB5 CP CeNeRx Pharma DMS2WB5 DT Small molecular drug DMS2WB5 PC 18687754 DMS2WB5 MW 348.27 DMS2WB5 FM C14H8F4O4S DMS2WB5 IC InChI=1S/C14H8F4O4S/c15-8-1-3-12-10(5-8)22-11-6-9(21-7-14(16,17)18)2-4-13(11)23(12,19)20/h1-6H,7H2 DMS2WB5 CS C1=CC2=C(C=C1OCC(F)(F)F)OC3=C(S2(=O)=O)C=CC(=C3)F DMS2WB5 IK PDIMOTRDGUQMNY-UHFFFAOYSA-N DMS2WB5 IU 3-fluoro-7-(2,2,2-trifluoroethoxy)phenoxathiine 10,10-dioxide DMS2WB5 CA CAS 205187-53-7 DMS2WB5 DE Mood disorder DMJD7H4 ID DMJD7H4 DMJD7H4 DN CX-1739 DMJD7H4 HS Phase 2 DMJD7H4 SN CX-1739 (injectable/AMPAKINE, respiratory depression); CX-717 follow-on compound (AMPAKINE), Cortex Pharmaceuticals; CX-1739 (injectable/AMPAKINE, respiratory depression), Biovail Laboratories; CX-1739 (injectable/AMPAKINE, respiratory depression), Cortex Pharmaceuticals; CX-1739 (injectable/AMPAKINE, respiratory depression), Valeant DMJD7H4 CP Cortex Pharmaceuticals Inc DMJD7H4 DE Attention deficit hyperactivity disorder DMA5D6T ID DMA5D6T DMA5D6T DN CX1789 DMA5D6T HS Phase 2 DMA5D6T CP RespireRx Pharmaceuticals Glen Rock, NJ DMA5D6T DE Obstructive sleep apnea DMU62I8 ID DMU62I8 DMU62I8 DN CX2009 DMU62I8 HS Phase 2 DMU62I8 CP CytomX Therapeutics DMU62I8 DT Probody drug conjugate DMU62I8 DE Solid tumour/cancer; Neoplasm DMWE7B9 ID DMWE7B9 DMWE7B9 DN CX-4945 DMWE7B9 HS Phase 2 DMWE7B9 SN 1009820-21-6; Silmitasertib; CX-4945; 5-((3-Chlorophenyl)amino)benzo[c][2,6]naphthyridine-8-carboxylic acid; CX4945; CX-4945 (Silmitasertib); CX 4945; UNII-C6RWP0N0L2; 5-[(3-chlorophenyl)amino]-Benzo[c]-2,6-naphthyridine-8-carboxylic acid; 5-(3-chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic acid; C6RWP0N0L2; CHEMBL1230165; AK-82006; 5-[(3-Chlorophenyl)amino]benzo[c][2,6]naphthyridine-8-Carboxylic Acid; 5-((3-Chlorophenyl)amino)benzo-[c][2,6]naphthyridine-8-carboxylic acid; C19H12ClN3O2; W-204393 DMWE7B9 CP Cylene Pharmaceuticals DMWE7B9 DT Small molecular drug DMWE7B9 PC 24748573 DMWE7B9 MW 349.8 DMWE7B9 FM C19H12ClN3O2 DMWE7B9 IC InChI=1S/C19H12ClN3O2/c20-12-2-1-3-13(9-12)22-18-15-6-7-21-10-16(15)14-5-4-11(19(24)25)8-17(14)23-18/h1-10H,(H,22,23)(H,24,25) DMWE7B9 CS C1=CC(=CC(=C1)Cl)NC2=NC3=C(C=CC(=C3)C(=O)O)C4=C2C=CN=C4 DMWE7B9 IK MUOKSQABCJCOPU-UHFFFAOYSA-N DMWE7B9 IU 5-(3-chloroanilino)benzo[c][2,6]naphthyridine-8-carboxylic acid DMWE7B9 CA CAS 1009820-21-6 DMWE7B9 DE Solid tumour/cancer; Cholangiocarcinoma; Coronavirus infection DMM65W1 ID DMM65W1 DMM65W1 DN CX-717 DMM65W1 HS Phase 2 DMM65W1 SN CX-1763; CX-546; CX-614; CX-727; CX-729; CX-743; CX-815; S-40929; First generation AMPA receptor modulators, Cortex/University of California; First-generation AMPAKINE compounds, University of California/Cortex DMM65W1 CP University of California DMM65W1 DT Small molecular drug DMM65W1 PC 3323368 DMM65W1 MW 233.22 DMM65W1 FM C11H11N3O3 DMM65W1 IC InChI=1S/C11H11N3O3/c15-11(14-3-5-16-6-4-14)8-1-2-9-10(7-8)13-17-12-9/h1-2,7H,3-6H2 DMM65W1 CS C1COCCN1C(=O)C2=CC3=NON=C3C=C2 DMM65W1 IK KFRQROSRKSVROW-UHFFFAOYSA-N DMM65W1 IU 2,1,3-benzoxadiazol-5-yl(morpholin-4-yl)methanone DMM65W1 CA CAS 211735-82-9 DMM65W1 DE Alzheimer disease; Spinal cord injury DM3GEHC ID DM3GEHC DM3GEHC DN CX-8998 DM3GEHC HS Phase 2 DM3GEHC CP Cavion Charlottesville, VA DM3GEHC DE Epilepsy; Essential tremor or related tremors; Parkinson disease DMM7Z6K ID DMM7Z6K DMM7Z6K DN CXA10 DMM7Z6K HS Phase 2 DMM7Z6K CP Complexa DMM7Z6K DT Small molecular drug DMM7Z6K DE Pulmonary arterial hypertension; Focal segmental glomerulosclerosis DM3JFZ2 ID DM3JFZ2 DM3JFZ2 DN CXL DM3JFZ2 HS Phase 2 DM3JFZ2 SN CYCLOHEXANOL; 108-93-0; Cyclohexyl alcohol; Hexahydrophenol; Hydrophenol; Hydroxycyclohexane; Hexalin; 1-Cyclohexanol; Hydralin; Adronal; Naxol; Adronol; Anol; Cykloheksanol; Cicloesanolo; Phenol, hexahydro-; Cicloesanolo [Italian]; Cykloheksanol [Polish]; Cyclohexanone cyclohexanol mixture; Cyclohexan-1-ol; HSDB 61; NSC 403656; UNII-8E7S519M3P; CCRIS 5896; EINECS 203-630-6; BRN 0906744; AI3-00040; CHEBI:18099; HPXRVTGHNJAIIH-UHFFFAOYSA-N; 8E7S519M3P; MFCD00003855; Cyclohexanol, 98%; CXL; Cyclohexanols; DSSTox_CID_1894; DSSTox_RID_76390 DM3JFZ2 CP AstraZeneca DM3JFZ2 DT Small molecular drug DM3JFZ2 PC 7966 DM3JFZ2 MW 100.16 DM3JFZ2 FM C6H12O DM3JFZ2 IC InChI=1S/C6H12O/c7-6-4-2-1-3-5-6/h6-7H,1-5H2 DM3JFZ2 CS C1CCC(CC1)O DM3JFZ2 IK HPXRVTGHNJAIIH-UHFFFAOYSA-N DM3JFZ2 IU cyclohexanol DM3JFZ2 CA CAS 108-93-0 DM3JFZ2 CB CHEBI:18099 DM3JFZ2 DE Methicillin-resistant staphylococci infection DMXR8WN ID DMXR8WN DMXR8WN DN CYCLOPLATAM DMXR8WN HS Phase 2 DMXR8WN SN Ammine(cyclopentanamine)[(S)-hydroxybutanedioato(2-)-O1,O4]platinum; (S)-(-)-Malatoammine(cyclopentylamine)platinum (II) DMXR8WN DT Small molecular drug DMXR8WN PC 3035239 DMXR8WN MW 429.33 DMXR8WN FM C9H18N2O5Pt DMXR8WN IC InChI=1S/C5H11N.C4H6O5.H3N.Pt/c6-5-3-1-2-4-5;5-2(4(8)9)1-3(6)7;;/h5H,1-4,6H2;2,5H,1H2,(H,6,7)(H,8,9);1H3;/q;;;+2/p-2 DMXR8WN CS C1CCC(C1)N.C(C(C(=O)[O-])O)C(=O)[O-].N.[Pt+2] DMXR8WN IK OPWOOOGFNULJAQ-UHFFFAOYSA-L DMXR8WN IU azane;cyclopentanamine;2-hydroxybutanedioate;platinum(2+) DMXR8WN CA CAS 109837-67-4 DMXR8WN DE Solid tumour/cancer DM0DT45 ID DM0DT45 DM0DT45 DN CYSTEMUSTINE DM0DT45 HS Phase 2 DM0DT45 SN CMSO2EN2; N-(2-Chloroethyl)-N'-[2-(methylsulfonyl)ethyl]-N-nitrosourea DM0DT45 DT Small molecular drug DM0DT45 PC 119545 DM0DT45 MW 257.7 DM0DT45 FM C6H12ClN3O4S DM0DT45 IC InChI=1S/C6H12ClN3O4S/c1-15(13,14)5-3-8-6(11)10(9-12)4-2-7/h2-5H2,1H3,(H,8,11) DM0DT45 CS CS(=O)(=O)CCNC(=O)N(CCCl)N=O DM0DT45 IK IUOVOJHLRFQQNS-UHFFFAOYSA-N DM0DT45 IU 1-(2-chloroethyl)-3-(2-methylsulfonylethyl)-1-nitrosourea DM0DT45 CA CAS 79955-36-5 DM0DT45 DE Solid tumour/cancer DMMWIHC ID DMMWIHC DMMWIHC DN CYT 99007 DMMWIHC HS Phase 2 DMMWIHC CP Cytheris DMMWIHC TC Anticancer Agents DMMWIHC DE Acquired immune deficiency syndrome DM4LJH8 ID DM4LJH8 DM4LJH8 DN CYT003 DM4LJH8 HS Phase 2 DM4LJH8 DE Asthma DMIRSWE ID DMIRSWE DMIRSWE DN CYT-006-AngQb DMIRSWE HS Phase 2 DMIRSWE SN AngQb; Immunodrug vaccines (hypertension), Cytos DMIRSWE CP Cytos Biotechnology AG DMIRSWE DT Vaccine DMIRSWE DE Hypertension DMUDMHA ID DMUDMHA DMUDMHA DN CZEN-002 DMUDMHA HS Phase 2 DMUDMHA SN Bis(N-acetyl-L-cysteinyl-L-lysyl-L-prolyl-L-valinamide) disulfide DMUDMHA DT Small molecular drug DMUDMHA PC 16133793 DMUDMHA MW 1664.9 DMUDMHA FM C77H109N21O19S DMUDMHA IC InChI=1S/C77H109N21O19S/c1-42(2)64(65(79)106)97-75(116)61-20-13-30-98(61)76(117)54(18-10-11-28-78)88-62(103)38-85-66(107)57(34-46-36-84-50-17-9-8-16-49(46)50)94-67(108)51(19-12-29-83-77(80)81)89-70(111)55(32-44-14-6-5-7-15-44)92-72(113)58(35-47-37-82-41-86-47)95-68(109)52(25-26-63(104)105)90-69(110)53(27-31-118-4)91-74(115)60(40-100)96-71(112)56(33-45-21-23-48(102)24-22-45)93-73(114)59(39-99)87-43(3)101/h5-9,14-17,21-24,36-37,41-42,51-61,64,84,99-100,102H,10-13,18-20,25-35,38-40,78H2,1-4H3,(H2,79,106)(H,82,86)(H,85,107)(H,87,101)(H,88,103)(H,89,111)(H,90,110)(H,91,115)(H,92,113)(H,93,114)(H,94,108)(H,95,109)(H,96,112)(H,97,116)(H,104,105)(H4,80,81,83)/t51-,52-,53-,54-,55-,56-,57-,58-,59-,60-,61-,64-/m0/s1 DMUDMHA CS CC(C)[C@@H](C(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CC2=CNC3=CC=CC=C32)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC4=CC=CC=C4)NC(=O)[C@H](CC5=CNC=N5)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CO)NC(=O)[C@H](CC6=CC=C(C=C6)O)NC(=O)[C@H](CO)NC(=O)C DMUDMHA IK WHNFPRLDDSXQCL-UAZQEYIDSA-N DMUDMHA IU (4S)-4-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-6-amino-1-[(2S)-2-[[(2S)-1-amino-3-methyl-1-oxobutan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxohexan-2-yl]amino]-2-oxoethyl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid DMUDMHA CA CAS 581-05-5 DMUDMHA DE Fungal infection DMP6MH9 ID DMP6MH9 DMP6MH9 DN DA-8031 DMP6MH9 HS Phase 2 DMP6MH9 SN Serotonin transporter inhibitor (premature ejaculation), Dong A DMP6MH9 CP Dong-A Pharmaceutical Co Ltd DMP6MH9 DE Premature ejaculation DMACTBM ID DMACTBM DMACTBM DN DAC-060 DMACTBM HS Phase 2 DMACTBM SN DAC-0060; DAC-60; HDAC inhibitor (topical, skin cancer/actinic keratosis), DAC DMACTBM CP DAC Srl DMACTBM DE Keratosis DM2U45Q ID DM2U45Q DM2U45Q DN Danegaptide DM2U45Q HS Phase 2 DM2U45Q SN SCHEMBL2399760; BCP17534; ZP 1609 DM2U45Q CP Pfizer; Zealand Pharma DM2U45Q DT Small molecular drug DM2U45Q PC 16656685 DM2U45Q MW 291.3 DM2U45Q FM C14H17N3O4 DM2U45Q IC InChI=1S/C14H17N3O4/c15-7-12(18)17-8-10(6-11(17)14(20)21)16-13(19)9-4-2-1-3-5-9/h1-5,10-11H,6-8,15H2,(H,16,19)(H,20,21)/t10-,11+/m1/s1 DM2U45Q CS C1[C@H](CN([C@@H]1C(=O)O)C(=O)CN)NC(=O)C2=CC=CC=C2 DM2U45Q IK BIZKIHUJGMSVFD-MNOVXSKESA-N DM2U45Q IU (2S,4R)-1-(2-aminoacetyl)-4-benzamidopyrrolidine-2-carboxylic acid DM2U45Q CA CAS 943134-39-2 DM2U45Q DE Atrial fibrillation DM20MDU ID DM20MDU DM20MDU DN Danoprevir DM20MDU HS Phase 2 DM20MDU SN 850876-88-9; Danoprevir (USAN/INN) DM20MDU CP InterMune; Genentech DM20MDU DT Small molecular drug DM20MDU PC 11285588 DM20MDU MW 731.8 DM20MDU FM C35H46FN5O9S DM20MDU IC InChI=1S/C35H46FN5O9S/c1-34(2,3)50-32(45)37-27-13-8-6-4-5-7-11-22-17-35(22,31(44)39-51(47,48)24-14-15-24)38-29(42)28-16-23(19-41(28)30(27)43)49-33(46)40-18-21-10-9-12-26(36)25(21)20-40/h7,9-12,22-24,27-28H,4-6,8,13-20H2,1-3H3,(H,37,45)(H,38,42)(H,39,44)/b11-7-/t22-,23-,27+,28+,35-/m1/s1 DM20MDU CS CC(C)(C)OC(=O)N[C@H]1CCCCC/C=C\\[C@@H]2C[C@]2(NC(=O)[C@@H]3C[C@H](CN3C1=O)OC(=O)N4CC5=C(C4)C(=CC=C5)F)C(=O)NS(=O)(=O)C6CC6 DM20MDU IK ZVTDLPBHTSMEJZ-JSZLBQEHSA-N DM20MDU IU [(1S,4R,6S,7Z,14S,18R)-4-(cyclopropylsulfonylcarbamoyl)-14-[(2-methylpropan-2-yl)oxycarbonylamino]-2,15-dioxo-3,16-diazatricyclo[14.3.0.04,6]nonadec-7-en-18-yl] 4-fluoro-1,3-dihydroisoindole-2-carboxylate DM20MDU CA CAS 850876-88-9 DM20MDU DE Hepatitis C virus infection DM7IH48 ID DM7IH48 DM7IH48 DN Dapansutrile DM7IH48 HS Phase 2 DM7IH48 SN 54863-37-5; OLT1177; UNII-2Z03364G96; 2Z03364G96; Dapansutrile [INN]; Dapansutrile [USAN:INN]; Dapansutrile (USAN/INN); 3-Methylsulfonylpropionitrile; 3-methanesulfonylpropanenitrile; 3-methylsulphonyl-propionitrile; SCHEMBL9934796; CHEMBL3989943; LQFRYKBDZNPJSW-UHFFFAOYSA-N; MolPort-008-545-498; ZINC32005410; Propanenitrile, 3-(methylsulfonyl)-; AKOS010140086; D10920; Z2719319073 DM7IH48 CP Olatec Therapeutics New York, NY DM7IH48 PC 12714644 DM7IH48 MW 133.17 DM7IH48 FM C4H7NO2S DM7IH48 IC InChI=1S/C4H7NO2S/c1-8(6,7)4-2-3-5/h2,4H2,1H3 DM7IH48 CS CS(=O)(=O)CCC#N DM7IH48 IK LQFRYKBDZNPJSW-UHFFFAOYSA-N DM7IH48 IU 3-methylsulfonylpropanenitrile DM7IH48 CA CAS 54863-37-5 DM7IH48 DE Acute gout flare; Musculoskeletal pain DMIYFWA ID DMIYFWA DMIYFWA DN Dapirolizumab pegol DMIYFWA HS Phase 2 DMIYFWA CP Biogen Cambridge, MAUCBSmyrna, GA DMIYFWA DE Systemic lupus erythematosus DMR5J6K ID DMR5J6K DMR5J6K DN DAPITANT DMR5J6K HS Phase 2 DMR5J6K SN CHEMBL2103951 DMR5J6K DT Small molecular drug DMR5J6K PC 132961 DMR5J6K MW 561.7 DMR5J6K FM C37H39NO4 DMR5J6K IC InChI=1S/C37H39NO4/c1-26(29-18-10-12-20-33(29)41-2)35(39)38-24-31-32(25-38)37(40,30-19-11-13-21-34(30)42-3)23-22-36(31,27-14-6-4-7-15-27)28-16-8-5-9-17-28/h4-21,26,31-32,40H,22-25H2,1-3H3/t26-,31-,32+,37+/m0/s1 DMR5J6K CS C[C@@H](C1=CC=CC=C1OC)C(=O)N2C[C@@H]3[C@H](C2)C(CC[C@]3(C4=CC=CC=C4OC)O)(C5=CC=CC=C5)C6=CC=CC=C6 DMR5J6K IK CCIWVEMVBWEMCY-RCFOMQFPSA-N DMR5J6K IU (2S)-1-[(3aS,4S,7aS)-4-hydroxy-4-(2-methoxyphenyl)-7,7-diphenyl-1,3,3a,5,6,7a-hexahydroisoindol-2-yl]-2-(2-methoxyphenyl)propan-1-one DMR5J6K CA CAS 153438-49-4 DMR5J6K DE Pain DMCU74R ID DMCU74R DMCU74R DN Daporinad DMCU74R HS Phase 2 DMCU74R SN APO-866; FK-866; WK-175 DMCU74R CP Astellas Pharma GmbH DMCU74R DT Small molecular drug DMCU74R PC 6914657 DMCU74R MW 391.5 DMCU74R FM C24H29N3O2 DMCU74R IC InChI=1S/C24H29N3O2/c28-23(12-11-21-8-6-15-25-19-21)26-16-5-4-7-20-13-17-27(18-14-20)24(29)22-9-2-1-3-10-22/h1-3,6,8-12,15,19-20H,4-5,7,13-14,16-18H2,(H,26,28)/b12-11+ DMCU74R CS C1CN(CCC1CCCCNC(=O)/C=C/C2=CN=CC=C2)C(=O)C3=CC=CC=C3 DMCU74R IK KPBNHDGDUADAGP-VAWYXSNFSA-N DMCU74R IU (E)-N-[4-(1-benzoylpiperidin-4-yl)butyl]-3-pyridin-3-ylprop-2-enamide DMCU74R CA CAS 658084-64-1 DMCU74R CB CHEBI:94671 DMCU74R DE leukaemia DM0Y8JP ID DM0Y8JP DM0Y8JP DN DAS-181 DM0Y8JP HS Phase 2 DM0Y8JP SN Fludase; NEX-DAS-181; Enzyme-based therapy (Tosap, influenza), NexBio DM0Y8JP CP Nexbio DM0Y8JP DE Influenza virus infection DMM3BPL ID DMM3BPL DMM3BPL DN DAS-431 DMM3BPL HS Phase 2 DMM3BPL CP DrugAbuse Sciences DMM3BPL DE Dementia DM7JV4O ID DM7JV4O DM7JV4O DN DB-041901 DM7JV4O HS Phase 2 DM7JV4O SN Pursennid; Senekot; Senna-lax; Sennaglucosides; Sennosides; Sennoside A&B; Sennoside [JAN]; Sennosides A and B; sennoside; (9,9'-Bianthracene)-2,2'-dicarboxylic acid, 5,5'-bis(beta-D-glucopyranosyloxy)-9,9',10,10'-tetrahydro-4,4'-dihydroxy-10,10'-dioxo-; 5,5'-Bis(beta-D-glucopyranosyloxy)-4,4'-dihydroxy(9,9'-bianthrachinon)-2,2'-dicarbonsaeure; 5,5'-Bis(beta-D-glucopyranosyloxy)-9,9',10,10'-tetrahydro-4,4'-dihydroxy-10,10'-dioxo(9,9'-bianthracene)-2,2'-dicarboxylic acid; 517-43-1; C42H38O20; EINECS 208-238-9; SENNA DM7JV4O PC 5199 DM7JV4O MW 862.7 DM7JV4O FM C42H38O20 DM7JV4O IC IPQVTOJGNYVQEO-UHFFFAOYSA-N DM7JV4O CS C1=CC2=C(C(=C1)OC3C(C(C(C(O3)CO)O)O)O)C(=O)C4=C(C2C5C6=C(C(=CC=C6)OC7C(C(C(C(O7)CO)O)O)O)C(=O)C8=C5C=C(C=C8O)C(=O)O)C=C(C=C4O)C(=O)O DM7JV4O IK 1S/C42H38O20/c43-11-23-31(47)35(51)37(53)41(61-23)59-21-5-1-3-15-25(17-7-13(39(55)56)9-19(45)27(17)33(49)29(15)21)26-16-4-2-6-22(60-42-38(54)36(52)32(48)24(12-44)62-42)30(16)34(50)28-18(26)8-14(40(57)58)10-20(28)46/h1-10,23-26,31-32,35-38,41-48,51-54H,11-12H2,(H,55,56)(H,57,58) DM7JV4O IU 9-[2-carboxy-4-hydroxy-10-oxo-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-9H-anthracen-9-yl]-4-hydroxy-10-oxo-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-9H-anthracene-2-carboxylic acid DM7JV4O CA CAS 517-43-1 DM7JV4O DE Opioid-induced constipation DMQRCX5 ID DMQRCX5 DMQRCX5 DN DCDS-4501A DMQRCX5 HS Phase 2 DMQRCX5 CP Genentech DMQRCX5 DT Antibody DMQRCX5 DE Diffuse large B-cell lymphoma; Non-hodgkin lymphoma DMCHWX1 ID DMCHWX1 DMCHWX1 DN DCR-PHXC DMCHWX1 HS Phase 2 DMCHWX1 SN nedosiran DMCHWX1 CP Dicerna Pharmaceuticals DMCHWX1 DT Small interfering RNA DMCHWX1 DE Hyperoxaluria DM9REBL ID DM9REBL DM9REBL DN DDP-225 DM9REBL HS Phase 2 DM9REBL SN AA-10021; AA-10025; AA-10026; 4-(2-fluorophenyl)-6-methyl-2-piperazin-1-ylthieno[2,3-d]pyrimidine hydrate hydrochloride DM9REBL CP Dynogen DM9REBL DT Small molecular drug DM9REBL PC 6918194 DM9REBL MW 382.9 DM9REBL FM C17H20ClFN4OS DM9REBL IC InChI=1S/C17H17FN4S.ClH.H2O/c1-11-10-13-15(12-4-2-3-5-14(12)18)20-17(21-16(13)23-11)22-8-6-19-7-9-22;;/h2-5,10,19H,6-9H2,1H3;1H;1H2 DM9REBL CS CC1=CC2=C(N=C(N=C2S1)N3CCNCC3)C4=CC=CC=C4F.O.Cl DM9REBL IK SAURKKOJWIFYSR-UHFFFAOYSA-N DM9REBL IU 4-(2-fluorophenyl)-6-methyl-2-piperazin-1-ylthieno[2,3-d]pyrimidine;hydrate;hydrochloride DM9REBL CA CAS 476148-82-0 DM9REBL DE Chronic functional vomiting; Irritable bowel syndrome DM5XT3G ID DM5XT3G DM5XT3G DN DE-098 DM5XT3G HS Phase 2 DM5XT3G SN ARG-098; Anti-Fas antibody, Santen; Anti-APO-1 antibody, Santen DM5XT3G CP Centocor Ortho Biotech Inc DM5XT3G DT Antibody DM5XT3G DE Rheumatoid arthritis DMCQL5I ID DMCQL5I DMCQL5I DN DE-110 DMCQL5I HS Phase 2 DMCQL5I SN Selective glucocorticoid receptor agonist (allergy), Santen DMCQL5I CP Santen Pharmaceutical Co Ltd DMCQL5I DE Xerophthalmia DMZW50O ID DMZW50O DMZW50O DN Debio 1347 DMZW50O HS Phase 2 DMZW50O CP Debiopharm DMZW50O PC 66555680 DMZW50O MW 356.4 DMZW50O FM C20H16N6O DMZW50O IC InChI=1S/C20H16N6O/c1-11-23-16-7-6-13(9-17(16)24-11)26-20(21)14(10-22-26)19(27)18-8-12-4-2-3-5-15(12)25-18/h2-10,25H,21H2,1H3,(H,23,24) DMZW50O CS CC1=NC2=C(N1)C=C(C=C2)N3C(=C(C=N3)C(=O)C4=CC5=CC=CC=C5N4)N DMZW50O IK BEMNJULZEQTDJY-UHFFFAOYSA-N DMZW50O IU [5-amino-1-(2-methyl-3H-benzimidazol-5-yl)pyrazol-4-yl]-(1H-indol-2-yl)methanone DMZW50O CA CAS 1265229-25-1 DMZW50O DE Breast cancer; Solid tumour/cancer DM1H7UK ID DM1H7UK DM1H7UK DN Dectrekumab DM1H7UK HS Phase 2 DM1H7UK SN QAX-576 DM1H7UK DT Antibody DM1H7UK DE Idiopathic pulmonary fibrosis DMX4DQH ID DMX4DQH DMX4DQH DN Delanzomib DMX4DQH HS Phase 2 DMX4DQH SN ((R)-1-((2S,3R)-3-hydroxy-2-(6-phenylpicolinamido)butanamido)-3-methylbutan-2-yl)boronic acid; s1157; ZINC202536926; SB16695; SW219161-1; boronic acid, b-[(1r)-1-[[(2s,3r)-3-hydroxy-1-oxo-2-[[(6-phenyl-2-pyridinyl)carbonyl]amino]butyl]amino]-3-methylbutyl]- DMX4DQH CP Cephalon DMX4DQH DT Small molecular drug DMX4DQH PC 24800541 DMX4DQH MW 413.3 DMX4DQH FM C21H28BN3O5 DMX4DQH IC InChI=1S/C21H28BN3O5/c1-13(2)12-18(22(29)30)24-21(28)19(14(3)26)25-20(27)17-11-7-10-16(23-17)15-8-5-4-6-9-15/h4-11,13-14,18-19,26,29-30H,12H2,1-3H3,(H,24,28)(H,25,27)/t14-,18+,19+/m1/s1 DMX4DQH CS B([C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)C1=CC=CC(=N1)C2=CC=CC=C2)(O)O DMX4DQH IK SJFBTAPEPRWNKH-CCKFTAQKSA-N DMX4DQH IU [(1R)-1-[[(2S,3R)-3-hydroxy-2-[(6-phenylpyridine-2-carbonyl)amino]butanoyl]amino]-3-methylbutyl]boronic acid DMX4DQH CA CAS 847499-27-8 DMX4DQH CB CHEBI:141530 DMX4DQH DE Multiple myeloma DMS2WIN ID DMS2WIN DMS2WIN DN Delphinidin DMS2WIN HS Phase 2 DMS2WIN SN IdB-1056; 3,3',4',5,5',7-Hexahydroxy-2-phenylbenzopyrylium chloride; 3,3',4',5,5',7-Hexahydroxyflavylium chloride;3,5,7-Trihydroxy-2-(3,4,5-trihydroxyphenyl)-1-benzopyrilium chloride DMS2WIN DT Small molecular drug DMS2WIN PC 68245 DMS2WIN MW 338.69 DMS2WIN FM C15H11ClO7 DMS2WIN IC InChI=1S/C15H10O7.ClH/c16-7-3-9(17)8-5-12(20)15(22-13(8)4-7)6-1-10(18)14(21)11(19)2-6;/h1-5H,(H5-,16,17,18,19,20,21);1H DMS2WIN CS C1=C(C=C(C(=C1O)O)O)C2=[O+]C3=CC(=CC(=C3C=C2O)O)O.[Cl-] DMS2WIN IK FFNDMZIBVDSQFI-UHFFFAOYSA-N DMS2WIN IU 2-(3,4,5-trihydroxyphenyl)chromenylium-3,5,7-triol;chloride DMS2WIN CA CAS 8012-95-1 DMS2WIN CB CHEBI:38701 DMS2WIN DE Cardiovascular disease DM5CB8U ID DM5CB8U DM5CB8U DN DELTIBANT DM5CB8U HS Phase 2 DM5CB8U SN CP-0127; Deltibant < Prop INN; SB-238592; Bradycor (Cortech, US); S,S'-(Hexane-1,6-diyl)bis(succinimide-1,3-diyl)bis[D-arginyl-L-arginyl-L-prolyl-(4-hydroxy)-L-prolyl-glycyl-L-phenylalanyl-L-cysteinyl-D-phenylalanyl-L-leucyl-L-arginine] DM5CB8U PC 70697628 DM5CB8U MW 2805.3 DM5CB8U FM C128H194N40O28S2 DM5CB8U IC InChI=1S/C128H194N40O28S2/c1-71(2)55-85(105(177)155-83(121(193)194)41-25-49-147-127(139)140)157-109(181)89(59-75-33-15-9-16-34-75)159-111(183)91(161-107(179)87(57-73-29-11-7-12-30-73)151-99(171)65-149-113(185)95-61-77(169)67-167(95)117(189)93-43-27-53-163(93)115(187)81(39-23-47-145-125(135)136)153-103(175)79(129)37-21-45-143-123(131)132)69-197-97-63-101(173)165(119(97)191)51-19-5-6-20-52-166-102(174)64-98(120(166)192)198-70-92(112(184)160-90(60-76-35-17-10-18-36-76)110(182)158-86(56-72(3)4)106(178)156-84(122(195)196)42-26-50-148-128(141)142)162-108(180)88(58-74-31-13-8-14-32-74)152-100(172)66-150-114(186)96-62-78(170)68-168(96)118(190)94-44-28-54-164(94)116(188)82(40-24-48-146-126(137)138)154-104(176)80(130)38-22-46-144-124(133)134/h7-18,29-36,71-72,77-98,169-170H,5-6,19-28,37-70,129-130H2,1-4H3,(H,149,185)(H,150,186)(H,151,171)(H,152,172)(H,153,175)(H,154,176)(H,155,177)(H,156,178)(H,157,181)(H,158,182)(H,159,183)(H,160,184)(H,161,179)(H,162,180)(H,193,194)(H,195,196)(H4,131,132,143)(H4,133,134,144)(H4,135,136,145)(H4,137,138,146)(H4,139,140,147)(H4,141,142,148)/t77-,78-,79-,80-,81+,82+,83+,84+,85+,86+,87+,88+,89-,90-,91+,92+,93+,94+,95+,96+,97-,98+/m1/s1 DM5CB8U CS CC(C)C[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)NC(=O)[C@@H](CC1=CC=CC=C1)NC(=O)[C@H](CS[C@@H]2CC(=O)N(C2=O)CCCCCCN3C(=O)C[C@@H](C3=O)SC[C@@H](C(=O)N[C@H](CC4=CC=CC=C4)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)CNC(=O)[C@@H]6C[C@H](CN6C(=O)[C@@H]7CCCN7C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)N)O)NC(=O)[C@H](CC8=CC=CC=C8)NC(=O)CNC(=O)[C@@H]9C[C@H](CN9C(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)N)O DM5CB8U IK JKUYFMHGTOPVMR-WQVVEKGHSA-N DM5CB8U IU (2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2S)-2-[[2-[[(2S,4R)-1-[(2S)-1-[(2S)-2-[[(2R)-2-amino-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]-4-hydroxypyrrolidine-2-carbonyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-[(3S)-1-[6-[(3R)-3-[(2R)-2-[[(2S)-2-[[2-[[(2S,4R)-1-[(2S)-1-[(2S)-2-[[(2R)-2-amino-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]-4-hydroxypyrrolidine-2-carbonyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-[[(2R)-1-[[(2S)-1-[[(1S)-4-carbamimidamido-1-carboxybutyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-oxopropyl]sulfanyl-2,5-dioxopyrrolidin-1-yl]hexyl]-2,5-dioxopyrrolidin-3-yl]sulfanylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]-5-carbamimidamidopentanoic acid DM5CB8U CA CAS 140661-97-8 DM5CB8U DE Sepsis DML4PMG ID DML4PMG DML4PMG DN Dendritic cell vaccine DML4PMG HS Phase 2 DML4PMG SN Dendritic cell vaccine, University of Bonn; Human telomerase reverse transcriptase (hTERT)-pulsed dendritic cells (cancer), University of Bonn DML4PMG CP University of Bonn DML4PMG DT Vaccine DML4PMG DE Ovarian cancer DM7GPMB ID DM7GPMB DM7GPMB DN Depatuxizumab DM7GPMB HS Phase 2 DM7GPMB CP AbbVieNorth Chicago, IL DM7GPMB DE Solid tumour/cancer; Glioblastoma of brain DMH96JW ID DMH96JW DMH96JW DN Dersalazine DMH96JW HS Phase 2 DMH96JW SN UR-12715; UR-12746 DMH96JW CP Grupo Uriach DMH96JW DT Small molecular drug DMH96JW PC 135484128 DMH96JW MW 600.7 DMH96JW FM C35H32N6O4 DMH96JW IC InChI=1S/C35H32N6O4/c1-23-37-31-21-36-16-13-32(31)41(23)22-24-14-17-40(18-15-24)34(43)20-29(25-5-3-2-4-6-25)26-7-9-27(10-8-26)38-39-28-11-12-33(42)30(19-28)35(44)45/h2-13,16,19-21,24,42H,14-15,17-18,22H2,1H3,(H,44,45)/b29-20-,39-38? DMH96JW CS CC1=NC2=C(N1CC3CCN(CC3)C(=O)/C=C(/C4=CC=CC=C4)\\C5=CC=C(C=C5)N=NC6=CC(=C(C=C6)O)C(=O)O)C=CN=C2 DMH96JW IK AYEAMZDTWLXZIJ-JEFTWCRZSA-N DMH96JW IU 2-hydroxy-5-[[4-[(Z)-3-[4-[(2-methylimidazo[4,5-c]pyridin-1-yl)methyl]piperidin-1-yl]-3-oxo-1-phenylprop-1-enyl]phenyl]diazenyl]benzoic acid DMH96JW CA CAS 188913-58-8 DMH96JW DE Inflammatory bowel disease DM63P1W ID DM63P1W DM63P1W DN Descartes-08 DM63P1W HS Phase 2 DM63P1W CP Cartesian Therapeutics DM63P1W DT CAR T Cell Therapy DM63P1W DE Multiple myeloma DM1UO4S ID DM1UO4S DM1UO4S DN Descartes-11 DM1UO4S HS Phase 2 DM1UO4S CP Cartesian Therapeutics DM1UO4S DT CAR T Cell Therapy DM1UO4S DE Multiple myeloma DMTY4KN ID DMTY4KN DMTY4KN DN Dexefaroxan DMTY4KN HS Phase 2 DMTY4KN SN Dexefaroxan [INN]; (+)-(r)-2-(2-ethyl-2,3-dihydro-2-benzofuranyl)-2-imidazoline; 2-[(2R)-2-ethyl-3H-1-benzofuran-2-yl]-4,5-dihydro-1H-imidazole DMTY4KN CP Pierre Fabre DMTY4KN DT Small molecular drug DMTY4KN PC 208820 DMTY4KN MW 216.28 DMTY4KN FM C13H16N2O DMTY4KN IC InChI=1S/C13H16N2O/c1-2-13(12-14-7-8-15-12)9-10-5-3-4-6-11(10)16-13/h3-6H,2,7-9H2,1H3,(H,14,15)/t13-/m1/s1 DMTY4KN CS CC[C@@]1(CC2=CC=CC=C2O1)C3=NCCN3 DMTY4KN IK RATZLMXRALDSJW-CYBMUJFWSA-N DMTY4KN IU 2-[(2R)-2-ethyl-3H-1-benzofuran-2-yl]-4,5-dihydro-1H-imidazole DMTY4KN CA CAS 143249-88-1 DMTY4KN DE Schizophrenia; Parkinson disease DM52HUD ID DM52HUD DM52HUD DN Dexloxiglumide DM52HUD HS Phase 2 DM52HUD SN Dexloxiglumide; 119817-90-2; (R)-4-(3,4-Dichlorobenzamido)-5-((3-methoxypropyl)(pentyl)amino)-5-oxopentanoic acid; UNII-69DY40RH9B; CR-2017; 69DY40RH9B; Dexloxiglumidum; Dexloxiglumida; Dexloxiglumide [INN]; Dexloxiglumidum [INN-Latin]; Dexloxiglumida [INN-Spanish]; PubChem16049; AC1Q3MXI; GTPL889; SCHEMBL366142; CHEMBL550781; AC1L24A8; DTXSID50152604; MolPort-006-170-001; CHEBI:135747; ZINC3801027; KS-000007QQ; AKOS000279054; PB12713; DB04856; CC-26372; AJ-45649; AK129760; AS-35102; KB-210163; AX8123879; CS-0054881; FT-0603098; Q-4119 DM52HUD DT Small molecular drug DM52HUD PC 65937 DM52HUD MW 461.4 DM52HUD FM C21H30Cl2N2O5 DM52HUD IC InChI=1S/C21H30Cl2N2O5/c1-3-4-5-11-25(12-6-13-30-2)21(29)18(9-10-19(26)27)24-20(28)15-7-8-16(22)17(23)14-15/h7-8,14,18H,3-6,9-13H2,1-2H3,(H,24,28)(H,26,27)/t18-/m1/s1 DM52HUD CS CCCCCN(CCCOC)C(=O)[C@@H](CCC(=O)O)NC(=O)C1=CC(=C(C=C1)Cl)Cl DM52HUD IK QNQZBKQEIFTHFZ-GOSISDBHSA-N DM52HUD IU (4R)-4-[(3,4-dichlorobenzoyl)amino]-5-[3-methoxypropyl(pentyl)amino]-5-oxopentanoic acid DM52HUD CA CAS 119817-90-2 DM52HUD CB CHEBI:135747 DM52HUD DE Pancreatic malfunction DM9L15R ID DM9L15R DM9L15R DN Dextofisopam DM9L15R HS Phase 2 DM9L15R SN R-Tofisopam; Dextofisopam (USAN/INN); (5R)-1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl-5H-2,3-benzodiazepine DM9L15R CP Vela Pharmaceuticals DM9L15R DT Small molecular drug DM9L15R PC 204105 DM9L15R MW 382.5 DM9L15R FM C22H26N2O4 DM9L15R IC InChI=1S/C22H26N2O4/c1-7-15-13(2)23-24-22(14-8-9-18(25-3)19(10-14)26-4)17-12-21(28-6)20(27-5)11-16(15)17/h8-12,15H,7H2,1-6H3/t15-/m0/s1 DM9L15R CS CC[C@H]1C(=NN=C(C2=CC(=C(C=C12)OC)OC)C3=CC(=C(C=C3)OC)OC)C DM9L15R IK RUJBDQSFYCKFAA-HNNXBMFYSA-N DM9L15R IU (5R)-1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl-5H-2,3-benzodiazepine DM9L15R CA CAS 82059-50-5 DM9L15R DE Irritable bowel syndrome DMFI5J4 ID DMFI5J4 DMFI5J4 DN Dextromethorphan+quinidine DMFI5J4 HS Phase 2 DMFI5J4 SN Dextromethorphan hydrobromide monohydrate; 6700-34-1; Dextromethorphan hydrobromide; Methorate; Drixoral Cough; PediaCare 1; Dextromethorphan hydrobromide hydrate; Dextromethorphan (hydrobromide hydrate); Hold; St. Joseph Cough Syrup; Chloraseptic DM; UNII-9D2RTI9KYH; Romilar; Tylenol Cough Liquid; Endotussin-NN Pediatric; Robitussin Cough Calmers; Robitussin Pediatric Cough; 9D2RTI9KYH; Dextromethorphan hydrobromide OROS Tablets; Drixoral Cough & Sore Throat; Robitussin Maximum Strength Cough DMFI5J4 CP Avanir DMFI5J4 DT Small molecular drug DMFI5J4 PC 5462351 DMFI5J4 MW 370.3 DMFI5J4 FM C18H28BrNO2 DMFI5J4 IC InChI=1S/C18H25NO.BrH.H2O/c1-19-10-9-18-8-4-3-5-15(18)17(19)11-13-6-7-14(20-2)12-16(13)18;;/h6-7,12,15,17H,3-5,8-11H2,1-2H3;1H;1H2/t15-,17+,18+;;/m1../s1 DMFI5J4 CS CN1CC[C@@]23CCCC[C@@H]2[C@@H]1CC4=C3C=C(C=C4)OC.O.Br DMFI5J4 IK STTADZBLEUMJRG-IKNOHUQMSA-N DMFI5J4 IU (1S,9S,10S)-4-methoxy-17-methyl-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-triene;hydrate;hydrobromide DMFI5J4 CA CAS 6700-34-1 DMFI5J4 CB CHEBI:4471 DMFI5J4 DE Diabetic neuropathy DMS9Y1T ID DMS9Y1T DMS9Y1T DN DG-17 DMS9Y1T HS Phase 2 DMS9Y1T SN DG-35; Nar DG-35 Prodrug; DG-35-VIII DMS9Y1T CP Narhex Life Sciences Ltd DMS9Y1T DE Human immunodeficiency virus infection DMK6FYR ID DMK6FYR DMK6FYR DN DiabeCell DMK6FYR HS Phase 2 DMK6FYR SN Porcine pancreatic islet cell therapy (Immupel encapsulated, type 1 diabetes), LCT; Porcine pancreatic islet celltherapy (alginate encapsulated, type 1 diabetes), LCT DMK6FYR CP Living Cell Technologies Ltd DMK6FYR DE Insulin-dependent diabetes DMTJOEL ID DMTJOEL DMTJOEL DN DIADENOSINE TETRAPHOSPHATE DMTJOEL HS Phase 2 DMTJOEL SN Ap4A; F-1500 (tetraNa salt); Diadenosine 5',5''-P1,P4-tetraphosphate DMTJOEL DT Small molecular drug DMTJOEL PC 21706 DMTJOEL MW 836.4 DMTJOEL FM C20H28N10O19P4 DMTJOEL IC InChI=1S/C20H28N10O19P4/c21-15-9-17(25-3-23-15)29(5-27-9)19-13(33)11(31)7(45-19)1-43-50(35,36)47-52(39,40)49-53(41,42)48-51(37,38)44-2-8-12(32)14(34)20(46-8)30-6-28-10-16(22)24-4-26-18(10)30/h3-8,11-14,19-20,31-34H,1-2H2,(H,35,36)(H,37,38)(H,39,40)(H,41,42)(H2,21,23,25)(H2,22,24,26)/t7-,8-,11-,12-,13-,14-,19-,20-/m1/s1 DMTJOEL CS C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)OP(=O)(O)OC[C@@H]4[C@H]([C@H]([C@@H](O4)N5C=NC6=C(N=CN=C65)N)O)O)O)O)N DMTJOEL IK YOAHKNVSNCMZGQ-XPWFQUROSA-N DMTJOEL IU [[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate DMTJOEL CA CAS 5542-28-9 DMTJOEL CB CHEBI:17422 DMTJOEL DE Cardiac arrhythmias DM7AFJ8 ID DM7AFJ8 DM7AFJ8 DN Diannexin DM7AFJ8 HS Phase 2 DM7AFJ8 CP Altavita Pharmaceuticals; Astellas Pharma DM7AFJ8 DE Myocardial reperfusion injury DM20ATW ID DM20ATW DM20ATW DN Diflomotecan DM20ATW HS Phase 2 DM20ATW SN BN-80915; R-1536; Diflomotecan; (+)-5(R)-Ethyl-9,10-difluoro-5-hydroxy-4,5,13,15-tetrahydro-1H,3H-oxepino[3',4':6,7]indolizino[1,2-b]quinoline-3,15-dione DM20ATW DT Small molecular drug DM20ATW PC 219023 DM20ATW MW 398.4 DM20ATW FM C21H16F2N2O4 DM20ATW IC InChI=1S/C21H16F2N2O4/c1-2-21(28)7-18(26)29-9-12-13(21)5-17-19-11(8-25(17)20(12)27)3-10-4-14(22)15(23)6-16(10)24-19/h3-6,28H,2,7-9H2,1H3/t21-/m1/s1 DM20ATW CS CC[C@]1(CC(=O)OCC2=C1C=C3C4=C(CN3C2=O)C=C5C=C(C(=CC5=N4)F)F)O DM20ATW IK LFQCJSBXBZRMTN-OAQYLSRUSA-N DM20ATW IU (20R)-20-ethyl-6,7-difluoro-20-hydroxy-17-oxa-3,13-diazapentacyclo[11.9.0.02,11.04,9.015,21]docosa-1(22),2(11),3,5,7,9,15(21)-heptaene-14,18-dione DM20ATW CA CAS 220997-97-7 DM20ATW CB CHEBI:144046 DM20ATW DE Solid tumour/cancer DMTLB92 ID DMTLB92 DMTLB92 DN DI-Leu16-IL2 DMTLB92 HS Phase 2 DMTLB92 CP Alopexx Oncology DMTLB92 DT Recombinant protein DMTLB92 DE B-cell lymphoma; Non-hodgkin lymphoma DMBYJ92 ID DMBYJ92 DMBYJ92 DN Dilmapimod DMBYJ92 HS Phase 2 DMBYJ92 SN Dilmapimod; SB-681323; 444606-18-2; UNII-Q3238VQW0N; GW 681323; SB 681323; Q3238VQW0N; GW681323; SB681323; Dilmapimod [USAN:INN]; GSK 681323; Dilmapimod (USAN/INN); GTPL7815; SCHEMBL1065268; CHEMBL2103838; ORVNHOYNEHYKJG-UHFFFAOYSA-N; BCP23819; ZINC34997404; CS-6731; DB12140; SB16737; 8-(2,6-difluorophenyl)-4-(4-fluoro-2-methylphenyl)-2-[[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-Pyrido[2,3-d]pyrimidin-7(8H)-one; HY-10404; GW-681323; DB-070558; FT-0718750; J3.498.915J; D09602; SB-681323; GW-681323 DMBYJ92 CP GSK DMBYJ92 TC Analgesics DMBYJ92 DT Small molecular drug DMBYJ92 PC 10297982 DMBYJ92 MW 456.4 DMBYJ92 FM C23H19F3N4O3 DMBYJ92 IC InChI=1S/C23H19F3N4O3/c1-12-9-13(24)5-6-15(12)20-16-7-8-19(33)30(21-17(25)3-2-4-18(21)26)22(16)29-23(28-20)27-14(10-31)11-32/h2-9,14,31-32H,10-11H2,1H3,(H,27,28,29) DMBYJ92 CS CC1=C(C=CC(=C1)F)C2=C3C=CC(=O)N(C3=NC(=N2)NC(CO)CO)C4=C(C=CC=C4F)F DMBYJ92 IK ORVNHOYNEHYKJG-UHFFFAOYSA-N DMBYJ92 IU 8-(2,6-difluorophenyl)-2-(1,3-dihydroxypropan-2-ylamino)-4-(4-fluoro-2-methylphenyl)pyrido[2,3-d]pyrimidin-7-one DMBYJ92 CA CAS 444606-18-2 DMBYJ92 DE Acute lung injury DMCATH2 ID DMCATH2 DMCATH2 DN Dilpacimab DMCATH2 HS Phase 2 DMCATH2 SN ABT-165 DMCATH2 DT Antibody DMCATH2 DE Solid tumour/cancer DM96NHM ID DM96NHM DM96NHM DN Dimiracetam DM96NHM HS Phase 2 DM96NHM SN BND-11624; Dimiracetam, Neurotune; NT-11624; NMDA receptor antagonist (oral, neuropathic pain/osteoarthritic pain), Neurotune DM96NHM CP Brane Discovery Srl DM96NHM DT Small molecular drug DM96NHM PC 65955 DM96NHM MW 140.14 DM96NHM FM C6H8N2O2 DM96NHM IC InChI=1S/C6H8N2O2/c9-5-3-8-4(7-5)1-2-6(8)10/h4H,1-3H2,(H,7,9) DM96NHM CS C1CC(=O)N2C1NC(=O)C2 DM96NHM IK XTXXOHPHLNROBN-UHFFFAOYSA-N DM96NHM IU 3,6,7,7a-tetrahydro-1H-pyrrolo[1,2-a]imidazole-2,5-dione DM96NHM CA CAS 126100-97-8 DM96NHM DE Neuropathic pain DM2QBDS ID DM2QBDS DM2QBDS DN Disitertide DM2QBDS HS Phase 2 DM2QBDS SN NAFB-001; Disitertide cream (skin disorders), Digna DM2QBDS CP University of Navarra DM2QBDS PC 9833838 DM2QBDS MW 1580.8 DM2QBDS FM C68H109N17O22S2 DM2QBDS IC InChI=1S/C68H109N17O22S2/c1-12-32(5)53(85-67(105)54(33(6)13-2)84-64(102)48(30-87)82-56(94)35(8)74-61(99)45(27-51(91)92)79-62(100)43(24-31(3)4)78-63(101)47(29-86)83-65(103)52(71)36(9)88)66(104)80-44(25-37-28-72-39-17-15-14-16-38(37)39)60(98)73-34(7)55(93)75-41(20-22-108-10)58(96)77-42(21-23-109-11)59(97)76-40(18-19-49(69)89)57(95)81-46(68(106)107)26-50(70)90/h14-17,28,31-36,40-48,52-54,72,86-88H,12-13,18-27,29-30,71H2,1-11H3,(H2,69,89)(H2,70,90)(H,73,98)(H,74,99)(H,75,93)(H,76,97)(H,77,96)(H,78,101)(H,79,100)(H,80,104)(H,81,95)(H,82,94)(H,83,103)(H,84,102)(H,85,105)(H,91,92)(H,106,107)/t32-,33-,34-,35-,36+,40-,41-,42-,43-,44-,45-,46-,47-,48-,52-,53-,54-/m0/s1 DM2QBDS CS CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)N DM2QBDS IK IUYPEUHIWDMJLM-SWHDLQTQSA-N DM2QBDS IU (2S)-4-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-amino-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-carboxypropanoyl]amino]propanoyl]amino]-3-hydroxypropanoyl]amino]-3-methylpentanoyl]amino]-3-methylpentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]propanoyl]amino]-4-methylsulfanylbutanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-oxopentanoyl]amino]-4-oxobutanoic acid DM2QBDS CA CAS 272105-42-7 DM2QBDS DE Macular degeneration DMYC2LE ID DMYC2LE DMYC2LE DN Disufenton DMYC2LE HS Phase 2 DMYC2LE SN 168021-77-0; UNII-797K01YF1M; 797K01YF1M; N-tert-butyl-1-(2,4-disulfophenyl)methanimine oxide; SCHEMBL727315; CHEMBL2111090; 2,4-disulfophenyl-N-t-butylnitrone; alpha-(2,4-disulfophenyl)-N-tert-butylnitrone; Q27266726 DMYC2LE CP Oblato DMYC2LE DT Small molecular drug DMYC2LE PC 151179 DMYC2LE MW 337.4 DMYC2LE FM C11H15NO7S2 DMYC2LE IC InChI=1S/C11H15NO7S2/c1-11(2,3)12(13)7-8-4-5-9(20(14,15)16)6-10(8)21(17,18)19/h4-7H,1-3H3,(H,14,15,16)(H,17,18,19) DMYC2LE CS CC(C)(C)[N+](=CC1=C(C=C(C=C1)S(=O)(=O)O)S(=O)(=O)O)[O-] DMYC2LE IK OVTCHWSLKGENKP-UHFFFAOYSA-N DMYC2LE IU N-tert-butyl-1-(2,4-disulfophenyl)methanimine oxide DMYC2LE CA CAS 168021-77-0 DMYC2LE DE Recurrent glioblastoma DMBMKV8 ID DMBMKV8 DMBMKV8 DN Disulfiram DMBMKV8 HS Phase 2 DMBMKV8 SN Abstenisil; Abstinil; Abstinyl; Alcophobin; Antabus; Antabuse; Antadix; Antaenyl; Antaethan; Antaethyl; Antaetil; Antalcol; Antetan; Antethyl; Antetil; Anteyl; Anthethyl; Antiaethan; Anticol; Antietanol; Antiethanol; Antietil; Antikol; Antivitium; Aversan; Averzan; Bonibal; Contralin; Contrapot; Cronetal; Dicupral; Disetil; Disulfan; Disulfirame; Disulfiramo; Disulfiramum; Disulfirm; Disulfram; Disulfuram; Disulphuram; Ephorran; Espenal; Esperal; Etabus; Ethyldithiourame; Ethyldithiurame; Exhoran; Exhorran; Gababentin; Hoca; Krotenal; Nocbin; Nocceler; Noxal; Refusal; Stopaethyl; Stopethyl; Stopety; Stopetyl; TATD; TETD; THIOCID; TTD; TTS; Tenurid; Tenutex; Tetidis; Tetradin; Tetradine; Tetraethylthiuram; Tetraetil; Teturam; Teturamin; Thireranide; Thiuranide; Tillram; Tiuram; Accel TET; Akrochem TETD; Ancazide ET; Antab use; Disulfirame [DCIT]; Ekagom DTET; Ekagom TEDS; Ekagom TETDS; Ekaland TETD; Esperal [France]; Eta bus; Ethyl Thiram; Ethyl Thiudad; Ethyl Thiurad; Ethyl Tuads Rodform; Ethyl Tuex; Ethyl tuads; Etyl Tuex; Nocceler TET; Perkacit TETD; Perkait TETD; Robac TET; Sanceler TET; Soxinol TET; TTS x; Tet raethylthiuram; Thiuram E; Dupon 4472; T 1132; Accel TET-R; Alk-aubs; Antabus (TN); Antabuse (TN); Anti-ethyl; Antivitium (Spain); ENT 27,340; Nocceler TET-G; Noxal (VAN); Ro-sulfiram; Sanceler TET-G; Tuads, ethyl; Usaf B-33; Ro-Sulfram-500 (USA) DMBMKV8 CP Odyssey Pharmaceuticals DMBMKV8 TC Antiviral Agents DMBMKV8 DT Small molecular drug DMBMKV8 PC 3117 DMBMKV8 MW 296.5 DMBMKV8 FM C10H20N2S4 DMBMKV8 IC InChI=1S/C10H20N2S4/c1-5-11(6-2)9(13)15-16-10(14)12(7-3)8-4/h5-8H2,1-4H3 DMBMKV8 CS CCN(CC)C(=S)SSC(=S)N(CC)CC DMBMKV8 IK AUZONCFQVSMFAP-UHFFFAOYSA-N DMBMKV8 IU diethylcarbamothioylsulfanyl N,N-diethylcarbamodithioate DMBMKV8 CA CAS 97-77-8 DMBMKV8 CB CHEBI:4659 DMBMKV8 DE Alcoholism; Coronavirus Disease 2019 (COVID-19); Middle East Respiratory Syndrome (MERS); Severe acute respiratory syndrome (SARS) DMOHT5V ID DMOHT5V DMOHT5V DN DKN-01 DMOHT5V HS Phase 2 DMOHT5V CP Leap Therapeutics DMOHT5V DT Antibody DMOHT5V DE Multiple myeloma; Cholangiocarcinoma; Esophageal cancer; Biliary tract cancer; Endometrial cancer; Oesophagogastric junction cancer; Ovarian cancer; Prostate cancer DMDJUWG ID DMDJUWG DMDJUWG DN DLX-105 DMDJUWG HS Phase 2 DMDJUWG SN DLX-106; ESBA-105 (intra-articular formulation), ESBATech; Anti-TNF alpha antibody fragment (intra-articular, osteoarthritis), Delenex; Anti-TNF alpha antibody fragment (intra-articular, osteoarthritis), ESBATech DMDJUWG CP ESBATech AG DMDJUWG DT Antibody DMDJUWG DE Osteoarthritis DM0157T ID DM0157T DM0157T DN DM199 DM0157T HS Phase 2 DM0157T CP DiaMedica Therapeutics DM0157T DT Recombinant?protein DM0157T DE Autoimmune diabetes; Ischemic stroke; Diabetic nephropathy; Cerebral ischemia DMMSIG7 ID DMMSIG7 DMMSIG7 DN DM-71 DMMSIG7 HS Phase 2 DMMSIG7 SN Insulin sensitizer (type 2 diabetes), DiaMedica; Bethanechol + n-acetyl cysteine (type 2 diabetes), DiaMedica DMMSIG7 CP DiaMedica Inc DMMSIG7 DE Type-2 diabetes DM1HG3U ID DM1HG3U DM1HG3U DN DM-99 DM1HG3U HS Phase 2 DM1HG3U CP DiaMedica Inc DM1HG3U DE Alzheimer disease DMBC7HZ ID DMBC7HZ DMBC7HZ DN DM-CHOC-PEN DMBC7HZ HS Phase 2 DMBC7HZ CP Dekk-Tec DMBC7HZ PC 16126905 DMBC7HZ MW 724 DMBC7HZ FM C35H48Cl5NO4 DMBC7HZ IC InChI=1S/C35H48Cl5NO4/c1-19(2)8-7-9-20(3)24-12-13-25-23-11-10-21-18-22(14-16-33(21,4)26(23)15-17-34(24,25)5)44-32(42)45-29-27(36)30(35(38,39)40)41-31(43-6)28(29)37/h10,19-20,22-26H,7-9,11-18H2,1-6H3/t20-,22+,23+,24-,25+,26+,33+,34-/m1/s1 DMBC7HZ CS C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)OC(=O)OC5=C(C(=NC(=C5Cl)OC)C(Cl)(Cl)Cl)Cl)C)C DMBC7HZ IK ZJUUIXYKTPSIOH-LEZJFEBPSA-N DMBC7HZ IU [3,5-dichloro-2-methoxy-6-(trichloromethyl)pyridin-4-yl] [(3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl] carbonate DMBC7HZ CA CAS 942149-56-6 DMBC7HZ DE Brain cancer; Brain metastases DM725UG ID DM725UG DM725UG DN DN24-02 DM725UG HS Phase 2 DM725UG SN Lapuleucel-T DM725UG CP Dendreon DM725UG DE Urogenital cancer; Colorectal cancer DMDTVYC ID DMDTVYC DMDTVYC DN DNCB DMDTVYC HS Phase 2 DMDTVYC SN 1-Chloro-2,4-dinitrobenzene DMDTVYC DT Small molecular drug DMDTVYC PC 6 DMDTVYC MW 202.55 DMDTVYC FM C6H3ClN2O4 DMDTVYC IC InChI=1S/C6H3ClN2O4/c7-5-2-1-4(8(10)11)3-6(5)9(12)13/h1-3H DMDTVYC CS C1=CC(=C(C=C1[N+](=O)[O-])[N+](=O)[O-])Cl DMDTVYC IK VYZAHLCBVHPDDF-UHFFFAOYSA-N DMDTVYC IU 1-chloro-2,4-dinitrobenzene DMDTVYC CA CAS 97-00-7 DMDTVYC CB CHEBI:34718 DMDTVYC DE Immune System disease DM89D6C ID DM89D6C DM89D6C DN DNL758 DM89D6C HS Phase 2 DM89D6C SN SAR443122 DM89D6C CP Denali Therapeutics DM89D6C DT Small molecular drug DM89D6C DE Cutaneous lupus erythematosus DM0QDC9 ID DM0QDC9 DM0QDC9 DN Dolastatin 10 DM0QDC9 HS Phase 2 DM0QDC9 SN Dolastatin 10; Dolastatin-10; Dolostatin 10; UNII-EI946JT51X; CCRIS 7310; CHEBI:67357; NSC 376128; EI946JT51X; L-Valinamide, N,N-dimethyl-L-valyl-N-[(1S,2R)-2-methoxy-4-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[[(1S)-2-phenyl-1-(2-thiazolyl)ethyl]amino]propyl]-1-pyrrolidinyl]-1-[(1S)-1-methylpropyl]-4-oxobutyl]-N-methyl- DM0QDC9 PC 9810929 DM0QDC9 MW 785.1 DM0QDC9 FM C42H68N6O6S DM0QDC9 IC InChI=1S/C42H68N6O6S/c1-13-28(6)37(47(10)42(52)35(26(2)3)45-40(51)36(27(4)5)46(8)9)33(53-11)25-34(49)48-22-17-20-32(48)38(54-12)29(7)39(50)44-31(41-43-21-23-55-41)24-30-18-15-14-16-19-30/h14-16,18-19,21,23,26-29,31-33,35-38H,13,17,20,22,24-25H2,1-12H3,(H,44,50)(H,45,51)/t28-,29+,31-,32-,33+,35-,36-,37-,38+/m0/s1 DM0QDC9 CS CCC(C)C(C(CC(=O)N1CCCC1C(C(C)C(=O)NC(CC2=CC=CC=C2)C3=NC=CS3)OC)OC)N(C)C(=O)C(C(C)C)NC(=O)C(C(C)C)N(C)C DM0QDC9 IK OFDNQWIFNXBECV-VFSYNPLYSA-N DM0QDC9 IU (2S)-2-[[(2S)-2-(dimethylamino)-3-methylbutanoyl]amino]-N-[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[[(1S)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-N,3-dimethylbutanamide DM0QDC9 CA CAS 110417-88-4 DM0QDC9 CB CHEBI:67357 DM0QDC9 DE Leukemia DMDUV1S ID DMDUV1S DMDUV1S DN DOLASTATIN-10 DMDUV1S HS Phase 2 DMDUV1S DT Small molecular drug DMDUV1S PC 9810929 DMDUV1S MW 785.1 DMDUV1S FM C42H68N6O6S DMDUV1S IC InChI=1S/C42H68N6O6S/c1-13-28(6)37(47(10)42(52)35(26(2)3)45-40(51)36(27(4)5)46(8)9)33(53-11)25-34(49)48-22-17-20-32(48)38(54-12)29(7)39(50)44-31(41-43-21-23-55-41)24-30-18-15-14-16-19-30/h14-16,18-19,21,23,26-29,31-33,35-38H,13,17,20,22,24-25H2,1-12H3,(H,44,50)(H,45,51)/t28-,29+,31-,32-,33+,35-,36-,37-,38+/m0/s1 DMDUV1S CS CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@@H]([C@@H](C)C(=O)N[C@@H](CC2=CC=CC=C2)C3=NC=CS3)OC)OC)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)N(C)C DMDUV1S IK OFDNQWIFNXBECV-VFSYNPLYSA-N DMDUV1S IU (2S)-2-[[(2S)-2-(dimethylamino)-3-methylbutanoyl]amino]-N-[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[[(1S)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-N,3-dimethylbutanamide DMDUV1S CA CAS 110417-88-4 DMDUV1S CB CHEBI:67357 DMDUV1S DE Solid tumour/cancer DMCT08V ID DMCT08V DMCT08V DN Domagrozumab DMCT08V HS Phase 2 DMCT08V CP Pfizer New York, NY DMCT08V DE Duchenne dystrophy DM8VWPH ID DM8VWPH DM8VWPH DN Doxorubicin-eluting beads DM8VWPH HS Phase 2 DM8VWPH SN DC Bead (TN) DM8VWPH CP Bayer HealthCare Pharmaceuticals; Biocompatibles DM8VWPH DE Liver cancer DM059CZ ID DM059CZ DM059CZ DN DPK-060 DM059CZ HS Phase 2 DM059CZ SN DP-9011; DP-9012; DP-9013; DP-9011-DP-9013 series (atopic dermatitis/impetigo), DermaGen DM059CZ CP DermaGen AB DM059CZ DE Atopic dermatitis DMMC3XR ID DMMC3XR DMMC3XR DN DPV-001 DMMC3XR HS Phase 2 DMMC3XR CP Ubivac DMMC3XR DE Non-small-cell lung cancer; Prostate cancer DMGD3XT ID DMGD3XT DMGD3XT DN DRL-17822 DMGD3XT HS Phase 2 DMGD3XT SN CETP inhibitor (dyslipidemia/atherosclerosis/cardiovascular diseases), Dr Reddy's DMGD3XT CP Dr Reddy's Laboratories Ltd DMGD3XT PC 58689743 DMGD3XT MW 603.6 DMGD3XT FM C30H31F6N7 DMGD3XT IC InChI=1S/C30H31F6N7/c1-18-4-3-5-22-12-23(27(37-26(18)22)42(14-19-6-7-19)15-20-8-9-20)17-43(28-38-40-41(2)39-28)16-21-10-24(29(31,32)33)13-25(11-21)30(34,35)36/h3-5,10-13,19-20H,6-9,14-17H2,1-2H3 DMGD3XT CS CC1=C2C(=CC=C1)C=C(C(=N2)N(CC3CC3)CC4CC4)CN(CC5=CC(=CC(=C5)C(F)(F)F)C(F)(F)F)C6=NN(N=N6)C DMGD3XT IK OCNBSSLDAIWTKS-UHFFFAOYSA-N DMGD3XT IU 3-[[[3,5-bis(trifluoromethyl)phenyl]methyl-(2-methyltetrazol-5-yl)amino]methyl]-N,N-bis(cyclopropylmethyl)-8-methylquinolin-2-amine DMGD3XT CA CAS 898911-09-6 DMGD3XT DE Arteriosclerosis DM8WU3O ID DM8WU3O DM8WU3O DN Drug 2862277 DM8WU3O HS Phase 2 DM8WU3O SN 2862277 DM8WU3O DT Antibody DM8WU3O DE Acute lung injury DMI69E5 ID DMI69E5 DMI69E5 DN DS-3201b DMI69E5 HS Phase 2 DMI69E5 SN Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551 DMI69E5 CP Daiichi Sankyo DMI69E5 DT Small molecular drug DMI69E5 PC 126481870 DMI69E5 MW 488 DMI69E5 FM C26H34ClN3O4 DMI69E5 IC InChI=1S/C26H34ClN3O4/c1-14-11-15(2)29-25(32)20(14)13-28-24(31)19-12-21(27)23-22(16(19)3)33-26(4,34-23)17-7-9-18(10-8-17)30(5)6/h11-12,17-18H,7-10,13H2,1-6H3,(H,28,31)(H,29,32)/t17?,18?,26-/m1/s1 DMI69E5 CS CC1=CC(=C(C(=O)N1)CNC(=O)C2=CC(=C3C(=C2C)O[C@@](O3)(C)C4CCC(CC4)N(C)C)Cl)C DMI69E5 IK SSDRNUPMYCFXGM-ZZHSESOFSA-N DMI69E5 IU (2R)-7-chloro-2-[4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide DMI69E5 CA CAS 1809336-39-7 DMI69E5 DE Acute myeloid leukaemia; Acute lymphoblastic leukaemia; Urothelial carcinoma; Renal cell carcinoma; Small-cell lung cancer; T-cell leukaemia DMUXIRM ID DMUXIRM DMUXIRM DN DS-8500 DMUXIRM HS Phase 2 DMUXIRM CP Daiichi Sankyo DMUXIRM PC 74889211 DMUXIRM MW 153.18 DMUXIRM FM C8H11NO2 DMUXIRM IC InChI=1S/C8H11NO2/c1-3-7-6(4-5-9-7)8(10)11-2/h4-5,9H,3H2,1-2H3 DMUXIRM CS CCC1=C(C=CN1)C(=O)OC DMUXIRM IK FWZOVQKKSCXOHE-UHFFFAOYSA-N DMUXIRM IU methyl 2-ethyl-1H-pyrrole-3-carboxylate DMUXIRM DE Diabetic complication; Type-2 diabetes DM6UGHA ID DM6UGHA DM6UGHA DN DSP-6952 DM6UGHA HS Phase 2 DM6UGHA SN Serotonin 4 receptor partial agonist (constipation), Dainippon Sumitomo DM6UGHA CP Dainippon Sumitomo Pharma Co Ltd DM6UGHA DE Constipation DMU2GP4 ID DMU2GP4 DMU2GP4 DN DT-1687 DMU2GP4 HS Phase 2 DMU2GP4 SN DT-1386; MGluR4 PAM (neurological disease/psychiatric disorder), Domain Therapeutics; MGluR4 PAM (neurological disease/psychiatric disorder), Merck Serono DMU2GP4 CP Domain Therapeutics SA DMU2GP4 PC 135565465 DMU2GP4 MW 421.5 DMU2GP4 FM C23H23N3O3S DMU2GP4 IC InChI=1S/C23H23N3O3S/c27-25-19-13-22(20-14-23-17(15-24-20)5-11-30-23)29-21-4-3-16(12-18(19)21)2-1-6-26-7-9-28-10-8-26/h3-5,11-15,27H,1-2,6-10H2/b25-19+ DMU2GP4 CS C1COCCN1CCCC2=CC\\3=C(C=C2)OC(=C/C3=N\\O)C4=NC=C5C=CSC5=C4 DMU2GP4 IK ZTEDNASHAWNBKQ-NCELDCMTSA-N DMU2GP4 IU (NE)-N-[6-(3-morpholin-4-ylpropyl)-2-thieno[3,2-c]pyridin-6-ylchromen-4-ylidene]hydroxylamine DMU2GP4 CA CAS 1883329-53-0 DMU2GP4 DE Neurological disorder; Parkinson disease DMV84OK ID DMV84OK DMV84OK DN DTI-0009 DMV84OK HS Phase 2 DMV84OK SN Selodenosan DMV84OK CP Aderis Pharmaceuticals DMV84OK DE Atrial fibrillation DMX27IT ID DMX27IT DMX27IT DN DTRM-555 DMX27IT HS Phase 2 DMX27IT CP Zhejiang DTRM Biopharma DMX27IT DT Small molecular drug DMX27IT DE Chronic lymphocytic leukaemia DM1ZJYS ID DM1ZJYS DM1ZJYS DN Dusigitumab DM1ZJYS HS Phase 2 DM1ZJYS CP MedImmune Gaithersburg, MD DM1ZJYS DE Breast cancer DM7USVA ID DM7USVA DM7USVA DN Duvelisib DM7USVA HS Phase 2 DM7USVA SN Duvelisib; 1201438-56-3; IPI-145; INK-1197; UNII-610V23S0JI; IPI 145; 610V23S0JI; INK-1147; Copiktra; IPI-145 (INK1197); Duvelisib [USAN:INN]; IPI145; INK1197; Copiktra (TN); AK145604; Duvelisib (IPI-145, INK1197); Duvel; Duvelisib DM7USVA TC Antiviral Agents DM7USVA DT Small molecular drug DM7USVA PC 50905713 DM7USVA MW 416.9 DM7USVA FM C22H17ClN6O DM7USVA IC InChI=1S/C22H17ClN6O/c1-13(28-21-19-20(25-11-24-19)26-12-27-21)17-10-14-6-5-9-16(23)18(14)22(30)29(17)15-7-3-2-4-8-15/h2-13H,1H3,(H2,24,25,26,27,28)/t13-/m0/s1 DM7USVA CS C[C@@H](C1=CC2=C(C(=CC=C2)Cl)C(=O)N1C3=CC=CC=C3)NC4=NC=NC5=C4NC=N5 DM7USVA IK SJVQHLPISAIATJ-ZDUSSCGKSA-N DM7USVA IU 8-chloro-2-phenyl-3-[(1S)-1-(7H-purin-6-ylamino)ethyl]isoquinolin-1-one DM7USVA CA CAS 1201438-56-3 DM7USVA CB CHEBI:131169 DM7USVA DE Coronavirus Disease 2019 (COVID-19) DMUGBQK ID DMUGBQK DMUGBQK DN DVC1-0101 DMUGBQK HS Phase 2 DMUGBQK SN Ischemia gene therapy, DNAVEC\Kyushu University; FGF2-carrying Sendai virus, DNAVEC\Kyushu University; SeV-FGF2 gene therapy (virus recombinant, ischaemia) DNAVEC\Kyushu University DMUGBQK CP DNAVEC Corp DMUGBQK DE Arteriosclerosis DMQKU2F ID DMQKU2F DMQKU2F DN DWP-05195 DMQKU2F HS Phase 2 DMQKU2F SN DWJ-204; DWP-0519 DMQKU2F CP Daewoong Pharmaceutical Co Ltd DMQKU2F DE Neuropathic pain DMBFZET ID DMBFZET DMBFZET DN DX-890 DMBFZET HS Phase 2 DMBFZET CP Dyax Corp. DMBFZET PC 56841753 DMBFZET MW 6231 DMBFZET FM C282H412N74O75S6 DMBFZET IC InChI=1S/C282H412N74O75S6/c1-21-150(15)229-273(424)312-154(19)232(383)328-185(117-157-58-30-24-31-59-157)255(406)339-196(123-160-64-36-27-37-65-160)277(428)353-110-52-76-205(353)267(418)324-177(74-50-108-300-282(296)297)246(397)332-189(124-164-129-301-170-67-39-38-66-168(164)170)250(401)310-153(18)231(382)327-184(116-156-56-28-23-29-57-156)253(404)334-193(128-224(380)381)251(402)311-155(20)234(385)347-225(146(7)8)270(421)325-171(68-40-44-102-283)236(387)304-132-215(367)313-173(69-41-45-103-284)242(393)344-202-142-436-435-141-201-262(413)319-176(73-49-107-299-281(294)295)244(395)321-180(95-100-222(376)377)248(399)330-188(121-163-84-90-167(360)91-85-163)257(408)342-198(241(392)307-135-218(370)346-228(149(13)14)278(429)356-113-55-79-208(356)279(430)431)138-432-434-140-200(341-233(384)152(17)309-235(386)169(287)92-98-220(372)373)263(414)333-192(127-212(291)364)259(410)337-194(115-145(5)6)275(426)355-112-54-78-207(355)269(420)351-230(151(16)22-2)274(425)349-227(148(11)12)271(422)326-172(72-48-106-298-280(292)293)237(388)308-136-219(371)352-109-51-75-204(352)266(417)345-203(265(416)350-229)143-437-433-139-199(316-214(366)131-302-213(365)130-303-239(390)183(119-161-80-86-165(358)87-81-161)335-268(419)206-77-53-111-354(206)276(427)195(122-159-62-34-26-35-63-159)338-252(403)182(114-144(3)4)336-272(423)226(147(9)10)348-264(202)415)261(412)320-178(93-97-209(288)361)238(389)305-133-216(368)314-190(125-210(289)362)240(391)306-134-217(369)315-191(126-211(290)363)258(409)318-175(71-43-47-105-286)245(396)329-186(118-158-60-32-25-33-61-158)254(405)331-187(120-162-82-88-166(359)89-83-162)256(407)340-197(137-357)260(411)323-179(94-99-221(374)375)247(398)317-174(70-42-46-104-285)243(394)322-181(249(400)343-201)96-101-223(378)379/h23-39,56-67,80-91,129,144-155,169,171-208,225-230,301,357-360H,21-22,40-55,68-79,92-128,130-143,283-287H2,1-20H3,(H2,288,361)(H2,289,362)(H2,290,363)(H2,291,364)(H,302,365)(H,303,390)(H,304,387)(H,305,389)(H,306,391)(H,307,392)(H,308,388)(H,309,386)(H,310,401)(H,311,402)(H,312,424)(H,313,367)(H,314,368)(H,315,369)(H,316,366)(H,317,398)(H,318,409)(H,319,413)(H,320,412)(H,321,395)(H,322,394)(H,323,411)(H,324,418)(H,325,421)(H,326,422)(H,327,382)(H,328,383)(H,329,396)(H,330,399)(H,331,405)(H,332,397)(H,333,414)(H,334,404)(H,335,419)(H,336,423)(H,337,410)(H,338,403)(H,339,406)(H,340,407)(H,341,384)(H,342,408)(H,343,400)(H,344,393)(H,345,417)(H,346,370)(H,347,385)(H,348,415)(H,349,425)(H,350,416)(H,351,420)(H,372,373)(H,374,375)(H,376,377)(H,378,379)(H,380,381)(H,430,431)(H4,292,293,298)(H4,294,295,299)(H4,296,297,300)/t150-,151-,152-,153-,154-,155-,169-,171-,172-,173-,174-,175-,176-,177-,178-,179-,180-,181-,182-,183-,184-,185-,186-,187-,188-,189-,190-,191-,192-,193-,194-,195-,196-,197-,198-,199-,200-,201-,202-,203-,204-,205-,206-,207-,208-,225-,226-,227-,228-,229-,230-/m0/s1 DMBFZET CS CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@H]3CSSC[C@H]4C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N5CCC[C@H]5C(=O)N[C@H](C(=O)NCC(=O)NCC(=O)N4)CC6=CC=C(C=C6)O)CC7=CC=CC=C7)CC(C)C)C(C)C)NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]8CCCN8C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC3=O)[C@@H](C)CC)C)CC9=CC=CC=C9)CC2=CC=CC=C2)CCCNC(=N)N)CC2=CNC3=CC=CC=C32)C)CC2=CC=CC=C2)CC(=O)O)C)C(C)C)CCCCN)CCCCN)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2CCC[C@H]2C(=O)N1)CC(C)C)CC(=O)N)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)N)C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)O)CC1=CC=C(C=C1)O)CCC(=O)O)CCCNC(=N)N)CCC(=O)O)CCCCN)CCC(=O)O)CO)CC1=CC=C(C=C1)O)CC1=CC=CC=C1)CCCCN)CC(=O)N)CC(=O)N)CCC(=O)N)CCCNC(=N)N)C(C)C DMBFZET IK CARVNSROHCBVAO-BUGJESOBSA-N DMBFZET IU (2S)-1-[(2S)-2-[[2-[[(1R,2aS,4S,8aS,11aS,13S,14aS,16S,17aR,19S,20aS,22S,26aS,28S,29aS,31S,32aS,34R,35aS,38aS,39R,41aS,42S,44aS,45S,47aS,48S,50aS,51R,54S,56aS,57S,59aS,60S,62aS,63S,65aS,66S,69S,72S,75S,81S,87S,90R,99S)-20a,26a,57,72-tetrakis(4-aminobutyl)-34-[[(2S)-2-[[(2S)-2-amino-4-carboxybutanoyl]amino]propanoyl]amino]-31,75,81-tris(2-amino-2-oxoethyl)-87-(3-amino-3-oxopropyl)-8a,38a,56a,59a,69-pentabenzyl-19,65a-bis[(2S)-butan-2-yl]-13,47a,48-tris(3-carbamimidamidopropyl)-45,54,60-tris(2-carboxyethyl)-35a-(carboxymethyl)-63-(hydroxymethyl)-42,66,99-tris[(4-hydroxyphenyl)methyl]-44a-(1H-indol-3-ylmethyl)-32a,41a,62a-trimethyl-11a,28-bis(2-methylpropyl)-1a,3,7a,9,10a,12,13a,15,16a,18,19a,21,22a,25a,27,28a,30,31a,33,34a,37a,40a,41,43a,44,46a,47,49a,50,53,55a,56,58a,59,61a,62,64a,65,67a,68,71,74,77,80,83,86,89,92,95,98-pentacontaoxo-14a,16,29a-tri(propan-2-yl)-36,37,69a,70a,73a,74a-hexathia-a,2,6a,8,9a,11,12a,14,15a,17,18a,20,21a,24a,26,27a,29,30a,32,33a,36a,39a,40,42a,43,45a,46,48a,49,52,54a,55,57a,58,60a,61,63a,64,66a,67,70,73,76,79,82,85,88,91,94,97-pentacontazaheptacyclo[88.77.4.451,117.04,8.022,26.0102,106.0150,154]pentaheptacontahectane-39-carbonyl]amino]acetyl]amino]-3-methylbutanoyl]pyrrolidine-2-carboxylic acid DMBFZET CA CAS 506433-25-6 DMBFZET DE Acute lung injury DMDYWM8 ID DMDYWM8 DMDYWM8 DN E-10030 DMDYWM8 HS Phase 2 DMDYWM8 SN PDGF-B antagonist (AMD), Eyetech/Archemix; PDGF-B antagonist (AMD), (OSI) Eyetech/Archemix; Platelet-derived growth factor B antagonist, (macular degernation), Eyetech/Archemix; Platelet-derived growth factor B antagonist, (macular degernation), (OSI) Eyetech/Archemix DMDYWM8 CP Archemix Corp DMDYWM8 DE Macular degeneration DMLS269 ID DMLS269 DMLS269 DN E-1224 DMLS269 HS Phase 2 DMLS269 SN BMS-292655; BMS-315801; BMS-379224; Ravuconazole prodrugs, BMS; Ravuconazole back-up compounds, Eisai; Ravuconazole prodrug (fungal infection), Brain Factory; Ravuconazole prodrugs, Bristol-Myers Squibb DMLS269 CP Bristol-Myers Squibb Co DMLS269 DT Small molecular drug DMLS269 PC 57416740 DMLS269 MW 273.14 DMLS269 FM C15H20BNO3 DMLS269 IC InChI=1S/C15H20BNO3/c1-11(18)13-12(7-6-10-17-13)8-9-16-19-14(2,3)15(4,5)20-16/h6-10H,1-5H3/b9-8+ DMLS269 CS B1(OC(C(O1)(C)C)(C)C)/C=C/C2=C(N=CC=C2)C(=O)C DMLS269 IK DAQLKAUMCVWOCH-CMDGGOBGSA-N DMLS269 IU 1-[3-[(E)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)ethenyl]pyridin-2-yl]ethanone DMLS269 DE Fungal infection DMK8SY6 ID DMK8SY6 DMK8SY6 DN E2027 DMK8SY6 HS Phase 2 DMK8SY6 CP Eisai DMK8SY6 DT Small molecular drug DMK8SY6 DE Alzheimer disease; Parkinson disease; Lewy body dementia DMC5PB2 ID DMC5PB2 DMC5PB2 DN E-4716 DMC5PB2 HS Phase 2 DMC5PB2 SN Mapinastine DMC5PB2 CP Laboratorios Dr Esteve SA DMC5PB2 DE Respiratory disease DMQERC6 ID DMQERC6 DMQERC6 DN E5555 DMQERC6 HS Phase 2 DMQERC6 SN Atopaxar DMQERC6 CP Eisai DMQERC6 DT Small molecular drug DMQERC6 PC 10459564 DMQERC6 MW 527.6 DMQERC6 FM C29H38FN3O5 DMQERC6 IC InChI=1S/C29H38FN3O5/c1-7-37-23-15-19-16-33(28(31)24(19)25(30)27(23)38-8-2)17-22(34)18-13-20(29(3,4)5)26(35-6)21(14-18)32-9-11-36-12-10-32/h13-15,31H,7-12,16-17H2,1-6H3 DMQERC6 CS CCOC1=C(C(=C2C(=C1)CN(C2=N)CC(=O)C3=CC(=C(C(=C3)N4CCOCC4)OC)C(C)(C)C)F)OCC DMQERC6 IK QWKAUGRRIXBIPO-UHFFFAOYSA-N DMQERC6 IU 1-(3-tert-butyl-4-methoxy-5-morpholin-4-ylphenyl)-2-(5,6-diethoxy-4-fluoro-3-imino-1H-isoindol-2-yl)ethanone DMQERC6 CA CAS 751475-53-3 DMQERC6 DE Acute coronary syndrome DM1S489 ID DM1S489 DM1S489 DN E6005 DM1S489 HS Phase 2 DM1S489 SN Lotamilast; 947620-48-6; E6005; E-6005; UNII-TO043KKB9C; TO043KKB9C; Methyl 4-((3-(6,7-dimethoxy-2-(methylamino)quinazolin-4-yl)phenyl)carbamoyl)benzoate; RVT-501; Methyl 4-({3-[6,7-dimethoxy-2-(methylamino)quinazolin-4-yl]phenyl}carbamoyl)benzoate; Lotamilast [USAN]; SCHEMBL369445; CHEMBL3989967; MolPort-046-033-604; BCP25249; EX-A1382; ZINC113676839; AKOS027337123; SB16962; DB12776; CS-7517; (Methyl 4-(((3-(6,7-dimethoxy-2-(methylamino)quinazolin-4-yl)phenyl(amino)carbonyl)benzoate; HY-12740; AS-52366; Benzoic acid, 4-(((3-(6,7 DM1S489 CP Eisai DM1S489 DT Small molecular drug DM1S489 PC 24864553 DM1S489 MW 472.5 DM1S489 FM C26H24N4O5 DM1S489 IC InChI=1S/C26H24N4O5/c1-27-26-29-20-14-22(34-3)21(33-2)13-19(20)23(30-26)17-6-5-7-18(12-17)28-24(31)15-8-10-16(11-9-15)25(32)35-4/h5-14H,1-4H3,(H,28,31)(H,27,29,30) DM1S489 CS CNC1=NC2=CC(=C(C=C2C(=N1)C3=CC(=CC=C3)NC(=O)C4=CC=C(C=C4)C(=O)OC)OC)OC DM1S489 IK BBTFKAOFCSOZMB-UHFFFAOYSA-N DM1S489 IU methyl 4-[[3-[6,7-dimethoxy-2-(methylamino)quinazolin-4-yl]phenyl]carbamoyl]benzoate DM1S489 CA CAS 947620-48-6 DM1S489 DE Atopic dermatitis DMOSL9P ID DMOSL9P DMOSL9P DN E6201 DMOSL9P HS Phase 2 DMOSL9P SN novel MEK inhibitors DMOSL9P CP Eisai Ltd. DMOSL9P DT Small molecular drug DMOSL9P PC 10172827 DMOSL9P MW 389.4 DMOSL9P FM C21H27NO6 DMOSL9P IC InChI=1S/C21H27NO6/c1-4-22-15-10-14-6-5-7-16(23)20(26)17(24)9-8-12(2)13(3)28-21(27)19(14)18(25)11-15/h5-6,8-13,16,20,22-23,25-26H,4,7H2,1-3H3/b6-5+,9-8-/t12-,13+,16+,20+/m1/s1 DMOSL9P CS CCNC1=CC\\2=C(C(=C1)O)C(=O)O[C@H]([C@@H](/C=C\\C(=O)[C@H]([C@H](C/C=C2)O)O)C)C DMOSL9P IK MWUFVYLAWAXDHQ-HMNLTAHHSA-N DMOSL9P IU (4S,5R,6Z,9S,10S,12E)-16-(ethylamino)-9,10,18-trihydroxy-4,5-dimethyl-3-oxabicyclo[12.4.0]octadeca-1(14),6,12,15,17-pentaene-2,8-dione DMOSL9P CA CAS 603987-35-5 DMOSL9P DE Psoriasis vulgaris DMUWJI4 ID DMUWJI4 DMUWJI4 DN E-6700 DMUWJI4 HS Phase 2 DMUWJI4 PC 9843006 DMUWJI4 MW 383.4 DMUWJI4 FM C22H25NO5 DMUWJI4 IC InChI=1S/C22H25NO5/c1-14-18(19(24)15(2)21(28-3)20(14)25)12-17(22(26)27)10-6-4-5-8-16-9-7-11-23-13-16/h7,9,11-13H,4-6,8,10H2,1-3H3,(H,26,27)/b17-12+ DMUWJI4 CS CC1=C(C(=O)C(=C(C1=O)OC)C)/C=C(\\CCCCCC2=CN=CC=C2)/C(=O)O DMUWJI4 IK WWYFKRSBSWBEGV-SFQUDFHCSA-N DMUWJI4 IU (2E)-2-[(4-methoxy-2,5-dimethyl-3,6-dioxocyclohexa-1,4-dien-1-yl)methylidene]-7-pyridin-3-ylheptanoic acid DMUWJI4 DE Asthma DMAHGKE ID DMAHGKE DMAHGKE DN E7016 DMAHGKE HS Phase 2 DMAHGKE SN UNII-M8926C7ILX; E-7016; M8926C7ILX; 902128-92-1; E7016; SCHEMBL1319757; CHEMBL3527000; BDBM97563; GPI 21016; GPI-21016; SB16889; Benzopyrano(4,3,2-de)phthalazin-3(2H)-one, 10-((4-hydroxy-1-piperidinyl)methyl)-; US8470825, 4i; E 7016 DMAHGKE CP Eisai DMAHGKE DT Small molecular drug DMAHGKE PC 11660296 DMAHGKE MW 349.4 DMAHGKE FM C20H19N3O3 DMAHGKE IC InChI=1S/C20H19N3O3/c24-13-6-8-23(9-7-13)11-12-4-5-16-15(10-12)19-18-14(20(25)22-21-19)2-1-3-17(18)26-16/h1-5,10,13,24H,6-9,11H2,(H,22,25) DMAHGKE CS C1CN(CCC1O)CC2=CC3=C(C=C2)OC4=CC=CC5=C4C3=NNC5=O DMAHGKE IK HAVFFEMDLROBGI-UHFFFAOYSA-N DMAHGKE IU 4-[(4-hydroxypiperidin-1-yl)methyl]-8-oxa-15,16-diazatetracyclo[7.7.1.02,7.013,17]heptadeca-1(16),2(7),3,5,9,11,13(17)-heptaen-14-one DMAHGKE CA CAS 902128-92-1 DMAHGKE DE Melanoma DMZRXTL ID DMZRXTL DMZRXTL DN E7820 DMZRXTL HS Phase 2 DMZRXTL SN E7820; 289483-69-8; E-7820; E 7820; UNII-TVH5K7949N; TVH5K7949N; 3-cyano-N-(3-cyano-4-methyl-1H-indol-7-yl)benzenesulfonamide; N-(3-cyano-4-methyl-1H-indol-7-yl)-3-cyanobenzene-sulfonamide; NSC-719239; N-(3-cyano-4-methyl-1H-indol-7-yl)-3-cyanobenzenesulfonamide; Benzenesulfonamide, 3-cyano-N-(3-cyano-4-methyl-1H-indol-7-yl)-; LWGUASZLXHYWIV-UHFFFAOYSA-N; AC1L52N5; ZINC8704; SCHEMBL1581157; DTXSID20183142; BCP25835; EX-A1818; 3-Cyano-N-(3-cyano-4-methyl-1H-indole-7-yl)benzensulfonamide; NSC719239; AKOS032944953; CS-6075 DMZRXTL CP Eisai DMZRXTL DT Small molecular drug DMZRXTL PC 196970 DMZRXTL MW 336.4 DMZRXTL FM C17H12N4O2S DMZRXTL IC InChI=1S/C17H12N4O2S/c1-11-5-6-15(17-16(11)13(9-19)10-20-17)21-24(22,23)14-4-2-3-12(7-14)8-18/h2-7,10,20-21H,1H3 DMZRXTL CS CC1=C2C(=CNC2=C(C=C1)NS(=O)(=O)C3=CC=CC(=C3)C#N)C#N DMZRXTL IK LWGUASZLXHYWIV-UHFFFAOYSA-N DMZRXTL IU 3-cyano-N-(3-cyano-4-methyl-1H-indol-7-yl)benzenesulfonamide DMZRXTL CA CAS 289483-69-8 DMZRXTL DE Solid tumour/cancer; Colorectal cancer DM8K5IF ID DM8K5IF DM8K5IF DN E7850 DM8K5IF HS Phase 2 DM8K5IF SN Irofulven DM8K5IF CP Eisai DM8K5IF DT Small molecular drug DM8K5IF PC 148189 DM8K5IF MW 246.3 DM8K5IF FM C15H18O3 DM8K5IF IC InChI=1S/C15H18O3/c1-8-6-10-12(11(8)7-16)9(2)15(4-5-15)14(3,18)13(10)17/h6,16,18H,4-5,7H2,1-3H3/t14-/m0/s1 DM8K5IF CS CC1=C(C2=C(C3(CC3)[C@@](C(=O)C2=C1)(C)O)C)CO DM8K5IF IK NICJCIQSJJKZAH-AWEZNQCLSA-N DM8K5IF IU (5'R)-5'-hydroxy-1'-(hydroxymethyl)-2',5',7'-trimethylspiro[cyclopropane-1,6'-indene]-4'-one DM8K5IF CA CAS 158440-71-2 DM8K5IF CB CHEBI:135002 DM8K5IF DE Solid tumour/cancer DM753H8 ID DM753H8 DM753H8 DN EB8018 DM753H8 HS Phase 2 DM753H8 SN Sibofimloc; 1616113-45-1; Antibiotic-202; VRT-1353385; UNII-00OF00QZC4; 1-[2,7-Bis[2-[(2R,3S,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]ethynyl]spiro[fluorene-9,4'-piperidine]-1'-yl]ethanone; 1-[2,7-bis({2-[(2R,3S,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]ethynyl})spiro[fluorene-9,4'-piperidine]-1'-yl]ethan-1-one; 1-[2,7-bis[2-[(2R,3S,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]ethynyl]spiro[fluorene-9,4'-piperidine]-1'-yl]ethanone; Sibofimloc [INN]; Sibofimloc [USAN]; Sibofimloc (USAN/INN); CHEMBL4594305; SCHEMBL15836795; EX-A750; Antibiotic-202;VRT-1353385; MFCD28144726; WHO 10950; ZINC209678340; ACN-052475; CS-5487; DA-43714; HY-12820; B5896; D11825; J-690221; 1-(2,7-Bis(2,6-anhydro-7,8-dideoxy-D-glycero-D-manno-oct-7-ynitol-8-yl)spiro(fluorene-9,4'-piperidin)-1'-yl)ethan-1-one; 1-[2,7-bis[2-[(2R,3S,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]ethynyl]spiro[fluorene-9,4a?piperidine]-1a?yl]ethanone; 8,8'-(1'-Acetylspiro(9H-fluorene-9,4'-piperidine)-2,7-diyl)bis(2,6-anhydro-7,8-dideoxy-D-glycero-D-manno-oct-7-ynitol); D-Glycero-D-manno-oct-7-ynitol, 8,8'-(1'-acetylspiro(9H-fluorene-9,4'-piperidine)-2,7-diyl)bis(2,6-anhydro-7,8-dideoxy- DM753H8 CP Enterome Biosciences DM753H8 DT Small molecular drug DM753H8 PC 76684239 DM753H8 MW 649.7 DM753H8 FM C35H39NO11 DM753H8 IC InChI=1S/C35H39NO11/c1-18(39)36-12-10-35(11-13-36)23-14-19(4-8-25-29(40)33(44)31(42)27(16-37)46-25)2-6-21(23)22-7-3-20(15-24(22)35)5-9-26-30(41)34(45)32(43)28(17-38)47-26/h2-3,6-7,14-15,25-34,37-38,40-45H,10-13,16-17H2,1H3/t25-,26-,27-,28-,29-,30-,31-,32-,33-,34-/m1/s1 DM753H8 CS CC(=O)N1CCC2(CC1)C3=C(C=CC(=C3)C#C[C@@H]4[C@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)C5=C2C=C(C=C5)C#C[C@@H]6[C@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O DM753H8 IK SFHMWDMKUYVSQJ-VECBPBMLSA-N DM753H8 IU 1-[2,7-bis[2-[(2R,3S,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]ethynyl]spiro[fluorene-9,4'-piperidine]-1'-yl]ethanone DM753H8 CA CAS 1616113-45-1 DM753H8 DE Crohn disease DM0KVJC ID DM0KVJC DM0KVJC DN EC-145 DM0KVJC HS Phase 2 DM0KVJC SN EC-0255; EC-0260 DM0KVJC CP Endocyte; Merck DM0KVJC PC 25014653 DM0KVJC MW 1917 DM0KVJC FM C86H109N21O26S2 DM0KVJC IC InChI=1S/C86H109N21O26S2/c1-6-82(129)35-42-36-85(78(127)132-5,64-47(21-26-106(39-42)41-82)46-12-8-9-13-50(46)95-64)49-30-48-57(34-58(49)131-4)105(3)75-84(48)23-27-107-25-11-22-83(7-2,74(84)107)76(125)86(75,130)77(126)103-104-81(128)133-28-29-134-135-40-56(73(123)124)100-70(119)55(33-62(113)114)99-69(118)54(32-61(111)112)98-67(116)51(14-10-24-90-79(87)88)96-68(117)53(31-60(109)110)94-59(108)20-19-52(72(121)122)97-66(115)43-15-17-44(18-16-43)91-37-45-38-92-65-63(93-45)71(120)102-80(89)101-65/h8-9,11-13,15-18,22,30,34,38,42,51-56,74-76,91,95,125,129-130H,6-7,10,14,19-21,23-29,31-33,35-37,39-41H2,1-5H3,(H,94,108)(H,96,117)(H,97,115)(H,98,116)(H,99,118)(H,100,119)(H,103,126)(H,104,128)(H,109,110)(H,111,112)(H,113,114)(H,121,122)(H,123,124)(H4,87,88,90)(H3,89,92,101,102,120)/t42-,51-,52-,53-,54-,55-,56-,74-,75+,76+,82-,83+,84+,85-,86-/m0/s1 DM0KVJC CS CC[C@@]1(C[C@H]2C[C@@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)NNC(=O)OCCSSC[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(=O)O)NC(=O)CC[C@@H](C(=O)O)NC(=O)C1=CC=C(C=C1)NCC1=CN=C2C(=N1)C(=O)NC(=N2)N)O)O)CC)OC)C(=O)OC)O DM0KVJC IK KUZYSQSABONDME-QRLOMCMNSA-N DM0KVJC IU (2S)-2-[[4-[(2-amino-4-oxo-3H-pteridin-6-yl)methylamino]benzoyl]amino]-5-[[(2S)-1-[[(2S)-5-carbamimidamido-1-[[(2S)-3-carboxy-1-[[(2S)-3-carboxy-1-[[(1R)-1-carboxy-2-[2-[[[(1R,9R,10S,11R,12R,19R)-12-ethyl-4-[(13S,15R,17S)-17-ethyl-17-hydroxy-13-methoxycarbonyl-1,11-diazatetracyclo[13.3.1.04,12.05,10]nonadeca-4(12),5,7,9-tetraen-13-yl]-10,11-dihydroxy-5-methoxy-8-methyl-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraene-10-carbonyl]amino]carbamoyloxy]ethyldisulfanyl]ethyl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopentan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-5-oxopentanoic acid DM0KVJC CA CAS 742092-03-1 DM0KVJC DE Solid tumour/cancer DM1LDIP ID DM1LDIP DM1LDIP DN Econail DM1LDIP HS Phase 2 DM1LDIP SN Econazole/SEPA DM1LDIP CP MacroChem Corporation DM1LDIP DT Small molecular drug DM1LDIP PC 68589 DM1LDIP MW 444.7 DM1LDIP FM C18H16Cl3N3O4 DM1LDIP IC InChI=1S/C18H15Cl3N2O.HNO3/c19-14-3-1-13(2-4-14)11-24-18(10-23-8-7-22-12-23)16-6-5-15(20)9-17(16)21;2-1(3)4/h1-9,12,18H,10-11H2;(H,2,3,4) DM1LDIP CS C1=CC(=CC=C1COC(CN2C=CN=C2)C3=C(C=C(C=C3)Cl)Cl)Cl.[N+](=O)(O)[O-] DM1LDIP IK DDXORDQKGIZAME-UHFFFAOYSA-N DM1LDIP IU 1-[2-[(4-chlorophenyl)methoxy]-2-(2,4-dichlorophenyl)ethyl]imidazole;nitric acid DM1LDIP CA CAS 24169-02-6 DM1LDIP DE Fungal infection DMKAUM9 ID DMKAUM9 DMKAUM9 DN Eculizumab DMKAUM9 HS Phase 2 DMKAUM9 SN Eculizumab (intravitreal, AMD); Eculizumab (intravitreal, AMD), Alexion; Eculizumab (intravitreal, age-related macular degeneration), Alexion DMKAUM9 CP Alexion Pharmaceuticals Inc DMKAUM9 TC Antiviral Agents DMKAUM9 DT Monoclonal antibody DMKAUM9 DE Age-related macular degeneration; Coronavirus Disease 2019 (COVID-19) DMQ08AJ ID DMQ08AJ DMQ08AJ DN Edotreotide DMQ08AJ HS Phase 2 DMQ08AJ SN Edotreotide; SMT-487; UNII-U194AS08HZ; 204318-14-9; U194AS08HZ; CHEMBL408350; DOTATOC; DOTA-D-PHE-CYS-TYR-D-TRP-LYS-THR-CYS-THR-OL (DISULFIDE BRIDGE: 2-7); SMT 487; Edotreotide [USAN:INN]; DOTA-TOC acetate; AC1L4KLV; SCHEMBL1649285; SCHEMBL19712197; RZHKDBRREKOZEW-AAXZNHDCSA-N; BDBM50165171; N-((4,7,10-Tris(carboxymethyl)-1,4,7,10-tetraazacycoldodec-1-yl)acetyl-D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryprophyl-L-lysyl-L-threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L-cysteinamide cyclic (2-7)-disulfide DMQ08AJ PC 158782 DMQ08AJ MW 1421.6 DMQ08AJ FM C65H92N14O18S2 DMQ08AJ IC InChI=1S/C65H92N14O18S2/c1-39(81)51(36-80)72-64(96)53-38-99-98-37-52(73-60(92)48(28-41-10-4-3-5-11-41)68-54(84)32-76-20-22-77(33-55(85)86)24-26-79(35-57(89)90)27-25-78(23-21-76)34-56(87)88)63(95)70-49(29-42-15-17-44(83)18-16-42)61(93)71-50(30-43-31-67-46-13-7-6-12-45(43)46)62(94)69-47(14-8-9-19-66)59(91)75-58(40(2)82)65(97)74-53/h3-7,10-13,15-18,31,39-40,47-53,58,67,80-83H,8-9,14,19-30,32-38,66H2,1-2H3,(H,68,84)(H,69,94)(H,70,95)(H,71,93)(H,72,96)(H,73,92)(H,74,97)(H,75,91)(H,85,86)(H,87,88)(H,89,90)/t39-,40-,47+,48-,49+,50-,51-,52+,53+,58+/m1/s1 DMQ08AJ CS C[C@H]([C@H]1C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@@H](CC5=CC=CC=C5)NC(=O)CN6CCN(CCN(CCN(CC6)CC(=O)O)CC(=O)O)CC(=O)O)C(=O)N[C@H](CO)[C@@H](C)O)O DMQ08AJ IK RZHKDBRREKOZEW-AAXZNHDCSA-N DMQ08AJ IU 2-[4-[2-[[(2R)-1-[[(4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-4-[[(2R,3R)-1,3-dihydroxybutan-2-yl]carbamoyl]-7-[(1R)-1-hydroxyethyl]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicos-19-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]-7,10-bis(carboxymethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetic acid DMQ08AJ CA CAS 204318-14-9 DMQ08AJ DE Acromegaly DMGJYZ8 ID DMGJYZ8 DMGJYZ8 DN EDP-305 DMGJYZ8 HS Phase 2 DMGJYZ8 DT Small molecular drug DMGJYZ8 DE Non-alcoholic steatohepatitis; Primary biliary cholangitis DM5WZ0O ID DM5WZ0O DM5WZ0O DN EDP-420 DM5WZ0O HS Phase 2 DM5WZ0O SN EP-013420 DM5WZ0O CP Enanta DM5WZ0O DT Small molecular drug DM5WZ0O PC 9875927 DM5WZ0O MW 841 DM5WZ0O FM C43H64N6O11 DM5WZ0O IC InChI=1S/C43H64N6O11/c1-12-33-43(9,54)39-26(4)35(46-29(7)50)24(2)19-42(8,56-23-31(22-55-39)47-57-21-30-14-15-34(44-20-30)49-17-13-16-45-49)38(27(5)36(51)28(6)40(53)59-33)60-41-37(52)32(48(10)11)18-25(3)58-41/h13-17,20,24-28,32-33,37-39,41,52,54H,12,18-19,21-23H2,1-11H3/b46-35?,47-31+/t24-,25-,26+,27+,28-,32+,33-,37-,38-,39-,41+,42-,43-/m1/s1 DM5WZ0O CS CC[C@@H]1[C@@]([C@H]2[C@H](C(=NC(=O)C)[C@@H](C[C@]([C@@H]([C@H](C(=O)[C@H](C(=O)O1)C)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(OC/C(=N/OCC4=CN=C(C=C4)N5C=CC=N5)/CO2)C)C)C)(C)O DM5WZ0O IK WLGSYOKBEDVHQB-ZIJNRMRWSA-N DM5WZ0O IU N-[(1R,2R,3R,6R,8R,9R,10R,13E,16S,18R)-9-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-3-ethyl-2-hydroxy-2,6,8,10,16,18-hexamethyl-5,7-dioxo-13-[(6-pyrazol-1-ylpyridin-3-yl)methoxyimino]-4,11,15-trioxabicyclo[8.5.4]nonadecan-17-ylidene]acetamide DM5WZ0O CA CAS 736992-12-4 DM5WZ0O DE Bacterial infection DM32UOC ID DM32UOC DM32UOC DN EDP-938 DM32UOC HS Phase 2 DM32UOC CP Enanta Pharmaceuticals DM32UOC DT Small molecular drug DM32UOC DE Respiratory syncytial virus infection DMX4RSD ID DMX4RSD DMX4RSD DN EFEGATRAN SULFATE HYDRATE DMX4RSD HS Phase 2 DMX4RSD SN Efegatran sulfate hydrate < Rec INNM; N-Methyl-D-phenylalanyl-L-prolyl-L-arginal sulfate hydrate; N-Methyl-D-phenylalanyl-N-[4-guanidino-1(S)-formylbutyl]-L-prolinamide sulfate hydrate DMX4RSD DT Small molecular drug DMX4RSD PC 6918161 DMX4RSD MW 532.6 DMX4RSD FM C21H36N6O8S DMX4RSD IC InChI=1S/C21H32N6O3.H2O4S.H2O/c1-24-17(13-15-7-3-2-4-8-15)20(30)27-12-6-10-18(27)19(29)26-16(14-28)9-5-11-25-21(22)23;1-5(2,3)4;/h2-4,7-8,14,16-18,24H,5-6,9-13H2,1H3,(H,26,29)(H4,22,23,25);(H2,1,2,3,4);1H2/t16-,17+,18-;;/m0../s1 DMX4RSD CS CN[C@H](CC1=CC=CC=C1)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCN=C(N)N)C=O.O.OS(=O)(=O)O DMX4RSD IK JJJFZLGPEFEADH-VWRRVXQQSA-N DMX4RSD IU (2S)-N-[(2S)-5-(diaminomethylideneamino)-1-oxopentan-2-yl]-1-[(2R)-2-(methylamino)-3-phenylpropanoyl]pyrrolidine-2-carboxamide;sulfuric acid;hydrate DMX4RSD DE Myocardial infarction DMX6RZG ID DMX6RZG DMX6RZG DN EFT508 DMX6RZG HS Phase 2 DMX6RZG SN Tomivosertib; eFT508; 1849590-01-7; EFT-508; UNII-U2H19X4WBV; U2H19X4WBV; Tomivosertib [INN]; Tomivosertib [USAN]; SCHEMBL17362622; GTPL10167; eFT-508 (eFT508); EFT 508; MolPort-044-560-418; BCP18993; EX-A2494; ZINC575623807; AKOS030627405; CS-5841; compound 23 [PMID: 29526098]; HY-100022; S8275; 6'-((6-aminopyrimidin-4-yl)amino)-8'-methyl-1'H-spiro[cyclohexane-1,3'-imidazo[1,5-a]pyridine]-1',5'(2'H)-dione; 6-[(6-aminopyrimidin-4-yl)amino]-8-methylspiro[2H-imidazo[1,5-a]pyridine-3,1'-cyclohexane]-1,5-dione DMX6RZG CP eFFECTOR Therapeutics San Diego, CA DMX6RZG PC 118598754 DMX6RZG MW 340.4 DMX6RZG FM C17H20N6O2 DMX6RZG IC InChI=1S/C17H20N6O2/c1-10-7-11(21-13-8-12(18)19-9-20-13)16(25)23-14(10)15(24)22-17(23)5-3-2-4-6-17/h7-9H,2-6H2,1H3,(H,22,24)(H3,18,19,20,21) DMX6RZG CS CC1=C2C(=O)NC3(N2C(=O)C(=C1)NC4=NC=NC(=C4)N)CCCCC3 DMX6RZG IK HKTBYUWLRDZAJK-UHFFFAOYSA-N DMX6RZG IU 6-[(6-aminopyrimidin-4-yl)amino]-8-methylspiro[2H-imidazo[1,5-a]pyridine-3,1'-cyclohexane]-1,5-dione DMX6RZG CA CAS 1849590-01-7 DMX6RZG DE Solid tumour/cancer; Colorectal cancer; Hepatocellular carcinoma; Lymphoma; Triple negative breast cancer DMBHP56 ID DMBHP56 DMBHP56 DN Efungumab DMBHP56 HS Phase 2 DMBHP56 SN Mycograb; Hsp90 mAb; Myc-123C28Y; Hsp90 mAb (cancer), NeuTec; Hsp90 mAb (Candida albicans infection/Cryptococcus neoformans meningitis), NeuTec DMBHP56 CP University of Manchester DMBHP56 DT Antibody DMBHP56 DE Breast cancer DM6L5TR ID DM6L5TR DM6L5TR DN EGEN-001 DM6L5TR HS Phase 2 DM6L5TR CP EGEN DM6L5TR DE Ovarian cancer; Peritoneal cancer; Fallopian tube cancer DMN1SWB ID DMN1SWB DMN1SWB DN EGS-21 DMN1SWB HS Phase 2 DMN1SWB SN Glucocerebroside, Enzo; Glucosylceramide, Enzo Biochem DMN1SWB CP Enzo Biochem Inc DMN1SWB DT Small molecular drug DMN1SWB PC 6475228 DMN1SWB MW 812.3 DMN1SWB FM C48H93NO8 DMN1SWB IC InChI=1S/C48H93NO8/c1-3-5-7-9-11-13-15-17-18-19-20-21-22-23-24-26-28-30-32-34-36-38-44(52)49-41(40-56-48-47(55)46(54)45(53)43(39-50)57-48)42(51)37-35-33-31-29-27-25-16-14-12-10-8-6-4-2/h35,37,41-43,45-48,50-51,53-55H,3-34,36,38-40H2,1-2H3,(H,49,52)/b37-35+/t41-,42+,43+,45+,46-,47+,48+/m0/s1 DMN1SWB CS CCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@@H](CO[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O)[C@@H](/C=C/CCCCCCCCCCCCC)O DMN1SWB IK POQRWMRXUOPCLD-GZXCKHLVSA-N DMN1SWB IU N-[(E,2S,3R)-3-hydroxy-1-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctadec-4-en-2-yl]tetracosanamide DMN1SWB CB CHEBI:84744 DMN1SWB DE Crohn disease DML7WP0 ID DML7WP0 DML7WP0 DN Eldacimibe DML7WP0 HS Phase 2 DML7WP0 SN ACA-147; WAY-ACA-147 DML7WP0 CP Wyeth DML7WP0 DT Small molecular drug DML7WP0 PC 170321 DML7WP0 MW 634.9 DML7WP0 FM C39H58N2O5 DML7WP0 IC InChI=1S/C39H58N2O5/c1-13-14-15-16-21-41(25-27-19-17-26(18-20-27)24-36(2,3)4)33(31-34(43)45-39(11,12)46-35(31)44)40-28-22-29(37(5,6)7)32(42)30(23-28)38(8,9)10/h17-20,22-23,40,42H,13-16,21,24-25H2,1-12H3 DML7WP0 CS CCCCCCN(CC1=CC=C(C=C1)CC(C)(C)C)C(=C2C(=O)OC(OC2=O)(C)C)NC3=CC(=C(C(=C3)C(C)(C)C)O)C(C)(C)C DML7WP0 IK HGLFNRGXRCKGSW-UHFFFAOYSA-N DML7WP0 IU 5-[(3,5-ditert-butyl-4-hydroxyanilino)-[[4-(2,2-dimethylpropyl)phenyl]methyl-hexylamino]methylidene]-2,2-dimethyl-1,3-dioxane-4,6-dione DML7WP0 CA CAS 141993-70-6 DML7WP0 DE Hyperlipidaemia DMCSXI4 ID DMCSXI4 DMCSXI4 DN Elezanumab DMCSXI4 HS Phase 2 DMCSXI4 CP AbbVie DMCSXI4 DT Antibody DMCSXI4 DE Multiple sclerosis; Spinal cord injury DMIOGZM ID DMIOGZM DMIOGZM DN ELIPRODIL DMIOGZM HS Phase 2 DMIOGZM SN Eliprodil; 119431-25-3; Eliprodil [INN]; C20H23ClFNO; SL 820715; SL 82-0715; CHEMBL28564; alpha-(4-Chlorophenyl)-4-[(4-fluorophenyl)methyl]-1-piperidineethanol; NCGC00092329-02; 1-Piperidineethanol, alpha-(4-chlorophenyl)-4-(4-fluorophenyl)-, (+-)-; DSSTox_RID_81089; DSSTox_CID_25744; DSSTox_GSID_45744; 1-(4-Chlorophenyl)-2-(4-(4-fluorobenzyl)piperidin-1-yl)ethanol; (+-)-alpha-(p-Chlorophenyl)-4-(p-fluorobenzyl)-1-piperidineethanol; 1-(4-chlorophenyl)-2-[4-[(4-fluorophenyl)methyl]piperidin-1-yl]ethanol DMIOGZM DT Small molecular drug DMIOGZM PC 60703 DMIOGZM MW 347.9 DMIOGZM FM C20H23ClFNO DMIOGZM IC InChI=1S/C20H23ClFNO/c21-18-5-3-17(4-6-18)20(24)14-23-11-9-16(10-12-23)13-15-1-7-19(22)8-2-15/h1-8,16,20,24H,9-14H2 DMIOGZM CS C1CN(CCC1CC2=CC=C(C=C2)F)CC(C3=CC=C(C=C3)Cl)O DMIOGZM IK GGUSQTSTQSHJAH-UHFFFAOYSA-N DMIOGZM IU 1-(4-chlorophenyl)-2-[4-[(4-fluorophenyl)methyl]piperidin-1-yl]ethanol DMIOGZM CA CAS 119431-25-3 DMIOGZM CB CHEBI:91784 DMIOGZM DE Multiple sclerosis DMB38KH ID DMB38KH DMB38KH DN Elisidepsin DMB38KH HS Phase 2 DMB38KH SN Irvalec; Elisidepsin trifluoroacetate; PM-02734; Erbb3 tyrosine kinase receptor inhibitor (cancer), PharmaMar; Kahalalide therapy (solid tumor), PharmaMar DMB38KH CP PharmaMar SA DMB38KH PC 9855343 DMB38KH MW 1477.9 DMB38KH FM C75H124N14O16 DMB38KH IC InChI=1S/C75H124N14O16/c1-20-43(15)33-34-53(91)80-54(38(5)6)68(97)87-61(46(18)90)72(101)82-56(40(9)10)69(98)83-57(41(11)12)74(103)89-36-28-32-52(89)66(95)78-50(31-27-35-76)64(93)85-59(44(16)21-2)71(100)88-62-47(19)105-75(104)58(42(13)14)84-63(92)49(23-4)77-65(94)51(37-48-29-25-24-26-30-48)79-67(96)55(39(7)8)81-70(99)60(45(17)22-3)86-73(62)102/h23-26,29-30,38-47,50-52,54-62,90H,20-22,27-28,31-37,76H2,1-19H3,(H,77,94)(H,78,95)(H,79,96)(H,80,91)(H,81,99)(H,82,101)(H,83,98)(H,84,92)(H,85,93)(H,86,102)(H,87,97)(H,88,100)/b49-23-/t43-,44-,45-,46+,47+,50-,51-,52+,54+,55+,56-,57+,58-,59+,60+,61-,62+/m0/s1 DMB38KH CS CC[C@H](C)CCC(=O)N[C@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@@H](CCCN)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]2[C@H](OC(=O)[C@@H](NC(=O)/C(=C/C)/NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@H](NC2=O)[C@@H](C)CC)C(C)C)CC3=CC=CC=C3)C(C)C)C DMB38KH IK ZNVCPJPCKSJWDH-UCTDCHLSSA-N DMB38KH IU (2R)-N-[(2S)-5-amino-1-[[(2R,3S)-1-[[(3S,6Z,9S,12R,15R,18R,19R)-9-benzyl-15-[(2S)-butan-2-yl]-6-ethylidene-19-methyl-2,5,8,11,14,17-hexaoxo-3,12-di(propan-2-yl)-1-oxa-4,7,10,13,16-pentazacyclononadec-18-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]-1-[(2R)-2-[[(2S)-2-[[(2S,3R)-3-hydroxy-2-[[(2R)-3-methyl-2-[[(4S)-4-methylhexanoyl]amino]butanoyl]amino]butanoyl]amino]-3-methylbutanoyl]amino]-3-methylbutanoyl]pyrrolidine-2-carboxamide DMB38KH CB CHEBI:83152 DMB38KH DE Psoriasis vulgaris DMR50I7 ID DMR50I7 DMR50I7 DN Elsamitrucin DMR50I7 HS Phase 2 DMR50I7 SN Elsamicin; Elsamitrucina; Elsamitrucine; Elsamitrucinum; Chartreusin analog; Elsamicin A; Antibiotic BBM 2478A; BBM 2478A; BMY 28090; SPI 28090; BBM-2478A; BMS-181171; BMY-28090; BU-2478A; Elsamitrucin [USAN:INN]; Elsamitrucina [INN-Spanish]; Elsamitrucine [INN-French]; Elsamitrucinum [INN-Latin]; E-87/025; 10-O-Elsaminosylelsarosylchartarin; 2-Amino-2,6-dideoxy-3-O-methyl-D-galactose DMR50I7 CP Spectrum DMR50I7 DT Small molecular drug DMR50I7 PC 5362259 DMR50I7 MW 653.6 DMR50I7 FM C33H35NO13 DMR50I7 IC InChI=1S/C33H35NO13/c1-11-9-10-16-19-17(11)29(38)46-25-18-14(24(36)21(20(19)25)30(39)44-16)7-6-8-15(18)45-32-28(33(4,40)27(37)13(3)43-32)47-31-22(34)26(41-5)23(35)12(2)42-31/h6-10,12-13,22-23,26-28,31-32,35-37,40H,34H2,1-5H3/t12-,13-,22-,23+,26-,27+,28+,31-,32+,33+/m1/s1 DMR50I7 CS C[C@@H]1[C@@H]([C@@H]([C@H]([C@H](O1)O[C@H]2[C@@H](O[C@@H]([C@@H]([C@]2(C)O)O)C)OC3=CC=CC4=C3C5=C6C7=C(C=CC(=C7C(=O)O5)C)OC(=O)C6=C4O)N)OC)O DMR50I7 IK MGQRRMONVLMKJL-KWJIQSIXSA-N DMR50I7 IU 3-[(2S,3R,4S,5S,6R)-3-[(2R,3R,4R,5S,6R)-3-amino-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy-8-hydroxy-15-methyl-11,18-dioxapentacyclo[10.6.2.02,7.09,19.016,20]icosa-1(19),2(7),3,5,8,12(20),13,15-octaene-10,17-dione DMR50I7 CA CAS 97068-30-9 DMR50I7 DE Solid tumour/cancer DMB7CPG ID DMB7CPG DMB7CPG DN Elsiglutide DMB7CPG HS Phase 2 DMB7CPG SN Tide ZP-1846; ZP-1846; GLP-2 analog (chemotherapy-induced diarrhoea), Zealand Pharma DMB7CPG CP Zealand Pharma A/S DMB7CPG DE Diarrhea DMYOUB6 ID DMYOUB6 DMYOUB6 DN EMA-401 DMYOUB6 HS Phase 2 DMYOUB6 SN Neuropathic pain targeting small molecules (postherpetic neuralgia), Spinifex DMYOUB6 CP Spinifex pharmaceuticals DMYOUB6 DT Small molecular drug DMYOUB6 PC 9937291 DMYOUB6 MW 507.6 DMYOUB6 FM C32H29NO5 DMYOUB6 IC InChI=1S/C32H29NO5/c1-37-28-18-17-25-20-33(31(34)29(23-13-7-3-8-14-23)24-15-9-4-10-16-24)27(32(35)36)19-26(25)30(28)38-21-22-11-5-2-6-12-22/h2-18,27,29H,19-21H2,1H3,(H,35,36)/t27-/m0/s1 DMYOUB6 CS COC1=C(C2=C(CN([C@@H](C2)C(=O)O)C(=O)C(C3=CC=CC=C3)C4=CC=CC=C4)C=C1)OCC5=CC=CC=C5 DMYOUB6 IK GHBCIXGRCZIPNQ-MHZLTWQESA-N DMYOUB6 IU (3S)-2-(2,2-diphenylacetyl)-6-methoxy-5-phenylmethoxy-3,4-dihydro-1H-isoquinoline-3-carboxylic acid DMYOUB6 CA CAS 1316755-16-4 DMYOUB6 DE Postherpetic neuralgia; Peripheral neuropathy DMCLT2F ID DMCLT2F DMCLT2F DN Emepepimut-S DMCLT2F HS Phase 2 DMCLT2F CP EMD Serono; Oncothyreon DMCLT2F DT Vaccine DMCLT2F DE Non-small-cell lung cancer DMT4MKF ID DMT4MKF DMT4MKF DN Emibetuzumab DMT4MKF HS Phase 2 DMT4MKF CP Eli Lilly Indianapolis, IN DMT4MKF DE Solid tumour/cancer DMQH1NV ID DMQH1NV DMQH1NV DN Emivirine DMQH1NV HS Phase 2 DMQH1NV SN Emivirine; Coactinon; MKC-442; 149950-60-7; I-EBU; 6-Benzyl-1-(ethoxymethyl)-5-isopropyluracil; 1EtOMe6Bz5i-Pr-U; Emivirine [USAN:INN]; Mkc 442; UNII-X87G8IX72O; 6-BENZYL-1-ETHOXYMETHYL-5-ISOPROPYL URACIL; DRG-0302; CHEMBL35033; X87G8IX72O; CHEBI:44143; 6-benzyl-1-(ethoxymethyl)-5-(1-methylethyl)uracil; 6-benzyl-1-(ethoxymethyl)-5-isopropylpyrimidine-2,4(1H,3H)-dione; 1-(ethoxymethyl)-5-(1-methylethyl)-6-(phenylmethyl)pyrimidine-2,4(1H,3H)-dione; 2,4(1H,3H)-Pyrimidinedione, 1-(ethoxymethyl)-5-(1-methylethyl)-6-(phenylmethyl) DMQH1NV DT Small molecular drug DMQH1NV PC 65013 DMQH1NV MW 302.37 DMQH1NV FM C17H22N2O3 DMQH1NV IC InChI=1S/C17H22N2O3/c1-4-22-11-19-14(10-13-8-6-5-7-9-13)15(12(2)3)16(20)18-17(19)21/h5-9,12H,4,10-11H2,1-3H3,(H,18,20,21) DMQH1NV CS CCOCN1C(=C(C(=O)NC1=O)C(C)C)CC2=CC=CC=C2 DMQH1NV IK MLILORUFDVLTSP-UHFFFAOYSA-N DMQH1NV IU 6-benzyl-1-(ethoxymethyl)-5-propan-2-ylpyrimidine-2,4-dione DMQH1NV CA CAS 149950-60-7 DMQH1NV CB CHEBI:44143 DMQH1NV DE Human immunodeficiency virus infection DMDEL3F ID DMDEL3F DMDEL3F DN EMZ701 DMDEL3F HS Phase 2 DMDEL3F SN Interferon enhancing therapy DMDEL3F CP Transition Therapeutics DMDEL3F DE Hepatitis B virus infection DMGFZOL ID DMGFZOL DMGFZOL DN Enadoline DMGFZOL HS Phase 2 DMGFZOL SN ENADOLINE; 124378-77-4; UNII-KJL283326C; CI-977; 2-(Benzofuran-4-yl)-N-methyl-N-((5R,7S,8S)-7-(pyrrolidin-1-yl)-1-oxaspiro[45]decan-8-yl)acetamide; CHEMBL318859; KJL283326C; CI 977; 4-Benzofuranacetamide, N-methyl-N-((5R,7S,8S)-7-(1-pyrrolidinyl)-1-oxaspiro(45)dec-8-yl)-; [3H]enadoline; Enadoline [INN]; [3H]-enadoline; C24H32N2O3; 2-(1-benzofuran-4-yl)-N-methyl-N-[(5R,7S,8S)-7-pyrrolidin-1-yl-1-oxaspiro[45]decan-8-yl]acetamide; [3H]CI977; [3H]CI-977; [3H]-CI977; AC1L1TVT; AC1Q5HUV; DSSTox_CID_27258; DSSTox_RID_82216; Enadoline hydrochloride; PD-129290 DMGFZOL CP Parke-Davis & Co DMGFZOL DT Small molecular drug DMGFZOL PC 60768 DMGFZOL MW 396.5 DMGFZOL FM C24H32N2O3 DMGFZOL IC InChI=1S/C24H32N2O3/c1-25(23(27)16-18-6-4-7-22-19(18)9-15-28-22)20-8-11-24(10-5-14-29-24)17-21(20)26-12-2-3-13-26/h4,6-7,9,15,20-21H,2-3,5,8,10-14,16-17H2,1H3/t20-,21-,24-/m0/s1 DMGFZOL CS CN([C@H]1CC[C@@]2(CCCO2)C[C@@H]1N3CCCC3)C(=O)CC4=C5C=COC5=CC=C4 DMGFZOL IK JMBYBVLCYODBJQ-HFMPRLQTSA-N DMGFZOL IU 2-(1-benzofuran-4-yl)-N-methyl-N-[(5R,7S,8S)-7-pyrrolidin-1-yl-1-oxaspiro[4.5]decan-8-yl]acetamide DMGFZOL CA CAS 124378-77-4 DMGFZOL DE Pain DMM8Z3Q ID DMM8Z3Q DMM8Z3Q DN Encequidar DMM8Z3Q HS Phase 2 DMM8Z3Q SN 849675-66-7; HM-30181-A; HM-30181; HM30181; UNII-K4I4I996O4; K4I4I996O4; 849675-66-7 (free base); HM 30181A; N-(2-(2-(4-(2-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)phenyl)-2H-tetrazol-5-yl)-4,5-dimethoxyphenyl)-4-oxo-4H-chromene-2-carboxamide; HM30181A; Encequidar [USAN]; HM-30181A; Encequidar (USAN/INN); HM-30181 free base; CHEMBL4594298; SCHEMBL13822558; EX-A3429A; BCP25240; MFCD25976625; WHO 10861; ZINC68014383; CS-6194; DB14070; SB18921; 4-Oxo-4H-chromene-2-carboxylic acid (2-(2-4-(2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-ethyl)-phenyl-2H-tetrazol-5-yl)-4,5-dimethoxy-phenyl)-amide; AS-35283; HY-13646; D11782; Q27281950; 4-oxo-4H-chromen-2-carboxylic acid [2-(2-{4-[2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-ethyl]-phenyl}-2H-tetrazol-5-yl)-4,5-dimethoxy-phenyl]-amide; 4H-1-Benzopyran-2-carboxamide, N-[2-[2-[4-[2-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)ethyl]phenyl]-2H-tetrazol-5-yl]-4,5-dimethoxyphenyl]-4-oxo-; N-(2-(2-(4-(2-(6,7-dimethoxy-3,4-dihydroisoquinoline-2(1H)-yl)ethyl)phenyl)-2H-tetrazol-5-yl)-4,5-dimethoxyphenyl)-4-oxo-4H-chromene-2-carboxamide; N-[2-[2-[4-[2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)ethyl]phenyl]tetrazol-5-yl]-4,5-dimethoxyphenyl]-4-oxochromene-2-carboxamide DMM8Z3Q CP Athenex Oncology DMM8Z3Q DT Small molecular drug DMM8Z3Q PC 11399764 DMM8Z3Q MW 688.7 DMM8Z3Q FM C38H36N6O7 DMM8Z3Q IC InChI=1S/C38H36N6O7/c1-47-32-17-24-14-16-43(22-25(24)18-33(32)48-2)15-13-23-9-11-26(12-10-23)44-41-37(40-42-44)28-19-34(49-3)35(50-4)20-29(28)39-38(46)36-21-30(45)27-7-5-6-8-31(27)51-36/h5-12,17-21H,13-16,22H2,1-4H3,(H,39,46) DMM8Z3Q CS COC1=C(C=C2CN(CCC2=C1)CCC3=CC=C(C=C3)N4N=C(N=N4)C5=CC(=C(C=C5NC(=O)C6=CC(=O)C7=CC=CC=C7O6)OC)OC)OC DMM8Z3Q IK AHJUHHDDCJQACA-UHFFFAOYSA-N DMM8Z3Q IU N-[2-[2-[4-[2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)ethyl]phenyl]tetrazol-5-yl]-4,5-dimethoxyphenyl]-4-oxochromene-2-carboxamide DMM8Z3Q CA CAS 849675-66-7 DMM8Z3Q DE Metastatic breast cancer DM8NLDI ID DM8NLDI DM8NLDI DN Endostatin DM8NLDI HS Phase 2 DM8NLDI CP EntreMed DM8NLDI PC 187888 DM8NLDI MW 178.19 DM8NLDI FM C9H10N2O2 DM8NLDI IC InChI=1S/C9H10N2O2/c1-11(10-13)7-9(12)8-5-3-2-4-6-8/h2-6H,7H2,1H3 DM8NLDI CS CN(CC(=O)C1=CC=CC=C1)N=O DM8NLDI IK AAFYOVPTFNNVDN-UHFFFAOYSA-N DM8NLDI IU N-methyl-N-phenacylnitrous amide DM8NLDI CA CAS 55984-52-6 DM8NLDI DE Solid tumour/cancer DMTX8IZ ID DMTX8IZ DMTX8IZ DN Endoxifen DMTX8IZ HS Phase 2 DMTX8IZ SN Endoxifen (topical formulation, cancer); Endoxifen (topical formulation, cancer), Jina Pharmaceuticals; Tamoxifen metabolite (topical formulation, cancer), Jina Pharmaceuticals DMTX8IZ CP Jina Pharmaceuticals Inc DMTX8IZ DT Small molecular drug DMTX8IZ PC 10090750 DMTX8IZ MW 373.5 DMTX8IZ FM C25H27NO2 DMTX8IZ IC InChI=1S/C25H27NO2/c1-3-24(19-7-5-4-6-8-19)25(20-9-13-22(27)14-10-20)21-11-15-23(16-12-21)28-18-17-26-2/h4-16,26-27H,3,17-18H2,1-2H3/b25-24- DMTX8IZ CS CC/C(=C(\\C1=CC=C(C=C1)O)/C2=CC=C(C=C2)OCCNC)/C3=CC=CC=C3 DMTX8IZ IK MHJBZVSGOZTKRH-IZHYLOQSSA-N DMTX8IZ IU 4-[(Z)-1-[4-[2-(methylamino)ethoxy]phenyl]-2-phenylbut-1-enyl]phenol DMTX8IZ CA CAS 112093-28-4 DMTX8IZ CB CHEBI:80555 DMTX8IZ DE Breast cancer DMMIHSO ID DMMIHSO DMMIHSO DN ENERGI-F701 DMMIHSO HS Phase 2 DMMIHSO CP Energenesis Biomedical DMMIHSO DT Small molecular drug DMMIHSO DE Alopecia DM96NCR ID DM96NCR DM96NCR DN Eniluracil DM96NCR HS Phase 2 DM96NCR SN Eniluracil; 5-ETHYNYLURACIL; 59989-18-3; 5-ethynylpyrimidine-2,4(1H,3H)-dione; Compound 776C; GW776C85; 5-Ethynylpyrimidine-2,4-diol; 776C85; UNII-2E2W0W5XIU; 5-ethynyl-1H-pyrimidine-2,4-dione; 5-Ethynyl-2,4(1H,3H)-pyrimidinedione; 5-Ethynyl-4-hydroxypyrimidin-2(1H)-one; 5-Ethynyl-6-hydroxypyrimidin-2(1H)-one; 5-Ethynyl-2-hydroxypyrimidin-4(3H)-one; 5-Ethynyl-2-hydroxypyrimidin-4(1H)-one; 5-Ethynyl-2,4(1H,3H)pyrimidinedione; 2E2W0W5XIU; 2,4(1H,3H)-Pyrimidinedione, 5-ethynyl-; CHEMBL355200; C6H4N2O2; Eniluracil [USAN] DM96NCR CP Adherex Technologies DM96NCR DT Small molecular drug DM96NCR PC 43157 DM96NCR MW 136.11 DM96NCR FM C6H4N2O2 DM96NCR IC InChI=1S/C6H4N2O2/c1-2-4-3-7-6(10)8-5(4)9/h1,3H,(H2,7,8,9,10) DM96NCR CS C#CC1=CNC(=O)NC1=O DM96NCR IK JOZGNYDSEBIJDH-UHFFFAOYSA-N DM96NCR IU 5-ethynyl-1H-pyrimidine-2,4-dione DM96NCR CA CAS 59989-18-3 DM96NCR DE Hyperlipidaemia DMJZVPB ID DMJZVPB DMJZVPB DN ENMD-2076 DMJZVPB HS Phase 2 DMJZVPB SN ENMD-2076; 934353-76-1; ENMD 2076; (E)-N-(5-Methyl-1H-pyrazol-3-yl)-6-(4-methylpiperazin-1-yl)-2-styrylpyrimidin-4-amine; UNII-J6U9WP10T7; ENMD2076; J6U9WP10T7; CHEMBL482968; 6-(4-methylpiperazin-1-yl)-N-(5-methyl-1H-pyrazol-3-yl)-2-[(E)-2-phenylethenyl]pyrimidin-4-amine; 6-(4-METHYL-1-PIPERAZINYL)-N-(5-METHYL-1H-PYRAZOL-3-YL)-2-[(1E)-2-PHENYLETHENYL]-4-PYRIMIDINAMINE; ENMD-981693; MLS006011042; SCHEMBL596481; GTPL7885; SCHEMBL15668060; SCHEMBL10122872; ENND-2076; EX-A235; DTXSID60239430; MolPort-009-679-391; AOB87159 DMJZVPB CP Entremed DMJZVPB DT Small molecular drug DMJZVPB PC 16041424 DMJZVPB MW 375.5 DMJZVPB FM C21H25N7 DMJZVPB IC InChI=1S/C21H25N7/c1-16-14-20(26-25-16)23-19-15-21(28-12-10-27(2)11-13-28)24-18(22-19)9-8-17-6-4-3-5-7-17/h3-9,14-15H,10-13H2,1-2H3,(H2,22,23,24,25,26)/b9-8+ DMJZVPB CS CC1=CC(=NN1)NC2=CC(=NC(=N2)/C=C/C3=CC=CC=C3)N4CCN(CC4)C DMJZVPB IK BLQYVHBZHAISJM-CMDGGOBGSA-N DMJZVPB IU 6-(4-methylpiperazin-1-yl)-N-(5-methyl-1H-pyrazol-3-yl)-2-[(E)-2-phenylethenyl]pyrimidin-4-amine DMJZVPB CA CAS 934353-76-1 DMJZVPB DE Acute myeloid leukaemia; Fibrolamellar liver cancer; Hepatocellular carcinoma; Triple negative breast cancer DMDS20X ID DMDS20X DMDS20X DN Enoblituzumab DMDS20X HS Phase 2 DMDS20X CP MacroGenics Rockville, MD DMDS20X DE Solid tumour/cancer; Prostate cancer DMLPRZJ ID DMLPRZJ DMLPRZJ DN Ensaculin hydrochloride DMLPRZJ HS Phase 2 DMLPRZJ SN Anseculin hydrochloride; Ensaculin hydrochloride; KA-672.HCl; 7-Methoxy-6-[3-[4-(2-methoxyphenyl)piperazin-1-yl]propoxy]-3,4-dimethyl-2H-1-benzopyran-2-one hydrochloride DMLPRZJ DT Small molecular drug DMLPRZJ PC 6918282 DMLPRZJ MW 489 DMLPRZJ FM C26H33ClN2O5 DMLPRZJ IC InChI=1S/C26H32N2O5.ClH/c1-18-19(2)26(29)33-23-17-24(31-4)25(16-20(18)23)32-15-7-10-27-11-13-28(14-12-27)21-8-5-6-9-22(21)30-3;/h5-6,8-9,16-17H,7,10-15H2,1-4H3;1H DMLPRZJ CS CC1=C(C(=O)OC2=CC(=C(C=C12)OCCCN3CCN(CC3)C4=CC=CC=C4OC)OC)C.Cl DMLPRZJ IK XMONKHCPLIYQCY-UHFFFAOYSA-N DMLPRZJ IU 7-methoxy-6-[3-[4-(2-methoxyphenyl)piperazin-1-yl]propoxy]-3,4-dimethylchromen-2-one;hydrochloride DMLPRZJ DE Parkinson disease DM69NF1 ID DM69NF1 DM69NF1 DN EP-101 DM69NF1 HS Phase 2 DM69NF1 SN 106-86-5; 1,2-Epoxy-4-vinylcyclohexane; 3-Vinyl-7-oxabicyclo[4.1.0]heptane; Epoxide 101; 4-Vinylcyclohexene oxide; Unoxat epoxide 101; Vinylcyclohexane monoxide; 4-Vinyl-1,2-epoxycyclohexane; 1-Vinyl-3,4-epoxycyclohexane; 4-Vinylcyclohexene monoxide; 3,4-Epoxycyclohexylethylene; 7-Oxabicyclo[4.1.0]heptane, 3-ethenyl-; 4-Vinylcyclohexane monoepoxide; EP-101; Vinylcyclohexene monoxide; 4-Vinylcyclohexene-1,2-epoxide; 4-Vinylcyclohexane, 1,2-epoxide; EINECS 203-436-1; 4-Vinyl-1-Cyclohexene 1,2-Epoxide; NSC 35409 DM69NF1 CP Elevation Pharmaceuticals DM69NF1 DT Small molecular drug DM69NF1 PC 7832 DM69NF1 MW 124.18 DM69NF1 FM C8H12O DM69NF1 IC InChI=1S/C8H12O/c1-2-6-3-4-7-8(5-6)9-7/h2,6-8H,1,3-5H2 DM69NF1 CS C=CC1CCC2C(C1)O2 DM69NF1 IK SLJFKNONPLNAPF-UHFFFAOYSA-N DM69NF1 IU 3-ethenyl-7-oxabicyclo[4.1.0]heptane DM69NF1 CA CAS 106-86-5 DM69NF1 DE Chronic obstructive pulmonary disease; Breast cancer DMPC4EK ID DMPC4EK DMPC4EK DN EP-217609 DMPC4EK HS Phase 2 DMPC4EK SN Neutralizable NAPAP analog (thrombosis), Endotis; Neutralizable NAPAP analog (thrombosis), Organon; Fondaparinux analog + thrombin inhibitor (thrombosis), Endotis; Neutralizable Factor IIa/Factor X dual inhibitor (thrombosis), Endotis; Neutralizable Factor IIa/Factor X dual inhibitor (thrombosis), Organon DMPC4EK CP Organon BioSciences DMPC4EK PC 11686894 DMPC4EK MW 2647.8 DMPC4EK FM C95H151N11O59S8 DMPC4EK IC InChI=1S/C95H151N11O59S8/c1-48-41-57(138-4)49(2)50(3)83(48)167(118,119)105-54(86(111)102-55(87(112)106-32-18-13-19-33-106)42-51-25-27-52(28-26-51)84(96)97)43-64(109)99-30-20-24-63(108)101-53(21-16-17-29-98-62(107)23-15-14-22-61-65-56(47-166-61)103-95(117)104-65)85(110)100-31-34-147-35-36-148-37-38-149-39-40-150-66-58(44-151-168(120,121)122)155-91(78(143-9)69(66)139-5)159-73-71(141-7)80(145-11)93(162-76(73)88(113)114)158-68-60(46-153-170(126,127)128)156-94(82(165-173(135,136)137)75(68)163-171(129,130)131)160-74-72(142-8)79(144-10)92(161-77(74)89(115)116)157-67-59(45-152-169(123,124)125)154-90(146-12)81(70(67)140-6)164-172(132,133)134/h25-28,41,53-56,58-61,65-82,90-94,105H,13-24,29-40,42-47H2,1-12H3,(H3,96,97)(H,98,107)(H,99,109)(H,100,110)(H,101,108)(H,102,111)(H,113,114)(H,115,116)(H2,103,104,117)(H,120,121,122)(H,123,124,125)(H,126,127,128)(H,129,130,131)(H,132,133,134)(H,135,136,137)/t53-,54-,55+,56-,58+,59+,60+,61-,65-,66+,67+,68+,69-,70-,71-,72-,73-,74-,75-,76-,77+,78+,79+,80+,81+,82+,90-,91+,92+,93+,94+/m0/s1 DMPC4EK CS CC1=CC(=C(C(=C1S(=O)(=O)N[C@@H](CC(=O)NCCCC(=O)N[C@@H](CCCCNC(=O)CCCC[C@H]2[C@@H]3[C@H](CS2)NC(=O)N3)C(=O)NCCOCCOCCOCCO[C@@H]4[C@H](O[C@@H]([C@@H]([C@H]4OC)OC)O[C@H]5[C@@H]([C@H]([C@@H](O[C@@H]5C(=O)O)O[C@@H]6[C@H](O[C@@H]([C@@H]([C@H]6OS(=O)(=O)O)OS(=O)(=O)O)O[C@H]7[C@@H]([C@H]([C@@H](O[C@H]7C(=O)O)O[C@@H]8[C@H](O[C@@H]([C@@H]([C@H]8OC)OS(=O)(=O)O)OC)COS(=O)(=O)O)OC)OC)COS(=O)(=O)O)OC)OC)COS(=O)(=O)O)C(=O)N[C@H](CC9=CC=C(C=C9)C(=N)N)C(=O)N1CCCCC1)C)C)OC DMPC4EK IK QIBHGITUGYXJDF-UDLCEBFESA-N DMPC4EK IU (2S,3S,4S,5R,6R)-3-[(2R,3R,4S,5R,6R)-5-[2-[2-[2-[2-[[(2S)-6-[5-[(3aS,4S,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-2-[4-[[(3S)-4-[[(2R)-3-(4-carbamimidoylphenyl)-1-oxo-1-piperidin-1-ylpropan-2-yl]amino]-3-[(4-methoxy-2,3,6-trimethylphenyl)sulfonylamino]-4-oxobutanoyl]amino]butanoylamino]hexanoyl]amino]ethoxy]ethoxy]ethoxy]ethoxy]-3,4-dimethoxy-6-(sulfooxymethyl)oxan-2-yl]oxy-6-[(2R,3R,4S,5R,6R)-6-[(2R,3S,4S,5R,6R)-2-carboxy-6-[(2R,3R,4S,5R,6S)-4,6-dimethoxy-5-sulfooxy-2-(sulfooxymethyl)oxan-3-yl]oxy-4,5-dimethoxyoxan-3-yl]oxy-4,5-disulfooxy-2-(sulfooxymethyl)oxan-3-yl]oxy-4,5-dimethoxyoxane-2-carboxylic acid DMPC4EK CA CAS 894494-99-6 DMPC4EK DE Thrombosis DMZT7EP ID DMZT7EP DMZT7EP DN EPI 589 DMZT7EP HS Phase 2 DMZT7EP SN (R)-troloxamide quinone; EPI-589 DMZT7EP CP BioElectron Technology Mountain View, CA Sumitomo Dainippon Pharma Osaka, Japan DMZT7EP DE Amyotrophic lateral sclerosis; Parkinson disease DMWK26Q ID DMWK26Q DMWK26Q DN EPX-200 DMWK26Q HS Phase 2 DMWK26Q CP Epygenix Therapeutics Paramus, NJ DMWK26Q DE Dravet syndrome DMUXDGZ ID DMUXDGZ DMUXDGZ DN EPX-300 DMUXDGZ HS Phase 2 DMUXDGZ CP Epygenix Therapeutics Paramus, NJ DMD4YRG ID DMD4YRG DMD4YRG DN EQ-917 DMD4YRG HS Phase 2 DMD4YRG CP Equispharm Co Ltd DMD4YRG DE Solid tumour/cancer DMCEPUA ID DMCEPUA DMCEPUA DN ERB-041 DMCEPUA HS Phase 2 DMCEPUA SN 2-(3-Fluoro-4-hydroxyphenyl)-7-vinylbenzoxazol-5-ol DMCEPUA DT Small molecular drug DMCEPUA PC 656954 DMCEPUA MW 271.24 DMCEPUA FM C15H10FNO3 DMCEPUA IC InChI=1S/C15H10FNO3/c1-2-8-5-10(18)7-12-14(8)20-15(17-12)9-3-4-13(19)11(16)6-9/h2-7,18-19H,1H2 DMCEPUA CS C=CC1=C2C(=CC(=C1)O)N=C(O2)C3=CC(=C(C=C3)O)F DMCEPUA IK MQIMZDXIAHJKQP-UHFFFAOYSA-N DMCEPUA IU 7-ethenyl-2-(3-fluoro-4-hydroxyphenyl)-1,3-benzoxazol-5-ol DMCEPUA CA CAS 524684-52-4 DMCEPUA DE Inflammatory bowel disease DMU1XZD ID DMU1XZD DMU1XZD DN Erteberel DMU1XZD HS Phase 2 DMU1XZD SN LY-500307; SERBA-1; ER beta agonist (BPH), Lilly; Lead estrogen receptor beta agonists (benign prostatic hyperplasia),Eli Lilly DMU1XZD CP Eli Lilly & Co DMU1XZD DT Small molecular drug DMU1XZD PC 10286159 DMU1XZD MW 282.3 DMU1XZD FM C18H18O3 DMU1XZD IC InChI=1S/C18H18O3/c19-12-6-4-11(5-7-12)18-15-3-1-2-14(15)16-10-13(20)8-9-17(16)21-18/h4-10,14-15,18-20H,1-3H2/t14-,15+,18+/m1/s1 DMU1XZD CS C1C[C@H]2[C@@H](C1)C3=C(C=CC(=C3)O)O[C@H]2C4=CC=C(C=C4)O DMU1XZD IK XIESSJVMWNJCGZ-VKJFTORMSA-N DMU1XZD IU (3aS,4R,9bR)-4-(4-hydroxyphenyl)-1,2,3,3a,4,9b-hexahydrocyclopenta[c]chromen-8-ol DMU1XZD CA CAS 533884-09-2 DMU1XZD DE Prostate hyperplasia DM5Z3VP ID DM5Z3VP DM5Z3VP DN Ertumaxomab DM5Z3VP HS Phase 2 DM5Z3VP SN Rexomab; Rexomun; Trifunctional antibody (breast cancer), TRION/Fresenius; Trifunctional bispecific (CD3/Her2/neu) antibody (breast cancer), TRION/Fresenius DM5Z3VP CP Trion DM5Z3VP DT Antibody DM5Z3VP DE Breast cancer DMYZWDC ID DMYZWDC DMYZWDC DN ESBA-105 DMYZWDC HS Phase 2 DMYZWDC SN ESBA-105 (ophthalmic liquid formulation); ESBA-105 (ophthalmic liquid formulation), ESBATech; Anti-cytokine single-chain antibody (inflammation), ESBATech DMYZWDC CP ESBATech AG DMYZWDC DT Antibody DMYZWDC DE Ocular disease DMTB63Q ID DMTB63Q DMTB63Q DN Estetrol DMTB63Q HS Phase 2 DMTB63Q SN Estetrol (oral, contraception/hormone deficiency/osteoporosis/cardiovascular disease/autoimmune disease/breast cancer/prostate cancer); Estetrol (oral, contraception/hormone deficiency/osteoporosis/cardiovascular disease/autoimmune disease/breast cancer/prostate cancer), Pantarhei; Estrogen receptor modulator (oral, contraception/hormone deficiency/autoimmune disease/breast cancer/prostate cancer/osteoporosis/cardiovascular disease), Pantarhei DMTB63Q CP Pantarhei Bioscience BV DMTB63Q DT Small molecular drug DMTB63Q PC 27125 DMTB63Q MW 304.4 DMTB63Q FM C18H24O4 DMTB63Q IC InChI=1S/C18H24O4/c1-18-7-6-12-11-5-3-10(19)8-9(11)2-4-13(12)14(18)15(20)16(21)17(18)22/h3,5,8,12-17,19-22H,2,4,6-7H2,1H3/t12-,13-,14-,15-,16-,17+,18+/m1/s1 DMTB63Q CS C[C@]12CC[C@H]3[C@H]([C@@H]1[C@H]([C@H]([C@@H]2O)O)O)CCC4=C3C=CC(=C4)O DMTB63Q IK AJIPIJNNOJSSQC-NYLIRDPKSA-N DMTB63Q IU (8R,9S,13S,14S,15R,16R,17R)-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,15,16,17-tetrol DMTB63Q CA CAS 15183-37-6 DMTB63Q CB CHEBI:142773 DMTB63Q DE Autoimmune diabetes DM71BZV ID DM71BZV DM71BZV DN Etamicastat DM71BZV HS Phase 2 DM71BZV SN BIA-5453; Dopamine beta hydroxylase inhibitors (cardiovascular diseases), BIAL; Dopamine beta hydroxylase inhibitors (cardiovascular diseases), Portela DM71BZV CP Portela & Ca SA DM71BZV DT Small molecular drug DM71BZV PC 10450387 DM71BZV MW 311.35 DM71BZV FM C14H15F2N3OS DM71BZV IC InChI=1S/C14H15F2N3OS/c15-9-3-8-4-11(7-20-13(8)12(16)5-9)19-10(1-2-17)6-18-14(19)21/h3,5-6,11H,1-2,4,7,17H2,(H,18,21)/t11-/m1/s1 DM71BZV CS C1[C@H](COC2=C1C=C(C=C2F)F)N3C(=CNC3=S)CCN DM71BZV IK CWWWTTYMUOYSQA-LLVKDONJSA-N DM71BZV IU 4-(2-aminoethyl)-3-[(3R)-6,8-difluoro-3,4-dihydro-2H-chromen-3-yl]-1H-imidazole-2-thione DM71BZV CA CAS 760173-05-5 DM71BZV DE Heart failure DMOCID7 ID DMOCID7 DMOCID7 DN Etazolate DMOCID7 HS Phase 2 DMOCID7 SN Etazolate hydrochloride; EHT-0202; SQ-20009 DMOCID7 CP Exonhit DMOCID7 DT Small molecular drug DMOCID7 PC 3277 DMOCID7 MW 289.33 DMOCID7 FM C14H19N5O2 DMOCID7 IC InChI=1S/C14H19N5O2/c1-5-19-13-10(8-16-19)12(18-17-9(3)4)11(7-15-13)14(20)21-6-2/h7-8H,5-6H2,1-4H3,(H,15,18) DMOCID7 CS CCN1C2=NC=C(C(=C2C=N1)NN=C(C)C)C(=O)OCC DMOCID7 IK OPQRBXUBWHDHPQ-UHFFFAOYSA-N DMOCID7 IU ethyl 1-ethyl-4-(2-propan-2-ylidenehydrazinyl)pyrazolo[3,4-b]pyridine-5-carboxylate DMOCID7 CA CAS 51022-77-6 DMOCID7 CB CHEBI:93135 DMOCID7 DE Neurodegenerative disorder DM68K39 ID DM68K39 DM68K39 DN ETIPREDNOL DICLOACETATE DM68K39 HS Phase 2 DM68K39 SN BNP-166; Cronaze (Ivax); Ethinase (Ivax); Etiprednol dicloacetate < USAN; Respicort (Ivax); (11beta,17alpha)-17-(2,2-Dichloroacetoxy)-11-hydroxy-3-oxoandrosta-1,4-diene-17-carboxylic acid ethyl ester DM68K39 CP Teva Pharmaceutical USA DM68K39 DT Small molecular drug DM68K39 PC 9935073 DM68K39 MW 485.4 DM68K39 FM C24H30Cl2O6 DM68K39 IC InChI=1S/C24H30Cl2O6/c1-4-31-21(30)24(32-20(29)19(25)26)10-8-16-15-6-5-13-11-14(27)7-9-22(13,2)18(15)17(28)12-23(16,24)3/h7,9,11,15-19,28H,4-6,8,10,12H2,1-3H3/t15-,16-,17-,18+,22-,23-,24-/m0/s1 DM68K39 CS CCOC(=O)[C@]1(CC[C@@H]2[C@@]1(C[C@@H]([C@H]3[C@H]2CCC4=CC(=O)C=C[C@]34C)O)C)OC(=O)C(Cl)Cl DM68K39 IK QAIOVDNCIZSSSF-RFAJLIJZSA-N DM68K39 IU ethyl (8S,9S,10R,11S,13S,14S,17R)-17-(2,2-dichloroacetyl)oxy-11-hydroxy-10,13-dimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthrene-17-carboxylate DM68K39 CA CAS 199331-40-3 DM68K39 CB CHEBI:135783 DM68K39 DE Rhinitis DMV96BY ID DMV96BY DMV96BY DN ETS-6218 DMV96BY HS Phase 2 DMV96BY SN Antihistamine+antiviral (fibromyalgia), e-Therapeutics DMV96BY CP E-Therapeutics Ltd DMV96BY DE Fibromyalgia DMZOA2L ID DMZOA2L DMZOA2L DN ETX-9101 DMZOA2L HS Phase 2 DMZOA2L CP E-Therapeutics Ltd DMZOA2L DE Asthma DM1FCDH ID DM1FCDH DM1FCDH DN EV-077 DM1FCDH HS Phase 2 DM1FCDH SN EV-077-3201; EV-077 series (diabetes), Evolva Biotech; EV-077-3201-2; EV-077-3201-2TBS; Thromboxane antagonist (cardiovascular/proteinuric renal disease), Evolva Holding; Thromboxane synthesis inhibitor (cardiovascular/ proteinuric renal disease), Evolva Holding; EV-0400 series (metabolic disease/diabetes), Evolva Biotech; PPAR-gamma agonists (metabolic disease/diabetes/proteinuric renal disease/cardiovascular), Evolva Biotech DM1FCDH CP Evolva SA DM1FCDH DE Type-2 diabetes DMWB94K ID DMWB94K DMWB94K DN Evenamide DMWB94K HS Phase 2 DMWB94K SN 1092977-61-1; 2-((3-Butoxyphenethyl)amino)-N,N-dimethylacetamide; UNII-ON5S6N53JS; ON5S6N53JS; MFCD28502433; 2-[(3-Butoxyphenethyl)amino]-N,N-dimethylacetamide; Evenamide [INN]; SCHEMBL3025285; CHEMBL3678076; 2-((2-(3-Butoxyphenyl)ethyl)amino)-N,N-dimethylacetamide; Acetamide, 2-((2-(3-butoxyphenyl)ethyl)amino)-N,N-dimethyl-; BDBM161090; NW-3509; SB18910; AS-48527; HY-17612; SY244487; CS-0014697; Q21098995; 2-[2-(3-butoxyphenyl)ethylamino]-N,N-dimethylacetamide; US9051240, 2-[2-(3-Butoxyphenyl)-ethylamino]-N,N-dimethylacetamide DMWB94K CP Newron Pharmaceuticals DMWB94K DT Small molecular drug DMWB94K PC 25105689 DMWB94K MW 278.39 DMWB94K FM C16H26N2O2 DMWB94K IC InChI=1S/C16H26N2O2/c1-4-5-11-20-15-8-6-7-14(12-15)9-10-17-13-16(19)18(2)3/h6-8,12,17H,4-5,9-11,13H2,1-3H3 DMWB94K CS CCCCOC1=CC=CC(=C1)CCNCC(=O)N(C)C DMWB94K IK GRHBODILPPXVKN-UHFFFAOYSA-N DMWB94K IU 2-[2-(3-butoxyphenyl)ethylamino]-N,N-dimethylacetamide DMWB94K CA CAS 1092977-61-1 DMWB94K DE Schizophrenia DM8QXEY ID DM8QXEY DM8QXEY DN Evt201 DM8QXEY HS Phase 2 DM8QXEY CP Evotec DM8QXEY DT Small molecular drug DM8QXEY DE Sleep-wake disorder DMQGBM1 ID DMQGBM1 DMQGBM1 DN EVT-201 DMQGBM1 HS Phase 2 DMQGBM1 SN IDDBCP221837 DMQGBM1 CP Roche Holding AG DMQGBM1 PC 9885841 DMQGBM1 MW 372.8 DMQGBM1 FM C17H17ClN6O2 DMQGBM1 IC InChI=1S/C17H17ClN6O2/c1-22(2)8-13-20-16(21-26-13)15-12-7-23(3)17(25)14-10(18)5-4-6-11(14)24(12)9-19-15/h4-6,9H,7-8H2,1-3H3 DMQGBM1 CS CN1CC2=C(N=CN2C3=C(C1=O)C(=CC=C3)Cl)C4=NOC(=N4)CN(C)C DMQGBM1 IK JCYLWUVDHLVGER-UHFFFAOYSA-N DMQGBM1 IU 7-chloro-3-[5-[(dimethylamino)methyl]-1,2,4-oxadiazol-3-yl]-5-methyl-4H-imidazo[1,5-a][1,4]benzodiazepin-6-one DMQGBM1 CA CAS 308239-86-3 DMQGBM1 DE Insomnia DM73XNG ID DM73XNG DM73XNG DN EVT302 DM73XNG HS Phase 2 DM73XNG CP Evotec Princeton, NJ DM73XNG DE Alzheimer disease DM4FBUH ID DM4FBUH DM4FBUH DN EXC 001 DM4FBUH HS Phase 2 DM4FBUH CP ISIS Pharm; Excaliard DM4FBUH DT Antisense drug DM4FBUH DE Fibrosis DMC1I56 ID DMC1I56 DMC1I56 DN Exherin DMC1I56 HS Phase 2 DMC1I56 SN Exherin; 229971-81-7; UNII-B058ME29VU; ADH-1; ADH1; B058ME29VU; ADH 1; ADH-1 pepide; Exherin (ADH-1); ADH-1;ADH1;ADH 1; SCHEMBL13857500; CHEMBL3818130; ZINC3939935; ADH-10001; AKOS030526741; CS-3450; L-Cysteinamide, N-acetyl-L-cysteinyl-L-histidyl-l-alanyl-L-valyl-, cyclic (1-5)-disulfide; HY-13541 DMC1I56 CP Adherex Technol. DMC1I56 TC Anticancer Agents DMC1I56 DT Small molecular drug DMC1I56 PC 9916058 DMC1I56 MW 570.7 DMC1I56 FM C22H34N8O6S2 DMC1I56 IC InChI=1S/C22H34N8O6S2/c1-10(2)17-22(36)29-15(18(23)32)7-37-38-8-16(27-12(4)31)21(35)28-14(5-13-6-24-9-25-13)20(34)26-11(3)19(33)30-17/h6,9-11,14-17H,5,7-8H2,1-4H3,(H2,23,32)(H,24,25)(H,26,34)(H,27,31)(H,28,35)(H,29,36)(H,30,33)/t11-,14-,15-,16-,17-/m0/s1 DMC1I56 CS C[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N1)CC2=CN=CN2)NC(=O)C)C(=O)N)C(C)C DMC1I56 IK FQVLRGLGWNWPSS-BXBUPLCLSA-N DMC1I56 IU (4R,7S,10S,13S,16R)-16-acetamido-13-(1H-imidazol-5-ylmethyl)-10-methyl-6,9,12,15-tetraoxo-7-propan-2-yl-1,2-dithia-5,8,11,14-tetrazacycloheptadecane-4-carboxamide DMC1I56 CA CAS 229971-81-7 DMC1I56 DE Solid tumour/cancer DM5PBLM ID DM5PBLM DM5PBLM DN EYP001 DM5PBLM HS Phase 2 DM5PBLM SN Vonafexor; 1192171-69-9; UNII-XG6DG6A1UN; XG6DG6A1UN; 4-chloro-5-[4-(2,6-dichlorobenzene-1-; sulfonyl)piperazin-1-yl]-1-benzofuran-2-carboxylic acid; Vonafexor [INN]; SCHEMBL1893285; Vonafexor(PLX007,EYP-001); BCP33693; EX-A4037; EYP001;EYP 001;EYP-001; HY-109197; CS-0119143; 2-Benzofurancarboxylic acid, 4-chloro-5-(4-((2,6-dichlorophenyl)sulfonyl)-1-piperazinyl)-; 4-chloro-5-[4-(2,6-dichlorophenyl)sulfonylpiperazin-1-yl]-1-benzofuran-2-carboxylic acid DM5PBLM CP ENYO Pharma DM5PBLM DT Small molecular drug DM5PBLM PC 67202717 DM5PBLM MW 489.8 DM5PBLM FM C19H15Cl3N2O5S DM5PBLM IC InChI=1S/C19H15Cl3N2O5S/c20-12-2-1-3-13(21)18(12)30(27,28)24-8-6-23(7-9-24)14-4-5-15-11(17(14)22)10-16(29-15)19(25)26/h1-5,10H,6-9H2,(H,25,26) DM5PBLM CS C1CN(CCN1C2=C(C3=C(C=C2)OC(=C3)C(=O)O)Cl)S(=O)(=O)C4=C(C=CC=C4Cl)Cl DM5PBLM IK XLGQSYUNOIJBNR-UHFFFAOYSA-N DM5PBLM IU 4-chloro-5-[4-(2,6-dichlorophenyl)sulfonylpiperazin-1-yl]-1-benzofuran-2-carboxylic acid DM5PBLM CA CAS 1192171-69-9 DM5PBLM DE Non-alcoholic steatohepatitis DM2L9CO ID DM2L9CO DM2L9CO DN Ezatiostat DM2L9CO HS Phase 2 DM2L9CO SN Telintra (TN) DM2L9CO CP Telik DM2L9CO DT Small molecular drug DM2L9CO PC 5310939 DM2L9CO MW 529.6 DM2L9CO FM C27H35N3O6S DM2L9CO IC InChI=1S/C27H35N3O6S/c1-3-35-26(33)21(28)15-16-23(31)29-22(18-37-17-19-11-7-5-8-12-19)25(32)30-24(27(34)36-4-2)20-13-9-6-10-14-20/h5-14,21-22,24H,3-4,15-18,28H2,1-2H3,(H,29,31)(H,30,32)/t21-,22-,24+/m0/s1 DM2L9CO CS CCOC(=O)[C@H](CCC(=O)N[C@@H](CSCC1=CC=CC=C1)C(=O)N[C@H](C2=CC=CC=C2)C(=O)OCC)N DM2L9CO IK GWEJFLVSOGNLSS-WPFOTENUSA-N DM2L9CO IU ethyl (2S)-2-amino-5-[[(2R)-3-benzylsulfanyl-1-[[(1R)-2-ethoxy-2-oxo-1-phenylethyl]amino]-1-oxopropan-2-yl]amino]-5-oxopentanoate DM2L9CO CA CAS 168682-53-9 DM2L9CO DE Myelodysplastic syndrome DMJ4BKT ID DMJ4BKT DMJ4BKT DN F-16-IL-2 fusion protein DMJ4BKT HS Phase 2 DMJ4BKT SN Teleukin; F-16-IL-2; F-16-IL-2 fusion protein (cancer); F-16-IL-2 fusion protein (cancer), Philogen DMJ4BKT CP Philogen SpA DMJ4BKT DE Solid tumour/cancer DMKP3SJ ID DMKP3SJ DMKP3SJ DN F-351 DMKP3SJ HS Phase 2 DMKP3SJ SN Liver cirrhosis, Gene Networks International; Liver cirrhosis, Shanghai; Liver fibrosis therapy, Shanghai Genomics; Liver fibrosis, Gene Networks International; Liver fibrosis, Shanghai DMKP3SJ CP GNI Ltd DMKP3SJ DT Small molecular drug DMKP3SJ PC 11217901 DMKP3SJ MW 201.22 DMKP3SJ FM C12H11NO2 DMKP3SJ IC InChI=1S/C12H11NO2/c1-9-2-7-12(15)13(8-9)10-3-5-11(14)6-4-10/h2-8,14H,1H3 DMKP3SJ CS CC1=CN(C(=O)C=C1)C2=CC=C(C=C2)O DMKP3SJ IK NETTXQJYJRFTFS-UHFFFAOYSA-N DMKP3SJ IU 1-(4-hydroxyphenyl)-5-methylpyridin-2-one DMKP3SJ CA CAS 851518-71-3 DMKP3SJ DE Liver disease DM6UQNW ID DM6UQNW DM6UQNW DN F4co vaccine DM6UQNW HS Phase 2 DM6UQNW SN F4co vaccine (AIDS/HIV infection) DM6UQNW CP GlaxoSmithKline plc DM6UQNW DT Vaccine DM6UQNW DE Human immunodeficiency virus infection DMDNJ18 ID DMDNJ18 DMDNJ18 DN F-627 DMDNJ18 HS Phase 2 DMDNJ18 SN Recombinant human G-CSF dimer (neutropenia), Generon (Shanghai) Corporation Ltd DMDNJ18 CP Generon DMDNJ18 DE Neutropenia DMBFPO1 ID DMBFPO1 DMBFPO1 DN F-8-IL-10 fusion protein DMBFPO1 HS Phase 2 DMBFPO1 SN Dekavil; F-8-IL-10; F-8-IL-10 fusion protein (rheumatoid arthritis/endometriosis); F-8-IL-10 fusion protein (rheumatoid arthritis/endometriosis), Philogen DMBFPO1 CP Pfizer DMBFPO1 DE Endometriosis; Inflammatory bowel disease; Rheumatoid arthritis DM2CUS0 ID DM2CUS0 DM2CUS0 DN F901318 DM2CUS0 HS Phase 2 DM2CUS0 SN Olorofim; F-901318; UNII-T34SH2H9HI; T34SH2H9HI; 1928707-56-5; 2-(1,5-dimethyl-3-phenyl-1H-pyrrol-2-yl)-N-(4-(4-(5-fluoropyrimidin-2-yl)piperazin-1-yl)phenyl)-2-oxoacetamide; CHEMBL4297609; SCHEMBL17767345; BCP25872; BDBM50526857; DB15245; SB19827; F901318; F 901318; Olorofim; HY-104029; CS-0025660; Q27896127; CN1C(=C(C=C1C)C1=CC=CC=C1)C(C(=O)NC1=CC=C(C=C1)N1CCN(CC1)C1=NC=C(C=N1)F)=O; 1H-Pyrrole-2-acetamide, N-(4-(4-(5-fluoro-2-pyrimidinyl)-1-piperazinyl)phenyl)-1,5-dimethyl-alpha-oxo-3-phenyl-; 2-(1,5-Dimethyl-3-phenyl-pyrrol-2-yl)-N-(4-(4-(5-fluoropyrimidin-2-yl)piperazin-1-yl)phenyl)-2-oxo-acetamide DM2CUS0 CP F2G DM2CUS0 DT Small molecular drug DM2CUS0 PC 91885568 DM2CUS0 MW 498.6 DM2CUS0 FM C28H27FN6O2 DM2CUS0 IC InChI=1S/C28H27FN6O2/c1-19-16-24(20-6-4-3-5-7-20)25(33(19)2)26(36)27(37)32-22-8-10-23(11-9-22)34-12-14-35(15-13-34)28-30-17-21(29)18-31-28/h3-11,16-18H,12-15H2,1-2H3,(H,32,37) DM2CUS0 CS CC1=CC(=C(N1C)C(=O)C(=O)NC2=CC=C(C=C2)N3CCN(CC3)C4=NC=C(C=N4)F)C5=CC=CC=C5 DM2CUS0 IK SUFPWYYDCOKDLL-UHFFFAOYSA-N DM2CUS0 IU 2-(1,5-dimethyl-3-phenylpyrrol-2-yl)-N-[4-[4-(5-fluoropyrimidin-2-yl)piperazin-1-yl]phenyl]-2-oxoacetamide DM2CUS0 CA CAS 1928707-56-5 DM2CUS0 DE Fungal infection DMXB6KG ID DMXB6KG DMXB6KG DN FAD-104 DMXB6KG HS Phase 2 DMXB6KG SN ME-2303; (8S,10S)-8-(6-Carboxyhexanoyloxyacetyl)-10-[(2,6-dideoxy-2-fluoro-alpha-L-talopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione; 7-O-(2,6-Dideoxy-2-fluoro-alpha-L-talopyranosyl)adriamycinone-14-O-hemipimelate; 7-O-(2,6-Dideoxy-2-fluoro-alpha-L-talopyranosyl)pimelyladryamycinone DMXB6KG DT Small molecular drug DMXB6KG PC 115362 DMXB6KG MW 704.6 DMXB6KG FM C34H37FO15 DMXB6KG IC InChI=1S/C34H37FO15/c1-14-27(40)32(45)26(35)33(49-14)50-18-12-34(46,19(36)13-48-21(39)10-5-3-4-9-20(37)38)11-16-23(18)31(44)25-24(29(16)42)28(41)15-7-6-8-17(47-2)22(15)30(25)43/h6-8,14,18,26-27,32-33,40,42,44-46H,3-5,9-13H2,1-2H3,(H,37,38)/t14-,18-,26+,27+,32-,33-,34-/m0/s1 DMXB6KG CS C[C@H]1[C@H]([C@H]([C@H]([C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)COC(=O)CCCCCC(=O)O)O)F)O)O DMXB6KG IK PQMIPLRIRFVQJZ-QBYYVRQOSA-N DMXB6KG IU 7-[2-[(2S,4S)-4-[(2R,3R,4R,5S,6S)-3-fluoro-4,5-dihydroxy-6-methyloxan-2-yl]oxy-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]-2-oxoethoxy]-7-oxoheptanoic acid DMXB6KG CA CAS 116521-53-0 DMXB6KG DE Solid tumour/cancer DM6RKG3 ID DM6RKG3 DM6RKG3 DN Fadolmidine DM6RKG3 HS Phase 2 DM6RKG3 SN Fadolmidine hydrochloride; MPV-2426 DM6RKG3 CP Orion Corp DM6RKG3 DT Small molecular drug DM6RKG3 PC 6433098 DM6RKG3 MW 214.26 DM6RKG3 FM C13H14N2O DM6RKG3 IC InChI=1S/C13H14N2O/c16-12-4-3-9-1-2-10(13(9)6-12)5-11-7-14-8-15-11/h3-4,6-8,10,16H,1-2,5H2,(H,14,15) DM6RKG3 CS C1CC2=C(C1CC3=CN=CN3)C=C(C=C2)O DM6RKG3 IK VTZPAJGVRWKMAG-UHFFFAOYSA-N DM6RKG3 IU 3-(1H-imidazol-5-ylmethyl)-2,3-dihydro-1H-inden-5-ol DM6RKG3 CA CAS 189353-31-9 DM6RKG3 DE Pain; Neuropathic pain DMSFWT7 ID DMSFWT7 DMSFWT7 DN Famitinib DMSFWT7 HS Phase 2 DMSFWT7 SN Receptor tyrosine kinase inhibitors (cancer); SHR-1020; Receptor tyrosine kinase inhibitors (cancer), Shanghai Hengrui; Tyrosine-kinase inhibitor (oral, cancer), Jiangsu Hengrui; C-Kit/VEGFR2/PDGFR/VEGFR3/Flt1/Flt3 inhibitor (oral, cancer), Jiangsu Hengrui DMSFWT7 CP Shanghai Hengrui Pharmaceutical Co Ltd; Jiangsu Hengrui Medicine Co Ltd DMSFWT7 DT Small molecular drug DMSFWT7 PC 16662431 DMSFWT7 MW 410.5 DMSFWT7 FM C23H27FN4O2 DMSFWT7 IC InChI=1S/C23H27FN4O2/c1-4-27(5-2)10-11-28-9-8-19-21(23(28)30)14(3)20(25-19)13-17-16-12-15(24)6-7-18(16)26-22(17)29/h6-7,12-13,25H,4-5,8-11H2,1-3H3,(H,26,29)/b17-13- DMSFWT7 CS CCN(CC)CCN1CCC2=C(C1=O)C(=C(N2)/C=C\\3/C4=C(C=CC(=C4)F)NC3=O)C DMSFWT7 IK GKEYKDOLBLYGRB-LGMDPLHJSA-N DMSFWT7 IU 5-[2-(diethylamino)ethyl]-2-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-3-methyl-6,7-dihydro-1H-pyrrolo[3,2-c]pyridin-4-one DMSFWT7 CA CAS 945380-27-8 DMSFWT7 DE Solid tumour/cancer DM563NC ID DM563NC DM563NC DN Fasitibant chloride DM563NC HS Phase 2 DM563NC SN MEN-16132; Bradykinin B2 antagonist (inflammation), Menarini; MEN-11270 analogs, Menarini DM563NC CP The Menarini Group DM563NC DT Small molecular drug DM563NC PC 11535140 DM563NC MW 800.2 DM563NC FM C36H49Cl3N6O6S DM563NC IC InChI=1S/C36H49Cl2N6O6S.ClH/c1-24-22-25(2)40-33-26(24)8-6-10-30(33)50-23-27-28(37)11-12-31(32(27)38)51(47,48)41-36(13-20-49-21-14-36)35(46)43-17-15-42(16-18-43)34(45)29(39)9-7-19-44(3,4)5;/h6,8,10-12,22,29,41H,7,9,13-21,23,39H2,1-5H3;1H/q+1;/p-1/t29-;/m0./s1 DM563NC CS CC1=CC(=NC2=C1C=CC=C2OCC3=C(C=CC(=C3Cl)S(=O)(=O)NC4(CCOCC4)C(=O)N5CCN(CC5)C(=O)[C@H](CCC[N+](C)(C)C)N)Cl)C.[Cl-] DM563NC IK ZNHJDJYKDVGQSH-JMAPEOGHSA-M DM563NC IU [(4S)-4-amino-5-[4-[4-[[2,4-dichloro-3-[(2,4-dimethylquinolin-8-yl)oxymethyl]phenyl]sulfonylamino]oxane-4-carbonyl]piperazin-1-yl]-5-oxopentyl]-trimethylazanium;chloride DM563NC DE Osteoarthritis DMR3952 ID DMR3952 DMR3952 DN FBS-0701 DMR3952 HS Phase 2 DMR3952 SN Desferrithiocin analog (oral, iron overload), FerroKin Biosciences; Iron chelator (oral, iron overload), FerroKin Biosciences DMR3952 CP FerroKin BioSciences Inc DMR3952 DT Small molecular drug DMR3952 PC 135565672 DMR3952 MW 399.5 DMR3952 FM C18H25NO7S DMR3952 IC InChI=1S/C18H25NO7S/c1-18(17(21)22)12-27-16(19-18)13-4-3-5-14(15(13)20)26-11-10-25-9-8-24-7-6-23-2/h3-5,20H,6-12H2,1-2H3,(H,21,22)/t18-/m1/s1 DMR3952 CS C[C@@]1(CSC(=N1)C2=C(C(=CC=C2)OCCOCCOCCOC)O)C(=O)O DMR3952 IK AWHIMFSHNAAMBM-GOSISDBHSA-N DMR3952 IU (4S)-2-[2-hydroxy-3-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]phenyl]-4-methyl-5H-1,3-thiazole-4-carboxylic acid DMR3952 CA CAS 945635-15-4 DMR3952 DE Iron overload disease DM3CVHQ ID DM3CVHQ DM3CVHQ DN FE-202158 DM3CVHQ HS Phase 2 DM3CVHQ SN V1a agonist (septic shock), Ferring; Vasopressin 1a agonist (septic shock), Ferring DM3CVHQ CP Ferring Pharmaceuticals Inc DM3CVHQ PC 53330936 DM3CVHQ MW 1048.3 DM3CVHQ FM C46H73N13O11S2 DM3CVHQ IC InChI=1S/C46H73N13O11S2/c1-5-26(4)38-45(69)54-30(14-9-17-35(48)60)41(65)56-32(21-36(49)61)42(66)57-33(24-72-71-23-28(47)39(63)55-31(43(67)58-38)20-27-12-7-6-8-13-27)46(70)59-19-11-16-34(59)44(68)53-29(15-10-18-51-25(2)3)40(64)52-22-37(50)62/h6-8,12-13,25-26,28-34,38,51H,5,9-11,14-24,47H2,1-4H3,(H2,48,60)(H2,49,61)(H2,50,62)(H,52,64)(H,53,68)(H,54,69)(H,55,63)(H,56,65)(H,57,66)(H,58,67)/t26-,28-,29-,30-,31-,32-,33-,34-,38-/m0/s1 DM3CVHQ CS CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N1)CC2=CC=CC=C2)N)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CCCNC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCCC(=O)N DM3CVHQ IK JCVQBJTWWDYUFQ-MRUTUVJXSA-N DM3CVHQ IU (2S)-1-[(4R,7S,10S,13S,16S,19R)-19-amino-10-(4-amino-4-oxobutyl)-7-(2-amino-2-oxoethyl)-16-benzyl-13-[(2S)-butan-2-yl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]-N-[(2S)-1-[(2-amino-2-oxoethyl)amino]-1-oxo-5-(propan-2-ylamino)pentan-2-yl]pyrrolidine-2-carboxamide DM3CVHQ CA CAS 876296-47-8 DM3CVHQ DE Sepsis DMDGZ1C ID DMDGZ1C DMDGZ1C DN FE-202767 DMDGZ1C HS Phase 2 DMDGZ1C SN Oxytocin agonists (erectile dysfunction), Ferring DMDGZ1C CP Ferring Pharmaceuticals Inc DMDGZ1C PC 102341060 DMDGZ1C MW 1042.2 DMDGZ1C FM C48H68FN11O12S DMDGZ1C IC InChI=1S/C48H68FN11O12S/c1-5-27(4)42-47(71)56-32(16-17-37(50)62)44(68)57-35(21-38(51)63)45(69)58-36(25-73-18-6-7-40(65)54-34(46(70)59-42)20-28-10-14-31(61)15-11-28)48(72)60(23-29-8-12-30(49)13-9-29)24-41(66)55-33(19-26(2)3)43(67)53-22-39(52)64/h8-15,26-27,32-36,42,61H,5-7,16-25H2,1-4H3,(H2,50,62)(H2,51,63)(H2,52,64)(H,53,67)(H,54,65)(H,55,66)(H,56,71)(H,57,68)(H,58,69)(H,59,70)/t27?,32-,33-,34-,35-,36-,42-/m0/s1 DMDGZ1C CS CCC(C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSCCCC(=O)N[C@H](C(=O)N1)CC2=CC=C(C=C2)O)C(=O)N(CC3=CC=C(C=C3)F)CC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N DMDGZ1C IK PVVHQWISMVJHFK-JWKDVPIGSA-N DMDGZ1C IU (3R,6S,9S,12S,15S)-6-(2-amino-2-oxoethyl)-N-[2-[[(2S)-1-[(2-amino-2-oxoethyl)amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]-9-(3-amino-3-oxopropyl)-12-butan-2-yl-N-[(4-fluorophenyl)methyl]-15-[(4-hydroxyphenyl)methyl]-5,8,11,14,17-pentaoxo-1-thia-4,7,10,13,16-pentazacycloicosane-3-carboxamide DMDGZ1C DE Erectile dysfunction DMICMXE ID DMICMXE DMICMXE DN Ferroquine DMICMXE HS Phase 2 DMICMXE SN Ferroquine; UNII-8D81JS19ET; 8D81JS19ET; SSR97193; Ferroquine [INN]; 185055-67-8 DMICMXE CP Sanofi DMICMXE DT Small molecular drug DMICMXE PC 56841801 DMICMXE MW 433.8 DMICMXE FM C23H24ClFeN3 DMICMXE IC InChI=1S/C18H19ClN3.C5H5.Fe/c1-22(2)12-14-5-3-4-13(14)11-21-17-8-9-20-18-10-15(19)6-7-16(17)18;1-2-4-5-3-1;/h4,6-10H,5,11-12H2,1-2H3,(H,20,21);1-3H,4H2;/q2*-1;+2 DMICMXE CS CN(C)CC1=C(C=[C-]C1)CNC2=C3C=CC(=CC3=NC=C2)Cl.C1C=CC=[C-]1.[Fe+2] DMICMXE IK DLYPREQTTOHKSM-UHFFFAOYSA-N DMICMXE IU 7-chloro-N-[[2-[(dimethylamino)methyl]cyclopenta-1,4-dien-1-yl]methyl]quinolin-4-amine;cyclopenta-1,3-diene;iron(2+) DMICMXE CA CAS 185055-67-8 DMICMXE DE Malaria DMJX2P4 ID DMJX2P4 DMJX2P4 DN Fezakinumab DMJX2P4 HS Phase 2 DMJX2P4 SN Fezakinumab (IV), fezakinumab (SC), ILV-094 (IV), ILV-094 (SC), PF-5212367 (IV) PF-5212367(SC) DMJX2P4 CP Wyeth; pfizer DMJX2P4 DT Antibody DMJX2P4 DE Psoriasis vulgaris DM7RYL4 ID DM7RYL4 DM7RYL4 DN FG-2216 DM7RYL4 HS Phase 2 DM7RYL4 PC 6914666 DM7RYL4 MW 280.66 DM7RYL4 FM C12H9ClN2O4 DM7RYL4 IC InChI=1S/C12H9ClN2O4/c13-11-7-4-2-1-3-6(7)10(18)9(15-11)12(19)14-5-8(16)17/h1-4,18H,5H2,(H,14,19)(H,16,17) DM7RYL4 CS C1=CC=C2C(=C1)C(=C(N=C2Cl)C(=O)NCC(=O)O)O DM7RYL4 IK OUQVKRKGTAUJQA-UHFFFAOYSA-N DM7RYL4 IU 2-[(1-chloro-4-hydroxyisoquinoline-3-carbonyl)amino]acetic acid DM7RYL4 CA CAS 223387-75-5 DM7RYL4 DE Kidney disease DMXMC8I ID DMXMC8I DMXMC8I DN FGF-1 DMXMC8I HS Phase 2 DMXMC8I CP CardioVascular BioTherape. DMXMC8I DE Coronary heart disease DMCIGRB ID DMCIGRB DMCIGRB DN Fialuridine DMCIGRB HS Phase 2 DMCIGRB SN FIAU DMCIGRB CP Oclassen Pharmaceuticals Inc DMCIGRB DT Small molecular drug DMCIGRB PC 50313 DMCIGRB MW 372.09 DMCIGRB FM C9H10FIN2O5 DMCIGRB IC InChI=1S/C9H10FIN2O5/c10-5-6(15)4(2-14)18-8(5)13-1-3(11)7(16)12-9(13)17/h1,4-6,8,14-15H,2H2,(H,12,16,17)/t4-,5+,6-,8-/m1/s1 DMCIGRB CS C1=C(C(=O)NC(=O)N1[C@H]2[C@H]([C@@H]([C@H](O2)CO)O)F)I DMCIGRB IK IPVFGAYTKQKGBM-BYPJNBLXSA-N DMCIGRB IU 1-[(2R,3S,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidine-2,4-dione DMCIGRB CA CAS 69123-98-4 DMCIGRB DE Hepatitis B virus infection DMG65WH ID DMG65WH DMG65WH DN Ficlatuzumab DMG65WH HS Phase 2 DMG65WH SN AV-299 DMG65WH CP AVEO Pharmaceuticals DMG65WH DT Monoclonal antibody DMG65WH DE Non-small-cell lung cancer; Multiple myeloma; Acute myeloid leukaemia; Pancreatic cancer; Squamous cell carcinoma DMNSYXB ID DMNSYXB DMNSYXB DN Filibuvir DMNSYXB HS Phase 2 DMNSYXB SN Filibuvir; 877130-28-4; PF-00868554; UNII-198J479Y2L; 198J479Y2L; (6R)-6-Cyclopentyl-6-(2-(2,6-diethylpyridin-4-yl)ethyl)-3-((5,7-dimethyl(1,2,4)triazolo(1,5-a)pyrimidin-2-yl)methyl)-4-hydroxy-5,6-dihydro-2H-pyran-2-one; (R)-6-Cyclopentyl-6-[2-(2,6-diethylpyridin-4-yl)ethyl]-3-[(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-5,6-dihydro-2H-pyran-2-one; Filibuvir [USAN:INN]; 3frz DMNSYXB CP Pfizer DMNSYXB DT Small molecular drug DMNSYXB PC 54708673 DMNSYXB MW 503.6 DMNSYXB FM C29H37N5O3 DMNSYXB IC InChI=1S/C29H37N5O3/c1-5-22-14-20(15-23(6-2)31-22)11-12-29(21-9-7-8-10-21)17-25(35)24(27(36)37-29)16-26-32-28-30-18(3)13-19(4)34(28)33-26/h13-15,21,35H,5-12,16-17H2,1-4H3/t29-/m1/s1 DMNSYXB CS CCC1=CC(=CC(=N1)CC)CC[C@@]2(CC(=C(C(=O)O2)CC3=NN4C(=CC(=NC4=N3)C)C)O)C5CCCC5 DMNSYXB IK SLVAPEZTBDBAPI-GDLZYMKVSA-N DMNSYXB IU (2R)-2-cyclopentyl-2-[2-(2,6-diethylpyridin-4-yl)ethyl]-5-[(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-3H-pyran-6-one DMNSYXB CA CAS 877130-28-4 DMNSYXB DE Hepatitis C virus infection DMG439E ID DMG439E DMG439E DN Fipamezole DMG439E HS Phase 2 DMG439E SN Fipamezole; 150586-58-6; JP-1730; 1H-Imidazole,5-(2-ethyl-5-fluoro-2,3-dihydro-1H-inden-2-yl)-; Fipamezole [INN]; ACMC-1BZQD; AC1Q4NYS; SCHEMBL935549; AC1L4U51; SCHEMBL18826053; CHEMBL1255582; CTK4C6705; 5-(2-ethyl-5-fluoro-1,3-dihydroinden-2-yl)-1H-imidazole; KXSUAWAUCNFBQJ-UHFFFAOYSA-N; 5-(2-ethyl-5-fluoro-2,3-dihydro-1h-inden-2-yl)-1h-imidazole; BDBM50417007; SB17014; 4-(2-ethyl-5-fluoro-indan-2-yl)-1H-imidazole; L001472; 4-((2RS)-2-Ethyl-5-fluoroindan-2-yl)-1H-imidazole DMG439E DT Small molecular drug DMG439E PC 213041 DMG439E MW 230.28 DMG439E FM C14H15FN2 DMG439E IC InChI=1S/C14H15FN2/c1-2-14(13-8-16-9-17-13)6-10-3-4-12(15)5-11(10)7-14/h3-5,8-9H,2,6-7H2,1H3,(H,16,17) DMG439E CS CCC1(CC2=C(C1)C=C(C=C2)F)C3=CN=CN3 DMG439E IK KXSUAWAUCNFBQJ-UHFFFAOYSA-N DMG439E IU 5-(2-ethyl-5-fluoro-1,3-dihydroinden-2-yl)-1H-imidazole DMG439E CA CAS 150586-58-6 DMG439E DE Acute myeloid leukaemia DMW2QYT ID DMW2QYT DMW2QYT DN Firategrast DMW2QYT HS Phase 2 DMW2QYT SN SB 683699; Firategrast (USAN); SB-683699; 2-[(2,6-difluorobenzoyl)amino]-3-[4-[4-(ethoxymethyl)-2,6-dimethoxy-phenyl]phenyl]propanoic Acid DMW2QYT CP GSK DMW2QYT DT Small molecular drug DMW2QYT PC 9935681 DMW2QYT MW 499.5 DMW2QYT FM C27H27F2NO6 DMW2QYT IC InChI=1S/C27H27F2NO6/c1-4-36-15-17-13-22(34-2)24(23(14-17)35-3)18-10-8-16(9-11-18)12-21(27(32)33)30-26(31)25-19(28)6-5-7-20(25)29/h5-11,13-14,21H,4,12,15H2,1-3H3,(H,30,31)(H,32,33)/t21-/m0/s1 DMW2QYT CS CCOCC1=CC(=C(C(=C1)OC)C2=CC=C(C=C2)C[C@@H](C(=O)O)NC(=O)C3=C(C=CC=C3F)F)OC DMW2QYT IK YLFZHHDVRSYTKT-NRFANRHFSA-N DMW2QYT IU (2S)-2-[(2,6-difluorobenzoyl)amino]-3-[4-[4-(ethoxymethyl)-2,6-dimethoxyphenyl]phenyl]propanoic acid DMW2QYT CA CAS 402567-16-2 DMW2QYT DE Multiple sclerosis DMJSD5W ID DMJSD5W DMJSD5W DN FK-070 DMJSD5W HS Phase 2 DMJSD5W SN KDI-792; Kdi 792; FK 070; FK-070; AC1O5X7F; SCHEMBL8657761; JGCFJVFIRFTRKJ-YOLZMAEBSA-N; 130047-30-2; FR-121070; 167678-84-4; (2S,4R)-2-[(Z)-5-carboxy-1-pentenyl]-4-(4-chlorophenylsulfonylamino)-1-(3-pyridylmethyl)pyrrolidine hydrochloride; 5-Hexenoic acid, 6-((2S,4R)-4-(((4-chlorophenyl)sulfonyl)amino)-1-(3- pyridinylmethyl)-2-pyrrolidinyl)-, monohydrochloride, (5Z)-; 178895-18-6; (Z)-6-[(2S,4R)-4-[(4-chlorophenyl)sulfonylamino]-1-(pyridin-3-ylmethyl)pyrrolidin-2-yl]hex-5-enoic acid hydrochloride DMJSD5W DT Small molecular drug DMJSD5W PC 6442424 DMJSD5W MW 500.4 DMJSD5W FM C22H27Cl2N3O4S DMJSD5W IC InChI=1S/C22H26ClN3O4S.ClH/c23-18-8-10-21(11-9-18)31(29,30)25-19-13-20(6-2-1-3-7-22(27)28)26(16-19)15-17-5-4-12-24-14-17;/h2,4-6,8-12,14,19-20,25H,1,3,7,13,15-16H2,(H,27,28);1H/b6-2-;/t19-,20-;/m1./s1 DMJSD5W CS C1[C@H](CN([C@@H]1/C=C\\CCCC(=O)O)CC2=CN=CC=C2)NS(=O)(=O)C3=CC=C(C=C3)Cl.Cl DMJSD5W IK JGCFJVFIRFTRKJ-YOLZMAEBSA-N DMJSD5W IU (Z)-6-[(2S,4R)-4-[(4-chlorophenyl)sulfonylamino]-1-(pyridin-3-ylmethyl)pyrrolidin-2-yl]hex-5-enoic acid;hydrochloride DMJSD5W CA CAS 130047-30-2 DMJSD5W DE Angina pectoris DMEL15U ID DMEL15U DMEL15U DN FK-143 DMEL15U HS Phase 2 DMEL15U SN FK-143; Fk 143; CHEMBL25083; 163136-03-6; 4-[3-[3-[bis(4-isobutylphenyl)methylamino]benzoyl]indol-1-yl]butyric acid; 4-[3-[3-(bis[4-isobutylphenyl)methylamino]benzoyl]indol-1-yl]butyric acid; SCHEMBL3504489; AC1L435G; CTK0H5706; DTXSID80167524; LACIBZRFAYFTOV-UHFFFAOYSA-N; BDBM50057477; 1H-Indole-1-butanoicacid, 3-[3-[[bis[4-(2-methylpropyl)phenyl]methyl]amino]benzoyl]-; 4-[3-[3-[bis[4-(2-methylpropyl)phenyl]methylamino]benzoyl]indol-1-yl]butanoic acid DMEL15U DT Small molecular drug DMEL15U PC 178077 DMEL15U MW 600.8 DMEL15U FM C40H44N2O3 DMEL15U IC InChI=1S/C40H44N2O3/c1-27(2)23-29-14-18-31(19-15-29)39(32-20-16-30(17-21-32)24-28(3)4)41-34-10-7-9-33(25-34)40(45)36-26-42(22-8-13-38(43)44)37-12-6-5-11-35(36)37/h5-7,9-12,14-21,25-28,39,41H,8,13,22-24H2,1-4H3,(H,43,44) DMEL15U CS CC(C)CC1=CC=C(C=C1)C(C2=CC=C(C=C2)CC(C)C)NC3=CC=CC(=C3)C(=O)C4=CN(C5=CC=CC=C54)CCCC(=O)O DMEL15U IK LACIBZRFAYFTOV-UHFFFAOYSA-N DMEL15U IU 4-[3-[3-[bis[4-(2-methylpropyl)phenyl]methylamino]benzoyl]indol-1-yl]butanoic acid DMEL15U CA CAS 163136-03-6 DMEL15U DE Prostate disease DML5AE4 ID DML5AE4 DML5AE4 DN FK-3311 DML5AE4 HS Phase 2 DML5AE4 SN 116686-15-8; FK 3311; FK-3311; FK3311; COX-2 Inhibitor V, FK3311; N-[4-acetyl-2-(2,4-difluorophenoxy)phenyl]methanesulfonamide; N-(4-Acetyl-2-(2,4-difluorophenoxy)phenyl)methanesulfonamide; 4'-Acetyl-2'-(2,4-difluorophenoxy)methanesulfonanilide; Methanesulfonamide, N-[4-acetyl-2-(2,4-difluorophenoxy)phenyl]-; C15H13F2NO4S; Methanesulfonamide, N-(4-acetyl-2-(2,4-difluorophenoxy)phenyl)-; DIIYLGZNZGPXRR-UHFFFAOYSA-N; AC1L4U0O; AC1Q6W4K; SCHEMBL441676; ZINC3880; DIIYLGZNZGPXRR-UHFFFAOYSA-; CTK8E9207; EX-A545; DTXSID90151474 DML5AE4 CP Fujisawa Pharmaceutical Co Ltd DML5AE4 DT Small molecular drug DML5AE4 PC 164009 DML5AE4 MW 341.3 DML5AE4 FM C15H13F2NO4S DML5AE4 IC InChI=1S/C15H13F2NO4S/c1-9(19)10-3-5-13(18-23(2,20)21)15(7-10)22-14-6-4-11(16)8-12(14)17/h3-8,18H,1-2H3 DML5AE4 CS CC(=O)C1=CC(=C(C=C1)NS(=O)(=O)C)OC2=C(C=C(C=C2)F)F DML5AE4 IK DIIYLGZNZGPXRR-UHFFFAOYSA-N DML5AE4 IU N-[4-acetyl-2-(2,4-difluorophenoxy)phenyl]methanesulfonamide DML5AE4 CA CAS 116686-15-8 DML5AE4 DE Rheumatoid arthritis DMKVXYS ID DMKVXYS DMKVXYS DN FK-409 DMKVXYS HS Phase 2 DMKVXYS SN nor-3; 3-Hexenamide, 4-ethyl-2-(hydroxyimino)-5-nitro-; 92454-83-6; 163180-49-2; ACMC-20eif3; AC1OAT8P; 4-ethyl-2-hydroxyimino-5-nitrohex-3-enamide; CTK3H0114; CTK4D1460 DMKVXYS CP Fujisawa Pharmaceutical Co Ltd DMKVXYS DT Small molecular drug DMKVXYS PC 6413529 DMKVXYS MW 215.21 DMKVXYS FM C8H13N3O4 DMKVXYS IC InChI=1S/C8H13N3O4/c1-3-6(5(2)11(14)15)4-7(10-13)8(9)12/h4-5,13H,3H2,1-2H3,(H2,9,12)/b6-4+,10-7- DMKVXYS CS CC/C(=C\\C(=N\\O)\\C(=O)N)/C(C)[N+](=O)[O-] DMKVXYS IK MZAGXDHQGXUDDX-JSRXJHBZSA-N DMKVXYS IU (E,2Z)-4-ethyl-2-hydroxyimino-5-nitrohex-3-enamide DMKVXYS CA CAS 92454-60-9 DMKVXYS DE Angina pectoris DMGROQP ID DMGROQP DMGROQP DN FK-505 DMGROQP HS Phase 2 DMGROQP SN FR-76505; 2-[3-(4-Bromo-2-fluorobenzyl)-7-fluoro-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-1-yl]acetic acid DMGROQP DT Small molecular drug DMGROQP PC 3086955 DMGROQP MW 425.2 DMGROQP FM C17H11BrF2N2O4 DMGROQP IC InChI=1S/C17H11BrF2N2O4/c18-10-2-1-9(13(20)5-10)7-22-16(25)12-4-3-11(19)6-14(12)21(17(22)26)8-15(23)24/h1-6H,7-8H2,(H,23,24) DMGROQP CS C1=CC2=C(C=C1F)N(C(=O)N(C2=O)CC3=C(C=C(C=C3)Br)F)CC(=O)O DMGROQP IK XLOHSVVOWVIPFC-UHFFFAOYSA-N DMGROQP IU 2-[3-[(4-bromo-2-fluorophenyl)methyl]-7-fluoro-2,4-dioxoquinazolin-1-yl]acetic acid DMGROQP CA CAS 112733-08-1 DMGROQP DE Hyperuricaemia DMY61TJ ID DMY61TJ DMY61TJ DN FK-614 DMY61TJ HS Phase 2 DMY61TJ SN ATx08-001; ATx08-001); PPAR gamma agonist (oral, neuropathic pain), Aestus DMY61TJ CP Fujisawa Pharmaceutical Co Ltd; aestus therapeutics DMY61TJ DT Small molecular drug DMY61TJ PC 9869229 DMY61TJ MW 468.4 DMY61TJ FM C21H23Cl2N3O3S DMY61TJ IC InChI=1S/C21H23Cl2N3O3S/c1-3-4-5-10-30(28,29)25-21(27)15-7-9-19-20(11-15)26(14(2)24-19)13-16-6-8-17(22)12-18(16)23/h6-9,11-12H,3-5,10,13H2,1-2H3,(H,25,27) DMY61TJ CS CCCCCS(=O)(=O)NC(=O)C1=CC2=C(C=C1)N=C(N2CC3=C(C=C(C=C3)Cl)Cl)C DMY61TJ IK UYGZODVVDUIDDQ-UHFFFAOYSA-N DMY61TJ IU 3-[(2,4-dichlorophenyl)methyl]-2-methyl-N-pentylsulfonylbenzimidazole-5-carboxamide DMY61TJ CA CAS 193012-35-0 DMY61TJ DE Type-2 diabetes DMV0MZ3 ID DMV0MZ3 DMV0MZ3 DN FK-962 DMV0MZ3 HS Phase 2 DMV0MZ3 SN FK-960 analog, Fujisawa DMV0MZ3 CP Fujisawa Pharmaceutical Co Ltd DMV0MZ3 DT Small molecular drug DMV0MZ3 PC 56842107 DMV0MZ3 MW 263.31 DMV0MZ3 FM C15H18FNO2 DMV0MZ3 IC InChI=1S/C15H18FNO2/c1-10(18)11-4-8-14(9-5-11)17-15(19)12-2-6-13(16)7-3-12/h2-3,6-7,11,14H,4-5,8-9H2,1H3,(H,17,19) DMV0MZ3 CS CC(=O)C1CCC(CC1)NC(=O)C2=CC=C(C=C2)F DMV0MZ3 IK PYMCWQVGVQEZNO-UHFFFAOYSA-N DMV0MZ3 IU N-(4-acetylcyclohexyl)-4-fluorobenzamide DMV0MZ3 CA CAS 283167-06-6 DMV0MZ3 DE Alzheimer disease DM2O7NM ID DM2O7NM DM2O7NM DN FKB01MD DM2O7NM HS Phase 2 DM2O7NM CP Fabre-Kramer Pharmaceuticals Houston, TX DMPXH7N ID DMPXH7N DMPXH7N DN FKW00GA DMPXH7N HS Phase 2 DMPXH7N CP Fabre-Kramer Pharmaceuticals Houston, TX DMPXH7N DE Social phobia DMKSUOI ID DMKSUOI DMKSUOI DN Flavopiridol DMKSUOI HS Phase 2 DMKSUOI SN FLAVO; Alvocidib [INN]; Flavopiridol hydrochloride; L 868275; HMR-1275; L-868275; L86-8275; HMR-1275, Alvocidib, L868275, Flavopiridol; (-)-cis-5,7-Dihydroxy-2-(2-chlorophenyl)-8-(4-(3-hydroxy-1-methyl)piperidinyl)-4H-1-benzopyran-4-one; 2-(2-CHLORO-PHENYL)-5,7-DIHYDROXY-8-(3-HYDROXY-1-METHYL-PIPERIDIN-4-YL)-4H-BENZOPYRAN-4-ONE; 2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methylpiperidin-4-yl]chromen-4-one DMKSUOI CP Sanofi-Aventis DMKSUOI DT Small molecular drug DMKSUOI PC 5287969 DMKSUOI MW 401.8 DMKSUOI FM C21H20ClNO5 DMKSUOI IC InChI=1S/C21H20ClNO5/c1-23-7-6-12(17(27)10-23)19-14(24)8-15(25)20-16(26)9-18(28-21(19)20)11-4-2-3-5-13(11)22/h2-5,8-9,12,17,24-25,27H,6-7,10H2,1H3/t12-,17+/m0/s1 DMKSUOI CS CN1CC[C@@H]([C@@H](C1)O)C2=C(C=C(C3=C2OC(=CC3=O)C4=CC=CC=C4Cl)O)O DMKSUOI IK BIIVYFLTOXDAOV-YVEFUNNKSA-N DMKSUOI IU 2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methylpiperidin-4-yl]chromen-4-one DMKSUOI CA CAS 146426-40-6 DMKSUOI CB CHEBI:47344 DMKSUOI DE Chronic lymphocytic leukaemia; Acute myeloid leukaemia DMCN4H6 ID DMCN4H6 DMCN4H6 DN Flezelastine DMCN4H6 HS Phase 2 DMCN4H6 SN D-18024 DMCN4H6 CP ASTA Medica AG DMCN4H6 DT Small molecular drug DMCN4H6 PC 60432 DMCN4H6 MW 455.6 DMCN4H6 FM C29H30FN3O DMCN4H6 IC InChI=1S/C29H30FN3O/c30-24-14-12-23(13-15-24)21-28-26-10-4-5-11-27(26)29(34)33(31-28)25-9-6-18-32(20-17-25)19-16-22-7-2-1-3-8-22/h1-5,7-8,10-15,25H,6,9,16-21H2 DMCN4H6 CS C1CC(CCN(C1)CCC2=CC=CC=C2)N3C(=O)C4=CC=CC=C4C(=N3)CC5=CC=C(C=C5)F DMCN4H6 IK HQFSNUYUXXPVKL-UHFFFAOYSA-N DMCN4H6 IU 4-[(4-fluorophenyl)methyl]-2-[1-(2-phenylethyl)azepan-4-yl]phthalazin-1-one DMCN4H6 CA CAS 135381-77-0 DMCN4H6 DE Asthma DMVR6OM ID DMVR6OM DMVR6OM DN Flotetuzumab DMVR6OM HS Phase 2 DMVR6OM CP MacroGenics Rockville, MD DMVR6OM DE Myelodysplastic syndrome; Acute myeloid leukaemia; Acute biphenotypic leukaemia DMMQ1YU ID DMMQ1YU DMMQ1YU DN FLUASTERONE DMMQ1YU HS Phase 2 DMMQ1YU SN HE-2500; 16alpha-Fluoroandrost-5-en-17-one; 8354 DMMQ1YU CP Aeson Therapeutics DMMQ1YU DT Small molecular drug DMMQ1YU PC 133967 DMMQ1YU MW 290.4 DMMQ1YU FM C19H27FO DMMQ1YU IC InChI=1S/C19H27FO/c1-18-9-4-3-5-12(18)6-7-13-14(18)8-10-19(2)15(13)11-16(20)17(19)21/h6,13-16H,3-5,7-11H2,1-2H3/t13-,14+,15+,16-,18+,19+/m1/s1 DMMQ1YU CS C[C@]12CCCCC1=CC[C@@H]3[C@@H]2CC[C@]4([C@H]3C[C@H](C4=O)F)C DMMQ1YU IK VHZXNQKVFDBFIK-NBBHSKLNSA-N DMMQ1YU IU (8R,9S,10R,13S,14S,16R)-16-fluoro-10,13-dimethyl-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-one DMMQ1YU CA CAS 112859-71-9 DMMQ1YU DE Arthritis DME01HT ID DME01HT DME01HT DN Fluciclatide F-18 DME01HT HS Phase 2 DME01HT CP GE Healthcare; National Cancer Institute DME01HT DT Small molecular drug DME01HT PC 139033064 DME01HT MW 1815 DME01HT FM C75H115FN18O27S3 DME01HT IC InChI=1S/C75H115FN18O27S3/c76-52-13-11-51(12-14-52)39-87-121-45-65(100)83-19-23-113-27-31-117-34-36-118-35-33-116-30-26-112-22-18-82-64(99)44-120-43-62(97)80-15-5-4-9-54-70(106)93-58-47-123-124-48-59(94-72(108)56(38-67(102)103)89-61(96)40-86-68(104)53(90-73(58)109)10-6-16-85-75(78)79)74(110)91-55(37-50-7-2-1-3-8-50)71(107)92-57(46-122-49-66(101)88-54)69(105)84-20-24-114-28-32-115-29-25-111-21-17-81-63(98)42-119-41-60(77)95/h1-3,7-8,11-14,39,53-59H,4-6,9-10,15-38,40-49H2,(H2,77,95)(H,80,97)(H,81,98)(H,82,99)(H,83,100)(H,84,105)(H,86,104)(H,88,101)(H,89,96)(H,90,109)(H,91,110)(H,92,107)(H,93,106)(H,94,108)(H,102,103)(H4,78,79,85)/b87-39-/t53-,54-,55-,56-,57-,58-,59-/m0/s1/i76-1 DME01HT CS C1[C@H]2C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CSS1)C(=O)N[C@H](C(=O)N[C@@H](CSCC(=O)N[C@H](C(=O)N2)CCCCNC(=O)COCC(=O)NCCOCCOCCOCCOCCOCCNC(=O)CO/N=C\\C3=CC=C(C=C3)[18F])C(=O)NCCOCCOCCOCCNC(=O)COCC(=O)N)CC4=CC=CC=C4)CC(=O)O)CCCN=C(N)N DME01HT IK VXFFXZSNVKXXIB-SOFHUQNMSA-N DME01HT IU 2-[(1R,4S,10R,13S,16R,19S,25S)-10-[2-[2-[2-[2-[[2-(2-amino-2-oxoethoxy)acetyl]amino]ethoxy]ethoxy]ethoxy]ethylcarbamoyl]-13-benzyl-25-[3-(diaminomethylideneamino)propyl]-4-[4-[[2-[2-[2-[2-[2-[2-[2-[2-[[2-[(Z)-(4-(18F)fluoranylphenyl)methylideneamino]oxyacetyl]amino]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethylamino]-2-oxoethoxy]acetyl]amino]butyl]-3,6,12,15,18,21,24,27-octaoxo-8,29,30-trithia-2,5,11,14,17,20,23,26-octazabicyclo[14.11.4]hentriacontan-19-yl]acetic acid DME01HT DE Solid tumour/cancer DM0G5O6 ID DM0G5O6 DM0G5O6 DN Flumatinib DM0G5O6 HS Phase 2 DM0G5O6 SN HH-GV-678 DM0G5O6 CP Shanghai Institute of Materia Medica of the Chinese Academy of Sciences DM0G5O6 DT Small molecular drug DM0G5O6 PC 46848036 DM0G5O6 MW 562.6 DM0G5O6 FM C29H29F3N8O DM0G5O6 IC InChI=1S/C29H29F3N8O/c1-19-26(38-28-34-9-7-25(37-28)21-4-3-8-33-16-21)15-23(17-35-19)36-27(41)20-5-6-22(24(14-20)29(30,31)32)18-40-12-10-39(2)11-13-40/h3-9,14-17H,10-13,18H2,1-2H3,(H,36,41)(H,34,37,38) DM0G5O6 CS CC1=C(C=C(C=N1)NC(=O)C2=CC(=C(C=C2)CN3CCN(CC3)C)C(F)(F)F)NC4=NC=CC(=N4)C5=CN=CC=C5 DM0G5O6 IK BJCJYEYYYGBROF-UHFFFAOYSA-N DM0G5O6 IU 4-[(4-methylpiperazin-1-yl)methyl]-N-[6-methyl-5-[(4-pyridin-3-ylpyrimidin-2-yl)amino]pyridin-3-yl]-3-(trifluoromethyl)benzamide DM0G5O6 CA CAS 895519-90-1 DM0G5O6 DE Chronic myelogenous leukaemia DMCEUOH ID DMCEUOH DMCEUOH DN Fluoropeptide vaccine DMCEUOH HS Phase 2 DMCEUOH SN FP-01; Fluoropeptide vaccine (influenza); Fluoropeptide vaccine (influenza), Immune Targeting Systems DMCEUOH CP Immune Targeting Systems Ltd DMCEUOH DT Vaccine DMCEUOH DE Influenza virus infection DMPBV9D ID DMPBV9D DMPBV9D DN Flupirtine DMPBV9D HS Phase 2 DMPBV9D SN Flupirtine; 56995-20-1; Flupirtine [INN:BAN]; Flupirtinum [INN-Latin]; Flupirtino [INN-Spanish]; UNII-MOH3ET196H; C15H17FN4O2; EINECS 260-503-8; MOH3ET196H; JUUFBMODXQKSTD-UHFFFAOYSA-N; ethyl N-[2-amino-6-[(4-fluorophenyl)methylamino]pyridin-3-yl]carbamate; D 9998; flupirtin maleate; ethyl 2-amino-6-(4-fluorobenzylamino)pyridin-3-ylcarbamate; Flupirtinum; Flupirtino; MLS002153180; Carbamic acid, (2-amino-6-(((4-fluorophenyl)methyl)amino)-3-pyridinyl)-, ethyl ester; NCGC00015451-03; SMR001230672; Flupirtin; Carbamic acid, [2-ami DMPBV9D CP Adeona Pharmaceuticals; MI Meda Pharmaceuticals DMPBV9D DT Small molecular drug DMPBV9D PC 53276 DMPBV9D MW 304.32 DMPBV9D FM C15H17FN4O2 DMPBV9D IC InChI=1S/C15H17FN4O2/c1-2-22-15(21)19-12-7-8-13(20-14(12)17)18-9-10-3-5-11(16)6-4-10/h3-8H,2,9H2,1H3,(H,19,21)(H3,17,18,20) DMPBV9D CS CCOC(=O)NC1=C(N=C(C=C1)NCC2=CC=C(C=C2)F)N DMPBV9D IK JUUFBMODXQKSTD-UHFFFAOYSA-N DMPBV9D IU ethyl N-[2-amino-6-[(4-fluorophenyl)methylamino]pyridin-3-yl]carbamate DMPBV9D CA CAS 56995-20-1 DMPBV9D CB CHEBI:94646 DMPBV9D DE Fibromyalgia; Cancer related pain DMQX5UA ID DMQX5UA DMQX5UA DN FLX-787 DMQX5UA HS Phase 2 DMQX5UA CP Flex Pharma, Boston, MA DMQX5UA DE Amyotrophic lateral sclerosis; Multiple sclerosis; Muscle spasm DMB9ADM ID DMB9ADM DMB9ADM DN FolateImmune DMB9ADM HS Phase 2 DMB9ADM SN Folate-FITC; EC-17; UNII-V7YQ6134AE; V7YQ6134AE; EC17 (Folate-FITC); Folate-fluorescein conjugate; DTXSID40207031; ZMTAPBHUSYTHBY-PMERELPUSA-N; EC 17; DB12559; 910661-23-3; 1159606-35-5 DMB9ADM CP Endocyte Inc DMB9ADM DT Small molecular drug DMB9ADM PC 135564966 DMB9ADM MW 872.9 DMB9ADM FM C42H36N10O10S DMB9ADM IC InChI=1S/C42H36N10O10S/c43-33(55)12-11-30(38(58)59)52(37(57)20-1-3-21(4-2-20)46-18-23-19-47-35-34(48-23)36(56)51-40(44)50-35)14-13-45-41(63)49-22-5-8-27-26(15-22)39(60)62-42(27)28-9-6-24(53)16-31(28)61-32-17-25(54)7-10-29(32)42/h1-10,15-17,19,30,46,53-54H,11-14,18H2,(H2,43,55)(H,58,59)(H2,45,49,63)(H3,44,47,50,51,56)/t30-/m0/s1 DMB9ADM CS C1=CC(=CC=C1C(=O)N(CCNC(=S)NC2=CC3=C(C=C2)C4(C5=C(C=C(C=C5)O)OC6=C4C=CC(=C6)O)OC3=O)[C@@H](CCC(=O)N)C(=O)O)NCC7=CN=C8C(=N7)C(=O)NC(=N8)N DMB9ADM IK ZMTAPBHUSYTHBY-PMERELPUSA-N DMB9ADM IU (2S)-5-amino-2-[[4-[(2-amino-4-oxo-3H-pteridin-6-yl)methylamino]benzoyl]-[2-[(3',6'-dihydroxy-3-oxospiro[2-benzofuran-1,9'-xanthene]-5-yl)carbamothioylamino]ethyl]amino]-5-oxopentanoic acid DMB9ADM CA CAS 583037-91-6 DMB9ADM DE Renal cell carcinoma; Solid tumour/cancer DMJNO3D ID DMJNO3D DMJNO3D DN Follicle stimulating hormone DMJNO3D HS Phase 2 DMJNO3D SN FSH-GEX; Follicle stimulating hormone (GEX, inferticlity); GT-GP 2.4 GEX; Follicle stimulating hormone (GEX, inferticlity), Glycotope DMJNO3D CP Glycotope GmbH DMJNO3D DE Infertility DMUAXS5 ID DMUAXS5 DMUAXS5 DN FP-1039 DMUAXS5 HS Phase 2 DMUAXS5 SN FPT-039; HGS-1036; Modified growth factor receptor (cancer), FivePrime Therapeutics; FGFR-1c antagonist (protein fusion/iv,cancer), FivePrime Therapeutics; FGFR-1c antagonist (protein fusion/iv, cancer), FivePrime Therapeutics/ Human Genome Sciences DMUAXS5 CP FivePrime Therapeutics Inc DMUAXS5 DE Solid tumour/cancer; Endometrial cancer DMC1F2T ID DMC1F2T DMC1F2T DN FP-1097 DMC1F2T HS Phase 2 DMC1F2T SN Urinary incontinence therapy, FemmePharma DMC1F2T CP FemmePharma Inc DMC1F2T DE Urinary incontinence DMXOTMP ID DMXOTMP DMXOTMP DN FPI-01 DMXOTMP HS Phase 2 DMXOTMP SN WT-1 therapeutic vaccine (cancer), Formula Pharmaceuticals DMXOTMP CP Formula pharmaceuticals DMXOTMP DT Vaccine DMXOTMP DE Acute myeloid leukaemia DMEL5SV ID DMEL5SV DMEL5SV DN FR139317 DMEL5SV HS Phase 2 DMEL5SV SN D-Alanine, N-((hexahydro-1H-azepin-1-yl)carbonyl)-L-leucyl-1-methyl-D-tryptophyl-3-(2-pyridinyl)-; FR 139317; 142375-60-8; CHEMBL352396; 2-((1-(Hexahydro-1H-azepinyl)carbonyl)amino-4-methylpentanoyl)-3-(-(1-methyl-1H-indolyl)propionyl)amino-3-(2-pyridyl)propionic acid; D-Alanine, N-(N-(N-((hexahydro-1H-azepin-1-yl)carbonyl)-L-leucyl)-1-methyl-D-tryptophyl)-3-(2-pyridinyl)-; GSK424887 DMEL5SV DT Small molecular drug DMEL5SV PC 107810 DMEL5SV MW 604.7 DMEL5SV FM C33H44N6O5 DMEL5SV IC InChI=1S/C33H44N6O5/c1-22(2)18-26(37-33(44)39-16-10-4-5-11-17-39)30(40)35-27(19-23-21-38(3)29-14-7-6-13-25(23)29)31(41)36-28(32(42)43)20-24-12-8-9-15-34-24/h6-9,12-15,21-22,26-28H,4-5,10-11,16-20H2,1-3H3,(H,35,40)(H,36,41)(H,37,44)(H,42,43)/t26-,27+,28+/m0/s1 DMEL5SV CS CC(C)C[C@@H](C(=O)N[C@H](CC1=CN(C2=CC=CC=C21)C)C(=O)N[C@H](CC3=CC=CC=N3)C(=O)O)NC(=O)N4CCCCCC4 DMEL5SV IK LIOKMIQQPDDTNO-UPRLRBBYSA-N DMEL5SV IU (2R)-2-[[(2R)-2-[[(2S)-2-(azepane-1-carbonylamino)-4-methylpentanoyl]amino]-3-(1-methylindol-3-yl)propanoyl]amino]-3-pyridin-2-ylpropanoic acid DMEL5SV CA CAS 142375-60-8 DMEL5SV DE Anxiety disorder; Depression; Hypertension DMGO45I ID DMGO45I DMGO45I DN FR-146687 DMGO45I HS Phase 2 DMGO45I SN FK-687; TF-505; 4-[1-[4-[1(S)-(4-Isobutylphenyl)butoxy]benzoyl]indolizin-3-yl]butyric acid DMGO45I DE Prostate disease DMFZ084 ID DMFZ084 DMFZ084 DN Fresolimumab DMFZ084 HS Phase 2 DMFZ084 SN GC-1008 DMFZ084 DT Antibody DMFZ084 DE Brain cancer DM9ORUW ID DM9ORUW DM9ORUW DN FRM-0962 DM9ORUW HS Phase 2 DM9ORUW CP Forum pharmaceuticals DM9ORUW DE Alzheimer disease DMPQFTA ID DMPQFTA DMPQFTA DN Fucoxanthin DMPQFTA HS Phase 2 DMPQFTA SN Fucoxanthin; UNII-06O0TC0VSM; CCRIS 4055; all-trans-Fucoxanthin; BRN 0073179; 06O0TC0VSM; beta,beta-Carotene, 3'-(acetyloxy)-6',7'-didehydro-5,6-epoxy-5,5',6,6',7,8-hexahydro-3,5'-dihydroxy-8-oxo-, (3S,3'S,5R,5'R,6S,6'R)-; (3S,5R,6S,3'S,5'R,6'R)-3,5'-dihydroxy-8-oxo-6',7'-didehydro-5,6-epoxy-5,6,7,8,5',6'-hexahydro-beta,beta-caroten-3'-yl acetate; (3'S,5'R,6'R)-3'-acetoxy-5,6-epoxy-3,5'-dihydroxy-6',7'-didehydro-5,6,7,8,5',6'-hexahydro-beta,beta-caroten-8-one DMPQFTA PC 5281239 DMPQFTA MW 658.9 DMPQFTA FM C42H58O6 DMPQFTA IC InChI=1S/C42H58O6/c1-29(18-14-19-31(3)22-23-37-38(6,7)26-35(47-33(5)43)27-40(37,10)46)16-12-13-17-30(2)20-15-21-32(4)36(45)28-42-39(8,9)24-34(44)25-41(42,11)48-42/h12-22,34-35,44,46H,24-28H2,1-11H3/b13-12+,18-14+,20-15+,29-16+,30-17+,31-19+,32-21+/t23?,34-,35-,40+,41+,42-/m0/s1 DMPQFTA CS CC(=CC=CC=C(C)C=CC=C(C)C(=O)CC12C(CC(CC1(O2)C)O)(C)C)C=CC=C(C)C=C=C3C(CC(CC3(C)O)OC(=O)C)(C)C DMPQFTA IK SJWWTRQNNRNTPU-ABBNZJFMSA-N DMPQFTA IU nan DMPQFTA CA CAS 3351-86-8 DMPQFTA CB CHEBI:5186 DMPQFTA DE Metabolic syndrome DMZLBAW ID DMZLBAW DMZLBAW DN Fucoxanthin DMZLBAW HS Phase 2 DMZLBAW SN 3351-86-8; UNII-06O0TC0VSM; all-trans-Fucoxanthin; (3'S,5'R,6'R)-3'-acetoxy-5,6-epoxy-3,5'-dihydroxy-6',7'-didehydro-5,6,7,8,5',6'-hexahydro-beta,beta-caroten-8-one; (3S,3'S,5R,5'R,6S,6'R)-3'-(acetyloxy)-6',7'-didehydro-5,6-epoxy-5,5',6,6',7,8-hexahydro-3,5'-dihydroxy-8-oxo-beta,beta-carotene; (3S,5R,6S,3'S,5'R,6'R)-3,5'-dihydroxy-8-oxo-6',7'-didehydro-5,6-epoxy-5,6,7,8,5',6'-hexahydro-beta,beta-caroten-3'-yl acetate; (1S,3R)-3-hydroxy-4-((3E,5E,7E,9E,11E,13E,15E)-18-((1S,4S,6R)-4-hydroxy-2,2,6-trimethyl-7-oxabicyclo[4.1.0]heptan-1-yl)-3,7,12,16-tetramethyl-17-oxooctadeca-1,3,5,7,9,11,13,15-octaen-1-ylidene)-3,5,5-trimethylcyclohexyl acetate; CCRIS 4055; BRN 0073179; Fucoxanthol; cis-Fucoxanthin; yl acetate; (3S,3'S,5R,5'R,6S,6'R,8'R)-3,5'-dihydroxy-8-oxo-6',7'-didehydro-5,5',6,6',7,8-hexahydro-5,6-epoxy-beta,beta-caroten-3'-yl acetate; C42H58O6; Beta-sitosterol 45%; SCHEMBL37284; 5-18-04-00673 (Beilstein Handbook Reference); beta,beta-Carotene, 3'-(acetyloxy)-6',7'-didehydro-5,6-epoxy-5,5',6,6',7,8-hexahydro-3,5'-dihydroxy-8-oxo-, (3S,3'S,5R,5'R,6S,6'R)-; MLS000728353; Fucoxanthin, analytical standard; CHEMBL1575074; SJWWTRQNNRNTPU-ABBNZJFMSA-; Fucoxanthin carotenoid antioxidant; Fucoxanthin, carotenoid antioxidant; HMS2219K22; Fucoxanthin (from Wakame) (Brown Seaweed) (Undaria Pinnatifida); HY-N2302; ZINC8221218; 1772AH; LMPR01070300; MFCD01745140; AKOS037514648; CS-8167; NCGC00247434-01; AS-56344; SMR000453597; C08596; Q96385; 351F868; Fucoxanthin solution, 1 mg/L in ethanol, analytical standard; (1S,3R)-3-hydroxy-4-((3E,5E,7E,9E,11E,13E,15E)-18-((1S,4S,6R)-4-hydroxy-2,2,6-trimethyl-7-oxabicyclo[4.1.0]heptan-1-yl)-3,7,12,16-tetramethyl-17-oxooctadeca-1,3,5,7,9,11,13,15-octaenylidene)-3,5,5-trimethylcyclohexyl acetate; (3S,3'S,5R,5'R,6S)-3'-Acetoxy-5alpha,6alpha-epoxy-3,5'-dihydroxy-8-oxo-6',7'-didehydro-5,6,7,8-tetrahydro-beta,beta-carotene; (3S,3'S,5R,5'R,6S,6'R,8'R)-3,5'-dihydroxy-8-oxo-6',7'-didehydro-5,5',6,6',7,8-hexahydro-5,6-epoxy-beta,beta-caroten-3'- DMZLBAW DT Small molecular drug DMZLBAW PC 5281239 DMZLBAW MW 658.9 DMZLBAW FM C42H58O6 DMZLBAW IC InChI=1S/C42H58O6/c1-29(18-14-19-31(3)22-23-37-38(6,7)26-35(47-33(5)43)27-40(37,10)46)16-12-13-17-30(2)20-15-21-32(4)36(45)28-42-39(8,9)24-34(44)25-41(42,11)48-42/h12-22,34-35,44,46H,24-28H2,1-11H3/b13-12+,18-14+,20-15+,29-16+,30-17+,31-19+,32-21+/t23?,34-,35-,40+,41+,42-/m0/s1 DMZLBAW CS C/C(=C\\C=C\\C=C(/C)\\C=C\\C=C(/C)\\C(=O)C[C@]12[C@](O1)(C[C@H](CC2(C)C)O)C)/C=C/C=C(\\C)/C=C=C3[C@](C[C@H](CC3(C)C)OC(=O)C)(C)O DMZLBAW IK SJWWTRQNNRNTPU-ABBNZJFMSA-N DMZLBAW CA CAS 3351-86-8 DMZLBAW DE Metabolic syndrome x DMKHNXA ID DMKHNXA DMKHNXA DN G100 DMKHNXA HS Phase 2 DMKHNXA SN Caffeine, 8-((3-methoxypropyl)amino)-; 8-((3-Methoxypropyl)amino)caffeine; CAFFEINE, 8-((3-METHOXYPROPYL)AMINO)-; BRN 1086127; 95982-26-6; 8-(gamma-Methoxypropyl)-aminocoffein [German]; 8-(3-methoxypropylamino)-1,3,7-trimethylpurine-2,6-dione; 8-[(3-methoxypropyl)amino]-1,3,7-trimethyl-3,7-dihydro-1H-purine-2,6-dione; 8-(gamma-Methoxypropyl)-aminocoffein; AC1L1M3J; CTK5H8490; DTXSID70242056; MolPort-002-837-706; CCG-22657; ZINC17172964; AKOS001669223; MCULE-8333260193; LS-48594; EU-0014431; G-100; AO-343/41780992 DMKHNXA CP Immune Design Seattle, WA DMKHNXA PC 56998 DMKHNXA MW 281.31 DMKHNXA FM C12H19N5O3 DMKHNXA IC InChI=1S/C12H19N5O3/c1-15-8-9(14-11(15)13-6-5-7-20-4)16(2)12(19)17(3)10(8)18/h5-7H2,1-4H3,(H,13,14) DMKHNXA CS CN1C2=C(N=C1NCCCOC)N(C(=O)N(C2=O)C)C DMKHNXA IK ZZQHGKMTMAORFI-UHFFFAOYSA-N DMKHNXA IU 8-(3-methoxypropylamino)-1,3,7-trimethylpurine-2,6-dione DMKHNXA CA CAS 95982-26-6 DMKHNXA DE Non-hodgkin lymphoma DMQO2IT ID DMQO2IT DMQO2IT DN G1T38 DMQO2IT HS Phase 2 DMQO2IT SN YPJRHEKCFKOVRT-UHFFFAOYSA-N; SCHEMBL16036885; CHEMBL3904602; BDBM253941; US9464092, GG; 1628256-23-4 DMQO2IT CP G1 Therapeutics Research Tringle Park, NC DMQO2IT PC 86269224 DMQO2IT MW 474.6 DMQO2IT FM C26H34N8O DMQO2IT IC InChI=1S/C26H34N8O/c1-18(2)32-10-12-33(13-11-32)20-6-7-22(27-16-20)30-25-28-15-19-14-21-24(35)29-17-26(8-4-3-5-9-26)34(21)23(19)31-25/h6-7,14-16,18H,3-5,8-13,17H2,1-2H3,(H,29,35)(H,27,28,30,31) DMQO2IT CS CC(C)N1CCN(CC1)C2=CN=C(C=C2)NC3=NC=C4C=C5C(=O)NCC6(N5C4=N3)CCCCC6 DMQO2IT IK YPJRHEKCFKOVRT-UHFFFAOYSA-N DMQO2IT IU 4-[[5-(4-propan-2-ylpiperazin-1-yl)pyridin-2-yl]amino]spiro[1,3,5,11-tetrazatricyclo[7.4.0.02,7]trideca-2,4,6,8-tetraene-13,1'-cyclohexane]-10-one DMQO2IT CA CAS 1628256-23-4 DMQO2IT DE Breast cancer; Non-small-cell lung cancer DMQR9I8 ID DMQR9I8 DMQR9I8 DN G-202 DMQR9I8 HS Phase 2 DMQR9I8 SN UNII-Q032I35QMX; Q032I35QMX; 1245732-48-2; Mipsagargin [USAN:INN]; Mipsagargin (USAN/INN); CHEMBL3989865; DB11813; D10715 DMQR9I8 CP GenSpera DMQR9I8 PC 24772106 DMQR9I8 MW 1409.5 DMQR9I8 FM C66H100N6O27 DMQR9I8 IC InChI=1S/C66H100N6O27/c1-8-10-11-17-20-24-51(81)96-55-53-52(37(4)54(55)97-62(91)36(3)9-2)56-66(94,65(7,93)63(92)98-56)44(35-64(53,6)99-38(5)73)95-50(80)23-21-18-15-13-12-14-16-19-22-33-68-48(77)34-39(67)57(82)72-43(61(89)90)27-31-47(76)70-41(59(85)86)25-29-45(74)69-40(58(83)84)26-30-46(75)71-42(60(87)88)28-32-49(78)79/h9,39-44,53-56,93-94H,8,10-35,67H2,1-7H3,(H,68,77)(H,69,74)(H,70,76)(H,71,75)(H,72,82)(H,78,79)(H,83,84)(H,85,86)(H,87,88)(H,89,90)/b36-9-/t39-,40-,41-,42-,43-,44-,53+,54-,55-,56-,64-,65+,66+/m0/s1 DMQR9I8 CS CCCCCCCC(=O)O[C@H]1[C@H]2C(=C([C@@H]1OC(=O)/C(=C\\C)/C)C)[C@H]3[C@]([C@H](C[C@]2(C)OC(=O)C)OC(=O)CCCCCCCCCCCNC(=O)C[C@@H](C(=O)N[C@@H](CCC(=O)N[C@@H](CCC(=O)N[C@@H](CCC(=O)N[C@@H](CCC(=O)O)C(=O)O)C(=O)O)C(=O)O)C(=O)O)N)([C@](C(=O)O3)(C)O)O DMQR9I8 IK UPYNTAIBQVNPIH-ODMLWHIESA-N DMQR9I8 IU (2S)-2-[[(4S)-4-[[(4S)-4-[[(4S)-4-[[(2S)-4-[[12-[[(3S,3aR,4S,6S,6aR,7S,8S,9bS)-6-acetyloxy-3,3a-dihydroxy-3,6,9-trimethyl-8-[(Z)-2-methylbut-2-enoyl]oxy-7-octanoyloxy-2-oxo-4,5,6a,7,8,9b-hexahydroazuleno[4,5-b]furan-4-yl]oxy]-12-oxododecyl]amino]-2-amino-4-oxobutanoyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]pentanedioic acid DMQR9I8 CA CAS 1245732-48-2 DMQR9I8 DE Solid tumour/cancer; Adenocarcinoma DMJY2TM ID DMJY2TM DMJY2TM DN Gabapentin enacarbil DMJY2TM HS Phase 2 DMJY2TM SN 1838262; ASP8825; Gabapentin-XP; GSK 1838262; Horizant; Regnite; Solzira; XP13512 DMJY2TM TC Neurology Agents DMJY2TM DT Small molecular drug DMJY2TM PC 9883933 DMJY2TM MW 329.39 DMJY2TM FM C16H27NO6 DMJY2TM IC InChI=1S/C16H27NO6/c1-11(2)14(20)22-12(3)23-15(21)17-10-16(9-13(18)19)7-5-4-6-8-16/h11-12H,4-10H2,1-3H3,(H,17,21)(H,18,19) DMJY2TM CS CC(C)C(=O)OC(C)OC(=O)NCC1(CCCCC1)CC(=O)O DMJY2TM IK TZDUHAJSIBHXDL-UHFFFAOYSA-N DMJY2TM IU 2-[1-[[1-(2-methylpropanoyloxy)ethoxycarbonylamino]methyl]cyclohexyl]acetic acid DMJY2TM CA CAS 478296-72-9 DMJY2TM CB CHEBI:68840 DMJY2TM DE Alcohol dependence DMTXCUS ID DMTXCUS DMTXCUS DN Galiximab DMTXCUS HS Phase 2 DMTXCUS CP Biogen Idec DMTXCUS DT Antibody DMTXCUS DE Lymphoma DMXBR27 ID DMXBR27 DMXBR27 DN Gallopamil DMXBR27 HS Phase 2 DMXBR27 SN 16662-47-8; methoxyverapamil; 5-((3,4-Dimethoxyphenethyl)(methyl)amino)-2-isopropyl-2-(3,4,5-trimethoxyphenyl)pentanenitrile; Galopamilo; Galopamilo [INN-Spanish]; Gallopamillum [INN-Latin]; Gallopamil [INN:BAN]; D600; D 600; C28H40N2O5; CHEBI:34772; (+/-)-Methoxyverapamil hydrochloride; 5-[(3,4-Dimethoxyphenethyl)methylamino]-2-isopropyl-2-(3,4,5-trimethoxyphenyl)valeronitrile; Benzeneacetonitrile, alpha-(3-((2-(3,4-dimethoxyphenyl)ethyl)methylamino)propyl)-3,4,5-trimethoxy-alpha-(1-methylethyl)-; Methoxyverapamil; GSK 796406 DMXBR27 DT Small molecular drug DMXBR27 PC 1234 DMXBR27 MW 484.6 DMXBR27 FM C28H40N2O5 DMXBR27 IC InChI=1S/C28H40N2O5/c1-20(2)28(19-29,22-17-25(33-6)27(35-8)26(18-22)34-7)13-9-14-30(3)15-12-21-10-11-23(31-4)24(16-21)32-5/h10-11,16-18,20H,9,12-15H2,1-8H3 DMXBR27 CS CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C(=C2)OC)OC)OC DMXBR27 IK XQLWNAFCTODIRK-UHFFFAOYSA-N DMXBR27 IU 5-[2-(3,4-dimethoxyphenyl)ethyl-methylamino]-2-propan-2-yl-2-(3,4,5-trimethoxyphenyl)pentanenitrile DMXBR27 CA CAS 16662-47-8 DMXBR27 CB CHEBI:34772 DMXBR27 DE Hypertension; Asthma DMAEWS1 ID DMAEWS1 DMAEWS1 DN GAM-501 DMAEWS1 HS Phase 2 DMAEWS1 SN Excellarate; Diabetic ulcer product, Selective Genetics; AdPDGF-B/GAM; Adenoviral gene therapy (PDGF-B), Selective Genetics; PDGF-B adenoviral gene therapy (collagen gel, diabetic foot ulcer), Tissue Repair Company DMAEWS1 CP Selective Genetics Inc DMAEWS1 DE Diabetic foot ulcer DM2IFJQ ID DM2IFJQ DM2IFJQ DN GBL-310 DM2IFJQ HS Phase 2 DM2IFJQ SN Anti-hyperproliferative (topical, actinic keratosis), Grannus DM2IFJQ CP Grannus BioSciences Ltd DM2IFJQ DE Keratosis DM2VO9T ID DM2VO9T DM2VO9T DN GBR 830 DM2VO9T HS Phase 2 DM2VO9T CP Glenmark Pharmaceuticals Mumbai, India DM2VO9T DE Atopic dermatitis DMYS6MW ID DMYS6MW DMYS6MW DN GCS-100 DMYS6MW HS Phase 2 DMYS6MW CP La jolla pharmaceutical DMYS6MW DE Chronic kidney disease DMY6WUV ID DMY6WUV DMY6WUV DN GDC-0077 DMY6WUV HS Phase 2 DMY6WUV SN RG6114; SGEUNORSOZVTOL-CABZTGNLSA-N; UNII-L4C1UY2NYH; L4C1UY2NYH; 2060571-02-8; GDC0077; GTPL9636; SCHEMBL18360780; EX-A2685; ZINC669678973; Ro7113755; CS-6459; HY-101562; Propanamide, 2-((2-((4S)-4-(difluoromethyl)-2-oxo-3-oxazolidinyl)-5,6-dihydroimidazo(1,2-d)(1,4)benzoxazepin-9-yl)amino)-, (2S)-; (S)-2-((2-((S)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino)propanamide; (2S)-2-[[2-[(4S)-4-(difluoromethyl)-2-oxo-1,3-oxazolidin-3-yl]-5,6-dihydroimidazo[1,2-d][1,4]benzoxa DMY6WUV CP GenentechSouth San Francisco, CA DMY6WUV PC 124173720 DMY6WUV MW 407.4 DMY6WUV FM C18H19F2N5O4 DMY6WUV IC InChI=1S/C18H19F2N5O4/c1-9(16(21)26)22-10-2-3-11-13(6-10)28-5-4-24-7-14(23-17(11)24)25-12(15(19)20)8-29-18(25)27/h2-3,6-7,9,12,15,22H,4-5,8H2,1H3,(H2,21,26)/t9-,12-/m0/s1 DMY6WUV CS C[C@@H](C(=O)N)NC1=CC2=C(C=C1)C3=NC(=CN3CCO2)N4[C@@H](COC4=O)C(F)F DMY6WUV IK SGEUNORSOZVTOL-CABZTGNLSA-N DMY6WUV IU (2S)-2-[[2-[(4S)-4-(difluoromethyl)-2-oxo-1,3-oxazolidin-3-yl]-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepin-9-yl]amino]propanamide DMY6WUV CA CAS 2060571-02-8 DMY6WUV DE Breast cancer; Solid tumour/cancer DMA9SEY ID DMA9SEY DMA9SEY DN GDC-0084 DMA9SEY HS Phase 2 DMA9SEY SN GDC-0084/RG7666 DMA9SEY CP Genentech DMA9SEY PC 57384863 DMA9SEY MW 382.4 DMA9SEY FM C18H22N8O2 DMA9SEY IC InChI=1S/C18H22N8O2/c1-18(2)16-22-12-14(25-3-6-27-7-4-25)23-13(11-9-20-17(19)21-10-11)24-15(12)26(16)5-8-28-18/h9-10H,3-8H2,1-2H3,(H2,19,20,21) DMA9SEY CS CC1(C2=NC3=C(N2CCO1)N=C(N=C3N4CCOCC4)C5=CN=C(N=C5)N)C DMA9SEY IK LGWACEZVCMBSKW-UHFFFAOYSA-N DMA9SEY IU 5-(6,6-dimethyl-4-morpholin-4-yl-8,9-dihydropurino[8,9-c][1,4]oxazin-2-yl)pyrimidin-2-amine DMA9SEY CA CAS 1382979-44-3 DMA9SEY DE Glioblastoma of brain DM1YAK6 ID DM1YAK6 DM1YAK6 DN GDC0941 DM1YAK6 HS Phase 2 DM1YAK6 SN Pictilisib; GDC-0941; 957054-30-7; PICTILISIB; Pictrelisib; GDC 0941; 4-(2-(1H-Indazol-4-yl)-6-((4-(methylsulfonyl)piperazin-1-yl)methyl)thieno[3,2-d]pyrimidin-4-yl)morpholine; 2-(1H-Indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine; UNII-ICY00EMP8P; ICY00EMP8P; Pictilisib (GDC-0941); CHEBI:65326; AK-40872; Thieno[3,2-d]pyrimidine, 2-(1H-indazol-4-yl)-6-[[4-(methylsulfonyl)-1-piperazinyl]methyl]-4-(4-morpholinyl)-; GD9; GDC-0941, GDC0941; 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine DM1YAK6 CP Genentech DM1YAK6 DT Small molecular drug DM1YAK6 PC 17755052 DM1YAK6 MW 513.6 DM1YAK6 FM C23H27N7O3S2 DM1YAK6 IC InChI=1S/C23H27N7O3S2/c1-35(31,32)30-7-5-28(6-8-30)15-16-13-20-21(34-16)23(29-9-11-33-12-10-29)26-22(25-20)17-3-2-4-19-18(17)14-24-27-19/h2-4,13-14H,5-12,15H2,1H3,(H,24,27) DM1YAK6 CS CS(=O)(=O)N1CCN(CC1)CC2=CC3=C(S2)C(=NC(=N3)C4=C5C=NNC5=CC=C4)N6CCOCC6 DM1YAK6 IK LHNIIDJUOCFXAP-UHFFFAOYSA-N DM1YAK6 IU 4-[2-(1H-indazol-4-yl)-6-[(4-methylsulfonylpiperazin-1-yl)methyl]thieno[3,2-d]pyrimidin-4-yl]morpholine DM1YAK6 CA CAS 957054-30-7 DM1YAK6 CB CHEBI:65326 DM1YAK6 DE Non-hodgkin lymphoma; Solid tumour/cancer; Breast cancer DMF3MV1 ID DMF3MV1 DMF3MV1 DN GDC-0980/RG7422 DMF3MV1 HS Phase 2 DMF3MV1 SN Apitolisib; 1032754-93-0; GDC-0980; GDC0980; RG7422; (S)-1-(4-((2-(2-aminopyrimidin-5-yl)-7-methyl-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-hydroxypropan-1-one; UNII-1C854K1MIJ; GDC-0980 (RG7422); Apitolisib (GDC-0980, RG7422); 1C854K1MIJ; CHEMBL1922094; RG-7422; (2s)-1-(4-{[2-(2-Aminopyrimidin-5-Yl)-7-Methyl-4-(Morpholin-4-Yl)thieno[3,2-D]pyrimidin-6-Yl]methyl}piperazin-1-Yl)-2-Hydroxypropan-1-One; J-502360; C23H30N8O3S DMF3MV1 CP Genentech; Roche DMF3MV1 DT Small molecular drug DMF3MV1 PC 25254071 DMF3MV1 MW 498.6 DMF3MV1 FM C23H30N8O3S DMF3MV1 IC InChI=1S/C23H30N8O3S/c1-14-17(13-29-3-5-31(6-4-29)22(33)15(2)32)35-19-18(14)27-20(16-11-25-23(24)26-12-16)28-21(19)30-7-9-34-10-8-30/h11-12,15,32H,3-10,13H2,1-2H3,(H2,24,25,26)/t15-/m0/s1 DMF3MV1 CS CC1=C(SC2=C1N=C(N=C2N3CCOCC3)C4=CN=C(N=C4)N)CN5CCN(CC5)C(=O)[C@H](C)O DMF3MV1 IK YOVVNQKCSKSHKT-HNNXBMFYSA-N DMF3MV1 IU (2S)-1-[4-[[2-(2-aminopyrimidin-5-yl)-7-methyl-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]piperazin-1-yl]-2-hydroxypropan-1-one DMF3MV1 CA CAS 1032754-93-0 DMF3MV1 DE Non-hodgkin lymphoma; Solid tumour/cancer DMMQY0O ID DMMQY0O DMMQY0O DN GED-0507-34-Levo DMMQY0O HS Phase 2 DMMQY0O SN GED-0507; GED-0507-34; GED-0507-34E2 DMMQY0O CP Giuliani SpA DMMQY0O PC 67008033 DMMQY0O MW 195.21 DMMQY0O FM C10H13NO3 DMMQY0O IC InChI=1S/C10H13NO3/c1-14-9(10(12)13)6-7-2-4-8(11)5-3-7/h2-5,9H,6,11H2,1H3,(H,12,13)/t9-/m0/s1 DMMQY0O CS CO[C@@H](CC1=CC=C(C=C1)N)C(=O)O DMMQY0O IK QLJYLJGYIDIJPT-VIFPVBQESA-N DMMQY0O IU (2S)-3-(4-aminophenyl)-2-methoxypropanoic acid DMMQY0O CA CAS 921195-93-9 DMMQY0O DE Inflammatory bowel disease DMJN09S ID DMJN09S DMJN09S DN GEN-1 DMJN09S HS Phase 2 DMJN09S CP Celsion DMJN09S DT Gene therapy DMJN09S DE Ovarian cancer DMO9WU8 ID DMO9WU8 DMO9WU8 DN Gepirone DMO9WU8 HS Phase 2 DMO9WU8 SN Gepirone; 4,4-Dimethyl-1-(4-(4-(pyrimidin-2-yl)piperazin-1-yl)butyl)piperidine-2,6-dione; Gepirone ER; Gepironum [Latin]; Gepirone [INN]; Gepirona [Spanish]; UNII-JW5Y7B8Z18; BMY-13805; JW5Y7B8Z18; CHEMBL284092; MJ-13805; Variza; Ariza; Gepironum; AK115965; Gepirona; 4,4-dimethyl-1-[4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]piperidine-2,6-dione; Travivo; 2,6-Piperidinedione, 4,4-dimethyl-1-(4-(4-(2-pyrimidinyl)-1-piperazinyl)butyl)-; BMY 13805; MJ 13805; gepiron ER; MJ 13805-1; ORG-13011(Gepirone); AC1L1IK6; AC1Q6F8Q DMO9WU8 PC 55191 DMO9WU8 MW 359.5 DMO9WU8 FM C19H29N5O2 DMO9WU8 IC InChI=1S/C19H29N5O2/c1-19(2)14-16(25)24(17(26)15-19)9-4-3-8-22-10-12-23(13-11-22)18-20-6-5-7-21-18/h5-7H,3-4,8-15H2,1-2H3 DMO9WU8 CS CC1(CC(=O)N(C(=O)C1)CCCCN2CCN(CC2)C3=NC=CC=N3)C DMO9WU8 IK QOIGKGMMAGJZNZ-UHFFFAOYSA-N DMO9WU8 IU 4,4-dimethyl-1-[4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]piperidine-2,6-dione DMO9WU8 CA CAS 83928-76-1 DMO9WU8 CB CHEBI:135990 DMO9WU8 DE Cocaine related disorders DMD3RU8 ID DMD3RU8 DMD3RU8 DN GFT14 DMD3RU8 HS Phase 2 DMD3RU8 CP Genfit DMD3RU8 DE Hyperlipidaemia DMTY4PG ID DMTY4PG DMTY4PG DN GI-4000 DMTY4PG HS Phase 2 DMTY4PG CP GlobeImmune DMTY4PG DT Vaccine DMTY4PG DE Colorectal cancer; Pancreatic cancer DMQ0XZE ID DMQ0XZE DMQ0XZE DN GI-4000 + gemcitabine DMQ0XZE HS Phase 2 DMQ0XZE CP GlobeImmune DMQ0XZE DE Pancreatic cancer DM72O6F ID DM72O6F DM72O6F DN GI-6207 DM72O6F HS Phase 2 DM72O6F CP GlobeImmune DM72O6F DE Thyroid cancer DMOMS7R ID DMOMS7R DMOMS7R DN GI-6301 DMOMS7R HS Phase 2 DMOMS7R CP GlobeImmune DMOMS7R DT Vaccine DMOMS7R DE Solid tumour/cancer; Advanced cancer; Chordoma DMSKMET ID DMSKMET DMSKMET DN Gimatecan DMSKMET HS Phase 2 DMSKMET SN LBQ-707; ST-1480; ST-1481; Camptothecin analogs, Sigma-Tau; 7-cyano-camptothecin DMSKMET CP Sigma-Tau Ind Farm Riunite SpA DMSKMET DT Small molecular drug DMSKMET PC 9577124 DMSKMET MW 447.5 DMSKMET FM C25H25N3O5 DMSKMET IC InChI=1S/C25H25N3O5/c1-5-25(31)18-10-20-21-16(12-28(20)22(29)17(18)13-32-23(25)30)15(11-26-33-24(2,3)4)14-8-6-7-9-19(14)27-21/h6-11,31H,5,12-13H2,1-4H3/b26-11+/t25-/m0/s1 DMSKMET CS CC[C@@]1(C2=C(COC1=O)C(=O)N3CC4=C(C5=CC=CC=C5N=C4C3=C2)/C=N/OC(C)(C)C)O DMSKMET IK UIVFUQKYVFCEKJ-OPTOVBNMSA-N DMSKMET IU (19S)-19-ethyl-19-hydroxy-10-[(E)-(2-methylpropan-2-yl)oxyiminomethyl]-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4,6,8,10,15(20)-heptaene-14,18-dione DMSKMET CA CAS 292618-32-7 DMSKMET DE Breast cancer DMG3O2Z ID DMG3O2Z DMG3O2Z DN Girentuximab I-124 DMG3O2Z HS Phase 2 DMG3O2Z SN Redectane (TN) DMG3O2Z CP Wilex DMG3O2Z DT Monoclonal antibody DMG3O2Z DE Renal cell carcinoma DMLFSMX ID DMLFSMX DMLFSMX DN GK1-399 DMLFSMX HS Phase 2 DMLFSMX SN TTP-399 DMLFSMX CP Forest Laboratories DMLFSMX DE Diabetic complication; Type-2 diabetes DMOVB3Y ID DMOVB3Y DMOVB3Y DN GKT-137831 DMOVB3Y HS Phase 2 DMOVB3Y SN GKT-01; NADPH oxidase inhibitor (oral, renal cancer/ idiopathic pulmonary fibrosis), GenKyoTex DMOVB3Y CP Genkyotex innovation DMOVB3Y DT Small molecular drug DMOVB3Y PC 58496428 DMOVB3Y MW 394.9 DMOVB3Y FM C21H19ClN4O2 DMOVB3Y IC InChI=1S/C21H19ClN4O2/c1-24(2)14-8-6-7-13(11-14)20-19-16(12-18(27)25(20)3)23-26(21(19)28)17-10-5-4-9-15(17)22/h4-12,23H,1-3H3 DMOVB3Y CS CN1C(=O)C=C2C(=C1C3=CC(=CC=C3)N(C)C)C(=O)N(N2)C4=CC=CC=C4Cl DMOVB3Y IK RGYQPQARIQKJKH-UHFFFAOYSA-N DMOVB3Y IU 2-(2-chlorophenyl)-4-[3-(dimethylamino)phenyl]-5-methyl-1H-pyrazolo[4,3-c]pyridine-3,6-dione DMOVB3Y CA CAS 1218942-37-0 DMOVB3Y DE Fibrosis DM17OZM ID DM17OZM DM17OZM DN GL-0817 DM17OZM HS Phase 2 DM17OZM SN 912762-70-0; MolPort-002-506-765; tert-butyl N-[(2Z)-2-(2,4-dimethoxyphenyl)-2-(hydroxyimino)ethyl]carbamate; ZINC103473003; AKOS005256100; [2-(2,4-DIMETHOXY-PHENYL)-2-HYDROXYIMINO-ETHYL]-CARBAMIC ACID TERT-BUTYL ESTER DM17OZM CP Gliknik DM17OZM DT Small molecular drug DM17OZM PC 122706930 DM17OZM MW 5758 DM17OZM FM C261H449N91O56 DM17OZM IC InChI=1S/C261H449N91O56/c1-30-147(26)204(249(406)339-186(124-153-70-38-33-39-71-153)234(391)342-190(131-354)238(395)322-159(75-43-49-99-263)210(367)309-149(28)207(364)341-189(130-353)240(397)344-192(133-356)241(398)343-191(132-355)239(396)335-180(118-137(6)7)230(387)324-175(93-96-195(270)358)223(380)331-178(116-135(2)3)228(385)320-168(84-58-108-298-255(279)280)218(375)313-160(76-44-50-100-264)212(369)312-161(77-45-51-101-265)213(370)314-165(81-55-105-295-252(273)274)216(373)315-167(83-57-107-297-254(277)278)219(376)323-174(92-95-194(269)357)222(379)318-166(82-56-106-296-253(275)276)217(374)316-169(85-59-109-299-256(281)282)220(377)329-177(250(407)408)90-64-114-304-261(291)292)351-248(405)203(146(24)25)348-225(382)171(87-61-111-301-258(285)286)319-215(372)163(79-47-53-103-267)327-245(402)200(143(18)19)347-227(384)173(89-63-113-303-260(289)290)328-246(403)201(144(20)21)349-236(393)182(120-139(10)11)330-206(363)148(27)308-211(368)164(80-54-104-294-251(271)272)325-242(399)193-91-65-115-352(193)196(359)129-306-209(366)187(125-154-127-305-158-74-41-40-72-156(154)158)338-231(388)181(119-138(8)9)334-232(389)184(122-151-66-34-31-35-67-151)336-221(378)170(86-60-110-300-257(283)284)317-214(371)162(78-46-52-102-266)326-244(401)199(142(16)17)346-226(383)172(88-62-112-302-259(287)288)321-229(386)179(117-136(4)5)333-233(390)185(123-152-68-36-32-37-69-152)337-235(392)188(126-155-128-293-134-307-155)340-247(404)202(145(22)23)350-237(394)183(121-140(12)13)332-224(381)176(94-97-197(360)361)311-205(362)150(29)310-243(400)198(141(14)15)345-208(365)157(268)73-42-48-98-262/h31-41,66-72,74,127-128,134-150,157,159-193,198-204,305,353-356H,30,42-65,73,75-126,129-133,262-268H2,1-29H3,(H2,269,357)(H2,270,358)(H,293,307)(H,306,366)(H,308,368)(H,309,367)(H,310,400)(H,311,362)(H,312,369)(H,313,375)(H,314,370)(H,315,373)(H,316,374)(H,317,371)(H,318,379)(H,319,372)(H,320,385)(H,321,386)(H,322,395)(H,323,376)(H,324,387)(H,325,399)(H,326,401)(H,327,402)(H,328,403)(H,329,377)(H,330,363)(H,331,380)(H,332,381)(H,333,390)(H,334,389)(H,335,396)(H,336,378)(H,337,392)(H,338,388)(H,339,406)(H,340,404)(H,341,364)(H,342,391)(H,343,398)(H,344,397)(H,345,365)(H,346,383)(H,347,384)(H,348,382)(H,349,393)(H,350,394)(H,351,405)(H,360,361)(H,407,408)(H4,271,272,294)(H4,273,274,295)(H4,275,276,296)(H4,277,278,297)(H4,279,280,298)(H4,281,282,299)(H4,283,284,300)(H4,285,286,301)(H4,287,288,302)(H4,289,290,303)(H4,291,292,304)/t147-,148-,149-,150-,157-,159-,160-,161-,162-,163-,164-,165-,166-,167-,168-,169-,170-,171-,172-,173-,174-,175-,176-,177-,178-,179-,180-,181-,182-,183-,184-,185-,186-,187-,188-,189-,190-,191-,192-,193-,198-,199-,200-,201-,202-,203-,204-/m0/s1 DM17OZM CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]2CCCN2C(=O)CNC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC6=CC=CC=C6)NC(=O)[C@H](CC7=CNC=N7)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCCN)N DM17OZM IK SSOORFWOBGFTHL-OTEJMHTDSA-N DM17OZM IU (4S)-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-5-carbamimidamido-1-[[(2S)-5-carbamimidamido-1-[[(1S)-4-carbamimidamido-1-carboxybutyl]amino]-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-[[(2S)-2-[[(2S)-2-[[(2S)-2,6-diaminohexanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-5-oxopentanoic acid DM17OZM CA CAS 911338-45-9 DM17OZM DE Head and neck cancer; Squamous cell carcinoma; Multiple myeloma; Oral cavity squamous cell carcinoma DMSVBND ID DMSVBND DMSVBND DN Glecaprevir DMSVBND HS Phase 2 DMSVBND SN A-1282576.0; ABT 493; ABT-493; ABT-493(Glecaprevir); CS-8098; D10814; DB13879; EX-A1940; Glecaprevir; Glecaprevir (USAN/INN); Glecaprevir [USAN]; HY-17634; J3.646.120I; K6BUU8J72P; SB19760; SCHEMBL883097; UNII-K6BUU8J72P; glecaprevirum DMSVBND TC Antiviral Agent DMSVBND DT Small molecular drug DMSVBND PC 66828839 DMSVBND MW 838.873 DMSVBND FM C38H46F4N6O9S DMSVBND IC InChI=1S/C38H46F4N6O9S/c1-35(2,3)28-32(50)48-19-20(17-24(48)30(49)46-37(18-21(37)29(39)40)33(51)47-58(53,54)36(4)14-15-36)56-31-27(43-22-9-5-6-10-23(22)44-31)38(41,42)13-8-16-55-25-11-7-12-26(25)57-34(52)45-28/h5-6,8-10,13,20-21,24-26,28-29H,7,11-12,14-19H2,1-4H3,(H,45,52)(H,46,49)(H,47,51)/b13-8+/t20-,21+,24+,25-,26-,28-,37-/m1/s1 DMSVBND CS CC1(CC1)S(=O)(=O)NC(=O)[C@]2(C[C@H]2C(F)F)NC(=O)[C@@H]3C[C@@H]4CN3C(=O)[C@@H](NC(=O)O[C@@H]5CCC[C@H]5OC/C=C/C(C6=NC7=CC=CC=C7N=C6O4)(F)F)C(C)(C)C DMSVBND IK CC1(CC1)S(=O)(=O)NC(=O)C2(CC2C(F)F)NC(=O)C3CC4CN3C(=O)C(NC(=O)OC5CCCC5OCC=CC(C6=NC7=CC=CC=C7N=C6O4)(F)F)C(C)(C)C DMSVBND IU (1R,14E,18R,22R,26S,29S)-26-tert-butyl-N-[(1R,2R)-2-(difluoromethyl)-1-[(1-methylcyclopropyl)sulfonylcarbamoyl]cyclopropyl]-13,13-difluoro-24,27-dioxo-2,17,23-trioxa-4,11,25,28-tetrazapentacyclo[26.2.1.03,12.05,10.018,22]hentriaconta-3,5,7,9,11,14-hexaene-29-carboxamide DMSVBND CA CAS 1365970-03-1 DMSVBND DE Chronic hepatitis C infection DMPHCDL ID DMPHCDL DMPHCDL DN GLPG-0634 DMPHCDL HS Phase 2 DMPHCDL SN Small molecule, JAK1/JAK2 inhibitor (rheumatoid arthritis), Galapagos/GSK DMPHCDL CP Abbvie; galapagos DMPHCDL DT Small molecular drug DMPHCDL PC 49831257 DMPHCDL MW 425.5 DMPHCDL FM C21H23N5O3S DMPHCDL IC InChI=1S/C21H23N5O3S/c27-20(17-8-9-17)23-21-22-19-3-1-2-18(26(19)24-21)16-6-4-15(5-7-16)14-25-10-12-30(28,29)13-11-25/h1-7,17H,8-14H2,(H,23,24,27) DMPHCDL CS C1CC1C(=O)NC2=NN3C(=N2)C=CC=C3C4=CC=C(C=C4)CN5CCS(=O)(=O)CC5 DMPHCDL IK RIJLVEAXPNLDTC-UHFFFAOYSA-N DMPHCDL IU N-[5-[4-[(1,1-dioxo-1,4-thiazinan-4-yl)methyl]phenyl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]cyclopropanecarboxamide DMPHCDL CA CAS 1206161-97-8 DMPHCDL DE Rheumatoid arthritis; Crohn disease; Cutaneous lupus erythematosus DMXO4T8 ID DMXO4T8 DMXO4T8 DN GLPG0974 DMXO4T8 HS Phase 2 DMXO4T8 SN compound 99 [PMID 25380412] DMXO4T8 DT Small molecular drug DMXO4T8 PC 57520598 DMXO4T8 MW 485 DMXO4T8 FM C25H25ClN2O4S DMXO4T8 IC InChI=1S/C25H25ClN2O4S/c1-25(11-13-28(25)23(31)20-16-33-21-9-3-2-8-19(20)21)24(32)27(12-5-10-22(29)30)15-17-6-4-7-18(26)14-17/h2-4,6-9,14,16H,5,10-13,15H2,1H3,(H,29,30)/t25-/m1/s1 DMXO4T8 CS C[C@@]1(CCN1C(=O)C2=CSC3=CC=CC=C32)C(=O)N(CCCC(=O)O)CC4=CC(=CC=C4)Cl DMXO4T8 IK MPMKMQHJHDHPBE-RUZDIDTESA-N DMXO4T8 IU 4-[[(2R)-1-(1-benzothiophene-3-carbonyl)-2-methylazetidine-2-carbonyl]-[(3-chlorophenyl)methyl]amino]butanoic acid DMXO4T8 CA CAS 1391076-61-1 DMXO4T8 DE Abortion DMOCRYB ID DMOCRYB DMOCRYB DN GLPG-1837 DMOCRYB HS Phase 2 DMOCRYB SN GHTGYZMBQPXTCQ-UHFFFAOYSA-N; GLPG1837; 1654725-02-6; SCHEMBL16444982; GLPG 1837; EX-A1819; BCP23611; GLPG-1837(ABBV-974); HY-111099; CS-0034220; N-(3-carbamoyl-5,5,7,7-tetramethyl-4,7-dihydro-5H-thieno[2,3-c]pyran-2-yl)-1H-pyrazole-3-carboxamide DMOCRYB CP Galapagos, AbbVie DMOCRYB PC 117857370 DMOCRYB MW 348.4 DMOCRYB FM C16H20N4O3S DMOCRYB IC InChI=1S/C16H20N4O3S/c1-15(2)7-8-10(12(17)21)14(24-11(8)16(3,4)23-15)19-13(22)9-5-6-18-20-9/h5-6H,7H2,1-4H3,(H2,17,21)(H,18,20)(H,19,22) DMOCRYB CS CC1(CC2=C(C(O1)(C)C)SC(=C2C(=O)N)NC(=O)C3=CC=NN3)C DMOCRYB IK GHTGYZMBQPXTCQ-UHFFFAOYSA-N DMOCRYB IU N-(3-carbamoyl-5,5,7,7-tetramethyl-4H-thieno[2,3-c]pyran-2-yl)-1H-pyrazole-5-carboxamide DMOCRYB DE Cystic fibrosis DMJ85FS ID DMJ85FS DMJ85FS DN Glutathione-S-S-glutathione DMJ85FS HS Phase 2 DMJ85FS SN oxiglutatione; glutathione disulfide; GSSG; oxidized glutathione; Glutathione disulphide; L-Glutathione oxidized; Glutathione-ssg; Glutathione, oxidized; Oxigluthione; glutathione oxidized; Glutathone disulfide; Bi(glutathion-S-yl); Oxidized L-glutathione; L-Oxidized glutathione; L(-)-Glutathione; Oxiglutatione [INN]; S,S'-Ethylenebis(glutathione); Oxiglutationum [INN-Latin]; Oxiglutationa [INN-Spanish]; CCRIS 780; OXIDIZED GLUTATHIONE DISULFIDE; Glutathiol; UNII-ULW86O013H DMJ85FS PC 65359 DMJ85FS MW 612.6 DMJ85FS FM C20H32N6O12S2 DMJ85FS IC InChI=1S/C20H32N6O12S2/c21-9(19(35)36)1-3-13(27)25-11(17(33)23-5-15(29)30)7-39-40-8-12(18(34)24-6-16(31)32)26-14(28)4-2-10(22)20(37)38/h9-12H,1-8,21-22H2,(H,23,33)(H,24,34)(H,25,27)(H,26,28)(H,29,30)(H,31,32)(H,35,36)(H,37,38)/t9-,10-,11-,12-/m0/s1 DMJ85FS CS C(CC(=O)NC(CSSCC(C(=O)NCC(=O)O)NC(=O)CCC(C(=O)O)N)C(=O)NCC(=O)O)C(C(=O)O)N DMJ85FS IK YPZRWBKMTBYPTK-BJDJZHNGSA-N DMJ85FS IU (2S)-2-amino-5-[[(2R)-3-[[(2R)-2-[[(4S)-4-amino-4-carboxybutanoyl]amino]-3-(carboxymethylamino)-3-oxopropyl]disulfanyl]-1-(carboxymethylamino)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid DMJ85FS CA CAS 27025-41-8 DMJ85FS CB CHEBI:17858 DMJ85FS DE Ovarian cancer DML6PO5 ID DML6PO5 DML6PO5 DN GM-CSF cancer vaccine DML6PO5 HS Phase 2 DML6PO5 CP Thomas Jefferson University DML6PO5 DT Vaccine DML6PO5 DE Solid tumour/cancer DMLWKZ7 ID DMLWKZ7 DMLWKZ7 DN GO-203-2c DMLWKZ7 HS Phase 2 DMLWKZ7 CP Genus Oncology DMLWKZ7 DE Solid tumour/cancer; Acute myeloid leukaemia DMKZN3A ID DMKZN3A DMKZN3A DN Golotimod DMKZN3A HS Phase 2 DMKZN3A SN 229305-39-9; SCV-07; gamma-D-Glu-L-trp; SCV07; gamma-D-Glutamyl-L-tryptophan; SCV 07; UNII-637C487Y09; 637C487Y09; (R)-2-Amino-5-(((S)-1-carboxy-2-(1H-indol-3-yl)ethyl)amino)-5-oxopentanoic acid; Golotimod [USAN:INN]; (2R)-2-amino-5-[[(1S)-1-carboxy-2-(1H-indol-3-yl)ethyl]amino]-5-oxopentanoic acid; (2R)-2-Amino-5-(((1S)-1-carboxy-2-(1H-indol-3-yl)ethyl)amino)-5-oxopentanoic acid; Golotimod (USAN/INN); GAMMA-D-GLU-TRP-OH; H-D-Glu(L-Trp-OH)-OH; SCHEMBL727944; (gamma-glutamyl-L-tryptophan); CHEMBL2103812; Golotimod (oral); Golotimod (oral), SciClone/Verta; SCV-07 (oral, tuberculosis), SciClone/Verta DMKZN3A CP Verta Ltd; SciClone Pharmaceuticals DMKZN3A DT Small molecular drug DMKZN3A PC 6992140 DMKZN3A MW 333.34 DMKZN3A FM C16H19N3O5 DMKZN3A IC InChI=1S/C16H19N3O5/c17-11(15(21)22)5-6-14(20)19-13(16(23)24)7-9-8-18-12-4-2-1-3-10(9)12/h1-4,8,11,13,18H,5-7,17H2,(H,19,20)(H,21,22)(H,23,24)/t11-,13+/m1/s1 DMKZN3A CS C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)O)NC(=O)CC[C@H](C(=O)O)N DMKZN3A IK CATMPQFFVNKDEY-YPMHNXCESA-N DMKZN3A IU (2R)-2-amino-5-[[(1S)-1-carboxy-2-(1H-indol-3-yl)ethyl]amino]-5-oxopentanoic acid DMKZN3A CA CAS 229305-39-9 DMKZN3A DE Inflammation; Immune System disease DMYWA0Z ID DMYWA0Z DMYWA0Z DN GORALATIDE DMYWA0Z HS Phase 2 DMYWA0Z SN AcSDKP; Seraspenide; BIM-32001; Goralatide; Acetyl-seryl-aspartyl-lysyl-proline DMYWA0Z DT Small molecular drug DMYWA0Z PC 65938 DMYWA0Z MW 487.5 DMYWA0Z FM C20H33N5O9 DMYWA0Z IC InChI=1S/C20H33N5O9/c1-11(27)22-14(10-26)18(31)24-13(9-16(28)29)17(30)23-12(5-2-3-7-21)19(32)25-8-4-6-15(25)20(33)34/h12-15,26H,2-10,21H2,1H3,(H,22,27)(H,23,30)(H,24,31)(H,28,29)(H,33,34)/t12-,13-,14-,15-/m0/s1 DMYWA0Z CS CC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)O DMYWA0Z IK HJDRXEQUFWLOGJ-AJNGGQMLSA-N DMYWA0Z IU (2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-6-aminohexanoyl]pyrrolidine-2-carboxylic acid DMYWA0Z CA CAS 120081-14-3 DMYWA0Z DE Constitutional neutropenia DMJWE3I ID DMJWE3I DMJWE3I DN Gossypol DMJWE3I HS Phase 2 DMJWE3I SN gossypol; 303-45-7; (-)-Gossypol; 90141-22-3; (+)-Gossypol; Pogosin; Tash 1; racemic-Gossypol; (R)-(-)-Gossypol; (R)-Gossypol; (+-)-Gossypol; (+/-)-Gossypol; CCRIS 2689; NSC56817; NSC 56817; NSC 624336; BRN 1917878; CHEMBL51483; AI3-22957; 20300-26-9; 1,1',6,6',7,7'-Hexahydroxy-5,5'-diisopropyl-3,3'-dimethyl-[2,2'-binaphthalene]-8,8'-dicarbaldehyde; 2,2'-bi[8-Formyl-1,6,7-trihydroxy-5-isopropyl-3-methylnaphthalene]; 2,2'-Bis(1,6,7-trihydroxy-3-methyl-5-isopropyl-8-aldehydonaphthalene); NSC624336; Gossypol acetate DMJWE3I DT Small molecular drug DMJWE3I PC 3503 DMJWE3I MW 518.6 DMJWE3I FM C30H30O8 DMJWE3I IC InChI=1S/C30H30O8/c1-11(2)19-15-7-13(5)21(27(35)23(15)17(9-31)25(33)29(19)37)22-14(6)8-16-20(12(3)4)30(38)26(34)18(10-32)24(16)28(22)36/h7-12,33-38H,1-6H3 DMJWE3I CS CC1=CC2=C(C(=C(C(=C2C(C)C)O)O)C=O)C(=C1C3=C(C4=C(C=C3C)C(=C(C(=C4C=O)O)O)C(C)C)O)O DMJWE3I IK QBKSWRVVCFFDOT-UHFFFAOYSA-N DMJWE3I IU 7-(8-formyl-1,6,7-trihydroxy-3-methyl-5-propan-2-ylnaphthalen-2-yl)-2,3,8-trihydroxy-6-methyl-4-propan-2-ylnaphthalene-1-carbaldehyde DMJWE3I CA CAS 20300-26-9 DMJWE3I DE Prostate cancer DM38ARE ID DM38ARE DM38ARE DN Gp100:209-217(210M) peptide vaccine DM38ARE HS Phase 2 DM38ARE SN Gp100 melanoma-associated antigen vaccine, NCI; Gp100:209-217(210M) peptide vaccine (melanoma); Gp100:209-217(210M) peptide vaccine (melanoma), NCI DM38ARE CP National Cancer Institute DM38ARE DT Vaccine DM38ARE DE Melanoma DMOHAS2 ID DMOHAS2 DMOHAS2 DN GPC-3298306 DMOHAS2 HS Phase 2 DMOHAS2 SN GPC3 peptide vaccine (hepatocellular carcinoma), Japanese National Cancer Center DMOHAS2 CP Japanese National Cancer Center DMOHAS2 DT Vaccine DMOHAS2 DE Hepatocellular carcinoma DMOQ7YI ID DMOQ7YI DMOQ7YI DN GPD-1116 DMOQ7YI HS Phase 2 DMOQ7YI PC 9841417 DMOQ7YI MW 352.4 DMOQ7YI FM C22H16N4O DMOQ7YI IC InChI=1S/C22H16N4O/c27-22-19-18(14-15-8-3-1-4-9-15)24-25-20(19)17-12-7-13-23-21(17)26(22)16-10-5-2-6-11-16/h1-13H,14H2,(H,24,25) DMOQ7YI CS C1=CC=C(C=C1)CC2=C3C(=NN2)C4=C(N=CC=C4)N(C3=O)C5=CC=CC=C5 DMOQ7YI IK NOZMPLJNURLIAQ-UHFFFAOYSA-N DMOQ7YI IU 3-benzyl-5-phenyl-2H-pyrazolo[4,3-c][1,8]naphthyridin-4-one DMOQ7YI DE Asthma DM64ZYM ID DM64ZYM DM64ZYM DN GPI-1485 DM64ZYM HS Phase 2 DM64ZYM SN 186268-78-0; GPI-1485; UNII-0709BVY57W; (2S)-1-(3,3-dimethyl-2-oxopentanoyl)pyrrolidine-2-carboxylic acid; (2S)-1-(1,2-DIOXO-3,3-DIMETHYLPENTYL)-2-PYRROLIDINECARBOXYLIC ACID; 0709BVY57W; (S)-1-(3,3-Dimethyl-2-oxopentanoyl)pyrrolidine-2-carboxylic acid; L-Proline, 1-(3,3-dimethyl-1,2-dioxopentyl)-; GPI 1485; SCHEMBL2006950; CTK6C7007; FOPALECPEUVCTL-QMMMGPOBSA-N; MolPort-023-219-569; ZX-RL003437; 1-(1,2-Dioxo-3,3-dimethylpentyl)-2-pyrrolidine carboxylic acid, 2S; ZINC33979157; 6256AD; AKOS015991368; DB05814; EG-0058 DM64ZYM CP Eisai DM64ZYM DT Small molecular drug DM64ZYM PC 9837656 DM64ZYM MW 241.28 DM64ZYM FM C12H19NO4 DM64ZYM IC InChI=1S/C12H19NO4/c1-4-12(2,3)9(14)10(15)13-7-5-6-8(13)11(16)17/h8H,4-7H2,1-3H3,(H,16,17)/t8-/m0/s1 DM64ZYM CS CCC(C)(C)C(=O)C(=O)N1CCC[C@H]1C(=O)O DM64ZYM IK FOPALECPEUVCTL-QMMMGPOBSA-N DM64ZYM IU (2S)-1-(3,3-dimethyl-2-oxopentanoyl)pyrrolidine-2-carboxylic acid DM64ZYM CA CAS 186268-78-0 DM64ZYM DE Parkinson disease DMHNIGB ID DMHNIGB DMHNIGB DN GPX-150D DMHNIGB HS Phase 2 DMHNIGB SN CNDO-101; CNDO-101); GPX-150; Doxorubicin analog (cancer), Coronado; 5-imino-13-deoxy-doxorubicin DMHNIGB CP Gem Pharmaceuticals LLC DMHNIGB DE Breast cancer; Soft tissue sarcoma DMMZQ7V ID DMMZQ7V DMMZQ7V DN Granotapide DMMZQ7V HS Phase 2 DMMZQ7V SN JTT-130 DMMZQ7V CP Japan Tobacco Inc DMMZQ7V DT Small molecular drug DMMZQ7V PC 11607299 DMMZQ7V MW 718.7 DMMZQ7V FM C39H37F3N2O8 DMMZQ7V IC InChI=1S/C39H37F3N2O8/c1-5-50-36(48)38(37(49)51-6-2,27-12-8-7-9-13-27)24-52-33(45)23-25-16-21-32(31(22-25)35(47)44(3)4)43-34(46)30-15-11-10-14-29(30)26-17-19-28(20-18-26)39(40,41)42/h7-22H,5-6,23-24H2,1-4H3,(H,43,46) DMMZQ7V CS CCOC(=O)C(COC(=O)CC1=CC(=C(C=C1)NC(=O)C2=CC=CC=C2C3=CC=C(C=C3)C(F)(F)F)C(=O)N(C)C)(C4=CC=CC=C4)C(=O)OCC DMMZQ7V IK FPUQGCOBYOXAED-UHFFFAOYSA-N DMMZQ7V IU diethyl 2-[[2-[3-(dimethylcarbamoyl)-4-[[2-[4-(trifluoromethyl)phenyl]benzoyl]amino]phenyl]acetyl]oxymethyl]-2-phenylpropanedioate DMMZQ7V CA CAS 594842-13-4 DMMZQ7V DE Hyperlipidaemia DMWXJSZ ID DMWXJSZ DMWXJSZ DN GRC-15300 DMWXJSZ HS Phase 2 DMWXJSZ CP Glenmark Pharmaceuticals Ltd DMWXJSZ DE Pain DM9QF65 ID DM9QF65 DM9QF65 DN GR-MD-02 DM9QF65 HS Phase 2 DM9QF65 SN Belapectin DM9QF65 CP Galectin therapeutics DM9QF65 DT Protein DM9QF65 DE Melanoma; Plaque psoriasis; Non-alcoholic steatohepatitis; Hypertension DMAHOEP ID DMAHOEP DMAHOEP DN GRNVAC1 DMAHOEP HS Phase 2 DMAHOEP CP Argos Therapeutics DMAHOEP DT Vaccine DMAHOEP DE Acute myeloid leukaemia DMHQV6R ID DMHQV6R DMHQV6R DN GS-4059 DMHQV6R HS Phase 2 DMHQV6R SN tirabrutinib; Tirabrutinib; 1351636-18-4; UNII-LXG44NDL2T; LXG44NDL2T; Tirabrutinib [INN]; ONO-4059(Free base); SCHEMBL14798454; MolPort-044-728-902; BDBM194087; ZINC72318699; AKOS030526437; CS-5676; HY-15771; US9199997, 9; F10085; (R)-6-amino-9-(1-(but-2-ynoyl)pyrrolidin-3-yl)-7-(4-phenoxyphenyl)-7H-purin-8(9H)-one; 6-Amino-9-((3R)-1-(2-butynoyl)-3-pyrrolidinyl)-7-(4-phenoxyphenyl)-7,9-dihydro-8H-purin-8-one; 8H-Purin-8-one,6-amino-7,9-dihydro-9-((3R)-1-(1-oxo-2-butyn-1-yl)-3-pyrrolidinyl)-7-(4-phenoxyphenyl); 6-Amino-9-[(3R)-1-(2-butyno DMHQV6R CP Gilead Sciences Foster City, CA DMHQV6R PC 54755438 DMHQV6R MW 454.5 DMHQV6R FM C25H22N6O3 DMHQV6R IC InChI=1S/C25H22N6O3/c1-2-6-21(32)29-14-13-18(15-29)31-24-22(23(26)27-16-28-24)30(25(31)33)17-9-11-20(12-10-17)34-19-7-4-3-5-8-19/h3-5,7-12,16,18H,13-15H2,1H3,(H2,26,27,28)/t18-/m1/s1 DMHQV6R CS CC#CC(=O)N1CC[C@H](C1)N2C3=NC=NC(=C3N(C2=O)C4=CC=C(C=C4)OC5=CC=CC=C5)N DMHQV6R IK SEJLPXCPMNSRAM-GOSISDBHSA-N DMHQV6R IU 6-amino-9-[(3R)-1-but-2-ynoylpyrrolidin-3-yl]-7-(4-phenoxyphenyl)purin-8-one DMHQV6R CA CAS 1351636-18-4 DMHQV6R DE B-cell lymphoma; Rheumatoid arthritis DMBDFN7 ID DMBDFN7 DMBDFN7 DN GS-4977 DMBDFN7 HS Phase 2 DMBDFN7 CP Gilead sciences DMBDFN7 DE Diabetic nephropathy DMNABMU ID DMNABMU DMNABMU DN GS-4997 DMNABMU HS Phase 2 DMNABMU PC 71245288 DMNABMU MW 445.5 DMNABMU FM C24H24FN7O DMNABMU IC InChI=1S/C24H24FN7O/c1-14(2)32-13-27-30-23(32)19-5-4-6-22(28-19)29-24(33)17-10-21(15(3)9-18(17)25)31-11-20(26-12-31)16-7-8-16/h4-6,9-14,16H,7-8H2,1-3H3,(H,28,29,33) DMNABMU CS CC1=CC(=C(C=C1N2C=C(N=C2)C3CC3)C(=O)NC4=CC=CC(=N4)C5=NN=CN5C(C)C)F DMNABMU IK YIDDLAAKOYYGJG-UHFFFAOYSA-N DMNABMU IU 5-(4-cyclopropylimidazol-1-yl)-2-fluoro-4-methyl-N-[6-(4-propan-2-yl-1,2,4-triazol-3-yl)pyridin-2-yl]benzamide DMNABMU CA CAS 1448428-04-3 DMNABMU DE Diabetic nephropathy; Pulmonary arterial hypertension DMDAHL6 ID DMDAHL6 DMDAHL6 DN GS-5806 DMDAHL6 HS Phase 2 DMDAHL6 CP GILEAD DMDAHL6 DT Small molecular drug DMDAHL6 PC 58029842 DMDAHL6 MW 532.1 DMDAHL6 FM C24H30ClN7O3S DMDAHL6 IC InChI=1S/C24H30ClN7O3S/c1-15-13-32-22(27-23(15)30-10-8-17(26)14-30)12-20(28-32)21-5-3-4-9-31(21)24(33)18-11-16(25)6-7-19(18)29-36(2,34)35/h6-7,11-13,17,21,29H,3-5,8-10,14,26H2,1-2H3/t17-,21-/m0/s1 DMDAHL6 CS CC1=CN2C(=CC(=N2)[C@@H]3CCCCN3C(=O)C4=C(C=CC(=C4)Cl)NS(=O)(=O)C)N=C1N5CC[C@@H](C5)N DMDAHL6 IK GOFXWTVKPWJNGD-UWJYYQICSA-N DMDAHL6 IU N-[2-[(2S)-2-[5-[(3S)-3-aminopyrrolidin-1-yl]-6-methylpyrazolo[1,5-a]pyrimidin-2-yl]piperidine-1-carbonyl]-4-chlorophenyl]methanesulfonamide DMDAHL6 CA CAS 1353625-73-6 DMDAHL6 DE Respiratory syncytial virus infection DMSL3DX ID DMSL3DX DMSL3DX DN GS-5885 DMSL3DX HS Phase 2 DMSL3DX SN Ledipasvir; 1256388-51-8; GS-5885; UNII-013TE6E4WV; GS5885; GS 5885; WHO 9796; Ledipasvir (GS5885); 013TE6E4WV; CHEBI:85089; methyl [(2S)-1-{(6S)-6-[4-(9,9-difluoro-7-{2-[(1R,3S,4S)-2-{(2S)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl}-2-azabicyclo[2.2.1]hept-3-yl]-1H-benzimidazol-5-yl}-9H-fluoren-2-yl)-1H-imidazol-2-yl]-5-azaspiro[2.4]hept-5-yl}-3-methyl-1-oxobutan-2-yl]carbamate; Ledipasvir [USAN:INN]; Ledipasvir (USAN); SCHEMBL2706494; SCHEMBL15116943; CHEMBL2374220; EX-A411; DTXSID90154829; MolPort-039-138-665 DMSL3DX CP Gilead Sciences Inc DMSL3DX DT Small molecular drug DMSL3DX PC 67505836 DMSL3DX MW 889 DMSL3DX FM C49H54F2N8O6 DMSL3DX IC InChI=1S/C49H54F2N8O6/c1-24(2)39(56-46(62)64-5)44(60)58-23-48(15-16-48)21-38(58)42-52-22-37(55-42)28-9-13-32-31-12-8-26(18-33(31)49(50,51)34(32)19-28)27-10-14-35-36(20-27)54-43(53-35)41-29-7-11-30(17-29)59(41)45(61)40(25(3)4)57-47(63)65-6/h8-10,12-14,18-20,22,24-25,29-30,38-41H,7,11,15-17,21,23H2,1-6H3,(H,52,55)(H,53,54)(H,56,62)(H,57,63)/t29-,30+,38-,39-,40-,41-/m0/s1 DMSL3DX CS CC(C)[C@@H](C(=O)N1CC2(CC2)C[C@H]1C3=NC=C(N3)C4=CC5=C(C=C4)C6=C(C5(F)F)C=C(C=C6)C7=CC8=C(C=C7)N=C(N8)[C@@H]9[C@H]1CC[C@H](C1)N9C(=O)[C@H](C(C)C)NC(=O)OC)NC(=O)OC DMSL3DX IK VRTWBAAJJOHBQU-KMWAZVGDSA-N DMSL3DX IU methyl N-[(2S)-1-[(6S)-6-[5-[9,9-difluoro-7-[2-[(1R,3S,4S)-2-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]-2-azabicyclo[2.2.1]heptan-3-yl]-3H-benzimidazol-5-yl]fluoren-2-yl]-1H-imidazol-2-yl]-5-azaspiro[2.4]heptan-5-yl]-3-methyl-1-oxobutan-2-yl]carbamate DMSL3DX CA CAS 1256388-51-8 DMSL3DX CB CHEBI:85089 DMSL3DX DE Hepatitis C virus infection DMV7ZU0 ID DMV7ZU0 DMV7ZU0 DN GS-6624 DMV7ZU0 HS Phase 2 DMV7ZU0 CP Gilead Sciences DMV7ZU0 DT Antibody DMV7ZU0 DE Colorectal cancer DMCZH5B ID DMCZH5B DMCZH5B DN GS-9256 DMCZH5B HS Phase 2 DMCZH5B SN GS-9256; UNII-8V42Y78HRU; 1001094-46-7; GS 9256; 8V42Y78HRU; [[8-chloro-2-[2-(isopropylamino)thiazol-4-yl]-7-methoxy-4-quinolyl]oxy-(cyclopentoxycarbonylamino)-dioxo-[ ]yl]-[(2,6-difluorophenyl)methyl]phosphinic acid; GS9256; SCHEMBL9987287; CHEMBL1956820; DTXSID70142946; DB12876 DMCZH5B CP Gilead DMCZH5B DT Small molecular drug DMCZH5B PC 24823649 DMCZH5B MW 957.5 DMCZH5B FM C46H56ClF2N6O8PS DMCZH5B IC InChI=1S/C46H56ClF2N6O8PS/c1-26(2)50-44-52-36(25-65-44)35-21-39(30-18-19-38(61-3)40(47)41(30)51-35)62-29-20-37-42(56)54-46(64(59,60)24-31-32(48)15-11-16-33(31)49)22-27(46)12-7-5-4-6-8-17-34(43(57)55(37)23-29)53-45(58)63-28-13-9-10-14-28/h11,15-16,18-19,21,25-29,34,37H,4-10,12-14,17,20,22-24H2,1-3H3,(H,50,52)(H,53,58)(H,54,56)(H,59,60)/t27-,29-,34+,37+,46+/m1/s1 DMCZH5B CS CC(C)NC1=NC(=CS1)C2=NC3=C(C=CC(=C3Cl)OC)C(=C2)O[C@@H]4C[C@H]5C(=O)N[C@@]6(C[C@H]6CCCCCCC[C@@H](C(=O)N5C4)NC(=O)OC7CCCC7)P(=O)(CC8=C(C=CC=C8F)F)O DMCZH5B IK RFGUWOCFYCYEDM-ZOMNBDOOSA-N DMCZH5B IU [(1S,4S,6R,14S,18R)-18-[8-chloro-7-methoxy-2-[2-(propan-2-ylamino)-1,3-thiazol-4-yl]quinolin-4-yl]oxy-14-(cyclopentyloxycarbonylamino)-2,15-dioxo-3,16-diazatricyclo[14.3.0.04,6]nonadecan-4-yl]-[(2,6-difluorophenyl)methyl]phosphinic acid DMCZH5B CA CAS 1001094-46-7 DMCZH5B DE Hepatitis C virus infection DMF910Q ID DMF910Q DMF910Q DN GS-9451 DMF910Q HS Phase 2 DMF910Q SN Vedroprevir; GS-9451; 1098189-15-1; UNII-KGD958X2B9; KGD958X2B9; CHEMBL2013174; Cyclopropanecarboxylic acid, N-[[(1a,3b,5a)-bicyclo[3.1.0]hex-3-yloxy]carbonyl]-3-methyl-L-valyl-(4R)-4-[[8-chloro-2-[2-[(1-methylethyl)amino]-4-thiazolyl]-7-[2-(4-morpholinyl)ethoxy]-4-quinolinyl]oxy]-L-prolyl-1-amino-2-ethyl-, (1R,2R)-; 1310824-24-8; Vedroprevir [USAN:INN]; GS 9451; GS9451; Vedroprevir (USAN); SCHEMBL10082460; SCHEMBL16241357; BDBM50379653; SB16765; DB12037; D10408 DMF910Q CP GILEAD DMF910Q DT Small molecular drug DMF910Q PC 25167947 DMF910Q MW 910.5 DMF910Q FM C45H60ClN7O9S DMF910Q IC InChI=1S/C45H60ClN7O9S/c1-7-27-21-45(27,41(56)57)51-39(54)33-19-29(22-53(33)40(55)38(44(4,5)6)50-43(58)62-28-17-25-16-26(25)18-28)61-35-20-31(32-23-63-42(49-32)47-24(2)3)48-37-30(35)8-9-34(36(37)46)60-15-12-52-10-13-59-14-11-52/h8-9,20,23-29,33,38H,7,10-19,21-22H2,1-6H3,(H,47,49)(H,50,58)(H,51,54)(H,56,57)/t25-,26+,27-,28?,29-,33+,38-,45-/m1/s1 DMF910Q CS CC[C@@H]1C[C@@]1(C(=O)O)NC(=O)[C@@H]2C[C@H](CN2C(=O)[C@H](C(C)(C)C)NC(=O)OC3C[C@H]4C[C@H]4C3)OC5=CC(=NC6=C5C=CC(=C6Cl)OCCN7CCOCC7)C8=CSC(=N8)NC(C)C DMF910Q IK OTXAMWFYPMNDME-OPUYQWCOSA-N DMF910Q IU (1R,2R)-1-[[(2S,4R)-1-[(2S)-2-[[(1S,5R)-3-bicyclo[3.1.0]hexanyl]oxycarbonylamino]-3,3-dimethylbutanoyl]-4-[8-chloro-7-(2-morpholin-4-ylethoxy)-2-[2-(propan-2-ylamino)-1,3-thiazol-4-yl]quinolin-4-yl]oxypyrrolidine-2-carbonyl]amino]-2-ethylcyclopropane-1-carboxylic acid DMF910Q CA CAS 1098189-15-1 DMF910Q DE Chronic HCV-1 infection DMG5C8D ID DMG5C8D DMG5C8D DN GS-9620 DMG5C8D HS Phase 2 DMG5C8D SN GS-9620; 1228585-88-3; Vesatolimod; GS9620; UNII-O8M467C50G; GS 9620; CHEMBL2424780; O8M467C50G; 8-(3-(pyrrolidin-1-ylmethyl)benzyl)-4-amino-2-butoxy-7,8-dihydropteridin-6(5H)-one; 4-amino-2-butoxy-8-[[3-(pyrrolidin-1-ylmethyl)phenyl]methyl]-5,7-dihydropteridin-6-one; 4-Amino-2-butoxy-8-(3-(pyrrolidin-1-ylmethyl)benzyl)-7,8-dihydropteridin-6(5H)-one; 4-azanyl-2-butoxy-8-[[3-(pyrrolidin-1-ylmethyl)phenyl]methyl]-5,7-dihydropteridin-6-one; Vesatolimod [INN]; Vesatolimod [USAN:INN]; Vesatolimod (USAN/INN); SCHEMBL10083191 DMG5C8D CP GILEAD DMG5C8D DT Small molecular drug DMG5C8D PC 46241268 DMG5C8D MW 410.5 DMG5C8D FM C22H30N6O2 DMG5C8D IC InChI=1S/C22H30N6O2/c1-2-3-11-30-22-25-20(23)19-21(26-22)28(15-18(29)24-19)14-17-8-6-7-16(12-17)13-27-9-4-5-10-27/h6-8,12H,2-5,9-11,13-15H2,1H3,(H,24,29)(H2,23,25,26) DMG5C8D CS CCCCOC1=NC(=C2C(=N1)N(CC(=O)N2)CC3=CC=CC(=C3)CN4CCCC4)N DMG5C8D IK VFOKSTCIRGDTBR-UHFFFAOYSA-N DMG5C8D IU 4-amino-2-butoxy-8-[[3-(pyrrolidin-1-ylmethyl)phenyl]methyl]-5,7-dihydropteridin-6-one DMG5C8D CA CAS 1228585-88-3 DMG5C8D DE Hepatitis B virus infection; Human immunodeficiency virus infection DMYU6P5 ID DMYU6P5 DMYU6P5 DN GS-9857 DMYU6P5 HS Phase 2 DMYU6P5 DT Small molecular drug DMYU6P5 PC 89921642 DMYU6P5 MW 868.9 DMYU6P5 FM C40H52F4N6O9S DMYU6P5 IC InChI=1S/C40H52F4N6O9S/c1-7-22-27-19-50(28(22)32(51)48-39(18-23(39)31(41)42)35(53)49-60(55,56)38(5)14-15-38)34(52)30(37(2,3)4)47-36(54)59-26-16-20(26)10-8-9-13-40(43,44)29-33(58-27)46-25-17-21(57-6)11-12-24(25)45-29/h11-12,17,20,22-23,26-28,30-31H,7-10,13-16,18-19H2,1-6H3,(H,47,54)(H,48,51)(H,49,53)/t20-,22-,23+,26-,27+,28+,30-,39-/m1/s1 DMYU6P5 CS CC[C@@H]1[C@@H]2CN([C@@H]1C(=O)N[C@@]3(C[C@H]3C(F)F)C(=O)NS(=O)(=O)C4(CC4)C)C(=O)[C@@H](NC(=O)O[C@@H]5C[C@H]5CCCCC(C6=NC7=C(C=C(C=C7)OC)N=C6O2)(F)F)C(C)(C)C DMYU6P5 IK MZBLZLWXUBZHSL-FZNJKFJKSA-N DMYU6P5 IU (1R,18R,20R,24S,27S,28S)-24-tert-butyl-N-[(1R,2R)-2-(difluoromethyl)-1-[(1-methylcyclopropyl)sulfonylcarbamoyl]cyclopropyl]-28-ethyl-13,13-difluoro-7-methoxy-22,25-dioxo-2,21-dioxa-4,11,23,26-tetrazapentacyclo[24.2.1.03,12.05,10.018,20]nonacosa-3,5(10),6,8,11-pentaene-27-carboxamide DMYU6P5 CA CAS 1535212-07-7 DMYU6P5 DE Hepatitis C virus infection DM9Q2B6 ID DM9Q2B6 DM9Q2B6 DN GS-9876 DM9Q2B6 HS Phase 2 DM9Q2B6 SN XCIGZBVOUQVIPI-UHFFFAOYSA-N; lanraplenib; UNII-A6U64OU57E; A6U64OU57E; 6-(6-aminopyrazin-2-yl)-N-[4-[4-(oxetan-3-yl)piperazin-1-yl]phenyl]imidazo[1,2-a]pyrazin-8-amine; 6-(6-Aminopyrazin-2-yl)-N-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine; Lanraplenib [INN]; GTPL9764; SCHEMBL16820581; CHEMBL3986824; example 2 [US9290505]; BDBM212271; GS9876; US9290505, Ex.-2; Ex.-2, US9290505; Imidazo(1,2-a)pyrazin-8-amine, 6-(6-amino-2-pyrazinyl)-N-(4-(4-(3-oxetanyl)-1-piperazinyl)phenyl)-; 6-(6-Aminopyr DM9Q2B6 CP Gilead Sciences Foster City, CA DM9Q2B6 PC 118161062 DM9Q2B6 MW 443.5 DM9Q2B6 FM C23H25N9O DM9Q2B6 IC InChI=1S/C23H25N9O/c24-21-12-25-11-19(28-21)20-13-32-6-5-26-23(32)22(29-20)27-16-1-3-17(4-2-16)30-7-9-31(10-8-30)18-14-33-15-18/h1-6,11-13,18H,7-10,14-15H2,(H2,24,28)(H,27,29) DM9Q2B6 CS C1CN(CCN1C2COC2)C3=CC=C(C=C3)NC4=NC(=CN5C4=NC=C5)C6=CN=CC(=N6)N DM9Q2B6 IK XCIGZBVOUQVIPI-UHFFFAOYSA-N DM9Q2B6 IU 6-(6-aminopyrazin-2-yl)-N-[4-[4-(oxetan-3-yl)piperazin-1-yl]phenyl]imidazo[1,2-a]pyrazin-8-amine DM9Q2B6 CA CAS 1800046-95-0 DM9Q2B6 DE Cutaneous lupus erythematosus; Rheumatoid arthritis DMKWCTR ID DMKWCTR DMKWCTR DN GS-9973 DMKWCTR HS Phase 2 DMKWCTR SN Entospletinib; 1229208-44-9; GS-9973; Entospletinib (GS-9973); gs9973; UNII-6I3O3W6O3B; 6-(1H-Indazol-6-yl)-N-(4-morpholinophenyl)imidazo[1,2-a]pyrazin-8-amine; GS 9973; 6I3O3W6O3B; CHEMBL3265032; C23H21N7O; 6-(1H-Indazol-6-yl)-N-(4-(morpholin-4-yl)phenyl)imidazo(1,2-a)pyrazin-8-amine; Entospletinib [INN]; Entospletinib [USAN:INN]; 4puz; 6-(1h-Indazol-6-Yl)-N-[4-(Morpholin-4-Yl)phenyl]imidazo[1,2-A]pyrazin-8-Amine; GS-9973; Entospletinib; SCHEMBL2483776; GTPL7889; MolPort-035-395-879; HMS3653D13; EX-A1120; BCP09582; AOB87385 DMKWCTR CP Gilead Sciences DMKWCTR DT Small molecular drug DMKWCTR PC 59473233 DMKWCTR MW 411.5 DMKWCTR FM C23H21N7O DMKWCTR IC InChI=1S/C23H21N7O/c1-2-17-14-25-28-20(17)13-16(1)21-15-30-8-7-24-23(30)22(27-21)26-18-3-5-19(6-4-18)29-9-11-31-12-10-29/h1-8,13-15H,9-12H2,(H,25,28)(H,26,27) DMKWCTR CS C1COCCN1C2=CC=C(C=C2)NC3=NC(=CN4C3=NC=C4)C5=CC6=C(C=C5)C=NN6 DMKWCTR IK XSMSNFMDVXXHGJ-UHFFFAOYSA-N DMKWCTR IU 6-(1H-indazol-6-yl)-N-(4-morpholin-4-ylphenyl)imidazo[1,2-a]pyrazin-8-amine DMKWCTR CA CAS 1229208-44-9 DMKWCTR DE B-cell lymphoma; Acute myeloid leukaemia; Haematological malignancy DMQGPLO ID DMQGPLO DMQGPLO DN GSK-1070806 DMQGPLO HS Phase 2 DMQGPLO SN Anti-IL-18 monoclonal antibody (intravenous, inflammatory bowel disease), GSK DMQGPLO CP GlaxoSmithKline DMQGPLO DT Antibody DMQGPLO DE Type-2 diabetes DMDMXKQ ID DMDMXKQ DMDMXKQ DN GSK1292263 DMDMXKQ HS Phase 2 DMDMXKQ CP GSK DMDMXKQ DT Small molecular drug DMDMXKQ PC 24996872 DMDMXKQ MW 456.6 DMDMXKQ FM C23H28N4O4S DMDMXKQ IC InChI=1S/C23H28N4O4S/c1-16(2)22-25-23(31-26-22)27-12-10-17(11-13-27)15-30-19-6-9-21(24-14-19)18-4-7-20(8-5-18)32(3,28)29/h4-9,14,16-17H,10-13,15H2,1-3H3 DMDMXKQ CS CC(C)C1=NOC(=N1)N2CCC(CC2)COC3=CN=C(C=C3)C4=CC=C(C=C4)S(=O)(=O)C DMDMXKQ IK AYJRTVVIBJSSKN-UHFFFAOYSA-N DMDMXKQ IU 5-[4-[[6-(4-methylsulfonylphenyl)pyridin-3-yl]oxymethyl]piperidin-1-yl]-3-propan-2-yl-1,2,4-oxadiazole DMDMXKQ CA CAS 1032823-75-8 DMDMXKQ DE Type-2 diabetes; Gastric adenocarcinoma DM1EPMF ID DM1EPMF DM1EPMF DN GSK1322322 DM1EPMF HS Phase 2 DM1EPMF SN GSK-1322322 DM1EPMF CP GlaxoSmithKline DM1EPMF PC 52918384 DM1EPMF MW 479.5 DM1EPMF FM C22H34FN7O4 DM1EPMF IC InChI=1S/C22H34FN7O4/c1-15-24-20(19(23)21(25-15)29-7-6-28-8-9-34-13-18(28)12-29)26-27-22(32)17(11-30(33)14-31)10-16-4-2-3-5-16/h14,16-18,33H,2-13H2,1H3,(H,27,32)(H,24,25,26)/t17-,18+/m1/s1 DM1EPMF CS CC1=NC(=C(C(=N1)N2CCN3CCOC[C@@H]3C2)F)NNC(=O)[C@H](CC4CCCC4)CN(C=O)O DM1EPMF IK SWHNZGMQMGFQGW-MSOLQXFVSA-N DM1EPMF IU N-[(2R)-3-[2-[6-[(9aS)-3,4,6,7,9,9a-hexahydro-1H-pyrazino[2,1-c][1,4]oxazin-8-yl]-5-fluoro-2-methylpyrimidin-4-yl]hydrazinyl]-2-(cyclopentylmethyl)-3-oxopropyl]-N-hydroxyformamide DM1EPMF CA CAS 1152107-25-9 DM1EPMF DE Bacterial infection DMA6RBF ID DMA6RBF DMA6RBF DN GSK1325756 DMA6RBF HS Phase 2 DMA6RBF SN Danirixin; 954126-98-8; GSK1325756; UNII-R318PGH5VP; GSK-1325756B; R318PGH5VP; GSK1325756B; Danirixin [USAN:INN]; GSK-1325756; GSK 1325756; Danirixin (USAN/INN); Danirixin(GSK1325756); GTPL8500; SCHEMBL1198688; CHEMBL3039531; MolPort-044-561-791; EX-A1178; ZINC95627831; AKOS030527036; DB11922; CS-5465; 1-(4-Chloro-2-hydroxy-3-(((3S)-piperidine-3-sulfonyl)phenyl)-3-(3-fluoro-2-methylphenyl)urea; HY-19768; D10387; (S)-1-(4-chloro-2-hydroxy-3-(piperidin-3-ylsulfonyl)phenyl)-3-(3-fluoro-2-methylphenyl)urea DMA6RBF CP GlaxoSmithKline DMA6RBF DT Small molecular drug DMA6RBF PC 24780598 DMA6RBF MW 441.9 DMA6RBF FM C19H21ClFN3O4S DMA6RBF IC InChI=1S/C19H21ClFN3O4S/c1-11-14(21)5-2-6-15(11)23-19(26)24-16-8-7-13(20)18(17(16)25)29(27,28)12-4-3-9-22-10-12/h2,5-8,12,22,25H,3-4,9-10H2,1H3,(H2,23,24,26)/t12-/m0/s1 DMA6RBF CS CC1=C(C=CC=C1F)NC(=O)NC2=C(C(=C(C=C2)Cl)S(=O)(=O)[C@H]3CCCNC3)O DMA6RBF IK NGYNBSHYFOFVLS-LBPRGKRZSA-N DMA6RBF IU 1-[4-chloro-2-hydroxy-3-[(3S)-piperidin-3-yl]sulfonylphenyl]-3-(3-fluoro-2-methylphenyl)urea DMA6RBF CA CAS 954126-98-8 DMA6RBF DE Chronic obstructive pulmonary disease DM6HBGN ID DM6HBGN DM6HBGN DN GSK-1399686 DM6HBGN HS Phase 2 DM6HBGN SN 1399686 DM6HBGN CP GlaxoSmithKline plc DM6HBGN DE Inflammatory bowel disease DMZHB37 ID DMZHB37 DMZHB37 DN GSK2110183 DMZHB37 HS Phase 2 DMZHB37 CP GlaxoSmithKline DMZHB37 DT Small molecular drug DMZHB37 PC 46843057 DMZHB37 MW 427.3 DMZHB37 FM C18H17Cl2FN4OS DMZHB37 IC InChI=1S/C18H17Cl2FN4OS/c1-25-16(14(19)9-23-25)13-7-15(27-17(13)20)18(26)24-12(8-22)6-10-3-2-4-11(21)5-10/h2-5,7,9,12H,6,8,22H2,1H3,(H,24,26)/t12-/m0/s1 DMZHB37 CS CN1C(=C(C=N1)Cl)C2=C(SC(=C2)C(=O)N[C@@H](CC3=CC(=CC=C3)F)CN)Cl DMZHB37 IK AFJRDFWMXUECEW-LBPRGKRZSA-N DMZHB37 IU N-[(2S)-1-amino-3-(3-fluorophenyl)propan-2-yl]-5-chloro-4-(4-chloro-2-methylpyrazol-3-yl)thiophene-2-carboxamide DMZHB37 CA CAS 1047644-62-1 DMZHB37 CB CHEBI:131168 DMZHB37 DE Multiple myeloma; leukaemia; Solid tumour/cancer DMSHE70 ID DMSHE70 DMSHE70 DN GSK2141795 DMSHE70 HS Phase 2 DMSHE70 SN Uprosertib; 1047634-65-0; GSK2141795; UNII-ZXM835LQ5E; Uprosertib (GSK2141795); GSK2141795C; ZXM835LQ5E; GSK795; GSK-2141795; 2-Furancarboxamide, N-[(1S)-2-amino-1-[(3,4-difluorophenyl)methyl]ethyl]-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-;2-Furancarboxamide, N-[(1S)-2-amino-1-[(3,4-difluorophenyl)methyl]ethyl]-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-; Uprosertib [USAN:INN]; Uprosertib (USAN/INN); Uprosertib, GSK2141795; SCHEMBL168584; GTPL7902; CHEMBL3137336; MolPort-044-560-307; AXTAPYRUEKNRBA-JTQLQIEISA-N DMSHE70 CP GlaxoSmithKline DMSHE70 DT Small molecular drug DMSHE70 PC 51042438 DMSHE70 MW 429.2 DMSHE70 FM C18H16Cl2F2N4O2 DMSHE70 IC InChI=1S/C18H16Cl2F2N4O2/c1-26-16(12(19)8-24-26)11-6-15(28-17(11)20)18(27)25-10(7-23)4-9-2-3-13(21)14(22)5-9/h2-3,5-6,8,10H,4,7,23H2,1H3,(H,25,27)/t10-/m0/s1 DMSHE70 CS CN1C(=C(C=N1)Cl)C2=C(OC(=C2)C(=O)N[C@@H](CC3=CC(=C(C=C3)F)F)CN)Cl DMSHE70 IK AXTAPYRUEKNRBA-JTQLQIEISA-N DMSHE70 IU N-[(2S)-1-amino-3-(3,4-difluorophenyl)propan-2-yl]-5-chloro-4-(4-chloro-2-methylpyrazol-3-yl)furan-2-carboxamide DMSHE70 CA CAS 1047634-65-0 DMSHE70 DE Lymphoma; Colorectal cancer DMBWPZJ ID DMBWPZJ DMBWPZJ DN GSK2245035 DMBWPZJ HS Phase 2 DMBWPZJ SN GSK-2245035 DMBWPZJ CP GlaxoSmithKline DMBWPZJ DT Small molecular drug DMBWPZJ PC 44623937 DMBWPZJ MW 390.5 DMBWPZJ FM C20H34N6O2 DMBWPZJ IC InChI=1S/C20H34N6O2/c1-3-10-15(2)28-19-23-17(21)16-18(24-19)26(20(27)22-16)14-9-5-8-13-25-11-6-4-7-12-25/h15H,3-14H2,1-2H3,(H,22,27)(H2,21,23,24)/t15-/m0/s1 DMBWPZJ CS CCC[C@H](C)OC1=NC(=C2C(=N1)N(C(=O)N2)CCCCCN3CCCCC3)N DMBWPZJ IK LFMPVTVPXHNXOT-HNNXBMFYSA-N DMBWPZJ IU 6-amino-2-[(2S)-pentan-2-yl]oxy-9-(5-piperidin-1-ylpentyl)-7H-purin-8-one DMBWPZJ CA CAS 1207629-49-9 DMBWPZJ DE Asthma DMG7YQL ID DMG7YQL DMG7YQL DN GSK2245840 DMG7YQL HS Phase 2 DMG7YQL SN Gepirone hydrochloride; GEPIRONE HYDROCHLORIDE; Gepirone HCl; UNII-80C9L8EP6V; Gepirone hydrochloride [USAN]; 80C9L8EP6V; 83928-66-9; CHEMBL1204187; Gepirone hydrochloride (USAN); BMY 138951; AC1Q3ELB; AC1L1IK3; SCHEMBL318838; DTXSID30232812; AOB5299; 83928-76-1 (Parent); ORG-33062; SB19633; BMY-13805-1; BMY 13805-1; 3,3-Dimethyl-1-(4-(4-(2-pyrimidinyl)-1-piperazinyl)butyl)glutarimide monohydrochloride; D04314; 4,4-dimethyl-1-[4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]piperidine-2,6-dione hydrochloride; 2,6-Piperidinedione, DMG7YQL CP GSK DMG7YQL DT Small molecular drug DMG7YQL PC 25108829 DMG7YQL MW 516.6 DMG7YQL FM C26H24N6O2S2 DMG7YQL IC InChI=1S/C26H24N6O2S2/c1-17-23(36-25(28-17)18-5-4-8-27-13-18)24(33)29-21-7-3-2-6-20(21)22-15-32-19(16-35-26(32)30-22)14-31-9-11-34-12-10-31/h2-8,13,15-16H,9-12,14H2,1H3,(H,29,33) DMG7YQL CS CC1=C(SC(=N1)C2=CN=CC=C2)C(=O)NC3=CC=CC=C3C4=CN5C(=CSC5=N4)CN6CCOCC6 DMG7YQL IK LAMQVIQMVKWXOC-UHFFFAOYSA-N DMG7YQL IU 4-methyl-N-[2-[3-(morpholin-4-ylmethyl)imidazo[2,1-b][1,3]thiazol-6-yl]phenyl]-2-pyridin-3-yl-1,3-thiazole-5-carboxamide DMG7YQL CA CAS 1093403-33-8 DMG7YQL DE Chronic obstructive pulmonary disease DMLFI7Q ID DMLFI7Q DMLFI7Q DN GSK-2251052 DMLFI7Q HS Phase 2 DMLFI7Q SN ABX; AN-3365; GSK '052; Boron-based LeuRS inhibitors (Gram-negative bacterial infection), Anacor/GSK; Boron-based leucyl-tRNA synthetase inhibitors (bacterial infection), Anacor/GSK DMLFI7Q CP Anacor Pharmaceuticals Inc DMLFI7Q DT Small molecular drug DMLFI7Q PC 46836890 DMLFI7Q MW 237.06 DMLFI7Q FM C11H16BNO4 DMLFI7Q IC InChI=1S/C11H16BNO4/c13-7-10-8-3-1-4-9(16-6-2-5-14)11(8)12(15)17-10/h1,3-4,10,14-15H,2,5-7,13H2/t10-/m1/s1 DMLFI7Q CS B1(C2=C(C=CC=C2OCCCO)[C@H](O1)CN)O DMLFI7Q IK FXQIIDINBDJDKL-SNVBAGLBSA-N DMLFI7Q IU 3-[[(3S)-3-(aminomethyl)-1-hydroxy-3H-2,1-benzoxaborol-7-yl]oxy]propan-1-ol DMLFI7Q CA CAS 1093643-37-8 DMLFI7Q DE Urinary tract infection DMIN0SV ID DMIN0SV DMIN0SV DN GSK2269557 DMIN0SV HS Phase 2 DMIN0SV CP Glaxosmithkline DMIN0SV PC 49784002 DMIN0SV MW 440.5 DMIN0SV FM C26H28N6O DMIN0SV IC InChI=1S/C26H28N6O/c1-17(2)32-10-8-31(9-11-32)16-19-14-28-26(33-19)22-12-18(13-25-23(22)15-29-30-25)20-4-3-5-24-21(20)6-7-27-24/h3-7,12-15,17,27H,8-11,16H2,1-2H3,(H,29,30) DMIN0SV CS CC(C)N1CCN(CC1)CC2=CN=C(O2)C3=C4C=NNC4=CC(=C3)C5=C6C=CNC6=CC=C5 DMIN0SV IK MCIDWGZGWVSZMK-UHFFFAOYSA-N DMIN0SV IU 2-[6-(1H-indol-4-yl)-1H-indazol-4-yl]-5-[(4-propan-2-ylpiperazin-1-yl)methyl]-1,3-oxazole DMIN0SV CA CAS 1254036-71-9 DMIN0SV DE Asthma DM4BTH8 ID DM4BTH8 DM4BTH8 DN GSK2330672 DM4BTH8 HS Phase 2 DM4BTH8 CP GlaxoSmithKline DM4BTH8 PC 53492727 DM4BTH8 MW 546.7 DM4BTH8 FM C28H38N2O7S DM4BTH8 IC InChI=1S/C28H38N2O7S/c1-4-6-12-28(5-2)18-38(35,36)24-13-20(17-29-21(14-25(31)32)15-26(33)34)23(37-3)16-22(24)27(30-28)19-10-8-7-9-11-19/h7-11,13,16,21,27,29-30H,4-6,12,14-15,17-18H2,1-3H3,(H,31,32)(H,33,34)/t27-,28-/m1/s1 DM4BTH8 CS CCCC[C@@]1(CS(=O)(=O)C2=C(C=C(C(=C2)CNC(CC(=O)O)CC(=O)O)OC)[C@H](N1)C3=CC=CC=C3)CC DM4BTH8 IK CZGVOBIGEBDYTP-VSGBNLITSA-N DM4BTH8 IU 3-[[(3R,5R)-3-butyl-3-ethyl-7-methoxy-1,1-dioxo-5-phenyl-4,5-dihydro-2H-1lambda6,4-benzothiazepin-8-yl]methylamino]pentanedioic acid DM4BTH8 CA CAS 1345982-69-5 DM4BTH8 DE Type-2 diabetes; Pruritus DMB0CXT ID DMB0CXT DMB0CXT DN GSK2330811 DMB0CXT HS Phase 2 DMB0CXT CP GlaxoSmithKline Research Triangle Park, NC DMB0CXT DE Systemic sclerosis; Crohn disease DMXUCG3 ID DMXUCG3 DMXUCG3 DN GSK233705 DMXUCG3 HS Phase 2 DMXUCG3 CP GlaxoSmithKline DMXUCG3 DE Chronic obstructive pulmonary disease DMRA3T2 ID DMRA3T2 DMRA3T2 DN GSK2339345 DMRA3T2 HS Phase 2 DMRA3T2 SN GSK-2339345 DMRA3T2 CP GlaxoSmithKline DMRA3T2 DE Cough DMBJMZC ID DMBJMZC DMBJMZC DN GSK239512 DMBJMZC HS Phase 2 DMBJMZC SN 720691-69-0; GSK-239512; 1-(6-((3-CYCLOBUTYL-2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPIN-7-YL)OXY)PYRIDIN-3-YL)PYRROLIDIN-2-ONE; GSK239512; UNII-4I7U5C459M; CHEMBL3092650; 4I7U5C459M; YFRBKEVUUCQYOW-UHFFFAOYSA-N; SCHEMBL167578; MolPort-035-776-189; ZINC3961802; BDBM50444496; AKOS025291102; SB16754; KS-0000063Q; AS-42474; AK171368; 2-Pyrrolidinone, 1-(6-((3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy)-3-pyridinyl)-; J3.497.402K DMBJMZC CP GSK DMBJMZC DT Small molecular drug DMBJMZC PC 9976892 DMBJMZC MW 377.5 DMBJMZC FM C23H27N3O2 DMBJMZC IC InChI=1S/C23H27N3O2/c27-23-5-2-12-26(23)20-7-9-22(24-16-20)28-21-8-6-17-10-13-25(19-3-1-4-19)14-11-18(17)15-21/h6-9,15-16,19H,1-5,10-14H2 DMBJMZC CS C1CC(C1)N2CCC3=C(CC2)C=C(C=C3)OC4=NC=C(C=C4)N5CCCC5=O DMBJMZC IK YFRBKEVUUCQYOW-UHFFFAOYSA-N DMBJMZC IU 1-[6-[(3-cyclobutyl-1,2,4,5-tetrahydro-3-benzazepin-7-yl)oxy]pyridin-3-yl]pyrrolidin-2-one DMBJMZC CA CAS 720691-69-0 DMBJMZC DE Dementia; Alzheimer disease DMFAU3Z ID DMFAU3Z DMFAU3Z DN GSK249320 DMFAU3Z HS Phase 2 DMFAU3Z CP GlaxoSmithKline DMFAU3Z DT Antibody DMFAU3Z DE Stroke DMMAIY2 ID DMMAIY2 DMMAIY2 DN GSK-256073 DMMAIY2 HS Phase 2 DMMAIY2 SN GPCR agonists (hyperlipidemia), GSK; GSK-256073-A; HM74A receptor agonists (hyperlipidemia), GSK; G protein-coupled receptor agonists (hyperlipidemia), GSK DMMAIY2 CP GlaxoSmithKline plc DMMAIY2 DT Small molecular drug DMMAIY2 PC 46215799 DMMAIY2 MW 256.69 DMMAIY2 FM C10H13ClN4O2 DMMAIY2 IC InChI=1S/C10H13ClN4O2/c1-2-3-4-5-15-7-6(12-9(11)13-7)8(16)14-10(15)17/h2-5H2,1H3,(H,12,13)(H,14,16,17) DMMAIY2 CS CCCCCN1C2=C(C(=O)NC1=O)NC(=N2)Cl DMMAIY2 IK CGAMDQCXAAOFSR-UHFFFAOYSA-N DMMAIY2 IU 8-chloro-3-pentyl-7H-purine-2,6-dione DMMAIY2 CA CAS 862892-90-8 DMMAIY2 DE Hyperlipidaemia DMA2IXQ ID DMA2IXQ DMA2IXQ DN GSK2586184 DMA2IXQ HS Phase 2 DMA2IXQ SN GSK-2586184 DMA2IXQ CP GlaxoSmithKline DMA2IXQ PC 44603362 DMA2IXQ MW 389.4 DMA2IXQ FM C22H23N5O2 DMA2IXQ IC InChI=1S/C22H23N5O2/c1-22(2)12-26(13-22)20(29)16-10-6-14(7-11-16)17-4-3-5-18-23-21(25-27(17)18)24-19(28)15-8-9-15/h3-7,10-11,15H,8-9,12-13H2,1-2H3,(H,24,25,28) DMA2IXQ CS CC1(CN(C1)C(=O)C2=CC=C(C=C2)C3=CC=CC4=NC(=NN43)NC(=O)C5CC5)C DMA2IXQ IK MPYACSQFXVMWNO-UHFFFAOYSA-N DMA2IXQ IU N-[5-[4-(3,3-dimethylazetidine-1-carbonyl)phenyl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]cyclopropanecarboxamide DMA2IXQ CA CAS 1206163-45-2 DMA2IXQ DE Arthritis; Systemic lupus erythematosus DMU5EVR ID DMU5EVR DMU5EVR DN GSK2586881 DMU5EVR HS Phase 2 DMU5EVR SN GSK-2586881 DMU5EVR CP GlaxoSmithKline DMU5EVR DE Acute lung injury; Pulmonary arterial hypertension DM7V96W ID DM7V96W DM7V96W DN GSK2798745 DM7V96W HS Phase 2 DM7V96W CP GlaxoSmithKline Research Triangle Park, NC DM7V96W DE Heart failure DMCIGRW ID DMCIGRW DMCIGRW DN GSK2838232 DMCIGRW HS Phase 2 DMCIGRW CP GlaxoSmithKline DMCIGRW DT Small molecular drug DMCIGRW DE Human immunodeficiency virus-1 infection DMT5YK7 ID DMT5YK7 DMT5YK7 DN GSK2890457 DMT5YK7 HS Phase 2 DMT5YK7 SN GSK-2890457 DMT5YK7 CP GlaxoSmithKline DMT5YK7 DE Obesity DM25YLM ID DM25YLM DM25YLM DN GSK2981278 DM25YLM HS Phase 2 DM25YLM SN ROR gama modulator 1; 1474110-21-8; UNII-L49V5G013I; L49V5G013I; N-(4-ethylphenyl)-3-(hydroxymethyl)-N-isobutyl-4-((tetrahydro-2H-pyran-4-yl)methoxy)benzenesulfonamide; GTPL9661; SCHEMBL15352875; LZLBRISQTJVZNP-UHFFFAOYSA-N; MolPort-044-561-790; EX-A1179; ZINC142250256; AKOS030526564; CS-5449; GSK-2981278; HY-19770; N-(4-ethylphenyl)-3-(hydroxymethyl)-N-(2-methylpropyl)-4-(oxan-4-ylmethoxy)benzenesulfonamide; Benzenesulfonamide, N-(4-ethylphenyl)-3-(hydroxymethyl)-N-(2-methylpropyl)-4-((tetrahydro-2H-pyran-4-yl) DM25YLM CP GlaxoSmithKline Research Triangle Park, NC DM25YLM PC 89875987 DM25YLM MW 461.6 DM25YLM FM C25H35NO5S DM25YLM IC InChI=1S/C25H35NO5S/c1-4-20-5-7-23(8-6-20)26(16-19(2)3)32(28,29)24-9-10-25(22(15-24)17-27)31-18-21-11-13-30-14-12-21/h5-10,15,19,21,27H,4,11-14,16-18H2,1-3H3 DM25YLM CS CCC1=CC=C(C=C1)N(CC(C)C)S(=O)(=O)C2=CC(=C(C=C2)OCC3CCOCC3)CO DM25YLM IK LZLBRISQTJVZNP-UHFFFAOYSA-N DM25YLM IU N-(4-ethylphenyl)-3-(hydroxymethyl)-N-(2-methylpropyl)-4-(oxan-4-ylmethoxy)benzenesulfonamide DM25YLM CA CAS 1474110-21-8 DM25YLM DE Plaque psoriasis DM7HNFV ID DM7HNFV DM7HNFV DN GSK2982772 DM7HNFV HS Phase 2 DM7HNFV SN LYPAFUINURXJSG-AWEZNQCLSA-N; 1622848-92-3; UNII-T5W3M0VO9B; T5W3M0VO9B; GSK-2982772; (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-3-yl)-1H-1,2,4-triazole-3-carboxamide; GTPL9554; SCHEMBL15956219; MolPort-044-830-634; s8484; AKOS030528033; compound 5 [PMID: 28151659]; ACN-041458; CS-6899; GSK 2982772; AS-35128; AC-29894; HY-101760; J3.650.802G; 5-benzyl-N-[(3S)-5-methyl-4-oxo-2,3-dihydro-1,5-benzoxazepin-3-yl]-1H-1,2,4-triazole-3-carboxamide; 3-Benzyl-N-[(3s)-5-Methyl-4-Oxo-2,3,4,5-Tetrahydr DM7HNFV CP GlaxoSmithKline Research Triangle Park, NC DM7HNFV PC 77108121 DM7HNFV MW 377.4 DM7HNFV FM C20H19N5O3 DM7HNFV IC InChI=1S/C20H19N5O3/c1-25-15-9-5-6-10-16(15)28-12-14(20(25)27)21-19(26)18-22-17(23-24-18)11-13-7-3-2-4-8-13/h2-10,14H,11-12H2,1H3,(H,21,26)(H,22,23,24)/t14-/m0/s1 DM7HNFV CS CN1C2=CC=CC=C2OC[C@@H](C1=O)NC(=O)C3=NNC(=N3)CC4=CC=CC=C4 DM7HNFV IK LYPAFUINURXJSG-AWEZNQCLSA-N DM7HNFV IU 5-benzyl-N-[(3S)-5-methyl-4-oxo-2,3-dihydro-1,5-benzoxazepin-3-yl]-1H-1,2,4-triazole-3-carboxamide DM7HNFV CA CAS 1622848-92-3 DM7HNFV DE Plaque psoriasis; Psoriasis vulgaris; Rheumatoid arthritis; Ulcerative colitis DMCDAVK ID DMCDAVK DMCDAVK DN GSK3036656 DMCDAVK HS Phase 2 DMCDAVK SN GSK656 HCl; GSK656; 2131798-13-3; UNII-P83HS633ZK; P83HS633ZK; CHEMBL4082159; 2131798-13-3 (HCl); GSK-656; GSK-070; BCP29367; EX-A3128; BDBM50241779; GSK-3036656; GSK3036656; GSK070 hydrochloride; HY-107775; CS-0030140; (S)-3-(Aminomethyl)-4-chloro-7-(2-hydroxyethoxy)benzo[c][1,2]oxaborol-1(3H)-ol hydrochloride; (S)3-(Aminomethyl)-4-chloro-7-(2-hydroxyethoxy)benzo[c][1,2]oxaborol-1(3H)ol hydrochloride; (S)a?-(Aminomethyl)-4-chloro-7-(2-hydroxyethoxy)benzo[c][1,2]oxaborol-1(3H)a'ol hydrochloride; Ethanol, 2-(((3S)-3-(aminomethyl)-4-chloro-1,3-dihydro-1-hydroxy-2,1-benzoxaborol-7-yl)oxy)-, hydrochloride (1:1) DMCDAVK CP GlaxoSmithKline DMCDAVK DT Small molecular drug DMCDAVK PC 134691736 DMCDAVK MW 293.94 DMCDAVK FM C10H14BCl2NO4 DMCDAVK IC InChI=1S/C10H13BClNO4.ClH/c12-6-1-2-7(16-4-3-14)10-9(6)8(5-13)17-11(10)15;/h1-2,8,14-15H,3-5,13H2;1H/t8-;/m1./s1 DMCDAVK CS B1(C2=C(C=CC(=C2[C@H](O1)CN)Cl)OCCO)O.Cl DMCDAVK IK FUOKBESTQMGROA-DDWIOCJRSA-N DMCDAVK IU 2-[[(3S)-3-(aminomethyl)-4-chloro-1-hydroxy-3H-2,1-benzoxaborol-7-yl]oxy]ethanol;hydrochloride DMCDAVK CA CAS 2131798-13-3 DMCDAVK DE Tuberculosis DMEXKF4 ID DMEXKF4 DMEXKF4 DN GSK3196165 DMEXKF4 HS Phase 2 DMEXKF4 CP GlaxoSmithKline Research Triangle Park, NC DMEXKF4 DE Rheumatoid arthritis DMPBK8N ID DMPBK8N DMPBK8N DN GSK3228836 DMPBK8N HS Phase 2 DMPBK8N SN IONIS-HBVRX; GSK'836 DMPBK8N CP GlaxoSmithKline DMPBK8N DT Antisense oligonucleotide DMPBK8N DE Hepatitis B DMJRD7A ID DMJRD7A DMJRD7A DN GSK3326595 DMJRD7A HS Phase 2 DMJRD7A SN JLCCNYVTIWRPIZ-NRFANRHFSA-N; 1616392-22-3; 6-[(1-acetylpiperidin-4-yl)amino]-N-[(2S)-2-hydroxy-3-(1,2,3,4-tetrahydroisoquinolin-2-yl)propyl]pyrimidine-4-carboxamide; SCHEMBL15825290; MolPort-044-813-754; BDBM178166; AKOS030528008; ZINC220119494; CS-6451; AS-53150; HY-101563; GSK3326595(EPZ015938); US9675614, 208; (S)-6-((1-acetylpiperidin-4-yl)amino)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)pyrimidine-4-carboxamide DMJRD7A CP GlaxoSmithKline Research Triangle Park, NC DMJRD7A PC 90241742 DMJRD7A MW 452.5 DMJRD7A FM C24H32N6O3 DMJRD7A IC InChI=1S/C24H32N6O3/c1-17(31)30-10-7-20(8-11-30)28-23-12-22(26-16-27-23)24(33)25-13-21(32)15-29-9-6-18-4-2-3-5-19(18)14-29/h2-5,12,16,20-21,32H,6-11,13-15H2,1H3,(H,25,33)(H,26,27,28)/t21-/m0/s1 DMJRD7A CS CC(=O)N1CCC(CC1)NC2=NC=NC(=C2)C(=O)NC[C@@H](CN3CCC4=CC=CC=C4C3)O DMJRD7A IK JLCCNYVTIWRPIZ-NRFANRHFSA-N DMJRD7A IU 6-[(1-acetylpiperidin-4-yl)amino]-N-[(2S)-3-(3,4-dihydro-1H-isoquinolin-2-yl)-2-hydroxypropyl]pyrimidine-4-carboxamide DMJRD7A CA CAS 1616392-22-3 DMJRD7A DE Non-hodgkin lymphoma; Solid tumour/cancer; Breast cancer DMO5JS3 ID DMO5JS3 DMO5JS3 DN GSK3389404 DMO5JS3 HS Phase 2 DMO5JS3 SN IONIS-HBV-LRX DMO5JS3 CP GlaxoSmithKline DMO5JS3 DT Antisense oligonucleotide DMO5JS3 DE Hepatitis B DMMOWT9 ID DMMOWT9 DMMOWT9 DN GSK3640254 DMMOWT9 HS Phase 2 DMMOWT9 SN GSK'254 DMMOWT9 CP ViiV Healthcare DMMOWT9 DE Human immunodeficiency virus infection DMV3TO4 ID DMV3TO4 DMV3TO4 DN GSK3810109 DMV3TO4 HS Phase 2 DMV3TO4 CP ViiV Healthcare DMV3TO4 DT Antibody DMV3TO4 DE Human immunodeficiency virus-1 infection DMV6SNU ID DMV6SNU DMV6SNU DN GSK4069889 DMV6SNU HS Phase 2 DMV6SNU SN TSR-022 DMV6SNU CP AnaptysBio DMV6SNU DT Antibody DMV6SNU DE Non-small cell lung cancer DM3ZL2O ID DM3ZL2O DM3ZL2O DN GSK-557296 DM3ZL2O HS Phase 2 DM3ZL2O SN Epelsiban; Epelsiban besylate; Premature ejaculation therapeutic (oral), GlaxoSmithKline DM3ZL2O CP GlaxoSmithKline plc DM3ZL2O DT Small molecular drug DM3ZL2O PC 11634973 DM3ZL2O MW 518.6 DM3ZL2O FM C30H38N4O4 DM3ZL2O IC InChI=1S/C30H38N4O4/c1-5-18(2)26-28(35)32-25(23-16-21-8-6-7-9-22(21)17-23)29(36)34(26)27(24-11-10-19(3)31-20(24)4)30(37)33-12-14-38-15-13-33/h6-11,18,23,25-27H,5,12-17H2,1-4H3,(H,32,35)/t18-,25+,26+,27+/m0/s1 DM3ZL2O CS CC[C@H](C)[C@@H]1C(=O)N[C@@H](C(=O)N1[C@H](C2=C(N=C(C=C2)C)C)C(=O)N3CCOCC3)C4CC5=CC=CC=C5C4 DM3ZL2O IK UWHCWRQFNKUYCG-QUZACWSFSA-N DM3ZL2O IU (3R,6R)-6-[(2S)-butan-2-yl]-3-(2,3-dihydro-1H-inden-2-yl)-1-[(1R)-1-(2,6-dimethylpyridin-3-yl)-2-morpholin-4-yl-2-oxoethyl]piperazine-2,5-dione DM3ZL2O CA CAS 872599-83-2 DM3ZL2O DE Premature ejaculation DMEVARK ID DMEVARK DMEVARK DN GSK561679 DMEVARK HS Phase 2 DMEVARK SN VERUCERFONT; 885220-61-1; GSK561679; GSK561679A; UNII-X60608B091; GSK 561679A; NBI-77860; X60608B091; GSK561679;3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[(1S)-1-(3-methyl-1,2,4-oxadiazol-5-yl)propyl]pyrazolo[1,5-a]pyrimidin-7-amine; NBI 77860; Verucerfont [USAN:INN]; GSK 561679; GSK-561679; Verucerfont (USAN/INN); Verucerfont,GSK561679; SCHEMBL205309; CHEMBL1287935; EX-A1718; BDBM50417503; ZINC34661169; SB17107; CS-8099; DB12512; KB-77609; HY-14875; AC-30339; D09695 DMEVARK CP GSK DMEVARK DT Small molecular drug DMEVARK PC 11596613 DMEVARK MW 406.5 DMEVARK FM C22H26N6O2 DMEVARK IC InChI=1S/C22H26N6O2/c1-7-18(22-24-15(5)27-30-22)25-19-11-13(3)23-21-20(14(4)26-28(19)21)17-9-8-16(29-6)10-12(17)2/h8-11,18,25H,7H2,1-6H3/t18-/m0/s1 DMEVARK CS CC[C@@H](C1=NC(=NO1)C)NC2=CC(=NC3=C(C(=NN23)C)C4=C(C=C(C=C4)OC)C)C DMEVARK IK VKHVAUKFLBBZFJ-SFHVURJKSA-N DMEVARK IU 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[(1S)-1-(3-methyl-1,2,4-oxadiazol-5-yl)propyl]pyrazolo[1,5-a]pyrimidin-7-amine DMEVARK CA CAS 885220-61-1 DMEVARK DE Major depressive disorder; Alcohol dependence DMGU05N ID DMGU05N DMGU05N DN GSK598809 DMGU05N HS Phase 2 DMGU05N CP GSK DMGU05N PC 24743758 DMGU05N MW 481.5 DMGU05N FM C22H23F4N5OS DMGU05N IC InChI=1S/C22H23F4N5OS/c1-13-18(32-12-27-13)19-28-29-20(30(19)2)33-7-3-6-31-10-15-9-21(15,11-31)16-5-4-14(8-17(16)23)22(24,25)26/h4-5,8,12,15H,3,6-7,9-11H2,1-2H3 DMGU05N CS CC1=C(OC=N1)C2=NN=C(N2C)SCCCN3CC4CC4(C3)C5=C(C=C(C=C5)C(F)(F)F)F DMGU05N IK ZKRWPAYTJMRKLJ-UHFFFAOYSA-N DMGU05N IU 5-[5-[3-[1-[2-fluoro-4-(trifluoromethyl)phenyl]-3-azabicyclo[3.1.0]hexan-3-yl]propylsulfanyl]-4-methyl-1,2,4-triazol-3-yl]-4-methyl-1,3-oxazole DMGU05N DE Drug abuse DMTW79H ID DMTW79H DMTW79H DN GSK683699 DMTW79H HS Phase 2 DMTW79H SN 4-Aminobutanoic acid; 4-aminobutyric acid; GABA; gamma-aminobutyric acid; 1956/12/2; Piperidic acid; Piperidinic acid; Aminalon; Mielogen; Gammalon; Gaballon; butanoic acid, 4-amino-; Mielomade; Gammalone; Gamarex; Gammasol; Gammar; Reanal; Immu-G; gamma-amino-n-butyric acid; gamma-Aminobutanoic acid; Butyric acid, 4-amino-; Gamastan; Gammagee; Gamulin; 4-aminobutyrate; omega-Aminobutyric acid; gamma-Aminobutyric acid; 3-Carboxypropylamine; gamma-Aminobuttersaeure; 4-amino-butanoic acid; gamma-Amino butyric acid; GAMMA-AMINO-BUTANOIC ACID DMTW79H CP GSK; Tanabe DMTW79H DT Small molecular drug DMTW79H PC 119 DMTW79H MW 103.12 DMTW79H FM C4H9NO2 DMTW79H IC InChI=1S/C4H9NO2/c5-3-1-2-4(6)7/h1-3,5H2,(H,6,7) DMTW79H CS C(CC(=O)O)CN DMTW79H IK BTCSSZJGUNDROE-UHFFFAOYSA-N DMTW79H IU 4-aminobutanoic acid DMTW79H CA CAS 56-12-2 DMTW79H CB CHEBI:16865 DMTW79H DE Inflammatory bowel disease DMPLKAH ID DMPLKAH DMPLKAH DN GSK-706769 DMPLKAH HS Phase 2 DMPLKAH SN GSK-163929; GSK-929; CCR5 antagonist (HIV), GSK; CCR5 antagonist (HIV), ViiV; CCR5 chemokine antagonists (HIV-1 infection),GlaxoSmithKline DMPLKAH CP GlaxoSmithKline plc DMPLKAH DE Human immunodeficiency virus infection DMIEXUM ID DMIEXUM DMIEXUM DN GSK768974 DMIEXUM HS Phase 2 DMIEXUM SN PTH analog, GlaxoSmithKline/Unigene; Parathyroid hormone analog (oral, Enteripep), Unigene/GlaxoSmithKline DMIEXUM CP Unigene Laboratories Inc DMIEXUM DE Osteoporosis DMX27Q1 ID DMX27Q1 DMX27Q1 DN GSK933776A DMX27Q1 HS Phase 2 DMX27Q1 CP GlaxoSmithKline DMX27Q1 DE Macular degeneration; Alzheimer disease DM6DKF9 ID DM6DKF9 DM6DKF9 DN GSK961081 DM6DKF9 HS Phase 2 DM6DKF9 SN CHEMBL1683934; SCHEMBL524583; NVEMUJANQDPDSC-DHUJRADRSA-N; BDBM50337878; Biphenyl-2-ylcarbamic acid 1-{9-[(R)-2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethylamino]nonyl}piperidin-4-yl ester; (R)-1-(9-(2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethylamino)nonyl)piperidin-4-yl biphenyl-2-ylcarbamate DM6DKF9 CP GSK DM6DKF9 DT Small molecular drug DM6DKF9 PC 10372836 DM6DKF9 MW 740.2 DM6DKF9 FM C40H42ClN5O7 DM6DKF9 IC InChI=1S/C40H42ClN5O7/c1-52-36-22-33(31(41)21-26(36)23-42-24-35(48)29-11-13-34(47)39-30(29)12-14-37(49)45-39)43-38(50)17-20-46-18-15-27(16-19-46)53-40(51)44-32-10-6-5-9-28(32)25-7-3-2-4-8-25/h2-14,21-22,27,35,42,47-48H,15-20,23-24H2,1H3,(H,43,50)(H,44,51)(H,45,49)/t35-/m0/s1 DM6DKF9 CS COC1=CC(=C(C=C1CNC[C@@H](C2=C3C=CC(=O)NC3=C(C=C2)O)O)Cl)NC(=O)CCN4CCC(CC4)OC(=O)NC5=CC=CC=C5C6=CC=CC=C6 DM6DKF9 IK URWYQGVSPQJGGB-DHUJRADRSA-N DM6DKF9 IU [1-[3-[2-chloro-4-[[[(2R)-2-hydroxy-2-(8-hydroxy-2-oxo-1H-quinolin-5-yl)ethyl]amino]methyl]-5-methoxyanilino]-3-oxopropyl]piperidin-4-yl] N-(2-phenylphenyl)carbamate DM6DKF9 CA CAS 743461-65-6 DM6DKF9 DE Chronic obstructive pulmonary disease DM8N3OQ ID DM8N3OQ DM8N3OQ DN GT-AADC DM8N3OQ HS Phase 2 DM8N3OQ CP PTC Therapeutics DM8N3OQ DT Gene therapy DM8N3OQ DE Aromatic L-amino acid decarboxylase deficiency DMN6IDO ID DMN6IDO DMN6IDO DN GTP-010 DMN6IDO HS Phase 2 DMN6IDO CP Gastrotech Pharma DMN6IDO DE Dyspepsia; Irritable bowel syndrome DM03NQS ID DM03NQS DM03NQS DN GTP-200 DM03NQS HS Phase 2 DM03NQS DE Solid tumour/cancer DMEN5KA ID DMEN5KA DMEN5KA DN GTS-21 DMEN5KA HS Phase 2 DMEN5KA SN Gts-21; DMXBA; Gts 21; DMXB-Anabaseine; GTS-21 (dihydrochloride); DMXB-A; (E)-3-((2,4-Dimethoxyphenyl)methylene)-3,4,5,6-tetrahydro-2,3'-bipyridine dihydrochloride; 2,3'-Bipyridine, 3-((2,4-dimethoxyphenyl)methylene)-3,4,5,6-tetrahydro-, dihydrochloride, (E)-; DMBX-anabaseine; DMBX-A; AC1O5PJQ; SCHEMBL2561893; SCHEMBL12274790; HY-14564A; CS-5486; SB16826; BC654014; AN-16572; GTS-21, > LS-173500; 3-(2,4-Dimethoxybenzylidene)anabaseine dihydrochloride DMEN5KA DT Small molecular drug DMEN5KA PC 5310985 DMEN5KA MW 308.4 DMEN5KA FM C19H20N2O2 DMEN5KA IC InChI=1S/C19H20N2O2/c1-22-17-8-7-14(18(12-17)23-2)11-15-5-4-10-21-19(15)16-6-3-9-20-13-16/h3,6-9,11-13H,4-5,10H2,1-2H3/b15-11+ DMEN5KA CS COC1=CC(=C(C=C1)/C=C/2\\CCCN=C2C3=CN=CC=C3)OC DMEN5KA IK RPYWXZCFYPVCNQ-RVDMUPIBSA-N DMEN5KA IU 3-[(5E)-5-[(2,4-dimethoxyphenyl)methylidene]-3,4-dihydro-2H-pyridin-6-yl]pyridine DMEN5KA CA CAS 148372-04-7 DMEN5KA DE Parkinson disease DMDWYZS ID DMDWYZS DMDWYZS DN GTx-758 DMDWYZS HS Phase 2 DMDWYZS CP GTx DMDWYZS PC 46861578 DMDWYZS MW 341.3 DMDWYZS FM C19H13F2NO3 DMDWYZS IC InChI=1S/C19H13F2NO3/c20-13-2-4-14(5-3-13)22(15-6-8-16(23)9-7-15)19(25)12-1-10-18(24)17(21)11-12/h1-11,23-24H DMDWYZS CS C1=CC(=CC=C1N(C2=CC=C(C=C2)F)C(=O)C3=CC(=C(C=C3)O)F)O DMDWYZS IK FBCQEUMZZNVQKD-UHFFFAOYSA-N DMDWYZS IU 3-fluoro-N-(4-fluorophenyl)-4-hydroxy-N-(4-hydroxyphenyl)benzamide DMDWYZS CA CAS 938067-78-8 DMDWYZS DE Prostate cancer DMY53PL ID DMY53PL DMY53PL DN GW 597599 DMY53PL HS Phase 2 DMY53PL SN Vestipitant mesylate < USAN; N-[1(R)-[3,5-Bis(trifluoromethyl)phenyl]ethyl]-2(S)-(4-fluoro-2-methylphenyl)-N-methylpiperazine-1-carboxamide methanesulfonate DMY53PL CP GlaxoSmithKline DMY53PL DT Small molecular drug DMY53PL PC 24969622 DMY53PL MW 587.6 DMY53PL FM C24H28F7N3O4S DMY53PL IC InChI=1S/C23H24F7N3O.CH4O3S/c1-13-8-18(24)4-5-19(13)20-12-31-6-7-33(20)21(34)32(3)14(2)15-9-16(22(25,26)27)11-17(10-15)23(28,29)30;1-5(2,3)4/h4-5,8-11,14,20,31H,6-7,12H2,1-3H3;1H3,(H,2,3,4)/t14-,20-;/m1./s1 DMY53PL CS CC1=C(C=CC(=C1)F)[C@H]2CNCCN2C(=O)N(C)[C@H](C)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F.CS(=O)(=O)O DMY53PL IK BHECXGHXWKHZOY-DXPOFMJKSA-N DMY53PL IU (2S)-N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-(4-fluoro-2-methylphenyl)-N-methylpiperazine-1-carboxamide;methanesulfonic acid DMY53PL CA CAS 334476-64-1 DMY53PL DE Mood disorder; Major depressive disorder DMZMCB1 ID DMZMCB1 DMZMCB1 DN GW274150 DMZMCB1 HS Phase 2 DMZMCB1 SN GW274150; GW-274150; UNII-0ZZF1V8G63; 0ZZF1V8G63; CHEMBL114551; SCHEMBL120693; L-Homocysteine, S-(2-((1-iminoethyl)amino)ethyl)-; GTPL9849; ZINC2004483; BDBM50086467; AKOS030526714; DB12237; CS-5419; HY-12119; GW-274150;GW 274150; [2-[(1-iminoethyl) amino]ethyl]-L-homocysteine; (S)-4-(2-Acetimidoylamino-ethylsulfanyl)-2-amino-butyric acid; (2S)-2-amino-4-[2-(1-aminoethylideneamino)ethylsulfanyl]butanoic acid DMZMCB1 DT Small molecular drug DMZMCB1 PC 9797017 DMZMCB1 MW 219.31 DMZMCB1 FM C8H17N3O2S DMZMCB1 IC InChI=1S/C8H17N3O2S/c1-6(9)11-3-5-14-4-2-7(10)8(12)13/h7H,2-5,10H2,1H3,(H2,9,11)(H,12,13)/t7-/m0/s1 DMZMCB1 CS CC(=NCCSCC[C@@H](C(=O)O)N)N DMZMCB1 IK MOLOJNHYNHBPCW-ZETCQYMHSA-N DMZMCB1 IU (2S)-2-amino-4-[2-(1-aminoethylideneamino)ethylsulfanyl]butanoic acid DMZMCB1 CA CAS 210354-22-6 DMZMCB1 DE Asthma DMY3KSU ID DMY3KSU DMY3KSU DN GW-42004 DMY3KSU HS Phase 2 DMY3KSU SN CB1/CB2 receptor antagonist (oral/capsule, obesity/type 2 diabetes/dyslipidemia), GW Pharmaceuticals DMY3KSU CP GW Pharmaceuticals plc DMY3KSU DE Lipid metabolism disorder DMBX9C0 ID DMBX9C0 DMBX9C0 DN GW-427353 DMBX9C0 HS Phase 2 DMBX9C0 SN UNII-GU14FR8D4A; GU14FR8D4A; GW427353B; Solabegron hydrochloride [USAN]; Solabegron hydrochloride (USAN); GW 427353B; Solabegron Hydrochloride; Solabegron HCl; SCHEMBL565177; CHEMBL2107299; PMXCGBVBIRYFPR-FTBISJDPSA-N; BCP28076; 3'-[(2-{[2-(3-chlorophenyl)-2-hydroxyethyl]amino}ethyl)amino]biphenyl-3-carboxylic acid hydrochloride; D05879; (1,1'-Biphenyl)-3-carboxylic acid, 3'-((2-(((2R)-2-(3-chlorophenyl)-2-hydroxyethyl)amino)ethyl)amino)-, hydrochloride DMBX9C0 CP GSK DMBX9C0 DT Small molecular drug DMBX9C0 PC 9887812 DMBX9C0 MW 410.9 DMBX9C0 FM C23H23ClN2O3 DMBX9C0 IC InChI=1S/C23H23ClN2O3/c24-20-8-2-6-18(13-20)22(27)15-25-10-11-26-21-9-3-5-17(14-21)16-4-1-7-19(12-16)23(28)29/h1-9,12-14,22,25-27H,10-11,15H2,(H,28,29)/t22-/m0/s1 DMBX9C0 CS C1=CC(=CC(=C1)C(=O)O)C2=CC(=CC=C2)NCCNC[C@@H](C3=CC(=CC=C3)Cl)O DMBX9C0 IK LLDXOPKUNJTIRF-QFIPXVFZSA-N DMBX9C0 IU 3-[3-[2-[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethylamino]phenyl]benzoic acid DMBX9C0 CA CAS 252920-94-8 DMBX9C0 CB CHEBI:141346 DMBX9C0 DE Urinary incontinence DMH0C8J ID DMH0C8J DMH0C8J DN GW-813893 DMH0C8J HS Phase 2 DMH0C8J SN Factor Xa inhibitors, GSK; Factor Xa inhibitors, GlaxoSmithKline; 813893 DMH0C8J CP GlaxoSmithKline plc DMH0C8J PC 9911502 DMH0C8J MW 448 DMH0C8J FM C17H22ClN3O5S2 DMH0C8J IC InChI=1S/C17H22ClN3O5S2/c1-12(16(22)20-7-9-26-10-8-20)21-6-4-14(17(21)23)19-28(24,25)11-5-13-2-3-15(18)27-13/h2-3,5,11-12,14,19H,4,6-10H2,1H3/b11-5+/t12-,14-/m0/s1 DMH0C8J CS C[C@@H](C(=O)N1CCOCC1)N2CC[C@@H](C2=O)NS(=O)(=O)/C=C/C3=CC=C(S3)Cl DMH0C8J IK ACEFOQMQINFMRW-DYCFVMESSA-N DMH0C8J IU (E)-2-(5-chlorothiophen-2-yl)-N-[(3S)-1-[(2S)-1-morpholin-4-yl-1-oxopropan-2-yl]-2-oxopyrrolidin-3-yl]ethenesulfonamide DMH0C8J CA CAS 478644-12-1 DMH0C8J DE Thrombosis DM489FT ID DM489FT DM489FT DN GW-870086-X DM489FT HS Phase 2 DM489FT SN GW-870086-X (topical, atopic dermatitis), GlaxoSmithKline DM489FT CP GlaxoSmithKline plc DM489FT DE Atopic dermatitis DMQEC9P ID DMQEC9P DMQEC9P DN GW-870086-X DMQEC9P HS Phase 2 DMQEC9P SN Glucocorticoid agonist (asthma), GlaxoSmithKline; GW-870086-X (inhaled, asthma), GlaxoSmithKline DMQEC9P CP GlaxoSmithKline plc DMQEC9P DE Asthma DM8XH3S ID DM8XH3S DM8XH3S DN H-1152 DM8XH3S HS Phase 2 DM8XH3S SN 451462-58-1; (S)-2-METHYL-1-[(4-METHYL-5-ISOQUINOLINE)SULFONYL]-HOMOPIPERAZINE; CHEBI:88220; H-1152P; (S)-H-1152 (hydrochloride); H52; dimethyl fasudil; 4-methyl-5-{[(2S)-2-methyl-1,4-diazepan-1-yl]sulfonyl}isoquinoline; 4-methyl-5-[[(2S)-2-methyl-1,4-diazepan-1-yl]sulfonyl]isoquinoline; 2gnh; 2gnl; 1q8u; AC1L9LJA; H 1152; SCHEMBL124161; CHEMBL406821; ZINC22706; BDBM14028; BCP16935; 3714AH; AKOS027263830; DB07876; CS-1536; HY-15720; LS-193100; W-5343; 4-methyl-5-[(2S)-2-methyl-1,4-diazepane-1-sulfonyl]isoquinoline DM8XH3S CP CoTherix DM8XH3S DT Small molecular drug DM8XH3S PC 448043 DM8XH3S MW 319.4 DM8XH3S FM C16H21N3O2S DM8XH3S IC InChI=1S/C16H21N3O2S/c1-12-9-18-11-14-5-3-6-15(16(12)14)22(20,21)19-8-4-7-17-10-13(19)2/h3,5-6,9,11,13,17H,4,7-8,10H2,1-2H3/t13-/m0/s1 DM8XH3S CS C[C@H]1CNCCCN1S(=O)(=O)C2=CC=CC3=C2C(=CN=C3)C DM8XH3S IK AWDORCFLUJZUQS-ZDUSSCGKSA-N DM8XH3S IU 4-methyl-5-[[(2S)-2-methyl-1,4-diazepan-1-yl]sulfonyl]isoquinoline DM8XH3S CA CAS 451462-58-1 DM8XH3S CB CHEBI:88220 DM8XH3S DE Pulmonary arterial hypertension DMO4I61 ID DMO4I61 DMO4I61 DN H5N1 influenza vaccine DMO4I61 HS Phase 2 DMO4I61 SN Daronrix; GSK-1119711A; H5N1 influenza vaccine (inactivated whole virus adjuvanted); Avian influenzavaccine (inactivated whole virus adjuvanted), GlaxoSmithKline; H5N1 influenza vaccine (inactivated whole virus adjuvanted), GlaxoSmithKline DMO4I61 CP GlaxoSmithKline plc DMO4I61 DT Vaccine DMO4I61 DE Influenza virus infection DM74ZKN ID DM74ZKN DM74ZKN DN HBI-3000 DM74ZKN HS Phase 2 DM74ZKN SN Sulcardine; Multi-ion channel blocker (oral, arrhythmia), SIMM; Multi-ion channel blocker (oral/iv, arrhythmia), HUYA DM74ZKN CP Shanghai Institute of Materia Medica of the Chinese Academy of Sciences DM74ZKN DE Heart arrhythmia; Atrial fibrillation DMSMCXN ID DMSMCXN DMSMCXN DN HBV vaccine DMSMCXN HS Phase 2 DMSMCXN SN HBV vaccine (adjuvanted); HBV vaccine (adjuvanted), GlaxoSmithKline Biologicals DMSMCXN CP GlaxoSmithKline Biologicals DMSMCXN DT Vaccine DMSMCXN DE Hepatitis B virus infection DMX8C6J ID DMX8C6J DMX8C6J DN HCB1019 DMX8C6J HS Phase 2 DMX8C6J CP OcuNexus Therapeutics DMX8C6J DT Small molecular drug DMX8C6J DE Diabetic macular edema DMRQGMZ ID DMRQGMZ DMRQGMZ DN HD-003 DMRQGMZ HS Phase 2 DMRQGMZ SN NZ-419; Selective hydroxy radical modulator (chronic kidney disease), Hyundai/ Nippon Zoki DMRQGMZ CP Nippon Zoki Pharmaceutical Co Ltd DMRQGMZ DE Kidney disease DMAX632 ID DMAX632 DMAX632 DN HDV-interferon DMAX632 HS Phase 2 DMAX632 SN HDV-interferon (sc, HCV infection); HDV-IFN (sc, HCV infection), Hepasome Pharmaceuticals; HDV-interferon (sc, HCV infection), Hepasome Pharmaceuticals DMAX632 CP Hepasome Pharmaceuticals DMAX632 DE Hepatitis C virus infection DMV50R1 ID DMV50R1 DMV50R1 DN HE3235 DMV50R1 HS Phase 2 DMV50R1 SN Apoptone; HE3235; UNII-891O182ZP5; 183387-50-0; HE 3235; 891O182ZP5; SCHEMBL3402872; Pregn-20-yne-3,17-diol, (3alpha,5alpha,17alpha)-; DTXSID70171418; MolPort-044-561-946; ZINC5921098 DMV50R1 CP Harbor Therapeutics DMV50R1 DT Small molecular drug DMV50R1 PC 42611099 DMV50R1 MW 316.5 DMV50R1 FM C21H32O2 DMV50R1 IC InChI=1S/C21H32O2/c1-4-21(23)12-9-18-16-6-5-14-13-15(22)7-10-19(14,2)17(16)8-11-20(18,21)3/h1,14-18,22-23H,5-13H2,2-3H3/t14-,15+,16+,17-,18-,19-,20-,21-/m0/s1 DMV50R1 CS C[C@]12CC[C@H](C[C@@H]1CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC[C@]4(C#C)O)C)O DMV50R1 IK CKAXZOYFIHQCBN-JRRMKBMNSA-N DMV50R1 IU (3R,5S,8R,9S,10S,13S,14S,17R)-17-ethynyl-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,14,15,16-tetradecahydrocyclopenta[a]phenanthrene-3,17-diol DMV50R1 CA CAS 183387-50-0 DMV50R1 DE Breast cancer DM9OZU5 ID DM9OZU5 DM9OZU5 DN Heat shock protein vaccine DM9OZU5 HS Phase 2 DM9OZU5 CP Agenus DM9OZU5 DT Vaccine DM9OZU5 DE Meningococcal infection DM8QGPE ID DM8QGPE DM8QGPE DN HepaStem DM8QGPE HS Phase 2 DM8QGPE CP Promethera Biosciences SA/NV DM8QGPE DE Liver failure DMX6B95 ID DMX6B95 DMX6B95 DN HER1-VSSP vaccine DMX6B95 HS Phase 2 DMX6B95 SN HER1-VSSP vaccine (cancer) DMX6B95 CP The Center of Molecular Immunology DMX6B95 DT Vaccine DMX6B95 DE Solid tumour/cancer DM8TOS0 ID DM8TOS0 DM8TOS0 DN HER-2 Protein AutoVac DM8TOS0 HS Phase 2 DM8TOS0 CP Pharmexa DM8TOS0 DE Breast cancer DMISETH ID DMISETH DMISETH DN HER2/neu peptide vaccine DMISETH HS Phase 2 DMISETH SN HER2/neu peptide vaccine (intradermal, breast cancer) DMISETH CP Fred Hutchinson Cancer Research Center DMISETH DT Vaccine DMISETH DE Breast cancer DMQTREC ID DMQTREC DMQTREC DN Her2-targeted autologous T-cell therapy DMQTREC HS Phase 2 DMQTREC SN Her2-targeted autologous T-cell therapy (cancer) DMQTREC CP Baylor College of Medicine DMQTREC DE Glioblastoma multiforme DMI4C90 ID DMI4C90 DMI4C90 DN HF-0220 DMI4C90 HS Phase 2 DMI4C90 SN Cytoprotective steroid (Alzheimer's disease), Newron; Prostaglandin D synthase stimulator (Alzheimer's disease), Newron; Prostaglandin J2 synthesis stimulator (Alzheimer's disease), Newron; Cytoprotective steroid (Alzheimer's disease), Hunter-Fleming; Prostaglandin D synthase stimulator (Alzheimer's disease), Hunter-Fleming; Prostaglandin J2 synthesis stimulator (Alzheimer's disease), Hunter-Fleming DMI4C90 CP Hunter-Fleming Ltd DMI4C90 PC 9836181 DMI4C90 MW 306.4 DMI4C90 FM C19H30O3 DMI4C90 IC InChI=1S/C19H30O3/c1-18-7-5-12(20)9-11(18)10-15(21)17-13-3-4-16(22)19(13,2)8-6-14(17)18/h11-15,17,20-21H,3-10H2,1-2H3/t11-,12+,13+,14+,15+,17+,18+,19+/m1/s1 DMI4C90 CS C[C@]12CC[C@@H](C[C@@H]1C[C@@H]([C@@H]3[C@@H]2CC[C@]4([C@H]3CCC4=O)C)O)O DMI4C90 IK VFPMCLQMAUVEHD-UCPSWNCLSA-N DMI4C90 IU (3S,5R,7S,8R,9S,10S,13S,14S)-3,7-dihydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,14,15,16-tetradecahydrocyclopenta[a]phenanthren-17-one DMI4C90 CA CAS 25848-69-5 DMI4C90 DE Alzheimer disease DMDZE3B ID DMDZE3B DMDZE3B DN HGT-1111 DMDZE3B HS Phase 2 DMDZE3B SN Metazym; M-0001; Recombinant arylsulfatase A (lysosomal storage disease), Shire; Recombinant arylsulfatase A (lysosomal storage disease), Zymenex; Recombinant arylsulfatase A (metachromatic leukodystrophy), Shire; Lysosomal arylsulfatase A replacement therapy (FGE, metachromatic leukodystrophy), Shire; Lysosomal asa replacement therapy (FGE, metachromatic leukodystrophy), Shire DMDZE3B CP Zymenex A/S DMDZE3B DE Metachromatic leukodystrophy DMHZ4JI ID DMHZ4JI DMHZ4JI DN HGT-1410 DMHZ4JI HS Phase 2 DMHZ4JI SN Intrathecal sulfamidase replacement therapy (FGE, Sanfilippo syndrome), Shire; Intrathecal heparin n-sulfamidase (FGE, Sanfilippo syndrome), Shire DMHZ4JI CP Shire Human Genetic Therapies Inc DMHZ4JI DE Sanfilippo syndrome DM0LA6E ID DM0LA6E DM0LA6E DN HGTV43 DM0LA6E HS Phase 2 DM0LA6E CP Enzo Biochem DM0LA6E TC Antisense DM0LA6E DT Antisense drug DM0LA6E DE Human immunodeficiency virus infection; Human immunodeficiency virus-1 infection DMO10JI ID DMO10JI DMO10JI DN HibTITER DMO10JI HS Phase 2 DMO10JI SN Haemophilus vaccine II, Praxis; Conjugate vaccine (Haemophilus influenzae type B/ meningitis), Nuron Biotech DMO10JI CP Nuron biotech DMO10JI DT Vaccine DMO10JI DE Pneumococcal infection DMLQDBH ID DMLQDBH DMLQDBH DN HM-5016504 DMLQDBH HS Phase 2 DMLQDBH SN C-Met inhibitor (cancer), Hutchison DMLQDBH CP Hutchison Medipharma Enterprises Ltd DMLQDBH DE Solid tumour/cancer DMZ3BER ID DMZ3BER DMZ3BER DN HM-78136B DMZ3BER HS Phase 2 DMZ3BER SN Pan-Her/EGFR inhibitors (cancer), Hanmi DMZ3BER CP Hanmi Pharmaceutical Co Ltd DMZ3BER DT Small molecular drug DMZ3BER PC 25127713 DMZ3BER MW 491.3 DMZ3BER FM C23H21Cl2FN4O3 DMZ3BER IC InChI=1S/C23H21Cl2FN4O3/c1-3-20(31)30-8-6-13(7-9-30)33-19-10-14-17(11-18(19)32-2)27-12-28-23(14)29-16-5-4-15(24)21(25)22(16)26/h3-5,10-13H,1,6-9H2,2H3,(H,27,28,29) DMZ3BER CS COC1=C(C=C2C(=C1)N=CN=C2NC3=C(C(=C(C=C3)Cl)Cl)F)OC4CCN(CC4)C(=O)C=C DMZ3BER IK LPFWVDIFUFFKJU-UHFFFAOYSA-N DMZ3BER IU 1-[4-[4-(3,4-dichloro-2-fluoroanilino)-7-methoxyquinazolin-6-yl]oxypiperidin-1-yl]prop-2-en-1-one DMZ3BER CA CAS 1092364-38-9 DMZ3BER DE Solid tumour/cancer; HER2-positive breast cancer; Non-small-cell lung cancer DMMQZ3I ID DMMQZ3I DMMQZ3I DN HMR59 DMMQZ3I HS Phase 2 DMMQZ3I SN AAVCAGsCD59 DMMQZ3I CP Hemera Biosciences DMMQZ3I DT Gene therapy DMMQZ3I DE Wet age-related macular degeneration; Dry age-related macular degeneration; Geographic retinal atrophy DMA6HQJ ID DMA6HQJ DMA6HQJ DN HO/03/03 DMA6HQJ HS Phase 2 DMA6HQJ SN PKC modulator (topical peptide, DU/VU/PU), HealOr DMA6HQJ CP HealOr Ltd DMA6HQJ DE Diabetic foot ulcer DMNOMV2 ID DMNOMV2 DMNOMV2 DN HP-184 DMNOMV2 HS Phase 2 DMNOMV2 SN Nerispirdine; Nerispirdine hydrochloride; HP 184; N-(3-fluoropyridin-4-yl)-3-methyl-N-propylindol-1-amine; N-(n-Propyl)-3-fluoro-4-pyridinyl-1H-3-methylindol-1-amine hydrochloride; N-(3-Fluoro-4-pyridinyl)-3-methyl-N-propyl-1H-indol-1-amine; 1H-Indol-1-amine, N-(3-fluoro-4-pyridinyl)-3-methyl-N-propyl-, monohydrochloride DMNOMV2 CP Sanofi-Aventis DMNOMV2 DT Small molecular drug DMNOMV2 PC 3081185 DMNOMV2 MW 283.34 DMNOMV2 FM C17H18FN3 DMNOMV2 IC InChI=1S/C17H18FN3/c1-3-10-20(17-8-9-19-11-15(17)18)21-12-13(2)14-6-4-5-7-16(14)21/h4-9,11-12H,3,10H2,1-2H3 DMNOMV2 CS CCCN(C1=C(C=NC=C1)F)N2C=C(C3=CC=CC=C32)C DMNOMV2 IK BTDHTARYCBHHPJ-UHFFFAOYSA-N DMNOMV2 IU N-(3-fluoropyridin-4-yl)-3-methyl-N-propylindol-1-amine DMNOMV2 CA CAS 119229-65-1 DMNOMV2 DE Multiple sclerosis DMNZ35F ID DMNZ35F DMNZ35F DN HP-228 DMNZ35F HS Phase 2 DMNZ35F SN HP 228; Ac-Nle-gln-his-D-phe-arg-D-trp-gly-NH2; AC1L2XO7; 109022-88-0; Acetyl-norleucyl-glutaminyl-histidyl-phenylalanyl-arginyl-tryptophyl-glycinamide; L-Norleucyl-L-glutaminyl-L-histidyl-L-phenylalanyl-L-arginyl-L-tryptophylglycinamide; Glycinamide, L-norleucyl-L-glutaminyl-L-histidyl-L-phenylalanyl-L-arginyl-L-tryptophyl- DMNZ35F CP LION bioscience Inc DMNZ35F DT Small molecular drug DMNZ35F PC 9876430 DMNZ35F MW 984.1 DMNZ35F FM C47H65N15O9 DMNZ35F IC InChI=1S/C47H65N15O9/c1-3-4-14-33(57-27(2)63)42(67)59-35(17-18-39(48)64)44(69)62-38(22-30-24-52-26-56-30)46(71)60-36(20-28-11-6-5-7-12-28)45(70)58-34(16-10-19-53-47(50)51)43(68)61-37(41(66)55-25-40(49)65)21-29-23-54-32-15-9-8-13-31(29)32/h5-9,11-13,15,23-24,26,33-38,54H,3-4,10,14,16-22,25H2,1-2H3,(H2,48,64)(H2,49,65)(H,52,56)(H,55,66)(H,57,63)(H,58,70)(H,59,67)(H,60,71)(H,61,68)(H,62,69)(H4,50,51,53)/t33-,34-,35-,36+,37+,38-/m0/s1 DMNZ35F CS CCCC[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@H](CC2=CC=CC=C2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@H](CC3=CNC4=CC=CC=C43)C(=O)NCC(=O)N)NC(=O)C DMNZ35F IK UHKZNDVUBSEJJO-XAYNKGEHSA-N DMNZ35F IU (2S)-2-[[(2S)-2-acetamidohexanoyl]amino]-N-[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2R)-1-[(2-amino-2-oxoethyl)amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]pentanediamide DMNZ35F DE Postoperative pain DM3WSL2 ID DM3WSL2 DM3WSL2 DN HPH-116 DM3WSL2 HS Phase 2 DM3WSL2 SN Azocarbonamide; Azodicarbonamide; ADA, Hubriphar; Azodicarbonamide, H-Phar DM3WSL2 CP H-Phar Co DM3WSL2 DE Human immunodeficiency virus infection DM25PQB ID DM25PQB DM25PQB DN HPPH DM25PQB HS Phase 2 DM25PQB SN CHEMBL500853; SCHEMBL12722713; EX-A2655; 14-Ethyl-9-(1-(hexyloxy)ethyl)-4,8,13,18-tetramethyl-20-oxo-3-phorbinepropanoic acid; HY-13722; 3-Phorbinepropanoic acid, 14-ethyl-9-[1-(hexyloxy)ethyl]-4,8,13,18-tetramethyl-20-oxo-, (3S,4S)-; CS-0007752 DM25PQB PC 148160 DM25PQB MW 636.8 DM25PQB FM C39H48N4O4 DM25PQB IC InChI=1S/C39H48N4O4/c1-8-10-11-12-15-47-24(7)36-22(5)30-17-29-21(4)26(13-14-35(45)46)38(42-29)27-16-34(44)37-23(6)31(43-39(27)37)18-32-25(9-2)20(3)28(40-32)19-33(36)41-30/h17-19,21,24,26,42,44H,8-16H2,1-7H3,(H,45,46)/t21-,24?,26-/m0/s1 DM25PQB CS CCCCCCOC(C)C1=C(C2=NC1=CC3=NC(=CC4=C(C5=C(CC(=C6C(C(C(=C2)N6)C)CCC(=O)O)C5=N4)O)C)C(=C3C)CC)C DM25PQB IK PUUBADHCONCMPA-USOGPTGWSA-N DM25PQB IU 3-[(21S,22S)-11-ethyl-16-(1-hexoxyethyl)-4-hydroxy-12,17,21,26-tetramethyl-7,23,24,25-tetrazahexacyclo[18.2.1.15,8.110,13.115,18.02,6]hexacosa-1,4,6,8(26),9,11,13(25),14,16,18(24),19-undecaen-22-yl]propanoic acid DM25PQB CA CAS 149402-51-7 DM25PQB DE Lung cancer DM7QUN0 ID DM7QUN0 DM7QUN0 DN HQK-1001 DM7QUN0 HS Phase 2 DM7QUN0 SN Sodium ST-20; Hematological disease therapeutic (oral), HemaQuest DM7QUN0 CP Hemaquest pharmaceuticals DM7QUN0 DT Small molecular drug DM7QUN0 PC 53247304 DM7QUN0 MW 138.14 DM7QUN0 FM C6H11NaO2 DM7QUN0 IC InChI=1S/C6H12O2.Na/c1-4-6(2,3)5(7)8;/h4H2,1-3H3,(H,7,8);/q;+1/p-1 DM7QUN0 CS CCC(C)(C)C(=O)[O-].[Na+] DM7QUN0 IK OOPXYEYPPHJHSE-UHFFFAOYSA-M DM7QUN0 IU sodium;2,2-dimethylbutanoate DM7QUN0 CA CAS 3934-02-9 DM7QUN0 DE Beta thalassemia DM3WX0K ID DM3WX0K DM3WX0K DN HQK-1004 DM3WX0K HS Phase 2 DM3WX0K SN Arginine butyrate; VX-105; VX-105); Arginine butyrate (hematological malignancies), HemaQuest DM3WX0K CP HemaQuest Pharmaceuticals Inc; Vertex Pharmaceuticals Inc DM3WX0K PC 23622962 DM3WX0K MW 875 DM3WX0K FM C34H74N12O14 DM3WX0K IC InChI=1S/3C6H14N4O2.4C4H8O2/c3*7-4(5(11)12)2-1-3-10-6(8)9;4*1-2-3-4(5)6/h3*4H,1-3,7H2,(H,11,12)(H4,8,9,10);4*2-3H2,1H3,(H,5,6)/t3*4-;;;;/m000..../s1 DM3WX0K CS CCCC(=O)O.CCCC(=O)O.CCCC(=O)O.CCCC(=O)O.C(C[C@@H](C(=O)O)N)CN=C(N)N.C(C[C@@H](C(=O)O)N)CN=C(N)N.C(C[C@@H](C(=O)O)N)CN=C(N)N DM3WX0K IK ZVEMACCDKBQNGX-KALODSIISA-N DM3WX0K IU (2S)-2-amino-5-(diaminomethylideneamino)pentanoic acid;butanoic acid DM3WX0K CA CAS 80407-72-3 DM3WX0K DE Solid tumour/cancer DMQ30X2 ID DMQ30X2 DMQ30X2 DN HQP1351 DMQ30X2 HS Phase 2 DMQ30X2 SN GZD824; 1257628-77-5; GZD-824; 3-((1H-pyrazolo[3,4-b]pyridin-5-yl)ethynyl)-4-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide; UNII-KV1M7Q3CBP; KV1M7Q3CBP; 4-methyl-N-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-3-[2-(1H-pyrazolo[3,4-b]pyridin-5-yl)ethynyl]benzamide; CHEMBL2316582; Benzamide, 4-methyl-N-[4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl]-3-[2-(1H-pyrazolo[3,4-b]pyridin-5-yl)ethynyl]-; HQP-1351; olverembatinib; 4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}-3-(2-{1H-pyrazolo[3,4-b]pyridin-5-yl}ethynyl)benzamide; Benzamide, 4-methyl-N-(4-((4-methyl-1-piperazinyl)methyl)-3-(trifluoromethyl)phenyl)-3-(2-(1H-pyrazolo(3,4-b)pyridin-5-yl)ethynyl)-; HQP1351 free base; HQP-1351 free base; SCHEMBL3424528; GTPL10630; EX-A829; AOB87323; BCP07502; BDBM50425780; ZINC95594040; AKOS026750647; CS-1444; SB16617; compound 10a [PMID: 23301703]; NCGC00351607-06; AK547162; AS-75170; HY-15666; D-824; FT-0700150; A16264; W-6136; J-690110; 4-Methyl-N-(4-((4-methyl-1-piperazinyl)methyl)-3-(trifluoromethyl)phenyl)-3-(2-(1H-pyrazolo(3,4-b)pyridin-5-yl)ethynyl)benzamide DMQ30X2 CP Ascentage Pharma DMQ30X2 DT Small molecular drug DMQ30X2 PC 51038269 DMQ30X2 MW 532.6 DMQ30X2 FM C29H27F3N6O DMQ30X2 IC InChI=1S/C29H27F3N6O/c1-19-3-5-22(14-21(19)6-4-20-13-24-17-34-36-27(24)33-16-20)28(39)35-25-8-7-23(26(15-25)29(30,31)32)18-38-11-9-37(2)10-12-38/h3,5,7-8,13-17H,9-12,18H2,1-2H3,(H,35,39)(H,33,34,36) DMQ30X2 CS CC1=C(C=C(C=C1)C(=O)NC2=CC(=C(C=C2)CN3CCN(CC3)C)C(F)(F)F)C#CC4=CC5=C(NN=C5)N=C4 DMQ30X2 IK TZKBVRDEOITLRB-UHFFFAOYSA-N DMQ30X2 IU 4-methyl-N-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-3-[2-(1H-pyrazolo[3,4-b]pyridin-5-yl)ethynyl]benzamide DMQ30X2 CA CAS 1257628-77-5 DMQ30X2 DE Chronic myeloid leukaemia DML4RCG ID DML4RCG DML4RCG DN HS-110 DML4RCG HS Phase 2 DML4RCG CP Heat Biologics DML4RCG DT Vaccine DML4RCG DE Non-small-cell lung cancer DM2WP8F ID DM2WP8F DM2WP8F DN HT-0712 DM2WP8F HS Phase 2 DM2WP8F SN IPL-455903; Small-molecule PDE4 inhibitors (memory disorders), Inflazyme/Helicon DM2WP8F CP Dart neuroscience DM2WP8F DT Small molecular drug DM2WP8F PC 9865375 DM2WP8F MW 393.5 DM2WP8F FM C25H31NO3 DM2WP8F IC InChI=1S/C25H31NO3/c1-17-6-5-7-18(12-17)13-20-14-21(16-26-25(20)27)19-10-11-23(28-2)24(15-19)29-22-8-3-4-9-22/h5-7,10-12,15,20-22H,3-4,8-9,13-14,16H2,1-2H3,(H,26,27)/t20-,21-/m1/s1 DM2WP8F CS CC1=CC(=CC=C1)C[C@@H]2C[C@H](CNC2=O)C3=CC(=C(C=C3)OC)OC4CCCC4 DM2WP8F IK ABEJDMOBAFLQNJ-NHCUHLMSSA-N DM2WP8F IU (3S,5S)-5-(3-cyclopentyloxy-4-methoxyphenyl)-3-[(3-methylphenyl)methyl]piperidin-2-one DM2WP8F CA CAS 617720-02-2 DM2WP8F DE Cognitive impairment DM2QIN1 ID DM2QIN1 DM2QIN1 DN HT-100 DM2QIN1 HS Phase 2 DM2QIN1 SN Halofunginone DM2QIN1 CP Halo therapeutics DM2QIN1 DT Small molecular drug DM2QIN1 PC 62894 DM2QIN1 MW 414.7 DM2QIN1 FM C16H17BrClN3O3 DM2QIN1 IC InChI=1S/C16H17BrClN3O3/c17-11-6-13-10(5-12(11)18)16(24)21(8-20-13)7-9(22)4-14-15(23)2-1-3-19-14/h5-6,8,14-15,19,23H,1-4,7H2 DM2QIN1 CS C1CC(C(NC1)CC(=O)CN2C=NC3=CC(=C(C=C3C2=O)Cl)Br)O DM2QIN1 IK LVASCWIMLIKXLA-UHFFFAOYSA-N DM2QIN1 IU 7-bromo-6-chloro-3-[3-(3-hydroxypiperidin-2-yl)-2-oxopropyl]quinazolin-4-one DM2QIN1 CA CAS 55837-20-2 DM2QIN1 DE Duchenne dystrophy DMURXMJ ID DMURXMJ DMURXMJ DN HTI-101 DMURXMJ HS Phase 2 DMURXMJ CP Hemodynamic Therapeutics DMURXMJ DE Obesity DM9MKQ5 ID DM9MKQ5 DM9MKQ5 DN Hu3F8 mAb DM9MKQ5 HS Phase 2 DM9MKQ5 CP Y-mAbs Therapeutics New York, NY DM9MKQ5 DE Neuroblastoma; Osteosarcoma DMKQ3MC ID DMKQ3MC DMKQ3MC DN Human interferon alpha oral DMKQ3MC HS Phase 2 DMKQ3MC CP Amarillo biosciences DMKQ3MC DE Hepatitis C virus infection DM0NJWG ID DM0NJWG DM0NJWG DN Human interleukin-2 DM0NJWG HS Phase 2 DM0NJWG SN Pulmoleukin; Human interleukin-2 (inhaled, renal cell carcinoma); Human IL-2 (inhaled, renal cell carcinoma),Immunservice; Human interleukin-2 (inhaled, renal cell carcinoma), Immunservice DM0NJWG CP Immunservice GmbH DM0NJWG DE Renal cell carcinoma DMOPWSX ID DMOPWSX DMOPWSX DN Ibrolipim DMOPWSX HS Phase 2 DMOPWSX SN Ibrolipim < Prop INN; NO-1886; OPF-009; 4-[N-(4-Bromo-2-cyanophenyl)carbamoyl]benzylphosphonic acid diethyl ester DMOPWSX CP TAP Pharmaceuticals DMOPWSX DT Small molecular drug DMOPWSX PC 131601 DMOPWSX MW 451.2 DMOPWSX FM C19H20BrN2O4P DMOPWSX IC InChI=1S/C19H20BrN2O4P/c1-3-25-27(24,26-4-2)13-14-5-7-15(8-6-14)19(23)22-18-10-9-17(20)11-16(18)12-21/h5-11H,3-4,13H2,1-2H3,(H,22,23) DMOPWSX CS CCOP(=O)(CC1=CC=C(C=C1)C(=O)NC2=C(C=C(C=C2)Br)C#N)OCC DMOPWSX IK KPRTURMJVWXURQ-UHFFFAOYSA-N DMOPWSX IU N-(4-bromo-2-cyanophenyl)-4-(diethoxyphosphorylmethyl)benzamide DMOPWSX CA CAS 133208-93-2 DMOPWSX DE Hyperlipidaemia DM37CX4 ID DM37CX4 DM37CX4 DN IC14 DM37CX4 HS Phase 2 DM37CX4 SN CD14 antibody DM37CX4 TC Antiviral Agents DM37CX4 DT Monoclonal antibody DM37CX4 DE Coronavirus Disease 2019 (COVID-19) DMUFCQG ID DMUFCQG DMUFCQG DN IC14 DMUFCQG HS Phase 2 DMUFCQG DT Antibody DMUFCQG DE Sepsis DMB1UYV ID DMB1UYV DMB1UYV DN IC-485 DMB1UYV HS Phase 2 DMB1UYV CP ICOS DMB1UYV DT Small molecular drug DMB1UYV PC 23724885 DMB1UYV DE Chronic obstructive pulmonary disease DMP925B ID DMP925B DMP925B DN ICA-105665 DMP925B HS Phase 2 DMP925B CP Icagen DMP925B DE Epilepsy DMRFY7I ID DMRFY7I DMRFY7I DN ICA-17043 DMRFY7I HS Phase 2 DMRFY7I SN Senicapoc; 289656-45-7; 2,2-bis(4-fluorophenyl)-2-phenylacetamide; UNII-TS6G201A6Q; TS6G201A6Q; 2,2-BIS(4-FLUOROPHENYL)-2-PHENYL-ACETAMIDE; AK-79332; Senicapoc (USAN); Bis(4-fluorophenyl)phenylacetamide; Senicapoc [USAN:INN]; ICA 17043; C20H15F2NO; PubChem19381; 4-Fluoro-alpha-(4-fluorophenyl)-alpha-phenylbenzeneacetamide; AC1Q4NLN; AC1L50IL; CHEMBL405821; SCHEMBL1443805; GTPL2331; CTK4G2492; DTXSID60276906; SCTZUZTYRMOMKT-UHFFFAOYSA-N; MolPort-019-996-128; BCP14507; ACT06676; ZINC3816408; KS-00000XJ3; BBL102413; STL556215; Senicapoc DMRFY7I CP Icagen DMRFY7I DT Small molecular drug DMRFY7I PC 216327 DMRFY7I MW 323.3 DMRFY7I FM C20H15F2NO DMRFY7I IC InChI=1S/C20H15F2NO/c21-17-10-6-15(7-11-17)20(19(23)24,14-4-2-1-3-5-14)16-8-12-18(22)13-9-16/h1-13H,(H2,23,24) DMRFY7I CS C1=CC=C(C=C1)C(C2=CC=C(C=C2)F)(C3=CC=C(C=C3)F)C(=O)N DMRFY7I IK SCTZUZTYRMOMKT-UHFFFAOYSA-N DMRFY7I IU 2,2-bis(4-fluorophenyl)-2-phenylacetamide DMRFY7I CA CAS 289656-45-7 DMRFY7I DE Constitutional neutropenia; Alzheimer disease DMGHQ37 ID DMGHQ37 DMGHQ37 DN Icaritin DMGHQ37 HS Phase 2 DMGHQ37 SN Icaritin; 118525-40-9; UNII-UFE666UELY; UFE666UELY; CHEMBL498485; 3,5,7-trihydroxy-2-(4-methoxyphenyl)-8-(3-methylbut-2-enyl)chromen-4-one; 3,5,7-Trihydroxy-2-(4-methoxyphenyl)-8-(3-methyl-2-buten-1-yl)-4H-1-benzopyran-4-one; Icartin; Anhydroicaritin; AC1NSXIV; Icaritin(Anhydroicaritin); MLS006010055; BIDD:ER0021; SCHEMBL4223542; Icaritin, > DTXSID00152154; MolPort-020-006-012; TUUXBSASAQJECY-UHFFFAOYSA-N; HY-N0678; ZINC14762797; BDBM50272527; AKOS015896858; CS-3679; DB12672; NCGC00345813-01; AK168251; SMR004701218 DMGHQ37 DT Small molecular drug DMGHQ37 PC 5318980 DMGHQ37 MW 368.4 DMGHQ37 FM C21H20O6 DMGHQ37 IC InChI=1S/C21H20O6/c1-11(2)4-9-14-15(22)10-16(23)17-18(24)19(25)20(27-21(14)17)12-5-7-13(26-3)8-6-12/h4-8,10,22-23,25H,9H2,1-3H3 DMGHQ37 CS CC(=CCC1=C2C(=C(C=C1O)O)C(=O)C(=C(O2)C3=CC=C(C=C3)OC)O)C DMGHQ37 IK TUUXBSASAQJECY-UHFFFAOYSA-N DMGHQ37 IU 3,5,7-trihydroxy-2-(4-methoxyphenyl)-8-(3-methylbut-2-enyl)chromen-4-one DMGHQ37 CA CAS 118525-40-9 DMGHQ37 DE Breast cancer DMC13BQ ID DMC13BQ DMC13BQ DN ICO-25 DMC13BQ HS Phase 2 DMC13BQ SN Imuteran; Anti-MUC1 monoclonal antibodies, P Hertzen Moscow Cancer Research Institute; Anti-AG-4 antibodies, P Hertzen Moscow Cancer Research Institute DMC13BQ CP Russian National Cancer Research Center DMC13BQ DT Antibody DMC13BQ DE Breast cancer DMTXNZK ID DMTXNZK DMTXNZK DN Icofungipen DMTXNZK HS Phase 2 DMTXNZK SN PLD-118; 198022-65-0; UNII-I20202Q8M8; BAY-10-8888; I20202Q8M8; Cyclopentanecarboxylic acid, 2-amino-4-methylene-, (1R,2S)-; Icofungipen [INN]; (1R,2S)-2-Amino-4-methylene-cyclopentanecarboxylic acid; PLD118; PLD 118; 156292-16-9; BAY 10-8888; (1r,2s)-2-amino-4-methylidenecyclopentanecarboxylic acid; AC1Q5QVF; AC1L50CI; 2-amino-4-methylenecyclopentane-1-carboxylic acid; SCHEMBL117349; CHEMBL343803; CTK0H0639; DTXSID90173515; RKOUGZGFAYMUIO-RITPCOANSA-N; (1R,2S)-2-amino-4-methylidenecyclopentane-1-carboxylic acid; Icofungipen [INN]; (1R,2S)-2-Amino-4-methylenecyclopentane-1-carboxylic acid; AHMA DMTXNZK TC Antifungal Agents DMTXNZK DT Small molecular drug DMTXNZK PC 216240 DMTXNZK MW 141.17 DMTXNZK FM C7H11NO2 DMTXNZK IC InChI=1S/C7H11NO2/c1-4-2-5(7(9)10)6(8)3-4/h5-6H,1-3,8H2,(H,9,10)/t5-,6+/m1/s1 DMTXNZK CS C=C1C[C@H]([C@H](C1)N)C(=O)O DMTXNZK IK RKOUGZGFAYMUIO-RITPCOANSA-N DMTXNZK IU (1R,2S)-2-amino-4-methylidenecyclopentane-1-carboxylic acid DMTXNZK CA CAS 198022-65-0 DMTXNZK DE Fungal infection DM524GR ID DM524GR DM524GR DN ICP-192 DM524GR HS Phase 2 DM524GR CP InnoCare Pharma DM524GR DE Bladder cancer DM7XIAJ ID DM7XIAJ DM7XIAJ DN ID-93/GLA-SE DM7XIAJ HS Phase 2 DM7XIAJ CP Infectious disease research institute; aeras global tb vaccine foundation DM7XIAJ DE Tuberculosis DMABRXY ID DMABRXY DMABRXY DN IDM-2101 DMABRXY HS Phase 2 DMABRXY CP Biotech Synergy DMABRXY DT Vaccine DMABRXY DE Colorectal cancer DMSRC5D ID DMSRC5D DMSRC5D DN IDX899 DMSRC5D HS Phase 2 DMSRC5D SN Fosdevirine; IDX-899; IDX899; GSK2248761; GSK-2248761; 1018450-26-4; UNII-Z4I0C281BJ; Z4I0C281BJ; Fosdevirine [USAN:INN]; GSK2248761A; GSK 2248761A; Fosdevirine (USAN/INN); SCHEMBL1035677; CHEMBL2104968; IDX 899; 1097733-15-7; IDX-12899; GSK 2248761; D09906 DMSRC5D CP GSK DMSRC5D DT Small molecular drug DMSRC5D PC 23583058 DMSRC5D MW 413.8 DMSRC5D FM C20H17ClN3O3P DMSRC5D IC InChI=1S/C20H17ClN3O3P/c1-12-8-13(4-3-7-22)10-15(9-12)28(26,27-2)19-16-11-14(21)5-6-17(16)24-18(19)20(23)25/h3-6,8-11,24H,1-2H3,(H2,23,25)/b4-3+ DMSRC5D CS CC1=CC(=CC(=C1)P(=O)(C2=C(NC3=C2C=C(C=C3)Cl)C(=O)N)OC)/C=C/C#N DMSRC5D IK CGBYTKOSZYQOPV-ONEGZZNKSA-N DMSRC5D IU 5-chloro-3-[[3-[(E)-2-cyanoethenyl]-5-methylphenyl]-methoxyphosphoryl]-1H-indole-2-carboxamide DMSRC5D DE Human immunodeficiency virus infection DMGWNCJ ID DMGWNCJ DMGWNCJ DN Ifabotuzumab DMGWNCJ HS Phase 2 DMGWNCJ CP Humanigen Brisbane, CA Olivia Newton-John Cancer Research Institute Heidelberg, Australia DMGWNCJ DE Acute myeloid leukaemia; Myelodysplastic syndrome; Recurrent glioblastoma DMZP84Y ID DMZP84Y DMZP84Y DN Ifetroban sodium DMZP84Y HS Phase 2 DMZP84Y SN BMS-180291 sodium salt; BMS-180291-02 DMZP84Y CP Bristol-Myers Squibb DMZP84Y DT Small molecular drug DMZP84Y PC 23663994 DMZP84Y MW 462.5 DMZP84Y FM C25H31N2NaO5 DMZP84Y IC InChI=1S/C25H32N2O5.Na/c1-2-3-6-13-26-24(30)19-15-31-25(27-19)23-18(20-10-11-21(23)32-20)14-17-8-5-4-7-16(17)9-12-22(28)29;/h4-5,7-8,15,18,20-21,23H,2-3,6,9-14H2,1H3,(H,26,30)(H,28,29);/q;+1/p-1/t18-,20-,21+,23-;/m0./s1 DMZP84Y CS CCCCCNC(=O)C1=COC(=N1)[C@@H]2[C@H]3CC[C@@H]([C@@H]2CC4=CC=CC=C4CCC(=O)[O-])O3.[Na+] DMZP84Y IK WOHSQDNIXPEQAE-QBKVZTCDSA-M DMZP84Y IU sodium;3-[2-[[(1S,2R,3S,4R)-3-[4-(pentylcarbamoyl)-1,3-oxazol-2-yl]-7-oxabicyclo[2.2.1]heptan-2-yl]methyl]phenyl]propanoate DMZP84Y DE Thrombosis DM4H8EZ ID DM4H8EZ DM4H8EZ DN IFN-alpha DM4H8EZ HS Phase 2 DM4H8EZ SN Hanferon; HL-143; IFN-alpha (sc injection, HCV infection); Belerofon (subcutaneous, HCV infection), Nautilus/HanAll; IFN-alpha (sc injection, HCV infection), HanAll; IFN-alpha (subcutaneous, HCV infection), Nautilus/HanAll; Interferon-alpha (subcutaneous, HCV infection), Nautilus/HanAll DM4H8EZ CP Hanall biopharma DM4H8EZ DE Hepatitis C virus infection; Hepatocellular carcinoma DMHI36A ID DMHI36A DMHI36A DN IFX-1 DMHI36A HS Phase 2 DMHI36A SN XZAPEHKCHWMSPW-MTALQEDYSA-N; Ifx-1; J3.560.481B DMHI36A CP InflaRx Planegg, Germany DMHI36A PC 137254326 DMHI36A MW 672.9 DMHI36A FM C43H60O6 DMHI36A IC InChI=1S/C43H60O6/c1-30(17-14-18-31(2)19-21-39-42(9,10)27-37(49-33(4)45)28-43(39,11)48)15-12-13-16-32(3)23-35(46)24-34(29-44)20-22-38-40(5,6)25-36(47)26-41(38,7)8/h12-24,29,36-38,47-48H,25-28H2,1-11H3/b15-12?,16-13?,18-14?,22-20+,30-17?,31-19?,32-23?,34-24-,39-21?/t36?,37-,38?,43-/m1/s1 DMHI36A CS CC(=CC=CC(=CC=C1[C@](C[C@@H](CC1(C)C)OC(=O)C)(C)O)C)C=CC=CC(=CC(=O)/C=C(/C=C/C2C(CC(CC2(C)C)O)(C)C)\\C=O)C DMHI36A IK XZAPEHKCHWMSPW-MTALQEDYSA-N DMHI36A IU [(1R,3R)-4-[(15Z,17E)-16-formyl-18-(4-hydroxy-2,2,6,6-tetramethylcyclohexyl)-3,7,12-trimethyl-14-oxooctadeca-2,4,6,8,10,12,15,17-octaenylidene]-3-hydroxy-3,5,5-trimethylcyclohexyl] acetate DMHI36A DE Hidradenitis suppurativa DMH97XA ID DMH97XA DMH97XA DN Igmesine DMH97XA HS Phase 2 DMH97XA SN Igmesine hydrochloride; JO-1784; UNII-JV6M14TY35; Igmesine Hydrochloride [USAN]; 130152-35-1; Cinnamyl-1-phenyl-1-N-methyl-N-cyclopropylene; JO 1784; CI 1019; CI-1019; JV6M14TY35; (+)-alpha-(E)-Cinnamyl)-N-(cyclopropylmethyl)-alpha-ethyl-N-methylbenzylamine; (+)-Igmesine hydrochloride; (+)-(E)-N-(Cyclopropylmethyl)-alpha-ethyl-N-methyl-alpha-(3-phenyl-2-propenyl)benzenemethanamine hydrochloride; Igmesine hydrochloride (USAN); (+)-alpha-((E)-Cinnamyl)-N-(cyclopropylmethyl)-alpha-ethyl-N-methylbenzylamine; Alphagen DMH97XA DT Small molecular drug DMH97XA PC 6438340 DMH97XA MW 319.5 DMH97XA FM C23H29N DMH97XA IC InChI=1S/C23H29N/c1-3-23(22-14-8-5-9-15-22,24(2)19-21-16-17-21)18-10-13-20-11-6-4-7-12-20/h4-15,21H,3,16-19H2,1-2H3/b13-10+ DMH97XA CS CCC(C/C=C/C1=CC=CC=C1)(C2=CC=CC=C2)N(C)CC3CC3 DMH97XA IK VCZSWYIFCKGTJI-JLHYYAGUSA-N DMH97XA IU (E)-N-(cyclopropylmethyl)-N-methyl-3,6-diphenylhex-5-en-3-amine DMH97XA CA CAS 140850-73-3 DMH97XA DE Cystic fibrosis; Chronic obstructive pulmonary disease; Major depressive disorder DMIHQ5G ID DMIHQ5G DMIHQ5G DN IL-2/CD40L-expressing leukemia vaccine DMIHQ5G HS Phase 2 DMIHQ5G SN Autologous vaccine (leukemia), Baylor College of Medicine; Autologous vaccine (leukemia), MaxCyte; Autologous vaccine (leukemia), Baylor College of Medicine/MaxCyte; IL-2/CD40L-expressing leukemia vaccine, Baylor College of Medicine; IL-2/CD40L-expressing leukemia vaccine, MaxCyte; IL-2/CD40L-expressing leukemia vaccine, Baylor College of Medicine/MaxCyte DMIHQ5G CP Baylor College of Medicine DMIHQ5G DT Vaccine DMIHQ5G DE Chronic lymphocytic leukaemia DM1E4VP ID DM1E4VP DM1E4VP DN IL-21 DM1E4VP HS Phase 2 DM1E4VP SN BMS-982470 DM1E4VP CP Bristol-Myers Squibb DM1E4VP DE Colorectal cancer DMYEGRH ID DMYEGRH DMYEGRH DN IL-4R DMYEGRH HS Phase 2 DMDNHRA ID DMDNHRA DMDNHRA DN Ilodecakin DMDNHRA HS Phase 2 DMDNHRA SN Prevascar; Ilodecakin, Renovo; Recombinant IL-10 (scarring), Renovo DMDNHRA CP Renovo Group plc DMDNHRA DE Sarcoidosis DMUJ1WV ID DMUJ1WV DMUJ1WV DN IMCgp100 DMUJ1WV HS Phase 2 DMUJ1WV CP Immunocore DMUJ1WV DT Monoclonal antibody DMUJ1WV DE Melanoma; Cutaneous melanoma DMU1MR9 ID DMU1MR9 DMU1MR9 DN IMD-1041 DMU1MR9 HS Phase 2 DMU1MR9 SN IMD-1041 (oral, COPD/interstitial cystis/type 2 diabetics/chronic inflammatory disease/metabolic syndrome/AD), IMMD DMU1MR9 CP Institute of Medicinal Molecular Design Inc DMU1MR9 DE Alzheimer disease DMMQFG2 ID DMMQFG2 DMMQFG2 DN Imeglimin DMMQFG2 HS Phase 2 DMMQFG2 SN 775351-65-0; UNII-UU226QGU97; UU226QGU97; Imeglimin [INN]; Emd 387008 (R-imeglimin) HCl; SCHEMBL2158106; SCHEMBL14868241; C6H13N5; DTXSID50228237; BCP11085; ZINC34380900; 3733AH; AKOS027338676; DB12509; CS-1751; HY-14771 DMMQFG2 CP Merck KGaA DMMQFG2 DT Small molecular drug DMMQFG2 PC 24812808 DMMQFG2 MW 155.2 DMMQFG2 FM C6H13N5 DMMQFG2 IC InChI=1S/C6H13N5/c1-4-8-5(7)10-6(9-4)11(2)3/h4H,1-3H3,(H3,7,8,9,10)/t4-/m1/s1 DMMQFG2 CS C[C@@H]1N=C(NC(=N1)N(C)C)N DMMQFG2 IK GFICWFZTBXUVIG-SCSAIBSYSA-N DMMQFG2 IU (4R)-6-N,6-N,4-trimethyl-1,4-dihydro-1,3,5-triazine-2,6-diamine DMMQFG2 CA CAS 775351-65-0 DMMQFG2 DE Type-2 diabetes; Diabetic complication DML9AVG ID DML9AVG DML9AVG DN IMG-7289 DML9AVG HS Phase 2 DML9AVG SN KQKBMHGOHXOHTD-KKUQBAQOSA-N; UNII-Y2T4ALDEAT; Y2T4ALDEAT; SCHEMBL17984236; Benzamide, N-((1S)-4-(((1R,2S)-2-(4-fluorophenyl)cyclopropyl)amino)-1-((4-methyl-1-piperazinyl)carbonyl)butyl)-4-(1H-1,2,3-triazol-1-yl)-; 1990504-34-1; N-[(2S)-1-(4-(methyl)piperazin-1-yl)-5-[[(1R,2S)-2-(4-fluorophenyl)-cyclopropyl]amino]-1-oxopentan-2-yl]-4-(1H-1,2,3-triazol-1-yl)benzamide DML9AVG CP Imago BioSciences San Carlos, CA DML9AVG PC 122460381 DML9AVG MW 519.6 DML9AVG FM C28H34FN7O2 DML9AVG IC InChI=1S/C28H34FN7O2/c1-34-15-17-35(18-16-34)28(38)25(3-2-12-30-26-19-24(26)20-4-8-22(29)9-5-20)32-27(37)21-6-10-23(11-7-21)36-14-13-31-33-36/h4-11,13-14,24-26,30H,2-3,12,15-19H2,1H3,(H,32,37)/t24-,25-,26+/m0/s1 DML9AVG CS CN1CCN(CC1)C(=O)[C@H](CCCN[C@@H]2C[C@H]2C3=CC=C(C=C3)F)NC(=O)C4=CC=C(C=C4)N5C=CN=N5 DML9AVG IK KQKBMHGOHXOHTD-KKUQBAQOSA-N DML9AVG IU N-[(2S)-5-[[(1R,2S)-2-(4-fluorophenyl)cyclopropyl]amino]-1-(4-methylpiperazin-1-yl)-1-oxopentan-2-yl]-4-(triazol-1-yl)benzamide DML9AVG CA CAS 1990504-34-1 DML9AVG DE Acute myeloid leukaemia; Myelodysplastic syndrome; Myelofibrosis DMNJ491 ID DMNJ491 DMNJ491 DN IMGN529 DMNJ491 HS Phase 2 DMNJ491 CP ImmunoGen DMNJ491 DT Antibody DMNJ491 DE Metastatic non-hodgkin's lymphoma; Non-hodgkin lymphoma DMIUC3M ID DMIUC3M DMIUC3M DN IMGN901 DMIUC3M HS Phase 2 DMIUC3M SN Lorvotuzumab mertansine DMIUC3M CP ImmunoGen DMIUC3M DE Solid tumour/cancer DME3POC ID DME3POC DME3POC DN Imisopasem manganese DME3POC HS Phase 2 DME3POC SN KM-4403; M-40403; Imisopasem manganese (dermatological, psoriasis/atopic dermatitis); Imisopasem manganese (dermatological,psoriasis/atopic dermatitis), ActivBiotics; Imisopasem manganese (dermatological, psoriasis/atopic dermatitis), Metaphore; M-40403 (dermatological, psoriasis/atopic dermatitis), Metaphore DME3POC CP MetaPhore Pharmaceuticals DME3POC DT Small molecular drug DME3POC PC 6918487 DME3POC MW 483.4 DME3POC FM C21H35Cl2MnN5 DME3POC IC InChI=1S/C21H35N5.2ClH.Mn/c1-3-10-20-18(8-1)22-12-13-23-19-9-2-4-11-21(19)25-15-17-7-5-6-16(26-17)14-24-20;;;/h5-7,18-25H,1-4,8-15H2;2*1H;/q;;;+2/p-2/t18-,19-,20-,21-;;;/m1.../s1 DME3POC CS C1CC[C@@H]2[C@@H](C1)NCCN[C@@H]3CCCC[C@H]3NCC4=CC=CC(=N4)CN2.Cl[Mn]Cl DME3POC IK WXEMWBBXVXHEPU-XNPJUPKFSA-L DME3POC IU dichloromanganese;(4R,9R,14R,19R)-3,10,13,20,26-pentazatetracyclo[20.3.1.04,9.014,19]hexacosa-1(26),22,24-triene DME3POC DE Pain DM6IQ3V ID DM6IQ3V DM6IQ3V DN IMO-2055 DM6IQ3V HS Phase 2 DM6IQ3V CP Idera Pharmaceuticals DM6IQ3V DE Solid tumour/cancer; Renal cell carcinoma DMM549D ID DMM549D DMM549D DN IMO-3100 DMM549D HS Phase 2 DMM549D CP Idera Pharmaceuticals DMM549D DE Autoimmune diabetes; Psoriasis vulgaris DMDPNCJ ID DMDPNCJ DMDPNCJ DN IMO-8400 DMDPNCJ HS Phase 2 DMDPNCJ SN Bazlitoran; Bazlitoran [INN]; Bazlitoran [USAN]; UNII-2U46M95B5M; 2U46M95B5M DMDPNCJ CP Idera Pharmaceuticals Cambridge, MA DMDPNCJ SQ CTATCTNNNNTTCTCTNN DMDPNCJ PC 119058029 DMDPNCJ MW 5801 DMDPNCJ FM C179H233N52O101P17S17 DMDPNCJ IC InChI=1S/C179H233N52O101P17S17/c1-71-41-221(172(252)200-143(71)184)123-32-85(106(303-123)62-293-347(274,364)330-136-109(313-160(140(136)278-10)220-26-19-117(234)199-171(220)251)66-297-349(276,366)332-138-111(315-162(142(138)280-12)231-70-193-134-148(231)203-165(188)206-158(134)245)65-296-346(273,363)328-92-39-130(228-48-78(8)155(242)213-179(228)259)310-105(92)60-289-337(264,354)320-84-31-122(218-24-17-115(183)197-169(218)249)302-98(84)53-285-341(268,358)324-89-36-127(225-45-75(5)152(239)210-176(225)256)308-103(89)58-291-344(271,361)329-93-40-131(229-68-191-132-144(185)189-67-190-146(132)229)311-107(93)61-292-343(270,360)326-86-33-124(222-42-72(2)149(236)207-173(222)253)304-99(86)54-281-333(260,350)316-80-27-119(298-94(80)49-232)215-21-14-112(180)194-166(215)246)321-338(265,355)282-50-95-81(28-118(299-95)214-20-13-79-145(214)201-163(186)204-156(79)243)317-334(261,351)286-55-100-90(37-128(305-100)226-46-76(6)153(240)211-177(226)257)325-342(269,359)290-57-102-88(35-126(307-102)224-44-74(4)151(238)209-175(224)255)323-340(267,357)284-51-96-82(29-120(300-96)216-22-15-113(181)195-167(216)247)318-335(262,352)287-56-101-87(34-125(306-101)223-43-73(3)150(237)208-174(223)254)322-339(266,356)283-52-97-83(30-121(301-97)217-23-16-114(182)196-168(217)248)319-336(263,353)288-59-104-91(38-129(309-104)227-47-77(7)154(241)212-178(227)258)327-345(272,362)295-64-110-137(141(279-11)161(314-110)230-69-192-133-147(230)202-164(187)205-157(133)244)331-348(275,365)294-63-108-135(235)139(277-9)159(312-108)219-25-18-116(233)198-170(219)250/h13-26,41-48,67-70,80-111,118-131,135-142,159-162,232,235H,27-40,49-66H2,1-12H3,(H,260,350)(H,261,351)(H,262,352)(H,263,353)(H,264,354)(H,265,355)(H,266,356)(H,267,357)(H,268,358)(H,269,359)(H,270,360)(H,271,361)(H,272,362)(H,273,363)(H,274,364)(H,275,365)(H,276,366)(H2,180,194,246)(H2,181,195,247)(H2,182,196,248)(H2,183,197,249)(H2,184,200,252)(H2,185,189,190)(H,198,233,250)(H,199,234,251)(H,207,236,253)(H,208,237,254)(H,209,238,255)(H,210,239,256)(H,211,240,257)(H,212,241,258)(H,213,242,259)(H3,186,201,204,243)(H3,187,202,205,244)(H3,188,203,206,245)/t80-,81-,82-,83-,84-,85-,86-,87-,88-,89-,90-,91-,92-,93-,94+,95+,96+,97+,98+,99+,100+,101+,102+,103+,104+,105+,106+,107+,108+,109+,110+,111+,118+,119+,120+,121+,122+,123+,124+,125+,126+,127+,128+,129+,130+,131+,135+,136+,137+,138+,139+,140+,141+,142+,159+,160+,161+,162+,333?,334?,335?,336?,337?,338?,339?,340?,341?,342?,343?,344?,345?,346?,347?,348?,349?/m0/s1 DMDPNCJ CS CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)COP(=S)(O)O[C@H]3C[C@@H](O[C@@H]3COP(=S)(O)O[C@H]4C[C@@H](O[C@@H]4COP(=S)(O)O[C@@H]5[C@H](O[C@H]([C@@H]5OC)N6C=CC(=O)NC6=O)COP(=S)(O)O[C@@H]7[C@H](O[C@H]([C@@H]7OC)N8C=NC9=C8N=C(NC9=O)N)COP(=S)(O)O[C@H]1C[C@@H](O[C@@H]1COP(=S)(O)O[C@H]1C[C@@H](O[C@@H]1COP(=S)(O)O[C@H]1C[C@@H](O[C@@H]1COP(=S)(O)O[C@H]1C[C@@H](O[C@@H]1COP(=O)(O[C@H]1C[C@@H](O[C@@H]1COP(=S)(O)O[C@H]1C[C@@H](O[C@@H]1CO)N1C=CC(=NC1=O)N)N1C=C(C(=O)NC1=O)C)S)N1C=NC2=C(N=CN=C21)N)N1C=C(C(=O)NC1=O)C)N1C=CC(=NC1=O)N)N1C=C(C(=O)NC1=O)C)N1C=C(C(=NC1=O)N)C)N1C=CC2=C1N=C(NC2=O)N)OP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N1C=C(C(=O)NC1=O)C)OP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N1C=CC(=NC1=O)N)OP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N1C=C(C(=O)NC1=O)C)OP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N1C=CC(=NC1=O)N)OP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N1C=C(C(=O)NC1=O)C)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=NC2=C1N=C(NC2=O)N)OC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=CC(=O)NC1=O)OC)O DMDPNCJ IK HDRGJRSISASRAJ-WKPMUQCKSA-N DMDPNCJ IU 1-[(2R,4S,5R)-5-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-2-[[[(2R,3R,4R,5R)-2-[[[(2R,3R,4R,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-2-(hydroxymethyl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-sulfanylphosphoryl]oxymethyl]-5-(6-aminopurin-9-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-4-methoxyoxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(2,4-dioxopyrimidin-1-yl)-4-methoxyoxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(2-amino-4-oxo-3H-pyrrolo[2,3-d]pyrimidin-7-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-4-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3R,4R,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[(2R,3R,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3-hydroxy-4-methoxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-methoxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]-5-methylpyrimidine-2,4-dione DMDPNCJ CA CAS 1378549-07-5 DMDPNCJ DE Diffuse large B-cell lymphoma; Rheumatoid arthritis; Waldenstrom macroglobulinemia DMTN16K ID DMTN16K DMTN16K DN Implitapide DMTN16K HS Phase 2 DMTN16K SN Implitapide [INN]; (2S)-2-cyclopentyl-2-[3-[(2,4-dimethylpyrido[2,3-b]indol-9-yl)methyl]phenyl]-N-[(1R)-2-hydroxy-1-phenylethyl]acetamide DMTN16K CP MRL international DMTN16K DT Small molecular drug DMTN16K PC 5745206 DMTN16K MW 531.7 DMTN16K FM C35H37N3O2 DMTN16K IC InChI=1S/C35H37N3O2/c1-23-19-24(2)36-34-32(23)29-17-8-9-18-31(29)38(34)21-25-11-10-16-28(20-25)33(27-14-6-7-15-27)35(40)37-30(22-39)26-12-4-3-5-13-26/h3-5,8-13,16-20,27,30,33,39H,6-7,14-15,21-22H2,1-2H3,(H,37,40)/t30-,33-/m0/s1 DMTN16K CS CC1=CC(=NC2=C1C3=CC=CC=C3N2CC4=CC(=CC=C4)[C@H](C5CCCC5)C(=O)N[C@@H](CO)C6=CC=CC=C6)C DMTN16K IK AMNXBQPRODZJQR-DITALETJSA-N DMTN16K IU (2S)-2-cyclopentyl-2-[3-[(2,4-dimethylpyrido[2,3-b]indol-9-yl)methyl]phenyl]-N-[(1R)-2-hydroxy-1-phenylethyl]acetamide DMTN16K CA CAS 177469-96-4 DMTN16K DE Hyperlipidaemia DMB1N6P ID DMB1N6P DMB1N6P DN Impoyz DMB1N6P HS Phase 2 DMB1N6P SN Clobetasol propionate; CLOBETASOL PROPIONATE; 25122-46-7; Clobetasol 17-propionate; Clobex; Temovate; Dermovate; Embeline; Embeline E; Clobesol; Cormax; Olux; Temovate E; Olux-E; clobetasol 17-propanoate; GR 2/925; C25H32ClFO5; MLS000028708; Clobestasol propionate; Clobetasol propionate [USAN:JAN]; CGP 9555; CCI 4725; EINECS 246-634-3; 21-Chloro-9-fluoro-11beta,17-dihydroxy-16beta-methylpregna-1,4-diene-3,20-dione 17-propionate; UNII-779619577M; [(8S,9R,10S,11S,13S,14S,16S,17R)-17-(2-chloroacetyl)-9-fluoro-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12 DMB1N6P CP Promius Pharma Princeton, NJ DMB1N6P PC 32798 DMB1N6P MW 467 DMB1N6P FM C25H32ClFO5 DMB1N6P IC InChI=1S/C25H32ClFO5/c1-5-21(31)32-25(20(30)13-26)14(2)10-18-17-7-6-15-11-16(28)8-9-22(15,3)24(17,27)19(29)12-23(18,25)4/h8-9,11,14,17-19,29H,5-7,10,12-13H2,1-4H3/t14-,17-,18-,19-,22-,23-,24-,25-/m0/s1 DMB1N6P CS CCC(=O)O[C@@]1([C@H](C[C@@H]2[C@@]1(C[C@@H]([C@]3([C@H]2CCC4=CC(=O)C=C[C@@]43C)F)O)C)C)C(=O)CCl DMB1N6P IK CBGUOGMQLZIXBE-XGQKBEPLSA-N DMB1N6P IU [(8S,9R,10S,11S,13S,14S,16S,17R)-17-(2-chloroacetyl)-9-fluoro-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] propanoate DMB1N6P CA CAS 25122-46-7 DMB1N6P CB CHEBI:31414 DMB1N6P DE Plaque psoriasis DM15MRZ ID DM15MRZ DM15MRZ DN IMR-687 DM15MRZ HS Phase 2 DM15MRZ SN Tovinontrine; UNII-W248Y1AKOR; W248Y1AKOR; 2062661-53-2; a]pyrazin-8(7H)-one; CHEMBL4297290; SCHEMBL20358493; BDBM426313; US10513524, Compound (P3; 6-{(3S,4S)-4-methyl-1-[(pyrimidin-2-; yl)methyl]pyrrolidin-3-yl}-3-(oxan-4-yl)imidazo[1,5-; 6-((3S,4S)-4-Methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl)-3-tetrahydropyran-4-yl-7himidazo(1,5-a)pyrazin-8-one; Imidazo(1,5-a)pyrazin-8(7H)-one, 6-((3S,4S)-4-methyl-1-(2-pyrimidinylmethyl)-3-pyrrolidinyl)-3-(tetrahydro-2H-pyran-4-yl)- DM15MRZ CP Imara DM15MRZ DT Small molecular drug DM15MRZ PC 124220601 DM15MRZ MW 394.5 DM15MRZ FM C21H26N6O2 DM15MRZ IC InChI=1S/C21H26N6O2/c1-14-10-26(13-19-22-5-2-6-23-19)11-16(14)17-12-27-18(21(28)25-17)9-24-20(27)15-3-7-29-8-4-15/h2,5-6,9,12,14-16H,3-4,7-8,10-11,13H2,1H3,(H,25,28)/t14-,16-/m1/s1 DM15MRZ CS C[C@@H]1CN(C[C@H]1C2=CN3C(=CN=C3C4CCOCC4)C(=O)N2)CC5=NC=CC=N5 DM15MRZ IK GWGNPYYVGANHRJ-GDBMZVCRSA-N DM15MRZ IU 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-(oxan-4-yl)-7H-imidazo[1,5-a]pyrazin-8-one DM15MRZ CA CAS 2062661-53-2 DM15MRZ DE Sickle-cell disorder DMNUXKA ID DMNUXKA DMNUXKA DN INCAGN01876 DMNUXKA HS Phase 2 DMNUXKA CP Agenis; Incyte DMNUXKA DT Antibody DMNUXKA DE Solid tumour/cancer DMK7OHI ID DMK7OHI DMK7OHI DN INCAGN01949 DMK7OHI HS Phase 2 DMK7OHI CP Agenis; Incyte DMK7OHI DT Antibody DMK7OHI DE Advanced malignancy; Metastatic malignant neoplasm DMFG8TI ID DMFG8TI DMFG8TI DN INCB00928 DMFG8TI HS Phase 2 DMFG8TI CP Incyte DMFG8TI DT Small molecular drug DMFG8TI DE Multiple myeloma; Myelodysplastic syndrome; Anemia DMD9RV3 ID DMD9RV3 DMD9RV3 DN INCB039110 DMD9RV3 HS Phase 2 DMD9RV3 SN Examlpe 294 [WO2011112662] DMD9RV3 DT Small molecular drug DMD9RV3 PC 53380437 DMD9RV3 MW 553.5 DMD9RV3 FM C26H23F4N9O DMD9RV3 IC InChI=1S/C26H23F4N9O/c27-20-18(1-7-32-22(20)26(28,29)30)24(40)37-9-3-17(4-10-37)38-13-25(14-38,5-6-31)39-12-16(11-36-39)21-19-2-8-33-23(19)35-15-34-21/h1-2,7-8,11-12,15,17H,3-5,9-10,13-14H2,(H,33,34,35) DMD9RV3 CS C1CN(CCC1N2CC(C2)(CC#N)N3C=C(C=N3)C4=C5C=CNC5=NC=N4)C(=O)C6=C(C(=NC=C6)C(F)(F)F)F DMD9RV3 IK KTBSXLIQKWEBRB-UHFFFAOYSA-N DMD9RV3 IU 2-[1-[1-[3-fluoro-2-(trifluoromethyl)pyridine-4-carbonyl]piperidin-4-yl]-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile DMD9RV3 CA CAS 1334298-90-6 DMD9RV3 DE Malignant neoplasm; Non-small-cell lung cancer DMZJP2T ID DMZJP2T DMZJP2T DN INCB50465 DMZJP2T HS Phase 2 DMZJP2T CP Incyte Wilmington, DE DMZJP2T DE Diffuse large B-cell lymphoma; Follicular lymphoma; Mantle cell lymphoma; Marginal zone lymphoma DMDK0HX ID DMDK0HX DMDK0HX DN INCB54707 DMDK0HX HS Phase 2 DMDK0HX CP Incyte Wilmington, DE DMDK0HX DE Hidradenitis suppurativa DMJN9PU ID DMJN9PU DMJN9PU DN INCB86550 DMJN9PU HS Phase 2 DMJN9PU CP Incyte DMJN9PU DT Small molecular drug DMJN9PU DE Solid tumour/cancer DM6OFJ8 ID DM6OFJ8 DM6OFJ8 DN Indibulin DM6OFJ8 HS Phase 2 DM6OFJ8 SN Indibulin; 204205-90-3; 2-(1-(4-chlorobenzyl)-1H-indol-3-yl)-2-oxo-N-(pyridin-4-yl)acetamide; d-24851; UNII-80K4H2RB8P; 80K4H2RB8P; ZIO-301; D 24851; 2-[1-(4-chlorobenzyl)-1h-indol-3-yl]-2-oxo-n-(pyridin-4-yl)acetamide; N-(Pyridin-4-yl)-[1-(4-chlorobenzyl)-indol-3-yl]-glyoxyl Amide; Indibulin [USAN:INN]; 2-{1-[(4-chlorophenyl)methyl]indol-3-yl}-2-oxo-N-(4-pyridyl)acetamide; 2-[1-[(4-chlorophenyl)methyl]indol-3-yl]-2-oxo-N-(4-pyridyl)acetamide; Indibulin (USAN/INN); AC1L1ESK; AC1Q5NS8; MLS006011745; CHEMBL49642 DM6OFJ8 CP ZioPharm DM6OFJ8 DT Small molecular drug DM6OFJ8 PC 2929 DM6OFJ8 MW 389.8 DM6OFJ8 FM C22H16ClN3O2 DM6OFJ8 IC InChI=1S/C22H16ClN3O2/c23-16-7-5-15(6-8-16)13-26-14-19(18-3-1-2-4-20(18)26)21(27)22(28)25-17-9-11-24-12-10-17/h1-12,14H,13H2,(H,24,25,28) DM6OFJ8 CS C1=CC=C2C(=C1)C(=CN2CC3=CC=C(C=C3)Cl)C(=O)C(=O)NC4=CC=NC=C4 DM6OFJ8 IK SOLIIYNRSAWTSQ-UHFFFAOYSA-N DM6OFJ8 IU 2-[1-[(4-chlorophenyl)methyl]indol-3-yl]-2-oxo-N-pyridin-4-ylacetamide DM6OFJ8 CA CAS 204205-90-3 DM6OFJ8 DE Advanced sarcoma DM9SX6Y ID DM9SX6Y DM9SX6Y DN Indisulam DM9SX6Y HS Phase 2 DM9SX6Y SN Indisulam; 165668-41-7; E7070; N-(3-chloro-1H-indol-7-yl)benzene-1,4-disulfonamide; UNII-WJ98J3NM90; E-7070; E 7070; N-(3-Chloro-1H-indol-7-yl)-1,4-benzenedisulfonamide; CHEMBL77517; WJ98J3NM90; N1-(3-chloro-1H-indol-7-yl)benzene-1,4-disulfonamide; 1,4-Benzenedisulfonamide, N-(3-chloro-1H-indol-7-yl)-; ER-35744; N-(3-Chloro-1H-indol-7-yl)benzene-1,4disulfonamide; Indisulam (IND); indisulam (e7070); Indisulam (USAN/INN); AC1Q6VCX; AC1L50QL; SCHEMBL91389; N-(3-chloro-7-indolyl)-1,4-benzenedisulphonamide; Indisulam [USAN:INN:BAN] DM9SX6Y DT Small molecular drug DM9SX6Y PC 216468 DM9SX6Y MW 385.8 DM9SX6Y FM C14H12ClN3O4S2 DM9SX6Y IC InChI=1S/C14H12ClN3O4S2/c15-12-8-17-14-11(12)2-1-3-13(14)18-24(21,22)10-6-4-9(5-7-10)23(16,19)20/h1-8,17-18H,(H2,16,19,20) DM9SX6Y CS C1=CC2=C(C(=C1)NS(=O)(=O)C3=CC=C(C=C3)S(=O)(=O)N)NC=C2Cl DM9SX6Y IK SETFNECMODOHTO-UHFFFAOYSA-N DM9SX6Y IU 4-N-(3-chloro-1H-indol-7-yl)benzene-1,4-disulfonamide DM9SX6Y CA CAS 165668-41-7 DM9SX6Y CB CHEBI:145431 DM9SX6Y DE Lymphoma DMU5SZP ID DMU5SZP DMU5SZP DN Inecalcitol oral DMU5SZP HS Phase 2 DMU5SZP SN Inecalcitol; TX-522; UNII-05FZV98342; TX 522; 163217-09-2; AC1OCD0K; 19-Nor-14-epi-23-yne-1,25 dihydroxyvitamin D3; 05FZV98342; (1R,3R)-5-[(2E)-2-[(1R,3aR,7aR)-1-[(2R)-6-hydroxy-6-methylhept-4-yn-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]cyclohexane-1,3-diol; (7E)-(1R,3R,14R)-19-nor-23-yne-9,10-seco-5,7-cholestadiene-1,3,25-triol; Inecalcitol [INN]; SCHEMBL754593; GTPL7747; CHEMBL2105107; LMST03020649; 8151AH; ZINC12504514; AKOS025312295; AN-7569; DB04796; Inecalcitol; TX-527; Vitamin D analogs, Catholic University of Leuven; Vitamin D analogs, KULeuven; Inecalcitol (oral, hyperthyroidism), Hybrigenics; Inecalcitol (sc, psoriasis), Hybrigenics; Vitamin D analog (sc, psoriasis), Hybrigenics; Inecalcitol (oral, prostate cancer/psoriasis), Hybrigenics; 19-nor-14-epi-23-yne-1,25 dihydroxyvitamin D3 DMU5SZP CP Catholic University of Leuven; Hybrigenics DMU5SZP DT Small molecular drug DMU5SZP PC 6915835 DMU5SZP MW 400.6 DMU5SZP FM C26H40O3 DMU5SZP IC InChI=1S/C26H40O3/c1-18(7-5-13-25(2,3)29)23-11-12-24-20(8-6-14-26(23,24)4)10-9-19-15-21(27)17-22(28)16-19/h9-10,18,21-24,27-29H,6-8,11-12,14-17H2,1-4H3/b20-10+/t18-,21-,22-,23-,24-,26-/m1/s1 DMU5SZP CS C[C@H](CC#CC(C)(C)O)[C@H]1CC[C@H]\\2[C@@]1(CCC/C2=C\\C=C3C[C@H](C[C@@H](C3)O)O)C DMU5SZP IK HHGRMHMXKPQNGF-WNSNRMDMSA-N DMU5SZP IU (1R,3R)-5-[(2E)-2-[(1R,3aR,7aR)-1-[(2R)-6-hydroxy-6-methylhept-4-yn-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]cyclohexane-1,3-diol DMU5SZP CA CAS 163217-09-2 DMU5SZP DE Prostate cancer; Acute myeloid leukaemia DMEO9Y7 ID DMEO9Y7 DMEO9Y7 DN INGAP peptide DMEO9Y7 HS Phase 2 DMEO9Y7 CP Exsulin DMEO9Y7 DE Type-1/2 diabetes DMF7J6D ID DMF7J6D DMF7J6D DN INGN-225 DMF7J6D HS Phase 2 DMF7J6D SN Cancer vaccine (p53), Introgen DMF7J6D CP Introgen Therapeutics DMF7J6D DT Vaccine DMF7J6D DE Head and neck cancer DM6P91T ID DM6P91T DM6P91T DN INGN-241 DM6P91T HS Phase 2 DM6P91T SN AD-IL-24, Introgen; AD-mda-7, Introgen; Adenovirus-IL-24, Introgen; Adenovirus-mda-7, Introgen DM6P91T CP Multivir; Introgen Therapeutics DM6P91T DE Solid tumour/cancer DMGO7QT ID DMGO7QT DMGO7QT DN INK128 DMGO7QT HS Phase 2 DMGO7QT SN 1224844-38-5; Sapanisertib; INK-128; INK 128; INK 128 (MLN0128); TAK-228; UNII-JGH0DF1U03; JGH0DF1U03; 5-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)benzo[d]oxazol-2-amine; INK-0128; 3-(2-Amino-5-benzoxazolyl)-1-(1-methylethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine; C15H15N7O; 5-(4-amino-1-propan-2-ylpyrazolo[3,4-d]pyrimidin-3-yl)-1,3-benzoxazol-2-amine; 5-(4-Amino-1-isopropyl-1H-pyrazolo[3,4-d]-pyrimidin-3-yl)benzo[d]oxazol-2-amine; Sapanisertib (USAN/INN) DMGO7QT CP Intellikine; MMRC DMGO7QT DT Small molecular drug DMGO7QT PC 45375953 DMGO7QT MW 309.33 DMGO7QT FM C15H15N7O DMGO7QT IC InChI=1S/C15H15N7O/c1-7(2)22-14-11(13(16)18-6-19-14)12(21-22)8-3-4-10-9(5-8)20-15(17)23-10/h3-7H,1-2H3,(H2,17,20)(H2,16,18,19) DMGO7QT CS CC(C)N1C2=NC=NC(=C2C(=N1)C3=CC4=C(C=C3)OC(=N4)N)N DMGO7QT IK GYLDXIAOMVERTK-UHFFFAOYSA-N DMGO7QT IU 5-(4-amino-1-propan-2-ylpyrazolo[3,4-d]pyrimidin-3-yl)-1,3-benzoxazol-2-amine DMGO7QT CA CAS 1224844-38-5 DMGO7QT CB CHEBI:91450 DMGO7QT DE Multiple myeloma; Breast cancer DMKRGVJ ID DMKRGVJ DMKRGVJ DN INS-1 DMKRGVJ HS Phase 2 DMKRGVJ SN Diabetes therapeutics, Insmed; Inositol phosphoglycans, Insmed; D-chiro-inositol, Insmed DMKRGVJ CP Insmed Inc DMKRGVJ DE Metabolic disorder DMF93RQ ID DMF93RQ DMF93RQ DN INS-37217 DMF93RQ HS Phase 2 DMF93RQ SN Denufosol tetrasodium; DCp4U; INS 37217; INS37217; Up4dC; Denufosol tetrasodium (USAN); Uridine 5'-(pentahydrogen tetraphosphate), P'''-5'-ester with 2'-deoxycytidine, tetrasodium salt; Tetrasodium [[(3S,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate DMF93RQ CP Inspire Pharmaceuticals DMF93RQ DT Small molecular drug DMF93RQ PC 10219163 DMF93RQ MW 861.3 DMF93RQ FM C18H23N5Na4O21P4 DMF93RQ IC InChI=1S/C18H27N5O21P4.4Na/c19-11-1-3-22(17(28)20-11)13-5-8(24)9(40-13)6-38-45(30,31)42-47(34,35)44-48(36,37)43-46(32,33)39-7-10-14(26)15(27)16(41-10)23-4-2-12(25)21-18(23)29;;;;/h1-4,8-10,13-16,24,26-27H,5-7H2,(H,30,31)(H,32,33)(H,34,35)(H,36,37)(H2,19,20,28)(H,21,25,29);;;;/q;4*+1/p-4/t8-,9+,10+,13+,14+,15+,16+;;;;/m0..../s1 DMF93RQ CS C1[C@@H]([C@H](O[C@H]1N2C=CC(=NC2=O)N)COP(=O)([O-])OP(=O)([O-])OP(=O)([O-])OP(=O)([O-])OC[C@@H]3[C@H]([C@H]([C@@H](O3)N4C=CC(=O)NC4=O)O)O)O.[Na+].[Na+].[Na+].[Na+] DMF93RQ IK PASYJVRFGUDDEW-WMUGRWSXSA-J DMF93RQ IU tetrasodium;[[(2R,3S,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-3-hydroxyoxolan-2-yl]methoxy-oxidophosphoryl] [[[(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-oxidophosphoryl]oxy-oxidophosphoryl] phosphate DMF93RQ CA CAS 318250-11-2 DMF93RQ DE Cystic fibrosis DMKZUVC ID DMKZUVC DMKZUVC DN INS-50589 DMKZUVC HS Phase 2 DMKZUVC SN Regrelor; UNII-Q6C8TY6SW1; Q6C8TY6SW1; CHEMBL1162175; INS-50589; 787548-03-2; Regrelor [INN]; GTPL1770; DTXSID80229272; INS 50589; BDBM50371580; [(2S,3aR,4R,6R,6aR)-6-[6-(ethylcarbamoylamino)purin-9-yl]-2-[(E)-2-phenylethenyl]-3a,4,6,6a-tetrahydrofuro[4,3-d][1,3]dioxol-4-yl]methyl dihydrogen phosphate DMKZUVC CP Inspire Pharmaceuticals DMKZUVC DT Small molecular drug DMKZUVC PC 11273179 DMKZUVC MW 532.4 DMKZUVC FM C22H25N6O8P DMKZUVC IC InChI=1S/C22H25N6O8P/c1-2-23-22(29)27-19-16-20(25-11-24-19)28(12-26-16)21-18-17(14(34-21)10-33-37(30,31)32)35-15(36-18)9-8-13-6-4-3-5-7-13/h3-9,11-12,14-15,17-18,21H,2,10H2,1H3,(H2,30,31,32)(H2,23,24,25,27,29)/b9-8+/t14-,15+,17-,18-,21-/m1/s1 DMKZUVC CS CCNC(=O)NC1=C2C(=NC=N1)N(C=N2)[C@H]3[C@H]4[C@@H]([C@H](O3)COP(=O)(O)O)O[C@@H](O4)/C=C/C5=CC=CC=C5 DMKZUVC IK NXHAXEBZOXCDKD-XIXRRVGJSA-N DMKZUVC IU [(2S,3aR,4R,6R,6aR)-4-[6-(ethylcarbamoylamino)purin-9-yl]-2-[(E)-2-phenylethenyl]-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3]dioxol-6-yl]methyl dihydrogen phosphate DMKZUVC CA CAS 787548-03-2 DMKZUVC DE Cardiovascular disease DMNKAFQ ID DMNKAFQ DMNKAFQ DN Instiladrin DMNKAFQ HS Phase 2 DMNKAFQ CP Fkd therapies DMNKAFQ DE Bladder cancer DMYTKF5 ID DMYTKF5 DMYTKF5 DN Interferon DMYTKF5 HS Phase 2 DMYTKF5 CP Amarillo biosciences DMYTKF5 DE Human papillomavirus infection; Hepatitis C virus infection DMVACTU ID DMVACTU DMVACTU DN Interferon alpha-2b DMVACTU HS Phase 2 DMVACTU SN IFN-alpha-XL; IFN-alpha (Medusa), Flamel; Interferon alpha-2b (subcutaneous/controlled release, Medusa); Interferon alpha-2b (subcutaneous/controlled release, Medusa), Flamel DMVACTU CP Hanall biopharma; medtronic DMVACTU DE Hepatitis C virus infection DMQSA7H ID DMQSA7H DMQSA7H DN Interferon beta 1a DMQSA7H HS Phase 2 DMQSA7H SN Aerosolised interferon beta 1a; AZD-9412; Inhaled interferon beta 1a; SNG-001 DMQSA7H TC Respiratory Agents DMQSA7H DE Discovery agent DM8YF01 ID DM8YF01 DM8YF01 DN Interferon-alpha lozenge DM8YF01 HS Phase 2 DM8YF01 SN Veldona (TN) DM8YF01 CP Amarillo Biosciences DM8YF01 DE Fibromyalgia; Chronic obstructive pulmonary disease; Behcet disease DMBXEG9 ID DMBXEG9 DMBXEG9 DN Intetumumab DMBXEG9 HS Phase 2 DMBXEG9 CP Janssen Biotech DMBXEG9 DT Monoclonal antibody DMBXEG9 DE Prostate cancer DMSTJ6Q ID DMSTJ6Q DMSTJ6Q DN INX-189 DMSTJ6Q HS Phase 2 DMSTJ6Q SN INX-08032; INX-08189; INX-108; Nucleoside polymerase inhibitors (HCV infection), Cardiff University/Rega Institute; Nucleoside polymerase inhibitors (oral, HCV infection), Inhibitex DMSTJ6Q CP Cardiff University DMSTJ6Q DT Small molecular drug DMSTJ6Q PC 46700744 DMSTJ6Q MW 658.6 DMSTJ6Q FM C30H39N6O9P DMSTJ6Q IC InChI=1S/C30H39N6O9P/c1-17(26(38)42-15-29(2,3)4)35-46(40,45-20-13-9-11-18-10-7-8-12-19(18)20)43-14-21-23(37)30(5,39)27(44-21)36-16-32-22-24(36)33-28(31)34-25(22)41-6/h7-13,16-17,21,23,27,37,39H,14-15H2,1-6H3,(H,35,40)(H2,31,33,34)/t17-,21+,23+,27+,30+,46?/m0/s1 DMSTJ6Q CS C[C@@H](C(=O)OCC(C)(C)C)NP(=O)(OC[C@@H]1[C@H]([C@@]([C@@H](O1)N2C=NC3=C2N=C(N=C3OC)N)(C)O)O)OC4=CC=CC5=CC=CC=C54 DMSTJ6Q IK YFXGICNMLCGLHJ-RSKRLRQZSA-N DMSTJ6Q IU 2,2-dimethylpropyl (2S)-2-[[[(2R,3R,4R,5R)-5-(2-amino-6-methoxypurin-9-yl)-3,4-dihydroxy-4-methyloxolan-2-yl]methoxy-naphthalen-1-yloxyphosphoryl]amino]propanoate DMSTJ6Q CA CAS 1234490-83-5 DMSTJ6Q DE Hepatitis C virus infection DMNW0DG ID DMNW0DG DMNW0DG DN Iodine-131-tositumomab DMNW0DG HS Phase 2 DMNW0DG DT Antibody DM5F0QY ID DM5F0QY DM5F0QY DN IONIS-416858 DM5F0QY HS Phase 2 DM5F0QY SN IONIS-FXI-LRx DM5F0QY CP Ionis Pharmaceuticals DM5F0QY DT Antisense oligonucleotide DM5F0QY DE Thrombosis DM6PDX2 ID DM6PDX2 DM6PDX2 DN IONIS-C9Rx DM6PDX2 HS Phase 2 DM6PDX2 SN BIIB078 DM6PDX2 CP Ionis Pharmaceuticals DM6PDX2 DT Antisense oligonucleotide DM6PDX2 DE Amyotrophic lateral sclerosis DM5LM3O ID DM5LM3O DM5LM3O DN IONIS-DNM2-2.5Rx DM5LM3O HS Phase 2 DM5LM3O CP Ionis Pharmaceuticals DM5LM3O DT Antisense oligonucleotide DM5LM3O DE Centronuclear myopathy DMJ2763 ID DMJ2763 DMJ2763 DN IONIS-FB-LRx DMJ2763 HS Phase 2 DMJ2763 CP Ionis Pharmaceuticals DMJ2763 DT Antisense oligonucleotide DMJ2763 DE IgA nephropathy DMWV2N1 ID DMWV2N1 DMWV2N1 DN IONIS-GCCRRX DMWV2N1 HS Phase 2 DMWV2N1 CP onis Pharmaceuticals Carlsbad, CA DMWV2N1 DE Type-2 diabetes DMB4GD9 ID DMB4GD9 DMB4GD9 DN IONIS-GCGR-Rx DMB4GD9 HS Phase 2 DMB4GD9 CP Ionis Pharmaceuticals DMB4GD9 DT Antisense oligonucleotide DMB4GD9 DE Type-2 diabetes; Type 2 diabetes DMGTJUP ID DMGTJUP DMGTJUP DN IONIS-PTP1BRX DMGTJUP HS Phase 2 DMGTJUP CP onis Pharmaceuticals Carlsbad, CA DMGTJUP DE Type-2 diabetes DM7VJE1 ID DM7VJE1 DM7VJE1 DN IONIS-TMPRSS6-LRx DM7VJE1 HS Phase 2 DM7VJE1 CP Ionis Pharmaceuticals DM7VJE1 DT Antisense oligonucleotide DM7VJE1 DE Beta thalassemia DM5TMYC ID DM5TMYC DM5TMYC DN iOWH032 DM5TMYC HS Phase 2 DM5TMYC SN IOWH-032; CFTR inhibitors (diarrhea), BioFocus DM5TMYC CP The Institute for OneWorld Health DM5TMYC PC 135565181 DM5TMYC MW 545.2 DM5TMYC FM C22H15Br2N3O4 DM5TMYC IC InChI=1S/C22H15Br2N3O4/c23-17-10-14(11-18(24)19(17)28)20-26-22(31-27-20)21(29)25-12-13-6-8-16(9-7-13)30-15-4-2-1-3-5-15/h1-11,28H,12H2,(H,25,29) DM5TMYC CS C1=CC=C(C=C1)OC2=CC=C(C=C2)CNC(=O)C3=NC(=NO3)C4=CC(=C(C(=C4)Br)O)Br DM5TMYC IK DSFNLJXHXBIKDS-UHFFFAOYSA-N DM5TMYC IU 3-(3,5-dibromo-4-hydroxyphenyl)-N-[(4-phenoxyphenyl)methyl]-1,2,4-oxadiazole-5-carboxamide DM5TMYC CA CAS 1191252-49-9 DM5TMYC DE Diarrhea DMANRGW ID DMANRGW DMANRGW DN IP10 C8 DMANRGW HS Phase 2 DMANRGW SN IP10C8 DMANRGW DE Psoriasis vulgaris DMDUVCZ ID DMDUVCZ DMDUVCZ DN IPH-2101 DMDUVCZ HS Phase 2 DMDUVCZ CP Innate Pharma DMDUVCZ DE Multiple myeloma DMPBR0D ID DMPBR0D DMPBR0D DN IPH-2102 DMPBR0D HS Phase 2 DMPBR0D CP Innate Pharma SA DMPBR0D DE Acute myeloid leukaemia DMQH2SF ID DMQH2SF DMQH2SF DN IPH4102 DMQH2SF HS Phase 2 DMQH2SF CP Innate Pharma Marseille, France DMQH2SF DE T-cell lymphoma DMG5Q7F ID DMG5Q7F DMG5Q7F DN IPI-549 DMG5Q7F HS Phase 2 DMG5Q7F SN XUMALORDVCFWKV-IBGZPJMESA-N; IPI549; 1693758-51-8; CHEMBL3984425; GTPL9563; SCHEMBL16629991; IPI 549; MolPort-044-756-207; EX-A1057; s8330; BDBM50192880; ZINC584906867; AKOS030627132; CS-6106; compound 26 [PMID: 27660692]; AC-29898; HY-100716; Pyrazolo[1,5-a]pyrimidine-3-carboxamide, 2-amino-N-[(1S)-1-[1,2-dihydro-8-[2-(1-methyl-1H-pyrazol-4-yl)ethynyl]-1-oxo-2-phenyl-3-isoquinolinyl]ethyl]-; 2-amino-N-[(1S)-1-[8-[2-(1-methylpyrazol-4-yl)ethynyl]-1-oxo-2-phenylisoquinolin-3-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide; (S)-2-amino-N-(1-(8-(( DMG5Q7F CP Infinity Pharmaceuticals Cambridge, MA DMG5Q7F PC 91933883 DMG5Q7F MW 528.6 DMG5Q7F FM C30H24N8O2 DMG5Q7F IC InChI=1S/C30H24N8O2/c1-19(34-29(39)26-27(31)35-37-15-7-14-32-28(26)37)24-16-22-9-6-8-21(13-12-20-17-33-36(2)18-20)25(22)30(40)38(24)23-10-4-3-5-11-23/h3-11,14-19H,1-2H3,(H2,31,35)(H,34,39)/t19-/m0/s1 DMG5Q7F CS C[C@@H](C1=CC2=C(C(=CC=C2)C#CC3=CN(N=C3)C)C(=O)N1C4=CC=CC=C4)NC(=O)C5=C6N=CC=CN6N=C5N DMG5Q7F IK XUMALORDVCFWKV-IBGZPJMESA-N DMG5Q7F IU 2-amino-N-[(1S)-1-[8-[2-(1-methylpyrazol-4-yl)ethynyl]-1-oxo-2-phenylisoquinolin-3-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide DMG5Q7F CA CAS 1693758-51-8 DMG5Q7F DE Adrenocortical carcinoma; Breast cancer; Head and neck cancer; Melanoma; Mesothelioma; Solid tumour/cancer; Bladder cancer DMW2IF9 ID DMW2IF9 DMW2IF9 DN IR502 DMW2IF9 HS Phase 2 DMW2IF9 SN Zorcell DMW2IF9 CP Orchestra Therapeutics DMW2IF9 DE Psoriatic disorder; Plaque psoriasis; Psoriasis vulgaris DMQ3RWN ID DMQ3RWN DMQ3RWN DN Iralukast DMQ3RWN HS Phase 2 DMQ3RWN SN CGP-45715A DMQ3RWN CP Novartis AG DMQ3RWN DT Small molecular drug DMQ3RWN PC 6913104 DMQ3RWN MW 710.8 DMQ3RWN FM C38H37F3O8S DMQ3RWN IC InChI=1S/C38H37F3O8S/c1-3-11-29-31(18-17-27(23(2)42)36(29)45)48-19-9-7-5-4-6-8-14-34(35(44)24-12-10-13-25(20-24)38(39,40)41)50-26-15-16-28-30(43)22-33(37(46)47)49-32(28)21-26/h4,6,8,10,12-18,20-22,34-35,44-45H,3,5,7,9,11,19H2,1-2H3,(H,46,47)/b6-4-,14-8+/t34-,35+/m0/s1 DMQ3RWN CS CCCC1=C(C=CC(=C1O)C(=O)C)OCCCC/C=C\\C=C\\[C@@H]([C@@H](C2=CC(=CC=C2)C(F)(F)F)O)SC3=CC4=C(C=C3)C(=O)C=C(O4)C(=O)O DMQ3RWN IK IXJCHVMUTFCRBH-SDUHDBOFSA-N DMQ3RWN IU 7-[(1R,2S,3E,5Z)-10-(4-acetyl-3-hydroxy-2-propylphenoxy)-1-hydroxy-1-[3-(trifluoromethyl)phenyl]deca-3,5-dien-2-yl]sulfanyl-4-oxochromene-2-carboxylic acid DMQ3RWN CA CAS 151581-24-7 DMQ3RWN DE Asthma DMI874B ID DMI874B DMI874B DN Iratumumab DMI874B HS Phase 2 DMI874B SN MDX-060; Anti-CD30 antibody, Medarex; 5F11 DMI874B CP Medarex DMI874B DT Antibody DMI874B DE Lymphoma DMCAFVN ID DMCAFVN DMCAFVN DN IRT-102 DMCAFVN HS Phase 2 DMCAFVN CP Tni biotech DMCAFVN DT Small molecular drug DMCAFVN PC 42785 DMCAFVN MW 573.7 DMCAFVN FM C27H35N5O7S DMCAFVN IC InChI=1S/C27H35N5O7S/c1-40-12-11-21(27(38)39)32-26(37)22(14-17-5-3-2-4-6-17)31-24(35)16-29-23(34)15-30-25(36)20(28)13-18-7-9-19(33)10-8-18/h2-10,20-22,33H,11-16,28H2,1H3,(H,29,34)(H,30,36)(H,31,35)(H,32,37)(H,38,39) DMCAFVN CS CSCCC(C(=O)O)NC(=O)C(CC1=CC=CC=C1)NC(=O)CNC(=O)CNC(=O)C(CC2=CC=C(C=C2)O)N DMCAFVN IK YFGBQHOOROIVKG-UHFFFAOYSA-N DMCAFVN IU 2-[[2-[[2-[[2-[[2-amino-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylsulfanylbutanoic acid DMCAFVN CA CAS 58569-55-4 DMCAFVN DE Pancreatic cancer DMODLN7 ID DMODLN7 DMODLN7 DN IRX-2 DMODLN7 HS Phase 2 DMODLN7 CP IRX Therapeutics DMODLN7 DE Head and neck cancer; Acute myeloid leukaemia; Breast cancer; Squamous cell carcinoma; leukaemia DMHOJ8W ID DMHOJ8W DMHOJ8W DN Isatoribine DMHOJ8W HS Phase 2 DMHOJ8W SN 7-Thia-8-oxoguanosine; ANA245; 122970-40-5; UNII-2DNT962H92; ANA-245; 2DNT962H92; Immusine; Isatoribine [USAN:INN]; 7-TOG; Immunosine; Satoribine; N10146; 7-Deaza-7-thia-8-oxoguanosine; AC1L2HO7; SCHEMBL127980; AC1Q6N18; SCHEMBL12592999; CHEMBL2105116; ANA 245; TZYVRXZQAWPIAB-FCLHUMLKSA-N; ZINC8214713; 5-Amino-3-ribofuranosylthiazolo(4,5-d)pyrimidine-2,7(3H,6H)-dione; DB04860; 5-amino-3-(; A-d-ribofuranosyl)[1,3]thiazolo[4,5-d]pyrimidine-2,7(3h,4h)-dione; BRD-K87535339-001-01-6 DMHOJ8W CP Anadys Pharmaceuticals DMHOJ8W DT Small molecular drug DMHOJ8W PC 135409474 DMHOJ8W MW 316.29 DMHOJ8W FM C10H12N4O6S DMHOJ8W IC InChI=1S/C10H12N4O6S/c11-9-12-6-5(7(18)13-9)21-10(19)14(6)8-4(17)3(16)2(1-15)20-8/h2-4,8,15-17H,1H2,(H3,11,12,13,18)/t2-,3-,4-,8-/m1/s1 DMHOJ8W CS C([C@@H]1[C@H]([C@H]([C@@H](O1)N2C3=C(C(=O)NC(=N3)N)SC2=O)O)O)O DMHOJ8W IK TZYVRXZQAWPIAB-FCLHUMLKSA-N DMHOJ8W IU 5-amino-3-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6H-[1,3]thiazolo[4,5-d]pyrimidine-2,7-dione DMHOJ8W CA CAS 122970-40-5 DMHOJ8W DE Hepatitis C virus infection DMBZK3P ID DMBZK3P DMBZK3P DN ISF35 DMBZK3P HS Phase 2 DMBZK3P CP Memgen DMBZK3P DE Small lymphocytic lymphoma; Mantle cell lymphoma; Chronic lymphocytic leukaemia DMUPD4G ID DMUPD4G DMUPD4G DN ISIS 113715 DMUPD4G HS Phase 2 DMUPD4G CP ISIS DMUPD4G TC Antisense DMUPD4G DT Antisense drug DMUPD4G SQ GCTCCTTCCACTGATCCTGC DMUPD4G DE Type-2 diabetes DMQ3C05 ID DMQ3C05 DMQ3C05 DN ISIS-APO(a) DMQ3C05 HS Phase 2 DMQ3C05 DT Antisense drug DMQ3C05 DE Coronary artery disease DML84CN ID DML84CN DML84CN DN ISIS-CRPRx DML84CN HS Phase 2 DML84CN CP ISIS pharmaceuticals DML84CN DE Coronary artery disease DMRN543 ID DMRN543 DMRN543 DN ISIS-EIF4E DMRN543 HS Phase 2 DMRN543 CP ISIS Pharm DMRN543 DT Antisense drug DMRN543 DE Prostate cancer; Non-small-cell lung cancer; Solid tumour/cancer DMNVZDT ID DMNVZDT DMNVZDT DN ISIS-FGFR4 DMNVZDT HS Phase 2 DMNVZDT CP ISIS Pharm DMNVZDT DT Antisense drug DMNVZDT DE Obesity DMHETPI ID DMHETPI DMHETPI DN ISIS-FXI DMHETPI HS Phase 2 DMHETPI CP ISIS Pharm DMHETPI DT Antisense drug DMHETPI DE Coagulation defect DMICMNU ID DMICMNU DMICMNU DN ISIS-GCCR DMICMNU HS Phase 2 DMICMNU CP ISIS Pharm DMICMNU DT Antisense drug DMICMNU DE Diabetic complication; Type-2 diabetes DMHNYWP ID DMHNYWP DMHNYWP DN ISIS-GCGR DMHNYWP HS Phase 2 DMHNYWP CP ISIS Pharm DMHNYWP DT Antisense drug DMHNYWP DE Diabetic complication; Type-2 diabetes DM4RXDQ ID DM4RXDQ DM4RXDQ DN ISIS-HBV DM4RXDQ HS Phase 2 DM4RXDQ DT Antisense drug DM4RXDQ DE Hepatitis B virus infection DMJGVXT ID DMJGVXT DMJGVXT DN ISIS-PTP1Brx DMJGVXT HS Phase 2 DMJGVXT CP Isis Pharmaceuticals DMJGVXT DT Antisense drug DMJGVXT DE Type-2 diabetes DM2RS0V ID DM2RS0V DM2RS0V DN Isofagomine tartrate DM2RS0V HS Phase 2 DM2RS0V SN Plicera; Afegostat tartrate; AT-2101; HGT-3410; Plicera (TN); NN-42-1007 DM2RS0V CP Amicus Therape. DM2RS0V DT Small molecular drug DM2RS0V PC 23581846 DM2RS0V MW 297.26 DM2RS0V FM C10H19NO9 DM2RS0V IC InChI=1S/C6H13NO3.C4H6O6/c8-3-4-1-7-2-5(9)6(4)10;5-1(3(7)8)2(6)4(9)10/h4-10H,1-3H2;1-2,5-6H,(H,7,8)(H,9,10)/t4-,5-,6-;1-,2-/m11/s1 DM2RS0V CS C1[C@@H]([C@H]([C@@H](CN1)O)O)CO.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O DM2RS0V IK ULBPPCHRAVUQMC-MUMXBIPUSA-N DM2RS0V IU (2R,3R)-2,3-dihydroxybutanedioic acid;(3R,4R,5R)-5-(hydroxymethyl)piperidine-3,4-diol DM2RS0V CA CAS 919364-56-0 DM2RS0V DE Metabolic disorder DMP2BWX ID DMP2BWX DMP2BWX DN Ispinesib DMP2BWX HS Phase 2 DMP2BWX SN SB-715992; Ispinesib (SB-715992 /CK0238273); SB-715992, CK0238273,Ispinesib; N-(3-aminopropyl)-N-[(1R)-1-(3-benzyl-7-chloro-4-oxoquinazolin-2-yl)-2-methylpropyl]-4-methylbenzamide DMP2BWX CP Cytokinetics DMP2BWX TC Anticancer Agents DMP2BWX DT Small molecular drug DMP2BWX PC 6851740 DMP2BWX MW 517.1 DMP2BWX FM C30H33ClN4O2 DMP2BWX IC InChI=1S/C30H33ClN4O2/c1-20(2)27(34(17-7-16-32)29(36)23-12-10-21(3)11-13-23)28-33-26-18-24(31)14-15-25(26)30(37)35(28)19-22-8-5-4-6-9-22/h4-6,8-15,18,20,27H,7,16-17,19,32H2,1-3H3/t27-/m1/s1 DMP2BWX CS CC1=CC=C(C=C1)C(=O)N(CCCN)[C@@H](C2=NC3=C(C=CC(=C3)Cl)C(=O)N2CC4=CC=CC=C4)C(C)C DMP2BWX IK QJZRFPJCWMNVAV-HHHXNRCGSA-N DMP2BWX IU N-(3-aminopropyl)-N-[(1R)-1-(3-benzyl-7-chloro-4-oxoquinazolin-2-yl)-2-methylpropyl]-4-methylbenzamide DMP2BWX CA CAS 336113-53-2 DMP2BWX CB CHEBI:94692 DMP2BWX DE Solid tumour/cancer; Ovarian cancer; Renal cell carcinoma; Head and neck cancer DMCY9PO ID DMCY9PO DMCY9PO DN Itarnafloxin DMCY9PO HS Phase 2 DMCY9PO SN Quarfloxin; CX-3385; CX-3543; Quadruplex DNA oncogene inhibitor (cancer), Cylene; C-Myc/VEGF oncogene inhibitor (cancer), Cylene DMCY9PO CP Cylene Pharmaceuticals Inc DMCY9PO DT Small molecular drug DMCY9PO PC 11635763 DMCY9PO MW 604.7 DMCY9PO FM C35H33FN6O3 DMCY9PO IC InChI=1S/C35H33FN6O3/c1-40-13-4-7-24(40)8-10-39-35(44)26-20-42-29-15-21-5-2-3-6-22(21)16-30(29)45-34-31(42)25(33(26)43)17-27(36)32(34)41-14-9-23(19-41)28-18-37-11-12-38-28/h2-3,5-6,11-12,15-18,20,23-24H,4,7-10,13-14,19H2,1H3,(H,39,44)/t23?,24-/m0/s1 DMCY9PO CS CN1CCC[C@H]1CCNC(=O)C2=CN3C4=CC5=CC=CC=C5C=C4OC6=C3C(=CC(=C6N7CCC(C7)C8=NC=CN=C8)F)C2=O DMCY9PO IK WOQIDNWTQOYDLF-CGAIIQECSA-N DMCY9PO IU 15-fluoro-N-[2-[(2S)-1-methylpyrrolidin-2-yl]ethyl]-18-oxo-14-(3-pyrazin-2-ylpyrrolidin-1-yl)-12-oxa-1-azapentacyclo[11.7.1.02,11.04,9.017,21]henicosa-2,4,6,8,10,13(21),14,16,19-nonaene-19-carboxamide DMCY9PO CA CAS 865311-47-3 DMCY9PO DE leukaemia DMDZWPL ID DMDZWPL DMDZWPL DN ITCA-638 DMDZWPL HS Phase 2 DMDZWPL SN Omega DUROS, BioMedicines/ ALZA; Omega DUROS, Intarcia/ALZA; Omega IFN (sustained release), BioMedicines/ ALZA; Omega IFN (sustained release, hepatitis C), Intarcia/ALZA; Omega interferon (sustained release/subcutaneous/DUROS, hepatitis C), BioMedicines/ ALZA; Omega interferon (sustained release/subcutaneous/DUROS, hepatitis C), Intarcia/ALZA DMDZWPL CP Intarcia Therapeutics Inc DMDZWPL DE Hepatitis C virus infection DM5UFRO ID DM5UFRO DM5UFRO DN Itriglumide DM5UFRO HS Phase 2 DM5UFRO SN CR-2945 DM5UFRO CP Rottapharm Madaus DM5UFRO DT Small molecular drug DM5UFRO PC 6604121 DM5UFRO MW 526.7 DM5UFRO FM C33H38N2O4 DM5UFRO IC InChI=1S/C33H38N2O4/c1-22-18-23(2)31(28(19-22)32(39)35-16-14-33(15-17-35)12-5-6-13-33)34-29(36)20-25(21-30(37)38)27-11-7-9-24-8-3-4-10-26(24)27/h3-4,7-11,18-19,25H,5-6,12-17,20-21H2,1-2H3,(H,34,36)(H,37,38)/t25-/m1/s1 DM5UFRO CS CC1=CC(=C(C(=C1)C(=O)N2CCC3(CCCC3)CC2)NC(=O)C[C@H](CC(=O)O)C4=CC=CC5=CC=CC=C54)C DM5UFRO IK MFOOVZCXWVAWOV-RUZDIDTESA-N DM5UFRO IU (3R)-5-[2-(8-azaspiro[4.5]decane-8-carbonyl)-4,6-dimethylanilino]-3-naphthalen-1-yl-5-oxopentanoic acid DM5UFRO CA CAS 201605-51-8 DM5UFRO DE Anxiety disorder DMCJX79 ID DMCJX79 DMCJX79 DN ITV-1 DMCJX79 HS Phase 2 DMCJX79 CP Immunotech Laboratories DMCJX79 DT Vaccine DMCJX79 DE Human immunodeficiency virus infection DMJV3AX ID DMJV3AX DMJV3AX DN IVA337 DMJV3AX HS Phase 2 DMJV3AX SN Lanifibranor; 927961-18-0; IVA-337; UNII-28Q8AG0PYL; 28Q8AG0PYL; CHEMBL4091374; CPD1537; 4-(1-(1,3-Benzothiazol-6-ylsulfonyl)-5-chloro-indol-2-yl)butanoic acid; 1H-Indole-2-butanoic acid, 1-(6-benzothiazolylsulfonyl)-5-chloro-; 4-[1-(1,3-benzothiazol-6-ylsulfonyl)-5-chloro-indol-2-yl]butanoic acid; 4-[1-(1,3-benzothiazol-6-ylsulfonyl)-5-chloroindol-2-yl]butanoic acid; Lanifbranor; Libfranor; Lanifbranor [INN]; Lanifibranor(IVA-337); SCHEMBL3528615; AMY16813; EX-A1511; BDBM50244350; s8770; DB14801; SB18746; AC-31451; AK689102; BS-17993; HY-104049; CS-0027586; Q27896056; 1-(6-Benzothiazolylsulfonyl)-5-chloro-1H-indole-2-butanoic Acid; 5-Chloro-1-((6-benzothiazolyl)sulfonyl)-1H-indole-2-butanoic acid; 4-(1-(benzo[d]thiazol-6-ylsulfonyl)-5-chloro-1H-indol-2-yl)butanoic acid; BJB DMJV3AX DT Small molecular drug DMJV3AX PC 68677842 DMJV3AX MW 434.9 DMJV3AX FM C19H15ClN2O4S2 DMJV3AX IC InChI=1S/C19H15ClN2O4S2/c20-13-4-7-17-12(8-13)9-14(2-1-3-19(23)24)22(17)28(25,26)15-5-6-16-18(10-15)27-11-21-16/h4-11H,1-3H2,(H,23,24) DMJV3AX CS C1=CC2=C(C=C1S(=O)(=O)N3C4=C(C=C(C=C4)Cl)C=C3CCCC(=O)O)SC=N2 DMJV3AX IK OQDQIFQRNZIEEJ-UHFFFAOYSA-N DMJV3AX IU 4-[1-(1,3-benzothiazol-6-ylsulfonyl)-5-chloroindol-2-yl]butanoic acid DMJV3AX CA CAS 927961-18-0 DMJV3AX DE Non-alcoholic steatohepatitis DM0OYLQ ID DM0OYLQ DM0OYLQ DN I-vation DM0OYLQ HS Phase 2 DM0OYLQ SN Triamcinolone implant DM0OYLQ CP SurModics DM0OYLQ DE Diabetic retinopathy DM457XO ID DM457XO DM457XO DN IW-1701 DM457XO HS Phase 2 DM457XO SN Olinciguat; 1628732-62-6; UNII-PD5F4ZXD21; PD5F4ZXD21; IW1701; 5-(1,2-oxazol-3-yl)-1H-pyrazol-; 3-yl}pyrimidin-4-yl)amino]methyl}-2-hydroxypropanamide; (2R)-3,3,3-trifluoro-2-{[(5-fluoro-2-{1-[(2-fluorophenyl)methyl]-; Olinciguat [INN]; Olinciguat [USAN]; Olinciguat (USAN/INN); Olinciguat [USAN:INN]; CHEMBL4297616; SCHEMBL16081945; GTPL10213; BDBM321744; DB15238; US10183021, Compound I-531; AC-31551; HY-109066; CS-0033431; D11475; (2~{R})-3,3,3-trifluoro-2-[[[5-fluoro-2-[1-[(2-fluorophenyl)methyl]-5-(1,2-oxazol-3-yl)pyrazol-3-yl]pyrimidin-4-yl]amino]methyl]-2-hydroxypropanamide; (2R)-3,3,3-trifluoro-2-[[[5-fluoro-2-[1-[(2-fluorophenyl)methyl]-5-(1,2-oxazol-3-yl)pyrazol-3-yl]pyrimidin-4-yl]amino]methyl]-2-hydroxypropanamide DM457XO CP Cyclerion Therapeutics DM457XO DT Small molecular drug DM457XO PC 90445883 DM457XO MW 509.4 DM457XO FM C21H16F5N7O3 DM457XO IC InChI=1S/C21H16F5N7O3/c22-12-4-2-1-3-11(12)9-33-16(14-5-6-36-32-14)7-15(31-33)18-28-8-13(23)17(30-18)29-10-20(35,19(27)34)21(24,25)26/h1-8,35H,9-10H2,(H2,27,34)(H,28,29,30)/t20-/m1/s1 DM457XO CS C1=CC=C(C(=C1)CN2C(=CC(=N2)C3=NC=C(C(=N3)NC[C@@](C(=O)N)(C(F)(F)F)O)F)C4=NOC=C4)F DM457XO IK YWQFJNWMWZMXRW-HXUWFJFHSA-N DM457XO IU (2R)-3,3,3-trifluoro-2-[[[5-fluoro-2-[1-[(2-fluorophenyl)methyl]-5-(1,2-oxazol-3-yl)pyrazol-3-yl]pyrimidin-4-yl]amino]methyl]-2-hydroxypropanamide DM457XO CA CAS 1628732-62-6 DM457XO DE Sickle-cell disorder DMK2T7J ID DMK2T7J DMK2T7J DN IW-1973 DMK2T7J HS Phase 2 DMK2T7J SN Praliciguat; UNII-R1S0H458SA; R1S0H458SA; 1628730-49-3; Praliciguat [INN]; GTPL9900; SCHEMBL16082414; IW1973; 1,1,1-trifluoro-3-[(5-fluoro-2-{1-[(2-fluorophenyl)methyl]-5-(1,2-oxazol-3-yl)-1H-pyrazol-3-yl}pyrimidin-4-yl)amino]-2-(trifluoromethyl)propan-2-ol; 2-Propanol, 1,1,1,3,3,3-hexafluoro-2-(((5-fluoro-2-(1-((2-fluorophenyl)methyl)-5-(3-isoxazolyl)-1H-pyrazol-3-yl)-4-pyrimidinyl)amino)methyl)- DMK2T7J CP Ironwood Pharmaceuticals Cambridge, MA DMK2T7J PC 86269973 DMK2T7J MW 534.4 DMK2T7J FM C21H14F8N6O2 DMK2T7J IC InChI=1S/C21H14F8N6O2/c22-12-4-2-1-3-11(12)9-35-16(14-5-6-37-34-14)7-15(33-35)18-30-8-13(23)17(32-18)31-10-19(36,20(24,25)26)21(27,28)29/h1-8,36H,9-10H2,(H,30,31,32) DMK2T7J CS C1=CC=C(C(=C1)CN2C(=CC(=N2)C3=NC=C(C(=N3)NCC(C(F)(F)F)(C(F)(F)F)O)F)C4=NOC=C4)F DMK2T7J IK CYSJNTQNMDWAJV-UHFFFAOYSA-N DMK2T7J IU 1,1,1,3,3,3-hexafluoro-2-[[[5-fluoro-2-[1-[(2-fluorophenyl)methyl]-5-(1,2-oxazol-3-yl)pyrazol-3-yl]pyrimidin-4-yl]amino]methyl]propan-2-ol DMK2T7J CA CAS 1628730-49-3 DMK2T7J CB CHEBI:142431 DMK2T7J DE Heart failure DMP42W1 ID DMP42W1 DMP42W1 DN IW-6118 DMP42W1 HS Phase 2 DMP42W1 CP Ironwood Pharmaceuticals Inc DMP42W1 DE Inflammation DM3WSDR ID DM3WSDR DM3WSDR DN IXT-m200 DM3WSDR HS Phase 2 DM3WSDR CP InterveXion Therapeutics DM3WSDR DT Antibody DM3WSDR DE Methamphetamine use disorder DM9XKJU ID DM9XKJU DM9XKJU DN J 591 Lu-177 DM9XKJU HS Phase 2 DM9XKJU CP BZL Biologics DM9XKJU DE Prostate cancer DMKU6MW ID DMKU6MW DMKU6MW DN JB991 DMKU6MW HS Phase 2 DMKU6MW CP Synphora DMKU6MW DE Sarcoidosis; Skin infection DM89ASO ID DM89ASO DM89ASO DN JCAR015 DM89ASO HS Phase 2 DM89ASO CP Juno Therapeutics, Inc. DM89ASO DT CAR T Cell Therapy DM89ASO DE B-cell lymphoma; Acute lymphoblastic leukaemia DMM02VJ ID DMM02VJ DMM02VJ DN JI-101 DMM02VJ HS Phase 2 DMM02VJ SN JI-101; 900573-88-8; CGI-1842; UNII-980M4N37DH; 980M4N37DH; 1-(1-((2-AMINOPYRIDIN-4-YL)METHYL)-1H-INDOL-4-YL)-3-(5-BROMO-2-METHOXYPHENYL)UREA; SCHEMBL5585996; CHEMBL3545155; MolPort-044-567-620; BCP16892; EX-A2371; JI 101; ZINC38255464; AKOS030526978; SB16904; DB12744; CS-5636; Urea, N-(1-((2-amino-4-pyridinyl)methyl)-1H-indol-4-yl)-N'-(5-bromo-2-methoxyphenyl)-; KB-77988; HY-16265 DMM02VJ CP Jubilant Biosys DMM02VJ DT Small molecular drug DMM02VJ PC 11691242 DMM02VJ MW 466.3 DMM02VJ FM C22H20BrN5O2 DMM02VJ IC InChI=1S/C22H20BrN5O2/c1-30-20-6-5-15(23)12-18(20)27-22(29)26-17-3-2-4-19-16(17)8-10-28(19)13-14-7-9-25-21(24)11-14/h2-12H,13H2,1H3,(H2,24,25)(H2,26,27,29) DMM02VJ CS COC1=C(C=C(C=C1)Br)NC(=O)NC2=C3C=CN(C3=CC=C2)CC4=CC(=NC=C4)N DMM02VJ IK ZXBFYBLSJMEBEP-UHFFFAOYSA-N DMM02VJ IU 1-[1-[(2-aminopyridin-4-yl)methyl]indol-4-yl]-3-(5-bromo-2-methoxyphenyl)urea DMM02VJ CA CAS 900573-88-8 DMM02VJ DE Solid tumour/cancer DMARQ0H ID DMARQ0H DMARQ0H DN JKB-122 DMARQ0H HS Phase 2 DMARQ0H SN Opioid receptor modulator (liver disease), Jenken Bioscience DMARQ0H CP Jenken Biosciences DMARQ0H DE Hepatitis virus infection DMJSVRL ID DMJSVRL DMJSVRL DN JM216 DMJSVRL HS Phase 2 DMJSVRL SN 129580-63-8; JM 216; satraplatin(jm216); Satraplatin (USAN/INN); C081294; YHI-601; C6H13N.C4H6Cl2O4Pt.H3N; Platinum, bis(acetato-O)amminedichloro(cyclohexanamine)-, (OC-6-43)-; 4023AH; AKOS015914237; BMS-182751; BC679462; FT-0601550; D05807; Bis(acetato-O)amminedichloro(cyclohexanamine)-pt; 580S638; I14-43013; Platinum (lV) cis-dichloro-trans-bis(acetato-O)ammine(cyclohexanamine) DMJSVRL DT Small molecular drug DMJSVRL PC 6918220 DMJSVRL MW 502.3 DMJSVRL FM C10H24Cl2N2O4Pt DMJSVRL IC InChI=1S/C6H13N.2C2H4O2.2ClH.H3N.Pt/c7-6-4-2-1-3-5-6;2*1-2(3)4;;;;/h6H,1-5,7H2;2*1H3,(H,3,4);2*1H;1H3;/q;;;;;;+2/p-2 DMJSVRL CS CC(=O)O.CC(=O)O.C1CCC(CC1)N.N.Cl[Pt]Cl DMJSVRL IK TWEQNPPRXJRHHM-UHFFFAOYSA-L DMJSVRL IU acetic acid;azane;cyclohexanamine;dichloroplatinum DMJSVRL DE Solid tumour/cancer DMBXWJ5 ID DMBXWJ5 DMBXWJ5 DN JNJ 63723283 DMBXWJ5 HS Phase 2 DMBXWJ5 CP Janssen Research & Development Raritan, NJ DMBXWJ5 DT Monoclonal antibody DMBXWJ5 DE Solid tumour/cancer; Multiple myeloma; Prostate cancer; Ulcerative colitis DMY7Q3I ID DMY7Q3I DMY7Q3I DN JNJ-10229570 DMY7Q3I HS Phase 2 DMY7Q3I SN JNJ-10229570-AAA; MC5R antagonist (topical, acne), Johnson & Johnson; Melanocortin-5 receptor antagonist (topical, acne), Johnson & Johnson DMY7Q3I CP Johnson & Johnson DMY7Q3I PC 10110895 DMY7Q3I MW 389.5 DMY7Q3I FM C22H19N3O2S DMY7Q3I IC InChI=1S/C22H19N3O2S/c1-26-19-14-8-6-12-17(19)21-24-22(23-16-10-4-3-5-11-16)28-25(21)18-13-7-9-15-20(18)27-2/h3-15H,1-2H3 DMY7Q3I CS COC1=CC=CC=C1C2=NC(=NC3=CC=CC=C3)SN2C4=CC=CC=C4OC DMY7Q3I IK XTHRTBCPBWJYRO-UHFFFAOYSA-N DMY7Q3I IU 2,3-bis(2-methoxyphenyl)-N-phenyl-1,2,4-thiadiazol-5-imine DMY7Q3I CA CAS 524923-88-4 DMY7Q3I DE Acne vulgaris DM7OTQS ID DM7OTQS DM7OTQS DN JNJ-10311795 DM7OTQS HS Phase 2 DM7OTQS SN JNJ-10311795; CHEMBL374027; 518062-14-1; SCHEMBL1260969; GTPL6563; BDBM50208224; Phosphonic acid, (2-(3-((methyl(1-(2-naphthalenylcarbonyl)-4-piperidinyl)amino)carbonyl)-2-naphthalenyl)-1-(1-naphthalenyl)-2-oxoethyl)-; Phosphonic acid, P-(2-(3-((methyl(1-(2-naphthalenylcarbonyl)-4-piperidinyl)amino)carbonyl)-2-naphthalenyl)-1-(1-naphthalenyl)-2-oxoethyl)-; [2-[3-[methyl-[1-(naphthalene-2-carbonyl)piperidin-4-yl]carbamoyl]naphthalen-2-yl]-1-naphthalen-1-yl-2-oxoethyl]phosphonic acid DM7OTQS DT Small molecular drug DM7OTQS PC 10146470 DM7OTQS MW 670.7 DM7OTQS FM C40H35N2O6P DM7OTQS IC InChI=1S/C40H35N2O6P/c1-41(32-19-21-42(22-20-32)39(44)31-18-17-26-9-2-3-11-28(26)23-31)40(45)36-25-30-13-5-4-12-29(30)24-35(36)37(43)38(49(46,47)48)34-16-8-14-27-10-6-7-15-33(27)34/h2-18,23-25,32,38H,19-22H2,1H3,(H2,46,47,48) DM7OTQS CS CN(C1CCN(CC1)C(=O)C2=CC3=CC=CC=C3C=C2)C(=O)C4=CC5=CC=CC=C5C=C4C(=O)C(C6=CC=CC7=CC=CC=C76)P(=O)(O)O DM7OTQS IK XUJQPDQURBZEGJ-UHFFFAOYSA-N DM7OTQS IU [2-[3-[methyl-[1-(naphthalene-2-carbonyl)piperidin-4-yl]carbamoyl]naphthalen-2-yl]-1-naphthalen-1-yl-2-oxoethyl]phosphonic acid DM7OTQS CA CAS 518062-14-1 DM7OTQS DE Chronic obstructive pulmonary disease DMPFG7H ID DMPFG7H DMPFG7H DN JNJ-16269110 DMPFG7H HS Phase 2 DMPFG7H SN SCHEMBL803531; CHEMBL2103860 DMPFG7H CP Janssen Research & Development DMPFG7H DT Small molecular drug DMPFG7H PC 56842069 DMPFG7H MW 572.6 DMPFG7H FM C34H31F3N2O3 DMPFG7H IC InChI=1S/C34H31F3N2O3/c1-42-33(41)31(26-7-3-2-4-8-26)39-21-19-24(20-22-39)23-13-17-28(18-14-23)38-32(40)30-10-6-5-9-29(30)25-11-15-27(16-12-25)34(35,36)37/h2-18,24,31H,19-22H2,1H3,(H,38,40)/t31-/m1/s1 DMPFG7H CS COC(=O)[C@@H](C1=CC=CC=C1)N2CCC(CC2)C3=CC=C(C=C3)NC(=O)C4=CC=CC=C4C5=CC=C(C=C5)C(F)(F)F DMPFG7H IK WSYALRNYQFNNGP-WJOKGBTCSA-N DMPFG7H IU methyl (2R)-2-phenyl-2-[4-[4-[[2-[4-(trifluoromethyl)phenyl]benzoyl]amino]phenyl]piperidin-1-yl]acetate DMPFG7H CA CAS 403989-79-7 DMPFG7H DE Type-2 diabetes DM1GRCU ID DM1GRCU DM1GRCU DN JNJ-17216498 DM1GRCU HS Phase 2 DM1GRCU SN Histamine H3 antagonist (oral, narcolepsy) J&J DM1GRCU CP Johnson & Johnson DM1GRCU DE Narcolepsy DMV1T59 ID DMV1T59 DMV1T59 DN JNJ-18038683 DMV1T59 HS Phase 2 DMV1T59 SN Serotonin 7 antagonist (depression), Johnson & Johnson; 5-HT 7 antagonist (depression), Johnson & Johnson DMV1T59 CP Johnson & Johnson DMV1T59 DT Small molecular drug DMV1T59 PC 11151899 DMV1T59 MW 337.8 DMV1T59 FM C20H20ClN3 DMV1T59 IC InChI=1S/C20H20ClN3/c21-17-8-6-16(7-9-17)20-18-10-12-22-13-11-19(18)24(23-20)14-15-4-2-1-3-5-15/h1-9,22H,10-14H2 DMV1T59 CS C1CNCCC2=C1C(=NN2CC3=CC=CC=C3)C4=CC=C(C=C4)Cl DMV1T59 IK UKJPMZGILXATGT-UHFFFAOYSA-N DMV1T59 IU 1-benzyl-3-(4-chlorophenyl)-5,6,7,8-tetrahydro-4H-pyrazolo[3,4-d]azepine DMV1T59 CA CAS 851373-91-6 DMV1T59 DE Major depressive disorder DMKIE9C ID DMKIE9C DMKIE9C DN JNJ-26481585 DMKIE9C HS Phase 2 DMKIE9C SN 875320-29-9; N-Hydroxy-2-(4-((((1-methyl-1H-indol-3-yl)methyl)amino)methyl)piperidin-1-yl)pyrimidine-5-carboxamide; UNII-9BJ85K1J8S; Quisinostat (JNJ-26481585); JNJ26481585; 9BJ85K1J8S; N-hydroxy-2-[4-[[(1-methylindol-3-yl)methylamino]methyl]piperidin-1-yl]pyrimidine-5-carboxamide; 2-[4-[[(1-methylindol-3-yl)methylamino]methyl]piperidin-1-yl]-~{N}-oxidanyl-pyrimidine-5-carboxamide; N-Hydroxy-2-(4-((((1-methyl-1H-indol-3-yl)methyl)amino)-methyl)piperidin-1-yl)pyrimidine-5-carboxamide DMKIE9C CP Janssen Research & Development DMKIE9C DT Small molecular drug DMKIE9C PC 11538455 DMKIE9C MW 394.5 DMKIE9C FM C21H26N6O2 DMKIE9C IC InChI=1S/C21H26N6O2/c1-26-14-17(18-4-2-3-5-19(18)26)11-22-10-15-6-8-27(9-7-15)21-23-12-16(13-24-21)20(28)25-29/h2-5,12-15,22,29H,6-11H2,1H3,(H,25,28) DMKIE9C CS CN1C=C(C2=CC=CC=C21)CNCC3CCN(CC3)C4=NC=C(C=N4)C(=O)NO DMKIE9C IK PAWIYAYFNXQGAP-UHFFFAOYSA-N DMKIE9C IU N-hydroxy-2-[4-[[(1-methylindol-3-yl)methylamino]methyl]piperidin-1-yl]pyrimidine-5-carboxamide DMKIE9C CA CAS 875320-29-9 DMKIE9C CB CHEBI:94771 DMKIE9C DE Advanced stage follicular lymphoma; Solid tumour/cancer DMQD1GN ID DMQD1GN DMQD1GN DN JNJ-32729463 DMQD1GN HS Phase 2 DMQD1GN SN Acorafloxacin HCl; Avarofloxacin hydrochloride; Acorafloxacin hydrochloride; UNII-1NWW5SKQ0N; JNJ-32729463-AAC; 1NWW5SKQ0N; Acorafloxacin hydrochloride [USAN]; 1001162-01-1 (HCl); Acorafloxacin hydrochloride (USAN); Avarofloxacin HCl; 1001162-01-1; (E)-7-(3-(2-amino-1-fluoroethylidene)piperidin-1-yl)-1-cyclopropyl-6-fluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid hydrochloride; JNJ-Q2 hydrochloride; SCHEMBL2190495; CHEMBL2364603; DTXSID70142966; JNJ-32729463AAC; Jnj-32729463; 7-((3E)-3-(2-Amino-1-fluoroethylidene)-1-piperidinyl)-1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid hydrochloride; D10544; Q27252661 DMQD1GN DT Small molecular drug DMQD1GN PC 67311433 DMQD1GN MW 455.9 DMQD1GN FM C21H24ClF2N3O4 DMQD1GN IC InChI=1S/C21H23F2N3O4.ClH/c1-30-20-17-13(19(27)14(21(28)29)10-26(17)12-4-5-12)7-15(22)18(20)25-6-2-3-11(9-25)16(23)8-24;/h7,10,12H,2-6,8-9,24H2,1H3,(H,28,29);1H/b16-11+; DMQD1GN CS COC1=C2C(=CC(=C1N3CCC/C(=C(/CN)\\F)/C3)F)C(=O)C(=CN2C4CC4)C(=O)O.Cl DMQD1GN IK RDXCNSOGHLLWDV-YFMOEUEHSA-N DMQD1GN IU 7-[(3E)-3-(2-amino-1-fluoroethylidene)piperidin-1-yl]-1-cyclopropyl-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid;hydrochloride DMQD1GN CA CAS 1001162-01-1 DMQD1GN DE Community-acquired pneumonia DMV41P5 ID DMV41P5 DMV41P5 DN JNJ-37822681 DMV41P5 HS Phase 2 DMV41P5 SN UNII-GJB2URS7NJ; JNJ-37822681; GJB2URS7NJ; CHEMBL3234237; 935776-74-2; SCHEMBL1022639; MolPort-039-267-898; BDBM50003063; ZINC34951380; DB12579; 3-Pyridazinamine, N-(1-((3,4-difluorophenyl)methyl)-4-piperidinyl)-6-(trifluoromethyl)-; NCGC00386644-01; Z1558691527 DMV41P5 CP Johnson & Johnson Pharmaceutical Research & Development DMV41P5 DT Small molecular drug DMV41P5 PC 16058752 DMV41P5 MW 372.34 DMV41P5 FM C17H17F5N4 DMV41P5 IC InChI=1S/C17H17F5N4/c18-13-2-1-11(9-14(13)19)10-26-7-5-12(6-8-26)23-16-4-3-15(24-25-16)17(20,21)22/h1-4,9,12H,5-8,10H2,(H,23,25) DMV41P5 CS C1CN(CCC1NC2=NN=C(C=C2)C(F)(F)F)CC3=CC(=C(C=C3)F)F DMV41P5 IK UVUYWJWYRLJHEN-UHFFFAOYSA-N DMV41P5 IU N-[1-[(3,4-difluorophenyl)methyl]piperidin-4-yl]-6-(trifluoromethyl)pyridazin-3-amine DMV41P5 CA CAS 935776-74-2 DMV41P5 DE Schizophrenia DM9UMIO ID DM9UMIO DM9UMIO DN JNJ-38518168 DM9UMIO HS Phase 2 DM9UMIO CP Janssen research & development DM9UMIO PC 23650961 DM9UMIO MW 392.5 DM9UMIO FM C23H32N6 DM9UMIO IC InChI=1S/C23H32N6/c1-15-12-16(2)21-20(13-15)27-22(28-21)19-14-25-23(26-17(19)3)24-9-5-6-18-7-10-29(4)11-8-18/h12-14,18H,5-11H2,1-4H3,(H,27,28)(H,24,25,26) DM9UMIO CS CC1=CC(=C2C(=C1)NC(=N2)C3=CN=C(N=C3C)NCCCC4CCN(CC4)C)C DM9UMIO IK FCRFVPZAXGJLPW-UHFFFAOYSA-N DM9UMIO IU 5-(4,6-dimethyl-1H-benzimidazol-2-yl)-4-methyl-N-[3-(1-methylpiperidin-4-yl)propyl]pyrimidin-2-amine DM9UMIO CA CAS 952494-46-1 DM9UMIO DE Rheumatoid arthritis; Plaque psoriasis DM0WY3H ID DM0WY3H DM0WY3H DN JNJ-39220675 DM0WY3H HS Phase 2 DM0WY3H SN Histamine H3 receptor antagonist (allergic rhinitis/alcoholism), Johnson & Johnson DM0WY3H CP Johnson & Johnson Pharmaceutical Research & Development LLC DM0WY3H DT Small molecular drug DM0WY3H PC 24771368 DM0WY3H MW 369.4 DM0WY3H FM C21H24FN3O2 DM0WY3H IC InChI=1S/C21H24FN3O2/c22-17-6-8-19(9-7-17)27-20-10-5-16(15-23-20)21(26)25-12-2-11-24(13-14-25)18-3-1-4-18/h5-10,15,18H,1-4,11-14H2 DM0WY3H CS C1CC(C1)N2CCCN(CC2)C(=O)C3=CN=C(C=C3)OC4=CC=C(C=C4)F DM0WY3H IK IQOWHZHNGJXGHG-UHFFFAOYSA-N DM0WY3H IU (4-cyclobutyl-1,4-diazepan-1-yl)-[6-(4-fluorophenoxy)pyridin-3-yl]methanone DM0WY3H CA CAS 959740-39-7 DM0WY3H DE Alcohol dependence DMUOEKM ID DMUOEKM DMUOEKM DN JNJ-39393406 DMUOEKM HS Phase 2 DMUOEKM SN JNJ-39393406; UNII-T930SOU82P; T930SOU82P; JNJ 39393406; 953428-73-4; SCHEMBL827762; CHEMBL3545291; DB11867; 1H-1,2,4-Triazole-1-propanamide, 3-((2,2-difluoro-1,3-benzodioxol-5-yl)amino)-N,N-dimethyl-5-(4-pyridinyl)- DMUOEKM CP Janssen Pharmaceutica NV DMUOEKM DT Small molecular drug DMUOEKM PC 16755766 DMUOEKM MW 416.4 DMUOEKM FM C19H18F2N6O3 DMUOEKM IC InChI=1S/C19H18F2N6O3/c1-26(2)16(28)7-10-27-17(12-5-8-22-9-6-12)24-18(25-27)23-13-3-4-14-15(11-13)30-19(20,21)29-14/h3-6,8-9,11H,7,10H2,1-2H3,(H,23,25) DMUOEKM CS CN(C)C(=O)CCN1C(=NC(=N1)NC2=CC3=C(C=C2)OC(O3)(F)F)C4=CC=NC=C4 DMUOEKM IK IURMHZBQEYNQOH-UHFFFAOYSA-N DMUOEKM IU 3-[3-[(2,2-difluoro-1,3-benzodioxol-5-yl)amino]-5-pyridin-4-yl-1,2,4-triazol-1-yl]-N,N-dimethylpropanamide DMUOEKM CA CAS 953428-73-4 DMUOEKM DE Cognitive impairment; Depression; Tobacco dependence DM219SF ID DM219SF DM219SF DN JNJ-40346527 DM219SF HS Phase 2 DM219SF CP Janssen Research & Development DM219SF PC 25230468 DM219SF MW 461.6 DM219SF FM C27H35N5O2 DM219SF IC InChI=1S/C27H35N5O2/c1-25(2)11-9-17(10-12-25)22-21(32-24(33)23-29-16-19(15-28)30-23)8-7-20(31-22)18-13-26(3,4)34-27(5,6)14-18/h7-9,16,18H,10-14H2,1-6H3,(H,29,30)(H,32,33) DM219SF CS CC1(CCC(=CC1)C2=C(C=CC(=N2)C3CC(OC(C3)(C)C)(C)C)NC(=O)C4=NC=C(N4)C#N)C DM219SF IK BNVPFDRNGHMRJS-UHFFFAOYSA-N DM219SF IU 5-cyano-N-[2-(4,4-dimethylcyclohexen-1-yl)-6-(2,2,6,6-tetramethyloxan-4-yl)pyridin-3-yl]-1H-imidazole-2-carboxamide DM219SF CA CAS 1142363-52-7 DM219SF DE Hodgkin lymphoma DM72GZO ID DM72GZO DM72GZO DN JNJ-42165279 DM72GZO HS Phase 2 DM72GZO CP Janssen research & development DM72GZO PC 54576693 DM72GZO MW 410.8 DM72GZO FM C18H17ClF2N4O3 DM72GZO IC InChI=1S/C18H17ClF2N4O3/c19-13-3-4-22-10-14(13)23-17(26)25-7-5-24(6-8-25)11-12-1-2-15-16(9-12)28-18(20,21)27-15/h1-4,9-10H,5-8,11H2,(H,23,26) DM72GZO CS C1CN(CCN1CC2=CC3=C(C=C2)OC(O3)(F)F)C(=O)NC4=C(C=CN=C4)Cl DM72GZO IK YWGYNGCRVZLMCS-UHFFFAOYSA-N DM72GZO IU N-(4-chloropyridin-3-yl)-4-[(2,2-difluoro-1,3-benzodioxol-5-yl)methyl]piperazine-1-carboxamide DM72GZO CA CAS 1346528-50-4 DM72GZO DE Anxiety disorder; Social anxiety disorder DMJ1FXL ID DMJ1FXL DMJ1FXL DN JNJ-53718678 DMJ1FXL HS Phase 2 DMJ1FXL SN Rilematovir; JNJ-678; UNII-NQ99E8OH3P; NQ99E8OH3P; 1383450-81-4; 3-((5-chloro-1-(3-(methylsulfonyl)propyl)-1H-indol-2-yl)methyl)-1-(2,2,2-trifluoroethyl)-1,3-dihydro-2H-imidazo[4,5-c]pyridin-2-one; 3-[[5-Chloranyl-1-(3-Methylsulfonylpropyl)indol-2-Yl]methyl]-1-[2,2,2-Tris(Fluoranyl)ethyl]imidazo[4,5-C]pyridin-2-One; Rilematovir [INN]; CHEMBL4437054; SCHEMBL17529353; HY-112180; CS-0043622; C(CCN1C(=CC2=CC(=CC=C12)Cl)CN1C2=C(N(C1=O)CC(F)(F)F)C=CN=C2)S(=O)(=O)C; 2H-Imidazo(4,5-C)pyridin-2-one, 3-((5-chloro-1-(3-(methylsulfonyl)propyl)-1H-indol-2-yl)methyl)-1,3-dihydro-1-(2,2,2-trifluoroethyl)-; 3-((5-Chloro-1-(3-methylsulfonylpropyl)indol-2-yl)methyl)-1-(2,2,2-trifluoroethyl)imidazo(4,5-C)pyridin-2-one; 6YA DMJ1FXL CP Janssen DMJ1FXL DT Small molecular drug DMJ1FXL PC 118892432 DMJ1FXL MW 500.9 DMJ1FXL FM C21H20ClF3N4O3S DMJ1FXL IC InChI=1S/C21H20ClF3N4O3S/c1-33(31,32)8-2-7-27-16(10-14-9-15(22)3-4-17(14)27)12-28-19-11-26-6-5-18(19)29(20(28)30)13-21(23,24)25/h3-6,9-11H,2,7-8,12-13H2,1H3 DMJ1FXL CS CS(=O)(=O)CCCN1C2=C(C=C(C=C2)Cl)C=C1CN3C4=C(C=CN=C4)N(C3=O)CC(F)(F)F DMJ1FXL IK GTQTUABHRCWVLL-UHFFFAOYSA-N DMJ1FXL IU 3-[[5-chloro-1-(3-methylsulfonylpropyl)indol-2-yl]methyl]-1-(2,2,2-trifluoroethyl)imidazo[4,5-c]pyridin-2-one DMJ1FXL CA CAS 1383450-81-4 DMJ1FXL DE Respiratory syncytial virus infection DM9RW6H ID DM9RW6H DM9RW6H DN JNJ-56136379 DM9RW6H HS Phase 2 DM9RW6H SN JNJ-6379 DM9RW6H CP Janssen DM9RW6H DT Antibody DM9RW6H DE Hepatitis B DME2S4D ID DME2S4D DME2S4D DN JNJ-61393215 DME2S4D HS Phase 2 DME2S4D SN Q66977422 DME2S4D CP Janssen DME2S4D DT Small molecular drug DME2S4D PC 139030979 DME2S4D MW 460.4 DME2S4D FM C23H18F4N4O2 DME2S4D IC InChI=1S/C23H18F4N4O2/c24-16-4-1-3-15(20(16)21-28-7-2-8-29-21)22(32)31-12-13-9-17(31)18(10-13)33-19-6-5-14(11-30-19)23(25,26)27/h1-8,11,13,17-18H,9-10,12H2/t13-,17+,18-/m1/s1/i12D2 DME2S4D CS [2H]C1([C@@H]2C[C@H](N1C(=O)C3=C(C(=CC=C3)F)C4=NC=CC=N4)[C@@H](C2)OC5=NC=C(C=C5)C(F)(F)F)[2H] DME2S4D IK HUKWIAXQBOHZIX-USKNZQBOSA-N DME2S4D IU [(1S,4R,6R)-3,3-dideuterio-6-[5-(trifluoromethyl)pyridin-2-yl]oxy-2-azabicyclo[2.2.1]heptan-2-yl]-(3-fluoro-2-pyrimidin-2-ylphenyl)methanone DME2S4D DE Major depressive disorder DMVSUH1 ID DMVSUH1 DMVSUH1 DN JNJ-64565111 DMVSUH1 HS Phase 2 DMVSUH1 CP Janssen Research & Development Raritan, NJ DMVSUH1 DE Type-2 diabetes; Obesity DM3ICO6 ID DM3ICO6 DM3ICO6 DN JNJ-74494550 DM3ICO6 HS Phase 2 DM3ICO6 SN Cusatuzumab DM3ICO6 CP Argen Boston; Janssen DM3ICO6 DT Antibody DM3ICO6 DE Myelodysplastic syndrome DMXTKCR ID DMXTKCR DMXTKCR DN JT02 DMXTKCR HS Phase 2 DMXTKCR CP JYANT Technologies Marietta, GA DMXTKCR DE Inflammatory bowel disease DM2LBHN ID DM2LBHN DM2LBHN DN JTE-051 DM2LBHN HS Phase 2 DM2LBHN DE Allergy; Plaque psoriasis DM1945H ID DM1945H DM1945H DN JTT-251 DM1945H HS Phase 2 DM1945H CP Akros pharma DM1945H DE Type-2 diabetes; Pulmonary arterial hypertension DMGLVBI ID DMGLVBI DMGLVBI DN JTT-302 DMGLVBI HS Phase 2 DMGLVBI SN CETP inhibitor (oral, dyslipidemia), Japan Tobacco DMGLVBI CP Japan Tobacco Inc DMGLVBI DE Lipid metabolism disorder DM50M2R ID DM50M2R DM50M2R DN JTT-654 DM50M2R HS Phase 2 DM50M2R SN 11-beta HSD1 inhibitor (oral, type 2 diabetes), Japan Tobacco; 11-beta hydroxysteroid dehydrogenase (oral, type 2 diabetes), Japan Tobacco DM50M2R CP Japan Tobacco Inc DM50M2R DE Type-2 diabetes DMED5J6 ID DMED5J6 DMED5J6 DN JTT-851 DMED5J6 HS Phase 2 DMED5J6 SN GPCR 40 agonist (type 2 diabetes) Japan Tobacco DMED5J6 CP Akros pharma DMED5J6 DE Type-2 diabetes DMGXTOP ID DMGXTOP DMGXTOP DN JTX-2011 DMGXTOP HS Phase 2 DMGXTOP CP Jounce Therapeutics Cambridge, MA DMGXTOP DE Solid tumour/cancer DMOT0M7 ID DMOT0M7 DMOT0M7 DN JTX-4014 DMOT0M7 HS Phase 2 DMOT0M7 SN Pimivalimab DMOT0M7 CP Jounce Therapeutics DMOT0M7 DT Antibody DMOT0M7 DE Non-small-cell lung cancer DMZKYNO ID DMZKYNO DMZKYNO DN Juvidex DMZKYNO HS Phase 2 DMZKYNO SN Adaprev; Mannose-6-phosphate (scarring), Renovo DMZKYNO CP Renovo Group plc DMZKYNO PC 6101690 DMZKYNO MW 260.14 DMZKYNO FM C6H13O9P DMZKYNO IC InChI=1S/C6H13O9P/c7-1-3(8)5(10)6(11)4(9)2-15-16(12,13)14/h1,3-6,8-11H,2H2,(H2,12,13,14)/t3-,4-,5-,6-/m1/s1 DMZKYNO CS C([C@H]([C@H]([C@@H]([C@@H](C=O)O)O)O)O)OP(=O)(O)O DMZKYNO IK VFRROHXSMXFLSN-KVTDHHQDSA-N DMZKYNO IU [(2R,3R,4S,5S)-2,3,4,5-tetrahydroxy-6-oxohexyl] dihydrogen phosphate DMZKYNO CA CAS 3672-15-9 DMZKYNO CB CHEBI:48042 DMZKYNO DE Sarcoidosis DMPMU38 ID DMPMU38 DMPMU38 DN JVRS-100 DMPMU38 HS Phase 2 DMPMU38 CP Colby Pharmaceutical DMPMU38 DT Vaccine DMPMU38 DE leukaemia DMD4OK0 ID DMD4OK0 DMD4OK0 DN K-134 DMD4OK0 HS Phase 2 DMD4OK0 SN SULBACTAM; 68373-14-8; sulbactam acid; Sulbactamum; Betamaze; Penicillanic Acid Sulfone; (2S,5R)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid 4,4-dioxide; penicillanic acid 1,1-dioxide; UNII-S4TF6I2330; CP 45899; CHEMBL403; CHEBI:9321; S4TF6I2330; Sulbactam;Penicillanic acid sulfone; (2S,5R)-3,3-Dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid 4,4-dioxide; Sulbactam [INN:BAN]; CP-45,899; Sulbactamum [INN-Latin]; DSSTox_CID_3605; DSSTox_RID_77104 DMD4OK0 CP Kowa Pharmaceuticals America DMD4OK0 DT Small molecular drug DMD4OK0 PC 9908900 DMD4OK0 MW 399.5 DMD4OK0 FM C22H29N3O4 DMD4OK0 IC InChI=1S/C22H29N3O4/c26-20-5-2-1-4-19(20)25(16-7-8-16)22(28)23-12-3-13-29-17-9-10-18-15(14-17)6-11-21(27)24-18/h6,9-11,14,16,19-20,26H,1-5,7-8,12-13H2,(H,23,28)(H,24,27)/t19-,20-/m1/s1 DMD4OK0 CS C1CC[C@H]([C@@H](C1)N(C2CC2)C(=O)NCCCOC3=CC4=C(C=C3)NC(=O)C=C4)O DMD4OK0 IK ULGNGSQNNMKROG-WOJBJXKFSA-N DMD4OK0 IU 1-cyclopropyl-1-[(1R,2R)-2-hydroxycyclohexyl]-3-[3-[(2-oxo-1H-quinolin-6-yl)oxy]propyl]urea DMD4OK0 CA CAS 189362-06-9 DMD4OK0 DE Arteriosclerosis DMZCVD7 ID DMZCVD7 DMZCVD7 DN K-201 DMZCVD7 HS Phase 2 DMZCVD7 SN DKKLXCRMAXNIJF-UHFFFAOYSA-N; UNII-0I621Y6R4Q; K201; 0I621Y6R4Q; 1038410-88-6; K 201; SCHEMBL194018; CHEMBL2440857; DTXSID90146108; K-201, Moberg; Dermatological drug combination (kaprolac, atopic dermatitis), Moberg; Urea + PEG/propylene glycol formulation (atopic dermatitis), Moberg; JTV 519 DMZCVD7 CP Moberg Derma AB DMZCVD7 DT Small molecular drug DMZCVD7 PC 9868902 DMZCVD7 MW 461.1 DMZCVD7 FM C25H33ClN2O2S DMZCVD7 IC InChI=1S/C25H32N2O2S.ClH/c1-29-23-7-8-24-22(18-23)19-27(15-16-30-24)25(28)11-14-26-12-9-21(10-13-26)17-20-5-3-2-4-6-20;/h2-8,18,21H,9-17,19H2,1H3;1H DMZCVD7 CS COC1=CC2=C(C=C1)SCCN(C2)C(=O)CCN3CCC(CC3)CC4=CC=CC=C4.Cl DMZCVD7 IK DKKLXCRMAXNIJF-UHFFFAOYSA-N DMZCVD7 IU 3-(4-benzylpiperidin-1-yl)-1-(7-methoxy-3,5-dihydro-2H-1,4-benzothiazepin-4-yl)propan-1-one;hydrochloride DMZCVD7 CA CAS 1038410-88-6 DMZCVD7 DE Atopic dermatitis DMQVN6P ID DMQVN6P DMQVN6P DN K-604 DMQVN6P HS Phase 2 DMQVN6P SN BDBM86691 DMQVN6P CP Kowa Pharmaceuticals America DMQVN6P DT Small molecular drug DMQVN6P PC 9892288 DMQVN6P MW 502.7 DMQVN6P FM C23H30N6OS3 DMQVN6P IC InChI=1S/C23H30N6OS3/c1-16-14-19(31-2)21(22(24-16)32-3)27-20(30)15-29-10-8-28(9-11-29)12-13-33-23-25-17-6-4-5-7-18(17)26-23/h4-7,14H,8-13,15H2,1-3H3,(H,25,26)(H,27,30) DMQVN6P CS CC1=CC(=C(C(=N1)SC)NC(=O)CN2CCN(CC2)CCSC3=NC4=CC=CC=C4N3)SC DMQVN6P IK VGGMTOYKEDKFLN-UHFFFAOYSA-N DMQVN6P IU 2-[4-[2-(1H-benzimidazol-2-ylsulfanyl)ethyl]piperazin-1-yl]-N-[6-methyl-2,4-bis(methylsulfanyl)pyridin-3-yl]acetamide DMQVN6P CA CAS 561023-90-3 DMQVN6P DE Arteriosclerosis DMJLNZQ ID DMJLNZQ DMJLNZQ DN K-828-AB DMJLNZQ HS Phase 2 DMJLNZQ SN GABA transaminase inhibitor (oral, dementia), Kowa DMJLNZQ CP Kowa Co Ltd DMJLNZQ DE Dementia DMMSTCF ID DMMSTCF DMMSTCF DN K-832 DMMSTCF HS Phase 2 DMMSTCF SN 10465-81-3; 1,1'-(Azodicarbonyl)-dipiperidine; AdDP; 1,1-(Azodicarbonyl)dipiperidine; 1,1'-(Azodicarbonyl)dipiperidine; diazene-1,2-diylbis(piperidin-1-ylmethanone); NSC356027; NSC 356027; (NE)-N-(piperidine-1-carbonylimino)piperidine-1-carboxamide; azodicarboxylic acid dipiperidine; (E)-diazene-1,2-diylbis(piperidin-1-ylmethanone); Azodicarboxylic acid dipiperidide; J-503690; SR-4077; (E)-diazene-1,2-diylbis(piperidin-1-yl methanone); SR 4077; PubChem19605; piperidyl (piperidylcarbonyl)diazenyl ketone; AC1Q5JWC; AC1NWBQ9 DMMSTCF CP Kowa DMMSTCF DT Small molecular drug DMMSTCF PC 9844960 DMMSTCF MW 418.9 DMMSTCF FM C24H19ClN2OS DMMSTCF IC InChI=1S/C24H19ClN2OS/c1-29-21-13-9-19(10-14-21)24-22(18-7-11-20(25)12-8-18)15-23(28)27(26-24)16-17-5-3-2-4-6-17/h2-15H,16H2,1H3 DMMSTCF CS CSC1=CC=C(C=C1)C2=NN(C(=O)C=C2C3=CC=C(C=C3)Cl)CC4=CC=CC=C4 DMMSTCF IK HEUAVAATAFEENP-UHFFFAOYSA-N DMMSTCF IU 2-benzyl-5-(4-chlorophenyl)-6-(4-methylsulfanylphenyl)pyridazin-3-one DMMSTCF DE Rheumatoid arthritis DMTMCPZ ID DMTMCPZ DMTMCPZ DN KB001A DMTMCPZ HS Phase 2 DMTMCPZ CP Sanofi DMTMCPZ DT Antibody DMTMCPZ DE Infectious disease; Cystic fibrosis DM60G5O ID DM60G5O DM60G5O DN KB002/003 DM60G5O HS Phase 2 DM60G5O CP KaloBios Pharmaceuticals DM60G5O DE Rheumatoid arthritis DM74KIM ID DM74KIM DM74KIM DN KB-003 DM74KIM HS Phase 2 DM74KIM SN KB-002; Anti-GM-CSF mAb (autoimmune disease), Ludwig/KaloBios; Anti-GM-CSF mAb (inflammatory disease/rheumatoid arthritis/asthma), KaloBios DM74KIM CP Kalobios pharmaceuticals DM74KIM DT Antibody DM74KIM DE Severe asthma DMZ4MCG ID DMZ4MCG DMZ4MCG DN KB-6806 DMZ4MCG HS Phase 2 DMZ4MCG SN Prucalopride succinate; 179474-85-2; Prucalopride Succinat; Prucalopride (succinate); UNII-4V2G75E1CK; R-108512; BUTANEDIOIC ACID 4-AMINO-5-CHLORO-2,3-DIHYDRO-N-[1-(3-METHOXYPROPYL)-4-PIPERIDINYL]-7-BENZOFURANCARBOXAMIDE; Prucalopride succinate [USAN]; 4V2G75E1CK; R 108512; AK175654; Prucalopride succinate (USAN); resotran; Butanedioic acid, compd. with 4-amino-5-chloro-2,3-dihydro-N-(1-(3-methoxypropyl)-4-piperidinyl)-7-benzofurancarboxamide (1:1); Butanedioic acid, compd. with 4-amino-5-chloro-2,3-dihydro-N-[1- DMZ4MCG CP Kanebo DMZ4MCG DT Small molecular drug DMZ4MCG PC 3073291 DMZ4MCG MW 307.82 DMZ4MCG FM C15H22ClN5 DMZ4MCG IC InChI=1S/C15H22ClN5/c1-10(2)21-14-9-12(17)11(16)8-13(14)18-15(21)20-6-4-19(3)5-7-20/h8-10H,4-7,17H2,1-3H3 DMZ4MCG CS CC(C)N1C2=C(C=C(C(=C2)N)Cl)N=C1N3CCN(CC3)C DMZ4MCG IK QEANRFDFBNUCJR-UHFFFAOYSA-N DMZ4MCG IU 6-chloro-2-(4-methylpiperazin-1-yl)-3-propan-2-ylbenzimidazol-5-amine DMZ4MCG CA CAS 148014-93-1 DMZ4MCG DE Chemotherapy-induced nausea DMEFW3G ID DMEFW3G DMEFW3G DN KD019 DMEFW3G HS Phase 2 DMEFW3G SN Tesevatinib; XL647; XL-647; 781613-23-8; EXEL-7647; UNII-F6XM2TN5A1; KD-019; XL 647; F6XM2TN5A1; 651031-01-5; 7-[[(3aS,6aR)-2-methyl-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrol-5-yl]methoxy]-N-(3,4-dichloro-2-fluorophenyl)-6-methoxyquinazolin-4-amine; Tesevatinib [USAN:INN]; EXEL 7647; 874286-84-7; KD 019; 1000599-06-3; SCHEMBL721994; SCHEMBL721993; SCHEMBL721992; C24H25Cl2FN4O2; GTPL7944; CHEMBL3544983; EX-A172; QCR-153; MolPort-044-724-458; BCP23438; ZINC38912363; 2809AH; AKOS027255007 DMEFW3G CP Kadmon Pharmaceuticals DMEFW3G DT Small molecular drug DMEFW3G PC 10458325 DMEFW3G MW 491.4 DMEFW3G FM C24H25Cl2FN4O2 DMEFW3G IC InChI=1S/C24H25Cl2FN4O2/c1-31-9-14-5-13(6-15(14)10-31)11-33-21-8-19-16(7-20(21)32-2)24(29-12-28-19)30-18-4-3-17(25)22(26)23(18)27/h3-4,7-8,12-15H,5-6,9-11H2,1-2H3,(H,28,29,30)/t13?,14-,15+ DMEFW3G CS CN1C[C@H]2CC(C[C@H]2C1)COC3=C(C=C4C(=C3)N=CN=C4NC5=C(C(=C(C=C5)Cl)Cl)F)OC DMEFW3G IK HVXKQKFEHMGHSL-GOOCMWNKSA-N DMEFW3G IU 7-[[(3aS,6aR)-2-methyl-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrol-5-yl]methoxy]-N-(3,4-dichloro-2-fluorophenyl)-6-methoxyquinazolin-4-amine DMEFW3G CA CAS 781613-23-8 DMEFW3G DE Non-small-cell lung cancer; Polycystic kidney disease; Brain metastases; Meningioma metastases; Recurrent glioblastoma DM548TK ID DM548TK DM548TK DN KD025 DM548TK HS Phase 2 DM548TK CP Kadmon DM548TK PC 11950170 DM548TK MW 452.5 DM548TK FM C26H24N6O2 DM548TK IC InChI=1S/C26H24N6O2/c1-16(2)28-24(33)15-34-20-7-5-6-17(13-20)25-30-23-9-4-3-8-21(23)26(31-25)29-19-10-11-22-18(12-19)14-27-32-22/h3-14,16H,15H2,1-2H3,(H,27,32)(H,28,33)(H,29,30,31) DM548TK CS CC(C)NC(=O)COC1=CC=CC(=C1)C2=NC3=CC=CC=C3C(=N2)NC4=CC5=C(C=C4)NN=C5 DM548TK IK GKHIVNAUVKXIIY-UHFFFAOYSA-N DM548TK IU 2-[3-[4-(1H-indazol-5-ylamino)quinazolin-2-yl]phenoxy]-N-propan-2-ylacetamide DM548TK CA CAS 911417-87-3 DM548TK DE Rheumatoid arthritis; Psoriasis vulgaris; Psoriatic arthritis; Scleroderma; Systemic lupus erythematosus DME1WV2 ID DME1WV2 DME1WV2 DN KD-7040 DME1WV2 HS Phase 2 DME1WV2 CP Kalypsys Inc DME1WV2 DE Pain DMFO6MH ID DMFO6MH DMFO6MH DN Kevetrin DMFO6MH HS Phase 2 DMFO6MH CP Cellceutix Corp DMFO6MH DT Small molecular drug DMFO6MH PC 437740 DMFO6MH MW 143.21 DMFO6MH FM C5H9N3S DMFO6MH IC InChI=1S/C5H9N3S/c6-3-1-2-4-9-5(7)8/h1-2,4H2,(H3,7,8) DMFO6MH CS C(CC#N)CSC(=N)N DMFO6MH IK PRDJGNVQBVXXEO-UHFFFAOYSA-N DMFO6MH IU 3-cyanopropyl carbamimidothioate DMFO6MH CA CAS 500863-50-3 DMFO6MH DE Solid tumour/cancer; Ovarian cancer DMF6CTI ID DMF6CTI DMF6CTI DN KHK-6188 DMF6CTI HS Phase 2 DMF6CTI CP Kyowa Hakko Kirin Co Ltd DMF6CTI DE Neuropathic pain DM40HOY ID DM40HOY DM40HOY DN KLH-2109 DM40HOY HS Phase 2 DM40HOY CP Kissei Pharmaceutical Co Ltd DM40HOY PC 16656889 DM40HOY MW 508.4 DM40HOY FM C22H15F3N2O7S DM40HOY IC InChI=1S/C22H15F3N2O7S/c1-32-14-4-3-10(23)18(25)9(14)7-34-16-6-13(11(24)5-15(16)33-2)27-20(28)17-12(26-22(27)31)8-35-19(17)21(29)30/h3-6,8H,7H2,1-2H3,(H,26,31)(H,29,30) DM40HOY CS COC1=C(C(=C(C=C1)F)F)COC2=C(C=C(C(=C2)N3C(=O)C4=C(SC=C4NC3=O)C(=O)O)F)OC DM40HOY IK BMAAMIIYNNPHAB-UHFFFAOYSA-N DM40HOY IU 3-[5-[(2,3-difluoro-6-methoxyphenyl)methoxy]-2-fluoro-4-methoxyphenyl]-2,4-dioxo-1H-thieno[3,4-d]pyrimidine-5-carboxylic acid DM40HOY CA CAS 935283-04-8 DM40HOY DE Endometriosis DM05TBE ID DM05TBE DM05TBE DN KLS-0611 DM05TBE HS Phase 2 DM05TBE SN Mucin stimulator (dry eye), Kissei DM05TBE CP Kissei Pharmaceutical Co Ltd DM05TBE DE Xerophthalmia DMNLH9W ID DMNLH9W DMNLH9W DN KN026 DMNLH9W HS Phase 2 DMNLH9W CP Alphamab Oncology DMNLH9W DT Antibody DMNLH9W DE Breast cancer DMKLMG6 ID DMKLMG6 DMKLMG6 DN KN035 DMKLMG6 HS Phase 2 DMKLMG6 SN Envafolimab DMKLMG6 CP TRACON Pharmaceuticals DMKLMG6 DT Antibody DMKLMG6 DE Advanced malignancy; Solid tumour/cancer; Pleomorphic sarcoma DMQZ5HF ID DMQZ5HF DMQZ5HF DN KNI-272 DMQZ5HF HS Phase 2 DMQZ5HF SN NSC651714; NSC-651714; AC1Q5L2H; (4r)-n-tert-butyl-3-[2-hydroxy-3-({n-[(isoquinolin-5-yloxy)acetyl]-s-methyl-l-cysteinyl}amino)-4-phenylbutanoyl]-1,3-thiazolidine-4-carboxamide; AC1L88B1; KNI 272; 3-(3,4-Dimethoxyphenyl)propionamide; NCI60_018063; 4-Thiazolidinecarboxamide,1-dimethylethyl)-3- [2-hydroxy-3-[[2-[[(5-isoquinolinyloxy)acetyl]amino]-3- (methylthio)-1-oxopropyl]amino]-1-oxo-4-phenylbutyl]-,[4R-[3[2S*,3S*(R*)],4R*]] DMQZ5HF DT Small molecular drug DMQZ5HF PC 60927 DMQZ5HF MW 667.8 DMQZ5HF FM C33H41N5O6S2 DMQZ5HF IC InChI=1S/C33H41N5O6S2/c1-33(2,3)37-31(42)26-19-46-20-38(26)32(43)29(40)24(15-21-9-6-5-7-10-21)36-30(41)25(18-45-4)35-28(39)17-44-27-12-8-11-22-16-34-14-13-23(22)27/h5-14,16,24-26,29,40H,15,17-20H2,1-4H3,(H,35,39)(H,36,41)(H,37,42)/t24-,25-,26-,29-/m0/s1 DMQZ5HF CS CC(C)(C)NC(=O)[C@@H]1CSCN1C(=O)[C@H]([C@H](CC2=CC=CC=C2)NC(=O)[C@H](CSC)NC(=O)COC3=CC=CC4=C3C=CN=C4)O DMQZ5HF IK NJBBLOIWMSYVCQ-VZTVMPNDSA-N DMQZ5HF IU (4R)-N-tert-butyl-3-[(2S,3S)-2-hydroxy-3-[[(2R)-2-[(2-isoquinolin-5-yloxyacetyl)amino]-3-methylsulfanylpropanoyl]amino]-4-phenylbutanoyl]-1,3-thiazolidine-4-carboxamide DMQZ5HF CA CAS 147318-81-8 DMQZ5HF CB CHEBI:80006 DMQZ5HF DE Human immunodeficiency virus infection DMCO8UZ ID DMCO8UZ DMCO8UZ DN KP-496 DMCO8UZ HS Phase 2 DMCO8UZ DE Asthma DM4WHOS ID DM4WHOS DM4WHOS DN KPP203 DM4WHOS HS Phase 2 DM4WHOS CP Novartis PharmaceuticalsEast Hanover, NJ DM4WHOS DE Subacute cutaneous lupus erythematosus DMQDLVW ID DMQDLVW DMQDLVW DN KRP-104 DMQDLVW HS Phase 2 DMQDLVW SN Antigen inhibitor DMQDLVW CP ActivX Biosciences DMQDLVW DE Type-2 diabetes DMOW9X2 ID DMOW9X2 DMOW9X2 DN KRP-203 DMOW9X2 HS Phase 2 DMOW9X2 SN KNF-299; KRP-203-P prodrug, Kyorin DMOW9X2 CP Kyorin Pharmaceutical Co Ltd DMOW9X2 DT Small molecular drug DMOW9X2 PC 11155873 DMOW9X2 MW 480.4 DMOW9X2 FM C24H27Cl2NO3S DMOW9X2 IC InChI=1S/C24H26ClNO3S.ClH/c25-23-14-22(10-9-19(23)11-12-24(26,16-27)17-28)30-21-8-4-7-20(13-21)29-15-18-5-2-1-3-6-18;/h1-10,13-14,27-28H,11-12,15-17,26H2;1H DMOW9X2 CS C1=CC=C(C=C1)COC2=CC(=CC=C2)SC3=CC(=C(C=C3)CCC(CO)(CO)N)Cl.Cl DMOW9X2 IK MYIFLDFUXIHOCJ-UHFFFAOYSA-N DMOW9X2 IU 2-amino-2-[2-[2-chloro-4-(3-phenylmethoxyphenyl)sulfanylphenyl]ethyl]propane-1,3-diol;hydrochloride DMOW9X2 CA CAS 509088-69-1 DMOW9X2 DE Cutaneous lupus erythematosus DM08F12 ID DM08F12 DM08F12 DN KT6-971 DM08F12 HS Phase 2 DM08F12 SN Cholesterol absorption inhibitor, Kotobuki DM08F12 CP Kotobuki Pharmaceutical Co Ltd DM08F12 DE Hypercholesterolaemia DMZL48U ID DMZL48U DMZL48U DN KUR-111 DMZL48U HS Phase 2 DMZL48U SN I-0401; I-040302; TGplPTH1-34; Fibrin-PTH (bone cysts), Kuros; Human parathyroid hormone (PTH) + TISSEEL fibrin sealant + hydroxyapatite/tri-calcium phosphate granules (bone fracture), Kuros/Baxter DMZL48U CP Kuros Biosurgery AG DMZL48U DE Bone disease DM2N0Z3 ID DM2N0Z3 DM2N0Z3 DN KUR-211 DM2N0Z3 HS Phase 2 DM2N0Z3 CP Baxter international; kuros biosurgery DM2N0Z3 DE Ulcer DMB4HCY ID DMB4HCY DMB4HCY DN KUR-212 DMB4HCY HS Phase 2 DMB4HCY SN I-020502; Fibrin-PDGF (wound healing), Baxter/Kuros; Fibrin-recombinant human platelet-derived growth factor (wound healing), Baxter/Kuros DMB4HCY CP Baxter International Inc DMB4HCY DE Wound healing DMK4VOU ID DMK4VOU DMK4VOU DN KVD001 DMK4VOU HS Phase 2 DMK4VOU CP KalVista Pharmaceuticals Cambridge, MA DMK4VOU DE Diabetic macular edema DM5N4OA ID DM5N4OA DM5N4OA DN KVD824 DM5N4OA HS Phase 2 DM5N4OA CP KalVista Pharmaceuticals DM5N4OA DE Diabetic macular edema DMJGL72 ID DMJGL72 DMJGL72 DN KW-2478 DMJGL72 HS Phase 2 DMJGL72 SN KW-2478; 819812-04-9; KW-2478 free base; 2-(2-ethyl-3,5-dihydroxy-6-(3-methoxy-4-(2-morpholinoethoxy)benzoyl)phenyl)-N,N-bis(2-methoxyethyl)acetamide; UNII-QY50S617NM; KW 2478; KW2478; QY50S617NM; 2-ethyl-3,5-dihydroxy-n,n-bis(2-methoxyethyl)-6-(3-methoxy-4-(2-(4-morpholinyl)ethoxy)benzoyl)benzeneacetamide; 2-[2-ethyl-3,5-dihydroxy-6-[3-methoxy-4-(2-morpholin-4-ylethoxy)benzoyl]phenyl]-N,N-bis(2-methoxyethyl)acetamide DMJGL72 CP Kyowa Hakko Kirin DMJGL72 DT Small molecular drug DMJGL72 PC 23116322 DMJGL72 MW 574.7 DMJGL72 FM C30H42N2O9 DMJGL72 IC InChI=1S/C30H42N2O9/c1-5-22-23(19-28(35)32(11-13-37-2)12-14-38-3)29(25(34)20-24(22)33)30(36)21-6-7-26(27(18-21)39-4)41-17-10-31-8-15-40-16-9-31/h6-7,18,20,33-34H,5,8-17,19H2,1-4H3 DMJGL72 CS CCC1=C(C(=C(C=C1O)O)C(=O)C2=CC(=C(C=C2)OCCN3CCOCC3)OC)CC(=O)N(CCOC)CCOC DMJGL72 IK VFUXSYAXEKYYMB-UHFFFAOYSA-N DMJGL72 IU 2-[2-ethyl-3,5-dihydroxy-6-[3-methoxy-4-(2-morpholin-4-ylethoxy)benzoyl]phenyl]-N,N-bis(2-methoxyethyl)acetamide DMJGL72 CA CAS 819812-04-9 DMJGL72 DE Solid tumour/cancer DM15RZO ID DM15RZO DM15RZO DN KYMRIAH DM15RZO HS Phase 2 DM15RZO CP Masonic Cancer Center, University of Minnesota DM15RZO DT CAR T Cell Therapy DM15RZO DE Acute lymphoblastic leukaemia DMLHPVW ID DMLHPVW DMLHPVW DN L1-79 DMLHPVW HS Phase 2 DMLHPVW SN alpha-methylparatyrosine DMLHPVW CP Yamo Pharmaceuticals DMLHPVW DE Autism spectrum disorder DMI2XP1 ID DMI2XP1 DMI2XP1 DN L19-IL-2 fusion protein DMI2XP1 HS Phase 2 DMI2XP1 SN Darleukin; Immunocytokine fusion protein, Bayer Schering; Immunocytokine fusion protein, Philogen; L19-IL-2 fusion protein, Bayer Schering; L19-IL-2 fusion protein, Philogen DMI2XP1 CP Philogen SpA DMI2XP1 DT Antibody DMI2XP1 DE Lymphoma DMW6NMP ID DMW6NMP DMW6NMP DN L19-TNF-alpha DMW6NMP HS Phase 2 DMW6NMP SN Fibromun DMW6NMP CP Philogen SpA DMW6NMP DT Antibody DMW6NMP DE Colorectal cancer DMA0DSJ ID DMA0DSJ DMA0DSJ DN L-694,458 DMA0DSJ HS Phase 2 DMA0DSJ SN DMP 777; 157341-41-8; DMP-777; UNII-3Q0469283P; (S)-N-((R)-1-(Benzo[d][1,3]dioxol-5-yl)butyl)-3,3-diethyl-2-(4-(4-methylpiperazine-1-carbonyl)phenoxy)-4-oxoazetidine-1-carboxamide; DMP777; CHEMBL310871; L-694458; 3Q0469283P; (S)-N-((R)-1-(Benzo[d][1,3]dioxol-5-yl)butyl)-3,3-diethyl-2-(4-(4methyl-piperazine-1-carbonyl)phenoxy)-4-oxoazetidine-1-carboxamide (3.5% w/w solution); L-694,458; L 694458; SCHEMBL6538142; AC1L433D; CTK4C9348; DTXSID00166251; MolPort-023-332-820; C31H40N4O6; ZINC3936307; KS-00001E6Q; BCP02269 DMA0DSJ DT Small molecular drug DMA0DSJ PC 177992 DMA0DSJ MW 564.7 DMA0DSJ FM C31H40N4O6 DMA0DSJ IC InChI=1S/C31H40N4O6/c1-5-8-24(22-11-14-25-26(19-22)40-20-39-25)32-30(38)35-28(37)31(6-2,7-3)29(35)41-23-12-9-21(10-13-23)27(36)34-17-15-33(4)16-18-34/h9-14,19,24,29H,5-8,15-18,20H2,1-4H3,(H,32,38)/t24-,29+/m1/s1 DMA0DSJ CS CCC[C@H](C1=CC2=C(C=C1)OCO2)NC(=O)N3[C@H](C(C3=O)(CC)CC)OC4=CC=C(C=C4)C(=O)N5CCN(CC5)C DMA0DSJ IK ZSDCIRYNTCVTMF-GIGWZHCTSA-N DMA0DSJ IU (2S)-N-[(1R)-1-(1,3-benzodioxol-5-yl)butyl]-3,3-diethyl-2-[4-(4-methylpiperazine-1-carbonyl)phenoxy]-4-oxoazetidine-1-carboxamide DMA0DSJ CA CAS 157341-41-8 DMA0DSJ DE Cystic fibrosis DMB7WT1 ID DMB7WT1 DMB7WT1 DN L-697,661 DMB7WT1 HS Phase 2 DMB7WT1 SN L-697661; L-697,661; 135525-78-9; L 697661; 3-(((4,7-Dichloro-1,3-benzoxazol-2-yl)methyl)amino)-5-ethyl-6-methylpyridin-2(1H)-one; CHEMBL268871; UNII-4660N666EZ; 4660N666EZ; 3-[(4,7-dichloro-1,3-benzoxazol-2-yl)methylamino]-5-ethyl-6-methyl-1H-pyridin-2-one; 2(1H)-Pyridinone, 3-(((4,7-dichloro-2-benzoxazolyl)methyl)amino)-5-ethyl-6-methyl-; ACMC-20mvsm; SCHEMBL599639; BDBM1317; AC1Q69B2; AC1L22E2; CTK0H5173; DTXSID10159457; AKOS030539285; LS-186956; LS-187602; L697,661; L 697,661 DMB7WT1 DT Small molecular drug DMB7WT1 PC 65002 DMB7WT1 MW 352.2 DMB7WT1 FM C16H15Cl2N3O2 DMB7WT1 IC InChI=1S/C16H15Cl2N3O2/c1-3-9-6-12(16(22)20-8(9)2)19-7-13-21-14-10(17)4-5-11(18)15(14)23-13/h4-6,19H,3,7H2,1-2H3,(H,20,22) DMB7WT1 CS CCC1=C(NC(=O)C(=C1)NCC2=NC3=C(C=CC(=C3O2)Cl)Cl)C DMB7WT1 IK WHFRDXVXYMGAJD-UHFFFAOYSA-N DMB7WT1 IU 3-[(4,7-dichloro-1,3-benzoxazol-2-yl)methylamino]-5-ethyl-6-methyl-1H-pyridin-2-one DMB7WT1 CA CAS 135525-78-9 DMB7WT1 DE Human immunodeficiency virus infection DMTGR25 ID DMTGR25 DMTGR25 DN L-745,870 DMTGR25 HS Phase 2 DMTGR25 SN 158985-00-3; L-745870; UNII-J3OLN3XSX7; J3OLN3XSX7; L-745,870; CHEMBL267014; L 745,870; 3-((4-(4-Chlorophenyl)piperazin-1-yl)methyl)-1H-pyrrolo[2,3-b]pyridine; 3-(4-[4-Chlorophenyl]piperazin-1-yl)-methyl-1H-pyrrolo[2,3-b]pyridine trihydrochloride; 3-((4-(4-chlorophenyl)piperazin-1-yl)methyl)-1H-pyrrolo(2,3-b)pyridine; 3-[[4-(4-chlorophenyl)piperazin-1-yl]methyl]-1H-pyrrolo[2,3-b]pyridine; CPMPP-3; Tocris-1002; Lopac-L-131; Biomol-NT_000049; AC1NSK75; L745870; Lopac0_000791; GTPL3303; BPBio1_001299; SCHEMBL1059886; CHEBI:92099 DMTGR25 DT Small molecular drug DMTGR25 PC 5311200 DMTGR25 MW 326.8 DMTGR25 FM C18H19ClN4 DMTGR25 IC InChI=1S/C18H19ClN4/c19-15-3-5-16(6-4-15)23-10-8-22(9-11-23)13-14-12-21-18-17(14)2-1-7-20-18/h1-7,12H,8-11,13H2,(H,20,21) DMTGR25 CS C1CN(CCN1CC2=CNC3=C2C=CC=N3)C4=CC=C(C=C4)Cl DMTGR25 IK OGJGQVFWEPNYSB-UHFFFAOYSA-N DMTGR25 IU 3-[[4-(4-chlorophenyl)piperazin-1-yl]methyl]-1H-pyrrolo[2,3-b]pyridine DMTGR25 CA CAS 158985-00-3 DMTGR25 CB CHEBI:92099 DMTGR25 DE Psychotic disorder DMNO5UE ID DMNO5UE DMNO5UE DN Labetuzumab I-131 DMNO5UE HS Phase 2 DMNO5UE SN IMMU-111 DMNO5UE CP Immunomedics DMNO5UE DT Antibody DMNO5UE DE Colorectal cancer DM7063I ID DM7063I DM7063I DN LADIRUBICIN DM7063I HS Phase 2 DM7063I SN FCE-28729; PNU-159548; Ladirubicin; 3'-(1-Aziridinyl)-3'-deamino-4-demethoxy-4'-O-(methanesulfonyl)daunomycin DM7063I DT Small molecular drug DM7063I PC 216232 DM7063I MW 601.6 DM7063I FM C29H31NO11S DM7063I IC InChI=1S/C29H31NO11S/c1-13-28(41-42(3,37)38)18(30-8-9-30)10-20(39-13)40-19-12-29(36,14(2)31)11-17-21(19)27(35)23-22(26(17)34)24(32)15-6-4-5-7-16(15)25(23)33/h4-7,13,18-20,28,34-36H,8-12H2,1-3H3/t13-,18-,19-,20-,28+,29-/m0/s1 DM7063I CS C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=CC=CC=C5C4=O)O)(C(=O)C)O)N6CC6)OS(=O)(=O)C DM7063I IK VMDWTZZCNDEKIO-CBNJBKGYSA-N DM7063I IU [(2S,3S,4S,6R)-6-[[(1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-2,4-dihydro-1H-tetracen-1-yl]oxy]-4-(aziridin-1-yl)-2-methyloxan-3-yl] methanesulfonate DM7063I CA CAS 171047-47-5 DM7063I DE Breast cancer DMJSY3Q ID DMJSY3Q DMJSY3Q DN Ladostigil DMJSY3Q HS Phase 2 DMJSY3Q SN Ladostigil tartrate; Alzheimer disease therapeutics, Teva; TV-3219; TV-3279; TV-3326 DMJSY3Q CP Hebrew University of Jerusalem DMJSY3Q DT Small molecular drug DMJSY3Q PC 208907 DMJSY3Q MW 272.34 DMJSY3Q FM C16H20N2O2 DMJSY3Q IC InChI=1S/C16H20N2O2/c1-4-10-17-15-9-7-12-6-8-13(11-14(12)15)20-16(19)18(3)5-2/h1,6,8,11,15,17H,5,7,9-10H2,2-3H3/t15-/m1/s1 DMJSY3Q CS CCN(C)C(=O)OC1=CC2=C(CC[C@H]2NCC#C)C=C1 DMJSY3Q IK LHXOCOHMBFOVJS-OAHLLOKOSA-N DMJSY3Q IU [(3R)-3-(prop-2-ynylamino)-2,3-dihydro-1H-inden-5-yl] N-ethyl-N-methylcarbamate DMJSY3Q CA CAS 209394-27-4 DMJSY3Q DE Alzheimer disease DMSIGAB ID DMSIGAB DMSIGAB DN L-alanosine DMSIGAB HS Phase 2 DMSIGAB SN SDX-102 DMSIGAB CP Salmedix DMSIGAB DT Small molecular drug DMSIGAB PC 135409347 DMSIGAB MW 149.11 DMSIGAB FM C3H7N3O4 DMSIGAB IC InChI=1S/C3H7N3O4/c4-2(3(7)8)1-6(10)5-9/h2,9H,1,4H2,(H,7,8)/b6-5-/t2-/m0/s1 DMSIGAB CS C([C@@H](C(=O)O)N)/[N+](=N/O)/[O-] DMSIGAB IK ZGNLFUXWZJGETL-YUSKDDKASA-N DMSIGAB IU (Z)-[(2S)-2-amino-2-carboxyethyl]-hydroxyimino-oxidoazanium DMSIGAB CA CAS 5854-93-3 DMSIGAB DE Brain cancer DMR0N74 ID DMR0N74 DMR0N74 DN LAM-002 DMR0N74 HS Phase 2 DMR0N74 CP LAM Therapeutics Guilford, CT DMR0N74 DE B-cell non-hodgkin lymphoma; Non-hodgkin lymphoma; Chronic lymphocytic leukaemia DM7MBV6 ID DM7MBV6 DM7MBV6 DN Lancovutide DM7MBV6 HS Phase 2 DM7MBV6 SN Duramycin; Lancovutide; Cystic fibrosis treatment, Molichem; Moli-1901; Moli-901; Duramycin(ophthalmic, dry eye), Lantibio; Lancovutide (ophthalmic, dry eye), Lantibio; Duramycin (inhaled, cystic fibrosis), Lantibio/AOP Orphan; Duramycin (inhaled, cystic fibrosis), Molichem/AOP Orphan; Lancovutide (inhaled, cystic fibrosis), Lantibio/AOP Orphan; Moli-1901 (ophthalmic, dry eye), Lantibio DM7MBV6 CP Lantibio Inc DM7MBV6 PC 86289378 DM7MBV6 MW 2013.3 DM7MBV6 FM C89H125N23O25S3 DM7MBV6 IC InChI=1S/C89H125N23O25S3/c1-44(2)67-85(131)107-60-42-138-41-59-80(126)106-61-43-140-46(4)69(87(133)103-56(76(122)108-67)35-49-23-12-7-13-24-49)109-77(123)55(34-48-21-10-6-11-22-48)102-83(129)62-27-18-32-112(62)66(116)39-96-73(119)54(33-47-19-8-5-9-20-47)101-79(125)58(104-81(61)127)37-94-31-17-15-26-53(88(134)135)100-86(132)68(110-78(124)57(36-64(93)114)97-65(115)38-95-84(130)70(111-82(60)128)71(117)89(136)137)45(3)139-40-50(91)72(118)98-51(25-14-16-30-90)74(120)99-52(75(121)105-59)28-29-63(92)113/h5-13,19-24,44-46,50-62,67-71,94,117H,14-18,25-43,90-91H2,1-4H3,(H2,92,113)(H2,93,114)(H,95,130)(H,96,119)(H,97,115)(H,98,118)(H,99,120)(H,100,132)(H,101,125)(H,102,129)(H,103,133)(H,104,127)(H,105,121)(H,106,126)(H,107,131)(H,108,122)(H,109,123)(H,110,124)(H,111,128)(H,134,135)(H,136,137)/t45?,46-,50-,51-,52-,53-,54-,55-,56-,57-,58-,59+,60-,61-,62-,67-,68+,69+,70-,71+/m0/s1 DM7MBV6 CS C[C@H]1[C@@H]2C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H]3CSC[C@@H]4C(=O)N[C@@H](CS1)C(=O)N[C@@H](CNCCCC[C@H](NC(=O)[C@@H](C(SC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N4)CCC(=O)N)CCCCN)N)C)NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC3=O)[C@H](C(=O)O)O)CC(=O)N)C(=O)O)C(=O)N[C@H](C(=O)NCC(=O)N5CCC[C@H]5C(=O)N[C@H](C(=O)N2)CC6=CC=CC=C6)CC7=CC=CC=C7)C(C)C)CC8=CC=CC=C8 DM7MBV6 IK SFWLDKQAUHFCBS-WWXQEMPQSA-N DM7MBV6 IU (1S,4S,13S,16S,19S,22S,25S,28R,31S,37S,40S,44R,47S,50S,53S,56R,65S,70S)-44-amino-47-(4-aminobutyl)-37-(2-amino-2-oxoethyl)-50-(3-amino-3-oxopropyl)-4,16,22-tribenzyl-31-[(R)-carboxy(hydroxy)methyl]-41,70-dimethyl-2,5,8,14,17,20,23,26,29,32,35,38,45,48,51,54,57,67-octadecaoxo-25-propan-2-yl-42,69,72-trithia-3,6,9,15,18,21,24,27,30,33,36,39,46,49,52,55,58,60,66-nonadecazapentacyclo[38.18.9.319,56.328,53.09,13]triheptacontane-65-carboxylic acid DM7MBV6 DE Chronic obstructive pulmonary disease DM1VK96 ID DM1VK96 DM1VK96 DN LANEPITANT DM1VK96 HS Phase 2 DM1VK96 SN LY-303870; LY-302654 (racemate); Lanepitant; N-[1(R)-(1H-Indol-3-ylmethyl)-2-[N-(2-methoxybenzyl)acetamido]ethyl]-2-[4-(1-piperidinyl)piperidin-1-yl]acetamide DM1VK96 DT Small molecular drug DM1VK96 PC 3086681 DM1VK96 MW 559.7 DM1VK96 FM C33H45N5O3 DM1VK96 IC InChI=1S/C33H45N5O3/c1-25(39)38(22-26-10-4-7-13-32(26)41-2)23-28(20-27-21-34-31-12-6-5-11-30(27)31)35-33(40)24-36-18-14-29(15-19-36)37-16-8-3-9-17-37/h4-7,10-13,21,28-29,34H,3,8-9,14-20,22-24H2,1-2H3,(H,35,40)/t28-/m1/s1 DM1VK96 CS CC(=O)N(CC1=CC=CC=C1OC)C[C@@H](CC2=CNC3=CC=CC=C32)NC(=O)CN4CCC(CC4)N5CCCCC5 DM1VK96 IK CVXJAPZTZWLRBP-MUUNZHRXSA-N DM1VK96 IU N-[(2R)-1-[acetyl-[(2-methoxyphenyl)methyl]amino]-3-(1H-indol-3-yl)propan-2-yl]-2-(4-piperidin-1-ylpiperidin-1-yl)acetamide DM1VK96 CA CAS 170566-84-4 DM1VK96 DE Pain DMPRZX4 ID DMPRZX4 DMPRZX4 DN LAS 100977 DMPRZX4 HS Phase 2 DMPRZX4 SN LABA DMPRZX4 CP Almirall; Forest Laboratories DMPRZX4 DT Small molecular drug DMPRZX4 PC 11962616 DMPRZX4 MW 460.5 DMPRZX4 FM C25H30F2N2O4 DMPRZX4 IC InChI=1S/C25H30F2N2O4/c26-25(27,18-8-4-3-5-9-18)17-33-15-7-2-1-6-14-28-16-22(31)19-10-12-21(30)24-20(19)11-13-23(32)29-24/h3-5,8-13,22,28,30-31H,1-2,6-7,14-17H2,(H,29,32)/t22-/m0/s1 DMPRZX4 CS C1=CC=C(C=C1)C(COCCCCCCNC[C@@H](C2=C3C=CC(=O)NC3=C(C=C2)O)O)(F)F DMPRZX4 IK SFYAXIFVXBKRPK-QFIPXVFZSA-N DMPRZX4 IU 5-[(1R)-2-[6-(2,2-difluoro-2-phenylethoxy)hexylamino]-1-hydroxyethyl]-8-hydroxy-1H-quinolin-2-one DMPRZX4 CA CAS 915133-65-2 DMPRZX4 CB CHEBI:142077 DMPRZX4 DE Chronic obstructive pulmonary disease DM3WY0B ID DM3WY0B DM3WY0B DN LAS-41002 DM3WY0B HS Phase 2 DM3WY0B SN Monovo; Corticosteroid receptor modulator (eczema, psoriasis), Almirall DM3WY0B CP Almirall Prodesfarma SA DM3WY0B DE Eczema DMC04SR ID DMC04SR DMC04SR DN LB-100 DMC04SR HS Phase 2 DMC04SR DT Small molecular drug DMC04SR PC 3578572 DMC04SR MW 268.31 DMC04SR FM C13H20N2O4 DMC04SR IC InChI=1S/C13H20N2O4/c1-14-4-6-15(7-5-14)12(16)10-8-2-3-9(19-8)11(10)13(17)18/h8-11H,2-7H2,1H3,(H,17,18) DMC04SR CS CN1CCN(CC1)C(=O)C2C3CCC(C2C(=O)O)O3 DMC04SR IK JUQMLSGOTNKJKI-UHFFFAOYSA-N DMC04SR IU 3-(4-methylpiperazine-1-carbonyl)-7-oxabicyclo[2.2.1]heptane-2-carboxylic acid DMC04SR DE Solid tumour/cancer; Astrocytoma DM0OHX3 ID DM0OHX3 DM0OHX3 DN LB-30870 DM0OHX3 HS Phase 2 DM0OHX3 SN N-(Carboxymethyl)-D-diphenylalanyl-L-proline 5-amidinothien-2-ylmethyl amide bis(trifluoroacetate) DM0OHX3 PC 9871765 DM0OHX3 MW 533.6 DM0OHX3 FM C28H31N5O4S DM0OHX3 IC InChI=1S/C28H31N5O4S/c29-26(30)22-14-13-20(38-22)16-32-27(36)21-12-7-15-33(21)28(37)25(31-17-23(34)35)24(18-8-3-1-4-9-18)19-10-5-2-6-11-19/h1-6,8-11,13-14,21,24-25,31H,7,12,15-17H2,(H3,29,30)(H,32,36)(H,34,35)/t21-,25+/m0/s1 DM0OHX3 CS C1C[C@H](N(C1)C(=O)[C@@H](C(C2=CC=CC=C2)C3=CC=CC=C3)NCC(=O)O)C(=O)NCC4=CC=C(S4)C(=N)N DM0OHX3 IK BIHPYGVYKSQDLA-SQJMNOBHSA-N DM0OHX3 IU 2-[[(2R)-1-[(2S)-2-[(5-carbamimidoylthiophen-2-yl)methylcarbamoyl]pyrrolidin-1-yl]-1-oxo-3,3-diphenylpropan-2-yl]amino]acetic acid DM0OHX3 CA CAS 280780-95-2 DM0OHX3 DE Myocardial infarction DMQZJNA ID DMQZJNA DMQZJNA DN LCAR-B38M CAR-T Cell DMQZJNA HS Phase 2 DMQZJNA CP Nanjing Legend Biotech Co. DMQZJNA DT CAR T Cell Therapy DMQZJNA DE Multiple myeloma DMY4IWC ID DMY4IWC DMY4IWC DN LCB-2183 DMY4IWC HS Phase 2 DMY4IWC PC 135418284 DMY4IWC MW 206.2 DMY4IWC FM C9H10N4O2 DMY4IWC IC InChI=1S/C9H10N4O2/c1-2-15-5-6-12-8-7(9(14)13-6)10-3-4-11-8/h3-4H,2,5H2,1H3,(H,11,12,13,14) DMY4IWC CS CCOCC1=NC2=NC=CN=C2C(=O)N1 DMY4IWC IK SFWVULIFVPNTOF-UHFFFAOYSA-N DMY4IWC IU 2-(ethoxymethyl)-3H-pteridin-4-one DMY4IWC CA CAS 133914-85-9 DMY4IWC DE Asthma DMTM4QA ID DMTM4QA DMTM4QA DN LCL161 DMTM4QA HS Phase 2 DMTM4QA CP Novartis DMTM4QA PC 24737642 DMTM4QA MW 500.6 DMTM4QA FM C26H33FN4O3S DMTM4QA IC InChI=1S/C26H33FN4O3S/c1-16(28-2)24(33)30-22(17-7-4-3-5-8-17)26(34)31-14-6-9-21(31)25-29-20(15-35-25)23(32)18-10-12-19(27)13-11-18/h10-13,15-17,21-22,28H,3-9,14H2,1-2H3,(H,30,33)/t16-,21-,22-/m0/s1 DMTM4QA CS C[C@@H](C(=O)N[C@@H](C1CCCCC1)C(=O)N2CCC[C@H]2C3=NC(=CS3)C(=O)C4=CC=C(C=C4)F)NC DMTM4QA IK UFPFGVNKHCLJJO-SSKFGXFMSA-N DMTM4QA IU (2S)-N-[(1S)-1-cyclohexyl-2-[(2S)-2-[4-(4-fluorobenzoyl)-1,3-thiazol-2-yl]pyrrolidin-1-yl]-2-oxoethyl]-2-(methylamino)propanamide DMTM4QA CA CAS 1005342-46-0 DMTM4QA DE Solid tumour/cancer; Breast cancer; Multiple myeloma; Myelofibrosis DMM9F25 ID DMM9F25 DMM9F25 DN LDE225 DMM9F25 HS Phase 2 DMM9F25 SN Erismodegib DMM9F25 CP Novartis Pharmaceuticals DMM9F25 DT Small molecular drug DMM9F25 PC 24775005 DMM9F25 MW 485.5 DMM9F25 FM C26H26F3N3O3 DMM9F25 IC InChI=1S/C26H26F3N3O3/c1-16-14-32(15-17(2)34-16)24-12-9-20(13-30-24)31-25(33)23-6-4-5-22(18(23)3)19-7-10-21(11-8-19)35-26(27,28)29/h4-13,16-17H,14-15H2,1-3H3,(H,31,33)/t16-,17+ DMM9F25 CS C[C@@H]1CN(C[C@@H](O1)C)C2=NC=C(C=C2)NC(=O)C3=CC=CC(=C3C)C4=CC=C(C=C4)OC(F)(F)F DMM9F25 IK VZZJRYRQSPEMTK-CALCHBBNSA-N DMM9F25 IU N-[6-[(2S,6R)-2,6-dimethylmorpholin-4-yl]pyridin-3-yl]-2-methyl-3-[4-(trifluoromethoxy)phenyl]benzamide DMM9F25 CA CAS 956697-53-3 DMM9F25 CB CHEBI:90863 DMM9F25 DE Skin cancer; Medulloblastoma DMIEZUB ID DMIEZUB DMIEZUB DN L-DOS47 DMIEZUB HS Phase 2 DMIEZUB CP Helix BioPharma DMIEZUB DE Lung cancer; Non-small-cell lung cancer; Non-small cell lung cancer DMS6E9J ID DMS6E9J DMS6E9J DN Lefitolimod DMS6E9J HS Phase 2 DMS6E9J SN MGN1703 DMS6E9J CP Mologen DMS6E9J DE Human immunodeficiency virus-1 infection DMV2YDK ID DMV2YDK DMV2YDK DN LEISH-F1 DMV2YDK HS Phase 2 DMV2YDK SN LeIF adjuvant, Corixa; Leish-111f; Leishmanial eukaryotic initiation factor, Corixa; Leishmaniasis vaccine (LeIF), Corixa; Leishmaniasis vaccine, Corixa/ Infectious Disease Research Institute; Vaccine (leishmania), Corixa; LeIF enhanced T-cell vaccine, Corixa, Infectious Disease Research Institute DMV2YDK CP Infectious Disease Research Institute DMV2YDK DT Vaccine DMV2YDK DE Leishmania infection DMZKBMG ID DMZKBMG DMZKBMG DN Lenapenem hydrochloride hydrate DMZKBMG HS Phase 2 DMZKBMG SN BO-2727; L-739428 DMZKBMG CP MSD Japan DMZKBMG DT Small molecular drug DMZKBMG PC 443100 DMZKBMG MW 454 DMZKBMG FM C18H32ClN3O6S DMZKBMG IC InChI=1S/C18H29N3O5S.ClH.H2O/c1-8-14-13(9(2)22)17(24)21(14)15(18(25)26)16(8)27-10-6-11(20-7-10)12(23)4-5-19-3;;/h8-14,19-20,22-23H,4-7H2,1-3H3,(H,25,26);1H;1H2/t8-,9-,10+,11+,12-,13-,14-;;/m1../s1 DMZKBMG CS C[C@@H]1[C@@H]2[C@H](C(=O)N2C(=C1S[C@H]3C[C@H](NC3)[C@@H](CCNC)O)C(=O)O)[C@@H](C)O.O.Cl DMZKBMG IK FNSICOGCVDQJPU-HCRFUVGVSA-N DMZKBMG IU (4R,5S,6S)-6-[(1R)-1-hydroxyethyl]-3-[(3S,5S)-5-[(1R)-1-hydroxy-3-(methylamino)propyl]pyrrolidin-3-yl]sulfanyl-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid;hydrate;hydrochloride DMZKBMG CA CAS 149882-71-3 DMZKBMG DE Bacterial infection DMWAD93 ID DMWAD93 DMWAD93 DN Leniolisib DMWAD93 HS Phase 2 DMWAD93 SN 1354690-24-6; Leniolisib free base; UNII-L22772Z9CP; (S)-1-(3-((6-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)propan-1-one; L22772Z9CP; 1354690-24-6 (free base); leniolisib(CDZ 173); CDZ173; CDZ-173; 1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one; Leniolisib [INN]; Leniolisib (CDZ173); Leniolisib; CDZ173; Leniolisib (USAN/INN); CDZ173-NX; SCHEMBL323054; GTPL9424; CHEMBL3643413; BDBM118299; EX-A2854; MFCD30470232; s8752; ZB1510; CS-7524; DC22326; SB18839; Example 67 [WO2012004299]; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-y; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one; AS-56217; HY-17635; A16796; D11158; US8653092, 67; Q27282602; 1-Propanone, 1-((3S)-3-((5,6,7,8-tetrahydro-6-(6-methoxy-5-(trifluoromethyl)-3-pyridinyl)pyrido(4,3-d)pyrimidin-4-yl)amino)-1-pyrrolidinyl)-; 9NQ DMWAD93 CP Novartis DMWAD93 DT Small molecular drug DMWAD93 PC 57495353 DMWAD93 MW 450.5 DMWAD93 FM C21H25F3N6O2 DMWAD93 IC InChI=1S/C21H25F3N6O2/c1-3-18(31)30-6-4-13(10-30)28-19-15-11-29(7-5-17(15)26-12-27-19)14-8-16(21(22,23)24)20(32-2)25-9-14/h8-9,12-13H,3-7,10-11H2,1-2H3,(H,26,27,28)/t13-/m0/s1 DMWAD93 CS CCC(=O)N1CC[C@@H](C1)NC2=NC=NC3=C2CN(CC3)C4=CC(=C(N=C4)OC)C(F)(F)F DMWAD93 IK MWKYMZXCGYXLPL-ZDUSSCGKSA-N DMWAD93 IU 1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one DMWAD93 CA CAS 1354690-24-6 DMWAD93 DE Sjogren syndrome DMR1MQW ID DMR1MQW DMR1MQW DN Lenzilumab DMR1MQW HS Phase 2 DMR1MQW CP Humanigen Brisbane, CA DMR1MQW DE Chronic myelogenous leukaemia; Coronavirus Disease 2019 (COVID-19) DM7W0JE ID DM7W0JE DM7W0JE DN LEO 124249 DM7W0JE HS Phase 2 DM7W0JE SN delgocitinib; Delgocitinib; UNII-9L0Q8KK220; JTE-052; 9L0Q8KK220; 1263774-59-9; Delgocitinib [USAN]; Delgocitinib (JAN/USAN); JTE052; JTE-052A; GTPL9619; SCHEMBL12547007; LEO 124249A; HY-109053; CS-0031558; D11046; 1,6-Diazaspiro(3.4)octane-1-propanenitrile, 3-methyl-beta-oxo-6-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)-, (3S,4R)-; 3-((3S,4R)-3-methyl-6-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)-1,6-diazaspiro(3.4)octan-1-yl)-3-oxopropanenitrile DM7W0JE CP LEO Pharma Madison, NJ DM7W0JE PC 50914062 DM7W0JE MW 310.35 DM7W0JE FM C16H18N6O DM7W0JE IC InChI=1S/C16H18N6O/c1-11-8-22(13(23)2-5-17)16(11)4-7-21(9-16)15-12-3-6-18-14(12)19-10-20-15/h3,6,10-11H,2,4,7-9H2,1H3,(H,18,19,20)/t11-,16-/m0/s1 DM7W0JE CS C[C@H]1CN([C@]12CCN(C2)C3=NC=NC4=C3C=CN4)C(=O)CC#N DM7W0JE IK LOWWYYZBZNSPDT-ZBEGNZNMSA-N DM7W0JE IU 3-[(3S,4R)-3-methyl-7-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,7-diazaspiro[3.4]octan-1-yl]-3-oxopropanenitrile DM7W0JE CA CAS 1263774-59-9 DM7W0JE DE Asthma; Eczema DMZ6Y0T ID DMZ6Y0T DMZ6Y0T DN LEO-32731 DMZ6Y0T HS Phase 2 DMZ6Y0T SN LP0058 DMZ6Y0T CP LEO Pharma A/S DMZ6Y0T PC 54765967 DMZ6Y0T MW 510.3 DMZ6Y0T FM C19H15Cl2F2NO7S DMZ6Y0T IC InChI=1S/C19H15Cl2F2NO7S/c20-12-8-24(26)9-13(21)11(12)7-14(25)10-1-2-15(29-18(22)23)17-16(10)30-19(31-17)3-5-32(27,28)6-4-19/h1-2,8-9,18H,3-7H2 DMZ6Y0T CS C1CS(=O)(=O)CCC12OC3=C(C=CC(=C3O2)OC(F)F)C(=O)CC4=C(C=[N+](C=C4Cl)[O-])Cl DMZ6Y0T IK ZININGNRPUGNSL-UHFFFAOYSA-N DMZ6Y0T IU 2-(3,5-dichloro-1-oxidopyridin-1-ium-4-yl)-1-[7-(difluoromethoxy)-1',1'-dioxospiro[1,3-benzodioxole-2,4'-thiane]-4-yl]ethanone DMZ6Y0T CA CAS 1353546-86-7 DMZ6Y0T DE Psoriasis vulgaris; Plaque psoriasis DM6DL5K ID DM6DL5K DM6DL5K DN Leridistim DM6DL5K HS Phase 2 DM6DL5K SN MPO, Searle; MPO-1; SC-70935; Myelopoietin (1), Searle DM6DL5K CP GD Searle & Co DM6DL5K DE Immune System disease DMMQ6VT ID DMMQ6VT DMMQ6VT DN Leronlimab DMMQ6VT HS Phase 2 DMMQ6VT SN PRO 140 DMMQ6VT TC Antiviral Agents DMMQ6VT DT Monoclonal antibody DMMQ6VT DE Coronavirus Disease 2019 (COVID-19) DMSEVBH ID DMSEVBH DMSEVBH DN Lersivirine DMSEVBH HS Phase 2 DMSEVBH SN cc-718; Lersivirine (UK-453061) DMSEVBH CP ViiV Healthcare DMSEVBH DT Small molecular drug DMSEVBH PC 16739244 DMSEVBH MW 310.35 DMSEVBH FM C17H18N4O2 DMSEVBH IC InChI=1S/C17H18N4O2/c1-3-15-17(16(4-2)21(20-15)5-6-22)23-14-8-12(10-18)7-13(9-14)11-19/h7-9,22H,3-6H2,1-2H3 DMSEVBH CS CCC1=C(C(=NN1CCO)CC)OC2=CC(=CC(=C2)C#N)C#N DMSEVBH IK MCPUZZJBAHRIPO-UHFFFAOYSA-N DMSEVBH IU 5-[3,5-diethyl-1-(2-hydroxyethyl)pyrazol-4-yl]oxybenzene-1,3-dicarbonitrile DMSEVBH CA CAS 473921-12-9 DMSEVBH DE Human immunodeficiency virus infection DMW50NF ID DMW50NF DMW50NF DN LE-SN38 DMW50NF HS Phase 2 DMW50NF SN 7-Ethyl-10-hydroxycamptothecin; 86639-52-3; SN-38; SN 38 lactone; 7-Ethyl-10-hydroxy-camptothecin; SN 38; 10-Hydroxy-7-ethylcamptothecin; 7-Ethyl-10-hydroxycamptothecine; SN38; 7-Ethyl-10-hydroxy-20(S)-camptothecin; UNII-0H43101T0J; Captothecin, 7-ethyl-10-hydroxy-; CHEBI:8988; (S)-4,11-Diethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; 7-Ethyl-10-hydroxy camptothecin; NSC673596; 0H43101T0J; (+)-7-ETHYL-10-HYDROXYCAMPTOTHECIN; 113015-38-6 DMW50NF CP NeoPharm DMW50NF DT Small molecular drug DMW50NF PC 104842 DMW50NF MW 392.4 DMW50NF FM C22H20N2O5 DMW50NF IC InChI=1S/C22H20N2O5/c1-3-12-13-7-11(25)5-6-17(13)23-19-14(12)9-24-18(19)8-16-15(20(24)26)10-29-21(27)22(16,28)4-2/h5-8,25,28H,3-4,9-10H2,1-2H3/t22-/m0/s1 DMW50NF CS CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)[C@@]4(CC)O)C2=NC5=C1C=C(C=C5)O DMW50NF IK FJHBVJOVLFPMQE-QFIPXVFZSA-N DMW50NF IU (19S)-10,19-diethyl-7,19-dihydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaene-14,18-dione DMW50NF CA CAS 86639-52-3 DMW50NF CB CHEBI:8988 DMW50NF DE Solid tumour/cancer; Colorectal cancer DMIFGLY ID DMIFGLY DMIFGLY DN Leukemia cancer vaccine DMIFGLY HS Phase 2 DMIFGLY CP BioSante Pharmaceuticals DMIFGLY DT Vaccine DMIFGLY DE Acute myeloid leukaemia DM5LQEI ID DM5LQEI DM5LQEI DN Leuvectin DM5LQEI HS Phase 2 DM5LQEI SN IL-2 gene therapy, Vical; Cytofectin (IL-2), Vical; Gene therapy (interleukin-2), Vical DM5LQEI CP Vical Inc DM5LQEI DE Melanoma DMOS5JZ ID DMOS5JZ DMOS5JZ DN Lexatumumab DMOS5JZ HS Phase 2 DMOS5JZ SN HGS-ETR2; TRAIL receptor-2 monoclonal antibodies (cancer), HGS/CAT; TRAIL-R2 mAbs (cancer), Human Genome Sciences/Cambridge Antibody Technology; TNF-related apoptosis-inducing ligand receptor-2 mAbs (cancer), HGS/CAT DMOS5JZ CP Cambridge Antibody Technology Group plc DMOS5JZ DT Antibody DMOS5JZ DE Solid tumour/cancer DMLEX1D ID DMLEX1D DMLEX1D DN Lexibulin DMLEX1D HS Phase 2 DMLEX1D SN Lexibulin; CYT-997; Microtubule inhibitor (oral, solid tumors) Cytopia; VDA anticancer program (iv), Cytopia; Lexibulin (iv infusion, cancer), YM BioSciences; Lexibulin (oral capsule, cancer), YM Biosciences; CYT-997 (iv infusion, cancer), Cytopia; CYT-997 (iv infusion, cancer), YM BioSciences; CYT-997 (oral capsule, cancer), Cytopia; CYT-997 (oral capsule, cancer), YM Biosciences; Vascular disrupting agent/ tubulin inhibitor (iv, cancer), Cytopia; Vascular disrupting agent/tubulin inhibitor (oral, cancer), Cytopia; Vascular targeting agent/ tubulin inhibitor (iv, cancer), Cytopia DMLEX1D CP Cytopia Ltd; Cytopia DMLEX1D DE Glioblastoma multiforme DMZ2YBE ID DMZ2YBE DMZ2YBE DN Lexipafant DMZ2YBE HS Phase 2 DMZ2YBE SN LEXIPAFANT; 139133-26-9; UNII-H14917M9YW; BB-882; CHEMBL322832; H14917M9YW; DO6; Lexipafant [USAN:INN:BAN]; BB 882; Lexipafant (USAN/INN); SCHEMBL194598; ZINC1851122; BDBM50048485; N-Methyl-N-((alpha-(2-methyl-1H-imidazo(4,5-c)pyridin-1-yl)-p-tolyl)sulfonyl)-L-leucine, ethyl ester; D04724; L-Leucine, N-methyl-N-((4-((2-methyl-1H-imidazo(4,5-c)pyridin-1-yl)ethyl)phenyl)sulfonyl)-, ethyl ester; ETHYL4-METHYL-2-[METHYL-[4-[(2-METHYLIMIDAZO[4,5-C]PYRIDIN-1-YL)METHYL]PHENYL]SULFONYLAMINO]PENTANOATE; Benzothiadiazines DMZ2YBE DT Small molecular drug DMZ2YBE PC 9804204 DMZ2YBE MW 458.6 DMZ2YBE FM C23H30N4O4S DMZ2YBE IC InChI=1S/C23H30N4O4S/c1-6-31-23(28)22(13-16(2)3)26(5)32(29,30)19-9-7-18(8-10-19)15-27-17(4)25-20-14-24-12-11-21(20)27/h7-12,14,16,22H,6,13,15H2,1-5H3/t22-/m0/s1 DMZ2YBE CS CCOC(=O)[C@H](CC(C)C)N(C)S(=O)(=O)C1=CC=C(C=C1)CN2C(=NC3=C2C=CN=C3)C DMZ2YBE IK AQRXDPFOYJSPMP-QFIPXVFZSA-N DMZ2YBE IU ethyl (2S)-4-methyl-2-[methyl-[4-[(2-methylimidazo[4,5-c]pyridin-1-yl)methyl]phenyl]sulfonylamino]pentanoate DMZ2YBE CA CAS 139133-26-9 DMZ2YBE DE Hepatovirus infection; Nerve injury DMCT1RQ ID DMCT1RQ DMCT1RQ DN LFG-316 DMCT1RQ HS Phase 2 DMCT1RQ CP Novartis AG DMCT1RQ DT Antibody DMCT1RQ DE Macular degeneration DM9T8A2 ID DM9T8A2 DM9T8A2 DN LGD-4665 DM9T8A2 HS Phase 2 DM9T8A2 CP Ligand DM9T8A2 DE Immune thrombocytopenic purpura DMPL9KG ID DMPL9KG DMPL9KG DN LGD-6972 DMPL9KG HS Phase 2 DMPL9KG SN MB-11262 DMPL9KG CP Ligand pharmaceuticals DMPL9KG PC 44625560 DMPL9KG MW 702.9 DMPL9KG FM C43H46N2O5S DMPL9KG IC InChI=1S/C43H46N2O5S/c1-28-25-29(2)40(30(3)26-28)35-17-21-38(22-18-35)45-42(47)39(27-31-7-9-36(10-8-31)41(46)44-23-24-51(48,49)50)34-13-11-32(12-14-34)33-15-19-37(20-16-33)43(4,5)6/h7-22,25-26,39H,23-24,27H2,1-6H3,(H,44,46)(H,45,47)(H,48,49,50)/t39-/m1/s1 DMPL9KG CS CC1=CC(=C(C(=C1)C)C2=CC=C(C=C2)NC(=O)[C@H](CC3=CC=C(C=C3)C(=O)NCCS(=O)(=O)O)C4=CC=C(C=C4)C5=CC=C(C=C5)C(C)(C)C)C DMPL9KG IK HKJMCBYPVCGZFB-LDLOPFEMSA-N DMPL9KG IU 2-[[4-[(2R)-2-[4-(4-tert-butylphenyl)phenyl]-3-oxo-3-[4-(2,4,6-trimethylphenyl)anilino]propyl]benzoyl]amino]ethanesulfonic acid DMPL9KG CA CAS 1207989-09-0 DMPL9KG DE Type-2 diabetes; Non-insulin dependent diabetes DMA0RI9 ID DMA0RI9 DMA0RI9 DN LIDORESTAT DMA0RI9 HS Phase 2 DMA0RI9 SN Lidorestat; 245116-90-9; IDD-676; UNII-R3734K0M7L; IDD-000676-01; {3-[(4,5,7-TRIFLUORO-1,3-BENZOTHIAZOL-2-YL)METHYL]-1H-INDOL-1-YL}ACETIC ACID; CHEMBL363387; R3734K0M7L; 1H-Indole-1-aceticacid, 3-[(4,5,7-trifluoro-2-benzothiazolyl)methyl]-; 3-[(4,5,7-TRIFLUOROBENZOTHIAZOL-2-YL)METHYL]INDOLE-N-ACETIC ACID; 3NA; Lidorestat [USAN:INN]; 2-[3-[(4,5,7-trifluoro-1,3-benzothiazol-2-yl)methyl]indol-1-yl]acetic acid; 1H-Indole-1-acetic acid, 3-[(4,5,7-trifluoro-2-benzothiazolyl)methyl]-; 1H-Indole-1-acetic acid, 3-((4,5,7-trifluor DMA0RI9 DT Small molecular drug DMA0RI9 PC 157839 DMA0RI9 MW 376.4 DMA0RI9 FM C18H11F3N2O2S DMA0RI9 IC InChI=1S/C18H11F3N2O2S/c19-11-6-12(20)18-17(16(11)21)22-14(26-18)5-9-7-23(8-15(24)25)13-4-2-1-3-10(9)13/h1-4,6-7H,5,8H2,(H,24,25) DMA0RI9 CS C1=CC=C2C(=C1)C(=CN2CC(=O)O)CC3=NC4=C(C(=CC(=C4S3)F)F)F DMA0RI9 IK KYHVTMFADJNSGS-UHFFFAOYSA-N DMA0RI9 IU 2-[3-[(4,5,7-trifluoro-1,3-benzothiazol-2-yl)methyl]indol-1-yl]acetic acid DMA0RI9 CA CAS 245116-90-9 DMA0RI9 DE Diabetic complication DM32NWD ID DM32NWD DM32NWD DN LIK-066 DM32NWD HS Phase 2 DM32NWD CP Novartis AG DM32NWD PC 52913524 DM32NWD MW 416.5 DM32NWD FM C23H28O7 DM32NWD IC InChI=1S/C23H28O7/c1-2-14-4-5-15(23-22(27)21(26)20(25)19(12-24)30-23)11-16(14)9-13-3-6-17-18(10-13)29-8-7-28-17/h3-6,10-11,19-27H,2,7-9,12H2,1H3/t19-,20-,21+,22-,23+/m1/s1 DM32NWD CS CCC1=C(C=C(C=C1)[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)CC3=CC4=C(C=C3)OCCO4 DM32NWD IK XFJAMQQAAMJFGB-ZQGJOIPISA-N DM32NWD IU (2S,3R,4R,5S,6R)-2-[3-(2,3-dihydro-1,4-benzodioxin-6-ylmethyl)-4-ethylphenyl]-6-(hydroxymethyl)oxane-3,4,5-triol DM32NWD CA CAS 1291094-73-9 DM32NWD DE Type-2 diabetes; Heart failure DM9ZHRS ID DM9ZHRS DM9ZHRS DN LIM-0705 DM9ZHRS HS Phase 2 DM9ZHRS CP Limerick Biopharma DM9ZHRS PC 20833257 DM9ZHRS MW 382.21 DM9ZHRS FM C15H11O10P DM9ZHRS IC InChI=1S/C15H11O10P/c16-7-4-9(18)12-11(5-7)24-15(14(20)13(12)19)6-1-2-8(17)10(3-6)25-26(21,22)23/h1-5,16-18,20H,(H2,21,22,23) DM9ZHRS CS C1=CC(=C(C=C1C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O)OP(=O)(O)O)O DM9ZHRS IK UWJBYNLLMAPJMM-UHFFFAOYSA-N DM9ZHRS IU [2-hydroxy-5-(3,5,7-trihydroxy-4-oxochromen-2-yl)phenyl] dihydrogen phosphate DM9ZHRS CA CAS 1111616-69-3 DM9ZHRS DE Insulin-resistant disorder DMSHGWN ID DMSHGWN DMSHGWN DN Lintopride DMSHGWN HS Phase 2 DMSHGWN SN SL-920075 DMSHGWN CP Synthelabo DMSHGWN DT Small molecular drug DMSHGWN PC 65900 DMSHGWN MW 310.78 DMSHGWN FM C14H19ClN4O2 DMSHGWN IC InChI=1S/C14H19ClN4O2/c1-3-19-5-4-17-13(19)8-18-14(20)9-6-10(15)11(16)7-12(9)21-2/h6-7H,3-5,8,16H2,1-2H3,(H,18,20) DMSHGWN CS CCN1CCN=C1CNC(=O)C2=CC(=C(C=C2OC)N)Cl DMSHGWN IK MJCKISCWHDATBN-UHFFFAOYSA-N DMSHGWN IU 4-amino-5-chloro-N-[(1-ethyl-4,5-dihydroimidazol-2-yl)methyl]-2-methoxybenzamide DMSHGWN CA CAS 107429-63-0 DMSHGWN DE Nausea DMWY0V1 ID DMWY0V1 DMWY0V1 DN LIPO-5 DMWY0V1 HS Phase 2 DMWY0V1 SN HIV vaccine (lipoprotein), ANRS/Aventis Pasteur DMWY0V1 CP Sanofi Pasteur DMWY0V1 DT Vaccine DMWY0V1 DE Human immunodeficiency virus infection DMNGT89 ID DMNGT89 DMNGT89 DN Lirilumab DMNGT89 HS Phase 2 DMNGT89 CP Bristol-Myers Squibb DMNGT89 DT Monoclonal antibody DMNGT89 DE Acute myeloid leukaemia; Solid tumour/cancer; Chronic lymphocytic leukaemia; Myelodysplastic syndrome DMD4KAU ID DMD4KAU DMD4KAU DN LIRIMILAST DMD4KAU HS Phase 2 DMD4KAU SN Lirimilast; Methanesulfonic acid 2-(2,4-dichlorophenylcarbonyl)-3-ureidobenzofuran-6-ylester DMD4KAU DT Small molecular drug DMD4KAU PC 6433118 DMD4KAU MW 443.3 DMD4KAU FM C17H12Cl2N2O6S DMD4KAU IC InChI=1S/C17H12Cl2N2O6S/c1-28(24,25)27-9-3-5-11-13(7-9)26-16(14(11)21-17(20)23)15(22)10-4-2-8(18)6-12(10)19/h2-7H,1H3,(H3,20,21,23) DMD4KAU CS CS(=O)(=O)OC1=CC2=C(C=C1)C(=C(O2)C(=O)C3=C(C=C(C=C3)Cl)Cl)NC(=O)N DMD4KAU IK YPFLFUJKZDAXRA-UHFFFAOYSA-N DMD4KAU IU [3-(carbamoylamino)-2-(2,4-dichlorobenzoyl)-1-benzofuran-6-yl] methanesulfonate DMD4KAU CA CAS 329306-27-6 DMD4KAU DE Chronic obstructive pulmonary disease DMVU9X1 ID DMVU9X1 DMVU9X1 DN Lisofylline DMVU9X1 HS Phase 2 DMVU9X1 SN LISOFYLLINE; (R)-Lisofylline; 100324-81-0; CT-1501R; ProTec; Lisophylline; NSMXQKNUPPXBRG-SECBINFHSA-N; (R)-Lisophylline; 3,7-Dihydro-1-[(5R)-5-hydroxyhexyl]-3,7-dimethyl-1H-purine-2,6-dione; UNII-L1F2Q2X956; 1-[(5R)-5-hydroxyhexyl]-3,7-dimethylpurine-2,6-dione; L1F2Q2X956; ProTec (TN); AC1L9UOZ; Lisofylline (USAN/INN); CHEMBL1411; SCHEMBL39131; GTPL9225; DTXSID7058709; CTK8E6838; CT1501R; MolPort-005-943-169; ZINC1887263; LSF; 1836AH; AKOS025394050; SB18959; DB12406; NCGC00186630-01; FT-0670822 DMVU9X1 CP DiaKine Therapeutics DMVU9X1 DT Small molecular drug DMVU9X1 PC 501254 DMVU9X1 MW 280.32 DMVU9X1 FM C13H20N4O3 DMVU9X1 IC InChI=1S/C13H20N4O3/c1-9(18)6-4-5-7-17-12(19)10-11(14-8-15(10)2)16(3)13(17)20/h8-9,18H,4-7H2,1-3H3/t9-/m1/s1 DMVU9X1 CS C[C@H](CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C)O DMVU9X1 IK NSMXQKNUPPXBRG-SECBINFHSA-N DMVU9X1 IU 1-[(5R)-5-hydroxyhexyl]-3,7-dimethylpurine-2,6-dione DMVU9X1 CA CAS 100324-81-0 DMVU9X1 CB CHEBI:143527 DMVU9X1 DE Type-1 diabetes DMZ3OU6 ID DMZ3OU6 DMZ3OU6 DN Lithium DMZ3OU6 HS Phase 2 DMZ3OU6 SN 7439-93-2; Li; litio; UNII-9FN79X2M3F; 9FN79X2M3F; CHEBI:30145; MFCD00134051; Litium; Lithium, metallic; Lithium, elemental; Lithium, 99+%, granular, dry; Lithium compounds; 3Li; HSDB 647; EINECS 231-102-5; UN1415; monolithium; Lithium standard solution, for AAS, 1 mg-ml Li in 2% HCl; Hydrure de lithium [French]; Lithium ribbon; Lithium rod; HSDB 549; Lithium granules; EINECS 231-484-3; UN1414; UN2805; Normothymin-E (TN); Epitope ID:114079; EC 231-102-5; Lithium, 99%, low sodium; Lithium, 99%, high sodium; CHEMBL2146126; DTXSID5036761; HSDB 6900; 7321AH; AKOS015833388; AKOS015902481; HSD6900000; Lithium wire, 3.2mm (0.125in) dia; Lithium [UN1415] [Dangerous when wet]; Lithium granules, 1-6mm (0.04-0.2in); Lithium, granular, 99% trace metals basis; FT-0627905; C15473; D08133; EC 231-484-3; Lithium hydride [UN1414] [Dangerous when wet]; Lithium, shot, 99%, 4-16 mesh, in mineral oil; Lithium, wire, diam. 3.2 mm, in mineral oil, >=98%; Lithium, ~25 wt % dispersion in mineral oil, high sodium; Lithium, AAS standard solution, Specpure?, Li 1000?g/ml; Lithium, ingot, diam. 5.7 cm, 99.9% trace metals basis; Lithium, rod, diam. 12.7 mm, 99.9% trace metals basis; Lithium foil, 0.75mm (0.03in) thick x 19mm (0.75in) wide; Lithium hydride, fused solid [UN2805] [Dangerous when wet]; Lithium ingot, 5.7cm (2.2in) dia x 8.6cm (3.4in) long; Lithium, Oil based standard solution, Specpure, Li 5000g/g; Lithium, plasma standard solution, Specpure?, Li 10,000?g/ml; Lithium, plasma standard solution, Specpure?, Li 1000?g/ml; Lithium, rod, 12.7 mm diameter, length 165 mm, purity 99%; Lithium, rod, 12.7 mm diameter, length 200 mm, purity 99%; Lithium, foil, 25x100mm, thickness 0.6mm, as rolled, 99.9%; Lithium, Oil based standard solution, Specpure(R), Li 1000?g/g; Lithium, foil, thickness 0.6 mm, size 25 x 300 mm, purity 99.9%; Lithium, Ion chromatography standard solution, Specpure, Li+ 1000?g/ml; Lithium, wire (in mineral oil), diam. 3.2 mm, 99.9% trace metals basis; Lithium, foil, not light tested, 38x200mm, thickness 0.20mm, as rolled, 99.9%; Lithium, foil, not light tested, 38x500mm, thickness 0.20mm, as rolled, 99.9%; Lithium, foil, not light tested, 45x200mm, thickness 0.12mm, as rolled, 99.9%; Lithium, granular, 4-10 mesh particle size, high sodium, 99% (metals basis); Lithium, ribbon, thickness x W 0.38 mm x 23 mm, 99.9% trace metals basis; Lithium, ribbon, thickness x W 0.75 mm x 19 mm, 99.9% trace metals basis; Lithium, ribbon, thickness x W 0.75 mm x 45 mm, 99.9% trace metals basis; Lithium, ribbon, thickness x W 1.5 mm x 100 mm, 99.9% trace metals basis DMZ3OU6 DT Small molecular drug DMZ3OU6 PC 3028194 DMZ3OU6 MW 7 DMZ3OU6 FM Li DMZ3OU6 IC InChI=1S/Li DMZ3OU6 CS [Li] DMZ3OU6 IK WHXSMMKQMYFTQS-UHFFFAOYSA-N DMZ3OU6 IU lithium DMZ3OU6 CA CAS 7439-93-2 DMZ3OU6 CB CHEBI:30145 DMZ3OU6 DE Fragile X syndrome DM3XRUH ID DM3XRUH DM3XRUH DN LJN452 DM3XRUH HS Phase 2 DM3XRUH SN Tropifexor; 1383816-29-2; UNII-NMZ08KM76Z; NMZ08KM76Z; CPD1549; Tropifexor [INN]; GTPL9725; SCHEMBL19178329; SCHEMBL17848159; LJN-452; EX-A1934; CS-8153; compound 1 [PMID: 29148806]; ACN-053193; AC-30341; 2-[(1R,3r,5S)-3-({5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl}methoxy)-8-azabicyclo[3.2.1]octan-8-yl]-4-fluoro-1,3-benzothiazole-6-carboxylic acid; HY-107418; 2-((1R,5S)-3-((5-cyclopropyl-3-(2-(trifluoromethoxy)phenyl)isoxazol-4-yl)methoxy)-8-azabicyclo[3.2.1]octan-8-yl)-4-fluorob DM3XRUH CP Novartis Pharmaceuticals East Hanover, NJ DM3XRUH PC 121418176 DM3XRUH MW 603.6 DM3XRUH FM C29H25F4N3O5S DM3XRUH IC InChI=1S/C29H25F4N3O5S/c30-21-9-15(27(37)38)10-23-25(21)34-28(42-23)36-16-7-8-17(36)12-18(11-16)39-13-20-24(35-41-26(20)14-5-6-14)19-3-1-2-4-22(19)40-29(31,32)33/h1-4,9-10,14,16-18H,5-8,11-13H2,(H,37,38)/t16-,17+,18? DM3XRUH CS C1C[C@H]2CC(C[C@@H]1N2C3=NC4=C(C=C(C=C4S3)C(=O)O)F)OCC5=C(ON=C5C6=CC=CC=C6OC(F)(F)F)C7CC7 DM3XRUH IK VYLOOGHLKSNNEK-JWTNVVGKSA-N DM3XRUH IU 2-[(1R,5S)-3-[[5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl]methoxy]-8-azabicyclo[3.2.1]octan-8-yl]-4-fluoro-1,3-benzothiazole-6-carboxylic acid DM3XRUH CA CAS 1383816-29-2 DM3XRUH DE Primary biliary cholangitis DMVM13R ID DMVM13R DMVM13R DN LJPC-401 DMVM13R HS Phase 2 DMVM13R CP La Jolla Pharmaceutical DMVM13R DT Peptide DMVM13R DE Hemochromatosis; Beta thalassemia DMCFGP3 ID DMCFGP3 DMCFGP3 DN LKA651 DMCFGP3 HS Phase 2 DMCFGP3 SN 9-Nov DMCFGP3 CP Novartis DMCFGP3 DT Antibody DMCFGP3 DE Diabetic macular edema DMSJOE3 ID DMSJOE3 DMSJOE3 DN LM-030 DMSJOE3 HS Phase 2 DMSJOE3 CP LifeMax Laboratories Palo Alto, CA DMSJOE3 DE Congenital ichthyosiform erythroderma DMW6VA0 ID DMW6VA0 DMW6VA0 DN LM-1507.NA DMW6VA0 HS Phase 2 DMW6VA0 SN MEN-91507; (E)-8-[2-[4-[4-(4-Fluorophenyl)butoxy]phenyl]vinyl]-2-(1H-tetrazol-5-yl)-4H-benzopyran-4-one sodium salt DMW6VA0 DE Asthma DMG7RAV ID DMG7RAV DMG7RAV DN LMB-2 DMG7RAV HS Phase 2 DMG7RAV SN LMB-2a; AntiTac(Fv)-PE38; Immunotoxin (cancer), National Cancer Institute DMG7RAV CP National Cancer Institute DMG7RAV DE Chronic lymphocytic leukaemia DMQOXNL ID DMQOXNL DMQOXNL DN LMB763 DMQOXNL HS Phase 2 DMQOXNL SN Nidufexor; 1773489-72-7; LMB-763; UNII-CJ1PL0TE6J; CJ1PL0TE6J; 4-[(N-benzyl-8-chloro-1-methyl-1,4-dihydro[1]benzopyrano[4,3-c]pyrazole-3-carboxamido)methyl]benzoic acid; Nidufexor [INN]; CHEMBL4297626; SCHEMBL16702097; GTPL10655; BCP28929; EX-A1854; Nidufexor pound LMB-763 pound(c); BDBM50527021; MFCD31657267; ZINC584641402; compound 1 [PMID: 31940200]; 4-((N-benzyl-8-chloro-1-methyl-1,4-dihydrochromeno[4,3-c]pyrazole-3-carboxamido)methyl)benzoic acid; BS-15605; HY-109096; CS-0039398; Cn1nc(C(=O)N(Cc2ccccc2)Cc2ccc(cc2)C(O)=O)c2COc3ccc(Cl)cc3-c12; 4-[[benzyl-(8-chloro-1-methyl-4H-chromeno[4,3-c]pyrazole-3-carbonyl)amino]methyl]benzoic acid; Benzoic acid, 4-((((8-chloro-1,4-dihydro-1-methyl(1)benzopyrano(4,3-C)pyrazol-3-yl)carbonyl)(phenylmethyl)amino)methyl)- DMQOXNL CP Novartis DMQOXNL DT Small molecular drug DMQOXNL PC 118063735 DMQOXNL MW 487.9 DMQOXNL FM C27H22ClN3O4 DMQOXNL IC InChI=1S/C27H22ClN3O4/c1-30-25-21-13-20(28)11-12-23(21)35-16-22(25)24(29-30)26(32)31(14-17-5-3-2-4-6-17)15-18-7-9-19(10-8-18)27(33)34/h2-13H,14-16H2,1H3,(H,33,34) DMQOXNL CS CN1C2=C(COC3=C2C=C(C=C3)Cl)C(=N1)C(=O)N(CC4=CC=CC=C4)CC5=CC=C(C=C5)C(=O)O DMQOXNL IK JYTIXGYXBIBOMN-UHFFFAOYSA-N DMQOXNL IU 4-[[benzyl-(8-chloro-1-methyl-4H-chromeno[4,3-c]pyrazole-3-carbonyl)amino]methyl]benzoic acid DMQOXNL CA CAS 1773489-72-7 DMQOXNL DE Non-alcoholic steatohepatitis; Diabetic nephropathy DM01SR6 ID DM01SR6 DM01SR6 DN L-NAME DM01SR6 HS Phase 2 DM01SR6 SN N-Nitroarginine methyl ester; NG-NITROARGININE METHYL ESTER; N(G)-Nitroarginine methyl ester; N-Nitro-L-arginine methylester; Ngamma-Nitro-L-arginine methyl ester; N(G)-Nitro-L-arginine methyl ester; N(sup G)-Nitro-L-arginine methyl ester; N-omega-Nitro-O-arginine methyl ester; Methyl (2S)-2-amino-5-[[amino(nitramido)methylidene]amino]pentanoate; Methyl N5-(N'-nitrocarbamimidoyl)-L-ornithinate; N(5)-(Imino(nitroamino)methyl)-L-ornithine methyl ester; N-.omega.-Nitro-O-arginine methyl ester; L-Ornithine, N(5)-(imino(nitroamino)methyl)-, methyl ester; Methyl (2S)-2-amino-5-[(amino-nitramido-methylidene)amino]pentanoate DM01SR6 CP Registry Operator DM01SR6 DT Small molecular drug DM01SR6 PC 39836 DM01SR6 MW 233.23 DM01SR6 FM C7H15N5O4 DM01SR6 IC InChI=1S/C7H15N5O4/c1-16-6(13)5(8)3-2-4-10-7(9)11-12(14)15/h5H,2-4,8H2,1H3,(H3,9,10,11)/t5-/m0/s1 DM01SR6 CS COC(=O)[C@H](CCCN=C(N)N[N+](=O)[O-])N DM01SR6 IK KCWZGJVSDFYRIX-YFKPBYRVSA-N DM01SR6 IU methyl (2S)-2-amino-5-[[amino(nitramido)methylidene]amino]pentanoate DM01SR6 CA CAS 50903-99-6 DM01SR6 CB CHEBI:7549 DM01SR6 DE Hypertension DMT3KB4 ID DMT3KB4 DMT3KB4 DN Lobeline DMT3KB4 HS Phase 2 DMT3KB4 SN lobeline; Lobelin; Inflatine; Lobeline [INN]; Lobelinum [INN-Latin]; Lobelina [INN-Spanish]; EINECS 202-012-3; BRN 0091533; AC1LEL62; ZINC56446; Ethanone, 2-(6-(2-hydroxy-2-phenylethyl)-1-methyl-2-piperidinyl)-1-phenyl-, (2R-(2alpha,6alpha(S*)))-; LS-88107 DMT3KB4 DT Small molecular drug DMT3KB4 PC 101616 DMT3KB4 MW 337.5 DMT3KB4 FM C22H27NO2 DMT3KB4 IC InChI=1S/C22H27NO2/c1-23-19(15-21(24)17-9-4-2-5-10-17)13-8-14-20(23)16-22(25)18-11-6-3-7-12-18/h2-7,9-12,19-21,24H,8,13-16H2,1H3/t19-,20+,21-/m0/s1 DMT3KB4 CS CN1[C@@H](CCC[C@@H]1CC(=O)C2=CC=CC=C2)C[C@@H](C3=CC=CC=C3)O DMT3KB4 IK MXYUKLILVYORSK-HBMCJLEFSA-N DMT3KB4 IU 2-[(2R,6S)-6-[(2S)-2-hydroxy-2-phenylethyl]-1-methylpiperidin-2-yl]-1-phenylethanone DMT3KB4 CA CAS 90-69-7 DMT3KB4 CB CHEBI:48723 DMT3KB4 DE Substance use disorder DMN0VS2 ID DMN0VS2 DMN0VS2 DN Lopinavir + ritonavir + ribavirin + interferon beta-1b DMN0VS2 HS Phase 2 DMN0VS2 SN Aluviran + norvir + rebetol + betaseron DMN0VS2 TC Antiviral Agents DMN0VS2 DT Combination drug DMN0VS2 DE Coronavirus Disease 2019 (COVID-19) DM0GZTD ID DM0GZTD DM0GZTD DN L-ornithine phenylacetate DM0GZTD HS Phase 2 DM0GZTD SN L-ornthine phenylacetate; OCR-002; UCL-L1V; L-ornithine phenylacetate (injectable, acute hepatic encephalopathy); Nitrogen metabolism modulator (injectable, AHE), Ocera; Nitrogen metabolism modulator (injectable, acute hepatic encephalopathy), Ocera; Nitrogen metabolism modulator (injectable, acute hepatic encephalopathy), UCL; Nitrogen metabolism modulator (injectable, hyperammonemia), Ocera; L-ornithine phenylacetate (injectable, AHE), Ocera; L-ornithine phenylacetate (injectable, acute hepatic encephalopathy), Ocera; L-ornithine phenylacetate (injectable, hyperammonemia), Ocera DM0GZTD CP Ocera therapeutics DM0GZTD DT Small molecular drug DM0GZTD PC 44247677 DM0GZTD MW 268.31 DM0GZTD FM C13H20N2O4 DM0GZTD IC InChI=1S/C8H8O2.C5H12N2O2/c9-8(10)6-7-4-2-1-3-5-7;6-3-1-2-4(7)5(8)9/h1-5H,6H2,(H,9,10);4H,1-3,6-7H2,(H,8,9)/t;4-/m.0/s1 DM0GZTD CS C1=CC=C(C=C1)CC(=O)O.C(C[C@@H](C(=O)O)N)CN DM0GZTD IK LRSYFEZBIMVWRY-VWMHFEHESA-N DM0GZTD IU (2S)-2,5-diaminopentanoic acid;2-phenylacetic acid DM0GZTD CA CAS 952154-79-9 DM0GZTD DE Acute liver failure DME8O5K ID DME8O5K DME8O5K DN LOU064 DME8O5K HS Phase 2 DME8O5K CP Novartis Pharmaceuticals East Hanover, NJ DME8O5K DE Chronic idiopathic urticaria DMIV9ZE ID DMIV9ZE DMIV9ZE DN LOXORIBINE DMIV9ZE HS Phase 2 DMIV9ZE SN AOG; Loxoribine < Rec INN; RWJ-21757; 7-(2-Propenyl)-8-oxo-7,8-dihydroguanosine; 7-Allyl-2-amino-9-beta-D-ribofuranosylpurine-6,8(1H,9H)-dione; 7-Allyl-8-oxo-7,8-dihydroguanosine; 7A8OGua DMIV9ZE DT Small molecular drug DMIV9ZE PC 135410906 DMIV9ZE MW 339.3 DMIV9ZE FM C13H17N5O6 DMIV9ZE IC InChI=1S/C13H17N5O6/c1-2-3-17-6-9(15-12(14)16-10(6)22)18(13(17)23)11-8(21)7(20)5(4-19)24-11/h2,5,7-8,11,19-21H,1,3-4H2,(H3,14,15,16,22)/t5-,7-,8-,11-/m1/s1 DMIV9ZE CS C=CCN1C2=C(N=C(NC2=O)N)N(C1=O)[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O DMIV9ZE IK VDCRFBBZFHHYGT-IOSLPCCCSA-N DMIV9ZE IU 2-amino-9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-enyl-1H-purine-6,8-dione DMIV9ZE CA CAS 121288-39-9 DMIV9ZE DE Immune System disease DM7BN5W ID DM7BN5W DM7BN5W DN LPN023 DM7BN5W HS Phase 2 DM7BN5W CP Novartis DM7BN5W DT Small molecular drug DM7BN5W DE IgA nephropathy DMZQBCL ID DMZQBCL DMZQBCL DN LR3001 DMZQBCL HS Phase 2 DMZQBCL CP Genta DMZQBCL TC Anticancer Agents DMZQBCL DT Antisense drug DMZQBCL DE Myeloid leukaemia DM0TZPL ID DM0TZPL DM0TZPL DN LS-71719 DM0TZPL HS Phase 2 DM0TZPL SN Galactooligosaccharide; LS-71719; NOCAS_276547; 4'-Galactooligosaccharide; D-Glucose, O-beta-D-galactopyranosyl-(1-4)-O-beta-D-galactopyranosyl-(1-4)-; DTXSID60276547; SCHEMBL12362685 DM0TZPL PC 165512 DM0TZPL MW 504.4 DM0TZPL FM C18H32O16 DM0TZPL IC RXVWSYJTUUKTEA-DSOVBJLESA-N DM0TZPL CS C(C1C(C(C(C(O1)OC2C(OC(C(C2O)O)OC(C(CO)O)C(C(C=O)O)O)CO)O)O)O)O DM0TZPL IK 1S/C18H32O16/c19-1-5(23)9(25)15(6(24)2-20)33-18-14(30)12(28)16(8(4-22)32-18)34-17-13(29)11(27)10(26)7(3-21)31-17/h1,5-18,20-30H,2-4H2/t5-,6+,7+,8+,9+,10-,11-,12+,13+,14+,15+,16-,17-,18-/m0/s1 DM0TZPL IU (2R,3R,4R,5R)-4-[(2S,3R,4R,5R,6R)-3,4-dihydroxy-6-(hydroxymethyl)-5-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-2,3,5,6-tetrahydroxyhexanal DM0TZPL CA CAS 6587-31-1 DM0TZPL DE Anxiety disorder DME26RS ID DME26RS DME26RS DN LTB4 DME26RS HS Phase 2 DME26RS SN Leukotriene B4; LEUKOTRIENE B4; 5,12-Dihete; 71160-24-2; 5,12-Hete; UNII-1HGW4DR56D; (5S,6Z,8E,10E,12R,14Z)-5,12-dihydroxyicosa-6,8,10,14-tetraenoic acid; 1HGW4DR56D; CHEMBL65061; 5S,12R-dihydroxy-6Z,8E,10E,14Z-eicosatetraenoic acid; CHEBI:15647; VNYSSYRCGWBHLG-AMOLWHMGSA-N; [5S,12R]-Dihydroxy-[6Z,8E,10E,14Z]-eicosatetraenoic acid; Leukotriene B; 5(S),12(R)-Dihydroxy-6-cis-8-trans-10-trans-14-cis-eicosatetraenoic Acid; (S-(R*,S*-(E,Z,E,Z)))-5,12-Dihydroxy-6,8,10,14-eicosatetraenoic acid; 6,8,10,14-Eicosatetraenoic acid,; Leukotriene B4 agonist (HIV infection), LTB4 Sweden AB; LEUKOTRIENE_B4 DME26RS CP LTB4 Sweden AB DME26RS DT Small molecular drug DME26RS PC 5280492 DME26RS MW 336.5 DME26RS FM C20H32O4 DME26RS IC InChI=1S/C20H32O4/c1-2-3-4-5-6-9-13-18(21)14-10-7-8-11-15-19(22)16-12-17-20(23)24/h6-11,14-15,18-19,21-22H,2-5,12-13,16-17H2,1H3,(H,23,24)/b8-7+,9-6-,14-10+,15-11-/t18-,19-/m1/s1 DME26RS CS CCCCC/C=C\\C[C@H](/C=C/C=C/C=C\\[C@H](CCCC(=O)O)O)O DME26RS IK VNYSSYRCGWBHLG-AMOLWHMGSA-N DME26RS IU (5S,6Z,8E,10E,12R,14Z)-5,12-dihydroxyicosa-6,8,10,14-tetraenoic acid DME26RS CA CAS 71160-24-2 DME26RS CB CHEBI:15647 DME26RS DE Human immunodeficiency virus infection DMXEQ0R ID DMXEQ0R DMXEQ0R DN LTX-109 DMXEQ0R HS Phase 2 DMXEQ0R SN Lytixar DMXEQ0R CP Lytix Biopharma AS DMXEQ0R DT Small molecular drug DMXEQ0R PC 25242323 DMXEQ0R MW 788.1 DMXEQ0R FM C43H69N11O3 DMXEQ0R IC InChI=1S/C43H69N11O3/c1-41(2,3)27-23-28-29(35(43(7,8)9)54-34(28)30(24-27)42(4,5)6)25-33(53-36(55)31(44)17-13-20-50-39(45)46)38(57)52-32(18-14-21-51-40(47)48)37(56)49-22-19-26-15-11-10-12-16-26/h10-12,15-16,23-24,31-33,54H,13-14,17-22,25,44H2,1-9H3,(H,49,56)(H,52,57)(H,53,55)(H4,45,46,50)(H4,47,48,51)/t31-,32-,33-/m0/s1 DMXEQ0R CS CC(C)(C)C1=CC2=C(C(=C1)C(C)(C)C)NC(=C2C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCCC3=CC=CC=C3)NC(=O)[C@H](CCCN=C(N)N)N)C(C)(C)C DMXEQ0R IK ZVOYWSKEBVVLGW-ZDCRTTOTSA-N DMXEQ0R IU (2S)-2-amino-5-(diaminomethylideneamino)-N-[(2S)-1-[[(2S)-5-(diaminomethylideneamino)-1-oxo-1-(2-phenylethylamino)pentan-2-yl]amino]-1-oxo-3-(2,5,7-tritert-butyl-1H-indol-3-yl)propan-2-yl]pentanamide DMXEQ0R CA CAS 1166254-80-3 DMXEQ0R CB CHEBI:77752 DMXEQ0R DE Bacterial infection DMJOYNZ ID DMJOYNZ DMJOYNZ DN Lu AF11167 DMJOYNZ HS Phase 2 DMJOYNZ CP Lundbeck DMJOYNZ DT Small molecular drug DMJOYNZ DE Schizophrenia DM2ZUXK ID DM2ZUXK DM2ZUXK DN Lu-AA34893 DM2ZUXK HS Phase 2 DM2ZUXK CP H Lundbeck A/S DM2ZUXK DE Anxiety disorder DM34FWR ID DM34FWR DM34FWR DN Lu-AA39959 DM34FWR HS Phase 2 DM34FWR CP H Lundbeck A/S DM34FWR DE Bipolar disorder DMY2L7V ID DMY2L7V DMY2L7V DN Lucatumumab DMY2L7V HS Phase 2 DMY2L7V SN HDC122 DMY2L7V CP Novartis Pharmaceuticals DMY2L7V DT Monoclonal antibody DMY2L7V DE Lymphoma DMCKNBA ID DMCKNBA DMCKNBA DN Lufironil DMCKNBA HS Phase 2 DMCKNBA SN Hoe-077 DMCKNBA CP Hoechst AG DMCKNBA DT Small molecular drug DMCKNBA PC 60788 DMCKNBA MW 281.31 DMCKNBA FM C13H19N3O4 DMCKNBA IC InChI=1S/C13H19N3O4/c1-19-7-5-15-12(17)10-3-4-14-11(9-10)13(18)16-6-8-20-2/h3-4,9H,5-8H2,1-2H3,(H,15,17)(H,16,18) DMCKNBA CS COCCNC(=O)C1=CC(=NC=C1)C(=O)NCCOC DMCKNBA IK JUCNGMPTCXPMNB-UHFFFAOYSA-N DMCKNBA IU 2-N,4-N-bis(2-methoxyethyl)pyridine-2,4-dicarboxamide DMCKNBA CA CAS 128075-79-6 DMCKNBA DE Liver cirrhosis DMGWZ93 ID DMGWZ93 DMGWZ93 DN Lulizumab pegol DMGWZ93 HS Phase 2 DMGWZ93 CP Bristol-Myers SquibbPrinceton, NJ DMGWZ93 DE Systemic lupus erythematosus DMQZXDW ID DMQZXDW DMQZXDW DN Lum001 DMQZXDW HS Phase 2 DMQZXDW SN SHP625 DMQZXDW CP Lumena pharmaceuticals DMQZXDW PC 9831642 DMQZXDW MW 710.4 DMQZXDW FM C40H56ClN3O4S DMQZXDW IC InChI=1S/C40H56N3O4S.ClH/c1-5-7-19-40(20-8-6-2)30-48(45,46)37-18-15-34(41(3)4)27-36(37)38(39(40)44)33-13-16-35(17-14-33)47-29-32-11-9-31(10-12-32)28-43-24-21-42(22-25-43)23-26-43;/h9-18,27,38-39,44H,5-8,19-26,28-30H2,1-4H3;1H/q+1;/p-1/t38-,39-;/m1./s1 DMQZXDW CS CCCCC1(CS(=O)(=O)C2=C(C=C(C=C2)N(C)C)[C@H]([C@H]1O)C3=CC=C(C=C3)OCC4=CC=C(C=C4)C[N+]56CCN(CC5)CC6)CCCC.[Cl-] DMQZXDW IK POMVPJBWDDJCMP-RUKDTIIFSA-M DMQZXDW IU (4R,5R)-5-[4-[[4-(4-aza-1-azoniabicyclo[2.2.2]octan-1-ylmethyl)phenyl]methoxy]phenyl]-3,3-dibutyl-7-(dimethylamino)-1,1-dioxo-4,5-dihydro-2H-1lambda6-benzothiepin-4-ol;chloride DMQZXDW CA CAS 228113-66-4 DMQZXDW DE Primary biliary cirrhosis; Primary biliary cholangitis; Primary sclerosing cholangitis; Progressive familial intrahepatic cholestasis; Structural developmental anomalies of liver DMCLWDJ ID DMCLWDJ DMCLWDJ DN Lumacaftor DMCLWDJ HS Phase 2 DMCLWDJ SN VRT-325; VRT-422; VRT-532; VX-809 DMCLWDJ CP Vertex Pharmaceuticals Inc DMCLWDJ DT Small molecular drug DMCLWDJ PC 16678941 DMCLWDJ MW 452.4 DMCLWDJ FM C24H18F2N2O5 DMCLWDJ IC InChI=1S/C24H18F2N2O5/c1-13-5-8-19(27-20(13)14-3-2-4-15(11-14)21(29)30)28-22(31)23(9-10-23)16-6-7-17-18(12-16)33-24(25,26)32-17/h2-8,11-12H,9-10H2,1H3,(H,29,30)(H,27,28,31) DMCLWDJ CS CC1=C(N=C(C=C1)NC(=O)C2(CC2)C3=CC4=C(C=C3)OC(O4)(F)F)C5=CC(=CC=C5)C(=O)O DMCLWDJ IK UFSKUSARDNFIRC-UHFFFAOYSA-N DMCLWDJ IU 3-[6-[[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropanecarbonyl]amino]-3-methylpyridin-2-yl]benzoic acid DMCLWDJ CA CAS 936727-05-8 DMCLWDJ CB CHEBI:90951 DMCLWDJ DE Cystic fibrosis DMLTI39 ID DMLTI39 DMLTI39 DN Lumiliximab DMLTI39 HS Phase 2 DMLTI39 SN Gomiliximab; IDEC-152; SI-3401; ST-152; PRIMATIZED anti-CD23 antibody, IDEC DMLTI39 CP IDEC Pharmaceuticals Corp; Biogen Idec DMLTI39 DT Antibody DMLTI39 DE leukaemia DMLRU9I ID DMLRU9I DMLRU9I DN Lunacalcipol DMLRU9I HS Phase 2 DMLRU9I SN CTA-018; MT-2832; Lunacalcipol (intravenous, secondary hyperparathyroidism); Lunacalcipol (intravenous, secondary hyperparathyroidism), Cytochroma; Vitamin D analogs (secondary hyperparathyroidism), Johns Hopkins/Cytochroma; CTA-018 (intravenous, secondary hyperparathyroidism), Cytochroma; CYP24 inhibitors (intravenous, secondary hyperparathyroidism), Johns Hopkins/Cytochroma DMLRU9I CP Johns Hopkins University DMLRU9I DT Small molecular drug DMLRU9I PC 10672195 DMLRU9I MW 474.7 DMLRU9I FM C28H42O4S DMLRU9I IC InChI=1S/C28H42O4S/c1-19(9-8-16-33(31,32)27(3,4)5)24-13-14-25-21(10-7-15-28(24,25)6)11-12-22-17-23(29)18-26(30)20(22)2/h8,11-13,16,19,23,25-26,29-30H,2,7,9-10,14-15,17-18H2,1,3-6H3/b16-8+,21-11+,22-12-/t19-,23-,25+,26+,28-/m1/s1 DMLRU9I CS C[C@H](C/C=C/S(=O)(=O)C(C)(C)C)C1=CC[C@@H]\\2[C@@]1(CCC/C2=C\\C=C/3\\C[C@H](C[C@@H](C3=C)O)O)C DMLRU9I IK RFQHCLMGLJGZNV-UXXOMSPDSA-N DMLRU9I IU (1R,3S,5Z)-5-[(2E)-2-[(3aS,7aS)-1-[(E,2R)-5-tert-butylsulfonylpent-4-en-2-yl]-7a-methyl-3a,5,6,7-tetrahydro-3H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol DMLRU9I CA CAS 250384-82-8 DMLRU9I DE Psoriasis vulgaris DMZ2XAP ID DMZ2XAP DMZ2XAP DN LX-1031 DMZ2XAP HS Phase 2 DMZ2XAP SN LG-103; LP-389924; LP-507518; LP-533401; LP-615819; TPH inhibitor (IBS), Lexicon; Tryptophan 5-hydroxylase inhibitor(IBS), Lexicon DMZ2XAP CP Lexicon Pharmaceuticals Inc DMZ2XAP DT Small molecular drug DMZ2XAP PC 23633604 DMZ2XAP MW 538.5 DMZ2XAP FM C28H25F3N4O4 DMZ2XAP IC InChI=1S/C28H25F3N4O4/c1-38-21-4-2-3-20(14-21)17-9-11-19(12-10-17)25(28(29,30)31)39-24-15-23(34-27(33)35-24)18-7-5-16(6-8-18)13-22(32)26(36)37/h2-12,14-15,22,25H,13,32H2,1H3,(H,36,37)(H2,33,34,35)/t22-,25+/m0/s1 DMZ2XAP CS COC1=CC=CC(=C1)C2=CC=C(C=C2)[C@H](C(F)(F)F)OC3=NC(=NC(=C3)C4=CC=C(C=C4)C[C@@H](C(=O)O)N)N DMZ2XAP IK XNMUICFMGGQSMZ-WIOPSUGQSA-N DMZ2XAP IU (2S)-2-amino-3-[4-[2-amino-6-[(1R)-2,2,2-trifluoro-1-[4-(3-methoxyphenyl)phenyl]ethoxy]pyrimidin-4-yl]phenyl]propanoic acid DMZ2XAP CA CAS 945976-76-1 DMZ2XAP DE Irritable bowel syndrome DMLA8H3 ID DMLA8H3 DMLA8H3 DN LX2931 DMLA8H3 HS Phase 2 DMLA8H3 CP Lexicon Pharmaceuticals DMLA8H3 DT Small molecular drug DMLA8H3 PC 135564845 DMLA8H3 MW 245.23 DMLA8H3 FM C9H15N3O5 DMLA8H3 IC InChI=1S/C9H15N3O5/c1-4(12-17)9-10-2-5(11-9)7(15)8(16)6(14)3-13/h2,6-8,13-17H,3H2,1H3,(H,10,11)/b12-4+/t6-,7-,8-/m1/s1 DMLA8H3 CS C/C(=N\\O)/C1=NC=C(N1)[C@H]([C@@H]([C@@H](CO)O)O)O DMLA8H3 IK AMXVYJYMZLDINS-RSWLNLDNSA-N DMLA8H3 IU (1R,2S,3R)-1-[2-[(E)-N-hydroxy-C-methylcarbonimidoyl]-1H-imidazol-5-yl]butane-1,2,3,4-tetrol DMLA8H3 CA CAS 948840-25-3 DMLA8H3 DE Rheumatoid arthritis; Hereditary acantholytic dermatoses DMLBD5I ID DMLBD5I DMLBD5I DN LXE408 DMLBD5I HS Phase 2 DMLBD5I SN SCHEMBL16822697; HY-131350; CS-0133456; FC1=C(C=C(C=C1)NC(=O)C1=C(N=C(O1)C)C)C1=NN2C(N=CC(=C2)C2=NC=CC=C2C)=N1; 1799330-15-6; N-(4-Fluoro-3-(6-(3-methylpyridin-2-yl)-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)phenyl)-2,4-dimethyloxazole-5-carboxamide DMLBD5I CP Novartis DMLBD5I DT Small molecular drug DMLBD5I PC 118162630 DMLBD5I MW 443.4 DMLBD5I FM C23H18FN7O2 DMLBD5I IC InChI=1S/C23H18FN7O2/c1-12-5-4-8-25-19(12)15-10-26-23-29-21(30-31(23)11-15)17-9-16(6-7-18(17)24)28-22(32)20-13(2)27-14(3)33-20/h4-11H,1-3H3,(H,28,32) DMLBD5I CS CC1=C(N=CC=C1)C2=CN3C(=NC(=N3)C4=C(C=CC(=C4)NC(=O)C5=C(N=C(O5)C)C)F)N=C2 DMLBD5I IK GNVVPYCWVLCWKV-UHFFFAOYSA-N DMLBD5I IU N-[4-fluoro-3-[6-(3-methylpyridin-2-yl)-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl]phenyl]-2,4-dimethyl-1,3-oxazole-5-carboxamide DMLBD5I DE Visceral leishmaniasis DM5IX9M ID DM5IX9M DM5IX9M DN LY-156735 DM5IX9M HS Phase 2 DM5IX9M SN LY 156735; N-[(2r)-2-(6-chloro-5-methoxy-1h-indol-3-yl)propyl]acetamide DM5IX9M CP Phase 2 Discovery DM5IX9M DT Small molecular drug DM5IX9M PC 219018 DM5IX9M MW 280.75 DM5IX9M FM C14H17ClN2O2 DM5IX9M IC InChI=1S/C14H17ClN2O2/c1-8(6-16-9(2)18)11-7-17-13-5-12(15)14(19-3)4-10(11)13/h4-5,7-8,17H,6H2,1-3H3,(H,16,18)/t8-/m0/s1 DM5IX9M CS C[C@@H](CNC(=O)C)C1=CNC2=CC(=C(C=C21)OC)Cl DM5IX9M IK RKHCTAKUYDTFHE-QMMMGPOBSA-N DM5IX9M IU N-[(2R)-2-(6-chloro-5-methoxy-1H-indol-3-yl)propyl]acetamide DM5IX9M CA CAS 118702-11-7 DM5IX9M DE Anxiety disorder DMTBFE4 ID DMTBFE4 DMTBFE4 DN LY2090314 DMTBFE4 HS Phase 2 DMTBFE4 SN 603288-22-8; LY-2090314; UNII-822M3GYM67; Kinome_3681; LY 2090314; CHEMBL362558; 822M3GYM67; 3-(9-Fluoro-2-(piperidine-1-carbonyl)-1,2,3,4-tetrahydro-[1,4]diazepino[6,7,1-hi]indol-7-yl)-4-(imidazo[1,2-a]pyridin-3-yl)-1H-pyrrole-2,5-dione; SCHEMBL633455; GTPL7958; DTXSID90209085; MolPort-035-944-332; EX-A2214; ZINC3817327; BCP07855; s7063; BDBM50150699; AKOS032950045; AKOS026750195; CS-1633; DB11913; SB16558; NCGC00378942-05; NCGC00378942-02; BC600682; QC-11735; HY-16294; KB-78238; FT-0698670; LY2090314, > DMTBFE4 CP Eli Lilly DMTBFE4 DT Small molecular drug DMTBFE4 PC 10029385 DMTBFE4 MW 512.5 DMTBFE4 FM C28H25FN6O3 DMTBFE4 IC InChI=1S/C28H25FN6O3/c29-18-12-17-15-34(28(38)32-7-3-1-4-8-32)11-10-33-16-20(19(13-18)25(17)33)23-24(27(37)31-26(23)36)21-14-30-22-6-2-5-9-35(21)22/h2,5-6,9,12-14,16H,1,3-4,7-8,10-11,15H2,(H,31,36,37) DMTBFE4 CS C1CCN(CC1)C(=O)N2CCN3C=C(C4=CC(=CC(=C43)C2)F)C5=C(C(=O)NC5=O)C6=CN=C7N6C=CC=C7 DMTBFE4 IK HRJWTAWVFDCTGO-UHFFFAOYSA-N DMTBFE4 IU 3-[6-fluoro-10-(piperidine-1-carbonyl)-1,10-diazatricyclo[6.4.1.04,13]trideca-2,4,6,8(13)-tetraen-3-yl]-4-imidazo[1,2-a]pyridin-3-ylpyrrole-2,5-dione DMTBFE4 CA CAS 603288-22-8 DMTBFE4 DE Acute myeloid leukaemia DMU81BH ID DMU81BH DMU81BH DN LY-2189102 DMU81BH HS Phase 2 DMU81BH SN Anti-IL-1 beta mAb (cardiovascular disease), Lilly; Anti IL-1 beta antibody (non-insulin dependent diabetes, rheumatoid athritis), Lilly DMU81BH CP Eli lilly DMU81BH DT Antibody DMU81BH DE Cardiovascular disease DMH3YKJ ID DMH3YKJ DMH3YKJ DN LY2382770 DMH3YKJ HS Phase 2 DMH3YKJ CP Eli Lilly & Co DMH3YKJ DT Antibody DMH3YKJ DE Diabetic nephropathy; Diabetic kidney disease DMZOIP4 ID DMZOIP4 DMZOIP4 DN LY-2409021 DMZOIP4 HS Phase 2 DMZOIP4 SN Oral glucagon receptor antagonist (type 2 diabetes), Eli Lilly DMZOIP4 CP Eli Lilly & Co DMZOIP4 PC 91933867 DMZOIP4 MW 555.6 DMZOIP4 FM C32H36F3NO4 DMZOIP4 IC InChI=1S/C32H36F3NO4/c1-20-18-26(19-21(2)29(20)23-10-12-25(13-11-23)31(3,4)5)40-27(14-16-32(33,34)35)22-6-8-24(9-7-22)30(39)36-17-15-28(37)38/h6-13,18-19,27H,14-17H2,1-5H3,(H,36,39)(H,37,38)/t27-/m0/s1 DMZOIP4 CS CC1=CC(=CC(=C1C2=CC=C(C=C2)C(C)(C)C)C)O[C@@H](CCC(F)(F)F)C3=CC=C(C=C3)C(=O)NCCC(=O)O DMZOIP4 IK FASLTMSUPQDLIB-MHZLTWQESA-N DMZOIP4 IU 3-[[4-[(1S)-1-[4-(4-tert-butylphenyl)-3,5-dimethylphenoxy]-4,4,4-trifluorobutyl]benzoyl]amino]propanoic acid DMZOIP4 CA CAS 1488363-78-5 DMZOIP4 DE Type-2 diabetes DMKYMS2 ID DMKYMS2 DMKYMS2 DN LY-2428757 DMKYMS2 HS Phase 2 DMKYMS2 SN GLP-PEG, Eli Lilly; GLP1-PEG, Eli Lilly DMKYMS2 CP Eli Lilly & Co DMKYMS2 DE Type-2 diabetes DMLTSDC ID DMLTSDC DMLTSDC DN LY-2456302 DMLTSDC HS Phase 2 DMLTSDC SN Opioid receptor kappa (KOR) antagonist (alcohol dependence), Eli Lilly DMLTSDC CP Eli Lilly & Co DMLTSDC DT Small molecular drug DMLTSDC PC 44129648 DMLTSDC MW 418.5 DMLTSDC FM C26H27FN2O2 DMLTSDC IC InChI=1S/C26H27FN2O2/c1-17-12-18(2)14-21(13-17)24-4-3-11-29(24)16-19-5-8-22(9-6-19)31-25-10-7-20(26(28)30)15-23(25)27/h5-10,12-15,24H,3-4,11,16H2,1-2H3,(H2,28,30)/t24-/m0/s1 DMLTSDC CS CC1=CC(=CC(=C1)[C@@H]2CCCN2CC3=CC=C(C=C3)OC4=C(C=C(C=C4)C(=O)N)F)C DMLTSDC IK ZHPMYDSXGRRERG-DEOSSOPVSA-N DMLTSDC IU 4-[4-[[(2S)-2-(3,5-dimethylphenyl)pyrrolidin-1-yl]methyl]phenoxy]-3-fluorobenzamide DMLTSDC CA CAS 1174130-61-0 DMLTSDC DE Alcohol dependence; Major depressive disorder DMM5JAN ID DMM5JAN DMM5JAN DN LY2495655 DMM5JAN HS Phase 2 DMM5JAN CP Eli Lilly DMM5JAN DE Disuse muscle atrophy DMCV602 ID DMCV602 DMCV602 DN LY2523355 DMCV602 HS Phase 2 DMCV602 SN Litronesib DMCV602 CP Lilly DMCV602 DT Small molecular drug DMCV602 PC 25167017 DMCV602 MW 511.7 DMCV602 FM C23H37N5O4S2 DMCV602 IC InChI=1S/C23H37N5O4S2/c1-8-24-14-15-34(31,32)25-16-23(17-12-10-9-11-13-17)28(19(30)22(5,6)7)27-20(33-23)26-18(29)21(2,3)4/h9-13,24-25H,8,14-16H2,1-7H3,(H,26,27,29)/t23-/m0/s1 DMCV602 CS CCNCCS(=O)(=O)NC[C@@]1(N(N=C(S1)NC(=O)C(C)(C)C)C(=O)C(C)(C)C)C2=CC=CC=C2 DMCV602 IK YVAFBXLHPINSIK-QHCPKHFHSA-N DMCV602 IU N-[(5R)-4-(2,2-dimethylpropanoyl)-5-[[2-(ethylamino)ethylsulfonylamino]methyl]-5-phenyl-1,3,4-thiadiazol-2-yl]-2,2-dimethylpropanamide DMCV602 CA CAS 910634-41-2 DMCV602 DE Acute myeloid leukaemia DMTVU2Q ID DMTVU2Q DMTVU2Q DN LY2541546 DMTVU2Q HS Phase 2 DMTVU2Q CP Eli Lilly DMTVU2Q DT Antibody DMTVU2Q DE Osteoporosis DM81UJW ID DM81UJW DM81UJW DN LY-2590443 DM81UJW HS Phase 2 DM81UJW CP Eli Lilly & Co DM81UJW DE Migraine DMMI0RH ID DMMI0RH DMMI0RH DN LY-2599506 DMMI0RH HS Phase 2 DMMI0RH SN PSN-010 DMMI0RH CP Prosidion Ltd DMMI0RH PC 11517248 DMMI0RH MW 415.5 DMMI0RH FM C21H25N3O4S DMMI0RH IC InChI=1S/C21H25N3O4S/c25-21(24-20-14-22-9-10-23-20)19(13-15-7-11-28-12-8-15)16-1-3-17(4-2-16)29(26,27)18-5-6-18/h1-4,9-10,14-15,18-19H,5-8,11-13H2,(H,23,24,25)/t19-/m1/s1 DMMI0RH CS C1CC1S(=O)(=O)C2=CC=C(C=C2)[C@@H](CC3CCOCC3)C(=O)NC4=NC=CN=C4 DMMI0RH IK DQIITKNITDKAJZ-LJQANCHMSA-N DMMI0RH IU (2R)-2-(4-cyclopropylsulfonylphenyl)-3-(oxan-4-yl)-N-pyrazin-2-ylpropanamide DMMI0RH CA CAS 745051-65-4 DMMI0RH DE Diabetic complication DMCXRZF ID DMCXRZF DMCXRZF DN LY2603618 DMCXRZF HS Phase 2 DMCXRZF SN LY2603618; Rabusertib; 911222-45-2; LY 2603618; LY-2603618; UNII-3S9L1NU6U7; 3S9L1NU6U7; IC-83; ly2603618 IC-83; (S)-1-(5-bromo-4-methyl-2-(morpholin-2-ylmethoxy)phenyl)-3-(5-methylpyrazin-2-yl)urea; n-(5-bromo-4-methyl-2-((2s)-2-morpholinylmethoxy)phenyl)-n'-(5-methyl-2-pyrazinyl)urea; LY2603618 (IC-83); Rabusertib [USAN:INN]; 3-(5-Bromo-4-methyl-2-[(2s)-morpholin-2-ylmethoxy]phenyl)-1-(5-methylpyrazin-2-yl)urea; N-[5-Bromo-4-methyl-2-[(2S)-2-morpholinylmethoxy)phenyl]-N'-(5-methyl-2-pyrazinyl)urea DMCXRZF CP Eli Lilly DMCXRZF DT Small molecular drug DMCXRZF PC 11955855 DMCXRZF MW 436.3 DMCXRZF FM C18H22BrN5O3 DMCXRZF IC InChI=1S/C18H22BrN5O3/c1-11-5-16(27-10-13-8-20-3-4-26-13)15(6-14(11)19)23-18(25)24-17-9-21-12(2)7-22-17/h5-7,9,13,20H,3-4,8,10H2,1-2H3,(H2,22,23,24,25)/t13-/m0/s1 DMCXRZF CS CC1=CC(=C(C=C1Br)NC(=O)NC2=NC=C(N=C2)C)OC[C@@H]3CNCCO3 DMCXRZF IK SYYBDNPGDKKJDU-ZDUSSCGKSA-N DMCXRZF IU 1-[5-bromo-4-methyl-2-[[(2S)-morpholin-2-yl]methoxy]phenyl]-3-(5-methylpyrazin-2-yl)urea DMCXRZF CA CAS 911222-45-2 DMCXRZF CB CHEBI:124917 DMCXRZF DE Pancreatic cancer DM4XMF7 ID DM4XMF7 DM4XMF7 DN LY2606368 DM4XMF7 HS Phase 2 DM4XMF7 SN prexasertib; Prexasertib; 1234015-52-1; UNII-820NH671E6; LY-2606368; 820NH671E6; Prexasertib [USAN]; 5-((5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-yl)amino)pyrazine-2-carbonitrile; 5-({5-[2-(3-aminopropoxy)-6-methoxyphenyl]-1H-pyrazol-3-yl}amino)pyrazine-2-carbonitrile; 5-[[5-[2-(3-aminopropoxy)-6-methoxyphenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile; SCHEMBL1975451; GTPL9549; SCHEMBL19457660; SCHEMBL18989301; CHEMBL3544911; EX-A758; DOTGPNHGTYJDEP-UHFFFAOYSA-N; AOB87325; ZINC95837013 DM4XMF7 CP Eli Lilly, Indianapolis, IN DM4XMF7 PC 46700756 DM4XMF7 MW 365.4 DM4XMF7 FM C18H19N7O2 DM4XMF7 IC InChI=1S/C18H19N7O2/c1-26-14-4-2-5-15(27-7-3-6-19)18(14)13-8-16(25-24-13)23-17-11-21-12(9-20)10-22-17/h2,4-5,8,10-11H,3,6-7,19H2,1H3,(H2,22,23,24,25) DM4XMF7 CS COC1=C(C(=CC=C1)OCCCN)C2=CC(=NN2)NC3=NC=C(N=C3)C#N DM4XMF7 IK DOTGPNHGTYJDEP-UHFFFAOYSA-N DM4XMF7 IU 5-[[5-[2-(3-aminopropoxy)-6-methoxyphenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile DM4XMF7 CA CAS 1234015-52-1 DM4XMF7 DE Head and neck cancer; Ovarian cancer; Small-cell lung cancer; Squamous cell anal carcinoma; Solid tumour/cancer DM4EF9Y ID DM4EF9Y DM4EF9Y DN LY-2608204 DM4EF9Y HS Phase 2 DM4EF9Y SN Glucokinase activator (type 2 diabetes), Eli Lilly DM4EF9Y CP Eli Lilly & Co DM4EF9Y DT Small molecular drug DM4EF9Y PC 46832368 DM4EF9Y MW 559.8 DM4EF9Y FM C28H37N3O3S3 DM4EF9Y IC InChI=1S/C28H37N3O3S3/c32-26(30-27-29-19-25(36-27)35-17-16-31-14-4-5-15-31)28(18-24(28)20-6-2-1-3-7-20)21-8-10-22(11-9-21)37(33,34)23-12-13-23/h8-11,19-20,23-24H,1-7,12-18H2,(H,29,30,32)/t24-,28-/m0/s1 DM4EF9Y CS C1CCC(CC1)[C@@H]2C[C@@]2(C3=CC=C(C=C3)S(=O)(=O)C4CC4)C(=O)NC5=NC=C(S5)SCCN6CCCC6 DM4EF9Y IK QIIVJLHCZUTGSD-CUBQBAPOSA-N DM4EF9Y IU (1R,2S)-2-cyclohexyl-1-(4-cyclopropylsulfonylphenyl)-N-[5-(2-pyrrolidin-1-ylethylsulfanyl)-1,3-thiazol-2-yl]cyclopropane-1-carboxamide DM4EF9Y CA CAS 1234703-40-2 DM4EF9Y DE Type-2 diabetes DMFGNB4 ID DMFGNB4 DMFGNB4 DN LY-2623091 DMFGNB4 HS Phase 2 DMFGNB4 SN Chronic renal disease therapy, Eli Lilly DMFGNB4 CP Eli Lilly & Co DMFGNB4 PC 42636651 DMFGNB4 MW 527.6 DMFGNB4 FM C30H30FN5O3 DMFGNB4 IC InChI=1S/C30H30FN5O3/c1-19(17-35-10-12-38-13-11-35)36-27-9-6-20(15-26(27)33-30(36)34-29(32)37)14-25-23-5-3-2-4-21(23)18-39-28-16-22(31)7-8-24(25)28/h2-9,14-16,19H,10-13,17-18H2,1H3,(H3,32,33,34,37)/b25-14+/t19-/m1/s1 DMFGNB4 CS C[C@H](CN1CCOCC1)N2C3=C(C=C(C=C3)/C=C\\4/C5=C(C=C(C=C5)F)OCC6=CC=CC=C64)N=C2NC(=O)N DMFGNB4 IK YPCLDHGBEKZGEB-RUDKWAFVSA-N DMFGNB4 IU [5-[(E)-(3-fluoro-6H-benzo[c][1]benzoxepin-11-ylidene)methyl]-1-[(2R)-1-morpholin-4-ylpropan-2-yl]benzimidazol-2-yl]urea DMFGNB4 CA CAS 1162264-07-4 DMFGNB4 DE Chronic kidney disease DMTPQUA ID DMTPQUA DMTPQUA DN LY-2624803 DMTPQUA HS Phase 2 DMTPQUA SN HY-10275; Insomnia therapy, Hypnion; Insomnia therapy, Lilly; Dual-acting oral H1 receptor inverse agonist/5-HT 2a receptor modulator (insomnia), Hypnion; Dual-acting oral H1 receptor inverse agonist/5-HT 2a receptor modulator (insomnia), Lilly DMTPQUA CP Hypnion DMTPQUA PC 11567064 DMTPQUA MW 379.5 DMTPQUA FM C22H25N3O3 DMTPQUA IC InChI=1S/C22H25N3O3/c1-22(2,21(26)27)15-24-11-13-25(14-12-24)20-16-7-3-5-9-18(16)28-19-10-6-4-8-17(19)23-20/h3-10H,11-15H2,1-2H3,(H,26,27) DMTPQUA CS CC(C)(CN1CCN(CC1)C2=NC3=CC=CC=C3OC4=CC=CC=C42)C(=O)O DMTPQUA IK UEFWDVMEDFCHGW-UHFFFAOYSA-N DMTPQUA IU 3-(4-benzo[b][1,4]benzoxazepin-6-ylpiperazin-1-yl)-2,2-dimethylpropanoic acid DMTPQUA CA CAS 879409-35-5 DMTPQUA DE Insomnia DMZASMP ID DMZASMP DMZASMP DN LY2784544 DMZASMP HS Phase 2 DMZASMP SN LY2784544; 1229236-86-5; GANDOTINIB; LY 2784544; LY-2784544; Gandotinib (LY2784544); UNII-ANC71R916O; LY2784544(Gandotinib); ANC71R916O; 3-(4-chloro-2-fluorobenzyl)-2-methyl-N-(5-methyl-1H-pyrazol-3-yl)-8-(morpholinomethyl)imidazo[1,2-b]pyridazin-6-amine; C23H25ClFN7O; 3-[(4-Chloro-2-fluorophenyl)methyl]-2-methyl-N-(5-methyl-1H-pyrazol-3-yl)-8-(4-morpholinylmethyl)imidazo[1,2-b]pyridazin-6-amine; 3-(4-chloro-2-fluorobenzyl)-2-methyl-N-(3-methyl-1H-pyrazol-5-yl)-8-(morpholinomethyl)imidazo[1,2-b]pyridazin-6-amine DMZASMP CP Eli Lilly DMZASMP DT Small molecular drug DMZASMP PC 46213929 DMZASMP MW 469.9 DMZASMP FM C23H25ClFN7O DMZASMP IC InChI=1S/C23H25ClFN7O/c1-14-9-21(29-28-14)27-22-11-17(13-31-5-7-33-8-6-31)23-26-15(2)20(32(23)30-22)10-16-3-4-18(24)12-19(16)25/h3-4,9,11-12H,5-8,10,13H2,1-2H3,(H2,27,28,29,30) DMZASMP CS CC1=CC(=NN1)NC2=NN3C(=C(N=C3C(=C2)CN4CCOCC4)C)CC5=C(C=C(C=C5)Cl)F DMZASMP IK SQSZANZGUXWJEA-UHFFFAOYSA-N DMZASMP IU 3-[(4-chloro-2-fluorophenyl)methyl]-2-methyl-N-(5-methyl-1H-pyrazol-3-yl)-8-(morpholin-4-ylmethyl)imidazo[1,2-b]pyridazin-6-amine DMZASMP CA CAS 1229236-86-5 DMZASMP DE Breast cancer; Myeloproliferative neoplasm DM0KJDY ID DM0KJDY DM0KJDY DN LY2801653 DM0KJDY HS Phase 2 DM0KJDY SN Merestinib; LY2801653; 1206799-15-6; LY-2801653; UNII-5OGS5K699E; N-(3-fluoro-4-((1-methyl-6-(1H-pyrazol-4-yl)-1H-indazol-5-yl)oxy)phenyl)-1-(4-fluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide; 5OGS5K699E; N-(3-Fluoro-4-{[1-Methyl-6-(1h-Pyrazol-4-Yl)-1h-Indazol-5-Yl]oxy}phenyl)-1-(4-Fluorophenyl)-6-Methyl-2-Oxo-1,2-Dihydropyridine-3-Carboxamide; C30H22F2N6O3; Merestinib [USAN]; SCHEMBL679002; LY2801653 (Merestinib); GTPL9841; CHEMBL3545307; QCR-139; DTXSID20659635; SYN1222; QHADVLVFMKEIIP-UHFFFAOYSA-N DM0KJDY CP Lilly DM0KJDY DT Small molecular drug DM0KJDY PC 44603533 DM0KJDY MW 552.5 DM0KJDY FM C30H22F2N6O3 DM0KJDY IC InChI=1S/C30H22F2N6O3/c1-17-3-9-23(30(40)38(17)22-7-4-20(31)5-8-22)29(39)36-21-6-10-27(25(32)12-21)41-28-11-18-16-35-37(2)26(18)13-24(28)19-14-33-34-15-19/h3-16H,1-2H3,(H,33,34)(H,36,39) DM0KJDY CS CC1=CC=C(C(=O)N1C2=CC=C(C=C2)F)C(=O)NC3=CC(=C(C=C3)OC4=C(C=C5C(=C4)C=NN5C)C6=CNN=C6)F DM0KJDY IK QHADVLVFMKEIIP-UHFFFAOYSA-N DM0KJDY IU N-[3-fluoro-4-[1-methyl-6-(1H-pyrazol-4-yl)indazol-5-yl]oxyphenyl]-1-(4-fluorophenyl)-6-methyl-2-oxopyridine-3-carboxamide DM0KJDY CA CAS 1206799-15-6 DM0KJDY DE Solid tumour/cancer; Biliary tract cancer DMO8IEZ ID DMO8IEZ DMO8IEZ DN LY-2828360 DMO8IEZ HS Phase 2 DMO8IEZ CP Eli Lilly & Co DMO8IEZ DE Pain DMZ0DMY ID DMZ0DMY DMZ0DMY DN LY2874455 DMZ0DMY HS Phase 2 DMZ0DMY SN LY2874455; 1254473-64-7; LY-2874455; UNII-E9M363811V; CHEMBL3828009; E9M363811V; AK186860; LY 2874455; (R,E)-2-(4-(2-(5-(1-(3,5-Dichloropyridin-4-yl)-ethoxy)-1H-indazol-3-yl)vinyl)-1H-pyrazol-1-yl)ethanol; C21H19Cl2N5O2; (R,E)-2-(4-(2-(5-(1-(3,5-dichloropyridin-4-yl)ethoxy)-1H-indazol-3-yl)vinyl)-1H-pyrazol-1-yl)ethanol; GKJCVYLDJWTWQU-CXLRFSCWSA-N; SCHEMBL298446; SCHEMBL298445; QCR-90; GTPL8104; DTXSID20154776; MolPort-044-724-281; MolPort-023-219-117; EX-A1340; BCP04756; ZINC73069242; BDBM50189781; 2529AH; s7057; AKOS027251051 DMZ0DMY CP Lilly DMZ0DMY DT Small molecular drug DMZ0DMY PC 46944259 DMZ0DMY MW 444.3 DMZ0DMY FM C21H19Cl2N5O2 DMZ0DMY IC InChI=1S/C21H19Cl2N5O2/c1-13(21-17(22)10-24-11-18(21)23)30-15-3-5-20-16(8-15)19(26-27-20)4-2-14-9-25-28(12-14)6-7-29/h2-5,8-13,29H,6-7H2,1H3,(H,26,27)/b4-2+/t13-/m1/s1 DMZ0DMY CS C[C@H](C1=C(C=NC=C1Cl)Cl)OC2=CC3=C(C=C2)NN=C3/C=C/C4=CN(N=C4)CCO DMZ0DMY IK GKJCVYLDJWTWQU-CXLRFSCWSA-N DMZ0DMY IU 2-[4-[(E)-2-[5-[(1R)-1-(3,5-dichloropyridin-4-yl)ethoxy]-1H-indazol-3-yl]ethenyl]pyrazol-1-yl]ethanol DMZ0DMY CA CAS 1254473-64-7 DMZ0DMY DE Solid tumour/cancer DMQV1OU ID DMQV1OU DMQV1OU DN LY-2875358 DMQV1OU HS Phase 2 DMQV1OU SN C-Met mAb (cancer), Eli Lilly; Anti-c-Met antibody (cancer), Lilly DMQV1OU CP Eli lilly DMQV1OU DT Antibody DMQV1OU DE Solid tumour/cancer DMV14LM ID DMV14LM DMV14LM DN LY2886721 DMV14LM HS Phase 2 DMV14LM SN LY2886721; 1262036-50-9; LY-2886721; UNII-2CQ62IWB67; LY 2886721; 2CQ62IWB67; N-(3-((4aS,7aS)-2-amino-4a,5,7,7a-tetrahydro-4H-furo[3,4-d][1,3]thiazin-7a-yl)-4-fluorophenyl)-5-fluoropicolinamide; CHEMBL2396989; N-{3-[(4as,7as)-2-Amino-4a,5-Dihydro-4h-Furo[3,4-D][1,3]thiazin-7a(7h)-Yl]-4-Fluorophenyl}-5-Fluoropyridine-2-Carboxamide; n-(3-((4as,7as)-2-amino-4a,5-dihydro-4h-furo(3,4-d)(1,3)thiazin-7a(7h)-yl)-4-fluorophenyl)-5-fluoro-2-pyridinecarboxamide; NIDRNVHMMDAAIK-YPMLDQLKSA-N; MLS006011070; SCHEMBL966802; GTPL6475 DMV14LM CP Lilly DMV14LM DT Small molecular drug DMV14LM PC 49837968 DMV14LM MW 390.4 DMV14LM FM C18H16F2N4O2S DMV14LM IC InChI=1S/C18H16F2N4O2S/c19-11-1-4-15(22-6-11)16(25)23-12-2-3-14(20)13(5-12)18-9-26-7-10(18)8-27-17(21)24-18/h1-6,10H,7-9H2,(H2,21,24)(H,23,25)/t10-,18-/m0/s1 DMV14LM CS C1[C@H]2CSC(=N[C@]2(CO1)C3=C(C=CC(=C3)NC(=O)C4=NC=C(C=C4)F)F)N DMV14LM IK NIDRNVHMMDAAIK-YPMLDQLKSA-N DMV14LM IU N-[3-[(4aS,7aS)-2-amino-4,4a,5,7-tetrahydrofuro[3,4-d][1,3]thiazin-7a-yl]-4-fluorophenyl]-5-fluoropyridine-2-carboxamide DMV14LM CA CAS 1262036-50-9 DMV14LM DE Alzheimer disease DMRDEKZ ID DMRDEKZ DMRDEKZ DN LY2928057 DMRDEKZ HS Phase 2 DMRDEKZ CP Lilly DMRDEKZ DE Anaemia DM4N6EK ID DM4N6EK DM4N6EK DN LY293558 DM4N6EK HS Phase 2 DM4N6EK SN Tezampanel; 154652-83-2; LY-293558; LY293558; Ted-isoquinoline-3-cooh; LY 293558; UNII-GA36S2O9C2; CHEMBL14935; GA36S2O9C2; 150131-78-5; Decahydro-6-(2-(1H-tetrazol-5-yl)ethyl)-3-isoquinolinecarboxylic acid; 6-(2-(1H-Tetrazol-5-yl)ethyl)-1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline-3-carboxylic acid; 3-Isoquinolinecarboxylic acid, decahydro-6-(2-(1H-tetrazol-5-yl)ethyl)-, (3S,4aR,6R,8aR)-; 3-Isoquinolinecarboxylic acid, decahydro-6-(2-(1H-tetrazol-5-yl)ethyl)-, (3S-(3alpha,4aalpha,6beta,8aalpha))-; Tezampanel [INN] DM4N6EK CP Eli Lilly DM4N6EK TC Analgesics DM4N6EK DT Small molecular drug DM4N6EK PC 127894 DM4N6EK MW 279.34 DM4N6EK FM C13H21N5O2 DM4N6EK IC InChI=1S/C13H21N5O2/c19-13(20)11-6-10-5-8(1-3-9(10)7-14-11)2-4-12-15-17-18-16-12/h8-11,14H,1-7H2,(H,19,20)(H,15,16,17,18)/t8-,9+,10-,11+/m1/s1 DM4N6EK CS C1C[C@H]2CN[C@@H](C[C@H]2C[C@H]1CCC3=NNN=N3)C(=O)O DM4N6EK IK ZXFRFPSZAKNPQQ-YTWAJWBKSA-N DM4N6EK IU (3S,4aR,6R,8aR)-6-[2-(2H-tetrazol-5-yl)ethyl]-1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline-3-carboxylic acid DM4N6EK CA CAS 154652-83-2 DM4N6EK DE Pain DMB5L6Q ID DMB5L6Q DMB5L6Q DN LY-2940094 DMB5L6Q HS Phase 2 DMB5L6Q CP Eli Lilly & Co DMB5L6Q PC 52914971 DMB5L6Q MW 481 DMB5L6Q FM C22H23ClF2N4O2S DMB5L6Q IC InChI=1S/C22H23ClF2N4O2S/c1-14-16(11-29(27-14)20-15(12-30)3-2-6-26-20)10-28-7-4-21(5-8-28)19-17(9-18(23)32-19)22(24,25)13-31-21/h2-3,6,9,11,30H,4-5,7-8,10,12-13H2,1H3 DMB5L6Q CS CC1=NN(C=C1CN2CCC3(CC2)C4=C(C=C(S4)Cl)C(CO3)(F)F)C5=C(C=CC=N5)CO DMB5L6Q IK NKQHBJNRBKHUQR-UHFFFAOYSA-N DMB5L6Q IU [2-[4-[(2-chloro-4,4-difluorospiro[5H-thieno[2,3-c]pyran-7,4'-piperidine]-1'-yl)methyl]-3-methylpyrazol-1-yl]pyridin-3-yl]methanol DMB5L6Q CA CAS 1307245-86-8 DMB5L6Q DE Major depressive disorder DML6XWR ID DML6XWR DML6XWR DN LY2944876 DML6XWR HS Phase 2 DML6XWR PC 121494121 DML6XWR MW 405.5 DML6XWR FM C16H27N3O7S DML6XWR IC InChI=1S/C16H27N3O7S/c1-25-7-8-26-6-2-4-18-13(20)3-5-19-14(21)9-12(15(19)22)27-10-11(17)16(23)24/h11-12H,2-10,17H2,1H3,(H,18,20)(H,23,24)/t11-,12?/m0/s1 DML6XWR CS COCCOCCCNC(=O)CCN1C(=O)CC(C1=O)SC[C@@H](C(=O)O)N DML6XWR IK DLVAZTPQKCTPLB-PXYINDEMSA-N DML6XWR IU (2R)-2-amino-3-[1-[3-[3-(2-methoxyethoxy)propylamino]-3-oxopropyl]-2,5-dioxopyrrolidin-3-yl]sulfanylpropanoic acid DML6XWR CA CAS 1492924-65-8 DML6XWR DE Diabetic complication DMRVEHY ID DMRVEHY DMRVEHY DN LY3012212 DMRVEHY HS Phase 2 DMRVEHY SN Icrucumab DMRVEHY CP Lilly DMRVEHY DE Bladder cancer; Arteriosclerosis DMFMKQ3 ID DMFMKQ3 DMFMKQ3 DN LY3015014 DMFMKQ3 HS Phase 2 DMFMKQ3 CP Eli lilly DMFMKQ3 DT Antibody DMFMKQ3 DE Cardiovascular disease DMD9KYF ID DMD9KYF DMD9KYF DN LY3023414 DMD9KYF HS Phase 2 DMD9KYF CP Lilly DMD9KYF PC 57519748 DMD9KYF MW 406.5 DMD9KYF FM C23H26N4O3 DMD9KYF IC InChI=1S/C23H26N4O3/c1-14(30-5)13-27-21-18-9-15(16-8-17(11-24-10-16)23(2,3)29)6-7-19(18)25-12-20(21)26(4)22(27)28/h6-12,14,29H,13H2,1-5H3/t14-/m0/s1 DMD9KYF CS C[C@@H](CN1C2=C3C=C(C=CC3=NC=C2N(C1=O)C)C4=CC(=CN=C4)C(C)(C)O)OC DMD9KYF IK ACCFLVVUVBJNGT-AWEZNQCLSA-N DMD9KYF IU 8-[5-(2-hydroxypropan-2-yl)pyridin-3-yl]-1-[(2S)-2-methoxypropyl]-3-methylimidazo[4,5-c]quinolin-2-one DMD9KYF CA CAS 1386874-06-1 DMD9KYF DE Solid tumour/cancer; Prostate cancer DMDFZK8 ID DMDFZK8 DMDFZK8 DN LY3113593 DMDFZK8 HS Phase 2 DMDFZK8 CP Eli Lilly DMDFZK8 DT Antibody DMDFZK8 DE Anaemia DMAC457 ID DMAC457 DMAC457 DN LY3127804 DMAC457 HS Phase 2 DMAC457 TC Antiviral Agents DMAC457 DT Monoclonal antibody DMAC457 DE Coronavirus Disease 2019 (COVID-19) DM7IFNB ID DM7IFNB DM7IFNB DN LY3202626 DM7IFNB HS Phase 2 DM7IFNB CP Eli Lilly Indianapolis, IN DM7IFNB DE Alzheimer disease DMGMC8H ID DMGMC8H DMGMC8H DN LY333531 DMGMC8H HS Phase 2 DMGMC8H SN Ruboxistaurin; 169939-94-0; LY-333531; Ruboxistaurin [INN]; LY 333531; UNII-721809WQCP; 721809WQCP; K00587a; 13-((Dimethylamino)methyl)-10,11,14,15-tetrahydro-4,9:16,21-dimetheno-1H,13H-dibenzo(e,k)pyrrolo(3,4-h)(1,4,13)oxadiazacyclohexadecene-1,3(2H)-dione; CHEMBL432130; (9S)-9-[(dimethylamino)methyl]-6,7,10,11-tetrahydro-9H,18H-5,21:12,17-di(metheno)dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecine-18,20(19H)-dione; Br-WR99210 DMGMC8H DT Small molecular drug DMGMC8H PC 153999 DMGMC8H MW 468.5 DMGMC8H FM C28H28N4O3 DMGMC8H IC InChI=1S/C28H28N4O3/c1-30(2)15-18-11-12-31-16-21(19-7-3-5-9-23(19)31)25-26(28(34)29-27(25)33)22-17-32(13-14-35-18)24-10-6-4-8-20(22)24/h3-10,16-18H,11-15H2,1-2H3,(H,29,33,34)/t18-/m0/s1 DMGMC8H CS CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C32)C4=C(C5=CN(CCO1)C6=CC=CC=C65)C(=O)NC4=O DMGMC8H IK ZCBUQCWBWNUWSU-SFHVURJKSA-N DMGMC8H IU (18S)-18-[(dimethylamino)methyl]-17-oxa-4,14,21-triazahexacyclo[19.6.1.17,14.02,6.08,13.022,27]nonacosa-1(28),2(6),7(29),8,10,12,22,24,26-nonaene-3,5-dione DMGMC8H CA CAS 169939-94-0 DMGMC8H DE Solid tumour/cancer DM43O9N ID DM43O9N DM43O9N DN LY-334370 DM43O9N HS Phase 2 DM43O9N SN LY334370; LY-334370; 182563-08-2; UNII-5Q7I1WL2UY; 5Q7I1WL2UY; LY 334370; CHEMBL101690; LY-334,370; 4-fluoro-N-[3-(1-methylpiperidin-4-yl)-1H-indol-5-yl]benzamide; 4-Fluoro-N-[3-(1-methyl-piperidin-4-yl)-1H-indol-5-yl]-benzamide; 4-Fluoro-N-(3-(1-methylpiperidin-4-yl)-1H-indol-5-yl)benzamide; AC1NSKBH; GTPL20; GTPL151; SCHEMBL6911508; DTXSID40415518; ZINC1488294; BCP29131; BDBM50130461; NCGC00378776-02; [3H]LY334370; HY-103107; CS-0025021; L000364; 4-fluoro-N-[3-(1-methyl-4-piperidinyl)-1h-indol-5-yl]-benzamide DM43O9N DT Small molecular drug DM43O9N PC 5311258 DM43O9N MW 351.4 DM43O9N FM C21H22FN3O DM43O9N IC InChI=1S/C21H22FN3O/c1-25-10-8-14(9-11-25)19-13-23-20-7-6-17(12-18(19)20)24-21(26)15-2-4-16(22)5-3-15/h2-7,12-14,23H,8-11H2,1H3,(H,24,26) DM43O9N CS CN1CCC(CC1)C2=CNC3=C2C=C(C=C3)NC(=O)C4=CC=C(C=C4)F DM43O9N IK MDMJLMDBRQXOOI-UHFFFAOYSA-N DM43O9N IU 4-fluoro-N-[3-(1-methylpiperidin-4-yl)-1H-indol-5-yl]benzamide DM43O9N CA CAS 182563-08-2 DM43O9N DE Migraine DMD09CT ID DMD09CT DMD09CT DN LY-362884 DMD09CT HS Phase 2 DMD09CT CP Eli Lilly DMD09CT PC 9870239 DMD09CT MW 491.5 DMD09CT FM C26H29N5O5 DMD09CT IC InChI=1S/C26H29N5O5/c1-26(2,29-14-18(32)15-35-21-5-3-4-20-23(21)31-25(34)30-20)12-16-6-9-19(10-7-16)36-22-11-8-17(13-28-22)24(27)33/h3-11,13,18,29,32H,12,14-15H2,1-2H3,(H2,27,33)(H2,30,31,34) DMD09CT CS CC(C)(CC1=CC=C(C=C1)OC2=NC=C(C=C2)C(=O)N)NCC(COC3=CC=CC4=C3NC(=O)N4)O DMD09CT IK RLYDBONATWKYQX-UHFFFAOYSA-N DMD09CT IU 6-[4-[2-[[2-hydroxy-3-[(2-oxo-1,3-dihydrobenzimidazol-4-yl)oxy]propyl]amino]-2-methylpropyl]phenoxy]pyridine-3-carboxamide DMD09CT DE Type-2 diabetes; Obesity DMZCU7I ID DMZCU7I DMZCU7I DN LY-377604 DMZCU7I HS Phase 2 DMZCU7I SN Ethanolamine analogs, Lilly; Obesity therapeutics, Lilly; Beta-3 adrenoceptor agonists, Lilly DMZCU7I CP Eli Lilly & Co DMZCU7I DT Small molecular drug DMZCU7I PC 9849699 DMZCU7I MW 524.6 DMZCU7I FM C31H32N4O4 DMZCU7I IC InChI=1S/C31H32N4O4/c1-31(2,16-20-10-13-23(14-11-20)39-28-15-12-21(17-33-28)30(32)37)34-18-22(36)19-38-27-9-5-8-26-29(27)24-6-3-4-7-25(24)35-26/h3-15,17,22,34-36H,16,18-19H2,1-2H3,(H2,32,37)/t22-/m0/s1 DMZCU7I CS CC(C)(CC1=CC=C(C=C1)OC2=NC=C(C=C2)C(=O)N)NC[C@@H](COC3=CC=CC4=C3C5=CC=CC=C5N4)O DMZCU7I IK RBSGUQYXRDKPAE-QFIPXVFZSA-N DMZCU7I IU 6-[4-[2-[[(2S)-3-(9H-carbazol-4-yloxy)-2-hydroxypropyl]amino]-2-methylpropyl]phenoxy]pyridine-3-carboxamide DMZCU7I CA CAS 204592-94-9 DMZCU7I DE Obesity DM8OG0J ID DM8OG0J DM8OG0J DN LY-517717 DM8OG0J HS Phase 2 DM8OG0J SN SCHEMBL676862 DM8OG0J CP Eli Lilly DM8OG0J DT Small molecular drug DM8OG0J PC 9939865 DM8OG0J MW 459.6 DM8OG0J FM C27H33N5O2 DM8OG0J IC InChI=1S/C27H33N5O2/c1-30-13-10-23(11-14-30)31-15-17-32(18-16-31)27(34)25(21-5-3-2-4-6-21)29-26(33)22-8-7-20-9-12-28-24(20)19-22/h2-9,12,19,23,25,28H,10-11,13-18H2,1H3,(H,29,33)/t25-/m1/s1 DM8OG0J CS CN1CCC(CC1)N2CCN(CC2)C(=O)[C@@H](C3=CC=CC=C3)NC(=O)C4=CC5=C(C=C4)C=CN5 DM8OG0J IK VYNKVNDKAOGAAQ-RUZDIDTESA-N DM8OG0J IU N-[(1R)-2-[4-(1-methylpiperidin-4-yl)piperazin-1-yl]-2-oxo-1-phenylethyl]-1H-indole-6-carboxamide DM8OG0J CA CAS 313489-71-3 DM8OG0J DE Thrombosis DMBM2I9 ID DMBM2I9 DMBM2I9 DN LY-518674 DMBM2I9 HS Phase 2 DMBM2I9 SN LY-674; 2-Methyl-2-[4-[3-[1-(4-methylbenzyl)-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl]propyl]phenoxy]propionic acid DMBM2I9 CP Eli Lilly DMBM2I9 DT Small molecular drug DMBM2I9 PC 135449333 DMBM2I9 MW 409.5 DMBM2I9 FM C23H27N3O4 DMBM2I9 IC InChI=1S/C23H27N3O4/c1-16-7-9-18(10-8-16)15-26-22(29)24-20(25-26)6-4-5-17-11-13-19(14-12-17)30-23(2,3)21(27)28/h7-14H,4-6,15H2,1-3H3,(H,27,28)(H,24,25,29) DMBM2I9 CS CC1=CC=C(C=C1)CN2C(=O)NC(=N2)CCCC3=CC=C(C=C3)OC(C)(C)C(=O)O DMBM2I9 IK PNHFDVSKDSLUFH-UHFFFAOYSA-N DMBM2I9 IU 2-methyl-2-[4-[3-[1-[(4-methylphenyl)methyl]-5-oxo-4H-1,2,4-triazol-3-yl]propyl]phenoxy]propanoic acid DMBM2I9 CA CAS 425671-29-0 DMBM2I9 DE Diabetic complication DMMSBW5 ID DMMSBW5 DMMSBW5 DN LY-545694 DMMSBW5 HS Phase 2 DMMSBW5 SN Lead iGluR5 antagonist (pain), Eli Lilly DMMSBW5 CP Eli Lilly & Co DMMSBW5 DE Neuropathic pain DMP05GL ID DMP05GL DMP05GL DN LYC-30937 DMP05GL HS Phase 2 DMP05GL CP Lycera Ann Arbor, MI DMP05GL DE Plaque psoriasis; Ulcerative colitis DMV8WU9 ID DMV8WU9 DMV8WU9 DN LYC-55716 DMV8WU9 HS Phase 2 DMV8WU9 SN Cintirorgon; UNII-LPN433P0EA; LPN433P0EA; 2055536-64-4; Cintirorgon [INN]; cintirorgon (proposed INN); SCHEMBL18302870; GTPL10045; LYC55716; BCP28882; EX-A2635; LYC 55716; CS-7496; compound 32J [WO2016201225A1]; HY-104037; 3-[(2S)-6-[3-(difluoromethoxy)-5-fluorophenyl]-4-[3-(trifluoromethyl)phenyl]sulfonyl-2,3-dihydro-1,4-benzoxazin-2-yl]-2,2-dimethylpropanoic acid DMV8WU9 CP Lycera Ann Arbor, MI DMV8WU9 PC 124126348 DMV8WU9 MW 603.5 DMV8WU9 FM C27H23F6NO6S DMV8WU9 IC InChI=1S/C27H23F6NO6S/c1-26(2,24(35)36)13-20-14-34(41(37,38)21-5-3-4-17(11-21)27(31,32)33)22-10-15(6-7-23(22)39-20)16-8-18(28)12-19(9-16)40-25(29)30/h3-12,20,25H,13-14H2,1-2H3,(H,35,36)/t20-/m0/s1 DMV8WU9 CS CC(C)(C[C@H]1CN(C2=C(O1)C=CC(=C2)C3=CC(=CC(=C3)F)OC(F)F)S(=O)(=O)C4=CC=CC(=C4)C(F)(F)F)C(=O)O DMV8WU9 IK GULSIMHVQYBADX-FQEVSTJZSA-N DMV8WU9 IU 3-[(2S)-6-[3-(difluoromethoxy)-5-fluorophenyl]-4-[3-(trifluoromethyl)phenyl]sulfonyl-2,3-dihydro-1,4-benzoxazin-2-yl]-2,2-dimethylpropanoic acid DMV8WU9 CA CAS 2055536-64-4 DMV8WU9 DE Solid tumour/cancer; Non-small-cell lung cancer DM23Y6K ID DM23Y6K DM23Y6K DN LYS228 DM23Y6K HS Phase 2 DM23Y6K SN 1810051-96-7 (free acid); 1-((((Z)-1-(2-aminothiazol-4-yl)-2-oxo-2-(((3S,4R)-2-oxo-4-((2-oxooxazolidin-3-yl)methyl)-1-sulfoazetidin-3-yl)amino)ethylidene)amino)oxy)cyclopropane-1-carboxylic acid; SCHEMBL17094584; 1-(((Z)-(1-(2-aminothiazol-4-yl)-2-oxo-2-(((3S,4R)-2-oxo-4-((2-oxooxazolidin-3-yl)methyl)-1-sulfoazetidin-3-yl)amino)ethylidene)amino)oxy)cyclopropanecarboxylic acid; l-(((Z)-(1-(2-aminothiazol-4-yl)-2-oxo-2-(((3S,4R)-2-oxo-4-((2-oxooxazolidin-3-yl)methyl)-1-sulfoazetidin-3-yl)amino)ethylidene)amino)oxy)cyclopropanecarboxylic acid DM23Y6K DT Small molecular drug DM23Y6K PC 118380292 DM23Y6K MW 518.5 DM23Y6K FM C16H18N6O10S2 DM23Y6K IC InChI=1S/C16H18N6O10S2/c17-14-18-7(6-33-14)9(20-32-16(1-2-16)13(25)26)11(23)19-10-8(5-21-3-4-31-15(21)27)22(12(10)24)34(28,29)30/h6,8,10H,1-5H2,(H2,17,18)(H,19,23)(H,25,26)(H,28,29,30)/b20-9+/t8-,10+/m1/s1 DM23Y6K CS C1CC1(C(=O)O)O/N=C(\\C2=CSC(=N2)N)/C(=O)N[C@H]3[C@H](N(C3=O)S(=O)(=O)O)CN4CCOC4=O DM23Y6K IK FWTGYTRQUBRVDW-UWGJAOEXSA-N DM23Y6K IU 1-[(E)-[1-(2-amino-1,3-thiazol-4-yl)-2-oxo-2-[[(3S,4R)-2-oxo-4-[(2-oxo-1,3-oxazolidin-3-yl)methyl]-1-sulfoazetidin-3-yl]amino]ethylidene]amino]oxycyclopropane-1-carboxylic acid DM23Y6K DE Urinary tract infection DML0I2Z ID DML0I2Z DML0I2Z DN M118 DML0I2Z HS Phase 2 DML0I2Z SN Adomiparin DML0I2Z CP Momenta Pharmaceuticals DML0I2Z DT Small molecular drug DML0I2Z PC 21156139 DML0I2Z MW 801.9 DML0I2Z FM C34H42Cl4N8O2Zn DML0I2Z IC InChI=1S/2C17H20N4O.4ClH.Zn/c2*1-4-21(5-2)11-6-7-14-15(8-11)22-17-10(3)12(18)9-13(19)16(17)20-14;;;;;/h2*6-9H,4-5H2,1-3H3,(H3,18,19);4*1H;/q;;;;;;+2/p-2 DML0I2Z CS CC[N+](=C1C=CC2=NC3=C(C=C(C(=C3OC2=C1)C)N)N)CC.CC[N+](=C1C=CC2=NC3=C(C=C(C(=C3OC2=C1)C)N)N)CC.Cl[Zn-2](Cl)(Cl)Cl DML0I2Z IK JJKNZNYHIUJGIC-UHFFFAOYSA-L DML0I2Z IU (7,9-diamino-6-methylphenoxazin-3-ylidene)-diethylazanium;tetrachlorozinc(2-) DML0I2Z DE Acute coronary syndrome DMZ7YX3 ID DMZ7YX3 DMZ7YX3 DN M-16209 DMZ7YX3 HS Phase 2 DMZ7YX3 SN 1-(3-Bromo-benzo[b]furan-2-ylsulfonyl)imidazolidine-2,4-dione; 1-(3-Bromobenzo[b]furan-2-ylsulfonyl)hydantoin DMZ7YX3 DT Small molecular drug DMZ7YX3 PC 164260 DMZ7YX3 MW 359.15 DMZ7YX3 FM C11H7BrN2O5S DMZ7YX3 IC InChI=1S/C11H7BrN2O5S/c12-9-6-3-1-2-4-7(6)19-10(9)20(17,18)14-5-8(15)13-11(14)16/h1-4H,5H2,(H,13,15,16) DMZ7YX3 CS C1C(=O)NC(=O)N1S(=O)(=O)C2=C(C3=CC=CC=C3O2)Br DMZ7YX3 IK ZJSUDHQFSBHLDV-UHFFFAOYSA-N DMZ7YX3 IU 1-[(3-bromo-1-benzofuran-2-yl)sulfonyl]imidazolidine-2,4-dione DMZ7YX3 CA CAS 128851-36-5 DMZ7YX3 DE Diabetic complication DMC5MQD ID DMC5MQD DMC5MQD DN M2951 DMC5MQD HS Phase 2 DMC5MQD SN evobrutinib; Evobrutinib; UNII-ZA45457L1K; ZA45457L1K; 1415823-73-2; 1-(4-(((6-amino-5-(4-phenoxyphenyl)pyrimidin-4-yl)amino)methyl)piperidin-1-yl)prop-2-en-1-one; 1-[4-[[[6-amino-5-(4-phenoxyphenyl)pyrimidin-4-yl]amino]methyl]piperidin-1-yl]prop-2-en-1-one; Evobrutinib [INN]; GTPL9752; SCHEMBL14165673; QUIWHXQETADMGN-UHFFFAOYSA-N; MSC2364447C; MSC-2364447C; ZINC205623965; AKOS032954004; CS-6303; MSC 2364447; HY-101215; A250 [WO2012170976]; N-[(1-acryloylpiperidin-4-yl)methyl]-5-(4-phenoxyphenyl)pyrimidine-4,6-diamine; 1-(4-((6-Amin DMC5MQD CP EMD Serono Rockland, MA DMC5MQD PC 71479709 DMC5MQD MW 429.5 DMC5MQD FM C25H27N5O2 DMC5MQD IC InChI=1S/C25H27N5O2/c1-2-22(31)30-14-12-18(13-15-30)16-27-25-23(24(26)28-17-29-25)19-8-10-21(11-9-19)32-20-6-4-3-5-7-20/h2-11,17-18H,1,12-16H2,(H3,26,27,28,29) DMC5MQD CS C=CC(=O)N1CCC(CC1)CNC2=NC=NC(=C2C3=CC=C(C=C3)OC4=CC=CC=C4)N DMC5MQD IK QUIWHXQETADMGN-UHFFFAOYSA-N DMC5MQD IU 1-[4-[[[6-amino-5-(4-phenoxyphenyl)pyrimidin-4-yl]amino]methyl]piperidin-1-yl]prop-2-en-1-one DMC5MQD CA CAS 1415823-73-2 DMC5MQD DE Multiple sclerosis; Rheumatoid arthritis; Systemic lupus erythematosus DMJCULI ID DMJCULI DMJCULI DN M7824 DMJCULI HS Phase 2 DMJCULI CP EMD SeronoRockland, MA DMJCULI DT Antibody DMJCULI DE Solid tumour/cancer DMQOBH4 ID DMQOBH4 DMQOBH4 DN mab 1-7F9 DMQOBH4 HS Phase 2 DMQOBH4 CP CeMines DMQOBH4 DT Antibody DMQOBH4 DE Multiple myeloma DMBYDNE ID DMBYDNE DMBYDNE DN Managlinat dialanetil DMBYDNE HS Phase 2 DMBYDNE SN CS-917; GP-3034; MB-05032; MB-06322; MB-06633; MB-6322; R-132917; Type 2 diabetes therapeutic, Gensia/Sankyo; Type 2 diabetes therapeutic, SICOR/Sankyo; Diabetes therapeutics, Metabasis/Sanyko/Daiichi Sankyo; Purine nucleotide analogs, Gensia/Sankyo/Daiichi Sankyo; Purine nucleotide analogs, Metabasis/Sanyko/Daiichi Sankyo; Purine nucleotide analogs, SICOR/Sankyo/Daiichi Sankyo DMBYDNE CP Metabasis Therapeutics Inc DMBYDNE PC 73014123 DMBYDNE MW 484.6 DMBYDNE FM C21H33N4O5PS DMBYDNE IC InChI=1S/C21H33N4O5PS/c1-7-28-19(26)13(5)24-31(25-14(6)20(27)29-8-2)17-10-9-15(30-17)18-16(11-12(3)4)32-21(22)23-18/h9-10,12-14,24-25H,7-8,11H2,1-6H3,(H2,22,23)/t13-,14-/m0/s1 DMBYDNE CS CCOC(=O)[C@H](C)NP(C1=CC=C(O1)C2=C(SC(=N2)N)CC(C)C)N[C@@H](C)C(=O)OCC DMBYDNE IK JGCMEVUWRCNKKE-KBPBESRZSA-N DMBYDNE IU ethyl (2S)-2-[[[5-[2-amino-5-(2-methylpropyl)-1,3-thiazol-4-yl]furan-2-yl]-[[(2S)-1-ethoxy-1-oxopropan-2-yl]amino]phosphanyl]amino]propanoate DMBYDNE DE Type-2 diabetes DMB4A8I ID DMB4A8I DMB4A8I DN MANOALIDE DMB4A8I HS Phase 2 DMB4A8I SN manoalide; UNII-E1DK0157K9; 75088-80-1; CHEMBL463914; CHEBI:66666; E1DK0157K9; 2(5H)-Furanone, 4-(3,6-dihydro-6-hydroxy-5-(4-methyl-6-(2,6,6-trimethyl-1-cyclohexen-1-yl)-3-hexenyl)-2H-pyran-2-yl)-5-hydroxy-; 2(5H)-Furanone, 4-((2R,6R)-3,6-dihydro-6-hydroxy-5-((3E)-4-methyl-6-(2,6,6-trimethyl-1-cyclohexen-1-yl)-3-hexenyl)-2H-pyran-2-yl)-5-hydroxy-, (5R)-; AC1O5NJS; SCHEMBL20551728; MolPort-020-000-975 DMB4A8I DT Small molecular drug DMB4A8I PC 6437368 DMB4A8I MW 416.5 DMB4A8I FM C25H36O5 DMB4A8I IC InChI=1S/C25H36O5/c1-16(10-12-20-17(2)8-6-14-25(20,3)4)7-5-9-18-11-13-21(29-23(18)27)19-15-22(26)30-24(19)28/h7,11,15,21,23-24,27-28H,5-6,8-10,12-14H2,1-4H3/b16-7+/t21-,23-,24-/m1/s1 DMB4A8I CS CC1=C(C(CCC1)(C)C)CC/C(=C/CCC2=CC[C@@H](O[C@H]2O)C3=CC(=O)O[C@H]3O)/C DMB4A8I IK FGJIDQWRRLDGDB-CPIXEKRISA-N DMB4A8I IU (2R)-2-hydroxy-3-[(2R,6R)-6-hydroxy-5-[(E)-4-methyl-6-(2,6,6-trimethylcyclohexen-1-yl)hex-3-enyl]-3,6-dihydro-2H-pyran-2-yl]-2H-furan-5-one DMB4A8I CA CAS 75088-80-1 DMB4A8I CB CHEBI:66666 DMB4A8I DE Arthritis DMGQ175 ID DMGQ175 DMGQ175 DN Mapatumumab DMGQ175 HS Phase 2 DMGQ175 CP Human Genome Sciences DMGQ175 DT Monoclonal antibody DMGQ175 DE Non-small-cell lung cancer DMDTI0L ID DMDTI0L DMDTI0L DN Masilukast DMDTI0L HS Phase 2 DMDTI0L SN D-3523; MCC-847; ZD-3523 DMDTI0L CP Zeneca Group plc DMDTI0L DT Small molecular drug DMDTI0L PC 204056 DMDTI0L MW 615.7 DMDTI0L FM C31H32F3N3O5S DMDTI0L IC InChI=1S/C31H32F3N3O5S/c1-19(16-31(32,33)34)17-35-29(38)22-11-12-26-25(14-22)24(18-37(26)3)13-21-9-10-23(15-27(21)42-4)30(39)36-43(40,41)28-8-6-5-7-20(28)2/h5-12,14-15,18-19H,13,16-17H2,1-4H3,(H,35,38)(H,36,39)/t19-/m1/s1 DMDTI0L CS CC1=CC=CC=C1S(=O)(=O)NC(=O)C2=CC(=C(C=C2)CC3=CN(C4=C3C=C(C=C4)C(=O)NC[C@H](C)CC(F)(F)F)C)OC DMDTI0L IK ULMFXAMQUGLVGA-LJQANCHMSA-N DMDTI0L IU 3-[[2-methoxy-4-[(2-methylphenyl)sulfonylcarbamoyl]phenyl]methyl]-1-methyl-N-[(2R)-4,4,4-trifluoro-2-methylbutyl]indole-5-carboxamide DMDTI0L CA CAS 136564-68-6 DMDTI0L DE Asthma DM2458E ID DM2458E DM2458E DN Matuzumab DM2458E HS Phase 2 DM2458E SN EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals DM2458E CP Merck KgaA; Merck KGaA DM2458E DT Antibody DM2458E SQ 3c08_H|Fab72000|Humanized||VH-CH1 (VH(1-115)+CH1(116-213))|||||||223||||MW 24063.8|MW 24063.8|: QVQLVQSGAEVKKPGASVKVSCKASGYTFTSHWMHWVRQAPGQGLEWIGEFNPSNGRTNYNEKFKSKATMTVDTSTNTAYMELSSLRSEDTAVYYCASRDYDYDGRYFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKS >3c08_L|Fab72000|Humanized||L-KAPPA (V-KAPPA(1-101)+C-KAPPA(102-206))|||||||212||||MW 23214.7|MW 23214.7|DIQMTQSPSSLSASVGDRVTITCSASSSVTYMYWYQQKPGKAPKLLIYDTSNLASGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQQWSSHIFTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGE >3c09_B|Fab72000|Humanized||L-KAPPA (V-KAPPA(1-106)+C-KAPPA(107-175))|||||||212||||MW 23214.7|MW 23214.7|DIQMTQSPSSLSASVGDRVTITCSASSSVTYMYWYQQKPGKAPKLLIYDTSNLASGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQQWSSHIFTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGE >3c09_C|Fab72000|Humanized||VH-CH1 (VH(1-121)+CH1(122-191))|||||||223||||MW 24019.8|MW 24019.8|QVQLVQSGAEVKKPGASVKVSCKASGYTFTSHWMHWVRQAPGQGLEWIGEFNPSNGRTNYNEKFKSKATMTVDTSTNTAYMELSSLRSEDTAVYYCASRDYDYAGRYFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKS DM2458E DE Gastric adenocarcinoma DMMVFRC ID DMMVFRC DMMVFRC DN Mavrilimumab DMMVFRC HS Phase 2 DMMVFRC CP MedImmune DMMVFRC DT Antibody DMMVFRC DE Rheumatoid arthritis DMWLIPJ ID DMWLIPJ DMWLIPJ DN MAXY-G34 DMWLIPJ HS Phase 2 DMWLIPJ SN Maxy-G21; MAXY-G-CSF; G-CSF agonist (neutropenia, leukopenia), Maxygen DMWLIPJ CP Maxygen DMWLIPJ DE Neutropenia DMJKHVX ID DMJKHVX DMJKHVX DN Mazapertine succinate DMJKHVX HS Phase 2 DMJKHVX SN RWJ-37796 DMJKHVX CP RW Johnson Pharmaceutical Research Institute DMJKHVX DT Small molecular drug DMJKHVX PC 60819 DMJKHVX MW 539.7 DMJKHVX FM C30H41N3O6 DMJKHVX IC InChI=1S/C26H35N3O2.C4H6O4/c1-21(2)31-25-12-5-4-11-24(25)28-17-15-27(16-18-28)20-22-9-8-10-23(19-22)26(30)29-13-6-3-7-14-29;5-3(6)1-2-4(7)8/h4-5,8-12,19,21H,3,6-7,13-18,20H2,1-2H3;1-2H2,(H,5,6)(H,7,8) DMJKHVX CS CC(C)OC1=CC=CC=C1N2CCN(CC2)CC3=CC(=CC=C3)C(=O)N4CCCCC4.C(CC(=O)O)C(=O)O DMJKHVX IK WAHFGTZTVZRLEY-UHFFFAOYSA-N DMJKHVX IU butanedioic acid;piperidin-1-yl-[3-[[4-(2-propan-2-yloxyphenyl)piperazin-1-yl]methyl]phenyl]methanone DMJKHVX CA CAS 134208-18-7 DMJKHVX DE Psychotic disorder DMHU8SJ ID DMHU8SJ DMHU8SJ DN MB07803 DMHU8SJ HS Phase 2 DMHU8SJ SN MB-07803; 882757-24-6; UNII-GG81XF45C2; MB 07803; GG81XF45C2; SCHEMBL14255484; DTXSID90236932; ACT04837; SB17400; DB05053; HY-16309; CS-0006389; Alanine, N,N'-((5-(2-amino-5-(2,2-dimethyl-1-oxopropyl)-4-thiazolyl)-2-furanyl)phosphinylidene)bis(2-methyl-, diethyl ester; n,n'-((5-(2-amino-5-(2,2-dimethyl-1-oxopropyl)-4-thiazolyl)-2-furanyl)phosphinylidene)bis(2-methylalanine) diethyl ester DMHU8SJ CP Metabasis Therape DMHU8SJ DT Small molecular drug DMHU8SJ PC 24770445 DMHU8SJ MW 556.6 DMHU8SJ FM C24H37N4O7PS DMHU8SJ IC InChI=1S/C24H37N4O7PS/c1-10-33-19(30)23(6,7)27-36(32,28-24(8,9)20(31)34-11-2)15-13-12-14(35-15)16-17(37-21(25)26-16)18(29)22(3,4)5/h12-13H,10-11H2,1-9H3,(H2,25,26)(H2,27,28,32) DMHU8SJ CS CCOC(=O)C(C)(C)NP(=O)(C1=CC=C(O1)C2=C(SC(=N2)N)C(=O)C(C)(C)C)NC(C)(C)C(=O)OCC DMHU8SJ IK CTKZZUXRWBCFEI-UHFFFAOYSA-N DMHU8SJ IU ethyl 2-[[[5-[2-amino-5-(2,2-dimethylpropanoyl)-1,3-thiazol-4-yl]furan-2-yl]-[(1-ethoxy-2-methyl-1-oxopropan-2-yl)amino]phosphoryl]amino]-2-methylpropanoate DMHU8SJ CA CAS 882757-24-6 DMHU8SJ DE Type-2 diabetes DM6JTSZ ID DM6JTSZ DM6JTSZ DN MB-07811 DM6JTSZ HS Phase 2 DM6JTSZ SN CHEMBL471897; MB-07811; SCHEMBL3147495; BDBM50242404 DM6JTSZ CP Ligand Pharmaceuticals DM6JTSZ DT Small molecular drug DM6JTSZ PC 15942005 DM6JTSZ MW 515 DM6JTSZ FM C28H32ClO5P DM6JTSZ IC InChI=1S/C28H32ClO5P/c1-18(2)25-14-21(8-9-27(25)30)15-26-19(3)12-24(13-20(26)4)32-17-35(31)33-11-10-28(34-35)22-6-5-7-23(29)16-22/h5-9,12-14,16,18,28,30H,10-11,15,17H2,1-4H3/t28-,35+/m0/s1 DM6JTSZ CS CC1=CC(=CC(=C1CC2=CC(=C(C=C2)O)C(C)C)C)OC[P@@]3(=O)OCC[C@H](O3)C4=CC(=CC=C4)Cl DM6JTSZ IK LGGPZDRLTDGYSQ-JADSYQMUSA-N DM6JTSZ IU 4-[[4-[[(2R,4S)-4-(3-chlorophenyl)-2-oxo-1,3,2lambda5-dioxaphosphinan-2-yl]methoxy]-2,6-dimethylphenyl]methyl]-2-propan-2-ylphenol DM6JTSZ CA CAS 852948-13-1 DM6JTSZ DE Hyperlipidaemia DMLPNVS ID DMLPNVS DMLPNVS DN MB-102 DMLPNVS HS Phase 2 DMLPNVS SN Relmapirazin; UNII-Q3UQB8PQ6H; Q3UQB8PQ6H; Relmapirazin [INN]; CHEMBL1949708; SCHEMBL16738795; N,N'-((3,6-Diamino-2,5-pyrazinediyl)dicarbonyl)bis(D-serine); D-Serine, N,N'-((3,6-diamino-2,5-pyrazinediyl)dicarbonyl)bis-; 1313706-17-0 DMLPNVS CP Mustang Bio New York, NY DMLPNVS PC 53389120 DMLPNVS MW 372.29 DMLPNVS FM C12H16N6O8 DMLPNVS IC InChI=1S/C12H16N6O8/c13-7-5(9(21)15-3(1-19)11(23)24)17-8(14)6(18-7)10(22)16-4(2-20)12(25)26/h3-4,19-20H,1-2H2,(H2,14,17)(H2,13,18)(H,15,21)(H,16,22)(H,23,24)(H,25,26)/t3-,4-/m1/s1 DMLPNVS CS C([C@H](C(=O)O)NC(=O)C1=C(N=C(C(=N1)N)C(=O)N[C@H](CO)C(=O)O)N)O DMLPNVS IK XHNJXRDGTITISI-QWWZWVQMSA-N DMLPNVS IU (2R)-2-[[3,6-diamino-5-[[(1R)-1-carboxy-2-hydroxyethyl]carbamoyl]pyrazine-2-carbonyl]amino]-3-hydroxypropanoic acid DMLPNVS CA CAS 1313706-17-0 DMLPNVS DE Acute myeloid leukaemia; Acute kidney injury DM3RBJW ID DM3RBJW DM3RBJW DN MB-11055 DM3RBJW HS Phase 2 DM3RBJW SN Cryptotanshinone, MD BioAlpha; Cryptotanshinone, Mazence; AMP activated protein kinase stimulator (liver cirrhosis/steatosis/steatohepatitis), Mazence; AMPK stimulator (liver cirrhosis/steatosis/steatohepatitis), Mazence; Lipid metabolism stimulator (liver cirrhosis/steatosis/steatohepatitis), Mazence DM3RBJW CP Mazence Inc DM3RBJW DE Fatty liver disease DMRSN2C ID DMRSN2C DMRSN2C DN MB-12066 DMRSN2C HS Phase 2 DMRSN2C SN B-lapachone (obesity), Mazence; Beta-lapachone (obesity), Mazence DMRSN2C CP Mazence Inc DMRSN2C DE Obesity DM0AOID ID DM0AOID DM0AOID DN MB-CART19.1 DM0AOID HS Phase 2 DM0AOID CP Shanghai Children's Medical Center DM0AOID DT CAR T Cell Therapy DM0AOID DE Precursor B-lymphoblastic neoplasm DMJVU7Y ID DMJVU7Y DMJVU7Y DN MBL-HCV1 DMJVU7Y HS Phase 2 DMJVU7Y SN Anti-HCV antibody, MassBiologics DMJVU7Y CP Massbiologics DMJVU7Y DE Hepatitis C virus infection DMQMTO1 ID DMQMTO1 DMQMTO1 DN MBX-2044 DMQMTO1 HS Phase 2 DMQMTO1 SN MBX-102 analogs, Metabolex DMQMTO1 CP Metabolex Inc DMQMTO1 DE Type-2 diabetes DM0W3R7 ID DM0W3R7 DM0W3R7 DN MCLA-128 DM0W3R7 HS Phase 2 DM0W3R7 CP MerusUtrecht, Netherlands DM0W3R7 DE Breast cancer DM0CL4I ID DM0CL4I DM0CL4I DN MCS-110 DM0CL4I HS Phase 2 DM0CL4I SN Colony stimulating factor-1 inhibiting antibody (cancer), Novartis; Anti-CSF-1 antibody (cancer), Novartis DM0CL4I CP Novartis pharmaceuticals DM0CL4I DE Bone metastases; Advanced malignancy; Breast cancer; Tenosynovial giant cell tumour; Triple negative breast cancer DMX4U0B ID DMX4U0B DMX4U0B DN MCS-18 DMX4U0B HS Phase 2 DMX4U0B SN Helleborus purpurascens-derived anti-inflammatory analgesic (injection, autoimmune disease), DoNatur DMX4U0B CP DoNatur GmbH DMX4U0B DE Autoimmune diabetes DMDR2SZ ID DMDR2SZ DMDR2SZ DN MCT-125 DMDR2SZ HS Phase 2 DMDR2SZ CP Laxdale Ltd DMDR2SZ DE Fatigue DM5DSGJ ID DM5DSGJ DM5DSGJ DN MD-0727 DM5DSGJ HS Phase 2 DM5DSGJ CP Ironwood Pharmaceuticals DM5DSGJ PC 11586434 DM5DSGJ MW 193.2 DM5DSGJ FM C10H11NO3 DM5DSGJ IC InChI=1S/C10H11NO3/c1-3-14-10(13)9-6-4-5-8(11-9)7(2)12/h4-6H,3H2,1-2H3 DM5DSGJ CS CCOC(=O)C1=CC=CC(=N1)C(=O)C DM5DSGJ IK COYXIUHSZNHMAS-UHFFFAOYSA-N DM5DSGJ IU ethyl 6-acetylpyridine-2-carboxylate DM5DSGJ CA CAS 114578-70-0 DM5DSGJ DE Hypercholesterolaemia DM9FXU7 ID DM9FXU7 DM9FXU7 DN MDL-27192 DM9FXU7 HS Phase 2 DM9FXU7 SN 3-(4-Chlorophenyl)-4-ethyl-1H-1,2,4-triazol-5(4H)-one; 5-(4-Chlorophenyl)-4-ethyl-3,4-dihydro-2H-1,2,4-triazol-3-one DM9FXU7 PC 35793 DM9FXU7 MW 223.66 DM9FXU7 FM C10H10ClN3O DM9FXU7 IC InChI=1S/C10H10ClN3O/c1-2-14-9(12-13-10(14)15)7-3-5-8(11)6-4-7/h3-6H,2H2,1H3,(H,13,15) DM9FXU7 CS CCN1C(=NNC1=O)C2=CC=C(C=C2)Cl DM9FXU7 IK PXINDYJACXPZIN-UHFFFAOYSA-N DM9FXU7 IU 3-(4-chlorophenyl)-4-ethyl-1H-1,2,4-triazol-5-one DM9FXU7 CA CAS 31409-32-2 DM9FXU7 DE Epileptic seizures DMCK8SX ID DMCK8SX DMCK8SX DN MDX-1097 DMCK8SX HS Phase 2 DMCK8SX SN CKap; MKap; K-1-21; Mab therapy, Immune System therapeutics/Medarex; Monoclonal antibody (multiple myeloma, humanized/murine/chimeric), PacMab/Medarex DMCK8SX CP Immune System Therapeutics Ltd DMCK8SX DT Antibody DMCK8SX DE Haematological malignancy DM0EZWI ID DM0EZWI DM0EZWI DN MDX-1100 DM0EZWI HS Phase 2 DM0EZWI CP Medarex DM0EZWI DT Antibody DM0EZWI DE Crohn disease DMKMSC4 ID DMKMSC4 DMKMSC4 DN MDX-1342 DMKMSC4 HS Phase 2 DMKMSC4 SN Anti-CD19 (cancer), MDX/BMS; Anti-CD19 antibody (cancer), Medarex/BMS DMKMSC4 CP Medarex DMKMSC4 DT Antibody DMKMSC4 DE leukaemia DMO84TL ID DMO84TL DMO84TL DN ME-3407 DMO84TL HS Phase 2 DMO84TL SN EF-4040; 2-(Butoxycarbonylmethylsulfinyl)thiazolo[5,4-b]pyridine; 2-(Thiazolo[5,4-b]pyridin-2-ylsulfinyl)acetic acid butyl ester DMO84TL DT Small molecular drug DMO84TL PC 6918179 DMO84TL MW 298.4 DMO84TL FM C12H14N2O3S2 DMO84TL IC InChI=1S/C12H14N2O3S2/c1-2-3-7-17-10(15)8-19(16)12-14-9-5-4-6-13-11(9)18-12/h4-6H,2-3,7-8H2,1H3 DMO84TL CS CCCCOC(=O)CS(=O)C1=NC2=C(S1)N=CC=C2 DMO84TL IK BUXNKFNNJJTLOS-UHFFFAOYSA-N DMO84TL IU butyl 2-([1,3]thiazolo[5,4-b]pyridin-2-ylsulfinyl)acetate DMO84TL DE Duodenal ulcer DMX9Y7V ID DMX9Y7V DMX9Y7V DN MEDETOMIDINE DMX9Y7V HS Phase 2 DMX9Y7V DT Small molecular drug DMX9Y7V PC 68602 DMX9Y7V MW 200.28 DMX9Y7V FM C13H16N2 DMX9Y7V IC InChI=1S/C13H16N2/c1-9-5-4-6-12(10(9)2)11(3)13-7-14-8-15-13/h4-8,11H,1-3H3,(H,14,15) DMX9Y7V CS CC1=C(C(=CC=C1)C(C)C2=CN=CN2)C DMX9Y7V IK CUHVIMMYOGQXCV-UHFFFAOYSA-N DMX9Y7V IU 5-[1-(2,3-dimethylphenyl)ethyl]-1H-imidazole DMX9Y7V CA CAS 86347-14-0 DMX9Y7V CB CHEBI:48552 DMX9Y7V DE Pain DMSV60C ID DMSV60C DMSV60C DN MEDI0382 DMSV60C HS Phase 2 DMSV60C SN Cotadutide; UNII-QL6A9B13HW; QL6A9B13HW; Cotadutide [INN]; Cotadutide [USAN]; MEDI-0382; MEDI 0382 [WHO-DD]; 1686108-82-6; His-Ser-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Lys-(gamma-glupalmitoyl)-Ser-Glu-Tyr-Leu-Asp-Ser-Glu-Arg-Ala-Arg-Asp- Phe-Val-Ala-Trp-Leu-Glu-Ala-Gly-Gly; Glycine, L-histidyl-L-seryl-L-glutaminylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-alpha-aspartyl-N6-(N-(1-oxotetradecyl)-L-gamma-glutamyl)-L-lysyl-L-seryl-L-alpha-glutamyl-L-tyrosyl-L-leucyl-L-alpha-aspartyl-L-seryl-L-alpha-glutamyl DMSV60C CP MedImmune Gaithersburg, MD DMSV60C PC 134694273 DMSV60C MW 3728 DMSV60C FM C167H252N42O55 DMSV60C IC InChI=1S/C167H252N42O55/c1-13-14-15-16-17-18-19-20-21-22-23-24-31-47-125(219)186-109(165(263)264)53-58-124(218)175-62-35-34-44-102(189-153(251)116(72-131(228)229)201-161(259)122(83-213)206-164(262)137(92(12)215)209-157(255)114(68-94-40-29-26-30-41-94)202-163(261)136(91(11)214)207-127(221)78-181-142(240)105(52-57-123(169)217)190-158(256)119(80-210)203-141(239)100(168)71-97-76-174-84-182-97)146(244)204-120(81-211)159(257)193-108(56-61-130(226)227)148(246)197-112(69-95-48-50-98(216)51-49-95)151(249)195-111(66-86(4)5)150(248)200-118(74-133(232)233)155(253)205-121(82-212)160(258)192-107(55-60-129(224)225)147(245)188-103(45-36-63-176-166(170)171)143(241)184-89(9)139(237)187-104(46-37-64-177-167(172)173)145(243)199-117(73-132(230)231)154(252)198-113(67-93-38-27-25-28-39-93)156(254)208-135(87(6)7)162(260)185-90(10)140(238)194-115(70-96-75-178-101-43-33-32-42-99(96)101)152(250)196-110(65-85(2)3)149(247)191-106(54-59-128(222)223)144(242)183-88(8)138(236)180-77-126(220)179-79-134(234)235/h25-30,32-33,38-43,48-51,75-76,84-92,100,102-122,135-137,178,210-216H,13-24,31,34-37,44-47,52-74,77-83,168H2,1-12H3,(H2,169,217)(H,174,182)(H,175,218)(H,179,220)(H,180,236)(H,181,240)(H,183,242)(H,184,241)(H,185,260)(H,186,219)(H,187,237)(H,188,245)(H,189,251)(H,190,256)(H,191,247)(H,192,258)(H,193,257)(H,194,238)(H,195,249)(H,196,250)(H,197,246)(H,198,252)(H,199,243)(H,200,248)(H,201,259)(H,202,261)(H,203,239)(H,204,244)(H,205,253)(H,206,262)(H,207,221)(H,208,254)(H,209,255)(H,222,223)(H,224,225)(H,226,227)(H,228,229)(H,230,231)(H,232,233)(H,234,235)(H,263,264)(H4,170,171,176)(H4,172,173,177)/t88-,89-,90-,91+,92+,100-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,135-,136-,137-/m0/s1 DMSV60C CS CCCCCCCCCCCCCCCC(=O)N[C@@H](CCC(=O)NCCCC[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](C)C(=O)NCC(=O)NCC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC6=CNC=N6)N)C(=O)O DMSV60C IK YEKUUBPJRPXMBM-PTCFZACGSA-N DMSV60C IU (2S)-5-[[(5S)-5-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-amino-3-(1H-imidazol-4-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-6-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-carbamimidamido-1-[[(2S)-1-[[(2S)-5-carbamimidamido-1-[[(2S)-3-carboxy-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-carboxy-1-[[(2S)-1-[[2-(carboxymethylamino)-2-oxoethyl]amino]-1-oxopropan-2-yl]amino]-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopentan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-6-oxohexyl]amino]-2-(hexadecanoylamino)-5-oxopentanoic acid DMSV60C CA CAS 1686108-82-6 DMSV60C DE Type-2 diabetes DMOXKIC ID DMOXKIC DMOXKIC DN MEDI3902 DMOXKIC HS Phase 2 DMOXKIC CP AstraZeneca DMOXKIC DT Antibody DMOXKIC DE Pseudomonas infection; Ventilator-associated pneumonia DMDYVN8 ID DMDYVN8 DMDYVN8 DN MEDI-528 DMDYVN8 HS Phase 2 DMDYVN8 CP MedImmune DMDYVN8 DT Monoclonal antibody DMDYVN8 DE Asthma DMPKWR3 ID DMPKWR3 DMPKWR3 DN MEDI-546 DMPKWR3 HS Phase 2 DMPKWR3 CP AstraZeneca DMPKWR3 DE Ovarian cancer DMBTVFE ID DMBTVFE DMBTVFE DN MEDI-551 DMBTVFE HS Phase 2 DMBTVFE CP MedImmune DMBTVFE DT Antibody DMBTVFE DE Chronic lymphocytic leukaemia; Encephalopathy; Neuromyelitis optica DMI9WVM ID DMI9WVM DMI9WVM DN MEDI-575 DMI9WVM HS Phase 2 DMI9WVM CP MedImmune DMI9WVM DT Antibody DMI9WVM DE Glioblastoma multiforme DMU4CS8 ID DMU4CS8 DMU4CS8 DN MEDI6012 DMU4CS8 HS Phase 2 DMU4CS8 SN RhLCAT; ACP-501 DMU4CS8 DE Acute coronary syndrome; Coronary artery disease DMGD1YP ID DMGD1YP DMGD1YP DN MEDI9929 DMGD1YP HS Phase 2 DMGD1YP CP AstraZeneca DMGD1YP DE Asthma DM2C1YN ID DM2C1YN DM2C1YN DN MEGF0444A DM2C1YN HS Phase 2 DM2C1YN CP Genentech DM2C1YN DE Non-small-cell lung cancer; Metastatic colorectal cancer DMHOF7T ID DMHOF7T DMHOF7T DN MEHD-7945A DMHOF7T HS Phase 2 DMHOF7T SN RG-7597; EGFR/HER3 dual monoclonal antibody, Genentech DMHOF7T CP Genentech Inc DMHOF7T DE Colorectal cancer; Solid tumour/cancer DMVJ6WS ID DMVJ6WS DMVJ6WS DN Melogliptin DMVJ6WS HS Phase 2 DMVJ6WS CP Glenmark pharma DMVJ6WS PC 11623906 DMVJ6WS MW 320.37 DMVJ6WS FM C15H21FN6O DMVJ6WS IC InChI=1S/C15H21FN6O/c16-12-4-14(5-17)22(8-12)15(23)6-19-13-2-1-11(3-13)7-21-10-18-9-20-21/h9-14,19H,1-4,6-8H2/t11-,12-,13+,14-/m0/s1 DMVJ6WS CS C1C[C@H](C[C@H]1CN2C=NC=N2)NCC(=O)N3C[C@H](C[C@H]3C#N)F DMVJ6WS IK JSYGLDMGERSRPC-FQUUOJAGSA-N DMVJ6WS IU (2S,4S)-4-fluoro-1-[2-[[(1R,3S)-3-(1,2,4-triazol-1-ylmethyl)cyclopentyl]amino]acetyl]pyrrolidine-2-carbonitrile DMVJ6WS CA CAS 868771-57-7 DMVJ6WS DE Type-2 diabetes DMPNDYU ID DMPNDYU DMPNDYU DN MEM-3454 DMPNDYU HS Phase 2 DMPNDYU CP Memory Pharmaceuticals DMPNDYU DT Small molecular drug DMPNDYU PC 10380472 DMPNDYU MW 306.79 DMPNDYU FM C15H19ClN4O DMPNDYU IC InChI=1S/C15H18N4O.ClH/c20-15(14-11-3-1-2-4-12(11)17-18-14)16-13-9-19-7-5-10(13)6-8-19;/h1-4,10,13H,5-9H2,(H,16,20)(H,17,18);1H/t13-;/m1./s1 DMPNDYU CS C1CN2CCC1[C@@H](C2)NC(=O)C3=NNC4=CC=CC=C43.Cl DMPNDYU IK CMRLNEYJEPELSM-BTQNPOSSSA-N DMPNDYU IU N-[(3S)-1-azabicyclo[2.2.2]octan-3-yl]-1H-indazole-3-carboxamide;hydrochloride DMPNDYU CA CAS 677305-02-1 DMPNDYU DE Schizophrenia DMUMCWS ID DMUMCWS DMUMCWS DN MEMP1972A DMUMCWS HS Phase 2 DMUMCWS SN RG7449 DMUMCWS CP Genentech DMUMCWS DE Allergic rhinitis; Asthma DMIVR9K ID DMIVR9K DMIVR9K DN MER-3001 DMIVR9K HS Phase 2 DMIVR9K SN Insulin B chain therapeutics (type 1 diabetes), Mercia Pharma/Joslin Diabetes Center DMIVR9K CP Mercia Pharma Inc DMIVR9K DE Type-1 diabetes; Type-2 diabetes DM89QXT ID DM89QXT DM89QXT DN MET409 DM89QXT HS Phase 2 DM89QXT CP Metacrine DM89QXT DT Small molecular drug DM89QXT DE Non-alcoholic steatohepatitis DMNST69 ID DMNST69 DMNST69 DN Metaiodobenzylguanidine I-131 DMNST69 HS Phase 2 DMNST69 SN Azedra (TN) DMNST69 CP Molecular Insights Pharmaceuticals DMNST69 DT Small molecular drug DMNST69 PC 71184 DMNST69 MW 279.09 DMNST69 FM C8H10IN3 DMNST69 IC InChI=1S/C8H10IN3/c9-7-3-1-2-6(4-7)5-12-8(10)11/h1-4H,5H2,(H4,10,11,12)/i9+4 DMNST69 CS C1=CC(=CC(=C1)[131I])CN=C(N)N DMNST69 IK PDWUPXJEEYOOTR-JRGAVVOBSA-N DMNST69 IU 2-[(3-(131I)iodanylphenyl)methyl]guanidine DMNST69 CA CAS 77679-27-7 DMNST69 CB CHEBI:135997 DMNST69 DE Neuroblastoma; Neuroendocrine cancer; Pheochromocytoma DMSZFTP ID DMSZFTP DMSZFTP DN Met-enkephalin DMSZFTP HS Phase 2 DMSZFTP SN MET-enkephalin; H-Tyr-Gly-Gly-Phe-Met-OH; 58569-55-4; Tyr-Gly-Gly-Phe-Met-OH; METENKEFALIN; [Met]enkephalin; [5-Methionine]Enkephalin; TYR-GLY-GLY-PHE-MET; Enkephalin M; UNII-9JEZ9OD3AS; (Met5)-enkephalin; Lupex; 9JEZ9OD3AS; CHEMBL13786; CHEBI:6618; ENKEPHALIN, METHIONINE; Opioid growth factor; [Met5]-ENKEPHALIN; [Met5]Enkephalin acetate salt hydrate; Porcine beta-endorphin 1-5; (2S,5S,14S)-14-Amino-5-benzyl-15-(4-hydroxyphenyl)-2-(2-(methylthio)ethyl)-4,7,10,13-tetraoxo-3,6,9,12-tetraazapentadecan-1-oic DMSZFTP DT Small molecular drug DMSZFTP PC 443363 DMSZFTP MW 573.7 DMSZFTP FM C27H35N5O7S DMSZFTP IC InChI=1S/C27H35N5O7S/c1-40-12-11-21(27(38)39)32-26(37)22(14-17-5-3-2-4-6-17)31-24(35)16-29-23(34)15-30-25(36)20(28)13-18-7-9-19(33)10-8-18/h2-10,20-22,33H,11-16,28H2,1H3,(H,29,34)(H,30,36)(H,31,35)(H,32,37)(H,38,39)/t20-,21-,22-/m0/s1 DMSZFTP CS CSCC[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)CNC(=O)[C@H](CC2=CC=C(C=C2)O)N DMSZFTP IK YFGBQHOOROIVKG-FKBYEOEOSA-N DMSZFTP IU (2S)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylsulfanylbutanoic acid DMSZFTP CA CAS 58569-55-4 DMSZFTP CB CHEBI:6618 DMSZFTP DE Pain DMS7FRI ID DMS7FRI DMS7FRI DN Methanesulfonyl fluoride DMS7FRI HS Phase 2 DMS7FRI SN Fluoride; Methanesulfonyl fluoride (oral, Alzheimer's disease/cognitive disorder) DMS7FRI CP University of Texas DMS7FRI DT Small molecular drug DMS7FRI PC 11207 DMS7FRI MW 98.1 DMS7FRI FM CH3FO2S DMS7FRI IC InChI=1S/CH3FO2S/c1-5(2,3)4/h1H3 DMS7FRI CS CS(=O)(=O)F DMS7FRI IK KNWQLFOXPQZGPX-UHFFFAOYSA-N DMS7FRI IU methanesulfonyl fluoride DMS7FRI CA CAS 558-25-8 DMS7FRI DE Alzheimer disease DMHSL87 ID DMHSL87 DMHSL87 DN Methoxyestradiol DMHSL87 HS Phase 2 DMHSL87 SN SCHEMBL18733359; CHEMBL1473145; HMS3229K11 DMHSL87 DT Small molecular drug DMHSL87 PC 129631909 DMHSL87 MW 302.4 DMHSL87 FM C19H26O3 DMHSL87 IC InChI=1S/C19H26O3/c1-19-8-7-14-13(15(19)5-6-17(19)21)4-3-11-9-12(20)10-16(22-2)18(11)14/h9-10,13-15,17,20-21H,3-8H2,1-2H3/t13-,14-,15-,17-,19-/m0/s1 DMHSL87 CS C[C@]12CC[C@H]3[C@@H]([C@@H]1CC[C@@H]2O)CCC4=C3C(=CC(=C4)O)OC DMHSL87 IK PJCUYTOXKIUJSL-SARNLOFESA-N DMHSL87 IU (8R,9S,13S,14S,17S)-1-methoxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol DM5GQD7 ID DM5GQD7 DM5GQD7 DN Metoprine DM5GQD7 HS Phase 2 DM5GQD7 SN METOPRINE; Methodichlorophen; DDMP; 7761-45-7; Metoprine [USAN]; BW-197U; TCMDC-123931; NSC-19494; SK 5265; 5-(3,4-DICHLOROPHENYL)-6-METHYLPYRIMIDINE-2,4-DIAMINE; U 197; NSC7364; U-197; UNII-2L9RKX796Q; Metoprine (USAN); BW 50-197; METOPRINE, METHODICHLOROPHEN; 5-(3,4-Dichlorophenyl)-6-methyl-2,4-pyrimidinediamine; NSC 7364; 2,4-Pyrimidinediamine, 5-(3,4-dichlorophenyl)-6-methyl-; NSC 19494; BW50197; BRN 0223622; 5-(3,4-Dichlorphenyl)-6-methyl-2,4-pyrimidindiamin; 2,4-Diamino-5-(3,4-dichlorophenyl)-6-methylpyrimidine; MLS002701892; DDMP; BW 197 U; BW 1970; BW 197U; BW 50197; BW 50,197; 2,4-Diamino-5-(3',4'-dichlorophenyl)-6-methyl pyrimidine; Chloroaniline 1 DM5GQD7 CP Werkheiser DM5GQD7 DT Small molecular drug DM5GQD7 PC 24466 DM5GQD7 MW 269.13 DM5GQD7 FM C11H10Cl2N4 DM5GQD7 IC InChI=1S/C11H10Cl2N4/c1-5-9(10(14)17-11(15)16-5)6-2-3-7(12)8(13)4-6/h2-4H,1H3,(H4,14,15,16,17) DM5GQD7 CS CC1=C(C(=NC(=N1)N)N)C2=CC(=C(C=C2)Cl)Cl DM5GQD7 IK VQJHOPSWBGJHQS-UHFFFAOYSA-N DM5GQD7 IU 5-(3,4-dichlorophenyl)-6-methylpyrimidine-2,4-diamine DM5GQD7 CA CAS 7761-45-7 DM5GQD7 DE Advanced cancer DMIXT2Y ID DMIXT2Y DMIXT2Y DN MGAH22 DMIXT2Y HS Phase 2 DMIXT2Y CP MacroGenics DMIXT2Y DE Solid tumour/cancer DMPBTVK ID DMPBTVK DMPBTVK DN MGB-BP-3 DMPBTVK HS Phase 2 DMPBTVK SN 1000277-08-6; MGB-BP3; UNII-532PWU9738; 532PWU9738; J2.725.402K; (E)-1-methyl-4-(1-methyl-4-(4-(2-(quinolin-3-yl)vinyl)benzamido)-1H-pyrrole-2-carboxamido)-N-(2-morpholinoethyl)-1H-pyrrole-2-carboxamide; 1-methyl-N-[1-methyl-5-(2-morpholin-4-ylethylcarbamoyl)pyrrol-3-yl]-4-[[4-[(E)-2-quinolin-3-ylethenyl]benzoyl]amino]pyrrole-2-carboxamide; 4-((4-(4-((E)-2-(3-Quinolyl)vinyl)benzoylamino)-1-methyl-1H-pyrrole-2-yl)carbonylamino)-1-methyl-N-(2-morpholinoethyl)-1H-pyrrole-2-carboxamide; 4-[[4-[4-[(E)-2-(3-Quinolyl)vinyl]benzoylamino]-1-methyl-1H-pyrrole-2-yl]carbonylamino]-1-methyl-N-(2-morpholinoethyl)-1H-pyrrole-2-carboxamide; CHEMBL236345; SCHEMBL2398755; GTPL10996; HY-U00035; ZINC28864451; CS-6785; DB12892; SB19161; compound 50 [PMID: 17960927]; Q27261055; 1H-Pyrrole-2-carboxamide, 1-methyl-N-(1-methyl-5-(((2-(4-morpholinyl)ethyl)amino)carbonyl)-1H-pyrrol-3-yl)-4-((4-((1E)-2-(3-quinolinyl)ethenyl)benzoyl)amino)- DMPBTVK CP MGB Biopharma DMPBTVK DT Small molecular drug DMPBTVK PC 23730143 DMPBTVK MW 631.7 DMPBTVK FM C36H37N7O4 DMPBTVK IC InChI=1S/C36H37N7O4/c1-41-24-30(20-32(41)35(45)37-13-14-43-15-17-47-18-16-43)40-36(46)33-21-29(23-42(33)2)39-34(44)27-11-9-25(10-12-27)7-8-26-19-28-5-3-4-6-31(28)38-22-26/h3-12,19-24H,13-18H2,1-2H3,(H,37,45)(H,39,44)(H,40,46)/b8-7+ DMPBTVK CS CN1C=C(C=C1C(=O)NC2=CN(C(=C2)C(=O)NCCN3CCOCC3)C)NC(=O)C4=CC=C(C=C4)/C=C/C5=CC6=CC=CC=C6N=C5 DMPBTVK IK OEKXCVYZBVOWBR-BQYQJAHWSA-N DMPBTVK IU 1-methyl-N-[1-methyl-5-(2-morpholin-4-ylethylcarbamoyl)pyrrol-3-yl]-4-[[4-[(E)-2-quinolin-3-ylethenyl]benzoyl]amino]pyrrole-2-carboxamide DMPBTVK CA CAS 1000277-08-6 DMPBTVK DE Clostridium infection DM726HX ID DM726HX DM726HX DN MGCD-0103 DM726HX HS Phase 2 DM726HX SN Mocetinostat; MG 0103; MG 4230; MG 4915; MG 5026; MG0103; MG4230; MG4915; MG5206; MGCD 0103; MGCD0103; MG-0103; MG-4230; MG-4915; MG-5026; Mocetinostat, MGCD0103; N-(2-aminophenyl)-4-[[(4-pyridin-3-ylpyrimidin-2-yl)amino]methyl]benzamide; N-(2-Aminophenyl)-4-((4-pyridin-3-ylpyrimidin-2-ylamino)methyl)benzamide DM726HX CP MethylGene Inc DM726HX TC Anticancer Agents DM726HX DT Small molecular drug DM726HX PC 9865515 DM726HX MW 396.4 DM726HX FM C23H20N6O DM726HX IC InChI=1S/C23H20N6O/c24-19-5-1-2-6-21(19)28-22(30)17-9-7-16(8-10-17)14-27-23-26-13-11-20(29-23)18-4-3-12-25-15-18/h1-13,15H,14,24H2,(H,28,30)(H,26,27,29) DM726HX CS C1=CC=C(C(=C1)N)NC(=O)C2=CC=C(C=C2)CNC3=NC=CC(=N3)C4=CN=CC=C4 DM726HX IK HRNLUBSXIHFDHP-UHFFFAOYSA-N DM726HX IU N-(2-aminophenyl)-4-[[(4-pyridin-3-ylpyrimidin-2-yl)amino]methyl]benzamide DM726HX CA CAS 726169-73-9 DM726HX CB CHEBI:94525 DM726HX DE Solid tumour/cancer; Diffuse large B-cell lymphoma; Melanoma; Non-small-cell lung cancer DMRPCF2 ID DMRPCF2 DMRPCF2 DN MGCD265 DMRPCF2 HS Phase 2 DMRPCF2 SN MGCD-265; 875337-44-3; MGCD265; MGCD-265 analog; MGCD 265; N-(3-fluoro-4-(2-(1-methyl-1H-imidazol-4-yl)thieno[3,2-b]pyridin-7-yloxy)phenylcarbamothioyl)-2-phenylacetamide; UNII-93M6577H9D; CHEMBL254760; 93M6577H9D; n-(3-fluoro-4-(2-(1-methyl-1h-imidazol-4-yl)thieno(3,2-b)pyridin-7-yloxy)phenylcarbamothioyl)-2-phenylacetamide; N-[(3-Fluoro-4-{[2-(1-methyl-1H-imidazol-4-yl)thieno[3,2-b]pyridin-7-yl]oxy}phenyl)carbamothioyl]-2-phenylacetamide DMRPCF2 CP MethylGene DMRPCF2 DT Small molecular drug DMRPCF2 PC 24901704 DMRPCF2 MW 517.6 DMRPCF2 FM C26H20FN5O2S2 DMRPCF2 IC InChI=1S/C26H20FN5O2S2/c1-32-14-20(29-15-32)23-13-19-25(36-23)22(9-10-28-19)34-21-8-7-17(12-18(21)27)30-26(35)31-24(33)11-16-5-3-2-4-6-16/h2-10,12-15H,11H2,1H3,(H2,30,31,33,35) DMRPCF2 CS CN1C=C(N=C1)C2=CC3=NC=CC(=C3S2)OC4=C(C=C(C=C4)NC(=S)NC(=O)CC5=CC=CC=C5)F DMRPCF2 IK UFICVEHDQUKCEA-UHFFFAOYSA-N DMRPCF2 IU N-[[3-fluoro-4-[2-(1-methylimidazol-4-yl)thieno[3,2-b]pyridin-7-yl]oxyphenyl]carbamothioyl]-2-phenylacetamide DMRPCF2 CA CAS 875337-44-3 DMRPCF2 CB CHEBI:91393 DMRPCF2 DE Non-small-cell lung cancer; Solid tumour/cancer DMRSK2I ID DMRSK2I DMRSK2I DN MGCD290 DMRSK2I HS Phase 2 DMRSK2I CP Mirati Therapeutics DMRSK2I DT Small molecular drug DMRSK2I DE Vulvovaginal Candidiasis DMNYPW7 ID DMNYPW7 DMNYPW7 DN MGI-114 DMNYPW7 HS Phase 2 DMNYPW7 SN Irofulven; Irofulven [USAN:INN]; MGI 114; MGI-114; (R)-6'-Hydroxy-3'-(hydroxymethyl)-2',4',6'-trimethylspiro(cyclopropane-1,5'-(5H)inden)-7'(6'H)-one; (R)-6'-hydroxy-3'-(hydroxymethyl)-2',4',6'-trimethylspiro[cyclopropane-1,5'-inden]-7'(6'H)-one; 158440-71-2; 6-(Hydroxymethyl)acylfulvene; 6-Hydroxymethylacylfulvene; 6B799IH05A; Acylfulvene, 6-(hydroxymethyl)-; HMAF; NSC 683863; NSC-683863; Spiro(cyclopropane-1,5'(5H)-inden)-7'(6'H)-one, 6'-hydroxy-3'-(hydroxymethyl)-2',4',6'-trimethyl-, (R)-; UNII-6B799IH05A DMNYPW7 PC 148189 DMNYPW7 MW 246.3 DMNYPW7 FM C15H18O3 DMNYPW7 IC NICJCIQSJJKZAH-AWEZNQCLSA-N DMNYPW7 CS CC1=C(C2=C(C3(CC3)C(C(=O)C2=C1)(C)O)C)CO DMNYPW7 IK 1S/C15H18O3/c1-8-6-10-12(11(8)7-16)9(2)15(4-5-15)14(3,18)13(10)17/h6,16,18H,4-5,7H2,1-3H3/t14-/m0/s1 DMNYPW7 IU (5'R)-5'-hydroxy-1'-(hydroxymethyl)-2',5',7'-trimethylspiro[cyclopropane-1,6'-indene]-4'-one DMNYPW7 CA CAS 158440-71-2 DMNYPW7 CB CHEBI:135002 DMNYPW7 DE Lung cancer DM1HC9R ID DM1HC9R DM1HC9R DN MGL-3196 DM1HC9R HS Phase 2 DM1HC9R CP Madrigal pharmaceuticals DM1HC9R PC 15981237 DM1HC9R MW 435.2 DM1HC9R FM C17H12Cl2N6O4 DM1HC9R IC InChI=1S/C17H12Cl2N6O4/c1-7(2)9-5-13(22-23-15(9)26)29-14-10(18)3-8(4-11(14)19)25-17(28)21-16(27)12(6-20)24-25/h3-5,7H,1-2H3,(H,23,26)(H,21,27,28) DM1HC9R CS CC(C)C1=CC(=NNC1=O)OC2=C(C=C(C=C2Cl)N3C(=O)NC(=O)C(=N3)C#N)Cl DM1HC9R IK FDBYIYFVSAHJLY-UHFFFAOYSA-N DM1HC9R IU 2-[3,5-dichloro-4-[(6-oxo-5-propan-2-yl-1H-pyridazin-3-yl)oxy]phenyl]-3,5-dioxo-1,2,4-triazine-6-carbonitrile DM1HC9R CA CAS 920509-32-6 DM1HC9R DE Hyperlipidaemia; Familial hypercholesterolemia; Hypercholesterolaemia DME5CSV ID DME5CSV DME5CSV DN Mibampator DME5CSV HS Phase 2 DME5CSV SN LY-450108; LY-451395; AMPA agonists (Alzheimer's Disease), Lilly; AMPA receptor agonist (agitation in Alzheimer's Disease), Eli Lilly DME5CSV CP Eli Lilly & Co DME5CSV DT Small molecular drug DME5CSV PC 9889366 DME5CSV MW 438.6 DME5CSV FM C21H30N2O4S2 DME5CSV IC InChI=1S/C21H30N2O4S2/c1-16(2)29(26,27)23-15-17(3)19-9-11-21(12-10-19)20-7-5-18(6-8-20)13-14-22-28(4,24)25/h5-12,16-17,22-23H,13-15H2,1-4H3/t17-/m0/s1 DME5CSV CS C[C@@H](CNS(=O)(=O)C(C)C)C1=CC=C(C=C1)C2=CC=C(C=C2)CCNS(=O)(=O)C DME5CSV IK ULRDYYKSPCRXAJ-KRWDZBQOSA-N DME5CSV IU N-[(2R)-2-[4-[4-[2-(methanesulfonamido)ethyl]phenyl]phenyl]propyl]propane-2-sulfonamide DME5CSV CA CAS 375345-95-2 DME5CSV DE Alzheimer disease DMGCRKY ID DMGCRKY DMGCRKY DN Midismase DMGCRKY HS Phase 2 DMGCRKY SN PC-01; SI-3501; PC-SOD (intravenous), LTT; Lecithin-bound superoxide dismutase (ulcerative colitis), LTT Bio-Pharma DMGCRKY CP Asahi Glass Co Ltd DMGCRKY DE Cerebral infarction DMN45RI ID DMN45RI DMN45RI DN MIJ821 DMN45RI HS Phase 2 DMN45RI SN CAD 9271 DMN45RI CP Novartis; Cadent Therapeutics DMN45RI DE Major depressive disorder DM50Z4U ID DM50Z4U DM50Z4U DN Milataxel DM50Z4U HS Phase 2 DM50Z4U SN M-10; MAC-321; Milataxel (oral); TL-00139; TL-139; Milataxel (oral), Taxolog; MAC-321 (injectable), Taxolog/Wyeth; MAC-321 (oral), Taxolog/Wyeth; TL-00139 (injectable), Taxolog/Wyeth; TL-00139 (oral), Taxolog/Wyeth; TL-139 (injectable), Taxolog/Wyeth; TL-139 (oral), Taxolog/Wyeth DM50Z4U CP Taxolog Inc DM50Z4U DT Small molecular drug DM50Z4U PC 6918589 DM50Z4U MW 853.9 DM50Z4U FM C44H55NO16 DM50Z4U IC InChI=1S/C44H55NO16/c1-10-29(47)58-27-19-28-43(21-56-28,60-23(3)46)34-36(59-37(51)24-15-12-11-13-16-24)44(54)20-26(22(2)30(41(44,7)8)32(48)35(50)42(27,34)9)57-38(52)33(49)31(25-17-14-18-55-25)45-39(53)61-40(4,5)6/h11-18,26-28,31-34,36,48-49,54H,10,19-21H2,1-9H3,(H,45,53)/t26-,27-,28+,31-,32+,33+,34-,36-,42+,43-,44+/m0/s1 DM50Z4U CS CCC(=O)O[C@H]1C[C@@H]2[C@@](CO2)([C@@H]3[C@@]1(C(=O)[C@@H](C4=C([C@H](C[C@@]([C@H]3OC(=O)C5=CC=CC=C5)(C4(C)C)O)OC(=O)[C@@H]([C@H](C6=CC=CO6)NC(=O)OC(C)(C)C)O)C)O)C)OC(=O)C DM50Z4U IK XIVMHSNIQAICTR-UQYHODNASA-N DM50Z4U IU [(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4-acetyloxy-15-[(2R,3R)-3-(furan-2-yl)-2-hydroxy-3-[(2-methylpropan-2-yl)oxycarbonylamino]propanoyl]oxy-1,12-dihydroxy-10,14,17,17-tetramethyl-11-oxo-9-propanoyloxy-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl] benzoate DM50Z4U CA CAS 352425-37-7 DM50Z4U DE Solid tumour/cancer DMSLIW6 ID DMSLIW6 DMSLIW6 DN MIN-117 DMSLIW6 HS Phase 2 DMSLIW6 CP Minerva neurosciences DMSLIW6 PC 74424169 DMSLIW6 MW 538.8 DMSLIW6 FM C25H26Cl3N3O4 DMSLIW6 IC InChI=1S/C25H25Cl2N3O4.ClH/c1-15-28-29-25(33-15)24-12-19-22(3-2-4-23(19)34-24)32-14-18(31)13-30-9-7-16(8-10-30)17-5-6-20(26)21(27)11-17;/h2-6,11-12,16,18,31H,7-10,13-14H2,1H3;1H DMSLIW6 CS CC1=NN=C(O1)C2=CC3=C(O2)C=CC=C3OCC(CN4CCC(CC4)C5=CC(=C(C=C5)Cl)Cl)O.Cl DMSLIW6 IK HRNDUKHBCUTNAL-UHFFFAOYSA-N DMSLIW6 IU 1-[4-(3,4-dichlorophenyl)piperidin-1-yl]-3-[[2-(5-methyl-1,3,4-oxadiazol-2-yl)-1-benzofuran-4-yl]oxy]propan-2-ol;hydrochloride DMSLIW6 DE Major depressive disorder DMZFW8V ID DMZFW8V DMZFW8V DN MIN-202 DMZFW8V HS Phase 2 DMZFW8V SN Seltorexant; 1293281-49-8; Seltorexant [USAN]; SCHEMBL1671257; GTPL9308; CHEMBL3597971; JNJ-922; SQOCEMCKYDVLMM-UHFFFAOYSA-N; BDBM118454; Methanone, (5-(4,6-dimethyl-2-pyrimidinyl)hexahydropyrrolo(3,4-C)pyrrol-2(1H)-yl)(2-fluoro-6-(2H-1,2,3-triazol-2-yl)phenyl)-; AKOS032954213; US8653263, 107; [2-(4,6-dimethylpyrimidin-2-yl)-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-5-yl]-[2-fluoro-6-(triazol-2-yl)phenyl]methanone; ((3aR,6aS)-5-(4,6-dimethylpyrimidin- 2-yl)hexahydropyrrolo(3,4-c)pyrrol-2(1H)-yl)(2 DMZFW8V CP Minerva Neurosciences Waltham, MA DMZFW8V PC 67116280 DMZFW8V MW 407.4 DMZFW8V FM C21H22FN7O DMZFW8V IC InChI=1S/C21H22FN7O/c1-13-8-14(2)26-21(25-13)28-11-15-9-27(10-16(15)12-28)20(30)19-17(22)4-3-5-18(19)29-23-6-7-24-29/h3-8,15-16H,9-12H2,1-2H3 DMZFW8V CS CC1=CC(=NC(=N1)N2CC3CN(CC3C2)C(=O)C4=C(C=CC=C4F)N5N=CC=N5)C DMZFW8V IK SQOCEMCKYDVLMM-UHFFFAOYSA-N DMZFW8V IU [2-(4,6-dimethylpyrimidin-2-yl)-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-5-yl]-[2-fluoro-6-(triazol-2-yl)phenyl]methanone DMZFW8V CA CAS 1293281-49-8 DMZFW8V DE Major depressive disorder DMWJMFZ ID DMWJMFZ DMWJMFZ DN Miravirsen DMWJMFZ HS Phase 2 DMWJMFZ SN Miravirsen; Miravirsen [INN]; SPC3649 Parent Acid; UNII-Q083AJW7VS; Q083AJW7VS; 1072874-90-8; RNA, (P-thio)((2'-O,4'-C-methylene)m5C-dC-(2'-O,4'-C-methylene)A-dT-dT-(2'-O,4'-C-methylene)G-(2'-O,4'-C-methylene)m5U-dC-dA-(2'-O,4'-C-methylene)m5C-dA-(2'-O,4'-C-methylene)m5C-dT-(2'-O,4'-C-methylene)m5C-(2'-O,4'-C-methylene)m5C) DMWJMFZ CP Santaris Pharma A/S DMWJMFZ DT Small molecular drug DMWJMFZ PC 56843415 DMWJMFZ MW 4897 DMWJMFZ FM C151H185N49O83P14S14 DMWJMFZ IC InChI=1S/C151H185N49O83P14S14/c1-60-26-193(140(215)182-119(60)203)87-21-66(74(258-87)34-245-290(225,304)281-110-102-130(199-58-171-94-114(161)165-55-168-117(94)199)268-150(110,44-239-102)50-252-291(226,305)272-65-20-86(187-13-6-79(153)174-134(187)209)256-72(65)33-243-286(221,300)277-105-97-125(262-144(105,37-201)38-234-97)189-15-8-81(155)176-136(189)211)271-285(220,299)241-30-73-67(22-88(257-73)194-27-61(2)120(204)183-141(194)216)273-293(228,307)253-51-151-45-240-103(131(269-151)200-59-172-95-118(200)180-132(162)181-123(95)207)111(151)283-297(232,311)254-52-149-43-238-101(129(267-149)196-29-63(4)122(206)185-143(196)218)109(149)280-289(224,303)244-32-71-64(19-85(255-71)186-12-5-78(152)173-133(186)208)270-284(219,298)242-31-76-69(24-90(260-76)197-56-169-92-112(159)163-53-166-115(92)197)275-294(229,308)249-47-147-41-236-99(127(265-147)191-17-10-83(157)178-138(191)213)107(147)279-288(223,302)247-36-77-70(25-91(261-77)198-57-170-93-113(160)164-54-167-116(93)198)276-295(230,309)250-48-146-40-235-98(126(264-146)190-16-9-82(156)177-137(190)212)106(146)278-287(222,301)246-35-75-68(23-89(259-75)195-28-62(3)121(205)184-142(195)217)274-292(227,306)251-49-148-42-237-100(128(266-148)192-18-11-84(158)179-139(192)214)108(148)282-296(231,310)248-46-145-39-233-96(104(145)202)124(263-145)188-14-7-80(154)175-135(188)210/h5-18,26-29,53-59,64-77,85-91,96-111,124-131,201-202H,19-25,30-52H2,1-4H3,(H,219,298)(H,220,299)(H,221,300)(H,222,301)(H,223,302)(H,224,303)(H,225,304)(H,226,305)(H,227,306)(H,228,307)(H,229,308)(H,230,309)(H,231,310)(H,232,311)(H2,152,173,208)(H2,153,174,209)(H2,154,175,210)(H2,155,176,211)(H2,156,177,212)(H2,157,178,213)(H2,158,179,214)(H2,159,163,166)(H2,160,164,167)(H2,161,165,168)(H,182,203,215)(H,183,204,216)(H,184,205,217)(H,185,206,218)(H3,162,180,181,207) DMWJMFZ CS CC1=CN(C(=O)NC1=O)C2CC(C(O2)COP(=S)(O)OC3C4C(OC3(CO4)COP(=S)(O)OC5CC(OC5COP(=S)(O)OC6C7C(OC6(CO7)CO)N8C=CC(=NC8=O)N)N9C=CC(=NC9=O)N)N1C=NC2=C(N=CN=C21)N)OP(=S)(O)OCC1C(CC(O1)N1C=C(C(=O)NC1=O)C)OP(=S)(O)OCC12COC(C1OP(=S)(O)OCC13COC(C1OP(=S)(O)OCC1C(CC(O1)N1C=CC(=NC1=O)N)OP(=S)(O)OCC1C(CC(O1)N1C=NC4=C(N=CN=C41)N)OP(=S)(O)OCC14COC(C1OP(=S)(O)OCC1C(CC(O1)N1C=NC5=C(N=CN=C51)N)OP(=S)(O)OCC15COC(C1OP(=S)(O)OCC1C(CC(O1)N1C=C(C(=O)NC1=O)C)OP(=S)(O)OCC16COC(C1OP(=S)(O)OCC17COC(C1O)C(O7)N1C=CC(=NC1=O)N)C(O6)N1C=CC(=NC1=O)N)C(O5)N1C=CC(=NC1=O)N)C(O4)N1C=CC(=NC1=O)N)C(O3)N1C=C(C(=O)NC1=O)C)C(O2)N1C=NC2=C1N=C(NC2=O)N DMWJMFZ IK OSOOBMBDIGGTCP-UHFFFAOYSA-N DMWJMFZ IU 1-[4-[[3-[[3-(2-amino-6-oxo-1H-purin-9-yl)-7-[[7-[[5-(4-amino-2-oxopyrimidin-1-yl)-3-[[3-[[3-(4-amino-2-oxopyrimidin-1-yl)-7-[[3-[[3-(4-amino-2-oxopyrimidin-1-yl)-7-[[3-[[3-(4-amino-2-oxopyrimidin-1-yl)-7-[[3-(4-amino-2-oxopyrimidin-1-yl)-7-hydroxy-2,5-dioxabicyclo[2.2.1]heptan-1-yl]methoxy-hydroxyphosphinothioyl]oxy-2,5-dioxabicyclo[2.2.1]heptan-1-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-2,5-dioxabicyclo[2.2.1]heptan-1-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-2,5-dioxabicyclo[2.2.1]heptan-1-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-3-(5-methyl-2,4-dioxopyrimidin-1-yl)-2,5-dioxabicyclo[2.2.1]heptan-1-yl]methoxy-hydroxyphosphinothioyl]oxy-2,5-dioxabicyclo[2.2.1]heptan-1-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-[[[1-[[[5-(4-amino-2-oxopyrimidin-1-yl)-2-[[[3-(4-amino-2-oxopyrimidin-1-yl)-1-(hydroxymethyl)-2,5-dioxabicyclo[2.2.1]heptan-7-yl]oxy-hydroxyphosphinothioyl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-3-(6-aminopurin-9-yl)-2,5-dioxabicyclo[2.2.1]heptan-7-yl]oxy-hydroxyphosphinothioyl]oxymethyl]oxolan-2-yl]-5-methylpyrimidine-2,4-dione DMWJMFZ CA CAS 1072874-90-8 DMWJMFZ DE Hepatitis C virus infection DM7K4YR ID DM7K4YR DM7K4YR DN MIS-416 DM7K4YR HS Phase 2 DM7K4YR SN Microparticle adjuvant (anthrax), Virionyx; Microparticle adjuvant (iv, autoimmune disease/cancer/anthrax), Innate Therapeutics DM7K4YR CP Innate Therapeutics Ltd DM7K4YR DE Bacillus anthracis infection; Autoimmune diabetes DMOJ7QA ID DMOJ7QA DMOJ7QA DN Mitemcinal fumarate DMOJ7QA HS Phase 2 DMOJ7QA SN (2S,4R,5R,8R,9S,10S,11R,12R)-5-ethyl-9-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-11-[(2S,3R,4S,6R)-3-hydroxy-6-methyl-4-[methyl(propan-2-yl)amino]oxan-2-yl]oxy-4-methoxy-2,4,8,10,12,14-hexamethyl-6,15-dioxabicyclo[10.2.1]pentadec-1(14)-ene-3,7-dione DMOJ7QA CP Roche DMOJ7QA DT Small molecular drug DMOJ7QA PC 11513721 DMOJ7QA MW 1628 DMOJ7QA FM C84H142N2O28 DMOJ7QA IC InChI=1S/2C40H69NO12.C4H4O4/c2*1-16-28-40(12,47-15)33(43)23(6)31-21(4)18-39(11,53-31)35(52-37-30(42)27(17-22(5)48-37)41(13)20(2)3)24(7)32(25(8)36(45)50-28)51-29-19-38(10,46-14)34(44)26(9)49-29;5-3(6)1-2-4(7)8/h2*20,22-30,32,34-35,37,42,44H,16-19H2,1-15H3;1-2H,(H,5,6)(H,7,8)/b;;2-1+/t2*22-,23+,24+,25-,26+,27+,28-,29+,30-,32+,34+,35-,37+,38-,39-,40-;/m11./s1 DMOJ7QA CS CC[C@@H]1[C@@](C(=O)[C@H](C2=C(C[C@@](O2)([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]3C[C@@]([C@H]([C@@H](O3)C)O)(C)OC)C)O[C@H]4[C@@H]([C@H](C[C@H](O4)C)N(C)C(C)C)O)C)C)C)(C)OC.CC[C@@H]1[C@@](C(=O)[C@H](C2=C(C[C@@](O2)([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]3C[C@@]([C@H]([C@@H](O3)C)O)(C)OC)C)O[C@H]4[C@@H]([C@H](C[C@H](O4)C)N(C)C(C)C)O)C)C)C)(C)OC.C(=C/C(=O)O)\\C(=O)O DMOJ7QA IK KQRXEQGYUDDPNW-QXRSSOOUSA-N DMOJ7QA IU (E)-but-2-enedioic acid;(2S,4R,5R,8R,9S,10S,11R,12R)-5-ethyl-9-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-11-[(2S,3R,4S,6R)-3-hydroxy-6-methyl-4-[methyl(propan-2-yl)amino]oxan-2-yl]oxy-4-methoxy-2,4,8,10,12,14-hexamethyl-6,15-dioxabicyclo[10.2.1]pentadec-1(14)-ene-3,7-dione DMOJ7QA CA CAS 154802-96-7 DMOJ7QA DE Pain DMIRPSA ID DMIRPSA DMIRPSA DN Mitoglitazone DMIRPSA HS Phase 2 DMIRPSA SN MSDC-0160; Mitoglitazone (TN) DMIRPSA CP Metabolic Solutions Development DMIRPSA DT Small molecular drug DMIRPSA PC 10429242 DMIRPSA MW 370.4 DMIRPSA FM C19H18N2O4S DMIRPSA IC InChI=1S/C19H18N2O4S/c1-2-12-5-8-15(20-10-12)16(22)11-25-14-6-3-13(4-7-14)9-17-18(23)21-19(24)26-17/h3-8,10,17H,2,9,11H2,1H3,(H,21,23,24) DMIRPSA CS CCC1=CN=C(C=C1)C(=O)COC2=CC=C(C=C2)CC3C(=O)NC(=O)S3 DMIRPSA IK IRNJSRAGRIZIHD-UHFFFAOYSA-N DMIRPSA IU 5-[[4-[2-(5-ethylpyridin-2-yl)-2-oxoethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione DMIRPSA CA CAS 146062-49-9 DMIRPSA CB CHEBI:94409 DMIRPSA DE Type-2 diabetes; Alzheimer disease DMKPZ0Q ID DMKPZ0Q DMKPZ0Q DN Mitoquinone DMKPZ0Q HS Phase 2 DMKPZ0Q SN mitoquinone; Mitoquinone cation; 444890-41-9; UNII-47BYS17IY0; 47BYS17IY0; MitoQ; 10-(4,5-dimethoxy-2-methyl-3,6-dioxocyclohexa-1,4-dien-1-yl)decyl-triphenylphosphanium; Mito-Q; Mitoquinone ion; MitoQ; MitoQ10; CHEMBL1229093; SCHEMBL12135674; EX-A926; BCP19134; HY-100116; CS-0018095; A17092; Q27259044; (10-(2,5-Dihydroxy-3,4-dimethoxy-6-methylphenyl)decyl)triphenyl phosphonium DMKPZ0Q DT Small molecular drug DMKPZ0Q PC 11388332 DMKPZ0Q MW 583.7 DMKPZ0Q FM C37H44O4P+ DMKPZ0Q IC InChI=1S/C37H44O4P/c1-29-33(35(39)37(41-3)36(40-2)34(29)38)27-19-8-6-4-5-7-9-20-28-42(30-21-13-10-14-22-30,31-23-15-11-16-24-31)32-25-17-12-18-26-32/h10-18,21-26H,4-9,19-20,27-28H2,1-3H3/q+1 DMKPZ0Q CS CC1=C(C(=O)C(=C(C1=O)OC)OC)CCCCCCCCCC[P+](C2=CC=CC=C2)(C3=CC=CC=C3)C4=CC=CC=C4 DMKPZ0Q IK OIIMUKXVVLRCAF-UHFFFAOYSA-N DMKPZ0Q IU 10-(4,5-dimethoxy-2-methyl-3,6-dioxocyclohexa-1,4-dien-1-yl)decyl-triphenylphosphanium DMKPZ0Q CA CAS 444890-41-9 DMKPZ0Q DE Hepatitis C virus infection DM2NF6X ID DM2NF6X DM2NF6X DN MIV-210 DM2NF6X HS Phase 2 DM2NF6X CP Medivir; Daewoong DM2NF6X DT Small molecular drug DM2NF6X PC 135431817 DM2NF6X MW 269.23 DM2NF6X FM C10H12FN5O3 DM2NF6X IC InChI=1S/C10H12FN5O3/c11-4-1-6(19-5(4)2-17)16-3-13-7-8(16)14-10(12)15-9(7)18/h3-6,17H,1-2H2,(H3,12,14,15,18)/t4-,5+,6+/m0/s1 DM2NF6X CS C1[C@@H]([C@H](O[C@H]1N2C=NC3=C2N=C(NC3=O)N)CO)F DM2NF6X IK RTJUXLYUUDBAJN-KVQBGUIXSA-N DM2NF6X IU 2-amino-9-[(2R,4S,5R)-4-fluoro-5-(hydroxymethyl)oxolan-2-yl]-1H-purin-6-one DM2NF6X CA CAS 92562-88-4 DM2NF6X DE Hepatitis B virus infection DMWFTRJ ID DMWFTRJ DMWFTRJ DN MK-0354 DMWFTRJ HS Phase 2 DMWFTRJ SN MK-0354; 851776-28-8; UNII-4U62D8JYIQ; 4U62D8JYIQ; CHEMBL456145; 3-(1H-tetrazol-5-yl)-1,4,5,6-tetrahydrocyclopenta[c]pyrazole; 3-(2H-tetrazol-5-yl)-1,4,5,6-tetrahydro-cyclopentapyrazole; 1,4,5,6-Tetrahydro-3-(1H-tetrazol-5-yl)cyclopenta[c]pyrazole; 3-(2H-tetrazol-5-yl)-1,4,5,6-tetrahydrocyclopenta[c]pyrazole; LTQYSJKGRPGMPO-UHFFFAOYSA-N; SCHEMBL1875705; GTPL5784; MolPort-009-683-033; 1,4,5,6-tetrahydro-3-(2H-tetrazol-5-yl)Cyclopentapyrazole; BCP18112; ZINC38312374; BDBM50273099; AKOS030526928; MK 0354; CS-4589 DMWFTRJ DT Small molecular drug DMWFTRJ PC 11159621 DMWFTRJ MW 176.18 DMWFTRJ FM C7H8N6 DMWFTRJ IC InChI=1S/C7H8N6/c1-2-4-5(3-1)8-9-6(4)7-10-12-13-11-7/h1-3H2,(H,8,9)(H,10,11,12,13) DMWFTRJ CS C1CC2=C(C1)NN=C2C3=NNN=N3 DMWFTRJ IK LTQYSJKGRPGMPO-UHFFFAOYSA-N DMWFTRJ IU 3-(2H-tetrazol-5-yl)-1,4,5,6-tetrahydrocyclopenta[c]pyrazole DMWFTRJ CA CAS 851776-28-8 DMLTAES ID DMLTAES DMLTAES DN MK-0752 DMLTAES HS Phase 2 DMLTAES SN MK-0752; 471905-41-6; MK0752; UNII-9JD9B4S53T; MK 0752; cis-4-[(4-Chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexanepropanoic acid; 9JD9B4S53T; 3-((1r,4s)-4-((4-chlorophenyl)sulfonyl)-4-(2,5-difluorophenyl)cyclohexyl)propanoic acid; 3-(cis-4-((4-Chlorophenyl)sulfonyl)-4-(2,5-difluorophenyl)cyclohexyl)propanoic acid; 3-((1r,4s)-4-(4-chlorophenylsulfonyl)-4-(2,5-difluorophenyl)cyclohexyl)propanoic acid; 952578-68-6; cc-14; C21H21ClF2O4S; MLS006011072; SCHEMBL756249; SCHEMBL756248; SCHEMBL756247; CHEMBL3392635 DMLTAES CP Merck DMLTAES DT Small molecular drug DMLTAES PC 9803433 DMLTAES MW 442.9 DMLTAES FM C21H21ClF2O4S DMLTAES IC InChI=1S/C21H21ClF2O4S/c22-15-2-5-17(6-3-15)29(27,28)21(18-13-16(23)4-7-19(18)24)11-9-14(10-12-21)1-8-20(25)26/h2-7,13-14H,1,8-12H2,(H,25,26) DMLTAES CS C1CC(CCC1CCC(=O)O)(C2=C(C=CC(=C2)F)F)S(=O)(=O)C3=CC=C(C=C3)Cl DMLTAES IK XCGJIFAKUZNNOR-UHFFFAOYSA-N DMLTAES IU 3-[4-(4-chlorophenyl)sulfonyl-4-(2,5-difluorophenyl)cyclohexyl]propanoic acid DMLTAES CA CAS 471905-41-6 DMLTAES DE Alzheimer disease DM2CJB4 ID DM2CJB4 DM2CJB4 DN MK-0773 DM2CJB4 HS Phase 2 DM2CJB4 SN C-8500; MK-773 DM2CJB4 CP Merck & Co Inc DM2CJB4 DT Small molecular drug DM2CJB4 PC 11950726 DM2CJB4 MW 479.6 DM2CJB4 FM C27H34FN5O2 DM2CJB4 IC InChI=1S/C27H34FN5O2/c1-26-11-10-17-15(6-9-21-27(17,2)13-19(28)25(35)33(21)3)16(26)7-8-18(26)24(34)30-14-22-31-20-5-4-12-29-23(20)32-22/h4-5,12-13,15-18,21H,6-11,14H2,1-3H3,(H,30,34)(H,29,31,32)/t15-,16-,17-,18+,21+,26-,27+/m0/s1 DM2CJB4 CS C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2C(=O)NCC4=NC5=C(N4)C=CC=N5)CC[C@@H]6[C@@]3(C=C(C(=O)N6C)F)C DM2CJB4 IK GBEUKTWTUSPHEE-JWJWXJQQSA-N DM2CJB4 IU (1S,3aS,3bS,5aR,9aS,9bS,11aS)-8-fluoro-N-(1H-imidazo[4,5-b]pyridin-2-ylmethyl)-6,9a,11a-trimethyl-7-oxo-2,3,3a,3b,4,5,5a,9b,10,11-decahydro-1H-indeno[5,4-f]quinoline-1-carboxamide DM2CJB4 CA CAS 606101-58-0 DM2CJB4 DE Osteoporosis DMRT8K4 ID DMRT8K4 DMRT8K4 DN MK-0812 DMRT8K4 HS Phase 2 DMRT8K4 SN C-6448; MK-812; CCR2 antagonist (rheumatoid arthritis/multiple sclerosis), Merck DMRT8K4 CP Merck & Co Inc DMRT8K4 DT Small molecular drug DMRT8K4 PC 11180808 DMRT8K4 MW 469.5 DMRT8K4 FM C24H34F3N3O3 DMRT8K4 IC InChI=1S/C24H34F3N3O3/c1-15(2)23(7-4-18(11-23)29-20-6-9-33-14-21(20)32-3)22(31)30-8-5-19-16(13-30)10-17(12-28-19)24(25,26)27/h10,12,15,18,20-21,29H,4-9,11,13-14H2,1-3H3/t18-,20+,21-,23+/m1/s1 DMRT8K4 CS CC(C)[C@@]1(CC[C@H](C1)N[C@H]2CCOC[C@H]2OC)C(=O)N3CCC4=C(C3)C=C(C=N4)C(F)(F)F DMRT8K4 IK MTMDXAIUENDNDL-RJSMDTJLSA-N DMRT8K4 IU [(1S,3R)-3-[[(3S,4S)-3-methoxyoxan-4-yl]amino]-1-propan-2-ylcyclopentyl]-[3-(trifluoromethyl)-7,8-dihydro-5H-1,6-naphthyridin-6-yl]methanone DMRT8K4 CA CAS 624733-88-6 DMRT8K4 DE Multiple sclerosis DM0568C ID DM0568C DM0568C DN MK-0873 DM0568C HS Phase 2 DM0568C SN MK-0873 (dermatological, psoriasis); MK-0873 (dermatological, psoriasis), Merck & Co DM0568C CP Merck & Co Inc DM0568C DT Small molecular drug DM0568C PC 9919680 DM0568C MW 422.4 DM0568C FM C25H18N4O3 DM0568C IC InChI=1S/C25H18N4O3/c30-23-21-7-2-12-26-24(21)29(16-22(23)25(31)27-19-10-11-19)20-6-1-4-17(14-20)8-9-18-5-3-13-28(32)15-18/h1-7,12-16,19H,10-11H2,(H,27,31) DM0568C CS C1CC1NC(=O)C2=CN(C3=C(C2=O)C=CC=N3)C4=CC=CC(=C4)C#CC5=C[N+](=CC=C5)[O-] DM0568C IK JJWKQXNHYDJXKF-UHFFFAOYSA-N DM0568C IU N-cyclopropyl-1-[3-[2-(1-oxidopyridin-1-ium-3-yl)ethynyl]phenyl]-4-oxo-1,8-naphthyridine-3-carboxamide DM0568C CA CAS 500355-52-2 DM0568C DE Psoriasis vulgaris DM8ZTW7 ID DM8ZTW7 DM8ZTW7 DN MK-1029 DM8ZTW7 HS Phase 2 DM8ZTW7 DE Asthma DMEDITW ID DMEDITW DMEDITW DN MK-1454 DMEDITW HS Phase 2 DMEDITW CP Merck DMEDITW DE Lymphoma; Solid tumour/cancer; Squamous head and neck cell carcinom DM3WDZ5 ID DM3WDZ5 DM3WDZ5 DN MK-1775 DM3WDZ5 HS Phase 2 DM3WDZ5 SN MK-1775; 955365-80-7; Adavosertib; MK1775; MK 1775; UNII-K2T6HJX3I3; AZD 1775; AZD-1775; AZD1775; 2-allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-6-(4-(4-methylpiperazin-1-yl)phenylamino)-1H-pyrazolo[3,4-d]pyrimidin-3(2H)-one; K2T6HJX3I3; 1-[6-(2-hydroxypropan-2-yl)pyridin-2-yl]-6-[4-(4-methylpiperazin-1-yl)anilino]-2-prop-2-enylpyrazolo[3,4-d]pyrimidin-3-one; 2-Allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-6-((4-(4-methylpiperazin-1-yl)phenyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-3(2H)-one; AK-99219 DM3WDZ5 CP Merck DM3WDZ5 DT Small molecular drug DM3WDZ5 PC 24856436 DM3WDZ5 MW 500.6 DM3WDZ5 FM C27H32N8O2 DM3WDZ5 IC InChI=1S/C27H32N8O2/c1-5-13-34-25(36)21-18-28-26(29-19-9-11-20(12-10-19)33-16-14-32(4)15-17-33)31-24(21)35(34)23-8-6-7-22(30-23)27(2,3)37/h5-12,18,37H,1,13-17H2,2-4H3,(H,28,29,31) DM3WDZ5 CS CC(C)(C1=NC(=CC=C1)N2C3=NC(=NC=C3C(=O)N2CC=C)NC4=CC=C(C=C4)N5CCN(CC5)C)O DM3WDZ5 IK BKWJAKQVGHWELA-UHFFFAOYSA-N DM3WDZ5 IU 1-[6-(2-hydroxypropan-2-yl)pyridin-2-yl]-6-[4-(4-methylpiperazin-1-yl)anilino]-2-prop-2-enylpyrazolo[3,4-d]pyrimidin-3-one DM3WDZ5 CA CAS 955365-80-7 DM3WDZ5 CB CHEBI:91414 DM3WDZ5 DE Ovarian cancer; Solid tumour/cancer DMVJB09 ID DMVJB09 DMVJB09 DN MK-1903 DMVJB09 HS Phase 2 DMVJB09 SN Second-generation niacin receptor agonists (oral, atherosclerosis), Arena/Merck & Co DMVJB09 CP Arena Pharmaceuticals Inc DMVJB09 DT Small molecular drug DMVJB09 PC 49763030 DMVJB09 MW 164.16 DMVJB09 FM C8H8N2O2 DMVJB09 IC InChI=1S/C8H8N2O2/c11-8(12)7-5-2-3-1-4(3)6(5)9-10-7/h3-4H,1-2H2,(H,9,10)(H,11,12)/t3-,4-/m1/s1 DMVJB09 CS C1[C@H]2[C@@H]1C3=C(C2)C(=NN3)C(=O)O DMVJB09 IK CUTZNERBKDMLAP-QWWZWVQMSA-N DMVJB09 IU (2R,4R)-8,9-diazatricyclo[4.3.0.02,4]nona-1(6),7-diene-7-carboxylic acid DMVJB09 CA CAS 1268882-43-4 DMVJB09 DE Arteriosclerosis DMT1OZ6 ID DMT1OZ6 DMT1OZ6 DN MK-2206 DMT1OZ6 HS Phase 2 DMT1OZ6 SN MK-2206; 1032349-93-1; UNII-51HZG6MP1K; MK 2206; 51HZG6MP1K; CHEMBL1079175; CHEBI:67271; NCGC00186465-01; 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-2H-[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3-one; DSSTox_RID_83143; DSSTox_CID_28874; 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-1,2,4-Triazolo[3,4-f][1,6]naphthyridin-3(2H)-one; DSSTox_GSID_48948; 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3(2H)-one; 1,2,4-Triazolo[3,4-f][1,6]naphthyridin-3(2H)-one, 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-; DMT1OZ6 CP Merck DMT1OZ6 DT Small molecular drug DMT1OZ6 PC 24964624 DMT1OZ6 MW 407.5 DMT1OZ6 FM C25H21N5O DMT1OZ6 IC InChI=1S/C25H21N5O/c26-25(12-4-13-25)18-9-7-17(8-10-18)22-19(16-5-2-1-3-6-16)15-20-21(27-22)11-14-30-23(20)28-29-24(30)31/h1-3,5-11,14-15H,4,12-13,26H2,(H,29,31) DMT1OZ6 CS C1CC(C1)(C2=CC=C(C=C2)C3=C(C=C4C(=N3)C=CN5C4=NNC5=O)C6=CC=CC=C6)N DMT1OZ6 IK ULDXWLCXEDXJGE-UHFFFAOYSA-N DMT1OZ6 IU 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-2H-[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3-one DMT1OZ6 CA CAS 1032349-93-1 DMT1OZ6 CB CHEBI:67271 DMT1OZ6 DE Rectal adenocarcinoma; Nasopharyngeal carcinoma DM1M57I ID DM1M57I DM1M57I DN MK-2578 DM1M57I HS Phase 2 DM1M57I CP Merck Bioventures DM1M57I DE Anemia DM6OLGC ID DM6OLGC DM6OLGC DN MK-3207 DM6OLGC HS Phase 2 DM6OLGC SN 957116-20-0; MK-3207 Hydrochloride; MK-3207 (Hydrochloride); MK-3207 HCl; MK-3207 HCl salt; 2-((R)-8-(3,5-Difluorophenyl)-10-oxo-6,9-diazaspiro[4.5]decan-9-yl)-N-((R)-2'-oxo-1,1',2',3-tetrahydrospiro[indene-2,3'-Pyrrolo[2,3-b]pyridin]-5-yl)acetamide hydrochloride; MK3207; (8R)-8-(3,5-Difluorophenyl)-10-oxo-n-[(2r)-1,1',2',3-tetrahydro-2'-oxospiro[2h-indene-2,3'-[3h]pyrrolo[2,3-b]pyridin]-5-yl]-6,9-diazaspiro[4.5]decane-9-acetamide hydrochloride; MK 3207 hydrochloride; MK-3207(Hydrochloride); MK3207 HCl DM6OLGC CP Merck & Co Inc DM6OLGC DT Small molecular drug DM6OLGC PC 25019940 DM6OLGC MW 557.6 DM6OLGC FM C31H29F2N5O3 DM6OLGC IC InChI=1S/C31H29F2N5O3/c32-21-10-19(11-22(33)13-21)25-16-35-31(7-1-2-8-31)29(41)38(25)17-26(39)36-23-6-5-18-14-30(15-20(18)12-23)24-4-3-9-34-27(24)37-28(30)40/h3-6,9-13,25,35H,1-2,7-8,14-17H2,(H,36,39)(H,34,37,40)/t25-,30+/m0/s1 DM6OLGC CS C1CCC2(C1)C(=O)N([C@@H](CN2)C3=CC(=CC(=C3)F)F)CC(=O)NC4=CC5=C(C[C@@]6(C5)C7=C(NC6=O)N=CC=C7)C=C4 DM6OLGC IK AZAANWYREOQRFB-SETSBSEESA-N DM6OLGC IU 2-[(8R)-8-(3,5-difluorophenyl)-10-oxo-6,9-diazaspiro[4.5]decan-9-yl]-N-[(2R)-2'-oxospiro[1,3-dihydroindene-2,3'-1H-pyrrolo[2,3-b]pyridine]-5-yl]acetamide DM6OLGC CA CAS 957118-49-9 DM6OLGC DE Migraine DM347TQ ID DM347TQ DM347TQ DN MK-3697 DM347TQ HS Phase 2 DM347TQ CP Merck DM347TQ PC 46190695 DM347TQ MW 447.5 DM347TQ FM C23H21N5O3S DM347TQ IC InChI=1S/C23H21N5O3S/c1-14-8-15(11-24-10-14)19-9-17(18(13-26-19)23-25-6-7-32-23)21(29)27-12-16-4-5-20(30-2)22(28-16)31-3/h4-11,13H,12H2,1-3H3,(H,27,29) DM347TQ CS CC1=CC(=CN=C1)C2=NC=C(C(=C2)C(=O)NCC3=NC(=C(C=C3)OC)OC)C4=NC=CS4 DM347TQ IK VSOUDUXMPUHJEU-UHFFFAOYSA-N DM347TQ IU N-[(5,6-dimethoxypyridin-2-yl)methyl]-2-(5-methylpyridin-3-yl)-5-(1,3-thiazol-2-yl)pyridine-4-carboxamide DM347TQ CA CAS 1224846-01-8 DM347TQ DE Insomnia DMSPWX6 ID DMSPWX6 DMSPWX6 DN MK-5172 DMSPWX6 HS Phase 2 DMSPWX6 SN UNII-RU4QU6O6X6; 1206524-85-7; RU4QU6O6X6; (1aR,5S,8S,10R,22aR)-5-tert-butyl-14-methoxy-3,6-dioxo-1,1a,3,4,5,6,9,10,18,19,20,21,22,22a-tetradecahydro-8H-7,10-methanocyclopropa[18,19][1,10,3,6]dioxadiazacyclononadecino[11,12-b]quinoxaline-8-carboxylic acid; 8H-7,10-Methanocyclopropa(18,19)(1,10,3,6)dioxadiazacyclononadecino(11,12-b)quinoxaline-8-carboxylic acid, 5-(1,1-dimethylethyl)-1,1a,3,4,5,6,9,10,18,19,20,21,22,22a-tetradecahydro-14-methoxy-3,6-dioxo-, (1aR,5S,8S,10R,22aR)- DMSPWX6 CP Merck DMSPWX6 DT Small molecular drug DMSPWX6 PC 46930991 DMSPWX6 MW 554.6 DMSPWX6 FM C29H38N4O7 DMSPWX6 IC InChI=1S/C29H38N4O7/c1-29(2,3)24-26(34)33-15-18(14-22(33)27(35)36)39-25-20(30-19-11-10-17(38-4)13-21(19)31-25)9-7-5-6-8-16-12-23(16)40-28(37)32-24/h10-11,13,16,18,22-24H,5-9,12,14-15H2,1-4H3,(H,32,37)(H,35,36)/t16-,18-,22+,23-,24-/m1/s1 DMSPWX6 CS CC(C)(C)[C@H]1C(=O)N2C[C@@H](C[C@H]2C(=O)O)OC3=NC4=C(C=CC(=C4)OC)N=C3CCCCC[C@@H]5C[C@H]5OC(=O)N1 DMSPWX6 IK IVROMYPOGKZNLP-FDOFPDFBSA-N DMSPWX6 IU (1R,18R,20R,24S,27S)-24-tert-butyl-7-methoxy-22,25-dioxo-2,21-dioxa-4,11,23,26-tetrazapentacyclo[24.2.1.03,12.05,10.018,20]nonacosa-3,5(10),6,8,11-pentaene-27-carboxylic acid DMSPWX6 CA CAS 1206524-85-7 DMSPWX6 DE Hepatitis C virus infection DMHTIGU ID DMHTIGU DMHTIGU DN MK-5442 DMHTIGU HS Phase 2 DMHTIGU CP Merck DMHTIGU PC 46917559 DMHTIGU MW 514 DMHTIGU FM C29H33ClFNO4 DMHTIGU IC InChI=1S/C29H33ClFNO4/c1-18-13-21(10-11-23(18)28(34)35)25-8-6-5-7-24(25)19(2)36-17-22(33)16-32-29(3,4)15-20-9-12-26(30)27(31)14-20/h5-14,19,22,32-33H,15-17H2,1-4H3,(H,34,35)/t19-,22-/m1/s1 DMHTIGU CS CC1=C(C=CC(=C1)C2=CC=CC=C2[C@@H](C)OC[C@@H](CNC(C)(C)CC3=CC(=C(C=C3)Cl)F)O)C(=O)O DMHTIGU IK UNFHDRVFEQPUEL-DENIHFKCSA-N DMHTIGU IU 4-[2-[(1R)-1-[(2R)-3-[[1-(4-chloro-3-fluorophenyl)-2-methylpropan-2-yl]amino]-2-hydroxypropoxy]ethyl]phenyl]-2-methylbenzoic acid DMHTIGU CA CAS 787583-71-5 DMHTIGU DE Osteoporosis DMLMV0O ID DMLMV0O DMLMV0O DN MK-7655 DMLMV0O HS Phase 2 DMLMV0O SN Relebactam; 1174018-99-5; Relebactam anhydrous; MK-7655; UNII-1OQF7TT3PF; 1OQF7TT3PF; CHEMBL3112741; Sulfuric acid, mono[(1R,2S,5R)-7-oxo-2-[(4-piperidinylamino)carbonyl]-1,6-diazabicyclo[3.2.1]oct-6-yl] ester; Relebactam [INN]; MK7655; MK 7655; (-)-Relebactam anhydrous; BDBM1858; SCHEMBL3721178; EX-A864; SMOBCLHAZXOKDQ-ZJUUUORDSA-N; MolPort-044-723-879; MK-7655A; ZINC43206319; BDBM50447651; AKOS027338697; SB16968; DB12377; CS-5391; Sulfuric acid mono-((2S,5R)-7-oxo-2-(piperidin-4-ylcarbamoyl)-1,6-diaza-bicyclo(3.2.1)oct-6-yl) est DMLMV0O CP Merck DMLMV0O DT Small molecular drug DMLMV0O PC 44129647 DMLMV0O MW 348.38 DMLMV0O FM C12H20N4O6S DMLMV0O IC InChI=1S/C12H20N4O6S/c17-11(14-8-3-5-13-6-4-8)10-2-1-9-7-15(10)12(18)16(9)22-23(19,20)21/h8-10,13H,1-7H2,(H,14,17)(H,19,20,21)/t9-,10+/m1/s1 DMLMV0O CS C1C[C@H](N2C[C@@H]1N(C2=O)OS(=O)(=O)O)C(=O)NC3CCNCC3 DMLMV0O IK SMOBCLHAZXOKDQ-ZJUUUORDSA-N DMLMV0O IU [(2S,5R)-7-oxo-2-(piperidin-4-ylcarbamoyl)-1,6-diazabicyclo[3.2.1]octan-6-yl] hydrogen sulfate DMLMV0O CA CAS 1174018-99-5 DMLMV0O DE Bacterial infection DMG6KXB ID DMG6KXB DMG6KXB DN MK-8245 DMG6KXB HS Phase 2 DMG6KXB SN MK-8245; 1030612-90-8; MK8245; MK 8245; UNII-537E7QE8LX; 537E7QE8LX; CHEMBL1938870; 5-[3-[4-(2-Bromo-5-fluorophenoxy)-1-piperidinyl]-5-isoxazolyl]-2H-tetrazole-2-acetic acid; 2H-Tetrazole-2-acetic acid, 5-[3-[4-(2-bromo-5-fluorophenoxy)-1-piperidinyl]-5-isoxazolyl]-;2H-Tetrazole-2-acetic acid, 5-[3-[4-(2-bromo-5-fluorophenoxy)-1-piperidinyl]-5-isoxazolyl]-; 2-(5-(3-(4-(2-bromo-5-fluorophenoxy)piperidin-1-yl)isoxazol-5-yl)-2H-tetrazol-2-yl)acetic acid; UJEAABFSXKCSGI-UHFFFAOYSA-N; C17H16BrFN6O4; MLS006011144 DMG6KXB DT Small molecular drug DMG6KXB PC 24988881 DMG6KXB MW 467.2 DMG6KXB FM C17H16BrFN6O4 DMG6KXB IC InChI=1S/C17H16BrFN6O4/c18-12-2-1-10(19)7-13(12)28-11-3-5-24(6-4-11)15-8-14(29-22-15)17-20-23-25(21-17)9-16(26)27/h1-2,7-8,11H,3-6,9H2,(H,26,27) DMG6KXB CS C1CN(CCC1OC2=C(C=CC(=C2)F)Br)C3=NOC(=C3)C4=NN(N=N4)CC(=O)O DMG6KXB IK UJEAABFSXKCSGI-UHFFFAOYSA-N DMG6KXB IU 2-[5-[3-[4-(2-bromo-5-fluorophenoxy)piperidin-1-yl]-1,2-oxazol-5-yl]tetrazol-2-yl]acetic acid DMG6KXB CA CAS 1030612-90-8 DMG6KXB DE Type-2 diabetes DMD6E5W ID DMD6E5W DMD6E5W DN MK-8342 DMD6E5W HS Phase 2 DMD6E5W CP Merck DMD6E5W DE Contraception DMVNAYE ID DMVNAYE DMVNAYE DN MK-8521 DMVNAYE HS Phase 2 DMVNAYE CP Merck DMVNAYE DE Type-2 diabetes DMQHS6B ID DMQHS6B DMQHS6B DN MK-866 DMQHS6B HS Phase 2 DMQHS6B TC Anticancer Agents DMQHS6B DE Discovery agent DMXKOW6 ID DMXKOW6 DMXKOW6 DN MKC-1106-MT DMXKOW6 HS Phase 2 DMXKOW6 SN Melanoma vaccine (MART-1/tyrosinase), Mannkind DMXKOW6 CP Colby pharmaceuticals DMXKOW6 DE Melanoma DM3I71U ID DM3I71U DM3I71U DN MKT-077 DM3I71U HS Phase 2 DM3I71U SN FJ-776 (formerly); SDZ-MKT-077; 1-Ethyl-2-[3-ethyl-5-(3-methyl-2,3-dihydrobenzothiazolin-2-ylidene)-4-oxothiazolidin-2-ylidenemethyl]pyridinium chloride DM3I71U DT Small molecular drug DM3I71U PC 6444403 DM3I71U MW 432 DM3I71U FM C21H22ClN3OS2 DM3I71U IC InChI=1S/C21H22N3OS2.ClH/c1-4-23-13-9-8-10-15(23)14-18-24(5-2)20(25)19(27-18)21-22(3)16-11-6-7-12-17(16)26-21;/h6-14H,4-5H2,1-3H3;1H/q+1;/p-1/b21-19+; DM3I71U CS CCN1/C(=C/C2=CC=CC=[N+]2CC)/S/C(=C/3\\N(C4=CC=CC=C4S3)C)/C1=O.[Cl-] DM3I71U IK VSKYOTRJSLYFHX-UXJRWBAGSA-M DM3I71U IU (2Z,5E)-3-ethyl-2-[(1-ethylpyridin-1-ium-2-yl)methylidene]-5-(3-methyl-1,3-benzothiazol-2-ylidene)-1,3-thiazolidin-4-one;chloride DM3I71U CA CAS 147366-41-4 DM3I71U DE Solid tumour/cancer DMQSO4L ID DMQSO4L DMQSO4L DN ML-04 DMQSO4L HS Phase 2 DMQSO4L SN BTL-cg; HP-4; ML-04A; Urological therapeutics, Milkhaus; Human chorionic gonadotropin (benign prostate hyperplasia/prostatitis/cancer), Beech Tree Labs DMQSO4L CP Milkhaus Laboratory Inc DMQSO4L DE Myelodysplastic syndrome DMI4E9K ID DMI4E9K DMI4E9K DN MLN0264 DMI4E9K HS Phase 2 DMI4E9K CP Millenium; The Takeda oncology company DMI4E9K DE Gastrointestinal cancer DM24SOL ID DM24SOL DM24SOL DN MLN1202 DM24SOL HS Phase 2 DM24SOL SN UNNCHYARSNZOPF-UHFFFAOYSA-L; RFI-641; UNII-FR2W015BG1; FR2W015BG1; WAY-154641; CHEMBL425633; SCHEMBL20741446; RF-1461 DM24SOL CP Novartis & Millenium DM24SOL DT Small molecular drug DM24SOL PC 16156223 DM24SOL MW 1683.6 DM24SOL FM C58H60N24Na2O22S6 DM24SOL IC InChI=1S/C58H62N24O22S6.2Na/c59-45(83)23-79(24-46(60)84)105(91,92)37-9-1-5-31(17-37)67-53-73-54(68-32-6-2-10-38(18-32)106(93,94)80(25-47(61)85)26-48(62)86)76-57(75-53)71-35-13-15-41(43(21-35)109(99,100)101)42-16-14-36(22-44(42)110(102,103)104)72-58-77-55(69-33-7-3-11-39(19-33)107(95,96)81(27-49(63)87)28-50(64)88)74-56(78-58)70-34-8-4-12-40(20-34)108(97,98)82(29-51(65)89)30-52(66)90;;/h1-22H,23-30H2,(H2,59,83)(H2,60,84)(H2,61,85)(H2,62,86)(H2,63,87)(H2,64,88)(H2,65,89)(H2,66,90)(H,99,100,101)(H,102,103,104)(H3,67,68,71,73,75,76)(H3,69,70,72,74,77,78);;/q;2*+1/p-2 DM24SOL CS C1=CC(=CC(=C1)S(=O)(=O)N(CC(=O)N)CC(=O)N)NC2=NC(=NC(=N2)NC3=CC(=C(C=C3)C4=C(C=C(C=C4)NC5=NC(=NC(=N5)NC6=CC(=CC=C6)S(=O)(=O)N(CC(=O)N)CC(=O)N)NC7=CC(=CC=C7)S(=O)(=O)N(CC(=O)N)CC(=O)N)S(=O)(=O)[O-])S(=O)(=O)[O-])NC8=CC(=CC=C8)S(=O)(=O)N(CC(=O)N)CC(=O)N.[Na+].[Na+] DM24SOL IK UNNCHYARSNZOPF-UHFFFAOYSA-L DM24SOL IU disodium;5-[[4,6-bis[3-[bis(2-amino-2-oxoethyl)sulfamoyl]anilino]-1,3,5-triazin-2-yl]amino]-2-[4-[[4,6-bis[3-[bis(2-amino-2-oxoethyl)sulfamoyl]anilino]-1,3,5-triazin-2-yl]amino]-2-sulfonatophenyl]benzenesulfonate DM24SOL CA CAS 197366-24-8 DM24SOL DE Multiple sclerosis; Metastatic cancer; Respiratory syncytial virus infection DMBR8NF ID DMBR8NF DMBR8NF DN MLN2480 DMBR8NF HS Phase 2 DMBR8NF SN VWMJHAFYPMOMGF-ZCFIWIBFSA-N; 1096708-71-2; MLN 2480; BIIB-024; Tak-580; MLN-2480; BIIB024; UNII-ZN90E4027M; BIIB 024; 4-Pyrimidinecarboxamide, 6-amino-5-chloro-N-[(1R)-1-[5-[[[5-chloro-4-(trifluoromethyl)-2-pyridinyl]amino]carbonyl]-2-thiazolyl]ethyl]-; ZN90E4027M; (r)-2-(1-(6-amino-5-chloropyrimidine-4-carboxamido)ethyl)-n-(5-chloro-4-(trifluoromethyl)pyridin-2-yl)thiazole-5-carboxamide; 4-Pyrimidinecarboxamide, 6-amino-5-chloro-N-((1R)-1-(5-(((5-chloro-4-(trifluoromethyl)-2-pyridinyl)amino)carbonyl)-2-thiazolyl)ethyl]-; AMG 2112819 DMBR8NF CP Millennium Pharmaceuticals DMBR8NF DT Small molecular drug DMBR8NF PC 25161177 DMBR8NF MW 506.3 DMBR8NF FM C17H12Cl2F3N7O2S DMBR8NF IC InChI=1S/C17H12Cl2F3N7O2S/c1-6(28-15(31)12-11(19)13(23)27-5-26-12)16-25-4-9(32-16)14(30)29-10-2-7(17(20,21)22)8(18)3-24-10/h2-6H,1H3,(H,28,31)(H2,23,26,27)(H,24,29,30)/t6-/m1/s1 DMBR8NF CS C[C@H](C1=NC=C(S1)C(=O)NC2=NC=C(C(=C2)C(F)(F)F)Cl)NC(=O)C3=C(C(=NC=N3)N)Cl DMBR8NF IK VWMJHAFYPMOMGF-ZCFIWIBFSA-N DMBR8NF IU 2-[(1R)-1-[(6-amino-5-chloropyrimidine-4-carbonyl)amino]ethyl]-N-[5-chloro-4-(trifluoromethyl)pyridin-2-yl]-1,3-thiazole-5-carboxamide DMBR8NF CA CAS 1096708-71-2 DMBR8NF DE Solid tumour/cancer; Melanoma DMJHVZC ID DMJHVZC DMJHVZC DN MLN-591RL DMJHVZC HS Phase 2 DMJHVZC SN HuJ591; J591; MLN-5591RL; MLN-591; ATG-J591:RC; Anti-PSMA, Millennium; Lutetium-177-J591; Yttrium-90-J591; Anti-PSMA, Millennium/BZL Biologics; Lutetium-177-MLN-591; Yttrium-90-MLN-591; 111In-J591; 177Lu-J591; 177Lu-MLN-591; 90Y-J591; 90Y-MLN-591 DMJHVZC CP Millennium Pharmaceuticals DMJHVZC DT Antibody DMJHVZC DE Prostate cancer DMXJWNS ID DMXJWNS DMXJWNS DN MM-093 DMXJWNS HS Phase 2 DMXJWNS SN ABI-001; Recombinant human alpha fetoprotein (autoimmune diseases), Merrimack; RhAFP (autoimmune diseases), Merrimack; Recombinant human alpha-fetoprotein (autoimmune disease), GTC Biotherapeutics DMXJWNS CP Merrimack Pharmaceuticals DMXJWNS SQ >Q4QR90|Q4QR90_RAT Alpha-fetoprotein - Rattus norvegicus (Rat).: MKQPATMKWSASISFLLLLNFAEPRVLHTNEFGIESTLDSSQCPTEKNMFNVATIVVAQFVQDATKAEVNKMSSDALAAMKENTGDGCLENQLSVFLDEICHETELFNKYGFSGCCNQSGVERHQCLLARKKTAPDSVPPFHFPETAESCPAYEENRAMSINTFIYDVSKRNPFLYAPTILYLAAQYDKAVPACCKADNMEECFQTKRASMAKELREGSMLNEHVCAVIRKFGSRNLQAVLIIKLSQKFPKANITEIRKLALDVAHIHEQCCHGNAMECLQDGESVMTHICSQQEILSSKTAECCKLPTIELGYCIIHAENGDKPEGLTLNPSEFLGDRNFAQFSSEEKLLFMASFLHEYSRNHPNLPVSVILKTAKSYQEILEKCSQSETPSKCQDNMEEELQKHIQESQALAKQSCDLYQKLGPYYLQNLFLIGYTRKAPQLTSAELIDLTGKMVSIASMCCQLSEEKRSACGEGLADIYIGHLCLRHEANPVNSGINHCCSSSYSNRRLCITSFLRDETYVPPPFSEDKFIFHKDLCQAQGRALQTMKQELLINLVKQKPEMTEEQHAAVTADFSGLLEKCCKDQDQEACFAKEGPKLISKTREALGV DMXJWNS DE Autoimmune diabetes DMO7MBS ID DMO7MBS DMO7MBS DN MM-111 DMO7MBS HS Phase 2 DMO7MBS CP Merrimack DMO7MBS DT Monoclonal antibody DMO7MBS DE Gastric adenocarcinoma; Breast cancer DMDJRU1 ID DMDJRU1 DMDJRU1 DN MM-121 DMDJRU1 HS Phase 2 DMDJRU1 SN SAR-256212; EGFR antibodies (cancer), Merrimack; ErbB antibodies (cancer), Merrimack; MM-1x1 program (cancer), Merrimack; EGFR family tyrosine kinase receptor inhibitor (intravenous formulation/monoclonal antibody, cancer/NSCLC), Merrimack Pharmaceuticals/sanofi-aventis; ErbB3 tyrosine kinase receptor modulator (intravenous formulation/monoclonal antibody, cancer/NSCLC), Merrimack Pharmaceuticals/sanofi-aventis DMDJRU1 CP Merrimack pharmaceuticals; sanofi us DMDJRU1 DE Breast cancer; Non-small-cell lung cancer DM2RJ4D ID DM2RJ4D DM2RJ4D DN MM-141 DM2RJ4D HS Phase 2 DM2RJ4D DE Solid tumour/cancer; Pancreatic cancer DM6VPIO ID DM6VPIO DM6VPIO DN MM36 DM6VPIO HS Phase 2 DM6VPIO SN CHEMBL225555 DM6VPIO CP Medimetriks Pharmaceuticals Fairfield, NJ DM6VPIO DT Small molecular drug DM6VPIO PC 57855696 DM6VPIO MW 446.4 DM6VPIO FM C23H24F2N2O5 DM6VPIO IC InChI=1S/C23H24F2N2O5/c1-4-29-18-8-6-5-7-17(18)21(28)26-12-16-13-30-22(27-16)15-9-10-19(32-23(24)25)20(11-15)31-14(2)3/h5-11,13-14,23H,4,12H2,1-3H3,(H,26,28) DM6VPIO CS CCOC1=CC=CC=C1C(=O)NCC2=COC(=N2)C3=CC(=C(C=C3)OC(F)F)OC(C)C DM6VPIO IK VFBILHPIHUPBPZ-UHFFFAOYSA-N DM6VPIO IU N-[[2-[4-(difluoromethoxy)-3-propan-2-yloxyphenyl]-1,3-oxazol-4-yl]methyl]-2-ethoxybenzamide DM6VPIO CA CAS 937782-05-3 DM6VPIO DE Atopic dermatitis DMBX2RE ID DMBX2RE DMBX2RE DN MN-221 DMBX2RE HS Phase 2 DMBX2RE SN Bedoradrine DMBX2RE CP MediciNova DMBX2RE DT Small molecular drug DMBX2RE PC 9963056 DMBX2RE MW 955.1 DMBX2RE FM C48H66N4O14S DMBX2RE IC InChI=1S/2C24H32N2O5.H2O4S/c2*1-26(2)24(30)15-31-21-7-4-16-3-6-20(12-19(16)13-21)25-14-23(29)17-5-8-22(28)18(11-17)9-10-27;1-5(2,3)4/h2*4-5,7-8,11,13,20,23,25,27-29H,3,6,9-10,12,14-15H2,1-2H3;(H2,1,2,3,4)/t2*20-,23-;/m00./s1 DMBX2RE CS CN(C)C(=O)COC1=CC2=C(CC[C@@H](C2)NC[C@@H](C3=CC(=C(C=C3)O)CCO)O)C=C1.CN(C)C(=O)COC1=CC2=C(CC[C@@H](C2)NC[C@@H](C3=CC(=C(C=C3)O)CCO)O)C=C1.OS(=O)(=O)O DMBX2RE IK VPCOODFYDJWLHD-YMZXMBPUSA-N DMBX2RE IU 2-[[(7S)-7-[[(2R)-2-hydroxy-2-[4-hydroxy-3-(2-hydroxyethyl)phenyl]ethyl]amino]-5,6,7,8-tetrahydronaphthalen-2-yl]oxy]-N,N-dimethylacetamide;sulfuric acid DMBX2RE CA CAS 194785-31-4 DMBX2RE DE Exacerbation of acute asthma; Aging skin DMUGN4B ID DMUGN4B DMUGN4B DN MN-305 DMUGN4B HS Phase 2 DMUGN4B SN Osemozotan hydrochloride; Mkc 242; MCI-242; MKC-242; 3-(1,3-benzodioxol-5-yloxy)-N-[[(3S)-2,3-dihydro-1,4-benzodioxin-3-yl]methyl]propan-1-amine hydrochloride; 5-(3-((2S)-(1,4-Benzodioxan-2-ylmethyl)amino)propoxy)-1,3-benzodioxol hydrochloride DMUGN4B CP MediciNova DMUGN4B DT Small molecular drug DMUGN4B PC 198746 DMUGN4B MW 379.8 DMUGN4B FM C19H22ClNO5 DMUGN4B IC InChI=1S/C19H21NO5.ClH/c1-2-5-18-16(4-1)22-12-15(25-18)11-20-8-3-9-21-14-6-7-17-19(10-14)24-13-23-17;/h1-2,4-7,10,15,20H,3,8-9,11-13H2;1H/t15-;/m0./s1 DMUGN4B CS C1[C@@H](OC2=CC=CC=C2O1)CNCCCOC3=CC4=C(C=C3)OCO4.Cl DMUGN4B IK GGNCUSDIUUCNKE-RSAXXLAASA-N DMUGN4B IU 3-(1,3-benzodioxol-5-yloxy)-N-[[(3S)-2,3-dihydro-1,4-benzodioxin-3-yl]methyl]propan-1-amine;hydrochloride DMUGN4B CA CAS 137275-80-0 DMUGN4B DE Mood disorder DMQA3MV ID DMQA3MV DMQA3MV DN MNX-100 DMQA3MV HS Phase 2 DMQA3MV CP MetronomX DMQA3MV DE Solid tumour/cancer; Medulloblastoma DMGK1JE ID DMGK1JE DMGK1JE DN MORAb-004 DMGK1JE HS Phase 2 DMGK1JE CP Eisai DMGK1JE DE Sarcoma; Melanoma; Colorectal cancer; Merkel cell carcinoma DMCXNIP ID DMCXNIP DMCXNIP DN MORAb-009 DMCXNIP HS Phase 2 DMCXNIP SN Amatuximab DMCXNIP CP Eisai DMCXNIP DT Antibody DMCXNIP DE Mesothelioma DMYCITZ ID DMYCITZ DMYCITZ DN MP-101 DMYCITZ HS Phase 2 DMYCITZ CP Mediti Pharma DMYCITZ DE Alzheimer disease DMELUAK ID DMELUAK DMELUAK DN MP470 DMELUAK HS Phase 2 DMELUAK SN Amuvatinib; 850879-09-3; MP-470; MP470; MP 470; Amuvatinib (MP-470); HPK56; UNII-SO9S6QZB4R; Amuvatinib(MP470); N-(benzo[d][1,3]dioxol-5-ylmethyl)-4-(benzofuro[3,2-d]pyrimidin-4-yl)piperazine-1-carbothioamide; SO9S6QZB4R; HPK-56; HPK 56; N-(Benzo[d][1,3]dioxol-5-ylmethyl)-4-(benzofuro-[3,2-d]pyrimidin-4-yl)piperazine-1-carbothioamide; N-(1,3-benzodioxol-5-ylmethyl)-4-([1]benzofuro[3,2-d]pyrimidin-4-yl)piperazine-1-carbothioamide; Amuvatinib [USAN:INN]; Amuvatinib (MP-470, HPK 56); PubChem22479; Amuvatinib (USAN/INN) DMELUAK CP SuperGen DMELUAK TC Anticancer Agents DMELUAK DT Small molecular drug DMELUAK PC 11282283 DMELUAK MW 447.5 DMELUAK FM C23H21N5O3S DMELUAK IC InChI=1S/C23H21N5O3S/c32-23(24-12-15-5-6-18-19(11-15)30-14-29-18)28-9-7-27(8-10-28)22-21-20(25-13-26-22)16-3-1-2-4-17(16)31-21/h1-6,11,13H,7-10,12,14H2,(H,24,32) DMELUAK CS C1CN(CCN1C2=NC=NC3=C2OC4=CC=CC=C43)C(=S)NCC5=CC6=C(C=C5)OCO6 DMELUAK IK FOFDIMHVKGYHRU-UHFFFAOYSA-N DMELUAK IU N-(1,3-benzodioxol-5-ylmethyl)-4-([1]benzofuro[3,2-d]pyrimidin-4-yl)piperazine-1-carbothioamide DMELUAK CA CAS 850879-09-3 DMELUAK CB CHEBI:91389 DMELUAK DE Solid tumour/cancer DMMRYEK ID DMMRYEK DMMRYEK DN MPSK3169A DMMRYEK HS Phase 2 DMMRYEK SN RG7652 DMMRYEK CP Genentech DMMRYEK DE Metabolic disorder; Cardiovascular disease DMQR23W ID DMQR23W DMQR23W DN MRE-0094 DMQR23W HS Phase 2 DMQR23W SN SCHEMBL13010610; MRE 0094 DMQR23W CP Aderis Pharmaceuticals Licensee; King Pharmaceuticals DMQR23W DT Small molecular drug DMQR23W PC 9910098 DMQR23W MW 421.8 DMQR23W FM C18H20ClN5O5 DMQR23W IC InChI=1S/C18H20ClN5O5/c19-10-3-1-9(2-4-10)5-6-28-18-22-15(20)12-16(23-18)24(8-21-12)17-14(27)13(26)11(7-25)29-17/h1-4,8,11,13-14,17,25-27H,5-7H2,(H2,20,22,23)/t11-,13-,14-,17-/m1/s1 DMQR23W CS C1=CC(=CC=C1CCOC2=NC(=C3C(=N2)N(C=N3)[C@H]4[C@@H]([C@@H]([C@H](O4)CO)O)O)N)Cl DMQR23W IK WUCQGGOGHZRELS-LSCFUAHRSA-N DMQR23W IU (2R,3R,4S,5R)-2-[6-amino-2-[2-(4-chlorophenyl)ethoxy]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol DMQR23W CA CAS 131865-88-8 DMQR23W DE Diabetic foot ulcer DMJK8L1 ID DMJK8L1 DMJK8L1 DN MRG002 DMJK8L1 HS Phase 2 DMJK8L1 CP Miracogen DMJK8L1 DT Antibody drug conjugate DMJK8L1 DE Urothelial carcinoma DM9M5WV ID DM9M5WV DM9M5WV DN MRG-201 DM9M5WV HS Phase 2 DM9M5WV CP miRagen Therapeutics Boulder, CO DM9M5WV DE Scleroderma; Keloid DMQZWYE ID DMQZWYE DMQZWYE DN MRX-4 DMQZWYE HS Phase 2 DMQZWYE SN Non-steroidal multifunctional anti-inflammatory drug (MFAID) (nasal spray, allergic rhinitis), Morria DMQZWYE CP Morria Biopharmaceuticals plc DMQZWYE PC 91864617 DMQZWYE MW 530.3 DMQZWYE FM C20H18F3N4O8P DMQZWYE IC InChI=1S/C20H18F3N4O8P/c1-11(28)35-36(31,32)27(16-4-7-33-24-16)10-13-9-26(20(30)34-13)15-8-14(21)19(18(23)17(15)22)25-5-2-12(29)3-6-25/h2,4-5,7-8,13H,3,6,9-10H2,1H3,(H,31,32)/t13-/m1/s1 DMQZWYE CS CC(=O)OP(=O)(N(C[C@H]1CN(C(=O)O1)C2=CC(=C(C(=C2F)F)N3CCC(=O)C=C3)F)C4=NOC=C4)O DMQZWYE IK YCRAGJLWFBGKFE-CYBMUJFWSA-N DMQZWYE IU acetyloxy-N-(1,2-oxazol-3-yl)-N-[[(5R)-2-oxo-3-[2,3,5-trifluoro-4-(4-oxo-2,3-dihydropyridin-1-yl)phenyl]-1,3-oxazolidin-5-yl]methyl]phosphonamidic acid DMQZWYE CA CAS 1807497-11-5 DMQZWYE DE Allergic rhinitis DMLVQKF ID DMLVQKF DMLVQKF DN MRX-6 DMLVQKF HS Phase 2 DMLVQKF SN CXCL10 gene inhibitor/phospholipase A2/ MIP 1 ligand inhibitor (contact dermatitis), Morria Biopharmaceuticals; IL 1 beta/IL-6/PGE 2 modulator (dermatological emulsion, contact dermatitis), Morria Biopharmaceuticals; Monocyte chemotactic protein 1/GM-CSF/TNF alpha ligand inhibitor (dermatological emulsion, contact dermatitis), Morria Biopharmaceuticals; Non-steroidal multifunctional anti-inflammatory drug (MFAID) (topical formulation, contact dermatitis), Morria DMLVQKF CP Morria Biopharmaceuticals plc DMLVQKF DE Contact dermatitis DMH1DYU ID DMH1DYU DMH1DYU DN MSC1936369B DMH1DYU HS Phase 2 DMH1DYU SN Pimasertib; 1236699-92-5; AS703026; AS-703026; Pimasertib (AS-703026); MSC1936369B; UNII-6ON9RK82AL; AS 703026; (S)-N-(2,3-dihydroxypropyl)-3-(2-fluoro-4-iodophenylamino)isonicotinamide; 6ON9RK82AL; N-[(2S)-2,3-Dihydroxypropyl]-3-[(2-fluoro-4-iodophenyl)amino]-4-pyridinecarboxamide; 1204531-26-9; C15H15FIN3O3; N-[(2S)-2,3-dihydroxypropyl]-3-(2-fluoro-4-iodo-anilino)pyridine-4-carboxamide; N-((2S)-2,3-dihydroxypropyl)-3-((2-fluoro-4-iodophenyl)amino)pyridine-4-carboxamide; Pimasertib [USAN:INN] DMH1DYU CP EMD Serono DMH1DYU DT Small molecular drug DMH1DYU PC 44187362 DMH1DYU MW 431.2 DMH1DYU FM C15H15FIN3O3 DMH1DYU IC InChI=1S/C15H15FIN3O3/c16-12-5-9(17)1-2-13(12)20-14-7-18-4-3-11(14)15(23)19-6-10(22)8-21/h1-5,7,10,20-22H,6,8H2,(H,19,23)/t10-/m0/s1 DMH1DYU CS C1=CC(=C(C=C1I)F)NC2=C(C=CN=C2)C(=O)NC[C@@H](CO)O DMH1DYU IK VIUAUNHCRHHYNE-JTQLQIEISA-N DMH1DYU IU N-[(2S)-2,3-dihydroxypropyl]-3-(2-fluoro-4-iodoanilino)pyridine-4-carboxamide DMH1DYU CA CAS 1204531-26-9 DMH1DYU CB CHEBI:94793 DMH1DYU DE Colorectal cancer DMGUI51 ID DMGUI51 DMGUI51 DN MSDC-0602 DMGUI51 HS Phase 2 DMGUI51 SN MSDC-0602; 1133819-87-0; MSDC 0602; 5-(4-(2-(3-methoxyphenyl)-2-oxoethoxy)benzyl)thiazolidine-2,4-dione; 2,4-Thiazolidinedione, 5-[[4-[2-(3-methoxyphenyl)-2-oxoethoxy]phenyl]methyl]-; YAUMOGALQJYOJQ-UHFFFAOYSA-N; SCHEMBL623654; AKOS027382993 DMGUI51 CP Metabolic Solutions Development DMGUI51 DT Small molecular drug DMGUI51 PC 25230266 DMGUI51 MW 371.4 DMGUI51 FM C19H17NO5S DMGUI51 IC InChI=1S/C19H17NO5S/c1-24-15-4-2-3-13(10-15)16(21)11-25-14-7-5-12(6-8-14)9-17-18(22)20-19(23)26-17/h2-8,10,17H,9,11H2,1H3,(H,20,22,23) DMGUI51 CS COC1=CC=CC(=C1)C(=O)COC2=CC=C(C=C2)CC3C(=O)NC(=O)S3 DMGUI51 IK YAUMOGALQJYOJQ-UHFFFAOYSA-N DMGUI51 IU 5-[[4-[2-(3-methoxyphenyl)-2-oxoethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione DMGUI51 CA CAS 1133819-87-0 DMGUI51 DE Type-2 diabetes DMUM370 ID DMUM370 DMUM370 DN MSH-1001 DMUM370 HS Phase 2 DMUM370 SN DNB-001; KR-31378; KR-31378); K+ channel activating compounds, Dongbu/KRICT DMUM370 CP Danube Pharmaceuticals Inc; Korea Research Institute of Chemical Technology DMUM370 PC 9823724 DMUM370 MW 425.5 DMUM370 FM C22H27N5O4 DMUM370 IC InChI=1S/C22H27N5O4/c1-22(20(29-2)30-3)19(28)18(16-11-15(24)9-10-17(16)31-22)27-21(26-13-23)25-12-14-7-5-4-6-8-14/h4-11,18-20,28H,12,24H2,1-3H3,(H2,25,26,27)/t18-,19+,22+/m1/s1 DMUM370 CS C[C@]1([C@H]([C@@H](C2=C(O1)C=CC(=C2)N)NC(=NCC3=CC=CC=C3)NC#N)O)C(OC)OC DMUM370 IK OZHUPJHJQIEDFA-DXIQSLLYSA-N DMUM370 IU 1-[(2S,3S,4R)-6-amino-2-(dimethoxymethyl)-3-hydroxy-2-methyl-3,4-dihydrochromen-4-yl]-2-benzyl-3-cyanoguanidine DMUM370 DE Ocular hypertension DMSE9TH ID DMSE9TH DMSE9TH DN MT-1303 DMSE9TH HS Phase 2 DMSE9TH CP Mitsubishi Tanabe Pharma Corp DMSE9TH DT Small molecular drug DMSE9TH PC 67418070 DMSE9TH MW 413.9 DMSE9TH FM C19H31ClF3NO3 DMSE9TH IC InChI=1S/C19H30F3NO3.ClH/c1-2-3-4-5-6-11-26-17-8-7-15(12-16(17)19(20,21)22)9-10-18(23,13-24)14-25;/h7-8,12,24-25H,2-6,9-11,13-14,23H2,1H3;1H DMSE9TH CS CCCCCCCOC1=C(C=C(C=C1)CCC(CO)(CO)N)C(F)(F)F.Cl DMSE9TH IK GEDVJGOVRLHFQG-UHFFFAOYSA-N DMSE9TH IU 2-amino-2-[2-[4-heptoxy-3-(trifluoromethyl)phenyl]ethyl]propane-1,3-diol;hydrochloride DMSE9TH CA CAS 942398-84-7 DMSE9TH DE Multiple sclerosis; Crohn disease DM7I0MT ID DM7I0MT DM7I0MT DN MT203 DM7I0MT HS Phase 2 DM7I0MT SN Namilumab DM7I0MT CP National Institute of Allergy and Infectious Diseases (NIAID) DM7I0MT DT Monoclonal antibody DM7I0MT DE Plaque psoriasis DMCNL7Z ID DMCNL7Z DMCNL7Z DN MT-3724 DMCNL7Z HS Phase 2 DMCNL7Z CP Molecular Templates DMCNL7Z DT Recombinant?protein DMCNL7Z DE B-cell chronic lymphocytic leukaemia; B-cell lymphoma; B-cell non-hodgkin lymphoma; Diffuse large B-cell lymphoma; Non-hodgkin lymphoma DMXSZA4 ID DMXSZA4 DMXSZA4 DN MT-3995 DMXSZA4 HS Phase 2 DMXSZA4 CP Mitsubishi tanabe pharma DMXSZA4 DE Diabetic nephropathy DM7VG8L ID DM7VG8L DM7VG8L DN MTC-896 DM7VG8L HS Phase 2 DM7VG8L SN MC-5 antagonists (dermatological disease), Mimetica DM7VG8L CP Mimetica Pty Ltd DM7VG8L DE Seborrhea DMT0K4F ID DMT0K4F DMT0K4F DN MTR105 DMT0K4F HS Phase 2 DMT0K4F SN UNII-CTD25O6OBI; CTD25O6OBI; MTR 105; S-Ethylisothiuronium diethyl phosphate; 21704-46-1; Carbamimidothioic acid, ethyl ester, mono(diethyl phospate); Phosphoric acid, diethyl ester, compd. with 2-ethyl-2-thiopseudourea (1:1); Difetur; AC1Q6SNE; AC1L4PKY; CTK4E7529; nitric oxide synthase inhibi-tors; ethyl carbamimidothioate- diethyl hydrogen phosphate(1:1); MTR-105; DTXSID60176093; AKOS030611139; LS-107705; diethyl hydrogen phosphate; Carbamimidothioic acid, ethyl ester, diethyl phosphate (1 DMT0K4F CP Meditor Pharmaceuticals DMT0K4F DT Small molecular drug DMT0K4F PC 210823 DMT0K4F MW 258.279 DMT0K4F FM C7H19N2O4PS DMT0K4F IC InChI=1S/C4H11O4P.C3H8N2S/c1-3-7-9(5,6)8-4-2;1-2-6-3(4)5/h3-4H2,1-2H3,(H,5,6);2H2,1H3,(H3,4,5) DMT0K4F CS CCOP(=O)(O)OCC.CCSC(=N)N DMT0K4F IK CSYSULGPHGCBQD-UHFFFAOYSA-N DMT0K4F IU diethyl hydrogen phosphate;ethyl carbamimidothioate DMT0K4F CA CAS 21704-46-1 DMT0K4F DE Hypotension DML7N4B ID DML7N4B DML7N4B DN MUC1-Poly-ICLC DML7N4B HS Phase 2 DML7N4B SN Mucin1 peptide vaccine (cancer), University of Pittsburgh DML7N4B CP University of Pittsburgh DML7N4B DT Vaccine DML7N4B DE Colorectal cancer DMN68ZL ID DMN68ZL DMN68ZL DN Multi-epitope tyrosinase/gp100 vaccine DMN68ZL HS Phase 2 DMN68ZL SN Melanoma vaccine, Memorial Sloan-Kettering; Multi-epitope tyrosinase/gp100 vaccine (melanoma); Multi-epitope tyrosinase/gp100 vaccine (melanoma), Memorial Sloan-Kettering DMN68ZL CP Memorial Sloan-Kettering Cancer Center DMN68ZL DT Vaccine DMN68ZL DE Melanoma DMM6KZR ID DMM6KZR DMM6KZR DN Mutant ras vaccine DMM6KZR HS Phase 2 DMM6KZR SN Mutant ras vaccine, NCI; Ras peptide vaccine, NCI; 13 mer ras peptide, NCI DMM6KZR CP National Cancer Institute DMM6KZR DT Vaccine DMM6KZR DE Solid tumour/cancer DMKDN1C ID DMKDN1C DMKDN1C DN MVA-85A DMKDN1C HS Phase 2 DMKDN1C SN AERAS-485; MVA-AG85A; MVA-85A vaccine (Mycobacterium tuberculosis infection), Oxford-Emergent Tuberculosis Consortium/TB-VAC; MVA-Ag85A vaccine (Mycobacterium tuberculosis infection), Oxford-Emergent Tuberculosis Consortium/TB-VAC DMKDN1C CP University of Oxford DMKDN1C DT Vaccine DMKDN1C DE Mycobacterium infection DMDN6FO ID DMDN6FO DMDN6FO DN MVI-816 DMDN6FO HS Phase 2 DMDN6FO CP Madison vaccines DMDN6FO DE Prostate cancer DM25VY8 ID DM25VY8 DM25VY8 DN Mydicar DM25VY8 HS Phase 2 DM25VY8 SN Mydicar (TN) DM25VY8 CP Celladon; Targeted Genetics DM25VY8 DE Heart failure DMO1XUK ID DMO1XUK DMO1XUK DN Myeloma cancer vaccine DMO1XUK HS Phase 2 DMO1XUK CP BioSante Pharmaceuticals DMO1XUK DT Vaccine DMO1XUK DE Multiple myeloma DM9BREJ ID DM9BREJ DM9BREJ DN MYK-491 DM9BREJ HS Phase 2 DM9BREJ SN Danicamtiv; UNII-7B2CS922HI; 7B2CS922HI; SAR440181; 1970972-74-7; Danicamtiv [INN]; Danicamtiv [USAN]; Danicamtiv (USAN/INN); MYK491; CHEMBL4594304; SCHEMBL17942536; WHO 10942; SAR-440181; HY-109128; CS-0086762; D11824; (R)-4-(1-((3-(Difluoromethyl)-1-methyl-1H-pyrazol-4-yl)sulfonyl)-1-fluoroethyl)-N-(isoxazol-3-yl)piperidine-1-carboxamide; 1-Piperidinecarboxamide, 4-((1R)-1-((3-(difluoromethyl)-1-methyl-1H-pyrazol-4-yl)sulfonyl)-1-fluoroethyl)-N-3-isoxazolyl- DM9BREJ CP MyoKardia; Sanofi DM9BREJ DT Small molecular drug DM9BREJ PC 122424426 DM9BREJ MW 435.4 DM9BREJ FM C16H20F3N5O4S DM9BREJ IC InChI=1S/C16H20F3N5O4S/c1-16(19,29(26,27)11-9-23(2)21-13(11)14(17)18)10-3-6-24(7-4-10)15(25)20-12-5-8-28-22-12/h5,8-10,14H,3-4,6-7H2,1-2H3,(H,20,22,25)/t16-/m1/s1 DM9BREJ CS C[C@@](C1CCN(CC1)C(=O)NC2=NOC=C2)(F)S(=O)(=O)C3=CN(N=C3C(F)F)C DM9BREJ IK NREKKBAMVWQRES-MRXNPFEDSA-N DM9BREJ IU 4-[(1R)-1-[3-(difluoromethyl)-1-methylpyrazol-4-yl]sulfonyl-1-fluoroethyl]-N-(1,2-oxazol-3-yl)piperidine-1-carboxamide DM9BREJ CA CAS 1970972-74-7 DM9BREJ DE Dilated cardiomyopathy DMQKSGI ID DMQKSGI DMQKSGI DN Myo-inositol DMQKSGI HS Phase 2 DMQKSGI SN Scyllo-inositol; inositol; Muco-Inositol; epi-Inositol; i-Inositol; meso-Inositol; Allo-inositol; 87-89-8; 1D-Chiro-inositol; 1L-Chiro-inositol; 488-59-5; Scyllitol; 643-12-9; D-(+)-chiro-Inositol; cis-Inositol; mesoinositol; Quercinitol; Myoinosite; Dambose; Cyclohexane-1,2,3,4,5,6-hexaol; Neo-inositol; Meat sugar; 6917-35-7; Phaseomannite; Inositina; Cocositol; D-chiro-Inositol; Inositene; Inosital; Iso-inositol; cyclohexane-1,2,3,4,5,6-hexol; Phaseomannitol; Cyclohexitol; Mesoinosit; Scyllite; Mesoinosite; Inosite DMQKSGI DT Small molecular drug DMQKSGI PC 892 DMQKSGI MW 180.16 DMQKSGI FM C6H12O6 DMQKSGI IC InChI=1S/C6H12O6/c7-1-2(8)4(10)6(12)5(11)3(1)9/h1-12H DMQKSGI CS C1(C(C(C(C(C1O)O)O)O)O)O DMQKSGI IK CDAISMWEOUEBRE-UHFFFAOYSA-N DMQKSGI IU cyclohexane-1,2,3,4,5,6-hexol DMQKSGI CA CAS 551-72-4 DMQKSGI CB CHEBI:17268 DMQKSGI DE Alzheimer disease DMUK6HC ID DMUK6HC DMUK6HC DN N-5984 DMUK6HC HS Phase 2 DMUK6HC SN N-5984; SCHEMBL364457; XSOXUIXLUNBLJA-RNRVQEDPSA-N; 6-(2-(R)-((2-(R)-(3-chlorophenyl)-2-hydroxyethyl)amino)-propyl)-2,3-dihydro-1,4-benzodioxin-2-(R)-carboxylic acid; 6-(2-(R)-((2-(R)-(3-chlorophenyl)-2-hydroxyethyl)amino )-propyl)-2,3-dihydro-1,4-benzodioxin-2-(R)-carboxylic acid DMUK6HC CP Nisshin Kyorin DMUK6HC DT Small molecular drug DMUK6HC PC 9865284 DMUK6HC MW 391.8 DMUK6HC FM C20H22ClNO5 DMUK6HC IC InChI=1S/C20H22ClNO5/c1-12(22-10-16(23)14-3-2-4-15(21)9-14)7-13-5-6-17-18(8-13)26-11-19(27-17)20(24)25/h2-6,8-9,12,16,19,22-23H,7,10-11H2,1H3,(H,24,25)/t12-,16+,19-/m1/s1 DMUK6HC CS C[C@H](CC1=CC2=C(C=C1)O[C@H](CO2)C(=O)O)NC[C@@H](C3=CC(=CC=C3)Cl)O DMUK6HC IK XSOXUIXLUNBLJA-RNRVQEDPSA-N DMUK6HC IU (2R)-6-[(2R)-2-[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]-2,3-dihydro-1,4-benzodioxine-2-carboxylic acid DMUK6HC DE Type-2 diabetes; Obesity DMN7EUO ID DMN7EUO DMN7EUO DN N6022 DMN7EUO HS Phase 2 DMN7EUO SN N6022; 1208315-24-5; N-6022; UNII-80LIU5P95D; 80LIU5P95D; CHEMBL1738699; 3-(5-(4-(1H-Imidazol-1-yl)phenyl)-1-(4-carbamoyl-2-methylphenyl)-1H-pyrrol-2-yl)propanoic acid; 3-{1-(4-Carbamoyl-2-Methylphenyl)-5-[4-(1h-Imidazol-1-Yl)phenyl]-1h-Pyrrol-2-Yl}propanoic Acid; N 6022; YVPGZQLRPAGKLA-UHFFFAOYSA-N; 3-[1-(4-carbamoyl-2-methylphenyl)-5-[4-(1H-imidazol-1-yl)phenyl]-1H-pyrrol-2-yl]propanoic acid; SCHEMBL244480; EX-A343; MolPort-035-789-691; HMS3653J15; BCP09367; s7589; ZINC66156654; BDBM50354475; 2573AH; AKOS030526322; DB12206 DMN7EUO DT Small molecular drug DMN7EUO PC 44623946 DMN7EUO MW 414.5 DMN7EUO FM C24H22N4O3 DMN7EUO IC InChI=1S/C24H22N4O3/c1-16-14-18(24(25)31)4-9-21(16)28-20(8-11-23(29)30)7-10-22(28)17-2-5-19(6-3-17)27-13-12-26-15-27/h2-7,9-10,12-15H,8,11H2,1H3,(H2,25,31)(H,29,30) DMN7EUO CS CC1=C(C=CC(=C1)C(=O)N)N2C(=CC=C2C3=CC=C(C=C3)N4C=CN=C4)CCC(=O)O DMN7EUO IK YVPGZQLRPAGKLA-UHFFFAOYSA-N DMN7EUO IU 3-[1-(4-carbamoyl-2-methylphenyl)-5-(4-imidazol-1-ylphenyl)pyrrol-2-yl]propanoic acid DMN7EUO CA CAS 1208315-24-5 DMN7EUO DE Asthma DM7P0WR ID DM7P0WR DM7P0WR DN NAI-acne DM7P0WR HS Phase 2 DM7P0WR CP Vicuron Pharmaceuticals Inc DM7P0WR DE Acne vulgaris DMSWUNX ID DMSWUNX DMSWUNX DN Naratuximab emtansine DMSWUNX HS Phase 2 DMSWUNX SN DEBIO 1562 DMSWUNX CP Debiopharm DMSWUNX DT Antibody DMSWUNX DE Diffuse large B-cell lymphoma; Non-hodgkin lymphoma DMD0E8U ID DMD0E8U DMD0E8U DN Naveglitazar DMD0E8U HS Phase 2 DMD0E8U SN LY 519818; LY-818; PPAR alpha/gamma co-agonists, Lilly/Ligand DMD0E8U CP Ligand Pharmaceuticals DMD0E8U DT Small molecular drug DMD0E8U PC 9888484 DMD0E8U MW 422.5 DMD0E8U FM C25H26O6 DMD0E8U IC InChI=1S/C25H26O6/c1-28-24(25(26)27)18-19-8-10-20(11-9-19)29-16-5-17-30-21-12-14-23(15-13-21)31-22-6-3-2-4-7-22/h2-4,6-15,24H,5,16-18H2,1H3,(H,26,27)/t24-/m0/s1 DMD0E8U CS CO[C@@H](CC1=CC=C(C=C1)OCCCOC2=CC=C(C=C2)OC3=CC=CC=C3)C(=O)O DMD0E8U IK OKJHGOPITGTTIM-DEOSSOPVSA-N DMD0E8U IU (2S)-2-methoxy-3-[4-[3-(4-phenoxyphenoxy)propoxy]phenyl]propanoic acid DMD0E8U CA CAS 476436-68-7 DMD0E8U DE Diabetic complication DMH9JFZ ID DMH9JFZ DMH9JFZ DN NBI-5788 DMH9JFZ HS Phase 2 DMH9JFZ SN Tiplimotide; CGP-77116; MSP-771; MSP-771A; APL (multiple sclerosis), Neurocrine/Novartis; Altered peptide ligand (MS), Neurocrine/Novartis DMH9JFZ CP Neurocrine Biosciences Inc DMH9JFZ PC 25084501 DMH9JFZ MW 1860.2 DMH9JFZ FM C87H142N24O21 DMH9JFZ IC InChI=1S/C87H142N24O21/c1-15-47(10)67(82(127)105-66(46(8)9)81(126)108-69(51(14)113)84(129)110-35-23-29-60(110)77(122)97-54(28-21-33-94-87(91)92)72(117)107-68(50(13)112)85(130)111-36-24-31-62(111)86(131)132)106-76(121)59(40-63(90)114)99-71(116)49(12)96-73(118)57(38-52-25-17-16-18-26-52)101-74(119)56(37-43(2)3)100-75(120)58(39-53-41-93-42-95-53)102-79(124)64(44(4)5)104-80(125)65(45(6)7)103-78(123)61-30-22-34-109(61)83(128)55(27-19-20-32-88)98-70(115)48(11)89/h16-18,25-26,41-51,54-62,64-69,112-113H,15,19-24,27-40,88-89H2,1-14H3,(H2,90,114)(H,93,95)(H,96,118)(H,97,122)(H,98,115)(H,99,116)(H,100,120)(H,101,119)(H,102,124)(H,103,123)(H,104,125)(H,105,127)(H,106,121)(H,107,117)(H,108,126)(H,131,132)(H4,91,92,94)/t47?,48-,49+,50?,51?,54+,55+,56+,57+,58+,59+,60+,61+,62+,64+,65+,66+,67+,68+,69+/m1/s1 DMH9JFZ CS CCC(C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](C(C)O)C(=O)N2CCC[C@H]2C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC4=CN=CN4)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]5CCCN5C(=O)[C@H](CCCCN)NC(=O)[C@@H](C)N DMH9JFZ IK NITUEMISTORFON-OOMTWUQISA-N DMH9JFZ IU (2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2R)-2-aminopropanoyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-phenylpropanoyl]amino]propanoyl]amino]-4-oxobutanoyl]amino]-3-methylpentanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carboxylic acid DMH9JFZ DE Multiple sclerosis DMT6O2E ID DMT6O2E DMT6O2E DN NC318 DMT6O2E HS Phase 2 DMT6O2E CP NextCure DMT6O2E DT Antibody DMT6O2E DE Non-small cell lung cancer DMVQKB3 ID DMVQKB3 DMVQKB3 DN NCI-C50000 DMVQKB3 HS Phase 2 DMVQKB3 SN Levomenthol; D-(-)-Menthol; Headache crystals; Hexahydrothymol; I-menthol; Levomentholum; Menthacamphor; Menthol (VAN); Menthol natural; Menthol racemic; Menthomenthol; Peppermint camphor; Racementhol; U.S.P. Menthol; d,l-Menthol; l-(-)-Menthol; l-Menthol; l-Menthol (natural); p-Menthan-3-ol; (+-)-Menthol; (-)-(1R,3R,4S)-Menthol; (-)-Menthyl alcohol; (-)-menthol; (-)-trans-p-Menthan-cis-ol; (1R)-(-)-Menthol; (1R,2S,5R)-2-Isopropyl-5-methylcyclohexanol; (1r,2s,5r)-(-)-menthol; (R)-(-)-Menthol; 1-Menthol; 2216-51-5; 89-78-1 DMVQKB3 PC 16666 DMVQKB3 MW 156.26 DMVQKB3 FM C10H20O DMVQKB3 IC NOOLISFMXDJSKH-KXUCPTDWSA-N DMVQKB3 CS CC1CCC(C(C1)O)C(C)C DMVQKB3 IK 1S/C10H20O/c1-7(2)9-5-4-8(3)6-10(9)11/h7-11H,4-6H2,1-3H3/t8-,9+,10-/m1/s1 DMVQKB3 IU (1R,2S,5R)-5-methyl-2-propan-2-ylcyclohexan-1-ol DMVQKB3 CA CAS 89-78-1 DMVQKB3 CB CHEBI:15409 DMVQKB3 DE Pruritus DM4W28K ID DM4W28K DM4W28K DN NCX 1022 DM4W28K HS Phase 2 DM4W28K CP NicOx SA DM4W28K DE Atopic dermatitis DM2YIZH ID DM2YIZH DM2YIZH DN NCX-1000 DM2YIZH HS Phase 2 DM2YIZH SN Nitric oxide ursodiol derivative, NicOx/Axcan; UDCA derivative, NicOx/Axcan; Ursodeoxycholic acid derivative, NicOx/Axcan DM2YIZH CP NicOx SA DM2YIZH DT Small molecular drug DM2YIZH PC 129628949 DM2YIZH MW 685.8 DM2YIZH FM C38H55NO10 DM2YIZH IC InChI=1S/C38H55NO10/c1-24(28-10-11-29-36-30(16-18-38(28,29)3)37(2)17-15-27(40)22-26(37)23-31(36)41)7-13-35(43)49-32-12-8-25(21-33(32)46-4)9-14-34(42)47-19-5-6-20-48-39(44)45/h8-9,12,14,21,24,26-31,36,40-41H,5-7,10-11,13,15-20,22-23H2,1-4H3/b14-9+/t24-,26+,27-,28-,29+,30+,31+,36+,37+,38-/m1/s1 DM2YIZH CS C[C@H](CCC(=O)OC1=C(C=C(C=C1)/C=C/C(=O)OCCCCO[N+](=O)[O-])OC)[C@H]2CC[C@@H]3[C@@]2(CC[C@H]4[C@H]3[C@H](C[C@H]5[C@@]4(CC[C@H](C5)O)C)O)C DM2YIZH IK WTAVOESJEWSDJC-OBOLPPCUSA-N DM2YIZH IU [2-methoxy-4-[(E)-3-(4-nitrooxybutoxy)-3-oxoprop-1-enyl]phenyl] (4R)-4-[(3R,5S,7S,8R,9S,10S,13R,14S,17R)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoate DM2YIZH CA CAS 401519-96-8 DM2YIZH DE Cardiovascular disease DMOX1CU ID DMOX1CU DMOX1CU DN NCX-4016 DMOX1CU HS Phase 2 DMOX1CU SN Nitroaspirin; Ncx 4016; NO-ASA; Nitric oxide-releasing aspirin; M-NO-ASA; M-NO-aspirin; [3-(nitrooxymethyl)phenyl] 2-acetyloxybenzoate; Benzoic acid, 2-(acetyloxy)-, 2-((nitrooxy)methyl)phenyl ester; Benzoic acid, 2-(acetyloxy)-, 3-((nitrooxy)methyl)phenyl ester; 2-((Nitrooxy)methyl)phenyl 2-(acetyloxy)benzoate; 2-Acetoxybenzoate-2-(1-nitroxymethyl)phenyl ester; 2-Acetoxybenzoic acid 3-(nitrooxymethyl)phenyl ester; 2-Acetoxybenzoic acid 3-nitrooxymethylphenyl ester; 3-((Nitrooxy)methyl)phenyl 2-(acetyloxy)benzoate; 3-(Nitroxymethyl)phenyl 2-acetoxybenzoate DMOX1CU CP NiCox SA DMOX1CU TC Analgesics DMOX1CU DT Small molecular drug DMOX1CU PC 119032 DMOX1CU MW 331.28 DMOX1CU FM C16H13NO7 DMOX1CU IC InChI=1S/C16H13NO7/c1-11(18)23-15-8-3-2-7-14(15)16(19)24-13-6-4-5-12(9-13)10-22-17(20)21/h2-9H,10H2,1H3 DMOX1CU CS CC(=O)OC1=CC=CC=C1C(=O)OC2=CC=CC(=C2)CO[N+](=O)[O-] DMOX1CU IK IOJUJUOXKXMJNF-UHFFFAOYSA-N DMOX1CU IU [3-(nitrooxymethyl)phenyl] 2-acetyloxybenzoate DMOX1CU CA CAS 175033-36-0 DMOX1CU CB CHEBI:125482 DMOX1CU DE Claudication; Nephropathy; Type-2 diabetes; Inflammation DM6S83X ID DM6S83X DM6S83X DN NDDP DM6S83X HS Phase 2 DM6S83X SN Cis-Bis(2,2-dimethyloctanoato)[trans-1(R),2(R)-diaminocyclohexane]platinum (II) DM6S83X DT Small molecular drug DM6S83X PC 56841091 DM6S83X MW 649.8 DM6S83X FM C26H50N2O4Pt DM6S83X IC InChI=1S/2C10H20O2.C6H12N2.Pt/c2*1-10(2,3)8-6-4-5-7-9(11)12;7-5-3-1-2-4-6(5)8;/h2*4-8H2,1-3H3,(H,11,12);5-8H,1-4H2;/q;;-2;+4/p-2 DM6S83X CS CC(C)(C)CCCCCC(=O)[O-].CC(C)(C)CCCCCC(=O)[O-].C1CCC(C(C1)[NH-])[NH-].[Pt+4] DM6S83X IK ALPHSAWEOKVWID-UHFFFAOYSA-L DM6S83X IU (2-azanidylcyclohexyl)azanide;7,7-dimethyloctanoate;platinum(4+) DM6S83X CA CAS 113427-19-3 DM6S83X DE Solid tumour/cancer DMVIRN3 ID DMVIRN3 DMVIRN3 DN N-DESMETHYLCLOZAPINE DMVIRN3 HS Phase 2 DMVIRN3 DT Small molecular drug DMVIRN3 PC 135409468 DMVIRN3 MW 312.8 DMVIRN3 FM C17H17ClN4 DMVIRN3 IC InChI=1S/C17H17ClN4/c18-12-5-6-15-16(11-12)21-17(22-9-7-19-8-10-22)13-3-1-2-4-14(13)20-15/h1-6,11,19-20H,7-10H2 DMVIRN3 CS C1CN(CCN1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42 DMVIRN3 IK JNNOSTQEZICQQP-UHFFFAOYSA-N DMVIRN3 IU 3-chloro-6-piperazin-1-yl-11H-benzo[b][1,4]benzodiazepine DMVIRN3 CA CAS 6104-71-8 DMVIRN3 CB CHEBI:64050 DMVIRN3 DE Schizoaffective disorder; Schizophrenia DMUPZFO ID DMUPZFO DMUPZFO DN Neihulizumab DMUPZFO HS Phase 2 DMUPZFO CP AbGenomics International Los Altos, CA DMUPZFO DE Psoriatic arthritis DMSVWI7 ID DMSVWI7 DMSVWI7 DN Neladenoson bialanate DMSVWI7 HS Phase 2 DMSVWI7 SN UNII-IV690462VZ; IV690462VZ; 1239309-58-0; Neladenoson dalanate; Neladenoson dalanate [INN]; Neladenoson bialanate [INN]; SCHEMBL7904070; AKOS032946515; DB13138; L-Alanine, L-alanyl-, 2-(4-(2-(((2-(4-chlorophenyl)-4-thiazolyl)methyl)thio)-3,5-dicyano-6-(1-pyrrolidinyl)-4-pyridinyl)phenoxy)ethyl ester; 2-(4-(2-(((2-(4-Chlorophenyl)-1,3-thiazol-4-yl)methyl)sulfanyl)-3,5-dicyano-6-(pyrrolidin-1-yl)pyridin-4-yl)phenoxy)ethyl L-alanyl-L-alaninate DMSVWI7 CP Bayer HealthCare Pharmaceuticals Whippany, NJ DMSVWI7 PC 56848985 DMSVWI7 MW 716.3 DMSVWI7 FM C35H34ClN7O4S2 DMSVWI7 IC InChI=1S/C35H34ClN7O4S2/c1-21(39)32(44)40-22(2)35(45)47-16-15-46-27-11-7-23(8-12-27)30-28(17-37)31(43-13-3-4-14-43)42-34(29(30)18-38)49-20-26-19-48-33(41-26)24-5-9-25(36)10-6-24/h5-12,19,21-22H,3-4,13-16,20,39H2,1-2H3,(H,40,44)/t21-,22-/m0/s1 DMSVWI7 CS C[C@@H](C(=O)N[C@@H](C)C(=O)OCCOC1=CC=C(C=C1)C2=C(C(=NC(=C2C#N)SCC3=CSC(=N3)C4=CC=C(C=C4)Cl)N5CCCC5)C#N)N DMSVWI7 IK WESNEIGKOAXSGX-VXKWHMMOSA-N DMSVWI7 IU 2-[4-[2-[[2-(4-chlorophenyl)-1,3-thiazol-4-yl]methylsulfanyl]-3,5-dicyano-6-pyrrolidin-1-ylpyridin-4-yl]phenoxy]ethyl (2S)-2-[[(2S)-2-aminopropanoyl]amino]propanoate DMSVWI7 CA CAS 1239309-58-0 DMSVWI7 DE Chronic heart failure DM4LKFO ID DM4LKFO DM4LKFO DN NELOTANSERIN DM4LKFO HS Phase 2 DM4LKFO SN NELOTANSERIN; 839713-36-9; UNII-4ZA73QEW2P; 4ZA73QEW2P; CHEMBL598172; APD125; APD-125; 1-[3-(4-Bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxyphenyl]-3-(2,4-difluorophenyl)urea; 1-[3-(4-BROMO-1-METHYL-1H-PYRAZOL-5-YL)-4-METHOXYPHENYL]-3-(2,4-DIFLUOROPHENYL)UREA; N-[3-(4-bromo-1-methyl-1H-pyrazol-5-yl)-4-methoxyphenyl]-N'-(2,4-difluorophenyl)-Urea; Nelotanserin [USAN:INN]; Nelotanserin (USAN/INN); SCHEMBL2345325; APD 125; DTXSID40232868; COSPVUFTLGQDQL-UHFFFAOYSA-N; BCP24992; ZINC38239930; BDBM50324541; AKOS027255058; DB12555 DM4LKFO DT Small molecular drug DM4LKFO PC 11683556 DM4LKFO MW 437.2 DM4LKFO FM C18H15BrF2N4O2 DM4LKFO IC InChI=1S/C18H15BrF2N4O2/c1-25-17(13(19)9-22-25)12-8-11(4-6-16(12)27-2)23-18(26)24-15-5-3-10(20)7-14(15)21/h3-9H,1-2H3,(H2,23,24,26) DM4LKFO CS CN1C(=C(C=N1)Br)C2=C(C=CC(=C2)NC(=O)NC3=C(C=C(C=C3)F)F)OC DM4LKFO IK COSPVUFTLGQDQL-UHFFFAOYSA-N DM4LKFO IU 1-[3-(4-bromo-2-methylpyrazol-3-yl)-4-methoxyphenyl]-3-(2,4-difluorophenyl)urea DM4LKFO CA CAS 839713-36-9 DM4LKFO DE Sleep-wake disorder; Lewy body dementia DMNM9DZ ID DMNM9DZ DMNM9DZ DN Nepicastat oral DMNM9DZ HS Phase 2 DMNM9DZ SN SYN117 DMNM9DZ CP Biotie Therapies DMNM9DZ DT Small molecular drug DMNM9DZ PC 9840545 DMNM9DZ MW 331.8 DMNM9DZ FM C14H16ClF2N3S DMNM9DZ IC InChI=1S/C14H15F2N3S.ClH/c15-9-3-8-4-10(1-2-12(8)13(16)5-9)19-11(6-17)7-18-14(19)20;/h3,5,7,10H,1-2,4,6,17H2,(H,18,20);1H/t10-;/m0./s1 DMNM9DZ CS C1CC2=C(C[C@H]1N3C(=CNC3=S)CN)C=C(C=C2F)F.Cl DMNM9DZ IK DIPDUAJWNBEVOY-PPHPATTJSA-N DMNM9DZ IU 4-(aminomethyl)-3-[(2S)-5,7-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl]-1H-imidazole-2-thione;hydrochloride DMNM9DZ CA CAS 170151-24-3 DMNM9DZ DE Post-traumatic stress disorder DM3ORVD ID DM3ORVD DM3ORVD DN Neramexane DM3ORVD HS Phase 2 DM3ORVD SN Neramexane [INN]; Mrz 2579; MRZ 2-579; 1,3,3,5,5-Pentamethylcyclohexanamine; 1,3,3,5,5-pentamethylcyclohexan-1-amine DM3ORVD CP Merz Pharmaceuticals GmbH DM3ORVD TC Analgesics DM3ORVD DT Small molecular drug DM3ORVD PC 6433106 DM3ORVD MW 169.31 DM3ORVD FM C11H23N DM3ORVD IC InChI=1S/C11H23N/c1-9(2)6-10(3,4)8-11(5,12)7-9/h6-8,12H2,1-5H3 DM3ORVD CS CC1(CC(CC(C1)(C)N)(C)C)C DM3ORVD IK OGZQTTHDGQBLBT-UHFFFAOYSA-N DM3ORVD IU 1,3,3,5,5-pentamethylcyclohexan-1-amine DM3ORVD CA CAS 219810-59-0 DM3ORVD DE Cancer related pain DMBJ3GL ID DMBJ3GL DMBJ3GL DN Nerenone DMBJ3GL HS Phase 2 DMBJ3GL CP Bayer healthcare pharmaceuticals DMBJ3GL DE Diabetic nephropathy DM8H7OA ID DM8H7OA DM8H7OA DN Netoglitazone DM8H7OA HS Phase 2 DM8H7OA SN Isaglitazone; Netoglitazone [USAN]; MCC 555; MCC-555; RWJ-241947; Netoglitazone (USAN/INN); 5-((6-((2-fluorophenyl)methoxy)-2-naphthalenyl)methyl)-2,4-thiazolidinedione; 5-({6-[(2-fluorobenzyl)oxy]naphthalen-2-yl}methyl)-1,3-thiazolidine-2,4-dione; 5-[[6-[(2-fluorophenyl)methoxy]naphthalen-2-yl]methyl]-1,3-thiazolidine-2,4-dione DM8H7OA CP Mitsubishi Pharma DM8H7OA DT Small molecular drug DM8H7OA PC 204109 DM8H7OA MW 381.4 DM8H7OA FM C21H16FNO3S DM8H7OA IC InChI=1S/C21H16FNO3S/c22-18-4-2-1-3-16(18)12-26-17-8-7-14-9-13(5-6-15(14)11-17)10-19-20(24)23-21(25)27-19/h1-9,11,19H,10,12H2,(H,23,24,25) DM8H7OA CS C1=CC=C(C(=C1)COC2=CC3=C(C=C2)C=C(C=C3)CC4C(=O)NC(=O)S4)F DM8H7OA IK PKWDZWYVIHVNKS-UHFFFAOYSA-N DM8H7OA IU 5-[[6-[(2-fluorophenyl)methoxy]naphthalen-2-yl]methyl]-1,3-thiazolidine-2,4-dione DM8H7OA CA CAS 161600-01-7 DM8H7OA DE Non-alcoholic fatty liver disease DMOZW4C ID DMOZW4C DMOZW4C DN Neublastin DMOZW4C HS Phase 2 DMOZW4C CP Biogen Idec DMOZW4C DE Pain DMIQDFW ID DMIQDFW DMIQDFW DN Neu-P11 DMIQDFW HS Phase 2 DMIQDFW SN Piromelatine; UNII-S3UN2146K9; 946846-83-9; S3UN2146K9; NEU-P11; Piromelatine [INN]; NEU-P-11; SCHEMBL8235551; DTXSID90241566; N-(2-(5-Methoxy-1H-indol-3-yl)ethyl)-4-oxo-4H-pyran-2-carboxamide; 4H-Pyran-2-carboxamide, N-(2-(5-methoxy-1H-indol-3-yl)ethyl)-4-oxo-; SB19819 DMIQDFW CP Neurim Pharmaceuticals DMIQDFW DT Small molecular drug DMIQDFW PC 24815904 DMIQDFW MW 312.32 DMIQDFW FM C17H16N2O4 DMIQDFW IC InChI=1S/C17H16N2O4/c1-22-13-2-3-15-14(9-13)11(10-19-15)4-6-18-17(21)16-8-12(20)5-7-23-16/h2-3,5,7-10,19H,4,6H2,1H3,(H,18,21) DMIQDFW CS COC1=CC2=C(C=C1)NC=C2CCNC(=O)C3=CC(=O)C=CO3 DMIQDFW IK PNTNBIHOAPJYDB-UHFFFAOYSA-N DMIQDFW IU N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-4-oxopyran-2-carboxamide DMIQDFW CA CAS 946846-83-9 DMIQDFW DE Insomnia; Alzheimer disease; Dementia DMINQP1 ID DMINQP1 DMINQP1 DN NEUROPEPTIDE-Y DMINQP1 HS Phase 2 DMINQP1 SN XKWCTHKJQNUFOQ-HRPSIEBRSA-N; Neuropeptide Y DMINQP1 DT Small molecular drug DMINQP1 PC 91928728 DMINQP1 MW 4254 DMINQP1 FM C190H287N55O57 DMINQP1 IC InChI=1S/C190H287N55O57/c1-16-94(9)149(180(296)235-129(81-141(194)255)169(285)227-124(74-93(7)8)172(288)240-150(95(10)17-2)181(297)241-151(100(15)248)182(298)222-116(32-23-67-209-190(203)204)156(272)221-118(57-60-140(193)254)161(277)219-114(30-21-65-207-188(199)200)157(273)224-121(152(196)268)76-102-39-49-108(250)50-40-102)239-173(289)127(79-105-45-55-111(253)56-46-105)230-168(284)128(80-106-86-205-90-211-106)231-159(275)115(31-22-66-208-189(201)202)220-165(281)123(73-92(5)6)225-155(271)97(12)213-174(290)134(88-246)237-167(283)126(78-104-43-53-110(252)54-44-104)229-166(282)125(77-103-41-51-109(251)52-42-103)228-158(274)113(29-20-64-206-187(197)198)217-153(269)96(11)212-163(279)122(72-91(3)4)226-170(286)131(84-147(264)265)233-162(278)119(59-62-145(260)261)218-154(270)98(13)214-177(293)137-34-25-68-242(137)183(299)99(14)215-164(280)130(83-146(262)263)232-160(276)117(58-61-144(258)259)216-143(257)87-210-176(292)136-33-24-70-244(136)186(302)133(82-142(195)256)236-171(287)132(85-148(266)267)234-178(294)139-36-27-71-245(139)185(301)120(28-18-19-63-191)223-175(291)135(89-247)238-179(295)138-35-26-69-243(138)184(300)112(192)75-101-37-47-107(249)48-38-101/h37-56,86,90-100,112-139,149-151,246-253H,16-36,57-85,87-89,191-192H2,1-15H3,(H2,193,254)(H2,194,255)(H2,195,256)(H2,196,268)(H,205,211)(H,210,292)(H,212,279)(H,213,290)(H,214,293)(H,215,280)(H,216,257)(H,217,269)(H,218,270)(H,219,277)(H,220,281)(H,221,272)(H,222,298)(H,223,291)(H,224,273)(H,225,271)(H,226,286)(H,227,285)(H,228,274)(H,229,282)(H,230,284)(H,231,275)(H,232,276)(H,233,278)(H,234,294)(H,235,296)(H,236,287)(H,237,283)(H,238,295)(H,239,289)(H,240,288)(H,241,297)(H,258,259)(H,260,261)(H,262,263)(H,264,265)(H,266,267)(H4,197,198,206)(H4,199,200,207)(H4,201,202,208)(H4,203,204,209)/t94-,95-,96-,97-,98-,99-,100+,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,127-,128-,129-,130-,131-,132-,133-,134-,135-,136-,137-,138-,139-,149-,150-,151-/m0/s1 DMINQP1 CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CC3=CN=CN3)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CC5=CC=C(C=C5)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@@H]6CCCN6C(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@@H]7CCCN7C(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H]8CCCN8C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@@H]9CCCN9C(=O)[C@H](CC1=CC=C(C=C1)O)N DMINQP1 IK URPYMXQQVHTUDU-OFGSCBOVSA-N DMINQP1 IU (4S)-5-[[(2S)-1-[[(2S)-1-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-4-amino-1-[[(2S)-1-[[(2S,3S)-1-[[(2S,3R)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-amino-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxopropan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-4-[[2-[[(2S)-1-[(2S)-4-amino-2-[[(2S)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-2-[[(2S)-1-[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-carboxypropanoyl]amino]-4-oxobutanoyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]-5-oxopentanoic acid DML5S71 ID DML5S71 DML5S71 DN Nexopamil DML5S71 HS Phase 2 DML5S71 SN LU-49938 DML5S71 CP BASF AG DML5S71 DT Small molecular drug DML5S71 PC 65984 DML5S71 MW 404.6 DML5S71 FM C24H40N2O3 DML5S71 IC InChI=1S/C24H40N2O3/c1-8-9-10-11-14-26(4)15-12-13-24(18-25,19(2)3)20-16-21(27-5)23(29-7)22(17-20)28-6/h16-17,19H,8-15H2,1-7H3/t24-/m0/s1 DML5S71 CS CCCCCCN(C)CCC[C@@](C#N)(C1=CC(=C(C(=C1)OC)OC)OC)C(C)C DML5S71 IK SKDZEFVVFACNLS-DEOSSOPVSA-N DML5S71 IU (2S)-5-[hexyl(methyl)amino]-2-propan-2-yl-2-(3,4,5-trimethoxyphenyl)pentanenitrile DML5S71 CA CAS 136033-49-3 DML5S71 DE Hypertension DMJKBAY ID DMJKBAY DMJKBAY DN NGX-267 DMJKBAY HS Phase 2 DMJKBAY SN 503431-81-0; AF267B; (2S)-2-ETHYL-8-METHYL-1-THIA-4,8-DIAZASPIRO[4,5]DECAN-3-ONE; UNII-8D3PZX7G73; AF 267B; 8D3PZX7G73; (S)-2-Ethyl-8-methyl-1-thia-4,8-diazaspiro[4.5]decan-3-one; NGX-267; NGX267; NGX 267; SCHEMBL3651146; CTK1G8674; DTXSID40198399; AF-267B; PHOZOHFUXHPOCK-QMMMGPOBSA-N; ZINC13816318; AKOS025295388; NCGC00162382-01; RT-005412; FT-0668336; (S)-2-Ethyl-8-methyl-1-thia-4,8-diaza-spiro[4.5]decan-3-one; 1-Thia-4,8-diazaspiro(4.5)decan-3-one, 2-ethyl-8-methyl-, (2S)- DMJKBAY DT Small molecular drug DMJKBAY PC 10013505 DMJKBAY MW 214.33 DMJKBAY FM C10H18N2OS DMJKBAY IC InChI=1S/C10H18N2OS/c1-3-8-9(13)11-10(14-8)4-6-12(2)7-5-10/h8H,3-7H2,1-2H3,(H,11,13)/t8-/m0/s1 DMJKBAY CS CC[C@H]1C(=O)NC2(S1)CCN(CC2)C DMJKBAY IK PHOZOHFUXHPOCK-QMMMGPOBSA-N DMJKBAY IU (2S)-2-ethyl-8-methyl-1-thia-4,8-diazaspiro[4.5]decan-3-one DMJKBAY CA CAS 503431-81-0 DMJKBAY DE Schizophrenia DMDY01J ID DMDY01J DMDY01J DN NHS-IL2-LT DMDY01J HS Phase 2 DMDY01J SN Selectikine; EMD-521873; Immunocytokine (solid tumors), Merck Serono DMDY01J CP Merck Serono SA DMDY01J DE Solid tumour/cancer DMRQUH4 ID DMRQUH4 DMRQUH4 DN NI-0801 DMRQUH4 HS Phase 2 DMRQUH4 SN Anti-interferon inducible protein 10, NovImmune DMRQUH4 CP NovImmune SA DMRQUH4 DT Antibody DMRQUH4 DE Autoimmune diabetes DMKLJMI ID DMKLJMI DMKLJMI DN NIC-002 DMKLJMI HS Phase 2 DMKLJMI SN NicQb; Nicotine-Qbeta; CYT-002-NicQb; Nicotine vaccine, Cytos/Novartis; Immunodrug (nicotine addiction), Cytos/Novartis DMKLJMI CP Cytos Biotechnology AG DMKLJMI DT Vaccine DMKLJMI DE Nicotine dependence DMG7XOC ID DMG7XOC DMG7XOC DN NIC5-15 DMG7XOC HS Phase 2 DMG7XOC SN D-Pinitol; Pinitol; 10284-63-6; 3-O-Methyl-D-chiro-inositol; (+)-Pinitol; D-(+)-Pinitol; Inzitol; Methylinositol; Sennitol; 1-D-4-O-METHYL-MYO-INOSITOL; Pinit; D-ononitol; Ononitol; 1D-4-O-Methyl-myo-inositol; 1D-3-O-methyl-chiro-inositol; D-chiro-Inositol, 3-O-methyl-; 4-O-Methyl-myo-inositol; UNII-TF9HZN9T0M; UNII-A998ME07KR; 5D-5-O-Methyl-chiro-inositol; 6090-97-7; (1r,2s,4s,5s)-6-methoxycyclohexane-1,2,3,4,5-pentol; TF9HZN9T0M; 484-68-4; Matezit; Sennit; CHEMBL493737; A998ME07KR; CHEBI:28548; DSCFFEYYQKSRSV-KLJZZCKASA-N; NSC 43336 DMG7XOC CP Humanetics Minneapolis, MN DMG7XOC DT Small molecular drug DMG7XOC PC 164619 DMG7XOC MW 194.18 DMG7XOC FM C7H14O6 DMG7XOC IC InChI=1S/C7H14O6/c1-13-7-5(11)3(9)2(8)4(10)6(7)12/h2-12H,1H3/t2?,3-,4-,5-,6+,7?/m0/s1 DMG7XOC CS COC1[C@@H]([C@H](C([C@@H]([C@@H]1O)O)O)O)O DMG7XOC IK DSCFFEYYQKSRSV-FEPQRWDDSA-N DMG7XOC IU (1S,2S,4S,5R)-6-methoxycyclohexane-1,2,3,4,5-pentol DMG7XOC CA CAS 484-68-4 DMG7XOC CB CHEBI:28548 DMG7XOC DE Alzheimer disease DM21Z68 ID DM21Z68 DM21Z68 DN Nimacimab DM21Z68 HS Phase 2 DM21Z68 SN Namacizumab DM21Z68 CP Bird Rock Bio DM21Z68 DT Antibody DM21Z68 DE Diabetic nephropathy DMPER4A ID DMPER4A DMPER4A DN NIR178 DMPER4A HS Phase 2 DMPER4A CP Novartis Oncology East Hanover, DMPER4A DE Non-hodgkin lymphoma; Solid tumour/cancer DM81SDB ID DM81SDB DM81SDB DN Niravoline DM81SDB HS Phase 2 DM81SDB SN AC1L24CB; AC1Q1ZY1; N-methyl-2-(3-nitrophenyl)-N-[(2S)-2-pyrrolidin-1-yl-2,3-dihydro-1H-inden-1-yl]acetamide DM81SDB DT Small molecular drug DM81SDB PC 9821174 DM81SDB MW 379.5 DM81SDB FM C22H25N3O3 DM81SDB IC InChI=1S/C22H25N3O3/c1-23(21(26)14-16-7-6-9-18(13-16)25(27)28)22-19-10-3-2-8-17(19)15-20(22)24-11-4-5-12-24/h2-3,6-10,13,20,22H,4-5,11-12,14-15H2,1H3/t20-,22-/m0/s1 DM81SDB CS CN([C@@H]1[C@H](CC2=CC=CC=C12)N3CCCC3)C(=O)CC4=CC(=CC=C4)[N+](=O)[O-] DM81SDB IK ZSDAQBWGAOKTSI-UNMCSNQZSA-N DM81SDB IU N-methyl-2-(3-nitrophenyl)-N-[(1S,2S)-2-pyrrolidin-1-yl-2,3-dihydro-1H-inden-1-yl]acetamide DM81SDB CA CAS 130610-93-4 DM81SDB DE Pain DM8LBYT ID DM8LBYT DM8LBYT DN NIS793 DM8LBYT HS Phase 2 DM8LBYT CP Novartis Oncology East Hanover, DM8LBYT DE Solid tumour/cancer; Pancreatic ductal carcinoma DMQHBSX ID DMQHBSX DMQHBSX DN NITD609 DMQHBSX HS Phase 2 DMQHBSX SN Cipargamin; 1193314-23-6; NITD-609; NITD 609; UNII-Z7Q4FWA04P; (1'R,3'S)-5,7'-Dichloro-6'-fluoro-3'-methyl-2',3',4',9'-tetrahydrospiro[indoline-3,1'-pyrido[3,4-b]indol]-2-one; Z7Q4FWA04P; CHEMBL1082723; Spiro[3H-indole-3,1'-[1H]pyrido[3,4-b]indol]-2(1H)-one, 5,7'-dichloro-6'-fluoro-2',3',4',9'-tetrahydro-3'-methyl-, (1'R,3'S)-; Cipargamin [INN]; 1252008-89-1; GTPL9721; SCHEMBL1306342; DTXSID70152424; MolPort-039-337-269; ZINC49037032; BDBM50318666; AKOS027253851; SB16518; DB12306; CS-7486; NCGC00263785-01 DMQHBSX DT Small molecular drug DMQHBSX PC 44469321 DMQHBSX MW 390.2 DMQHBSX FM C19H14Cl2FN3O DMQHBSX IC InChI=1S/C19H14Cl2FN3O/c1-8-4-11-10-6-14(22)13(21)7-16(10)23-17(11)19(25-8)12-5-9(20)2-3-15(12)24-18(19)26/h2-3,5-8,23,25H,4H2,1H3,(H,24,26)/t8-,19+/m0/s1 DMQHBSX CS C[C@H]1CC2=C([C@]3(N1)C4=C(C=CC(=C4)Cl)NC3=O)NC5=CC(=C(C=C25)F)Cl DMQHBSX IK CKLPLPZSUQEDRT-WPCRTTGESA-N DMQHBSX IU (3R,3'S)-5,7'-dichloro-6'-fluoro-3'-methylspiro[1H-indole-3,1'-2,3,4,9-tetrahydropyrido[3,4-b]indole]-2-one DMQHBSX CA CAS 1193314-23-6 DMQHBSX DE Malaria DMAOUZV ID DMAOUZV DMAOUZV DN Nivatrotamab DMAOUZV HS Phase 2 DMAOUZV CP Memorial Sloan Kettering; Y-mAbs Therapeutics DMAOUZV DT Antibody DMAOUZV DE Solid tumour/cancer; Small-cell lung cancer DMUX8JZ ID DMUX8JZ DMUX8JZ DN Nivocasan DMUX8JZ HS Phase 2 DMUX8JZ SN GS-9450; LB-84451 DMUX8JZ CP LG Life Sciences Ltd DMUX8JZ PC 11633038 DMUX8JZ MW 415.4 DMUX8JZ FM C21H22FN3O5 DMUX8JZ IC InChI=1S/C21H22FN3O5/c1-12(2)20(19(27)24-16-9-17(26)29-21(16,28)11-22)10-15(25-30-20)18-14-6-4-3-5-13(14)7-8-23-18/h3-8,12,16,28H,9-11H2,1-2H3,(H,24,27)/t16-,20+,21+/m0/s1 DMUX8JZ CS CC(C)[C@]1(CC(=NO1)C2=NC=CC3=CC=CC=C32)C(=O)N[C@H]4CC(=O)O[C@@]4(CF)O DMUX8JZ IK VYFGDLGHHBUDTQ-ZLGUVYLKSA-N DMUX8JZ IU (5R)-N-[(2S,3S)-2-(fluoromethyl)-2-hydroxy-5-oxooxolan-3-yl]-3-isoquinolin-1-yl-5-propan-2-yl-4H-1,2-oxazole-5-carboxamide DMUX8JZ CA CAS 908253-63-4 DMUX8JZ DE Fibrosis DMTVGMZ ID DMTVGMZ DMTVGMZ DN NKP 608 DMTVGMZ HS Phase 2 DMTVGMZ SN AV608) DMTVGMZ CP Novartis; Avera Pharmaceuticals DMTVGMZ PC 9917079 DMTVGMZ MW 620 DMTVGMZ FM C31H24ClF6N3O2 DMTVGMZ IC InChI=1S/C31H24ClF6N3O2/c32-22-7-5-18(6-8-22)13-24-17-23(40-28(42)26-9-11-39-27-4-2-1-3-25(26)27)10-12-41(24)29(43)19-14-20(30(33,34)35)16-21(15-19)31(36,37)38/h1-9,11,14-16,23-24H,10,12-13,17H2,(H,40,42)/t23-,24+/m0/s1 DMTVGMZ CS C1CN([C@@H](C[C@H]1NC(=O)C2=CC=NC3=CC=CC=C23)CC4=CC=C(C=C4)Cl)C(=O)C5=CC(=CC(=C5)C(F)(F)F)C(F)(F)F DMTVGMZ IK NXLUTEDAEFXMQR-BJKOFHAPSA-N DMTVGMZ IU N-[(2R,4S)-1-[3,5-bis(trifluoromethyl)benzoyl]-2-[(4-chlorophenyl)methyl]piperidin-4-yl]quinoline-4-carboxamide DMTVGMZ CA CAS 177707-12-9 DMTVGMZ DE Mood disorder DMKD5ZO ID DMKD5ZO DMKD5ZO DN NN-8226 DMKD5ZO HS Phase 2 DMKD5ZO SN NNC-109-0012; IL-20 monoclonal antibody (inflammation), Novo Nordisk; Anti-IL20 (inflammation), ZymoGenetics/Novo Nordisk; Anti-IL20mAb (RA), ZymoGenetics/Novo Nordisk; Anti-interleukin-20 (rheumatoid arthritis), ZymoGenetics/Novo Nordisk DMKD5ZO CP ZymoGenetics Inc DMKD5ZO DT Antibody DMKD5ZO DE Psoriasis vulgaris DM3IEHP ID DM3IEHP DM3IEHP DN NN8555 DM3IEHP HS Phase 2 DM3IEHP CP Novo Nordisk DM3IEHP DE Rheumatoid arthritis; Crohn disease DMCFPBE ID DMCFPBE DMCFPBE DN NN8765 DMCFPBE HS Phase 2 DMCFPBE CP Novo Nordisk DMCFPBE DE Rheumatoid arthritis DMDTNOS ID DMDTNOS DMDTNOS DN NNC-0123-0000-0338 DMDTNOS HS Phase 2 DMDTNOS CP Novo Nordisk A/S DMDTNOS DE Diabetic complication DMU3KOH ID DMU3KOH DMU3KOH DN NNC-0151-0000-0000 DMU3KOH HS Phase 2 DMU3KOH SN Neutrazumab; Anti-C5aR monoclonal antibodies (rheumatoid arthritis/SLE), G2/Novo Nordisk DMU3KOH CP G2 Therapies Ltd DMU3KOH DT Antibody DMU3KOH DE Rheumatoid arthritis DMPZ97S ID DMPZ97S DMPZ97S DN NNZ-2566 DMPZ97S HS Phase 2 DMPZ97S SN Glypromate analogs (oral, neuroprotection), Neuren; NNZ-2566 (oral, neurodegeneration/injury); NNZ-2566 (oral, neurodegeneration/injury), Neuren DMPZ97S CP Neuren pharmaceuticals DMPZ97S DT Small molecular drug DMPZ97S PC 11318905 DMPZ97S MW 315.32 DMPZ97S FM C13H21N3O6 DMPZ97S IC InChI=1S/C13H21N3O6/c1-13(5-2-6-16(13)9(17)7-14)12(22)15-8(11(20)21)3-4-10(18)19/h8H,2-7,14H2,1H3,(H,15,22)(H,18,19)(H,20,21)/t8-,13-/m0/s1 DMPZ97S CS C[C@]1(CCCN1C(=O)CN)C(=O)N[C@@H](CCC(=O)O)C(=O)O DMPZ97S IK BUSXWGRAOZQTEY-SDBXPKJASA-N DMPZ97S IU (2S)-2-[[(2S)-1-(2-aminoacetyl)-2-methylpyrrolidine-2-carbonyl]amino]pentanedioic acid DMPZ97S CA CAS 853400-76-7 DMPZ97S DE Fragile X syndrome; Rett syndrome; Traumatic brain injury; Type-1 diabetes DME8IFQ ID DME8IFQ DME8IFQ DN Noberastine DME8IFQ HS Phase 2 DME8IFQ SN Flamizole; R-64947; R-72075 DME8IFQ CP Janssen Pharmaceutica NV DME8IFQ DT Small molecular drug DME8IFQ PC 60531 DME8IFQ MW 311.4 DME8IFQ FM C17H21N5O DME8IFQ IC InChI=1S/C17H21N5O/c1-12-4-5-14(23-12)11-22-16-15(3-2-8-19-16)21-17(22)20-13-6-9-18-10-7-13/h2-5,8,13,18H,6-7,9-11H2,1H3,(H,20,21) DME8IFQ CS CC1=CC=C(O1)CN2C3=C(C=CC=N3)N=C2NC4CCNCC4 DME8IFQ IK VNIOQSAWKLOGLY-UHFFFAOYSA-N DME8IFQ IU 3-[(5-methylfuran-2-yl)methyl]-N-piperidin-4-ylimidazo[4,5-b]pyridin-2-amine DME8IFQ CA CAS 110588-56-2 DME8IFQ DE Asthma DMEHOI1 ID DMEHOI1 DMEHOI1 DN Novaferon DMEHOI1 HS Phase 2 DMEHOI1 SN Recombinant interferon-like protein, Genova/Novagenetics/Novagen; Recombinant huIFN-alpha-like protein (cancer, viral infection), Genova/Novagenetics/Novagen DMEHOI1 CP Novagenetics Inc DMEHOI1 DE Colorectal cancer DMHG3UR ID DMHG3UR DMHG3UR DN NOX-E36 DMHG3UR HS Phase 2 DMHG3UR SN Monocyte chemoattractant protein-1 ligand inhibitor(spiegelmer, diabetic complications), NOXXON; MCP-1 inhibitor (spiegelmer/injectable, diabetic complications/diabetic nephropathy), NOXXON DMHG3UR CP NOXXON Pharma AG DMHG3UR DE Diabetic complication DM5HPZU ID DM5HPZU DM5HPZU DN NOX-H94 DM5HPZU HS Phase 2 DM5HPZU CP NOXXON Pharma AG; Avant Immunotherapeutics DM5HPZU DE Anemia DMP1W9Z ID DMP1W9Z DMP1W9Z DN NP-01 DMP1W9Z HS Phase 2 DMP1W9Z SN Vanadium (buccal, nanodroplet emulsion (Aonys), type 2 diabetes/metabolic syndrome), Medesis DMP1W9Z CP Medesis Pharma SA DMP1W9Z DE Type-2 diabetes DMLMZ6Q ID DMLMZ6Q DMLMZ6Q DN NP-2 DMLMZ6Q HS Phase 2 DMLMZ6Q SN NP2 Enkephalin; NPE-1; NPE-2; Enkephalin-expressing gene therapy (HSV carrier, pain), Diamyd; Enkephalin-expressinggene therapy (HSV carrier/NTDDS, pain), Nurel DMLMZ6Q CP Periphagen holdings DMLMZ6Q DT Small molecular drug DMLMZ6Q PC 16130887 DMLMZ6Q MW 3855 DMLMZ6Q FM C161H282N62O36S6 DMLMZ6Q IC InChI=1S/C161H282N62O36S6/c1-20-84(15)120(148(254)206-91(38-25-51-182-153(163)164)125(231)192-70-115(224)197-92(39-26-52-183-154(165)166)132(238)220-121(85(16)21-2)149(255)212-106(67-90-68-181-77-193-90)151(257)223-61-35-48-114(223)145(251)210-103(64-80(7)8)136(242)215-112(76-265)143(249)217-110(74-263)141(247)203-97(44-31-57-188-159(175)176)130(236)207-100(152(258)259)46-33-59-190-161(179)180)221-133(239)98(45-32-58-189-160(177)178)204-140(246)109(73-262)216-137(243)104(66-89-36-23-22-24-37-89)198-116(225)69-191-122(228)86(17)194-126(232)93(40-27-53-184-155(167)168)199-128(234)95(42-29-55-186-157(171)172)201-131(237)99(49-50-117(226)227)205-134(240)102(63-79(5)6)209-144(250)113-47-34-60-222(113)150(256)105(65-81(9)10)211-142(248)111(75-264)214-135(241)101(62-78(3)4)208-123(229)87(18)195-127(233)94(41-28-54-185-156(169)170)200-129(235)96(43-30-56-187-158(173)174)202-139(245)108(72-261)213-124(230)88(19)196-138(244)107(71-260)218-147(253)119(83(13)14)219-146(252)118(162)82(11)12/h22-24,36-37,68,77-88,91-114,118-121,260-265H,20-21,25-35,38-67,69-76,162H2,1-19H3,(H,181,193)(H,191,228)(H,192,231)(H,194,232)(H,195,233)(H,196,244)(H,197,224)(H,198,225)(H,199,234)(H,200,235)(H,201,237)(H,202,245)(H,203,247)(H,204,246)(H,205,240)(H,206,254)(H,207,236)(H,208,229)(H,209,250)(H,210,251)(H,211,248)(H,212,255)(H,213,230)(H,214,241)(H,215,242)(H,216,243)(H,217,249)(H,218,253)(H,219,252)(H,220,238)(H,221,239)(H,226,227)(H,258,259)(H4,163,164,182)(H4,165,166,183)(H4,167,168,184)(H4,169,170,185)(H4,171,172,186)(H4,173,174,187)(H4,175,176,188)(H4,177,178,189)(H4,179,180,190)/t84-,85-,86-,87-,88-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,118-,119-,120-,121-/m0/s1 DMLMZ6Q CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CN=CN1)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CS)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)N DMLMZ6Q IK AEUKDPKXTPNBNY-XEYRWQBLSA-N DMLMZ6Q IU (4S)-4-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-sulfanylpropanoyl]amino]propanoyl]amino]-3-sulfanylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylpentanoyl]pyrrolidine-2-carbonyl]amino]-4-methylpentanoyl]amino]-5-[[(2S)-5-carbamimidamido-1-[[(2S)-5-carbamimidamido-1-[[(2S)-1-[[2-[[(2S)-1-[[(2R)-1-[[(2S)-5-carbamimidamido-1-[[(2S,3S)-1-[[(2S)-5-carbamimidamido-1-[[2-[[(2S)-5-carbamimidamido-1-[[(2S,3S)-1-[[(2S)-1-[(2S)-2-[[(2S)-1-[[(2R)-1-[[(2R)-1-[[(2S)-5-carbamimidamido-1-[[(1S)-4-carbamimidamido-1-carboxybutyl]amino]-1-oxopentan-2-yl]amino]-1-oxo-3-sulfanylpropan-2-yl]amino]-1-oxo-3-sulfanylpropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxopentan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]amino]-1-oxo-3-sulfanylpropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]amino]-1-oxopropan-2-yl]amino]-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]amino]-5-oxopentanoic acid DMLMZ6Q CA CAS 88086-40-2 DMLMZ6Q DE Influenza A virus infection DME6KAF ID DME6KAF DME6KAF DN NPC-15199 DME6KAF HS Phase 2 DME6KAF SN 2-(9H-Fluoren-9-ylmethoxycarbonylamino)-4-methylpentanoic acid; F-L-Leu; CHEMBL294989; PPARgamma Activator, Fmoc-Leu; 2-(9H-fluoren-9-ylmethoxycarbonylamino)-4-methylpentanoic acid; Fmoc-DL-leucine; N-alpha-Fmoc-L-leucine; NSC334290; ACMC-209iik; AC1L1HVH; n-[(9h-fluoren-9-ylmethoxy)carbonyl]leucin; ACMC-2099ky; AC1Q5SK7; 126727-03-5; 2-(9H-Fluoren-9-ylmethoxycarbonylamino)-4-methyl-pentanoic acid; (2S)-2-[(fluoren-9-ylmethoxy)carbonylamino]-4-methylpentanoic acid; GTPL2705; SCHEMBL1002861; CHEBI:91726; CTK8G6077; MolPort-003-700-319; HMS3266H19; SBB056939; IN1334; BDBM50034787; AKOS017268980 DME6KAF CP Scios Inc DME6KAF DT Small molecular drug DME6KAF PC 1549133 DME6KAF MW 353.4 DME6KAF FM C21H23NO4 DME6KAF IC InChI=1S/C21H23NO4/c1-13(2)11-19(20(23)24)22-21(25)26-12-18-16-9-5-3-7-14(16)15-8-4-6-10-17(15)18/h3-10,13,18-19H,11-12H2,1-2H3,(H,22,25)(H,23,24)/t19-/m0/s1 DME6KAF CS CC(C)C[C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C3=CC=CC=C13 DME6KAF IK CBPJQFCAFFNICX-IBGZPJMESA-N DME6KAF IU (2S)-2-(9H-fluoren-9-ylmethoxycarbonylamino)-4-methylpentanoic acid DME6KAF CA CAS 35661-60-0 DME6KAF DE Inflammation DM9VEAL ID DM9VEAL DM9VEAL DN NPC-1C DM9VEAL HS Phase 2 DM9VEAL SN Ensituximab DM9VEAL CP Neogenix Oncology DM9VEAL DT Antibody DM9VEAL DE Colorectal cancer; Pancreatic tumour; Pancreatic cancer DM3DQXG ID DM3DQXG DM3DQXG DN NPSP-795 DM3DQXG HS Phase 2 DM3DQXG SN NPSP-790; SB-423557; SB-423557A; SB-423562; SB-423562A DM3DQXG CP GlaxoSmithKline plc DM3DQXG PC 9910902 DM3DQXG MW 436.5 DM3DQXG FM C26H32N2O4 DM3DQXG IC InChI=1S/C26H32N2O4/c1-26(2,14-19-11-20-5-3-4-6-21(20)12-19)28-16-23(29)17-32-24-13-18(8-10-25(30)31)7-9-22(24)15-27/h3-7,9,13,19,23,28-29H,8,10-12,14,16-17H2,1-2H3,(H,30,31)/t23-/m1/s1 DM3DQXG CS CC(C)(CC1CC2=CC=CC=C2C1)NC[C@H](COC3=C(C=CC(=C3)CCC(=O)O)C#N)O DM3DQXG IK NJBFJCJKWWIKRD-HSZRJFAPSA-N DM3DQXG IU 3-[4-cyano-3-[(2R)-3-[[1-(2,3-dihydro-1H-inden-2-yl)-2-methylpropan-2-yl]amino]-2-hydroxypropoxy]phenyl]propanoic acid DM3DQXG CA CAS 351490-27-2 DM3DQXG DE Osteoporosis DMYXOU2 ID DMYXOU2 DMYXOU2 DN NRX-4204 DMYXOU2 HS Phase 2 DMYXOU2 SN AGN-190205; AGN-191659; AGN-191701; AGN-192326; AGN-192327; AGN-192509; AGN-192599; AGN-192870; AGN-194277; AGN-195393; AGN-4202; ALRT-326; ALRT-4204; LGD-4204; LGD-4326; NRX-194202; RXR ligands, ALRT; RXR ligands, Allergan; Retinoid X receptor agonists, ALRT; Retinoid X receptor agonists, Allergan; VTP-4204; RXR agonists, Allergan/Pfizer; Rexinoid receptor agonist (cancer), NuRx; RXR agonists (cancer/ diabetes), Vitae Pharmaceuticals; RXR agonists, Allergan/Parke-Davis DMYXOU2 CP Allergan Ligand Retinoid Therapeutics Inc DMYXOU2 DT Small molecular drug DMYXOU2 PC 9863342 DMYXOU2 MW 352.5 DMYXOU2 FM C24H32O2 DMYXOU2 IC InChI=1S/C24H32O2/c1-16(13-21(25)26)7-8-18-15-24(18,6)17-9-10-19-20(14-17)23(4,5)12-11-22(19,2)3/h7-10,13-14,18H,11-12,15H2,1-6H3,(H,25,26)/b8-7+,16-13+ DMYXOU2 CS C/C(=C\\C(=O)O)/C=C/C1CC1(C)C2=CC3=C(C=C2)C(CCC3(C)C)(C)C DMYXOU2 IK BOOOLEGQBVUTKC-YWRSBGDESA-N DMYXOU2 IU (2E,4E)-3-methyl-5-[2-methyl-2-(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)cyclopropyl]penta-2,4-dienoic acid DMYXOU2 DE Diabetic complication DM9EFH0 ID DM9EFH0 DM9EFH0 DN NS 1209 DM9EFH0 HS Phase 2 DM9EFH0 CP NeuroSearch DM9EFH0 TC Analgesics DM9EFH0 DT Small molecular drug DM9EFH0 PC 135456058 DM9EFH0 MW 516.6 DM9EFH0 FM C24H28N4O7S DM9EFH0 IC InChI=1S/C24H28N4O7S/c1-27(2)36(33,34)15-6-4-14(5-7-15)17-12-18-21(19-13-28(3)10-8-16(17)19)25-23(30)22(18)26-35-20(9-11-29)24(31)32/h4-7,12,20,29H,8-11,13H2,1-3H3,(H,31,32)(H,25,26,30) DM9EFH0 CS CN1CCC2=C(C1)C3=C(C=C2C4=CC=C(C=C4)S(=O)(=O)N(C)C)/C(=N/OC(CCO)C(=O)O)/C(=O)N3 DM9EFH0 IK CFJRSKULEDUDKL-UHFFFAOYSA-N DM9EFH0 IU 2-[(Z)-[5-[4-(dimethylsulfamoyl)phenyl]-8-methyl-2-oxo-1,6,7,9-tetrahydropyrrolo[3,2-h]isoquinolin-3-ylidene]amino]oxy-4-hydroxybutanoic acid DM9EFH0 CA CAS 245063-59-6 DM9EFH0 DE Neuropathic pain; Epilepsy DMI5HFU ID DMI5HFU DMI5HFU DN NS 2359 DMI5HFU HS Phase 2 DMI5HFU SN FPTPUYCHSWIWIB-FUTJPDQTSA-N; SCHEMBL2640060; (1R,2R,3S,5S)-2-methoxymethyl-3-(3,4-dichlorophenyl)-8-azabicyclo-[321]octane; GSK372475 DMI5HFU CP GlaxoSmithKline DMI5HFU DT Small molecular drug DMI5HFU PC 68470595 DMI5HFU MW 314.2 DMI5HFU FM C16H21Cl2NO DMI5HFU IC InChI=1S/C16H21Cl2NO/c1-19-11-4-6-16(19)13(9-20-2)12(8-11)10-3-5-14(17)15(18)7-10/h3,5,7,11-13,16H,4,6,8-9H2,1-2H3/t11-,12+,13+,16+/m0/s1 DMI5HFU CS CN1[C@H]2CC[C@@H]1[C@@H]([C@H](C2)C3=CC(=C(C=C3)Cl)Cl)COC DMI5HFU IK PGYDXVBZYKQYCS-VPWBDBDCSA-N DMI5HFU IU (1R,2R,3S,5S)-3-(3,4-dichlorophenyl)-2-(methoxymethyl)-8-methyl-8-azabicyclo[3.2.1]octane DMI5HFU CA CAS 195875-68-4 DMI5HFU DE Cocaine addiction; Attention deficit hyperactivity disorder; Mood disorder DMMUR6V ID DMMUR6V DMMUR6V DN NS-2710 DMMUR6V HS Phase 2 DMMUR6V SN ME-3127 DMMUR6V CP NeuroSearch A/S DMMUR6V DT Small molecular drug DMMUR6V PC 9863520 DMMUR6V MW 356.4 DMMUR6V FM C22H20N4O DMMUR6V IC InChI=1S/C22H20N4O/c1-3-27-25-16(2)17-9-10-22-21(13-17)24-15-26(22)20-8-4-6-18(12-20)19-7-5-11-23-14-19/h4-15H,3H2,1-2H3/b25-16+ DMMUR6V CS CCO/N=C(\\C)/C1=CC2=C(C=C1)N(C=N2)C3=CC=CC(=C3)C4=CN=CC=C4 DMMUR6V IK NHJFEXZXSCFYRX-PCLIKHOPSA-N DMMUR6V IU (E)-N-ethoxy-1-[1-(3-pyridin-3-ylphenyl)benzimidazol-5-yl]ethanimine DMMUR6V CA CAS 184220-36-8 DMMUR6V DE Anxiety disorder DM3H82Q ID DM3H82Q DM3H82Q DN NS-7 DM3H82Q HS Phase 2 DM3H82Q SN (3r)-3-Cyclopentyl-6-Methyl-7-[(4-Methylpiperazin-1-Yl)sulfonyl]-3,4-Dihydro-2h-1,2-Benzothiazine 1,1-Dioxide; DB08305; NS7 DM3H82Q TC Analgesics DM3H82Q DT Small molecular drug DM3H82Q PC 9800750 DM3H82Q MW 393.9 DM3H82Q FM C21H29ClFN3O DM3H82Q IC InChI=1S/C21H28FN3O.ClH/c1-17-23-20(18-8-10-19(22)11-9-18)16-21(24-17)26-15-7-3-6-14-25-12-4-2-5-13-25;/h8-11,16H,2-7,12-15H2,1H3;1H DM3H82Q CS CC1=NC(=CC(=N1)OCCCCCN2CCCCC2)C3=CC=C(C=C3)F.Cl DM3H82Q IK VLYZLIWXMLUPLD-UHFFFAOYSA-N DM3H82Q IU 4-(4-fluorophenyl)-2-methyl-6-(5-piperidin-1-ylpentoxy)pyrimidine;hydrochloride DM3H82Q CA CAS 178429-67-9 DM3H82Q DE Nerve injury DMPJQZG ID DMPJQZG DMPJQZG DN NSC-645809 DMPJQZG HS Phase 2 DMPJQZG SN XF-02; NSC-645809; C-1311; Imidacrine; Symadex; CHEMBL3545337; XJYNBZQTAZDMHZ-UHFFFAOYSA-N; Imidazoacridone dihydrocheloride hydrate; 138154-55-9; 5-((2-(diethylamino)ethyl)amino)-8-hydroxy-6H-imidazo[4,5,1-de]acridin-6-one dihydrochloride hydrate DMPJQZG DT Small molecular drug DMPJQZG PC 132127 DMPJQZG MW 350.4 DMPJQZG FM C20H22N4O2 DMPJQZG IC InChI=1S/C20H22N4O2/c1-3-23(4-2)10-9-21-15-6-7-16-19-18(15)20(26)14-11-13(25)5-8-17(14)24(19)12-22-16/h5-8,11-12,21,25H,3-4,9-10H2,1-2H3 DMPJQZG CS CCN(CC)CCNC1=C2C3=C(C=C1)N=CN3C4=C(C2=O)C=C(C=C4)O DMPJQZG IK CUNDRHORZHFPLY-UHFFFAOYSA-N DMPJQZG IU 10-[2-(diethylamino)ethylamino]-5-hydroxy-1,14-diazatetracyclo[7.6.1.02,7.013,16]hexadeca-2(7),3,5,9,11,13(16),14-heptaen-8-one DMPJQZG CA CAS 138154-39-9 DMPJQZG DE Breast cancer DMRYLBW ID DMRYLBW DMRYLBW DN NTO-1151 DMRYLBW HS Phase 2 DMRYLBW CP Nanotherapeutics; national cancer institute DMRYLBW DE Cervical cancer DMORNVB ID DMORNVB DMORNVB DN NU-172 DMORNVB HS Phase 2 DMORNVB CP ARCA biopharma DMORNVB DE Thrombosis DMO0C5R ID DMO0C5R DMO0C5R DN NU300 DMO0C5R HS Phase 2 DMO0C5R CP Nuron biotech DMO0C5R DE Influenza virus infection DMOJA5G ID DMOJA5G DMOJA5G DN Nuplazid DMOJA5G HS Phase 2 DMOJA5G SN Pimavanserin tartrate; UNII-NA83F1SJSR; 706782-28-7; ACP 103; ACP-103; 706782-28-7 (tartrate); NA83F1SJSR; Pimavanserin tartrate [USAN]; Bis(1-(4-Fluorobenzyl)-1-(1-methylpiperidin-4-yl)-3-(4-(2-methylpropoxy)benzyl)urea) (2R,3R)-2,3-dihydroxybutanedioate; Pimavanserin tartrate (USAN); 1-(4-fluorobenzyl)-3-(4-isobutoxybenzyl)-1-(1-methylpiperidin-4-yl)urea, ((2R,3R)-2,3-dihydroxysuccinate) (2:1); Nuplazide (TN); pimavanserin hemitartrate; DTXSID50220958; CHEBI:133014; HMS3886L06; HY-14557A; Pimavanserin Dihydroxysuccinate(2:1); AKOS027327334; CCG-270608; CS-7954; 1-(4-fluorobenzyl)-3-(4-isobutoxybenzyl)-1-(1-methylpiperidin-4-yl)urea (2R,3R)-2,3-dihydroxysuccinate; AC-29901; AS-56699; N-(4-Fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1); Urea, N-((4-fluorophenyl)methyl)-N-(1-methyl-4-piperidinyl)-N'-((4-(2-methylpropoxy)phenyl)methyl)-, (2R,3R)-2,3-dihydroxybutanedioate (2:1); D08969; Q27284759; bis(4-{[(4-fluorophenyl)methyl]({[4-(2-methylpropoxy)phenyl]methyl}carbamoyl)amino}-1-methylpiperidin-1-ium) (2R,3R)-2,3-dihydroxybutanedioate; bis{N-[(4-fluorophenyl)methyl]-N-(1-methylpiperidin-4-yl)-N'-{[4-(2-methylpropoxy)phenyl]methyl}urea} (2R,3R)-2,3-dihydroxybutanedioate DMOJA5G CP ACADIA Pharmaceuticals DMOJA5G DT Small molecular drug DMOJA5G PC 11672491 DMOJA5G MW 1005.2 DMOJA5G FM C54H74F2N6O10 DMOJA5G IC InChI=1S/2C25H34FN3O2.C4H6O6/c2*1-19(2)18-31-24-10-6-20(7-11-24)16-27-25(30)29(23-12-14-28(3)15-13-23)17-21-4-8-22(26)9-5-21;5-1(3(7)8)2(6)4(9)10/h2*4-11,19,23H,12-18H2,1-3H3,(H,27,30);1-2,5-6H,(H,7,8)(H,9,10)/t;;1-,2-/m..1/s1 DMOJA5G CS CC(C)COC1=CC=C(C=C1)CNC(=O)N(CC2=CC=C(C=C2)F)C3CCN(CC3)C.CC(C)COC1=CC=C(C=C1)CNC(=O)N(CC2=CC=C(C=C2)F)C3CCN(CC3)C.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O DMOJA5G IK RGSULKHNAKTFIZ-CEAXSRTFSA-N DMOJA5G IU (2R,3R)-2,3-dihydroxybutanedioic acid;1-[(4-fluorophenyl)methyl]-1-(1-methylpiperidin-4-yl)-3-[[4-(2-methylpropoxy)phenyl]methyl]urea DMOJA5G CA CAS 706782-28-7 DMOJA5G CB CHEBI:133014 DMOJA5G DE Alzheimer disease DMTYXQF ID DMTYXQF DMTYXQF DN NVP-AUY922 DMTYXQF HS Phase 2 DMTYXQF SN Luminespib; 747412-49-3; AUY922; VER-52296; AUY-922; UNII-C6V1DAR5EB; AUY922 (NVP-AUY922); Luminespib (NVP-AUY922); NVP-AUY 922; 5-(2,4-dihydroxy-5-isopropylphenyl)-N-ethyl-4-(4-(morpholinomethyl)phenyl)isoxazole-3-carboxamide; C6V1DAR5EB; Luminespib (AUY-922, NVP-AUY922); CHEBI:83656; 5-[2,4-DIHYDROXY-5-ISOPROPYLPHENYL]-N-ETHYL-4-[4-(4-MORPHOLINYLMETHYL)PHENYL]-3-ISOXAZOLECARBOXAMIDE; AK174786; 5-[2,4-Dihydroxy-5-(1-Methylethyl)phenyl]-N-Ethyl-4-[4-(Morpholin-4-Ylmethyl)phenyl]isoxazole-3-Carboxamide DMTYXQF CP Vernalis; Novartis DMTYXQF TC Anticancer Agents DMTYXQF DT Small molecular drug DMTYXQF PC 135539077 DMTYXQF MW 465.5 DMTYXQF FM C26H31N3O5 DMTYXQF IC InChI=1S/C26H31N3O5/c1-4-27-26(32)24-23(18-7-5-17(6-8-18)15-29-9-11-33-12-10-29)25(34-28-24)20-13-19(16(2)3)21(30)14-22(20)31/h5-8,13-14,16,30-31H,4,9-12,15H2,1-3H3,(H,27,32) DMTYXQF CS CCNC(=O)C1=NOC(=C1C2=CC=C(C=C2)CN3CCOCC3)C4=CC(=C(C=C4O)O)C(C)C DMTYXQF IK NDAZATDQFDPQBD-UHFFFAOYSA-N DMTYXQF IU 5-(2,4-dihydroxy-5-propan-2-ylphenyl)-N-ethyl-4-[4-(morpholin-4-ylmethyl)phenyl]-1,2-oxazole-3-carboxamide DMTYXQF CA CAS 747412-49-3 DMTYXQF CB CHEBI:83656 DMTYXQF DE Multiple myeloma; Solid tumour/cancer DM2UJ1H ID DM2UJ1H DM2UJ1H DN NW-3509 DM2UJ1H HS Phase 2 DM2UJ1H SN NW-3381; Sodium channel blockers (epilepsy/pain/mania), Newron DM2UJ1H CP Newron pharmaceuticals DM2UJ1H DE Schizophrenia DMMBAIH ID DMMBAIH DMMBAIH DN NXN-188 DMMBAIH HS Phase 2 DMMBAIH SN 6634-56-6; 4,4-bis[4-hydroxy-3-(morpholin-4-ylmethyl)phenyl]pentanoic acid; NSC51920; AC1Q5VTF; AC1L6AFP; CTK5C4317; ZINC4721635; NSC-51920; AKOS030583716; KB-274877 DMMBAIH CP Neuraxon DMMBAIH DT Small molecular drug DMMBAIH PC 242911 DMMBAIH MW 484.6 DMMBAIH FM C27H36N2O6 DMMBAIH IC InChI=1S/C27H36N2O6/c1-27(7-6-26(32)33,22-2-4-24(30)20(16-22)18-28-8-12-34-13-9-28)23-3-5-25(31)21(17-23)19-29-10-14-35-15-11-29/h2-5,16-17,30-31H,6-15,18-19H2,1H3,(H,32,33) DMMBAIH CS CC(CCC(=O)O)(C1=CC(=C(C=C1)O)CN2CCOCC2)C3=CC(=C(C=C3)O)CN4CCOCC4 DMMBAIH IK JWNUBAIGCVTLMJ-UHFFFAOYSA-N DMMBAIH IU 4,4-bis[4-hydroxy-3-(morpholin-4-ylmethyl)phenyl]pentanoic acid DMMBAIH CA CAS 6634-56-6 DMMBAIH DE Migraine DMWVBS2 ID DMWVBS2 DMWVBS2 DN NXN-462 DMWVBS2 HS Phase 2 DMWVBS2 SN NNOS inhibitor (chronic headache), Neuraxon; NNOS inhibitor (neuropathic pain), NeurAxon DMWVBS2 CP Neuraxon DMWVBS2 DE Headache DM1P60V ID DM1P60V DM1P60V DN NYX-2925 DM1P60V HS Phase 2 DM1P60V CP Aptinyx Evanston, IL DM1P60V DE Peripheral neuropathy; Fibromyalgia DMX04O8 ID DMX04O8 DMX04O8 DN NYX-2925 DMX04O8 HS Phase 2 DMX04O8 SN 2012536-16-0 DMX04O8 CP Aptinyx DMX04O8 DT Small molecular drug DMX04O8 PC 134820579 DMX04O8 MW 297.35 DMX04O8 FM C14H23N3O4 DMX04O8 IC InChI=1S/C14H23N3O4/c1-8(2)12(20)17-6-4-5-14(17)7-16(13(14)21)10(9(3)18)11(15)19/h8-10,18H,4-7H2,1-3H3,(H2,15,19)/t9-,10+,14-/m0/s1 DMX04O8 CS C[C@@H]([C@H](C(=O)N)N1C[C@]2(C1=O)CCCN2C(=O)C(C)C)O DMX04O8 IK NFXPEHLDVKVVKA-RBZYPMLTSA-N DMX04O8 IU (2R,3S)-3-hydroxy-2-[(4S)-5-(2-methylpropanoyl)-3-oxo-2,5-diazaspiro[3.4]octan-2-yl]butanamide DMX04O8 DE Diabetic neuropathy; Fibromyalgia DMAVM2E ID DMAVM2E DMAVM2E DN NYX-783 DMAVM2E HS Phase 2 DMAVM2E CP Aptinyx DMAVM2E DT Small molecular drug DMAVM2E DE Post-traumatic stress disorder DMXM34I ID DMXM34I DMXM34I DN O-304 DMXM34I HS Phase 2 DMXM34I SN 1261289-04-6; O304; 4-chloro-N-(2-(4-chlorobenzyl)-3-oxo-2,3-dihydro-1,2,4-thiadiazol-5-yl)benzamide; 4-chloro-N-[2-[(4-chlorophenyl)methyl]-2,3-dihydro-3-oxo-1,2,4-thiadiazol-5-yl]-benzamide; SCHEMBL1050337; BCP29039; EX-A1990; MFCD31657425; 4-chloro-N-[2-[(4-chlorophenyl)methyl]-3-oxo-1,2,4-thiadiazol-5-yl]benzamide; BS-14854; HY-112233; CS-0044210; O 304; S0795 DMXM34I CP Betagenon DMXM34I DT Small molecular drug DMXM34I PC 50923806 DMXM34I MW 380.2 DMXM34I FM C16H11Cl2N3O2S DMXM34I IC InChI=1S/C16H11Cl2N3O2S/c17-12-5-1-10(2-6-12)9-21-16(23)20-15(24-21)19-14(22)11-3-7-13(18)8-4-11/h1-8H,9H2,(H,19,20,22,23) DMXM34I CS C1=CC(=CC=C1CN2C(=O)N=C(S2)NC(=O)C3=CC=C(C=C3)Cl)Cl DMXM34I IK WEDWLYRQKUTOAX-UHFFFAOYSA-N DMXM34I IU 4-chloro-N-[2-[(4-chlorophenyl)methyl]-3-oxo-1,2,4-thiadiazol-5-yl]benzamide DMXM34I DE Type 2 diabetes DMPF9ZM ID DMPF9ZM DMPF9ZM DN Obatoclax DMPF9ZM HS Phase 2 DMPF9ZM SN CHEMBL408194; UNII-QN4128B52A; QN4128B52A; SCHEMBL631676; SCHEMBL16340850; BDBM50376902; ZINC136873052; DB12191; NCGC00387855-01; BRD-K15600710-066-01-7 DMPF9ZM CP Cephalon DMPF9ZM DT Small molecular drug DMPF9ZM PC 11404337 DMPF9ZM MW 317.4 DMPF9ZM FM C20H19N3O DMPF9ZM IC InChI=1S/C20H19N3O/c1-12-8-13(2)21-16(12)10-19-20(24-3)11-18(23-19)17-9-14-6-4-5-7-15(14)22-17/h4-11,21,23H,1-3H3/b18-17-,19-10- DMPF9ZM CS CC1=CC(=C(N1)/C=C\\2/C(=C/C(=C/3\\C=C4C=CC=CC4=N3)/N2)OC)C DMPF9ZM IK CVCLJVVBHYOXDC-IAZSKANUSA-N DMPF9ZM IU (2Z)-2-[(5Z)-5-[(3,5-dimethyl-1H-pyrrol-2-yl)methylidene]-4-methoxypyrrol-2-ylidene]indole DMPF9ZM CA CAS 803712-67-6 DMPF9ZM DE Solid tumour/cancer DMJIBSG ID DMJIBSG DMJIBSG DN OBE-101 DMJIBSG HS Phase 2 DMJIBSG CP OBEcure DMJIBSG DE Obesity DM5D6Y7 ID DM5D6Y7 DM5D6Y7 DN OBI-3424 DM5D6Y7 HS Phase 2 DM5D6Y7 SN UNII-X6SH5T8H76; X6SH5T8H76; CHEMBL4297474; SCHEMBL20870529; 2097713-68-1; 3-(5-((1R)-1-(Bis(aziridin-1-yl(phosphoryloxy)ethyl)-2-nitrophenoxy)-N,N-dimethylbenzamide; Phosphinic acid, P,P-bis(1-aziridinyl)-, (1R)-1-(3-(3-((dimethylamino)carbonyl)phenoxy)-4-nitrophenyl)ethyl ester DM5D6Y7 CP OBI Pharma DM5D6Y7 DT Small molecular drug DM5D6Y7 PC 126961329 DM5D6Y7 MW 460.4 DM5D6Y7 FM C21H25N4O6P DM5D6Y7 IC InChI=1S/C21H25N4O6P/c1-15(31-32(29,23-9-10-23)24-11-12-24)16-7-8-19(25(27)28)20(14-16)30-18-6-4-5-17(13-18)21(26)22(2)3/h4-8,13-15H,9-12H2,1-3H3/t15-/m1/s1 DM5D6Y7 CS C[C@H](C1=CC(=C(C=C1)[N+](=O)[O-])OC2=CC=CC(=C2)C(=O)N(C)C)OP(=O)(N3CC3)N4CC4 DM5D6Y7 IK NWGZZGNICQFUHV-OAHLLOKOSA-N DM5D6Y7 IU 3-[5-[(1R)-1-[bis(aziridin-1-yl)phosphoryloxy]ethyl]-2-nitrophenoxy]-N,N-dimethylbenzamide DM5D6Y7 CA CAS 2097713-68-1 DM5D6Y7 DE Hepatocellular carcinoma; Prostate cancer; Solid tumour/cancer; Acute lymphoblastic leukaemia DMVXZC4 ID DMVXZC4 DMVXZC4 DN OBP-601 DMVXZC4 HS Phase 2 DMVXZC4 SN Festinavir; Ed4T; Nucleoside reverse transcriptase inhibitor (HIV infection), Oncolys; Nucleoside reverse transcriptase inhibitor (HIV infection), Yale; 4'-Ed4T; 4'-ethynylstavudine DMVXZC4 CP Bristol-myers squibb DMVXZC4 DT Small molecular drug DMVXZC4 PC 3008897 DMVXZC4 MW 248.23 DMVXZC4 FM C12H12N2O4 DMVXZC4 IC InChI=1S/C12H12N2O4/c1-3-12(7-15)5-4-9(18-12)14-6-8(2)10(16)13-11(14)17/h1,4-6,9,15H,7H2,2H3,(H,13,16,17)/t9-,12+/m1/s1 DMVXZC4 CS CC1=CN(C(=O)NC1=O)[C@H]2C=C[C@](O2)(CO)C#C DMVXZC4 IK OSYWBJSVKUFFSU-SKDRFNHKSA-N DMVXZC4 IU 1-[(2R,5R)-5-ethynyl-5-(hydroxymethyl)-2H-furan-2-yl]-5-methylpyrimidine-2,4-dione DMVXZC4 CA CAS 634907-30-5 DMVXZC4 DE Human immunodeficiency virus-1 infection DM1JBD8 ID DM1JBD8 DM1JBD8 DN OC-000459 DM1JBD8 HS Phase 2 DM1JBD8 SN OC-1768; OC-2125; OC-2184; OC-459; OC-499; ODC-9101; CRTH2 antagonists (asthma/allergy), Oxagen DM1JBD8 CP Oxagen Ltd DM1JBD8 DT Small molecular drug DM1JBD8 PC 11462174 DM1JBD8 MW 348.4 DM1JBD8 FM C21H17FN2O2 DM1JBD8 IC InChI=1S/C21H17FN2O2/c1-13-17(11-16-8-6-14-4-2-3-5-19(14)23-16)18-10-15(22)7-9-20(18)24(13)12-21(25)26/h2-10H,11-12H2,1H3,(H,25,26) DM1JBD8 CS CC1=C(C2=C(N1CC(=O)O)C=CC(=C2)F)CC3=NC4=CC=CC=C4C=C3 DM1JBD8 IK FATGTHLOZSXOBC-UHFFFAOYSA-N DM1JBD8 IU 2-[5-fluoro-2-methyl-3-(quinolin-2-ylmethyl)indol-1-yl]acetic acid DM1JBD8 CA CAS 851723-84-7 DM1JBD8 DE Allergy DMP6B59 ID DMP6B59 DMP6B59 DN Ocaperidone DMP6B59 HS Phase 2 DMP6B59 SN Ocaperidona; 129029-23-8; UNII-26HUS7139V; 3-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)ethyl)-2,9-dimethyl-4H-pyrido(1,2-a)pyrimidin-4-one; 26HUS7139V; Ocaperidonum; Ocaperidonum [INN-Latin]; Ocaperidona [INN-Spanish]; 4H-Pyrido[1,2-a]pyrimidin-4-one,3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2,9-dimethyl-; Ocaperidone (USAN); Ocaperidone [USAN:INN:BAN]; 3-[2-[4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethyl-4H-pyrido[1,2-a]pyrimidin-4-one; Ocaperidona; 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethylpyrido[1,2-a]pyrimidin-4-one; 8-[2-[4-(6-fluorobenzo[d]isoxazol-3-yl)-1-piperidyl]ethyl]-2,9-dimethyl-6,10-diazabicyclo[440]deca-2,4,8,10-tetraen-7-one; FG-3019 DMP6B59 CP Johnson & Johnson DMP6B59 DT Small molecular drug DMP6B59 PC 71351 DMP6B59 MW 420.5 DMP6B59 FM C24H25FN4O2 DMP6B59 IC InChI=1S/C24H25FN4O2/c1-15-4-3-10-29-23(15)26-16(2)19(24(29)30)9-13-28-11-7-17(8-12-28)22-20-6-5-18(25)14-21(20)31-27-22/h3-6,10,14,17H,7-9,11-13H2,1-2H3 DMP6B59 CS CC1=CC=CN2C1=NC(=C(C2=O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F)C DMP6B59 IK ZZQNEJILGNNOEP-UHFFFAOYSA-N DMP6B59 IU 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethylpyrido[1,2-a]pyrimidin-4-one DMP6B59 CA CAS 129029-23-8 DMP6B59 DE Schizoaffective disorder; Schizophrenia; Idiopathic pulmonary fibrosis; Type-2 diabetes; Diabetic nephropathy; Pancreatic cancer DM8TDBY ID DM8TDBY DM8TDBY DN OCFENTANIL DM8TDBY HS Phase 2 DM8TDBY SN Ocfentanil < Rec INN; A-3217 (hydrochloride); N-(2-Fluorophenyl)-2-methoxy-N-[1-(2-phenylethyl)-4-piperidinyl]acetamide; 1-(2-Phenylethyl)-4-[N-(2-fluorophenyl)methoxyacetamido]piperidine; 2'-Fluoro-2-methoxy-N-(1-phenethyl-4-piperidinyl)acetanilide DM8TDBY DT Small molecular drug DM8TDBY PC 60575 DM8TDBY MW 370.5 DM8TDBY FM C22H27FN2O2 DM8TDBY IC InChI=1S/C22H27FN2O2/c1-27-17-22(26)25(21-10-6-5-9-20(21)23)19-12-15-24(16-13-19)14-11-18-7-3-2-4-8-18/h2-10,19H,11-17H2,1H3 DM8TDBY CS COCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3F DM8TDBY IK NYISTOZKVCMVEL-UHFFFAOYSA-N DM8TDBY IU N-(2-fluorophenyl)-2-methoxy-N-[1-(2-phenylethyl)piperidin-4-yl]acetamide DM8TDBY CA CAS 101343-69-5 DM8TDBY DE Pain DMT9QI2 ID DMT9QI2 DMT9QI2 DN OCV-101 DMT9QI2 HS Phase 2 DMT9QI2 SN OTS-11101 DMT9QI2 CP OncoTherapy Science Inc DMT9QI2 DE Pancreatic cancer DMK0MJP ID DMK0MJP DMK0MJP DN Odelepran DMK0MJP HS Phase 2 DMK0MJP SN Odelepran hydrochloride; LY2196044 HCl; LY-2196044; OpRA (alcohol dependence), Eli Lilly; OpRA II (alcoholism), Eli Lilly; Opioid receptor antagonist (alcoholism), Eli Lilly DMK0MJP CP Eli Lilly & Co DMK0MJP DT Small molecular drug DMK0MJP PC 10457387 DMK0MJP MW 373.4 DMK0MJP FM C20H24FN3O3 DMK0MJP IC InChI=1S/C20H24FN3O3/c21-17-11-15(12-23-8-5-14-6-9-26-10-7-14)1-3-18(17)27-19-4-2-16(13-24-19)20(22)25/h1-4,11,13-14,23H,5-10,12H2,(H2,22,25) DMK0MJP CS C1COCCC1CCNCC2=CC(=C(C=C2)OC3=NC=C(C=C3)C(=O)N)F DMK0MJP IK QWNDOCKIKKQJNN-UHFFFAOYSA-N DMK0MJP IU 6-[2-fluoro-4-[[2-(oxan-4-yl)ethylamino]methyl]phenoxy]pyridine-3-carboxamide DMK0MJP CA CAS 676501-25-0 DMK0MJP DE Alcohol dependence DMJL4A7 ID DMJL4A7 DMJL4A7 DN O-desulfated heparin DMJL4A7 HS Phase 2 DMJL4A7 SN Intravenous DMJL4A7 CP ParinGenix DMJL4A7 DE Chronic obstructive pulmonary disease DMWCBY7 ID DMWCBY7 DMWCBY7 DN Odiparcil DMWCBY7 HS Phase 2 DMWCBY7 SN SB-424323 DMWCBY7 CP GlaxoSmithKline DMWCBY7 DT Small molecular drug DMWCBY7 PC 216385 DMWCBY7 MW 324.4 DMWCBY7 FM C15H16O6S DMWCBY7 IC InChI=1S/C15H16O6S/c1-7-4-12(17)21-11-5-8(2-3-9(7)11)20-15-14(19)13(18)10(16)6-22-15/h2-5,10,13-16,18-19H,6H2,1H3/t10-,13+,14-,15-/m1/s1 DMWCBY7 CS CC1=CC(=O)OC2=C1C=CC(=C2)O[C@H]3[C@@H]([C@H]([C@@H](CS3)O)O)O DMWCBY7 IK JRHNIQQUVJOPQC-AQNFWKISSA-N DMWCBY7 IU 4-methyl-7-[(2R,3R,4S,5S)-3,4,5-trihydroxythian-2-yl]oxychromen-2-one DMWCBY7 CA CAS 137215-12-4 DMWCBY7 DE Cardiovascular disease DMVC90W ID DMVC90W DMVC90W DN Oglemilast DMVC90W HS Phase 2 DMVC90W SN GRC-3886; Oglemilast (oral, COPD/asthma), Glenmark DMVC90W CP Glenmark Pharmaceuticals Ltd DMVC90W DT Small molecular drug DMVC90W PC 11387409 DMVC90W MW 516.299 DMVC90W FM C20H13Cl2F2N3O5S DMVC90W IC InChI=1S/C20H13Cl2F2N3O5S/c1-33(29,30)27-9-2-4-14-11(6-9)16-10(3-5-15(18(16)31-14)32-20(23)24)19(28)26-17-12(21)7-25-8-13(17)22/h2-8,20,27H,1H3,(H,25,26,28) DMVC90W CS CS(=O)(=O)NC1=CC2=C(C=C1)OC3=C(C=CC(=C23)C(=O)NC4=C(C=NC=C4Cl)Cl)OC(F)F DMVC90W IK OKFDRAHPFKMAJH-UHFFFAOYSA-N DMVC90W IU N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)-8-(methanesulfonamido)dibenzofuran-1-carboxamide DMVC90W CA CAS 778576-62-8 DMVC90W DE Asthma DMJTU8D ID DMJTU8D DMJTU8D DN OGX-427 DMJTU8D HS Phase 2 DMJTU8D CP Isis Pharmaceuticals & OncoGenex DMJTU8D TC Antisense DMJTU8D DT Antisense drug DMJTU8D PC 71710946 DMJTU8D MW 7157 DMJTU8D FM C224H304N79O116P19S19 DMJTU8D IC InChI=1S/C224H304N79O116P19S19/c1-88-46-284(216(318)257-168(88)225)129-34-97(401-420(327,439)363-60-114-102(39-134(386-114)289-52-94(7)187(306)281-222(289)324)406-421(328,440)362-56-110-98(35-130(381-110)285-47-89(2)169(226)258-217(285)319)402-422(329,441)368-63-119-107(44-139(390-119)297-81-252-147-182(297)267-211(237)276-194(147)313)411-430(337,449)372-66-121-108(45-140(392-121)298-82-253-148-183(298)268-212(238)277-195(148)314)412-431(338,450)375-69-123-154(163(357-29-21-349-13)201(396-123)292-54-96(9)189(308)283-224(292)326)414-435(342,454)377-70-124-155(162(356-28-20-348-12)200(395-124)290-51-93(6)173(230)262-221(290)323)415-436(343,455)378-72-126-157(165(359-31-23-351-15)203(398-126)300-84-247-142-175(232)243-76-245-177(142)300)417-433(340,452)374-68-122-152(305)160(354-26-18-346-10)199(394-122)291-53-95(8)188(307)282-223(291)325)111(382-129)57-364-426(333,445)407-103-40-135(293-77-248-143-178(293)263-207(233)272-190(143)309)387-116(103)61-367-423(330,442)403-99-36-131(286-48-90(3)170(227)259-218(286)320)384-113(99)59-366-428(335,447)409-105-42-137(295-79-250-145-180(295)265-209(235)274-192(145)311)391-120(105)65-371-429(336,448)410-106-43-138(296-80-251-146-181(296)266-210(236)275-193(146)312)389-118(106)62-369-424(331,443)404-100-37-132(287-49-91(4)171(228)260-219(287)321)383-112(100)58-365-427(334,446)408-104-41-136(294-78-249-144-179(294)264-208(234)273-191(144)310)388-117(104)64-370-425(332,444)405-101-38-133(288-50-92(5)172(229)261-220(288)322)385-115(101)67-373-432(339,451)416-156-125(397-202(164(156)358-30-22-350-14)299-83-246-141-174(231)242-75-244-176(141)299)71-379-437(344,456)419-159-128(400-206(167(159)361-33-25-353-17)303-87-256-151-186(303)271-215(241)280-198(151)317)74-380-438(345,457)418-158-127(399-205(166(158)360-32-24-352-16)302-86-255-150-185(302)270-214(240)279-197(150)316)73-376-434(341,453)413-153-109(55-304)393-204(161(153)355-27-19-347-11)301-85-254-149-184(301)269-213(239)278-196(149)315/h46-54,75-87,97-140,152-167,199-206,304-305H,18-45,55-74H2,1-17H3,(H,327,439)(H,328,440)(H,329,441)(H,330,442)(H,331,443)(H,332,444)(H,333,445)(H,334,446)(H,335,447)(H,336,448)(H,337,449)(H,338,450)(H,339,451)(H,340,452)(H,341,453)(H,342,454)(H,343,455)(H,344,456)(H,345,457)(H2,225,257,318)(H2,226,258,319)(H2,227,259,320)(H2,228,260,321)(H2,229,261,322)(H2,230,262,323)(H2,231,242,244)(H2,232,243,245)(H,281,306,324)(H,282,307,325)(H,283,308,326)(H3,233,263,272,309)(H3,234,264,273,310)(H3,235,265,274,311)(H3,236,266,275,312)(H3,237,267,276,313)(H3,238,268,277,314)(H3,239,269,278,315)(H3,240,270,279,316)(H3,241,271,280,317)/t97?,98?,99?,100?,101?,102?,103?,104?,105?,106?,107?,108?,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,127-,128-,129-,130-,131-,132-,133-,134-,135-,136-,137-,138-,139-,140-,152?,153?,154?,155?,156?,157?,158?,159?,160?,161?,162?,163?,164?,165?,166?,167?,199-,200-,201-,202-,203-,204-,205-,206-,420?,421?,422?,423?,424?,425?,426?,427?,428?,429?,430?,431?,432?,433?,434?,435?,436?,437?,438?/m1/s1 DMJTU8D CS CC1=CN(C(=O)NC1=O)[C@H]2CC([C@H](O2)COP(=S)(O)OC3C[C@@H](O[C@@H]3COP(=S)(O)OC4C[C@@H](O[C@@H]4COP(=S)(O)OC5C[C@@H](O[C@@H]5COP(=S)(O)OC6C[C@@H](O[C@@H]6COP(=S)(O)OC7C[C@@H](O[C@@H]7COP(=S)(O)OC8C[C@@H](O[C@@H]8COP(=O)(OC9C[C@@H](O[C@@H]9COP(=S)(O)OC1C[C@@H](O[C@@H]1COP(=S)(O)OC1[C@H](O[C@H](C1OCCOC)N1C=NC2=C(N=CN=C21)N)COP(=S)(O)OC1[C@H](O[C@H](C1OCCOC)N1C=NC2=C1N=C(NC2=O)N)COP(=S)(O)OC1[C@H](O[C@H](C1OCCOC)N1C=NC2=C1N=C(NC2=O)N)COP(=S)(O)OC1[C@H](O[C@H](C1OCCOC)N1C=NC2=C1N=C(NC2=O)N)CO)N1C=C(C(=NC1=O)N)C)N1C=NC2=C1N=C(NC2=O)N)S)N1C=C(C(=NC1=O)N)C)N1C=NC2=C1N=C(NC2=O)N)N1C=NC2=C1N=C(NC2=O)N)N1C=C(C(=NC1=O)N)C)N1C=NC2=C1N=C(NC2=O)N)N1C=C(C(=NC1=O)N)C)OP(=S)(O)OC[C@@H]1C(C[C@@H](O1)N1C=C(C(=NC1=O)N)C)OP(=S)(O)OC[C@@H]1C(C[C@@H](O1)N1C=NC2=C1N=C(NC2=O)N)OP(=S)(O)OC[C@@H]1C(C[C@@H](O1)N1C=NC2=C1N=C(NC2=O)N)OP(=S)(O)OC[C@@H]1C(C([C@@H](O1)N1C=C(C(=O)NC1=O)C)OCCOC)OP(=S)(O)OC[C@@H]1C(C([C@@H](O1)N1C=C(C(=NC1=O)N)C)OCCOC)OP(=S)(O)OC[C@@H]1C(C([C@@H](O1)N1C=NC2=C1N=CNC2=N)OCCOC)OP(=S)(O)OC[C@@H]1C(C([C@@H](O1)N1C=C(C(=O)NC1=O)C)OCCOC)O DMJTU8D IK RMTMMKNSPRRFHW-SVAVBUBPSA-N DMJTU8D IU 1-[(2R,5R)-5-[[[(2R,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-2-[[[(2R,5R)-2-[[[(2R,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-2-[[[(2R,5R)-2-[[[(2R,5R)-2-[[[(2R,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-2-[[[(2R,5R)-2-[[[(2R,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-2-[[[(2R,5R)-2-[[[(2R,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[(2R,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[(2R,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-2-(hydroxymethyl)-4-(2-methoxyethoxy)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-4-(2-methoxyethoxy)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-4-(2-methoxyethoxy)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(6-aminopurin-9-yl)-4-(2-methoxyethoxy)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(2-amino-6-oxo-1H-purin-9-yl)oxolan-3-yl]oxy-sulfanylphosphoryl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(2-amino-6-oxo-1H-purin-9-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(2-amino-6-oxo-1H-purin-9-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(2-amino-6-oxo-1H-purin-9-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-4-[[(2R,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[(2R,5R)-3-[[(2R,5R)-3-[[(2R,5R)-3-[[(2R,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[hydroxy-[[(2R,5R)-3-[hydroxy-[[(2R,5R)-3-hydroxy-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy]phosphinothioyl]oxy-5-(6-imino-1H-purin-9-yl)-4-(2-methoxyethoxy)oxolan-2-yl]methoxy]phosphinothioyl]oxy-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(2-amino-6-oxo-1H-purin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(2-amino-6-oxo-1H-purin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]-5-methylpyrimidine-2,4-dione DMJTU8D CA CAS 1002331-21-6 DMJTU8D DE Lung cancer; Prostate cancer; Bladder cancer; Ovarian cancer; Breast cancer DMNEHY1 ID DMNEHY1 DMNEHY1 DN OI338GT DMNEHY1 HS Phase 2 DMNEHY1 CP Novo Nordisk DMNEHY1 DE Type-1/2 diabetes; Type-1 diabetes; Type-2 diabetes DMVW5KR ID DMVW5KR DMVW5KR DN Olcegepant DMVW5KR HS Phase 2 DMVW5KR SN Olcegepant [INN]; BIBN 4096; BIBN 4096 BS; BIBN-4096; BIBN-4096BS; N-((1R)-2-(((1S)-5-Amino-1-((4-(pyridin-4-yl)piperazin-1-yl)carbonyl)pentyl)amino)-1-(3,5-dibromo-4-hydroxybenzyl)-2-oxoethyl)-4-(2-oxo-1,4-dihydroquinazolin-3(2H)-yl)piperidine-1-carboxamide; N-[(2R)-1-[[(2S)-6-amino-1-oxo-1-(4-pyridin-4-ylpiperazin-1-yl)hexan-2-yl]amino]-3-(3,5-dibromo-4-hydroxyphenyl)-1-oxopropan-2-yl]-4-(2-oxo-1,4-dihydroquinazolin-3-yl)piperidine-1-carboxamide DMVW5KR CP Boehringer Ingelheim DMVW5KR DT Small molecular drug DMVW5KR PC 6918509 DMVW5KR MW 869.6 DMVW5KR FM C38H47Br2N9O5 DMVW5KR IC InChI=1S/C38H47Br2N9O5/c39-29-21-25(22-30(40)34(29)50)23-33(45-37(53)48-15-10-28(11-16-48)49-24-26-5-1-2-6-31(26)44-38(49)54)35(51)43-32(7-3-4-12-41)36(52)47-19-17-46(18-20-47)27-8-13-42-14-9-27/h1-2,5-6,8-9,13-14,21-22,28,32-33,50H,3-4,7,10-12,15-20,23-24,41H2,(H,43,51)(H,44,54)(H,45,53)/t32-,33+/m0/s1 DMVW5KR CS C1CN(CCC1N2CC3=CC=CC=C3NC2=O)C(=O)N[C@H](CC4=CC(=C(C(=C4)Br)O)Br)C(=O)N[C@@H](CCCCN)C(=O)N5CCN(CC5)C6=CC=NC=C6 DMVW5KR IK ITIXDWVDFFXNEG-JHOUSYSJSA-N DMVW5KR IU N-[(2R)-1-[[(2S)-6-amino-1-oxo-1-(4-pyridin-4-ylpiperazin-1-yl)hexan-2-yl]amino]-3-(3,5-dibromo-4-hydroxyphenyl)-1-oxopropan-2-yl]-4-(2-oxo-1,4-dihydroquinazolin-3-yl)piperidine-1-carboxamide DMVW5KR CA CAS 204697-65-4 DMVW5KR DE Migraine DM0RA8F ID DM0RA8F DM0RA8F DN Oleoyl-estrone DM0RA8F HS Phase 2 DM0RA8F SN Anti-obesity hormone-based therapy, Manhattan DM0RA8F CP Oleoyl-Estrone Developments DM0RA8F DT Small molecular drug DM0RA8F PC 6918373 DM0RA8F MW 534.8 DM0RA8F FM C36H54O3 DM0RA8F IC InChI=1S/C36H54O3/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-35(38)39-29-20-22-30-28(27-29)19-21-32-31(30)25-26-36(2)33(32)23-24-34(36)37/h10-11,20,22,27,31-33H,3-9,12-19,21,23-26H2,1-2H3/b11-10-/t31-,32-,33+,36+/m1/s1 DM0RA8F CS CCCCCCCC/C=C\\CCCCCCCC(=O)OC1=CC2=C(C=C1)[C@H]3CC[C@]4([C@H]([C@@H]3CC2)CCC4=O)C DM0RA8F IK IMIPDPVHGGHVNH-YWVHRCQQSA-N DM0RA8F IU [(8R,9S,13S,14S)-13-methyl-17-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-yl] (Z)-octadec-9-enoate DM0RA8F CA CAS 180003-17-2 DM0RA8F DE Obesity; Alzheimer disease; Psychotic disorder DMXL7HO ID DMXL7HO DMXL7HO DN OLX10010 DMXL7HO HS Phase 2 DMXL7HO SN OLX 101A DMXL7HO CP Olix Pharmaceuticals DMXL7HO DT Small interfering RNA DMXL7HO DE Hypertrophic scars DMLMNFX ID DMLMNFX DMLMNFX DN Omaveloxolone DMLMNFX HS Phase 2 DMLMNFX SN RJCWBNBKOKFWNY-HGNIWHNWSA-N; N-((4aR,6aR,6bS,12aS,14aR,14bR)-11-cyano-2,2,6a,6b,9,9,12a-heptamethyl-10,14-dioxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,12a,14,14a,14b-octadecahydropicen-4a-yl)-2,2-difluoropropanamide; 1474034-05-3; AKOS030526563 DMLMNFX CP Reata Pharmaceuticals Irving, TX DMLMNFX DT Small molecular drug DMLMNFX PC 71811910 DMLMNFX MW 554.7 DMLMNFX FM C33H44F2N2O3 DMLMNFX IC InChI=1S/C33H44F2N2O3/c1-27(2)11-13-33(37-26(40)32(8,34)35)14-12-31(7)24(20(33)17-27)21(38)15-23-29(5)16-19(18-36)25(39)28(3,4)22(29)9-10-30(23,31)6/h15-16,20,22,24H,9-14,17H2,1-8H3,(H,37,40)/t20-,22-,24-,29-,30+,31+,33-/m0/s1 DMLMNFX CS C[C@@]12CC[C@]3(CCC(C[C@H]3[C@H]1C(=O)C=C4[C@]2(CC[C@@H]5[C@@]4(C=C(C(=O)C5(C)C)C#N)C)C)(C)C)NC(=O)C(C)(F)F DMLMNFX IK RJCWBNBKOKFWNY-IDPLTSGASA-N DMLMNFX IU N-[(4aS,6aR,6bS,8aR,12aS,14aR,14bS)-11-cyano-2,2,6a,6b,9,9,12a-heptamethyl-10,14-dioxo-1,3,4,5,6,7,8,8a,14a,14b-decahydropicen-4a-yl]-2,2-difluoropropanamide DMLMNFX CA CAS 1474034-05-3 DMLMNFX DE Friedreich's ataxia; Melanoma; Psychiatric disorder DMH9RTV ID DMH9RTV DMH9RTV DN Omigapil DMH9RTV HS Phase 2 DMH9RTV SN Omigapil); CGP-3466; CGP-3499B; Neuroprotectant, Novartis; Neuroprotectant, Santhera; Nootropic agent, Novartis; Nootropicagent, Santhera; SNT-317; TCH-346; TCH-346B DMH9RTV CP Novartis AG DMH9RTV DT Small molecular drug DMH9RTV PC 6419718 DMH9RTV MW 275.3 DMH9RTV FM C19H17NO DMH9RTV IC InChI=1S/C19H17NO/c1-3-12-20(2)14-16-13-15-8-4-6-10-18(15)21-19-11-7-5-9-17(16)19/h1,4-11,13H,12,14H2,2H3 DMH9RTV CS CN(CC#C)CC1=CC2=CC=CC=C2OC3=CC=CC=C31 DMH9RTV IK QLMMOGWZCFQAPU-UHFFFAOYSA-N DMH9RTV IU N-(benzo[b][1]benzoxepin-5-ylmethyl)-N-methylprop-2-yn-1-amine DMH9RTV CA CAS 181296-84-4 DMH9RTV CB CHEBI:41778 DMH9RTV DE Lateral sclerosis; Muscular dystrophy DMWC36Y ID DMWC36Y DMWC36Y DN OMS405 DMWC36Y HS Phase 2 DMWC36Y CP Omeros DMWC36Y DE Nicotine dependence; Opioid dependence DMA4OGL ID DMA4OGL DMA4OGL DN OMS824 DMA4OGL HS Phase 2 DMA4OGL SN OMS-824 DMA4OGL CP Omeros DMA4OGL DE Huntington disease DMT6E5N ID DMT6E5N DMT6E5N DN Onapristone DMT6E5N HS Phase 2 DMT6E5N SN Onapristone; 96346-61-1; Onapristone [INN]; ZK-98299; Onapristonum [Latin]; Onapristona [Spanish]; UNII-H6H7G23O3N; ZK 299; CCRIS 6530; ZK 98299; ZK-299; H6H7G23O3N; C29H39NO3; Onapristone (INN); Onapristonum; Onapristona; (8S,11R,13R,14S,17S)-11-(4-dimethylaminophenyl)-17-hydroxy-17-(3-hydroxypropyl)-13-methyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one; Estra-4,9-dien-3-one, 11-(4-(dimethylamino)phenyl)-17-hydroxy-17-(3-hydroxypropyl)-, (11-beta,13-alpha,17-alpha)- DMT6E5N CP Context Therapeutics DMT6E5N DT Small molecular drug DMT6E5N PC 5311505 DMT6E5N MW 449.6 DMT6E5N FM C29H39NO3 DMT6E5N IC InChI=1S/C29H39NO3/c1-28-18-25(19-5-8-21(9-6-19)30(2)3)27-23-12-10-22(32)17-20(23)7-11-24(27)26(28)13-15-29(28,33)14-4-16-31/h5-6,8-9,17,24-26,31,33H,4,7,10-16,18H2,1-3H3/t24-,25+,26-,28+,29+/m0/s1 DMT6E5N CS C[C@@]12C[C@@H](C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(CCCO)O)C5=CC=C(C=C5)N(C)C DMT6E5N IK IEXUMDBQLIVNHZ-YOUGDJEHSA-N DMT6E5N IU (8S,11R,13R,14S,17S)-11-[4-(dimethylamino)phenyl]-17-hydroxy-17-(3-hydroxypropyl)-13-methyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one DMT6E5N CA CAS 96346-61-1 DMT6E5N DE Breast cancer DMM5SCF ID DMM5SCF DMM5SCF DN ONC201 DMM5SCF HS Phase 2 DMM5SCF SN Onc-201; TIC10; 1616632-77-9; UNII-9U35A31JAI; 9U35A31JAI; TIC10(ONC-201); 7-Benzyl-4-(2-methylbenzyl)-1,2,6,7,8,9-hexahydroimidazo[1,2-A]pyrido[3,4-E]pyrimidin-5(4H)-one; TIC 10 active isomer; ONC201(TIC10 isomer); TIC 10; GTPL9978; SCHEMBL16227974; EX-A669; ONC 201; AOB2892; MolPort-039-137-731; HY-15615A; 3388AH; s7963; ZINC169620396; AKOS025404904; NSC 350625; CS-3564; AS-16735; AK174891; KB-335104; FT-0700231; J-690224; 1342897-86-2; 2,4,6,7,8,9-Hexahydro-4-((2-methylphenyl)methyl)-7-phenylmethyl)imidazo)(1,2-a)pyrido(3,4-e)pyrimid DMM5SCF CP Oncoceutics Philadelphia, PA DMM5SCF PC 73777259 DMM5SCF MW 386.5 DMM5SCF FM C24H26N4O DMM5SCF IC InChI=1S/C24H26N4O/c1-18-7-5-6-10-20(18)16-28-23(29)21-17-26(15-19-8-3-2-4-9-19)13-11-22(21)27-14-12-25-24(27)28/h2-10H,11-17H2,1H3 DMM5SCF CS CC1=CC=CC=C1CN2C(=O)C3=C(CCN(C3)CC4=CC=CC=C4)N5C2=NCC5 DMM5SCF IK VLULRUCCHYVXOH-UHFFFAOYSA-N DMM5SCF IU 11-benzyl-7-[(2-methylphenyl)methyl]-2,5,7,11-tetrazatricyclo[7.4.0.02,6]trideca-1(9),5-dien-8-one DMM5SCF CA CAS 1616632-77-9 DMM5SCF DE Glioma; Endometrial cancer; leukaemia; Lymphoma; Multiple myeloma; Neuroendocrine cancer; Recurring respiratory infection; Solid tumour/cancer DMKIZAL ID DMKIZAL DMKIZAL DN ONO-1603 DMKIZAL HS Phase 2 DMKIZAL SN N-(4-Chlorobenzyl)-4-[2(S)-formylpyrrolidin-1-yl]-4-oxobutyramide DMKIZAL DT Small molecular drug DMKIZAL PC 9797271 DMKIZAL MW 322.78 DMKIZAL FM C16H19ClN2O3 DMKIZAL IC InChI=1S/C16H19ClN2O3/c17-13-5-3-12(4-6-13)10-18-15(21)7-8-16(22)19-9-1-2-14(19)11-20/h3-6,11,14H,1-2,7-10H2,(H,18,21)/t14-/m0/s1 DMKIZAL CS C1C[C@H](N(C1)C(=O)CCC(=O)NCC2=CC=C(C=C2)Cl)C=O DMKIZAL IK KGDFDVHLEYUZLN-AWEZNQCLSA-N DMKIZAL IU N-[(4-chlorophenyl)methyl]-4-[(2S)-2-formylpyrrolidin-1-yl]-4-oxobutanamide DMKIZAL DE Cognitive impairment DMOT0WR ID DMOT0WR DMOT0WR DN ONO-2333Ms DMOT0WR HS Phase 2 DMOT0WR SN Corticotropin-releasing factor-1 antagonist (oral, anxiety/depression), Ono DMOT0WR CP Ono Pharmaceutical Co Ltd DMOT0WR PC 9801039 DMOT0WR MW 398.9 DMOT0WR FM C22H27ClN4O DMOT0WR IC InChI=1S/C22H27ClN4O/c1-5-14(6-2)24-21-17-8-7-9-19(17)25-22-20(13(3)26-27(21)22)16-11-10-15(28-4)12-18(16)23/h10-12,14,24H,5-9H2,1-4H3 DMOT0WR CS CCC(CC)NC1=C2CCCC2=NC3=C(C(=NN31)C)C4=C(C=C(C=C4)OC)Cl DMOT0WR IK LDIOUQIXNSSOGU-UHFFFAOYSA-N DMOT0WR IU 10-(2-chloro-4-methoxyphenyl)-11-methyl-N-pentan-3-yl-1,8,12-triazatricyclo[7.3.0.03,7]dodeca-2,7,9,11-tetraen-2-amine DMOT0WR CA CAS 441060-02-2 DMOT0WR DE Anxiety disorder DMOGYQ0 ID DMOGYQ0 DMOGYQ0 DN ONO-2952 DMOGYQ0 HS Phase 2 DMOGYQ0 SN Translocator protein 18kDr (TSPO) antagonist (irritable bowel syndrome), Ono Pharmaceutical DMOGYQ0 CP Ono Pharmaceutical Co Ltd DMOGYQ0 PC 11524127 DMOGYQ0 MW 398.9 DMOGYQ0 FM C22H20ClFN2O2 DMOGYQ0 IC InChI=1S/C22H20ClFN2O2/c1-12(27)26-11-22(8-9-22)19-18-15(24)4-3-5-16(18)25-20(19)21(26)14-7-6-13(23)10-17(14)28-2/h3-7,10,21,25H,8-9,11H2,1-2H3/t21-/m0/s1 DMOGYQ0 CS CC(=O)N1CC2(CC2)C3=C([C@@H]1C4=C(C=C(C=C4)Cl)OC)NC5=C3C(=CC=C5)F DMOGYQ0 IK ZBQMTQGDBFZUBG-NRFANRHFSA-N DMOGYQ0 IU 1-[(1S)-1-(4-chloro-2-methoxyphenyl)-5-fluorospiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,1'-cyclopropane]-2-yl]ethanone DMOGYQ0 CA CAS 895169-20-7 DMOGYQ0 DE Irritable bowel syndrome DMQGO74 ID DMQGO74 DMQGO74 DN ONO-3307 DMQGO74 HS Phase 2 DMQGO74 SN 4-Guanidinobenzoic acid 4-sulfamoylphenyl ester methanesulfonate DMQGO74 DT Small molecular drug DMQGO74 PC 127139 DMQGO74 MW 334.35 DMQGO74 FM C14H14N4O4S DMQGO74 IC InChI=1S/C14H14N4O4S/c15-14(16)18-10-3-1-9(2-4-10)13(19)22-11-5-7-12(8-6-11)23(17,20)21/h1-8H,(H4,15,16,18)(H2,17,20,21) DMQGO74 CS C1=CC(=CC=C1C(=O)OC2=CC=C(C=C2)S(=O)(=O)N)N=C(N)N DMQGO74 IK YFUQTMNUQVFBBS-UHFFFAOYSA-N DMQGO74 IU (4-sulfamoylphenyl) 4-(diaminomethylideneamino)benzoate DMQGO74 CA CAS 76472-28-1 DMQGO74 DE Coagulation defect DMX4MVP ID DMX4MVP DMX4MVP DN ONO-4053 DMX4MVP HS Phase 2 DMX4MVP SN PGD2 receptor antagonist (allergic rhinitis), Ono Pharmaceutical; Prostaglandin D2 receptor antagonists (allergy/inflammation), Ono Pharmaceutical DMX4MVP CP Ono Pharmaceutical Co Ltd DMX4MVP DE Allergic rhinitis DMLUM3Y ID DMLUM3Y DMLUM3Y DN ONO-4641 DMLUM3Y HS Phase 2 DMLUM3Y SN Sphingosine-1-phosphate agonist (tablet, mutiple sclerosis), Ono DMLUM3Y CP Emd serono DMLUM3Y PC 11502996 DMLUM3Y MW 435.6 DMLUM3Y FM C27H33NO4 DMLUM3Y IC InChI=1S/C27H33NO4/c1-4-5-19-6-7-22(26(12-19)31-3)17-32-24-10-11-25-18(2)21(9-8-20(25)13-24)14-28-15-23(16-28)27(29)30/h6-7,10-13,23H,4-5,8-9,14-17H2,1-3H3,(H,29,30) DMLUM3Y CS CCCC1=CC(=C(C=C1)COC2=CC3=C(C=C2)C(=C(CC3)CN4CC(C4)C(=O)O)C)OC DMLUM3Y IK QDDQIPUKAXBMBX-UHFFFAOYSA-N DMLUM3Y IU 1-[[6-[(2-methoxy-4-propylphenyl)methoxy]-1-methyl-3,4-dihydronaphthalen-2-yl]methyl]azetidine-3-carboxylic acid DMLUM3Y CA CAS 891859-12-4 DMLUM3Y DE Rheumatoid arthritis DMFX3P1 ID DMFX3P1 DMFX3P1 DN ONO-5129 DMFX3P1 HS Phase 2 DMFX3P1 SN Dual PPAR alpha/gamma agonist (metabolic disorder), Ono DMFX3P1 CP Ono Pharmaceutical Co Ltd DMFX3P1 DE Diabetic complication DMRT28X ID DMRT28X DMRT28X DN ONO-6126 DMRT28X HS Phase 2 DMRT28X SN 21-Cyanosaframycin-B; NSC 325663; 66082-27-7; C29H30N4O8; 21-cyanosaframycin B; AC1L2P2O; SCHEMBL637953; CHEMBL452709 DMRT28X CP Ono Pharmaceuticals DMRT28X DT Small molecular drug DMRT28X PC 9864321 DMRT28X MW 373.4 DMRT28X FM C20H27N3O4 DMRT28X IC InChI=1S/C20H27N3O4/c1-26-17-7-6-15(12-18(17)27-16-4-2-3-5-16)20(14-21)8-10-23(11-9-20)13-19(24)22-25/h6-7,12,16,25H,2-5,8-11,13H2,1H3,(H,22,24) DMRT28X CS COC1=C(C=C(C=C1)C2(CCN(CC2)CC(=O)NO)C#N)OC3CCCC3 DMRT28X IK VXYDHPDQMSVQCU-UHFFFAOYSA-N DMRT28X IU 2-[4-cyano-4-(3-cyclopentyloxy-4-methoxyphenyl)piperidin-1-yl]-N-hydroxyacetamide DMRT28X CA CAS 401519-28-6 DMRT28X DE Chronic obstructive pulmonary disease DM5O6GC ID DM5O6GC DM5O6GC DN ONO-9054 DM5O6GC HS Phase 2 DM5O6GC CP Ono pharmaceutical DM5O6GC DE Glaucoma/ocular hypertension DMCUGI8 ID DMCUGI8 DMCUGI8 DN ONO-AE1-437 DMCUGI8 HS Phase 2 DMCUGI8 SN 16-[3-(Methoxymethyl)phenyl]-5-thia-17,18,19,20-tetranorprostaglandin E1 DMCUGI8 DT Small molecular drug DMCUGI8 PC 9824353 DMCUGI8 MW 436.6 DMCUGI8 FM C23H32O6S DMCUGI8 IC InChI=1S/C23H32O6S/c1-29-15-17-5-2-4-16(12-17)13-18(24)7-8-19-20(22(26)14-21(19)25)9-11-30-10-3-6-23(27)28/h2,4-5,7-8,12,18-21,24-25H,3,6,9-11,13-15H2,1H3,(H,27,28)/b8-7+/t18-,19-,20-,21-/m1/s1 DMCUGI8 CS COCC1=CC=CC(=C1)C[C@@H](/C=C/[C@H]2[C@@H](CC(=O)[C@@H]2CCSCCCC(=O)O)O)O DMCUGI8 IK ORSJUPRAHPZYRL-XHTUOEPPSA-N DMCUGI8 IU 4-[2-[(1R,2R,3R)-3-hydroxy-2-[(E,3S)-3-hydroxy-4-[3-(methoxymethyl)phenyl]but-1-enyl]-5-oxocyclopentyl]ethylsulfanyl]butanoic acid DMCUGI8 CA CAS 256382-23-7 DMCUGI8 DE Asthma DMS8Q7A ID DMS8Q7A DMS8Q7A DN Ontazolast DMS8Q7A HS Phase 2 DMS8Q7A SN Ontazolast; UNII-8P8TW6B25I; BIRM-270; 147432-77-7; 8P8TW6B25I; N-[(1S)-2-cyclohexyl-1-pyridin-2-ylethyl]-5-methyl-1,3-benzoxazol-2-amine; Ontazolast [USAN:INN]; AC1Q4WID; Ontazolast (USAN/INN); SCHEMBL75875; AC1L2G78; CHEMBL2104845; 2-(((S)-2-Cyclohexyl-1-(2-pyridyl)ethyl)amino)-5-methylbenzoxazole; n-[(1s)-2-cyclohexyl-1-(2-pyridinyl)ethyl]-5-methyl-2-benzoxazolamine; D02847; 32254-EP2311827A1; 32254-EP2301933A1; 32254-EP2281815A1; 32254-EP2305640A2; 2-Benzoxazolamine, N-(2-cyclohexyl-1-(2-pyridinyl)ethyl)-5-methyl-, (S)- DMS8Q7A CP Boehringer Ingelheim Corp DMS8Q7A DT Small molecular drug DMS8Q7A PC 71458 DMS8Q7A MW 335.4 DMS8Q7A FM C21H25N3O DMS8Q7A IC InChI=1S/C21H25N3O/c1-15-10-11-20-19(13-15)24-21(25-20)23-18(17-9-5-6-12-22-17)14-16-7-3-2-4-8-16/h5-6,9-13,16,18H,2-4,7-8,14H2,1H3,(H,23,24)/t18-/m0/s1 DMS8Q7A CS CC1=CC2=C(C=C1)OC(=N2)N[C@@H](CC3CCCCC3)C4=CC=CC=N4 DMS8Q7A IK RVXKHAITGKBBAC-SFHVURJKSA-N DMS8Q7A IU N-[(1S)-2-cyclohexyl-1-pyridin-2-ylethyl]-5-methyl-1,3-benzoxazol-2-amine DMS8Q7A CA CAS 147432-77-7 DMS8Q7A DE Asthma DM0FJIE ID DM0FJIE DM0FJIE DN Ontuxizumab DM0FJIE HS Phase 2 DM0FJIE SN Amatuximab DM0FJIE CP EisaiWoodcliff Lake, NJ MorphotekExton, PA DM0FJIE DT Antibody DM0FJIE DE Melanoma; Merkel cell carcinoma; Soft tissue sarcoma; Colorectal cancer DMB1WF3 ID DMB1WF3 DMB1WF3 DN OPC-14523 DMB1WF3 HS Phase 2 DMB1WF3 SN OPC-14523; UNII-1981OTB4DS; 1981OTB4DS; CHEMBL294144; 145969-30-8; OPC-14523 free base; SCHEMBL5022801; ZINC598353; BDBM50005656; 1-(3-(4-(3-chlorophenyl)-1-piperazinyl)propyl)-5-methoxy-3,4-dihydro-2-quinolinone; L001554; 2(1H)-Quinolinone, 1-(3-(4-(3-chlorophenyl)-1-piperazinyl)propyl)-3,4-dihydro-5-methoxy- DMB1WF3 CP Otsuka Pharmaceutical and Vela Pharmaceuticals; Pharmos and Otsaku DMB1WF3 DT Small molecular drug DMB1WF3 PC 9892540 DMB1WF3 MW 413.9 DMB1WF3 FM C23H28ClN3O2 DMB1WF3 IC InChI=1S/C23H28ClN3O2/c1-29-22-8-3-7-21-20(22)9-10-23(28)27(21)12-4-11-25-13-15-26(16-14-25)19-6-2-5-18(24)17-19/h2-3,5-8,17H,4,9-16H2,1H3 DMB1WF3 CS COC1=CC=CC2=C1CCC(=O)N2CCCN3CCN(CC3)C4=CC(=CC=C4)Cl DMB1WF3 IK TZZGTNZBLPCBIS-UHFFFAOYSA-N DMB1WF3 IU 1-[3-[4-(3-chlorophenyl)piperazin-1-yl]propyl]-5-methoxy-3,4-dihydroquinolin-2-one DMB1WF3 CA CAS 145969-30-8 DMB1WF3 DE Mood disorder; Bulimia nervosa; Female sexual arousal dysfunction DMIK2AD ID DMIK2AD DMIK2AD DN OPC-64005 DMIK2AD HS Phase 2 DMIK2AD CP Otsuka Pharmaceutical DMIK2AD DE Attention deficit hyperactivity disorder DML6TAS ID DML6TAS DML6TAS DN OPI-1002 DML6TAS HS Phase 2 DML6TAS CP Quark Pharm; Pfizer DML6TAS DT siRNA drug DML6TAS DE Acute kidney injury DM1IBRT ID DM1IBRT DM1IBRT DN OPN-305 DM1IBRT HS Phase 2 DM1IBRT SN OPN-301; TLR-specific mAbs (inflammatory diseases), Opsona; Toll-like receptor specific monoclonal antibodies (inflammatory diseases), Opsona DM1IBRT CP Opsona therapeutics DM1IBRT DT Antibody DM1IBRT DE Myelodysplastic syndrome DMYG1ZQ ID DMYG1ZQ DMYG1ZQ DN OPNT001 DMYG1ZQ HS Phase 2 DMYG1ZQ CP Opiant Pharmaceuticals Santa Monica, CA DMYG1ZQ DE Eating disorder DM16RIC ID DM16RIC DM16RIC DN Oprozomib DM16RIC HS Phase 2 DM16RIC CP Onyx Pharmaceuticals DM16RIC DT Small molecular drug DM16RIC PC 25067547 DM16RIC MW 532.6 DM16RIC FM C25H32N4O7S DM16RIC IC InChI=1S/C25H32N4O7S/c1-15-26-11-20(37-15)24(33)29-19(13-35-4)23(32)28-18(12-34-3)22(31)27-17(21(30)25(2)14-36-25)10-16-8-6-5-7-9-16/h5-9,11,17-19H,10,12-14H2,1-4H3,(H,27,31)(H,28,32)(H,29,33)/t17-,18-,19-,25+/m0/s1 DM16RIC CS CC1=NC=C(S1)C(=O)N[C@@H](COC)C(=O)N[C@@H](COC)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)[C@]3(CO3)C DM16RIC IK SWZXEVABPLUDIO-WSZYKNRRSA-N DM16RIC IU N-[(2S)-3-methoxy-1-[[(2S)-3-methoxy-1-[[(2S)-1-[(2R)-2-methyloxiran-2-yl]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]-2-methyl-1,3-thiazole-5-carboxamide DM16RIC CA CAS 935888-69-0 DM16RIC DE Solid tumour/cancer; Hodgkin lymphoma; Multiple myeloma; Haematological malignancy DMS4XFI ID DMS4XFI DMS4XFI DN OPT-302 DMS4XFI HS Phase 2 DMS4XFI CP Opthea DMS4XFI DE Diabetic macular edema DMR3P98 ID DMR3P98 DMR3P98 DN ORG 34517/34850 DMR3P98 HS Phase 2 DMR3P98 SN Sardomozide; 4-Aiah; SAM 486A; Cgp 48664; UNII-CEB05S0B9I; SAM486A; 149400-88-4; CEB05S0B9I; 4-amidinoindan-1-one 2'-amidinohydrazone; (E)-2-(4-carbamimidoyl-2,3-dihydro-1H-inden-1-ylidene)hydrazinecarboximidamide; Urea azine with 1-oxo-4-indancarboxamidine; Sardomozide chloride; Hydrazinecarboximidamide, 2-(4-(aminoiminomethyl)-2,3-dihydro-1H-inden-1-ylidene)-; 4-AMIDINOINDAN-1-ONE-2'-AMIDINOHYDRAZONE; 1443105-76-7; C11H14N6; Cgp 48664A; CHEMBL1202793; Sardomozide [INN] DMR3P98 CP Organon DMR3P98 DT Small molecular drug DMR3P98 PC 9576789 DMR3P98 MW 230.27 DMR3P98 FM C11H14N6 DMR3P98 IC InChI=1S/C11H14N6/c12-10(13)8-3-1-2-7-6(8)4-5-9(7)16-17-11(14)15/h1-3H,4-5H2,(H3,12,13)(H4,14,15,17)/b16-9+ DMR3P98 CS C1C/C(=N\\N=C(N)N)/C2=C1C(=CC=C2)C(=N)N DMR3P98 IK CYPGNVSXMAUSJY-CXUHLZMHSA-N DMR3P98 IU (1E)-1-(diaminomethylidenehydrazinylidene)-2,3-dihydroindene-4-carboximidamide DMR3P98 CA CAS 149400-88-4 DMR3P98 DE Solid tumour/cancer; Mood disorder DMAWXJT ID DMAWXJT DMAWXJT DN ORG-13011 DMAWXJT HS Phase 2 DMAWXJT SN FIBOFLAPON; 936350-00-4; UNII-Y1NA96IX3T; Y1NA96IX3T; CHEMBL1922660; Fiboflapon [USAN:INN]; AM803; Fiboflapon (USAN); AM-803; AM 803; SCHEMBL11820; DTXSID20239496; DFQGDHBGRSTTHX-UHFFFAOYSA-N; GSK2190915B; ZINC68247071; BDBM50359080; AKOS030527019; SB16524; CS-3604; Fiboflapon; NCGC00485966-01; HY-15874; 1H-Indole-2-propanoic acid, 3-((1,1-dimethylethyl)thio)-1-((4-(6-ethoxy-3-pyridinyl)phenyl)methyl)-alpha,alpha-Dimethyl-5-((5-methyl-2-pyridinyl)methoxy)-; D10069 DMAWXJT DT Small molecular drug DMAWXJT PC 9907401 DMAWXJT MW 370.4 DMAWXJT FM C18H25F3N4O DMAWXJT IC InChI=1S/C18H25F3N4O/c19-18(20,21)15-5-6-22-16(14-15)24-12-10-23(11-13-24)7-1-2-8-25-9-3-4-17(25)26/h5-6,14H,1-4,7-13H2 DMAWXJT CS C1CC(=O)N(C1)CCCCN2CCN(CC2)C3=NC=CC(=C3)C(F)(F)F DMAWXJT IK YKJJCYZZWWSBEW-UHFFFAOYSA-N DMAWXJT IU 1-[4-[4-[4-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl]butyl]pyrrolidin-2-one DMAWXJT CA CAS 142494-12-0 DMAWXJT DE Psychotic disorder; Anxiety disorder; Major depressive disorder DMWN2EC ID DMWN2EC DMWN2EC DN ORG-25935 DMWN2EC HS Phase 2 DMWN2EC SN Cis-N-(6-Methoxy-1-phenyl-1,2,3,4-tetrahydronaphthalen-2-ylmethyl)-N-methylglycine hydrochloride DMWN2EC DT Small molecular drug DMWN2EC PC 11717074 DMWN2EC MW 339.4 DMWN2EC FM C21H25NO3 DMWN2EC IC InChI=1S/C21H25NO3/c1-22(14-20(23)24)13-17-9-8-16-12-18(25-2)10-11-19(16)21(17)15-6-4-3-5-7-15/h3-7,10-12,17,21H,8-9,13-14H2,1-2H3,(H,23,24)/t17-,21+/m1/s1 DMWN2EC CS CN(C[C@H]1CCC2=C([C@H]1C3=CC=CC=C3)C=CC(=C2)OC)CC(=O)O DMWN2EC IK UEBBYLJZCHTLEG-UTKZUKDTSA-N DMWN2EC IU 2-[[(1R,2S)-6-methoxy-1-phenyl-1,2,3,4-tetrahydronaphthalen-2-yl]methyl-methylamino]acetic acid DMWN2EC CA CAS 1147011-84-4 DMWN2EC DE Psychotic disorder DMDZ4R2 ID DMDZ4R2 DMDZ4R2 DN Org-30029 DMDZ4R2 HS Phase 2 DMDZ4R2 SN Org-30029; Org 30029; 101041-95-6; N'-Hydroxy-5,6-dimethoxybenzo[b]thiophene-2-carboximidamide hydrochloride; DTXSID50143698; AKOS015848621; Benzo(b)thiophene-2-carboximidamide, N-hydroxy-5,6-dimethoxy-, monohydrochloride; (Z)-N'-hydroxy-5,6-dimethoxy-1-benzothiophene-2-carboximidamide hydrochloride DMDZ4R2 CP Organon BioSciences DMDZ4R2 DT Small molecular drug DMDZ4R2 PC 9576838 DMDZ4R2 MW 288.75 DMDZ4R2 FM C11H13ClN2O3S DMDZ4R2 IC InChI=1S/C11H12N2O3S.ClH/c1-15-7-3-6-4-10(11(12)13-14)17-9(6)5-8(7)16-2;/h3-5,14H,1-2H3,(H2,12,13);1H DMDZ4R2 CS COC1=C(C=C2C(=C1)C=C(S2)/C(=N/O)/N)OC.Cl DMDZ4R2 IK DVWBMWJOYIFITF-UHFFFAOYSA-N DMDZ4R2 IU N'-hydroxy-5,6-dimethoxy-1-benzothiophene-2-carboximidamide;hydrochloride DMDZ4R2 CA CAS 101041-95-6 DMDZ4R2 DE Heart failure DMIO59F ID DMIO59F DMIO59F DN ORG-34517 DMIO59F HS Phase 2 DMIO59F SN 11beta-(1,3-Benzodioxol-5-yl)-17beta-hydroxy-17-(1-propynyl)estra-4,9-dien-3-one DMIO59F CP Organon DMIO59F DT Small molecular drug DMIO59F PC 9867361 DMIO59F MW 430.5 DMIO59F FM C28H30O4 DMIO59F IC InChI=1S/C28H30O4/c1-3-11-28(30)12-10-23-21-7-4-17-13-19(29)6-8-20(17)26(21)22(15-27(23,28)2)18-5-9-24-25(14-18)32-16-31-24/h5,9,13-14,21-23,30H,4,6-8,10,12,15-16H2,1-2H3/t21-,22+,23-,27-,28-/m0/s1 DMIO59F CS CC#C[C@@]1(CC[C@@H]2[C@@]1(C[C@@H](C3=C4CCC(=O)C=C4CC[C@@H]23)C5=CC6=C(C=C5)OCO6)C)O DMIO59F IK DFELGYQKEOCHOA-BZAFBGKRSA-N DMIO59F IU (8S,11R,13S,14S,17S)-11-(1,3-benzodioxol-5-yl)-17-hydroxy-13-methyl-17-prop-1-ynyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one DMIO59F CA CAS 189035-07-2 DMIO59F DE Depression DM8ARQW ID DM8ARQW DM8ARQW DN ORM-12741 DM8ARQW HS Phase 2 DM8ARQW SN Alpha 2c adrenoceptor antagonist (neurological diseases), Orion; Alpha 2c adrenoceptor antagonist (psychiatric disorders), Orion DM8ARQW CP Orion Corp DM8ARQW DT Small molecular drug DM8ARQW PC 71301276 DM8ARQW MW 285.4 DM8ARQW FM C18H23NO2 DM8ARQW IC InChI=1S/C18H23NO2/c1-18(12-20-2)9-5-10-19-11-8-14-13-6-3-4-7-15(13)21-16(14)17(18)19/h3-4,6-7,17H,5,8-12H2,1-2H3/t17-,18-/m1/s1 DM8ARQW CS C[C@@]1(CCCN2[C@@H]1C3=C(CC2)C4=CC=CC=C4O3)COC DM8ARQW IK OCUKPFWNSAAHRP-QZTJIDSGSA-N DM8ARQW IU (1S,12bS)-1-(methoxymethyl)-1-methyl-2,3,4,6,7,12b-hexahydro-[1]benzofuro[2,3-a]quinolizine DM8ARQW CA CAS 610782-82-6 DM8ARQW DE Alzheimer disease DMRIO6D ID DMRIO6D DMRIO6D DN ORMD-0901 DMRIO6D HS Phase 2 DMRIO6D SN Exenatide-4 (oral, diabetes), Oramed; GLP1-analog (oral, non-insulin dependent diabetes), Oramed Pharmaceuticals DMRIO6D CP Oramed Pharmaceuticals Inc DMRIO6D DE Type-2 diabetes DM1EK5D ID DM1EK5D DM1EK5D DN Ortataxel DM1EK5D HS Phase 2 DM1EK5D SN UNII-8H61Y4E29N; 186348-23-2; 8H61Y4E29N; IDN-5109; IDN 5109; Ortataxel [INN]; Bay-59-8862; SB-T-101131; SB-T 101131; idn5109; SCHEMBL9932772; CHEMBL382300; BAY-59; IND-5109; DB11669; Z-3102; Hexanoic acid, 3-(((1,1-dimethylethoxy)carbonyl)amino)-2-hydroxy-5-methyl-,; Hexanoic acid; IND5109; 13-(N-tert-butoxycarbonyl-beta-isobutyisoserinyl)-14-hydroxy-baccatin-1,14-carbonate; 13-(N-tert-butoxycarbonyl-beta-isobutyisoserinyl)-14-hydroxybaccatin-1,14-carbonate; Genz29155 DM1EK5D CP Spectrum DM1EK5D DT Small molecular drug DM1EK5D PC 6918412 DM1EK5D MW 871.9 DM1EK5D FM C44H57NO17 DM1EK5D IC InChI=1S/C44H57NO17/c1-20(2)17-25(45-38(53)61-40(6,7)8)29(49)37(52)57-30-21(3)28-31(56-22(4)46)33(50)42(11)26(48)18-27-43(19-55-27,60-23(5)47)32(42)35(58-36(51)24-15-13-12-14-16-24)44(41(28,9)10)34(30)59-39(54)62-44/h12-16,20,25-27,29-32,34-35,48-49H,17-19H2,1-11H3,(H,45,53)/t25-,26-,27+,29+,30+,31+,32-,34-,35-,42+,43-,44+/m0/s1 DM1EK5D CS CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@]5(C2(C)C)[C@H]([C@@H]1OC(=O)[C@@H]([C@H](CC(C)C)NC(=O)OC(C)(C)C)O)OC(=O)O5)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)OC(=O)C DM1EK5D IK BWKDAMBGCPRVPI-ZQRPHVBESA-N DM1EK5D IU [(1S,2S,3R,4S,7R,9S,10S,12R,15R,16S)-4,12-diacetyloxy-9-hydroxy-15-[(2R,3S)-2-hydroxy-5-methyl-3-[(2-methylpropan-2-yl)oxycarbonylamino]hexanoyl]oxy-10,14,20,20-tetramethyl-11,18-dioxo-6,17,19-trioxapentacyclo[11.6.1.01,16.03,10.04,7]icos-13-en-2-yl] benzoate DM1EK5D CA CAS 186348-23-2 DM1EK5D DE Solid tumour/cancer; Heart transplant rejection DMSO846 ID DMSO846 DMSO846 DN Orvepitant DMSO846 HS Phase 2 DMSO846 SN Orvepitant; UNII-IIU6V0W3JD; 579475-18-6; GW823296X; IIU6V0W3JD; GW823296; Orvepitant [USAN:INN]; Orvepitant (USAN/INN); SCHEMBL1421784; CHEMBL2105667; XWNBGDJPEXZSQM-VZOBGQTKSA-N; BDBM50442585; ZINC56898864; AKOS030231272; SB17117; DB12427; NCGC00386593-01; (2R,4S)-N-((R)-1-(3,5-Bis(trifluoromethyl)phenyl)ethyl)-2-(4-fluoro-2-methylphenyl)-N-methyl-4-((S)-6-oxohexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl)piperidine-1-c; D09650 DMSO846 CP GSK DMSO846 DT Small molecular drug DMSO846 PC 9852175 DMSO846 MW 628.6 DMSO846 FM C31H35F7N4O2 DMSO846 IC InChI=1S/C31H35F7N4O2/c1-18-12-23(32)4-6-26(18)27-16-24(40-10-11-41-25(17-40)5-7-28(41)43)8-9-42(27)29(44)39(3)19(2)20-13-21(30(33,34)35)15-22(14-20)31(36,37)38/h4,6,12-15,19,24-25,27H,5,7-11,16-17H2,1-3H3/t19-,24+,25+,27-/m1/s1 DMSO846 CS CC1=C(C=CC(=C1)F)[C@H]2C[C@H](CCN2C(=O)N(C)[C@H](C)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)N4CCN5[C@H](C4)CCC5=O DMSO846 IK XWNBGDJPEXZSQM-VZOBGQTKSA-N DMSO846 IU (2R,4S)-4-[(8aS)-6-oxo-1,3,4,7,8,8a-hexahydropyrrolo[1,2-a]pyrazin-2-yl]-N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-(4-fluoro-2-methylphenyl)-N-methylpiperidine-1-carboxamide DMSO846 CA CAS 579475-18-6 DMSO846 DE Anxiety disorder; Depression DMJX3O8 ID DMJX3O8 DMJX3O8 DN OSI-027 DMJX3O8 HS Phase 2 DMJX3O8 CP OSI DMJX3O8 DT Small molecular drug DMJX3O8 PC 135398516 DMJX3O8 MW 406.4 DMJX3O8 FM C21H22N6O3 DMJX3O8 IC InChI=1S/C21H22N6O3/c1-30-15-4-2-3-13-9-14(25-16(13)15)17-18-19(22)23-10-24-27(18)20(26-17)11-5-7-12(8-6-11)21(28)29/h2-4,9-12,25H,5-8H2,1H3,(H,28,29)(H2,22,23,24) DMJX3O8 CS COC1=CC=CC2=C1NC(=C2)C3=C4C(=NC=NN4C(=N3)C5CCC(CC5)C(=O)O)N DMJX3O8 IK JROFGZPOBKIAEW-UHFFFAOYSA-N DMJX3O8 IU 4-[4-amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl]cyclohexane-1-carboxylic acid DMJX3O8 CA CAS 936890-98-1 DMJX3O8 CB CHEBI:91363 DMJX3O8 DE Renal cell carcinoma DMBVI6E ID DMBVI6E DMBVI6E DN Ostabolin-C DMBVI6E HS Phase 2 DMBVI6E CP Zelos Therape. DMBVI6E DE Osteoporosis DMHKIOF ID DMHKIOF DMHKIOF DN OT551 DMHKIOF HS Phase 2 DMHKIOF CP Colby Pharmaceuticals DMHKIOF DT Small interfering RNA DMHKIOF DE Age-related macular degeneration DMTNOXQ ID DMTNOXQ DMTNOXQ DN OT-551 DMTNOXQ HS Phase 2 DMTNOXQ SN Tempol-H prodrug, Othera DMTNOXQ CP Othera Pharmaceuticals Inc DMTNOXQ DT Small molecular drug DMTNOXQ PC 10131000 DMTNOXQ MW 241.33 DMTNOXQ FM C13H23NO3 DMTNOXQ IC InChI=1S/C13H23NO3/c1-12(2)7-10(8-13(3,4)14(12)16)17-11(15)9-5-6-9/h9-10,16H,5-8H2,1-4H3 DMTNOXQ CS CC1(CC(CC(N1O)(C)C)OC(=O)C2CC2)C DMTNOXQ IK ZWEXEKJLDHNLLA-UHFFFAOYSA-N DMTNOXQ IU (1-hydroxy-2,2,6,6-tetramethylpiperidin-4-yl) cyclopropanecarboxylate DMTNOXQ CA CAS 627085-11-4 DMTNOXQ DE Ocular inflammation DMFNDBC ID DMFNDBC DMFNDBC DN Otelixizumab DMFNDBC HS Phase 2 DMFNDBC CP GSK DMFNDBC DT Monoclonal antibody DMFNDBC DE Type-1 diabetes DM1AQLW ID DM1AQLW DM1AQLW DN Otilimab DM1AQLW HS Phase 2 DM1AQLW SN Otilimab [USAN]; UNII-Y8127R3VCH; Y8127R3VCH; MOR103; GSK3196165; 1638332-55-4; human monoclonal antibody DM1AQLW TC Antiviral Agents DM1AQLW DT Monoclonal antibody DM1AQLW DE Coronavirus Disease 2019 (COVID-19) DMAZIND ID DMAZIND DMAZIND DN Otlertuzumab DMAZIND HS Phase 2 DMAZIND CP Aptevo Therapeutics Seattle, WA DMAZIND DE Chronic lymphocytic leukaemia; Peripheral T-cell lymphoma DM5Q9RY ID DM5Q9RY DM5Q9RY DN OX-914 DM5Q9RY HS Phase 2 DM5Q9RY CP Inflazyme Pharmaceuticals DM5Q9RY DE Asthma DMBM47Z ID DMBM47Z DMBM47Z DN Oxazolidinones DMBM47Z HS Phase 2 DMBM47Z SN 2-Oxazolidone; Oxazolidin-2-one; 2-Oxazolidinone; 497-25-6; 1,3-Oxazolidin-2-one; Oxazolidinone; Oxazolidone; UNII-Z4D49W92PP; EINECS 207-840-9; NSC 35382; BRN 0106251; AI3-38980; CHEBI:1237; Z4D49W92PP; IZXIZTKNFFYFOF-UHFFFAOYSA-N; Carbamic acid, (2-hydroxyethyl)-, gamma-lactone; MFCD00005268; 2-Oxazolidone, 98%; WLN: T5MVOTJ; 51667-26-6; Carbamic acid, .gamma.-lactone; Oxazolidinones; SMR000857362; oxazolodinone; hydroxyoxazoline; 2-oxazolidinon; hydroxy-oxazoline; 2-Oxazolidine; oxazolidine-2-one; PubChem8624; ACMC-209upq; AC1Q6HSI DMBM47Z DT Small molecular drug DMBM47Z PC 73949 DMBM47Z MW 87.08 DMBM47Z FM C3H5NO2 DMBM47Z IC InChI=1S/C3H5NO2/c5-3-4-1-2-6-3/h1-2H2,(H,4,5) DMBM47Z CS C1COC(=O)N1 DMBM47Z IK IZXIZTKNFFYFOF-UHFFFAOYSA-N DMBM47Z IU 1,3-oxazolidin-2-one DMBM47Z CA CAS 497-25-6 DMBM47Z CB CHEBI:1237 DMBM47Z DE Gram-positive bacterial infection DMSNL51 ID DMSNL51 DMSNL51 DN Oxfendazole DMSNL51 HS Phase 2 DMSNL51 SN Oxfendazole; Fenbendazole sulfoxide; Synanthic; Systamex; OFDZ; Systemax; Repidose; Oxfendazolum; Oxfendazol; Synanthic (Veterinary); RS-8858; fenbendazole S-oxide; RS 8858; 5-Phenylsulfinyl-2-carbomethoxyaminobenzimidazole; Oxfendazol [INN-Spanish]; Oxfendazolum [INN-Latin]; UNII-OMP2H17F9E; HOE 8105; methyl [5-(phenylsulfinyl)-1H-benzimidazol-2-yl]carbamate; Oxfendazole [USAN:BAN:INN]; Methyl 5-(phenylsulfinyl)-2-benzimidazolecarbamate; Oxfendazole (USP/INN) DMSNL51 PC 40854 DMSNL51 MW 315.3 DMSNL51 FM C15H13N3O3S DMSNL51 IC InChI=1S/C15H13N3O3S/c1-21-15(19)18-14-16-12-8-7-11(9-13(12)17-14)22(20)10-5-3-2-4-6-10/h2-9H,1H3,(H2,16,17,18,19) DMSNL51 CS COC(=O)NC1=NC2=C(N1)C=C(C=C2)S(=O)C3=CC=CC=C3 DMSNL51 IK BEZZFPOZAYTVHN-UHFFFAOYSA-N DMSNL51 IU methyl N-[6-(benzenesulfinyl)-1H-benzimidazol-2-yl]carbamate DMSNL51 CA CAS 53716-50-0 DMSNL51 CB CHEBI:35812 DMSNL51 DE Trichuris infection DMC3PJS ID DMC3PJS DMC3PJS DN Oxytrex DMC3PJS HS Phase 2 DMC3PJS DE Pain DMEGTH1 ID DMEGTH1 DMEGTH1 DN Ozarelix DMEGTH1 HS Phase 2 DMEGTH1 CP Spectrum DMEGTH1 PC 25080293 DMEGTH1 MW 1459.1 DMEGTH1 FM C72H96ClN17O14 DMEGTH1 IC InChI=1S/C72H96ClN17O14/c1-5-6-17-52(63(96)85-54(19-12-33-79-71(75)76)70(103)90-34-13-20-59(90)67(100)81-42(2)61(74)94)83-62(95)53(18-9-10-32-80-72(77)104)84-68(101)60(39-45-24-29-51(93)30-25-45)89(4)69(102)58(41-91)88-66(99)57(38-47-14-11-31-78-40-47)87-65(98)56(36-44-22-27-50(73)28-23-44)86-64(97)55(82-43(3)92)37-46-21-26-48-15-7-8-16-49(48)35-46/h7-8,11,14-16,21-31,35,40,42,52-60,91,93H,5-6,9-10,12-13,17-20,32-34,36-39,41H2,1-4H3,(H2,74,94)(H,81,100)(H,82,92)(H,83,95)(H,84,101)(H,85,96)(H,86,97)(H,87,98)(H,88,99)(H4,75,76,79)(H3,77,80,104)/t42-,52+,53-,54+,55-,56-,57-,58+,59+,60+/m1/s1 DMEGTH1 CS CCCC[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(=O)N)NC(=O)[C@@H](CCCCNC(=O)N)NC(=O)[C@H](CC2=CC=C(C=C2)O)N(C)C(=O)[C@H](CO)NC(=O)[C@@H](CC3=CN=CC=C3)NC(=O)[C@@H](CC4=CC=C(C=C4)Cl)NC(=O)[C@@H](CC5=CC6=CC=CC=C6C=C5)NC(=O)C DMEGTH1 IK KATZUZNTRINHDT-HALMFYTRSA-N DMEGTH1 IU (2S)-1-[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]-methylamino]-3-(4-hydroxyphenyl)propanoyl]amino]-6-(carbamoylamino)hexanoyl]amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]-N-[(2R)-1-amino-1-oxopropan-2-yl]pyrrolidine-2-carboxamide DMEGTH1 CA CAS 295350-45-7 DMEGTH1 DE Prostate disease DMEYQPN ID DMEYQPN DMEYQPN DN P-1736 DMEYQPN HS Phase 2 DMEYQPN SN Pyyy; GPR40 modulators (diabetes), Nicholas Piramal; GPR40 modulators (diabetes), Piramal Life Sciences; P-1736-05; GPR40 modulators (diabetes), NPIL Research & Development DMEYQPN CP Piramal Healthcare Ltd DMEYQPN DE Diabetic complication DMMJUHD ID DMMJUHD DMMJUHD DN P-276 DMMJUHD HS Phase 2 DMMJUHD SN CDK4 inhibitor (cancer), Nicholas Piramal; P-664-02; CDK4 inhibitor (iv, cancer), Piramal Life Sciences; CDK4 inhibitor(iv, cancer), NPIL Research & Development DMMJUHD CP Piramal Healthcare Ltd DMMJUHD DT Small molecular drug DMMJUHD PC 23643976 DMMJUHD MW 401.8 DMMJUHD FM C21H20ClNO5 DMMJUHD IC InChI=1S/C21H20ClNO5/c1-23-7-6-12(14(23)10-24)19-15(25)8-16(26)20-17(27)9-18(28-21(19)20)11-4-2-3-5-13(11)22/h2-5,8-9,12,14,24-26H,6-7,10H2,1H3/t12-,14+/m1/s1 DMMJUHD CS CN1CC[C@H]([C@@H]1CO)C2=C(C=C(C3=C2OC(=CC3=O)C4=CC=CC=C4Cl)O)O DMMJUHD IK QLUYMIVVAYRECT-OCCSQVGLSA-N DMMJUHD IU 2-(2-chlorophenyl)-5,7-dihydroxy-8-[(2R,3S)-2-(hydroxymethyl)-1-methylpyrrolidin-3-yl]chromen-4-one DMMJUHD DE Breast cancer DM9DJL2 ID DM9DJL2 DM9DJL2 DN P276-00 DM9DJL2 HS Phase 2 DM9DJL2 SN CHEMBL2312181; SCHEMBL1180418 DM9DJL2 CP Nicholas Piramal DM9DJL2 DT Small molecular drug DM9DJL2 PC 23643975 DM9DJL2 MW 438.3 DM9DJL2 FM C21H21Cl2NO5 DM9DJL2 IC InChI=1S/C21H20ClNO5.ClH/c1-23-7-6-12(14(23)10-24)19-15(25)8-16(26)20-17(27)9-18(28-21(19)20)11-4-2-3-5-13(11)22;/h2-5,8-9,12,14,24-26H,6-7,10H2,1H3;1H/t12-,14+;/m1./s1 DM9DJL2 CS CN1CC[C@H]([C@@H]1CO)C2=C(C=C(C3=C2OC(=CC3=O)C4=CC=CC=C4Cl)O)O.Cl DM9DJL2 IK OOVTUOCTLAERQD-OJMBIDBESA-N DM9DJL2 IU 2-(2-chlorophenyl)-5,7-dihydroxy-8-[(2R,3S)-2-(hydroxymethyl)-1-methylpyrrolidin-3-yl]chromen-4-one;hydrochloride DM9DJL2 CA CAS 920113-03-7 DM9DJL2 DE Mantle cell lymphoma DMW1OI6 ID DMW1OI6 DMW1OI6 DN P32/98 DMW1OI6 HS Phase 2 DMW1OI6 SN Isoleucine-thiazolidide; AC1OCFGS; MolPort-044-561-375 DMW1OI6 DT Small molecular drug DMW1OI6 PC 6918464 DMW1OI6 MW 318.39 DMW1OI6 FM C13H22N2O5S DMW1OI6 IC InChI=1S/C9H18N2OS.C4H4O4/c1-3-7(2)8(10)9(12)11-4-5-13-6-11;5-3(6)1-2-4(7)8/h7-8H,3-6,10H2,1-2H3;1-2H,(H,5,6)(H,7,8)/b;2-1+/t7-,8-;/m0./s1 DMW1OI6 CS CC[C@H](C)[C@@H](C(=O)N1CCSC1)N.C(=C/C(=O)O)\\C(=O)O DMW1OI6 IK ZSOPWZQRZHWYFY-NUXPJIRBSA-N DMW1OI6 IU (2S,3S)-2-amino-3-methyl-1-(1,3-thiazolidin-3-yl)pentan-1-one;(E)-but-2-enedioic acid DMW1OI6 DE Autism spectrum disorder DMCBEYH ID DMCBEYH DMCBEYH DN P54 DMCBEYH HS Phase 2 DMCBEYH DE Solid tumour/cancer DMG8NLI ID DMG8NLI DMG8NLI DN P-9808 DMG8NLI HS Phase 2 DMG8NLI SN Porphogen; Porphozym; PBGD, HemeBiotech; PBGD, Zymenex; Recombinant porphobilinogen deaminase, HemeBiotech; Recombinant porphobilinogen deaminase, Zymenex DMG8NLI CP Zymenex A/S DMG8NLI DE Porphyria DM3816P ID DM3816P DM3816P DN PAC-14028 DM3816P HS Phase 2 DM3816P CP Pacific Pharmaceuticals Co Ltd DM3816P PC 56649347 DM3816P MW 491.5 DM3816P FM C21H22F5N3O3S DM3816P IC InChI=1S/C21H22F5N3O3S/c1-4-5-17-13(6-8-18(28-17)21(24,25)26)7-9-19(30)27-12(2)14-10-15(22)20(16(23)11-14)29-33(3,31)32/h6-12,29H,4-5H2,1-3H3,(H,27,30)/b9-7+/t12-/m1/s1 DM3816P CS CCCC1=C(C=CC(=N1)C(F)(F)F)/C=C/C(=O)N[C@H](C)C2=CC(=C(C(=C2)F)NS(=O)(=O)C)F DM3816P IK UKGJZDSUJSPAJL-YPUOHESYSA-N DM3816P IU (E)-N-[(1R)-1-[3,5-difluoro-4-(methanesulfonamido)phenyl]ethyl]-3-[2-propyl-6-(trifluoromethyl)pyridin-3-yl]prop-2-enamide DM3816P CA CAS 1005168-10-4 DM3816P DE Atopic dermatitis DMMIYZ7 ID DMMIYZ7 DMMIYZ7 DN Palifosfamide DMMIYZ7 HS Phase 2 DMMIYZ7 SN ZIO-201 DMMIYZ7 CP ZIOPHARM Oncology DMMIYZ7 DT Small molecular drug DMMIYZ7 PC 100427 DMMIYZ7 MW 221.02 DMMIYZ7 FM C4H11Cl2N2O2P DMMIYZ7 IC InChI=1S/C4H11Cl2N2O2P/c5-1-3-7-11(9,10)8-4-2-6/h1-4H2,(H3,7,8,9,10) DMMIYZ7 CS C(CCl)NP(=O)(NCCCl)O DMMIYZ7 IK BKCJZNIZRWYHBN-UHFFFAOYSA-N DMMIYZ7 IU bis(2-chloroethylamino)phosphinic acid DMMIYZ7 CA CAS 31645-39-3 DMMIYZ7 CB CHEBI:80566 DMMIYZ7 DE Soft tissue sarcoma DMX8ZAQ ID DMX8ZAQ DMX8ZAQ DN Paliroden DMX8ZAQ HS Phase 2 DMX8ZAQ SN SR-57667; SR-57667B DMX8ZAQ CP Sanofi-aventis DMX8ZAQ DT Small molecular drug DMX8ZAQ PC 11567682 DMX8ZAQ MW 407.5 DMX8ZAQ FM C26H24F3N DMX8ZAQ IC InChI=1S/C26H24F3N/c27-26(28,29)25-8-4-7-24(19-25)23-14-17-30(18-15-23)16-13-20-9-11-22(12-10-20)21-5-2-1-3-6-21/h1-12,14,19H,13,15-18H2 DMX8ZAQ CS C1CN(CC=C1C2=CC(=CC=C2)C(F)(F)F)CCC3=CC=C(C=C3)C4=CC=CC=C4 DMX8ZAQ IK CNEWKIDCGDXBDE-UHFFFAOYSA-N DMX8ZAQ IU 1-[2-(4-phenylphenyl)ethyl]-4-[3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-pyridine DMX8ZAQ CA CAS 188396-77-2 DMX8ZAQ DE Parkinson disease DMAZ460 ID DMAZ460 DMAZ460 DN Pankomab-GEX DMAZ460 HS Phase 2 DMAZ460 SN GT-MAB 2.5 GEX; PankoMab (GlycoExpress, cancer), Glycotope DMAZ460 CP Glycotope GmbH DMAZ460 DT Antibody DMAZ460 DE Solid tumour/cancer DMV27SP ID DMV27SP DMV27SP DN Panobacumab DMV27SP HS Phase 2 DMV27SP SN KBPA-101; Human monoclonal antibody (Pseudomonas aeruginosa), Berna; MAb (Pseudomonas aeruginosa), Berna DMV27SP CP Aridis Pharmaceuticals DMV27SP DT Monoclonal antibody DMV27SP DE Ventilator-associated pneumonia; Hospital-acquired pneumonia; Pseudomonas infection DMPO4M1 ID DMPO4M1 DMPO4M1 DN Paquinimod DMPO4M1 HS Phase 2 DMPO4M1 SN ABR-215757; ABR-25757; Project 57-57, Active Biotech DMPO4M1 CP Active Biotech AB DMPO4M1 DT Small molecular drug DMPO4M1 PC 54684617 DMPO4M1 MW 350.4 DMPO4M1 FM C21H22N2O3 DMPO4M1 IC InChI=1S/C21H22N2O3/c1-4-14-10-9-13-16-17(14)19(24)18(20(25)22(16)3)21(26)23(5-2)15-11-7-6-8-12-15/h6-13,24H,4-5H2,1-3H3 DMPO4M1 CS CCC1=C2C(=CC=C1)N(C(=O)C(=C2O)C(=O)N(CC)C3=CC=CC=C3)C DMPO4M1 IK DIKSYHCCYVYKRO-UHFFFAOYSA-N DMPO4M1 IU N,5-diethyl-4-hydroxy-1-methyl-2-oxo-N-phenylquinoline-3-carboxamide DMPO4M1 CA CAS 248282-01-1 DMPO4M1 DE Lupus DMD275X ID DMD275X DMD275X DN Pardoprunox DMD275X HS Phase 2 DMD275X SN Pardoprunox (USAN/INN); 7-(4-methylpiperazin-1-yl)-3H-1,3-benzoxazol-2-one; 7-(4-methylpiperazin-1-yl)-3H-benzooxazol-2-one DMD275X CP Solvay DMD275X DT Small molecular drug DMD275X PC 6918525 DMD275X MW 233.27 DMD275X FM C12H15N3O2 DMD275X IC InChI=1S/C12H15N3O2/c1-14-5-7-15(8-6-14)10-4-2-3-9-11(10)17-12(16)13-9/h2-4H,5-8H2,1H3,(H,13,16) DMD275X CS CN1CCN(CC1)C2=CC=CC3=C2OC(=O)N3 DMD275X IK YVPUUUDAZYFFQT-UHFFFAOYSA-N DMD275X IU 7-(4-methylpiperazin-1-yl)-3H-1,3-benzoxazol-2-one DMD275X CA CAS 269718-84-5 DMD275X DE Parkinson disease DM4N7BT ID DM4N7BT DM4N7BT DN Paritaprevir DM4N7BT HS Phase 2 DM4N7BT SN (2R,6S,13aS,14aR,16aS,Z)-N-(cyclopropylsulfonyl)-6-(5-methylpyrazine-2-carboxamido)-5,16-dioxo-2-(phenanthridin-6-yloxy)-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a-carboxamide; ABT 450; ABT-450; ABT450; CHEMBL3391662; EX-A2278; OU2YM37K86; Paritaprevir; Paritaprevir [USAN:INN]; Paritaprevir(ABT-450); Paritaprevir(Veruprevir ABT-450); SCHEMBL3069964; UNII-OU2YM37K86; Veruprevir; Veruprevir [INN]; Veruprevir anhydrous DM4N7BT TC Antiviral Agent DM4N7BT DT Small molecular drug DM4N7BT PC 45110509 DM4N7BT MW 765.886 DM4N7BT FM C40H43N7O7S DM4N7BT IC InChI=1S/C40H43N7O7S/c1-24-21-42-33(22-41-24)35(48)43-32-16-6-4-2-3-5-11-25-20-40(25,39(51)46-55(52,53)27-17-18-27)45-36(49)34-19-26(23-47(34)38(32)50)54-37-30-14-8-7-12-28(30)29-13-9-10-15-31(29)44-37/h5,7-15,21-22,25-27,32,34H,2-4,6,16-20,23H2,1H3,(H,43,48)(H,45,49)(H,46,51)/b11-5-/t25-,26-,32+,34+,40-/m1/s1 DM4N7BT CS CC1=NC=C(N=C1)C(=O)NC2CCCCCC=CC3CC3(NC(=O)C4CC(CN4C2=O)OC5=NC6=CC=CC=C6C7=CC=CC=C75)C(=O)NS(=O)(=O)C8CC8 DM4N7BT IK UAUIUKWPKRJZJV-QPLHLKROSA-N DM4N7BT IU (1S,4R,6S,7Z,14S,18R)-N-cyclopropylsulfonyl-14-[(5-methylpyrazine-2-carbonyl)amino]-2,15-dioxo-18-phenanthridin-6-yloxy-3,16-diazatricyclo[14.3.0.04,6]nonadec-7-ene-4-carboxamide DM4N7BT CA CAS 1216941-48-8 DM4N7BT DE Hepatitis C virus infection DMYBIFS ID DMYBIFS DMYBIFS DN Parsaclisib DMYBIFS HS Phase 2 DMYBIFS SN INCB050465; Parsaclisib free base; UNII-OS7097575K; 1426698-88-5 (free base); OS7097575K; 1426698-88-5; (4R)-4-{3-[(1S)-1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-ethoxy-6-fluorophenyl}pyrrolidin-2-one; INCB-050465; (4R)-4-(3-((1S)-1-(4-Amino-3-methyl-1H-pyrazolo(3,4-d)pyrimidin-1-yl)ethyl)-5-chloro-2-ethoxy-6-fluorophenyl)pyrrolidin-2-one; Parsaclisib [INN]; Parsaclisib [USAN]; Parsaclisib (USAN/INN); Parsaclisib [USAN:INN]; INCB050465 free base; INCB-050465 free base; CHEMBL4297615; SCHEMBL14736228; BDBM272573; EX-A2638; WHO 10589; DB14867; US10065963, 32c; HY-109068; CS-0033435; D11437; (R)-4-(3-((S)-1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl)-5-chloro-2-ethoxy-6-fluorophenyl)pyrrolidin-2-one; 2-Pyrrolidinone, 4-(3-((1S)-1-(4-amino-3-methyl-1H-pyrazolo(3,4-d)pyrimidin-1-yl)ethyl)-5-chloro-2-ethoxy-6-fluorophenyl)-, (4R)- DMYBIFS CP Incyte DMYBIFS DT Small molecular drug DMYBIFS PC 86677874 DMYBIFS MW 432.9 DMYBIFS FM C20H22ClFN6O2 DMYBIFS IC InChI=1S/C20H22ClFN6O2/c1-4-30-18-12(6-13(21)17(22)16(18)11-5-14(29)24-7-11)10(3)28-20-15(9(2)27-28)19(23)25-8-26-20/h6,8,10-11H,4-5,7H2,1-3H3,(H,24,29)(H2,23,25,26)/t10-,11-/m0/s1 DMYBIFS CS CCOC1=C(C(=C(C=C1[C@H](C)N2C3=NC=NC(=C3C(=N2)C)N)Cl)F)[C@H]4CC(=O)NC4 DMYBIFS IK ZQPDJCIXJHUERQ-QWRGUYRKSA-N DMYBIFS IU (4R)-4-[3-[(1S)-1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-ethoxy-6-fluorophenyl]pyrrolidin-2-one DMYBIFS CA CAS 1426698-88-5 DMYBIFS DE Follicular lymphoma DMCQBFT ID DMCQBFT DMCQBFT DN Parthenolide DMCQBFT HS Phase 2 DMCQBFT SN parthenolide; 20554-84-1; (-)-Parthenolide; CHEBI:7939; Parthenolide, Tanacetum parthenium; 4,5-alpha-Epoxy-6-beta-hydroxygermacra-1(10),11(13)-dien-12-oic acid gamma-lactone; partenolide; C15H20O3; 29552-41-8; Prestwick2_000550; Prestwick3_000550; Epitope ID:115014; SCHEMBL8220; BSPBio_001308; BSPBio_000599; MLS002153872; CHEMBL465158; BPBio1_000659; SCHEMBL13367522; BCBcMAP01_000041; Parthenolide, > MolPort-008-268-168; MolPort-003-959-089; HMS1361B10; HMS3402B10; HMS1989B10; HMS1791B10; HMS1569N21; HMS2096N21 DMCQBFT DT Small molecular drug DMCQBFT PC 7251185 DMCQBFT MW 248.32 DMCQBFT FM C15H20O3 DMCQBFT IC InChI=1S/C15H20O3/c1-9-5-4-8-15(3)13(18-15)12-11(7-6-9)10(2)14(16)17-12/h5,11-13H,2,4,6-8H2,1,3H3/b9-5+/t11-,12-,13+,15+/m0/s1 DMCQBFT CS C/C/1=C\\CC[C@@]2([C@H](O2)[C@@H]3[C@@H](CC1)C(=C)C(=O)O3)C DMCQBFT IK KTEXNACQROZXEV-PVLRGYAZSA-N DMCQBFT IU (1S,2R,4R,7E,11S)-4,8-dimethyl-12-methylidene-3,14-dioxatricyclo[9.3.0.02,4]tetradec-7-en-13-one DMCQBFT CA CAS 20554-84-1 DMCQBFT CB CHEBI:7939 DMU3XJP ID DMU3XJP DMU3XJP DN Pascolizumab DMU3XJP HS Phase 2 DMU3XJP SN SB-240683; Interleukin-4 antibody, SmithKline Beecham; Anti-IL-4 antibody (humanized), PDL; Anti-IL-4 antibody (humanized), Protein Design Labs DMU3XJP CP Novartis DMU3XJP DT Monoclonal antibody DMU3XJP DE Asthma DM2NJYC ID DM2NJYC DM2NJYC DN Patidegib DM2NJYC HS Phase 2 DM2NJYC SN Patidegib hydrochloride; UNII-ZL14FCA5PK; 1169829-40-6; ZL14FCA5PK; IPI-926 Hydrochloride; Saridegib HCl; Patidegib [USAN:INN]; Saridegib [Rescinded USAN]; Saridegib hydrochloride (USAN); CHEMBL2105764; D10325; Methanesulfonamide, N-((2S,3R,3'R,3aS,4'aR,6S,6'aR,6'bS,7aR,12'aS,12'bS)- 2',3',3a,4,4',4'a,5,5',6,6',6'a,6'b,7,7',7a,8',10',12',12'a,12'b-eicosahydro-3,6,11',12'b-tetramethylspiro(furo(3,2-b)pyridine-2(3H),9'(1'H)-naphth(2,1-a)azulen)-3'-yl)- DM2NJYC CP PellePharm San Francisco, CA DM2NJYC PC 25027363 DM2NJYC MW 504.8 DM2NJYC FM C29H48N2O3S DM2NJYC IC InChI=1S/C29H48N2O3S/c1-17-12-26-27(30-16-17)19(3)29(34-26)11-9-22-23-7-6-20-13-21(31-35(5,32)33)8-10-28(20,4)25(23)14-24(22)18(2)15-29/h17,19-23,25-27,30-31H,6-16H2,1-5H3/t17-,19+,20+,21+,22-,23-,25-,26+,27-,28-,29-/m0/s1 DM2NJYC CS C[C@H]1C[C@@H]2[C@H]([C@H]([C@]3(O2)CC[C@H]4[C@@H]5CC[C@@H]6C[C@@H](CC[C@@]6([C@H]5CC4=C(C3)C)C)NS(=O)(=O)C)C)NC1 DM2NJYC IK HZLFFNCLTRVYJG-WWGOJCOQSA-N DM2NJYC IU N-[(3R,3'R,3'aS,4aR,6'S,6aR,6bS,7'aR,9S,12aS,12bS)-3',6',11,12b-tetramethylspiro[1,2,3,4,4a,5,6,6a,6b,7,8,10,12,12a-tetradecahydronaphtho[2,1-a]azulene-9,2'-3a,4,5,6,7,7a-hexahydro-3H-furo[3,2-b]pyridine]-3-yl]methanesulfonamide DM2NJYC CA CAS 1037210-93-7 DM2NJYC DE Basal cell carcinoma; Basal cell nevus syndrome; Chondrosarcoma DMU0812 ID DMU0812 DMU0812 DN PAZ-320 DMU0812 HS Phase 2 DMU0812 CP Boston Therapeutics DMU0812 DE Type-2 diabetes DMVJD2W ID DMVJD2W DMVJD2W DN Pazopanib + Tyverb/Tykerb DMVJD2W HS Phase 2 DMVJD2W CP GSK DMVJD2W DT Combination drug DMVJD2W PC 10113978; 9941095 DMVJD2W DE Inflammatory breast cancer DMZCI04 ID DMZCI04 DMZCI04 DN PB-1023 DMZCI04 HS Phase 2 DMZCI04 CP PhaseBio Pharmaceuticals DMZCI04 DE Type-2 diabetes DM8MJ3F ID DM8MJ3F DM8MJ3F DN PB1046 DM8MJ3F HS Phase 2 DM8MJ3F SN Pemziviptadil; PB1046 Vasomera; PB-1120 Vasomera DM8MJ3F CP Phasebio pharmaceuticals DM8MJ3F DT Recombinant protein DM8MJ3F DE Hypertension; Cardiomyopathy; Duchenne dystrophy; Heart failure; Pulmonary arterial hypertension DM05WIU ID DM05WIU DM05WIU DN PBI-05204 DM05WIU HS Phase 2 DM05WIU CP Phoenix Biotechnology DM05WIU PC 11541511 DM05WIU MW 576.7 DM05WIU FM C32H48O9 DM05WIU IC InChI=1S/C32H48O9/c1-17-29(35)24(37-5)14-27(39-17)41-21-8-10-30(3)20(13-21)6-7-23-22(30)9-11-31(4)28(19-12-26(34)38-16-19)25(40-18(2)33)15-32(23,31)36/h12,17,20-25,27-29,35-36H,6-11,13-16H2,1-5H3/t17-,20+,21-,22-,23+,24-,25-,27-,28-,29-,30-,31+,32-/m0/s1 DM05WIU CS C[C@H]1[C@@H]([C@H](C[C@@H](O1)O[C@H]2CC[C@]3([C@@H](C2)CC[C@@H]4[C@@H]3CC[C@]5([C@@]4(C[C@@H]([C@@H]5C6=CC(=O)OC6)OC(=O)C)O)C)C)OC)O DM05WIU IK JLPDBLFIVFSOCC-XYXFTTADSA-N DM05WIU IU [(3S,5R,8R,9S,10S,13R,14S,16S,17R)-14-hydroxy-3-[(2R,4S,5S,6S)-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy-10,13-dimethyl-17-(5-oxo-2H-furan-3-yl)-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-16-yl] acetate DM05WIU CA CAS 465-16-7 DM05WIU CB CHEBI:59030 DM05WIU DE Solid tumour/cancer; Pancreatic cancer DMPXK27 ID DMPXK27 DMPXK27 DN PBI-4050 DMPXK27 HS Phase 2 DMPXK27 SN setogepram; (3-pentylphenyl)acetic acid; 2-(3-Pentylphenyl)acetic acid; 1002101-19-0; 3-Pentylbenzeneacetic acid; UNII-879OVM0Y1S; Benzeneacetic acid, 3-pentyl-; 879OVM0Y1S; 1002101-19-0 (free acid); Fezagepras; SCHEMBL289216; CHEMBL4297635; GTPL10043; PBI4050; ZINC113492390; DB15447; HY-100775A; AS-59875; CS-0062694; A1-19258; Q27895887 DMPXK27 CP Liminal BioSciences DMPXK27 DT Small molecular drug DMPXK27 PC 24749700 DMPXK27 MW 206.28 DMPXK27 FM C13H18O2 DMPXK27 IC InChI=1S/C13H18O2/c1-2-3-4-6-11-7-5-8-12(9-11)10-13(14)15/h5,7-9H,2-4,6,10H2,1H3,(H,14,15) DMPXK27 CS CCCCCC1=CC(=CC=C1)CC(=O)O DMPXK27 IK PEGQOIGYZLJMIB-UHFFFAOYSA-N DMPXK27 IU 2-(3-pentylphenyl)acetic acid DMPXK27 CA CAS 1002101-19-0 DMPXK27 DE Idiopathic pulmonary fibrosis DMKWGS1 ID DMKWGS1 DMKWGS1 DN PBT-2 DMKWGS1 HS Phase 2 DMKWGS1 SN AD/HD therapy, Prana; Alzheimers/Huntingtons disease therapy (chelating agent), Prana DMKWGS1 CP Prana biotechnology DMKWGS1 DT Small molecular drug DMKWGS1 PC 10016012 DMKWGS1 MW 271.14 DMKWGS1 FM C12H12Cl2N2O DMKWGS1 IC InChI=1S/C12H12Cl2N2O/c1-16(2)6-7-3-4-8-9(13)5-10(14)12(17)11(8)15-7/h3-5,17H,6H2,1-2H3 DMKWGS1 CS CN(C)CC1=NC2=C(C=C1)C(=CC(=C2O)Cl)Cl DMKWGS1 IK YZPOQCQXOSEMAZ-UHFFFAOYSA-N DMKWGS1 IU 5,7-dichloro-2-[(dimethylamino)methyl]quinolin-8-ol DMKWGS1 CA CAS 747408-78-2 DMKWGS1 DE Alzheimer disease; Huntington disease DMYRIHZ ID DMYRIHZ DMYRIHZ DN PCL-016 DMYRIHZ HS Phase 2 DMYRIHZ CP Novactyl DMYRIHZ DE Acne vulgaris DMYFRTB ID DMYFRTB DMYFRTB DN PCM-075 DMYFRTB HS Phase 2 DMYFRTB SN Onvansertib DMYFRTB CP TrovaGene San Diego, CA DMYFRTB PC 49792852 DMYFRTB MW 532.5 DMYFRTB FM C24H27F3N8O3 DMYFRTB IC InChI=1S/C24H27F3N8O3/c1-33-6-8-34(9-7-33)15-3-5-18(38-24(25,26)27)17(12-15)30-23-29-13-14-2-4-16-20(22(28)37)32-35(10-11-36)21(16)19(14)31-23/h3,5,12-13,36H,2,4,6-11H2,1H3,(H2,28,37)(H,29,30,31) DMYFRTB CS CN1CCN(CC1)C2=CC(=C(C=C2)OC(F)(F)F)NC3=NC=C4CCC5=C(C4=N3)N(N=C5C(=O)N)CCO DMYFRTB IK QHLVBNKYJGBCQJ-UHFFFAOYSA-N DMYFRTB IU 1-(2-hydroxyethyl)-8-[5-(4-methylpiperazin-1-yl)-2-(trifluoromethoxy)anilino]-4,5-dihydropyrazolo[4,3-h]quinazoline-3-carboxamide DMYFRTB CA CAS 1034616-18-6 DMYFRTB DE Acute myeloid leukaemia; Solid tumour/cancer; Prostate cancer DMUHDX3 ID DMUHDX3 DMUHDX3 DN PC-SOD DMUHDX3 HS Phase 2 DMUHDX3 SN PC-SOD (inhaled) DMUHDX3 CP LTT Bio-Pharma Co Ltd DMUHDX3 DE Interstitial lung disease DM27D4J ID DM27D4J DM27D4J DN PD-0325901 DM27D4J HS Phase 2 DM27D4J SN PD 0325901; PD 325901; PD0325901; PD325901; PD-325901; S06-0029; N-[((R)-2,3-dihydroxypropyl)oxy]-3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]benzamide; N-[(2R)-2,3-dihydroxypropoxy]-3,4-difluoro-2-[(2-fluoro-4-iodo-phenyl)amino]benzamide; N-{[(2R)-2,3-dihydroxypropyl]oxy}-3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]benzamide DM27D4J CP Pfizer DM27D4J TC Anticancer Agents DM27D4J DT Small molecular drug DM27D4J PC 9826528 DM27D4J MW 482.19 DM27D4J FM C16H14F3IN2O4 DM27D4J IC InChI=1S/C16H14F3IN2O4/c17-11-3-2-10(16(25)22-26-7-9(24)6-23)15(14(11)19)21-13-4-1-8(20)5-12(13)18/h1-5,9,21,23-24H,6-7H2,(H,22,25)/t9-/m1/s1 DM27D4J CS C1=CC(=C(C=C1I)F)NC2=C(C=CC(=C2F)F)C(=O)NOC[C@@H](CO)O DM27D4J IK SUDAHWBOROXANE-SECBINFHSA-N DM27D4J IU N-[(2R)-2,3-dihydroxypropoxy]-3,4-difluoro-2-(2-fluoro-4-iodoanilino)benzamide DM27D4J CA CAS 391210-10-9 DM27D4J CB CHEBI:88249 DM27D4J DE Breast cancer DMXAH4G ID DMXAH4G DMXAH4G DN PD-143188 DMXAH4G HS Phase 2 DMXAH4G SN PD-147693; PD-149394; PD-155144; PD-163637; PD-163639 DMXAH4G CP Parke-Davis & Co DMXAH4G DT Small molecular drug DMXAH4G PC 101650979 DMXAH4G MW 329.5 DMXAH4G FM C24H27N DMXAH4G IC InChI=1S/C24H27N/c1-3-9-21(10-4-1)23-14-16-25(17-15-23)19-20-8-7-13-24(18-20)22-11-5-2-6-12-22/h1-7,9-14,20,24H,8,15-19H2/t20-,24?/m1/s1 DMXAH4G CS C1CN(CC=C1C2=CC=CC=C2)C[C@@H]3CC=CC(C3)C4=CC=CC=C4 DMXAH4G IK SDOHTVBFDDPWNE-CGHJUBPDSA-N DMXAH4G IU 4-phenyl-1-[[(1R)-5-phenylcyclohex-3-en-1-yl]methyl]-3,6-dihydro-2H-pyridine DMXAH4G DE Psychotic disorder DMWVBTQ ID DMWVBTQ DMWVBTQ DN PD-145065 DMWVBTQ HS Phase 2 DMWVBTQ SN N-Acetyl-2-D-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)glycyl-L-leucyl-L-aspartyl-L-isoleucyl-L-isoleucyl-L-tryptophan DMWVBTQ DT Small molecular drug DMWVBTQ PC 123959 DMWVBTQ MW 950.1 DMWVBTQ FM C52H67N7O10 DMWVBTQ IC InChI=1S/C52H67N7O10/c1-8-29(5)44(49(65)57-41(52(68)69)25-34-27-53-38-21-15-14-18-35(34)38)59-50(66)45(30(6)9-2)58-48(64)40(26-42(61)62)55-47(63)39(24-28(3)4)56-51(67)46(54-31(7)60)43-36-19-12-10-16-32(36)22-23-33-17-11-13-20-37(33)43/h10-21,27-30,39-41,43-46,53H,8-9,22-26H2,1-7H3,(H,54,60)(H,55,63)(H,56,67)(H,57,65)(H,58,64)(H,59,66)(H,61,62)(H,68,69)/t29-,30-,39-,40-,41-,44-,45-,46+/m0/s1 DMWVBTQ CS CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](C3C4=CC=CC=C4CCC5=CC=CC=C35)NC(=O)C DMWVBTQ IK HRAQSWKGRRUBDJ-OMUAVVNCSA-N DMWVBTQ IU (3S)-3-[[(2S)-2-[[(2R)-2-acetamido-2-(2-tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,11,13-hexaenyl)acetyl]amino]-4-methylpentanoyl]amino]-4-[[(2S,3S)-1-[[(2S,3S)-1-[[(1S)-1-carboxy-2-(1H-indol-3-yl)ethyl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-4-oxobutanoic acid DMWVBTQ CA CAS 153049-49-1 DMWVBTQ DE Hypertension DMPW28M ID DMPW28M DMPW28M DN PD-200390 DMPW28M HS Phase 2 DMPW28M SN AC1L4NQF; SCHEMBL9494809; YPPRSIHNTQEZCJ-UHFFFAOYSA-N; 3-(3,5-ditert-butyl-4-hydroxyphenyl)sulfanyl-N-methyl-N-(2-pyridin-2-ylethyl)propanamide; 3-[[3,5-Bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-N-[2-(2-pyridyl)ethyl]-N-methylpropanamide; 3-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-N-methyl-N-[2-(2-pyridinyl)ethyl]propanamide DMPW28M CP Pfizer DMPW28M DT Small molecular drug DMPW28M PC 188931 DMPW28M MW 428.6 DMPW28M FM C25H36N2O2S DMPW28M IC InChI=1S/C25H36N2O2S/c1-24(2,3)20-16-19(17-21(23(20)29)25(4,5)6)30-15-12-22(28)27(7)14-11-18-10-8-9-13-26-18/h8-10,13,16-17,29H,11-12,14-15H2,1-7H3 DMPW28M CS CC(C)(C)C1=CC(=CC(=C1O)C(C)(C)C)SCCC(=O)N(C)CCC2=CC=CC=N2 DMPW28M IK YPPRSIHNTQEZCJ-UHFFFAOYSA-N DMPW28M IU 3-(3,5-ditert-butyl-4-hydroxyphenyl)sulfanyl-N-methyl-N-(2-pyridin-2-ylethyl)propanamide DMPW28M DE Insomnia DM6F5EV ID DM6F5EV DM6F5EV DN PD-360324 DM6F5EV HS Phase 2 DM6F5EV SN PD-0360324; MCSF mAb (RA), Pfizer; Macrophage colony stimulating factor monoclonal antibody (rheumatoid arthritis), Pfizer DM6F5EV CP Pfizer DM6F5EV DE Rheumatoid arthritis DMGP9VN ID DMGP9VN DMGP9VN DN PDC-1421 DMGP9VN HS Phase 2 DMGP9VN CP BioLite DMGP9VN DE Attention deficit hyperactivity disorder DM6OC53 ID DM6OC53 DM6OC53 DN PDX-101 DM6OC53 HS Phase 2 DM6OC53 SN Belinostat; 414864-00-9; PXD101; PXD-101; Belinostat (PXD101); Beleodaq; 866323-14-0; (E)-N-hydroxy-3-(3-(N-phenylsulfamoyl)phenyl)acrylamide; PXD 101; N-HYDROXY-3-(3-PHENYLSULFAMOYLPHENYL)ACRYLAMIDE; UNII-F4H96P17NZ; Belinostat(Random Configuration); NSC726630; PX105684; PX 105684; F4H96P17NZ; CHEBI:61076; (2E)-N-hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamide; N-HYDROXY-3-[3-[(PHENYLAMINO)SULFONYL]PHENYL]-2-PROPENAMIDE; (E)-N-hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamide; PX-105684 DM6OC53 CP National Cancer Institute (NCI) DM6OC53 TC Anticancer Agents DM6OC53 DT Small molecular drug DM6OC53 PC 6918638 DM6OC53 MW 318.3 DM6OC53 FM C15H14N2O4S DM6OC53 IC InChI=1S/C15H14N2O4S/c18-15(16-19)10-9-12-5-4-8-14(11-12)22(20,21)17-13-6-2-1-3-7-13/h1-11,17,19H,(H,16,18)/b10-9+ DM6OC53 CS C1=CC=C(C=C1)NS(=O)(=O)C2=CC=CC(=C2)/C=C/C(=O)NO DM6OC53 IK NCNRHFGMJRPRSK-MDZDMXLPSA-N DM6OC53 IU (E)-N-hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamide DM6OC53 CA CAS 866323-14-0 DM6OC53 CB CHEBI:61076 DM6OC53 DE Solid tumour/cancer; Haematological malignancy; Peripheral T-cell lymphoma DMFL96Z ID DMFL96Z DMFL96Z DN Pegamotecan DMFL96Z HS Phase 2 DMFL96Z SN Prothecan; EZ-246; PEG-camptothecin; PEG-camptothecin, Enzon; Polyethylene glycol-camptothecin, Enzon DMFL96Z CP Enzon Pharmaceuticals Inc DMFL96Z DT Small molecular drug DMFL96Z PC 11297617 DMFL96Z MW 981 DMFL96Z FM C52H48N6O14 DMFL96Z IC InChI=1S/C52H48N6O14/c1-5-51(35-19-39-43-31(17-29-11-7-9-13-37(29)55-43)21-57(39)45(61)33(35)23-69-49(51)65)71-47(63)27(3)53-41(59)25-67-15-16-68-26-42(60)54-28(4)48(64)72-52(6-2)36-20-40-44-32(18-30-12-8-10-14-38(30)56-44)22-58(40)46(62)34(36)24-70-50(52)66/h7-14,17-20,27-28H,5-6,15-16,21-26H2,1-4H3,(H,53,59)(H,54,60)/t27-,28-,51-,52-/m0/s1 DMFL96Z CS CC[C@@]1(C2=C(COC1=O)C(=O)N3CC4=CC5=CC=CC=C5N=C4C3=C2)OC(=O)[C@H](C)NC(=O)COCCOCC(=O)N[C@@H](C)C(=O)O[C@]6(C7=C(COC6=O)C(=O)N8CC9=CC1=CC=CC=C1N=C9C8=C7)CC DMFL96Z IK DZNNFZGDBUXWMV-ZUWDIFAMSA-N DMFL96Z IU [(19S)-19-ethyl-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4,6,8,10,15(20)-heptaen-19-yl] (2S)-2-[[2-[2-[2-[[(2S)-1-[[(19S)-19-ethyl-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4,6,8,10,15(20)-heptaen-19-yl]oxy]-1-oxopropan-2-yl]amino]-2-oxoethoxy]ethoxy]acetyl]amino]propanoate DMFL96Z CA CAS 581079-18-7 DMFL96Z DE Esophageal cancer DMPD3X6 ID DMPD3X6 DMPD3X6 DN Pegmusirudin DMPD3X6 HS Phase 2 DMPD3X6 SN BSF-87981; LU-57291; LU-87981; Polyethylene glycol hirudin, Knoll; SPP-200; PEG-hirudin, Knoll DMPD3X6 CP Knoll GmbH DMPD3X6 PC 56841834 DMPD3X6 MW 7266 DMPD3X6 FM C299H462N84O115S6 DMPD3X6 IC InChI=1S/C299H462N84O115S6/c1-27-142(21)234-289(485)361-171(97-134(5)6)244(440)323-120-216(410)335-188(124-385)273(469)337-154(45-34-36-86-317-298(493)497-95-93-495-29-3)240(436)319-114-210(404)332-161(67-80-221(418)419)250(446)338-156(47-38-88-315-296(310)311)248(444)356-180(106-205(305)399)266(462)343-162(61-74-201(301)395)257(453)367-194(130-502-499-127-191-247(443)326-116-209(403)329-157(64-77-218(412)413)241(437)320-117-213(407)333-179(105-204(304)398)265(461)339-155(46-35-37-87-318-299(494)498-96-94-496-30-4)249(445)366-195(279(475)376-234)131-503-500-128-192(276(472)340-159(66-79-220(416)417)243(439)321-119-215(409)336-189(125-386)274(470)359-183(109-208(308)402)272(468)373-231(139(15)16)287(483)371-191)368-261(457)174(100-137(11)12)352-277(473)193-129-501-504-132-196(370-270(466)186(112-229(434)435)363-291(487)238(146(25)390)378-271(467)177(103-150-54-58-153(393)59-55-150)362-286(482)232(140(17)18)375-284(480)230(309)138(13)14)280(476)379-237(145(24)389)290(486)347-167(71-84-225(426)427)256(452)364-187(123-384)246(442)325-115-211(405)331-160(60-73-200(300)394)251(447)357-181(107-206(306)400)267(463)351-173(99-136(9)10)260(456)369-193)278(474)374-233(141(19)20)288(484)380-236(144(23)388)285(481)327-121-212(406)330-158(65-78-219(414)415)242(438)322-122-217(411)372-239(147(26)391)294(490)383-92-42-51-199(383)283(479)348-169(48-39-89-316-297(312)313)292(488)381-90-40-49-197(381)281(477)345-163(62-75-202(302)396)255(451)365-190(126-387)275(471)355-178(104-151-113-314-133-328-151)264(460)358-182(108-207(307)401)268(464)360-184(110-227(430)431)245(441)324-118-214(408)334-185(111-228(432)433)269(465)354-175(101-148-43-32-31-33-44-148)262(458)344-164(68-81-222(420)421)252(448)342-168(72-85-226(428)429)258(454)377-235(143(22)28-2)293(489)382-91-41-50-198(382)282(478)346-166(70-83-224(424)425)253(449)341-165(69-82-223(422)423)254(450)353-176(102-149-52-56-152(392)57-53-149)263(459)350-172(98-135(7)8)259(455)349-170(295(491)492)63-76-203(303)397/h31-33,43-44,52-59,113,133-147,154-199,230-239,384-393H,27-30,34-42,45-51,60-112,114-132,309H2,1-26H3,(H2,300,394)(H2,301,395)(H2,302,396)(H2,303,397)(H2,304,398)(H2,305,399)(H2,306,400)(H2,307,401)(H2,308,402)(H,314,328)(H,317,493)(H,318,494)(H,319,436)(H,320,437)(H,321,439)(H,322,438)(H,323,440)(H,324,441)(H,325,442)(H,326,443)(H,327,481)(H,329,403)(H,330,406)(H,331,405)(H,332,404)(H,333,407)(H,334,408)(H,335,410)(H,336,409)(H,337,469)(H,338,446)(H,339,461)(H,340,472)(H,341,449)(H,342,448)(H,343,462)(H,344,458)(H,345,477)(H,346,478)(H,347,486)(H,348,479)(H,349,455)(H,350,459)(H,351,463)(H,352,473)(H,353,450)(H,354,465)(H,355,471)(H,356,444)(H,357,447)(H,358,460)(H,359,470)(H,360,464)(H,361,485)(H,362,482)(H,363,487)(H,364,452)(H,365,451)(H,366,445)(H,367,453)(H,368,457)(H,369,456)(H,370,466)(H,371,483)(H,372,411)(H,373,468)(H,374,474)(H,375,480)(H,376,475)(H,377,454)(H,378,467)(H,379,476)(H,380,484)(H,412,413)(H,414,415)(H,416,417)(H,418,419)(H,420,421)(H,422,423)(H,424,425)(H,426,427)(H,428,429)(H,430,431)(H,432,433)(H,434,435)(H,491,492)(H4,310,311,315)(H4,312,313,316)/t142-,143-,144+,145+,146+,147+,154-,155-,156-,157-,158-,159-,160-,161-,162-,163-,164-,165-,166-,167-,168-,169-,170-,171-,172-,173-,174-,175-,176-,177-,178-,179-,180-,181-,182-,183-,184-,185-,186-,187-,188-,189-,190-,191-,192-,193-,194-,195-,196-,197-,198-,199-,230-,231-,232-,233-,234-,235-,236-,237-,238-,239-/m0/s1 DMPD3X6 CS CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H]2C(=O)NCC(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)C(C)C)CC(=O)N)CO)CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]3CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N3)CC(C)C)CC(=O)N)CCC(=O)N)CO)CCC(=O)O)[C@@H](C)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)N)C(=O)N1)CCCCNC(=O)OCCOCC)CC(=O)N)CCC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N5CCC[C@H]5C(=O)N[C@@H](CCCNC(=N)N)C(=O)N6CCC[C@H]6C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC7=CN=CN7)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)NCC(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC8=CC=CC=C8)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N9CCC[C@H]9C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)O)CCC(=O)N)CC(=O)N)CCCNC(=N)N)CCC(=O)O)CCCCNC(=O)OCCOCC)CO)CC(C)C DMPD3X6 IK MFPRYDMAZLLTGM-IJDGSQHYSA-N DMPD3X6 IU (2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S)-2-[[(2S)-1-[(2S,3R)-2-[[2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2S)-2-[[(1R,6R,9S,12S,15S,18S,24S,27S,33S,36S,39R,44R,47S,53S,56S,59S,67S,73S,76S)-44-[[(2S)-2-[[(4R,7S,10S,13S,19S,22S,25S,28R)-28-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxybutanoyl]amino]-3-carboxypropanoyl]amino]-10-(2-amino-2-oxoethyl)-13-(3-amino-3-oxopropyl)-22-(2-carboxyethyl)-25-[(1R)-1-hydroxyethyl]-19-(hydroxymethyl)-7-(2-methylpropyl)-6,9,12,15,18,21,24,27-octaoxo-1,2-dithia-5,8,11,14,17,20,23,26-octazacyclononacosane-4-carbonyl]amino]-4-methylpentanoyl]amino]-12,56,73-tris(2-amino-2-oxoethyl)-9-(3-amino-3-oxopropyl)-36-[(2S)-butan-2-yl]-15-(3-carbamimidamidopropyl)-18,47,67-tris(2-carboxyethyl)-24,76-bis[4-(2-ethoxyethoxycarbonylamino)butyl]-27,53-bis(hydroxymethyl)-33-(2-methylpropyl)-8,11,14,17,20,23,26,29,32,35,38,45,48,51,54,57,60,62,65,68,71,74,77-tricosaoxo-59-propan-2-yl-3,4,41,42-tetrathia-7,10,13,16,19,22,25,28,31,34,37,46,49,52,55,58,61,63,66,69,72,75,78-tricosazabicyclo[37.22.17]octaheptacontane-6-carbonyl]amino]-3-methylbutanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]-4-carboxybutanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-oxobutanoyl]amino]-3-carboxypropanoyl]amino]acetyl]amino]-3-carboxypropanoyl]amino]-3-phenylpropanoyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbonyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-5-oxopentanoic acid DMPD3X6 DE Angina pectoris DM26YJ1 ID DM26YJ1 DM26YJ1 DN PEGPH20 DM26YJ1 HS Phase 2 DM26YJ1 CP Halozyme Therapeutics San Diego, CA DM26YJ1 DE Pancreatic cancer; Gallbladder disease; Gastric adenocarcinoma; Non-small-cell lung cancer DMX9ZM4 ID DMX9ZM4 DMX9ZM4 DN PEG-SN38 DMX9ZM4 HS Phase 2 DMX9ZM4 SN EZN-2208 DMX9ZM4 CP Enzon pharmaceuticals DMX9ZM4 DT Small molecular drug DMX9ZM4 PC 59443782 DMX9ZM4 MW 2300.3 DMX9ZM4 FM C118H122N12O37 DMX9ZM4 IC InChI=1S/C118H122N12O37/c1-9-67-71-33-61(131)17-21-87(71)123-103-75(67)45-127-91(103)37-83-79(107(127)143)53-160-111(147)115(83,13-5)164-99(139)41-119-95(135)57-153-27-25-151-49-65(158-31-29-155-59-97(137)121-43-101(141)166-117(15-7)85-39-93-105-77(47-129(93)109(145)81(85)55-162-113(117)149)69(11-3)73-35-63(133)19-23-89(73)125-105)51-157-52-66(159-32-30-156-60-98(138)122-44-102(142)167-118(16-8)86-40-94-106-78(48-130(94)110(146)82(86)56-163-114(118)150)70(12-4)74-36-64(134)20-24-90(74)126-106)50-152-26-28-154-58-96(136)120-42-100(140)165-116(14-6)84-38-92-104-76(46-128(92)108(144)80(84)54-161-112(116)148)68(10-2)72-34-62(132)18-22-88(72)124-104/h17-24,33-40,65-66,131-134H,9-16,25-32,41-60H2,1-8H3,(H,119,135)(H,120,136)(H,121,137)(H,122,138)/t65?,66?,115-,116-,117-,118-/m0/s1 DMX9ZM4 CS CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)[C@@]4(CC)OC(=O)CNC(=O)COCCOCC(COCC(COCCOCC(=O)NCC(=O)O[C@]5(C6=C(COC5=O)C(=O)N7CC8=C(C9=C(C=CC(=C9)O)N=C8C7=C6)CC)CC)OCCOCC(=O)NCC(=O)O[C@]3(C4=C(COC3=O)C(=O)N3CC5=C(C6=C(C=CC(=C6)O)N=C5C3=C4)CC)CC)OCCOCC(=O)NCC(=O)O[C@]3(C4=C(COC3=O)C(=O)N3CC5=C(C6=C(C=CC(=C6)O)N=C5C3=C4)CC)CC)C2=NC2=C1C=C(C=C2)O DMX9ZM4 IK CXWRXYDTWCBSJF-DPTNTHPESA-N DMX9ZM4 IU [(19S)-10,19-diethyl-7-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaen-19-yl] 2-[[2-[2-[3-[2,3-bis[2-[2-[[2-[[(19S)-10,19-diethyl-7-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaen-19-yl]oxy]-2-oxoethyl]amino]-2-oxoethoxy]ethoxy]propoxy]-2-[2-[2-[[2-[[(19S)-10,19-diethyl-7-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaen-19-yl]oxy]-2-oxoethyl]amino]-2-oxoethoxy]ethoxy]propoxy]ethoxy]acetyl]amino]acetate DMX9ZM4 CA CAS 946062-05-1 DMX9ZM4 DE Metastatic colorectal cancer; Breast cancer DMTDANB ID DMTDANB DMTDANB DN Pegsunercept DMTDANB HS Phase 2 DMTDANB SN STNF-R1 DMTDANB CP Amgen DMTDANB DE Rheumatoid arthritis DMBPJ9U ID DMBPJ9U DMBPJ9U DN PEGylated pitrakinra DMBPJ9U HS Phase 2 DMBPJ9U SN Aeroderm; Dermalast; AER-003; PEGylated pitrakinra (subcutaneous, eczema/allergy), Aerovance; PEGylated AER-001 (subcutaneous, eczema/allergy), Aerovance; PEGylated IL-4 variant (subcutaneous, eczema/allergy), Aerovance DMBPJ9U CP Aerovance DMBPJ9U DT Monoclonal antibody DMBPJ9U DE Allergy; Asthma DMOMN31 ID DMOMN31 DMOMN31 DN PEITC DMOMN31 HS Phase 2 DMOMN31 SN Phenethyl-isothiocyanate DMOMN31 CP New York University DMOMN31 DT Small molecular drug DMOMN31 PC 16741 DMOMN31 MW 163.24 DMOMN31 FM C9H9NS DMOMN31 IC InChI=1S/C9H9NS/c11-8-10-7-6-9-4-2-1-3-5-9/h1-5H,6-7H2 DMOMN31 CS C1=CC=C(C=C1)CCN=C=S DMOMN31 IK IZJDOKYDEWTZSO-UHFFFAOYSA-N DMOMN31 IU 2-isothiocyanatoethylbenzene DMOMN31 CA CAS 2257-09-2 DMOMN31 CB CHEBI:351346 DMOMN31 DE Prostate cancer DMIW453 ID DMIW453 DMIW453 DN Pelitinib DMIW453 HS Phase 2 DMIW453 SN EKB-569; EKI-569; WAY-EKB-569 DMIW453 CP Wyeth DMIW453 DT Small molecular drug DMIW453 PC 6445562 DMIW453 MW 467.9 DMIW453 FM C24H23ClFN5O2 DMIW453 IC InChI=1S/C24H23ClFN5O2/c1-4-33-22-12-20-17(11-21(22)30-23(32)6-5-9-31(2)3)24(15(13-27)14-28-20)29-16-7-8-19(26)18(25)10-16/h5-8,10-12,14H,4,9H2,1-3H3,(H,28,29)(H,30,32)/b6-5+ DMIW453 CS CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)F)Cl)C#N)NC(=O)/C=C/CN(C)C DMIW453 IK WVUNYSQLFKLYNI-AATRIKPKSA-N DMIW453 IU (E)-N-[4-(3-chloro-4-fluoroanilino)-3-cyano-7-ethoxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide DMIW453 CA CAS 257933-82-7 DMIW453 CB CHEBI:38927 DMIW453 DE Lymphoma DMR6USG ID DMR6USG DMR6USG DN PELITREXOL DMR6USG HS Phase 2 DMR6USG SN AG-2037; Pelitrexol < USAN; AG-2032 (racemate); AG-2038 ((6R)-isomer); N-[5-[2-[2-Amino-4-oxo-3,4,5,6,7,8-hexahydropyrido[2,3-d]pyrimidin-6(S)-yl]ethyl]-4-methylthien-2-ylcarbonyl]-L-glutamic acid DMR6USG DT Small molecular drug DMR6USG PC 135431074 DMR6USG MW 463.5 DMR6USG FM C20H25N5O6S DMR6USG IC InChI=1S/C20H25N5O6S/c1-9-6-14(18(29)23-12(19(30)31)3-5-15(26)27)32-13(9)4-2-10-7-11-16(22-8-10)24-20(21)25-17(11)28/h6,10,12H,2-5,7-8H2,1H3,(H,23,29)(H,26,27)(H,30,31)(H4,21,22,24,25,28)/t10-,12-/m0/s1 DMR6USG CS CC1=C(SC(=C1)C(=O)N[C@@H](CCC(=O)O)C(=O)O)CC[C@H]2CC3=C(NC2)N=C(NC3=O)N DMR6USG IK QXOPTIPQEVJERB-JQWIXIFHSA-N DMR6USG IU (2S)-2-[[5-[2-[(6S)-2-amino-4-oxo-5,6,7,8-tetrahydro-3H-pyrido[2,3-d]pyrimidin-6-yl]ethyl]-4-methylthiophene-2-carbonyl]amino]pentanedioic acid DMR6USG CA CAS 446022-33-9 DMR6USG DE Solid tumour/cancer DMGY5JC ID DMGY5JC DMGY5JC DN Pentacea DMGY5JC HS Phase 2 DMGY5JC SN HMN14-734; Bispecific CEA antibody (radiotherapeutic pretargeting), IBC; Anti-CEA/anti-In-DTPA antibody, IBC DMGY5JC CP IBC Pharmaceuticals Inc DMGY5JC DT Antibody DMGY5JC DE Small-cell lung cancer DMNU48O ID DMNU48O DMNU48O DN Peptide YY 3-36 DMNU48O HS Phase 2 DMNU48O SN YY 3-36; Peptide YY 3-36 (oral, eligen) DMNU48O CP Emisphere Technologies Inc DMNU48O DE Obesity DMFM6OU ID DMFM6OU DMFM6OU DN PerioPatch DMFM6OU HS Phase 2 DMFM6OU CP Izun Pharmaceuticals Corp DMFM6OU DE Periodontal disease DMNM4CK ID DMNM4CK DMNM4CK DN PF-00734200 DMNM4CK HS Phase 2 DMNM4CK SN GOSOGLIPTIN; 869490-23-3; UNII-GI718UO477; PF-00734200; PF-734200; CHEMBL515387; GI718UO477; 2-(4-{(3s,5s)-5-[(3,3-Difluoropyrrolidin-1-Yl)carbonyl]pyrrolidin-3-Yl}piperazin-1-Yl)pyrimidine; 869490-47-1; (3,3-difluoropyrrolidin-1-yl)-[(2S,4S)-4-(4-pyrimidin-2-ylpiperazin-1-yl)pyrrolidin-2-yl]methanone; (3,3-difluoropyrrolidin-1-yl)((2S,4S)-4-(4-(pyrimidin-2-yl)piperazin-1-yl)pyrrolidin-2-yl)methanone; (3,3-DIFLUOROPYRROLIDIN-1-YL)[(2S,4S)-4-[4-(PYRIMIDIN-2-YL)PIPERAZIN-1-YL]PYRROLIDIN-2-YL]METHANONE; Gosogliptin [USAN: DMNM4CK DT Small molecular drug DMNM4CK PC 11516136 DMNM4CK MW 366.4 DMNM4CK FM C17H24F2N6O DMNM4CK IC InChI=1S/C17H24F2N6O/c18-17(19)2-5-25(12-17)15(26)14-10-13(11-22-14)23-6-8-24(9-7-23)16-20-3-1-4-21-16/h1,3-4,13-14,22H,2,5-12H2/t13-,14-/m0/s1 DMNM4CK CS C1CN(CC1(F)F)C(=O)[C@@H]2C[C@@H](CN2)N3CCN(CC3)C4=NC=CC=N4 DMNM4CK IK QWEWGXUTRTXFRF-KBPBESRZSA-N DMNM4CK IU (3,3-difluoropyrrolidin-1-yl)-[(2S,4S)-4-(4-pyrimidin-2-ylpiperazin-1-yl)pyrrolidin-2-yl]methanone DMNM4CK CA CAS 869490-23-3 DMNM4CK DE Type-2 diabetes DMJPE61 ID DMJPE61 DMJPE61 DN PF-02545920 DMJPE61 HS Phase 2 DMJPE61 SN 1037309-45-7; 2-((4-(1-Methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)quinoline succinate; UNII-TJ5KAZ8T5G; TJ5KAZ8T5G; PF-2545920 succinate; SCHEMBL439127; CTK8C0559; DTXSID90647726; ANW-64894; AKOS016005150; KB-80291; Quinoline, 2-((4-(1-methyl-4-(4-pyridinyl)-1H-pyrazol-3-yl)phenoxy)methyl)-, butanedioate (1:1); AX8234870; TC-153639; Quinoline,2-[[4-[1-methyl-4-(4-pyridinyl)-1H-pyrazol-3-yl]phenoxy]methyl]-,succinate salt; 2-[[4-[1-Methyl-4-(4-pyridyl)pyrazol-3-yl]phenoxy]methyl]quinoline DMJPE61 CP Pfizer DMJPE61 DT Small molecular drug DMJPE61 PC 11581936 DMJPE61 MW 392.5 DMJPE61 FM C25H20N4O DMJPE61 IC InChI=1S/C25H20N4O/c1-29-16-23(18-12-14-26-15-13-18)25(28-29)20-7-10-22(11-8-20)30-17-21-9-6-19-4-2-3-5-24(19)27-21/h2-16H,17H2,1H3 DMJPE61 CS CN1C=C(C(=N1)C2=CC=C(C=C2)OCC3=NC4=CC=CC=C4C=C3)C5=CC=NC=C5 DMJPE61 IK AZEXWHKOMMASPA-UHFFFAOYSA-N DMJPE61 IU 2-[[4-(1-methyl-4-pyridin-4-ylpyrazol-3-yl)phenoxy]methyl]quinoline DMJPE61 CA CAS 898562-94-2 DMJPE61 DE Schizophrenia; Huntington disease DMTJWNE ID DMTJWNE DMTJWNE DN PF-03446962 DMTJWNE HS Phase 2 DMTJWNE CP Pfizer New York, NY DMTJWNE DE Solid tumour/cancer DM826SW ID DM826SW DM826SW DN PF-04236921 DM826SW HS Phase 2 DM826SW CP Pfizer New York, NY DM826SW DE Systemic lupus erythematosus; Crohn disease DMPRYU1 ID DMPRYU1 DMPRYU1 DN PF-04457845 DMPRYU1 HS Phase 2 DMPRYU1 SN PF-04457845; 1020315-31-4; UNII-H4C81M8YYW; H4C81M8YYW; CHEMBL1651534; PF 04457845; PF04457845; C23H20F3N5O2; N-pyridazin-3-yl-4-(3-{[5-(trifluoromethyl)pyridin-2-yl]oxy}benzylidene)piperidine-1-carboxamide; N-Pyridazin-3-yl-4-((3-(5-(trifluoromethyl)pyridin-2-yl)oxyphenyl)methylidene)piperidine-1-carboxamide; 1-Piperidinecarboxamide, N-3-pyridazinyl-4-[[3-[[5-(trifluoromethyl)-2-pyridinyl]oxy]phenyl]methylene]-;1-Piperidinecarboxamide, N-3-pyridazinyl-4-[[3-[[5-(trifluoromethyl)-2-pyridinyl]oxy]phenyl]methylene]- DMPRYU1 DT Small molecular drug DMPRYU1 PC 24771824 DMPRYU1 MW 455.4 DMPRYU1 FM C23H20F3N5O2 DMPRYU1 IC InChI=1S/C23H20F3N5O2/c24-23(25,26)18-6-7-21(27-15-18)33-19-4-1-3-17(14-19)13-16-8-11-31(12-9-16)22(32)29-20-5-2-10-28-30-20/h1-7,10,13-15H,8-9,11-12H2,(H,29,30,32) DMPRYU1 CS C1CN(CCC1=CC2=CC(=CC=C2)OC3=NC=C(C=C3)C(F)(F)F)C(=O)NC4=NN=CC=C4 DMPRYU1 IK BATCTBJIJJEPHM-UHFFFAOYSA-N DMPRYU1 IU N-pyridazin-3-yl-4-[[3-[5-(trifluoromethyl)pyridin-2-yl]oxyphenyl]methylidene]piperidine-1-carboxamide DMPRYU1 CA CAS 1020315-31-4 DMPRYU1 DE Liver disease DMZMUIL ID DMZMUIL DMZMUIL DN PF-04518600 DMZMUIL HS Phase 2 DMZMUIL CP Pfizer New York, NY DMZMUIL DE Solid tumour/cancer DMA9MBR ID DMA9MBR DMA9MBR DN PF-04523655 DMA9MBR HS Phase 2 DMA9MBR CP Pfizer; Quark Pharmaceuticals DMA9MBR TC siRNA DMA9MBR DT siRNA drug DMA9MBR DE Diabetic macular edema DMS610L ID DMS610L DMS610L DN PF-04691502 DMS610L HS Phase 2 DMS610L SN PF-04691502; 1013101-36-4; PF 04691502; UNII-4W39NS61KI; 4W39NS61KI; 2-amino-8-((1r,4r)-4-(2-hydroxyethoxy)cyclohexyl)-6-(6-methoxypyridin-3-yl)-4-methylpyrido[2,3-d]pyrimidin-7(8H)-one; CHEMBL1234354; PF04691502; 2-Amino-8-[trans-4-(2-Hydroxyethoxy)cyclohexyl]-6-(6-Methoxypyridin-3-Yl)-4-Methylpyrido[2,3-D]pyrimidin-7(8h)-One; 2-Amino-8-[4-(2-hydroxyethoxy)cyclohexyl]-6-(6-methoxypyridin-3-yl)-4-methylpyrido[2,3-d]pyrimidin-7-one DMS610L CP Pfizer New York, NY DMS610L DT Small molecular drug DMS610L PC 25033539 DMS610L MW 425.5 DMS610L FM C22H27N5O4 DMS610L IC InChI=1S/C22H27N5O4/c1-13-17-11-18(14-3-8-19(30-2)24-12-14)21(29)27(20(17)26-22(23)25-13)15-4-6-16(7-5-15)31-10-9-28/h3,8,11-12,15-16,28H,4-7,9-10H2,1-2H3,(H2,23,25,26) DMS610L CS CC1=C2C=C(C(=O)N(C2=NC(=N1)N)C3CCC(CC3)OCCO)C4=CN=C(C=C4)OC DMS610L IK XDLYKKIQACFMJG-UHFFFAOYSA-N DMS610L IU 2-amino-8-[4-(2-hydroxyethoxy)cyclohexyl]-6-(6-methoxypyridin-3-yl)-4-methylpyrido[2,3-d]pyrimidin-7-one DMS610L CA CAS 1013101-36-4 DMS610L DE Endometrial cancer DMQMF4O ID DMQMF4O DMQMF4O DN PF-04937319 DMQMF4O HS Phase 2 DMQMF4O CP Pfizer DMQMF4O PC 46916694 DMQMF4O MW 432.4 DMQMF4O FM C22H20N6O4 DMQMF4O IC InChI=1S/C22H20N6O4/c1-12-8-24-19(11-23-12)27-21(29)14-6-17-16(5-13(2)31-17)18(7-14)32-15-9-25-20(26-10-15)22(30)28(3)4/h5-11H,1-4H3,(H,24,27,29) DMQMF4O CS CC1=CC2=C(O1)C=C(C=C2OC3=CN=C(N=C3)C(=O)N(C)C)C(=O)NC4=NC=C(N=C4)C DMQMF4O IK MASKQITXHVYVFL-UHFFFAOYSA-N DMQMF4O IU N,N-dimethyl-5-[[2-methyl-6-[(5-methylpyrazin-2-yl)carbamoyl]-1-benzofuran-4-yl]oxy]pyrimidine-2-carboxamide DMQMF4O CA CAS 1245603-92-2 DMQMF4O DE Type-2 diabetes DMRAFBK ID DMRAFBK DMRAFBK DN PF-04958242 DMRAFBK HS Phase 2 DMRAFBK CP Pfizer DMRAFBK PC 49853967 DMRAFBK MW 392.5 DMRAFBK FM C18H20N2O4S2 DMRAFBK IC InChI=1S/C18H20N2O4S2/c1-12(2)26(21,22)20-16-10-23-11-17(16)24-14-5-3-13(4-6-14)18-8-7-15(9-19)25-18/h3-8,12,16-17,20H,10-11H2,1-2H3/t16-,17+/m0/s1 DMRAFBK CS CC(C)S(=O)(=O)N[C@H]1COC[C@H]1OC2=CC=C(C=C2)C3=CC=C(S3)C#N DMRAFBK IK TTYKUKSFWHEBLI-DLBZAZTESA-N DMRAFBK IU N-[(3S,4S)-4-[4-(5-cyanothiophen-2-yl)phenoxy]oxolan-3-yl]propane-2-sulfonamide DMRAFBK CA CAS 1258963-59-5 DMRAFBK DE Schizophrenia DM94NBE ID DM94NBE DM94NBE DN PF-04991532 DM94NBE HS Phase 2 DM94NBE CP Pfizer DM94NBE PC 46181428 DM94NBE MW 396.4 DM94NBE FM C18H19F3N4O3 DM94NBE IC InChI=1S/C18H19F3N4O3/c19-18(20,21)14-9-25(10-23-14)13(7-11-3-1-2-4-11)16(26)24-15-6-5-12(8-22-15)17(27)28/h5-6,8-11,13H,1-4,7H2,(H,27,28)(H,22,24,26)/t13-/m0/s1 DM94NBE CS C1CCC(C1)C[C@@H](C(=O)NC2=NC=C(C=C2)C(=O)O)N3C=C(N=C3)C(F)(F)F DM94NBE IK GKMLFBRLRVQVJO-ZDUSSCGKSA-N DM94NBE IU 6-[[(2S)-3-cyclopentyl-2-[4-(trifluoromethyl)imidazol-1-yl]propanoyl]amino]pyridine-3-carboxylic acid DM94NBE CA CAS 1215197-37-7 DM94NBE DE Diabetic complication DMD74BJ ID DMD74BJ DMD74BJ DN PF-05089771 DMD74BJ HS Phase 2 DMD74BJ SN Nav1.7 blockers (pain), Pfizer; SCN9A blockers (pain), Pfizer/Icagen/Birkbeck; Voltage-gated sodium channel 1.7 blockers (pain), Pfizer DMD74BJ CP Pfizer DMD74BJ PC 46840946 DMD74BJ MW 500.4 DMD74BJ FM C18H12Cl2FN5O3S2 DMD74BJ IC InChI=1S/C18H12Cl2FN5O3S2/c19-9-1-2-14(10(3-9)11-6-24-25-18(11)22)29-15-5-13(21)16(4-12(15)20)31(27,28)26-17-7-30-8-23-17/h1-8,26H,(H3,22,24,25) DMD74BJ CS C1=CC(=C(C=C1Cl)C2=C(NN=C2)N)OC3=CC(=C(C=C3Cl)S(=O)(=O)NC4=CSC=N4)F DMD74BJ IK ZYSCOUXLBXGGIM-UHFFFAOYSA-N DMD74BJ IU 4-[2-(5-amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-(1,3-thiazol-4-yl)benzenesulfonamide DMD74BJ CA CAS 1235403-62-9 DMD74BJ DE Chronic pain DMLQ3OK ID DMLQ3OK DMLQ3OK DN PF-05175157 DMLQ3OK HS Phase 2 DMLQ3OK CP Pfizer DMLQ3OK PC 52934180 DMLQ3OK MW 405.5 DMLQ3OK FM C23H27N5O2 DMLQ3OK IC InChI=1S/C23H27N5O2/c1-14(2)28-21-17(13-24-28)11-23(12-20(21)29)6-8-27(9-7-23)22(30)16-4-5-18-19(10-16)26-15(3)25-18/h4-5,10,13-14H,6-9,11-12H2,1-3H3,(H,25,26) DMLQ3OK CS CC1=NC2=C(N1)C=C(C=C2)C(=O)N3CCC4(CC3)CC5=C(C(=O)C4)N(N=C5)C(C)C DMLQ3OK IK BDXXSFOJPYSYOC-UHFFFAOYSA-N DMLQ3OK IU 1'-(2-methyl-3H-benzimidazole-5-carbonyl)-1-propan-2-ylspiro[4,6-dihydroindazole-5,4'-piperidine]-7-one DMLQ3OK CA CAS 1301214-47-0 DMLQ3OK DE Type-2 diabetes DMPVQYR ID DMPVQYR DMPVQYR DN PF-05212377 DMPVQYR HS Phase 2 DMPVQYR SN SAM-760 DMPVQYR CP Pfizer New York, NY DMPVQYR DE Alzheimer disease DMBL3VD ID DMBL3VD DMBL3VD DN PF-05212384 DMBL3VD HS Phase 2 DMBL3VD SN PKI-587; 1197160-78-3; Gedatolisib; PF-05212384; PKI587; PKI 587; 1-(4-(4-(Dimethylamino)piperidine-1-carbonyl)phenyl)-3-(4-(4,6-dimorpholino-1,3,5-triazin-2-yl)phenyl)urea; PF 05212384; UNII-96265TNH2R; PF-05212384 (PKI-587); CHEMBL592445; 96265TNH2R; N-[4-[[4-(Dimethylamino)-1-piperidinyl]carbonyl]phenyl]-N'-[4-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]phenyl]urea; Gedatolisib (PF-05212384, PKI-587); Urea, N-(4-((4-(dimethylamino)-1-piperidinyl)carbonyl)phenyl)-N'-(4-(4,6-di-4-morpholinyl-1,3,5-triazin-2-yl)phenyl)- DMBL3VD CP Pfizer New York, NY DMBL3VD DT Small molecular drug DMBL3VD PC 44516953 DMBL3VD MW 615.7 DMBL3VD FM C32H41N9O4 DMBL3VD IC InChI=1S/C32H41N9O4/c1-38(2)27-11-13-39(14-12-27)29(42)24-5-9-26(10-6-24)34-32(43)33-25-7-3-23(4-8-25)28-35-30(40-15-19-44-20-16-40)37-31(36-28)41-17-21-45-22-18-41/h3-10,27H,11-22H2,1-2H3,(H2,33,34,43) DMBL3VD CS CN(C)C1CCN(CC1)C(=O)C2=CC=C(C=C2)NC(=O)NC3=CC=C(C=C3)C4=NC(=NC(=N4)N5CCOCC5)N6CCOCC6 DMBL3VD IK DWZAEMINVBZMHQ-UHFFFAOYSA-N DMBL3VD IU 1-[4-[4-(dimethylamino)piperidine-1-carbonyl]phenyl]-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea DMBL3VD CA CAS 1197160-78-3 DMBL3VD DE Solid tumour/cancer DMQLZOF ID DMQLZOF DMQLZOF DN PF-06252616 DMQLZOF HS Phase 2 DMQLZOF CP Pfizer DMQLZOF DT Antibody DMQLZOF DE Muscular dystrophy; Duchenne dystrophy DMUAOFM ID DMUAOFM DMUAOFM DN PF-06290510 DMUAOFM HS Phase 2 DMUAOFM CP Pfizer DMUAOFM DT Vaccine DMUAOFM DE Staphylococcus infection; Major depressive disorder DMN94QM ID DMN94QM DMN94QM DN PF-06291874 DMN94QM HS Phase 2 DMN94QM CP Pfizer DMN94QM PC 60151939 DMN94QM MW 503.5 DMN94QM FM C26H28F3N3O4 DMN94QM IC InChI=1S/C26H28F3N3O4/c1-4-5-22(18-6-8-19(9-7-18)25(35)30-11-10-23(33)34)36-21-12-16(2)24(17(3)13-21)32-15-20(14-31-32)26(27,28)29/h6-9,12-15,22H,4-5,10-11H2,1-3H3,(H,30,35)(H,33,34)/t22-/m0/s1 DMN94QM CS CCC[C@@H](C1=CC=C(C=C1)C(=O)NCCC(=O)O)OC2=CC(=C(C(=C2)C)N3C=C(C=N3)C(F)(F)F)C DMN94QM IK IBDYYOQKQCCSDP-QFIPXVFZSA-N DMN94QM IU 3-[[4-[(1S)-1-[3,5-dimethyl-4-[4-(trifluoromethyl)pyrazol-1-yl]phenoxy]butyl]benzoyl]amino]propanoic acid DMN94QM CA CAS 1393124-08-7 DMN94QM DE Type-2 diabetes DMKM7EW ID DMKM7EW DMKM7EW DN PF-06463922 DMKM7EW HS Phase 2 DMKM7EW SN SCHEMBL15274056 DMKM7EW CP Pfizer DMKM7EW DT Small molecular drug DMKM7EW PC 71731823 DMKM7EW MW 406.4 DMKM7EW FM C21H19FN6O2 DMKM7EW IC InChI=1S/C21H19FN6O2/c1-11-15-7-13(22)4-5-14(15)21(29)27(2)10-16-19(17(8-23)28(3)26-16)12-6-18(30-11)20(24)25-9-12/h4-7,9,11H,10H2,1-3H3,(H2,24,25)/t11-/m1/s1 DMKM7EW CS C[C@@H]1C2=C(C=CC(=C2)F)C(=O)N(CC3=NN(C(=C3C4=CC(=C(N=C4)N)O1)C#N)C)C DMKM7EW IK IIXWYSCJSQVBQM-LLVKDONJSA-N DMKM7EW IU (16R)-19-amino-13-fluoro-4,8,16-trimethyl-9-oxo-17-oxa-4,5,8,20-tetrazatetracyclo[16.3.1.02,6.010,15]docosa-1(22),2,5,10(15),11,13,18,20-octaene-3-carbonitrile DMKM7EW CA CAS 1454846-35-5 DMKM7EW CB CHEBI:143117 DMKM7EW DE Solid tumour/cancer; Non-small-cell lung cancer DM9S3P7 ID DM9S3P7 DM9S3P7 DN PF-06473871 DM9S3P7 HS Phase 2 DM9S3P7 CP Pfizer DM9S3P7 DT Antisense oligonucleotide DM9S3P7 DE Hypertrophic scars DMMGSFV ID DMMGSFV DMMGSFV DN PF-06700841 DMMGSFV HS Phase 2 DMMGSFV SN BUWBRTXGQRBBHG-RUXDESIVSA-N; 2140301-96-6; PF-06700841 free base; EX-A2762; 1883299-62-4; ((S)-2,2-difluorocyclopropyl)(3-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone DMMGSFV CP Pfizer New York, NY DMMGSFV PC 118878093 DMMGSFV MW 389.4 DMMGSFV FM C18H21F2N7O DMMGSFV IC InChI=1S/C18H21F2N7O/c1-25-8-11(7-22-25)23-17-21-5-4-15(24-17)26-9-12-2-3-13(10-26)27(12)16(28)14-6-18(14,19)20/h4-5,7-8,12-14H,2-3,6,9-10H2,1H3,(H,21,23,24)/t12-,13+,14-/m0/s1 DMMGSFV CS CN1C=C(C=N1)NC2=NC=CC(=N2)N3C[C@H]4CC[C@@H](C3)N4C(=O)[C@@H]5CC5(F)F DMMGSFV IK BUWBRTXGQRBBHG-MJBXVCDLSA-N DMMGSFV IU [(1S)-2,2-difluorocyclopropyl]-[(1R,5S)-3-[2-[(1-methylpyrazol-4-yl)amino]pyrimidin-4-yl]-3,8-diazabicyclo[3.2.1]octan-8-yl]methanone DMMGSFV CA CAS 1883299-62-4 DMMGSFV DE Asthma; Plaque psoriasis; Psoriasis vulgaris DM8C1H4 ID DM8C1H4 DM8C1H4 DN PF-06823859 DM8C1H4 HS Phase 2 DM8C1H4 CP Pfizer, New York, NY DM8C1H4 DE Lupus; Rheumatoid arthritis; Dermatomycosis DM5H8V1 ID DM5H8V1 DM5H8V1 DN PF-06826647 DM5H8V1 HS Phase 2 DM5H8V1 SN Tyk2-IN-8; 2127109-84-4; Tyk2-IN-9; (1r,3r)-3-(Cyanomethyl)-3-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)-1H-pyrazol-1-yl)cyclobutane-1-carbonitrile; Ropsacitinib; Ropsacitinib [USAN]; UNII-HY5SOV7O0Q; HY5SOV7O0Q; CHEMBL4459585; SCHEMBL19253418; SCHEMBL19253420; SCHEMBL19271747; SCHEMBL19276506; BDBM305820; BDBM305821; BCP33615; EX-A4020; US10144738, Example 19; US10144738, Example 20; MFCD32197240; s9676; WHO 11834; HY-126290A; HY-126290; CS-0101462; CS-0114967; (1s,3s)-3-(Cyanomethyl)-3-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)-1H-pyrazol-1-yl)cyclobutane-1-carbonitrile; Cyclobutaneacetonitrile, 3-cyano-1-(4-(6-(1-methyl-1H-pyrazol-4- yl)pyrazolo(1,5-a)pyrazin-4-yl)-1H-pyrazol-1-yl)-, trans-; trans-3-(Cyanomethyl)-3-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)-1H-pyrazol-1-yl)cyclobutanecarbonitrile; trans-3-Cyano-1-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo(1,5-a)pyrazin-4-yl)- 1H-pyrazol-1-yl)-cyclobutaneacetonitrile DM5H8V1 CP Pfizer DM5H8V1 DT Small molecular drug DM5H8V1 PC 130339268 DM5H8V1 MW 383.4 DM5H8V1 FM C20H17N9 DM5H8V1 IC InChI=1S/C20H17N9/c1-27-11-15(9-24-27)17-13-28-18(2-5-23-28)19(26-17)16-10-25-29(12-16)20(3-4-21)6-14(7-20)8-22/h2,5,9-14H,3,6-7H2,1H3 DM5H8V1 CS CN1C=C(C=N1)C2=CN3C(=CC=N3)C(=N2)C4=CN(N=C4)C5(CC(C5)C#N)CC#N DM5H8V1 IK XPLZTJWZDBFWDE-UHFFFAOYSA-N DM5H8V1 IU 3-(cyanomethyl)-3-[4-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]pyrazol-1-yl]cyclobutane-1-carbonitrile DM5H8V1 CA CAS 2127109-84-4 DM5H8V1 DE Plaque psoriasis DM7EJ8S ID DM7EJ8S DM7EJ8S DN PF-06882961 DM7EJ8S HS Phase 2 DM7EJ8S SN 2230198-02-2; UNII-DN9IUI24GP; DN9IUI24GP; 2230198-02-2 (free acid); (S)-2-((4-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)piperidin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid; 2-[(4-{6-[(4-cyano-2-fluorophenyl)methoxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-{[(2S)-oxetan-2-yl]methyl}-1H-benzimidazole-6-carboxylic acid; Danuglipron; UK4; Danuglipron [USAN]; CHEMBL4518483; SCHEMBL20266351; BDBM349662; EX-A3607; WHO 11630; US10208019, Example 1A-09; US10208019, Example 4A-01; 2-[[4-[6-[(4-cyano-2-fluoro-phenyl)methoxy]-2-pyridyl]-1-piperidyl]methyl]-3-[[(2S)-oxetan-2-yl]methyl]benzimidazole-5-carboxylic acid; AC-31472; PF6882961; Q63141738; 1H-Benzimidazole-6-carboxylic acid, 2-((4-(6-((4-cyano-2-fluorophenyl)methoxy)-2-pyridinyl)-1-piperidinyl)methyl)-1-((2S)-2-oxetanylmethyl)-; 2-{[4-(6-{[(4-cyano-2-fluorophenyl)(methyl-d2)]oxy}pyridin-2-yl)piperidin-1-yl]methyl}-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid; C(#N)C1=CC(=C(COC2=CC=CC(=N2)C2CCN(CC2)CC2=NC3=C(N2C[C@H]2OCC2)C=C(C=C3)C(=O)O)C=C1)F DM7EJ8S CP Pfizer DM7EJ8S DT Small molecular drug DM7EJ8S PC 134611040 DM7EJ8S MW 555.6 DM7EJ8S FM C31H30FN5O4 DM7EJ8S IC InChI=1S/C31H30FN5O4/c32-25-14-20(16-33)4-5-23(25)19-41-30-3-1-2-26(35-30)21-8-11-36(12-9-21)18-29-34-27-7-6-22(31(38)39)15-28(27)37(29)17-24-10-13-40-24/h1-7,14-15,21,24H,8-13,17-19H2,(H,38,39)/t24-/m0/s1 DM7EJ8S CS C1CO[C@@H]1CN2C3=C(C=CC(=C3)C(=O)O)N=C2CN4CCC(CC4)C5=NC(=CC=C5)OCC6=C(C=C(C=C6)C#N)F DM7EJ8S IK HYBAKUMPISVZQP-DEOSSOPVSA-N DM7EJ8S IU 2-[[4-[6-[(4-cyano-2-fluorophenyl)methoxy]pyridin-2-yl]piperidin-1-yl]methyl]-3-[[(2S)-oxetan-2-yl]methyl]benzimidazole-5-carboxylic acid DM7EJ8S CA CAS 2230198-02-2 DM7EJ8S DE Type 2 diabetes DM8T6KQ ID DM8T6KQ DM8T6KQ DN PF-232798 DM8T6KQ HS Phase 2 DM8T6KQ SN PF-00232798 DM8T6KQ CP Pfizer Inc DM8T6KQ DT Small molecular drug DM8T6KQ PC 53316710 DM8T6KQ MW 509.7 DM8T6KQ FM C29H40FN5O2 DM8T6KQ IC InChI=1S/C29H40FN5O2/c1-18(2)29(37)33-12-11-28-27(17-33)31-19(3)35(28)25-15-23-8-9-24(16-25)34(23)13-10-26(32-20(4)36)21-6-5-7-22(30)14-21/h5-7,14,18,23-26H,8-13,15-17H2,1-4H3,(H,32,36)/t23-,24+,25?,26-/m0/s1 DM8T6KQ CS CC1=NC2=C(N1C3C[C@H]4CC[C@@H](C3)N4CC[C@@H](C5=CC(=CC=C5)F)NC(=O)C)CCN(C2)C(=O)C(C)C DM8T6KQ IK QETUKYDWZIRTEI-HLMSNRGBSA-N DM8T6KQ IU N-[(1S)-1-(3-fluorophenyl)-3-[(1R,5S)-3-[2-methyl-5-(2-methylpropanoyl)-6,7-dihydro-4H-imidazo[4,5-c]pyridin-1-yl]-8-azabicyclo[3.2.1]octan-8-yl]propyl]acetamide DM8T6KQ CA CAS 849753-15-7 DM8T6KQ DE Human immunodeficiency virus infection DMO02LU ID DMO02LU DMO02LU DN PF-3463275 DMO02LU HS Phase 2 DMO02LU SN PF-03463275 DMO02LU CP Pfizer Inc DMO02LU PC 44156901 DMO02LU MW 376.9 DMO02LU FM C19H22ClFN4O DMO02LU IC InChI=1S/C19H22ClFN4O/c1-23-7-13-14(8-23)15(13)9-25(19(26)18-10-24(2)11-22-18)6-12-3-4-17(21)16(20)5-12/h3-5,10-11,13-15H,6-9H2,1-2H3/t13-,14+,15? DMO02LU CS CN1C[C@@H]2[C@H](C1)C2CN(CC3=CC(=C(C=C3)F)Cl)C(=O)C4=CN(C=N4)C DMO02LU IK KYLOBHXXQOZRKK-YIONKMFJSA-N DMO02LU IU N-[(3-chloro-4-fluorophenyl)methyl]-1-methyl-N-[[(1R,5S)-3-methyl-3-azabicyclo[3.1.0]hexan-6-yl]methyl]imidazole-4-carboxamide DMO02LU CA CAS 1173239-39-8 DMO02LU DE Schizophrenia DMC2FAL ID DMC2FAL DMC2FAL DN PF-3893787 DMC2FAL HS Phase 2 DMC2FAL SN PF-03893787; PF-3826719 DMC2FAL CP Pfizer Inc DMC2FAL DT Small molecular drug DMC2FAL PC 24745335 DMC2FAL MW 262.35 DMC2FAL FM C13H22N6 DMC2FAL IC InChI=1S/C13H22N6/c1-15-10-4-5-19(8-10)12-6-11(17-13(14)18-12)16-7-9-2-3-9/h6,9-10,15H,2-5,7-8H2,1H3,(H3,14,16,17,18)/t10-/m1/s1 DMC2FAL CS CN[C@@H]1CCN(C1)C2=NC(=NC(=C2)NCC3CC3)N DMC2FAL IK ISBHYKVAFKTATD-SNVBAGLBSA-N DMC2FAL IU 4-N-(cyclopropylmethyl)-6-[(3R)-3-(methylamino)pyrrolidin-1-yl]pyrimidine-2,4-diamine DMC2FAL CA CAS 943057-12-3 DMC2FAL DE Asthma; Atopic dermatitis; Plaque psoriasis DM3DWKN ID DM3DWKN DM3DWKN DN PF-4191834 DM3DWKN HS Phase 2 DM3DWKN SN PF-04191834 DM3DWKN CP Pfizer Inc DM3DWKN DT Small molecular drug DM3DWKN PC 24986635 DM3DWKN MW 393.5 DM3DWKN FM C22H23N3O2S DM3DWKN IC InChI=1S/C22H23N3O2S/c1-25-20(9-12-24-25)16-5-7-18(8-6-16)28-19-4-2-3-17(15-19)22(21(23)26)10-13-27-14-11-22/h2-9,12,15H,10-11,13-14H2,1H3,(H2,23,26) DM3DWKN CS CN1C(=CC=N1)C2=CC=C(C=C2)SC3=CC=CC(=C3)C4(CCOCC4)C(=O)N DM3DWKN IK DVNQWYLVSNPCJZ-UHFFFAOYSA-N DM3DWKN IU 4-[3-[4-(2-methylpyrazol-3-yl)phenyl]sulfanylphenyl]oxane-4-carboxamide DM3DWKN CA CAS 1029317-21-2 DM3DWKN DE Asthma DM81D4I ID DM81D4I DM81D4I DN PF-4447943 DM81D4I HS Phase 2 DM81D4I SN BCP16255 DM81D4I CP Pfizer Inc DM81D4I DT Small molecular drug DM81D4I PC 135564558 DM81D4I MW 395.5 DM81D4I FM C20H25N7O2 DM81D4I IC InChI=1S/C20H25N7O2/c1-13-10-26(12-17-21-5-2-6-22-17)11-16(13)18-24-19-15(20(28)25-18)9-23-27(19)14-3-7-29-8-4-14/h2,5-6,9,13-14,16H,3-4,7-8,10-12H2,1H3,(H,24,25,28)/t13-,16-/m1/s1 DM81D4I CS C[C@@H]1CN(C[C@H]1C2=NC3=C(C=NN3C4CCOCC4)C(=O)N2)CC5=NC=CC=N5 DM81D4I IK IWXUVYOOUMLUTQ-CZUORRHYSA-N DM81D4I IU 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(oxan-4-yl)-5H-pyrazolo[3,4-d]pyrimidin-4-one DM81D4I CA CAS 1082744-20-4 DM81D4I DE Alzheimer disease; Sickle-cell disorder DML38VU ID DML38VU DML38VU DN PF-446687 DML38VU HS Phase 2 DML38VU SN PF-00446687; PF-2336652 DML38VU CP Pfizer Inc DML38VU DE Female sexual arousal dysfunction DM3YIKR ID DM3YIKR DM3YIKR DN PF-4523655 DM3YIKR HS Phase 2 DM3YIKR CP Quark Pharm; Pfizer DM3YIKR DT siRNA drug DM3YIKR DE Age-related macular degeneration; Diabetic macular degeneration DM24I0N ID DM24I0N DM24I0N DN PF-4878691 DM24I0N HS Phase 2 DM24I0N SN PF-04878691; PF-4171455 DM24I0N CP Pfizer Inc DM24I0N PC 10309114 DM24I0N MW 361.5 DM24I0N FM C17H23N5O2S DM24I0N IC InChI=1S/C17H23N5O2S/c1-3-14-21-15-16(12-8-4-5-9-13(12)20-17(15)18)22(14)11-7-6-10-19-25(2,23)24/h4-5,8-9,19H,3,6-7,10-11H2,1-2H3,(H2,18,20) DM24I0N CS CCC1=NC2=C(N1CCCCNS(=O)(=O)C)C3=CC=CC=C3N=C2N DM24I0N IK YZOQZEXYFLXNKA-UHFFFAOYSA-N DM24I0N IU N-[4-(4-amino-2-ethylimidazo[4,5-c]quinolin-1-yl)butyl]methanesulfonamide DM24I0N CA CAS 532959-63-0 DM24I0N DE Hepatitis C virus infection; Melanoma DM3C8GQ ID DM3C8GQ DM3C8GQ DN PF-489791 DM3C8GQ HS Phase 2 DM3C8GQ SN UNII-2S27T3DSZ3; PF-489791; PF-00489791; 853003-48-2; 2S27T3DSZ3; PF-489,791; ZUHZNKJIJDAJFD-UHFFFAOYSA-N; UK-489,791; SCHEMBL331279; SCHEMBL8042129; GTPL8377; DB11736; SB16722; 1H-Pyrazolo(4,3-d)pyrimidine-3-carboxamide, 1-(2-ethoxyethyl)-5-(ethylmethylamino)-7-((4-methyl-2-pyridinyl)amino)-N-(methylsulfonyl); n-[1-(2-ethoxyethyl)-5-(n-ethyl-n-methylamino)-7-(4-methylpyridin-2-yl-amino)-1h-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide DM3C8GQ CP Pfizer New York, NY DM3C8GQ DT Small molecular drug DM3C8GQ PC 11465695 DM3C8GQ MW 476.6 DM3C8GQ FM C20H28N8O4S DM3C8GQ IC InChI=1S/C20H28N8O4S/c1-6-27(4)20-23-15-16(19(29)26-33(5,30)31)25-28(10-11-32-7-2)17(15)18(24-20)22-14-12-13(3)8-9-21-14/h8-9,12H,6-7,10-11H2,1-5H3,(H,26,29)(H,21,22,23,24) DM3C8GQ CS CCN(C)C1=NC2=C(C(=N1)NC3=NC=CC(=C3)C)N(N=C2C(=O)NS(=O)(=O)C)CCOCC DM3C8GQ IK ZUHZNKJIJDAJFD-UHFFFAOYSA-N DM3C8GQ IU 1-(2-ethoxyethyl)-5-[ethyl(methyl)amino]-7-[(4-methylpyridin-2-yl)amino]-N-methylsulfonylpyrazolo[4,3-d]pyrimidine-3-carboxamide DM3C8GQ CA CAS 853003-48-2 DM3C8GQ DE Raynaud disease; Chronic obstructive pulmonary disease DM0KRLJ ID DM0KRLJ DM0KRLJ DN PF-885706 DM0KRLJ HS Phase 2 DM0KRLJ SN PF-00885706 DM0KRLJ CP Pfizer Inc DM0KRLJ DE Gastroesophageal reflux disease DMF5YEN ID DMF5YEN DMF5YEN DN PG-102 DMF5YEN HS Phase 2 DMF5YEN SN TNX-100; 5-D12 DMF5YEN CP PanGenetics BV DMF5YEN DE Autoimmune diabetes DMJTYO4 ID DMJTYO4 DMJTYO4 DN PGL-2 DMJTYO4 HS Phase 2 DMJTYO4 CP ProSci DMJTYO4 DE Endometriosis DMKA705 ID DMKA705 DMKA705 DN PGL-2001 DMKA705 HS Phase 2 DMKA705 SN Steroid sulfatase inhibitor (endometriosis), PregLem DMKA705 CP Ipsen DMKA705 PC 6918339 DMKA705 MW 351.5 DMKA705 FM C18H25NO4S DMKA705 IC InChI=1S/C18H25NO4S/c1-18-9-8-14-13-5-3-12(23-24(19,21)22)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h3,5,10,14-17,20H,2,4,6-9H2,1H3,(H2,19,21,22)/t14-,15-,16+,17+,18+/m1/s1 DMKA705 CS C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CCC4=C3C=CC(=C4)OS(=O)(=O)N DMKA705 IK YXYXCSOJKUAPJI-ZBRFXRBCSA-N DMKA705 IU [(8R,9S,13S,14S,17S)-17-hydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-yl] sulfamate DMKA705 CA CAS 172377-52-5 DMKA705 DE Endometriosis DM9JGTQ ID DM9JGTQ DM9JGTQ DN PH10 nasal spray DM9JGTQ HS Phase 2 DM9JGTQ CP Pherin Pharmaceuticals Los Altos, CA DM9JGTQ DE Major depressive disorder DM71HVW ID DM71HVW DM71HVW DN PH-794428 DM71HVW HS Phase 2 DM71HVW SN PHA-794428 DM71HVW CP Pfizer DM71HVW DE Growth hormone deficiency DMGYBZI ID DMGYBZI DMGYBZI DN PHA-739358 DMGYBZI HS Phase 2 DMGYBZI SN Danusertib; PHA 739358; Danusertib, PHA-739358; (R)-N-(5-(2-methoxy-2-phenylacetyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl)-4-(4-methylpiperazin-1-yl)benzamide; 5-Amido-pyrrolopyrazole 9d DMGYBZI CP Pfizer; Nerviano DMGYBZI DT Small molecular drug DMGYBZI PC 11442891 DMGYBZI MW 474.6 DMGYBZI FM C26H30N6O3 DMGYBZI IC InChI=1S/C26H30N6O3/c1-30-12-14-31(15-13-30)20-10-8-19(9-11-20)25(33)27-24-21-16-32(17-22(21)28-29-24)26(34)23(35-2)18-6-4-3-5-7-18/h3-11,23H,12-17H2,1-2H3,(H2,27,28,29,33)/t23-/m1/s1 DMGYBZI CS CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=NNC4=C3CN(C4)C(=O)[C@@H](C5=CC=CC=C5)OC DMGYBZI IK XKFTZKGMDDZMJI-HSZRJFAPSA-N DMGYBZI IU N-[5-[(2R)-2-methoxy-2-phenylacetyl]-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl]-4-(4-methylpiperazin-1-yl)benzamide DMGYBZI CA CAS 827318-97-8 DMGYBZI CB CHEBI:94490 DMGYBZI DE Prostate cancer DMS2Q9G ID DMS2Q9G DMS2Q9G DN PHA848125 DMS2Q9G HS Phase 2 DMS2Q9G SN Milciclib; PHA-848125; 802539-81-7; PHA 848125; Milciclib (PHA-848125); UNII-688000M8S8; PHA848125; MMV676602; 4,5-dihydro-N,1,4,4-tetramethyl-8-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-1H-Pyrazolo[4,3-h]quinazoline-3-carboxamide; 688000M8S8; N,1,4,4-tetramethyl-8-(4-(4-methylpiperazin-1-yl)phenylamino)-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide; Milciclib [INN]; N,1,4,4-Tetramethyl-8-{[4-(4-Methylpiperazin-1-Yl)phenyl]amino}-4,5-Dihydro-1h-Pyrazolo[4,3-H]quinazoline-3-Carboxamide DMS2Q9G CP Nerviano Medical Services DMS2Q9G DT Small molecular drug DMS2Q9G PC 16718576 DMS2Q9G MW 460.6 DMS2Q9G FM C25H32N8O DMS2Q9G IC InChI=1S/C25H32N8O/c1-25(2)14-16-15-27-24(29-20(16)22-19(25)21(23(34)26-3)30-32(22)5)28-17-6-8-18(9-7-17)33-12-10-31(4)11-13-33/h6-9,15H,10-14H2,1-5H3,(H,26,34)(H,27,28,29) DMS2Q9G CS CC1(CC2=CN=C(N=C2C3=C1C(=NN3C)C(=O)NC)NC4=CC=C(C=C4)N5CCN(CC5)C)C DMS2Q9G IK RXZMYLDMFYNEIM-UHFFFAOYSA-N DMS2Q9G IU N,1,4,4-tetramethyl-8-[4-(4-methylpiperazin-1-yl)anilino]-5H-pyrazolo[4,3-h]quinazoline-3-carboxamide DMS2Q9G CA CAS 802539-81-7 DMS2Q9G DE Thymic cancer DMRP3CV ID DMRP3CV DMRP3CV DN Phenylalanine hydroxylase DMRP3CV HS Phase 2 DMRP3CV SN Oralase; Phenylase; AvPAL-PEG; Phenylalanine hydroxylase, BioMarin; Phenylalanine hydroxylase, IBEX; Poly ethylene glycol-phenylalanine ammonia lyase; Phenylketonuria therapy (enzyme), BioMarin DMRP3CV CP Biomarin pharmaceutical DMRP3CV DE Autoimmune diabetes DMBHPDW ID DMBHPDW DMBHPDW DN Phenylbutyrate DMBHPDW HS Phase 2 DMBHPDW SN Benzenebutyric acid; Phenyl butanoate; Phenyl butyrate; HDInhib_000004; Butanoic acid, phenyl ester; Butyric acid, phenyl ester; FR-2080; Gamma-Phenylbutyric acid; Omega-Phenylbutanoic acid; GAMMA-PHENYL-BUTYRIC ACID; Butyric acid, 4-phenyl-(8CI); 1-Phenylbutyric acid; 4-PHENYL-BUTANOIC ACID; 4-PHENYLBUTYRIC ACID; 4-Phenylbutanoic acid; 4-phenylbutans; 4-phenylbutyrate DMBHPDW CP Scandinavian DMBHPDW DT Small molecular drug DMBHPDW PC 4775 DMBHPDW MW 164.2 DMBHPDW FM C10H12O2 DMBHPDW IC InChI=1S/C10H12O2/c11-10(12)8-4-7-9-5-2-1-3-6-9/h1-3,5-6H,4,7-8H2,(H,11,12) DMBHPDW CS C1=CC=C(C=C1)CCCC(=O)O DMBHPDW IK OBKXEAXTFZPCHS-UHFFFAOYSA-N DMBHPDW IU 4-phenylbutanoic acid DMBHPDW CA CAS 1821-12-1 DMBHPDW CB CHEBI:41500 DMBHPDW DE Urea cycle disorder DMJWD62 ID DMJWD62 DMJWD62 DN phorbol 12-myristate 13-acetate DMJWD62 HS Phase 2 DMJWD62 SN TPA; 12-O-tetradecanoylphorbol-13-acetate; tetradecanoyl-beta-phorbol acetate DMJWD62 DT Small molecular drug DMJWD62 PC 27924 DMJWD62 MW 616.8 DMJWD62 FM C36H56O8 DMJWD62 IC InChI=1S/C36H56O8/c1-7-8-9-10-11-12-13-14-15-16-17-18-29(39)43-32-24(3)35(42)27(30-33(5,6)36(30,32)44-25(4)38)20-26(22-37)21-34(41)28(35)19-23(2)31(34)40/h19-20,24,27-28,30,32,37,41-42H,7-18,21-22H2,1-6H3/t24-,27+,28-,30-,32-,34-,35-,36-/m1/s1 DMJWD62 CS CCCCCCCCCCCCCC(=O)O[C@@H]1[C@H]([C@]2([C@@H](C=C(C[C@]3([C@H]2C=C(C3=O)C)O)CO)[C@H]4[C@@]1(C4(C)C)OC(=O)C)O)C DMJWD62 IK PHEDXBVPIONUQT-RGYGYFBISA-N DMJWD62 IU [(1S,2S,6R,10S,11R,13S,14R,15R)-13-acetyloxy-1,6-dihydroxy-8-(hydroxymethyl)-4,12,12,15-tetramethyl-5-oxo-14-tetracyclo[8.5.0.02,6.011,13]pentadeca-3,8-dienyl] tetradecanoate DMJWD62 CA CAS 16561-29-8 DMJWD62 CB CHEBI:37537 DMJWD62 DE Acute myeloid leukaemia; Hodgkin lymphoma DM4FIWC ID DM4FIWC DM4FIWC DN PI-88/Taxotere DM4FIWC HS Phase 2 DM4FIWC SN PI-88/docetaxel DM4FIWC CP Progen Industries DM4FIWC DE Solid tumour/cancer DM3ZEYL ID DM3ZEYL DM3ZEYL DN Piboserod DM3ZEYL HS Phase 2 DM3ZEYL SN Piboserod; 152811-62-6; UNII-4UQ3S81B25; SB-207266; SB207256; 4UQ3S81B25; N-((1-butylpiperidin-4-yl)methyl)-3,4-dihydro-2H-[1,3]oxazino[3,2-a]indole-10-carboxamide; SB 207266; N-[(1-butyl-4-piperidinyl)methyl]-3,4-dihydro-2H-[1,3]-oxazino[3,2-a]indole-10-carboxamide; N-[(1-butylpiperidin-4-yl)methyl]-3,4-dihydro-2H-[1,3]oxazino[3,2-a]indole-10-carboxamide; Piboserod [INN:BAN]; Serotonin 5-HT4 Receptor Antagonists; SB207266(Piboserod); AC1L42OO; GTPL225; SCHEMBL467339; CHEMBL356359; BDBM85026; DTXSID60165129 DM3ZEYL DT Small molecular drug DM3ZEYL PC 177336 DM3ZEYL MW 369.5 DM3ZEYL FM C22H31N3O2 DM3ZEYL IC InChI=1S/C22H31N3O2/c1-2-3-11-24-13-9-17(10-14-24)16-23-21(26)20-18-7-4-5-8-19(18)25-12-6-15-27-22(20)25/h4-5,7-8,17H,2-3,6,9-16H2,1H3,(H,23,26) DM3ZEYL CS CCCCN1CCC(CC1)CNC(=O)C2=C3N(CCCO3)C4=CC=CC=C42 DM3ZEYL IK KVCSJPATKXABRQ-UHFFFAOYSA-N DM3ZEYL IU N-[(1-butylpiperidin-4-yl)methyl]-3,4-dihydro-2H-[1,3]oxazino[3,2-a]indole-10-carboxamide DM3ZEYL CA CAS 152811-62-6 DM3ZEYL DE Atrial fibrillation DMYL7VR ID DMYL7VR DMYL7VR DN Piclamilast DMYL7VR HS Phase 2 DMYL7VR SN Piclamilast; 144035-83-6; Cpodpmb; RP 73401; 3-(Cyclopentyloxy)-N-(3,5-dichloropyridin-4-yl)-4-methoxybenzamide; UNII-WM58D7C3ZT; RP 73-401; RP-73401; RP-73-401; RPR 73401; 3-(Cyclopentyloxy)-N-(3,5-dichloro-4-pyridinyl)-4-methoxybenzamide; WM58D7C3ZT; Benzamide, 3-(cyclopentyloxy)-N-(3,5-dichloro-4-pyridinyl)-4-methoxy-; CHEMBL42126; CHEBI:47619; RRRUXBQSQLKHEL-UHFFFAOYSA-N; RPR-73401; 3-(Cyclopentyloxy)-N-(3,5-dichloro-4-pyridyl)-p-anisamide; 3-(Cyclopentyloxy)-N-(3,5-dichloro-4-pyridyl)-4-methoxybenzamide; PIL DMYL7VR DT Small molecular drug DMYL7VR PC 154575 DMYL7VR MW 381.2 DMYL7VR FM C18H18Cl2N2O3 DMYL7VR IC InChI=1S/C18H18Cl2N2O3/c1-24-15-7-6-11(8-16(15)25-12-4-2-3-5-12)18(23)22-17-13(19)9-21-10-14(17)20/h6-10,12H,2-5H2,1H3,(H,21,22,23) DMYL7VR CS COC1=C(C=C(C=C1)C(=O)NC2=C(C=NC=C2Cl)Cl)OC3CCCC3 DMYL7VR IK RRRUXBQSQLKHEL-UHFFFAOYSA-N DMYL7VR IU 3-cyclopentyloxy-N-(3,5-dichloropyridin-4-yl)-4-methoxybenzamide DMYL7VR CA CAS 144035-83-6 DMYL7VR CB CHEBI:47619 DMYL7VR DE Rheumatoid arthritis DMMO46E ID DMMO46E DMMO46E DN Pidilizumab DMMO46E HS Phase 2 DMMO46E SN CT-011 DMMO46E CP CureTech DMMO46E DT Monoclonal antibody DMMO46E DE Diffuse large B-cell lymphoma DMAFZ84 ID DMAFZ84 DMAFZ84 DN PIKAMILONE DMAFZ84 HS Phase 2 DMAFZ84 SN N-Nicotinoyl-gamma-aminobutyric acid sodium salt; N-(3-Pyridylcarbonyl)-4-aminobutyric acid sodium salt DMAFZ84 DT Small molecular drug DMAFZ84 PC 60608 DMAFZ84 MW 208.21 DMAFZ84 FM C10H12N2O3 DMAFZ84 IC InChI=1S/C10H12N2O3/c13-9(14)4-2-6-12-10(15)8-3-1-5-11-7-8/h1,3,5,7H,2,4,6H2,(H,12,15)(H,13,14) DMAFZ84 CS C1=CC(=CN=C1)C(=O)NCCCC(=O)O DMAFZ84 IK NAJVRARAUNYNDX-UHFFFAOYSA-N DMAFZ84 IU 4-(pyridine-3-carbonylamino)butanoic acid DMAFZ84 CA CAS 34562-97-5 DMAFZ84 DE Anxiety disorder DM96VWD ID DM96VWD DM96VWD DN PINOCEMBRIN DM96VWD HS Phase 2 DM96VWD SN Pinocembrin; 480-39-7; (+)-Pinocembrin; (2S)-pinocembrin; Dihydrochrysin; UNII-8T7C8CH791; NSC 43318; NSC 279005; NSC 661207; 4H-1-Benzopyran-4-one, 2,3-dihydro-5,7-dihydroxy-2-phenyl-, (2S)-; (S)-5,7-dihydroxyflavanone; (S)-5,7-dihydroxy-2-phenylchroman-4-one; CHEMBL399910; CHEBI:28157; (2s)-5,7-dihydroxy-2-phenyl-2,3-dihydro-4h-chromen-4-one; (S)-2,3-Dihydro-5,7-dihydroxy-2-phenyl-4H-1-benzopyran-4-one; 8T7C8CH791; Pinocembrin (6CI); 4H-1-Benzopyran-4-one, 2,3-dihydro-5,7-dihydroxy-2-phenyl-, (-)- DM96VWD DT Small molecular drug DM96VWD PC 68071 DM96VWD MW 256.25 DM96VWD FM C15H12O4 DM96VWD IC InChI=1S/C15H12O4/c16-10-6-11(17)15-12(18)8-13(19-14(15)7-10)9-4-2-1-3-5-9/h1-7,13,16-17H,8H2/t13-/m0/s1 DM96VWD CS C1[C@H](OC2=CC(=CC(=C2C1=O)O)O)C3=CC=CC=C3 DM96VWD IK URFCJEUYXNAHFI-ZDUSSCGKSA-N DM96VWD IU (2S)-5,7-dihydroxy-2-phenyl-2,3-dihydrochromen-4-one DM96VWD CA CAS 480-39-7 DM96VWD CB CHEBI:28157 DM276N1 ID DM276N1 DM276N1 DN Piritrexim DM276N1 HS Phase 2 DM276N1 SN Piritrexim; 72732-56-0; Piritrexim [INN]; Piritreximum [Latin]; Piritrexime [French]; 6-(2,5-dimethoxybenzyl)-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine; Piritrexima [Spanish]; BW 301U; UNII-MK2A783ZUT; BW-301U; TCMDC-137235; BRN 5768301; MK2A783ZUT; CHEMBL7492; 2,4-Diamino-5-methyl-6-(2,5-dimethoxybenzyl)pyrido(2,3-d)pyrimidine; 6-(2,5-DIMETHOXY-BENZYL)-5-METHYL-PYRIDO[2,3-D]PYRIMIDINE-2,4-DIAMINE; 6-((2,5-Dimethoxyphenyl)methyl)-5-methylpyrido(2,3-d)pyrimidine-2,4-diamine DM276N1 DT Small molecular drug DM276N1 PC 54369 DM276N1 MW 325.4 DM276N1 FM C17H19N5O2 DM276N1 IC InChI=1S/C17H19N5O2/c1-9-11(6-10-7-12(23-2)4-5-13(10)24-3)8-20-16-14(9)15(18)21-17(19)22-16/h4-5,7-8H,6H2,1-3H3,(H4,18,19,20,21,22) DM276N1 CS CC1=C2C(=NC(=NC2=NC=C1CC3=C(C=CC(=C3)OC)OC)N)N DM276N1 IK VJXSSYDSOJBUAV-UHFFFAOYSA-N DM276N1 IU 6-[(2,5-dimethoxyphenyl)methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine DM276N1 CA CAS 72732-56-0 DM276N1 DE Bladder cancer DMC3T2S ID DMC3T2S DMC3T2S DN PIRODOMAST DMC3T2S HS Phase 2 DMC3T2S SN Sch-37224; Pirodomast; 1-(4-Hydroxy-2-oxo-1-phenyl-1,2-dihydro-1,8-naphthyridin-3-yl)pyrrolidine; 1-(4-Hydroxy-2-oxo-1-phenyl-1,2-dihydro-1,8-naphthyridin-3-yl)pyrrolidinium hydroxide inner salt; 4-Hydroxy-1-phenyl-3-(1-pyrrolidinyl)-1,8-naphthyridin-2(1H)-one DMC3T2S DT Small molecular drug DMC3T2S PC 54680204 DMC3T2S MW 307.3 DMC3T2S FM C18H17N3O2 DMC3T2S IC InChI=1S/C18H17N3O2/c22-16-14-9-6-10-19-17(14)21(13-7-2-1-3-8-13)18(23)15(16)20-11-4-5-12-20/h1-3,6-10,22H,4-5,11-12H2 DMC3T2S CS C1CCN(C1)C2=C(C3=C(N=CC=C3)N(C2=O)C4=CC=CC=C4)O DMC3T2S IK ULGABHCZIJXUFO-UHFFFAOYSA-N DMC3T2S IU 4-hydroxy-1-phenyl-3-pyrrolidin-1-yl-1,8-naphthyridin-2-one DMC3T2S CA CAS 108310-20-9 DMC3T2S DE Asthma DMHI6GE ID DMHI6GE DMHI6GE DN Pirsidomine DMHI6GE HS Phase 2 DMHI6GE SN C87-3754; CAS-936 DMHI6GE CP Hoechst Marion Roussel Inc DMHI6GE DT Small molecular drug DMHI6GE PC 9571076 DMHI6GE MW 330.4 DMHI6GE FM C17H22N4O3 DMHI6GE IC InChI=1S/C17H22N4O3/c1-12-5-4-6-13(2)21(12)20-11-16(24-19-20)18-17(22)14-7-9-15(23-3)10-8-14/h7-13H,4-6H2,1-3H3/t12-,13+ DMHI6GE CS C[C@@H]1CCC[C@@H](N1[N+]2=NOC(=C2)/N=C(/C3=CC=C(C=C3)OC)\\[O-])C DMHI6GE IK TXPUBJSOHAMNEI-BETUJISGSA-N DMHI6GE IU (1Z)-N-[3-[(2S,6R)-2,6-dimethylpiperidin-1-yl]oxadiazol-3-ium-5-yl]-4-methoxybenzenecarboximidate DMHI6GE CA CAS 132722-74-8 DMHI6GE DE Angina pectoris DMKEV7N ID DMKEV7N DMKEV7N DN PK1 DMKEV7N HS Phase 2 DMKEV7N SN FCE-28068; N-(2-Hydroxypropyl)methacrylamide (HPMA) copolymer linked to Gly-Phe-Leu-Gly-doxorubicin DMKEV7N DT Small molecular drug DMKEV7N PC 59235249 DMKEV7N MW 381.3 DMKEV7N FM C17H14Cl2N2O2S DMKEV7N IC InChI=1S/C17H14Cl2N2O2S/c1-17(10-3-6-12(22)7-4-10)15(23)21(16(24)20(17)2)11-5-8-13(18)14(19)9-11/h3-9,22H,1-2H3/t17-/m1/s1 DMKEV7N CS C[C@]1(C(=O)N(C(=S)N1C)C2=CC(=C(C=C2)Cl)Cl)C3=CC=C(C=C3)O DMKEV7N IK YPONBLYNQFHCLA-QGZVFWFLSA-N DMKEV7N IU (5R)-3-(3,4-dichlorophenyl)-5-(4-hydroxyphenyl)-1,5-dimethyl-2-sulfanylideneimidazolidin-4-one DMKEV7N DE Solid tumour/cancer DMHUCQS ID DMHUCQS DMHUCQS DN PL-3994 DMHUCQS HS Phase 2 DMHUCQS PC 121488161 DMHUCQS MW 1875.2 DMHUCQS FM C82H127N27O20S2 DMHUCQS IC InChI=1S/C82H127N27O20S2/c1-6-9-11-15-25-62(112)98-59-41-130-131-42-60(76(126)104-56(34-47-26-28-49(111)29-27-47)79(129)109-39-57(66(83)116)105-77(127)61(109)24-18-32-93-82(88)89)107-74(124)58(40-110)106-78(128)65(44(4)8-3)108-70(120)52(23-17-31-92-81(86)87)100-73(123)55(36-64(114)115)103-69(119)51(21-10-7-2)99-68(118)50(22-16-30-91-80(84)85)97-63(113)38-94-67(117)45(5)96-71(121)53(33-46-19-13-12-14-20-46)101-72(122)54(102-75(59)125)35-48-37-90-43-95-48/h12-14,19-20,26-29,37,43-45,50-61,65,110-111H,6-11,15-18,21-25,30-36,38-42H2,1-5H3,(H2,83,116)(H,90,95)(H,94,117)(H,96,121)(H,97,113)(H,98,112)(H,99,118)(H,100,123)(H,101,122)(H,102,125)(H,103,119)(H,104,126)(H,105,127)(H,106,128)(H,107,124)(H,108,120)(H,114,115)(H4,84,85,91)(H4,86,87,92)(H4,88,89,93)/t44-,45+,50-,51+,52-,53-,54-,55-,56-,57+,58-,59+,60-,61-,65-/m0/s1 DMHUCQS CS CCCCCCC(=O)N[C@@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC1=O)CC2=CNC=N2)CC3=CC=CC=C3)C)CCCNC(=N)N)CCCC)CC(=O)O)CCCNC(=N)N)[C@@H](C)CC)CO)C(=O)N[C@@H](CC4=CC=C(C=C4)O)C(=O)N5C[C@@H](NC(=O)[C@@H]5CCCNC(=N)N)C(=O)N DMHUCQS IK HSHVZRILAMZYHY-WXSGKXQHSA-N DMHUCQS IU 2-[(4R,7S,10S,13S,16S,19R,22S,28R,31S,34S,37S)-31-benzyl-10-[(2S)-butan-2-yl]-19-butyl-13,22-bis(3-carbamimidamidopropyl)-4-[[(2S)-1-[(2S,5R)-2-(3-carbamimidamidopropyl)-5-carbamoyl-3-oxopiperazin-1-yl]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]carbamoyl]-37-(heptanoylamino)-7-(hydroxymethyl)-34-(1H-imidazol-4-ylmethyl)-28-methyl-6,9,12,15,18,21,24,27,30,33,36-undecaoxo-1,2-dithia-5,8,11,14,17,20,23,26,29,32,35-undecazacyclooctatriacont-16-yl]acetic acid DMHUCQS CA CAS 952295-80-6 DMHUCQS DE Hypertension; Congestive heart failure; Asthma DMYUO6B ID DMYUO6B DMYUO6B DN PlaMavax DMYUO6B HS Phase 2 DMYUO6B SN AdCh63-ME-TRAP; MVA-ME-TRAP; ME-TRAP fusion antigen adenoviral vector vaccine (Malaria), Okairos DMYUO6B CP University of Oxford DMYUO6B DT Vaccine DMYUO6B DE Malaria DMOB1EM ID DMOB1EM DMOB1EM DN Plasmin DMOB1EM HS Phase 2 DMOB1EM SN Plasmin (plasma-derived, peripheral arterial occlusion/ischemic stroke); Plasmin (plasma-derived, peripheral arterial occlusion/ischemic stroke), Talecris Biotherapeutics DMOB1EM CP Grifols therapeutics DMOB1EM DE Occlusive disease; Peripheral arterial disease DMK10ZC ID DMK10ZC DMK10ZC DN PLECONARIL DMK10ZC HS Phase 2 DMK10ZC SN Picovir; Pleconaril < Prop INN; SR-263843; SR-63843; VP-63843; Win-63843; 3-[3,5-Dimethyl-4-[3-(3-methylisoxazol-5-yl)propoxy]phenyl]-5-(trifluoromethyl)-1,2,4-oxadiazole DMK10ZC CP ViroPharma DMK10ZC DT Small molecular drug DMK10ZC PC 1684 DMK10ZC MW 381.3 DMK10ZC FM C18H18F3N3O3 DMK10ZC IC InChI=1S/C18H18F3N3O3/c1-10-7-13(16-22-17(27-24-16)18(19,20)21)8-11(2)15(10)25-6-4-5-14-9-12(3)23-26-14/h7-9H,4-6H2,1-3H3 DMK10ZC CS CC1=CC(=CC(=C1OCCCC2=CC(=NO2)C)C)C3=NOC(=N3)C(F)(F)F DMK10ZC IK KQOXLKOJHVFTRN-UHFFFAOYSA-N DMK10ZC IU 3-[3,5-dimethyl-4-[3-(3-methyl-1,2-oxazol-5-yl)propoxy]phenyl]-5-(trifluoromethyl)-1,2,4-oxadiazole DMK10ZC CA CAS 153168-05-9 DMK10ZC DE Virus infection DM7Y60I ID DM7Y60I DM7Y60I DN Plevitrexed DM7Y60I HS Phase 2 DM7Y60I SN ZD 9331; ZD9331; 153537-73-6; Plevitrexed [INN]; ZD-9331; NSC 696259; UNII-L9P2881C3H; CHEMBL126648; (2s)-2-[(2-fluoro-4-{[(4-hydroxy-2,7-dimethylquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino}benzoyl)amino]-4-(2h-tetrazol-5-yl)butanoic acid; L9P2881C3H; Plevitrexed (INN); 172521-94-7; (2S)-2-[[4-[(2,7-dimethyl-4-oxo-1H-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid; 1H-Tetrazole-5-butanoic acid, DM7Y60I CP BTG DM7Y60I DT Small molecular drug DM7Y60I PC 135430970 DM7Y60I MW 532.5 DM7Y60I FM C26H25FN8O4 DM7Y60I IC InChI=1S/C26H25FN8O4/c1-4-9-35(13-16-11-19-22(10-14(16)2)28-15(3)29-25(19)37)17-5-6-18(20(27)12-17)24(36)30-21(26(38)39)7-8-23-31-33-34-32-23/h1,5-6,10-12,21H,7-9,13H2,2-3H3,(H,30,36)(H,38,39)(H,28,29,37)(H,31,32,33,34)/t21-/m0/s1 DM7Y60I CS CC1=CC2=C(C=C1CN(CC#C)C3=CC(=C(C=C3)C(=O)N[C@@H](CCC4=NNN=N4)C(=O)O)F)C(=O)NC(=N2)C DM7Y60I IK IEJSCSAMMLUINT-NRFANRHFSA-N DM7Y60I IU (2S)-2-[[4-[(2,7-dimethyl-4-oxo-3H-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid DM7Y60I CA CAS 153537-73-6 DM7Y60I DE Gastric adenocarcinoma DMTL39C ID DMTL39C DMTL39C DN Plevitrexed (R)-isomer DMTL39C HS Phase 2 DMTL39C SN YW3548 DMTL39C CP BTG DMTL39C DT Small molecular drug DMTL39C PC 213022 DMTL39C DE Gastric adenocarcinoma DMRTD7I ID DMRTD7I DMRTD7I DN PLX8394 DMRTD7I HS Phase 2 DMRTD7I CP Daiichi sankyo parsippany DMRTD7I PC 90116675 DMRTD7I MW 542.5 DMRTD7I FM C25H21F3N6O3S DMRTD7I IC InChI=1S/C25H21F3N6O3S/c26-16-5-6-34(12-16)38(36,37)33-20-4-3-19(27)21(22(20)28)23(35)18-11-32-25-17(18)7-14(8-31-25)15-9-29-24(30-10-15)13-1-2-13/h3-4,7-11,13,16,33H,1-2,5-6,12H2,(H,31,32)/t16-/m1/s1 DMRTD7I CS C1CN(C[C@@H]1F)S(=O)(=O)NC2=C(C(=C(C=C2)F)C(=O)C3=CNC4=C3C=C(C=N4)C5=CN=C(N=C5)C6CC6)F DMRTD7I IK YYACLQUDUDXAPA-MRXNPFEDSA-N DMRTD7I IU (3R)-N-[3-[5-(2-cyclopropylpyrimidin-5-yl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluorophenyl]-3-fluoropyrrolidine-1-sulfonamide DMRTD7I CA CAS 1393466-87-9 DMRTD7I DE Melanoma; Solid tumour/cancer DMMKOPX ID DMMKOPX DMMKOPX DN PM-00104 DMMKOPX HS Phase 2 DMMKOPX SN Zalypsis; PM00104; UNII-C21EZR41AY; C21EZR41AY; PM-00104; 308359-57-1; (6aS,7R,13S,14S,16R)-8,14-dihydroxy-9-methoxy-4,10,17-trimethyl-16-[({(2E)-3-[3-(trifluoromethyl)phenyl]prop-2-enoyl}amino)methyl]-6,7,12,13,14,16-hexahydro-6aH-7,13-epimino[1,3]dioxolo[7,8]isoquino[3,2-b][3]benzazocin-5-yl acetate; SCHEMBL7975282; DTXSID0044026; NOCAS_44026; DB12454; CS-1940; HY-16401; 2-Propenamide, N-(((6aS,7R,13S,14S,16R)-5-(acetyloxy)-6,6a,7,13,14,16-hexahydro-8,14-dihydroxy-9-methoxy-4,10,17-trimethyl-7,13-imino-12H-1,3-dioxolo DMMKOPX CP PharmaMar DMMKOPX DT Small molecular drug DMMKOPX PC 16061448 DMMKOPX MW 709.7 DMMKOPX FM C37H38F3N3O8 DMMKOPX IC InChI=1S/C37H38F3N3O8/c1-17-11-21-13-25-36(47)43-24(30(42(25)4)28(21)31(46)32(17)48-5)14-23-29(35-34(49-16-50-35)18(2)33(23)51-19(3)44)26(43)15-41-27(45)10-9-20-7-6-8-22(12-20)37(38,39)40/h6-12,24-26,30,36,46-47H,13-16H2,1-5H3,(H,41,45)/b10-9+/t24-,25-,26-,30-,36-/m0/s1 DMMKOPX CS CC1=CC2=C([C@@H]3[C@@H]4CC5=C(C(=C6C(=C5[C@@H](N4[C@H]([C@H](C2)N3C)O)CNC(=O)/C=C/C7=CC(=CC=C7)C(F)(F)F)OCO6)C)OC(=O)C)C(=C1OC)O DMMKOPX IK VPAHZSUNBOYNQY-DLVGLDQCSA-N DMMKOPX IU [(1R,2S,13R,15S,16S)-15,22-dihydroxy-21-methoxy-6,20,24-trimethyl-13-[[[(E)-3-[3-(trifluoromethyl)phenyl]prop-2-enoyl]amino]methyl]-8,10-dioxa-14,24-diazahexacyclo[14.7.1.02,14.04,12.07,11.018,23]tetracosa-4,6,11,18(23),19,21-hexaen-5-yl] acetate DMMKOPX CA CAS 308359-57-1 DMMKOPX DE Solid tumour/cancer DMS34YO ID DMS34YO DMS34YO DN PM184 DMS34YO HS Phase 2 DMS34YO CP PharmaMar Madrid, Spain DMS34YO DE Colorectal cancer DM0OVZ2 ID DM0OVZ2 DM0OVZ2 DN PMID27841036-Compound-37 DM0OVZ2 HS Phase 2 DM0OVZ2 SN 2X-121 DM0OVZ2 CP EISAI INC. XU, Weizheng DELAHANTY, Greg WEI, Ling ZHANG, Jie DM0OVZ2 DT Small molecular drug DM0OVZ2 PC 135565981 DM0OVZ2 MW 317.3 DM0OVZ2 FM C18H15N5O DM0OVZ2 IC InChI=1S/C18H15N5O/c24-18-13-6-3-7-14-16(13)17(21-22-18)20-15(19-14)10-23-8-11-4-1-2-5-12(11)9-23/h1-7H,8-10H2,(H,22,24)(H,19,20,21) DM0OVZ2 CS C1C2=CC=CC=C2CN1CC3=NC4=NNC(=O)C5=C4C(=CC=C5)N3 DM0OVZ2 IK JLFSBHQQXIAQEC-UHFFFAOYSA-N DM0OVZ2 IU 11-(1,3-dihydroisoindol-2-ylmethyl)-2,3,10,12-tetrazatricyclo[7.3.1.05,13]trideca-1,5(13),6,8,11-pentaen-4-one DM0OVZ2 CA CAS 1140964-99-3 DM0OVZ2 DE Ovarian cancer DMZUAJ4 ID DMZUAJ4 DMZUAJ4 DN PMX-53 DMZUAJ4 HS Phase 2 DMZUAJ4 SN YOKBGCTZYPOSQM-HPSWDUTRSA-N; PMX53; CHEMBL41547; (2S)-2-acetamido-N-[(3S,9S,12S,15R,18S)-15-(cyclohexylmethyl)-9-[3-(diaminomethylideneamino)propyl]-12-(1H-indol-3-ylmethyl)-2,8,11,14,17-pentaoxo-1,7,10,13,16-pentazabicyclo[1630]henicosan-3-yl]-3-phenylpropanamide; PMX 53; AcF-[OP(D-Cha)WR]; Ac-Phe-[Orn-Pro-cha-Trp-Arg]; C5aR-AP; AC1OCFH0; GTPL579; SCHEMBL16492460; SCHEMBL12971688; 219639-75-5; BDBM50111445; AcF-[OP(D-Cha)WR]; N-Acetyl-L-phenylalanyl-L-ornithyl-L-prolyl-3-cyclohexyl-D-alanyl-L-tryptophyl-D-arginine N-52-C-16-lactam DMZUAJ4 DT Small molecular drug DMZUAJ4 PC 6918468 DMZUAJ4 MW 896.1 DMZUAJ4 FM C47H65N11O7 DMZUAJ4 IC InChI=1S/C47H65N11O7/c1-29(59)53-37(25-30-13-4-2-5-14-30)42(61)55-36-20-11-22-50-41(60)35(19-10-23-51-47(48)49)54-44(63)39(27-32-28-52-34-18-9-8-17-33(32)34)56-43(62)38(26-31-15-6-3-7-16-31)57-45(64)40-21-12-24-58(40)46(36)65/h2,4-5,8-9,13-14,17-18,28,31,35-40,52H,3,6-7,10-12,15-16,19-27H2,1H3,(H,50,60)(H,53,59)(H,54,63)(H,55,61)(H,56,62)(H,57,64)(H4,48,49,51)/t35-,36-,37-,38+,39-,40-/m0/s1 DMZUAJ4 CS CC(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@H]2CCCNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H]3CCCN3C2=O)CC4CCCCC4)CC5=CNC6=CC=CC=C65)CCCN=C(N)N DMZUAJ4 IK YOKBGCTZYPOSQM-HPSWDUTRSA-N DMZUAJ4 IU (2S)-2-acetamido-N-[(3S,9S,12S,15R,18S)-15-(cyclohexylmethyl)-9-[3-(diaminomethylideneamino)propyl]-12-(1H-indol-3-ylmethyl)-2,8,11,14,17-pentaoxo-1,7,10,13,16-pentazabicyclo[16.3.0]henicosan-3-yl]-3-phenylpropanamide DMZUAJ4 DE Atopic dermatitis DMWT73D ID DMWT73D DMWT73D DN PMX-60056 DMWT73D HS Phase 2 DMWT73D SN PMX-150; PMX-60054; PMX-60065; PMX-60077; PMX-60079; PMX-60087; PMX-640; PMX-686; PMX-747; PMX-801; Heparin andlow molecular weight heparin (LMWH) reversing agents, PolyMedix DMWT73D CP PolyMedix Inc DMWT73D DT Small molecular drug DMWT73D PC 51349239 DMWT73D MW 1126.3 DMWT73D FM C56H79N13O12 DMWT73D IC InChI=1S/C56H79N13O12/c1-78-45-21-17-33(29-37(45)49(62)70)64-54(75)42(14-6-10-26-58)67-51(72)39-31-35(19-23-47(39)80-3)66-56(77)44(16-8-12-28-60)69-52(73)40-32-36(20-24-48(40)81-4)65-55(76)43(15-7-11-27-59)68-50(71)38-30-34(18-22-46(38)79-2)63-53(74)41(61)13-5-9-25-57/h17-24,29-32,41-44H,5-16,25-28,57-61H2,1-4H3,(H2,62,70)(H,63,74)(H,64,75)(H,65,76)(H,66,77)(H,67,72)(H,68,71)(H,69,73)/t41-,42-,43-,44-/m0/s1 DMWT73D CS COC1=C(C=C(C=C1)NC(=O)[C@H](CCCCN)N)C(=O)N[C@@H](CCCCN)C(=O)NC2=CC(=C(C=C2)OC)C(=O)N[C@@H](CCCCN)C(=O)NC3=CC(=C(C=C3)OC)C(=O)N[C@@H](CCCCN)C(=O)NC4=CC(=C(C=C4)OC)C(=O)N DMWT73D IK PWFIFNGOPQUNIT-ITMZJIMRSA-N DMWT73D IU N-[(2S)-6-amino-1-[3-[[(2S)-6-amino-1-[3-[[(2S)-6-amino-1-(3-carbamoyl-4-methoxyanilino)-1-oxohexan-2-yl]carbamoyl]-4-methoxyanilino]-1-oxohexan-2-yl]carbamoyl]-4-methoxyanilino]-1-oxohexan-2-yl]-5-[[(2S)-2,6-diaminohexanoyl]amino]-2-methoxybenzamide DMWT73D CA CAS 872454-31-4 DMWT73D DE Coagulation defect DMUVON0 ID DMUVON0 DMUVON0 DN PNT-2258 DMUVON0 HS Phase 2 DMUVON0 CP ProNAi Therapeutics Inc DMUVON0 DT Antisense drug DMUVON0 DE Solid tumour/cancer; Diffuse large B-cell lymphoma DMM8IAQ ID DMM8IAQ DMM8IAQ DN PNU-142731A DMM8IAQ HS Phase 2 DMM8IAQ SN 9-[2-Oxo-2-(pyrrolidin-1-yl)ethyl]-2,4-bis(pyrrolidin-1-yl)-9H-pyrimido[4,5-b]indole hydrochloride DMM8IAQ PC 9846800 DMM8IAQ MW 455 DMM8IAQ FM C24H31ClN6O DMM8IAQ IC InChI=1S/C24H30N6O.ClH/c31-20(27-11-3-4-12-27)17-30-19-10-2-1-9-18(19)21-22(28-13-5-6-14-28)25-24(26-23(21)30)29-15-7-8-16-29;/h1-2,9-10H,3-8,11-17H2;1H DMM8IAQ CS C1CCN(C1)C2=NC(=NC3=C2C4=CC=CC=C4N3CC(=O)N5CCCC5)N6CCCC6.Cl DMM8IAQ IK RLFYAIUQWFELJD-UHFFFAOYSA-N DMM8IAQ IU 2-(2,4-dipyrrolidin-1-ylpyrimido[4,5-b]indol-9-yl)-1-pyrrolidin-1-ylethanone;hydrochloride DMM8IAQ CA CAS 214212-38-1 DMM8IAQ DE Asthma DM4OT29 ID DM4OT29 DM4OT29 DN POL-6326 DM4OT29 HS Phase 2 DM4OT29 SN CXCR4 antagonists, Polyphor; POL-2438; POL-3026; Epitope mimetics (HIV fusion), Polyphor; CXCR4 antagonists (cancer/HIV), Polyphor DM4OT29 CP Polyphor Ltd DM4OT29 DE Human immunodeficiency virus infection; Breast cancer DMFCIKN ID DMFCIKN DMFCIKN DN Polivy DMFCIKN HS Phase 2 DMFCIKN SN Polatuzumab vedotin-piiq DMFCIKN CP Roche/Genentech DMFCIKN DT Antibody DMFCIKN DE Mantle cell lymphoma DMUXEBQ ID DMUXEBQ DMUXEBQ DN Polyamine DMUXEBQ HS Phase 2 DMUXEBQ DE Subjective cognitive decline DMXROM7 ID DMXROM7 DMXROM7 DN Polyglutamate camptothecin DMXROM7 HS Phase 2 DMXROM7 SN CT-2106; PG-interferon; Polyglutamate camptothecin, Cell Therapeutics; Polyglutamate-camptothecin; CPT-Gly-PG; Camptothecin-glycine-polyglutamate; PG-CPT, Cell Therapeutics; PG-camptothecin, CT; Polyglutamate-linked anticancer agents, Cell Therapeutics; PG-G-CSF, Cell Therapeutics DMXROM7 CP Cell Therapeutics Inc DMXROM7 DE Solid tumour/cancer DM2570B ID DM2570B DM2570B DN Poly-ICLC DM2570B HS Phase 2 DM2570B CP Oncovir DM2570B DT Small molecular drug DM2570B PC 136033680 DM2570B MW 879.6 DM2570B FM C26H43N9O21P2 DM2570B IC InChI=1S/C10H13N4O8P.C9H14N3O8P.C5H12N2O2.C2H4O3/c15-6-4(1-21-23(18,19)20)22-10(7(6)16)14-3-13-5-8(14)11-2-12-9(5)17;10-5-1-2-12(9(15)11-5)8-7(14)6(13)4(20-8)3-19-21(16,17)18;6-3-1-2-4-7-5(8)9;3-1-2(4)5/h2-4,6-7,10,15-16H,1H2,(H,11,12,17)(H2,18,19,20);1-2,4,6-8,13-14H,3H2,(H2,10,11,15)(H2,16,17,18);7H,1-4,6H2,(H,8,9);3H,1H2,(H,4,5) DM2570B CS C1=CN(C(=O)N=C1N)C2C(C(C(O2)COP(=O)(O)O)O)O.C1=NC2=C(C(=O)N1)N=CN2C3C(C(C(O3)COP(=O)(O)O)O)O.C(CCNC(=O)O)CN.C(C(=O)O)O DM2570B IK MRYYMYCQXMFJNE-UHFFFAOYSA-N DM2570B IU 4-aminobutylcarbamic acid;[5-(4-amino-2-oxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate;[3,4-dihydroxy-5-(6-oxo-1H-purin-9-yl)oxolan-2-yl]methyl dihydrogen phosphate;2-hydroxyacetic acid DM2570B DE Glioblastoma multiforme; Recurrent glioblastoma; Solid tumour/cancer DM3QDA6 ID DM3QDA6 DM3QDA6 DN Polynoma-1 DM3QDA6 HS Phase 2 DM3QDA6 SN Polyvalent melanoma vaccine, Vaccinoma DM3QDA6 CP Vaccinoma Inc DM3QDA6 DT Vaccine DM3QDA6 DE Melanoma DMIAZ13 ID DMIAZ13 DMIAZ13 DN Ponezumab DMIAZ13 HS Phase 2 DMIAZ13 SN Neurological disease and injury therapeutics, Pfizer; PF-04360365; PF-4360365; RI-1014; RI-1219; RI-409; RN-1219 DMIAZ13 CP Rinat Neuroscience Corp DMIAZ13 DT Antibody DMIAZ13 DE Alzheimer disease DM5HMTB ID DM5HMTB DM5HMTB DN Porphobilinogen DM5HMTB HS Phase 2 DM5HMTB SN porphobilinogen; 487-90-1; 3-[5-(AMINOMETHYL)-4-(CARBOXYMETHYL)-1H-PYRROL-3-YL]PROPANOIC ACID; UNII-74KHC72QXK; 1H-Pyrrole-3-propanoic acid, 5-(aminomethyl)-4-(carboxymethyl)-; 2-aminomethylpyrrol-3-acetic acid 4-propionic acid; 74KHC72QXK; PBG; CHEBI:17381; 5-(Aminomethyl)-4-(carboxymethyl)-1H-pyrrole-3-propanoic acid; 5-(Aminomethyl)-4-(carboxymethyl)-1H-pyrrole-3-propionic acid; 3-(5-(Aminomethyl)-4-(carboxymethyl)-1H-pyrrol-3-yl)propanoic acid; 5-(aminomethyl)-4-(carboxymethyl)-pyrrole-3-propionic acid DM5HMTB DT Small molecular drug DM5HMTB PC 1021 DM5HMTB MW 226.23 DM5HMTB FM C10H14N2O4 DM5HMTB IC InChI=1S/C10H14N2O4/c11-4-8-7(3-10(15)16)6(5-12-8)1-2-9(13)14/h5,12H,1-4,11H2,(H,13,14)(H,15,16) DM5HMTB CS C1=C(C(=C(N1)CN)CC(=O)O)CCC(=O)O DM5HMTB IK QSHWIQZFGQKFMA-UHFFFAOYSA-N DM5HMTB IU 3-[5-(aminomethyl)-4-(carboxymethyl)-1H-pyrrol-3-yl]propanoic acid DM5HMTB CA CAS 487-90-1 DM5HMTB CB CHEBI:17381 DMH0LM2 ID DMH0LM2 DMH0LM2 DN POT-4 DMH0LM2 HS Phase 2 DMH0LM2 SN AL-78898A; POT-4 EOS Insert; Compstatin complement-inhibiting peptides, Pennsylvania/Potentia; 4(1MeW)7W DMH0LM2 CP University of Pennsylvania DMH0LM2 DE Macular degeneration DMTE8DC ID DMTE8DC DMTE8DC DN Pozelimab DMTE8DC HS Phase 2 DMTE8DC SN REGN3918 DMTE8DC CP Regeneron Pharmaceuticals DMTE8DC DT Antibody DMTE8DC DE Paroxysmal nocturnal haemoglobinuria DM4EHVB ID DM4EHVB DM4EHVB DN PPI-668 DM4EHVB HS Phase 2 DM4EHVB CP Presidio pharmaceuticals DM4EHVB PC 71665718 DM4EHVB MW 835.8 DM4EHVB FM C42H52Cl2N8O6 DM4EHVB IC InChI=1S/C42H50N8O6.2ClH/c1-23(2)35(47-41(53)55-5)39(51)49-17-7-9-33(49)37-43-22-32(46-37)29-14-13-25-19-26(11-12-27(25)20-29)28-15-16-30-31(21-28)45-38(44-30)34-10-8-18-50(34)40(52)36(24(3)4)48-42(54)56-6;;/h11-16,19-24,33-36H,7-10,17-18H2,1-6H3,(H,43,46)(H,44,45)(H,47,53)(H,48,54);2*1H/t33-,34-,35-,36-;;/m0../s1 DM4EHVB CS CC(C)[C@@H](C(=O)N1CCC[C@H]1C2=NC3=C(N2)C=C(C=C3)C4=CC5=C(C=C4)C=C(C=C5)C6=CN=C(N6)[C@@H]7CCCN7C(=O)[C@H](C(C)C)NC(=O)OC)NC(=O)OC.Cl.Cl DM4EHVB IK JYLMWUZJMRNMDA-SPRBZRACSA-N DM4EHVB IU methyl N-[(2S)-1-[(2S)-2-[5-[6-[2-[(2S)-1-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]pyrrolidin-2-yl]-3H-benzimidazol-5-yl]naphthalen-2-yl]-1H-imidazol-2-yl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate;dihydrochloride DM4EHVB CA CAS 1303533-81-4 DM4EHVB DE Hepatitis C virus infection DMM6J5Z ID DMM6J5Z DMM6J5Z DN PQ-912 DMM6J5Z HS Phase 2 DMM6J5Z PC 51030870 DMM6J5Z MW 336.4 DMM6J5Z FM C19H20N4O2 DMM6J5Z IC InChI=1S/C19H20N4O2/c1-2-9-25-15-6-3-13(4-7-15)18-11-20-19(24)23(18)14-5-8-16-17(10-14)22-12-21-16/h3-8,10,12,18H,2,9,11H2,1H3,(H,20,24)(H,21,22)/t18-/m1/s1 DMM6J5Z CS CCCOC1=CC=C(C=C1)[C@H]2CNC(=O)N2C3=CC4=C(C=C3)N=CN4 DMM6J5Z IK XHIKZWOEFZENIX-GOSISDBHSA-N DMM6J5Z IU (5S)-1-(3H-benzimidazol-5-yl)-5-(4-propoxyphenyl)imidazolidin-2-one DMM6J5Z CA CAS 1276021-65-8 DMM6J5Z DE Dementia DMMCYZ8 ID DMMCYZ8 DMMCYZ8 DN PQR309 DMMCYZ8 HS Phase 2 DMMCYZ8 SN Bimiralisib; PQR309; 1225037-39-7; PI3K-IN-2; PQR-309; UNII-6Z3QHB00LB; 6Z3QHB00LB; 5-(4,6-dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine; 5-[bis(morpholin-4-yl)-1,3,5-triazin-2-yl]-4-(trifluoromethyl)pyridin-2-amine; 5-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine; Bimiralisib [INN]; Bimiralisib [USAN]; PQR309; Bimiralisib; Bimiralisib [WHO-DD]; NCB5; SCHEMBL1309049; GTPL8383; PQR309; Bimiralisib free base; ADGGYDAFIHSYFI-UHFFFAOYSA-N; EX-A2018; BCP15887; PQR-309(PI3K-IN-2) DMMCYZ8 DT Small molecular drug DMMCYZ8 PC 58507717 DMMCYZ8 MW 411.4 DMMCYZ8 FM C17H20F3N7O2 DMMCYZ8 IC InChI=1S/C17H20F3N7O2/c18-17(19,20)12-9-13(21)22-10-11(12)14-23-15(26-1-5-28-6-2-26)25-16(24-14)27-3-7-29-8-4-27/h9-10H,1-8H2,(H2,21,22) DMMCYZ8 CS C1COCCN1C2=NC(=NC(=N2)C3=CN=C(C=C3C(F)(F)F)N)N4CCOCC4 DMMCYZ8 IK ADGGYDAFIHSYFI-UHFFFAOYSA-N DMMCYZ8 IU 5-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine DMMCYZ8 CA CAS 1225037-39-7 DMMCYZ8 DE Pain; Squamous head and neck cell carcinom DM1O0DV ID DM1O0DV DM1O0DV DN Pradefovir DM1O0DV HS Phase 2 DM1O0DV SN Remofovir; Pradefovir mesylate; Remofovir mesylate; Hepavir-B; ICN 2001-3; MB-06866; MB-6866; Pradefovir (oral, hepatitis B), Ligand/Chiva DM1O0DV CP Metabasis Therapeutics Inc DM1O0DV DT Small molecular drug DM1O0DV PC 9604654 DM1O0DV MW 423.8 DM1O0DV FM C17H19ClN5O4P DM1O0DV IC InChI=1S/C17H19ClN5O4P/c18-13-3-1-2-12(8-13)14-4-6-26-28(24,27-14)11-25-7-5-23-10-22-15-16(19)20-9-21-17(15)23/h1-3,8-10,14H,4-7,11H2,(H2,19,20,21)/t14-,28+/m0/s1 DM1O0DV CS C1CO[P@@](=O)(O[C@@H]1C2=CC(=CC=C2)Cl)COCCN3C=NC4=C(N=CN=C43)N DM1O0DV IK GWNHAOBXDGOXRR-HJFSHJIFSA-N DM1O0DV IU 9-[2-[[(2R,4S)-4-(3-chlorophenyl)-2-oxo-1,3,2lambda5-dioxaphosphinan-2-yl]methoxy]ethyl]purin-6-amine DM1O0DV CA CAS 625095-60-5 DM1O0DV DE Hepatitis virus infection DMIVMR3 ID DMIVMR3 DMIVMR3 DN Prajmaline DMIVMR3 HS Phase 2 DMIVMR3 SN N(sup 4)-Propylajmalinium; N-Propylajmaline; N-Propylajmalinium; Prajmaline; Prajmalium; Prajmalum; (17R,21-alpha)-17,21-Dihydroxy-4-propylajmalanium; 35080-11-6; 75934UD4GJ; Ajmalanium, 17,21-dihydroxy-4-propyl-, (17R,21-alpha)-; CHEBI:135560; UNII-75934UD4GJ DMIVMR3 PC 76959818 DMIVMR3 MW 369.5 DMIVMR3 FM C23H33N2O2+ DMIVMR3 IC UAUHEPXILIZYCU-ALHOSYKFSA-N DMIVMR3 CS CCC[N+]12C3CC(C(C1O)CC)C4C2CC5(C3N(C6=CC=CC=C65)C)C4O DMIVMR3 IK 1S/C23H33N2O2/c1-4-10-25-17-11-14(13(5-2)22(25)27)19-18(25)12-23(21(19)26)15-8-6-7-9-16(15)24(3)20(17)23/h6-9,13-14,17-22,26-27H,4-5,10-12H2,1-3H3/q+1/t13-,14-,17-,18-,19-,20-,21+,22+,23+,25-/m0/s1 DMIVMR3 IU (1R,9R,10S,12R,13S,14R,15R,16S,17S,18R)-13-ethyl-8-methyl-15-propyl-8-aza-15-azoniahexacyclo[14.2.1.01,9.02,7.010,15.012,17]nonadeca-2,4,6-triene-14,18-diol DMIVMR3 CA CAS 35080-11-6 DMIVMR3 CB CHEBI:135560 DMIVMR3 DE Atherosclerosis DM73UTG ID DM73UTG DM73UTG DN PRALNACASAN DM73UTG HS Phase 2 DM73UTG SN Pralnacasan; VX-740; UNII-N986NI319S; 192755-52-5; N986NI319S; HMR3480/VX-740; Pralnacasan [USAN:INN]; HMR 3480; VX 470; Pralnacasan (USAN/INN); AC1L4A1A; SCHEMBL142187; GTPL6467; CHEMBL437526; DTXSID60172873; HMR3480; HMR-3480; BDBM50189360; AKOS030230853; DB04875; D08978; (4S,7S)-N-[(2R,3S)-2-ethoxy-5-oxooxolan-3-yl]-7-(isoquinoline-1-carbonylamino)-6,10-dioxo-2,3,4,7,8,9-hexahydro-1H-pyridazino[1,2-a]diazepine-4-carboxamide DM73UTG DT Small molecular drug DM73UTG PC 153270 DM73UTG MW 523.5 DM73UTG FM C26H29N5O7 DM73UTG IC InChI=1S/C26H29N5O7/c1-2-37-26-18(14-21(33)38-26)29-23(34)19-8-5-13-30-20(32)10-9-17(25(36)31(19)30)28-24(35)22-16-7-4-3-6-15(16)11-12-27-22/h3-4,6-7,11-12,17-19,26H,2,5,8-10,13-14H2,1H3,(H,28,35)(H,29,34)/t17-,18-,19-,26+/m0/s1 DM73UTG CS CCO[C@H]1[C@H](CC(=O)O1)NC(=O)[C@@H]2CCCN3N2C(=O)[C@H](CCC3=O)NC(=O)C4=NC=CC5=CC=CC=C54 DM73UTG IK CXAGHAZMQSCAKJ-WAHHBDPQSA-N DM73UTG IU (4S,7S)-N-[(2R,3S)-2-ethoxy-5-oxooxolan-3-yl]-7-(isoquinoline-1-carbonylamino)-6,10-dioxo-2,3,4,7,8,9-hexahydro-1H-pyridazino[1,2-a]diazepine-4-carboxamide DM73UTG CA CAS 192755-52-5 DM73UTG DE Rheumatoid arthritis DMBH7XI ID DMBH7XI DMBH7XI DN Pramiconazole DMBH7XI HS Phase 2 DMBH7XI SN Azoline; Antifungals, Janssen Research Foundation; R-126638 DMBH7XI CP Barrier Therapeutics DMBH7XI DT Small molecular drug DMBH7XI PC 3013050 DMBH7XI MW 659.7 DMBH7XI FM C35H39F2N7O4 DMBH7XI IC InChI=1S/C35H39F2N7O4/c1-25(2)43-17-18-44(34(43)45)29-6-4-27(5-7-29)40-13-15-41(16-14-40)28-8-10-30(11-9-28)46-20-33-47-22-35(4